id|nct_id|result_group_id|ctgov_group_code|period|reason|count
5983221|NCT00440531|9572953|FG000|Overall Study|Adverse Event|1
6064476|NCT00513604|9666161|FG000|Overall Study|Not treated|2
6064477|NCT00513604|9666162|FG001|Overall Study|Not treated|0
6064478|NCT00513604|9666163|FG002|Overall Study|Not treated|1
6064479|NCT00513604|9666164|FG003|Overall Study|Not treated|0
6064480|NCT00513604|9666165|FG004|Overall Study|Not treated|0
6064481|NCT00513604|9666161|FG000|Overall Study|Death during treatment|0
6064482|NCT00513604|9666162|FG001|Overall Study|Death during treatment|3
6064483|NCT00513604|9666163|FG002|Overall Study|Death during treatment|2
6064484|NCT00513604|9666164|FG003|Overall Study|Death during treatment|0
6064485|NCT00513604|9666165|FG004|Overall Study|Death during treatment|0
6064486|NCT00513682|9666177|FG000|Washout Phase|Adverse Event|2
6064487|NCT00513695|9666184|FG000|Overall Study|Discontinued therapy|2
6064488|NCT00513695|9666184|FG000|Overall Study|Progression prior to surgery|3
6064489|NCT00513708|9666191|FG000|Overall Study|Lost to Follow-up|4
6064490|NCT00513708|9666192|FG001|Overall Study|Lost to Follow-up|4
6064491|NCT00513708|9666193|FG002|Overall Study|Lost to Follow-up|4
6064492|NCT00514020|9666237|FG000|Overall Study|Adverse Event|6
6064493|NCT00514020|9666237|FG000|Overall Study|Withdrawal by Subject|3
6064494|NCT00514020|9666237|FG000|Overall Study|Physician Decision|1
6064495|NCT00514020|9666237|FG000|Overall Study|disease progression|9
6064496|NCT00514020|9666237|FG000|Overall Study|other complicating disease|2
6064497|NCT00514020|9666237|FG000|Overall Study|patient went to radiation treatment|1
6064498|NCT00514020|9666237|FG000|Overall Study|"patients moved to the no tx group"|6
6064499|NCT00514046|9666250|FG000|Overall Study|transferred to another protocol|2
6064500|NCT00514046|9666251|FG001|Overall Study|transferred to another protocol|1
6064501|NCT00514046|9666252|FG002|Overall Study|transferred to another protocol|3
6064502|NCT00514046|9666253|FG003|Overall Study|transferred to another protocol|0
6064503|NCT00514046|9666254|FG004|Overall Study|transferred to another protocol|1
6064504|NCT00514046|9666255|FG005|Overall Study|transferred to another protocol|0
6064505|NCT00514046|9666256|FG006|Overall Study|transferred to another protocol|0
6064506|NCT00514046|9666257|FG007|Overall Study|transferred to another protocol|0
6064507|NCT00514046|9666258|FG008|Overall Study|transferred to another protocol|0
6064508|NCT00514046|9666250|FG000|Overall Study|Getting vandetanib via the REMS program|1
6064509|NCT00514046|9666251|FG001|Overall Study|Getting vandetanib via the REMS program|0
6064510|NCT00514046|9666252|FG002|Overall Study|Getting vandetanib via the REMS program|0
6064511|NCT00514046|9666253|FG003|Overall Study|Getting vandetanib via the REMS program|0
6064512|NCT00514046|9666254|FG004|Overall Study|Getting vandetanib via the REMS program|0
6064513|NCT00514046|9666255|FG005|Overall Study|Getting vandetanib via the REMS program|0
6064514|NCT00514046|9666256|FG006|Overall Study|Getting vandetanib via the REMS program|0
6064515|NCT00514046|9666257|FG007|Overall Study|Getting vandetanib via the REMS program|1
6064516|NCT00514046|9666258|FG008|Overall Study|Getting vandetanib via the REMS program|1
6064517|NCT00514046|9666250|FG000|Overall Study|Disease progression on study|0
6064518|NCT00514046|9666251|FG001|Overall Study|Disease progression on study|0
6064519|NCT00514046|9666252|FG002|Overall Study|Disease progression on study|2
6064520|NCT00514046|9666253|FG003|Overall Study|Disease progression on study|0
6064521|NCT00514046|9666254|FG004|Overall Study|Disease progression on study|0
6064522|NCT00514046|9666255|FG005|Overall Study|Disease progression on study|1
6064523|NCT00514046|9666256|FG006|Overall Study|Disease progression on study|0
6064524|NCT00514046|9666257|FG007|Overall Study|Disease progression on study|0
6064525|NCT00514046|9666258|FG008|Overall Study|Disease progression on study|0
6064526|NCT00514449|9666290|FG000|Overall Study|Withdrawal by Subject|1
6064527|NCT00514449|9666291|FG001|Overall Study|Withdrawal by Subject|2
6064528|NCT00514449|9666290|FG000|Overall Study|Protocol Violation|1
6064529|NCT00514449|9666291|FG001|Overall Study|Protocol Violation|2
6064530|NCT00514449|9666290|FG000|Overall Study|Lost to Follow-up|1
6064531|NCT00514449|9666291|FG001|Overall Study|Lost to Follow-up|0
6064532|NCT00514514|9666307|FG000|Pre-phase|Death|10
6064533|NCT00514514|9666308|FG001|Pre-phase|Death|0
6064534|NCT00514514|9666309|FG002|Pre-phase|Death|0
6064535|NCT00514514|9666307|FG000|Pre-phase|administrative problems|2
6064536|NCT00514514|9666308|FG001|Pre-phase|administrative problems|0
6064537|NCT00514514|9666309|FG002|Pre-phase|administrative problems|0
6064538|NCT00514514|9666307|FG000|Pre-phase|Protocol Violation|6
6064539|NCT00514514|9666308|FG001|Pre-phase|Protocol Violation|0
6064540|NCT00514514|9666309|FG002|Pre-phase|Protocol Violation|0
6064541|NCT00514514|9666307|FG000|Pre-phase|condition no longer requires study drug|7
6064542|NCT00514514|9666308|FG001|Pre-phase|condition no longer requires study drug|0
6064543|NCT00514514|9666309|FG002|Pre-phase|condition no longer requires study drug|0
6064544|NCT00514514|9666307|FG000|Pre-phase|abnormal test procedure results|15
6064545|NCT00514514|9666308|FG001|Pre-phase|abnormal test procedure results|0
6064546|NCT00514514|9666309|FG002|Pre-phase|abnormal test procedure results|0
6064547|NCT00514514|9666307|FG000|Pre-phase|Lost to Follow-up|2
6064548|NCT00514514|9666308|FG001|Pre-phase|Lost to Follow-up|0
6064549|NCT00514514|9666309|FG002|Pre-phase|Lost to Follow-up|0
6064550|NCT00514514|9666307|FG000|Pre-phase|abnormal lab values|23
6064551|NCT00514514|9666308|FG001|Pre-phase|abnormal lab values|0
6064552|NCT00514514|9666309|FG002|Pre-phase|abnormal lab values|0
6064553|NCT00514514|9666307|FG000|Pre-phase|Lack of Efficacy|35
5983222|NCT00440531|9572954|FG001|Overall Study|Adverse Event|0
6145750|NCT01072877|9780221|FG000|Overall Study|Lost to Follow-up|1
5983223|NCT00440531|9572955|FG002|Overall Study|Adverse Event|2
5983224|NCT00440531|9572953|FG000|Overall Study|Withdrawal by Subject|2
5983225|NCT00440531|9572954|FG001|Overall Study|Withdrawal by Subject|0
5983226|NCT00440531|9572955|FG002|Overall Study|Withdrawal by Subject|0
5983227|NCT00440531|9572953|FG000|Overall Study|Protocol Violation|1
5983228|NCT00440531|9572954|FG001|Overall Study|Protocol Violation|2
5983229|NCT00440531|9572955|FG002|Overall Study|Protocol Violation|0
5983230|NCT00440531|9572953|FG000|Overall Study|Lost to Follow-up|4
6306794|NCT02594098|10033040|FG000|Overall Study|Lack of Efficacy|17
6306795|NCT02594098|10033041|FG001|Overall Study|Lack of Efficacy|6
6306796|NCT02594098|10033040|FG000|Overall Study|Withdrawal by Subject|1
6306797|NCT02594098|10033041|FG001|Overall Study|Withdrawal by Subject|3
6306798|NCT02594098|10033040|FG000|Overall Study|Terminated participation|6
6306799|NCT02594098|10033041|FG001|Overall Study|Terminated participation|2
6306800|NCT02594098|10033040|FG000|Overall Study|Seek alternative treatment|2
6306801|NCT02594098|10033041|FG001|Overall Study|Seek alternative treatment|1
6306802|NCT02594098|10033040|FG000|Overall Study|Other|0
6306803|NCT02594098|10033041|FG001|Overall Study|Other|1
6306804|NCT02594163|10033060|FG000|Treatment Period|Progressive disease|2
6306805|NCT02594163|10033061|FG001|Treatment Period|Progressive disease|3
6306806|NCT02594163|10033060|FG000|Treatment Period|Adverse Event|1
6306807|NCT02594163|10033061|FG001|Treatment Period|Adverse Event|5
6306808|NCT02594163|10033060|FG000|Treatment Period|Physician Decision|1
6306809|NCT02594163|10033061|FG001|Treatment Period|Physician Decision|3
6306810|NCT02594163|10033060|FG000|Treatment Period|Study termination by sponsor|2
6306811|NCT02594163|10033061|FG001|Treatment Period|Study termination by sponsor|1
6064554|NCT00514514|9666308|FG001|Pre-phase|Lack of Efficacy|0
6064555|NCT00514514|9666309|FG002|Pre-phase|Lack of Efficacy|0
6064556|NCT00514514|9666307|FG000|Pre-phase|Adverse Event|137
6064557|NCT00514514|9666308|FG001|Pre-phase|Adverse Event|0
6064558|NCT00514514|9666309|FG002|Pre-phase|Adverse Event|0
6064559|NCT00514514|9666307|FG000|Pre-phase|Withdrawal by Subject|66
6064560|NCT00514514|9666308|FG001|Pre-phase|Withdrawal by Subject|0
6064561|NCT00514514|9666309|FG002|Pre-phase|Withdrawal by Subject|0
6064562|NCT00514514|9666307|FG000|Randomized - 9 Month|Death|3
6064563|NCT00514514|9666308|FG001|Randomized - 9 Month|Death|2
6064564|NCT00514514|9666309|FG002|Randomized - 9 Month|Death|2
6064565|NCT00514514|9666307|FG000|Randomized - 9 Month|Administrative problems|1
6064566|NCT00514514|9666308|FG001|Randomized - 9 Month|Administrative problems|1
6064567|NCT00514514|9666309|FG002|Randomized - 9 Month|Administrative problems|2
6064568|NCT00514514|9666307|FG000|Randomized - 9 Month|Withdrawal by Subject|7
6064569|NCT00514514|9666308|FG001|Randomized - 9 Month|Withdrawal by Subject|7
6064570|NCT00514514|9666309|FG002|Randomized - 9 Month|Withdrawal by Subject|5
6064571|NCT00514514|9666307|FG000|Randomized - 9 Month|Protocol Violation|1
6064572|NCT00514514|9666308|FG001|Randomized - 9 Month|Protocol Violation|1
6064573|NCT00514514|9666309|FG002|Randomized - 9 Month|Protocol Violation|0
6064574|NCT00514514|9666307|FG000|Randomized - 9 Month|Lack of Efficacy|2
6064575|NCT00514514|9666308|FG001|Randomized - 9 Month|Lack of Efficacy|3
6064576|NCT00514514|9666309|FG002|Randomized - 9 Month|Lack of Efficacy|1
6064577|NCT00514514|9666307|FG000|Randomized - 9 Month|Abnormal laboratory values|0
6064578|NCT00514514|9666308|FG001|Randomized - 9 Month|Abnormal laboratory values|3
6064579|NCT00514514|9666309|FG002|Randomized - 9 Month|Abnormal laboratory values|1
6064580|NCT00514514|9666307|FG000|Randomized - 9 Month|Adverse Event|25
6064581|NCT00514514|9666308|FG001|Randomized - 9 Month|Adverse Event|44
6064582|NCT00514514|9666309|FG002|Randomized - 9 Month|Adverse Event|27
6064583|NCT00514514|9666307|FG000|Extension - 4 Years|Withdrawal by Subject|5
6145751|NCT01072877|9780222|FG001|Overall Study|Lost to Follow-up|1
6145752|NCT01072877|9780223|FG002|Overall Study|Lost to Follow-up|0
6145753|NCT01072877|9780224|FG003|Overall Study|Lost to Follow-up|2
6145754|NCT01072877|9780225|FG004|Overall Study|Lost to Follow-up|0
6145755|NCT01072929|9780242|FG000|Overall Study|Adverse Event|8
6145756|NCT01072929|9780243|FG001|Overall Study|Adverse Event|11
6145757|NCT01072929|9780244|FG002|Overall Study|Adverse Event|2
6145758|NCT01072929|9780242|FG000|Overall Study|Lack of Efficacy|7
6145759|NCT01072929|9780243|FG001|Overall Study|Lack of Efficacy|4
6145760|NCT01072929|9780244|FG002|Overall Study|Lack of Efficacy|0
6145761|NCT01072929|9780242|FG000|Overall Study|Withdrawal by Subject|7
6145762|NCT01072929|9780243|FG001|Overall Study|Withdrawal by Subject|15
6145763|NCT01072929|9780244|FG002|Overall Study|Withdrawal by Subject|3
6145764|NCT01072929|9780242|FG000|Overall Study|Protocol Violation|13
6145765|NCT01072929|9780243|FG001|Overall Study|Protocol Violation|11
6226199|NCT01708915|9898652|FG000|Overall Study|Adverse Event|1
6226200|NCT01708915|9898653|FG001|Overall Study|Adverse Event|0
6306812|NCT02594163|10033060|FG000|Treatment Period|Other, Non-AE|1
6306813|NCT02594163|10033061|FG001|Treatment Period|Other, Non-AE|0
6306814|NCT02594163|10033060|FG000|Follow-up Period|Withdrawal by Subject|0
5983231|NCT00440531|9572954|FG001|Overall Study|Lost to Follow-up|3
6064584|NCT00514514|9666308|FG001|Extension - 4 Years|Withdrawal by Subject|2
6064585|NCT00514514|9666309|FG002|Extension - 4 Years|Withdrawal by Subject|2
6145766|NCT01072929|9780244|FG002|Overall Study|Protocol Violation|2
6145767|NCT01072929|9780242|FG000|Overall Study|Lost to Follow-up|8
6226201|NCT01708915|9898654|FG002|Overall Study|Adverse Event|9
6306815|NCT02594163|10033061|FG001|Follow-up Period|Withdrawal by Subject|1
6306816|NCT02594163|10033060|FG000|Follow-up Period|Study Termination by Sponsor|6
6064586|NCT00514514|9666307|FG000|Extension - 4 Years|Lost to Follow-up|12
6064587|NCT00514514|9666308|FG001|Extension - 4 Years|Lost to Follow-up|10
6064588|NCT00514514|9666309|FG002|Extension - 4 Years|Lost to Follow-up|9
6064589|NCT00514514|9666307|FG000|Extension - 4 Years|Administrative problems|3
6064590|NCT00514514|9666308|FG001|Extension - 4 Years|Administrative problems|1
6064591|NCT00514514|9666309|FG002|Extension - 4 Years|Administrative problems|1
6064592|NCT00514514|9666307|FG000|Extension - 4 Years|Death|8
6064593|NCT00514514|9666308|FG001|Extension - 4 Years|Death|3
6064594|NCT00514514|9666309|FG002|Extension - 4 Years|Death|6
6064595|NCT00514514|9666307|FG000|Extension - 4 Years|Adverse Event|9
6064596|NCT00514514|9666308|FG001|Extension - 4 Years|Adverse Event|6
6064597|NCT00514514|9666309|FG002|Extension - 4 Years|Adverse Event|3
6064598|NCT00514540|9666317|FG000|First-Line Chemo|Withdrawal by Subject|1
6145768|NCT01072929|9780243|FG001|Overall Study|Lost to Follow-up|4
6145769|NCT01072929|9780244|FG002|Overall Study|Lost to Follow-up|1
6145770|NCT01072929|9780242|FG000|Overall Study|Noncompliance with study medication|0
6145771|NCT01072929|9780243|FG001|Overall Study|Noncompliance with study medication|3
6145772|NCT01072929|9780244|FG002|Overall Study|Noncompliance with study medication|0
6145773|NCT01072929|9780242|FG000|Overall Study|Noncompliance with study procedures|1
6145774|NCT01072929|9780243|FG001|Overall Study|Noncompliance with study procedures|0
6145775|NCT01072929|9780244|FG002|Overall Study|Noncompliance with study procedures|1
6145776|NCT01072929|9780242|FG000|Overall Study|Other|0
6145777|NCT01072929|9780243|FG001|Overall Study|Other|3
6145778|NCT01072929|9780244|FG002|Overall Study|Other|0
6145779|NCT01073020|9780257|FG000|Overall Study|Withdrawal by Subject|6
6145780|NCT01073020|9780258|FG001|Overall Study|Withdrawal by Subject|4
6145781|NCT01073020|9780259|FG002|Overall Study|Withdrawal by Subject|1
6145782|NCT01073020|9780260|FG003|Overall Study|Withdrawal by Subject|2
6145783|NCT01073020|9780257|FG000|Overall Study|Physician Decision|1
6145784|NCT01073020|9780258|FG001|Overall Study|Physician Decision|0
6145785|NCT01073020|9780259|FG002|Overall Study|Physician Decision|2
6145786|NCT01073020|9780260|FG003|Overall Study|Physician Decision|0
6145787|NCT01073020|9780257|FG000|Overall Study|Death|0
6145788|NCT01073020|9780258|FG001|Overall Study|Death|1
6145789|NCT01073020|9780259|FG002|Overall Study|Death|0
6145790|NCT01073020|9780260|FG003|Overall Study|Death|0
6145791|NCT01073163|9780270|FG000|Overall Study|Adverse Event|1
6145792|NCT01073163|9780270|FG000|Overall Study|Disease Progression|1
6145793|NCT01073163|9780270|FG000|Overall Study|Early termination|1
6145794|NCT01073267|9780278|FG000|Overall Study|Disease Progression|3
6145795|NCT01073293|9780284|FG000|Overall Study|Lost to Follow-up|0
6145796|NCT01073293|9780285|FG001|Overall Study|Lost to Follow-up|1
6145797|NCT01073293|9780284|FG000|Overall Study|Withdrawal by Subject|5
6145798|NCT01073293|9780285|FG001|Overall Study|Withdrawal by Subject|10
6145799|NCT01073462|9780295|FG000|Overall Study|Death|14
6145800|NCT01073462|9780295|FG000|Overall Study|Kidney transplant|10
6145801|NCT01073462|9780295|FG000|Overall Study|Low parathyroid hormone levels|8
6145802|NCT01073462|9780295|FG000|Overall Study|Serious adverse event|2
6145803|NCT01073462|9780295|FG000|Overall Study|Lost to Follow-up|7
6145804|NCT01073566|9780301|FG000|Period 2 (6 Weeks)|Adverse Event|1
6145805|NCT01073566|9780302|FG001|Period 2 (6 Weeks)|Adverse Event|0
6145806|NCT01073605|9780311|FG000|Overall Study|Ongoing at Cutoff Date|1
6145807|NCT01073605|9780312|FG001|Overall Study|Ongoing at Cutoff Date|1
6145808|NCT01073605|9780313|FG002|Overall Study|Ongoing at Cutoff Date|0
6145809|NCT01073605|9780311|FG000|Overall Study|Adverse Event|2
6145810|NCT01073605|9780312|FG001|Overall Study|Adverse Event|1
6145811|NCT01073605|9780313|FG002|Overall Study|Adverse Event|0
6145812|NCT01073605|9780311|FG000|Overall Study|Lost to Follow-up|3
6145813|NCT01073605|9780312|FG001|Overall Study|Lost to Follow-up|4
6145814|NCT01073605|9780313|FG002|Overall Study|Lost to Follow-up|9
6145815|NCT01073605|9780311|FG000|Overall Study|Other|25
6145816|NCT01073605|9780312|FG001|Overall Study|Other|21
6145817|NCT01073605|9780313|FG002|Overall Study|Other|29
6145818|NCT01073605|9780311|FG000|Overall Study|Withdrawal by Subject|31
6145819|NCT01073605|9780312|FG001|Overall Study|Withdrawal by Subject|39
6145820|NCT01073605|9780313|FG002|Overall Study|Withdrawal by Subject|22
6145821|NCT01073605|9780311|FG000|Overall Study|Randomized But Not Treated|0
6145822|NCT01073605|9780312|FG001|Overall Study|Randomized But Not Treated|1
6145823|NCT01073605|9780313|FG002|Overall Study|Randomized But Not Treated|1
6145824|NCT01073618|9780321|FG000|Overall Study|Death|208
6145825|NCT01073618|9780321|FG000|Overall Study|Adverse Event|19
6145826|NCT01073618|9780321|FG000|Overall Study|Other|80
6145827|NCT01073631|9780325|FG000|Overall Study|Death|82
6145828|NCT01073631|9780325|FG000|Overall Study|Adverse Event|24
6145829|NCT01073631|9780325|FG000|Overall Study|Other|63
6145830|NCT01073865|9780340|FG000|Overall Study|Reasons other than below|19
6145831|NCT01073865|9780341|FG001|Overall Study|Reasons other than below|31
6145832|NCT01073865|9780340|FG000|Overall Study|Lost to Follow-up|1
6145833|NCT01073865|9780341|FG001|Overall Study|Lost to Follow-up|1
6145834|NCT01073865|9780340|FG000|Overall Study|Death|3
6145835|NCT01073865|9780341|FG001|Overall Study|Death|2
6145836|NCT01073865|9780340|FG000|Overall Study|Withdrawal by Subject|5
6145837|NCT01073865|9780341|FG001|Overall Study|Withdrawal by Subject|5
6145838|NCT01073930|9780349|FG000|Overall Study|Withdrawal by Subject|3
6145839|NCT01073930|9780350|FG001|Overall Study|Withdrawal by Subject|2
6145840|NCT01073930|9780349|FG000|Overall Study|Lost to Follow-up|0
6145841|NCT01073930|9780350|FG001|Overall Study|Lost to Follow-up|1
6145842|NCT01073930|9780349|FG000|Overall Study|Adverse Event|0
6145843|NCT01073930|9780350|FG001|Overall Study|Adverse Event|1
6145844|NCT01073930|9780349|FG000|Overall Study|Noncompliance with study drug|0
6145845|NCT01073930|9780350|FG001|Overall Study|Noncompliance with study drug|1
6145846|NCT01073930|9780349|FG000|Overall Study|Inadequate prep; unable to do procedure|0
6145847|NCT01073930|9780350|FG001|Overall Study|Inadequate prep; unable to do procedure|1
6226202|NCT01708915|9898655|FG003|Overall Study|Adverse Event|13
6226203|NCT01708915|9898652|FG000|Overall Study|Lack of Efficacy|84
6226204|NCT01708915|9898653|FG001|Overall Study|Lack of Efficacy|60
6226205|NCT01708915|9898654|FG002|Overall Study|Lack of Efficacy|35
6226206|NCT01708915|9898655|FG003|Overall Study|Lack of Efficacy|15
6226207|NCT01708915|9898652|FG000|Overall Study|Protocol Violation|0
6226208|NCT01708915|9898653|FG001|Overall Study|Protocol Violation|0
6226209|NCT01708915|9898654|FG002|Overall Study|Protocol Violation|0
6226210|NCT01708915|9898655|FG003|Overall Study|Protocol Violation|1
6226211|NCT01708915|9898652|FG000|Overall Study|Withdrawal by Subject|0
6226212|NCT01708915|9898653|FG001|Overall Study|Withdrawal by Subject|1
6226213|NCT01708915|9898654|FG002|Overall Study|Withdrawal by Subject|2
6226214|NCT01708915|9898655|FG003|Overall Study|Withdrawal by Subject|2
6226215|NCT01708915|9898652|FG000|Overall Study|Other reasons than stated above|1
6226216|NCT01708915|9898653|FG001|Overall Study|Other reasons than stated above|1
6226217|NCT01708915|9898654|FG002|Overall Study|Other reasons than stated above|0
6226218|NCT01708915|9898655|FG003|Overall Study|Other reasons than stated above|2
6226219|NCT01709084|9898681|FG000|Overall Study|Lost to Follow-up|4
6226220|NCT01709084|9898682|FG001|Overall Study|Lost to Follow-up|7
6226221|NCT01709084|9898681|FG000|Overall Study|Withdrawal by Subject|2
6226222|NCT01709084|9898682|FG001|Overall Study|Withdrawal by Subject|2
6226223|NCT01709084|9898681|FG000|Overall Study|Adverse Event|5
6226224|NCT01709084|9898682|FG001|Overall Study|Adverse Event|0
6226225|NCT01709084|9898681|FG000|Overall Study|Other|5
6226226|NCT01709084|9898682|FG001|Overall Study|Other|3
6226227|NCT01709084|9898681|FG000|Overall Study|Participant Reached a Virologic Endpoint|0
6226228|NCT01709084|9898682|FG001|Overall Study|Participant Reached a Virologic Endpoint|1
6226229|NCT01709084|9898681|FG000|Overall Study|Not Treated|0
6226230|NCT01709084|9898682|FG001|Overall Study|Not Treated|2
6226231|NCT01709110|9898690|FG000|Overall Study|Adverse Event|56
6226232|NCT01709110|9898691|FG001|Overall Study|Adverse Event|48
6226233|NCT01709110|9898690|FG000|Overall Study|Death|14
6226234|NCT01709110|9898691|FG001|Overall Study|Death|6
6226235|NCT01709110|9898690|FG000|Overall Study|Lost to Follow-up|7
6226236|NCT01709110|9898691|FG001|Overall Study|Lost to Follow-up|5
6226237|NCT01709110|9898690|FG000|Overall Study|Protocol Violation|4
6226238|NCT01709110|9898691|FG001|Overall Study|Protocol Violation|6
6226239|NCT01709110|9898690|FG000|Overall Study|Withdrawal by Subject|96
6226240|NCT01709110|9898691|FG001|Overall Study|Withdrawal by Subject|89
6226241|NCT01709110|9898690|FG000|Overall Study|Physician Decision|4
6226242|NCT01709110|9898691|FG001|Overall Study|Physician Decision|10
6226243|NCT01709110|9898690|FG000|Overall Study|Sponsor Decision|2
6226244|NCT01709110|9898691|FG001|Overall Study|Sponsor Decision|2
6226245|NCT01709110|9898690|FG000|Overall Study|Lack of Efficacy|1
6226246|NCT01709110|9898691|FG001|Overall Study|Lack of Efficacy|1
6226247|NCT01709110|9898690|FG000|Overall Study|Caregiver Decision|1
6226248|NCT01709110|9898691|FG001|Overall Study|Caregiver Decision|1
6226249|NCT01709149|9898700|FG000|Open-label Lead-in Phase|Adverse Event|109
6226250|NCT01709149|9898701|FG001|Open-label Lead-in Phase|Adverse Event|0
6226251|NCT01709149|9898702|FG002|Open-label Lead-in Phase|Adverse Event|0
6226252|NCT01709149|9898700|FG000|Open-label Lead-in Phase|Withdrawal by Subject|2
6226253|NCT01709149|9898701|FG001|Open-label Lead-in Phase|Withdrawal by Subject|0
6226254|NCT01709149|9898702|FG002|Open-label Lead-in Phase|Withdrawal by Subject|0
6226255|NCT01709149|9898700|FG000|Open-label Lead-in Phase|Death|1
6226256|NCT01709149|9898701|FG001|Open-label Lead-in Phase|Death|0
6226257|NCT01709149|9898702|FG002|Open-label Lead-in Phase|Death|0
6226258|NCT01709149|9898700|FG000|Open-label Lead-in Phase|Protocol Violation|3
6226259|NCT01709149|9898701|FG001|Open-label Lead-in Phase|Protocol Violation|0
6226260|NCT01709149|9898702|FG002|Open-label Lead-in Phase|Protocol Violation|0
6226261|NCT01709149|9898700|FG000|Double-blind, Placebo-controlled Phase|Adverse Event|0
6226262|NCT01709149|9898701|FG001|Double-blind, Placebo-controlled Phase|Adverse Event|12
6226263|NCT01709149|9898702|FG002|Double-blind, Placebo-controlled Phase|Adverse Event|78
6226264|NCT01709149|9898700|FG000|Double-blind, Placebo-controlled Phase|Withdrawal by Subject|0
6226265|NCT01709149|9898701|FG001|Double-blind, Placebo-controlled Phase|Withdrawal by Subject|7
6226266|NCT01709149|9898702|FG002|Double-blind, Placebo-controlled Phase|Withdrawal by Subject|12
6226267|NCT01709149|9898700|FG000|Double-blind, Placebo-controlled Phase|Physician Decision|0
6226268|NCT01709149|9898701|FG001|Double-blind, Placebo-controlled Phase|Physician Decision|2
6226269|NCT01709149|9898702|FG002|Double-blind, Placebo-controlled Phase|Physician Decision|5
6226270|NCT01709149|9898700|FG000|Double-blind, Placebo-controlled Phase|Death|0
6226271|NCT01709149|9898701|FG001|Double-blind, Placebo-controlled Phase|Death|2
6226272|NCT01709149|9898702|FG002|Double-blind, Placebo-controlled Phase|Death|0
6226273|NCT01709149|9898700|FG000|Double-blind, Placebo-controlled Phase|not defined|0
6226274|NCT01709149|9898701|FG001|Double-blind, Placebo-controlled Phase|not defined|1
6269508|NCT02141659|9969863|FG001|Overall Study|Major Protocol Deviation|1
6145848|NCT01073943|9780358|FG000|Overall Study|Withdrawal by Subject|8
6145849|NCT01073943|9780359|FG001|Overall Study|Withdrawal by Subject|2
6145850|NCT01073943|9780358|FG000|Overall Study|Protocol Violation|2
6145851|NCT01073943|9780359|FG001|Overall Study|Protocol Violation|1
6145852|NCT01073943|9780358|FG000|Overall Study|Adverse Event|1
6145853|NCT01073943|9780359|FG001|Overall Study|Adverse Event|1
6145854|NCT01073943|9780358|FG000|Overall Study|Lost to Follow-up|0
6145855|NCT01073943|9780359|FG001|Overall Study|Lost to Follow-up|2
6145856|NCT01073943|9780358|FG000|Overall Study|Power outage; colonoscopy not done|1
6145857|NCT01073943|9780359|FG001|Overall Study|Power outage; colonoscopy not done|0
6145858|NCT01073943|9780358|FG000|Overall Study|Subject forgot|0
6145859|NCT01073943|9780359|FG001|Overall Study|Subject forgot|1
6145860|NCT01073943|9780358|FG000|Overall Study|Unable to return for follow-up|0
6145861|NCT01073943|9780359|FG001|Overall Study|Unable to return for follow-up|1
6145862|NCT01073943|9780358|FG000|Overall Study|Could not tolerate prep|1
6145863|NCT01073943|9780359|FG001|Overall Study|Could not tolerate prep|0
6145864|NCT01074008|9780374|FG000|Overall Study|Adverse Event|0
6145865|NCT01074008|9780375|FG001|Overall Study|Adverse Event|1
6145866|NCT01074008|9780376|FG002|Overall Study|Adverse Event|0
6145867|NCT01074008|9780377|FG003|Overall Study|Adverse Event|0
6145868|NCT01074008|9780378|FG004|Overall Study|Adverse Event|0
6145869|NCT01074008|9780379|FG005|Overall Study|Adverse Event|0
6145870|NCT01074008|9780380|FG006|Overall Study|Adverse Event|0
6145871|NCT01074008|9780381|FG007|Overall Study|Adverse Event|0
6145872|NCT01074008|9780382|FG008|Overall Study|Adverse Event|0
6145873|NCT01074008|9780374|FG000|Overall Study|Withdrawal by Subject|1
6145874|NCT01074008|9780375|FG001|Overall Study|Withdrawal by Subject|1
6145875|NCT01074008|9780376|FG002|Overall Study|Withdrawal by Subject|1
6145876|NCT01074008|9780377|FG003|Overall Study|Withdrawal by Subject|0
6145877|NCT01074008|9780378|FG004|Overall Study|Withdrawal by Subject|1
6145878|NCT01074008|9780379|FG005|Overall Study|Withdrawal by Subject|0
6145879|NCT01074008|9780380|FG006|Overall Study|Withdrawal by Subject|0
6145880|NCT01074008|9780381|FG007|Overall Study|Withdrawal by Subject|0
6145881|NCT01074008|9780382|FG008|Overall Study|Withdrawal by Subject|0
6145882|NCT01074008|9780374|FG000|Overall Study|Lost to Follow-up|0
6145883|NCT01074008|9780375|FG001|Overall Study|Lost to Follow-up|1
6145884|NCT01074008|9780376|FG002|Overall Study|Lost to Follow-up|1
6145885|NCT01074008|9780377|FG003|Overall Study|Lost to Follow-up|1
6145886|NCT01074008|9780378|FG004|Overall Study|Lost to Follow-up|1
6145887|NCT01074008|9780379|FG005|Overall Study|Lost to Follow-up|0
6145888|NCT01074008|9780380|FG006|Overall Study|Lost to Follow-up|1
6145889|NCT01074008|9780381|FG007|Overall Study|Lost to Follow-up|0
6145890|NCT01074008|9780382|FG008|Overall Study|Lost to Follow-up|4
6145891|NCT01074047|9780418|FG000|Treatment Phase|Adverse Event|89
6145892|NCT01074047|9780419|FG001|Treatment Phase|Adverse Event|66
6145893|NCT01074047|9780418|FG000|Treatment Phase|Disease Progression|16
6145894|NCT01074047|9780419|FG001|Treatment Phase|Disease Progression|21
6145895|NCT01074047|9780418|FG000|Treatment Phase|Withdrawal by Subject|27
6145896|NCT01074047|9780419|FG001|Treatment Phase|Withdrawal by Subject|48
6145897|NCT01074047|9780418|FG000|Treatment Phase|Death|53
6145898|NCT01074047|9780419|FG001|Treatment Phase|Death|58
6145899|NCT01074047|9780418|FG000|Treatment Phase|Lost to Follow-up|0
6145900|NCT01074047|9780419|FG001|Treatment Phase|Lost to Follow-up|1
6145901|NCT01074047|9780418|FG000|Treatment Phase|Protocol Violation|0
6145902|NCT01074047|9780419|FG001|Treatment Phase|Protocol Violation|1
6145903|NCT01074047|9780418|FG000|Treatment Phase|Miscellaneous|32
6145904|NCT01074047|9780419|FG001|Treatment Phase|Miscellaneous|39
6145905|NCT01074047|9780418|FG000|Survival Follow-Up Phase|Withdrawal by Subject|5
6145906|NCT01074047|9780419|FG001|Survival Follow-Up Phase|Withdrawal by Subject|8
6145907|NCT01074047|9780418|FG000|Survival Follow-Up Phase|Lost to Follow-up|2
6145908|NCT01074047|9780419|FG001|Survival Follow-Up Phase|Lost to Follow-up|1
6145909|NCT01074047|9780418|FG000|Survival Follow-Up Phase|Death|116
6145910|NCT01074047|9780419|FG001|Survival Follow-Up Phase|Death|124
6145911|NCT01074047|9780418|FG000|Survival Follow-Up Phase|Alive at study closure|1
6145912|NCT01074047|9780419|FG001|Survival Follow-Up Phase|Alive at study closure|3
6145913|NCT01074047|9780418|FG000|Extension Phase|Physician Decision|1
6145914|NCT01074047|9780419|FG001|Extension Phase|Physician Decision|0
6145915|NCT01074047|9780418|FG000|Extension Phase|Adverse Event|5
6145916|NCT01074047|9780419|FG001|Extension Phase|Adverse Event|0
6145917|NCT01074047|9780418|FG000|Extension Phase|Disease Progression|9
6145918|NCT01074047|9780419|FG001|Extension Phase|Disease Progression|0
6145919|NCT01074047|9780418|FG000|Extension Phase|Withdrawal by Subject|2
6145920|NCT01074047|9780419|FG001|Extension Phase|Withdrawal by Subject|0
6145921|NCT01074047|9780418|FG000|Extension Phase|Death|5
6145922|NCT01074047|9780419|FG001|Extension Phase|Death|0
6145923|NCT01074216|9780470|FG000|Overall Study|Physician Decision|1
6145924|NCT01074216|9780470|FG000|Overall Study|Not Treated|12
6145925|NCT01074229|9780477|FG000|Overall Study|Lost to Follow-up|1
6145926|NCT01074229|9780478|FG001|Overall Study|Lost to Follow-up|0
6145927|NCT01074229|9780479|FG002|Overall Study|Lost to Follow-up|0
6145928|NCT01074229|9780477|FG000|Overall Study|Change to open surgical procedure|1
6145929|NCT01074229|9780478|FG001|Overall Study|Change to open surgical procedure|3
6145930|NCT01074229|9780479|FG002|Overall Study|Change to open surgical procedure|4
6145931|NCT01074242|9780489|FG000|Overall Study|Case report before date of contract|40
6145932|NCT01074242|9780489|FG000|Overall Study|Lost to Follow-up|1
6145933|NCT01074242|9780489|FG000|Overall Study|Case report unclear|6
6145934|NCT01074242|9780489|FG000|Overall Study|Violation of vaccine dose or dosage|351
6145935|NCT01074242|9780489|FG000|Overall Study|Duplicate Case Report Form|5
6145936|NCT01074255|9780493|FG000|Overall Study|Did not receive EMEND|2
6145937|NCT01074268|9780499|FG000|Main: Week 0 to 26 (NN1250-3585)|Adverse Event|3
6145938|NCT01074268|9780500|FG001|Main: Week 0 to 26 (NN1250-3585)|Adverse Event|1
6145939|NCT01074268|9780499|FG000|Main: Week 0 to 26 (NN1250-3585)|Lack of Efficacy|0
6226275|NCT01709149|9898702|FG002|Double-blind, Placebo-controlled Phase|not defined|2
6226276|NCT01709149|9898700|FG000|Double-blind, Placebo-controlled Phase|Lost to Follow-up|0
6226277|NCT01709149|9898701|FG001|Double-blind, Placebo-controlled Phase|Lost to Follow-up|2
6226278|NCT01709149|9898702|FG002|Double-blind, Placebo-controlled Phase|Lost to Follow-up|0
6226279|NCT01709162|9898711|FG000|Overall Study|Disease progression|3
6226280|NCT01709162|9898712|FG001|Overall Study|Disease progression|3
6226281|NCT01709162|9898711|FG000|Overall Study|Study drug toxicity|2
6226282|NCT01709162|9898712|FG001|Overall Study|Study drug toxicity|0
6226283|NCT01709162|9898711|FG000|Overall Study|Administrative reason by sponsor|0
6226284|NCT01709162|9898712|FG001|Overall Study|Administrative reason by sponsor|1
6226285|NCT01709162|9898711|FG000|Overall Study|Other|1
6226286|NCT01709162|9898712|FG001|Overall Study|Other|0
6226287|NCT01709162|9898711|FG000|Overall Study|Withdrawal by Subject|0
6226288|NCT01709162|9898712|FG001|Overall Study|Withdrawal by Subject|1
6226289|NCT01709227|9898720|FG000|Overall Study|Physician Decision|1
6226290|NCT01709227|9898721|FG001|Overall Study|Physician Decision|0
6226291|NCT01709227|9898720|FG000|Overall Study|Pleural Peritoneal communication|0
6226292|NCT01709227|9898721|FG001|Overall Study|Pleural Peritoneal communication|9
6226293|NCT01709305|9898728|FG000|Phase 1|Clinical Adverse Event|80
6226294|NCT01709305|9898729|FG001|Phase 1|Clinical Adverse Event|0
6226295|NCT01709305|9898730|FG002|Phase 1|Clinical Adverse Event|0
6226296|NCT01709305|9898731|FG003|Phase 1|Clinical Adverse Event|0
6226297|NCT01709305|9898732|FG004|Phase 1|Clinical Adverse Event|0
6226298|NCT01709305|9898728|FG000|Phase 1|Death|2
6226299|NCT01709305|9898729|FG001|Phase 1|Death|0
6226300|NCT01709305|9898730|FG002|Phase 1|Death|0
6226301|NCT01709305|9898731|FG003|Phase 1|Death|0
6226302|NCT01709305|9898732|FG004|Phase 1|Death|0
6226303|NCT01709305|9898728|FG000|Phase 1|Hyperglycemia (lack of efficacy)|13
6226304|NCT01709305|9898729|FG001|Phase 1|Hyperglycemia (lack of efficacy)|0
6226305|NCT01709305|9898730|FG002|Phase 1|Hyperglycemia (lack of efficacy)|0
6226306|NCT01709305|9898731|FG003|Phase 1|Hyperglycemia (lack of efficacy)|0
6226307|NCT01709305|9898732|FG004|Phase 1|Hyperglycemia (lack of efficacy)|0
6226308|NCT01709305|9898728|FG000|Phase 1|Laboratory Adverse Event|16
6226309|NCT01709305|9898729|FG001|Phase 1|Laboratory Adverse Event|0
6226310|NCT01709305|9898730|FG002|Phase 1|Laboratory Adverse Event|0
6226311|NCT01709305|9898731|FG003|Phase 1|Laboratory Adverse Event|0
6226312|NCT01709305|9898732|FG004|Phase 1|Laboratory Adverse Event|0
6226313|NCT01709305|9898728|FG000|Phase 1|Lost to Follow-up|147
6226314|NCT01709305|9898729|FG001|Phase 1|Lost to Follow-up|0
6226315|NCT01709305|9898730|FG002|Phase 1|Lost to Follow-up|0
6226316|NCT01709305|9898731|FG003|Phase 1|Lost to Follow-up|0
6226317|NCT01709305|9898732|FG004|Phase 1|Lost to Follow-up|0
6226318|NCT01709305|9898728|FG000|Phase 1|Travel, moving, etc.|30
6226319|NCT01709305|9898729|FG001|Phase 1|Travel, moving, etc.|0
6226320|NCT01709305|9898730|FG002|Phase 1|Travel, moving, etc.|0
6226321|NCT01709305|9898731|FG003|Phase 1|Travel, moving, etc.|0
6226322|NCT01709305|9898732|FG004|Phase 1|Travel, moving, etc.|0
6226323|NCT01709305|9898728|FG000|Phase 1|Physician Decision|13
6226324|NCT01709305|9898729|FG001|Phase 1|Physician Decision|0
6226325|NCT01709305|9898730|FG002|Phase 1|Physician Decision|0
6226326|NCT01709305|9898731|FG003|Phase 1|Physician Decision|0
6226327|NCT01709305|9898732|FG004|Phase 1|Physician Decision|0
6226328|NCT01709305|9898728|FG000|Phase 1|Protocol Violation|118
6226329|NCT01709305|9898729|FG001|Phase 1|Protocol Violation|0
6226330|NCT01709305|9898730|FG002|Phase 1|Protocol Violation|0
6226331|NCT01709305|9898731|FG003|Phase 1|Protocol Violation|0
6226332|NCT01709305|9898732|FG004|Phase 1|Protocol Violation|0
6226333|NCT01709305|9898728|FG000|Phase 1|Withdrawal by Subject|218
6226334|NCT01709305|9898729|FG001|Phase 1|Withdrawal by Subject|0
6226335|NCT01709305|9898730|FG002|Phase 1|Withdrawal by Subject|0
6226336|NCT01709305|9898731|FG003|Phase 1|Withdrawal by Subject|0
6226337|NCT01709305|9898732|FG004|Phase 1|Withdrawal by Subject|0
6226338|NCT01709305|9898728|FG000|Phase 2|Clinical Adverse Event|0
6226339|NCT01709305|9898729|FG001|Phase 2|Clinical Adverse Event|10
6226340|NCT01709305|9898730|FG002|Phase 2|Clinical Adverse Event|10
6226341|NCT01709305|9898731|FG003|Phase 2|Clinical Adverse Event|6
6226342|NCT01709305|9898732|FG004|Phase 2|Clinical Adverse Event|11
6226343|NCT01709305|9898728|FG000|Phase 2|Death|0
6226344|NCT01709305|9898729|FG001|Phase 2|Death|0
6226345|NCT01709305|9898730|FG002|Phase 2|Death|1
6226346|NCT01709305|9898731|FG003|Phase 2|Death|0
6226347|NCT01709305|9898732|FG004|Phase 2|Death|0
6226348|NCT01709305|9898728|FG000|Phase 2|Hyperglycemia (lack of efficacy)|0
6226349|NCT01709305|9898729|FG001|Phase 2|Hyperglycemia (lack of efficacy)|0
6226350|NCT01709305|9898730|FG002|Phase 2|Hyperglycemia (lack of efficacy)|0
6226351|NCT01709305|9898731|FG003|Phase 2|Hyperglycemia (lack of efficacy)|0
6226352|NCT01709305|9898732|FG004|Phase 2|Hyperglycemia (lack of efficacy)|2
6226353|NCT01709305|9898728|FG000|Phase 2|Laboratory Adverse Event|0
6145940|NCT01074268|9780500|FG001|Main: Week 0 to 26 (NN1250-3585)|Lack of Efficacy|2
6145941|NCT01074268|9780499|FG000|Main: Week 0 to 26 (NN1250-3585)|Protocol Violation|3
6145942|NCT01074268|9780500|FG001|Main: Week 0 to 26 (NN1250-3585)|Protocol Violation|4
6145943|NCT01074268|9780499|FG000|Main: Week 0 to 26 (NN1250-3585)|Withdrawal criteria|6
6145944|NCT01074268|9780500|FG001|Main: Week 0 to 26 (NN1250-3585)|Withdrawal criteria|3
6145945|NCT01074268|9780499|FG000|Main: Week 0 to 26 (NN1250-3585)|Unclassified|8
6145946|NCT01074268|9780500|FG001|Main: Week 0 to 26 (NN1250-3585)|Unclassified|5
6145947|NCT01074268|9780499|FG000|Extension: Week 27 to 52 (NN1250-3725)|Adverse Event|1
6145948|NCT01074268|9780500|FG001|Extension: Week 27 to 52 (NN1250-3725)|Adverse Event|1
6145949|NCT01074268|9780499|FG000|Extension: Week 27 to 52 (NN1250-3725)|Protocol Violation|0
6145950|NCT01074268|9780500|FG001|Extension: Week 27 to 52 (NN1250-3725)|Protocol Violation|2
6145951|NCT01074268|9780499|FG000|Extension: Week 27 to 52 (NN1250-3725)|Withdrawal criteria|2
6145952|NCT01074268|9780500|FG001|Extension: Week 27 to 52 (NN1250-3725)|Withdrawal criteria|2
6145953|NCT01074268|9780499|FG000|Extension: Week 27 to 52 (NN1250-3725)|Unclassified|3
6145954|NCT01074268|9780500|FG001|Extension: Week 27 to 52 (NN1250-3725)|Unclassified|2
6145955|NCT01074307|9780508|FG000|Overall Study|No primary endpoint evaluation|14
6145956|NCT01074307|9780509|FG001|Overall Study|No primary endpoint evaluation|6
6145957|NCT01074307|9780508|FG000|Overall Study|Exclusion criterion|0
6145958|NCT01074307|9780509|FG001|Overall Study|Exclusion criterion|1
6145959|NCT01074307|9780508|FG000|Overall Study|Protocol Violation|8
6145960|NCT01074307|9780509|FG001|Overall Study|Protocol Violation|5
6145961|NCT01074450|9780517|FG000|First Intervention|Emesis in Dosing Interval|0
6145962|NCT01074450|9780518|FG001|First Intervention|Emesis in Dosing Interval|2
6145963|NCT01074450|9780517|FG000|Second Intervention|Protocol Violation|1
6145964|NCT01074450|9780518|FG001|Second Intervention|Protocol Violation|0
6145965|NCT01074450|9780517|FG000|Second Intervention|Physician Decision|0
6145966|NCT01074450|9780518|FG001|Second Intervention|Physician Decision|1
6145967|NCT01074554|9780535|FG000|Overall Study|Adverse Event|3
6145968|NCT01074554|9780536|FG001|Overall Study|Adverse Event|3
6145969|NCT01074554|9780535|FG000|Overall Study|Lost to Follow-up|0
6145970|NCT01074554|9780536|FG001|Overall Study|Lost to Follow-up|1
6145971|NCT01074658|9780542|FG000|Overall Study|No implant attempted|19
6145972|NCT01074931|9780546|FG000|Overall Study|Economic reasons|1
6145973|NCT01074931|9780546|FG000|Overall Study|Death|5
6145974|NCT01074944|9780554|FG000|Lead-in Period (up to 78 Weeks)|Adverse Event|2
6145975|NCT01074944|9780555|FG001|Lead-in Period (up to 78 Weeks)|Adverse Event|0
6145976|NCT01074944|9780556|FG002|Lead-in Period (up to 78 Weeks)|Adverse Event|0
6145977|NCT01074944|9780557|FG003|Lead-in Period (up to 78 Weeks)|Adverse Event|0
6145978|NCT01074944|9780558|FG004|Lead-in Period (up to 78 Weeks)|Adverse Event|0
6145979|NCT01074944|9780554|FG000|Lead-in Period (up to 78 Weeks)|Non-Compliance With Protocol|1
6145980|NCT01074944|9780555|FG001|Lead-in Period (up to 78 Weeks)|Non-Compliance With Protocol|0
6145981|NCT01074944|9780556|FG002|Lead-in Period (up to 78 Weeks)|Non-Compliance With Protocol|0
6145982|NCT01074944|9780557|FG003|Lead-in Period (up to 78 Weeks)|Non-Compliance With Protocol|0
6145983|NCT01074944|9780558|FG004|Lead-in Period (up to 78 Weeks)|Non-Compliance With Protocol|0
6145984|NCT01074944|9780554|FG000|Lead-in Period (up to 78 Weeks)|Pregnancy|4
6145985|NCT01074944|9780555|FG001|Lead-in Period (up to 78 Weeks)|Pregnancy|0
6145986|NCT01074944|9780556|FG002|Lead-in Period (up to 78 Weeks)|Pregnancy|0
6145987|NCT01074944|9780557|FG003|Lead-in Period (up to 78 Weeks)|Pregnancy|0
6145988|NCT01074944|9780558|FG004|Lead-in Period (up to 78 Weeks)|Pregnancy|0
6145989|NCT01074944|9780554|FG000|Lead-in Period (up to 78 Weeks)|Withdrawal by Subject|6
6145990|NCT01074944|9780555|FG001|Lead-in Period (up to 78 Weeks)|Withdrawal by Subject|0
6145991|NCT01074944|9780556|FG002|Lead-in Period (up to 78 Weeks)|Withdrawal by Subject|0
6145992|NCT01074944|9780557|FG003|Lead-in Period (up to 78 Weeks)|Withdrawal by Subject|0
6145993|NCT01074944|9780558|FG004|Lead-in Period (up to 78 Weeks)|Withdrawal by Subject|0
6226354|NCT01709305|9898729|FG001|Phase 2|Laboratory Adverse Event|1
6226355|NCT01709305|9898730|FG002|Phase 2|Laboratory Adverse Event|0
6226356|NCT01709305|9898731|FG003|Phase 2|Laboratory Adverse Event|1
6226357|NCT01709305|9898732|FG004|Phase 2|Laboratory Adverse Event|1
6226358|NCT01709305|9898728|FG000|Phase 2|Lost to Follow-up|0
6226359|NCT01709305|9898729|FG001|Phase 2|Lost to Follow-up|10
6226360|NCT01709305|9898730|FG002|Phase 2|Lost to Follow-up|6
6226361|NCT01709305|9898731|FG003|Phase 2|Lost to Follow-up|9
6226362|NCT01709305|9898732|FG004|Phase 2|Lost to Follow-up|5
6226363|NCT01709305|9898728|FG000|Phase 2|Travel, moving, etc.|0
6226364|NCT01709305|9898729|FG001|Phase 2|Travel, moving, etc.|2
6226365|NCT01709305|9898730|FG002|Phase 2|Travel, moving, etc.|3
6226366|NCT01709305|9898731|FG003|Phase 2|Travel, moving, etc.|3
6226367|NCT01709305|9898732|FG004|Phase 2|Travel, moving, etc.|5
6226368|NCT01709305|9898728|FG000|Phase 2|Physician Decision|0
6226369|NCT01709305|9898729|FG001|Phase 2|Physician Decision|2
6226370|NCT01709305|9898730|FG002|Phase 2|Physician Decision|0
6226371|NCT01709305|9898731|FG003|Phase 2|Physician Decision|1
6226372|NCT01709305|9898732|FG004|Phase 2|Physician Decision|2
6226373|NCT01709305|9898728|FG000|Phase 2|Protocol Violation|0
6226374|NCT01709305|9898729|FG001|Phase 2|Protocol Violation|19
6226375|NCT01709305|9898730|FG002|Phase 2|Protocol Violation|19
6226376|NCT01709305|9898731|FG003|Phase 2|Protocol Violation|13
6226377|NCT01709305|9898732|FG004|Phase 2|Protocol Violation|9
6226378|NCT01709305|9898728|FG000|Phase 2|Withdrawal by Subject|0
6226379|NCT01709305|9898729|FG001|Phase 2|Withdrawal by Subject|8
6226380|NCT01709305|9898730|FG002|Phase 2|Withdrawal by Subject|6
6226381|NCT01709305|9898731|FG003|Phase 2|Withdrawal by Subject|15
6226382|NCT01709305|9898732|FG004|Phase 2|Withdrawal by Subject|12
6226383|NCT01709383|9898749|FG000|Overall Study|Lost to Follow-up|1
6226384|NCT01709383|9898750|FG001|Overall Study|Lost to Follow-up|0
6226385|NCT01709409|9898760|FG000|Overall Study|Protocol Violation|1
6226386|NCT01709409|9898761|FG001|Overall Study|Protocol Violation|0
6226387|NCT01709500|9898789|FG000|Overall Study|Randomized but not treated|0
6226388|NCT01709500|9898790|FG001|Overall Study|Randomized but not treated|1
6226389|NCT01709500|9898789|FG000|Overall Study|Adverse Event|5
6226390|NCT01709500|9898790|FG001|Overall Study|Adverse Event|1
6226391|NCT01709500|9898789|FG000|Overall Study|Poor compliance to protocol|2
6226392|NCT01709500|9898790|FG001|Overall Study|Poor compliance to protocol|1
6226393|NCT01709500|9898789|FG000|Overall Study|Other|3
6226394|NCT01709500|9898790|FG001|Overall Study|Other|1
6226395|NCT01709500|9898789|FG000|Overall Study|Related to IMP administration|1
6226396|NCT01709500|9898790|FG001|Overall Study|Related to IMP administration|0
6226397|NCT01709500|9898789|FG000|Overall Study|Treatment ongoing|156
6226398|NCT01709500|9898790|FG001|Overall Study|Treatment ongoing|78
6226399|NCT01709513|9898799|FG000|Overall Study|Randomized but not treated|0
6226400|NCT01709513|9898800|FG001|Overall Study|Randomized but not treated|1
6226401|NCT01709513|9898801|FG002|Overall Study|Randomized but not treated|0
6226402|NCT01709513|9898799|FG000|Overall Study|Adverse Event|16
6226403|NCT01709513|9898800|FG001|Overall Study|Adverse Event|31
6226404|NCT01709513|9898801|FG002|Overall Study|Adverse Event|23
6226405|NCT01709513|9898799|FG000|Overall Study|Poor compliance to protocol|2
6226406|NCT01709513|9898800|FG001|Overall Study|Poor compliance to protocol|0
6226407|NCT01709513|9898801|FG002|Overall Study|Poor compliance to protocol|0
6226408|NCT01709513|9898799|FG000|Overall Study|Other|3
6226409|NCT01709513|9898800|FG001|Overall Study|Other|11
6226410|NCT01709513|9898801|FG002|Overall Study|Other|7
6226411|NCT01709578|9898815|FG000|Overall Study|Rescued and entered in long term safety|63
6226412|NCT01709578|9898816|FG001|Overall Study|Rescued and entered in long term safety|25
6226413|NCT01709578|9898817|FG002|Overall Study|Rescued and entered in long term safety|26
6226414|NCT01709578|9898815|FG000|Overall Study|Adverse Event|9
6226415|NCT01709578|9898816|FG001|Overall Study|Adverse Event|18
6226416|NCT01709578|9898817|FG002|Overall Study|Adverse Event|17
6226417|NCT01709578|9898815|FG000|Overall Study|Lack of Efficacy|5
6226418|NCT01709578|9898816|FG001|Overall Study|Lack of Efficacy|4
6226419|NCT01709578|9898817|FG002|Overall Study|Lack of Efficacy|2
6226420|NCT01709578|9898815|FG000|Overall Study|Poor compliance to protocol|1
6226421|NCT01709578|9898816|FG001|Overall Study|Poor compliance to protocol|2
6226422|NCT01709578|9898817|FG002|Overall Study|Poor compliance to protocol|1
6226423|NCT01709578|9898815|FG000|Overall Study|Other, not related to safety or efficacy|2
6226424|NCT01709578|9898816|FG001|Overall Study|Other, not related to safety or efficacy|7
6226425|NCT01709578|9898817|FG002|Overall Study|Other, not related to safety or efficacy|5
6226426|NCT01709695|9898827|FG000|Overall Study|Withdrawal by Subject|1
6226427|NCT01709695|9898828|FG001|Overall Study|Withdrawal by Subject|1
6226428|NCT01709708|9898836|FG000|Overall Study|Protocol Violation|1
6226429|NCT01709708|9898837|FG001|Overall Study|Protocol Violation|2
6306817|NCT02594163|10033061|FG001|Follow-up Period|Study Termination by Sponsor|4
6306818|NCT02594163|10033060|FG000|Follow-up Period|Lost to Follow-up|1
6306819|NCT02594163|10033061|FG001|Follow-up Period|Lost to Follow-up|0
6306820|NCT02594163|10033060|FG000|Follow-up Period|Death|2
6306821|NCT02594163|10033061|FG001|Follow-up Period|Death|5
6306822|NCT02594163|10033060|FG000|Follow-up Period|Adverse Event|0
6306823|NCT02594163|10033061|FG001|Follow-up Period|Adverse Event|1
6306824|NCT02594163|10033060|FG000|Follow-up Period|Progressive Disease|2
6306825|NCT02594163|10033061|FG001|Follow-up Period|Progressive Disease|0
6306826|NCT02594163|10033060|FG000|Follow-up Period|Physician Decision|0
6306827|NCT02594163|10033061|FG001|Follow-up Period|Physician Decision|1
6306828|NCT02595008|10033097|FG000|Overall Study|Enrolled In Error|1
6306829|NCT02595008|10033098|FG001|Overall Study|Enrolled In Error|0
6306830|NCT02595073|10033106|FG000|Overall Study|Progressive Disease|0
6306831|NCT02595073|10033107|FG001|Overall Study|Progressive Disease|1
6306832|NCT02595073|10033106|FG000|Overall Study|Protocol Violation|2
6306833|NCT02595073|10033107|FG001|Overall Study|Protocol Violation|0
6306834|NCT02595398|10033115|FG000|Overall Study|Non-compliance|1
6306835|NCT02595398|10033116|FG001|Overall Study|Non-compliance|0
6306836|NCT02595398|10033115|FG000|Overall Study|Withdrawal by Subject|2
6306837|NCT02595398|10033116|FG001|Overall Study|Withdrawal by Subject|1
6226430|NCT01709721|9898847|FG000|Open Label Phase|Withdrawal by Subject|0
6226431|NCT01709721|9898848|FG001|Open Label Phase|Withdrawal by Subject|0
6226432|NCT01709721|9898849|FG002|Open Label Phase|Withdrawal by Subject|5
6226433|NCT01709721|9898847|FG000|Open Label Phase|Adverse Event|0
6226434|NCT01709721|9898848|FG001|Open Label Phase|Adverse Event|0
6226435|NCT01709721|9898849|FG002|Open Label Phase|Adverse Event|8
6226436|NCT01709721|9898847|FG000|Open Label Phase|Non-compliance With Study Drug|0
6226437|NCT01709721|9898848|FG001|Open Label Phase|Non-compliance With Study Drug|0
6226438|NCT01709721|9898849|FG002|Open Label Phase|Non-compliance With Study Drug|3
6226439|NCT01709721|9898847|FG000|Open Label Phase|Investigator Decision|0
6226440|NCT01709721|9898848|FG001|Open Label Phase|Investigator Decision|0
6226441|NCT01709721|9898849|FG002|Open Label Phase|Investigator Decision|1
6226442|NCT01709721|9898847|FG000|Open Label Phase|Sponsor Decision|0
6226443|NCT01709721|9898848|FG001|Open Label Phase|Sponsor Decision|0
6226444|NCT01709721|9898849|FG002|Open Label Phase|Sponsor Decision|2
6226445|NCT01709721|9898847|FG000|Open Label Phase|Protocol Violation|0
6226446|NCT01709721|9898848|FG001|Open Label Phase|Protocol Violation|0
6226447|NCT01709721|9898849|FG002|Open Label Phase|Protocol Violation|1
6226448|NCT01709721|9898847|FG000|Open Label Phase|Changes In The Subject's Condition Render The Subject Unacceptable For Further Treatment|0
6226449|NCT01709721|9898848|FG001|Open Label Phase|Changes In The Subject's Condition Render The Subject Unacceptable For Further Treatment|0
6226450|NCT01709721|9898849|FG002|Open Label Phase|Changes In The Subject's Condition Render The Subject Unacceptable For Further Treatment|1
6226451|NCT01709721|9898847|FG000|Open Label Phase|Inadequate Pain Control|0
6226452|NCT01709721|9898848|FG001|Open Label Phase|Inadequate Pain Control|0
6226453|NCT01709721|9898849|FG002|Open Label Phase|Inadequate Pain Control|37
6226454|NCT01709721|9898847|FG000|Open Label Phase|Other, Specify in text field in database|0
6226455|NCT01709721|9898848|FG001|Open Label Phase|Other, Specify in text field in database|0
6226456|NCT01709721|9898849|FG002|Open Label Phase|Other, Specify in text field in database|14
6226457|NCT01709721|9898847|FG000|Randomized Phase|Adverse Event|0
6226458|NCT01709721|9898848|FG001|Randomized Phase|Adverse Event|1
6226459|NCT01709721|9898849|FG002|Randomized Phase|Adverse Event|0
6226460|NCT01709721|9898847|FG000|Randomized Phase|Lost to Follow-up|1
6226461|NCT01709721|9898848|FG001|Randomized Phase|Lost to Follow-up|0
6226462|NCT01709721|9898849|FG002|Randomized Phase|Lost to Follow-up|0
6226463|NCT01709721|9898847|FG000|Randomized Phase|Inadequate Pain Control|1
6226464|NCT01709721|9898848|FG001|Randomized Phase|Inadequate Pain Control|2
6226465|NCT01709721|9898849|FG002|Randomized Phase|Inadequate Pain Control|0
6226466|NCT01709721|9898847|FG000|Randomized Phase|Other, Specify text field in database|1
6226467|NCT01709721|9898848|FG001|Randomized Phase|Other, Specify text field in database|3
6226468|NCT01709721|9898849|FG002|Randomized Phase|Other, Specify text field in database|0
6226469|NCT01709838|9898881|FG000|Overall Study|Withdrawal by Subject|21
6226470|NCT01709838|9898881|FG000|Overall Study|Lost to Follow-up|16
6226471|NCT01709838|9898881|FG000|Overall Study|Pregnancy|10
6226472|NCT01709838|9898881|FG000|Overall Study|Subject/guardian decision|8
6226473|NCT01709838|9898881|FG000|Overall Study|Adverse Event|4
6226474|NCT01709838|9898881|FG000|Overall Study|Physician Decision|4
6226475|NCT01709838|9898881|FG000|Overall Study|Death|3
6226476|NCT01709838|9898881|FG000|Overall Study|Protocol Violation|1
6226477|NCT01709864|9898889|FG000|Overall Study|Physician Decision|0
6226478|NCT01709864|9898890|FG001|Overall Study|Physician Decision|1
6226479|NCT01709864|9898889|FG000|Overall Study|subject/guardian decision|5
6226480|NCT01709864|9898890|FG001|Overall Study|subject/guardian decision|6
6226481|NCT01709864|9898889|FG000|Overall Study|Lost to Follow-up|1
6226482|NCT01709864|9898890|FG001|Overall Study|Lost to Follow-up|0
6226483|NCT01709864|9898889|FG000|Overall Study|non-compliance with study treatment|1
6226484|NCT01709864|9898890|FG001|Overall Study|non-compliance with study treatment|1
6226485|NCT01709864|9898889|FG000|Overall Study|Adverse Event|0
6226486|NCT01709864|9898890|FG001|Overall Study|Adverse Event|2
6226487|NCT01709864|9898889|FG000|Overall Study|Death|0
6226488|NCT01709864|9898890|FG001|Overall Study|Death|1
5983232|NCT00440531|9572955|FG002|Overall Study|Lost to Follow-up|5
5983233|NCT00440531|9572953|FG000|Overall Study|see pre-assignment details|2
5983234|NCT00440531|9572954|FG001|Overall Study|see pre-assignment details|0
6226489|NCT01709903|9898898|FG000|Overall Study|administrative problems|2
6226490|NCT01709903|9898899|FG001|Overall Study|administrative problems|6
6226491|NCT01709903|9898898|FG000|Overall Study|Abnormal test procedure results|1
6226492|NCT01709903|9898899|FG001|Overall Study|Abnormal test procedure results|0
6226493|NCT01709903|9898898|FG000|Overall Study|In ability to use device|1
6226494|NCT01709903|9898899|FG001|Overall Study|In ability to use device|1
6226495|NCT01709903|9898898|FG000|Overall Study|no longer needed study drug|0
6226496|NCT01709903|9898899|FG001|Overall Study|no longer needed study drug|1
6226497|NCT01709903|9898898|FG000|Overall Study|Lost to Follow-up|0
6226498|NCT01709903|9898899|FG001|Overall Study|Lost to Follow-up|2
6226499|NCT01709903|9898898|FG000|Overall Study|Death|2
6226500|NCT01709903|9898899|FG001|Overall Study|Death|0
6226501|NCT01709903|9898898|FG000|Overall Study|Protocol Violation|3
6226502|NCT01709903|9898899|FG001|Overall Study|Protocol Violation|2
6226503|NCT01709903|9898898|FG000|Overall Study|Lack of Efficacy|3
6226504|NCT01709903|9898899|FG001|Overall Study|Lack of Efficacy|3
6226505|NCT01709903|9898898|FG000|Overall Study|Withdrawal by Subject|6
6226506|NCT01709903|9898899|FG001|Overall Study|Withdrawal by Subject|6
6226507|NCT01709903|9898898|FG000|Overall Study|Adverse Event|11
6226508|NCT01709903|9898899|FG001|Overall Study|Adverse Event|18
6226509|NCT01710020|9898905|FG000|Period 1|Protocol Violation|1
6226510|NCT01710033|9898915|FG000|Stage 2|Adverse Event|0
6226511|NCT01710033|9898916|FG001|Stage 2|Adverse Event|0
6226512|NCT01710033|9898917|FG002|Stage 2|Adverse Event|0
6226513|NCT01710033|9898918|FG003|Stage 2|Adverse Event|0
6226514|NCT01710033|9898919|FG004|Stage 2|Adverse Event|1
6226515|NCT01710046|9898934|FG000|Overall Study|Lost to Follow-up|1
6226516|NCT01710046|9898935|FG001|Overall Study|Lost to Follow-up|0
6226517|NCT01710345|9898976|FG000|Overall Study|Adverse Event|0
6226518|NCT01710345|9898977|FG001|Overall Study|Adverse Event|2
6226519|NCT01710345|9898978|FG002|Overall Study|Adverse Event|0
6226520|NCT01710345|9898976|FG000|Overall Study|Lack of Efficacy|2
6226521|NCT01710345|9898977|FG001|Overall Study|Lack of Efficacy|3
6226522|NCT01710345|9898978|FG002|Overall Study|Lack of Efficacy|1
6226523|NCT01710345|9898976|FG000|Overall Study|Drug Dosing Error|1
6226524|NCT01710345|9898977|FG001|Overall Study|Drug Dosing Error|0
6226525|NCT01710345|9898978|FG002|Overall Study|Drug Dosing Error|0
6226526|NCT01710358|9898989|FG000|Treatment Period Part A (Weeks 0 to 24)|Adverse Event|15
6226527|NCT01710358|9898990|FG001|Treatment Period Part A (Weeks 0 to 24)|Adverse Event|18
6226528|NCT01710358|9898991|FG002|Treatment Period Part A (Weeks 0 to 24)|Adverse Event|7
6226529|NCT01710358|9898989|FG000|Treatment Period Part A (Weeks 0 to 24)|Death|0
6226530|NCT01710358|9898990|FG001|Treatment Period Part A (Weeks 0 to 24)|Death|2
6226531|NCT01710358|9898991|FG002|Treatment Period Part A (Weeks 0 to 24)|Death|0
6226532|NCT01710358|9898989|FG000|Treatment Period Part A (Weeks 0 to 24)|Entry Criteria Not Met|0
6226533|NCT01710358|9898990|FG001|Treatment Period Part A (Weeks 0 to 24)|Entry Criteria Not Met|1
6226534|NCT01710358|9898991|FG002|Treatment Period Part A (Weeks 0 to 24)|Entry Criteria Not Met|1
6226535|NCT01710358|9898989|FG000|Treatment Period Part A (Weeks 0 to 24)|Lack of Efficacy|15
6226536|NCT01710358|9898990|FG001|Treatment Period Part A (Weeks 0 to 24)|Lack of Efficacy|1
6226537|NCT01710358|9898991|FG002|Treatment Period Part A (Weeks 0 to 24)|Lack of Efficacy|3
6226538|NCT01710358|9898989|FG000|Treatment Period Part A (Weeks 0 to 24)|Lost to Follow-up|0
6226539|NCT01710358|9898990|FG001|Treatment Period Part A (Weeks 0 to 24)|Lost to Follow-up|1
6226540|NCT01710358|9898991|FG002|Treatment Period Part A (Weeks 0 to 24)|Lost to Follow-up|0
6306838|NCT02595398|10033115|FG000|Overall Study|Lost to Follow-up|1
6306839|NCT02595398|10033116|FG001|Overall Study|Lost to Follow-up|0
6306840|NCT02595437|10033122|FG000|Triferic Via IV|Withdrawal by Subject|1
6306841|NCT02595450|10033134|FG000|Overall Study|Unspecified (only completed 1 cycle)|73
6306842|NCT02595450|10033134|FG000|Overall Study|Enrolled, but not treated|8
6306843|NCT02595502|10033138|FG000|Period 1|Adverse Event|0
6306844|NCT02595502|10033139|FG001|Period 1|Adverse Event|1
6306845|NCT02595502|10033138|FG000|Period 1|Withdrawal by Subject|1
6306846|NCT02595502|10033139|FG001|Period 1|Withdrawal by Subject|0
6306847|NCT02595502|10033138|FG000|Period 1|Lost to Follow-up|0
6306848|NCT02595502|10033139|FG001|Period 1|Lost to Follow-up|1
6306849|NCT02595502|10033138|FG000|Period 2|Adverse Event|1
6306850|NCT02595502|10033139|FG001|Period 2|Adverse Event|1
6306851|NCT02595502|10033138|FG000|Period 2|Received incorrect lens at Period 1|0
6306852|NCT02595502|10033139|FG001|Period 2|Received incorrect lens at Period 1|1
6306853|NCT02595502|10033138|FG000|Period 3|Protocol Violation|0
6306854|NCT02595502|10033139|FG001|Period 3|Protocol Violation|1
6306855|NCT02595502|10033138|FG000|Period 3|Lost to Follow-up|1
6306856|NCT02595502|10033139|FG001|Period 3|Lost to Follow-up|0
6226541|NCT01710358|9898989|FG000|Treatment Period Part A (Weeks 0 to 24)|Physician Decision|1
6226542|NCT01710358|9898990|FG001|Treatment Period Part A (Weeks 0 to 24)|Physician Decision|0
6226543|NCT01710358|9898991|FG002|Treatment Period Part A (Weeks 0 to 24)|Physician Decision|0
6226544|NCT01710358|9898989|FG000|Treatment Period Part A (Weeks 0 to 24)|Sponsor Decision|4
6226545|NCT01710358|9898990|FG001|Treatment Period Part A (Weeks 0 to 24)|Sponsor Decision|0
6226546|NCT01710358|9898991|FG002|Treatment Period Part A (Weeks 0 to 24)|Sponsor Decision|0
6226547|NCT01710358|9898989|FG000|Treatment Period Part A (Weeks 0 to 24)|Withdrawal by Subject|15
6226548|NCT01710358|9898990|FG001|Treatment Period Part A (Weeks 0 to 24)|Withdrawal by Subject|5
6226549|NCT01710358|9898991|FG002|Treatment Period Part A (Weeks 0 to 24)|Withdrawal by Subject|12
6226550|NCT01710358|9898989|FG000|Treatment Period Part A (Weeks 0 to 24)|Randomized But Not Treated|1
6226551|NCT01710358|9898990|FG001|Treatment Period Part A (Weeks 0 to 24)|Randomized But Not Treated|1
6226552|NCT01710358|9898991|FG002|Treatment Period Part A (Weeks 0 to 24)|Randomized But Not Treated|0
6226553|NCT01710358|9898989|FG000|Treatment Period Part B (Weeks 24 to 52)|Adverse Event|10
6226554|NCT01710358|9898990|FG001|Treatment Period Part B (Weeks 24 to 52)|Adverse Event|16
6226555|NCT01710358|9898991|FG002|Treatment Period Part B (Weeks 24 to 52)|Adverse Event|5
6226556|NCT01710358|9898989|FG000|Treatment Period Part B (Weeks 24 to 52)|Death|1
6226557|NCT01710358|9898990|FG001|Treatment Period Part B (Weeks 24 to 52)|Death|0
6226558|NCT01710358|9898991|FG002|Treatment Period Part B (Weeks 24 to 52)|Death|1
6226559|NCT01710358|9898989|FG000|Treatment Period Part B (Weeks 24 to 52)|Lack of Efficacy|0
6226560|NCT01710358|9898990|FG001|Treatment Period Part B (Weeks 24 to 52)|Lack of Efficacy|0
6226561|NCT01710358|9898991|FG002|Treatment Period Part B (Weeks 24 to 52)|Lack of Efficacy|1
6226562|NCT01710358|9898989|FG000|Treatment Period Part B (Weeks 24 to 52)|Lost to Follow-up|0
6226563|NCT01710358|9898990|FG001|Treatment Period Part B (Weeks 24 to 52)|Lost to Follow-up|0
6226564|NCT01710358|9898991|FG002|Treatment Period Part B (Weeks 24 to 52)|Lost to Follow-up|1
6226565|NCT01710358|9898989|FG000|Treatment Period Part B (Weeks 24 to 52)|Physician Decision|0
6226566|NCT01710358|9898990|FG001|Treatment Period Part B (Weeks 24 to 52)|Physician Decision|1
6226567|NCT01710358|9898991|FG002|Treatment Period Part B (Weeks 24 to 52)|Physician Decision|0
6226568|NCT01710358|9898989|FG000|Treatment Period Part B (Weeks 24 to 52)|Sponsor Decision|1
6226569|NCT01710358|9898990|FG001|Treatment Period Part B (Weeks 24 to 52)|Sponsor Decision|2
6226570|NCT01710358|9898991|FG002|Treatment Period Part B (Weeks 24 to 52)|Sponsor Decision|0
6269509|NCT02141659|9969864|FG002|Overall Study|Major Protocol Deviation|0
6306857|NCT02595502|10033138|FG000|Period 3|Received Incorrect Treatment at period 3|0
6306858|NCT02595502|10033139|FG001|Period 3|Received Incorrect Treatment at period 3|1
6306859|NCT02595528|10033149|FG000|Overall Study|Withdrawal by Subject|1
6226571|NCT01710358|9898989|FG000|Treatment Period Part B (Weeks 24 to 52)|Withdrawal by Subject|4
6226572|NCT01710358|9898990|FG001|Treatment Period Part B (Weeks 24 to 52)|Withdrawal by Subject|3
6226573|NCT01710358|9898991|FG002|Treatment Period Part B (Weeks 24 to 52)|Withdrawal by Subject|7
6226574|NCT01710358|9898989|FG000|Rescue Period|Adverse Event|0
6226575|NCT01710358|9898990|FG001|Rescue Period|Adverse Event|15
6226576|NCT01710358|9898991|FG002|Rescue Period|Adverse Event|0
6226577|NCT01710358|9898989|FG000|Rescue Period|Death|0
6226578|NCT01710358|9898990|FG001|Rescue Period|Death|1
6226579|NCT01710358|9898991|FG002|Rescue Period|Death|0
6226580|NCT01710358|9898989|FG000|Rescue Period|Lack of Efficacy|0
6226581|NCT01710358|9898990|FG001|Rescue Period|Lack of Efficacy|7
6226582|NCT01710358|9898991|FG002|Rescue Period|Lack of Efficacy|0
6226583|NCT01710358|9898989|FG000|Rescue Period|Withdrawal by Subject|0
6226584|NCT01710358|9898990|FG001|Rescue Period|Withdrawal by Subject|8
6226585|NCT01710358|9898991|FG002|Rescue Period|Withdrawal by Subject|0
6269510|NCT02141659|9969865|FG003|Overall Study|Major Protocol Deviation|0
6269511|NCT02141659|9969866|FG004|Overall Study|Major Protocol Deviation|0
6269512|NCT02141659|9969867|FG005|Overall Study|Major Protocol Deviation|0
6269513|NCT02141659|9969862|FG000|Overall Study|Lack of Efficacy|0
6269514|NCT02141659|9969863|FG001|Overall Study|Lack of Efficacy|0
6269515|NCT02141659|9969864|FG002|Overall Study|Lack of Efficacy|0
6269516|NCT02141659|9969865|FG003|Overall Study|Lack of Efficacy|0
6269517|NCT02141659|9969866|FG004|Overall Study|Lack of Efficacy|0
6269518|NCT02141659|9969867|FG005|Overall Study|Lack of Efficacy|1
6269519|NCT02141659|9969862|FG000|Overall Study|Pretreatment Event/ Adverse Event|0
6269520|NCT02141659|9969863|FG001|Overall Study|Pretreatment Event/ Adverse Event|0
6269521|NCT02141659|9969864|FG002|Overall Study|Pretreatment Event/ Adverse Event|0
6269522|NCT02141659|9969865|FG003|Overall Study|Pretreatment Event/ Adverse Event|0
6269523|NCT02141659|9969866|FG004|Overall Study|Pretreatment Event/ Adverse Event|2
6269524|NCT02141659|9969867|FG005|Overall Study|Pretreatment Event/ Adverse Event|1
6269525|NCT02141672|9969884|FG000|Overall Study|Adverse Event|0
6269526|NCT02141672|9969885|FG001|Overall Study|Adverse Event|1
6269527|NCT02141672|9969886|FG002|Overall Study|Adverse Event|0
6269528|NCT02141672|9969884|FG000|Overall Study|Death|10
6269529|NCT02141672|9969885|FG001|Overall Study|Death|2
6269530|NCT02141672|9969886|FG002|Overall Study|Death|1
6269531|NCT02141672|9969884|FG000|Overall Study|Lack of Efficacy|0
6269532|NCT02141672|9969885|FG001|Overall Study|Lack of Efficacy|0
6269533|NCT02141672|9969886|FG002|Overall Study|Lack of Efficacy|2
6269534|NCT02141672|9969884|FG000|Overall Study|Lost to Follow-up|1
6269535|NCT02141672|9969885|FG001|Overall Study|Lost to Follow-up|1
6269536|NCT02141672|9969886|FG002|Overall Study|Lost to Follow-up|3
6269537|NCT02141672|9969884|FG000|Overall Study|Physician Decision|1
6269538|NCT02141672|9969885|FG001|Overall Study|Physician Decision|2
6269539|NCT02141672|9969886|FG002|Overall Study|Physician Decision|5
6269540|NCT02141672|9969884|FG000|Overall Study|Protocol Violation|0
6269541|NCT02141672|9969885|FG001|Overall Study|Protocol Violation|0
6269542|NCT02141672|9969886|FG002|Overall Study|Protocol Violation|1
6269543|NCT02141672|9969884|FG000|Overall Study|Withdrawal by Subject|3
6269544|NCT02141672|9969885|FG001|Overall Study|Withdrawal by Subject|2
6269545|NCT02141672|9969886|FG002|Overall Study|Withdrawal by Subject|5
6269546|NCT02141672|9969884|FG000|Overall Study|refused to follow-up|1
6269547|NCT02141672|9969885|FG001|Overall Study|refused to follow-up|0
6269548|NCT02141672|9969886|FG002|Overall Study|refused to follow-up|1
6269549|NCT02141854|9969899|FG000|Run-In Period (Pre-assignment)|Inclusion criteria not met|25
6269550|NCT02141854|9969900|FG001|Run-In Period (Pre-assignment)|Inclusion criteria not met|0
6269551|NCT02141854|9969901|FG002|Run-In Period (Pre-assignment)|Inclusion criteria not met|0
6269552|NCT02141854|9969902|FG003|Run-In Period (Pre-assignment)|Inclusion criteria not met|0
6306860|NCT02595528|10033150|FG001|Overall Study|Withdrawal by Subject|2
6306861|NCT02595528|10033151|FG002|Overall Study|Withdrawal by Subject|1
6306862|NCT02595528|10033152|FG003|Overall Study|Withdrawal by Subject|3
6306863|NCT02595528|10033149|FG000|Overall Study|Lost to Follow-up|1
6306864|NCT02595528|10033150|FG001|Overall Study|Lost to Follow-up|1
6306865|NCT02595528|10033151|FG002|Overall Study|Lost to Follow-up|0
6306866|NCT02595528|10033152|FG003|Overall Study|Lost to Follow-up|1
6306867|NCT02595723|10033178|FG000|First Washout (21 Days)|Withdrawal by Subject|1
5983235|NCT00440531|9572955|FG002|Overall Study|see pre-assignment details|0
6269553|NCT02141854|9969903|FG004|Run-In Period (Pre-assignment)|Inclusion criteria not met|0
6306868|NCT02595723|10033179|FG001|First Washout (21 Days)|Withdrawal by Subject|0
6306869|NCT02595723|10033180|FG002|First Washout (21 Days)|Withdrawal by Subject|0
6306870|NCT02595723|10033178|FG000|First Washout (21 Days)|Lost to Follow-up|1
6306871|NCT02595723|10033179|FG001|First Washout (21 Days)|Lost to Follow-up|0
6306872|NCT02595723|10033180|FG002|First Washout (21 Days)|Lost to Follow-up|0
6269554|NCT02141854|9969904|FG005|Run-In Period (Pre-assignment)|Inclusion criteria not met|0
6269555|NCT02141854|9969899|FG000|Run-In Period (Pre-assignment)|Randomization criteria not met|76
6269556|NCT02141854|9969900|FG001|Run-In Period (Pre-assignment)|Randomization criteria not met|0
6269557|NCT02141854|9969901|FG002|Run-In Period (Pre-assignment)|Randomization criteria not met|0
6269558|NCT02141854|9969902|FG003|Run-In Period (Pre-assignment)|Randomization criteria not met|0
6269559|NCT02141854|9969903|FG004|Run-In Period (Pre-assignment)|Randomization criteria not met|0
6306873|NCT02595749|10033190|FG000|Overall Study|Withdrawal by Subject|12
6306874|NCT02595749|10033191|FG001|Overall Study|Withdrawal by Subject|7
6226586|NCT01710501|9899015|FG000|Overall Study|Lost to Follow-up|2
6226587|NCT01710501|9899016|FG001|Overall Study|Lost to Follow-up|0
6226588|NCT01710501|9899017|FG002|Overall Study|Lost to Follow-up|0
6226589|NCT01710514|9899027|FG000|Overall Study|Adverse Event|6
6226590|NCT01710514|9899028|FG001|Overall Study|Adverse Event|7
6226591|NCT01710514|9899027|FG000|Overall Study|Withdrawal by Subject|1
6226592|NCT01710514|9899028|FG001|Overall Study|Withdrawal by Subject|0
6226593|NCT01710527|9899037|FG000|Period 2: Washout Period (7 Days)|Personal reasons|0
6226594|NCT01710527|9899038|FG001|Period 2: Washout Period (7 Days)|Personal reasons|1
6226595|NCT01710657|9899047|FG000|Overall Study|Lost to Follow-up|2
6226596|NCT01710657|9899048|FG001|Overall Study|Lost to Follow-up|0
6226597|NCT01710657|9899049|FG002|Overall Study|Lost to Follow-up|1
6226598|NCT01710657|9899047|FG000|Overall Study|Protocol Violation|2
6306875|NCT02595970|10033197|FG000|Overall Study|Withdrawal by Subject|2
6306876|NCT02595970|10033197|FG000|Overall Study|Physician Decision|2
6306877|NCT02595970|10033197|FG000|Overall Study|Protocol Violation|4
6306878|NCT02595970|10033197|FG000|Overall Study|Adverse Event|5
6306879|NCT02595970|10033197|FG000|Overall Study|Lack of Efficacy|7
6226599|NCT01710657|9899048|FG001|Overall Study|Protocol Violation|2
6226600|NCT01710657|9899049|FG002|Overall Study|Protocol Violation|0
6306880|NCT02596009|10033206|FG000|Overall Study|Administrative problems|0
6306881|NCT02596009|10033207|FG001|Overall Study|Administrative problems|1
6306882|NCT02596009|10033208|FG002|Overall Study|Administrative problems|0
6306883|NCT02596009|10033209|FG003|Overall Study|Administrative problems|0
6306884|NCT02596009|10033210|FG004|Overall Study|Administrative problems|0
6306885|NCT02596009|10033211|FG005|Overall Study|Administrative problems|0
6306886|NCT02596230|10033231|FG000|Screening Period for Objective 2|Participants not participating in obj 2|3714
6306887|NCT02596230|10033232|FG001|Screening Period for Objective 2|Participants not participating in obj 2|228
6306888|NCT02596230|10033233|FG002|Screening Period for Objective 2|Participants not participating in obj 2|0
6306889|NCT02596230|10033234|FG003|Screening Period for Objective 2|Participants not participating in obj 2|846
6306890|NCT02596230|10033235|FG004|Screening Period for Objective 2|Participants not participating in obj 2|0
6306891|NCT02596230|10033231|FG000|Objective 2, One Year|Lost to Follow-up|0
6306892|NCT02596230|10033232|FG001|Objective 2, One Year|Lost to Follow-up|41
6306893|NCT02596230|10033233|FG002|Objective 2, One Year|Lost to Follow-up|41
6306894|NCT02596230|10033234|FG003|Objective 2, One Year|Lost to Follow-up|32
6306895|NCT02596230|10033235|FG004|Objective 2, One Year|Lost to Follow-up|46
6306896|NCT02596230|10033231|FG000|Objective 2, One Year|Withdrawal by Subject|0
6306897|NCT02596230|10033232|FG001|Objective 2, One Year|Withdrawal by Subject|11
6306898|NCT02596230|10033233|FG002|Objective 2, One Year|Withdrawal by Subject|14
6306899|NCT02596230|10033234|FG003|Objective 2, One Year|Withdrawal by Subject|5
6306900|NCT02596230|10033235|FG004|Objective 2, One Year|Withdrawal by Subject|2
6306901|NCT02596230|10033231|FG000|Objective 2, One Year|Adverse drug reaction|0
6306902|NCT02596230|10033232|FG001|Objective 2, One Year|Adverse drug reaction|1
6306903|NCT02596230|10033233|FG002|Objective 2, One Year|Adverse drug reaction|0
6306904|NCT02596230|10033234|FG003|Objective 2, One Year|Adverse drug reaction|0
6306905|NCT02596230|10033235|FG004|Objective 2, One Year|Adverse drug reaction|0
6306906|NCT02596230|10033231|FG000|Objective 2, One Year|Death|0
6306907|NCT02596230|10033232|FG001|Objective 2, One Year|Death|12
6306908|NCT02596230|10033233|FG002|Objective 2, One Year|Death|41
6306909|NCT02596230|10033234|FG003|Objective 2, One Year|Death|21
6306910|NCT02596230|10033235|FG004|Objective 2, One Year|Death|30
6306911|NCT02596230|10033231|FG000|Objective 2, One Year|Other|0
6306912|NCT02596230|10033232|FG001|Objective 2, One Year|Other|3
6306913|NCT02596230|10033233|FG002|Objective 2, One Year|Other|2
6306914|NCT02596230|10033234|FG003|Objective 2, One Year|Other|0
6306915|NCT02596230|10033235|FG004|Objective 2, One Year|Other|0
6306916|NCT02596620|10033268|FG000|Overall Study|Lost to Follow-up|1
6306917|NCT02596620|10033269|FG001|Overall Study|Lost to Follow-up|1
6306918|NCT02596711|10033278|FG000|Overall Study|Lost to Follow-up|1
6306919|NCT02596711|10033279|FG001|Overall Study|Lost to Follow-up|2
6306920|NCT02596711|10033280|FG002|Overall Study|Lost to Follow-up|3
6306921|NCT02596854|10033298|FG000|Overall Study|Withdrawn|8
6306922|NCT02596893|10033311|FG000|Overall Double-Blind Period Weeks 0-52|Study Terminated by Sponsor|61
6306923|NCT02596893|10033312|FG001|Overall Double-Blind Period Weeks 0-52|Study Terminated by Sponsor|56
6306924|NCT02596893|10033313|FG002|Overall Double-Blind Period Weeks 0-52|Study Terminated by Sponsor|48
6306925|NCT02596893|10033314|FG003|Overall Double-Blind Period Weeks 0-52|Study Terminated by Sponsor|58
6306926|NCT02596893|10033311|FG000|Overall Double-Blind Period Weeks 0-52|Adverse Event|11
6306927|NCT02596893|10033312|FG001|Overall Double-Blind Period Weeks 0-52|Adverse Event|15
6306928|NCT02596893|10033313|FG002|Overall Double-Blind Period Weeks 0-52|Adverse Event|15
6306929|NCT02596893|10033314|FG003|Overall Double-Blind Period Weeks 0-52|Adverse Event|12
6306930|NCT02596893|10033311|FG000|Overall Double-Blind Period Weeks 0-52|Pregnancy|0
6306931|NCT02596893|10033312|FG001|Overall Double-Blind Period Weeks 0-52|Pregnancy|0
6306932|NCT02596893|10033313|FG002|Overall Double-Blind Period Weeks 0-52|Pregnancy|0
6306933|NCT02596893|10033314|FG003|Overall Double-Blind Period Weeks 0-52|Pregnancy|1
6306934|NCT02596893|10033311|FG000|Overall Double-Blind Period Weeks 0-52|Lack of Efficacy|15
6306935|NCT02596893|10033312|FG001|Overall Double-Blind Period Weeks 0-52|Lack of Efficacy|14
6306936|NCT02596893|10033313|FG002|Overall Double-Blind Period Weeks 0-52|Lack of Efficacy|14
6306937|NCT02596893|10033314|FG003|Overall Double-Blind Period Weeks 0-52|Lack of Efficacy|13
6306938|NCT02596893|10033311|FG000|Overall Double-Blind Period Weeks 0-52|Withdrawal by Subject|10
6306939|NCT02596893|10033312|FG001|Overall Double-Blind Period Weeks 0-52|Withdrawal by Subject|4
6306940|NCT02596893|10033313|FG002|Overall Double-Blind Period Weeks 0-52|Withdrawal by Subject|13
6306941|NCT02596893|10033314|FG003|Overall Double-Blind Period Weeks 0-52|Withdrawal by Subject|5
6306942|NCT02596893|10033311|FG000|Overall Double-Blind Period Weeks 0-52|Miscellaneous|1
6306943|NCT02596893|10033312|FG001|Overall Double-Blind Period Weeks 0-52|Miscellaneous|2
6306944|NCT02596893|10033313|FG002|Overall Double-Blind Period Weeks 0-52|Miscellaneous|0
6306945|NCT02596893|10033314|FG003|Overall Double-Blind Period Weeks 0-52|Miscellaneous|2
6306946|NCT02596893|10033311|FG000|Overall Double-Blind Period Weeks 0-52|Lost to Follow-up|0
6306947|NCT02596893|10033312|FG001|Overall Double-Blind Period Weeks 0-52|Lost to Follow-up|1
6306948|NCT02596893|10033313|FG002|Overall Double-Blind Period Weeks 0-52|Lost to Follow-up|1
6306949|NCT02596893|10033314|FG003|Overall Double-Blind Period Weeks 0-52|Lost to Follow-up|1
6306950|NCT02596893|10033311|FG000|Overall Double-Blind Period Weeks 0-52|Non-Compliance with Study Drug|0
6306951|NCT02596893|10033312|FG001|Overall Double-Blind Period Weeks 0-52|Non-Compliance with Study Drug|0
6306952|NCT02596893|10033313|FG002|Overall Double-Blind Period Weeks 0-52|Non-Compliance with Study Drug|1
6306953|NCT02596893|10033314|FG003|Overall Double-Blind Period Weeks 0-52|Non-Compliance with Study Drug|2
6306954|NCT02596893|10033311|FG000|Overall Double-Blind Period Weeks 0-52|Death|0
6306955|NCT02596893|10033312|FG001|Overall Double-Blind Period Weeks 0-52|Death|0
6306956|NCT02596893|10033313|FG002|Overall Double-Blind Period Weeks 0-52|Death|1
6306957|NCT02596893|10033314|FG003|Overall Double-Blind Period Weeks 0-52|Death|0
6306958|NCT02596893|10033311|FG000|Overall Double-Blind Period Weeks 0-52|Protocol Violation|0
6306959|NCT02596893|10033312|FG001|Overall Double-Blind Period Weeks 0-52|Protocol Violation|0
6306960|NCT02596893|10033313|FG002|Overall Double-Blind Period Weeks 0-52|Protocol Violation|0
6306961|NCT02596893|10033314|FG003|Overall Double-Blind Period Weeks 0-52|Protocol Violation|2
6306962|NCT02596893|10033311|FG000|Overall Double-Blind Period Weeks 0-52|Early Escape|66
6306963|NCT02596893|10033312|FG001|Overall Double-Blind Period Weeks 0-52|Early Escape|76
6306964|NCT02596893|10033313|FG002|Overall Double-Blind Period Weeks 0-52|Early Escape|69
6306965|NCT02596893|10033314|FG003|Overall Double-Blind Period Weeks 0-52|Early Escape|70
6306966|NCT02596945|10033333|FG000|Overall Study|No documentation of study drug dosing|3
6306967|NCT02596945|10033333|FG000|Overall Study|Other|32
6306968|NCT02596945|10033333|FG000|Overall Study|Change to hemodialysis|15
6306969|NCT02596945|10033333|FG000|Overall Study|Other Erythropoietin stimulating agent|4
6306970|NCT02596945|10033333|FG000|Overall Study|Withdrawal by Subject|1
6306971|NCT02596945|10033333|FG000|Overall Study|Missing|1
6306972|NCT02596958|10033337|FG000|Overall Study|Serious Adverse Drug Reactions|44
6306973|NCT02596958|10033337|FG000|Overall Study|Cancer Progression|441
6306974|NCT02596958|10033337|FG000|Overall Study|Death From Cancer|112
6306975|NCT02596958|10033337|FG000|Overall Study|Death From Other Cause|33
6306976|NCT02596958|10033337|FG000|Overall Study|Refusal of Treatment/Poor Cooperation|61
6306977|NCT02596958|10033337|FG000|Overall Study|Administrative Reasons/Other|231
6306978|NCT02596958|10033337|FG000|Overall Study|Lost to Follow-up|33
6306979|NCT02596958|10033337|FG000|Overall Study|Missing|32
6306980|NCT02596958|10033337|FG000|Overall Study|Excluded Due to Second Line Treatment|9
6306981|NCT02596971|10033344|FG000|Overall Study|Death|5
6306982|NCT02596971|10033345|FG001|Overall Study|Death|1
6306983|NCT02596971|10033346|FG002|Overall Study|Death|5
6306984|NCT02596971|10033344|FG000|Overall Study|Withdrawal by Subject|5
6306985|NCT02596971|10033345|FG001|Overall Study|Withdrawal by Subject|1
6306986|NCT02596971|10033346|FG002|Overall Study|Withdrawal by Subject|4
6306987|NCT02597049|10033360|FG000|Overall Study|Lost to Follow-up|0
6306988|NCT02597049|10033361|FG001|Overall Study|Lost to Follow-up|3
6306989|NCT02597049|10033362|FG002|Overall Study|Lost to Follow-up|2
6306990|NCT02597049|10033360|FG000|Overall Study|Withdrawal by Subject|2
6306991|NCT02597049|10033361|FG001|Overall Study|Withdrawal by Subject|2
6306992|NCT02597049|10033362|FG002|Overall Study|Withdrawal by Subject|1
6306993|NCT02597049|10033360|FG000|Overall Study|Adverse Event|2
6306994|NCT02597049|10033361|FG001|Overall Study|Adverse Event|0
6306995|NCT02597049|10033362|FG002|Overall Study|Adverse Event|0
6306996|NCT02597049|10033360|FG000|Overall Study|Death|2
6306997|NCT02597049|10033361|FG001|Overall Study|Death|0
6306998|NCT02597049|10033362|FG002|Overall Study|Death|0
6306999|NCT02597049|10033360|FG000|Overall Study|Noncompliant with Study Visits|1
6307000|NCT02597049|10033361|FG001|Overall Study|Noncompliant with Study Visits|0
6307001|NCT02597049|10033362|FG002|Overall Study|Noncompliant with Study Visits|0
6307002|NCT02597452|10033433|FG000|Overall Study|testing incomplete|30
6307003|NCT02597478|10033439|FG000|Overall Study|Withdrawal by Subject|2
6307004|NCT02597478|10033440|FG001|Overall Study|Withdrawal by Subject|0
6307005|NCT02597478|10033439|FG000|Overall Study|Change of opioid dose|1
6307006|NCT02597478|10033440|FG001|Overall Study|Change of opioid dose|0
6307007|NCT02597478|10033439|FG000|Overall Study|Insufficient exertional dyspnea|0
6307008|NCT02597478|10033440|FG001|Overall Study|Insufficient exertional dyspnea|1
6307009|NCT02597712|10033486|FG000|Overall Study|Baseline biopsies showed indefinite for dysplasia|2
6307010|NCT02597712|10033487|FG001|Overall Study|Baseline biopsies showed indefinite for dysplasia|0
6307011|NCT02597712|10033486|FG000|Overall Study|Baseline biopsies showed low grade dysplasia|1
6307012|NCT02597712|10033487|FG001|Overall Study|Baseline biopsies showed low grade dysplasia|0
6307013|NCT02597712|10033486|FG000|Overall Study|Recurrent metastatic prostate cancer|0
6307014|NCT02597712|10033487|FG001|Overall Study|Recurrent metastatic prostate cancer|1
6307015|NCT02597855|10033495|FG000|Overall Study|Lost to Follow-up|2
6307016|NCT02597855|10033496|FG001|Overall Study|Lost to Follow-up|1
6307017|NCT02597920|10033514|FG000|Overall Study|Worsening of other pre-existing disease|0
6307018|NCT02597920|10033515|FG001|Overall Study|Worsening of other pre-existing disease|1
6307019|NCT02597920|10033516|FG002|Overall Study|Worsening of other pre-existing disease|0
6307020|NCT02597920|10033514|FG000|Overall Study|Other adverse event|20
6307021|NCT02597920|10033515|FG001|Overall Study|Other adverse event|30
6307022|NCT02597920|10033516|FG002|Overall Study|Other adverse event|0
6307023|NCT02597920|10033514|FG000|Overall Study|Lost to Follow-up|7
6307024|NCT02597920|10033515|FG001|Overall Study|Lost to Follow-up|9
6307025|NCT02597920|10033516|FG002|Overall Study|Lost to Follow-up|0
6307026|NCT02597920|10033514|FG000|Overall Study|Refuse to continue in the study|3
6307027|NCT02597920|10033515|FG001|Overall Study|Refuse to continue in the study|13
6307028|NCT02597920|10033516|FG002|Overall Study|Refuse to continue in the study|1
6307029|NCT02597920|10033514|FG000|Overall Study|Other than specified|10
6307030|NCT02597920|10033515|FG001|Overall Study|Other than specified|31
6307031|NCT02597920|10033516|FG002|Overall Study|Other than specified|5
6307032|NCT02597920|10033514|FG000|Overall Study|Other|1
6307033|NCT02597920|10033515|FG001|Overall Study|Other|0
6307034|NCT02597920|10033516|FG002|Overall Study|Other|0
6307035|NCT02597933|10033528|FG000|Overall Study|Withdrawal by Subject|7
6307036|NCT02597933|10033529|FG001|Overall Study|Withdrawal by Subject|5
6307037|NCT02597933|10033528|FG000|Overall Study|Protocol Violation|2
6307038|NCT02597933|10033529|FG001|Overall Study|Protocol Violation|2
6307039|NCT02597933|10033528|FG000|Overall Study|Adverse Event|20
6307040|NCT02597933|10033529|FG001|Overall Study|Adverse Event|28
6307041|NCT02597933|10033528|FG000|Overall Study|Not treated|2
6307042|NCT02597933|10033529|FG001|Overall Study|Not treated|2
6307043|NCT02597933|10033528|FG000|Overall Study|Other than stated above|7
6307044|NCT02597933|10033529|FG001|Overall Study|Other than stated above|14
6307045|NCT02597946|10033535|FG000|Overall Study|Withdrawal by Subject|1
6307046|NCT02597946|10033535|FG000|Overall Study|Progressive disease|16
6307047|NCT02597946|10033535|FG000|Overall Study|Other than above|1
6307048|NCT02598076|10033541|FG000|Overall Study|Lost to Follow-up|2
6307049|NCT02598076|10033542|FG001|Overall Study|Lost to Follow-up|3
6307050|NCT02598128|10033564|FG000|Period A: Days -7 to -1|Adverse Event|1
6307051|NCT02598128|10033565|FG001|Period A: Days -7 to -1|Adverse Event|0
6307052|NCT02598128|10033566|FG002|Period A: Days -7 to -1|Adverse Event|0
6307053|NCT02598128|10033567|FG003|Period A: Days -7 to -1|Adverse Event|0
6307054|NCT02598193|10033579|FG000|Overall Study|Adverse Event|13
6307055|NCT02598193|10033579|FG000|Overall Study|Withdrawal by Subject|1
6307056|NCT02598193|10033579|FG000|Overall Study|Listed in active lung transplant list|1
6307057|NCT02598193|10033579|FG000|Overall Study|Does not want to take Nintedanib|1
6307058|NCT02598297|10033585|FG000|Overall Study|Study terminated by Sponsor|21
6307059|NCT02598297|10033586|FG001|Overall Study|Study terminated by Sponsor|23
6307060|NCT02598297|10033585|FG000|Overall Study|Adverse Event|1
6307061|NCT02598297|10033586|FG001|Overall Study|Adverse Event|1
6307062|NCT02598297|10033585|FG000|Overall Study|Physician Decision|1
6307063|NCT02598297|10033586|FG001|Overall Study|Physician Decision|0
6307064|NCT02598297|10033585|FG000|Overall Study|Subject/guardian decision|1
6307065|NCT02598297|10033586|FG001|Overall Study|Subject/guardian decision|0
6307066|NCT02598297|10033585|FG000|Overall Study|Followed for survival|1
6307067|NCT02598297|10033586|FG001|Overall Study|Followed for survival|0
6307068|NCT02598934|10033594|FG000|Overall Study|Adverse Event|11
6307069|NCT02598934|10033595|FG001|Overall Study|Adverse Event|13
6307070|NCT02598934|10033594|FG000|Overall Study|Failure to Return|3
6307071|NCT02598934|10033595|FG001|Overall Study|Failure to Return|3
6307072|NCT02598934|10033594|FG000|Overall Study|Withdrawal by Subject|2
6307073|NCT02598934|10033595|FG001|Overall Study|Withdrawal by Subject|3
6307074|NCT02598934|10033594|FG000|Overall Study|Administrative|2
6307075|NCT02598934|10033595|FG001|Overall Study|Administrative|1
6307076|NCT02598934|10033594|FG000|Overall Study|Protocol Violation|1
6307077|NCT02598934|10033595|FG001|Overall Study|Protocol Violation|2
6307078|NCT02599129|10033603|FG000|Overall Study|Lack of Efficacy|2
6307079|NCT02599129|10033604|FG001|Overall Study|Lack of Efficacy|2
6307080|NCT02599129|10033603|FG000|Overall Study|Lost to Follow-up|1
6307081|NCT02599129|10033604|FG001|Overall Study|Lost to Follow-up|0
6307082|NCT02599129|10033603|FG000|Overall Study|Withdrawal by Subject|2
6307083|NCT02599129|10033604|FG001|Overall Study|Withdrawal by Subject|1
6307084|NCT02599402|10033616|FG000|Overall Study|Disease progression|153
6307085|NCT02599402|10033616|FG000|Overall Study|Study drug toxicity|201
6307086|NCT02599402|10033616|FG000|Overall Study|Death|26
6307087|NCT02599402|10033616|FG000|Overall Study|Adverse Event unrelated to study drug|23
6307088|NCT02599402|10033616|FG000|Overall Study|Participant request to discontinue study treatment|13
6307089|NCT02599402|10033616|FG000|Overall Study|Participant withdrew consent|5
6307090|NCT02599402|10033616|FG000|Overall Study|Lost to Follow-up|1
6307091|NCT02599402|10033616|FG000|Overall Study|Maximum Clinical Benefit|7
6307092|NCT02599402|10033616|FG000|Overall Study|Poor/non-compliance|1
6307093|NCT02599402|10033616|FG000|Overall Study|Pregnancy|1
6307094|NCT02599402|10033616|FG000|Overall Study|Participant no longer met study criteria|7
6307095|NCT02599402|10033616|FG000|Overall Study|Other Reasons|95
6307096|NCT02599688|10033667|FG000|Overall Study|Lack of Efficacy|1
6307097|NCT02599688|10033667|FG000|Overall Study|Withdrawal by Subject|1
6307098|NCT02599688|10033667|FG000|Overall Study|Termination by Sponsor|2
6307099|NCT02599961|10033679|FG000|Overall Study|Withdrawal by Subject|1
6307100|NCT02599961|10033679|FG000|Overall Study|Subject Non-Compliance|2
6307101|NCT02599961|10033679|FG000|Overall Study|Discontinuation of Study by Sponsor|9
6307102|NCT02599961|10033679|FG000|Overall Study|Other, Not Specified|3
6307103|NCT02600351|10033691|FG000|Overall Study|Lack of Efficacy|3
6307104|NCT02600351|10033692|FG001|Overall Study|Lack of Efficacy|0
6307105|NCT02600351|10033693|FG002|Overall Study|Lack of Efficacy|5
6307106|NCT02600351|10033694|FG003|Overall Study|Lack of Efficacy|2
6307107|NCT02600351|10033691|FG000|Overall Study|Lost to Follow-up|1
6307108|NCT02600351|10033692|FG001|Overall Study|Lost to Follow-up|0
6307109|NCT02600351|10033693|FG002|Overall Study|Lost to Follow-up|0
6307110|NCT02600351|10033694|FG003|Overall Study|Lost to Follow-up|0
6307111|NCT02600351|10033691|FG000|Overall Study|Randomized but Not Treated|1
6307112|NCT02600351|10033692|FG001|Overall Study|Randomized but Not Treated|0
6307113|NCT02600351|10033693|FG002|Overall Study|Randomized but Not Treated|1
6307114|NCT02600351|10033694|FG003|Overall Study|Randomized but Not Treated|3
6307115|NCT02600559|10033722|FG000|Overall Study|Withdrawal by Subject|3
6307116|NCT02600559|10033722|FG000|Overall Study|Lost to Follow-up|20
6307117|NCT02600819|10033760|FG000|GEN Phase|Adverse Event|2
6307118|NCT02600819|10033761|FG001|GEN Phase|Adverse Event|0
6307119|NCT02600819|10033760|FG000|GEN Phase|Death|2
6307120|NCT02600819|10033761|FG001|GEN Phase|Death|0
6307121|NCT02600819|10033760|FG000|GEN Phase|Investigator's Discretion|4
6307122|NCT02600819|10033761|FG001|GEN Phase|Investigator's Discretion|0
6307123|NCT02600819|10033760|FG000|GEN Phase|Non-Compliance with Study Drug|1
6307124|NCT02600819|10033761|FG001|GEN Phase|Non-Compliance with Study Drug|0
6307125|NCT02600819|10033760|FG000|GEN Phase|Withdrew Consent|5
6307126|NCT02600819|10033761|FG001|GEN Phase|Withdrew Consent|0
6307127|NCT02600819|10033760|FG000|GEN Phase|Lost to Follow-up|2
6307128|NCT02600819|10033761|FG001|GEN Phase|Lost to Follow-up|0
6307129|NCT02600845|10033767|FG000|Overall Study|Reason Not Specified|3
6307130|NCT02600845|10033767|FG000|Overall Study|Non-compliance with Study Procedures|10
6307131|NCT02600845|10033767|FG000|Overall Study|Consent Withdrawal|5
6307132|NCT02600871|10033773|FG000|Overall Study|Lost to Follow-up|13
6307133|NCT02600871|10033774|FG001|Overall Study|Lost to Follow-up|10
6307134|NCT02601001|10033784|FG000|Dosing Period 2|Adverse Event|0
6307135|NCT02601001|10033785|FG001|Dosing Period 2|Adverse Event|0
6307136|NCT02601001|10033786|FG002|Dosing Period 2|Adverse Event|0
6307137|NCT02601001|10033787|FG003|Dosing Period 2|Adverse Event|0
6307138|NCT02601001|10033788|FG004|Dosing Period 2|Adverse Event|0
6307139|NCT02601001|10033789|FG005|Dosing Period 2|Adverse Event|0
6307140|NCT02601001|10033790|FG006|Dosing Period 2|Adverse Event|1
6307141|NCT02601027|10033813|FG000|Registration to Surgery|Withdrawal by Subject|20
6307142|NCT02601027|10033814|FG001|Registration to Surgery|Withdrawal by Subject|10
6307143|NCT02601300|10033835|FG000|Induction Phase|Lack of Efficacy|2
6307144|NCT02601300|10033835|FG000|Induction Phase|Protocol Violation|1
6307145|NCT02601300|10033835|FG000|Extension Phase|Withdrawal by Subject|3
6307146|NCT02601300|10033835|FG000|Extension Phase|Adverse Event|4
6307147|NCT02601300|10033835|FG000|Extension Phase|Lack of Efficacy|10
6307148|NCT02601469|10033843|FG000|Overall Study|Enrolled in Error|1
6307149|NCT02601469|10033844|FG001|Overall Study|Enrolled in Error|0
6307150|NCT02601560|10033858|FG000|Overall Study|Other|0
6307151|NCT02601560|10033859|FG001|Overall Study|Other|0
6307152|NCT02601560|10033860|FG002|Overall Study|Other|0
6307153|NCT02601560|10033861|FG003|Overall Study|Other|0
6307154|NCT02601560|10033862|FG004|Overall Study|Other|0
6307155|NCT02601560|10033863|FG005|Overall Study|Other|0
6307156|NCT02601560|10033864|FG006|Overall Study|Other|1
6307157|NCT02601560|10033865|FG007|Overall Study|Other|0
6307158|NCT02601573|10033895|FG000|Overall Study|Lost to Follow-up|0
6307159|NCT02601573|10033896|FG001|Overall Study|Lost to Follow-up|3
6307160|NCT02601573|10033897|FG002|Overall Study|Lost to Follow-up|1
6307161|NCT02601573|10033898|FG003|Overall Study|Lost to Follow-up|0
6307162|NCT02601573|10033899|FG004|Overall Study|Lost to Follow-up|2
6307163|NCT02601573|10033895|FG000|Overall Study|Withdrawal by Subject|0
6307164|NCT02601573|10033896|FG001|Overall Study|Withdrawal by Subject|1
6307165|NCT02601573|10033897|FG002|Overall Study|Withdrawal by Subject|0
6307166|NCT02601573|10033898|FG003|Overall Study|Withdrawal by Subject|1
6307167|NCT02601573|10033899|FG004|Overall Study|Withdrawal by Subject|0
6307168|NCT02601625|10033915|FG000|Overall Study|Lost to Follow-up|0
6307169|NCT02601625|10033916|FG001|Overall Study|Lost to Follow-up|0
6307170|NCT02601625|10033917|FG002|Overall Study|Lost to Follow-up|1
6307171|NCT02601625|10033918|FG003|Overall Study|Lost to Follow-up|1
6307172|NCT02601820|10033942|FG000|Early On-Treatment (T2)|Missing T2 Record|51
6307173|NCT02601820|10033942|FG000|Late On-Treatment (T3)|missing T3 Record|49
6307174|NCT02601820|10033942|FG000|12 Weeks Post-Treatment (T4)|Missing T4 record|3
6307175|NCT02601820|10033942|FG000|1-Yr Post-Treatment (T5)|Missing T5 Record|88
6307176|NCT02602080|10033978|FG000|Overall Study|Protocol Violation|6
6307177|NCT02602080|10033979|FG001|Overall Study|Protocol Violation|1
6307178|NCT02602080|10033980|FG002|Overall Study|Protocol Violation|3
6307179|NCT02603107|10034009|FG000|Randomized Phase|Withdrew consent|8
6307180|NCT02603107|10034010|FG001|Randomized Phase|Withdrew consent|15
6307181|NCT02603107|10034009|FG000|Randomized Phase|Lost to Follow-up|1
6307182|NCT02603107|10034010|FG001|Randomized Phase|Lost to Follow-up|3
6307183|NCT02603107|10034009|FG000|Randomized Phase|Adverse Event|2
6307184|NCT02603107|10034010|FG001|Randomized Phase|Adverse Event|0
6307185|NCT02603107|10034009|FG000|Randomized Phase|Death|1
6307186|NCT02603107|10034010|FG001|Randomized Phase|Death|1
6307187|NCT02603107|10034009|FG000|Randomized Phase|Non-compliance with study drug|1
6307188|NCT02603107|10034010|FG001|Randomized Phase|Non-compliance with study drug|1
6307189|NCT02603107|10034009|FG000|Randomized Phase|Investigator's discretion|0
6307190|NCT02603107|10034010|FG001|Randomized Phase|Investigator's discretion|1
6307191|NCT02603107|10034009|FG000|Randomized Phase|Lack of Efficacy|1
6307192|NCT02603107|10034010|FG001|Randomized Phase|Lack of Efficacy|0
6307193|NCT02603107|10034009|FG000|Randomized Phase|Protocol Violation|1
6307194|NCT02603107|10034010|FG001|Randomized Phase|Protocol Violation|0
6307195|NCT02603107|10034009|FG000|Optional Extension Phase|Lost to Follow-up|3
6307196|NCT02603107|10034010|FG001|Optional Extension Phase|Lost to Follow-up|3
6307197|NCT02603107|10034009|FG000|Optional Extension Phase|Withdrew consent|3
6307198|NCT02603107|10034010|FG001|Optional Extension Phase|Withdrew consent|2
6307199|NCT02603107|10034009|FG000|Optional Extension Phase|Investigator's discretion|2
6307200|NCT02603107|10034010|FG001|Optional Extension Phase|Investigator's discretion|2
6307201|NCT02603107|10034009|FG000|Optional Extension Phase|Pregnancy|0
6307202|NCT02603107|10034010|FG001|Optional Extension Phase|Pregnancy|3
6307203|NCT02603107|10034009|FG000|Optional Extension Phase|Adverse Event|0
6307204|NCT02603107|10034010|FG001|Optional Extension Phase|Adverse Event|2
6307205|NCT02603107|10034009|FG000|Optional Extension Phase|Not treated in extension phase|0
6307206|NCT02603107|10034010|FG001|Optional Extension Phase|Not treated in extension phase|1
6307207|NCT02603107|10034009|FG000|Optional Extension Phase|Protocol Violation|1
6307208|NCT02603107|10034010|FG001|Optional Extension Phase|Protocol Violation|0
6307209|NCT02603120|10034020|FG000|Double-Blind Treatment Phase|Withdrew consent|4
6307210|NCT02603120|10034021|FG001|Double-Blind Treatment Phase|Withdrew consent|8
6307211|NCT02603120|10034020|FG000|Double-Blind Treatment Phase|Adverse Event|3
6307212|NCT02603120|10034021|FG001|Double-Blind Treatment Phase|Adverse Event|3
6307213|NCT02603120|10034020|FG000|Double-Blind Treatment Phase|Lost to Follow-up|4
6307214|NCT02603120|10034021|FG001|Double-Blind Treatment Phase|Lost to Follow-up|2
6307215|NCT02603120|10034020|FG000|Double-Blind Treatment Phase|Death|2
6307216|NCT02603120|10034021|FG001|Double-Blind Treatment Phase|Death|0
6307217|NCT02603120|10034020|FG000|Double-Blind Treatment Phase|Investigator's discretion|2
6307218|NCT02603120|10034021|FG001|Double-Blind Treatment Phase|Investigator's discretion|0
6307219|NCT02603120|10034020|FG000|Double-Blind Treatment Phase|Pregnancy|1
6307220|NCT02603120|10034021|FG001|Double-Blind Treatment Phase|Pregnancy|1
6307221|NCT02603120|10034020|FG000|Double-Blind Treatment Phase|Non-compliance with study drug|1
6307222|NCT02603120|10034021|FG001|Double-Blind Treatment Phase|Non-compliance with study drug|0
6307223|NCT02603120|10034020|FG000|Double-Blind Treatment Phase|Did not receive study drug|2
6307224|NCT02603120|10034021|FG001|Double-Blind Treatment Phase|Did not receive study drug|2
6307225|NCT02603120|10034020|FG000|OL Extension B/F/TAF Treatment Phase|Lost to Follow-up|3
6307226|NCT02603120|10034021|FG001|OL Extension B/F/TAF Treatment Phase|Lost to Follow-up|4
6307227|NCT02603120|10034020|FG000|OL Extension B/F/TAF Treatment Phase|Investigator's discretion|1
6307228|NCT02603120|10034021|FG001|OL Extension B/F/TAF Treatment Phase|Investigator's discretion|2
6307229|NCT02603120|10034020|FG000|OL Extension B/F/TAF Treatment Phase|Withdrew consent|1
6307230|NCT02603120|10034021|FG001|OL Extension B/F/TAF Treatment Phase|Withdrew consent|2
6307231|NCT02603120|10034020|FG000|OL Extension B/F/TAF Treatment Phase|Adverse Event|0
6307232|NCT02603120|10034021|FG001|OL Extension B/F/TAF Treatment Phase|Adverse Event|1
6307233|NCT02603120|10034020|FG000|OL Extension B/F/TAF Treatment Phase|Death|0
6307234|NCT02603120|10034021|FG001|OL Extension B/F/TAF Treatment Phase|Death|1
6307235|NCT02603120|10034020|FG000|OL Extension B/F/TAF Treatment Phase|Lack of Efficacy|0
6307236|NCT02603120|10034021|FG001|OL Extension B/F/TAF Treatment Phase|Lack of Efficacy|1
6307237|NCT02603172|10034037|FG000|Part A (Approximately 16 Weeks)|Adverse Event|0
6307238|NCT02603172|10034038|FG001|Part A (Approximately 16 Weeks)|Adverse Event|0
6307239|NCT02603172|10034039|FG002|Part A (Approximately 16 Weeks)|Adverse Event|1
6307240|NCT02603172|10034040|FG003|Part A (Approximately 16 Weeks)|Adverse Event|0
6307241|NCT02603172|10034041|FG004|Part A (Approximately 16 Weeks)|Adverse Event|0
6307242|NCT02603172|10034042|FG005|Part A (Approximately 16 Weeks)|Adverse Event|0
6307243|NCT02603172|10034043|FG006|Part A (Approximately 16 Weeks)|Adverse Event|0
6307244|NCT02603172|10034044|FG007|Part A (Approximately 16 Weeks)|Adverse Event|0
6307245|NCT02603393|10034067|FG000|Overall Study|Patient/guardian decision|32
6307246|NCT02603393|10034068|FG001|Overall Study|Patient/guardian decision|18
6307247|NCT02603393|10034067|FG000|Overall Study|Adverse Event|17
6307248|NCT02603393|10034068|FG001|Overall Study|Adverse Event|15
6307249|NCT02603393|10034067|FG000|Overall Study|Technical problems|4
6307250|NCT02603393|10034068|FG001|Overall Study|Technical problems|7
6307251|NCT02603393|10034067|FG000|Overall Study|Lack of Efficacy|7
6307252|NCT02603393|10034068|FG001|Overall Study|Lack of Efficacy|2
6307253|NCT02603393|10034067|FG000|Overall Study|Death|3
6307254|NCT02603393|10034068|FG001|Overall Study|Death|4
6307255|NCT02603393|10034067|FG000|Overall Study|Physician Decision|3
6307256|NCT02603393|10034068|FG001|Overall Study|Physician Decision|3
6307257|NCT02603393|10034067|FG000|Overall Study|Protocol deviation|2
6307258|NCT02603393|10034068|FG001|Overall Study|Protocol deviation|3
6307259|NCT02603393|10034067|FG000|Overall Study|Lost to Follow-up|1
6307260|NCT02603393|10034068|FG001|Overall Study|Lost to Follow-up|2
6307261|NCT02603393|10034067|FG000|Overall Study|Non-compliance with study treatment|1
6307262|NCT02603393|10034068|FG001|Overall Study|Non-compliance with study treatment|0
6307263|NCT02603393|10034067|FG000|Overall Study|Sponsor decision|1
6307264|NCT02603393|10034068|FG001|Overall Study|Sponsor decision|0
6307265|NCT02603419|10034080|FG000|Lead-in Phase:Maximum Exposure:123Weeks|Death|0
6307266|NCT02603419|10034081|FG001|Lead-in Phase:Maximum Exposure:123Weeks|Death|1
6307267|NCT02603419|10034082|FG002|Lead-in Phase:Maximum Exposure:123Weeks|Death|0
6307268|NCT02603419|10034083|FG003|Lead-in Phase:Maximum Exposure:123Weeks|Death|0
6307269|NCT02603419|10034084|FG004|Lead-in Phase:Maximum Exposure:123Weeks|Death|0
6307270|NCT02603419|10034085|FG005|Lead-in Phase:Maximum Exposure:123Weeks|Death|0
6307271|NCT02603419|10034080|FG000|Lead-in Phase:Maximum Exposure:123Weeks|Progressive Disease|2
6307272|NCT02603419|10034081|FG001|Lead-in Phase:Maximum Exposure:123Weeks|Progressive Disease|4
6307273|NCT02603419|10034082|FG002|Lead-in Phase:Maximum Exposure:123Weeks|Progressive Disease|2
6307274|NCT02603419|10034083|FG003|Lead-in Phase:Maximum Exposure:123Weeks|Progressive Disease|4
6307275|NCT02603419|10034084|FG004|Lead-in Phase:Maximum Exposure:123Weeks|Progressive Disease|3
6307276|NCT02603419|10034085|FG005|Lead-in Phase:Maximum Exposure:123Weeks|Progressive Disease|0
6307277|NCT02603419|10034080|FG000|Lead-in Phase:Maximum Exposure:123Weeks|Adverse Event|2
6307278|NCT02603419|10034081|FG001|Lead-in Phase:Maximum Exposure:123Weeks|Adverse Event|0
6307279|NCT02603419|10034082|FG002|Lead-in Phase:Maximum Exposure:123Weeks|Adverse Event|3
6307280|NCT02603419|10034083|FG003|Lead-in Phase:Maximum Exposure:123Weeks|Adverse Event|0
6307281|NCT02603419|10034084|FG004|Lead-in Phase:Maximum Exposure:123Weeks|Adverse Event|1
6307282|NCT02603419|10034085|FG005|Lead-in Phase:Maximum Exposure:123Weeks|Adverse Event|0
6307283|NCT02603419|10034080|FG000|Lead-in Phase:Maximum Exposure:123Weeks|Physician Decision|0
6307284|NCT02603419|10034081|FG001|Lead-in Phase:Maximum Exposure:123Weeks|Physician Decision|0
6307285|NCT02603419|10034082|FG002|Lead-in Phase:Maximum Exposure:123Weeks|Physician Decision|0
6307286|NCT02603419|10034083|FG003|Lead-in Phase:Maximum Exposure:123Weeks|Physician Decision|0
6307287|NCT02603419|10034084|FG004|Lead-in Phase:Maximum Exposure:123Weeks|Physician Decision|1
6307288|NCT02603419|10034085|FG005|Lead-in Phase:Maximum Exposure:123Weeks|Physician Decision|0
6307289|NCT02603419|10034080|FG000|Lead-in Phase:Maximum Exposure:123Weeks|No Longer Meets Eligibility Criteria|0
6307290|NCT02603419|10034081|FG001|Lead-in Phase:Maximum Exposure:123Weeks|No Longer Meets Eligibility Criteria|1
6307291|NCT02603419|10034082|FG002|Lead-in Phase:Maximum Exposure:123Weeks|No Longer Meets Eligibility Criteria|0
6307292|NCT02603419|10034083|FG003|Lead-in Phase:Maximum Exposure:123Weeks|No Longer Meets Eligibility Criteria|0
6307293|NCT02603419|10034084|FG004|Lead-in Phase:Maximum Exposure:123Weeks|No Longer Meets Eligibility Criteria|0
6307294|NCT02603419|10034085|FG005|Lead-in Phase:Maximum Exposure:123Weeks|No Longer Meets Eligibility Criteria|0
6307295|NCT02603419|10034080|FG000|Lead-in Phase:Maximum Exposure:123Weeks|Other|2
6307296|NCT02603419|10034081|FG001|Lead-in Phase:Maximum Exposure:123Weeks|Other|1
6307297|NCT02603419|10034082|FG002|Lead-in Phase:Maximum Exposure:123Weeks|Other|1
6307298|NCT02603419|10034083|FG003|Lead-in Phase:Maximum Exposure:123Weeks|Other|0
6307299|NCT02603419|10034084|FG004|Lead-in Phase:Maximum Exposure:123Weeks|Other|1
6307300|NCT02603419|10034085|FG005|Lead-in Phase:Maximum Exposure:123Weeks|Other|0
6307301|NCT02603419|10034080|FG000|Lead-in Phase:Maximum Exposure:123Weeks|Withdrawal by Subject|0
6307302|NCT02603419|10034081|FG001|Lead-in Phase:Maximum Exposure:123Weeks|Withdrawal by Subject|0
6307303|NCT02603419|10034082|FG002|Lead-in Phase:Maximum Exposure:123Weeks|Withdrawal by Subject|0
6307304|NCT02603419|10034083|FG003|Lead-in Phase:Maximum Exposure:123Weeks|Withdrawal by Subject|2
6307305|NCT02603419|10034084|FG004|Lead-in Phase:Maximum Exposure:123Weeks|Withdrawal by Subject|0
6307306|NCT02603419|10034085|FG005|Lead-in Phase:Maximum Exposure:123Weeks|Withdrawal by Subject|0
6307307|NCT02603419|10034080|FG000|Expansion Phase:Maximum Exposure:48Weeks|Lost to Follow-up|0
6307308|NCT02603419|10034081|FG001|Expansion Phase:Maximum Exposure:48Weeks|Lost to Follow-up|0
6307309|NCT02603419|10034082|FG002|Expansion Phase:Maximum Exposure:48Weeks|Lost to Follow-up|0
6307310|NCT02603419|10034083|FG003|Expansion Phase:Maximum Exposure:48Weeks|Lost to Follow-up|0
6307311|NCT02603419|10034084|FG004|Expansion Phase:Maximum Exposure:48Weeks|Lost to Follow-up|0
6307312|NCT02603419|10034085|FG005|Expansion Phase:Maximum Exposure:48Weeks|Lost to Follow-up|1
6307313|NCT02603419|10034080|FG000|Expansion Phase:Maximum Exposure:48Weeks|Death|0
6307314|NCT02603419|10034081|FG001|Expansion Phase:Maximum Exposure:48Weeks|Death|0
6307315|NCT02603419|10034082|FG002|Expansion Phase:Maximum Exposure:48Weeks|Death|0
6307316|NCT02603419|10034083|FG003|Expansion Phase:Maximum Exposure:48Weeks|Death|0
6307317|NCT02603419|10034084|FG004|Expansion Phase:Maximum Exposure:48Weeks|Death|0
6307318|NCT02603419|10034085|FG005|Expansion Phase:Maximum Exposure:48Weeks|Death|1
6307319|NCT02603419|10034080|FG000|Expansion Phase:Maximum Exposure:48Weeks|Withdrawal by Subject|0
6307320|NCT02603419|10034081|FG001|Expansion Phase:Maximum Exposure:48Weeks|Withdrawal by Subject|0
6307321|NCT02603419|10034082|FG002|Expansion Phase:Maximum Exposure:48Weeks|Withdrawal by Subject|0
6307322|NCT02603419|10034083|FG003|Expansion Phase:Maximum Exposure:48Weeks|Withdrawal by Subject|0
6307323|NCT02603419|10034084|FG004|Expansion Phase:Maximum Exposure:48Weeks|Withdrawal by Subject|0
6307324|NCT02603419|10034085|FG005|Expansion Phase:Maximum Exposure:48Weeks|Withdrawal by Subject|1
6307325|NCT02603809|10034110|FG000|Overall Study|Withdrawal by Subject|4
6307326|NCT02603809|10034111|FG001|Overall Study|Withdrawal by Subject|1
6307327|NCT02603809|10034112|FG002|Overall Study|Withdrawal by Subject|2
6307328|NCT02603809|10034113|FG003|Overall Study|Withdrawal by Subject|3
6307329|NCT02603809|10034114|FG004|Overall Study|Withdrawal by Subject|3
6307330|NCT02603809|10034115|FG005|Overall Study|Withdrawal by Subject|4
6307331|NCT02603809|10034110|FG000|Overall Study|Lost to Follow-up|2
6307332|NCT02603809|10034111|FG001|Overall Study|Lost to Follow-up|3
6307333|NCT02603809|10034112|FG002|Overall Study|Lost to Follow-up|1
6307334|NCT02603809|10034113|FG003|Overall Study|Lost to Follow-up|4
6307335|NCT02603809|10034114|FG004|Overall Study|Lost to Follow-up|2
6307336|NCT02603809|10034115|FG005|Overall Study|Lost to Follow-up|2
5983236|NCT00439738|9572963|FG000|Overall Study|Withdrawal by Subject|16
5983237|NCT00439738|9572964|FG001|Overall Study|Withdrawal by Subject|13
5983238|NCT00439738|9572963|FG000|Overall Study|Adverse Event|6
5983239|NCT00439738|9572964|FG001|Overall Study|Adverse Event|4
5983240|NCT00439738|9572963|FG000|Overall Study|Lost to Follow-up|5
5983241|NCT00439738|9572964|FG001|Overall Study|Lost to Follow-up|6
5983242|NCT00439738|9572963|FG000|Overall Study|Protocol Violation|6
5983243|NCT00439738|9572964|FG001|Overall Study|Protocol Violation|3
5983244|NCT00439738|9572963|FG000|Overall Study|Lack of Efficacy|2
5983245|NCT00439738|9572964|FG001|Overall Study|Lack of Efficacy|2
5983246|NCT00439738|9572963|FG000|Overall Study|Abnormal Lab Values|1
5983247|NCT00439738|9572964|FG001|Overall Study|Abnormal Lab Values|0
5983248|NCT00430950|9572977|FG000|Overall Study|Adverse Event|7
5983249|NCT00430950|9572978|FG001|Overall Study|Adverse Event|6
5983250|NCT00430950|9572977|FG000|Overall Study|Withdrawal by Subject|1
5983251|NCT00430950|9572978|FG001|Overall Study|Withdrawal by Subject|0
5983252|NCT00430950|9572977|FG000|Overall Study|concomitant medication,etc.|5
5983253|NCT00430950|9572978|FG001|Overall Study|concomitant medication,etc.|7
6064599|NCT00514540|9666317|FG000|First-Line Chemo|Protocol Violation|7
6064600|NCT00514540|9666317|FG000|Second-Line|Physician/Patient Decision|31
6064601|NCT00514683|9666334|FG000|Overall Study|Not treated|2
6064602|NCT00514683|9666335|FG001|Overall Study|Not treated|1
6064603|NCT00514683|9666336|FG002|Overall Study|Not treated|0
6064604|NCT00514683|9666337|FG003|Overall Study|Not treated|0
6064605|NCT00514683|9666338|FG004|Overall Study|Not treated|1
6064606|NCT00514683|9666334|FG000|Overall Study|Adverse Event|21
6064607|NCT00514683|9666335|FG001|Overall Study|Adverse Event|20
6064608|NCT00514683|9666336|FG002|Overall Study|Adverse Event|15
6064609|NCT00514683|9666337|FG003|Overall Study|Adverse Event|13
6064610|NCT00514683|9666338|FG004|Overall Study|Adverse Event|27
6064611|NCT00514683|9666334|FG000|Overall Study|Protocol Violation|1
6064612|NCT00514683|9666335|FG001|Overall Study|Protocol Violation|1
6064613|NCT00514683|9666336|FG002|Overall Study|Protocol Violation|0
6064614|NCT00514683|9666337|FG003|Overall Study|Protocol Violation|1
6064615|NCT00514683|9666338|FG004|Overall Study|Protocol Violation|0
6064616|NCT00514683|9666334|FG000|Overall Study|Withdrawal by Subject|2
6064617|NCT00514683|9666335|FG001|Overall Study|Withdrawal by Subject|2
6064618|NCT00514683|9666336|FG002|Overall Study|Withdrawal by Subject|1
6064619|NCT00514683|9666337|FG003|Overall Study|Withdrawal by Subject|0
6064620|NCT00514683|9666338|FG004|Overall Study|Withdrawal by Subject|4
6064621|NCT00514683|9666334|FG000|Overall Study|Reason other than listed above|0
6064622|NCT00514683|9666335|FG001|Overall Study|Reason other than listed above|1
6064623|NCT00514683|9666336|FG002|Overall Study|Reason other than listed above|2
6064624|NCT00514683|9666337|FG003|Overall Study|Reason other than listed above|0
6064625|NCT00514683|9666338|FG004|Overall Study|Reason other than listed above|1
6064626|NCT00514735|9666367|FG000|Overall Study|Withdrawal by Subject|13
6064627|NCT00514735|9666368|FG001|Overall Study|Withdrawal by Subject|5
6064628|NCT00514735|9666367|FG000|Overall Study|Death|1
6064629|NCT00514735|9666368|FG001|Overall Study|Death|0
6064630|NCT00514735|9666367|FG000|Overall Study|Lost to Follow-up|0
6064631|NCT00514735|9666368|FG001|Overall Study|Lost to Follow-up|1
6064632|NCT00514904|9666387|FG000|Overall Study|Withdrawal by Subject|3
6064633|NCT00514904|9666388|FG001|Overall Study|Withdrawal by Subject|2
6064634|NCT00514904|9666387|FG000|Overall Study|Lost to Follow-up|21
6064635|NCT00514904|9666388|FG001|Overall Study|Lost to Follow-up|3
6064636|NCT00514917|9666396|FG000|Overall Study|Death|4
6064637|NCT00514917|9666397|FG001|Overall Study|Death|10
6064638|NCT00514917|9666396|FG000|Overall Study|Protocol Violation|1
6064639|NCT00514917|9666397|FG001|Overall Study|Protocol Violation|0
6064640|NCT00514917|9666396|FG000|Overall Study|Lost to Follow-up|4
6064641|NCT00514917|9666397|FG001|Overall Study|Lost to Follow-up|3
6064642|NCT00514917|9666396|FG000|Overall Study|Withdrawal by Subject|18
6064643|NCT00514917|9666397|FG001|Overall Study|Withdrawal by Subject|16
6064644|NCT00514917|9666396|FG000|Overall Study|Discontinued due to study closure|88
6064645|NCT00514917|9666397|FG001|Overall Study|Discontinued due to study closure|81
6064646|NCT00514917|9666396|FG000|Overall Study|Undefined|11
6064647|NCT00514917|9666397|FG001|Overall Study|Undefined|5
6064648|NCT00514943|9666407|FG000|Stage 1|Progressive disease|4
6064649|NCT00514943|9666408|FG001|Stage 1|Progressive disease|8
6064650|NCT00514943|9666407|FG000|Stage 1|Other Adverse Event|16
6064651|NCT00514943|9666408|FG001|Stage 1|Other Adverse Event|6
6064652|NCT00514943|9666407|FG000|Stage 1|Not treated|1
6064653|NCT00514943|9666408|FG001|Stage 1|Not treated|2
6064654|NCT00514943|9666407|FG000|Stage 1|Patient refused to continue study meds|8
6064655|NCT00514943|9666408|FG001|Stage 1|Patient refused to continue study meds|3
6064656|NCT00514943|9666407|FG000|Stage 1|Other than stated above|1
6064657|NCT00514943|9666408|FG001|Stage 1|Other than stated above|7
6064658|NCT00514943|9666407|FG000|Stage 2|Progressive disease|27
6064659|NCT00514943|9666408|FG001|Stage 2|Progressive disease|24
6064660|NCT00514943|9666407|FG000|Stage 2|Other Adverse Event|3
6064661|NCT00514943|9666408|FG001|Stage 2|Other Adverse Event|10
6064662|NCT00514943|9666407|FG000|Stage 2|Patient refused to continue study meds|2
6064663|NCT00514943|9666408|FG001|Stage 2|Patient refused to continue study meds|0
6064664|NCT00514943|9666407|FG000|Stage 2|Other than stated above|0
6064665|NCT00514943|9666408|FG001|Stage 2|Other than stated above|2
6064666|NCT00515008|9666431|FG000|Overall Study|Lost to Follow-up|1
6064667|NCT00515008|9666432|FG001|Overall Study|Lost to Follow-up|0
6064668|NCT00515008|9666431|FG000|Overall Study|Declined|0
6064669|NCT00515008|9666432|FG001|Overall Study|Declined|3
6064670|NCT00515008|9666431|FG000|Overall Study|Left the Boston Area|1
6064671|NCT00515008|9666432|FG001|Overall Study|Left the Boston Area|1
6064672|NCT00515008|9666431|FG000|Overall Study|Scheduling conflict|1
6064673|NCT00515008|9666432|FG001|Overall Study|Scheduling conflict|0
6064674|NCT00515034|9666456|FG000|Overall Study|Adverse Event|2
6064675|NCT00515034|9666457|FG001|Overall Study|Adverse Event|0
6064676|NCT00515034|9666458|FG002|Overall Study|Adverse Event|1
6064677|NCT00515034|9666459|FG003|Overall Study|Adverse Event|0
6064678|NCT00515034|9666456|FG000|Overall Study|Death|4
6064679|NCT00515034|9666457|FG001|Overall Study|Death|2
6064680|NCT00515034|9666458|FG002|Overall Study|Death|1
6064681|NCT00515034|9666459|FG003|Overall Study|Death|3
6064682|NCT00515034|9666456|FG000|Overall Study|Withdrawal by Subject|1
6064683|NCT00515034|9666457|FG001|Overall Study|Withdrawal by Subject|0
6064684|NCT00515034|9666458|FG002|Overall Study|Withdrawal by Subject|3
6064685|NCT00515034|9666459|FG003|Overall Study|Withdrawal by Subject|0
6064686|NCT00515034|9666456|FG000|Overall Study|Physician Decision|0
6064687|NCT00515034|9666457|FG001|Overall Study|Physician Decision|0
6064688|NCT00515034|9666458|FG002|Overall Study|Physician Decision|1
6064689|NCT00515034|9666459|FG003|Overall Study|Physician Decision|1
6064690|NCT00515034|9666456|FG000|Overall Study|Other|1
6064691|NCT00515034|9666457|FG001|Overall Study|Other|0
6064692|NCT00515034|9666458|FG002|Overall Study|Other|2
6064693|NCT00515034|9666459|FG003|Overall Study|Other|1
6064694|NCT00515073|9666469|FG000|Overall Study|Withdrawal by Subject|1
6064695|NCT00515073|9666469|FG000|Overall Study|Physician Decision|1
6064696|NCT00515086|9666477|FG000|Overall Study|Adverse Event|1
6064697|NCT00515086|9666478|FG001|Overall Study|Adverse Event|1
6064698|NCT00515086|9666479|FG002|Overall Study|Adverse Event|2
6064699|NCT00515086|9666480|FG003|Overall Study|Adverse Event|3
6064700|NCT00515086|9666477|FG000|Overall Study|Administrative|1
5983254|NCT00430508|9572986|FG000|Overall Study|Adverse Event|2
6145994|NCT01074944|9780554|FG000|Primary Analysis Period (up to 52 Weeks)|Adverse Event|0
6064701|NCT00515086|9666478|FG001|Overall Study|Administrative|1
6064702|NCT00515086|9666479|FG002|Overall Study|Administrative|0
6064703|NCT00515086|9666480|FG003|Overall Study|Administrative|0
6064704|NCT00515086|9666477|FG000|Overall Study|Withdrawal by Subject|1
6064705|NCT00515086|9666478|FG001|Overall Study|Withdrawal by Subject|0
6064706|NCT00515086|9666479|FG002|Overall Study|Withdrawal by Subject|0
6064707|NCT00515086|9666480|FG003|Overall Study|Withdrawal by Subject|1
6064708|NCT00515086|9666477|FG000|Overall Study|Unsatisfactory therapeutic effect|18
6064709|NCT00515086|9666478|FG001|Overall Study|Unsatisfactory therapeutic effect|3
6064710|NCT00515086|9666479|FG002|Overall Study|Unsatisfactory therapeutic effect|3
6064711|NCT00515086|9666480|FG003|Overall Study|Unsatisfactory therapeutic effect|2
6064712|NCT00515086|9666477|FG000|Overall Study|Lost to Follow-up|1
5983255|NCT00430508|9572987|FG001|Overall Study|Adverse Event|3
5983256|NCT00430508|9572988|FG002|Overall Study|Adverse Event|5
5983257|NCT00430508|9572989|FG003|Overall Study|Adverse Event|3
5983258|NCT00430508|9572986|FG000|Overall Study|Withdrawal by Subject|0
5983259|NCT00430508|9572987|FG001|Overall Study|Withdrawal by Subject|1
5983260|NCT00430508|9572988|FG002|Overall Study|Withdrawal by Subject|1
5983261|NCT00430508|9572989|FG003|Overall Study|Withdrawal by Subject|1
5983262|NCT00430508|9572986|FG000|Overall Study|responder at visit 4|0
5983263|NCT00430508|9572987|FG001|Overall Study|responder at visit 4|0
5983264|NCT00430508|9572988|FG002|Overall Study|responder at visit 4|2
5983265|NCT00430508|9572989|FG003|Overall Study|responder at visit 4|0
5983266|NCT00430508|9572986|FG000|Overall Study|conmed-BP-pulse-ABPM withdrawal criteria|0
5983267|NCT00430508|9572987|FG001|Overall Study|conmed-BP-pulse-ABPM withdrawal criteria|1
5983268|NCT00430508|9572988|FG002|Overall Study|conmed-BP-pulse-ABPM withdrawal criteria|2
5983269|NCT00430508|9572989|FG003|Overall Study|conmed-BP-pulse-ABPM withdrawal criteria|1
5983270|NCT00430508|9572986|FG000|Overall Study|Other|1
5983271|NCT00430508|9572987|FG001|Overall Study|Other|1
5983272|NCT00430508|9572988|FG002|Overall Study|Other|3
5983273|NCT00430508|9572989|FG003|Overall Study|Other|0
5983274|NCT00430092|9572998|FG000|Overall Study|Adverse Event|0
5983275|NCT00430092|9572999|FG001|Overall Study|Adverse Event|0
5983276|NCT00430092|9573000|FG002|Overall Study|Adverse Event|1
5983277|NCT00430092|9572998|FG000|Overall Study|Lack of Efficacy|5
5983278|NCT00430092|9572999|FG001|Overall Study|Lack of Efficacy|2
5983279|NCT00430092|9573000|FG002|Overall Study|Lack of Efficacy|54
5983280|NCT00430092|9572998|FG000|Overall Study|Lost to Follow-up|1
5983281|NCT00430092|9572999|FG001|Overall Study|Lost to Follow-up|0
5983282|NCT00430092|9573000|FG002|Overall Study|Lost to Follow-up|0
5983283|NCT00430092|9572998|FG000|Overall Study|Protocol Violation|0
5983284|NCT00430092|9572999|FG001|Overall Study|Protocol Violation|1
5983285|NCT00430092|9573000|FG002|Overall Study|Protocol Violation|1
5983286|NCT00430092|9572998|FG000|Overall Study|Withdrawal by Subject|0
5983287|NCT00430092|9572999|FG001|Overall Study|Withdrawal by Subject|1
5983288|NCT00430092|9573000|FG002|Overall Study|Withdrawal by Subject|1
6043770|NCT00391976|9642544|FG000|Overall Study|Unable to classify|0
6043771|NCT00391976|9642545|FG001|Overall Study|Unable to classify|0
6043772|NCT00391976|9642546|FG002|Overall Study|Unable to classify|1
6043773|NCT00391976|9642544|FG000|Overall Study|Positive P. aeruginosa antibody test|0
6043774|NCT00391976|9642545|FG001|Overall Study|Positive P. aeruginosa antibody test|0
6043775|NCT00391976|9642546|FG002|Overall Study|Positive P. aeruginosa antibody test|31
6043776|NCT00392015|9642566|FG000|Overall Study|Lost to Follow-up|2
6043777|NCT00392015|9642567|FG001|Overall Study|Lost to Follow-up|0
6043778|NCT00392015|9642568|FG002|Overall Study|Lost to Follow-up|2
6043779|NCT00392015|9642569|FG003|Overall Study|Lost to Follow-up|1
6043780|NCT00392015|9642570|FG004|Overall Study|Lost to Follow-up|1
6043781|NCT00392015|9642571|FG005|Overall Study|Lost to Follow-up|0
6043782|NCT00392015|9642566|FG000|Overall Study|Withdrawal by Subject|0
6043783|NCT00392015|9642567|FG001|Overall Study|Withdrawal by Subject|0
6043784|NCT00392015|9642568|FG002|Overall Study|Withdrawal by Subject|2
6043785|NCT00392015|9642569|FG003|Overall Study|Withdrawal by Subject|0
6043786|NCT00392015|9642570|FG004|Overall Study|Withdrawal by Subject|0
6043787|NCT00392015|9642571|FG005|Overall Study|Withdrawal by Subject|0
6043788|NCT00392015|9642566|FG000|Overall Study|Adverse Event|0
6043789|NCT00392015|9642567|FG001|Overall Study|Adverse Event|0
6043790|NCT00392015|9642568|FG002|Overall Study|Adverse Event|0
6043791|NCT00392015|9642569|FG003|Overall Study|Adverse Event|0
6043792|NCT00392015|9642570|FG004|Overall Study|Adverse Event|1
6043793|NCT00392015|9642571|FG005|Overall Study|Adverse Event|0
6043794|NCT00392015|9642566|FG000|Overall Study|Previous trial recipient|0
6043795|NCT00392015|9642567|FG001|Overall Study|Previous trial recipient|0
6043796|NCT00392015|9642568|FG002|Overall Study|Previous trial recipient|0
6043797|NCT00392015|9642569|FG003|Overall Study|Previous trial recipient|0
6043798|NCT00392015|9642570|FG004|Overall Study|Previous trial recipient|1
6043799|NCT00392015|9642571|FG005|Overall Study|Previous trial recipient|0
6043800|NCT00392171|9642612|FG000|Overall Study|Did not meet inclusion criteria|4
6043801|NCT00392171|9642612|FG000|Overall Study|Disease progression|101
6043802|NCT00392197|9642618|FG000|Overall Study|Adverse Event|4
6043803|NCT00392197|9642619|FG001|Overall Study|Adverse Event|12
6043804|NCT00392197|9642618|FG000|Overall Study|Lack of Efficacy|3
6043805|NCT00392197|9642619|FG001|Overall Study|Lack of Efficacy|4
6043806|NCT00392197|9642618|FG000|Overall Study|Lost to Follow-up|0
6043807|NCT00392197|9642619|FG001|Overall Study|Lost to Follow-up|1
6043808|NCT00392197|9642618|FG000|Overall Study|Physician Decision|3
6043809|NCT00392197|9642619|FG001|Overall Study|Physician Decision|2
6043810|NCT00392197|9642618|FG000|Overall Study|Protocol Violation|7
6043811|NCT00392197|9642619|FG001|Overall Study|Protocol Violation|5
6043812|NCT00392197|9642618|FG000|Overall Study|Withdrawal by Subject|4
6043813|NCT00392197|9642619|FG001|Overall Study|Withdrawal by Subject|6
6043814|NCT00392210|9642627|FG000|First Voiding Trial|Physician Decision|2
6043815|NCT00392210|9642628|FG001|First Voiding Trial|Physician Decision|2
6043816|NCT00392223|9642636|FG000|Overall Study|Adverse Event|5
6043817|NCT00392223|9642637|FG001|Overall Study|Adverse Event|4
6043818|NCT00392223|9642636|FG000|Overall Study|Lost to Follow-up|1
6043819|NCT00392223|9642637|FG001|Overall Study|Lost to Follow-up|4
6043820|NCT00392223|9642636|FG000|Overall Study|Protocol Violation|0
6043821|NCT00392223|9642637|FG001|Overall Study|Protocol Violation|3
6043822|NCT00392223|9642636|FG000|Overall Study|Withdrawal by Subject|3
6043823|NCT00392223|9642637|FG001|Overall Study|Withdrawal by Subject|2
6043824|NCT00392288|9642655|FG000|Overall Study|Adverse Event|17
6043825|NCT00392288|9642656|FG001|Overall Study|Adverse Event|7
6043826|NCT00392288|9642657|FG002|Overall Study|Adverse Event|8
6043827|NCT00392288|9642655|FG000|Overall Study|Lack of Efficacy|8
6043828|NCT00392288|9642656|FG001|Overall Study|Lack of Efficacy|5
6043829|NCT00392288|9642657|FG002|Overall Study|Lack of Efficacy|3
6043830|NCT00392288|9642655|FG000|Overall Study|Protocol Violation|1
6043831|NCT00392288|9642656|FG001|Overall Study|Protocol Violation|3
6043832|NCT00392288|9642657|FG002|Overall Study|Protocol Violation|1
6043833|NCT00392288|9642655|FG000|Overall Study|Lost to Follow-up|1
6043834|NCT00392288|9642656|FG001|Overall Study|Lost to Follow-up|1
6043835|NCT00392288|9642657|FG002|Overall Study|Lost to Follow-up|1
6043836|NCT00392288|9642655|FG000|Overall Study|Withdrawal by Subject|1
6043837|NCT00392288|9642656|FG001|Overall Study|Withdrawal by Subject|0
6145995|NCT01074944|9780555|FG001|Primary Analysis Period (up to 52 Weeks)|Adverse Event|2
6145996|NCT01074944|9780556|FG002|Primary Analysis Period (up to 52 Weeks)|Adverse Event|3
6145997|NCT01074944|9780557|FG003|Primary Analysis Period (up to 52 Weeks)|Adverse Event|0
6145998|NCT01074944|9780558|FG004|Primary Analysis Period (up to 52 Weeks)|Adverse Event|0
6145999|NCT01074944|9780554|FG000|Primary Analysis Period (up to 52 Weeks)|Treatment Failure|0
6146000|NCT01074944|9780555|FG001|Primary Analysis Period (up to 52 Weeks)|Treatment Failure|6
5983289|NCT00429923|9573008|FG000|Overall Study|Adverse Event|0
5983290|NCT00429923|9573009|FG001|Overall Study|Adverse Event|2
5983291|NCT00429923|9573010|FG002|Overall Study|Adverse Event|3
5983292|NCT00429923|9573008|FG000|Overall Study|Lack of Efficacy|4
5983293|NCT00429923|9573009|FG001|Overall Study|Lack of Efficacy|1
5983294|NCT00429923|9573010|FG002|Overall Study|Lack of Efficacy|33
5983295|NCT00429923|9573008|FG000|Overall Study|Lost to Follow-up|0
5983296|NCT00429923|9573009|FG001|Overall Study|Lost to Follow-up|0
5983297|NCT00429923|9573010|FG002|Overall Study|Lost to Follow-up|2
5983298|NCT00429923|9573008|FG000|Overall Study|Withdrew Consent|1
5983299|NCT00429923|9573009|FG001|Overall Study|Withdrew Consent|0
5983300|NCT00429923|9573010|FG002|Overall Study|Withdrew Consent|1
5983301|NCT00429923|9573008|FG000|Overall Study|Early Termination|0
5983302|NCT00429923|9573009|FG001|Overall Study|Early Termination|1
5983303|NCT00429923|9573010|FG002|Overall Study|Early Termination|0
5983304|NCT00425100|9573015|FG000|Overall Study|Adverse Event|36
5983305|NCT00425100|9573015|FG000|Overall Study|Lack of Efficacy|4
5983306|NCT00425100|9573015|FG000|Overall Study|Lost to Follow-up|2
5983307|NCT00425100|9573015|FG000|Overall Study|Protocol Violation|4
5983308|NCT00425100|9573015|FG000|Overall Study|Withdrawal by Subject|7
5983309|NCT00415623|9573022|FG000|Overall Study|Adverse Event|3
5983310|NCT00415623|9573023|FG001|Overall Study|Adverse Event|4
5983311|NCT00415623|9573022|FG000|Overall Study|Death|1
5983312|NCT00415623|9573023|FG001|Overall Study|Death|0
5983313|NCT00415623|9573022|FG000|Overall Study|Withdrawal by Subject|1
5983314|NCT00415623|9573023|FG001|Overall Study|Withdrawal by Subject|1
5983315|NCT00412932|9573030|FG000|Olmesartan (Olm) 20 mg|Adverse Event|1
5983316|NCT00412932|9573030|FG000|Olmesartan (Olm) 20 mg|Lack of Efficacy|2
5983317|NCT00412932|9573030|FG000|Olmesartan (Olm) 20 mg|Protocol Violation|1
5983318|NCT00412932|9573030|FG000|Olmesartan (Olm) 20 mg|Withdrawal by Subject|2
5983319|NCT00412932|9573030|FG000|Olmesartan (Olm) 20 mg|Other|1
5983320|NCT00412932|9573030|FG000|Olmesartan 40 mg|Adverse Event|4
5983321|NCT00412932|9573030|FG000|Olmesartan 40 mg|Lack of Efficacy|3
5983322|NCT00412932|9573030|FG000|Olmesartan 40 mg|Withdrawal by Subject|1
5983323|NCT00412932|9573030|FG000|Olm+Hydrochlorothiazide 12.5 mg|Adverse Event|3
5983324|NCT00412932|9573030|FG000|Olm+Hydrochlorothiazide 12.5 mg|Withdrawal by Subject|3
5983325|NCT00412932|9573030|FG000|Olm+ Hydrochlorothiazide 25 mg|Adverse Event|1
5983326|NCT00412932|9573030|FG000|Olm+ Hydrochlorothiazide 25 mg|Lost to Follow-up|1
5983327|NCT00397254|9573033|FG000|Overall Study|Lost to Follow-up|2
5983328|NCT00397254|9573034|FG001|Overall Study|Lost to Follow-up|2
6043838|NCT00392288|9642657|FG002|Overall Study|Withdrawal by Subject|2
6043839|NCT00392288|9642655|FG000|Overall Study|Parent/legal guardian withdrawal|1
6043840|NCT00392288|9642656|FG001|Overall Study|Parent/legal guardian withdrawal|2
6043841|NCT00392288|9642657|FG002|Overall Study|Parent/legal guardian withdrawal|1
6043842|NCT00392288|9642655|FG000|Overall Study|Other|3
6043843|NCT00392288|9642656|FG001|Overall Study|Other|4
6043844|NCT00392288|9642657|FG002|Overall Study|Other|1
6043845|NCT00392379|9642667|FG000|Overall Study|Withdrawal by Subject|17
6043846|NCT00392379|9642668|FG001|Overall Study|Withdrawal by Subject|28
6043847|NCT00392379|9642667|FG000|Overall Study|Lost to Follow-up|4
6043848|NCT00392379|9642668|FG001|Overall Study|Lost to Follow-up|9
6043849|NCT00392379|9642667|FG000|Overall Study|Adverse Event|1
6043850|NCT00392379|9642668|FG001|Overall Study|Adverse Event|1
6043851|NCT00392665|9642688|FG000|Overall Study|Death|16
6043852|NCT00392665|9642689|FG001|Overall Study|Death|14
6043853|NCT00392665|9642688|FG000|Overall Study|Lost to Follow-up|1
6043854|NCT00392665|9642689|FG001|Overall Study|Lost to Follow-up|1
6043855|NCT00392769|9642725|FG000|Overall Study|Clinical Deterioration|9
6043856|NCT00392769|9642725|FG000|Overall Study|Adverse Event|1
6043857|NCT00392808|9642737|FG000|Overall Study|Lost to Follow-up|3
6043858|NCT00392808|9642738|FG001|Overall Study|Lost to Follow-up|2
6043859|NCT00392808|9642739|FG002|Overall Study|Lost to Follow-up|1
6043860|NCT00392808|9642740|FG003|Overall Study|Lost to Follow-up|2
6043861|NCT00392808|9642737|FG000|Overall Study|Unable to withdraw blood|3
6043862|NCT00392808|9642738|FG001|Overall Study|Unable to withdraw blood|1
6043863|NCT00392808|9642739|FG002|Overall Study|Unable to withdraw blood|1
6043864|NCT00392808|9642740|FG003|Overall Study|Unable to withdraw blood|2
6043865|NCT00392925|9642763|FG000|4 Week Lead-In Period - Non-Randomized|Withdrawal by Subject|11
6043866|NCT00392925|9642764|FG001|4 Week Lead-In Period - Non-Randomized|Withdrawal by Subject|0
6043867|NCT00392925|9642765|FG002|4 Week Lead-In Period - Non-Randomized|Withdrawal by Subject|0
6043868|NCT00392925|9642766|FG003|4 Week Lead-In Period - Non-Randomized|Withdrawal by Subject|0
6043869|NCT00392925|9642763|FG000|4 Week Lead-In Period - Non-Randomized|Adverse Event|5
6043870|NCT00392925|9642764|FG001|4 Week Lead-In Period - Non-Randomized|Adverse Event|0
6043871|NCT00392925|9642765|FG002|4 Week Lead-In Period - Non-Randomized|Adverse Event|0
6043872|NCT00392925|9642766|FG003|4 Week Lead-In Period - Non-Randomized|Adverse Event|0
6043873|NCT00392925|9642763|FG000|4 Week Lead-In Period - Non-Randomized|Physician Decision|1
6043874|NCT00392925|9642764|FG001|4 Week Lead-In Period - Non-Randomized|Physician Decision|0
6043875|NCT00392925|9642765|FG002|4 Week Lead-In Period - Non-Randomized|Physician Decision|0
6146001|NCT01074944|9780556|FG002|Primary Analysis Period (up to 52 Weeks)|Treatment Failure|1
6146002|NCT01074944|9780557|FG003|Primary Analysis Period (up to 52 Weeks)|Treatment Failure|0
6146003|NCT01074944|9780558|FG004|Primary Analysis Period (up to 52 Weeks)|Treatment Failure|0
6193342|NCT01437397|9850966|FG000|Overall Study|Adverse Event|21
5983329|NCT00338104|9573062|FG000|Overall Study|Protocol Violation|2
5983330|NCT00338104|9573063|FG001|Overall Study|Protocol Violation|1
5983331|NCT00338104|9573064|FG002|Overall Study|Protocol Violation|3
5983332|NCT00326183|9573074|FG000|Overall Study|Lost to Follow-up|104
5983333|NCT00326183|9573075|FG001|Overall Study|Lost to Follow-up|56
5983334|NCT00326183|9573074|FG000|Overall Study|Protocol Violation|6
5983335|NCT00326183|9573075|FG001|Overall Study|Protocol Violation|3
5983336|NCT00326183|9573074|FG000|Overall Study|Withdrawal by Subject|35
5983337|NCT00326183|9573075|FG001|Overall Study|Withdrawal by Subject|7
5983338|NCT00326183|9573074|FG000|Overall Study|Subject Moved|7
5983339|NCT00326183|9573075|FG001|Overall Study|Subject Moved|4
5983340|NCT00326183|9573074|FG000|Overall Study|Other|47
5983341|NCT00326183|9573075|FG001|Overall Study|Other|13
5983342|NCT00326183|9573074|FG000|Overall Study|Adverse Event|1
5983343|NCT00326183|9573075|FG001|Overall Study|Adverse Event|0
5983344|NCT00318656|9573088|FG000|Overall Study|Took Avandamet instead of Glim/Met|0
5983345|NCT00318656|9573089|FG001|Overall Study|Took Avandamet instead of Glim/Met|1
5983346|NCT00318656|9573088|FG000|Overall Study|Did not receive any treatment|0
5983347|NCT00318656|9573089|FG001|Overall Study|Did not receive any treatment|1
6043876|NCT00392925|9642766|FG003|4 Week Lead-In Period - Non-Randomized|Physician Decision|0
6043877|NCT00392925|9642763|FG000|4 Week Lead-In Period - Non-Randomized|Lost to Follow-up|5
6043878|NCT00392925|9642764|FG001|4 Week Lead-In Period - Non-Randomized|Lost to Follow-up|0
6043879|NCT00392925|9642765|FG002|4 Week Lead-In Period - Non-Randomized|Lost to Follow-up|0
6043880|NCT00392925|9642766|FG003|4 Week Lead-In Period - Non-Randomized|Lost to Follow-up|0
6043881|NCT00392925|9642763|FG000|4 Week Lead-In Period - Non-Randomized|did not meet weight loss criteria|16
6043882|NCT00392925|9642764|FG001|4 Week Lead-In Period - Non-Randomized|did not meet weight loss criteria|0
6043883|NCT00392925|9642765|FG002|4 Week Lead-In Period - Non-Randomized|did not meet weight loss criteria|0
6043884|NCT00392925|9642766|FG003|4 Week Lead-In Period - Non-Randomized|did not meet weight loss criteria|0
6043885|NCT00392925|9642763|FG000|Randomization to Treatment Group Period|Withdrawal by Subject|0
6043886|NCT00392925|9642764|FG001|Randomization to Treatment Group Period|Withdrawal by Subject|2
6043887|NCT00392925|9642765|FG002|Randomization to Treatment Group Period|Withdrawal by Subject|6
6043888|NCT00392925|9642766|FG003|Randomization to Treatment Group Period|Withdrawal by Subject|8
6043889|NCT00392925|9642763|FG000|Randomization to Treatment Group Period|Adverse Event|0
6043890|NCT00392925|9642764|FG001|Randomization to Treatment Group Period|Adverse Event|3
6043891|NCT00392925|9642765|FG002|Randomization to Treatment Group Period|Adverse Event|3
6043892|NCT00392925|9642766|FG003|Randomization to Treatment Group Period|Adverse Event|5
6043893|NCT00392925|9642763|FG000|Randomization to Treatment Group Period|Protocol Violation|0
6043894|NCT00392925|9642764|FG001|Randomization to Treatment Group Period|Protocol Violation|0
6043895|NCT00392925|9642765|FG002|Randomization to Treatment Group Period|Protocol Violation|2
6043896|NCT00392925|9642766|FG003|Randomization to Treatment Group Period|Protocol Violation|1
6043897|NCT00392925|9642763|FG000|Randomization to Treatment Group Period|Lost to Follow-up|0
6043898|NCT00392925|9642764|FG001|Randomization to Treatment Group Period|Lost to Follow-up|3
6043899|NCT00392925|9642765|FG002|Randomization to Treatment Group Period|Lost to Follow-up|8
6043900|NCT00392925|9642766|FG003|Randomization to Treatment Group Period|Lost to Follow-up|4
6043901|NCT00392990|9642788|FG000|Treatment on Study|Adverse Event|3
6043902|NCT00392990|9642789|FG001|Treatment on Study|Adverse Event|1
6043903|NCT00392990|9642788|FG000|Follow up for 2 Years|Death|4
6043904|NCT00392990|9642789|FG001|Follow up for 2 Years|Death|0
6043905|NCT00393029|9642797|FG000|Overall Study|Not treated|0
6043906|NCT00393029|9642798|FG001|Overall Study|Not treated|1
6043907|NCT00393042|9642805|FG000|First Intervention|Withdrawal by Subject|1
6043908|NCT00393042|9642806|FG001|First Intervention|Withdrawal by Subject|2
6043909|NCT00393042|9642805|FG000|First Intervention|Lost to Follow-up|3
6043910|NCT00393042|9642806|FG001|First Intervention|Lost to Follow-up|3
6043911|NCT00393042|9642805|FG000|First Intervention|Protocol Violation|1
6043912|NCT00393042|9642806|FG001|First Intervention|Protocol Violation|0
6043913|NCT00393042|9642805|FG000|First Intervention|Adverse Event|0
6043914|NCT00393042|9642806|FG001|First Intervention|Adverse Event|1
6043915|NCT00393042|9642805|FG000|Second Intervetion|Adverse Event|0
5983348|NCT00301262|9573095|FG000|Double Blind Phase (DB)|Adverse Event|1
5983349|NCT00301262|9573096|FG001|Double Blind Phase (DB)|Adverse Event|0
5983350|NCT00301262|9573095|FG000|Double Blind Phase (DB)|Lack of Efficacy|0
5983351|NCT00301262|9573096|FG001|Double Blind Phase (DB)|Lack of Efficacy|1
5983352|NCT00301262|9573095|FG000|Double Blind Phase (DB)|Lost to Follow-up|3
5983353|NCT00301262|9573096|FG001|Double Blind Phase (DB)|Lost to Follow-up|3
5983354|NCT00301262|9573095|FG000|Double Blind Phase (DB)|Withdrawal by Subject|5
5983355|NCT00301262|9573096|FG001|Double Blind Phase (DB)|Withdrawal by Subject|5
5983356|NCT00301262|9573095|FG000|Double Blind Phase (DB)|Other|1
5983357|NCT00301262|9573096|FG001|Double Blind Phase (DB)|Other|4
5983358|NCT00301262|9573095|FG000|Open Label Phase (OL)|Adverse Event|1
5983359|NCT00301262|9573096|FG001|Open Label Phase (OL)|Adverse Event|0
5983360|NCT00301262|9573095|FG000|Open Label Phase (OL)|Lost to Follow-up|1
5983361|NCT00301262|9573096|FG001|Open Label Phase (OL)|Lost to Follow-up|2
5983362|NCT00301262|9573095|FG000|Open Label Phase (OL)|Other|2
5983363|NCT00301262|9573096|FG001|Open Label Phase (OL)|Other|0
5983364|NCT00283868|9573123|FG000|Overall Study|Lost to Follow-up|7
5983365|NCT00283868|9573124|FG001|Overall Study|Lost to Follow-up|8
5983366|NCT00282867|9573131|FG000|Overall Study|d/c prior to prim outcome, 3 m f/u done|1
5983367|NCT00282867|9573132|FG001|Overall Study|d/c prior to prim outcome, 3 m f/u done|1
5983368|NCT00282867|9573133|FG002|Overall Study|d/c prior to prim outcome, 3 m f/u done|0
5983369|NCT00275340|9573140|FG000|Overall Study|Lost to Follow-up|2
5983370|NCT00275340|9573141|FG001|Overall Study|Lost to Follow-up|4
5983371|NCT00271544|9573145|FG000|Overall Study|Subjects did not receive a 4196 lead|7
5983372|NCT00271544|9573145|FG000|Overall Study|Model 4196 lead not attempted|9
5983373|NCT00271544|9573145|FG000|Overall Study|Implant not attempted|4
5983374|NCT00235326|9573182|FG000|Overall Study|Lost to Follow-up|746
5983375|NCT00235326|9573183|FG001|Overall Study|Lost to Follow-up|1400
5983376|NCT00232141|9573189|FG000|Overall Study|Adverse Event|9
5983377|NCT00232141|9573190|FG001|Overall Study|Adverse Event|4
5983378|NCT00232141|9573189|FG000|Overall Study|Lack of Efficacy|0
5983379|NCT00232141|9573190|FG001|Overall Study|Lack of Efficacy|3
5983380|NCT00232141|9573189|FG000|Overall Study|Lost to Follow-up|9
5983381|NCT00232141|9573190|FG001|Overall Study|Lost to Follow-up|6
5983382|NCT00232141|9573189|FG000|Overall Study|Other|8
5983383|NCT00232141|9573190|FG001|Overall Study|Other|10
5983384|NCT00232141|9573189|FG000|Overall Study|Withdrawal by Subject|5
5983385|NCT00232141|9573190|FG001|Overall Study|Withdrawal by Subject|3
5983386|NCT00224003|9573201|FG000|Overall Study|Adverse Event|1
5983387|NCT00224003|9573201|FG000|Overall Study|Protocol Violation|2
5983388|NCT00224003|9573201|FG000|Overall Study|Withdrawal by Subject|1
5983389|NCT00224003|9573201|FG000|Overall Study|unk|3
6043916|NCT00393042|9642806|FG001|Second Intervetion|Adverse Event|3
6043917|NCT00393042|9642805|FG000|Second Intervetion|Withdrawal by Subject|0
6043918|NCT00393042|9642806|FG001|Second Intervetion|Withdrawal by Subject|2
6043919|NCT00393042|9642805|FG000|Second Intervetion|Lack of Efficacy|1
6043920|NCT00393042|9642806|FG001|Second Intervetion|Lack of Efficacy|0
6043921|NCT00393042|9642805|FG000|Second Intervetion|Lost to Follow-up|0
6043922|NCT00393042|9642806|FG001|Second Intervetion|Lost to Follow-up|2
6043923|NCT00393042|9642805|FG000|Second Intervetion|Protocol Violation|1
6043924|NCT00393042|9642806|FG001|Second Intervetion|Protocol Violation|1
6043925|NCT00393094|9642860|FG000|Period1Bevacizumab & Irinotecan Patients|Disease progression before treatment|1
6043926|NCT00393094|9642860|FG000|Disease Progression After Trtmt: Onstudy|Refused further treatment|1
6043927|NCT00393367|9642868|FG000|Overall Study|Protocol Violation|2
6043928|NCT00393367|9642869|FG001|Overall Study|Protocol Violation|5
6043929|NCT00393367|9642868|FG000|Overall Study|Withdrawal by Subject|0
6043930|NCT00393367|9642869|FG001|Overall Study|Withdrawal by Subject|2
6043931|NCT00393458|9642885|FG000|Overall Study|Adverse Event|35
6043932|NCT00393458|9642886|FG001|Overall Study|Adverse Event|24
6043933|NCT00393458|9642887|FG002|Overall Study|Adverse Event|40
6043934|NCT00393458|9642888|FG003|Overall Study|Adverse Event|35
6043935|NCT00393458|9642885|FG000|Overall Study|Subject withdrew consent|27
6043936|NCT00393458|9642886|FG001|Overall Study|Subject withdrew consent|40
6043937|NCT00393458|9642887|FG002|Overall Study|Subject withdrew consent|33
6043938|NCT00393458|9642888|FG003|Overall Study|Subject withdrew consent|50
6043939|NCT00393458|9642885|FG000|Overall Study|Unsatisfactory therapeutic effect|12
6043940|NCT00393458|9642886|FG001|Overall Study|Unsatisfactory therapeutic effect|9
6043941|NCT00393458|9642887|FG002|Overall Study|Unsatisfactory therapeutic effect|12
6043942|NCT00393458|9642888|FG003|Overall Study|Unsatisfactory therapeutic effect|30
6043943|NCT00393458|9642885|FG000|Overall Study|Protocol deviation|11
6043944|NCT00393458|9642886|FG001|Overall Study|Protocol deviation|11
6043945|NCT00393458|9642887|FG002|Overall Study|Protocol deviation|11
6043946|NCT00393458|9642888|FG003|Overall Study|Protocol deviation|10
6043947|NCT00393458|9642885|FG000|Overall Study|Administrative problems|7
6043948|NCT00393458|9642886|FG001|Overall Study|Administrative problems|8
6043949|NCT00393458|9642887|FG002|Overall Study|Administrative problems|5
6043950|NCT00393458|9642888|FG003|Overall Study|Administrative problems|2
6043951|NCT00393458|9642885|FG000|Overall Study|Lost to Follow-up|5
6043952|NCT00393458|9642886|FG001|Overall Study|Lost to Follow-up|6
6043953|NCT00393458|9642887|FG002|Overall Study|Lost to Follow-up|5
6043954|NCT00393458|9642888|FG003|Overall Study|Lost to Follow-up|3
6043955|NCT00393458|9642885|FG000|Overall Study|Abnormal laboratory value(s)|1
5983390|NCT00162942|9573206|FG000|Overall Study|Adverse Event|10
5983391|NCT00162942|9573207|FG001|Overall Study|Adverse Event|6
5983392|NCT00162942|9573206|FG000|Overall Study|Death|1
5983393|NCT00162942|9573207|FG001|Overall Study|Death|0
5983394|NCT00162942|9573206|FG000|Overall Study|Withdrawal by Subject|3
5983395|NCT00162942|9573207|FG001|Overall Study|Withdrawal by Subject|6
5983396|NCT00162942|9573206|FG000|Overall Study|Physician Decision|1
5983397|NCT00162942|9573207|FG001|Overall Study|Physician Decision|0
5983398|NCT00162942|9573206|FG000|Overall Study|Enter Open-Label Study|76
5983399|NCT00162942|9573207|FG001|Overall Study|Enter Open-Label Study|35
5983400|NCT00162942|9573206|FG000|Overall Study|Alternate Therapy|6
5983401|NCT00162942|9573207|FG001|Overall Study|Alternate Therapy|2
5983402|NCT00162942|9573206|FG000|Overall Study|Lack of Efficacy|1
5983403|NCT00162942|9573207|FG001|Overall Study|Lack of Efficacy|0
5983404|NCT00162942|9573206|FG000|Overall Study|Flare During Active Treatment|7
5983405|NCT00162942|9573207|FG001|Overall Study|Flare During Active Treatment|3
5983406|NCT00162942|9573206|FG000|Overall Study|2 or more consecutive treatments missed|1
5983407|NCT00162942|9573207|FG001|Overall Study|2 or more consecutive treatments missed|0
5983408|NCT00126776|9573227|FG000|Overall Study|follow up complete on all patients|0
5983409|NCT00126776|9573228|FG001|Overall Study|follow up complete on all patients|0
5983410|NCT00120042|9573235|FG000|Overall Study|all completed protocl|0
5983411|NCT00120042|9573236|FG001|Overall Study|all completed protocl|0
5983412|NCT00120042|9573237|FG002|Overall Study|all completed protocl|0
5983413|NCT00106626|9573246|FG000|Overall Study|Adverse Event|5
5983414|NCT00106626|9573247|FG001|Overall Study|Adverse Event|4
5983415|NCT00106626|9573248|FG002|Overall Study|Adverse Event|3
5983416|NCT00106626|9573249|FG003|Overall Study|Adverse Event|3
5983417|NCT00106626|9573246|FG000|Overall Study|Progressive Disease|4
5983418|NCT00106626|9573247|FG001|Overall Study|Progressive Disease|1
5983419|NCT00106626|9573248|FG002|Overall Study|Progressive Disease|9
5983420|NCT00106626|9573249|FG003|Overall Study|Progressive Disease|10
5983421|NCT00106626|9573246|FG000|Overall Study|Received radiation on new therapy|1
5983422|NCT00106626|9573247|FG001|Overall Study|Received radiation on new therapy|0
5983423|NCT00106626|9573248|FG002|Overall Study|Received radiation on new therapy|0
5983424|NCT00106626|9573249|FG003|Overall Study|Received radiation on new therapy|0
5983425|NCT00106626|9573246|FG000|Overall Study|> 14 day delay in therapy start|0
5983426|NCT00106626|9573247|FG001|Overall Study|> 14 day delay in therapy start|1
5983427|NCT00106626|9573248|FG002|Overall Study|> 14 day delay in therapy start|0
5983428|NCT00106626|9573249|FG003|Overall Study|> 14 day delay in therapy start|0
5983429|NCT00089141|9573266|FG000|Overall Study|Termination of trial|18
5983430|NCT00089141|9573267|FG001|Overall Study|Termination of trial|24
5983431|NCT00083759|9573273|FG000|Overall Study|Adverse Event|5
5983432|NCT00083759|9573274|FG001|Overall Study|Adverse Event|3
5983433|NCT00083759|9573273|FG000|Overall Study|Lost to Follow-up|1
5983434|NCT00083759|9573274|FG001|Overall Study|Lost to Follow-up|0
5983435|NCT00083759|9573273|FG000|Overall Study|Death|1
5983436|NCT00083759|9573274|FG001|Overall Study|Death|1
5983437|NCT00083759|9573273|FG000|Overall Study|Inadequate Therapeutic Response|32
5983438|NCT00083759|9573274|FG001|Overall Study|Inadequate Therapeutic Response|35
5983439|NCT00083759|9573273|FG000|Overall Study|Subject Withdrew Consent|2
5983440|NCT00083759|9573274|FG001|Overall Study|Subject Withdrew Consent|2
5983441|NCT00083759|9573273|FG000|Overall Study|Non-Compliance|1
5983442|NCT00083759|9573274|FG001|Overall Study|Non-Compliance|0
5983443|NCT00083759|9573273|FG000|Overall Study|Sponsor's Discretion|28
5983444|NCT00083759|9573274|FG001|Overall Study|Sponsor's Discretion|29
5983445|NCT00083759|9573273|FG000|Overall Study|Other|14
5983446|NCT00083759|9573274|FG001|Overall Study|Other|13
5983447|NCT03513068|9573280|FG000|Overall Study|Death|1
5983448|NCT03513068|9573281|FG001|Overall Study|Death|0
5983449|NCT03513068|9573280|FG000|Overall Study|Withdrawal by Subject|4
5983450|NCT03513068|9573281|FG001|Overall Study|Withdrawal by Subject|6
5983451|NCT03507127|9573289|FG000|Overall Study|Withdrawal by Subject|1
5983452|NCT03507127|9573290|FG001|Overall Study|Withdrawal by Subject|0
5983453|NCT03507127|9573289|FG000|Overall Study|Unable to meet smoking abstinence criterion|1
5983454|NCT03507127|9573290|FG001|Overall Study|Unable to meet smoking abstinence criterion|1
5983455|NCT03502811|9573296|FG000|Overall Study|Death|157
5983456|NCT03502811|9573296|FG000|Overall Study|Withdrawal by Subject|105
5983457|NCT03502811|9573296|FG000|Overall Study|Lost to Follow-up|26
5983458|NCT03502811|9573296|FG000|Overall Study|No Visits (Missed)|31
5983459|NCT04428333|9573321|FG000|Overall Study|Physician Decision|2
5983460|NCT04428333|9573322|FG001|Overall Study|Physician Decision|0
5983461|NCT04428333|9573321|FG000|Overall Study|Withdrawal by Subject|0
5983462|NCT04428333|9573322|FG001|Overall Study|Withdrawal by Subject|1
5983463|NCT04428333|9573321|FG000|Overall Study|In Follow-Up|5
5983464|NCT04428333|9573322|FG001|Overall Study|In Follow-Up|10
5983465|NCT04428333|9573321|FG000|Overall Study|On Study Treatment (pembrolizumab) All participants discontinued feladilimab/placebo|47
5983466|NCT04428333|9573322|FG001|Overall Study|On Study Treatment (pembrolizumab) All participants discontinued feladilimab/placebo|47
5983467|NCT03530995|9573343|FG000|Part 1 Period 3|Withdrawal by Subject|2
5983468|NCT03530995|9573344|FG001|Part 1 Period 3|Withdrawal by Subject|0
5983469|NCT03530995|9573343|FG000|Part 1 Period 3|Protocol Violation|1
5983470|NCT03530995|9573344|FG001|Part 1 Period 3|Protocol Violation|0
5983471|NCT03530995|9573343|FG000|Part 1 Period 4|Physician Decision|1
5983472|NCT03530995|9573344|FG001|Part 1 Period 4|Physician Decision|0
5983473|NCT03530995|9573343|FG000|Part 1 Period 4|Withdrawal by Subject|1
5983474|NCT03530995|9573344|FG001|Part 1 Period 4|Withdrawal by Subject|0
5983475|NCT03204812|9573374|FG000|Overall Study|Adverse Event|3
5983476|NCT03199391|9573378|FG000|Overall Study|Death|1
5983477|NCT03199391|9573378|FG000|Overall Study|Lost to Follow-up|3
5983478|NCT03199391|9573378|FG000|Overall Study|Adverse Event|2
5983479|NCT03199391|9573378|FG000|Overall Study|Withdrawal by Subject|10
5983480|NCT03084471|9573382|FG000|Overall Study|Development of study specific discontinuation criteria|2
5983481|NCT03084471|9573382|FG000|Overall Study|Condition under investigation worsened|84
5983482|NCT03084471|9573382|FG000|Overall Study|Lack of therapeutic response|2
5983483|NCT03084471|9573382|FG000|Overall Study|Protocol Violation|1
5983484|NCT03084471|9573382|FG000|Overall Study|Adverse Event|73
5983485|NCT03084471|9573382|FG000|Overall Study|Withdrawal by Subject|12
5983486|NCT03084471|9573382|FG000|Overall Study|Disease relapse|181
5983487|NCT03084471|9573382|FG000|Overall Study|Subjective disease progression|359
5983488|NCT03084471|9573382|FG000|Overall Study|Other (as recorded)|33
5983489|NCT03084471|9573382|FG000|Overall Study|Patients who were still on study treatment at Data Cutoff|120
5983490|NCT03072459|9573389|FG000|Overall Study|Device revised/removed|1
5983491|NCT03072459|9573389|FG000|Overall Study|Subject not able to return|1
5983492|NCT03029234|9573393|FG000|Overall Study|Sponsor Decision|1
5983493|NCT03029234|9573393|FG000|Overall Study|Withdrawal by Subject|5
5983494|NCT03029234|9573393|FG000|Overall Study|Death|91
5983495|NCT03029234|9573393|FG000|Overall Study|Lost to Follow-up|2
5983496|NCT03019406|9573401|FG000|ETP: Ongoing From Week 26|Ongoing|6
5983497|NCT03019406|9573402|FG001|ETP: Ongoing From Week 26|Ongoing|5
5983498|NCT03019406|9573403|FG002|ETP: Ongoing From Week 26|Ongoing|5
5983499|NCT03019406|9573404|FG003|ETP: Ongoing From Week 26|Ongoing|3
5983500|NCT02874144|9573419|FG000|Overall Study|Lost to Follow-up|3
5983501|NCT02874144|9573420|FG001|Overall Study|Lost to Follow-up|5
5983502|NCT02652949|9573426|FG000|30-Day Follow-up for Primary Endpoint|Death|1
5983503|NCT02652949|9573426|FG000|30-Day Follow-up for Secondary Endpoint|Death|1
5983504|NCT02652949|9573426|FG000|6-Month Follow-up Secondary Endpoint|Death|5
5983505|NCT02652949|9573426|FG000|6-Month Follow-up Secondary Endpoint|Withdrawal by Subject|2
5983506|NCT02652949|9573426|FG000|6-Month Follow-up Secondary Endpoint|Lost to Follow-up|1
5983507|NCT02652949|9573426|FG000|12-Month Follow-up Secondary Endpoint|Death|4
5983508|NCT02652949|9573426|FG000|24-Month Follow-up Secondary Endpoint|Death|2
5983509|NCT02652949|9573426|FG000|24-Month Follow-up Secondary Endpoint|Withdrawal by Subject|3
5983510|NCT02652949|9573426|FG000|24-Month Follow-up Secondary Endpoint|Lost to Follow-up|2
5983511|NCT02652949|9573426|FG000|24-Month Follow-up Secondary Endpoint|Subject declined reconsenting to extended follow-up out to 5 years|27
5983512|NCT02652949|9573426|FG000|36-Month Follow-up Secondary Endpoint|Death|2
5983513|NCT02652949|9573426|FG000|36-Month Follow-up Secondary Endpoint|Withdrawal by Subject|1
5983514|NCT02652949|9573426|FG000|36-Month Follow-up Secondary Endpoint|Subject declined extended follow up at 12 month timepoint. Data entry error-to be corrected by site|1
5983515|NCT02625324|9573436|FG000|30-Day Follow-up for Primary Endpoint|Death|1
5983516|NCT02625324|9573436|FG000|30-Day Follow-up for Secondary Endpoint|Death|1
5983517|NCT02625324|9573436|FG000|6-Month Follow-up Subject Accountability|Death|5
5983518|NCT02625324|9573436|FG000|6-Month Follow-up Subject Accountability|Withdrawal by Subject|2
5983519|NCT02625324|9573436|FG000|6-Month Follow-up Subject Accountability|Lost to Follow-up|1
5983520|NCT02625324|9573436|FG000|12-Month Follow-up Secondary Endpoint|Death|4
5983521|NCT02625324|9573436|FG000|24-Month Follow-up Secondary Endpoint|Death|2
5983522|NCT02625324|9573436|FG000|24-Month Follow-up Secondary Endpoint|Withdrawal by Subject|3
5983523|NCT02625324|9573436|FG000|24-Month Follow-up Secondary Endpoint|Lost to Follow-up|2
5983524|NCT02625324|9573436|FG000|24-Month Follow-up Secondary Endpoint|Subject declined reconsenting to extended follow-up out to 5 years|27
5983525|NCT02625324|9573436|FG000|36-Month Follow-up Secondary Endpoint|Death|2
5983526|NCT02625324|9573436|FG000|36-Month Follow-up Secondary Endpoint|Withdrawal by Subject|1
5983527|NCT02625324|9573436|FG000|36-Month Follow-up Secondary Endpoint|Subject declined extended follow up at 12 month timepoint. Data entry error to be corrected by site|1
5983528|NCT02611830|9573451|FG000|OL Induction Phase|Pretreatment Event/Adverse Event|9
5983529|NCT02611830|9573452|FG001|OL Induction Phase|Pretreatment Event/Adverse Event|0
5983530|NCT02611830|9573453|FG002|OL Induction Phase|Pretreatment Event/Adverse Event|0
5983531|NCT02611830|9573454|FG003|OL Induction Phase|Pretreatment Event/Adverse Event|0
5983532|NCT02611830|9573451|FG000|OL Induction Phase|Significant Protocol Deviation|4
5983533|NCT02611830|9573452|FG001|OL Induction Phase|Significant Protocol Deviation|0
5983534|NCT02611830|9573453|FG002|OL Induction Phase|Significant Protocol Deviation|0
5983535|NCT02611830|9573454|FG003|OL Induction Phase|Significant Protocol Deviation|0
5983536|NCT02611830|9573451|FG000|OL Induction Phase|Voluntary Withdrawal|5
5983537|NCT02611830|9573452|FG001|OL Induction Phase|Voluntary Withdrawal|0
5983538|NCT02611830|9573453|FG002|OL Induction Phase|Voluntary Withdrawal|0
5983539|NCT02611830|9573454|FG003|OL Induction Phase|Voluntary Withdrawal|0
5983540|NCT02611830|9573451|FG000|OL Induction Phase|Lack of Efficacy|9
5983541|NCT02611830|9573452|FG001|OL Induction Phase|Lack of Efficacy|0
5983542|NCT02611830|9573453|FG002|OL Induction Phase|Lack of Efficacy|0
5983543|NCT02611830|9573454|FG003|OL Induction Phase|Lack of Efficacy|0
5983544|NCT02611830|9573451|FG000|OL Induction Phase|Reason not specified|3
5983545|NCT02611830|9573452|FG001|OL Induction Phase|Reason not specified|0
5983546|NCT02611830|9573453|FG002|OL Induction Phase|Reason not specified|0
5983547|NCT02611830|9573454|FG003|OL Induction Phase|Reason not specified|0
5983548|NCT02611830|9573451|FG000|Maintenance Phase|Lack of Efficacy|0
5983549|NCT02611830|9573452|FG001|Maintenance Phase|Lack of Efficacy|29
5983550|NCT02611830|9573453|FG002|Maintenance Phase|Lack of Efficacy|18
5983551|NCT02611830|9573454|FG003|Maintenance Phase|Lack of Efficacy|6
5983552|NCT02611830|9573451|FG000|Maintenance Phase|Pretreatment Event/Adverse Event|0
5983553|NCT02611830|9573452|FG001|Maintenance Phase|Pretreatment Event/Adverse Event|5
5983554|NCT02611830|9573453|FG002|Maintenance Phase|Pretreatment Event/Adverse Event|5
5983555|NCT02611830|9573454|FG003|Maintenance Phase|Pretreatment Event/Adverse Event|2
5983556|NCT02611830|9573451|FG000|Maintenance Phase|Significant Protocol Deviation|0
5983557|NCT02611830|9573452|FG001|Maintenance Phase|Significant Protocol Deviation|0
5983558|NCT02611830|9573453|FG002|Maintenance Phase|Significant Protocol Deviation|1
5983559|NCT02611830|9573454|FG003|Maintenance Phase|Significant Protocol Deviation|1
5983560|NCT02611830|9573451|FG000|Maintenance Phase|Lost to Follow-up|0
5983561|NCT02611830|9573452|FG001|Maintenance Phase|Lost to Follow-up|0
5983562|NCT02611830|9573453|FG002|Maintenance Phase|Lost to Follow-up|0
5983563|NCT02611830|9573454|FG003|Maintenance Phase|Lost to Follow-up|1
5983564|NCT02611830|9573451|FG000|Maintenance Phase|Voluntary Withdrawal|0
5983565|NCT02611830|9573452|FG001|Maintenance Phase|Voluntary Withdrawal|1
5983566|NCT02611830|9573453|FG002|Maintenance Phase|Voluntary Withdrawal|2
5983567|NCT02611830|9573454|FG003|Maintenance Phase|Voluntary Withdrawal|5
5983568|NCT02611830|9573451|FG000|Maintenance Phase|Pregnancy|0
5983569|NCT02611830|9573452|FG001|Maintenance Phase|Pregnancy|0
5983570|NCT02611830|9573453|FG002|Maintenance Phase|Pregnancy|1
5983571|NCT02611830|9573454|FG003|Maintenance Phase|Pregnancy|0
5983572|NCT02611830|9573451|FG000|Maintenance Phase|Reason not specified|0
5983573|NCT02611830|9573452|FG001|Maintenance Phase|Reason not specified|1
5983574|NCT02611830|9573453|FG002|Maintenance Phase|Reason not specified|4
5983575|NCT02611830|9573454|FG003|Maintenance Phase|Reason not specified|0
5983576|NCT02611817|9573466|FG000|Open-label Induction Phase|Reason not Specified|9
5983577|NCT02611817|9573467|FG001|Open-label Induction Phase|Reason not Specified|0
5983578|NCT02611817|9573468|FG002|Open-label Induction Phase|Reason not Specified|0
5983579|NCT02611817|9573466|FG000|Open-label Induction Phase|Lack of Efficacy|8
5983580|NCT02611817|9573467|FG001|Open-label Induction Phase|Lack of Efficacy|0
5983581|NCT02611817|9573468|FG002|Open-label Induction Phase|Lack of Efficacy|0
5983582|NCT02611817|9573466|FG000|Open-label Induction Phase|Pregnancy|1
5983583|NCT02611817|9573467|FG001|Open-label Induction Phase|Pregnancy|0
5983584|NCT02611817|9573468|FG002|Open-label Induction Phase|Pregnancy|0
5983585|NCT02611817|9573466|FG000|Open-label Induction Phase|Withdrawal by Subject|9
5983586|NCT02611817|9573467|FG001|Open-label Induction Phase|Withdrawal by Subject|0
5983587|NCT02611817|9573468|FG002|Open-label Induction Phase|Withdrawal by Subject|0
5983588|NCT02611817|9573466|FG000|Open-label Induction Phase|Lost to Follow-up|2
5983589|NCT02611817|9573467|FG001|Open-label Induction Phase|Lost to Follow-up|0
5983590|NCT02611817|9573468|FG002|Open-label Induction Phase|Lost to Follow-up|0
5983591|NCT02611817|9573466|FG000|Open-label Induction Phase|Protocol Violation|5
5983592|NCT02611817|9573467|FG001|Open-label Induction Phase|Protocol Violation|0
5983593|NCT02611817|9573468|FG002|Open-label Induction Phase|Protocol Violation|0
5983594|NCT02611817|9573466|FG000|Open-label Induction Phase|Adverse Event|16
5983595|NCT02611817|9573467|FG001|Open-label Induction Phase|Adverse Event|0
5983596|NCT02611817|9573468|FG002|Open-label Induction Phase|Adverse Event|0
5983597|NCT02611817|9573466|FG000|Double-blind Maintenance Phase|Adverse Event|0
5983598|NCT02611817|9573467|FG001|Double-blind Maintenance Phase|Adverse Event|12
5983599|NCT02611817|9573468|FG002|Double-blind Maintenance Phase|Adverse Event|11
5983600|NCT02611817|9573466|FG000|Double-blind Maintenance Phase|Randomized but not Treated|0
5983601|NCT02611817|9573467|FG001|Double-blind Maintenance Phase|Randomized but not Treated|1
5983602|NCT02611817|9573468|FG002|Double-blind Maintenance Phase|Randomized but not Treated|0
5983603|NCT02611817|9573466|FG000|Double-blind Maintenance Phase|Reason not Specified|0
5983604|NCT02611817|9573467|FG001|Double-blind Maintenance Phase|Reason not Specified|1
5983605|NCT02611817|9573468|FG002|Double-blind Maintenance Phase|Reason not Specified|2
5983606|NCT02611817|9573466|FG000|Double-blind Maintenance Phase|Lack of Efficacy|0
5983607|NCT02611817|9573467|FG001|Double-blind Maintenance Phase|Lack of Efficacy|43
5983608|NCT02611817|9573468|FG002|Double-blind Maintenance Phase|Lack of Efficacy|78
5983609|NCT02611817|9573466|FG000|Double-blind Maintenance Phase|Pregnancy|0
5983610|NCT02611817|9573467|FG001|Double-blind Maintenance Phase|Pregnancy|0
5983611|NCT02611817|9573468|FG002|Double-blind Maintenance Phase|Pregnancy|1
5983612|NCT02611817|9573466|FG000|Double-blind Maintenance Phase|Withdrawal by Subject|0
5983613|NCT02611817|9573467|FG001|Double-blind Maintenance Phase|Withdrawal by Subject|5
5983614|NCT02611817|9573468|FG002|Double-blind Maintenance Phase|Withdrawal by Subject|14
5983615|NCT02611817|9573466|FG000|Double-blind Maintenance Phase|Lost to Follow-up|0
5983616|NCT02611817|9573467|FG001|Double-blind Maintenance Phase|Lost to Follow-up|0
5983617|NCT02611817|9573468|FG002|Double-blind Maintenance Phase|Lost to Follow-up|1
5983618|NCT02557139|9573478|FG000|Overall Study|Significant liver elevation|1
5983619|NCT02557139|9573479|FG001|Overall Study|Significant liver elevation|0
5983620|NCT02557139|9573480|FG002|Overall Study|Significant liver elevation|1
5983621|NCT02557139|9573478|FG000|Overall Study|Withdrawal by Subject|1
5983622|NCT02557139|9573479|FG001|Overall Study|Withdrawal by Subject|0
5983623|NCT02557139|9573480|FG002|Overall Study|Withdrawal by Subject|0
5983624|NCT02557139|9573478|FG000|Overall Study|Illness of prohibited medication|0
5983625|NCT02557139|9573479|FG001|Overall Study|Illness of prohibited medication|0
5983626|NCT02557139|9573480|FG002|Overall Study|Illness of prohibited medication|1
5983627|NCT02488759|9573503|FG000|Overall Study|Disease progression|74
5983628|NCT02488759|9573504|FG001|Overall Study|Disease progression|110
5983629|NCT02488759|9573505|FG002|Overall Study|Disease progression|62
5983630|NCT02488759|9573506|FG003|Overall Study|Disease progression|7
5983631|NCT02488759|9573507|FG004|Overall Study|Disease progression|4
5983632|NCT02488759|9573508|FG005|Overall Study|Disease progression|2
5983633|NCT02488759|9573503|FG000|Overall Study|Study drug toxicity|11
5983634|NCT02488759|9573504|FG001|Overall Study|Study drug toxicity|33
5983635|NCT02488759|9573505|FG002|Overall Study|Study drug toxicity|31
5983636|NCT02488759|9573506|FG003|Overall Study|Study drug toxicity|0
5983637|NCT02488759|9573507|FG004|Overall Study|Study drug toxicity|0
5983638|NCT02488759|9573508|FG005|Overall Study|Study drug toxicity|2
5983639|NCT02488759|9573503|FG000|Overall Study|Adverse event unrelated to study drug|9
5983640|NCT02488759|9573504|FG001|Overall Study|Adverse event unrelated to study drug|11
5983641|NCT02488759|9573505|FG002|Overall Study|Adverse event unrelated to study drug|7
5983642|NCT02488759|9573506|FG003|Overall Study|Adverse event unrelated to study drug|0
5983643|NCT02488759|9573507|FG004|Overall Study|Adverse event unrelated to study drug|1
5983644|NCT02488759|9573508|FG005|Overall Study|Adverse event unrelated to study drug|0
5983645|NCT02488759|9573503|FG000|Overall Study|Participant request to discontinue study treatment|7
5983646|NCT02488759|9573504|FG001|Overall Study|Participant request to discontinue study treatment|8
5983647|NCT02488759|9573505|FG002|Overall Study|Participant request to discontinue study treatment|4
5983648|NCT02488759|9573506|FG003|Overall Study|Participant request to discontinue study treatment|0
5983649|NCT02488759|9573507|FG004|Overall Study|Participant request to discontinue study treatment|0
5983650|NCT02488759|9573508|FG005|Overall Study|Participant request to discontinue study treatment|0
5983651|NCT02488759|9573503|FG000|Overall Study|Withdrawal by Subject|2
5983652|NCT02488759|9573504|FG001|Overall Study|Withdrawal by Subject|0
5983653|NCT02488759|9573505|FG002|Overall Study|Withdrawal by Subject|3
5983654|NCT02488759|9573506|FG003|Overall Study|Withdrawal by Subject|0
5983655|NCT02488759|9573507|FG004|Overall Study|Withdrawal by Subject|0
5983656|NCT02488759|9573508|FG005|Overall Study|Withdrawal by Subject|2
5983657|NCT02488759|9573503|FG000|Overall Study|Lost to Follow-up|0
5983658|NCT02488759|9573504|FG001|Overall Study|Lost to Follow-up|1
5983659|NCT02488759|9573505|FG002|Overall Study|Lost to Follow-up|2
5983660|NCT02488759|9573506|FG003|Overall Study|Lost to Follow-up|0
5983661|NCT02488759|9573507|FG004|Overall Study|Lost to Follow-up|0
5983662|NCT02488759|9573508|FG005|Overall Study|Lost to Follow-up|0
5983663|NCT02488759|9573503|FG000|Overall Study|Maximum clinical benefit|3
5983664|NCT02488759|9573504|FG001|Overall Study|Maximum clinical benefit|0
5983665|NCT02488759|9573505|FG002|Overall Study|Maximum clinical benefit|1
5983666|NCT02488759|9573506|FG003|Overall Study|Maximum clinical benefit|0
5983667|NCT02488759|9573507|FG004|Overall Study|Maximum clinical benefit|0
5983668|NCT02488759|9573508|FG005|Overall Study|Maximum clinical benefit|0
5983669|NCT02488759|9573503|FG000|Overall Study|Completed treatment|0
5983670|NCT02488759|9573504|FG001|Overall Study|Completed treatment|0
5983671|NCT02488759|9573505|FG002|Overall Study|Completed treatment|0
5983672|NCT02488759|9573506|FG003|Overall Study|Completed treatment|0
5983673|NCT02488759|9573507|FG004|Overall Study|Completed treatment|0
5983674|NCT02488759|9573508|FG005|Overall Study|Completed treatment|116
5983675|NCT02488759|9573503|FG000|Overall Study|Other reasons|5
5983676|NCT02488759|9573504|FG001|Overall Study|Other reasons|32
5983677|NCT02488759|9573505|FG002|Overall Study|Other reasons|21
5983678|NCT02488759|9573506|FG003|Overall Study|Other reasons|1
5983679|NCT02488759|9573507|FG004|Overall Study|Other reasons|1
5983680|NCT02488759|9573508|FG005|Overall Study|Other reasons|1
5983681|NCT02211131|9573524|FG000|Overall Study|Death|20
5983682|NCT02211131|9573525|FG001|Overall Study|Death|11
5983683|NCT02211131|9573524|FG000|Overall Study|Lost to Follow-up|1
5983684|NCT02211131|9573525|FG001|Overall Study|Lost to Follow-up|0
5983685|NCT02211131|9573524|FG000|Overall Study|Decision by Sponsor|1
5983686|NCT02211131|9573525|FG001|Overall Study|Decision by Sponsor|1
5983687|NCT02211131|9573524|FG000|Overall Study|Withdrawal by Subject|3
5983688|NCT02211131|9573525|FG001|Overall Study|Withdrawal by Subject|4
5983689|NCT02211131|9573524|FG000|Overall Study|Continuing on Study|49
5983690|NCT02211131|9573525|FG001|Overall Study|Continuing on Study|60
5983691|NCT02186847|9573540|FG000|Overall Study|Protocol Violation|3
5983692|NCT02186847|9573541|FG001|Overall Study|Protocol Violation|0
5983693|NCT02101034|9573552|FG000|Overall Study|Enrolled but did not start treatment|0
5983694|NCT02101034|9573553|FG001|Overall Study|Enrolled but did not start treatment|0
5983695|NCT02101034|9573554|FG002|Overall Study|Enrolled but did not start treatment|1
5983696|NCT02101034|9573555|FG003|Overall Study|Enrolled but did not start treatment|0
5983697|NCT02101034|9573556|FG004|Overall Study|Enrolled but did not start treatment|0
5983698|NCT02041533|9573576|FG000|Overall Study|Disease Progression|168
5983699|NCT02041533|9573577|FG001|Overall Study|Disease Progression|142
5983700|NCT02041533|9573576|FG000|Overall Study|Study drug toxicity|27
5983701|NCT02041533|9573577|FG001|Overall Study|Study drug toxicity|30
5983702|NCT02041533|9573576|FG000|Overall Study|Death|1
5983703|NCT02041533|9573577|FG001|Overall Study|Death|0
6049033|NCT00420927|9648203|FG004|Period 2|Took prohibited medication|1
5983704|NCT02041533|9573576|FG000|Overall Study|Adverse Event unrelated to study drug|20
5983705|NCT02041533|9573577|FG001|Overall Study|Adverse Event unrelated to study drug|21
5983706|NCT02041533|9573576|FG000|Overall Study|Subject request to discontinue treatment|5
5983707|NCT02041533|9573577|FG001|Overall Study|Subject request to discontinue treatment|9
5983708|NCT02041533|9573576|FG000|Overall Study|Withdrawal by Subject|2
5983709|NCT02041533|9573577|FG001|Overall Study|Withdrawal by Subject|1
5983710|NCT02041533|9573576|FG000|Overall Study|Maximum clinical benefit|0
5983711|NCT02041533|9573577|FG001|Overall Study|Maximum clinical benefit|18
5983712|NCT02041533|9573576|FG000|Overall Study|Poor/non-compliance|1
5983713|NCT02041533|9573577|FG001|Overall Study|Poor/non-compliance|0
5983714|NCT02041533|9573576|FG000|Overall Study|Other reasons|0
5983715|NCT02041533|9573577|FG001|Overall Study|Other reasons|1
5983716|NCT02041533|9573576|FG000|Overall Study|Completed max number of chemo cycles|0
5983717|NCT02041533|9573577|FG001|Overall Study|Completed max number of chemo cycles|29
5983718|NCT02041533|9573576|FG000|Overall Study|Randomized, not treated|4
5983719|NCT02041533|9573577|FG001|Overall Study|Randomized, not treated|7
5983720|NCT01865617|9573596|FG000|Overall Study|Death|27
5983721|NCT01865617|9573597|FG001|Overall Study|Death|3
5983722|NCT01865617|9573598|FG002|Overall Study|Death|1
5983723|NCT01865617|9573599|FG003|Overall Study|Death|1
5983724|NCT01865617|9573600|FG004|Overall Study|Death|5
5983725|NCT01865617|9573601|FG005|Overall Study|Death|1
5983726|NCT01865617|9573602|FG006|Overall Study|Death|11
5983727|NCT01865617|9573603|FG007|Overall Study|Death|1
5983728|NCT01865617|9573604|FG008|Overall Study|Death|11
5983729|NCT01865617|9573605|FG009|Overall Study|Death|3
5983730|NCT01865617|9573606|FG010|Overall Study|Death|32
5983731|NCT01865617|9573607|FG011|Overall Study|Death|6
5983732|NCT01865617|9573608|FG012|Overall Study|Death|13
5983733|NCT01865617|9573596|FG000|Overall Study|Lost to Follow-up|2
5983734|NCT01865617|9573597|FG001|Overall Study|Lost to Follow-up|0
5983735|NCT01865617|9573598|FG002|Overall Study|Lost to Follow-up|0
5983736|NCT01865617|9573599|FG003|Overall Study|Lost to Follow-up|0
5983737|NCT01865617|9573600|FG004|Overall Study|Lost to Follow-up|0
5983738|NCT01865617|9573601|FG005|Overall Study|Lost to Follow-up|0
5983739|NCT01865617|9573602|FG006|Overall Study|Lost to Follow-up|0
5983740|NCT01865617|9573603|FG007|Overall Study|Lost to Follow-up|0
5983741|NCT01865617|9573604|FG008|Overall Study|Lost to Follow-up|0
5983742|NCT01865617|9573605|FG009|Overall Study|Lost to Follow-up|0
5983743|NCT01865617|9573606|FG010|Overall Study|Lost to Follow-up|0
5983744|NCT01865617|9573607|FG011|Overall Study|Lost to Follow-up|0
5983745|NCT01865617|9573608|FG012|Overall Study|Lost to Follow-up|0
5983746|NCT01865617|9573596|FG000|Overall Study|Withdrawal by Subject|1
5983747|NCT01865617|9573597|FG001|Overall Study|Withdrawal by Subject|0
5983748|NCT01865617|9573598|FG002|Overall Study|Withdrawal by Subject|0
5983749|NCT01865617|9573599|FG003|Overall Study|Withdrawal by Subject|0
5983750|NCT01865617|9573600|FG004|Overall Study|Withdrawal by Subject|0
5983751|NCT01865617|9573601|FG005|Overall Study|Withdrawal by Subject|0
5983752|NCT01865617|9573602|FG006|Overall Study|Withdrawal by Subject|0
5983753|NCT01865617|9573603|FG007|Overall Study|Withdrawal by Subject|0
5983754|NCT01865617|9573604|FG008|Overall Study|Withdrawal by Subject|0
5983755|NCT01865617|9573605|FG009|Overall Study|Withdrawal by Subject|0
5983756|NCT01865617|9573606|FG010|Overall Study|Withdrawal by Subject|0
5983757|NCT01865617|9573607|FG011|Overall Study|Withdrawal by Subject|0
5983758|NCT01865617|9573608|FG012|Overall Study|Withdrawal by Subject|0
5983759|NCT01865617|9573596|FG000|Overall Study|Patient proceeded to new therapy|0
5983760|NCT01865617|9573597|FG001|Overall Study|Patient proceeded to new therapy|0
5983761|NCT01865617|9573598|FG002|Overall Study|Patient proceeded to new therapy|0
5983762|NCT01865617|9573599|FG003|Overall Study|Patient proceeded to new therapy|0
5983763|NCT01865617|9573600|FG004|Overall Study|Patient proceeded to new therapy|2
5983764|NCT01865617|9573601|FG005|Overall Study|Patient proceeded to new therapy|0
5983765|NCT01865617|9573602|FG006|Overall Study|Patient proceeded to new therapy|0
5983766|NCT01865617|9573603|FG007|Overall Study|Patient proceeded to new therapy|0
5983767|NCT01865617|9573604|FG008|Overall Study|Patient proceeded to new therapy|0
5983768|NCT01865617|9573605|FG009|Overall Study|Patient proceeded to new therapy|0
5983769|NCT01865617|9573606|FG010|Overall Study|Patient proceeded to new therapy|0
5983770|NCT01865617|9573607|FG011|Overall Study|Patient proceeded to new therapy|0
5983771|NCT01865617|9573608|FG012|Overall Study|Patient proceeded to new therapy|0
5983772|NCT01865617|9573596|FG000|Overall Study|Other|0
5983773|NCT01865617|9573597|FG001|Overall Study|Other|0
5983774|NCT01865617|9573598|FG002|Overall Study|Other|0
5983775|NCT01865617|9573599|FG003|Overall Study|Other|0
5983776|NCT01865617|9573600|FG004|Overall Study|Other|0
5983777|NCT01865617|9573601|FG005|Overall Study|Other|0
5983778|NCT01865617|9573602|FG006|Overall Study|Other|1
5983779|NCT01865617|9573603|FG007|Overall Study|Other|0
5983780|NCT01865617|9573604|FG008|Overall Study|Other|0
5983781|NCT01865617|9573605|FG009|Overall Study|Other|0
5983782|NCT01865617|9573606|FG010|Overall Study|Other|0
5983783|NCT01865617|9573607|FG011|Overall Study|Other|0
5983784|NCT01865617|9573608|FG012|Overall Study|Other|0
5983785|NCT01828112|9573641|FG000|Overall Study|Adverse Event|6
5983786|NCT01828112|9573642|FG001|Overall Study|Adverse Event|8
5983787|NCT01828112|9573641|FG000|Overall Study|Death|9
5983788|NCT01828112|9573642|FG001|Overall Study|Death|5
5983789|NCT01828112|9573641|FG000|Overall Study|Physician Decision|5
5983790|NCT01828112|9573642|FG001|Overall Study|Physician Decision|5
5983791|NCT01828112|9573641|FG000|Overall Study|Progressive disease|56
5983792|NCT01828112|9573642|FG001|Overall Study|Progressive disease|82
5983793|NCT01828112|9573641|FG000|Overall Study|Subject/guardian decision|6
5983794|NCT01828112|9573642|FG001|Overall Study|Subject/guardian decision|8
5983795|NCT01670500|9573676|FG000|Overall Study|Withdrawal by Subject|1
5983796|NCT01670500|9573677|FG001|Overall Study|Withdrawal by Subject|0
5983797|NCT01593254|9573685|FG000|Treatment Period|Treatment Failure|1
5983798|NCT01593254|9573686|FG001|Treatment Period|Treatment Failure|2
5983799|NCT01593254|9573685|FG000|Treatment Period|Pregnancy|0
5983800|NCT01593254|9573686|FG001|Treatment Period|Pregnancy|1
5983801|NCT01593254|9573685|FG000|Treatment Period|Poor/Non-Compliance|2
5983802|NCT01593254|9573686|FG001|Treatment Period|Poor/Non-Compliance|1
5983803|NCT01593254|9573685|FG000|Treatment Period|Maximum clinical benefit|1
5983804|NCT01593254|9573686|FG001|Treatment Period|Maximum clinical benefit|0
5983805|NCT01593254|9573685|FG000|Treatment Period|Subject withdrew consent|0
5983806|NCT01593254|9573686|FG001|Treatment Period|Subject withdrew consent|5
5983807|NCT01593254|9573685|FG000|Treatment Period|Subject Request to Discontinue|1
5983808|NCT01593254|9573686|FG001|Treatment Period|Subject Request to Discontinue|1
5983809|NCT01593254|9573685|FG000|Treatment Period|AE unrelated to Study Drug|0
5983810|NCT01593254|9573686|FG001|Treatment Period|AE unrelated to Study Drug|1
5983811|NCT01593254|9573685|FG000|Treatment Period|Death|2
5983812|NCT01593254|9573686|FG001|Treatment Period|Death|1
5983813|NCT01593254|9573685|FG000|Treatment Period|Study Drug Toxicity|3
5983814|NCT01593254|9573686|FG001|Treatment Period|Study Drug Toxicity|9
5983815|NCT01593254|9573685|FG000|Treatment Period|Disease Progression|1
5983816|NCT01593254|9573686|FG001|Treatment Period|Disease Progression|6
5983817|NCT01593254|9573685|FG000|Treatment Period|Did Not Achieve RCC|0
5983818|NCT01593254|9573686|FG001|Treatment Period|Did Not Achieve RCC|1
5983819|NCT01593254|9573685|FG000|Treatment Period|Patient Refused to Return|0
5983820|NCT01593254|9573686|FG001|Treatment Period|Patient Refused to Return|1
5983821|NCT01593254|9573685|FG000|Treatment Period|No Response|1
5983822|NCT01593254|9573686|FG001|Treatment Period|No Response|0
5983823|NCT01593254|9573685|FG000|Treatment Period|T315I MUTATION|0
5983824|NCT01593254|9573686|FG001|Treatment Period|T315I MUTATION|1
5983825|NCT01593254|9573685|FG000|Treatment Period|Investigator Decision|2
5983826|NCT01593254|9573686|FG001|Treatment Period|Investigator Decision|1
5983827|NCT01593254|9573685|FG000|Follow-Up Period|Withdrawal by Subject|0
5983828|NCT01593254|9573686|FG001|Follow-Up Period|Withdrawal by Subject|2
5983829|NCT01593254|9573685|FG000|Follow-Up Period|Non-Compliance|1
5983830|NCT01593254|9573686|FG001|Follow-Up Period|Non-Compliance|0
5983831|NCT01593254|9573685|FG000|Follow-Up Period|Death|2
5983832|NCT01593254|9573686|FG001|Follow-Up Period|Death|2
5983833|NCT01593254|9573685|FG000|Follow-Up Period|Subject request to Discontinue|0
5983834|NCT01593254|9573686|FG001|Follow-Up Period|Subject request to Discontinue|1
5983835|NCT01593254|9573685|FG000|Follow-Up Period|Pregnancy|0
5983836|NCT01593254|9573686|FG001|Follow-Up Period|Pregnancy|1
5983837|NCT01593254|9573685|FG000|Follow-Up Period|Study Drug Toxicity|0
5983838|NCT01593254|9573686|FG001|Follow-Up Period|Study Drug Toxicity|1
5983839|NCT01593254|9573685|FG000|Follow-Up Period|Patient refused to return|0
5983840|NCT01593254|9573686|FG001|Follow-Up Period|Patient refused to return|1
5983841|NCT01593254|9573685|FG000|Follow-Up Period|Fundus Hemorrhage|0
5983842|NCT01593254|9573686|FG001|Follow-Up Period|Fundus Hemorrhage|1
5983843|NCT01593254|9573685|FG000|Follow-Up Period|Disease Progression|0
5983844|NCT01593254|9573686|FG001|Follow-Up Period|Disease Progression|1
5983845|NCT01593254|9573685|FG000|Follow-Up Period|Study Drug Side Effects|0
5983846|NCT01593254|9573686|FG001|Follow-Up Period|Study Drug Side Effects|1
6043956|NCT00393458|9642886|FG001|Overall Study|Abnormal laboratory value(s)|1
6043957|NCT00393458|9642887|FG002|Overall Study|Abnormal laboratory value(s)|0
6043958|NCT00393458|9642888|FG003|Overall Study|Abnormal laboratory value(s)|0
6043959|NCT00393458|9642885|FG000|Overall Study|Death|1
6043960|NCT00393458|9642886|FG001|Overall Study|Death|1
6043961|NCT00393458|9642887|FG002|Overall Study|Death|5
6043962|NCT00393458|9642888|FG003|Overall Study|Death|5
6043963|NCT00393458|9642885|FG000|Overall Study|Abnormal test procedure result(s)|0
6043964|NCT00393458|9642886|FG001|Overall Study|Abnormal test procedure result(s)|1
6043965|NCT00393458|9642887|FG002|Overall Study|Abnormal test procedure result(s)|1
6043966|NCT00393458|9642888|FG003|Overall Study|Abnormal test procedure result(s)|2
6043967|NCT00393458|9642885|FG000|Overall Study|Subject no longer requires study drug|0
6043968|NCT00393458|9642886|FG001|Overall Study|Subject no longer requires study drug|1
6043969|NCT00393458|9642887|FG002|Overall Study|Subject no longer requires study drug|0
6043970|NCT00393458|9642888|FG003|Overall Study|Subject no longer requires study drug|0
6043971|NCT00393484|9642900|FG000|Double-blind Period (Day 1 to Week 96)|Adverse Event|0
6043972|NCT00393484|9642901|FG001|Double-blind Period (Day 1 to Week 96)|Adverse Event|1
6043973|NCT00393484|9642900|FG000|Double-blind Period (Day 1 to Week 96)|Withdrawal by Subject|2
6043974|NCT00393484|9642901|FG001|Double-blind Period (Day 1 to Week 96)|Withdrawal by Subject|0
6043975|NCT00393484|9642900|FG000|Double-blind Period (Day 1 to Week 96)|No longer met inclusion criteria|0
6043976|NCT00393484|9642901|FG001|Double-blind Period (Day 1 to Week 96)|No longer met inclusion criteria|3
6043977|NCT00393484|9642900|FG000|Double-blind Period (Day 1 to Week 96)|Lack of Efficacy|0
5983847|NCT04604184|9573699|FG000|Overall Study|Adverse Event|5
5983848|NCT04604184|9573700|FG001|Overall Study|Adverse Event|5
5983849|NCT04604184|9573699|FG000|Overall Study|Death|2
5983850|NCT04604184|9573700|FG001|Overall Study|Death|1
5983851|NCT04604184|9573699|FG000|Overall Study|Withdrawal by Subject|1
5983852|NCT04604184|9573700|FG001|Overall Study|Withdrawal by Subject|3
5983853|NCT04604184|9573699|FG000|Overall Study|Not treated|2
5983854|NCT04604184|9573700|FG001|Overall Study|Not treated|2
5983855|NCT04604184|9573699|FG000|Overall Study|Due to sponsor decision|9
5983856|NCT04604184|9573700|FG001|Overall Study|Due to sponsor decision|7
5983857|NCT04604184|9573699|FG000|Overall Study|Physician Decision|0
5983858|NCT04604184|9573700|FG001|Overall Study|Physician Decision|1
5983859|NCT04604184|9573699|FG000|Overall Study|Transfer to healthcare|1
5983860|NCT04604184|9573700|FG001|Overall Study|Transfer to healthcare|0
5983861|NCT04368429|9573708|FG000|Overall Study|Adverse Event|1
5983862|NCT04368429|9573709|FG001|Overall Study|Adverse Event|0
5983863|NCT03865316|9573727|FG000|Overall Study|Procedure Cancelled|4
5983864|NCT03865316|9573727|FG000|Overall Study|Equipment failure|4
5983865|NCT03688555|9573733|FG000|Treatment Period|Adverse Event|0
5983866|NCT03688555|9573734|FG001|Treatment Period|Adverse Event|0
5983867|NCT03688555|9573735|FG002|Treatment Period|Adverse Event|1
5983868|NCT03593213|9573745|FG000|Open-label Treatment Period (18 Weeks)|Adverse Event|39
5983869|NCT03593213|9573746|FG001|Open-label Treatment Period (18 Weeks)|Adverse Event|0
5983870|NCT03593213|9573747|FG002|Open-label Treatment Period (18 Weeks)|Adverse Event|0
5983871|NCT03593213|9573748|FG003|Open-label Treatment Period (18 Weeks)|Adverse Event|0
5983872|NCT03593213|9573745|FG000|Open-label Treatment Period (18 Weeks)|Lack of Efficacy|14
5983873|NCT03593213|9573746|FG001|Open-label Treatment Period (18 Weeks)|Lack of Efficacy|0
5983874|NCT03593213|9573747|FG002|Open-label Treatment Period (18 Weeks)|Lack of Efficacy|0
5983875|NCT03593213|9573748|FG003|Open-label Treatment Period (18 Weeks)|Lack of Efficacy|0
5983876|NCT03593213|9573745|FG000|Open-label Treatment Period (18 Weeks)|Withdrawal by Subject|85
5983877|NCT03593213|9573746|FG001|Open-label Treatment Period (18 Weeks)|Withdrawal by Subject|0
5983878|NCT03593213|9573747|FG002|Open-label Treatment Period (18 Weeks)|Withdrawal by Subject|0
5983879|NCT03593213|9573748|FG003|Open-label Treatment Period (18 Weeks)|Withdrawal by Subject|0
5983880|NCT03593213|9573745|FG000|Open-label Treatment Period (18 Weeks)|Lost to Follow-up|51
5983881|NCT03593213|9573746|FG001|Open-label Treatment Period (18 Weeks)|Lost to Follow-up|0
5983882|NCT03593213|9573747|FG002|Open-label Treatment Period (18 Weeks)|Lost to Follow-up|0
5983883|NCT03593213|9573748|FG003|Open-label Treatment Period (18 Weeks)|Lost to Follow-up|0
5983884|NCT03593213|9573745|FG000|Open-label Treatment Period (18 Weeks)|Death|1
5983885|NCT03593213|9573746|FG001|Open-label Treatment Period (18 Weeks)|Death|0
5983886|NCT03593213|9573747|FG002|Open-label Treatment Period (18 Weeks)|Death|0
5983887|NCT03593213|9573748|FG003|Open-label Treatment Period (18 Weeks)|Death|0
5983888|NCT03593213|9573745|FG000|Open-label Treatment Period (18 Weeks)|Protocol Deviation|5
5983889|NCT03593213|9573746|FG001|Open-label Treatment Period (18 Weeks)|Protocol Deviation|0
5983890|NCT03593213|9573747|FG002|Open-label Treatment Period (18 Weeks)|Protocol Deviation|0
5983891|NCT03593213|9573748|FG003|Open-label Treatment Period (18 Weeks)|Protocol Deviation|0
5983892|NCT03593213|9573745|FG000|Open-label Treatment Period (18 Weeks)|Non-compliance with Study Drug|23
5983893|NCT03593213|9573746|FG001|Open-label Treatment Period (18 Weeks)|Non-compliance with Study Drug|0
5983894|NCT03593213|9573747|FG002|Open-label Treatment Period (18 Weeks)|Non-compliance with Study Drug|0
5983895|NCT03593213|9573748|FG003|Open-label Treatment Period (18 Weeks)|Non-compliance with Study Drug|0
5983896|NCT03593213|9573745|FG000|Open-label Treatment Period (18 Weeks)|Study Terminated by the Sponsor|90
5983897|NCT03593213|9573746|FG001|Open-label Treatment Period (18 Weeks)|Study Terminated by the Sponsor|0
5983898|NCT03593213|9573747|FG002|Open-label Treatment Period (18 Weeks)|Study Terminated by the Sponsor|0
5983899|NCT03593213|9573748|FG003|Open-label Treatment Period (18 Weeks)|Study Terminated by the Sponsor|0
5983900|NCT03593213|9573745|FG000|Open-label Treatment Period (18 Weeks)|Reason not Specified|13
5983901|NCT03593213|9573746|FG001|Open-label Treatment Period (18 Weeks)|Reason not Specified|0
5983902|NCT03593213|9573747|FG002|Open-label Treatment Period (18 Weeks)|Reason not Specified|0
5983903|NCT03593213|9573748|FG003|Open-label Treatment Period (18 Weeks)|Reason not Specified|0
5983904|NCT03593213|9573745|FG000|Open-label Treatment Period (18 Weeks)|Failure to Meet Randomization Criteria|104
5983905|NCT03593213|9573746|FG001|Open-label Treatment Period (18 Weeks)|Failure to Meet Randomization Criteria|0
5983906|NCT03593213|9573747|FG002|Open-label Treatment Period (18 Weeks)|Failure to Meet Randomization Criteria|0
5983907|NCT03593213|9573748|FG003|Open-label Treatment Period (18 Weeks)|Failure to Meet Randomization Criteria|0
5983908|NCT03593213|9573745|FG000|Double-blind Treatment Period (26 Weeks)|Number of Participants with Relapse Event|0
5983909|NCT03593213|9573746|FG001|Double-blind Treatment Period (26 Weeks)|Number of Participants with Relapse Event|15
5983910|NCT03593213|9573747|FG002|Double-blind Treatment Period (26 Weeks)|Number of Participants with Relapse Event|9
5983911|NCT03593213|9573748|FG003|Double-blind Treatment Period (26 Weeks)|Number of Participants with Relapse Event|8
5983912|NCT03593213|9573745|FG000|Double-blind Treatment Period (26 Weeks)|Adverse Event|0
5983913|NCT03593213|9573746|FG001|Double-blind Treatment Period (26 Weeks)|Adverse Event|2
5983914|NCT03593213|9573747|FG002|Double-blind Treatment Period (26 Weeks)|Adverse Event|0
5983915|NCT03593213|9573748|FG003|Double-blind Treatment Period (26 Weeks)|Adverse Event|4
5983916|NCT03593213|9573745|FG000|Double-blind Treatment Period (26 Weeks)|Withdrawal by Subject|0
5983917|NCT03593213|9573746|FG001|Double-blind Treatment Period (26 Weeks)|Withdrawal by Subject|4
5983918|NCT03593213|9573747|FG002|Double-blind Treatment Period (26 Weeks)|Withdrawal by Subject|2
5983919|NCT03593213|9573748|FG003|Double-blind Treatment Period (26 Weeks)|Withdrawal by Subject|3
5983920|NCT03593213|9573745|FG000|Double-blind Treatment Period (26 Weeks)|Lost to Follow-up|0
5983921|NCT03593213|9573746|FG001|Double-blind Treatment Period (26 Weeks)|Lost to Follow-up|5
5983922|NCT03593213|9573747|FG002|Double-blind Treatment Period (26 Weeks)|Lost to Follow-up|4
5983923|NCT03593213|9573748|FG003|Double-blind Treatment Period (26 Weeks)|Lost to Follow-up|1
5983924|NCT03593213|9573745|FG000|Double-blind Treatment Period (26 Weeks)|Pregnancy|0
5983925|NCT03593213|9573746|FG001|Double-blind Treatment Period (26 Weeks)|Pregnancy|0
5983926|NCT03593213|9573747|FG002|Double-blind Treatment Period (26 Weeks)|Pregnancy|0
5983927|NCT03593213|9573748|FG003|Double-blind Treatment Period (26 Weeks)|Pregnancy|1
5983928|NCT03593213|9573745|FG000|Double-blind Treatment Period (26 Weeks)|Protocol Deviation|0
5983929|NCT03593213|9573746|FG001|Double-blind Treatment Period (26 Weeks)|Protocol Deviation|3
5983930|NCT03593213|9573747|FG002|Double-blind Treatment Period (26 Weeks)|Protocol Deviation|2
5983931|NCT03593213|9573748|FG003|Double-blind Treatment Period (26 Weeks)|Protocol Deviation|5
5983932|NCT03593213|9573745|FG000|Double-blind Treatment Period (26 Weeks)|Non-compliance with Study Drug|0
5983933|NCT03593213|9573746|FG001|Double-blind Treatment Period (26 Weeks)|Non-compliance with Study Drug|1
5983934|NCT03593213|9573747|FG002|Double-blind Treatment Period (26 Weeks)|Non-compliance with Study Drug|2
5983935|NCT03593213|9573748|FG003|Double-blind Treatment Period (26 Weeks)|Non-compliance with Study Drug|0
5983936|NCT03593213|9573745|FG000|Double-blind Treatment Period (26 Weeks)|Study Terminated by Sponsor|0
5983937|NCT03593213|9573746|FG001|Double-blind Treatment Period (26 Weeks)|Study Terminated by Sponsor|9
5983938|NCT03593213|9573747|FG002|Double-blind Treatment Period (26 Weeks)|Study Terminated by Sponsor|11
5983939|NCT03593213|9573748|FG003|Double-blind Treatment Period (26 Weeks)|Study Terminated by Sponsor|13
5983940|NCT03593213|9573745|FG000|Double-blind Treatment Period (26 Weeks)|Reason not Specified|0
5983941|NCT03593213|9573746|FG001|Double-blind Treatment Period (26 Weeks)|Reason not Specified|1
5983942|NCT03593213|9573747|FG002|Double-blind Treatment Period (26 Weeks)|Reason not Specified|3
5983943|NCT03593213|9573748|FG003|Double-blind Treatment Period (26 Weeks)|Reason not Specified|0
6043978|NCT00393484|9642901|FG001|Double-blind Period (Day 1 to Week 96)|Lack of Efficacy|6
6043979|NCT00393484|9642900|FG000|Double-blind Period (Day 1 to Week 96)|Lost to Follow-up|0
6043980|NCT00393484|9642901|FG001|Double-blind Period (Day 1 to Week 96)|Lost to Follow-up|2
6043981|NCT00393484|9642900|FG000|Open-label Period (Weeks 96 to 240)|Withdrawal by Subject|4
6043982|NCT00393484|9642901|FG001|Open-label Period (Weeks 96 to 240)|Withdrawal by Subject|1
6043983|NCT00393484|9642900|FG000|Open-label Period (Weeks 96 to 240)|Death|1
6043984|NCT00393484|9642901|FG001|Open-label Period (Weeks 96 to 240)|Death|0
6043985|NCT00393484|9642900|FG000|Open-label Period (Weeks 96 to 240)|Lost to Follow-up|1
6043986|NCT00393484|9642901|FG001|Open-label Period (Weeks 96 to 240)|Lost to Follow-up|2
6043987|NCT00393484|9642900|FG000|Open-label Period (Weeks 96 to 240)|Noncompliance|2
6043988|NCT00393484|9642901|FG001|Open-label Period (Weeks 96 to 240)|Noncompliance|2
6043989|NCT00393484|9642900|FG000|Open-label Period (Weeks 96 to 240)|Lack of Efficacy|0
6043990|NCT00393484|9642901|FG001|Open-label Period (Weeks 96 to 240)|Lack of Efficacy|18
6043991|NCT00393510|9642911|FG000|Overall Study|Physician Decision|3
6043992|NCT00393510|9642912|FG001|Overall Study|Physician Decision|9
6043993|NCT00393523|9642923|FG000|Overall Study|Lost to Follow-up|0
6043994|NCT00393523|9642924|FG001|Overall Study|Lost to Follow-up|0
6043995|NCT00393523|9642925|FG002|Overall Study|Lost to Follow-up|0
6043996|NCT00393523|9642926|FG003|Overall Study|Lost to Follow-up|2
6043997|NCT00393523|9642927|FG004|Overall Study|Lost to Follow-up|1
6043998|NCT00393523|9642923|FG000|Overall Study|Protocol Violation|6
6043999|NCT00393523|9642924|FG001|Overall Study|Protocol Violation|2
6044000|NCT00393523|9642925|FG002|Overall Study|Protocol Violation|0
6044001|NCT00393523|9642926|FG003|Overall Study|Protocol Violation|1
6044002|NCT00393523|9642927|FG004|Overall Study|Protocol Violation|0
6044003|NCT00393523|9642923|FG000|Overall Study|Withdrawal by Subject|6
6044004|NCT00393523|9642924|FG001|Overall Study|Withdrawal by Subject|7
6044005|NCT00393523|9642925|FG002|Overall Study|Withdrawal by Subject|2
6044006|NCT00393523|9642926|FG003|Overall Study|Withdrawal by Subject|3
6044007|NCT00393523|9642927|FG004|Overall Study|Withdrawal by Subject|0
6044008|NCT00393523|9642923|FG000|Overall Study|Difficulties in specimen collection|0
6044009|NCT00393523|9642924|FG001|Overall Study|Difficulties in specimen collection|0
6044010|NCT00393523|9642925|FG002|Overall Study|Difficulties in specimen collection|1
6044011|NCT00393523|9642926|FG003|Overall Study|Difficulties in specimen collection|0
6044012|NCT00393523|9642927|FG004|Overall Study|Difficulties in specimen collection|0
6044013|NCT00393523|9642923|FG000|Overall Study|Vaccine supply issue|0
6044014|NCT00393523|9642924|FG001|Overall Study|Vaccine supply issue|0
6044015|NCT00393523|9642925|FG002|Overall Study|Vaccine supply issue|1
6044016|NCT00393523|9642926|FG003|Overall Study|Vaccine supply issue|0
6044017|NCT00393523|9642927|FG004|Overall Study|Vaccine supply issue|0
6044018|NCT00393705|9642940|FG000|Overall Study|Adverse Event|0
6044019|NCT00393705|9642941|FG001|Overall Study|Adverse Event|2
6044020|NCT00393705|9642940|FG000|Overall Study|Death|0
6044021|NCT00393705|9642941|FG001|Overall Study|Death|1
6044022|NCT00393705|9642940|FG000|Overall Study|Lost to Follow-up|2
6044023|NCT00393705|9642941|FG001|Overall Study|Lost to Follow-up|2
5983944|NCT03248531|9573797|FG000|Overall Study|Adverse Event|0
5983945|NCT03248531|9573798|FG001|Overall Study|Adverse Event|0
5983946|NCT03248531|9573799|FG002|Overall Study|Adverse Event|1
5983947|NCT03248531|9573797|FG000|Overall Study|Lost to Follow-up|1
5983948|NCT03248531|9573798|FG001|Overall Study|Lost to Follow-up|0
5983949|NCT03248531|9573799|FG002|Overall Study|Lost to Follow-up|5
5983950|NCT03248531|9573797|FG000|Overall Study|Withdrawal by Subject|3
5983951|NCT03248531|9573798|FG001|Overall Study|Withdrawal by Subject|3
5983952|NCT03248531|9573799|FG002|Overall Study|Withdrawal by Subject|2
5983953|NCT03248531|9573797|FG000|Overall Study|Sponsor Request|0
5983954|NCT03248531|9573798|FG001|Overall Study|Sponsor Request|2
5983955|NCT03248531|9573799|FG002|Overall Study|Sponsor Request|0
5983956|NCT03205605|9573814|FG000|Overall Study|Withdrawal by Subject|1
5983957|NCT02484456|9573830|FG000|Washout Period|Withdrawal by Subject|0
5983958|NCT02484456|9573831|FG001|Washout Period|Withdrawal by Subject|1
5983959|NCT02484456|9573830|FG000|Second Treatment Period: Week 1|Adverse Event|1
5983960|NCT02484456|9573831|FG001|Second Treatment Period: Week 1|Adverse Event|0
5983961|NCT02484456|9573830|FG000|Second Treatment Period: Week 1|Withdrawal by Subject|0
5983962|NCT02484456|9573831|FG001|Second Treatment Period: Week 1|Withdrawal by Subject|1
5983963|NCT02484456|9573830|FG000|Second Treatment Period: Week 2|Adverse Event|0
5983964|NCT02484456|9573831|FG001|Second Treatment Period: Week 2|Adverse Event|1
5983965|NCT02481830|9573840|FG000|Overall Study|No longer meets Study Criteria|1
5983966|NCT02481830|9573841|FG001|Overall Study|No longer meets Study Criteria|4
5983967|NCT02481830|9573840|FG000|Overall Study|Withdrawal by Subject|0
5983968|NCT02481830|9573841|FG001|Overall Study|Withdrawal by Subject|14
5983969|NCT02481830|9573840|FG000|Overall Study|Disease Progression|1
5983970|NCT02481830|9573841|FG001|Overall Study|Disease Progression|1
5983971|NCT02481830|9573840|FG000|Overall Study|Participant not eligible for trial|0
5983972|NCT02481830|9573841|FG001|Overall Study|Participant not eligible for trial|1
5983973|NCT02234323|9573847|FG000|All Enrolled|Not Treated: Completed study in database|2
5983974|NCT02234323|9573847|FG000|All Enrolled|Not Treated:Consent withdrawn by subject|2
5983975|NCT02234323|9573847|FG000|All Enrolled|Not Treated: Exceeded lab value limit|1
5983976|NCT02234323|9573847|FG000|All Treated|Death|1
5983977|NCT02234323|9573847|FG000|All Treated|Physician Decision|5
5983978|NCT02234323|9573847|FG000|All Treated|Lack of Efficacy|3
5983979|NCT02234323|9573847|FG000|All Treated|Exceeded lab value limit|2
5983980|NCT02234323|9573847|FG000|All Treated|Other|7
5983981|NCT02220855|9573853|FG000|Overall Study|Adverse Event|8
5983982|NCT02220855|9573853|FG000|Overall Study|Disease Progression|5
5983983|NCT02220855|9573853|FG000|Overall Study|Withdrawal by Subject|1
5983984|NCT01791595|9573864|FG000|Part 1 AZD3965 Cohort 1 (5 mg OD)|Death|1
5983985|NCT01791595|9573865|FG001|Part 1 AZD3965 Cohort 1 (5 mg OD)|Death|0
5983986|NCT01791595|9573866|FG002|Part 1 AZD3965 Cohort 1 (5 mg OD)|Death|0
5983987|NCT01791595|9573867|FG003|Part 1 AZD3965 Cohort 1 (5 mg OD)|Death|0
5983988|NCT01791595|9573868|FG004|Part 1 AZD3965 Cohort 1 (5 mg OD)|Death|0
5983989|NCT01791595|9573869|FG005|Part 1 AZD3965 Cohort 1 (5 mg OD)|Death|0
5983990|NCT01791595|9573870|FG006|Part 1 AZD3965 Cohort 1 (5 mg OD)|Death|0
5983991|NCT01791595|9573864|FG000|Part 1 AZD3965 Cohort 1 (5 mg OD)|Evidence of disease progression|2
5983992|NCT01791595|9573865|FG001|Part 1 AZD3965 Cohort 1 (5 mg OD)|Evidence of disease progression|0
5983993|NCT01791595|9573866|FG002|Part 1 AZD3965 Cohort 1 (5 mg OD)|Evidence of disease progression|0
5983994|NCT01791595|9573867|FG003|Part 1 AZD3965 Cohort 1 (5 mg OD)|Evidence of disease progression|0
5983995|NCT01791595|9573868|FG004|Part 1 AZD3965 Cohort 1 (5 mg OD)|Evidence of disease progression|0
5983996|NCT01791595|9573869|FG005|Part 1 AZD3965 Cohort 1 (5 mg OD)|Evidence of disease progression|0
5983997|NCT01791595|9573870|FG006|Part 1 AZD3965 Cohort 1 (5 mg OD)|Evidence of disease progression|0
5983998|NCT01791595|9573864|FG000|Part 1 AZD3965 Cohort 2 (10 mg OD)|Evidence of disease progression|0
5983999|NCT01791595|9573865|FG001|Part 1 AZD3965 Cohort 2 (10 mg OD)|Evidence of disease progression|5
5984000|NCT01791595|9573866|FG002|Part 1 AZD3965 Cohort 2 (10 mg OD)|Evidence of disease progression|0
5984001|NCT01791595|9573867|FG003|Part 1 AZD3965 Cohort 2 (10 mg OD)|Evidence of disease progression|0
5984002|NCT01791595|9573868|FG004|Part 1 AZD3965 Cohort 2 (10 mg OD)|Evidence of disease progression|0
5984003|NCT01791595|9573869|FG005|Part 1 AZD3965 Cohort 2 (10 mg OD)|Evidence of disease progression|0
5984004|NCT01791595|9573870|FG006|Part 1 AZD3965 Cohort 2 (10 mg OD)|Evidence of disease progression|0
5984005|NCT01791595|9573864|FG000|Part 1 AZD3965 Cohort 3 (20 mg OD)|Adverse Event|0
5984006|NCT01791595|9573865|FG001|Part 1 AZD3965 Cohort 3 (20 mg OD)|Adverse Event|0
5984007|NCT01791595|9573866|FG002|Part 1 AZD3965 Cohort 3 (20 mg OD)|Adverse Event|1
5984008|NCT01791595|9573867|FG003|Part 1 AZD3965 Cohort 3 (20 mg OD)|Adverse Event|0
5984009|NCT01791595|9573868|FG004|Part 1 AZD3965 Cohort 3 (20 mg OD)|Adverse Event|0
5984010|NCT01791595|9573869|FG005|Part 1 AZD3965 Cohort 3 (20 mg OD)|Adverse Event|0
5984011|NCT01791595|9573870|FG006|Part 1 AZD3965 Cohort 3 (20 mg OD)|Adverse Event|0
5984012|NCT01791595|9573864|FG000|Part 1 AZD3965 Cohort 3 (20 mg OD)|Evidence of disease progression|0
6146004|NCT01074944|9780554|FG000|Primary Analysis Period (up to 52 Weeks)|Withdrawal by Subject|0
6146005|NCT01074944|9780555|FG001|Primary Analysis Period (up to 52 Weeks)|Withdrawal by Subject|1
6146006|NCT01074944|9780556|FG002|Primary Analysis Period (up to 52 Weeks)|Withdrawal by Subject|1
6146007|NCT01074944|9780557|FG003|Primary Analysis Period (up to 52 Weeks)|Withdrawal by Subject|0
6146008|NCT01074944|9780558|FG004|Primary Analysis Period (up to 52 Weeks)|Withdrawal by Subject|0
6146009|NCT01074944|9780554|FG000|Primary Analysis Period (up to 52 Weeks)|Pregnancy|0
5984013|NCT01791595|9573865|FG001|Part 1 AZD3965 Cohort 3 (20 mg OD)|Evidence of disease progression|0
5984014|NCT01791595|9573866|FG002|Part 1 AZD3965 Cohort 3 (20 mg OD)|Evidence of disease progression|6
5984015|NCT01791595|9573867|FG003|Part 1 AZD3965 Cohort 3 (20 mg OD)|Evidence of disease progression|0
5984016|NCT01791595|9573868|FG004|Part 1 AZD3965 Cohort 3 (20 mg OD)|Evidence of disease progression|0
5984017|NCT01791595|9573869|FG005|Part 1 AZD3965 Cohort 3 (20 mg OD)|Evidence of disease progression|0
5984018|NCT01791595|9573870|FG006|Part 1 AZD3965 Cohort 3 (20 mg OD)|Evidence of disease progression|0
5984019|NCT01791595|9573864|FG000|Part 1 AZD3965 Cohort 3 (20 mg OD)|Physician Decision|0
5984020|NCT01791595|9573865|FG001|Part 1 AZD3965 Cohort 3 (20 mg OD)|Physician Decision|0
5984021|NCT01791595|9573866|FG002|Part 1 AZD3965 Cohort 3 (20 mg OD)|Physician Decision|1
5984022|NCT01791595|9573867|FG003|Part 1 AZD3965 Cohort 3 (20 mg OD)|Physician Decision|0
5984023|NCT01791595|9573868|FG004|Part 1 AZD3965 Cohort 3 (20 mg OD)|Physician Decision|0
5984024|NCT01791595|9573869|FG005|Part 1 AZD3965 Cohort 3 (20 mg OD)|Physician Decision|0
5984025|NCT01791595|9573870|FG006|Part 1 AZD3965 Cohort 3 (20 mg OD)|Physician Decision|0
5984026|NCT01791595|9573864|FG000|Part 1 AZD3965 Cohort 4 (30 mg OD)|Adverse Event|0
5984027|NCT01791595|9573865|FG001|Part 1 AZD3965 Cohort 4 (30 mg OD)|Adverse Event|0
5984028|NCT01791595|9573866|FG002|Part 1 AZD3965 Cohort 4 (30 mg OD)|Adverse Event|0
5984029|NCT01791595|9573867|FG003|Part 1 AZD3965 Cohort 4 (30 mg OD)|Adverse Event|2
5984030|NCT01791595|9573868|FG004|Part 1 AZD3965 Cohort 4 (30 mg OD)|Adverse Event|0
5984031|NCT01791595|9573869|FG005|Part 1 AZD3965 Cohort 4 (30 mg OD)|Adverse Event|0
5984032|NCT01791595|9573870|FG006|Part 1 AZD3965 Cohort 4 (30 mg OD)|Adverse Event|0
5984033|NCT01791595|9573864|FG000|Part 1 AZD3965 Cohort 4 (30 mg OD)|Evidence of disease progression|0
5984034|NCT01791595|9573865|FG001|Part 1 AZD3965 Cohort 4 (30 mg OD)|Evidence of disease progression|0
5984035|NCT01791595|9573866|FG002|Part 1 AZD3965 Cohort 4 (30 mg OD)|Evidence of disease progression|0
5984036|NCT01791595|9573867|FG003|Part 1 AZD3965 Cohort 4 (30 mg OD)|Evidence of disease progression|2
5984037|NCT01791595|9573868|FG004|Part 1 AZD3965 Cohort 4 (30 mg OD)|Evidence of disease progression|0
5984038|NCT01791595|9573869|FG005|Part 1 AZD3965 Cohort 4 (30 mg OD)|Evidence of disease progression|0
5984039|NCT01791595|9573870|FG006|Part 1 AZD3965 Cohort 4 (30 mg OD)|Evidence of disease progression|0
5984040|NCT01791595|9573864|FG000|Part 1 AZD3965 Cohort 5 (15 mg BD)|Adverse Event|0
5984041|NCT01791595|9573865|FG001|Part 1 AZD3965 Cohort 5 (15 mg BD)|Adverse Event|0
5984042|NCT01791595|9573866|FG002|Part 1 AZD3965 Cohort 5 (15 mg BD)|Adverse Event|0
5984043|NCT01791595|9573867|FG003|Part 1 AZD3965 Cohort 5 (15 mg BD)|Adverse Event|0
5984044|NCT01791595|9573868|FG004|Part 1 AZD3965 Cohort 5 (15 mg BD)|Adverse Event|4
5984045|NCT01791595|9573869|FG005|Part 1 AZD3965 Cohort 5 (15 mg BD)|Adverse Event|0
5984046|NCT01791595|9573870|FG006|Part 1 AZD3965 Cohort 5 (15 mg BD)|Adverse Event|0
5984047|NCT01791595|9573864|FG000|Part 1 AZD3965 Cohort 5 (15 mg BD)|Evidence of disease progression|0
5984048|NCT01791595|9573865|FG001|Part 1 AZD3965 Cohort 5 (15 mg BD)|Evidence of disease progression|0
5984049|NCT01791595|9573866|FG002|Part 1 AZD3965 Cohort 5 (15 mg BD)|Evidence of disease progression|0
5984050|NCT01791595|9573867|FG003|Part 1 AZD3965 Cohort 5 (15 mg BD)|Evidence of disease progression|0
5984051|NCT01791595|9573868|FG004|Part 1 AZD3965 Cohort 5 (15 mg BD)|Evidence of disease progression|5
5984052|NCT01791595|9573869|FG005|Part 1 AZD3965 Cohort 5 (15 mg BD)|Evidence of disease progression|0
5984053|NCT01791595|9573870|FG006|Part 1 AZD3965 Cohort 5 (15 mg BD)|Evidence of disease progression|0
5984054|NCT01791595|9573864|FG000|Part 1 AZD3965 Cohort 5 (15 mg BD)|Withdrawal by Subject|0
5984055|NCT01791595|9573865|FG001|Part 1 AZD3965 Cohort 5 (15 mg BD)|Withdrawal by Subject|0
5984056|NCT01791595|9573866|FG002|Part 1 AZD3965 Cohort 5 (15 mg BD)|Withdrawal by Subject|0
5984057|NCT01791595|9573867|FG003|Part 1 AZD3965 Cohort 5 (15 mg BD)|Withdrawal by Subject|0
5984058|NCT01791595|9573868|FG004|Part 1 AZD3965 Cohort 5 (15 mg BD)|Withdrawal by Subject|1
5984059|NCT01791595|9573869|FG005|Part 1 AZD3965 Cohort 5 (15 mg BD)|Withdrawal by Subject|0
5984060|NCT01791595|9573870|FG006|Part 1 AZD3965 Cohort 5 (15 mg BD)|Withdrawal by Subject|0
5984061|NCT01791595|9573864|FG000|Part 1 AZD3965 Cohort 5 (15 mg BD)|Physician Decision|0
5984062|NCT01791595|9573865|FG001|Part 1 AZD3965 Cohort 5 (15 mg BD)|Physician Decision|0
5984063|NCT01791595|9573866|FG002|Part 1 AZD3965 Cohort 5 (15 mg BD)|Physician Decision|0
5984064|NCT01791595|9573867|FG003|Part 1 AZD3965 Cohort 5 (15 mg BD)|Physician Decision|0
5984065|NCT01791595|9573868|FG004|Part 1 AZD3965 Cohort 5 (15 mg BD)|Physician Decision|1
5984066|NCT01791595|9573869|FG005|Part 1 AZD3965 Cohort 5 (15 mg BD)|Physician Decision|0
5984067|NCT01791595|9573870|FG006|Part 1 AZD3965 Cohort 5 (15 mg BD)|Physician Decision|0
5984068|NCT01791595|9573864|FG000|Part 1 AZD3965 Cohort 6 (10 mg BD)|Adverse Event|0
5984069|NCT01791595|9573865|FG001|Part 1 AZD3965 Cohort 6 (10 mg BD)|Adverse Event|0
5984070|NCT01791595|9573866|FG002|Part 1 AZD3965 Cohort 6 (10 mg BD)|Adverse Event|0
5984071|NCT01791595|9573867|FG003|Part 1 AZD3965 Cohort 6 (10 mg BD)|Adverse Event|0
5984072|NCT01791595|9573868|FG004|Part 1 AZD3965 Cohort 6 (10 mg BD)|Adverse Event|0
5984073|NCT01791595|9573869|FG005|Part 1 AZD3965 Cohort 6 (10 mg BD)|Adverse Event|5
5984074|NCT01791595|9573870|FG006|Part 1 AZD3965 Cohort 6 (10 mg BD)|Adverse Event|0
5984075|NCT01791595|9573864|FG000|Part 1 AZD3965 Cohort 6 (10 mg BD)|Evidence of disease progression|0
5984076|NCT01791595|9573865|FG001|Part 1 AZD3965 Cohort 6 (10 mg BD)|Evidence of disease progression|0
5984077|NCT01791595|9573866|FG002|Part 1 AZD3965 Cohort 6 (10 mg BD)|Evidence of disease progression|0
5984078|NCT01791595|9573867|FG003|Part 1 AZD3965 Cohort 6 (10 mg BD)|Evidence of disease progression|0
5984079|NCT01791595|9573868|FG004|Part 1 AZD3965 Cohort 6 (10 mg BD)|Evidence of disease progression|0
5984080|NCT01791595|9573869|FG005|Part 1 AZD3965 Cohort 6 (10 mg BD)|Evidence of disease progression|3
5984081|NCT01791595|9573870|FG006|Part 1 AZD3965 Cohort 6 (10 mg BD)|Evidence of disease progression|0
5984082|NCT01791595|9573864|FG000|Part 2 AZD3965 Expansion (10 mg BD)|Adverse Event|0
5984083|NCT01791595|9573865|FG001|Part 2 AZD3965 Expansion (10 mg BD)|Adverse Event|0
5984084|NCT01791595|9573866|FG002|Part 2 AZD3965 Expansion (10 mg BD)|Adverse Event|0
5984085|NCT01791595|9573867|FG003|Part 2 AZD3965 Expansion (10 mg BD)|Adverse Event|0
5984086|NCT01791595|9573868|FG004|Part 2 AZD3965 Expansion (10 mg BD)|Adverse Event|0
5984087|NCT01791595|9573869|FG005|Part 2 AZD3965 Expansion (10 mg BD)|Adverse Event|0
5984088|NCT01791595|9573870|FG006|Part 2 AZD3965 Expansion (10 mg BD)|Adverse Event|1
5984089|NCT01791595|9573864|FG000|Part 2 AZD3965 Expansion (10 mg BD)|Evidence of disease progression|0
5984090|NCT01791595|9573865|FG001|Part 2 AZD3965 Expansion (10 mg BD)|Evidence of disease progression|0
5984091|NCT01791595|9573866|FG002|Part 2 AZD3965 Expansion (10 mg BD)|Evidence of disease progression|0
5984092|NCT01791595|9573867|FG003|Part 2 AZD3965 Expansion (10 mg BD)|Evidence of disease progression|0
5984093|NCT01791595|9573868|FG004|Part 2 AZD3965 Expansion (10 mg BD)|Evidence of disease progression|0
5984094|NCT01791595|9573869|FG005|Part 2 AZD3965 Expansion (10 mg BD)|Evidence of disease progression|0
5984095|NCT01791595|9573870|FG006|Part 2 AZD3965 Expansion (10 mg BD)|Evidence of disease progression|6
5984096|NCT01791595|9573864|FG000|Part 2 AZD3965 Expansion (10 mg BD)|Withdrawal by Subject|0
5984097|NCT01791595|9573865|FG001|Part 2 AZD3965 Expansion (10 mg BD)|Withdrawal by Subject|0
5984098|NCT01791595|9573866|FG002|Part 2 AZD3965 Expansion (10 mg BD)|Withdrawal by Subject|0
5984099|NCT01791595|9573867|FG003|Part 2 AZD3965 Expansion (10 mg BD)|Withdrawal by Subject|0
5984100|NCT01791595|9573868|FG004|Part 2 AZD3965 Expansion (10 mg BD)|Withdrawal by Subject|0
5984101|NCT01791595|9573869|FG005|Part 2 AZD3965 Expansion (10 mg BD)|Withdrawal by Subject|0
5984102|NCT01791595|9573870|FG006|Part 2 AZD3965 Expansion (10 mg BD)|Withdrawal by Subject|2
5984103|NCT01791595|9573864|FG000|Part 2 AZD3965 Expansion (10 mg BD)|Physician Decision|0
5984104|NCT01791595|9573865|FG001|Part 2 AZD3965 Expansion (10 mg BD)|Physician Decision|0
5984105|NCT01791595|9573866|FG002|Part 2 AZD3965 Expansion (10 mg BD)|Physician Decision|0
5984106|NCT01791595|9573867|FG003|Part 2 AZD3965 Expansion (10 mg BD)|Physician Decision|0
5984107|NCT01791595|9573868|FG004|Part 2 AZD3965 Expansion (10 mg BD)|Physician Decision|0
5984108|NCT01791595|9573869|FG005|Part 2 AZD3965 Expansion (10 mg BD)|Physician Decision|0
5984109|NCT01791595|9573870|FG006|Part 2 AZD3965 Expansion (10 mg BD)|Physician Decision|1
6044024|NCT00393705|9642940|FG000|Overall Study|Entry Criteria Not Met|10
6044025|NCT00393705|9642941|FG001|Overall Study|Entry Criteria Not Met|10
6044026|NCT00393705|9642940|FG000|Overall Study|Protocol Violation|4
6044027|NCT00393705|9642941|FG001|Overall Study|Protocol Violation|3
6044028|NCT00393705|9642940|FG000|Overall Study|Withdrawal by Subject|5
6044029|NCT00393705|9642941|FG001|Overall Study|Withdrawal by Subject|3
6044030|NCT00393705|9642940|FG000|Overall Study|Physician Decision|2
6044031|NCT00393705|9642941|FG001|Overall Study|Physician Decision|2
6049034|NCT00420927|9648204|FG005|Period 2|Took prohibited medication|0
6049035|NCT00420927|9648205|FG006|Period 2|Took prohibited medication|0
6049036|NCT00421148|9648249|FG000|Overall Study|Lost to Follow-up|0
6049037|NCT00421148|9648250|FG001|Overall Study|Lost to Follow-up|0
6049038|NCT00421148|9648251|FG002|Overall Study|Lost to Follow-up|0
6049039|NCT00421148|9648252|FG003|Overall Study|Lost to Follow-up|0
6049040|NCT00421148|9648253|FG004|Overall Study|Lost to Follow-up|0
6049041|NCT00421148|9648254|FG005|Overall Study|Lost to Follow-up|0
6049042|NCT00421148|9648255|FG006|Overall Study|Lost to Follow-up|0
6049043|NCT00421148|9648256|FG007|Overall Study|Lost to Follow-up|0
6049044|NCT00421148|9648257|FG008|Overall Study|Lost to Follow-up|0
6049045|NCT00421148|9648258|FG009|Overall Study|Lost to Follow-up|0
6049046|NCT00421148|9648259|FG010|Overall Study|Lost to Follow-up|0
6049047|NCT00421148|9648260|FG011|Overall Study|Lost to Follow-up|0
6049048|NCT00421148|9648261|FG012|Overall Study|Lost to Follow-up|0
6049049|NCT00421148|9648262|FG013|Overall Study|Lost to Follow-up|0
6049050|NCT00421148|9648263|FG014|Overall Study|Lost to Follow-up|0
6049051|NCT00421148|9648264|FG015|Overall Study|Lost to Follow-up|0
6049052|NCT00421148|9648265|FG016|Overall Study|Lost to Follow-up|0
6049053|NCT00421148|9648266|FG017|Overall Study|Lost to Follow-up|1
6049054|NCT00421148|9648267|FG018|Overall Study|Lost to Follow-up|0
6049055|NCT00421148|9648268|FG019|Overall Study|Lost to Follow-up|0
6049056|NCT00421148|9648249|FG000|Overall Study|Withdrawal by Subject|0
6049057|NCT00421148|9648250|FG001|Overall Study|Withdrawal by Subject|0
6049058|NCT00421148|9648251|FG002|Overall Study|Withdrawal by Subject|0
6049059|NCT00421148|9648252|FG003|Overall Study|Withdrawal by Subject|0
6146010|NCT01074944|9780555|FG001|Primary Analysis Period (up to 52 Weeks)|Pregnancy|1
6146011|NCT01074944|9780556|FG002|Primary Analysis Period (up to 52 Weeks)|Pregnancy|0
6146012|NCT01074944|9780557|FG003|Primary Analysis Period (up to 52 Weeks)|Pregnancy|0
6146013|NCT01074944|9780558|FG004|Primary Analysis Period (up to 52 Weeks)|Pregnancy|0
6146014|NCT01074944|9780554|FG000|Primary Analysis Period (up to 52 Weeks)|Non-Compliant to Protocol|0
6146015|NCT01074944|9780555|FG001|Primary Analysis Period (up to 52 Weeks)|Non-Compliant to Protocol|1
6146016|NCT01074944|9780556|FG002|Primary Analysis Period (up to 52 Weeks)|Non-Compliant to Protocol|1
6146017|NCT01074944|9780557|FG003|Primary Analysis Period (up to 52 Weeks)|Non-Compliant to Protocol|0
6049060|NCT00421148|9648253|FG004|Overall Study|Withdrawal by Subject|0
6049061|NCT00421148|9648254|FG005|Overall Study|Withdrawal by Subject|0
6049062|NCT00421148|9648255|FG006|Overall Study|Withdrawal by Subject|0
5984110|NCT01192776|9573894|FG000|Overall Study|Death|8
5984111|NCT01192776|9573895|FG001|Overall Study|Death|15
5984112|NCT01192776|9573896|FG002|Overall Study|Death|18
5984113|NCT01192776|9573897|FG003|Overall Study|Death|15
5984114|NCT01192776|9573894|FG000|Overall Study|Lost to Follow-up|3
5984115|NCT01192776|9573895|FG001|Overall Study|Lost to Follow-up|6
5984116|NCT01192776|9573896|FG002|Overall Study|Lost to Follow-up|3
5984117|NCT01192776|9573897|FG003|Overall Study|Lost to Follow-up|5
5984118|NCT00089791|9573929|FG000|Overall Study|Physician Decision|6
5984119|NCT00089791|9573930|FG001|Overall Study|Physician Decision|3
5984120|NCT00089791|9573929|FG000|Overall Study|Adverse Event|81
5984121|NCT00089791|9573930|FG001|Overall Study|Adverse Event|93
5984122|NCT00089791|9573929|FG000|Overall Study|Withdrawal by Subject|403
5984123|NCT00089791|9573930|FG001|Overall Study|Withdrawal by Subject|344
5984124|NCT00089791|9573929|FG000|Overall Study|Death|78
5984125|NCT00089791|9573930|FG001|Overall Study|Death|62
5984126|NCT00089791|9573929|FG000|Overall Study|Disease progression|7
5984127|NCT00089791|9573930|FG001|Overall Study|Disease progression|3
5984128|NCT00089791|9573929|FG000|Overall Study|Ineligibility determined|12
5984129|NCT00089791|9573930|FG001|Overall Study|Ineligibility determined|9
5984130|NCT00089791|9573929|FG000|Overall Study|Lost to Follow-up|57
5984131|NCT00089791|9573930|FG001|Overall Study|Lost to Follow-up|57
5984132|NCT00089791|9573929|FG000|Overall Study|Noncompliance|17
5984133|NCT00089791|9573930|FG001|Overall Study|Noncompliance|13
5984134|NCT00089791|9573929|FG000|Overall Study|Other|20
5984135|NCT00089791|9573930|FG001|Overall Study|Other|32
5984136|NCT00089791|9573929|FG000|Overall Study|Protocol deviation|12
5984137|NCT00089791|9573930|FG001|Overall Study|Protocol deviation|10
5984138|NCT00089791|9573929|FG000|Overall Study|Requirement for alternative therapy|7
5984139|NCT00089791|9573930|FG001|Overall Study|Requirement for alternative therapy|4
6044032|NCT00393718|9642949|FG000|Overall Study|Adverse Event|20
6044033|NCT00393718|9642950|FG001|Overall Study|Adverse Event|8
6044034|NCT00393718|9642949|FG000|Overall Study|Protocol Violation|1
6044035|NCT00393718|9642950|FG001|Overall Study|Protocol Violation|2
6044036|NCT00393718|9642949|FG000|Overall Study|Lack of Efficacy|10
6044037|NCT00393718|9642950|FG001|Overall Study|Lack of Efficacy|9
6044038|NCT00393718|9642949|FG000|Overall Study|Hypoglycaemia|3
6044039|NCT00393718|9642950|FG001|Overall Study|Hypoglycaemia|2
6044040|NCT00393718|9642949|FG000|Overall Study|Subject decision|5
6044041|NCT00393718|9642950|FG001|Overall Study|Subject decision|0
6044042|NCT00393718|9642949|FG000|Overall Study|Withdrawal of consent|2
6044043|NCT00393718|9642950|FG001|Overall Study|Withdrawal of consent|1
6044044|NCT00393718|9642949|FG000|Overall Study|Missed measurement|1
6044045|NCT00393718|9642950|FG001|Overall Study|Missed measurement|0
6044046|NCT00393718|9642949|FG000|Overall Study|Move|1
6044047|NCT00393718|9642950|FG001|Overall Study|Move|0
6044048|NCT00393848|9642969|FG000|Overall Study|Surgical schedule|0
6044049|NCT00393848|9642970|FG001|Overall Study|Surgical schedule|0
6044050|NCT00393848|9642971|FG002|Overall Study|Surgical schedule|0
6044051|NCT00393848|9642972|FG003|Overall Study|Surgical schedule|1
6044052|NCT00393848|9642969|FG000|Overall Study|Personal reasons|0
6044053|NCT00393848|9642970|FG001|Overall Study|Personal reasons|0
6044054|NCT00393848|9642971|FG002|Overall Study|Personal reasons|2
6044055|NCT00393848|9642972|FG003|Overall Study|Personal reasons|0
6044056|NCT00393861|9642983|FG000|Overall Study|Adverse Event|2
6044057|NCT00393861|9642983|FG000|Overall Study|Disease Progression|24
6044058|NCT00393887|9643005|FG000|Overall Study|Physician Decision|5
6044059|NCT00393887|9643006|FG001|Overall Study|Physician Decision|0
6044060|NCT00393887|9643005|FG000|Overall Study|Lost to Follow-up|11
6044061|NCT00393887|9643006|FG001|Overall Study|Lost to Follow-up|9
6044062|NCT00393913|9643012|FG000|Initial Assessment|diagnosed with other sleep disorder|21
6044063|NCT00393913|9643012|FG000|Initial Assessment|Withdrawal by Subject|16
6044064|NCT00393913|9643012|FG000|CPAP|Withdrawal by Subject|3
6044065|NCT00393913|9643012|FG000|CPAP|Physician Decision|1
6044066|NCT00393913|9643012|FG000|CPAP|TEchnical problem with CPAP|3
6044067|NCT00393939|9643019|FG000|Overall Study|Protocol Violation|1
6044068|NCT00393939|9643020|FG001|Overall Study|Protocol Violation|1
6044069|NCT00393939|9643019|FG000|Overall Study|Lost to Follow-up|2
6044070|NCT00393939|9643020|FG001|Overall Study|Lost to Follow-up|4
6044071|NCT00393939|9643019|FG000|Overall Study|Death|10
6044072|NCT00393939|9643020|FG001|Overall Study|Death|4
6044073|NCT00393939|9643019|FG000|Overall Study|Sponsor|5
6044074|NCT00393939|9643020|FG001|Overall Study|Sponsor|13
6044075|NCT00393939|9643019|FG000|Overall Study|Objective progression or relapse|239
6044076|NCT00393939|9643020|FG001|Overall Study|Objective progression or relapse|223
6193343|NCT01437397|9850967|FG001|Overall Study|Adverse Event|22
6044077|NCT00393939|9643019|FG000|Overall Study|Withdrawal by Subject|2
6044078|NCT00393939|9643020|FG001|Overall Study|Withdrawal by Subject|7
6044079|NCT00393939|9643019|FG000|Overall Study|Other|37
6044080|NCT00393939|9643020|FG001|Overall Study|Other|45
6044081|NCT00394082|9643035|FG000|Overall Study|Unacceptable toxicity|15
6044082|NCT00394082|9643035|FG000|Overall Study|Adverse Event|4
6044083|NCT00394082|9643035|FG000|Overall Study|Physician Decision|4
6044084|NCT00394082|9643035|FG000|Overall Study|Withdrawal by Subject|2
6044085|NCT00394082|9643035|FG000|Overall Study|Other|1
6044086|NCT00394095|9643041|FG000|Overall Study|Adverse Event|1
6044087|NCT00394095|9643042|FG001|Overall Study|Adverse Event|0
6044088|NCT00394212|9643051|FG000|Overall Study|Lost to Follow-up|3
5984140|NCT03392883|9573939|FG000|Overall Study|Lost to Follow-up|122
5984141|NCT03392883|9573940|FG001|Overall Study|Lost to Follow-up|13
5984142|NCT03392883|9573941|FG002|Overall Study|Lost to Follow-up|9
5984143|NCT03392883|9573939|FG000|Overall Study|Death|4
5984144|NCT03392883|9573940|FG001|Overall Study|Death|0
5984145|NCT03392883|9573941|FG002|Overall Study|Death|0
5984146|NCT03392883|9573939|FG000|Overall Study|Lack of Efficacy|29
5984147|NCT03392883|9573940|FG001|Overall Study|Lack of Efficacy|0
5984148|NCT03392883|9573941|FG002|Overall Study|Lack of Efficacy|0
5984149|NCT03392883|9573939|FG000|Overall Study|Withdrawal by Subject|180
5984150|NCT03392883|9573940|FG001|Overall Study|Withdrawal by Subject|0
5984151|NCT03392883|9573941|FG002|Overall Study|Withdrawal by Subject|0
5984152|NCT03392883|9573939|FG000|Overall Study|Adverse Event|1
5984153|NCT03392883|9573940|FG001|Overall Study|Adverse Event|0
5984154|NCT03392883|9573941|FG002|Overall Study|Adverse Event|0
5984155|NCT03376789|9573949|FG000|Overall Study|Withdrawal by Subject|3
5984156|NCT03376789|9573950|FG001|Overall Study|Withdrawal by Subject|5
5984157|NCT03376789|9573949|FG000|Overall Study|Protocol Violation|0
5984158|NCT03376789|9573950|FG001|Overall Study|Protocol Violation|1
5984159|NCT03376789|9573949|FG000|Overall Study|Adverse Event|0
5984160|NCT03376789|9573950|FG001|Overall Study|Adverse Event|1
5984161|NCT03376789|9573949|FG000|Overall Study|Lost to Follow-up|1
5984162|NCT03376789|9573950|FG001|Overall Study|Lost to Follow-up|1
5984163|NCT03376789|9573949|FG000|Overall Study|Per sponsor due to noncompliance|1
5984164|NCT03376789|9573950|FG001|Overall Study|Per sponsor due to noncompliance|0
5984165|NCT03376789|9573949|FG000|Overall Study|Subject off study medication|0
5984166|NCT03376789|9573950|FG001|Overall Study|Subject off study medication|1
5984167|NCT03307967|9573978|FG000|Overall Study|Lost to Follow-up|4
5984168|NCT03288129|9573988|FG000|Overall Study|Adverse Event|10
5984169|NCT03288129|9573988|FG000|Overall Study|Lost to Follow-up|3
5984170|NCT03288129|9573988|FG000|Overall Study|Withdrawal by Subject|3
5984171|NCT03288129|9573988|FG000|Overall Study|Withdrawal of consent/assent|1
5984172|NCT03288129|9573988|FG000|Overall Study|Other|5
5984173|NCT03241225|9574020|FG000|Overall Study|Lost to Follow-up|2
5984174|NCT03241225|9574021|FG001|Overall Study|Lost to Follow-up|1
5984175|NCT03241225|9574020|FG000|Overall Study|Protocol Violation|4
5984176|NCT03241225|9574021|FG001|Overall Study|Protocol Violation|1
5984177|NCT03241225|9574020|FG000|Overall Study|Withdrawal by Subject|1
5984178|NCT03241225|9574021|FG001|Overall Study|Withdrawal by Subject|0
5984179|NCT03225846|9574034|FG000|Overall Study|Adverse Event|0
5984180|NCT03225846|9574035|FG001|Overall Study|Adverse Event|0
5984181|NCT03225846|9574036|FG002|Overall Study|Adverse Event|0
5984182|NCT03225846|9574037|FG003|Overall Study|Adverse Event|0
5984183|NCT03225846|9574038|FG004|Overall Study|Adverse Event|0
5984184|NCT03225846|9574039|FG005|Overall Study|Adverse Event|0
5984185|NCT03225846|9574040|FG006|Overall Study|Adverse Event|6
5984186|NCT03225846|9574034|FG000|Overall Study|Withdrawal by Subject|0
5984187|NCT03225846|9574035|FG001|Overall Study|Withdrawal by Subject|1
5984188|NCT03225846|9574036|FG002|Overall Study|Withdrawal by Subject|0
5984189|NCT03225846|9574037|FG003|Overall Study|Withdrawal by Subject|0
5984190|NCT03225846|9574038|FG004|Overall Study|Withdrawal by Subject|0
5984191|NCT03225846|9574039|FG005|Overall Study|Withdrawal by Subject|0
5984192|NCT03225846|9574040|FG006|Overall Study|Withdrawal by Subject|0
5984193|NCT03225846|9574034|FG000|Overall Study|Death|0
5984194|NCT03225846|9574035|FG001|Overall Study|Death|1
5984195|NCT03225846|9574036|FG002|Overall Study|Death|0
5984196|NCT03225846|9574037|FG003|Overall Study|Death|0
5984197|NCT03225846|9574038|FG004|Overall Study|Death|0
5984198|NCT03225846|9574039|FG005|Overall Study|Death|0
5984199|NCT03225846|9574040|FG006|Overall Study|Death|0
5984200|NCT03225846|9574034|FG000|Overall Study|Patient did not wish to comply with IC/EC|0
5984201|NCT03225846|9574035|FG001|Overall Study|Patient did not wish to comply with IC/EC|0
5984202|NCT03225846|9574036|FG002|Overall Study|Patient did not wish to comply with IC/EC|1
5984203|NCT03225846|9574037|FG003|Overall Study|Patient did not wish to comply with IC/EC|0
5984204|NCT03225846|9574038|FG004|Overall Study|Patient did not wish to comply with IC/EC|0
5984205|NCT03225846|9574039|FG005|Overall Study|Patient did not wish to comply with IC/EC|0
5984206|NCT03225846|9574040|FG006|Overall Study|Patient did not wish to comply with IC/EC|0
5984207|NCT03225846|9574034|FG000|Overall Study|Patient decision|0
5984208|NCT03225846|9574035|FG001|Overall Study|Patient decision|0
5984209|NCT03225846|9574036|FG002|Overall Study|Patient decision|0
5984210|NCT03225846|9574037|FG003|Overall Study|Patient decision|0
5984211|NCT03225846|9574038|FG004|Overall Study|Patient decision|0
5984212|NCT03225846|9574039|FG005|Overall Study|Patient decision|0
5984213|NCT03225846|9574040|FG006|Overall Study|Patient decision|1
5984214|NCT03191903|9574083|FG000|Overall Study|Withdrawal by Subject|6
5984215|NCT03191903|9574084|FG001|Overall Study|Withdrawal by Subject|5
5984216|NCT03191903|9574085|FG002|Overall Study|Withdrawal by Subject|4
5984217|NCT03191903|9574083|FG000|Overall Study|Adverse Event|1
5984218|NCT03191903|9574084|FG001|Overall Study|Adverse Event|0
5984219|NCT03191903|9574085|FG002|Overall Study|Adverse Event|0
5984220|NCT03186794|9574098|FG000|Overall Study|Physician Decision|2
5984221|NCT03186794|9574098|FG000|Overall Study|Withdrawal due to COVID-19 pandemic closure|2
5984222|NCT04289051|9574103|FG000|Overall Study|Lost to Follow-up|0
5984223|NCT04289051|9574104|FG001|Overall Study|Lost to Follow-up|0
5984224|NCT04289051|9574105|FG002|Overall Study|Lost to Follow-up|2
5984225|NCT04210180|9574113|FG000|Overall Study|Withdrawal by Subject|2
6044089|NCT00394212|9643052|FG001|Overall Study|Lost to Follow-up|0
6044090|NCT00394212|9643051|FG000|Overall Study|Withdrawal by Subject|4
6044091|NCT00394212|9643052|FG001|Overall Study|Withdrawal by Subject|1
6044092|NCT00394251|9643060|FG000|Overall Study|Adverse Event|7
6044093|NCT00394251|9643061|FG001|Overall Study|Adverse Event|5
6044094|NCT00394251|9643060|FG000|Overall Study|Unacceptable Toxicity|20
6044095|NCT00394251|9643061|FG001|Overall Study|Unacceptable Toxicity|18
6044096|NCT00394251|9643060|FG000|Overall Study|Physician Decision|1
6044097|NCT00394251|9643061|FG001|Overall Study|Physician Decision|1
6044098|NCT00394251|9643060|FG000|Overall Study|Protocol Violation|0
6044099|NCT00394251|9643061|FG001|Overall Study|Protocol Violation|1
6044100|NCT00394251|9643060|FG000|Overall Study|Withdrawal by Subject|7
6044101|NCT00394251|9643061|FG001|Overall Study|Withdrawal by Subject|11
6044102|NCT00394251|9643060|FG000|Overall Study|Non-compliance, pt moved, pt/inv agree|2
6044103|NCT00394251|9643061|FG001|Overall Study|Non-compliance, pt moved, pt/inv agree|2
6044104|NCT00394433|9643111|FG000|Overall Study|Adverse Event|2
6044105|NCT00394433|9643111|FG000|Overall Study|Alternative Therapy|1
6044106|NCT00394472|9643117|FG000|Overall Study|Protocol Violation|1
6044107|NCT00394472|9643118|FG001|Overall Study|Protocol Violation|3
6044108|NCT00394472|9643117|FG000|Overall Study|incorrect enrolment|4
6044109|NCT00394472|9643118|FG001|Overall Study|incorrect enrolment|2
6044110|NCT00394472|9643117|FG000|Overall Study|Adverse Event|4
6044111|NCT00394472|9643118|FG001|Overall Study|Adverse Event|2
6044112|NCT00394472|9643117|FG000|Overall Study|Withdrawal by Subject|0
6044113|NCT00394472|9643118|FG001|Overall Study|Withdrawal by Subject|2
6044114|NCT00394472|9643117|FG000|Overall Study|Physician Decision|0
6044115|NCT00394472|9643118|FG001|Overall Study|Physician Decision|1
6044116|NCT00394472|9643117|FG000|Overall Study|Lost to Follow-up|0
6044117|NCT00394472|9643118|FG001|Overall Study|Lost to Follow-up|1
6044118|NCT00394524|9643126|FG000|Overall Study|Protocol Violation|2
6044119|NCT00394524|9643127|FG001|Overall Study|Protocol Violation|3
6044120|NCT00394524|9643126|FG000|Overall Study|Death|1
6044121|NCT00394524|9643127|FG001|Overall Study|Death|0
6146018|NCT01074944|9780558|FG004|Primary Analysis Period (up to 52 Weeks)|Non-Compliant to Protocol|0
6044122|NCT00394524|9643126|FG000|Overall Study|Withdrawal by Subject|0
6044123|NCT00394524|9643127|FG001|Overall Study|Withdrawal by Subject|1
6044124|NCT00394589|9643138|FG000|Overall Study|Adverse Event|2
6044125|NCT00394589|9643139|FG001|Overall Study|Adverse Event|1
6044126|NCT00394589|9643140|FG002|Overall Study|Adverse Event|2
6044127|NCT00394589|9643138|FG000|Overall Study|Lack of Efficacy|2
6044128|NCT00394589|9643139|FG001|Overall Study|Lack of Efficacy|2
6044129|NCT00394589|9643140|FG002|Overall Study|Lack of Efficacy|3
6044130|NCT00394589|9643138|FG000|Overall Study|Protocol Violation|4
6044131|NCT00394589|9643139|FG001|Overall Study|Protocol Violation|0
6044132|NCT00394589|9643140|FG002|Overall Study|Protocol Violation|2
6044133|NCT00394654|9643150|FG000|Overall Study|Lost to Follow-up|1
6044134|NCT00394654|9643151|FG001|Overall Study|Lost to Follow-up|0
6044135|NCT00394654|9643150|FG000|Overall Study|PARTICIPANT LEFT STDUY REGION|1
6044136|NCT00394654|9643151|FG001|Overall Study|PARTICIPANT LEFT STDUY REGION|0
6044137|NCT00394706|9643165|FG000|Overall Study|Withdrawal by Subject|2
6044138|NCT00394706|9643166|FG001|Overall Study|Withdrawal by Subject|0
6044139|NCT00394706|9643167|FG002|Overall Study|Withdrawal by Subject|1
6044140|NCT00394706|9643168|FG003|Overall Study|Withdrawal by Subject|0
6044141|NCT00394706|9643169|FG004|Overall Study|Withdrawal by Subject|0
6044142|NCT00394706|9643170|FG005|Overall Study|Withdrawal by Subject|2
6044143|NCT00394706|9643171|FG006|Overall Study|Withdrawal by Subject|1
6044144|NCT00394706|9643172|FG007|Overall Study|Withdrawal by Subject|0
6044145|NCT00394706|9643165|FG000|Overall Study|Lost to Follow-up|2
6044146|NCT00394706|9643166|FG001|Overall Study|Lost to Follow-up|2
6044147|NCT00394706|9643167|FG002|Overall Study|Lost to Follow-up|8
6044148|NCT00394706|9643168|FG003|Overall Study|Lost to Follow-up|1
6044149|NCT00394706|9643169|FG004|Overall Study|Lost to Follow-up|2
6044150|NCT00394706|9643170|FG005|Overall Study|Lost to Follow-up|5
6044151|NCT00394706|9643171|FG006|Overall Study|Lost to Follow-up|2
6146019|NCT01074944|9780554|FG000|Long Term Treatment|Adverse Event|0
6146020|NCT01074944|9780555|FG001|Long Term Treatment|Adverse Event|0
6146021|NCT01074944|9780556|FG002|Long Term Treatment|Adverse Event|0
6146022|NCT01074944|9780557|FG003|Long Term Treatment|Adverse Event|3
6146023|NCT01074944|9780558|FG004|Long Term Treatment|Adverse Event|0
6146024|NCT01074944|9780554|FG000|Long Term Treatment|Lost to Follow-up|0
6146025|NCT01074944|9780555|FG001|Long Term Treatment|Lost to Follow-up|0
6044152|NCT00394706|9643172|FG007|Overall Study|Lost to Follow-up|0
6044153|NCT00394771|9643190|FG000|Overall Study|Did not meet protocol requirements|1
6044154|NCT00394771|9643191|FG001|Overall Study|Did not meet protocol requirements|0
6044155|NCT00394771|9643192|FG002|Overall Study|Did not meet protocol requirements|2
6044156|NCT00394771|9643193|FG003|Overall Study|Did not meet protocol requirements|0
6044157|NCT00394771|9643190|FG000|Overall Study|Protocol Violation|2
6044158|NCT00394771|9643191|FG001|Overall Study|Protocol Violation|4
6044159|NCT00394771|9643192|FG002|Overall Study|Protocol Violation|9
6044160|NCT00394771|9643193|FG003|Overall Study|Protocol Violation|7
6044161|NCT00394771|9643190|FG000|Overall Study|Withdrawal by Subject|10
6044162|NCT00394771|9643191|FG001|Overall Study|Withdrawal by Subject|6
6044163|NCT00394771|9643192|FG002|Overall Study|Withdrawal by Subject|8
5984226|NCT03675308|9574156|FG000|Overall Study|Adverse Event|3
5984227|NCT03675308|9574157|FG001|Overall Study|Adverse Event|2
5984228|NCT03675308|9574156|FG000|Overall Study|Withdrawal by Subject|6
5984229|NCT03675308|9574157|FG001|Overall Study|Withdrawal by Subject|4
5984230|NCT03675308|9574156|FG000|Overall Study|Lost to Follow-up|3
5984231|NCT03675308|9574157|FG001|Overall Study|Lost to Follow-up|0
5984232|NCT03675308|9574156|FG000|Overall Study|Lack of Efficacy|1
5984233|NCT03675308|9574157|FG001|Overall Study|Lack of Efficacy|1
5984234|NCT03675308|9574156|FG000|Overall Study|Coronavirus Disease-2019 (COVID-19) Logistical Restrictions|1
5984235|NCT03675308|9574157|FG001|Overall Study|Coronavirus Disease-2019 (COVID-19) Logistical Restrictions|2
5984236|NCT03675308|9574156|FG000|Overall Study|Other|0
5984237|NCT03675308|9574157|FG001|Overall Study|Other|1
5984238|NCT03573817|9574165|FG000|Overall Study|Adverse Event|0
5984239|NCT03573817|9574166|FG001|Overall Study|Adverse Event|2
5984240|NCT03573817|9574165|FG000|Overall Study|Protocol Violation|0
5984241|NCT03573817|9574166|FG001|Overall Study|Protocol Violation|1
5984242|NCT03573817|9574165|FG000|Overall Study|Withdrawal by Subject|1
5984243|NCT03573817|9574166|FG001|Overall Study|Withdrawal by Subject|1
5984244|NCT03318861|9574182|FG000|Overall Study|Death|1
6146026|NCT01074944|9780556|FG002|Long Term Treatment|Lost to Follow-up|0
6146027|NCT01074944|9780557|FG003|Long Term Treatment|Lost to Follow-up|2
6146028|NCT01074944|9780558|FG004|Long Term Treatment|Lost to Follow-up|0
6146029|NCT01074944|9780554|FG000|Long Term Treatment|Transitioned to Commercial Eliglustat|0
6146030|NCT01074944|9780555|FG001|Long Term Treatment|Transitioned to Commercial Eliglustat|0
6146031|NCT01074944|9780556|FG002|Long Term Treatment|Transitioned to Commercial Eliglustat|0
5984245|NCT03318861|9574183|FG001|Overall Study|Death|2
5984246|NCT03318861|9574184|FG002|Overall Study|Death|2
5984247|NCT03318861|9574185|FG003|Overall Study|Death|1
5984248|NCT03318861|9574186|FG004|Overall Study|Death|1
5984249|NCT03318861|9574182|FG000|Overall Study|Still on Study|2
5984250|NCT03318861|9574183|FG001|Overall Study|Still on Study|1
5984251|NCT03318861|9574184|FG002|Overall Study|Still on Study|1
5984252|NCT03318861|9574185|FG003|Overall Study|Still on Study|2
5984253|NCT03318861|9574186|FG004|Overall Study|Still on Study|1
5984254|NCT03318861|9574182|FG000|Overall Study|Enrolled But Did Not Initiate KITE-585|0
5984255|NCT03318861|9574183|FG001|Overall Study|Enrolled But Did Not Initiate KITE-585|1
5984256|NCT03318861|9574184|FG002|Overall Study|Enrolled But Did Not Initiate KITE-585|0
5984257|NCT03318861|9574185|FG003|Overall Study|Enrolled But Did Not Initiate KITE-585|1
5984258|NCT03318861|9574186|FG004|Overall Study|Enrolled But Did Not Initiate KITE-585|1
5984259|NCT03170349|9574198|FG000|At 30 Days Follow-up|Death|1
5984260|NCT03170349|9574198|FG000|At 6 Months Follow-up|Death|3
5984261|NCT03170349|9574198|FG000|At 6 Months Follow-up|Withdrawal by Subject|1
5984262|NCT03170349|9574198|FG000|At 6 Months Follow-up|Exited for Other Reasons|5
5984263|NCT02919683|9574254|FG000|Post-Surgery Follow-Up|Death|2
5984264|NCT02919683|9574255|FG001|Post-Surgery Follow-Up|Death|2
5984265|NCT02919683|9574254|FG000|Post-Surgery Follow-Up|Patient is still completing follow-ups|1
5984266|NCT02919683|9574255|FG001|Post-Surgery Follow-Up|Patient is still completing follow-ups|0
5984267|NCT02901548|9574262|FG000|Overall Study|Withdrew after month 3 biopsy showed persistent cancer|4
5984268|NCT02790138|9574268|FG000|Overall Study|Adverse Event|5
5984269|NCT02790138|9574269|FG001|Overall Study|Adverse Event|2
5984270|NCT02790138|9574268|FG000|Overall Study|Significant Protocol Deviation|0
5984271|NCT02790138|9574269|FG001|Overall Study|Significant Protocol Deviation|1
5984272|NCT02790138|9574268|FG000|Overall Study|Lost to Follow-up|1
5984273|NCT02790138|9574269|FG001|Overall Study|Lost to Follow-up|0
5984274|NCT02790138|9574268|FG000|Overall Study|Voluntary Withdrawal|8
5984275|NCT02790138|9574269|FG001|Overall Study|Voluntary Withdrawal|9
5984276|NCT02790138|9574268|FG000|Overall Study|Lack of Efficacy|6
5984277|NCT02790138|9574269|FG001|Overall Study|Lack of Efficacy|7
5984278|NCT02790138|9574268|FG000|Overall Study|Reason not Specified|1
5984279|NCT02790138|9574269|FG001|Overall Study|Reason not Specified|0
5984280|NCT02514239|9574303|FG000|Overall Study|Refused to continue trial medication|0
5984281|NCT02514239|9574304|FG001|Overall Study|Refused to continue trial medication|0
5984282|NCT02514239|9574305|FG002|Overall Study|Refused to continue trial medication|0
5984283|NCT02514239|9574306|FG003|Overall Study|Refused to continue trial medication|0
5984284|NCT02514239|9574307|FG004|Overall Study|Refused to continue trial medication|0
5984285|NCT02514239|9574308|FG005|Overall Study|Refused to continue trial medication|0
5984286|NCT02514239|9574309|FG006|Overall Study|Refused to continue trial medication|0
5984287|NCT02514239|9574310|FG007|Overall Study|Refused to continue trial medication|0
5984288|NCT02514239|9574311|FG008|Overall Study|Refused to continue trial medication|0
5984289|NCT02514239|9574312|FG009|Overall Study|Refused to continue trial medication|1
5984290|NCT02514239|9574303|FG000|Overall Study|Dose-limiting toxicity (DLT)|0
5984291|NCT02514239|9574304|FG001|Overall Study|Dose-limiting toxicity (DLT)|0
5984292|NCT02514239|9574305|FG002|Overall Study|Dose-limiting toxicity (DLT)|0
5984293|NCT02514239|9574306|FG003|Overall Study|Dose-limiting toxicity (DLT)|0
5984294|NCT02514239|9574307|FG004|Overall Study|Dose-limiting toxicity (DLT)|0
5984295|NCT02514239|9574308|FG005|Overall Study|Dose-limiting toxicity (DLT)|0
5984296|NCT02514239|9574309|FG006|Overall Study|Dose-limiting toxicity (DLT)|0
5984297|NCT02514239|9574310|FG007|Overall Study|Dose-limiting toxicity (DLT)|0
5984298|NCT02514239|9574311|FG008|Overall Study|Dose-limiting toxicity (DLT)|1
5984299|NCT02514239|9574312|FG009|Overall Study|Dose-limiting toxicity (DLT)|2
5984300|NCT02514239|9574303|FG000|Overall Study|Not treated|0
5984301|NCT02514239|9574304|FG001|Overall Study|Not treated|1
5984302|NCT02514239|9574305|FG002|Overall Study|Not treated|0
5984303|NCT02514239|9574306|FG003|Overall Study|Not treated|0
5984304|NCT02514239|9574307|FG004|Overall Study|Not treated|0
5984305|NCT02514239|9574308|FG005|Overall Study|Not treated|0
5984306|NCT02514239|9574309|FG006|Overall Study|Not treated|0
5984307|NCT02514239|9574310|FG007|Overall Study|Not treated|0
5984308|NCT02514239|9574311|FG008|Overall Study|Not treated|0
5984309|NCT02514239|9574312|FG009|Overall Study|Not treated|0
5984310|NCT02514239|9574303|FG000|Overall Study|Other Adverse Events|2
5984311|NCT02514239|9574304|FG001|Overall Study|Other Adverse Events|0
5984312|NCT02514239|9574305|FG002|Overall Study|Other Adverse Events|0
5984313|NCT02514239|9574306|FG003|Overall Study|Other Adverse Events|1
5984314|NCT02514239|9574307|FG004|Overall Study|Other Adverse Events|0
5984315|NCT02514239|9574308|FG005|Overall Study|Other Adverse Events|1
5984316|NCT02514239|9574309|FG006|Overall Study|Other Adverse Events|0
5984317|NCT02514239|9574310|FG007|Overall Study|Other Adverse Events|1
5984318|NCT02514239|9574311|FG008|Overall Study|Other Adverse Events|2
5984319|NCT02514239|9574312|FG009|Overall Study|Other Adverse Events|0
5984320|NCT02514239|9574303|FG000|Overall Study|Progressive disease|3
5984321|NCT02514239|9574304|FG001|Overall Study|Progressive disease|3
5984322|NCT02514239|9574305|FG002|Overall Study|Progressive disease|2
5984323|NCT02514239|9574306|FG003|Overall Study|Progressive disease|2
5984324|NCT02514239|9574307|FG004|Overall Study|Progressive disease|3
5984325|NCT02514239|9574308|FG005|Overall Study|Progressive disease|3
5984326|NCT02514239|9574309|FG006|Overall Study|Progressive disease|4
5984327|NCT02514239|9574310|FG007|Overall Study|Progressive disease|2
5984328|NCT02514239|9574311|FG008|Overall Study|Progressive disease|5
5984329|NCT02514239|9574312|FG009|Overall Study|Progressive disease|0
5984330|NCT02245672|9574381|FG000|Overall Study|Adverse Event|4
5984331|NCT02245672|9574382|FG001|Overall Study|Adverse Event|4
5984332|NCT02245672|9574383|FG002|Overall Study|Adverse Event|4
5984333|NCT02245672|9574381|FG000|Overall Study|Lost to Follow-up|3
5984334|NCT02245672|9574382|FG001|Overall Study|Lost to Follow-up|5
5984335|NCT02245672|9574383|FG002|Overall Study|Lost to Follow-up|1
5984336|NCT02245672|9574381|FG000|Overall Study|Withdrawal by Subject|6
5984337|NCT02245672|9574382|FG001|Overall Study|Withdrawal by Subject|3
5984338|NCT02245672|9574383|FG002|Overall Study|Withdrawal by Subject|0
5984339|NCT02245672|9574381|FG000|Overall Study|Randomized in error (not treated)|0
5984340|NCT02245672|9574382|FG001|Overall Study|Randomized in error (not treated)|1
5984341|NCT02245672|9574383|FG002|Overall Study|Randomized in error (not treated)|0
5984342|NCT02109172|9574391|FG000|Overall Study|Withdrawal by Subject|1
5984343|NCT02109172|9574392|FG001|Overall Study|Withdrawal by Subject|0
5984344|NCT02109172|9574393|FG002|Overall Study|Withdrawal by Subject|0
5984345|NCT02109172|9574394|FG003|Overall Study|Withdrawal by Subject|1
5984346|NCT02109172|9574395|FG004|Overall Study|Withdrawal by Subject|0
5984347|NCT02109172|9574396|FG005|Overall Study|Withdrawal by Subject|0
5984348|NCT02109172|9574391|FG000|Overall Study|Adverse Event|0
5984349|NCT02109172|9574392|FG001|Overall Study|Adverse Event|0
5984350|NCT02109172|9574393|FG002|Overall Study|Adverse Event|1
5984351|NCT02109172|9574394|FG003|Overall Study|Adverse Event|0
5984352|NCT02109172|9574395|FG004|Overall Study|Adverse Event|0
5984353|NCT02109172|9574396|FG005|Overall Study|Adverse Event|1
5984354|NCT02109172|9574391|FG000|Overall Study|Death|0
5984355|NCT02109172|9574392|FG001|Overall Study|Death|0
5984356|NCT02109172|9574393|FG002|Overall Study|Death|0
5984357|NCT02109172|9574394|FG003|Overall Study|Death|0
5984358|NCT02109172|9574395|FG004|Overall Study|Death|1
5984359|NCT02109172|9574396|FG005|Overall Study|Death|0
6044164|NCT00394771|9643193|FG003|Overall Study|Withdrawal by Subject|12
6044165|NCT00394771|9643190|FG000|Overall Study|Adverse Event|10
6044166|NCT00394771|9643191|FG001|Overall Study|Adverse Event|5
6044167|NCT00394771|9643192|FG002|Overall Study|Adverse Event|12
6044168|NCT00394771|9643193|FG003|Overall Study|Adverse Event|8
6044169|NCT00394771|9643190|FG000|Overall Study|Participant pregnant|0
6044170|NCT00394771|9643191|FG001|Overall Study|Participant pregnant|1
6044171|NCT00394771|9643192|FG002|Overall Study|Participant pregnant|2
6044172|NCT00394771|9643193|FG003|Overall Study|Participant pregnant|2
6044173|NCT00394771|9643190|FG000|Overall Study|Lost to Follow-up|15
6044174|NCT00394771|9643191|FG001|Overall Study|Lost to Follow-up|15
6044175|NCT00394771|9643192|FG002|Overall Study|Lost to Follow-up|13
6044176|NCT00394771|9643193|FG003|Overall Study|Lost to Follow-up|10
6044177|NCT00394771|9643190|FG000|Overall Study|Other|3
6044178|NCT00394771|9643191|FG001|Overall Study|Other|3
6044179|NCT00394771|9643192|FG002|Overall Study|Other|1
6044180|NCT00394771|9643193|FG003|Overall Study|Other|0
6044181|NCT00394836|9643205|FG000|Teatment or Follow-up Phase|Adverse Event|0
6044182|NCT00394836|9643206|FG001|Teatment or Follow-up Phase|Adverse Event|2
6044183|NCT00394836|9643205|FG000|Teatment or Follow-up Phase|Protocol Violation|0
6044184|NCT00394836|9643206|FG001|Teatment or Follow-up Phase|Protocol Violation|2
6044185|NCT00394836|9643205|FG000|Teatment or Follow-up Phase|Disease Progression|27
6044186|NCT00394836|9643206|FG001|Teatment or Follow-up Phase|Disease Progression|60
6044187|NCT00394836|9643205|FG000|Teatment or Follow-up Phase|Patient Refusal|1
5984360|NCT00799396|9574454|FG000|Clopidogrel Treatment|Adverse Event|6
5984361|NCT00799396|9574454|FG000|Clopidogrel Treatment|Physician Decision|5
5984362|NCT00799396|9574454|FG000|Clopidogrel Treatment|Withdrawal by Subject|2
5984363|NCT00799396|9574454|FG000|Clopidogrel Plus Aspirin|Adverse Event|2
5984364|NCT00799396|9574454|FG000|Clopidogrel Plus Aspirin|Physician Decision|4
5984365|NCT00069238|9574458|FG000|Cohort 1 - Dose Level 1 (Weeks 1 - 18)|Toxicity|9
5984366|NCT00069238|9574459|FG001|Cohort 1 - Dose Level 1 (Weeks 1 - 18)|Toxicity|0
5984367|NCT00069238|9574460|FG002|Cohort 1 - Dose Level 1 (Weeks 1 - 18)|Toxicity|0
5984368|NCT00069238|9574458|FG000|Cohort 2 - Dose Level 2 (Weeks 1-18)|Toxicity|0
5984369|NCT00069238|9574459|FG001|Cohort 2 - Dose Level 2 (Weeks 1-18)|Toxicity|2
5984370|NCT00069238|9574460|FG002|Cohort 2 - Dose Level 2 (Weeks 1-18)|Toxicity|0
5984371|NCT00069238|9574458|FG000|Cohort 3 - Dose Level 3 (Weeks 1-18)|Toxicity|0
5984372|NCT00069238|9574459|FG001|Cohort 3 - Dose Level 3 (Weeks 1-18)|Toxicity|0
5984373|NCT00069238|9574460|FG002|Cohort 3 - Dose Level 3 (Weeks 1-18)|Toxicity|2
5984374|NCT03138499|9574467|FG000|Overall Study|Lost to Follow-up|1
5984375|NCT03138499|9574468|FG001|Overall Study|Lost to Follow-up|0
5984376|NCT03138499|9574467|FG000|Overall Study|Participants withdrew consent|1
5984377|NCT03138499|9574468|FG001|Overall Study|Participants withdrew consent|0
5984378|NCT03138499|9574467|FG000|Overall Study|Participant discontinued study before treatment|0
5984379|NCT03138499|9574468|FG001|Overall Study|Participant discontinued study before treatment|1
5984380|NCT03138499|9574467|FG000|Overall Study|Disease Progression|2
5984381|NCT03138499|9574468|FG001|Overall Study|Disease Progression|6
5984382|NCT03138499|9574467|FG000|Overall Study|Study drug toxicity|2
5984383|NCT03138499|9574468|FG001|Overall Study|Study drug toxicity|2
5984384|NCT03138499|9574467|FG000|Overall Study|Participant request to discontinue study treatment|1
5984385|NCT03138499|9574468|FG001|Overall Study|Participant request to discontinue study treatment|1
5984386|NCT03138499|9574467|FG000|Overall Study|Other reasons|2
5984387|NCT03138499|9574468|FG001|Overall Study|Other reasons|0
5984388|NCT04189588|9574521|FG000|Overall Study|Death|0
5984389|NCT04189588|9574522|FG001|Overall Study|Death|1
5984390|NCT04189588|9574521|FG000|Overall Study|Lost to Follow-up|0
5984391|NCT04189588|9574522|FG001|Overall Study|Lost to Follow-up|1
5984470|NCT03994731|9574605|FG001|Pegloticase + IMM Period|Lost to Follow-up|6
5984471|NCT03994731|9574604|FG000|Pegloticase + IMM Period|Withdrawal by Subject|15
5984472|NCT03994731|9574605|FG001|Pegloticase + IMM Period|Withdrawal by Subject|9
6044188|NCT00394836|9643206|FG001|Teatment or Follow-up Phase|Patient Refusal|2
6044189|NCT00394836|9643205|FG000|Teatment or Follow-up Phase|Death|0
6044190|NCT00394836|9643206|FG001|Teatment or Follow-up Phase|Death|1
6044191|NCT00394836|9643205|FG000|Teatment or Follow-up Phase|Patient refuses to continue with CT scan|0
6044192|NCT00394836|9643206|FG001|Teatment or Follow-up Phase|Patient refuses to continue with CT scan|1
6044193|NCT00394836|9643205|FG000|Teatment or Follow-up Phase|Started alternative treatment|0
6044194|NCT00394836|9643206|FG001|Teatment or Follow-up Phase|Started alternative treatment|6
6044195|NCT00394836|9643205|FG000|Teatment or Follow-up Phase|Suspicion of cholangiocarcinoma|0
6044196|NCT00394836|9643206|FG001|Teatment or Follow-up Phase|Suspicion of cholangiocarcinoma|1
6044197|NCT00394836|9643205|FG000|Teatment or Follow-up Phase|Physician Decision|0
6044198|NCT00394836|9643206|FG001|Teatment or Follow-up Phase|Physician Decision|1
6044199|NCT00394836|9643205|FG000|Teatment or Follow-up Phase|Patient progressed, return to Pakistan|0
6044200|NCT00394836|9643206|FG001|Teatment or Follow-up Phase|Patient progressed, return to Pakistan|1
6044201|NCT00394836|9643205|FG000|Teatment or Follow-up Phase|Non compliance|0
6044202|NCT00394836|9643206|FG001|Teatment or Follow-up Phase|Non compliance|1
6044203|NCT00394836|9643205|FG000|Extended Follow-up Phase (2-5 Years)|Lost to Follow-up|0
6044204|NCT00394836|9643206|FG001|Extended Follow-up Phase (2-5 Years)|Lost to Follow-up|1
6044205|NCT00394836|9643205|FG000|Extended Follow-up Phase (2-5 Years)|Death|0
6044206|NCT00394836|9643206|FG001|Extended Follow-up Phase (2-5 Years)|Death|1
6044207|NCT00394836|9643205|FG000|Extended Follow-up Phase (2-5 Years)|Alternative treatment|13
6044208|NCT00394836|9643206|FG001|Extended Follow-up Phase (2-5 Years)|Alternative treatment|41
6044209|NCT00394836|9643205|FG000|Extended Follow-up Phase (2-5 Years)|Medical Reasons|7
6044210|NCT00394836|9643206|FG001|Extended Follow-up Phase (2-5 Years)|Medical Reasons|10
6044211|NCT00394901|9643229|FG000|Baseline Phase|Protocol Violation|0
6044212|NCT00394901|9643230|FG001|Baseline Phase|Protocol Violation|0
6044213|NCT00394901|9643231|FG002|Baseline Phase|Protocol Violation|1
6044214|NCT00394901|9643232|FG003|Baseline Phase|Protocol Violation|0
6044215|NCT00394901|9643229|FG000|Double-blind Phase|Adverse Event|5
6044216|NCT00394901|9643230|FG001|Double-blind Phase|Adverse Event|7
6044217|NCT00394901|9643231|FG002|Double-blind Phase|Adverse Event|16
6044218|NCT00394901|9643232|FG003|Double-blind Phase|Adverse Event|20
6044219|NCT00394901|9643229|FG000|Double-blind Phase|Lack of Efficacy|6
6044220|NCT00394901|9643230|FG001|Double-blind Phase|Lack of Efficacy|4
6044221|NCT00394901|9643231|FG002|Double-blind Phase|Lack of Efficacy|1
6044222|NCT00394901|9643232|FG003|Double-blind Phase|Lack of Efficacy|3
6044223|NCT00394901|9643229|FG000|Double-blind Phase|Withdrawal by Subject|2
6044224|NCT00394901|9643230|FG001|Double-blind Phase|Withdrawal by Subject|0
6044225|NCT00394901|9643231|FG002|Double-blind Phase|Withdrawal by Subject|0
6044226|NCT00394901|9643232|FG003|Double-blind Phase|Withdrawal by Subject|0
6044227|NCT00394901|9643229|FG000|Double-blind Phase|Lost to Follow-up|0
6044228|NCT00394901|9643230|FG001|Double-blind Phase|Lost to Follow-up|0
5984392|NCT04115748|9574537|FG000|Main Study (Up to 16 Weeks)|Study terminated by sponsor|15
5984393|NCT04115748|9574538|FG001|Main Study (Up to 16 Weeks)|Study terminated by sponsor|16
5984394|NCT04115748|9574539|FG002|Main Study (Up to 16 Weeks)|Study terminated by sponsor|7
5984395|NCT04115748|9574540|FG003|Main Study (Up to 16 Weeks)|Study terminated by sponsor|15
5984396|NCT04115748|9574541|FG004|Main Study (Up to 16 Weeks)|Study terminated by sponsor|0
5984397|NCT04115748|9574542|FG005|Main Study (Up to 16 Weeks)|Study terminated by sponsor|0
5984398|NCT04115748|9574543|FG006|Main Study (Up to 16 Weeks)|Study terminated by sponsor|0
5984399|NCT04115748|9574544|FG007|Main Study (Up to 16 Weeks)|Study terminated by sponsor|0
5984400|NCT04115748|9574545|FG008|Main Study (Up to 16 Weeks)|Study terminated by sponsor|0
5984401|NCT04115748|9574546|FG009|Main Study (Up to 16 Weeks)|Study terminated by sponsor|0
5984402|NCT04115748|9574537|FG000|Main Study (Up to 16 Weeks)|Withdrew consent|0
5984403|NCT04115748|9574538|FG001|Main Study (Up to 16 Weeks)|Withdrew consent|0
5984404|NCT04115748|9574539|FG002|Main Study (Up to 16 Weeks)|Withdrew consent|0
5984405|NCT04115748|9574540|FG003|Main Study (Up to 16 Weeks)|Withdrew consent|1
5984406|NCT04115748|9574541|FG004|Main Study (Up to 16 Weeks)|Withdrew consent|0
5984407|NCT04115748|9574542|FG005|Main Study (Up to 16 Weeks)|Withdrew consent|0
5984408|NCT04115748|9574543|FG006|Main Study (Up to 16 Weeks)|Withdrew consent|0
5984409|NCT04115748|9574544|FG007|Main Study (Up to 16 Weeks)|Withdrew consent|0
5984410|NCT04115748|9574545|FG008|Main Study (Up to 16 Weeks)|Withdrew consent|0
5984411|NCT04115748|9574546|FG009|Main Study (Up to 16 Weeks)|Withdrew consent|0
5984412|NCT04115748|9574537|FG000|LTE (After 16 Weeks to Week 50)|Study terminated by sponsor|0
5984413|NCT04115748|9574538|FG001|LTE (After 16 Weeks to Week 50)|Study terminated by sponsor|0
5984414|NCT04115748|9574539|FG002|LTE (After 16 Weeks to Week 50)|Study terminated by sponsor|0
5984415|NCT04115748|9574540|FG003|LTE (After 16 Weeks to Week 50)|Study terminated by sponsor|0
5984416|NCT04115748|9574541|FG004|LTE (After 16 Weeks to Week 50)|Study terminated by sponsor|4
5984417|NCT04115748|9574542|FG005|LTE (After 16 Weeks to Week 50)|Study terminated by sponsor|3
5984418|NCT04115748|9574543|FG006|LTE (After 16 Weeks to Week 50)|Study terminated by sponsor|1
5984419|NCT04115748|9574544|FG007|LTE (After 16 Weeks to Week 50)|Study terminated by sponsor|1
5984420|NCT04115748|9574545|FG008|LTE (After 16 Weeks to Week 50)|Study terminated by sponsor|1
5984421|NCT04115748|9574546|FG009|LTE (After 16 Weeks to Week 50)|Study terminated by sponsor|2
5984422|NCT04115748|9574537|FG000|LTE (After 16 Weeks to Week 50)|Adverse Event|0
5984423|NCT04115748|9574538|FG001|LTE (After 16 Weeks to Week 50)|Adverse Event|0
5984424|NCT04115748|9574539|FG002|LTE (After 16 Weeks to Week 50)|Adverse Event|0
5984425|NCT04115748|9574540|FG003|LTE (After 16 Weeks to Week 50)|Adverse Event|0
5984426|NCT04115748|9574541|FG004|LTE (After 16 Weeks to Week 50)|Adverse Event|0
5984427|NCT04115748|9574542|FG005|LTE (After 16 Weeks to Week 50)|Adverse Event|0
5984428|NCT04115748|9574543|FG006|LTE (After 16 Weeks to Week 50)|Adverse Event|0
5984429|NCT04115748|9574544|FG007|LTE (After 16 Weeks to Week 50)|Adverse Event|0
5984430|NCT04115748|9574545|FG008|LTE (After 16 Weeks to Week 50)|Adverse Event|1
5984431|NCT04115748|9574546|FG009|LTE (After 16 Weeks to Week 50)|Adverse Event|0
5984432|NCT04044664|9574571|FG000|Stage 1|Adverse Event|3
5984433|NCT04044664|9574572|FG001|Stage 1|Adverse Event|3
5984434|NCT04044664|9574573|FG002|Stage 1|Adverse Event|1
5984435|NCT04044664|9574571|FG000|Stage 1|Lost to Follow-up|3
5984436|NCT04044664|9574572|FG001|Stage 1|Lost to Follow-up|2
5984437|NCT04044664|9574573|FG002|Stage 1|Lost to Follow-up|2
5984438|NCT04044664|9574571|FG000|Stage 1|Withdrawal by Subject|9
5984439|NCT04044664|9574572|FG001|Stage 1|Withdrawal by Subject|1
5984440|NCT04044664|9574573|FG002|Stage 1|Withdrawal by Subject|0
5984441|NCT04044664|9574571|FG000|Stage 1|noncompliance, personal reason|2
5984442|NCT04044664|9574572|FG001|Stage 1|noncompliance, personal reason|0
5984443|NCT04044664|9574573|FG002|Stage 1|noncompliance, personal reason|0
5984444|NCT04044664|9574571|FG000|Stage 1|randomization error|0
5984445|NCT04044664|9574572|FG001|Stage 1|randomization error|1
5984446|NCT04044664|9574573|FG002|Stage 1|randomization error|0
5984447|NCT04044664|9574571|FG000|Stage 2|Adverse Event|2
5984448|NCT04044664|9574572|FG001|Stage 2|Adverse Event|0
5984449|NCT04044664|9574573|FG002|Stage 2|Adverse Event|0
5984450|NCT04044664|9574571|FG000|Stage 2|Lost to Follow-up|3
5984451|NCT04044664|9574572|FG001|Stage 2|Lost to Follow-up|2
5984452|NCT04044664|9574573|FG002|Stage 2|Lost to Follow-up|1
5984453|NCT04044664|9574571|FG000|Stage 2|Withdrawal by Subject|3
5984454|NCT04044664|9574572|FG001|Stage 2|Withdrawal by Subject|0
5984455|NCT04044664|9574573|FG002|Stage 2|Withdrawal by Subject|0
5984456|NCT04044664|9574571|FG000|Stage 2|protocol deviation|1
5984457|NCT04044664|9574572|FG001|Stage 2|protocol deviation|0
5984458|NCT04044664|9574573|FG002|Stage 2|protocol deviation|0
5984459|NCT04025632|9574583|FG000|Overall Study|Adverse Event|1
5984460|NCT04025632|9574584|FG001|Overall Study|Adverse Event|1
5984461|NCT04025632|9574583|FG000|Overall Study|Withdrawal by Subject|1
5984462|NCT04025632|9574584|FG001|Overall Study|Withdrawal by Subject|1
5984463|NCT04025632|9574583|FG000|Overall Study|Study Terminated by Sponsor|10
5984464|NCT04025632|9574584|FG001|Overall Study|Study Terminated by Sponsor|9
5984465|NCT04025632|9574583|FG000|Overall Study|Physician Decision|3
5984466|NCT04025632|9574584|FG001|Overall Study|Physician Decision|1
5984467|NCT03994731|9574604|FG000|Pegloticase + IMM Period|Death|2
5984468|NCT03994731|9574605|FG001|Pegloticase + IMM Period|Death|0
5984469|NCT03994731|9574604|FG000|Pegloticase + IMM Period|Lost to Follow-up|3
5984488|NCT03679767|9574703|FG000|Overall Study|Death|16
5984473|NCT03924622|9574633|FG000|Overall Study|Study closed due to pandemic with approval of funding agency/IRB|2
5984474|NCT03924622|9574634|FG001|Overall Study|Study closed due to pandemic with approval of funding agency/IRB|3
5984475|NCT03924622|9574635|FG002|Overall Study|Study closed due to pandemic with approval of funding agency/IRB|3
5984476|NCT03924622|9574636|FG003|Overall Study|Study closed due to pandemic with approval of funding agency/IRB|4
5984477|NCT03924622|9574637|FG004|Overall Study|Study closed due to pandemic with approval of funding agency/IRB|3
5984478|NCT03924622|9574638|FG005|Overall Study|Study closed due to pandemic with approval of funding agency/IRB|3
5984479|NCT03807843|9574679|FG000|Overall Study|Lost to Follow-up|1
5984480|NCT03807843|9574680|FG001|Overall Study|Lost to Follow-up|0
5984481|NCT03802513|9574686|FG000|Overall Study|Lost to Follow-up|1
5984482|NCT03681184|9574692|FG000|6-Month Double-Blind Period|Parent/Caregiver Withdrew Consent|0
5984483|NCT03681184|9574693|FG001|6-Month Double-Blind Period|Parent/Caregiver Withdrew Consent|1
5984484|NCT03681184|9574692|FG000|3-Month Blinded Extension Period|Remained in this Period at Time of Data Cut|12
5984485|NCT03681184|9574693|FG001|3-Month Blinded Extension Period|Remained in this Period at Time of Data Cut|23
5984486|NCT03681184|9574692|FG000|Open-Label Extension Period|Remained in this Period at Time of Data Cut|1
5984487|NCT03681184|9574693|FG001|Open-Label Extension Period|Remained in this Period at Time of Data Cut|1
5984489|NCT03679767|9574704|FG001|Overall Study|Death|10
5984490|NCT03679767|9574705|FG002|Overall Study|Death|16
5984491|NCT03679767|9574706|FG003|Overall Study|Death|10
5984492|NCT03679767|9574703|FG000|Overall Study|Lost to Follow-up|1
5984493|NCT03679767|9574704|FG001|Overall Study|Lost to Follow-up|0
5984494|NCT03679767|9574705|FG002|Overall Study|Lost to Follow-up|1
5984495|NCT03679767|9574706|FG003|Overall Study|Lost to Follow-up|1
5984496|NCT03679767|9574703|FG000|Overall Study|Withdrawal by Subject|0
5984497|NCT03679767|9574704|FG001|Overall Study|Withdrawal by Subject|0
5984498|NCT03679767|9574705|FG002|Overall Study|Withdrawal by Subject|0
5984499|NCT03679767|9574706|FG003|Overall Study|Withdrawal by Subject|1
5984500|NCT03679767|9574703|FG000|Overall Study|Follow-up Completed|4
5984501|NCT03679767|9574704|FG001|Overall Study|Follow-up Completed|1
5984502|NCT03679767|9574705|FG002|Overall Study|Follow-up Completed|3
5984503|NCT03679767|9574706|FG003|Overall Study|Follow-up Completed|5
5984504|NCT03679767|9574703|FG000|Overall Study|Ongoing|14
5984505|NCT03679767|9574704|FG001|Overall Study|Ongoing|12
5984506|NCT03679767|9574705|FG002|Overall Study|Ongoing|9
5984507|NCT03679767|9574706|FG003|Overall Study|Ongoing|17
5984508|NCT03576716|9574720|FG000|Overall Study|Withdrawal by Subject|0
5984509|NCT03576716|9574721|FG001|Overall Study|Withdrawal by Subject|1
5984510|NCT03500692|9574727|FG000|Overall Study|Death|76
5984511|NCT03500692|9574727|FG000|Overall Study|Missed visit|30
5984512|NCT03500692|9574727|FG000|Overall Study|Termination Reasons|3
5984513|NCT03367819|9574733|FG000|Overall Study|Adverse Event|4
5984514|NCT03367819|9574734|FG001|Overall Study|Adverse Event|4
5984515|NCT03367819|9574733|FG000|Overall Study|Progressive Disease|15
5984516|NCT03367819|9574734|FG001|Overall Study|Progressive Disease|13
5984517|NCT03367819|9574733|FG000|Overall Study|Withdrawal by Subject|1
5984518|NCT03367819|9574734|FG001|Overall Study|Withdrawal by Subject|0
5984519|NCT03367819|9574733|FG000|Overall Study|Other|4
5984520|NCT03367819|9574734|FG001|Overall Study|Other|2
5984521|NCT03182868|9574750|FG000|Overall Study|Protocol Violation|3
5984522|NCT03182868|9574751|FG001|Overall Study|Protocol Violation|0
5984523|NCT03182868|9574752|FG002|Overall Study|Protocol Violation|4
5984524|NCT03182868|9574753|FG003|Overall Study|Protocol Violation|1
5984525|NCT03182868|9574754|FG004|Overall Study|Protocol Violation|8
5984526|NCT03125902|9574767|FG000|Overall Study|Death|52
5984527|NCT03125902|9574768|FG001|Overall Study|Death|123
5984528|NCT03125902|9574767|FG000|Overall Study|Lost to Follow-up|1
5984529|NCT03125902|9574768|FG001|Overall Study|Lost to Follow-up|0
5984530|NCT03125902|9574767|FG000|Overall Study|Mastectomy|0
5984531|NCT03125902|9574768|FG001|Overall Study|Mastectomy|1
5984532|NCT03125902|9574767|FG000|Overall Study|Physician Decision|1
5984533|NCT03125902|9574768|FG001|Overall Study|Physician Decision|0
5984534|NCT03125902|9574767|FG000|Overall Study|Withdrawal by Subject|13
5984535|NCT03125902|9574768|FG001|Overall Study|Withdrawal by Subject|25
5984536|NCT03125902|9574767|FG000|Overall Study|Study is ongoing|153
5984537|NCT03125902|9574768|FG001|Overall Study|Study is ongoing|282
5984538|NCT03077620|9574779|FG000|Overall Study|Unable to place lumbar catheter|1
5984539|NCT03077620|9574780|FG001|Overall Study|Unable to place lumbar catheter|0
5984540|NCT03077620|9574781|FG002|Overall Study|Unable to place lumbar catheter|1
5984541|NCT03077620|9574782|FG003|Overall Study|Unable to place lumbar catheter|0
5984542|NCT03077620|9574779|FG000|Overall Study|Withdrawal by Subject|0
5984543|NCT03077620|9574780|FG001|Overall Study|Withdrawal by Subject|1
5984544|NCT03077620|9574781|FG002|Overall Study|Withdrawal by Subject|0
5984545|NCT03077620|9574782|FG003|Overall Study|Withdrawal by Subject|0
5984546|NCT03077620|9574779|FG000|Overall Study|Physician Decision|0
5984547|NCT03077620|9574780|FG001|Overall Study|Physician Decision|0
5984548|NCT03077620|9574781|FG002|Overall Study|Physician Decision|1
5984549|NCT03077620|9574782|FG003|Overall Study|Physician Decision|0
5984550|NCT02951052|9574807|FG000|Overall Study|Adverse Event|13
5984551|NCT02951052|9574808|FG001|Overall Study|Adverse Event|5
5984552|NCT02951052|9574807|FG000|Overall Study|Withdrawal by Subject|1
5984553|NCT02951052|9574808|FG001|Overall Study|Withdrawal by Subject|5
5984554|NCT02951052|9574807|FG000|Overall Study|Physician Decision|2
5984555|NCT02951052|9574808|FG001|Overall Study|Physician Decision|0
5984556|NCT02951052|9574807|FG000|Overall Study|Lost to Follow-up|1
5984557|NCT02951052|9574808|FG001|Overall Study|Lost to Follow-up|1
5984558|NCT02951052|9574807|FG000|Overall Study|Protocol-specified withdrawal criterion|1
5984559|NCT02951052|9574808|FG001|Overall Study|Protocol-specified withdrawal criterion|0
5984560|NCT02951052|9574807|FG000|Overall Study|Protocol Violation|5
5984561|NCT02951052|9574808|FG001|Overall Study|Protocol Violation|3
5984562|NCT02951052|9574807|FG000|Overall Study|Lack of Efficacy|3
5984563|NCT02951052|9574808|FG001|Overall Study|Lack of Efficacy|4
5984564|NCT02951052|9574807|FG000|Overall Study|Ongoing|1
5984565|NCT02951052|9574808|FG001|Overall Study|Ongoing|0
6044229|NCT00394901|9643231|FG002|Double-blind Phase|Lost to Follow-up|0
6044230|NCT00394901|9643232|FG003|Double-blind Phase|Lost to Follow-up|1
6044231|NCT00394901|9643229|FG000|Double-blind Phase|Protocol Violation|0
6044232|NCT00394901|9643230|FG001|Double-blind Phase|Protocol Violation|0
6044233|NCT00394901|9643231|FG002|Double-blind Phase|Protocol Violation|0
6044234|NCT00394901|9643232|FG003|Double-blind Phase|Protocol Violation|1
6044235|NCT00394901|9643229|FG000|Double-blind Phase|Death|1
6044236|NCT00394901|9643230|FG001|Double-blind Phase|Death|0
6044237|NCT00394901|9643231|FG002|Double-blind Phase|Death|0
6044238|NCT00394901|9643232|FG003|Double-blind Phase|Death|0
6044239|NCT00394901|9643229|FG000|Double-blind Phase|Subject's Personal Reason|1
6044240|NCT00394901|9643230|FG001|Double-blind Phase|Subject's Personal Reason|0
6044241|NCT00394901|9643231|FG002|Double-blind Phase|Subject's Personal Reason|0
6044242|NCT00394901|9643232|FG003|Double-blind Phase|Subject's Personal Reason|1
6044243|NCT00394901|9643229|FG000|Double-blind Phase|Lack of Compliance|0
6044244|NCT00394901|9643230|FG001|Double-blind Phase|Lack of Compliance|3
6044245|NCT00394901|9643231|FG002|Double-blind Phase|Lack of Compliance|0
6044246|NCT00394901|9643232|FG003|Double-blind Phase|Lack of Compliance|0
6044247|NCT00394901|9643229|FG000|Double-blind Phase|Entry into another study was found|0
6044248|NCT00394901|9643230|FG001|Double-blind Phase|Entry into another study was found|0
6044249|NCT00394901|9643231|FG002|Double-blind Phase|Entry into another study was found|1
6044250|NCT00394901|9643232|FG003|Double-blind Phase|Entry into another study was found|0
6044251|NCT00394901|9643229|FG000|Double-blind Phase|Found not to meet entrance criteria|0
6044252|NCT00394901|9643230|FG001|Double-blind Phase|Found not to meet entrance criteria|0
6044253|NCT00394901|9643231|FG002|Double-blind Phase|Found not to meet entrance criteria|0
6044254|NCT00394901|9643232|FG003|Double-blind Phase|Found not to meet entrance criteria|1
6044255|NCT00394914|9643247|FG000|Treatment Period|Adverse Event|0
6044256|NCT00394914|9643248|FG001|Treatment Period|Adverse Event|3
6044257|NCT00394914|9643249|FG002|Treatment Period|Adverse Event|1
6044258|NCT00394914|9643247|FG000|Treatment Period|Lost to Follow-up|0
6044259|NCT00394914|9643248|FG001|Treatment Period|Lost to Follow-up|1
6044260|NCT00394914|9643249|FG002|Treatment Period|Lost to Follow-up|0
6044261|NCT00394914|9643247|FG000|Treatment Period|Withdrawal by Subject|0
6044262|NCT00394914|9643248|FG001|Treatment Period|Withdrawal by Subject|2
6044263|NCT00394914|9643249|FG002|Treatment Period|Withdrawal by Subject|2
6044264|NCT00394914|9643247|FG000|Treatment Period|Noncompliance with protocol|0
6044265|NCT00394914|9643248|FG001|Treatment Period|Noncompliance with protocol|3
6044266|NCT00394914|9643249|FG002|Treatment Period|Noncompliance with protocol|2
6044267|NCT00394914|9643247|FG000|Treatment Period|Did not meet protocol eligibility|0
6044268|NCT00394914|9643248|FG001|Treatment Period|Did not meet protocol eligibility|1
6044269|NCT00394914|9643249|FG002|Treatment Period|Did not meet protocol eligibility|1
6044270|NCT00394953|9643257|FG000|First Treatment Period|Adverse Event|1
6044271|NCT00394953|9643258|FG001|First Treatment Period|Adverse Event|2
6044272|NCT00394953|9643257|FG000|First Treatment Period|Death|6
6044273|NCT00394953|9643258|FG001|First Treatment Period|Death|7
6044274|NCT00394953|9643257|FG000|First Treatment Period|Lack of Efficacy|1
6044275|NCT00394953|9643258|FG001|First Treatment Period|Lack of Efficacy|1
6044276|NCT00394953|9643257|FG000|First Treatment Period|Withdrawal by Subject|6
6044277|NCT00394953|9643258|FG001|First Treatment Period|Withdrawal by Subject|3
6044278|NCT00394953|9643257|FG000|First Treatment Period|Lost to Follow-up|0
6044279|NCT00394953|9643258|FG001|First Treatment Period|Lost to Follow-up|1
6044280|NCT00394953|9643257|FG000|First Treatment Period|Renal transplant|11
6044281|NCT00394953|9643258|FG001|First Treatment Period|Renal transplant|7
6044282|NCT00394953|9643257|FG000|First Treatment Period|Not defined|4
6044283|NCT00394953|9643258|FG001|First Treatment Period|Not defined|1
6044284|NCT00394953|9643257|FG000|Second Treatment Period|Adverse Event|2
6044285|NCT00394953|9643258|FG001|Second Treatment Period|Adverse Event|5
6044286|NCT00394953|9643257|FG000|Second Treatment Period|Death|8
6044287|NCT00394953|9643258|FG001|Second Treatment Period|Death|4
6044288|NCT00394953|9643257|FG000|Second Treatment Period|Lack of Efficacy|9
6044289|NCT00394953|9643258|FG001|Second Treatment Period|Lack of Efficacy|47
6044290|NCT00394953|9643257|FG000|Second Treatment Period|Withdrawal by Subject|3
6044291|NCT00394953|9643258|FG001|Second Treatment Period|Withdrawal by Subject|3
6044292|NCT00394953|9643257|FG000|Second Treatment Period|Lost to Follow-up|0
6044293|NCT00394953|9643258|FG001|Second Treatment Period|Lost to Follow-up|1
6044294|NCT00394953|9643257|FG000|Second Treatment Period|Renal transplant|4
6044295|NCT00394953|9643258|FG001|Second Treatment Period|Renal transplant|6
6044296|NCT00394953|9643257|FG000|Second Treatment Period|Not defined|3
6044297|NCT00394953|9643258|FG001|Second Treatment Period|Not defined|8
5984566|NCT02598583|9574829|FG000|Extension Period|Withdrawal by Subject|1
5984567|NCT02598583|9574830|FG001|Extension Period|Withdrawal by Subject|0
5984568|NCT02574481|9574840|FG000|Overall Study|Withdrawal by Subject|6
5984569|NCT02574481|9574841|FG001|Overall Study|Withdrawal by Subject|4
5984570|NCT02574481|9574842|FG002|Overall Study|Withdrawal by Subject|1
5984571|NCT02574481|9574843|FG003|Overall Study|Withdrawal by Subject|0
5984572|NCT02574481|9574840|FG000|Overall Study|Adverse Event|2
5984573|NCT02574481|9574841|FG001|Overall Study|Adverse Event|0
5984574|NCT02574481|9574842|FG002|Overall Study|Adverse Event|0
5984575|NCT02574481|9574843|FG003|Overall Study|Adverse Event|0
5984576|NCT02574481|9574840|FG000|Overall Study|Visit Missed|12
5984577|NCT02574481|9574841|FG001|Overall Study|Visit Missed|4
5984578|NCT02574481|9574842|FG002|Overall Study|Visit Missed|2
5984579|NCT02574481|9574843|FG003|Overall Study|Visit Missed|0
5984580|NCT02574481|9574840|FG000|Overall Study|Other|1
5984581|NCT02574481|9574841|FG001|Overall Study|Other|0
5984582|NCT02574481|9574842|FG002|Overall Study|Other|0
5984583|NCT02574481|9574843|FG003|Overall Study|Other|0
5984584|NCT02574481|9574840|FG000|Overall Study|Death|6
5984585|NCT02574481|9574841|FG001|Overall Study|Death|6
5984586|NCT02574481|9574842|FG002|Overall Study|Death|0
5984587|NCT02574481|9574843|FG003|Overall Study|Death|0
5984588|NCT02536794|9574865|FG000|Reached 1st Response Assessment|Adverse Event|2
5984589|NCT02536794|9574865|FG000|Reached 1st Response Assessment|Progressive Disease|2
5984590|NCT02536794|9574865|FG000|Reached 1st Response Assessment|Withdrawal by Subject|1
5984591|NCT02536794|9574865|FG000|Reached 1st Response Assessment|Protocol Violation|1
5984592|NCT02536794|9574865|FG000|Continued Treatment After 1st Response|Progressive disease|7
5984593|NCT02536794|9574865|FG000|Continued Treatment After 1st Response|Adverse Event|1
5984594|NCT02285114|9574885|FG000|Overall Study|Investigator's Discretion|0
5984595|NCT02285114|9574886|FG001|Overall Study|Investigator's Discretion|2
5984596|NCT02285114|9574887|FG002|Overall Study|Investigator's Discretion|0
5984597|NCT02285114|9574885|FG000|Overall Study|Withdrew Consent|0
5984598|NCT02285114|9574886|FG001|Overall Study|Withdrew Consent|0
5984599|NCT02285114|9574887|FG002|Overall Study|Withdrew Consent|1
5984600|NCT02285114|9574885|FG000|Overall Study|Enrolled but not treated|1
5984601|NCT02285114|9574886|FG001|Overall Study|Enrolled but not treated|0
5984602|NCT02285114|9574887|FG002|Overall Study|Enrolled but not treated|0
5984603|NCT02285114|9574885|FG000|Overall Study|Still on study|21
5984604|NCT02285114|9574886|FG001|Overall Study|Still on study|5
5984605|NCT02285114|9574887|FG002|Overall Study|Still on study|2
5984606|NCT02263508|9574904|FG000|Overall Study|Withdrawal by Subject|1
5984607|NCT02263508|9574905|FG001|Overall Study|Withdrawal by Subject|23
5984608|NCT02263508|9574906|FG002|Overall Study|Withdrawal by Subject|17
5984609|NCT02263508|9574904|FG000|Overall Study|Sponsor Decision|12
5984610|NCT02263508|9574905|FG001|Overall Study|Sponsor Decision|165
5984611|NCT02263508|9574906|FG002|Overall Study|Sponsor Decision|182
5984612|NCT02263508|9574904|FG000|Overall Study|Lost to Follow-up|2
5984613|NCT02263508|9574905|FG001|Overall Study|Lost to Follow-up|7
5984614|NCT02263508|9574906|FG002|Overall Study|Lost to Follow-up|7
5984615|NCT02263508|9574904|FG000|Overall Study|Death|6
5984616|NCT02263508|9574905|FG001|Overall Study|Death|151
5984617|NCT02263508|9574906|FG002|Overall Study|Death|140
5984618|NCT02246530|9574919|FG000|Overall Study|Lost to Follow-up|4
5984619|NCT02246530|9574920|FG001|Overall Study|Lost to Follow-up|0
5984620|NCT01936857|9574953|FG000|Overall Study|Sent to prison or 06 center|11
5984621|NCT01936857|9574954|FG001|Overall Study|Sent to prison or 06 center|12
5984622|NCT01936857|9574953|FG000|Overall Study|Lost to Follow-up|10
5984623|NCT01936857|9574954|FG001|Overall Study|Lost to Follow-up|7
5984624|NCT01936857|9574953|FG000|Overall Study|Death|7
5984625|NCT01936857|9574954|FG001|Overall Study|Death|3
5984626|NCT01936857|9574953|FG000|Overall Study|Moved|2
5984627|NCT01936857|9574954|FG001|Overall Study|Moved|1
5984628|NCT01936857|9574953|FG000|Overall Study|Withdrawal by Subject|1
5984629|NCT01936857|9574954|FG001|Overall Study|Withdrawal by Subject|0
5984630|NCT01936857|9574953|FG000|Overall Study|Side effect of medication|1
5984631|NCT01936857|9574954|FG001|Overall Study|Side effect of medication|0
5984632|NCT01936857|9574953|FG000|Overall Study|Other|2
5984633|NCT01936857|9574954|FG001|Overall Study|Other|2
5984634|NCT01856192|9574971|FG000|Overall Study|Adverse Event|12
5984635|NCT01856192|9574972|FG001|Overall Study|Adverse Event|4
5984636|NCT01856192|9574971|FG000|Overall Study|Alternative therapy|0
5984637|NCT01856192|9574972|FG001|Overall Study|Alternative therapy|3
5984638|NCT01856192|9574971|FG000|Overall Study|Death|3
5984639|NCT01856192|9574972|FG001|Overall Study|Death|5
5984640|NCT01856192|9574971|FG000|Overall Study|Lack of Efficacy|0
5984641|NCT01856192|9574972|FG001|Overall Study|Lack of Efficacy|5
5984642|NCT01856192|9574971|FG000|Overall Study|Withdrawal by Subject|1
5984643|NCT01856192|9574972|FG001|Overall Study|Withdrawal by Subject|1
5984644|NCT01856192|9574971|FG000|Overall Study|Other diseases|1
5984645|NCT01856192|9574972|FG001|Overall Study|Other diseases|0
5984646|NCT01856192|9574971|FG000|Overall Study|Never started treatment|7
5984647|NCT01856192|9574972|FG001|Overall Study|Never started treatment|5
5984648|NCT01856192|9574971|FG000|Overall Study|Path ineligible|20
5984649|NCT01856192|9574972|FG001|Overall Study|Path ineligible|34
5984650|NCT01856192|9574971|FG000|Overall Study|Non-path ineligible|2
5984651|NCT01856192|9574972|FG001|Overall Study|Non-path ineligible|2
5984652|NCT01856192|9574971|FG000|Overall Study|Physician Decision|1
5984653|NCT01856192|9574972|FG001|Overall Study|Physician Decision|1
5984654|NCT01856192|9574971|FG000|Overall Study|Suspicion of progressive disease|1
5984655|NCT01856192|9574972|FG001|Overall Study|Suspicion of progressive disease|0
5984656|NCT01856192|9574971|FG000|Overall Study|Non-compliance|1
5984657|NCT01856192|9574972|FG001|Overall Study|Non-compliance|0
5984658|NCT01715285|9574980|FG000|Treatment Period|Adverse Event|60
5984659|NCT01715285|9574981|FG001|Treatment Period|Adverse Event|33
5984660|NCT01715285|9574982|FG002|Treatment Period|Adverse Event|0
5984661|NCT01715285|9574980|FG000|Treatment Period|Lost to Follow-up|3
5984662|NCT01715285|9574981|FG001|Treatment Period|Lost to Follow-up|2
5984663|NCT01715285|9574982|FG002|Treatment Period|Lost to Follow-up|0
5984664|NCT01715285|9574980|FG000|Treatment Period|Death|36
5984665|NCT01715285|9574981|FG001|Treatment Period|Death|23
5984666|NCT01715285|9574982|FG002|Treatment Period|Death|0
5984667|NCT01715285|9574980|FG000|Treatment Period|Noncompliance With Study Drug|4
5984668|NCT01715285|9574981|FG001|Treatment Period|Noncompliance With Study Drug|2
5984669|NCT01715285|9574982|FG002|Treatment Period|Noncompliance With Study Drug|0
5984670|NCT01715285|9574980|FG000|Treatment Period|Progressive Disease|254
5984671|NCT01715285|9574981|FG001|Treatment Period|Progressive Disease|388
5984672|NCT01715285|9574982|FG002|Treatment Period|Progressive Disease|0
5984673|NCT01715285|9574980|FG000|Treatment Period|Withdrawal Of Consent|52
5984674|NCT01715285|9574981|FG001|Treatment Period|Withdrawal Of Consent|47
5984675|NCT01715285|9574982|FG002|Treatment Period|Withdrawal Of Consent|0
5984676|NCT01715285|9574980|FG000|Treatment Period|Physician Decision|21
5984677|NCT01715285|9574981|FG001|Treatment Period|Physician Decision|23
5984678|NCT01715285|9574982|FG002|Treatment Period|Physician Decision|0
5984679|NCT01715285|9574980|FG000|Treatment Period|Ongoing|157
5984680|NCT01715285|9574981|FG001|Treatment Period|Ongoing|0
5984681|NCT01715285|9574982|FG002|Treatment Period|Ongoing|0
5984682|NCT01715285|9574980|FG000|Treatment Period|Other|10
5984683|NCT01715285|9574981|FG001|Treatment Period|Other|12
5984684|NCT01715285|9574982|FG002|Treatment Period|Other|0
5984685|NCT01715285|9574980|FG000|Treatment Period|Placebo Cross-over|0
5984686|NCT01715285|9574981|FG001|Treatment Period|Placebo Cross-over|72
5984687|NCT01715285|9574982|FG002|Treatment Period|Placebo Cross-over|0
5984688|NCT01715285|9574980|FG000|Open-label (OL) Extension Phase|Ongoing|157
5984689|NCT01715285|9574981|FG001|Open-label (OL) Extension Phase|Ongoing|0
5984690|NCT01715285|9574982|FG002|Open-label (OL) Extension Phase|Ongoing|72
6044298|NCT00395018|9643264|FG000|On-Treatment|Death|4
6044299|NCT00395018|9643264|FG000|On-Treatment|Other Reason|2
6044300|NCT00395018|9643264|FG000|On-Treatment|Poor/non-compliance|2
6044301|NCT00395018|9643264|FG000|On-Treatment|Subject no longer meets study criteria|2
6044302|NCT00395018|9643264|FG000|Off-Treatment Follow-up|Followup no longer required per protocol|1
6044303|NCT00395018|9643264|FG000|Off-Treatment Follow-up|Lost to Follow-up|2
6044304|NCT00395018|9643264|FG000|Off-Treatment Follow-up|Poor/non-compliance|1
6044305|NCT00395083|9643296|FG000|Overall Study|Withdrawal by Subject|6
6044306|NCT00395083|9643297|FG001|Overall Study|Withdrawal by Subject|5
6044307|NCT00395083|9643296|FG000|Overall Study|Developed another disease|4
6044308|NCT00395083|9643297|FG001|Overall Study|Developed another disease|3
6044309|NCT00395226|9643336|FG000|Overall Study|Adverse Event|4
6044310|NCT00395226|9643337|FG001|Overall Study|Adverse Event|3
6044311|NCT00395226|9643336|FG000|Overall Study|Withdrawal by Subject|0
6044312|NCT00395226|9643337|FG001|Overall Study|Withdrawal by Subject|1
6044313|NCT00395226|9643336|FG000|Overall Study|Lost to Follow-up|0
6044314|NCT00395226|9643337|FG001|Overall Study|Lost to Follow-up|1
6044315|NCT00395304|9643350|FG000|Treatment Period 1|Withdrawal by Subject|0
6044316|NCT00395304|9643351|FG001|Treatment Period 1|Withdrawal by Subject|3
6044317|NCT00395304|9643352|FG002|Treatment Period 1|Withdrawal by Subject|0
6044318|NCT00395304|9643353|FG003|Treatment Period 1|Withdrawal by Subject|2
6044319|NCT00395304|9643354|FG004|Treatment Period 1|Withdrawal by Subject|1
6044320|NCT00395304|9643355|FG005|Treatment Period 1|Withdrawal by Subject|1
6044321|NCT00395304|9643350|FG000|Treatment Period 1|Lost to Follow-up|1
6044322|NCT00395304|9643351|FG001|Treatment Period 1|Lost to Follow-up|0
6044323|NCT00395304|9643352|FG002|Treatment Period 1|Lost to Follow-up|0
6044324|NCT00395304|9643353|FG003|Treatment Period 1|Lost to Follow-up|1
6044325|NCT00395304|9643354|FG004|Treatment Period 1|Lost to Follow-up|0
6044326|NCT00395304|9643355|FG005|Treatment Period 1|Lost to Follow-up|1
6044327|NCT00395304|9643350|FG000|Treatment Period 1|Physician Decision|0
6044328|NCT00395304|9643351|FG001|Treatment Period 1|Physician Decision|1
6044329|NCT00395304|9643352|FG002|Treatment Period 1|Physician Decision|0
6044330|NCT00395304|9643353|FG003|Treatment Period 1|Physician Decision|0
6044331|NCT00395304|9643354|FG004|Treatment Period 1|Physician Decision|0
6044332|NCT00395304|9643355|FG005|Treatment Period 1|Physician Decision|0
6044333|NCT00395304|9643350|FG000|Treatment Period 2|Withdrawal by Subject|0
6044334|NCT00395304|9643351|FG001|Treatment Period 2|Withdrawal by Subject|0
6044335|NCT00395304|9643352|FG002|Treatment Period 2|Withdrawal by Subject|0
6044336|NCT00395304|9643353|FG003|Treatment Period 2|Withdrawal by Subject|1
6044337|NCT00395304|9643354|FG004|Treatment Period 2|Withdrawal by Subject|0
6044338|NCT00395304|9643355|FG005|Treatment Period 2|Withdrawal by Subject|2
6044339|NCT00395304|9643350|FG000|Treatment Period 2|Lost to Follow-up|0
6044340|NCT00395304|9643351|FG001|Treatment Period 2|Lost to Follow-up|3
6044341|NCT00395304|9643352|FG002|Treatment Period 2|Lost to Follow-up|0
5984691|NCT01295944|9575016|FG000|Overall Study|Switched to alternative treatment|1
5984692|NCT01295944|9575016|FG000|Overall Study|Ineligible|9
5984693|NCT01295944|9575016|FG000|Overall Study|Withdrawal by Subject|4
5984694|NCT01295944|9575016|FG000|Overall Study|Participant chose to be treated in Peru|1
5984695|NCT01295944|9575016|FG000|Overall Study|Participant wanting a local endoscopy surgery to remove more tumor|1
5984696|NCT01295944|9575016|FG000|Overall Study|Participant was diagnosed with stage 1 infiltrated ductal carcinoma of the right breast(10/03/2013).|1
5984697|NCT01295944|9575016|FG000|Overall Study|Participant decided to pursue other treatment before beginning protocol treatment|1
5984698|NCT01285557|9575022|FG000|Overall Study|Death|173
5984699|NCT01285557|9575023|FG001|Overall Study|Death|90
5984700|NCT01285557|9575022|FG000|Overall Study|Lost to Follow-up|6
5984701|NCT01285557|9575023|FG001|Overall Study|Lost to Follow-up|2
5984702|NCT01285557|9575022|FG000|Overall Study|Withdrew Consent|6
5984703|NCT01285557|9575023|FG001|Overall Study|Withdrew Consent|1
5984704|NCT01285557|9575022|FG000|Overall Study|Sponsor Study Termination|23
5984705|NCT01285557|9575023|FG001|Overall Study|Sponsor Study Termination|13
5984706|NCT01285557|9575022|FG000|Overall Study|Randomized but not treated|1
5984707|NCT01285557|9575023|FG001|Overall Study|Randomized but not treated|1
5984708|NCT01285557|9575022|FG000|Overall Study|Study follow-up ongoing|28
5984709|NCT01285557|9575023|FG001|Overall Study|Study follow-up ongoing|14
5984710|NCT01285557|9575022|FG000|Overall Study|Sponsor Decision|2
5984711|NCT01285557|9575023|FG001|Overall Study|Sponsor Decision|1
6064713|NCT00515086|9666478|FG001|Overall Study|Lost to Follow-up|0
6064714|NCT00515086|9666479|FG002|Overall Study|Lost to Follow-up|0
6064715|NCT00515086|9666480|FG003|Overall Study|Lost to Follow-up|0
6064716|NCT00515086|9666477|FG000|Overall Study|Study drug no longer required|0
6064717|NCT00515086|9666478|FG001|Overall Study|Study drug no longer required|1
6064718|NCT00515086|9666479|FG002|Overall Study|Study drug no longer required|0
6064719|NCT00515086|9666480|FG003|Overall Study|Study drug no longer required|0
6064720|NCT00515086|9666477|FG000|Overall Study|Death|2
6064721|NCT00515086|9666478|FG001|Overall Study|Death|0
6064722|NCT00515086|9666479|FG002|Overall Study|Death|0
6064723|NCT00515086|9666480|FG003|Overall Study|Death|0
6146032|NCT01074944|9780557|FG003|Long Term Treatment|Transitioned to Commercial Eliglustat|18
6146033|NCT01074944|9780558|FG004|Long Term Treatment|Transitioned to Commercial Eliglustat|0
5984760|NCT00964002|9575070|FG000|Overall Study|Protocol Violation|8
5984761|NCT00790218|9575083|FG000|Overall Study|Death|1
5984762|NCT00790218|9575084|FG001|Overall Study|Death|0
5984763|NCT00790218|9575085|FG002|Overall Study|Death|0
5984764|NCT00352027|9575146|FG000|Overall Study|Progressive disease|3
5984765|NCT00334815|9575174|FG000|Overall Study|Adverse Event|3
5984766|NCT00334815|9575175|FG001|Overall Study|Adverse Event|2
5984767|NCT00334815|9575174|FG000|Overall Study|Death|0
5984768|NCT00334815|9575175|FG001|Overall Study|Death|2
5984769|NCT00334815|9575174|FG000|Overall Study|Progression|1
5984770|NCT00334815|9575175|FG001|Overall Study|Progression|0
5984771|NCT00334815|9575174|FG000|Overall Study|ineligible|1
5984772|NCT00334815|9575175|FG001|Overall Study|ineligible|1
5984773|NCT00334815|9575174|FG000|Overall Study|patient refused treatment|0
5984774|NCT00334815|9575175|FG001|Overall Study|patient refused treatment|1
5984775|NCT00334815|9575174|FG000|Overall Study|Physician Decision|2
5984776|NCT00334815|9575175|FG001|Overall Study|Physician Decision|4
5984777|NCT00145600|9575187|FG000|Overall Study|Death|1
5984778|NCT00145600|9575188|FG001|Overall Study|Death|2
5984779|NCT00145600|9575189|FG002|Overall Study|Death|2
5984780|NCT00145600|9575190|FG003|Overall Study|Death|6
5984781|NCT00145600|9575187|FG000|Overall Study|Ineligible|3
5984782|NCT00145600|9575188|FG001|Overall Study|Ineligible|0
5984783|NCT00145600|9575189|FG002|Overall Study|Ineligible|1
5984784|NCT00145600|9575190|FG003|Overall Study|Ineligible|5
5984785|NCT00145600|9575187|FG000|Overall Study|Lost to Follow-up|2
5984786|NCT00145600|9575188|FG001|Overall Study|Lost to Follow-up|6
5984787|NCT00145600|9575189|FG002|Overall Study|Lost to Follow-up|2
5984788|NCT00145600|9575190|FG003|Overall Study|Lost to Follow-up|4
5984789|NCT00145600|9575187|FG000|Overall Study|Noncompliance|1
5984790|NCT00145600|9575188|FG001|Overall Study|Noncompliance|0
5984791|NCT00145600|9575189|FG002|Overall Study|Noncompliance|0
5984792|NCT00145600|9575190|FG003|Overall Study|Noncompliance|0
5984793|NCT00145600|9575187|FG000|Overall Study|Withdrawal by Subject|1
5984794|NCT00145600|9575188|FG001|Overall Study|Withdrawal by Subject|2
5984795|NCT00145600|9575189|FG002|Overall Study|Withdrawal by Subject|0
5984796|NCT00145600|9575190|FG003|Overall Study|Withdrawal by Subject|1
6044342|NCT00395304|9643353|FG003|Treatment Period 2|Lost to Follow-up|0
6044343|NCT00395304|9643354|FG004|Treatment Period 2|Lost to Follow-up|0
6044344|NCT00395304|9643355|FG005|Treatment Period 2|Lost to Follow-up|0
6044345|NCT00395304|9643350|FG000|Treatment Period 2|Physician Decision|0
6044346|NCT00395304|9643351|FG001|Treatment Period 2|Physician Decision|0
6044347|NCT00395304|9643352|FG002|Treatment Period 2|Physician Decision|1
6044348|NCT00395304|9643353|FG003|Treatment Period 2|Physician Decision|0
6044349|NCT00395304|9643354|FG004|Treatment Period 2|Physician Decision|0
6044350|NCT00395304|9643355|FG005|Treatment Period 2|Physician Decision|0
6044351|NCT00395304|9643350|FG000|Treatment Period 2|Other|0
6044352|NCT00395304|9643351|FG001|Treatment Period 2|Other|1
6044353|NCT00395304|9643352|FG002|Treatment Period 2|Other|0
6044354|NCT00395304|9643353|FG003|Treatment Period 2|Other|0
6044355|NCT00395304|9643354|FG004|Treatment Period 2|Other|0
6044356|NCT00395304|9643355|FG005|Treatment Period 2|Other|0
6044357|NCT00395304|9643350|FG000|Treatment Period 3|Withdrawal by Subject|0
6044358|NCT00395304|9643351|FG001|Treatment Period 3|Withdrawal by Subject|0
6044359|NCT00395304|9643352|FG002|Treatment Period 3|Withdrawal by Subject|0
6044360|NCT00395304|9643353|FG003|Treatment Period 3|Withdrawal by Subject|1
6044361|NCT00395304|9643354|FG004|Treatment Period 3|Withdrawal by Subject|0
6044362|NCT00395304|9643355|FG005|Treatment Period 3|Withdrawal by Subject|1
6044363|NCT00395304|9643350|FG000|Treatment Period 3|Lost to Follow-up|1
6044364|NCT00395304|9643351|FG001|Treatment Period 3|Lost to Follow-up|1
6044365|NCT00395304|9643352|FG002|Treatment Period 3|Lost to Follow-up|0
6044366|NCT00395304|9643353|FG003|Treatment Period 3|Lost to Follow-up|0
6044367|NCT00395304|9643354|FG004|Treatment Period 3|Lost to Follow-up|0
6044368|NCT00395304|9643355|FG005|Treatment Period 3|Lost to Follow-up|0
6044369|NCT00395304|9643350|FG000|Treatment Period 3|Physician Decision|0
6044370|NCT00395304|9643351|FG001|Treatment Period 3|Physician Decision|1
6044371|NCT00395304|9643352|FG002|Treatment Period 3|Physician Decision|0
6044372|NCT00395304|9643353|FG003|Treatment Period 3|Physician Decision|0
6044373|NCT00395304|9643354|FG004|Treatment Period 3|Physician Decision|0
6044374|NCT00395304|9643355|FG005|Treatment Period 3|Physician Decision|0
6044375|NCT00395304|9643350|FG000|Treatment Period 3|Other|0
6044376|NCT00395304|9643351|FG001|Treatment Period 3|Other|0
6044377|NCT00395304|9643352|FG002|Treatment Period 3|Other|0
6044378|NCT00395304|9643353|FG003|Treatment Period 3|Other|1
6044379|NCT00395304|9643354|FG004|Treatment Period 3|Other|0
6044380|NCT00395304|9643355|FG005|Treatment Period 3|Other|0
6146034|NCT01074944|9780554|FG000|Long Term Treatment|Entered in Period, But Not Treated|0
6146035|NCT01074944|9780555|FG001|Long Term Treatment|Entered in Period, But Not Treated|0
6146036|NCT01074944|9780556|FG002|Long Term Treatment|Entered in Period, But Not Treated|0
6146037|NCT01074944|9780557|FG003|Long Term Treatment|Entered in Period, But Not Treated|1
6146038|NCT01074944|9780558|FG004|Long Term Treatment|Entered in Period, But Not Treated|0
6146039|NCT01074944|9780554|FG000|Long Term Treatment|Withdrawal by Subject|0
6146040|NCT01074944|9780555|FG001|Long Term Treatment|Withdrawal by Subject|0
6146041|NCT01074944|9780556|FG002|Long Term Treatment|Withdrawal by Subject|0
6146042|NCT01074944|9780557|FG003|Long Term Treatment|Withdrawal by Subject|2
5984797|NCT03084367|9575236|FG000|Overall Study|Lost to Follow-up|32
5984798|NCT03084367|9575236|FG000|Overall Study|Withdrawal by Subject|4
5984799|NCT03084367|9575236|FG000|Overall Study|Other|1
5984800|NCT04980040|9575316|FG000|Overall Study|Violated the Inclusion Criteria|260
5984801|NCT04980040|9575316|FG000|Overall Study|Violated the Administration & Dosage|225
5984802|NCT04980040|9575316|FG000|Overall Study|Lost to Safety-Follow-up|4
5984803|NCT04980040|9575316|FG000|Overall Study|Administered the study drug prior to signing the informed consent form|3
5984804|NCT04167670|9575332|FG000|Overall Study|Pretreatment Event, Adverse Event, or Serious Adverse Event|1
5984805|NCT04167670|9575333|FG001|Overall Study|Pretreatment Event, Adverse Event, or Serious Adverse Event|7
5984806|NCT04167670|9575334|FG002|Overall Study|Pretreatment Event, Adverse Event, or Serious Adverse Event|4
5984807|NCT04167670|9575332|FG000|Overall Study|Significant protocol deviation|3
5984808|NCT04167670|9575333|FG001|Overall Study|Significant protocol deviation|1
5984809|NCT04167670|9575334|FG002|Overall Study|Significant protocol deviation|0
5984810|NCT04167670|9575332|FG000|Overall Study|Lost to Follow-up|0
5984811|NCT04167670|9575333|FG001|Overall Study|Lost to Follow-up|3
5984812|NCT04167670|9575334|FG002|Overall Study|Lost to Follow-up|3
5984813|NCT04167670|9575332|FG000|Overall Study|Voluntary Withdrawal|0
5984814|NCT04167670|9575333|FG001|Overall Study|Voluntary Withdrawal|1
5984815|NCT04167670|9575334|FG002|Overall Study|Voluntary Withdrawal|1
5984816|NCT04167670|9575332|FG000|Overall Study|Withdrawal of Consent|4
5984817|NCT04167670|9575333|FG001|Overall Study|Withdrawal of Consent|1
5984818|NCT04167670|9575334|FG002|Overall Study|Withdrawal of Consent|3
5984819|NCT04167670|9575332|FG000|Overall Study|Miscellaneous|7
5984820|NCT04167670|9575333|FG001|Overall Study|Miscellaneous|5
5984821|NCT04167670|9575334|FG002|Overall Study|Miscellaneous|3
5984822|NCT04076917|9575342|FG000|Overall Study|No AF episodes detected during Pre-Holter Observation period|49
5984823|NCT04076917|9575342|FG000|Overall Study|Study closure|13
5984824|NCT04076917|9575342|FG000|Overall Study|Physician Decision|3
5984825|NCT04076917|9575342|FG000|Overall Study|Death|1
5984826|NCT04076917|9575342|FG000|Overall Study|Lost to Follow-up|1
5984827|NCT04076917|9575342|FG000|Overall Study|Withdrawal by Subject|1
5984828|NCT04076917|9575342|FG000|Overall Study|Mean R-wave sensing is < 0.25 mV during Pre-Holter observation period|1
5984829|NCT04000009|9575346|FG000|Overall Study|Adverse Event|13
5984830|NCT04000009|9575346|FG000|Overall Study|Lack of Efficacy|7
5984831|NCT04000009|9575346|FG000|Overall Study|Lost to Follow-up|8
5984832|NCT04000009|9575346|FG000|Overall Study|Noncompliance with study drug|4
5984833|NCT04000009|9575346|FG000|Overall Study|Physician Decision|1
5984834|NCT04000009|9575346|FG000|Overall Study|Use of prohibited medication|3
5984835|NCT04000009|9575346|FG000|Overall Study|Pregnancy|1
5984836|NCT04000009|9575346|FG000|Overall Study|Withdrawal by Subject|22
5984837|NCT04000009|9575346|FG000|Overall Study|Study terminated by sponsor|98
5984838|NCT04000009|9575346|FG000|Overall Study|Not further specified|8
5984839|NCT03674112|9575374|FG000|Overall Study|Adverse Event|1
5984840|NCT03674112|9575375|FG001|Overall Study|Adverse Event|0
5984841|NCT03674112|9575374|FG000|Overall Study|Ongoing in the Study|79
5984842|NCT03674112|9575375|FG001|Overall Study|Ongoing in the Study|80
5984843|NCT03205371|9575427|FG000|Overall Study|Withdrawal by Subject|4
5984844|NCT03205371|9575428|FG001|Overall Study|Withdrawal by Subject|1
5984845|NCT03205371|9575429|FG002|Overall Study|Withdrawal by Subject|0
5984846|NCT03205371|9575430|FG003|Overall Study|Withdrawal by Subject|0
5984847|NCT03205371|9575431|FG004|Overall Study|Withdrawal by Subject|0
5984848|NCT03205371|9575432|FG005|Overall Study|Withdrawal by Subject|0
5984849|NCT03205371|9575433|FG006|Overall Study|Withdrawal by Subject|4
5984850|NCT03205371|9575434|FG007|Overall Study|Withdrawal by Subject|0
5984851|NCT03205371|9575435|FG008|Overall Study|Withdrawal by Subject|2
5984852|NCT03205371|9575436|FG009|Overall Study|Withdrawal by Subject|0
5984853|NCT03205371|9575437|FG010|Overall Study|Withdrawal by Subject|0
5984854|NCT03205371|9575438|FG011|Overall Study|Withdrawal by Subject|1
5984855|NCT03205371|9575427|FG000|Overall Study|Lost to Follow-up|0
5984856|NCT03205371|9575428|FG001|Overall Study|Lost to Follow-up|0
5984857|NCT03205371|9575429|FG002|Overall Study|Lost to Follow-up|0
5984858|NCT03205371|9575430|FG003|Overall Study|Lost to Follow-up|0
5984859|NCT03205371|9575431|FG004|Overall Study|Lost to Follow-up|0
5984860|NCT03205371|9575432|FG005|Overall Study|Lost to Follow-up|0
5984861|NCT03205371|9575433|FG006|Overall Study|Lost to Follow-up|5
5984862|NCT03205371|9575434|FG007|Overall Study|Lost to Follow-up|2
5984863|NCT03205371|9575435|FG008|Overall Study|Lost to Follow-up|3
5984864|NCT03205371|9575436|FG009|Overall Study|Lost to Follow-up|0
5984865|NCT03205371|9575437|FG010|Overall Study|Lost to Follow-up|0
5984866|NCT03205371|9575438|FG011|Overall Study|Lost to Follow-up|0
5984867|NCT03205371|9575427|FG000|Overall Study|Protocol Violation|0
5984868|NCT03205371|9575428|FG001|Overall Study|Protocol Violation|0
5984869|NCT03205371|9575429|FG002|Overall Study|Protocol Violation|0
5984870|NCT03205371|9575430|FG003|Overall Study|Protocol Violation|0
5984871|NCT03205371|9575431|FG004|Overall Study|Protocol Violation|0
5984872|NCT03205371|9575432|FG005|Overall Study|Protocol Violation|0
5984873|NCT03205371|9575433|FG006|Overall Study|Protocol Violation|1
5984874|NCT03205371|9575434|FG007|Overall Study|Protocol Violation|0
5984875|NCT03205371|9575435|FG008|Overall Study|Protocol Violation|0
5984876|NCT03205371|9575436|FG009|Overall Study|Protocol Violation|0
5984877|NCT03205371|9575437|FG010|Overall Study|Protocol Violation|0
5984878|NCT03205371|9575438|FG011|Overall Study|Protocol Violation|0
5984879|NCT03205371|9575427|FG000|Overall Study|Adverse Event|0
5984880|NCT03205371|9575428|FG001|Overall Study|Adverse Event|0
5984881|NCT03205371|9575429|FG002|Overall Study|Adverse Event|0
5984882|NCT03205371|9575430|FG003|Overall Study|Adverse Event|0
5984883|NCT03205371|9575431|FG004|Overall Study|Adverse Event|0
5984884|NCT03205371|9575432|FG005|Overall Study|Adverse Event|0
5984885|NCT03205371|9575433|FG006|Overall Study|Adverse Event|0
5984886|NCT03205371|9575434|FG007|Overall Study|Adverse Event|1
5984887|NCT03205371|9575435|FG008|Overall Study|Adverse Event|0
5984888|NCT03205371|9575436|FG009|Overall Study|Adverse Event|0
5984889|NCT03205371|9575437|FG010|Overall Study|Adverse Event|0
5984890|NCT03205371|9575438|FG011|Overall Study|Adverse Event|0
5984891|NCT03165721|9575487|FG000|Overall Study|Refused further treatment|3
5984892|NCT03165721|9575488|FG001|Overall Study|Refused further treatment|0
5984893|NCT03165721|9575489|FG002|Overall Study|Refused further treatment|0
5984894|NCT03165721|9575487|FG000|Overall Study|Physician Decision|1
5984895|NCT03165721|9575488|FG001|Overall Study|Physician Decision|0
5984896|NCT03165721|9575489|FG002|Overall Study|Physician Decision|0
5984897|NCT03130959|9575509|FG000|Treatment Period|Disease progression|18
5984898|NCT03130959|9575510|FG001|Treatment Period|Disease progression|15
5984899|NCT03130959|9575511|FG002|Treatment Period|Disease progression|12
5984900|NCT03130959|9575512|FG003|Treatment Period|Disease progression|8
5984901|NCT03130959|9575513|FG004|Treatment Period|Disease progression|12
5984902|NCT03130959|9575514|FG005|Treatment Period|Disease progression|11
5984903|NCT03130959|9575515|FG006|Treatment Period|Disease progression|6
5984904|NCT03130959|9575516|FG007|Treatment Period|Disease progression|9
5984905|NCT03130959|9575517|FG008|Treatment Period|Disease progression|15
5984906|NCT03130959|9575518|FG009|Treatment Period|Disease progression|9
5984907|NCT03130959|9575509|FG000|Treatment Period|Study drug toxicity|2
5984908|NCT03130959|9575510|FG001|Treatment Period|Study drug toxicity|3
5984909|NCT03130959|9575511|FG002|Treatment Period|Study drug toxicity|1
5984910|NCT03130959|9575512|FG003|Treatment Period|Study drug toxicity|2
5984911|NCT03130959|9575513|FG004|Treatment Period|Study drug toxicity|1
5984912|NCT03130959|9575514|FG005|Treatment Period|Study drug toxicity|2
5984913|NCT03130959|9575515|FG006|Treatment Period|Study drug toxicity|3
5984914|NCT03130959|9575516|FG007|Treatment Period|Study drug toxicity|0
5984915|NCT03130959|9575517|FG008|Treatment Period|Study drug toxicity|3
5984916|NCT03130959|9575518|FG009|Treatment Period|Study drug toxicity|4
5984917|NCT03130959|9575509|FG000|Treatment Period|Other reasons|1
5984918|NCT03130959|9575510|FG001|Treatment Period|Other reasons|0
5984919|NCT03130959|9575511|FG002|Treatment Period|Other reasons|0
5984920|NCT03130959|9575512|FG003|Treatment Period|Other reasons|0
5984921|NCT03130959|9575513|FG004|Treatment Period|Other reasons|0
5984922|NCT03130959|9575514|FG005|Treatment Period|Other reasons|0
5984923|NCT03130959|9575515|FG006|Treatment Period|Other reasons|1
5984924|NCT03130959|9575516|FG007|Treatment Period|Other reasons|0
5984925|NCT03130959|9575517|FG008|Treatment Period|Other reasons|0
5984926|NCT03130959|9575518|FG009|Treatment Period|Other reasons|0
5984927|NCT03130959|9575509|FG000|Treatment Period|Participant request to stop therapy|0
5984928|NCT03130959|9575510|FG001|Treatment Period|Participant request to stop therapy|1
5984929|NCT03130959|9575511|FG002|Treatment Period|Participant request to stop therapy|1
5984930|NCT03130959|9575512|FG003|Treatment Period|Participant request to stop therapy|1
5984931|NCT03130959|9575513|FG004|Treatment Period|Participant request to stop therapy|0
5984932|NCT03130959|9575514|FG005|Treatment Period|Participant request to stop therapy|0
5984933|NCT03130959|9575515|FG006|Treatment Period|Participant request to stop therapy|1
5984934|NCT03130959|9575516|FG007|Treatment Period|Participant request to stop therapy|1
5984935|NCT03130959|9575517|FG008|Treatment Period|Participant request to stop therapy|0
5984936|NCT03130959|9575518|FG009|Treatment Period|Participant request to stop therapy|0
5984937|NCT03130959|9575509|FG000|Treatment Period|Not reported|0
5984938|NCT03130959|9575510|FG001|Treatment Period|Not reported|2
5984939|NCT03130959|9575511|FG002|Treatment Period|Not reported|0
5984940|NCT03130959|9575512|FG003|Treatment Period|Not reported|1
5984941|NCT03130959|9575513|FG004|Treatment Period|Not reported|0
5984942|NCT03130959|9575514|FG005|Treatment Period|Not reported|2
5984943|NCT03130959|9575515|FG006|Treatment Period|Not reported|0
5984944|NCT03130959|9575516|FG007|Treatment Period|Not reported|0
5984945|NCT03130959|9575517|FG008|Treatment Period|Not reported|0
5984946|NCT03130959|9575518|FG009|Treatment Period|Not reported|2
5984947|NCT03130959|9575509|FG000|Treatment Period|Adverse Event unrelated to drug|0
5984948|NCT03130959|9575510|FG001|Treatment Period|Adverse Event unrelated to drug|0
5984949|NCT03130959|9575511|FG002|Treatment Period|Adverse Event unrelated to drug|1
5984950|NCT03130959|9575512|FG003|Treatment Period|Adverse Event unrelated to drug|1
5984951|NCT03130959|9575513|FG004|Treatment Period|Adverse Event unrelated to drug|1
5984952|NCT03130959|9575514|FG005|Treatment Period|Adverse Event unrelated to drug|0
5984953|NCT03130959|9575515|FG006|Treatment Period|Adverse Event unrelated to drug|1
5984954|NCT03130959|9575516|FG007|Treatment Period|Adverse Event unrelated to drug|0
5984955|NCT03130959|9575517|FG008|Treatment Period|Adverse Event unrelated to drug|1
5984956|NCT03130959|9575518|FG009|Treatment Period|Adverse Event unrelated to drug|1
5984957|NCT03130959|9575509|FG000|Treatment Period|Participant withdrew consent|0
5984958|NCT03130959|9575510|FG001|Treatment Period|Participant withdrew consent|0
5984959|NCT03130959|9575511|FG002|Treatment Period|Participant withdrew consent|0
5984960|NCT03130959|9575512|FG003|Treatment Period|Participant withdrew consent|2
5984961|NCT03130959|9575513|FG004|Treatment Period|Participant withdrew consent|1
5984962|NCT03130959|9575514|FG005|Treatment Period|Participant withdrew consent|0
5984963|NCT03130959|9575515|FG006|Treatment Period|Participant withdrew consent|0
5984964|NCT03130959|9575516|FG007|Treatment Period|Participant withdrew consent|0
5984965|NCT03130959|9575517|FG008|Treatment Period|Participant withdrew consent|0
5984966|NCT03130959|9575518|FG009|Treatment Period|Participant withdrew consent|2
5984967|NCT03130959|9575509|FG000|Follow-up Period|Death|16
5984968|NCT03130959|9575510|FG001|Follow-up Period|Death|17
5984969|NCT03130959|9575511|FG002|Follow-up Period|Death|12
5984970|NCT03130959|9575512|FG003|Follow-up Period|Death|10
5984971|NCT03130959|9575513|FG004|Follow-up Period|Death|11
5984972|NCT03130959|9575514|FG005|Follow-up Period|Death|8
5984973|NCT03130959|9575515|FG006|Follow-up Period|Death|9
5984974|NCT03130959|9575516|FG007|Follow-up Period|Death|7
5984975|NCT03130959|9575517|FG008|Follow-up Period|Death|17
5984976|NCT03130959|9575518|FG009|Follow-up Period|Death|10
5984977|NCT03130959|9575509|FG000|Follow-up Period|Participant withdrew consent|3
5984978|NCT03130959|9575510|FG001|Follow-up Period|Participant withdrew consent|1
5984979|NCT03130959|9575511|FG002|Follow-up Period|Participant withdrew consent|0
5984980|NCT03130959|9575512|FG003|Follow-up Period|Participant withdrew consent|3
5984981|NCT03130959|9575513|FG004|Follow-up Period|Participant withdrew consent|3
5984982|NCT03130959|9575514|FG005|Follow-up Period|Participant withdrew consent|0
5984983|NCT03130959|9575515|FG006|Follow-up Period|Participant withdrew consent|0
5984984|NCT03130959|9575516|FG007|Follow-up Period|Participant withdrew consent|1
5984985|NCT03130959|9575517|FG008|Follow-up Period|Participant withdrew consent|1
5984986|NCT03130959|9575518|FG009|Follow-up Period|Participant withdrew consent|3
5984987|NCT03130959|9575509|FG000|Follow-up Period|Lost to Follow-up|1
5984988|NCT03130959|9575510|FG001|Follow-up Period|Lost to Follow-up|1
5984989|NCT03130959|9575511|FG002|Follow-up Period|Lost to Follow-up|0
5984990|NCT03130959|9575512|FG003|Follow-up Period|Lost to Follow-up|0
5984991|NCT03130959|9575513|FG004|Follow-up Period|Lost to Follow-up|0
5984992|NCT03130959|9575514|FG005|Follow-up Period|Lost to Follow-up|2
5984993|NCT03130959|9575515|FG006|Follow-up Period|Lost to Follow-up|0
5984994|NCT03130959|9575516|FG007|Follow-up Period|Lost to Follow-up|0
5984995|NCT03130959|9575517|FG008|Follow-up Period|Lost to Follow-up|0
5984996|NCT03130959|9575518|FG009|Follow-up Period|Lost to Follow-up|1
5984997|NCT03130959|9575509|FG000|Follow-up Period|Other reasons|0
5984998|NCT03130959|9575510|FG001|Follow-up Period|Other reasons|1
5984999|NCT03130959|9575511|FG002|Follow-up Period|Other reasons|0
5985000|NCT03130959|9575512|FG003|Follow-up Period|Other reasons|1
5985001|NCT03130959|9575513|FG004|Follow-up Period|Other reasons|0
5985002|NCT03130959|9575514|FG005|Follow-up Period|Other reasons|0
5985003|NCT03130959|9575515|FG006|Follow-up Period|Other reasons|0
5985004|NCT03130959|9575516|FG007|Follow-up Period|Other reasons|0
5985005|NCT03130959|9575517|FG008|Follow-up Period|Other reasons|0
5985006|NCT03130959|9575518|FG009|Follow-up Period|Other reasons|2
5985007|NCT02955797|9575557|FG000|Overall Study|Protocol Violation|1
5985008|NCT02955797|9575558|FG001|Overall Study|Protocol Violation|0
5985009|NCT02955797|9575559|FG002|Overall Study|Protocol Violation|0
5985010|NCT02955797|9575560|FG003|Overall Study|Protocol Violation|1
5985011|NCT02955797|9575557|FG000|Overall Study|Withdrawal by Subject|2
5985012|NCT02955797|9575558|FG001|Overall Study|Withdrawal by Subject|2
5985013|NCT02955797|9575559|FG002|Overall Study|Withdrawal by Subject|0
5985014|NCT02955797|9575560|FG003|Overall Study|Withdrawal by Subject|1
5985015|NCT02955797|9575557|FG000|Overall Study|Lost to Follow-up|0
5985016|NCT02955797|9575558|FG001|Overall Study|Lost to Follow-up|1
5985017|NCT02955797|9575559|FG002|Overall Study|Lost to Follow-up|0
5985018|NCT02955797|9575560|FG003|Overall Study|Lost to Follow-up|0
5985019|NCT02859415|9575575|FG000|Overall Study|Physician Decision|1
5985020|NCT02859415|9575576|FG001|Overall Study|Physician Decision|0
5985021|NCT02859415|9575575|FG000|Overall Study|Off treatment due to cardiac event|0
5985022|NCT02859415|9575576|FG001|Overall Study|Off treatment due to cardiac event|1
5985023|NCT02842866|9575585|FG000|Overall Study|Serious Adverse Event|0
5985024|NCT02842866|9575586|FG001|Overall Study|Serious Adverse Event|1
5985025|NCT02842866|9575585|FG000|Overall Study|Protocol Violation|4
5985026|NCT02842866|9575586|FG001|Overall Study|Protocol Violation|2
5985027|NCT02842866|9575585|FG000|Overall Study|Lost to Follow-up|2
5985028|NCT02842866|9575586|FG001|Overall Study|Lost to Follow-up|0
5985029|NCT02842866|9575585|FG000|Overall Study|Withdrawal by Subject|1
5985030|NCT02842866|9575586|FG001|Overall Study|Withdrawal by Subject|0
5985031|NCT02842853|9575596|FG000|Overall Study|Non-compliance with the protocol|3
5985032|NCT02842853|9575597|FG001|Overall Study|Non-compliance with the protocol|7
5985033|NCT02842853|9575598|FG002|Overall Study|Non-compliance with the protocol|2
5985034|NCT02842853|9575599|FG003|Overall Study|Non-compliance with the protocol|5
5985035|NCT02842853|9575596|FG000|Overall Study|Subject met exclusion criteria|0
5985036|NCT02842853|9575597|FG001|Overall Study|Subject met exclusion criteria|1
5985037|NCT02842853|9575598|FG002|Overall Study|Subject met exclusion criteria|0
5985038|NCT02842853|9575599|FG003|Overall Study|Subject met exclusion criteria|0
5985039|NCT02842853|9575596|FG000|Overall Study|Withdrawal by Subject|11
5985040|NCT02842853|9575597|FG001|Overall Study|Withdrawal by Subject|13
5985041|NCT02842853|9575598|FG002|Overall Study|Withdrawal by Subject|9
5985042|NCT02842853|9575599|FG003|Overall Study|Withdrawal by Subject|8
5985043|NCT02842853|9575596|FG000|Overall Study|Lost to Follow-up|9
5985044|NCT02842853|9575597|FG001|Overall Study|Lost to Follow-up|13
5985045|NCT02842853|9575598|FG002|Overall Study|Lost to Follow-up|10
5985046|NCT02842853|9575599|FG003|Overall Study|Lost to Follow-up|11
5985047|NCT02752906|9575613|FG000|Overall Study|Protocol Violation|2
5985048|NCT02752906|9575614|FG001|Overall Study|Protocol Violation|1
5985049|NCT02752906|9575613|FG000|Overall Study|Withdrawal by Subject|2
5985050|NCT02752906|9575614|FG001|Overall Study|Withdrawal by Subject|2
5985051|NCT02752906|9575613|FG000|Overall Study|Lost to Follow-up|3
5985052|NCT02752906|9575614|FG001|Overall Study|Lost to Follow-up|2
5985053|NCT02693691|9575620|FG000|Primary Endpoint Analysis (First 12M)|Death|30
5985054|NCT02693691|9575620|FG000|Primary Endpoint Analysis (First 12M)|Withdrawal by Subject|12
5985055|NCT02693691|9575620|FG000|Primary Endpoint Analysis (First 12M)|Physician Decision|7
5985056|NCT02693691|9575620|FG000|Primary Endpoint Analysis (First 12M)|Adverse Event|1
5985057|NCT02693691|9575620|FG000|Extended Follow-Up (Until Last pt 12M)|Death|12
5985058|NCT02693691|9575620|FG000|Extended Follow-Up (Until Last pt 12M)|Withdrawal by Subject|11
5985059|NCT02693691|9575620|FG000|Extended Follow-Up (Until Last pt 12M)|Physician Decision|1
6044381|NCT00395343|9643364|FG000|Overall Study|Adverse Event|13
6044382|NCT00395343|9643365|FG001|Overall Study|Adverse Event|5
6044383|NCT00395343|9643364|FG000|Overall Study|Lack of Efficacy|0
6044384|NCT00395343|9643365|FG001|Overall Study|Lack of Efficacy|1
6044385|NCT00395343|9643364|FG000|Overall Study|Lost to Follow-up|4
6044386|NCT00395343|9643365|FG001|Overall Study|Lost to Follow-up|4
6044387|NCT00395343|9643364|FG000|Overall Study|Physician Decision|2
6044388|NCT00395343|9643365|FG001|Overall Study|Physician Decision|4
6044389|NCT00395343|9643364|FG000|Overall Study|Protocol Violation|6
6044390|NCT00395343|9643365|FG001|Overall Study|Protocol Violation|8
6044391|NCT00395343|9643364|FG000|Overall Study|Withdrawal by Subject|11
6044392|NCT00395343|9643365|FG001|Overall Study|Withdrawal by Subject|12
6044393|NCT00395343|9643364|FG000|Overall Study|Other|5
6044394|NCT00395343|9643365|FG001|Overall Study|Other|2
6044395|NCT00395447|9643373|FG000|Overall Study|Death|37
6044396|NCT00395447|9643374|FG001|Overall Study|Death|32
6044397|NCT00395447|9643373|FG000|Overall Study|Lost to Follow-up|52
6044398|NCT00395447|9643374|FG001|Overall Study|Lost to Follow-up|43
6044399|NCT00395447|9643373|FG000|Overall Study|Withdrawal by Subject|24
6044400|NCT00395447|9643374|FG001|Overall Study|Withdrawal by Subject|19
6044401|NCT00395447|9643373|FG000|Overall Study|Withdrawl - Other (not subject)|8
6044402|NCT00395447|9643374|FG001|Overall Study|Withdrawl - Other (not subject)|17
6044403|NCT00395460|9643382|FG000|Overall Study|Withdrawal by Subject|1
6044404|NCT00395460|9643383|FG001|Overall Study|Withdrawal by Subject|0
6044405|NCT00395486|9643391|FG000|Overall Study|Adverse Event|1
6044406|NCT00395486|9643392|FG001|Overall Study|Adverse Event|2
6044407|NCT00395486|9643391|FG000|Overall Study|Withdrawal by Subject|5
6044408|NCT00395486|9643392|FG001|Overall Study|Withdrawal by Subject|2
6044409|NCT00395486|9643391|FG000|Overall Study|Lost to Follow-up|0
6044410|NCT00395486|9643392|FG001|Overall Study|Lost to Follow-up|1
6044411|NCT00395512|9643402|FG000|Overall Study|Adverse Event|3
6044412|NCT00395512|9643403|FG001|Overall Study|Adverse Event|8
6044413|NCT00395512|9643404|FG002|Overall Study|Adverse Event|6
6044414|NCT00395512|9643405|FG003|Overall Study|Adverse Event|6
6044415|NCT00395512|9643402|FG000|Overall Study|Protocol Violation|2
6044416|NCT00395512|9643403|FG001|Overall Study|Protocol Violation|3
6044417|NCT00395512|9643404|FG002|Overall Study|Protocol Violation|6
6044418|NCT00395512|9643405|FG003|Overall Study|Protocol Violation|7
6044419|NCT00395512|9643402|FG000|Overall Study|Lost to Follow-up|2
6044420|NCT00395512|9643403|FG001|Overall Study|Lost to Follow-up|6
6044421|NCT00395512|9643404|FG002|Overall Study|Lost to Follow-up|5
6044422|NCT00395512|9643405|FG003|Overall Study|Lost to Follow-up|5
6044423|NCT00395512|9643402|FG000|Overall Study|Withdrawal by Subject|6
6044424|NCT00395512|9643403|FG001|Overall Study|Withdrawal by Subject|5
6044425|NCT00395512|9643404|FG002|Overall Study|Withdrawal by Subject|5
6044426|NCT00395512|9643405|FG003|Overall Study|Withdrawal by Subject|12
6044427|NCT00395512|9643402|FG000|Overall Study|Physician Decision|6
6044428|NCT00395512|9643403|FG001|Overall Study|Physician Decision|4
6044429|NCT00395512|9643404|FG002|Overall Study|Physician Decision|2
6044430|NCT00395512|9643405|FG003|Overall Study|Physician Decision|2
6044431|NCT00395512|9643402|FG000|Overall Study|Other|1
6044432|NCT00395512|9643403|FG001|Overall Study|Other|1
6044433|NCT00395512|9643404|FG002|Overall Study|Other|0
6044434|NCT00395512|9643405|FG003|Overall Study|Other|0
6044435|NCT00395512|9643402|FG000|Overall Study|Hyperglycemic Rescue|18
6044436|NCT00395512|9643403|FG001|Overall Study|Hyperglycemic Rescue|10
6044437|NCT00395512|9643404|FG002|Overall Study|Hyperglycemic Rescue|4
5985060|NCT02388906|9575642|FG000|Pre-Treatment Period|Participant withdrew consent|1
5985061|NCT02388906|9575643|FG001|Pre-Treatment Period|Participant withdrew consent|0
5985062|NCT02388906|9575642|FG000|Treatment Period|Disease progression|121
5985063|NCT02388906|9575643|FG001|Treatment Period|Disease progression|101
5985064|NCT02388906|9575642|FG000|Treatment Period|Study drug toxicity|41
5985065|NCT02388906|9575643|FG001|Treatment Period|Study drug toxicity|208
5985066|NCT02388906|9575642|FG000|Treatment Period|Adverse Event (AE) unrelated to study drug|5
5985067|NCT02388906|9575643|FG001|Treatment Period|Adverse Event (AE) unrelated to study drug|5
5985068|NCT02388906|9575642|FG000|Treatment Period|Participant request to stop treatment|5
5985069|NCT02388906|9575643|FG001|Treatment Period|Participant request to stop treatment|9
5985070|NCT02388906|9575642|FG000|Treatment Period|Participant withdrew consent|2
5985071|NCT02388906|9575643|FG001|Treatment Period|Participant withdrew consent|3
5985072|NCT02388906|9575642|FG000|Treatment Period|Poor/non-compliance|0
5985073|NCT02388906|9575643|FG001|Treatment Period|Poor/non-compliance|1
5985074|NCT02388906|9575642|FG000|Treatment Period|Participant no longer meets study criteria|0
5985075|NCT02388906|9575643|FG001|Treatment Period|Participant no longer meets study criteria|1
5985076|NCT02388906|9575642|FG000|Treatment Period|Other reasons|3
5985077|NCT02388906|9575643|FG001|Treatment Period|Other reasons|3
5985078|NCT02384993|9575651|FG000|Overall Study|Adverse Event|0
5985079|NCT02384993|9575652|FG001|Overall Study|Adverse Event|1
5985080|NCT02304302|9575661|FG000|Overall Study|Adverse Event|2
5985081|NCT02304302|9575662|FG001|Overall Study|Adverse Event|3
5985082|NCT02304302|9575661|FG000|Overall Study|Lost to Follow-up|1
5985083|NCT02304302|9575662|FG001|Overall Study|Lost to Follow-up|4
5985084|NCT02304302|9575661|FG000|Overall Study|Removed from analysis due to low medication compliance|0
5985085|NCT02304302|9575662|FG001|Overall Study|Removed from analysis due to low medication compliance|1
5985086|NCT02294461|9575674|FG000|Double-blind Period (up to 29.4 Months)|Death|6
5985087|NCT02294461|9575675|FG001|Double-blind Period (up to 29.4 Months)|Death|4
5985088|NCT02294461|9575674|FG000|Double-blind Period (up to 29.4 Months)|Miscellaneous|30
5985089|NCT02294461|9575675|FG001|Double-blind Period (up to 29.4 Months)|Miscellaneous|66
5985090|NCT02294461|9575674|FG000|Double-blind Period (up to 29.4 Months)|Withdrawal by Subject|27
5985091|NCT02294461|9575675|FG001|Double-blind Period (up to 29.4 Months)|Withdrawal by Subject|54
5985092|NCT02294461|9575674|FG000|Double-blind Period (up to 29.4 Months)|Protocol Deviation|0
5985093|NCT02294461|9575675|FG001|Double-blind Period (up to 29.4 Months)|Protocol Deviation|2
5985094|NCT02294461|9575674|FG000|Double-blind Period (up to 29.4 Months)|Lost to Follow-up|1
5985095|NCT02294461|9575675|FG001|Double-blind Period (up to 29.4 Months)|Lost to Follow-up|0
5985096|NCT02294461|9575674|FG000|Double-blind Period (up to 29.4 Months)|Progressive Disease|38
5985097|NCT02294461|9575675|FG001|Double-blind Period (up to 29.4 Months)|Progressive Disease|51
5985098|NCT02294461|9575674|FG000|Double-blind Period (up to 29.4 Months)|Adverse Event|16
5985099|NCT02294461|9575675|FG001|Double-blind Period (up to 29.4 Months)|Adverse Event|15
5985100|NCT02294461|9575674|FG000|Open-label Period (up to 54.3 Months)|Ongoing|19
5985101|NCT02294461|9575675|FG001|Open-label Period (up to 54.3 Months)|Ongoing|9
5985102|NCT02294461|9575674|FG000|Open-label Period (up to 54.3 Months)|Miscellaneous|16
5985103|NCT02294461|9575675|FG001|Open-label Period (up to 54.3 Months)|Miscellaneous|12
5985104|NCT02294461|9575674|FG000|Open-label Period (up to 54.3 Months)|Withdrawal by Subject|18
5985105|NCT02294461|9575675|FG001|Open-label Period (up to 54.3 Months)|Withdrawal by Subject|9
5985106|NCT02294461|9575674|FG000|Open-label Period (up to 54.3 Months)|Protocol Deviation|2
5985107|NCT02294461|9575675|FG001|Open-label Period (up to 54.3 Months)|Protocol Deviation|0
5985108|NCT02294461|9575674|FG000|Open-label Period (up to 54.3 Months)|Lost to Follow-up|3
5985109|NCT02294461|9575675|FG001|Open-label Period (up to 54.3 Months)|Lost to Follow-up|1
5985110|NCT02294461|9575674|FG000|Open-label Period (up to 54.3 Months)|Progressive Disease|15
5985111|NCT02294461|9575675|FG001|Open-label Period (up to 54.3 Months)|Progressive Disease|9
5985112|NCT02294461|9575674|FG000|Open-label Period (up to 54.3 Months)|Death|6
5985113|NCT02294461|9575675|FG001|Open-label Period (up to 54.3 Months)|Death|5
5985114|NCT02294461|9575674|FG000|Open-label Period (up to 54.3 Months)|Adverse Event|6
5985115|NCT02294461|9575675|FG001|Open-label Period (up to 54.3 Months)|Adverse Event|6
5985116|NCT02269670|9575693|FG000|Overall Study|All subjects have not completed all research related interventions|3
5985117|NCT01860976|9575703|FG000|Blinded Treatment|Adverse Event|1
5985118|NCT01860976|9575704|FG001|Blinded Treatment|Adverse Event|3
5985119|NCT01860976|9575703|FG000|Blinded Treatment|Lack of Efficacy|5
5985120|NCT01860976|9575704|FG001|Blinded Treatment|Lack of Efficacy|12
5985121|NCT01860976|9575703|FG000|Blinded Treatment|Subject request to discontinue treatment|2
5985122|NCT01860976|9575704|FG001|Blinded Treatment|Subject request to discontinue treatment|3
5985123|NCT01860976|9575703|FG000|Blinded Treatment|Withdrawal by Subject|3
5985124|NCT01860976|9575704|FG001|Blinded Treatment|Withdrawal by Subject|5
5985125|NCT01860976|9575703|FG000|Blinded Treatment|Subject no longer met criteria|1
5985126|NCT01860976|9575704|FG001|Blinded Treatment|Subject no longer met criteria|0
5985127|NCT01860976|9575703|FG000|Blinded Treatment|Entered Open-Label in error|0
5985128|NCT01860976|9575704|FG001|Blinded Treatment|Entered Open-Label in error|1
5985129|NCT01860976|9575703|FG000|Blinded Treatment|Early Escape: Transitioned to OL period|76
5985130|NCT01860976|9575704|FG001|Blinded Treatment|Early Escape: Transitioned to OL period|89
5985131|NCT01860976|9575703|FG000|Open-Label|Adverse Event|2
5985132|NCT01860976|9575704|FG001|Open-Label|Adverse Event|4
5985133|NCT01860976|9575703|FG000|Open-Label|Lack of Efficacy|16
5985134|NCT01860976|9575704|FG001|Open-Label|Lack of Efficacy|8
5985135|NCT01860976|9575703|FG000|Open-Label|Lost to Follow-up|1
5985136|NCT01860976|9575704|FG001|Open-Label|Lost to Follow-up|2
5985137|NCT01860976|9575703|FG000|Open-Label|Subject request discontinue treatment|4
5985138|NCT01860976|9575704|FG001|Open-Label|Subject request discontinue treatment|3
5985139|NCT01860976|9575703|FG000|Open-Label|Withdrawal by Subject|4
5985140|NCT01860976|9575704|FG001|Open-Label|Withdrawal by Subject|1
5985141|NCT01860976|9575703|FG000|Open-Label|Other Reasons|1
5985142|NCT01860976|9575704|FG001|Open-Label|Other Reasons|1
5985143|NCT01860976|9575703|FG000|Long Term Extension|Adverse Event|4
5985144|NCT01860976|9575704|FG001|Long Term Extension|Adverse Event|0
5985145|NCT01860976|9575703|FG000|Long Term Extension|Lack of Efficacy|2
5985146|NCT01860976|9575704|FG001|Long Term Extension|Lack of Efficacy|0
5985147|NCT01860976|9575703|FG000|Long Term Extension|Subject request to discontinue treatment|10
5985148|NCT01860976|9575704|FG001|Long Term Extension|Subject request to discontinue treatment|0
5985149|NCT01860976|9575703|FG000|Long Term Extension|Lost to Follow-up|2
5985150|NCT01860976|9575704|FG001|Long Term Extension|Lost to Follow-up|0
5985151|NCT01860976|9575703|FG000|Long Term Extension|subject withdrew consent|7
5985152|NCT01860976|9575704|FG001|Long Term Extension|subject withdrew consent|0
5985153|NCT01761266|9575715|FG000|Overall Study|Death|415
5985154|NCT01761266|9575716|FG001|Overall Study|Death|402
5985155|NCT01761266|9575715|FG000|Overall Study|Lost to Follow-up|8
5985156|NCT01761266|9575716|FG001|Overall Study|Lost to Follow-up|12
5985157|NCT01761266|9575715|FG000|Overall Study|Withdrawal by Subject|14
5985158|NCT01761266|9575716|FG001|Overall Study|Withdrawal by Subject|10
5985159|NCT01761266|9575715|FG000|Overall Study|Sponsor Decision|41
5985160|NCT01761266|9575716|FG001|Overall Study|Sponsor Decision|52
5985161|NCT01550289|9575727|FG000|Overall Study|Protocol Violation|1
5985162|NCT01550289|9575728|FG001|Overall Study|Protocol Violation|0
5985163|NCT01550289|9575727|FG000|Overall Study|Lost to Follow-up|1
5985164|NCT01550289|9575728|FG001|Overall Study|Lost to Follow-up|1
5985165|NCT01550289|9575727|FG000|Overall Study|Withdrawal by Subject|11
5985166|NCT01550289|9575728|FG001|Overall Study|Withdrawal by Subject|3
5985167|NCT01346709|9575736|FG000|Overall Study|Protocol Violation|35
5985168|NCT01346709|9575736|FG000|Overall Study|Lost to Follow-up|31
5985169|NCT01346709|9575736|FG000|Overall Study|Missing data in candidate risk factor|285
5985170|NCT01081951|9575746|FG000|Overall Study|Death|54
5985171|NCT01081951|9575747|FG001|Overall Study|Death|47
5985172|NCT01081951|9575746|FG000|Overall Study|Withdrawal by Subject|2
5985173|NCT01081951|9575747|FG001|Overall Study|Withdrawal by Subject|6
5985174|NCT01081951|9575746|FG000|Overall Study|Allocated treatment but did not take it|0
5985175|NCT01081951|9575747|FG001|Overall Study|Allocated treatment but did not take it|1
5985176|NCT01081951|9575746|FG000|Overall Study|Lost to Follow-up|0
5985177|NCT01081951|9575747|FG001|Overall Study|Lost to Follow-up|1
5985178|NCT01074190|9575756|FG000|Overall Study|Emergency Cesarean Delivery|1
5985179|NCT01074190|9575757|FG001|Overall Study|Emergency Cesarean Delivery|2
5985180|NCT01074190|9575758|FG002|Overall Study|Emergency Cesarean Delivery|1
5985181|NCT01074190|9575756|FG000|Overall Study|Protocol Violation|2
5985182|NCT01074190|9575757|FG001|Overall Study|Protocol Violation|1
5985183|NCT01074190|9575758|FG002|Overall Study|Protocol Violation|0
5985184|NCT01074190|9575756|FG000|Overall Study|Delivered in under 90 minutes|0
5985185|NCT01074190|9575757|FG001|Overall Study|Delivered in under 90 minutes|2
5985186|NCT01074190|9575758|FG002|Overall Study|Delivered in under 90 minutes|1
5985187|NCT01074190|9575756|FG000|Overall Study|Subject withdrew consent|1
5985188|NCT01074190|9575757|FG001|Overall Study|Subject withdrew consent|1
5985189|NCT01074190|9575758|FG002|Overall Study|Subject withdrew consent|1
5985190|NCT00875524|9575771|FG000|Overall Study|Serious adverse event|0
5985191|NCT00875524|9575772|FG001|Overall Study|Serious adverse event|1
5985192|NCT00875524|9575771|FG000|Overall Study|Protocol Violation|4
5985193|NCT00875524|9575772|FG001|Overall Study|Protocol Violation|0
5985194|NCT00875524|9575771|FG000|Overall Study|Lost to Follow-up|1
5985195|NCT00875524|9575772|FG001|Overall Study|Lost to Follow-up|0
5985196|NCT00875524|9575771|FG000|Overall Study|Withdrawal by Subject|3
5985197|NCT00875524|9575772|FG001|Overall Study|Withdrawal by Subject|5
5985198|NCT00842530|9575780|FG000|Overall Study|Serious adverse event|0
5985199|NCT00842530|9575781|FG001|Overall Study|Serious adverse event|6
5985200|NCT00842530|9575780|FG000|Overall Study|Other adverse event|6
5985201|NCT00842530|9575781|FG001|Overall Study|Other adverse event|1
5985202|NCT00842530|9575780|FG000|Overall Study|Protocol Violation|32
5985203|NCT00842530|9575781|FG001|Overall Study|Protocol Violation|14
5985204|NCT00842530|9575780|FG000|Overall Study|Lost to Follow-up|6
5985205|NCT00842530|9575781|FG001|Overall Study|Lost to Follow-up|8
5985206|NCT00842530|9575780|FG000|Overall Study|Withdrawal by Subject|73
5985207|NCT00842530|9575781|FG001|Overall Study|Withdrawal by Subject|28
5985208|NCT00788151|9575790|FG000|Overall Study|Other adverse event|0
5985209|NCT00788151|9575791|FG001|Overall Study|Other adverse event|2
5985210|NCT00788151|9575790|FG000|Overall Study|Protocol Violation|0
5985211|NCT00788151|9575791|FG001|Overall Study|Protocol Violation|1
5985212|NCT00788151|9575790|FG000|Overall Study|Withdrawal by Subject|13
5985213|NCT00788151|9575791|FG001|Overall Study|Withdrawal by Subject|6
5985214|NCT00788151|9575790|FG000|Overall Study|Enrolled but not treated|1
5985215|NCT00788151|9575791|FG001|Overall Study|Enrolled but not treated|1
5985216|NCT00539591|9575800|FG000|Overall Study|Toxicity|3
5985217|NCT00539591|9575801|FG001|Overall Study|Toxicity|0
5985218|NCT00539591|9575802|FG002|Overall Study|Toxicity|0
5985219|NCT00539591|9575800|FG000|Overall Study|Disease progression|2
5985220|NCT00539591|9575801|FG001|Overall Study|Disease progression|2
5985221|NCT00539591|9575802|FG002|Overall Study|Disease progression|3
6044438|NCT00395512|9643405|FG003|Overall Study|Hyperglycemic Rescue|6
6044439|NCT00395538|9643418|FG000|Overall Study|Did not re-consent to revised protocol|1
6044440|NCT00395538|9643419|FG001|Overall Study|Did not re-consent to revised protocol|10
6044441|NCT00395538|9643420|FG002|Overall Study|Did not re-consent to revised protocol|0
6044442|NCT00395538|9643418|FG000|Overall Study|FDA partial hold on PTH|0
6044443|NCT00395538|9643419|FG001|Overall Study|FDA partial hold on PTH|0
6044444|NCT00395538|9643420|FG002|Overall Study|FDA partial hold on PTH|11
6044445|NCT00395538|9643418|FG000|Overall Study|Failed screening|0
6044446|NCT00395538|9643419|FG001|Overall Study|Failed screening|0
6044447|NCT00395538|9643420|FG002|Overall Study|Failed screening|4
6044448|NCT00395538|9643418|FG000|Overall Study|Switch to Natpara|0
6044449|NCT00395538|9643419|FG001|Overall Study|Switch to Natpara|0
6044450|NCT00395538|9643420|FG002|Overall Study|Switch to Natpara|3
6044451|NCT00395538|9643418|FG000|Overall Study|Adverse Event|1
6044452|NCT00395538|9643419|FG001|Overall Study|Adverse Event|0
6044453|NCT00395538|9643420|FG002|Overall Study|Adverse Event|2
6044454|NCT00395538|9643418|FG000|Overall Study|DXA or QCT z-score or t-score<-2|0
6044455|NCT00395538|9643419|FG001|Overall Study|DXA or QCT z-score or t-score<-2|2
6044456|NCT00395538|9643420|FG002|Overall Study|DXA or QCT z-score or t-score<-2|0
6044457|NCT00395538|9643418|FG000|Overall Study|Non-compliance with study protocol|0
6044458|NCT00395538|9643419|FG001|Overall Study|Non-compliance with study protocol|1
6044459|NCT00395538|9643420|FG002|Overall Study|Non-compliance with study protocol|0
6044460|NCT00395538|9643418|FG000|Overall Study|PTH resistance|0
6044461|NCT00395538|9643419|FG001|Overall Study|PTH resistance|0
6044462|NCT00395538|9643420|FG002|Overall Study|PTH resistance|1
6044463|NCT00395538|9643418|FG000|Overall Study|Pregnancy|1
6044464|NCT00395538|9643419|FG001|Overall Study|Pregnancy|0
6044465|NCT00395538|9643420|FG002|Overall Study|Pregnancy|0
6044466|NCT00395538|9643418|FG000|Overall Study|Partial recovery of parathyroid function|0
6044467|NCT00395538|9643419|FG001|Overall Study|Partial recovery of parathyroid function|0
6044468|NCT00395538|9643420|FG002|Overall Study|Partial recovery of parathyroid function|1
6044469|NCT00395538|9643418|FG000|Overall Study|Participant elected to discontinue|0
6044470|NCT00395538|9643419|FG001|Overall Study|Participant elected to discontinue|0
6044471|NCT00395538|9643420|FG002|Overall Study|Participant elected to discontinue|1
6044472|NCT00395629|9643431|FG000|Core Study|Adverse Event|0
6044473|NCT00395629|9643432|FG001|Core Study|Adverse Event|3
6044474|NCT00395629|9643433|FG002|Core Study|Adverse Event|4
6044475|NCT00395629|9643431|FG000|Core Study|Abnormal laboratory value(s)|0
6044476|NCT00395629|9643432|FG001|Core Study|Abnormal laboratory value(s)|0
6044477|NCT00395629|9643433|FG002|Core Study|Abnormal laboratory value(s)|1
6044478|NCT00395629|9643431|FG000|Core Study|Protocol Violation|1
6044479|NCT00395629|9643432|FG001|Core Study|Protocol Violation|0
6044480|NCT00395629|9643433|FG002|Core Study|Protocol Violation|0
6044481|NCT00395629|9643431|FG000|Core Study|Withdrawal by Subject|0
6044482|NCT00395629|9643432|FG001|Core Study|Withdrawal by Subject|1
6044483|NCT00395629|9643433|FG002|Core Study|Withdrawal by Subject|1
6044484|NCT00395629|9643431|FG000|Core Study|Lost to Follow-up|0
6044485|NCT00395629|9643432|FG001|Core Study|Lost to Follow-up|0
6044486|NCT00395629|9643433|FG002|Core Study|Lost to Follow-up|1
6044487|NCT00395629|9643431|FG000|Extension Study|Adverse Event|0
6044488|NCT00395629|9643432|FG001|Extension Study|Adverse Event|0
6044489|NCT00395629|9643433|FG002|Extension Study|Adverse Event|2
6044490|NCT00395629|9643431|FG000|Extension Study|Administrative problems|0
6044491|NCT00395629|9643432|FG001|Extension Study|Administrative problems|0
6044492|NCT00395629|9643433|FG002|Extension Study|Administrative problems|1
6044493|NCT00395642|9643444|FG000|Overall Study|Death|4
6044494|NCT00395642|9643444|FG000|Overall Study|Lost to Follow-up|1
6044495|NCT00395642|9643444|FG000|Overall Study|Physician Decision|7
6044496|NCT00395642|9643444|FG000|Overall Study|Withdrawal by Subject|1
6044497|NCT00395694|9643450|FG000|Escalation Phase + Maintenance Phase|Adverse Event|1
6044498|NCT00395694|9643451|FG001|Escalation Phase + Maintenance Phase|Adverse Event|2
6044499|NCT00395694|9643450|FG000|Continuation Phase|Adverse Event|1
6044500|NCT00395694|9643451|FG001|Continuation Phase|Adverse Event|0
6044501|NCT00395694|9643450|FG000|Continuation Phase|Lack of Efficacy|12
6044502|NCT00395694|9643451|FG001|Continuation Phase|Lack of Efficacy|11
6044503|NCT00395694|9643450|FG000|Continuation Phase|Withdrawal Due to Wishes of Family|1
6044504|NCT00395694|9643451|FG001|Continuation Phase|Withdrawal Due to Wishes of Family|0
6044505|NCT00395694|9643450|FG000|Continuation Phase|Poor Compliance|1
6044506|NCT00395694|9643451|FG001|Continuation Phase|Poor Compliance|0
6044507|NCT00395694|9643450|FG000|Continuation Phase|Withdrawal by Subject|0
6044508|NCT00395694|9643451|FG001|Continuation Phase|Withdrawal by Subject|2
6044509|NCT00395733|9643462|FG000|Period 2|Withdrawal by Subject|1
6044510|NCT00395733|9643463|FG001|Period 2|Withdrawal by Subject|2
6044511|NCT00395733|9643462|FG000|Period 2|Protocol Violation|0
6044512|NCT00395733|9643463|FG001|Period 2|Protocol Violation|1
6044513|NCT00395733|9643462|FG000|Period 2|Adverse Event|0
6044514|NCT00395733|9643463|FG001|Period 2|Adverse Event|2
6044515|NCT00395733|9643462|FG000|Period 2|Technical problems|1
5985222|NCT04794270|9575847|FG000|Period 1|Non Compliance|1
5985223|NCT04794270|9575848|FG001|Period 1|Non Compliance|0
5985224|NCT04794270|9575847|FG000|Period 1|Adverse Event|1
5985225|NCT04794270|9575848|FG001|Period 1|Adverse Event|0
5985226|NCT04794270|9575847|FG000|Period 2|Unsatisfactory Lens Fitting due to Test Article|1
5985227|NCT04794270|9575848|FG001|Period 2|Unsatisfactory Lens Fitting due to Test Article|0
5985228|NCT04392583|9575896|FG000|Overall Study|Participant declined follow-up and subsequently withdrawn|1
5985229|NCT04351269|9575903|FG000|Overall Study|Subjects did not meet Inclusion criteria after protocol revision B|70
5985230|NCT04351269|9575904|FG001|Overall Study|Subjects did not meet Inclusion criteria after protocol revision B|32
5985231|NCT04351269|9575905|FG002|Overall Study|Subjects did not meet Inclusion criteria after protocol revision B|29
5985232|NCT04351269|9575903|FG000|Overall Study|CanGaroo Envelope used during a previous procedure|0
5985233|NCT04351269|9575904|FG001|Overall Study|CanGaroo Envelope used during a previous procedure|1
5985234|NCT04351269|9575905|FG002|Overall Study|CanGaroo Envelope used during a previous procedure|0
5985235|NCT04351269|9575903|FG000|Overall Study|Subjects had both CanGaroo Envelope and TYRX Envelope used during procedure|1
5985236|NCT04351269|9575904|FG001|Overall Study|Subjects had both CanGaroo Envelope and TYRX Envelope used during procedure|1
5985237|NCT04351269|9575905|FG002|Overall Study|Subjects had both CanGaroo Envelope and TYRX Envelope used during procedure|0
5985238|NCT04351269|9575903|FG000|Overall Study|Subjects followed long-term at different health care system|0
5985239|NCT04351269|9575904|FG001|Overall Study|Subjects followed long-term at different health care system|4
5985240|NCT04351269|9575905|FG002|Overall Study|Subjects followed long-term at different health care system|0
5985241|NCT04351269|9575903|FG000|Overall Study|Lost to Follow-up|1
5985242|NCT04351269|9575904|FG001|Overall Study|Lost to Follow-up|3
5985243|NCT04351269|9575905|FG002|Overall Study|Lost to Follow-up|0
5985244|NCT04327986|9575913|FG000|Overall Study|Physician Decision|2
5985245|NCT04327986|9575914|FG001|Overall Study|Physician Decision|0
5985246|NCT04327986|9575915|FG002|Overall Study|Physician Decision|0
5985247|NCT04327986|9575913|FG000|Overall Study|Death|1
5985248|NCT04327986|9575914|FG001|Overall Study|Death|0
5985249|NCT04327986|9575915|FG002|Overall Study|Death|0
5985250|NCT04086121|9575919|FG000|Overall Study|Other than listed|7
5985251|NCT04086121|9575919|FG000|Overall Study|Withdrawal by Subject|3
5985252|NCT04086121|9575919|FG000|Overall Study|Lost to Follow-up|2
5985253|NCT04086121|9575919|FG000|Overall Study|Adverse Event|1
5985254|NCT03655054|9575950|FG000|Overall Study|Lost to Follow-up|1
5985305|NCT03373760|9576020|FG000|Overall Study|Adverse Event|8
5985306|NCT03373760|9576020|FG000|Overall Study|Disease Progression|46
5985307|NCT03373760|9576020|FG000|Overall Study|Death|4
5985308|NCT03338790|9576031|FG000|Overall Study|Disease Progression|65
5985309|NCT03338790|9576032|FG001|Overall Study|Disease Progression|43
5985310|NCT03338790|9576033|FG002|Overall Study|Disease Progression|50
5985311|NCT03338790|9576034|FG003|Overall Study|Disease Progression|37
5985312|NCT03338790|9576031|FG000|Overall Study|Study Drug Toxicity|9
5985313|NCT03338790|9576032|FG001|Overall Study|Study Drug Toxicity|8
5985314|NCT03338790|9576033|FG002|Overall Study|Study Drug Toxicity|15
5985315|NCT03338790|9576034|FG003|Overall Study|Study Drug Toxicity|0
5985316|NCT03338790|9576031|FG000|Overall Study|Death|1
5985317|NCT03338790|9576032|FG001|Overall Study|Death|1
5985318|NCT03338790|9576033|FG002|Overall Study|Death|1
5985319|NCT03338790|9576034|FG003|Overall Study|Death|0
5985320|NCT03338790|9576031|FG000|Overall Study|Adverse Event unrelated to Study Drug|4
5985321|NCT03338790|9576032|FG001|Overall Study|Adverse Event unrelated to Study Drug|4
5985322|NCT03338790|9576033|FG002|Overall Study|Adverse Event unrelated to Study Drug|6
5985323|NCT03338790|9576034|FG003|Overall Study|Adverse Event unrelated to Study Drug|4
5985324|NCT03338790|9576031|FG000|Overall Study|Participant request to discontinue study treatment|3
5985325|NCT03338790|9576032|FG001|Overall Study|Participant request to discontinue study treatment|3
5985326|NCT03338790|9576033|FG002|Overall Study|Participant request to discontinue study treatment|2
5985327|NCT03338790|9576034|FG003|Overall Study|Participant request to discontinue study treatment|1
5985328|NCT03338790|9576031|FG000|Overall Study|Poor/non-compliance|0
5985329|NCT03338790|9576032|FG001|Overall Study|Poor/non-compliance|1
5985330|NCT03338790|9576033|FG002|Overall Study|Poor/non-compliance|0
5985331|NCT03338790|9576034|FG003|Overall Study|Poor/non-compliance|0
5985332|NCT03338790|9576031|FG000|Overall Study|Participant withdrew consent|1
5985333|NCT03338790|9576032|FG001|Overall Study|Participant withdrew consent|0
5985334|NCT03338790|9576033|FG002|Overall Study|Participant withdrew consent|1
5985335|NCT03338790|9576034|FG003|Overall Study|Participant withdrew consent|1
5985336|NCT03338790|9576031|FG000|Overall Study|Other reasons|0
5985337|NCT03338790|9576032|FG001|Overall Study|Other reasons|5
5985338|NCT03338790|9576033|FG002|Overall Study|Other reasons|0
5985339|NCT03338790|9576034|FG003|Overall Study|Other reasons|2
5985340|NCT03338790|9576031|FG000|Overall Study|Not reported|0
5985341|NCT03338790|9576032|FG001|Overall Study|Not reported|0
5985342|NCT03338790|9576033|FG002|Overall Study|Not reported|1
5985343|NCT03338790|9576034|FG003|Overall Study|Not reported|0
5985344|NCT03338790|9576031|FG000|Overall Study|Completed treatment period|1
5985345|NCT03338790|9576032|FG001|Overall Study|Completed treatment period|2
5985346|NCT03338790|9576033|FG002|Overall Study|Completed treatment period|0
5985347|NCT03338790|9576034|FG003|Overall Study|Completed treatment period|0
5985348|NCT03253627|9576046|FG000|Overall Study|Lost to Follow-up|1
5985349|NCT03253627|9576047|FG001|Overall Study|Lost to Follow-up|2
5985350|NCT03253627|9576046|FG000|Overall Study|Withdrawal by Subject|0
5985255|NCT03542266|9575969|FG000|Treatment Phase|Withdrawal by Subject|1
5985256|NCT03542266|9575969|FG000|Treatment Phase|Adverse Event|1
5985257|NCT03542266|9575969|FG000|Treatment Phase|PD|1
5985258|NCT03529409|9575976|FG000|Randomized|Lost to Follow-up|0
5985259|NCT03529409|9575977|FG001|Randomized|Lost to Follow-up|0
5985260|NCT03529409|9575978|FG002|Randomized|Lost to Follow-up|4
5985261|NCT03529409|9575976|FG000|Randomized|Excluded|0
5985262|NCT03529409|9575977|FG001|Randomized|Excluded|0
5985263|NCT03529409|9575978|FG002|Randomized|Excluded|1
5985264|NCT03529409|9575976|FG000|Post-treatment Assessment|Death|1
5985265|NCT03529409|9575977|FG001|Post-treatment Assessment|Death|0
5985266|NCT03529409|9575978|FG002|Post-treatment Assessment|Death|0
5985267|NCT03529409|9575976|FG000|Post-treatment Assessment|Lost to Follow-up|1
5985268|NCT03529409|9575977|FG001|Post-treatment Assessment|Lost to Follow-up|1
5985269|NCT03529409|9575978|FG002|Post-treatment Assessment|Lost to Follow-up|0
5985270|NCT03529409|9575976|FG000|Post-treatment Assessment|Unable to contact for this assessment, but attended later assessments|2
5985271|NCT03529409|9575977|FG001|Post-treatment Assessment|Unable to contact for this assessment, but attended later assessments|4
5985272|NCT03529409|9575978|FG002|Post-treatment Assessment|Unable to contact for this assessment, but attended later assessments|0
5985273|NCT03529409|9575976|FG000|Follow-up Assessment|Death|1
5985274|NCT03529409|9575977|FG001|Follow-up Assessment|Death|0
5985275|NCT03529409|9575978|FG002|Follow-up Assessment|Death|0
5985276|NCT03529409|9575976|FG000|Follow-up Assessment|Withdrawal by Subject|0
5985277|NCT03529409|9575977|FG001|Follow-up Assessment|Withdrawal by Subject|1
5985278|NCT03529409|9575978|FG002|Follow-up Assessment|Withdrawal by Subject|0
5985279|NCT03516812|9575985|FG000|Overall Study|Adverse Event|4
5985280|NCT03516812|9575985|FG000|Overall Study|Lack of Efficacy|2
5985281|NCT03463577|9575999|FG000|Overall Study|Lost to Follow-up|238
5985282|NCT03463577|9576000|FG001|Overall Study|Lost to Follow-up|435
5985283|NCT03463577|9576001|FG002|Overall Study|Lost to Follow-up|0
5985284|NCT03463577|9576002|FG003|Overall Study|Lost to Follow-up|0
5985285|NCT03463577|9576003|FG004|Overall Study|Lost to Follow-up|0
5985286|NCT03463577|9576004|FG005|Overall Study|Lost to Follow-up|0
5985287|NCT03463577|9575999|FG000|Overall Study|With unknown pregnancy outcome|0
5985288|NCT03463577|9576000|FG001|Overall Study|With unknown pregnancy outcome|5
5985289|NCT03463577|9576001|FG002|Overall Study|With unknown pregnancy outcome|0
5985290|NCT03463577|9576002|FG003|Overall Study|With unknown pregnancy outcome|0
5985291|NCT03463577|9576003|FG004|Overall Study|With unknown pregnancy outcome|0
5985292|NCT03463577|9576004|FG005|Overall Study|With unknown pregnancy outcome|0
5985293|NCT03463577|9575999|FG000|Overall Study|Maternal death|2
5985294|NCT03463577|9576000|FG001|Overall Study|Maternal death|0
5985295|NCT03463577|9576001|FG002|Overall Study|Maternal death|0
5985296|NCT03463577|9576002|FG003|Overall Study|Maternal death|0
5985297|NCT03463577|9576003|FG004|Overall Study|Maternal death|0
5985298|NCT03463577|9576004|FG005|Overall Study|Maternal death|0
5985299|NCT03463577|9575999|FG000|Overall Study|Neonatal death|0
5985300|NCT03463577|9576000|FG001|Overall Study|Neonatal death|0
5985301|NCT03463577|9576001|FG002|Overall Study|Neonatal death|0
5985302|NCT03463577|9576002|FG003|Overall Study|Neonatal death|15
5985303|NCT03463577|9576003|FG004|Overall Study|Neonatal death|17
5985304|NCT03463577|9576004|FG005|Overall Study|Neonatal death|0
5985351|NCT03253627|9576047|FG001|Overall Study|Withdrawal by Subject|2
5985352|NCT03253627|9576046|FG000|Overall Study|Inability to complete MRI|1
5985353|NCT03253627|9576047|FG001|Overall Study|Inability to complete MRI|0
5985354|NCT03219333|9576055|FG000|Overall Study|Withdrawal by Subject|8
5985355|NCT03219333|9576056|FG001|Overall Study|Withdrawal by Subject|3
5985356|NCT03219333|9576055|FG000|Overall Study|Lost to Follow-up|1
5985357|NCT03219333|9576056|FG001|Overall Study|Lost to Follow-up|0
5985358|NCT03219333|9576055|FG000|Overall Study|Death|94
5985359|NCT03219333|9576056|FG001|Overall Study|Death|44
5985360|NCT03219333|9576055|FG000|Overall Study|Includes 4 participants who were enrolled and never received study treatment.|2
5985361|NCT03219333|9576056|FG001|Overall Study|Includes 4 participants who were enrolled and never received study treatment.|2
5985362|NCT03168555|9576066|FG000|Visit 1 (Pro-operative)|intercurrent disease, drop-out before visit 1|1
5985363|NCT03168555|9576066|FG000|Visit 2 (Post-operative)|Lost to Follow-up|1
5985364|NCT03168555|9576066|FG000|Visit 2 (Post-operative)|Adverse Event|1
5985365|NCT03168555|9576066|FG000|Visit 2 (Post-operative)|Withdrawal by Subject|2
5985366|NCT03135119|9576075|FG000|Overall Study|Lost to Follow-up|2
5985367|NCT03135119|9576076|FG001|Overall Study|Lost to Follow-up|0
5985368|NCT03135119|9576075|FG000|Overall Study|Physician Decision|1
5985369|NCT03135119|9576076|FG001|Overall Study|Physician Decision|1
5985370|NCT03135119|9576075|FG000|Overall Study|COVID-19 Shutdown|2
5985371|NCT03135119|9576076|FG001|Overall Study|COVID-19 Shutdown|2
5985372|NCT03128411|9576082|FG000|Treatment Phase|Adverse Event|21
5985373|NCT03128411|9576082|FG000|Treatment Phase|Physician Decision|1
5985374|NCT03128411|9576082|FG000|Treatment Phase|Other|2
5985375|NCT03128411|9576082|FG000|Long Term Follow-up Phase|Death|2
5985376|NCT03097328|9576086|FG000|Overall Study|Still on Therapy|2
5985377|NCT03097328|9576086|FG000|Overall Study|Progressive Disease|29
5985378|NCT03097328|9576086|FG000|Overall Study|Adverse Event|4
5985379|NCT03097328|9576086|FG000|Overall Study|Withdrawal by Subject|1
5985380|NCT03097328|9576086|FG000|Overall Study|Physician Decision|1
5985381|NCT03097328|9576086|FG000|Overall Study|Patient Decision|1
5985382|NCT03097328|9576086|FG000|Overall Study|Ineligible for Study Drug|1
6044516|NCT00395733|9643463|FG001|Period 2|Technical problems|0
6044517|NCT00395746|9643472|FG000|Overall Study|Adverse Event|5
6044518|NCT00395746|9643473|FG001|Overall Study|Adverse Event|2
6044519|NCT00395746|9643474|FG002|Overall Study|Adverse Event|2
6044520|NCT00395746|9643472|FG000|Overall Study|Protocol Violation|0
6044521|NCT00395746|9643473|FG001|Overall Study|Protocol Violation|1
6044522|NCT00395746|9643474|FG002|Overall Study|Protocol Violation|0
6044523|NCT00395746|9643472|FG000|Overall Study|Lack of Efficacy|2
6044524|NCT00395746|9643473|FG001|Overall Study|Lack of Efficacy|0
6044525|NCT00395746|9643474|FG002|Overall Study|Lack of Efficacy|17
6044526|NCT00395746|9643472|FG000|Overall Study|Hypoglycaemia|2
6044527|NCT00395746|9643473|FG001|Overall Study|Hypoglycaemia|1
6044528|NCT00395746|9643474|FG002|Overall Study|Hypoglycaemia|0
6044529|NCT00395746|9643472|FG000|Overall Study|Subject decision|0
6044530|NCT00395746|9643473|FG001|Overall Study|Subject decision|0
6044531|NCT00395746|9643474|FG002|Overall Study|Subject decision|1
6044532|NCT00395746|9643472|FG000|Overall Study|Withdrawal of consent|0
6044533|NCT00395746|9643473|FG001|Overall Study|Withdrawal of consent|0
6044534|NCT00395746|9643474|FG002|Overall Study|Withdrawal of consent|1
6044535|NCT00395746|9643472|FG000|Overall Study|Difficultulty in use of device|0
6044536|NCT00395746|9643473|FG001|Overall Study|Difficultulty in use of device|0
6044537|NCT00395746|9643474|FG002|Overall Study|Difficultulty in use of device|1
6044538|NCT00395746|9643472|FG000|Overall Study|Unable to visit site on schedule|1
6044539|NCT00395746|9643473|FG001|Overall Study|Unable to visit site on schedule|0
6044540|NCT00395746|9643474|FG002|Overall Study|Unable to visit site on schedule|0
6044541|NCT00395850|9643486|FG000|Pre-randomization Baseline/Induction|noncompliance (missed med/urine)|6
6044542|NCT00395850|9643487|FG001|Pre-randomization Baseline/Induction|noncompliance (missed med/urine)|0
6044543|NCT00395850|9643488|FG002|Pre-randomization Baseline/Induction|noncompliance (missed med/urine)|0
6044544|NCT00395850|9643489|FG003|Pre-randomization Baseline/Induction|noncompliance (missed med/urine)|0
6044545|NCT00395850|9643486|FG000|Pre-randomization Baseline/Induction|Withdrawal by Subject|4
6044546|NCT00395850|9643487|FG001|Pre-randomization Baseline/Induction|Withdrawal by Subject|0
6044547|NCT00395850|9643488|FG002|Pre-randomization Baseline/Induction|Withdrawal by Subject|0
6044548|NCT00395850|9643489|FG003|Pre-randomization Baseline/Induction|Withdrawal by Subject|0
6044549|NCT00395850|9643486|FG000|Pre-randomization Baseline/Induction|Inconsistent attendance|1
6044550|NCT00395850|9643487|FG001|Pre-randomization Baseline/Induction|Inconsistent attendance|0
6044551|NCT00395850|9643488|FG002|Pre-randomization Baseline/Induction|Inconsistent attendance|0
6044552|NCT00395850|9643489|FG003|Pre-randomization Baseline/Induction|Inconsistent attendance|0
6044553|NCT00395850|9643486|FG000|Randomization to Disulfiram/ Pre-admin|noncompliance - missed med/urines|2
6044554|NCT00395850|9643487|FG001|Randomization to Disulfiram/ Pre-admin|noncompliance - missed med/urines|2
6044555|NCT00395850|9643488|FG002|Randomization to Disulfiram/ Pre-admin|noncompliance - missed med/urines|6
6044556|NCT00395850|9643489|FG003|Randomization to Disulfiram/ Pre-admin|noncompliance - missed med/urines|4
6044557|NCT00395850|9643486|FG000|Randomization to Disulfiram/ Pre-admin|noncompliance with alcohol use|1
6044558|NCT00395850|9643487|FG001|Randomization to Disulfiram/ Pre-admin|noncompliance with alcohol use|0
6044559|NCT00395850|9643488|FG002|Randomization to Disulfiram/ Pre-admin|noncompliance with alcohol use|0
6044560|NCT00395850|9643489|FG003|Randomization to Disulfiram/ Pre-admin|noncompliance with alcohol use|0
6044561|NCT00395850|9643486|FG000|Randomization to Disulfiram/ Pre-admin|suicidal ideation|1
6044562|NCT00395850|9643487|FG001|Randomization to Disulfiram/ Pre-admin|suicidal ideation|0
6044563|NCT00395850|9643488|FG002|Randomization to Disulfiram/ Pre-admin|suicidal ideation|0
6044564|NCT00395850|9643489|FG003|Randomization to Disulfiram/ Pre-admin|suicidal ideation|0
6044565|NCT00395850|9643486|FG000|Randomization to Disulfiram/ Pre-admin|work schedule conflict|1
6044566|NCT00395850|9643487|FG001|Randomization to Disulfiram/ Pre-admin|work schedule conflict|0
6044567|NCT00395850|9643488|FG002|Randomization to Disulfiram/ Pre-admin|work schedule conflict|0
6044568|NCT00395850|9643489|FG003|Randomization to Disulfiram/ Pre-admin|work schedule conflict|0
6044569|NCT00395863|9643501|FG000|Overall Study|Patients did not complete both exams|2
6044570|NCT00395863|9643502|FG001|Overall Study|Patients did not complete both exams|3
6044571|NCT00395967|9643520|FG000|Treatment Period|Failed Mobilization|1
6044572|NCT00395967|9643520|FG000|Follow-up Period|Death|1
6044573|NCT00395967|9643520|FG000|Follow-up Period|Lost to Follow-up|1
6044574|NCT00396084|9643567|FG000|Overall Study|Adverse Event|0
6044575|NCT00396084|9643568|FG001|Overall Study|Adverse Event|0
6044576|NCT00396084|9643569|FG002|Overall Study|Adverse Event|0
6044577|NCT00396084|9643570|FG003|Overall Study|Adverse Event|0
6044578|NCT00396084|9643571|FG004|Overall Study|Adverse Event|1
6044579|NCT00396084|9643572|FG005|Overall Study|Adverse Event|2
6044580|NCT00396084|9643567|FG000|Overall Study|Withdrawal by Subject|0
6044581|NCT00396084|9643568|FG001|Overall Study|Withdrawal by Subject|0
6044582|NCT00396084|9643569|FG002|Overall Study|Withdrawal by Subject|0
6044583|NCT00396084|9643570|FG003|Overall Study|Withdrawal by Subject|1
6044584|NCT00396084|9643571|FG004|Overall Study|Withdrawal by Subject|0
6044585|NCT00396084|9643572|FG005|Overall Study|Withdrawal by Subject|0
6044586|NCT00396097|9643592|FG000|Overall Study|Withdrawal by Subject|17
6044587|NCT00396097|9643593|FG001|Overall Study|Withdrawal by Subject|17
6044588|NCT00396097|9643592|FG000|Overall Study|Lost to Follow-up|4
6044589|NCT00396097|9643593|FG001|Overall Study|Lost to Follow-up|9
5985383|NCT03068715|9576105|FG000|Overall Study|No longer met inclusion criteria|1
5985384|NCT03068715|9576106|FG001|Overall Study|No longer met inclusion criteria|0
5985385|NCT02981472|9576116|FG000|Pre-Treatment Period|Participant withdrew consent|2
5985386|NCT02981472|9576117|FG001|Pre-Treatment Period|Participant withdrew consent|1
5985387|NCT02981472|9576116|FG000|Pre-Treatment Period|Participant no longer meets study criteria|1
5985388|NCT02981472|9576117|FG001|Pre-Treatment Period|Participant no longer meets study criteria|0
5985389|NCT02981472|9576116|FG000|Treatment Period|Adverse Event|6
5985390|NCT02981472|9576117|FG001|Treatment Period|Adverse Event|1
5985391|NCT02981472|9576116|FG000|Treatment Period|Participant withdrew consent|1
5985392|NCT02981472|9576117|FG001|Treatment Period|Participant withdrew consent|0
5985393|NCT02981472|9576116|FG000|Treatment Period|Lost to Follow-up|0
5985394|NCT02981472|9576117|FG001|Treatment Period|Lost to Follow-up|1
5985395|NCT02961374|9576129|FG000|Overall Study|Adverse Event|4
5985396|NCT02853760|9576142|FG000|Washout (1 Week)|acute illness (not connected with the study)|0
5985397|NCT02853760|9576143|FG001|Washout (1 Week)|acute illness (not connected with the study)|0
5985398|NCT02853760|9576144|FG002|Washout (1 Week)|acute illness (not connected with the study)|1
5985399|NCT02853760|9576145|FG003|Washout (1 Week)|acute illness (not connected with the study)|2
5985400|NCT02853760|9576146|FG004|Washout (1 Week)|acute illness (not connected with the study)|0
5985401|NCT02853760|9576147|FG005|Washout (1 Week)|acute illness (not connected with the study)|2
5985402|NCT02789657|9576159|FG000|Overall Study|Withdrawal by Subject|2
5985403|NCT02789657|9576160|FG001|Overall Study|Withdrawal by Subject|0
5985404|NCT02789657|9576161|FG002|Overall Study|Withdrawal by Subject|0
5985405|NCT02789657|9576162|FG003|Overall Study|Withdrawal by Subject|0
5985406|NCT02743871|9576185|FG000|Overall Study|Lost to Follow-up|0
5985407|NCT02743871|9576186|FG001|Overall Study|Lost to Follow-up|0
5985408|NCT02743871|9576187|FG002|Overall Study|Lost to Follow-up|0
5985409|NCT02743871|9576188|FG003|Overall Study|Lost to Follow-up|1
5985410|NCT02743871|9576189|FG004|Overall Study|Lost to Follow-up|0
5985411|NCT02743871|9576190|FG005|Overall Study|Lost to Follow-up|0
5985412|NCT02743871|9576191|FG006|Overall Study|Lost to Follow-up|1
5985413|NCT02743871|9576192|FG007|Overall Study|Lost to Follow-up|0
5985414|NCT02743871|9576193|FG008|Overall Study|Lost to Follow-up|0
5985415|NCT02743871|9576194|FG009|Overall Study|Lost to Follow-up|0
5985416|NCT02743871|9576195|FG010|Overall Study|Lost to Follow-up|0
5985417|NCT02743871|9576196|FG011|Overall Study|Lost to Follow-up|2
5985418|NCT02743871|9576197|FG012|Overall Study|Lost to Follow-up|0
5985419|NCT02743871|9576198|FG013|Overall Study|Lost to Follow-up|0
5985420|NCT02743871|9576185|FG000|Overall Study|Withdrawal by Subject|0
5985421|NCT02743871|9576186|FG001|Overall Study|Withdrawal by Subject|0
5985422|NCT02743871|9576187|FG002|Overall Study|Withdrawal by Subject|0
5985423|NCT02743871|9576188|FG003|Overall Study|Withdrawal by Subject|0
5985424|NCT02743871|9576189|FG004|Overall Study|Withdrawal by Subject|0
5985425|NCT02743871|9576190|FG005|Overall Study|Withdrawal by Subject|0
5985426|NCT02743871|9576191|FG006|Overall Study|Withdrawal by Subject|0
5985427|NCT02743871|9576192|FG007|Overall Study|Withdrawal by Subject|0
5985428|NCT02743871|9576193|FG008|Overall Study|Withdrawal by Subject|0
5985429|NCT02743871|9576194|FG009|Overall Study|Withdrawal by Subject|0
5985430|NCT02743871|9576195|FG010|Overall Study|Withdrawal by Subject|1
5985431|NCT02743871|9576196|FG011|Overall Study|Withdrawal by Subject|0
5985432|NCT02743871|9576197|FG012|Overall Study|Withdrawal by Subject|12
5985433|NCT02743871|9576198|FG013|Overall Study|Withdrawal by Subject|6
5985434|NCT02743871|9576185|FG000|Overall Study|Adverse Event|1
5985435|NCT02743871|9576186|FG001|Overall Study|Adverse Event|0
5985436|NCT02743871|9576187|FG002|Overall Study|Adverse Event|0
5985437|NCT02743871|9576188|FG003|Overall Study|Adverse Event|0
5985438|NCT02743871|9576189|FG004|Overall Study|Adverse Event|0
5985439|NCT02743871|9576190|FG005|Overall Study|Adverse Event|0
5985440|NCT02743871|9576191|FG006|Overall Study|Adverse Event|0
5985441|NCT02743871|9576192|FG007|Overall Study|Adverse Event|0
5985442|NCT02743871|9576193|FG008|Overall Study|Adverse Event|0
5985443|NCT02743871|9576194|FG009|Overall Study|Adverse Event|0
5985444|NCT02743871|9576195|FG010|Overall Study|Adverse Event|0
5985445|NCT02743871|9576196|FG011|Overall Study|Adverse Event|0
5985446|NCT02743871|9576197|FG012|Overall Study|Adverse Event|0
5985447|NCT02743871|9576198|FG013|Overall Study|Adverse Event|0
5985448|NCT02743871|9576185|FG000|Overall Study|Other|0
5985449|NCT02743871|9576186|FG001|Overall Study|Other|0
5985450|NCT02743871|9576187|FG002|Overall Study|Other|0
5985451|NCT02743871|9576188|FG003|Overall Study|Other|0
5985452|NCT02743871|9576189|FG004|Overall Study|Other|0
5985453|NCT02743871|9576190|FG005|Overall Study|Other|0
5985454|NCT02743871|9576191|FG006|Overall Study|Other|0
5985455|NCT02743871|9576192|FG007|Overall Study|Other|0
5985456|NCT02743871|9576193|FG008|Overall Study|Other|0
5985457|NCT02743871|9576194|FG009|Overall Study|Other|0
5985458|NCT02743871|9576195|FG010|Overall Study|Other|0
5985459|NCT02743871|9576196|FG011|Overall Study|Other|1
5985460|NCT02743871|9576197|FG012|Overall Study|Other|1
5985461|NCT02743871|9576198|FG013|Overall Study|Other|1
5985462|NCT02743871|9576185|FG000|Overall Study|Protocol Violation|0
5985463|NCT02743871|9576186|FG001|Overall Study|Protocol Violation|0
5985464|NCT02743871|9576187|FG002|Overall Study|Protocol Violation|0
5985465|NCT02743871|9576188|FG003|Overall Study|Protocol Violation|0
5985466|NCT02743871|9576189|FG004|Overall Study|Protocol Violation|0
5985467|NCT02743871|9576190|FG005|Overall Study|Protocol Violation|0
5985468|NCT02743871|9576191|FG006|Overall Study|Protocol Violation|0
5985469|NCT02743871|9576192|FG007|Overall Study|Protocol Violation|0
5985470|NCT02743871|9576193|FG008|Overall Study|Protocol Violation|0
5985471|NCT02743871|9576194|FG009|Overall Study|Protocol Violation|0
5985472|NCT02743871|9576195|FG010|Overall Study|Protocol Violation|0
5985473|NCT02743871|9576196|FG011|Overall Study|Protocol Violation|0
5985474|NCT02743871|9576197|FG012|Overall Study|Protocol Violation|2
5985475|NCT02743871|9576198|FG013|Overall Study|Protocol Violation|0
6044590|NCT00396097|9643592|FG000|Overall Study|Other|3
6044591|NCT00396097|9643593|FG001|Overall Study|Other|5
6044592|NCT00396097|9643592|FG000|Overall Study|Protocol Violation|0
6044593|NCT00396097|9643593|FG001|Overall Study|Protocol Violation|6
6044594|NCT00396097|9643592|FG000|Overall Study|Adverse Event|1
6044595|NCT00396097|9643593|FG001|Overall Study|Adverse Event|5
6044596|NCT00396097|9643592|FG000|Overall Study|Insufficient Clinical Response|1
6044597|NCT00396097|9643593|FG001|Overall Study|Insufficient Clinical Response|4
6044598|NCT00396136|9643603|FG000|Overall Study|Death|43
6044599|NCT00396136|9643603|FG000|Overall Study|Withdrawal by Subject|59
6044600|NCT00396136|9643603|FG000|Overall Study|Lost to Follow-up|15
6044601|NCT00396136|9643603|FG000|Overall Study|Study device explanted|8
6044602|NCT00396162|9643609|FG000|Overall Study|Withdrawal by Subject|2
6044603|NCT00396162|9643610|FG001|Overall Study|Withdrawal by Subject|3
6044604|NCT00396253|9643625|FG000|Overall Study|Protocol Violation|1
6044605|NCT00396253|9643625|FG000|Overall Study|Withdrawal by Subject|7
6044606|NCT00396253|9643625|FG000|Overall Study|Death|3
6044607|NCT00396253|9643625|FG000|Overall Study|Physician Decision|1
6044608|NCT00396253|9643625|FG000|Overall Study|Change in eligibility status|1
6044609|NCT00396279|9643642|FG000|Overall Study|Ongoing in study|26
6044610|NCT00396279|9643642|FG000|Overall Study|Disease progression|2
6044611|NCT00396279|9643642|FG000|Overall Study|Withdrawal by Subject|1
6044612|NCT00396279|9643642|FG000|Overall Study|Physician Decision|1
6044613|NCT00396318|9643655|FG000|At Least One Dose of Tenecteplase (MITT)|Subject withdrew consent|5
6044614|NCT00396331|9643663|FG000|Overall Study|Failed to mobilize - no transplant|8
6044615|NCT00396331|9643663|FG000|Overall Study|Did not go on to transplant|5
6044616|NCT00396331|9643663|FG000|Overall Study|Lost to Follow-up|3
6044617|NCT00396331|9643663|FG000|Overall Study|Death|16
6044618|NCT00396383|9643675|FG000|Overall Study|Death|2
6044619|NCT00396383|9643675|FG000|Overall Study|Lost to Follow-up|1
6044620|NCT00396409|9643681|FG000|Period 1 - 2007|Adverse Event|0
6044621|NCT00396409|9643682|FG001|Period 1 - 2007|Adverse Event|1
6044622|NCT00396409|9643681|FG000|Period 1 - 2007|Lack of Efficacy|0
6044623|NCT00396409|9643682|FG001|Period 1 - 2007|Lack of Efficacy|1
6044624|NCT00396409|9643681|FG000|Period 1 - 2007|Withdrawal by Subject|1
6044625|NCT00396409|9643682|FG001|Period 1 - 2007|Withdrawal by Subject|1
6044626|NCT00396409|9643681|FG000|Period 1 - 2007|Lost to Follow-up|2
6044627|NCT00396409|9643682|FG001|Period 1 - 2007|Lost to Follow-up|3
6044628|NCT00396409|9643681|FG000|Between Period 1 and Period 2|Withdrawal by Subject|3
6044629|NCT00396409|9643682|FG001|Between Period 1 and Period 2|Withdrawal by Subject|2
6044630|NCT00396409|9643681|FG000|Period 2 - 2008|Protocol Violation|1
6044631|NCT00396409|9643682|FG001|Period 2 - 2008|Protocol Violation|0
6044632|NCT00396409|9643681|FG000|Period 2 - 2008|Withdrawal by Subject|3
6044633|NCT00396409|9643682|FG001|Period 2 - 2008|Withdrawal by Subject|1
6044634|NCT00396409|9643681|FG000|Period 2 - 2008|Lost to Follow-up|3
6044635|NCT00396409|9643682|FG001|Period 2 - 2008|Lost to Follow-up|1
6044636|NCT00396565|9643693|FG000|Overall Study|Physician Decision|3
6044637|NCT00396565|9643694|FG001|Overall Study|Physician Decision|1
6044638|NCT00396565|9643695|FG002|Overall Study|Physician Decision|2
6044639|NCT00396565|9643693|FG000|Overall Study|Adverse Event|5
6044640|NCT00396565|9643694|FG001|Overall Study|Adverse Event|13
6044641|NCT00396565|9643695|FG002|Overall Study|Adverse Event|3
6044642|NCT00396565|9643693|FG000|Overall Study|Withdrawal by Subject|8
6044643|NCT00396565|9643694|FG001|Overall Study|Withdrawal by Subject|13
6044644|NCT00396565|9643695|FG002|Overall Study|Withdrawal by Subject|1
6044645|NCT00396565|9643693|FG000|Overall Study|Lack of Efficacy|32
6044646|NCT00396565|9643694|FG001|Overall Study|Lack of Efficacy|64
6044647|NCT00396565|9643695|FG002|Overall Study|Lack of Efficacy|11
6044648|NCT00396591|9643703|FG000|Overall Study|Disease Progression|13
6044649|NCT00396591|9643703|FG000|Overall Study|Adverse Event|2
6044650|NCT00396591|9643703|FG000|Overall Study|Participant request|1
6044651|NCT00396630|9643709|FG000|Overall Study|Lost to Follow-up|1
6044652|NCT00396630|9643710|FG001|Overall Study|Lost to Follow-up|1
6044653|NCT00396630|9643709|FG000|Overall Study|Withdrawal by Subject|1
6044654|NCT00396630|9643710|FG001|Overall Study|Withdrawal by Subject|1
6044655|NCT00396630|9643709|FG000|Overall Study|Not vaccinated at Visit 3|3
6044656|NCT00396630|9643710|FG001|Overall Study|Not vaccinated at Visit 3|3
6044657|NCT00396656|9643717|FG000|First Treatment Period|Withdrawal by Subject|0
6044658|NCT00396656|9643718|FG001|First Treatment Period|Withdrawal by Subject|2
6044659|NCT00396656|9643717|FG000|Second Treatment Period|Adverse Event|0
6044660|NCT00396656|9643718|FG001|Second Treatment Period|Adverse Event|1
6044661|NCT00396812|9643724|FG000|Overall Study|Physician Decision|1
6044662|NCT00396877|9643730|FG000|Overall Study|Lost to Follow-up|2
6044663|NCT00396877|9643731|FG001|Overall Study|Lost to Follow-up|1
6049063|NCT00421148|9648256|FG007|Overall Study|Withdrawal by Subject|0
5985476|NCT02614261|9576260|FG000|Double-Blind Treatment Phase|Adverse Event|7
5985477|NCT02614261|9576261|FG001|Double-Blind Treatment Phase|Adverse Event|3
5985478|NCT02614261|9576262|FG002|Double-Blind Treatment Phase|Adverse Event|2
5985479|NCT02614261|9576263|FG003|Double-Blind Treatment Phase|Adverse Event|0
5985480|NCT02614261|9576260|FG000|Double-Blind Treatment Phase|Lack of Efficacy|4
5985481|NCT02614261|9576261|FG001|Double-Blind Treatment Phase|Lack of Efficacy|0
5985482|NCT02614261|9576262|FG002|Double-Blind Treatment Phase|Lack of Efficacy|0
5985483|NCT02614261|9576263|FG003|Double-Blind Treatment Phase|Lack of Efficacy|0
5985484|NCT02614261|9576260|FG000|Double-Blind Treatment Phase|Lost to Follow-up|9
5985485|NCT02614261|9576261|FG001|Double-Blind Treatment Phase|Lost to Follow-up|4
5985486|NCT02614261|9576262|FG002|Double-Blind Treatment Phase|Lost to Follow-up|1
5985487|NCT02614261|9576263|FG003|Double-Blind Treatment Phase|Lost to Follow-up|0
5985488|NCT02614261|9576260|FG000|Double-Blind Treatment Phase|Physician Decision|2
5985489|NCT02614261|9576261|FG001|Double-Blind Treatment Phase|Physician Decision|1
5985490|NCT02614261|9576262|FG002|Double-Blind Treatment Phase|Physician Decision|1
5985491|NCT02614261|9576263|FG003|Double-Blind Treatment Phase|Physician Decision|0
5985492|NCT02614261|9576260|FG000|Double-Blind Treatment Phase|Pregnancy|2
5985493|NCT02614261|9576261|FG001|Double-Blind Treatment Phase|Pregnancy|2
5985494|NCT02614261|9576262|FG002|Double-Blind Treatment Phase|Pregnancy|0
5985495|NCT02614261|9576263|FG003|Double-Blind Treatment Phase|Pregnancy|0
5985496|NCT02614261|9576260|FG000|Double-Blind Treatment Phase|Protocol Violation|6
5985497|NCT02614261|9576261|FG001|Double-Blind Treatment Phase|Protocol Violation|1
5985498|NCT02614261|9576262|FG002|Double-Blind Treatment Phase|Protocol Violation|0
5985499|NCT02614261|9576263|FG003|Double-Blind Treatment Phase|Protocol Violation|0
5985500|NCT02614261|9576260|FG000|Double-Blind Treatment Phase|Screen failure|0
5985501|NCT02614261|9576261|FG001|Double-Blind Treatment Phase|Screen failure|1
5985502|NCT02614261|9576262|FG002|Double-Blind Treatment Phase|Screen failure|2
5985503|NCT02614261|9576263|FG003|Double-Blind Treatment Phase|Screen failure|0
5985504|NCT02614261|9576260|FG000|Double-Blind Treatment Phase|Withdrawal by Subject|20
5985505|NCT02614261|9576261|FG001|Double-Blind Treatment Phase|Withdrawal by Subject|5
5985506|NCT02614261|9576262|FG002|Double-Blind Treatment Phase|Withdrawal by Subject|7
5985507|NCT02614261|9576263|FG003|Double-Blind Treatment Phase|Withdrawal by Subject|0
5985508|NCT02614261|9576260|FG000|Open-Label Extension Phase|Adverse Event|23
5985509|NCT02614261|9576261|FG001|Open-Label Extension Phase|Adverse Event|12
5985510|NCT02614261|9576262|FG002|Open-Label Extension Phase|Adverse Event|11
5985511|NCT02614261|9576263|FG003|Open-Label Extension Phase|Adverse Event|0
5985512|NCT02614261|9576260|FG000|Open-Label Extension Phase|Lack of Efficacy|14
5985513|NCT02614261|9576261|FG001|Open-Label Extension Phase|Lack of Efficacy|12
5985514|NCT02614261|9576262|FG002|Open-Label Extension Phase|Lack of Efficacy|14
5985515|NCT02614261|9576263|FG003|Open-Label Extension Phase|Lack of Efficacy|0
5985516|NCT02614261|9576260|FG000|Open-Label Extension Phase|Lost to Follow-up|15
5985517|NCT02614261|9576261|FG001|Open-Label Extension Phase|Lost to Follow-up|7
5985518|NCT02614261|9576262|FG002|Open-Label Extension Phase|Lost to Follow-up|9
5985519|NCT02614261|9576263|FG003|Open-Label Extension Phase|Lost to Follow-up|0
5985520|NCT02614261|9576260|FG000|Open-Label Extension Phase|Physician Decision|2
5985521|NCT02614261|9576261|FG001|Open-Label Extension Phase|Physician Decision|0
5985522|NCT02614261|9576262|FG002|Open-Label Extension Phase|Physician Decision|0
5985523|NCT02614261|9576263|FG003|Open-Label Extension Phase|Physician Decision|0
5985524|NCT02614261|9576260|FG000|Open-Label Extension Phase|Pregnancy|1
5985525|NCT02614261|9576261|FG001|Open-Label Extension Phase|Pregnancy|2
5985526|NCT02614261|9576262|FG002|Open-Label Extension Phase|Pregnancy|1
5985527|NCT02614261|9576263|FG003|Open-Label Extension Phase|Pregnancy|0
5985528|NCT02614261|9576260|FG000|Open-Label Extension Phase|Protocol Violation|3
5985529|NCT02614261|9576261|FG001|Open-Label Extension Phase|Protocol Violation|4
5985530|NCT02614261|9576262|FG002|Open-Label Extension Phase|Protocol Violation|1
5985531|NCT02614261|9576263|FG003|Open-Label Extension Phase|Protocol Violation|0
5985532|NCT02614261|9576260|FG000|Open-Label Extension Phase|Withdrawal by Subject|30
5985533|NCT02614261|9576261|FG001|Open-Label Extension Phase|Withdrawal by Subject|18
5985534|NCT02614261|9576262|FG002|Open-Label Extension Phase|Withdrawal by Subject|18
5985535|NCT02614261|9576263|FG003|Open-Label Extension Phase|Withdrawal by Subject|0
5985536|NCT02614261|9576260|FG000|Follow-up Phase|Adverse Event|2
5985537|NCT02614261|9576261|FG001|Follow-up Phase|Adverse Event|0
5985538|NCT02614261|9576262|FG002|Follow-up Phase|Adverse Event|1
5985539|NCT02614261|9576263|FG003|Follow-up Phase|Adverse Event|0
5985540|NCT02614261|9576260|FG000|Follow-up Phase|Lost to Follow-up|12
5985541|NCT02614261|9576261|FG001|Follow-up Phase|Lost to Follow-up|5
5985542|NCT02614261|9576262|FG002|Follow-up Phase|Lost to Follow-up|2
5985543|NCT02614261|9576263|FG003|Follow-up Phase|Lost to Follow-up|0
5985544|NCT02614261|9576260|FG000|Follow-up Phase|Physician Decision|5
5985545|NCT02614261|9576261|FG001|Follow-up Phase|Physician Decision|1
5985546|NCT02614261|9576262|FG002|Follow-up Phase|Physician Decision|0
5985547|NCT02614261|9576263|FG003|Follow-up Phase|Physician Decision|0
5985548|NCT02614261|9576260|FG000|Follow-up Phase|Pregnancy|0
5985549|NCT02614261|9576261|FG001|Follow-up Phase|Pregnancy|1
5985550|NCT02614261|9576262|FG002|Follow-up Phase|Pregnancy|0
5985551|NCT02614261|9576263|FG003|Follow-up Phase|Pregnancy|0
5985552|NCT02614261|9576260|FG000|Follow-up Phase|Protocol Violation|1
5985553|NCT02614261|9576261|FG001|Follow-up Phase|Protocol Violation|0
5985554|NCT02614261|9576262|FG002|Follow-up Phase|Protocol Violation|0
5985555|NCT02614261|9576263|FG003|Follow-up Phase|Protocol Violation|0
5985556|NCT02614261|9576260|FG000|Follow-up Phase|Withdrawal by Subject|12
5985557|NCT02614261|9576261|FG001|Follow-up Phase|Withdrawal by Subject|4
5985558|NCT02614261|9576262|FG002|Follow-up Phase|Withdrawal by Subject|11
5985559|NCT02614261|9576263|FG003|Follow-up Phase|Withdrawal by Subject|0
5985560|NCT02614261|9576260|FG000|Israel Addendum|Withdrawal by Subject|0
5985561|NCT02614261|9576261|FG001|Israel Addendum|Withdrawal by Subject|0
5985562|NCT02614261|9576262|FG002|Israel Addendum|Withdrawal by Subject|0
5985563|NCT02614261|9576263|FG003|Israel Addendum|Withdrawal by Subject|4
5985564|NCT02527434|9576292|FG000|Overall Study|Lost to Follow-up|2
5985565|NCT02527434|9576293|FG001|Overall Study|Lost to Follow-up|2
5985566|NCT02527434|9576294|FG002|Overall Study|Lost to Follow-up|0
5985567|NCT02527434|9576292|FG000|Overall Study|Death|19
5985568|NCT02527434|9576293|FG001|Overall Study|Death|6
5985569|NCT02527434|9576294|FG002|Overall Study|Death|17
5985570|NCT02527434|9576292|FG000|Overall Study|Withdrawal by Subject|5
5985571|NCT02527434|9576293|FG001|Overall Study|Withdrawal by Subject|3
5985572|NCT02527434|9576294|FG002|Overall Study|Withdrawal by Subject|3
5985573|NCT02527434|9576292|FG000|Overall Study|Reason Not Specified|1
5985574|NCT02527434|9576293|FG001|Overall Study|Reason Not Specified|0
5985575|NCT02527434|9576294|FG002|Overall Study|Reason Not Specified|0
5985576|NCT02527434|9576292|FG000|Overall Study|Site closure|1
5985577|NCT02527434|9576293|FG001|Overall Study|Site closure|0
5985578|NCT02527434|9576294|FG002|Overall Study|Site closure|0
5985579|NCT02513667|9576314|FG000|Overall Study|Withdrawal by Subject|0
5985580|NCT02513667|9576315|FG001|Overall Study|Withdrawal by Subject|1
5985581|NCT02446600|9576325|FG000|Overall Study|Never treated|20
5985582|NCT02446600|9576326|FG001|Overall Study|Never treated|2
5985583|NCT02446600|9576327|FG002|Overall Study|Never treated|6
5985584|NCT02446600|9576328|FG003|Overall Study|Never treated|0
5985585|NCT02446600|9576325|FG000|Overall Study|Withdrawal by Subject|19
5985586|NCT02446600|9576326|FG001|Overall Study|Withdrawal by Subject|5
5985587|NCT02446600|9576327|FG002|Overall Study|Withdrawal by Subject|17
5985588|NCT02446600|9576328|FG003|Overall Study|Withdrawal by Subject|0
5985589|NCT02446600|9576325|FG000|Overall Study|Ineligible|1
5985590|NCT02446600|9576326|FG001|Overall Study|Ineligible|4
5985591|NCT02446600|9576327|FG002|Overall Study|Ineligible|4
5985592|NCT02446600|9576328|FG003|Overall Study|Ineligible|1
5985593|NCT02446600|9576325|FG000|Overall Study|Duplicate Enrollment|0
5985594|NCT02446600|9576326|FG001|Overall Study|Duplicate Enrollment|1
5985595|NCT02446600|9576327|FG002|Overall Study|Duplicate Enrollment|0
5985596|NCT02446600|9576328|FG003|Overall Study|Duplicate Enrollment|0
5985597|NCT02422615|9576340|FG000|Overall Study|Progressive disease|193
5985598|NCT02422615|9576341|FG001|Overall Study|Progressive disease|142
5985599|NCT02422615|9576340|FG000|Overall Study|Adverse Event|41
5985600|NCT02422615|9576341|FG001|Overall Study|Adverse Event|10
5985601|NCT02422615|9576340|FG000|Overall Study|Physician Decision|22
5985602|NCT02422615|9576341|FG001|Overall Study|Physician Decision|7
5985603|NCT02422615|9576340|FG000|Overall Study|Subject/guardian decision|21
5985604|NCT02422615|9576341|FG001|Overall Study|Subject/guardian decision|5
5985605|NCT02422615|9576340|FG000|Overall Study|Death|2
5985606|NCT02422615|9576341|FG001|Overall Study|Death|0
5985607|NCT02422615|9576340|FG000|Overall Study|Protocol Violation|1
5985608|NCT02422615|9576341|FG001|Overall Study|Protocol Violation|1
5985609|NCT02422615|9576340|FG000|Overall Study|Technical problems|0
5985610|NCT02422615|9576341|FG001|Overall Study|Technical problems|1
5985611|NCT02415556|9576351|FG000|Overall Study|Adverse Event|3
5985612|NCT02415556|9576352|FG001|Overall Study|Adverse Event|4
5985613|NCT02415556|9576353|FG002|Overall Study|Adverse Event|2
5985614|NCT02415556|9576354|FG003|Overall Study|Adverse Event|4
5985615|NCT02415556|9576351|FG000|Overall Study|Lost to Follow-up|4
5985616|NCT02415556|9576352|FG001|Overall Study|Lost to Follow-up|5
5985617|NCT02415556|9576353|FG002|Overall Study|Lost to Follow-up|4
5985618|NCT02415556|9576354|FG003|Overall Study|Lost to Follow-up|1
5985619|NCT02415556|9576351|FG000|Overall Study|Withdrawal by Subject|13
5985620|NCT02415556|9576352|FG001|Overall Study|Withdrawal by Subject|4
5985621|NCT02415556|9576353|FG002|Overall Study|Withdrawal by Subject|14
5985622|NCT02415556|9576354|FG003|Overall Study|Withdrawal by Subject|12
5985623|NCT02415556|9576351|FG000|Overall Study|Physician Decision|1
5985624|NCT02415556|9576352|FG001|Overall Study|Physician Decision|3
5985625|NCT02415556|9576353|FG002|Overall Study|Physician Decision|1
5985626|NCT02415556|9576354|FG003|Overall Study|Physician Decision|2
5985627|NCT02415556|9576351|FG000|Overall Study|Censored - study completion|4
5985628|NCT02415556|9576352|FG001|Overall Study|Censored - study completion|5
5985629|NCT02415556|9576353|FG002|Overall Study|Censored - study completion|1
5985630|NCT02415556|9576354|FG003|Overall Study|Censored - study completion|0
5985631|NCT02415556|9576351|FG000|Overall Study|Family-related issues|0
5985632|NCT02415556|9576352|FG001|Overall Study|Family-related issues|0
5985633|NCT02415556|9576353|FG002|Overall Study|Family-related issues|0
5985634|NCT02415556|9576354|FG003|Overall Study|Family-related issues|1
5985635|NCT02386839|9576380|FG000|Overall Study|Death|1
5985636|NCT02386839|9576381|FG001|Overall Study|Death|0
5985637|NCT02386839|9576380|FG000|Overall Study|Withdrawal by Subject|9
5985638|NCT02386839|9576381|FG001|Overall Study|Withdrawal by Subject|10
5985639|NCT02386839|9576380|FG000|Overall Study|Lost to Follow-up|4
5985640|NCT02386839|9576381|FG001|Overall Study|Lost to Follow-up|4
5985641|NCT02386839|9576380|FG000|Overall Study|Other (Site Terminated by Sponsor)|1
5985642|NCT02386839|9576381|FG001|Overall Study|Other (Site Terminated by Sponsor)|0
5985643|NCT02386839|9576380|FG000|Overall Study|Other (Covid 19 Pandemic)|0
5985644|NCT02386839|9576381|FG001|Overall Study|Other (Covid 19 Pandemic)|1
5985645|NCT02386839|9576380|FG000|Overall Study|Other (unspecified)|1
5985646|NCT02386839|9576381|FG001|Overall Study|Other (unspecified)|0
5985647|NCT02362503|9576394|FG000|Double-blind Period-Up to 8 Days|Adverse Event|0
5985648|NCT02362503|9576395|FG001|Double-blind Period-Up to 8 Days|Adverse Event|2
5985649|NCT02362503|9576396|FG002|Double-blind Period-Up to 8 Days|Adverse Event|0
5985650|NCT02362503|9576394|FG000|Double-blind Period-Up to 8 Days|Death|1
5985651|NCT02362503|9576395|FG001|Double-blind Period-Up to 8 Days|Death|0
5985652|NCT02362503|9576396|FG002|Double-blind Period-Up to 8 Days|Death|0
5985653|NCT02362503|9576394|FG000|Double-blind Period-Up to 8 Days|Lost to Follow-up|0
5985654|NCT02362503|9576395|FG001|Double-blind Period-Up to 8 Days|Lost to Follow-up|1
5985655|NCT02362503|9576396|FG002|Double-blind Period-Up to 8 Days|Lost to Follow-up|0
5985656|NCT02362503|9576394|FG000|Double-blind Period-Up to 8 Days|No longer meets study criteria|0
5985657|NCT02362503|9576395|FG001|Double-blind Period-Up to 8 Days|No longer meets study criteria|1
5985658|NCT02362503|9576396|FG002|Double-blind Period-Up to 8 Days|No longer meets study criteria|0
5985659|NCT02362503|9576394|FG000|Open Label Period-Up to 96 Weeks|Other|0
5985660|NCT02362503|9576395|FG001|Open Label Period-Up to 96 Weeks|Other|1
5985661|NCT02362503|9576396|FG002|Open Label Period-Up to 96 Weeks|Other|1
5985662|NCT02362503|9576394|FG000|Open Label Period-Up to 96 Weeks|No longer meets criteria|0
5985663|NCT02362503|9576395|FG001|Open Label Period-Up to 96 Weeks|No longer meets criteria|4
5985664|NCT02362503|9576396|FG002|Open Label Period-Up to 96 Weeks|No longer meets criteria|4
5985665|NCT02362503|9576394|FG000|Open Label Period-Up to 96 Weeks|Pregnancy|0
5985666|NCT02362503|9576395|FG001|Open Label Period-Up to 96 Weeks|Pregnancy|1
5985667|NCT02362503|9576396|FG002|Open Label Period-Up to 96 Weeks|Pregnancy|0
5985668|NCT02362503|9576394|FG000|Open Label Period-Up to 96 Weeks|Non-compliance with study drug|3
5985669|NCT02362503|9576395|FG001|Open Label Period-Up to 96 Weeks|Non-compliance with study drug|8
5985670|NCT02362503|9576396|FG002|Open Label Period-Up to 96 Weeks|Non-compliance with study drug|6
5985671|NCT02362503|9576394|FG000|Open Label Period-Up to 96 Weeks|Lost to Follow-up|4
5985672|NCT02362503|9576395|FG001|Open Label Period-Up to 96 Weeks|Lost to Follow-up|3
5985673|NCT02362503|9576396|FG002|Open Label Period-Up to 96 Weeks|Lost to Follow-up|1
5985674|NCT02362503|9576394|FG000|Open Label Period-Up to 96 Weeks|Death|1
5985675|NCT02362503|9576395|FG001|Open Label Period-Up to 96 Weeks|Death|7
5985676|NCT02362503|9576396|FG002|Open Label Period-Up to 96 Weeks|Death|15
5985677|NCT02362503|9576394|FG000|Open Label Period-Up to 96 Weeks|Withdrawal by Subject|0
5985678|NCT02362503|9576395|FG001|Open Label Period-Up to 96 Weeks|Withdrawal by Subject|5
5985679|NCT02362503|9576396|FG002|Open Label Period-Up to 96 Weeks|Withdrawal by Subject|1
5985680|NCT02362503|9576394|FG000|Open Label Period-Up to 96 Weeks|Adverse Event|3
5985681|NCT02362503|9576395|FG001|Open Label Period-Up to 96 Weeks|Adverse Event|2
5985682|NCT02362503|9576396|FG002|Open Label Period-Up to 96 Weeks|Adverse Event|4
5985683|NCT02362503|9576394|FG000|Open Label Period-Up to 96 Weeks|Lack of Efficacy|3
5985684|NCT02362503|9576395|FG001|Open Label Period-Up to 96 Weeks|Lack of Efficacy|9
5985685|NCT02362503|9576396|FG002|Open Label Period-Up to 96 Weeks|Lack of Efficacy|6
5985686|NCT02362503|9576394|FG000|Open Label Period-Up to 96 Weeks|Ongoing at the time of analysis|54
5985687|NCT02362503|9576395|FG001|Open Label Period-Up to 96 Weeks|Ongoing at the time of analysis|159
5985688|NCT02362503|9576396|FG002|Open Label Period-Up to 96 Weeks|Ongoing at the time of analysis|61
5985689|NCT02312258|9576421|FG000|Overall Study|Adverse Event|15
5985690|NCT02312258|9576422|FG001|Overall Study|Adverse Event|47
5985691|NCT02312258|9576421|FG000|Overall Study|Lost to Follow-up|0
5985692|NCT02312258|9576422|FG001|Overall Study|Lost to Follow-up|1
5985693|NCT02312258|9576421|FG000|Overall Study|Progressive Disease|174
5985694|NCT02312258|9576422|FG001|Overall Study|Progressive Disease|188
5985695|NCT02312258|9576421|FG000|Overall Study|Withdrawal by Subject|8
5985696|NCT02312258|9576422|FG001|Overall Study|Withdrawal by Subject|9
5985697|NCT02312258|9576421|FG000|Overall Study|Reason not Specified|11
5985698|NCT02312258|9576422|FG001|Overall Study|Reason not Specified|31
5985699|NCT02312258|9576421|FG000|Overall Study|Participants Ongoing Treatment|43
5985700|NCT02312258|9576422|FG001|Overall Study|Participants Ongoing Treatment|83
5985701|NCT02243605|9576430|FG000|Stage 1 - Interim Analysis Population|Protocol Violation|1
5985702|NCT02243605|9576431|FG001|Stage 1 - Interim Analysis Population|Protocol Violation|1
5985703|NCT02243605|9576430|FG000|Stage 1 - Interim Analysis Population|Adverse Event|1
5985704|NCT02243605|9576431|FG001|Stage 1 - Interim Analysis Population|Adverse Event|0
5985705|NCT02243605|9576430|FG000|Stage 2 - Final Analysis Population|Protocol Violation|5
5985706|NCT02243605|9576431|FG001|Stage 2 - Final Analysis Population|Protocol Violation|1
5985707|NCT02243605|9576430|FG000|Stage 2 - Final Analysis Population|Adverse Event|1
5985708|NCT02243605|9576431|FG001|Stage 2 - Final Analysis Population|Adverse Event|1
5985709|NCT02243605|9576430|FG000|Stage 2 - Final Analysis Population|Progression|0
5985710|NCT02243605|9576431|FG001|Stage 2 - Final Analysis Population|Progression|1
5985711|NCT02213380|9576443|FG000|Underwent Randomization|Withdrawal by Subject|2
5985712|NCT02213380|9576444|FG001|Underwent Randomization|Withdrawal by Subject|0
5985713|NCT02213380|9576443|FG000|Underwent Randomization|Not treated|3
5985714|NCT02213380|9576444|FG001|Underwent Randomization|Not treated|3
5985715|NCT02213380|9576443|FG000|Per-protocol Analysis|Protocol Violation|32
5985716|NCT02213380|9576444|FG001|Per-protocol Analysis|Protocol Violation|36
5985717|NCT02184195|9576452|FG000|Overall Study|Patient decision|3
5985718|NCT02184195|9576453|FG001|Overall Study|Patient decision|1
5985719|NCT02184195|9576452|FG000|Overall Study|Eligibility criteria not fulfilled|0
5985720|NCT02184195|9576453|FG001|Overall Study|Eligibility criteria not fulfilled|1
5985721|NCT02184195|9576452|FG000|Overall Study|Death|40
5985722|NCT02184195|9576453|FG001|Overall Study|Death|29
5985723|NCT02184195|9576452|FG000|Overall Study|Lost to Follow-up|0
5985724|NCT02184195|9576453|FG001|Overall Study|Lost to Follow-up|2
5985725|NCT02184195|9576452|FG000|Overall Study|Other|0
5985726|NCT02184195|9576453|FG001|Overall Study|Other|2
5985727|NCT02089685|9576474|FG000|Overall Study|Adverse Event|1
5985728|NCT02089685|9576475|FG001|Overall Study|Adverse Event|0
5985729|NCT02089685|9576476|FG002|Overall Study|Adverse Event|0
5985730|NCT02089685|9576477|FG003|Overall Study|Adverse Event|0
5985731|NCT02089685|9576478|FG004|Overall Study|Adverse Event|1
5985732|NCT02089685|9576479|FG005|Overall Study|Adverse Event|0
5985733|NCT02089685|9576474|FG000|Overall Study|Clinical Progression|4
5985734|NCT02089685|9576475|FG001|Overall Study|Clinical Progression|0
5985735|NCT02089685|9576476|FG002|Overall Study|Clinical Progression|0
5985736|NCT02089685|9576477|FG003|Overall Study|Clinical Progression|5
5985737|NCT02089685|9576478|FG004|Overall Study|Clinical Progression|1
5985738|NCT02089685|9576479|FG005|Overall Study|Clinical Progression|2
5985739|NCT02089685|9576474|FG000|Overall Study|Excluded Medication|1
5985740|NCT02089685|9576475|FG001|Overall Study|Excluded Medication|0
5985741|NCT02089685|9576476|FG002|Overall Study|Excluded Medication|0
5985742|NCT02089685|9576477|FG003|Overall Study|Excluded Medication|11
5985743|NCT02089685|9576478|FG004|Overall Study|Excluded Medication|2
5985744|NCT02089685|9576479|FG005|Overall Study|Excluded Medication|1
5985745|NCT02089685|9576474|FG000|Overall Study|Progressive disease|13
5985746|NCT02089685|9576475|FG001|Overall Study|Progressive disease|10
5985747|NCT02089685|9576476|FG002|Overall Study|Progressive disease|3
5985748|NCT02089685|9576477|FG003|Overall Study|Progressive disease|51
5985749|NCT02089685|9576478|FG004|Overall Study|Progressive disease|17
5985750|NCT02089685|9576479|FG005|Overall Study|Progressive disease|12
5985751|NCT02089685|9576474|FG000|Overall Study|Follow up ended by sponsor|2
5985752|NCT02089685|9576475|FG001|Overall Study|Follow up ended by sponsor|2
5985753|NCT02089685|9576476|FG002|Overall Study|Follow up ended by sponsor|0
5985754|NCT02089685|9576477|FG003|Overall Study|Follow up ended by sponsor|70
5985755|NCT02089685|9576478|FG004|Overall Study|Follow up ended by sponsor|26
5985756|NCT02089685|9576479|FG005|Overall Study|Follow up ended by sponsor|26
5985757|NCT02089685|9576474|FG000|Overall Study|Withdrawal by Subject|0
5985758|NCT02089685|9576475|FG001|Overall Study|Withdrawal by Subject|2
5985759|NCT02089685|9576476|FG002|Overall Study|Withdrawal by Subject|0
5985760|NCT02089685|9576477|FG003|Overall Study|Withdrawal by Subject|8
6146043|NCT01074944|9780558|FG004|Long Term Treatment|Withdrawal by Subject|0
5985761|NCT02089685|9576478|FG004|Overall Study|Withdrawal by Subject|1
5985762|NCT02089685|9576479|FG005|Overall Study|Withdrawal by Subject|1
5985763|NCT02089685|9576474|FG000|Overall Study|Status not recorded|1
5985764|NCT02089685|9576475|FG001|Overall Study|Status not recorded|0
5985765|NCT02089685|9576476|FG002|Overall Study|Status not recorded|0
5985766|NCT02089685|9576477|FG003|Overall Study|Status not recorded|0
5985767|NCT02089685|9576478|FG004|Overall Study|Status not recorded|1
5985768|NCT02089685|9576479|FG005|Overall Study|Status not recorded|0
5985769|NCT02089685|9576474|FG000|Overall Study|Death|0
5985770|NCT02089685|9576475|FG001|Overall Study|Death|0
5985771|NCT02089685|9576476|FG002|Overall Study|Death|0
5985772|NCT02089685|9576477|FG003|Overall Study|Death|7
5985773|NCT02089685|9576478|FG004|Overall Study|Death|2
5985774|NCT02089685|9576479|FG005|Overall Study|Death|5
5985775|NCT02089685|9576474|FG000|Overall Study|Lost to Follow-up|0
5985776|NCT02089685|9576475|FG001|Overall Study|Lost to Follow-up|0
5985777|NCT02089685|9576476|FG002|Overall Study|Lost to Follow-up|0
5985778|NCT02089685|9576477|FG003|Overall Study|Lost to Follow-up|1
5985779|NCT02089685|9576478|FG004|Overall Study|Lost to Follow-up|0
5985780|NCT02089685|9576479|FG005|Overall Study|Lost to Follow-up|0
5985781|NCT02089685|9576474|FG000|Overall Study|Physician Decision|0
5985782|NCT02089685|9576475|FG001|Overall Study|Physician Decision|0
5985783|NCT02089685|9576476|FG002|Overall Study|Physician Decision|0
5985784|NCT02089685|9576477|FG003|Overall Study|Physician Decision|0
5985785|NCT02089685|9576478|FG004|Overall Study|Physician Decision|0
5985786|NCT02089685|9576479|FG005|Overall Study|Physician Decision|4
5985787|NCT02089685|9576474|FG000|Overall Study|Screen failure|1
5985788|NCT02089685|9576475|FG001|Overall Study|Screen failure|0
5985789|NCT02089685|9576476|FG002|Overall Study|Screen failure|0
5985790|NCT02089685|9576477|FG003|Overall Study|Screen failure|0
5985791|NCT02089685|9576478|FG004|Overall Study|Screen failure|0
5985792|NCT02089685|9576479|FG005|Overall Study|Screen failure|0
6044664|NCT00396877|9643730|FG000|Overall Study|Parent(s)/guardian(s)'s request|4
6044665|NCT00396877|9643731|FG001|Overall Study|Parent(s)/guardian(s)'s request|7
6044666|NCT00397033|9643758|FG000|Overall Study|Adverse Event|7
6044667|NCT00397033|9643759|FG001|Overall Study|Adverse Event|10
6044668|NCT00397033|9643760|FG002|Overall Study|Adverse Event|4
6044669|NCT00397033|9643758|FG000|Overall Study|Lack of Efficacy|22
6044670|NCT00397033|9643759|FG001|Overall Study|Lack of Efficacy|12
6044671|NCT00397033|9643760|FG002|Overall Study|Lack of Efficacy|9
5985793|NCT02075320|9576503|FG000|Overall Study|Withdrawal by Subject|2
5985794|NCT02007512|9576511|FG000|Double Blind Treatment Period|Adverse Event|4
5985795|NCT02007512|9576512|FG001|Double Blind Treatment Period|Adverse Event|2
5985796|NCT02007512|9576513|FG002|Double Blind Treatment Period|Adverse Event|6
5985797|NCT02007512|9576514|FG003|Double Blind Treatment Period|Adverse Event|2
5985798|NCT02007512|9576511|FG000|Double Blind Treatment Period|Death|1
5985799|NCT02007512|9576512|FG001|Double Blind Treatment Period|Death|0
5985800|NCT02007512|9576513|FG002|Double Blind Treatment Period|Death|0
5985801|NCT02007512|9576514|FG003|Double Blind Treatment Period|Death|0
5985802|NCT02007512|9576511|FG000|Double Blind Treatment Period|Disease progression|44
5985803|NCT02007512|9576512|FG001|Double Blind Treatment Period|Disease progression|49
5985804|NCT02007512|9576513|FG002|Double Blind Treatment Period|Disease progression|45
5985805|NCT02007512|9576514|FG003|Double Blind Treatment Period|Disease progression|51
5985806|NCT02007512|9576511|FG000|Double Blind Treatment Period|Withdrawal by Subject|4
5985807|NCT02007512|9576512|FG001|Double Blind Treatment Period|Withdrawal by Subject|2
5985808|NCT02007512|9576513|FG002|Double Blind Treatment Period|Withdrawal by Subject|3
5985809|NCT02007512|9576514|FG003|Double Blind Treatment Period|Withdrawal by Subject|3
5985810|NCT02007512|9576511|FG000|Double Blind Treatment Period|Protocol Violation|0
5985811|NCT02007512|9576512|FG001|Double Blind Treatment Period|Protocol Violation|0
5985812|NCT02007512|9576513|FG002|Double Blind Treatment Period|Protocol Violation|0
5985813|NCT02007512|9576514|FG003|Double Blind Treatment Period|Protocol Violation|1
5985814|NCT02007512|9576511|FG000|Double Blind Treatment Period|Other|0
5985815|NCT02007512|9576512|FG001|Double Blind Treatment Period|Other|0
5985816|NCT02007512|9576513|FG002|Double Blind Treatment Period|Other|1
5985817|NCT02007512|9576514|FG003|Double Blind Treatment Period|Other|2
5985818|NCT02007512|9576511|FG000|Double Blind Treatment Period|Ongoing as of data cutoff (23 Sep 2016)|10
5985819|NCT02007512|9576512|FG001|Double Blind Treatment Period|Ongoing as of data cutoff (23 Sep 2016)|11
5985820|NCT02007512|9576513|FG002|Double Blind Treatment Period|Ongoing as of data cutoff (23 Sep 2016)|5
5985821|NCT02007512|9576514|FG003|Double Blind Treatment Period|Ongoing as of data cutoff (23 Sep 2016)|1
5985822|NCT02007512|9576511|FG000|Open Label Treatment Period|Adverse Event|0
5985823|NCT02007512|9576512|FG001|Open Label Treatment Period|Adverse Event|1
5985824|NCT02007512|9576513|FG002|Open Label Treatment Period|Adverse Event|0
5985825|NCT02007512|9576514|FG003|Open Label Treatment Period|Adverse Event|0
5985826|NCT02007512|9576511|FG000|Open Label Treatment Period|Other|0
5985827|NCT02007512|9576512|FG001|Open Label Treatment Period|Other|0
5985828|NCT02007512|9576513|FG002|Open Label Treatment Period|Other|0
5985829|NCT02007512|9576514|FG003|Open Label Treatment Period|Other|1
5985830|NCT02007512|9576511|FG000|Open Label Treatment Period|Disease progression|0
5985831|NCT02007512|9576512|FG001|Open Label Treatment Period|Disease progression|17
5985832|NCT02007512|9576513|FG002|Open Label Treatment Period|Disease progression|0
5985833|NCT02007512|9576514|FG003|Open Label Treatment Period|Disease progression|11
5985834|NCT02007512|9576511|FG000|Open Label Treatment Period|Ongoing as of data cutoff (23 Sep 2016)|0
5985835|NCT02007512|9576512|FG001|Open Label Treatment Period|Ongoing as of data cutoff (23 Sep 2016)|3
5985836|NCT02007512|9576513|FG002|Open Label Treatment Period|Ongoing as of data cutoff (23 Sep 2016)|0
5985837|NCT02007512|9576514|FG003|Open Label Treatment Period|Ongoing as of data cutoff (23 Sep 2016)|0
5985838|NCT01999179|9576527|FG000|Overall Study|Adverse Event|1
5985839|NCT01999179|9576527|FG000|Overall Study|Lost to Follow-up|1
5985840|NCT01999179|9576527|FG000|Overall Study|Change in Therapy|3
5985841|NCT01999179|9576527|FG000|Overall Study|New catheter|2
5985842|NCT01858688|9576531|FG000|Overall Study|Withdrawal by Subject|8
5985843|NCT01858688|9576531|FG000|Overall Study|Participant began another therapy|3
5985844|NCT01858688|9576531|FG000|Overall Study|Physician Decision|2
5985845|NCT01858688|9576531|FG000|Overall Study|Progressive Disease|2
5985846|NCT01858688|9576531|FG000|Overall Study|Reason not reproted|5
5985847|NCT01796197|9576535|FG000|Overall Study|Lost to Follow-up|1
5985848|NCT01796197|9576535|FG000|Overall Study|Lack of Efficacy|1
5985849|NCT01751906|9576541|FG000|Overall Study|Lost to Follow-up|151
5985850|NCT01751906|9576542|FG001|Overall Study|Lost to Follow-up|68
5985851|NCT01751906|9576541|FG000|Overall Study|Withdrawal by Subject|22
5985852|NCT01751906|9576542|FG001|Overall Study|Withdrawal by Subject|18
5985853|NCT01751906|9576541|FG000|Overall Study|Physician Decision|5
5985854|NCT01751906|9576542|FG001|Overall Study|Physician Decision|2
5985855|NCT01751906|9576541|FG000|Overall Study|Death|84
5985856|NCT01751906|9576542|FG001|Overall Study|Death|43
5985857|NCT01751906|9576541|FG000|Overall Study|Denied on premises for follow-up by law|1
5985858|NCT01751906|9576542|FG001|Overall Study|Denied on premises for follow-up by law|0
5985859|NCT01665144|9576550|FG000|Overall Study|New therapy for study indication|2
5985860|NCT01665144|9576551|FG001|Overall Study|New therapy for study indication|1
5985861|NCT01665144|9576550|FG000|Overall Study|Technical problems|2
5985862|NCT01665144|9576551|FG001|Overall Study|Technical problems|0
5985863|NCT01665144|9576550|FG000|Overall Study|Death|3
5985864|NCT01665144|9576551|FG001|Overall Study|Death|1
5985865|NCT01665144|9576550|FG000|Overall Study|Protocol deviation|3
5985866|NCT01665144|9576551|FG001|Overall Study|Protocol deviation|1
5985867|NCT01665144|9576550|FG000|Overall Study|Non-compliance w/study treatment|5
5985868|NCT01665144|9576551|FG001|Overall Study|Non-compliance w/study treatment|0
5985869|NCT01665144|9576550|FG000|Overall Study|Progressive disease|8
5985870|NCT01665144|9576551|FG001|Overall Study|Progressive disease|4
5985871|NCT01665144|9576550|FG000|Overall Study|Lost to Follow-up|9
5985872|NCT01665144|9576551|FG001|Overall Study|Lost to Follow-up|8
5985873|NCT01665144|9576550|FG000|Overall Study|Physician Decision|13
5985874|NCT01665144|9576551|FG001|Overall Study|Physician Decision|1
5985875|NCT01665144|9576550|FG000|Overall Study|Lack of Efficacy|16
5985876|NCT01665144|9576551|FG001|Overall Study|Lack of Efficacy|11
5985877|NCT01665144|9576550|FG000|Overall Study|Adverse Event|45
5985878|NCT01665144|9576551|FG001|Overall Study|Adverse Event|18
5985879|NCT01665144|9576550|FG000|Overall Study|Withdrawal by Subject|96
5985880|NCT01665144|9576551|FG001|Overall Study|Withdrawal by Subject|77
5985881|NCT01585103|9576557|FG000|Overall Study|Unable to swallow Cytosponge|6
5985882|NCT00669669|9576596|FG000|Overall Study|To late to start treatment|1
5985883|NCT00601900|9576602|FG000|Overall Study|Withdrawal by Subject|0
5985884|NCT00601900|9576603|FG001|Overall Study|Withdrawal by Subject|3
5985885|NCT00549848|9576612|FG000|Overall Study|Death|1
5985886|NCT00549848|9576613|FG001|Overall Study|Death|4
5985887|NCT00549848|9576614|FG002|Overall Study|Death|13
5985888|NCT00549848|9576612|FG000|Overall Study|Physician Decision|0
5985889|NCT00549848|9576613|FG001|Overall Study|Physician Decision|0
5985890|NCT00549848|9576614|FG002|Overall Study|Physician Decision|4
5985891|NCT00549848|9576612|FG000|Overall Study|Bone Marrow (BM) or Extramedullary Relapse|3
5985892|NCT00549848|9576613|FG001|Overall Study|Bone Marrow (BM) or Extramedullary Relapse|4
5985893|NCT00549848|9576614|FG002|Overall Study|Bone Marrow (BM) or Extramedullary Relapse|4
5985894|NCT00549848|9576612|FG000|Overall Study|Failure to achieve Complete Remission (CR)|1
5985895|NCT00549848|9576613|FG001|Overall Study|Failure to achieve Complete Remission (CR)|0
5985896|NCT00549848|9576614|FG002|Overall Study|Failure to achieve Complete Remission (CR)|1
5985897|NCT00549848|9576612|FG000|Overall Study|Participant/Family Withdraw|2
5985898|NCT00549848|9576613|FG001|Overall Study|Participant/Family Withdraw|3
5985899|NCT00549848|9576614|FG002|Overall Study|Participant/Family Withdraw|5
5985900|NCT00549848|9576612|FG000|Overall Study|Second Malignancy|1
5985901|NCT00549848|9576613|FG001|Overall Study|Second Malignancy|0
5985902|NCT00549848|9576614|FG002|Overall Study|Second Malignancy|0
5985903|NCT00549848|9576612|FG000|Overall Study|Transplant|3
5985904|NCT00549848|9576613|FG001|Overall Study|Transplant|3
5985905|NCT00549848|9576614|FG002|Overall Study|Transplant|18
5985906|NCT00549848|9576612|FG000|Overall Study|Unacceptable Toxicity|1
5985907|NCT00549848|9576613|FG001|Overall Study|Unacceptable Toxicity|6
5985908|NCT00549848|9576614|FG002|Overall Study|Unacceptable Toxicity|6
5985909|NCT00433511|9576642|FG000|Step 1|Adverse Event|50
5985910|NCT00433511|9576643|FG001|Step 1|Adverse Event|157
5985911|NCT00433511|9576644|FG002|Step 1|Adverse Event|153
5985912|NCT00433511|9576642|FG000|Step 1|Withdrawal by Subject|45
5985913|NCT00433511|9576643|FG001|Step 1|Withdrawal by Subject|143
5985914|NCT00433511|9576644|FG002|Step 1|Withdrawal by Subject|154
5985915|NCT00433511|9576642|FG000|Step 1|Death|3
5985916|NCT00433511|9576643|FG001|Step 1|Death|1
5985917|NCT00433511|9576644|FG002|Step 1|Death|1
5985918|NCT00433511|9576642|FG000|Step 1|Physician Decision|1
5985919|NCT00433511|9576643|FG001|Step 1|Physician Decision|4
5985920|NCT00433511|9576644|FG002|Step 1|Physician Decision|3
5985921|NCT00433511|9576642|FG000|Step 1|Never started protocol therapy|28
5985922|NCT00433511|9576643|FG001|Step 1|Never started protocol therapy|64
5985923|NCT00433511|9576644|FG002|Step 1|Never started protocol therapy|66
5985924|NCT00433511|9576642|FG000|Step 1|Alternative therapy|2
5985925|NCT00433511|9576643|FG001|Step 1|Alternative therapy|1
5985926|NCT00433511|9576644|FG002|Step 1|Alternative therapy|3
5985927|NCT00433511|9576642|FG000|Step 1|Disease progression, relapse|5
5985928|NCT00433511|9576643|FG001|Step 1|Disease progression, relapse|3
5985929|NCT00433511|9576644|FG002|Step 1|Disease progression, relapse|3
5985930|NCT00433511|9576642|FG000|Step 1|Other complicating disease|2
5985931|NCT00433511|9576643|FG001|Step 1|Other complicating disease|6
5985932|NCT00433511|9576644|FG002|Step 1|Other complicating disease|3
5985933|NCT00433511|9576642|FG000|Step 1|Non-breast cancer surgery/wound issues|0
5985934|NCT00433511|9576643|FG001|Step 1|Non-breast cancer surgery/wound issues|4
5985935|NCT00433511|9576644|FG002|Step 1|Non-breast cancer surgery/wound issues|1
5985936|NCT00433511|9576642|FG000|Step 1|Suspected recurrence|0
5985937|NCT00433511|9576643|FG001|Step 1|Suspected recurrence|1
5985938|NCT00433511|9576644|FG002|Step 1|Suspected recurrence|0
5985939|NCT00433511|9576642|FG000|Step 1|Insurance/drug distribution issues|0
5985940|NCT00433511|9576643|FG001|Step 1|Insurance/drug distribution issues|1
5985941|NCT00433511|9576644|FG002|Step 1|Insurance/drug distribution issues|2
5985942|NCT00433511|9576642|FG000|Step 1|Patient moved|0
5985943|NCT00433511|9576643|FG001|Step 1|Patient moved|0
5985944|NCT00433511|9576644|FG002|Step 1|Patient moved|1
5985945|NCT00433511|9576642|FG000|Step 2 (Arm D)|Adverse Event|0
5985946|NCT00433511|9576643|FG001|Step 2 (Arm D)|Adverse Event|0
5985947|NCT00433511|9576644|FG002|Step 2 (Arm D)|Adverse Event|135
5985948|NCT00433511|9576642|FG000|Step 2 (Arm D)|Withdrawal by Subject|0
5985949|NCT00433511|9576643|FG001|Step 2 (Arm D)|Withdrawal by Subject|0
5985950|NCT00433511|9576644|FG002|Step 2 (Arm D)|Withdrawal by Subject|181
5985951|NCT00433511|9576642|FG000|Step 2 (Arm D)|Never started protocol therapy|0
5985952|NCT00433511|9576643|FG001|Step 2 (Arm D)|Never started protocol therapy|0
5985953|NCT00433511|9576644|FG002|Step 2 (Arm D)|Never started protocol therapy|148
5985954|NCT00433511|9576642|FG000|Step 2 (Arm D)|Physician Decision|0
5985955|NCT00433511|9576643|FG001|Step 2 (Arm D)|Physician Decision|0
5985956|NCT00433511|9576644|FG002|Step 2 (Arm D)|Physician Decision|9
5985957|NCT00433511|9576642|FG000|Step 2 (Arm D)|Disease progression, relapse|0
5985958|NCT00433511|9576643|FG001|Step 2 (Arm D)|Disease progression, relapse|0
5985959|NCT00433511|9576644|FG002|Step 2 (Arm D)|Disease progression, relapse|7
5985960|NCT00433511|9576642|FG000|Step 2 (Arm D)|Other complicating disease|0
5985961|NCT00433511|9576643|FG001|Step 2 (Arm D)|Other complicating disease|0
5985962|NCT00433511|9576644|FG002|Step 2 (Arm D)|Other complicating disease|3
5985963|NCT00433511|9576642|FG000|Step 2 (Arm D)|Non-breast cancer surgery/wound issues|0
5985964|NCT00433511|9576643|FG001|Step 2 (Arm D)|Non-breast cancer surgery/wound issues|0
5985965|NCT00433511|9576644|FG002|Step 2 (Arm D)|Non-breast cancer surgery/wound issues|2
5985966|NCT00433511|9576642|FG000|Step 2 (Arm D)|Suspected recurrence|0
5985967|NCT00433511|9576643|FG001|Step 2 (Arm D)|Suspected recurrence|0
5985968|NCT00433511|9576644|FG002|Step 2 (Arm D)|Suspected recurrence|1
5985969|NCT00433511|9576642|FG000|Step 2 (Arm D)|Insurance/drug distribution issues|0
5985970|NCT00433511|9576643|FG001|Step 2 (Arm D)|Insurance/drug distribution issues|0
5985971|NCT00433511|9576644|FG002|Step 2 (Arm D)|Insurance/drug distribution issues|4
5985972|NCT00433511|9576642|FG000|Step 2 (Arm D)|Unknown (Missing off treatment form)|0
5985973|NCT00433511|9576643|FG001|Step 2 (Arm D)|Unknown (Missing off treatment form)|0
5985974|NCT00433511|9576644|FG002|Step 2 (Arm D)|Unknown (Missing off treatment form)|1
6044672|NCT00397033|9643758|FG000|Overall Study|Lost to Follow-up|3
6044673|NCT00397033|9643759|FG001|Overall Study|Lost to Follow-up|3
6044674|NCT00397033|9643760|FG002|Overall Study|Lost to Follow-up|3
6044675|NCT00397033|9643758|FG000|Overall Study|Withdrawal by Subject|12
6044676|NCT00397033|9643759|FG001|Overall Study|Withdrawal by Subject|7
6044677|NCT00397033|9643760|FG002|Overall Study|Withdrawal by Subject|5
6044678|NCT00397033|9643758|FG000|Overall Study|Other|0
6044679|NCT00397033|9643759|FG001|Overall Study|Other|5
6044680|NCT00397033|9643760|FG002|Overall Study|Other|2
6044681|NCT00397046|9643772|FG000|Overall Study|Disease Progression|3
6044682|NCT00397046|9643773|FG001|Overall Study|Disease Progression|3
6044683|NCT00397046|9643774|FG002|Overall Study|Disease Progression|10
6044684|NCT00397046|9643775|FG003|Overall Study|Disease Progression|5
6044685|NCT00397189|9643797|FG000|3 Weeks Period|Lost to Follow-up|5
6044686|NCT00397189|9643798|FG001|3 Weeks Period|Lost to Follow-up|4
6044687|NCT00397189|9643797|FG000|3 Weeks Period|Adverse Event|3
6044688|NCT00397189|9643798|FG001|3 Weeks Period|Adverse Event|2
6044689|NCT00397189|9643797|FG000|3 Weeks Period|Withdrawal by Subject|13
6044690|NCT00397189|9643798|FG001|3 Weeks Period|Withdrawal by Subject|9
6044691|NCT00397189|9643797|FG000|3 Weeks Period|Physician Decision|0
6044692|NCT00397189|9643798|FG001|3 Weeks Period|Physician Decision|2
6044693|NCT00397189|9643797|FG000|3 Weeks Period|Protocol Violation|0
6044694|NCT00397189|9643798|FG001|3 Weeks Period|Protocol Violation|3
6044695|NCT00397189|9643797|FG000|3 Weeks Period|Other|0
6044696|NCT00397189|9643798|FG001|3 Weeks Period|Other|2
6044697|NCT00397215|9643810|FG000|Month 0 (Day 0)|Adverse Event|0
6044698|NCT00397215|9643811|FG001|Month 0 (Day 0)|Adverse Event|1
6044699|NCT00397215|9643812|FG002|Month 0 (Day 0)|Adverse Event|0
6044700|NCT00397215|9643813|FG003|Month 0 (Day 0)|Adverse Event|0
6044701|NCT00397215|9643810|FG000|Month 0 (Day 0)|Withdrawal by Subject|3
6044702|NCT00397215|9643811|FG001|Month 0 (Day 0)|Withdrawal by Subject|3
6044703|NCT00397215|9643812|FG002|Month 0 (Day 0)|Withdrawal by Subject|3
6044704|NCT00397215|9643813|FG003|Month 0 (Day 0)|Withdrawal by Subject|1
6044705|NCT00397215|9643810|FG000|Month 0 (Day 0)|Other|4
6044706|NCT00397215|9643811|FG001|Month 0 (Day 0)|Other|1
6044707|NCT00397215|9643812|FG002|Month 0 (Day 0)|Other|3
6044708|NCT00397215|9643813|FG003|Month 0 (Day 0)|Other|3
6044709|NCT00397215|9643810|FG000|Month 6 (Day 180)|Adverse Event|0
6044710|NCT00397215|9643811|FG001|Month 6 (Day 180)|Adverse Event|3
6044711|NCT00397215|9643812|FG002|Month 6 (Day 180)|Adverse Event|2
6044712|NCT00397215|9643813|FG003|Month 6 (Day 180)|Adverse Event|0
6044713|NCT00397215|9643810|FG000|Month 6 (Day 180)|Other|2
6044714|NCT00397215|9643811|FG001|Month 6 (Day 180)|Other|0
6044715|NCT00397215|9643812|FG002|Month 6 (Day 180)|Other|3
6044716|NCT00397215|9643813|FG003|Month 6 (Day 180)|Other|0
6044717|NCT00397488|9643839|FG000|Overall Study|Withdrawal by Subject|3
6044718|NCT00397488|9643839|FG000|Overall Study|Adverse Event|3
6044719|NCT00397488|9643839|FG000|Overall Study|Death|1
6044720|NCT00397514|9643843|FG000|Overall Study|Withdrawal by Subject|1
6044721|NCT00397514|9643843|FG000|Overall Study|Pacing wire malfunction|1
6044722|NCT00397514|9643843|FG000|Overall Study|Not able to capture & pace LV intraoper.|4
6044723|NCT00397514|9643843|FG000|Overall Study|early extubation|2
6044724|NCT00397514|9643843|FG000|Overall Study|poor echocardiographic windows|1
6044725|NCT00397540|9643855|FG000|Overall Study|short follow-up duration < 12 months|1
6044726|NCT00397540|9643856|FG001|Overall Study|short follow-up duration < 12 months|0
6044727|NCT00397631|9643869|FG000|Overall Study|Adverse Event|5
6044728|NCT00397631|9643870|FG001|Overall Study|Adverse Event|6
6044729|NCT00397631|9643869|FG000|Overall Study|Lack of Efficacy|7
6044730|NCT00397631|9643870|FG001|Overall Study|Lack of Efficacy|10
6044731|NCT00397631|9643869|FG000|Overall Study|Lost to Follow-up|8
6044732|NCT00397631|9643870|FG001|Overall Study|Lost to Follow-up|9
6044733|NCT00397631|9643869|FG000|Overall Study|Physician Decision|2
6044734|NCT00397631|9643870|FG001|Overall Study|Physician Decision|0
6044735|NCT00397631|9643869|FG000|Overall Study|Protocol Violation|0
6044736|NCT00397631|9643870|FG001|Overall Study|Protocol Violation|1
6146044|NCT01074944|9780554|FG000|Extended Treatment (up to 42 Months)|Pregnancy|0
6193344|NCT01437397|9850968|FG002|Overall Study|Adverse Event|16
5985975|NCT00314366|9576670|FG000|Overall Study|not treated due to patient medical condi|1
5985976|NCT00314366|9576671|FG001|Overall Study|not treated due to patient medical condi|0
6044737|NCT00397631|9643869|FG000|Overall Study|Withdrawal by Subject|7
6044738|NCT00397631|9643870|FG001|Overall Study|Withdrawal by Subject|14
6044739|NCT00397631|9643869|FG000|Overall Study|protocol discontinuation criteria|1
6044740|NCT00397631|9643870|FG001|Overall Study|protocol discontinuation criteria|4
6044741|NCT00397891|9643919|FG000|Overall Study|Withdrawal by Subject|1
6044742|NCT00397891|9643920|FG001|Overall Study|Withdrawal by Subject|0
6044743|NCT00397891|9643921|FG002|Overall Study|Withdrawal by Subject|0
6044744|NCT00397891|9643922|FG003|Overall Study|Withdrawal by Subject|0
6044745|NCT00397891|9643923|FG004|Overall Study|Withdrawal by Subject|1
6044746|NCT00397930|9643941|FG000|Overall Study|Personal reasons|14
6044747|NCT00397930|9643942|FG001|Overall Study|Personal reasons|8
6044748|NCT00397930|9643941|FG000|Overall Study|Other medical|9
6044749|NCT00397930|9643942|FG001|Overall Study|Other medical|4
6044750|NCT00397930|9643941|FG000|Overall Study|Unknown reasons|9
6044751|NCT00397930|9643942|FG001|Overall Study|Unknown reasons|14
6044752|NCT00397930|9643941|FG000|Overall Study|Noncompliant|3
6044753|NCT00397930|9643942|FG001|Overall Study|Noncompliant|2
6044754|NCT00397930|9643941|FG000|Overall Study|Too time-consuming|2
6044755|NCT00397930|9643942|FG001|Overall Study|Too time-consuming|9
6044756|NCT00397930|9643941|FG000|Overall Study|Started own yoga program|1
6044757|NCT00397930|9643942|FG001|Overall Study|Started own yoga program|1
6044758|NCT00397930|9643941|FG000|Overall Study|Did not want to be in control group|0
6044759|NCT00397930|9643942|FG001|Overall Study|Did not want to be in control group|1
6044760|NCT00397930|9643941|FG000|Overall Study|Withdrawal by Subject|0
6044761|NCT00397930|9643942|FG001|Overall Study|Withdrawal by Subject|8
6044762|NCT00397930|9643941|FG000|Overall Study|Missing data|0
6044763|NCT00397930|9643942|FG001|Overall Study|Missing data|4
6044764|NCT00397943|9643953|FG000|Overall Study|Unspecified reasons|12
6044765|NCT00397943|9643954|FG001|Overall Study|Unspecified reasons|9
6044766|NCT00397943|9643955|FG002|Overall Study|Unspecified reasons|0
6044767|NCT00397943|9643956|FG003|Overall Study|Unspecified reasons|0
6044768|NCT00397943|9643957|FG004|Overall Study|Unspecified reasons|0
6044769|NCT00397982|9643969|FG000|Overall Study|Withdrawal by Subject|1
6044770|NCT00397982|9643969|FG000|Overall Study|Adverse Event|1
6044771|NCT00397982|9643969|FG000|Overall Study|noncompliance|1
6044772|NCT00397982|9643969|FG000|Overall Study|Unrelated health issues|1
6044773|NCT00398047|9643974|FG000|Overall Study|all patient progressed before completion|3
6044774|NCT00398073|9643981|FG000|Overall Study|Withdrawal by Subject|1
6044775|NCT00398073|9643982|FG001|Overall Study|Withdrawal by Subject|0
6044776|NCT00398086|9643991|FG000|Overall Study|Unacceptable Toxicity|2
6044777|NCT00398086|9643992|FG001|Overall Study|Unacceptable Toxicity|8
6044778|NCT00398086|9643993|FG002|Overall Study|Unacceptable Toxicity|2
6044779|NCT00398086|9643991|FG000|Overall Study|Adverse Event|1
6044780|NCT00398086|9643992|FG001|Overall Study|Adverse Event|4
6044781|NCT00398086|9643993|FG002|Overall Study|Adverse Event|0
6044782|NCT00398086|9643991|FG000|Overall Study|Physician Decision|1
6044783|NCT00398086|9643992|FG001|Overall Study|Physician Decision|4
6044784|NCT00398086|9643993|FG002|Overall Study|Physician Decision|0
6044785|NCT00398086|9643991|FG000|Overall Study|Withdrawal by Subject|5
6044786|NCT00398086|9643992|FG001|Overall Study|Withdrawal by Subject|7
6044787|NCT00398086|9643993|FG002|Overall Study|Withdrawal by Subject|0
6044788|NCT00398112|9644001|FG000|Overall Study|Adverse Event|4
6044789|NCT00398112|9644001|FG000|Overall Study|Disease progression|9
6044790|NCT00398112|9644001|FG000|Overall Study|Alternative treatment|1
6044791|NCT00398112|9644001|FG000|Overall Study|Withdrawal by Subject|3
6044792|NCT00398112|9644001|FG000|Overall Study|Death|1
6044793|NCT00398138|9644005|FG000|Overall Study|Adverse Event|2
6049064|NCT00421148|9648257|FG008|Overall Study|Withdrawal by Subject|0
6049065|NCT00421148|9648258|FG009|Overall Study|Withdrawal by Subject|0
6049066|NCT00421148|9648259|FG010|Overall Study|Withdrawal by Subject|0
6049067|NCT00421148|9648260|FG011|Overall Study|Withdrawal by Subject|0
6049068|NCT00421148|9648261|FG012|Overall Study|Withdrawal by Subject|0
6049069|NCT00421148|9648262|FG013|Overall Study|Withdrawal by Subject|0
6049070|NCT00421148|9648263|FG014|Overall Study|Withdrawal by Subject|0
6049071|NCT00421148|9648264|FG015|Overall Study|Withdrawal by Subject|0
6049072|NCT00421148|9648265|FG016|Overall Study|Withdrawal by Subject|0
6049073|NCT00421148|9648266|FG017|Overall Study|Withdrawal by Subject|1
6049074|NCT00421148|9648267|FG018|Overall Study|Withdrawal by Subject|0
6049075|NCT00421148|9648268|FG019|Overall Study|Withdrawal by Subject|0
6049076|NCT00421148|9648249|FG000|Overall Study|Protocol Violation|0
6049077|NCT00421148|9648250|FG001|Overall Study|Protocol Violation|0
6049078|NCT00421148|9648251|FG002|Overall Study|Protocol Violation|0
6049079|NCT00421148|9648252|FG003|Overall Study|Protocol Violation|0
6049080|NCT00421148|9648253|FG004|Overall Study|Protocol Violation|0
6049081|NCT00421148|9648254|FG005|Overall Study|Protocol Violation|1
6049082|NCT00421148|9648255|FG006|Overall Study|Protocol Violation|0
6049083|NCT00421148|9648256|FG007|Overall Study|Protocol Violation|0
6049084|NCT00421148|9648257|FG008|Overall Study|Protocol Violation|0
6049085|NCT00421148|9648258|FG009|Overall Study|Protocol Violation|0
6049086|NCT00421148|9648259|FG010|Overall Study|Protocol Violation|0
5985977|NCT04482647|9576736|FG000|Overall Study|Time constraints|2
5985978|NCT04482647|9576736|FG000|Overall Study|Health issues|1
5985979|NCT04482647|9576736|FG000|Overall Study|Death in the family|1
5985980|NCT04482647|9576736|FG000|Overall Study|Disliked the intervention|1
5985981|NCT04482647|9576736|FG000|Overall Study|No reasons specified|7
5985982|NCT04405570|9576744|FG000|Overall Study|Adverse Event|0
5985983|NCT04405570|9576745|FG001|Overall Study|Adverse Event|1
5985984|NCT04405570|9576746|FG002|Overall Study|Adverse Event|1
5985985|NCT04405570|9576747|FG003|Overall Study|Adverse Event|1
5985986|NCT04405570|9576744|FG000|Overall Study|Lost to Follow-up|0
5985987|NCT04405570|9576745|FG001|Overall Study|Lost to Follow-up|1
5985988|NCT04405570|9576746|FG002|Overall Study|Lost to Follow-up|0
5985989|NCT04405570|9576747|FG003|Overall Study|Lost to Follow-up|0
5985990|NCT04405570|9576744|FG000|Overall Study|Physician Decision|0
5985991|NCT04405570|9576745|FG001|Overall Study|Physician Decision|0
5985992|NCT04405570|9576746|FG002|Overall Study|Physician Decision|1
5985993|NCT04405570|9576747|FG003|Overall Study|Physician Decision|0
5985994|NCT04405570|9576744|FG000|Overall Study|Withdrawal by Subject|0
5985995|NCT04405570|9576745|FG001|Overall Study|Withdrawal by Subject|1
5985996|NCT04405570|9576746|FG002|Overall Study|Withdrawal by Subject|1
5985997|NCT04405570|9576747|FG003|Overall Study|Withdrawal by Subject|0
5985998|NCT04405570|9576744|FG000|Overall Study|Randomized not dosed|0
5985999|NCT04405570|9576745|FG001|Overall Study|Randomized not dosed|2
5986000|NCT04405570|9576746|FG002|Overall Study|Randomized not dosed|0
5986001|NCT04405570|9576747|FG003|Overall Study|Randomized not dosed|0
5986002|NCT04135937|9576760|FG000|Overall Study|Lost to Follow-up|2
5986003|NCT04135937|9576760|FG000|Overall Study|Withdrawal by Subject|1
5986004|NCT03989232|9576766|FG000|Overall Study|Lost to Follow-up|3
5986005|NCT03989232|9576767|FG001|Overall Study|Lost to Follow-up|10
5986006|NCT03989232|9576766|FG000|Overall Study|Withdrawal by Subject|6
5986007|NCT03989232|9576767|FG001|Overall Study|Withdrawal by Subject|6
5986008|NCT03989232|9576766|FG000|Overall Study|Death|1
5986009|NCT03989232|9576767|FG001|Overall Study|Death|2
5986010|NCT03896295|9576775|FG000|Overall Study|Adverse Event|0
5986011|NCT03896295|9576776|FG001|Overall Study|Adverse Event|1
5986012|NCT03896295|9576775|FG000|Overall Study|COVID-19|7
5986013|NCT03896295|9576776|FG001|Overall Study|COVID-19|29
5986014|NCT03213457|9576790|FG000|Overall Study|Not Treated|1
5986015|NCT03213457|9576791|FG001|Overall Study|Not Treated|1
5986016|NCT03213457|9576792|FG002|Overall Study|Not Treated|0
5986017|NCT03213457|9576790|FG000|Overall Study|Adverse Event|16
5986018|NCT03213457|9576791|FG001|Overall Study|Adverse Event|9
5986019|NCT03213457|9576792|FG002|Overall Study|Adverse Event|41
5986020|NCT03213457|9576790|FG000|Overall Study|Non-Compliance With Study Drug|1
5986021|NCT03213457|9576791|FG001|Overall Study|Non-Compliance With Study Drug|2
5986022|NCT03213457|9576792|FG002|Overall Study|Non-Compliance With Study Drug|7
5986023|NCT03213457|9576790|FG000|Overall Study|Non-Compliance Other, Not Specified|0
5986024|NCT03213457|9576791|FG001|Overall Study|Non-Compliance Other, Not Specified|1
5986025|NCT03213457|9576792|FG002|Overall Study|Non-Compliance Other, Not Specified|5
5986026|NCT03213457|9576790|FG000|Overall Study|Withdrawal by Subject|18
5986027|NCT03213457|9576791|FG001|Overall Study|Withdrawal by Subject|7
5986028|NCT03213457|9576792|FG002|Overall Study|Withdrawal by Subject|35
5986029|NCT03213457|9576790|FG000|Overall Study|Lost to Follow-up|12
5986030|NCT03213457|9576791|FG001|Overall Study|Lost to Follow-up|12
5986031|NCT03213457|9576792|FG002|Overall Study|Lost to Follow-up|33
5986032|NCT03213457|9576790|FG000|Overall Study|Pregnancy|11
5986033|NCT03213457|9576791|FG001|Overall Study|Pregnancy|0
5986034|NCT03213457|9576792|FG002|Overall Study|Pregnancy|7
5986035|NCT03213457|9576790|FG000|Overall Study|Protocol Violation|1
5986036|NCT03213457|9576791|FG001|Overall Study|Protocol Violation|1
5986037|NCT03213457|9576792|FG002|Overall Study|Protocol Violation|6
5986038|NCT03213457|9576790|FG000|Overall Study|Requires Surgery/Invasive Intervention for Endometriosis Treatment|4
5986039|NCT03213457|9576791|FG001|Overall Study|Requires Surgery/Invasive Intervention for Endometriosis Treatment|0
5986040|NCT03213457|9576792|FG002|Overall Study|Requires Surgery/Invasive Intervention for Endometriosis Treatment|2
5986041|NCT03213457|9576790|FG000|Overall Study|Dual Energy X-Ray Absorptiometry Finding|1
5986042|NCT03213457|9576791|FG001|Overall Study|Dual Energy X-Ray Absorptiometry Finding|1
5986043|NCT03213457|9576792|FG002|Overall Study|Dual Energy X-Ray Absorptiometry Finding|3
5986044|NCT03213457|9576790|FG000|Overall Study|Lack of Efficacy|12
5986045|NCT03213457|9576791|FG001|Overall Study|Lack of Efficacy|2
5986046|NCT03213457|9576792|FG002|Overall Study|Lack of Efficacy|9
5986047|NCT03213457|9576790|FG000|Overall Study|Other, Not Specified|11
5986048|NCT03213457|9576791|FG001|Overall Study|Other, Not Specified|3
5986049|NCT03213457|9576792|FG002|Overall Study|Other, Not Specified|26
5986050|NCT02982720|9576800|FG000|Overall Study|Adverse Event|3
5986051|NCT02982720|9576800|FG000|Overall Study|Death|1
5986052|NCT02375672|9576813|FG000|Overall Study|remain on follow up|20
5986053|NCT02329327|9576819|FG000|Overall Study|Death|78
5986054|NCT02329327|9576820|FG001|Overall Study|Death|0
5986055|NCT02329327|9576819|FG000|Overall Study|Withdrawal by Subject|3
5986056|NCT02329327|9576820|FG001|Overall Study|Withdrawal by Subject|0
5986057|NCT02329327|9576819|FG000|Overall Study|Lost to Follow-up|4
5986058|NCT02329327|9576820|FG001|Overall Study|Lost to Follow-up|0
5986059|NCT02063724|9576865|FG000|Overall Study|Disease progression|1
5986060|NCT01942135|9576871|FG000|Overall Study|Adverse Event|9
5986061|NCT01942135|9576872|FG001|Overall Study|Adverse Event|3
5986062|NCT01942135|9576871|FG000|Overall Study|Global deterioration of health status|8
5986063|NCT01942135|9576872|FG001|Overall Study|Global deterioration of health status|3
5986064|NCT01942135|9576871|FG000|Overall Study|Randomized Not Treated|2
5986065|NCT01942135|9576872|FG001|Overall Study|Randomized Not Treated|2
5986066|NCT01942135|9576871|FG000|Overall Study|Death|0
5986067|NCT01942135|9576872|FG001|Overall Study|Death|1
5986068|NCT01942135|9576871|FG000|Overall Study|ObjectiveProgression+Progressive Disease|85
5986069|NCT01942135|9576872|FG001|Overall Study|ObjectiveProgression+Progressive Disease|87
5986070|NCT01942135|9576871|FG000|Overall Study|Participant Refused toContinue Treatment|1
5986071|NCT01942135|9576872|FG001|Overall Study|Participant Refused toContinue Treatment|1
5986072|NCT01942135|9576871|FG000|Overall Study|Withdrawal by Subject|4
5986073|NCT01942135|9576872|FG001|Overall Study|Withdrawal by Subject|2
5986074|NCT01942135|9576871|FG000|Overall Study|Ongoing at date of cut-off (05 Dec 2014)|238
5986075|NCT01942135|9576872|FG001|Overall Study|Ongoing at date of cut-off (05 Dec 2014)|75
5986076|NCT01566149|9576891|FG000|Overall Study|Adverse Event|0
5986077|NCT01566149|9576892|FG001|Overall Study|Adverse Event|1
5986078|NCT01566149|9576891|FG000|Overall Study|Non-compliance with study medication|2
5986079|NCT01566149|9576892|FG001|Overall Study|Non-compliance with study medication|0
5986080|NCT01566149|9576891|FG000|Overall Study|Protocol Violation|0
5986081|NCT01566149|9576892|FG001|Overall Study|Protocol Violation|1
5986082|NCT01566149|9576891|FG000|Overall Study|Withdrawal by Subject|1
5986083|NCT01566149|9576892|FG001|Overall Study|Withdrawal by Subject|0
5986084|NCT01386125|9576909|FG000|Overall Study|Lost to Follow-up|3
5986085|NCT01386125|9576910|FG001|Overall Study|Lost to Follow-up|9
5986086|NCT01386125|9576909|FG000|Overall Study|Physician Decision|0
5986087|NCT01386125|9576910|FG001|Overall Study|Physician Decision|1
5986088|NCT01386125|9576909|FG000|Overall Study|Protocol Violation|5
5986089|NCT01386125|9576910|FG001|Overall Study|Protocol Violation|7
5986090|NCT01386125|9576909|FG000|Overall Study|Disease Progress|1
5986091|NCT01386125|9576910|FG001|Overall Study|Disease Progress|2
5986092|NCT01386125|9576909|FG000|Overall Study|Withdrawal by Subject|13
5986093|NCT01386125|9576910|FG001|Overall Study|Withdrawal by Subject|12
5986094|NCT01386125|9576909|FG000|Overall Study|Adverse Event|2
5986095|NCT01386125|9576910|FG001|Overall Study|Adverse Event|5
5986096|NCT01386125|9576909|FG000|Overall Study|Lack of Efficacy|0
5986097|NCT01386125|9576910|FG001|Overall Study|Lack of Efficacy|1
5986098|NCT01386125|9576909|FG000|Overall Study|Participant Leaving Country|1
5986099|NCT01386125|9576910|FG001|Overall Study|Participant Leaving Country|0
5986100|NCT01257568|9576916|FG000|Overall Study|Lost to Follow-up|2
5986101|NCT01257568|9576916|FG000|Overall Study|Withdrawal by Subject|6
5986102|NCT01257568|9576916|FG000|Overall Study|Terminated|1
5986103|NCT01257568|9576916|FG000|Overall Study|Component Revision|24
5986104|NCT01165424|9576922|FG000|Overall Study|Clinical adverse experiences|1
5986105|NCT01165424|9576922|FG000|Overall Study|Laboratory adverse experiences|1
5986106|NCT01165424|9576922|FG000|Overall Study|Did not meet entry criteria|1
5986107|NCT01165424|9576922|FG000|Overall Study|Participant moved (relocated)|1
5986108|NCT01135134|9576928|FG000|Overall Study|Adverse Event|1
5986109|NCT01135134|9576929|FG001|Overall Study|Adverse Event|1
5986110|NCT01135134|9576928|FG000|Overall Study|Did not meet protocol eligibility|1
5986111|NCT01135134|9576929|FG001|Overall Study|Did not meet protocol eligibility|0
5986112|NCT00867165|9576937|FG000|Overall Study|Adverse Event|3
5986113|NCT00867165|9576938|FG001|Overall Study|Adverse Event|0
5986114|NCT00867165|9576937|FG000|Overall Study|Withdrawal by Subject|1
5986115|NCT00867165|9576938|FG001|Overall Study|Withdrawal by Subject|0
5986116|NCT00733005|9576946|FG000|Overall Study|Adverse Event|0
5986117|NCT00733005|9576947|FG001|Overall Study|Adverse Event|1
5986118|NCT00733005|9576946|FG000|Overall Study|Treatment Failure|0
5986119|NCT00733005|9576947|FG001|Overall Study|Treatment Failure|1
5986120|NCT00733005|9576946|FG000|Overall Study|Withdrawal by Subject|0
5986121|NCT00733005|9576947|FG001|Overall Study|Withdrawal by Subject|1
5986122|NCT00733005|9576946|FG000|Overall Study|Protocol Violation|2
5986123|NCT00733005|9576947|FG001|Overall Study|Protocol Violation|0
5986124|NCT00732381|9576955|FG000|Overall Study|Adverse Event|1
5986125|NCT00732381|9576956|FG001|Overall Study|Adverse Event|0
5986126|NCT00732381|9576955|FG000|Overall Study|Treatment Failure|1
5986127|NCT00732381|9576956|FG001|Overall Study|Treatment Failure|1
5986128|NCT00654095|9576962|FG000|Overall Study|Drop in low density lipoprotein (1)|2
5986129|NCT00654095|9576962|FG000|Overall Study|Elevated triglyceride level (2)|1
5986130|NCT00654095|9576962|FG000|Overall Study|Elevated alanine aminotransferase (3)|1
5986131|NCT00654095|9576962|FG000|Overall Study|Adverse Event|11
5986132|NCT00654095|9576962|FG000|Overall Study|Withdrawal by Subject|5
5986133|NCT00654095|9576962|FG000|Overall Study|Elevated alanine aminotransferase (4)|7
5986134|NCT00654095|9576962|FG000|Overall Study|Adverse reaction did not improve (5)|4
5986135|NCT00654095|9576962|FG000|Overall Study|Did not meet inclusion criteria|1
5986136|NCT00653523|9576966|FG000|Overall Study|Drop in low density lipoprotein (1)|2
5986137|NCT00653523|9576966|FG000|Overall Study|Elevated creatine phosphokinase (2)|1
5986138|NCT00653523|9576966|FG000|Overall Study|Adverse Event|7
5986139|NCT00653523|9576966|FG000|Overall Study|Withdrawal by Subject|6
5986140|NCT00653523|9576966|FG000|Overall Study|Elevated alanine aminotransferase (3)|2
5986141|NCT00653523|9576966|FG000|Overall Study|Adverse reaction did not improve (4)|1
5986142|NCT00599027|9576972|FG000|Overall Study|Withdrawal by Subject|1
5986143|NCT00599027|9576973|FG001|Overall Study|Withdrawal by Subject|1
5986144|NCT00599027|9576972|FG000|Overall Study|Adverse Event|0
5986145|NCT00599027|9576973|FG001|Overall Study|Adverse Event|1
5986146|NCT00599027|9576972|FG000|Overall Study|Treatment Failure|0
5986147|NCT00599027|9576973|FG001|Overall Study|Treatment Failure|1
5986148|NCT00552032|9576981|FG000|Overall Study|Withdrawal by Subject|2
5986149|NCT00552032|9576982|FG001|Overall Study|Withdrawal by Subject|2
5986150|NCT00552032|9576981|FG000|Overall Study|Protocol Violation|7
5986151|NCT00552032|9576982|FG001|Overall Study|Protocol Violation|12
5986152|NCT00552032|9576981|FG000|Overall Study|Lost to Follow-up|8
5986153|NCT00552032|9576982|FG001|Overall Study|Lost to Follow-up|5
5986154|NCT00546052|9576988|FG000|Overall Study|Adverse Event|47
5986155|NCT00546052|9576988|FG000|Overall Study|Lost to Follow-up|144
5986156|NCT00546052|9576988|FG000|Overall Study|Protocol Violation|9
5986157|NCT00546052|9576988|FG000|Overall Study|Withdrawal by Subject|20
5986158|NCT00546052|9576988|FG000|Overall Study|Non Compliance|7
5986159|NCT00442117|9576997|FG000|Overall Study|Adverse Event|3
5986160|NCT00442117|9576998|FG001|Overall Study|Adverse Event|2
5986161|NCT00442117|9576997|FG000|Overall Study|Lack of Efficacy|2
5986162|NCT00442117|9576998|FG001|Overall Study|Lack of Efficacy|6
5986163|NCT00442117|9576997|FG000|Overall Study|Lost to Follow-up|1
5986164|NCT00442117|9576998|FG001|Overall Study|Lost to Follow-up|2
5986165|NCT00442117|9576997|FG000|Overall Study|Withdrawal by Subject|2
5986166|NCT00442117|9576998|FG001|Overall Study|Withdrawal by Subject|2
5986167|NCT00442117|9576997|FG000|Overall Study|Major Deviation|25
5986168|NCT00442117|9576998|FG001|Overall Study|Major Deviation|20
5986169|NCT00442117|9576997|FG000|Overall Study|Non compliance with protocol|3
5986170|NCT00442117|9576998|FG001|Overall Study|Non compliance with protocol|5
5986171|NCT00442117|9576997|FG000|Overall Study|Met Withdrawal Criteria|2
5986172|NCT00442117|9576998|FG001|Overall Study|Met Withdrawal Criteria|1
5986173|NCT00424008|9577006|FG000|Overall Study|Adverse Event|8
5986174|NCT00424008|9577007|FG001|Overall Study|Adverse Event|6
5986175|NCT00424008|9577006|FG000|Overall Study|Lack of Efficacy|40
5986176|NCT00424008|9577007|FG001|Overall Study|Lack of Efficacy|34
5986177|NCT00424008|9577006|FG000|Overall Study|Lost to Follow-up|1
5986178|NCT00424008|9577007|FG001|Overall Study|Lost to Follow-up|2
5986179|NCT00424008|9577006|FG000|Overall Study|Withdrawal by Subject|5
5986180|NCT00424008|9577007|FG001|Overall Study|Withdrawal by Subject|8
5986181|NCT00424008|9577006|FG000|Overall Study|Noncompliance with protocol|13
5986182|NCT00424008|9577007|FG001|Overall Study|Noncompliance with protocol|7
5986183|NCT00424008|9577006|FG000|Overall Study|Did not meet protocol eligibility|16
5986184|NCT00424008|9577007|FG001|Overall Study|Did not meet protocol eligibility|21
5986185|NCT00424008|9577006|FG000|Overall Study|Administrative|266
5986186|NCT00424008|9577007|FG001|Overall Study|Administrative|257
5986187|NCT00423176|9577016|FG000|Overall Study|Adverse Event|4
5986188|NCT00423176|9577017|FG001|Overall Study|Adverse Event|6
5986189|NCT00423176|9577016|FG000|Overall Study|Treatment Failure|1
5986190|NCT00423176|9577017|FG001|Overall Study|Treatment Failure|6
5986191|NCT00423176|9577016|FG000|Overall Study|Lost to Follow-up|4
5986192|NCT00423176|9577017|FG001|Overall Study|Lost to Follow-up|7
5986193|NCT00423176|9577016|FG000|Overall Study|Withdrawal by Subject|4
5986194|NCT00423176|9577017|FG001|Overall Study|Withdrawal by Subject|3
5986195|NCT00423176|9577016|FG000|Overall Study|Protocol Violation|1
5986196|NCT00423176|9577017|FG001|Overall Study|Protocol Violation|3
5986197|NCT00423176|9577016|FG000|Overall Study|Did not meet protocol eligibility|2
5986198|NCT00423176|9577017|FG001|Overall Study|Did not meet protocol eligibility|4
5986199|NCT00383240|9577027|FG000|Overall Study|Adverse Event|4
5986200|NCT00383240|9577028|FG001|Overall Study|Adverse Event|6
5986201|NCT00383240|9577029|FG002|Overall Study|Adverse Event|9
5986202|NCT00383240|9577030|FG003|Overall Study|Adverse Event|7
5986203|NCT00383240|9577027|FG000|Overall Study|Treatment Failure|8
5986204|NCT00383240|9577028|FG001|Overall Study|Treatment Failure|13
5986205|NCT00383240|9577029|FG002|Overall Study|Treatment Failure|47
5986206|NCT00383240|9577030|FG003|Overall Study|Treatment Failure|46
5986207|NCT00383240|9577027|FG000|Overall Study|Lost to Follow-up|3
5986208|NCT00383240|9577028|FG001|Overall Study|Lost to Follow-up|0
5986209|NCT00383240|9577029|FG002|Overall Study|Lost to Follow-up|0
5986210|NCT00383240|9577030|FG003|Overall Study|Lost to Follow-up|2
5986211|NCT00383240|9577027|FG000|Overall Study|Withdrawal by subject, reasons unrelated|6
5986212|NCT00383240|9577028|FG001|Overall Study|Withdrawal by subject, reasons unrelated|3
5986213|NCT00383240|9577029|FG002|Overall Study|Withdrawal by subject, reasons unrelated|8
5986214|NCT00383240|9577030|FG003|Overall Study|Withdrawal by subject, reasons unrelated|8
5986215|NCT00383240|9577027|FG000|Overall Study|Withdrawal by subjects, reasons related|0
5986216|NCT00383240|9577028|FG001|Overall Study|Withdrawal by subjects, reasons related|1
5986217|NCT00383240|9577029|FG002|Overall Study|Withdrawal by subjects, reasons related|3
5986218|NCT00383240|9577030|FG003|Overall Study|Withdrawal by subjects, reasons related|5
5986219|NCT00383240|9577027|FG000|Overall Study|Protocol Violation|4
5986220|NCT00383240|9577028|FG001|Overall Study|Protocol Violation|5
5986221|NCT00383240|9577029|FG002|Overall Study|Protocol Violation|9
5986222|NCT00383240|9577030|FG003|Overall Study|Protocol Violation|6
5986223|NCT00383240|9577027|FG000|Overall Study|Did not meet protocol eligibility|9
5986224|NCT00383240|9577028|FG001|Overall Study|Did not meet protocol eligibility|4
5986225|NCT00383240|9577029|FG002|Overall Study|Did not meet protocol eligibility|9
5986226|NCT00383240|9577030|FG003|Overall Study|Did not meet protocol eligibility|3
5986227|NCT00383240|9577027|FG000|Overall Study|Administrative|1
5986228|NCT00383240|9577028|FG001|Overall Study|Administrative|1
5986229|NCT00383240|9577029|FG002|Overall Study|Administrative|0
5986230|NCT00383240|9577030|FG003|Overall Study|Administrative|0
6044794|NCT00398216|9644014|FG000|Overall Study|Adverse Event|4
6044795|NCT00398216|9644015|FG001|Overall Study|Adverse Event|2
6044796|NCT00398216|9644016|FG002|Overall Study|Adverse Event|5
6044797|NCT00398216|9644017|FG003|Overall Study|Adverse Event|7
6044798|NCT00398216|9644018|FG004|Overall Study|Adverse Event|2
6044799|NCT00398216|9644014|FG000|Overall Study|Protocol Violation|2
6044800|NCT00398216|9644015|FG001|Overall Study|Protocol Violation|4
6044801|NCT00398216|9644016|FG002|Overall Study|Protocol Violation|5
6044802|NCT00398216|9644017|FG003|Overall Study|Protocol Violation|7
6044803|NCT00398216|9644018|FG004|Overall Study|Protocol Violation|5
6044804|NCT00398216|9644014|FG000|Overall Study|Lost to Follow-up|1
6044805|NCT00398216|9644015|FG001|Overall Study|Lost to Follow-up|6
6044806|NCT00398216|9644016|FG002|Overall Study|Lost to Follow-up|4
6044807|NCT00398216|9644017|FG003|Overall Study|Lost to Follow-up|4
6044808|NCT00398216|9644018|FG004|Overall Study|Lost to Follow-up|1
6044809|NCT00398216|9644014|FG000|Overall Study|Death|0
6044810|NCT00398216|9644015|FG001|Overall Study|Death|3
6044811|NCT00398216|9644016|FG002|Overall Study|Death|0
6044812|NCT00398216|9644017|FG003|Overall Study|Death|0
6044813|NCT00398216|9644018|FG004|Overall Study|Death|0
6044814|NCT00398216|9644014|FG000|Overall Study|Withdrawal by Subject|1
6044815|NCT00398216|9644015|FG001|Overall Study|Withdrawal by Subject|0
6044816|NCT00398216|9644016|FG002|Overall Study|Withdrawal by Subject|3
6044817|NCT00398216|9644017|FG003|Overall Study|Withdrawal by Subject|1
6044818|NCT00398216|9644018|FG004|Overall Study|Withdrawal by Subject|2
6044819|NCT00398216|9644014|FG000|Overall Study|administrative reasons|3
6044820|NCT00398216|9644015|FG001|Overall Study|administrative reasons|4
6044821|NCT00398216|9644016|FG002|Overall Study|administrative reasons|4
6044822|NCT00398216|9644017|FG003|Overall Study|administrative reasons|3
6044823|NCT00398216|9644018|FG004|Overall Study|administrative reasons|3
6044824|NCT00398216|9644014|FG000|Overall Study|entrance criteria|0
6044825|NCT00398216|9644015|FG001|Overall Study|entrance criteria|0
6044826|NCT00398216|9644016|FG002|Overall Study|entrance criteria|0
6044827|NCT00398216|9644017|FG003|Overall Study|entrance criteria|0
6044828|NCT00398216|9644018|FG004|Overall Study|entrance criteria|2
6044829|NCT00398320|9644030|FG000|Overall Study|Death|1
6044830|NCT00398320|9644030|FG000|Overall Study|Adverse Event|4
6044831|NCT00398320|9644030|FG000|Overall Study|Physician Decision|1
6044832|NCT00398411|9644040|FG000|Overall Study|Death|0
6044833|NCT00398411|9644041|FG001|Overall Study|Death|1
6044834|NCT00398567|9644059|FG000|Overall Study|Disease Progression|3
6044835|NCT00398567|9644060|FG001|Overall Study|Disease Progression|4
6044836|NCT00398567|9644061|FG002|Overall Study|Disease Progression|27
6044837|NCT00398567|9644059|FG000|Overall Study|Withdrawal by Subject|1
6044838|NCT00398567|9644060|FG001|Overall Study|Withdrawal by Subject|0
6044839|NCT00398567|9644061|FG002|Overall Study|Withdrawal by Subject|4
6044840|NCT00398567|9644059|FG000|Overall Study|Adverse Event|0
6044841|NCT00398567|9644060|FG001|Overall Study|Adverse Event|0
6044842|NCT00398567|9644061|FG002|Overall Study|Adverse Event|2
6044843|NCT00398567|9644059|FG000|Overall Study|Protocol Violation|0
6044844|NCT00398567|9644060|FG001|Overall Study|Protocol Violation|0
6044845|NCT00398567|9644061|FG002|Overall Study|Protocol Violation|1
6044846|NCT00398632|9644067|FG000|Overall Study|Withdrawal by Subject|1
6044847|NCT00398632|9644067|FG000|Overall Study|Lack of Efficacy|1
6044848|NCT00398866|9644075|FG000|Overall Study|Adverse Event|1
6044849|NCT00398866|9644076|FG001|Overall Study|Adverse Event|0
6044850|NCT00398866|9644077|FG002|Overall Study|Adverse Event|0
6044851|NCT00398866|9644075|FG000|Overall Study|Lack of Efficacy|0
6044852|NCT00398866|9644076|FG001|Overall Study|Lack of Efficacy|0
6044853|NCT00398866|9644077|FG002|Overall Study|Lack of Efficacy|1
6044854|NCT00398866|9644075|FG000|Overall Study|Lost to Follow-up|7
6044855|NCT00398866|9644076|FG001|Overall Study|Lost to Follow-up|6
6044856|NCT00398866|9644077|FG002|Overall Study|Lost to Follow-up|4
6044857|NCT00398866|9644075|FG000|Overall Study|Withdrawal by Subject|5
6044858|NCT00398866|9644076|FG001|Overall Study|Withdrawal by Subject|1
6044859|NCT00398866|9644077|FG002|Overall Study|Withdrawal by Subject|2
6044860|NCT00398866|9644075|FG000|Overall Study|Unable to complete requirements of study|1
6044861|NCT00398866|9644076|FG001|Overall Study|Unable to complete requirements of study|1
6044862|NCT00398866|9644077|FG002|Overall Study|Unable to complete requirements of study|1
6044863|NCT00399035|9644102|FG000|Overall Study|Death|289
6044864|NCT00399035|9644103|FG001|Overall Study|Death|141
6044865|NCT00399035|9644104|FG002|Overall Study|Death|234
6044866|NCT00399035|9644102|FG000|Overall Study|Lost to Follow-up|2
6044867|NCT00399035|9644103|FG001|Overall Study|Lost to Follow-up|1
6044868|NCT00399035|9644104|FG002|Overall Study|Lost to Follow-up|5
6044869|NCT00399035|9644102|FG000|Overall Study|Withdrawal by Subject|19
6044870|NCT00399035|9644103|FG001|Overall Study|Withdrawal by Subject|15
6044871|NCT00399035|9644104|FG002|Overall Study|Withdrawal by Subject|12
6044872|NCT00399035|9644102|FG000|Overall Study|Incorrect enrolment/eligib not fulfilled|1
6044873|NCT00399035|9644103|FG001|Overall Study|Incorrect enrolment/eligib not fulfilled|0
5986231|NCT02765399|9577061|FG000|Overall Study|Nausea|1
5986232|NCT02765399|9577062|FG001|Overall Study|Nausea|0
5986233|NCT04539262|9577076|FG000|Overall Study|Adverse Event|0
5986234|NCT04539262|9577077|FG001|Overall Study|Adverse Event|0
5986235|NCT04539262|9577078|FG002|Overall Study|Adverse Event|1
5986236|NCT04539262|9577079|FG003|Overall Study|Adverse Event|0
5986237|NCT04539262|9577080|FG004|Overall Study|Adverse Event|0
5986238|NCT04539262|9577081|FG005|Overall Study|Adverse Event|0
5986239|NCT04539262|9577082|FG006|Overall Study|Adverse Event|0
5986240|NCT04539262|9577083|FG007|Overall Study|Adverse Event|0
5986241|NCT04539262|9577076|FG000|Overall Study|Withdrew Consent|0
5986242|NCT04539262|9577077|FG001|Overall Study|Withdrew Consent|0
5986243|NCT04539262|9577078|FG002|Overall Study|Withdrew Consent|0
5986244|NCT04539262|9577079|FG003|Overall Study|Withdrew Consent|1
5986245|NCT04539262|9577080|FG004|Overall Study|Withdrew Consent|0
5986246|NCT04539262|9577081|FG005|Overall Study|Withdrew Consent|0
5986247|NCT04539262|9577082|FG006|Overall Study|Withdrew Consent|0
5986248|NCT04539262|9577083|FG007|Overall Study|Withdrew Consent|0
5986249|NCT04539262|9577076|FG000|Overall Study|Randomized, Not treated|0
5986250|NCT04539262|9577077|FG001|Overall Study|Randomized, Not treated|1
5986251|NCT04539262|9577078|FG002|Overall Study|Randomized, Not treated|0
5986252|NCT04539262|9577079|FG003|Overall Study|Randomized, Not treated|0
5986253|NCT04539262|9577080|FG004|Overall Study|Randomized, Not treated|0
5986254|NCT04539262|9577081|FG005|Overall Study|Randomized, Not treated|0
5986255|NCT04539262|9577082|FG006|Overall Study|Randomized, Not treated|1
5986256|NCT04539262|9577083|FG007|Overall Study|Randomized, Not treated|0
5986257|NCT04482439|9577104|FG000|Overall Study|Lost to Follow-up|1
5986258|NCT04482439|9577104|FG000|Overall Study|Unrelated illness|1
5986277|NCT03950674|9577163|FG000|Overall Study|Death|3
5986278|NCT03950674|9577164|FG001|Overall Study|Death|7
5986279|NCT03950674|9577163|FG000|Overall Study|Ongoing in Study|22
5986280|NCT03950674|9577164|FG001|Overall Study|Ongoing in Study|8
5986349|NCT03529773|9577351|FG038|Overall Study|Adverse Event|1
5986350|NCT03529773|9577352|FG039|Overall Study|Adverse Event|1
5986351|NCT03529773|9577313|FG000|Overall Study|Death|0
5986352|NCT03529773|9577314|FG001|Overall Study|Death|0
5986353|NCT03529773|9577315|FG002|Overall Study|Death|0
5986354|NCT03529773|9577316|FG003|Overall Study|Death|0
5986355|NCT03529773|9577317|FG004|Overall Study|Death|0
5986356|NCT03529773|9577318|FG005|Overall Study|Death|0
5986357|NCT03529773|9577319|FG006|Overall Study|Death|0
5986358|NCT03529773|9577320|FG007|Overall Study|Death|0
5986359|NCT03529773|9577321|FG008|Overall Study|Death|0
5986360|NCT03529773|9577322|FG009|Overall Study|Death|0
5986361|NCT03529773|9577323|FG010|Overall Study|Death|0
5986362|NCT03529773|9577324|FG011|Overall Study|Death|0
5986363|NCT03529773|9577325|FG012|Overall Study|Death|1
5986364|NCT03529773|9577326|FG013|Overall Study|Death|0
5986365|NCT03529773|9577327|FG014|Overall Study|Death|0
5986366|NCT03529773|9577328|FG015|Overall Study|Death|0
5986367|NCT03529773|9577329|FG016|Overall Study|Death|0
5986368|NCT03529773|9577330|FG017|Overall Study|Death|0
5986369|NCT03529773|9577331|FG018|Overall Study|Death|0
5986370|NCT03529773|9577332|FG019|Overall Study|Death|1
5986371|NCT03529773|9577333|FG020|Overall Study|Death|0
5986372|NCT03529773|9577334|FG021|Overall Study|Death|0
5986373|NCT03529773|9577335|FG022|Overall Study|Death|1
5986374|NCT03529773|9577336|FG023|Overall Study|Death|0
5986375|NCT03529773|9577337|FG024|Overall Study|Death|0
5986376|NCT03529773|9577338|FG025|Overall Study|Death|0
5986377|NCT03529773|9577339|FG026|Overall Study|Death|0
5986378|NCT03529773|9577340|FG027|Overall Study|Death|0
5986379|NCT03529773|9577341|FG028|Overall Study|Death|0
5986380|NCT03529773|9577342|FG029|Overall Study|Death|0
5986381|NCT03529773|9577343|FG030|Overall Study|Death|0
5986382|NCT03529773|9577344|FG031|Overall Study|Death|0
5986383|NCT03529773|9577345|FG032|Overall Study|Death|0
5986384|NCT03529773|9577346|FG033|Overall Study|Death|1
5986385|NCT03529773|9577347|FG034|Overall Study|Death|1
5986386|NCT03529773|9577348|FG035|Overall Study|Death|0
5986387|NCT03529773|9577349|FG036|Overall Study|Death|1
5986388|NCT03529773|9577350|FG037|Overall Study|Death|0
5986389|NCT03529773|9577351|FG038|Overall Study|Death|0
5986390|NCT03529773|9577352|FG039|Overall Study|Death|0
5986391|NCT03529773|9577313|FG000|Overall Study|Lost to Follow-up|0
5986392|NCT03529773|9577314|FG001|Overall Study|Lost to Follow-up|0
5986393|NCT03529773|9577315|FG002|Overall Study|Lost to Follow-up|1
5986394|NCT03529773|9577316|FG003|Overall Study|Lost to Follow-up|0
5986395|NCT03529773|9577317|FG004|Overall Study|Lost to Follow-up|1
5986396|NCT03529773|9577318|FG005|Overall Study|Lost to Follow-up|1
5986397|NCT03529773|9577319|FG006|Overall Study|Lost to Follow-up|0
5986398|NCT03529773|9577320|FG007|Overall Study|Lost to Follow-up|0
5986399|NCT03529773|9577321|FG008|Overall Study|Lost to Follow-up|0
5986400|NCT03529773|9577322|FG009|Overall Study|Lost to Follow-up|0
5986401|NCT03529773|9577323|FG010|Overall Study|Lost to Follow-up|0
5986402|NCT03529773|9577324|FG011|Overall Study|Lost to Follow-up|0
5986403|NCT03529773|9577325|FG012|Overall Study|Lost to Follow-up|0
5986404|NCT03529773|9577326|FG013|Overall Study|Lost to Follow-up|1
5986405|NCT03529773|9577327|FG014|Overall Study|Lost to Follow-up|4
5986406|NCT03529773|9577328|FG015|Overall Study|Lost to Follow-up|1
5986407|NCT03529773|9577329|FG016|Overall Study|Lost to Follow-up|1
5986259|NCT04404725|9577113|FG000|First Intervention|Withdrawal by Subject|0
5986260|NCT04404725|9577114|FG001|First Intervention|Withdrawal by Subject|2
5986261|NCT04404725|9577113|FG000|Second Intervention|Adverse Event|1
5986262|NCT04404725|9577114|FG001|Second Intervention|Adverse Event|1
5986263|NCT04404725|9577113|FG000|Second Intervention|Withdrawal by Subject|0
5986264|NCT04404725|9577114|FG001|Second Intervention|Withdrawal by Subject|1
5986265|NCT04382586|9577122|FG000|Overall Study|Death|3
5986266|NCT04382586|9577123|FG001|Overall Study|Death|4
5986267|NCT04382586|9577122|FG000|Overall Study|Lost to Follow-up|11
5986268|NCT04382586|9577123|FG001|Overall Study|Lost to Follow-up|8
5986269|NCT04382586|9577122|FG000|Overall Study|Withdrawal by Subject|3
5986270|NCT04382586|9577123|FG001|Overall Study|Withdrawal by Subject|1
5986271|NCT04382586|9577122|FG000|Overall Study|Physician Decision|0
5986272|NCT04382586|9577123|FG001|Overall Study|Physician Decision|3
5986273|NCT04348656|9577131|FG000|Overall Study|Withdrawal by Subject|2
5986274|NCT04348656|9577132|FG001|Overall Study|Withdrawal by Subject|0
5986275|NCT04348656|9577131|FG000|Overall Study|Lost to Follow-up|11
5986276|NCT04348656|9577132|FG001|Overall Study|Lost to Follow-up|6
5986281|NCT03847974|9577175|FG000|Overall Study|relocated out of region|3
5986282|NCT03847974|9577175|FG000|Overall Study|Withdrawal by Subject|2
5986283|NCT03847974|9577175|FG000|Overall Study|Adverse Event|1
5986284|NCT03846427|9577179|FG000|Overall Study|Death|7
5986285|NCT03846427|9577179|FG000|Overall Study|Withdrawal by Subject|2
5986286|NCT03846427|9577179|FG000|Overall Study|Remaining in study|59
5986287|NCT03671148|9577208|FG000|Overall Study|Adverse Event|3
5986288|NCT03671148|9577209|FG001|Overall Study|Adverse Event|2
5986289|NCT03671148|9577208|FG000|Overall Study|Withdrawal by Subject|8
5986290|NCT03671148|9577209|FG001|Overall Study|Withdrawal by Subject|2
5986291|NCT03671148|9577208|FG000|Overall Study|Lost to Follow-up|1
5986292|NCT03671148|9577209|FG001|Overall Study|Lost to Follow-up|2
5986293|NCT03671148|9577208|FG000|Overall Study|Lack of Efficacy|7
5986294|NCT03671148|9577209|FG001|Overall Study|Lack of Efficacy|2
5986295|NCT03671148|9577208|FG000|Overall Study|COVID-19 Logistical Restrictions|0
5986296|NCT03671148|9577209|FG001|Overall Study|COVID-19 Logistical Restrictions|1
5986297|NCT03671148|9577208|FG000|Overall Study|Other|1
5986298|NCT03671148|9577209|FG001|Overall Study|Other|0
5986299|NCT03671148|9577208|FG000|Overall Study|Incomplete Randomization Visit|1
5986300|NCT03671148|9577209|FG001|Overall Study|Incomplete Randomization Visit|0
5986307|NCT03607487|9577245|FG000|Overall Study|Withdrawal by Subject|2
5986308|NCT03607487|9577246|FG001|Overall Study|Withdrawal by Subject|0
5986309|NCT03607487|9577247|FG002|Overall Study|Withdrawal by Subject|0
5986310|NCT03607487|9577248|FG003|Overall Study|Withdrawal by Subject|1
5986311|NCT03529773|9577313|FG000|Overall Study|Adverse Event|0
5986312|NCT03529773|9577314|FG001|Overall Study|Adverse Event|0
5986313|NCT03529773|9577315|FG002|Overall Study|Adverse Event|0
5986314|NCT03529773|9577316|FG003|Overall Study|Adverse Event|0
5986315|NCT03529773|9577317|FG004|Overall Study|Adverse Event|0
5986316|NCT03529773|9577318|FG005|Overall Study|Adverse Event|0
5986317|NCT03529773|9577319|FG006|Overall Study|Adverse Event|0
5986318|NCT03529773|9577320|FG007|Overall Study|Adverse Event|0
5986319|NCT03529773|9577321|FG008|Overall Study|Adverse Event|0
5986320|NCT03529773|9577322|FG009|Overall Study|Adverse Event|0
5986321|NCT03529773|9577323|FG010|Overall Study|Adverse Event|0
5986322|NCT03529773|9577324|FG011|Overall Study|Adverse Event|0
5986323|NCT03529773|9577325|FG012|Overall Study|Adverse Event|0
5986324|NCT03529773|9577326|FG013|Overall Study|Adverse Event|0
5986325|NCT03529773|9577327|FG014|Overall Study|Adverse Event|0
5986326|NCT03529773|9577328|FG015|Overall Study|Adverse Event|0
5986327|NCT03529773|9577329|FG016|Overall Study|Adverse Event|0
5986328|NCT03529773|9577330|FG017|Overall Study|Adverse Event|0
5986329|NCT03529773|9577331|FG018|Overall Study|Adverse Event|0
5986330|NCT03529773|9577332|FG019|Overall Study|Adverse Event|0
5986331|NCT03529773|9577333|FG020|Overall Study|Adverse Event|0
5986332|NCT03529773|9577334|FG021|Overall Study|Adverse Event|0
5986333|NCT03529773|9577335|FG022|Overall Study|Adverse Event|0
5986334|NCT03529773|9577336|FG023|Overall Study|Adverse Event|0
5986335|NCT03529773|9577337|FG024|Overall Study|Adverse Event|0
5986336|NCT03529773|9577338|FG025|Overall Study|Adverse Event|0
5986337|NCT03529773|9577339|FG026|Overall Study|Adverse Event|0
5986338|NCT03529773|9577340|FG027|Overall Study|Adverse Event|0
5986339|NCT03529773|9577341|FG028|Overall Study|Adverse Event|0
5986340|NCT03529773|9577342|FG029|Overall Study|Adverse Event|0
5986341|NCT03529773|9577343|FG030|Overall Study|Adverse Event|1
5986342|NCT03529773|9577344|FG031|Overall Study|Adverse Event|0
5986343|NCT03529773|9577345|FG032|Overall Study|Adverse Event|0
5986344|NCT03529773|9577346|FG033|Overall Study|Adverse Event|0
5986345|NCT03529773|9577347|FG034|Overall Study|Adverse Event|0
5986346|NCT03529773|9577348|FG035|Overall Study|Adverse Event|1
5986347|NCT03529773|9577349|FG036|Overall Study|Adverse Event|0
5986348|NCT03529773|9577350|FG037|Overall Study|Adverse Event|0
6146045|NCT01074944|9780555|FG001|Extended Treatment (up to 42 Months)|Pregnancy|0
5986408|NCT03529773|9577330|FG017|Overall Study|Lost to Follow-up|0
5986409|NCT03529773|9577331|FG018|Overall Study|Lost to Follow-up|1
5986410|NCT03529773|9577332|FG019|Overall Study|Lost to Follow-up|1
5986411|NCT03529773|9577333|FG020|Overall Study|Lost to Follow-up|2
5986412|NCT03529773|9577334|FG021|Overall Study|Lost to Follow-up|4
5986413|NCT03529773|9577335|FG022|Overall Study|Lost to Follow-up|3
5986414|NCT03529773|9577336|FG023|Overall Study|Lost to Follow-up|4
5986415|NCT03529773|9577337|FG024|Overall Study|Lost to Follow-up|3
5986416|NCT03529773|9577338|FG025|Overall Study|Lost to Follow-up|5
5986417|NCT03529773|9577339|FG026|Overall Study|Lost to Follow-up|5
5986418|NCT03529773|9577340|FG027|Overall Study|Lost to Follow-up|0
5986419|NCT03529773|9577341|FG028|Overall Study|Lost to Follow-up|0
5986420|NCT03529773|9577342|FG029|Overall Study|Lost to Follow-up|0
5986421|NCT03529773|9577343|FG030|Overall Study|Lost to Follow-up|1
5986422|NCT03529773|9577344|FG031|Overall Study|Lost to Follow-up|0
5986423|NCT03529773|9577345|FG032|Overall Study|Lost to Follow-up|0
5986424|NCT03529773|9577346|FG033|Overall Study|Lost to Follow-up|1
5986425|NCT03529773|9577347|FG034|Overall Study|Lost to Follow-up|1
5986426|NCT03529773|9577348|FG035|Overall Study|Lost to Follow-up|0
5986427|NCT03529773|9577349|FG036|Overall Study|Lost to Follow-up|0
5986428|NCT03529773|9577350|FG037|Overall Study|Lost to Follow-up|3
5986429|NCT03529773|9577351|FG038|Overall Study|Lost to Follow-up|1
5986430|NCT03529773|9577352|FG039|Overall Study|Lost to Follow-up|1
5986431|NCT03529773|9577313|FG000|Overall Study|No longer meets eligibility criteria|0
5986432|NCT03529773|9577314|FG001|Overall Study|No longer meets eligibility criteria|0
5986433|NCT03529773|9577315|FG002|Overall Study|No longer meets eligibility criteria|0
5986434|NCT03529773|9577316|FG003|Overall Study|No longer meets eligibility criteria|0
5986435|NCT03529773|9577317|FG004|Overall Study|No longer meets eligibility criteria|0
5986436|NCT03529773|9577318|FG005|Overall Study|No longer meets eligibility criteria|0
5986437|NCT03529773|9577319|FG006|Overall Study|No longer meets eligibility criteria|0
5986438|NCT03529773|9577320|FG007|Overall Study|No longer meets eligibility criteria|0
5986439|NCT03529773|9577321|FG008|Overall Study|No longer meets eligibility criteria|0
5986440|NCT03529773|9577322|FG009|Overall Study|No longer meets eligibility criteria|0
5986441|NCT03529773|9577323|FG010|Overall Study|No longer meets eligibility criteria|0
5986442|NCT03529773|9577324|FG011|Overall Study|No longer meets eligibility criteria|0
5986443|NCT03529773|9577325|FG012|Overall Study|No longer meets eligibility criteria|0
5986444|NCT03529773|9577326|FG013|Overall Study|No longer meets eligibility criteria|0
5986445|NCT03529773|9577327|FG014|Overall Study|No longer meets eligibility criteria|0
5986446|NCT03529773|9577328|FG015|Overall Study|No longer meets eligibility criteria|0
5986447|NCT03529773|9577329|FG016|Overall Study|No longer meets eligibility criteria|0
5986448|NCT03529773|9577330|FG017|Overall Study|No longer meets eligibility criteria|0
5986449|NCT03529773|9577331|FG018|Overall Study|No longer meets eligibility criteria|0
5986450|NCT03529773|9577332|FG019|Overall Study|No longer meets eligibility criteria|0
5986451|NCT03529773|9577333|FG020|Overall Study|No longer meets eligibility criteria|0
5986452|NCT03529773|9577334|FG021|Overall Study|No longer meets eligibility criteria|0
5986453|NCT03529773|9577335|FG022|Overall Study|No longer meets eligibility criteria|1
5986454|NCT03529773|9577336|FG023|Overall Study|No longer meets eligibility criteria|0
5986455|NCT03529773|9577337|FG024|Overall Study|No longer meets eligibility criteria|0
5986456|NCT03529773|9577338|FG025|Overall Study|No longer meets eligibility criteria|0
5986457|NCT03529773|9577339|FG026|Overall Study|No longer meets eligibility criteria|0
5986458|NCT03529773|9577340|FG027|Overall Study|No longer meets eligibility criteria|0
5986459|NCT03529773|9577341|FG028|Overall Study|No longer meets eligibility criteria|0
5986460|NCT03529773|9577342|FG029|Overall Study|No longer meets eligibility criteria|0
5986461|NCT03529773|9577343|FG030|Overall Study|No longer meets eligibility criteria|0
5986462|NCT03529773|9577344|FG031|Overall Study|No longer meets eligibility criteria|0
5986463|NCT03529773|9577345|FG032|Overall Study|No longer meets eligibility criteria|0
5986464|NCT03529773|9577346|FG033|Overall Study|No longer meets eligibility criteria|0
5986465|NCT03529773|9577347|FG034|Overall Study|No longer meets eligibility criteria|0
5986466|NCT03529773|9577348|FG035|Overall Study|No longer meets eligibility criteria|0
5986467|NCT03529773|9577349|FG036|Overall Study|No longer meets eligibility criteria|0
5986468|NCT03529773|9577350|FG037|Overall Study|No longer meets eligibility criteria|0
5986469|NCT03529773|9577351|FG038|Overall Study|No longer meets eligibility criteria|1
5986470|NCT03529773|9577352|FG039|Overall Study|No longer meets eligibility criteria|0
5986471|NCT03529773|9577313|FG000|Overall Study|Other|0
5986472|NCT03529773|9577314|FG001|Overall Study|Other|0
5986473|NCT03529773|9577315|FG002|Overall Study|Other|0
5986474|NCT03529773|9577316|FG003|Overall Study|Other|0
5986475|NCT03529773|9577317|FG004|Overall Study|Other|0
5986476|NCT03529773|9577318|FG005|Overall Study|Other|0
5986477|NCT03529773|9577319|FG006|Overall Study|Other|0
5986478|NCT03529773|9577320|FG007|Overall Study|Other|0
5986479|NCT03529773|9577321|FG008|Overall Study|Other|0
5986480|NCT03529773|9577322|FG009|Overall Study|Other|0
5986481|NCT03529773|9577323|FG010|Overall Study|Other|0
5986482|NCT03529773|9577324|FG011|Overall Study|Other|0
5986483|NCT03529773|9577325|FG012|Overall Study|Other|1
5986484|NCT03529773|9577326|FG013|Overall Study|Other|0
5986485|NCT03529773|9577327|FG014|Overall Study|Other|2
5986486|NCT03529773|9577328|FG015|Overall Study|Other|0
5986487|NCT03529773|9577329|FG016|Overall Study|Other|0
5986488|NCT03529773|9577330|FG017|Overall Study|Other|3
5986489|NCT03529773|9577331|FG018|Overall Study|Other|0
5986490|NCT03529773|9577332|FG019|Overall Study|Other|0
5986491|NCT03529773|9577333|FG020|Overall Study|Other|1
5986492|NCT03529773|9577334|FG021|Overall Study|Other|0
5986493|NCT03529773|9577335|FG022|Overall Study|Other|1
5986494|NCT03529773|9577336|FG023|Overall Study|Other|0
5986495|NCT03529773|9577337|FG024|Overall Study|Other|3
5986496|NCT03529773|9577338|FG025|Overall Study|Other|2
5986497|NCT03529773|9577339|FG026|Overall Study|Other|2
5986498|NCT03529773|9577340|FG027|Overall Study|Other|0
5986499|NCT03529773|9577341|FG028|Overall Study|Other|0
5986500|NCT03529773|9577342|FG029|Overall Study|Other|0
5986501|NCT03529773|9577343|FG030|Overall Study|Other|0
5986502|NCT03529773|9577344|FG031|Overall Study|Other|0
5986503|NCT03529773|9577345|FG032|Overall Study|Other|0
5986504|NCT03529773|9577346|FG033|Overall Study|Other|0
5986505|NCT03529773|9577347|FG034|Overall Study|Other|1
5986506|NCT03529773|9577348|FG035|Overall Study|Other|1
5986507|NCT03529773|9577349|FG036|Overall Study|Other|0
5986508|NCT03529773|9577350|FG037|Overall Study|Other|0
5986509|NCT03529773|9577351|FG038|Overall Study|Other|0
5986510|NCT03529773|9577352|FG039|Overall Study|Other|0
5986511|NCT03529773|9577313|FG000|Overall Study|Physician Decision|0
5986512|NCT03529773|9577314|FG001|Overall Study|Physician Decision|0
5986513|NCT03529773|9577315|FG002|Overall Study|Physician Decision|0
5986514|NCT03529773|9577316|FG003|Overall Study|Physician Decision|0
5986515|NCT03529773|9577317|FG004|Overall Study|Physician Decision|0
5986516|NCT03529773|9577318|FG005|Overall Study|Physician Decision|0
5986517|NCT03529773|9577319|FG006|Overall Study|Physician Decision|0
5986518|NCT03529773|9577320|FG007|Overall Study|Physician Decision|0
5986519|NCT03529773|9577321|FG008|Overall Study|Physician Decision|0
5986520|NCT03529773|9577322|FG009|Overall Study|Physician Decision|0
5986521|NCT03529773|9577323|FG010|Overall Study|Physician Decision|0
5986522|NCT03529773|9577324|FG011|Overall Study|Physician Decision|0
5986523|NCT03529773|9577325|FG012|Overall Study|Physician Decision|0
5986524|NCT03529773|9577326|FG013|Overall Study|Physician Decision|0
5986525|NCT03529773|9577327|FG014|Overall Study|Physician Decision|0
5986526|NCT03529773|9577328|FG015|Overall Study|Physician Decision|0
5986527|NCT03529773|9577329|FG016|Overall Study|Physician Decision|0
5986528|NCT03529773|9577330|FG017|Overall Study|Physician Decision|0
5986529|NCT03529773|9577331|FG018|Overall Study|Physician Decision|0
5986530|NCT03529773|9577332|FG019|Overall Study|Physician Decision|1
5986531|NCT03529773|9577333|FG020|Overall Study|Physician Decision|1
5986532|NCT03529773|9577334|FG021|Overall Study|Physician Decision|0
5986533|NCT03529773|9577335|FG022|Overall Study|Physician Decision|0
5986534|NCT03529773|9577336|FG023|Overall Study|Physician Decision|0
5986535|NCT03529773|9577337|FG024|Overall Study|Physician Decision|0
5986536|NCT03529773|9577338|FG025|Overall Study|Physician Decision|0
5986537|NCT03529773|9577339|FG026|Overall Study|Physician Decision|0
5986538|NCT03529773|9577340|FG027|Overall Study|Physician Decision|0
5986539|NCT03529773|9577341|FG028|Overall Study|Physician Decision|0
5986540|NCT03529773|9577342|FG029|Overall Study|Physician Decision|0
5986541|NCT03529773|9577343|FG030|Overall Study|Physician Decision|0
5986542|NCT03529773|9577344|FG031|Overall Study|Physician Decision|0
5986543|NCT03529773|9577345|FG032|Overall Study|Physician Decision|0
5986544|NCT03529773|9577346|FG033|Overall Study|Physician Decision|0
5986545|NCT03529773|9577347|FG034|Overall Study|Physician Decision|0
5986546|NCT03529773|9577348|FG035|Overall Study|Physician Decision|0
5986547|NCT03529773|9577349|FG036|Overall Study|Physician Decision|0
5986548|NCT03529773|9577350|FG037|Overall Study|Physician Decision|0
5986549|NCT03529773|9577351|FG038|Overall Study|Physician Decision|0
5986550|NCT03529773|9577352|FG039|Overall Study|Physician Decision|0
5986551|NCT03529773|9577313|FG000|Overall Study|Protocol Violation|0
5986552|NCT03529773|9577314|FG001|Overall Study|Protocol Violation|0
5986553|NCT03529773|9577315|FG002|Overall Study|Protocol Violation|0
5986554|NCT03529773|9577316|FG003|Overall Study|Protocol Violation|0
5986555|NCT03529773|9577317|FG004|Overall Study|Protocol Violation|0
5986556|NCT03529773|9577318|FG005|Overall Study|Protocol Violation|0
5986557|NCT03529773|9577319|FG006|Overall Study|Protocol Violation|0
5986558|NCT03529773|9577320|FG007|Overall Study|Protocol Violation|0
5986559|NCT03529773|9577321|FG008|Overall Study|Protocol Violation|0
5986560|NCT03529773|9577322|FG009|Overall Study|Protocol Violation|0
5986561|NCT03529773|9577323|FG010|Overall Study|Protocol Violation|0
5986562|NCT03529773|9577324|FG011|Overall Study|Protocol Violation|0
5986563|NCT03529773|9577325|FG012|Overall Study|Protocol Violation|0
5986564|NCT03529773|9577326|FG013|Overall Study|Protocol Violation|0
5986565|NCT03529773|9577327|FG014|Overall Study|Protocol Violation|0
5986566|NCT03529773|9577328|FG015|Overall Study|Protocol Violation|0
5986567|NCT03529773|9577329|FG016|Overall Study|Protocol Violation|0
5986568|NCT03529773|9577330|FG017|Overall Study|Protocol Violation|0
5986569|NCT03529773|9577331|FG018|Overall Study|Protocol Violation|0
5986570|NCT03529773|9577332|FG019|Overall Study|Protocol Violation|0
5986571|NCT03529773|9577333|FG020|Overall Study|Protocol Violation|0
5986572|NCT03529773|9577334|FG021|Overall Study|Protocol Violation|0
5986573|NCT03529773|9577335|FG022|Overall Study|Protocol Violation|0
5986574|NCT03529773|9577336|FG023|Overall Study|Protocol Violation|0
5986575|NCT03529773|9577337|FG024|Overall Study|Protocol Violation|0
5986576|NCT03529773|9577338|FG025|Overall Study|Protocol Violation|0
5986577|NCT03529773|9577339|FG026|Overall Study|Protocol Violation|0
5986578|NCT03529773|9577340|FG027|Overall Study|Protocol Violation|0
5986579|NCT03529773|9577341|FG028|Overall Study|Protocol Violation|0
5986580|NCT03529773|9577342|FG029|Overall Study|Protocol Violation|0
5986581|NCT03529773|9577343|FG030|Overall Study|Protocol Violation|1
5986582|NCT03529773|9577344|FG031|Overall Study|Protocol Violation|0
5986583|NCT03529773|9577345|FG032|Overall Study|Protocol Violation|0
5986584|NCT03529773|9577346|FG033|Overall Study|Protocol Violation|0
5986585|NCT03529773|9577347|FG034|Overall Study|Protocol Violation|0
5986586|NCT03529773|9577348|FG035|Overall Study|Protocol Violation|0
5986587|NCT03529773|9577349|FG036|Overall Study|Protocol Violation|0
5986588|NCT03529773|9577350|FG037|Overall Study|Protocol Violation|0
5986589|NCT03529773|9577351|FG038|Overall Study|Protocol Violation|0
5986590|NCT03529773|9577352|FG039|Overall Study|Protocol Violation|0
5986591|NCT03529773|9577313|FG000|Overall Study|Withdrawal by Subject|0
5986592|NCT03529773|9577314|FG001|Overall Study|Withdrawal by Subject|0
5986593|NCT03529773|9577315|FG002|Overall Study|Withdrawal by Subject|0
5986594|NCT03529773|9577316|FG003|Overall Study|Withdrawal by Subject|0
5986595|NCT03529773|9577317|FG004|Overall Study|Withdrawal by Subject|0
5986596|NCT03529773|9577318|FG005|Overall Study|Withdrawal by Subject|0
5986597|NCT03529773|9577319|FG006|Overall Study|Withdrawal by Subject|0
5986598|NCT03529773|9577320|FG007|Overall Study|Withdrawal by Subject|1
5986599|NCT03529773|9577321|FG008|Overall Study|Withdrawal by Subject|0
5986600|NCT03529773|9577322|FG009|Overall Study|Withdrawal by Subject|1
5986601|NCT03529773|9577323|FG010|Overall Study|Withdrawal by Subject|1
5986602|NCT03529773|9577324|FG011|Overall Study|Withdrawal by Subject|0
5986603|NCT03529773|9577325|FG012|Overall Study|Withdrawal by Subject|0
5986604|NCT03529773|9577326|FG013|Overall Study|Withdrawal by Subject|0
5986605|NCT03529773|9577327|FG014|Overall Study|Withdrawal by Subject|0
5986606|NCT03529773|9577328|FG015|Overall Study|Withdrawal by Subject|3
5986607|NCT03529773|9577329|FG016|Overall Study|Withdrawal by Subject|0
5986608|NCT03529773|9577330|FG017|Overall Study|Withdrawal by Subject|2
5986609|NCT03529773|9577331|FG018|Overall Study|Withdrawal by Subject|3
5986610|NCT03529773|9577332|FG019|Overall Study|Withdrawal by Subject|1
5986611|NCT03529773|9577333|FG020|Overall Study|Withdrawal by Subject|3
5986612|NCT03529773|9577334|FG021|Overall Study|Withdrawal by Subject|1
5986613|NCT03529773|9577335|FG022|Overall Study|Withdrawal by Subject|1
5986614|NCT03529773|9577336|FG023|Overall Study|Withdrawal by Subject|2
5986615|NCT03529773|9577337|FG024|Overall Study|Withdrawal by Subject|2
5986616|NCT03529773|9577338|FG025|Overall Study|Withdrawal by Subject|4
5986617|NCT03529773|9577339|FG026|Overall Study|Withdrawal by Subject|2
5986618|NCT03529773|9577340|FG027|Overall Study|Withdrawal by Subject|1
5986619|NCT03529773|9577341|FG028|Overall Study|Withdrawal by Subject|1
5986620|NCT03529773|9577342|FG029|Overall Study|Withdrawal by Subject|0
5986621|NCT03529773|9577343|FG030|Overall Study|Withdrawal by Subject|0
5986622|NCT03529773|9577344|FG031|Overall Study|Withdrawal by Subject|0
5986623|NCT03529773|9577345|FG032|Overall Study|Withdrawal by Subject|0
5986624|NCT03529773|9577346|FG033|Overall Study|Withdrawal by Subject|0
5986625|NCT03529773|9577347|FG034|Overall Study|Withdrawal by Subject|1
5986626|NCT03529773|9577348|FG035|Overall Study|Withdrawal by Subject|2
5986627|NCT03529773|9577349|FG036|Overall Study|Withdrawal by Subject|0
5986628|NCT03529773|9577350|FG037|Overall Study|Withdrawal by Subject|2
5986629|NCT03529773|9577351|FG038|Overall Study|Withdrawal by Subject|1
5986630|NCT03529773|9577352|FG039|Overall Study|Withdrawal by Subject|1
5986631|NCT03529773|9577313|FG000|Overall Study|Screen Failure|0
5986632|NCT03529773|9577314|FG001|Overall Study|Screen Failure|0
5986633|NCT03529773|9577315|FG002|Overall Study|Screen Failure|0
5986634|NCT03529773|9577316|FG003|Overall Study|Screen Failure|0
5986635|NCT03529773|9577317|FG004|Overall Study|Screen Failure|0
5986636|NCT03529773|9577318|FG005|Overall Study|Screen Failure|0
5986637|NCT03529773|9577319|FG006|Overall Study|Screen Failure|0
5986638|NCT03529773|9577320|FG007|Overall Study|Screen Failure|0
5986639|NCT03529773|9577321|FG008|Overall Study|Screen Failure|0
5986640|NCT03529773|9577322|FG009|Overall Study|Screen Failure|0
5986641|NCT03529773|9577323|FG010|Overall Study|Screen Failure|0
5986642|NCT03529773|9577324|FG011|Overall Study|Screen Failure|0
5986643|NCT03529773|9577325|FG012|Overall Study|Screen Failure|0
5986644|NCT03529773|9577326|FG013|Overall Study|Screen Failure|0
5986645|NCT03529773|9577327|FG014|Overall Study|Screen Failure|0
5986646|NCT03529773|9577328|FG015|Overall Study|Screen Failure|0
5986647|NCT03529773|9577329|FG016|Overall Study|Screen Failure|0
5986648|NCT03529773|9577330|FG017|Overall Study|Screen Failure|0
5986649|NCT03529773|9577331|FG018|Overall Study|Screen Failure|0
5986650|NCT03529773|9577332|FG019|Overall Study|Screen Failure|0
5986651|NCT03529773|9577333|FG020|Overall Study|Screen Failure|0
5986652|NCT03529773|9577334|FG021|Overall Study|Screen Failure|0
5986653|NCT03529773|9577335|FG022|Overall Study|Screen Failure|0
5986654|NCT03529773|9577336|FG023|Overall Study|Screen Failure|0
5986655|NCT03529773|9577337|FG024|Overall Study|Screen Failure|0
5986656|NCT03529773|9577338|FG025|Overall Study|Screen Failure|0
5986657|NCT03529773|9577339|FG026|Overall Study|Screen Failure|0
5986658|NCT03529773|9577340|FG027|Overall Study|Screen Failure|0
5986659|NCT03529773|9577341|FG028|Overall Study|Screen Failure|0
5986660|NCT03529773|9577342|FG029|Overall Study|Screen Failure|0
5986661|NCT03529773|9577343|FG030|Overall Study|Screen Failure|0
5986662|NCT03529773|9577344|FG031|Overall Study|Screen Failure|0
5986663|NCT03529773|9577345|FG032|Overall Study|Screen Failure|0
5986664|NCT03529773|9577346|FG033|Overall Study|Screen Failure|0
5986665|NCT03529773|9577347|FG034|Overall Study|Screen Failure|0
5986666|NCT03529773|9577348|FG035|Overall Study|Screen Failure|0
5986667|NCT03529773|9577349|FG036|Overall Study|Screen Failure|1
5986668|NCT03529773|9577350|FG037|Overall Study|Screen Failure|1
5986669|NCT03529773|9577351|FG038|Overall Study|Screen Failure|0
5986670|NCT03529773|9577352|FG039|Overall Study|Screen Failure|1
5986671|NCT03529773|9577313|FG000|Overall Study|Randomized but not vaccinated|0
5986672|NCT03529773|9577314|FG001|Overall Study|Randomized but not vaccinated|0
5986673|NCT03529773|9577315|FG002|Overall Study|Randomized but not vaccinated|0
5986674|NCT03529773|9577316|FG003|Overall Study|Randomized but not vaccinated|0
5986675|NCT03529773|9577317|FG004|Overall Study|Randomized but not vaccinated|0
5986676|NCT03529773|9577318|FG005|Overall Study|Randomized but not vaccinated|0
5986677|NCT03529773|9577319|FG006|Overall Study|Randomized but not vaccinated|0
5986678|NCT03529773|9577320|FG007|Overall Study|Randomized but not vaccinated|0
5986679|NCT03529773|9577321|FG008|Overall Study|Randomized but not vaccinated|0
5986680|NCT03529773|9577322|FG009|Overall Study|Randomized but not vaccinated|0
5986681|NCT03529773|9577323|FG010|Overall Study|Randomized but not vaccinated|0
5986682|NCT03529773|9577324|FG011|Overall Study|Randomized but not vaccinated|0
5986683|NCT03529773|9577325|FG012|Overall Study|Randomized but not vaccinated|0
5986684|NCT03529773|9577326|FG013|Overall Study|Randomized but not vaccinated|0
5986685|NCT03529773|9577327|FG014|Overall Study|Randomized but not vaccinated|0
5986686|NCT03529773|9577328|FG015|Overall Study|Randomized but not vaccinated|0
5986687|NCT03529773|9577329|FG016|Overall Study|Randomized but not vaccinated|0
5986688|NCT03529773|9577330|FG017|Overall Study|Randomized but not vaccinated|1
5986689|NCT03529773|9577331|FG018|Overall Study|Randomized but not vaccinated|0
5986690|NCT03529773|9577332|FG019|Overall Study|Randomized but not vaccinated|0
5986691|NCT03529773|9577333|FG020|Overall Study|Randomized but not vaccinated|0
5986692|NCT03529773|9577334|FG021|Overall Study|Randomized but not vaccinated|0
5986693|NCT03529773|9577335|FG022|Overall Study|Randomized but not vaccinated|0
5986694|NCT03529773|9577336|FG023|Overall Study|Randomized but not vaccinated|0
5986695|NCT03529773|9577337|FG024|Overall Study|Randomized but not vaccinated|0
5986696|NCT03529773|9577338|FG025|Overall Study|Randomized but not vaccinated|0
5986697|NCT03529773|9577339|FG026|Overall Study|Randomized but not vaccinated|0
5986698|NCT03529773|9577340|FG027|Overall Study|Randomized but not vaccinated|1
5986699|NCT03529773|9577341|FG028|Overall Study|Randomized but not vaccinated|0
5986700|NCT03529773|9577342|FG029|Overall Study|Randomized but not vaccinated|0
5986701|NCT03529773|9577343|FG030|Overall Study|Randomized but not vaccinated|0
5986702|NCT03529773|9577344|FG031|Overall Study|Randomized but not vaccinated|0
5986703|NCT03529773|9577345|FG032|Overall Study|Randomized but not vaccinated|0
5986704|NCT03529773|9577346|FG033|Overall Study|Randomized but not vaccinated|0
5986705|NCT03529773|9577347|FG034|Overall Study|Randomized but not vaccinated|0
5986706|NCT03529773|9577348|FG035|Overall Study|Randomized but not vaccinated|0
5986707|NCT03529773|9577349|FG036|Overall Study|Randomized but not vaccinated|0
5986708|NCT03529773|9577350|FG037|Overall Study|Randomized but not vaccinated|0
5986709|NCT03529773|9577351|FG038|Overall Study|Randomized but not vaccinated|0
5986710|NCT03529773|9577352|FG039|Overall Study|Randomized but not vaccinated|0
5986711|NCT03502070|9577455|FG000|Overall Study|Withdrawal by Subject|1
5986712|NCT03502070|9577455|FG000|Overall Study|Screen Failure|1
6044874|NCT00399035|9644104|FG002|Overall Study|Incorrect enrolment/eligib not fulfilled|1
6044875|NCT00399035|9644102|FG000|Overall Study|Severe non-compliance with protocol|2
6044876|NCT00399035|9644103|FG001|Overall Study|Severe non-compliance with protocol|1
6044877|NCT00399035|9644104|FG002|Overall Study|Severe non-compliance with protocol|0
6044878|NCT00399360|9644128|FG000|Overall Study|Lost to Follow-up|2
6044879|NCT00399360|9644129|FG001|Overall Study|Lost to Follow-up|1
6044880|NCT00399360|9644130|FG002|Overall Study|Lost to Follow-up|2
6044881|NCT00399360|9644131|FG003|Overall Study|Lost to Follow-up|4
6044882|NCT00399360|9644128|FG000|Overall Study|Adverse Event|0
6044883|NCT00399360|9644129|FG001|Overall Study|Adverse Event|0
6044884|NCT00399360|9644130|FG002|Overall Study|Adverse Event|1
6044885|NCT00399360|9644131|FG003|Overall Study|Adverse Event|0
6044886|NCT00399360|9644128|FG000|Overall Study|Withdrawal by Subject|0
6044887|NCT00399360|9644129|FG001|Overall Study|Withdrawal by Subject|2
6044888|NCT00399360|9644130|FG002|Overall Study|Withdrawal by Subject|0
6044889|NCT00399360|9644131|FG003|Overall Study|Withdrawal by Subject|2
6044890|NCT00399490|9644146|FG000|Overall Study|Adverse Event|19
6044891|NCT00399490|9644146|FG000|Overall Study|Lack of Efficacy|31
6044892|NCT00399490|9644146|FG000|Overall Study|Lost to Follow-up|5
6044893|NCT00399490|9644146|FG000|Overall Study|Withdrawal by Subject|18
6044894|NCT00399490|9644146|FG000|Overall Study|Other|25
6044895|NCT00399516|9644152|FG000|Overall Study|Lost to Follow-up|2
6044896|NCT00399529|9644156|FG000|Overall Study|Off Study Prior to Treatment|2
6044897|NCT00399542|9644163|FG000|Overall Study|Adverse Event|18
6044898|NCT00399542|9644164|FG001|Overall Study|Adverse Event|15
6044899|NCT00399542|9644163|FG000|Overall Study|Protocol Violation|13
6044900|NCT00399542|9644164|FG001|Overall Study|Protocol Violation|3
6044901|NCT00399542|9644163|FG000|Overall Study|Withdrawal by Subject|28
5986713|NCT03485911|9577462|FG000|Overall Study|Withdrawal by Subject|0
5986714|NCT03485911|9577463|FG001|Overall Study|Withdrawal by Subject|2
5986715|NCT03485911|9577464|FG002|Overall Study|Withdrawal by Subject|2
5986716|NCT03485911|9577462|FG000|Overall Study|Adverse Event|1
5986717|NCT03485911|9577463|FG001|Overall Study|Adverse Event|0
5986718|NCT03485911|9577464|FG002|Overall Study|Adverse Event|1
5986719|NCT03485911|9577462|FG000|Overall Study|High frequency of HAE attacks|0
5986720|NCT03485911|9577463|FG001|Overall Study|High frequency of HAE attacks|0
5986721|NCT03485911|9577464|FG002|Overall Study|High frequency of HAE attacks|1
5986722|NCT03403634|9577472|FG000|Overall Study|Disease progression|3
5986723|NCT03403634|9577472|FG000|Overall Study|Did not meet eligibility criteria|4
5986724|NCT03382041|9577478|FG000|Overall Study|Consent Form Lost|2
5986725|NCT03382041|9577479|FG001|Overall Study|Consent Form Lost|1
5986726|NCT03382041|9577478|FG000|Overall Study|Withdrawal by Subject|1
5986727|NCT03382041|9577479|FG001|Overall Study|Withdrawal by Subject|4
5986728|NCT03382041|9577478|FG000|Overall Study|Lost to Follow-up|1
5986729|NCT03382041|9577479|FG001|Overall Study|Lost to Follow-up|4
5986730|NCT03332095|9577487|FG000|Overall Study|Lost to Follow-up|1
5986731|NCT03332095|9577488|FG001|Overall Study|Lost to Follow-up|0
5986732|NCT03332095|9577487|FG000|Overall Study|Pregnancy|0
5986733|NCT03332095|9577488|FG001|Overall Study|Pregnancy|1
5986734|NCT03201419|9577503|FG000|Overall Study|Adverse Event|3
5986735|NCT03201419|9577504|FG001|Overall Study|Adverse Event|1
5986736|NCT03201419|9577505|FG002|Overall Study|Adverse Event|0
5986737|NCT03201419|9577506|FG003|Overall Study|Adverse Event|0
5986738|NCT03201419|9577507|FG004|Overall Study|Adverse Event|1
5986739|NCT03201419|9577508|FG005|Overall Study|Adverse Event|1
5986740|NCT03201419|9577509|FG006|Overall Study|Adverse Event|5
5986741|NCT03201419|9577510|FG007|Overall Study|Adverse Event|0
6146046|NCT01074944|9780556|FG002|Extended Treatment (up to 42 Months)|Pregnancy|0
6146047|NCT01074944|9780557|FG003|Extended Treatment (up to 42 Months)|Pregnancy|0
6146048|NCT01074944|9780558|FG004|Extended Treatment (up to 42 Months)|Pregnancy|2
6146049|NCT01074944|9780554|FG000|Extended Treatment (up to 42 Months)|Transitioned to Commercial Eliglustat|0
6146050|NCT01074944|9780555|FG001|Extended Treatment (up to 42 Months)|Transitioned to Commercial Eliglustat|0
6146051|NCT01074944|9780556|FG002|Extended Treatment (up to 42 Months)|Transitioned to Commercial Eliglustat|0
6146052|NCT01074944|9780557|FG003|Extended Treatment (up to 42 Months)|Transitioned to Commercial Eliglustat|0
6146053|NCT01074944|9780558|FG004|Extended Treatment (up to 42 Months)|Transitioned to Commercial Eliglustat|3
6146054|NCT01075048|9780569|FG000|Overall Study|Death|4
6146055|NCT01075048|9780570|FG001|Overall Study|Death|17
6146056|NCT01075048|9780571|FG002|Overall Study|Death|12
6146057|NCT01075048|9780569|FG000|Overall Study|Start of other or new therapy|4
6146058|NCT01075048|9780570|FG001|Overall Study|Start of other or new therapy|36
6146059|NCT01075048|9780571|FG002|Overall Study|Start of other or new therapy|46
6146060|NCT01075048|9780569|FG000|Overall Study|Withdrawal by Subject|1
6146061|NCT01075048|9780570|FG001|Overall Study|Withdrawal by Subject|6
6146062|NCT01075048|9780571|FG002|Overall Study|Withdrawal by Subject|3
6146063|NCT01075048|9780569|FG000|Overall Study|Lost to Follow-up|0
6146064|NCT01075048|9780570|FG001|Overall Study|Lost to Follow-up|1
6146065|NCT01075048|9780571|FG002|Overall Study|Lost to Follow-up|1
6146066|NCT01075074|9780585|FG000|Overall Study|Surgeon changed to open incisional case|1
6146067|NCT01075074|9780586|FG001|Overall Study|Surgeon changed to open incisional case|2
6146068|NCT01075074|9780587|FG002|Overall Study|Surgeon changed to open incisional case|2
6146069|NCT01075100|9780610|FG000|Overall Study|Adverse Event|15
6146070|NCT01075100|9780611|FG001|Overall Study|Adverse Event|18
6146071|NCT01075100|9780610|FG000|Overall Study|Patient Request|4
6146072|NCT01075100|9780611|FG001|Overall Study|Patient Request|4
6146073|NCT01075100|9780610|FG000|Overall Study|Investigator Request|2
6146074|NCT01075100|9780611|FG001|Overall Study|Investigator Request|1
6146075|NCT01075100|9780610|FG000|Overall Study|Disease Progression|25
6146076|NCT01075100|9780611|FG001|Overall Study|Disease Progression|29
6146077|NCT01075100|9780610|FG000|Overall Study|Other|3
6146078|NCT01075100|9780611|FG001|Overall Study|Other|1
6146079|NCT01075152|9780621|FG000|Overall Study|Withdrawal by Subject|1
6146080|NCT01075152|9780622|FG001|Overall Study|Withdrawal by Subject|0
6146081|NCT01075178|9780632|FG000|Subject Matching|eligible but not matched|130
6146082|NCT01075178|9780633|FG001|Subject Matching|eligible but not matched|403
6146083|NCT01075178|9780632|FG000|Subject Chart Review|died before chart review period|0
6146084|NCT01075178|9780633|FG001|Subject Chart Review|died before chart review period|2
6146085|NCT01075178|9780632|FG000|Subject Chart Review|no data collected due to site closure|3
6146086|NCT01075178|9780633|FG001|Subject Chart Review|no data collected due to site closure|4
6146087|NCT01075178|9780632|FG000|Subject Chart Review|matched partner excluded (reasons above)|6
6146088|NCT01075178|9780633|FG001|Subject Chart Review|matched partner excluded (reasons above)|3
6146089|NCT01075191|9780639|FG000|Overall Study|Death|1
6226601|NCT01710657|9899047|FG000|Overall Study|Adverse Event|14
6226602|NCT01710657|9899048|FG001|Overall Study|Adverse Event|8
6226603|NCT01710657|9899049|FG002|Overall Study|Adverse Event|28
6226604|NCT01710657|9899047|FG000|Overall Study|Withdrawal by Subject|0
6226605|NCT01710657|9899048|FG001|Overall Study|Withdrawal by Subject|1
5986742|NCT03201419|9577511|FG008|Overall Study|Adverse Event|0
5986743|NCT03201419|9577503|FG000|Overall Study|Lost to Follow-up|1
6226606|NCT01710657|9899049|FG002|Overall Study|Withdrawal by Subject|2
6226607|NCT01710657|9899047|FG000|Overall Study|Lack of Efficacy|0
6226608|NCT01710657|9899048|FG001|Overall Study|Lack of Efficacy|1
6226609|NCT01710657|9899049|FG002|Overall Study|Lack of Efficacy|1
6226610|NCT01710709|9899057|FG000|Overall Study|Lost to Follow-up|29
6226611|NCT01710709|9899057|FG000|Overall Study|Adverse Event|48
6226612|NCT01710709|9899057|FG000|Overall Study|Participant met withdrawal criteria|33
6226613|NCT01710709|9899057|FG000|Overall Study|Participant withdrawn by investigator|2
6226614|NCT01710709|9899057|FG000|Overall Study|Withdrawal by Subject|53
6226615|NCT01710709|9899057|FG000|Overall Study|Protocol Violation|5
6226616|NCT01710709|9899057|FG000|Overall Study|Lack of Efficacy|3
6226617|NCT01710800|9899075|FG000|Overall Study|Withdrawal by Subject|21
6226618|NCT01710800|9899075|FG000|Overall Study|Protocol Violation|1
6226619|NCT01711216|9899112|FG000|Overall Study|Adverse Event|4
5986744|NCT03201419|9577504|FG001|Overall Study|Lost to Follow-up|0
5986745|NCT03201419|9577505|FG002|Overall Study|Lost to Follow-up|0
5986746|NCT03201419|9577506|FG003|Overall Study|Lost to Follow-up|0
5986747|NCT03201419|9577507|FG004|Overall Study|Lost to Follow-up|0
5986748|NCT03201419|9577508|FG005|Overall Study|Lost to Follow-up|0
5986749|NCT03201419|9577509|FG006|Overall Study|Lost to Follow-up|0
5986750|NCT03201419|9577510|FG007|Overall Study|Lost to Follow-up|0
5986751|NCT03201419|9577511|FG008|Overall Study|Lost to Follow-up|0
5986752|NCT03201419|9577503|FG000|Overall Study|Protocol Deviation|0
5986753|NCT03201419|9577504|FG001|Overall Study|Protocol Deviation|0
5986754|NCT03201419|9577505|FG002|Overall Study|Protocol Deviation|0
5986755|NCT03201419|9577506|FG003|Overall Study|Protocol Deviation|0
5986756|NCT03201419|9577507|FG004|Overall Study|Protocol Deviation|0
5986757|NCT03201419|9577508|FG005|Overall Study|Protocol Deviation|0
5986758|NCT03201419|9577509|FG006|Overall Study|Protocol Deviation|1
5986759|NCT03201419|9577510|FG007|Overall Study|Protocol Deviation|0
5986760|NCT03201419|9577511|FG008|Overall Study|Protocol Deviation|0
5986761|NCT03201419|9577503|FG000|Overall Study|Withdrawal by Subject|4
5986762|NCT03201419|9577504|FG001|Overall Study|Withdrawal by Subject|2
5986763|NCT03201419|9577505|FG002|Overall Study|Withdrawal by Subject|1
5986764|NCT03201419|9577506|FG003|Overall Study|Withdrawal by Subject|0
5986765|NCT03201419|9577507|FG004|Overall Study|Withdrawal by Subject|0
5986766|NCT03201419|9577508|FG005|Overall Study|Withdrawal by Subject|0
5986767|NCT03201419|9577509|FG006|Overall Study|Withdrawal by Subject|0
5986768|NCT03201419|9577510|FG007|Overall Study|Withdrawal by Subject|1
5986769|NCT03201419|9577511|FG008|Overall Study|Withdrawal by Subject|2
5986770|NCT03201419|9577503|FG000|Overall Study|Other|0
5986771|NCT03201419|9577504|FG001|Overall Study|Other|0
5986772|NCT03201419|9577505|FG002|Overall Study|Other|1
5986773|NCT03201419|9577506|FG003|Overall Study|Other|0
5986774|NCT03201419|9577507|FG004|Overall Study|Other|0
5986775|NCT03201419|9577508|FG005|Overall Study|Other|0
5986776|NCT03201419|9577509|FG006|Overall Study|Other|0
5986777|NCT03201419|9577510|FG007|Overall Study|Other|0
5986778|NCT03201419|9577511|FG008|Overall Study|Other|0
5986779|NCT03197766|9577547|FG000|Overall Study|Withdrawal by Subject|2
5986780|NCT03197766|9577548|FG001|Overall Study|Withdrawal by Subject|0
6044902|NCT00399542|9644164|FG001|Overall Study|Withdrawal by Subject|10
6044903|NCT00399542|9644163|FG000|Overall Study|Lack of Efficacy|18
6044904|NCT00399542|9644164|FG001|Overall Study|Lack of Efficacy|8
6044905|NCT00399542|9644163|FG000|Overall Study|Lost to Follow-up|6
6044906|NCT00399542|9644164|FG001|Overall Study|Lost to Follow-up|6
6044907|NCT00399542|9644163|FG000|Overall Study|Other|1
6044908|NCT00399542|9644164|FG001|Overall Study|Other|0
6044909|NCT00399542|9644163|FG000|Overall Study|Physician Decision|0
6044910|NCT00399542|9644164|FG001|Overall Study|Physician Decision|1
6044911|NCT00399568|9644172|FG000|Overall Study|Adverse Event|1
6044912|NCT00399568|9644173|FG001|Overall Study|Adverse Event|2
6044913|NCT00399568|9644172|FG000|Overall Study|Withdrawal by Subject|7
6044914|NCT00399568|9644173|FG001|Overall Study|Withdrawal by Subject|3
6044915|NCT00399568|9644172|FG000|Overall Study|Protocol non-compliance|2
6044916|NCT00399568|9644173|FG001|Overall Study|Protocol non-compliance|2
6044917|NCT00399568|9644172|FG000|Overall Study|Lost to Follow-up|2
6044918|NCT00399568|9644173|FG001|Overall Study|Lost to Follow-up|2
6044919|NCT00399763|9644183|FG000|Overall Study|Lost to Follow-up|2
6044920|NCT00399763|9644184|FG001|Overall Study|Lost to Follow-up|3
6044921|NCT00399802|9644192|FG000|Overall Study|Adverse Event|0
6044922|NCT00399802|9644193|FG001|Overall Study|Adverse Event|2
6044923|NCT00399802|9644192|FG000|Overall Study|Participant discontinued by mistake|0
6044924|NCT00399802|9644193|FG001|Overall Study|Participant discontinued by mistake|1
6044925|NCT00399893|9644210|FG000|Overall Study|Withdrawal by Subject|1
6044926|NCT00399893|9644211|FG001|Overall Study|Withdrawal by Subject|0
6044927|NCT00400153|9644220|FG000|Overall Study|AE due to study disease worsening|14
6044928|NCT00400153|9644221|FG001|Overall Study|AE due to study disease worsening|19
6044929|NCT00400153|9644222|FG002|Overall Study|AE due to study disease worsening|20
6044930|NCT00400153|9644220|FG000|Overall Study|AE due to other disease worsening|2
6044931|NCT00400153|9644221|FG001|Overall Study|AE due to other disease worsening|1
6044932|NCT00400153|9644222|FG002|Overall Study|AE due to other disease worsening|0
6226620|NCT01711216|9899112|FG000|Overall Study|Pregnancy|56
6226621|NCT01711216|9899112|FG000|Overall Study|Withdrawal by Subject|6
6226622|NCT01711216|9899112|FG000|Overall Study|Lost to Follow-up|46
5986781|NCT04516759|9577566|FG000|Overall Study|Withdrawal by Subject|1
5986782|NCT04516759|9577567|FG001|Overall Study|Withdrawal by Subject|1
5986783|NCT04516759|9577566|FG000|Overall Study|Other|0
5986784|NCT04516759|9577567|FG001|Overall Study|Other|1
5986785|NCT03409276|9577596|FG000|Overall Study|Withdrawal by Subject|0
5986786|NCT03409276|9577597|FG001|Overall Study|Withdrawal by Subject|0
5986787|NCT03409276|9577598|FG002|Overall Study|Withdrawal by Subject|0
5986788|NCT03409276|9577599|FG003|Overall Study|Withdrawal by Subject|0
5986789|NCT03409276|9577600|FG004|Overall Study|Withdrawal by Subject|1
5986790|NCT03409276|9577596|FG000|Overall Study|Lost to Follow-up|0
5986791|NCT03409276|9577597|FG001|Overall Study|Lost to Follow-up|0
5986792|NCT03409276|9577598|FG002|Overall Study|Lost to Follow-up|0
5986793|NCT03409276|9577599|FG003|Overall Study|Lost to Follow-up|2
5986794|NCT03409276|9577600|FG004|Overall Study|Lost to Follow-up|2
5986795|NCT03312907|9577619|FG000|Overall Study|Adverse Event|1
5986796|NCT03312907|9577620|FG001|Overall Study|Adverse Event|6
5986797|NCT03312907|9577621|FG002|Overall Study|Adverse Event|1
5986798|NCT03312907|9577619|FG000|Overall Study|Protocol Violation|2
5986799|NCT03312907|9577620|FG001|Overall Study|Protocol Violation|3
5986800|NCT03312907|9577621|FG002|Overall Study|Protocol Violation|4
5986801|NCT03312907|9577619|FG000|Overall Study|Lost to Follow-up|2
5986802|NCT03312907|9577620|FG001|Overall Study|Lost to Follow-up|3
5986803|NCT03312907|9577621|FG002|Overall Study|Lost to Follow-up|2
5986804|NCT03312907|9577619|FG000|Overall Study|Physician Decision|3
5986805|NCT03312907|9577620|FG001|Overall Study|Physician Decision|4
5986806|NCT03312907|9577621|FG002|Overall Study|Physician Decision|2
5986807|NCT03312907|9577619|FG000|Overall Study|Withdrawal by Subject|9
5986808|NCT03312907|9577620|FG001|Overall Study|Withdrawal by Subject|14
5986809|NCT03312907|9577621|FG002|Overall Study|Withdrawal by Subject|10
5986810|NCT03148756|9577631|FG000|Overall Study|Study Terminated|0
5986811|NCT03148756|9577632|FG001|Overall Study|Study Terminated|1
5986812|NCT03079102|9577640|FG000|Overall Study|Physician Decision|0
5986813|NCT03079102|9577641|FG001|Overall Study|Physician Decision|1
5986814|NCT02944513|9577649|FG000|Overall Study|Withdrawal by Subject|4
5986815|NCT02944513|9577650|FG001|Overall Study|Withdrawal by Subject|1
5986816|NCT02734433|9577667|FG000|Overall Study|Disease progression|1
5986817|NCT02734433|9577668|FG001|Overall Study|Disease progression|5
5986818|NCT02734433|9577667|FG000|Overall Study|Clinical progression|0
5986819|NCT02734433|9577668|FG001|Overall Study|Clinical progression|1
5986820|NCT02734433|9577667|FG000|Overall Study|Withdrawal by Subject|1
5986821|NCT02734433|9577668|FG001|Overall Study|Withdrawal by Subject|2
5986822|NCT02120469|9577695|FG000|Overall Study|HER-2/neu-amplified|1
5986823|NCT02120469|9577696|FG001|Overall Study|HER-2/neu-amplified|0
5986824|NCT02120469|9577697|FG002|Overall Study|HER-2/neu-amplified|1
5986825|NCT02091960|9577707|FG000|Overall Study|Death|7
5986826|NCT02091960|9577707|FG000|Overall Study|Withdrawal by Subject|1
5986827|NCT02091960|9577707|FG000|Overall Study|Miscellaneous Reasons|31
5986828|NCT02091960|9577707|FG000|Overall Study|On Study at Data Cut-off|12
5986829|NCT02048722|9577711|FG000|2 Cycles of Treatment|Adverse Event|2
5986830|NCT02048722|9577711|FG000|2 Cycles of Treatment|Withdrawal by Subject|4
5986831|NCT02048722|9577711|FG000|2 Cycles of Treatment|Progressive Disease|2
5986832|NCT02048722|9577711|FG000|Reached 1st Response/Continued Treatment|Progressive Disease|10
5986833|NCT02048722|9577711|FG000|Follow up 5 Years or Cut of Timepoint|Death|24
5986834|NCT02048722|9577711|FG000|Follow up 5 Years or Cut of Timepoint|Withdrawal by Subject|3
5986835|NCT01896102|9577715|FG000|Overall Study|Death|1
5986836|NCT01896102|9577715|FG000|Overall Study|Participant to receive allogenic transplant|2
5986837|NCT01885078|9577728|FG000|Treatment Period|Adverse Event|52
5986838|NCT01885078|9577729|FG001|Treatment Period|Adverse Event|136
5986839|NCT01885078|9577730|FG002|Treatment Period|Adverse Event|30
5986840|NCT01885078|9577731|FG003|Treatment Period|Adverse Event|73
5986841|NCT01885078|9577732|FG004|Treatment Period|Adverse Event|17
5986842|NCT01885078|9577733|FG005|Treatment Period|Adverse Event|72
5986843|NCT01885078|9577734|FG006|Treatment Period|Adverse Event|24
5986844|NCT01885078|9577735|FG007|Treatment Period|Adverse Event|5
5986845|NCT01885078|9577736|FG008|Treatment Period|Adverse Event|0
5986846|NCT01885078|9577737|FG009|Treatment Period|Adverse Event|0
5986847|NCT01885078|9577728|FG000|Treatment Period|Death|13
5986848|NCT01885078|9577729|FG001|Treatment Period|Death|33
5986849|NCT01885078|9577730|FG002|Treatment Period|Death|5
5986850|NCT01885078|9577731|FG003|Treatment Period|Death|9
5986851|NCT01885078|9577732|FG004|Treatment Period|Death|2
5986852|NCT01885078|9577733|FG005|Treatment Period|Death|10
5986853|NCT01885078|9577734|FG006|Treatment Period|Death|3
5986854|NCT01885078|9577735|FG007|Treatment Period|Death|2
5986855|NCT01885078|9577736|FG008|Treatment Period|Death|0
5986856|NCT01885078|9577737|FG009|Treatment Period|Death|0
5986857|NCT01885078|9577728|FG000|Treatment Period|Lack of Efficacy|12
5986858|NCT01885078|9577729|FG001|Treatment Period|Lack of Efficacy|33
5986859|NCT01885078|9577730|FG002|Treatment Period|Lack of Efficacy|10
5986860|NCT01885078|9577731|FG003|Treatment Period|Lack of Efficacy|23
5986861|NCT01885078|9577732|FG004|Treatment Period|Lack of Efficacy|24
5986862|NCT01885078|9577733|FG005|Treatment Period|Lack of Efficacy|58
5986863|NCT01885078|9577734|FG006|Treatment Period|Lack of Efficacy|9
5986864|NCT01885078|9577735|FG007|Treatment Period|Lack of Efficacy|5
5986865|NCT01885078|9577736|FG008|Treatment Period|Lack of Efficacy|0
5986866|NCT01885078|9577737|FG009|Treatment Period|Lack of Efficacy|0
5986867|NCT01885078|9577728|FG000|Treatment Period|Lost to Follow-up|16
5986868|NCT01885078|9577729|FG001|Treatment Period|Lost to Follow-up|19
5986869|NCT01885078|9577730|FG002|Treatment Period|Lost to Follow-up|7
5986870|NCT01885078|9577731|FG003|Treatment Period|Lost to Follow-up|9
5986871|NCT01885078|9577732|FG004|Treatment Period|Lost to Follow-up|2
5986872|NCT01885078|9577733|FG005|Treatment Period|Lost to Follow-up|8
5986873|NCT01885078|9577734|FG006|Treatment Period|Lost to Follow-up|2
5986874|NCT01885078|9577735|FG007|Treatment Period|Lost to Follow-up|0
5986875|NCT01885078|9577736|FG008|Treatment Period|Lost to Follow-up|0
5986876|NCT01885078|9577737|FG009|Treatment Period|Lost to Follow-up|0
5986877|NCT01885078|9577728|FG000|Treatment Period|Physician Decision|19
5986878|NCT01885078|9577729|FG001|Treatment Period|Physician Decision|21
5986879|NCT01885078|9577730|FG002|Treatment Period|Physician Decision|5
5986880|NCT01885078|9577731|FG003|Treatment Period|Physician Decision|12
5986881|NCT01885078|9577732|FG004|Treatment Period|Physician Decision|9
5986882|NCT01885078|9577733|FG005|Treatment Period|Physician Decision|24
5986883|NCT01885078|9577734|FG006|Treatment Period|Physician Decision|4
5986884|NCT01885078|9577735|FG007|Treatment Period|Physician Decision|3
5986885|NCT01885078|9577736|FG008|Treatment Period|Physician Decision|0
5986886|NCT01885078|9577737|FG009|Treatment Period|Physician Decision|0
5986887|NCT01885078|9577728|FG000|Treatment Period|Protocol Violation|3
5986888|NCT01885078|9577729|FG001|Treatment Period|Protocol Violation|5
5986889|NCT01885078|9577730|FG002|Treatment Period|Protocol Violation|0
5986890|NCT01885078|9577731|FG003|Treatment Period|Protocol Violation|3
5986891|NCT01885078|9577732|FG004|Treatment Period|Protocol Violation|1
5986892|NCT01885078|9577733|FG005|Treatment Period|Protocol Violation|6
5986893|NCT01885078|9577734|FG006|Treatment Period|Protocol Violation|0
5986894|NCT01885078|9577735|FG007|Treatment Period|Protocol Violation|0
5986895|NCT01885078|9577736|FG008|Treatment Period|Protocol Violation|0
5986896|NCT01885078|9577737|FG009|Treatment Period|Protocol Violation|0
5986897|NCT01885078|9577728|FG000|Treatment Period|Sponsor Decision|245
5986898|NCT01885078|9577729|FG001|Treatment Period|Sponsor Decision|648
5986899|NCT01885078|9577730|FG002|Treatment Period|Sponsor Decision|49
5986900|NCT01885078|9577731|FG003|Treatment Period|Sponsor Decision|90
5986901|NCT01885078|9577732|FG004|Treatment Period|Sponsor Decision|20
5986902|NCT01885078|9577733|FG005|Treatment Period|Sponsor Decision|38
5986903|NCT01885078|9577734|FG006|Treatment Period|Sponsor Decision|162
5986904|NCT01885078|9577735|FG007|Treatment Period|Sponsor Decision|3
5986905|NCT01885078|9577736|FG008|Treatment Period|Sponsor Decision|0
5986906|NCT01885078|9577737|FG009|Treatment Period|Sponsor Decision|0
5986907|NCT01885078|9577728|FG000|Treatment Period|Withdrawal by Subject|72
5986908|NCT01885078|9577729|FG001|Treatment Period|Withdrawal by Subject|132
5986909|NCT01885078|9577730|FG002|Treatment Period|Withdrawal by Subject|25
5986910|NCT01885078|9577731|FG003|Treatment Period|Withdrawal by Subject|63
5986911|NCT01885078|9577732|FG004|Treatment Period|Withdrawal by Subject|15
5986912|NCT01885078|9577733|FG005|Treatment Period|Withdrawal by Subject|34
5986913|NCT01885078|9577734|FG006|Treatment Period|Withdrawal by Subject|17
5986914|NCT01885078|9577735|FG007|Treatment Period|Withdrawal by Subject|10
5986915|NCT01885078|9577736|FG008|Treatment Period|Withdrawal by Subject|0
5986916|NCT01885078|9577737|FG009|Treatment Period|Withdrawal by Subject|0
5986917|NCT01885078|9577728|FG000|Treatment Period|Other|0
5986918|NCT01885078|9577729|FG001|Treatment Period|Other|0
5986919|NCT01885078|9577730|FG002|Treatment Period|Other|0
5986920|NCT01885078|9577731|FG003|Treatment Period|Other|1
5986921|NCT01885078|9577732|FG004|Treatment Period|Other|0
5986922|NCT01885078|9577733|FG005|Treatment Period|Other|0
5986923|NCT01885078|9577734|FG006|Treatment Period|Other|0
5986924|NCT01885078|9577735|FG007|Treatment Period|Other|0
5986925|NCT01885078|9577736|FG008|Treatment Period|Other|0
5986926|NCT01885078|9577737|FG009|Treatment Period|Other|0
5986927|NCT01885078|9577728|FG000|Step-down Period|Sponsor Decision|0
5986928|NCT01885078|9577729|FG001|Step-down Period|Sponsor Decision|0
5986929|NCT01885078|9577730|FG002|Step-down Period|Sponsor Decision|0
5986930|NCT01885078|9577731|FG003|Step-down Period|Sponsor Decision|0
5986931|NCT01885078|9577732|FG004|Step-down Period|Sponsor Decision|0
5986932|NCT01885078|9577733|FG005|Step-down Period|Sponsor Decision|0
5986933|NCT01885078|9577734|FG006|Step-down Period|Sponsor Decision|0
5986934|NCT01885078|9577735|FG007|Step-down Period|Sponsor Decision|0
5986935|NCT01885078|9577736|FG008|Step-down Period|Sponsor Decision|1
5986936|NCT01885078|9577737|FG009|Step-down Period|Sponsor Decision|1
5986937|NCT01885078|9577728|FG000|Step-down Period|Adverse Event|0
5986938|NCT01885078|9577729|FG001|Step-down Period|Adverse Event|0
5986939|NCT01885078|9577730|FG002|Step-down Period|Adverse Event|0
5986940|NCT01885078|9577731|FG003|Step-down Period|Adverse Event|0
5986941|NCT01885078|9577732|FG004|Step-down Period|Adverse Event|0
5986942|NCT01885078|9577733|FG005|Step-down Period|Adverse Event|0
5986943|NCT01885078|9577734|FG006|Step-down Period|Adverse Event|0
5986944|NCT01885078|9577735|FG007|Step-down Period|Adverse Event|0
5986945|NCT01885078|9577736|FG008|Step-down Period|Adverse Event|29
5986946|NCT01885078|9577737|FG009|Step-down Period|Adverse Event|38
5986947|NCT01885078|9577728|FG000|Step-down Period|Withdrawal by Subject|0
5986948|NCT01885078|9577729|FG001|Step-down Period|Withdrawal by Subject|0
5986949|NCT01885078|9577730|FG002|Step-down Period|Withdrawal by Subject|0
5986950|NCT01885078|9577731|FG003|Step-down Period|Withdrawal by Subject|0
5986951|NCT01885078|9577732|FG004|Step-down Period|Withdrawal by Subject|0
5986952|NCT01885078|9577733|FG005|Step-down Period|Withdrawal by Subject|0
5986953|NCT01885078|9577734|FG006|Step-down Period|Withdrawal by Subject|0
5986954|NCT01885078|9577735|FG007|Step-down Period|Withdrawal by Subject|0
5986955|NCT01885078|9577736|FG008|Step-down Period|Withdrawal by Subject|25
5986956|NCT01885078|9577737|FG009|Step-down Period|Withdrawal by Subject|15
5986957|NCT01885078|9577728|FG000|Step-down Period|Physician Decision|0
5986958|NCT01885078|9577729|FG001|Step-down Period|Physician Decision|0
5986959|NCT01885078|9577730|FG002|Step-down Period|Physician Decision|0
5986960|NCT01885078|9577731|FG003|Step-down Period|Physician Decision|0
5986961|NCT01885078|9577732|FG004|Step-down Period|Physician Decision|0
5986962|NCT01885078|9577733|FG005|Step-down Period|Physician Decision|0
5986963|NCT01885078|9577734|FG006|Step-down Period|Physician Decision|0
5986964|NCT01885078|9577735|FG007|Step-down Period|Physician Decision|0
5986965|NCT01885078|9577736|FG008|Step-down Period|Physician Decision|7
5986966|NCT01885078|9577737|FG009|Step-down Period|Physician Decision|2
5986967|NCT01885078|9577728|FG000|Step-down Period|Death|0
5986968|NCT01885078|9577729|FG001|Step-down Period|Death|0
5986969|NCT01885078|9577730|FG002|Step-down Period|Death|0
5986970|NCT01885078|9577731|FG003|Step-down Period|Death|0
5986971|NCT01885078|9577732|FG004|Step-down Period|Death|0
5986972|NCT01885078|9577733|FG005|Step-down Period|Death|0
5986973|NCT01885078|9577734|FG006|Step-down Period|Death|0
5986974|NCT01885078|9577735|FG007|Step-down Period|Death|0
5986975|NCT01885078|9577736|FG008|Step-down Period|Death|4
5986976|NCT01885078|9577737|FG009|Step-down Period|Death|3
5986977|NCT01885078|9577728|FG000|Step-down Period|Lost to Follow-up|0
5986978|NCT01885078|9577729|FG001|Step-down Period|Lost to Follow-up|0
5986979|NCT01885078|9577730|FG002|Step-down Period|Lost to Follow-up|0
5986980|NCT01885078|9577731|FG003|Step-down Period|Lost to Follow-up|0
5986981|NCT01885078|9577732|FG004|Step-down Period|Lost to Follow-up|0
5986982|NCT01885078|9577733|FG005|Step-down Period|Lost to Follow-up|0
5986983|NCT01885078|9577734|FG006|Step-down Period|Lost to Follow-up|0
5986984|NCT01885078|9577735|FG007|Step-down Period|Lost to Follow-up|0
5986985|NCT01885078|9577736|FG008|Step-down Period|Lost to Follow-up|1
5986986|NCT01885078|9577737|FG009|Step-down Period|Lost to Follow-up|1
5986987|NCT01885078|9577728|FG000|Step-down Period|Lack of Efficacy|0
5986988|NCT01885078|9577729|FG001|Step-down Period|Lack of Efficacy|0
5986989|NCT01885078|9577730|FG002|Step-down Period|Lack of Efficacy|0
5986990|NCT01885078|9577731|FG003|Step-down Period|Lack of Efficacy|0
5986991|NCT01885078|9577732|FG004|Step-down Period|Lack of Efficacy|0
5986992|NCT01885078|9577733|FG005|Step-down Period|Lack of Efficacy|0
5986993|NCT01885078|9577734|FG006|Step-down Period|Lack of Efficacy|0
5986994|NCT01885078|9577735|FG007|Step-down Period|Lack of Efficacy|0
5986995|NCT01885078|9577736|FG008|Step-down Period|Lack of Efficacy|1
5986996|NCT01885078|9577737|FG009|Step-down Period|Lack of Efficacy|0
5986997|NCT01885078|9577728|FG000|Step-down Period|Protocol Violation|0
5986998|NCT01885078|9577729|FG001|Step-down Period|Protocol Violation|0
5986999|NCT01885078|9577730|FG002|Step-down Period|Protocol Violation|0
5987000|NCT01885078|9577731|FG003|Step-down Period|Protocol Violation|0
5987001|NCT01885078|9577732|FG004|Step-down Period|Protocol Violation|0
5987002|NCT01885078|9577733|FG005|Step-down Period|Protocol Violation|0
5987003|NCT01885078|9577734|FG006|Step-down Period|Protocol Violation|0
5987004|NCT01885078|9577735|FG007|Step-down Period|Protocol Violation|0
5987005|NCT01885078|9577736|FG008|Step-down Period|Protocol Violation|1
5987006|NCT01885078|9577737|FG009|Step-down Period|Protocol Violation|1
5987007|NCT01047683|9577761|FG000|Overall Study|Adverse Event|3
5987008|NCT01047683|9577762|FG001|Overall Study|Adverse Event|1
5987009|NCT01047683|9577763|FG002|Overall Study|Adverse Event|0
5987010|NCT01047683|9577761|FG000|Overall Study|Withdrew Consent|1
5987011|NCT01047683|9577762|FG001|Overall Study|Withdrew Consent|4
5987012|NCT01047683|9577763|FG002|Overall Study|Withdrew Consent|2
5987013|NCT01047683|9577761|FG000|Overall Study|Lost to Follow-up|0
5987014|NCT01047683|9577762|FG001|Overall Study|Lost to Follow-up|1
5987015|NCT01047683|9577763|FG002|Overall Study|Lost to Follow-up|0
5987016|NCT01047683|9577761|FG000|Overall Study|Triglycerides >2000 mg/dL|1
5987017|NCT01047683|9577762|FG001|Overall Study|Triglycerides >2000 mg/dL|0
5987018|NCT01047683|9577763|FG002|Overall Study|Triglycerides >2000 mg/dL|1
5987019|NCT01047501|9577774|FG000|Overall Study|Adverse Event|7
5987020|NCT01047501|9577775|FG001|Overall Study|Adverse Event|8
5987021|NCT01047501|9577776|FG002|Overall Study|Adverse Event|5
5987022|NCT01047501|9577774|FG000|Overall Study|Withdrew Consent|6
5987023|NCT01047501|9577775|FG001|Overall Study|Withdrew Consent|2
5987024|NCT01047501|9577776|FG002|Overall Study|Withdrew Consent|4
5987025|NCT01047501|9577774|FG000|Overall Study|Lost to Follow-up|0
5987026|NCT01047501|9577775|FG001|Overall Study|Lost to Follow-up|1
5987027|NCT01047501|9577776|FG002|Overall Study|Lost to Follow-up|1
5987028|NCT01047501|9577774|FG000|Overall Study|Triglycerides >800 mg/dL|1
5987029|NCT01047501|9577775|FG001|Overall Study|Triglycerides >800 mg/dL|0
5987030|NCT01047501|9577776|FG002|Overall Study|Triglycerides >800 mg/dL|0
5987031|NCT01047501|9577774|FG000|Overall Study|Death|1
5987032|NCT01047501|9577775|FG001|Overall Study|Death|0
5987033|NCT01047501|9577776|FG002|Overall Study|Death|0
5987034|NCT01047501|9577774|FG000|Overall Study|Other discontinuation|1
5987035|NCT01047501|9577775|FG001|Overall Study|Other discontinuation|0
5987036|NCT01047501|9577776|FG002|Overall Study|Other discontinuation|1
5987037|NCT01047501|9577774|FG000|Overall Study|Investigator judgement|0
5987038|NCT01047501|9577775|FG001|Overall Study|Investigator judgement|0
5987039|NCT01047501|9577776|FG002|Overall Study|Investigator judgement|1
5987040|NCT00981656|9577784|FG000|Overall Study|Protocol Violation|1
5987041|NCT00981656|9577784|FG000|Overall Study|Did not start protocol treatment|2
5987042|NCT00838526|9577790|FG000|Overall Study|Adverse Event|3
5987043|NCT00838526|9577791|FG001|Overall Study|Adverse Event|12
5987044|NCT00838526|9577790|FG000|Overall Study|Lost to Follow-up|4
5987045|NCT00838526|9577791|FG001|Overall Study|Lost to Follow-up|12
5987046|NCT00838526|9577790|FG000|Overall Study|Withdrawal by Subject|4
5987047|NCT00838526|9577791|FG001|Overall Study|Withdrawal by Subject|5
5987048|NCT00838526|9577790|FG000|Overall Study|Lack of Efficacy|2
5987049|NCT00838526|9577791|FG001|Overall Study|Lack of Efficacy|3
5987050|NCT00838526|9577790|FG000|Overall Study|Other|11
5987051|NCT00838526|9577791|FG001|Overall Study|Other|7
5987052|NCT00126672|9577797|FG000|Overall Study|Adverse Event|4
5987053|NCT00126672|9577797|FG000|Overall Study|Lost to Follow-up|4
5987054|NCT03151304|9577814|FG000|Overall Study|Termination of study by Sponsor|23
5987055|NCT03151304|9577814|FG000|Overall Study|missing|3
5987056|NCT03151304|9577814|FG000|Overall Study|Withdrawal by Subject|8
5987057|NCT03151304|9577814|FG000|Overall Study|multiple reasons|30
5987058|NCT03113409|9577818|FG000|Overall Study|Withdrawal by Subject|5
5987059|NCT03113409|9577819|FG001|Overall Study|Withdrawal by Subject|0
5987060|NCT03113409|9577820|FG002|Overall Study|Withdrawal by Subject|0
5987061|NCT03007979|9577824|FG000|Overall Study|Deemed not eligible prior to starting palbociclib|1
5987062|NCT02953340|9577830|FG000|Overall Study|Death|0
5987063|NCT02953340|9577831|FG001|Overall Study|Death|1
5987064|NCT02953340|9577830|FG000|Overall Study|Investigator Decision|3
5987065|NCT02953340|9577831|FG001|Overall Study|Investigator Decision|3
5987066|NCT02953340|9577830|FG000|Overall Study|Initiated Non-Protocol Therapy|5
5987067|NCT02953340|9577831|FG001|Overall Study|Initiated Non-Protocol Therapy|14
5987068|NCT02953340|9577830|FG000|Overall Study|Myeloid Growth Factors Treatment|0
5987069|NCT02953340|9577831|FG001|Overall Study|Myeloid Growth Factors Treatment|1
5987070|NCT02953340|9577830|FG000|Overall Study|Withdrawal by Subject|9
5987071|NCT02953340|9577831|FG001|Overall Study|Withdrawal by Subject|9
5987072|NCT02953340|9577830|FG000|Overall Study|Sponsor decision|0
5987073|NCT02953340|9577831|FG001|Overall Study|Sponsor decision|2
5987074|NCT02953340|9577830|FG000|Overall Study|Lost to Follow-up|3
5987075|NCT02953340|9577831|FG001|Overall Study|Lost to Follow-up|2
5987076|NCT02953340|9577830|FG000|Overall Study|Reason not specified|2
5987077|NCT02953340|9577831|FG001|Overall Study|Reason not specified|2
5987078|NCT02855944|9577854|FG000|Period 1: Treatment|Ongoing|44
5987079|NCT02855944|9577855|FG001|Period 1: Treatment|Ongoing|5
5987080|NCT02855944|9577854|FG000|Period 1: Treatment|Discontinued prior to starting study drug|1
5987081|NCT02855944|9577855|FG001|Period 1: Treatment|Discontinued prior to starting study drug|3
5987082|NCT02855944|9577854|FG000|Period 2: Crossover to Rucaparib|Ongoing|0
5987083|NCT02855944|9577855|FG001|Period 2: Crossover to Rucaparib|Ongoing|27
5987084|NCT02851407|9577864|FG000|Overall Study|Withdrawal by parent/guardian|2
5987085|NCT02851407|9577865|FG001|Overall Study|Withdrawal by parent/guardian|7
5987086|NCT02851407|9577864|FG000|Overall Study|Protocol deviation|0
5987087|NCT02851407|9577865|FG001|Overall Study|Protocol deviation|1
5987088|NCT02851407|9577864|FG000|Overall Study|Transferred to another hospital to continue|1
5987089|NCT02851407|9577865|FG001|Overall Study|Transferred to another hospital to continue|0
5987090|NCT02851407|9577864|FG000|Overall Study|Other Death|30
5987091|NCT02851407|9577865|FG001|Overall Study|Other Death|20
5987092|NCT02851407|9577864|FG000|Overall Study|Adverse event, serious fatal|6
5987093|NCT02851407|9577865|FG001|Overall Study|Adverse event, serious fatal|8
5987094|NCT02851407|9577864|FG000|Overall Study|Consent withdrawn by participant|5
5987095|NCT02851407|9577865|FG001|Overall Study|Consent withdrawn by participant|3
5987096|NCT02851407|9577864|FG000|Overall Study|Screen failure|2
5987097|NCT02851407|9577865|FG001|Overall Study|Screen failure|1
5987098|NCT02851407|9577864|FG000|Overall Study|Disease relapse|9
5987099|NCT02851407|9577865|FG001|Overall Study|Disease relapse|6
5987100|NCT02851407|9577864|FG000|Overall Study|Physician Decision|7
5987101|NCT02851407|9577865|FG001|Overall Study|Physician Decision|6
5987102|NCT02851407|9577864|FG000|Overall Study|Transferred to hospital closer to home|0
5987103|NCT02851407|9577865|FG001|Overall Study|Transferred to hospital closer to home|1
5987104|NCT02851407|9577864|FG000|Overall Study|Enrolled in an investigational study|0
5987105|NCT02851407|9577865|FG001|Overall Study|Enrolled in an investigational study|1
5987106|NCT02851407|9577864|FG000|Overall Study|Early recovery|1
5987107|NCT02851407|9577865|FG001|Overall Study|Early recovery|0
5987108|NCT02851407|9577864|FG000|Overall Study|Adverse event, non-fatal|7
5987109|NCT02851407|9577865|FG001|Overall Study|Adverse event, non-fatal|5
5987110|NCT02851407|9577864|FG000|Overall Study|Lost to Follow-up|0
5987111|NCT02851407|9577865|FG001|Overall Study|Lost to Follow-up|2
5987112|NCT02666430|9577890|FG000|Period 1|Lost to Follow-up|1
5987113|NCT02666430|9577891|FG001|Period 1|Lost to Follow-up|0
5987114|NCT02666430|9577890|FG000|Period 1|Adverse Event|0
5987115|NCT02666430|9577891|FG001|Period 1|Adverse Event|1
5987116|NCT02666430|9577890|FG000|Period 2|Withdrawal by Subject|1
5987117|NCT02666430|9577891|FG001|Period 2|Withdrawal by Subject|4
5987118|NCT02666430|9577890|FG000|Period 3|Lost to Follow-up|1
5987119|NCT02666430|9577891|FG001|Period 3|Lost to Follow-up|0
5987120|NCT02643420|9577899|FG000|Overall Study|Initiation of Non-Protocol Therapy for Breast Cancer|6
5987121|NCT02643420|9577900|FG001|Overall Study|Initiation of Non-Protocol Therapy for Breast Cancer|12
5987122|NCT02643420|9577899|FG000|Overall Study|Withdrawal by Subject|25
5987123|NCT02643420|9577900|FG001|Overall Study|Withdrawal by Subject|19
5987124|NCT02643420|9577899|FG000|Overall Study|Treatment with Additional Myeloid Growth Factors During Follow-up|6
5987125|NCT02643420|9577900|FG001|Overall Study|Treatment with Additional Myeloid Growth Factors During Follow-up|10
5987126|NCT02643420|9577899|FG000|Overall Study|Lost to Follow-up|6
5987127|NCT02643420|9577900|FG001|Overall Study|Lost to Follow-up|10
5987128|NCT02643420|9577899|FG000|Overall Study|Investigator Decision|2
5987129|NCT02643420|9577900|FG001|Overall Study|Investigator Decision|4
5987130|NCT02643420|9577899|FG000|Overall Study|Sponsor decision|1
5987131|NCT02643420|9577900|FG001|Overall Study|Sponsor decision|1
5987132|NCT02643420|9577899|FG000|Overall Study|Death|0
5987133|NCT02643420|9577900|FG001|Overall Study|Death|2
5987134|NCT02643420|9577899|FG000|Overall Study|Reason not Specified|8
5987135|NCT02643420|9577900|FG001|Overall Study|Reason not Specified|7
5987136|NCT02639559|9577914|FG000|Overall Study|Mobilization failure|0
5987137|NCT02639559|9577915|FG001|Overall Study|Mobilization failure|3
5987138|NCT02639559|9577914|FG000|Overall Study|Issues with vascular acess|1
5987139|NCT02639559|9577915|FG001|Overall Study|Issues with vascular acess|0
5987140|NCT02569476|9577921|FG000|Overall Study|Roll over to Long-Term Extension Study|73
5987141|NCT02569476|9577921|FG000|Overall Study|Death|33
5987142|NCT02569476|9577921|FG000|Overall Study|Withdrawal by Subject|9
5987143|NCT02569476|9577921|FG000|Overall Study|Progressive disease at study withdrawal and death by end of study|1
5987144|NCT02569476|9577921|FG000|Overall Study|Palliative care|1
5987145|NCT02569476|9577921|FG000|Overall Study|Transitioned to Long Term Follow Up Study|1
5987146|NCT02569476|9577921|FG000|Overall Study|Transitioned to Long Term Extension Study|1
5987147|NCT02496676|9577937|FG000|Phase 1 - Period 1|Adverse Event|0
5987148|NCT02496676|9577938|FG001|Phase 1 - Period 1|Adverse Event|1
5987149|NCT02496676|9577937|FG000|Phase 2 - IV MgSO4|Adverse Event|0
5987150|NCT02496676|9577938|FG001|Phase 2 - IV MgSO4|Adverse Event|1
6044933|NCT00400153|9644220|FG000|Overall Study|AE due to other condition|3
6044934|NCT00400153|9644221|FG001|Overall Study|AE due to other condition|14
6044935|NCT00400153|9644222|FG002|Overall Study|AE due to other condition|15
6044936|NCT00400153|9644220|FG000|Overall Study|Protocol Violation|7
6044937|NCT00400153|9644221|FG001|Overall Study|Protocol Violation|4
6044938|NCT00400153|9644222|FG002|Overall Study|Protocol Violation|9
6044939|NCT00400153|9644220|FG000|Overall Study|Lost to Follow-up|2
6044940|NCT00400153|9644221|FG001|Overall Study|Lost to Follow-up|1
6044941|NCT00400153|9644222|FG002|Overall Study|Lost to Follow-up|4
6044942|NCT00400153|9644220|FG000|Overall Study|Withdrawal by Subject|12
6044943|NCT00400153|9644221|FG001|Overall Study|Withdrawal by Subject|11
6044944|NCT00400153|9644222|FG002|Overall Study|Withdrawal by Subject|10
6044945|NCT00400153|9644220|FG000|Overall Study|Other reasons - not mentioned above|8
6044946|NCT00400153|9644221|FG001|Overall Study|Other reasons - not mentioned above|5
6044947|NCT00400153|9644222|FG002|Overall Study|Other reasons - not mentioned above|3
6044948|NCT00400179|9644237|FG000|Overall Study|Adverse Event|2
6044949|NCT00400179|9644238|FG001|Overall Study|Adverse Event|2
6044950|NCT00400179|9644237|FG000|Overall Study|Death|1
6044951|NCT00400179|9644238|FG001|Overall Study|Death|2
6044952|NCT00400179|9644237|FG000|Overall Study|Withdrew Consent|1
6044953|NCT00400179|9644238|FG001|Overall Study|Withdrew Consent|5
6044954|NCT00400179|9644237|FG000|Overall Study|Disease progression|1
6044955|NCT00400179|9644238|FG001|Overall Study|Disease progression|1
6044956|NCT00400179|9644237|FG000|Overall Study|Intercurrent illness|0
6044957|NCT00400179|9644238|FG001|Overall Study|Intercurrent illness|1
6044958|NCT00400179|9644237|FG000|Overall Study|Investigator judgment|0
6044959|NCT00400179|9644238|FG001|Overall Study|Investigator judgment|1
6044960|NCT00400179|9644237|FG000|Overall Study|Randomization error/patient ineligible|1
6044961|NCT00400179|9644238|FG001|Overall Study|Randomization error/patient ineligible|6
6044962|NCT00400400|9644251|FG000|Overall Study|Adverse Event|9
6044963|NCT00400400|9644252|FG001|Overall Study|Adverse Event|8
6044964|NCT00400400|9644251|FG000|Overall Study|Protocol Violation|2
6044965|NCT00400400|9644252|FG001|Overall Study|Protocol Violation|0
6044966|NCT00400400|9644251|FG000|Overall Study|Withdrawal by Subject|1
6044967|NCT00400400|9644252|FG001|Overall Study|Withdrawal by Subject|3
6044968|NCT00400400|9644251|FG000|Overall Study|Administrative Problem|1
6044969|NCT00400400|9644252|FG001|Overall Study|Administrative Problem|0
6044970|NCT00400400|9644251|FG000|Overall Study|Lost to Follow-up|0
6044971|NCT00400400|9644252|FG001|Overall Study|Lost to Follow-up|1
6044972|NCT00400400|9644251|FG000|Overall Study|Did not receive study drug|1
6044973|NCT00400400|9644252|FG001|Overall Study|Did not receive study drug|3
6044974|NCT00400517|9644267|FG000|Overall Study|Withdrawal by Subject|1
6044975|NCT00400517|9644267|FG000|Overall Study|Physician Decision|1
6044976|NCT00400569|9644271|FG000|Overall Study|Death|1
6044977|NCT00400712|9644293|FG000|Overall Study|Death|1
6044978|NCT00400712|9644294|FG001|Overall Study|Death|0
6044979|NCT00400712|9644293|FG000|Overall Study|Withdrawal by Subject|11
6044980|NCT00400712|9644294|FG001|Overall Study|Withdrawal by Subject|12
6044981|NCT00400712|9644293|FG000|Overall Study|Physician Decision|5
6044982|NCT00400712|9644294|FG001|Overall Study|Physician Decision|4
6044983|NCT00400764|9644307|FG000|Phase Ib|Adverse Event|1
5987151|NCT02412618|9577963|FG000|Overall Study|Withdrawal by Subject|1
5987152|NCT02412618|9577964|FG001|Overall Study|Withdrawal by Subject|1
5987153|NCT02412618|9577963|FG000|Overall Study|Expulsion|1
5987154|NCT02412618|9577964|FG001|Overall Study|Expulsion|1
5987155|NCT02351180|9577981|FG000|Overall Study|Withdrawal by Subject|1
5987156|NCT02351180|9577982|FG001|Overall Study|Withdrawal by Subject|0
5987157|NCT02337764|9577988|FG000|Overall Study|Pretreatment Event/Adverse Event|46
5987158|NCT02337764|9577988|FG000|Overall Study|Voluntary Withdrawal|12
5987159|NCT02337764|9577988|FG000|Overall Study|Lack of Efficacy|2
5987160|NCT02337738|9577995|FG000|Overall Study|Major Protocol Deviation (Pre-Treatment)|0
5987161|NCT02337738|9577996|FG001|Overall Study|Major Protocol Deviation (Pre-Treatment)|1
5987162|NCT02337738|9577997|FG002|Overall Study|Major Protocol Deviation (Pre-Treatment)|0
5987163|NCT02337738|9577995|FG000|Overall Study|Pretreatment Event/Adverse Event|9
5987164|NCT02337738|9577996|FG001|Overall Study|Pretreatment Event/Adverse Event|18
5987165|NCT02337738|9577997|FG002|Overall Study|Pretreatment Event/Adverse Event|21
5987166|NCT02337738|9577995|FG000|Overall Study|Major Protocol Deviation (in-Treatment)|0
5987167|NCT02337738|9577996|FG001|Overall Study|Major Protocol Deviation (in-Treatment)|1
5987168|NCT02337738|9577997|FG002|Overall Study|Major Protocol Deviation (in-Treatment)|0
5987169|NCT02337738|9577995|FG000|Overall Study|Voluntary Withdrawal|10
5987170|NCT02337738|9577996|FG001|Overall Study|Voluntary Withdrawal|5
5987171|NCT02337738|9577997|FG002|Overall Study|Voluntary Withdrawal|2
5987172|NCT02337738|9577995|FG000|Overall Study|Lack of Efficacy|2
5987173|NCT02337738|9577996|FG001|Overall Study|Lack of Efficacy|4
5987174|NCT02337738|9577997|FG002|Overall Study|Lack of Efficacy|0
5987175|NCT02337738|9577995|FG000|Overall Study|Investigator's Judgment|1
5987176|NCT02337738|9577996|FG001|Overall Study|Investigator's Judgment|1
5987177|NCT02337738|9577997|FG002|Overall Study|Investigator's Judgment|3
5987178|NCT02332187|9578007|FG000|Overall Study|Withdrawal by Subject|2
5987179|NCT02332187|9578008|FG001|Overall Study|Withdrawal by Subject|2
5987180|NCT02332187|9578007|FG000|Overall Study|Adverse Event|0
5987181|NCT02332187|9578008|FG001|Overall Study|Adverse Event|1
5987182|NCT02227875|9578016|FG000|Overall Study|Protocol Violation|10
5987183|NCT02227875|9578017|FG001|Overall Study|Protocol Violation|7
5987184|NCT02227875|9578016|FG000|Overall Study|Other|1
5987185|NCT02227875|9578017|FG001|Overall Study|Other|3
5987186|NCT02227875|9578016|FG000|Overall Study|Physician Decision|1
5987187|NCT02227875|9578017|FG001|Overall Study|Physician Decision|0
5987188|NCT02227875|9578016|FG000|Overall Study|Adverse Event|3
5987189|NCT02227875|9578017|FG001|Overall Study|Adverse Event|0
5987190|NCT02227875|9578016|FG000|Overall Study|Withdrawal by Subject|12
5987191|NCT02227875|9578017|FG001|Overall Study|Withdrawal by Subject|13
5987192|NCT02227875|9578016|FG000|Overall Study|Lost to Follow-up|10
5987193|NCT02227875|9578017|FG001|Overall Study|Lost to Follow-up|10
5987194|NCT02227862|9578025|FG000|Overall Study|Protocol Violation|7
5987195|NCT02227862|9578026|FG001|Overall Study|Protocol Violation|9
5987196|NCT02227862|9578025|FG000|Overall Study|Other|0
5987197|NCT02227862|9578026|FG001|Overall Study|Other|2
5987198|NCT02227862|9578025|FG000|Overall Study|Adverse Event|4
5987199|NCT02227862|9578026|FG001|Overall Study|Adverse Event|3
5987200|NCT02227862|9578025|FG000|Overall Study|Withdrawal by Subject|7
5987201|NCT02227862|9578026|FG001|Overall Study|Withdrawal by Subject|6
5987202|NCT02227862|9578025|FG000|Overall Study|Lost to Follow-up|1
5987203|NCT02227862|9578026|FG001|Overall Study|Lost to Follow-up|2
5987204|NCT02200939|9578034|FG000|Overall Study|Participant withdrew consent|0
5987205|NCT02200939|9578035|FG001|Overall Study|Participant withdrew consent|1
5987206|NCT02200939|9578034|FG000|Overall Study|Lost to Follow-up|2
5987207|NCT02200939|9578035|FG001|Overall Study|Lost to Follow-up|9
5987208|NCT02200939|9578034|FG000|Overall Study|Subject moved out of town and unable to make it back to study|0
5987209|NCT02200939|9578035|FG001|Overall Study|Subject moved out of town and unable to make it back to study|1
5987210|NCT02108964|9578053|FG000|Overall Study|Progressive disease|12
5987211|NCT02108964|9578054|FG001|Overall Study|Progressive disease|25
5987212|NCT02108964|9578055|FG002|Overall Study|Progressive disease|50
5987213|NCT02108964|9578056|FG003|Overall Study|Progressive disease|6
5987214|NCT02108964|9578057|FG004|Overall Study|Progressive disease|18
5987215|NCT02108964|9578058|FG005|Overall Study|Progressive disease|5
5987216|NCT02108964|9578059|FG006|Overall Study|Progressive disease|7
5987217|NCT02108964|9578060|FG007|Overall Study|Progressive disease|9
5987218|NCT02108964|9578053|FG000|Overall Study|Physician Decision|1
5987219|NCT02108964|9578054|FG001|Overall Study|Physician Decision|5
5987220|NCT02108964|9578055|FG002|Overall Study|Physician Decision|6
5987221|NCT02108964|9578056|FG003|Overall Study|Physician Decision|0
5987222|NCT02108964|9578057|FG004|Overall Study|Physician Decision|1
5987223|NCT02108964|9578058|FG005|Overall Study|Physician Decision|0
5987224|NCT02108964|9578059|FG006|Overall Study|Physician Decision|0
5987225|NCT02108964|9578060|FG007|Overall Study|Physician Decision|0
5987226|NCT02108964|9578053|FG000|Overall Study|Adverse Event|0
5987227|NCT02108964|9578054|FG001|Overall Study|Adverse Event|0
5987228|NCT02108964|9578055|FG002|Overall Study|Adverse Event|4
5987229|NCT02108964|9578056|FG003|Overall Study|Adverse Event|0
5987230|NCT02108964|9578057|FG004|Overall Study|Adverse Event|1
5987231|NCT02108964|9578058|FG005|Overall Study|Adverse Event|0
5987232|NCT02108964|9578059|FG006|Overall Study|Adverse Event|3
5987233|NCT02108964|9578060|FG007|Overall Study|Adverse Event|1
5987234|NCT02108964|9578053|FG000|Overall Study|Death|1
5987235|NCT02108964|9578054|FG001|Overall Study|Death|1
5987236|NCT02108964|9578055|FG002|Overall Study|Death|2
5987237|NCT02108964|9578056|FG003|Overall Study|Death|0
5987238|NCT02108964|9578057|FG004|Overall Study|Death|3
5987239|NCT02108964|9578058|FG005|Overall Study|Death|0
5987240|NCT02108964|9578059|FG006|Overall Study|Death|0
5987241|NCT02108964|9578060|FG007|Overall Study|Death|1
5987242|NCT02108964|9578053|FG000|Overall Study|Subject/Guardian decision|0
5987243|NCT02108964|9578054|FG001|Overall Study|Subject/Guardian decision|1
5987244|NCT02108964|9578055|FG002|Overall Study|Subject/Guardian decision|3
5987245|NCT02108964|9578056|FG003|Overall Study|Subject/Guardian decision|0
5987246|NCT02108964|9578057|FG004|Overall Study|Subject/Guardian decision|2
5987247|NCT02108964|9578058|FG005|Overall Study|Subject/Guardian decision|0
5987248|NCT02108964|9578059|FG006|Overall Study|Subject/Guardian decision|1
5987249|NCT02108964|9578060|FG007|Overall Study|Subject/Guardian decision|1
5987250|NCT01922895|9578103|FG000|Overall Study|Death|0
5987251|NCT01922895|9578104|FG001|Overall Study|Death|1
5987252|NCT01922895|9578103|FG000|Overall Study|Withdrawal by Subject|1
5987253|NCT01922895|9578104|FG001|Overall Study|Withdrawal by Subject|2
5987254|NCT01922895|9578103|FG000|Overall Study|Lost to Follow-up|5
5987255|NCT01922895|9578104|FG001|Overall Study|Lost to Follow-up|11
5987256|NCT01901289|9578110|FG000|Overall Study|Death|32
5987257|NCT01901289|9578110|FG000|Overall Study|Lost to Follow-up|16
5987258|NCT01901289|9578110|FG000|Overall Study|Withdrawal by Subject|35
5987259|NCT01901289|9578110|FG000|Overall Study|Other type of endpoint met|2
5987260|NCT01595581|9578129|FG000|Overall Study|Withdrawal by Subject|1
5987261|NCT01595581|9578130|FG001|Overall Study|Withdrawal by Subject|0
5987262|NCT01514682|9578140|FG000|Overall Study|Withdrawal by Subject|2
5987263|NCT01514682|9578141|FG001|Overall Study|Withdrawal by Subject|3
5987264|NCT01514682|9578140|FG000|Overall Study|Physician Decision|4
5987265|NCT01514682|9578141|FG001|Overall Study|Physician Decision|3
5987266|NCT01453140|9578147|FG000|Overall Study|Adverse Event|3
5987267|NCT01408641|9578157|FG000|Overall Study|Physician Decision|1
5987268|NCT01408641|9578158|FG001|Overall Study|Physician Decision|0
5987269|NCT00679783|9578180|FG000|Overall Study|Adverse Event|0
5987270|NCT00679783|9578181|FG001|Overall Study|Adverse Event|0
5987271|NCT00679783|9578182|FG002|Overall Study|Adverse Event|0
5987272|NCT00679783|9578183|FG003|Overall Study|Adverse Event|3
5987273|NCT00679783|9578184|FG004|Overall Study|Adverse Event|0
5987274|NCT00679783|9578185|FG005|Overall Study|Adverse Event|0
5987275|NCT00679783|9578186|FG006|Overall Study|Adverse Event|1
5987276|NCT00679783|9578180|FG000|Overall Study|Lack of Efficacy|0
5987277|NCT00679783|9578181|FG001|Overall Study|Lack of Efficacy|1
5987278|NCT00679783|9578182|FG002|Overall Study|Lack of Efficacy|0
5987279|NCT00679783|9578183|FG003|Overall Study|Lack of Efficacy|2
5987280|NCT00679783|9578184|FG004|Overall Study|Lack of Efficacy|0
5987281|NCT00679783|9578185|FG005|Overall Study|Lack of Efficacy|0
5987282|NCT00679783|9578186|FG006|Overall Study|Lack of Efficacy|0
5987283|NCT00679783|9578180|FG000|Overall Study|Withdrawal by Subject|0
5987284|NCT00679783|9578181|FG001|Overall Study|Withdrawal by Subject|0
5987285|NCT00679783|9578182|FG002|Overall Study|Withdrawal by Subject|1
5987286|NCT00679783|9578183|FG003|Overall Study|Withdrawal by Subject|1
5987287|NCT00679783|9578184|FG004|Overall Study|Withdrawal by Subject|0
5987288|NCT00679783|9578185|FG005|Overall Study|Withdrawal by Subject|0
5987289|NCT00679783|9578186|FG006|Overall Study|Withdrawal by Subject|0
5987290|NCT00679783|9578180|FG000|Overall Study|Not Captured|0
5987291|NCT00679783|9578181|FG001|Overall Study|Not Captured|0
5987292|NCT00679783|9578182|FG002|Overall Study|Not Captured|0
5987293|NCT00679783|9578183|FG003|Overall Study|Not Captured|5
5987294|NCT00679783|9578184|FG004|Overall Study|Not Captured|0
5987295|NCT00679783|9578185|FG005|Overall Study|Not Captured|0
5987296|NCT00679783|9578186|FG006|Overall Study|Not Captured|0
5987297|NCT00679783|9578180|FG000|Overall Study|Ongoing at data cut-off|2
5987298|NCT00679783|9578181|FG001|Overall Study|Ongoing at data cut-off|2
5987299|NCT00679783|9578182|FG002|Overall Study|Ongoing at data cut-off|0
5987300|NCT00679783|9578183|FG003|Overall Study|Ongoing at data cut-off|9
5987301|NCT00679783|9578184|FG004|Overall Study|Ongoing at data cut-off|1
5987302|NCT00679783|9578185|FG005|Overall Study|Ongoing at data cut-off|0
5987303|NCT00679783|9578186|FG006|Overall Study|Ongoing at data cut-off|0
5987304|NCT00653068|9578206|FG000|Overall Study|Death|9
5987305|NCT00653068|9578206|FG000|Overall Study|Lack of Efficacy|34
5987306|NCT00653068|9578206|FG000|Overall Study|Physician Decision|4
5987307|NCT00653068|9578206|FG000|Overall Study|Withdrawal by Subject|1
5987308|NCT00653068|9578206|FG000|Overall Study|Ineligible|2
5987309|NCT00193479|9578213|FG000|Induction Chemotherapy|Adverse Event|2
5987310|NCT00193479|9578213|FG000|Induction Chemotherapy|Disease Progression|1
5987311|NCT00193479|9578213|FG000|Maintenance Rituximab|Opted for full course rituximab/chemotherapy|2
5987312|NCT00193479|9578213|FG000|Maintenance Rituximab|Withdrawal by Subject|2
5987313|NCT00085735|9578232|FG000|Overall Study|Adverse Event|1
5987314|NCT00085735|9578233|FG001|Overall Study|Adverse Event|0
5987315|NCT00085735|9578234|FG002|Overall Study|Adverse Event|0
5987316|NCT00085735|9578235|FG003|Overall Study|Adverse Event|0
5987317|NCT00085735|9578236|FG004|Overall Study|Adverse Event|0
5987318|NCT00085735|9578237|FG005|Overall Study|Adverse Event|0
5987319|NCT00085735|9578232|FG000|Overall Study|Lack of Efficacy|2
5987320|NCT00085735|9578233|FG001|Overall Study|Lack of Efficacy|4
5987321|NCT00085735|9578234|FG002|Overall Study|Lack of Efficacy|6
5987322|NCT00085735|9578235|FG003|Overall Study|Lack of Efficacy|3
5987323|NCT00085735|9578236|FG004|Overall Study|Lack of Efficacy|4
5987324|NCT00085735|9578237|FG005|Overall Study|Lack of Efficacy|3
5987325|NCT00085735|9578232|FG000|Overall Study|Lost to Follow-up|0
5987326|NCT00085735|9578233|FG001|Overall Study|Lost to Follow-up|1
5987327|NCT00085735|9578234|FG002|Overall Study|Lost to Follow-up|0
5987328|NCT00085735|9578235|FG003|Overall Study|Lost to Follow-up|0
5987329|NCT00085735|9578236|FG004|Overall Study|Lost to Follow-up|1
5987330|NCT00085735|9578237|FG005|Overall Study|Lost to Follow-up|0
5987331|NCT00085735|9578232|FG000|Overall Study|Physician Decision|2
5987332|NCT00085735|9578233|FG001|Overall Study|Physician Decision|3
5987333|NCT00085735|9578234|FG002|Overall Study|Physician Decision|2
5987334|NCT00085735|9578235|FG003|Overall Study|Physician Decision|3
5987335|NCT00085735|9578236|FG004|Overall Study|Physician Decision|11
5987336|NCT00085735|9578237|FG005|Overall Study|Physician Decision|8
5987337|NCT00085735|9578232|FG000|Overall Study|Protocol Violation|1
5987338|NCT00085735|9578233|FG001|Overall Study|Protocol Violation|0
5987339|NCT00085735|9578234|FG002|Overall Study|Protocol Violation|0
5987340|NCT00085735|9578235|FG003|Overall Study|Protocol Violation|0
5987341|NCT00085735|9578236|FG004|Overall Study|Protocol Violation|0
5987342|NCT00085735|9578237|FG005|Overall Study|Protocol Violation|0
5987343|NCT00085735|9578232|FG000|Overall Study|Withdrawal by Subject|1
5987344|NCT00085735|9578233|FG001|Overall Study|Withdrawal by Subject|0
5987345|NCT00085735|9578234|FG002|Overall Study|Withdrawal by Subject|4
5987346|NCT00085735|9578235|FG003|Overall Study|Withdrawal by Subject|5
5987347|NCT00085735|9578236|FG004|Overall Study|Withdrawal by Subject|7
5987348|NCT00085735|9578237|FG005|Overall Study|Withdrawal by Subject|8
5987349|NCT00085735|9578232|FG000|Overall Study|Patient ineligible|1
5987350|NCT00085735|9578233|FG001|Overall Study|Patient ineligible|0
5987351|NCT00085735|9578234|FG002|Overall Study|Patient ineligible|3
5987352|NCT00085735|9578235|FG003|Overall Study|Patient ineligible|7
5987353|NCT00085735|9578236|FG004|Overall Study|Patient ineligible|17
5987354|NCT00085735|9578237|FG005|Overall Study|Patient ineligible|8
5987355|NCT00085735|9578232|FG000|Overall Study|Excess residual disease|2
5987356|NCT00085735|9578233|FG001|Overall Study|Excess residual disease|2
5987357|NCT00085735|9578234|FG002|Overall Study|Excess residual disease|1
5987358|NCT00085735|9578235|FG003|Overall Study|Excess residual disease|1
5987359|NCT00085735|9578236|FG004|Overall Study|Excess residual disease|1
5987360|NCT00085735|9578237|FG005|Overall Study|Excess residual disease|4
5987361|NCT00085735|9578232|FG000|Overall Study|Reason not documented|1
5987362|NCT00085735|9578233|FG001|Overall Study|Reason not documented|0
5987363|NCT00085735|9578234|FG002|Overall Study|Reason not documented|1
5987364|NCT00085735|9578235|FG003|Overall Study|Reason not documented|0
5987365|NCT00085735|9578236|FG004|Overall Study|Reason not documented|1
5987366|NCT00085735|9578237|FG005|Overall Study|Reason not documented|0
5987367|NCT00085735|9578232|FG000|Overall Study|Pt transferred to inst w/out study open|1
5987368|NCT00085735|9578233|FG001|Overall Study|Pt transferred to inst w/out study open|0
5987369|NCT00085735|9578234|FG002|Overall Study|Pt transferred to inst w/out study open|0
5987370|NCT00085735|9578235|FG003|Overall Study|Pt transferred to inst w/out study open|0
5987371|NCT00085735|9578236|FG004|Overall Study|Pt transferred to inst w/out study open|0
5987372|NCT00085735|9578237|FG005|Overall Study|Pt transferred to inst w/out study open|0
5987373|NCT00002874|9578275|FG000|Overall Study|Withdrawal by Subject|1
5987374|NCT00002874|9578276|FG001|Overall Study|Withdrawal by Subject|1
5987375|NCT00002874|9578275|FG000|Overall Study|Protocol Violation|44
5987376|NCT00002874|9578276|FG001|Overall Study|Protocol Violation|34
6044984|NCT00400764|9644308|FG001|Phase Ib|Adverse Event|0
6044985|NCT00400764|9644309|FG002|Phase Ib|Adverse Event|0
6044986|NCT00400764|9644310|FG003|Phase Ib|Adverse Event|0
6044987|NCT00400764|9644311|FG004|Phase Ib|Adverse Event|0
6044988|NCT00400764|9644307|FG000|Phase Ib|Death|1
6044989|NCT00400764|9644308|FG001|Phase Ib|Death|0
6044990|NCT00400764|9644309|FG002|Phase Ib|Death|0
6044991|NCT00400764|9644310|FG003|Phase Ib|Death|0
6044992|NCT00400764|9644311|FG004|Phase Ib|Death|0
6044993|NCT00400764|9644307|FG000|Phase Ib|Disease Progression|4
6044994|NCT00400764|9644308|FG001|Phase Ib|Disease Progression|4
6044995|NCT00400764|9644309|FG002|Phase Ib|Disease Progression|0
6044996|NCT00400764|9644310|FG003|Phase Ib|Disease Progression|0
6044997|NCT00400764|9644311|FG004|Phase Ib|Disease Progression|0
6044998|NCT00400764|9644307|FG000|Phase II|Death|0
6044999|NCT00400764|9644308|FG001|Phase II|Death|0
6045000|NCT00400764|9644309|FG002|Phase II|Death|1
6045001|NCT00400764|9644310|FG003|Phase II|Death|2
6045002|NCT00400764|9644311|FG004|Phase II|Death|0
6045003|NCT00400764|9644307|FG000|Phase II|Lost to Follow-up|0
6045004|NCT00400764|9644308|FG001|Phase II|Lost to Follow-up|0
6045005|NCT00400764|9644309|FG002|Phase II|Lost to Follow-up|1
6045006|NCT00400764|9644310|FG003|Phase II|Lost to Follow-up|0
6045007|NCT00400764|9644311|FG004|Phase II|Lost to Follow-up|0
6045008|NCT00400764|9644307|FG000|Phase II|Physician Decision|0
6045009|NCT00400764|9644308|FG001|Phase II|Physician Decision|0
6045010|NCT00400764|9644309|FG002|Phase II|Physician Decision|1
6045011|NCT00400764|9644310|FG003|Phase II|Physician Decision|1
6045012|NCT00400764|9644311|FG004|Phase II|Physician Decision|0
6045013|NCT00400764|9644307|FG000|Phase II|Sponsor's decision to terminate|0
5987377|NCT04399356|9578284|FG000|Overall Study|Lost to Follow-up|1
5987378|NCT04399356|9578285|FG001|Overall Study|Lost to Follow-up|1
5987379|NCT04399356|9578284|FG000|Overall Study|Discontinued Niclosamide/ Placebo|1
5987380|NCT04399356|9578285|FG001|Overall Study|Discontinued Niclosamide/ Placebo|2
5987381|NCT04399356|9578284|FG000|Overall Study|Withdrawal by Subject|1
5987382|NCT04399356|9578285|FG001|Overall Study|Withdrawal by Subject|0
5987383|NCT04156399|9578315|FG000|Overall Study|hospitalization unrelated to acupuncture|1
5987384|NCT04156399|9578315|FG000|Overall Study|study suspension due to COVID pandemic|3
5987385|NCT04052620|9578334|FG000|Overall Study|aspartate aminotransferase (AST) >= 2 times upper limit of normal (ULN)|1
5987386|NCT04052620|9578335|FG001|Overall Study|aspartate aminotransferase (AST) >= 2 times upper limit of normal (ULN)|0
5987387|NCT04052620|9578334|FG000|Overall Study|Withdrawal by Subject|1
5987388|NCT04052620|9578335|FG001|Overall Study|Withdrawal by Subject|0
5987389|NCT04052620|9578334|FG000|Overall Study|Lost to Follow-up|1
5987390|NCT04052620|9578335|FG001|Overall Study|Lost to Follow-up|1
5987391|NCT04052620|9578334|FG000|Overall Study|Adverse Event|1
5987392|NCT04052620|9578335|FG001|Overall Study|Adverse Event|0
5987393|NCT04052620|9578334|FG000|Overall Study|Subject did not meet study Criteria|0
5987394|NCT04052620|9578335|FG001|Overall Study|Subject did not meet study Criteria|1
5987395|NCT04052620|9578334|FG000|Overall Study|Screened failure, randomized by mistake|0
5987396|NCT04052620|9578335|FG001|Overall Study|Screened failure, randomized by mistake|1
5987397|NCT04052620|9578334|FG000|Overall Study|Personal reasons|2
5987398|NCT04052620|9578335|FG001|Overall Study|Personal reasons|4
5987399|NCT04052620|9578334|FG000|Overall Study|alanine aminotransferase (ALT) >= 2 times ULN|1
5987400|NCT04052620|9578335|FG001|Overall Study|alanine aminotransferase (ALT) >= 2 times ULN|0
5987401|NCT03933449|9578343|FG000|Overall Study|Adverse Event|6
5987402|NCT03933449|9578344|FG001|Overall Study|Adverse Event|4
5987403|NCT03933449|9578343|FG000|Overall Study|Death|36
5987404|NCT03933449|9578344|FG001|Overall Study|Death|51
5987405|NCT03933449|9578343|FG000|Overall Study|Ongoing in Study|20
5987406|NCT03933449|9578344|FG001|Overall Study|Ongoing in Study|6
5987407|NCT03826667|9578350|FG000|Overall Study|Protocol deviation|21
5987408|NCT03600909|9578363|FG000|Overall Study|Not treated|0
5987409|NCT03600909|9578364|FG001|Overall Study|Not treated|3
5987410|NCT03600909|9578365|FG002|Overall Study|Not treated|0
5987411|NCT03366428|9578381|FG000|Overall Study|Progressive disease per RECIST v1.1|33
5987412|NCT03366428|9578381|FG000|Overall Study|Adverse Event|12
5987413|NCT03366428|9578381|FG000|Overall Study|Clinical progression|2
5987414|NCT03366428|9578381|FG000|Overall Study|Withdrawal by Subject|4
5987415|NCT03131219|9578393|FG000|Initial Evaluation Period|Adverse Event|1
5987416|NCT03131219|9578394|FG001|Initial Evaluation Period|Adverse Event|0
5987417|NCT03131219|9578393|FG000|Initial Evaluation Period|Protocol Violation|1
5987418|NCT03131219|9578394|FG001|Initial Evaluation Period|Protocol Violation|0
5987419|NCT03131219|9578393|FG000|Initial Evaluation Period|Deemed ineligible post treatment|2
5987420|NCT03131219|9578394|FG001|Initial Evaluation Period|Deemed ineligible post treatment|0
5987421|NCT03075527|9578400|FG000|Overall Study|Ongoing treatment|2
5987422|NCT02756611|9578404|FG000|Overall Study|Death|39
5987423|NCT02756611|9578404|FG000|Overall Study|Withdrawal by Subject|1
5987424|NCT02756611|9578404|FG000|Overall Study|Lost to Follow-up|2
5987425|NCT02756611|9578404|FG000|Overall Study|Other|7
5987426|NCT02756611|9578404|FG000|Overall Study|Missing|2
5987427|NCT02756611|9578404|FG000|Overall Study|Active on Study|205
5987428|NCT02724878|9578408|FG000|Overall Study|Still on Active Therapy|15
5987429|NCT02724878|9578408|FG000|Overall Study|Disease Progression|31
5987430|NCT02724878|9578408|FG000|Overall Study|Toxicity|5
5987431|NCT02724878|9578408|FG000|Overall Study|Death|1
5987432|NCT02724878|9578408|FG000|Overall Study|Withdrawal by Subject|4
5987433|NCT02724878|9578408|FG000|Overall Study|Lost to Follow-up|2
5987434|NCT02724878|9578408|FG000|Overall Study|Protocol Violation|1
5987435|NCT02724878|9578408|FG000|Overall Study|Ineligible for Study Drug|5
5987436|NCT02724878|9578408|FG000|Overall Study|not started|1
5987437|NCT02562235|9578429|FG000|Overall Study|Adverse Event|3
5987438|NCT02487095|9578452|FG000|Dose Expansion|Unable to scan/restage participant|0
5987439|NCT02487095|9578453|FG001|Dose Expansion|Unable to scan/restage participant|0
5987440|NCT02487095|9578454|FG002|Dose Expansion|Unable to scan/restage participant|0
5987441|NCT02487095|9578455|FG003|Dose Expansion|Unable to scan/restage participant|0
5987442|NCT02487095|9578456|FG004|Dose Expansion|Unable to scan/restage participant|1
5987443|NCT02335658|9578503|FG000|Overall Study|Adverse Event|18
5987444|NCT02335658|9578504|FG001|Overall Study|Adverse Event|12
5987445|NCT02335658|9578503|FG000|Overall Study|Lack of Efficacy|4
5987446|NCT02335658|9578504|FG001|Overall Study|Lack of Efficacy|5
5987447|NCT02335658|9578503|FG000|Overall Study|Pregnancy|1
5987448|NCT02335658|9578504|FG001|Overall Study|Pregnancy|0
5987449|NCT02335658|9578503|FG000|Overall Study|Withdrawal by Subject|13
5987450|NCT02335658|9578504|FG001|Overall Study|Withdrawal by Subject|21
5987451|NCT02335658|9578503|FG000|Overall Study|non-compliance|2
5987452|NCT02335658|9578504|FG001|Overall Study|non-compliance|3
5987453|NCT02335658|9578503|FG000|Overall Study|other reason|2
5987454|NCT02335658|9578504|FG001|Overall Study|other reason|3
5987455|NCT02287584|9578515|FG000|the Double-blind Phase|Adverse Event|17
5987456|NCT02287584|9578516|FG001|the Double-blind Phase|Adverse Event|17
5987457|NCT02287584|9578517|FG002|the Double-blind Phase|Adverse Event|12
5987458|NCT02287584|9578518|FG003|the Double-blind Phase|Adverse Event|0
5987459|NCT02287584|9578519|FG004|the Double-blind Phase|Adverse Event|0
5987460|NCT02287584|9578520|FG005|the Double-blind Phase|Adverse Event|0
5987461|NCT02287584|9578515|FG000|the Double-blind Phase|Lack of Efficacy|18
5987462|NCT02287584|9578516|FG001|the Double-blind Phase|Lack of Efficacy|8
5987463|NCT02287584|9578517|FG002|the Double-blind Phase|Lack of Efficacy|8
5987464|NCT02287584|9578518|FG003|the Double-blind Phase|Lack of Efficacy|0
5987465|NCT02287584|9578519|FG004|the Double-blind Phase|Lack of Efficacy|0
5987466|NCT02287584|9578520|FG005|the Double-blind Phase|Lack of Efficacy|0
5987467|NCT02287584|9578515|FG000|the Double-blind Phase|Lost to Follow-up|0
5987468|NCT02287584|9578516|FG001|the Double-blind Phase|Lost to Follow-up|1
5987469|NCT02287584|9578517|FG002|the Double-blind Phase|Lost to Follow-up|1
5987470|NCT02287584|9578518|FG003|the Double-blind Phase|Lost to Follow-up|0
5987471|NCT02287584|9578519|FG004|the Double-blind Phase|Lost to Follow-up|0
5987472|NCT02287584|9578520|FG005|the Double-blind Phase|Lost to Follow-up|0
5987473|NCT02287584|9578515|FG000|the Double-blind Phase|Withdrawal by Subject|17
5987474|NCT02287584|9578516|FG001|the Double-blind Phase|Withdrawal by Subject|17
5987475|NCT02287584|9578517|FG002|the Double-blind Phase|Withdrawal by Subject|11
5987476|NCT02287584|9578518|FG003|the Double-blind Phase|Withdrawal by Subject|0
5987477|NCT02287584|9578519|FG004|the Double-blind Phase|Withdrawal by Subject|0
5987478|NCT02287584|9578520|FG005|the Double-blind Phase|Withdrawal by Subject|0
5987479|NCT02287584|9578515|FG000|the Double-blind Phase|Pregnancy|0
5987480|NCT02287584|9578516|FG001|the Double-blind Phase|Pregnancy|1
5987481|NCT02287584|9578517|FG002|the Double-blind Phase|Pregnancy|0
5987482|NCT02287584|9578518|FG003|the Double-blind Phase|Pregnancy|0
5987483|NCT02287584|9578519|FG004|the Double-blind Phase|Pregnancy|0
5987484|NCT02287584|9578520|FG005|the Double-blind Phase|Pregnancy|0
5987485|NCT02287584|9578515|FG000|the Double-blind Phase|Protocol Violation|0
5987486|NCT02287584|9578516|FG001|the Double-blind Phase|Protocol Violation|3
5987487|NCT02287584|9578517|FG002|the Double-blind Phase|Protocol Violation|0
5987488|NCT02287584|9578518|FG003|the Double-blind Phase|Protocol Violation|0
5987489|NCT02287584|9578519|FG004|the Double-blind Phase|Protocol Violation|0
5987490|NCT02287584|9578520|FG005|the Double-blind Phase|Protocol Violation|0
5987491|NCT02287584|9578515|FG000|the Double-blind Phase|other reasons|0
5987492|NCT02287584|9578516|FG001|the Double-blind Phase|other reasons|0
5987493|NCT02287584|9578517|FG002|the Double-blind Phase|other reasons|1
5987494|NCT02287584|9578518|FG003|the Double-blind Phase|other reasons|0
5987495|NCT02287584|9578519|FG004|the Double-blind Phase|other reasons|0
5987496|NCT02287584|9578520|FG005|the Double-blind Phase|other reasons|0
5987497|NCT02287584|9578515|FG000|the Open-label Phase|Did not receive drug|0
5987498|NCT02287584|9578516|FG001|the Open-label Phase|Did not receive drug|0
5987499|NCT02287584|9578517|FG002|the Open-label Phase|Did not receive drug|0
5987500|NCT02287584|9578518|FG003|the Open-label Phase|Did not receive drug|7
5987501|NCT02287584|9578519|FG004|the Open-label Phase|Did not receive drug|6
5987502|NCT02287584|9578520|FG005|the Open-label Phase|Did not receive drug|4
5987503|NCT02287584|9578515|FG000|the Open-label Phase|Adverse Event|0
5987504|NCT02287584|9578516|FG001|the Open-label Phase|Adverse Event|0
5987505|NCT02287584|9578517|FG002|the Open-label Phase|Adverse Event|0
5987506|NCT02287584|9578518|FG003|the Open-label Phase|Adverse Event|15
5987507|NCT02287584|9578519|FG004|the Open-label Phase|Adverse Event|12
5987508|NCT02287584|9578520|FG005|the Open-label Phase|Adverse Event|16
5987509|NCT02287584|9578515|FG000|the Open-label Phase|Lack of Efficacy|0
5987510|NCT02287584|9578516|FG001|the Open-label Phase|Lack of Efficacy|0
5987511|NCT02287584|9578517|FG002|the Open-label Phase|Lack of Efficacy|0
5987512|NCT02287584|9578518|FG003|the Open-label Phase|Lack of Efficacy|8
5987513|NCT02287584|9578519|FG004|the Open-label Phase|Lack of Efficacy|3
5987514|NCT02287584|9578520|FG005|the Open-label Phase|Lack of Efficacy|7
5987515|NCT02287584|9578515|FG000|the Open-label Phase|Lost to Follow-up|0
5987516|NCT02287584|9578516|FG001|the Open-label Phase|Lost to Follow-up|0
5987517|NCT02287584|9578517|FG002|the Open-label Phase|Lost to Follow-up|0
5987518|NCT02287584|9578518|FG003|the Open-label Phase|Lost to Follow-up|4
5987519|NCT02287584|9578519|FG004|the Open-label Phase|Lost to Follow-up|1
5987520|NCT02287584|9578520|FG005|the Open-label Phase|Lost to Follow-up|2
5987521|NCT02287584|9578515|FG000|the Open-label Phase|Withdrawal by Subject|0
5987522|NCT02287584|9578516|FG001|the Open-label Phase|Withdrawal by Subject|0
5987523|NCT02287584|9578517|FG002|the Open-label Phase|Withdrawal by Subject|0
5987524|NCT02287584|9578518|FG003|the Open-label Phase|Withdrawal by Subject|18
5987525|NCT02287584|9578519|FG004|the Open-label Phase|Withdrawal by Subject|29
5987526|NCT02287584|9578520|FG005|the Open-label Phase|Withdrawal by Subject|21
5987527|NCT02287584|9578515|FG000|the Open-label Phase|non-compliance|0
5987528|NCT02287584|9578516|FG001|the Open-label Phase|non-compliance|0
5987529|NCT02287584|9578517|FG002|the Open-label Phase|non-compliance|0
5987530|NCT02287584|9578518|FG003|the Open-label Phase|non-compliance|2
5987531|NCT02287584|9578519|FG004|the Open-label Phase|non-compliance|5
5987532|NCT02287584|9578520|FG005|the Open-label Phase|non-compliance|1
5987533|NCT02287584|9578515|FG000|the Open-label Phase|other reasons|0
5987534|NCT02287584|9578516|FG001|the Open-label Phase|other reasons|0
5987535|NCT02287584|9578517|FG002|the Open-label Phase|other reasons|0
5987536|NCT02287584|9578518|FG003|the Open-label Phase|other reasons|3
5987537|NCT02287584|9578519|FG004|the Open-label Phase|other reasons|6
5987538|NCT02287584|9578520|FG005|the Open-label Phase|other reasons|6
5987539|NCT02178566|9578536|FG000|Overall Study|patient did not complete due to noncompliance|0
5987540|NCT02178566|9578537|FG001|Overall Study|patient did not complete due to noncompliance|1
6045014|NCT00400764|9644308|FG001|Phase II|Sponsor's decision to terminate|0
6045015|NCT00400764|9644309|FG002|Phase II|Sponsor's decision to terminate|18
6045016|NCT00400764|9644310|FG003|Phase II|Sponsor's decision to terminate|22
6045017|NCT00400764|9644311|FG004|Phase II|Sponsor's decision to terminate|11
6045018|NCT00400764|9644307|FG000|Phase II|Patient began new, non-protocol, therapy|0
6045019|NCT00400764|9644308|FG001|Phase II|Patient began new, non-protocol, therapy|0
6045020|NCT00400764|9644309|FG002|Phase II|Patient began new, non-protocol, therapy|1
6045021|NCT00400764|9644310|FG003|Phase II|Patient began new, non-protocol, therapy|0
6045022|NCT00400764|9644311|FG004|Phase II|Patient began new, non-protocol, therapy|0
6045023|NCT00400764|9644307|FG000|Phase II|Withdrawal by Subject|0
6045024|NCT00400764|9644308|FG001|Phase II|Withdrawal by Subject|0
6045025|NCT00400764|9644309|FG002|Phase II|Withdrawal by Subject|1
6045026|NCT00400764|9644310|FG003|Phase II|Withdrawal by Subject|1
6045027|NCT00400764|9644311|FG004|Phase II|Withdrawal by Subject|0
6045028|NCT00400946|9644355|FG000|Overall Study|Ineligible|0
6045029|NCT00400946|9644356|FG001|Overall Study|Ineligible|0
6045030|NCT00400946|9644357|FG002|Overall Study|Ineligible|0
6045031|NCT00400946|9644358|FG003|Overall Study|Ineligible|5
6045032|NCT00400946|9644359|FG004|Overall Study|Ineligible|1
6045033|NCT00400946|9644355|FG000|Overall Study|Induction Failure|0
6045034|NCT00400946|9644356|FG001|Overall Study|Induction Failure|0
6045035|NCT00400946|9644357|FG002|Overall Study|Induction Failure|0
6045036|NCT00400946|9644358|FG003|Overall Study|Induction Failure|11
6045037|NCT00400946|9644359|FG004|Overall Study|Induction Failure|8
6045038|NCT00400946|9644355|FG000|Overall Study|Induction Death|0
6045039|NCT00400946|9644356|FG001|Overall Study|Induction Death|0
6045040|NCT00400946|9644357|FG002|Overall Study|Induction Death|0
6045041|NCT00400946|9644358|FG003|Overall Study|Induction Death|13
6045042|NCT00400946|9644359|FG004|Overall Study|Induction Death|3
6045043|NCT00400946|9644355|FG000|Overall Study|Lost to Follow-up|1
6045044|NCT00400946|9644356|FG001|Overall Study|Lost to Follow-up|1
6045045|NCT00400946|9644357|FG002|Overall Study|Lost to Follow-up|0
6045046|NCT00400946|9644358|FG003|Overall Study|Lost to Follow-up|0
6045047|NCT00400946|9644359|FG004|Overall Study|Lost to Follow-up|1
6045048|NCT00400946|9644355|FG000|Overall Study|Remission Death|1
6045049|NCT00400946|9644356|FG001|Overall Study|Remission Death|1
6045050|NCT00400946|9644357|FG002|Overall Study|Remission Death|0
6045051|NCT00400946|9644358|FG003|Overall Study|Remission Death|0
6045052|NCT00400946|9644359|FG004|Overall Study|Remission Death|1
6045053|NCT00400946|9644355|FG000|Overall Study|Relapse|9
6045054|NCT00400946|9644356|FG001|Overall Study|Relapse|2
6045055|NCT00400946|9644357|FG002|Overall Study|Relapse|1
6045056|NCT00400946|9644358|FG003|Overall Study|Relapse|1
6045057|NCT00400946|9644359|FG004|Overall Study|Relapse|5
6045058|NCT00400946|9644355|FG000|Overall Study|Transplant in CR1|0
6045059|NCT00400946|9644356|FG001|Overall Study|Transplant in CR1|0
6045060|NCT00400946|9644357|FG002|Overall Study|Transplant in CR1|0
6045061|NCT00400946|9644358|FG003|Overall Study|Transplant in CR1|10
6045062|NCT00400946|9644359|FG004|Overall Study|Transplant in CR1|1
6045063|NCT00400946|9644355|FG000|Overall Study|Withdrawal by Subject|2
6045064|NCT00400946|9644356|FG001|Overall Study|Withdrawal by Subject|5
6045065|NCT00400946|9644357|FG002|Overall Study|Withdrawal by Subject|1
6045066|NCT00400946|9644358|FG003|Overall Study|Withdrawal by Subject|5
6045067|NCT00400946|9644359|FG004|Overall Study|Withdrawal by Subject|8
6045068|NCT00400946|9644355|FG000|Overall Study|Clinical|1
6045069|NCT00400946|9644356|FG001|Overall Study|Clinical|2
6045070|NCT00400946|9644357|FG002|Overall Study|Clinical|0
6045071|NCT00400946|9644358|FG003|Overall Study|Clinical|2
6045072|NCT00400946|9644359|FG004|Overall Study|Clinical|9
6045073|NCT00400946|9644355|FG000|Overall Study|Other|0
6045074|NCT00400946|9644356|FG001|Overall Study|Other|0
6045075|NCT00400946|9644357|FG002|Overall Study|Other|0
6045076|NCT00400946|9644358|FG003|Overall Study|Other|0
6045077|NCT00400946|9644359|FG004|Overall Study|Other|1
6045078|NCT00400985|9644377|FG000|Overall Study|Withdrawal by Subject|5
6045079|NCT00400985|9644377|FG000|Overall Study|system modification|8
6045080|NCT00400985|9644377|FG000|Overall Study|Death|30
6045081|NCT00400985|9644377|FG000|Overall Study|Lost to Follow-up|9
6045082|NCT00401193|9644388|FG000|Overall Study|Adverse Event|1
6045083|NCT00401193|9644389|FG001|Overall Study|Adverse Event|3
6045084|NCT00401193|9644390|FG002|Overall Study|Adverse Event|1
6045085|NCT00401193|9644388|FG000|Overall Study|Protocol Violation|3
6045086|NCT00401193|9644389|FG001|Overall Study|Protocol Violation|1
6045087|NCT00401193|9644390|FG002|Overall Study|Protocol Violation|1
6045088|NCT00401193|9644388|FG000|Overall Study|Lost to Follow-up|6
6045089|NCT00401193|9644389|FG001|Overall Study|Lost to Follow-up|5
6045090|NCT00401193|9644390|FG002|Overall Study|Lost to Follow-up|1
6045091|NCT00401193|9644388|FG000|Overall Study|Withdrawal by Subject|2
6045092|NCT00401193|9644389|FG001|Overall Study|Withdrawal by Subject|0
6045093|NCT00401193|9644390|FG002|Overall Study|Withdrawal by Subject|1
6045094|NCT00401193|9644388|FG000|Overall Study|Other Event|3
6045095|NCT00401193|9644389|FG001|Overall Study|Other Event|2
6045096|NCT00401193|9644390|FG002|Overall Study|Other Event|2
6045097|NCT00401245|9644403|FG000|Double Blind Titration Phase|Adverse Event|3
6045098|NCT00401245|9644404|FG001|Double Blind Titration Phase|Adverse Event|2
5987541|NCT02173301|9578547|FG000|Overall Study|Adverse Event|7
5987542|NCT02173301|9578548|FG001|Overall Study|Adverse Event|8
5987543|NCT02173301|9578549|FG002|Overall Study|Adverse Event|13
5987544|NCT02173301|9578550|FG003|Overall Study|Adverse Event|5
5987545|NCT02173301|9578547|FG000|Overall Study|Withdrawal by Subject|8
5987546|NCT02173301|9578548|FG001|Overall Study|Withdrawal by Subject|10
5987547|NCT02173301|9578549|FG002|Overall Study|Withdrawal by Subject|4
5987548|NCT02173301|9578550|FG003|Overall Study|Withdrawal by Subject|8
5987549|NCT02173301|9578547|FG000|Overall Study|Lost to Follow-up|4
5987550|NCT02173301|9578548|FG001|Overall Study|Lost to Follow-up|4
5987551|NCT02173301|9578549|FG002|Overall Study|Lost to Follow-up|2
5987552|NCT02173301|9578550|FG003|Overall Study|Lost to Follow-up|2
5987553|NCT02173301|9578547|FG000|Overall Study|Protocol Violation|0
5987554|NCT02173301|9578548|FG001|Overall Study|Protocol Violation|1
5987555|NCT02173301|9578549|FG002|Overall Study|Protocol Violation|0
5987556|NCT02173301|9578550|FG003|Overall Study|Protocol Violation|0
5987557|NCT02173301|9578547|FG000|Overall Study|Physician Decision|0
5987558|NCT02173301|9578548|FG001|Overall Study|Physician Decision|0
5987559|NCT02173301|9578549|FG002|Overall Study|Physician Decision|1
5987560|NCT02173301|9578550|FG003|Overall Study|Physician Decision|0
5987561|NCT02173301|9578547|FG000|Overall Study|Subject unable to return for week 16 assessment within Sponsor timelines for study completion|1
5987562|NCT02173301|9578548|FG001|Overall Study|Subject unable to return for week 16 assessment within Sponsor timelines for study completion|0
5987563|NCT02173301|9578549|FG002|Overall Study|Subject unable to return for week 16 assessment within Sponsor timelines for study completion|0
5987564|NCT02173301|9578550|FG003|Overall Study|Subject unable to return for week 16 assessment within Sponsor timelines for study completion|0
5987565|NCT02043678|9578562|FG000|Overall Study|Never treated|11
5987566|NCT02043678|9578563|FG001|Overall Study|Never treated|9
5987567|NCT02043678|9578562|FG000|Overall Study|AE with clinical progressive disease(PD)|18
5987568|NCT02043678|9578563|FG001|Overall Study|AE with clinical progressive disease(PD)|18
5987569|NCT02043678|9578562|FG000|Overall Study|AE without clinical PD|51
5987570|NCT02043678|9578563|FG001|Overall Study|AE without clinical PD|34
5987571|NCT02043678|9578562|FG000|Overall Study|Lost to Follow-up|1
5987572|NCT02043678|9578563|FG001|Overall Study|Lost to Follow-up|1
5987573|NCT02043678|9578562|FG000|Overall Study|Other|19
5987574|NCT02043678|9578563|FG001|Overall Study|Other|16
5987575|NCT02043678|9578562|FG000|Overall Study|Clinical PD|108
5987576|NCT02043678|9578563|FG001|Overall Study|Clinical PD|138
5987577|NCT02043678|9578562|FG000|Overall Study|Radiological PD|91
5987578|NCT02043678|9578563|FG001|Overall Study|Radiological PD|80
5987579|NCT02043678|9578562|FG000|Overall Study|Protocol-driven decision point|56
5987580|NCT02043678|9578563|FG001|Overall Study|Protocol-driven decision point|56
5987581|NCT02043678|9578562|FG000|Overall Study|Withdrawal by Subject|12
5987582|NCT02043678|9578563|FG001|Overall Study|Withdrawal by Subject|15
5987583|NCT02043678|9578562|FG000|Overall Study|Ongoing with treatment|34
5987584|NCT02043678|9578563|FG001|Overall Study|Ongoing with treatment|38
5987585|NCT01986114|9578569|FG000|Overall Study|Adverse Event|59
5987586|NCT01986114|9578569|FG000|Overall Study|Lack of Efficacy|23
5987587|NCT01986114|9578569|FG000|Overall Study|Withdrawal by Subject|58
5987588|NCT01986114|9578569|FG000|Overall Study|Noncompliance|3
5987589|NCT01986114|9578569|FG000|Overall Study|Protocol Violation|1
5987590|NCT01986114|9578569|FG000|Overall Study|Lost to Follow-up|5
5987591|NCT01986114|9578569|FG000|Overall Study|Other reason|7
5987592|NCT01813305|9578634|FG000|Overall Study|Withdrawal by Subject|12
5987593|NCT01813305|9578635|FG001|Overall Study|Withdrawal by Subject|5
5987594|NCT01813305|9578634|FG000|Overall Study|Safety Concern|4
5987595|NCT01813305|9578635|FG001|Overall Study|Safety Concern|0
5987596|NCT01813305|9578634|FG000|Overall Study|Ulcer became worse|4
5987597|NCT01813305|9578635|FG001|Overall Study|Ulcer became worse|0
5987598|NCT01813305|9578634|FG000|Overall Study|Physician Decision|4
5987599|NCT01813305|9578635|FG001|Overall Study|Physician Decision|0
5987600|NCT01813305|9578634|FG000|Overall Study|Lost to Follow-up|3
5987601|NCT01813305|9578635|FG001|Overall Study|Lost to Follow-up|1
5987602|NCT01813305|9578634|FG000|Overall Study|Protocol Violation|1
5987603|NCT01813305|9578635|FG001|Overall Study|Protocol Violation|0
5987604|NCT01813305|9578634|FG000|Overall Study|Prohibited Medication Administration or Condition Worsening|7
5987605|NCT01813305|9578635|FG001|Overall Study|Prohibited Medication Administration or Condition Worsening|2
5987606|NCT01740427|9578645|FG000|Overall Study|Ongoing at date of cutoff (26 Feb 2016)|205
5987607|NCT01740427|9578646|FG001|Overall Study|Ongoing at date of cutoff (26 Feb 2016)|61
5987608|NCT01740427|9578645|FG000|Overall Study|Objective progression or relapse|172
5987609|NCT01740427|9578646|FG001|Overall Study|Objective progression or relapse|125
5987610|NCT01740427|9578645|FG000|Overall Study|Adverse Event|20
5987611|NCT01740427|9578646|FG001|Overall Study|Adverse Event|9
5987612|NCT01740427|9578645|FG000|Overall Study|Global deterioration of health status|16
5987613|NCT01740427|9578646|FG001|Overall Study|Global deterioration of health status|9
5987614|NCT01740427|9578645|FG000|Overall Study|Subject refused continued treatment|12
5987615|NCT01740427|9578646|FG001|Overall Study|Subject refused continued treatment|9
5987616|NCT01740427|9578645|FG000|Overall Study|Unspecified reasons|6
5987617|NCT01740427|9578646|FG001|Overall Study|Unspecified reasons|4
5987618|NCT01740427|9578645|FG000|Overall Study|Death|6
5987619|NCT01740427|9578646|FG001|Overall Study|Death|2
5987620|NCT01740427|9578645|FG000|Overall Study|Protocol Violation|5
5987621|NCT01740427|9578646|FG001|Overall Study|Protocol Violation|3
5987622|NCT01740427|9578645|FG000|Overall Study|Lost to Follow-up|1
5987623|NCT01740427|9578646|FG001|Overall Study|Lost to Follow-up|0
5987624|NCT01740427|9578645|FG000|Overall Study|Study terminated by Sponsor|1
5987625|NCT01740427|9578646|FG001|Overall Study|Study terminated by Sponsor|0
5987626|NCT01680965|9578656|FG000|Overall Study|Death|0
5987627|NCT01680965|9578657|FG001|Overall Study|Death|0
5987628|NCT01680965|9578658|FG002|Overall Study|Death|0
5987629|NCT01680965|9578659|FG003|Overall Study|Death|6
5987630|NCT01592370|9578691|FG000|Overall Study|Disease Progression|62
5987631|NCT01592370|9578692|FG001|Overall Study|Disease Progression|16
5987632|NCT01592370|9578693|FG002|Overall Study|Disease Progression|52
5987633|NCT01592370|9578694|FG003|Overall Study|Disease Progression|3
5987634|NCT01592370|9578695|FG004|Overall Study|Disease Progression|3
5987635|NCT01592370|9578696|FG005|Overall Study|Disease Progression|31
5987636|NCT01592370|9578697|FG006|Overall Study|Disease Progression|14
5987637|NCT01592370|9578691|FG000|Overall Study|Study Drug Toxicity|14
5987638|NCT01592370|9578692|FG001|Overall Study|Study Drug Toxicity|3
5987639|NCT01592370|9578693|FG002|Overall Study|Study Drug Toxicity|0
5987640|NCT01592370|9578694|FG003|Overall Study|Study Drug Toxicity|0
5987641|NCT01592370|9578695|FG004|Overall Study|Study Drug Toxicity|0
5987642|NCT01592370|9578696|FG005|Overall Study|Study Drug Toxicity|0
5987643|NCT01592370|9578697|FG006|Overall Study|Study Drug Toxicity|1
5987644|NCT01592370|9578691|FG000|Overall Study|AE unrelated to study drug|4
5987645|NCT01592370|9578692|FG001|Overall Study|AE unrelated to study drug|3
5987646|NCT01592370|9578693|FG002|Overall Study|AE unrelated to study drug|0
5987647|NCT01592370|9578694|FG003|Overall Study|AE unrelated to study drug|0
5987648|NCT01592370|9578695|FG004|Overall Study|AE unrelated to study drug|0
5987649|NCT01592370|9578696|FG005|Overall Study|AE unrelated to study drug|0
5987650|NCT01592370|9578697|FG006|Overall Study|AE unrelated to study drug|1
5987651|NCT01592370|9578691|FG000|Overall Study|Request to discontinue study treatment|5
5987652|NCT01592370|9578692|FG001|Overall Study|Request to discontinue study treatment|0
5987653|NCT01592370|9578693|FG002|Overall Study|Request to discontinue study treatment|2
5987654|NCT01592370|9578694|FG003|Overall Study|Request to discontinue study treatment|0
5987655|NCT01592370|9578695|FG004|Overall Study|Request to discontinue study treatment|1
5987656|NCT01592370|9578696|FG005|Overall Study|Request to discontinue study treatment|2
5987657|NCT01592370|9578697|FG006|Overall Study|Request to discontinue study treatment|0
5987658|NCT01592370|9578691|FG000|Overall Study|Withdrew consent|1
5987659|NCT01592370|9578692|FG001|Overall Study|Withdrew consent|2
5987660|NCT01592370|9578693|FG002|Overall Study|Withdrew consent|1
5987661|NCT01592370|9578694|FG003|Overall Study|Withdrew consent|1
5987662|NCT01592370|9578695|FG004|Overall Study|Withdrew consent|0
5987663|NCT01592370|9578696|FG005|Overall Study|Withdrew consent|0
5987664|NCT01592370|9578697|FG006|Overall Study|Withdrew consent|0
5987665|NCT01592370|9578691|FG000|Overall Study|Maximum clinical benefit|11
5987666|NCT01592370|9578692|FG001|Overall Study|Maximum clinical benefit|1
5987667|NCT01592370|9578693|FG002|Overall Study|Maximum clinical benefit|7
5987668|NCT01592370|9578694|FG003|Overall Study|Maximum clinical benefit|1
5987669|NCT01592370|9578695|FG004|Overall Study|Maximum clinical benefit|0
5987670|NCT01592370|9578696|FG005|Overall Study|Maximum clinical benefit|0
5987671|NCT01592370|9578697|FG006|Overall Study|Maximum clinical benefit|0
5987672|NCT01592370|9578691|FG000|Overall Study|No longer meets study criteria|1
5987673|NCT01592370|9578692|FG001|Overall Study|No longer meets study criteria|0
5987674|NCT01592370|9578693|FG002|Overall Study|No longer meets study criteria|0
5987675|NCT01592370|9578694|FG003|Overall Study|No longer meets study criteria|0
5987676|NCT01592370|9578695|FG004|Overall Study|No longer meets study criteria|0
5987677|NCT01592370|9578696|FG005|Overall Study|No longer meets study criteria|0
5987678|NCT01592370|9578697|FG006|Overall Study|No longer meets study criteria|0
5987679|NCT01592370|9578691|FG000|Overall Study|Other Reasons|6
5987680|NCT01592370|9578692|FG001|Overall Study|Other Reasons|0
5987681|NCT01592370|9578693|FG002|Overall Study|Other Reasons|10
5987682|NCT01592370|9578694|FG003|Overall Study|Other Reasons|0
5987683|NCT01592370|9578695|FG004|Overall Study|Other Reasons|0
5987684|NCT01592370|9578696|FG005|Overall Study|Other Reasons|1
5987685|NCT01592370|9578697|FG006|Overall Study|Other Reasons|0
5987686|NCT00152477|9578738|FG000|Chemotherapy Period|Adverse Event|9
5987687|NCT00152477|9578739|FG001|Chemotherapy Period|Adverse Event|4
5987688|NCT00152477|9578740|FG002|Chemotherapy Period|Adverse Event|5
5987689|NCT00152477|9578738|FG000|Chemotherapy Period|Death|1
5987690|NCT00152477|9578739|FG001|Chemotherapy Period|Death|3
5987691|NCT00152477|9578740|FG002|Chemotherapy Period|Death|3
5987692|NCT00152477|9578738|FG000|Chemotherapy Period|Lack of Efficacy|4
5987693|NCT00152477|9578739|FG001|Chemotherapy Period|Lack of Efficacy|5
5987694|NCT00152477|9578740|FG002|Chemotherapy Period|Lack of Efficacy|6
5987695|NCT00152477|9578738|FG000|Chemotherapy Period|Lost to Follow-up|1
5987696|NCT00152477|9578739|FG001|Chemotherapy Period|Lost to Follow-up|0
5987697|NCT00152477|9578740|FG002|Chemotherapy Period|Lost to Follow-up|1
5987698|NCT00152477|9578738|FG000|Chemotherapy Period|Protocol Violation|1
5987699|NCT00152477|9578739|FG001|Chemotherapy Period|Protocol Violation|1
5987700|NCT00152477|9578740|FG002|Chemotherapy Period|Protocol Violation|0
5987701|NCT00152477|9578738|FG000|Chemotherapy Period|Withdrawal by Subject|5
5987702|NCT00152477|9578739|FG001|Chemotherapy Period|Withdrawal by Subject|1
5987703|NCT00152477|9578740|FG002|Chemotherapy Period|Withdrawal by Subject|0
5987704|NCT00152477|9578738|FG000|Chemotherapy Period|Progression of Disease|6
5987705|NCT00152477|9578739|FG001|Chemotherapy Period|Progression of Disease|8
5987706|NCT00152477|9578740|FG002|Chemotherapy Period|Progression of Disease|4
5987707|NCT00152477|9578738|FG000|Chemotherapy Period|Investigator decision|0
5987708|NCT00152477|9578739|FG001|Chemotherapy Period|Investigator decision|0
5987709|NCT00152477|9578740|FG002|Chemotherapy Period|Investigator decision|1
5987710|NCT00152477|9578738|FG000|Chemotherapy Period|Patient condition worsened|1
5987711|NCT00152477|9578739|FG001|Chemotherapy Period|Patient condition worsened|0
5987712|NCT00152477|9578740|FG002|Chemotherapy Period|Patient condition worsened|0
5987713|NCT00152477|9578738|FG000|Monotherapy Period|Adverse Event|1
5987714|NCT00152477|9578739|FG001|Monotherapy Period|Adverse Event|0
5987715|NCT00152477|9578740|FG002|Monotherapy Period|Adverse Event|5
5987716|NCT00152477|9578738|FG000|Monotherapy Period|Death|2
5987717|NCT00152477|9578739|FG001|Monotherapy Period|Death|0
5987718|NCT00152477|9578740|FG002|Monotherapy Period|Death|1
5987719|NCT00152477|9578738|FG000|Monotherapy Period|Lack of Efficacy|7
5987720|NCT00152477|9578739|FG001|Monotherapy Period|Lack of Efficacy|16
5987721|NCT00152477|9578740|FG002|Monotherapy Period|Lack of Efficacy|10
5987722|NCT00152477|9578738|FG000|Monotherapy Period|Protocol Violation|0
5987723|NCT00152477|9578739|FG001|Monotherapy Period|Protocol Violation|1
5987724|NCT00152477|9578740|FG002|Monotherapy Period|Protocol Violation|0
5987725|NCT00152477|9578738|FG000|Monotherapy Period|Withdrawal by Subject|0
5987726|NCT00152477|9578739|FG001|Monotherapy Period|Withdrawal by Subject|0
5987727|NCT00152477|9578740|FG002|Monotherapy Period|Withdrawal by Subject|4
5987728|NCT00152477|9578738|FG000|Monotherapy Period|Progression of Disease|5
5987729|NCT00152477|9578739|FG001|Monotherapy Period|Progression of Disease|11
5987730|NCT00152477|9578740|FG002|Monotherapy Period|Progression of Disease|12
5987731|NCT00152477|9578738|FG000|Monotherapy Period|Patient decision|0
5987732|NCT00152477|9578739|FG001|Monotherapy Period|Patient decision|1
5987733|NCT00152477|9578740|FG002|Monotherapy Period|Patient decision|1
5987734|NCT00152477|9578738|FG000|Monotherapy Period|Study personel decision|0
5987735|NCT00152477|9578739|FG001|Monotherapy Period|Study personel decision|0
5987736|NCT00152477|9578740|FG002|Monotherapy Period|Study personel decision|1
6045099|NCT00401245|9644405|FG002|Double Blind Titration Phase|Adverse Event|5
6045100|NCT00401245|9644406|FG003|Double Blind Titration Phase|Adverse Event|12
6045101|NCT00401245|9644407|FG004|Double Blind Titration Phase|Adverse Event|0
6045102|NCT00401245|9644408|FG005|Double Blind Titration Phase|Adverse Event|0
6045103|NCT00401245|9644409|FG006|Double Blind Titration Phase|Adverse Event|0
6045104|NCT00401245|9644410|FG007|Double Blind Titration Phase|Adverse Event|0
6045105|NCT00401245|9644403|FG000|Double Blind Titration Phase|Other|0
6045106|NCT00401245|9644404|FG001|Double Blind Titration Phase|Other|0
6045107|NCT00401245|9644405|FG002|Double Blind Titration Phase|Other|1
6045108|NCT00401245|9644406|FG003|Double Blind Titration Phase|Other|0
6045109|NCT00401245|9644407|FG004|Double Blind Titration Phase|Other|0
6045110|NCT00401245|9644408|FG005|Double Blind Titration Phase|Other|0
6045111|NCT00401245|9644409|FG006|Double Blind Titration Phase|Other|0
6045112|NCT00401245|9644410|FG007|Double Blind Titration Phase|Other|0
6045113|NCT00401245|9644403|FG000|Double Blind Titration Phase|Protocol Violation|0
6045114|NCT00401245|9644404|FG001|Double Blind Titration Phase|Protocol Violation|0
6045115|NCT00401245|9644405|FG002|Double Blind Titration Phase|Protocol Violation|0
6045116|NCT00401245|9644406|FG003|Double Blind Titration Phase|Protocol Violation|1
6045117|NCT00401245|9644407|FG004|Double Blind Titration Phase|Protocol Violation|0
6045118|NCT00401245|9644408|FG005|Double Blind Titration Phase|Protocol Violation|0
6045119|NCT00401245|9644409|FG006|Double Blind Titration Phase|Protocol Violation|0
6045120|NCT00401245|9644410|FG007|Double Blind Titration Phase|Protocol Violation|0
6045121|NCT00401245|9644403|FG000|Double Blind Titration Phase|Withdrawal by Subject|1
6045122|NCT00401245|9644404|FG001|Double Blind Titration Phase|Withdrawal by Subject|1
6045123|NCT00401245|9644405|FG002|Double Blind Titration Phase|Withdrawal by Subject|0
6045124|NCT00401245|9644406|FG003|Double Blind Titration Phase|Withdrawal by Subject|2
6045125|NCT00401245|9644407|FG004|Double Blind Titration Phase|Withdrawal by Subject|0
6045126|NCT00401245|9644408|FG005|Double Blind Titration Phase|Withdrawal by Subject|0
6045127|NCT00401245|9644409|FG006|Double Blind Titration Phase|Withdrawal by Subject|0
6045128|NCT00401245|9644410|FG007|Double Blind Titration Phase|Withdrawal by Subject|0
6045129|NCT00401245|9644403|FG000|Between Titration and Open Label Phase|Did not enter the open label phase|0
6045130|NCT00401245|9644404|FG001|Between Titration and Open Label Phase|Did not enter the open label phase|2
6045131|NCT00401245|9644405|FG002|Between Titration and Open Label Phase|Did not enter the open label phase|0
6045132|NCT00401245|9644406|FG003|Between Titration and Open Label Phase|Did not enter the open label phase|2
6045133|NCT00401245|9644407|FG004|Between Titration and Open Label Phase|Did not enter the open label phase|0
6045134|NCT00401245|9644408|FG005|Between Titration and Open Label Phase|Did not enter the open label phase|0
6045135|NCT00401245|9644409|FG006|Between Titration and Open Label Phase|Did not enter the open label phase|0
6045136|NCT00401245|9644410|FG007|Between Titration and Open Label Phase|Did not enter the open label phase|0
6045137|NCT00401245|9644403|FG000|Open Label Phase|Adverse Event|5
6045138|NCT00401245|9644404|FG001|Open Label Phase|Adverse Event|14
6045139|NCT00401245|9644405|FG002|Open Label Phase|Adverse Event|6
6045140|NCT00401245|9644406|FG003|Open Label Phase|Adverse Event|7
6045141|NCT00401245|9644407|FG004|Open Label Phase|Adverse Event|0
5987737|NCT04585646|9578755|FG000|First Intervention|Physician Decision|1
5987738|NCT04585646|9578756|FG001|First Intervention|Physician Decision|0
5987739|NCT04585646|9578755|FG000|First Intervention|Lost to Follow-up|0
5987740|NCT04585646|9578756|FG001|First Intervention|Lost to Follow-up|3
5987741|NCT04585646|9578755|FG000|First Intervention|Withdrawal by Subject|0
5987742|NCT04585646|9578756|FG001|First Intervention|Withdrawal by Subject|1
5987743|NCT04584645|9578765|FG000|Overall Study|"Those participants who did not complete the 3 or 6 month surveys are considered not completed."|18995
5987744|NCT04584645|9578766|FG001|Overall Study|"Those participants who did not complete the 3 or 6 month surveys are considered not completed."|18906
5987755|NCT04003623|9578853|FG000|Overall Study|Withdrawal by Subject|1
5987756|NCT04003623|9578854|FG001|Overall Study|Withdrawal by Subject|0
5987757|NCT03905694|9578870|FG000|Long-term Extension Period|Remained in this Period at Time of Data Cut|18
5987758|NCT03828383|9578876|FG000|Overall Study|Lost to Follow-up|3
5987759|NCT03828383|9578877|FG001|Overall Study|Lost to Follow-up|2
5987760|NCT03828383|9578876|FG000|Overall Study|Withdrawal by Subject|4
5987761|NCT03828383|9578877|FG001|Overall Study|Withdrawal by Subject|5
5987762|NCT03817853|9578883|FG000|Induction Phase|Adverse Event|5
5987763|NCT03817853|9578884|FG001|Induction Phase|Adverse Event|0
5987764|NCT03817853|9578885|FG002|Induction Phase|Adverse Event|0
5987765|NCT03817853|9578883|FG000|Induction Phase|Measures due to covid19; transformation to double hit high-grade b lymphoma; discontinuation of trt.|3
5987766|NCT03817853|9578884|FG001|Induction Phase|Measures due to covid19; transformation to double hit high-grade b lymphoma; discontinuation of trt.|0
5987767|NCT03817853|9578885|FG002|Induction Phase|Measures due to covid19; transformation to double hit high-grade b lymphoma; discontinuation of trt.|0
5987768|NCT03817853|9578883|FG000|Induction Phase|Physician Decision|2
5987769|NCT03817853|9578884|FG001|Induction Phase|Physician Decision|0
5987770|NCT03817853|9578885|FG002|Induction Phase|Physician Decision|0
5987771|NCT03817853|9578883|FG000|Induction Phase|Progressive Disease|4
5987772|NCT03817853|9578884|FG001|Induction Phase|Progressive Disease|0
5987773|NCT03817853|9578885|FG002|Induction Phase|Progressive Disease|0
5987774|NCT03817853|9578883|FG000|Induction Phase|Withdrawal by Subject|3
5987775|NCT03817853|9578884|FG001|Induction Phase|Withdrawal by Subject|0
5987776|NCT03817853|9578885|FG002|Induction Phase|Withdrawal by Subject|0
5987777|NCT03817853|9578883|FG000|Induction Phase|Continuing on Study|34
5987778|NCT03817853|9578884|FG001|Induction Phase|Continuing on Study|0
5987779|NCT03817853|9578885|FG002|Induction Phase|Continuing on Study|0
5987780|NCT03817853|9578883|FG000|Maintenance/ Follow-up Phase|Adverse Event|0
5987781|NCT03817853|9578884|FG001|Maintenance/ Follow-up Phase|Adverse Event|1
5987782|NCT03817853|9578885|FG002|Maintenance/ Follow-up Phase|Adverse Event|0
5987783|NCT03817853|9578883|FG000|Maintenance/ Follow-up Phase|Death|0
5987784|NCT03817853|9578884|FG001|Maintenance/ Follow-up Phase|Death|1
5987785|NCT03817853|9578885|FG002|Maintenance/ Follow-up Phase|Death|1
5987786|NCT03817853|9578883|FG000|Maintenance/ Follow-up Phase|Progressive Disease|0
5987787|NCT03817853|9578884|FG001|Maintenance/ Follow-up Phase|Progressive Disease|1
5987788|NCT03817853|9578885|FG002|Maintenance/ Follow-up Phase|Progressive Disease|3
5987789|NCT03817853|9578883|FG000|Maintenance/ Follow-up Phase|Withdrawal by Subject|0
5987790|NCT03817853|9578884|FG001|Maintenance/ Follow-up Phase|Withdrawal by Subject|1
5987791|NCT03817853|9578885|FG002|Maintenance/ Follow-up Phase|Withdrawal by Subject|0
5987792|NCT03817853|9578883|FG000|Maintenance/ Follow-up Phase|Continuing on Study|0
5987793|NCT03817853|9578884|FG001|Maintenance/ Follow-up Phase|Continuing on Study|52
5987794|NCT03817853|9578885|FG002|Maintenance/ Follow-up Phase|Continuing on Study|2
5987795|NCT03717480|9578893|FG000|Overall Study|Never received investigational product due to product viability limitations.|1
5987796|NCT03624036|9578901|FG000|Overall Study|Still on Study|5
5987797|NCT03624036|9578902|FG001|Overall Study|Still on Study|1
5987798|NCT03624036|9578903|FG002|Overall Study|Still on Study|3
5987799|NCT03624036|9578904|FG003|Overall Study|Still on Study|3
5987800|NCT03624036|9578901|FG000|Overall Study|Death|1
5987801|NCT03624036|9578902|FG001|Overall Study|Death|2
5987802|NCT03624036|9578903|FG002|Overall Study|Death|0
5987803|NCT03624036|9578904|FG003|Overall Study|Death|0
5987804|NCT03624036|9578901|FG000|Overall Study|Enrolled but Never Treated|1
5987805|NCT03624036|9578902|FG001|Overall Study|Enrolled but Never Treated|0
5987806|NCT03624036|9578903|FG002|Overall Study|Enrolled but Never Treated|0
5987807|NCT03624036|9578904|FG003|Overall Study|Enrolled but Never Treated|0
5987808|NCT03615066|9578917|FG000|Main Study|Withdrew Consent|0
5987809|NCT03615066|9578918|FG001|Main Study|Withdrew Consent|1
5987810|NCT03615066|9578919|FG002|Main Study|Withdrew Consent|1
5987811|NCT03615066|9578917|FG000|Main Study|Lost to Follow-up|0
5987812|NCT03615066|9578918|FG001|Main Study|Lost to Follow-up|0
5987813|NCT03615066|9578919|FG002|Main Study|Lost to Follow-up|1
5987814|NCT03615066|9578917|FG000|Treatment-free Follow-up (TFFU) Phase|Adverse Event|1
5987815|NCT03615066|9578918|FG001|Treatment-free Follow-up (TFFU) Phase|Adverse Event|0
5987816|NCT03615066|9578919|FG002|Treatment-free Follow-up (TFFU) Phase|Adverse Event|0
5987817|NCT03615066|9578917|FG000|Treatment-free Follow-up (TFFU) Phase|Protocol Violation|1
5987818|NCT03615066|9578918|FG001|Treatment-free Follow-up (TFFU) Phase|Protocol Violation|0
5987819|NCT03615066|9578919|FG002|Treatment-free Follow-up (TFFU) Phase|Protocol Violation|0
5987820|NCT03615066|9578917|FG000|Treatment-free Follow-up (TFFU) Phase|Withdrew Consent|0
5987821|NCT03615066|9578918|FG001|Treatment-free Follow-up (TFFU) Phase|Withdrew Consent|1
5987745|NCT04451330|9578792|FG000|Overall Study|Adverse Event|1
5987746|NCT04451330|9578793|FG001|Overall Study|Adverse Event|2
5987747|NCT04451330|9578792|FG000|Overall Study|Lost to Follow-up|5
5987748|NCT04451330|9578793|FG001|Overall Study|Lost to Follow-up|0
5987749|NCT04451330|9578792|FG000|Overall Study|Withdrawal by Subject|3
5987750|NCT04451330|9578793|FG001|Overall Study|Withdrawal by Subject|1
5987751|NCT04451330|9578792|FG000|Overall Study|Withdrawal by parent/guardian|1
5987752|NCT04451330|9578793|FG001|Overall Study|Withdrawal by parent/guardian|0
5987753|NCT04451330|9578792|FG000|Overall Study|Other than specified|0
5987754|NCT04451330|9578793|FG001|Overall Study|Other than specified|1
5987822|NCT03615066|9578919|FG002|Treatment-free Follow-up (TFFU) Phase|Withdrew Consent|0
5987823|NCT03589469|9578931|FG000|Overall Study|Ongoing in study|58
5987824|NCT03589469|9578931|FG000|Overall Study|Withdrawal by Subject|6
5987825|NCT03589469|9578931|FG000|Overall Study|Physician Decision|1
5987826|NCT03589469|9578931|FG000|Overall Study|Death|77
5987827|NCT03589469|9578931|FG000|Overall Study|Lost to Follow-up|3
5987828|NCT03557931|9578938|FG000|Overall Study|Adverse Event|4
5987829|NCT03557931|9578939|FG001|Overall Study|Adverse Event|6
5987830|NCT03557931|9578940|FG002|Overall Study|Adverse Event|1
5987831|NCT03557931|9578938|FG000|Overall Study|Lost to Follow-up|4
5987832|NCT03557931|9578939|FG001|Overall Study|Lost to Follow-up|4
5987833|NCT03557931|9578940|FG002|Overall Study|Lost to Follow-up|1
5987834|NCT03557931|9578938|FG000|Overall Study|Protocol Violation|1
5987835|NCT03557931|9578939|FG001|Overall Study|Protocol Violation|4
5987836|NCT03557931|9578940|FG002|Overall Study|Protocol Violation|1
5987837|NCT03557931|9578938|FG000|Overall Study|Withdrawal by Subject|14
5987838|NCT03557931|9578939|FG001|Overall Study|Withdrawal by Subject|0
5987839|NCT03557931|9578940|FG002|Overall Study|Withdrawal by Subject|7
5987840|NCT03557931|9578938|FG000|Overall Study|Miscellaneous|8
5987841|NCT03557931|9578939|FG001|Overall Study|Miscellaneous|5
5987842|NCT03557931|9578940|FG002|Overall Study|Miscellaneous|3
6045142|NCT00401245|9644408|FG005|Open Label Phase|Adverse Event|0
6045143|NCT00401245|9644409|FG006|Open Label Phase|Adverse Event|0
6045144|NCT00401245|9644410|FG007|Open Label Phase|Adverse Event|0
6045145|NCT00401245|9644403|FG000|Open Label Phase|Lost to Follow-up|5
6045146|NCT00401245|9644404|FG001|Open Label Phase|Lost to Follow-up|7
6045147|NCT00401245|9644405|FG002|Open Label Phase|Lost to Follow-up|5
6045148|NCT00401245|9644406|FG003|Open Label Phase|Lost to Follow-up|4
6045149|NCT00401245|9644407|FG004|Open Label Phase|Lost to Follow-up|0
6045150|NCT00401245|9644408|FG005|Open Label Phase|Lost to Follow-up|0
6045151|NCT00401245|9644409|FG006|Open Label Phase|Lost to Follow-up|0
6045152|NCT00401245|9644410|FG007|Open Label Phase|Lost to Follow-up|0
6045153|NCT00401245|9644403|FG000|Open Label Phase|Other|4
6045154|NCT00401245|9644404|FG001|Open Label Phase|Other|8
6045155|NCT00401245|9644405|FG002|Open Label Phase|Other|7
6045156|NCT00401245|9644406|FG003|Open Label Phase|Other|8
6045157|NCT00401245|9644407|FG004|Open Label Phase|Other|0
6045158|NCT00401245|9644408|FG005|Open Label Phase|Other|0
6045159|NCT00401245|9644409|FG006|Open Label Phase|Other|0
6045160|NCT00401245|9644410|FG007|Open Label Phase|Other|0
6045161|NCT00401245|9644403|FG000|Open Label Phase|Protocol Violation|0
6045162|NCT00401245|9644404|FG001|Open Label Phase|Protocol Violation|1
6045163|NCT00401245|9644405|FG002|Open Label Phase|Protocol Violation|0
6045164|NCT00401245|9644406|FG003|Open Label Phase|Protocol Violation|1
6045165|NCT00401245|9644407|FG004|Open Label Phase|Protocol Violation|0
6045166|NCT00401245|9644408|FG005|Open Label Phase|Protocol Violation|0
6045167|NCT00401245|9644409|FG006|Open Label Phase|Protocol Violation|0
6045168|NCT00401245|9644410|FG007|Open Label Phase|Protocol Violation|0
6045169|NCT00401245|9644403|FG000|Open Label Phase|Withdrawal by Subject|3
6045170|NCT00401245|9644404|FG001|Open Label Phase|Withdrawal by Subject|3
6045171|NCT00401245|9644405|FG002|Open Label Phase|Withdrawal by Subject|2
6045172|NCT00401245|9644406|FG003|Open Label Phase|Withdrawal by Subject|1
6045173|NCT00401245|9644407|FG004|Open Label Phase|Withdrawal by Subject|0
6045174|NCT00401245|9644408|FG005|Open Label Phase|Withdrawal by Subject|0
6045175|NCT00401245|9644409|FG006|Open Label Phase|Withdrawal by Subject|0
6045176|NCT00401245|9644410|FG007|Open Label Phase|Withdrawal by Subject|0
6045177|NCT00401245|9644403|FG000|Open Label Phase|Lack of Efficacy|4
6045178|NCT00401245|9644404|FG001|Open Label Phase|Lack of Efficacy|2
6045179|NCT00401245|9644405|FG002|Open Label Phase|Lack of Efficacy|3
6045180|NCT00401245|9644406|FG003|Open Label Phase|Lack of Efficacy|0
6045181|NCT00401245|9644407|FG004|Open Label Phase|Lack of Efficacy|0
6045182|NCT00401245|9644408|FG005|Open Label Phase|Lack of Efficacy|0
6045183|NCT00401245|9644409|FG006|Open Label Phase|Lack of Efficacy|0
6045184|NCT00401245|9644410|FG007|Open Label Phase|Lack of Efficacy|0
6045185|NCT00401245|9644403|FG000|Double Blind Tapering Phase|Adverse Event|0
6045186|NCT00401245|9644404|FG001|Double Blind Tapering Phase|Adverse Event|0
6045187|NCT00401245|9644405|FG002|Double Blind Tapering Phase|Adverse Event|0
6045188|NCT00401245|9644406|FG003|Double Blind Tapering Phase|Adverse Event|0
6045189|NCT00401245|9644407|FG004|Double Blind Tapering Phase|Adverse Event|1
6045190|NCT00401245|9644408|FG005|Double Blind Tapering Phase|Adverse Event|1
6045191|NCT00401245|9644409|FG006|Double Blind Tapering Phase|Adverse Event|2
6045192|NCT00401245|9644410|FG007|Double Blind Tapering Phase|Adverse Event|4
6045193|NCT00401245|9644403|FG000|Double Blind Tapering Phase|Investigator request|0
6045194|NCT00401245|9644404|FG001|Double Blind Tapering Phase|Investigator request|0
5987843|NCT02886572|9578959|FG000|Baseline Through Follow up MRI|Death|8
5987844|NCT02596035|9578966|FG000|Overall Study|Disease Progression|62
5987845|NCT02596035|9578967|FG001|Overall Study|Disease Progression|32
5987846|NCT02596035|9578968|FG002|Overall Study|Disease Progression|1
5987847|NCT02596035|9578966|FG000|Overall Study|Study Drug Toxicity|11
5987848|NCT02596035|9578967|FG001|Overall Study|Study Drug Toxicity|3
5987849|NCT02596035|9578968|FG002|Overall Study|Study Drug Toxicity|0
5987850|NCT02596035|9578966|FG000|Overall Study|Adverse Event|6
5987851|NCT02596035|9578967|FG001|Overall Study|Adverse Event|2
5987852|NCT02596035|9578968|FG002|Overall Study|Adverse Event|0
5987853|NCT02596035|9578966|FG000|Overall Study|Withdrawal by Subject|4
5987854|NCT02596035|9578967|FG001|Overall Study|Withdrawal by Subject|2
5987855|NCT02596035|9578968|FG002|Overall Study|Withdrawal by Subject|0
5987856|NCT02596035|9578966|FG000|Overall Study|Poor/Non-Compliance|0
5987857|NCT02596035|9578967|FG001|Overall Study|Poor/Non-Compliance|1
5987858|NCT02596035|9578968|FG002|Overall Study|Poor/Non-Compliance|0
5987859|NCT02596035|9578966|FG000|Overall Study|Other Reasons|3
5987860|NCT02596035|9578967|FG001|Overall Study|Other Reasons|4
5987861|NCT02596035|9578968|FG002|Overall Study|Other Reasons|0
5987862|NCT02576509|9578977|FG000|Pre-Treatment Period|Participant request to stop therapy|0
5987863|NCT02576509|9578978|FG001|Pre-Treatment Period|Participant request to stop therapy|2
5987864|NCT02576509|9578977|FG000|Pre-Treatment Period|Participant withdrew consent|1
5987865|NCT02576509|9578978|FG001|Pre-Treatment Period|Participant withdrew consent|5
5987866|NCT02576509|9578977|FG000|Pre-Treatment Period|Participant no longer meets criteria|3
5987867|NCT02576509|9578978|FG001|Pre-Treatment Period|Participant no longer meets criteria|2
5987868|NCT02576509|9578977|FG000|Treatment Period|Disease progression|245
5987869|NCT02576509|9578978|FG001|Treatment Period|Disease progression|240
5987870|NCT02576509|9578977|FG000|Treatment Period|Study drug toxicity|32
5987871|NCT02576509|9578978|FG001|Treatment Period|Study drug toxicity|41
5987872|NCT02576509|9578977|FG000|Treatment Period|Death|1
5987873|NCT02576509|9578978|FG001|Treatment Period|Death|1
5987874|NCT02576509|9578977|FG000|Treatment Period|Adverse event unrelated to study drug|37
5987875|NCT02576509|9578978|FG001|Treatment Period|Adverse event unrelated to study drug|40
5987876|NCT02576509|9578977|FG000|Treatment Period|Participant request to stop treatment|8
5987877|NCT02576509|9578978|FG001|Treatment Period|Participant request to stop treatment|17
5987878|NCT02576509|9578977|FG000|Treatment Period|Participant withdrew consent|2
5987879|NCT02576509|9578978|FG001|Treatment Period|Participant withdrew consent|7
5987880|NCT02576509|9578977|FG000|Treatment Period|Lost to Follow-up|0
5987881|NCT02576509|9578978|FG001|Treatment Period|Lost to Follow-up|1
5987882|NCT02576509|9578977|FG000|Treatment Period|Maximum clinical benefit|1
5987883|NCT02576509|9578978|FG001|Treatment Period|Maximum clinical benefit|0
5987884|NCT02576509|9578977|FG000|Treatment Period|Poor/non-compliance|0
5987885|NCT02576509|9578978|FG001|Treatment Period|Poor/non-compliance|1
5987886|NCT02576509|9578977|FG000|Treatment Period|Participant no longer meets criteria|1
5987887|NCT02576509|9578978|FG001|Treatment Period|Participant no longer meets criteria|0
5987888|NCT02576509|9578977|FG000|Treatment Period|Other reason|2
5987889|NCT02576509|9578978|FG001|Treatment Period|Other reason|7
5987890|NCT02576509|9578977|FG000|Follow-up Period|Death|41
5987891|NCT02576509|9578978|FG001|Follow-up Period|Death|35
5987892|NCT02576509|9578977|FG000|Follow-up Period|Participant withdrew consent|7
5987893|NCT02576509|9578978|FG001|Follow-up Period|Participant withdrew consent|14
5987894|NCT02576509|9578977|FG000|Follow-up Period|Lost to Follow-up|0
5987895|NCT02576509|9578978|FG001|Follow-up Period|Lost to Follow-up|1
5987896|NCT02576509|9578977|FG000|Follow-up Period|Other reason|1
5987897|NCT02576509|9578978|FG001|Follow-up Period|Other reason|2
5987898|NCT02476916|9578995|FG000|Core Period|Adverse Event|2
5987899|NCT02476916|9578996|FG001|Core Period|Adverse Event|2
5987900|NCT02476916|9578995|FG000|Core Period|Investigator decision|1
5987901|NCT02476916|9578996|FG001|Core Period|Investigator decision|1
5987902|NCT02476916|9578995|FG000|Core Period|Withdrawal by Subject|3
5987903|NCT02476916|9578996|FG001|Core Period|Withdrawal by Subject|0
5987904|NCT02476916|9578995|FG000|Extension Period|Prematurely Discontinued Treatment|6
5987905|NCT02476916|9578996|FG001|Extension Period|Prematurely Discontinued Treatment|1
5987906|NCT02476916|9578995|FG000|Extension Period|On Treatment|12
5987907|NCT02476916|9578996|FG001|Extension Period|On Treatment|17
5987908|NCT02448225|9579003|FG000|Overall Study|Withdrawal by Subject|1
5987909|NCT02448225|9579003|FG000|Overall Study|Did not get FSPG scan|18
5987910|NCT02448225|9579003|FG000|Overall Study|Treated between the FDG and FSPG scan|1
5987911|NCT02352948|9579016|FG000|Overall Study|Death|47
5987912|NCT02352948|9579017|FG001|Overall Study|Death|48
5987913|NCT02352948|9579018|FG002|Overall Study|Death|114
5987914|NCT02352948|9579019|FG003|Overall Study|Death|74
5987915|NCT02352948|9579020|FG004|Overall Study|Death|77
5987916|NCT02352948|9579021|FG005|Overall Study|Death|44
5987917|NCT02352948|9579016|FG000|Overall Study|Lost to Follow-up|1
5987918|NCT02352948|9579017|FG001|Overall Study|Lost to Follow-up|0
5987919|NCT02352948|9579018|FG002|Overall Study|Lost to Follow-up|2
5987920|NCT02352948|9579019|FG003|Overall Study|Lost to Follow-up|1
5987921|NCT02352948|9579020|FG004|Overall Study|Lost to Follow-up|2
5987922|NCT02352948|9579021|FG005|Overall Study|Lost to Follow-up|1
5987923|NCT02352948|9579016|FG000|Overall Study|Withdrawal by Subject|1
5987924|NCT02352948|9579017|FG001|Overall Study|Withdrawal by Subject|10
5987925|NCT02352948|9579018|FG002|Overall Study|Withdrawal by Subject|11
5987926|NCT02352948|9579019|FG003|Overall Study|Withdrawal by Subject|23
5987927|NCT02352948|9579020|FG004|Overall Study|Withdrawal by Subject|9
5987928|NCT02352948|9579021|FG005|Overall Study|Withdrawal by Subject|4
5987929|NCT02352948|9579016|FG000|Overall Study|Eligibility criteria not fulfilled|0
5987930|NCT02352948|9579017|FG001|Overall Study|Eligibility criteria not fulfilled|1
5987931|NCT02352948|9579018|FG002|Overall Study|Eligibility criteria not fulfilled|0
5987932|NCT02352948|9579019|FG003|Overall Study|Eligibility criteria not fulfilled|1
5987933|NCT02352948|9579020|FG004|Overall Study|Eligibility criteria not fulfilled|0
5987934|NCT02352948|9579021|FG005|Overall Study|Eligibility criteria not fulfilled|0
5987935|NCT02352948|9579016|FG000|Overall Study|Other|0
5987936|NCT02352948|9579017|FG001|Overall Study|Other|0
5987937|NCT02352948|9579018|FG002|Overall Study|Other|2
5987938|NCT02352948|9579019|FG003|Overall Study|Other|0
5987939|NCT02352948|9579020|FG004|Overall Study|Other|0
5987940|NCT02352948|9579021|FG005|Overall Study|Other|0
5987941|NCT02318095|9579041|FG000|Overall Study|Adverse Event|1
5987942|NCT02257528|9579046|FG000|Overall Study|Never received study treatment|1
5987943|NCT02155647|9579052|FG000|Overall Study|Still on Treatment|26
5987944|NCT02155647|9579053|FG001|Overall Study|Still on Treatment|26
5987945|NCT02155647|9579052|FG000|Overall Study|Off-Treatment, but follow up ongoing|15
5987946|NCT02155647|9579053|FG001|Overall Study|Off-Treatment, but follow up ongoing|26
5987947|NCT02059265|9579059|FG000|Overall Study|Ineligible|4
5987948|NCT01965704|9579084|FG000|Overall Study|Withdrawal by Subject|2
5987949|NCT01965704|9579085|FG001|Overall Study|Withdrawal by Subject|2
5987950|NCT01965704|9579086|FG002|Overall Study|Withdrawal by Subject|1
5987951|NCT01965704|9579087|FG003|Overall Study|Withdrawal by Subject|1
5987952|NCT01965704|9579084|FG000|Overall Study|Delivered at home|1
5987953|NCT01965704|9579085|FG001|Overall Study|Delivered at home|1
5987954|NCT01965704|9579086|FG002|Overall Study|Delivered at home|0
5987955|NCT01965704|9579087|FG003|Overall Study|Delivered at home|0
5987956|NCT01965704|9579084|FG000|Overall Study|Experienced complications|0
5987957|NCT01965704|9579085|FG001|Overall Study|Experienced complications|0
5987958|NCT01965704|9579086|FG002|Overall Study|Experienced complications|2
5987959|NCT01965704|9579087|FG003|Overall Study|Experienced complications|2
5987960|NCT01965704|9579084|FG000|Overall Study|Adverse Event|0
5987961|NCT01965704|9579085|FG001|Overall Study|Adverse Event|0
5987962|NCT01965704|9579086|FG002|Overall Study|Adverse Event|1
5987963|NCT01965704|9579087|FG003|Overall Study|Adverse Event|1
5987964|NCT01965704|9579084|FG000|Overall Study|Did not meet inclusion criteria|0
5987965|NCT01965704|9579085|FG001|Overall Study|Did not meet inclusion criteria|0
5987966|NCT01965704|9579086|FG002|Overall Study|Did not meet inclusion criteria|1
5987967|NCT01965704|9579087|FG003|Overall Study|Did not meet inclusion criteria|1
5987968|NCT01904903|9579095|FG000|Overall Study|Withdrawal by Subject|1
5987969|NCT01827384|9579113|FG000|Overall Study|Switched to alternative treatment|0
5987970|NCT01827384|9579114|FG001|Overall Study|Switched to alternative treatment|0
5987971|NCT01827384|9579115|FG002|Overall Study|Switched to alternative treatment|0
5987972|NCT01827384|9579116|FG003|Overall Study|Switched to alternative treatment|0
5987973|NCT01827384|9579117|FG004|Overall Study|Switched to alternative treatment|0
5987974|NCT01827384|9579118|FG005|Overall Study|Switched to alternative treatment|0
5987975|NCT01827384|9579119|FG006|Overall Study|Switched to alternative treatment|0
5987976|NCT01827384|9579120|FG007|Overall Study|Switched to alternative treatment|0
5987977|NCT01827384|9579121|FG008|Overall Study|Switched to alternative treatment|0
5987978|NCT01827384|9579122|FG009|Overall Study|Switched to alternative treatment|0
5987979|NCT01827384|9579123|FG010|Overall Study|Switched to alternative treatment|0
5987980|NCT01827384|9579124|FG011|Overall Study|Switched to alternative treatment|0
5987981|NCT01827384|9579125|FG012|Overall Study|Switched to alternative treatment|0
5987982|NCT01827384|9579126|FG013|Overall Study|Switched to alternative treatment|2
5987983|NCT01827384|9579113|FG000|Overall Study|Disease progression before treatment|0
5987984|NCT01827384|9579114|FG001|Overall Study|Disease progression before treatment|0
5987985|NCT01827384|9579115|FG002|Overall Study|Disease progression before treatment|0
5987986|NCT01827384|9579116|FG003|Overall Study|Disease progression before treatment|0
5987987|NCT01827384|9579117|FG004|Overall Study|Disease progression before treatment|0
5987988|NCT01827384|9579118|FG005|Overall Study|Disease progression before treatment|0
5987989|NCT01827384|9579119|FG006|Overall Study|Disease progression before treatment|0
5987990|NCT01827384|9579120|FG007|Overall Study|Disease progression before treatment|0
5987991|NCT01827384|9579121|FG008|Overall Study|Disease progression before treatment|0
5987992|NCT01827384|9579122|FG009|Overall Study|Disease progression before treatment|0
5987993|NCT01827384|9579123|FG010|Overall Study|Disease progression before treatment|0
5987994|NCT01827384|9579124|FG011|Overall Study|Disease progression before treatment|0
5987995|NCT01827384|9579125|FG012|Overall Study|Disease progression before treatment|0
5987996|NCT01827384|9579126|FG013|Overall Study|Disease progression before treatment|4
5987997|NCT01827384|9579113|FG000|Overall Study|Ineligible|0
5987998|NCT01827384|9579114|FG001|Overall Study|Ineligible|0
5987999|NCT01827384|9579115|FG002|Overall Study|Ineligible|0
5988000|NCT01827384|9579116|FG003|Overall Study|Ineligible|0
5988001|NCT01827384|9579117|FG004|Overall Study|Ineligible|0
5988002|NCT01827384|9579118|FG005|Overall Study|Ineligible|0
5988003|NCT01827384|9579119|FG006|Overall Study|Ineligible|0
5988004|NCT01827384|9579120|FG007|Overall Study|Ineligible|0
5988005|NCT01827384|9579121|FG008|Overall Study|Ineligible|0
5988006|NCT01827384|9579122|FG009|Overall Study|Ineligible|0
5988007|NCT01827384|9579123|FG010|Overall Study|Ineligible|0
5988008|NCT01827384|9579124|FG011|Overall Study|Ineligible|0
5988009|NCT01827384|9579125|FG012|Overall Study|Ineligible|0
5988010|NCT01827384|9579126|FG013|Overall Study|Ineligible|19
5988011|NCT01827384|9579113|FG000|Overall Study|Participant died before treatment|0
5988012|NCT01827384|9579114|FG001|Overall Study|Participant died before treatment|0
5988013|NCT01827384|9579115|FG002|Overall Study|Participant died before treatment|0
5988014|NCT01827384|9579116|FG003|Overall Study|Participant died before treatment|0
5988015|NCT01827384|9579117|FG004|Overall Study|Participant died before treatment|0
5988016|NCT01827384|9579118|FG005|Overall Study|Participant died before treatment|0
5988017|NCT01827384|9579119|FG006|Overall Study|Participant died before treatment|0
5988018|NCT01827384|9579120|FG007|Overall Study|Participant died before treatment|0
5988019|NCT01827384|9579121|FG008|Overall Study|Participant died before treatment|0
5988020|NCT01827384|9579122|FG009|Overall Study|Participant died before treatment|0
5988021|NCT01827384|9579123|FG010|Overall Study|Participant died before treatment|0
5988022|NCT01827384|9579124|FG011|Overall Study|Participant died before treatment|0
5988023|NCT01827384|9579125|FG012|Overall Study|Participant died before treatment|0
5988024|NCT01827384|9579126|FG013|Overall Study|Participant died before treatment|5
5988025|NCT01827384|9579113|FG000|Overall Study|Insufficient tumor cells|0
5988026|NCT01827384|9579114|FG001|Overall Study|Insufficient tumor cells|0
5988027|NCT01827384|9579115|FG002|Overall Study|Insufficient tumor cells|0
5988028|NCT01827384|9579116|FG003|Overall Study|Insufficient tumor cells|0
5988029|NCT01827384|9579117|FG004|Overall Study|Insufficient tumor cells|0
5988030|NCT01827384|9579118|FG005|Overall Study|Insufficient tumor cells|0
5988031|NCT01827384|9579119|FG006|Overall Study|Insufficient tumor cells|0
5988032|NCT01827384|9579120|FG007|Overall Study|Insufficient tumor cells|0
5988033|NCT01827384|9579121|FG008|Overall Study|Insufficient tumor cells|0
5988034|NCT01827384|9579122|FG009|Overall Study|Insufficient tumor cells|0
5988035|NCT01827384|9579123|FG010|Overall Study|Insufficient tumor cells|0
5988036|NCT01827384|9579124|FG011|Overall Study|Insufficient tumor cells|0
5988037|NCT01827384|9579125|FG012|Overall Study|Insufficient tumor cells|0
5988038|NCT01827384|9579126|FG013|Overall Study|Insufficient tumor cells|13
5988039|NCT01827384|9579113|FG000|Overall Study|No actionable mutation|0
5988040|NCT01827384|9579114|FG001|Overall Study|No actionable mutation|0
5988041|NCT01827384|9579115|FG002|Overall Study|No actionable mutation|0
5988042|NCT01827384|9579116|FG003|Overall Study|No actionable mutation|0
5988043|NCT01827384|9579117|FG004|Overall Study|No actionable mutation|0
5988044|NCT01827384|9579118|FG005|Overall Study|No actionable mutation|0
5988045|NCT01827384|9579119|FG006|Overall Study|No actionable mutation|0
5988046|NCT01827384|9579120|FG007|Overall Study|No actionable mutation|0
5988047|NCT01827384|9579121|FG008|Overall Study|No actionable mutation|0
5988048|NCT01827384|9579122|FG009|Overall Study|No actionable mutation|0
5988049|NCT01827384|9579123|FG010|Overall Study|No actionable mutation|0
5988050|NCT01827384|9579124|FG011|Overall Study|No actionable mutation|0
5988051|NCT01827384|9579125|FG012|Overall Study|No actionable mutation|0
5988052|NCT01827384|9579126|FG013|Overall Study|No actionable mutation|73
5988053|NCT01827384|9579113|FG000|Overall Study|Participant declined to participate (before treatment started)|0
5988054|NCT01827384|9579114|FG001|Overall Study|Participant declined to participate (before treatment started)|0
5988055|NCT01827384|9579115|FG002|Overall Study|Participant declined to participate (before treatment started)|0
5988056|NCT01827384|9579116|FG003|Overall Study|Participant declined to participate (before treatment started)|0
5988057|NCT01827384|9579117|FG004|Overall Study|Participant declined to participate (before treatment started)|0
5988058|NCT01827384|9579118|FG005|Overall Study|Participant declined to participate (before treatment started)|0
5988059|NCT01827384|9579119|FG006|Overall Study|Participant declined to participate (before treatment started)|0
5988060|NCT01827384|9579120|FG007|Overall Study|Participant declined to participate (before treatment started)|0
5988061|NCT01827384|9579121|FG008|Overall Study|Participant declined to participate (before treatment started)|0
5988062|NCT01827384|9579122|FG009|Overall Study|Participant declined to participate (before treatment started)|0
5988063|NCT01827384|9579123|FG010|Overall Study|Participant declined to participate (before treatment started)|0
5988064|NCT01827384|9579124|FG011|Overall Study|Participant declined to participate (before treatment started)|0
5988065|NCT01827384|9579125|FG012|Overall Study|Participant declined to participate (before treatment started)|0
5988066|NCT01827384|9579126|FG013|Overall Study|Participant declined to participate (before treatment started)|15
5988067|NCT01636258|9579162|FG000|Overall Study|Lost to Follow-up|1
5988068|NCT01636258|9579163|FG001|Overall Study|Lost to Follow-up|0
5988069|NCT01517802|9579224|FG000|Overall Study|Death|1
5988070|NCT01134614|9579230|FG000|Overall Study|Still on treatment as of March 2013|21
5988071|NCT01134614|9579231|FG001|Overall Study|Still on treatment as of March 2013|13
5988072|NCT01134614|9579230|FG000|Overall Study|Progressive disease|60
5988073|NCT01134614|9579231|FG001|Overall Study|Progressive disease|54
5988074|NCT01134614|9579230|FG000|Overall Study|Adverse Event|26
5988075|NCT01134614|9579231|FG001|Overall Study|Adverse Event|39
5988076|NCT01134614|9579230|FG000|Overall Study|Death|5
5988077|NCT01134614|9579231|FG001|Overall Study|Death|8
5988078|NCT01134614|9579230|FG000|Overall Study|Withdrawal by Subject|3
5988079|NCT01134614|9579231|FG001|Overall Study|Withdrawal by Subject|2
5988080|NCT01134614|9579230|FG000|Overall Study|Alternative therapy|2
5988081|NCT01134614|9579231|FG001|Overall Study|Alternative therapy|0
5988082|NCT01134614|9579230|FG000|Overall Study|Complicating disease|2
5988083|NCT01134614|9579231|FG001|Overall Study|Complicating disease|1
5988084|NCT01134614|9579230|FG000|Overall Study|Physician's decision|0
5988085|NCT01134614|9579231|FG001|Overall Study|Physician's decision|1
5988086|NCT01134614|9579230|FG000|Overall Study|Never started treatment|4
5988087|NCT01134614|9579231|FG001|Overall Study|Never started treatment|1
5988088|NCT01134614|9579230|FG000|Overall Study|Pt received tx not allowed on study|0
5988089|NCT01134614|9579231|FG001|Overall Study|Pt received tx not allowed on study|1
5988090|NCT01134614|9579230|FG000|Overall Study|Symptomatic deterioration|0
5988091|NCT01134614|9579231|FG001|Overall Study|Symptomatic deterioration|1
5988092|NCT01134614|9579230|FG000|Overall Study|Patient in hospice care|0
5988093|NCT01134614|9579231|FG001|Overall Study|Patient in hospice care|1
5988094|NCT01038778|9579256|FG000|Overall Study|Withdrawal by Subject|0
5988095|NCT01038778|9579257|FG001|Overall Study|Withdrawal by Subject|2
5988096|NCT01038778|9579258|FG002|Overall Study|Withdrawal by Subject|3
5988097|NCT00972478|9579267|FG000|Overall Study|Adverse Event|3
5988098|NCT00972478|9579268|FG001|Overall Study|Adverse Event|16
5988099|NCT00972478|9579267|FG000|Overall Study|Withdrawal by Subject|1
5988100|NCT00972478|9579268|FG001|Overall Study|Withdrawal by Subject|8
5988101|NCT00972478|9579267|FG000|Overall Study|Progression/Relapse|0
5988102|NCT00972478|9579268|FG001|Overall Study|Progression/Relapse|2
5988103|NCT00972478|9579267|FG000|Overall Study|Death|0
5988104|NCT00972478|9579268|FG001|Overall Study|Death|2
5988105|NCT00972478|9579267|FG000|Overall Study|Not protocol specified|1
5988106|NCT00972478|9579268|FG001|Overall Study|Not protocol specified|1
5988107|NCT00972478|9579267|FG000|Overall Study|Ineligible|1
5988108|NCT00972478|9579268|FG001|Overall Study|Ineligible|7
5988109|NCT00972478|9579267|FG000|Overall Study|Not start protocol treatment|1
5988110|NCT00972478|9579268|FG001|Overall Study|Not start protocol treatment|2
5988111|NCT00455325|9579275|FG000|Cohort 1: Placebo|Started exclusionary drug|1
5988112|NCT00455325|9579276|FG001|Cohort 1: Placebo|Started exclusionary drug|0
5988113|NCT00455325|9579277|FG002|Cohort 1: Placebo|Started exclusionary drug|0
5988114|NCT00455325|9579278|FG003|Cohort 1: Placebo|Started exclusionary drug|0
5988115|NCT00455325|9579275|FG000|Cohort 1: Placebo|Withdrawal by Subject|4
5988116|NCT00455325|9579276|FG001|Cohort 1: Placebo|Withdrawal by Subject|0
5988117|NCT00455325|9579277|FG002|Cohort 1: Placebo|Withdrawal by Subject|0
5988118|NCT00455325|9579278|FG003|Cohort 1: Placebo|Withdrawal by Subject|0
5988119|NCT00455325|9579275|FG000|Cohort 1: Placebo|Lost to Follow-up|1
5988120|NCT00455325|9579276|FG001|Cohort 1: Placebo|Lost to Follow-up|0
5988121|NCT00455325|9579277|FG002|Cohort 1: Placebo|Lost to Follow-up|0
5988122|NCT00455325|9579278|FG003|Cohort 1: Placebo|Lost to Follow-up|0
5988123|NCT00455325|9579275|FG000|Cohort 1: Placebo|New diagnosis of Type 2 Diabetes|1
5988124|NCT00455325|9579276|FG001|Cohort 1: Placebo|New diagnosis of Type 2 Diabetes|0
5988125|NCT00455325|9579277|FG002|Cohort 1: Placebo|New diagnosis of Type 2 Diabetes|0
5988126|NCT00455325|9579278|FG003|Cohort 1: Placebo|New diagnosis of Type 2 Diabetes|0
5988127|NCT00455325|9579275|FG000|Cohort 1: Placebo|DIFFICULTY WITH IV ACCESS|1
5988128|NCT00455325|9579276|FG001|Cohort 1: Placebo|DIFFICULTY WITH IV ACCESS|0
5988129|NCT00455325|9579277|FG002|Cohort 1: Placebo|DIFFICULTY WITH IV ACCESS|0
5988130|NCT00455325|9579278|FG003|Cohort 1: Placebo|DIFFICULTY WITH IV ACCESS|0
5988131|NCT00455325|9579275|FG000|Cohort 2: 80 mg Chloroquine Weekly|Adverse Event|0
5988132|NCT00455325|9579276|FG001|Cohort 2: 80 mg Chloroquine Weekly|Adverse Event|1
5988133|NCT00455325|9579277|FG002|Cohort 2: 80 mg Chloroquine Weekly|Adverse Event|0
5988134|NCT00455325|9579278|FG003|Cohort 2: 80 mg Chloroquine Weekly|Adverse Event|0
5988135|NCT00455325|9579275|FG000|Cohort 3: 80 mg Chloroquine Daily|Started exclusionary drug|0
5988136|NCT00455325|9579276|FG001|Cohort 3: 80 mg Chloroquine Daily|Started exclusionary drug|0
5988137|NCT00455325|9579277|FG002|Cohort 3: 80 mg Chloroquine Daily|Started exclusionary drug|1
5988138|NCT00455325|9579278|FG003|Cohort 3: 80 mg Chloroquine Daily|Started exclusionary drug|0
5988139|NCT00321555|9579289|FG000|Overall Study|Developed antibodies|1
5988140|NCT00321555|9579289|FG000|Overall Study|Switched to alternative treatment|3
5988141|NCT00321555|9579289|FG000|Overall Study|Physician Decision|1
5988142|NCT00321555|9579289|FG000|Overall Study|Disease progression on study|1
5988143|NCT00098475|9579295|FG000|Step 1|Progressive disease|33
5988144|NCT00098475|9579296|FG001|Step 1|Progressive disease|35
5988145|NCT00098475|9579297|FG002|Step 1|Progressive disease|2
5988146|NCT00098475|9579298|FG003|Step 1|Progressive disease|1
5988147|NCT00098475|9579295|FG000|Step 1|Adverse Event|56
5988148|NCT00098475|9579296|FG001|Step 1|Adverse Event|37
5988149|NCT00098475|9579297|FG002|Step 1|Adverse Event|0
5988150|NCT00098475|9579298|FG003|Step 1|Adverse Event|1
5988151|NCT00098475|9579295|FG000|Step 1|Death|8
5988152|NCT00098475|9579296|FG001|Step 1|Death|5
5988153|NCT00098475|9579297|FG002|Step 1|Death|0
5988154|NCT00098475|9579298|FG003|Step 1|Death|1
5988155|NCT00098475|9579295|FG000|Step 1|Withdrawal by Subject|14
5988156|NCT00098475|9579296|FG001|Step 1|Withdrawal by Subject|11
5988157|NCT00098475|9579297|FG002|Step 1|Withdrawal by Subject|0
5988158|NCT00098475|9579298|FG003|Step 1|Withdrawal by Subject|0
5988159|NCT00098475|9579295|FG000|Step 1|Physician Decision|5
5988160|NCT00098475|9579296|FG001|Step 1|Physician Decision|2
5988161|NCT00098475|9579297|FG002|Step 1|Physician Decision|0
5988162|NCT00098475|9579298|FG003|Step 1|Physician Decision|0
5988163|NCT00098475|9579295|FG000|Step 1|Alternative therapy|31
5988164|NCT00098475|9579296|FG001|Step 1|Alternative therapy|43
5988165|NCT00098475|9579297|FG002|Step 1|Alternative therapy|1
5988166|NCT00098475|9579298|FG003|Step 1|Alternative therapy|0
5988167|NCT00098475|9579295|FG000|Step 1|Other disease|2
5988168|NCT00098475|9579296|FG001|Step 1|Other disease|1
5988169|NCT00098475|9579297|FG002|Step 1|Other disease|1
5988170|NCT00098475|9579298|FG003|Step 1|Other disease|0
5988171|NCT00098475|9579295|FG000|Step 1|Never started treatment|0
5988172|NCT00098475|9579296|FG001|Step 1|Never started treatment|2
5988173|NCT00098475|9579297|FG002|Step 1|Never started treatment|0
5988174|NCT00098475|9579298|FG003|Step 1|Never started treatment|0
5988175|NCT00098475|9579295|FG000|Step 1|Still on treatment as of this analysis|14
5988176|NCT00098475|9579296|FG001|Step 1|Still on treatment as of this analysis|27
5988177|NCT00098475|9579297|FG002|Step 1|Still on treatment as of this analysis|0
5988178|NCT00098475|9579298|FG003|Step 1|Still on treatment as of this analysis|0
5988179|NCT00098475|9579295|FG000|Step 1|Knee surgery|1
5988180|NCT00098475|9579296|FG001|Step 1|Knee surgery|0
5988181|NCT00098475|9579297|FG002|Step 1|Knee surgery|0
5988182|NCT00098475|9579298|FG003|Step 1|Knee surgery|0
5988183|NCT00098475|9579295|FG000|Step 1|Complications|1
5988184|NCT00098475|9579296|FG001|Step 1|Complications|0
5988185|NCT00098475|9579297|FG002|Step 1|Complications|0
5988186|NCT00098475|9579298|FG003|Step 1|Complications|0
5988187|NCT00098475|9579295|FG000|Step 1|Cannot comply due to other tx|0
5988188|NCT00098475|9579296|FG001|Step 1|Cannot comply due to other tx|1
5988189|NCT00098475|9579297|FG002|Step 1|Cannot comply due to other tx|0
5988190|NCT00098475|9579298|FG003|Step 1|Cannot comply due to other tx|0
5988191|NCT00098475|9579295|FG000|Step 1|Both patient and physician's decision|2
5988192|NCT00098475|9579296|FG001|Step 1|Both patient and physician's decision|1
5988193|NCT00098475|9579297|FG002|Step 1|Both patient and physician's decision|0
5988194|NCT00098475|9579298|FG003|Step 1|Both patient and physician's decision|0
5988195|NCT00098475|9579295|FG000|Step 1|Incorrect disease assessment|2
5988196|NCT00098475|9579296|FG001|Step 1|Incorrect disease assessment|0
5988197|NCT00098475|9579297|FG002|Step 1|Incorrect disease assessment|0
5988198|NCT00098475|9579298|FG003|Step 1|Incorrect disease assessment|0
5988199|NCT00098475|9579295|FG000|Step 1|Off treatment for > specified timeframe|1
5988200|NCT00098475|9579296|FG001|Step 1|Off treatment for > specified timeframe|1
5988201|NCT00098475|9579297|FG002|Step 1|Off treatment for > specified timeframe|0
5988202|NCT00098475|9579298|FG003|Step 1|Off treatment for > specified timeframe|0
5988203|NCT00098475|9579295|FG000|Step 1|Declining performance status|0
5988204|NCT00098475|9579296|FG001|Step 1|Declining performance status|1
5988205|NCT00098475|9579297|FG002|Step 1|Declining performance status|0
5988206|NCT00098475|9579298|FG003|Step 1|Declining performance status|0
5988207|NCT00098475|9579295|FG000|Step 1|Insurance issue|0
5988208|NCT00098475|9579296|FG001|Step 1|Insurance issue|1
5988209|NCT00098475|9579297|FG002|Step 1|Insurance issue|0
5988210|NCT00098475|9579298|FG003|Step 1|Insurance issue|0
5988211|NCT00098475|9579295|FG000|Step 1|Rising paraprotein|0
5988212|NCT00098475|9579296|FG001|Step 1|Rising paraprotein|1
5988213|NCT00098475|9579297|FG002|Step 1|Rising paraprotein|0
5988214|NCT00098475|9579298|FG003|Step 1|Rising paraprotein|0
5988215|NCT00098475|9579295|FG000|Step 1|Referred to other physicians|0
5988216|NCT00098475|9579296|FG001|Step 1|Referred to other physicians|1
5988217|NCT00098475|9579297|FG002|Step 1|Referred to other physicians|0
5988218|NCT00098475|9579298|FG003|Step 1|Referred to other physicians|0
5988219|NCT00098475|9579295|FG000|Step 1|Criteria to continue treatment not met|0
5988220|NCT00098475|9579296|FG001|Step 1|Criteria to continue treatment not met|1
5988221|NCT00098475|9579297|FG002|Step 1|Criteria to continue treatment not met|0
5988222|NCT00098475|9579298|FG003|Step 1|Criteria to continue treatment not met|0
5988223|NCT00098475|9579295|FG000|Step 1|Misinterpretation of lab data|0
5988224|NCT00098475|9579296|FG001|Step 1|Misinterpretation of lab data|1
5988225|NCT00098475|9579297|FG002|Step 1|Misinterpretation of lab data|0
5988226|NCT00098475|9579298|FG003|Step 1|Misinterpretation of lab data|0
5988227|NCT00098475|9579295|FG000|Step 1|Patient fell with fracture|1
5988228|NCT00098475|9579296|FG001|Step 1|Patient fell with fracture|0
5988229|NCT00098475|9579297|FG002|Step 1|Patient fell with fracture|0
5988230|NCT00098475|9579298|FG003|Step 1|Patient fell with fracture|0
5988231|NCT00098475|9579295|FG000|Step 1|Not documented|0
5988232|NCT00098475|9579296|FG001|Step 1|Not documented|1
5988233|NCT00098475|9579297|FG002|Step 1|Not documented|0
6226623|NCT01711216|9899112|FG000|Overall Study|variety of other minor reasons|83
5988234|NCT00098475|9579298|FG003|Step 1|Not documented|0
5988235|NCT00098475|9579295|FG000|Step 2|Disease progression|1
5988236|NCT00098475|9579296|FG001|Step 2|Disease progression|4
5988237|NCT00098475|9579297|FG002|Step 2|Disease progression|0
5988238|NCT00098475|9579298|FG003|Step 2|Disease progression|0
5988239|NCT00098475|9579295|FG000|Step 2|Adverse Event|2
5988240|NCT00098475|9579296|FG001|Step 2|Adverse Event|0
5988241|NCT00098475|9579297|FG002|Step 2|Adverse Event|0
5988242|NCT00098475|9579298|FG003|Step 2|Adverse Event|0
5988243|NCT00098475|9579295|FG000|Step 2|Withdrawal by Subject|0
5988244|NCT00098475|9579296|FG001|Step 2|Withdrawal by Subject|2
5988245|NCT00098475|9579297|FG002|Step 2|Withdrawal by Subject|0
5988246|NCT00098475|9579298|FG003|Step 2|Withdrawal by Subject|0
5988247|NCT00098475|9579295|FG000|Step 2|Physician Decision|0
5988248|NCT00098475|9579296|FG001|Step 2|Physician Decision|1
5988249|NCT00098475|9579297|FG002|Step 2|Physician Decision|0
5988250|NCT00098475|9579298|FG003|Step 2|Physician Decision|0
5988251|NCT00098475|9579295|FG000|Step 2|Alternative therapy|1
5988252|NCT00098475|9579296|FG001|Step 2|Alternative therapy|2
5988253|NCT00098475|9579297|FG002|Step 2|Alternative therapy|0
5988254|NCT00098475|9579298|FG003|Step 2|Alternative therapy|0
5988255|NCT00098475|9579295|FG000|Step 2|Never started treatment|1
5988256|NCT00098475|9579296|FG001|Step 2|Never started treatment|1
5988257|NCT00098475|9579297|FG002|Step 2|Never started treatment|0
5988258|NCT00098475|9579298|FG003|Step 2|Never started treatment|0
6045195|NCT00401245|9644405|FG002|Double Blind Tapering Phase|Investigator request|0
6045196|NCT00401245|9644406|FG003|Double Blind Tapering Phase|Investigator request|0
6045197|NCT00401245|9644407|FG004|Double Blind Tapering Phase|Investigator request|0
6045198|NCT00401245|9644408|FG005|Double Blind Tapering Phase|Investigator request|0
6045199|NCT00401245|9644409|FG006|Double Blind Tapering Phase|Investigator request|0
6045200|NCT00401245|9644410|FG007|Double Blind Tapering Phase|Investigator request|1
6045201|NCT00401245|9644403|FG000|Double Blind Tapering Phase|Other|0
6045202|NCT00401245|9644404|FG001|Double Blind Tapering Phase|Other|0
6045203|NCT00401245|9644405|FG002|Double Blind Tapering Phase|Other|0
6045204|NCT00401245|9644406|FG003|Double Blind Tapering Phase|Other|0
6045205|NCT00401245|9644407|FG004|Double Blind Tapering Phase|Other|1
6045206|NCT00401245|9644408|FG005|Double Blind Tapering Phase|Other|0
6045207|NCT00401245|9644409|FG006|Double Blind Tapering Phase|Other|2
6045208|NCT00401245|9644410|FG007|Double Blind Tapering Phase|Other|2
6045209|NCT00401245|9644403|FG000|Double Blind Tapering Phase|Withdrawal by Subject|0
6045210|NCT00401245|9644404|FG001|Double Blind Tapering Phase|Withdrawal by Subject|0
6045211|NCT00401245|9644405|FG002|Double Blind Tapering Phase|Withdrawal by Subject|0
6045212|NCT00401245|9644406|FG003|Double Blind Tapering Phase|Withdrawal by Subject|0
6045213|NCT00401245|9644407|FG004|Double Blind Tapering Phase|Withdrawal by Subject|2
6045214|NCT00401245|9644408|FG005|Double Blind Tapering Phase|Withdrawal by Subject|2
6045215|NCT00401245|9644409|FG006|Double Blind Tapering Phase|Withdrawal by Subject|3
6045216|NCT00401245|9644410|FG007|Double Blind Tapering Phase|Withdrawal by Subject|0
6045217|NCT00401245|9644403|FG000|Double Blind Tapering Phase|Lack of Efficacy|0
6045218|NCT00401245|9644404|FG001|Double Blind Tapering Phase|Lack of Efficacy|0
6045219|NCT00401245|9644405|FG002|Double Blind Tapering Phase|Lack of Efficacy|0
6045220|NCT00401245|9644406|FG003|Double Blind Tapering Phase|Lack of Efficacy|0
6045221|NCT00401245|9644407|FG004|Double Blind Tapering Phase|Lack of Efficacy|0
6045222|NCT00401245|9644408|FG005|Double Blind Tapering Phase|Lack of Efficacy|1
6045223|NCT00401245|9644409|FG006|Double Blind Tapering Phase|Lack of Efficacy|0
6045224|NCT00401245|9644410|FG007|Double Blind Tapering Phase|Lack of Efficacy|0
6045225|NCT00401258|9644430|FG000|Overall Study|Adverse Event|7
6045226|NCT00401375|9644437|FG000|Overall Study|Protocol Violation|2
6045227|NCT00401375|9644438|FG001|Overall Study|Protocol Violation|2
6045228|NCT00401375|9644439|FG002|Overall Study|Protocol Violation|1
6045229|NCT00401375|9644437|FG000|Overall Study|Adverse Event|6
6045230|NCT00401375|9644438|FG001|Overall Study|Adverse Event|11
6045231|NCT00401375|9644439|FG002|Overall Study|Adverse Event|10
6045232|NCT00401375|9644437|FG000|Overall Study|Withdrawal by Subject|9
6045233|NCT00401375|9644438|FG001|Overall Study|Withdrawal by Subject|7
6045234|NCT00401375|9644439|FG002|Overall Study|Withdrawal by Subject|7
6045235|NCT00401375|9644437|FG000|Overall Study|Lost to Follow-up|0
6045236|NCT00401375|9644438|FG001|Overall Study|Lost to Follow-up|1
6045237|NCT00401375|9644439|FG002|Overall Study|Lost to Follow-up|1
6226624|NCT01711216|9899112|FG000|Overall Study|no reason specified|22
6226625|NCT01711359|9899132|FG000|Treatment Period|Withdrawal by Subject|18
6226626|NCT01711359|9899133|FG001|Treatment Period|Withdrawal by Subject|7
6226627|NCT01711359|9899134|FG002|Treatment Period|Withdrawal by Subject|13
6226628|NCT01711359|9899132|FG000|Treatment Period|Lack of Efficacy|13
6226629|NCT01711359|9899133|FG001|Treatment Period|Lack of Efficacy|2
6226630|NCT01711359|9899134|FG002|Treatment Period|Lack of Efficacy|2
6226631|NCT01711359|9899132|FG000|Treatment Period|Adverse Event|8
6226632|NCT01711359|9899133|FG001|Treatment Period|Adverse Event|10
6226633|NCT01711359|9899134|FG002|Treatment Period|Adverse Event|24
6226634|NCT01711359|9899132|FG000|Treatment Period|Physician Decision|4
6226635|NCT01711359|9899133|FG001|Treatment Period|Physician Decision|3
6226636|NCT01711359|9899134|FG002|Treatment Period|Physician Decision|2
6226637|NCT01711359|9899132|FG000|Treatment Period|Death|3
6226638|NCT01711359|9899133|FG001|Treatment Period|Death|0
6226639|NCT01711359|9899134|FG002|Treatment Period|Death|0
6226640|NCT01711359|9899132|FG000|Treatment Period|Entry Criteria Not Met|1
6045238|NCT00401375|9644437|FG000|Overall Study|Other than specified|2
6045239|NCT00401375|9644438|FG001|Overall Study|Other than specified|1
6226641|NCT01711359|9899133|FG001|Treatment Period|Entry Criteria Not Met|0
6045240|NCT00401375|9644439|FG002|Overall Study|Other than specified|3
6226642|NCT01711359|9899134|FG002|Treatment Period|Entry Criteria Not Met|0
6045241|NCT00401375|9644437|FG000|Overall Study|Randomized but not treated|3
6045242|NCT00401375|9644438|FG001|Overall Study|Randomized but not treated|3
6045243|NCT00401375|9644439|FG002|Overall Study|Randomized but not treated|3
6226643|NCT01711359|9899132|FG000|Treatment Period|Sponsor Decision|1
6226644|NCT01711359|9899133|FG001|Treatment Period|Sponsor Decision|0
6226645|NCT01711359|9899134|FG002|Treatment Period|Sponsor Decision|0
5988259|NCT04471935|9579308|FG000|Overall Study|Withdrawal by Subject|1
5988260|NCT04471935|9579308|FG000|Overall Study|Deemed ineligible to participate|1
5988261|NCT04439344|9579312|FG000|Overall Study|Never started threapy|3
5988262|NCT04439344|9579312|FG000|Overall Study|Ineligible|3
5988263|NCT04439344|9579312|FG000|Overall Study|Adverse Event|13
5988264|NCT04439344|9579312|FG000|Overall Study|Death|2
5988265|NCT04439344|9579312|FG000|Overall Study|Disease progression|29
5988266|NCT04439344|9579312|FG000|Overall Study|Withdrawal by Subject|2
5988267|NCT04439344|9579312|FG000|Overall Study|Alternative therapy|1
5988268|NCT04439279|9579316|FG000|Overall Study|Adverse Event|7
5988269|NCT04439279|9579316|FG000|Overall Study|Death|4
5988270|NCT04439279|9579316|FG000|Overall Study|Disease progression|17
5988271|NCT04439279|9579316|FG000|Overall Study|Complicating disease|3
5988272|NCT04439279|9579316|FG000|Overall Study|Withdrawal by Subject|2
5988273|NCT04439279|9579316|FG000|Overall Study|Ineligible|1
5988274|NCT04439279|9579316|FG000|Overall Study|Treatment still ongoing|1
5988275|NCT04439123|9579320|FG000|Overall Study|Adverse Event|11
5988276|NCT04439123|9579320|FG000|Overall Study|Death|1
5988277|NCT04439123|9579320|FG000|Overall Study|Disease progression|19
5988278|NCT04439123|9579320|FG000|Overall Study|Withdrawal by Subject|2
5988279|NCT04439123|9579320|FG000|Overall Study|Still on treatment|2
5988280|NCT04439110|9579324|FG000|Overall Study|Ineligible|2
5988281|NCT04439110|9579324|FG000|Overall Study|Adverse Event|4
5988282|NCT04439110|9579324|FG000|Overall Study|Death|2
5988283|NCT04439110|9579324|FG000|Overall Study|Disease proression|25
5988284|NCT04439110|9579324|FG000|Overall Study|Withdrawal by Subject|1
5988285|NCT04439110|9579324|FG000|Overall Study|Alternative therapy|1
5988286|NCT04439110|9579324|FG000|Overall Study|Other complicating disease|1
5988287|NCT04439110|9579324|FG000|Overall Study|Personal reasons|1
5988288|NCT04439110|9579324|FG000|Overall Study|Still on treatment|1
5988289|NCT04498832|9579356|FG000|Overall Study|Adverse Event|1
5988290|NCT04498832|9579357|FG001|Overall Study|Adverse Event|3
5988291|NCT04498832|9579356|FG000|Overall Study|Withdrawal by Subject|0
5988292|NCT04498832|9579357|FG001|Overall Study|Withdrawal by Subject|1
6045244|NCT00401531|9644498|FG000|Overall Study|Adverse Event|2
6045245|NCT00401531|9644499|FG001|Overall Study|Adverse Event|0
6045246|NCT00401531|9644498|FG000|Overall Study|Protocol Violation|3
6045247|NCT00401531|9644499|FG001|Overall Study|Protocol Violation|7
6045248|NCT00401531|9644498|FG000|Overall Study|Lost to Follow-up|1
6045249|NCT00401531|9644499|FG001|Overall Study|Lost to Follow-up|1
6045250|NCT00401531|9644498|FG000|Overall Study|Withdrawal by Subject|3
6045251|NCT00401531|9644499|FG001|Overall Study|Withdrawal by Subject|2
6045252|NCT00401544|9644509|FG000|Overall Study|Adverse Event|5
6045253|NCT00401544|9644510|FG001|Overall Study|Adverse Event|1
6045254|NCT00401544|9644511|FG002|Overall Study|Adverse Event|1
6045255|NCT00401544|9644512|FG003|Overall Study|Adverse Event|1
6045256|NCT00401544|9644509|FG000|Overall Study|Death|3
6045257|NCT00401544|9644510|FG001|Overall Study|Death|6
6045258|NCT00401544|9644511|FG002|Overall Study|Death|2
6045259|NCT00401544|9644512|FG003|Overall Study|Death|5
6045260|NCT00401544|9644509|FG000|Overall Study|Lost to Follow-up|2
6045261|NCT00401544|9644510|FG001|Overall Study|Lost to Follow-up|0
6045262|NCT00401544|9644511|FG002|Overall Study|Lost to Follow-up|1
6045263|NCT00401544|9644512|FG003|Overall Study|Lost to Follow-up|1
6045264|NCT00401544|9644509|FG000|Overall Study|Withdrawal by Subject|7
6045265|NCT00401544|9644510|FG001|Overall Study|Withdrawal by Subject|6
6045266|NCT00401544|9644511|FG002|Overall Study|Withdrawal by Subject|6
6045267|NCT00401544|9644512|FG003|Overall Study|Withdrawal by Subject|5
6226646|NCT01711359|9899132|FG000|Treatment Period|Lost to Follow-up|1
6226647|NCT01711359|9899133|FG001|Treatment Period|Lost to Follow-up|1
6226648|NCT01711359|9899134|FG002|Treatment Period|Lost to Follow-up|1
6226649|NCT01711359|9899132|FG000|Treatment Period|Randomized, Not Treated|3
6226650|NCT01711359|9899133|FG001|Treatment Period|Randomized, Not Treated|1
6226651|NCT01711359|9899134|FG002|Treatment Period|Randomized, Not Treated|0
6226652|NCT01711619|9899161|FG000|Overall Study|Early study termination|10
6226653|NCT01711619|9899162|FG001|Overall Study|Early study termination|14
6226654|NCT01711619|9899161|FG000|Overall Study|Withdrawal by Subject|3
6226655|NCT01711619|9899162|FG001|Overall Study|Withdrawal by Subject|7
6226656|NCT01711619|9899161|FG000|Overall Study|Protocol Violation|2
6226657|NCT01711619|9899162|FG001|Overall Study|Protocol Violation|3
6045268|NCT00401544|9644509|FG000|Overall Study|Physician Decision|1
6045269|NCT00401544|9644510|FG001|Overall Study|Physician Decision|3
6045270|NCT00401544|9644511|FG002|Overall Study|Physician Decision|0
6045271|NCT00401544|9644512|FG003|Overall Study|Physician Decision|0
6045272|NCT00401544|9644509|FG000|Overall Study|Ineligibility determined|0
6045273|NCT00401544|9644510|FG001|Overall Study|Ineligibility determined|1
6045274|NCT00401544|9644511|FG002|Overall Study|Ineligibility determined|0
6045275|NCT00401544|9644512|FG003|Overall Study|Ineligibility determined|2
6045276|NCT00401544|9644509|FG000|Overall Study|Disease progression|0
6045277|NCT00401544|9644510|FG001|Overall Study|Disease progression|1
6045278|NCT00401544|9644511|FG002|Overall Study|Disease progression|0
6045279|NCT00401544|9644512|FG003|Overall Study|Disease progression|0
6045280|NCT00401544|9644509|FG000|Overall Study|Other|0
6045281|NCT00401544|9644510|FG001|Overall Study|Other|0
6045282|NCT00401544|9644511|FG002|Overall Study|Other|2
6226658|NCT01711619|9899161|FG000|Overall Study|Adverse Event|2
5988293|NCT04109222|9579366|FG000|Overall Study|Adverse Event|1
5988294|NCT04109222|9579367|FG001|Overall Study|Adverse Event|0
5988295|NCT04109222|9579368|FG002|Overall Study|Adverse Event|0
5988296|NCT04046939|9579380|FG000|Primary Assessment Period|Adverse Event|1
5988297|NCT04046939|9579381|FG001|Primary Assessment Period|Adverse Event|0
5988298|NCT04046939|9579382|FG002|Primary Assessment Period|Adverse Event|0
5988299|NCT04046939|9579383|FG003|Primary Assessment Period|Adverse Event|0
5988300|NCT04046939|9579380|FG000|Primary Assessment Period|Withdrawal by Subject|1
5988301|NCT04046939|9579381|FG001|Primary Assessment Period|Withdrawal by Subject|0
5988302|NCT04046939|9579382|FG002|Primary Assessment Period|Withdrawal by Subject|1
5988303|NCT04046939|9579383|FG003|Primary Assessment Period|Withdrawal by Subject|0
5988304|NCT04046939|9579380|FG000|Primary Assessment Period|Physician Decision|0
5988305|NCT04046939|9579381|FG001|Primary Assessment Period|Physician Decision|0
5988306|NCT04046939|9579382|FG002|Primary Assessment Period|Physician Decision|1
5988307|NCT04046939|9579383|FG003|Primary Assessment Period|Physician Decision|0
5988308|NCT04046939|9579380|FG000|Eosinophil Recovery Period|Withdrawal by Subject|1
5988309|NCT04046939|9579381|FG001|Eosinophil Recovery Period|Withdrawal by Subject|0
6226659|NCT01711619|9899162|FG001|Overall Study|Adverse Event|0
6226660|NCT01711619|9899161|FG000|Overall Study|Lost to Follow-up|1
6226661|NCT01711619|9899162|FG001|Overall Study|Lost to Follow-up|0
6226662|NCT01711645|9899168|FG000|Overall Study|Withdrawal by Subject|8
6226663|NCT01711645|9899168|FG000|Overall Study|Lost to Follow-up|6
6226664|NCT01711645|9899168|FG000|Overall Study|Physician Decision|5
6226665|NCT01711736|9899183|FG000|Overall Study|Lost to Follow-up|4
6226666|NCT01711736|9899184|FG001|Overall Study|Lost to Follow-up|1
6226667|NCT01711736|9899183|FG000|Overall Study|Withdrawal by Subject|6
6226668|NCT01711736|9899184|FG001|Overall Study|Withdrawal by Subject|6
6226669|NCT01711736|9899183|FG000|Overall Study|Migrated/moved from study area|2
6226670|NCT01711736|9899184|FG001|Overall Study|Migrated/moved from study area|1
6226671|NCT01711853|9899191|FG000|Overall Study|Not treated|3
6226672|NCT01711866|9899195|FG000|Overall Study|Noncompliant|3
6226673|NCT01711866|9899195|FG000|Overall Study|Withdrawal by Subject|3
6226674|NCT01711866|9899195|FG000|Overall Study|Adverse Event|2
6226675|NCT01711983|9899203|FG000|6-Month Clinical Success Evaluation|Missed Echocardiograph|32
6226676|NCT01711983|9899203|FG000|6-Month Closure Evaluation|Technical Failure (No Test Device)|26
6226677|NCT01711983|9899203|FG000|36-Month Closure Evaluation|Test Device Removal|2
6226678|NCT01711983|9899203|FG000|36-Month Closure Evaluation|Missed Echocardiograph|62
6226679|NCT01712009|9899210|FG000|Overall Study|Withdrawal by Subject|24
6226680|NCT01712009|9899211|FG001|Overall Study|Withdrawal by Subject|15
6226681|NCT01712009|9899212|FG002|Overall Study|Withdrawal by Subject|8
6226682|NCT01712009|9899210|FG000|Overall Study|Lost to Follow-up|2
6226683|NCT01712009|9899211|FG001|Overall Study|Lost to Follow-up|0
6226684|NCT01712009|9899212|FG002|Overall Study|Lost to Follow-up|1
6226685|NCT01712009|9899210|FG000|Overall Study|Decision by Sponsor|12
6226686|NCT01712009|9899211|FG001|Overall Study|Decision by Sponsor|14
6226687|NCT01712009|9899212|FG002|Overall Study|Decision by Sponsor|12
6226688|NCT01712061|9899222|FG000|Overall Study|Adverse Event|4
6226689|NCT01712061|9899223|FG001|Overall Study|Adverse Event|9
6226690|NCT01712061|9899224|FG002|Overall Study|Adverse Event|5
6226691|NCT01712061|9899222|FG000|Overall Study|Death|0
6226692|NCT01712061|9899223|FG001|Overall Study|Death|0
6226693|NCT01712061|9899224|FG002|Overall Study|Death|1
6226694|NCT01712061|9899222|FG000|Overall Study|Lost to Follow-up|1
6226695|NCT01712061|9899223|FG001|Overall Study|Lost to Follow-up|0
6226696|NCT01712061|9899224|FG002|Overall Study|Lost to Follow-up|1
6226697|NCT01712061|9899222|FG000|Overall Study|Did Not Meet Entrance Criteria|4
6226698|NCT01712061|9899223|FG001|Overall Study|Did Not Meet Entrance Criteria|6
6226699|NCT01712061|9899224|FG002|Overall Study|Did Not Meet Entrance Criteria|3
6226700|NCT01712061|9899222|FG000|Overall Study|Medication Error Without Associated AE|0
6226701|NCT01712061|9899223|FG001|Overall Study|Medication Error Without Associated AE|1
6226702|NCT01712061|9899224|FG002|Overall Study|Medication Error Without Associated AE|0
6226703|NCT01712061|9899222|FG000|Overall Study|Withdrawal by Subject|1
6226704|NCT01712061|9899223|FG001|Overall Study|Withdrawal by Subject|7
6226705|NCT01712061|9899224|FG002|Overall Study|Withdrawal by Subject|1
6226706|NCT01712061|9899222|FG000|Overall Study|Other|0
6226707|NCT01712061|9899223|FG001|Overall Study|Other|3
6226708|NCT01712061|9899224|FG002|Overall Study|Other|0
6226709|NCT01712074|9899236|FG000|Placebo Run-in Period|Adverse Event|2
6226710|NCT01712074|9899237|FG001|Placebo Run-in Period|Adverse Event|0
6226711|NCT01712074|9899238|FG002|Placebo Run-in Period|Adverse Event|0
6226712|NCT01712074|9899236|FG000|Placebo Run-in Period|Lost to Follow-up|1
6226713|NCT01712074|9899237|FG001|Placebo Run-in Period|Lost to Follow-up|0
6226714|NCT01712074|9899238|FG002|Placebo Run-in Period|Lost to Follow-up|0
6226715|NCT01712074|9899236|FG000|Placebo Run-in Period|No longer meets eligibility criteria|5
6226716|NCT01712074|9899237|FG001|Placebo Run-in Period|No longer meets eligibility criteria|0
5988310|NCT04046939|9579382|FG002|Eosinophil Recovery Period|Withdrawal by Subject|0
5988311|NCT04046939|9579383|FG003|Eosinophil Recovery Period|Withdrawal by Subject|1
6226717|NCT01712074|9899238|FG002|Placebo Run-in Period|No longer meets eligibility criteria|0
6226718|NCT01712074|9899236|FG000|Placebo Run-in Period|Other|1
6226719|NCT01712074|9899237|FG001|Placebo Run-in Period|Other|0
6226720|NCT01712074|9899238|FG002|Placebo Run-in Period|Other|0
5988312|NCT03912259|9579401|FG000|Overall Study|Adverse Event (AE)|2
5988313|NCT03912259|9579402|FG001|Overall Study|Adverse Event (AE)|4
5988314|NCT03912259|9579401|FG000|Overall Study|Lack of Efficacy|4
5988315|NCT03912259|9579402|FG001|Overall Study|Lack of Efficacy|1
5988316|NCT03912259|9579401|FG000|Overall Study|Withdrawal by Subject|11
5988317|NCT03912259|9579402|FG001|Overall Study|Withdrawal by Subject|1
5988318|NCT03890367|9579412|FG000|Overall Study|Withdrawal by parent/guardian|1
5988319|NCT03890367|9579413|FG001|Overall Study|Withdrawal by parent/guardian|3
5988320|NCT03890367|9579414|FG002|Overall Study|Withdrawal by parent/guardian|0
5988321|NCT03890367|9579412|FG000|Overall Study|Protocol deviation|2
5988322|NCT03890367|9579413|FG001|Overall Study|Protocol deviation|2
5988323|NCT03890367|9579414|FG002|Overall Study|Protocol deviation|1
5988324|NCT03890367|9579412|FG000|Overall Study|Lost to Follow-up|1
5988325|NCT03890367|9579413|FG001|Overall Study|Lost to Follow-up|1
5988326|NCT03890367|9579414|FG002|Overall Study|Lost to Follow-up|0
6045283|NCT00401544|9644512|FG003|Overall Study|Other|2
6045284|NCT00401726|9644538|FG000|Overall Study|Adverse Event|34
6045285|NCT00401726|9644539|FG001|Overall Study|Adverse Event|45
6045286|NCT00401726|9644538|FG000|Overall Study|Death|0
6045287|NCT00401726|9644539|FG001|Overall Study|Death|3
6045288|NCT00401726|9644538|FG000|Overall Study|Sponsor Request|0
6045289|NCT00401726|9644539|FG001|Overall Study|Sponsor Request|1
6045290|NCT00401726|9644538|FG000|Overall Study|Physician Decision|3
6045291|NCT00401726|9644539|FG001|Overall Study|Physician Decision|6
6045292|NCT00401726|9644538|FG000|Overall Study|Lost to Follow-up|23
6045293|NCT00401726|9644539|FG001|Overall Study|Lost to Follow-up|20
6045294|NCT00401726|9644538|FG000|Overall Study|Protocol Violation|6
6045295|NCT00401726|9644539|FG001|Overall Study|Protocol Violation|3
6045296|NCT00401726|9644538|FG000|Overall Study|Withdrawal by Subject|18
6045297|NCT00401726|9644539|FG001|Overall Study|Withdrawal by Subject|24
6045298|NCT00401726|9644538|FG000|Overall Study|Lack of Efficacy|4
6045299|NCT00401726|9644539|FG001|Overall Study|Lack of Efficacy|6
6045300|NCT00401726|9644538|FG000|Overall Study|Protocol Deviation|9
6045301|NCT00401726|9644539|FG001|Overall Study|Protocol Deviation|4
6045302|NCT00401752|9644547|FG000|Overall Study|Adverse Event|2
6045303|NCT00401752|9644548|FG001|Overall Study|Adverse Event|5
6045304|NCT00401752|9644547|FG000|Overall Study|Withdrawal by Subject|2
6045305|NCT00401752|9644548|FG001|Overall Study|Withdrawal by Subject|6
6045306|NCT00401752|9644547|FG000|Overall Study|Lost to Follow-up|1
6045307|NCT00401752|9644548|FG001|Overall Study|Lost to Follow-up|4
6045308|NCT00401752|9644547|FG000|Overall Study|Development of any exclusion criteria|4
6226721|NCT01712074|9899236|FG000|Placebo Run-in Period|No longer willing to participate|1
6226722|NCT01712074|9899237|FG001|Placebo Run-in Period|No longer willing to participate|0
6226723|NCT01712074|9899238|FG002|Placebo Run-in Period|No longer willing to participate|0
6226724|NCT01712074|9899236|FG000|Double Blind Period|Adverse Event|0
6226725|NCT01712074|9899237|FG001|Double Blind Period|Adverse Event|2
6226726|NCT01712074|9899238|FG002|Double Blind Period|Adverse Event|1
6226727|NCT01712074|9899236|FG000|Double Blind Period|No longer willing to participate|0
6226728|NCT01712074|9899237|FG001|Double Blind Period|No longer willing to participate|2
6226729|NCT01712074|9899238|FG002|Double Blind Period|No longer willing to participate|4
6226730|NCT01712074|9899236|FG000|Double Blind Period|Death|0
6226731|NCT01712074|9899237|FG001|Double Blind Period|Death|1
6226732|NCT01712074|9899238|FG002|Double Blind Period|Death|0
6226733|NCT01712074|9899236|FG000|Double Blind Period|Lost to Follow-up|0
6226734|NCT01712074|9899237|FG001|Double Blind Period|Lost to Follow-up|2
6226735|NCT01712074|9899238|FG002|Double Blind Period|Lost to Follow-up|1
6226736|NCT01712074|9899236|FG000|Double Blind Period|Other|0
6226737|NCT01712074|9899237|FG001|Double Blind Period|Other|4
6226738|NCT01712074|9899238|FG002|Double Blind Period|Other|1
6045309|NCT00401752|9644548|FG001|Overall Study|Development of any exclusion criteria|2
6045310|NCT00401752|9644547|FG000|Overall Study|Physician Decision|1
6045311|NCT00401752|9644548|FG001|Overall Study|Physician Decision|1
6045312|NCT00401830|9644574|FG000|Overall Study|Adverse Event|10
6045313|NCT00401830|9644575|FG001|Overall Study|Adverse Event|18
6045314|NCT00401830|9644574|FG000|Overall Study|Lack of Efficacy|11
6045315|NCT00401830|9644575|FG001|Overall Study|Lack of Efficacy|5
6045316|NCT00401830|9644574|FG000|Overall Study|Withdrawal by Subject|4
6045317|NCT00401830|9644575|FG001|Overall Study|Withdrawal by Subject|3
6045318|NCT00401830|9644574|FG000|Overall Study|Protocol Violation|3
6045319|NCT00401830|9644575|FG001|Overall Study|Protocol Violation|3
6045320|NCT00401830|9644574|FG000|Overall Study|Non-compliance with drug study|1
6045321|NCT00401830|9644575|FG001|Overall Study|Non-compliance with drug study|0
6045322|NCT00401830|9644574|FG000|Overall Study|Lost to Follow-up|1
6045323|NCT00401830|9644575|FG001|Overall Study|Lost to Follow-up|3
6226739|NCT01712074|9899236|FG000|Double Blind Period|Protocol Violation|0
6226740|NCT01712074|9899237|FG001|Double Blind Period|Protocol Violation|0
6226741|NCT01712074|9899238|FG002|Double Blind Period|Protocol Violation|1
6226742|NCT01712074|9899236|FG000|Double Blind Period|No longer met eligibility criteria|0
6226743|NCT01712074|9899237|FG001|Double Blind Period|No longer met eligibility criteria|3
6226744|NCT01712074|9899238|FG002|Double Blind Period|No longer met eligibility criteria|0
6045324|NCT00401830|9644574|FG000|Overall Study|Other: Personal / Family problems|1
6226745|NCT01712178|9899255|FG000|Overall Study|Withdrew consent due to an adverse event|1
6226746|NCT01712178|9899256|FG001|Overall Study|Withdrew consent due to an adverse event|1
5988327|NCT03607422|9579432|FG000|Overall Study|Adverse Event|7
5988328|NCT03607422|9579433|FG001|Overall Study|Adverse Event|3
5988329|NCT03607422|9579434|FG002|Overall Study|Adverse Event|2
5988330|NCT03607422|9579435|FG003|Overall Study|Adverse Event|0
5988331|NCT03607422|9579436|FG004|Overall Study|Adverse Event|2
5988332|NCT03607422|9579437|FG005|Overall Study|Adverse Event|0
5988333|NCT03607422|9579432|FG000|Overall Study|Withdrawal by Subject|11
5988334|NCT03607422|9579433|FG001|Overall Study|Withdrawal by Subject|3
5988335|NCT03607422|9579434|FG002|Overall Study|Withdrawal by Subject|6
5988336|NCT03607422|9579435|FG003|Overall Study|Withdrawal by Subject|2
5988337|NCT03607422|9579436|FG004|Overall Study|Withdrawal by Subject|0
5988338|NCT03607422|9579437|FG005|Overall Study|Withdrawal by Subject|0
5988339|NCT03607422|9579432|FG000|Overall Study|Lost to Follow-up|0
5988340|NCT03607422|9579433|FG001|Overall Study|Lost to Follow-up|0
5988341|NCT03607422|9579434|FG002|Overall Study|Lost to Follow-up|1
5988342|NCT03607422|9579435|FG003|Overall Study|Lost to Follow-up|0
5988343|NCT03607422|9579436|FG004|Overall Study|Lost to Follow-up|0
5988344|NCT03607422|9579437|FG005|Overall Study|Lost to Follow-up|0
5988345|NCT03607422|9579432|FG000|Overall Study|Other|12
5988346|NCT03607422|9579433|FG001|Overall Study|Other|4
5988347|NCT03607422|9579434|FG002|Overall Study|Other|1
5988348|NCT03607422|9579435|FG003|Overall Study|Other|2
5988349|NCT03607422|9579436|FG004|Overall Study|Other|0
5988350|NCT03607422|9579437|FG005|Overall Study|Other|2
5988351|NCT03607422|9579432|FG000|Overall Study|Ongoing at Time of Analysis|8
5988352|NCT03607422|9579433|FG001|Overall Study|Ongoing at Time of Analysis|0
5988353|NCT03607422|9579434|FG002|Overall Study|Ongoing at Time of Analysis|2
5988354|NCT03607422|9579435|FG003|Overall Study|Ongoing at Time of Analysis|1
5988355|NCT03607422|9579436|FG004|Overall Study|Ongoing at Time of Analysis|1
5988356|NCT03607422|9579437|FG005|Overall Study|Ongoing at Time of Analysis|1
5988357|NCT03600805|9579455|FG000|Overall Study|Adverse Event|2
5988358|NCT03600805|9579456|FG001|Overall Study|Adverse Event|1
5988359|NCT03600805|9579457|FG002|Overall Study|Adverse Event|1
5988360|NCT03600805|9579458|FG003|Overall Study|Adverse Event|7
5988361|NCT03600805|9579455|FG000|Overall Study|Lack of Efficacy|2
5988362|NCT03600805|9579456|FG001|Overall Study|Lack of Efficacy|1
5988363|NCT03600805|9579457|FG002|Overall Study|Lack of Efficacy|0
5988364|NCT03600805|9579458|FG003|Overall Study|Lack of Efficacy|0
5988365|NCT03600805|9579455|FG000|Overall Study|Withdrawal by Subject|1
5988366|NCT03600805|9579456|FG001|Overall Study|Withdrawal by Subject|0
5988367|NCT03600805|9579457|FG002|Overall Study|Withdrawal by Subject|0
5988368|NCT03600805|9579458|FG003|Overall Study|Withdrawal by Subject|1
5988369|NCT03600805|9579455|FG000|Overall Study|Other unspecified|14
5988370|NCT03600805|9579456|FG001|Overall Study|Other unspecified|6
5988371|NCT03600805|9579457|FG002|Overall Study|Other unspecified|7
5988372|NCT03600805|9579458|FG003|Overall Study|Other unspecified|11
5988373|NCT03434119|9579481|FG000|Overall Study|Randomized but not treated|1
5988374|NCT03434119|9579482|FG001|Overall Study|Randomized but not treated|0
5988375|NCT03434119|9579481|FG000|Overall Study|Adverse Event|1
5988376|NCT03434119|9579482|FG001|Overall Study|Adverse Event|0
5988377|NCT03434119|9579481|FG000|Overall Study|Poor Compliance to Protocol|0
5988378|NCT03434119|9579482|FG001|Overall Study|Poor Compliance to Protocol|1
5988379|NCT03434119|9579481|FG000|Overall Study|Study Terminated by Sponsor|91
5988380|NCT03434119|9579482|FG001|Overall Study|Study Terminated by Sponsor|102
5988381|NCT03434119|9579481|FG000|Overall Study|Withdrawal by Subject|7
5988382|NCT03434119|9579482|FG001|Overall Study|Withdrawal by Subject|5
5988383|NCT03434119|9579481|FG000|Overall Study|Other than specified|7
5988384|NCT03434119|9579482|FG001|Overall Study|Other than specified|5
5988385|NCT03417245|9579490|FG000|Overall Study|Adverse Event|1
6226747|NCT01712178|9899255|FG000|Overall Study|Serious adverse event/withdrew consent|0
6226748|NCT01712178|9899256|FG001|Overall Study|Serious adverse event/withdrew consent|1
5988386|NCT03417245|9579491|FG001|Overall Study|Adverse Event|0
5988387|NCT03417245|9579490|FG000|Overall Study|Protocol Violation|1
5988388|NCT03417245|9579491|FG001|Overall Study|Protocol Violation|0
5988389|NCT03417245|9579490|FG000|Overall Study|Withdrawal by Subject|1
5988390|NCT03417245|9579491|FG001|Overall Study|Withdrawal by Subject|1
5988391|NCT03417102|9579499|FG000|Overall Study|Adverse Event|0
5988392|NCT03417102|9579500|FG001|Overall Study|Adverse Event|1
5988393|NCT03417102|9579499|FG000|Overall Study|Related to Coronavirus Pandemic (Covid-19)|0
5988394|NCT03417102|9579500|FG001|Overall Study|Related to Coronavirus Pandemic (Covid-19)|3
5988395|NCT03417102|9579499|FG000|Overall Study|Other|0
5988396|NCT03417102|9579500|FG001|Overall Study|Other|1
5988397|NCT03278626|9579512|FG000|Overall Study|Death|2
5988398|NCT03278626|9579512|FG000|Overall Study|Toxicity|1
5988399|NCT03278626|9579512|FG000|Overall Study|Disease Progression|2
6064724|NCT00515099|9666498|FG000|Overall Study|Lost to Follow-up|0
5988400|NCT03211858|9579518|FG000|Overall Study|Adverse Event|8
5988401|NCT03211858|9579519|FG001|Overall Study|Adverse Event|6
5988402|NCT03211858|9579518|FG000|Overall Study|Lack of Efficacy|0
5988403|NCT03211858|9579519|FG001|Overall Study|Lack of Efficacy|4
5988404|NCT03211858|9579518|FG000|Overall Study|Poor compliance to protocol|6
5988405|NCT03211858|9579519|FG001|Overall Study|Poor compliance to protocol|2
5988406|NCT03211858|9579518|FG000|Overall Study|Non-serious Hypoglycemia|1
5988407|NCT03211858|9579519|FG001|Overall Study|Non-serious Hypoglycemia|0
6064725|NCT00515099|9666499|FG001|Overall Study|Lost to Follow-up|4
5988408|NCT03211858|9579518|FG000|Overall Study|Other than specified above|22
5988409|NCT03211858|9579519|FG001|Overall Study|Other than specified above|21
5988410|NCT03077438|9579535|FG000|Overall Study|Protocol Violation|3
5988411|NCT03077438|9579536|FG001|Overall Study|Protocol Violation|5
5988412|NCT03077438|9579535|FG000|Overall Study|Withdrawal by Subject|3
5988413|NCT03077438|9579536|FG001|Overall Study|Withdrawal by Subject|6
5988414|NCT03077438|9579535|FG000|Overall Study|Lost to Follow-up|6
5988415|NCT03077438|9579536|FG001|Overall Study|Lost to Follow-up|3
5988416|NCT02948959|9579552|FG000|52 Weeks Treatment Period|Poor compliance to protocol|0
5988417|NCT02948959|9579553|FG001|52 Weeks Treatment Period|Poor compliance to protocol|2
5988418|NCT02948959|9579552|FG000|52 Weeks Treatment Period|Adverse Event|2
5988419|NCT02948959|9579553|FG001|52 Weeks Treatment Period|Adverse Event|5
5988420|NCT02948959|9579552|FG000|52 Weeks Treatment Period|Withdrawal by Subject|2
5988421|NCT02948959|9579553|FG001|52 Weeks Treatment Period|Withdrawal by Subject|2
5988422|NCT02948959|9579552|FG000|52 Weeks Treatment Period|Participant used protocol prohibited vaccine|1
5988423|NCT02948959|9579553|FG001|52 Weeks Treatment Period|Participant used protocol prohibited vaccine|6
5988424|NCT02948959|9579552|FG000|52 Weeks Treatment Period|Randomized by error|0
5988425|NCT02948959|9579553|FG001|52 Weeks Treatment Period|Randomized by error|5
5988426|NCT02948959|9579552|FG000|52 Weeks Treatment Period|Randomized and not treated|0
5988427|NCT02948959|9579553|FG001|52 Weeks Treatment Period|Randomized and not treated|3
5988428|NCT02948959|9579552|FG000|52 Weeks Treatment Period|Non-compliant to study treatment|0
5988429|NCT02948959|9579553|FG001|52 Weeks Treatment Period|Non-compliant to study treatment|1
5988430|NCT02948959|9579552|FG000|52 Weeks Treatment Period|Change of residence location|0
5988431|NCT02948959|9579553|FG001|52 Weeks Treatment Period|Change of residence location|1
5988432|NCT02948959|9579552|FG000|12 Weeks Follow-up Period|Adverse Event|0
5988433|NCT02948959|9579553|FG001|12 Weeks Follow-up Period|Adverse Event|2
5988434|NCT02948959|9579552|FG000|12 Weeks Follow-up Period|Poor compliance to protocol|1
5988435|NCT02948959|9579553|FG001|12 Weeks Follow-up Period|Poor compliance to protocol|2
5988436|NCT02948959|9579552|FG000|12 Weeks Follow-up Period|Withdrawal by Subject|3
5988437|NCT02948959|9579553|FG001|12 Weeks Follow-up Period|Withdrawal by Subject|3
5988438|NCT02948959|9579552|FG000|12 Weeks Follow-up Period|Randomized by error|0
5988439|NCT02948959|9579553|FG001|12 Weeks Follow-up Period|Randomized by error|3
5988440|NCT02948959|9579552|FG000|12 Weeks Follow-up Period|Change of residence location|0
5988441|NCT02948959|9579553|FG001|12 Weeks Follow-up Period|Change of residence location|2
5988442|NCT02948959|9579552|FG000|12 Weeks Follow-up Period|Study site closure|1
5988443|NCT02948959|9579553|FG001|12 Weeks Follow-up Period|Study site closure|0
5988444|NCT02878603|9579569|FG000|Overall Study|Lost to Follow-up|4
5988445|NCT02878603|9579570|FG001|Overall Study|Lost to Follow-up|1
5988446|NCT02878603|9579569|FG000|Overall Study|Withdrawal by Subject|1
5988447|NCT02878603|9579570|FG001|Overall Study|Withdrawal by Subject|1
5988448|NCT02878603|9579569|FG000|Overall Study|Death|1
5988449|NCT02878603|9579570|FG001|Overall Study|Death|0
5988450|NCT02878603|9579569|FG000|Overall Study|Physician Decision|0
5988451|NCT02878603|9579570|FG001|Overall Study|Physician Decision|3
5988452|NCT02864407|9579576|FG000|Overall Study|Protocol Violation|3
5988453|NCT02864407|9579576|FG000|Overall Study|Lost to Follow-up|115
5988454|NCT02864407|9579576|FG000|Overall Study|Not treated with Vahelva® Respimat®|1
5988455|NCT02864407|9579576|FG000|Overall Study|Were administered Vahelva® Respimat® prior to the consent date|3
5988456|NCT02864407|9579576|FG000|Overall Study|Consent prior to the contract date|1
5988457|NCT02846532|9579583|FG000|Overall Study|Lost to Follow-up|0
5988458|NCT02846532|9579584|FG001|Overall Study|Lost to Follow-up|1
5988459|NCT02846532|9579585|FG002|Overall Study|Lost to Follow-up|1
5988460|NCT02846532|9579583|FG000|Overall Study|Withdrawal by Subject|1
5988461|NCT02846532|9579584|FG001|Overall Study|Withdrawal by Subject|2
5988462|NCT02846532|9579585|FG002|Overall Study|Withdrawal by Subject|0
5988463|NCT02688933|9579595|FG000|Overall Study|Adverse Event|3
5988464|NCT02688933|9579596|FG001|Overall Study|Adverse Event|1
5988465|NCT02688933|9579595|FG000|Overall Study|Lack of Efficacy|2
5988466|NCT02688933|9579596|FG001|Overall Study|Lack of Efficacy|2
5988467|NCT02688933|9579595|FG000|Overall Study|Poor compliance to protocol|7
5988468|NCT02688933|9579596|FG001|Overall Study|Poor compliance to protocol|4
6226749|NCT01712178|9899255|FG000|Overall Study|Lost to Follow-up|0
6226750|NCT01712178|9899256|FG001|Overall Study|Lost to Follow-up|1
6226751|NCT01712204|9899264|FG000|Overall Study|Adverse Event|3
6226752|NCT01712204|9899265|FG001|Overall Study|Adverse Event|1
6226753|NCT01712204|9899264|FG000|Overall Study|Withdrawal by Subject|3
6226754|NCT01712204|9899265|FG001|Overall Study|Withdrawal by Subject|3
6226755|NCT01712204|9899264|FG000|Overall Study|Lost to Follow-up|1
6226756|NCT01712204|9899265|FG001|Overall Study|Lost to Follow-up|0
6226757|NCT01712204|9899264|FG000|Overall Study|Protocol Violation|1
6226758|NCT01712204|9899265|FG001|Overall Study|Protocol Violation|1
6226759|NCT01712256|9899284|FG000|Overall Study|Lost to Follow-up|1
5988469|NCT02688933|9579595|FG000|Overall Study|Hypoglycemia|2
5988470|NCT02688933|9579596|FG001|Overall Study|Hypoglycemia|0
5988471|NCT02688933|9579595|FG000|Overall Study|Other than Specified|14
5988472|NCT02688933|9579596|FG001|Overall Study|Other than Specified|25
5988473|NCT02688933|9579595|FG000|Overall Study|Lost to Follow-up|1
6226760|NCT01712334|9899288|FG000|Treatment Period 1|Randomized in Error|0
6226761|NCT01712334|9899289|FG001|Treatment Period 1|Randomized in Error|2
6226762|NCT01712399|9899318|FG000|Overall Study|Lost to Follow-up|1
6226763|NCT01712399|9899318|FG000|Overall Study|Withdrawal by Subject|39
5988474|NCT02688933|9579596|FG001|Overall Study|Lost to Follow-up|5
5988475|NCT02492165|9579615|FG000|Overall Study|Withdrawal by Subject|0
5988476|NCT02492165|9579616|FG001|Overall Study|Withdrawal by Subject|1
5988477|NCT02492165|9579617|FG002|Overall Study|Withdrawal by Subject|0
5988478|NCT02492165|9579618|FG003|Overall Study|Withdrawal by Subject|0
5988479|NCT02476006|9579628|FG000|Overall Study|Death|4
5988480|NCT02476006|9579628|FG000|Overall Study|Lack of treatment efficacy|2
5988481|NCT02476006|9579628|FG000|Overall Study|Pregnancy|1
5988482|NCT02476006|9579628|FG000|Overall Study|Participant did not wish to continue|39
5988483|NCT02476006|9579628|FG000|Overall Study|Adverse Event|41
5988484|NCT02476006|9579628|FG000|Overall Study|Poor compliance to study protocol|3
6226764|NCT01712399|9899318|FG000|Overall Study|Death|1
5988485|NCT02476006|9579628|FG000|Overall Study|Sponsor decision|6
5988486|NCT02476006|9579628|FG000|Overall Study|Lost to Follow-up|5
5988487|NCT02476006|9579628|FG000|Overall Study|Physician Decision|5
5988488|NCT02476006|9579628|FG000|Overall Study|Study ended treatment not available|4
5988489|NCT02476006|9579628|FG000|Overall Study|Switched to commercial drug|4
5988490|NCT02476006|9579628|FG000|Overall Study|Excluded from study|1
5988491|NCT02476006|9579628|FG000|Overall Study|Protocol Violation|1
5988492|NCT02476006|9579628|FG000|Overall Study|Enrolled but not treated|4
6226765|NCT01712399|9899318|FG000|Overall Study|Adverse Event|11
6226766|NCT01712399|9899318|FG000|Overall Study|Study closure|345
6226767|NCT01712438|9899322|FG000|Overall Study|Not treated with Human-cl rhFVIII|2
6226768|NCT01712438|9899322|FG000|Overall Study|Ongoing ITI treatment|6
6226769|NCT01712438|9899322|FG000|Overall Study|Violated inclusion & exclusion criteria|4
6226770|NCT01712438|9899322|FG000|Overall Study|Prematurely Discontinued|25
6226771|NCT01712516|9899335|FG000|Overall Study|Technical problems|0
6226772|NCT01712516|9899336|FG001|Overall Study|Technical problems|0
6226773|NCT01712516|9899337|FG002|Overall Study|Technical problems|0
6226774|NCT01712516|9899338|FG003|Overall Study|Technical problems|2
6226775|NCT01712516|9899335|FG000|Overall Study|Lost to Follow-up|0
5988493|NCT02468414|9579634|FG000|Overall Study|Early Study Termination by Sponsor|1
5988494|NCT02468414|9579635|FG001|Overall Study|Early Study Termination by Sponsor|0
5988495|NCT02468414|9579634|FG000|Overall Study|Poor in-vitro secreting TARGTs|1
5988496|NCT02468414|9579635|FG001|Overall Study|Poor in-vitro secreting TARGTs|0
6226776|NCT01712516|9899336|FG001|Overall Study|Lost to Follow-up|0
6226777|NCT01712516|9899337|FG002|Overall Study|Lost to Follow-up|2
6226778|NCT01712516|9899338|FG003|Overall Study|Lost to Follow-up|1
6226779|NCT01712516|9899335|FG000|Overall Study|Death|0
6226780|NCT01712516|9899336|FG001|Overall Study|Death|1
6226781|NCT01712516|9899337|FG002|Overall Study|Death|0
6226782|NCT01712516|9899338|FG003|Overall Study|Death|0
6226783|NCT01712516|9899335|FG000|Overall Study|Protocol deviation|1
6226784|NCT01712516|9899336|FG001|Overall Study|Protocol deviation|0
6226785|NCT01712516|9899337|FG002|Overall Study|Protocol deviation|1
6226786|NCT01712516|9899338|FG003|Overall Study|Protocol deviation|0
6226787|NCT01712516|9899335|FG000|Overall Study|Physician Decision|2
6226788|NCT01712516|9899336|FG001|Overall Study|Physician Decision|0
6226789|NCT01712516|9899337|FG002|Overall Study|Physician Decision|0
6226790|NCT01712516|9899338|FG003|Overall Study|Physician Decision|1
6226791|NCT01712516|9899335|FG000|Overall Study|Withdrawal by Subject|3
6226792|NCT01712516|9899336|FG001|Overall Study|Withdrawal by Subject|9
6226793|NCT01712516|9899337|FG002|Overall Study|Withdrawal by Subject|3
6226794|NCT01712516|9899338|FG003|Overall Study|Withdrawal by Subject|9
6226795|NCT01712685|9899348|FG000|Overall Study|pt declined to participate before trmt|1
6226796|NCT01712984|9899373|FG000|Overall Study|Adverse Event|0
6226797|NCT01712984|9899374|FG001|Overall Study|Adverse Event|0
6226798|NCT01712984|9899375|FG002|Overall Study|Adverse Event|1
6226799|NCT01712984|9899373|FG000|Overall Study|Protocol Violation|2
6226800|NCT01712984|9899374|FG001|Overall Study|Protocol Violation|0
6226801|NCT01712984|9899375|FG002|Overall Study|Protocol Violation|1
6226802|NCT01712984|9899373|FG000|Overall Study|Lost to Follow-up|8
6226803|NCT01712984|9899374|FG001|Overall Study|Lost to Follow-up|10
6226804|NCT01712984|9899375|FG002|Overall Study|Lost to Follow-up|1
6226805|NCT01712984|9899373|FG000|Overall Study|Withdrawal by Subject|6
6226806|NCT01712984|9899374|FG001|Overall Study|Withdrawal by Subject|6
6226807|NCT01712984|9899375|FG002|Overall Study|Withdrawal by Subject|7
6226808|NCT01713036|9899383|FG000|Overall Study|Death|1
6226809|NCT01713283|9899397|FG000|Overall Study|Lack of Efficacy|10
6226810|NCT01713283|9899398|FG001|Overall Study|Lack of Efficacy|2
6226811|NCT01713283|9899397|FG000|Overall Study|Lost to Follow-up|1
6226812|NCT01713283|9899398|FG001|Overall Study|Lost to Follow-up|1
6226813|NCT01713348|9899412|FG000|Overall Study|Withdrawal by Subject|3
6226814|NCT01713348|9899413|FG001|Overall Study|Withdrawal by Subject|2
6226815|NCT01713348|9899414|FG002|Overall Study|Withdrawal by Subject|2
6226816|NCT01713348|9899415|FG003|Overall Study|Withdrawal by Subject|0
6226817|NCT01713348|9899412|FG000|Overall Study|Lost to Follow-up|1
6226818|NCT01713348|9899413|FG001|Overall Study|Lost to Follow-up|0
6226819|NCT01713348|9899414|FG002|Overall Study|Lost to Follow-up|0
6226820|NCT01713348|9899415|FG003|Overall Study|Lost to Follow-up|0
6226821|NCT01713530|9899436|FG000|Overall Study|Adverse Event|0
6226822|NCT01713530|9899437|FG001|Overall Study|Adverse Event|5
6226823|NCT01713530|9899436|FG000|Overall Study|Withdrawal criteria|21
6226824|NCT01713530|9899437|FG001|Overall Study|Withdrawal criteria|12
6226825|NCT01713530|9899436|FG000|Overall Study|Unclassified|4
6226826|NCT01713530|9899437|FG001|Overall Study|Unclassified|2
5988497|NCT02468414|9579634|FG000|Overall Study|Screen Failure|1
5988498|NCT02468414|9579635|FG001|Overall Study|Screen Failure|0
5988499|NCT02462876|9579641|FG000|Overall Study|Death|3
5988500|NCT02462876|9579641|FG000|Overall Study|Lost to Follow-up|7
5988501|NCT02462876|9579641|FG000|Overall Study|Surgical Bypass|9
5988502|NCT02462876|9579641|FG000|Overall Study|Amputation Above the Metatarsals|1
6226827|NCT01713582|9899464|FG000|Overall Study|Disease progression|3
6226828|NCT01713582|9899465|FG001|Overall Study|Disease progression|3
6226829|NCT01713582|9899466|FG002|Overall Study|Disease progression|3
6226830|NCT01713582|9899467|FG003|Overall Study|Disease progression|2
6226831|NCT01713582|9899468|FG004|Overall Study|Disease progression|3
6226832|NCT01713582|9899469|FG005|Overall Study|Disease progression|3
5988503|NCT02462876|9579641|FG000|Overall Study|36 months follow-up visit missed|1
5988504|NCT02462876|9579641|FG000|Overall Study|Patient did not come back since 4 months follow-up|1
5988505|NCT02462876|9579641|FG000|Overall Study|Patient did not come back to the vascular department|1
5988506|NCT02462876|9579641|FG000|Overall Study|Patient contacted by phone but never came back for his follow-up visits|1
5988507|NCT02462876|9579641|FG000|Overall Study|Patient refused to come back|1
5988508|NCT02462876|9579641|FG000|Overall Study|Patient was contacted on Sep 2020. He is fine but refused to come back for his 36 months|1
5988509|NCT02462876|9579641|FG000|Overall Study|Patient cancelled the follow-up visit twice time|1
5988510|NCT02332590|9579647|FG000|DB Period (up to 24 Weeks)|Adverse Event|15
5988511|NCT02332590|9579648|FG001|DB Period (up to 24 Weeks)|Adverse Event|11
5988512|NCT02332590|9579647|FG000|DB Period (up to 24 Weeks)|Lack of Efficacy|4
5988513|NCT02332590|9579648|FG001|DB Period (up to 24 Weeks)|Lack of Efficacy|2
5988514|NCT02332590|9579647|FG000|DB Period (up to 24 Weeks)|Poor compliance to protocol|3
5988515|NCT02332590|9579648|FG001|DB Period (up to 24 Weeks)|Poor compliance to protocol|1
5988516|NCT02332590|9579647|FG000|DB Period (up to 24 Weeks)|Randomized but not treated|1
5988517|NCT02332590|9579648|FG001|DB Period (up to 24 Weeks)|Randomized but not treated|0
5988518|NCT02332590|9579647|FG000|DB Period (up to 24 Weeks)|Other than specified above|6
5988519|NCT02332590|9579648|FG001|DB Period (up to 24 Weeks)|Other than specified above|5
5988520|NCT02332590|9579647|FG000|OLE Period (Week 24 up to Week 300)|Adverse Event|20
5988521|NCT02332590|9579648|FG001|OLE Period (Week 24 up to Week 300)|Adverse Event|23
5988522|NCT02332590|9579647|FG000|OLE Period (Week 24 up to Week 300)|Lack of Efficacy|2
5988523|NCT02332590|9579648|FG001|OLE Period (Week 24 up to Week 300)|Lack of Efficacy|6
5988524|NCT02332590|9579647|FG000|OLE Period (Week 24 up to Week 300)|Poor compliance to protocol|5
5988525|NCT02332590|9579648|FG001|OLE Period (Week 24 up to Week 300)|Poor compliance to protocol|1
5988526|NCT02332590|9579647|FG000|OLE Period (Week 24 up to Week 300)|Other Unspecified|20
5988527|NCT02332590|9579648|FG001|OLE Period (Week 24 up to Week 300)|Other Unspecified|15
5988528|NCT02255656|9579656|FG000|Overall Study|Adverse Event|11
5988529|NCT02255656|9579656|FG000|Overall Study|Poor compliance to protocol|3
5988530|NCT02255656|9579656|FG000|Overall Study|Lost to Follow-up|30
5988531|NCT02255656|9579656|FG000|Overall Study|Due to Coronavirus Disease (Covid-19)|300
5988532|NCT02255656|9579656|FG000|Overall Study|Other|126
5988533|NCT02134028|9579675|FG000|Overall Study|Lack of Efficacy|1
5988534|NCT02134028|9579676|FG001|Overall Study|Lack of Efficacy|0
5988535|NCT02134028|9579677|FG002|Overall Study|Lack of Efficacy|3
6226833|NCT01713582|9899470|FG006|Overall Study|Disease progression|3
6226834|NCT01713582|9899471|FG007|Overall Study|Disease progression|3
6226835|NCT01713582|9899472|FG008|Overall Study|Disease progression|3
6226836|NCT01713582|9899473|FG009|Overall Study|Disease progression|11
5988536|NCT02134028|9579678|FG003|Overall Study|Lack of Efficacy|2
5988537|NCT02134028|9579679|FG004|Overall Study|Lack of Efficacy|1
5988538|NCT02134028|9579680|FG005|Overall Study|Lack of Efficacy|2
5988539|NCT02134028|9579681|FG006|Overall Study|Lack of Efficacy|1
5988540|NCT02134028|9579682|FG007|Overall Study|Lack of Efficacy|0
5988541|NCT02134028|9579675|FG000|Overall Study|Poor compliance to protocol|1
5988542|NCT02134028|9579676|FG001|Overall Study|Poor compliance to protocol|1
5988543|NCT02134028|9579677|FG002|Overall Study|Poor compliance to protocol|3
5988544|NCT02134028|9579678|FG003|Overall Study|Poor compliance to protocol|7
5988545|NCT02134028|9579679|FG004|Overall Study|Poor compliance to protocol|1
5988546|NCT02134028|9579680|FG005|Overall Study|Poor compliance to protocol|1
5988547|NCT02134028|9579681|FG006|Overall Study|Poor compliance to protocol|0
5988548|NCT02134028|9579682|FG007|Overall Study|Poor compliance to protocol|0
5988549|NCT02134028|9579675|FG000|Overall Study|Other unspecified|4
5988550|NCT02134028|9579676|FG001|Overall Study|Other unspecified|22
5988551|NCT02134028|9579677|FG002|Overall Study|Other unspecified|33
5988552|NCT02134028|9579678|FG003|Overall Study|Other unspecified|64
5988553|NCT02134028|9579679|FG004|Overall Study|Other unspecified|8
5988554|NCT02134028|9579680|FG005|Overall Study|Other unspecified|6
5988555|NCT02134028|9579681|FG006|Overall Study|Other unspecified|2
5988556|NCT02134028|9579682|FG007|Overall Study|Other unspecified|1
5988557|NCT02134028|9579675|FG000|Overall Study|Adverse Event|3
6226837|NCT01713582|9899474|FG010|Overall Study|Disease progression|10
6226838|NCT01713582|9899475|FG011|Overall Study|Disease progression|5
6226839|NCT01713582|9899476|FG012|Overall Study|Disease progression|3
6226840|NCT01713582|9899477|FG013|Overall Study|Disease progression|3
6226841|NCT01713582|9899478|FG014|Overall Study|Disease progression|6
6226842|NCT01713582|9899479|FG015|Overall Study|Disease progression|6
6226843|NCT01713582|9899480|FG016|Overall Study|Disease progression|5
6226844|NCT01713582|9899481|FG017|Overall Study|Disease progression|2
6226845|NCT01713582|9899482|FG018|Overall Study|Disease progression|3
6226846|NCT01713582|9899483|FG019|Overall Study|Disease progression|5
6226847|NCT01713582|9899484|FG020|Overall Study|Disease progression|15
6226848|NCT01713582|9899464|FG000|Overall Study|Death|0
6226849|NCT01713582|9899465|FG001|Overall Study|Death|0
6226850|NCT01713582|9899466|FG002|Overall Study|Death|0
6226851|NCT01713582|9899467|FG003|Overall Study|Death|1
6226852|NCT01713582|9899468|FG004|Overall Study|Death|1
6226853|NCT01713582|9899469|FG005|Overall Study|Death|3
6226854|NCT01713582|9899470|FG006|Overall Study|Death|3
6226855|NCT01713582|9899471|FG007|Overall Study|Death|2
6226856|NCT01713582|9899472|FG008|Overall Study|Death|3
6226857|NCT01713582|9899473|FG009|Overall Study|Death|4
6226858|NCT01713582|9899474|FG010|Overall Study|Death|3
6226859|NCT01713582|9899475|FG011|Overall Study|Death|0
6226860|NCT01713582|9899476|FG012|Overall Study|Death|0
6226861|NCT01713582|9899477|FG013|Overall Study|Death|0
6226862|NCT01713582|9899478|FG014|Overall Study|Death|0
6226863|NCT01713582|9899479|FG015|Overall Study|Death|0
6226864|NCT01713582|9899480|FG016|Overall Study|Death|0
6226865|NCT01713582|9899481|FG017|Overall Study|Death|0
6226866|NCT01713582|9899482|FG018|Overall Study|Death|0
6226867|NCT01713582|9899483|FG019|Overall Study|Death|0
6226868|NCT01713582|9899484|FG020|Overall Study|Death|0
6226869|NCT01713582|9899464|FG000|Overall Study|Adverse event-related|0
6226870|NCT01713582|9899465|FG001|Overall Study|Adverse event-related|0
6226871|NCT01713582|9899466|FG002|Overall Study|Adverse event-related|0
6226872|NCT01713582|9899467|FG003|Overall Study|Adverse event-related|0
6226873|NCT01713582|9899468|FG004|Overall Study|Adverse event-related|0
6226874|NCT01713582|9899469|FG005|Overall Study|Adverse event-related|0
6226875|NCT01713582|9899470|FG006|Overall Study|Adverse event-related|0
6226876|NCT01713582|9899471|FG007|Overall Study|Adverse event-related|0
5988558|NCT02134028|9579676|FG001|Overall Study|Adverse Event|19
5988559|NCT02134028|9579677|FG002|Overall Study|Adverse Event|13
5988560|NCT02134028|9579678|FG003|Overall Study|Adverse Event|32
5988561|NCT02134028|9579679|FG004|Overall Study|Adverse Event|4
5988562|NCT02134028|9579680|FG005|Overall Study|Adverse Event|5
5988563|NCT02134028|9579681|FG006|Overall Study|Adverse Event|1
5988564|NCT02134028|9579682|FG007|Overall Study|Adverse Event|2
6045325|NCT00401830|9644575|FG001|Overall Study|Other: Personal / Family problems|0
6045326|NCT00401843|9644584|FG000|Overall Study|Achieved Complete Response|1
6045327|NCT00401843|9644585|FG001|Overall Study|Achieved Complete Response|5
6045328|NCT00401843|9644586|FG002|Overall Study|Achieved Complete Response|11
6226877|NCT01713582|9899472|FG008|Overall Study|Adverse event-related|0
6226878|NCT01713582|9899473|FG009|Overall Study|Adverse event-related|1
6226879|NCT01713582|9899474|FG010|Overall Study|Adverse event-related|1
6045329|NCT00401843|9644584|FG000|Overall Study|Adverse Event|7
6045330|NCT00401843|9644585|FG001|Overall Study|Adverse Event|26
6045331|NCT00401843|9644586|FG002|Overall Study|Adverse Event|27
6045332|NCT00401843|9644584|FG000|Overall Study|Death|0
6045333|NCT00401843|9644585|FG001|Overall Study|Death|8
6045334|NCT00401843|9644586|FG002|Overall Study|Death|10
6045335|NCT00401843|9644584|FG000|Overall Study|Disease progression|10
6045336|NCT00401843|9644585|FG001|Overall Study|Disease progression|60
6045337|NCT00401843|9644586|FG002|Overall Study|Disease progression|49
6045338|NCT00401843|9644584|FG000|Overall Study|End of Study|1
6045339|NCT00401843|9644585|FG001|Overall Study|End of Study|1
6045340|NCT00401843|9644586|FG002|Overall Study|End of Study|2
6045341|NCT00401843|9644584|FG000|Overall Study|Lost to Follow-up|0
6226880|NCT01713582|9899475|FG011|Overall Study|Adverse event-related|0
6226881|NCT01713582|9899476|FG012|Overall Study|Adverse event-related|0
5988565|NCT01902173|9579712|FG000|Phase 1 Doublet Regimen Cohort 1|Adverse Event|1
5988566|NCT01902173|9579713|FG001|Phase 1 Doublet Regimen Cohort 1|Adverse Event|0
5988567|NCT01902173|9579714|FG002|Phase 1 Doublet Regimen Cohort 1|Adverse Event|0
5988568|NCT01902173|9579715|FG003|Phase 1 Doublet Regimen Cohort 1|Adverse Event|0
5988569|NCT01902173|9579716|FG004|Phase 1 Doublet Regimen Cohort 1|Adverse Event|0
5988570|NCT01902173|9579717|FG005|Phase 1 Doublet Regimen Cohort 1|Adverse Event|0
5988571|NCT01902173|9579712|FG000|Phase 1 Doublet Regimen Cohort 1|Progression/relapse|2
5988572|NCT01902173|9579713|FG001|Phase 1 Doublet Regimen Cohort 1|Progression/relapse|0
5988573|NCT01902173|9579714|FG002|Phase 1 Doublet Regimen Cohort 1|Progression/relapse|0
5988574|NCT01902173|9579715|FG003|Phase 1 Doublet Regimen Cohort 1|Progression/relapse|0
5988575|NCT01902173|9579716|FG004|Phase 1 Doublet Regimen Cohort 1|Progression/relapse|0
5988576|NCT01902173|9579717|FG005|Phase 1 Doublet Regimen Cohort 1|Progression/relapse|0
5988577|NCT01902173|9579712|FG000|Phase 1 Doublet Regimen Cohort 2|Progression/relapse|0
5988578|NCT01902173|9579713|FG001|Phase 1 Doublet Regimen Cohort 2|Progression/relapse|5
5988579|NCT01902173|9579714|FG002|Phase 1 Doublet Regimen Cohort 2|Progression/relapse|0
5988580|NCT01902173|9579715|FG003|Phase 1 Doublet Regimen Cohort 2|Progression/relapse|0
5988581|NCT01902173|9579716|FG004|Phase 1 Doublet Regimen Cohort 2|Progression/relapse|0
5988582|NCT01902173|9579717|FG005|Phase 1 Doublet Regimen Cohort 2|Progression/relapse|0
5988583|NCT01902173|9579712|FG000|Phase 1 Doublet Regimen Cohort 2|Ineligible|0
5988584|NCT01902173|9579713|FG001|Phase 1 Doublet Regimen Cohort 2|Ineligible|1
5988585|NCT01902173|9579714|FG002|Phase 1 Doublet Regimen Cohort 2|Ineligible|0
5988586|NCT01902173|9579715|FG003|Phase 1 Doublet Regimen Cohort 2|Ineligible|0
5988587|NCT01902173|9579716|FG004|Phase 1 Doublet Regimen Cohort 2|Ineligible|0
5988588|NCT01902173|9579717|FG005|Phase 1 Doublet Regimen Cohort 2|Ineligible|0
5988589|NCT01902173|9579712|FG000|Phase 1 Doublet Regimen Cohort 2|No treated|0
5988590|NCT01902173|9579713|FG001|Phase 1 Doublet Regimen Cohort 2|No treated|3
5988591|NCT01902173|9579714|FG002|Phase 1 Doublet Regimen Cohort 2|No treated|0
5988592|NCT01902173|9579715|FG003|Phase 1 Doublet Regimen Cohort 2|No treated|0
5988593|NCT01902173|9579716|FG004|Phase 1 Doublet Regimen Cohort 2|No treated|0
5988594|NCT01902173|9579717|FG005|Phase 1 Doublet Regimen Cohort 2|No treated|0
5988595|NCT01902173|9579712|FG000|Phase 1 Triplet Regimen Cohort 1|Progression/relapse|0
5988596|NCT01902173|9579713|FG001|Phase 1 Triplet Regimen Cohort 1|Progression/relapse|0
5988597|NCT01902173|9579714|FG002|Phase 1 Triplet Regimen Cohort 1|Progression/relapse|3
6226882|NCT01713582|9899477|FG013|Overall Study|Adverse event-related|0
6226883|NCT01713582|9899478|FG014|Overall Study|Adverse event-related|0
6226884|NCT01713582|9899479|FG015|Overall Study|Adverse event-related|0
6226885|NCT01713582|9899480|FG016|Overall Study|Adverse event-related|0
6226886|NCT01713582|9899481|FG017|Overall Study|Adverse event-related|0
5988598|NCT01902173|9579715|FG003|Phase 1 Triplet Regimen Cohort 1|Progression/relapse|0
5988599|NCT01902173|9579716|FG004|Phase 1 Triplet Regimen Cohort 1|Progression/relapse|0
5988600|NCT01902173|9579717|FG005|Phase 1 Triplet Regimen Cohort 1|Progression/relapse|0
5988601|NCT01902173|9579712|FG000|Phase 1 Triplet Regimen Cohort 1|Ineligible|0
5988602|NCT01902173|9579713|FG001|Phase 1 Triplet Regimen Cohort 1|Ineligible|0
5988603|NCT01902173|9579714|FG002|Phase 1 Triplet Regimen Cohort 1|Ineligible|1
5988604|NCT01902173|9579715|FG003|Phase 1 Triplet Regimen Cohort 1|Ineligible|0
5988605|NCT01902173|9579716|FG004|Phase 1 Triplet Regimen Cohort 1|Ineligible|0
5988606|NCT01902173|9579717|FG005|Phase 1 Triplet Regimen Cohort 1|Ineligible|0
5988607|NCT01902173|9579712|FG000|Phase 1 Triplet Regimen Cohort 2|Ongoing treatment|0
5988608|NCT01902173|9579713|FG001|Phase 1 Triplet Regimen Cohort 2|Ongoing treatment|0
5988609|NCT01902173|9579714|FG002|Phase 1 Triplet Regimen Cohort 2|Ongoing treatment|0
5988610|NCT01902173|9579715|FG003|Phase 1 Triplet Regimen Cohort 2|Ongoing treatment|1
5988611|NCT01902173|9579716|FG004|Phase 1 Triplet Regimen Cohort 2|Ongoing treatment|0
5988612|NCT01902173|9579717|FG005|Phase 1 Triplet Regimen Cohort 2|Ongoing treatment|0
5988613|NCT01902173|9579712|FG000|Phase 1 Triplet Regimen Cohort 2|Progression/relapse|0
5988614|NCT01902173|9579713|FG001|Phase 1 Triplet Regimen Cohort 2|Progression/relapse|0
5988615|NCT01902173|9579714|FG002|Phase 1 Triplet Regimen Cohort 2|Progression/relapse|0
6226887|NCT01713582|9899482|FG018|Overall Study|Adverse event-related|1
6226888|NCT01713582|9899483|FG019|Overall Study|Adverse event-related|0
6226889|NCT01713582|9899484|FG020|Overall Study|Adverse event-related|0
6226890|NCT01713582|9899464|FG000|Overall Study|Adverse event-unrelated|0
6226891|NCT01713582|9899465|FG001|Overall Study|Adverse event-unrelated|0
6226892|NCT01713582|9899466|FG002|Overall Study|Adverse event-unrelated|0
6226893|NCT01713582|9899467|FG003|Overall Study|Adverse event-unrelated|0
6226894|NCT01713582|9899468|FG004|Overall Study|Adverse event-unrelated|0
6226895|NCT01713582|9899469|FG005|Overall Study|Adverse event-unrelated|1
5988616|NCT01902173|9579715|FG003|Phase 1 Triplet Regimen Cohort 2|Progression/relapse|2
5988617|NCT01902173|9579716|FG004|Phase 1 Triplet Regimen Cohort 2|Progression/relapse|0
5988618|NCT01902173|9579717|FG005|Phase 1 Triplet Regimen Cohort 2|Progression/relapse|0
5988619|NCT01902173|9579712|FG000|Phase 1 Triplet Regimen Cohort 3|Ongoing|0
5988620|NCT01902173|9579713|FG001|Phase 1 Triplet Regimen Cohort 3|Ongoing|0
5988621|NCT01902173|9579714|FG002|Phase 1 Triplet Regimen Cohort 3|Ongoing|0
5988622|NCT01902173|9579715|FG003|Phase 1 Triplet Regimen Cohort 3|Ongoing|0
5988623|NCT01902173|9579716|FG004|Phase 1 Triplet Regimen Cohort 3|Ongoing|1
5988624|NCT01902173|9579717|FG005|Phase 1 Triplet Regimen Cohort 3|Ongoing|0
5988625|NCT01902173|9579712|FG000|Phase 1 Triplet Regimen Cohort 3|Progression/relapse|0
5988626|NCT01902173|9579713|FG001|Phase 1 Triplet Regimen Cohort 3|Progression/relapse|0
5988627|NCT01902173|9579714|FG002|Phase 1 Triplet Regimen Cohort 3|Progression/relapse|0
5988628|NCT01902173|9579715|FG003|Phase 1 Triplet Regimen Cohort 3|Progression/relapse|0
5988629|NCT01902173|9579716|FG004|Phase 1 Triplet Regimen Cohort 3|Progression/relapse|2
6226896|NCT01713582|9899470|FG006|Overall Study|Adverse event-unrelated|1
6226897|NCT01713582|9899471|FG007|Overall Study|Adverse event-unrelated|1
6226898|NCT01713582|9899472|FG008|Overall Study|Adverse event-unrelated|0
6226899|NCT01713582|9899473|FG009|Overall Study|Adverse event-unrelated|0
6226900|NCT01713582|9899474|FG010|Overall Study|Adverse event-unrelated|0
6226901|NCT01713582|9899475|FG011|Overall Study|Adverse event-unrelated|0
6226902|NCT01713582|9899476|FG012|Overall Study|Adverse event-unrelated|0
6226903|NCT01713582|9899477|FG013|Overall Study|Adverse event-unrelated|1
6226904|NCT01713582|9899478|FG014|Overall Study|Adverse event-unrelated|1
6226905|NCT01713582|9899479|FG015|Overall Study|Adverse event-unrelated|0
6226906|NCT01713582|9899480|FG016|Overall Study|Adverse event-unrelated|0
6226907|NCT01713582|9899481|FG017|Overall Study|Adverse event-unrelated|0
6226908|NCT01713582|9899482|FG018|Overall Study|Adverse event-unrelated|0
6226909|NCT01713582|9899483|FG019|Overall Study|Adverse event-unrelated|0
6226910|NCT01713582|9899484|FG020|Overall Study|Adverse event-unrelated|0
6226911|NCT01713582|9899464|FG000|Overall Study|Withdrawal of consent|0
6226912|NCT01713582|9899465|FG001|Overall Study|Withdrawal of consent|0
6226913|NCT01713582|9899466|FG002|Overall Study|Withdrawal of consent|1
6226914|NCT01713582|9899467|FG003|Overall Study|Withdrawal of consent|0
6226915|NCT01713582|9899468|FG004|Overall Study|Withdrawal of consent|0
6226916|NCT01713582|9899469|FG005|Overall Study|Withdrawal of consent|1
6226917|NCT01713582|9899470|FG006|Overall Study|Withdrawal of consent|0
5988630|NCT01902173|9579717|FG005|Phase 1 Triplet Regimen Cohort 3|Progression/relapse|0
5988631|NCT01902173|9579712|FG000|Phase 1 Triplet Regimen Cohort 4|Adverse Event|0
5988632|NCT01902173|9579713|FG001|Phase 1 Triplet Regimen Cohort 4|Adverse Event|0
5988633|NCT01902173|9579714|FG002|Phase 1 Triplet Regimen Cohort 4|Adverse Event|0
5988634|NCT01902173|9579715|FG003|Phase 1 Triplet Regimen Cohort 4|Adverse Event|0
5988635|NCT01902173|9579716|FG004|Phase 1 Triplet Regimen Cohort 4|Adverse Event|0
5988636|NCT01902173|9579717|FG005|Phase 1 Triplet Regimen Cohort 4|Adverse Event|1
5988637|NCT01902173|9579712|FG000|Phase 1 Triplet Regimen Cohort 4|Progression/relapse|0
5988638|NCT01902173|9579713|FG001|Phase 1 Triplet Regimen Cohort 4|Progression/relapse|0
5988639|NCT01902173|9579714|FG002|Phase 1 Triplet Regimen Cohort 4|Progression/relapse|0
5988640|NCT01902173|9579715|FG003|Phase 1 Triplet Regimen Cohort 4|Progression/relapse|0
5988641|NCT01902173|9579716|FG004|Phase 1 Triplet Regimen Cohort 4|Progression/relapse|0
5988642|NCT01902173|9579717|FG005|Phase 1 Triplet Regimen Cohort 4|Progression/relapse|3
5988643|NCT01902173|9579712|FG000|Phase 1 Triplet Regimen Cohort 4|Death|0
5988644|NCT01902173|9579713|FG001|Phase 1 Triplet Regimen Cohort 4|Death|0
5988645|NCT01902173|9579714|FG002|Phase 1 Triplet Regimen Cohort 4|Death|0
5988646|NCT01902173|9579715|FG003|Phase 1 Triplet Regimen Cohort 4|Death|0
5988647|NCT01902173|9579716|FG004|Phase 1 Triplet Regimen Cohort 4|Death|0
5988648|NCT01902173|9579717|FG005|Phase 1 Triplet Regimen Cohort 4|Death|1
5988649|NCT01900444|9579734|FG000|Overall Study|Protocol Violation|2
5988650|NCT01900444|9579734|FG000|Overall Study|Lost to Follow-up|1
5988651|NCT01887912|9579740|FG000|Overall Study|Serious adverse event|400
5988652|NCT01887912|9579741|FG001|Overall Study|Serious adverse event|198
5988653|NCT01887912|9579740|FG000|Overall Study|Other Adverse Event|34
5988654|NCT01887912|9579741|FG001|Overall Study|Other Adverse Event|15
5988655|NCT01887912|9579740|FG000|Overall Study|Protocol Violation|67
5988656|NCT01887912|9579741|FG001|Overall Study|Protocol Violation|37
6226918|NCT01713582|9899471|FG007|Overall Study|Withdrawal of consent|0
6226919|NCT01713582|9899472|FG008|Overall Study|Withdrawal of consent|0
6226920|NCT01713582|9899473|FG009|Overall Study|Withdrawal of consent|1
6226921|NCT01713582|9899474|FG010|Overall Study|Withdrawal of consent|0
6226922|NCT01713582|9899475|FG011|Overall Study|Withdrawal of consent|0
6226923|NCT01713582|9899476|FG012|Overall Study|Withdrawal of consent|0
6226924|NCT01713582|9899477|FG013|Overall Study|Withdrawal of consent|0
6226925|NCT01713582|9899478|FG014|Overall Study|Withdrawal of consent|0
6226926|NCT01713582|9899479|FG015|Overall Study|Withdrawal of consent|0
6226927|NCT01713582|9899480|FG016|Overall Study|Withdrawal of consent|0
5988657|NCT01887912|9579740|FG000|Overall Study|Lost to Follow-up|163
5988658|NCT01887912|9579741|FG001|Overall Study|Lost to Follow-up|74
5988659|NCT01887912|9579740|FG000|Overall Study|Withdrawal by Subject|606
5988660|NCT01887912|9579741|FG001|Overall Study|Withdrawal by Subject|349
6226928|NCT01713582|9899481|FG017|Overall Study|Withdrawal of consent|0
5988661|NCT01887912|9579740|FG000|Overall Study|Other|122
6226929|NCT01713582|9899482|FG018|Overall Study|Withdrawal of consent|1
5988662|NCT01887912|9579741|FG001|Overall Study|Other|58
6226930|NCT01713582|9899483|FG019|Overall Study|Withdrawal of consent|0
5988663|NCT01437423|9579784|FG000|Overall Study|Lost to Follow-up|12
5988664|NCT01437423|9579784|FG000|Overall Study|Off label usage|3
5988665|NCT01410890|9579790|FG000|Overall Study|Withdrawal by Subject|0
6226931|NCT01713582|9899484|FG020|Overall Study|Withdrawal of consent|0
6226932|NCT01713582|9899464|FG000|Overall Study|Lack of Efficacy|0
6226933|NCT01713582|9899465|FG001|Overall Study|Lack of Efficacy|0
6226934|NCT01713582|9899466|FG002|Overall Study|Lack of Efficacy|0
6226935|NCT01713582|9899467|FG003|Overall Study|Lack of Efficacy|0
6226936|NCT01713582|9899468|FG004|Overall Study|Lack of Efficacy|0
6226937|NCT01713582|9899469|FG005|Overall Study|Lack of Efficacy|0
6226938|NCT01713582|9899470|FG006|Overall Study|Lack of Efficacy|0
6226939|NCT01713582|9899471|FG007|Overall Study|Lack of Efficacy|0
6226940|NCT01713582|9899472|FG008|Overall Study|Lack of Efficacy|0
6226941|NCT01713582|9899473|FG009|Overall Study|Lack of Efficacy|1
6226942|NCT01713582|9899474|FG010|Overall Study|Lack of Efficacy|2
6226943|NCT01713582|9899475|FG011|Overall Study|Lack of Efficacy|0
6226944|NCT01713582|9899476|FG012|Overall Study|Lack of Efficacy|0
6226945|NCT01713582|9899477|FG013|Overall Study|Lack of Efficacy|0
6226946|NCT01713582|9899478|FG014|Overall Study|Lack of Efficacy|0
6226947|NCT01713582|9899479|FG015|Overall Study|Lack of Efficacy|0
6226948|NCT01713582|9899480|FG016|Overall Study|Lack of Efficacy|0
6226949|NCT01713582|9899481|FG017|Overall Study|Lack of Efficacy|0
6226950|NCT01713582|9899482|FG018|Overall Study|Lack of Efficacy|0
6226951|NCT01713582|9899483|FG019|Overall Study|Lack of Efficacy|0
6226952|NCT01713582|9899484|FG020|Overall Study|Lack of Efficacy|0
5988666|NCT01410890|9579791|FG001|Overall Study|Withdrawal by Subject|1
6226953|NCT01713582|9899464|FG000|Overall Study|Withdrawal by Subject|0
5988667|NCT01251861|9579801|FG000|Overall Study|Disease progression|6
5988668|NCT01251861|9579802|FG001|Overall Study|Disease progression|6
5988669|NCT01251861|9579801|FG000|Overall Study|Adverse Event|2
5988670|NCT01251861|9579802|FG001|Overall Study|Adverse Event|17
5988671|NCT01251861|9579801|FG000|Overall Study|Withdrawal by Subject|2
5988672|NCT01251861|9579802|FG001|Overall Study|Withdrawal by Subject|2
5988673|NCT01251861|9579801|FG000|Overall Study|Alternative therapy|1
6226954|NCT01713582|9899465|FG001|Overall Study|Withdrawal by Subject|0
6226955|NCT01713582|9899466|FG002|Overall Study|Withdrawal by Subject|0
6226956|NCT01713582|9899467|FG003|Overall Study|Withdrawal by Subject|0
6226957|NCT01713582|9899468|FG004|Overall Study|Withdrawal by Subject|0
6226958|NCT01713582|9899469|FG005|Overall Study|Withdrawal by Subject|0
6226959|NCT01713582|9899470|FG006|Overall Study|Withdrawal by Subject|0
6226960|NCT01713582|9899471|FG007|Overall Study|Withdrawal by Subject|0
6226961|NCT01713582|9899472|FG008|Overall Study|Withdrawal by Subject|0
6226962|NCT01713582|9899473|FG009|Overall Study|Withdrawal by Subject|0
6226963|NCT01713582|9899474|FG010|Overall Study|Withdrawal by Subject|0
6226964|NCT01713582|9899475|FG011|Overall Study|Withdrawal by Subject|0
6226965|NCT01713582|9899476|FG012|Overall Study|Withdrawal by Subject|0
6226966|NCT01713582|9899477|FG013|Overall Study|Withdrawal by Subject|0
6226967|NCT01713582|9899478|FG014|Overall Study|Withdrawal by Subject|0
5988674|NCT01251861|9579802|FG001|Overall Study|Alternative therapy|0
5988675|NCT01251861|9579801|FG000|Overall Study|Other complicating disease|0
5988676|NCT01251861|9579802|FG001|Overall Study|Other complicating disease|1
5988677|NCT01251861|9579801|FG000|Overall Study|Physician Decision|1
5988678|NCT01251861|9579802|FG001|Overall Study|Physician Decision|0
5988679|NCT01251861|9579801|FG000|Overall Study|Continued treatment beyond 18 cycles|1
5988680|NCT01251861|9579802|FG001|Overall Study|Continued treatment beyond 18 cycles|0
5988681|NCT01251861|9579801|FG000|Overall Study|Other|1
5988682|NCT01251861|9579802|FG001|Overall Study|Other|0
5988683|NCT01251861|9579801|FG000|Overall Study|Never started therapy|4
5988684|NCT01251861|9579802|FG001|Overall Study|Never started therapy|1
5988685|NCT01251861|9579801|FG000|Overall Study|Potential interaction of drugs|0
5988686|NCT01251861|9579802|FG001|Overall Study|Potential interaction of drugs|1
6226968|NCT01713582|9899479|FG015|Overall Study|Withdrawal by Subject|0
6226969|NCT01713582|9899480|FG016|Overall Study|Withdrawal by Subject|0
6226970|NCT01713582|9899481|FG017|Overall Study|Withdrawal by Subject|1
6226971|NCT01713582|9899482|FG018|Overall Study|Withdrawal by Subject|0
6226972|NCT01713582|9899483|FG019|Overall Study|Withdrawal by Subject|0
6226973|NCT01713582|9899484|FG020|Overall Study|Withdrawal by Subject|0
6226974|NCT01713582|9899464|FG000|Overall Study|Stopped to receive bone marrow graft|0
6226975|NCT01713582|9899465|FG001|Overall Study|Stopped to receive bone marrow graft|0
6226976|NCT01713582|9899466|FG002|Overall Study|Stopped to receive bone marrow graft|0
6226977|NCT01713582|9899467|FG003|Overall Study|Stopped to receive bone marrow graft|0
6226978|NCT01713582|9899468|FG004|Overall Study|Stopped to receive bone marrow graft|0
6226979|NCT01713582|9899469|FG005|Overall Study|Stopped to receive bone marrow graft|0
6226980|NCT01713582|9899470|FG006|Overall Study|Stopped to receive bone marrow graft|0
6226981|NCT01713582|9899471|FG007|Overall Study|Stopped to receive bone marrow graft|0
6226982|NCT01713582|9899472|FG008|Overall Study|Stopped to receive bone marrow graft|0
6226983|NCT01713582|9899473|FG009|Overall Study|Stopped to receive bone marrow graft|0
6226984|NCT01713582|9899474|FG010|Overall Study|Stopped to receive bone marrow graft|0
6226985|NCT01713582|9899475|FG011|Overall Study|Stopped to receive bone marrow graft|0
6226986|NCT01713582|9899476|FG012|Overall Study|Stopped to receive bone marrow graft|0
6226987|NCT01713582|9899477|FG013|Overall Study|Stopped to receive bone marrow graft|0
6226988|NCT01713582|9899478|FG014|Overall Study|Stopped to receive bone marrow graft|0
6226989|NCT01713582|9899479|FG015|Overall Study|Stopped to receive bone marrow graft|0
6226990|NCT01713582|9899480|FG016|Overall Study|Stopped to receive bone marrow graft|1
6226991|NCT01713582|9899481|FG017|Overall Study|Stopped to receive bone marrow graft|0
6226992|NCT01713582|9899482|FG018|Overall Study|Stopped to receive bone marrow graft|0
6226993|NCT01713582|9899483|FG019|Overall Study|Stopped to receive bone marrow graft|0
6226994|NCT01713582|9899484|FG020|Overall Study|Stopped to receive bone marrow graft|0
6226995|NCT01713582|9899464|FG000|Overall Study|Disease progression and adverse event|0
6226996|NCT01713582|9899465|FG001|Overall Study|Disease progression and adverse event|0
6226997|NCT01713582|9899466|FG002|Overall Study|Disease progression and adverse event|0
6226998|NCT01713582|9899467|FG003|Overall Study|Disease progression and adverse event|0
6226999|NCT01713582|9899468|FG004|Overall Study|Disease progression and adverse event|0
6227000|NCT01713582|9899469|FG005|Overall Study|Disease progression and adverse event|0
6227001|NCT01713582|9899470|FG006|Overall Study|Disease progression and adverse event|0
6227002|NCT01713582|9899471|FG007|Overall Study|Disease progression and adverse event|0
5988687|NCT01190228|9579811|FG000|Overall Study|Protocol Violation|4
5988688|NCT01190228|9579812|FG001|Overall Study|Protocol Violation|0
5988689|NCT01190228|9579813|FG002|Overall Study|Protocol Violation|0
5988690|NCT01190228|9579811|FG000|Overall Study|Withdrawal by Subject|1
5988691|NCT01190228|9579812|FG001|Overall Study|Withdrawal by Subject|0
5988692|NCT01190228|9579813|FG002|Overall Study|Withdrawal by Subject|0
5988693|NCT01146652|9579825|FG000|Overall Study|Adverse Event|506
5988694|NCT01146652|9579826|FG001|Overall Study|Adverse Event|15
5988695|NCT01146652|9579825|FG000|Overall Study|Lack of Efficacy|91
5988696|NCT01146652|9579826|FG001|Overall Study|Lack of Efficacy|7
5988697|NCT01146652|9579825|FG000|Overall Study|Poor compliance to protocol|38
5988698|NCT01146652|9579826|FG001|Overall Study|Poor compliance to protocol|1
5988699|NCT01146652|9579825|FG000|Overall Study|Other unspecified reasons|314
5988700|NCT01146652|9579826|FG001|Overall Study|Other unspecified reasons|22
5988701|NCT01146652|9579825|FG000|Overall Study|Enrolled but not treated|2
5988702|NCT01146652|9579826|FG001|Overall Study|Enrolled but not treated|0
5988703|NCT01049035|9579846|FG000|Overall Study|Serious adverse event|0
5988704|NCT01049035|9579847|FG001|Overall Study|Serious adverse event|1
5988705|NCT01049035|9579848|FG002|Overall Study|Serious adverse event|1
5988706|NCT01049035|9579849|FG003|Overall Study|Serious adverse event|2
5988707|NCT01049035|9579850|FG004|Overall Study|Serious adverse event|0
5988708|NCT01049035|9579851|FG005|Overall Study|Serious adverse event|0
5988709|NCT01049035|9579852|FG006|Overall Study|Serious adverse event|0
5988710|NCT01049035|9579846|FG000|Overall Study|Other adverse event (AE)|0
5988711|NCT01049035|9579847|FG001|Overall Study|Other adverse event (AE)|0
5988712|NCT01049035|9579848|FG002|Overall Study|Other adverse event (AE)|0
6227003|NCT01713582|9899472|FG008|Overall Study|Disease progression and adverse event|0
6227004|NCT01713582|9899473|FG009|Overall Study|Disease progression and adverse event|0
6227005|NCT01713582|9899474|FG010|Overall Study|Disease progression and adverse event|0
6227006|NCT01713582|9899475|FG011|Overall Study|Disease progression and adverse event|0
6227007|NCT01713582|9899476|FG012|Overall Study|Disease progression and adverse event|0
6227008|NCT01713582|9899477|FG013|Overall Study|Disease progression and adverse event|0
6227009|NCT01713582|9899478|FG014|Overall Study|Disease progression and adverse event|0
6227010|NCT01713582|9899479|FG015|Overall Study|Disease progression and adverse event|0
6227011|NCT01713582|9899480|FG016|Overall Study|Disease progression and adverse event|1
6227012|NCT01713582|9899481|FG017|Overall Study|Disease progression and adverse event|0
6227013|NCT01713582|9899482|FG018|Overall Study|Disease progression and adverse event|0
6227014|NCT01713582|9899483|FG019|Overall Study|Disease progression and adverse event|0
6227015|NCT01713582|9899484|FG020|Overall Study|Disease progression and adverse event|0
6227016|NCT01713686|9899571|FG000|Overall Study|Lost to Follow-up|9
6227017|NCT01713686|9899571|FG000|Overall Study|Withdrawal by Subject|6
6227018|NCT01713933|9899594|FG000|Overall Study|Lost to Follow-up|2
6227019|NCT01713933|9899594|FG000|Overall Study|Withdrawal by Subject|3
6227020|NCT01713933|9899594|FG000|Overall Study|Excluded from analysis as a BMI outlier|1
6227021|NCT01713946|9899601|FG000|Overall Study|Death|0
6227022|NCT01713946|9899602|FG001|Overall Study|Death|2
6227023|NCT01713946|9899603|FG002|Overall Study|Death|2
6227024|NCT01713946|9899601|FG000|Overall Study|Adverse Event|19
6227025|NCT01713946|9899602|FG001|Overall Study|Adverse Event|14
6227026|NCT01713946|9899603|FG002|Overall Study|Adverse Event|13
6227027|NCT01713946|9899601|FG000|Overall Study|Withdrawal by Subject|12
6227028|NCT01713946|9899602|FG001|Overall Study|Withdrawal by Subject|12
6227029|NCT01713946|9899603|FG002|Overall Study|Withdrawal by Subject|8
6227030|NCT01713946|9899601|FG000|Overall Study|Lack of Efficacy|8
6227031|NCT01713946|9899602|FG001|Overall Study|Lack of Efficacy|8
6227032|NCT01713946|9899603|FG002|Overall Study|Lack of Efficacy|14
5988713|NCT01049035|9579849|FG003|Overall Study|Other adverse event (AE)|1
5988714|NCT01049035|9579850|FG004|Overall Study|Other adverse event (AE)|0
5988715|NCT01049035|9579851|FG005|Overall Study|Other adverse event (AE)|0
6227033|NCT01713946|9899601|FG000|Overall Study|Protocol Violation|2
5988716|NCT01049035|9579852|FG006|Overall Study|Other adverse event (AE)|0
5988717|NCT01049035|9579846|FG000|Overall Study|Non-compliance with the protocol|12
5988718|NCT01049035|9579847|FG001|Overall Study|Non-compliance with the protocol|6
5988719|NCT01049035|9579848|FG002|Overall Study|Non-compliance with the protocol|14
5988720|NCT01049035|9579849|FG003|Overall Study|Non-compliance with the protocol|5
5988721|NCT01049035|9579850|FG004|Overall Study|Non-compliance with the protocol|3
5988722|NCT01049035|9579851|FG005|Overall Study|Non-compliance with the protocol|4
5988723|NCT01049035|9579852|FG006|Overall Study|Non-compliance with the protocol|10
5988724|NCT01049035|9579846|FG000|Overall Study|Lost to Follow-up|5
5988725|NCT01049035|9579847|FG001|Overall Study|Lost to Follow-up|4
5988726|NCT01049035|9579848|FG002|Overall Study|Lost to Follow-up|4
5988727|NCT01049035|9579849|FG003|Overall Study|Lost to Follow-up|1
5988728|NCT01049035|9579850|FG004|Overall Study|Lost to Follow-up|0
5988729|NCT01049035|9579851|FG005|Overall Study|Lost to Follow-up|3
5988730|NCT01049035|9579852|FG006|Overall Study|Lost to Follow-up|3
5988731|NCT01049035|9579846|FG000|Overall Study|Voluntary withdrawal not due to an AE|16
6227034|NCT01713946|9899602|FG001|Overall Study|Protocol Violation|4
6227035|NCT01713946|9899603|FG002|Overall Study|Protocol Violation|1
6227036|NCT01713946|9899601|FG000|Overall Study|Lost to Follow-up|0
6227037|NCT01713946|9899602|FG001|Overall Study|Lost to Follow-up|0
6227038|NCT01713946|9899603|FG002|Overall Study|Lost to Follow-up|1
6227039|NCT01713946|9899601|FG000|Overall Study|Administrative problems|1
6227040|NCT01713946|9899602|FG001|Overall Study|Administrative problems|0
6227041|NCT01713946|9899603|FG002|Overall Study|Administrative problems|0
6227042|NCT01713946|9899601|FG000|Overall Study|Did not continue in Ext|0
6227043|NCT01713946|9899602|FG001|Overall Study|Did not continue in Ext|3
6227044|NCT01713946|9899603|FG002|Overall Study|Did not continue in Ext|0
6227045|NCT01713946|9899601|FG000|Overall Study|Did not continue in Post-Ext. Phase|1
6227046|NCT01713946|9899602|FG001|Overall Study|Did not continue in Post-Ext. Phase|2
6227047|NCT01713946|9899603|FG002|Overall Study|Did not continue in Post-Ext. Phase|0
6227048|NCT01713946|9899601|FG000|Overall Study|Patients never switched to everolimus|0
6227049|NCT01713946|9899602|FG001|Overall Study|Patients never switched to everolimus|0
6227050|NCT01713946|9899603|FG002|Overall Study|Patients never switched to everolimus|5
6227051|NCT01713998|9899632|FG000|Overall Study|Lost to Follow-up|2
6227052|NCT01713998|9899633|FG001|Overall Study|Lost to Follow-up|0
6227053|NCT01713998|9899634|FG002|Overall Study|Lost to Follow-up|2
6227054|NCT01713998|9899632|FG000|Overall Study|Withdrawal by Subject|1
6227055|NCT01713998|9899633|FG001|Overall Study|Withdrawal by Subject|0
6227056|NCT01713998|9899634|FG002|Overall Study|Withdrawal by Subject|0
6227057|NCT01714063|9899664|FG000|Overall Study|Equipment malfunction|2
6227058|NCT01714310|9899679|FG000|Open Lisdexamfetamine Titration|Protocol Violation|0
6227059|NCT01714310|9899680|FG001|Open Lisdexamfetamine Titration|Protocol Violation|0
6227060|NCT01714310|9899681|FG002|Open Lisdexamfetamine Titration|Protocol Violation|1
6227061|NCT01714310|9899679|FG000|Open Lisdexamfetamine Titration|Adverse Event|0
6227062|NCT01714310|9899680|FG001|Open Lisdexamfetamine Titration|Adverse Event|0
6227063|NCT01714310|9899681|FG002|Open Lisdexamfetamine Titration|Adverse Event|3
6227064|NCT01714310|9899679|FG000|Double Blind Adjunctive Treatment|Adverse Event|1
6227065|NCT01714310|9899680|FG001|Double Blind Adjunctive Treatment|Adverse Event|1
5988732|NCT01049035|9579847|FG001|Overall Study|Voluntary withdrawal not due to an AE|10
5988733|NCT01049035|9579848|FG002|Overall Study|Voluntary withdrawal not due to an AE|8
5988734|NCT01049035|9579849|FG003|Overall Study|Voluntary withdrawal not due to an AE|2
5988735|NCT01049035|9579850|FG004|Overall Study|Voluntary withdrawal not due to an AE|1
6227066|NCT01714310|9899681|FG002|Double Blind Adjunctive Treatment|Adverse Event|0
6227067|NCT01714310|9899679|FG000|Double Blind Adjunctive Treatment|Protocol Violation|1
5988736|NCT01049035|9579851|FG005|Overall Study|Voluntary withdrawal not due to an AE|5
5988737|NCT01049035|9579852|FG006|Overall Study|Voluntary withdrawal not due to an AE|2
5988738|NCT00728884|9579878|FG000|Permanent Prosthesis Placement|Lost to Follow-up|13
5988739|NCT00728884|9579878|FG000|One Year Post Placement Follow-up|Lost to Follow-up|4
5988740|NCT00726063|9579895|FG000|Overall Study|Adverse Event|9
5988741|NCT00726063|9579896|FG001|Overall Study|Adverse Event|7
5988742|NCT00713206|9579913|FG000|Overall Study|Lost to Follow-up|4
5988743|NCT00713206|9579914|FG001|Overall Study|Lost to Follow-up|4
5988744|NCT00713206|9579913|FG000|Overall Study|Death|1
5988745|NCT00713206|9579914|FG001|Overall Study|Death|0
5988746|NCT00658814|9579922|FG000|Remission Induction Chemotherapy|Adverse Event|1
6227068|NCT01714310|9899680|FG001|Double Blind Adjunctive Treatment|Protocol Violation|2
6227069|NCT01714310|9899681|FG002|Double Blind Adjunctive Treatment|Protocol Violation|0
6227070|NCT01714544|9899729|FG000|Overall Study|Lost to Follow-up|1
6227071|NCT01714544|9899729|FG000|Overall Study|Physician Decision|1
5988747|NCT00658814|9579923|FG001|Remission Induction Chemotherapy|Adverse Event|3
6227072|NCT01714544|9899729|FG000|Overall Study|Withdrawal by Subject|1
6227073|NCT01714609|9899735|FG000|Overall Study|Protocol Violation|1
6227074|NCT01714609|9899736|FG001|Overall Study|Protocol Violation|0
6227075|NCT01714635|9899745|FG000|Overall Study|Discontinued|1
6227076|NCT01714635|9899746|FG001|Overall Study|Discontinued|0
6227077|NCT01714635|9899747|FG002|Overall Study|Discontinued|2
6227078|NCT01714635|9899745|FG000|Overall Study|Missed 6-month exam|1
6227079|NCT01714635|9899746|FG001|Overall Study|Missed 6-month exam|0
6227080|NCT01714635|9899747|FG002|Overall Study|Missed 6-month exam|0
6227081|NCT01714687|9899757|FG000|Overall Study|Withdrawal by Subject|1
6227082|NCT01714687|9899758|FG001|Overall Study|Withdrawal by Subject|0
6227083|NCT01714687|9899757|FG000|Overall Study|Lost to Follow-up|2
6227084|NCT01714687|9899758|FG001|Overall Study|Lost to Follow-up|4
6227085|NCT01714726|9899768|FG000|Double-Blinded Induction Period|Subject not in open label period|3
6227086|NCT01714726|9899769|FG001|Double-Blinded Induction Period|Subject not in open label period|1
6227087|NCT01714726|9899770|FG002|Double-Blinded Induction Period|Subject not in open label period|0
6227088|NCT01714726|9899771|FG003|Double-Blinded Induction Period|Subject not in open label period|0
6227089|NCT01714726|9899768|FG000|Double-Blinded Induction Period|Adverse Event|0
6227090|NCT01714726|9899769|FG001|Double-Blinded Induction Period|Adverse Event|1
6227091|NCT01714726|9899770|FG002|Double-Blinded Induction Period|Adverse Event|0
5988748|NCT00658814|9579922|FG000|Remission Induction Chemotherapy|Withdrawal by Subject|3
5988749|NCT00658814|9579923|FG001|Remission Induction Chemotherapy|Withdrawal by Subject|4
5988750|NCT00658814|9579922|FG000|Remission Induction Chemotherapy|Progression/Relapse|0
5988751|NCT00658814|9579923|FG001|Remission Induction Chemotherapy|Progression/Relapse|1
5988752|NCT00658814|9579922|FG000|Remission Induction Chemotherapy|Death|1
5988753|NCT00658814|9579923|FG001|Remission Induction Chemotherapy|Death|4
5988754|NCT00658814|9579922|FG000|Remission Induction Chemotherapy|Not protocol specified|2
5988755|NCT00658814|9579923|FG001|Remission Induction Chemotherapy|Not protocol specified|4
5988756|NCT00658814|9579922|FG000|Remission Induction Chemotherapy|Not eligible|1
5988757|NCT00658814|9579923|FG001|Remission Induction Chemotherapy|Not eligible|2
5988758|NCT00658814|9579922|FG000|Consolidation Therapy|Not protocol specified|0
5988759|NCT00658814|9579923|FG001|Consolidation Therapy|Not protocol specified|1
5988760|NCT00658814|9579922|FG000|Consolidation Therapy|Not eligible|2
5988761|NCT00658814|9579923|FG001|Consolidation Therapy|Not eligible|2
5988762|NCT00658814|9579922|FG000|Maintenance Therapy|Adverse Event|1
5988763|NCT00658814|9579923|FG001|Maintenance Therapy|Adverse Event|1
5988764|NCT00658814|9579922|FG000|Maintenance Therapy|Not protocol specified|1
5988765|NCT00658814|9579923|FG001|Maintenance Therapy|Not protocol specified|0
5988766|NCT00658814|9579922|FG000|Maintenance Therapy|Not eligible|1
5988767|NCT00658814|9579923|FG001|Maintenance Therapy|Not eligible|0
5988768|NCT00569127|9579935|FG000|Overall Study|Adverse Event|57
5988769|NCT00569127|9579936|FG001|Overall Study|Adverse Event|47
5988770|NCT00569127|9579935|FG000|Overall Study|Withdrawal by Subject|13
5988771|NCT00569127|9579936|FG001|Overall Study|Withdrawal by Subject|27
5988772|NCT00569127|9579935|FG000|Overall Study|Progression|99
5988773|NCT00569127|9579936|FG001|Overall Study|Progression|100
5988774|NCT00569127|9579935|FG000|Overall Study|Death|4
5988775|NCT00569127|9579936|FG001|Overall Study|Death|3
5988776|NCT00569127|9579935|FG000|Overall Study|Other|20
5988777|NCT00569127|9579936|FG001|Overall Study|Other|19
5988778|NCT00569127|9579935|FG000|Overall Study|Lost to Follow-up|0
5988779|NCT00569127|9579936|FG001|Overall Study|Lost to Follow-up|3
5988780|NCT00569127|9579935|FG000|Overall Study|Not Eligible|14
5988781|NCT00569127|9579936|FG001|Overall Study|Not Eligible|11
5988782|NCT00569127|9579935|FG000|Overall Study|Still on Treatment|7
5988783|NCT00569127|9579936|FG001|Overall Study|Still on Treatment|3
6045342|NCT00401843|9644585|FG001|Overall Study|Lost to Follow-up|0
6045343|NCT00401843|9644586|FG002|Overall Study|Lost to Follow-up|2
6045344|NCT00401843|9644584|FG000|Overall Study|Other Unspecified|0
6045345|NCT00401843|9644585|FG001|Overall Study|Other Unspecified|3
6227092|NCT01714726|9899771|FG003|Double-Blinded Induction Period|Adverse Event|0
6227093|NCT01714726|9899768|FG000|Double-Blinded Induction Period|Withdrawal by Subject|5
6227094|NCT01714726|9899769|FG001|Double-Blinded Induction Period|Withdrawal by Subject|3
5988784|NCT04422990|9579949|FG000|Overall Study|Withdrawal by Subject|0
5988785|NCT04422990|9579950|FG001|Overall Study|Withdrawal by Subject|1
5988786|NCT04422990|9579949|FG000|Overall Study|Travel|3
5988787|NCT04422990|9579950|FG001|Overall Study|Travel|0
5988788|NCT04358549|9579965|FG000|Overall Study|Adverse Event|0
5988789|NCT04358549|9579966|FG001|Overall Study|Adverse Event|1
5988790|NCT04358549|9579965|FG000|Overall Study|Death|1
5988791|NCT04358549|9579966|FG001|Overall Study|Death|0
6227095|NCT01714726|9899770|FG002|Double-Blinded Induction Period|Withdrawal by Subject|0
6227096|NCT01714726|9899771|FG003|Double-Blinded Induction Period|Withdrawal by Subject|0
6227097|NCT01714726|9899768|FG000|Double-Blinded Induction Period|Lost to Follow-up|0
6227098|NCT01714726|9899769|FG001|Double-Blinded Induction Period|Lost to Follow-up|2
6227099|NCT01714726|9899770|FG002|Double-Blinded Induction Period|Lost to Follow-up|0
6227100|NCT01714726|9899771|FG003|Double-Blinded Induction Period|Lost to Follow-up|0
6227101|NCT01714726|9899768|FG000|Open-Label Period|Other|0
6227102|NCT01714726|9899769|FG001|Open-Label Period|Other|0
6227103|NCT01714726|9899770|FG002|Open-Label Period|Other|1
6227104|NCT01714726|9899771|FG003|Open-Label Period|Other|3
6227105|NCT01714726|9899768|FG000|Open-Label Period|Adverse Event|0
6227106|NCT01714726|9899769|FG001|Open-Label Period|Adverse Event|0
6227107|NCT01714726|9899770|FG002|Open-Label Period|Adverse Event|1
6227108|NCT01714726|9899771|FG003|Open-Label Period|Adverse Event|0
6227109|NCT01714726|9899768|FG000|Open-Label Period|Withdrawal by Subject|0
6227110|NCT01714726|9899769|FG001|Open-Label Period|Withdrawal by Subject|0
6227111|NCT01714726|9899770|FG002|Open-Label Period|Withdrawal by Subject|9
6227112|NCT01714726|9899771|FG003|Open-Label Period|Withdrawal by Subject|19
6227113|NCT01714726|9899768|FG000|Open-Label Period|Developed specific withdrawal criteria|0
6227114|NCT01714726|9899769|FG001|Open-Label Period|Developed specific withdrawal criteria|0
6227115|NCT01714726|9899770|FG002|Open-Label Period|Developed specific withdrawal criteria|5
6227116|NCT01714726|9899771|FG003|Open-Label Period|Developed specific withdrawal criteria|2
6227117|NCT01714726|9899768|FG000|Open-Label Period|Lost to Follow-up|0
6227118|NCT01714726|9899769|FG001|Open-Label Period|Lost to Follow-up|0
6227119|NCT01714726|9899770|FG002|Open-Label Period|Lost to Follow-up|3
6227120|NCT01714726|9899771|FG003|Open-Label Period|Lost to Follow-up|4
6227121|NCT01714947|9899797|FG000|Part B|Progressive Disease|3
6227122|NCT01715129|9899810|FG000|Overall Study|Adverse Event, fatal|1
6227123|NCT01715129|9899810|FG000|Overall Study|Lack of Efficacy|3
6227124|NCT01715129|9899810|FG000|Overall Study|Protocol Violation|1
6227125|NCT01715129|9899810|FG000|Overall Study|Consent Withdrawn|2
6227126|NCT01715129|9899810|FG000|Overall Study|Lost to Follow-up|1
6227127|NCT01715129|9899810|FG000|Overall Study|Other|1
6227128|NCT01715298|9899832|FG000|Overall Study|Lost to Follow-up|0
6227129|NCT01715298|9899833|FG001|Overall Study|Lost to Follow-up|2
6227130|NCT01715298|9899832|FG000|Overall Study|Patient/guardian decision|7
6227131|NCT01715298|9899833|FG001|Overall Study|Patient/guardian decision|9
6227132|NCT01715415|9899841|FG000|Double-blind Treatment|Did Not Receive Study Drug|0
6227133|NCT01715415|9899842|FG001|Double-blind Treatment|Did Not Receive Study Drug|1
6227134|NCT01715415|9899841|FG000|Double-blind Treatment|Adverse Event|3
6227135|NCT01715415|9899842|FG001|Double-blind Treatment|Adverse Event|0
6227136|NCT01715415|9899841|FG000|Double-blind Treatment|Withdrawal by Subject|1
6227137|NCT01715415|9899842|FG001|Double-blind Treatment|Withdrawal by Subject|1
6227138|NCT01715415|9899841|FG000|Double-blind Treatment|Other|1
6227139|NCT01715415|9899842|FG001|Double-blind Treatment|Other|0
6227140|NCT01715415|9899841|FG000|Open-label Treatment|Adverse Event|0
6227141|NCT01715415|9899842|FG001|Open-label Treatment|Adverse Event|1
6227142|NCT01715415|9899841|FG000|Open-label Treatment|Subject Noncompliant|0
6227143|NCT01715415|9899842|FG001|Open-label Treatment|Subject Noncompliant|1
6227144|NCT01715571|9899849|FG000|Overall Study|Lost to Follow-up|8
6227145|NCT01715805|9899853|FG000|Placebo + ADT Lead-in Period|Adverse Event|41
6227146|NCT01715805|9899854|FG001|Placebo + ADT Lead-in Period|Adverse Event|0
6227147|NCT01715805|9899855|FG002|Placebo + ADT Lead-in Period|Adverse Event|0
6227148|NCT01715805|9899856|FG003|Placebo + ADT Lead-in Period|Adverse Event|0
6227149|NCT01715805|9899853|FG000|Placebo + ADT Lead-in Period|Insufficient therapeutic response|6
6227150|NCT01715805|9899854|FG001|Placebo + ADT Lead-in Period|Insufficient therapeutic response|0
6227151|NCT01715805|9899855|FG002|Placebo + ADT Lead-in Period|Insufficient therapeutic response|0
6227152|NCT01715805|9899856|FG003|Placebo + ADT Lead-in Period|Insufficient therapeutic response|0
6227153|NCT01715805|9899853|FG000|Placebo + ADT Lead-in Period|Protocol Violation|74
6227154|NCT01715805|9899854|FG001|Placebo + ADT Lead-in Period|Protocol Violation|0
5988792|NCT04358549|9579965|FG000|Overall Study|Lost to Follow-up|2
5988793|NCT04358549|9579966|FG001|Overall Study|Lost to Follow-up|1
6227155|NCT01715805|9899855|FG002|Placebo + ADT Lead-in Period|Protocol Violation|0
6227156|NCT01715805|9899856|FG003|Placebo + ADT Lead-in Period|Protocol Violation|0
6227157|NCT01715805|9899853|FG000|Placebo + ADT Lead-in Period|Withdrawal of Consent|49
6227158|NCT01715805|9899854|FG001|Placebo + ADT Lead-in Period|Withdrawal of Consent|0
5988794|NCT04358549|9579965|FG000|Overall Study|Withdrawal by Subject|6
5988795|NCT04358549|9579966|FG001|Overall Study|Withdrawal by Subject|6
5988796|NCT04358549|9579965|FG000|Overall Study|Start remdesivir|1
5988797|NCT04358549|9579966|FG001|Overall Study|Start remdesivir|0
6227159|NCT01715805|9899855|FG002|Placebo + ADT Lead-in Period|Withdrawal of Consent|0
6227160|NCT01715805|9899856|FG003|Placebo + ADT Lead-in Period|Withdrawal of Consent|0
5988798|NCT04532099|9579995|FG000|First Wear Period (30 Days)|Withdrawal by Subject|1
5988799|NCT04532099|9579996|FG001|First Wear Period (30 Days)|Withdrawal by Subject|0
5988800|NCT04532099|9579997|FG002|First Wear Period (30 Days)|Withdrawal by Subject|0
6045346|NCT00401843|9644586|FG002|Overall Study|Other Unspecified|5
6045347|NCT00401843|9644584|FG000|Overall Study|Physician Decision|0
6045348|NCT00401843|9644585|FG001|Overall Study|Physician Decision|16
6045349|NCT00401843|9644586|FG002|Overall Study|Physician Decision|10
6045350|NCT00401843|9644584|FG000|Overall Study|Protocol Violation|0
6045351|NCT00401843|9644585|FG001|Overall Study|Protocol Violation|0
6045352|NCT00401843|9644586|FG002|Overall Study|Protocol Violation|1
6045353|NCT00401843|9644584|FG000|Overall Study|Withdrawal by Subject|1
6045354|NCT00401843|9644585|FG001|Overall Study|Withdrawal by Subject|5
6045355|NCT00401843|9644586|FG002|Overall Study|Withdrawal by Subject|5
6227161|NCT01715805|9899853|FG000|Placebo + ADT Lead-in Period|Lost to Follow-up|34
6227162|NCT01715805|9899854|FG001|Placebo + ADT Lead-in Period|Lost to Follow-up|0
6227163|NCT01715805|9899855|FG002|Placebo + ADT Lead-in Period|Lost to Follow-up|0
6227164|NCT01715805|9899856|FG003|Placebo + ADT Lead-in Period|Lost to Follow-up|0
6227165|NCT01715805|9899853|FG000|Placebo + ADT Lead-in Period|Site Terminated by Sponsor|1
6227166|NCT01715805|9899854|FG001|Placebo + ADT Lead-in Period|Site Terminated by Sponsor|0
6227167|NCT01715805|9899855|FG002|Placebo + ADT Lead-in Period|Site Terminated by Sponsor|0
6227168|NCT01715805|9899856|FG003|Placebo + ADT Lead-in Period|Site Terminated by Sponsor|0
6227169|NCT01715805|9899853|FG000|Placebo + ADT Lead-in Period|Other Reason Not Specified|10
6227170|NCT01715805|9899854|FG001|Placebo + ADT Lead-in Period|Other Reason Not Specified|0
6227171|NCT01715805|9899855|FG002|Placebo + ADT Lead-in Period|Other Reason Not Specified|0
6227172|NCT01715805|9899856|FG003|Placebo + ADT Lead-in Period|Other Reason Not Specified|0
6227173|NCT01715805|9899853|FG000|Double-Blind or Continued Treatment|Study or Site Terminated by Sponsor|0
6227174|NCT01715805|9899854|FG001|Double-Blind or Continued Treatment|Study or Site Terminated by Sponsor|0
6227175|NCT01715805|9899855|FG002|Double-Blind or Continued Treatment|Study or Site Terminated by Sponsor|0
6227176|NCT01715805|9899856|FG003|Double-Blind or Continued Treatment|Study or Site Terminated by Sponsor|1
6227177|NCT01715805|9899853|FG000|Double-Blind or Continued Treatment|Adverse Event|0
6227178|NCT01715805|9899854|FG001|Double-Blind or Continued Treatment|Adverse Event|3
6227179|NCT01715805|9899855|FG002|Double-Blind or Continued Treatment|Adverse Event|23
6227180|NCT01715805|9899856|FG003|Double-Blind or Continued Treatment|Adverse Event|2
6227181|NCT01715805|9899853|FG000|Double-Blind or Continued Treatment|Protocol Violation|0
6045356|NCT00401843|9644584|FG000|Overall Study|Withdrawal of consent to study agent|1
6045357|NCT00401843|9644585|FG001|Overall Study|Withdrawal of consent to study agent|15
6045358|NCT00401843|9644586|FG002|Overall Study|Withdrawal of consent to study agent|17
6045359|NCT00401843|9644584|FG000|Overall Study|Randomized but not Treated|0
6045360|NCT00401843|9644585|FG001|Overall Study|Randomized but not Treated|2
6045361|NCT00401843|9644586|FG002|Overall Study|Randomized but not Treated|3
6045362|NCT00401843|9644584|FG000|Overall Study|Received incorrect treatment|0
6045363|NCT00401843|9644585|FG001|Overall Study|Received incorrect treatment|3
6045364|NCT00401843|9644586|FG002|Overall Study|Received incorrect treatment|0
6045365|NCT00401960|9644613|FG000|Overall Study|Lost to Follow-up|3
6045366|NCT00401960|9644614|FG001|Overall Study|Lost to Follow-up|0
6045367|NCT00401960|9644613|FG000|Overall Study|Death|2
6045368|NCT00401960|9644614|FG001|Overall Study|Death|0
6045369|NCT00401973|9644625|FG000|Overall Study|Adverse Event|2
6045370|NCT00401973|9644626|FG001|Overall Study|Adverse Event|8
6045371|NCT00401973|9644627|FG002|Overall Study|Adverse Event|4
6045372|NCT00401973|9644625|FG000|Overall Study|Clinical Relapse|0
6045373|NCT00401973|9644626|FG001|Overall Study|Clinical Relapse|1
6045374|NCT00401973|9644627|FG002|Overall Study|Clinical Relapse|1
6045375|NCT00401973|9644625|FG000|Overall Study|Lack of Efficacy|0
6045376|NCT00401973|9644626|FG001|Overall Study|Lack of Efficacy|0
6045377|NCT00401973|9644627|FG002|Overall Study|Lack of Efficacy|3
6045378|NCT00401973|9644625|FG000|Overall Study|Lost to Follow-up|2
6045379|NCT00401973|9644626|FG001|Overall Study|Lost to Follow-up|2
6064726|NCT00515099|9666498|FG000|Overall Study|Withdrawal by Subject|2
6064727|NCT00515099|9666499|FG001|Overall Study|Withdrawal by Subject|0
6064728|NCT00515099|9666498|FG000|Overall Study|IRB Recommendation|1
6064729|NCT00515099|9666499|FG001|Overall Study|IRB Recommendation|0
6064730|NCT00515216|9666524|FG000|Overall Study|Withdrawal by Subject|1
6064731|NCT00515294|9666533|FG000|Overall Study|Lost to Follow-up|3
6064732|NCT00515294|9666534|FG001|Overall Study|Lost to Follow-up|2
6064733|NCT00515294|9666535|FG002|Overall Study|Lost to Follow-up|3
6064734|NCT00515294|9666536|FG003|Overall Study|Lost to Follow-up|1
6064735|NCT00515294|9666533|FG000|Overall Study|Driver simulator problems|1
6064736|NCT00515294|9666534|FG001|Overall Study|Driver simulator problems|1
6064737|NCT00515294|9666535|FG002|Overall Study|Driver simulator problems|1
6064738|NCT00515294|9666536|FG003|Overall Study|Driver simulator problems|3
6064739|NCT00515294|9666533|FG000|Overall Study|Caffeine amount inaccurate|5
6227182|NCT01715805|9899854|FG001|Double-Blind or Continued Treatment|Protocol Violation|14
6045380|NCT00401973|9644627|FG002|Overall Study|Lost to Follow-up|2
6045381|NCT00401973|9644625|FG000|Overall Study|Physician Decision|2
6045382|NCT00401973|9644626|FG001|Overall Study|Physician Decision|0
6045383|NCT00401973|9644627|FG002|Overall Study|Physician Decision|1
6064740|NCT00515294|9666534|FG001|Overall Study|Caffeine amount inaccurate|0
5988801|NCT04385199|9580011|FG000|Overall Study|Withdrawal by Subject|1
5988802|NCT04385199|9580012|FG001|Overall Study|Withdrawal by Subject|0
5988803|NCT04382053|9580020|FG000|Overall Study|Death|6
5988804|NCT04382053|9580021|FG001|Overall Study|Death|8
5988805|NCT04382053|9580020|FG000|Overall Study|Lost to Follow-up|0
5988806|NCT04382053|9580021|FG001|Overall Study|Lost to Follow-up|2
5988807|NCT04382053|9580020|FG000|Overall Study|Protocol Deviation|1
5988808|NCT04382053|9580021|FG001|Overall Study|Protocol Deviation|2
5988809|NCT04382053|9580020|FG000|Overall Study|Withdrawal by Subject|2
6271847|NCT02168387|9973865|FG001|Overall Study|Planned exubation|3
5988810|NCT04382053|9580021|FG001|Overall Study|Withdrawal by Subject|1
5988811|NCT04360187|9580030|FG000|Double-Blind Treatment|Adverse Event|9
5988812|NCT04360187|9580031|FG001|Double-Blind Treatment|Adverse Event|11
5988813|NCT04360187|9580030|FG000|Double-Blind Treatment|Lack of Efficacy|7
5988814|NCT04360187|9580031|FG001|Double-Blind Treatment|Lack of Efficacy|2
5988815|NCT04360187|9580030|FG000|Double-Blind Treatment|Physician Decision|1
5988816|NCT04360187|9580031|FG001|Double-Blind Treatment|Physician Decision|0
5988817|NCT04360187|9580030|FG000|Double-Blind Treatment|Withdrawal by Subject|4
5988818|NCT04360187|9580031|FG001|Double-Blind Treatment|Withdrawal by Subject|2
5988819|NCT04360187|9580030|FG000|Double-Blind Treatment|Withdrawal By Parent/Guardian|2
5988820|NCT04360187|9580031|FG001|Double-Blind Treatment|Withdrawal By Parent/Guardian|0
5988821|NCT04360187|9580030|FG000|Follow-Up|Lost to Follow-up|1
5988822|NCT04360187|9580031|FG001|Follow-Up|Lost to Follow-up|0
5988823|NCT04311177|9580039|FG000|Overall Study|Adverse Event|3
5988824|NCT04311177|9580040|FG001|Overall Study|Adverse Event|1
5988825|NCT04311177|9580039|FG000|Overall Study|Physician Decision|4
5988826|NCT04311177|9580040|FG001|Overall Study|Physician Decision|3
5988827|NCT04311177|9580039|FG000|Overall Study|Withdrawal by Subject|1
5988828|NCT04311177|9580040|FG001|Overall Study|Withdrawal by Subject|0
6227183|NCT01715805|9899855|FG002|Double-Blind or Continued Treatment|Protocol Violation|12
6227184|NCT01715805|9899856|FG003|Double-Blind or Continued Treatment|Protocol Violation|19
6227185|NCT01715805|9899853|FG000|Double-Blind or Continued Treatment|Withdrawal of consent|0
6227186|NCT01715805|9899854|FG001|Double-Blind or Continued Treatment|Withdrawal of consent|11
6227187|NCT01715805|9899855|FG002|Double-Blind or Continued Treatment|Withdrawal of consent|11
6227188|NCT01715805|9899856|FG003|Double-Blind or Continued Treatment|Withdrawal of consent|13
6227189|NCT01715805|9899853|FG000|Double-Blind or Continued Treatment|Lost to Follow-up|0
6227190|NCT01715805|9899854|FG001|Double-Blind or Continued Treatment|Lost to Follow-up|7
6227191|NCT01715805|9899855|FG002|Double-Blind or Continued Treatment|Lost to Follow-up|10
6227192|NCT01715805|9899856|FG003|Double-Blind or Continued Treatment|Lost to Follow-up|10
6227193|NCT01715805|9899853|FG000|Double-Blind or Continued Treatment|Other Reason Not Specified|0
6227194|NCT01715805|9899854|FG001|Double-Blind or Continued Treatment|Other Reason Not Specified|1
6227195|NCT01715805|9899855|FG002|Double-Blind or Continued Treatment|Other Reason Not Specified|0
6227196|NCT01715805|9899856|FG003|Double-Blind or Continued Treatment|Other Reason Not Specified|3
6227197|NCT01715805|9899853|FG000|Double-Blind or Continued Treatment|Did not ingest Double-Blind Treatment|0
6227198|NCT01715805|9899854|FG001|Double-Blind or Continued Treatment|Did not ingest Double-Blind Treatment|3
6045384|NCT00401973|9644625|FG000|Overall Study|Protocol Violation|1
6045385|NCT00401973|9644626|FG001|Overall Study|Protocol Violation|2
6045386|NCT00401973|9644627|FG002|Overall Study|Protocol Violation|3
6045387|NCT00401973|9644625|FG000|Overall Study|Sponsor Decision|0
6045388|NCT00401973|9644626|FG001|Overall Study|Sponsor Decision|1
6045389|NCT00401973|9644627|FG002|Overall Study|Sponsor Decision|0
6045390|NCT00401973|9644625|FG000|Overall Study|Withdrawal by Subject|4
6045391|NCT00401973|9644626|FG001|Overall Study|Withdrawal by Subject|12
6045392|NCT00401973|9644627|FG002|Overall Study|Withdrawal by Subject|9
6045393|NCT00402025|9644649|FG000|Overall Study|Adverse Event|0
6227199|NCT01715805|9899855|FG002|Double-Blind or Continued Treatment|Did not ingest Double-Blind Treatment|0
6227200|NCT01715805|9899856|FG003|Double-Blind or Continued Treatment|Did not ingest Double-Blind Treatment|0
6227201|NCT01715831|9899864|FG000|Overall Study|Adverse Event|1
6227202|NCT01715857|9899868|FG000|Overall Study|Did Not Meet Eligibility Criteria|96
6227203|NCT01715896|9899879|FG000|Overall Study|Lost to Follow-up|0
6227204|NCT01715896|9899880|FG001|Overall Study|Lost to Follow-up|2
6227205|NCT01715896|9899879|FG000|Overall Study|Withdrawal by Subject|1
6227206|NCT01715896|9899880|FG001|Overall Study|Withdrawal by Subject|4
6227207|NCT01715896|9899879|FG000|Overall Study|Other|2
6227208|NCT01715896|9899880|FG001|Overall Study|Other|5
6227209|NCT01716104|9899932|FG000|Overall Study|Do not meet inclusion criteria|6
6227210|NCT01716104|9899933|FG001|Overall Study|Do not meet inclusion criteria|7
6227211|NCT01716156|9899942|FG000|Overall Study|Protocol Violation|1
6227212|NCT01716156|9899943|FG001|Overall Study|Protocol Violation|0
6227213|NCT01716156|9899944|FG002|Overall Study|Protocol Violation|0
6227214|NCT01716156|9899942|FG000|Overall Study|Withdrawal by Subject|0
6227215|NCT01716156|9899943|FG001|Overall Study|Withdrawal by Subject|1
6227216|NCT01716156|9899944|FG002|Overall Study|Withdrawal by Subject|2
6227217|NCT01716156|9899942|FG000|Overall Study|Lost to Follow-up|1
6227218|NCT01716156|9899943|FG001|Overall Study|Lost to Follow-up|0
6227219|NCT01716156|9899944|FG002|Overall Study|Lost to Follow-up|0
6227220|NCT01716169|9899956|FG000|Overall Study|Adverse Event|1
6227221|NCT01716169|9899956|FG000|Overall Study|Lost to Follow-up|1
6227222|NCT01716169|9899956|FG000|Overall Study|Withdrawal by Subject|1
6227223|NCT01716169|9899956|FG000|Overall Study|inconsistent dressing application|1
6045394|NCT00402025|9644650|FG001|Overall Study|Adverse Event|0
6045395|NCT00402025|9644651|FG002|Overall Study|Adverse Event|2
6045396|NCT00402025|9644649|FG000|Overall Study|Death|0
6227224|NCT01716234|9899993|FG000|Overall Study|Protocol Violation|0
6227225|NCT01716234|9899994|FG001|Overall Study|Protocol Violation|0
6227226|NCT01716234|9899995|FG002|Overall Study|Protocol Violation|0
6227227|NCT01716234|9899996|FG003|Overall Study|Protocol Violation|1
6227228|NCT01716234|9899997|FG004|Overall Study|Protocol Violation|1
6045397|NCT00402025|9644650|FG001|Overall Study|Death|1
6045398|NCT00402025|9644651|FG002|Overall Study|Death|5
6045399|NCT00402025|9644649|FG000|Overall Study|Disease Progression|1
5988829|NCT04241133|9580048|FG000|Overall Study|COVID19 Precautions|14
5988830|NCT04241133|9580049|FG001|Overall Study|COVID19 Precautions|34
5988831|NCT04150068|9580079|FG000|Maintenance Period (Week 26 Analysis)|Still on study|24
5988832|NCT04150068|9580080|FG001|Maintenance Period (Week 26 Analysis)|Still on study|12
5988833|NCT04150068|9580081|FG002|Maintenance Period (Week 26 Analysis)|Still on study|35
5988834|NCT04150068|9580079|FG000|Maintenance Period (Week 26 Analysis)|Death|0
5988835|NCT04150068|9580080|FG001|Maintenance Period (Week 26 Analysis)|Death|0
5988836|NCT04150068|9580081|FG002|Maintenance Period (Week 26 Analysis)|Death|1
5988837|NCT04133519|9580090|FG000|Overall Study|Withdrawal by Subject|5
5988838|NCT04133519|9580091|FG001|Overall Study|Withdrawal by Subject|4
5988839|NCT04133519|9580090|FG000|Overall Study|Protocol Violation|0
5988840|NCT04133519|9580091|FG001|Overall Study|Protocol Violation|1
5988841|NCT04133519|9580090|FG000|Overall Study|Never started treatment|1
5988842|NCT04133519|9580091|FG001|Overall Study|Never started treatment|1
6227229|NCT01716234|9899998|FG005|Overall Study|Protocol Violation|1
6227230|NCT01716234|9899999|FG006|Overall Study|Protocol Violation|0
6227231|NCT01716234|9899993|FG000|Overall Study|Lack of Efficacy|0
6227232|NCT01716234|9899994|FG001|Overall Study|Lack of Efficacy|0
6227233|NCT01716234|9899995|FG002|Overall Study|Lack of Efficacy|0
6227234|NCT01716234|9899996|FG003|Overall Study|Lack of Efficacy|1
6227235|NCT01716234|9899997|FG004|Overall Study|Lack of Efficacy|0
6227236|NCT01716234|9899998|FG005|Overall Study|Lack of Efficacy|0
6227237|NCT01716234|9899999|FG006|Overall Study|Lack of Efficacy|0
6227238|NCT01716234|9899993|FG000|Overall Study|Did not meet protocol eligibility|0
6227239|NCT01716234|9899994|FG001|Overall Study|Did not meet protocol eligibility|0
6227240|NCT01716234|9899995|FG002|Overall Study|Did not meet protocol eligibility|1
6227241|NCT01716234|9899996|FG003|Overall Study|Did not meet protocol eligibility|0
6227242|NCT01716234|9899997|FG004|Overall Study|Did not meet protocol eligibility|0
6227243|NCT01716234|9899998|FG005|Overall Study|Did not meet protocol eligibility|4
6227244|NCT01716234|9899999|FG006|Overall Study|Did not meet protocol eligibility|0
6227245|NCT01716234|9899993|FG000|Overall Study|Adverse Event|7
6307337|NCT02603809|10034110|FG000|Overall Study|Pre-specified discontinuation criteria|3
6307338|NCT02603809|10034111|FG001|Overall Study|Pre-specified discontinuation criteria|3
6307339|NCT02603809|10034112|FG002|Overall Study|Pre-specified discontinuation criteria|2
6307340|NCT02603809|10034113|FG003|Overall Study|Pre-specified discontinuation criteria|2
6307341|NCT02603809|10034114|FG004|Overall Study|Pre-specified discontinuation criteria|3
6307342|NCT02603809|10034115|FG005|Overall Study|Pre-specified discontinuation criteria|1
6307343|NCT02603809|10034110|FG000|Overall Study|Physician Decision|0
6307344|NCT02603809|10034111|FG001|Overall Study|Physician Decision|0
6307345|NCT02603809|10034112|FG002|Overall Study|Physician Decision|0
6307346|NCT02603809|10034113|FG003|Overall Study|Physician Decision|1
6307347|NCT02603809|10034114|FG004|Overall Study|Physician Decision|2
6307348|NCT02603809|10034115|FG005|Overall Study|Physician Decision|1
6307349|NCT02603809|10034110|FG000|Overall Study|Adverse Event|3
6307350|NCT02603809|10034111|FG001|Overall Study|Adverse Event|0
6307351|NCT02603809|10034112|FG002|Overall Study|Adverse Event|2
6307352|NCT02603809|10034113|FG003|Overall Study|Adverse Event|2
6307353|NCT02603809|10034114|FG004|Overall Study|Adverse Event|1
6307354|NCT02603809|10034115|FG005|Overall Study|Adverse Event|1
6307355|NCT02603809|10034110|FG000|Overall Study|Lack of Efficacy|0
6307356|NCT02603809|10034111|FG001|Overall Study|Lack of Efficacy|1
6307357|NCT02603809|10034112|FG002|Overall Study|Lack of Efficacy|0
6307358|NCT02603809|10034113|FG003|Overall Study|Lack of Efficacy|0
6307359|NCT02603809|10034114|FG004|Overall Study|Lack of Efficacy|0
6307360|NCT02603809|10034115|FG005|Overall Study|Lack of Efficacy|1
6307361|NCT02603952|10034140|FG000|Overall Study|Withdrawal by Subject|1
6307362|NCT02603952|10034141|FG001|Overall Study|Withdrawal by Subject|0
6307363|NCT02603952|10034142|FG002|Overall Study|Withdrawal by Subject|0
6307364|NCT02603952|10034143|FG003|Overall Study|Withdrawal by Subject|0
6307365|NCT02603952|10034140|FG000|Overall Study|Received oseltamivir by error|0
6307366|NCT02603952|10034141|FG001|Overall Study|Received oseltamivir by error|0
6307367|NCT02603952|10034142|FG002|Overall Study|Received oseltamivir by error|0
6307368|NCT02603952|10034143|FG003|Overall Study|Received oseltamivir by error|1
6307369|NCT02604017|10034158|FG000|Overall Study|Withdrew Consent|0
6307370|NCT02604017|10034159|FG001|Overall Study|Withdrew Consent|2
6307371|NCT02604017|10034158|FG000|Overall Study|Lost to Follow-up|5
6307372|NCT02604017|10034159|FG001|Overall Study|Lost to Follow-up|6
5988843|NCT04098367|9580111|FG000|Overall Study|Adverse Event|0
5988844|NCT04098367|9580112|FG001|Overall Study|Adverse Event|0
5988845|NCT04098367|9580113|FG002|Overall Study|Adverse Event|1
6307373|NCT02604017|10034158|FG000|Overall Study|Other|1
6307374|NCT02604017|10034159|FG001|Overall Study|Other|0
6307375|NCT02604160|10034167|FG000|Overall Study|Protocol Violation|0
6307376|NCT02604160|10034168|FG001|Overall Study|Protocol Violation|1
6307377|NCT02604160|10034167|FG000|Overall Study|Physician Decision|0
6307378|NCT02604160|10034168|FG001|Overall Study|Physician Decision|1
6307379|NCT02604199|10034193|FG000|Overall Study|Pregnancy|0
6307380|NCT02604199|10034194|FG001|Overall Study|Pregnancy|0
6307381|NCT02604199|10034195|FG002|Overall Study|Pregnancy|0
6307382|NCT02604199|10034196|FG003|Overall Study|Pregnancy|1
6307383|NCT02604199|10034193|FG000|Overall Study|Study terminated by sponsor|0
5988846|NCT04098367|9580111|FG000|Overall Study|Lost to Follow-up|1
5988847|NCT04098367|9580112|FG001|Overall Study|Lost to Follow-up|5
5988848|NCT04098367|9580113|FG002|Overall Study|Lost to Follow-up|2
5988849|NCT04098367|9580111|FG000|Overall Study|Withdrawal by Subject|0
5988850|NCT04098367|9580112|FG001|Overall Study|Withdrawal by Subject|0
5988851|NCT04098367|9580113|FG002|Overall Study|Withdrawal by Subject|1
5988852|NCT04098367|9580111|FG000|Overall Study|Sick . Could not attend visit|1
5988853|NCT04098367|9580112|FG001|Overall Study|Sick . Could not attend visit|0
5988854|NCT04098367|9580113|FG002|Overall Study|Sick . Could not attend visit|0
5988855|NCT04091087|9580130|FG000|Overall Study|Not treated|1
5988856|NCT04091087|9580131|FG001|Overall Study|Not treated|0
5988857|NCT04091087|9580130|FG000|Overall Study|Adverse Event|4
5988858|NCT04091087|9580131|FG001|Overall Study|Adverse Event|4
5988859|NCT04091087|9580130|FG000|Overall Study|Protocol Violation|0
5988860|NCT04091087|9580131|FG001|Overall Study|Protocol Violation|1
5988861|NCT04091087|9580130|FG000|Overall Study|Withdrawal by Subject|5
5988862|NCT04091087|9580131|FG001|Overall Study|Withdrawal by Subject|2
5988863|NCT04066023|9580140|FG000|Overall Study|Adverse Event|0
5988864|NCT04066023|9580141|FG001|Overall Study|Adverse Event|0
5988865|NCT04066023|9580142|FG002|Overall Study|Adverse Event|1
5988866|NCT04066023|9580140|FG000|Overall Study|Sponsor decision|3
5988867|NCT04066023|9580141|FG001|Overall Study|Sponsor decision|6
5988868|NCT04066023|9580142|FG002|Overall Study|Sponsor decision|2
5988869|NCT04066023|9580140|FG000|Overall Study|Physician Decision|0
5988870|NCT04066023|9580141|FG001|Overall Study|Physician Decision|0
5988871|NCT04066023|9580142|FG002|Overall Study|Physician Decision|1
5988872|NCT04066023|9580140|FG000|Overall Study|Lost to Follow-up|0
5988873|NCT04066023|9580141|FG001|Overall Study|Lost to Follow-up|1
5988874|NCT04066023|9580142|FG002|Overall Study|Lost to Follow-up|1
5988875|NCT04066023|9580140|FG000|Overall Study|Noncompliance|0
5988876|NCT04066023|9580141|FG001|Overall Study|Noncompliance|1
5988877|NCT04066023|9580142|FG002|Overall Study|Noncompliance|1
5988878|NCT04009629|9580152|FG000|Overall Study|Withdrawal by Subject|2
6307384|NCT02604199|10034194|FG001|Overall Study|Study terminated by sponsor|2
6307385|NCT02604199|10034195|FG002|Overall Study|Study terminated by sponsor|0
6307386|NCT02604199|10034196|FG003|Overall Study|Study terminated by sponsor|2
6307387|NCT02604199|10034193|FG000|Overall Study|Withdrawal by Subject|0
6307388|NCT02604199|10034194|FG001|Overall Study|Withdrawal by Subject|1
6307389|NCT02604199|10034195|FG002|Overall Study|Withdrawal by Subject|0
6307390|NCT02604199|10034196|FG003|Overall Study|Withdrawal by Subject|0
6307391|NCT02604212|10034213|FG000|Overall Study|Study Terminated by Sponsor|2
6307392|NCT02604212|10034214|FG001|Overall Study|Study Terminated by Sponsor|1
6307393|NCT02604212|10034215|FG002|Overall Study|Study Terminated by Sponsor|3
6307394|NCT02604212|10034216|FG003|Overall Study|Study Terminated by Sponsor|3
6307395|NCT02604212|10034213|FG000|Overall Study|Withdrawal by Subject|0
6307396|NCT02604212|10034214|FG001|Overall Study|Withdrawal by Subject|0
6307397|NCT02604212|10034215|FG002|Overall Study|Withdrawal by Subject|1
6307398|NCT02604212|10034216|FG003|Overall Study|Withdrawal by Subject|0
6307399|NCT02604264|10034233|FG000|Intervention|Didn't use CVC for at least 21 days|200
6307400|NCT02604264|10034234|FG001|Intervention|Didn't use CVC for at least 21 days|242
6307401|NCT02604342|10034242|FG000|Overall Study|Death|32
6307402|NCT02604342|10034243|FG001|Overall Study|Death|16
6307403|NCT02604342|10034242|FG000|Overall Study|Progression of disease|1
6307404|NCT02604342|10034243|FG001|Overall Study|Progression of disease|0
6307405|NCT02604342|10034242|FG000|Overall Study|Withdrawal by Subject|5
6307406|NCT02604342|10034243|FG001|Overall Study|Withdrawal by Subject|6
6307407|NCT02604342|10034242|FG000|Overall Study|Other|1
6307408|NCT02604342|10034243|FG001|Overall Study|Other|0
6307409|NCT02604342|10034242|FG000|Overall Study|Study Termination by Sponsor|1
6307410|NCT02604342|10034243|FG001|Overall Study|Study Termination by Sponsor|0
6307411|NCT02604342|10034242|FG000|Overall Study|Lost to Follow-up|1
6307412|NCT02604342|10034243|FG001|Overall Study|Lost to Follow-up|1
6307413|NCT02604342|10034242|FG000|Overall Study|Physician Decision|2
6307414|NCT02604342|10034243|FG001|Overall Study|Physician Decision|0
6307415|NCT02604407|10034252|FG000|Overall Study|Adverse Event|0
6307416|NCT02604407|10034253|FG001|Overall Study|Adverse Event|7
6307417|NCT02604407|10034254|FG002|Overall Study|Adverse Event|5
6307418|NCT02604407|10034252|FG000|Overall Study|Protocol Violation|2
6307419|NCT02604407|10034253|FG001|Overall Study|Protocol Violation|0
6307420|NCT02604407|10034254|FG002|Overall Study|Protocol Violation|0
5988879|NCT04009629|9580153|FG001|Overall Study|Withdrawal by Subject|0
5988880|NCT03937908|9580172|FG000|Overall Study|Study discontinuation due to pandemic restrictions|0
5988881|NCT03937908|9580173|FG001|Overall Study|Study discontinuation due to pandemic restrictions|1
6307421|NCT02604407|10034252|FG000|Overall Study|Withdrawal by Subject|3
6307422|NCT02604407|10034253|FG001|Overall Study|Withdrawal by Subject|3
6307423|NCT02604407|10034254|FG002|Overall Study|Withdrawal by Subject|5
6307424|NCT02604407|10034252|FG000|Overall Study|Lost to Follow-up|2
6307425|NCT02604407|10034253|FG001|Overall Study|Lost to Follow-up|1
6045400|NCT00402025|9644650|FG001|Overall Study|Disease Progression|1
6045401|NCT00402025|9644651|FG002|Overall Study|Disease Progression|2
6045402|NCT00402025|9644649|FG000|Overall Study|Physician Decision|1
6045403|NCT00402025|9644650|FG001|Overall Study|Physician Decision|1
6045404|NCT00402025|9644651|FG002|Overall Study|Physician Decision|0
6045405|NCT00402025|9644649|FG000|Overall Study|Participant Decision|0
6307426|NCT02604407|10034254|FG002|Overall Study|Lost to Follow-up|2
5988882|NCT03891264|9580179|FG000|Overall Study|Adverse Event|1
5988883|NCT03891264|9580179|FG000|Overall Study|Withdrawal by Subject|2
5988884|NCT03891264|9580179|FG000|Overall Study|Physician Decision|2
5988885|NCT03823300|9580203|FG000|Overall Study|Withdrawal by Subject|5
5988886|NCT03823300|9580204|FG001|Overall Study|Withdrawal by Subject|8
5988887|NCT03823300|9580203|FG000|Overall Study|Death|2
5988888|NCT03823300|9580204|FG001|Overall Study|Death|5
5988889|NCT03823300|9580203|FG000|Overall Study|Adverse Event|2
5988890|NCT03823300|9580204|FG001|Overall Study|Adverse Event|0
5988891|NCT03823300|9580203|FG000|Overall Study|Physician Decision|0
5988892|NCT03823300|9580204|FG001|Overall Study|Physician Decision|2
5988893|NCT03823300|9580203|FG000|Overall Study|Protocol Violation|1
5988894|NCT03823300|9580204|FG001|Overall Study|Protocol Violation|1
5988895|NCT03823300|9580203|FG000|Overall Study|Lost to Follow-up|0
5988896|NCT03823300|9580204|FG001|Overall Study|Lost to Follow-up|1
5988897|NCT03823300|9580203|FG000|Overall Study|Not Eligible|0
5988898|NCT03823300|9580204|FG001|Overall Study|Not Eligible|1
5988899|NCT03823300|9580203|FG000|Overall Study|Ongoing in the study at Primary Completion Date|321
5988900|NCT03823300|9580204|FG001|Overall Study|Ongoing in the study at Primary Completion Date|309
5988901|NCT03823287|9580212|FG000|Overall Study|Withdrawal by Subject|7
5988902|NCT03823287|9580213|FG001|Overall Study|Withdrawal by Subject|6
5988903|NCT03823287|9580212|FG000|Overall Study|Death|4
5988904|NCT03823287|9580213|FG001|Overall Study|Death|1
5988905|NCT03823287|9580212|FG000|Overall Study|Lost to Follow-up|2
5988906|NCT03823287|9580213|FG001|Overall Study|Lost to Follow-up|3
5988907|NCT03823287|9580212|FG000|Overall Study|Physician Decision|2
5988908|NCT03823287|9580213|FG001|Overall Study|Physician Decision|1
5988909|NCT03823287|9580212|FG000|Overall Study|Adverse Event|0
6307427|NCT02604407|10034252|FG000|Overall Study|Lack of Efficacy|1
6307428|NCT02604407|10034253|FG001|Overall Study|Lack of Efficacy|0
6307429|NCT02604407|10034254|FG002|Overall Study|Lack of Efficacy|0
6307430|NCT02604407|10034252|FG000|Overall Study|Other|3
6307431|NCT02604407|10034253|FG001|Overall Study|Other|1
6307432|NCT02604407|10034254|FG002|Overall Study|Other|4
6307433|NCT02604550|10034264|FG000|Overall Study|Lost to Follow-up|7
6307434|NCT02604550|10034265|FG001|Overall Study|Lost to Follow-up|6
6307435|NCT02604550|10034264|FG000|Overall Study|Withdrawal by Subject|0
6307436|NCT02604550|10034265|FG001|Overall Study|Withdrawal by Subject|1
6307437|NCT02604550|10034264|FG000|Overall Study|Incomplete data using paper journal|18
6307438|NCT02604550|10034265|FG001|Overall Study|Incomplete data using paper journal|19
6307439|NCT02604589|10034274|FG000|Overall Study|catheter dislodgement|0
6307440|NCT02604589|10034275|FG001|Overall Study|catheter dislodgement|0
6307441|NCT02604589|10034276|FG002|Overall Study|catheter dislodgement|1
6307442|NCT02605122|10034292|FG000|Overall Study|Withdrawal by Subject|4
6307443|NCT02605122|10034293|FG001|Overall Study|Withdrawal by Subject|1
6307444|NCT02605122|10034292|FG000|Overall Study|Lost to Follow-up|1
6307445|NCT02605122|10034293|FG001|Overall Study|Lost to Follow-up|1
6307446|NCT02605174|10034303|FG000|Overall Study|Adverse Event|0
6307447|NCT02605174|10034304|FG001|Overall Study|Adverse Event|0
6307448|NCT02605174|10034305|FG002|Overall Study|Adverse Event|1
6307449|NCT02605174|10034306|FG003|Overall Study|Adverse Event|0
6307450|NCT02605174|10034307|FG004|Overall Study|Adverse Event|4
6307451|NCT02605174|10034308|FG005|Overall Study|Adverse Event|0
6307452|NCT02605174|10034309|FG006|Overall Study|Adverse Event|0
6307453|NCT02605174|10034303|FG000|Overall Study|Lost to Follow-up|20
6307454|NCT02605174|10034304|FG001|Overall Study|Lost to Follow-up|7
6307455|NCT02605174|10034305|FG002|Overall Study|Lost to Follow-up|27
6307456|NCT02605174|10034306|FG003|Overall Study|Lost to Follow-up|10
6307457|NCT02605174|10034307|FG004|Overall Study|Lost to Follow-up|20
6307458|NCT02605174|10034308|FG005|Overall Study|Lost to Follow-up|10
6307459|NCT02605174|10034309|FG006|Overall Study|Lost to Follow-up|29
6307460|NCT02605174|10034303|FG000|Overall Study|Protocol Violation|10
6307461|NCT02605174|10034304|FG001|Overall Study|Protocol Violation|4
6307462|NCT02605174|10034305|FG002|Overall Study|Protocol Violation|14
6307463|NCT02605174|10034306|FG003|Overall Study|Protocol Violation|6
6307464|NCT02605174|10034307|FG004|Overall Study|Protocol Violation|7
6307465|NCT02605174|10034308|FG005|Overall Study|Protocol Violation|7
6307466|NCT02605174|10034309|FG006|Overall Study|Protocol Violation|12
6307467|NCT02605174|10034303|FG000|Overall Study|Pregnancy|1
5988910|NCT03823287|9580213|FG001|Overall Study|Adverse Event|3
5988911|NCT03823287|9580212|FG000|Overall Study|Ongoing in the study at Primary Completion Date|319
5988912|NCT03823287|9580213|FG001|Overall Study|Ongoing in the study at Primary Completion Date|323
5988913|NCT03815175|9580219|FG000|Overall Study|Subject Lost to Follow-up|6
5988914|NCT03815175|9580219|FG000|Overall Study|Subject Withdrew Consent|48
6307468|NCT02605174|10034304|FG001|Overall Study|Pregnancy|0
6307469|NCT02605174|10034305|FG002|Overall Study|Pregnancy|0
6307470|NCT02605174|10034306|FG003|Overall Study|Pregnancy|2
6307471|NCT02605174|10034307|FG004|Overall Study|Pregnancy|0
6307472|NCT02605174|10034308|FG005|Overall Study|Pregnancy|0
5988915|NCT03815175|9580219|FG000|Overall Study|Subject Withdrawn by Physician/Site|10
5988916|NCT03815175|9580219|FG000|Overall Study|Death|86
6307473|NCT02605174|10034309|FG006|Overall Study|Pregnancy|0
6307474|NCT02605174|10034303|FG000|Overall Study|Withdrawal by Subject|9
6307475|NCT02605174|10034304|FG001|Overall Study|Withdrawal by Subject|6
6307476|NCT02605174|10034305|FG002|Overall Study|Withdrawal by Subject|14
6307477|NCT02605174|10034306|FG003|Overall Study|Withdrawal by Subject|11
5988917|NCT03815175|9580219|FG000|Overall Study|Improper/Duplicate SubjectEnrollment|1
5988918|NCT03815175|9580219|FG000|Overall Study|Subject Discontinued by Sponsor|2
5988919|NCT03815175|9580219|FG000|Overall Study|Other Status Change Reason|1
5988920|NCT03815175|9580219|FG000|Overall Study|Missed Visit|12
5988921|NCT03812224|9580225|FG000|Double-blind Treatment Period|Withdrawal by Subject|4
5988922|NCT03812224|9580226|FG001|Double-blind Treatment Period|Withdrawal by Subject|2
5988923|NCT03812224|9580225|FG000|Double-blind Treatment Period|Decision by Sponsor|0
5988924|NCT03812224|9580226|FG001|Double-blind Treatment Period|Decision by Sponsor|1
5988925|NCT03812224|9580225|FG000|Open-label Treatment Period|Withdrawal by Subject|2
5988926|NCT03812224|9580226|FG001|Open-label Treatment Period|Withdrawal by Subject|2
5988927|NCT03812224|9580225|FG000|Open-label Treatment Period|Decision by Sponsor|0
5988928|NCT03812224|9580226|FG001|Open-label Treatment Period|Decision by Sponsor|1
6045406|NCT00402025|9644650|FG001|Overall Study|Participant Decision|0
6045407|NCT00402025|9644651|FG002|Overall Study|Participant Decision|1
6045408|NCT00402051|9644661|FG000|Overall Study|Progressive Disease|13
6045409|NCT00402051|9644662|FG001|Overall Study|Progressive Disease|20
6045410|NCT00402051|9644661|FG000|Overall Study|Adverse Event|11
6045411|NCT00402051|9644662|FG001|Overall Study|Adverse Event|4
6045412|NCT00402051|9644661|FG000|Overall Study|Physician Decision|7
6045413|NCT00402051|9644662|FG001|Overall Study|Physician Decision|3
6045414|NCT00402051|9644661|FG000|Overall Study|Withdrawal by Subject|3
6307478|NCT02605174|10034307|FG004|Overall Study|Withdrawal by Subject|6
6307479|NCT02605174|10034308|FG005|Overall Study|Withdrawal by Subject|4
6307480|NCT02605174|10034309|FG006|Overall Study|Withdrawal by Subject|15
6307481|NCT02605174|10034303|FG000|Overall Study|Physician Decision|2
6307482|NCT02605174|10034304|FG001|Overall Study|Physician Decision|0
6307483|NCT02605174|10034305|FG002|Overall Study|Physician Decision|0
6307484|NCT02605174|10034306|FG003|Overall Study|Physician Decision|0
6307485|NCT02605174|10034307|FG004|Overall Study|Physician Decision|0
6307486|NCT02605174|10034308|FG005|Overall Study|Physician Decision|0
6307487|NCT02605174|10034309|FG006|Overall Study|Physician Decision|3
6307488|NCT02605174|10034303|FG000|Overall Study|Randomization Failure|22
6307489|NCT02605174|10034304|FG001|Overall Study|Randomization Failure|6
6307490|NCT02605174|10034305|FG002|Overall Study|Randomization Failure|20
6307491|NCT02605174|10034306|FG003|Overall Study|Randomization Failure|7
6045415|NCT00402051|9644662|FG001|Overall Study|Withdrawal by Subject|3
6045416|NCT00402051|9644661|FG000|Overall Study|Death - Related to Study Drug|1
6049087|NCT00421148|9648260|FG011|Overall Study|Protocol Violation|0
6307492|NCT02605174|10034307|FG004|Overall Study|Randomization Failure|16
6307493|NCT02605174|10034308|FG005|Overall Study|Randomization Failure|11
6307494|NCT02605174|10034309|FG006|Overall Study|Randomization Failure|30
6307495|NCT02605447|10034368|FG000|Overall Study|Death|66
6307496|NCT02605447|10034368|FG000|Overall Study|Physician Decision|1
6307497|NCT02605447|10034368|FG000|Overall Study|Lost to Follow-up|24
6307498|NCT02605447|10034368|FG000|Overall Study|Withdrawal by Subject|10
6307499|NCT02605447|10034368|FG000|Overall Study|Not disclosed|1
6307500|NCT02605642|10034375|FG000|Overall Study|Other|11
6307501|NCT02605642|10034376|FG001|Overall Study|Other|1
5988929|NCT03689374|9580284|FG000|Run-in Period (12 Weeks)|Run-in failure|526
5988930|NCT03689374|9580285|FG001|Run-in Period (12 Weeks)|Run-in failure|0
5988931|NCT03689374|9580286|FG002|Run-in Period (12 Weeks)|Run-in failure|0
5988932|NCT03689374|9580284|FG000|Treatment Period (Week 0 to 52)|Withdrawal by Subject|0
5988933|NCT03689374|9580285|FG001|Treatment Period (Week 0 to 52)|Withdrawal by Subject|10
5988934|NCT03689374|9580286|FG002|Treatment Period (Week 0 to 52)|Withdrawal by Subject|38
5988935|NCT03689374|9580284|FG000|Treatment Period (Week 0 to 52)|Lost to Follow-up|0
5988936|NCT03689374|9580285|FG001|Treatment Period (Week 0 to 52)|Lost to Follow-up|3
5988937|NCT03689374|9580286|FG002|Treatment Period (Week 0 to 52)|Lost to Follow-up|4
5988938|NCT03689374|9580284|FG000|Treatment Period (Week 0 to 52)|Death|0
5988939|NCT03689374|9580285|FG001|Treatment Period (Week 0 to 52)|Death|11
5988940|NCT03689374|9580286|FG002|Treatment Period (Week 0 to 52)|Death|1
5988941|NCT03603639|9580301|FG000|Washout Period (at Least 3 Weeks)|Adverse Event|0
5988942|NCT03603639|9580302|FG001|Washout Period (at Least 3 Weeks)|Adverse Event|0
5988943|NCT03603639|9580303|FG002|Washout Period (at Least 3 Weeks)|Adverse Event|0
5988944|NCT03603639|9580304|FG003|Washout Period (at Least 3 Weeks)|Adverse Event|1
5988945|NCT03603639|9580305|FG004|Washout Period (at Least 3 Weeks)|Adverse Event|0
5988946|NCT03603639|9580306|FG005|Washout Period (at Least 3 Weeks)|Adverse Event|0
6307502|NCT02605642|10034375|FG000|Overall Study|Participant non-compliance|2
6307503|NCT02605642|10034376|FG001|Overall Study|Participant non-compliance|4
6307504|NCT02605642|10034375|FG000|Overall Study|Physician Decision|10
6307505|NCT02605642|10034376|FG001|Overall Study|Physician Decision|0
6307506|NCT02605642|10034375|FG000|Overall Study|Lost to Follow-up|12
6307507|NCT02605642|10034376|FG001|Overall Study|Lost to Follow-up|1
6307508|NCT02605642|10034375|FG000|Overall Study|Adverse Event|14
6307509|NCT02605642|10034376|FG001|Overall Study|Adverse Event|2
6307510|NCT02605642|10034375|FG000|Overall Study|Withdrawal by Subject|23
6307511|NCT02605642|10034376|FG001|Overall Study|Withdrawal by Subject|2
6307512|NCT02605642|10034375|FG000|Overall Study|Lack of response|24
6307513|NCT02605642|10034376|FG001|Overall Study|Lack of response|11
6307514|NCT02605837|10034384|FG000|Overall Study|Adverse Event|3
6307515|NCT02605837|10034385|FG001|Overall Study|Adverse Event|1
6307516|NCT02605837|10034384|FG000|Overall Study|Non-Compliance with Study Drug|0
6307517|NCT02605837|10034385|FG001|Overall Study|Non-Compliance with Study Drug|1
6307518|NCT02605837|10034384|FG000|Overall Study|Withdrawal by Subject|8
6307519|NCT02605837|10034385|FG001|Overall Study|Withdrawal by Subject|8
6307520|NCT02605837|10034384|FG000|Overall Study|Physician Decision|0
6307521|NCT02605837|10034385|FG001|Overall Study|Physician Decision|1
5988947|NCT03603639|9580301|FG000|Washout Period (at Least 3 Weeks)|Study terminated by sponsor|0
5988948|NCT03603639|9580302|FG001|Washout Period (at Least 3 Weeks)|Study terminated by sponsor|0
5988949|NCT03603639|9580303|FG002|Washout Period (at Least 3 Weeks)|Study terminated by sponsor|1
5988950|NCT03603639|9580304|FG003|Washout Period (at Least 3 Weeks)|Study terminated by sponsor|0
5988951|NCT03603639|9580305|FG004|Washout Period (at Least 3 Weeks)|Study terminated by sponsor|1
5988952|NCT03603639|9580306|FG005|Washout Period (at Least 3 Weeks)|Study terminated by sponsor|1
5988953|NCT03587636|9580318|FG000|Overall Study|Lost to Follow-up|2
5988954|NCT03587636|9580319|FG001|Overall Study|Lost to Follow-up|5
5988955|NCT03573336|9580349|FG000|Overall Study|Study terminated|2
5988956|NCT03573336|9580350|FG001|Overall Study|Study terminated|4
5988957|NCT03573336|9580351|FG002|Overall Study|Study terminated|2
5988958|NCT03570697|9580361|FG000|Overall Study|Lost to Follow-up|0
6307522|NCT02605928|10034414|FG000|Overall Study|Model tuning phase|28
6307523|NCT02605928|10034414|FG000|Overall Study|Lack of Efficacy|5
6307524|NCT02605954|10034420|FG000|Overall Study|Adverse Event|5
5988959|NCT03570697|9580362|FG001|Overall Study|Lost to Follow-up|1
5988960|NCT03570697|9580361|FG000|Overall Study|Death|2
6307525|NCT02605954|10034421|FG001|Overall Study|Adverse Event|1
6307526|NCT02605954|10034420|FG000|Overall Study|Investigator's Discretion|1
6307527|NCT02605954|10034421|FG001|Overall Study|Investigator's Discretion|0
6307528|NCT02605954|10034420|FG000|Overall Study|Non-Compliance with Study Drug|1
6307529|NCT02605954|10034421|FG001|Overall Study|Non-Compliance with Study Drug|0
6307530|NCT02605954|10034420|FG000|Overall Study|Withdrew Consent|2
6307531|NCT02605954|10034421|FG001|Overall Study|Withdrew Consent|2
6307532|NCT02605954|10034420|FG000|Overall Study|Lost to Follow-up|3
6307533|NCT02605954|10034421|FG001|Overall Study|Lost to Follow-up|0
6307534|NCT02605954|10034420|FG000|Overall Study|Randomized but not treated|0
6307535|NCT02605954|10034421|FG001|Overall Study|Randomized but not treated|1
6307536|NCT02606253|10034433|FG000|Overall Study|Adverse Event|2
6307537|NCT02606253|10034434|FG001|Overall Study|Adverse Event|0
6307538|NCT02606253|10034435|FG002|Overall Study|Adverse Event|0
6307539|NCT02606253|10034433|FG000|Overall Study|Protocol Violation|2
6307540|NCT02606253|10034434|FG001|Overall Study|Protocol Violation|1
6307541|NCT02606253|10034435|FG002|Overall Study|Protocol Violation|0
6307542|NCT02606253|10034433|FG000|Overall Study|Physician Decision|1
6307543|NCT02606253|10034434|FG001|Overall Study|Physician Decision|1
6307544|NCT02606253|10034435|FG002|Overall Study|Physician Decision|0
6307545|NCT02606643|10034465|FG000|Overall Study|did not meet inclusion criteria|1
6307546|NCT02606643|10034466|FG001|Overall Study|did not meet inclusion criteria|3
6307547|NCT02606877|10034494|FG000|Overall Study|Adverse Event|3
6307548|NCT02606877|10034495|FG001|Overall Study|Adverse Event|0
6307549|NCT02606877|10034494|FG000|Overall Study|Non-compliance with protocol|0
6307550|NCT02606877|10034495|FG001|Overall Study|Non-compliance with protocol|1
6307551|NCT02606877|10034494|FG000|Overall Study|Other than listed above|1
6307552|NCT02606877|10034495|FG001|Overall Study|Other than listed above|0
6307553|NCT02607228|10034524|FG000|Overall Study|Progressive Disease|4
6307554|NCT02607228|10034525|FG001|Overall Study|Progressive Disease|3
6307555|NCT02607228|10034526|FG002|Overall Study|Progressive Disease|1
6307556|NCT02607228|10034527|FG003|Overall Study|Progressive Disease|5
6307557|NCT02607228|10034528|FG004|Overall Study|Progressive Disease|4
6307558|NCT02607228|10034529|FG005|Overall Study|Progressive Disease|3
6307559|NCT02607228|10034530|FG006|Overall Study|Progressive Disease|1
6307560|NCT02607228|10034524|FG000|Overall Study|Adverse Event|1
6307561|NCT02607228|10034525|FG001|Overall Study|Adverse Event|0
6307562|NCT02607228|10034526|FG002|Overall Study|Adverse Event|1
6307563|NCT02607228|10034527|FG003|Overall Study|Adverse Event|0
6307564|NCT02607228|10034528|FG004|Overall Study|Adverse Event|1
6307565|NCT02607228|10034529|FG005|Overall Study|Adverse Event|1
6307566|NCT02607228|10034530|FG006|Overall Study|Adverse Event|1
6307567|NCT02607228|10034524|FG000|Overall Study|Investigator's Discretion|0
6307568|NCT02607228|10034525|FG001|Overall Study|Investigator's Discretion|0
6307569|NCT02607228|10034526|FG002|Overall Study|Investigator's Discretion|1
6307570|NCT02607228|10034527|FG003|Overall Study|Investigator's Discretion|0
6307571|NCT02607228|10034528|FG004|Overall Study|Investigator's Discretion|0
6307572|NCT02607228|10034529|FG005|Overall Study|Investigator's Discretion|1
6307573|NCT02607228|10034530|FG006|Overall Study|Investigator's Discretion|0
6307574|NCT02607228|10034524|FG000|Overall Study|Withdrew Consent|0
6307575|NCT02607228|10034525|FG001|Overall Study|Withdrew Consent|1
6307576|NCT02607228|10034526|FG002|Overall Study|Withdrew Consent|0
6307577|NCT02607228|10034527|FG003|Overall Study|Withdrew Consent|0
6307578|NCT02607228|10034528|FG004|Overall Study|Withdrew Consent|0
6307579|NCT02607228|10034529|FG005|Overall Study|Withdrew Consent|1
6307580|NCT02607228|10034530|FG006|Overall Study|Withdrew Consent|0
6307581|NCT02607228|10034524|FG000|Overall Study|Study Terminated by Sponsor|0
6307582|NCT02607228|10034525|FG001|Overall Study|Study Terminated by Sponsor|0
6307583|NCT02607228|10034526|FG002|Overall Study|Study Terminated by Sponsor|0
6307584|NCT02607228|10034527|FG003|Overall Study|Study Terminated by Sponsor|1
6307585|NCT02607228|10034528|FG004|Overall Study|Study Terminated by Sponsor|0
6307586|NCT02607228|10034529|FG005|Overall Study|Study Terminated by Sponsor|0
6307587|NCT02607228|10034530|FG006|Overall Study|Study Terminated by Sponsor|0
6307588|NCT02607280|10034568|FG000|Overall Study|Adverse Event|4
6307589|NCT02607280|10034569|FG001|Overall Study|Adverse Event|0
6307590|NCT02607280|10034568|FG000|Overall Study|Decrease in CrCl <15|0
5988961|NCT03570697|9580362|FG001|Overall Study|Death|0
5988962|NCT03570697|9580361|FG000|Overall Study|Withdrawal by Subject|4
5988963|NCT03570697|9580362|FG001|Overall Study|Withdrawal by Subject|2
5988964|NCT03548051|9580370|FG000|Overall Study|Death|1
5988965|NCT03548051|9580371|FG001|Overall Study|Death|1
5988966|NCT03548051|9580370|FG000|Overall Study|Withdrawal by Subject|1
5988967|NCT03548051|9580371|FG001|Overall Study|Withdrawal by Subject|0
5988968|NCT03503318|9580397|FG000|Overall Study|Death|1
5988969|NCT03503318|9580398|FG001|Overall Study|Death|0
5988970|NCT03503318|9580399|FG002|Overall Study|Death|4
5988971|NCT03503318|9580397|FG000|Overall Study|Adverse Event|3
5988972|NCT03503318|9580398|FG001|Overall Study|Adverse Event|4
5988973|NCT03503318|9580399|FG002|Overall Study|Adverse Event|2
5988974|NCT03503318|9580397|FG000|Overall Study|Withdrawal by Subject|12
5988975|NCT03503318|9580398|FG001|Overall Study|Withdrawal by Subject|17
5988976|NCT03503318|9580399|FG002|Overall Study|Withdrawal by Subject|16
5988977|NCT03503318|9580397|FG000|Overall Study|Protocol Violation|5
5988978|NCT03503318|9580398|FG001|Overall Study|Protocol Violation|0
5988979|NCT03503318|9580399|FG002|Overall Study|Protocol Violation|3
5988980|NCT03503318|9580397|FG000|Overall Study|Lost to Follow-up|17
5988981|NCT03503318|9580398|FG001|Overall Study|Lost to Follow-up|15
5988982|NCT03503318|9580399|FG002|Overall Study|Lost to Follow-up|12
5988983|NCT03503318|9580397|FG000|Overall Study|Other than specified|1
5988984|NCT03503318|9580398|FG001|Overall Study|Other than specified|3
5988985|NCT03503318|9580399|FG002|Overall Study|Other than specified|3
6045417|NCT00402051|9644662|FG001|Overall Study|Death - Related to Study Drug|2
6045418|NCT00402051|9644661|FG000|Overall Study|Death Due to Study Disease|2
6045419|NCT00402051|9644662|FG001|Overall Study|Death Due to Study Disease|1
6045420|NCT00402051|9644661|FG000|Overall Study|Death Due to Adverse Event|0
6045421|NCT00402051|9644662|FG001|Overall Study|Death Due to Adverse Event|2
6045422|NCT00402051|9644661|FG000|Overall Study|Lost to Follow-up|1
6045423|NCT00402051|9644662|FG001|Overall Study|Lost to Follow-up|0
6045424|NCT00402103|9644670|FG000|Overall Study|Adverse Event|60
6045425|NCT00402103|9644671|FG001|Overall Study|Adverse Event|7
6045426|NCT00402103|9644670|FG000|Overall Study|Unsatisfactory therapeutic effect|1
6045427|NCT00402103|9644671|FG001|Overall Study|Unsatisfactory therapeutic effect|2
6045428|NCT00402103|9644670|FG000|Overall Study|Condition no longer requires study drug|2
6045429|NCT00402103|9644671|FG001|Overall Study|Condition no longer requires study drug|0
6045430|NCT00402103|9644670|FG000|Overall Study|Protocol Deviation|8
6045431|NCT00402103|9644671|FG001|Overall Study|Protocol Deviation|0
6045432|NCT00402103|9644670|FG000|Overall Study|Patient withdrew consent|12
6045433|NCT00402103|9644671|FG001|Overall Study|Patient withdrew consent|1
6307591|NCT02607280|10034569|FG001|Overall Study|Decrease in CrCl <15|1
6307592|NCT02607306|10034578|FG000|Overall Study|Adverse Event|8
6307593|NCT02607306|10034579|FG001|Overall Study|Adverse Event|6
6307594|NCT02607306|10034580|FG002|Overall Study|Adverse Event|6
6307595|NCT02607306|10034578|FG000|Overall Study|Unclassified|1
6307596|NCT02607306|10034579|FG001|Overall Study|Unclassified|4
6307597|NCT02607306|10034580|FG002|Overall Study|Unclassified|0
6307598|NCT02607306|10034578|FG000|Overall Study|Withdrawal by Subject|8
6307599|NCT02607306|10034579|FG001|Overall Study|Withdrawal by Subject|10
6307600|NCT02607306|10034580|FG002|Overall Study|Withdrawal by Subject|2
6307601|NCT02607306|10034578|FG000|Overall Study|Lack of Efficacy|0
6307602|NCT02607306|10034579|FG001|Overall Study|Lack of Efficacy|1
6307603|NCT02607306|10034580|FG002|Overall Study|Lack of Efficacy|1
6307604|NCT02607306|10034578|FG000|Overall Study|Protocol Violation|4
6307605|NCT02607306|10034579|FG001|Overall Study|Protocol Violation|2
6307606|NCT02607306|10034580|FG002|Overall Study|Protocol Violation|1
6307607|NCT02607735|10034600|FG000|Primary Study|Randomized but Never Treated|1
6307608|NCT02607735|10034601|FG001|Primary Study|Randomized but Never Treated|0
6307609|NCT02607735|10034602|FG002|Primary Study|Randomized but Never Treated|0
6045434|NCT00402103|9644670|FG000|Overall Study|Lost to Follow-up|6
6045435|NCT00402103|9644671|FG001|Overall Study|Lost to Follow-up|3
6045436|NCT00402103|9644670|FG000|Overall Study|Administrative problems|2
6045437|NCT00402103|9644671|FG001|Overall Study|Administrative problems|0
6045438|NCT00402116|9644684|FG000|Overall Study|Jaw infection after surgery-other|1
6045439|NCT00402116|9644685|FG001|Overall Study|Jaw infection after surgery-other|0
6045440|NCT00402116|9644686|FG002|Overall Study|Jaw infection after surgery-other|0
6045441|NCT00402116|9644684|FG000|Overall Study|Withdrawal by Subject|1
6045442|NCT00402116|9644685|FG001|Overall Study|Withdrawal by Subject|0
6045443|NCT00402116|9644686|FG002|Overall Study|Withdrawal by Subject|5
6045444|NCT00402116|9644684|FG000|Overall Study|Treatment completed per protocol|1
6045445|NCT00402116|9644685|FG001|Overall Study|Treatment completed per protocol|1
6045446|NCT00402116|9644686|FG002|Overall Study|Treatment completed per protocol|2
6307610|NCT02607735|10034600|FG000|Primary Study|Lost to Follow-up|4
6307611|NCT02607735|10034601|FG001|Primary Study|Lost to Follow-up|0
6307612|NCT02607735|10034602|FG002|Primary Study|Lost to Follow-up|0
6307613|NCT02607735|10034600|FG000|Primary Study|Withdrew Consent|2
6045447|NCT00402116|9644684|FG000|Overall Study|other complicating disease|0
6045448|NCT00402116|9644685|FG001|Overall Study|other complicating disease|0
6307614|NCT02607735|10034601|FG001|Primary Study|Withdrew Consent|0
6307615|NCT02607735|10034602|FG002|Primary Study|Withdrew Consent|0
6307616|NCT02607735|10034600|FG000|Deferred Treatment Substudy|Lost to Follow-up|0
5988986|NCT03493854|9580409|FG000|Neoadjuvant Treatment Phase (24 Weeks)|Adverse Event|3
5988987|NCT03493854|9580410|FG001|Neoadjuvant Treatment Phase (24 Weeks)|Adverse Event|5
5988988|NCT03493854|9580409|FG000|Neoadjuvant Treatment Phase (24 Weeks)|Death|1
5988989|NCT03493854|9580410|FG001|Neoadjuvant Treatment Phase (24 Weeks)|Death|1
5988990|NCT03493854|9580409|FG000|Neoadjuvant Treatment Phase (24 Weeks)|Protocol Violation|0
5988991|NCT03493854|9580410|FG001|Neoadjuvant Treatment Phase (24 Weeks)|Protocol Violation|1
5988992|NCT03493854|9580409|FG000|Neoadjuvant Treatment Phase (24 Weeks)|Withdrawal by Subject|1
6307617|NCT02607735|10034601|FG001|Deferred Treatment Substudy|Lost to Follow-up|0
6307618|NCT02607735|10034602|FG002|Deferred Treatment Substudy|Lost to Follow-up|4
6307619|NCT02607735|10034600|FG000|Deferred Treatment Substudy|Withdrew Consent|0
6307620|NCT02607735|10034601|FG001|Deferred Treatment Substudy|Withdrew Consent|0
6307621|NCT02607735|10034602|FG002|Deferred Treatment Substudy|Withdrew Consent|1
6307622|NCT02607800|10034612|FG000|Overall Study|Lost to Follow-up|7
6307623|NCT02607800|10034613|FG001|Overall Study|Lost to Follow-up|10
6307624|NCT02607800|10034612|FG000|Overall Study|Withdrew Consent|2
6307625|NCT02607800|10034613|FG001|Overall Study|Withdrew Consent|0
6307626|NCT02607800|10034612|FG000|Overall Study|Randomized/Enrolled but Not Treated|1
6307627|NCT02607800|10034613|FG001|Overall Study|Randomized/Enrolled but Not Treated|1
6307628|NCT02607865|10034624|FG000|Overall Study|Lost to Follow-up|9
6307629|NCT02607865|10034625|FG001|Overall Study|Lost to Follow-up|7
6307630|NCT02607865|10034626|FG002|Overall Study|Lost to Follow-up|7
6307631|NCT02607865|10034627|FG003|Overall Study|Lost to Follow-up|5
6307632|NCT02607865|10034624|FG000|Overall Study|Withdrawal by Subject|18
6307633|NCT02607865|10034625|FG001|Overall Study|Withdrawal by Subject|18
6307634|NCT02607865|10034626|FG002|Overall Study|Withdrawal by Subject|17
6307635|NCT02607865|10034627|FG003|Overall Study|Withdrawal by Subject|8
6307636|NCT02607865|10034624|FG000|Overall Study|Death|5
6307637|NCT02607865|10034625|FG001|Overall Study|Death|4
6307638|NCT02607865|10034626|FG002|Overall Study|Death|1
6307639|NCT02607865|10034627|FG003|Overall Study|Death|3
6307640|NCT02607865|10034624|FG000|Overall Study|Unclassified|1
6307641|NCT02607865|10034625|FG001|Overall Study|Unclassified|1
6307642|NCT02607865|10034626|FG002|Overall Study|Unclassified|2
6307643|NCT02607865|10034627|FG003|Overall Study|Unclassified|0
6307644|NCT02608099|10034639|FG000|Overall Study|Ablation procedure not initiated|3
6307645|NCT02608099|10034640|FG001|Overall Study|Ablation procedure not initiated|2
6307646|NCT02608450|10034670|FG000|Overall Study|Lost to Follow-up|39
6307647|NCT02608450|10034671|FG001|Overall Study|Lost to Follow-up|32
6307648|NCT02608450|10034670|FG000|Overall Study|Withdrawal by Subject|21
6307649|NCT02608450|10034671|FG001|Overall Study|Withdrawal by Subject|15
6307650|NCT02608450|10034670|FG000|Overall Study|Adverse Event|3
6307651|NCT02608450|10034671|FG001|Overall Study|Adverse Event|6
6307652|NCT02608450|10034670|FG000|Overall Study|Withdrawal by parent|2
6307653|NCT02608450|10034671|FG001|Overall Study|Withdrawal by parent|3
6307654|NCT02608450|10034670|FG000|Overall Study|Lack of Efficacy|0
6307655|NCT02608450|10034671|FG001|Overall Study|Lack of Efficacy|3
6307656|NCT02608450|10034670|FG000|Overall Study|Noncompliance with study drug|0
6307657|NCT02608450|10034671|FG001|Overall Study|Noncompliance with study drug|2
6307658|NCT02608450|10034670|FG000|Overall Study|Physician Decision|0
6307659|NCT02608450|10034671|FG001|Overall Study|Physician Decision|1
6307660|NCT02608450|10034670|FG000|Overall Study|Pregnancy|0
6307661|NCT02608450|10034671|FG001|Overall Study|Pregnancy|1
6307662|NCT02608450|10034670|FG000|Overall Study|Progressive disease|1
6307663|NCT02608450|10034671|FG001|Overall Study|Progressive disease|0
6307664|NCT02608450|10034670|FG000|Overall Study|Multiple reasons|0
6307665|NCT02608450|10034671|FG001|Overall Study|Multiple reasons|2
6307666|NCT02608476|10034693|FG000|Overall Study|Withdrawal by Subject|30
6307667|NCT02608476|10034694|FG001|Overall Study|Withdrawal by Subject|37
6307668|NCT02608476|10034693|FG000|Overall Study|Lost to Follow-up|24
6307669|NCT02608476|10034694|FG001|Overall Study|Lost to Follow-up|24
6307670|NCT02608476|10034693|FG000|Overall Study|Adverse Event|2
6307671|NCT02608476|10034694|FG001|Overall Study|Adverse Event|8
6307672|NCT02608476|10034693|FG000|Overall Study|Withdrawal by Parent/Guardian|5
6307673|NCT02608476|10034694|FG001|Overall Study|Withdrawal by Parent/Guardian|4
6307674|NCT02608476|10034693|FG000|Overall Study|Noncompliance with treatment|1
6307675|NCT02608476|10034694|FG001|Overall Study|Noncompliance with treatment|5
6307676|NCT02608476|10034693|FG000|Overall Study|Lack of Efficacy|3
6307677|NCT02608476|10034694|FG001|Overall Study|Lack of Efficacy|1
6307678|NCT02608476|10034693|FG000|Overall Study|Other|0
6307679|NCT02608476|10034694|FG001|Overall Study|Other|1
6307680|NCT02608476|10034693|FG000|Overall Study|Physician Decision|1
6307681|NCT02608476|10034694|FG001|Overall Study|Physician Decision|0
6307682|NCT02608476|10034693|FG000|Overall Study|Pregnancy|0
6307683|NCT02608476|10034694|FG001|Overall Study|Pregnancy|1
6307684|NCT02608476|10034693|FG000|Overall Study|Progressive disease|1
6307685|NCT02608476|10034694|FG001|Overall Study|Progressive disease|0
6307686|NCT02608879|10034712|FG000|Overall Study|Lost to Follow-up|1
6307687|NCT02608879|10034713|FG001|Overall Study|Lost to Follow-up|0
6307688|NCT02608879|10034714|FG002|Overall Study|Lost to Follow-up|0
6307689|NCT02608879|10034712|FG000|Overall Study|Did not meet continuation criteria|0
6307690|NCT02608879|10034713|FG001|Overall Study|Did not meet continuation criteria|0
6307691|NCT02608879|10034714|FG002|Overall Study|Did not meet continuation criteria|3
6307692|NCT02608892|10034724|FG000|Overall Study|Lost to Follow-up|1
6307693|NCT02608892|10034725|FG001|Overall Study|Lost to Follow-up|0
6307694|NCT02609178|10034752|FG000|First Crown|Withdrawal by Subject|0
6307695|NCT02609178|10034753|FG001|First Crown|Withdrawal by Subject|0
6307696|NCT02609178|10034754|FG002|First Crown|Withdrawal by Subject|1
6307697|NCT02609178|10034755|FG003|First Crown|Withdrawal by Subject|1
6307698|NCT02609178|10034756|FG004|First Crown|Withdrawal by Subject|0
6307699|NCT02609178|10034757|FG005|First Crown|Withdrawal by Subject|0
6307700|NCT02609399|10034779|FG000|Influenza Season 2015-2016|Lost to Follow-up|3
6307701|NCT02609399|10034780|FG001|Influenza Season 2015-2016|Lost to Follow-up|2
6307702|NCT02609399|10034779|FG000|Influenza Season 2016-2017|Lost to Follow-up|8
6307703|NCT02609399|10034780|FG001|Influenza Season 2016-2017|Lost to Follow-up|5
6307704|NCT02609399|10034779|FG000|Influenza Season 2016-2017|Found ineligible after randomization|1
6307705|NCT02609399|10034780|FG001|Influenza Season 2016-2017|Found ineligible after randomization|0
6307706|NCT02609607|10034790|FG000|Overall Study|Lost to Follow-up|0
6307707|NCT02609607|10034791|FG001|Overall Study|Lost to Follow-up|1
6307708|NCT02609633|10034799|FG000|Overall Study|Consent Withdrawn|0
6307709|NCT02609633|10034800|FG001|Overall Study|Consent Withdrawn|1
6307710|NCT02609633|10034799|FG000|Overall Study|Protocol Deviation|1
6307711|NCT02609633|10034800|FG001|Overall Study|Protocol Deviation|0
6307712|NCT02609633|10034799|FG000|Overall Study|Non-Compliant with Study Procedures|2
6307713|NCT02609633|10034800|FG001|Overall Study|Non-Compliant with Study Procedures|0
6307714|NCT02609633|10034799|FG000|Overall Study|Reason not Specified|2
6307715|NCT02609633|10034800|FG001|Overall Study|Reason not Specified|1
6307716|NCT02609659|10034807|FG000|Overall Study|Adverse Event|1
6307717|NCT02609659|10034807|FG000|Overall Study|Lost to Follow-up|6
6307718|NCT02609659|10034807|FG000|Overall Study|Other|1
6307719|NCT02609672|10034813|FG000|Overall Study|Lost to Follow-up|3
6307720|NCT02609672|10034814|FG001|Overall Study|Lost to Follow-up|1
6307721|NCT02609984|10034830|FG000|Overall Study|Death|29
6307722|NCT02609984|10034831|FG001|Overall Study|Death|26
6307723|NCT02609984|10034830|FG000|Overall Study|Participation Discontinued by Sponsor|12
6307724|NCT02609984|10034831|FG001|Overall Study|Participation Discontinued by Sponsor|10
6307725|NCT02609984|10034830|FG000|Overall Study|Lost to Follow-up|1
6307726|NCT02609984|10034831|FG001|Overall Study|Lost to Follow-up|2
6307727|NCT02609984|10034830|FG000|Overall Study|Withdrawal by Subject|0
6307728|NCT02609984|10034831|FG001|Overall Study|Withdrawal by Subject|1
6307729|NCT02609984|10034830|FG000|Overall Study|Disease Progression|2
6307730|NCT02609984|10034831|FG001|Overall Study|Disease Progression|0
6307731|NCT02610140|10034839|FG000|Randomization and Treatment Period|Radiological progression|23
6307732|NCT02610140|10034840|FG001|Randomization and Treatment Period|Radiological progression|15
6307733|NCT02610140|10034839|FG000|Randomization and Treatment Period|Progressive disease - radiological|54
5988993|NCT03493854|9580410|FG001|Neoadjuvant Treatment Phase (24 Weeks)|Withdrawal by Subject|2
5988994|NCT03493854|9580409|FG000|Neoadjuvant Treatment Phase (24 Weeks)|Progressive Disease|3
5988995|NCT03493854|9580410|FG001|Neoadjuvant Treatment Phase (24 Weeks)|Progressive Disease|3
5988996|NCT03493854|9580409|FG000|Neoadjuvant Treatment Phase (24 Weeks)|Other|1
5988997|NCT03493854|9580410|FG001|Neoadjuvant Treatment Phase (24 Weeks)|Other|2
5988998|NCT03493854|9580409|FG000|Neoadjuvant Treatment Phase (24 Weeks)|Other|1
5988999|NCT03493854|9580410|FG001|Neoadjuvant Treatment Phase (24 Weeks)|Other|0
5989000|NCT03493854|9580409|FG000|Surgery & Adjuvant Treatment (42 Weeks)|Ongoing Adjuvant Treatment|229
5989001|NCT03493854|9580410|FG001|Surgery & Adjuvant Treatment (42 Weeks)|Ongoing Adjuvant Treatment|228
5989002|NCT03493854|9580409|FG000|Surgery & Adjuvant Treatment (42 Weeks)|Adverse Event|2
6307734|NCT02610140|10034840|FG001|Randomization and Treatment Period|Progressive disease - radiological|23
6307735|NCT02610140|10034839|FG000|Randomization and Treatment Period|Protocol Violation|1
6307736|NCT02610140|10034840|FG001|Randomization and Treatment Period|Protocol Violation|0
6307737|NCT02610140|10034839|FG000|Randomization and Treatment Period|Physician Decision|0
6307738|NCT02610140|10034840|FG001|Randomization and Treatment Period|Physician Decision|1
6307739|NCT02610140|10034839|FG000|Randomization and Treatment Period|Lack of Efficacy|1
6307740|NCT02610140|10034840|FG001|Randomization and Treatment Period|Lack of Efficacy|0
6307741|NCT02610140|10034839|FG000|Randomization and Treatment Period|Death|7
6307742|NCT02610140|10034840|FG001|Randomization and Treatment Period|Death|1
6307743|NCT02610140|10034839|FG000|Randomization and Treatment Period|Withdrawal by Subject|12
6307744|NCT02610140|10034840|FG001|Randomization and Treatment Period|Withdrawal by Subject|12
6307745|NCT02610140|10034839|FG000|Randomization and Treatment Period|Adverse Event|44
6307746|NCT02610140|10034840|FG001|Randomization and Treatment Period|Adverse Event|13
6307747|NCT02610140|10034839|FG000|Randomization and Treatment Period|Progressive disease - clinical|12
6307748|NCT02610140|10034840|FG001|Randomization and Treatment Period|Progressive disease - clinical|5
6307749|NCT02610140|10034839|FG000|Randomization and Treatment Period|Ongoing but not completed|9
6307750|NCT02610140|10034840|FG001|Randomization and Treatment Period|Ongoing but not completed|2
6307751|NCT02610140|10034839|FG000|Randomization and Treatment Period|Not treated|3
6307752|NCT02610140|10034840|FG001|Randomization and Treatment Period|Not treated|10
6307753|NCT02610140|10034839|FG000|Safety Follow-up|Other|0
6307754|NCT02610140|10034840|FG001|Safety Follow-up|Other|2
6307755|NCT02610140|10034839|FG000|Safety Follow-up|Lost to Follow-up|1
6307756|NCT02610140|10034840|FG001|Safety Follow-up|Lost to Follow-up|0
6307757|NCT02610140|10034839|FG000|Safety Follow-up|No follow-up|5
6307758|NCT02610140|10034840|FG001|Safety Follow-up|No follow-up|3
6307759|NCT02610140|10034839|FG000|Safety Follow-up|Death|12
6307760|NCT02610140|10034840|FG001|Safety Follow-up|Death|2
6307761|NCT02610140|10034839|FG000|Safety Follow-up|Deterioration of general conditions|15
6307762|NCT02610140|10034840|FG001|Safety Follow-up|Deterioration of general conditions|5
6307763|NCT02610140|10034839|FG000|Safety Follow-up|Withdrawal by Subject|12
6307764|NCT02610140|10034840|FG001|Safety Follow-up|Withdrawal by Subject|12
6307765|NCT02610140|10034839|FG000|Active Follow-up|Progressive disease - radiological|30
6307766|NCT02610140|10034840|FG001|Active Follow-up|Progressive disease - radiological|22
6307767|NCT02610140|10034839|FG000|Active Follow-up|Death|8
6307768|NCT02610140|10034840|FG001|Active Follow-up|Death|1
6307769|NCT02610140|10034839|FG000|Active Follow-up|Withdrawal by Subject|4
6307770|NCT02610140|10034840|FG001|Active Follow-up|Withdrawal by Subject|0
6307771|NCT02610140|10034839|FG000|Active Follow-up|Progressive disease - clinical|1
6307772|NCT02610140|10034840|FG001|Active Follow-up|Progressive disease - clinical|2
6307773|NCT02610140|10034839|FG000|Active Follow-up|Deterioration of general conditions|1
6307774|NCT02610140|10034840|FG001|Active Follow-up|Deterioration of general conditions|0
6307775|NCT02610140|10034839|FG000|Active Follow-up|Ongoing but not completed|4
6307776|NCT02610140|10034840|FG001|Active Follow-up|Ongoing but not completed|1
6307777|NCT02610140|10034839|FG000|Long-term Follow-up|Death|86
6307778|NCT02610140|10034840|FG001|Long-term Follow-up|Death|44
6307779|NCT02610140|10034839|FG000|Long-term Follow-up|Withdrawal by Subject|6
6307780|NCT02610140|10034840|FG001|Long-term Follow-up|Withdrawal by Subject|3
6307781|NCT02610140|10034839|FG000|Long-term Follow-up|Lost to Follow-up|1
6307782|NCT02610140|10034840|FG001|Long-term Follow-up|Lost to Follow-up|2
6307783|NCT02610140|10034839|FG000|Long-term Follow-up|Ongoing but not completed|30
6307784|NCT02610140|10034840|FG001|Long-term Follow-up|Ongoing but not completed|17
6307785|NCT02610192|10034846|FG000|Overall Study|Received other treatment|8
6307786|NCT02610192|10034846|FG000|Overall Study|Physician Decision|1
6307787|NCT02610231|10034850|FG000|Overall Study|Withdrawal by Subject|27
6307788|NCT02610231|10034850|FG000|Overall Study|Adverse Event|20
6307789|NCT02610231|10034850|FG000|Overall Study|Death|5
6307790|NCT02610231|10034850|FG000|Overall Study|Surgery|2
6307791|NCT02610231|10034850|FG000|Overall Study|Physician Decision|1
6307792|NCT02610231|10034850|FG000|Overall Study|Non Compliance|2
6307793|NCT02610231|10034850|FG000|Overall Study|Other|3
6307794|NCT02610725|10034866|FG000|Overall Study|Lost to Follow-up|197
6307795|NCT02610725|10034866|FG000|Overall Study|self-reported contraindication|9
6307796|NCT02610777|10034872|FG000|Overall Study|Ongoing in Follow-up|14
6307797|NCT02610777|10034873|FG001|Overall Study|Ongoing in Follow-up|12
6307798|NCT02610777|10034872|FG000|Overall Study|Withdrawal by Subject|1
6307799|NCT02610777|10034873|FG001|Overall Study|Withdrawal by Subject|2
6307800|NCT02610777|10034872|FG000|Overall Study|Other|0
6307801|NCT02610777|10034873|FG001|Overall Study|Other|1
6307802|NCT02610777|10034872|FG000|Overall Study|Ongoing on Treatment|6
6307803|NCT02610777|10034873|FG001|Overall Study|Ongoing on Treatment|7
6307804|NCT02610816|10034881|FG000|Phase 1|Withdrawal by Subject|2
6307805|NCT02610816|10034882|FG001|Phase 1|Withdrawal by Subject|6
6307806|NCT02610816|10034883|FG002|Phase 1|Withdrawal by Subject|0
6307807|NCT02610816|10034884|FG003|Phase 1|Withdrawal by Subject|0
6307808|NCT02610816|10034881|FG000|Phase 1|Lost to Follow-up|2
6307809|NCT02610816|10034882|FG001|Phase 1|Lost to Follow-up|1
6307810|NCT02610816|10034883|FG002|Phase 1|Lost to Follow-up|0
6307811|NCT02610816|10034884|FG003|Phase 1|Lost to Follow-up|0
6307812|NCT02610816|10034881|FG000|Phase 1|Physician Decision|0
6307813|NCT02610816|10034882|FG001|Phase 1|Physician Decision|1
6307814|NCT02610816|10034883|FG002|Phase 1|Physician Decision|0
6307815|NCT02610816|10034884|FG003|Phase 1|Physician Decision|0
6307816|NCT02610816|10034881|FG000|Phase 2|Withdrawal by Subject|0
6307817|NCT02610816|10034882|FG001|Phase 2|Withdrawal by Subject|0
6307818|NCT02610816|10034883|FG002|Phase 2|Withdrawal by Subject|9
6307819|NCT02610816|10034884|FG003|Phase 2|Withdrawal by Subject|3
6307820|NCT02610816|10034881|FG000|Phase 2|Lost to Follow-up|0
6307821|NCT02610816|10034882|FG001|Phase 2|Lost to Follow-up|0
6307822|NCT02610816|10034883|FG002|Phase 2|Lost to Follow-up|2
6307823|NCT02610816|10034884|FG003|Phase 2|Lost to Follow-up|0
6307824|NCT02610816|10034881|FG000|Phase 2|Physician Decision|0
6307825|NCT02610816|10034882|FG001|Phase 2|Physician Decision|0
6307826|NCT02610816|10034883|FG002|Phase 2|Physician Decision|0
6307827|NCT02610816|10034884|FG003|Phase 2|Physician Decision|2
6307828|NCT02610816|10034881|FG000|Phase 2|Pregnancy|0
6307829|NCT02610816|10034882|FG001|Phase 2|Pregnancy|0
6307830|NCT02610816|10034883|FG002|Phase 2|Pregnancy|0
6307831|NCT02610816|10034884|FG003|Phase 2|Pregnancy|1
6307832|NCT02610842|10034894|FG000|Overall Study|Lost to Follow-up|5
6307833|NCT02611362|10034950|FG000|Overall Study|Withdrawal by Subject|7
6307834|NCT02611362|10034951|FG001|Overall Study|Withdrawal by Subject|2
6307835|NCT02611362|10034950|FG000|Overall Study|Lost to Follow-up|2
6307836|NCT02611362|10034951|FG001|Overall Study|Lost to Follow-up|4
6307837|NCT02611479|10034958|FG000|Baseline Enrollment|Exited study|13
6307838|NCT02611479|10034958|FG000|Post-Surgery Follow-up at 30-90 Days|No surgery reported|2
6307839|NCT02611479|10034958|FG000|Post-Surgery Follow-up at 1-Year|Lost to Follow-up|18
6307840|NCT02611479|10034958|FG000|Data Cleaning|No baseline function or pain metrics|2
6307841|NCT02611752|10034964|FG000|Overall Study|Adverse Event|0
6307842|NCT02611752|10034965|FG001|Overall Study|Adverse Event|1
6307843|NCT02611778|10034995|FG000|Overall Study|Withdrawal by Subject|2
6307844|NCT02611778|10034996|FG001|Overall Study|Withdrawal by Subject|8
6307845|NCT02611778|10034995|FG000|Overall Study|Adverse Event|1
6307846|NCT02611778|10034996|FG001|Overall Study|Adverse Event|2
6307847|NCT02611778|10034995|FG000|Overall Study|Death|2
6307848|NCT02611778|10034996|FG001|Overall Study|Death|1
6307849|NCT02611778|10034995|FG000|Overall Study|Protocol Violation|1
6307850|NCT02611778|10034996|FG001|Overall Study|Protocol Violation|0
6307851|NCT02611778|10034995|FG000|Overall Study|Lost to Follow-up|3
6307852|NCT02611778|10034996|FG001|Overall Study|Lost to Follow-up|1
6307853|NCT02611778|10034995|FG000|Overall Study|Need for alternative treatment|1
6307854|NCT02611778|10034996|FG001|Overall Study|Need for alternative treatment|0
6307855|NCT02611778|10034995|FG000|Overall Study|Other Reason|2
6307856|NCT02611778|10034996|FG001|Overall Study|Other Reason|1
6307857|NCT02611882|10035006|FG000|Overall Study|Did not complete prostatectomy per protocol stipulation|33
6307858|NCT02611882|10035007|FG001|Overall Study|Did not complete prostatectomy per protocol stipulation|0
6307859|NCT02611882|10035008|FG002|Overall Study|Did not complete prostatectomy per protocol stipulation|0
6307860|NCT02612064|10035017|FG000|Overall Study|Withdrawal by Subject|1
6307861|NCT02612064|10035018|FG001|Overall Study|Withdrawal by Subject|1
6307862|NCT02612064|10035017|FG000|Overall Study|Other|0
6307863|NCT02612064|10035018|FG001|Overall Study|Other|2
6307864|NCT02612077|10035024|FG000|Overall Study|Adverse Event|3
6307865|NCT02612077|10035024|FG000|Overall Study|Withdrawal by Subject|9
6307866|NCT02612077|10035024|FG000|Overall Study|Protocol Violation|28
6307867|NCT02612077|10035024|FG000|Overall Study|Lost to Follow-up|20
6307868|NCT02612077|10035024|FG000|Overall Study|Death|377
6307869|NCT02612077|10035024|FG000|Overall Study|Moved or Changed Medical Team|23
6307870|NCT02612077|10035024|FG000|Overall Study|Enrollment in a Clinical Trial|1
6307871|NCT02612077|10035024|FG000|Overall Study|Disease Progression|3
6307872|NCT02612077|10035024|FG000|Overall Study|Unknown reason|2
6307873|NCT02612155|10035033|FG000|Overall Study|Death|1
6307874|NCT02612155|10035034|FG001|Overall Study|Death|1
6307875|NCT02612155|10035033|FG000|Overall Study|Lost to Follow-up|2
6307876|NCT02612155|10035034|FG001|Overall Study|Lost to Follow-up|2
6307877|NCT02612428|10035042|FG000|VTL-308|Death|14
6307878|NCT02612428|10035043|FG001|VTL-308|Death|16
6307879|NCT02612428|10035042|FG000|VTL-308|Withdrawal by Subject|0
6307880|NCT02612428|10035043|FG001|VTL-308|Withdrawal by Subject|1
6307881|NCT02612428|10035042|FG000|VTL-308E|Death|9
6307882|NCT02612428|10035043|FG001|VTL-308E|Death|7
6307883|NCT02612428|10035042|FG000|VTL-308E|Lost to Follow-up|2
6307884|NCT02612428|10035043|FG001|VTL-308E|Lost to Follow-up|0
6307885|NCT02612610|10035053|FG000|Overall Study|Withdrawal by Subject|1
6307886|NCT02612610|10035054|FG001|Overall Study|Withdrawal by Subject|1
6307887|NCT02612610|10035055|FG002|Overall Study|Withdrawal by Subject|0
6307888|NCT02612610|10035056|FG003|Overall Study|Withdrawal by Subject|2
6307889|NCT02612610|10035053|FG000|Overall Study|Adverse Event|2
6307890|NCT02612610|10035054|FG001|Overall Study|Adverse Event|2
6307891|NCT02612610|10035055|FG002|Overall Study|Adverse Event|3
6307892|NCT02612610|10035056|FG003|Overall Study|Adverse Event|10
6307893|NCT02612610|10035053|FG000|Overall Study|Lost to Follow-up|0
6307894|NCT02612610|10035054|FG001|Overall Study|Lost to Follow-up|1
6307895|NCT02612610|10035055|FG002|Overall Study|Lost to Follow-up|0
6307896|NCT02612610|10035056|FG003|Overall Study|Lost to Follow-up|0
6307897|NCT02612610|10035053|FG000|Overall Study|Protocol Violation|0
6307898|NCT02612610|10035054|FG001|Overall Study|Protocol Violation|1
6307899|NCT02612610|10035055|FG002|Overall Study|Protocol Violation|1
6307900|NCT02612610|10035056|FG003|Overall Study|Protocol Violation|0
6307901|NCT02612610|10035053|FG000|Overall Study|Lack of Efficacy|1
6307902|NCT02612610|10035054|FG001|Overall Study|Lack of Efficacy|2
6307903|NCT02612610|10035055|FG002|Overall Study|Lack of Efficacy|0
6307904|NCT02612610|10035056|FG003|Overall Study|Lack of Efficacy|1
6307905|NCT02612610|10035053|FG000|Overall Study|Physician Decision|0
6307906|NCT02612610|10035054|FG001|Overall Study|Physician Decision|1
6307907|NCT02612610|10035055|FG002|Overall Study|Physician Decision|0
6307908|NCT02612610|10035056|FG003|Overall Study|Physician Decision|0
6307909|NCT02612610|10035053|FG000|Overall Study|Noncompliance|1
6307910|NCT02612610|10035054|FG001|Overall Study|Noncompliance|0
6307911|NCT02612610|10035055|FG002|Overall Study|Noncompliance|0
6307912|NCT02612610|10035056|FG003|Overall Study|Noncompliance|0
6307913|NCT02612610|10035053|FG000|Overall Study|Cough Improvement|0
6307914|NCT02612610|10035054|FG001|Overall Study|Cough Improvement|0
6307915|NCT02612610|10035055|FG002|Overall Study|Cough Improvement|1
6307916|NCT02612610|10035056|FG003|Overall Study|Cough Improvement|0
6307917|NCT02612623|10035070|FG000|Overall Study|Withdrawal by Subject|0
6307918|NCT02612623|10035071|FG001|Overall Study|Withdrawal by Subject|1
6307919|NCT02612623|10035072|FG002|Overall Study|Withdrawal by Subject|0
6307920|NCT02612623|10035073|FG003|Overall Study|Withdrawal by Subject|0
6307921|NCT02612623|10035070|FG000|Overall Study|Adverse Event|1
6307922|NCT02612623|10035071|FG001|Overall Study|Adverse Event|0
6307923|NCT02612623|10035072|FG002|Overall Study|Adverse Event|1
6307924|NCT02612623|10035073|FG003|Overall Study|Adverse Event|0
6307925|NCT02612727|10035096|FG000|Overall Study|Parent request|4
6307926|NCT02612727|10035097|FG001|Overall Study|Parent request|1
6307927|NCT02612727|10035096|FG000|Overall Study|Needed treatment incompatible with PT|1
6307928|NCT02612727|10035097|FG001|Overall Study|Needed treatment incompatible with PT|1
6307929|NCT02612727|10035096|FG000|Overall Study|Direct hyperbilirubinemia|0
6307930|NCT02612727|10035097|FG001|Overall Study|Direct hyperbilirubinemia|2
6307931|NCT02612779|10035105|FG000|Overall Study|Administrative reason by sponsor|4
6307932|NCT02612779|10035106|FG001|Overall Study|Administrative reason by sponsor|1
6307933|NCT02612779|10035105|FG000|Overall Study|No longer meet study criteria|0
6307934|NCT02612779|10035106|FG001|Overall Study|No longer meet study criteria|1
5989003|NCT03493854|9580410|FG001|Surgery & Adjuvant Treatment (42 Weeks)|Adverse Event|2
6307935|NCT02612779|10035105|FG000|Overall Study|Disease progression|29
6307936|NCT02612779|10035106|FG001|Overall Study|Disease progression|2
6307937|NCT02612779|10035105|FG000|Overall Study|Study drug toxicity|10
6307938|NCT02612779|10035106|FG001|Overall Study|Study drug toxicity|1
6307939|NCT02612779|10035105|FG000|Overall Study|Death|1
6307940|NCT02612779|10035106|FG001|Overall Study|Death|0
6307941|NCT02612779|10035105|FG000|Overall Study|Adverse event unrelated to study drug|5
6307942|NCT02612779|10035106|FG001|Overall Study|Adverse event unrelated to study drug|0
6307943|NCT02612779|10035105|FG000|Overall Study|Participant withdrew consent|4
6307944|NCT02612779|10035106|FG001|Overall Study|Participant withdrew consent|0
6307945|NCT02612779|10035105|FG000|Overall Study|Lost to Follow-up|1
6307946|NCT02612779|10035106|FG001|Overall Study|Lost to Follow-up|0
6307947|NCT02612779|10035105|FG000|Overall Study|Maximum clinical benefit|10
6307948|NCT02612779|10035106|FG001|Overall Study|Maximum clinical benefit|1
6307949|NCT02612779|10035105|FG000|Overall Study|Other reasons|4
6307950|NCT02612779|10035106|FG001|Overall Study|Other reasons|0
6307951|NCT02612909|10035131|FG000|Phase 2|Withdrawal by Subject|2
6307952|NCT02612909|10035132|FG001|Phase 2|Withdrawal by Subject|5
6307953|NCT02612909|10035133|FG002|Phase 2|Withdrawal by Subject|0
6307954|NCT02612909|10035134|FG003|Phase 2|Withdrawal by Subject|0
6307955|NCT02612909|10035135|FG004|Phase 2|Withdrawal by Subject|0
6307956|NCT02612909|10035131|FG000|Phase 2|Pregnancy|0
6307957|NCT02612909|10035132|FG001|Phase 2|Pregnancy|0
6307958|NCT02612909|10035133|FG002|Phase 2|Pregnancy|1
6307959|NCT02612909|10035134|FG003|Phase 2|Pregnancy|0
6307960|NCT02612909|10035135|FG004|Phase 2|Pregnancy|0
6307961|NCT02612909|10035131|FG000|Phase 3|Withdrawal by Subject|0
6307962|NCT02612909|10035132|FG001|Phase 3|Withdrawal by Subject|0
6307963|NCT02612909|10035133|FG002|Phase 3|Withdrawal by Subject|0
6307964|NCT02612909|10035134|FG003|Phase 3|Withdrawal by Subject|1
6307965|NCT02612909|10035135|FG004|Phase 3|Withdrawal by Subject|0
6307966|NCT02613169|10035160|FG000|Overall Study|Withdrawal by Subject|4
6307967|NCT02613169|10035161|FG001|Overall Study|Withdrawal by Subject|1
6307968|NCT02613169|10035160|FG000|Overall Study|Lost to Follow-up|0
6307969|NCT02613169|10035161|FG001|Overall Study|Lost to Follow-up|5
6307970|NCT02613169|10035160|FG000|Overall Study|HIV|0
6307971|NCT02613169|10035161|FG001|Overall Study|HIV|2
6307972|NCT02613169|10035160|FG000|Overall Study|No TB infection endpoint|14
6307973|NCT02613169|10035161|FG001|Overall Study|No TB infection endpoint|9
6307974|NCT02613182|10035167|FG000|Overall Study|Death|6
6307975|NCT02613182|10035167|FG000|Overall Study|Physician Decision|1
6307976|NCT02613182|10035167|FG000|Overall Study|Study Terminated by Sponsor|21
6307977|NCT02613182|10035167|FG000|Overall Study|Withdrawal by Subject|6
6307978|NCT02613208|10035171|FG000|Overall Study|Withdrawal by Subject|1
6307979|NCT02613208|10035171|FG000|Overall Study|Change of address|2
6307980|NCT02613208|10035171|FG000|Overall Study|Physician Decision|2
6307981|NCT02613208|10035171|FG000|Overall Study|Lost to Follow-up|5
6307982|NCT02613208|10035171|FG000|Overall Study|Death|37
6307983|NCT02613221|10035175|FG000|Overall Study|Lack of efficacy (exacerbation)|50
6307984|NCT02613221|10035175|FG000|Overall Study|Adverse Event|2
6307985|NCT02613221|10035175|FG000|Overall Study|Voluntary Discontinuation|1
6307986|NCT02613221|10035175|FG000|Overall Study|Delayed Treatment|1
6307987|NCT02613221|10035175|FG000|Overall Study|Enrolled but Not Treated|1
6307988|NCT02613364|10035186|FG000|Overall Study|Other|19
6307989|NCT02613364|10035187|FG001|Overall Study|Other|29
6307990|NCT02613364|10035188|FG002|Overall Study|Other|17
6307991|NCT02613364|10035186|FG000|Overall Study|Too time consuming|21
6307992|NCT02613364|10035187|FG001|Overall Study|Too time consuming|26
6307993|NCT02613364|10035188|FG002|Overall Study|Too time consuming|26
6307994|NCT02613364|10035186|FG000|Overall Study|Withdrawal by Subject|13
6307995|NCT02613364|10035187|FG001|Overall Study|Withdrawal by Subject|18
6307996|NCT02613364|10035188|FG002|Overall Study|Withdrawal by Subject|17
6307997|NCT02613364|10035186|FG000|Overall Study|Medical|12
6307998|NCT02613364|10035187|FG001|Overall Study|Medical|13
6307999|NCT02613364|10035188|FG002|Overall Study|Medical|9
6308000|NCT02613364|10035186|FG000|Overall Study|Disliked Study Procedure|1
6308001|NCT02613364|10035187|FG001|Overall Study|Disliked Study Procedure|1
6308002|NCT02613364|10035188|FG002|Overall Study|Disliked Study Procedure|4
6308003|NCT02613364|10035186|FG000|Overall Study|Disliked Intervention|0
6308004|NCT02613364|10035187|FG001|Overall Study|Disliked Intervention|3
6308005|NCT02613364|10035188|FG002|Overall Study|Disliked Intervention|3
6308006|NCT02613403|10035200|FG000|Overall Study|Lost to Follow-up|0
6308007|NCT02613403|10035201|FG001|Overall Study|Lost to Follow-up|1
6308008|NCT02613403|10035202|FG002|Overall Study|Lost to Follow-up|0
6308009|NCT02613403|10035203|FG003|Overall Study|Lost to Follow-up|0
6308010|NCT02613403|10035204|FG004|Overall Study|Lost to Follow-up|0
6308011|NCT02613403|10035200|FG000|Overall Study|Withdrawal by Subject|2
6308012|NCT02613403|10035201|FG001|Overall Study|Withdrawal by Subject|0
6308013|NCT02613403|10035202|FG002|Overall Study|Withdrawal by Subject|0
6308014|NCT02613403|10035203|FG003|Overall Study|Withdrawal by Subject|0
6308015|NCT02613403|10035204|FG004|Overall Study|Withdrawal by Subject|0
6308016|NCT02613481|10035214|FG000|Overall Study|Lost to Follow-up|7
6308017|NCT02613481|10035214|FG000|Overall Study|Withdrawal by Subject|2
6308018|NCT02613572|10035221|FG000|Phase I: Tolerability, 600, 800, 1200 mg|Physician Decision|1
6308019|NCT02613572|10035222|FG001|Phase I: Tolerability, 600, 800, 1200 mg|Physician Decision|0
5989004|NCT03493854|9580409|FG000|Surgery & Adjuvant Treatment (42 Weeks)|Lack of Efficacy|0
6308020|NCT02613572|10035223|FG002|Phase I: Tolerability, 600, 800, 1200 mg|Physician Decision|0
6308021|NCT02613572|10035221|FG000|Phase II: Double-Blind Rand Plac Control|Death|0
6308022|NCT02613572|10035222|FG001|Phase II: Double-Blind Rand Plac Control|Death|1
6308023|NCT02613572|10035223|FG002|Phase II: Double-Blind Rand Plac Control|Death|0
6308024|NCT02613871|10035235|FG000|Overall Study|Death|2
6308025|NCT02613871|10035235|FG000|Overall Study|Withdrew Consent|1
6308026|NCT02613884|10035239|FG000|Overall Study|Death|1
6308027|NCT02613884|10035239|FG000|Overall Study|Lost to Follow-up|1
6308028|NCT02613910|10035258|FG000|Overall Study|Termination of study|1
6308029|NCT02614079|10035262|FG000|Overall Study|Withdrawal by Subject|1
6308030|NCT02614131|10035273|FG000|Overall Study|Withdrawal by Subject|1
6308031|NCT02614131|10035274|FG001|Overall Study|Withdrawal by Subject|0
6308032|NCT02614131|10035275|FG002|Overall Study|Withdrawal by Subject|0
6308033|NCT02614131|10035276|FG003|Overall Study|Withdrawal by Subject|0
6308034|NCT02614131|10035277|FG004|Overall Study|Withdrawal by Subject|0
6308035|NCT02614131|10035278|FG005|Overall Study|Withdrawal by Subject|0
6308036|NCT02614131|10035279|FG006|Overall Study|Withdrawal by Subject|0
6308037|NCT02614131|10035273|FG000|Overall Study|Adverse Event|0
6308038|NCT02614131|10035274|FG001|Overall Study|Adverse Event|0
6308039|NCT02614131|10035275|FG002|Overall Study|Adverse Event|0
6308040|NCT02614131|10035276|FG003|Overall Study|Adverse Event|0
6308041|NCT02614131|10035277|FG004|Overall Study|Adverse Event|0
6308042|NCT02614131|10035278|FG005|Overall Study|Adverse Event|0
6308043|NCT02614131|10035279|FG006|Overall Study|Adverse Event|1
6308044|NCT02614183|10035304|FG000|Double Blind Treatment Phase|Adverse Event|10
6308045|NCT02614183|10035305|FG001|Double Blind Treatment Phase|Adverse Event|9
6308046|NCT02614183|10035306|FG002|Double Blind Treatment Phase|Adverse Event|7
6308047|NCT02614183|10035304|FG000|Double Blind Treatment Phase|Lack of Efficacy|10
6308048|NCT02614183|10035305|FG001|Double Blind Treatment Phase|Lack of Efficacy|1
6308049|NCT02614183|10035306|FG002|Double Blind Treatment Phase|Lack of Efficacy|2
5989005|NCT03493854|9580410|FG001|Surgery & Adjuvant Treatment (42 Weeks)|Lack of Efficacy|1
5989006|NCT03493854|9580409|FG000|Surgery & Adjuvant Treatment (42 Weeks)|Progressive Disease|3
5989007|NCT03493854|9580410|FG001|Surgery & Adjuvant Treatment (42 Weeks)|Progressive Disease|0
6308050|NCT02614183|10035304|FG000|Double Blind Treatment Phase|Lost to Follow-up|18
6308051|NCT02614183|10035305|FG001|Double Blind Treatment Phase|Lost to Follow-up|9
6308052|NCT02614183|10035306|FG002|Double Blind Treatment Phase|Lost to Follow-up|5
6308053|NCT02614183|10035304|FG000|Double Blind Treatment Phase|Physician Decision|7
6308054|NCT02614183|10035305|FG001|Double Blind Treatment Phase|Physician Decision|3
6308055|NCT02614183|10035306|FG002|Double Blind Treatment Phase|Physician Decision|2
6308056|NCT02614183|10035304|FG000|Double Blind Treatment Phase|Pregnancy|2
6308057|NCT02614183|10035305|FG001|Double Blind Treatment Phase|Pregnancy|1
6308058|NCT02614183|10035306|FG002|Double Blind Treatment Phase|Pregnancy|3
6308059|NCT02614183|10035304|FG000|Double Blind Treatment Phase|Protocol Violation|2
6308060|NCT02614183|10035305|FG001|Double Blind Treatment Phase|Protocol Violation|2
6308061|NCT02614183|10035306|FG002|Double Blind Treatment Phase|Protocol Violation|2
6308062|NCT02614183|10035304|FG000|Double Blind Treatment Phase|Withdrawal by Subject|33
6308063|NCT02614183|10035305|FG001|Double Blind Treatment Phase|Withdrawal by Subject|11
5989008|NCT03493854|9580409|FG000|Surgery & Adjuvant Treatment (42 Weeks)|Protocol Violation|1
5989009|NCT03493854|9580410|FG001|Surgery & Adjuvant Treatment (42 Weeks)|Protocol Violation|0
5989010|NCT03493854|9580409|FG000|Surgery & Adjuvant Treatment (42 Weeks)|Withdrawal by Subject|2
5989011|NCT03493854|9580410|FG001|Surgery & Adjuvant Treatment (42 Weeks)|Withdrawal by Subject|0
5989012|NCT03493854|9580409|FG000|Surgery & Adjuvant Treatment (42 Weeks)|Other|5
5989013|NCT03493854|9580410|FG001|Surgery & Adjuvant Treatment (42 Weeks)|Other|3
5989014|NCT03493854|9580409|FG000|Treatment-Free Follow-Up (up to 3 Years)|Withdrawal by Subject|1
5989015|NCT03493854|9580410|FG001|Treatment-Free Follow-Up (up to 3 Years)|Withdrawal by Subject|1
5989016|NCT03493854|9580409|FG000|Treatment-Free Follow-Up (up to 3 Years)|Ongoing in Follow-Up|18
5989017|NCT03493854|9580410|FG001|Treatment-Free Follow-Up (up to 3 Years)|Ongoing in Follow-Up|16
6308064|NCT02614183|10035306|FG002|Double Blind Treatment Phase|Withdrawal by Subject|16
6308065|NCT02614183|10035304|FG000|Double Blind Treatment Phase|Did not receive study drug|1
6308066|NCT02614183|10035305|FG001|Double Blind Treatment Phase|Did not receive study drug|1
6308067|NCT02614183|10035306|FG002|Double Blind Treatment Phase|Did not receive study drug|2
6308068|NCT02614183|10035304|FG000|Post Treatment Follow-up Phase|Lost to Follow-up|5
6308069|NCT02614183|10035305|FG001|Post Treatment Follow-up Phase|Lost to Follow-up|3
6308070|NCT02614183|10035306|FG002|Post Treatment Follow-up Phase|Lost to Follow-up|5
6308071|NCT02614183|10035304|FG000|Post Treatment Follow-up Phase|Physician Decision|5
6308072|NCT02614183|10035305|FG001|Post Treatment Follow-up Phase|Physician Decision|1
6308073|NCT02614183|10035306|FG002|Post Treatment Follow-up Phase|Physician Decision|2
6308074|NCT02614183|10035304|FG000|Post Treatment Follow-up Phase|Protocol Violation|1
6308075|NCT02614183|10035305|FG001|Post Treatment Follow-up Phase|Protocol Violation|0
6308076|NCT02614183|10035306|FG002|Post Treatment Follow-up Phase|Protocol Violation|0
6308077|NCT02614183|10035304|FG000|Post Treatment Follow-up Phase|Withdrawal by Subject|7
6308078|NCT02614183|10035305|FG001|Post Treatment Follow-up Phase|Withdrawal by Subject|2
6308079|NCT02614183|10035306|FG002|Post Treatment Follow-up Phase|Withdrawal by Subject|5
6308080|NCT02614196|10035326|FG000|Double Blind Treatment Phase|Adverse Event|8
6308081|NCT02614196|10035327|FG001|Double Blind Treatment Phase|Adverse Event|5
6308082|NCT02614196|10035328|FG002|Double Blind Treatment Phase|Adverse Event|9
6308083|NCT02614196|10035329|FG003|Double Blind Treatment Phase|Adverse Event|0
6308084|NCT02614196|10035330|FG004|Double Blind Treatment Phase|Adverse Event|0
6308085|NCT02614196|10035331|FG005|Double Blind Treatment Phase|Adverse Event|0
6308086|NCT02614196|10035326|FG000|Double Blind Treatment Phase|Lack of Efficacy|6
6308087|NCT02614196|10035327|FG001|Double Blind Treatment Phase|Lack of Efficacy|1
6308088|NCT02614196|10035328|FG002|Double Blind Treatment Phase|Lack of Efficacy|1
6308089|NCT02614196|10035329|FG003|Double Blind Treatment Phase|Lack of Efficacy|0
6308090|NCT02614196|10035330|FG004|Double Blind Treatment Phase|Lack of Efficacy|0
6308091|NCT02614196|10035331|FG005|Double Blind Treatment Phase|Lack of Efficacy|0
6308092|NCT02614196|10035326|FG000|Double Blind Treatment Phase|Lost to Follow-up|10
6308093|NCT02614196|10035327|FG001|Double Blind Treatment Phase|Lost to Follow-up|7
6308094|NCT02614196|10035328|FG002|Double Blind Treatment Phase|Lost to Follow-up|1
6308095|NCT02614196|10035329|FG003|Double Blind Treatment Phase|Lost to Follow-up|0
6308096|NCT02614196|10035330|FG004|Double Blind Treatment Phase|Lost to Follow-up|0
6308097|NCT02614196|10035331|FG005|Double Blind Treatment Phase|Lost to Follow-up|0
6308098|NCT02614196|10035326|FG000|Double Blind Treatment Phase|Physician Decision|4
6308099|NCT02614196|10035327|FG001|Double Blind Treatment Phase|Physician Decision|0
6308100|NCT02614196|10035328|FG002|Double Blind Treatment Phase|Physician Decision|2
6308101|NCT02614196|10035329|FG003|Double Blind Treatment Phase|Physician Decision|0
6308102|NCT02614196|10035330|FG004|Double Blind Treatment Phase|Physician Decision|0
6308103|NCT02614196|10035331|FG005|Double Blind Treatment Phase|Physician Decision|0
6308104|NCT02614196|10035326|FG000|Double Blind Treatment Phase|Pregnancy|1
6308105|NCT02614196|10035327|FG001|Double Blind Treatment Phase|Pregnancy|2
6308106|NCT02614196|10035328|FG002|Double Blind Treatment Phase|Pregnancy|0
6308107|NCT02614196|10035329|FG003|Double Blind Treatment Phase|Pregnancy|0
6308108|NCT02614196|10035330|FG004|Double Blind Treatment Phase|Pregnancy|0
6308109|NCT02614196|10035331|FG005|Double Blind Treatment Phase|Pregnancy|0
6308110|NCT02614196|10035326|FG000|Double Blind Treatment Phase|Protocol Violation|5
5989018|NCT03493451|9580419|FG000|Overall Study|Death|11
5989019|NCT03493451|9580420|FG001|Overall Study|Death|26
5989020|NCT03493451|9580421|FG002|Overall Study|Death|3
5989021|NCT03493451|9580419|FG000|Overall Study|Lost to Follow-up|1
5989022|NCT03493451|9580420|FG001|Overall Study|Lost to Follow-up|4
5989023|NCT03493451|9580421|FG002|Overall Study|Lost to Follow-up|1
5989024|NCT03493451|9580419|FG000|Overall Study|Withdrawal by Subject|1
5989025|NCT03493451|9580420|FG001|Overall Study|Withdrawal by Subject|1
6308111|NCT02614196|10035327|FG001|Double Blind Treatment Phase|Protocol Violation|2
6308112|NCT02614196|10035328|FG002|Double Blind Treatment Phase|Protocol Violation|1
6308113|NCT02614196|10035329|FG003|Double Blind Treatment Phase|Protocol Violation|0
6308114|NCT02614196|10035330|FG004|Double Blind Treatment Phase|Protocol Violation|1
6308115|NCT02614196|10035331|FG005|Double Blind Treatment Phase|Protocol Violation|0
6308116|NCT02614196|10035326|FG000|Double Blind Treatment Phase|Terminated by sponsor|1
6308117|NCT02614196|10035327|FG001|Double Blind Treatment Phase|Terminated by sponsor|0
6308118|NCT02614196|10035328|FG002|Double Blind Treatment Phase|Terminated by sponsor|0
6308119|NCT02614196|10035329|FG003|Double Blind Treatment Phase|Terminated by sponsor|0
6308120|NCT02614196|10035330|FG004|Double Blind Treatment Phase|Terminated by sponsor|0
6308121|NCT02614196|10035331|FG005|Double Blind Treatment Phase|Terminated by sponsor|0
6308122|NCT02614196|10035326|FG000|Double Blind Treatment Phase|Withdrawal by Subject|39
6308123|NCT02614196|10035327|FG001|Double Blind Treatment Phase|Withdrawal by Subject|11
6308124|NCT02614196|10035328|FG002|Double Blind Treatment Phase|Withdrawal by Subject|14
6308125|NCT02614196|10035329|FG003|Double Blind Treatment Phase|Withdrawal by Subject|4
6308126|NCT02614196|10035330|FG004|Double Blind Treatment Phase|Withdrawal by Subject|0
6308127|NCT02614196|10035331|FG005|Double Blind Treatment Phase|Withdrawal by Subject|0
6308128|NCT02614196|10035326|FG000|Double Blind Treatment Phase|Did not receive study drug|2
6308129|NCT02614196|10035327|FG001|Double Blind Treatment Phase|Did not receive study drug|2
6308130|NCT02614196|10035328|FG002|Double Blind Treatment Phase|Did not receive study drug|3
6308131|NCT02614196|10035329|FG003|Double Blind Treatment Phase|Did not receive study drug|0
5989026|NCT03493451|9580421|FG002|Overall Study|Withdrawal by Subject|2
5989027|NCT03493451|9580419|FG000|Overall Study|Progressive Disease|1
5989028|NCT03493451|9580420|FG001|Overall Study|Progressive Disease|0
6308132|NCT02614196|10035330|FG004|Double Blind Treatment Phase|Did not receive study drug|0
6308133|NCT02614196|10035331|FG005|Double Blind Treatment Phase|Did not receive study drug|0
6308134|NCT02614196|10035326|FG000|Post Treatment Follow-up Phase|Lost to Follow-up|8
6308135|NCT02614196|10035327|FG001|Post Treatment Follow-up Phase|Lost to Follow-up|3
6308136|NCT02614196|10035328|FG002|Post Treatment Follow-up Phase|Lost to Follow-up|3
6308137|NCT02614196|10035329|FG003|Post Treatment Follow-up Phase|Lost to Follow-up|0
6308138|NCT02614196|10035330|FG004|Post Treatment Follow-up Phase|Lost to Follow-up|1
6308139|NCT02614196|10035331|FG005|Post Treatment Follow-up Phase|Lost to Follow-up|0
6308140|NCT02614196|10035326|FG000|Post Treatment Follow-up Phase|Pregnancy|2
6308141|NCT02614196|10035327|FG001|Post Treatment Follow-up Phase|Pregnancy|0
6308142|NCT02614196|10035328|FG002|Post Treatment Follow-up Phase|Pregnancy|0
6308143|NCT02614196|10035329|FG003|Post Treatment Follow-up Phase|Pregnancy|0
6308144|NCT02614196|10035330|FG004|Post Treatment Follow-up Phase|Pregnancy|0
6308145|NCT02614196|10035331|FG005|Post Treatment Follow-up Phase|Pregnancy|0
6308146|NCT02614196|10035326|FG000|Post Treatment Follow-up Phase|Protocol Violation|0
6308147|NCT02614196|10035327|FG001|Post Treatment Follow-up Phase|Protocol Violation|1
6308148|NCT02614196|10035328|FG002|Post Treatment Follow-up Phase|Protocol Violation|0
6308149|NCT02614196|10035329|FG003|Post Treatment Follow-up Phase|Protocol Violation|0
6308150|NCT02614196|10035330|FG004|Post Treatment Follow-up Phase|Protocol Violation|1
6308151|NCT02614196|10035331|FG005|Post Treatment Follow-up Phase|Protocol Violation|0
6308152|NCT02614196|10035326|FG000|Post Treatment Follow-up Phase|Withdrawal by Subject|10
6308153|NCT02614196|10035327|FG001|Post Treatment Follow-up Phase|Withdrawal by Subject|1
6308154|NCT02614196|10035328|FG002|Post Treatment Follow-up Phase|Withdrawal by Subject|5
6308155|NCT02614196|10035329|FG003|Post Treatment Follow-up Phase|Withdrawal by Subject|1
6308156|NCT02614196|10035330|FG004|Post Treatment Follow-up Phase|Withdrawal by Subject|0
6308157|NCT02614196|10035331|FG005|Post Treatment Follow-up Phase|Withdrawal by Subject|0
6308158|NCT02614287|10035374|FG000|Open Label (OL) Treatment Phase|Adverse Event|7
6308159|NCT02614287|10035375|FG001|Open Label (OL) Treatment Phase|Adverse Event|6
6308160|NCT02614287|10035374|FG000|Open Label (OL) Treatment Phase|Lack of Efficacy|13
6308161|NCT02614287|10035375|FG001|Open Label (OL) Treatment Phase|Lack of Efficacy|5
6308162|NCT02614287|10035374|FG000|Open Label (OL) Treatment Phase|Lost to Follow-up|7
6308163|NCT02614287|10035375|FG001|Open Label (OL) Treatment Phase|Lost to Follow-up|4
6308164|NCT02614287|10035374|FG000|Open Label (OL) Treatment Phase|Physician Decision|1
6308165|NCT02614287|10035375|FG001|Open Label (OL) Treatment Phase|Physician Decision|0
6308166|NCT02614287|10035374|FG000|Open Label (OL) Treatment Phase|Withdrawal by Subject|10
6308167|NCT02614287|10035375|FG001|Open Label (OL) Treatment Phase|Withdrawal by Subject|7
6308168|NCT02614287|10035374|FG000|Post Treatment Follow-up Phase|Adverse Event|1
6308169|NCT02614287|10035375|FG001|Post Treatment Follow-up Phase|Adverse Event|0
6308170|NCT02614287|10035374|FG000|Post Treatment Follow-up Phase|Lost to Follow-up|2
6308171|NCT02614287|10035375|FG001|Post Treatment Follow-up Phase|Lost to Follow-up|2
6308172|NCT02614287|10035374|FG000|Post Treatment Follow-up Phase|Withdrawal by Subject|6
6308173|NCT02614287|10035375|FG001|Post Treatment Follow-up Phase|Withdrawal by Subject|3
6308174|NCT02614560|10035397|FG000|Overall Study|Death|6
6308175|NCT02614560|10035398|FG001|Overall Study|Death|2
6308176|NCT02614703|10035406|FG000|Overall Study|Withdrawal by Subject|7
6308177|NCT02614703|10035407|FG001|Overall Study|Withdrawal by Subject|1
6308178|NCT02614729|10035415|FG000|Overall Study|Withdrawal by Subject|1
6308179|NCT02614729|10035416|FG001|Overall Study|Withdrawal by Subject|0
6308180|NCT02614794|10035426|FG000|Overall Study|On treatment|118
6308181|NCT02614794|10035427|FG001|Overall Study|On treatment|27
6308182|NCT02614794|10035426|FG000|Overall Study|In long term follow up|148
6308183|NCT02614794|10035427|FG001|Overall Study|In long term follow up|85
6308184|NCT02614794|10035426|FG000|Overall Study|Death|126
6308185|NCT02614794|10035427|FG001|Overall Study|Death|84
6308186|NCT02614794|10035426|FG000|Overall Study|Withdrawal by Subject|16
6308187|NCT02614794|10035427|FG001|Overall Study|Withdrawal by Subject|5
6308188|NCT02614794|10035426|FG000|Overall Study|Lost to Follow-up|2
6308189|NCT02614794|10035427|FG001|Overall Study|Lost to Follow-up|0
6308190|NCT02614794|10035426|FG000|Overall Study|Physician Decision|0
6308191|NCT02614794|10035427|FG001|Overall Study|Physician Decision|1
6308192|NCT02615145|10035446|FG000|Overall Study|Did Not Start Treatment|0
6308193|NCT02615145|10035447|FG001|Overall Study|Did Not Start Treatment|0
6308194|NCT02615145|10035448|FG002|Overall Study|Did Not Start Treatment|1
6308195|NCT02615145|10035449|FG003|Overall Study|Did Not Start Treatment|1
6308196|NCT02615145|10035446|FG000|Overall Study|Failure to Return|20
6308197|NCT02615145|10035447|FG001|Overall Study|Failure to Return|10
6308198|NCT02615145|10035448|FG002|Overall Study|Failure to Return|7
6308199|NCT02615145|10035449|FG003|Overall Study|Failure to Return|0
6308200|NCT02615145|10035446|FG000|Overall Study|Death|2
6308201|NCT02615145|10035447|FG001|Overall Study|Death|3
6308202|NCT02615145|10035448|FG002|Overall Study|Death|0
6308203|NCT02615145|10035449|FG003|Overall Study|Death|0
6308204|NCT02615145|10035446|FG000|Overall Study|Other, Not Specified|5
6308205|NCT02615145|10035447|FG001|Overall Study|Other, Not Specified|2
6308206|NCT02615145|10035448|FG002|Overall Study|Other, Not Specified|0
6308207|NCT02615145|10035449|FG003|Overall Study|Other, Not Specified|0
6308208|NCT02615171|10035490|FG000|Overall Study|Lost to Follow-up|2
6308209|NCT02615171|10035491|FG001|Overall Study|Lost to Follow-up|1
6308210|NCT02615249|10035497|FG000|Overall Study|Withdrawal by Subject|1
6308211|NCT02615470|10035504|FG000|Overall Study|Lost to Follow-up|21
6308212|NCT02615470|10035505|FG001|Overall Study|Lost to Follow-up|32
6308213|NCT02615509|10035511|FG000|Overall Study|Lost to Follow-up|134
6308214|NCT02615509|10035511|FG000|Overall Study|Death|4
6308215|NCT02615509|10035511|FG000|Overall Study|Withdrawal by Subject|8
6308216|NCT02616029|10035544|FG000|Overall Study|Adverse Event|1
6308217|NCT02616029|10035545|FG001|Overall Study|Adverse Event|0
6308218|NCT02616029|10035544|FG000|Overall Study|Death|0
6308219|NCT02616029|10035545|FG001|Overall Study|Death|1
6308220|NCT02616029|10035544|FG000|Overall Study|Protocol Violation|1
6308221|NCT02616029|10035545|FG001|Overall Study|Protocol Violation|0
6308222|NCT02616029|10035544|FG000|Overall Study|Withdrew Consent|1
6308223|NCT02616029|10035545|FG001|Overall Study|Withdrew Consent|0
6308224|NCT02616029|10035544|FG000|Overall Study|Enrolled and Never Treated|1
6308225|NCT02616029|10035545|FG001|Overall Study|Enrolled and Never Treated|1
6308226|NCT02616380|10035560|FG000|Overall Study|Lost to Follow-up|1
6308227|NCT02616380|10035560|FG000|Overall Study|Other|2
6308228|NCT02616601|10035583|FG000|Overall Study|Withdrawal by Subject|4
6308229|NCT02616601|10035584|FG001|Overall Study|Withdrawal by Subject|4
6308230|NCT02616601|10035585|FG002|Overall Study|Withdrawal by Subject|3
5989029|NCT03493451|9580421|FG002|Overall Study|Progressive Disease|0
5989030|NCT03493451|9580419|FG000|Overall Study|Transferred to long term extension study|8
5989031|NCT03493451|9580420|FG001|Overall Study|Transferred to long term extension study|13
5989032|NCT03493451|9580421|FG002|Overall Study|Transferred to long term extension study|5
5989033|NCT03476239|9580429|FG000|Overall Study|Withdrawal by Subject|10
5989034|NCT03476239|9580429|FG000|Overall Study|Death|80
5989035|NCT03476239|9580429|FG000|Overall Study|Lost to Follow-up|8
5989036|NCT03401749|9580445|FG000|Overall Study|Lost to Follow-up|20
5989037|NCT03401749|9580446|FG001|Overall Study|Lost to Follow-up|16
5989038|NCT03401749|9580447|FG002|Overall Study|Lost to Follow-up|26
5989039|NCT03337113|9580459|FG000|Overall Study|Adverse Event|1
5989040|NCT03337113|9580460|FG001|Overall Study|Adverse Event|1
5989041|NCT03337113|9580461|FG002|Overall Study|Adverse Event|0
5989042|NCT03337113|9580462|FG003|Overall Study|Adverse Event|1
5989043|NCT03337113|9580459|FG000|Overall Study|Physician Decision|0
5989044|NCT03337113|9580460|FG001|Overall Study|Physician Decision|2
5989045|NCT03337113|9580461|FG002|Overall Study|Physician Decision|0
5989046|NCT03337113|9580462|FG003|Overall Study|Physician Decision|1
5989047|NCT03337113|9580459|FG000|Overall Study|Withdrawal by Subject|0
5989048|NCT03337113|9580460|FG001|Overall Study|Withdrawal by Subject|0
5989049|NCT03337113|9580461|FG002|Overall Study|Withdrawal by Subject|1
5989050|NCT03337113|9580462|FG003|Overall Study|Withdrawal by Subject|0
5989051|NCT03299049|9580474|FG000|Overall Study|On-going|486
5989052|NCT03299049|9580475|FG001|Overall Study|On-going|481
5989053|NCT03299049|9580474|FG000|Overall Study|Withdrawal by Subject|6
5989054|NCT03299049|9580475|FG001|Overall Study|Withdrawal by Subject|21
6308231|NCT02616601|10035583|FG000|Overall Study|Adverse Event|2
6308232|NCT02616601|10035584|FG001|Overall Study|Adverse Event|0
6308233|NCT02616601|10035585|FG002|Overall Study|Adverse Event|2
6308234|NCT02616601|10035583|FG000|Overall Study|Death|1
6308235|NCT02616601|10035584|FG001|Overall Study|Death|0
6308236|NCT02616601|10035585|FG002|Overall Study|Death|0
6308237|NCT02616601|10035583|FG000|Overall Study|Lost to Follow-up|1
6308238|NCT02616601|10035584|FG001|Overall Study|Lost to Follow-up|0
6308239|NCT02616601|10035585|FG002|Overall Study|Lost to Follow-up|1
6308240|NCT02616601|10035583|FG000|Overall Study|Non-Compliance with Test Article|1
6308241|NCT02616601|10035584|FG001|Overall Study|Non-Compliance with Test Article|0
6308242|NCT02616601|10035585|FG002|Overall Study|Non-Compliance with Test Article|1
6308243|NCT02616614|10035596|FG000|Overall Study|Withdrawal by Subject|10
6308244|NCT02616614|10035597|FG001|Overall Study|Withdrawal by Subject|5
6308245|NCT02616614|10035598|FG002|Overall Study|Withdrawal by Subject|6
5989055|NCT03299049|9580474|FG000|Overall Study|Physician Decision|5
5989056|NCT03299049|9580475|FG001|Overall Study|Physician Decision|1
5989057|NCT03299049|9580474|FG000|Overall Study|Lost to Follow-up|2
5989058|NCT03299049|9580475|FG001|Overall Study|Lost to Follow-up|0
5989059|NCT03299049|9580474|FG000|Overall Study|Pregnancy|1
5989060|NCT03299049|9580475|FG001|Overall Study|Pregnancy|3
5989061|NCT03299049|9580474|FG000|Overall Study|Protocol Violation|1
5989062|NCT03299049|9580475|FG001|Overall Study|Protocol Violation|1
6308246|NCT02616614|10035596|FG000|Overall Study|Physician Decision|2
6308247|NCT02616614|10035597|FG001|Overall Study|Physician Decision|1
6308248|NCT02616614|10035598|FG002|Overall Study|Physician Decision|0
5989063|NCT03299049|9580474|FG000|Overall Study|Lack of Efficacy|9
5989064|NCT03299049|9580475|FG001|Overall Study|Lack of Efficacy|3
5989065|NCT03299049|9580474|FG000|Overall Study|Adverse Event|12
5989066|NCT03299049|9580475|FG001|Overall Study|Adverse Event|13
6308249|NCT02616614|10035596|FG000|Overall Study|Adverse Event|1
6308250|NCT02616614|10035597|FG001|Overall Study|Adverse Event|4
6308251|NCT02616614|10035598|FG002|Overall Study|Adverse Event|1
6308252|NCT02616614|10035596|FG000|Overall Study|Protocol Violation|0
6308253|NCT02616614|10035597|FG001|Overall Study|Protocol Violation|3
6308254|NCT02616614|10035598|FG002|Overall Study|Protocol Violation|1
6308255|NCT02616614|10035596|FG000|Overall Study|Prohibited Medication|12
6308256|NCT02616614|10035597|FG001|Overall Study|Prohibited Medication|9
6308257|NCT02616614|10035598|FG002|Overall Study|Prohibited Medication|5
5989067|NCT03257631|9580492|FG000|Overall Study|Death|8
6308258|NCT02616614|10035596|FG000|Overall Study|More than 3 applications missed|6
6308259|NCT02616614|10035597|FG001|Overall Study|More than 3 applications missed|8
6308260|NCT02616614|10035598|FG002|Overall Study|More than 3 applications missed|1
6308261|NCT02616614|10035596|FG000|Overall Study|Lost to Follow-up|31
6308262|NCT02616614|10035597|FG001|Overall Study|Lost to Follow-up|28
6308263|NCT02616614|10035598|FG002|Overall Study|Lost to Follow-up|13
6308264|NCT02616614|10035596|FG000|Overall Study|Pregnancy|2
6308265|NCT02616614|10035597|FG001|Overall Study|Pregnancy|0
6308266|NCT02616614|10035598|FG002|Overall Study|Pregnancy|1
6308267|NCT02616614|10035596|FG000|Overall Study|Other|1
6308268|NCT02616614|10035597|FG001|Overall Study|Other|2
6308269|NCT02616614|10035598|FG002|Overall Study|Other|1
6308270|NCT02616783|10035609|FG000|Overall Study|Randomized but Not Treated|1
6308271|NCT02616783|10035610|FG001|Overall Study|Randomized but Not Treated|0
6308272|NCT02616783|10035609|FG000|Overall Study|Adverse Event|1
6308273|NCT02616783|10035610|FG001|Overall Study|Adverse Event|0
6308274|NCT02616783|10035609|FG000|Overall Study|Death|1
6308275|NCT02616783|10035610|FG001|Overall Study|Death|0
6308276|NCT02616783|10035609|FG000|Overall Study|Non-Compliance with Study Drug|1
6308277|NCT02616783|10035610|FG001|Overall Study|Non-Compliance with Study Drug|0
6308278|NCT02616783|10035609|FG000|Overall Study|Protocol Violation|1
6308279|NCT02616783|10035610|FG001|Overall Study|Protocol Violation|1
6308280|NCT02616783|10035609|FG000|Overall Study|Withdrew Consent|1
6308281|NCT02616783|10035610|FG001|Overall Study|Withdrew Consent|1
6308282|NCT02616900|10035616|FG000|Overall Study|Lack of Efficacy|7
6308283|NCT02616900|10035616|FG000|Overall Study|Lost to Follow-up|2
6308284|NCT02616900|10035616|FG000|Overall Study|Protocol Violation|5
6308285|NCT02616900|10035616|FG000|Overall Study|Withdrawal by Subject|3
6308286|NCT02616900|10035616|FG000|Overall Study|Incomplete data|6
6308287|NCT02617628|10035622|FG000|Overall Study|Withdr, Transfers-other prisons, dropout|62
6308288|NCT02617628|10035623|FG001|Overall Study|Withdr, Transfers-other prisons, dropout|61
6308289|NCT02618382|10035711|FG000|Overall Study|Physician Decision|1
6308290|NCT02618382|10035711|FG000|Overall Study|Withdrawal by Subject|1
6308291|NCT02618382|10035711|FG000|Overall Study|Protocol Violation|1
6308292|NCT02618616|10035721|FG000|Overall Study|Lack of Efficacy|4
6308293|NCT02618616|10035722|FG001|Overall Study|Lack of Efficacy|0
6308294|NCT02618616|10035721|FG000|Overall Study|Pregnancy|0
6308295|NCT02618616|10035722|FG001|Overall Study|Pregnancy|1
6308296|NCT02618616|10035721|FG000|Overall Study|Adverse Event|8
6308297|NCT02618616|10035722|FG001|Overall Study|Adverse Event|0
6308298|NCT02618616|10035721|FG000|Overall Study|Failure to comply with dosing/evaluation|1
6308299|NCT02618616|10035722|FG001|Overall Study|Failure to comply with dosing/evaluation|0
6308300|NCT02618616|10035721|FG000|Overall Study|Consent withdrawn by subject|8
6308301|NCT02618616|10035722|FG001|Overall Study|Consent withdrawn by subject|5
6308302|NCT02618616|10035721|FG000|Overall Study|Lost to Follow-up|0
6308303|NCT02618616|10035722|FG001|Overall Study|Lost to Follow-up|1
6308304|NCT02618759|10035755|FG000|Overall Study|Lost to Follow-up|0
6308305|NCT02618759|10035756|FG001|Overall Study|Lost to Follow-up|1
5989068|NCT03257631|9580493|FG001|Overall Study|Death|5
6308306|NCT02618759|10035755|FG000|Overall Study|Withdrawal by Subject|1
6308307|NCT02618759|10035756|FG001|Overall Study|Withdrawal by Subject|0
6308308|NCT02618759|10035755|FG000|Overall Study|Other Reasons|1
6308309|NCT02618759|10035756|FG001|Overall Study|Other Reasons|4
6308310|NCT02618928|10035782|FG000|Overall Study|Failure to Return|28
6308311|NCT02618928|10035782|FG000|Overall Study|Insufficient Virological Response|1
6308312|NCT02618928|10035782|FG000|Overall Study|Withdrawal by Subject|2
6308313|NCT02618928|10035782|FG000|Overall Study|Death|3
6308314|NCT02618928|10035782|FG000|Overall Study|Other|11
6308315|NCT02618928|10035782|FG000|Overall Study|Missing|6
6308316|NCT02618928|10035782|FG000|Overall Study|Treatment Never Started|7
6308317|NCT02618967|10035797|FG000|Overall Study|Lost to Follow-up|0
6308318|NCT02618967|10035798|FG001|Overall Study|Lost to Follow-up|0
6308319|NCT02618967|10035799|FG002|Overall Study|Lost to Follow-up|1
6308320|NCT02618967|10035800|FG003|Overall Study|Lost to Follow-up|0
6308321|NCT02618967|10035801|FG004|Overall Study|Lost to Follow-up|2
6308322|NCT02618967|10035802|FG005|Overall Study|Lost to Follow-up|0
6308323|NCT02618967|10035803|FG006|Overall Study|Lost to Follow-up|0
6308324|NCT02618967|10035804|FG007|Overall Study|Lost to Follow-up|0
6308325|NCT02618967|10035797|FG000|Overall Study|Withdrawal by Subject|1
6308326|NCT02618967|10035798|FG001|Overall Study|Withdrawal by Subject|0
6308327|NCT02618967|10035799|FG002|Overall Study|Withdrawal by Subject|0
6308328|NCT02618967|10035800|FG003|Overall Study|Withdrawal by Subject|0
6308329|NCT02618967|10035801|FG004|Overall Study|Withdrawal by Subject|0
5989069|NCT03257631|9580494|FG002|Overall Study|Death|13
6308330|NCT02618967|10035802|FG005|Overall Study|Withdrawal by Subject|0
6308331|NCT02618967|10035803|FG006|Overall Study|Withdrawal by Subject|0
6308332|NCT02618967|10035804|FG007|Overall Study|Withdrawal by Subject|0
6308333|NCT02619175|10035824|FG000|Overall Study|Withdrawal by Subject|1
6308334|NCT02619175|10035825|FG001|Overall Study|Withdrawal by Subject|0
6308335|NCT02619175|10035824|FG000|Overall Study|foot pain|1
6308336|NCT02619175|10035825|FG001|Overall Study|foot pain|0
6308337|NCT02619617|10035883|FG000|Period 2 SOM230 - 2nd Attack|Protocol Violation|0
6308338|NCT02619617|10035884|FG001|Period 2 SOM230 - 2nd Attack|Protocol Violation|1
6308339|NCT02619617|10035883|FG000|Period 2 SOM230 - 2nd Attack|Physician Decision|0
6308340|NCT02619617|10035884|FG001|Period 2 SOM230 - 2nd Attack|Physician Decision|3
6308341|NCT02620020|10035905|FG000|Overall Study|Adverse Event|8
6308342|NCT02620020|10035906|FG001|Overall Study|Adverse Event|4
6308343|NCT02620020|10035907|FG002|Overall Study|Adverse Event|3
6308344|NCT02620020|10035908|FG003|Overall Study|Adverse Event|5
6308345|NCT02620020|10035905|FG000|Overall Study|Lost to Follow-up|4
6308346|NCT02620020|10035906|FG001|Overall Study|Lost to Follow-up|8
6308347|NCT02620020|10035907|FG002|Overall Study|Lost to Follow-up|1
6308348|NCT02620020|10035908|FG003|Overall Study|Lost to Follow-up|4
6308349|NCT02620020|10035905|FG000|Overall Study|Physician Decision|7
6308350|NCT02620020|10035906|FG001|Overall Study|Physician Decision|4
6308351|NCT02620020|10035907|FG002|Overall Study|Physician Decision|3
6308352|NCT02620020|10035908|FG003|Overall Study|Physician Decision|4
6308353|NCT02620020|10035905|FG000|Overall Study|Protocol Violation|5
6308354|NCT02620020|10035906|FG001|Overall Study|Protocol Violation|2
6308355|NCT02620020|10035907|FG002|Overall Study|Protocol Violation|1
6308356|NCT02620020|10035908|FG003|Overall Study|Protocol Violation|1
6308357|NCT02620020|10035905|FG000|Overall Study|Withdrawal by Subject|20
6308358|NCT02620020|10035906|FG001|Overall Study|Withdrawal by Subject|16
6308359|NCT02620020|10035907|FG002|Overall Study|Withdrawal by Subject|17
6308360|NCT02620020|10035908|FG003|Overall Study|Withdrawal by Subject|12
6308361|NCT02620020|10035905|FG000|Overall Study|Death|0
6308362|NCT02620020|10035906|FG001|Overall Study|Death|1
6308363|NCT02620020|10035907|FG002|Overall Study|Death|0
5989070|NCT03257631|9580495|FG003|Overall Study|Death|5
5989071|NCT03257631|9580492|FG000|Overall Study|Progressive Disease|0
5989072|NCT03257631|9580493|FG001|Overall Study|Progressive Disease|0
6308364|NCT02620020|10035908|FG003|Overall Study|Death|0
6308365|NCT02620384|10035920|FG000|Overall Study|Adverse Event|2
6308366|NCT02620384|10035921|FG001|Overall Study|Adverse Event|1
6308367|NCT02620384|10035920|FG000|Overall Study|Discharged prior to 2nd dose|2
6308368|NCT02620384|10035921|FG001|Overall Study|Discharged prior to 2nd dose|5
5989073|NCT03257631|9580494|FG002|Overall Study|Progressive Disease|1
5989074|NCT03257631|9580495|FG003|Overall Study|Progressive Disease|0
5989075|NCT03257631|9580492|FG000|Overall Study|Withdrawal by Parent/Guardian|0
5989076|NCT03257631|9580493|FG001|Overall Study|Withdrawal by Parent/Guardian|2
6308369|NCT02620384|10035920|FG000|Overall Study|Drug shortage prevented 2nd dose|0
6308370|NCT02620384|10035921|FG001|Overall Study|Drug shortage prevented 2nd dose|1
6308371|NCT02620787|10035944|FG000|Overall Study|Adverse Event|1
6308372|NCT02620787|10035945|FG001|Overall Study|Adverse Event|0
6308373|NCT02620787|10035944|FG000|Overall Study|Eligibility Criteria Not Met|1
6308374|NCT02620787|10035945|FG001|Overall Study|Eligibility Criteria Not Met|0
6308375|NCT02621034|10035976|FG000|Overall Study|Lost to Follow-up|3
6308376|NCT02621034|10035977|FG001|Overall Study|Lost to Follow-up|2
6308377|NCT02621034|10035978|FG002|Overall Study|Lost to Follow-up|5
6308378|NCT02621047|10035991|FG000|Overall Study|Adverse Event|0
6308379|NCT02621047|10035992|FG001|Overall Study|Adverse Event|0
6308380|NCT02621047|10035993|FG002|Overall Study|Adverse Event|1
6308381|NCT02621073|10036013|FG000|Overall Study|Lost to Follow-up|0
6308382|NCT02621073|10036014|FG001|Overall Study|Lost to Follow-up|1
6308383|NCT02621073|10036013|FG000|Overall Study|Physician Decision|3
6308384|NCT02621073|10036014|FG001|Overall Study|Physician Decision|2
6308385|NCT02621931|10036045|FG000|Overall Study|Death|0
6308386|NCT02621931|10036046|FG001|Overall Study|Death|1
6308387|NCT02621931|10036047|FG002|Overall Study|Death|0
6308388|NCT02621931|10036045|FG000|Overall Study|Adverse Event|8
6308389|NCT02621931|10036046|FG001|Overall Study|Adverse Event|5
6308390|NCT02621931|10036047|FG002|Overall Study|Adverse Event|7
6308391|NCT02621931|10036045|FG000|Overall Study|Withdrawal by Subject|12
6308392|NCT02621931|10036046|FG001|Overall Study|Withdrawal by Subject|10
6308393|NCT02621931|10036047|FG002|Overall Study|Withdrawal by Subject|11
6308394|NCT02621931|10036045|FG000|Overall Study|Protocol Violation|2
6308395|NCT02621931|10036046|FG001|Overall Study|Protocol Violation|2
6308396|NCT02621931|10036047|FG002|Overall Study|Protocol Violation|2
6308397|NCT02621931|10036045|FG000|Overall Study|Pregnancy|2
6308398|NCT02621931|10036046|FG001|Overall Study|Pregnancy|0
6308399|NCT02621931|10036047|FG002|Overall Study|Pregnancy|0
6308400|NCT02621931|10036045|FG000|Overall Study|Noncompliance to study procedures|0
6308401|NCT02621931|10036046|FG001|Overall Study|Noncompliance to study procedures|1
5989077|NCT03257631|9580494|FG002|Overall Study|Withdrawal by Parent/Guardian|4
5989078|NCT03257631|9580495|FG003|Overall Study|Withdrawal by Parent/Guardian|1
5989079|NCT03257631|9580492|FG000|Overall Study|Lost to Follow-up|0
5989080|NCT03257631|9580493|FG001|Overall Study|Lost to Follow-up|0
5989081|NCT03257631|9580494|FG002|Overall Study|Lost to Follow-up|1
5989082|NCT03257631|9580495|FG003|Overall Study|Lost to Follow-up|0
5989083|NCT03257631|9580492|FG000|Overall Study|Still on Study|3
5989084|NCT03257631|9580493|FG001|Overall Study|Still on Study|2
6308402|NCT02621931|10036047|FG002|Overall Study|Noncompliance to study procedures|2
6308403|NCT02621931|10036045|FG000|Overall Study|Lost to Follow-up|8
6308404|NCT02621931|10036046|FG001|Overall Study|Lost to Follow-up|7
6308405|NCT02621931|10036047|FG002|Overall Study|Lost to Follow-up|10
6308406|NCT02621931|10036045|FG000|Overall Study|Lack of Efficacy|0
6308407|NCT02621931|10036046|FG001|Overall Study|Lack of Efficacy|0
6308408|NCT02621931|10036047|FG002|Overall Study|Lack of Efficacy|1
6308409|NCT02621931|10036045|FG000|Overall Study|Other|1
6308410|NCT02621931|10036046|FG001|Overall Study|Other|1
6308411|NCT02621931|10036047|FG002|Overall Study|Other|3
6308412|NCT02622074|10036072|FG000|Overall Study|Death|4
6308413|NCT02622074|10036073|FG001|Overall Study|Death|0
6308414|NCT02622074|10036074|FG002|Overall Study|Death|0
6308415|NCT02622074|10036075|FG003|Overall Study|Death|1
6308416|NCT02622074|10036076|FG004|Overall Study|Death|1
5989085|NCT03257631|9580494|FG002|Overall Study|Still on Study|4
5989086|NCT03257631|9580495|FG003|Overall Study|Still on Study|4
5989087|NCT03253796|9580510|FG000|Period 1: Run-In|Adverse Event|4
5989088|NCT03253796|9580511|FG001|Period 1: Run-In|Adverse Event|0
5989089|NCT03253796|9580512|FG002|Period 1: Run-In|Adverse Event|0
5989090|NCT03253796|9580513|FG003|Period 1: Run-In|Adverse Event|0
5989091|NCT03253796|9580514|FG004|Period 1: Run-In|Adverse Event|0
5989092|NCT03253796|9580510|FG000|Period 1: Run-In|Lack of Efficacy|1
5989093|NCT03253796|9580511|FG001|Period 1: Run-In|Lack of Efficacy|0
5989094|NCT03253796|9580512|FG002|Period 1: Run-In|Lack of Efficacy|0
5989095|NCT03253796|9580513|FG003|Period 1: Run-In|Lack of Efficacy|0
5989096|NCT03253796|9580514|FG004|Period 1: Run-In|Lack of Efficacy|0
5989097|NCT03253796|9580510|FG000|Period 1: Run-In|Lack of Qualifying Event|98
5989098|NCT03253796|9580511|FG001|Period 1: Run-In|Lack of Qualifying Event|0
5989099|NCT03253796|9580512|FG002|Period 1: Run-In|Lack of Qualifying Event|0
5989100|NCT03253796|9580513|FG003|Period 1: Run-In|Lack of Qualifying Event|0
5989101|NCT03253796|9580514|FG004|Period 1: Run-In|Lack of Qualifying Event|0
5989102|NCT03253796|9580510|FG000|Period 1: Run-In|Protocol Violation|5
5989103|NCT03253796|9580511|FG001|Period 1: Run-In|Protocol Violation|0
5989104|NCT03253796|9580512|FG002|Period 1: Run-In|Protocol Violation|0
5989105|NCT03253796|9580513|FG003|Period 1: Run-In|Protocol Violation|0
5989106|NCT03253796|9580514|FG004|Period 1: Run-In|Protocol Violation|0
5989107|NCT03253796|9580510|FG000|Period 1: Run-In|Withdrawal by Subject|8
5989108|NCT03253796|9580511|FG001|Period 1: Run-In|Withdrawal by Subject|0
5989109|NCT03253796|9580512|FG002|Period 1: Run-In|Withdrawal by Subject|0
5989110|NCT03253796|9580513|FG003|Period 1: Run-In|Withdrawal by Subject|0
5989111|NCT03253796|9580514|FG004|Period 1: Run-In|Withdrawal by Subject|0
5989112|NCT03253796|9580510|FG000|Period 2: Withdrawal vs Continued Tx|Adverse Event|0
5989113|NCT03253796|9580511|FG001|Period 2: Withdrawal vs Continued Tx|Adverse Event|0
5989114|NCT03253796|9580512|FG002|Period 2: Withdrawal vs Continued Tx|Adverse Event|2
5989115|NCT03253796|9580513|FG003|Period 2: Withdrawal vs Continued Tx|Adverse Event|0
5989116|NCT03253796|9580514|FG004|Period 2: Withdrawal vs Continued Tx|Adverse Event|0
5989117|NCT03253796|9580510|FG000|Period 2: Withdrawal vs Continued Tx|Physician Decision|0
5989118|NCT03253796|9580511|FG001|Period 2: Withdrawal vs Continued Tx|Physician Decision|0
5989119|NCT03253796|9580512|FG002|Period 2: Withdrawal vs Continued Tx|Physician Decision|1
5989120|NCT03253796|9580513|FG003|Period 2: Withdrawal vs Continued Tx|Physician Decision|0
5989121|NCT03253796|9580514|FG004|Period 2: Withdrawal vs Continued Tx|Physician Decision|0
5989122|NCT03253796|9580510|FG000|Period 2: Withdrawal vs Continued Tx|Withdrawal by Subject|0
5989123|NCT03253796|9580511|FG001|Period 2: Withdrawal vs Continued Tx|Withdrawal by Subject|0
5989124|NCT03253796|9580512|FG002|Period 2: Withdrawal vs Continued Tx|Withdrawal by Subject|2
5989125|NCT03253796|9580513|FG003|Period 2: Withdrawal vs Continued Tx|Withdrawal by Subject|3
5989126|NCT03253796|9580514|FG004|Period 2: Withdrawal vs Continued Tx|Withdrawal by Subject|0
5989127|NCT03253796|9580510|FG000|Period 2: Withdrawal vs Continued Tx|Did not attain inactive disease in Period 1|0
5989128|NCT03253796|9580511|FG001|Period 2: Withdrawal vs Continued Tx|Did not attain inactive disease in Period 1|0
5989129|NCT03253796|9580512|FG002|Period 2: Withdrawal vs Continued Tx|Did not attain inactive disease in Period 1|1
5989130|NCT03253796|9580513|FG003|Period 2: Withdrawal vs Continued Tx|Did not attain inactive disease in Period 1|0
5989131|NCT03253796|9580514|FG004|Period 2: Withdrawal vs Continued Tx|Did not attain inactive disease in Period 1|0
5989132|NCT03253796|9580510|FG000|Period 2: Withdrawal vs Continued Tx|Disease Flare, transitioned to Open-label retreatment|0
6308417|NCT02622074|10036077|FG005|Overall Study|Death|0
6308418|NCT02622074|10036072|FG000|Overall Study|Withdrawal by Subject|0
6308419|NCT02622074|10036073|FG001|Overall Study|Withdrawal by Subject|1
6308420|NCT02622074|10036074|FG002|Overall Study|Withdrawal by Subject|0
6308421|NCT02622074|10036075|FG003|Overall Study|Withdrawal by Subject|0
6308422|NCT02622074|10036076|FG004|Overall Study|Withdrawal by Subject|0
6308423|NCT02622074|10036077|FG005|Overall Study|Withdrawal by Subject|0
6308424|NCT02622113|10036093|FG000|Overall Study|Adverse Event|4
6308425|NCT02622113|10036094|FG001|Overall Study|Adverse Event|4
6308426|NCT02622113|10036093|FG000|Overall Study|Physician Decision|0
6308427|NCT02622113|10036094|FG001|Overall Study|Physician Decision|1
6308428|NCT02622113|10036093|FG000|Overall Study|Withdrawal by Subject|0
6308429|NCT02622113|10036094|FG001|Overall Study|Withdrawal by Subject|2
6308430|NCT02622113|10036093|FG000|Overall Study|Stopping Criteria|1
5989133|NCT03253796|9580511|FG001|Period 2: Withdrawal vs Continued Tx|Disease Flare, transitioned to Open-label retreatment|10
5989134|NCT03253796|9580512|FG002|Period 2: Withdrawal vs Continued Tx|Disease Flare, transitioned to Open-label retreatment|15
5989135|NCT03253796|9580513|FG003|Period 2: Withdrawal vs Continued Tx|Disease Flare, transitioned to Open-label retreatment|38
6045449|NCT00402116|9644686|FG002|Overall Study|other complicating disease|2
6308431|NCT02622113|10036094|FG001|Overall Study|Stopping Criteria|3
6308432|NCT02622321|10036128|FG000|Overall Study|Withdrawal by Subject|2
6308433|NCT02622321|10036129|FG001|Overall Study|Withdrawal by Subject|0
6308434|NCT02622321|10036130|FG002|Overall Study|Withdrawal by Subject|0
6308435|NCT02622321|10036131|FG003|Overall Study|Withdrawal by Subject|0
6308436|NCT02622321|10036128|FG000|Overall Study|Death|0
6308437|NCT02622321|10036129|FG001|Overall Study|Death|0
6308438|NCT02622321|10036130|FG002|Overall Study|Death|1
6308439|NCT02622321|10036131|FG003|Overall Study|Death|0
6308440|NCT02622321|10036128|FG000|Overall Study|Physician Decision|1
6308441|NCT02622321|10036129|FG001|Overall Study|Physician Decision|0
6308442|NCT02622321|10036130|FG002|Overall Study|Physician Decision|0
6308443|NCT02622321|10036131|FG003|Overall Study|Physician Decision|0
6308444|NCT02622568|10036157|FG000|Overall Study|Lost to Follow-up|5
6308445|NCT02622568|10036158|FG001|Overall Study|Lost to Follow-up|5
6308446|NCT02622724|10036166|FG000|Overall Study|Death|51
6308447|NCT02622724|10036167|FG001|Overall Study|Death|53
6308448|NCT02622724|10036166|FG000|Overall Study|Lost to Follow-UP, withdrawal of consent|4
6308449|NCT02622724|10036167|FG001|Overall Study|Lost to Follow-UP, withdrawal of consent|7
6308450|NCT02622724|10036166|FG000|Overall Study|Early termination of study|38
6308451|NCT02622724|10036167|FG001|Overall Study|Early termination of study|43
6308452|NCT02623218|10036184|FG000|Overall Study|Lost to Follow-up|0
6308453|NCT02623218|10036185|FG001|Overall Study|Lost to Follow-up|1
6308454|NCT02623218|10036186|FG002|Overall Study|Lost to Follow-up|0
6308455|NCT02623218|10036187|FG003|Overall Study|Lost to Follow-up|0
6308456|NCT02623218|10036188|FG004|Overall Study|Lost to Follow-up|0
6308457|NCT02623322|10036203|FG000|Overall Study|Lost to Follow-up|2
6308458|NCT02623322|10036204|FG001|Overall Study|Lost to Follow-up|1
6308459|NCT02623322|10036205|FG002|Overall Study|Lost to Follow-up|0
6308460|NCT02623335|10036217|FG000|Overall Study|Death|8
6308461|NCT02623335|10036218|FG001|Overall Study|Death|7
6308462|NCT02623335|10036217|FG000|Overall Study|Lost to Follow-up|15
6308463|NCT02623335|10036218|FG001|Overall Study|Lost to Follow-up|23
6308464|NCT02623335|10036217|FG000|Overall Study|Withdrawal by Subject|2
6308465|NCT02623335|10036218|FG001|Overall Study|Withdrawal by Subject|5
6308466|NCT02623335|10036217|FG000|Overall Study|Protocol Violation|2
6308467|NCT02623335|10036218|FG001|Overall Study|Protocol Violation|1
6308468|NCT02623361|10036235|FG000|Overall Study|Protocol Violation|0
6308469|NCT02623361|10036236|FG001|Overall Study|Protocol Violation|1
6308470|NCT02623361|10036235|FG000|Overall Study|Withdrawal by Subject|0
6308471|NCT02623361|10036236|FG001|Overall Study|Withdrawal by Subject|1
6308472|NCT02623829|10036253|FG000|Overall Study|Lost to Follow-up|1
6308473|NCT02623829|10036254|FG001|Overall Study|Lost to Follow-up|1
6308474|NCT02624050|10036271|FG000|Overall Study|Physician Decision|4
6308475|NCT02624050|10036272|FG001|Overall Study|Physician Decision|0
6308476|NCT02624050|10036271|FG000|Overall Study|Protocol Violation|2
6308477|NCT02624050|10036272|FG001|Overall Study|Protocol Violation|0
6308478|NCT02624284|10036290|FG000|Overall Study|Withdrawal by Subject|3
6308479|NCT02624284|10036291|FG001|Overall Study|Withdrawal by Subject|6
6308480|NCT02624284|10036292|FG002|Overall Study|Withdrawal by Subject|3
6308481|NCT02624284|10036290|FG000|Overall Study|Protocol Violation|9
6308482|NCT02624284|10036291|FG001|Overall Study|Protocol Violation|10
6308483|NCT02624284|10036292|FG002|Overall Study|Protocol Violation|7
6308484|NCT02624284|10036290|FG000|Overall Study|Revealed exclusionary condition|2
6308485|NCT02624284|10036291|FG001|Overall Study|Revealed exclusionary condition|2
6308486|NCT02624284|10036292|FG002|Overall Study|Revealed exclusionary condition|0
6308487|NCT02624284|10036290|FG000|Overall Study|Adverse Event|0
6308488|NCT02624284|10036291|FG001|Overall Study|Adverse Event|0
6308489|NCT02624284|10036292|FG002|Overall Study|Adverse Event|1
6308490|NCT02624492|10036307|FG000|Overall Study|Adverse Event|2
6308491|NCT02624492|10036308|FG001|Overall Study|Adverse Event|2
6308492|NCT02624492|10036309|FG002|Overall Study|Adverse Event|2
6308493|NCT02624492|10036307|FG000|Overall Study|Progressive disease|0
6308494|NCT02624492|10036308|FG001|Overall Study|Progressive disease|2
6308495|NCT02624492|10036309|FG002|Overall Study|Progressive disease|3
6308496|NCT02624687|10036319|FG000|Overall Study|Withdrawal by Subject|1
6308497|NCT02624687|10036320|FG001|Overall Study|Withdrawal by Subject|1
6308498|NCT02624687|10036319|FG000|Overall Study|medical leave from work|0
6308499|NCT02624687|10036320|FG001|Overall Study|medical leave from work|1
6308500|NCT02624713|10036339|FG000|Overall Study|Lost to Follow-up|14
6308501|NCT02624713|10036340|FG001|Overall Study|Lost to Follow-up|0
6308502|NCT02624791|10036347|FG000|Overall Study|Withdrawal by Subject|2
6308503|NCT02624791|10036348|FG001|Overall Study|Withdrawal by Subject|0
6308504|NCT02624791|10036349|FG002|Overall Study|Withdrawal by Subject|0
6308505|NCT02624791|10036350|FG003|Overall Study|Withdrawal by Subject|0
6308506|NCT02624791|10036351|FG004|Overall Study|Withdrawal by Subject|0
6308507|NCT02624791|10036352|FG005|Overall Study|Withdrawal by Subject|0
6308508|NCT02624986|10036377|FG000|Overall Study|Death|0
6308509|NCT02624986|10036378|FG001|Overall Study|Death|1
6308510|NCT02624986|10036379|FG002|Overall Study|Death|2
6308511|NCT02624986|10036380|FG003|Overall Study|Death|2
6308512|NCT02624986|10036381|FG004|Overall Study|Death|2
6308513|NCT02624986|10036382|FG005|Overall Study|Death|0
6308514|NCT02624986|10036383|FG006|Overall Study|Death|0
6308515|NCT02624986|10036384|FG007|Overall Study|Death|1
6308516|NCT02624986|10036377|FG000|Overall Study|Study Terminated by Sponsor|1
6308517|NCT02624986|10036378|FG001|Overall Study|Study Terminated by Sponsor|1
6308518|NCT02624986|10036379|FG002|Overall Study|Study Terminated by Sponsor|0
6308519|NCT02624986|10036380|FG003|Overall Study|Study Terminated by Sponsor|1
6308520|NCT02624986|10036381|FG004|Overall Study|Study Terminated by Sponsor|2
6308521|NCT02624986|10036382|FG005|Overall Study|Study Terminated by Sponsor|2
6308522|NCT02624986|10036383|FG006|Overall Study|Study Terminated by Sponsor|4
6308523|NCT02624986|10036384|FG007|Overall Study|Study Terminated by Sponsor|3
6308524|NCT02624986|10036377|FG000|Overall Study|Progressive Disease|0
6308525|NCT02624986|10036378|FG001|Overall Study|Progressive Disease|1
6308526|NCT02624986|10036379|FG002|Overall Study|Progressive Disease|0
5989136|NCT03253796|9580514|FG004|Period 2: Withdrawal vs Continued Tx|Disease Flare, transitioned to Open-label retreatment|0
5989137|NCT03253796|9580510|FG000|Period 2: Open-Label Retreatment|Withdrawal by Subject|0
5989138|NCT03253796|9580511|FG001|Period 2: Open-Label Retreatment|Withdrawal by Subject|0
6308527|NCT02624986|10036380|FG003|Overall Study|Progressive Disease|0
6308528|NCT02624986|10036381|FG004|Overall Study|Progressive Disease|0
6308529|NCT02624986|10036382|FG005|Overall Study|Progressive Disease|0
6308530|NCT02624986|10036383|FG006|Overall Study|Progressive Disease|0
6308531|NCT02624986|10036384|FG007|Overall Study|Progressive Disease|0
6308532|NCT02624986|10036377|FG000|Overall Study|Protocol Violation|1
6308533|NCT02624986|10036378|FG001|Overall Study|Protocol Violation|0
6308534|NCT02624986|10036379|FG002|Overall Study|Protocol Violation|0
6308535|NCT02624986|10036380|FG003|Overall Study|Protocol Violation|0
6308536|NCT02624986|10036381|FG004|Overall Study|Protocol Violation|0
6308537|NCT02624986|10036382|FG005|Overall Study|Protocol Violation|0
6308538|NCT02624986|10036383|FG006|Overall Study|Protocol Violation|0
6308539|NCT02624986|10036384|FG007|Overall Study|Protocol Violation|0
6308540|NCT02624986|10036377|FG000|Overall Study|Withdrawal by Subject|0
6308541|NCT02624986|10036378|FG001|Overall Study|Withdrawal by Subject|0
6308542|NCT02624986|10036379|FG002|Overall Study|Withdrawal by Subject|0
6308543|NCT02624986|10036380|FG003|Overall Study|Withdrawal by Subject|0
6308544|NCT02624986|10036381|FG004|Overall Study|Withdrawal by Subject|0
6308545|NCT02624986|10036382|FG005|Overall Study|Withdrawal by Subject|0
6308546|NCT02624986|10036383|FG006|Overall Study|Withdrawal by Subject|0
6308547|NCT02624986|10036384|FG007|Overall Study|Withdrawal by Subject|1
6308548|NCT02625220|10036440|FG000|Overall Study|Adverse Event|2
6308549|NCT02625220|10036440|FG000|Overall Study|Lost to Follow-up|2
6308550|NCT02625220|10036440|FG000|Overall Study|Protocol Violation|1
6308551|NCT02625220|10036440|FG000|Overall Study|Study discontinued at site|2
6308552|NCT02625233|10036446|FG000|Overall Study|Adverse Event|2
6308553|NCT02625233|10036447|FG001|Overall Study|Adverse Event|0
6308554|NCT02625259|10036458|FG000|First Intervention (Day 1)|Other|0
6308555|NCT02625259|10036459|FG001|First Intervention (Day 1)|Other|0
6308556|NCT02625259|10036460|FG002|First Intervention (Day 1)|Other|1
6308557|NCT02625259|10036461|FG003|First Intervention (Day 1)|Other|0
6308558|NCT02625259|10036462|FG004|First Intervention (Day 1)|Other|0
6308559|NCT02625259|10036458|FG000|First Intervention (Day 1)|Adverse Event|2
6308560|NCT02625259|10036459|FG001|First Intervention (Day 1)|Adverse Event|1
6308561|NCT02625259|10036460|FG002|First Intervention (Day 1)|Adverse Event|0
6308562|NCT02625259|10036461|FG003|First Intervention (Day 1)|Adverse Event|0
6308563|NCT02625259|10036462|FG004|First Intervention (Day 1)|Adverse Event|0
6308564|NCT02625259|10036458|FG000|First Intervention (Day 1)|Withdrawal by Subject|0
6308565|NCT02625259|10036459|FG001|First Intervention (Day 1)|Withdrawal by Subject|0
6308566|NCT02625259|10036460|FG002|First Intervention (Day 1)|Withdrawal by Subject|0
6308567|NCT02625259|10036461|FG003|First Intervention (Day 1)|Withdrawal by Subject|1
6308568|NCT02625259|10036462|FG004|First Intervention (Day 1)|Withdrawal by Subject|0
6308569|NCT02625610|10036516|FG000|Overall Study|Ongoing|34
6308570|NCT02625610|10036517|FG001|Overall Study|Ongoing|54
6308571|NCT02625623|10036525|FG000|Overall Study|Participants randomized but not treated|9
6308572|NCT02625623|10036526|FG001|Overall Study|Participants randomized but not treated|1
6308573|NCT02625909|10036540|FG000|Overall Study|Death|2
6308574|NCT02625909|10036541|FG001|Overall Study|Death|0
6308575|NCT02625909|10036540|FG000|Overall Study|Lost to Follow-up|3
6308576|NCT02625909|10036541|FG001|Overall Study|Lost to Follow-up|5
6308577|NCT02625909|10036540|FG000|Overall Study|Lack of Efficacy|9
6308578|NCT02625909|10036541|FG001|Overall Study|Lack of Efficacy|2
6308579|NCT02625909|10036540|FG000|Overall Study|Reinfection|3
6308580|NCT02625909|10036541|FG001|Overall Study|Reinfection|2
6308581|NCT02625922|10036549|FG000|Overall Study|Non-availability of IMP|1
6308582|NCT02625922|10036550|FG001|Overall Study|Non-availability of IMP|1
6308583|NCT02625922|10036549|FG000|Overall Study|Systolic blood pressure < 125 mmHg|1
6308584|NCT02625922|10036550|FG001|Overall Study|Systolic blood pressure < 125 mmHg|1
6308585|NCT02625974|10036561|FG000|Overall Study|Adverse Event|12
6308586|NCT02625974|10036562|FG001|Overall Study|Adverse Event|2
5989139|NCT03253796|9580512|FG002|Period 2: Open-Label Retreatment|Withdrawal by Subject|0
5989140|NCT03253796|9580513|FG003|Period 2: Open-Label Retreatment|Withdrawal by Subject|0
6308587|NCT02625974|10036561|FG000|Overall Study|Withdrawal by Subject|3
5989141|NCT03253796|9580514|FG004|Period 2: Open-Label Retreatment|Withdrawal by Subject|5
6308588|NCT02625974|10036562|FG001|Overall Study|Withdrawal by Subject|1
6308589|NCT02625974|10036561|FG000|Overall Study|positive parasitemia|1
6308590|NCT02625974|10036562|FG001|Overall Study|positive parasitemia|0
6308591|NCT02625974|10036561|FG000|Overall Study|non-compliance with study drug|0
6308592|NCT02625974|10036562|FG001|Overall Study|non-compliance with study drug|2
6308593|NCT02625974|10036561|FG000|Overall Study|Protocol Violation|0
6308594|NCT02625974|10036562|FG001|Overall Study|Protocol Violation|1
6045450|NCT00402116|9644684|FG000|Overall Study|Disease Progression|0
6308595|NCT02626000|10036604|FG000|Overall Study|Decision by Sponsor|1
6045451|NCT00402116|9644685|FG001|Overall Study|Disease Progression|4
5989142|NCT03233048|9580529|FG000|Overall Study|Withdrawal by Subject|1
6308596|NCT02626000|10036604|FG000|Overall Study|Death|29
6308597|NCT02626026|10036615|FG000|Overall Study|Randomized but Never Treated|0
6308598|NCT02626026|10036616|FG001|Overall Study|Randomized but Never Treated|0
6308599|NCT02626026|10036617|FG002|Overall Study|Randomized but Never Treated|0
6308600|NCT02626026|10036618|FG003|Overall Study|Randomized but Never Treated|0
6308601|NCT02626026|10036619|FG004|Overall Study|Randomized but Never Treated|1
6308602|NCT02626026|10036620|FG005|Overall Study|Randomized but Never Treated|0
6308603|NCT02626182|10036661|FG000|Overall Study|Adverse Event|2
6308604|NCT02626182|10036662|FG001|Overall Study|Adverse Event|0
5989143|NCT03194646|9580537|FG000|Overall Study|Adverse Event|24
5989144|NCT03194646|9580538|FG001|Overall Study|Adverse Event|25
5989145|NCT03194646|9580539|FG002|Overall Study|Adverse Event|14
5989146|NCT03194646|9580540|FG003|Overall Study|Adverse Event|17
5989147|NCT03194646|9580537|FG000|Overall Study|Lack of Efficacy|4
5989148|NCT03194646|9580538|FG001|Overall Study|Lack of Efficacy|2
5989149|NCT03194646|9580539|FG002|Overall Study|Lack of Efficacy|2
5989150|NCT03194646|9580540|FG003|Overall Study|Lack of Efficacy|12
5989151|NCT03194646|9580537|FG000|Overall Study|Lost to Follow-up|30
5989152|NCT03194646|9580538|FG001|Overall Study|Lost to Follow-up|22
5989153|NCT03194646|9580539|FG002|Overall Study|Lost to Follow-up|12
5989154|NCT03194646|9580540|FG003|Overall Study|Lost to Follow-up|35
5989155|NCT03194646|9580537|FG000|Overall Study|Non-compliance with study drug|4
5989156|NCT03194646|9580538|FG001|Overall Study|Non-compliance with study drug|0
5989157|NCT03194646|9580539|FG002|Overall Study|Non-compliance with study drug|1
6308605|NCT02626780|10036688|FG000|Overall Study|Withdrawal by Subject|3
6308606|NCT02626819|10036694|FG000|Overall Study|Lost to Follow-up|3
6308607|NCT02626819|10036695|FG001|Overall Study|Lost to Follow-up|2
6308608|NCT02626819|10036694|FG000|Overall Study|Withdrawal by Subject|1
6308609|NCT02626819|10036695|FG001|Overall Study|Withdrawal by Subject|0
6308610|NCT02626819|10036694|FG000|Overall Study|Diagnosed w/ catastrophic illness|0
6308611|NCT02626819|10036695|FG001|Overall Study|Diagnosed w/ catastrophic illness|1
6308612|NCT02627144|10036732|FG000|Overall Study|Serious adverse event|32
6308613|NCT02627144|10036732|FG000|Overall Study|Cancer progression|171
6308614|NCT02627144|10036732|FG000|Overall Study|Death from cancer|20
6308615|NCT02627144|10036732|FG000|Overall Study|Death from other cause|8
6308616|NCT02627144|10036732|FG000|Overall Study|Refusal of treatment / poor cooperation|38
6308617|NCT02627144|10036732|FG000|Overall Study|Administrative reasons|65
6308618|NCT02627144|10036732|FG000|Overall Study|Lost to Follow-up|8
6308619|NCT02627144|10036732|FG000|Overall Study|Enrolled, not treated|6
6308620|NCT02627144|10036732|FG000|Overall Study|Other|17
6308621|NCT02627495|10036736|FG000|Overall Study|Withdrawal by Subject|4
6308622|NCT02627677|10036743|FG000|Overall Study|Adverse event (not progressive disease)|1
6308623|NCT02627677|10036744|FG001|Overall Study|Adverse event (not progressive disease)|4
6308624|NCT02627677|10036745|FG002|Overall Study|Adverse event (not progressive disease)|1
6308625|NCT02627677|10036743|FG000|Overall Study|Progressive disease|1
6308626|NCT02627677|10036744|FG001|Overall Study|Progressive disease|3
6308627|NCT02627677|10036745|FG002|Overall Study|Progressive disease|0
6064741|NCT00515294|9666535|FG002|Overall Study|Caffeine amount inaccurate|7
6308628|NCT02627677|10036743|FG000|Overall Study|Lack of Efficacy|1
6308629|NCT02627677|10036744|FG001|Overall Study|Lack of Efficacy|2
6308630|NCT02627677|10036745|FG002|Overall Study|Lack of Efficacy|0
6308631|NCT02627677|10036743|FG000|Overall Study|Lost to Follow-up|0
6308632|NCT02627677|10036744|FG001|Overall Study|Lost to Follow-up|0
6308633|NCT02627677|10036745|FG002|Overall Study|Lost to Follow-up|1
6308634|NCT02627677|10036743|FG000|Overall Study|Pregnancy|0
6308635|NCT02627677|10036744|FG001|Overall Study|Pregnancy|1
6308636|NCT02627677|10036745|FG002|Overall Study|Pregnancy|0
6308637|NCT02627677|10036743|FG000|Overall Study|Study Terminated by Sponsor|5
6308638|NCT02627677|10036744|FG001|Overall Study|Study Terminated by Sponsor|10
6308639|NCT02627677|10036745|FG002|Overall Study|Study Terminated by Sponsor|6
6308640|NCT02627677|10036743|FG000|Overall Study|Physician Decision|0
6308641|NCT02627677|10036744|FG001|Overall Study|Physician Decision|0
6308642|NCT02627677|10036745|FG002|Overall Study|Physician Decision|2
6308643|NCT02627677|10036743|FG000|Overall Study|Withdrawal by Subject|2
6308644|NCT02627677|10036744|FG001|Overall Study|Withdrawal by Subject|1
6308645|NCT02627677|10036745|FG002|Overall Study|Withdrawal by Subject|1
6308646|NCT02627677|10036743|FG000|Overall Study|Reason not Specified|0
6308647|NCT02627677|10036744|FG001|Overall Study|Reason not Specified|0
6308648|NCT02627677|10036745|FG002|Overall Study|Reason not Specified|1
6308649|NCT02627677|10036743|FG000|Overall Study|Randomized but not Treated|1
6308650|NCT02627677|10036744|FG001|Overall Study|Randomized but not Treated|0
6308651|NCT02627677|10036745|FG002|Overall Study|Randomized but not Treated|0
6308652|NCT02628028|10036776|FG000|Dosing Period|Withdrawal by Subject|0
6308653|NCT02628028|10036777|FG001|Dosing Period|Withdrawal by Subject|0
6308654|NCT02628028|10036778|FG002|Dosing Period|Withdrawal by Subject|1
6308655|NCT02628028|10036779|FG003|Dosing Period|Withdrawal by Subject|0
6308656|NCT02628028|10036780|FG004|Dosing Period|Withdrawal by Subject|2
6308657|NCT02628028|10036781|FG005|Dosing Period|Withdrawal by Subject|4
6308658|NCT02628028|10036782|FG006|Dosing Period|Withdrawal by Subject|1
6308659|NCT02628028|10036783|FG007|Dosing Period|Withdrawal by Subject|1
6308660|NCT02628028|10036776|FG000|Dosing Period|Adverse Event|0
6308661|NCT02628028|10036777|FG001|Dosing Period|Adverse Event|0
6308662|NCT02628028|10036778|FG002|Dosing Period|Adverse Event|0
6308663|NCT02628028|10036779|FG003|Dosing Period|Adverse Event|0
6308664|NCT02628028|10036780|FG004|Dosing Period|Adverse Event|2
6308665|NCT02628028|10036781|FG005|Dosing Period|Adverse Event|1
6308666|NCT02628028|10036782|FG006|Dosing Period|Adverse Event|3
6308667|NCT02628028|10036783|FG007|Dosing Period|Adverse Event|2
6308668|NCT02628028|10036776|FG000|Dosing Period|Death|0
6308669|NCT02628028|10036777|FG001|Dosing Period|Death|0
6308670|NCT02628028|10036778|FG002|Dosing Period|Death|0
6308671|NCT02628028|10036779|FG003|Dosing Period|Death|0
6308672|NCT02628028|10036780|FG004|Dosing Period|Death|0
6308673|NCT02628028|10036781|FG005|Dosing Period|Death|0
5989158|NCT03194646|9580540|FG003|Overall Study|Non-compliance with study drug|1
5989159|NCT03194646|9580537|FG000|Overall Study|Other|87
6308674|NCT02628028|10036782|FG006|Dosing Period|Death|0
6308675|NCT02628028|10036783|FG007|Dosing Period|Death|1
6308676|NCT02628028|10036776|FG000|Dosing Period|Lack of Efficacy|0
6308677|NCT02628028|10036777|FG001|Dosing Period|Lack of Efficacy|0
6308678|NCT02628028|10036778|FG002|Dosing Period|Lack of Efficacy|0
6308679|NCT02628028|10036779|FG003|Dosing Period|Lack of Efficacy|0
6308680|NCT02628028|10036780|FG004|Dosing Period|Lack of Efficacy|3
6308681|NCT02628028|10036781|FG005|Dosing Period|Lack of Efficacy|0
6308682|NCT02628028|10036782|FG006|Dosing Period|Lack of Efficacy|1
6308683|NCT02628028|10036783|FG007|Dosing Period|Lack of Efficacy|0
6308684|NCT02628028|10036776|FG000|Dosing Period|Study Terminated by Sponsor|0
6308685|NCT02628028|10036777|FG001|Dosing Period|Study Terminated by Sponsor|0
6308686|NCT02628028|10036778|FG002|Dosing Period|Study Terminated by Sponsor|0
6308687|NCT02628028|10036779|FG003|Dosing Period|Study Terminated by Sponsor|0
6308688|NCT02628028|10036780|FG004|Dosing Period|Study Terminated by Sponsor|7
6308689|NCT02628028|10036781|FG005|Dosing Period|Study Terminated by Sponsor|6
6308690|NCT02628028|10036782|FG006|Dosing Period|Study Terminated by Sponsor|7
6308691|NCT02628028|10036783|FG007|Dosing Period|Study Terminated by Sponsor|7
6308692|NCT02628028|10036776|FG000|Dosing Period|Physician Decision|0
6308693|NCT02628028|10036777|FG001|Dosing Period|Physician Decision|0
6308694|NCT02628028|10036778|FG002|Dosing Period|Physician Decision|0
6308695|NCT02628028|10036779|FG003|Dosing Period|Physician Decision|0
6308696|NCT02628028|10036780|FG004|Dosing Period|Physician Decision|0
6308697|NCT02628028|10036781|FG005|Dosing Period|Physician Decision|1
6308698|NCT02628028|10036782|FG006|Dosing Period|Physician Decision|0
6308699|NCT02628028|10036783|FG007|Dosing Period|Physician Decision|0
6308700|NCT02628028|10036776|FG000|Dosing Period|Site Terminated by Sponsor|0
6308701|NCT02628028|10036777|FG001|Dosing Period|Site Terminated by Sponsor|0
6308702|NCT02628028|10036778|FG002|Dosing Period|Site Terminated by Sponsor|0
6308703|NCT02628028|10036779|FG003|Dosing Period|Site Terminated by Sponsor|0
6308704|NCT02628028|10036780|FG004|Dosing Period|Site Terminated by Sponsor|0
6308705|NCT02628028|10036781|FG005|Dosing Period|Site Terminated by Sponsor|1
6308706|NCT02628028|10036782|FG006|Dosing Period|Site Terminated by Sponsor|1
6308707|NCT02628028|10036783|FG007|Dosing Period|Site Terminated by Sponsor|0
6308708|NCT02628028|10036776|FG000|Dosing Period|Lost to Follow-up|0
6308709|NCT02628028|10036777|FG001|Dosing Period|Lost to Follow-up|0
6308710|NCT02628028|10036778|FG002|Dosing Period|Lost to Follow-up|0
6308711|NCT02628028|10036779|FG003|Dosing Period|Lost to Follow-up|0
6308712|NCT02628028|10036780|FG004|Dosing Period|Lost to Follow-up|0
6308713|NCT02628028|10036781|FG005|Dosing Period|Lost to Follow-up|0
6308714|NCT02628028|10036782|FG006|Dosing Period|Lost to Follow-up|1
6308715|NCT02628028|10036783|FG007|Dosing Period|Lost to Follow-up|0
6308716|NCT02628028|10036776|FG000|Dosing Period|Other|0
6308717|NCT02628028|10036777|FG001|Dosing Period|Other|0
6308718|NCT02628028|10036778|FG002|Dosing Period|Other|0
6308719|NCT02628028|10036779|FG003|Dosing Period|Other|0
6308720|NCT02628028|10036780|FG004|Dosing Period|Other|2
6308721|NCT02628028|10036781|FG005|Dosing Period|Other|1
6308722|NCT02628028|10036782|FG006|Dosing Period|Other|2
6308723|NCT02628028|10036783|FG007|Dosing Period|Other|4
6308724|NCT02628028|10036776|FG000|Long-term Extension (LTE) Period|Adverse Event|0
6308725|NCT02628028|10036777|FG001|Long-term Extension (LTE) Period|Adverse Event|0
5989160|NCT03194646|9580538|FG001|Overall Study|Other|67
6308726|NCT02628028|10036778|FG002|Long-term Extension (LTE) Period|Adverse Event|0
6308727|NCT02628028|10036779|FG003|Long-term Extension (LTE) Period|Adverse Event|0
6308728|NCT02628028|10036780|FG004|Long-term Extension (LTE) Period|Adverse Event|0
6308729|NCT02628028|10036781|FG005|Long-term Extension (LTE) Period|Adverse Event|1
6308730|NCT02628028|10036782|FG006|Long-term Extension (LTE) Period|Adverse Event|0
6308731|NCT02628028|10036783|FG007|Long-term Extension (LTE) Period|Adverse Event|3
6308732|NCT02628028|10036776|FG000|Long-term Extension (LTE) Period|Lack of Efficacy|0
6308733|NCT02628028|10036777|FG001|Long-term Extension (LTE) Period|Lack of Efficacy|0
6308734|NCT02628028|10036778|FG002|Long-term Extension (LTE) Period|Lack of Efficacy|0
6308735|NCT02628028|10036779|FG003|Long-term Extension (LTE) Period|Lack of Efficacy|0
6308736|NCT02628028|10036780|FG004|Long-term Extension (LTE) Period|Lack of Efficacy|0
6308737|NCT02628028|10036781|FG005|Long-term Extension (LTE) Period|Lack of Efficacy|2
6308738|NCT02628028|10036782|FG006|Long-term Extension (LTE) Period|Lack of Efficacy|0
6308739|NCT02628028|10036783|FG007|Long-term Extension (LTE) Period|Lack of Efficacy|1
6308740|NCT02628028|10036776|FG000|Long-term Extension (LTE) Period|Study Terminated by Sponsor|0
6308741|NCT02628028|10036777|FG001|Long-term Extension (LTE) Period|Study Terminated by Sponsor|0
6308742|NCT02628028|10036778|FG002|Long-term Extension (LTE) Period|Study Terminated by Sponsor|0
6308743|NCT02628028|10036779|FG003|Long-term Extension (LTE) Period|Study Terminated by Sponsor|0
6308744|NCT02628028|10036780|FG004|Long-term Extension (LTE) Period|Study Terminated by Sponsor|0
6308745|NCT02628028|10036781|FG005|Long-term Extension (LTE) Period|Study Terminated by Sponsor|52
6308746|NCT02628028|10036782|FG006|Long-term Extension (LTE) Period|Study Terminated by Sponsor|51
6308747|NCT02628028|10036783|FG007|Long-term Extension (LTE) Period|Study Terminated by Sponsor|51
6308748|NCT02628028|10036776|FG000|Long-term Extension (LTE) Period|Withdrawal by Subject|0
6308749|NCT02628028|10036777|FG001|Long-term Extension (LTE) Period|Withdrawal by Subject|0
6308750|NCT02628028|10036778|FG002|Long-term Extension (LTE) Period|Withdrawal by Subject|0
6308751|NCT02628028|10036779|FG003|Long-term Extension (LTE) Period|Withdrawal by Subject|0
6308752|NCT02628028|10036780|FG004|Long-term Extension (LTE) Period|Withdrawal by Subject|0
6308753|NCT02628028|10036781|FG005|Long-term Extension (LTE) Period|Withdrawal by Subject|2
6308754|NCT02628028|10036782|FG006|Long-term Extension (LTE) Period|Withdrawal by Subject|3
5989161|NCT03194646|9580539|FG002|Overall Study|Other|34
5989162|NCT03194646|9580540|FG003|Overall Study|Other|31
6308755|NCT02628028|10036783|FG007|Long-term Extension (LTE) Period|Withdrawal by Subject|3
6308756|NCT02628028|10036776|FG000|Long-term Extension (LTE) Period|Other|0
6308757|NCT02628028|10036777|FG001|Long-term Extension (LTE) Period|Other|0
6308758|NCT02628028|10036778|FG002|Long-term Extension (LTE) Period|Other|0
6308759|NCT02628028|10036779|FG003|Long-term Extension (LTE) Period|Other|0
6308760|NCT02628028|10036780|FG004|Long-term Extension (LTE) Period|Other|0
6308761|NCT02628028|10036781|FG005|Long-term Extension (LTE) Period|Other|3
6308762|NCT02628028|10036782|FG006|Long-term Extension (LTE) Period|Other|4
6308763|NCT02628028|10036783|FG007|Long-term Extension (LTE) Period|Other|3
6308764|NCT02628418|10036833|FG000|Overall Study|Lost to Follow-up|1
6308765|NCT02628418|10036834|FG001|Overall Study|Lost to Follow-up|2
6308766|NCT02628600|10036848|FG000|Overall Study|Death|2
6308767|NCT02628600|10036849|FG001|Overall Study|Death|1
6308768|NCT02628600|10036848|FG000|Overall Study|Adverse Event|3
6308769|NCT02628600|10036849|FG001|Overall Study|Adverse Event|20
6308770|NCT02628600|10036848|FG000|Overall Study|Protocol Violation|0
6308771|NCT02628600|10036849|FG001|Overall Study|Protocol Violation|1
6308772|NCT02628600|10036848|FG000|Overall Study|Lack of Efficacy|2
6308773|NCT02628600|10036849|FG001|Overall Study|Lack of Efficacy|0
6308774|NCT02628600|10036848|FG000|Overall Study|Withdrawal by Subject|13
6308775|NCT02628600|10036849|FG001|Overall Study|Withdrawal by Subject|8
6308776|NCT02628600|10036848|FG000|Overall Study|Lost to Follow-up|1
6308777|NCT02628600|10036849|FG001|Overall Study|Lost to Follow-up|0
6308778|NCT02628600|10036848|FG000|Overall Study|Physician Decision|2
6308779|NCT02628600|10036849|FG001|Overall Study|Physician Decision|2
6308780|NCT02628600|10036848|FG000|Overall Study|Other not specified|1
6308781|NCT02628600|10036849|FG001|Overall Study|Other not specified|0
6308782|NCT02628743|10036855|FG000|Overall Study|Other|3
5989163|NCT03194646|9580537|FG000|Overall Study|Physician Decision|7
5989164|NCT03194646|9580538|FG001|Overall Study|Physician Decision|9
6308783|NCT02628743|10036855|FG000|Overall Study|Withdrawal by Subject|50
6308784|NCT02628743|10036855|FG000|Overall Study|Study Terminated by Sponsor|76
6308785|NCT02628743|10036855|FG000|Overall Study|Physician Decision|2
6308786|NCT02628769|10036859|FG000|First Intervention|Adverse Event|1
6308787|NCT02628769|10036860|FG001|First Intervention|Adverse Event|0
6308788|NCT02628769|10036859|FG000|First Intervention|Withdrawal by Subject|0
6308789|NCT02628769|10036860|FG001|First Intervention|Withdrawal by Subject|1
6308790|NCT02628769|10036859|FG000|Second Intervention|Adverse Event|2
6308791|NCT02628769|10036860|FG001|Second Intervention|Adverse Event|0
6308792|NCT02628769|10036859|FG000|Second Intervention|Physician Decision|0
6308793|NCT02628769|10036860|FG001|Second Intervention|Physician Decision|1
6308794|NCT02628873|10036868|FG000|Break (1 Hour)|Withdrawal by Subject|0
6308795|NCT02628873|10036869|FG001|Break (1 Hour)|Withdrawal by Subject|1
6308796|NCT02628873|10036868|FG000|Second Test (1 Hour)|Physician Decision|1
6308797|NCT02628873|10036869|FG001|Second Test (1 Hour)|Physician Decision|0
6308798|NCT02628938|10036878|FG000|Overall Study|Did not attend the follow up recall|2
6308799|NCT02628938|10036879|FG001|Overall Study|Did not attend the follow up recall|2
6308800|NCT02628938|10036880|FG002|Overall Study|Did not attend the follow up recall|1
6308801|NCT02628938|10036878|FG000|Overall Study|Failure to comply with the instructions|3
6308802|NCT02628938|10036879|FG001|Overall Study|Failure to comply with the instructions|0
6308803|NCT02628938|10036880|FG002|Overall Study|Failure to comply with the instructions|3
6308804|NCT02629133|10036903|FG000|Overall Study|Lost to Follow-up|3
6308805|NCT02629133|10036904|FG001|Overall Study|Lost to Follow-up|1
6308806|NCT02629133|10036903|FG000|Overall Study|Withdrawal by Subject|1
6308807|NCT02629133|10036904|FG001|Overall Study|Withdrawal by Subject|1
6308808|NCT02629822|10036919|FG000|Base Study|Lost to Follow-up|2
6308809|NCT02629822|10036919|FG000|Base Study|Non-Compliance With Study Drug|1
6308810|NCT02629822|10036919|FG000|Extension Study|Adverse Event|1
6308811|NCT02629822|10036919|FG000|Extension Study|Lost to Follow-up|1
6308812|NCT02629861|10036927|FG000|Overall Study|Adverse Event|7
6308813|NCT02629861|10036928|FG001|Overall Study|Adverse Event|5
6308814|NCT02629861|10036929|FG002|Overall Study|Adverse Event|4
6308815|NCT02629861|10036927|FG000|Overall Study|Withdrawal by Subject|5
6308816|NCT02629861|10036928|FG001|Overall Study|Withdrawal by Subject|8
6308817|NCT02629861|10036929|FG002|Overall Study|Withdrawal by Subject|13
6308818|NCT02629861|10036927|FG000|Overall Study|Protocol Violation|2
6308819|NCT02629861|10036928|FG001|Overall Study|Protocol Violation|3
5989165|NCT03194646|9580539|FG002|Overall Study|Physician Decision|5
6308820|NCT02629861|10036929|FG002|Overall Study|Protocol Violation|7
6308821|NCT02629861|10036927|FG000|Overall Study|Lost to Follow-up|12
6308822|NCT02629861|10036928|FG001|Overall Study|Lost to Follow-up|9
6308823|NCT02629861|10036929|FG002|Overall Study|Lost to Follow-up|4
6308824|NCT02629861|10036927|FG000|Overall Study|Other|1
6308825|NCT02629861|10036928|FG001|Overall Study|Other|1
6308826|NCT02629861|10036929|FG002|Overall Study|Other|0
6308827|NCT02629861|10036927|FG000|Overall Study|Pregnancy|2
6308828|NCT02629861|10036928|FG001|Overall Study|Pregnancy|1
6308829|NCT02629861|10036929|FG002|Overall Study|Pregnancy|0
6308830|NCT02629965|10036937|FG000|Period 1|Adverse Event|1
6308831|NCT02629965|10036938|FG001|Period 1|Adverse Event|0
6308832|NCT02629965|10036937|FG000|Period 1|Unexpected worsening of disease|2
6308833|NCT02629965|10036938|FG001|Period 1|Unexpected worsening of disease|0
6308834|NCT02629965|10036937|FG000|Period 1|Other than listed above|1
6308835|NCT02629965|10036938|FG001|Period 1|Other than listed above|2
6308836|NCT02629965|10036937|FG000|Period 2|Adverse Event|1
6308837|NCT02629965|10036938|FG001|Period 2|Adverse Event|0
6308838|NCT02630186|10036975|FG000|Overall Study|Withdrawal by Subject|1
6308839|NCT02630251|10036983|FG000|Overall Study|Physician Decision|0
6308840|NCT02630251|10036984|FG001|Overall Study|Physician Decision|0
6308841|NCT02630251|10036985|FG002|Overall Study|Physician Decision|1
6308842|NCT02630251|10036986|FG003|Overall Study|Physician Decision|0
6308843|NCT02630563|10037005|FG000|Overall Study|Administrative|1
6308844|NCT02630693|10037012|FG000|Overall Study|No receive treatment|0
6308845|NCT02630693|10037013|FG001|Overall Study|No receive treatment|1
6308846|NCT02630706|10037022|FG000|Overall Study|Adverse Event|2
6308847|NCT02630706|10037023|FG001|Overall Study|Adverse Event|1
6308848|NCT02630706|10037024|FG002|Overall Study|Adverse Event|1
6308849|NCT02630706|10037022|FG000|Overall Study|Lost to Follow-up|0
6308850|NCT02630706|10037023|FG001|Overall Study|Lost to Follow-up|1
6308851|NCT02630706|10037024|FG002|Overall Study|Lost to Follow-up|2
6308852|NCT02630706|10037022|FG000|Overall Study|Physician Decision|1
6308853|NCT02630706|10037023|FG001|Overall Study|Physician Decision|1
6308854|NCT02630706|10037024|FG002|Overall Study|Physician Decision|0
6308855|NCT02630706|10037022|FG000|Overall Study|Pregnancy|0
6308856|NCT02630706|10037023|FG001|Overall Study|Pregnancy|1
6308857|NCT02630706|10037024|FG002|Overall Study|Pregnancy|0
6308858|NCT02630706|10037022|FG000|Overall Study|Withdrawal by Subject|4
6308859|NCT02630706|10037023|FG001|Overall Study|Withdrawal by Subject|5
6308860|NCT02630706|10037024|FG002|Overall Study|Withdrawal by Subject|7
6308861|NCT02630966|10037052|FG000|Overall Study|Adverse Event|1
6308862|NCT02630966|10037053|FG001|Overall Study|Adverse Event|3
6308863|NCT02630966|10037052|FG000|Overall Study|Significant Protocol Deviation|0
6308864|NCT02630966|10037053|FG001|Overall Study|Significant Protocol Deviation|2
6308865|NCT02630966|10037052|FG000|Overall Study|Voluntary Withdrawal|1
6308866|NCT02630966|10037053|FG001|Overall Study|Voluntary Withdrawal|1
6308867|NCT02630966|10037052|FG000|Overall Study|Lack of Efficacy|0
6308868|NCT02630966|10037053|FG001|Overall Study|Lack of Efficacy|2
6308869|NCT02631538|10037085|FG000|Treatment Period (Up to Week 52)|Adverse Event|1
6308870|NCT02631538|10037086|FG001|Treatment Period (Up to Week 52)|Adverse Event|5
6308871|NCT02631538|10037087|FG002|Treatment Period (Up to Week 52)|Adverse Event|2
6308872|NCT02631538|10037088|FG003|Treatment Period (Up to Week 52)|Adverse Event|2
6308873|NCT02631538|10037085|FG000|Treatment Period (Up to Week 52)|Withdrawal by Subject|1
6308874|NCT02631538|10037086|FG001|Treatment Period (Up to Week 52)|Withdrawal by Subject|1
6308875|NCT02631538|10037087|FG002|Treatment Period (Up to Week 52)|Withdrawal by Subject|2
6308876|NCT02631538|10037088|FG003|Treatment Period (Up to Week 52)|Withdrawal by Subject|5
6308877|NCT02631538|10037085|FG000|Treatment Period (Up to Week 52)|Lack of Efficacy|1
6308878|NCT02631538|10037086|FG001|Treatment Period (Up to Week 52)|Lack of Efficacy|1
6308879|NCT02631538|10037087|FG002|Treatment Period (Up to Week 52)|Lack of Efficacy|0
6308880|NCT02631538|10037088|FG003|Treatment Period (Up to Week 52)|Lack of Efficacy|0
6308881|NCT02631538|10037085|FG000|Treatment Period (Up to Week 52)|Physician Decision|1
6308882|NCT02631538|10037086|FG001|Treatment Period (Up to Week 52)|Physician Decision|0
6308883|NCT02631538|10037087|FG002|Treatment Period (Up to Week 52)|Physician Decision|0
6308884|NCT02631538|10037088|FG003|Treatment Period (Up to Week 52)|Physician Decision|1
6308885|NCT02631538|10037085|FG000|Treatment Period (Up to Week 52)|Reached stopping criteria|0
6308886|NCT02631538|10037086|FG001|Treatment Period (Up to Week 52)|Reached stopping criteria|0
6308887|NCT02631538|10037087|FG002|Treatment Period (Up to Week 52)|Reached stopping criteria|1
6308888|NCT02631538|10037088|FG003|Treatment Period (Up to Week 52)|Reached stopping criteria|0
6308889|NCT02631538|10037085|FG000|General Follow-up (GFU) (Up to Week 68)|Lost to Follow-up|1
6308890|NCT02631538|10037086|FG001|General Follow-up (GFU) (Up to Week 68)|Lost to Follow-up|0
6308891|NCT02631538|10037087|FG002|General Follow-up (GFU) (Up to Week 68)|Lost to Follow-up|0
6308892|NCT02631538|10037088|FG003|General Follow-up (GFU) (Up to Week 68)|Lost to Follow-up|1
6308893|NCT02631551|10037102|FG000|Overall Study|Adverse Event|1
6308894|NCT02631551|10037103|FG001|Overall Study|Adverse Event|2
6308895|NCT02631551|10037104|FG002|Overall Study|Adverse Event|4
6308896|NCT02631551|10037105|FG003|Overall Study|Adverse Event|0
6308897|NCT02631551|10037102|FG000|Overall Study|Lack of Efficacy|0
6308898|NCT02631551|10037103|FG001|Overall Study|Lack of Efficacy|0
6308899|NCT02631551|10037104|FG002|Overall Study|Lack of Efficacy|1
6308900|NCT02631551|10037105|FG003|Overall Study|Lack of Efficacy|0
6308901|NCT02631551|10037102|FG000|Overall Study|Lost to Follow-up|1
6308902|NCT02631551|10037103|FG001|Overall Study|Lost to Follow-up|2
6308903|NCT02631551|10037104|FG002|Overall Study|Lost to Follow-up|0
6308904|NCT02631551|10037105|FG003|Overall Study|Lost to Follow-up|3
6308905|NCT02631551|10037102|FG000|Overall Study|Withdrawal by Subject|2
6308906|NCT02631551|10037103|FG001|Overall Study|Withdrawal by Subject|2
6308907|NCT02631551|10037104|FG002|Overall Study|Withdrawal by Subject|0
6308908|NCT02631551|10037105|FG003|Overall Study|Withdrawal by Subject|5
6308909|NCT02631551|10037102|FG000|Overall Study|Protocol deviation|3
6308910|NCT02631551|10037103|FG001|Overall Study|Protocol deviation|6
6308911|NCT02631551|10037104|FG002|Overall Study|Protocol deviation|3
6308912|NCT02631551|10037105|FG003|Overall Study|Protocol deviation|0
6308913|NCT02631551|10037102|FG000|Overall Study|Non-compliance with study procedures|0
6308914|NCT02631551|10037103|FG001|Overall Study|Non-compliance with study procedures|0
6308915|NCT02631551|10037104|FG002|Overall Study|Non-compliance with study procedures|1
6308916|NCT02631551|10037105|FG003|Overall Study|Non-compliance with study procedures|1
6308917|NCT02631551|10037102|FG000|Overall Study|Non-compliance with study drug|1
6308918|NCT02631551|10037103|FG001|Overall Study|Non-compliance with study drug|0
6308919|NCT02631551|10037104|FG002|Overall Study|Non-compliance with study drug|0
6308920|NCT02631551|10037105|FG003|Overall Study|Non-compliance with study drug|0
6308921|NCT02631551|10037102|FG000|Overall Study|Other, specific reasons not collected|5
6308922|NCT02631551|10037103|FG001|Overall Study|Other, specific reasons not collected|7
6308923|NCT02631551|10037104|FG002|Overall Study|Other, specific reasons not collected|2
6308924|NCT02631551|10037105|FG003|Overall Study|Other, specific reasons not collected|2
6308925|NCT02631746|10037119|FG000|Overall Study|Lack of Efficacy|3
6308926|NCT02631850|10037136|FG000|Treatment Period|Lost to Follow-up|0
6308927|NCT02631850|10037137|FG001|Treatment Period|Lost to Follow-up|1
6308928|NCT02631850|10037138|FG002|Treatment Period|Lost to Follow-up|0
6308929|NCT02631850|10037139|FG003|Treatment Period|Lost to Follow-up|0
6308930|NCT02631850|10037136|FG000|Treatment Period|Protocol Violation|1
6308931|NCT02631850|10037137|FG001|Treatment Period|Protocol Violation|0
6308932|NCT02631850|10037138|FG002|Treatment Period|Protocol Violation|0
6308933|NCT02631850|10037139|FG003|Treatment Period|Protocol Violation|0
6308934|NCT02631850|10037136|FG000|Treatment Period|Withdrawal by Subject|0
6308935|NCT02631850|10037137|FG001|Treatment Period|Withdrawal by Subject|5
6308936|NCT02631850|10037138|FG002|Treatment Period|Withdrawal by Subject|2
6308937|NCT02631850|10037139|FG003|Treatment Period|Withdrawal by Subject|2
6308938|NCT02631850|10037136|FG000|Treatment Period|Adverse Event|1
6308939|NCT02631850|10037137|FG001|Treatment Period|Adverse Event|0
6308940|NCT02631850|10037138|FG002|Treatment Period|Adverse Event|2
6308941|NCT02631850|10037139|FG003|Treatment Period|Adverse Event|3
6308942|NCT02631850|10037136|FG000|Treatment Period|Family medical issue|1
6308943|NCT02631850|10037137|FG001|Treatment Period|Family medical issue|0
6308944|NCT02631850|10037138|FG002|Treatment Period|Family medical issue|0
6308945|NCT02631850|10037139|FG003|Treatment Period|Family medical issue|0
6308946|NCT02631850|10037136|FG000|6 Month Follow up|Lost to Follow-up|5
6308947|NCT02631850|10037137|FG001|6 Month Follow up|Lost to Follow-up|8
6308948|NCT02631850|10037138|FG002|6 Month Follow up|Lost to Follow-up|3
6308949|NCT02631850|10037139|FG003|6 Month Follow up|Lost to Follow-up|5
6308950|NCT02631850|10037136|FG000|6 Month Follow up|Withdrawal by Subject|1
6308951|NCT02631850|10037137|FG001|6 Month Follow up|Withdrawal by Subject|0
6308952|NCT02631850|10037138|FG002|6 Month Follow up|Withdrawal by Subject|0
6308953|NCT02631850|10037139|FG003|6 Month Follow up|Withdrawal by Subject|2
6308954|NCT02631850|10037136|FG000|6 Month Follow up|Adverse Event|1
6308955|NCT02631850|10037137|FG001|6 Month Follow up|Adverse Event|4
6308956|NCT02631850|10037138|FG002|6 Month Follow up|Adverse Event|1
6308957|NCT02631850|10037139|FG003|6 Month Follow up|Adverse Event|3
6308958|NCT02631850|10037136|FG000|6 Month Follow up|moved out of state, transportation issues, family medical issue|0
6308959|NCT02631850|10037137|FG001|6 Month Follow up|moved out of state, transportation issues, family medical issue|1
6308960|NCT02631850|10037138|FG002|6 Month Follow up|moved out of state, transportation issues, family medical issue|2
6308961|NCT02631850|10037139|FG003|6 Month Follow up|moved out of state, transportation issues, family medical issue|1
6308962|NCT02631876|10037152|FG000|Overall Study|Death|96
6308963|NCT02631876|10037153|FG001|Overall Study|Death|50
6308964|NCT02631876|10037152|FG000|Overall Study|Investigator's discretion|1
6308965|NCT02631876|10037153|FG001|Overall Study|Investigator's discretion|0
6308966|NCT02631876|10037152|FG000|Overall Study|Lost to Follow-up|2
6308967|NCT02631876|10037153|FG001|Overall Study|Lost to Follow-up|0
6308968|NCT02631876|10037152|FG000|Overall Study|Withdrawal by Subject|16
6308969|NCT02631876|10037153|FG001|Overall Study|Withdrawal by Subject|9
6308970|NCT02631876|10037152|FG000|Overall Study|Other than specified|4
6308971|NCT02631876|10037153|FG001|Overall Study|Other than specified|4
6308972|NCT02632110|10037174|FG000|Overall Study|Withdrawal by Subject|1
6308973|NCT02632110|10037175|FG001|Overall Study|Withdrawal by Subject|1
6308974|NCT02632110|10037176|FG002|Overall Study|Withdrawal by Subject|0
6308975|NCT02632110|10037177|FG003|Overall Study|Withdrawal by Subject|0
6308976|NCT02632110|10037178|FG004|Overall Study|Withdrawal by Subject|1
6308977|NCT02632110|10037179|FG005|Overall Study|Withdrawal by Subject|1
6308978|NCT02632110|10037180|FG006|Overall Study|Withdrawal by Subject|3
6308979|NCT02632110|10037181|FG007|Overall Study|Withdrawal by Subject|3
6308980|NCT02632110|10037182|FG008|Overall Study|Withdrawal by Subject|1
6308981|NCT02632110|10037183|FG009|Overall Study|Withdrawal by Subject|1
6308982|NCT02632552|10037258|FG000|Overall Study|Lost to Follow-up|14
6308983|NCT02632552|10037259|FG001|Overall Study|Lost to Follow-up|8
6308984|NCT02632552|10037258|FG000|Overall Study|Withdrawal by Subject|2
6308985|NCT02632552|10037259|FG001|Overall Study|Withdrawal by Subject|0
6308986|NCT02632552|10037258|FG000|Overall Study|Did not receive allocated protocol (did not enroll in texting program)|7
6308987|NCT02632552|10037259|FG001|Overall Study|Did not receive allocated protocol (did not enroll in texting program)|2
6308988|NCT02632747|10037268|FG000|Wash-out Period|Adverse Event|1
6308989|NCT02632747|10037269|FG001|Wash-out Period|Adverse Event|0
6308990|NCT02632786|10037277|FG000|Overall Study|Adverse Event|2
6308991|NCT02632786|10037278|FG001|Overall Study|Adverse Event|1
6308992|NCT02632786|10037277|FG000|Overall Study|Death|3
6308993|NCT02632786|10037278|FG001|Overall Study|Death|2
6308994|NCT02632786|10037277|FG000|Overall Study|Physician Decision|5
6308995|NCT02632786|10037278|FG001|Overall Study|Physician Decision|4
6308996|NCT02632786|10037277|FG000|Overall Study|Withdrawal by Subject|1
6308997|NCT02632786|10037278|FG001|Overall Study|Withdrawal by Subject|0
6308998|NCT02632838|10037296|FG000|Overall Study|Withdrawal by Subject|3
6308999|NCT02632838|10037297|FG001|Overall Study|Withdrawal by Subject|0
6309000|NCT02632838|10037296|FG000|Overall Study|Lost to Follow-up|0
6309001|NCT02632838|10037297|FG001|Overall Study|Lost to Follow-up|2
6309002|NCT02633020|10037309|FG000|Overall Study|Adverse Event|1
6309003|NCT02633020|10037310|FG001|Overall Study|Adverse Event|0
6309004|NCT02633046|10037316|FG000|Overall Study|Adverse Event|8
5989166|NCT03194646|9580540|FG003|Overall Study|Physician Decision|4
5989167|NCT03194646|9580537|FG000|Overall Study|Pregnancy|4
5989168|NCT03194646|9580538|FG001|Overall Study|Pregnancy|5
6309005|NCT02633046|10037316|FG000|Overall Study|Physician Decision|7
6309006|NCT02633046|10037316|FG000|Overall Study|Withdrawal by Subject|8
6309007|NCT02633046|10037316|FG000|Overall Study|Increased proteinuria|2
6309008|NCT02633046|10037316|FG000|Overall Study|Participant decided not to continue with open label extension|1
6309009|NCT02633046|10037316|FG000|Overall Study|Mutual decision patient and physician|1
6309010|NCT02633215|10037322|FG000|Overall Study|Lost to Follow-up|2
6309011|NCT02633215|10037323|FG001|Overall Study|Lost to Follow-up|3
6309012|NCT02633306|10037329|FG000|Overall Study|Withdrawal by Subject|3
6309013|NCT02633501|10037363|FG000|Overall Study|Adverse Event|0
6309014|NCT02633501|10037364|FG001|Overall Study|Adverse Event|0
6309015|NCT02633501|10037365|FG002|Overall Study|Adverse Event|1
6309016|NCT02633501|10037366|FG003|Overall Study|Adverse Event|0
6309017|NCT02633501|10037367|FG004|Overall Study|Adverse Event|1
6309018|NCT02633501|10037368|FG005|Overall Study|Adverse Event|1
6309019|NCT02633501|10037363|FG000|Overall Study|Withdrawal by Subject|2
6309020|NCT02633501|10037364|FG001|Overall Study|Withdrawal by Subject|1
6309021|NCT02633501|10037365|FG002|Overall Study|Withdrawal by Subject|2
6309022|NCT02633501|10037366|FG003|Overall Study|Withdrawal by Subject|2
6309023|NCT02633501|10037367|FG004|Overall Study|Withdrawal by Subject|1
6309024|NCT02633501|10037368|FG005|Overall Study|Withdrawal by Subject|3
6309025|NCT02633501|10037363|FG000|Overall Study|Various other reasons|0
6309026|NCT02633501|10037364|FG001|Overall Study|Various other reasons|2
6309027|NCT02633501|10037365|FG002|Overall Study|Various other reasons|4
6309028|NCT02633501|10037366|FG003|Overall Study|Various other reasons|1
6309029|NCT02633501|10037367|FG004|Overall Study|Various other reasons|7
6309030|NCT02633501|10037368|FG005|Overall Study|Various other reasons|11
6309031|NCT02633501|10037363|FG000|Overall Study|Lost to Follow-up|0
6309032|NCT02633501|10037364|FG001|Overall Study|Lost to Follow-up|0
6309033|NCT02633501|10037365|FG002|Overall Study|Lost to Follow-up|0
6309034|NCT02633501|10037366|FG003|Overall Study|Lost to Follow-up|1
6309035|NCT02633501|10037367|FG004|Overall Study|Lost to Follow-up|2
6309036|NCT02633501|10037368|FG005|Overall Study|Lost to Follow-up|0
6309037|NCT02633527|10037392|FG000|Overall Study|Failed to meet eligibility|0
6309038|NCT02633527|10037393|FG001|Overall Study|Failed to meet eligibility|1
6309039|NCT02633527|10037394|FG002|Overall Study|Failed to meet eligibility|1
6309040|NCT02633527|10037395|FG003|Overall Study|Failed to meet eligibility|0
6309041|NCT02633527|10037396|FG004|Overall Study|Failed to meet eligibility|1
6309042|NCT02633527|10037392|FG000|Overall Study|Adverse Event|0
6309043|NCT02633527|10037393|FG001|Overall Study|Adverse Event|4
6309044|NCT02633527|10037394|FG002|Overall Study|Adverse Event|3
6309045|NCT02633527|10037395|FG003|Overall Study|Adverse Event|1
6309046|NCT02633527|10037396|FG004|Overall Study|Adverse Event|5
6309047|NCT02633527|10037392|FG000|Overall Study|Lost to Follow-up|1
6309048|NCT02633527|10037393|FG001|Overall Study|Lost to Follow-up|2
6309049|NCT02633527|10037394|FG002|Overall Study|Lost to Follow-up|5
6309050|NCT02633527|10037395|FG003|Overall Study|Lost to Follow-up|5
6309051|NCT02633527|10037396|FG004|Overall Study|Lost to Follow-up|4
6309052|NCT02633527|10037392|FG000|Overall Study|Withdrawal by Subject|0
6309053|NCT02633527|10037393|FG001|Overall Study|Withdrawal by Subject|3
6309054|NCT02633527|10037394|FG002|Overall Study|Withdrawal by Subject|5
6309055|NCT02633527|10037395|FG003|Overall Study|Withdrawal by Subject|4
5989169|NCT03194646|9580539|FG002|Overall Study|Pregnancy|1
6309056|NCT02633527|10037396|FG004|Overall Study|Withdrawal by Subject|4
6309057|NCT02633527|10037392|FG000|Overall Study|Protocol Violation|0
6309058|NCT02633527|10037393|FG001|Overall Study|Protocol Violation|1
6309059|NCT02633527|10037394|FG002|Overall Study|Protocol Violation|1
6309060|NCT02633527|10037395|FG003|Overall Study|Protocol Violation|1
6309061|NCT02633527|10037396|FG004|Overall Study|Protocol Violation|1
6309062|NCT02633527|10037392|FG000|Overall Study|Physician Decision|0
6309063|NCT02633527|10037393|FG001|Overall Study|Physician Decision|0
6309064|NCT02633527|10037394|FG002|Overall Study|Physician Decision|0
6309065|NCT02633527|10037395|FG003|Overall Study|Physician Decision|0
6309066|NCT02633527|10037396|FG004|Overall Study|Physician Decision|1
6309067|NCT02633527|10037392|FG000|Overall Study|Administrative reason|1
6309068|NCT02633527|10037393|FG001|Overall Study|Administrative reason|0
6309069|NCT02633527|10037394|FG002|Overall Study|Administrative reason|0
6309070|NCT02633527|10037395|FG003|Overall Study|Administrative reason|1
6309071|NCT02633527|10037396|FG004|Overall Study|Administrative reason|0
6309072|NCT02633527|10037392|FG000|Overall Study|Multiple reasons|1
6309073|NCT02633527|10037393|FG001|Overall Study|Multiple reasons|0
6309074|NCT02633527|10037394|FG002|Overall Study|Multiple reasons|2
6309075|NCT02633527|10037395|FG003|Overall Study|Multiple reasons|2
6309076|NCT02633527|10037396|FG004|Overall Study|Multiple reasons|1
6309077|NCT02633787|10037417|FG000|Overall Study|Withdrawal by Subject|1
6309078|NCT02633800|10037423|FG000|Overall Study|Death|3
6309079|NCT02633800|10037424|FG001|Overall Study|Death|3
6309080|NCT02633800|10037423|FG000|Overall Study|Reason not provided|1
6309081|NCT02633800|10037424|FG001|Overall Study|Reason not provided|0
6309082|NCT02633800|10037423|FG000|Overall Study|Radiologic(al) progression|23
6309083|NCT02633800|10037424|FG001|Overall Study|Radiologic(al) progression|23
6309084|NCT02633800|10037423|FG000|Overall Study|Clinical progression|3
6309085|NCT02633800|10037424|FG001|Overall Study|Clinical progression|6
6309086|NCT02633800|10037423|FG000|Overall Study|Study terminated by sponsor|6
6309087|NCT02633800|10037424|FG001|Overall Study|Study terminated by sponsor|5
6309088|NCT02633800|10037423|FG000|Overall Study|Adverse event, non-fatal|7
6309089|NCT02633800|10037424|FG001|Overall Study|Adverse event, non-fatal|2
6309090|NCT02633800|10037423|FG000|Overall Study|Withdrawal by Subject|0
6309091|NCT02633800|10037424|FG001|Overall Study|Withdrawal by Subject|3
6309092|NCT02633800|10037423|FG000|Overall Study|Patient Request|1
6309093|NCT02633800|10037424|FG001|Overall Study|Patient Request|1
6309094|NCT02634151|10037466|FG000|Overall Study|Withdrawal by Subject|1
6309095|NCT02634151|10037467|FG001|Overall Study|Withdrawal by Subject|0
6309096|NCT02634151|10037466|FG000|Overall Study|Non-Compliance|0
6309097|NCT02634151|10037467|FG001|Overall Study|Non-Compliance|1
6309098|NCT02634151|10037466|FG000|Overall Study|Other|0
6309099|NCT02634151|10037467|FG001|Overall Study|Other|1
6309100|NCT02634320|10037482|FG000|Overall Study|Adverse Event|2
6309101|NCT02634320|10037482|FG000|Overall Study|Lost to Follow-up|3
6309102|NCT02634320|10037482|FG000|Overall Study|Moved out of area|2
6309103|NCT02634320|10037482|FG000|Overall Study|Out of window for study visits|1
6309104|NCT02634320|10037482|FG000|Overall Study|Protocol Violation|1
6309105|NCT02634320|10037482|FG000|Overall Study|Withdrawal by Subject|5
6309106|NCT02634320|10037482|FG000|Overall Study|Lack of Efficacy|2
6309107|NCT02634333|10037488|FG000|Overall Study|Completed out of Window|3
6309108|NCT02634333|10037489|FG001|Overall Study|Completed out of Window|2
6309109|NCT02634333|10037488|FG000|Overall Study|Missed Visit|5
6309110|NCT02634333|10037489|FG001|Overall Study|Missed Visit|2
6309111|NCT02634333|10037488|FG000|Overall Study|Lost to Follow-up|12
6309112|NCT02634333|10037489|FG001|Overall Study|Lost to Follow-up|7
6309113|NCT02634333|10037488|FG000|Overall Study|Withdrawal by Subject|9
6309114|NCT02634333|10037489|FG001|Overall Study|Withdrawal by Subject|13
6309115|NCT02634333|10037488|FG000|Overall Study|Death|11
6309116|NCT02634333|10037489|FG001|Overall Study|Death|8
6309117|NCT02634346|10037499|FG000|Overall Study|Withdrawal by Subject|8
6309118|NCT02634346|10037500|FG001|Overall Study|Withdrawal by Subject|9
6309119|NCT02634346|10037501|FG002|Overall Study|Withdrawal by Subject|8
6309120|NCT02634346|10037499|FG000|Overall Study|Adverse Event|2
6309121|NCT02634346|10037500|FG001|Overall Study|Adverse Event|2
6309122|NCT02634346|10037501|FG002|Overall Study|Adverse Event|7
6309123|NCT02634346|10037499|FG000|Overall Study|Lack of Efficacy|1
6309124|NCT02634346|10037500|FG001|Overall Study|Lack of Efficacy|2
6309125|NCT02634346|10037501|FG002|Overall Study|Lack of Efficacy|8
6309126|NCT02634346|10037499|FG000|Overall Study|Lost to Follow-up|1
6309127|NCT02634346|10037500|FG001|Overall Study|Lost to Follow-up|0
6309128|NCT02634346|10037501|FG002|Overall Study|Lost to Follow-up|0
6309129|NCT02634346|10037499|FG000|Overall Study|Protocol Violation|0
6309130|NCT02634346|10037500|FG001|Overall Study|Protocol Violation|1
5989170|NCT03194646|9580540|FG003|Overall Study|Pregnancy|2
6309131|NCT02634346|10037501|FG002|Overall Study|Protocol Violation|0
6309132|NCT02634580|10037513|FG000|Double-blind Treatment Period|Subject Request|1
6309133|NCT02634580|10037514|FG001|Double-blind Treatment Period|Subject Request|0
6309134|NCT02634580|10037515|FG002|Double-blind Treatment Period|Subject Request|1
6309135|NCT02634580|10037516|FG003|Double-blind Treatment Period|Subject Request|1
6309136|NCT02634580|10037513|FG000|Open-label Extension Period|Withdrawal by Subject|0
6309137|NCT02634580|10037514|FG001|Open-label Extension Period|Withdrawal by Subject|1
6309138|NCT02634580|10037515|FG002|Open-label Extension Period|Withdrawal by Subject|0
6309139|NCT02634580|10037516|FG003|Open-label Extension Period|Withdrawal by Subject|1
6309140|NCT02634788|10037546|FG000|Overall Study|Adverse Event|0
6309141|NCT02634788|10037547|FG001|Overall Study|Adverse Event|8
6309142|NCT02634788|10037548|FG002|Overall Study|Adverse Event|3
6309143|NCT02634788|10037549|FG003|Overall Study|Adverse Event|1
6309144|NCT02634788|10037546|FG000|Overall Study|Lack of Efficacy|4
6309145|NCT02634788|10037547|FG001|Overall Study|Lack of Efficacy|0
6309146|NCT02634788|10037548|FG002|Overall Study|Lack of Efficacy|1
6309147|NCT02634788|10037549|FG003|Overall Study|Lack of Efficacy|4
6309148|NCT02634788|10037546|FG000|Overall Study|Lost to Follow-up|0
6309149|NCT02634788|10037547|FG001|Overall Study|Lost to Follow-up|1
6309150|NCT02634788|10037548|FG002|Overall Study|Lost to Follow-up|0
6309151|NCT02634788|10037549|FG003|Overall Study|Lost to Follow-up|0
6309152|NCT02634788|10037546|FG000|Overall Study|Withdrawal by Subject|0
6309153|NCT02634788|10037547|FG001|Overall Study|Withdrawal by Subject|1
6309154|NCT02634788|10037548|FG002|Overall Study|Withdrawal by Subject|1
6309155|NCT02634788|10037549|FG003|Overall Study|Withdrawal by Subject|0
6309156|NCT02634801|10037562|FG000|Treatment Period (Weeks 0 to 24)|Adverse Event|2
6309157|NCT02634801|10037563|FG001|Treatment Period (Weeks 0 to 24)|Adverse Event|20
6309158|NCT02634801|10037564|FG002|Treatment Period (Weeks 0 to 24)|Adverse Event|0
6309159|NCT02634801|10037562|FG000|Treatment Period (Weeks 0 to 24)|Lack of Efficacy|0
6309160|NCT02634801|10037563|FG001|Treatment Period (Weeks 0 to 24)|Lack of Efficacy|2
6309161|NCT02634801|10037564|FG002|Treatment Period (Weeks 0 to 24)|Lack of Efficacy|0
6309162|NCT02634801|10037562|FG000|Treatment Period (Weeks 0 to 24)|Lost to Follow-up|2
6309163|NCT02634801|10037563|FG001|Treatment Period (Weeks 0 to 24)|Lost to Follow-up|1
6309164|NCT02634801|10037564|FG002|Treatment Period (Weeks 0 to 24)|Lost to Follow-up|1
6309165|NCT02634801|10037562|FG000|Treatment Period (Weeks 0 to 24)|Protocol Violation|0
6309166|NCT02634801|10037563|FG001|Treatment Period (Weeks 0 to 24)|Protocol Violation|0
6309167|NCT02634801|10037564|FG002|Treatment Period (Weeks 0 to 24)|Protocol Violation|1
6309168|NCT02634801|10037562|FG000|Treatment Period (Weeks 0 to 24)|Withdrawal by Subject|0
6309169|NCT02634801|10037563|FG001|Treatment Period (Weeks 0 to 24)|Withdrawal by Subject|8
6309170|NCT02634801|10037564|FG002|Treatment Period (Weeks 0 to 24)|Withdrawal by Subject|3
6309171|NCT02634801|10037562|FG000|Extension Period (Weeks 24 to 36)|Adverse Event|0
6309172|NCT02634801|10037563|FG001|Extension Period (Weeks 24 to 36)|Adverse Event|0
6309173|NCT02634801|10037564|FG002|Extension Period (Weeks 24 to 36)|Adverse Event|1
6309174|NCT02634801|10037562|FG000|Extension Period (Weeks 24 to 36)|Lost to Follow-up|1
6309175|NCT02634801|10037563|FG001|Extension Period (Weeks 24 to 36)|Lost to Follow-up|0
6309176|NCT02634801|10037564|FG002|Extension Period (Weeks 24 to 36)|Lost to Follow-up|0
6309177|NCT02634801|10037562|FG000|Extension Period (Weeks 24 to 36)|Withdrawal by Subject|1
6309178|NCT02634801|10037563|FG001|Extension Period (Weeks 24 to 36)|Withdrawal by Subject|1
6309179|NCT02634801|10037564|FG002|Extension Period (Weeks 24 to 36)|Withdrawal by Subject|1
6309180|NCT02634801|10037562|FG000|Extension Period (Weeks 24 to 36)|Missing|1
6309181|NCT02634801|10037563|FG001|Extension Period (Weeks 24 to 36)|Missing|0
6309182|NCT02634801|10037564|FG002|Extension Period (Weeks 24 to 36)|Missing|0
6309183|NCT02634801|10037562|FG000|Follow-up Period|Lost to Follow-up|3
6309184|NCT02634801|10037563|FG001|Follow-up Period|Lost to Follow-up|1
6309185|NCT02634801|10037564|FG002|Follow-up Period|Lost to Follow-up|2
6309186|NCT02634801|10037562|FG000|Follow-up Period|Physician Decision|0
6309187|NCT02634801|10037563|FG001|Follow-up Period|Physician Decision|0
6309188|NCT02634801|10037564|FG002|Follow-up Period|Physician Decision|1
6309189|NCT02634801|10037562|FG000|Follow-up Period|Withdrawal by Subject|1
6309190|NCT02634801|10037563|FG001|Follow-up Period|Withdrawal by Subject|2
6309191|NCT02634801|10037564|FG002|Follow-up Period|Withdrawal by Subject|5
6309192|NCT02634801|10037562|FG000|Follow-up Period|Adverse Event|1
6309193|NCT02634801|10037563|FG001|Follow-up Period|Adverse Event|5
6309194|NCT02634801|10037564|FG002|Follow-up Period|Adverse Event|0
6309195|NCT02634983|10037589|FG000|Period 2 (Second Treatment, 8-10 Days)|Adverse Event|2
6309196|NCT02634983|10037590|FG001|Period 2 (Second Treatment, 8-10 Days)|Adverse Event|0
6309197|NCT02635204|10037607|FG000|Overall Study|Adverse Event|1
6309198|NCT02635204|10037608|FG001|Overall Study|Adverse Event|0
6309199|NCT02635204|10037607|FG000|Overall Study|Lost to Follow-up|1
6309200|NCT02635204|10037608|FG001|Overall Study|Lost to Follow-up|1
6309201|NCT02635347|10037616|FG000|Overall Study|Failed screening|20
6309202|NCT02635347|10037617|FG001|Overall Study|Failed screening|7
6309203|NCT02635386|10037629|FG000|Overall Study|Pregnancy|2
6309204|NCT02635386|10037630|FG001|Overall Study|Pregnancy|0
6309205|NCT02635386|10037631|FG002|Overall Study|Pregnancy|0
6309206|NCT02635386|10037632|FG003|Overall Study|Pregnancy|0
6309207|NCT02635386|10037633|FG004|Overall Study|Pregnancy|2
6309208|NCT02635386|10037629|FG000|Overall Study|Withdrawal by Subject|1
6309209|NCT02635386|10037630|FG001|Overall Study|Withdrawal by Subject|1
6309210|NCT02635386|10037631|FG002|Overall Study|Withdrawal by Subject|0
6309211|NCT02635386|10037632|FG003|Overall Study|Withdrawal by Subject|1
6309212|NCT02635386|10037633|FG004|Overall Study|Withdrawal by Subject|0
6309213|NCT02635386|10037629|FG000|Overall Study|Physician Decision|0
6309214|NCT02635386|10037630|FG001|Overall Study|Physician Decision|1
6309215|NCT02635386|10037631|FG002|Overall Study|Physician Decision|0
6309216|NCT02635386|10037632|FG003|Overall Study|Physician Decision|0
6309217|NCT02635386|10037633|FG004|Overall Study|Physician Decision|0
6309218|NCT02635386|10037629|FG000|Overall Study|Moved Out of State|0
6309219|NCT02635386|10037630|FG001|Overall Study|Moved Out of State|1
6309220|NCT02635386|10037631|FG002|Overall Study|Moved Out of State|0
6309221|NCT02635386|10037632|FG003|Overall Study|Moved Out of State|0
6309222|NCT02635386|10037633|FG004|Overall Study|Moved Out of State|0
6309223|NCT02635386|10037629|FG000|Overall Study|Noncompliant|0
6309224|NCT02635386|10037630|FG001|Overall Study|Noncompliant|2
6309225|NCT02635386|10037631|FG002|Overall Study|Noncompliant|1
6309226|NCT02635386|10037632|FG003|Overall Study|Noncompliant|1
6309227|NCT02635386|10037633|FG004|Overall Study|Noncompliant|1
6309228|NCT02635386|10037629|FG000|Overall Study|side effects|0
6309229|NCT02635386|10037630|FG001|Overall Study|side effects|0
6309230|NCT02635386|10037631|FG002|Overall Study|side effects|1
6309231|NCT02635386|10037632|FG003|Overall Study|side effects|4
6309232|NCT02635386|10037633|FG004|Overall Study|side effects|6
6309233|NCT02635386|10037629|FG000|Overall Study|needed other major surgery|0
6309234|NCT02635386|10037630|FG001|Overall Study|needed other major surgery|1
6309235|NCT02635386|10037631|FG002|Overall Study|needed other major surgery|0
6309236|NCT02635386|10037632|FG003|Overall Study|needed other major surgery|0
6309237|NCT02635386|10037633|FG004|Overall Study|needed other major surgery|0
6309238|NCT02635386|10037629|FG000|Overall Study|Other medical problems not drug related|0
6309239|NCT02635386|10037630|FG001|Overall Study|Other medical problems not drug related|0
6309240|NCT02635386|10037631|FG002|Overall Study|Other medical problems not drug related|0
6309241|NCT02635386|10037632|FG003|Overall Study|Other medical problems not drug related|1
6309242|NCT02635386|10037633|FG004|Overall Study|Other medical problems not drug related|0
6309243|NCT02635646|10037670|FG000|Overall Study|Lost to Follow-up|24
6309244|NCT02635646|10037671|FG001|Overall Study|Lost to Follow-up|25
5989171|NCT03194646|9580537|FG000|Overall Study|Protocol Violation|4
5989172|NCT03194646|9580538|FG001|Overall Study|Protocol Violation|2
5989173|NCT03194646|9580539|FG002|Overall Study|Protocol Violation|1
5989174|NCT03194646|9580540|FG003|Overall Study|Protocol Violation|1
5989175|NCT03194646|9580537|FG000|Overall Study|Site terminated by sponsor|0
5989176|NCT03194646|9580538|FG001|Overall Study|Site terminated by sponsor|0
5989177|NCT03194646|9580539|FG002|Overall Study|Site terminated by sponsor|2
5989178|NCT03194646|9580540|FG003|Overall Study|Site terminated by sponsor|0
5989179|NCT03194646|9580537|FG000|Overall Study|Study terminated by sponsor|60
5989180|NCT03194646|9580538|FG001|Overall Study|Study terminated by sponsor|61
5989181|NCT03194646|9580539|FG002|Overall Study|Study terminated by sponsor|30
5989182|NCT03194646|9580540|FG003|Overall Study|Study terminated by sponsor|34
5989183|NCT03194646|9580537|FG000|Overall Study|Withdrawal by Subject|74
5989184|NCT03194646|9580538|FG001|Overall Study|Withdrawal by Subject|75
5989185|NCT03194646|9580539|FG002|Overall Study|Withdrawal by Subject|36
5989186|NCT03194646|9580540|FG003|Overall Study|Withdrawal by Subject|131
5989187|NCT03194646|9580537|FG000|Overall Study|Missing|4
5989188|NCT03194646|9580538|FG001|Overall Study|Missing|0
5989189|NCT03194646|9580539|FG002|Overall Study|Missing|1
5989190|NCT03194646|9580540|FG003|Overall Study|Missing|12
5989191|NCT03116399|9580566|FG000|Overall Study|Death|8
5989192|NCT03116399|9580567|FG001|Overall Study|Death|3
5989193|NCT03116399|9580566|FG000|Overall Study|Lost to Follow-up|7
5989194|NCT03116399|9580567|FG001|Overall Study|Lost to Follow-up|11
5989195|NCT03116399|9580566|FG000|Overall Study|Investigator Decision|1
5989196|NCT03116399|9580567|FG001|Overall Study|Investigator Decision|1
5989197|NCT03116399|9580566|FG000|Overall Study|Withdrawal by Subject|24
5989198|NCT03116399|9580567|FG001|Overall Study|Withdrawal by Subject|9
5989199|NCT03064126|9580577|FG000|Overall Study|Death|6
5989200|NCT03064126|9580578|FG001|Overall Study|Death|2
5989201|NCT03064126|9580579|FG002|Overall Study|Death|2
5989202|NCT03064126|9580580|FG003|Overall Study|Death|1
5989203|NCT03064126|9580577|FG000|Overall Study|Investigator Discretion|1
5989204|NCT03064126|9580578|FG001|Overall Study|Investigator Discretion|0
5989205|NCT03064126|9580579|FG002|Overall Study|Investigator Discretion|0
5989206|NCT03064126|9580580|FG003|Overall Study|Investigator Discretion|0
5989207|NCT03064126|9580577|FG000|Overall Study|Withdrawal by Subject|7
5989208|NCT03064126|9580578|FG001|Overall Study|Withdrawal by Subject|4
5989209|NCT03064126|9580579|FG002|Overall Study|Withdrawal by Subject|0
5989210|NCT03064126|9580580|FG003|Overall Study|Withdrawal by Subject|0
5989211|NCT03064126|9580577|FG000|Overall Study|Subject moved|1
5989212|NCT03064126|9580578|FG001|Overall Study|Subject moved|0
5989213|NCT03064126|9580579|FG002|Overall Study|Subject moved|0
5989214|NCT03064126|9580580|FG003|Overall Study|Subject moved|0
5989215|NCT03064126|9580577|FG000|Overall Study|Protocol Violation|11
5989216|NCT03064126|9580578|FG001|Overall Study|Protocol Violation|1
5989217|NCT03064126|9580579|FG002|Overall Study|Protocol Violation|1
5989218|NCT03064126|9580580|FG003|Overall Study|Protocol Violation|0
5989219|NCT03020160|9580593|FG000|Overall Study|Continuing to receive emicizumab|7
5989220|NCT03020160|9580594|FG001|Overall Study|Continuing to receive emicizumab|41
5989221|NCT02943993|9580601|FG000|Overall Study|Withdrawal by Subject|52
5989222|NCT02943993|9580601|FG000|Overall Study|Transfer to another institution|6
5989223|NCT02943993|9580601|FG000|Overall Study|Lost to Follow-up|135
5989224|NCT02943993|9580601|FG000|Overall Study|Death|98
5989225|NCT02943993|9580601|FG000|Overall Study|Other reason for premature termination|32
5989226|NCT02943993|9580601|FG000|Overall Study|Missing reason for termination|7
5989227|NCT02893930|9580616|FG000|Overall Study|Adverse Event|3
5989228|NCT02893930|9580616|FG000|Overall Study|Death|1
5989229|NCT02893930|9580616|FG000|Overall Study|Disease progression|5
5989230|NCT02893930|9580616|FG000|Overall Study|Withdrawal by Subject|2
5989231|NCT02893930|9580616|FG000|Overall Study|Physician Decision|1
5989232|NCT02893930|9580616|FG000|Overall Study|Ineligible|1
5989233|NCT02890355|9580622|FG000|Overall Study|Adverse Event|5
5989234|NCT02890355|9580623|FG001|Overall Study|Adverse Event|5
5989235|NCT02890355|9580622|FG000|Overall Study|Refusal unrelated to adverse event|5
6045452|NCT00402116|9644686|FG002|Overall Study|Disease Progression|38
5989236|NCT02890355|9580623|FG001|Overall Study|Refusal unrelated to adverse event|10
5989237|NCT02890355|9580622|FG000|Overall Study|Progression/relapse|46
5989238|NCT02890355|9580623|FG001|Overall Study|Progression/relapse|39
5989239|NCT02890355|9580622|FG000|Overall Study|Not protocol specified|3
5989240|NCT02890355|9580623|FG001|Overall Study|Not protocol specified|4
5989241|NCT02877134|9580638|FG000|Overall Study|Death|0
5989242|NCT02877134|9580639|FG001|Overall Study|Death|1
5989243|NCT02877134|9580640|FG002|Overall Study|Death|0
5989244|NCT02877134|9580641|FG003|Overall Study|Death|0
5989245|NCT02877134|9580642|FG004|Overall Study|Death|0
5989246|NCT02877134|9580643|FG005|Overall Study|Death|1
5989247|NCT02877134|9580644|FG006|Overall Study|Death|0
5989248|NCT02877134|9580638|FG000|Overall Study|Lost to Follow-up|0
5989249|NCT02877134|9580639|FG001|Overall Study|Lost to Follow-up|4
5989250|NCT02877134|9580640|FG002|Overall Study|Lost to Follow-up|0
5989251|NCT02877134|9580641|FG003|Overall Study|Lost to Follow-up|1
5989252|NCT02877134|9580642|FG004|Overall Study|Lost to Follow-up|0
5989253|NCT02877134|9580643|FG005|Overall Study|Lost to Follow-up|0
5989254|NCT02877134|9580644|FG006|Overall Study|Lost to Follow-up|0
5989255|NCT02877134|9580638|FG000|Overall Study|Withdrawal by Subject|13
5989256|NCT02877134|9580639|FG001|Overall Study|Withdrawal by Subject|19
5989257|NCT02877134|9580640|FG002|Overall Study|Withdrawal by Subject|4
5989258|NCT02877134|9580641|FG003|Overall Study|Withdrawal by Subject|6
5989259|NCT02877134|9580642|FG004|Overall Study|Withdrawal by Subject|3
5989260|NCT02877134|9580643|FG005|Overall Study|Withdrawal by Subject|5
5989261|NCT02877134|9580644|FG006|Overall Study|Withdrawal by Subject|0
5989262|NCT02877134|9580638|FG000|Overall Study|Other|1
5989263|NCT02877134|9580639|FG001|Overall Study|Other|1
5989264|NCT02877134|9580640|FG002|Overall Study|Other|2
5989265|NCT02877134|9580641|FG003|Overall Study|Other|6
5989266|NCT02877134|9580642|FG004|Overall Study|Other|3
5989267|NCT02877134|9580643|FG005|Overall Study|Other|1
5989268|NCT02877134|9580644|FG006|Overall Study|Other|1
5989269|NCT02847637|9580666|FG000|Overall Study|Withdrew from treatment due to AE|0
5989270|NCT02847637|9580667|FG001|Overall Study|Withdrew from treatment due to AE|0
5989271|NCT02847637|9580668|FG002|Overall Study|Withdrew from treatment due to AE|1
5989272|NCT02847637|9580669|FG003|Overall Study|Withdrew from treatment due to AE|0
5989273|NCT02847637|9580666|FG000|Overall Study|Ongoing treatment with emicizumab|16
5989274|NCT02847637|9580667|FG001|Overall Study|Ongoing treatment with emicizumab|35
5989275|NCT02847637|9580668|FG002|Overall Study|Ongoing treatment with emicizumab|34
5989276|NCT02847637|9580669|FG003|Overall Study|Ongoing treatment with emicizumab|63
5989277|NCT02847637|9580666|FG000|Overall Study|First emicizumab dose delayed|1
5989278|NCT02847637|9580667|FG001|Overall Study|First emicizumab dose delayed|0
5989279|NCT02847637|9580668|FG002|Overall Study|First emicizumab dose delayed|0
5989280|NCT02847637|9580669|FG003|Overall Study|First emicizumab dose delayed|0
5989281|NCT02763579|9580710|FG000|Overall Study|Death|101
5989282|NCT02763579|9580711|FG001|Overall Study|Death|132
5989283|NCT02763579|9580710|FG000|Overall Study|Lost to Follow-up|3
5989284|NCT02763579|9580711|FG001|Overall Study|Lost to Follow-up|1
5989285|NCT02763579|9580710|FG000|Overall Study|Withdrawal by Subject|18
5989286|NCT02763579|9580711|FG001|Overall Study|Withdrawal by Subject|9
5989287|NCT02763579|9580710|FG000|Overall Study|Physician Decision|2
6064742|NCT00515294|9666536|FG003|Overall Study|Caffeine amount inaccurate|0
6146090|NCT01075191|9780639|FG000|Overall Study|Intensification|3
6146091|NCT01075191|9780639|FG000|Overall Study|Co-morbidities|1
5989288|NCT02763579|9580711|FG001|Overall Study|Physician Decision|0
5989289|NCT02763579|9580710|FG000|Overall Study|On-going in study|77
5989290|NCT02763579|9580711|FG001|Overall Study|On-going in study|60
5989291|NCT02762708|9580721|FG000|Study 1 - RYGB vs Caloric Restriction|Withdrawal by Subject|0
5989292|NCT02762708|9580722|FG001|Study 1 - RYGB vs Caloric Restriction|Withdrawal by Subject|2
5989293|NCT02762708|9580723|FG002|Study 1 - RYGB vs Caloric Restriction|Withdrawal by Subject|0
5989294|NCT02762708|9580724|FG003|Study 1 - RYGB vs Caloric Restriction|Withdrawal by Subject|0
5989295|NCT02743494|9580736|FG000|Pre-treatment Period|Participant request to discontinue treatment|0
5989296|NCT02743494|9580737|FG001|Pre-treatment Period|Participant request to discontinue treatment|1
5989297|NCT02743494|9580736|FG000|Pre-treatment Period|Participant no longer meeting study criteria|0
5989298|NCT02743494|9580737|FG001|Pre-treatment Period|Participant no longer meeting study criteria|1
5989299|NCT02743494|9580736|FG000|Treatment Period|Completed treatment|229
5989300|NCT02743494|9580737|FG001|Treatment Period|Completed treatment|99
5989301|NCT02743494|9580736|FG000|Treatment Period|Disease recurrence|149
5989302|NCT02743494|9580737|FG001|Treatment Period|Disease recurrence|113
5989303|NCT02743494|9580736|FG000|Treatment Period|Study drug toxicity|57
5989304|NCT02743494|9580737|FG001|Treatment Period|Study drug toxicity|8
5989305|NCT02743494|9580736|FG000|Treatment Period|Death|1
5989306|NCT02743494|9580737|FG001|Treatment Period|Death|0
5989307|NCT02743494|9580736|FG000|Treatment Period|Adverse event unrelated to study drug|15
5989308|NCT02743494|9580737|FG001|Treatment Period|Adverse event unrelated to study drug|9
5989309|NCT02743494|9580736|FG000|Treatment Period|Participant request to discontinue treatment|30
5989310|NCT02743494|9580737|FG001|Treatment Period|Participant request to discontinue treatment|5
5989311|NCT02743494|9580736|FG000|Treatment Period|Participant withdrew consent|12
5989312|NCT02743494|9580737|FG001|Treatment Period|Participant withdrew consent|4
5989313|NCT02743494|9580736|FG000|Treatment Period|Lost to Follow-up|0
5989314|NCT02743494|9580737|FG001|Treatment Period|Lost to Follow-up|1
5989315|NCT02743494|9580736|FG000|Treatment Period|Poor/Non-compliance|1
5989316|NCT02743494|9580737|FG001|Treatment Period|Poor/Non-compliance|0
5989317|NCT02743494|9580736|FG000|Treatment Period|Other reasons|7
5989318|NCT02743494|9580737|FG001|Treatment Period|Other reasons|2
5989319|NCT02741570|9580745|FG000|Pre-Treatment Period|Other reasons|0
5989320|NCT02741570|9580746|FG001|Pre-Treatment Period|Other reasons|3
5989321|NCT02741570|9580745|FG000|Pre-Treatment Period|Participant no longer meets study criteria|3
5989322|NCT02741570|9580746|FG001|Pre-Treatment Period|Participant no longer meets study criteria|6
5989323|NCT02741570|9580745|FG000|Pre-Treatment Period|Poor/non-compliance|0
5989324|NCT02741570|9580746|FG001|Pre-Treatment Period|Poor/non-compliance|1
5989325|NCT02741570|9580745|FG000|Pre-Treatment Period|Lost to Follow-up|0
5989326|NCT02741570|9580746|FG001|Pre-Treatment Period|Lost to Follow-up|2
5989327|NCT02741570|9580745|FG000|Pre-Treatment Period|Participant withdrew consent|0
5989328|NCT02741570|9580746|FG001|Pre-Treatment Period|Participant withdrew consent|18
5989329|NCT02741570|9580745|FG000|Pre-Treatment Period|Participant request to discontinue study treatment|0
5989330|NCT02741570|9580746|FG001|Pre-Treatment Period|Participant request to discontinue study treatment|2
5989331|NCT02741570|9580745|FG000|Pre-Treatment Period|Adverse event unrelated to study drug|1
5989332|NCT02741570|9580746|FG001|Pre-Treatment Period|Adverse event unrelated to study drug|0
5989333|NCT02741570|9580745|FG000|Pre-Treatment Period|Death|0
5989334|NCT02741570|9580746|FG001|Pre-Treatment Period|Death|1
5989335|NCT02741570|9580745|FG000|Pre-Treatment Period|Disease progression|0
5989336|NCT02741570|9580746|FG001|Pre-Treatment Period|Disease progression|1
5989337|NCT02741570|9580745|FG000|Treatment Period|Other reasons|47
5989338|NCT02741570|9580746|FG001|Treatment Period|Other reasons|8
5989339|NCT02741570|9580745|FG000|Treatment Period|Poor/non-compliance|0
5989340|NCT02741570|9580746|FG001|Treatment Period|Poor/non-compliance|1
5989341|NCT02741570|9580745|FG000|Treatment Period|Maximum clinical benefit|3
5989342|NCT02741570|9580746|FG001|Treatment Period|Maximum clinical benefit|5
5989343|NCT02741570|9580745|FG000|Treatment Period|Lost to Follow-up|1
5989344|NCT02741570|9580746|FG001|Treatment Period|Lost to Follow-up|3
5989345|NCT02741570|9580745|FG000|Treatment Period|Participant withdrew consent|9
5989346|NCT02741570|9580746|FG001|Treatment Period|Participant withdrew consent|13
5989347|NCT02741570|9580745|FG000|Treatment Period|Participant request to discontinue treatment|8
5989348|NCT02741570|9580746|FG001|Treatment Period|Participant request to discontinue treatment|23
5989349|NCT02741570|9580745|FG000|Treatment Period|Adverse event unrelated to study drug|41
5989350|NCT02741570|9580746|FG001|Treatment Period|Adverse event unrelated to study drug|25
5989351|NCT02741570|9580745|FG000|Treatment Period|Death|9
5989352|NCT02741570|9580746|FG001|Treatment Period|Death|7
5989353|NCT02741570|9580745|FG000|Treatment Period|Study drug toxicity|55
5989354|NCT02741570|9580746|FG001|Treatment Period|Study drug toxicity|45
5989355|NCT02741570|9580745|FG000|Treatment Period|Disease progression|295
5989356|NCT02741570|9580746|FG001|Treatment Period|Disease progression|304
5989357|NCT02677896|9580762|FG000|Double Blind Period (up to 35 Months)|Death|113
5989358|NCT02677896|9580763|FG001|Double Blind Period (up to 35 Months)|Death|189
5989359|NCT02677896|9580762|FG000|Double Blind Period (up to 35 Months)|Lost to Follow-up|12
5989360|NCT02677896|9580763|FG001|Double Blind Period (up to 35 Months)|Lost to Follow-up|12
5989361|NCT02677896|9580762|FG000|Double Blind Period (up to 35 Months)|Progressive disease|3
5989362|NCT02677896|9580763|FG001|Double Blind Period (up to 35 Months)|Progressive disease|4
5989363|NCT02677896|9580762|FG000|Double Blind Period (up to 35 Months)|Withdrawal by Subject|41
5989364|NCT02677896|9580763|FG001|Double Blind Period (up to 35 Months)|Withdrawal by Subject|69
5989365|NCT02677896|9580762|FG000|Double Blind Period (up to 35 Months)|Miscellaneous|9
5989366|NCT02677896|9580763|FG001|Double Blind Period (up to 35 Months)|Miscellaneous|14
5989367|NCT02677896|9580762|FG000|Double Blind Period (up to 35 Months)|Continued in OLE|365
5989368|NCT02677896|9580763|FG001|Double Blind Period (up to 35 Months)|Continued in OLE|180
5989369|NCT02677896|9580762|FG000|Double Blind Period (up to 35 Months)|Followed-up for OS|31
5989370|NCT02677896|9580763|FG001|Double Blind Period (up to 35 Months)|Followed-up for OS|108
5989371|NCT02677896|9580762|FG000|Open-Label Extension (up to 25 Months)|Death|40
5989372|NCT02677896|9580763|FG001|Open-Label Extension (up to 25 Months)|Death|14
5989373|NCT02677896|9580762|FG000|Open-Label Extension (up to 25 Months)|Lost to Follow-up|2
5989374|NCT02677896|9580763|FG001|Open-Label Extension (up to 25 Months)|Lost to Follow-up|1
5989375|NCT02677896|9580762|FG000|Open-Label Extension (up to 25 Months)|Progressive disease|3
5989376|NCT02677896|9580763|FG001|Open-Label Extension (up to 25 Months)|Progressive disease|1
5989377|NCT02677896|9580762|FG000|Open-Label Extension (up to 25 Months)|Withdrawal by Subject|10
5989378|NCT02677896|9580763|FG001|Open-Label Extension (up to 25 Months)|Withdrawal by Subject|9
5989379|NCT02677896|9580762|FG000|Open-Label Extension (up to 25 Months)|Miscellaneous|0
5989380|NCT02677896|9580763|FG001|Open-Label Extension (up to 25 Months)|Miscellaneous|1
5989381|NCT02677896|9580762|FG000|Open-Label Extension (up to 25 Months)|OLE treatment ongoing|261
5989382|NCT02677896|9580763|FG001|Open-Label Extension (up to 25 Months)|OLE treatment ongoing|136
5989383|NCT02677896|9580762|FG000|Open-Label Extension (up to 25 Months)|Followed up for OS|49
5989384|NCT02677896|9580763|FG001|Open-Label Extension (up to 25 Months)|Followed up for OS|18
5989385|NCT02667587|9580772|FG000|Pre-Treatment|Not reported|1
5989386|NCT02667587|9580773|FG001|Pre-Treatment|Not reported|0
5989387|NCT02667587|9580772|FG000|Pre-Treatment|Participant no longer meets study criteria|2
5989388|NCT02667587|9580773|FG001|Pre-Treatment|Participant no longer meets study criteria|2
5989389|NCT02667587|9580772|FG000|Pre-Treatment|Participant withdrew consent|0
5989390|NCT02667587|9580773|FG001|Pre-Treatment|Participant withdrew consent|1
5989391|NCT02667587|9580772|FG000|Pre-Treatment|Adverse event unrelated to study drug|1
5989392|NCT02667587|9580773|FG001|Pre-Treatment|Adverse event unrelated to study drug|0
5989393|NCT02667587|9580772|FG000|End of Treatment|Other reasons|11
5989394|NCT02667587|9580773|FG001|End of Treatment|Other reasons|8
5989395|NCT02667587|9580772|FG000|End of Treatment|Participant no Longer Meets Study Criteria|1
5989396|NCT02667587|9580773|FG001|End of Treatment|Participant no Longer Meets Study Criteria|2
5989397|NCT02667587|9580772|FG000|End of Treatment|Poor/Non-Compliance|0
5989398|NCT02667587|9580773|FG001|End of Treatment|Poor/Non-Compliance|1
5989399|NCT02667587|9580772|FG000|End of Treatment|Maximum Clinical Benefit|3
5989400|NCT02667587|9580773|FG001|End of Treatment|Maximum Clinical Benefit|3
5989401|NCT02667587|9580772|FG000|End of Treatment|Participant Withdrew Consent|5
5989402|NCT02667587|9580773|FG001|End of Treatment|Participant Withdrew Consent|6
5989403|NCT02667587|9580772|FG000|End of Treatment|Participants Request to Discontinue Study Treatment|25
5989404|NCT02667587|9580773|FG001|End of Treatment|Participants Request to Discontinue Study Treatment|26
5989405|NCT02667587|9580772|FG000|End of Treatment|Adverse Event Unrelated to Study Drug|19
5989406|NCT02667587|9580773|FG001|End of Treatment|Adverse Event Unrelated to Study Drug|20
5989407|NCT02667587|9580772|FG000|End of Treatment|Death|2
5989408|NCT02667587|9580773|FG001|End of Treatment|Death|1
5989409|NCT02667587|9580772|FG000|End of Treatment|Study Drug Toxicity|74
5989410|NCT02667587|9580773|FG001|End of Treatment|Study Drug Toxicity|18
5989411|NCT02667587|9580772|FG000|End of Treatment|Disease progression|177
5989412|NCT02667587|9580773|FG001|End of Treatment|Disease progression|222
5989413|NCT02667587|9580772|FG000|End of Treatment|Lost to Follow-up|1
5989414|NCT02667587|9580773|FG001|End of Treatment|Lost to Follow-up|3
5989415|NCT02621606|9580782|FG000|Overall Study|Withdrawal by Subject|0
5989416|NCT02621606|9580783|FG001|Overall Study|Withdrawal by Subject|1
5989417|NCT02621606|9580784|FG002|Overall Study|Withdrawal by Subject|0
5989418|NCT02613507|9580794|FG000|Overall Study|Disease Progression|237
5989419|NCT02613507|9580795|FG001|Overall Study|Disease Progression|109
5989420|NCT02613507|9580794|FG000|Overall Study|Study Drug Toxicity|15
5989421|NCT02613507|9580795|FG001|Overall Study|Study Drug Toxicity|14
5989422|NCT02613507|9580794|FG000|Overall Study|Death|3
5989423|NCT02613507|9580795|FG001|Overall Study|Death|0
5989424|NCT02613507|9580794|FG000|Overall Study|Adverse Event Unrelated to Study Drug|17
5989425|NCT02613507|9580795|FG001|Overall Study|Adverse Event Unrelated to Study Drug|2
5989426|NCT02613507|9580794|FG000|Overall Study|Request to Discontinue Study Treatment|8
5989427|NCT02613507|9580795|FG001|Overall Study|Request to Discontinue Study Treatment|17
5989428|NCT02613507|9580794|FG000|Overall Study|Participant Withdrew Consent|0
5989429|NCT02613507|9580795|FG001|Overall Study|Participant Withdrew Consent|2
5989430|NCT02613507|9580794|FG000|Overall Study|Lost to Follow-up|1
5989431|NCT02613507|9580795|FG001|Overall Study|Lost to Follow-up|0
5989432|NCT02613507|9580794|FG000|Overall Study|Maximum Clinical Benefit|4
5989433|NCT02613507|9580795|FG001|Overall Study|Maximum Clinical Benefit|10
5989434|NCT02613507|9580794|FG000|Overall Study|Brain Radiotherapy Activity Limited|1
5989435|NCT02613507|9580795|FG001|Overall Study|Brain Radiotherapy Activity Limited|0
5989436|NCT02613507|9580794|FG000|Overall Study|Subject no Longer Meets Study Criteria|1
5989437|NCT02613507|9580795|FG001|Overall Study|Subject no Longer Meets Study Criteria|0
5989438|NCT02613507|9580794|FG000|Overall Study|Randomized but not Treated|1
5989439|NCT02613507|9580795|FG001|Overall Study|Randomized but not Treated|10
5989440|NCT02550873|9580833|FG000|Randomized Double Blind|Adverse Event|3
5989441|NCT02550873|9580834|FG001|Randomized Double Blind|Adverse Event|1
5989442|NCT02550873|9580835|FG002|Randomized Double Blind|Adverse Event|0
5989443|NCT02550873|9580833|FG000|Randomized Double Blind|Disease progression|1
5989444|NCT02550873|9580834|FG001|Randomized Double Blind|Disease progression|1
5989445|NCT02550873|9580835|FG002|Randomized Double Blind|Disease progression|0
5989446|NCT02550873|9580833|FG000|Open Label Extension|Study ongoing|0
5989447|NCT02550873|9580834|FG001|Open Label Extension|Study ongoing|0
5989448|NCT02550873|9580835|FG002|Open Label Extension|Study ongoing|111
5989449|NCT02542267|9580857|FG000|Overall Study|Withdrawal by Subject|10
5989450|NCT02542267|9580857|FG000|Overall Study|Physician Decision|6
5989451|NCT02542267|9580857|FG000|Overall Study|Lost to Follow-up|4
5989452|NCT02542267|9580857|FG000|Overall Study|Death|13
5989453|NCT02542267|9580857|FG000|Overall Study|Surgical Bypass of All Study Devices|13
5989454|NCT02542267|9580857|FG000|Overall Study|Other|9
5989455|NCT02500797|9580869|FG000|Overall Study|Cancel (rapid disease progression)|0
5989456|NCT02500797|9580870|FG001|Overall Study|Cancel (rapid disease progression)|0
5989457|NCT02500797|9580871|FG002|Overall Study|Cancel (rapid disease progression)|0
5989458|NCT02500797|9580872|FG003|Overall Study|Cancel (rapid disease progression)|0
5989459|NCT02500797|9580873|FG004|Overall Study|Cancel (rapid disease progression)|1
5989460|NCT02500797|9580874|FG005|Overall Study|Cancel (rapid disease progression)|1
5989461|NCT02500797|9580875|FG006|Overall Study|Cancel (rapid disease progression)|0
5989462|NCT02500797|9580876|FG007|Overall Study|Cancel (rapid disease progression)|0
5989463|NCT02500797|9580869|FG000|Overall Study|Withdrawal by Subject|1
5989464|NCT02500797|9580870|FG001|Overall Study|Withdrawal by Subject|0
5989465|NCT02500797|9580871|FG002|Overall Study|Withdrawal by Subject|0
5989466|NCT02500797|9580872|FG003|Overall Study|Withdrawal by Subject|0
5989467|NCT02500797|9580873|FG004|Overall Study|Withdrawal by Subject|0
5989468|NCT02500797|9580874|FG005|Overall Study|Withdrawal by Subject|0
5989469|NCT02500797|9580875|FG006|Overall Study|Withdrawal by Subject|0
5989470|NCT02500797|9580876|FG007|Overall Study|Withdrawal by Subject|0
5989471|NCT02483585|9580903|FG000|Double-blind Treatment Phase|Decision by Sponsor|1
5989472|NCT02483585|9580904|FG001|Double-blind Treatment Phase|Decision by Sponsor|1
5989473|NCT02483585|9580903|FG000|Double-blind Treatment Phase|Withdrawal by Subject|12
5989474|NCT02483585|9580904|FG001|Double-blind Treatment Phase|Withdrawal by Subject|12
5989475|NCT02483585|9580903|FG000|Double-blind Treatment Phase|Lost to Follow-up|3
5989476|NCT02483585|9580904|FG001|Double-blind Treatment Phase|Lost to Follow-up|2
5989477|NCT02483585|9580903|FG000|Open-label Treatment Phase|Protocol-specified Criteria|6
5989478|NCT02483585|9580904|FG001|Open-label Treatment Phase|Protocol-specified Criteria|5
5989479|NCT02483585|9580903|FG000|Open-label Treatment Phase|Decision by Sponsor|0
6064743|NCT00515463|9666578|FG000|Overall Study|Physician Decision|4
6064744|NCT00515463|9666579|FG001|Overall Study|Physician Decision|2
6064745|NCT00515463|9666578|FG000|Overall Study|Adverse Event|1
5989480|NCT02483585|9580904|FG001|Open-label Treatment Phase|Decision by Sponsor|1
5989481|NCT02483585|9580903|FG000|Open-label Treatment Phase|Withdrawal by Subject|18
5989482|NCT02483585|9580904|FG001|Open-label Treatment Phase|Withdrawal by Subject|14
5989483|NCT02483585|9580903|FG000|Open-label Treatment Phase|Lost to Follow-up|3
5989484|NCT02483585|9580904|FG001|Open-label Treatment Phase|Lost to Follow-up|5
5989485|NCT02462603|9580914|FG000|Overall Study|Investigator Decision|1
5989486|NCT02462603|9580914|FG000|Overall Study|Non-Compliance|1
5989487|NCT02462603|9580914|FG000|Overall Study|Withdrawal by Subject|2
5989488|NCT02456740|9580921|FG000|Double-blind Treatment Phase (24 Weeks)|Decision by Sponsor|1
5989489|NCT02456740|9580922|FG001|Double-blind Treatment Phase (24 Weeks)|Decision by Sponsor|1
5989490|NCT02456740|9580923|FG002|Double-blind Treatment Phase (24 Weeks)|Decision by Sponsor|1
5989491|NCT02456740|9580924|FG003|Double-blind Treatment Phase (24 Weeks)|Decision by Sponsor|0
5989492|NCT02456740|9580925|FG004|Double-blind Treatment Phase (24 Weeks)|Decision by Sponsor|0
5989493|NCT02456740|9580926|FG005|Double-blind Treatment Phase (24 Weeks)|Decision by Sponsor|0
5989494|NCT02456740|9580927|FG006|Double-blind Treatment Phase (24 Weeks)|Decision by Sponsor|0
5989495|NCT02456740|9580928|FG007|Double-blind Treatment Phase (24 Weeks)|Decision by Sponsor|0
5989496|NCT02456740|9580929|FG008|Double-blind Treatment Phase (24 Weeks)|Decision by Sponsor|0
5989497|NCT02456740|9580921|FG000|Double-blind Treatment Phase (24 Weeks)|Withdrawal by Subject|27
5989498|NCT02456740|9580922|FG001|Double-blind Treatment Phase (24 Weeks)|Withdrawal by Subject|28
5989499|NCT02456740|9580923|FG002|Double-blind Treatment Phase (24 Weeks)|Withdrawal by Subject|21
5989500|NCT02456740|9580924|FG003|Double-blind Treatment Phase (24 Weeks)|Withdrawal by Subject|0
5989501|NCT02456740|9580925|FG004|Double-blind Treatment Phase (24 Weeks)|Withdrawal by Subject|0
5989502|NCT02456740|9580926|FG005|Double-blind Treatment Phase (24 Weeks)|Withdrawal by Subject|0
5989503|NCT02456740|9580927|FG006|Double-blind Treatment Phase (24 Weeks)|Withdrawal by Subject|0
5989504|NCT02456740|9580928|FG007|Double-blind Treatment Phase (24 Weeks)|Withdrawal by Subject|0
5989505|NCT02456740|9580929|FG008|Double-blind Treatment Phase (24 Weeks)|Withdrawal by Subject|0
5989506|NCT02456740|9580921|FG000|Double-blind Treatment Phase (24 Weeks)|Lost to Follow-up|9
5989507|NCT02456740|9580922|FG001|Double-blind Treatment Phase (24 Weeks)|Lost to Follow-up|4
5989508|NCT02456740|9580923|FG002|Double-blind Treatment Phase (24 Weeks)|Lost to Follow-up|5
5989509|NCT02456740|9580924|FG003|Double-blind Treatment Phase (24 Weeks)|Lost to Follow-up|0
5989510|NCT02456740|9580925|FG004|Double-blind Treatment Phase (24 Weeks)|Lost to Follow-up|0
5989511|NCT02456740|9580926|FG005|Double-blind Treatment Phase (24 Weeks)|Lost to Follow-up|0
5989512|NCT02456740|9580927|FG006|Double-blind Treatment Phase (24 Weeks)|Lost to Follow-up|0
5989513|NCT02456740|9580928|FG007|Double-blind Treatment Phase (24 Weeks)|Lost to Follow-up|0
5989514|NCT02456740|9580929|FG008|Double-blind Treatment Phase (24 Weeks)|Lost to Follow-up|0
5989515|NCT02456740|9580921|FG000|Active Treatment Phase (Weeks 24 - 52)|Protocol Specified Criteria|0
5989516|NCT02456740|9580922|FG001|Active Treatment Phase (Weeks 24 - 52)|Protocol Specified Criteria|0
5989517|NCT02456740|9580923|FG002|Active Treatment Phase (Weeks 24 - 52)|Protocol Specified Criteria|0
5989518|NCT02456740|9580924|FG003|Active Treatment Phase (Weeks 24 - 52)|Protocol Specified Criteria|1
5989519|NCT02456740|9580925|FG004|Active Treatment Phase (Weeks 24 - 52)|Protocol Specified Criteria|4
5989520|NCT02456740|9580926|FG005|Active Treatment Phase (Weeks 24 - 52)|Protocol Specified Criteria|0
5989521|NCT02456740|9580927|FG006|Active Treatment Phase (Weeks 24 - 52)|Protocol Specified Criteria|0
5989522|NCT02456740|9580928|FG007|Active Treatment Phase (Weeks 24 - 52)|Protocol Specified Criteria|0
5989523|NCT02456740|9580929|FG008|Active Treatment Phase (Weeks 24 - 52)|Protocol Specified Criteria|5
5989524|NCT02456740|9580921|FG000|Active Treatment Phase (Weeks 24 - 52)|Withdrawal by Subject|0
5989525|NCT02456740|9580922|FG001|Active Treatment Phase (Weeks 24 - 52)|Withdrawal by Subject|0
5989526|NCT02456740|9580923|FG002|Active Treatment Phase (Weeks 24 - 52)|Withdrawal by Subject|0
5989527|NCT02456740|9580924|FG003|Active Treatment Phase (Weeks 24 - 52)|Withdrawal by Subject|10
5989528|NCT02456740|9580925|FG004|Active Treatment Phase (Weeks 24 - 52)|Withdrawal by Subject|11
5989529|NCT02456740|9580926|FG005|Active Treatment Phase (Weeks 24 - 52)|Withdrawal by Subject|9
5989530|NCT02456740|9580927|FG006|Active Treatment Phase (Weeks 24 - 52)|Withdrawal by Subject|8
5989531|NCT02456740|9580928|FG007|Active Treatment Phase (Weeks 24 - 52)|Withdrawal by Subject|8
5989532|NCT02456740|9580929|FG008|Active Treatment Phase (Weeks 24 - 52)|Withdrawal by Subject|9
5989533|NCT02456740|9580921|FG000|Active Treatment Phase (Weeks 24 - 52)|Death|0
5989534|NCT02456740|9580922|FG001|Active Treatment Phase (Weeks 24 - 52)|Death|0
5989535|NCT02456740|9580923|FG002|Active Treatment Phase (Weeks 24 - 52)|Death|0
5989536|NCT02456740|9580924|FG003|Active Treatment Phase (Weeks 24 - 52)|Death|0
5989537|NCT02456740|9580925|FG004|Active Treatment Phase (Weeks 24 - 52)|Death|0
5989538|NCT02456740|9580926|FG005|Active Treatment Phase (Weeks 24 - 52)|Death|0
5989539|NCT02456740|9580927|FG006|Active Treatment Phase (Weeks 24 - 52)|Death|0
5989540|NCT02456740|9580928|FG007|Active Treatment Phase (Weeks 24 - 52)|Death|1
5989541|NCT02456740|9580929|FG008|Active Treatment Phase (Weeks 24 - 52)|Death|0
5989542|NCT02456740|9580921|FG000|Active Treatment Phase (Weeks 24 - 52)|Lost to Follow-up|0
5989543|NCT02456740|9580922|FG001|Active Treatment Phase (Weeks 24 - 52)|Lost to Follow-up|0
5989544|NCT02456740|9580923|FG002|Active Treatment Phase (Weeks 24 - 52)|Lost to Follow-up|0
5989545|NCT02456740|9580924|FG003|Active Treatment Phase (Weeks 24 - 52)|Lost to Follow-up|3
5989546|NCT02456740|9580925|FG004|Active Treatment Phase (Weeks 24 - 52)|Lost to Follow-up|2
6045453|NCT00402116|9644684|FG000|Overall Study|mistaken thrombocytopenia|0
5989547|NCT02456740|9580926|FG005|Active Treatment Phase (Weeks 24 - 52)|Lost to Follow-up|4
5989548|NCT02456740|9580927|FG006|Active Treatment Phase (Weeks 24 - 52)|Lost to Follow-up|1
5989549|NCT02456740|9580928|FG007|Active Treatment Phase (Weeks 24 - 52)|Lost to Follow-up|3
5989550|NCT02456740|9580929|FG008|Active Treatment Phase (Weeks 24 - 52)|Lost to Follow-up|4
6045454|NCT00402116|9644685|FG001|Overall Study|mistaken thrombocytopenia|0
6045455|NCT00402116|9644686|FG002|Overall Study|mistaken thrombocytopenia|1
6045456|NCT00402116|9644684|FG000|Overall Study|decline related hyponatremia/tumor|0
6045457|NCT00402116|9644685|FG001|Overall Study|decline related hyponatremia/tumor|0
6045458|NCT00402116|9644686|FG002|Overall Study|decline related hyponatremia/tumor|1
6045459|NCT00402116|9644684|FG000|Overall Study|Adverse Event|0
6045460|NCT00402116|9644685|FG001|Overall Study|Adverse Event|1
6045461|NCT00402116|9644686|FG002|Overall Study|Adverse Event|6
6045462|NCT00402168|9644716|FG000|Randomized|Lost to Follow-up|1
6045463|NCT00402168|9644717|FG001|Randomized|Lost to Follow-up|0
6045464|NCT00402168|9644716|FG000|Randomized|Withdrawal by Subject|0
6045465|NCT00402168|9644717|FG001|Randomized|Withdrawal by Subject|1
6045466|NCT00402168|9644716|FG000|Treatment (up to 12 Months)|Death|0
6045467|NCT00402168|9644717|FG001|Treatment (up to 12 Months)|Death|1
6045468|NCT00402168|9644716|FG000|Treatment (up to 12 Months)|Lack of Efficacy|2
6045469|NCT00402168|9644717|FG001|Treatment (up to 12 Months)|Lack of Efficacy|0
6045470|NCT00402168|9644716|FG000|Treatment (up to 12 Months)|non-specified|0
6045471|NCT00402168|9644717|FG001|Treatment (up to 12 Months)|non-specified|1
6045472|NCT00402168|9644716|FG000|Long Term (LT)|Adverse Event|1
6045473|NCT00402168|9644717|FG001|Long Term (LT)|Adverse Event|5
6045474|NCT00402168|9644716|FG000|Long Term (LT)|Withdrawal by Subject|4
6045475|NCT00402168|9644717|FG001|Long Term (LT)|Withdrawal by Subject|7
6045476|NCT00402168|9644716|FG000|Long Term (LT)|Pregnancy|0
6045477|NCT00402168|9644717|FG001|Long Term (LT)|Pregnancy|1
6045478|NCT00402168|9644716|FG000|Long Term (LT)|Lost to Follow-up|1
6045479|NCT00402168|9644717|FG001|Long Term (LT)|Lost to Follow-up|0
6045480|NCT00402168|9644716|FG000|Long Term (LT)|Death|4
6045481|NCT00402168|9644717|FG001|Long Term (LT)|Death|0
6045482|NCT00402168|9644716|FG000|Long Term (LT)|Lack of Efficacy|0
6045483|NCT00402168|9644717|FG001|Long Term (LT)|Lack of Efficacy|2
6045484|NCT00402168|9644716|FG000|Long Term (LT)|non-specified|1
6045485|NCT00402168|9644717|FG001|Long Term (LT)|non-specified|2
6045486|NCT00402168|9644716|FG000|Switched From CNI to Belatacept in LT|Withdrawal by Subject|2
6045487|NCT00402168|9644717|FG001|Switched From CNI to Belatacept in LT|Withdrawal by Subject|0
6045488|NCT00402168|9644716|FG000|Switched From CNI to Belatacept in LT|Adverse Event|4
6045489|NCT00402168|9644717|FG001|Switched From CNI to Belatacept in LT|Adverse Event|0
6045490|NCT00402233|9644744|FG000|Overall Study|Adverse Event|1
6045491|NCT00402233|9644745|FG001|Overall Study|Adverse Event|7
6045492|NCT00402233|9644746|FG002|Overall Study|Adverse Event|9
6045493|NCT00402233|9644747|FG003|Overall Study|Adverse Event|9
6045494|NCT00402233|9644744|FG000|Overall Study|Protocol Violation|0
5989551|NCT02420717|9580956|FG000|Overall Study|Did not receive all study medication|2
5989552|NCT02420717|9580957|FG001|Overall Study|Did not receive all study medication|0
5989553|NCT02420717|9580958|FG002|Overall Study|Did not receive all study medication|0
5989554|NCT02408068|9580966|FG000|Treatment 3 (1.5 Days)|Adverse Event|0
5989555|NCT02408068|9580967|FG001|Treatment 3 (1.5 Days)|Adverse Event|0
5989556|NCT02408068|9580968|FG002|Treatment 3 (1.5 Days)|Adverse Event|1
5989557|NCT02408068|9580969|FG003|Treatment 3 (1.5 Days)|Adverse Event|0
5989558|NCT02408068|9580970|FG004|Treatment 3 (1.5 Days)|Adverse Event|0
5989559|NCT02408068|9580971|FG005|Treatment 3 (1.5 Days)|Adverse Event|0
5989560|NCT02315703|9580990|FG000|Overall Study|Adverse Event|0
5989561|NCT02315703|9580991|FG001|Overall Study|Adverse Event|0
5989562|NCT02315703|9580992|FG002|Overall Study|Adverse Event|0
5989563|NCT02315703|9580993|FG003|Overall Study|Adverse Event|1
5989564|NCT02315703|9580994|FG004|Overall Study|Adverse Event|1
5989565|NCT02315703|9580995|FG005|Overall Study|Adverse Event|0
5989566|NCT02315703|9580996|FG006|Overall Study|Adverse Event|1
5989567|NCT02315703|9580997|FG007|Overall Study|Adverse Event|0
5989568|NCT02315703|9580990|FG000|Overall Study|Lost to Follow-up|1
5989569|NCT02315703|9580991|FG001|Overall Study|Lost to Follow-up|5
5989570|NCT02315703|9580992|FG002|Overall Study|Lost to Follow-up|3
5989571|NCT02315703|9580993|FG003|Overall Study|Lost to Follow-up|3
5989572|NCT02315703|9580994|FG004|Overall Study|Lost to Follow-up|2
5989573|NCT02315703|9580995|FG005|Overall Study|Lost to Follow-up|1
5989574|NCT02315703|9580996|FG006|Overall Study|Lost to Follow-up|2
5989575|NCT02315703|9580997|FG007|Overall Study|Lost to Follow-up|2
5989576|NCT02315703|9580990|FG000|Overall Study|Pregnancy|0
5989577|NCT02315703|9580991|FG001|Overall Study|Pregnancy|0
5989578|NCT02315703|9580992|FG002|Overall Study|Pregnancy|0
5989579|NCT02315703|9580993|FG003|Overall Study|Pregnancy|0
5989580|NCT02315703|9580994|FG004|Overall Study|Pregnancy|0
5989581|NCT02315703|9580995|FG005|Overall Study|Pregnancy|0
5989582|NCT02315703|9580996|FG006|Overall Study|Pregnancy|0
5989583|NCT02315703|9580997|FG007|Overall Study|Pregnancy|1
5989584|NCT02315703|9580990|FG000|Overall Study|Withdrawal by Subject|1
5989585|NCT02315703|9580991|FG001|Overall Study|Withdrawal by Subject|3
5989586|NCT02315703|9580992|FG002|Overall Study|Withdrawal by Subject|0
5989587|NCT02315703|9580993|FG003|Overall Study|Withdrawal by Subject|3
5989588|NCT02315703|9580994|FG004|Overall Study|Withdrawal by Subject|4
5989589|NCT02315703|9580995|FG005|Overall Study|Withdrawal by Subject|1
5989590|NCT02315703|9580996|FG006|Overall Study|Withdrawal by Subject|1
5989591|NCT02315703|9580997|FG007|Overall Study|Withdrawal by Subject|2
5989592|NCT02315703|9580990|FG000|Overall Study|Physician Decision|0
5989593|NCT02315703|9580991|FG001|Overall Study|Physician Decision|0
5989594|NCT02315703|9580992|FG002|Overall Study|Physician Decision|0
5989595|NCT02315703|9580993|FG003|Overall Study|Physician Decision|0
5989596|NCT02315703|9580994|FG004|Overall Study|Physician Decision|0
5989597|NCT02315703|9580995|FG005|Overall Study|Physician Decision|2
5989598|NCT02315703|9580996|FG006|Overall Study|Physician Decision|1
5989599|NCT02315703|9580997|FG007|Overall Study|Physician Decision|0
5989600|NCT02315703|9580990|FG000|Overall Study|Other|4
5989601|NCT02315703|9580991|FG001|Overall Study|Other|2
5989602|NCT02315703|9580992|FG002|Overall Study|Other|2
5989603|NCT02315703|9580993|FG003|Overall Study|Other|2
5989604|NCT02315703|9580994|FG004|Overall Study|Other|1
5989605|NCT02315703|9580995|FG005|Overall Study|Other|2
5989606|NCT02315703|9580996|FG006|Overall Study|Other|8
5989607|NCT02315703|9580997|FG007|Overall Study|Other|2
5989608|NCT02288247|9581015|FG000|Period 1: OL Treatment (Max: 315 Weeks)|Adverse Event|52
5989609|NCT02288247|9581016|FG001|Period 1: OL Treatment (Max: 315 Weeks)|Adverse Event|0
5989610|NCT02288247|9581015|FG000|Period 1: OL Treatment (Max: 315 Weeks)|Death|35
5989611|NCT02288247|9581016|FG001|Period 1: OL Treatment (Max: 315 Weeks)|Death|0
5989612|NCT02288247|9581015|FG000|Period 1: OL Treatment (Max: 315 Weeks)|Lost to Follow-up|1
5989613|NCT02288247|9581016|FG001|Period 1: OL Treatment (Max: 315 Weeks)|Lost to Follow-up|0
5989614|NCT02288247|9581015|FG000|Period 1: OL Treatment (Max: 315 Weeks)|Progressive Disease|392
5989615|NCT02288247|9581016|FG001|Period 1: OL Treatment (Max: 315 Weeks)|Progressive Disease|0
5989616|NCT02288247|9581015|FG000|Period 1: OL Treatment (Max: 315 Weeks)|Protocol Violation|9
5989617|NCT02288247|9581016|FG001|Period 1: OL Treatment (Max: 315 Weeks)|Protocol Violation|0
5989618|NCT02288247|9581015|FG000|Period 1: OL Treatment (Max: 315 Weeks)|Withdrawal by Subject|52
5989619|NCT02288247|9581016|FG001|Period 1: OL Treatment (Max: 315 Weeks)|Withdrawal by Subject|0
5989620|NCT02288247|9581015|FG000|Period 1: OL Treatment (Max: 315 Weeks)|Other|106
5989621|NCT02288247|9581016|FG001|Period 1: OL Treatment (Max: 315 Weeks)|Other|0
5989622|NCT02288247|9581015|FG000|Period 2: DB Treatment (Max: 180 Weeks)|Adverse Event|10
5989623|NCT02288247|9581016|FG001|Period 2: DB Treatment (Max: 180 Weeks)|Adverse Event|8
5989624|NCT02288247|9581015|FG000|Period 2: DB Treatment (Max: 180 Weeks)|Death|8
5989625|NCT02288247|9581016|FG001|Period 2: DB Treatment (Max: 180 Weeks)|Death|4
5989626|NCT02288247|9581015|FG000|Period 2: DB Treatment (Max: 180 Weeks)|Lost to Follow-up|1
5989627|NCT02288247|9581016|FG001|Period 2: DB Treatment (Max: 180 Weeks)|Lost to Follow-up|0
5989628|NCT02288247|9581015|FG000|Period 2: DB Treatment (Max: 180 Weeks)|Progressive Disease|87
5989629|NCT02288247|9581016|FG001|Period 2: DB Treatment (Max: 180 Weeks)|Progressive Disease|94
5989630|NCT02288247|9581015|FG000|Period 2: DB Treatment (Max: 180 Weeks)|Protocol Violation|2
5989631|NCT02288247|9581016|FG001|Period 2: DB Treatment (Max: 180 Weeks)|Protocol Violation|1
5989632|NCT02288247|9581015|FG000|Period 2: DB Treatment (Max: 180 Weeks)|Withdrawal by Subject|7
5989633|NCT02288247|9581016|FG001|Period 2: DB Treatment (Max: 180 Weeks)|Withdrawal by Subject|7
5989634|NCT02288247|9581015|FG000|Period 2: DB Treatment (Max: 180 Weeks)|Other|20
5989635|NCT02288247|9581016|FG001|Period 2: DB Treatment (Max: 180 Weeks)|Other|21
6309245|NCT02635646|10037670|FG000|Overall Study|Pregnancy|1
6309246|NCT02635646|10037671|FG001|Overall Study|Pregnancy|1
6309247|NCT02635724|10037686|FG000|Overall Study|Withdrawal by Subject|0
6309248|NCT02635724|10037687|FG001|Overall Study|Withdrawal by Subject|1
6309249|NCT02635724|10037688|FG002|Overall Study|Withdrawal by Subject|0
6309250|NCT02635737|10037696|FG000|Overall Study|Protocol Violation|1
6309251|NCT02635984|10037710|FG000|Overall Study|Lost to Follow-up|2
6309252|NCT02635984|10037711|FG001|Overall Study|Lost to Follow-up|4
6309253|NCT02635984|10037710|FG000|Overall Study|Study Arm Closed|1
6309254|NCT02635984|10037711|FG001|Overall Study|Study Arm Closed|0
6309255|NCT02636361|10037723|FG000|Period 4|Physician Decision|0
6309256|NCT02636361|10037724|FG001|Period 4|Physician Decision|0
6309257|NCT02636361|10037725|FG002|Period 4|Physician Decision|0
6309258|NCT02636361|10037726|FG003|Period 4|Physician Decision|1
6309259|NCT02636361|10037727|FG004|Period 4|Physician Decision|0
6309260|NCT02636595|10037741|FG000|Overall Study|Lost to Follow-up|1
6309261|NCT02636595|10037741|FG000|Overall Study|Other|1
6309262|NCT02636608|10037745|FG000|Overall Study|Failure to Return|4
6309263|NCT02636608|10037745|FG000|Overall Study|Insufficient Virological Response|1
6309264|NCT02636608|10037745|FG000|Overall Study|Death|3
6309265|NCT02636608|10037745|FG000|Overall Study|Other|2
6309266|NCT02636608|10037745|FG000|Overall Study|Did Not Receive Treatment|1
5989636|NCT02288247|9581015|FG000|Period 2: DB Treatment (Max: 180 Weeks)|Randomized but not treated|1
6309267|NCT02636699|10037754|FG000|Overall Study|Adverse Event|4
6309268|NCT02636699|10037755|FG001|Overall Study|Adverse Event|0
6309269|NCT02636699|10037754|FG000|Overall Study|Lost to Follow-up|3
6309270|NCT02636699|10037755|FG001|Overall Study|Lost to Follow-up|3
6309271|NCT02636699|10037754|FG000|Overall Study|Non-compliance with the investigational product (IP)|2
6309272|NCT02636699|10037755|FG001|Overall Study|Non-compliance with the investigational product (IP)|0
6309273|NCT02636699|10037754|FG000|Overall Study|Physician Decision|0
6309274|NCT02636699|10037755|FG001|Overall Study|Physician Decision|1
6309275|NCT02636699|10037754|FG000|Overall Study|Withdrawal by Subject|13
6309276|NCT02636699|10037755|FG001|Overall Study|Withdrawal by Subject|6
6309277|NCT02636699|10037754|FG000|Overall Study|Other|3
6309278|NCT02636699|10037755|FG001|Overall Study|Other|1
6309279|NCT02636725|10037766|FG000|Baseline|Adverse Event|1
6309280|NCT02636725|10037766|FG000|Baseline|Lack of Efficacy|2
6309281|NCT02636868|10037773|FG000|Overall Study|Death|0
6309282|NCT02636868|10037774|FG001|Overall Study|Death|1
6045495|NCT00402233|9644745|FG001|Overall Study|Protocol Violation|1
6309283|NCT02636868|10037775|FG002|Overall Study|Death|2
6309284|NCT02636907|10037783|FG000|Autoinjector Assessment Period|Adverse Event|2
5989637|NCT02288247|9581016|FG001|Period 2: DB Treatment (Max: 180 Weeks)|Randomized but not treated|0
5989638|NCT02181413|9581026|FG000|Overall Study|Adverse Event|7
5989639|NCT02181413|9581027|FG001|Overall Study|Adverse Event|24
5989640|NCT02181413|9581026|FG000|Overall Study|Progressive Disease|121
5989641|NCT02181413|9581027|FG001|Overall Study|Progressive Disease|143
5989642|NCT02181413|9581026|FG000|Overall Study|Withdrawal by Subject|5
5989643|NCT02181413|9581027|FG001|Overall Study|Withdrawal by Subject|8
5989644|NCT02181413|9581026|FG000|Overall Study|Reason Not Specified|19
5989645|NCT02181413|9581027|FG001|Overall Study|Reason Not Specified|20
5989646|NCT02181413|9581026|FG000|Overall Study|Ongoing Study Treatment|0
5989647|NCT02181413|9581027|FG001|Overall Study|Ongoing Study Treatment|1
5989648|NCT02181413|9581026|FG000|Overall Study|Lost to Follow-up|0
5989649|NCT02181413|9581027|FG001|Overall Study|Lost to Follow-up|1
5989650|NCT02174861|9581033|FG000|Overall Study|Decision by sponsor|8
5989651|NCT02174861|9581033|FG000|Overall Study|Withdrawal by Subject|124
5989652|NCT02174861|9581033|FG000|Overall Study|Lost to Follow-up|26
5989653|NCT02052739|9581041|FG000|Overall Study|Withdrew due to Adverse Event|3
5989654|NCT02052739|9581042|FG001|Overall Study|Withdrew due to Adverse Event|0
5989655|NCT02052739|9581041|FG000|Overall Study|Participant Died|2
5989656|NCT02052739|9581042|FG001|Overall Study|Participant Died|1
5989657|NCT01958021|9581052|FG000|Overall Study|Progressive disease|87
5989658|NCT01958021|9581053|FG001|Overall Study|Progressive disease|146
5989659|NCT01958021|9581052|FG000|Overall Study|Adverse Event|25
5989660|NCT01958021|9581053|FG001|Overall Study|Adverse Event|7
5989661|NCT01958021|9581052|FG000|Overall Study|Subject/guardian decision|12
5989662|NCT01958021|9581053|FG001|Overall Study|Subject/guardian decision|13
5989663|NCT01958021|9581052|FG000|Overall Study|Physician Decision|10
5989664|NCT01958021|9581053|FG001|Overall Study|Physician Decision|13
5989665|NCT01958021|9581052|FG000|Overall Study|Protocol Violation|3
5989666|NCT01958021|9581053|FG001|Overall Study|Protocol Violation|1
5989667|NCT01958021|9581052|FG000|Overall Study|Death|2
5989668|NCT01958021|9581053|FG001|Overall Study|Death|0
5989669|NCT01944020|9581061|FG000|Overall Study|Withdrawal by Subject|5
5989670|NCT01944020|9581062|FG001|Overall Study|Withdrawal by Subject|0
5989671|NCT01920932|9581080|FG000|Overall Study|Death|1
5989672|NCT01920932|9581080|FG000|Overall Study|Withdrawal of consent|1
5989673|NCT01844505|9581104|FG000|Overall Study|Disease progression|170
5989674|NCT01844505|9581105|FG001|Overall Study|Disease progression|88
5989675|NCT01844505|9581106|FG002|Overall Study|Disease progression|224
5989676|NCT01844505|9581104|FG000|Overall Study|Study drug toxicity|40
5989677|NCT01844505|9581105|FG001|Overall Study|Study drug toxicity|131
5989678|NCT01844505|9581106|FG002|Overall Study|Study drug toxicity|50
5989679|NCT01844505|9581104|FG000|Overall Study|Death|1
5989680|NCT01844505|9581105|FG001|Overall Study|Death|3
5989681|NCT01844505|9581106|FG002|Overall Study|Death|1
5989682|NCT01844505|9581104|FG000|Overall Study|Adverse event unrelated to study drug|7
5989683|NCT01844505|9581105|FG001|Overall Study|Adverse event unrelated to study drug|15
5989684|NCT01844505|9581106|FG002|Overall Study|Adverse event unrelated to study drug|6
5989685|NCT01844505|9581104|FG000|Overall Study|Subject request discontinue treatment|17
5989686|NCT01844505|9581105|FG001|Overall Study|Subject request discontinue treatment|14
5989687|NCT01844505|9581106|FG002|Overall Study|Subject request discontinue treatment|8
5989688|NCT01844505|9581104|FG000|Overall Study|Withdrawal by Subject|0
5989689|NCT01844505|9581105|FG001|Overall Study|Withdrawal by Subject|3
5989690|NCT01844505|9581106|FG002|Overall Study|Withdrawal by Subject|0
5989691|NCT01844505|9581104|FG000|Overall Study|Lost to Follow-up|1
5989692|NCT01844505|9581105|FG001|Overall Study|Lost to Follow-up|0
5989693|NCT01844505|9581106|FG002|Overall Study|Lost to Follow-up|0
5989694|NCT01844505|9581104|FG000|Overall Study|Maximum clinical benefit|8
5989695|NCT01844505|9581105|FG001|Overall Study|Maximum clinical benefit|11
5989696|NCT01844505|9581106|FG002|Overall Study|Maximum clinical benefit|2
5989697|NCT01844505|9581104|FG000|Overall Study|Poor/non-compliance|1
5989698|NCT01844505|9581105|FG001|Overall Study|Poor/non-compliance|1
5989699|NCT01844505|9581106|FG002|Overall Study|Poor/non-compliance|1
5989700|NCT01844505|9581104|FG000|Overall Study|Subject no longer meets criteria|0
5989701|NCT01844505|9581105|FG001|Overall Study|Subject no longer meets criteria|1
5989702|NCT01844505|9581106|FG002|Overall Study|Subject no longer meets criteria|0
5989703|NCT01844505|9581104|FG000|Overall Study|Other Reasons|4
5989704|NCT01844505|9581105|FG001|Overall Study|Other Reasons|2
5989705|NCT01844505|9581106|FG002|Overall Study|Other Reasons|2
5989706|NCT01844505|9581104|FG000|Overall Study|Not Reported|0
5989707|NCT01844505|9581105|FG001|Overall Study|Not Reported|0
5989708|NCT01844505|9581106|FG002|Overall Study|Not Reported|1
5989709|NCT01689519|9581116|FG000|Intent to Treat|Death|157
5989710|NCT01689519|9581117|FG001|Intent to Treat|Death|167
5989711|NCT01689519|9581116|FG000|Intent to Treat|Lost to Follow-up|4
5989712|NCT01689519|9581117|FG001|Intent to Treat|Lost to Follow-up|8
5989713|NCT01689519|9581116|FG000|Intent to Treat|Other|2
5989714|NCT01689519|9581117|FG001|Intent to Treat|Other|4
5989715|NCT01689519|9581116|FG000|Intent to Treat|Physician Decision|4
5989716|NCT01689519|9581117|FG001|Intent to Treat|Physician Decision|1
5989717|NCT01689519|9581116|FG000|Intent to Treat|Study terminated by Spon6sor|59
5989718|NCT01689519|9581117|FG001|Intent to Treat|Study terminated by Spon6sor|48
5989719|NCT01689519|9581116|FG000|Intent to Treat|Withdrawal by Subject|21
5989720|NCT01689519|9581117|FG001|Intent to Treat|Withdrawal by Subject|20
5989721|NCT01689519|9581116|FG000|Safety Population|Death|158
5989722|NCT01689519|9581117|FG001|Safety Population|Death|165
5989723|NCT01689519|9581116|FG000|Safety Population|Lost to Follow-up|4
5989724|NCT01689519|9581117|FG001|Safety Population|Lost to Follow-up|8
5989725|NCT01689519|9581116|FG000|Safety Population|Other|2
5989726|NCT01689519|9581117|FG001|Safety Population|Other|4
5989727|NCT01689519|9581116|FG000|Safety Population|Physician Decision|4
5989728|NCT01689519|9581117|FG001|Safety Population|Physician Decision|1
5989729|NCT01689519|9581116|FG000|Safety Population|Study Terminated By Sponsor|60
5989730|NCT01689519|9581117|FG001|Safety Population|Study Terminated By Sponsor|47
5989731|NCT01689519|9581116|FG000|Safety Population|Withdrawal by Subject|20
5989732|NCT01689519|9581117|FG001|Safety Population|Withdrawal by Subject|20
5989733|NCT01622088|9581123|FG000|Overall Study|Adverse Event|20
5989734|NCT01622088|9581123|FG000|Overall Study|Lost to Follow-up|1
5989735|NCT01622088|9581123|FG000|Overall Study|Withdrawal by Subject|20
5989736|NCT01622088|9581123|FG000|Overall Study|Investigator Decision|1
5989737|NCT01622088|9581123|FG000|Overall Study|Death|53
5989738|NCT01622088|9581123|FG000|Overall Study|STUDY TERMINATED EARLY BY SPONSOR|521
6045496|NCT00402233|9644746|FG002|Overall Study|Protocol Violation|0
6045497|NCT00402233|9644747|FG003|Overall Study|Protocol Violation|0
6045498|NCT00402233|9644744|FG000|Overall Study|Withdrawal by Subject|2
6045499|NCT00402233|9644745|FG001|Overall Study|Withdrawal by Subject|1
6045500|NCT00402233|9644746|FG002|Overall Study|Withdrawal by Subject|2
6045501|NCT00402233|9644747|FG003|Overall Study|Withdrawal by Subject|2
6045502|NCT00402233|9644744|FG000|Overall Study|Worsening of disease under study|2
6045503|NCT00402233|9644745|FG001|Overall Study|Worsening of disease under study|0
6045504|NCT00402233|9644746|FG002|Overall Study|Worsening of disease under study|0
6045505|NCT00402233|9644747|FG003|Overall Study|Worsening of disease under study|0
5989739|NCT01486264|9581130|FG000|Overall Study|Death|1
5989740|NCT01486264|9581131|FG001|Overall Study|Death|1
5989741|NCT01486264|9581130|FG000|Overall Study|Adverse Event|3
5989742|NCT01486264|9581131|FG001|Overall Study|Adverse Event|3
5989743|NCT01486264|9581130|FG000|Overall Study|Lack of Efficacy|6
5989744|NCT01486264|9581131|FG001|Overall Study|Lack of Efficacy|10
5989745|NCT01486264|9581130|FG000|Overall Study|Withdrawal by Subject|7
5989746|NCT01486264|9581131|FG001|Overall Study|Withdrawal by Subject|18
5989747|NCT01486264|9581130|FG000|Overall Study|Physician Decision|1
5989748|NCT01486264|9581131|FG001|Overall Study|Physician Decision|1
5989749|NCT01486264|9581130|FG000|Overall Study|Protocol Violation|3
5989750|NCT01486264|9581131|FG001|Overall Study|Protocol Violation|0
5989751|NCT01486264|9581130|FG000|Overall Study|Lost to Follow-up|3
5989752|NCT01486264|9581131|FG001|Overall Study|Lost to Follow-up|2
5989753|NCT01486264|9581130|FG000|Overall Study|Other|5
5989754|NCT01486264|9581131|FG001|Overall Study|Other|11
5989755|NCT01486264|9581130|FG000|Overall Study|Not treated|0
5989756|NCT01486264|9581131|FG001|Overall Study|Not treated|1
5989757|NCT01419080|9581137|FG000|Overall Study|Withdrawal by Subject|75
5989758|NCT01419080|9581137|FG000|Overall Study|Death|30
5989759|NCT01419080|9581137|FG000|Overall Study|Lost to Follow-up|23
5989760|NCT01419080|9581137|FG000|Overall Study|Too Ill|3
5989761|NCT01317160|9581145|FG000|Overall Study|Incorrect inclusion|1
5989762|NCT01317160|9581146|FG001|Overall Study|Incorrect inclusion|1
5989763|NCT01317160|9581145|FG000|Overall Study|Lost to Follow-up|3
5989764|NCT01317160|9581146|FG001|Overall Study|Lost to Follow-up|3
5989765|NCT01317160|9581145|FG000|Overall Study|Withdrawal by Subject|0
5989766|NCT01317160|9581146|FG001|Overall Study|Withdrawal by Subject|2
5989767|NCT01256398|9581152|FG000|Overall Study|Withdrawal by Subject|1
5989768|NCT01196390|9581162|FG000|Overall Study|Protocol Violation|4
5989769|NCT01196390|9581163|FG001|Overall Study|Protocol Violation|5
5989770|NCT01145495|9581186|FG000|Overall Study|Adverse Event|6
5989771|NCT01145495|9581186|FG000|Overall Study|Withdrawal by Subject|5
5989772|NCT01145495|9581186|FG000|Overall Study|Disease progression after respone|1
5989773|NCT01116648|9581214|FG000|Phase 1 Dose Level 3|Adverse Event|0
5989774|NCT01116648|9581215|FG001|Phase 1 Dose Level 3|Adverse Event|0
5989775|NCT01116648|9581216|FG002|Phase 1 Dose Level 3|Adverse Event|0
5989776|NCT01116648|9581217|FG003|Phase 1 Dose Level 3|Adverse Event|2
5989777|NCT01116648|9581218|FG004|Phase 1 Dose Level 3|Adverse Event|0
5989778|NCT01116648|9581219|FG005|Phase 1 Dose Level 3|Adverse Event|0
5989779|NCT01116648|9581220|FG006|Phase 1 Dose Level 3|Adverse Event|0
5989780|NCT01116648|9581221|FG007|Phase 1 Dose Level 3|Adverse Event|0
5989781|NCT01116648|9581222|FG008|Phase 1 Dose Level 3|Adverse Event|0
5989782|NCT01116648|9581223|FG009|Phase 1 Dose Level 3|Adverse Event|0
5989783|NCT01116648|9581224|FG010|Phase 1 Dose Level 3|Adverse Event|0
5989784|NCT01116648|9581225|FG011|Phase 1 Dose Level 3|Adverse Event|0
5989785|NCT01116648|9581226|FG012|Phase 1 Dose Level 3|Adverse Event|0
5989786|NCT01116648|9581227|FG013|Phase 1 Dose Level 3|Adverse Event|0
5989787|NCT01116648|9581228|FG014|Phase 1 Dose Level 3|Adverse Event|0
5989788|NCT01094782|9581259|FG000|Overall Study|Withdrawal by Subject|5
5989789|NCT01094782|9581260|FG001|Overall Study|Withdrawal by Subject|5
5989790|NCT01094782|9581261|FG002|Overall Study|Withdrawal by Subject|1
5989791|NCT01094782|9581262|FG003|Overall Study|Withdrawal by Subject|5
5989792|NCT01094782|9581263|FG004|Overall Study|Withdrawal by Subject|5
5989793|NCT01094782|9581264|FG005|Overall Study|Withdrawal by Subject|0
5989794|NCT01094782|9581259|FG000|Overall Study|Lost to Follow-up|1
5989795|NCT01094782|9581260|FG001|Overall Study|Lost to Follow-up|0
5989796|NCT01094782|9581261|FG002|Overall Study|Lost to Follow-up|0
5989797|NCT01094782|9581262|FG003|Overall Study|Lost to Follow-up|2
5989798|NCT01094782|9581263|FG004|Overall Study|Lost to Follow-up|1
5989799|NCT01094782|9581264|FG005|Overall Study|Lost to Follow-up|4
5989800|NCT01094782|9581259|FG000|Overall Study|Positive Drug Screen|2
5989801|NCT01094782|9581260|FG001|Overall Study|Positive Drug Screen|2
5989802|NCT01094782|9581261|FG002|Overall Study|Positive Drug Screen|1
5989803|NCT01094782|9581262|FG003|Overall Study|Positive Drug Screen|1
5989804|NCT01094782|9581263|FG004|Overall Study|Positive Drug Screen|3
5989805|NCT01094782|9581264|FG005|Overall Study|Positive Drug Screen|2
5989806|NCT01094782|9581259|FG000|Overall Study|Sensory Deficit at Site of QST|0
5989807|NCT01094782|9581260|FG001|Overall Study|Sensory Deficit at Site of QST|1
5989808|NCT01094782|9581261|FG002|Overall Study|Sensory Deficit at Site of QST|0
5989809|NCT01094782|9581262|FG003|Overall Study|Sensory Deficit at Site of QST|0
5989810|NCT01094782|9581263|FG004|Overall Study|Sensory Deficit at Site of QST|0
5989811|NCT01094782|9581264|FG005|Overall Study|Sensory Deficit at Site of QST|0
5989812|NCT01094782|9581259|FG000|Overall Study|Unable to Complete Questionnaires|0
5989813|NCT01094782|9581260|FG001|Overall Study|Unable to Complete Questionnaires|1
5989814|NCT01094782|9581261|FG002|Overall Study|Unable to Complete Questionnaires|0
5989815|NCT01094782|9581262|FG003|Overall Study|Unable to Complete Questionnaires|0
5989816|NCT01094782|9581263|FG004|Overall Study|Unable to Complete Questionnaires|0
5989817|NCT01094782|9581264|FG005|Overall Study|Unable to Complete Questionnaires|0
5989818|NCT01094782|9581259|FG000|Overall Study|Healthy Subject Had Pain|0
5989819|NCT01094782|9581260|FG001|Overall Study|Healthy Subject Had Pain|1
5989820|NCT01094782|9581261|FG002|Overall Study|Healthy Subject Had Pain|0
5989821|NCT01094782|9581262|FG003|Overall Study|Healthy Subject Had Pain|0
5989822|NCT01094782|9581263|FG004|Overall Study|Healthy Subject Had Pain|0
5989823|NCT01094782|9581264|FG005|Overall Study|Healthy Subject Had Pain|0
5989824|NCT01094782|9581259|FG000|Overall Study|Hypertension|0
5989825|NCT01094782|9581260|FG001|Overall Study|Hypertension|0
5989826|NCT01094782|9581261|FG002|Overall Study|Hypertension|1
5989827|NCT01094782|9581262|FG003|Overall Study|Hypertension|0
5989828|NCT01094782|9581263|FG004|Overall Study|Hypertension|0
5989829|NCT01094782|9581264|FG005|Overall Study|Hypertension|0
5989830|NCT01094782|9581259|FG000|Overall Study|Wrong Pain Condition|0
5989831|NCT01094782|9581260|FG001|Overall Study|Wrong Pain Condition|0
5989832|NCT01094782|9581261|FG002|Overall Study|Wrong Pain Condition|0
5989833|NCT01094782|9581262|FG003|Overall Study|Wrong Pain Condition|2
5989834|NCT01094782|9581263|FG004|Overall Study|Wrong Pain Condition|1
5989835|NCT01094782|9581264|FG005|Overall Study|Wrong Pain Condition|1
5989836|NCT01094782|9581259|FG000|Overall Study|Recent Interventional Injection|0
5989837|NCT01094782|9581260|FG001|Overall Study|Recent Interventional Injection|0
5989838|NCT01094782|9581261|FG002|Overall Study|Recent Interventional Injection|0
5989839|NCT01094782|9581262|FG003|Overall Study|Recent Interventional Injection|0
5989840|NCT01094782|9581263|FG004|Overall Study|Recent Interventional Injection|0
5989841|NCT01094782|9581264|FG005|Overall Study|Recent Interventional Injection|1
5989842|NCT01094782|9581259|FG000|Overall Study|Low Visual Analog Scale (VAS) Score|0
5989843|NCT01094782|9581260|FG001|Overall Study|Low Visual Analog Scale (VAS) Score|0
5989844|NCT01094782|9581261|FG002|Overall Study|Low Visual Analog Scale (VAS) Score|0
5989845|NCT01094782|9581262|FG003|Overall Study|Low Visual Analog Scale (VAS) Score|0
5989846|NCT01094782|9581263|FG004|Overall Study|Low Visual Analog Scale (VAS) Score|1
5989847|NCT01094782|9581264|FG005|Overall Study|Low Visual Analog Scale (VAS) Score|0
5989848|NCT01094782|9581259|FG000|Overall Study|Noncompliance With Study Schedule|0
5989849|NCT01094782|9581260|FG001|Overall Study|Noncompliance With Study Schedule|0
5989850|NCT01094782|9581261|FG002|Overall Study|Noncompliance With Study Schedule|0
5989851|NCT01094782|9581262|FG003|Overall Study|Noncompliance With Study Schedule|1
5989852|NCT01094782|9581263|FG004|Overall Study|Noncompliance With Study Schedule|0
5989853|NCT01094782|9581264|FG005|Overall Study|Noncompliance With Study Schedule|0
5989902|NCT01015833|9581319|FG000|Overall Study|Death|1
5989903|NCT01015833|9581320|FG001|Overall Study|Death|0
5989904|NCT01015833|9581319|FG000|Overall Study|Withdrawal by Subject|3
5989905|NCT01015833|9581320|FG001|Overall Study|Withdrawal by Subject|2
5989906|NCT01015833|9581319|FG000|Overall Study|Adverse Event|0
5989907|NCT01015833|9581320|FG001|Overall Study|Adverse Event|1
5989908|NCT01015833|9581319|FG000|Overall Study|Physician Decision|2
5989909|NCT01015833|9581320|FG001|Overall Study|Physician Decision|0
5989910|NCT01015833|9581319|FG000|Overall Study|Symptomatic deterioration|0
5989911|NCT01015833|9581320|FG001|Overall Study|Symptomatic deterioration|1
5989912|NCT01015833|9581319|FG000|Overall Study|Other|5
5989913|NCT01015833|9581320|FG001|Overall Study|Other|1
5989914|NCT01015833|9581319|FG000|Overall Study|Motor Vehicle Accidents|1
5989915|NCT01015833|9581320|FG001|Overall Study|Motor Vehicle Accidents|0
5989916|NCT01015833|9581319|FG000|Overall Study|Did not start treatment|1
5989917|NCT01015833|9581320|FG001|Overall Study|Did not start treatment|0
5989918|NCT00942331|9581328|FG000|Overall Study|Did not start treatment|15
5989919|NCT00942331|9581329|FG001|Overall Study|Did not start treatment|22
5989920|NCT00932737|9581337|FG000|Overall Study|Not treated in second episode|1
5989921|NCT00932737|9581338|FG001|Overall Study|Not treated in second episode|0
5989922|NCT00932737|9581337|FG000|Overall Study|Adverse Event|0
5989923|NCT00932737|9581338|FG001|Overall Study|Adverse Event|1
5989924|NCT00792948|9581362|FG000|Overall Study|Adverse Event|6
5989925|NCT00792948|9581362|FG000|Overall Study|Death|4
5989926|NCT00792948|9581362|FG000|Overall Study|Withdrawal by Subject|3
5989927|NCT00792948|9581362|FG000|Overall Study|Ineligible|2
5989928|NCT00792948|9581362|FG000|Overall Study|Insurance denial - not treated|1
5989929|NCT00792948|9581362|FG000|Overall Study|Physician Decision|11
5989930|NCT00792948|9581362|FG000|Overall Study|Protocol Violation|1
5989931|NCT00769379|9581371|FG000|Overall Study|No follow up data mapped to Other.|3
5989932|NCT00769379|9581372|FG001|Overall Study|No follow up data mapped to Other.|13
5989933|NCT00710710|9581380|FG000|Overall Study|Consent withdrawn|2
5989934|NCT00710710|9581381|FG001|Overall Study|Consent withdrawn|2
5989935|NCT00710710|9581380|FG000|Overall Study|Protocol Violation|0
5989936|NCT00710710|9581381|FG001|Overall Study|Protocol Violation|1
5989937|NCT00710710|9581380|FG000|Overall Study|Adverse Event|3
5989938|NCT00710710|9581381|FG001|Overall Study|Adverse Event|3
5989939|NCT00710710|9581380|FG000|Overall Study|Progressive disease|40
5989940|NCT00710710|9581381|FG001|Overall Study|Progressive disease|38
5989941|NCT00608023|9581390|FG000|Overall Study|Withdrawal by Subject|8
5989942|NCT00608023|9581391|FG001|Overall Study|Withdrawal by Subject|10
5989943|NCT00608023|9581392|FG002|Overall Study|Withdrawal by Subject|7
5989944|NCT00608023|9581390|FG000|Overall Study|Adverse Event|1
5989945|NCT00608023|9581391|FG001|Overall Study|Adverse Event|4
5989946|NCT00608023|9581392|FG002|Overall Study|Adverse Event|5
5989947|NCT00608023|9581390|FG000|Overall Study|Lost to Follow-up|2
5989948|NCT00608023|9581391|FG001|Overall Study|Lost to Follow-up|2
5989949|NCT00608023|9581392|FG002|Overall Study|Lost to Follow-up|1
5989950|NCT00608023|9581390|FG000|Overall Study|Protocol Violation|1
5989951|NCT00608023|9581391|FG001|Overall Study|Protocol Violation|3
5989952|NCT00608023|9581392|FG002|Overall Study|Protocol Violation|1
5989953|NCT00608023|9581390|FG000|Overall Study|Unknown reason|0
5989954|NCT00608023|9581391|FG001|Overall Study|Unknown reason|3
5989955|NCT00608023|9581392|FG002|Overall Study|Unknown reason|0
5989956|NCT00551616|9581405|FG000|Overall Study|Lost to Follow-up|48
5989957|NCT00551616|9581406|FG001|Overall Study|Lost to Follow-up|40
5989958|NCT00520767|9581412|FG000|Overall Study|Death|2
5989959|NCT00492050|9581416|FG000|Overall Study|Adverse Event|1
5989960|NCT00492050|9581416|FG000|Overall Study|Lack of Efficacy|1
5989961|NCT00492050|9581416|FG000|Overall Study|Withdrawal by Subject|3
5989962|NCT00492050|9581416|FG000|Overall Study|Unable to collect SCT|2
5989963|NCT00492050|9581416|FG000|Overall Study|Progressive Disease|2
5989964|NCT00127127|9581455|FG000|Overall Study|Adverse Event|0
5989965|NCT00127127|9581456|FG001|Overall Study|Adverse Event|2
5989966|NCT00127127|9581457|FG002|Overall Study|Adverse Event|0
5989967|NCT00127127|9581458|FG003|Overall Study|Adverse Event|1
5989968|NCT00127127|9581455|FG000|Overall Study|Lack of Efficacy|1
5989969|NCT00127127|9581456|FG001|Overall Study|Lack of Efficacy|3
5989970|NCT00127127|9581457|FG002|Overall Study|Lack of Efficacy|0
5989971|NCT00127127|9581458|FG003|Overall Study|Lack of Efficacy|2
5989972|NCT00061945|9581501|FG000|Registration Through Course 3|Not Alemtuzumab Eligible|18
5989973|NCT00061945|9581502|FG001|Registration Through Course 3|Not Alemtuzumab Eligible|25
5989974|NCT00061945|9581501|FG000|Registration Through Course 3|Early discontinuation during course I-IV|76
5989975|NCT00061945|9581502|FG001|Registration Through Course 3|Early discontinuation during course I-IV|90
5989976|NCT00061945|9581501|FG000|Course IV: Alemtuzumab|Declined Alemtuzumab|1
5989977|NCT00061945|9581502|FG001|Course IV: Alemtuzumab|Declined Alemtuzumab|1
5989978|NCT00061945|9581501|FG000|Course IV: Alemtuzumab|Early exits|6
5989979|NCT00061945|9581502|FG001|Course IV: Alemtuzumab|Early exits|15
5989980|NCT04018612|9581514|FG000|Overall Study|Withdrawal by Subject|1
5989981|NCT04018612|9581515|FG001|Overall Study|Withdrawal by Subject|0
5989982|NCT04018612|9581516|FG002|Overall Study|Withdrawal by Subject|1
5989983|NCT03976648|9581526|FG000|Overall Study|Adverse Event|0
5989984|NCT03976648|9581527|FG001|Overall Study|Adverse Event|2
5989985|NCT03976648|9581526|FG000|Overall Study|Study terminated by sponsor|21
5989986|NCT03976648|9581527|FG001|Overall Study|Study terminated by sponsor|8
6045506|NCT00402233|9644744|FG000|Overall Study|Worsening of other pre-existing disease|0
6045507|NCT00402233|9644745|FG001|Overall Study|Worsening of other pre-existing disease|1
6045508|NCT00402233|9644746|FG002|Overall Study|Worsening of other pre-existing disease|0
6045509|NCT00402233|9644747|FG003|Overall Study|Worsening of other pre-existing disease|0
6045510|NCT00402246|9644759|FG000|Overall Study|Death|62
6045511|NCT00402246|9644760|FG001|Overall Study|Death|58
6045512|NCT00402246|9644759|FG000|Overall Study|Lost to Follow-up|20
6045513|NCT00402246|9644760|FG001|Overall Study|Lost to Follow-up|28
6045514|NCT00402246|9644759|FG000|Overall Study|Withdrawal by Subject|72
6045515|NCT00402246|9644760|FG001|Overall Study|Withdrawal by Subject|87
6045516|NCT00402246|9644759|FG000|Overall Study|Physician Decision|24
6045517|NCT00402246|9644760|FG001|Overall Study|Physician Decision|26
6045518|NCT00402246|9644759|FG000|Overall Study|Protocol Violation|25
6045519|NCT00402246|9644760|FG001|Overall Study|Protocol Violation|24
6045520|NCT00402246|9644759|FG000|Overall Study|Missed Final Visit|1
6045521|NCT00402246|9644760|FG001|Overall Study|Missed Final Visit|2
6045522|NCT00402246|9644759|FG000|Overall Study|Insurance Issues|2
6045523|NCT00402246|9644760|FG001|Overall Study|Insurance Issues|1
6045524|NCT00402246|9644759|FG000|Overall Study|Heart Transplant|0
6045525|NCT00402246|9644760|FG001|Overall Study|Heart Transplant|1
6045526|NCT00402246|9644759|FG000|Overall Study|Patient's device explanted|6
6045527|NCT00402246|9644760|FG001|Overall Study|Patient's device explanted|2
6045528|NCT00402246|9644759|FG000|Overall Study|Center Closure|5
6045529|NCT00402246|9644760|FG001|Overall Study|Center Closure|3
6045530|NCT00402246|9644759|FG000|Overall Study|Deterioriating Condition|3
6045531|NCT00402246|9644760|FG001|Overall Study|Deterioriating Condition|2
6045532|NCT00402285|9644771|FG000|Overall Study|insufficient RNA quality|7
6045533|NCT00402285|9644772|FG001|Overall Study|insufficient RNA quality|6
6045534|NCT00402285|9644773|FG002|Overall Study|insufficient RNA quality|2
6045535|NCT00402298|9644781|FG000|Overall Study|Withdrawal by Subject|1
6045536|NCT00402298|9644782|FG001|Overall Study|Withdrawal by Subject|0
6045537|NCT00402324|9644790|FG000|Overall Study|Lost to Follow-up|11
6045538|NCT00402324|9644791|FG001|Overall Study|Lost to Follow-up|11
5989987|NCT03619902|9581537|FG000|Overall Study|Termination of Study by Investigator|1
5989988|NCT03619902|9581537|FG000|Overall Study|Use of Excluded/Prohibited Medication|1
5989989|NCT03517449|9581578|FG000|Overall Study|Death|184
5989990|NCT03517449|9581579|FG001|Overall Study|Death|236
5989991|NCT03517449|9581578|FG000|Overall Study|Lost to Follow-up|0
5989992|NCT03517449|9581579|FG001|Overall Study|Lost to Follow-up|2
5989993|NCT03517449|9581578|FG000|Overall Study|Withdrawal by Subject|7
5989994|NCT03517449|9581579|FG001|Overall Study|Withdrawal by Subject|26
5989995|NCT03517449|9581578|FG000|Overall Study|Participants Ongoing|220
5989996|NCT03517449|9581579|FG001|Overall Study|Participants Ongoing|152
5989997|NCT03470922|9581587|FG000|Overall Study|Death|107
5989998|NCT03470922|9581588|FG001|Overall Study|Death|118
5989999|NCT03470922|9581587|FG000|Overall Study|Lost to Follow-up|5
5990000|NCT03470922|9581588|FG001|Overall Study|Lost to Follow-up|5
5990001|NCT03470922|9581587|FG000|Overall Study|Participant Withdrew Consent|4
5990002|NCT03470922|9581588|FG001|Overall Study|Participant Withdrew Consent|9
5990003|NCT03470922|9581587|FG000|Overall Study|Other reasons|1
5990004|NCT03470922|9581588|FG001|Overall Study|Other reasons|0
5990005|NCT03470922|9581587|FG000|Overall Study|Not reported|1
5990006|NCT03470922|9581588|FG001|Overall Study|Not reported|0
5990007|NCT03387852|9581598|FG000|Overall Study|Adverse event (AE)|3
5990008|NCT03387852|9581599|FG001|Overall Study|Adverse event (AE)|0
5990009|NCT03387852|9581600|FG002|Overall Study|Adverse event (AE)|2
5990010|NCT03387852|9581601|FG003|Overall Study|Adverse event (AE)|0
5990011|NCT03387852|9581598|FG000|Overall Study|Loss of asthma control (LOAC)|28
5990012|NCT03387852|9581599|FG001|Overall Study|Loss of asthma control (LOAC)|16
5990013|NCT03387852|9581600|FG002|Overall Study|Loss of asthma control (LOAC)|20
5990014|NCT03387852|9581601|FG003|Overall Study|Loss of asthma control (LOAC)|14
5990015|NCT03387852|9581598|FG000|Overall Study|Withdrawal by participant|1
5990016|NCT03387852|9581599|FG001|Overall Study|Withdrawal by participant|1
5990017|NCT03387852|9581600|FG002|Overall Study|Withdrawal by participant|3
5990018|NCT03387852|9581601|FG003|Overall Study|Withdrawal by participant|2
5990019|NCT03387852|9581598|FG000|Overall Study|Other- Unspecified|1
5990020|NCT03387852|9581599|FG001|Overall Study|Other- Unspecified|1
5990021|NCT03387852|9581600|FG002|Overall Study|Other- Unspecified|2
5990022|NCT03387852|9581601|FG003|Overall Study|Other- Unspecified|1
5990023|NCT03387852|9581598|FG000|Overall Study|Poor compliance to protocol|0
5990024|NCT03387852|9581599|FG001|Overall Study|Poor compliance to protocol|0
5990025|NCT03387852|9581600|FG002|Overall Study|Poor compliance to protocol|0
5990026|NCT03387852|9581601|FG003|Overall Study|Poor compliance to protocol|1
5990027|NCT03387852|9581598|FG000|Overall Study|Randomized and not treated|0
5990028|NCT03387852|9581599|FG001|Overall Study|Randomized and not treated|0
5990029|NCT03387852|9581600|FG002|Overall Study|Randomized and not treated|0
5990030|NCT03387852|9581601|FG003|Overall Study|Randomized and not treated|1
5990031|NCT03308825|9581616|FG000|Overall Study|Lost to Follow-up|2
5990032|NCT03308825|9581617|FG001|Overall Study|Lost to Follow-up|2
5990033|NCT03308825|9581618|FG002|Overall Study|Lost to Follow-up|1
5990034|NCT03308825|9581619|FG003|Overall Study|Lost to Follow-up|0
5990035|NCT03308825|9581616|FG000|Overall Study|Protocol Violation|0
5990036|NCT03308825|9581617|FG001|Overall Study|Protocol Violation|2
5990037|NCT03308825|9581618|FG002|Overall Study|Protocol Violation|0
5990038|NCT03308825|9581619|FG003|Overall Study|Protocol Violation|0
5990039|NCT02915302|9581635|FG000|Overall Study|Adverse Event|3
5990040|NCT02915302|9581636|FG001|Overall Study|Adverse Event|0
5990041|NCT02915302|9581635|FG000|Overall Study|Protocol Violation|20
5990042|NCT02915302|9581636|FG001|Overall Study|Protocol Violation|27
5990043|NCT02915302|9581635|FG000|Overall Study|Lost to Follow-up|19
5990044|NCT02915302|9581636|FG001|Overall Study|Lost to Follow-up|22
5990045|NCT02915302|9581635|FG000|Overall Study|Withdrawal by Subject|22
5990046|NCT02915302|9581636|FG001|Overall Study|Withdrawal by Subject|29
5990047|NCT02915302|9581635|FG000|Overall Study|Other|1
6064746|NCT00515463|9666579|FG001|Overall Study|Adverse Event|2
6064747|NCT00515463|9666578|FG000|Overall Study|Withdrawal by Subject|3
6064748|NCT00515463|9666579|FG001|Overall Study|Withdrawal by Subject|4
6064749|NCT00515463|9666578|FG000|Overall Study|Lost to Follow-up|6
6064750|NCT00515463|9666579|FG001|Overall Study|Lost to Follow-up|5
6064751|NCT00515463|9666578|FG000|Overall Study|Other|0
6064752|NCT00515463|9666579|FG001|Overall Study|Other|1
6064753|NCT00515502|9666586|FG000|Treatment Period 1|Adverse Event|0
6064754|NCT00515502|9666587|FG001|Treatment Period 1|Adverse Event|0
6064755|NCT00515502|9666588|FG002|Treatment Period 1|Adverse Event|0
6064756|NCT00515502|9666589|FG003|Treatment Period 1|Adverse Event|0
6064757|NCT00515502|9666590|FG004|Treatment Period 1|Adverse Event|0
6064758|NCT00515502|9666591|FG005|Treatment Period 1|Adverse Event|0
6064759|NCT00515502|9666592|FG006|Treatment Period 1|Adverse Event|1
6064760|NCT00515502|9666593|FG007|Treatment Period 1|Adverse Event|0
6064761|NCT00515502|9666594|FG008|Treatment Period 1|Adverse Event|1
6064762|NCT00515502|9666595|FG009|Treatment Period 1|Adverse Event|0
6064763|NCT00515502|9666596|FG010|Treatment Period 1|Adverse Event|0
6064764|NCT00515502|9666597|FG011|Treatment Period 1|Adverse Event|1
6064765|NCT00515502|9666586|FG000|Treatment Period 2|Adverse Event|0
6064766|NCT00515502|9666587|FG001|Treatment Period 2|Adverse Event|1
6064767|NCT00515502|9666588|FG002|Treatment Period 2|Adverse Event|0
6064768|NCT00515502|9666589|FG003|Treatment Period 2|Adverse Event|0
6064769|NCT00515502|9666590|FG004|Treatment Period 2|Adverse Event|0
6064770|NCT00515502|9666591|FG005|Treatment Period 2|Adverse Event|0
6064771|NCT00515502|9666592|FG006|Treatment Period 2|Adverse Event|0
6064772|NCT00515502|9666593|FG007|Treatment Period 2|Adverse Event|0
6064773|NCT00515502|9666594|FG008|Treatment Period 2|Adverse Event|0
6064774|NCT00515502|9666595|FG009|Treatment Period 2|Adverse Event|0
6064775|NCT00515502|9666596|FG010|Treatment Period 2|Adverse Event|0
6064776|NCT00515502|9666597|FG011|Treatment Period 2|Adverse Event|0
6064777|NCT00515541|9666627|FG000|Overall Study|Physician Decision|0
6064778|NCT00515541|9666628|FG001|Overall Study|Physician Decision|2
6064779|NCT00515541|9666629|FG002|Overall Study|Physician Decision|0
6064780|NCT00515541|9666630|FG003|Overall Study|Physician Decision|1
6064781|NCT00515541|9666627|FG000|Overall Study|No show for appointments|0
6064782|NCT00515541|9666628|FG001|Overall Study|No show for appointments|1
6064783|NCT00515541|9666629|FG002|Overall Study|No show for appointments|0
5990048|NCT02915302|9581636|FG001|Overall Study|Other|0
5990049|NCT02744040|9581659|FG000|Overall Study|Withdrawal by Subject|3
5990050|NCT02744040|9581660|FG001|Overall Study|Withdrawal by Subject|2
5990051|NCT02744040|9581661|FG002|Overall Study|Withdrawal by Subject|2
5990052|NCT02744040|9581659|FG000|Overall Study|Physician Decision|0
5990053|NCT02744040|9581660|FG001|Overall Study|Physician Decision|8
6064784|NCT00515541|9666630|FG003|Overall Study|No show for appointments|2
6064785|NCT00515541|9666627|FG000|Overall Study|Withdrawal by Subject|0
5990054|NCT02744040|9581661|FG002|Overall Study|Physician Decision|13
5990055|NCT02744040|9581659|FG000|Overall Study|Lost to Follow-up|3
5990056|NCT02744040|9581660|FG001|Overall Study|Lost to Follow-up|1
6064786|NCT00515541|9666628|FG001|Overall Study|Withdrawal by Subject|2
6064787|NCT00515541|9666629|FG002|Overall Study|Withdrawal by Subject|0
6064788|NCT00515541|9666630|FG003|Overall Study|Withdrawal by Subject|2
6064789|NCT00515619|9666640|FG000|Overall Study|Adverse Event|34
6064790|NCT00515619|9666640|FG000|Overall Study|Lack of Efficacy|92
6064791|NCT00515619|9666640|FG000|Overall Study|Withdrawal by Subject|66
6064792|NCT00515619|9666640|FG000|Overall Study|Protocol Violation|3
6309285|NCT02636907|10037783|FG000|Autoinjector Assessment Period|Withdrawal by Subject|2
5990057|NCT02744040|9581661|FG002|Overall Study|Lost to Follow-up|7
5990058|NCT02698826|9581669|FG000|Overall Study|Death|13
5990059|NCT02698826|9581669|FG000|Overall Study|Adverse Event|1
5990060|NCT02617589|9581677|FG000|All Randomized|Request to discontinue study treatment|1
5990061|NCT02617589|9581678|FG001|All Randomized|Request to discontinue study treatment|3
5990062|NCT02617589|9581677|FG000|All Randomized|Participant Withdrew Consent|1
5990063|NCT02617589|9581678|FG001|All Randomized|Participant Withdrew Consent|2
5990064|NCT02617589|9581677|FG000|Treatment Period|Other Reasons|2
5990065|NCT02617589|9581678|FG001|Treatment Period|Other Reasons|2
5990066|NCT02617589|9581677|FG000|Treatment Period|Not reported|1
5990067|NCT02617589|9581678|FG001|Treatment Period|Not reported|0
5990068|NCT02617589|9581677|FG000|Treatment Period|Poor/Non compliance|1
5990069|NCT02617589|9581678|FG001|Treatment Period|Poor/Non compliance|1
5990070|NCT02617589|9581677|FG000|Treatment Period|Maximum Clinical Benefit|0
5990071|NCT02617589|9581678|FG001|Treatment Period|Maximum Clinical Benefit|2
5990072|NCT02617589|9581677|FG000|Treatment Period|Participant Withdrew Consent|2
5990073|NCT02617589|9581678|FG001|Treatment Period|Participant Withdrew Consent|6
6309286|NCT02636907|10037783|FG000|Extension Phase|Adverse Event|2
6309287|NCT02636907|10037783|FG000|Extension Phase|Withdrawal by Subject|4
6309288|NCT02636907|10037783|FG000|Extension Phase|Physician Decision|1
6309289|NCT02636907|10037783|FG000|Extension Phase|Lost to Follow-up|2
6309290|NCT02636907|10037783|FG000|Extension Phase|Lack of Efficacy|1
6309291|NCT02637037|10037789|FG000|Overall Study|Positive drug screen at admission|1
6309292|NCT02637037|10037790|FG001|Overall Study|Positive drug screen at admission|0
6309293|NCT02637037|10037789|FG000|Overall Study|Withdrawal by Subject|2
6309294|NCT02637037|10037790|FG001|Overall Study|Withdrawal by Subject|1
6309295|NCT02637037|10037789|FG000|Overall Study|Adverse Event|1
6309296|NCT02637037|10037790|FG001|Overall Study|Adverse Event|0
6309297|NCT02637063|10037811|FG000|Overall Study|Lost to Follow-up|3
6309298|NCT02637063|10037812|FG001|Overall Study|Lost to Follow-up|2
6309299|NCT02637063|10037813|FG002|Overall Study|Lost to Follow-up|3
6309300|NCT02637063|10037811|FG000|Overall Study|Withdrawal by Subject|2
6309301|NCT02637063|10037812|FG001|Overall Study|Withdrawal by Subject|2
6309302|NCT02637063|10037813|FG002|Overall Study|Withdrawal by Subject|3
6309303|NCT02637076|10037823|FG000|Overall Study|due to technical difficulties, the 1 hour post PET scan was not completed at the one hour time point|1
6309304|NCT02637076|10037824|FG001|Overall Study|due to technical difficulties, the 1 hour post PET scan was not completed at the one hour time point|1
5990074|NCT02617589|9581677|FG000|Treatment Period|Participant Request to discontinue|12
5990075|NCT02617589|9581678|FG001|Treatment Period|Participant Request to discontinue|20
5990076|NCT02617589|9581677|FG000|Treatment Period|Adverse event unrelated to study drug|15
5990077|NCT02617589|9581678|FG001|Treatment Period|Adverse event unrelated to study drug|9
5990078|NCT02617589|9581677|FG000|Treatment Period|Death|1
5990079|NCT02617589|9581678|FG001|Treatment Period|Death|1
5990080|NCT02617589|9581677|FG000|Treatment Period|Study Drug Toxicity|26
5990081|NCT02617589|9581678|FG001|Treatment Period|Study Drug Toxicity|20
5990082|NCT02617589|9581677|FG000|Treatment Period|Disease Progression|214
5990083|NCT02617589|9581678|FG001|Treatment Period|Disease Progression|137
5990084|NCT02617589|9581677|FG000|Treatment Period|Completed Treatment|0
5990085|NCT02617589|9581678|FG001|Treatment Period|Completed Treatment|76
5990086|NCT02614859|9581686|FG000|Overall Study|Physician Decision|0
5990087|NCT02614859|9581687|FG001|Overall Study|Physician Decision|1
5990088|NCT02614066|9581699|FG000|Overall Study|Initiated KTE-X19 and Died|5
5990089|NCT02614066|9581700|FG001|Overall Study|Initiated KTE-X19 and Died|12
5990090|NCT02614066|9581701|FG002|Overall Study|Initiated KTE-X19 and Died|11
5990091|NCT02614066|9581702|FG003|Overall Study|Initiated KTE-X19 and Died|20
5990092|NCT02614066|9581699|FG000|Overall Study|Full Consent Withdrawn|0
5990093|NCT02614066|9581700|FG001|Overall Study|Full Consent Withdrawn|1
5990094|NCT02614066|9581701|FG002|Overall Study|Full Consent Withdrawn|0
5990095|NCT02614066|9581702|FG003|Overall Study|Full Consent Withdrawn|3
5990096|NCT02614066|9581699|FG000|Overall Study|Lost to Follow-up|0
5990097|NCT02614066|9581700|FG001|Overall Study|Lost to Follow-up|1
5990098|NCT02614066|9581701|FG002|Overall Study|Lost to Follow-up|0
5990099|NCT02614066|9581702|FG003|Overall Study|Lost to Follow-up|0
5990100|NCT02614066|9581699|FG000|Overall Study|Still on-study|1
5990101|NCT02614066|9581700|FG001|Overall Study|Still on-study|9
5990102|NCT02614066|9581701|FG002|Overall Study|Still on-study|5
5990103|NCT02614066|9581702|FG003|Overall Study|Still on-study|32
5990104|NCT02614066|9581699|FG000|Overall Study|Enrolled But Did Not Initiate KTE-X19|0
5990105|NCT02614066|9581700|FG001|Overall Study|Enrolled But Did Not Initiate KTE-X19|5
5990106|NCT02614066|9581701|FG002|Overall Study|Enrolled But Did Not Initiate KTE-X19|4
5990107|NCT02614066|9581702|FG003|Overall Study|Enrolled But Did Not Initiate KTE-X19|16
5990108|NCT02519348|9581730|FG000|Overall Study|Death|31
5990109|NCT02519348|9581731|FG001|Overall Study|Death|74
5990110|NCT02519348|9581732|FG002|Overall Study|Death|47
5990111|NCT02519348|9581733|FG003|Overall Study|Death|54
5990112|NCT02519348|9581734|FG004|Overall Study|Death|63
5990113|NCT02519348|9581735|FG005|Overall Study|Death|18
5990114|NCT02519348|9581736|FG006|Overall Study|Death|2
5990115|NCT02519348|9581737|FG007|Overall Study|Death|5
5990116|NCT02519348|9581738|FG008|Overall Study|Death|5
5990117|NCT02519348|9581730|FG000|Overall Study|Withdrawal by Subject|4
5990118|NCT02519348|9581731|FG001|Overall Study|Withdrawal by Subject|7
5990119|NCT02519348|9581732|FG002|Overall Study|Withdrawal by Subject|4
5990120|NCT02519348|9581733|FG003|Overall Study|Withdrawal by Subject|3
5990121|NCT02519348|9581734|FG004|Overall Study|Withdrawal by Subject|3
5990122|NCT02519348|9581735|FG005|Overall Study|Withdrawal by Subject|2
5990123|NCT02519348|9581736|FG006|Overall Study|Withdrawal by Subject|0
5990124|NCT02519348|9581737|FG007|Overall Study|Withdrawal by Subject|0
5990125|NCT02519348|9581738|FG008|Overall Study|Withdrawal by Subject|1
5990126|NCT02519348|9581730|FG000|Overall Study|Lost to Follow-up|0
5990127|NCT02519348|9581731|FG001|Overall Study|Lost to Follow-up|0
5990128|NCT02519348|9581732|FG002|Overall Study|Lost to Follow-up|1
5990129|NCT02519348|9581733|FG003|Overall Study|Lost to Follow-up|0
5990130|NCT02519348|9581734|FG004|Overall Study|Lost to Follow-up|2
5990131|NCT02519348|9581735|FG005|Overall Study|Lost to Follow-up|1
5990132|NCT02519348|9581736|FG006|Overall Study|Lost to Follow-up|1
5990133|NCT02519348|9581737|FG007|Overall Study|Lost to Follow-up|0
5990134|NCT02519348|9581738|FG008|Overall Study|Lost to Follow-up|0
5990135|NCT02519348|9581730|FG000|Overall Study|Other|0
5990136|NCT02519348|9581731|FG001|Overall Study|Other|3
5990137|NCT02519348|9581732|FG002|Overall Study|Other|0
5990138|NCT02519348|9581733|FG003|Overall Study|Other|0
5990139|NCT02519348|9581734|FG004|Overall Study|Other|1
5990140|NCT02519348|9581735|FG005|Overall Study|Other|0
5990141|NCT02519348|9581736|FG006|Overall Study|Other|0
5990142|NCT02519348|9581737|FG007|Overall Study|Other|0
5990143|NCT02519348|9581738|FG008|Overall Study|Other|0
5990144|NCT02519348|9581730|FG000|Overall Study|Ongoing at the time of data cut-off date|5
5990145|NCT02519348|9581731|FG001|Overall Study|Ongoing at the time of data cut-off date|20
5990146|NCT02519348|9581732|FG002|Overall Study|Ongoing at the time of data cut-off date|23
5990147|NCT02519348|9581733|FG003|Overall Study|Ongoing at the time of data cut-off date|12
5990148|NCT02519348|9581734|FG004|Overall Study|Ongoing at the time of data cut-off date|15
5990149|NCT02519348|9581735|FG005|Overall Study|Ongoing at the time of data cut-off date|26
5990150|NCT02519348|9581736|FG006|Overall Study|Ongoing at the time of data cut-off date|0
5990151|NCT02519348|9581737|FG007|Overall Study|Ongoing at the time of data cut-off date|0
5990152|NCT02519348|9581738|FG008|Overall Study|Ongoing at the time of data cut-off date|0
5990153|NCT02429414|9581761|FG000|Overall Study|Physician Decision|0
5990154|NCT02429414|9581762|FG001|Overall Study|Physician Decision|1
5990155|NCT02258659|9581772|FG000|Overall Study|Withdrawal by Subject|1
5990156|NCT02111850|9581787|FG000|Phase 1 Dose Escalation|Participant found to be ineligible and not treated.|0
5990157|NCT02111850|9581788|FG001|Phase 1 Dose Escalation|Participant found to be ineligible and not treated.|0
5990158|NCT02111850|9581789|FG002|Phase 1 Dose Escalation|Participant found to be ineligible and not treated.|0
5990159|NCT02111850|9581790|FG003|Phase 1 Dose Escalation|Participant found to be ineligible and not treated.|0
5990160|NCT02111850|9581791|FG004|Phase 1 Dose Escalation|Participant found to be ineligible and not treated.|1
5990161|NCT02111850|9581792|FG005|Phase 1 Dose Escalation|Participant found to be ineligible and not treated.|0
5990162|NCT02111850|9581793|FG006|Phase 1 Dose Escalation|Participant found to be ineligible and not treated.|0
5990163|NCT02111850|9581794|FG007|Phase 1 Dose Escalation|Participant found to be ineligible and not treated.|0
5990164|NCT02111850|9581795|FG008|Phase 1 Dose Escalation|Participant found to be ineligible and not treated.|0
5990165|NCT02111850|9581796|FG009|Phase 1 Dose Escalation|Participant found to be ineligible and not treated.|0
5990166|NCT02111850|9581797|FG010|Phase 1 Dose Escalation|Participant found to be ineligible and not treated.|0
6045539|NCT00402324|9644790|FG000|Overall Study|Protocol Entry Criteria Not Met|5
6045540|NCT00402324|9644791|FG001|Overall Study|Protocol Entry Criteria Not Met|4
6045541|NCT00402324|9644790|FG000|Overall Study|Protocol Violation|8
6045542|NCT00402324|9644791|FG001|Overall Study|Protocol Violation|7
6045543|NCT00402324|9644790|FG000|Overall Study|Withdrawal by Subject|5
6045544|NCT00402324|9644791|FG001|Overall Study|Withdrawal by Subject|2
6045545|NCT00402324|9644790|FG000|Overall Study|Physician Decision|2
6045546|NCT00402324|9644791|FG001|Overall Study|Physician Decision|4
6045547|NCT00402324|9644790|FG000|Overall Study|Sponsor Decision|4
6045548|NCT00402324|9644791|FG001|Overall Study|Sponsor Decision|5
6045549|NCT00402324|9644790|FG000|Overall Study|Lack of Efficacy|1
6045550|NCT00402324|9644791|FG001|Overall Study|Lack of Efficacy|4
6045551|NCT00402324|9644790|FG000|Overall Study|Adverse Event|6
6045552|NCT00402324|9644791|FG001|Overall Study|Adverse Event|4
6045553|NCT00402324|9644790|FG000|Overall Study|Death|1
6045554|NCT00402324|9644791|FG001|Overall Study|Death|0
6045555|NCT00402337|9644802|FG000|Overall Study|Adverse Event|0
6045556|NCT00402337|9644803|FG001|Overall Study|Adverse Event|2
6045557|NCT00402337|9644804|FG002|Overall Study|Adverse Event|2
6045558|NCT00402337|9644805|FG003|Overall Study|Adverse Event|3
6045559|NCT00402337|9644806|FG004|Overall Study|Adverse Event|2
6045560|NCT00402337|9644802|FG000|Overall Study|Noncompliance|0
6045561|NCT00402337|9644803|FG001|Overall Study|Noncompliance|0
6045562|NCT00402337|9644804|FG002|Overall Study|Noncompliance|0
6045563|NCT00402337|9644805|FG003|Overall Study|Noncompliance|0
6045564|NCT00402337|9644806|FG004|Overall Study|Noncompliance|2
6045565|NCT00402337|9644802|FG000|Overall Study|Withdrawal by Subject|5
6045566|NCT00402337|9644803|FG001|Overall Study|Withdrawal by Subject|3
6045567|NCT00402337|9644804|FG002|Overall Study|Withdrawal by Subject|1
6045568|NCT00402337|9644805|FG003|Overall Study|Withdrawal by Subject|6
6045569|NCT00402337|9644806|FG004|Overall Study|Withdrawal by Subject|4
6045570|NCT00402337|9644802|FG000|Overall Study|Lost to Follow-up|0
6045571|NCT00402337|9644803|FG001|Overall Study|Lost to Follow-up|0
6045572|NCT00402337|9644804|FG002|Overall Study|Lost to Follow-up|1
6045573|NCT00402337|9644805|FG003|Overall Study|Lost to Follow-up|2
6045574|NCT00402337|9644806|FG004|Overall Study|Lost to Follow-up|0
6045575|NCT00402337|9644802|FG000|Overall Study|Physician Decision|0
6045576|NCT00402337|9644803|FG001|Overall Study|Physician Decision|0
6045577|NCT00402337|9644804|FG002|Overall Study|Physician Decision|0
6045578|NCT00402337|9644805|FG003|Overall Study|Physician Decision|1
6045579|NCT00402337|9644806|FG004|Overall Study|Physician Decision|0
6045580|NCT00402337|9644802|FG000|Overall Study|Other Reason|0
6045581|NCT00402337|9644803|FG001|Overall Study|Other Reason|1
6045582|NCT00402337|9644804|FG002|Overall Study|Other Reason|0
6045583|NCT00402337|9644805|FG003|Overall Study|Other Reason|0
6045584|NCT00402337|9644806|FG004|Overall Study|Other Reason|0
6045585|NCT00402363|9644822|FG000|Overall Study|Adverse Event|9
6045586|NCT00402363|9644823|FG001|Overall Study|Adverse Event|14
6045587|NCT00402363|9644824|FG002|Overall Study|Adverse Event|2
6045588|NCT00402363|9644825|FG003|Overall Study|Adverse Event|2
6045589|NCT00402363|9644822|FG000|Overall Study|Withdrew Consent|10
6045590|NCT00402363|9644823|FG001|Overall Study|Withdrew Consent|5
6045591|NCT00402363|9644824|FG002|Overall Study|Withdrew Consent|2
5990167|NCT01483027|9581838|FG000|Overall Study|Administrative Reasons|2
5990168|NCT01483027|9581839|FG001|Overall Study|Administrative Reasons|1
5990169|NCT01483027|9581838|FG000|Overall Study|Withdrawal by Subject|21
5990170|NCT01483027|9581839|FG001|Overall Study|Withdrawal by Subject|32
5990171|NCT01483027|9581838|FG000|Overall Study|Discontinuation by Investigator or Sponsor for any reason|22
5990172|NCT01483027|9581839|FG001|Overall Study|Discontinuation by Investigator or Sponsor for any reason|24
5990173|NCT01483027|9581838|FG000|Overall Study|Lost to Follow-up|1
5990174|NCT01483027|9581839|FG001|Overall Study|Lost to Follow-up|1
5990175|NCT01483027|9581838|FG000|Overall Study|Adverse Event|0
5990176|NCT01483027|9581839|FG001|Overall Study|Adverse Event|1
5990177|NCT01483027|9581838|FG000|Overall Study|Withdrawal by Subject|0
5990178|NCT01483027|9581839|FG001|Overall Study|Withdrawal by Subject|1
5990179|NCT01379781|9581851|FG000|Overall Study|Lost to Follow-up|11
5990180|NCT01379781|9581852|FG001|Overall Study|Lost to Follow-up|8
5990181|NCT02513394|9581864|FG000|Overall Study|Withdrawal by Subject|11
5990182|NCT02513394|9581865|FG001|Overall Study|Withdrawal by Subject|23
5990183|NCT02513394|9581864|FG000|Overall Study|Ineligible|1
5990184|NCT02513394|9581865|FG001|Overall Study|Ineligible|0
5990185|NCT02445339|9581900|FG000|Overall Study|Physician Decision|1
5990186|NCT02445339|9581901|FG001|Overall Study|Physician Decision|0
5990187|NCT02445339|9581900|FG000|Overall Study|Lost to Follow-up|11
5990188|NCT02445339|9581901|FG001|Overall Study|Lost to Follow-up|15
5990189|NCT03298867|9581922|FG000|Double-Masked 24-Week Treatment Period|Adverse Event|1
5990190|NCT03298867|9581923|FG001|Double-Masked 24-Week Treatment Period|Adverse Event|1
5990191|NCT03298867|9581922|FG000|Double-Masked 24-Week Treatment Period|Withdrawal by Subject|1
5990192|NCT03298867|9581923|FG001|Double-Masked 24-Week Treatment Period|Withdrawal by Subject|1
5990193|NCT03298867|9581922|FG000|48-Week Follow-Up Period (Weeks 24-72)|Relapsed/Entered OPTIC-X|1
5990194|NCT03298867|9581923|FG001|48-Week Follow-Up Period (Weeks 24-72)|Relapsed/Entered OPTIC-X|9
5990195|NCT03298867|9581922|FG000|48-Week Follow-Up Period (Weeks 24-72)|Relapsed/Did not enter OPTIC-X|0
5990196|NCT03298867|9581923|FG001|48-Week Follow-Up Period (Weeks 24-72)|Relapsed/Did not enter OPTIC-X|1
5990197|NCT03298867|9581922|FG000|48-Week Follow-Up Period (Weeks 24-72)|Physician Decision|0
5990198|NCT03298867|9581923|FG001|48-Week Follow-Up Period (Weeks 24-72)|Physician Decision|1
5990199|NCT03298867|9581922|FG000|48-Week Follow-Up Period (Weeks 24-72)|Withdrawal by Subject|0
5990200|NCT03298867|9581923|FG001|48-Week Follow-Up Period (Weeks 24-72)|Withdrawal by Subject|2
5990201|NCT03298867|9581922|FG000|48-Week Follow-Up Period (Weeks 24-72)|Other, Not Specified|0
5990202|NCT03298867|9581923|FG001|48-Week Follow-Up Period (Weeks 24-72)|Other, Not Specified|1
5990203|NCT03298867|9581922|FG000|48-Week Follow-Up Period (Weeks 24-72)|Mis-classified as Responders|0
5990204|NCT03298867|9581923|FG001|48-Week Follow-Up Period (Weeks 24-72)|Mis-classified as Responders|2
5990205|NCT03298867|9581922|FG000|48-Week Follow-Up Contact (Weeks 96-120)|Lost to Follow-up|0
5990206|NCT03298867|9581923|FG001|48-Week Follow-Up Contact (Weeks 96-120)|Lost to Follow-up|1
5990207|NCT03227224|9581933|FG000|Double-blind Treatment Period (6 Weeks)|Lost to Follow-up|1
5990208|NCT03227224|9581934|FG001|Double-blind Treatment Period (6 Weeks)|Lost to Follow-up|0
5990209|NCT03227224|9581935|FG002|Double-blind Treatment Period (6 Weeks)|Lost to Follow-up|2
5990210|NCT03227224|9581936|FG003|Double-blind Treatment Period (6 Weeks)|Lost to Follow-up|0
5990211|NCT03227224|9581933|FG000|Double-blind Treatment Period (6 Weeks)|Protocol Violation|2
5990212|NCT03227224|9581934|FG001|Double-blind Treatment Period (6 Weeks)|Protocol Violation|2
5990213|NCT03227224|9581935|FG002|Double-blind Treatment Period (6 Weeks)|Protocol Violation|0
5990214|NCT03227224|9581936|FG003|Double-blind Treatment Period (6 Weeks)|Protocol Violation|0
5990215|NCT03227224|9581933|FG000|Double-blind Treatment Period (6 Weeks)|Withdrawal by Subject|3
5990216|NCT03227224|9581934|FG001|Double-blind Treatment Period (6 Weeks)|Withdrawal by Subject|2
5990217|NCT03227224|9581935|FG002|Double-blind Treatment Period (6 Weeks)|Withdrawal by Subject|3
5990218|NCT03227224|9581936|FG003|Double-blind Treatment Period (6 Weeks)|Withdrawal by Subject|2
5990219|NCT03227224|9581933|FG000|Double-blind Treatment Period (6 Weeks)|Lack of Efficacy|1
5990220|NCT03227224|9581934|FG001|Double-blind Treatment Period (6 Weeks)|Lack of Efficacy|0
5990221|NCT03227224|9581935|FG002|Double-blind Treatment Period (6 Weeks)|Lack of Efficacy|0
5990222|NCT03227224|9581936|FG003|Double-blind Treatment Period (6 Weeks)|Lack of Efficacy|0
5990223|NCT03227224|9581933|FG000|Double-blind Treatment Period (6 Weeks)|Received a Disallowed Concomitant Treatment|0
5990224|NCT03227224|9581934|FG001|Double-blind Treatment Period (6 Weeks)|Received a Disallowed Concomitant Treatment|0
5990225|NCT03227224|9581935|FG002|Double-blind Treatment Period (6 Weeks)|Received a Disallowed Concomitant Treatment|1
5990226|NCT03227224|9581936|FG003|Double-blind Treatment Period (6 Weeks)|Received a Disallowed Concomitant Treatment|0
5990227|NCT03227224|9581933|FG000|Double-blind Treatment Period (6 Weeks)|Adverse Event|2
5990228|NCT03227224|9581934|FG001|Double-blind Treatment Period (6 Weeks)|Adverse Event|1
5990229|NCT03227224|9581935|FG002|Double-blind Treatment Period (6 Weeks)|Adverse Event|1
5990230|NCT03227224|9581936|FG003|Double-blind Treatment Period (6 Weeks)|Adverse Event|4
6146092|NCT01075191|9780639|FG000|Overall Study|Adverse Event|4
6146093|NCT01075191|9780639|FG000|Overall Study|Noncompliance|3
6146094|NCT01075191|9780639|FG000|Overall Study|Therapy Break|3
6146095|NCT01075191|9780639|FG000|Overall Study|Patient's Wish|2
6146096|NCT01075191|9780639|FG000|Overall Study|Unknown Reasons|1
6146097|NCT01075217|9780649|FG000|Overall Study|Adverse Event|1
6146098|NCT01075217|9780650|FG001|Overall Study|Adverse Event|1
6146099|NCT01075217|9780649|FG000|Overall Study|Physician Decision|1
6146100|NCT01075217|9780650|FG001|Overall Study|Physician Decision|0
6146101|NCT01075243|9780667|FG000|Overall Study|Lost to Follow-up|5
6146102|NCT01075243|9780668|FG001|Overall Study|Lost to Follow-up|2
6146103|NCT01075243|9780669|FG002|Overall Study|Lost to Follow-up|0
6146104|NCT01075243|9780667|FG000|Overall Study|Withdrawal by Subject|1
5990231|NCT03227224|9581933|FG000|Double-blind Treatment Period (6 Weeks)|Non-Compliance with Study Drug|2
5990232|NCT03227224|9581934|FG001|Double-blind Treatment Period (6 Weeks)|Non-Compliance with Study Drug|1
5990233|NCT03227224|9581935|FG002|Double-blind Treatment Period (6 Weeks)|Non-Compliance with Study Drug|0
5990234|NCT03227224|9581936|FG003|Double-blind Treatment Period (6 Weeks)|Non-Compliance with Study Drug|1
5990235|NCT03227224|9581933|FG000|Double-blind Treatment Period (6 Weeks)|Other|4
5990236|NCT03227224|9581934|FG001|Double-blind Treatment Period (6 Weeks)|Other|0
5990237|NCT03227224|9581935|FG002|Double-blind Treatment Period (6 Weeks)|Other|1
6146105|NCT01075243|9780668|FG001|Overall Study|Withdrawal by Subject|1
6146106|NCT01075243|9780669|FG002|Overall Study|Withdrawal by Subject|0
6146107|NCT01075256|9780682|FG000|Overall Study|Withdrawal by Subject|1
6146108|NCT01075256|9780683|FG001|Overall Study|Withdrawal by Subject|0
6146109|NCT01075256|9780684|FG002|Overall Study|Withdrawal by Subject|0
5990238|NCT03227224|9581936|FG003|Double-blind Treatment Period (6 Weeks)|Other|0
5990239|NCT03227224|9581933|FG000|Follow-up Phase (2 Weeks)|Other|4
5990240|NCT03227224|9581934|FG001|Follow-up Phase (2 Weeks)|Other|4
5990241|NCT03227224|9581935|FG002|Follow-up Phase (2 Weeks)|Other|6
5990242|NCT03227224|9581936|FG003|Follow-up Phase (2 Weeks)|Other|3
5990243|NCT03220581|9581955|FG000|Overall Study|Withdrawal by Subject|0
5990244|NCT03220581|9581956|FG001|Overall Study|Withdrawal by Subject|1
5990245|NCT03220581|9581955|FG000|Overall Study|Lost to Follow-up|3
5990246|NCT03220581|9581956|FG001|Overall Study|Lost to Follow-up|6
6045592|NCT00402363|9644825|FG003|Overall Study|Withdrew Consent|1
6045593|NCT00402363|9644822|FG000|Overall Study|Protocol Violation|3
6045594|NCT00402363|9644823|FG001|Overall Study|Protocol Violation|5
6146110|NCT01075282|9780700|FG000|Overall Study|Withdrawal by Subject|11
6146111|NCT01075282|9780701|FG001|Overall Study|Withdrawal by Subject|7
6146112|NCT01075282|9780702|FG002|Overall Study|Withdrawal by Subject|11
6146113|NCT01075282|9780700|FG000|Overall Study|Adverse Event|9
6146114|NCT01075282|9780701|FG001|Overall Study|Adverse Event|8
6146115|NCT01075282|9780702|FG002|Overall Study|Adverse Event|5
6146116|NCT01075282|9780700|FG000|Overall Study|Entry Criteria Not Met|3
6146117|NCT01075282|9780701|FG001|Overall Study|Entry Criteria Not Met|2
6146118|NCT01075282|9780702|FG002|Overall Study|Entry Criteria Not Met|0
6045595|NCT00402363|9644824|FG002|Overall Study|Protocol Violation|0
6146119|NCT01075282|9780700|FG000|Overall Study|Lost to Follow-up|3
6146120|NCT01075282|9780701|FG001|Overall Study|Lost to Follow-up|3
5990247|NCT02991482|9581970|FG000|Overall Study|Disease progression|56
5990248|NCT02991482|9581971|FG001|Overall Study|Disease progression|47
5990249|NCT02991482|9581970|FG000|Overall Study|Death|4
5990250|NCT02991482|9581971|FG001|Overall Study|Death|4
5990251|NCT02991482|9581970|FG000|Overall Study|Adverse Event|1
5990252|NCT02991482|9581971|FG001|Overall Study|Adverse Event|6
5990253|NCT02991482|9581970|FG000|Overall Study|Patient decision|1
5990254|NCT02991482|9581971|FG001|Overall Study|Patient decision|1
5990255|NCT02991482|9581970|FG000|Overall Study|Physician Decision|0
5990256|NCT02991482|9581971|FG001|Overall Study|Physician Decision|6
5990257|NCT02991482|9581970|FG000|Overall Study|Clinical deterioration|1
5990258|NCT02991482|9581971|FG001|Overall Study|Clinical deterioration|0
5990259|NCT02991482|9581970|FG000|Overall Study|Patient feeling too unwell|1
5990260|NCT02991482|9581971|FG001|Overall Study|Patient feeling too unwell|0
5990261|NCT02991482|9581970|FG000|Overall Study|Worsening of performance status|0
5990262|NCT02991482|9581971|FG001|Overall Study|Worsening of performance status|1
5990263|NCT02991482|9581970|FG000|Overall Study|Death prior to study drug initiation|1
5990264|NCT02991482|9581971|FG001|Overall Study|Death prior to study drug initiation|0
5990265|NCT02991482|9581970|FG000|Overall Study|Consent withdrawal prior to study drug initiation|0
5990266|NCT02991482|9581971|FG001|Overall Study|Consent withdrawal prior to study drug initiation|1
5990267|NCT02768870|9581977|FG000|Overall Study|Not Implanted with Device|2
5990268|NCT02768870|9581977|FG000|Overall Study|Death|1
5990269|NCT02768870|9581977|FG000|Overall Study|Reoperation|4
5990270|NCT02768870|9581977|FG000|Overall Study|On Study|19
5990271|NCT02648698|9581983|FG000|Overall Study|Protocol Violation|1
5990272|NCT02648698|9581984|FG001|Overall Study|Protocol Violation|5
5990273|NCT02432196|9581990|FG000|Overall Study|Not Implanted with Device|1
5990274|NCT02432196|9581990|FG000|Overall Study|Death|2
5990275|NCT02432196|9581990|FG000|Overall Study|Reoperation|3
5990276|NCT02432196|9581990|FG000|Overall Study|On Study|20
5990277|NCT02000882|9581998|FG000|Overall Study|Adverse Event|3
6146121|NCT01075282|9780702|FG002|Overall Study|Lost to Follow-up|3
6146122|NCT01075282|9780700|FG000|Overall Study|Physician Decision|3
6146123|NCT01075282|9780701|FG001|Overall Study|Physician Decision|3
6146124|NCT01075282|9780702|FG002|Overall Study|Physician Decision|3
6146125|NCT01075282|9780700|FG000|Overall Study|Lack of Efficacy|1
6146126|NCT01075282|9780701|FG001|Overall Study|Lack of Efficacy|1
6146127|NCT01075282|9780702|FG002|Overall Study|Lack of Efficacy|0
6146128|NCT01075282|9780700|FG000|Overall Study|Treatment Non-compliance|1
6146129|NCT01075282|9780701|FG001|Overall Study|Treatment Non-compliance|2
6146130|NCT01075282|9780702|FG002|Overall Study|Treatment Non-compliance|2
6146131|NCT01075282|9780700|FG000|Overall Study|Protocol Violation|0
6146132|NCT01075282|9780701|FG001|Overall Study|Protocol Violation|2
6146133|NCT01075282|9780702|FG002|Overall Study|Protocol Violation|1
6146134|NCT01075282|9780700|FG000|Overall Study|Death|0
5990278|NCT02000882|9581998|FG000|Overall Study|Physician Decision|2
5990279|NCT02000882|9581998|FG000|Overall Study|Withdrawal by Subject|1
5990280|NCT01642004|9582017|FG000|Randomization|Adverse Event unrelated to study drug|1
5990281|NCT01642004|9582018|FG001|Randomization|Adverse Event unrelated to study drug|0
5990282|NCT01642004|9582017|FG000|Randomization|Withdrawal by Subject|1
5990283|NCT01642004|9582018|FG001|Randomization|Withdrawal by Subject|6
5990284|NCT01642004|9582017|FG000|Randomization|No longer meets study criteria|2
5990285|NCT01642004|9582018|FG001|Randomization|No longer meets study criteria|2
5990286|NCT01642004|9582017|FG000|Treatment|Disease progression|88
5990287|NCT01642004|9582018|FG001|Treatment|Disease progression|80
5990288|NCT01642004|9582017|FG000|Treatment|Study drug toxicity|5
5990289|NCT01642004|9582018|FG001|Treatment|Study drug toxicity|13
5990290|NCT01642004|9582017|FG000|Treatment|Death|1
5990291|NCT01642004|9582018|FG001|Treatment|Death|0
5990292|NCT01642004|9582017|FG000|Treatment|Adverse event unrelated to study drug|6
5990293|NCT01642004|9582018|FG001|Treatment|Adverse event unrelated to study drug|13
5990294|NCT01642004|9582017|FG000|Treatment|Withdrawal by Subject|5
5990295|NCT01642004|9582018|FG001|Treatment|Withdrawal by Subject|9
5990296|NCT01642004|9582017|FG000|Treatment|Maximum clinical benefit|2
5990297|NCT01642004|9582018|FG001|Treatment|Maximum clinical benefit|7
6146135|NCT01075282|9780701|FG001|Overall Study|Death|1
6146136|NCT01075282|9780702|FG002|Overall Study|Death|2
6146137|NCT01075321|9780711|FG000|Overall Study|Withdrawal by Subject|0
5990298|NCT01642004|9582017|FG000|Treatment|Poor/non-compliance|1
5990299|NCT01642004|9582018|FG001|Treatment|Poor/non-compliance|0
5990300|NCT01642004|9582017|FG000|Treatment|No longer meets study criteria|1
5990301|NCT01642004|9582018|FG001|Treatment|No longer meets study criteria|2
5990302|NCT01642004|9582017|FG000|Treatment|Other|1
5990303|NCT01642004|9582018|FG001|Treatment|Other|2
5990304|NCT01642004|9582017|FG000|Treatment|Missing from data|0
5990305|NCT01642004|9582018|FG001|Treatment|Missing from data|1
5990306|NCT01366092|9582024|FG000|Overall Study|Progressive cGVHD|2
5990307|NCT01366092|9582024|FG000|Overall Study|Physician Decision|1
5990308|NCT01366092|9582024|FG000|Overall Study|Withdrawal by Subject|1
5990309|NCT01326104|9582030|FG000|Overall Study|progressed prior to vaccine|0
5990310|NCT01326104|9582031|FG001|Overall Study|progressed prior to vaccine|2
5990311|NCT01326104|9582030|FG000|Overall Study|unable to make vaccine|0
5990312|NCT01326104|9582031|FG001|Overall Study|unable to make vaccine|2
5990313|NCT01244815|9582041|FG000|Overall Study|Not Treated|0
5990314|NCT01244815|9582042|FG001|Overall Study|Not Treated|1
5990315|NCT01244815|9582043|FG002|Overall Study|Not Treated|0
5990316|NCT01244815|9582044|FG003|Overall Study|Not Treated|0
5990317|NCT01244815|9582041|FG000|Overall Study|Adverse Event|4
5990318|NCT01244815|9582042|FG001|Overall Study|Adverse Event|7
5990319|NCT01244815|9582043|FG002|Overall Study|Adverse Event|5
5990320|NCT01244815|9582044|FG003|Overall Study|Adverse Event|5
5990321|NCT01244815|9582041|FG000|Overall Study|Treatment Failure|0
5990322|NCT01244815|9582042|FG001|Overall Study|Treatment Failure|0
5990323|NCT01244815|9582043|FG002|Overall Study|Treatment Failure|0
5990324|NCT01244815|9582044|FG003|Overall Study|Treatment Failure|1
5990325|NCT01244815|9582041|FG000|Overall Study|Lost to Follow-up|3
5990326|NCT01244815|9582042|FG001|Overall Study|Lost to Follow-up|2
5990327|NCT01244815|9582043|FG002|Overall Study|Lost to Follow-up|3
5990328|NCT01244815|9582044|FG003|Overall Study|Lost to Follow-up|2
5990329|NCT01244815|9582041|FG000|Overall Study|Withdrawal by Subject|0
5990330|NCT01244815|9582042|FG001|Overall Study|Withdrawal by Subject|2
5990331|NCT01244815|9582043|FG002|Overall Study|Withdrawal by Subject|0
5990332|NCT01244815|9582044|FG003|Overall Study|Withdrawal by Subject|3
5990333|NCT01244815|9582041|FG000|Overall Study|Protocol Violation|7
5990334|NCT01244815|9582042|FG001|Overall Study|Protocol Violation|4
5990335|NCT01244815|9582043|FG002|Overall Study|Protocol Violation|3
5990336|NCT01244815|9582044|FG003|Overall Study|Protocol Violation|1
5990337|NCT01244815|9582041|FG000|Overall Study|Did Not Meet Protocol Eligibility|0
5990338|NCT01244815|9582042|FG001|Overall Study|Did Not Meet Protocol Eligibility|1
5990339|NCT01244815|9582043|FG002|Overall Study|Did Not Meet Protocol Eligibility|0
5990340|NCT01244815|9582044|FG003|Overall Study|Did Not Meet Protocol Eligibility|0
5990341|NCT01142596|9582056|FG000|Overall Study|Withdrawal by Subject|9
5990342|NCT01142596|9582057|FG001|Overall Study|Withdrawal by Subject|35
5990343|NCT01142596|9582056|FG000|Overall Study|Adverse Event|8
5990344|NCT01142596|9582057|FG001|Overall Study|Adverse Event|35
5990345|NCT01142596|9582056|FG000|Overall Study|Lack of Efficacy|5
5990346|NCT01142596|9582057|FG001|Overall Study|Lack of Efficacy|9
5990347|NCT01142596|9582056|FG000|Overall Study|Lost to Follow-up|2
5990348|NCT01142596|9582057|FG001|Overall Study|Lost to Follow-up|3
5990349|NCT01142596|9582056|FG000|Overall Study|Other reason (not specified)|5
5990350|NCT01142596|9582057|FG001|Overall Study|Other reason (not specified)|4
5990351|NCT01098110|9582066|FG000|Overall Study|Withdrawal by Subject|14
5990352|NCT01098110|9582067|FG001|Overall Study|Withdrawal by Subject|24
5990353|NCT01098110|9582068|FG002|Overall Study|Withdrawal by Subject|19
5990354|NCT01098110|9582066|FG000|Overall Study|Adverse Event|30
5990355|NCT01098110|9582067|FG001|Overall Study|Adverse Event|32
5990356|NCT01098110|9582068|FG002|Overall Study|Adverse Event|43
5990357|NCT01098110|9582066|FG000|Overall Study|Lack of Efficacy|13
5990358|NCT01098110|9582067|FG001|Overall Study|Lack of Efficacy|9
5990359|NCT01098110|9582068|FG002|Overall Study|Lack of Efficacy|27
5990360|NCT01098110|9582066|FG000|Overall Study|Other|4
5990361|NCT01098110|9582067|FG001|Overall Study|Other|7
5990362|NCT01098110|9582068|FG002|Overall Study|Other|5
5990363|NCT01098110|9582066|FG000|Overall Study|Untreated|1
5990364|NCT01098110|9582067|FG001|Overall Study|Untreated|1
5990365|NCT01098110|9582068|FG002|Overall Study|Untreated|0
5990366|NCT01006265|9582080|FG000|Overall Study|Lost to Follow-up|1
5990367|NCT01006265|9582081|FG001|Overall Study|Lost to Follow-up|0
5990368|NCT01006265|9582082|FG002|Overall Study|Lost to Follow-up|1
5990369|NCT01006265|9582083|FG003|Overall Study|Lost to Follow-up|0
5990370|NCT01006265|9582080|FG000|Overall Study|Withdrawal by Subject|4
5990371|NCT01006265|9582081|FG001|Overall Study|Withdrawal by Subject|7
5990372|NCT01006265|9582082|FG002|Overall Study|Withdrawal by Subject|5
5990373|NCT01006265|9582083|FG003|Overall Study|Withdrawal by Subject|5
5990374|NCT01006265|9582080|FG000|Overall Study|Administrative reason|1
5990375|NCT01006265|9582081|FG001|Overall Study|Administrative reason|2
5990376|NCT01006265|9582082|FG002|Overall Study|Administrative reason|3
5990377|NCT01006265|9582083|FG003|Overall Study|Administrative reason|0
5990378|NCT00534976|9582105|FG000|Period 2: Treatment Montelukast/ Placebo|Protocol Violation|0
5990379|NCT00534976|9582106|FG001|Period 2: Treatment Montelukast/ Placebo|Protocol Violation|1
5990380|NCT00534976|9582105|FG000|Period 3: Crossover Placebo/ Montelukast|Physician Decision|1
5990381|NCT00534976|9582106|FG001|Period 3: Crossover Placebo/ Montelukast|Physician Decision|0
5990382|NCT00534976|9582105|FG000|Period 3: Crossover Placebo/ Montelukast|Withdrawal by Subject|1
5990383|NCT00534976|9582106|FG001|Period 3: Crossover Placebo/ Montelukast|Withdrawal by Subject|0
5990384|NCT00337675|9582115|FG000|Overall Study|Adverse Event|10
5990385|NCT00337675|9582116|FG001|Overall Study|Adverse Event|9
5990386|NCT00337675|9582117|FG002|Overall Study|Adverse Event|19
5990387|NCT00337675|9582115|FG000|Overall Study|Lack of Efficacy|10
5990388|NCT00337675|9582116|FG001|Overall Study|Lack of Efficacy|7
5990389|NCT00337675|9582117|FG002|Overall Study|Lack of Efficacy|9
5990390|NCT00337675|9582115|FG000|Overall Study|Lost to Follow-up|22
5990391|NCT00337675|9582116|FG001|Overall Study|Lost to Follow-up|19
5990392|NCT00337675|9582117|FG002|Overall Study|Lost to Follow-up|17
5990393|NCT00337675|9582115|FG000|Overall Study|Physician Decision|9
5990394|NCT00337675|9582116|FG001|Overall Study|Physician Decision|17
5990395|NCT00337675|9582117|FG002|Overall Study|Physician Decision|14
5990396|NCT00337675|9582115|FG000|Overall Study|Protocol Violation|21
5990397|NCT00337675|9582116|FG001|Overall Study|Protocol Violation|24
5990398|NCT00337675|9582117|FG002|Overall Study|Protocol Violation|19
5990399|NCT00337675|9582115|FG000|Overall Study|Withdrawal by Subject|25
5990400|NCT00337675|9582116|FG001|Overall Study|Withdrawal by Subject|25
5990401|NCT00337675|9582117|FG002|Overall Study|Withdrawal by Subject|19
5990402|NCT00337675|9582115|FG000|Overall Study|Progressive Disease|0
5990403|NCT00337675|9582116|FG001|Overall Study|Progressive Disease|2
5990404|NCT00337675|9582117|FG002|Overall Study|Progressive Disease|0
5990405|NCT00337675|9582115|FG000|Overall Study|Trial Terminated|0
5990406|NCT00337675|9582116|FG001|Overall Study|Trial Terminated|0
5990407|NCT00337675|9582117|FG002|Overall Study|Trial Terminated|2
5990408|NCT00317772|9582129|FG000|Overall Study|Adverse Event|0
5990409|NCT00317772|9582130|FG001|Overall Study|Adverse Event|0
5990410|NCT00317772|9582131|FG002|Overall Study|Adverse Event|0
5990411|NCT00317772|9582132|FG003|Overall Study|Adverse Event|2
5990412|NCT00317772|9582129|FG000|Overall Study|Disease Progression|2
5990413|NCT00317772|9582130|FG001|Overall Study|Disease Progression|2
5990414|NCT00317772|9582131|FG002|Overall Study|Disease Progression|1
5990415|NCT00317772|9582132|FG003|Overall Study|Disease Progression|7
5990416|NCT00291486|9582148|FG000|Overall Study|Adverse Event|0
5990417|NCT00291486|9582149|FG001|Overall Study|Adverse Event|3
5990418|NCT00291486|9582150|FG002|Overall Study|Adverse Event|0
5990419|NCT00291486|9582151|FG003|Overall Study|Adverse Event|1
5990420|NCT00291486|9582152|FG004|Overall Study|Adverse Event|0
5990421|NCT00291486|9582148|FG000|Overall Study|Withdrawal by Subject|0
5990422|NCT00291486|9582149|FG001|Overall Study|Withdrawal by Subject|0
5990423|NCT00291486|9582150|FG002|Overall Study|Withdrawal by Subject|0
5990424|NCT00291486|9582151|FG003|Overall Study|Withdrawal by Subject|0
5990425|NCT00291486|9582152|FG004|Overall Study|Withdrawal by Subject|1
5990426|NCT00291486|9582148|FG000|Overall Study|Disease progression|1
5990427|NCT00291486|9582149|FG001|Overall Study|Disease progression|0
5990428|NCT00291486|9582150|FG002|Overall Study|Disease progression|1
5990429|NCT00291486|9582151|FG003|Overall Study|Disease progression|0
5990430|NCT00291486|9582152|FG004|Overall Study|Disease progression|0
5990431|NCT00284856|9582176|FG000|Overall Study|Adverse Event|3
5990432|NCT00284856|9582177|FG001|Overall Study|Adverse Event|3
5990433|NCT00284856|9582178|FG002|Overall Study|Adverse Event|3
5990434|NCT00284856|9582176|FG000|Overall Study|Lack of Efficacy|2
5990435|NCT00284856|9582177|FG001|Overall Study|Lack of Efficacy|1
5990436|NCT00284856|9582178|FG002|Overall Study|Lack of Efficacy|8
5990437|NCT00284856|9582176|FG000|Overall Study|Lost to Follow-up|25
5990438|NCT00284856|9582177|FG001|Overall Study|Lost to Follow-up|21
5990439|NCT00284856|9582178|FG002|Overall Study|Lost to Follow-up|22
5990440|NCT00284856|9582176|FG000|Overall Study|Protocol Violation|5
5990441|NCT00284856|9582177|FG001|Overall Study|Protocol Violation|4
5990442|NCT00284856|9582178|FG002|Overall Study|Protocol Violation|5
5990443|NCT00284856|9582176|FG000|Overall Study|Withdrawal by Subject|12
5990444|NCT00284856|9582177|FG001|Overall Study|Withdrawal by Subject|16
5990445|NCT00284856|9582178|FG002|Overall Study|Withdrawal by Subject|18
5990446|NCT00284856|9582176|FG000|Overall Study|Other|4
5990447|NCT00284856|9582177|FG001|Overall Study|Other|5
5990448|NCT00284856|9582178|FG002|Overall Study|Other|4
5990449|NCT00070707|9582188|FG000|Overall Study|Adverse Event|1
5990450|NCT00070707|9582189|FG001|Overall Study|Adverse Event|2
5990451|NCT00070707|9582188|FG000|Overall Study|Lack of Efficacy|4
5990452|NCT00070707|9582189|FG001|Overall Study|Lack of Efficacy|1
5990453|NCT00070707|9582188|FG000|Overall Study|Protocol Violation|8
5990454|NCT00070707|9582189|FG001|Overall Study|Protocol Violation|4
5990455|NCT00070707|9582188|FG000|Overall Study|Unrelated to Study Medication|1
5990456|NCT00070707|9582189|FG001|Overall Study|Unrelated to Study Medication|0
6045596|NCT00402363|9644825|FG003|Overall Study|Protocol Violation|3
6045597|NCT00402363|9644822|FG000|Overall Study|Lost to Follow-up|5
6045598|NCT00402363|9644823|FG001|Overall Study|Lost to Follow-up|4
6045599|NCT00402363|9644824|FG002|Overall Study|Lost to Follow-up|0
6045600|NCT00402363|9644825|FG003|Overall Study|Lost to Follow-up|2
6045601|NCT00402363|9644822|FG000|Overall Study|"Captured as Other"|6
6045602|NCT00402363|9644823|FG001|Overall Study|"Captured as Other"|2
6045603|NCT00402363|9644824|FG002|Overall Study|"Captured as Other"|2
6146138|NCT01075321|9780712|FG001|Overall Study|Withdrawal by Subject|0
6146139|NCT01075321|9780713|FG002|Overall Study|Withdrawal by Subject|1
5990457|NCT04474197|9582219|FG000|Overall Study|Withdrawal of consent (not due to adverse event)|0
5990458|NCT04474197|9582220|FG001|Overall Study|Withdrawal of consent (not due to adverse event)|1
5990459|NCT04474197|9582221|FG002|Overall Study|Withdrawal of consent (not due to adverse event)|0
5990460|NCT04474197|9582222|FG003|Overall Study|Withdrawal of consent (not due to adverse event)|0
5990461|NCT04391894|9582242|FG000|Overall Study|Adverse Event|1
5990462|NCT04391894|9582243|FG001|Overall Study|Adverse Event|1
5990463|NCT04391894|9582244|FG002|Overall Study|Adverse Event|1
5990464|NCT04391894|9582245|FG003|Overall Study|Adverse Event|1
5990465|NCT04391894|9582246|FG004|Overall Study|Adverse Event|1
5990466|NCT04391894|9582242|FG000|Overall Study|Lost to Follow-up|1
5990467|NCT04391894|9582243|FG001|Overall Study|Lost to Follow-up|0
5990468|NCT04391894|9582244|FG002|Overall Study|Lost to Follow-up|0
5990469|NCT04391894|9582245|FG003|Overall Study|Lost to Follow-up|0
5990470|NCT04391894|9582246|FG004|Overall Study|Lost to Follow-up|0
5990471|NCT04391894|9582242|FG000|Overall Study|Protocol Violation|0
5990472|NCT04391894|9582243|FG001|Overall Study|Protocol Violation|0
5990473|NCT04391894|9582244|FG002|Overall Study|Protocol Violation|0
5990474|NCT04391894|9582245|FG003|Overall Study|Protocol Violation|1
5990475|NCT04391894|9582246|FG004|Overall Study|Protocol Violation|0
5990476|NCT04391894|9582242|FG000|Overall Study|Withdrawal by Subject|2
5990477|NCT04391894|9582243|FG001|Overall Study|Withdrawal by Subject|0
5990478|NCT04391894|9582244|FG002|Overall Study|Withdrawal by Subject|3
5990479|NCT04391894|9582245|FG003|Overall Study|Withdrawal by Subject|0
5990480|NCT04391894|9582246|FG004|Overall Study|Withdrawal by Subject|1
5990481|NCT04391894|9582242|FG000|Overall Study|Unsatisfactory Therapeutic effect|0
5990482|NCT04391894|9582243|FG001|Overall Study|Unsatisfactory Therapeutic effect|0
5990483|NCT04391894|9582244|FG002|Overall Study|Unsatisfactory Therapeutic effect|0
5990484|NCT04391894|9582245|FG003|Overall Study|Unsatisfactory Therapeutic effect|0
5990485|NCT04391894|9582246|FG004|Overall Study|Unsatisfactory Therapeutic effect|1
5990486|NCT04369950|9582260|FG000|Overall Study|Protocol Violation|2
5990487|NCT04369950|9582261|FG001|Overall Study|Protocol Violation|2
5990488|NCT04070326|9582269|FG000|Treatment Period A (Weeks 1 to 26)|Withdrawal by Parent/Guardian|1
5990489|NCT04070326|9582270|FG001|Treatment Period A (Weeks 1 to 26)|Withdrawal by Parent/Guardian|0
5990490|NCT04003610|9582281|FG000|Overall Study|Lost to Follow-up|0
5990491|NCT04003610|9582282|FG001|Overall Study|Lost to Follow-up|1
5990492|NCT04003610|9582283|FG002|Overall Study|Lost to Follow-up|0
5990493|NCT04003610|9582281|FG000|Overall Study|Death|0
5990494|NCT04003610|9582282|FG001|Overall Study|Death|0
5990495|NCT04003610|9582283|FG002|Overall Study|Death|3
5990496|NCT04003610|9582281|FG000|Overall Study|Study Terminated by Sponsor|0
5990497|NCT04003610|9582282|FG001|Overall Study|Study Terminated by Sponsor|0
5990498|NCT04003610|9582283|FG002|Overall Study|Study Terminated by Sponsor|3
5990499|NCT03920293|9582294|FG000|Overall Study|Withdrawal by Subject|2
5990500|NCT03920293|9582295|FG001|Overall Study|Withdrawal by Subject|1
5990501|NCT03920293|9582294|FG000|Overall Study|Physician Decision|1
5990502|NCT03920293|9582295|FG001|Overall Study|Physician Decision|2
5990503|NCT03920293|9582294|FG000|Overall Study|Adverse Event|0
5990504|NCT03920293|9582295|FG001|Overall Study|Adverse Event|2
5990505|NCT03920293|9582294|FG000|Overall Study|Sponsor Decision|0
5990506|NCT03920293|9582295|FG001|Overall Study|Sponsor Decision|1
5990507|NCT03920293|9582294|FG000|Overall Study|Death|2
5990508|NCT03920293|9582295|FG001|Overall Study|Death|0
5990509|NCT03920293|9582294|FG000|Overall Study|Protocol Violation|1
5990510|NCT03920293|9582295|FG001|Overall Study|Protocol Violation|0
5990511|NCT03920293|9582294|FG000|Overall Study|Noncompliance|1
5990512|NCT03920293|9582295|FG001|Overall Study|Noncompliance|0
5990513|NCT03712345|9582321|FG000|Overall Study|Failure to meet randomization criteria|0
5990514|NCT03712345|9582322|FG001|Overall Study|Failure to meet randomization criteria|0
5990515|NCT03712345|9582323|FG002|Overall Study|Failure to meet randomization criteria|1
5990516|NCT03694275|9582333|FG000|Overall Study|Adverse Event|0
5990517|NCT03694275|9582334|FG001|Overall Study|Adverse Event|1
5990518|NCT03694275|9582333|FG000|Overall Study|Reason not Specified|0
5990519|NCT03694275|9582334|FG001|Overall Study|Reason not Specified|1
5990520|NCT03391232|9582343|FG000|Part B - Additional 2 Doses (13-38weeks)|Physician Decision|0
5990521|NCT03391232|9582344|FG001|Part B - Additional 2 Doses (13-38weeks)|Physician Decision|1
5990522|NCT03391232|9582343|FG000|Part B - Additional 2 Doses (13-38weeks)|Withdrawal by Subject|0
5990523|NCT03391232|9582344|FG001|Part B - Additional 2 Doses (13-38weeks)|Withdrawal by Subject|2
5990524|NCT03323736|9582355|FG000|Overall Study|Screen Failure|14
5990525|NCT03323736|9582356|FG001|Overall Study|Screen Failure|9
6146140|NCT01075321|9780714|FG003|Overall Study|Withdrawal by Subject|1
6146141|NCT01075321|9780711|FG000|Overall Study|Protocol Violation|0
6146142|NCT01075321|9780712|FG001|Overall Study|Protocol Violation|0
6146143|NCT01075321|9780713|FG002|Overall Study|Protocol Violation|1
5990526|NCT03323736|9582357|FG002|Overall Study|Screen Failure|1
5990527|NCT03323736|9582355|FG000|Overall Study|Withdrawal Before Treatment|3
5990528|NCT03323736|9582356|FG001|Overall Study|Withdrawal Before Treatment|1
5990529|NCT03323736|9582357|FG002|Overall Study|Withdrawal Before Treatment|1
5990530|NCT03323736|9582355|FG000|Overall Study|Iontophoresis fill/no iontophoresis|2
5990531|NCT03323736|9582356|FG001|Overall Study|Iontophoresis fill/no iontophoresis|2
5990532|NCT03323736|9582357|FG002|Overall Study|Iontophoresis fill/no iontophoresis|0
5990533|NCT03073980|9582379|FG000|Overall Study|Lost to Follow-up|10
5990534|NCT03073980|9582380|FG001|Overall Study|Lost to Follow-up|2
5990535|NCT03073980|9582381|FG002|Overall Study|Lost to Follow-up|9
5990536|NCT03073980|9582379|FG000|Overall Study|No post-procedure data|0
5990537|NCT03073980|9582380|FG001|Overall Study|No post-procedure data|0
5990538|NCT03073980|9582381|FG002|Overall Study|No post-procedure data|2
5990539|NCT02544074|9582423|FG000|Overall Study|Withdrawal by Subject|0
5990540|NCT02544074|9582424|FG001|Overall Study|Withdrawal by Subject|1
5990541|NCT02544074|9582425|FG002|Overall Study|Withdrawal by Subject|0
5990542|NCT02544074|9582426|FG003|Overall Study|Withdrawal by Subject|0
5990543|NCT02544074|9582427|FG004|Overall Study|Withdrawal by Subject|0
5990544|NCT02544074|9582428|FG005|Overall Study|Withdrawal by Subject|0
5990545|NCT02544074|9582429|FG006|Overall Study|Withdrawal by Subject|0
5990546|NCT02544074|9582430|FG007|Overall Study|Withdrawal by Subject|0
5990547|NCT02544074|9582431|FG008|Overall Study|Withdrawal by Subject|0
5990548|NCT02544074|9582432|FG009|Overall Study|Withdrawal by Subject|0
5990549|NCT02544074|9582433|FG010|Overall Study|Withdrawal by Subject|0
5990550|NCT02544074|9582434|FG011|Overall Study|Withdrawal by Subject|0
5990551|NCT02544074|9582435|FG012|Overall Study|Withdrawal by Subject|0
5990552|NCT02544074|9582436|FG013|Overall Study|Withdrawal by Subject|0
5990553|NCT02544074|9582437|FG014|Overall Study|Withdrawal by Subject|0
5990554|NCT02544074|9582438|FG015|Overall Study|Withdrawal by Subject|0
5990555|NCT02544074|9582439|FG016|Overall Study|Withdrawal by Subject|0
5990556|NCT02544074|9582440|FG017|Overall Study|Withdrawal by Subject|0
5990557|NCT02544074|9582441|FG018|Overall Study|Withdrawal by Subject|0
5990558|NCT02544074|9582442|FG019|Overall Study|Withdrawal by Subject|0
5990559|NCT02544074|9582443|FG020|Overall Study|Withdrawal by Subject|0
5990560|NCT02544074|9582423|FG000|Overall Study|Tablet error|0
5990561|NCT02544074|9582424|FG001|Overall Study|Tablet error|0
5990562|NCT02544074|9582425|FG002|Overall Study|Tablet error|0
5990563|NCT02544074|9582426|FG003|Overall Study|Tablet error|0
5990564|NCT02544074|9582427|FG004|Overall Study|Tablet error|0
5990565|NCT02544074|9582428|FG005|Overall Study|Tablet error|1
5990566|NCT02544074|9582429|FG006|Overall Study|Tablet error|0
5990567|NCT02544074|9582430|FG007|Overall Study|Tablet error|0
5990568|NCT02544074|9582431|FG008|Overall Study|Tablet error|0
5990569|NCT02544074|9582432|FG009|Overall Study|Tablet error|1
5990570|NCT02544074|9582433|FG010|Overall Study|Tablet error|0
5990571|NCT02544074|9582434|FG011|Overall Study|Tablet error|0
5990572|NCT02544074|9582435|FG012|Overall Study|Tablet error|0
5990573|NCT02544074|9582436|FG013|Overall Study|Tablet error|0
5990574|NCT02544074|9582437|FG014|Overall Study|Tablet error|0
5990575|NCT02544074|9582438|FG015|Overall Study|Tablet error|0
5990576|NCT02544074|9582439|FG016|Overall Study|Tablet error|0
5990577|NCT02544074|9582440|FG017|Overall Study|Tablet error|0
5990578|NCT02544074|9582441|FG018|Overall Study|Tablet error|0
5990579|NCT02544074|9582442|FG019|Overall Study|Tablet error|0
5990580|NCT02544074|9582443|FG020|Overall Study|Tablet error|0
5990581|NCT02367040|9582479|FG000|Overall Study|Lost to Follow-up|1
5990582|NCT02367040|9582480|FG001|Overall Study|Lost to Follow-up|1
5990583|NCT02367040|9582479|FG000|Overall Study|Lack of Efficacy|1
5990584|NCT02367040|9582480|FG001|Overall Study|Lack of Efficacy|0
5990585|NCT02367040|9582479|FG000|Overall Study|Additional primary malignancy|0
5990586|NCT02367040|9582480|FG001|Overall Study|Additional primary malignancy|1
5990587|NCT02367040|9582479|FG000|Overall Study|AE not associated with clinical disease progression|104
5990588|NCT02367040|9582480|FG001|Overall Study|AE not associated with clinical disease progression|9
5990589|NCT02367040|9582479|FG000|Overall Study|AE associated with clinical disease progression|1
5990590|NCT02367040|9582480|FG001|Overall Study|AE associated with clinical disease progression|3
5990591|NCT02367040|9582479|FG000|Overall Study|Physician Decision|2
5990592|NCT02367040|9582480|FG001|Overall Study|Physician Decision|8
5990593|NCT02367040|9582479|FG000|Overall Study|Non-compliance with study drug|1
5990594|NCT02367040|9582480|FG001|Overall Study|Non-compliance with study drug|0
5990595|NCT02367040|9582479|FG000|Overall Study|Failure to meet continuation criteria|1
5990596|NCT02367040|9582480|FG001|Overall Study|Failure to meet continuation criteria|0
5990597|NCT02367040|9582479|FG000|Overall Study|Switching to other therapy|2
5990598|NCT02367040|9582480|FG001|Overall Study|Switching to other therapy|0
5990599|NCT02367040|9582479|FG000|Overall Study|Withdrawal by Subject|41
5990600|NCT02367040|9582480|FG001|Overall Study|Withdrawal by Subject|14
5990601|NCT02367040|9582479|FG000|Overall Study|Patient decision: COVID-19 pandemic related|1
5990602|NCT02367040|9582480|FG001|Overall Study|Patient decision: COVID-19 pandemic related|0
5990603|NCT02367040|9582479|FG000|Overall Study|Patient decision|35
5990604|NCT02367040|9582480|FG001|Overall Study|Patient decision|11
5990605|NCT02367040|9582479|FG000|Overall Study|Required procedure failed|1
5990606|NCT02367040|9582480|FG001|Overall Study|Required procedure failed|0
5990607|NCT02367040|9582479|FG000|Overall Study|Randomized by mistake with study treatment|1
5990608|NCT02367040|9582480|FG001|Overall Study|Randomized by mistake with study treatment|0
5990609|NCT02367040|9582479|FG000|Overall Study|Protocol Violation|1
5990610|NCT02367040|9582480|FG001|Overall Study|Protocol Violation|0
5990611|NCT02367040|9582479|FG000|Overall Study|Progressive disease - radiological progression|39
5990612|NCT02367040|9582480|FG001|Overall Study|Progressive disease - radiological progression|67
5990613|NCT02367040|9582479|FG000|Overall Study|Progressive disease - clinical progression|2
5990614|NCT02367040|9582480|FG001|Overall Study|Progressive disease - clinical progression|6
5990615|NCT02367040|9582479|FG000|Overall Study|Drug not administered|3
5990616|NCT02367040|9582480|FG001|Overall Study|Drug not administered|2
5990617|NCT02317627|9582489|FG000|Overall Study|Withdrawal by Subject|0
5990618|NCT02317627|9582490|FG001|Overall Study|Withdrawal by Subject|1
5990619|NCT02317627|9582491|FG002|Overall Study|Withdrawal by Subject|1
5990620|NCT02317627|9582489|FG000|Overall Study|Lost to Follow-up|2
5990621|NCT02317627|9582490|FG001|Overall Study|Lost to Follow-up|0
5990622|NCT02317627|9582491|FG002|Overall Study|Lost to Follow-up|0
5990623|NCT02317627|9582489|FG000|Overall Study|Stopped by Investigator|0
5990624|NCT02317627|9582490|FG001|Overall Study|Stopped by Investigator|1
5990625|NCT02317627|9582491|FG002|Overall Study|Stopped by Investigator|0
5990626|NCT02317627|9582489|FG000|Overall Study|Adverse Event|0
5990627|NCT02317627|9582490|FG001|Overall Study|Adverse Event|2
5990628|NCT02317627|9582491|FG002|Overall Study|Adverse Event|3
6064793|NCT00515619|9666640|FG000|Overall Study|Lost to Follow-up|4
6064794|NCT00515619|9666640|FG000|Overall Study|Unsatisfactory compliance|6
6064795|NCT00515619|9666640|FG000|Overall Study|Other: Site discontinuing trials|2
6064796|NCT00515619|9666640|FG000|Overall Study|Other: Subject cannot attend visits|2
6064797|NCT00515619|9666640|FG000|Overall Study|Other: Subject required surgery|1
6064798|NCT00515619|9666640|FG000|Overall Study|Other: Subject moved to another country|1
6064799|NCT00515619|9666640|FG000|Overall Study|Other: Investigator decision|1
6064800|NCT00515619|9666640|FG000|Overall Study|Other: Subject became pregnant|1
6064801|NCT00515619|9666640|FG000|Overall Study|Other: Request from sponsor|1
5990629|NCT02317627|9582489|FG000|Overall Study|Non-compliance with study drug|0
5990630|NCT02317627|9582490|FG001|Overall Study|Non-compliance with study drug|1
5990631|NCT02317627|9582491|FG002|Overall Study|Non-compliance with study drug|0
5990632|NCT01935128|9582505|FG000|Overall Study|Death|1
5990633|NCT01935128|9582505|FG000|Overall Study|Adverse Event|6
5990634|NCT01915498|9582527|FG000|Main Analysis (Sept 2013 - Sept 2017)|Withdrawal by Subject|0
5990635|NCT01915498|9582528|FG001|Main Analysis (Sept 2013 - Sept 2017)|Withdrawal by Subject|0
5990636|NCT01915498|9582529|FG002|Main Analysis (Sept 2013 - Sept 2017)|Withdrawal by Subject|0
5990637|NCT01915498|9582530|FG003|Main Analysis (Sept 2013 - Sept 2017)|Withdrawal by Subject|1
5990638|NCT01915498|9582531|FG004|Main Analysis (Sept 2013 - Sept 2017)|Withdrawal by Subject|1
5990639|NCT01915498|9582532|FG005|Main Analysis (Sept 2013 - Sept 2017)|Withdrawal by Subject|0
5990640|NCT01915498|9582533|FG006|Main Analysis (Sept 2013 - Sept 2017)|Withdrawal by Subject|0
5990641|NCT01915498|9582534|FG007|Main Analysis (Sept 2013 - Sept 2017)|Withdrawal by Subject|0
5990642|NCT01915498|9582535|FG008|Main Analysis (Sept 2013 - Sept 2017)|Withdrawal by Subject|0
5990643|NCT01915498|9582536|FG009|Main Analysis (Sept 2013 - Sept 2017)|Withdrawal by Subject|1
5990644|NCT01915498|9582537|FG010|Main Analysis (Sept 2013 - Sept 2017)|Withdrawal by Subject|0
5990645|NCT01915498|9582538|FG011|Main Analysis (Sept 2013 - Sept 2017)|Withdrawal by Subject|0
5990646|NCT01915498|9582539|FG012|Main Analysis (Sept 2013 - Sept 2017)|Withdrawal by Subject|1
5990647|NCT01915498|9582540|FG013|Main Analysis (Sept 2013 - Sept 2017)|Withdrawal by Subject|5
5990648|NCT01915498|9582541|FG014|Main Analysis (Sept 2013 - Sept 2017)|Withdrawal by Subject|1
5990649|NCT01915498|9582542|FG015|Main Analysis (Sept 2013 - Sept 2017)|Withdrawal by Subject|2
5990650|NCT01915498|9582543|FG016|Main Analysis (Sept 2013 - Sept 2017)|Withdrawal by Subject|2
6064802|NCT00515619|9666640|FG000|Overall Study|Other: Drug available on license|1
6064803|NCT00515619|9666640|FG000|Overall Study|Other: Subject interested in other AED|1
6064804|NCT00515827|9666668|FG000|First Intervention (12 Weeks)|Unwilling to adhere to study requirement|1
6064805|NCT00515827|9666669|FG001|First Intervention (12 Weeks)|Unwilling to adhere to study requirement|1
6064806|NCT00515827|9666668|FG000|Second Intervention (12 Weeks)|Consent withdraw|1
6064807|NCT00515827|9666669|FG001|Second Intervention (12 Weeks)|Consent withdraw|0
6064808|NCT00516048|9666690|FG000|Overall Study|Death|0
6064809|NCT00516048|9666691|FG001|Overall Study|Death|0
6064810|NCT00516048|9666692|FG002|Overall Study|Death|1
6064811|NCT00516048|9666690|FG000|Overall Study|Subject Decision|0
6064812|NCT00516048|9666691|FG001|Overall Study|Subject Decision|2
6064813|NCT00516048|9666692|FG002|Overall Study|Subject Decision|0
6064814|NCT00516074|9666702|FG000|Overall Study|Adverse Event|0
6064815|NCT00516074|9666703|FG001|Overall Study|Adverse Event|1
6064816|NCT00516074|9666702|FG000|Overall Study|Subject Decision|4
6064817|NCT00516074|9666703|FG001|Overall Study|Subject Decision|2
6064818|NCT00516074|9666702|FG000|Overall Study|Loss of Glucose Control|2
6064819|NCT00516074|9666703|FG001|Overall Study|Loss of Glucose Control|0
6064820|NCT00516139|9666709|FG000|Overall Study|Adverse Event|27
6064821|NCT00516139|9666709|FG000|Overall Study|Lost to Follow-up|1
6064822|NCT00516139|9666709|FG000|Overall Study|Protocol Violation|1
6064823|NCT00516139|9666709|FG000|Overall Study|Withdrawal by Subject|8
6064824|NCT00516139|9666709|FG000|Overall Study|Lack of Efficacy|1
6064825|NCT00516269|9666727|FG000|Overall Study|Adverse Event|2
5990651|NCT01915498|9582544|FG017|Main Analysis (Sept 2013 - Sept 2017)|Withdrawal by Subject|5
5990652|NCT01915498|9582545|FG018|Main Analysis (Sept 2013 - Sept 2017)|Withdrawal by Subject|0
5990653|NCT01915498|9582527|FG000|Main Analysis (Sept 2013 - Sept 2017)|Adverse Event|2
5990654|NCT01915498|9582528|FG001|Main Analysis (Sept 2013 - Sept 2017)|Adverse Event|0
5990655|NCT01915498|9582529|FG002|Main Analysis (Sept 2013 - Sept 2017)|Adverse Event|1
5990656|NCT01915498|9582530|FG003|Main Analysis (Sept 2013 - Sept 2017)|Adverse Event|1
5990657|NCT01915498|9582531|FG004|Main Analysis (Sept 2013 - Sept 2017)|Adverse Event|0
5990658|NCT01915498|9582532|FG005|Main Analysis (Sept 2013 - Sept 2017)|Adverse Event|0
5990659|NCT01915498|9582533|FG006|Main Analysis (Sept 2013 - Sept 2017)|Adverse Event|1
5990660|NCT01915498|9582534|FG007|Main Analysis (Sept 2013 - Sept 2017)|Adverse Event|4
5990661|NCT01915498|9582535|FG008|Main Analysis (Sept 2013 - Sept 2017)|Adverse Event|1
5990662|NCT01915498|9582536|FG009|Main Analysis (Sept 2013 - Sept 2017)|Adverse Event|2
5990663|NCT01915498|9582537|FG010|Main Analysis (Sept 2013 - Sept 2017)|Adverse Event|1
6045604|NCT00402363|9644825|FG003|Overall Study|"Captured as Other"|2
6064826|NCT00516269|9666728|FG001|Overall Study|Adverse Event|1
5990664|NCT01915498|9582538|FG011|Main Analysis (Sept 2013 - Sept 2017)|Adverse Event|1
5990665|NCT01915498|9582539|FG012|Main Analysis (Sept 2013 - Sept 2017)|Adverse Event|2
5990666|NCT01915498|9582540|FG013|Main Analysis (Sept 2013 - Sept 2017)|Adverse Event|4
5990667|NCT01915498|9582541|FG014|Main Analysis (Sept 2013 - Sept 2017)|Adverse Event|1
5990668|NCT01915498|9582542|FG015|Main Analysis (Sept 2013 - Sept 2017)|Adverse Event|4
5990669|NCT01915498|9582543|FG016|Main Analysis (Sept 2013 - Sept 2017)|Adverse Event|2
5990670|NCT01915498|9582544|FG017|Main Analysis (Sept 2013 - Sept 2017)|Adverse Event|16
5990671|NCT01915498|9582545|FG018|Main Analysis (Sept 2013 - Sept 2017)|Adverse Event|0
5990672|NCT01915498|9582527|FG000|Main Analysis (Sept 2013 - Sept 2017)|Disease Progression|1
5990673|NCT01915498|9582528|FG001|Main Analysis (Sept 2013 - Sept 2017)|Disease Progression|3
5990674|NCT01915498|9582529|FG002|Main Analysis (Sept 2013 - Sept 2017)|Disease Progression|3
5990675|NCT01915498|9582530|FG003|Main Analysis (Sept 2013 - Sept 2017)|Disease Progression|4
5990676|NCT01915498|9582531|FG004|Main Analysis (Sept 2013 - Sept 2017)|Disease Progression|2
5990677|NCT01915498|9582532|FG005|Main Analysis (Sept 2013 - Sept 2017)|Disease Progression|5
5990678|NCT01915498|9582533|FG006|Main Analysis (Sept 2013 - Sept 2017)|Disease Progression|5
5990679|NCT01915498|9582534|FG007|Main Analysis (Sept 2013 - Sept 2017)|Disease Progression|15
5990680|NCT01915498|9582535|FG008|Main Analysis (Sept 2013 - Sept 2017)|Disease Progression|4
5990681|NCT01915498|9582536|FG009|Main Analysis (Sept 2013 - Sept 2017)|Disease Progression|7
5990682|NCT01915498|9582537|FG010|Main Analysis (Sept 2013 - Sept 2017)|Disease Progression|3
5990683|NCT01915498|9582538|FG011|Main Analysis (Sept 2013 - Sept 2017)|Disease Progression|2
5990684|NCT01915498|9582539|FG012|Main Analysis (Sept 2013 - Sept 2017)|Disease Progression|3
5990685|NCT01915498|9582540|FG013|Main Analysis (Sept 2013 - Sept 2017)|Disease Progression|24
5990686|NCT01915498|9582541|FG014|Main Analysis (Sept 2013 - Sept 2017)|Disease Progression|14
5990687|NCT01915498|9582542|FG015|Main Analysis (Sept 2013 - Sept 2017)|Disease Progression|9
5990688|NCT01915498|9582543|FG016|Main Analysis (Sept 2013 - Sept 2017)|Disease Progression|8
5990689|NCT01915498|9582544|FG017|Main Analysis (Sept 2013 - Sept 2017)|Disease Progression|41
5990690|NCT01915498|9582545|FG018|Main Analysis (Sept 2013 - Sept 2017)|Disease Progression|0
5990691|NCT01915498|9582527|FG000|Main Analysis (Sept 2013 - Sept 2017)|Lost to Follow-up|0
5990692|NCT01915498|9582528|FG001|Main Analysis (Sept 2013 - Sept 2017)|Lost to Follow-up|0
5990693|NCT01915498|9582529|FG002|Main Analysis (Sept 2013 - Sept 2017)|Lost to Follow-up|0
5990694|NCT01915498|9582530|FG003|Main Analysis (Sept 2013 - Sept 2017)|Lost to Follow-up|0
5990695|NCT01915498|9582531|FG004|Main Analysis (Sept 2013 - Sept 2017)|Lost to Follow-up|0
5990696|NCT01915498|9582532|FG005|Main Analysis (Sept 2013 - Sept 2017)|Lost to Follow-up|0
5990697|NCT01915498|9582533|FG006|Main Analysis (Sept 2013 - Sept 2017)|Lost to Follow-up|0
5990698|NCT01915498|9582534|FG007|Main Analysis (Sept 2013 - Sept 2017)|Lost to Follow-up|0
5990699|NCT01915498|9582535|FG008|Main Analysis (Sept 2013 - Sept 2017)|Lost to Follow-up|0
5990700|NCT01915498|9582536|FG009|Main Analysis (Sept 2013 - Sept 2017)|Lost to Follow-up|0
5990701|NCT01915498|9582537|FG010|Main Analysis (Sept 2013 - Sept 2017)|Lost to Follow-up|1
5990702|NCT01915498|9582538|FG011|Main Analysis (Sept 2013 - Sept 2017)|Lost to Follow-up|0
5990703|NCT01915498|9582539|FG012|Main Analysis (Sept 2013 - Sept 2017)|Lost to Follow-up|0
5990704|NCT01915498|9582540|FG013|Main Analysis (Sept 2013 - Sept 2017)|Lost to Follow-up|0
5990705|NCT01915498|9582541|FG014|Main Analysis (Sept 2013 - Sept 2017)|Lost to Follow-up|0
5990706|NCT01915498|9582542|FG015|Main Analysis (Sept 2013 - Sept 2017)|Lost to Follow-up|0
5990707|NCT01915498|9582543|FG016|Main Analysis (Sept 2013 - Sept 2017)|Lost to Follow-up|0
5990708|NCT01915498|9582544|FG017|Main Analysis (Sept 2013 - Sept 2017)|Lost to Follow-up|0
5990709|NCT01915498|9582545|FG018|Main Analysis (Sept 2013 - Sept 2017)|Lost to Follow-up|0
5990710|NCT01915498|9582527|FG000|Main Analysis (Sept 2013 - Sept 2017)|Death|2
5990711|NCT01915498|9582528|FG001|Main Analysis (Sept 2013 - Sept 2017)|Death|1
5990712|NCT01915498|9582529|FG002|Main Analysis (Sept 2013 - Sept 2017)|Death|1
5990713|NCT01915498|9582530|FG003|Main Analysis (Sept 2013 - Sept 2017)|Death|1
5990714|NCT01915498|9582531|FG004|Main Analysis (Sept 2013 - Sept 2017)|Death|1
5990715|NCT01915498|9582532|FG005|Main Analysis (Sept 2013 - Sept 2017)|Death|2
5990716|NCT01915498|9582533|FG006|Main Analysis (Sept 2013 - Sept 2017)|Death|0
5990717|NCT01915498|9582534|FG007|Main Analysis (Sept 2013 - Sept 2017)|Death|1
5990718|NCT01915498|9582535|FG008|Main Analysis (Sept 2013 - Sept 2017)|Death|0
5990719|NCT01915498|9582536|FG009|Main Analysis (Sept 2013 - Sept 2017)|Death|0
5990720|NCT01915498|9582537|FG010|Main Analysis (Sept 2013 - Sept 2017)|Death|2
5990721|NCT01915498|9582538|FG011|Main Analysis (Sept 2013 - Sept 2017)|Death|0
5990722|NCT01915498|9582539|FG012|Main Analysis (Sept 2013 - Sept 2017)|Death|0
5990723|NCT01915498|9582540|FG013|Main Analysis (Sept 2013 - Sept 2017)|Death|4
5990724|NCT01915498|9582541|FG014|Main Analysis (Sept 2013 - Sept 2017)|Death|1
5990725|NCT01915498|9582542|FG015|Main Analysis (Sept 2013 - Sept 2017)|Death|4
5990726|NCT01915498|9582543|FG016|Main Analysis (Sept 2013 - Sept 2017)|Death|3
5990727|NCT01915498|9582544|FG017|Main Analysis (Sept 2013 - Sept 2017)|Death|16
5990728|NCT01915498|9582545|FG018|Main Analysis (Sept 2013 - Sept 2017)|Death|0
5990729|NCT01915498|9582527|FG000|Main Analysis (Sept 2013 - Sept 2017)|Protocol Violation|0
6045605|NCT00402597|9644846|FG000|Overall Study|Death|15
6064827|NCT00516269|9666727|FG000|Overall Study|Lost to Follow-up|0
6064828|NCT00516269|9666728|FG001|Overall Study|Lost to Follow-up|1
6064829|NCT00516269|9666727|FG000|Overall Study|Protocol Violation|0
6064830|NCT00516269|9666728|FG001|Overall Study|Protocol Violation|1
5990730|NCT01915498|9582528|FG001|Main Analysis (Sept 2013 - Sept 2017)|Protocol Violation|0
5990731|NCT01915498|9582529|FG002|Main Analysis (Sept 2013 - Sept 2017)|Protocol Violation|0
5990732|NCT01915498|9582530|FG003|Main Analysis (Sept 2013 - Sept 2017)|Protocol Violation|0
5990733|NCT01915498|9582531|FG004|Main Analysis (Sept 2013 - Sept 2017)|Protocol Violation|1
5990734|NCT01915498|9582532|FG005|Main Analysis (Sept 2013 - Sept 2017)|Protocol Violation|0
5990735|NCT01915498|9582533|FG006|Main Analysis (Sept 2013 - Sept 2017)|Protocol Violation|0
5990736|NCT01915498|9582534|FG007|Main Analysis (Sept 2013 - Sept 2017)|Protocol Violation|0
5990737|NCT01915498|9582535|FG008|Main Analysis (Sept 2013 - Sept 2017)|Protocol Violation|0
5990738|NCT01915498|9582536|FG009|Main Analysis (Sept 2013 - Sept 2017)|Protocol Violation|1
5990739|NCT01915498|9582537|FG010|Main Analysis (Sept 2013 - Sept 2017)|Protocol Violation|0
5990740|NCT01915498|9582538|FG011|Main Analysis (Sept 2013 - Sept 2017)|Protocol Violation|0
5990741|NCT01915498|9582539|FG012|Main Analysis (Sept 2013 - Sept 2017)|Protocol Violation|0
5990742|NCT01915498|9582540|FG013|Main Analysis (Sept 2013 - Sept 2017)|Protocol Violation|0
5990743|NCT01915498|9582541|FG014|Main Analysis (Sept 2013 - Sept 2017)|Protocol Violation|0
5990744|NCT01915498|9582542|FG015|Main Analysis (Sept 2013 - Sept 2017)|Protocol Violation|0
5990745|NCT01915498|9582543|FG016|Main Analysis (Sept 2013 - Sept 2017)|Protocol Violation|0
5990746|NCT01915498|9582544|FG017|Main Analysis (Sept 2013 - Sept 2017)|Protocol Violation|0
5990747|NCT01915498|9582545|FG018|Main Analysis (Sept 2013 - Sept 2017)|Protocol Violation|0
5990748|NCT01915498|9582527|FG000|Main Analysis (Sept 2013 - Sept 2017)|Miscellaneous|0
5990749|NCT01915498|9582528|FG001|Main Analysis (Sept 2013 - Sept 2017)|Miscellaneous|1
5990750|NCT01915498|9582529|FG002|Main Analysis (Sept 2013 - Sept 2017)|Miscellaneous|2
5990751|NCT01915498|9582530|FG003|Main Analysis (Sept 2013 - Sept 2017)|Miscellaneous|0
5990752|NCT01915498|9582531|FG004|Main Analysis (Sept 2013 - Sept 2017)|Miscellaneous|0
5990753|NCT01915498|9582532|FG005|Main Analysis (Sept 2013 - Sept 2017)|Miscellaneous|0
5990754|NCT01915498|9582533|FG006|Main Analysis (Sept 2013 - Sept 2017)|Miscellaneous|0
5990755|NCT01915498|9582534|FG007|Main Analysis (Sept 2013 - Sept 2017)|Miscellaneous|1
5990756|NCT01915498|9582535|FG008|Main Analysis (Sept 2013 - Sept 2017)|Miscellaneous|1
5990757|NCT01915498|9582536|FG009|Main Analysis (Sept 2013 - Sept 2017)|Miscellaneous|1
6064831|NCT00516295|9666737|FG000|Overall Study|Lack of Efficacy|2
6064832|NCT00516295|9666738|FG001|Overall Study|Lack of Efficacy|0
6064833|NCT00516295|9666739|FG002|Overall Study|Lack of Efficacy|0
6064834|NCT00516295|9666737|FG000|Overall Study|Ineligible|1
6064835|NCT00516295|9666738|FG001|Overall Study|Ineligible|0
5990758|NCT01915498|9582537|FG010|Main Analysis (Sept 2013 - Sept 2017)|Miscellaneous|0
6146144|NCT01075321|9780714|FG003|Overall Study|Protocol Violation|0
6146145|NCT01075321|9780711|FG000|Overall Study|Treatment Incomplete due to progression|1
6146146|NCT01075321|9780712|FG001|Overall Study|Treatment Incomplete due to progression|0
6146147|NCT01075321|9780713|FG002|Overall Study|Treatment Incomplete due to progression|0
6146148|NCT01075321|9780714|FG003|Overall Study|Treatment Incomplete due to progression|0
6146149|NCT01075321|9780711|FG000|Overall Study|Ineligible (miscalculated lab value)|0
6146150|NCT01075321|9780712|FG001|Overall Study|Ineligible (miscalculated lab value)|0
6146151|NCT01075321|9780713|FG002|Overall Study|Ineligible (miscalculated lab value)|0
5990759|NCT01915498|9582538|FG011|Main Analysis (Sept 2013 - Sept 2017)|Miscellaneous|1
5990760|NCT01915498|9582539|FG012|Main Analysis (Sept 2013 - Sept 2017)|Miscellaneous|0
5990761|NCT01915498|9582540|FG013|Main Analysis (Sept 2013 - Sept 2017)|Miscellaneous|1
5990762|NCT01915498|9582541|FG014|Main Analysis (Sept 2013 - Sept 2017)|Miscellaneous|0
5990763|NCT01915498|9582542|FG015|Main Analysis (Sept 2013 - Sept 2017)|Miscellaneous|1
5990764|NCT01915498|9582543|FG016|Main Analysis (Sept 2013 - Sept 2017)|Miscellaneous|4
5990765|NCT01915498|9582544|FG017|Main Analysis (Sept 2013 - Sept 2017)|Miscellaneous|8
5990766|NCT01915498|9582545|FG018|Main Analysis (Sept 2013 - Sept 2017)|Miscellaneous|0
5990767|NCT01915498|9582527|FG000|Main Analysis (Sept 2013 - Sept 2017)|Bone Marrow Transplant (BMT)|1
5990768|NCT01915498|9582528|FG001|Main Analysis (Sept 2013 - Sept 2017)|Bone Marrow Transplant (BMT)|2
5990769|NCT01915498|9582529|FG002|Main Analysis (Sept 2013 - Sept 2017)|Bone Marrow Transplant (BMT)|0
5990770|NCT01915498|9582530|FG003|Main Analysis (Sept 2013 - Sept 2017)|Bone Marrow Transplant (BMT)|1
5990771|NCT01915498|9582531|FG004|Main Analysis (Sept 2013 - Sept 2017)|Bone Marrow Transplant (BMT)|0
5990772|NCT01915498|9582532|FG005|Main Analysis (Sept 2013 - Sept 2017)|Bone Marrow Transplant (BMT)|0
5990773|NCT01915498|9582533|FG006|Main Analysis (Sept 2013 - Sept 2017)|Bone Marrow Transplant (BMT)|1
5990774|NCT01915498|9582534|FG007|Main Analysis (Sept 2013 - Sept 2017)|Bone Marrow Transplant (BMT)|0
5990775|NCT01915498|9582535|FG008|Main Analysis (Sept 2013 - Sept 2017)|Bone Marrow Transplant (BMT)|0
5990776|NCT01915498|9582536|FG009|Main Analysis (Sept 2013 - Sept 2017)|Bone Marrow Transplant (BMT)|0
5990777|NCT01915498|9582537|FG010|Main Analysis (Sept 2013 - Sept 2017)|Bone Marrow Transplant (BMT)|1
5990778|NCT01915498|9582538|FG011|Main Analysis (Sept 2013 - Sept 2017)|Bone Marrow Transplant (BMT)|0
5990779|NCT01915498|9582539|FG012|Main Analysis (Sept 2013 - Sept 2017)|Bone Marrow Transplant (BMT)|1
5990780|NCT01915498|9582540|FG013|Main Analysis (Sept 2013 - Sept 2017)|Bone Marrow Transplant (BMT)|6
5990781|NCT01915498|9582541|FG014|Main Analysis (Sept 2013 - Sept 2017)|Bone Marrow Transplant (BMT)|5
5990782|NCT01915498|9582542|FG015|Main Analysis (Sept 2013 - Sept 2017)|Bone Marrow Transplant (BMT)|2
5990783|NCT01915498|9582543|FG016|Main Analysis (Sept 2013 - Sept 2017)|Bone Marrow Transplant (BMT)|2
5990784|NCT01915498|9582544|FG017|Main Analysis (Sept 2013 - Sept 2017)|Bone Marrow Transplant (BMT)|9
5990785|NCT01915498|9582545|FG018|Main Analysis (Sept 2013 - Sept 2017)|Bone Marrow Transplant (BMT)|0
5990786|NCT01915498|9582527|FG000|Main Analysis (Sept 2013 - Sept 2017)|Development of Intercurrent Condition|0
5990787|NCT01915498|9582528|FG001|Main Analysis (Sept 2013 - Sept 2017)|Development of Intercurrent Condition|0
5990788|NCT01915498|9582529|FG002|Main Analysis (Sept 2013 - Sept 2017)|Development of Intercurrent Condition|0
5990789|NCT01915498|9582530|FG003|Main Analysis (Sept 2013 - Sept 2017)|Development of Intercurrent Condition|0
5990790|NCT01915498|9582531|FG004|Main Analysis (Sept 2013 - Sept 2017)|Development of Intercurrent Condition|0
5990791|NCT01915498|9582532|FG005|Main Analysis (Sept 2013 - Sept 2017)|Development of Intercurrent Condition|0
5990792|NCT01915498|9582533|FG006|Main Analysis (Sept 2013 - Sept 2017)|Development of Intercurrent Condition|0
5990793|NCT01915498|9582534|FG007|Main Analysis (Sept 2013 - Sept 2017)|Development of Intercurrent Condition|0
5990794|NCT01915498|9582535|FG008|Main Analysis (Sept 2013 - Sept 2017)|Development of Intercurrent Condition|0
5990795|NCT01915498|9582536|FG009|Main Analysis (Sept 2013 - Sept 2017)|Development of Intercurrent Condition|0
5990796|NCT01915498|9582537|FG010|Main Analysis (Sept 2013 - Sept 2017)|Development of Intercurrent Condition|1
5990797|NCT01915498|9582538|FG011|Main Analysis (Sept 2013 - Sept 2017)|Development of Intercurrent Condition|0
5990798|NCT01915498|9582539|FG012|Main Analysis (Sept 2013 - Sept 2017)|Development of Intercurrent Condition|0
5990799|NCT01915498|9582540|FG013|Main Analysis (Sept 2013 - Sept 2017)|Development of Intercurrent Condition|1
5990800|NCT01915498|9582541|FG014|Main Analysis (Sept 2013 - Sept 2017)|Development of Intercurrent Condition|0
5990801|NCT01915498|9582542|FG015|Main Analysis (Sept 2013 - Sept 2017)|Development of Intercurrent Condition|0
5990802|NCT01915498|9582543|FG016|Main Analysis (Sept 2013 - Sept 2017)|Development of Intercurrent Condition|1
5990803|NCT01915498|9582544|FG017|Main Analysis (Sept 2013 - Sept 2017)|Development of Intercurrent Condition|1
5990804|NCT01915498|9582545|FG018|Main Analysis (Sept 2013 - Sept 2017)|Development of Intercurrent Condition|0
5990805|NCT01915498|9582527|FG000|Main Analysis (Sept 2013 - Sept 2017)|Other Medical Condition|1
5990806|NCT01915498|9582528|FG001|Main Analysis (Sept 2013 - Sept 2017)|Other Medical Condition|0
5990807|NCT01915498|9582529|FG002|Main Analysis (Sept 2013 - Sept 2017)|Other Medical Condition|0
5990808|NCT01915498|9582530|FG003|Main Analysis (Sept 2013 - Sept 2017)|Other Medical Condition|0
5990809|NCT01915498|9582531|FG004|Main Analysis (Sept 2013 - Sept 2017)|Other Medical Condition|0
5990810|NCT01915498|9582532|FG005|Main Analysis (Sept 2013 - Sept 2017)|Other Medical Condition|1
5990811|NCT01915498|9582533|FG006|Main Analysis (Sept 2013 - Sept 2017)|Other Medical Condition|0
5990812|NCT01915498|9582534|FG007|Main Analysis (Sept 2013 - Sept 2017)|Other Medical Condition|0
5990813|NCT01915498|9582535|FG008|Main Analysis (Sept 2013 - Sept 2017)|Other Medical Condition|0
5990814|NCT01915498|9582536|FG009|Main Analysis (Sept 2013 - Sept 2017)|Other Medical Condition|0
5990815|NCT01915498|9582537|FG010|Main Analysis (Sept 2013 - Sept 2017)|Other Medical Condition|0
5990816|NCT01915498|9582538|FG011|Main Analysis (Sept 2013 - Sept 2017)|Other Medical Condition|0
5990817|NCT01915498|9582539|FG012|Main Analysis (Sept 2013 - Sept 2017)|Other Medical Condition|0
5990818|NCT01915498|9582540|FG013|Main Analysis (Sept 2013 - Sept 2017)|Other Medical Condition|0
5990819|NCT01915498|9582541|FG014|Main Analysis (Sept 2013 - Sept 2017)|Other Medical Condition|1
5990820|NCT01915498|9582542|FG015|Main Analysis (Sept 2013 - Sept 2017)|Other Medical Condition|0
5990821|NCT01915498|9582543|FG016|Main Analysis (Sept 2013 - Sept 2017)|Other Medical Condition|0
5990822|NCT01915498|9582544|FG017|Main Analysis (Sept 2013 - Sept 2017)|Other Medical Condition|2
5990823|NCT01915498|9582545|FG018|Main Analysis (Sept 2013 - Sept 2017)|Other Medical Condition|0
5990824|NCT01915498|9582527|FG000|Main Analysis (Sept 2013 - Sept 2017)|Physician Decision|0
5990825|NCT01915498|9582528|FG001|Main Analysis (Sept 2013 - Sept 2017)|Physician Decision|0
5990826|NCT01915498|9582529|FG002|Main Analysis (Sept 2013 - Sept 2017)|Physician Decision|0
5990827|NCT01915498|9582530|FG003|Main Analysis (Sept 2013 - Sept 2017)|Physician Decision|0
5990828|NCT01915498|9582531|FG004|Main Analysis (Sept 2013 - Sept 2017)|Physician Decision|0
5990829|NCT01915498|9582532|FG005|Main Analysis (Sept 2013 - Sept 2017)|Physician Decision|1
5990830|NCT01915498|9582533|FG006|Main Analysis (Sept 2013 - Sept 2017)|Physician Decision|0
6045606|NCT00402597|9644847|FG001|Overall Study|Death|7
5990831|NCT01915498|9582534|FG007|Main Analysis (Sept 2013 - Sept 2017)|Physician Decision|0
5990832|NCT01915498|9582535|FG008|Main Analysis (Sept 2013 - Sept 2017)|Physician Decision|0
5990833|NCT01915498|9582536|FG009|Main Analysis (Sept 2013 - Sept 2017)|Physician Decision|2
5990834|NCT01915498|9582537|FG010|Main Analysis (Sept 2013 - Sept 2017)|Physician Decision|0
5990835|NCT01915498|9582538|FG011|Main Analysis (Sept 2013 - Sept 2017)|Physician Decision|0
5990836|NCT01915498|9582539|FG012|Main Analysis (Sept 2013 - Sept 2017)|Physician Decision|0
5990837|NCT01915498|9582540|FG013|Main Analysis (Sept 2013 - Sept 2017)|Physician Decision|1
5990838|NCT01915498|9582541|FG014|Main Analysis (Sept 2013 - Sept 2017)|Physician Decision|2
5990839|NCT01915498|9582542|FG015|Main Analysis (Sept 2013 - Sept 2017)|Physician Decision|1
5990840|NCT01915498|9582543|FG016|Main Analysis (Sept 2013 - Sept 2017)|Physician Decision|2
5990841|NCT01915498|9582544|FG017|Main Analysis (Sept 2013 - Sept 2017)|Physician Decision|2
5990842|NCT01915498|9582545|FG018|Main Analysis (Sept 2013 - Sept 2017)|Physician Decision|0
5990843|NCT01915498|9582527|FG000|Safety Follow-up (Sept 2017 to July 2019|Ongoing Treatment|0
5990844|NCT01915498|9582528|FG001|Safety Follow-up (Sept 2017 to July 2019|Ongoing Treatment|0
5990845|NCT01915498|9582529|FG002|Safety Follow-up (Sept 2017 to July 2019|Ongoing Treatment|0
5990846|NCT01915498|9582530|FG003|Safety Follow-up (Sept 2017 to July 2019|Ongoing Treatment|0
5990847|NCT01915498|9582531|FG004|Safety Follow-up (Sept 2017 to July 2019|Ongoing Treatment|0
5990848|NCT01915498|9582532|FG005|Safety Follow-up (Sept 2017 to July 2019|Ongoing Treatment|0
5990849|NCT01915498|9582533|FG006|Safety Follow-up (Sept 2017 to July 2019|Ongoing Treatment|0
5990850|NCT01915498|9582534|FG007|Safety Follow-up (Sept 2017 to July 2019|Ongoing Treatment|0
5990851|NCT01915498|9582535|FG008|Safety Follow-up (Sept 2017 to July 2019|Ongoing Treatment|0
5990852|NCT01915498|9582536|FG009|Safety Follow-up (Sept 2017 to July 2019|Ongoing Treatment|0
5990853|NCT01915498|9582537|FG010|Safety Follow-up (Sept 2017 to July 2019|Ongoing Treatment|0
5990854|NCT01915498|9582538|FG011|Safety Follow-up (Sept 2017 to July 2019|Ongoing Treatment|0
5990855|NCT01915498|9582539|FG012|Safety Follow-up (Sept 2017 to July 2019|Ongoing Treatment|0
5990856|NCT01915498|9582540|FG013|Safety Follow-up (Sept 2017 to July 2019|Ongoing Treatment|0
5990857|NCT01915498|9582541|FG014|Safety Follow-up (Sept 2017 to July 2019|Ongoing Treatment|0
5990858|NCT01915498|9582542|FG015|Safety Follow-up (Sept 2017 to July 2019|Ongoing Treatment|0
5990859|NCT01915498|9582543|FG016|Safety Follow-up (Sept 2017 to July 2019|Ongoing Treatment|0
5990860|NCT01915498|9582544|FG017|Safety Follow-up (Sept 2017 to July 2019|Ongoing Treatment|0
5990861|NCT01915498|9582545|FG018|Safety Follow-up (Sept 2017 to July 2019|Ongoing Treatment|2
5990862|NCT01909934|9582633|FG000|Overall Study|Ongoing|23
5990863|NCT01909934|9582633|FG000|Overall Study|Withdrawal by Subject|3
5990864|NCT01909934|9582633|FG000|Overall Study|Lost to Follow-up|1
5990865|NCT01909934|9582633|FG000|Overall Study|Withdrawal of Informed Consent|1
5990866|NCT01909934|9582633|FG000|Overall Study|Death|22
5990867|NCT01841359|9582637|FG000|Overall Study|Underwent reversal of Roux-en-Y gastric bypass (RYGB)|2
5990868|NCT01841359|9582637|FG000|Overall Study|Concommitant medical issues|2
5990869|NCT01841359|9582637|FG000|Overall Study|Adverse Event|3
5990870|NCT01841359|9582637|FG000|Overall Study|Did not receive study drug at visit 4 prior to mixed meal testing|1
5990871|NCT01459666|9582646|FG000|Overall Study|PI left institution|5
5990872|NCT01459666|9582647|FG001|Overall Study|PI left institution|4
5990873|NCT01369199|9582653|FG000|Overall Study|Withdrawal by Subject|1
5990874|NCT01369199|9582653|FG000|Overall Study|Lost to Follow-up|2
5990875|NCT01368497|9582657|FG000|Overall Study|Lost to Follow-up|2
5990876|NCT01065454|9582665|FG000|Treatment|Adverse Event|7
5990877|NCT01065454|9582666|FG001|Treatment|Adverse Event|4
5990878|NCT01065454|9582667|FG002|Treatment|Adverse Event|3
5990879|NCT01065454|9582668|FG003|Treatment|Adverse Event|6
5990880|NCT01065454|9582665|FG000|Treatment|Death|1
5990881|NCT01065454|9582666|FG001|Treatment|Death|0
5990882|NCT01065454|9582667|FG002|Treatment|Death|0
5990883|NCT01065454|9582668|FG003|Treatment|Death|0
5990884|NCT01065454|9582665|FG000|Treatment|Non-compliance|1
5990885|NCT01065454|9582666|FG001|Treatment|Non-compliance|0
5990886|NCT01065454|9582667|FG002|Treatment|Non-compliance|0
5990887|NCT01065454|9582668|FG003|Treatment|Non-compliance|1
5990888|NCT01065454|9582665|FG000|Treatment|Protocol Decision|0
5990889|NCT01065454|9582666|FG001|Treatment|Protocol Decision|0
5990890|NCT01065454|9582667|FG002|Treatment|Protocol Decision|3
5990891|NCT01065454|9582668|FG003|Treatment|Protocol Decision|2
5990892|NCT01065454|9582665|FG000|Treatment|Protocol Violation|1
5990893|NCT01065454|9582666|FG001|Treatment|Protocol Violation|0
5990894|NCT01065454|9582667|FG002|Treatment|Protocol Violation|1
5990895|NCT01065454|9582668|FG003|Treatment|Protocol Violation|0
5990896|NCT01065454|9582665|FG000|Treatment|Withdrawal by Subject|3
5990897|NCT01065454|9582666|FG001|Treatment|Withdrawal by Subject|1
5990898|NCT01065454|9582667|FG002|Treatment|Withdrawal by Subject|2
5990899|NCT01065454|9582668|FG003|Treatment|Withdrawal by Subject|3
5990900|NCT01065454|9582665|FG000|Follow up|Adverse Event|1
5990901|NCT01065454|9582666|FG001|Follow up|Adverse Event|0
5990902|NCT01065454|9582667|FG002|Follow up|Adverse Event|0
5990903|NCT01065454|9582668|FG003|Follow up|Adverse Event|1
5990904|NCT01065454|9582665|FG000|Follow up|Death|0
5990905|NCT01065454|9582666|FG001|Follow up|Death|1
5990906|NCT01065454|9582667|FG002|Follow up|Death|1
5990907|NCT01065454|9582668|FG003|Follow up|Death|0
5990908|NCT01065454|9582665|FG000|Follow up|Lost to Follow-up|0
5990909|NCT01065454|9582666|FG001|Follow up|Lost to Follow-up|0
5990910|NCT01065454|9582667|FG002|Follow up|Lost to Follow-up|0
5990911|NCT01065454|9582668|FG003|Follow up|Lost to Follow-up|1
5990912|NCT01065454|9582665|FG000|Follow up|Progressive disease|0
5990913|NCT01065454|9582666|FG001|Follow up|Progressive disease|0
5990914|NCT01065454|9582667|FG002|Follow up|Progressive disease|0
5990915|NCT01065454|9582668|FG003|Follow up|Progressive disease|1
5990916|NCT01065454|9582665|FG000|Follow up|Withdrawal by Subject|1
5990917|NCT01065454|9582666|FG001|Follow up|Withdrawal by Subject|1
5990918|NCT01065454|9582667|FG002|Follow up|Withdrawal by Subject|1
5990919|NCT01065454|9582668|FG003|Follow up|Withdrawal by Subject|0
5990920|NCT01065454|9582665|FG000|Follow up|study ongoing|37
5990921|NCT01065454|9582666|FG001|Follow up|study ongoing|22
5990922|NCT01065454|9582667|FG002|Follow up|study ongoing|15
5990923|NCT01065454|9582668|FG003|Follow up|study ongoing|41
5990924|NCT00977574|9582681|FG000|Overall Study|Never Treated|4
5990925|NCT00977574|9582682|FG001|Overall Study|Never Treated|2
5990926|NCT00977574|9582683|FG002|Overall Study|Never Treated|4
6045607|NCT00402597|9644848|FG002|Overall Study|Death|6
6045608|NCT00402597|9644849|FG003|Overall Study|Death|4
6045609|NCT00402597|9644850|FG004|Overall Study|Death|6
6045610|NCT00402597|9644846|FG000|Overall Study|Adverse Event|81
6045611|NCT00402597|9644847|FG001|Overall Study|Adverse Event|18
6064836|NCT00516295|9666739|FG002|Overall Study|Ineligible|0
6064837|NCT00516321|9666749|FG000|Open-label (OL) Pre-Antiviral Treatment|Lack of Efficacy|11
6064838|NCT00516321|9666750|FG001|Open-label (OL) Pre-Antiviral Treatment|Lack of Efficacy|0
6064839|NCT00516321|9666751|FG002|Open-label (OL) Pre-Antiviral Treatment|Lack of Efficacy|0
6064840|NCT00516321|9666749|FG000|Open-label (OL) Pre-Antiviral Treatment|Adverse Event|9
6064841|NCT00516321|9666750|FG001|Open-label (OL) Pre-Antiviral Treatment|Adverse Event|0
6064842|NCT00516321|9666751|FG002|Open-label (OL) Pre-Antiviral Treatment|Adverse Event|0
6064843|NCT00516321|9666749|FG000|Open-label (OL) Pre-Antiviral Treatment|Protocol Violation|1
6064844|NCT00516321|9666750|FG001|Open-label (OL) Pre-Antiviral Treatment|Protocol Violation|0
6064845|NCT00516321|9666751|FG002|Open-label (OL) Pre-Antiviral Treatment|Protocol Violation|0
6064846|NCT00516321|9666749|FG000|Open-label (OL) Pre-Antiviral Treatment|Lost to Follow-up|2
6064847|NCT00516321|9666750|FG001|Open-label (OL) Pre-Antiviral Treatment|Lost to Follow-up|0
6064848|NCT00516321|9666751|FG002|Open-label (OL) Pre-Antiviral Treatment|Lost to Follow-up|0
6064849|NCT00516321|9666749|FG000|Open-label (OL) Pre-Antiviral Treatment|Investigator Discretion|7
6064850|NCT00516321|9666750|FG001|Open-label (OL) Pre-Antiviral Treatment|Investigator Discretion|0
6064851|NCT00516321|9666751|FG002|Open-label (OL) Pre-Antiviral Treatment|Investigator Discretion|0
6064852|NCT00516321|9666749|FG000|Open-label (OL) Pre-Antiviral Treatment|Withdrawal by Subject|3
6064853|NCT00516321|9666750|FG001|Open-label (OL) Pre-Antiviral Treatment|Withdrawal by Subject|0
6064854|NCT00516321|9666751|FG002|Open-label (OL) Pre-Antiviral Treatment|Withdrawal by Subject|0
6064855|NCT00516321|9666749|FG000|Double-blind (DB) Antiviral Treatment|Lost to Follow-up|0
6045612|NCT00402597|9644848|FG002|Overall Study|Adverse Event|106
6045613|NCT00402597|9644849|FG003|Overall Study|Adverse Event|39
6045614|NCT00402597|9644850|FG004|Overall Study|Adverse Event|71
6045615|NCT00402597|9644846|FG000|Overall Study|Lost to Follow-up|8
6045616|NCT00402597|9644847|FG001|Overall Study|Lost to Follow-up|1
6045617|NCT00402597|9644848|FG002|Overall Study|Lost to Follow-up|8
5990927|NCT05096312|9582693|FG000|Overall Study|Lost to Follow-up|2
5990928|NCT05096312|9582694|FG001|Overall Study|Lost to Follow-up|4
5990929|NCT05096312|9582693|FG000|Overall Study|Adverse Event|1
5990930|NCT05096312|9582694|FG001|Overall Study|Adverse Event|0
5990931|NCT02853344|9582702|FG000|Overall Study|Death|23
5990932|NCT02853344|9582703|FG001|Overall Study|Death|84
5990933|NCT02853344|9582702|FG000|Overall Study|Withdrawal by Subject|1
5990934|NCT02853344|9582703|FG001|Overall Study|Withdrawal by Subject|3
5990935|NCT02853344|9582702|FG000|Overall Study|Ongoing|86
5990936|NCT02853344|9582703|FG001|Overall Study|Ongoing|78
5990937|NCT03560258|9582714|FG000|Overall Study|Lost to Follow-up|3
5990938|NCT03560258|9582715|FG001|Overall Study|Lost to Follow-up|0
5990939|NCT03560258|9582716|FG002|Overall Study|Lost to Follow-up|0
5990940|NCT03560258|9582714|FG000|Overall Study|Protocol Violation|0
6064856|NCT00516321|9666750|FG001|Double-blind (DB) Antiviral Treatment|Lost to Follow-up|12
6064857|NCT00516321|9666751|FG002|Double-blind (DB) Antiviral Treatment|Lost to Follow-up|22
6064858|NCT00516321|9666749|FG000|Double-blind (DB) Antiviral Treatment|Withdrawal by Subject|0
6064859|NCT00516321|9666750|FG001|Double-blind (DB) Antiviral Treatment|Withdrawal by Subject|13
6064860|NCT00516321|9666751|FG002|Double-blind (DB) Antiviral Treatment|Withdrawal by Subject|18
6064861|NCT00516321|9666749|FG000|Double-blind (DB) Antiviral Treatment|Adverse Event|0
6064862|NCT00516321|9666750|FG001|Double-blind (DB) Antiviral Treatment|Adverse Event|8
6064863|NCT00516321|9666751|FG002|Double-blind (DB) Antiviral Treatment|Adverse Event|13
6064864|NCT00516321|9666749|FG000|Double-blind (DB) Antiviral Treatment|Protocol Violation|0
6064865|NCT00516321|9666750|FG001|Double-blind (DB) Antiviral Treatment|Protocol Violation|0
6064866|NCT00516321|9666751|FG002|Double-blind (DB) Antiviral Treatment|Protocol Violation|1
6064867|NCT00516321|9666749|FG000|Double-blind (DB) Antiviral Treatment|Physician Decision|0
6064868|NCT00516321|9666750|FG001|Double-blind (DB) Antiviral Treatment|Physician Decision|2
6064869|NCT00516321|9666751|FG002|Double-blind (DB) Antiviral Treatment|Physician Decision|0
6064870|NCT00516386|9666759|FG000|Overall Study|not interested in the study|4
6064871|NCT00516386|9666759|FG000|Overall Study|Lost to Follow-up|2
6064872|NCT00516893|9666772|FG000|Overall Study|Lost to Follow-up|4
6064873|NCT00516893|9666772|FG000|Overall Study|Adverse Event|3
6064874|NCT00516893|9666772|FG000|Overall Study|Withdrawal by Subject|2
6064875|NCT00516893|9666772|FG000|Overall Study|Noncompliance|2
6064876|NCT00516893|9666772|FG000|Overall Study|Death|1
6064877|NCT00516893|9666772|FG000|Overall Study|Persistent Antibodies per Protocol|6
6064878|NCT00516893|9666772|FG000|Overall Study|Relocated|1
6064879|NCT00516893|9666772|FG000|Overall Study|Pregnancy|1
6064880|NCT00516893|9666772|FG000|Overall Study|Received Medication From Another Study|1
6064881|NCT00516906|9666778|FG000|Overall Study|Final Dressing Removal Data not captured|6
6064882|NCT00516906|9666779|FG001|Overall Study|Final Dressing Removal Data not captured|2
6064883|NCT00517296|9666798|FG000|Overall Study|Withdrawal by Subject|1
6064884|NCT00517296|9666799|FG001|Overall Study|Withdrawal by Subject|0
6064885|NCT00517413|9666805|FG000|Overall Study|Adverse Event|7
6064886|NCT00517413|9666805|FG000|Overall Study|Death|13
6064887|NCT00517413|9666805|FG000|Overall Study|Protocol Violation|15
6064888|NCT00517413|9666805|FG000|Overall Study|Withdrawal by Subject|2
6064889|NCT00517413|9666805|FG000|Overall Study|Failure to return|1
6064890|NCT00517413|9666805|FG000|Overall Study|Other-Reasons|23
6064891|NCT00517634|9666866|FG000|Second Treatment Period|Withdrawal by Subject|0
6064892|NCT00517634|9666867|FG001|Second Treatment Period|Withdrawal by Subject|0
6064893|NCT00517634|9666868|FG002|Second Treatment Period|Withdrawal by Subject|0
6064894|NCT00517634|9666869|FG003|Second Treatment Period|Withdrawal by Subject|0
6064895|NCT00517634|9666870|FG004|Second Treatment Period|Withdrawal by Subject|1
6064896|NCT00517634|9666871|FG005|Second Treatment Period|Withdrawal by Subject|0
6064897|NCT00517751|9666879|FG000|Overall Study|Death|3
6064898|NCT00517751|9666879|FG000|Overall Study|Withdrawal by Subject|37
6064899|NCT00517751|9666879|FG000|Overall Study|Lost to Follow-up|4
6064900|NCT00517751|9666879|FG000|Overall Study|patient not over due|6
6064901|NCT00517751|9666879|FG000|Overall Study|Patient not due for visit|76
6064902|NCT00517751|9666879|FG000|Overall Study|Missing|3
6064903|NCT00517829|9666885|FG000|Overall Study|Adverse Event|22
6064904|NCT00517829|9666886|FG001|Overall Study|Adverse Event|34
6064905|NCT00517829|9666885|FG000|Overall Study|Disease Progression|39
6064906|NCT00517829|9666886|FG001|Overall Study|Disease Progression|32
6064907|NCT00517829|9666885|FG000|Overall Study|Patient Request|6
6064908|NCT00517829|9666886|FG001|Overall Study|Patient Request|5
6064909|NCT00517829|9666885|FG000|Overall Study|Investigator Request|5
6064910|NCT00517829|9666886|FG001|Overall Study|Investigator Request|3
6064911|NCT00517829|9666885|FG000|Overall Study|Other|3
6064912|NCT00517829|9666886|FG001|Overall Study|Other|1
6064913|NCT00517881|9666892|FG000|Overall Study|Protocol Violation|2
6064914|NCT00517881|9666892|FG000|Overall Study|Adverse Event|1
6064915|NCT00517881|9666892|FG000|Overall Study|Renal transplantation|2
6064916|NCT00517933|9666898|FG000|Period 1|Death|2
6064917|NCT00517933|9666899|FG001|Period 1|Death|1
6064918|NCT00517933|9666898|FG000|Period 1|Adverse Event|4
5990941|NCT03560258|9582715|FG001|Overall Study|Protocol Violation|1
6064919|NCT00517933|9666899|FG001|Period 1|Adverse Event|4
6064920|NCT00517933|9666898|FG000|Period 1|Lost to Follow-up|2
6064921|NCT00517933|9666899|FG001|Period 1|Lost to Follow-up|0
6064922|NCT00517933|9666898|FG000|Period 1|Underwent lung transplant|0
6064923|NCT00517933|9666899|FG001|Period 1|Underwent lung transplant|1
6064924|NCT00517933|9666898|FG000|Period 2|Death|2
6064925|NCT00517933|9666899|FG001|Period 2|Death|4
6064926|NCT00517933|9666898|FG000|Period 2|Adverse Event|2
6064927|NCT00517933|9666899|FG001|Period 2|Adverse Event|4
6064928|NCT00517933|9666898|FG000|Period 2|Physician Decision|1
6064929|NCT00517933|9666899|FG001|Period 2|Physician Decision|0
6064930|NCT00517933|9666898|FG000|Period 2|Withdrawal by Subject|1
6064931|NCT00517933|9666899|FG001|Period 2|Withdrawal by Subject|3
6064932|NCT00517933|9666898|FG000|Period 2|Underwent lung transplant|0
6064933|NCT00517933|9666899|FG001|Period 2|Underwent lung transplant|2
6064934|NCT00518011|9666910|FG000|Overall Study|Death|1
6064935|NCT00518011|9666911|FG001|Overall Study|Death|1
6064936|NCT00518011|9666910|FG000|Overall Study|Adverse Event|2
6064937|NCT00518011|9666911|FG001|Overall Study|Adverse Event|3
6064938|NCT00518011|9666910|FG000|Overall Study|Disease Progression|2
6064939|NCT00518011|9666911|FG001|Overall Study|Disease Progression|2
6064940|NCT00518011|9666910|FG000|Overall Study|Other Reasons|3
6064941|NCT00518011|9666911|FG001|Overall Study|Other Reasons|2
6064942|NCT00518011|9666910|FG000|Overall Study|Withdrawal by Subject|1
6064943|NCT00518011|9666911|FG001|Overall Study|Withdrawal by Subject|0
5990942|NCT03560258|9582716|FG002|Overall Study|Protocol Violation|0
5990943|NCT03560258|9582714|FG000|Overall Study|Withdrawal by Subject|0
6146152|NCT01075321|9780714|FG003|Overall Study|Ineligible (miscalculated lab value)|1
6146153|NCT01075412|9780741|FG000|Overall Study|Withdrawal by Subject|0
5990944|NCT03560258|9582715|FG001|Overall Study|Withdrawal by Subject|0
5990945|NCT03560258|9582716|FG002|Overall Study|Withdrawal by Subject|1
6045618|NCT00402597|9644849|FG003|Overall Study|Lost to Follow-up|2
6045619|NCT00402597|9644850|FG004|Overall Study|Lost to Follow-up|3
6045620|NCT00402597|9644846|FG000|Overall Study|Withdrawal by Subject|57
6146154|NCT01075412|9780742|FG001|Overall Study|Withdrawal by Subject|1
6146155|NCT01075516|9780749|FG000|Overall Study|Death|5
6146156|NCT01075516|9780750|FG001|Overall Study|Death|9
6146157|NCT01075516|9780749|FG000|Overall Study|Lost to Follow-up|10
6146158|NCT01075516|9780750|FG001|Overall Study|Lost to Follow-up|2
6146159|NCT01075516|9780749|FG000|Overall Study|Withdrawal by Subject|3
6146160|NCT01075516|9780750|FG001|Overall Study|Withdrawal by Subject|5
6146161|NCT01075646|9780760|FG000|Overall Study|Lost to Follow-up|4
6146162|NCT01075646|9780761|FG001|Overall Study|Lost to Follow-up|3
6146163|NCT01075646|9780762|FG002|Overall Study|Lost to Follow-up|1
6146164|NCT01075646|9780763|FG003|Overall Study|Lost to Follow-up|2
6191303|NCT01421342|9847961|FG001|Continuation of Treatment (Week 12 - 36)|Due to Other Illness|2
6191304|NCT01421342|9847962|FG002|Continuation of Treatment (Week 12 - 36)|Due to Other Illness|2
6191305|NCT01421342|9847960|FG000|Continuation of Treatment (Week 12 - 36)|Other reason for withdrawal|6
6193345|NCT01437397|9850969|FG003|Overall Study|Adverse Event|14
6064944|NCT00518115|9666937|FG000|Overall Study|Adverse Event|6
6064945|NCT00518115|9666938|FG001|Overall Study|Adverse Event|1
6064946|NCT00518115|9666939|FG002|Overall Study|Adverse Event|5
6064947|NCT00518115|9666940|FG003|Overall Study|Adverse Event|6
6064948|NCT00518115|9666941|FG004|Overall Study|Adverse Event|5
6064949|NCT00518115|9666942|FG005|Overall Study|Adverse Event|5
6045621|NCT00402597|9644847|FG001|Overall Study|Withdrawal by Subject|16
6045622|NCT00402597|9644848|FG002|Overall Study|Withdrawal by Subject|65
6064950|NCT00518115|9666943|FG006|Overall Study|Adverse Event|5
6064951|NCT00518115|9666944|FG007|Overall Study|Adverse Event|10
6064952|NCT00518115|9666945|FG008|Overall Study|Adverse Event|2
6064953|NCT00518115|9666946|FG009|Overall Study|Adverse Event|9
6064954|NCT00518115|9666937|FG000|Overall Study|Lost to Follow-up|0
6064955|NCT00518115|9666938|FG001|Overall Study|Lost to Follow-up|0
5990946|NCT03684304|9582726|FG000|Overall Study|Lost to Follow-up|19
5990947|NCT03684304|9582727|FG001|Overall Study|Lost to Follow-up|17
5990948|NCT04528641|9582748|FG000|Overall Study|Withdrawal by Subject|0
5990949|NCT04528641|9582749|FG001|Overall Study|Withdrawal by Subject|0
5990950|NCT04528641|9582750|FG002|Overall Study|Withdrawal by Subject|0
5990951|NCT04528641|9582751|FG003|Overall Study|Withdrawal by Subject|1
5990952|NCT04528641|9582752|FG004|Overall Study|Withdrawal by Subject|0
5990953|NCT04528641|9582753|FG005|Overall Study|Withdrawal by Subject|1
5990954|NCT04034238|9582789|FG000|Dose Escalation Phase|Withdrawal by Subject|1
5990955|NCT04034238|9582790|FG001|Dose Escalation Phase|Withdrawal by Subject|0
5990956|NCT04034238|9582791|FG002|Dose Escalation Phase|Withdrawal by Subject|0
5990957|NCT04034238|9582792|FG003|Dose Escalation Phase|Withdrawal by Subject|0
5990958|NCT04034238|9582789|FG000|Dose Escalation Phase|Screen failures|0
5990959|NCT04034238|9582790|FG001|Dose Escalation Phase|Screen failures|0
5990960|NCT04034238|9582791|FG002|Dose Escalation Phase|Screen failures|0
5990961|NCT04034238|9582792|FG003|Dose Escalation Phase|Screen failures|2
5990962|NCT04034238|9582789|FG000|Dose Expansion Phase|Not treated due to study hold.|0
5990963|NCT04034238|9582790|FG001|Dose Expansion Phase|Not treated due to study hold.|0
5990964|NCT04034238|9582791|FG002|Dose Expansion Phase|Not treated due to study hold.|0
5990965|NCT04034238|9582792|FG003|Dose Expansion Phase|Not treated due to study hold.|1
5990966|NCT04034238|9582789|FG000|Dose Expansion Phase|Discontinued treatment before received LMB-100 during first cycle|0
5990967|NCT04034238|9582790|FG001|Dose Expansion Phase|Discontinued treatment before received LMB-100 during first cycle|0
5990968|NCT04034238|9582791|FG002|Dose Expansion Phase|Discontinued treatment before received LMB-100 during first cycle|1
6064956|NCT00518115|9666939|FG002|Overall Study|Lost to Follow-up|2
6064957|NCT00518115|9666940|FG003|Overall Study|Lost to Follow-up|3
6064958|NCT00518115|9666941|FG004|Overall Study|Lost to Follow-up|1
6064959|NCT00518115|9666942|FG005|Overall Study|Lost to Follow-up|3
6064960|NCT00518115|9666943|FG006|Overall Study|Lost to Follow-up|0
6064961|NCT00518115|9666944|FG007|Overall Study|Lost to Follow-up|1
6064962|NCT00518115|9666945|FG008|Overall Study|Lost to Follow-up|1
6064963|NCT00518115|9666946|FG009|Overall Study|Lost to Follow-up|1
6064964|NCT00518115|9666937|FG000|Overall Study|Protocol Violation|1
6064965|NCT00518115|9666938|FG001|Overall Study|Protocol Violation|3
6064966|NCT00518115|9666939|FG002|Overall Study|Protocol Violation|1
6064967|NCT00518115|9666940|FG003|Overall Study|Protocol Violation|0
6064968|NCT00518115|9666941|FG004|Overall Study|Protocol Violation|0
6064969|NCT00518115|9666942|FG005|Overall Study|Protocol Violation|0
6064970|NCT00518115|9666943|FG006|Overall Study|Protocol Violation|0
6064971|NCT00518115|9666944|FG007|Overall Study|Protocol Violation|0
6064972|NCT00518115|9666945|FG008|Overall Study|Protocol Violation|0
6064973|NCT00518115|9666946|FG009|Overall Study|Protocol Violation|0
6064974|NCT00518115|9666937|FG000|Overall Study|Withdrawal by Subject|1
6064975|NCT00518115|9666938|FG001|Overall Study|Withdrawal by Subject|1
6064976|NCT00518115|9666939|FG002|Overall Study|Withdrawal by Subject|5
5990969|NCT04034238|9582792|FG003|Dose Expansion Phase|Discontinued treatment before received LMB-100 during first cycle|0
6045623|NCT00402597|9644849|FG003|Overall Study|Withdrawal by Subject|15
6045624|NCT00402597|9644850|FG004|Overall Study|Withdrawal by Subject|24
6045625|NCT00402597|9644846|FG000|Overall Study|reason not specified|30
6045626|NCT00402597|9644847|FG001|Overall Study|reason not specified|4
6045627|NCT00402597|9644848|FG002|Overall Study|reason not specified|27
6045628|NCT00402597|9644849|FG003|Overall Study|reason not specified|14
6045629|NCT00402597|9644850|FG004|Overall Study|reason not specified|20
6045630|NCT00402649|9644862|FG000|Overall Study|Lost to Follow-up|1
6045631|NCT00402649|9644862|FG000|Overall Study|Withdrawal by Subject|1
6045632|NCT00402688|9644869|FG000|Overall Study|Adverse Event|12
6045633|NCT00402688|9644870|FG001|Overall Study|Adverse Event|9
6045634|NCT00402688|9644871|FG002|Overall Study|Adverse Event|3
6045635|NCT00402688|9644869|FG000|Overall Study|Withdrawal by Subject|3
6045636|NCT00402688|9644870|FG001|Overall Study|Withdrawal by Subject|1
6045637|NCT00402688|9644871|FG002|Overall Study|Withdrawal by Subject|1
6045638|NCT00402688|9644869|FG000|Overall Study|Physician Decision|0
6045639|NCT00402688|9644870|FG001|Overall Study|Physician Decision|0
6045640|NCT00402688|9644871|FG002|Overall Study|Physician Decision|1
6045641|NCT00402688|9644869|FG000|Overall Study|Lack of Efficacy|4
6045642|NCT00402688|9644870|FG001|Overall Study|Lack of Efficacy|4
6045643|NCT00402688|9644871|FG002|Overall Study|Lack of Efficacy|5
6045644|NCT00402688|9644869|FG000|Overall Study|Protocol Violation|1
6045645|NCT00402688|9644870|FG001|Overall Study|Protocol Violation|1
6045646|NCT00402688|9644871|FG002|Overall Study|Protocol Violation|1
6045647|NCT00402688|9644869|FG000|Overall Study|Lost to Follow-up|1
6045648|NCT00402688|9644870|FG001|Overall Study|Lost to Follow-up|0
6045649|NCT00402688|9644871|FG002|Overall Study|Lost to Follow-up|2
6045650|NCT00402688|9644869|FG000|Overall Study|Culture Show Fluoroquinolone Resistance|0
6045651|NCT00402688|9644870|FG001|Overall Study|Culture Show Fluoroquinolone Resistance|1
6045652|NCT00402688|9644871|FG002|Overall Study|Culture Show Fluoroquinolone Resistance|0
6045653|NCT00402688|9644869|FG000|Overall Study|Urine Cult. Yield Resistant to Levaquin|0
6045654|NCT00402688|9644870|FG001|Overall Study|Urine Cult. Yield Resistant to Levaquin|0
6045655|NCT00402688|9644871|FG002|Overall Study|Urine Cult. Yield Resistant to Levaquin|1
6045656|NCT00402688|9644869|FG000|Overall Study|Patient Left Town and Forgot Medication|0
6045657|NCT00402688|9644870|FG001|Overall Study|Patient Left Town and Forgot Medication|0
6045658|NCT00402688|9644871|FG002|Overall Study|Patient Left Town and Forgot Medication|1
5990970|NCT03984305|9582805|FG000|Overall Study|Sponsor Request due to Study Discontinuation|19
5990971|NCT03984305|9582806|FG001|Overall Study|Sponsor Request due to Study Discontinuation|15
5990972|NCT03984305|9582805|FG000|Overall Study|Withdrawal by Subject|3
5990973|NCT03984305|9582806|FG001|Overall Study|Withdrawal by Subject|3
5990974|NCT03984305|9582805|FG000|Overall Study|Lost to Follow-up|1
5990975|NCT03984305|9582806|FG001|Overall Study|Lost to Follow-up|0
5990976|NCT03982368|9582815|FG000|Overall Study|Adverse Event|6
5990977|NCT03982368|9582816|FG001|Overall Study|Adverse Event|4
5990978|NCT03982368|9582817|FG002|Overall Study|Adverse Event|3
5990979|NCT03982368|9582815|FG000|Overall Study|Lost to Follow-up|2
5990980|NCT03982368|9582816|FG001|Overall Study|Lost to Follow-up|1
5990981|NCT03982368|9582817|FG002|Overall Study|Lost to Follow-up|0
5990982|NCT03982368|9582815|FG000|Overall Study|Withdrawal by Subject|1
5990983|NCT03982368|9582816|FG001|Overall Study|Withdrawal by Subject|2
5990984|NCT03982368|9582817|FG002|Overall Study|Withdrawal by Subject|0
5990985|NCT03982368|9582815|FG000|Overall Study|unknow|4
5990986|NCT03982368|9582816|FG001|Overall Study|unknow|0
5990987|NCT03982368|9582817|FG002|Overall Study|unknow|2
5990988|NCT03952143|9582830|FG000|Lead-In Period|Adverse Event|2
5990989|NCT03952143|9582831|FG001|Lead-In Period|Adverse Event|0
5990990|NCT03952143|9582832|FG002|Lead-In Period|Adverse Event|0
5990991|NCT03952143|9582830|FG000|Lead-In Period|Lack of Efficacy|2
5990992|NCT03952143|9582831|FG001|Lead-In Period|Lack of Efficacy|0
5990993|NCT03952143|9582832|FG002|Lead-In Period|Lack of Efficacy|0
5990994|NCT03952143|9582830|FG000|Lead-In Period|Physician Decision|5
5990995|NCT03952143|9582831|FG001|Lead-In Period|Physician Decision|0
5990996|NCT03952143|9582832|FG002|Lead-In Period|Physician Decision|0
5990997|NCT03952143|9582830|FG000|Lead-In Period|Protocol Violation|5
5990998|NCT03952143|9582831|FG001|Lead-In Period|Protocol Violation|0
5990999|NCT03952143|9582832|FG002|Lead-In Period|Protocol Violation|0
5991000|NCT03952143|9582830|FG000|Lead-In Period|Withdrawal by Subject|19
5991001|NCT03952143|9582831|FG001|Lead-In Period|Withdrawal by Subject|0
5991002|NCT03952143|9582832|FG002|Lead-In Period|Withdrawal by Subject|0
5991003|NCT03952143|9582830|FG000|Treatment Period|Adverse Event|0
5991004|NCT03952143|9582831|FG001|Treatment Period|Adverse Event|0
5991005|NCT03952143|9582832|FG002|Treatment Period|Adverse Event|1
5991006|NCT03952143|9582830|FG000|Treatment Period|Lost to Follow-up|0
5991007|NCT03952143|9582831|FG001|Treatment Period|Lost to Follow-up|2
5991008|NCT03952143|9582832|FG002|Treatment Period|Lost to Follow-up|0
5991009|NCT03952143|9582830|FG000|Treatment Period|Physician Decision|0
5991010|NCT03952143|9582831|FG001|Treatment Period|Physician Decision|0
5991011|NCT03952143|9582832|FG002|Treatment Period|Physician Decision|2
5991012|NCT03952143|9582830|FG000|Treatment Period|Protocol Violation|0
5991013|NCT03952143|9582831|FG001|Treatment Period|Protocol Violation|0
5991014|NCT03952143|9582832|FG002|Treatment Period|Protocol Violation|1
5991015|NCT03952143|9582830|FG000|Treatment Period|Withdrawal by Subject|0
5991016|NCT03952143|9582831|FG001|Treatment Period|Withdrawal by Subject|5
5991017|NCT03952143|9582832|FG002|Treatment Period|Withdrawal by Subject|26
5991018|NCT03952143|9582830|FG000|Treatment Period|Due to COVID 19 restrictions|0
5991019|NCT03952143|9582831|FG001|Treatment Period|Due to COVID 19 restrictions|2
5991020|NCT03952143|9582832|FG002|Treatment Period|Due to COVID 19 restrictions|5
5991021|NCT03952143|9582830|FG000|Treatment Period|Participant had taken prohibited concomitant medication|0
5991022|NCT03952143|9582831|FG001|Treatment Period|Participant had taken prohibited concomitant medication|0
5991023|NCT03952143|9582832|FG002|Treatment Period|Participant had taken prohibited concomitant medication|1
5991024|NCT03691428|9582849|FG000|Overall Study|Withdrawal by Subject|6
5991025|NCT03691428|9582850|FG001|Overall Study|Withdrawal by Subject|8
5991026|NCT03685708|9582859|FG000|Overall Study|Withdrawal by Subject|0
5991027|NCT03685708|9582860|FG001|Overall Study|Withdrawal by Subject|0
5991028|NCT03685708|9582861|FG002|Overall Study|Withdrawal by Subject|1
5991029|NCT03685708|9582859|FG000|Overall Study|Screen Fail|0
5991030|NCT03685708|9582860|FG001|Overall Study|Screen Fail|1
5991031|NCT03685708|9582861|FG002|Overall Study|Screen Fail|1
5991032|NCT03685708|9582859|FG000|Overall Study|COVID 19 Pandemic|1
5991033|NCT03685708|9582860|FG001|Overall Study|COVID 19 Pandemic|1
5991034|NCT03685708|9582861|FG002|Overall Study|COVID 19 Pandemic|6
5991035|NCT03685708|9582859|FG000|Overall Study|Disease Progression|0
5991036|NCT03685708|9582860|FG001|Overall Study|Disease Progression|0
5991037|NCT03685708|9582861|FG002|Overall Study|Disease Progression|1
5991038|NCT03669588|9582871|FG000|Overall Study|Adverse Event|1
5991039|NCT03669588|9582872|FG001|Overall Study|Adverse Event|0
5991040|NCT03669588|9582871|FG000|Overall Study|Physician Decision|0
5991041|NCT03669588|9582872|FG001|Overall Study|Physician Decision|1
5991042|NCT03669588|9582871|FG000|Overall Study|Protocol Violation|1
5991043|NCT03669588|9582872|FG001|Overall Study|Protocol Violation|0
5991044|NCT03669588|9582871|FG000|Overall Study|Sponsor Decision|1
5991045|NCT03669588|9582872|FG001|Overall Study|Sponsor Decision|1
5991046|NCT03669588|9582871|FG000|Overall Study|Withdrawal by Subject|1
5991047|NCT03669588|9582872|FG001|Overall Study|Withdrawal by Subject|4
5991048|NCT03669588|9582871|FG000|Overall Study|Rescue Therapy Needed|0
5991049|NCT03669588|9582872|FG001|Overall Study|Rescue Therapy Needed|1
5991050|NCT03531632|9582881|FG000|Overall Study|Adverse Event|0
5991051|NCT03531632|9582882|FG001|Overall Study|Adverse Event|0
5991052|NCT03531632|9582883|FG002|Overall Study|Adverse Event|1
5991053|NCT03531632|9582881|FG000|Overall Study|Death|4
5991054|NCT03531632|9582882|FG001|Overall Study|Death|0
5991055|NCT03531632|9582883|FG002|Overall Study|Death|14
5991056|NCT03531632|9582881|FG000|Overall Study|Study Terminated|1
5991057|NCT03531632|9582882|FG001|Overall Study|Study Terminated|3
5991058|NCT03531632|9582883|FG002|Overall Study|Study Terminated|11
5991059|NCT03412604|9582906|FG000|Overall Study|Withdrawal by Subject|1
6045659|NCT00402727|9644892|FG000|Overall Study|Adverse Event|10
6045660|NCT00402727|9644893|FG001|Overall Study|Adverse Event|6
6045661|NCT00402727|9644892|FG000|Overall Study|Death|1
6045662|NCT00402727|9644893|FG001|Overall Study|Death|0
6045663|NCT00402727|9644892|FG000|Overall Study|Lack of Efficacy|1
6045664|NCT00402727|9644893|FG001|Overall Study|Lack of Efficacy|3
6045665|NCT00402727|9644892|FG000|Overall Study|Lost to Follow-up|24
6045666|NCT00402727|9644893|FG001|Overall Study|Lost to Follow-up|11
6045667|NCT00402727|9644892|FG000|Overall Study|Physician Decision|1
6045668|NCT00402727|9644893|FG001|Overall Study|Physician Decision|1
6045669|NCT00402727|9644892|FG000|Overall Study|Protocol Violation|0
6045670|NCT00402727|9644893|FG001|Overall Study|Protocol Violation|4
6045671|NCT00402727|9644892|FG000|Overall Study|Withdrawal by Subject|3
6045672|NCT00402727|9644893|FG001|Overall Study|Withdrawal by Subject|7
6045673|NCT00402727|9644892|FG000|Overall Study|supply problems|2
6045674|NCT00402727|9644893|FG001|Overall Study|supply problems|1
6045675|NCT00402727|9644892|FG000|Overall Study|non-compliance|0
6045676|NCT00402727|9644893|FG001|Overall Study|non-compliance|1
6045677|NCT00402740|9644899|FG000|Overall Study|Withdrawal by Subject|18
6045678|NCT00402740|9644899|FG000|Overall Study|Death|50
6045679|NCT00402740|9644899|FG000|Overall Study|Lost to Follow-up|6
6045680|NCT00402740|9644899|FG000|Overall Study|No stent. Completed FU at 30 days.|5
6045681|NCT00402740|9644899|FG000|Overall Study|Subject disposition unknown.|1
6045682|NCT00402779|9644909|FG000|Overall Study|Screen Failure|77
6045683|NCT00402779|9644910|FG001|Overall Study|Screen Failure|76
6045684|NCT00402831|9644918|FG000|Overall Study|Lost to Follow-up|1
6045685|NCT00402831|9644919|FG001|Overall Study|Lost to Follow-up|2
6045686|NCT00402831|9644918|FG000|Overall Study|Non-compliance with protocol|0
6045687|NCT00402831|9644919|FG001|Overall Study|Non-compliance with protocol|1
6045688|NCT00402987|9644935|FG000|Overall Study|Lack of Efficacy|0
6045689|NCT00402987|9644936|FG001|Overall Study|Lack of Efficacy|0
6045690|NCT00402987|9644937|FG002|Overall Study|Lack of Efficacy|1
6045691|NCT00402987|9644938|FG003|Overall Study|Lack of Efficacy|0
6045692|NCT00403130|9644993|FG000|2 Years From Start of Treatment|Not Eligible|3
6045693|NCT00403130|9644993|FG000|2 Years From Start of Treatment|Lost to Follow up|1
6045694|NCT00403130|9644993|FG000|2 Years From Start of Treatment|Withdrawal by Subject|1
6045695|NCT00403130|9644993|FG000|Survival Follow-up up to 6 Years|Lost to Follow-up|10
6045696|NCT00403234|9645001|FG000|Overall Study|Withdrawal by Subject|0
6045697|NCT00403234|9645002|FG001|Overall Study|Withdrawal by Subject|1
6045698|NCT00403234|9645003|FG002|Overall Study|Withdrawal by Subject|0
6045699|NCT00403234|9645004|FG003|Overall Study|Withdrawal by Subject|0
6045700|NCT00403234|9645001|FG000|Overall Study|Adverse Event|1
6045701|NCT00403234|9645002|FG001|Overall Study|Adverse Event|0
6045702|NCT00403234|9645003|FG002|Overall Study|Adverse Event|1
6045703|NCT00403234|9645004|FG003|Overall Study|Adverse Event|0
6045704|NCT00403260|9645016|FG000|Overall Study|Adverse Event|5
6045705|NCT00403260|9645017|FG001|Overall Study|Adverse Event|4
6045706|NCT00403260|9645016|FG000|Overall Study|Withdrawal by Subject|5
6045707|NCT00403260|9645017|FG001|Overall Study|Withdrawal by Subject|6
6045708|NCT00403260|9645016|FG000|Overall Study|Lost to Follow-up|49
6045709|NCT00403260|9645017|FG001|Overall Study|Lost to Follow-up|25
6045710|NCT00403260|9645016|FG000|Overall Study|Re-appearance of P. falciparum|34
6045711|NCT00403260|9645017|FG001|Overall Study|Re-appearance of P. falciparum|25
6045712|NCT00403260|9645016|FG000|Overall Study|P. vivax infection|26
6045713|NCT00403260|9645017|FG001|Overall Study|P. vivax infection|4
5991060|NCT03206073|9582914|FG000|Overall Study|Participant Noncompliance|0
5991061|NCT03206073|9582915|FG001|Overall Study|Participant Noncompliance|1
5991062|NCT03206073|9582916|FG002|Overall Study|Participant Noncompliance|0
5991063|NCT03206073|9582917|FG003|Overall Study|Participant Noncompliance|0
5991064|NCT03206073|9582914|FG000|Overall Study|Unable to complete the dose limiting toxicity period|1
5991065|NCT03206073|9582915|FG001|Overall Study|Unable to complete the dose limiting toxicity period|0
5991066|NCT03206073|9582916|FG002|Overall Study|Unable to complete the dose limiting toxicity period|0
5991067|NCT03206073|9582917|FG003|Overall Study|Unable to complete the dose limiting toxicity period|0
5991068|NCT03206073|9582914|FG000|Overall Study|Death|0
6064977|NCT00518115|9666940|FG003|Overall Study|Withdrawal by Subject|0
6064978|NCT00518115|9666941|FG004|Overall Study|Withdrawal by Subject|2
6064979|NCT00518115|9666942|FG005|Overall Study|Withdrawal by Subject|1
6064980|NCT00518115|9666943|FG006|Overall Study|Withdrawal by Subject|0
6064981|NCT00518115|9666944|FG007|Overall Study|Withdrawal by Subject|2
6064982|NCT00518115|9666945|FG008|Overall Study|Withdrawal by Subject|1
6064983|NCT00518115|9666946|FG009|Overall Study|Withdrawal by Subject|3
6064984|NCT00518115|9666937|FG000|Overall Study|Lack of Efficacy|1
6064985|NCT00518115|9666938|FG001|Overall Study|Lack of Efficacy|0
6064986|NCT00518115|9666939|FG002|Overall Study|Lack of Efficacy|1
6064987|NCT00518115|9666940|FG003|Overall Study|Lack of Efficacy|1
6064988|NCT00518115|9666941|FG004|Overall Study|Lack of Efficacy|0
6064989|NCT00518115|9666942|FG005|Overall Study|Lack of Efficacy|0
6064990|NCT00518115|9666943|FG006|Overall Study|Lack of Efficacy|0
6064991|NCT00518115|9666944|FG007|Overall Study|Lack of Efficacy|1
6064992|NCT00518115|9666945|FG008|Overall Study|Lack of Efficacy|0
6064993|NCT00518115|9666946|FG009|Overall Study|Lack of Efficacy|0
6064994|NCT00518115|9666937|FG000|Overall Study|Non-Compliance|1
6064995|NCT00518115|9666938|FG001|Overall Study|Non-Compliance|0
6064996|NCT00518115|9666939|FG002|Overall Study|Non-Compliance|1
6064997|NCT00518115|9666940|FG003|Overall Study|Non-Compliance|0
6064998|NCT00518115|9666941|FG004|Overall Study|Non-Compliance|1
6064999|NCT00518115|9666942|FG005|Overall Study|Non-Compliance|1
6065000|NCT00518115|9666943|FG006|Overall Study|Non-Compliance|1
6065001|NCT00518115|9666944|FG007|Overall Study|Non-Compliance|1
6065002|NCT00518115|9666945|FG008|Overall Study|Non-Compliance|0
6065003|NCT00518115|9666946|FG009|Overall Study|Non-Compliance|1
6065004|NCT00518115|9666937|FG000|Overall Study|Treatment Eligibility Criteria Not Met|1
6065005|NCT00518115|9666938|FG001|Overall Study|Treatment Eligibility Criteria Not Met|1
6065006|NCT00518115|9666939|FG002|Overall Study|Treatment Eligibility Criteria Not Met|0
6065007|NCT00518115|9666940|FG003|Overall Study|Treatment Eligibility Criteria Not Met|0
6065008|NCT00518115|9666941|FG004|Overall Study|Treatment Eligibility Criteria Not Met|0
6065009|NCT00518115|9666942|FG005|Overall Study|Treatment Eligibility Criteria Not Met|4
6065010|NCT00518115|9666943|FG006|Overall Study|Treatment Eligibility Criteria Not Met|0
6065011|NCT00518115|9666944|FG007|Overall Study|Treatment Eligibility Criteria Not Met|0
6065012|NCT00518115|9666945|FG008|Overall Study|Treatment Eligibility Criteria Not Met|0
6065013|NCT00518115|9666946|FG009|Overall Study|Treatment Eligibility Criteria Not Met|0
6065014|NCT00518115|9666937|FG000|Overall Study|Physician Prescribed Antidiabetic Drug|1
6065015|NCT00518115|9666938|FG001|Overall Study|Physician Prescribed Antidiabetic Drug|0
5991069|NCT03206073|9582915|FG001|Overall Study|Death|0
5991070|NCT03206073|9582916|FG002|Overall Study|Death|1
5991071|NCT03206073|9582917|FG003|Overall Study|Death|0
5991072|NCT03206073|9582914|FG000|Overall Study|Taken off active treatment|0
5991073|NCT03206073|9582915|FG001|Overall Study|Taken off active treatment|0
5991074|NCT03206073|9582916|FG002|Overall Study|Taken off active treatment|3
5991075|NCT03206073|9582917|FG003|Overall Study|Taken off active treatment|0
5991076|NCT03102034|9582942|FG000|Overall Study|Withdrawal by Subject|1
5991077|NCT03102034|9582943|FG001|Overall Study|Withdrawal by Subject|0
5991078|NCT02723864|9582960|FG000|Overall Study|Refused further treatment|1
5991079|NCT02723864|9582961|FG001|Overall Study|Refused further treatment|0
5991080|NCT02723864|9582962|FG002|Overall Study|Refused further treatment|0
5991081|NCT02723864|9582963|FG003|Overall Study|Refused further treatment|0
5991082|NCT02723864|9582964|FG004|Overall Study|Refused further treatment|1
5991083|NCT02723864|9582965|FG005|Overall Study|Refused further treatment|2
5991084|NCT02723864|9582966|FG006|Overall Study|Refused further treatment|0
5991085|NCT02723864|9582960|FG000|Overall Study|Exceed treatment hold time|0
5991086|NCT02723864|9582961|FG001|Overall Study|Exceed treatment hold time|1
5991087|NCT02723864|9582962|FG002|Overall Study|Exceed treatment hold time|0
5991088|NCT02723864|9582963|FG003|Overall Study|Exceed treatment hold time|0
5991089|NCT02723864|9582964|FG004|Overall Study|Exceed treatment hold time|0
5991090|NCT02723864|9582965|FG005|Overall Study|Exceed treatment hold time|0
5991091|NCT02723864|9582966|FG006|Overall Study|Exceed treatment hold time|0
5991092|NCT02723864|9582960|FG000|Overall Study|Clinical progression|0
5991093|NCT02723864|9582961|FG001|Overall Study|Clinical progression|0
5991094|NCT02723864|9582962|FG002|Overall Study|Clinical progression|1
5991095|NCT02723864|9582963|FG003|Overall Study|Clinical progression|0
5991096|NCT02723864|9582964|FG004|Overall Study|Clinical progression|0
5991097|NCT02723864|9582965|FG005|Overall Study|Clinical progression|3
5991098|NCT02723864|9582966|FG006|Overall Study|Clinical progression|1
5991099|NCT02723864|9582960|FG000|Overall Study|Physician Decision|0
5991100|NCT02723864|9582961|FG001|Overall Study|Physician Decision|0
5991101|NCT02723864|9582962|FG002|Overall Study|Physician Decision|0
5991102|NCT02723864|9582963|FG003|Overall Study|Physician Decision|0
5991103|NCT02723864|9582964|FG004|Overall Study|Physician Decision|0
5991104|NCT02723864|9582965|FG005|Overall Study|Physician Decision|0
5991105|NCT02723864|9582966|FG006|Overall Study|Physician Decision|1
5991106|NCT02723864|9582960|FG000|Overall Study|Changes in patient condition|0
5991107|NCT02723864|9582961|FG001|Overall Study|Changes in patient condition|0
5991108|NCT02723864|9582962|FG002|Overall Study|Changes in patient condition|0
5991109|NCT02723864|9582963|FG003|Overall Study|Changes in patient condition|0
5991110|NCT02723864|9582964|FG004|Overall Study|Changes in patient condition|0
5991111|NCT02723864|9582965|FG005|Overall Study|Changes in patient condition|1
5991112|NCT02723864|9582966|FG006|Overall Study|Changes in patient condition|0
5991113|NCT02723864|9582960|FG000|Overall Study|Patient choice|0
5991114|NCT02723864|9582961|FG001|Overall Study|Patient choice|0
5991115|NCT02723864|9582962|FG002|Overall Study|Patient choice|0
5991116|NCT02723864|9582963|FG003|Overall Study|Patient choice|0
5991117|NCT02723864|9582964|FG004|Overall Study|Patient choice|0
5991118|NCT02723864|9582965|FG005|Overall Study|Patient choice|1
5991119|NCT02723864|9582966|FG006|Overall Study|Patient choice|0
5991120|NCT02723864|9582960|FG000|Overall Study|Adverse Event|0
5991121|NCT02723864|9582961|FG001|Overall Study|Adverse Event|0
5991122|NCT02723864|9582962|FG002|Overall Study|Adverse Event|0
5991123|NCT02723864|9582963|FG003|Overall Study|Adverse Event|0
5991124|NCT02723864|9582964|FG004|Overall Study|Adverse Event|0
5991125|NCT02723864|9582965|FG005|Overall Study|Adverse Event|1
5991126|NCT02723864|9582966|FG006|Overall Study|Adverse Event|0
5991127|NCT02723864|9582960|FG000|Overall Study|Started new treatment|0
5991128|NCT02723864|9582961|FG001|Overall Study|Started new treatment|0
5991129|NCT02723864|9582962|FG002|Overall Study|Started new treatment|0
5991130|NCT02723864|9582963|FG003|Overall Study|Started new treatment|0
5991131|NCT02723864|9582964|FG004|Overall Study|Started new treatment|0
5991132|NCT02723864|9582965|FG005|Overall Study|Started new treatment|1
5991133|NCT02723864|9582966|FG006|Overall Study|Started new treatment|0
5991134|NCT02723864|9582960|FG000|Overall Study|Switched to alternative treatment|0
5991135|NCT02723864|9582961|FG001|Overall Study|Switched to alternative treatment|0
5991136|NCT02723864|9582962|FG002|Overall Study|Switched to alternative treatment|0
5991137|NCT02723864|9582963|FG003|Overall Study|Switched to alternative treatment|0
5991138|NCT02723864|9582964|FG004|Overall Study|Switched to alternative treatment|0
5991139|NCT02723864|9582965|FG005|Overall Study|Switched to alternative treatment|1
5991140|NCT02723864|9582966|FG006|Overall Study|Switched to alternative treatment|0
5991141|NCT02723864|9582960|FG000|Overall Study|Late determination of ineligibility|0
5991142|NCT02723864|9582961|FG001|Overall Study|Late determination of ineligibility|0
5991143|NCT02723864|9582962|FG002|Overall Study|Late determination of ineligibility|0
5991144|NCT02723864|9582963|FG003|Overall Study|Late determination of ineligibility|0
5991145|NCT02723864|9582964|FG004|Overall Study|Late determination of ineligibility|0
5991146|NCT02723864|9582965|FG005|Overall Study|Late determination of ineligibility|1
5991147|NCT02723864|9582966|FG006|Overall Study|Late determination of ineligibility|0
5991148|NCT02691013|9583014|FG000|Overall Study|Withdrawal by Subject|3
5991149|NCT02691013|9583015|FG001|Overall Study|Withdrawal by Subject|0
5991150|NCT02597062|9583023|FG000|Overall Study|Ineligible|1
5991151|NCT02130882|9583029|FG000|Overall Study|Withdrawal by Subject|0
5991152|NCT02130882|9583030|FG001|Overall Study|Withdrawal by Subject|1
5991153|NCT01850563|9583038|FG000|Overall Study|Not eligible|3
5991154|NCT01850563|9583039|FG001|Overall Study|Not eligible|0
5991155|NCT01827111|9583046|FG000|Overall Study|Disease Progression|1
5991156|NCT01437111|9583050|FG000|Overall Study|Adverse Event|2
5991157|NCT01437111|9583050|FG000|Overall Study|Withdrawal by Subject|4
5991158|NCT01437111|9583050|FG000|Overall Study|Not reported|5
5991159|NCT01437111|9583050|FG000|Overall Study|Physician Decision|1
5991160|NCT01437111|9583050|FG000|Overall Study|Lost to Follow-up|5
5991161|NCT01437111|9583050|FG000|Overall Study|Protocol Violation|1
5991162|NCT01004263|9583087|FG000|Overall Study|Adverse Event|15
5991163|NCT01004263|9583087|FG000|Overall Study|Withdrawal by Subject|58
5991164|NCT01004263|9583087|FG000|Overall Study|Protocol Violation|10
5991165|NCT01004263|9583087|FG000|Overall Study|Lost to Follow-up|64
5991166|NCT01004263|9583087|FG000|Overall Study|Lack of Efficacy|13
5991167|NCT01004263|9583087|FG000|Overall Study|Pregnancy|2
5991168|NCT01004263|9583087|FG000|Overall Study|Physician Decision|15
5991169|NCT01004263|9583087|FG000|Overall Study|Lack of Qualifying Event|2
5991170|NCT01001234|9583096|FG000|Overall Study|Withdrawal by Subject|2
5991171|NCT01001234|9583097|FG001|Overall Study|Withdrawal by Subject|0
5991172|NCT01001234|9583098|FG002|Overall Study|Withdrawal by Subject|3
5991173|NCT01001234|9583099|FG003|Overall Study|Withdrawal by Subject|0
5991174|NCT01001234|9583100|FG004|Overall Study|Withdrawal by Subject|0
5991175|NCT01001234|9583096|FG000|Overall Study|Protocol Violation|34
5991176|NCT01001234|9583097|FG001|Overall Study|Protocol Violation|3
5991177|NCT01001234|9583098|FG002|Overall Study|Protocol Violation|19
5991178|NCT01001234|9583099|FG003|Overall Study|Protocol Violation|18
5991179|NCT01001234|9583100|FG004|Overall Study|Protocol Violation|0
5991180|NCT01001234|9583096|FG000|Overall Study|Lost to Follow-up|0
5991181|NCT01001234|9583097|FG001|Overall Study|Lost to Follow-up|0
5991182|NCT01001234|9583098|FG002|Overall Study|Lost to Follow-up|1
5991183|NCT01001234|9583099|FG003|Overall Study|Lost to Follow-up|2
5991184|NCT01001234|9583100|FG004|Overall Study|Lost to Follow-up|0
5991185|NCT01001234|9583096|FG000|Overall Study|Physician Decision|1
5991186|NCT01001234|9583097|FG001|Overall Study|Physician Decision|0
5991187|NCT01001234|9583098|FG002|Overall Study|Physician Decision|0
5991188|NCT01001234|9583099|FG003|Overall Study|Physician Decision|0
5991189|NCT01001234|9583100|FG004|Overall Study|Physician Decision|0
5991190|NCT01001234|9583096|FG000|Overall Study|Not Treated: Adverse Event|1
5991191|NCT01001234|9583097|FG001|Overall Study|Not Treated: Adverse Event|0
5991192|NCT01001234|9583098|FG002|Overall Study|Not Treated: Adverse Event|0
5991193|NCT01001234|9583099|FG003|Overall Study|Not Treated: Adverse Event|0
5991194|NCT01001234|9583100|FG004|Overall Study|Not Treated: Adverse Event|0
5991195|NCT01001234|9583096|FG000|Overall Study|Not Treated: Withdrawal by Subject|23
5991196|NCT01001234|9583097|FG001|Overall Study|Not Treated: Withdrawal by Subject|2
5991197|NCT01001234|9583098|FG002|Overall Study|Not Treated: Withdrawal by Subject|2
5991198|NCT01001234|9583099|FG003|Overall Study|Not Treated: Withdrawal by Subject|0
5991199|NCT01001234|9583100|FG004|Overall Study|Not Treated: Withdrawal by Subject|0
5991200|NCT01001234|9583096|FG000|Overall Study|Not Treated: Protocol Violation|3
5991201|NCT01001234|9583097|FG001|Overall Study|Not Treated: Protocol Violation|0
5991202|NCT01001234|9583098|FG002|Overall Study|Not Treated: Protocol Violation|0
5991203|NCT01001234|9583099|FG003|Overall Study|Not Treated: Protocol Violation|0
5991204|NCT01001234|9583100|FG004|Overall Study|Not Treated: Protocol Violation|0
5991205|NCT01001234|9583096|FG000|Overall Study|Not Treated: Lost to Follow-up|53
5991206|NCT01001234|9583097|FG001|Overall Study|Not Treated: Lost to Follow-up|4
5991207|NCT01001234|9583098|FG002|Overall Study|Not Treated: Lost to Follow-up|7
5991208|NCT01001234|9583099|FG003|Overall Study|Not Treated: Lost to Follow-up|5
5991209|NCT01001234|9583100|FG004|Overall Study|Not Treated: Lost to Follow-up|0
5991210|NCT01001234|9583096|FG000|Overall Study|Not Treated: Pregnancy|3
5991211|NCT01001234|9583097|FG001|Overall Study|Not Treated: Pregnancy|0
5991212|NCT01001234|9583098|FG002|Overall Study|Not Treated: Pregnancy|0
5991213|NCT01001234|9583099|FG003|Overall Study|Not Treated: Pregnancy|0
5991214|NCT01001234|9583100|FG004|Overall Study|Not Treated: Pregnancy|0
5991215|NCT01001234|9583096|FG000|Overall Study|Not Treated: Physician Decision|37
5991216|NCT01001234|9583097|FG001|Overall Study|Not Treated: Physician Decision|4
5991217|NCT01001234|9583098|FG002|Overall Study|Not Treated: Physician Decision|0
5991218|NCT01001234|9583099|FG003|Overall Study|Not Treated: Physician Decision|0
5991219|NCT01001234|9583100|FG004|Overall Study|Not Treated: Physician Decision|0
5991220|NCT01001234|9583096|FG000|Overall Study|Not Treated: Lack of Qualifying Event|248
5991221|NCT01001234|9583097|FG001|Overall Study|Not Treated: Lack of Qualifying Event|13
5991222|NCT01001234|9583098|FG002|Overall Study|Not Treated: Lack of Qualifying Event|0
5991223|NCT01001234|9583099|FG003|Overall Study|Not Treated: Lack of Qualifying Event|0
5991224|NCT01001234|9583100|FG004|Overall Study|Not Treated: Lack of Qualifying Event|0
5991225|NCT00924170|9583108|FG000|Overall Study|Refused further treatment|0
5991226|NCT00924170|9583109|FG001|Overall Study|Refused further treatment|1
5991227|NCT00924170|9583108|FG000|Overall Study|Physician Decision|0
5991228|NCT00924170|9583109|FG001|Overall Study|Physician Decision|1
5991229|NCT00924170|9583108|FG000|Overall Study|Progressive disease|3
5991230|NCT00924170|9583109|FG001|Overall Study|Progressive disease|6
5991231|NCT00924170|9583108|FG000|Overall Study|Stopped due to neutralizing antibodies|3
5991232|NCT00924170|9583109|FG001|Overall Study|Stopped due to neutralizing antibodies|0
5991233|NCT00924170|9583108|FG000|Overall Study|Death|1
5991234|NCT00924170|9583109|FG001|Overall Study|Death|0
5991235|NCT00894556|9583124|FG000|Baseline Phase|Did not meet Randomization Criteria|0
5991236|NCT00894556|9583125|FG001|Baseline Phase|Did not meet Randomization Criteria|0
5991237|NCT00894556|9583126|FG002|Baseline Phase|Did not meet Randomization Criteria|0
5991238|NCT00894556|9583127|FG003|Baseline Phase|Did not meet Randomization Criteria|85
5991239|NCT00894556|9583124|FG000|Treatment Phase|Lost to Follow-up|2
5991240|NCT00894556|9583125|FG001|Treatment Phase|Lost to Follow-up|3
5991241|NCT00894556|9583126|FG002|Treatment Phase|Lost to Follow-up|1
5991242|NCT00894556|9583127|FG003|Treatment Phase|Lost to Follow-up|0
5991243|NCT00894556|9583124|FG000|Treatment Phase|Lack of Qualifying Event|2
5991244|NCT00894556|9583125|FG001|Treatment Phase|Lack of Qualifying Event|1
5991245|NCT00894556|9583126|FG002|Treatment Phase|Lack of Qualifying Event|0
5991246|NCT00894556|9583127|FG003|Treatment Phase|Lack of Qualifying Event|0
5991247|NCT00840177|9583137|FG000|Overall Study|Adverse Event|5
5991248|NCT00840177|9583138|FG001|Overall Study|Adverse Event|1
5991249|NCT00840177|9583139|FG002|Overall Study|Adverse Event|1
5991250|NCT00840177|9583137|FG000|Overall Study|Refusal unrelated to adverse events|1
5991251|NCT00840177|9583138|FG001|Overall Study|Refusal unrelated to adverse events|0
5991252|NCT00840177|9583139|FG002|Overall Study|Refusal unrelated to adverse events|1
5991253|NCT00840177|9583137|FG000|Overall Study|Progression/relapse|2
5991254|NCT00840177|9583138|FG001|Overall Study|Progression/relapse|0
5991255|NCT00840177|9583139|FG002|Overall Study|Progression/relapse|0
5991256|NCT00840177|9583137|FG000|Overall Study|Death|4
5991257|NCT00840177|9583138|FG001|Overall Study|Death|5
5991258|NCT00840177|9583139|FG002|Overall Study|Death|5
5991259|NCT00840177|9583137|FG000|Overall Study|not protocol specified|6
5991260|NCT00840177|9583138|FG001|Overall Study|not protocol specified|3
5991261|NCT00840177|9583139|FG002|Overall Study|not protocol specified|0
5991262|NCT00840177|9583137|FG000|Overall Study|Ineligible|0
5991263|NCT00840177|9583138|FG001|Overall Study|Ineligible|0
5991264|NCT00840177|9583139|FG002|Overall Study|Ineligible|3
5991265|NCT00840177|9583137|FG000|Overall Study|Did not start treatment|0
5991266|NCT00840177|9583138|FG001|Overall Study|Did not start treatment|0
5991267|NCT00840177|9583139|FG002|Overall Study|Did not start treatment|1
5991268|NCT00820950|9583152|FG000|Overall Study|Scheduling Conflict|0
5991269|NCT00820950|9583153|FG001|Overall Study|Scheduling Conflict|0
5991270|NCT00820950|9583154|FG002|Overall Study|Scheduling Conflict|0
5991271|NCT00820950|9583155|FG003|Overall Study|Scheduling Conflict|0
5991272|NCT00820950|9583156|FG004|Overall Study|Scheduling Conflict|0
5991273|NCT00820950|9583157|FG005|Overall Study|Scheduling Conflict|0
5991274|NCT00820950|9583158|FG006|Overall Study|Scheduling Conflict|1
5991275|NCT00820950|9583159|FG007|Overall Study|Scheduling Conflict|1
5991276|NCT00820950|9583160|FG008|Overall Study|Scheduling Conflict|0
5991277|NCT00820950|9583161|FG009|Overall Study|Scheduling Conflict|0
5991278|NCT00820950|9583152|FG000|Overall Study|Protocol Violation|1
5991279|NCT00820950|9583153|FG001|Overall Study|Protocol Violation|1
5991280|NCT00820950|9583154|FG002|Overall Study|Protocol Violation|0
5991281|NCT00820950|9583155|FG003|Overall Study|Protocol Violation|0
5991282|NCT00820950|9583156|FG004|Overall Study|Protocol Violation|0
5991283|NCT00820950|9583157|FG005|Overall Study|Protocol Violation|0
5991284|NCT00820950|9583158|FG006|Overall Study|Protocol Violation|0
5991285|NCT00820950|9583159|FG007|Overall Study|Protocol Violation|0
5991286|NCT00820950|9583160|FG008|Overall Study|Protocol Violation|0
5991287|NCT00820950|9583161|FG009|Overall Study|Protocol Violation|0
6065016|NCT00518115|9666939|FG002|Overall Study|Physician Prescribed Antidiabetic Drug|0
6065017|NCT00518115|9666940|FG003|Overall Study|Physician Prescribed Antidiabetic Drug|0
6065018|NCT00518115|9666941|FG004|Overall Study|Physician Prescribed Antidiabetic Drug|0
6065019|NCT00518115|9666942|FG005|Overall Study|Physician Prescribed Antidiabetic Drug|0
6065020|NCT00518115|9666943|FG006|Overall Study|Physician Prescribed Antidiabetic Drug|0
6065021|NCT00518115|9666944|FG007|Overall Study|Physician Prescribed Antidiabetic Drug|0
6065022|NCT00518115|9666945|FG008|Overall Study|Physician Prescribed Antidiabetic Drug|0
6065023|NCT00518115|9666946|FG009|Overall Study|Physician Prescribed Antidiabetic Drug|0
6065024|NCT00518115|9666937|FG000|Overall Study|Different Monotherapy Diabetic Drug|0
6065025|NCT00518115|9666938|FG001|Overall Study|Different Monotherapy Diabetic Drug|0
6065026|NCT00518115|9666939|FG002|Overall Study|Different Monotherapy Diabetic Drug|1
6065027|NCT00518115|9666940|FG003|Overall Study|Different Monotherapy Diabetic Drug|0
6065028|NCT00518115|9666941|FG004|Overall Study|Different Monotherapy Diabetic Drug|0
6065029|NCT00518115|9666942|FG005|Overall Study|Different Monotherapy Diabetic Drug|0
6065030|NCT00518115|9666943|FG006|Overall Study|Different Monotherapy Diabetic Drug|0
6065031|NCT00518115|9666944|FG007|Overall Study|Different Monotherapy Diabetic Drug|0
6065032|NCT00518115|9666945|FG008|Overall Study|Different Monotherapy Diabetic Drug|1
6065033|NCT00518115|9666946|FG009|Overall Study|Different Monotherapy Diabetic Drug|0
6065034|NCT00518115|9666937|FG000|Overall Study|Wrong Monotherapy Administered|0
6065035|NCT00518115|9666938|FG001|Overall Study|Wrong Monotherapy Administered|0
6065036|NCT00518115|9666939|FG002|Overall Study|Wrong Monotherapy Administered|1
6065037|NCT00518115|9666940|FG003|Overall Study|Wrong Monotherapy Administered|0
6065038|NCT00518115|9666941|FG004|Overall Study|Wrong Monotherapy Administered|0
6065039|NCT00518115|9666942|FG005|Overall Study|Wrong Monotherapy Administered|0
6065040|NCT00518115|9666943|FG006|Overall Study|Wrong Monotherapy Administered|1
6065041|NCT00518115|9666944|FG007|Overall Study|Wrong Monotherapy Administered|0
6065042|NCT00518115|9666945|FG008|Overall Study|Wrong Monotherapy Administered|0
6065043|NCT00518115|9666946|FG009|Overall Study|Wrong Monotherapy Administered|0
6065044|NCT00518115|9666937|FG000|Overall Study|Violation of Exclusion Criteria|0
6065045|NCT00518115|9666938|FG001|Overall Study|Violation of Exclusion Criteria|0
6065046|NCT00518115|9666939|FG002|Overall Study|Violation of Exclusion Criteria|0
6065047|NCT00518115|9666940|FG003|Overall Study|Violation of Exclusion Criteria|1
6065048|NCT00518115|9666941|FG004|Overall Study|Violation of Exclusion Criteria|0
6065049|NCT00518115|9666942|FG005|Overall Study|Violation of Exclusion Criteria|0
6065050|NCT00518115|9666943|FG006|Overall Study|Violation of Exclusion Criteria|1
6065051|NCT00518115|9666944|FG007|Overall Study|Violation of Exclusion Criteria|0
6065052|NCT00518115|9666945|FG008|Overall Study|Violation of Exclusion Criteria|0
6065053|NCT00518115|9666946|FG009|Overall Study|Violation of Exclusion Criteria|0
6065054|NCT00518115|9666937|FG000|Overall Study|Family Emergency; Had to Go to England|0
6065055|NCT00518115|9666938|FG001|Overall Study|Family Emergency; Had to Go to England|0
6065056|NCT00518115|9666939|FG002|Overall Study|Family Emergency; Had to Go to England|0
6065057|NCT00518115|9666940|FG003|Overall Study|Family Emergency; Had to Go to England|0
6065058|NCT00518115|9666941|FG004|Overall Study|Family Emergency; Had to Go to England|1
6065059|NCT00518115|9666942|FG005|Overall Study|Family Emergency; Had to Go to England|0
6065060|NCT00518115|9666943|FG006|Overall Study|Family Emergency; Had to Go to England|0
6065061|NCT00518115|9666944|FG007|Overall Study|Family Emergency; Had to Go to England|0
6065062|NCT00518115|9666945|FG008|Overall Study|Family Emergency; Had to Go to England|0
6065063|NCT00518115|9666946|FG009|Overall Study|Family Emergency; Had to Go to England|0
6065064|NCT00518115|9666937|FG000|Overall Study|Withdrew Consent|0
6065065|NCT00518115|9666938|FG001|Overall Study|Withdrew Consent|0
6065066|NCT00518115|9666939|FG002|Overall Study|Withdrew Consent|0
5991288|NCT00806416|9583203|FG000|Period 1 - Part I|Adverse Event|0
5991289|NCT00806416|9583204|FG001|Period 1 - Part I|Adverse Event|1
5991290|NCT00806416|9583205|FG002|Period 1 - Part I|Adverse Event|0
5991291|NCT00806416|9583206|FG003|Period 1 - Part I|Adverse Event|0
5991292|NCT00806416|9583203|FG000|Period 1 - Part I|Lost to Follow-up|0
5991293|NCT00806416|9583204|FG001|Period 1 - Part I|Lost to Follow-up|2
5991294|NCT00806416|9583205|FG002|Period 1 - Part I|Lost to Follow-up|0
5991295|NCT00806416|9583206|FG003|Period 1 - Part I|Lost to Follow-up|0
5991296|NCT00806416|9583203|FG000|Period 1 - Part I|Withdrawal by Subject|3
5991297|NCT00806416|9583204|FG001|Period 1 - Part I|Withdrawal by Subject|1
5991298|NCT00806416|9583205|FG002|Period 1 - Part I|Withdrawal by Subject|0
5991299|NCT00806416|9583206|FG003|Period 1 - Part I|Withdrawal by Subject|0
5991300|NCT00806416|9583203|FG000|Period 1 - Part II|Withdrawal by Subject|0
5991301|NCT00806416|9583204|FG001|Period 1 - Part II|Withdrawal by Subject|0
5991302|NCT00806416|9583205|FG002|Period 1 - Part II|Withdrawal by Subject|0
5991303|NCT00806416|9583206|FG003|Period 1 - Part II|Withdrawal by Subject|2
5991304|NCT00729651|9583216|FG000|Overall Study|Withdrawal by Subject|5
5991305|NCT00729651|9583217|FG001|Overall Study|Withdrawal by Subject|6
5991306|NCT00729651|9583216|FG000|Overall Study|Lost to Follow-up|5
5991307|NCT00729651|9583217|FG001|Overall Study|Lost to Follow-up|4
5991308|NCT00729651|9583216|FG000|Overall Study|Protocol Violation|0
5991309|NCT00729651|9583217|FG001|Overall Study|Protocol Violation|1
5991310|NCT00729651|9583216|FG000|Overall Study|Adverse Event|7
5991311|NCT00729651|9583217|FG001|Overall Study|Adverse Event|3
5991312|NCT00729651|9583216|FG000|Overall Study|Visit 3, 25 OHD level ≤9 ng/mL|0
5991313|NCT00729651|9583217|FG001|Overall Study|Visit 3, 25 OHD level ≤9 ng/mL|4
5991314|NCT00729651|9583216|FG000|Overall Study|Subject's private reason|2
5991315|NCT00729651|9583217|FG001|Overall Study|Subject's private reason|0
5991316|NCT00698815|9583226|FG000|Overall Study|Death|1
5991317|NCT00698815|9583227|FG001|Overall Study|Death|2
5991318|NCT00698815|9583228|FG002|Overall Study|Death|4
5991319|NCT00698815|9583226|FG000|Overall Study|Withdrawal by Subject|6
5991320|NCT00698815|9583227|FG001|Overall Study|Withdrawal by Subject|3
5991321|NCT00698815|9583228|FG002|Overall Study|Withdrawal by Subject|2
5991322|NCT00698815|9583226|FG000|Overall Study|MD discretion|2
5991323|NCT00698815|9583227|FG001|Overall Study|MD discretion|7
5991324|NCT00698815|9583228|FG002|Overall Study|MD discretion|2
6227246|NCT01716234|9899994|FG001|Overall Study|Adverse Event|10
6227247|NCT01716234|9899995|FG002|Overall Study|Adverse Event|2
6227248|NCT01716234|9899996|FG003|Overall Study|Adverse Event|8
6227249|NCT01716234|9899997|FG004|Overall Study|Adverse Event|3
6227250|NCT01716234|9899998|FG005|Overall Study|Adverse Event|6
6227251|NCT01716234|9899999|FG006|Overall Study|Adverse Event|0
6227252|NCT01716234|9899993|FG000|Overall Study|Withdrawal by Subject|3
6227253|NCT01716234|9899994|FG001|Overall Study|Withdrawal by Subject|0
6227254|NCT01716234|9899995|FG002|Overall Study|Withdrawal by Subject|2
6227255|NCT01716234|9899996|FG003|Overall Study|Withdrawal by Subject|2
6227256|NCT01716234|9899997|FG004|Overall Study|Withdrawal by Subject|1
6227257|NCT01716234|9899998|FG005|Overall Study|Withdrawal by Subject|3
6227258|NCT01716234|9899999|FG006|Overall Study|Withdrawal by Subject|0
6227259|NCT01716520|9900041|FG000|Treatment Period 1 (14 Days)|Adverse Event|1
6227260|NCT01716520|9900042|FG001|Treatment Period 1 (14 Days)|Adverse Event|0
6227261|NCT01716520|9900043|FG002|Treatment Period 1 (14 Days)|Adverse Event|0
5991325|NCT00698815|9583226|FG000|Overall Study|Did not receive protocol treatment|1
5991326|NCT00698815|9583227|FG001|Overall Study|Did not receive protocol treatment|2
5991327|NCT00698815|9583228|FG002|Overall Study|Did not receive protocol treatment|2
6045714|NCT00403260|9645016|FG000|Overall Study|Mixed infection with P. vivax|2
6045715|NCT00403260|9645017|FG001|Overall Study|Mixed infection with P. vivax|0
6045716|NCT00403260|9645016|FG000|Overall Study|Mixed infection with P. falciparum|1
6045717|NCT00403260|9645017|FG001|Overall Study|Mixed infection with P. falciparum|0
6045718|NCT00403260|9645016|FG000|Overall Study|P. vivax infection at screening|1
6045719|NCT00403260|9645017|FG001|Overall Study|P. vivax infection at screening|0
6045720|NCT00403260|9645016|FG000|Overall Study|P. ovale infection|1
6045721|NCT00403260|9645017|FG001|Overall Study|P. ovale infection|0
6045722|NCT00403260|9645016|FG000|Overall Study|Gametocyte re-appearance|1
6045723|NCT00403260|9645017|FG001|Overall Study|Gametocyte re-appearance|1
6045724|NCT00403260|9645016|FG000|Overall Study|Withdrawn from study accidentally|0
6045725|NCT00403260|9645017|FG001|Overall Study|Withdrawn from study accidentally|1
6045726|NCT00403273|9645025|FG000|Overall Study|Lost to Follow-up|3
6045727|NCT00403273|9645026|FG001|Overall Study|Lost to Follow-up|2
6045728|NCT00403273|9645025|FG000|Overall Study|Physician Decision|0
6045729|NCT00403273|9645026|FG001|Overall Study|Physician Decision|1
6045730|NCT00403273|9645025|FG000|Overall Study|pt. wanted to have a surgical procedure|0
6045731|NCT00403273|9645026|FG001|Overall Study|pt. wanted to have a surgical procedure|1
6045732|NCT00403390|9645036|FG000|Overall Study|Withdrawal by Subject|1
6227262|NCT01716520|9900044|FG003|Treatment Period 1 (14 Days)|Adverse Event|0
5991328|NCT00692913|9583251|FG000|Overall Study|Adverse Event|8
5991329|NCT00692913|9583252|FG001|Overall Study|Adverse Event|4
5991330|NCT00692913|9583251|FG000|Overall Study|Lost to Follow-up|3
5991331|NCT00692913|9583252|FG001|Overall Study|Lost to Follow-up|5
5991332|NCT00692913|9583251|FG000|Overall Study|Physician Decision|2
5991333|NCT00692913|9583252|FG001|Overall Study|Physician Decision|0
5991334|NCT00692913|9583251|FG000|Overall Study|Protocol Violation|1
5991335|NCT00692913|9583252|FG001|Overall Study|Protocol Violation|1
6065067|NCT00518115|9666940|FG003|Overall Study|Withdrew Consent|0
6065068|NCT00518115|9666941|FG004|Overall Study|Withdrew Consent|0
6065069|NCT00518115|9666942|FG005|Overall Study|Withdrew Consent|1
6065070|NCT00518115|9666943|FG006|Overall Study|Withdrew Consent|0
6065071|NCT00518115|9666944|FG007|Overall Study|Withdrew Consent|0
6065072|NCT00518115|9666945|FG008|Overall Study|Withdrew Consent|0
6065073|NCT00518115|9666946|FG009|Overall Study|Withdrew Consent|0
6065074|NCT00518115|9666937|FG000|Overall Study|Moved Out of State|0
6065075|NCT00518115|9666938|FG001|Overall Study|Moved Out of State|0
6065076|NCT00518115|9666939|FG002|Overall Study|Moved Out of State|0
6065077|NCT00518115|9666940|FG003|Overall Study|Moved Out of State|0
6065078|NCT00518115|9666941|FG004|Overall Study|Moved Out of State|0
6065079|NCT00518115|9666942|FG005|Overall Study|Moved Out of State|0
6065080|NCT00518115|9666943|FG006|Overall Study|Moved Out of State|0
6065081|NCT00518115|9666944|FG007|Overall Study|Moved Out of State|0
6065082|NCT00518115|9666945|FG008|Overall Study|Moved Out of State|0
6065083|NCT00518115|9666946|FG009|Overall Study|Moved Out of State|1
6065084|NCT00518180|9666976|FG000|Overall Study|Withdrawal by Subject|29
6065085|NCT00518180|9666977|FG001|Overall Study|Withdrawal by Subject|30
6065086|NCT00518180|9666978|FG002|Overall Study|Withdrawal by Subject|42
6065087|NCT00518180|9666976|FG000|Overall Study|Lost to Follow-up|30
6065088|NCT00518180|9666977|FG001|Overall Study|Lost to Follow-up|28
6065089|NCT00518180|9666978|FG002|Overall Study|Lost to Follow-up|34
6065090|NCT00518180|9666976|FG000|Overall Study|Administrative reason|0
6065091|NCT00518180|9666977|FG001|Overall Study|Administrative reason|2
6065092|NCT00518180|9666978|FG002|Overall Study|Administrative reason|2
6065093|NCT00518180|9666976|FG000|Overall Study|Protocol Violation|5
6065094|NCT00518180|9666977|FG001|Overall Study|Protocol Violation|7
6065095|NCT00518180|9666978|FG002|Overall Study|Protocol Violation|4
6065096|NCT00518180|9666976|FG000|Overall Study|Unable to classify|0
6065097|NCT00518180|9666977|FG001|Overall Study|Unable to classify|2
6065098|NCT00518180|9666978|FG002|Overall Study|Unable to classify|0
6065099|NCT00518180|9666976|FG000|Overall Study|Adverse Event|1
6065100|NCT00518180|9666977|FG001|Overall Study|Adverse Event|0
6065101|NCT00518180|9666978|FG002|Overall Study|Adverse Event|0
6065102|NCT00518206|9666997|FG000|Overall Study|Disease Progression Requiring Therapy|6
6065103|NCT00518206|9666998|FG001|Overall Study|Disease Progression Requiring Therapy|6
6065104|NCT00518206|9666997|FG000|Overall Study|Withdrawal by Subject|2
6065105|NCT00518206|9666998|FG001|Overall Study|Withdrawal by Subject|0
6065106|NCT00518206|9666997|FG000|Overall Study|Drug Supply Issue|1
6065107|NCT00518206|9666998|FG001|Overall Study|Drug Supply Issue|0
6065108|NCT00518206|9666997|FG000|Overall Study|Reason Unknown|1
6065109|NCT00518206|9666998|FG001|Overall Study|Reason Unknown|0
6065110|NCT00518206|9666997|FG000|Overall Study|Completion Status Unknown|1
6065111|NCT00518206|9666998|FG001|Overall Study|Completion Status Unknown|0
6065112|NCT00518284|9667008|FG000|Overall Study|Adverse Event|0
6065113|NCT00518284|9667009|FG001|Overall Study|Adverse Event|1
6065114|NCT00518284|9667010|FG002|Overall Study|Adverse Event|0
5991336|NCT00692913|9583251|FG000|Overall Study|Withdrawal by Subject|15
5991337|NCT00692913|9583252|FG001|Overall Study|Withdrawal by Subject|20
5991338|NCT00617708|9583298|FG000|Overall Study|Adverse Event|0
5991339|NCT00617708|9583299|FG001|Overall Study|Adverse Event|6
5991340|NCT00617708|9583300|FG002|Overall Study|Adverse Event|9
5991341|NCT00617708|9583298|FG000|Overall Study|Withdrawal by Subject|1
5991342|NCT00617708|9583299|FG001|Overall Study|Withdrawal by Subject|1
5991343|NCT00617708|9583300|FG002|Overall Study|Withdrawal by Subject|7
5991344|NCT00617708|9583298|FG000|Overall Study|Death|0
5991345|NCT00617708|9583299|FG001|Overall Study|Death|6
5991346|NCT00617708|9583300|FG002|Overall Study|Death|5
5991347|NCT00617708|9583298|FG000|Overall Study|Progression/Relapse|7
5991348|NCT00617708|9583299|FG001|Overall Study|Progression/Relapse|40
5991349|NCT00617708|9583300|FG002|Overall Study|Progression/Relapse|36
5991350|NCT00617708|9583298|FG000|Overall Study|Not protocol specified|1
5991351|NCT00617708|9583299|FG001|Overall Study|Not protocol specified|4
6065115|NCT00518284|9667011|FG003|Overall Study|Adverse Event|0
5991352|NCT00617708|9583300|FG002|Overall Study|Not protocol specified|2
5991353|NCT00617708|9583298|FG000|Overall Study|Not eligible|1
5991354|NCT00617708|9583299|FG001|Overall Study|Not eligible|3
5991355|NCT00617708|9583300|FG002|Overall Study|Not eligible|5
5991356|NCT00516737|9583312|FG000|Overall Study|Lost to Follow-up|2
5991357|NCT00516737|9583313|FG001|Overall Study|Lost to Follow-up|0
5991358|NCT00516737|9583312|FG000|Overall Study|Physician Decision|0
5991359|NCT00516737|9583313|FG001|Overall Study|Physician Decision|1
5991360|NCT00516737|9583312|FG000|Overall Study|Withdrawal by Subject|0
5991361|NCT00516737|9583313|FG001|Overall Study|Withdrawal by Subject|1
5991362|NCT00516737|9583312|FG000|Overall Study|Lack of Qualifying Event|9
5991363|NCT00516737|9583313|FG001|Overall Study|Lack of Qualifying Event|6
5991364|NCT00358527|9583321|FG000|Overall Study|Adverse Event|4
5991365|NCT00358527|9583322|FG001|Overall Study|Adverse Event|0
5991366|NCT00358527|9583321|FG000|Overall Study|Withdrawal by Subject|1
5991367|NCT00358527|9583322|FG001|Overall Study|Withdrawal by Subject|1
5991368|NCT00358527|9583321|FG000|Overall Study|Non-compliance with protocol|6
5991369|NCT00358527|9583322|FG001|Overall Study|Non-compliance with protocol|1
5991370|NCT00358527|9583321|FG000|Overall Study|Administrative|2
5991371|NCT00358527|9583322|FG001|Overall Study|Administrative|1
5991372|NCT00326898|9583331|FG000|Overall Study|Disease progression|52
5991373|NCT00326898|9583332|FG001|Overall Study|Disease progression|54
5991374|NCT00326898|9583333|FG002|Overall Study|Disease progression|102
5991375|NCT00326898|9583331|FG000|Overall Study|Adverse Event|124
5991376|NCT00326898|9583332|FG001|Overall Study|Adverse Event|128
5991377|NCT00326898|9583333|FG002|Overall Study|Adverse Event|33
5991378|NCT00326898|9583331|FG000|Overall Study|Death|2
5991379|NCT00326898|9583332|FG001|Overall Study|Death|0
5991380|NCT00326898|9583333|FG002|Overall Study|Death|0
5991381|NCT00326898|9583331|FG000|Overall Study|Withdrawal by Subject|134
5991382|NCT00326898|9583332|FG001|Overall Study|Withdrawal by Subject|128
5991383|NCT00326898|9583333|FG002|Overall Study|Withdrawal by Subject|32
5991384|NCT00326898|9583331|FG000|Overall Study|Alternative therapy|1
5991385|NCT00326898|9583332|FG001|Overall Study|Alternative therapy|0
5991386|NCT00326898|9583333|FG002|Overall Study|Alternative therapy|0
5991387|NCT00326898|9583331|FG000|Overall Study|Other complicating disease|5
5991388|NCT00326898|9583332|FG001|Overall Study|Other complicating disease|5
5991389|NCT00326898|9583333|FG002|Overall Study|Other complicating disease|4
5991390|NCT00326898|9583331|FG000|Overall Study|Other/Missing/Unknown|33
5991391|NCT00326898|9583332|FG001|Overall Study|Other/Missing/Unknown|28
5991392|NCT00326898|9583333|FG002|Overall Study|Other/Missing/Unknown|32
5991393|NCT00156065|9583344|FG000|Overall Study|Enrolled But Never Received Treatment|1
5991394|NCT00156065|9583345|FG001|Overall Study|Enrolled But Never Received Treatment|1
6045733|NCT00403390|9645037|FG001|Overall Study|Withdrawal by Subject|0
5991395|NCT00156065|9583346|FG002|Overall Study|Enrolled But Never Received Treatment|0
5991396|NCT00156065|9583344|FG000|Overall Study|Adverse Event|8
5991397|NCT00156065|9583345|FG001|Overall Study|Adverse Event|11
5991398|NCT00156065|9583346|FG002|Overall Study|Adverse Event|4
5991399|NCT00156065|9583344|FG000|Overall Study|Lack of Efficacy|2
5991400|NCT00156065|9583345|FG001|Overall Study|Lack of Efficacy|9
5991401|NCT00156065|9583346|FG002|Overall Study|Lack of Efficacy|3
5991402|NCT00156065|9583344|FG000|Overall Study|Withdrawal by Subject|13
5991403|NCT00156065|9583345|FG001|Overall Study|Withdrawal by Subject|26
5991404|NCT00156065|9583346|FG002|Overall Study|Withdrawal by Subject|16
5991405|NCT00156065|9583344|FG000|Overall Study|Lost to Follow-up|5
5991406|NCT00156065|9583345|FG001|Overall Study|Lost to Follow-up|7
5991407|NCT00156065|9583346|FG002|Overall Study|Lost to Follow-up|1
5991408|NCT00156065|9583344|FG000|Overall Study|Other|2
5991409|NCT00156065|9583345|FG001|Overall Study|Other|9
5991410|NCT00156065|9583346|FG002|Overall Study|Other|3
5991411|NCT00150176|9583356|FG000|Overall Study|Adverse Event|16
5991412|NCT00150176|9583357|FG001|Overall Study|Adverse Event|53
5991413|NCT00150176|9583356|FG000|Overall Study|Relapse/Impending relapse, non-AE|10
5991414|NCT00150176|9583357|FG001|Overall Study|Relapse/Impending relapse, non-AE|39
5991415|NCT00150176|9583356|FG000|Overall Study|Withdrawal by Subject|19
5991416|NCT00150176|9583357|FG001|Overall Study|Withdrawal by Subject|12
5991417|NCT00150176|9583356|FG000|Overall Study|Lost to Follow-up|3
5991418|NCT00150176|9583357|FG001|Overall Study|Lost to Follow-up|3
5991419|NCT00150176|9583356|FG000|Overall Study|OTHER|11
5991420|NCT00150176|9583357|FG001|Overall Study|OTHER|13
5991421|NCT00145509|9583366|FG000|Overall Study|Adverse Event|10
5991422|NCT00145509|9583367|FG001|Overall Study|Adverse Event|3
5991423|NCT00145509|9583366|FG000|Overall Study|Lack of Efficacy|3
5991424|NCT00145509|9583367|FG001|Overall Study|Lack of Efficacy|1
5991425|NCT00145509|9583366|FG000|Overall Study|Lost to Follow-up|5
5991426|NCT00145509|9583367|FG001|Overall Study|Lost to Follow-up|9
5991427|NCT00145509|9583366|FG000|Overall Study|Withdrew Consent|2
5991428|NCT00145509|9583367|FG001|Overall Study|Withdrew Consent|7
5991429|NCT00145509|9583366|FG000|Overall Study|Reason not provided|2
5991430|NCT00145509|9583367|FG001|Overall Study|Reason not provided|1
5991431|NCT00145496|9583375|FG000|Overall Study|Adverse Event|42
5991432|NCT00145496|9583376|FG001|Overall Study|Adverse Event|30
5991433|NCT00145496|9583375|FG000|Overall Study|Lack of Efficacy|12
5991434|NCT00145496|9583376|FG001|Overall Study|Lack of Efficacy|7
5991435|NCT00145496|9583375|FG000|Overall Study|Withdrawal by Subject|32
5991436|NCT00145496|9583376|FG001|Overall Study|Withdrawal by Subject|26
5991437|NCT00145496|9583375|FG000|Overall Study|Lost to Follow-up|12
5991438|NCT00145496|9583376|FG001|Overall Study|Lost to Follow-up|5
5991439|NCT00145496|9583375|FG000|Overall Study|Other|25
5991440|NCT00145496|9583376|FG001|Overall Study|Other|13
5991441|NCT00145470|9583384|FG000|Overall Study|Adverse Event|19
5991442|NCT00145470|9583385|FG001|Overall Study|Adverse Event|25
5991443|NCT00145470|9583384|FG000|Overall Study|Lack of Efficacy|27
5991444|NCT00145470|9583385|FG001|Overall Study|Lack of Efficacy|13
5991445|NCT00145470|9583384|FG000|Overall Study|Withdrawal by Subject|36
5991446|NCT00145470|9583385|FG001|Overall Study|Withdrawal by Subject|34
5991447|NCT00145470|9583384|FG000|Overall Study|Lost to Follow-up|21
5991448|NCT00145470|9583385|FG001|Overall Study|Lost to Follow-up|17
5991449|NCT00145470|9583384|FG000|Overall Study|Reason Not Reported|9
5991450|NCT00145470|9583385|FG001|Overall Study|Reason Not Reported|9
5991451|NCT00129402|9583393|FG000|Start Period1 to End Period1 (Week 1-6)|Adverse Event|0
5991452|NCT00129402|9583394|FG001|Start Period1 to End Period1 (Week 1-6)|Adverse Event|1
5991453|NCT00129402|9583395|FG002|Start Period1 to End Period1 (Week 1-6)|Adverse Event|1
5991454|NCT00129402|9583396|FG003|Start Period1 to End Period1 (Week 1-6)|Adverse Event|0
5991455|NCT00129402|9583397|FG004|Start Period1 to End Period1 (Week 1-6)|Adverse Event|0
5991456|NCT00129402|9583398|FG005|Start Period1 to End Period1 (Week 1-6)|Adverse Event|1
5991457|NCT00129402|9583399|FG006|Start Period1 to End Period1 (Week 1-6)|Adverse Event|0
5991458|NCT00129402|9583393|FG000|Start Period1 to End Period1 (Week 1-6)|Lost to Follow-up|0
5991459|NCT00129402|9583394|FG001|Start Period1 to End Period1 (Week 1-6)|Lost to Follow-up|0
5991460|NCT00129402|9583395|FG002|Start Period1 to End Period1 (Week 1-6)|Lost to Follow-up|0
5991461|NCT00129402|9583396|FG003|Start Period1 to End Period1 (Week 1-6)|Lost to Follow-up|0
5991462|NCT00129402|9583397|FG004|Start Period1 to End Period1 (Week 1-6)|Lost to Follow-up|0
5991463|NCT00129402|9583398|FG005|Start Period1 to End Period1 (Week 1-6)|Lost to Follow-up|1
5991464|NCT00129402|9583399|FG006|Start Period1 to End Period1 (Week 1-6)|Lost to Follow-up|0
5991465|NCT00129402|9583393|FG000|Start Period1 to End Period1 (Week 1-6)|Protocol Violation|0
5991466|NCT00129402|9583394|FG001|Start Period1 to End Period1 (Week 1-6)|Protocol Violation|0
5991467|NCT00129402|9583395|FG002|Start Period1 to End Period1 (Week 1-6)|Protocol Violation|0
5991468|NCT00129402|9583396|FG003|Start Period1 to End Period1 (Week 1-6)|Protocol Violation|1
5991469|NCT00129402|9583397|FG004|Start Period1 to End Period1 (Week 1-6)|Protocol Violation|0
5991470|NCT00129402|9583398|FG005|Start Period1 to End Period1 (Week 1-6)|Protocol Violation|0
5991471|NCT00129402|9583399|FG006|Start Period1 to End Period1 (Week 1-6)|Protocol Violation|0
6065116|NCT00518284|9667008|FG000|Overall Study|Study Termination|0
6065117|NCT00518284|9667009|FG001|Overall Study|Study Termination|2
6065118|NCT00518284|9667010|FG002|Overall Study|Study Termination|1
6065119|NCT00518284|9667011|FG003|Overall Study|Study Termination|2
6065120|NCT00518323|9667025|FG000|Overall Study|Lack of Efficacy|14
6065121|NCT00518323|9667026|FG001|Overall Study|Lack of Efficacy|2
6065122|NCT00518323|9667027|FG002|Overall Study|Lack of Efficacy|4
6065123|NCT00518323|9667028|FG003|Overall Study|Lack of Efficacy|20
6065124|NCT00518323|9667025|FG000|Overall Study|Withdrawal by Subject|1
6065125|NCT00518323|9667026|FG001|Overall Study|Withdrawal by Subject|2
6065126|NCT00518323|9667027|FG002|Overall Study|Withdrawal by Subject|4
6065127|NCT00518323|9667028|FG003|Overall Study|Withdrawal by Subject|2
6065128|NCT00518323|9667025|FG000|Overall Study|Lost to Follow-up|0
6065129|NCT00518323|9667026|FG001|Overall Study|Lost to Follow-up|2
6065130|NCT00518323|9667027|FG002|Overall Study|Lost to Follow-up|1
6065131|NCT00518323|9667028|FG003|Overall Study|Lost to Follow-up|3
6065132|NCT00518323|9667025|FG000|Overall Study|Adverse Event|1
6065133|NCT00518323|9667026|FG001|Overall Study|Adverse Event|1
6065134|NCT00518323|9667027|FG002|Overall Study|Adverse Event|1
6065135|NCT00518323|9667028|FG003|Overall Study|Adverse Event|0
6065136|NCT00518323|9667025|FG000|Overall Study|Prohibited medication and others|3
6065137|NCT00518323|9667026|FG001|Overall Study|Prohibited medication and others|1
6065138|NCT00518323|9667027|FG002|Overall Study|Prohibited medication and others|1
6065139|NCT00518323|9667028|FG003|Overall Study|Prohibited medication and others|0
6065140|NCT00518336|9667040|FG000|Year 7|Lost to Follow-up|2
6065141|NCT00518336|9667041|FG001|Year 7|Lost to Follow-up|0
6065142|NCT00518336|9667040|FG000|Year 7|Could not attend in time|0
6065143|NCT00518336|9667041|FG001|Year 7|Could not attend in time|3
6065144|NCT00518336|9667040|FG000|Year 8|Lost to Follow-up|1
6065145|NCT00518336|9667041|FG001|Year 8|Lost to Follow-up|1
6065146|NCT00518336|9667040|FG000|Year 8|Could not attend in time|0
6065147|NCT00518336|9667041|FG001|Year 8|Could not attend in time|1
6065148|NCT00518336|9667040|FG000|Year 9|Migrated/moved from study area|1
6065149|NCT00518336|9667041|FG001|Year 9|Migrated/moved from study area|1
6065150|NCT00518336|9667040|FG000|Year 9|Lost to Follow-up|3
6065151|NCT00518336|9667041|FG001|Year 9|Lost to Follow-up|0
6065152|NCT00518336|9667040|FG000|Year 9|Personal reasons|1
6065153|NCT00518336|9667041|FG001|Year 9|Personal reasons|0
6065154|NCT00518531|9667058|FG000|Treatment Period 1|Adverse Event|5
6065155|NCT00518531|9667059|FG001|Treatment Period 1|Adverse Event|0
6065156|NCT00518531|9667058|FG000|Treatment Period 1|Lost to Follow-up|5
6065157|NCT00518531|9667059|FG001|Treatment Period 1|Lost to Follow-up|3
5991472|NCT00129402|9583393|FG000|Start Period1 to End Period1 (Week 1-6)|Withdrawal by Subject|0
5991473|NCT00129402|9583394|FG001|Start Period1 to End Period1 (Week 1-6)|Withdrawal by Subject|0
5991474|NCT00129402|9583395|FG002|Start Period1 to End Period1 (Week 1-6)|Withdrawal by Subject|1
5991475|NCT00129402|9583396|FG003|Start Period1 to End Period1 (Week 1-6)|Withdrawal by Subject|0
5991476|NCT00129402|9583397|FG004|Start Period1 to End Period1 (Week 1-6)|Withdrawal by Subject|1
5991477|NCT00129402|9583398|FG005|Start Period1 to End Period1 (Week 1-6)|Withdrawal by Subject|0
5991478|NCT00129402|9583399|FG006|Start Period1 to End Period1 (Week 1-6)|Withdrawal by Subject|0
5991479|NCT00129402|9583393|FG000|Start Period2 to End Period2 (Week 7-33)|Adverse Event|0
5991480|NCT00129402|9583394|FG001|Start Period2 to End Period2 (Week 7-33)|Adverse Event|0
5991481|NCT00129402|9583395|FG002|Start Period2 to End Period2 (Week 7-33)|Adverse Event|2
5991482|NCT00129402|9583396|FG003|Start Period2 to End Period2 (Week 7-33)|Adverse Event|0
5991483|NCT00129402|9583397|FG004|Start Period2 to End Period2 (Week 7-33)|Adverse Event|0
5991484|NCT00129402|9583398|FG005|Start Period2 to End Period2 (Week 7-33)|Adverse Event|0
5991485|NCT00129402|9583399|FG006|Start Period2 to End Period2 (Week 7-33)|Adverse Event|0
5991486|NCT00129402|9583393|FG000|Start Period2 to End Period2 (Week 7-33)|Laboratory Adverse Event|0
5991487|NCT00129402|9583394|FG001|Start Period2 to End Period2 (Week 7-33)|Laboratory Adverse Event|0
5991488|NCT00129402|9583395|FG002|Start Period2 to End Period2 (Week 7-33)|Laboratory Adverse Event|3
5991489|NCT00129402|9583396|FG003|Start Period2 to End Period2 (Week 7-33)|Laboratory Adverse Event|0
5991490|NCT00129402|9583397|FG004|Start Period2 to End Period2 (Week 7-33)|Laboratory Adverse Event|0
5991491|NCT00129402|9583398|FG005|Start Period2 to End Period2 (Week 7-33)|Laboratory Adverse Event|1
5991492|NCT00129402|9583399|FG006|Start Period2 to End Period2 (Week 7-33)|Laboratory Adverse Event|0
5991493|NCT00129402|9583393|FG000|Start Period2 to End Period2 (Week 7-33)|Lost to Follow-up|0
5991494|NCT00129402|9583394|FG001|Start Period2 to End Period2 (Week 7-33)|Lost to Follow-up|0
5991495|NCT00129402|9583395|FG002|Start Period2 to End Period2 (Week 7-33)|Lost to Follow-up|1
5991496|NCT00129402|9583396|FG003|Start Period2 to End Period2 (Week 7-33)|Lost to Follow-up|0
5991497|NCT00129402|9583397|FG004|Start Period2 to End Period2 (Week 7-33)|Lost to Follow-up|0
5991498|NCT00129402|9583398|FG005|Start Period2 to End Period2 (Week 7-33)|Lost to Follow-up|0
5991499|NCT00129402|9583399|FG006|Start Period2 to End Period2 (Week 7-33)|Lost to Follow-up|0
5991500|NCT00129402|9583393|FG000|Start Period2 to End Period2 (Week 7-33)|Withdrawal by Subject|0
5991501|NCT00129402|9583394|FG001|Start Period2 to End Period2 (Week 7-33)|Withdrawal by Subject|0
5991502|NCT00129402|9583395|FG002|Start Period2 to End Period2 (Week 7-33)|Withdrawal by Subject|1
5991503|NCT00129402|9583396|FG003|Start Period2 to End Period2 (Week 7-33)|Withdrawal by Subject|0
5991504|NCT00129402|9583397|FG004|Start Period2 to End Period2 (Week 7-33)|Withdrawal by Subject|0
5991505|NCT00129402|9583398|FG005|Start Period2 to End Period2 (Week 7-33)|Withdrawal by Subject|3
5991506|NCT00129402|9583399|FG006|Start Period2 to End Period2 (Week 7-33)|Withdrawal by Subject|0
5991507|NCT00129402|9583393|FG000|Start Period2 to End Period2 (Week 7-33)|Protocol Violation|0
5991508|NCT00129402|9583394|FG001|Start Period2 to End Period2 (Week 7-33)|Protocol Violation|0
5991509|NCT00129402|9583395|FG002|Start Period2 to End Period2 (Week 7-33)|Protocol Violation|1
5991510|NCT00129402|9583396|FG003|Start Period2 to End Period2 (Week 7-33)|Protocol Violation|0
5991511|NCT00129402|9583397|FG004|Start Period2 to End Period2 (Week 7-33)|Protocol Violation|0
5991512|NCT00129402|9583398|FG005|Start Period2 to End Period2 (Week 7-33)|Protocol Violation|1
5991513|NCT00129402|9583399|FG006|Start Period2 to End Period2 (Week 7-33)|Protocol Violation|0
5991514|NCT00129402|9583393|FG000|Start Period3 to End Period3(Week 34-53)|Lost to Follow-up|0
5991515|NCT00129402|9583394|FG001|Start Period3 to End Period3(Week 34-53)|Lost to Follow-up|0
5991516|NCT00129402|9583395|FG002|Start Period3 to End Period3(Week 34-53)|Lost to Follow-up|0
5991517|NCT00129402|9583396|FG003|Start Period3 to End Period3(Week 34-53)|Lost to Follow-up|0
5991518|NCT00129402|9583397|FG004|Start Period3 to End Period3(Week 34-53)|Lost to Follow-up|0
5991519|NCT00129402|9583398|FG005|Start Period3 to End Period3(Week 34-53)|Lost to Follow-up|0
5991520|NCT00129402|9583399|FG006|Start Period3 to End Period3(Week 34-53)|Lost to Follow-up|1
5991521|NCT00129402|9583393|FG000|Start Period3 to End Period3(Week 34-53)|Withdrawal by Subject|0
6065158|NCT00518531|9667058|FG000|Treatment Period 1|Physician Decision|1
6065159|NCT00518531|9667059|FG001|Treatment Period 1|Physician Decision|0
6065160|NCT00518531|9667058|FG000|Treatment Period 1|Protocol Violation|2
6065161|NCT00518531|9667059|FG001|Treatment Period 1|Protocol Violation|0
6065162|NCT00518531|9667058|FG000|Treatment Period 1|Withdrawal by Subject|4
6065163|NCT00518531|9667059|FG001|Treatment Period 1|Withdrawal by Subject|6
6065164|NCT00518531|9667058|FG000|Treatment Period 1|Early crossover|1
6065165|NCT00518531|9667059|FG001|Treatment Period 1|Early crossover|3
6065166|NCT00518531|9667058|FG000|Treatment Period 2|Withdrawal by Subject|0
6065167|NCT00518531|9667059|FG001|Treatment Period 2|Withdrawal by Subject|8
6065168|NCT00518531|9667058|FG000|Treatment Period 2|Complete out of scheduled visit window|1
6065169|NCT00518531|9667059|FG001|Treatment Period 2|Complete out of scheduled visit window|2
6065170|NCT00518531|9667058|FG000|Treatment Period 2|Adverse Event|1
6065171|NCT00518531|9667059|FG001|Treatment Period 2|Adverse Event|7
6065172|NCT00518531|9667058|FG000|Treatment Period 2|Protocol-specified criteria|0
6065173|NCT00518531|9667059|FG001|Treatment Period 2|Protocol-specified criteria|1
6065174|NCT00518531|9667058|FG000|Treatment Period 2|Non-compliance|1
6065175|NCT00518531|9667059|FG001|Treatment Period 2|Non-compliance|2
6065176|NCT00518622|9667075|FG000|Overall Study|Lost to Follow-up|0
6065177|NCT00518622|9667076|FG001|Overall Study|Lost to Follow-up|0
6065178|NCT00518622|9667077|FG002|Overall Study|Lost to Follow-up|1
6065179|NCT00518622|9667078|FG003|Overall Study|Lost to Follow-up|0
6065180|NCT00518622|9667079|FG004|Overall Study|Lost to Follow-up|0
6065181|NCT00518622|9667080|FG005|Overall Study|Lost to Follow-up|0
6065182|NCT00518622|9667081|FG006|Overall Study|Lost to Follow-up|0
6065183|NCT00518622|9667082|FG007|Overall Study|Lost to Follow-up|0
6065184|NCT00518622|9667075|FG000|Overall Study|Study medication taken incorrectly|0
6065185|NCT00518622|9667076|FG001|Overall Study|Study medication taken incorrectly|1
6065186|NCT00518622|9667077|FG002|Overall Study|Study medication taken incorrectly|0
6065187|NCT00518622|9667078|FG003|Overall Study|Study medication taken incorrectly|0
6065188|NCT00518622|9667079|FG004|Overall Study|Study medication taken incorrectly|0
6065189|NCT00518622|9667080|FG005|Overall Study|Study medication taken incorrectly|0
6065190|NCT00518622|9667081|FG006|Overall Study|Study medication taken incorrectly|0
6065191|NCT00518622|9667082|FG007|Overall Study|Study medication taken incorrectly|0
6065192|NCT00518687|9667102|FG000|Overall Study|Adverse Event|201
6065193|NCT00518687|9667103|FG001|Overall Study|Adverse Event|177
6065194|NCT00518687|9667102|FG000|Overall Study|Lost to Follow-up|144
6065195|NCT00518687|9667103|FG001|Overall Study|Lost to Follow-up|155
6065196|NCT00518687|9667102|FG000|Overall Study|Physician Decision|42
6065197|NCT00518687|9667103|FG001|Overall Study|Physician Decision|48
6065198|NCT00518687|9667102|FG000|Overall Study|Progressive disease|2
6065199|NCT00518687|9667103|FG001|Overall Study|Progressive disease|2
6065200|NCT00518687|9667102|FG000|Overall Study|Protocol Violation|8
6065201|NCT00518687|9667103|FG001|Overall Study|Protocol Violation|10
6065202|NCT00518687|9667102|FG000|Overall Study|Study terminated by sponsor|930
6065203|NCT00518687|9667103|FG001|Overall Study|Study terminated by sponsor|918
6065204|NCT00518687|9667102|FG000|Overall Study|Withdrawal by Subject|110
6065205|NCT00518687|9667103|FG001|Overall Study|Withdrawal by Subject|110
6065206|NCT00518882|9667128|FG000|Double-Blind, Week 0-26|Adverse Event|23
6065207|NCT00518882|9667129|FG001|Double-Blind, Week 0-26|Adverse Event|31
6065208|NCT00518882|9667128|FG000|Double-Blind, Week 0-26|Lack of Efficacy|1
6065209|NCT00518882|9667129|FG001|Double-Blind, Week 0-26|Lack of Efficacy|0
6065210|NCT00518882|9667128|FG000|Double-Blind, Week 0-26|Protocol Violation|4
6065211|NCT00518882|9667129|FG001|Double-Blind, Week 0-26|Protocol Violation|3
6065212|NCT00518882|9667128|FG000|Double-Blind, Week 0-26|Withdrawal criteria|1
6065213|NCT00518882|9667129|FG001|Double-Blind, Week 0-26|Withdrawal criteria|1
6065214|NCT00518882|9667128|FG000|Double-Blind, Week 0-26|Lost to follow up|2
6065215|NCT00518882|9667129|FG001|Double-Blind, Week 0-26|Lost to follow up|1
6065216|NCT00518882|9667128|FG000|Double-Blind, Week 0-26|Subject decision|1
6065217|NCT00518882|9667129|FG001|Double-Blind, Week 0-26|Subject decision|1
6065218|NCT00518882|9667128|FG000|Double-Blind, Week 0-26|Withdrawal of consent|1
6065219|NCT00518882|9667129|FG001|Double-Blind, Week 0-26|Withdrawal of consent|3
6065220|NCT00518882|9667128|FG000|Double-Blind, Week 0-26|Loss of trust|0
6065221|NCT00518882|9667129|FG001|Double-Blind, Week 0-26|Loss of trust|1
6065222|NCT00518882|9667128|FG000|Double-Blind, Week 0-26|Fear of hypoglycaemia|0
6065223|NCT00518882|9667129|FG001|Double-Blind, Week 0-26|Fear of hypoglycaemia|1
6065224|NCT00518882|9667128|FG000|Double-Blind, Week 0-26|Hypoglycaemia|0
6065225|NCT00518882|9667129|FG001|Double-Blind, Week 0-26|Hypoglycaemia|2
6065226|NCT00518882|9667128|FG000|Double-Blind, Week 0-26|Mutual consent|0
6065227|NCT00518882|9667129|FG001|Double-Blind, Week 0-26|Mutual consent|1
6065228|NCT00518882|9667128|FG000|Open-Label Extension, Week 26-78|Adverse Event|3
6065229|NCT00518882|9667129|FG001|Open-Label Extension, Week 26-78|Adverse Event|9
6065230|NCT00518882|9667128|FG000|Open-Label Extension, Week 26-78|Lack of Efficacy|6
6065231|NCT00518882|9667129|FG001|Open-Label Extension, Week 26-78|Lack of Efficacy|5
6065232|NCT00518882|9667128|FG000|Open-Label Extension, Week 26-78|Protocol Violation|3
6065233|NCT00518882|9667129|FG001|Open-Label Extension, Week 26-78|Protocol Violation|4
6227263|NCT01716520|9900045|FG004|Treatment Period 1 (14 Days)|Adverse Event|0
6227264|NCT01716520|9900046|FG005|Treatment Period 1 (14 Days)|Adverse Event|0
6227265|NCT01716520|9900041|FG000|Treatment Period 1 (14 Days)|Protocol-defined Stopping Criteria|1
6227266|NCT01716520|9900042|FG001|Treatment Period 1 (14 Days)|Protocol-defined Stopping Criteria|0
6227267|NCT01716520|9900043|FG002|Treatment Period 1 (14 Days)|Protocol-defined Stopping Criteria|2
6227268|NCT01716520|9900044|FG003|Treatment Period 1 (14 Days)|Protocol-defined Stopping Criteria|1
6227269|NCT01716520|9900045|FG004|Treatment Period 1 (14 Days)|Protocol-defined Stopping Criteria|0
6227270|NCT01716520|9900046|FG005|Treatment Period 1 (14 Days)|Protocol-defined Stopping Criteria|1
6227271|NCT01716520|9900041|FG000|Treatment Period 1 (14 Days)|Withdrawal by Subject|0
6227272|NCT01716520|9900042|FG001|Treatment Period 1 (14 Days)|Withdrawal by Subject|1
6227273|NCT01716520|9900043|FG002|Treatment Period 1 (14 Days)|Withdrawal by Subject|0
6227274|NCT01716520|9900044|FG003|Treatment Period 1 (14 Days)|Withdrawal by Subject|0
6227275|NCT01716520|9900045|FG004|Treatment Period 1 (14 Days)|Withdrawal by Subject|0
6227276|NCT01716520|9900046|FG005|Treatment Period 1 (14 Days)|Withdrawal by Subject|0
6227277|NCT01716520|9900041|FG000|Washout Period 1 (10 to 14 Days)|Adverse Event|0
6227278|NCT01716520|9900042|FG001|Washout Period 1 (10 to 14 Days)|Adverse Event|1
6065234|NCT00518882|9667128|FG000|Open-Label Extension, Week 26-78|Withdrawel criteria|1
6065235|NCT00518882|9667129|FG001|Open-Label Extension, Week 26-78|Withdrawel criteria|2
6065236|NCT00518882|9667128|FG000|Open-Label Extension, Week 26-78|Hypoglycaemia|0
6065237|NCT00518882|9667129|FG001|Open-Label Extension, Week 26-78|Hypoglycaemia|1
6065238|NCT00518882|9667128|FG000|Open-Label Extension, Week 26-78|Lost to follow up|1
6065239|NCT00518882|9667129|FG001|Open-Label Extension, Week 26-78|Lost to follow up|1
6065240|NCT00518882|9667128|FG000|Open-Label Extension, Week 26-78|Consent withdrawn|2
6065241|NCT00518882|9667129|FG001|Open-Label Extension, Week 26-78|Consent withdrawn|1
6065242|NCT00518882|9667128|FG000|Open-Label Extension, Week 26-78|Change in treatment|1
6065243|NCT00518882|9667129|FG001|Open-Label Extension, Week 26-78|Change in treatment|1
6065244|NCT00518882|9667128|FG000|Open-Label Extension, Week 26-78|Creatine increased|1
6065245|NCT00518882|9667129|FG001|Open-Label Extension, Week 26-78|Creatine increased|0
6065246|NCT00518882|9667128|FG000|Open-Label Extension, Week 26-78|Decreased kidney function|1
6065247|NCT00518882|9667129|FG001|Open-Label Extension, Week 26-78|Decreased kidney function|0
6065248|NCT00518882|9667128|FG000|Open-Label Extension, Week 26-78|Exclusion criteria|2
6065249|NCT00518882|9667129|FG001|Open-Label Extension, Week 26-78|Exclusion criteria|0
6065250|NCT00518882|9667128|FG000|Open-Label Extension, Week 26-78|Subject decision|2
6065251|NCT00518882|9667129|FG001|Open-Label Extension, Week 26-78|Subject decision|0
6065252|NCT00518882|9667128|FG000|Open-Label Extension, Week 26-78|Completed extension 1 (weeks 26-40)|18
6065253|NCT00518882|9667129|FG001|Open-Label Extension, Week 26-78|Completed extension 1 (weeks 26-40)|25
6065254|NCT00518973|9667137|FG000|Overall Study|Withdrawal by Subject|3
6065255|NCT00518973|9667138|FG001|Overall Study|Withdrawal by Subject|2
6065256|NCT00518986|9667146|FG000|Overall Study|Adverse Event|12
6065257|NCT00518986|9667147|FG001|Overall Study|Adverse Event|7
6065258|NCT00518986|9667146|FG000|Overall Study|Lack of Efficacy|0
6065259|NCT00518986|9667147|FG001|Overall Study|Lack of Efficacy|2
6065260|NCT00518986|9667146|FG000|Overall Study|Lost to Follow-up|3
6065261|NCT00518986|9667147|FG001|Overall Study|Lost to Follow-up|2
6065262|NCT00518986|9667146|FG000|Overall Study|Physician Decision|0
6065263|NCT00518986|9667147|FG001|Overall Study|Physician Decision|3
6065264|NCT00518986|9667146|FG000|Overall Study|Protocol Violation|5
6065265|NCT00518986|9667147|FG001|Overall Study|Protocol Violation|7
6065266|NCT00518986|9667146|FG000|Overall Study|Withdrawal by Subject|4
6065267|NCT00518986|9667147|FG001|Overall Study|Withdrawal by Subject|4
6065268|NCT00518986|9667146|FG000|Overall Study|Non-Specific|2
6065269|NCT00518986|9667147|FG001|Overall Study|Non-Specific|1
6087081|NCT00666458|9697241|FG001|Overall Study|Medical history of anemia|0
6087082|NCT00666536|9697249|FG000|Overall Study|Adverse Event|9
6065270|NCT00519077|9667153|FG000|Overall Study|Death|6
6065271|NCT00519077|9667153|FG000|Overall Study|Other|2
6065272|NCT00519194|9667157|FG000|Overall Study|Withdrawal by Subject|9
6065273|NCT00519194|9667157|FG000|Overall Study|Death|9
6065274|NCT00519194|9667157|FG000|Overall Study|Lost to Follow-up|3
6065275|NCT00519285|9667163|FG000|Overall Study|Adverse Event|127
6065276|NCT00519285|9667164|FG001|Overall Study|Adverse Event|266
6065277|NCT00519285|9667163|FG000|Overall Study|Disease progression|334
6065278|NCT00519285|9667164|FG001|Overall Study|Disease progression|186
6065279|NCT00519285|9667163|FG000|Overall Study|Physician Decision|75
6065280|NCT00519285|9667164|FG001|Overall Study|Physician Decision|47
6065281|NCT00519285|9667163|FG000|Overall Study|Participant's request|53
6065282|NCT00519285|9667164|FG001|Overall Study|Participant's request|84
6065283|NCT00519285|9667163|FG000|Overall Study|Consent withdrawn|4
6065284|NCT00519285|9667164|FG001|Overall Study|Consent withdrawn|5
6065285|NCT00519285|9667163|FG000|Overall Study|Poor compliance to protocol|5
6065286|NCT00519285|9667164|FG001|Overall Study|Poor compliance to protocol|7
6065287|NCT00519285|9667163|FG000|Overall Study|Reason unspecified|5
6065288|NCT00519285|9667164|FG001|Overall Study|Reason unspecified|8
6065289|NCT00519285|9667163|FG000|Overall Study|Not treated|8
6065290|NCT00519285|9667164|FG001|Overall Study|Not treated|7
6065291|NCT00519285|9667163|FG000|Overall Study|Treatment ongoing|1
6065292|NCT00519285|9667164|FG001|Overall Study|Treatment ongoing|2
6065293|NCT00519376|9667170|FG000|Treatment Period 2|Unable Evaluate Cardiovascular Endpoints|0
6065294|NCT00519376|9667171|FG001|Treatment Period 2|Unable Evaluate Cardiovascular Endpoints|0
6065295|NCT00519376|9667172|FG002|Treatment Period 2|Unable Evaluate Cardiovascular Endpoints|0
6065296|NCT00519376|9667173|FG003|Treatment Period 2|Unable Evaluate Cardiovascular Endpoints|0
6065297|NCT00519376|9667174|FG004|Treatment Period 2|Unable Evaluate Cardiovascular Endpoints|0
6065298|NCT00519376|9667175|FG005|Treatment Period 2|Unable Evaluate Cardiovascular Endpoints|0
6065299|NCT00519376|9667176|FG006|Treatment Period 2|Unable Evaluate Cardiovascular Endpoints|0
6065300|NCT00519376|9667177|FG007|Treatment Period 2|Unable Evaluate Cardiovascular Endpoints|0
6065301|NCT00519376|9667178|FG008|Treatment Period 2|Unable Evaluate Cardiovascular Endpoints|0
6065302|NCT00519376|9667179|FG009|Treatment Period 2|Unable Evaluate Cardiovascular Endpoints|0
6065303|NCT00519376|9667180|FG010|Treatment Period 2|Unable Evaluate Cardiovascular Endpoints|0
6065304|NCT00519376|9667181|FG011|Treatment Period 2|Unable Evaluate Cardiovascular Endpoints|0
6065305|NCT00519376|9667182|FG012|Treatment Period 2|Unable Evaluate Cardiovascular Endpoints|1
6065306|NCT00519376|9667183|FG013|Treatment Period 2|Unable Evaluate Cardiovascular Endpoints|0
6065307|NCT00519376|9667184|FG014|Treatment Period 2|Unable Evaluate Cardiovascular Endpoints|0
6065308|NCT00519376|9667185|FG015|Treatment Period 2|Unable Evaluate Cardiovascular Endpoints|0
6065309|NCT00519376|9667170|FG000|Treatment Period 4|Lost to Follow-up|0
6065310|NCT00519376|9667171|FG001|Treatment Period 4|Lost to Follow-up|0
6065311|NCT00519376|9667172|FG002|Treatment Period 4|Lost to Follow-up|1
6065312|NCT00519376|9667173|FG003|Treatment Period 4|Lost to Follow-up|0
6065313|NCT00519376|9667174|FG004|Treatment Period 4|Lost to Follow-up|0
6065314|NCT00519376|9667175|FG005|Treatment Period 4|Lost to Follow-up|0
6065315|NCT00519376|9667176|FG006|Treatment Period 4|Lost to Follow-up|0
6065316|NCT00519376|9667177|FG007|Treatment Period 4|Lost to Follow-up|0
6065317|NCT00519376|9667178|FG008|Treatment Period 4|Lost to Follow-up|0
6065318|NCT00519376|9667179|FG009|Treatment Period 4|Lost to Follow-up|0
6065319|NCT00519376|9667180|FG010|Treatment Period 4|Lost to Follow-up|0
6065320|NCT00519376|9667181|FG011|Treatment Period 4|Lost to Follow-up|0
6065321|NCT00519376|9667182|FG012|Treatment Period 4|Lost to Follow-up|0
6065322|NCT00519376|9667183|FG013|Treatment Period 4|Lost to Follow-up|0
6065323|NCT00519376|9667184|FG014|Treatment Period 4|Lost to Follow-up|0
6065324|NCT00519376|9667185|FG015|Treatment Period 4|Lost to Follow-up|0
6065325|NCT00519428|9667200|FG000|Overall Study|Adverse Event|5
6065326|NCT00519428|9667201|FG001|Overall Study|Adverse Event|2
6065327|NCT00519428|9667202|FG002|Overall Study|Adverse Event|10
6065328|NCT00519428|9667200|FG000|Overall Study|Lost to Follow-up|7
6065329|NCT00519428|9667201|FG001|Overall Study|Lost to Follow-up|7
6065330|NCT00519428|9667202|FG002|Overall Study|Lost to Follow-up|6
6065331|NCT00519428|9667200|FG000|Overall Study|Withdrawal by Subject|8
6065332|NCT00519428|9667201|FG001|Overall Study|Withdrawal by Subject|3
6065333|NCT00519428|9667202|FG002|Overall Study|Withdrawal by Subject|7
6065334|NCT00519428|9667200|FG000|Overall Study|unstated|1
6065335|NCT00519428|9667201|FG001|Overall Study|unstated|3
6065336|NCT00519428|9667202|FG002|Overall Study|unstated|2
6065337|NCT00519532|9667213|FG000|Overall Study|Adverse Event|11
6065338|NCT00519532|9667213|FG000|Overall Study|Withdrawal by Subject|5
6065339|NCT00519532|9667213|FG000|Overall Study|Lost to Follow-up|2
6065340|NCT00519623|9667234|FG000|Overall Study|Adverse Event|1
6065341|NCT00519636|9667242|FG000|Treatment Period 1|Adverse Event|1
6065342|NCT00519636|9667243|FG001|Treatment Period 1|Adverse Event|0
6065343|NCT00519636|9667244|FG002|Treatment Period 1|Adverse Event|1
6065344|NCT00519636|9667245|FG003|Treatment Period 1|Adverse Event|0
6065345|NCT00519636|9667242|FG000|Treatment Period 1|Sponsor request due to missed visit|1
6065346|NCT00519636|9667243|FG001|Treatment Period 1|Sponsor request due to missed visit|0
6065347|NCT00519636|9667244|FG002|Treatment Period 1|Sponsor request due to missed visit|0
6065348|NCT00519636|9667245|FG003|Treatment Period 1|Sponsor request due to missed visit|0
6065349|NCT00519636|9667242|FG000|Washout Period|Adverse Event|2
6065350|NCT00519636|9667243|FG001|Washout Period|Adverse Event|1
6065351|NCT00519636|9667244|FG002|Washout Period|Adverse Event|1
6065352|NCT00519636|9667245|FG003|Washout Period|Adverse Event|0
6065353|NCT00519636|9667242|FG000|Washout Period|Lost to Follow-up|1
6065354|NCT00519636|9667243|FG001|Washout Period|Lost to Follow-up|0
6065355|NCT00519636|9667244|FG002|Washout Period|Lost to Follow-up|0
6065356|NCT00519636|9667245|FG003|Washout Period|Lost to Follow-up|0
6065357|NCT00519636|9667242|FG000|Washout Period|Protocol Violation|0
6065358|NCT00519636|9667243|FG001|Washout Period|Protocol Violation|0
6065359|NCT00519636|9667244|FG002|Washout Period|Protocol Violation|1
6065360|NCT00519636|9667245|FG003|Washout Period|Protocol Violation|2
6065361|NCT00519636|9667242|FG000|Washout Period|Withdrawal by Subject|1
6065362|NCT00519636|9667243|FG001|Washout Period|Withdrawal by Subject|0
6065363|NCT00519636|9667244|FG002|Washout Period|Withdrawal by Subject|1
6065364|NCT00519636|9667245|FG003|Washout Period|Withdrawal by Subject|0
6065365|NCT00519636|9667242|FG000|Washout Period|Failed to meet continuation criteria|14
6065366|NCT00519636|9667243|FG001|Washout Period|Failed to meet continuation criteria|11
6065367|NCT00519636|9667244|FG002|Washout Period|Failed to meet continuation criteria|9
6065368|NCT00519636|9667245|FG003|Washout Period|Failed to meet continuation criteria|3
6065369|NCT00519636|9667242|FG000|Washout Period|Out of pollen area > 48 hours|1
6065370|NCT00519636|9667243|FG001|Washout Period|Out of pollen area > 48 hours|0
6065371|NCT00519636|9667244|FG002|Washout Period|Out of pollen area > 48 hours|0
6065372|NCT00519636|9667245|FG003|Washout Period|Out of pollen area > 48 hours|0
6065373|NCT00519636|9667242|FG000|Washout Period|Participating in study at another site|1
6065374|NCT00519636|9667243|FG001|Washout Period|Participating in study at another site|0
6065375|NCT00519636|9667244|FG002|Washout Period|Participating in study at another site|0
6065376|NCT00519636|9667245|FG003|Washout Period|Participating in study at another site|0
6065377|NCT00519636|9667242|FG000|Washout Period|Non-compliant|0
6065378|NCT00519636|9667243|FG001|Washout Period|Non-compliant|1
6065379|NCT00519636|9667244|FG002|Washout Period|Non-compliant|0
6065380|NCT00519636|9667245|FG003|Washout Period|Non-compliant|0
6065381|NCT00519636|9667242|FG000|Washout Period|Per doctors request|0
6065382|NCT00519636|9667243|FG001|Washout Period|Per doctors request|1
6065383|NCT00519636|9667244|FG002|Washout Period|Per doctors request|0
6065384|NCT00519636|9667245|FG003|Washout Period|Per doctors request|0
6065385|NCT00519636|9667242|FG000|Washout Period|Subject randomized in error|0
6065386|NCT00519636|9667243|FG001|Washout Period|Subject randomized in error|0
6065387|NCT00519636|9667244|FG002|Washout Period|Subject randomized in error|1
6065388|NCT00519636|9667245|FG003|Washout Period|Subject randomized in error|0
6065389|NCT00519636|9667242|FG000|Washout Period|Prohibited medications|0
6065390|NCT00519636|9667243|FG001|Washout Period|Prohibited medications|0
6065391|NCT00519636|9667244|FG002|Washout Period|Prohibited medications|1
6065392|NCT00519636|9667245|FG003|Washout Period|Prohibited medications|0
6065393|NCT00519636|9667242|FG000|Treatment Period 2|Failed To Meet Continuation Criteria|0
6065394|NCT00519636|9667243|FG001|Treatment Period 2|Failed To Meet Continuation Criteria|0
6065395|NCT00519636|9667244|FG002|Treatment Period 2|Failed To Meet Continuation Criteria|0
6065396|NCT00519636|9667245|FG003|Treatment Period 2|Failed To Meet Continuation Criteria|1
6065397|NCT00519636|9667242|FG000|Treatment Period 2|Subject randomized in error|0
6065398|NCT00519636|9667243|FG001|Treatment Period 2|Subject randomized in error|1
6065399|NCT00519636|9667244|FG002|Treatment Period 2|Subject randomized in error|0
6065400|NCT00519636|9667245|FG003|Treatment Period 2|Subject randomized in error|0
6065401|NCT00519636|9667242|FG000|Treatment Period 2|Per doctors request|0
6065402|NCT00519636|9667243|FG001|Treatment Period 2|Per doctors request|0
6065403|NCT00519636|9667244|FG002|Treatment Period 2|Per doctors request|1
6065404|NCT00519636|9667245|FG003|Treatment Period 2|Per doctors request|0
6065405|NCT00519636|9667242|FG000|Treatment Period 2|Subject misrandomized|0
6065406|NCT00519636|9667243|FG001|Treatment Period 2|Subject misrandomized|0
6065407|NCT00519636|9667244|FG002|Treatment Period 2|Subject misrandomized|0
5991522|NCT00129402|9583394|FG001|Start Period3 to End Period3(Week 34-53)|Withdrawal by Subject|0
5991523|NCT00129402|9583395|FG002|Start Period3 to End Period3(Week 34-53)|Withdrawal by Subject|0
5991524|NCT00129402|9583396|FG003|Start Period3 to End Period3(Week 34-53)|Withdrawal by Subject|0
5991525|NCT00129402|9583397|FG004|Start Period3 to End Period3(Week 34-53)|Withdrawal by Subject|0
5991526|NCT00129402|9583398|FG005|Start Period3 to End Period3(Week 34-53)|Withdrawal by Subject|0
5991527|NCT00129402|9583399|FG006|Start Period3 to End Period3(Week 34-53)|Withdrawal by Subject|3
5991528|NCT00129402|9583393|FG000|Start Period3 to End Period3(Week 34-53)|Subject moved|0
6065408|NCT00519636|9667245|FG003|Treatment Period 2|Subject misrandomized|1
6065409|NCT00519636|9667242|FG000|Post Study Period|Subject randomized in error|0
6065410|NCT00519636|9667243|FG001|Post Study Period|Subject randomized in error|0
6065411|NCT00519636|9667244|FG002|Post Study Period|Subject randomized in error|0
6065412|NCT00519636|9667245|FG003|Post Study Period|Subject randomized in error|1
6065413|NCT00519649|9667259|FG000|Overall Study|Withdrawal by Subject|1
6065414|NCT00519779|9667265|FG000|Overall Study|Withdrawal by Subject|0
6065415|NCT00519779|9667266|FG001|Overall Study|Withdrawal by Subject|1
6065416|NCT00519831|9667272|FG000|Overall Study|Adverse Event|3
6065417|NCT00519896|9667276|FG000|Overall Study|Protocol Violation|1
6065418|NCT00519896|9667276|FG000|Overall Study|Adverse Event|1
6065419|NCT00520013|9667283|FG000|Overall Study|Withdrawal by Subject|0
6065420|NCT00520013|9667284|FG001|Overall Study|Withdrawal by Subject|0
6065421|NCT00520013|9667285|FG002|Overall Study|Withdrawal by Subject|1
6065422|NCT00520013|9667283|FG000|Overall Study|Adverse Event|2
6065423|NCT00520013|9667284|FG001|Overall Study|Adverse Event|10
6065424|NCT00520013|9667285|FG002|Overall Study|Adverse Event|7
6065425|NCT00520013|9667283|FG000|Overall Study|Progressive Disease|7
6065426|NCT00520013|9667284|FG001|Overall Study|Progressive Disease|3
6065427|NCT00520013|9667285|FG002|Overall Study|Progressive Disease|0
6065428|NCT00520013|9667283|FG000|Overall Study|Clinical Progression|3
6065429|NCT00520013|9667284|FG001|Overall Study|Clinical Progression|1
6065430|NCT00520013|9667285|FG002|Overall Study|Clinical Progression|0
5991529|NCT00129402|9583394|FG001|Start Period3 to End Period3(Week 34-53)|Subject moved|0
5991530|NCT00129402|9583395|FG002|Start Period3 to End Period3(Week 34-53)|Subject moved|0
5991531|NCT00129402|9583396|FG003|Start Period3 to End Period3(Week 34-53)|Subject moved|0
5991532|NCT00129402|9583397|FG004|Start Period3 to End Period3(Week 34-53)|Subject moved|0
5991533|NCT00129402|9583398|FG005|Start Period3 to End Period3(Week 34-53)|Subject moved|0
5991534|NCT00129402|9583399|FG006|Start Period3 to End Period3(Week 34-53)|Subject moved|1
5991535|NCT00129402|9583393|FG000|Start Period3 to End Period3(Week 34-53)|Protocol Violation|0
5991536|NCT00129402|9583394|FG001|Start Period3 to End Period3(Week 34-53)|Protocol Violation|0
5991537|NCT00129402|9583395|FG002|Start Period3 to End Period3(Week 34-53)|Protocol Violation|0
5991538|NCT00129402|9583396|FG003|Start Period3 to End Period3(Week 34-53)|Protocol Violation|0
5991539|NCT00129402|9583397|FG004|Start Period3 to End Period3(Week 34-53)|Protocol Violation|0
5991540|NCT00129402|9583398|FG005|Start Period3 to End Period3(Week 34-53)|Protocol Violation|0
5991541|NCT00129402|9583399|FG006|Start Period3 to End Period3(Week 34-53)|Protocol Violation|1
5991542|NCT00101439|9583409|FG000|Period 2|Withdrawal by Subject|0
5991543|NCT00101439|9583410|FG001|Period 2|Withdrawal by Subject|2
5991544|NCT00096200|9583419|FG000|Overall Study|Adverse Event|0
6065431|NCT00520013|9667283|FG000|Overall Study|Death|0
6065432|NCT00520013|9667284|FG001|Overall Study|Death|1
6065433|NCT00520013|9667285|FG002|Overall Study|Death|0
6065434|NCT00520013|9667283|FG000|Overall Study|Physician Decision|0
6065435|NCT00520013|9667284|FG001|Overall Study|Physician Decision|0
5991545|NCT00096200|9583420|FG001|Overall Study|Adverse Event|4
5991546|NCT00096200|9583421|FG002|Overall Study|Adverse Event|0
5991547|NCT00096200|9583419|FG000|Overall Study|Withdrawal by Subject|1
5991548|NCT00096200|9583420|FG001|Overall Study|Withdrawal by Subject|2
6065436|NCT00520013|9667285|FG002|Overall Study|Physician Decision|3
6065437|NCT00520039|9667293|FG000|Overall Study|Exclusion criteria met at first visit|7
6065438|NCT00520039|9667294|FG001|Overall Study|Exclusion criteria met at first visit|5
6065439|NCT00520130|9667304|FG000|Overall Study|Disease progression on study|4
6065440|NCT00520130|9667305|FG001|Overall Study|Disease progression on study|0
6065441|NCT00520130|9667304|FG000|Overall Study|Physician Decision|1
6065442|NCT00520130|9667305|FG001|Overall Study|Physician Decision|1
6065443|NCT00520299|9667337|FG000|Overall Study|Withdrawal by Subject|0
6065444|NCT00520299|9667338|FG001|Overall Study|Withdrawal by Subject|0
6065445|NCT00520299|9667339|FG002|Overall Study|Withdrawal by Subject|2
5991549|NCT00096200|9583421|FG002|Overall Study|Withdrawal by Subject|0
5991550|NCT00096200|9583419|FG000|Overall Study|Ineligible pathology|0
5991551|NCT00096200|9583420|FG001|Overall Study|Ineligible pathology|1
5991552|NCT00096200|9583421|FG002|Overall Study|Ineligible pathology|0
6045734|NCT00403390|9645036|FG000|Overall Study|samples lost|1
6045735|NCT00403390|9645037|FG001|Overall Study|samples lost|0
6045736|NCT00403390|9645036|FG000|Overall Study|non-compliant|1
6045737|NCT00403390|9645037|FG001|Overall Study|non-compliant|0
6045738|NCT00403455|9645052|FG000|Overall Study|Withdrawal by Subject|1
6045739|NCT00403481|9645056|FG000|Olmesartan Medoxomil (Olm) 20 mg|Adverse Event|1
6045740|NCT00403481|9645056|FG000|Olmesartan Medoxomil (Olm) 20 mg|Physician Decision|1
6045741|NCT00403481|9645056|FG000|Olmesartan Medoxomil (Olm) 20 mg|Protocol Violation|3
6045742|NCT00403481|9645056|FG000|Olmesartan Medoxomil (Olm) 20 mg|Withdrawal by Subject|1
6045743|NCT00403481|9645056|FG000|Olm 40 mg|Adverse Event|2
6045744|NCT00403481|9645056|FG000|Olm 40 mg|Protocol Violation|1
6045745|NCT00403481|9645056|FG000|Olm 40 mg|Withdrawal by Subject|1
6045746|NCT00403481|9645056|FG000|Olm 40 mg|Other|1
6045747|NCT00403481|9645056|FG000|Olm 40 mg + Hydrochlorothiazide 12.5 mg|Adverse Event|2
6045748|NCT00403481|9645056|FG000|Olm 40 mg + Hydrochlorothiazide 12.5 mg|Protocol Violation|1
6045749|NCT00403481|9645056|FG000|Olm 40 mg + Hydrochlorothiazide 12.5 mg|Withdrawal by Subject|1
6045750|NCT00403481|9645056|FG000|Olm 40 mg + Hydrochlorothiazide 12.5 mg|Other|1
6045751|NCT00403481|9645056|FG000|Olm 40 mg + Hydrochlorothiazide 25 mg|Withdrawal by Subject|1
6045752|NCT00403481|9645056|FG000|Olm 40 mg + Hydrochlorothiazide 25 mg|Lost to Follow-up|1
6045753|NCT00403494|9645065|FG000|Overall Study|Adverse Event|10
6045754|NCT00403494|9645066|FG001|Overall Study|Adverse Event|8
6045755|NCT00403494|9645065|FG000|Overall Study|Withdrew Consent|3
6045756|NCT00403494|9645066|FG001|Overall Study|Withdrew Consent|2
6045757|NCT00403494|9645065|FG000|Overall Study|Inappropriately enrolled|0
6045758|NCT00403494|9645066|FG001|Overall Study|Inappropriately enrolled|1
6045759|NCT00403494|9645065|FG000|Overall Study|Lost to Follow-up|0
6045760|NCT00403494|9645066|FG001|Overall Study|Lost to Follow-up|2
6045761|NCT00403494|9645065|FG000|Overall Study|Protocol noncompliance|0
6045762|NCT00403494|9645066|FG001|Overall Study|Protocol noncompliance|1
6045763|NCT00403494|9645065|FG000|Overall Study|Death|1
6045764|NCT00403494|9645066|FG001|Overall Study|Death|0
6045765|NCT00403494|9645065|FG000|Overall Study|Sponsor Request|1
6045766|NCT00403494|9645066|FG001|Overall Study|Sponsor Request|0
6045767|NCT00403546|9645076|FG000|Signed Informed Consent/Open-Label|Withdrew Consent|6
6045768|NCT00403546|9645077|FG001|Signed Informed Consent/Open-Label|Withdrew Consent|0
6045769|NCT00403546|9645078|FG002|Signed Informed Consent/Open-Label|Withdrew Consent|0
6045770|NCT00403546|9645076|FG000|Signed Informed Consent/Open-Label|Early Termination|8
6045771|NCT00403546|9645077|FG001|Signed Informed Consent/Open-Label|Early Termination|0
6045772|NCT00403546|9645078|FG002|Signed Informed Consent/Open-Label|Early Termination|0
6045773|NCT00403546|9645076|FG000|Signed Informed Consent/Open-Label|Terminated by Investigator|9
6045774|NCT00403546|9645077|FG001|Signed Informed Consent/Open-Label|Terminated by Investigator|0
6045775|NCT00403546|9645078|FG002|Signed Informed Consent/Open-Label|Terminated by Investigator|0
6045776|NCT00403546|9645076|FG000|Signed Informed Consent/Open-Label|Adverse Event|5
6045777|NCT00403546|9645077|FG001|Signed Informed Consent/Open-Label|Adverse Event|0
6045778|NCT00403546|9645078|FG002|Signed Informed Consent/Open-Label|Adverse Event|0
6045779|NCT00403546|9645076|FG000|Screening Phase|Screening Failure|22
6065446|NCT00520299|9667337|FG000|Overall Study|Progressive disease|0
6065447|NCT00520299|9667338|FG001|Overall Study|Progressive disease|3
6065448|NCT00520299|9667339|FG002|Overall Study|Progressive disease|4
6065449|NCT00520351|9667349|FG000|First Intervention|Withdrawal by Subject|1
6065450|NCT00520351|9667350|FG001|First Intervention|Withdrawal by Subject|1
6065451|NCT00520403|9667356|FG000|Bevacizumab + IFN/Vinblastine|Radiological progression of cancer|6
6065452|NCT00520403|9667356|FG000|Bevacizumab + IFN/Vinblastine|Adverse Event|4
6065453|NCT00520403|9667356|FG000|Bevacizumab + IFN/Vinblastine|Withdrawal of consent|4
6065454|NCT00520403|9667356|FG000|Bevacizumab + IFN/Vinblastine|Death|2
6065455|NCT00520403|9667356|FG000|Bevacizumab + IFN/Vinblastine|Discontinuation of study/background drug|1
6065456|NCT00520403|9667356|FG000|Bevacizumab + IFN/Vinblastine|Protocol Deviation affecting safety|1
6065457|NCT00520403|9667356|FG000|Bevacizumab Monotherapy|Radiological progression of cancer|1
6065458|NCT00520403|9667356|FG000|Bevacizumab Monotherapy|Symptomatic progression of cancer|1
6065459|NCT00520481|9667366|FG000|Overall Study|Adverse Event|4
6065460|NCT00520481|9667367|FG001|Overall Study|Adverse Event|1
6065461|NCT00520481|9667366|FG000|Overall Study|Withdrawal by Subject|3
6065462|NCT00520481|9667367|FG001|Overall Study|Withdrawal by Subject|0
6065463|NCT00520494|9667375|FG000|Overall Study|Withdrawal by Subject|1
6065464|NCT00520533|9667379|FG000|Overall Study|Death|1
6065465|NCT00520533|9667379|FG000|Overall Study|Suspension of the study for safety reasons|1
6065466|NCT00520533|9667379|FG000|Overall Study|Withdrawal by Subject|1
6065467|NCT00520533|9667379|FG000|Overall Study|Physician Decision|1
6065468|NCT00520546|9667384|FG000|Overall Study|Withdrawal by Subject|1
6065469|NCT00520546|9667384|FG000|Overall Study|failed radiopharmaceut. synthesis of FEC|5
6065470|NCT00520572|9667399|FG000|Overall Study|Adverse Event|9
6065471|NCT00520572|9667400|FG001|Overall Study|Adverse Event|3
6065472|NCT00520572|9667401|FG002|Overall Study|Adverse Event|6
6065473|NCT00520572|9667402|FG003|Overall Study|Adverse Event|9
6065474|NCT00520572|9667403|FG004|Overall Study|Adverse Event|7
6065475|NCT00520572|9667404|FG005|Overall Study|Adverse Event|2
6065476|NCT00520572|9667399|FG000|Overall Study|Withdrawal by Subject|0
6065477|NCT00520572|9667400|FG001|Overall Study|Withdrawal by Subject|9
6065478|NCT00520572|9667401|FG002|Overall Study|Withdrawal by Subject|5
6065479|NCT00520572|9667402|FG003|Overall Study|Withdrawal by Subject|2
6065480|NCT00520572|9667403|FG004|Overall Study|Withdrawal by Subject|2
6065481|NCT00520572|9667404|FG005|Overall Study|Withdrawal by Subject|0
6065482|NCT00520572|9667399|FG000|Overall Study|Protocol Violation|0
6065483|NCT00520572|9667400|FG001|Overall Study|Protocol Violation|0
6065484|NCT00520572|9667401|FG002|Overall Study|Protocol Violation|1
6065485|NCT00520572|9667402|FG003|Overall Study|Protocol Violation|0
6065486|NCT00520572|9667403|FG004|Overall Study|Protocol Violation|0
6065487|NCT00520572|9667404|FG005|Overall Study|Protocol Violation|0
6065488|NCT00520572|9667399|FG000|Overall Study|Lack of Efficacy|1
6065489|NCT00520572|9667400|FG001|Overall Study|Lack of Efficacy|1
6065490|NCT00520572|9667401|FG002|Overall Study|Lack of Efficacy|1
6065491|NCT00520572|9667402|FG003|Overall Study|Lack of Efficacy|2
6065492|NCT00520572|9667403|FG004|Overall Study|Lack of Efficacy|1
6065493|NCT00520572|9667404|FG005|Overall Study|Lack of Efficacy|0
6065494|NCT00520572|9667399|FG000|Overall Study|Lost to Follow-up|0
6065495|NCT00520572|9667400|FG001|Overall Study|Lost to Follow-up|0
6065496|NCT00520572|9667401|FG002|Overall Study|Lost to Follow-up|0
6065497|NCT00520572|9667402|FG003|Overall Study|Lost to Follow-up|0
6065498|NCT00520572|9667403|FG004|Overall Study|Lost to Follow-up|1
6065499|NCT00520572|9667404|FG005|Overall Study|Lost to Follow-up|0
6065500|NCT00520572|9667399|FG000|Overall Study|Incorrect enrollment|1
6065501|NCT00520572|9667400|FG001|Overall Study|Incorrect enrollment|0
6065502|NCT00520572|9667401|FG002|Overall Study|Incorrect enrollment|1
6065503|NCT00520572|9667402|FG003|Overall Study|Incorrect enrollment|0
6065504|NCT00520572|9667403|FG004|Overall Study|Incorrect enrollment|1
6065505|NCT00520572|9667404|FG005|Overall Study|Incorrect enrollment|0
6065506|NCT00520572|9667399|FG000|Overall Study|Oral corticotherapy for acute urticaria|0
6065507|NCT00520572|9667400|FG001|Overall Study|Oral corticotherapy for acute urticaria|1
6065508|NCT00520572|9667401|FG002|Overall Study|Oral corticotherapy for acute urticaria|0
6065509|NCT00520572|9667402|FG003|Overall Study|Oral corticotherapy for acute urticaria|0
6065510|NCT00520572|9667403|FG004|Overall Study|Oral corticotherapy for acute urticaria|0
6065511|NCT00520572|9667404|FG005|Overall Study|Oral corticotherapy for acute urticaria|0
6065512|NCT00520572|9667399|FG000|Overall Study|Long break in taking Medication|0
6065513|NCT00520572|9667400|FG001|Overall Study|Long break in taking Medication|0
6065514|NCT00520572|9667401|FG002|Overall Study|Long break in taking Medication|0
6065515|NCT00520572|9667402|FG003|Overall Study|Long break in taking Medication|1
6065516|NCT00520572|9667403|FG004|Overall Study|Long break in taking Medication|0
6065517|NCT00520572|9667404|FG005|Overall Study|Long break in taking Medication|0
6065518|NCT00520572|9667399|FG000|Overall Study|Did not receive Treatment|1
6065519|NCT00520572|9667400|FG001|Overall Study|Did not receive Treatment|0
6065520|NCT00520572|9667401|FG002|Overall Study|Did not receive Treatment|1
6065521|NCT00520572|9667402|FG003|Overall Study|Did not receive Treatment|0
6065522|NCT00520572|9667403|FG004|Overall Study|Did not receive Treatment|0
6065523|NCT00520572|9667404|FG005|Overall Study|Did not receive Treatment|0
6065524|NCT00520676|9667420|FG000|Overall Study|Death|84
6065525|NCT00520676|9667421|FG001|Overall Study|Death|81
6065526|NCT00520676|9667420|FG000|Overall Study|Lost to Follow-up|6
6065527|NCT00520676|9667421|FG001|Overall Study|Lost to Follow-up|10
6065528|NCT00520676|9667420|FG000|Overall Study|Physician Decision|4
6065529|NCT00520676|9667421|FG001|Overall Study|Physician Decision|1
6065530|NCT00520676|9667420|FG000|Overall Study|Withdrawal by Subject|7
6065531|NCT00520676|9667421|FG001|Overall Study|Withdrawal by Subject|11
6065532|NCT00520741|9667429|FG000|Overall Study|Adverse Event|16
6065533|NCT00520741|9667430|FG001|Overall Study|Adverse Event|56
6065534|NCT00520741|9667429|FG000|Overall Study|Lack of Efficacy|11
6065535|NCT00520741|9667430|FG001|Overall Study|Lack of Efficacy|30
6065536|NCT00520741|9667429|FG000|Overall Study|Withdrawal by Subject|0
6065537|NCT00520741|9667430|FG001|Overall Study|Withdrawal by Subject|11
6065538|NCT00520741|9667429|FG000|Overall Study|Protocol Violation|2
6065539|NCT00520741|9667430|FG001|Overall Study|Protocol Violation|15
6065540|NCT00520741|9667429|FG000|Overall Study|Unsatisfactory compliance of subject|4
6065541|NCT00520741|9667430|FG001|Overall Study|Unsatisfactory compliance of subject|3
6065542|NCT00520741|9667429|FG000|Overall Study|Lost to Follow-up|4
6065543|NCT00520741|9667430|FG001|Overall Study|Lost to Follow-up|4
6065544|NCT00520741|9667429|FG000|Overall Study|Other reasons for premature termination|0
6065545|NCT00520741|9667430|FG001|Overall Study|Other reasons for premature termination|6
6065546|NCT00520845|9667438|FG000|Overall Study|Death|3
6065547|NCT00520845|9667438|FG000|Overall Study|Adverse Event|4
6065548|NCT00520845|9667438|FG000|Overall Study|Disease Progression, relapse|13
6065549|NCT00520845|9667438|FG000|Overall Study|Withdrawal by Subject|1
6065550|NCT00520845|9667438|FG000|Overall Study|Alternative Therapy|1
6065551|NCT00520936|9667471|FG000|Overall Study|Physician Decision|0
6065552|NCT00520936|9667472|FG001|Overall Study|Physician Decision|2
6065553|NCT00520936|9667473|FG002|Overall Study|Physician Decision|1
6065554|NCT00520936|9667474|FG003|Overall Study|Physician Decision|0
6065555|NCT00520936|9667475|FG004|Overall Study|Physician Decision|0
6065556|NCT00520936|9667476|FG005|Overall Study|Physician Decision|0
6065557|NCT00520936|9667477|FG006|Overall Study|Physician Decision|0
6065558|NCT00520936|9667478|FG007|Overall Study|Physician Decision|0
6065559|NCT00520936|9667471|FG000|Overall Study|Withdrawal by Subject|0
6065560|NCT00520936|9667472|FG001|Overall Study|Withdrawal by Subject|0
6065561|NCT00520936|9667473|FG002|Overall Study|Withdrawal by Subject|0
6065562|NCT00520936|9667474|FG003|Overall Study|Withdrawal by Subject|0
6065563|NCT00520936|9667475|FG004|Overall Study|Withdrawal by Subject|0
6065564|NCT00520936|9667476|FG005|Overall Study|Withdrawal by Subject|0
6065565|NCT00520936|9667477|FG006|Overall Study|Withdrawal by Subject|0
6065566|NCT00520936|9667478|FG007|Overall Study|Withdrawal by Subject|1
6065567|NCT00520936|9667471|FG000|Overall Study|Toxicity Requiring Removal from Study|0
6065568|NCT00520936|9667472|FG001|Overall Study|Toxicity Requiring Removal from Study|1
6065569|NCT00520936|9667473|FG002|Overall Study|Toxicity Requiring Removal from Study|0
6065570|NCT00520936|9667474|FG003|Overall Study|Toxicity Requiring Removal from Study|0
6065571|NCT00520936|9667475|FG004|Overall Study|Toxicity Requiring Removal from Study|0
6065572|NCT00520936|9667476|FG005|Overall Study|Toxicity Requiring Removal from Study|0
6065573|NCT00520936|9667477|FG006|Overall Study|Toxicity Requiring Removal from Study|2
6065574|NCT00520936|9667478|FG007|Overall Study|Toxicity Requiring Removal from Study|0
6065575|NCT00520936|9667471|FG000|Overall Study|Death|0
6065576|NCT00520936|9667472|FG001|Overall Study|Death|0
6065577|NCT00520936|9667473|FG002|Overall Study|Death|0
6065578|NCT00520936|9667474|FG003|Overall Study|Death|0
6065579|NCT00520936|9667475|FG004|Overall Study|Death|0
6065580|NCT00520936|9667476|FG005|Overall Study|Death|0
6065581|NCT00520936|9667477|FG006|Overall Study|Death|1
6065582|NCT00520936|9667478|FG007|Overall Study|Death|0
6065583|NCT00520936|9667471|FG000|Overall Study|Protocol Violation|0
6065584|NCT00520936|9667472|FG001|Overall Study|Protocol Violation|1
6065585|NCT00520936|9667473|FG002|Overall Study|Protocol Violation|1
6065586|NCT00520936|9667474|FG003|Overall Study|Protocol Violation|0
6065587|NCT00520936|9667475|FG004|Overall Study|Protocol Violation|1
6065588|NCT00520936|9667476|FG005|Overall Study|Protocol Violation|0
6065589|NCT00520936|9667477|FG006|Overall Study|Protocol Violation|1
6065590|NCT00520936|9667478|FG007|Overall Study|Protocol Violation|0
6065591|NCT00520975|9667491|FG000|Overall Study|Disease progression|31
6065592|NCT00520975|9667492|FG001|Overall Study|Disease progression|23
6065593|NCT00520975|9667491|FG000|Overall Study|Adverse Event|7
6065594|NCT00520975|9667492|FG001|Overall Study|Adverse Event|10
6065595|NCT00520975|9667491|FG000|Overall Study|Death|0
6065596|NCT00520975|9667492|FG001|Overall Study|Death|2
6065597|NCT00520975|9667491|FG000|Overall Study|Withdrawal by Subject|3
6065598|NCT00520975|9667492|FG001|Overall Study|Withdrawal by Subject|5
6065599|NCT00520975|9667491|FG000|Overall Study|Other therapy|2
6065600|NCT00520975|9667492|FG001|Overall Study|Other therapy|4
6065601|NCT00520975|9667491|FG000|Overall Study|Other reasons|4
6065602|NCT00520975|9667492|FG001|Overall Study|Other reasons|2
6065603|NCT00520975|9667491|FG000|Overall Study|Not start protocol therapy|1
6065604|NCT00520975|9667492|FG001|Overall Study|Not start protocol therapy|2
6065605|NCT00521001|9667498|FG000|Overall Study|Ineligible|1
6065606|NCT00521014|9667502|FG000|Overall Study|Inevaluable, not treated|1
6065607|NCT00521053|9667506|FG000|Observation Phase|Disease Progression|55
6065608|NCT00521053|9667506|FG000|Observation Phase|Additional PV-10 via alternate protocol|8
6065609|NCT00521053|9667506|FG000|Observation Phase|Death|2
6065610|NCT00521053|9667506|FG000|Observation Phase|Adverse Event|1
6065611|NCT00521053|9667506|FG000|Observation Phase|Other non-study melanoma treatment|1
6065612|NCT00521053|9667506|FG000|Observation Phase|Physician Decision|1
6065613|NCT00521079|9667515|FG000|Overall Study|Adverse Event|7
6065614|NCT00521079|9667516|FG001|Overall Study|Adverse Event|1
6065615|NCT00521079|9667515|FG000|Overall Study|Lost to Follow-up|2
6065616|NCT00521079|9667516|FG001|Overall Study|Lost to Follow-up|1
6065617|NCT00521079|9667515|FG000|Overall Study|Withdrawal by Subject|5
6065618|NCT00521079|9667516|FG001|Overall Study|Withdrawal by Subject|3
6065619|NCT00521144|9667527|FG000|Overall Study|Not Treated|0
6065620|NCT00521144|9667528|FG001|Overall Study|Not Treated|0
6065621|NCT00521144|9667529|FG002|Overall Study|Not Treated|0
6065622|NCT00521144|9667530|FG003|Overall Study|Not Treated|1
6065623|NCT00521144|9667531|FG004|Overall Study|Not Treated|0
6065624|NCT00521144|9667527|FG000|Overall Study|Adverse Event|0
6065625|NCT00521144|9667528|FG001|Overall Study|Adverse Event|1
6065626|NCT00521144|9667529|FG002|Overall Study|Adverse Event|0
6065627|NCT00521144|9667530|FG003|Overall Study|Adverse Event|0
6065628|NCT00521144|9667531|FG004|Overall Study|Adverse Event|1
6065629|NCT00521144|9667527|FG000|Overall Study|Progressive Disease|4
6065630|NCT00521144|9667528|FG001|Overall Study|Progressive Disease|2
6065631|NCT00521144|9667529|FG002|Overall Study|Progressive Disease|2
6065632|NCT00521144|9667530|FG003|Overall Study|Progressive Disease|0
6065633|NCT00521144|9667531|FG004|Overall Study|Progressive Disease|6
6065634|NCT00521339|9667543|FG000|Treatment Phase|Adverse Event|2
6065635|NCT00521339|9667544|FG001|Treatment Phase|Adverse Event|0
6065636|NCT00521339|9667545|FG002|Treatment Phase|Adverse Event|0
6065637|NCT00521339|9667543|FG000|Treatment Phase|Intolerability to study drug|2
6065638|NCT00521339|9667544|FG001|Treatment Phase|Intolerability to study drug|0
6065639|NCT00521339|9667545|FG002|Treatment Phase|Intolerability to study drug|0
6065640|NCT00521339|9667543|FG000|Treatment Phase|Lack of Efficacy|3
6065641|NCT00521339|9667544|FG001|Treatment Phase|Lack of Efficacy|0
6065642|NCT00521339|9667545|FG002|Treatment Phase|Lack of Efficacy|0
6065643|NCT00521339|9667543|FG000|Treatment Phase|Withdrawal by Subject|3
6065644|NCT00521339|9667544|FG001|Treatment Phase|Withdrawal by Subject|0
6065645|NCT00521339|9667545|FG002|Treatment Phase|Withdrawal by Subject|0
6065646|NCT00521339|9667543|FG000|Treatment Phase|Lost to Follow-up|1
6065647|NCT00521339|9667544|FG001|Treatment Phase|Lost to Follow-up|0
6065648|NCT00521339|9667545|FG002|Treatment Phase|Lost to Follow-up|0
6065649|NCT00521339|9667543|FG000|Treatment Phase|Protocol Violation|1
6065650|NCT00521339|9667544|FG001|Treatment Phase|Protocol Violation|0
6065651|NCT00521339|9667545|FG002|Treatment Phase|Protocol Violation|0
6065652|NCT00521339|9667543|FG000|Treatment Extension Phase|Withdrawal by Subject|0
6065653|NCT00521339|9667544|FG001|Treatment Extension Phase|Withdrawal by Subject|0
6065654|NCT00521339|9667545|FG002|Treatment Extension Phase|Withdrawal by Subject|2
6065655|NCT00521339|9667543|FG000|Treatment Extension Phase|Death|0
6065656|NCT00521339|9667544|FG001|Treatment Extension Phase|Death|0
6065657|NCT00521339|9667545|FG002|Treatment Extension Phase|Death|1
6065658|NCT00521365|9667575|FG000|Overall Study|Adverse Event|3
6065659|NCT00521365|9667575|FG000|Overall Study|Lost to Follow-up|6
6065660|NCT00521365|9667575|FG000|Overall Study|Protocol deviation|2
6065661|NCT00521365|9667575|FG000|Overall Study|Drug compliance|3
6065662|NCT00521365|9667575|FG000|Overall Study|Usage of not allowed drugs|6
6065663|NCT00521404|9667579|FG000|Overall Study|Adverse Event|13
6065664|NCT00521404|9667579|FG000|Overall Study|Disease Progression|33
6065665|NCT00521404|9667579|FG000|Overall Study|Investigator decision|5
6065666|NCT00521404|9667579|FG000|Overall Study|Withdrawal of consent|3
6065667|NCT00521404|9667579|FG000|Overall Study|Noncompliance or lack of cooperation|1
6065668|NCT00521404|9667579|FG000|Overall Study|Other|7
6065669|NCT00521586|9667594|FG000|Initial Vaccination (Year 0)|Subject request|8
6065670|NCT00521586|9667595|FG001|Initial Vaccination (Year 0)|Subject request|11
6065671|NCT00521586|9667594|FG000|Initial Vaccination (Year 0)|Lost to Follow-up|5
6065672|NCT00521586|9667595|FG001|Initial Vaccination (Year 0)|Lost to Follow-up|10
6065673|NCT00521586|9667594|FG000|Initial Vaccination (Year 0)|Protocol Violation|2
6065674|NCT00521586|9667595|FG001|Initial Vaccination (Year 0)|Protocol Violation|5
6065675|NCT00521586|9667594|FG000|Initial Vaccination (Year 0)|Other, unspecified|3
6065676|NCT00521586|9667595|FG001|Initial Vaccination (Year 0)|Other, unspecified|1
6065677|NCT00521586|9667594|FG000|Initial Vaccination (Year 0)|Investigator request|2
6065678|NCT00521586|9667595|FG001|Initial Vaccination (Year 0)|Investigator request|0
6065679|NCT00521586|9667594|FG000|Initial Vaccination (Year 0)|Adverse Event|0
6065680|NCT00521586|9667595|FG001|Initial Vaccination (Year 0)|Adverse Event|1
6065681|NCT00521586|9667594|FG000|Initial Vaccination (Year 0)|Death|1
6065682|NCT00521586|9667595|FG001|Initial Vaccination (Year 0)|Death|0
6065683|NCT00521586|9667594|FG000|Initial Vaccination (Year 0)|Failed to return|0
6065684|NCT00521586|9667595|FG001|Initial Vaccination (Year 0)|Failed to return|1
6065685|NCT00521586|9667594|FG000|Follow-up (From 6-month[Year 0]-Year 5)|Adverse Event|5
6065686|NCT00521586|9667595|FG001|Follow-up (From 6-month[Year 0]-Year 5)|Adverse Event|1
6065687|NCT00521586|9667594|FG000|Follow-up (From 6-month[Year 0]-Year 5)|Death|5
6065688|NCT00521586|9667595|FG001|Follow-up (From 6-month[Year 0]-Year 5)|Death|2
6065689|NCT00521586|9667594|FG000|Follow-up (From 6-month[Year 0]-Year 5)|Failed to return|7
6065690|NCT00521586|9667595|FG001|Follow-up (From 6-month[Year 0]-Year 5)|Failed to return|3
6065691|NCT00521586|9667594|FG000|Follow-up (From 6-month[Year 0]-Year 5)|Investigator request|3
6065692|NCT00521586|9667595|FG001|Follow-up (From 6-month[Year 0]-Year 5)|Investigator request|3
6065693|NCT00521586|9667594|FG000|Follow-up (From 6-month[Year 0]-Year 5)|Lost to Follow-up|55
6065694|NCT00521586|9667595|FG001|Follow-up (From 6-month[Year 0]-Year 5)|Lost to Follow-up|56
6065695|NCT00521586|9667594|FG000|Follow-up (From 6-month[Year 0]-Year 5)|Other|22
6065696|NCT00521586|9667595|FG001|Follow-up (From 6-month[Year 0]-Year 5)|Other|26
6065697|NCT00521586|9667594|FG000|Follow-up (From 6-month[Year 0]-Year 5)|Protocol Violation|18
6065698|NCT00521586|9667595|FG001|Follow-up (From 6-month[Year 0]-Year 5)|Protocol Violation|22
6065699|NCT00521586|9667594|FG000|Follow-up (From 6-month[Year 0]-Year 5)|Subject request|54
6065700|NCT00521586|9667595|FG001|Follow-up (From 6-month[Year 0]-Year 5)|Subject request|57
6065701|NCT00521586|9667594|FG000|Revaccination With 13vPnC (Year 5)|Subject request|0
6065702|NCT00521586|9667595|FG001|Revaccination With 13vPnC (Year 5)|Subject request|1
6065703|NCT00521586|9667594|FG000|Revaccination With 13vPnC (Year 5)|Failed to return|1
6065704|NCT00521586|9667595|FG001|Revaccination With 13vPnC (Year 5)|Failed to return|4
6065705|NCT00521586|9667594|FG000|Revaccination With 13vPnC (Year 5)|Lost to Follow-up|2
6065706|NCT00521586|9667595|FG001|Revaccination With 13vPnC (Year 5)|Lost to Follow-up|7
6065707|NCT00522041|9667640|FG000|Overall Study|Adverse Event|9
6065708|NCT00522041|9667641|FG001|Overall Study|Adverse Event|3
6065709|NCT00522041|9667640|FG000|Overall Study|Protocol Violation|2
6065710|NCT00522041|9667641|FG001|Overall Study|Protocol Violation|0
6065711|NCT00522041|9667640|FG000|Overall Study|Lost to Follow-up|1
6065712|NCT00522041|9667641|FG001|Overall Study|Lost to Follow-up|4
6065713|NCT00522041|9667640|FG000|Overall Study|Voluntary withdrawal|5
6065714|NCT00522041|9667641|FG001|Overall Study|Voluntary withdrawal|4
6065715|NCT00522041|9667640|FG000|Overall Study|Did not receive treatment|0
6065716|NCT00522041|9667641|FG001|Overall Study|Did not receive treatment|1
6065717|NCT00522275|9667657|FG000|Overall Study|Adverse Event|35
6065718|NCT00522275|9667657|FG000|Overall Study|Lack of Efficacy|80
6065719|NCT00522275|9667657|FG000|Overall Study|Subject withdrew consent|16
6065720|NCT00522275|9667657|FG000|Overall Study|Protocol deviation|1
6065721|NCT00522275|9667657|FG000|Overall Study|Unsatisfactory compliance|11
6065722|NCT00522275|9667657|FG000|Overall Study|Lost to Follow-up|8
6065723|NCT00522275|9667657|FG000|Overall Study|Other: Subject wants to become pregnant|2
6065724|NCT00522275|9667657|FG000|Overall Study|Other: Subject is pregnant|2
6065725|NCT00522275|9667657|FG000|Overall Study|Other: Subject relocated|2
6065726|NCT00522275|9667657|FG000|Overall Study|Other: Subject arrested|1
6065727|NCT00522275|9667657|FG000|Overall Study|Other: Site / clinic closed|4
6065728|NCT00522275|9667657|FG000|Overall Study|Other: Travel to / from site difficulty|3
6065729|NCT00522275|9667657|FG000|Overall Study|Other: Sponsor request|2
6065730|NCT00522275|9667657|FG000|Overall Study|Other: Subject ran out of medication|1
6065731|NCT00522275|9667657|FG000|Overall Study|Other: Subject had surgery for epilepsy|2
6065732|NCT00522379|9667666|FG000|Overall Study|Adverse Event|12
6065733|NCT00522379|9667667|FG001|Overall Study|Adverse Event|15
6065734|NCT00522379|9667668|FG002|Overall Study|Adverse Event|12
6065735|NCT00522379|9667669|FG003|Overall Study|Adverse Event|5
6065736|NCT00522379|9667670|FG004|Overall Study|Adverse Event|17
6065737|NCT00522379|9667666|FG000|Overall Study|Lack of Efficacy|3
6065738|NCT00522379|9667667|FG001|Overall Study|Lack of Efficacy|0
6065739|NCT00522379|9667668|FG002|Overall Study|Lack of Efficacy|2
6065740|NCT00522379|9667669|FG003|Overall Study|Lack of Efficacy|2
6065741|NCT00522379|9667670|FG004|Overall Study|Lack of Efficacy|7
6065742|NCT00522379|9667666|FG000|Overall Study|Withdrawal by Subject|2
6065743|NCT00522379|9667667|FG001|Overall Study|Withdrawal by Subject|3
6065744|NCT00522379|9667668|FG002|Overall Study|Withdrawal by Subject|1
6065745|NCT00522379|9667669|FG003|Overall Study|Withdrawal by Subject|2
6065746|NCT00522379|9667670|FG004|Overall Study|Withdrawal by Subject|0
6065747|NCT00522379|9667666|FG000|Overall Study|Protocol Violation|1
6065748|NCT00522379|9667667|FG001|Overall Study|Protocol Violation|1
6065749|NCT00522379|9667668|FG002|Overall Study|Protocol Violation|2
6065750|NCT00522379|9667669|FG003|Overall Study|Protocol Violation|0
6065751|NCT00522379|9667670|FG004|Overall Study|Protocol Violation|0
6065752|NCT00522379|9667666|FG000|Overall Study|Unsatisfactory Subject Compliance|1
6065753|NCT00522379|9667667|FG001|Overall Study|Unsatisfactory Subject Compliance|2
6065754|NCT00522379|9667668|FG002|Overall Study|Unsatisfactory Subject Compliance|0
6065755|NCT00522379|9667669|FG003|Overall Study|Unsatisfactory Subject Compliance|0
6065756|NCT00522379|9667670|FG004|Overall Study|Unsatisfactory Subject Compliance|0
6065757|NCT00522379|9667666|FG000|Overall Study|Lost to Follow-up|1
6065758|NCT00522379|9667667|FG001|Overall Study|Lost to Follow-up|0
6065759|NCT00522379|9667668|FG002|Overall Study|Lost to Follow-up|4
6065760|NCT00522379|9667669|FG003|Overall Study|Lost to Follow-up|2
6065761|NCT00522379|9667670|FG004|Overall Study|Lost to Follow-up|2
6065762|NCT00522379|9667666|FG000|Overall Study|Randomization error|0
6065763|NCT00522379|9667667|FG001|Overall Study|Randomization error|0
6065764|NCT00522379|9667668|FG002|Overall Study|Randomization error|0
6065765|NCT00522379|9667669|FG003|Overall Study|Randomization error|0
6065766|NCT00522379|9667670|FG004|Overall Study|Randomization error|1
6065767|NCT00522379|9667666|FG000|Overall Study|Dispensing error|1
6065768|NCT00522379|9667667|FG001|Overall Study|Dispensing error|0
6065769|NCT00522379|9667668|FG002|Overall Study|Dispensing error|0
6065770|NCT00522379|9667669|FG003|Overall Study|Dispensing error|1
6065771|NCT00522379|9667670|FG004|Overall Study|Dispensing error|0
6065772|NCT00522379|9667666|FG000|Overall Study|Subject Moved|1
6065773|NCT00522379|9667667|FG001|Overall Study|Subject Moved|1
6065774|NCT00522379|9667668|FG002|Overall Study|Subject Moved|0
6065775|NCT00522379|9667669|FG003|Overall Study|Subject Moved|0
6065776|NCT00522379|9667670|FG004|Overall Study|Subject Moved|0
6065777|NCT00522379|9667666|FG000|Overall Study|Sponsor Request|0
6065778|NCT00522379|9667667|FG001|Overall Study|Sponsor Request|1
6065779|NCT00522379|9667668|FG002|Overall Study|Sponsor Request|0
6065780|NCT00522379|9667669|FG003|Overall Study|Sponsor Request|0
6065781|NCT00522379|9667670|FG004|Overall Study|Sponsor Request|0
6065782|NCT00522379|9667666|FG000|Overall Study|Family Problem|0
6065783|NCT00522379|9667667|FG001|Overall Study|Family Problem|0
6065784|NCT00522379|9667668|FG002|Overall Study|Family Problem|1
6065785|NCT00522379|9667669|FG003|Overall Study|Family Problem|0
6065786|NCT00522379|9667670|FG004|Overall Study|Family Problem|0
6065787|NCT00522379|9667666|FG000|Overall Study|Site Closed|0
6065788|NCT00522379|9667667|FG001|Overall Study|Site Closed|0
6065789|NCT00522379|9667668|FG002|Overall Study|Site Closed|0
6065790|NCT00522379|9667669|FG003|Overall Study|Site Closed|1
6065791|NCT00522379|9667670|FG004|Overall Study|Site Closed|0
6065792|NCT00522379|9667666|FG000|Overall Study|Subject Withdrawal|0
6065793|NCT00522379|9667667|FG001|Overall Study|Subject Withdrawal|0
6065794|NCT00522379|9667668|FG002|Overall Study|Subject Withdrawal|0
6065795|NCT00522379|9667669|FG003|Overall Study|Subject Withdrawal|1
6065796|NCT00522379|9667670|FG004|Overall Study|Subject Withdrawal|0
6065797|NCT00522392|9667684|FG000|Overall Study|Disease progression|0
6065798|NCT00522392|9667685|FG001|Overall Study|Disease progression|3
6065799|NCT00522392|9667684|FG000|Overall Study|Adverse Event|7
6065800|NCT00522392|9667685|FG001|Overall Study|Adverse Event|7
6065801|NCT00522392|9667684|FG000|Overall Study|Withdrawal by Subject|1
6065802|NCT00522392|9667685|FG001|Overall Study|Withdrawal by Subject|1
6065803|NCT00522392|9667684|FG000|Overall Study|Physician Decision|0
6065804|NCT00522392|9667685|FG001|Overall Study|Physician Decision|1
6065805|NCT00522392|9667684|FG000|Overall Study|Non-compliance|0
6065806|NCT00522392|9667685|FG001|Overall Study|Non-compliance|1
6065807|NCT00522418|9667693|FG000|Overall Study|Local IRB Consent Violation|5
6065808|NCT00522418|9667694|FG001|Overall Study|Local IRB Consent Violation|5
6065809|NCT00522418|9667693|FG000|Overall Study|Early Study Termination|46
6065810|NCT00522418|9667694|FG001|Overall Study|Early Study Termination|47
6065811|NCT00522418|9667693|FG000|Overall Study|Noncompliance|2
6065812|NCT00522418|9667694|FG001|Overall Study|Noncompliance|2
6065813|NCT00522418|9667693|FG000|Overall Study|Reason Not Specified|3
6065814|NCT00522418|9667694|FG001|Overall Study|Reason Not Specified|1
6065815|NCT00522418|9667693|FG000|Overall Study|Consent Withdraw|1
6065816|NCT00522418|9667694|FG001|Overall Study|Consent Withdraw|2
6065817|NCT00522418|9667693|FG000|Overall Study|Lack of Efficacy|0
6065818|NCT00522418|9667694|FG001|Overall Study|Lack of Efficacy|1
6065819|NCT00522431|9667702|FG000|Overall Study|Adverse Event|5
6065820|NCT00522431|9667702|FG000|Overall Study|Protocol Violation|2
6065821|NCT00522431|9667702|FG000|Overall Study|Withdrawal by Subject|2
6065822|NCT00522431|9667702|FG000|Overall Study|Subject non-compliance|1
6065823|NCT00522431|9667702|FG000|Overall Study|Other/unknown|1
6065824|NCT00522548|9667708|FG000|Overall Study|Adverse Event|2
6065825|NCT00522548|9667709|FG001|Overall Study|Adverse Event|2
6065826|NCT00522548|9667708|FG000|Overall Study|Withdrawal by Subject|0
6065827|NCT00522548|9667709|FG001|Overall Study|Withdrawal by Subject|2
6065828|NCT00522626|9667715|FG000|Overall Study|Lost to Follow-up|7
6065829|NCT00522873|9667725|FG000|Overall Study|Adverse Event|41
6065830|NCT00522873|9667726|FG001|Overall Study|Adverse Event|26
6065831|NCT00522873|9667725|FG000|Overall Study|Withdrawal by Subject|20
6065832|NCT00522873|9667726|FG001|Overall Study|Withdrawal by Subject|9
6065833|NCT00522873|9667725|FG000|Overall Study|Protocol Violation|14
6065834|NCT00522873|9667726|FG001|Overall Study|Protocol Violation|4
6065835|NCT00522873|9667725|FG000|Overall Study|Lost to Follow-up|11
6065836|NCT00522873|9667726|FG001|Overall Study|Lost to Follow-up|3
6065837|NCT00522873|9667725|FG000|Overall Study|Personal Reasons|8
6065838|NCT00522873|9667726|FG001|Overall Study|Personal Reasons|1
6065839|NCT00522873|9667725|FG000|Overall Study|Medication Errors|1
6065840|NCT00522873|9667726|FG001|Overall Study|Medication Errors|1
6065841|NCT00522873|9667725|FG000|Overall Study|Never Received Medication|1
6065842|NCT00522873|9667726|FG001|Overall Study|Never Received Medication|0
6065843|NCT00522951|9667745|FG000|Period 1|body motion|0
6065844|NCT00522951|9667746|FG001|Period 1|body motion|1
6065845|NCT00522951|9667745|FG000|Washout Period|Adverse Event|0
6065846|NCT00522951|9667746|FG001|Washout Period|Adverse Event|1
6065847|NCT00522951|9667745|FG000|Washout Period|Death|0
6065848|NCT00522951|9667746|FG001|Washout Period|Death|1
6065849|NCT00522951|9667745|FG000|Period 2|Withdrawal by Subject|1
6065850|NCT00522951|9667746|FG001|Period 2|Withdrawal by Subject|0
6065851|NCT00522951|9667745|FG000|Period 2|residual contrast medium|1
6065852|NCT00522951|9667746|FG001|Period 2|residual contrast medium|1
6065853|NCT00523341|9667771|FG000|Overall Study|Withdrawal by Subject|399
6065854|NCT00523341|9667772|FG001|Overall Study|Withdrawal by Subject|427
6065855|NCT00523341|9667771|FG000|Overall Study|Other|181
6065856|NCT00523341|9667772|FG001|Overall Study|Other|198
6065857|NCT00523341|9667771|FG000|Overall Study|Adverse Event|122
6065858|NCT00523341|9667772|FG001|Overall Study|Adverse Event|155
6065859|NCT00523341|9667771|FG000|Overall Study|Death|101
6065860|NCT00523341|9667772|FG001|Overall Study|Death|110
6065861|NCT00523341|9667771|FG000|Overall Study|Lost to Follow-up|73
6065862|NCT00523341|9667772|FG001|Overall Study|Lost to Follow-up|61
6065863|NCT00523341|9667771|FG000|Overall Study|Non-compliance|20
6065864|NCT00523341|9667772|FG001|Overall Study|Non-compliance|13
6065865|NCT00523341|9667771|FG000|Overall Study|Physician Decision|14
6065866|NCT00523341|9667772|FG001|Overall Study|Physician Decision|13
6065867|NCT00523341|9667771|FG000|Overall Study|Requirement for Alternative Therapy|4
6065868|NCT00523341|9667772|FG001|Overall Study|Requirement for Alternative Therapy|14
6065869|NCT00523341|9667771|FG000|Overall Study|Protocol Deviation|6
6065870|NCT00523341|9667772|FG001|Overall Study|Protocol Deviation|5
6065871|NCT00523341|9667771|FG000|Overall Study|Ineligibility Determined|3
6065872|NCT00523341|9667772|FG001|Overall Study|Ineligibility Determined|4
6065873|NCT00523341|9667771|FG000|Overall Study|Disease Progression|1
6065874|NCT00523341|9667772|FG001|Overall Study|Disease Progression|0
6065875|NCT00523367|9667778|FG000|Overall Study|19 screen failures|19
6065876|NCT00523367|9667778|FG000|Overall Study|4 Withdrawn by PI|4
6065877|NCT00523419|9667782|FG000|Overall Study|Adverse Event|1
6065878|NCT00523419|9667782|FG000|Overall Study|Withdrawal by Subject|1
6065879|NCT00523419|9667782|FG000|Overall Study|Physician Decision|2
6065880|NCT00523419|9667782|FG000|Overall Study|Progressive Disease|22
6065881|NCT00523419|9667782|FG000|Overall Study|Death due to Study Disease|4
6065882|NCT00523419|9667782|FG000|Overall Study|Death due to Adverse Event|2
6065883|NCT00523549|9667788|FG000|Overall Study|Adverse Event|6
6065884|NCT00523549|9667789|FG001|Overall Study|Adverse Event|3
6065885|NCT00523549|9667788|FG000|Overall Study|Unsatisfactory therapeutic effect|0
6065886|NCT00523549|9667789|FG001|Overall Study|Unsatisfactory therapeutic effect|1
6065887|NCT00523549|9667788|FG000|Overall Study|Protocol Deviation|3
6065888|NCT00523549|9667789|FG001|Overall Study|Protocol Deviation|1
6065889|NCT00523549|9667788|FG000|Overall Study|Patient withdrew consent|7
6065890|NCT00523549|9667789|FG001|Overall Study|Patient withdrew consent|6
6065891|NCT00523549|9667788|FG000|Overall Study|Lost to Follow-up|3
6065892|NCT00523549|9667789|FG001|Overall Study|Lost to Follow-up|5
6065893|NCT00523640|9667804|FG000|Overall Study|Death|1
6065894|NCT00523705|9667810|FG000|Overall Study|No time for study.|0
6065895|NCT00523705|9667811|FG001|Overall Study|No time for study.|1
6065896|NCT00523718|9667819|FG000|Overall Study|Withdrawal by Subject|1
6065897|NCT00523718|9667820|FG001|Overall Study|Withdrawal by Subject|0
6065898|NCT00523718|9667819|FG000|Overall Study|Protocol Violation|2
6065899|NCT00523718|9667820|FG001|Overall Study|Protocol Violation|0
6065900|NCT00523744|9667826|FG000|Phase 1 - Amlodipine+Olmesartan|Adverse Event|2
6065901|NCT00523744|9667826|FG000|Phase 1 - Amlodipine+Olmesartan|Withdrawal by Subject|1
6065902|NCT00523744|9667826|FG000|Phase 1 - Amlodipine+Olmesartan|Lost to Follow-up|2
6065903|NCT00523744|9667826|FG000|Phase 1 - Amlodipine+Olmesartan|Administrative problems|1
6065904|NCT00523744|9667826|FG000|Phase 2 - Amlodipine+Valsartan|Adverse Event|2
6065905|NCT00523744|9667826|FG000|Phase 2 - Amlodipine+Valsartan|Lost to Follow-up|1
6065906|NCT00523848|9667833|FG000|Overall Study|Adverse Event|11
6065907|NCT00523848|9667833|FG000|Overall Study|Withdrawal by Subject|2
6065908|NCT00523848|9667833|FG000|Overall Study|NOT TREATED (Became ineligible)|2
6065909|NCT00523848|9667833|FG000|Overall Study|Disease Progression|5
6065910|NCT00523848|9667833|FG000|Overall Study|Other, unspecified|4
6065911|NCT00523978|9667839|FG000|Overall Study|Withdrawal by Subject|3
6065912|NCT00523978|9667840|FG001|Overall Study|Withdrawal by Subject|7
6065913|NCT00523978|9667839|FG000|Overall Study|Screen Failures|5
6065914|NCT00523978|9667840|FG001|Overall Study|Screen Failures|1
6065915|NCT00523978|9667839|FG000|Overall Study|Death|1
6065916|NCT00523978|9667840|FG001|Overall Study|Death|0
6065917|NCT00523991|9667849|FG000|Overall Study|Adverse Event|6
6065918|NCT00523991|9667850|FG001|Overall Study|Adverse Event|5
6065919|NCT00523991|9667849|FG000|Overall Study|Protocol Violation|1
6065920|NCT00523991|9667850|FG001|Overall Study|Protocol Violation|4
6065921|NCT00523991|9667849|FG000|Overall Study|Lost to Follow-up|4
6065922|NCT00523991|9667850|FG001|Overall Study|Lost to Follow-up|1
6065923|NCT00523991|9667849|FG000|Overall Study|Withdrawal by Subject|7
6065924|NCT00523991|9667850|FG001|Overall Study|Withdrawal by Subject|17
6065925|NCT00523991|9667849|FG000|Overall Study|Other reason (not specified)|3
6065926|NCT00523991|9667850|FG001|Overall Study|Other reason (not specified)|0
6065927|NCT00524030|9667867|FG000|Overall Study|Lack of Efficacy|10
6065928|NCT00524030|9667868|FG001|Overall Study|Lack of Efficacy|24
6065929|NCT00524030|9667867|FG000|Overall Study|Lost to Follow-up|0
6065930|NCT00524030|9667868|FG001|Overall Study|Lost to Follow-up|2
6065931|NCT00524030|9667867|FG000|Overall Study|Withdrawal by Subject|3
6065932|NCT00524030|9667868|FG001|Overall Study|Withdrawal by Subject|8
6065933|NCT00524030|9667867|FG000|Overall Study|Noncompliance/Investigator discretion|0
6065934|NCT00524030|9667868|FG001|Overall Study|Noncompliance/Investigator discretion|2
6065935|NCT00524030|9667867|FG000|Overall Study|Protocol Violation|0
6065936|NCT00524030|9667868|FG001|Overall Study|Protocol Violation|1
6065937|NCT00524030|9667867|FG000|Overall Study|Pregnancy|1
6065938|NCT00524030|9667868|FG001|Overall Study|Pregnancy|0
6065939|NCT00524030|9667867|FG000|Overall Study|Adverse Event|3
6065940|NCT00524030|9667868|FG001|Overall Study|Adverse Event|21
6065941|NCT00524030|9667867|FG000|Overall Study|Death|0
6065942|NCT00524030|9667868|FG001|Overall Study|Death|1
6065943|NCT00524043|9667878|FG000|Overall Study|Lack of Efficacy|15
6065944|NCT00524043|9667879|FG001|Overall Study|Lack of Efficacy|13
6065945|NCT00524043|9667880|FG002|Overall Study|Lack of Efficacy|14
6065946|NCT00524043|9667878|FG000|Overall Study|Withdrawal by Subject|5
6065947|NCT00524043|9667879|FG001|Overall Study|Withdrawal by Subject|7
6065948|NCT00524043|9667880|FG002|Overall Study|Withdrawal by Subject|7
6065949|NCT00524043|9667878|FG000|Overall Study|Adverse Event|5
6065950|NCT00524043|9667879|FG001|Overall Study|Adverse Event|2
6065951|NCT00524043|9667880|FG002|Overall Study|Adverse Event|7
6065952|NCT00524043|9667878|FG000|Overall Study|Lost to Follow-up|3
6065953|NCT00524043|9667879|FG001|Overall Study|Lost to Follow-up|5
6065954|NCT00524043|9667880|FG002|Overall Study|Lost to Follow-up|3
6065955|NCT00524043|9667878|FG000|Overall Study|Various (eg, incarceration)|2
6065956|NCT00524043|9667879|FG001|Overall Study|Various (eg, incarceration)|1
6065957|NCT00524043|9667880|FG002|Overall Study|Various (eg, incarceration)|0
6065958|NCT00524121|9667888|FG000|Overall Study|Disease progression|6
6065959|NCT00524121|9667888|FG000|Overall Study|Adverse Event|4
6065960|NCT00524121|9667888|FG000|Overall Study|Patient refused|2
6065961|NCT00524121|9667888|FG000|Overall Study|Other|1
6065962|NCT00524121|9667888|FG000|Overall Study|Death|1
6065963|NCT00524121|9667888|FG000|Overall Study|Not treated (became ineligible)|4
6065964|NCT00524121|9667888|FG000|Overall Study|Not treated (changed mind)|1
6065965|NCT00524173|9667905|FG000|Overall Study|Lost to Follow-up|0
6065966|NCT00524173|9667906|FG001|Overall Study|Lost to Follow-up|1
6065967|NCT00524173|9667905|FG000|Overall Study|Death|1
6065968|NCT00524173|9667906|FG001|Overall Study|Death|0
6065969|NCT00524173|9667905|FG000|Overall Study|Had not reached endpoint at study close|4
6065970|NCT00524173|9667906|FG001|Overall Study|Had not reached endpoint at study close|1
6065971|NCT00524303|9667929|FG000|Overall Study|Lost to Follow-up|6
6065972|NCT00524303|9667930|FG001|Overall Study|Lost to Follow-up|0
6065973|NCT00524303|9667931|FG002|Overall Study|Lost to Follow-up|3
6065974|NCT00524303|9667929|FG000|Overall Study|Protocol Violation|0
6065975|NCT00524303|9667930|FG001|Overall Study|Protocol Violation|1
6065976|NCT00524303|9667931|FG002|Overall Study|Protocol Violation|1
6065977|NCT00524303|9667929|FG000|Overall Study|Withdrawal by Subject|3
6065978|NCT00524303|9667930|FG001|Overall Study|Withdrawal by Subject|0
6065979|NCT00524303|9667931|FG002|Overall Study|Withdrawal by Subject|4
6065980|NCT00524303|9667929|FG000|Overall Study|Death|0
6065981|NCT00524303|9667930|FG001|Overall Study|Death|2
6065982|NCT00524303|9667931|FG002|Overall Study|Death|3
6065983|NCT00524303|9667929|FG000|Overall Study|Adverse Event|1
6065984|NCT00524303|9667930|FG001|Overall Study|Adverse Event|2
6065985|NCT00524303|9667931|FG002|Overall Study|Adverse Event|3
6065986|NCT00524303|9667929|FG000|Overall Study|Did not Complete Study Dosing|1
6065987|NCT00524303|9667930|FG001|Overall Study|Did not Complete Study Dosing|0
6065988|NCT00524303|9667931|FG002|Overall Study|Did not Complete Study Dosing|0
6065989|NCT00524303|9667929|FG000|Overall Study|Worsening Peripheral Neuropathy|1
6065990|NCT00524303|9667930|FG001|Overall Study|Worsening Peripheral Neuropathy|0
6065991|NCT00524303|9667931|FG002|Overall Study|Worsening Peripheral Neuropathy|0
6065992|NCT00524303|9667929|FG000|Overall Study|Disease Progression|0
6065993|NCT00524303|9667930|FG001|Overall Study|Disease Progression|4
6065994|NCT00524303|9667931|FG002|Overall Study|Disease Progression|1
6065995|NCT00524303|9667929|FG000|Overall Study|Disease Recurrence|0
6065996|NCT00524303|9667930|FG001|Overall Study|Disease Recurrence|1
6065997|NCT00524303|9667931|FG002|Overall Study|Disease Recurrence|0
6065998|NCT00524303|9667929|FG000|Overall Study|Sponsor Request|0
6065999|NCT00524303|9667930|FG001|Overall Study|Sponsor Request|0
6066000|NCT00524303|9667931|FG002|Overall Study|Sponsor Request|1
6066001|NCT00524303|9667929|FG000|Overall Study|Physician Decision|0
6066002|NCT00524303|9667930|FG001|Overall Study|Physician Decision|0
6066003|NCT00524303|9667931|FG002|Overall Study|Physician Decision|1
6066004|NCT00524303|9667929|FG000|Overall Study|Completed 5 years|0
6066005|NCT00524303|9667930|FG001|Overall Study|Completed 5 years|0
6066006|NCT00524303|9667931|FG002|Overall Study|Completed 5 years|1
6066007|NCT00524316|9667942|FG000|Overall Study|Withdrawal by Subject|2
6066008|NCT00524316|9667942|FG000|Overall Study|Adverse Event|7
6066009|NCT00524316|9667942|FG000|Overall Study|Disease Progression|7
6066010|NCT00524368|9667952|FG000|Overall Study|Adverse Event|10
6066011|NCT00524368|9667953|FG001|Overall Study|Adverse Event|12
6066012|NCT00524368|9667952|FG000|Overall Study|Lost to Follow-up|9
6066013|NCT00524368|9667953|FG001|Overall Study|Lost to Follow-up|13
6066014|NCT00524368|9667952|FG000|Overall Study|Withdrawal by Subject|4
6066015|NCT00524368|9667953|FG001|Overall Study|Withdrawal by Subject|5
6066016|NCT00524368|9667952|FG000|Overall Study|Non-compliant|8
6066017|NCT00524368|9667953|FG001|Overall Study|Non-compliant|9
6066018|NCT00524368|9667952|FG000|Overall Study|Reached a Virologic Endpoint|3
6066019|NCT00524368|9667953|FG001|Overall Study|Reached a Virologic Endpoint|2
6066020|NCT00524368|9667952|FG000|Overall Study|Sponsor's Decision|2
6066021|NCT00524368|9667953|FG001|Overall Study|Sponsor's Decision|0
6066022|NCT00524368|9667952|FG000|Overall Study|Ineligible to Continue the study|2
6066023|NCT00524368|9667953|FG001|Overall Study|Ineligible to Continue the study|5
6066024|NCT00524368|9667952|FG000|Overall Study|Other|3
6066025|NCT00524368|9667953|FG001|Overall Study|Other|2
6066026|NCT00524420|9667961|FG000|Overall Study|Lack of Efficacy|1
6066027|NCT00524420|9667962|FG001|Overall Study|Lack of Efficacy|0
6066028|NCT00524589|9667992|FG000|Overall Study|Withdrawal by Subject|2
6066029|NCT00524589|9667992|FG000|Overall Study|Disease Progression|16
6066030|NCT00524680|9668000|FG000|Overall Study|progression|0
6066031|NCT00524680|9668001|FG001|Overall Study|progression|0
6066032|NCT00524680|9668002|FG002|Overall Study|progression|0
6066033|NCT00524680|9668003|FG003|Overall Study|progression|1
6066034|NCT00524680|9668000|FG000|Overall Study|Adverse Event|2
6066035|NCT00524680|9668001|FG001|Overall Study|Adverse Event|0
6066036|NCT00524680|9668002|FG002|Overall Study|Adverse Event|0
6066037|NCT00524680|9668003|FG003|Overall Study|Adverse Event|1
6066038|NCT00524680|9668000|FG000|Overall Study|Other|0
6066039|NCT00524680|9668001|FG001|Overall Study|Other|1
6066040|NCT00524680|9668002|FG002|Overall Study|Other|2
6066041|NCT00524680|9668003|FG003|Overall Study|Other|3
6066042|NCT00524680|9668000|FG000|Overall Study|Withdrawal by Subject|1
6066043|NCT00524680|9668001|FG001|Overall Study|Withdrawal by Subject|0
6066044|NCT00524680|9668002|FG002|Overall Study|Withdrawal by Subject|1
6066045|NCT00524680|9668003|FG003|Overall Study|Withdrawal by Subject|1
6066046|NCT00524745|9668017|FG000|Overall Study|subject withdrawal or lost to follow up|34
6066047|NCT00524745|9668018|FG001|Overall Study|subject withdrawal or lost to follow up|13
6066048|NCT00524745|9668019|FG002|Overall Study|subject withdrawal or lost to follow up|29
6066049|NCT00524745|9668020|FG003|Overall Study|subject withdrawal or lost to follow up|22
6066050|NCT00524771|9668032|FG000|Overall Study|Protocol Violation|220
6066051|NCT00524771|9668033|FG001|Overall Study|Protocol Violation|585
6066052|NCT00525031|9668046|FG000|Overall Study|Disease Progression|1
6066053|NCT00525031|9668047|FG001|Overall Study|Disease Progression|1
6066054|NCT00525044|9668056|FG000|Overall Study|Lost to Follow-up|0
6066055|NCT00525044|9668057|FG001|Overall Study|Lost to Follow-up|1
6066056|NCT00525148|9668080|FG000|Overall Study|Other Adverse Event|3
6066057|NCT00525148|9668081|FG001|Overall Study|Other Adverse Event|5
6066058|NCT00525148|9668082|FG002|Overall Study|Other Adverse Event|1
6066059|NCT00525148|9668083|FG003|Overall Study|Other Adverse Event|8
6066060|NCT00525148|9668080|FG000|Overall Study|Progressive disease|18
6066061|NCT00525148|9668081|FG001|Overall Study|Progressive disease|30
6066062|NCT00525148|9668082|FG002|Overall Study|Progressive disease|6
6066063|NCT00525148|9668083|FG003|Overall Study|Progressive disease|49
6066064|NCT00525148|9668080|FG000|Overall Study|Refused continuation of study medication|0
6066065|NCT00525148|9668081|FG001|Overall Study|Refused continuation of study medication|2
6066066|NCT00525148|9668082|FG002|Overall Study|Refused continuation of study medication|0
6066067|NCT00525148|9668083|FG003|Overall Study|Refused continuation of study medication|1
6066068|NCT00525148|9668080|FG000|Overall Study|Other than stated|2
6066069|NCT00525148|9668081|FG001|Overall Study|Other than stated|1
6066070|NCT00525148|9668082|FG002|Overall Study|Other than stated|0
6066071|NCT00525148|9668083|FG003|Overall Study|Other than stated|3
6066072|NCT00525161|9668093|FG000|Overall Study|Adverse Event|1
6087083|NCT00666536|9697250|FG001|Overall Study|Adverse Event|19
6087084|NCT00666536|9697249|FG000|Overall Study|Unsatisfactory therapeutic effect|2
6087085|NCT00666536|9697250|FG001|Overall Study|Unsatisfactory therapeutic effect|0
6087086|NCT00666536|9697249|FG000|Overall Study|Protocol deviation(s)|8
6087087|NCT00666536|9697250|FG001|Overall Study|Protocol deviation(s)|6
6087088|NCT00666536|9697249|FG000|Overall Study|Withdrawal by Subject|10
6087089|NCT00666536|9697250|FG001|Overall Study|Withdrawal by Subject|9
6087090|NCT00666536|9697249|FG000|Overall Study|Lost to Follow-up|4
6087091|NCT00666536|9697250|FG001|Overall Study|Lost to Follow-up|3
6087092|NCT00666562|9697259|FG000|Overall Study|Withdrawal by Subject|0
6087093|NCT00666562|9697260|FG001|Overall Study|Withdrawal by Subject|1
6087094|NCT00666562|9697261|FG002|Overall Study|Withdrawal by Subject|0
6087095|NCT00666562|9697259|FG000|Overall Study|Concomitant Medication|0
6087096|NCT00666562|9697260|FG001|Overall Study|Concomitant Medication|1
6087097|NCT00666562|9697261|FG002|Overall Study|Concomitant Medication|0
6087098|NCT00666588|9697280|FG000|Overall Study|ineligible|2
6087099|NCT00666588|9697281|FG001|Overall Study|ineligible|0
6087100|NCT00666588|9697282|FG002|Overall Study|ineligible|0
6087101|NCT00666588|9697283|FG003|Overall Study|ineligible|2
6087102|NCT00666588|9697280|FG000|Overall Study|inevaluable|2
6087103|NCT00666588|9697281|FG001|Overall Study|inevaluable|0
6087104|NCT00666588|9697282|FG002|Overall Study|inevaluable|0
6087105|NCT00666588|9697283|FG003|Overall Study|inevaluable|0
6087106|NCT00666679|9697299|FG000|First Intervention|Lost to Follow-up|1
6087107|NCT00666679|9697300|FG001|First Intervention|Lost to Follow-up|0
6087108|NCT00666679|9697299|FG000|First Intervention|Protocol Violation|1
6087109|NCT00666679|9697300|FG001|First Intervention|Protocol Violation|0
6087110|NCT00666679|9697299|FG000|First Intervention|Withdrawal by Subject|1
6087111|NCT00666679|9697300|FG001|First Intervention|Withdrawal by Subject|0
6087112|NCT00666679|9697299|FG000|First Intervention|Randomized did not start treatment|1
6087113|NCT00666679|9697300|FG001|First Intervention|Randomized did not start treatment|1
6087114|NCT00666679|9697299|FG000|Washout Period of 1 Week|Lost to Follow-up|0
6087115|NCT00666679|9697300|FG001|Washout Period of 1 Week|Lost to Follow-up|1
6087116|NCT00666679|9697299|FG000|Washout Period of 1 Week|Protocol Violation|0
6087117|NCT00666679|9697300|FG001|Washout Period of 1 Week|Protocol Violation|1
6087118|NCT00666679|9697299|FG000|Second Intervention|Adverse Event|1
6087119|NCT00666679|9697300|FG001|Second Intervention|Adverse Event|0
6087120|NCT00666679|9697299|FG000|Second Intervention|Death|0
6087121|NCT00666679|9697300|FG001|Second Intervention|Death|1
6087122|NCT00666705|9697306|FG000|Overall Study|Withdrawal by Subject|1
6087123|NCT00666718|9697317|FG000|Overall Study|Adverse Event|0
6087124|NCT00666718|9697318|FG001|Overall Study|Adverse Event|1
6087125|NCT00666718|9697317|FG000|Overall Study|Death|1
6087126|NCT00666718|9697318|FG001|Overall Study|Death|0
6087127|NCT00666718|9697317|FG000|Overall Study|Lost to Follow-up|1
6087128|NCT00666718|9697318|FG001|Overall Study|Lost to Follow-up|0
6087129|NCT00666718|9697317|FG000|Overall Study|Entry Criteria Not Met|2
6087130|NCT00666718|9697318|FG001|Overall Study|Entry Criteria Not Met|0
6087131|NCT00666718|9697317|FG000|Overall Study|Protocol Violation|1
6087132|NCT00666718|9697318|FG001|Overall Study|Protocol Violation|3
6087133|NCT00666718|9697317|FG000|Overall Study|Withdrawal by Subject|7
5991553|NCT03257267|9583431|FG000|Overall Study|Adverse Event|9
5991554|NCT03257267|9583432|FG001|Overall Study|Adverse Event|7
5991555|NCT03257267|9583431|FG000|Overall Study|Death|92
5991556|NCT03257267|9583432|FG001|Overall Study|Death|95
5991557|NCT03257267|9583431|FG000|Overall Study|Lost to Follow-up|2
5991558|NCT03257267|9583432|FG001|Overall Study|Lost to Follow-up|2
5991559|NCT03257267|9583431|FG000|Overall Study|Non-compliance with Study Drug|0
5991560|NCT03257267|9583432|FG001|Overall Study|Non-compliance with Study Drug|1
5991561|NCT03257267|9583431|FG000|Overall Study|Participant Decision|34
5991562|NCT03257267|9583432|FG001|Overall Study|Participant Decision|42
5991563|NCT03257267|9583431|FG000|Overall Study|Physician Decision|1
5991564|NCT03257267|9583432|FG001|Overall Study|Physician Decision|3
5991565|NCT03257267|9583431|FG000|Overall Study|Disease Progression|98
5991566|NCT03257267|9583432|FG001|Overall Study|Disease Progression|117
6309305|NCT02637076|10037823|FG000|Overall Study|Withdrawal by Subject|0
6309306|NCT02637076|10037824|FG001|Overall Study|Withdrawal by Subject|4
6309307|NCT02637141|10037833|FG000|Overall Study|Adverse Event|1
6309308|NCT02637141|10037834|FG001|Overall Study|Adverse Event|1
6309309|NCT02637141|10037835|FG002|Overall Study|Adverse Event|0
6309310|NCT02637141|10037833|FG000|Overall Study|Withdrawal by Subject|1
6309311|NCT02637141|10037834|FG001|Overall Study|Withdrawal by Subject|1
6309312|NCT02637141|10037835|FG002|Overall Study|Withdrawal by Subject|1
5991567|NCT03257267|9583431|FG000|Overall Study|Withdrawal of Consent|8
5991568|NCT03257267|9583432|FG001|Overall Study|Withdrawal of Consent|26
6309313|NCT02637232|10037843|FG000|Overall Study|Lost to Follow-up|42
6309314|NCT02637232|10037843|FG000|Overall Study|Adverse Event|11
6309315|NCT02637232|10037843|FG000|Overall Study|patient 's decision|2
6309316|NCT02637323|10037849|FG000|Overall Study|Lost to Follow-up|2
6309317|NCT02637323|10037850|FG001|Overall Study|Lost to Follow-up|0
6309318|NCT02637323|10037849|FG000|Overall Study|Protocol Violation|0
6309319|NCT02637323|10037850|FG001|Overall Study|Protocol Violation|1
6309320|NCT02637557|10037870|FG000|Overall Study|Adverse Event|3
6309321|NCT02637557|10037871|FG001|Overall Study|Adverse Event|1
6309322|NCT02637557|10037872|FG002|Overall Study|Adverse Event|3
6309323|NCT02637557|10037873|FG003|Overall Study|Adverse Event|3
6309324|NCT02637557|10037870|FG000|Overall Study|Lost to Follow-up|1
6309325|NCT02637557|10037871|FG001|Overall Study|Lost to Follow-up|1
5991569|NCT03257267|9583431|FG000|Overall Study|Study Ongoing|53
5991570|NCT03257267|9583432|FG001|Overall Study|Study Ongoing|11
5991571|NCT04223830|9583460|FG000|Overall Study|Lost to Follow-up|9
5991572|NCT04223830|9583460|FG000|Overall Study|Adverse Event|1
5991573|NCT04153188|9583476|FG000|Overall Study|Lost to Follow-up|1
5991574|NCT04153188|9583477|FG001|Overall Study|Lost to Follow-up|1
5991575|NCT04153188|9583476|FG000|Overall Study|Withdrawal by Subject|2
5991576|NCT04153188|9583477|FG001|Overall Study|Withdrawal by Subject|0
5991577|NCT04153188|9583476|FG000|Overall Study|Subject withdrew due to rebound erythema when Oxymetazoline wore off|0
5991578|NCT04153188|9583477|FG001|Overall Study|Subject withdrew due to rebound erythema when Oxymetazoline wore off|1
5991579|NCT03886220|9583520|FG000|Treatment Period|Discontinued study drug during the treatment period|5
5991580|NCT03886220|9583521|FG001|Treatment Period|Discontinued study drug during the treatment period|12
5991581|NCT03886220|9583520|FG000|Post-Treatment Follow-Up Period|Withdrawal by Subject|1
5991582|NCT03886220|9583521|FG001|Post-Treatment Follow-Up Period|Withdrawal by Subject|0
6309326|NCT02637557|10037872|FG002|Overall Study|Lost to Follow-up|0
5972163|NCT04151290|9557826|FG000|Overall Study|The COVID-19 Pandemic made it hard for subjects to complete the study.|286
5972164|NCT04038385|9557832|FG000|Overall Study|Completed baseline assessment only|7
5972165|NCT04038385|9557833|FG001|Overall Study|Completed baseline assessment only|4
5972166|NCT04038385|9557832|FG000|Overall Study|Moved out of area|4
5972167|NCT04038385|9557833|FG001|Overall Study|Moved out of area|2
5972168|NCT04038385|9557832|FG000|Overall Study|Discontinued study involvement|6
5972169|NCT04038385|9557833|FG001|Overall Study|Discontinued study involvement|1
5972170|NCT03978091|9557845|FG000|Overall Study|Lost to Follow-up|0
5972171|NCT03978091|9557846|FG001|Overall Study|Lost to Follow-up|0
5972172|NCT03978091|9557847|FG002|Overall Study|Lost to Follow-up|1
5972173|NCT03978091|9557848|FG003|Overall Study|Lost to Follow-up|0
5972174|NCT03978091|9557849|FG004|Overall Study|Lost to Follow-up|0
5972175|NCT03978091|9557850|FG005|Overall Study|Lost to Follow-up|0
5972176|NCT03978091|9557845|FG000|Overall Study|Withdrawal by Subject|0
5972177|NCT03978091|9557846|FG001|Overall Study|Withdrawal by Subject|0
5972178|NCT03978091|9557847|FG002|Overall Study|Withdrawal by Subject|0
5972179|NCT03978091|9557848|FG003|Overall Study|Withdrawal by Subject|1
5972180|NCT03978091|9557849|FG004|Overall Study|Withdrawal by Subject|1
5972181|NCT03978091|9557850|FG005|Overall Study|Withdrawal by Subject|0
5972266|NCT03987919|9557985|FG002|Overall Study|Other - as reported by the investigator|2
5972267|NCT03987919|9557986|FG003|Overall Study|Other - as reported by the investigator|0
5972268|NCT03861039|9558015|FG000|Overall Study|Adverse Event|2
5972269|NCT03861039|9558016|FG001|Overall Study|Adverse Event|5
5972270|NCT03861039|9558017|FG002|Overall Study|Adverse Event|11
5972271|NCT03861039|9558015|FG000|Overall Study|Withdrawal by Subject|1
5972272|NCT03861039|9558016|FG001|Overall Study|Withdrawal by Subject|3
5972273|NCT03861039|9558017|FG002|Overall Study|Withdrawal by Subject|4
5972274|NCT03759587|9558027|FG000|Overall Study|Ongoing|19
5972275|NCT03730662|9558035|FG000|Treatment Period (52 Weeks)|Adverse Event|3
5972276|NCT03730662|9558036|FG001|Treatment Period (52 Weeks)|Adverse Event|2
5972277|NCT03730662|9558037|FG002|Treatment Period (52 Weeks)|Adverse Event|0
5972278|NCT03730662|9558038|FG003|Treatment Period (52 Weeks)|Adverse Event|3
5972279|NCT03730662|9558035|FG000|Treatment Period (52 Weeks)|Screen Failure|0
5972280|NCT03730662|9558036|FG001|Treatment Period (52 Weeks)|Screen Failure|1
6066073|NCT00525265|9668108|FG000|Overall Study|Protocol Violation|1
6066074|NCT00525265|9668109|FG001|Overall Study|Protocol Violation|0
6066075|NCT00525499|9668128|FG000|Overall Study|Lost to Follow-up|2
6066076|NCT00525499|9668129|FG001|Overall Study|Lost to Follow-up|4
6066077|NCT00525499|9668130|FG002|Overall Study|Lost to Follow-up|1
6066078|NCT00525499|9668131|FG003|Overall Study|Lost to Follow-up|4
6066079|NCT00525499|9668128|FG000|Overall Study|Adverse Event|0
6066080|NCT00525499|9668129|FG001|Overall Study|Adverse Event|1
6066081|NCT00525499|9668130|FG002|Overall Study|Adverse Event|0
6066082|NCT00525499|9668131|FG003|Overall Study|Adverse Event|1
6066083|NCT00525499|9668128|FG000|Overall Study|Withdrawal by Subject|5
6066084|NCT00525499|9668129|FG001|Overall Study|Withdrawal by Subject|1
6066085|NCT00525499|9668130|FG002|Overall Study|Withdrawal by Subject|5
6066086|NCT00525499|9668131|FG003|Overall Study|Withdrawal by Subject|2
6066087|NCT00525499|9668128|FG000|Overall Study|Protocol Violation|0
6066088|NCT00525499|9668129|FG001|Overall Study|Protocol Violation|1
5991583|NCT03886220|9583520|FG000|Post-Treatment Follow-Up Period|Lost to Follow-up|1
5991584|NCT03886220|9583521|FG001|Post-Treatment Follow-Up Period|Lost to Follow-up|2
6045780|NCT00403546|9645077|FG001|Screening Phase|Screening Failure|0
6045781|NCT00403546|9645078|FG002|Screening Phase|Screening Failure|0
6045782|NCT00403546|9645076|FG000|Screening Phase|Adverse Event|1
6045783|NCT00403546|9645077|FG001|Screening Phase|Adverse Event|0
6045784|NCT00403546|9645078|FG002|Screening Phase|Adverse Event|0
6066089|NCT00525499|9668130|FG002|Overall Study|Protocol Violation|1
6066090|NCT00525499|9668131|FG003|Overall Study|Protocol Violation|0
6066091|NCT00525512|9668143|FG000|Double-Blind Phase|Adverse Event|48
6066092|NCT00525512|9668144|FG001|Double-Blind Phase|Adverse Event|28
6066093|NCT00525512|9668145|FG002|Double-Blind Phase|Adverse Event|0
6066094|NCT00525512|9668146|FG003|Double-Blind Phase|Adverse Event|0
6066095|NCT00525512|9668143|FG000|Double-Blind Phase|Protocol Violation|3
6066096|NCT00525512|9668144|FG001|Double-Blind Phase|Protocol Violation|1
6066097|NCT00525512|9668145|FG002|Double-Blind Phase|Protocol Violation|0
6066098|NCT00525512|9668146|FG003|Double-Blind Phase|Protocol Violation|0
6066099|NCT00525512|9668143|FG000|Double-Blind Phase|Lost to Follow-up|3
6066100|NCT00525512|9668144|FG001|Double-Blind Phase|Lost to Follow-up|7
6066101|NCT00525512|9668145|FG002|Double-Blind Phase|Lost to Follow-up|0
6066102|NCT00525512|9668146|FG003|Double-Blind Phase|Lost to Follow-up|0
6066103|NCT00525512|9668143|FG000|Double-Blind Phase|Withdrawal by Subject|17
6066104|NCT00525512|9668144|FG001|Double-Blind Phase|Withdrawal by Subject|12
6066105|NCT00525512|9668145|FG002|Double-Blind Phase|Withdrawal by Subject|0
6066106|NCT00525512|9668146|FG003|Double-Blind Phase|Withdrawal by Subject|0
6066107|NCT00525512|9668143|FG000|Double-Blind Phase|Lack of Efficacy|13
6066108|NCT00525512|9668144|FG001|Double-Blind Phase|Lack of Efficacy|5
6066109|NCT00525512|9668145|FG002|Double-Blind Phase|Lack of Efficacy|0
6066110|NCT00525512|9668146|FG003|Double-Blind Phase|Lack of Efficacy|0
6066111|NCT00525512|9668143|FG000|Double-Blind Phase|Other reason (not specified)|12
6066112|NCT00525512|9668144|FG001|Double-Blind Phase|Other reason (not specified)|13
6066113|NCT00525512|9668145|FG002|Double-Blind Phase|Other reason (not specified)|0
6066114|NCT00525512|9668146|FG003|Double-Blind Phase|Other reason (not specified)|0
6066115|NCT00525512|9668143|FG000|Open-Label Phase|Adverse Event|0
6066116|NCT00525512|9668144|FG001|Open-Label Phase|Adverse Event|0
6045785|NCT00403546|9645076|FG000|Screening Phase|Terminated Prior to Randomization|5
6045786|NCT00403546|9645077|FG001|Screening Phase|Terminated Prior to Randomization|0
6045787|NCT00403546|9645078|FG002|Screening Phase|Terminated Prior to Randomization|0
6045788|NCT00403546|9645076|FG000|Randomized Trial|Early Terminations|0
6146165|NCT01075685|9780775|FG000|Overall Study|Protocol Violation|9
6146166|NCT01075685|9780776|FG001|Overall Study|Protocol Violation|1
6146167|NCT01075685|9780775|FG000|Overall Study|Withdrawal by Subject|20
6146168|NCT01075685|9780776|FG001|Overall Study|Withdrawal by Subject|5
6146169|NCT01075685|9780775|FG000|Overall Study|Lost to Follow-up|563
6146170|NCT01075685|9780776|FG001|Overall Study|Lost to Follow-up|220
6066117|NCT00525512|9668145|FG002|Open-Label Phase|Adverse Event|1
6066118|NCT00525512|9668146|FG003|Open-Label Phase|Adverse Event|0
6045789|NCT00403546|9645077|FG001|Randomized Trial|Early Terminations|17
6045790|NCT00403546|9645078|FG002|Randomized Trial|Early Terminations|16
6066119|NCT00525512|9668143|FG000|Open-Label Phase|Lost to Follow-up|0
6066120|NCT00525512|9668144|FG001|Open-Label Phase|Lost to Follow-up|0
6066121|NCT00525512|9668145|FG002|Open-Label Phase|Lost to Follow-up|1
6066122|NCT00525512|9668146|FG003|Open-Label Phase|Lost to Follow-up|0
6066123|NCT00525512|9668143|FG000|Open-Label Phase|Other reason (not specified)|0
6066124|NCT00525512|9668144|FG001|Open-Label Phase|Other reason (not specified)|0
6066125|NCT00525512|9668145|FG002|Open-Label Phase|Other reason (not specified)|4
6066126|NCT00525512|9668146|FG003|Open-Label Phase|Other reason (not specified)|5
6066127|NCT00525590|9668167|FG000|Overall Study|Adverse Event|3
6066128|NCT00525590|9668167|FG000|Overall Study|Physician Decision|3
6066129|NCT00525590|9668167|FG000|Overall Study|Withdrawal by Subject|16
6066130|NCT00525590|9668167|FG000|Overall Study|Lost to Follow-up|1
6066131|NCT00525590|9668167|FG000|Overall Study|Death|9
6066132|NCT00525590|9668167|FG000|Overall Study|Other|13
6066133|NCT00525785|9668191|FG000|Overall Study|Withdrawal by Subject|1
6066134|NCT00525785|9668191|FG000|Overall Study|Lack of Efficacy|1
6066135|NCT00525785|9668191|FG000|Overall Study|Physician Decision|1
6066136|NCT00525824|9668208|FG000|Overall Study|Adverse Event|7
6066137|NCT00525824|9668209|FG001|Overall Study|Adverse Event|11
6066138|NCT00525824|9668210|FG002|Overall Study|Adverse Event|6
6066139|NCT00525824|9668211|FG003|Overall Study|Adverse Event|7
6066140|NCT00525824|9668208|FG000|Overall Study|Withdrawal by Subject|5
6066141|NCT00525824|9668209|FG001|Overall Study|Withdrawal by Subject|9
6066142|NCT00525824|9668210|FG002|Overall Study|Withdrawal by Subject|3
6066143|NCT00525824|9668211|FG003|Overall Study|Withdrawal by Subject|4
6066144|NCT00525824|9668208|FG000|Overall Study|Lost to Follow-up|4
6066145|NCT00525824|9668209|FG001|Overall Study|Lost to Follow-up|2
6066146|NCT00525824|9668210|FG002|Overall Study|Lost to Follow-up|4
6066147|NCT00525824|9668211|FG003|Overall Study|Lost to Follow-up|0
6066148|NCT00525824|9668208|FG000|Overall Study|Incorrect enrolment/mis-randomisation|1
6066149|NCT00525824|9668209|FG001|Overall Study|Incorrect enrolment/mis-randomisation|2
6066150|NCT00525824|9668210|FG002|Overall Study|Incorrect enrolment/mis-randomisation|1
6066151|NCT00525824|9668211|FG003|Overall Study|Incorrect enrolment/mis-randomisation|2
6066152|NCT00525824|9668208|FG000|Overall Study|Severe non-compliance|0
6066153|NCT00525824|9668209|FG001|Overall Study|Severe non-compliance|1
6066154|NCT00525824|9668210|FG002|Overall Study|Severe non-compliance|1
6066155|NCT00525824|9668211|FG003|Overall Study|Severe non-compliance|1
6066156|NCT00525824|9668208|FG000|Overall Study|Safety reasons|1
6066157|NCT00525824|9668209|FG001|Overall Study|Safety reasons|0
6066158|NCT00525824|9668210|FG002|Overall Study|Safety reasons|1
6066159|NCT00525824|9668211|FG003|Overall Study|Safety reasons|0
6066160|NCT00525824|9668208|FG000|Overall Study|Other|1
6066161|NCT00525824|9668209|FG001|Overall Study|Other|3
6066162|NCT00525824|9668210|FG002|Overall Study|Other|3
6066163|NCT00525824|9668211|FG003|Overall Study|Other|1
6066164|NCT00525902|9668239|FG000|Overall Study|Lack of Efficacy|1
6066165|NCT00525915|9668245|FG000|Overall Study|Non-Compliance|0
6066166|NCT00525915|9668246|FG001|Overall Study|Non-Compliance|1
6066167|NCT00525915|9668245|FG000|Overall Study|Disease Progression|5
6066168|NCT00525915|9668246|FG001|Overall Study|Disease Progression|6
6066169|NCT00525915|9668245|FG000|Overall Study|Withdrawal by Subject|1
6066170|NCT00525915|9668246|FG001|Overall Study|Withdrawal by Subject|0
6066171|NCT00525915|9668245|FG000|Overall Study|Refused Surgery|1
6066172|NCT00525915|9668246|FG001|Overall Study|Refused Surgery|2
6066173|NCT00525915|9668245|FG000|Overall Study|Unrelated illness|1
6066174|NCT00525915|9668246|FG001|Overall Study|Unrelated illness|0
6066175|NCT00526071|9668261|FG000|Overall Study|Adverse Event|1
6066176|NCT00526071|9668261|FG000|Overall Study|Withdrawal by Subject|1
6066177|NCT00526071|9668261|FG000|Overall Study|Lack of Response to Study Drug|4
6066178|NCT00526097|9668271|FG000|Overall Study|Adverse Event|6
6066179|NCT00526097|9668272|FG001|Overall Study|Adverse Event|44
6066180|NCT00526097|9668271|FG000|Overall Study|Protocol Violation|4
6066181|NCT00526097|9668272|FG001|Overall Study|Protocol Violation|10
6066182|NCT00526097|9668271|FG000|Overall Study|Withdrawal by Subject|3
6066183|NCT00526097|9668272|FG001|Overall Study|Withdrawal by Subject|1
6066184|NCT00526097|9668271|FG000|Overall Study|Other|2
6066185|NCT00526097|9668272|FG001|Overall Study|Other|1
6066186|NCT00526110|9668280|FG000|Overall Study|Adverse Event|2
6066187|NCT00526110|9668281|FG001|Overall Study|Adverse Event|9
6066188|NCT00526110|9668280|FG000|Overall Study|Disease Progression|0
6066189|NCT00526110|9668281|FG001|Overall Study|Disease Progression|19
6066190|NCT00526110|9668280|FG000|Overall Study|Maximal Response|0
6066191|NCT00526110|9668281|FG001|Overall Study|Maximal Response|6
6066192|NCT00526110|9668280|FG000|Overall Study|Withdrawal by Subject|0
6066193|NCT00526110|9668281|FG001|Overall Study|Withdrawal by Subject|2
6066194|NCT00526110|9668280|FG000|Overall Study|Poor Tolerance|0
6066195|NCT00526110|9668281|FG001|Overall Study|Poor Tolerance|5
5991585|NCT03627091|9583543|FG000|Overall Study|Adverse Event|0
5991586|NCT03627091|9583544|FG001|Overall Study|Adverse Event|0
5991587|NCT03627091|9583545|FG002|Overall Study|Adverse Event|2
5991588|NCT03627091|9583543|FG000|Overall Study|Withdrawal by Subject|2
5991589|NCT03627091|9583544|FG001|Overall Study|Withdrawal by Subject|0
5991590|NCT03627091|9583545|FG002|Overall Study|Withdrawal by Subject|2
5991591|NCT03627091|9583543|FG000|Overall Study|Physician Decision|2
5991592|NCT03627091|9583544|FG001|Overall Study|Physician Decision|0
5991593|NCT03627091|9583545|FG002|Overall Study|Physician Decision|0
5991594|NCT03627091|9583543|FG000|Overall Study|Site terminated by sponsor|0
5991595|NCT03627091|9583544|FG001|Overall Study|Site terminated by sponsor|1
5991596|NCT03627091|9583545|FG002|Overall Study|Site terminated by sponsor|0
5991597|NCT03627091|9583543|FG000|Overall Study|Disease relapse|7
6066196|NCT00526162|9668296|FG000|Overall Study|Device not implanted|3
6066197|NCT00526630|9668332|FG000|First Intervention Period - 12 Weeks|Withdrawn|0
6066198|NCT00526630|9668333|FG001|First Intervention Period - 12 Weeks|Withdrawn|3
6066199|NCT00526630|9668332|FG000|Second Intervention Period - 12 Weeks|Withdrawn|2
5991598|NCT03627091|9583544|FG001|Overall Study|Disease relapse|5
5991599|NCT03627091|9583545|FG002|Overall Study|Disease relapse|1
5991600|NCT03627091|9583543|FG000|Overall Study|Other|1
5991601|NCT03627091|9583544|FG001|Overall Study|Other|0
5991602|NCT03627091|9583545|FG002|Overall Study|Other|0
5991603|NCT03568318|9583560|FG000|Overall Study|Adverse Event|3
5991604|NCT03568318|9583561|FG001|Overall Study|Adverse Event|1
5991605|NCT03568318|9583562|FG002|Overall Study|Adverse Event|1
5991606|NCT03568318|9583563|FG003|Overall Study|Adverse Event|0
5991607|NCT03568318|9583564|FG004|Overall Study|Adverse Event|1
5991608|NCT03568318|9583565|FG005|Overall Study|Adverse Event|0
5991609|NCT03568318|9583560|FG000|Overall Study|Withdrawal by Subject|6
5991610|NCT03568318|9583561|FG001|Overall Study|Withdrawal by Subject|5
5991611|NCT03568318|9583562|FG002|Overall Study|Withdrawal by Subject|2
5991612|NCT03568318|9583563|FG003|Overall Study|Withdrawal by Subject|1
5991613|NCT03568318|9583564|FG004|Overall Study|Withdrawal by Subject|0
5991614|NCT03568318|9583565|FG005|Overall Study|Withdrawal by Subject|0
5991615|NCT03568318|9583560|FG000|Overall Study|Lost to Follow-up|3
5991616|NCT03568318|9583561|FG001|Overall Study|Lost to Follow-up|2
5991617|NCT03568318|9583562|FG002|Overall Study|Lost to Follow-up|2
5991618|NCT03568318|9583563|FG003|Overall Study|Lost to Follow-up|2
5991619|NCT03568318|9583564|FG004|Overall Study|Lost to Follow-up|1
5991620|NCT03568318|9583565|FG005|Overall Study|Lost to Follow-up|0
5991621|NCT03568318|9583560|FG000|Overall Study|Other|3
5991622|NCT03568318|9583561|FG001|Overall Study|Other|1
5991623|NCT03568318|9583562|FG002|Overall Study|Other|3
5991624|NCT03568318|9583563|FG003|Overall Study|Other|0
5991625|NCT03568318|9583564|FG004|Overall Study|Other|0
5991626|NCT03568318|9583565|FG005|Overall Study|Other|0
5991627|NCT03568318|9583560|FG000|Overall Study|Ongoing at Time of Analysis|5
5991628|NCT03568318|9583561|FG001|Overall Study|Ongoing at Time of Analysis|3
5991629|NCT03568318|9583562|FG002|Overall Study|Ongoing at Time of Analysis|2
5991630|NCT03568318|9583563|FG003|Overall Study|Ongoing at Time of Analysis|1
5991631|NCT03568318|9583564|FG004|Overall Study|Ongoing at Time of Analysis|0
5991632|NCT03568318|9583565|FG005|Overall Study|Ongoing at Time of Analysis|0
5991633|NCT03498560|9583579|FG000|Overall Study|Found Ineligible|2
5991634|NCT03498560|9583579|FG000|Overall Study|Withdrawal by Subject|14
5991635|NCT03498560|9583579|FG000|Overall Study|Lost to Follow-up|4
5991636|NCT03498560|9583579|FG000|Overall Study|Death|1
5991637|NCT03441360|9583587|FG000|Overall Study|Radiological disease progression|5
5991638|NCT03441360|9583588|FG001|Overall Study|Radiological disease progression|6
5991639|NCT03441360|9583589|FG002|Overall Study|Radiological disease progression|4
5991640|NCT03441360|9583587|FG000|Overall Study|Clinical disease progression|2
5991641|NCT03441360|9583588|FG001|Overall Study|Clinical disease progression|2
5991642|NCT03441360|9583589|FG002|Overall Study|Clinical disease progression|0
5991643|NCT03441360|9583587|FG000|Overall Study|Adverse Event|1
5991644|NCT03441360|9583588|FG001|Overall Study|Adverse Event|0
5991645|NCT03441360|9583589|FG002|Overall Study|Adverse Event|1
5991646|NCT03434379|9583599|FG000|Global Period|Lost to Follow-up|3
5991647|NCT03434379|9583600|FG001|Global Period|Lost to Follow-up|1
5991648|NCT03434379|9583601|FG002|Global Period|Lost to Follow-up|0
5991649|NCT03434379|9583602|FG003|Global Period|Lost to Follow-up|0
5991650|NCT03434379|9583599|FG000|Global Period|Death|99
5991651|NCT03434379|9583600|FG001|Global Period|Death|179
6066200|NCT00526630|9668333|FG001|Second Intervention Period - 12 Weeks|Withdrawn|1
6066201|NCT00526656|9668341|FG000|Overall Study|Death|1
6066202|NCT00526656|9668341|FG000|Overall Study|Refused surgery|1
6066203|NCT00526669|9668346|FG000|Combined Treatment Phase|Lost to Follow-up|0
6066204|NCT00526669|9668347|FG001|Combined Treatment Phase|Lost to Follow-up|2
5991652|NCT03434379|9583601|FG002|Global Period|Death|0
5991653|NCT03434379|9583602|FG003|Global Period|Death|0
5991654|NCT03434379|9583599|FG000|Global Period|Withdrawal by Subject|20
5991655|NCT03434379|9583600|FG001|Global Period|Withdrawal by Subject|20
5991656|NCT03434379|9583601|FG002|Global Period|Withdrawal by Subject|0
5991657|NCT03434379|9583602|FG003|Global Period|Withdrawal by Subject|0
5991658|NCT03434379|9583599|FG000|Global Period|On Study|43
5991659|NCT03434379|9583600|FG001|Global Period|On Study|136
5991660|NCT03434379|9583601|FG002|Global Period|On Study|0
5991661|NCT03434379|9583602|FG003|Global Period|On Study|0
5991662|NCT03434379|9583599|FG000|China Extension Period|Lost to Follow-up|0
6066205|NCT00526669|9668346|FG000|Combined Treatment Phase|Withdrawal by Subject|0
6066206|NCT00526669|9668347|FG001|Combined Treatment Phase|Withdrawal by Subject|2
6066207|NCT00526669|9668346|FG000|Combined Treatment Phase|Sponsor Terminated Study|0
6066208|NCT00526669|9668347|FG001|Combined Treatment Phase|Sponsor Terminated Study|2
6066209|NCT00526669|9668346|FG000|Combined Treatment Phase|Death|0
6066210|NCT00526669|9668347|FG001|Combined Treatment Phase|Death|2
6066211|NCT00526799|9668355|FG000|Overall Study|Withdrawal by Subject|1
6066212|NCT00526799|9668356|FG001|Overall Study|Withdrawal by Subject|0
6066213|NCT00526799|9668355|FG000|Overall Study|Intercurrent Complicating Disease|0
6066214|NCT00526799|9668356|FG001|Overall Study|Intercurrent Complicating Disease|1
6066215|NCT00526890|9668362|FG000|Overall Study|Adverse Event|2
6066216|NCT00526994|9668369|FG000|Overall Study|Lost to Follow-up|98
6066217|NCT00526994|9668370|FG001|Overall Study|Lost to Follow-up|108
6066218|NCT00526994|9668371|FG002|Overall Study|Lost to Follow-up|96
6066219|NCT00526994|9668369|FG000|Overall Study|Death|4
5991663|NCT03434379|9583600|FG001|China Extension Period|Lost to Follow-up|0
5991664|NCT03434379|9583601|FG002|China Extension Period|Lost to Follow-up|1
5991665|NCT03434379|9583602|FG003|China Extension Period|Lost to Follow-up|0
5991666|NCT03434379|9583599|FG000|China Extension Period|Death|0
5991667|NCT03434379|9583600|FG001|China Extension Period|Death|0
5991668|NCT03434379|9583601|FG002|China Extension Period|Death|38
5991669|NCT03434379|9583602|FG003|China Extension Period|Death|61
5991670|NCT03434379|9583599|FG000|China Extension Period|Withdrawal by Subject|0
5991671|NCT03434379|9583600|FG001|China Extension Period|Withdrawal by Subject|0
5991672|NCT03434379|9583601|FG002|China Extension Period|Withdrawal by Subject|7
5991673|NCT03434379|9583602|FG003|China Extension Period|Withdrawal by Subject|6
5991674|NCT03434379|9583599|FG000|China Extension Period|On Study|0
5991675|NCT03434379|9583600|FG001|China Extension Period|On Study|0
5991676|NCT03434379|9583601|FG002|China Extension Period|On Study|15
5991677|NCT03434379|9583602|FG003|China Extension Period|On Study|66
6045791|NCT00403585|9645087|FG000|Initial Treatment Phase|Lost to Follow-up|2
6045792|NCT00403585|9645087|FG000|Open-Label Phase; Extension Study|Withdrawal by Subject|2
6045793|NCT00403585|9645087|FG000|Open-Label Phase; Extension Study|HBV DNA Mutation Positive|4
6045794|NCT00403754|9645091|FG000|Core Treatment Period 1|Withdrawal by Subject|0
6045795|NCT00403754|9645092|FG001|Core Treatment Period 1|Withdrawal by Subject|1
6045796|NCT00403754|9645093|FG002|Core Treatment Period 1|Withdrawal by Subject|0
6045797|NCT00403754|9645094|FG003|Core Treatment Period 1|Withdrawal by Subject|0
6045798|NCT00403754|9645091|FG000|Core Treatment Period 2|Lack of Efficacy|0
6045799|NCT00403754|9645092|FG001|Core Treatment Period 2|Lack of Efficacy|0
6045800|NCT00403754|9645093|FG002|Core Treatment Period 2|Lack of Efficacy|1
6045801|NCT00403754|9645094|FG003|Core Treatment Period 2|Lack of Efficacy|0
6045802|NCT00403767|9645108|FG000|Overall Study|Adverse Event|993
6045803|NCT00403767|9645109|FG001|Overall Study|Adverse Event|919
6066220|NCT00526994|9668370|FG001|Overall Study|Death|3
6066221|NCT00526994|9668371|FG002|Overall Study|Death|3
6066222|NCT00526994|9668369|FG000|Overall Study|Withdrawal by Subject|2
6066223|NCT00526994|9668370|FG001|Overall Study|Withdrawal by Subject|7
6066224|NCT00526994|9668371|FG002|Overall Study|Withdrawal by Subject|5
6066225|NCT00526994|9668369|FG000|Overall Study|incarcerated, impaired, incomplete|4
6066226|NCT00526994|9668370|FG001|Overall Study|incarcerated, impaired, incomplete|3
6066227|NCT00526994|9668371|FG002|Overall Study|incarcerated, impaired, incomplete|3
6066228|NCT00527072|9668379|FG000|Overall Study|Adverse Event|13
6066229|NCT00527072|9668379|FG000|Overall Study|Lack of Efficacy|11
6066230|NCT00527072|9668379|FG000|Overall Study|Lost to Follow-up|3
6066231|NCT00527072|9668379|FG000|Overall Study|Protocol Violation|2
6066232|NCT00527072|9668379|FG000|Overall Study|Withdrawal by Subject|7
6066233|NCT00527111|9668394|FG000|Overall Study|Adverse Event|14
6066234|NCT00527111|9668395|FG001|Overall Study|Adverse Event|13
6066235|NCT00527111|9668394|FG000|Overall Study|Death|0
6066236|NCT00527111|9668395|FG001|Overall Study|Death|1
6066237|NCT00527111|9668394|FG000|Overall Study|Investigator Request|2
6066238|NCT00527111|9668395|FG001|Overall Study|Investigator Request|1
6066239|NCT00527111|9668394|FG000|Overall Study|Patient Request|2
6066240|NCT00527111|9668395|FG001|Overall Study|Patient Request|5
6066241|NCT00527111|9668394|FG000|Overall Study|Other|2
6066242|NCT00527111|9668395|FG001|Overall Study|Other|2
6066243|NCT00527319|9668413|FG000|Overall Study|Withdrawal by Subject|5
6066244|NCT00527319|9668414|FG001|Overall Study|Withdrawal by Subject|0
6066245|NCT00527319|9668415|FG002|Overall Study|Withdrawal by Subject|1
6066246|NCT00527319|9668413|FG000|Overall Study|Lost to Follow-up|1
6066247|NCT00527319|9668414|FG001|Overall Study|Lost to Follow-up|0
6066248|NCT00527319|9668415|FG002|Overall Study|Lost to Follow-up|0
6066249|NCT00527319|9668413|FG000|Overall Study|Death|0
6066250|NCT00527319|9668414|FG001|Overall Study|Death|3
6066251|NCT00527319|9668415|FG002|Overall Study|Death|1
6066252|NCT00527319|9668413|FG000|Overall Study|Intercurrent Medical Illness|0
6066253|NCT00527319|9668414|FG001|Overall Study|Intercurrent Medical Illness|1
6066254|NCT00527319|9668415|FG002|Overall Study|Intercurrent Medical Illness|3
6066255|NCT00527319|9668413|FG000|Overall Study|Adverse Event|0
6066256|NCT00527319|9668414|FG001|Overall Study|Adverse Event|0
6066257|NCT00527319|9668415|FG002|Overall Study|Adverse Event|1
6066258|NCT00527332|9668425|FG000|Overall Study|Protocol Violation|4
6066259|NCT00527332|9668426|FG001|Overall Study|Protocol Violation|8
6066260|NCT00527332|9668425|FG000|Overall Study|Withdrew consent|5
6066261|NCT00527332|9668426|FG001|Overall Study|Withdrew consent|1
6066262|NCT00527397|9668432|FG000|Overall Study|Adverse Event|3
6066263|NCT00527397|9668432|FG000|Overall Study|Lack of Efficacy|1
6066264|NCT00527397|9668432|FG000|Overall Study|Protocol Violation|1
6066265|NCT00527397|9668432|FG000|Overall Study|Withdrawal by Subject|6
5991678|NCT03368170|9583616|FG000|Overall Study|Adverse Event|2
5991679|NCT03368170|9583617|FG001|Overall Study|Adverse Event|1
5991680|NCT03336528|9583625|FG000|Overall Study|Protocol Violation|1
5991681|NCT03336528|9583626|FG001|Overall Study|Protocol Violation|1
6049088|NCT00421148|9648261|FG012|Overall Study|Protocol Violation|0
5991682|NCT03336528|9583625|FG000|Overall Study|Discharged within 48 hours of study medication|8
5991683|NCT03336528|9583626|FG001|Overall Study|Discharged within 48 hours of study medication|6
5991684|NCT03336528|9583625|FG000|Overall Study|Did not receive study medication|1
5991685|NCT03336528|9583626|FG001|Overall Study|Did not receive study medication|2
5991686|NCT03334409|9583636|FG000|Overall Study|Did not meet inclusion criteria|1
6066266|NCT00527397|9668432|FG000|Overall Study|Study terminated by sponsor|13
6066267|NCT00527423|9668439|FG000|Overall Study|Protocol Violation|1
6066268|NCT00527423|9668439|FG000|Overall Study|Adverse Event|5
6066269|NCT00527423|9668439|FG000|Overall Study|Physician Decision|4
6066270|NCT00527423|9668439|FG000|Overall Study|Withdrawal by Subject|10
6066271|NCT00527423|9668439|FG000|Overall Study|Lost to Follow-up|4
6066272|NCT00527423|9668439|FG000|Overall Study|OTHER|4
6066273|NCT00527423|9668439|FG000|Overall Study|Death|9
6066274|NCT00527488|9668458|FG000|Overall Study|Withdrawn prior to dosing|0
6066275|NCT00527488|9668459|FG001|Overall Study|Withdrawn prior to dosing|1
6066276|NCT00527488|9668460|FG002|Overall Study|Withdrawn prior to dosing|1
6066277|NCT00527488|9668461|FG003|Overall Study|Withdrawn prior to dosing|0
6066278|NCT00527514|9668471|FG000|Weeks 1-3: Amlodipine (Aml) 5mg|Adverse Event|1
6066279|NCT00527514|9668471|FG000|Weeks 4-6: Aml 5mg+Olmesartan 20 mg|Withdrawal by Subject|2
6066280|NCT00527514|9668471|FG000|Weeks 7-9: Aml 5 mg + Olmesartan 40 mg|Adverse Event|1
6066281|NCT00527514|9668471|FG000|Weeks 7-9: Aml 5 mg + Olmesartan 40 mg|Lost to Follow-up|1
6066282|NCT00527514|9668471|FG000|Weeks 7-9: Aml 5 mg + Olmesartan 40 mg|Withdrawal by Subject|1
6066283|NCT00527514|9668471|FG000|Weeks 10-12:Aml 10 mg +Olmesartan 40 mg|Adverse Event|1
6066284|NCT00527514|9668471|FG000|Weeks 10-12:Aml 10 mg +Olmesartan 40 mg|Withdrawal by Subject|1
6066285|NCT00527605|9668496|FG000|Overall Study|Adverse Event|3
6066286|NCT00527605|9668497|FG001|Overall Study|Adverse Event|0
5991687|NCT03334409|9583637|FG001|Overall Study|Did not meet inclusion criteria|0
5991688|NCT03332498|9583646|FG000|Overall Study|Severe illness prior to Day 1 of treatment|0
5991689|NCT03332498|9583647|FG001|Overall Study|Severe illness prior to Day 1 of treatment|0
5991690|NCT03332498|9583648|FG002|Overall Study|Severe illness prior to Day 1 of treatment|2
5991691|NCT03230292|9583664|FG000|Overall Study|Adverse Event|1
5991692|NCT03230292|9583664|FG000|Overall Study|Protocol Violation|1
5991693|NCT03230292|9583664|FG000|Overall Study|Lost to Follow-up|1
5991694|NCT03230292|9583664|FG000|Overall Study|Withdrawal by Subject|3
6066287|NCT00527605|9668496|FG000|Overall Study|Withdrawal by Subject|3
6066288|NCT00527605|9668497|FG001|Overall Study|Withdrawal by Subject|7
6066289|NCT00527605|9668496|FG000|Overall Study|Lost to Follow-up|6
6066290|NCT00527605|9668497|FG001|Overall Study|Lost to Follow-up|2
6066291|NCT00527605|9668496|FG000|Overall Study|Protocol Violation|1
6066292|NCT00527605|9668497|FG001|Overall Study|Protocol Violation|2
6066293|NCT00527618|9668503|FG000|Week 1-12 (First Intervention)|Lost to Follow-up|3
6066294|NCT00527618|9668504|FG001|Week 1-12 (First Intervention)|Lost to Follow-up|1
6066295|NCT00527618|9668503|FG000|Week 1-12 (First Intervention)|Adverse Event|0
6066296|NCT00527618|9668504|FG001|Week 1-12 (First Intervention)|Adverse Event|1
6066297|NCT00527618|9668503|FG000|Week 13-14 (Washout)|Lost to Follow-up|1
6066298|NCT00527618|9668504|FG001|Week 13-14 (Washout)|Lost to Follow-up|0
6066299|NCT00527618|9668503|FG000|Week 15-18 (Second Intervention)|Lost to Follow-up|0
6066300|NCT00527618|9668504|FG001|Week 15-18 (Second Intervention)|Lost to Follow-up|1
6066301|NCT00527618|9668503|FG000|Week 15-18 (Second Intervention)|Censored on initiation of HAART|0
6066302|NCT00527618|9668504|FG001|Week 15-18 (Second Intervention)|Censored on initiation of HAART|1
6066303|NCT00527618|9668503|FG000|Week 15-18 (Second Intervention)|Withdrawal by Subject|0
6066304|NCT00527618|9668504|FG001|Week 15-18 (Second Intervention)|Withdrawal by Subject|1
6066305|NCT00527735|9668527|FG000|Overall Study|Disease progression|47
6066306|NCT00527735|9668528|FG001|Overall Study|Disease progression|61
6066307|NCT00527735|9668529|FG002|Overall Study|Disease progression|53
6066308|NCT00527735|9668527|FG000|Overall Study|Death|23
6066309|NCT00527735|9668528|FG001|Overall Study|Death|13
6066310|NCT00527735|9668529|FG002|Overall Study|Death|15
6066311|NCT00527735|9668527|FG000|Overall Study|Completed treatment in treatment phase|14
6066312|NCT00527735|9668528|FG001|Overall Study|Completed treatment in treatment phase|13
5991695|NCT03131960|9583685|FG000|Overall Study|Adverse Event|0
5991696|NCT03131960|9583686|FG001|Overall Study|Adverse Event|1
6066313|NCT00527735|9668529|FG002|Overall Study|Completed treatment in treatment phase|18
6066314|NCT00527735|9668527|FG000|Overall Study|Adverse Event|10
6066315|NCT00527735|9668528|FG001|Overall Study|Adverse Event|6
6066316|NCT00527735|9668529|FG002|Overall Study|Adverse Event|7
6066317|NCT00527735|9668527|FG000|Overall Study|Not identified|5
6066318|NCT00527735|9668528|FG001|Overall Study|Not identified|5
6066319|NCT00527735|9668529|FG002|Overall Study|Not identified|5
6066320|NCT00527735|9668527|FG000|Overall Study|Withdrawal by Subject|5
6066321|NCT00527735|9668528|FG001|Overall Study|Withdrawal by Subject|4
6066322|NCT00527735|9668529|FG002|Overall Study|Withdrawal by Subject|3
6066323|NCT00527735|9668527|FG000|Overall Study|No longer met study criteria|2
6066324|NCT00527735|9668528|FG001|Overall Study|No longer met study criteria|2
6066325|NCT00527735|9668529|FG002|Overall Study|No longer met study criteria|1
6066326|NCT00527735|9668527|FG000|Overall Study|Lost to Follow-up|0
6066327|NCT00527735|9668528|FG001|Overall Study|Lost to Follow-up|0
6066328|NCT00527735|9668529|FG002|Overall Study|Lost to Follow-up|3
6066329|NCT00527735|9668527|FG000|Overall Study|Poor compliance or noncompliance|0
6066330|NCT00527735|9668528|FG001|Overall Study|Poor compliance or noncompliance|1
6066331|NCT00527735|9668529|FG002|Overall Study|Poor compliance or noncompliance|1
6066332|NCT00527735|9668527|FG000|Overall Study|Completed treatment during maintenance|2
6066333|NCT00527735|9668528|FG001|Overall Study|Completed treatment during maintenance|2
6066334|NCT00527735|9668529|FG002|Overall Study|Completed treatment during maintenance|1
6066335|NCT00527787|9668551|FG000|Overall Study|Adverse Event|14
6066336|NCT00527787|9668552|FG001|Overall Study|Adverse Event|24
6066337|NCT00527787|9668551|FG000|Overall Study|Withdrawal by Subject|13
6066338|NCT00527787|9668552|FG001|Overall Study|Withdrawal by Subject|25
6066339|NCT00527787|9668551|FG000|Overall Study|Lost to Follow-up|5
6066340|NCT00527787|9668552|FG001|Overall Study|Lost to Follow-up|2
6066341|NCT00527787|9668551|FG000|Overall Study|Duodenal Ulcer|1
6066342|NCT00527787|9668552|FG001|Overall Study|Duodenal Ulcer|10
6066343|NCT00527787|9668551|FG000|Overall Study|misc|5
6066344|NCT00527787|9668552|FG001|Overall Study|misc|2
6066345|NCT00527826|9668560|FG000|Overall Study|Adverse Event|10
6066346|NCT00527826|9668561|FG001|Overall Study|Adverse Event|10
6066347|NCT00527826|9668560|FG000|Overall Study|Lost to Follow-up|3
6066348|NCT00527826|9668561|FG001|Overall Study|Lost to Follow-up|2
6066349|NCT00527826|9668560|FG000|Overall Study|Withdrawal by Subject|5
6066350|NCT00527826|9668561|FG001|Overall Study|Withdrawal by Subject|8
6066351|NCT00527826|9668560|FG000|Overall Study|Inclusion Criteria Not Met|3
6066352|NCT00527826|9668561|FG001|Overall Study|Inclusion Criteria Not Met|3
6066353|NCT00527826|9668560|FG000|Overall Study|Alpha-1 Antitrypsin Deficiency|0
6066354|NCT00527826|9668561|FG001|Overall Study|Alpha-1 Antitrypsin Deficiency|1
6066355|NCT00527826|9668560|FG000|Overall Study|Additional Intake of Viani forte|0
6066356|NCT00527826|9668561|FG001|Overall Study|Additional Intake of Viani forte|1
6066357|NCT00527826|9668560|FG000|Overall Study|Participant moved away|0
6066358|NCT00527826|9668561|FG001|Overall Study|Participant moved away|1
6066359|NCT00527904|9668577|FG000|Overall Study|Adverse Event|45
6066360|NCT00527904|9668577|FG000|Overall Study|Withdrawal by Subject|21
6066361|NCT00527904|9668577|FG000|Overall Study|Lost to Follow-up|8
6066362|NCT00527904|9668577|FG000|Overall Study|misc|22
6066363|NCT00528021|9668594|FG000|Overall Study|Lack of Efficacy|17
6066364|NCT00528021|9668595|FG001|Overall Study|Lack of Efficacy|13
6066365|NCT00528021|9668596|FG002|Overall Study|Lack of Efficacy|7
6066366|NCT00528021|9668597|FG003|Overall Study|Lack of Efficacy|9
6066367|NCT00528112|9668609|FG000|Treatment up to 3 Years|Adverse Event|313
6066368|NCT00528112|9668610|FG001|Treatment up to 3 Years|Adverse Event|278
6066369|NCT00528112|9668609|FG000|Treatment up to 3 Years|Withdrawal by Subject|26
6066370|NCT00528112|9668610|FG001|Treatment up to 3 Years|Withdrawal by Subject|31
6066371|NCT00528112|9668609|FG000|Treatment up to 3 Years|Protocol Violation|16
6066372|NCT00528112|9668610|FG001|Treatment up to 3 Years|Protocol Violation|16
6066373|NCT00528112|9668609|FG000|Treatment up to 3 Years|Death|0
6066374|NCT00528112|9668610|FG001|Treatment up to 3 Years|Death|1
6066375|NCT00528112|9668609|FG000|Treatment up to 3 Years|Lost to Follow-up|63
6066376|NCT00528112|9668610|FG001|Treatment up to 3 Years|Lost to Follow-up|61
6066377|NCT00528112|9668609|FG000|Treatment up to 3 Years|Pregnancy|9
6066378|NCT00528112|9668610|FG001|Treatment up to 3 Years|Pregnancy|10
6066379|NCT00528112|9668609|FG000|Treatment up to 3 Years|Other reasons|186
6066380|NCT00528112|9668610|FG001|Treatment up to 3 Years|Other reasons|186
6066381|NCT00528112|9668609|FG000|Extension Phase|Withdrawal by Subject|0
6066382|NCT00528112|9668610|FG001|Extension Phase|Withdrawal by Subject|3
6066383|NCT00528112|9668609|FG000|Extension Phase|Other reasons|0
6066384|NCT00528112|9668610|FG001|Extension Phase|Other reasons|100
6066385|NCT00528112|9668609|FG000|Extension Phase|Pregnancy|0
6066386|NCT00528112|9668610|FG001|Extension Phase|Pregnancy|3
6066387|NCT00528112|9668609|FG000|Extension Phase|Lost to Follow-up|0
6066388|NCT00528112|9668610|FG001|Extension Phase|Lost to Follow-up|12
6066389|NCT00528112|9668609|FG000|Extension Phase|Death|0
6066390|NCT00528112|9668610|FG001|Extension Phase|Death|1
6066391|NCT00528112|9668609|FG000|Extension Phase|Adverse Event|0
6066392|NCT00528112|9668610|FG001|Extension Phase|Adverse Event|36
6066393|NCT00528112|9668609|FG000|Extension Phase|Protocol Violation|0
6066394|NCT00528112|9668610|FG001|Extension Phase|Protocol Violation|2
6066395|NCT00528372|9668645|FG000|Short-term (ST) Period (Day 1-Week 24)|Lack of Efficacy|2
6066396|NCT00528372|9668646|FG001|Short-term (ST) Period (Day 1-Week 24)|Lack of Efficacy|0
6066397|NCT00528372|9668647|FG002|Short-term (ST) Period (Day 1-Week 24)|Lack of Efficacy|0
6066398|NCT00528372|9668648|FG003|Short-term (ST) Period (Day 1-Week 24)|Lack of Efficacy|0
6066399|NCT00528372|9668649|FG004|Short-term (ST) Period (Day 1-Week 24)|Lack of Efficacy|0
6066400|NCT00528372|9668650|FG005|Short-term (ST) Period (Day 1-Week 24)|Lack of Efficacy|0
6066401|NCT00528372|9668651|FG006|Short-term (ST) Period (Day 1-Week 24)|Lack of Efficacy|0
6066402|NCT00528372|9668652|FG007|Short-term (ST) Period (Day 1-Week 24)|Lack of Efficacy|0
6066403|NCT00528372|9668653|FG008|Short-term (ST) Period (Day 1-Week 24)|Lack of Efficacy|0
6066404|NCT00528372|9668645|FG000|Short-term (ST) Period (Day 1-Week 24)|Adverse Event|0
6066405|NCT00528372|9668646|FG001|Short-term (ST) Period (Day 1-Week 24)|Adverse Event|2
6066406|NCT00528372|9668647|FG002|Short-term (ST) Period (Day 1-Week 24)|Adverse Event|2
6066407|NCT00528372|9668648|FG003|Short-term (ST) Period (Day 1-Week 24)|Adverse Event|6
6066408|NCT00528372|9668649|FG004|Short-term (ST) Period (Day 1-Week 24)|Adverse Event|0
6066409|NCT00528372|9668650|FG005|Short-term (ST) Period (Day 1-Week 24)|Adverse Event|3
6066410|NCT00528372|9668651|FG006|Short-term (ST) Period (Day 1-Week 24)|Adverse Event|3
6066411|NCT00528372|9668652|FG007|Short-term (ST) Period (Day 1-Week 24)|Adverse Event|0
6066412|NCT00528372|9668653|FG008|Short-term (ST) Period (Day 1-Week 24)|Adverse Event|0
6066413|NCT00528372|9668645|FG000|Short-term (ST) Period (Day 1-Week 24)|Withdrawal by Subject|1
6066414|NCT00528372|9668646|FG001|Short-term (ST) Period (Day 1-Week 24)|Withdrawal by Subject|2
6066415|NCT00528372|9668647|FG002|Short-term (ST) Period (Day 1-Week 24)|Withdrawal by Subject|7
6066416|NCT00528372|9668648|FG003|Short-term (ST) Period (Day 1-Week 24)|Withdrawal by Subject|1
6066417|NCT00528372|9668649|FG004|Short-term (ST) Period (Day 1-Week 24)|Withdrawal by Subject|6
6066418|NCT00528372|9668650|FG005|Short-term (ST) Period (Day 1-Week 24)|Withdrawal by Subject|4
6066419|NCT00528372|9668651|FG006|Short-term (ST) Period (Day 1-Week 24)|Withdrawal by Subject|6
6087134|NCT00666718|9697318|FG001|Overall Study|Withdrawal by Subject|12
6087135|NCT00666718|9697317|FG000|Overall Study|Physician Decision|0
5991697|NCT03084536|9583695|FG000|Overall Study|Determined to be ineligible|0
5991698|NCT03084536|9583696|FG001|Overall Study|Determined to be ineligible|0
5991699|NCT03084536|9583697|FG002|Overall Study|Determined to be ineligible|16
5991700|NCT03084536|9583695|FG000|Overall Study|Withdrawal by Subject|0
5991701|NCT03084536|9583696|FG001|Overall Study|Withdrawal by Subject|0
5991702|NCT03084536|9583697|FG002|Overall Study|Withdrawal by Subject|4
5991703|NCT03084536|9583695|FG000|Overall Study|Physician Decision|0
5991704|NCT03084536|9583696|FG001|Overall Study|Physician Decision|0
5991705|NCT03084536|9583697|FG002|Overall Study|Physician Decision|3
5991706|NCT03084536|9583695|FG000|Overall Study|Death|0
5991707|NCT03084536|9583696|FG001|Overall Study|Death|0
5991708|NCT03084536|9583697|FG002|Overall Study|Death|1
5991709|NCT03084536|9583695|FG000|Overall Study|Lost to Follow-up|0
5991710|NCT03084536|9583696|FG001|Overall Study|Lost to Follow-up|0
5991711|NCT03084536|9583697|FG002|Overall Study|Lost to Follow-up|1
5991712|NCT03084536|9583695|FG000|Overall Study|Protocol Violation|0
6066420|NCT00528372|9668652|FG007|Short-term (ST) Period (Day 1-Week 24)|Withdrawal by Subject|2
6066421|NCT00528372|9668653|FG008|Short-term (ST) Period (Day 1-Week 24)|Withdrawal by Subject|4
6066422|NCT00528372|9668645|FG000|Short-term (ST) Period (Day 1-Week 24)|Lost to Follow-up|5
6066423|NCT00528372|9668646|FG001|Short-term (ST) Period (Day 1-Week 24)|Lost to Follow-up|1
6066424|NCT00528372|9668647|FG002|Short-term (ST) Period (Day 1-Week 24)|Lost to Follow-up|2
6066425|NCT00528372|9668648|FG003|Short-term (ST) Period (Day 1-Week 24)|Lost to Follow-up|3
6066426|NCT00528372|9668649|FG004|Short-term (ST) Period (Day 1-Week 24)|Lost to Follow-up|3
6066427|NCT00528372|9668650|FG005|Short-term (ST) Period (Day 1-Week 24)|Lost to Follow-up|2
6066428|NCT00528372|9668651|FG006|Short-term (ST) Period (Day 1-Week 24)|Lost to Follow-up|2
6066429|NCT00528372|9668652|FG007|Short-term (ST) Period (Day 1-Week 24)|Lost to Follow-up|3
6066430|NCT00528372|9668653|FG008|Short-term (ST) Period (Day 1-Week 24)|Lost to Follow-up|1
6066431|NCT00528372|9668645|FG000|Short-term (ST) Period (Day 1-Week 24)|Poor or noncompliance|0
6066432|NCT00528372|9668646|FG001|Short-term (ST) Period (Day 1-Week 24)|Poor or noncompliance|0
6066433|NCT00528372|9668647|FG002|Short-term (ST) Period (Day 1-Week 24)|Poor or noncompliance|0
6066434|NCT00528372|9668648|FG003|Short-term (ST) Period (Day 1-Week 24)|Poor or noncompliance|2
6066435|NCT00528372|9668649|FG004|Short-term (ST) Period (Day 1-Week 24)|Poor or noncompliance|0
6066436|NCT00528372|9668650|FG005|Short-term (ST) Period (Day 1-Week 24)|Poor or noncompliance|1
6066437|NCT00528372|9668651|FG006|Short-term (ST) Period (Day 1-Week 24)|Poor or noncompliance|0
6066438|NCT00528372|9668652|FG007|Short-term (ST) Period (Day 1-Week 24)|Poor or noncompliance|0
6066439|NCT00528372|9668653|FG008|Short-term (ST) Period (Day 1-Week 24)|Poor or noncompliance|0
6066440|NCT00528372|9668645|FG000|Short-term (ST) Period (Day 1-Week 24)|Administration reason by sponsor|1
6066441|NCT00528372|9668646|FG001|Short-term (ST) Period (Day 1-Week 24)|Administration reason by sponsor|0
6066442|NCT00528372|9668647|FG002|Short-term (ST) Period (Day 1-Week 24)|Administration reason by sponsor|1
6066443|NCT00528372|9668648|FG003|Short-term (ST) Period (Day 1-Week 24)|Administration reason by sponsor|0
6066444|NCT00528372|9668649|FG004|Short-term (ST) Period (Day 1-Week 24)|Administration reason by sponsor|0
6066445|NCT00528372|9668650|FG005|Short-term (ST) Period (Day 1-Week 24)|Administration reason by sponsor|1
6066446|NCT00528372|9668651|FG006|Short-term (ST) Period (Day 1-Week 24)|Administration reason by sponsor|0
6066447|NCT00528372|9668652|FG007|Short-term (ST) Period (Day 1-Week 24)|Administration reason by sponsor|0
6066448|NCT00528372|9668653|FG008|Short-term (ST) Period (Day 1-Week 24)|Administration reason by sponsor|0
6066449|NCT00528372|9668645|FG000|Short-term (ST) Period (Day 1-Week 24)|Other|3
6066450|NCT00528372|9668646|FG001|Short-term (ST) Period (Day 1-Week 24)|Other|0
6066451|NCT00528372|9668647|FG002|Short-term (ST) Period (Day 1-Week 24)|Other|0
6066452|NCT00528372|9668648|FG003|Short-term (ST) Period (Day 1-Week 24)|Other|1
6066453|NCT00528372|9668649|FG004|Short-term (ST) Period (Day 1-Week 24)|Other|0
6066454|NCT00528372|9668650|FG005|Short-term (ST) Period (Day 1-Week 24)|Other|0
6066455|NCT00528372|9668651|FG006|Short-term (ST) Period (Day 1-Week 24)|Other|0
6066456|NCT00528372|9668652|FG007|Short-term (ST) Period (Day 1-Week 24)|Other|1
6066457|NCT00528372|9668653|FG008|Short-term (ST) Period (Day 1-Week 24)|Other|0
6066458|NCT00528372|9668645|FG000|Long-term (LT) Period (Weeks 24-102)|Lack of Efficacy|6
6066459|NCT00528372|9668646|FG001|Long-term (LT) Period (Weeks 24-102)|Lack of Efficacy|6
6066460|NCT00528372|9668647|FG002|Long-term (LT) Period (Weeks 24-102)|Lack of Efficacy|1
6066461|NCT00528372|9668648|FG003|Long-term (LT) Period (Weeks 24-102)|Lack of Efficacy|7
6066462|NCT00528372|9668649|FG004|Long-term (LT) Period (Weeks 24-102)|Lack of Efficacy|7
5991713|NCT03084536|9583696|FG001|Overall Study|Protocol Violation|0
5991714|NCT03084536|9583697|FG002|Overall Study|Protocol Violation|1
5991715|NCT03084536|9583695|FG000|Overall Study|Withdrawn due to time of surgery being moved up.|0
5991716|NCT03084536|9583696|FG001|Overall Study|Withdrawn due to time of surgery being moved up.|0
5991717|NCT03084536|9583697|FG002|Overall Study|Withdrawn due to time of surgery being moved up.|1
6045804|NCT00403767|9645108|FG000|Overall Study|Non-compliant with study medication|134
6045805|NCT00403767|9645109|FG001|Overall Study|Non-compliant with study medication|164
6045806|NCT00403767|9645108|FG000|Overall Study|Consent withdrawn|671
6066463|NCT00528372|9668650|FG005|Long-term (LT) Period (Weeks 24-102)|Lack of Efficacy|7
6066464|NCT00528372|9668651|FG006|Long-term (LT) Period (Weeks 24-102)|Lack of Efficacy|2
6066465|NCT00528372|9668652|FG007|Long-term (LT) Period (Weeks 24-102)|Lack of Efficacy|0
6066466|NCT00528372|9668653|FG008|Long-term (LT) Period (Weeks 24-102)|Lack of Efficacy|0
6066467|NCT00528372|9668645|FG000|Long-term (LT) Period (Weeks 24-102)|Adverse Event|3
6066468|NCT00528372|9668646|FG001|Long-term (LT) Period (Weeks 24-102)|Adverse Event|1
6066469|NCT00528372|9668647|FG002|Long-term (LT) Period (Weeks 24-102)|Adverse Event|1
6066470|NCT00528372|9668648|FG003|Long-term (LT) Period (Weeks 24-102)|Adverse Event|0
6066471|NCT00528372|9668649|FG004|Long-term (LT) Period (Weeks 24-102)|Adverse Event|2
6066472|NCT00528372|9668650|FG005|Long-term (LT) Period (Weeks 24-102)|Adverse Event|3
6066473|NCT00528372|9668651|FG006|Long-term (LT) Period (Weeks 24-102)|Adverse Event|4
6066474|NCT00528372|9668652|FG007|Long-term (LT) Period (Weeks 24-102)|Adverse Event|0
6066475|NCT00528372|9668653|FG008|Long-term (LT) Period (Weeks 24-102)|Adverse Event|0
6066476|NCT00528372|9668645|FG000|Long-term (LT) Period (Weeks 24-102)|Withdrawal by Subject|6
6066477|NCT00528372|9668646|FG001|Long-term (LT) Period (Weeks 24-102)|Withdrawal by Subject|6
6066478|NCT00528372|9668647|FG002|Long-term (LT) Period (Weeks 24-102)|Withdrawal by Subject|3
6066479|NCT00528372|9668648|FG003|Long-term (LT) Period (Weeks 24-102)|Withdrawal by Subject|3
6066480|NCT00528372|9668649|FG004|Long-term (LT) Period (Weeks 24-102)|Withdrawal by Subject|7
6066481|NCT00528372|9668650|FG005|Long-term (LT) Period (Weeks 24-102)|Withdrawal by Subject|0
6066482|NCT00528372|9668651|FG006|Long-term (LT) Period (Weeks 24-102)|Withdrawal by Subject|4
6066483|NCT00528372|9668652|FG007|Long-term (LT) Period (Weeks 24-102)|Withdrawal by Subject|2
6066484|NCT00528372|9668653|FG008|Long-term (LT) Period (Weeks 24-102)|Withdrawal by Subject|4
6066485|NCT00528372|9668645|FG000|Long-term (LT) Period (Weeks 24-102)|Lost to Follow-up|3
6066486|NCT00528372|9668646|FG001|Long-term (LT) Period (Weeks 24-102)|Lost to Follow-up|2
6066487|NCT00528372|9668647|FG002|Long-term (LT) Period (Weeks 24-102)|Lost to Follow-up|1
6066488|NCT00528372|9668648|FG003|Long-term (LT) Period (Weeks 24-102)|Lost to Follow-up|1
6066489|NCT00528372|9668649|FG004|Long-term (LT) Period (Weeks 24-102)|Lost to Follow-up|0
6066490|NCT00528372|9668650|FG005|Long-term (LT) Period (Weeks 24-102)|Lost to Follow-up|4
6066491|NCT00528372|9668651|FG006|Long-term (LT) Period (Weeks 24-102)|Lost to Follow-up|2
6066492|NCT00528372|9668652|FG007|Long-term (LT) Period (Weeks 24-102)|Lost to Follow-up|3
6066493|NCT00528372|9668653|FG008|Long-term (LT) Period (Weeks 24-102)|Lost to Follow-up|1
6066494|NCT00528372|9668645|FG000|Long-term (LT) Period (Weeks 24-102)|Poor compliance or noncompliance|0
6066495|NCT00528372|9668646|FG001|Long-term (LT) Period (Weeks 24-102)|Poor compliance or noncompliance|1
6066496|NCT00528372|9668647|FG002|Long-term (LT) Period (Weeks 24-102)|Poor compliance or noncompliance|1
6066497|NCT00528372|9668648|FG003|Long-term (LT) Period (Weeks 24-102)|Poor compliance or noncompliance|1
6066498|NCT00528372|9668649|FG004|Long-term (LT) Period (Weeks 24-102)|Poor compliance or noncompliance|0
6066499|NCT00528372|9668650|FG005|Long-term (LT) Period (Weeks 24-102)|Poor compliance or noncompliance|0
6045807|NCT00403767|9645109|FG001|Overall Study|Consent withdrawn|673
6045808|NCT00403767|9645108|FG000|Overall Study|Investigator dec./not protocol-related|191
6045809|NCT00403767|9645109|FG001|Overall Study|Investigator dec./not protocol-related|178
6045810|NCT00403767|9645108|FG000|Overall Study|Lost to Follow-up|6
5991718|NCT02988661|9583749|FG000|Overall Study|Death|2
5991719|NCT02988661|9583750|FG001|Overall Study|Death|18
5991720|NCT02988661|9583749|FG000|Overall Study|Lost to Follow-up|0
5991721|NCT02988661|9583750|FG001|Overall Study|Lost to Follow-up|33
5991722|NCT02988661|9583749|FG000|Overall Study|Withdrawal by Subject|0
5991723|NCT02988661|9583750|FG001|Overall Study|Withdrawal by Subject|6
5991724|NCT02988661|9583749|FG000|Overall Study|Unable to complete the 18-month survey|1
5991725|NCT02988661|9583750|FG001|Overall Study|Unable to complete the 18-month survey|27
5991726|NCT02951767|9583756|FG000|Overall Study|Ongoing at data cutoff 04 July 2016|54
5991727|NCT02951767|9583756|FG000|Overall Study|Withdrawal by Subject|5
5991728|NCT02951767|9583756|FG000|Overall Study|Death|59
5991729|NCT02951767|9583756|FG000|Overall Study|Lost to Follow-up|1
5991730|NCT02921776|9583766|FG000|Overall Study|patient deterioration, fatigue|2
5991731|NCT02921776|9583767|FG001|Overall Study|patient deterioration, fatigue|6
5991732|NCT02921776|9583768|FG002|Overall Study|patient deterioration, fatigue|0
5991733|NCT02921776|9583769|FG003|Overall Study|patient deterioration, fatigue|0
5991734|NCT02921776|9583770|FG004|Overall Study|patient deterioration, fatigue|0
5991735|NCT02921776|9583771|FG005|Overall Study|patient deterioration, fatigue|0
5991736|NCT02921776|9583772|FG006|Overall Study|patient deterioration, fatigue|0
5991737|NCT02921776|9583773|FG007|Overall Study|patient deterioration, fatigue|0
5991738|NCT02921776|9583766|FG000|Overall Study|Withdrawal by Subject|0
5991739|NCT02921776|9583767|FG001|Overall Study|Withdrawal by Subject|2
5991740|NCT02921776|9583768|FG002|Overall Study|Withdrawal by Subject|0
5991741|NCT02921776|9583769|FG003|Overall Study|Withdrawal by Subject|1
5991742|NCT02921776|9583770|FG004|Overall Study|Withdrawal by Subject|1
5991743|NCT02921776|9583771|FG005|Overall Study|Withdrawal by Subject|0
5991744|NCT02921776|9583772|FG006|Overall Study|Withdrawal by Subject|8
6309327|NCT02637557|10037873|FG003|Overall Study|Lost to Follow-up|1
6309328|NCT02637557|10037870|FG000|Overall Study|Physician Decision|1
6309329|NCT02637557|10037871|FG001|Overall Study|Physician Decision|0
6309330|NCT02637557|10037872|FG002|Overall Study|Physician Decision|0
6309331|NCT02637557|10037873|FG003|Overall Study|Physician Decision|0
5991745|NCT02921776|9583773|FG007|Overall Study|Withdrawal by Subject|1
5991746|NCT02921776|9583766|FG000|Overall Study|Death|0
5991747|NCT02921776|9583767|FG001|Overall Study|Death|0
5991748|NCT02921776|9583768|FG002|Overall Study|Death|0
5991749|NCT02921776|9583769|FG003|Overall Study|Death|2
5991750|NCT02921776|9583770|FG004|Overall Study|Death|0
5991751|NCT02921776|9583771|FG005|Overall Study|Death|0
5991752|NCT02921776|9583772|FG006|Overall Study|Death|0
5991753|NCT02921776|9583773|FG007|Overall Study|Death|0
5991754|NCT02921776|9583766|FG000|Overall Study|extubation or early discharge|0
5991755|NCT02921776|9583767|FG001|Overall Study|extubation or early discharge|0
5991756|NCT02921776|9583768|FG002|Overall Study|extubation or early discharge|0
5991757|NCT02921776|9583769|FG003|Overall Study|extubation or early discharge|5
5991758|NCT02921776|9583770|FG004|Overall Study|extubation or early discharge|5
5991759|NCT02921776|9583771|FG005|Overall Study|extubation or early discharge|0
5991760|NCT02921776|9583772|FG006|Overall Study|extubation or early discharge|0
5991761|NCT02921776|9583773|FG007|Overall Study|extubation or early discharge|0
5991762|NCT02921776|9583766|FG000|Overall Study|Lost to Follow-up|0
5991763|NCT02921776|9583767|FG001|Overall Study|Lost to Follow-up|0
5991764|NCT02921776|9583768|FG002|Overall Study|Lost to Follow-up|0
5991765|NCT02921776|9583769|FG003|Overall Study|Lost to Follow-up|0
5991766|NCT02921776|9583770|FG004|Overall Study|Lost to Follow-up|0
5991767|NCT02921776|9583771|FG005|Overall Study|Lost to Follow-up|2
5991768|NCT02921776|9583772|FG006|Overall Study|Lost to Follow-up|3
5991769|NCT02921776|9583773|FG007|Overall Study|Lost to Follow-up|6
5991770|NCT02898259|9583802|FG000|Overall Study|Adverse Event|0
5991771|NCT02898259|9583803|FG001|Overall Study|Adverse Event|0
5991772|NCT02898259|9583804|FG002|Overall Study|Adverse Event|1
5991773|NCT02898259|9583805|FG003|Overall Study|Adverse Event|0
5991774|NCT02898259|9583806|FG004|Overall Study|Adverse Event|0
5991775|NCT02898259|9583802|FG000|Overall Study|Lack of Efficacy|1
5991776|NCT02898259|9583803|FG001|Overall Study|Lack of Efficacy|1
5991777|NCT02898259|9583804|FG002|Overall Study|Lack of Efficacy|3
5991778|NCT02898259|9583805|FG003|Overall Study|Lack of Efficacy|0
5991779|NCT02898259|9583806|FG004|Overall Study|Lack of Efficacy|0
5991780|NCT02898259|9583802|FG000|Overall Study|Lost to Follow-up|0
5991781|NCT02898259|9583803|FG001|Overall Study|Lost to Follow-up|0
5991782|NCT02898259|9583804|FG002|Overall Study|Lost to Follow-up|1
5991783|NCT02898259|9583805|FG003|Overall Study|Lost to Follow-up|0
5991784|NCT02898259|9583806|FG004|Overall Study|Lost to Follow-up|0
5991785|NCT02898259|9583802|FG000|Overall Study|Transformation before study began|0
5991786|NCT02898259|9583803|FG001|Overall Study|Transformation before study began|0
5991787|NCT02898259|9583804|FG002|Overall Study|Transformation before study began|0
5991788|NCT02898259|9583805|FG003|Overall Study|Transformation before study began|1
5991789|NCT02898259|9583806|FG004|Overall Study|Transformation before study began|0
6309332|NCT02637557|10037870|FG000|Overall Study|Protocol Violation|2
5991790|NCT02870348|9583819|FG000|Overall Study|Participants were discontinued and assessed for entry into post-marketing study (GTI1401-EXP)|4
5991791|NCT02841280|9583825|FG000|Overall Study|Adverse Event|2
5991792|NCT02841280|9583826|FG001|Overall Study|Adverse Event|1
5991793|NCT02841280|9583825|FG000|Overall Study|Death|1
5991794|NCT02841280|9583826|FG001|Overall Study|Death|0
6066500|NCT00528372|9668651|FG006|Long-term (LT) Period (Weeks 24-102)|Poor compliance or noncompliance|1
6066501|NCT00528372|9668652|FG007|Long-term (LT) Period (Weeks 24-102)|Poor compliance or noncompliance|0
6066502|NCT00528372|9668653|FG008|Long-term (LT) Period (Weeks 24-102)|Poor compliance or noncompliance|0
6066503|NCT00528372|9668645|FG000|Long-term (LT) Period (Weeks 24-102)|No longer met study criteria|0
6066504|NCT00528372|9668646|FG001|Long-term (LT) Period (Weeks 24-102)|No longer met study criteria|0
6066505|NCT00528372|9668647|FG002|Long-term (LT) Period (Weeks 24-102)|No longer met study criteria|0
6066506|NCT00528372|9668648|FG003|Long-term (LT) Period (Weeks 24-102)|No longer met study criteria|0
6066507|NCT00528372|9668649|FG004|Long-term (LT) Period (Weeks 24-102)|No longer met study criteria|2
6066508|NCT00528372|9668650|FG005|Long-term (LT) Period (Weeks 24-102)|No longer met study criteria|1
6066509|NCT00528372|9668651|FG006|Long-term (LT) Period (Weeks 24-102)|No longer met study criteria|0
6066510|NCT00528372|9668652|FG007|Long-term (LT) Period (Weeks 24-102)|No longer met study criteria|0
6066511|NCT00528372|9668653|FG008|Long-term (LT) Period (Weeks 24-102)|No longer met study criteria|0
6066512|NCT00528372|9668645|FG000|Long-term (LT) Period (Weeks 24-102)|Administrative reason by sponsor|0
6066513|NCT00528372|9668646|FG001|Long-term (LT) Period (Weeks 24-102)|Administrative reason by sponsor|1
6066514|NCT00528372|9668647|FG002|Long-term (LT) Period (Weeks 24-102)|Administrative reason by sponsor|0
6066515|NCT00528372|9668648|FG003|Long-term (LT) Period (Weeks 24-102)|Administrative reason by sponsor|0
6066516|NCT00528372|9668649|FG004|Long-term (LT) Period (Weeks 24-102)|Administrative reason by sponsor|0
6066517|NCT00528372|9668650|FG005|Long-term (LT) Period (Weeks 24-102)|Administrative reason by sponsor|0
6066518|NCT00528372|9668651|FG006|Long-term (LT) Period (Weeks 24-102)|Administrative reason by sponsor|1
6066519|NCT00528372|9668652|FG007|Long-term (LT) Period (Weeks 24-102)|Administrative reason by sponsor|0
5991795|NCT02841280|9583825|FG000|Overall Study|Lost to Follow-up|2
5991796|NCT02841280|9583826|FG001|Overall Study|Lost to Follow-up|2
6066520|NCT00528372|9668653|FG008|Long-term (LT) Period (Weeks 24-102)|Administrative reason by sponsor|1
6066521|NCT00528372|9668645|FG000|Long-term (LT) Period (Weeks 24-102)|Other|2
6066522|NCT00528372|9668646|FG001|Long-term (LT) Period (Weeks 24-102)|Other|2
6066523|NCT00528372|9668647|FG002|Long-term (LT) Period (Weeks 24-102)|Other|1
6066524|NCT00528372|9668648|FG003|Long-term (LT) Period (Weeks 24-102)|Other|2
6087136|NCT00666718|9697318|FG001|Overall Study|Physician Decision|2
5991797|NCT02841280|9583825|FG000|Overall Study|Withdrawal by Subject|7
5991798|NCT02841280|9583826|FG001|Overall Study|Withdrawal by Subject|3
5991799|NCT02841280|9583825|FG000|Overall Study|Stop Point: BP above threshold|2
5991800|NCT02841280|9583826|FG001|Overall Study|Stop Point: BP above threshold|0
5991801|NCT02771275|9583849|FG000|Overall Study|Reoperation|2
5991802|NCT02771275|9583849|FG000|Overall Study|On Study|11
5991803|NCT02675426|9583856|FG000|Overall Study|Adverse Event|6
5991804|NCT02675426|9583857|FG001|Overall Study|Adverse Event|2
5991805|NCT02675426|9583858|FG002|Overall Study|Adverse Event|9
5991806|NCT02675426|9583856|FG000|Overall Study|Withdrawal by Subject|3
5991807|NCT02675426|9583857|FG001|Overall Study|Withdrawal by Subject|5
5991808|NCT02675426|9583858|FG002|Overall Study|Withdrawal by Subject|5
5991809|NCT02675426|9583856|FG000|Overall Study|Lost to Follow-up|1
5991810|NCT02675426|9583857|FG001|Overall Study|Lost to Follow-up|0
5991811|NCT02675426|9583858|FG002|Overall Study|Lost to Follow-up|2
5991812|NCT02675426|9583856|FG000|Overall Study|Other|3
5991813|NCT02675426|9583857|FG001|Overall Study|Other|1
5991814|NCT02675426|9583858|FG002|Overall Study|Other|2
5991815|NCT02639546|9583874|FG000|Overall Study|Death|2
5991816|NCT02639546|9583875|FG001|Overall Study|Death|2
5991817|NCT02639546|9583876|FG002|Overall Study|Death|1
5991818|NCT02639546|9583877|FG003|Overall Study|Death|2
5991819|NCT02639546|9583878|FG004|Overall Study|Death|2
5991820|NCT02639546|9583879|FG005|Overall Study|Death|2
5991821|NCT02639546|9583880|FG006|Overall Study|Death|0
5991822|NCT02639546|9583881|FG007|Overall Study|Death|0
5991823|NCT02639546|9583874|FG000|Overall Study|Lost to Follow-up|0
5991824|NCT02639546|9583875|FG001|Overall Study|Lost to Follow-up|0
5991825|NCT02639546|9583876|FG002|Overall Study|Lost to Follow-up|1
5991826|NCT02639546|9583877|FG003|Overall Study|Lost to Follow-up|0
5991827|NCT02639546|9583878|FG004|Overall Study|Lost to Follow-up|1
5991828|NCT02639546|9583879|FG005|Overall Study|Lost to Follow-up|1
5991829|NCT02639546|9583880|FG006|Overall Study|Lost to Follow-up|0
5991830|NCT02639546|9583881|FG007|Overall Study|Lost to Follow-up|1
5991831|NCT02639546|9583874|FG000|Overall Study|PI, physician decision; no response to trt.|2
5991832|NCT02639546|9583875|FG001|Overall Study|PI, physician decision; no response to trt.|0
5991833|NCT02639546|9583876|FG002|Overall Study|PI, physician decision; no response to trt.|0
6066525|NCT00528372|9668649|FG004|Long-term (LT) Period (Weeks 24-102)|Other|3
6066526|NCT00528372|9668650|FG005|Long-term (LT) Period (Weeks 24-102)|Other|0
6066527|NCT00528372|9668651|FG006|Long-term (LT) Period (Weeks 24-102)|Other|3
6066528|NCT00528372|9668652|FG007|Long-term (LT) Period (Weeks 24-102)|Other|1
6066529|NCT00528372|9668653|FG008|Long-term (LT) Period (Weeks 24-102)|Other|0
6066530|NCT00528411|9668706|FG000|Overall Study|Adverse Event|4
6066531|NCT00528411|9668707|FG001|Overall Study|Adverse Event|0
6066532|NCT00528411|9668708|FG002|Overall Study|Adverse Event|1
6066533|NCT00528411|9668706|FG000|Overall Study|Incorrect Enrolment|1
6066534|NCT00528411|9668707|FG001|Overall Study|Incorrect Enrolment|1
6066535|NCT00528411|9668708|FG002|Overall Study|Incorrect Enrolment|0
6066536|NCT00528411|9668706|FG000|Overall Study|Severe non-compliance to protocol|0
6066537|NCT00528411|9668707|FG001|Overall Study|Severe non-compliance to protocol|1
6066538|NCT00528411|9668708|FG002|Overall Study|Severe non-compliance to protocol|0
6066539|NCT00528411|9668706|FG000|Overall Study|Prior commitment medication|0
6066540|NCT00528411|9668707|FG001|Overall Study|Prior commitment medication|1
6066541|NCT00528411|9668708|FG002|Overall Study|Prior commitment medication|0
6066542|NCT00528424|9668716|FG000|Overall Study|Lost to Follow-up|13
6066543|NCT00528424|9668716|FG000|Overall Study|Withdrew consent|2
6066544|NCT00528424|9668716|FG000|Overall Study|Administrative reason|2
6066545|NCT00528424|9668716|FG000|Overall Study|Other|12
6066546|NCT00528528|9668728|FG000|Overall Study|Lost to Follow-up|0
6066547|NCT00528528|9668729|FG001|Overall Study|Lost to Follow-up|0
6066548|NCT00528528|9668730|FG002|Overall Study|Lost to Follow-up|1
6066549|NCT00528528|9668731|FG003|Overall Study|Lost to Follow-up|1
6066550|NCT00528528|9668728|FG000|Overall Study|Ineligible to continue the trial|0
6066551|NCT00528528|9668729|FG001|Overall Study|Ineligible to continue the trial|0
6066552|NCT00528528|9668730|FG002|Overall Study|Ineligible to continue the trial|0
6146171|NCT01075763|9780784|FG000|Overall Study|Lost to Follow-up|2
6146172|NCT01075763|9780785|FG001|Overall Study|Lost to Follow-up|1
6146173|NCT01075763|9780784|FG000|Overall Study|Lack of Efficacy|0
6146174|NCT01075763|9780785|FG001|Overall Study|Lack of Efficacy|1
6146175|NCT01075763|9780784|FG000|Overall Study|Withdrawal by Subject|2
6146176|NCT01075763|9780785|FG001|Overall Study|Withdrawal by Subject|2
5991834|NCT02639546|9583877|FG003|Overall Study|PI, physician decision; no response to trt.|0
5991835|NCT02639546|9583878|FG004|Overall Study|PI, physician decision; no response to trt.|0
5991836|NCT02639546|9583879|FG005|Overall Study|PI, physician decision; no response to trt.|1
5991837|NCT02639546|9583880|FG006|Overall Study|PI, physician decision; no response to trt.|0
5991838|NCT02639546|9583881|FG007|Overall Study|PI, physician decision; no response to trt.|1
5991839|NCT02639546|9583874|FG000|Overall Study|Study Terminated By Sponsor|0
5991840|NCT02639546|9583875|FG001|Overall Study|Study Terminated By Sponsor|2
5991841|NCT02639546|9583876|FG002|Overall Study|Study Terminated By Sponsor|3
5991842|NCT02639546|9583877|FG003|Overall Study|Study Terminated By Sponsor|4
5991843|NCT02639546|9583878|FG004|Overall Study|Study Terminated By Sponsor|4
5991844|NCT02639546|9583879|FG005|Overall Study|Study Terminated By Sponsor|3
5991845|NCT02639546|9583880|FG006|Overall Study|Study Terminated By Sponsor|3
5991846|NCT02639546|9583881|FG007|Overall Study|Study Terminated By Sponsor|9
5991847|NCT02639546|9583874|FG000|Overall Study|Withdrawal by Subject|2
5991848|NCT02639546|9583875|FG001|Overall Study|Withdrawal by Subject|2
5991849|NCT02639546|9583876|FG002|Overall Study|Withdrawal by Subject|1
5991850|NCT02639546|9583877|FG003|Overall Study|Withdrawal by Subject|0
5991851|NCT02639546|9583878|FG004|Overall Study|Withdrawal by Subject|0
5991852|NCT02639546|9583879|FG005|Overall Study|Withdrawal by Subject|1
5991853|NCT02639546|9583880|FG006|Overall Study|Withdrawal by Subject|2
5991854|NCT02639546|9583881|FG007|Overall Study|Withdrawal by Subject|1
5991855|NCT02575339|9583916|FG000|Study Treatment|Patient Withdrawal After Therapy Start|1
5991856|NCT02575339|9583917|FG001|Study Treatment|Patient Withdrawal After Therapy Start|0
5991857|NCT02575339|9583918|FG002|Study Treatment|Patient Withdrawal After Therapy Start|0
5991858|NCT02575339|9583916|FG000|Study Treatment|Disease Progression|5
5991859|NCT02575339|9583917|FG001|Study Treatment|Disease Progression|2
5991860|NCT02575339|9583918|FG002|Study Treatment|Disease Progression|0
5991861|NCT02575339|9583916|FG000|Study Treatment|Adverse Event|1
5991862|NCT02575339|9583917|FG001|Study Treatment|Adverse Event|2
5991863|NCT02575339|9583918|FG002|Study Treatment|Adverse Event|0
5991864|NCT02575339|9583916|FG000|Follow up|Death|6
5991865|NCT02575339|9583917|FG001|Follow up|Death|2
5991866|NCT02575339|9583918|FG002|Follow up|Death|0
5991867|NCT02575339|9583916|FG000|Follow up|Study Terminated|0
5991868|NCT02575339|9583917|FG001|Follow up|Study Terminated|2
5991869|NCT02575339|9583918|FG002|Follow up|Study Terminated|0
5991870|NCT02575339|9583916|FG000|Follow up|Death due to progressive disease after coming off treatment early|1
5991871|NCT02575339|9583917|FG001|Follow up|Death due to progressive disease after coming off treatment early|0
6045811|NCT00403767|9645109|FG001|Overall Study|Lost to Follow-up|8
6146177|NCT01075815|9780793|FG000|Overall Study|Withdrawal before r-hCG administration|6
6146178|NCT01075815|9780794|FG001|Overall Study|Withdrawal before r-hCG administration|1
6146179|NCT01075815|9780793|FG000|Overall Study|Withdrawal between rhCG-ovum pickup(OPU)|1
6146180|NCT01075815|9780794|FG001|Overall Study|Withdrawal between rhCG-ovum pickup(OPU)|1
6066553|NCT00528528|9668731|FG003|Overall Study|Ineligible to continue the trial|1
6066554|NCT00528528|9668728|FG000|Overall Study|Other|0
6066555|NCT00528528|9668729|FG001|Overall Study|Other|1
6066556|NCT00528528|9668730|FG002|Overall Study|Other|0
6066557|NCT00528528|9668731|FG003|Overall Study|Other|0
6066558|NCT00528528|9668728|FG000|Overall Study|Withdrawal by Subject|3
6066559|NCT00528528|9668729|FG001|Overall Study|Withdrawal by Subject|2
6066560|NCT00528528|9668730|FG002|Overall Study|Withdrawal by Subject|1
6066561|NCT00528528|9668731|FG003|Overall Study|Withdrawal by Subject|1
6066562|NCT00528528|9668728|FG000|Overall Study|Ongoing participant|0
6066563|NCT00528528|9668729|FG001|Overall Study|Ongoing participant|0
6066564|NCT00528528|9668730|FG002|Overall Study|Ongoing participant|1
6066565|NCT00528528|9668731|FG003|Overall Study|Ongoing participant|0
6066566|NCT00528567|9668754|FG000|Overall Study|Death|4
6066567|NCT00528567|9668755|FG001|Overall Study|Death|5
6066568|NCT00528567|9668754|FG000|Overall Study|Breast Cancer Recurrence/2nd Primary|30
6066569|NCT00528567|9668755|FG001|Overall Study|Breast Cancer Recurrence/2nd Primary|60
6066570|NCT00528567|9668754|FG000|Overall Study|Adverse Event/Intermittent Illness|255
6066571|NCT00528567|9668755|FG001|Overall Study|Adverse Event/Intermittent Illness|29
6066572|NCT00528567|9668754|FG000|Overall Study|Violation Criteria at Entry|3
6066573|NCT00528567|9668755|FG001|Overall Study|Violation Criteria at Entry|17
6066574|NCT00528567|9668754|FG000|Overall Study|Withdrew Consent|59
6066575|NCT00528567|9668755|FG001|Overall Study|Withdrew Consent|55
6066576|NCT00528567|9668754|FG000|Overall Study|Refused Treatment/Did Not Cooperate|52
6066577|NCT00528567|9668755|FG001|Overall Study|Refused Treatment/Did Not Cooperate|42
6066578|NCT00528567|9668754|FG000|Overall Study|Failure to Return|1
6066579|NCT00528567|9668755|FG001|Overall Study|Failure to Return|4
6066580|NCT00528567|9668754|FG000|Overall Study|Other Protocol Violation|5
6066581|NCT00528567|9668755|FG001|Overall Study|Other Protocol Violation|21
6066582|NCT00528567|9668754|FG000|Overall Study|Administrative/Other|22
6066583|NCT00528567|9668755|FG001|Overall Study|Administrative/Other|75
6066584|NCT00528606|9668779|FG000|Overall Study|Withdrew consent|4
6066585|NCT00528606|9668780|FG001|Overall Study|Withdrew consent|3
6066586|NCT00528606|9668779|FG000|Overall Study|Lost to Follow-up|4
6066587|NCT00528606|9668780|FG001|Overall Study|Lost to Follow-up|1
6066588|NCT00528606|9668779|FG000|Overall Study|Adverse Event|3
6066589|NCT00528606|9668780|FG001|Overall Study|Adverse Event|0
6066590|NCT00528606|9668779|FG000|Overall Study|Other|2
6066591|NCT00528606|9668780|FG001|Overall Study|Other|0
6066592|NCT00528645|9668786|FG000|Overall Study|Adverse Event|3
6066593|NCT00528801|9668797|FG000|Overall Study|Withdrawal by Subject|1
6066594|NCT00528801|9668798|FG001|Overall Study|Withdrawal by Subject|1
6066595|NCT00528801|9668797|FG000|Overall Study|Protocol Violation|11
6066596|NCT00528801|9668798|FG001|Overall Study|Protocol Violation|5
6066597|NCT00528801|9668797|FG000|Overall Study|Lost to Follow-up|15
6066598|NCT00528801|9668798|FG001|Overall Study|Lost to Follow-up|4
6066599|NCT00528801|9668797|FG000|Overall Study|Administrative Reasons|0
6066600|NCT00528801|9668798|FG001|Overall Study|Administrative Reasons|1
6066601|NCT00528840|9668804|FG000|Overall Study|Lost to Follow-up|10
6066602|NCT00528840|9668804|FG000|Overall Study|Adverse Event|1
6066603|NCT00528840|9668804|FG000|Overall Study|Withdrawal by Subject|17
6066604|NCT00528840|9668804|FG000|Overall Study|Death|2
6066605|NCT00528840|9668804|FG000|Overall Study|Administrative Reasons|1
6066606|NCT00528840|9668804|FG000|Overall Study|Other|2
6066607|NCT00528866|9668808|FG000|Overall Study|Protocol Violation|6
6066608|NCT00528879|9668817|FG000|Short-term Period (Day 1 to Week 24)|Lack of Efficacy|3
6066609|NCT00528879|9668818|FG001|Short-term Period (Day 1 to Week 24)|Lack of Efficacy|0
6066610|NCT00528879|9668819|FG002|Short-term Period (Day 1 to Week 24)|Lack of Efficacy|1
6066611|NCT00528879|9668820|FG003|Short-term Period (Day 1 to Week 24)|Lack of Efficacy|0
6066612|NCT00528879|9668817|FG000|Short-term Period (Day 1 to Week 24)|Adverse Event|4
6066613|NCT00528879|9668818|FG001|Short-term Period (Day 1 to Week 24)|Adverse Event|4
6066614|NCT00528879|9668819|FG002|Short-term Period (Day 1 to Week 24)|Adverse Event|2
6066615|NCT00528879|9668820|FG003|Short-term Period (Day 1 to Week 24)|Adverse Event|4
6066616|NCT00528879|9668817|FG000|Short-term Period (Day 1 to Week 24)|Withdrawal by Subject|7
6066617|NCT00528879|9668818|FG001|Short-term Period (Day 1 to Week 24)|Withdrawal by Subject|5
6066618|NCT00528879|9668819|FG002|Short-term Period (Day 1 to Week 24)|Withdrawal by Subject|5
6066619|NCT00528879|9668820|FG003|Short-term Period (Day 1 to Week 24)|Withdrawal by Subject|3
6066620|NCT00528879|9668817|FG000|Short-term Period (Day 1 to Week 24)|Lost to Follow-up|5
6066621|NCT00528879|9668818|FG001|Short-term Period (Day 1 to Week 24)|Lost to Follow-up|4
6066622|NCT00528879|9668819|FG002|Short-term Period (Day 1 to Week 24)|Lost to Follow-up|4
6066623|NCT00528879|9668820|FG003|Short-term Period (Day 1 to Week 24)|Lost to Follow-up|5
6066624|NCT00528879|9668817|FG000|Short-term Period (Day 1 to Week 24)|Poor compliance/noncompliance|0
6066625|NCT00528879|9668818|FG001|Short-term Period (Day 1 to Week 24)|Poor compliance/noncompliance|0
5991872|NCT02575339|9583918|FG002|Follow up|Death due to progressive disease after coming off treatment early|0
6066626|NCT00528879|9668819|FG002|Short-term Period (Day 1 to Week 24)|Poor compliance/noncompliance|2
6066627|NCT00528879|9668820|FG003|Short-term Period (Day 1 to Week 24)|Poor compliance/noncompliance|0
6066628|NCT00528879|9668817|FG000|Short-term Period (Day 1 to Week 24)|No longer meets study criteria|2
6066629|NCT00528879|9668818|FG001|Short-term Period (Day 1 to Week 24)|No longer meets study criteria|3
6066630|NCT00528879|9668819|FG002|Short-term Period (Day 1 to Week 24)|No longer meets study criteria|0
6066631|NCT00528879|9668820|FG003|Short-term Period (Day 1 to Week 24)|No longer meets study criteria|2
6066632|NCT00528879|9668817|FG000|Short-term Period (Day 1 to Week 24)|Administrative reason by author|1
6066633|NCT00528879|9668818|FG001|Short-term Period (Day 1 to Week 24)|Administrative reason by author|1
6066634|NCT00528879|9668819|FG002|Short-term Period (Day 1 to Week 24)|Administrative reason by author|0
6066635|NCT00528879|9668820|FG003|Short-term Period (Day 1 to Week 24)|Administrative reason by author|1
6066636|NCT00528879|9668817|FG000|Short-term Period (Day 1 to Week 24)|Other|0
6066637|NCT00528879|9668818|FG001|Short-term Period (Day 1 to Week 24)|Other|0
6066638|NCT00528879|9668819|FG002|Short-term Period (Day 1 to Week 24)|Other|1
6066639|NCT00528879|9668820|FG003|Short-term Period (Day 1 to Week 24)|Other|1
6066640|NCT00528879|9668817|FG000|Long-term Period (Weeks 24 to 102)|Lack of Efficacy|27
6066641|NCT00528879|9668818|FG001|Long-term Period (Weeks 24 to 102)|Lack of Efficacy|16
6066642|NCT00528879|9668819|FG002|Long-term Period (Weeks 24 to 102)|Lack of Efficacy|17
6066643|NCT00528879|9668820|FG003|Long-term Period (Weeks 24 to 102)|Lack of Efficacy|9
6066644|NCT00528879|9668817|FG000|Long-term Period (Weeks 24 to 102)|Adverse Event|5
6066645|NCT00528879|9668818|FG001|Long-term Period (Weeks 24 to 102)|Adverse Event|4
6066646|NCT00528879|9668819|FG002|Long-term Period (Weeks 24 to 102)|Adverse Event|3
6066647|NCT00528879|9668820|FG003|Long-term Period (Weeks 24 to 102)|Adverse Event|2
6066648|NCT00528879|9668817|FG000|Long-term Period (Weeks 24 to 102)|Withdrawal by Subject|4
6066649|NCT00528879|9668818|FG001|Long-term Period (Weeks 24 to 102)|Withdrawal by Subject|6
6066650|NCT00528879|9668819|FG002|Long-term Period (Weeks 24 to 102)|Withdrawal by Subject|8
6066651|NCT00528879|9668820|FG003|Long-term Period (Weeks 24 to 102)|Withdrawal by Subject|4
6066652|NCT00528879|9668817|FG000|Long-term Period (Weeks 24 to 102)|Death|0
6066653|NCT00528879|9668818|FG001|Long-term Period (Weeks 24 to 102)|Death|1
6066654|NCT00528879|9668819|FG002|Long-term Period (Weeks 24 to 102)|Death|0
6066655|NCT00528879|9668820|FG003|Long-term Period (Weeks 24 to 102)|Death|0
6066656|NCT00528879|9668817|FG000|Long-term Period (Weeks 24 to 102)|Lost to Follow-up|4
6066657|NCT00528879|9668818|FG001|Long-term Period (Weeks 24 to 102)|Lost to Follow-up|5
6066658|NCT00528879|9668819|FG002|Long-term Period (Weeks 24 to 102)|Lost to Follow-up|3
6066659|NCT00528879|9668820|FG003|Long-term Period (Weeks 24 to 102)|Lost to Follow-up|7
6066660|NCT00528879|9668817|FG000|Long-term Period (Weeks 24 to 102)|Poor compliance/noncompliance|0
6066661|NCT00528879|9668818|FG001|Long-term Period (Weeks 24 to 102)|Poor compliance/noncompliance|5
6066662|NCT00528879|9668819|FG002|Long-term Period (Weeks 24 to 102)|Poor compliance/noncompliance|1
6066663|NCT00528879|9668820|FG003|Long-term Period (Weeks 24 to 102)|Poor compliance/noncompliance|2
6066664|NCT00528879|9668817|FG000|Long-term Period (Weeks 24 to 102)|Pregnancy|1
6066665|NCT00528879|9668818|FG001|Long-term Period (Weeks 24 to 102)|Pregnancy|0
6066666|NCT00528879|9668819|FG002|Long-term Period (Weeks 24 to 102)|Pregnancy|0
6066667|NCT00528879|9668820|FG003|Long-term Period (Weeks 24 to 102)|Pregnancy|0
6066668|NCT00528879|9668817|FG000|Long-term Period (Weeks 24 to 102)|No longer meets study criteria|1
6066669|NCT00528879|9668818|FG001|Long-term Period (Weeks 24 to 102)|No longer meets study criteria|1
6066670|NCT00528879|9668819|FG002|Long-term Period (Weeks 24 to 102)|No longer meets study criteria|1
6066671|NCT00528879|9668820|FG003|Long-term Period (Weeks 24 to 102)|No longer meets study criteria|0
6066672|NCT00528931|9668830|FG000|Overall Study|Lost to Follow-up|1
6066673|NCT00528957|9668837|FG000|Randomized Phase (Baseline to Week 48)|Withdrew Consent|2
6066674|NCT00528957|9668838|FG001|Randomized Phase (Baseline to Week 48)|Withdrew Consent|1
6066675|NCT00528957|9668837|FG000|Randomized Phase (Baseline to Week 48)|Safety, Tolerability, or Efficacy Reason|2
6066676|NCT00528957|9668838|FG001|Randomized Phase (Baseline to Week 48)|Safety, Tolerability, or Efficacy Reason|0
6066677|NCT00528957|9668837|FG000|First Extension (Week 48 to Week 144)|Investigator's Discretion|2
6066678|NCT00528957|9668838|FG001|First Extension (Week 48 to Week 144)|Investigator's Discretion|0
6066679|NCT00528957|9668837|FG000|First Extension (Week 48 to Week 144)|Safety, Tolerability, or Efficacy Reason|1
6066680|NCT00528957|9668838|FG001|First Extension (Week 48 to Week 144)|Safety, Tolerability, or Efficacy Reason|0
6066681|NCT00528957|9668837|FG000|First Extension (Week 48 to Week 144)|Withdrew Consent|0
6066682|NCT00528957|9668838|FG001|First Extension (Week 48 to Week 144)|Withdrew Consent|1
6066683|NCT00528957|9668837|FG000|Second Extension (Week 144 to Week 240)|Safety, Tolerability, or Efficacy Reason|4
6066684|NCT00528957|9668838|FG001|Second Extension (Week 144 to Week 240)|Safety, Tolerability, or Efficacy Reason|3
6066685|NCT00528957|9668837|FG000|Second Extension (Week 144 to Week 240)|Investigator's Discretion|3
6066686|NCT00528957|9668838|FG001|Second Extension (Week 144 to Week 240)|Investigator's Discretion|0
6066687|NCT00528957|9668837|FG000|Third Extension (Week 240 to Week 336)|Safety, Tolerability, or Efficacy Reason|5
6066688|NCT00528957|9668838|FG001|Third Extension (Week 240 to Week 336)|Safety, Tolerability, or Efficacy Reason|4
6066689|NCT00528957|9668837|FG000|Third Extension (Week 240 to Week 336)|Lost to Follow-up|0
6066690|NCT00528957|9668838|FG001|Third Extension (Week 240 to Week 336)|Lost to Follow-up|3
6066691|NCT00528957|9668837|FG000|Third Extension (Week 240 to Week 336)|= 18 yr old & TDF approved in adults|1
6066692|NCT00528957|9668838|FG001|Third Extension (Week 240 to Week 336)|= 18 yr old & TDF approved in adults|1
6066693|NCT00528957|9668837|FG000|Third Extension (Week 240 to Week 336)|Investigator's Discretion|0
6066694|NCT00528957|9668838|FG001|Third Extension (Week 240 to Week 336)|Investigator's Discretion|1
6066695|NCT00528957|9668837|FG000|Third Extension (Week 240 to Week 336)|Withdrew Consent|0
6066696|NCT00528957|9668838|FG001|Third Extension (Week 240 to Week 336)|Withdrew Consent|1
6066697|NCT00528957|9668837|FG000|Long-Term Extension (Week 336 and On)|Rolled Over to Study GS-US-311-1269|4
6066698|NCT00528957|9668838|FG001|Long-Term Extension (Week 336 and On)|Rolled Over to Study GS-US-311-1269|10
6066699|NCT00528957|9668837|FG000|Long-Term Extension (Week 336 and On)|Safety, Tolerability, or Efficacy Reason|3
6066700|NCT00528957|9668838|FG001|Long-Term Extension (Week 336 and On)|Safety, Tolerability, or Efficacy Reason|5
6066701|NCT00528957|9668837|FG000|Long-Term Extension (Week 336 and On)|Withdrew Consent|2
6066702|NCT00528957|9668838|FG001|Long-Term Extension (Week 336 and On)|Withdrew Consent|1
6066703|NCT00528957|9668837|FG000|Long-Term Extension (Week 336 and On)|Investigator's Discretion|1
6066704|NCT00528957|9668838|FG001|Long-Term Extension (Week 336 and On)|Investigator's Discretion|1
6066705|NCT00528970|9668857|FG000|Overall Study|Adverse Event|6
6066706|NCT00528970|9668858|FG001|Overall Study|Adverse Event|8
6066707|NCT00528970|9668859|FG002|Overall Study|Adverse Event|5
6066708|NCT00528970|9668857|FG000|Overall Study|Lost to Follow-up|0
6066709|NCT00528970|9668858|FG001|Overall Study|Lost to Follow-up|0
6066710|NCT00528970|9668859|FG002|Overall Study|Lost to Follow-up|1
6066711|NCT00528970|9668857|FG000|Overall Study|Other than specified|2
6066712|NCT00528970|9668858|FG001|Overall Study|Other than specified|3
6066713|NCT00528970|9668859|FG002|Overall Study|Other than specified|3
6066714|NCT00528970|9668857|FG000|Overall Study|Protocol Violation|2
6066715|NCT00528970|9668858|FG001|Overall Study|Protocol Violation|1
6066716|NCT00528970|9668859|FG002|Overall Study|Protocol Violation|4
6066717|NCT00528970|9668857|FG000|Overall Study|Lack of Efficacy|0
6066718|NCT00528970|9668858|FG001|Overall Study|Lack of Efficacy|0
6066719|NCT00528970|9668859|FG002|Overall Study|Lack of Efficacy|1
6066720|NCT00528970|9668857|FG000|Overall Study|Withdrawal by Subject|4
6066721|NCT00528970|9668858|FG001|Overall Study|Withdrawal by Subject|3
6066722|NCT00528970|9668859|FG002|Overall Study|Withdrawal by Subject|5
6066723|NCT00528970|9668857|FG000|Overall Study|Randomized but not treated|0
6066724|NCT00528970|9668858|FG001|Overall Study|Randomized but not treated|0
6066725|NCT00528970|9668859|FG002|Overall Study|Randomized but not treated|1
6066726|NCT00528996|9668872|FG000|Overall Study|Other reasons than listing|6
6066727|NCT00528996|9668873|FG001|Overall Study|Other reasons than listing|7
6066728|NCT00528996|9668874|FG002|Overall Study|Other reasons than listing|14
6066729|NCT00528996|9668875|FG003|Overall Study|Other reasons than listing|11
6066730|NCT00528996|9668876|FG004|Overall Study|Other reasons than listing|5
6066731|NCT00528996|9668872|FG000|Overall Study|Refused continue medication|16
6066732|NCT00528996|9668873|FG001|Overall Study|Refused continue medication|0
6066733|NCT00528996|9668874|FG002|Overall Study|Refused continue medication|3
6066734|NCT00528996|9668875|FG003|Overall Study|Refused continue medication|3
6066735|NCT00528996|9668876|FG004|Overall Study|Refused continue medication|6
6066736|NCT00528996|9668872|FG000|Overall Study|Lost to Follow-up|2
6066737|NCT00528996|9668873|FG001|Overall Study|Lost to Follow-up|0
6066738|NCT00528996|9668874|FG002|Overall Study|Lost to Follow-up|4
6066739|NCT00528996|9668875|FG003|Overall Study|Lost to Follow-up|1
6066740|NCT00528996|9668876|FG004|Overall Study|Lost to Follow-up|3
6066741|NCT00528996|9668872|FG000|Overall Study|Protocol Violation|1
6066742|NCT00528996|9668873|FG001|Overall Study|Protocol Violation|2
6066743|NCT00528996|9668874|FG002|Overall Study|Protocol Violation|3
6066744|NCT00528996|9668875|FG003|Overall Study|Protocol Violation|3
6066745|NCT00528996|9668876|FG004|Overall Study|Protocol Violation|2
6066746|NCT00528996|9668872|FG000|Overall Study|Lack of Efficacy|7
6066747|NCT00528996|9668873|FG001|Overall Study|Lack of Efficacy|2
6066748|NCT00528996|9668874|FG002|Overall Study|Lack of Efficacy|1
6066749|NCT00528996|9668875|FG003|Overall Study|Lack of Efficacy|3
6066750|NCT00528996|9668876|FG004|Overall Study|Lack of Efficacy|3
6066751|NCT00528996|9668872|FG000|Overall Study|Adverse Event|32
6066752|NCT00528996|9668873|FG001|Overall Study|Adverse Event|13
6066753|NCT00528996|9668874|FG002|Overall Study|Adverse Event|18
6066754|NCT00528996|9668875|FG003|Overall Study|Adverse Event|29
6066755|NCT00528996|9668876|FG004|Overall Study|Adverse Event|18
6066756|NCT00529035|9668891|FG000|Overall Study|Withdrawal by Subject|1
6066757|NCT00529087|9668905|FG000|Overall Study|Adverse Event|10
6066758|NCT00529087|9668906|FG001|Overall Study|Adverse Event|13
6066759|NCT00529087|9668907|FG002|Overall Study|Adverse Event|4
6066760|NCT00529087|9668905|FG000|Overall Study|Lost to Follow-up|6
6066761|NCT00529087|9668906|FG001|Overall Study|Lost to Follow-up|4
6066762|NCT00529087|9668907|FG002|Overall Study|Lost to Follow-up|1
6066763|NCT00529087|9668905|FG000|Overall Study|Protocol Violation|8
6066764|NCT00529087|9668906|FG001|Overall Study|Protocol Violation|7
6066765|NCT00529087|9668907|FG002|Overall Study|Protocol Violation|6
6066766|NCT00529087|9668905|FG000|Overall Study|Withdrawal by Subject|3
6066767|NCT00529087|9668906|FG001|Overall Study|Withdrawal by Subject|3
6066768|NCT00529087|9668907|FG002|Overall Study|Withdrawal by Subject|3
6066769|NCT00529087|9668905|FG000|Overall Study|Protocol deviation|1
6066770|NCT00529087|9668906|FG001|Overall Study|Protocol deviation|1
6066771|NCT00529087|9668907|FG002|Overall Study|Protocol deviation|2
6066772|NCT00529100|9668928|FG000|Overall Study|Adverse Event|0
6066773|NCT00529100|9668929|FG001|Overall Study|Adverse Event|5
6066774|NCT00529100|9668928|FG000|Overall Study|Protocol Violation|0
6066775|NCT00529100|9668929|FG001|Overall Study|Protocol Violation|1
6066776|NCT00529100|9668928|FG000|Overall Study|Progressive Disease|0
6066777|NCT00529100|9668929|FG001|Overall Study|Progressive Disease|1
6066778|NCT00529100|9668928|FG000|Overall Study|Withdrawal by Subject|0
6066779|NCT00529100|9668929|FG001|Overall Study|Withdrawal by Subject|1
6066780|NCT00529100|9668928|FG000|Overall Study|Participant Ineligibility|0
6066781|NCT00529100|9668929|FG001|Overall Study|Participant Ineligibility|1
6066782|NCT00529217|9668978|FG000|Overall Study|Lack of Efficacy|2
6066783|NCT00529217|9668978|FG000|Overall Study|Unable to adhere to study schedule|2
6066784|NCT00529243|9668983|FG000|Overall Study|Adverse Event|1
6066785|NCT00529243|9668983|FG000|Overall Study|Death|1
6066786|NCT00529243|9668983|FG000|Overall Study|Relocated|1
6066787|NCT00529308|9668989|FG000|Overall Study|Withdrawal by Subject|1
6066788|NCT00529308|9668990|FG001|Overall Study|Withdrawal by Subject|1
6066789|NCT00529373|9668998|FG000|Base Study|Adverse Event|525
6066790|NCT00529373|9668999|FG001|Base Study|Adverse Event|470
6066791|NCT00529373|9668998|FG000|Base Study|Lack of Efficacy|16
6066792|NCT00529373|9668999|FG001|Base Study|Lack of Efficacy|75
6066793|NCT00529373|9668998|FG000|Base Study|Lost to Follow-up|221
6066794|NCT00529373|9668999|FG001|Base Study|Lost to Follow-up|208
6066795|NCT00529373|9668998|FG000|Base Study|Other Protocol Specified Criteria|19
6066796|NCT00529373|9668999|FG001|Base Study|Other Protocol Specified Criteria|20
6066797|NCT00529373|9668998|FG000|Base Study|Physician Decision|60
6066798|NCT00529373|9668999|FG001|Base Study|Physician Decision|52
6066799|NCT00529373|9668998|FG000|Base Study|Protocol Violation|48
6066800|NCT00529373|9668999|FG001|Base Study|Protocol Violation|38
6066801|NCT00529373|9668998|FG000|Base Study|Withdrawal by Subject|1062
6066802|NCT00529373|9668999|FG001|Base Study|Withdrawal by Subject|967
6066803|NCT00529373|9668998|FG000|Base Study|Did not continue into Extension|1795
6066804|NCT00529373|9668999|FG001|Base Study|Did not continue into Extension|2238
6066805|NCT00529373|9668998|FG000|First Extension Study|Adverse Event|162
6066806|NCT00529373|9668999|FG001|First Extension Study|Adverse Event|142
6066807|NCT00529373|9668998|FG000|First Extension Study|Lack of Efficacy|65
6066808|NCT00529373|9668999|FG001|First Extension Study|Lack of Efficacy|427
6066809|NCT00529373|9668998|FG000|First Extension Study|Lost to Follow-up|41
6066810|NCT00529373|9668999|FG001|First Extension Study|Lost to Follow-up|37
6066811|NCT00529373|9668998|FG000|First Extension Study|Other|27
6066812|NCT00529373|9668999|FG001|First Extension Study|Other|47
6066813|NCT00529373|9668998|FG000|First Extension Study|Physician Decision|50
6066814|NCT00529373|9668999|FG001|First Extension Study|Physician Decision|45
6066815|NCT00529373|9668998|FG000|First Extension Study|Protocol Violation|16
6066816|NCT00529373|9668999|FG001|First Extension Study|Protocol Violation|13
6066817|NCT00529373|9668998|FG000|First Extension Study|Withdrawal by Subject|296
6066818|NCT00529373|9668999|FG001|First Extension Study|Withdrawal by Subject|287
6066819|NCT00529373|9668998|FG000|First Extension Study|Disposition record non-existing|0
6066820|NCT00529373|9668999|FG001|First Extension Study|Disposition record non-existing|1
6066821|NCT00529373|9668998|FG000|First Extension Study|Discontinued after 5 years completion|208
6066822|NCT00529373|9668999|FG001|First Extension Study|Discontinued after 5 years completion|346
6066823|NCT00529373|9668998|FG000|First Extension Study|Did not cont. into 2nd Ext (verified)|256
6066824|NCT00529373|9668999|FG001|First Extension Study|Did not cont. into 2nd Ext (verified)|281
6066825|NCT00529373|9668998|FG000|First Extension Study|Did not cont. into 2nd Ext (unknown)|32
6066826|NCT00529373|9668999|FG001|First Extension Study|Did not cont. into 2nd Ext (unknown)|25
6066827|NCT00529373|9668998|FG000|Second Extension Study|Adverse Event|101
6066828|NCT00529373|9668999|FG001|Second Extension Study|Adverse Event|51
6066829|NCT00529373|9668998|FG000|Second Extension Study|Lack of Efficacy|7
6066830|NCT00529373|9668999|FG001|Second Extension Study|Lack of Efficacy|15
6066831|NCT00529373|9668998|FG000|Second Extension Study|Lost to Follow-up|18
6066832|NCT00529373|9668999|FG001|Second Extension Study|Lost to Follow-up|12
6066833|NCT00529373|9668998|FG000|Second Extension Study|Other|7
6066834|NCT00529373|9668999|FG001|Second Extension Study|Other|12
6066835|NCT00529373|9668998|FG000|Second Extension Study|Physician Decision|63
6066836|NCT00529373|9668999|FG001|Second Extension Study|Physician Decision|26
6066837|NCT00529373|9668998|FG000|Second Extension Study|Protocol Violation|2
6066838|NCT00529373|9668999|FG001|Second Extension Study|Protocol Violation|1
6066839|NCT00529373|9668998|FG000|Second Extension Study|Withdrawal by Subject|97
6066840|NCT00529373|9668999|FG001|Second Extension Study|Withdrawal by Subject|75
6066841|NCT00529373|9668998|FG000|Second Extension Study|Status Missing|5
6066842|NCT00529373|9668999|FG001|Second Extension Study|Status Missing|5
6066843|NCT00529386|9669013|FG000|Overall Study|Lost to Follow-up|1
6066844|NCT00529399|9669020|FG000|Overall Study|Lost to Follow-up|1
6066845|NCT00529399|9669021|FG001|Overall Study|Lost to Follow-up|0
6066846|NCT00529399|9669022|FG002|Overall Study|Lost to Follow-up|1
6066847|NCT00529399|9669020|FG000|Overall Study|Withdrawal by Subject|1
6066848|NCT00529399|9669021|FG001|Overall Study|Withdrawal by Subject|0
6066849|NCT00529399|9669022|FG002|Overall Study|Withdrawal by Subject|1
6066850|NCT00529399|9669020|FG000|Overall Study|Non-compliant|0
6066851|NCT00529399|9669021|FG001|Overall Study|Non-compliant|1
6066852|NCT00529399|9669022|FG002|Overall Study|Non-compliant|0
6066853|NCT00529451|9669034|FG000|Overall Study|Subject withdrew consent|16
6066854|NCT00529451|9669035|FG001|Overall Study|Subject withdrew consent|21
6066855|NCT00529451|9669036|FG002|Overall Study|Subject withdrew consent|13
6066856|NCT00529451|9669037|FG003|Overall Study|Subject withdrew consent|12
6066857|NCT00529451|9669034|FG000|Overall Study|Adverse Event|9
6066858|NCT00529451|9669035|FG001|Overall Study|Adverse Event|16
6066859|NCT00529451|9669036|FG002|Overall Study|Adverse Event|14
6066860|NCT00529451|9669037|FG003|Overall Study|Adverse Event|8
6066861|NCT00529451|9669034|FG000|Overall Study|Unsatisfactory therapeutic response|6
5991873|NCT02498444|9583930|FG000|Overall Study|Withdrawal by Subject|3
5991874|NCT02498444|9583931|FG001|Overall Study|Withdrawal by Subject|0
5991875|NCT02498444|9583930|FG000|Overall Study|Physician Decision|1
5991876|NCT02498444|9583931|FG001|Overall Study|Physician Decision|0
5991877|NCT02487108|9583941|FG000|Overall Study|Adverse Event|1
5991878|NCT02487108|9583942|FG001|Overall Study|Adverse Event|6
5991879|NCT02487108|9583943|FG002|Overall Study|Adverse Event|12
5991880|NCT02487108|9583944|FG003|Overall Study|Adverse Event|6
5991881|NCT02487108|9583941|FG000|Overall Study|Withdrawal by Subject|8
5991882|NCT02487108|9583942|FG001|Overall Study|Withdrawal by Subject|5
5991883|NCT02487108|9583943|FG002|Overall Study|Withdrawal by Subject|5
6066862|NCT00529451|9669035|FG001|Overall Study|Unsatisfactory therapeutic response|2
6066863|NCT00529451|9669036|FG002|Overall Study|Unsatisfactory therapeutic response|5
6066864|NCT00529451|9669037|FG003|Overall Study|Unsatisfactory therapeutic response|4
6066865|NCT00529451|9669034|FG000|Overall Study|Lost to Follow-up|4
6066866|NCT00529451|9669035|FG001|Overall Study|Lost to Follow-up|7
6066867|NCT00529451|9669036|FG002|Overall Study|Lost to Follow-up|4
6066868|NCT00529451|9669037|FG003|Overall Study|Lost to Follow-up|4
6066869|NCT00529451|9669034|FG000|Overall Study|Protocol deviation|1
6066870|NCT00529451|9669035|FG001|Overall Study|Protocol deviation|1
6066871|NCT00529451|9669036|FG002|Overall Study|Protocol deviation|4
6066872|NCT00529451|9669037|FG003|Overall Study|Protocol deviation|1
6066873|NCT00529451|9669034|FG000|Overall Study|Administrative problems|1
6066874|NCT00529451|9669035|FG001|Overall Study|Administrative problems|1
6066875|NCT00529451|9669036|FG002|Overall Study|Administrative problems|0
6066876|NCT00529451|9669037|FG003|Overall Study|Administrative problems|2
6066877|NCT00529516|9669053|FG000|Overall Study|Adverse Event|2
6066878|NCT00529516|9669054|FG001|Overall Study|Adverse Event|1
6066879|NCT00529516|9669055|FG002|Overall Study|Adverse Event|0
6066880|NCT00529516|9669053|FG000|Overall Study|Withdrawal by Subject|1
6066881|NCT00529516|9669054|FG001|Overall Study|Withdrawal by Subject|1
6066882|NCT00529516|9669055|FG002|Overall Study|Withdrawal by Subject|0
6066883|NCT00529516|9669053|FG000|Overall Study|Lost to Follow-up|0
6066884|NCT00529516|9669054|FG001|Overall Study|Lost to Follow-up|0
6066885|NCT00529516|9669055|FG002|Overall Study|Lost to Follow-up|1
6066886|NCT00529529|9669066|FG000|Overall Study|Adverse Event|12
6066887|NCT00529529|9669067|FG001|Overall Study|Adverse Event|17
6066888|NCT00529529|9669068|FG002|Overall Study|Adverse Event|8
6066889|NCT00529529|9669066|FG000|Overall Study|Subject withdrew consent|12
6066890|NCT00529529|9669067|FG001|Overall Study|Subject withdrew consent|9
6066891|NCT00529529|9669068|FG002|Overall Study|Subject withdrew consent|12
6066892|NCT00529529|9669066|FG000|Overall Study|Protocol deviation|8
6066893|NCT00529529|9669067|FG001|Overall Study|Protocol deviation|12
6066894|NCT00529529|9669068|FG002|Overall Study|Protocol deviation|5
6066895|NCT00529529|9669066|FG000|Overall Study|Lost to Follow-up|5
6066896|NCT00529529|9669067|FG001|Overall Study|Lost to Follow-up|3
6066897|NCT00529529|9669068|FG002|Overall Study|Lost to Follow-up|1
6066898|NCT00529529|9669066|FG000|Overall Study|Unsatisfactory therapeutic effect|2
6066899|NCT00529529|9669067|FG001|Overall Study|Unsatisfactory therapeutic effect|2
6066900|NCT00529529|9669068|FG002|Overall Study|Unsatisfactory therapeutic effect|2
6066901|NCT00529529|9669066|FG000|Overall Study|Death|2
6066902|NCT00529529|9669067|FG001|Overall Study|Death|0
6066903|NCT00529529|9669068|FG002|Overall Study|Death|0
6066904|NCT00529529|9669066|FG000|Overall Study|Abnormal test procedure result(s)|1
6066905|NCT00529529|9669067|FG001|Overall Study|Abnormal test procedure result(s)|0
6066906|NCT00529529|9669068|FG002|Overall Study|Abnormal test procedure result(s)|0
5991884|NCT02487108|9583944|FG003|Overall Study|Withdrawal by Subject|0
5991885|NCT02487108|9583941|FG000|Overall Study|Non-compliance to study medication|3
5991886|NCT02487108|9583942|FG001|Overall Study|Non-compliance to study medication|2
5991887|NCT02487108|9583943|FG002|Overall Study|Non-compliance to study medication|5
6066907|NCT00529529|9669066|FG000|Overall Study|Administrative problems|1
6066908|NCT00529529|9669067|FG001|Overall Study|Administrative problems|0
6066909|NCT00529529|9669068|FG002|Overall Study|Administrative problems|3
5991888|NCT02487108|9583944|FG003|Overall Study|Non-compliance to study medication|4
5991889|NCT02487108|9583941|FG000|Overall Study|Protocol Violation|1
6066910|NCT00529542|9669078|FG000|Overall Study|Withdrawal by Subject|1
6066911|NCT00529542|9669079|FG001|Overall Study|Withdrawal by Subject|0
6146181|NCT01075815|9780793|FG000|Overall Study|Withdrawal between OPU - embryo transfer|3
6146182|NCT01075815|9780794|FG001|Overall Study|Withdrawal between OPU - embryo transfer|2
6146183|NCT01075958|9780800|FG000|Overall Study|Blood sample could not be obtained|44
6146184|NCT01075984|9780813|FG000|Treatment Phase|Adverse Event|0
6146185|NCT01075984|9780814|FG001|Treatment Phase|Adverse Event|1
6146186|NCT01075984|9780815|FG002|Treatment Phase|Adverse Event|3
6146187|NCT01075984|9780816|FG003|Treatment Phase|Adverse Event|7
6146188|NCT01075984|9780817|FG004|Treatment Phase|Adverse Event|35
6146189|NCT01075984|9780813|FG000|Treatment Phase|Protocol Violation|0
6146190|NCT01075984|9780814|FG001|Treatment Phase|Protocol Violation|0
6066912|NCT00529542|9669078|FG000|Overall Study|Lost to Follow-up|0
6066913|NCT00529542|9669079|FG001|Overall Study|Lost to Follow-up|1
6066914|NCT00529568|9669100|FG000|Open-label Pre-Antiviral Treatment Phase|Adverse Event|5
6066915|NCT00529568|9669101|FG001|Open-label Pre-Antiviral Treatment Phase|Adverse Event|0
6066916|NCT00529568|9669102|FG002|Open-label Pre-Antiviral Treatment Phase|Adverse Event|0
6066917|NCT00529568|9669100|FG000|Open-label Pre-Antiviral Treatment Phase|Lost to Follow-up|12
6066918|NCT00529568|9669101|FG001|Open-label Pre-Antiviral Treatment Phase|Lost to Follow-up|0
6066919|NCT00529568|9669102|FG002|Open-label Pre-Antiviral Treatment Phase|Lost to Follow-up|0
6066920|NCT00529568|9669100|FG000|Open-label Pre-Antiviral Treatment Phase|Protocol Violation|5
6066921|NCT00529568|9669101|FG001|Open-label Pre-Antiviral Treatment Phase|Protocol Violation|0
6066922|NCT00529568|9669102|FG002|Open-label Pre-Antiviral Treatment Phase|Protocol Violation|0
6066923|NCT00529568|9669100|FG000|Open-label Pre-Antiviral Treatment Phase|Physician Decision|8
6066924|NCT00529568|9669101|FG001|Open-label Pre-Antiviral Treatment Phase|Physician Decision|0
6066925|NCT00529568|9669102|FG002|Open-label Pre-Antiviral Treatment Phase|Physician Decision|0
6066926|NCT00529568|9669100|FG000|Open-label Pre-Antiviral Treatment Phase|Insufficient Platelet Response|13
6066927|NCT00529568|9669101|FG001|Open-label Pre-Antiviral Treatment Phase|Insufficient Platelet Response|0
6066928|NCT00529568|9669102|FG002|Open-label Pre-Antiviral Treatment Phase|Insufficient Platelet Response|0
6066929|NCT00529568|9669100|FG000|Open-label Pre-Antiviral Treatment Phase|Withdrawal by Subject|3
6066930|NCT00529568|9669101|FG001|Open-label Pre-Antiviral Treatment Phase|Withdrawal by Subject|0
6066931|NCT00529568|9669102|FG002|Open-label Pre-Antiviral Treatment Phase|Withdrawal by Subject|0
6066932|NCT00529568|9669100|FG000|Double-bilnd Antiviral Treatment Phase|Adverse Event|0
6066933|NCT00529568|9669101|FG001|Double-bilnd Antiviral Treatment Phase|Adverse Event|10
6066934|NCT00529568|9669102|FG002|Double-bilnd Antiviral Treatment Phase|Adverse Event|27
6066935|NCT00529568|9669100|FG000|Double-bilnd Antiviral Treatment Phase|Protocol Violation|0
6066936|NCT00529568|9669101|FG001|Double-bilnd Antiviral Treatment Phase|Protocol Violation|1
6066937|NCT00529568|9669102|FG002|Double-bilnd Antiviral Treatment Phase|Protocol Violation|0
6066938|NCT00529568|9669100|FG000|Double-bilnd Antiviral Treatment Phase|Lost to Follow-up|0
6066939|NCT00529568|9669101|FG001|Double-bilnd Antiviral Treatment Phase|Lost to Follow-up|15
6066940|NCT00529568|9669102|FG002|Double-bilnd Antiviral Treatment Phase|Lost to Follow-up|48
6066941|NCT00529568|9669100|FG000|Double-bilnd Antiviral Treatment Phase|Physician Decision|0
6066942|NCT00529568|9669101|FG001|Double-bilnd Antiviral Treatment Phase|Physician Decision|5
6066943|NCT00529568|9669102|FG002|Double-bilnd Antiviral Treatment Phase|Physician Decision|8
6066944|NCT00529568|9669100|FG000|Double-bilnd Antiviral Treatment Phase|Withdrawal by Subject|0
6066945|NCT00529568|9669101|FG001|Double-bilnd Antiviral Treatment Phase|Withdrawal by Subject|17
6066946|NCT00529568|9669102|FG002|Double-bilnd Antiviral Treatment Phase|Withdrawal by Subject|19
6066947|NCT00529633|9669113|FG000|Overall Study|Withdrawal by Subject|1
6066948|NCT00529633|9669114|FG001|Overall Study|Withdrawal by Subject|1
6066949|NCT00529659|9669122|FG000|Overall Study|Adverse Event|8
6066950|NCT00529659|9669123|FG001|Overall Study|Adverse Event|7
6066951|NCT00529659|9669122|FG000|Overall Study|Lost to Follow-up|0
6066952|NCT00529659|9669123|FG001|Overall Study|Lost to Follow-up|2
6066953|NCT00529659|9669122|FG000|Overall Study|Physician Decision|0
6066954|NCT00529659|9669123|FG001|Overall Study|Physician Decision|2
6066955|NCT00529659|9669122|FG000|Overall Study|Protocol Violation|2
6066956|NCT00529659|9669123|FG001|Overall Study|Protocol Violation|6
6066957|NCT00529659|9669122|FG000|Overall Study|Withdrawal by Subject|1
6066958|NCT00529659|9669123|FG001|Overall Study|Withdrawal by Subject|6
6087137|NCT00666757|9697326|FG000|Overall Study|Lost to Follow-up|39
6087138|NCT00666757|9697327|FG001|Overall Study|Lost to Follow-up|35
6087139|NCT00666757|9697326|FG000|Overall Study|Protocol Violation|23
6087140|NCT00666757|9697327|FG001|Overall Study|Protocol Violation|24
6087141|NCT00666757|9697326|FG000|Overall Study|Adverse Event|22
6087142|NCT00666757|9697327|FG001|Overall Study|Adverse Event|12
6087143|NCT00666757|9697326|FG000|Overall Study|Withdrawal by Subject|13
6087144|NCT00666757|9697327|FG001|Overall Study|Withdrawal by Subject|17
6087145|NCT00666757|9697326|FG000|Overall Study|Lack of Efficacy|3
6087146|NCT00666757|9697327|FG001|Overall Study|Lack of Efficacy|6
6087147|NCT00666757|9697326|FG000|Overall Study|Physician Decision|0
6087148|NCT00666757|9697327|FG001|Overall Study|Physician Decision|2
6087149|NCT00666757|9697326|FG000|Overall Study|Sponsor decision|0
6146191|NCT01075984|9780815|FG002|Treatment Phase|Protocol Violation|1
6146192|NCT01075984|9780816|FG003|Treatment Phase|Protocol Violation|0
6066959|NCT00529789|9669129|FG000|Study Period II/III|Parent/Caregiver Decision|9
6066960|NCT00529789|9669129|FG000|Study Period II/III|Adverse Event|3
6066961|NCT00529789|9669129|FG000|Study Period II/III|Lack of Efficacy|2
6066962|NCT00529789|9669129|FG000|Study Period II/III|Withdrawal by Subject|1
6066963|NCT00529789|9669129|FG000|Study Period II/III|Protocol Violation|3
6066964|NCT00529789|9669129|FG000|Study Period II/III|Physician Decision|3
6066965|NCT00529789|9669129|FG000|Study Period II/III|Lost to Follow-up|3
6066966|NCT00529789|9669129|FG000|Study Period IV|Parent/Caregiver Decision|1
6066967|NCT00529789|9669129|FG000|Study Period IV|Adverse Event|1
6066968|NCT00529789|9669129|FG000|Study Period IV|Lack of Efficacy|1
6066969|NCT00529789|9669129|FG000|Study Period IV|Lost to Follow-up|3
6066970|NCT00529802|9669139|FG000|Evaluable for Primary Endpoint|Did not complete 2d CT scan|3
6066971|NCT00529802|9669139|FG000|Evaluable for Primary Endpoint|Worsening performance status|2
6066972|NCT00529802|9669139|FG000|Evaluable for Primary Endpoint|Adverse Event|2
6066973|NCT00529802|9669139|FG000|Evaluable for Primary Endpoint|Death|1
6066974|NCT00529802|9669139|FG000|Evaluable for Primary Endpoint|Lack of Efficacy|1
6066975|NCT00529802|9669139|FG000|Evaluable for Primary Endpoint|Lost to Follow-up|1
6066976|NCT00529802|9669139|FG000|Evaluable for Secondary Endpoint|Did not complete 2d FDG-PET scan|2
6066977|NCT00529958|9669148|FG000|2-Year Follow-up|Lost to Follow-up|1
6066978|NCT00529958|9669149|FG001|2-Year Follow-up|Lost to Follow-up|2
6066979|NCT00529958|9669150|FG002|2-Year Follow-up|Lost to Follow-up|2
6066980|NCT00529958|9669148|FG000|2-Year Follow-up|Withdrawal by Subject|3
6066981|NCT00529958|9669149|FG001|2-Year Follow-up|Withdrawal by Subject|0
6066982|NCT00529958|9669150|FG002|2-Year Follow-up|Withdrawal by Subject|0
6066983|NCT00529958|9669148|FG000|5-Year Follow-up|Lost to Follow-up|2
6066984|NCT00529958|9669149|FG001|5-Year Follow-up|Lost to Follow-up|3
6066985|NCT00529958|9669150|FG002|5-Year Follow-up|Lost to Follow-up|1
6066986|NCT00529958|9669148|FG000|5-Year Follow-up|Withdrawal by Subject|1
6066987|NCT00529958|9669149|FG001|5-Year Follow-up|Withdrawal by Subject|0
6066988|NCT00529958|9669150|FG002|5-Year Follow-up|Withdrawal by Subject|0
6066989|NCT00530023|9669160|FG000|Overall Study|Withdrawal by Subject|0
6066990|NCT00530023|9669161|FG001|Overall Study|Withdrawal by Subject|1
6066991|NCT00530075|9669167|FG000|Overall Study|Adverse Event|1
6066992|NCT00530075|9669167|FG000|Overall Study|Death|1
6066993|NCT00530075|9669167|FG000|Overall Study|Lack of Efficacy|3
6066994|NCT00530075|9669167|FG000|Overall Study|Protocol Violation|1
6066995|NCT00530075|9669167|FG000|Overall Study|Withdrawal by Subject|1
6066996|NCT00530088|9669171|FG000|Overall Study|Disease Progression|4
6066997|NCT00530088|9669171|FG000|Overall Study|Physician Decision|4
6066998|NCT00530088|9669171|FG000|Overall Study|Other Not Specified|2
6066999|NCT00530218|9669175|FG000|Overall Study|CMV Not Detected|13
6067000|NCT00530218|9669175|FG000|Overall Study|Death|12
6067001|NCT00530257|9669182|FG000|Overall Study|Lost to Follow-up|1
6067002|NCT00530270|9669191|FG000|Overall Study|Protocol Violation|1
6067003|NCT00530270|9669192|FG001|Overall Study|Protocol Violation|0
6067004|NCT00530335|9669198|FG000|Overall Study|Adverse Event|3
6067005|NCT00530335|9669198|FG000|Overall Study|Protocol Violation|1
6067006|NCT00530335|9669198|FG000|Overall Study|Withdrawal by Subject|1
6067007|NCT00530335|9669198|FG000|Overall Study|Physician Decision|1
6067008|NCT00530348|9669204|FG000|Overall Study|Adverse Event|5
6067009|NCT00530348|9669205|FG001|Overall Study|Adverse Event|1
6067010|NCT00530348|9669204|FG000|Overall Study|Death|0
6067011|NCT00530348|9669205|FG001|Overall Study|Death|1
6067012|NCT00530348|9669204|FG000|Overall Study|Lack of Efficacy|2
6067013|NCT00530348|9669205|FG001|Overall Study|Lack of Efficacy|0
6067014|NCT00530348|9669204|FG000|Overall Study|Lost to Follow-up|0
6067015|NCT00530348|9669205|FG001|Overall Study|Lost to Follow-up|2
6067016|NCT00530348|9669204|FG000|Overall Study|Physician Decision|1
6067017|NCT00530348|9669205|FG001|Overall Study|Physician Decision|2
6067018|NCT00530348|9669204|FG000|Overall Study|Pregnancy|1
6067019|NCT00530348|9669205|FG001|Overall Study|Pregnancy|0
6067020|NCT00530348|9669204|FG000|Overall Study|Withdrawal by Subject|12
6067021|NCT00530348|9669205|FG001|Overall Study|Withdrawal by Subject|12
6067022|NCT00530348|9669204|FG000|Overall Study|Randomised in error|1
6067023|NCT00530348|9669205|FG001|Overall Study|Randomised in error|0
6067024|NCT00530348|9669204|FG000|Overall Study|Noncompliance with inclusion criterion 3|0
6067025|NCT00530348|9669205|FG001|Overall Study|Noncompliance with inclusion criterion 3|1
6067026|NCT00530439|9669213|FG000|Overall Study|GDM|9
6067027|NCT00530439|9669214|FG001|Overall Study|GDM|3
6067028|NCT00530439|9669213|FG000|Overall Study|Withdraw|18
6067029|NCT00530439|9669214|FG001|Overall Study|Withdraw|14
6067030|NCT00530439|9669213|FG000|Overall Study|Missed abortion|1
6067031|NCT00530439|9669214|FG001|Overall Study|Missed abortion|4
6067032|NCT00530439|9669213|FG000|Overall Study|Misclassification|2
6067033|NCT00530439|9669214|FG001|Overall Study|Misclassification|0
6067034|NCT00530439|9669213|FG000|Overall Study|Twin pregnancy|0
6067035|NCT00530439|9669214|FG001|Overall Study|Twin pregnancy|2
6067036|NCT00530439|9669213|FG000|Overall Study|Severe malformation/abortion|0
6067037|NCT00530439|9669214|FG001|Overall Study|Severe malformation/abortion|3
6067038|NCT00530504|9669220|FG000|Overall Study|Death|54
6067039|NCT00530504|9669220|FG000|Overall Study|Lost to Follow-up|26
6067040|NCT00530504|9669220|FG000|Overall Study|Withdrawal by Subject|39
6067041|NCT00530504|9669220|FG000|Overall Study|Exited study due to other reasons|33
6067042|NCT00530621|9669226|FG000|Overall Study|Adverse Event|11
6067043|NCT00530621|9669227|FG001|Overall Study|Adverse Event|8
6067044|NCT00530621|9669226|FG000|Overall Study|Physician Decision|2
6067045|NCT00530621|9669227|FG001|Overall Study|Physician Decision|4
6067046|NCT00530621|9669226|FG000|Overall Study|Progressive Disease (PD)|47
6067047|NCT00530621|9669227|FG001|Overall Study|Progressive Disease (PD)|40
6067048|NCT00530621|9669226|FG000|Overall Study|Sponsor Decision|12
6067049|NCT00530621|9669227|FG001|Overall Study|Sponsor Decision|15
6067050|NCT00530621|9669226|FG000|Overall Study|Subject Decision|4
6067051|NCT00530621|9669227|FG001|Overall Study|Subject Decision|7
6067052|NCT00530621|9669226|FG000|Overall Study|Death|3
6067053|NCT00530621|9669227|FG001|Overall Study|Death|6
6067054|NCT00530621|9669226|FG000|Overall Study|Not Treated Due to PD Prior to Dosing|1
6067055|NCT00530621|9669227|FG001|Overall Study|Not Treated Due to PD Prior to Dosing|0
6067056|NCT00530712|9669241|FG000|30 Day Follow-up Visit|Withdrawal by Subject|2
6067057|NCT00530712|9669241|FG000|30 Day Follow-up Visit|Missed Visit|5
6067058|NCT00530712|9669241|FG000|6 Month Follow-up Visit|Withdrawal by Subject|4
6067059|NCT00530712|9669241|FG000|6 Month Follow-up Visit|Missed Visit|3
6067060|NCT00530712|9669241|FG000|6 Month Follow-up Visit|Lost to Follow-up|3
6067061|NCT00530712|9669241|FG000|6 Month Follow-up Visit|Death|2
6067062|NCT00530712|9669241|FG000|12 Month Follow-up Visit|Withdrawal by Subject|5
6067063|NCT00530712|9669241|FG000|12 Month Follow-up Visit|Missed Visit|3
6067064|NCT00530712|9669241|FG000|12 Month Follow-up Visit|Lost to Follow-up|7
6067065|NCT00530712|9669241|FG000|12 Month Follow-up Visit|Death|9
6067066|NCT00530777|9669268|FG000|Overall Study|Lost to Follow-up|0
6067067|NCT00530777|9669269|FG001|Overall Study|Lost to Follow-up|1
6067068|NCT00530777|9669268|FG000|Overall Study|Death|1
6067069|NCT00530777|9669269|FG001|Overall Study|Death|2
6067070|NCT00530777|9669268|FG000|Overall Study|Physician Decision|1
6067071|NCT00530777|9669269|FG001|Overall Study|Physician Decision|0
6067072|NCT00530777|9669268|FG000|Overall Study|Withdrawal by Subject|0
6067073|NCT00530777|9669269|FG001|Overall Study|Withdrawal by Subject|1
6067074|NCT00530777|9669268|FG000|Overall Study|Unable to adhere to visit schedule|5
6067075|NCT00530777|9669269|FG001|Overall Study|Unable to adhere to visit schedule|1
6067076|NCT00530790|9669275|FG000|Overall Study|Adverse Event|2
6067077|NCT00530790|9669275|FG000|Overall Study|Withdrawal by Subject|2
6067078|NCT00530790|9669275|FG000|Overall Study|Physician Decision|1
6067079|NCT00530816|9669291|FG000|Overall Study|Progressive Disease|16
6067080|NCT00530816|9669292|FG001|Overall Study|Progressive Disease|24
6067081|NCT00530816|9669293|FG002|Overall Study|Progressive Disease|24
6067082|NCT00530816|9669291|FG000|Overall Study|Adverse Event|6
6067083|NCT00530816|9669292|FG001|Overall Study|Adverse Event|13
6067084|NCT00530816|9669293|FG002|Overall Study|Adverse Event|7
6067085|NCT00530816|9669291|FG000|Overall Study|Other|3
6067086|NCT00530816|9669292|FG001|Overall Study|Other|3
6067087|NCT00530816|9669293|FG002|Overall Study|Other|4
6067088|NCT00530816|9669291|FG000|Overall Study|Withdrawal by Subject|1
6067089|NCT00530816|9669292|FG001|Overall Study|Withdrawal by Subject|2
6067090|NCT00530816|9669293|FG002|Overall Study|Withdrawal by Subject|6
6067091|NCT00530842|9669303|FG000|Overall Study|Adverse Event|10
6067092|NCT00530842|9669304|FG001|Overall Study|Adverse Event|6
6067093|NCT00530842|9669303|FG000|Overall Study|Lack of Efficacy|2
6067094|NCT00530842|9669304|FG001|Overall Study|Lack of Efficacy|1
6067095|NCT00530842|9669303|FG000|Overall Study|Lost to Follow-up|0
6067096|NCT00530842|9669304|FG001|Overall Study|Lost to Follow-up|4
6067097|NCT00530842|9669303|FG000|Overall Study|Protocol Violation|3
6067098|NCT00530842|9669304|FG001|Overall Study|Protocol Violation|2
6067099|NCT00530842|9669303|FG000|Overall Study|Withdrawal by Subject|4
6067100|NCT00530842|9669304|FG001|Overall Study|Withdrawal by Subject|5
6067101|NCT00530842|9669303|FG000|Overall Study|Individual different reasons|4
6067102|NCT00530842|9669304|FG001|Overall Study|Individual different reasons|3
6067103|NCT00530842|9669303|FG000|Period 1|Adverse Event|7
6067104|NCT00530842|9669304|FG001|Period 1|Adverse Event|3
6067105|NCT00530842|9669303|FG000|Period 1|Lack of Efficacy|1
6067106|NCT00530842|9669304|FG001|Period 1|Lack of Efficacy|1
6067107|NCT00530842|9669303|FG000|Period 1|Protocol Violation|2
6067108|NCT00530842|9669304|FG001|Period 1|Protocol Violation|1
6067109|NCT00530842|9669303|FG000|Period 1|Withdrawal by Subject|2
6067110|NCT00530842|9669304|FG001|Period 1|Withdrawal by Subject|3
6067111|NCT00530842|9669303|FG000|Period 1|Individual different reasons|2
6067112|NCT00530842|9669304|FG001|Period 1|Individual different reasons|3
6067113|NCT00530842|9669303|FG000|Period 2|Adverse Event|3
6067114|NCT00530842|9669304|FG001|Period 2|Adverse Event|3
6067115|NCT00530842|9669303|FG000|Period 2|Lack of Efficacy|1
6067116|NCT00530842|9669304|FG001|Period 2|Lack of Efficacy|0
6067117|NCT00530842|9669303|FG000|Period 2|Lost to Follow-up|0
6067118|NCT00530842|9669304|FG001|Period 2|Lost to Follow-up|4
6067119|NCT00530842|9669303|FG000|Period 2|Protocol Violation|1
6067120|NCT00530842|9669304|FG001|Period 2|Protocol Violation|0
6067121|NCT00530842|9669303|FG000|Period 2|Withdrawal by Subject|1
6067122|NCT00530842|9669304|FG001|Period 2|Withdrawal by Subject|2
6067123|NCT00530842|9669303|FG000|Period 2|Individual different reasons|2
6067124|NCT00530842|9669304|FG001|Period 2|Individual different reasons|0
6067125|NCT00530855|9669312|FG000|Overall Study|Lack of Efficacy|20
6067126|NCT00530855|9669312|FG000|Overall Study|Withdrawal by Subject|30
6067127|NCT00530855|9669312|FG000|Overall Study|Fatal Serious AE|3
6067128|NCT00530855|9669312|FG000|Overall Study|Non Fatal Serious AE|7
6067129|NCT00530855|9669312|FG000|Overall Study|Non Fatal Non Serious AE|12
6067130|NCT00530855|9669312|FG000|Overall Study|Protocol Violation|3
6067131|NCT00530855|9669312|FG000|Overall Study|Unsatisfactory compliance of subject|11
6067132|NCT00530855|9669312|FG000|Overall Study|Lost to Follow-up|9
6067133|NCT00530855|9669312|FG000|Overall Study|Other reason for premature termination|17
6067134|NCT00530894|9669320|FG000|Overall Study|Death|84
6067135|NCT00530894|9669321|FG001|Overall Study|Death|89
6067136|NCT00530894|9669322|FG002|Overall Study|Death|55
6067137|NCT00530894|9669323|FG003|Overall Study|Death|89
6067138|NCT00530894|9669320|FG000|Overall Study|Lost to Follow-up|1
6067139|NCT00530894|9669321|FG001|Overall Study|Lost to Follow-up|3
6067140|NCT00530894|9669322|FG002|Overall Study|Lost to Follow-up|0
6067141|NCT00530894|9669323|FG003|Overall Study|Lost to Follow-up|0
6067142|NCT00530894|9669320|FG000|Overall Study|Withdrawal by Subject|1
6067143|NCT00530894|9669321|FG001|Overall Study|Withdrawal by Subject|23
6067144|NCT00530894|9669322|FG002|Overall Study|Withdrawal by Subject|0
6067145|NCT00530894|9669323|FG003|Overall Study|Withdrawal by Subject|5
6067146|NCT00530894|9669320|FG000|Overall Study|Alive and censored prior to 1 year|2
6067147|NCT00530894|9669321|FG001|Overall Study|Alive and censored prior to 1 year|0
6067148|NCT00530894|9669322|FG002|Overall Study|Alive and censored prior to 1 year|0
6067149|NCT00530894|9669323|FG003|Overall Study|Alive and censored prior to 1 year|0
6067150|NCT00530920|9669338|FG000|Overall Study|Randomized but not treated|0
6067151|NCT00530920|9669339|FG001|Overall Study|Randomized but not treated|2
6067152|NCT00530920|9669340|FG002|Overall Study|Randomized but not treated|0
6067153|NCT00530920|9669338|FG000|Overall Study|Adverse Event|0
6067154|NCT00530920|9669339|FG001|Overall Study|Adverse Event|0
6067155|NCT00530920|9669340|FG002|Overall Study|Adverse Event|3
6067156|NCT00530920|9669338|FG000|Overall Study|Withdrawal by Subject|0
6067157|NCT00530920|9669339|FG001|Overall Study|Withdrawal by Subject|0
6067158|NCT00530920|9669340|FG002|Overall Study|Withdrawal by Subject|1
6067159|NCT00530946|9669353|FG000|Overall Study|Adverse Event|1
6067160|NCT00530946|9669354|FG001|Overall Study|Adverse Event|2
6067161|NCT00530946|9669355|FG002|Overall Study|Adverse Event|1
6067162|NCT00530946|9669356|FG003|Overall Study|Adverse Event|1
6067163|NCT00530946|9669353|FG000|Overall Study|Protocol Violation|0
6067164|NCT00530946|9669354|FG001|Overall Study|Protocol Violation|0
6067165|NCT00530946|9669355|FG002|Overall Study|Protocol Violation|0
6067166|NCT00530946|9669356|FG003|Overall Study|Protocol Violation|1
6067167|NCT00530946|9669353|FG000|Overall Study|Noncompliance|1
6067168|NCT00530946|9669354|FG001|Overall Study|Noncompliance|0
6067169|NCT00530946|9669355|FG002|Overall Study|Noncompliance|0
6067170|NCT00530946|9669356|FG003|Overall Study|Noncompliance|0
6067171|NCT00531011|9669368|FG000|Overall Study|Withdrawal by Subject|2
6067172|NCT00531011|9669369|FG001|Overall Study|Withdrawal by Subject|4
6067173|NCT00531011|9669368|FG000|Overall Study|Death|1
6067174|NCT00531011|9669369|FG001|Overall Study|Death|0
6067175|NCT00531011|9669368|FG000|Overall Study|Lost to Follow-up|1
6067176|NCT00531011|9669369|FG001|Overall Study|Lost to Follow-up|0
6067177|NCT00531011|9669368|FG000|Overall Study|Physician Decision|0
6067178|NCT00531011|9669369|FG001|Overall Study|Physician Decision|3
6067179|NCT00531050|9669381|FG000|Part 1: Period 1|Adverse Event|0
6067180|NCT00531050|9669382|FG001|Part 1: Period 1|Adverse Event|1
6067181|NCT00531050|9669383|FG002|Part 1: Period 1|Adverse Event|0
6067182|NCT00531050|9669384|FG003|Part 1: Period 1|Adverse Event|0
6067183|NCT00531050|9669385|FG004|Part 1: Period 1|Adverse Event|0
6067184|NCT00531050|9669386|FG005|Part 1: Period 1|Adverse Event|0
6067185|NCT00531050|9669381|FG000|Part 1: Period 1|Protocol Deviation|0
6067186|NCT00531050|9669382|FG001|Part 1: Period 1|Protocol Deviation|0
6067187|NCT00531050|9669383|FG002|Part 1: Period 1|Protocol Deviation|0
6067188|NCT00531050|9669384|FG003|Part 1: Period 1|Protocol Deviation|1
6067189|NCT00531050|9669385|FG004|Part 1: Period 1|Protocol Deviation|0
6067190|NCT00531050|9669386|FG005|Part 1: Period 1|Protocol Deviation|0
6067191|NCT00531050|9669381|FG000|Part 1: Period 3|Adverse Event|1
6067192|NCT00531050|9669382|FG001|Part 1: Period 3|Adverse Event|0
6067193|NCT00531050|9669383|FG002|Part 1: Period 3|Adverse Event|0
6067194|NCT00531050|9669384|FG003|Part 1: Period 3|Adverse Event|0
6067195|NCT00531050|9669385|FG004|Part 1: Period 3|Adverse Event|0
6067196|NCT00531050|9669386|FG005|Part 1: Period 3|Adverse Event|0
6067197|NCT00531050|9669381|FG000|Part 2: Period 1|Adverse Event|0
6067198|NCT00531050|9669382|FG001|Part 2: Period 1|Adverse Event|0
6067199|NCT00531050|9669383|FG002|Part 2: Period 1|Adverse Event|0
6067200|NCT00531050|9669384|FG003|Part 2: Period 1|Adverse Event|0
6067201|NCT00531050|9669385|FG004|Part 2: Period 1|Adverse Event|0
6067202|NCT00531050|9669386|FG005|Part 2: Period 1|Adverse Event|1
6067203|NCT00531050|9669381|FG000|Part 2: Period 3|Abnormal test procedure|1
6067204|NCT00531050|9669382|FG001|Part 2: Period 3|Abnormal test procedure|0
5991890|NCT02487108|9583942|FG001|Overall Study|Protocol Violation|1
5991891|NCT02487108|9583943|FG002|Overall Study|Protocol Violation|2
5991892|NCT02487108|9583944|FG003|Overall Study|Protocol Violation|0
5991893|NCT02487108|9583941|FG000|Overall Study|Non-compliance to study procedures|0
5991894|NCT02487108|9583942|FG001|Overall Study|Non-compliance to study procedures|0
5991895|NCT02487108|9583943|FG002|Overall Study|Non-compliance to study procedures|0
6067205|NCT00531050|9669383|FG002|Part 2: Period 3|Abnormal test procedure|0
6067206|NCT00531050|9669384|FG003|Part 2: Period 3|Abnormal test procedure|0
6067207|NCT00531050|9669385|FG004|Part 2: Period 3|Abnormal test procedure|0
6067208|NCT00531050|9669386|FG005|Part 2: Period 3|Abnormal test procedure|1
6067209|NCT00531206|9669403|FG000|Overall Study|Adverse Event related|5
6067210|NCT00531206|9669403|FG000|Overall Study|Lack of Efficacy|2
6067211|NCT00531206|9669403|FG000|Overall Study|Lost to Follow-up|5
6067212|NCT00531206|9669403|FG000|Overall Study|including non-related adverse events|8
6067213|NCT00531284|9669424|FG000|Overall Study|Progressive Disease|1
6067214|NCT00531284|9669425|FG001|Overall Study|Progressive Disease|3
6067215|NCT00531284|9669426|FG002|Overall Study|Progressive Disease|5
6067216|NCT00531284|9669427|FG003|Overall Study|Progressive Disease|42
6067217|NCT00531284|9669428|FG004|Overall Study|Progressive Disease|4
6067218|NCT00531284|9669429|FG005|Overall Study|Progressive Disease|4
6067219|NCT00531284|9669430|FG006|Overall Study|Progressive Disease|3
6067220|NCT00531284|9669431|FG007|Overall Study|Progressive Disease|8
6067221|NCT00531284|9669432|FG008|Overall Study|Progressive Disease|6
6067222|NCT00531284|9669433|FG009|Overall Study|Progressive Disease|3
6067223|NCT00531284|9669434|FG010|Overall Study|Progressive Disease|3
6067224|NCT00531284|9669435|FG011|Overall Study|Progressive Disease|14
6067225|NCT00531284|9669436|FG012|Overall Study|Progressive Disease|2
6067226|NCT00531284|9669437|FG013|Overall Study|Progressive Disease|1
6067227|NCT00531284|9669438|FG014|Overall Study|Progressive Disease|2
6067228|NCT00531284|9669439|FG015|Overall Study|Progressive Disease|11
6067229|NCT00531284|9669440|FG016|Overall Study|Progressive Disease|5
6067230|NCT00531284|9669424|FG000|Overall Study|Adverse Event|0
6067231|NCT00531284|9669425|FG001|Overall Study|Adverse Event|1
6067232|NCT00531284|9669426|FG002|Overall Study|Adverse Event|1
6067233|NCT00531284|9669427|FG003|Overall Study|Adverse Event|7
6067234|NCT00531284|9669428|FG004|Overall Study|Adverse Event|0
6067235|NCT00531284|9669429|FG005|Overall Study|Adverse Event|2
6067236|NCT00531284|9669430|FG006|Overall Study|Adverse Event|3
6067237|NCT00531284|9669431|FG007|Overall Study|Adverse Event|2
6067238|NCT00531284|9669432|FG008|Overall Study|Adverse Event|3
6067239|NCT00531284|9669433|FG009|Overall Study|Adverse Event|0
6067240|NCT00531284|9669434|FG010|Overall Study|Adverse Event|0
6067241|NCT00531284|9669435|FG011|Overall Study|Adverse Event|5
6067242|NCT00531284|9669436|FG012|Overall Study|Adverse Event|0
6067243|NCT00531284|9669437|FG013|Overall Study|Adverse Event|1
6067244|NCT00531284|9669438|FG014|Overall Study|Adverse Event|1
6067245|NCT00531284|9669439|FG015|Overall Study|Adverse Event|0
6067246|NCT00531284|9669440|FG016|Overall Study|Adverse Event|2
6067247|NCT00531284|9669424|FG000|Overall Study|Withdrawal by Subject|1
6067248|NCT00531284|9669425|FG001|Overall Study|Withdrawal by Subject|0
6067249|NCT00531284|9669426|FG002|Overall Study|Withdrawal by Subject|0
6067250|NCT00531284|9669427|FG003|Overall Study|Withdrawal by Subject|4
6067251|NCT00531284|9669428|FG004|Overall Study|Withdrawal by Subject|0
6067252|NCT00531284|9669429|FG005|Overall Study|Withdrawal by Subject|0
6067253|NCT00531284|9669430|FG006|Overall Study|Withdrawal by Subject|0
6067254|NCT00531284|9669431|FG007|Overall Study|Withdrawal by Subject|0
6067255|NCT00531284|9669432|FG008|Overall Study|Withdrawal by Subject|0
6067256|NCT00531284|9669433|FG009|Overall Study|Withdrawal by Subject|0
6067257|NCT00531284|9669434|FG010|Overall Study|Withdrawal by Subject|0
6067258|NCT00531284|9669435|FG011|Overall Study|Withdrawal by Subject|3
6067259|NCT00531284|9669436|FG012|Overall Study|Withdrawal by Subject|0
6067260|NCT00531284|9669437|FG013|Overall Study|Withdrawal by Subject|1
6067261|NCT00531284|9669438|FG014|Overall Study|Withdrawal by Subject|0
5991896|NCT02487108|9583944|FG003|Overall Study|Non-compliance to study procedures|1
5991897|NCT02487108|9583941|FG000|Overall Study|Other than specified|3
5991898|NCT02487108|9583942|FG001|Overall Study|Other than specified|2
5991899|NCT02487108|9583943|FG002|Overall Study|Other than specified|2
6067262|NCT00531284|9669439|FG015|Overall Study|Withdrawal by Subject|1
6067263|NCT00531284|9669440|FG016|Overall Study|Withdrawal by Subject|1
6067264|NCT00531284|9669424|FG000|Overall Study|Other|1
6067265|NCT00531284|9669425|FG001|Overall Study|Other|0
6067266|NCT00531284|9669426|FG002|Overall Study|Other|0
6067267|NCT00531284|9669427|FG003|Overall Study|Other|10
6067268|NCT00531284|9669428|FG004|Overall Study|Other|2
5991900|NCT02487108|9583944|FG003|Overall Study|Other than specified|0
6067269|NCT00531284|9669429|FG005|Overall Study|Other|1
6067270|NCT00531284|9669430|FG006|Overall Study|Other|0
5991901|NCT02455557|9583954|FG000|Overall Study|Withdrawal by Subject|2
5991902|NCT02435849|9583958|FG000|Overall Study|Enrolled but not infused|18
5991903|NCT02435849|9583958|FG000|Overall Study|Death|16
5991904|NCT02435849|9583958|FG000|Overall Study|Lack of Efficacy|9
5991905|NCT02435849|9583958|FG000|Overall Study|New therapy for study indication|7
5991906|NCT02435849|9583958|FG000|Overall Study|Subject/guardian decision|2
5991907|NCT02435849|9583958|FG000|Overall Study|Study follow-up ongoing|45
6045812|NCT00403767|9645108|FG000|Overall Study|Protocol Violation|142
6045813|NCT00403767|9645109|FG001|Overall Study|Protocol Violation|124
6045814|NCT00403767|9645108|FG000|Overall Study|Clinical efficacy endpoint reached|300
6067271|NCT00531284|9669431|FG007|Overall Study|Other|0
6045815|NCT00403767|9645109|FG001|Overall Study|Clinical efficacy endpoint reached|332
6045816|NCT00403767|9645108|FG000|Overall Study|Study terminated by sponsor|82
6045817|NCT00403767|9645109|FG001|Overall Study|Study terminated by sponsor|69
6045818|NCT00403767|9645108|FG000|Overall Study|Missing/incomplete data|1
6045819|NCT00403767|9645109|FG001|Overall Study|Missing/incomplete data|1
6045820|NCT00403845|9645115|FG000|Treatment Period 1|Subject withdrew consent|1
6045821|NCT00403845|9645116|FG001|Treatment Period 1|Subject withdrew consent|0
6045822|NCT00403845|9645117|FG002|Treatment Period 1|Subject withdrew consent|0
6045823|NCT00403845|9645118|FG003|Treatment Period 1|Subject withdrew consent|0
6045824|NCT00403845|9645115|FG000|Treatment Period 1|Subject no longer needs study drug|0
6045825|NCT00403845|9645116|FG001|Treatment Period 1|Subject no longer needs study drug|0
6045826|NCT00403845|9645117|FG002|Treatment Period 1|Subject no longer needs study drug|0
6045827|NCT00403845|9645118|FG003|Treatment Period 1|Subject no longer needs study drug|1
6045828|NCT00403845|9645115|FG000|Treatment Period 2|Subject withdrew consent|1
6045829|NCT00403845|9645116|FG001|Treatment Period 2|Subject withdrew consent|0
6045830|NCT00403845|9645117|FG002|Treatment Period 2|Subject withdrew consent|0
6045831|NCT00403845|9645118|FG003|Treatment Period 2|Subject withdrew consent|0
6045832|NCT00403845|9645115|FG000|Treatment Period 3|Subject withdrew consent|0
6045833|NCT00403845|9645116|FG001|Treatment Period 3|Subject withdrew consent|0
6045834|NCT00403845|9645117|FG002|Treatment Period 3|Subject withdrew consent|0
6045835|NCT00403845|9645118|FG003|Treatment Period 3|Subject withdrew consent|1
6045836|NCT00403845|9645115|FG000|Treatment Period 3|Adverse Event|0
6045837|NCT00403845|9645116|FG001|Treatment Period 3|Adverse Event|0
6045838|NCT00403845|9645117|FG002|Treatment Period 3|Adverse Event|0
6045839|NCT00403845|9645118|FG003|Treatment Period 3|Adverse Event|1
6045840|NCT00404066|9645128|FG000|Overall Study|Withdrawal by Subject - Pre-treatment|1
6045841|NCT00404066|9645128|FG000|Overall Study|Withdrawal by Subject - Adverse event|2
6045842|NCT00404079|9645134|FG000|Overall Study|Lost to follow up, adverse event etc|22
6045843|NCT00404079|9645135|FG001|Overall Study|Lost to follow up, adverse event etc|20
6045844|NCT00404092|9645145|FG000|Overall Study|Death|1
6045845|NCT00404092|9645146|FG001|Overall Study|Death|0
6045846|NCT00404092|9645147|FG002|Overall Study|Death|0
6045847|NCT00404092|9645148|FG003|Overall Study|Death|0
6045848|NCT00404092|9645145|FG000|Overall Study|Adverse Event|0
6045849|NCT00404092|9645146|FG001|Overall Study|Adverse Event|0
6045850|NCT00404092|9645147|FG002|Overall Study|Adverse Event|1
6045851|NCT00404092|9645148|FG003|Overall Study|Adverse Event|0
6049089|NCT00421148|9648262|FG013|Overall Study|Protocol Violation|0
6049090|NCT00421148|9648263|FG014|Overall Study|Protocol Violation|0
6049091|NCT00421148|9648264|FG015|Overall Study|Protocol Violation|0
6049092|NCT00421148|9648265|FG016|Overall Study|Protocol Violation|0
6049093|NCT00421148|9648266|FG017|Overall Study|Protocol Violation|0
6049094|NCT00421148|9648267|FG018|Overall Study|Protocol Violation|1
6049095|NCT00421148|9648268|FG019|Overall Study|Protocol Violation|0
6049096|NCT00421174|9648312|FG000|Overall Study|Withdrawal by Subject|0
6049097|NCT00421174|9648313|FG001|Overall Study|Withdrawal by Subject|1
6049098|NCT00421174|9648312|FG000|Overall Study|Ineligible due to infection|2
6049099|NCT00421174|9648313|FG001|Overall Study|Ineligible due to infection|0
6049100|NCT00421304|9648322|FG000|Overall Study|Lost to Follow-up|5
6049101|NCT00421304|9648323|FG001|Overall Study|Lost to Follow-up|2
6049102|NCT00421304|9648324|FG002|Overall Study|Lost to Follow-up|5
6049103|NCT00421304|9648322|FG000|Overall Study|Withdrawal by Subject|2
6049104|NCT00421304|9648323|FG001|Overall Study|Withdrawal by Subject|2
6049105|NCT00421304|9648324|FG002|Overall Study|Withdrawal by Subject|2
6067272|NCT00531284|9669432|FG008|Overall Study|Other|2
6067273|NCT00531284|9669433|FG009|Overall Study|Other|1
6067274|NCT00531284|9669434|FG010|Overall Study|Other|0
6067275|NCT00531284|9669435|FG011|Overall Study|Other|2
6067276|NCT00531284|9669436|FG012|Overall Study|Other|0
6067277|NCT00531284|9669437|FG013|Overall Study|Other|0
6067278|NCT00531284|9669438|FG014|Overall Study|Other|1
6067279|NCT00531284|9669439|FG015|Overall Study|Other|0
6067280|NCT00531284|9669440|FG016|Overall Study|Other|0
6067281|NCT00531427|9669498|FG000|Overall Study|Withdrawal by Subject|7
6067282|NCT00531427|9669499|FG001|Overall Study|Withdrawal by Subject|13
6067283|NCT00531427|9669498|FG000|Overall Study|Adverse Event|44
6067284|NCT00531427|9669499|FG001|Overall Study|Adverse Event|30
6067285|NCT00531427|9669498|FG000|Overall Study|Lost to Follow-up|4
6067286|NCT00531427|9669499|FG001|Overall Study|Lost to Follow-up|3
6067287|NCT00531427|9669498|FG000|Overall Study|Lack of Efficacy|14
6067288|NCT00531427|9669499|FG001|Overall Study|Lack of Efficacy|39
6067289|NCT00531427|9669498|FG000|Overall Study|Administrative|4
6067290|NCT00531427|9669499|FG001|Overall Study|Administrative|9
6067291|NCT00531479|9669517|FG000|Overall Study|Death|68
6067292|NCT00531479|9669518|FG001|Overall Study|Death|71
6067293|NCT00531479|9669517|FG000|Overall Study|Lost to Follow-up|0
6067294|NCT00531479|9669518|FG001|Overall Study|Lost to Follow-up|2
6067295|NCT00531479|9669517|FG000|Overall Study|Other|0
6067296|NCT00531479|9669518|FG001|Overall Study|Other|1
6067297|NCT00531479|9669517|FG000|Overall Study|Withdrawal by Subject|6
6067298|NCT00531479|9669518|FG001|Overall Study|Withdrawal by Subject|6
6067299|NCT00531479|9669517|FG000|Overall Study|Did not receive treatment|2
6067300|NCT00531479|9669518|FG001|Overall Study|Did not receive treatment|3
6067301|NCT00531752|9669549|FG000|First Double-blind Intervention Period|Adverse Event|2
6067302|NCT00531752|9669550|FG001|First Double-blind Intervention Period|Adverse Event|0
6067303|NCT00531752|9669551|FG002|First Double-blind Intervention Period|Adverse Event|1
6067304|NCT00531752|9669552|FG003|First Double-blind Intervention Period|Adverse Event|1
6067305|NCT00531752|9669549|FG000|First Double-blind Intervention Period|Other|1
6067306|NCT00531752|9669550|FG001|First Double-blind Intervention Period|Other|4
6067307|NCT00531752|9669551|FG002|First Double-blind Intervention Period|Other|4
6067308|NCT00531752|9669552|FG003|First Double-blind Intervention Period|Other|0
6067309|NCT00531752|9669549|FG000|First Double-blind Intervention Period|Withdrawal by Subject|2
6067310|NCT00531752|9669550|FG001|First Double-blind Intervention Period|Withdrawal by Subject|0
6067311|NCT00531752|9669551|FG002|First Double-blind Intervention Period|Withdrawal by Subject|1
6067312|NCT00531752|9669552|FG003|First Double-blind Intervention Period|Withdrawal by Subject|1
6067313|NCT00531752|9669549|FG000|First Double-blind Intervention Period|Lost to Follow-up|0
6067314|NCT00531752|9669550|FG001|First Double-blind Intervention Period|Lost to Follow-up|0
6067315|NCT00531752|9669551|FG002|First Double-blind Intervention Period|Lost to Follow-up|1
6067316|NCT00531752|9669552|FG003|First Double-blind Intervention Period|Lost to Follow-up|1
6067317|NCT00531752|9669549|FG000|First Double-blind Intervention Period|Randomized but not treated|1
6067318|NCT00531752|9669550|FG001|First Double-blind Intervention Period|Randomized but not treated|0
6067319|NCT00531752|9669551|FG002|First Double-blind Intervention Period|Randomized but not treated|0
6067320|NCT00531752|9669552|FG003|First Double-blind Intervention Period|Randomized but not treated|0
6067321|NCT00531752|9669549|FG000|Second Double-blind Intervention Period|Adverse Event|1
6067322|NCT00531752|9669550|FG001|Second Double-blind Intervention Period|Adverse Event|1
6067323|NCT00531752|9669551|FG002|Second Double-blind Intervention Period|Adverse Event|0
6067324|NCT00531752|9669552|FG003|Second Double-blind Intervention Period|Adverse Event|0
6067325|NCT00531752|9669549|FG000|Second Double-blind Intervention Period|Other|1
6067326|NCT00531752|9669550|FG001|Second Double-blind Intervention Period|Other|1
6067327|NCT00531752|9669551|FG002|Second Double-blind Intervention Period|Other|0
6067328|NCT00531752|9669552|FG003|Second Double-blind Intervention Period|Other|0
6067329|NCT00531752|9669549|FG000|Second Double-blind Intervention Period|Withdrawal by Subject|0
6067330|NCT00531752|9669550|FG001|Second Double-blind Intervention Period|Withdrawal by Subject|0
6067331|NCT00531752|9669551|FG002|Second Double-blind Intervention Period|Withdrawal by Subject|0
6067332|NCT00531752|9669552|FG003|Second Double-blind Intervention Period|Withdrawal by Subject|1
6067333|NCT00531752|9669549|FG000|Second Double-blind Intervention Period|Lost to Follow-up|0
6067334|NCT00531752|9669550|FG001|Second Double-blind Intervention Period|Lost to Follow-up|0
6067335|NCT00531752|9669551|FG002|Second Double-blind Intervention Period|Lost to Follow-up|0
6067336|NCT00531752|9669552|FG003|Second Double-blind Intervention Period|Lost to Follow-up|1
6067337|NCT00531934|9669594|FG000|Overall Study|Adverse Event|4
6067338|NCT00531934|9669595|FG001|Overall Study|Adverse Event|8
6067339|NCT00531934|9669594|FG000|Overall Study|Progression|52
6067340|NCT00531934|9669595|FG001|Overall Study|Progression|42
6067341|NCT00531934|9669594|FG000|Overall Study|Death|7
6067342|NCT00531934|9669595|FG001|Overall Study|Death|10
6067343|NCT00531934|9669594|FG000|Overall Study|Withdrawal by Subject|1
6067344|NCT00531934|9669595|FG001|Overall Study|Withdrawal by Subject|1
6067345|NCT00531934|9669594|FG000|Overall Study|Other|2
6067346|NCT00531934|9669595|FG001|Overall Study|Other|2
6067347|NCT00531947|9669603|FG000|Overall Study|Adverse Event|5
6067348|NCT00531947|9669604|FG001|Overall Study|Adverse Event|10
6067349|NCT00531947|9669603|FG000|Overall Study|Lost to Follow-up|12
6067350|NCT00531947|9669604|FG001|Overall Study|Lost to Follow-up|9
6067351|NCT00531947|9669603|FG000|Overall Study|Withdrawal by Subject|14
6067352|NCT00531947|9669604|FG001|Overall Study|Withdrawal by Subject|19
6067353|NCT00531947|9669603|FG000|Overall Study|Protocol Violation|2
6067354|NCT00531947|9669604|FG001|Overall Study|Protocol Violation|1
6067355|NCT00531947|9669603|FG000|Overall Study|Non-Compliance|4
6067356|NCT00531947|9669604|FG001|Overall Study|Non-Compliance|7
6067357|NCT00531947|9669603|FG000|Overall Study|Other (e.g., Lack of Efficacy)|5
6067358|NCT00531947|9669604|FG001|Overall Study|Other (e.g., Lack of Efficacy)|5
6067359|NCT00531960|9669612|FG000|Overall Study|Adverse Event|5
6067360|NCT00531960|9669613|FG001|Overall Study|Adverse Event|4
6067361|NCT00531960|9669612|FG000|Overall Study|Death|3
6067362|NCT00531960|9669613|FG001|Overall Study|Death|2
6067363|NCT00531960|9669612|FG000|Overall Study|Lack of Efficacy|42
6067364|NCT00531960|9669613|FG001|Overall Study|Lack of Efficacy|41
5991908|NCT02387996|9583971|FG000|Overall Study|Disease Progression|144
5991909|NCT02387996|9583971|FG000|Overall Study|Study Drug Toxicity|14
5991910|NCT02387996|9583971|FG000|Overall Study|Adverse Event Unrelated to Study Drug|34
5991911|NCT02387996|9583971|FG000|Overall Study|Subject Request to Discontinue Treatment|9
5991912|NCT02387996|9583971|FG000|Overall Study|Subject Withdrew Consent|1
5991913|NCT02387996|9583971|FG000|Overall Study|Lost to Follow-up|1
5991914|NCT02387996|9583971|FG000|Overall Study|Poor/Non-Compliance|1
5991915|NCT02351856|9583988|FG000|Overall Study|Adverse Event|2
5991916|NCT02351856|9583988|FG000|Overall Study|Physician Decision|5
5991917|NCT02351856|9583988|FG000|Overall Study|Study terminated by sponsor|1
5991918|NCT02349386|9583996|FG000|24-Week Double-Blind Main Study|Adverse Event|0
5991919|NCT02349386|9583997|FG001|24-Week Double-Blind Main Study|Adverse Event|0
5991920|NCT02349386|9583998|FG002|24-Week Double-Blind Main Study|Adverse Event|1
5991921|NCT02349386|9583999|FG003|24-Week Double-Blind Main Study|Adverse Event|1
5991922|NCT02349386|9583996|FG000|24-Week Double-Blind Main Study|Lack of Efficacy|6
5991923|NCT02349386|9583997|FG001|24-Week Double-Blind Main Study|Lack of Efficacy|6
5991924|NCT02349386|9583998|FG002|24-Week Double-Blind Main Study|Lack of Efficacy|2
5991925|NCT02349386|9583999|FG003|24-Week Double-Blind Main Study|Lack of Efficacy|7
5991926|NCT02349386|9583996|FG000|24-Week Double-Blind Main Study|Withdrawal by Subject|0
5991927|NCT02349386|9583997|FG001|24-Week Double-Blind Main Study|Withdrawal by Subject|0
5991928|NCT02349386|9583998|FG002|24-Week Double-Blind Main Study|Withdrawal by Subject|1
5991929|NCT02349386|9583999|FG003|24-Week Double-Blind Main Study|Withdrawal by Subject|0
5991930|NCT02349386|9583996|FG000|24-Week Double-Blind Main Study|Patient underwent transurethral resection of prostate (exclusionary procedure)|0
5991931|NCT02349386|9583997|FG001|24-Week Double-Blind Main Study|Patient underwent transurethral resection of prostate (exclusionary procedure)|0
5991932|NCT02349386|9583998|FG002|24-Week Double-Blind Main Study|Patient underwent transurethral resection of prostate (exclusionary procedure)|1
6067365|NCT00531960|9669612|FG000|Overall Study|Violation of Selection Criteria|2
6067366|NCT00531960|9669613|FG001|Overall Study|Violation of Selection Criteria|0
5991933|NCT02349386|9583999|FG003|24-Week Double-Blind Main Study|Patient underwent transurethral resection of prostate (exclusionary procedure)|0
5991934|NCT02349386|9583996|FG000|28-Week Double-Blind Optional Extension|Lack of Efficacy|2
5991935|NCT02349386|9583997|FG001|28-Week Double-Blind Optional Extension|Lack of Efficacy|0
5991936|NCT02349386|9583998|FG002|28-Week Double-Blind Optional Extension|Lack of Efficacy|2
5991937|NCT02349386|9583999|FG003|28-Week Double-Blind Optional Extension|Lack of Efficacy|0
5991938|NCT02349386|9583996|FG000|28-Week Double-Blind Optional Extension|Withdrawal by Subject|0
5991939|NCT02349386|9583997|FG001|28-Week Double-Blind Optional Extension|Withdrawal by Subject|0
5991940|NCT02349386|9583998|FG002|28-Week Double-Blind Optional Extension|Withdrawal by Subject|1
5991941|NCT02349386|9583999|FG003|28-Week Double-Blind Optional Extension|Withdrawal by Subject|0
5991942|NCT02328014|9584013|FG000|Overall Study|Adverse Event|1
5991943|NCT02328014|9584014|FG001|Overall Study|Adverse Event|0
5991944|NCT02328014|9584015|FG002|Overall Study|Adverse Event|0
5991945|NCT02328014|9584016|FG003|Overall Study|Adverse Event|1
5991946|NCT02328014|9584013|FG000|Overall Study|Death|0
5991947|NCT02328014|9584014|FG001|Overall Study|Death|0
5991948|NCT02328014|9584015|FG002|Overall Study|Death|0
5991949|NCT02328014|9584016|FG003|Overall Study|Death|4
5991950|NCT02328014|9584013|FG000|Overall Study|Physician Decision|0
5991951|NCT02328014|9584014|FG001|Overall Study|Physician Decision|0
5991952|NCT02328014|9584015|FG002|Overall Study|Physician Decision|0
5991953|NCT02328014|9584016|FG003|Overall Study|Physician Decision|1
5991954|NCT02328014|9584013|FG000|Overall Study|Disease Progression|1
5991955|NCT02328014|9584014|FG001|Overall Study|Disease Progression|0
5991956|NCT02328014|9584015|FG002|Overall Study|Disease Progression|1
6067367|NCT00531960|9669612|FG000|Overall Study|Refused Treatment|5
6067368|NCT00531960|9669613|FG001|Overall Study|Refused Treatment|6
6067369|NCT00531960|9669612|FG000|Overall Study|Other|4
6067370|NCT00531960|9669613|FG001|Overall Study|Other|10
6067371|NCT00532129|9669619|FG000|Treatment Period|Adverse event/Serious adverse event|25
6067372|NCT00532129|9669619|FG000|Treatment Period|Physician Decision|15
6067373|NCT00532129|9669619|FG000|Treatment Period|Disease progression|3
6067374|NCT00532129|9669619|FG000|Treatment Period|Protocol Violation|1
6067375|NCT00532129|9669619|FG000|Treatment Period|Other|5
6067376|NCT00532129|9669619|FG000|Follow-up Period|Adverse event/Serious adverse event|1
6067377|NCT00532129|9669619|FG000|Follow-up Period|Disease progression|57
6067378|NCT00532129|9669619|FG000|Follow-up Period|Lost to Follow-up|1
6067379|NCT00532129|9669619|FG000|Follow-up Period|Other|6
6067380|NCT00532155|9669625|FG000|Overall Study|Adverse Event|66
6067381|NCT00532155|9669626|FG001|Overall Study|Adverse Event|123
6067382|NCT00532155|9669625|FG000|Overall Study|Lack of Efficacy|332
6067383|NCT00532155|9669626|FG001|Overall Study|Lack of Efficacy|255
6067384|NCT00532155|9669625|FG000|Overall Study|Protocol Violation|1
6067385|NCT00532155|9669626|FG001|Overall Study|Protocol Violation|3
6067386|NCT00532155|9669625|FG000|Overall Study|Lost to Follow-up|2
6067387|NCT00532155|9669626|FG001|Overall Study|Lost to Follow-up|0
6067388|NCT00532155|9669625|FG000|Overall Study|Physician Decision|16
6067389|NCT00532155|9669626|FG001|Overall Study|Physician Decision|15
6067390|NCT00532155|9669625|FG000|Overall Study|Withdrawal by Subject|23
6067391|NCT00532155|9669626|FG001|Overall Study|Withdrawal by Subject|44
6067392|NCT00532155|9669625|FG000|Overall Study|Consent withdrawn|5
6067393|NCT00532155|9669626|FG001|Overall Study|Consent withdrawn|7
6067394|NCT00532155|9669625|FG000|Overall Study|Moved|1
6067395|NCT00532155|9669626|FG001|Overall Study|Moved|0
6067396|NCT00532155|9669625|FG000|Overall Study|Pre-existing brain metastasis (by MRI)|1
6067397|NCT00532155|9669626|FG001|Overall Study|Pre-existing brain metastasis (by MRI)|0
6067398|NCT00532155|9669625|FG000|Overall Study|Occurence of a second cancer|0
6067399|NCT00532155|9669626|FG001|Overall Study|Occurence of a second cancer|1
6067400|NCT00532155|9669625|FG000|Overall Study|Occurence of a secondary cancer|0
6067401|NCT00532155|9669626|FG001|Overall Study|Occurence of a secondary cancer|1
6067402|NCT00532155|9669625|FG000|Overall Study|Promotor ended study|1
6067403|NCT00532155|9669626|FG001|Overall Study|Promotor ended study|0
6309333|NCT02637557|10037871|FG001|Overall Study|Protocol Violation|0
6309334|NCT02637557|10037872|FG002|Overall Study|Protocol Violation|2
6309335|NCT02637557|10037873|FG003|Overall Study|Protocol Violation|1
6309336|NCT02637557|10037870|FG000|Overall Study|Withdrawal by Subject|1
6309337|NCT02637557|10037871|FG001|Overall Study|Withdrawal by Subject|3
6309338|NCT02637557|10037872|FG002|Overall Study|Withdrawal by Subject|4
5991957|NCT02328014|9584016|FG003|Overall Study|Disease Progression|3
5991958|NCT02328014|9584013|FG000|Overall Study|Study Terminated by Sponsor|4
5991959|NCT02328014|9584014|FG001|Overall Study|Study Terminated by Sponsor|1
5991960|NCT02328014|9584015|FG002|Overall Study|Study Terminated by Sponsor|1
5991961|NCT02328014|9584016|FG003|Overall Study|Study Terminated by Sponsor|0
5991962|NCT02328014|9584013|FG000|Overall Study|Subject Started Another Cancer Therapy|0
5991963|NCT02328014|9584014|FG001|Overall Study|Subject Started Another Cancer Therapy|5
5991964|NCT02328014|9584015|FG002|Overall Study|Subject Started Another Cancer Therapy|4
5991965|NCT02328014|9584016|FG003|Overall Study|Subject Started Another Cancer Therapy|12
5991966|NCT02328014|9584013|FG000|Overall Study|Withdrawal by Subject|0
6309339|NCT02637557|10037873|FG003|Overall Study|Withdrawal by Subject|2
6067404|NCT00532155|9669625|FG000|Overall Study|Progressive disease (by incorrect scan)|0
6087150|NCT00666757|9697327|FG001|Overall Study|Sponsor decision|1
5991967|NCT02328014|9584014|FG001|Overall Study|Withdrawal by Subject|0
5991968|NCT02328014|9584015|FG002|Overall Study|Withdrawal by Subject|0
5991969|NCT02328014|9584016|FG003|Overall Study|Withdrawal by Subject|1
5991970|NCT02108652|9584039|FG000|Overall Study|Death|226
5991971|NCT02108652|9584039|FG000|Overall Study|Lost to Follow-up|2
6309340|NCT02637856|10037905|FG000|Main Study (Baseline to Week 100)|Adverse Event|9
6309341|NCT02637856|10037906|FG001|Main Study (Baseline to Week 100)|Adverse Event|0
6309342|NCT02637856|10037905|FG000|Main Study (Baseline to Week 100)|Lost to Follow-up|5
6309343|NCT02637856|10037906|FG001|Main Study (Baseline to Week 100)|Lost to Follow-up|0
5991972|NCT02108652|9584039|FG000|Overall Study|Withdrawal by Subject|8
5991973|NCT02108652|9584039|FG000|Overall Study|Ongoing at data cutoff 04 July 2016|74
5991974|NCT01904032|9584054|FG000|Overall Study|Adverse Event|3
5991975|NCT01904032|9584055|FG001|Overall Study|Adverse Event|1
5991976|NCT01904032|9584054|FG000|Overall Study|Lost to Follow-up|4
5991977|NCT01904032|9584055|FG001|Overall Study|Lost to Follow-up|2
5991978|NCT01772472|9584072|FG000|Overall Study|Death|56
6309344|NCT02637856|10037905|FG000|Main Study (Baseline to Week 100)|Physician Decision|2
6067405|NCT00532155|9669626|FG001|Overall Study|Progressive disease (by incorrect scan)|1
6067406|NCT00532155|9669625|FG000|Overall Study|Had brain metastasis, was mis-randomized|1
6067407|NCT00532155|9669626|FG001|Overall Study|Had brain metastasis, was mis-randomized|0
6067408|NCT00532155|9669625|FG000|Overall Study|Study stopped|1
5991979|NCT01772472|9584073|FG001|Overall Study|Death|42
5991980|NCT01772472|9584072|FG000|Overall Study|Physician Decision|1
5991981|NCT01772472|9584073|FG001|Overall Study|Physician Decision|3
5991982|NCT01772472|9584072|FG000|Overall Study|Other|5
5991983|NCT01772472|9584073|FG001|Overall Study|Other|5
5991984|NCT01772472|9584072|FG000|Overall Study|Lost to Follow-up|12
5991985|NCT01772472|9584073|FG001|Overall Study|Lost to Follow-up|8
5991986|NCT01772472|9584072|FG000|Overall Study|Withdrawal by Subject|72
5991987|NCT01772472|9584073|FG001|Overall Study|Withdrawal by Subject|50
5991988|NCT01772472|9584072|FG000|Overall Study|Ongoing|597
5991989|NCT01772472|9584073|FG001|Overall Study|Ongoing|635
6067409|NCT00532155|9669626|FG001|Overall Study|Study stopped|0
5991990|NCT01632878|9584090|FG000|Screening|Physician Decision|268
6067410|NCT00532155|9669625|FG000|Overall Study|Study terminated by sponsor|1
6067411|NCT00532155|9669626|FG001|Overall Study|Study terminated by sponsor|0
6067412|NCT00532155|9669625|FG000|Overall Study|Study termination stop further treatment|4
6067413|NCT00532155|9669626|FG001|Overall Study|Study termination stop further treatment|0
6067414|NCT00532155|9669625|FG000|Overall Study|Did not receive study medication|2
6067415|NCT00532155|9669626|FG001|Overall Study|Did not receive study medication|6
6067416|NCT00532259|9669632|FG000|Overall Study|Withdrawal by Subject|2
6067417|NCT00532259|9669632|FG000|Overall Study|Adverse Event|1
6067418|NCT00532259|9669632|FG000|Overall Study|Death|1
6067419|NCT00532259|9669632|FG000|Overall Study|Lack of Efficacy|21
6067420|NCT00532259|9669632|FG000|Overall Study|Lost to Follow-up|3
6067421|NCT00532259|9669632|FG000|Overall Study|Physician Decision|3
6067422|NCT00532259|9669632|FG000|Overall Study|Protocol Violation|1
6067423|NCT00532298|9669643|FG000|Overall Study|Adverse Event|1
6067424|NCT00532298|9669644|FG001|Overall Study|Adverse Event|0
6067425|NCT00532298|9669645|FG002|Overall Study|Adverse Event|0
6067426|NCT00532298|9669646|FG003|Overall Study|Adverse Event|0
6067427|NCT00532298|9669647|FG004|Overall Study|Adverse Event|1
5991991|NCT01632878|9584090|FG000|Treatment|Lost to Follow-up|41
5991992|NCT01632878|9584090|FG000|Treatment|Withdrawal by Subject|36
5991993|NCT01632878|9584090|FG000|Treatment|Physician Decision|34
5991994|NCT01632878|9584090|FG000|Treatment|missing information|4
5991995|NCT01632878|9584090|FG000|Treatment|no information on study completion|43
5991996|NCT01097005|9584098|FG000|Overall Study|Case Report Form not collected|18
5991997|NCT01097005|9584098|FG000|Overall Study|Subjects cannot visit the hospital|1
5991998|NCT01097005|9584098|FG000|Overall Study|Poor medication compliance|1
5991999|NCT01097005|9584098|FG000|Overall Study|No examination data available|244
5992000|NCT01097005|9584098|FG000|Overall Study|Deviation from exclusion criteria|37
5992001|NCT01097005|9584098|FG000|Overall Study|Adverse Event|14
5992002|NCT01097005|9584098|FG000|Overall Study|Discontinuance by complication|50
5992003|NCT00931255|9584110|FG000|Overall Study|Follow up biopsy not done|2
5992004|NCT00931255|9584111|FG001|Overall Study|Follow up biopsy not done|3
6045852|NCT00404235|9645160|FG000|Overall Study|Withdrawal by Subject|1
6045853|NCT00404235|9645161|FG001|Overall Study|Withdrawal by Subject|2
6045854|NCT00404248|9645170|FG000|Overall Study|pts declining status|0
6045855|NCT00404248|9645171|FG001|Overall Study|pts declining status|1
6045856|NCT00404248|9645172|FG002|Overall Study|pts declining status|0
6045857|NCT00404248|9645173|FG003|Overall Study|pts declining status|0
6045858|NCT00404248|9645174|FG004|Overall Study|pts declining status|0
6067428|NCT00532298|9669648|FG005|Overall Study|Adverse Event|1
6067429|NCT00532298|9669643|FG000|Overall Study|Lost to Follow-up|1
6067430|NCT00532298|9669644|FG001|Overall Study|Lost to Follow-up|1
6067431|NCT00532298|9669645|FG002|Overall Study|Lost to Follow-up|1
6067432|NCT00532298|9669646|FG003|Overall Study|Lost to Follow-up|0
6067433|NCT00532298|9669647|FG004|Overall Study|Lost to Follow-up|0
6067434|NCT00532298|9669648|FG005|Overall Study|Lost to Follow-up|1
6067435|NCT00532441|9669662|FG000|Overall Study|Death|1
6067436|NCT00532441|9669663|FG001|Overall Study|Death|0
5992005|NCT04537078|9584157|FG000|Overall Study|Protocol Violation|3
5992006|NCT04537078|9584158|FG001|Overall Study|Protocol Violation|2
5992007|NCT04537078|9584157|FG000|Overall Study|Lost to Follow-up|1
5992008|NCT04537078|9584158|FG001|Overall Study|Lost to Follow-up|0
5992009|NCT04537078|9584157|FG000|Overall Study|Withdrawal by Subject|0
5992010|NCT04537078|9584158|FG001|Overall Study|Withdrawal by Subject|1
5992011|NCT04425252|9584173|FG000|Overall Study|Withdrawal by Subject|2
5992012|NCT04425252|9584174|FG001|Overall Study|Withdrawal by Subject|1
5992013|NCT04425252|9584173|FG000|Overall Study|Lost to Follow-up|1
5992014|NCT04425252|9584174|FG001|Overall Study|Lost to Follow-up|0
5992015|NCT04425252|9584173|FG000|Overall Study|Subject did not return due to COVID-19 restrictions.|1
5992016|NCT04425252|9584174|FG001|Overall Study|Subject did not return due to COVID-19 restrictions.|1
5992017|NCT03875313|9584203|FG000|Overall Study|Withdrawal by Subject|1
5992018|NCT03875313|9584204|FG001|Overall Study|Withdrawal by Subject|3
5992019|NCT03875313|9584205|FG002|Overall Study|Withdrawal by Subject|0
5992020|NCT03875313|9584206|FG003|Overall Study|Withdrawal by Subject|0
5992021|NCT03875313|9584207|FG004|Overall Study|Withdrawal by Subject|0
5992022|NCT03875313|9584203|FG000|Overall Study|Death|0
5992023|NCT03875313|9584204|FG001|Overall Study|Death|0
5992024|NCT03875313|9584205|FG002|Overall Study|Death|0
5992025|NCT03875313|9584206|FG003|Overall Study|Death|0
5992026|NCT03875313|9584207|FG004|Overall Study|Death|1
5992027|NCT03875313|9584203|FG000|Overall Study|Lost to Follow-up|0
5992028|NCT03875313|9584204|FG001|Overall Study|Lost to Follow-up|0
5992029|NCT03875313|9584205|FG002|Overall Study|Lost to Follow-up|0
5992030|NCT03875313|9584206|FG003|Overall Study|Lost to Follow-up|0
5992031|NCT03875313|9584207|FG004|Overall Study|Lost to Follow-up|1
5992032|NCT03875313|9584203|FG000|Overall Study|Study Termination by Sponsor|0
5992033|NCT03875313|9584204|FG001|Overall Study|Study Termination by Sponsor|1
5992034|NCT03875313|9584205|FG002|Overall Study|Study Termination by Sponsor|1
5992035|NCT03875313|9584206|FG003|Overall Study|Study Termination by Sponsor|0
6067437|NCT00532493|9669678|FG000|Overall Study|Death|1
6067438|NCT00532493|9669679|FG001|Overall Study|Death|1
6067439|NCT00532493|9669678|FG000|Overall Study|Lost to Follow-up|10
6067440|NCT00532493|9669679|FG001|Overall Study|Lost to Follow-up|7
6067441|NCT00532493|9669678|FG000|Overall Study|Withdrawal by Subject|7
6067442|NCT00532493|9669679|FG001|Overall Study|Withdrawal by Subject|9
6067443|NCT00532493|9669678|FG000|Overall Study|Physician Decision|1
6067444|NCT00532493|9669679|FG001|Overall Study|Physician Decision|6
6067445|NCT00532493|9669678|FG000|Overall Study|Adverse Event|6
6067446|NCT00532493|9669679|FG001|Overall Study|Adverse Event|5
6067447|NCT00532493|9669678|FG000|Overall Study|Protocol Deviation|1
6067448|NCT00532493|9669679|FG001|Overall Study|Protocol Deviation|0
6067449|NCT00532493|9669678|FG000|Overall Study|Subject Moved Away|3
6067450|NCT00532493|9669679|FG001|Overall Study|Subject Moved Away|1
6067451|NCT00532493|9669678|FG000|Overall Study|Contraindicative Medication|1
6067452|NCT00532493|9669679|FG001|Overall Study|Contraindicative Medication|0
6067453|NCT00532779|9669690|FG000|Overall Study|Adverse Event|122
6067454|NCT00532779|9669691|FG001|Overall Study|Adverse Event|112
6067455|NCT00532779|9669692|FG002|Overall Study|Adverse Event|56
6067456|NCT00532779|9669690|FG000|Overall Study|Lost to Follow-up|76
6067457|NCT00532779|9669691|FG001|Overall Study|Lost to Follow-up|65
6067458|NCT00532779|9669692|FG002|Overall Study|Lost to Follow-up|66
6067459|NCT00532779|9669690|FG000|Overall Study|Withdrawal by Subject|63
6067460|NCT00532779|9669691|FG001|Overall Study|Withdrawal by Subject|60
6067461|NCT00532779|9669692|FG002|Overall Study|Withdrawal by Subject|90
6067462|NCT00532779|9669690|FG000|Overall Study|Lack of Efficacy|12
6067463|NCT00532779|9669691|FG001|Overall Study|Lack of Efficacy|12
6067464|NCT00532779|9669692|FG002|Overall Study|Lack of Efficacy|40
6067465|NCT00532779|9669690|FG000|Overall Study|Protocol Violation|5
6067466|NCT00532779|9669691|FG001|Overall Study|Protocol Violation|9
6067467|NCT00532779|9669692|FG002|Overall Study|Protocol Violation|7
6067468|NCT00532779|9669690|FG000|Overall Study|Pregnancy|2
6067469|NCT00532779|9669691|FG001|Overall Study|Pregnancy|5
6067470|NCT00532779|9669692|FG002|Overall Study|Pregnancy|3
6067471|NCT00532779|9669690|FG000|Overall Study|Death|0
6067472|NCT00532779|9669691|FG001|Overall Study|Death|1
6067473|NCT00532779|9669692|FG002|Overall Study|Death|0
6067474|NCT00532779|9669690|FG000|Overall Study|Drug noncompliance, moved, other|14
6067475|NCT00532779|9669691|FG001|Overall Study|Drug noncompliance, moved, other|23
6067476|NCT00532779|9669692|FG002|Overall Study|Drug noncompliance, moved, other|29
6067477|NCT00532844|9669702|FG000|Treatment Period - Day 1 to Day 14|Withdrawal of consent|0
6067478|NCT00532844|9669703|FG001|Treatment Period - Day 1 to Day 14|Withdrawal of consent|1
6067479|NCT00532844|9669702|FG000|Treatment Period - Day 15 to Day 28|Pregnancy|1
6067480|NCT00532844|9669703|FG001|Treatment Period - Day 15 to Day 28|Pregnancy|0
6067481|NCT00532844|9669702|FG000|Treatment Period - Day 15 to Day 28|Personal reasons|1
6067482|NCT00532844|9669703|FG001|Treatment Period - Day 15 to Day 28|Personal reasons|0
6067483|NCT00532844|9669702|FG000|Treatment Period - Day 15 to Day 28|Adverse Event|1
6067484|NCT00532844|9669703|FG001|Treatment Period - Day 15 to Day 28|Adverse Event|0
6067485|NCT00532844|9669702|FG000|Treatment Period - Day 15 to Day 28|withdrawal of consent|1
6067486|NCT00532844|9669703|FG001|Treatment Period - Day 15 to Day 28|withdrawal of consent|0
6067487|NCT00532883|9669726|FG000|Overall Study|Adverse Event|1
6067488|NCT00532883|9669727|FG001|Overall Study|Adverse Event|0
6067489|NCT00532883|9669728|FG002|Overall Study|Adverse Event|0
6067490|NCT00532883|9669729|FG003|Overall Study|Adverse Event|1
6067491|NCT00532883|9669726|FG000|Overall Study|Lost to Follow-up|1
6067492|NCT00532883|9669727|FG001|Overall Study|Lost to Follow-up|1
6067493|NCT00532883|9669728|FG002|Overall Study|Lost to Follow-up|1
6067494|NCT00532883|9669729|FG003|Overall Study|Lost to Follow-up|0
6067495|NCT00532883|9669726|FG000|Overall Study|Withdrawal by Subject|0
6067496|NCT00532883|9669727|FG001|Overall Study|Withdrawal by Subject|1
6067497|NCT00532883|9669728|FG002|Overall Study|Withdrawal by Subject|1
6067498|NCT00532883|9669729|FG003|Overall Study|Withdrawal by Subject|0
6067499|NCT00532883|9669726|FG000|Overall Study|Subject was Nonadherent|0
6067500|NCT00532883|9669727|FG001|Overall Study|Subject was Nonadherent|1
6067501|NCT00532883|9669728|FG002|Overall Study|Subject was Nonadherent|1
6067502|NCT00532883|9669729|FG003|Overall Study|Subject was Nonadherent|0
6067503|NCT00532883|9669726|FG000|Overall Study|Early Study Termination|4
6067504|NCT00532883|9669727|FG001|Overall Study|Early Study Termination|4
6067505|NCT00532883|9669728|FG002|Overall Study|Early Study Termination|1
6067506|NCT00532883|9669729|FG003|Overall Study|Early Study Termination|4
5992036|NCT03875313|9584207|FG004|Overall Study|Study Termination by Sponsor|1
5992037|NCT03875313|9584203|FG000|Overall Study|New Anticancer Treatment|0
5992038|NCT03875313|9584204|FG001|Overall Study|New Anticancer Treatment|1
5992039|NCT03875313|9584205|FG002|Overall Study|New Anticancer Treatment|2
5992040|NCT03875313|9584206|FG003|Overall Study|New Anticancer Treatment|1
5992041|NCT03875313|9584207|FG004|Overall Study|New Anticancer Treatment|0
5992042|NCT03875313|9584203|FG000|Overall Study|Other, Not Specified|2
5992043|NCT03875313|9584204|FG001|Overall Study|Other, Not Specified|11
5992044|NCT03875313|9584205|FG002|Overall Study|Other, Not Specified|3
5992045|NCT03875313|9584206|FG003|Overall Study|Other, Not Specified|3
5992046|NCT03875313|9584207|FG004|Overall Study|Other, Not Specified|1
5992047|NCT03694353|9584219|FG000|Overall Study|Withdrawal by Subject|1
5992048|NCT03694353|9584219|FG000|Overall Study|Subject received <= 40 mg/day for > 32 weeks|1
5992049|NCT03583554|9584223|FG000|Period 2|Did not receive treatment due to loss of contact|1
5992050|NCT03583554|9584224|FG001|Period 2|Did not receive treatment due to loss of contact|0
5992051|NCT03583554|9584225|FG002|Period 2|Did not receive treatment due to loss of contact|1
5992052|NCT03408873|9584242|FG000|Visit 1 Assessment (Baseline)|Lost to Follow-up|3
5992053|NCT03408873|9584242|FG000|Visit 2 Assessment|Lost to Follow-up|1
5992054|NCT03408873|9584242|FG000|Visit 3 Assessment|Withdrawal by Subject|1
5992055|NCT03408873|9584242|FG000|Visit 4 Assessment|Lost to Follow-up|2
5992056|NCT03408873|9584242|FG000|Visit 5 Assessment|Lost to Follow-up|1
5992057|NCT03408873|9584242|FG000|Visit 6 Assessment|Withdrawal by Subject|1
5992058|NCT03132467|9584246|FG000|Overall Study|Adverse Event|2
5992059|NCT03132467|9584246|FG000|Overall Study|Withdrawal by Subject|2
6045859|NCT00404248|9645175|FG005|Overall Study|pts declining status|0
6045860|NCT00404248|9645176|FG006|Overall Study|pts declining status|0
6045861|NCT00404248|9645177|FG007|Overall Study|pts declining status|0
6045862|NCT00404248|9645178|FG008|Overall Study|pts declining status|0
6045863|NCT00404352|9645207|FG000|Double Blind (up to 24 Month)|Adverse Event|5
6045864|NCT00404352|9645208|FG001|Double Blind (up to 24 Month)|Adverse Event|4
6045865|NCT00404352|9645209|FG002|Double Blind (up to 24 Month)|Adverse Event|6
6045866|NCT00404352|9645210|FG003|Double Blind (up to 24 Month)|Adverse Event|0
6045867|NCT00404352|9645211|FG004|Double Blind (up to 24 Month)|Adverse Event|0
6045868|NCT00404352|9645212|FG005|Double Blind (up to 24 Month)|Adverse Event|0
6045869|NCT00404352|9645213|FG006|Double Blind (up to 24 Month)|Adverse Event|0
6045870|NCT00404352|9645214|FG007|Double Blind (up to 24 Month)|Adverse Event|0
6045871|NCT00404352|9645215|FG008|Double Blind (up to 24 Month)|Adverse Event|0
6045872|NCT00404352|9645207|FG000|Double Blind (up to 24 Month)|Pregnancy|0
6045873|NCT00404352|9645208|FG001|Double Blind (up to 24 Month)|Pregnancy|0
6045874|NCT00404352|9645209|FG002|Double Blind (up to 24 Month)|Pregnancy|2
6045875|NCT00404352|9645210|FG003|Double Blind (up to 24 Month)|Pregnancy|0
6045876|NCT00404352|9645211|FG004|Double Blind (up to 24 Month)|Pregnancy|0
6045877|NCT00404352|9645212|FG005|Double Blind (up to 24 Month)|Pregnancy|0
6045878|NCT00404352|9645213|FG006|Double Blind (up to 24 Month)|Pregnancy|0
6045879|NCT00404352|9645214|FG007|Double Blind (up to 24 Month)|Pregnancy|0
6045880|NCT00404352|9645215|FG008|Double Blind (up to 24 Month)|Pregnancy|0
6045881|NCT00404352|9645207|FG000|Double Blind (up to 24 Month)|Death|0
6045882|NCT00404352|9645208|FG001|Double Blind (up to 24 Month)|Death|0
6045883|NCT00404352|9645209|FG002|Double Blind (up to 24 Month)|Death|1
6045884|NCT00404352|9645210|FG003|Double Blind (up to 24 Month)|Death|0
6045885|NCT00404352|9645211|FG004|Double Blind (up to 24 Month)|Death|0
6045886|NCT00404352|9645212|FG005|Double Blind (up to 24 Month)|Death|0
6045887|NCT00404352|9645213|FG006|Double Blind (up to 24 Month)|Death|0
6045888|NCT00404352|9645214|FG007|Double Blind (up to 24 Month)|Death|0
6045889|NCT00404352|9645215|FG008|Double Blind (up to 24 Month)|Death|0
6045890|NCT00404352|9645207|FG000|Double Blind (up to 24 Month)|Lost to Follow-up|1
6045891|NCT00404352|9645208|FG001|Double Blind (up to 24 Month)|Lost to Follow-up|2
6045892|NCT00404352|9645209|FG002|Double Blind (up to 24 Month)|Lost to Follow-up|1
5992060|NCT03096288|9584255|FG000|Overall Study|Withdrawal by Subject|0
5992061|NCT03096288|9584256|FG001|Overall Study|Withdrawal by Subject|1
5992062|NCT03096288|9584257|FG002|Overall Study|Withdrawal by Subject|0
5992063|NCT03096288|9584258|FG003|Overall Study|Withdrawal by Subject|1
5992064|NCT02919436|9584270|FG000|Overall Study|Did not undergo surgery|16
5992065|NCT02919436|9584271|FG001|Overall Study|Did not undergo surgery|20
5992066|NCT02919436|9584270|FG000|Overall Study|Enrolled before trial registration|44
5992067|NCT02919436|9584271|FG001|Overall Study|Enrolled before trial registration|33
5992068|NCT02028884|9584285|FG000|Double-blind Period|Adverse Event|5
5992069|NCT02028884|9584286|FG001|Double-blind Period|Adverse Event|3
6067507|NCT00532935|9669741|FG000|Overall Study|Adverse Event|11
6067508|NCT00532935|9669742|FG001|Overall Study|Adverse Event|12
6067509|NCT00532935|9669741|FG000|Overall Study|Lack of Efficacy|0
6067510|NCT00532935|9669742|FG001|Overall Study|Lack of Efficacy|3
6067511|NCT00532935|9669741|FG000|Overall Study|Lost to Follow-up|10
6067512|NCT00532935|9669742|FG001|Overall Study|Lost to Follow-up|6
6067513|NCT00532935|9669741|FG000|Overall Study|Physician Decision|4
6067514|NCT00532935|9669742|FG001|Overall Study|Physician Decision|5
6067515|NCT00532935|9669741|FG000|Overall Study|Pregnancy|1
6067516|NCT00532935|9669742|FG001|Overall Study|Pregnancy|0
6067517|NCT00532935|9669741|FG000|Overall Study|Protocol Violation|4
6067518|NCT00532935|9669742|FG001|Overall Study|Protocol Violation|2
6067519|NCT00532935|9669741|FG000|Overall Study|Withdrawal by Subject|10
6067520|NCT00532935|9669742|FG001|Overall Study|Withdrawal by Subject|9
6067521|NCT00532935|9669741|FG000|Overall Study|Protocol Specific Criteria|11
6067522|NCT00532935|9669742|FG001|Overall Study|Protocol Specific Criteria|15
6067523|NCT00532948|9669751|FG000|Overall Study|Protocol Violation|1
6067524|NCT00532948|9669752|FG001|Overall Study|Protocol Violation|0
6067525|NCT00532948|9669753|FG002|Overall Study|Protocol Violation|0
6067526|NCT00532948|9669751|FG000|Overall Study|Death|3
6067527|NCT00532948|9669752|FG001|Overall Study|Death|3
6067528|NCT00532948|9669753|FG002|Overall Study|Death|4
6067529|NCT00532948|9669751|FG000|Overall Study|Violation of selection criteria at entry|0
6067530|NCT00532948|9669752|FG001|Overall Study|Violation of selection criteria at entry|1
6067531|NCT00532948|9669753|FG002|Overall Study|Violation of selection criteria at entry|0
6067532|NCT00532948|9669751|FG000|Overall Study|Failure to return|0
6067533|NCT00532948|9669752|FG001|Overall Study|Failure to return|1
6067534|NCT00532948|9669753|FG002|Overall Study|Failure to return|0
6067535|NCT00533273|9669784|FG000|Double-blind|Withdrew consent|0
5992070|NCT02028884|9584285|FG000|Double-blind Period|Eligibility Violation|1
5992071|NCT02028884|9584286|FG001|Double-blind Period|Eligibility Violation|0
6067536|NCT00533273|9669785|FG001|Double-blind|Withdrew consent|2
6067537|NCT00533273|9669784|FG000|Open-label|Withdrawal by Subject|6
6067538|NCT00533273|9669785|FG001|Open-label|Withdrawal by Subject|0
6067539|NCT00533429|9669793|FG000|Overall Study|Adverse Event|3
6067540|NCT00533429|9669794|FG001|Overall Study|Adverse Event|1
6067541|NCT00533429|9669793|FG000|Overall Study|Death|1
6067542|NCT00533429|9669794|FG001|Overall Study|Death|0
6067543|NCT00533429|9669793|FG000|Overall Study|Withdrawal by Subject|2
6067544|NCT00533429|9669794|FG001|Overall Study|Withdrawal by Subject|0
6067545|NCT00533429|9669793|FG000|Overall Study|Progressive Disease|12
6067546|NCT00533429|9669794|FG001|Overall Study|Progressive Disease|13
6067547|NCT00533429|9669793|FG000|Overall Study|Symptomatic deterioration|1
6067548|NCT00533429|9669794|FG001|Overall Study|Symptomatic deterioration|2
6067549|NCT00533507|9669813|FG000|Overall Study|Withdrawal by Subject|1
6067550|NCT00533702|9669824|FG000|Overall Study|Withdrawal by Subject|3
6067551|NCT00533702|9669825|FG001|Overall Study|Withdrawal by Subject|1
6067552|NCT00533702|9669824|FG000|Overall Study|Found ineligible after randomization|2
6067553|NCT00533702|9669825|FG001|Overall Study|Found ineligible after randomization|1
5992072|NCT02028884|9584285|FG000|Double-blind Period|Non-Compliance With Study Drug|2
5992073|NCT02028884|9584286|FG001|Double-blind Period|Non-Compliance With Study Drug|0
5992074|NCT02028884|9584285|FG000|Double-blind Period|Withdrawal by Subject|2
5992075|NCT02028884|9584286|FG001|Double-blind Period|Withdrawal by Subject|0
5992076|NCT02028884|9584285|FG000|Double-blind Period|On-going in Study|8
5992077|NCT02028884|9584286|FG001|Double-blind Period|On-going in Study|20
5992078|NCT02028884|9584285|FG000|Open-label Extension Period|Adverse Event|2
5992079|NCT02028884|9584286|FG001|Open-label Extension Period|Adverse Event|1
5992080|NCT02028884|9584285|FG000|Open-label Extension Period|Lack of Efficacy|3
5992081|NCT02028884|9584286|FG001|Open-label Extension Period|Lack of Efficacy|0
5992082|NCT02028884|9584285|FG000|Open-label Extension Period|Non-Compliance With Study Drug|0
5992083|NCT02028884|9584286|FG001|Open-label Extension Period|Non-Compliance With Study Drug|1
5992084|NCT02028884|9584285|FG000|Open-label Extension Period|Withdrawal by Subject|0
6067554|NCT00533845|9669833|FG000|Overall Study|Physician Decision|1
6067555|NCT00533845|9669834|FG001|Overall Study|Physician Decision|0
6067556|NCT00533897|9669843|FG000|Lead-in (LI) Period 1|Adverse Event|1
6067557|NCT00533897|9669844|FG001|Lead-in (LI) Period 1|Adverse Event|0
6067558|NCT00533897|9669845|FG002|Lead-in (LI) Period 1|Adverse Event|0
6067559|NCT00533897|9669846|FG003|Lead-in (LI) Period 1|Adverse Event|0
6067560|NCT00533897|9669847|FG004|Lead-in (LI) Period 1|Adverse Event|0
6067561|NCT00533897|9669848|FG005|Lead-in (LI) Period 1|Adverse Event|0
6067562|NCT00533897|9669849|FG006|Lead-in (LI) Period 1|Adverse Event|0
6067563|NCT00533897|9669850|FG007|Lead-in (LI) Period 1|Adverse Event|0
6067564|NCT00533897|9669843|FG000|Lead-in (LI) Period 1|Participant Withdrew Consent|2
6067565|NCT00533897|9669844|FG001|Lead-in (LI) Period 1|Participant Withdrew Consent|0
6067566|NCT00533897|9669845|FG002|Lead-in (LI) Period 1|Participant Withdrew Consent|0
6067567|NCT00533897|9669846|FG003|Lead-in (LI) Period 1|Participant Withdrew Consent|0
6067568|NCT00533897|9669847|FG004|Lead-in (LI) Period 1|Participant Withdrew Consent|0
6067569|NCT00533897|9669848|FG005|Lead-in (LI) Period 1|Participant Withdrew Consent|0
6067570|NCT00533897|9669849|FG006|Lead-in (LI) Period 1|Participant Withdrew Consent|0
6067571|NCT00533897|9669850|FG007|Lead-in (LI) Period 1|Participant Withdrew Consent|0
6067572|NCT00533897|9669843|FG000|Lead-in (LI) Period 1|Lost to Follow-up|1
6067573|NCT00533897|9669844|FG001|Lead-in (LI) Period 1|Lost to Follow-up|0
6067574|NCT00533897|9669845|FG002|Lead-in (LI) Period 1|Lost to Follow-up|0
6067575|NCT00533897|9669846|FG003|Lead-in (LI) Period 1|Lost to Follow-up|0
6067576|NCT00533897|9669847|FG004|Lead-in (LI) Period 1|Lost to Follow-up|0
5992085|NCT02028884|9584286|FG001|Open-label Extension Period|Withdrawal by Subject|2
5992086|NCT02028884|9584285|FG000|Open-label Extension Period|On-going in Study|19
5992087|NCT02028884|9584286|FG001|Open-label Extension Period|On-going in Study|14
5992088|NCT01983774|9584297|FG000|Overall Study|Lung Transplant|0
5992089|NCT01983774|9584298|FG001|Overall Study|Lung Transplant|1
5992090|NCT01983774|9584297|FG000|Overall Study|Lost to Follow-up|1
6067577|NCT00533897|9669848|FG005|Lead-in (LI) Period 1|Lost to Follow-up|0
6067578|NCT00533897|9669849|FG006|Lead-in (LI) Period 1|Lost to Follow-up|0
6067579|NCT00533897|9669850|FG007|Lead-in (LI) Period 1|Lost to Follow-up|0
6067580|NCT00533897|9669843|FG000|Lead-in (LI) Period 1|Administrative Reason By Sponsor|2
6067581|NCT00533897|9669844|FG001|Lead-in (LI) Period 1|Administrative Reason By Sponsor|0
5992091|NCT01983774|9584298|FG001|Overall Study|Lost to Follow-up|0
5992092|NCT01974206|9584308|FG000|Overall Study|Did Not Take Study Drug|0
5992093|NCT01974206|9584309|FG001|Overall Study|Did Not Take Study Drug|1
5992094|NCT01974206|9584308|FG000|Overall Study|Physician Decision|1
5992095|NCT01974206|9584309|FG001|Overall Study|Physician Decision|0
5992096|NCT01974206|9584308|FG000|Overall Study|Withdrawal by Subject|3
5992097|NCT01974206|9584309|FG001|Overall Study|Withdrawal by Subject|0
5992098|NCT01974206|9584308|FG000|Overall Study|Lost to Follow-up|1
5992099|NCT01974206|9584309|FG001|Overall Study|Lost to Follow-up|0
5992100|NCT01974206|9584308|FG000|Overall Study|Death|1
5992101|NCT01974206|9584309|FG001|Overall Study|Death|0
5992102|NCT01970865|9584332|FG000|Overall Study|Death|3
5992103|NCT01970865|9584333|FG001|Overall Study|Death|1
5992104|NCT01970865|9584334|FG002|Overall Study|Death|3
5992105|NCT01970865|9584335|FG003|Overall Study|Death|4
5992106|NCT01970865|9584336|FG004|Overall Study|Death|6
5992107|NCT01970865|9584337|FG005|Overall Study|Death|3
5992108|NCT01970865|9584338|FG006|Overall Study|Death|1
5992109|NCT01970865|9584339|FG007|Overall Study|Death|3
5992110|NCT01970865|9584340|FG008|Overall Study|Death|2
5992111|NCT01970865|9584341|FG009|Overall Study|Death|1
5992112|NCT01970865|9584342|FG010|Overall Study|Death|1
6067582|NCT00533897|9669845|FG002|Lead-in (LI) Period 1|Administrative Reason By Sponsor|0
5992113|NCT01970865|9584343|FG011|Overall Study|Death|4
5992114|NCT01970865|9584344|FG012|Overall Study|Death|14
5992115|NCT01970865|9584345|FG013|Overall Study|Death|19
5992116|NCT01970865|9584346|FG014|Overall Study|Death|15
5992117|NCT01970865|9584347|FG015|Overall Study|Death|10
5992118|NCT01970865|9584348|FG016|Overall Study|Death|1
5992119|NCT01970865|9584332|FG000|Overall Study|Lost to Follow-up|0
5992120|NCT01970865|9584333|FG001|Overall Study|Lost to Follow-up|0
5992121|NCT01970865|9584334|FG002|Overall Study|Lost to Follow-up|0
5992122|NCT01970865|9584335|FG003|Overall Study|Lost to Follow-up|1
5992123|NCT01970865|9584336|FG004|Overall Study|Lost to Follow-up|1
5992124|NCT01970865|9584337|FG005|Overall Study|Lost to Follow-up|0
5992125|NCT01970865|9584338|FG006|Overall Study|Lost to Follow-up|0
5992126|NCT01970865|9584339|FG007|Overall Study|Lost to Follow-up|0
5992127|NCT01970865|9584340|FG008|Overall Study|Lost to Follow-up|0
5992128|NCT01970865|9584341|FG009|Overall Study|Lost to Follow-up|0
6067583|NCT00533897|9669846|FG003|Lead-in (LI) Period 1|Administrative Reason By Sponsor|0
6067584|NCT00533897|9669847|FG004|Lead-in (LI) Period 1|Administrative Reason By Sponsor|0
6067585|NCT00533897|9669848|FG005|Lead-in (LI) Period 1|Administrative Reason By Sponsor|0
6067586|NCT00533897|9669849|FG006|Lead-in (LI) Period 1|Administrative Reason By Sponsor|0
6067587|NCT00533897|9669850|FG007|Lead-in (LI) Period 1|Administrative Reason By Sponsor|0
6067588|NCT00533897|9669843|FG000|Lead-in (LI) Period 1|Lack of Efficacy|3
6067589|NCT00533897|9669844|FG001|Lead-in (LI) Period 1|Lack of Efficacy|0
6067590|NCT00533897|9669845|FG002|Lead-in (LI) Period 1|Lack of Efficacy|0
6067591|NCT00533897|9669846|FG003|Lead-in (LI) Period 1|Lack of Efficacy|0
6067592|NCT00533897|9669847|FG004|Lead-in (LI) Period 1|Lack of Efficacy|0
6067593|NCT00533897|9669848|FG005|Lead-in (LI) Period 1|Lack of Efficacy|0
6067594|NCT00533897|9669849|FG006|Lead-in (LI) Period 1|Lack of Efficacy|0
6067595|NCT00533897|9669850|FG007|Lead-in (LI) Period 1|Lack of Efficacy|0
6067596|NCT00533897|9669843|FG000|Lead-in (LI) Period 1|Missed 2 Consecutive Doses of Study Drug|1
6067597|NCT00533897|9669844|FG001|Lead-in (LI) Period 1|Missed 2 Consecutive Doses of Study Drug|0
6067598|NCT00533897|9669845|FG002|Lead-in (LI) Period 1|Missed 2 Consecutive Doses of Study Drug|0
6067599|NCT00533897|9669846|FG003|Lead-in (LI) Period 1|Missed 2 Consecutive Doses of Study Drug|0
6067600|NCT00533897|9669847|FG004|Lead-in (LI) Period 1|Missed 2 Consecutive Doses of Study Drug|0
6067601|NCT00533897|9669848|FG005|Lead-in (LI) Period 1|Missed 2 Consecutive Doses of Study Drug|0
6067602|NCT00533897|9669849|FG006|Lead-in (LI) Period 1|Missed 2 Consecutive Doses of Study Drug|0
6067603|NCT00533897|9669850|FG007|Lead-in (LI) Period 1|Missed 2 Consecutive Doses of Study Drug|0
6067604|NCT00533897|9669843|FG000|Double-blind Withdrawal (DBW) Period 2|Lack of Efficacy|0
6067605|NCT00533897|9669844|FG001|Double-blind Withdrawal (DBW) Period 2|Lack of Efficacy|1
6067606|NCT00533897|9669845|FG002|Double-blind Withdrawal (DBW) Period 2|Lack of Efficacy|2
6067607|NCT00533897|9669846|FG003|Double-blind Withdrawal (DBW) Period 2|Lack of Efficacy|0
6067608|NCT00533897|9669847|FG004|Double-blind Withdrawal (DBW) Period 2|Lack of Efficacy|0
6067609|NCT00533897|9669848|FG005|Double-blind Withdrawal (DBW) Period 2|Lack of Efficacy|0
6067610|NCT00533897|9669849|FG006|Double-blind Withdrawal (DBW) Period 2|Lack of Efficacy|0
6067611|NCT00533897|9669850|FG007|Double-blind Withdrawal (DBW) Period 2|Lack of Efficacy|0
6067612|NCT00533897|9669843|FG000|Double-blind Withdrawal (DBW) Period 2|Poor/Non-Compliance|0
6067613|NCT00533897|9669844|FG001|Double-blind Withdrawal (DBW) Period 2|Poor/Non-Compliance|0
6067614|NCT00533897|9669845|FG002|Double-blind Withdrawal (DBW) Period 2|Poor/Non-Compliance|1
6067615|NCT00533897|9669846|FG003|Double-blind Withdrawal (DBW) Period 2|Poor/Non-Compliance|0
6067616|NCT00533897|9669847|FG004|Double-blind Withdrawal (DBW) Period 2|Poor/Non-Compliance|0
6067617|NCT00533897|9669848|FG005|Double-blind Withdrawal (DBW) Period 2|Poor/Non-Compliance|0
6067618|NCT00533897|9669849|FG006|Double-blind Withdrawal (DBW) Period 2|Poor/Non-Compliance|0
6087151|NCT00666835|9697338|FG000|Overall Study|Withdrawal by Subject|5
5992129|NCT01970865|9584342|FG010|Overall Study|Lost to Follow-up|0
5992130|NCT01970865|9584343|FG011|Overall Study|Lost to Follow-up|0
5992131|NCT01970865|9584344|FG012|Overall Study|Lost to Follow-up|1
5992132|NCT01970865|9584345|FG013|Overall Study|Lost to Follow-up|0
5992133|NCT01970865|9584346|FG014|Overall Study|Lost to Follow-up|0
5992134|NCT01970865|9584347|FG015|Overall Study|Lost to Follow-up|0
5992135|NCT01970865|9584348|FG016|Overall Study|Lost to Follow-up|0
5992136|NCT01970865|9584332|FG000|Overall Study|Withdrawal by Subject|0
5992137|NCT01970865|9584333|FG001|Overall Study|Withdrawal by Subject|0
5992138|NCT01970865|9584334|FG002|Overall Study|Withdrawal by Subject|0
5992139|NCT01970865|9584335|FG003|Overall Study|Withdrawal by Subject|1
5992140|NCT01970865|9584336|FG004|Overall Study|Withdrawal by Subject|2
5992141|NCT01970865|9584337|FG005|Overall Study|Withdrawal by Subject|0
5992142|NCT01970865|9584338|FG006|Overall Study|Withdrawal by Subject|0
5992143|NCT01970865|9584339|FG007|Overall Study|Withdrawal by Subject|0
5992144|NCT01970865|9584340|FG008|Overall Study|Withdrawal by Subject|0
5992145|NCT01970865|9584341|FG009|Overall Study|Withdrawal by Subject|0
5992146|NCT01970865|9584342|FG010|Overall Study|Withdrawal by Subject|0
5992147|NCT01970865|9584343|FG011|Overall Study|Withdrawal by Subject|1
5992148|NCT01970865|9584344|FG012|Overall Study|Withdrawal by Subject|2
5992149|NCT01970865|9584345|FG013|Overall Study|Withdrawal by Subject|5
5992150|NCT01970865|9584346|FG014|Overall Study|Withdrawal by Subject|2
5992151|NCT01970865|9584347|FG015|Overall Study|Withdrawal by Subject|7
5992152|NCT01970865|9584348|FG016|Overall Study|Withdrawal by Subject|0
5992153|NCT01970865|9584332|FG000|Overall Study|Other|0
5992154|NCT01970865|9584333|FG001|Overall Study|Other|0
6067619|NCT00533897|9669850|FG007|Double-blind Withdrawal (DBW) Period 2|Poor/Non-Compliance|0
6067620|NCT00533897|9669843|FG000|Re-introduction (RI) Period 3|Participant Withdrew Consent|0
6067621|NCT00533897|9669844|FG001|Re-introduction (RI) Period 3|Participant Withdrew Consent|0
6067622|NCT00533897|9669845|FG002|Re-introduction (RI) Period 3|Participant Withdrew Consent|0
6067623|NCT00533897|9669846|FG003|Re-introduction (RI) Period 3|Participant Withdrew Consent|0
6067624|NCT00533897|9669847|FG004|Re-introduction (RI) Period 3|Participant Withdrew Consent|0
6067625|NCT00533897|9669848|FG005|Re-introduction (RI) Period 3|Participant Withdrew Consent|1
6067626|NCT00533897|9669849|FG006|Re-introduction (RI) Period 3|Participant Withdrew Consent|0
6067627|NCT00533897|9669850|FG007|Re-introduction (RI) Period 3|Participant Withdrew Consent|0
6067628|NCT00533897|9669843|FG000|Re-introduction (RI) Period 3|No Longer Meets Study Criteria|0
6067629|NCT00533897|9669844|FG001|Re-introduction (RI) Period 3|No Longer Meets Study Criteria|0
6067630|NCT00533897|9669845|FG002|Re-introduction (RI) Period 3|No Longer Meets Study Criteria|0
6067631|NCT00533897|9669846|FG003|Re-introduction (RI) Period 3|No Longer Meets Study Criteria|0
6067632|NCT00533897|9669847|FG004|Re-introduction (RI) Period 3|No Longer Meets Study Criteria|0
6067633|NCT00533897|9669848|FG005|Re-introduction (RI) Period 3|No Longer Meets Study Criteria|1
6067634|NCT00533897|9669849|FG006|Re-introduction (RI) Period 3|No Longer Meets Study Criteria|0
6067635|NCT00533897|9669850|FG007|Re-introduction (RI) Period 3|No Longer Meets Study Criteria|0
6067636|NCT00533897|9669843|FG000|Long Term Extension (LTE)|Participant Withdrew Consent|0
6067637|NCT00533897|9669844|FG001|Long Term Extension (LTE)|Participant Withdrew Consent|0
6067638|NCT00533897|9669845|FG002|Long Term Extension (LTE)|Participant Withdrew Consent|0
6067639|NCT00533897|9669846|FG003|Long Term Extension (LTE)|Participant Withdrew Consent|0
6067640|NCT00533897|9669847|FG004|Long Term Extension (LTE)|Participant Withdrew Consent|0
6067641|NCT00533897|9669848|FG005|Long Term Extension (LTE)|Participant Withdrew Consent|0
6067642|NCT00533897|9669849|FG006|Long Term Extension (LTE)|Participant Withdrew Consent|2
6067643|NCT00533897|9669850|FG007|Long Term Extension (LTE)|Participant Withdrew Consent|5
6067644|NCT00533897|9669843|FG000|Long Term Extension (LTE)|Death|0
6067645|NCT00533897|9669844|FG001|Long Term Extension (LTE)|Death|0
6067646|NCT00533897|9669845|FG002|Long Term Extension (LTE)|Death|0
6067647|NCT00533897|9669846|FG003|Long Term Extension (LTE)|Death|0
6067648|NCT00533897|9669847|FG004|Long Term Extension (LTE)|Death|0
6067649|NCT00533897|9669848|FG005|Long Term Extension (LTE)|Death|0
6067650|NCT00533897|9669849|FG006|Long Term Extension (LTE)|Death|1
6067651|NCT00533897|9669850|FG007|Long Term Extension (LTE)|Death|3
6067652|NCT00533897|9669843|FG000|Long Term Extension (LTE)|Lack of Efficacy|0
6067653|NCT00533897|9669844|FG001|Long Term Extension (LTE)|Lack of Efficacy|0
6067654|NCT00533897|9669845|FG002|Long Term Extension (LTE)|Lack of Efficacy|0
6067655|NCT00533897|9669846|FG003|Long Term Extension (LTE)|Lack of Efficacy|0
6067656|NCT00533897|9669847|FG004|Long Term Extension (LTE)|Lack of Efficacy|0
6067657|NCT00533897|9669848|FG005|Long Term Extension (LTE)|Lack of Efficacy|0
6067658|NCT00533897|9669849|FG006|Long Term Extension (LTE)|Lack of Efficacy|5
6067659|NCT00533897|9669850|FG007|Long Term Extension (LTE)|Lack of Efficacy|3
6067660|NCT00533897|9669843|FG000|Long Term Extension (LTE)|Poor/Non-compliance|0
6067661|NCT00533897|9669844|FG001|Long Term Extension (LTE)|Poor/Non-compliance|0
6067662|NCT00533897|9669845|FG002|Long Term Extension (LTE)|Poor/Non-compliance|0
6067663|NCT00533897|9669846|FG003|Long Term Extension (LTE)|Poor/Non-compliance|0
6067664|NCT00533897|9669847|FG004|Long Term Extension (LTE)|Poor/Non-compliance|0
6067665|NCT00533897|9669848|FG005|Long Term Extension (LTE)|Poor/Non-compliance|0
6067666|NCT00533897|9669849|FG006|Long Term Extension (LTE)|Poor/Non-compliance|1
6067667|NCT00533897|9669850|FG007|Long Term Extension (LTE)|Poor/Non-compliance|0
5992155|NCT01970865|9584334|FG002|Overall Study|Other|0
6067668|NCT00533897|9669843|FG000|Long Term Extension (LTE)|Adverse Event|0
6067669|NCT00533897|9669844|FG001|Long Term Extension (LTE)|Adverse Event|0
6067670|NCT00533897|9669845|FG002|Long Term Extension (LTE)|Adverse Event|0
6067671|NCT00533897|9669846|FG003|Long Term Extension (LTE)|Adverse Event|0
6067672|NCT00533897|9669847|FG004|Long Term Extension (LTE)|Adverse Event|0
6067673|NCT00533897|9669848|FG005|Long Term Extension (LTE)|Adverse Event|0
6067674|NCT00533897|9669849|FG006|Long Term Extension (LTE)|Adverse Event|2
6067675|NCT00533897|9669850|FG007|Long Term Extension (LTE)|Adverse Event|5
6067676|NCT00533897|9669843|FG000|Long Term Extension (LTE)|Pregnancy|0
6067677|NCT00533897|9669844|FG001|Long Term Extension (LTE)|Pregnancy|0
6067678|NCT00533897|9669845|FG002|Long Term Extension (LTE)|Pregnancy|0
6067679|NCT00533897|9669846|FG003|Long Term Extension (LTE)|Pregnancy|0
6067680|NCT00533897|9669847|FG004|Long Term Extension (LTE)|Pregnancy|0
6067681|NCT00533897|9669848|FG005|Long Term Extension (LTE)|Pregnancy|0
6067682|NCT00533897|9669849|FG006|Long Term Extension (LTE)|Pregnancy|0
6067683|NCT00533897|9669850|FG007|Long Term Extension (LTE)|Pregnancy|2
6067684|NCT00533897|9669843|FG000|Long Term Extension (LTE)|Lost to Follow-up|0
6067685|NCT00533897|9669844|FG001|Long Term Extension (LTE)|Lost to Follow-up|0
6067686|NCT00533897|9669845|FG002|Long Term Extension (LTE)|Lost to Follow-up|0
6067687|NCT00533897|9669846|FG003|Long Term Extension (LTE)|Lost to Follow-up|0
6067688|NCT00533897|9669847|FG004|Long Term Extension (LTE)|Lost to Follow-up|0
6067689|NCT00533897|9669848|FG005|Long Term Extension (LTE)|Lost to Follow-up|0
5992156|NCT01970865|9584335|FG003|Overall Study|Other|1
5992157|NCT01970865|9584336|FG004|Overall Study|Other|0
5992158|NCT01970865|9584337|FG005|Overall Study|Other|0
5992159|NCT01970865|9584338|FG006|Overall Study|Other|0
5992160|NCT01970865|9584339|FG007|Overall Study|Other|0
5992161|NCT01970865|9584340|FG008|Overall Study|Other|0
5992162|NCT01970865|9584341|FG009|Overall Study|Other|0
5992163|NCT01970865|9584342|FG010|Overall Study|Other|0
5992164|NCT01970865|9584343|FG011|Overall Study|Other|0
5992165|NCT01970865|9584344|FG012|Overall Study|Other|0
5992166|NCT01970865|9584345|FG013|Overall Study|Other|1
5992167|NCT01970865|9584346|FG014|Overall Study|Other|0
5992168|NCT01970865|9584347|FG015|Overall Study|Other|1
5992169|NCT01970865|9584348|FG016|Overall Study|Other|0
5992170|NCT01970865|9584332|FG000|Overall Study|Study ongoing|0
5992171|NCT01970865|9584333|FG001|Overall Study|Study ongoing|2
5992172|NCT01970865|9584334|FG002|Overall Study|Study ongoing|0
5992173|NCT01970865|9584335|FG003|Overall Study|Study ongoing|6
5992174|NCT01970865|9584336|FG004|Overall Study|Study ongoing|8
5992175|NCT01970865|9584337|FG005|Overall Study|Study ongoing|0
5992176|NCT01970865|9584338|FG006|Overall Study|Study ongoing|2
5992177|NCT01970865|9584339|FG007|Overall Study|Study ongoing|0
5992178|NCT01970865|9584340|FG008|Overall Study|Study ongoing|1
5992179|NCT01970865|9584341|FG009|Overall Study|Study ongoing|3
5992180|NCT01970865|9584342|FG010|Overall Study|Study ongoing|29
5992181|NCT01970865|9584343|FG011|Overall Study|Study ongoing|22
5992182|NCT01970865|9584344|FG012|Overall Study|Study ongoing|43
5992183|NCT01970865|9584345|FG013|Overall Study|Study ongoing|41
5992184|NCT01970865|9584346|FG014|Overall Study|Study ongoing|29
5992185|NCT01970865|9584347|FG015|Overall Study|Study ongoing|29
5992186|NCT01970865|9584348|FG016|Overall Study|Study ongoing|2
5992187|NCT00589420|9584409|FG000|Overall Study|screen failure|1
6045893|NCT00404352|9645210|FG003|Double Blind (up to 24 Month)|Lost to Follow-up|0
6045894|NCT00404352|9645211|FG004|Double Blind (up to 24 Month)|Lost to Follow-up|0
6045895|NCT00404352|9645212|FG005|Double Blind (up to 24 Month)|Lost to Follow-up|0
6045896|NCT00404352|9645213|FG006|Double Blind (up to 24 Month)|Lost to Follow-up|0
6045897|NCT00404352|9645214|FG007|Double Blind (up to 24 Month)|Lost to Follow-up|0
6045898|NCT00404352|9645215|FG008|Double Blind (up to 24 Month)|Lost to Follow-up|0
6045899|NCT00404352|9645207|FG000|Double Blind (up to 24 Month)|Withdrawal by Subject|11
6045900|NCT00404352|9645208|FG001|Double Blind (up to 24 Month)|Withdrawal by Subject|8
6045901|NCT00404352|9645209|FG002|Double Blind (up to 24 Month)|Withdrawal by Subject|7
6045902|NCT00404352|9645210|FG003|Double Blind (up to 24 Month)|Withdrawal by Subject|0
6045903|NCT00404352|9645211|FG004|Double Blind (up to 24 Month)|Withdrawal by Subject|0
6045904|NCT00404352|9645212|FG005|Double Blind (up to 24 Month)|Withdrawal by Subject|0
6045905|NCT00404352|9645213|FG006|Double Blind (up to 24 Month)|Withdrawal by Subject|0
6045906|NCT00404352|9645214|FG007|Double Blind (up to 24 Month)|Withdrawal by Subject|0
6045907|NCT00404352|9645215|FG008|Double Blind (up to 24 Month)|Withdrawal by Subject|0
6045908|NCT00404352|9645207|FG000|Double Blind (up to 24 Month)|Disease progression|3
6045909|NCT00404352|9645208|FG001|Double Blind (up to 24 Month)|Disease progression|0
6045910|NCT00404352|9645209|FG002|Double Blind (up to 24 Month)|Disease progression|2
6045911|NCT00404352|9645210|FG003|Double Blind (up to 24 Month)|Disease progression|0
6045912|NCT00404352|9645211|FG004|Double Blind (up to 24 Month)|Disease progression|0
6045913|NCT00404352|9645212|FG005|Double Blind (up to 24 Month)|Disease progression|0
6087152|NCT00666835|9697339|FG001|Overall Study|Withdrawal by Subject|2
5992188|NCT04993339|9584419|FG000|Overall Study|Lost to Follow-up|0
5992189|NCT04993339|9584420|FG001|Overall Study|Lost to Follow-up|1
5992190|NCT04993339|9584419|FG000|Overall Study|no MRI scan|3
5992191|NCT04993339|9584420|FG001|Overall Study|no MRI scan|1
5992192|NCT04919161|9584462|FG000|Overall Study|Early participant discharge from rehabilitation program after session 4|1
5992193|NCT04919161|9584463|FG001|Overall Study|Early participant discharge from rehabilitation program after session 4|0
5992194|NCT04919161|9584462|FG000|Overall Study|Flare-up of existing orthopedic condition after session 4|0
5992195|NCT04919161|9584463|FG001|Overall Study|Flare-up of existing orthopedic condition after session 4|1
5992196|NCT04919161|9584462|FG000|Overall Study|Acute ankle sprain after session 1|0
5992197|NCT04919161|9584463|FG001|Overall Study|Acute ankle sprain after session 1|1
5992198|NCT04883541|9584554|FG000|Overall Study|Not attending regular yoga class|16
5992199|NCT04883541|9584555|FG001|Overall Study|Not attending regular yoga class|0
5992200|NCT04883541|9584554|FG000|Overall Study|Not attending the pregnancy school|0
5992201|NCT04883541|9584555|FG001|Overall Study|Not attending the pregnancy school|9
5992202|NCT04357782|9584571|FG000|Overall Study|Discharged from hospital|1
5992203|NCT04357782|9584572|FG001|Overall Study|Discharged from hospital|0
5992204|NCT04357782|9584571|FG000|Overall Study|Death|0
5992205|NCT04357782|9584572|FG001|Overall Study|Death|2
6045914|NCT00404352|9645213|FG006|Double Blind (up to 24 Month)|Disease progression|0
6045915|NCT00404352|9645214|FG007|Double Blind (up to 24 Month)|Disease progression|0
6045916|NCT00404352|9645215|FG008|Double Blind (up to 24 Month)|Disease progression|0
6045917|NCT00404352|9645207|FG000|Double Blind (up to 24 Month)|Poor compliance|1
6045918|NCT00404352|9645208|FG001|Double Blind (up to 24 Month)|Poor compliance|0
6045919|NCT00404352|9645209|FG002|Double Blind (up to 24 Month)|Poor compliance|0
6045920|NCT00404352|9645210|FG003|Double Blind (up to 24 Month)|Poor compliance|0
6045921|NCT00404352|9645211|FG004|Double Blind (up to 24 Month)|Poor compliance|0
6067690|NCT00533897|9669849|FG006|Long Term Extension (LTE)|Lost to Follow-up|1
6067691|NCT00533897|9669850|FG007|Long Term Extension (LTE)|Lost to Follow-up|1
6067692|NCT00533897|9669843|FG000|Long Term Extension (LTE)|Other|0
6067693|NCT00533897|9669844|FG001|Long Term Extension (LTE)|Other|0
6067694|NCT00533897|9669845|FG002|Long Term Extension (LTE)|Other|0
6067695|NCT00533897|9669846|FG003|Long Term Extension (LTE)|Other|0
6067696|NCT00533897|9669847|FG004|Long Term Extension (LTE)|Other|0
6067697|NCT00533897|9669848|FG005|Long Term Extension (LTE)|Other|0
6067698|NCT00533897|9669849|FG006|Long Term Extension (LTE)|Other|1
6067699|NCT00533897|9669850|FG007|Long Term Extension (LTE)|Other|6
6045922|NCT00404352|9645212|FG005|Double Blind (up to 24 Month)|Poor compliance|0
6045923|NCT00404352|9645213|FG006|Double Blind (up to 24 Month)|Poor compliance|0
6045924|NCT00404352|9645214|FG007|Double Blind (up to 24 Month)|Poor compliance|0
6045925|NCT00404352|9645215|FG008|Double Blind (up to 24 Month)|Poor compliance|0
6045926|NCT00404352|9645207|FG000|Double Blind (up to 24 Month)|Switched to open label phase|31
6045927|NCT00404352|9645208|FG001|Double Blind (up to 24 Month)|Switched to open label phase|30
6045928|NCT00404352|9645209|FG002|Double Blind (up to 24 Month)|Switched to open label phase|59
6045929|NCT00404352|9645210|FG003|Double Blind (up to 24 Month)|Switched to open label phase|0
6045930|NCT00404352|9645211|FG004|Double Blind (up to 24 Month)|Switched to open label phase|0
6045931|NCT00404352|9645212|FG005|Double Blind (up to 24 Month)|Switched to open label phase|0
6045932|NCT00404352|9645213|FG006|Double Blind (up to 24 Month)|Switched to open label phase|0
6045933|NCT00404352|9645214|FG007|Double Blind (up to 24 Month)|Switched to open label phase|0
6045934|NCT00404352|9645215|FG008|Double Blind (up to 24 Month)|Switched to open label phase|0
6045935|NCT00404352|9645207|FG000|Double Blind (up to 24 Month)|Randomized but not treated|0
6045936|NCT00404352|9645208|FG001|Double Blind (up to 24 Month)|Randomized but not treated|2
6045937|NCT00404352|9645209|FG002|Double Blind (up to 24 Month)|Randomized but not treated|0
6045938|NCT00404352|9645210|FG003|Double Blind (up to 24 Month)|Randomized but not treated|0
6045939|NCT00404352|9645211|FG004|Double Blind (up to 24 Month)|Randomized but not treated|0
6045940|NCT00404352|9645212|FG005|Double Blind (up to 24 Month)|Randomized but not treated|0
6045941|NCT00404352|9645213|FG006|Double Blind (up to 24 Month)|Randomized but not treated|0
6045942|NCT00404352|9645214|FG007|Double Blind (up to 24 Month)|Randomized but not treated|0
6045943|NCT00404352|9645215|FG008|Double Blind (up to 24 Month)|Randomized but not treated|0
6045944|NCT00404352|9645207|FG000|Double Blind (up to 24 Month)|Physician Decision|0
6045945|NCT00404352|9645208|FG001|Double Blind (up to 24 Month)|Physician Decision|0
6045946|NCT00404352|9645209|FG002|Double Blind (up to 24 Month)|Physician Decision|1
6045947|NCT00404352|9645210|FG003|Double Blind (up to 24 Month)|Physician Decision|0
6045948|NCT00404352|9645211|FG004|Double Blind (up to 24 Month)|Physician Decision|0
6045949|NCT00404352|9645212|FG005|Double Blind (up to 24 Month)|Physician Decision|0
6045950|NCT00404352|9645213|FG006|Double Blind (up to 24 Month)|Physician Decision|0
6067700|NCT00533949|9669894|FG000|Overall Study|Protocol Violation|12
6067701|NCT00533949|9669895|FG001|Overall Study|Protocol Violation|12
6067702|NCT00533949|9669896|FG002|Overall Study|Protocol Violation|9
6067703|NCT00533949|9669897|FG003|Overall Study|Protocol Violation|9
6067704|NCT00533949|9669894|FG000|Overall Study|Withdrawal by Subject|3
6067705|NCT00533949|9669895|FG001|Overall Study|Withdrawal by Subject|2
6067706|NCT00533949|9669896|FG002|Overall Study|Withdrawal by Subject|1
6067707|NCT00533949|9669897|FG003|Overall Study|Withdrawal by Subject|1
6067708|NCT00534092|9669926|FG000|Overall Study|Lost to Follow-up|1
6067709|NCT00534092|9669927|FG001|Overall Study|Lost to Follow-up|0
6067710|NCT00534092|9669926|FG000|Overall Study|personal reasons/family concerns|1
6067711|NCT00534092|9669927|FG001|Overall Study|personal reasons/family concerns|0
6067712|NCT00534105|9669937|FG000|Overall Study|Lost to Follow-up|23
6067713|NCT00534105|9669938|FG001|Overall Study|Lost to Follow-up|39
6067714|NCT00534248|9669973|FG000|Overall Study|Adverse Event|19
6067715|NCT00534248|9669974|FG001|Overall Study|Adverse Event|29
6067716|NCT00534248|9669973|FG000|Overall Study|Lost to Follow-up|353
6067717|NCT00534248|9669974|FG001|Overall Study|Lost to Follow-up|375
6067718|NCT00534248|9669973|FG000|Overall Study|Other protocol specified criteria|13
6067719|NCT00534248|9669974|FG001|Overall Study|Other protocol specified criteria|3
6067720|NCT00534248|9669973|FG000|Overall Study|Physician Decision|10
6067721|NCT00534248|9669974|FG001|Overall Study|Physician Decision|7
6067722|NCT00534248|9669973|FG000|Overall Study|Protocol Violation|3
6067723|NCT00534248|9669974|FG001|Overall Study|Protocol Violation|4
6067724|NCT00534248|9669973|FG000|Overall Study|Withdrawal by Subject|263
6067725|NCT00534248|9669974|FG001|Overall Study|Withdrawal by Subject|255
6067726|NCT00534313|9669984|FG000|Short-term Period|Adverse Event|1
6067727|NCT00534313|9669985|FG001|Short-term Period|Adverse Event|2
6067728|NCT00534313|9669986|FG002|Short-term Period|Adverse Event|1
6067729|NCT00534313|9669987|FG003|Short-term Period|Adverse Event|3
6067730|NCT00534313|9669984|FG000|Short-term Period|Lack of Efficacy|3
6067731|NCT00534313|9669985|FG001|Short-term Period|Lack of Efficacy|4
6067732|NCT00534313|9669986|FG002|Short-term Period|Lack of Efficacy|0
6067733|NCT00534313|9669987|FG003|Short-term Period|Lack of Efficacy|3
6067734|NCT00534313|9669984|FG000|Short-term Period|Participant not meeting study criteria|0
6067735|NCT00534313|9669985|FG001|Short-term Period|Participant not meeting study criteria|0
6067736|NCT00534313|9669986|FG002|Short-term Period|Participant not meeting study criteria|0
6067737|NCT00534313|9669987|FG003|Short-term Period|Participant not meeting study criteria|1
6067738|NCT00534313|9669984|FG000|Short-term Period|Participant withdrew consent|2
6067739|NCT00534313|9669985|FG001|Short-term Period|Participant withdrew consent|0
6067740|NCT00534313|9669986|FG002|Short-term Period|Participant withdrew consent|0
6067741|NCT00534313|9669987|FG003|Short-term Period|Participant withdrew consent|2
6067742|NCT00534313|9669984|FG000|Short-term Period|Pregnancy|0
6067743|NCT00534313|9669985|FG001|Short-term Period|Pregnancy|0
6067744|NCT00534313|9669986|FG002|Short-term Period|Pregnancy|1
6067745|NCT00534313|9669987|FG003|Short-term Period|Pregnancy|0
6067746|NCT00534313|9669984|FG000|Long-term Period|Adverse Event|2
6067747|NCT00534313|9669985|FG001|Long-term Period|Adverse Event|1
6067748|NCT00534313|9669986|FG002|Long-term Period|Adverse Event|0
6067749|NCT00534313|9669987|FG003|Long-term Period|Adverse Event|1
6067750|NCT00534313|9669984|FG000|Long-term Period|Lack of Efficacy|14
6067751|NCT00534313|9669985|FG001|Long-term Period|Lack of Efficacy|10
6067752|NCT00534313|9669986|FG002|Long-term Period|Lack of Efficacy|14
6067753|NCT00534313|9669987|FG003|Long-term Period|Lack of Efficacy|12
6067754|NCT00534313|9669984|FG000|Long-term Period|Lost to Follow-up|1
6067755|NCT00534313|9669985|FG001|Long-term Period|Lost to Follow-up|2
6067756|NCT00534313|9669986|FG002|Long-term Period|Lost to Follow-up|0
6067757|NCT00534313|9669987|FG003|Long-term Period|Lost to Follow-up|0
6067758|NCT00534313|9669984|FG000|Long-term Period|Withdrawal by Subject|2
6067759|NCT00534313|9669985|FG001|Long-term Period|Withdrawal by Subject|2
6067760|NCT00534313|9669986|FG002|Long-term Period|Withdrawal by Subject|0
6067761|NCT00534313|9669987|FG003|Long-term Period|Withdrawal by Subject|0
6067762|NCT00534313|9669984|FG000|Long-term Period|No longer meets study criteria|0
6067763|NCT00534313|9669985|FG001|Long-term Period|No longer meets study criteria|1
6067764|NCT00534313|9669986|FG002|Long-term Period|No longer meets study criteria|0
6067765|NCT00534313|9669987|FG003|Long-term Period|No longer meets study criteria|0
6067766|NCT00534313|9669984|FG000|Long-term Period|Poor compliance/noncompliance|0
6067767|NCT00534313|9669985|FG001|Long-term Period|Poor compliance/noncompliance|1
6067768|NCT00534313|9669986|FG002|Long-term Period|Poor compliance/noncompliance|1
6067769|NCT00534313|9669987|FG003|Long-term Period|Poor compliance/noncompliance|0
6067770|NCT00534313|9669984|FG000|Long-term Period|Administrative reason by sponsor|17
6067771|NCT00534313|9669985|FG001|Long-term Period|Administrative reason by sponsor|15
6067772|NCT00534313|9669986|FG002|Long-term Period|Administrative reason by sponsor|26
6067773|NCT00534313|9669987|FG003|Long-term Period|Administrative reason by sponsor|18
6067774|NCT00534313|9669984|FG000|Long-term Period|Other|1
6067775|NCT00534313|9669985|FG001|Long-term Period|Other|2
6067776|NCT00534313|9669986|FG002|Long-term Period|Other|2
6067777|NCT00534313|9669987|FG003|Long-term Period|Other|2
6067778|NCT00534352|9670032|FG000|Treatment A: TMC125 + TDF/FTC|Physician Decision|1
6067779|NCT00534352|9670032|FG000|Treatment A: TMC125 + TDF/FTC|Lost to Follow-up|1
6067780|NCT00534352|9670032|FG000|Treatment C: DRV/Rtv + TDF/FTC|Physician Decision|1
6067781|NCT00534352|9670032|FG000|Optional Extension: DRV/Rtv + TDF/FTC|Physician Decision|1
6067782|NCT00534352|9670032|FG000|Optional Extension: DRV/Rtv + TDF/FTC|Lost to Follow-up|2
6067783|NCT00534352|9670032|FG000|Optional Extension: DRV/Rtv + TDF/FTC|Pregnancy|1
6067784|NCT00534404|9670059|FG000|Overall Study|Death|0
6067785|NCT00534404|9670060|FG001|Overall Study|Death|0
6067786|NCT00534404|9670061|FG002|Overall Study|Death|2
6067787|NCT00534404|9670059|FG000|Overall Study|Withdrawal by Subject|8
6067788|NCT00534404|9670060|FG001|Overall Study|Withdrawal by Subject|2
6067789|NCT00534404|9670061|FG002|Overall Study|Withdrawal by Subject|38
6067790|NCT00534404|9670059|FG000|Overall Study|Removed by study staff|2
6067791|NCT00534404|9670060|FG001|Overall Study|Removed by study staff|3
6067792|NCT00534404|9670061|FG002|Overall Study|Removed by study staff|1
6067793|NCT00534404|9670059|FG000|Overall Study|Lost to Follow-up|170
6067794|NCT00534404|9670060|FG001|Overall Study|Lost to Follow-up|138
6067795|NCT00534404|9670061|FG002|Overall Study|Lost to Follow-up|201
6067796|NCT00534495|9670075|FG000|Double Blind Placebo Phase Week 0-4|randomized in error|0
6067797|NCT00534495|9670076|FG001|Double Blind Placebo Phase Week 0-4|randomized in error|1
6067798|NCT00534495|9670077|FG002|Double Blind Placebo Phase Week 0-4|randomized in error|0
6067799|NCT00534495|9670075|FG000|All Active Treatment Phase Week 4-24|Adverse Event|1
6067800|NCT00534495|9670076|FG001|All Active Treatment Phase Week 4-24|Adverse Event|0
6067801|NCT00534495|9670077|FG002|All Active Treatment Phase Week 4-24|Adverse Event|0
6067802|NCT00534495|9670075|FG000|All Active Treatment Phase Week 4-24|Lack of Efficacy|1
6067803|NCT00534495|9670076|FG001|All Active Treatment Phase Week 4-24|Lack of Efficacy|7
6067804|NCT00534495|9670077|FG002|All Active Treatment Phase Week 4-24|Lack of Efficacy|0
6067805|NCT00534495|9670075|FG000|All Active Treatment Phase Week 4-24|Lost to Follow-up|1
6067806|NCT00534495|9670076|FG001|All Active Treatment Phase Week 4-24|Lost to Follow-up|1
6067807|NCT00534495|9670077|FG002|All Active Treatment Phase Week 4-24|Lost to Follow-up|0
6067808|NCT00534495|9670075|FG000|All Active Treatment Phase Week 4-24|Withdrawal by Subject|1
6067809|NCT00534495|9670076|FG001|All Active Treatment Phase Week 4-24|Withdrawal by Subject|1
6067810|NCT00534495|9670077|FG002|All Active Treatment Phase Week 4-24|Withdrawal by Subject|0
6067811|NCT00534495|9670075|FG000|Long Term Ext. Phase Week 24-month 21|Adverse Event|0
6067812|NCT00534495|9670076|FG001|Long Term Ext. Phase Week 24-month 21|Adverse Event|0
6067813|NCT00534495|9670077|FG002|Long Term Ext. Phase Week 24-month 21|Adverse Event|1
6067814|NCT00534495|9670075|FG000|Long Term Ext. Phase Week 24-month 21|Lack of Efficacy|0
6067815|NCT00534495|9670076|FG001|Long Term Ext. Phase Week 24-month 21|Lack of Efficacy|0
6067816|NCT00534495|9670077|FG002|Long Term Ext. Phase Week 24-month 21|Lack of Efficacy|5
5992206|NCT03760068|9584599|FG000|Overall Study|Withdrawal by Subject|7
5992207|NCT03760068|9584600|FG001|Overall Study|Withdrawal by Subject|8
5992208|NCT03760068|9584599|FG000|Overall Study|Adverse Event|1
5992209|NCT03760068|9584600|FG001|Overall Study|Adverse Event|2
5992210|NCT03760068|9584599|FG000|Overall Study|Administrative Decision by Sponsor|0
5992211|NCT03760068|9584600|FG001|Overall Study|Administrative Decision by Sponsor|2
5992212|NCT03760068|9584599|FG000|Overall Study|Physician Decision|1
5992213|NCT03760068|9584600|FG001|Overall Study|Physician Decision|2
5992214|NCT03760068|9584599|FG000|Overall Study|Lost to Follow-up|4
5992215|NCT03760068|9584600|FG001|Overall Study|Lost to Follow-up|9
5992216|NCT03760068|9584599|FG000|Overall Study|Subject Moved Out of State|1
5992217|NCT03760068|9584600|FG001|Overall Study|Subject Moved Out of State|0
5992218|NCT03628781|9584618|FG000|Overall Study|Lost to Follow-up|16
5992219|NCT03628781|9584619|FG001|Overall Study|Lost to Follow-up|8
6067817|NCT00534495|9670075|FG000|Long Term Ext. Phase Week 24-month 21|Withdrawal by Subject|0
6067818|NCT00534495|9670076|FG001|Long Term Ext. Phase Week 24-month 21|Withdrawal by Subject|0
6067819|NCT00534495|9670077|FG002|Long Term Ext. Phase Week 24-month 21|Withdrawal by Subject|3
6067820|NCT00534495|9670075|FG000|Long Term Ext. Phase Week 24-month 21|non compliance|0
6067821|NCT00534495|9670076|FG001|Long Term Ext. Phase Week 24-month 21|non compliance|0
6067822|NCT00534495|9670077|FG002|Long Term Ext. Phase Week 24-month 21|non compliance|2
6067823|NCT00534599|9670090|FG000|Overall Study|Adverse Event|25
6067824|NCT00534599|9670091|FG001|Overall Study|Adverse Event|4
6067825|NCT00534599|9670090|FG000|Overall Study|Incorrect enrollment|2
6067826|NCT00534599|9670091|FG001|Overall Study|Incorrect enrollment|1
6067827|NCT00534599|9670090|FG000|Overall Study|Mis-randomization|2
6067828|NCT00534599|9670091|FG001|Overall Study|Mis-randomization|2
6067829|NCT00534599|9670090|FG000|Overall Study|Developed study-specific d/c criteria|5
6067830|NCT00534599|9670091|FG001|Overall Study|Developed study-specific d/c criteria|0
6067831|NCT00534599|9670090|FG000|Overall Study|Lack of Efficacy|0
6067832|NCT00534599|9670091|FG001|Overall Study|Lack of Efficacy|1
6067833|NCT00534599|9670090|FG000|Overall Study|Generalized anxiety disorder worsened|0
6067834|NCT00534599|9670091|FG001|Overall Study|Generalized anxiety disorder worsened|1
6067835|NCT00534599|9670090|FG000|Overall Study|Protocol Violation|1
6067836|NCT00534599|9670091|FG001|Overall Study|Protocol Violation|3
6067837|NCT00534599|9670090|FG000|Overall Study|Lost to Follow-up|11
6067838|NCT00534599|9670091|FG001|Overall Study|Lost to Follow-up|14
6067839|NCT00534599|9670090|FG000|Overall Study|Withdrawal by Subject|4
6067840|NCT00534599|9670091|FG001|Overall Study|Withdrawal by Subject|6
6067841|NCT00534599|9670090|FG000|Overall Study|Other|7
6067842|NCT00534599|9670091|FG001|Overall Study|Other|0
6067843|NCT00534638|9670099|FG000|Overall Study|Withdrawal by Subject|3
6067844|NCT00534638|9670100|FG001|Overall Study|Withdrawal by Subject|4
6067845|NCT00534638|9670099|FG000|Overall Study|Migrated/moved from study area|13
6067846|NCT00534638|9670100|FG001|Overall Study|Migrated/moved from study area|11
6067847|NCT00534638|9670099|FG000|Overall Study|Lost to follow-up,incomplete vaccination|83
6067848|NCT00534638|9670100|FG001|Overall Study|Lost to follow-up,incomplete vaccination|117
6067849|NCT00534638|9670099|FG000|Overall Study|Lost to follow-up, complete vaccination|4707
6067850|NCT00534638|9670100|FG001|Overall Study|Lost to follow-up, complete vaccination|10757
6067851|NCT00534638|9670099|FG000|Overall Study|Other|1685
6067852|NCT00534638|9670100|FG001|Overall Study|Other|902
6067853|NCT00535132|9670184|FG000|Safety Analysis Set|Did Not Receive Study Medication|2
6067854|NCT00535132|9670185|FG001|Safety Analysis Set|Did Not Receive Study Medication|2
6067855|NCT00535132|9670184|FG000|Intent-to-Treat (ITT) Analysis Set|No Follow-up Efficacy Data|3
6067856|NCT00535132|9670185|FG001|Intent-to-Treat (ITT) Analysis Set|No Follow-up Efficacy Data|3
6067857|NCT00535145|9670193|FG000|Phase I|Adverse Event|3
6067858|NCT00535145|9670193|FG000|Phase I|Lost to Follow-up|7
6067859|NCT00535145|9670193|FG000|Phase I|Withdrawal by Subject|6
6067860|NCT00535145|9670193|FG000|Phase I|(eligibility)|8
6067861|NCT00535145|9670193|FG000|Phase I|(protocol violation)|1
6067862|NCT00535145|9670193|FG000|Phase I|(PI decision)|1
6067863|NCT00535145|9670193|FG000|Phase I|(diagnosis)|3
6067864|NCT00535145|9670193|FG000|Phase II|Adverse Event|2
6067865|NCT00535145|9670193|FG000|Phase II|Lack of Efficacy|1
6067866|NCT00535145|9670193|FG000|Phase II|Lost to Follow-up|5
6067867|NCT00535145|9670193|FG000|Phase II|Withdrawal by Subject|5
6067868|NCT00535145|9670193|FG000|Phase II|Subject non-compliance|2
6067869|NCT00535223|9670203|FG000|Overall Study|Withdrawal by Subject|4
6067870|NCT00535223|9670204|FG001|Overall Study|Withdrawal by Subject|1
6067871|NCT00535236|9670220|FG000|Overall Study|Adverse Event|1
6067872|NCT00535236|9670221|FG001|Overall Study|Adverse Event|0
6067873|NCT00535236|9670222|FG002|Overall Study|Adverse Event|9
5992220|NCT03628781|9584618|FG000|Overall Study|Withdrawal by Subject|16
5992221|NCT03628781|9584619|FG001|Overall Study|Withdrawal by Subject|1
5992222|NCT03560206|9584627|FG000|Overall Study|Lost to Follow-up|19
5992223|NCT03560206|9584628|FG001|Overall Study|Lost to Follow-up|11
5992224|NCT03560206|9584627|FG000|Overall Study|Withdrawal by Subject|2
5992225|NCT03560206|9584628|FG001|Overall Study|Withdrawal by Subject|4
5992226|NCT03560206|9584627|FG000|Overall Study|caregivers' health condition and not becoming non-caregiver|5
5992227|NCT03560206|9584628|FG001|Overall Study|caregivers' health condition and not becoming non-caregiver|0
5992228|NCT03560206|9584627|FG000|Overall Study|Busy schedule|14
5992229|NCT03560206|9584628|FG001|Overall Study|Busy schedule|2
5992230|NCT03560206|9584627|FG000|Overall Study|patients' new health condition such as cancer|10
5992231|NCT03560206|9584628|FG001|Overall Study|patients' new health condition such as cancer|1
5992232|NCT03340766|9584637|FG000|Overall Study|Death|6
5992233|NCT03340766|9584638|FG001|Overall Study|Death|6
5992234|NCT03340766|9584639|FG002|Overall Study|Death|2
5992235|NCT03340766|9584637|FG000|Overall Study|Withdrawal by Subject|2
5992236|NCT03340766|9584638|FG001|Overall Study|Withdrawal by Subject|1
5992237|NCT03340766|9584639|FG002|Overall Study|Withdrawal by Subject|2
5992238|NCT03340766|9584637|FG000|Overall Study|Continuing Study|3
5992239|NCT03340766|9584638|FG001|Overall Study|Continuing Study|3
5992240|NCT03340766|9584639|FG002|Overall Study|Continuing Study|5
5992241|NCT02706847|9584673|FG000|Day 1 to Week 12|Adverse Event|2
5992242|NCT02706847|9584674|FG001|Day 1 to Week 12|Adverse Event|2
5992243|NCT02706847|9584675|FG002|Day 1 to Week 12|Adverse Event|1
5992244|NCT02706847|9584676|FG003|Day 1 to Week 12|Adverse Event|12
6067874|NCT00535236|9670223|FG003|Overall Study|Adverse Event|3
6067875|NCT00535236|9670224|FG004|Overall Study|Adverse Event|3
6067876|NCT00535236|9670225|FG005|Overall Study|Adverse Event|0
6067877|NCT00535236|9670226|FG006|Overall Study|Adverse Event|5
6067878|NCT00535236|9670227|FG007|Overall Study|Adverse Event|1
6067879|NCT00535236|9670228|FG008|Overall Study|Adverse Event|2
6067880|NCT00535236|9670229|FG009|Overall Study|Adverse Event|1
6067881|NCT00535236|9670220|FG000|Overall Study|Lost to Follow-up|1
6067882|NCT00535236|9670221|FG001|Overall Study|Lost to Follow-up|2
6067883|NCT00535236|9670222|FG002|Overall Study|Lost to Follow-up|0
6067884|NCT00535236|9670223|FG003|Overall Study|Lost to Follow-up|0
6067885|NCT00535236|9670224|FG004|Overall Study|Lost to Follow-up|2
6067886|NCT00535236|9670225|FG005|Overall Study|Lost to Follow-up|0
6067887|NCT00535236|9670226|FG006|Overall Study|Lost to Follow-up|0
6067888|NCT00535236|9670227|FG007|Overall Study|Lost to Follow-up|0
6067889|NCT00535236|9670228|FG008|Overall Study|Lost to Follow-up|6
6067890|NCT00535236|9670229|FG009|Overall Study|Lost to Follow-up|1
6067891|NCT00535236|9670220|FG000|Overall Study|Physician Decision|0
6067892|NCT00535236|9670221|FG001|Overall Study|Physician Decision|0
6067893|NCT00535236|9670222|FG002|Overall Study|Physician Decision|0
6067894|NCT00535236|9670223|FG003|Overall Study|Physician Decision|0
6067895|NCT00535236|9670224|FG004|Overall Study|Physician Decision|1
6067896|NCT00535236|9670225|FG005|Overall Study|Physician Decision|0
6067897|NCT00535236|9670226|FG006|Overall Study|Physician Decision|1
6067898|NCT00535236|9670227|FG007|Overall Study|Physician Decision|0
6067899|NCT00535236|9670228|FG008|Overall Study|Physician Decision|0
6067900|NCT00535236|9670229|FG009|Overall Study|Physician Decision|0
6067901|NCT00535236|9670220|FG000|Overall Study|Protocol Violation|2
6067902|NCT00535236|9670221|FG001|Overall Study|Protocol Violation|0
6067903|NCT00535236|9670222|FG002|Overall Study|Protocol Violation|1
6067904|NCT00535236|9670223|FG003|Overall Study|Protocol Violation|0
6067905|NCT00535236|9670224|FG004|Overall Study|Protocol Violation|0
6067906|NCT00535236|9670225|FG005|Overall Study|Protocol Violation|0
6067907|NCT00535236|9670226|FG006|Overall Study|Protocol Violation|0
6067908|NCT00535236|9670227|FG007|Overall Study|Protocol Violation|0
6067909|NCT00535236|9670228|FG008|Overall Study|Protocol Violation|1
6067910|NCT00535236|9670229|FG009|Overall Study|Protocol Violation|0
6067911|NCT00535236|9670220|FG000|Overall Study|Withdrawal by Subject|3
6067912|NCT00535236|9670221|FG001|Overall Study|Withdrawal by Subject|0
6067913|NCT00535236|9670222|FG002|Overall Study|Withdrawal by Subject|2
6067914|NCT00535236|9670223|FG003|Overall Study|Withdrawal by Subject|1
6067915|NCT00535236|9670224|FG004|Overall Study|Withdrawal by Subject|6
6067916|NCT00535236|9670225|FG005|Overall Study|Withdrawal by Subject|1
6067917|NCT00535236|9670226|FG006|Overall Study|Withdrawal by Subject|5
6067918|NCT00535236|9670227|FG007|Overall Study|Withdrawal by Subject|0
6067919|NCT00535236|9670228|FG008|Overall Study|Withdrawal by Subject|4
6067920|NCT00535236|9670229|FG009|Overall Study|Withdrawal by Subject|2
6067921|NCT00535288|9670259|FG000|Overall Study|Adverse Event|20
6067922|NCT00535288|9670260|FG001|Overall Study|Adverse Event|19
6067923|NCT00535288|9670261|FG002|Overall Study|Adverse Event|25
6067924|NCT00535288|9670262|FG003|Overall Study|Adverse Event|20
6067925|NCT00535288|9670263|FG004|Overall Study|Adverse Event|30
6067926|NCT00535288|9670259|FG000|Overall Study|Lost to Follow-up|0
6067927|NCT00535288|9670260|FG001|Overall Study|Lost to Follow-up|3
6067928|NCT00535288|9670261|FG002|Overall Study|Lost to Follow-up|0
6067929|NCT00535288|9670262|FG003|Overall Study|Lost to Follow-up|0
6067930|NCT00535288|9670263|FG004|Overall Study|Lost to Follow-up|0
6067931|NCT00535288|9670259|FG000|Overall Study|Lack of Efficacy|26
6067932|NCT00535288|9670260|FG001|Overall Study|Lack of Efficacy|3
6067933|NCT00535288|9670261|FG002|Overall Study|Lack of Efficacy|4
6067934|NCT00535288|9670262|FG003|Overall Study|Lack of Efficacy|4
6067935|NCT00535288|9670263|FG004|Overall Study|Lack of Efficacy|7
6067936|NCT00535288|9670259|FG000|Overall Study|Unwilling to cooperate|6
6067937|NCT00535288|9670260|FG001|Overall Study|Unwilling to cooperate|6
6067938|NCT00535288|9670261|FG002|Overall Study|Unwilling to cooperate|3
6067939|NCT00535288|9670262|FG003|Overall Study|Unwilling to cooperate|3
6067940|NCT00535288|9670263|FG004|Overall Study|Unwilling to cooperate|4
6067941|NCT00535288|9670259|FG000|Overall Study|Other|2
5992245|NCT02706847|9584673|FG000|Day 1 to Week 12|Withdrawal by Subject|2
5992246|NCT02706847|9584674|FG001|Day 1 to Week 12|Withdrawal by Subject|1
5992247|NCT02706847|9584675|FG002|Day 1 to Week 12|Withdrawal by Subject|4
5992248|NCT02706847|9584676|FG003|Day 1 to Week 12|Withdrawal by Subject|2
5992249|NCT02706847|9584673|FG000|Day 1 to Week 12|Lost to Follow-up|2
5992250|NCT02706847|9584674|FG001|Day 1 to Week 12|Lost to Follow-up|1
6067942|NCT00535288|9670260|FG001|Overall Study|Other|1
6067943|NCT00535288|9670261|FG002|Overall Study|Other|1
6067944|NCT00535288|9670262|FG003|Overall Study|Other|2
6067945|NCT00535288|9670263|FG004|Overall Study|Other|1
6067946|NCT00535496|9670297|FG000|Overall Study|Lost to Follow-up|0
6067947|NCT00535496|9670298|FG001|Overall Study|Lost to Follow-up|1
5992251|NCT02706847|9584675|FG002|Day 1 to Week 12|Lost to Follow-up|0
5992252|NCT02706847|9584676|FG003|Day 1 to Week 12|Lost to Follow-up|0
5992253|NCT02706847|9584673|FG000|Day 1 to Week 12|Other|4
5992254|NCT02706847|9584674|FG001|Day 1 to Week 12|Other|4
5992255|NCT02706847|9584675|FG002|Day 1 to Week 12|Other|2
5992256|NCT02706847|9584676|FG003|Day 1 to Week 12|Other|2
5992257|NCT02706847|9584673|FG000|Day 1 to Week 12|Randomized in Error|0
5992258|NCT02706847|9584674|FG001|Day 1 to Week 12|Randomized in Error|0
5992259|NCT02706847|9584675|FG002|Day 1 to Week 12|Randomized in Error|1
5992260|NCT02706847|9584676|FG003|Day 1 to Week 12|Randomized in Error|0
5992261|NCT02706847|9584673|FG000|Week 12 to Week 24|Adverse Event|1
6067948|NCT00535496|9670299|FG002|Overall Study|Lost to Follow-up|0
5992262|NCT02706847|9584674|FG001|Week 12 to Week 24|Adverse Event|2
5992263|NCT02706847|9584675|FG002|Week 12 to Week 24|Adverse Event|2
5992264|NCT02706847|9584676|FG003|Week 12 to Week 24|Adverse Event|5
5992265|NCT02706847|9584673|FG000|Week 12 to Week 24|Withdrawal by Subject|1
5992266|NCT02706847|9584674|FG001|Week 12 to Week 24|Withdrawal by Subject|0
5992267|NCT02706847|9584675|FG002|Week 12 to Week 24|Withdrawal by Subject|1
5992268|NCT02706847|9584676|FG003|Week 12 to Week 24|Withdrawal by Subject|4
5992269|NCT02706847|9584673|FG000|Week 12 to Week 24|Lost to Follow-up|0
5992270|NCT02706847|9584674|FG001|Week 12 to Week 24|Lost to Follow-up|0
5992271|NCT02706847|9584675|FG002|Week 12 to Week 24|Lost to Follow-up|0
5992272|NCT02706847|9584676|FG003|Week 12 to Week 24|Lost to Follow-up|1
5992273|NCT02706847|9584673|FG000|Week 12 to Week 24|Other|1
5992274|NCT02706847|9584674|FG001|Week 12 to Week 24|Other|0
5992275|NCT02706847|9584675|FG002|Week 12 to Week 24|Other|1
5992276|NCT02706847|9584676|FG003|Week 12 to Week 24|Other|4
5992277|NCT02701777|9584690|FG000|Overall Study|Some subjects did not like the stimulation.|4
5992278|NCT02701777|9584691|FG001|Overall Study|Some subjects did not like the stimulation.|0
5992279|NCT02701777|9584692|FG002|Overall Study|Some subjects did not like the stimulation.|0
5992280|NCT02701777|9584693|FG003|Overall Study|Some subjects did not like the stimulation.|2
5992281|NCT02701777|9584690|FG000|Overall Study|Some subjects were unable to commit to the training study.|0
5992282|NCT02701777|9584691|FG001|Overall Study|Some subjects were unable to commit to the training study.|3
5992283|NCT02701777|9584692|FG002|Overall Study|Some subjects were unable to commit to the training study.|4
5992284|NCT02701777|9584693|FG003|Overall Study|Some subjects were unable to commit to the training study.|0
5992285|NCT02564900|9584722|FG000|Dose Escalation|Progressive disease per RECIST|2
5992286|NCT02564900|9584723|FG001|Dose Escalation|Progressive disease per RECIST|3
5992287|NCT02564900|9584724|FG002|Dose Escalation|Progressive disease per RECIST|3
5992288|NCT02564900|9584725|FG003|Dose Escalation|Progressive disease per RECIST|3
5992289|NCT02564900|9584726|FG004|Dose Escalation|Progressive disease per RECIST|3
5992290|NCT02564900|9584727|FG005|Dose Escalation|Progressive disease per RECIST|1
5992291|NCT02564900|9584728|FG006|Dose Escalation|Progressive disease per RECIST|0
5992292|NCT02564900|9584729|FG007|Dose Escalation|Progressive disease per RECIST|0
5992293|NCT02564900|9584730|FG008|Dose Escalation|Progressive disease per RECIST|0
5992294|NCT02564900|9584731|FG009|Dose Escalation|Progressive disease per RECIST|0
5992295|NCT02564900|9584732|FG010|Dose Escalation|Progressive disease per RECIST|0
5992296|NCT02564900|9584733|FG011|Dose Escalation|Progressive disease per RECIST|0
5992297|NCT02564900|9584734|FG012|Dose Escalation|Progressive disease per RECIST|0
5992298|NCT02564900|9584735|FG013|Dose Escalation|Progressive disease per RECIST|0
5992299|NCT02564900|9584736|FG014|Dose Escalation|Progressive disease per RECIST|0
5992300|NCT02564900|9584722|FG000|Dose Escalation|Ongoing|1
5992301|NCT02564900|9584723|FG001|Dose Escalation|Ongoing|0
5992302|NCT02564900|9584724|FG002|Dose Escalation|Ongoing|0
5992303|NCT02564900|9584725|FG003|Dose Escalation|Ongoing|2
5992304|NCT02564900|9584726|FG004|Dose Escalation|Ongoing|2
5992305|NCT02564900|9584727|FG005|Dose Escalation|Ongoing|2
5992306|NCT02564900|9584728|FG006|Dose Escalation|Ongoing|0
5992307|NCT02564900|9584729|FG007|Dose Escalation|Ongoing|0
5992308|NCT02564900|9584730|FG008|Dose Escalation|Ongoing|0
5992309|NCT02564900|9584731|FG009|Dose Escalation|Ongoing|0
5992310|NCT02564900|9584732|FG010|Dose Escalation|Ongoing|0
5992311|NCT02564900|9584733|FG011|Dose Escalation|Ongoing|0
5992312|NCT02564900|9584734|FG012|Dose Escalation|Ongoing|0
5992313|NCT02564900|9584735|FG013|Dose Escalation|Ongoing|0
5992314|NCT02564900|9584736|FG014|Dose Escalation|Ongoing|0
5992315|NCT02564900|9584722|FG000|Dose Escalation|Adverse Event|0
5992316|NCT02564900|9584723|FG001|Dose Escalation|Adverse Event|0
5992317|NCT02564900|9584724|FG002|Dose Escalation|Adverse Event|0
5992318|NCT02564900|9584725|FG003|Dose Escalation|Adverse Event|1
5992319|NCT02564900|9584726|FG004|Dose Escalation|Adverse Event|1
5992320|NCT02564900|9584727|FG005|Dose Escalation|Adverse Event|3
5992321|NCT02564900|9584728|FG006|Dose Escalation|Adverse Event|0
5992322|NCT02564900|9584729|FG007|Dose Escalation|Adverse Event|0
5992323|NCT02564900|9584730|FG008|Dose Escalation|Adverse Event|0
5992324|NCT02564900|9584731|FG009|Dose Escalation|Adverse Event|0
5992325|NCT02564900|9584732|FG010|Dose Escalation|Adverse Event|0
5992326|NCT02564900|9584733|FG011|Dose Escalation|Adverse Event|0
5992327|NCT02564900|9584734|FG012|Dose Escalation|Adverse Event|0
5992328|NCT02564900|9584735|FG013|Dose Escalation|Adverse Event|0
5992329|NCT02564900|9584736|FG014|Dose Escalation|Adverse Event|0
6067949|NCT00535496|9670300|FG003|Overall Study|Lost to Follow-up|0
6067950|NCT00535496|9670297|FG000|Overall Study|Not treated with sugammadex|0
6067951|NCT00535496|9670298|FG001|Overall Study|Not treated with sugammadex|1
6067952|NCT00535496|9670299|FG002|Overall Study|Not treated with sugammadex|0
6067953|NCT00535496|9670300|FG003|Overall Study|Not treated with sugammadex|0
6067954|NCT00535626|9670331|FG000|Overall Study|Death|15
6067955|NCT00535626|9670331|FG000|Overall Study|Lost to Follow-up|29
6067956|NCT00535626|9670331|FG000|Overall Study|Withdrawal by Subject|20
6067957|NCT00535626|9670331|FG000|Overall Study|Removal/revision of study component|8
6067958|NCT00535626|9670331|FG000|Overall Study|Subject terminated|31
6067959|NCT00535626|9670331|FG000|Overall Study|Unable to return|2
6067960|NCT00535730|9670342|FG000|Overall Study|Adverse Event|1
6067961|NCT00535730|9670343|FG001|Overall Study|Adverse Event|1
6067962|NCT00535730|9670342|FG000|Overall Study|Lost to Follow-up|0
6067963|NCT00535730|9670343|FG001|Overall Study|Lost to Follow-up|1
6067964|NCT00535730|9670342|FG000|Overall Study|Physician Decision|0
6067965|NCT00535730|9670343|FG001|Overall Study|Physician Decision|1
6067966|NCT00535730|9670342|FG000|Overall Study|Protocol Violation|1
6067967|NCT00535730|9670343|FG001|Overall Study|Protocol Violation|0
6067968|NCT00535730|9670342|FG000|Overall Study|Withdrawal by Subject|0
6067969|NCT00535730|9670343|FG001|Overall Study|Withdrawal by Subject|4
6087153|NCT00666835|9697338|FG000|Overall Study|Lack of Efficacy|0
6087154|NCT00666835|9697339|FG001|Overall Study|Lack of Efficacy|1
6087155|NCT00666835|9697338|FG000|Overall Study|Incl./excl. not fulfilled|7
6087156|NCT00666835|9697339|FG001|Overall Study|Incl./excl. not fulfilled|2
6087157|NCT00666835|9697338|FG000|Overall Study|Adverse Event|7
6087158|NCT00666835|9697339|FG001|Overall Study|Adverse Event|6
5992330|NCT02564900|9584722|FG000|Dose Expansion|Progressive disease per RECIST|0
5992331|NCT02564900|9584723|FG001|Dose Expansion|Progressive disease per RECIST|0
5992332|NCT02564900|9584724|FG002|Dose Expansion|Progressive disease per RECIST|0
5992333|NCT02564900|9584725|FG003|Dose Expansion|Progressive disease per RECIST|0
5992334|NCT02564900|9584726|FG004|Dose Expansion|Progressive disease per RECIST|0
5992335|NCT02564900|9584727|FG005|Dose Expansion|Progressive disease per RECIST|0
5992336|NCT02564900|9584728|FG006|Dose Expansion|Progressive disease per RECIST|19
5992337|NCT02564900|9584729|FG007|Dose Expansion|Progressive disease per RECIST|17
5992338|NCT02564900|9584730|FG008|Dose Expansion|Progressive disease per RECIST|8
5992339|NCT02564900|9584731|FG009|Dose Expansion|Progressive disease per RECIST|16
5992340|NCT02564900|9584732|FG010|Dose Expansion|Progressive disease per RECIST|13
5992341|NCT02564900|9584733|FG011|Dose Expansion|Progressive disease per RECIST|19
5992342|NCT02564900|9584734|FG012|Dose Expansion|Progressive disease per RECIST|10
5992343|NCT02564900|9584735|FG013|Dose Expansion|Progressive disease per RECIST|13
5992344|NCT02564900|9584736|FG014|Dose Expansion|Progressive disease per RECIST|11
5992345|NCT02564900|9584722|FG000|Dose Expansion|Clinical progression|0
5992346|NCT02564900|9584723|FG001|Dose Expansion|Clinical progression|0
5992347|NCT02564900|9584724|FG002|Dose Expansion|Clinical progression|0
5992348|NCT02564900|9584725|FG003|Dose Expansion|Clinical progression|0
5992349|NCT02564900|9584726|FG004|Dose Expansion|Clinical progression|0
5992350|NCT02564900|9584727|FG005|Dose Expansion|Clinical progression|0
5992351|NCT02564900|9584728|FG006|Dose Expansion|Clinical progression|5
5992352|NCT02564900|9584729|FG007|Dose Expansion|Clinical progression|12
5992353|NCT02564900|9584730|FG008|Dose Expansion|Clinical progression|0
5992354|NCT02564900|9584731|FG009|Dose Expansion|Clinical progression|3
5992355|NCT02564900|9584732|FG010|Dose Expansion|Clinical progression|2
5992356|NCT02564900|9584733|FG011|Dose Expansion|Clinical progression|0
5992357|NCT02564900|9584734|FG012|Dose Expansion|Clinical progression|1
5992358|NCT02564900|9584735|FG013|Dose Expansion|Clinical progression|3
6087159|NCT00666835|9697338|FG000|Overall Study|Protocol Violation|2
6087160|NCT00666835|9697339|FG001|Overall Study|Protocol Violation|0
6087161|NCT00666835|9697338|FG000|Overall Study|Death|15
6087162|NCT00666835|9697339|FG001|Overall Study|Death|4
5992359|NCT02564900|9584736|FG014|Dose Expansion|Clinical progression|1
6087163|NCT00666835|9697338|FG000|Overall Study|Kidney Transplantation (NTX)|10
6087164|NCT00666835|9697339|FG001|Overall Study|Kidney Transplantation (NTX)|2
6087165|NCT00666835|9697338|FG000|Overall Study|Hemoglobulin concentration|4
5992360|NCT02564900|9584722|FG000|Dose Expansion|Adverse Event|0
5992361|NCT02564900|9584723|FG001|Dose Expansion|Adverse Event|0
5992362|NCT02564900|9584724|FG002|Dose Expansion|Adverse Event|0
5992363|NCT02564900|9584725|FG003|Dose Expansion|Adverse Event|0
5992364|NCT02564900|9584726|FG004|Dose Expansion|Adverse Event|0
5992365|NCT02564900|9584727|FG005|Dose Expansion|Adverse Event|0
5992366|NCT02564900|9584728|FG006|Dose Expansion|Adverse Event|9
5992367|NCT02564900|9584729|FG007|Dose Expansion|Adverse Event|22
5992368|NCT02564900|9584730|FG008|Dose Expansion|Adverse Event|0
6067970|NCT00535847|9670480|FG000|Overall Study|Adverse Event|5
6067971|NCT00535847|9670481|FG001|Overall Study|Adverse Event|3
6067972|NCT00535847|9670482|FG002|Overall Study|Adverse Event|2
6067973|NCT00535847|9670480|FG000|Overall Study|Non compliance|1
6067974|NCT00535847|9670481|FG001|Overall Study|Non compliance|1
6067975|NCT00535847|9670482|FG002|Overall Study|Non compliance|0
6067976|NCT00535847|9670480|FG000|Overall Study|Protocol-defined Virologic Stopping Rule|16
6067977|NCT00535847|9670481|FG001|Overall Study|Protocol-defined Virologic Stopping Rule|10
5992369|NCT02564900|9584731|FG009|Dose Expansion|Adverse Event|11
5992370|NCT02564900|9584732|FG010|Dose Expansion|Adverse Event|0
5992371|NCT02564900|9584733|FG011|Dose Expansion|Adverse Event|5
6067978|NCT00535847|9670482|FG002|Overall Study|Protocol-defined Virologic Stopping Rule|0
6067979|NCT00536107|9670520|FG000|Overall Study|Death|5
6067980|NCT00536107|9670521|FG001|Overall Study|Death|1
6067981|NCT00536107|9670520|FG000|Overall Study|Incorrect enrolment|1
6067982|NCT00536107|9670521|FG001|Overall Study|Incorrect enrolment|0
6067983|NCT00536107|9670520|FG000|Overall Study|Withdrawal by Subject|0
6067984|NCT00536107|9670521|FG001|Overall Study|Withdrawal by Subject|1
6067985|NCT00536107|9670520|FG000|Overall Study|Study Termination|2
6067986|NCT00536107|9670521|FG001|Overall Study|Study Termination|4
6067987|NCT00536120|9670529|FG000|Overall Study|Lost to Follow-up|1
6067988|NCT00536120|9670530|FG001|Overall Study|Lost to Follow-up|0
6067989|NCT00536120|9670529|FG000|Overall Study|Positive for Anti-natalizumab Antibodies|3
6067990|NCT00536120|9670530|FG001|Overall Study|Positive for Anti-natalizumab Antibodies|0
6067991|NCT00536120|9670529|FG000|Overall Study|Non-compliance|1
6067992|NCT00536120|9670530|FG001|Overall Study|Non-compliance|0
6067993|NCT00536120|9670529|FG000|Overall Study|Sponsor Decision Due to Lab Values|1
6067994|NCT00536120|9670530|FG001|Overall Study|Sponsor Decision Due to Lab Values|0
6067995|NCT00536120|9670529|FG000|Overall Study|Steroid Use|0
6067996|NCT00536120|9670530|FG001|Overall Study|Steroid Use|2
6067997|NCT00536120|9670529|FG000|Overall Study|Missed Study Visit|0
6067998|NCT00536120|9670530|FG001|Overall Study|Missed Study Visit|1
6067999|NCT00536198|9670547|FG000|Overall Study|Lost to Follow-up|15
6068000|NCT00536198|9670548|FG001|Overall Study|Lost to Follow-up|14
6068001|NCT00536198|9670547|FG000|Overall Study|Withdrawal by Subject|16
6068002|NCT00536198|9670548|FG001|Overall Study|Withdrawal by Subject|12
6068003|NCT00536198|9670547|FG000|Overall Study|Adverse Event|2
6068004|NCT00536198|9670548|FG001|Overall Study|Adverse Event|2
6068005|NCT00536198|9670547|FG000|Overall Study|Rescue|3
6068006|NCT00536198|9670548|FG001|Overall Study|Rescue|9
6068007|NCT00536198|9670547|FG000|Overall Study|Pregnancy|1
6068008|NCT00536198|9670548|FG001|Overall Study|Pregnancy|1
6068009|NCT00536198|9670547|FG000|Overall Study|Protocol Violation|0
6068010|NCT00536198|9670548|FG001|Overall Study|Protocol Violation|1
6068011|NCT00536263|9670559|FG000|Overall Study|Adverse Event|5
6068012|NCT00536263|9670560|FG001|Overall Study|Adverse Event|5
6068013|NCT00536263|9670561|FG002|Overall Study|Adverse Event|7
6068014|NCT00536263|9670559|FG000|Overall Study|Lost to Follow-up|3
6068015|NCT00536263|9670560|FG001|Overall Study|Lost to Follow-up|4
6068016|NCT00536263|9670561|FG002|Overall Study|Lost to Follow-up|4
6068017|NCT00536263|9670559|FG000|Overall Study|Subject withdrew - not treatment related|2
6068018|NCT00536263|9670560|FG001|Overall Study|Subject withdrew - not treatment related|0
6068019|NCT00536263|9670561|FG002|Overall Study|Subject withdrew - not treatment related|5
6068020|NCT00536263|9670559|FG000|Overall Study|Subject withdrew - treatment related|0
6068021|NCT00536263|9670560|FG001|Overall Study|Subject withdrew - treatment related|3
6068022|NCT00536263|9670561|FG002|Overall Study|Subject withdrew - treatment related|2
6068023|NCT00536263|9670559|FG000|Overall Study|Noncompliance with protocol|0
6068024|NCT00536263|9670560|FG001|Overall Study|Noncompliance with protocol|0
6068025|NCT00536263|9670561|FG002|Overall Study|Noncompliance with protocol|1
6068026|NCT00536263|9670559|FG000|Overall Study|Did not meet protocol eligibility|1
6068027|NCT00536263|9670560|FG001|Overall Study|Did not meet protocol eligibility|2
6068028|NCT00536263|9670561|FG002|Overall Study|Did not meet protocol eligibility|2
6068029|NCT00536471|9670583|FG000|Overall Study|Lost to Follow-up|48
6068030|NCT00536471|9670584|FG001|Overall Study|Lost to Follow-up|23
6068031|NCT00536471|9670585|FG002|Overall Study|Lost to Follow-up|48
6068032|NCT00536471|9670586|FG003|Overall Study|Lost to Follow-up|22
6068033|NCT00536471|9670583|FG000|Overall Study|Adverse Event|32
6068034|NCT00536471|9670584|FG001|Overall Study|Adverse Event|16
6068035|NCT00536471|9670585|FG002|Overall Study|Adverse Event|28
6068036|NCT00536471|9670586|FG003|Overall Study|Adverse Event|13
6068037|NCT00536471|9670583|FG000|Overall Study|Withdrawal by Subject|40
6068038|NCT00536471|9670584|FG001|Overall Study|Withdrawal by Subject|24
6068039|NCT00536471|9670585|FG002|Overall Study|Withdrawal by Subject|43
6068040|NCT00536471|9670586|FG003|Overall Study|Withdrawal by Subject|21
6068041|NCT00536471|9670583|FG000|Overall Study|Lack of Efficacy|17
6068042|NCT00536471|9670584|FG001|Overall Study|Lack of Efficacy|18
6068043|NCT00536471|9670585|FG002|Overall Study|Lack of Efficacy|11
6068044|NCT00536471|9670586|FG003|Overall Study|Lack of Efficacy|9
6068045|NCT00536471|9670583|FG000|Overall Study|Protocol Violation|8
6068046|NCT00536471|9670584|FG001|Overall Study|Protocol Violation|1
6068047|NCT00536471|9670585|FG002|Overall Study|Protocol Violation|2
6068048|NCT00536471|9670586|FG003|Overall Study|Protocol Violation|3
6068049|NCT00536471|9670583|FG000|Overall Study|Physician Decision|11
6068050|NCT00536471|9670584|FG001|Overall Study|Physician Decision|1
6068051|NCT00536471|9670585|FG002|Overall Study|Physician Decision|3
6068052|NCT00536471|9670586|FG003|Overall Study|Physician Decision|2
6068053|NCT00536471|9670583|FG000|Overall Study|Death|0
6068054|NCT00536471|9670584|FG001|Overall Study|Death|0
6068055|NCT00536471|9670585|FG002|Overall Study|Death|1
6068056|NCT00536471|9670586|FG003|Overall Study|Death|2
6068057|NCT00536471|9670583|FG000|Overall Study|Sponsor Decision|0
6068058|NCT00536471|9670584|FG001|Overall Study|Sponsor Decision|1
6068059|NCT00536471|9670585|FG002|Overall Study|Sponsor Decision|3
6068060|NCT00536471|9670586|FG003|Overall Study|Sponsor Decision|2
6068061|NCT00536484|9670605|FG000|Overall Study|Adverse Event|21
6068062|NCT00536484|9670606|FG001|Overall Study|Adverse Event|34
6068063|NCT00536484|9670605|FG000|Overall Study|Withdrawal by Subject|11
6068064|NCT00536484|9670606|FG001|Overall Study|Withdrawal by Subject|11
6068065|NCT00536484|9670605|FG000|Overall Study|Lost to Follow-up|8
6068066|NCT00536484|9670606|FG001|Overall Study|Lost to Follow-up|6
6068067|NCT00536484|9670605|FG000|Overall Study|Lack of Efficacy|16
6068068|NCT00536484|9670606|FG001|Overall Study|Lack of Efficacy|5
6068069|NCT00536484|9670605|FG000|Overall Study|Other|4
6068070|NCT00536484|9670606|FG001|Overall Study|Other|0
6068071|NCT00536510|9670614|FG000|Overall Study|Adverse Event|27
6068072|NCT00536510|9670615|FG001|Overall Study|Adverse Event|4
6068073|NCT00536510|9670614|FG000|Overall Study|Lost to Follow-up|11
6068074|NCT00536510|9670615|FG001|Overall Study|Lost to Follow-up|8
6068075|NCT00536510|9670614|FG000|Overall Study|Protocol Violation|4
6068076|NCT00536510|9670615|FG001|Overall Study|Protocol Violation|5
6068077|NCT00536510|9670614|FG000|Overall Study|Withdrawal by Subject|16
6068078|NCT00536510|9670615|FG001|Overall Study|Withdrawal by Subject|9
6068079|NCT00536510|9670614|FG000|Overall Study|Flushing with Product|20
6068080|NCT00536510|9670615|FG001|Overall Study|Flushing with Product|0
6068081|NCT00536510|9670614|FG000|Overall Study|Laboratory Adverse Event|2
6068082|NCT00536510|9670615|FG001|Overall Study|Laboratory Adverse Event|1
6068083|NCT00536510|9670614|FG000|Overall Study|Patient Discontinued for Other Reasons|2
6068084|NCT00536510|9670615|FG001|Overall Study|Patient Discontinued for Other Reasons|2
6068085|NCT00536575|9670621|FG000|Overall Study|Withdrawal by Subject|1
6068086|NCT00536575|9670621|FG000|Overall Study|Death|1
6068087|NCT00536731|9670649|FG000|Overall Study|Adverse Event|3
6068088|NCT00536731|9670650|FG001|Overall Study|Adverse Event|2
6068089|NCT00536731|9670651|FG002|Overall Study|Adverse Event|3
5992372|NCT02564900|9584734|FG012|Dose Expansion|Adverse Event|2
5992373|NCT02564900|9584735|FG013|Dose Expansion|Adverse Event|2
5992374|NCT02564900|9584736|FG014|Dose Expansion|Adverse Event|1
5992375|NCT02564900|9584722|FG000|Dose Expansion|Ongoing|0
5992376|NCT02564900|9584723|FG001|Dose Expansion|Ongoing|0
5992377|NCT02564900|9584724|FG002|Dose Expansion|Ongoing|0
5992378|NCT02564900|9584725|FG003|Dose Expansion|Ongoing|0
5992379|NCT02564900|9584726|FG004|Dose Expansion|Ongoing|0
5992380|NCT02564900|9584727|FG005|Dose Expansion|Ongoing|0
5992381|NCT02564900|9584728|FG006|Dose Expansion|Ongoing|9
5992382|NCT02564900|9584729|FG007|Dose Expansion|Ongoing|10
5992383|NCT02564900|9584730|FG008|Dose Expansion|Ongoing|11
6068090|NCT00536731|9670649|FG000|Overall Study|Withdrawal by Subject|0
6068091|NCT00536731|9670650|FG001|Overall Study|Withdrawal by Subject|2
6068092|NCT00536731|9670651|FG002|Overall Study|Withdrawal by Subject|0
6068093|NCT00536731|9670649|FG000|Overall Study|Intake of prohibited conc. medication|0
6068094|NCT00536731|9670650|FG001|Overall Study|Intake of prohibited conc. medication|0
6068095|NCT00536731|9670651|FG002|Overall Study|Intake of prohibited conc. medication|1
6068096|NCT00536731|9670649|FG000|Overall Study|Safety reasons|0
6068097|NCT00536731|9670650|FG001|Overall Study|Safety reasons|0
6068098|NCT00536731|9670651|FG002|Overall Study|Safety reasons|1
6068099|NCT00536731|9670649|FG000|Overall Study|Other|1
6068100|NCT00536731|9670650|FG001|Overall Study|Other|1
6068101|NCT00536731|9670651|FG002|Overall Study|Other|0
6068102|NCT00536744|9670661|FG000|Overall Study|Adverse Event|13
6068103|NCT00536744|9670662|FG001|Overall Study|Adverse Event|10
6068104|NCT00536744|9670661|FG000|Overall Study|Death|2
6068105|NCT00536744|9670662|FG001|Overall Study|Death|1
6068106|NCT00536744|9670661|FG000|Overall Study|Physician Decision|3
6068107|NCT00536744|9670662|FG001|Overall Study|Physician Decision|1
6068108|NCT00536744|9670661|FG000|Overall Study|Lost to Follow-up|3
6068109|NCT00536744|9670662|FG001|Overall Study|Lost to Follow-up|5
6068110|NCT00536744|9670661|FG000|Overall Study|Withdrawal by Subject|7
6068111|NCT00536744|9670662|FG001|Overall Study|Withdrawal by Subject|8
6068112|NCT00536744|9670661|FG000|Overall Study|PI tried alternative treatment|1
6068113|NCT00536744|9670662|FG001|Overall Study|PI tried alternative treatment|3
6068114|NCT00536809|9670668|FG000|Phase II|Adverse Event|1
6068115|NCT00536809|9670668|FG000|Phase II|Referred for surgical resection|1
6068116|NCT00536874|9670672|FG000|Overall Study|Adverse Event|1
6068117|NCT00536874|9670672|FG000|Overall Study|Death|2
6068118|NCT00536874|9670672|FG000|Overall Study|Withdrawal by Subject|1
6068119|NCT00536939|9670685|FG000|Overall Study|Withdrawal by Subject|1
6068120|NCT00536939|9670686|FG001|Overall Study|Withdrawal by Subject|0
6068121|NCT00536939|9670685|FG000|Overall Study|Other Complicating Disease|1
6068122|NCT00536939|9670686|FG001|Overall Study|Other Complicating Disease|0
6068123|NCT00536991|9670691|FG000|Overall Study|Withdrawal by Subject|10
6068124|NCT00536991|9670691|FG000|Overall Study|Physician Decision|1
6068125|NCT00536991|9670691|FG000|Overall Study|patient ineligible|2
6068126|NCT00537017|9670696|FG000|Treatment Phase|Adverse Event|19
6068127|NCT00537017|9670696|FG000|Treatment Phase|Withdrawal by Subject|13
6068128|NCT00537017|9670696|FG000|Treatment Phase|Protocol Violation|2
6068129|NCT00537017|9670696|FG000|Follow-up Phase|Withdrawal by Subject|9
6068130|NCT00537030|9670700|FG000|Overall Study|Physician Decision|2
6068131|NCT00537030|9670700|FG000|Overall Study|Withdrawal by Subject|2
6068132|NCT00537030|9670700|FG000|Overall Study|≥ Grade 2 allergy|7
6068133|NCT00537030|9670700|FG000|Overall Study|Disease progression/ relapse during Tx|1
6068134|NCT00537030|9670700|FG000|Overall Study|Ineligible|2
6068135|NCT00537030|9670700|FG000|Overall Study|Inevaluable|2
6068136|NCT00537056|9670704|FG000|Interim PET/CT|scheduling conflicts and/or exposure|5
6068137|NCT00537082|9670713|FG000|Overall Study|Adverse Event|6
6068138|NCT00537082|9670714|FG001|Overall Study|Adverse Event|6
6068139|NCT00537082|9670715|FG002|Overall Study|Adverse Event|3
6068140|NCT00537082|9670713|FG000|Overall Study|Protocol Violation|0
5992384|NCT02564900|9584731|FG009|Dose Expansion|Ongoing|3
5992385|NCT02564900|9584732|FG010|Dose Expansion|Ongoing|0
6068141|NCT00537082|9670714|FG001|Overall Study|Protocol Violation|2
6068142|NCT00537082|9670715|FG002|Overall Study|Protocol Violation|1
6068143|NCT00537082|9670713|FG000|Overall Study|Lack of Efficacy|0
6068144|NCT00537082|9670714|FG001|Overall Study|Lack of Efficacy|0
5992386|NCT02564900|9584733|FG011|Dose Expansion|Ongoing|0
5992387|NCT02564900|9584734|FG012|Dose Expansion|Ongoing|4
5992388|NCT02564900|9584735|FG013|Dose Expansion|Ongoing|0
5992389|NCT02564900|9584736|FG014|Dose Expansion|Ongoing|6
6068145|NCT00537082|9670715|FG002|Overall Study|Lack of Efficacy|2
5992390|NCT02564900|9584722|FG000|Dose Expansion|Death|0
5992391|NCT02564900|9584723|FG001|Dose Expansion|Death|0
5992392|NCT02564900|9584724|FG002|Dose Expansion|Death|0
5992393|NCT02564900|9584725|FG003|Dose Expansion|Death|0
5992394|NCT02564900|9584726|FG004|Dose Expansion|Death|0
5992395|NCT02564900|9584727|FG005|Dose Expansion|Death|0
5992396|NCT02564900|9584728|FG006|Dose Expansion|Death|1
5992397|NCT02564900|9584729|FG007|Dose Expansion|Death|0
5992398|NCT02564900|9584730|FG008|Dose Expansion|Death|0
5992399|NCT02564900|9584731|FG009|Dose Expansion|Death|0
5992400|NCT02564900|9584732|FG010|Dose Expansion|Death|1
5992401|NCT02564900|9584733|FG011|Dose Expansion|Death|0
5992402|NCT02564900|9584734|FG012|Dose Expansion|Death|1
6068146|NCT00537082|9670713|FG000|Overall Study|Withdrawal by Subject|0
6068147|NCT00537082|9670714|FG001|Overall Study|Withdrawal by Subject|1
6068148|NCT00537082|9670715|FG002|Overall Study|Withdrawal by Subject|0
6068149|NCT00537082|9670713|FG000|Overall Study|Discontinued before initiating treatment|3
6068150|NCT00537082|9670714|FG001|Overall Study|Discontinued before initiating treatment|0
6068151|NCT00537082|9670715|FG002|Overall Study|Discontinued before initiating treatment|0
6068152|NCT00537095|9670725|FG000|Overall Study|surgery|1
6068153|NCT00537095|9670726|FG001|Overall Study|surgery|0
6068154|NCT00537095|9670725|FG000|Overall Study|Adverse Event|24
6068155|NCT00537095|9670726|FG001|Overall Study|Adverse Event|4
6068156|NCT00537095|9670725|FG000|Overall Study|disease progression|21
6068157|NCT00537095|9670726|FG001|Overall Study|disease progression|48
6068158|NCT00537095|9670725|FG000|Overall Study|Death|3
6068159|NCT00537095|9670726|FG001|Overall Study|Death|1
6068160|NCT00537095|9670725|FG000|Overall Study|Withdrawal by Subject|2
6068161|NCT00537095|9670726|FG001|Overall Study|Withdrawal by Subject|2
6068162|NCT00537095|9670725|FG000|Overall Study|subjective disease progression|0
6068163|NCT00537095|9670726|FG001|Overall Study|subjective disease progression|1
6068164|NCT00537095|9670725|FG000|Overall Study|Incorrect enrolment|0
6068165|NCT00537095|9670726|FG001|Overall Study|Incorrect enrolment|1
6068166|NCT00537238|9670734|FG000|Overall Study|Death|1
6068167|NCT00537238|9670735|FG001|Overall Study|Death|2
6068168|NCT00537238|9670734|FG000|Overall Study|Adverse Event|31
6068169|NCT00537238|9670735|FG001|Overall Study|Adverse Event|22
6068170|NCT00537238|9670734|FG000|Overall Study|Lack of Efficacy|20
6068171|NCT00537238|9670735|FG001|Overall Study|Lack of Efficacy|21
6068172|NCT00537238|9670734|FG000|Overall Study|Lost to Follow-up|12
6068173|NCT00537238|9670735|FG001|Overall Study|Lost to Follow-up|8
6068174|NCT00537238|9670734|FG000|Overall Study|Withdrawal by Subject|51
6068175|NCT00537238|9670735|FG001|Overall Study|Withdrawal by Subject|47
6068176|NCT00537238|9670734|FG000|Overall Study|Protocol Violation|15
6068177|NCT00537238|9670735|FG001|Overall Study|Protocol Violation|19
6068178|NCT00537238|9670734|FG000|Overall Study|Does not meet entrance criteria|0
6068179|NCT00537238|9670735|FG001|Overall Study|Does not meet entrance criteria|2
6068180|NCT00537238|9670734|FG000|Overall Study|Other|44
6068181|NCT00537238|9670735|FG001|Overall Study|Other|52
6068182|NCT00537277|9670741|FG000|Overall Study|Adverse Event|1
6068183|NCT00537277|9670741|FG000|Overall Study|Lack of Efficacy|2
6068184|NCT00537277|9670741|FG000|Overall Study|Lost to Follow-up|12
6068185|NCT00537277|9670741|FG000|Overall Study|Protocol Violation|11
6068186|NCT00537277|9670741|FG000|Overall Study|Unclassified|4
6068187|NCT00537277|9670741|FG000|Overall Study|Inability to tolerate trial medication|4
6068188|NCT00537277|9670741|FG000|Overall Study|Non-compliance with trial procedures|15
6068189|NCT00537303|9670751|FG000|Overall Study|Adverse Event|1
6068190|NCT00537303|9670752|FG001|Overall Study|Adverse Event|4
6068191|NCT00537303|9670751|FG000|Overall Study|Lack of Efficacy|6
6068192|NCT00537303|9670752|FG001|Overall Study|Lack of Efficacy|7
5992403|NCT02564900|9584735|FG013|Dose Expansion|Death|1
5992404|NCT02564900|9584736|FG014|Dose Expansion|Death|0
5992405|NCT02564900|9584722|FG000|Dose Expansion|Withdrawal by Subject|0
5992406|NCT02564900|9584723|FG001|Dose Expansion|Withdrawal by Subject|0
5992407|NCT02564900|9584724|FG002|Dose Expansion|Withdrawal by Subject|0
5992408|NCT02564900|9584725|FG003|Dose Expansion|Withdrawal by Subject|0
5992409|NCT02564900|9584726|FG004|Dose Expansion|Withdrawal by Subject|0
6068193|NCT00537303|9670751|FG000|Overall Study|Protocol Violation|8
6068194|NCT00537303|9670752|FG001|Overall Study|Protocol Violation|4
5992410|NCT02564900|9584727|FG005|Dose Expansion|Withdrawal by Subject|0
6068195|NCT00537303|9670751|FG000|Overall Study|Withdrawal criteria|3
6068196|NCT00537303|9670752|FG001|Overall Study|Withdrawal criteria|3
6068197|NCT00537303|9670751|FG000|Overall Study|Unclassified|8
6068198|NCT00537303|9670752|FG001|Overall Study|Unclassified|7
6068199|NCT00537316|9670764|FG000|Part 1|Adverse Event|7
6068200|NCT00537316|9670765|FG001|Part 1|Adverse Event|11
6068201|NCT00537316|9670766|FG002|Part 1|Adverse Event|8
6068202|NCT00537316|9670767|FG003|Part 1|Adverse Event|0
6068203|NCT00537316|9670768|FG004|Part 1|Adverse Event|0
6068204|NCT00537316|9670769|FG005|Part 1|Adverse Event|0
6068205|NCT00537316|9670770|FG006|Part 1|Adverse Event|0
6068206|NCT00537316|9670764|FG000|Part 1|Protocol defined clinical event|1
5992411|NCT02564900|9584728|FG006|Dose Expansion|Withdrawal by Subject|4
5992412|NCT02564900|9584729|FG007|Dose Expansion|Withdrawal by Subject|0
5992413|NCT02564900|9584730|FG008|Dose Expansion|Withdrawal by Subject|0
5992414|NCT02564900|9584731|FG009|Dose Expansion|Withdrawal by Subject|0
5992415|NCT02564900|9584732|FG010|Dose Expansion|Withdrawal by Subject|1
5992416|NCT02564900|9584733|FG011|Dose Expansion|Withdrawal by Subject|0
5992417|NCT02564900|9584734|FG012|Dose Expansion|Withdrawal by Subject|0
5992418|NCT02564900|9584735|FG013|Dose Expansion|Withdrawal by Subject|1
5992419|NCT02564900|9584736|FG014|Dose Expansion|Withdrawal by Subject|1
5992420|NCT02564900|9584722|FG000|Dose Expansion|Other|0
5992421|NCT02564900|9584723|FG001|Dose Expansion|Other|0
5992422|NCT02564900|9584724|FG002|Dose Expansion|Other|0
5992423|NCT02564900|9584725|FG003|Dose Expansion|Other|0
5992424|NCT02564900|9584726|FG004|Dose Expansion|Other|0
5992425|NCT02564900|9584727|FG005|Dose Expansion|Other|0
5992426|NCT02564900|9584728|FG006|Dose Expansion|Other|1
5992427|NCT02564900|9584729|FG007|Dose Expansion|Other|0
5992428|NCT02564900|9584730|FG008|Dose Expansion|Other|1
5992429|NCT02564900|9584731|FG009|Dose Expansion|Other|0
5992430|NCT02564900|9584732|FG010|Dose Expansion|Other|0
5992431|NCT02564900|9584733|FG011|Dose Expansion|Other|0
5992432|NCT02564900|9584734|FG012|Dose Expansion|Other|0
5992433|NCT02564900|9584735|FG013|Dose Expansion|Other|0
5992434|NCT02564900|9584736|FG014|Dose Expansion|Other|1
5992435|NCT02564900|9584722|FG000|Dose Expansion|Did not receive treatment|0
5992436|NCT02564900|9584723|FG001|Dose Expansion|Did not receive treatment|0
5992437|NCT02564900|9584724|FG002|Dose Expansion|Did not receive treatment|0
5992438|NCT02564900|9584725|FG003|Dose Expansion|Did not receive treatment|0
5992439|NCT02564900|9584726|FG004|Dose Expansion|Did not receive treatment|0
5992440|NCT02564900|9584727|FG005|Dose Expansion|Did not receive treatment|0
5992441|NCT02564900|9584728|FG006|Dose Expansion|Did not receive treatment|1
6068207|NCT00537316|9670765|FG001|Part 1|Protocol defined clinical event|0
6068208|NCT00537316|9670766|FG002|Part 1|Protocol defined clinical event|0
6068209|NCT00537316|9670767|FG003|Part 1|Protocol defined clinical event|0
6068210|NCT00537316|9670768|FG004|Part 1|Protocol defined clinical event|0
6068211|NCT00537316|9670769|FG005|Part 1|Protocol defined clinical event|0
6068212|NCT00537316|9670770|FG006|Part 1|Protocol defined clinical event|0
6068213|NCT00537316|9670764|FG000|Part 1|Lost to Follow-up|1
6068214|NCT00537316|9670765|FG001|Part 1|Lost to Follow-up|0
6068215|NCT00537316|9670766|FG002|Part 1|Lost to Follow-up|0
6068216|NCT00537316|9670767|FG003|Part 1|Lost to Follow-up|0
6068217|NCT00537316|9670768|FG004|Part 1|Lost to Follow-up|0
6068218|NCT00537316|9670769|FG005|Part 1|Lost to Follow-up|0
6068219|NCT00537316|9670770|FG006|Part 1|Lost to Follow-up|0
6068220|NCT00537316|9670764|FG000|Part 1|Withdrawal by Subject|3
6068221|NCT00537316|9670765|FG001|Part 1|Withdrawal by Subject|8
6068222|NCT00537316|9670766|FG002|Part 1|Withdrawal by Subject|4
6068223|NCT00537316|9670767|FG003|Part 1|Withdrawal by Subject|0
6068224|NCT00537316|9670768|FG004|Part 1|Withdrawal by Subject|0
6068225|NCT00537316|9670769|FG005|Part 1|Withdrawal by Subject|0
6068226|NCT00537316|9670770|FG006|Part 1|Withdrawal by Subject|0
6068227|NCT00537316|9670764|FG000|Part 1|Protocol Violation|1
6068228|NCT00537316|9670765|FG001|Part 1|Protocol Violation|5
6068229|NCT00537316|9670766|FG002|Part 1|Protocol Violation|1
6068230|NCT00537316|9670767|FG003|Part 1|Protocol Violation|0
6068231|NCT00537316|9670768|FG004|Part 1|Protocol Violation|0
6068232|NCT00537316|9670769|FG005|Part 1|Protocol Violation|0
5992442|NCT02564900|9584729|FG007|Dose Expansion|Did not receive treatment|1
6068233|NCT00537316|9670770|FG006|Part 1|Protocol Violation|0
5992443|NCT02564900|9584730|FG008|Dose Expansion|Did not receive treatment|0
5992444|NCT02564900|9584731|FG009|Dose Expansion|Did not receive treatment|0
6068234|NCT00537316|9670764|FG000|Part 1|Did not meet protocol eligibility|1
5992445|NCT02564900|9584732|FG010|Dose Expansion|Did not receive treatment|0
6068235|NCT00537316|9670765|FG001|Part 1|Did not meet protocol eligibility|3
6068236|NCT00537316|9670766|FG002|Part 1|Did not meet protocol eligibility|2
6068237|NCT00537316|9670767|FG003|Part 1|Did not meet protocol eligibility|0
6068238|NCT00537316|9670768|FG004|Part 1|Did not meet protocol eligibility|0
6068239|NCT00537316|9670769|FG005|Part 1|Did not meet protocol eligibility|0
6068240|NCT00537316|9670770|FG006|Part 1|Did not meet protocol eligibility|0
6068241|NCT00537316|9670764|FG000|Part 1|Administrative|0
6068242|NCT00537316|9670765|FG001|Part 1|Administrative|0
6068243|NCT00537316|9670766|FG002|Part 1|Administrative|2
6068244|NCT00537316|9670767|FG003|Part 1|Administrative|0
6068245|NCT00537316|9670768|FG004|Part 1|Administrative|0
6068246|NCT00537316|9670769|FG005|Part 1|Administrative|0
6068247|NCT00537316|9670770|FG006|Part 1|Administrative|0
6068248|NCT00537316|9670764|FG000|Part 2|Never entered follow-up|0
6068249|NCT00537316|9670765|FG001|Part 2|Never entered follow-up|0
6068250|NCT00537316|9670766|FG002|Part 2|Never entered follow-up|0
6068251|NCT00537316|9670767|FG003|Part 2|Never entered follow-up|0
6068252|NCT00537316|9670768|FG004|Part 2|Never entered follow-up|0
6068253|NCT00537316|9670769|FG005|Part 2|Never entered follow-up|0
6068254|NCT00537316|9670770|FG006|Part 2|Never entered follow-up|1
6068255|NCT00537316|9670764|FG000|Part 2|Adverse Event|4
6068256|NCT00537316|9670765|FG001|Part 2|Adverse Event|0
6068257|NCT00537316|9670766|FG002|Part 2|Adverse Event|2
6068258|NCT00537316|9670767|FG003|Part 2|Adverse Event|0
6068259|NCT00537316|9670768|FG004|Part 2|Adverse Event|0
6068260|NCT00537316|9670769|FG005|Part 2|Adverse Event|0
6068261|NCT00537316|9670770|FG006|Part 2|Adverse Event|0
6068262|NCT00537316|9670764|FG000|Part 2|Lost to Follow-up|1
6068263|NCT00537316|9670765|FG001|Part 2|Lost to Follow-up|0
6068264|NCT00537316|9670766|FG002|Part 2|Lost to Follow-up|2
6068265|NCT00537316|9670767|FG003|Part 2|Lost to Follow-up|0
6068266|NCT00537316|9670768|FG004|Part 2|Lost to Follow-up|0
6068267|NCT00537316|9670769|FG005|Part 2|Lost to Follow-up|0
6068268|NCT00537316|9670770|FG006|Part 2|Lost to Follow-up|0
6068269|NCT00537316|9670764|FG000|Part 2|Withdrawal by Subject|5
6068270|NCT00537316|9670765|FG001|Part 2|Withdrawal by Subject|1
6068271|NCT00537316|9670766|FG002|Part 2|Withdrawal by Subject|4
6068272|NCT00537316|9670767|FG003|Part 2|Withdrawal by Subject|0
6068273|NCT00537316|9670768|FG004|Part 2|Withdrawal by Subject|0
6068274|NCT00537316|9670769|FG005|Part 2|Withdrawal by Subject|0
6068275|NCT00537316|9670770|FG006|Part 2|Withdrawal by Subject|0
6068276|NCT00537316|9670764|FG000|Part 2|Administrative|16
6068277|NCT00537316|9670765|FG001|Part 2|Administrative|8
6068278|NCT00537316|9670766|FG002|Part 2|Administrative|24
6068279|NCT00537316|9670767|FG003|Part 2|Administrative|3
6068280|NCT00537316|9670768|FG004|Part 2|Administrative|1
6068281|NCT00537316|9670769|FG005|Part 2|Administrative|4
6068282|NCT00537316|9670770|FG006|Part 2|Administrative|1
6068283|NCT00537329|9670789|FG000|Overall Study|Death|10
6068284|NCT00537329|9670789|FG000|Overall Study|Adverse Event|3
6068285|NCT00537329|9670789|FG000|Overall Study|Lack of Efficacy|2
6068286|NCT00537329|9670789|FG000|Overall Study|Lost to Follow-up|6
6068287|NCT00537329|9670789|FG000|Overall Study|Withdrawal by Subject|4
6068288|NCT00537329|9670789|FG000|Overall Study|Other|1
6068289|NCT00537381|9670795|FG000|Overall Study|Adverse Event|13
6068290|NCT00537381|9670796|FG001|Overall Study|Adverse Event|9
6068291|NCT00537381|9670795|FG000|Overall Study|Death|3
6068292|NCT00537381|9670796|FG001|Overall Study|Death|3
6068293|NCT00537381|9670795|FG000|Overall Study|Withdrawal by Subject|5
6068294|NCT00537381|9670796|FG001|Overall Study|Withdrawal by Subject|14
6068295|NCT00537381|9670795|FG000|Overall Study|Physician Decision|7
6068296|NCT00537381|9670796|FG001|Overall Study|Physician Decision|6
6068297|NCT00537381|9670795|FG000|Overall Study|Disease Progression|9
6068298|NCT00537381|9670796|FG001|Overall Study|Disease Progression|18
6068299|NCT00537381|9670795|FG000|Overall Study|Sponsor decision|14
6068300|NCT00537381|9670796|FG001|Overall Study|Sponsor decision|9
5992446|NCT02564900|9584733|FG011|Dose Expansion|Did not receive treatment|0
5992447|NCT02564900|9584734|FG012|Dose Expansion|Did not receive treatment|0
5992448|NCT02564900|9584735|FG013|Dose Expansion|Did not receive treatment|0
5992449|NCT02564900|9584736|FG014|Dose Expansion|Did not receive treatment|1
5992450|NCT02561299|9584779|FG000|Overall Study|Death|2
5992451|NCT02561299|9584780|FG001|Overall Study|Death|4
5992452|NCT02561299|9584779|FG000|Overall Study|Lost to Follow-up|1
5992453|NCT02561299|9584780|FG001|Overall Study|Lost to Follow-up|0
5992454|NCT02561299|9584779|FG000|Overall Study|Withdrawal by Subject|2
5992455|NCT02561299|9584780|FG001|Overall Study|Withdrawal by Subject|2
5992456|NCT02548143|9584788|FG000|Overall Study|Adverse Event|1
5992457|NCT02548143|9584789|FG001|Overall Study|Adverse Event|0
5992458|NCT02548143|9584788|FG000|Overall Study|Withdrawal by Subject|0
5992459|NCT02548143|9584789|FG001|Overall Study|Withdrawal by Subject|1
5992460|NCT02448680|9584797|FG000|Overall Study|Physician Decision|1
5992461|NCT02448680|9584798|FG001|Overall Study|Physician Decision|1
5992462|NCT02448680|9584797|FG000|Overall Study|Withdrawal by Subject|0
5992463|NCT02448680|9584798|FG001|Overall Study|Withdrawal by Subject|2
5992464|NCT02393859|9584808|FG000|Overall Study|Decision by Sponsor|1
5992465|NCT02393859|9584809|FG001|Overall Study|Decision by Sponsor|1
5992466|NCT02393859|9584808|FG000|Overall Study|Withdrawal by Subject|5
5992467|NCT02393859|9584809|FG001|Overall Study|Withdrawal by Subject|2
5992468|NCT02393859|9584808|FG000|Overall Study|Death|16
5992469|NCT02393859|9584809|FG001|Overall Study|Death|8
5992470|NCT02393859|9584808|FG000|Overall Study|Continuing Study|32
5992471|NCT02393859|9584809|FG001|Overall Study|Continuing Study|43
5992472|NCT02178358|9584841|FG000|Overall Study|Withdrawal by Subject|0
5992473|NCT02178358|9584842|FG001|Overall Study|Withdrawal by Subject|2
5992474|NCT02178358|9584843|FG002|Overall Study|Withdrawal by Subject|2
5992475|NCT02178358|9584841|FG000|Overall Study|Lost to Follow-up|1
5992476|NCT02178358|9584842|FG001|Overall Study|Lost to Follow-up|0
5992477|NCT02178358|9584843|FG002|Overall Study|Lost to Follow-up|0
5992478|NCT02073279|9584854|FG000|Double-blind Period|Adverse Event|1
5992479|NCT02073279|9584855|FG001|Double-blind Period|Adverse Event|1
5992480|NCT02073279|9584854|FG000|Double-blind Period|Protocol Deviation|0
5992481|NCT02073279|9584855|FG001|Double-blind Period|Protocol Deviation|1
5992482|NCT02073279|9584854|FG000|Double-blind Period|Withdrawal by Subject|2
5992483|NCT02073279|9584855|FG001|Double-blind Period|Withdrawal by Subject|2
5992484|NCT02073279|9584854|FG000|Double-blind Period|Reason Not Specified|1
5992485|NCT02073279|9584855|FG001|Double-blind Period|Reason Not Specified|2
5992486|NCT02073279|9584854|FG000|Double-blind Period|Refused Treatment/Did Not Cooperate|0
5992487|NCT02073279|9584855|FG001|Double-blind Period|Refused Treatment/Did Not Cooperate|1
5992488|NCT02073279|9584854|FG000|Double-blind Period|On-going in Study|11
5992489|NCT02073279|9584855|FG001|Double-blind Period|On-going in Study|40
5992490|NCT02073279|9584854|FG000|Open-label Extension Period|Lack of Efficacy|1
5992491|NCT02073279|9584855|FG001|Open-label Extension Period|Lack of Efficacy|0
5992492|NCT02073279|9584854|FG000|Open-label Extension Period|Refused Treatment/Did Not Cooperate|0
5992493|NCT02073279|9584855|FG001|Open-label Extension Period|Refused Treatment/Did Not Cooperate|1
5992494|NCT02073279|9584854|FG000|Open-label Extension Period|Withdrawal by Subject|1
5992495|NCT02073279|9584855|FG001|Open-label Extension Period|Withdrawal by Subject|1
5992496|NCT02073279|9584854|FG000|Open-label Extension Period|Reason Not Specified|1
5992497|NCT02073279|9584855|FG001|Open-label Extension Period|Reason Not Specified|1
5992498|NCT02073279|9584854|FG000|Open-label Extension Period|On-going in Study|14
5992499|NCT02073279|9584855|FG001|Open-label Extension Period|On-going in Study|13
5992500|NCT01544127|9584867|FG000|Overall Study|Lost to Follow-up|4
5992501|NCT01544127|9584868|FG001|Overall Study|Lost to Follow-up|2
5992502|NCT01544127|9584869|FG002|Overall Study|Lost to Follow-up|9
5992503|NCT01544127|9584867|FG000|Overall Study|Withdrawal by Subject|2
6068301|NCT00537381|9670795|FG000|Overall Study|Other|5
6068302|NCT00537381|9670796|FG001|Overall Study|Other|3
6068303|NCT00537394|9670807|FG000|First Year of Follow-up|Death|7
6068304|NCT00537394|9670808|FG001|First Year of Follow-up|Death|0
6068305|NCT00537394|9670809|FG002|First Year of Follow-up|Death|0
6068306|NCT00537394|9670807|FG000|First Year of Follow-up|Severe debilitation|1
6068307|NCT00537394|9670808|FG001|First Year of Follow-up|Severe debilitation|0
6068308|NCT00537394|9670809|FG002|First Year of Follow-up|Severe debilitation|1
6068309|NCT00537394|9670807|FG000|First Year of Follow-up|Withdrawal by Subject|3
6068310|NCT00537394|9670808|FG001|First Year of Follow-up|Withdrawal by Subject|6
6068311|NCT00537394|9670809|FG002|First Year of Follow-up|Withdrawal by Subject|1
6068312|NCT00537394|9670807|FG000|First Year of Follow-up|Lost to Follow-up|1
6068313|NCT00537394|9670808|FG001|First Year of Follow-up|Lost to Follow-up|5
6068314|NCT00537394|9670809|FG002|First Year of Follow-up|Lost to Follow-up|1
6068315|NCT00537394|9670807|FG000|2nd Year of Follow-up|Death|4
6068316|NCT00537394|9670808|FG001|2nd Year of Follow-up|Death|1
6068317|NCT00537394|9670809|FG002|2nd Year of Follow-up|Death|2
6068318|NCT00537394|9670807|FG000|2nd Year of Follow-up|Withdrawal by Subject|0
6068319|NCT00537394|9670808|FG001|2nd Year of Follow-up|Withdrawal by Subject|1
6068320|NCT00537394|9670809|FG002|2nd Year of Follow-up|Withdrawal by Subject|2
6068321|NCT00537394|9670807|FG000|2nd Year of Follow-up|Lost to Follow-up|6
6068322|NCT00537394|9670808|FG001|2nd Year of Follow-up|Lost to Follow-up|7
6068323|NCT00537394|9670809|FG002|2nd Year of Follow-up|Lost to Follow-up|2
6068324|NCT00537394|9670807|FG000|2nd Year of Follow-up|Clinic site closure|1
6068325|NCT00537394|9670808|FG001|2nd Year of Follow-up|Clinic site closure|0
6068326|NCT00537394|9670809|FG002|2nd Year of Follow-up|Clinic site closure|0
6068327|NCT00537485|9670842|FG000|Overall Study|Adverse Event|10
6068328|NCT00537485|9670843|FG001|Overall Study|Adverse Event|5
6068329|NCT00537485|9670842|FG000|Overall Study|Withdrawal by Subject|3
6068330|NCT00537485|9670843|FG001|Overall Study|Withdrawal by Subject|2
6068331|NCT00537485|9670842|FG000|Overall Study|Withdrawal by Subject|1
6068332|NCT00537485|9670843|FG001|Overall Study|Withdrawal by Subject|3
6068333|NCT00537485|9670842|FG000|Overall Study|Physician Decision|1
6068334|NCT00537485|9670843|FG001|Overall Study|Physician Decision|0
6068335|NCT00537745|9670904|FG000|Overall Study|Did not meet eligibility criteria|2
6068336|NCT00537745|9670904|FG000|Overall Study|Withdrawal by Subject|2
6068337|NCT00537745|9670904|FG000|Overall Study|Subject unable to provide Interlock info|1
6068338|NCT00537771|9670911|FG000|Overall Study|Withdrawal by Subject|6
6068339|NCT00537771|9670912|FG001|Overall Study|Withdrawal by Subject|23
6068340|NCT00537771|9670911|FG000|Overall Study|Adverse Event|8
6068341|NCT00537771|9670912|FG001|Overall Study|Adverse Event|15
6068342|NCT00537771|9670911|FG000|Overall Study|Lost to Follow-up|9
6068343|NCT00537771|9670912|FG001|Overall Study|Lost to Follow-up|15
6068344|NCT00537771|9670911|FG000|Overall Study|Protocol Violation|2
6068345|NCT00537771|9670912|FG001|Overall Study|Protocol Violation|6
6068346|NCT00537771|9670911|FG000|Overall Study|Severe Non-Compliance to Protocol|4
6068347|NCT00537771|9670912|FG001|Overall Study|Severe Non-Compliance to Protocol|2
6068348|NCT00537810|9670922|FG000|Overall Study|Withdrawal by Subject|4
6068349|NCT00537810|9670923|FG001|Overall Study|Withdrawal by Subject|11
5992504|NCT01544127|9584868|FG001|Overall Study|Withdrawal by Subject|2
5992505|NCT01544127|9584869|FG002|Overall Study|Withdrawal by Subject|1
6068350|NCT00537810|9670924|FG002|Overall Study|Withdrawal by Subject|4
6068351|NCT00537810|9670925|FG003|Overall Study|Withdrawal by Subject|3
6068352|NCT00537810|9670922|FG000|Overall Study|Medically withdrawn|2
6068353|NCT00537810|9670923|FG001|Overall Study|Medically withdrawn|2
6068354|NCT00537810|9670924|FG002|Overall Study|Medically withdrawn|0
6068355|NCT00537810|9670925|FG003|Overall Study|Medically withdrawn|1
6068356|NCT00537823|9670937|FG000|Overall Study|Adverse Event|2
6068357|NCT00537823|9670938|FG001|Overall Study|Adverse Event|0
6068358|NCT00537940|9670947|FG000|Overall Study|Adverse Event|20
6068359|NCT00537940|9670948|FG001|Overall Study|Adverse Event|19
5992506|NCT01544127|9584867|FG000|Overall Study|Discharged out of catchment area|1
5992507|NCT01544127|9584868|FG001|Overall Study|Discharged out of catchment area|1
6068360|NCT00537940|9670947|FG000|Overall Study|Lack of Efficacy|8
6068361|NCT00537940|9670948|FG001|Overall Study|Lack of Efficacy|16
6068362|NCT00537940|9670947|FG000|Overall Study|Lost to Follow-up|23
6068363|NCT00537940|9670948|FG001|Overall Study|Lost to Follow-up|29
6068364|NCT00537940|9670947|FG000|Overall Study|Withdrawal by Subject|113
6068365|NCT00537940|9670948|FG001|Overall Study|Withdrawal by Subject|95
6068366|NCT00537940|9670947|FG000|Overall Study|Protocol Violation|6
6068367|NCT00537940|9670948|FG001|Overall Study|Protocol Violation|4
6068368|NCT00537940|9670947|FG000|Overall Study|Pregnancy|1
6068369|NCT00537940|9670948|FG001|Overall Study|Pregnancy|1
6068370|NCT00537940|9670947|FG000|Overall Study|Study terminated by sponsor|2
6068371|NCT00537940|9670948|FG001|Overall Study|Study terminated by sponsor|3
6068372|NCT00537940|9670947|FG000|Overall Study|Other|10
6068373|NCT00537940|9670948|FG001|Overall Study|Other|12
6068374|NCT00537979|9670956|FG000|Overall Study|Adverse Event|2
6068375|NCT00537979|9670957|FG001|Overall Study|Adverse Event|2
6068376|NCT00537979|9670956|FG000|Overall Study|Withdrawal by Subject|1
6068377|NCT00537979|9670957|FG001|Overall Study|Withdrawal by Subject|4
6068378|NCT00537979|9670956|FG000|Overall Study|Lost to Follow-up|1
6068379|NCT00537979|9670957|FG001|Overall Study|Lost to Follow-up|4
6068380|NCT00537979|9670956|FG000|Overall Study|Lack of Efficacy|0
6068381|NCT00537979|9670957|FG001|Overall Study|Lack of Efficacy|1
6068382|NCT00537979|9670956|FG000|Overall Study|Non-compliance with treatment/procedure|2
6068383|NCT00537979|9670957|FG001|Overall Study|Non-compliance with treatment/procedure|2
6068384|NCT00537979|9670956|FG000|Overall Study|Death|0
6068385|NCT00537979|9670957|FG001|Overall Study|Death|3
6068386|NCT00537979|9670956|FG000|Overall Study|Kidney transplant|0
6068387|NCT00537979|9670957|FG001|Overall Study|Kidney transplant|3
6068388|NCT00537979|9670956|FG000|Overall Study|Heart failure|0
6068389|NCT00537979|9670957|FG001|Overall Study|Heart failure|1
6068390|NCT00538291|9670978|FG000|Overall Study|Adverse Event|2
6068391|NCT00538291|9670978|FG000|Overall Study|Withdrawal by Subject|1
6068392|NCT00538473|9671011|FG000|Overall Study|Adverse Event|1
6068393|NCT00538473|9671012|FG001|Overall Study|Adverse Event|0
6068394|NCT00538590|9671033|FG000|Overall Study|Death|1
6068395|NCT00538590|9671034|FG001|Overall Study|Death|0
6068396|NCT00538629|9671049|FG000|Overall Study|At subject's request|1
6068397|NCT00538629|9671049|FG000|Overall Study|Adverse Event|2
6068398|NCT00538629|9671049|FG000|Overall Study|Lack of Efficacy|12
6068399|NCT00538629|9671049|FG000|Overall Study|Lost to Follow-up|6
6068400|NCT00538629|9671049|FG000|Overall Study|Subject's untimely distrust of medicine|1
6068401|NCT00538681|9671067|FG000|Overall Study|Progressive Disease|7
6068402|NCT00538681|9671068|FG001|Overall Study|Progressive Disease|0
6068403|NCT00538681|9671069|FG002|Overall Study|Progressive Disease|1
6068404|NCT00538681|9671070|FG003|Overall Study|Progressive Disease|0
6068405|NCT00538681|9671067|FG000|Overall Study|Sponsor Decision|1
5992508|NCT01544127|9584869|FG002|Overall Study|Discharged out of catchment area|1
5992509|NCT01544127|9584867|FG000|Overall Study|Death|1
5992510|NCT01544127|9584868|FG001|Overall Study|Death|0
5992511|NCT01544127|9584869|FG002|Overall Study|Death|0
5992512|NCT01544127|9584867|FG000|Overall Study|Jail or Prison|1
5992513|NCT01544127|9584868|FG001|Overall Study|Jail or Prison|1
6068406|NCT00538681|9671068|FG001|Overall Study|Sponsor Decision|3
5992514|NCT01544127|9584869|FG002|Overall Study|Jail or Prison|2
6068407|NCT00538681|9671069|FG002|Overall Study|Sponsor Decision|8
6068408|NCT00538681|9671070|FG003|Overall Study|Sponsor Decision|9
6068409|NCT00538681|9671067|FG000|Overall Study|Adverse Event|1
6068410|NCT00538681|9671068|FG001|Overall Study|Adverse Event|1
6068411|NCT00538681|9671069|FG002|Overall Study|Adverse Event|1
6068412|NCT00538681|9671070|FG003|Overall Study|Adverse Event|0
6068413|NCT00538681|9671067|FG000|Overall Study|Death|0
6068414|NCT00538681|9671068|FG001|Overall Study|Death|0
6068415|NCT00538681|9671069|FG002|Overall Study|Death|1
6068416|NCT00538681|9671070|FG003|Overall Study|Death|1
5992515|NCT01544127|9584867|FG000|Overall Study|Became Psychotic|1
6068417|NCT00538681|9671067|FG000|Overall Study|Investigator Decision|0
5992516|NCT01544127|9584868|FG001|Overall Study|Became Psychotic|0
5992517|NCT01544127|9584869|FG002|Overall Study|Became Psychotic|0
5992518|NCT01544127|9584867|FG000|Overall Study|Researcher withdrew|1
5992519|NCT01544127|9584868|FG001|Overall Study|Researcher withdrew|0
5992520|NCT01544127|9584869|FG002|Overall Study|Researcher withdrew|0
5992521|NCT01544127|9584867|FG000|Overall Study|Went active duty|0
6068418|NCT00538681|9671068|FG001|Overall Study|Investigator Decision|0
6068419|NCT00538681|9671069|FG002|Overall Study|Investigator Decision|0
6068420|NCT00538681|9671070|FG003|Overall Study|Investigator Decision|1
5992522|NCT01544127|9584868|FG001|Overall Study|Went active duty|0
5992523|NCT01544127|9584869|FG002|Overall Study|Went active duty|1
5992524|NCT00442559|9584896|FG000|Overall Study|Lost to Follow-up|32
5992525|NCT00442559|9584897|FG001|Overall Study|Lost to Follow-up|34
5992526|NCT00442559|9584896|FG000|Overall Study|Protocol Violation|1
5992527|NCT00442559|9584897|FG001|Overall Study|Protocol Violation|1
5992528|NCT00442559|9584896|FG000|Overall Study|Withdrawal by Subject|1
5992529|NCT00442559|9584897|FG001|Overall Study|Withdrawal by Subject|0
5992530|NCT00117338|9584911|FG000|Overall Study|Adverse Event|0
5992531|NCT00117338|9584912|FG001|Overall Study|Adverse Event|1
5992532|NCT00117338|9584911|FG000|Overall Study|Protocol Violation|3
5992533|NCT00117338|9584912|FG001|Overall Study|Protocol Violation|2
5992534|NCT00117338|9584911|FG000|Overall Study|Withdrawal by Subject|1
5992535|NCT00117338|9584912|FG001|Overall Study|Withdrawal by Subject|0
5992536|NCT00117338|9584911|FG000|Overall Study|Did not meet Inclusion Criteria|1
5992537|NCT00117338|9584912|FG001|Overall Study|Did not meet Inclusion Criteria|0
5992538|NCT00117338|9584911|FG000|Overall Study|Lack of Efficacy|0
5992539|NCT00117338|9584912|FG001|Overall Study|Lack of Efficacy|1
6045951|NCT00404352|9645214|FG007|Double Blind (up to 24 Month)|Physician Decision|0
6045952|NCT00404352|9645215|FG008|Double Blind (up to 24 Month)|Physician Decision|0
6045953|NCT00404352|9645207|FG000|Double Blind (up to 24 Month)|Other|0
6045954|NCT00404352|9645208|FG001|Double Blind (up to 24 Month)|Other|1
6045955|NCT00404352|9645209|FG002|Double Blind (up to 24 Month)|Other|0
6045956|NCT00404352|9645210|FG003|Double Blind (up to 24 Month)|Other|0
6045957|NCT00404352|9645211|FG004|Double Blind (up to 24 Month)|Other|0
6045958|NCT00404352|9645212|FG005|Double Blind (up to 24 Month)|Other|0
6045959|NCT00404352|9645213|FG006|Double Blind (up to 24 Month)|Other|0
6045960|NCT00404352|9645214|FG007|Double Blind (up to 24 Month)|Other|0
6045961|NCT00404352|9645215|FG008|Double Blind (up to 24 Month)|Other|0
6045962|NCT00404352|9645207|FG000|Open Label (up to 24 Month)|Adverse Event|0
6045963|NCT00404352|9645208|FG001|Open Label (up to 24 Month)|Adverse Event|0
6045964|NCT00404352|9645209|FG002|Open Label (up to 24 Month)|Adverse Event|0
6045965|NCT00404352|9645210|FG003|Open Label (up to 24 Month)|Adverse Event|2
6045966|NCT00404352|9645211|FG004|Open Label (up to 24 Month)|Adverse Event|1
6045967|NCT00404352|9645212|FG005|Open Label (up to 24 Month)|Adverse Event|1
6045968|NCT00404352|9645213|FG006|Open Label (up to 24 Month)|Adverse Event|0
6068421|NCT00538733|9671081|FG000|Overall Study|Adverse Event|8
5992540|NCT04851314|9584920|FG000|Overall Study|Unable to complete research set-up procedures|0
5992541|NCT04851314|9584921|FG001|Overall Study|Unable to complete research set-up procedures|2
5992542|NCT04851314|9584920|FG000|Overall Study|Change in Anesthesia Plan (patient no longer meets inclusion criteria)|3
5992543|NCT04851314|9584921|FG001|Overall Study|Change in Anesthesia Plan (patient no longer meets inclusion criteria)|2
5992544|NCT04823494|9584948|FG000|Overall Study|Programming software malfunction.|1
5992545|NCT04823494|9584949|FG001|Overall Study|Programming software malfunction.|0
5992546|NCT04823494|9584948|FG000|Overall Study|Withdrawal by Subject|1
5992547|NCT04823494|9584949|FG001|Overall Study|Withdrawal by Subject|0
5992548|NCT04823494|9584948|FG000|Overall Study|Devices lost|0
5992549|NCT04823494|9584949|FG001|Overall Study|Devices lost|1
5992553|NCT04799782|9584972|FG000|Washout|Physician Decision|2
5992554|NCT04799782|9584973|FG001|Washout|Physician Decision|0
5992555|NCT04799782|9584972|FG000|Washout|Withdrawal by Subject|0
5992556|NCT04799782|9584973|FG001|Washout|Withdrawal by Subject|2
5992557|NCT04799782|9584972|FG000|Washout|Lost to Follow-up|0
6309345|NCT02637856|10037906|FG001|Main Study (Baseline to Week 100)|Physician Decision|0
6309346|NCT02637856|10037905|FG000|Main Study (Baseline to Week 100)|Pregnancy|7
6309347|NCT02637856|10037906|FG001|Main Study (Baseline to Week 100)|Pregnancy|0
6309348|NCT02637856|10037905|FG000|Main Study (Baseline to Week 100)|Withdrawal by Subject|20
5992558|NCT04799782|9584973|FG001|Washout|Lost to Follow-up|1
5992559|NCT04755595|9585008|FG000|Overall Study|Lost to Follow-up|1
5992560|NCT04749745|9585013|FG000|Overall Study|Withdrawal by Subject|1
5992561|NCT04749745|9585014|FG001|Overall Study|Withdrawal by Subject|0
5992562|NCT04748341|9585022|FG000|Overall Study|Lost to Follow-up|1
5992563|NCT04748341|9585023|FG001|Overall Study|Lost to Follow-up|1
5992564|NCT04737278|9585031|FG000|Overall Study|Lost to Follow-up|1
5992565|NCT04737278|9585032|FG001|Overall Study|Lost to Follow-up|1
5992566|NCT04737278|9585031|FG000|Overall Study|Withdrawal by Subject|1
5992567|NCT04737278|9585032|FG001|Overall Study|Withdrawal by Subject|0
5992568|NCT04737278|9585031|FG000|Overall Study|Protocol Violation|1
5992569|NCT04737278|9585032|FG001|Overall Study|Protocol Violation|1
5992570|NCT04737278|9585031|FG000|Overall Study|failure to complete questionnaire|1
5992571|NCT04737278|9585032|FG001|Overall Study|failure to complete questionnaire|1
5992572|NCT04524598|9585066|FG000|Phase I - Feasibility|Lost to Follow-up|2
5992573|NCT04524598|9585067|FG001|Phase I - Feasibility|Lost to Follow-up|4
5992574|NCT04524598|9585068|FG002|Phase I - Feasibility|Lost to Follow-up|0
5992575|NCT04524598|9585069|FG003|Phase I - Feasibility|Lost to Follow-up|0
5992576|NCT04524598|9585070|FG004|Phase I - Feasibility|Lost to Follow-up|0
5992577|NCT04524598|9585066|FG000|Phase I - Feasibility|Dropped for missing two consecutive weekly safety check-ins.|2
5992578|NCT04524598|9585067|FG001|Phase I - Feasibility|Dropped for missing two consecutive weekly safety check-ins.|1
5992579|NCT04524598|9585068|FG002|Phase I - Feasibility|Dropped for missing two consecutive weekly safety check-ins.|0
6045969|NCT00404352|9645214|FG007|Open Label (up to 24 Month)|Adverse Event|0
6068422|NCT00538733|9671081|FG000|Overall Study|Death|1
6068423|NCT00538733|9671081|FG000|Overall Study|declined to participate|2
6068424|NCT00538733|9671081|FG000|Overall Study|still on therapy|1
6068425|NCT00538785|9671099|FG000|Overall Study|Death|9
6068426|NCT00538785|9671100|FG001|Overall Study|Death|10
6068427|NCT00538785|9671099|FG000|Overall Study|Withdrawal of consent|9
6068428|NCT00538785|9671100|FG001|Overall Study|Withdrawal of consent|7
6068429|NCT00538785|9671099|FG000|Overall Study|Lost to Follow-up|1
6068430|NCT00538785|9671100|FG001|Overall Study|Lost to Follow-up|0
6068431|NCT00538902|9671127|FG000|DB Wk 0 Through 12 (Primary D/C Reasons)|Adverse Event|1
6068432|NCT00538902|9671128|FG001|DB Wk 0 Through 12 (Primary D/C Reasons)|Adverse Event|2
6068433|NCT00538902|9671129|FG002|DB Wk 0 Through 12 (Primary D/C Reasons)|Adverse Event|3
6068434|NCT00538902|9671127|FG000|DB Wk 0 Through 12 (Primary D/C Reasons)|Withdrawal by Subject|0
6068435|NCT00538902|9671128|FG001|DB Wk 0 Through 12 (Primary D/C Reasons)|Withdrawal by Subject|0
6068436|NCT00538902|9671129|FG002|DB Wk 0 Through 12 (Primary D/C Reasons)|Withdrawal by Subject|1
6068437|NCT00538902|9671127|FG000|DB Wk 0 Through 12 (Primary D/C Reasons)|Lost to Follow-up|0
6068438|NCT00538902|9671128|FG001|DB Wk 0 Through 12 (Primary D/C Reasons)|Lost to Follow-up|0
6068439|NCT00538902|9671129|FG002|DB Wk 0 Through 12 (Primary D/C Reasons)|Lost to Follow-up|1
6068440|NCT00538902|9671127|FG000|DB Wk 0 Through 12 (Primary D/C Reasons)|Various|0
6068441|NCT00538902|9671128|FG001|DB Wk 0 Through 12 (Primary D/C Reasons)|Various|0
6068442|NCT00538902|9671129|FG002|DB Wk 0 Through 12 (Primary D/C Reasons)|Various|0
6068443|NCT00538902|9671127|FG000|OL Wk 24 to End (Primary D/C Reasons)|Adverse Event|2
6068444|NCT00538902|9671128|FG001|OL Wk 24 to End (Primary D/C Reasons)|Adverse Event|10
6068445|NCT00538902|9671129|FG002|OL Wk 24 to End (Primary D/C Reasons)|Adverse Event|11
6068446|NCT00538902|9671127|FG000|OL Wk 24 to End (Primary D/C Reasons)|Withdrawal by Subject|15
6068447|NCT00538902|9671128|FG001|OL Wk 24 to End (Primary D/C Reasons)|Withdrawal by Subject|19
6068448|NCT00538902|9671129|FG002|OL Wk 24 to End (Primary D/C Reasons)|Withdrawal by Subject|25
6068449|NCT00538902|9671127|FG000|OL Wk 24 to End (Primary D/C Reasons)|Lost to Follow-up|1
6068450|NCT00538902|9671128|FG001|OL Wk 24 to End (Primary D/C Reasons)|Lost to Follow-up|10
6068451|NCT00538902|9671129|FG002|OL Wk 24 to End (Primary D/C Reasons)|Lost to Follow-up|6
6068452|NCT00538902|9671127|FG000|OL Wk 24 to End (Primary D/C Reasons)|Various|18
6068453|NCT00538902|9671128|FG001|OL Wk 24 to End (Primary D/C Reasons)|Various|25
6068454|NCT00538902|9671129|FG002|OL Wk 24 to End (Primary D/C Reasons)|Various|22
6068455|NCT00539006|9671147|FG000|Pre-treatment|Other|0
6068456|NCT00539006|9671148|FG001|Pre-treatment|Other|1
6068457|NCT00539006|9671149|FG002|Pre-treatment|Other|0
6068458|NCT00539006|9671150|FG003|Pre-treatment|Other|0
6068459|NCT00539006|9671147|FG000|Treatment Period 1|Lost to Follow-up|0
6068460|NCT00539006|9671148|FG001|Treatment Period 1|Lost to Follow-up|0
6068461|NCT00539006|9671149|FG002|Treatment Period 1|Lost to Follow-up|1
6068462|NCT00539006|9671150|FG003|Treatment Period 1|Lost to Follow-up|0
6068463|NCT00539006|9671147|FG000|Treatment Period 1|Protocol Violation|0
6068464|NCT00539006|9671148|FG001|Treatment Period 1|Protocol Violation|0
6068465|NCT00539006|9671149|FG002|Treatment Period 1|Protocol Violation|1
6068466|NCT00539006|9671150|FG003|Treatment Period 1|Protocol Violation|0
6068467|NCT00539006|9671147|FG000|Treatment Period 1|Lack of Efficacy|0
6068468|NCT00539006|9671148|FG001|Treatment Period 1|Lack of Efficacy|0
6068469|NCT00539006|9671149|FG002|Treatment Period 1|Lack of Efficacy|0
6068470|NCT00539006|9671150|FG003|Treatment Period 1|Lack of Efficacy|1
6068471|NCT00539006|9671147|FG000|Washout|Adverse Event|2
6068472|NCT00539006|9671148|FG001|Washout|Adverse Event|1
6068473|NCT00539006|9671149|FG002|Washout|Adverse Event|0
6068474|NCT00539006|9671150|FG003|Washout|Adverse Event|0
6068475|NCT00539006|9671147|FG000|Washout|Protocol Violation|1
6068476|NCT00539006|9671148|FG001|Washout|Protocol Violation|1
6068477|NCT00539006|9671149|FG002|Washout|Protocol Violation|0
6068478|NCT00539006|9671150|FG003|Washout|Protocol Violation|0
6068479|NCT00539006|9671147|FG000|Washout|Withdrawal by Subject|0
6068480|NCT00539006|9671148|FG001|Washout|Withdrawal by Subject|2
6068481|NCT00539006|9671149|FG002|Washout|Withdrawal by Subject|0
6068482|NCT00539006|9671150|FG003|Washout|Withdrawal by Subject|0
6068483|NCT00539006|9671147|FG000|Washout|Failed to meet continuation criteria|16
6068484|NCT00539006|9671148|FG001|Washout|Failed to meet continuation criteria|5
6068485|NCT00539006|9671149|FG002|Washout|Failed to meet continuation criteria|14
6068486|NCT00539006|9671150|FG003|Washout|Failed to meet continuation criteria|6
5992550|NCT04821245|9584957|FG000|Overall Study|Withdrawal by Subject|3
5992551|NCT04821245|9584957|FG000|Overall Study|Physician Decision|1
5992552|NCT04821245|9584957|FG000|Overall Study|Protocol Violation|5
5992580|NCT04524598|9585069|FG003|Phase I - Feasibility|Dropped for missing two consecutive weekly safety check-ins.|0
5992581|NCT04524598|9585070|FG004|Phase I - Feasibility|Dropped for missing two consecutive weekly safety check-ins.|0
5992582|NCT04524598|9585066|FG000|Phase II - Outcomes|Lost to Follow-up|0
5992583|NCT04524598|9585067|FG001|Phase II - Outcomes|Lost to Follow-up|0
5992584|NCT04524598|9585068|FG002|Phase II - Outcomes|Lost to Follow-up|16
5992585|NCT04524598|9585069|FG003|Phase II - Outcomes|Lost to Follow-up|8
5992586|NCT04524598|9585070|FG004|Phase II - Outcomes|Lost to Follow-up|0
5992587|NCT04524598|9585066|FG000|Phase II - Outcomes|Withdrawal by Subject|0
5992588|NCT04524598|9585067|FG001|Phase II - Outcomes|Withdrawal by Subject|0
5992589|NCT04524598|9585068|FG002|Phase II - Outcomes|Withdrawal by Subject|2
5992590|NCT04524598|9585069|FG003|Phase II - Outcomes|Withdrawal by Subject|0
5992591|NCT04524598|9585070|FG004|Phase II - Outcomes|Withdrawal by Subject|0
5992592|NCT04524598|9585066|FG000|Phase II - Outcomes|Dropped for missing two consecutive weekly safety check-ins.|0
5992593|NCT04524598|9585067|FG001|Phase II - Outcomes|Dropped for missing two consecutive weekly safety check-ins.|0
5992594|NCT04524598|9585068|FG002|Phase II - Outcomes|Dropped for missing two consecutive weekly safety check-ins.|8
5992595|NCT04524598|9585069|FG003|Phase II - Outcomes|Dropped for missing two consecutive weekly safety check-ins.|5
5992596|NCT04524598|9585070|FG004|Phase II - Outcomes|Dropped for missing two consecutive weekly safety check-ins.|0
5992597|NCT04524598|9585066|FG000|Phase II - Control Extension|Lost to Follow-up|0
5992598|NCT04524598|9585067|FG001|Phase II - Control Extension|Lost to Follow-up|0
5992599|NCT04524598|9585068|FG002|Phase II - Control Extension|Lost to Follow-up|0
5992600|NCT04524598|9585069|FG003|Phase II - Control Extension|Lost to Follow-up|0
5992601|NCT04524598|9585070|FG004|Phase II - Control Extension|Lost to Follow-up|6
5992602|NCT04524598|9585066|FG000|Phase II - Control Extension|Dropped for missing two consecutive weekly safety check-ins.|0
5992603|NCT04524598|9585067|FG001|Phase II - Control Extension|Dropped for missing two consecutive weekly safety check-ins.|0
5992604|NCT04524598|9585068|FG002|Phase II - Control Extension|Dropped for missing two consecutive weekly safety check-ins.|0
5992605|NCT04524598|9585069|FG003|Phase II - Control Extension|Dropped for missing two consecutive weekly safety check-ins.|0
5992606|NCT04524598|9585070|FG004|Phase II - Control Extension|Dropped for missing two consecutive weekly safety check-ins.|6
5992607|NCT04334460|9585086|FG000|Full Analysis Set (FAS)|Patients did not receive any study drug & are therefore excluded from the FAS.|4
5992608|NCT04334460|9585087|FG001|Full Analysis Set (FAS)|Patients did not receive any study drug & are therefore excluded from the FAS.|1
5992609|NCT04334460|9585086|FG000|Safety Analysis Population|Patients did not receive any study drug & are therefore excluded from the Safety analysis set.|4
6068487|NCT00539006|9671147|FG000|Washout|Other|1
6068488|NCT00539006|9671148|FG001|Washout|Other|1
6068489|NCT00539006|9671149|FG002|Washout|Other|2
6068490|NCT00539006|9671150|FG003|Washout|Other|3
6068491|NCT00539006|9671147|FG000|Treatment Period 2|Protocol Violation|1
6068492|NCT00539006|9671148|FG001|Treatment Period 2|Protocol Violation|0
6068493|NCT00539006|9671149|FG002|Treatment Period 2|Protocol Violation|0
6068494|NCT00539006|9671150|FG003|Treatment Period 2|Protocol Violation|0
6068495|NCT00539006|9671147|FG000|Treatment Period 2|Other|0
6068496|NCT00539006|9671148|FG001|Treatment Period 2|Other|1
6068497|NCT00539006|9671149|FG002|Treatment Period 2|Other|0
6068498|NCT00539006|9671150|FG003|Treatment Period 2|Other|0
6068499|NCT00539032|9671168|FG000|Overall Study|Withdrawal by Subject|2
6068500|NCT00539032|9671169|FG001|Overall Study|Withdrawal by Subject|1
6068501|NCT00539188|9671186|FG000|Overall Study|Withdrawal by Subject|1
6068502|NCT00539188|9671187|FG001|Overall Study|Withdrawal by Subject|0
6068503|NCT00539188|9671186|FG000|Overall Study|Lost to Follow-up|2
6068504|NCT00539188|9671187|FG001|Overall Study|Lost to Follow-up|1
6068505|NCT00539240|9671196|FG000|Overall Study|Withdrawal by Subject|0
6068506|NCT00539240|9671197|FG001|Overall Study|Withdrawal by Subject|2
6068507|NCT00539240|9671198|FG002|Overall Study|Withdrawal by Subject|0
6068508|NCT00539240|9671196|FG000|Overall Study|Protocol Violation|1
6068509|NCT00539240|9671197|FG001|Overall Study|Protocol Violation|1
6068510|NCT00539240|9671198|FG002|Overall Study|Protocol Violation|4
6068511|NCT00539240|9671196|FG000|Overall Study|Lost to Follow-up|2
6068512|NCT00539240|9671197|FG001|Overall Study|Lost to Follow-up|3
6068513|NCT00539240|9671198|FG002|Overall Study|Lost to Follow-up|1
6068514|NCT00539240|9671196|FG000|Overall Study|Adverse Event|3
6068515|NCT00539240|9671197|FG001|Overall Study|Adverse Event|1
6068516|NCT00539240|9671198|FG002|Overall Study|Adverse Event|10
6068517|NCT00539279|9671212|FG000|Treatment|Withdrawal by Subject|10
6068518|NCT00539279|9671213|FG001|Treatment|Withdrawal by Subject|8
6068519|NCT00539279|9671212|FG000|Treatment|Death|1
5992610|NCT04334460|9585087|FG001|Safety Analysis Population|Patients did not receive any study drug & are therefore excluded from the Safety analysis set.|1
5992611|NCT04247828|9585094|FG000|Overall Study|covid-19 mandated patient recruitment restrictions|9
6045970|NCT00404352|9645215|FG008|Open Label (up to 24 Month)|Adverse Event|0
6045971|NCT00404352|9645207|FG000|Open Label (up to 24 Month)|Pregnancy|0
6045972|NCT00404352|9645208|FG001|Open Label (up to 24 Month)|Pregnancy|0
6045973|NCT00404352|9645209|FG002|Open Label (up to 24 Month)|Pregnancy|0
6045974|NCT00404352|9645210|FG003|Open Label (up to 24 Month)|Pregnancy|0
6045975|NCT00404352|9645211|FG004|Open Label (up to 24 Month)|Pregnancy|0
6045976|NCT00404352|9645212|FG005|Open Label (up to 24 Month)|Pregnancy|1
6045977|NCT00404352|9645213|FG006|Open Label (up to 24 Month)|Pregnancy|0
6045978|NCT00404352|9645214|FG007|Open Label (up to 24 Month)|Pregnancy|0
6045979|NCT00404352|9645215|FG008|Open Label (up to 24 Month)|Pregnancy|0
6045980|NCT00404352|9645207|FG000|Open Label (up to 24 Month)|Lost to Follow-up|0
6045981|NCT00404352|9645208|FG001|Open Label (up to 24 Month)|Lost to Follow-up|0
6045982|NCT00404352|9645209|FG002|Open Label (up to 24 Month)|Lost to Follow-up|0
6045983|NCT00404352|9645210|FG003|Open Label (up to 24 Month)|Lost to Follow-up|0
6045984|NCT00404352|9645211|FG004|Open Label (up to 24 Month)|Lost to Follow-up|1
6045985|NCT00404352|9645212|FG005|Open Label (up to 24 Month)|Lost to Follow-up|0
6045986|NCT00404352|9645213|FG006|Open Label (up to 24 Month)|Lost to Follow-up|0
6045987|NCT00404352|9645214|FG007|Open Label (up to 24 Month)|Lost to Follow-up|0
6045988|NCT00404352|9645215|FG008|Open Label (up to 24 Month)|Lost to Follow-up|0
6045989|NCT00404352|9645207|FG000|Open Label (up to 24 Month)|Withdrawal by Subject|0
6045990|NCT00404352|9645208|FG001|Open Label (up to 24 Month)|Withdrawal by Subject|0
6045991|NCT00404352|9645209|FG002|Open Label (up to 24 Month)|Withdrawal by Subject|0
6045992|NCT00404352|9645210|FG003|Open Label (up to 24 Month)|Withdrawal by Subject|0
6045993|NCT00404352|9645211|FG004|Open Label (up to 24 Month)|Withdrawal by Subject|0
6045994|NCT00404352|9645212|FG005|Open Label (up to 24 Month)|Withdrawal by Subject|5
6045995|NCT00404352|9645213|FG006|Open Label (up to 24 Month)|Withdrawal by Subject|0
6045996|NCT00404352|9645214|FG007|Open Label (up to 24 Month)|Withdrawal by Subject|0
6045997|NCT00404352|9645215|FG008|Open Label (up to 24 Month)|Withdrawal by Subject|0
6045998|NCT00404352|9645207|FG000|Open Label (up to 24 Month)|Disease progression|0
6045999|NCT00404352|9645208|FG001|Open Label (up to 24 Month)|Disease progression|0
6046000|NCT00404352|9645209|FG002|Open Label (up to 24 Month)|Disease progression|0
6046001|NCT00404352|9645210|FG003|Open Label (up to 24 Month)|Disease progression|1
6046002|NCT00404352|9645211|FG004|Open Label (up to 24 Month)|Disease progression|0
6046003|NCT00404352|9645212|FG005|Open Label (up to 24 Month)|Disease progression|0
6046004|NCT00404352|9645213|FG006|Open Label (up to 24 Month)|Disease progression|0
6046005|NCT00404352|9645214|FG007|Open Label (up to 24 Month)|Disease progression|0
6046006|NCT00404352|9645215|FG008|Open Label (up to 24 Month)|Disease progression|0
6046007|NCT00404352|9645207|FG000|Open Label Extension (up to 36 Months)|Adverse Event|0
6046008|NCT00404352|9645208|FG001|Open Label Extension (up to 36 Months)|Adverse Event|0
6046009|NCT00404352|9645209|FG002|Open Label Extension (up to 36 Months)|Adverse Event|0
6046010|NCT00404352|9645210|FG003|Open Label Extension (up to 36 Months)|Adverse Event|0
6046011|NCT00404352|9645211|FG004|Open Label Extension (up to 36 Months)|Adverse Event|0
6046012|NCT00404352|9645212|FG005|Open Label Extension (up to 36 Months)|Adverse Event|0
6046013|NCT00404352|9645213|FG006|Open Label Extension (up to 36 Months)|Adverse Event|1
6046014|NCT00404352|9645214|FG007|Open Label Extension (up to 36 Months)|Adverse Event|1
6046015|NCT00404352|9645215|FG008|Open Label Extension (up to 36 Months)|Adverse Event|0
6046016|NCT00404352|9645207|FG000|Open Label Extension (up to 36 Months)|Other|0
6046017|NCT00404352|9645208|FG001|Open Label Extension (up to 36 Months)|Other|0
6046018|NCT00404352|9645209|FG002|Open Label Extension (up to 36 Months)|Other|0
6046019|NCT00404352|9645210|FG003|Open Label Extension (up to 36 Months)|Other|0
6046020|NCT00404352|9645211|FG004|Open Label Extension (up to 36 Months)|Other|0
6046021|NCT00404352|9645212|FG005|Open Label Extension (up to 36 Months)|Other|0
6046022|NCT00404352|9645213|FG006|Open Label Extension (up to 36 Months)|Other|0
5992612|NCT04084769|9585102|FG000|Overall Study|Protocol Violation|1
5992613|NCT04084769|9585103|FG001|Overall Study|Protocol Violation|3
5992614|NCT04084769|9585104|FG002|Overall Study|Protocol Violation|0
5992615|NCT04084769|9585105|FG003|Overall Study|Protocol Violation|1
5992616|NCT04084769|9585102|FG000|Overall Study|Withdrawal by Subject|0
5992617|NCT04084769|9585103|FG001|Overall Study|Withdrawal by Subject|1
5992618|NCT04084769|9585104|FG002|Overall Study|Withdrawal by Subject|0
5992619|NCT04084769|9585105|FG003|Overall Study|Withdrawal by Subject|0
5992620|NCT04084769|9585102|FG000|Overall Study|Withdrawal by parent/guardian|1
5992621|NCT04084769|9585103|FG001|Overall Study|Withdrawal by parent/guardian|0
5992622|NCT04084769|9585104|FG002|Overall Study|Withdrawal by parent/guardian|0
5992623|NCT04084769|9585105|FG003|Overall Study|Withdrawal by parent/guardian|1
5992624|NCT04084769|9585102|FG000|Overall Study|Lost to Follow-up|2
5992625|NCT04084769|9585103|FG001|Overall Study|Lost to Follow-up|0
5992626|NCT04084769|9585104|FG002|Overall Study|Lost to Follow-up|0
5992627|NCT04084769|9585105|FG003|Overall Study|Lost to Follow-up|0
5992628|NCT04024228|9585122|FG000|Overall Study|Adverse Event|1
5992629|NCT04024228|9585123|FG001|Overall Study|Adverse Event|0
5992630|NCT04024228|9585122|FG000|Overall Study|Protocol Deviation|0
5992631|NCT04024228|9585123|FG001|Overall Study|Protocol Deviation|2
5992632|NCT04024228|9585122|FG000|Overall Study|Withdrawal by Subject|3
5992633|NCT04024228|9585123|FG001|Overall Study|Withdrawal by Subject|4
5992634|NCT03980938|9585146|FG000|Treatment Period 1|Study Terminated|1
5992635|NCT03980938|9585147|FG001|Treatment Period 1|Study Terminated|1
5992636|NCT03980938|9585146|FG000|Treatment Period 2|Study Terminated|2
5992637|NCT03980938|9585147|FG001|Treatment Period 2|Study Terminated|2
5992638|NCT03863353|9585155|FG000|Overall Study|incomplete baseline; surgical complication; no opioid prescription|24
5992639|NCT03863353|9585156|FG001|Overall Study|incomplete baseline; surgical complication; no opioid prescription|20
5992640|NCT03622593|9585165|FG000|Overall Study|Withdrawal by Subject|5
5992641|NCT03622593|9585166|FG001|Overall Study|Withdrawal by Subject|4
5992642|NCT03622593|9585167|FG002|Overall Study|Withdrawal by Subject|3
6068520|NCT00539279|9671213|FG001|Treatment|Death|0
5992643|NCT03622593|9585165|FG000|Overall Study|Death|5
5992644|NCT03622593|9585166|FG001|Overall Study|Death|0
5992645|NCT03622593|9585167|FG002|Overall Study|Death|5
5992646|NCT03622593|9585165|FG000|Overall Study|Lost to Follow-up|5
5992647|NCT03622593|9585166|FG001|Overall Study|Lost to Follow-up|2
5992648|NCT03622593|9585167|FG002|Overall Study|Lost to Follow-up|3
5992649|NCT03622593|9585165|FG000|Overall Study|Adverse Event|2
5992650|NCT03622593|9585166|FG001|Overall Study|Adverse Event|1
5992651|NCT03622593|9585167|FG002|Overall Study|Adverse Event|3
5992652|NCT03622593|9585165|FG000|Overall Study|Physician Decision|1
5992653|NCT03622593|9585166|FG001|Overall Study|Physician Decision|0
5992654|NCT03622593|9585167|FG002|Overall Study|Physician Decision|1
5992655|NCT03622593|9585165|FG000|Overall Study|Other|1
5992656|NCT03622593|9585166|FG001|Overall Study|Other|0
5992657|NCT03622593|9585167|FG002|Overall Study|Other|1
5992658|NCT03622593|9585165|FG000|Overall Study|Completed up to Week 56 (study was still ongoing)|298
5992659|NCT03622593|9585166|FG001|Overall Study|Completed up to Week 56 (study was still ongoing)|312
5992660|NCT03622593|9585167|FG002|Overall Study|Completed up to Week 56 (study was still ongoing)|299
5992661|NCT03622580|9585179|FG000|Overall Study|Death|7
5992662|NCT03622580|9585180|FG001|Overall Study|Death|9
5992663|NCT03622580|9585181|FG002|Overall Study|Death|4
5992664|NCT03622580|9585179|FG000|Overall Study|Adverse Event|5
5992665|NCT03622580|9585180|FG001|Overall Study|Adverse Event|6
5992666|NCT03622580|9585181|FG002|Overall Study|Adverse Event|2
5992667|NCT03622580|9585179|FG000|Overall Study|Withdrawal by Subject|5
5992668|NCT03622580|9585180|FG001|Overall Study|Withdrawal by Subject|3
5992669|NCT03622580|9585181|FG002|Overall Study|Withdrawal by Subject|9
5992670|NCT03622580|9585179|FG000|Overall Study|Lost to Follow-up|5
5992671|NCT03622580|9585180|FG001|Overall Study|Lost to Follow-up|6
5992672|NCT03622580|9585181|FG002|Overall Study|Lost to Follow-up|2
5992673|NCT03622580|9585179|FG000|Overall Study|Protocol Violation|1
5992674|NCT03622580|9585180|FG001|Overall Study|Protocol Violation|0
5992675|NCT03622580|9585181|FG002|Overall Study|Protocol Violation|1
5992676|NCT03622580|9585179|FG000|Overall Study|Lack of Efficacy|0
5992677|NCT03622580|9585180|FG001|Overall Study|Lack of Efficacy|0
5992678|NCT03622580|9585181|FG002|Overall Study|Lack of Efficacy|1
5992679|NCT03622580|9585179|FG000|Overall Study|Physician Decision|1
5992680|NCT03622580|9585180|FG001|Overall Study|Physician Decision|0
5992681|NCT03622580|9585181|FG002|Overall Study|Physician Decision|1
5992682|NCT03622580|9585179|FG000|Overall Study|Completed up to Week 56 (study was still ongoing)|291
5992683|NCT03622580|9585180|FG001|Overall Study|Completed up to Week 56 (study was still ongoing)|289
5992684|NCT03622580|9585181|FG002|Overall Study|Completed up to Week 56 (study was still ongoing)|292
5992685|NCT03333928|9585221|FG000|Initial Dosing Period (Period 1)|Protocol Violation|0
5992686|NCT03333928|9585222|FG001|Initial Dosing Period (Period 1)|Protocol Violation|0
5992687|NCT03333928|9585223|FG002|Initial Dosing Period (Period 1)|Protocol Violation|1
5992688|NCT03333928|9585221|FG000|Initial Dosing Period (Period 1)|Withdrawal by Subject|0
5992689|NCT03333928|9585222|FG001|Initial Dosing Period (Period 1)|Withdrawal by Subject|1
5992690|NCT03333928|9585223|FG002|Initial Dosing Period (Period 1)|Withdrawal by Subject|1
5992691|NCT03333928|9585221|FG000|Initial Dosing Period (Period 1)|Corporate decision to not initiate dosing in new patients because of COVID-19|1
5992692|NCT03333928|9585222|FG001|Initial Dosing Period (Period 1)|Corporate decision to not initiate dosing in new patients because of COVID-19|0
5992693|NCT03333928|9585223|FG002|Initial Dosing Period (Period 1)|Corporate decision to not initiate dosing in new patients because of COVID-19|1
5992694|NCT03333928|9585221|FG000|Initial Dosing Period (Period 1)|Adverse Event|0
5992695|NCT03333928|9585222|FG001|Initial Dosing Period (Period 1)|Adverse Event|3
5992696|NCT03333928|9585223|FG002|Initial Dosing Period (Period 1)|Adverse Event|1
5992697|NCT03333928|9585221|FG000|Dose-controlled Extension (Period 2)|Adverse Event|2
5992698|NCT03333928|9585222|FG001|Dose-controlled Extension (Period 2)|Adverse Event|1
5992699|NCT03333928|9585223|FG002|Dose-controlled Extension (Period 2)|Adverse Event|0
5992700|NCT03333928|9585221|FG000|Dose-controlled Extension (Period 2)|Lost to Follow-up|1
5992701|NCT03333928|9585222|FG001|Dose-controlled Extension (Period 2)|Lost to Follow-up|0
5992702|NCT03333928|9585223|FG002|Dose-controlled Extension (Period 2)|Lost to Follow-up|0
5992703|NCT03333928|9585221|FG000|Randomized Withdrawal (Period 3)|Adverse Event|1
5992704|NCT03333928|9585222|FG001|Randomized Withdrawal (Period 3)|Adverse Event|0
5992705|NCT03333928|9585223|FG002|Randomized Withdrawal (Period 3)|Adverse Event|0
5992706|NCT03333928|9585221|FG000|Randomized Withdrawal (Period 3)|Lost to Follow-up|1
5992707|NCT03333928|9585222|FG001|Randomized Withdrawal (Period 3)|Lost to Follow-up|0
5992708|NCT03333928|9585223|FG002|Randomized Withdrawal (Period 3)|Lost to Follow-up|1
5992709|NCT03298984|9585243|FG000|Overall Study|Physician Decision|1
5992710|NCT03298984|9585244|FG001|Overall Study|Physician Decision|0
5992711|NCT03298984|9585245|FG002|Overall Study|Physician Decision|0
5992712|NCT03298984|9585246|FG003|Overall Study|Physician Decision|6
5992713|NCT03298984|9585243|FG000|Overall Study|Lack of Efficacy|0
5992714|NCT03298984|9585244|FG001|Overall Study|Lack of Efficacy|1
5992715|NCT03298984|9585245|FG002|Overall Study|Lack of Efficacy|1
5992716|NCT03298984|9585246|FG003|Overall Study|Lack of Efficacy|4
5992717|NCT03298984|9585243|FG000|Overall Study|Relapsed disease (following remission)|0
5992718|NCT03298984|9585244|FG001|Overall Study|Relapsed disease (following remission)|0
5992719|NCT03298984|9585245|FG002|Overall Study|Relapsed disease (following remission)|1
5992720|NCT03298984|9585246|FG003|Overall Study|Relapsed disease (following remission)|1
5992721|NCT03298984|9585243|FG000|Overall Study|Adverse Event|0
5992722|NCT03298984|9585244|FG001|Overall Study|Adverse Event|0
5992723|NCT03298984|9585245|FG002|Overall Study|Adverse Event|0
5992724|NCT03298984|9585246|FG003|Overall Study|Adverse Event|1
5992725|NCT03298984|9585243|FG000|Overall Study|Death|0
5992726|NCT03298984|9585244|FG001|Overall Study|Death|0
5992727|NCT03298984|9585245|FG002|Overall Study|Death|0
5992728|NCT03298984|9585246|FG003|Overall Study|Death|2
5992729|NCT03298984|9585243|FG000|Overall Study|Insurance Company Decision|0
5992730|NCT03298984|9585244|FG001|Overall Study|Insurance Company Decision|0
5992731|NCT03298984|9585245|FG002|Overall Study|Insurance Company Decision|0
5992732|NCT03298984|9585246|FG003|Overall Study|Insurance Company Decision|1
6046023|NCT00404352|9645214|FG007|Open Label Extension (up to 36 Months)|Other|0
6046024|NCT00404352|9645215|FG008|Open Label Extension (up to 36 Months)|Other|2
6046025|NCT00404495|9645234|FG000|Overall Study|Death|37
6046026|NCT00404495|9645235|FG001|Overall Study|Death|11
6046027|NCT00404495|9645234|FG000|Overall Study|Lost to Follow-up|5
6046028|NCT00404495|9645235|FG001|Overall Study|Lost to Follow-up|0
6046029|NCT00404495|9645234|FG000|Overall Study|Other|1
6046030|NCT00404495|9645235|FG001|Overall Study|Other|0
6046031|NCT00404495|9645234|FG000|Overall Study|Withdrawal by Subject|1
6046032|NCT00404495|9645235|FG001|Overall Study|Withdrawal by Subject|0
6046033|NCT00404547|9645243|FG000|Overall Study|Adverse Event|39
6046034|NCT00404547|9645244|FG001|Overall Study|Adverse Event|6
6046035|NCT00404547|9645243|FG000|Overall Study|Withdrawal by Subject|19
6046036|NCT00404547|9645244|FG001|Overall Study|Withdrawal by Subject|2
6046037|NCT00404547|9645243|FG000|Overall Study|Protocol Violation|0
6046038|NCT00404547|9645244|FG001|Overall Study|Protocol Violation|1
6046039|NCT00404547|9645243|FG000|Overall Study|Lost to Follow-up|20
6046040|NCT00404547|9645244|FG001|Overall Study|Lost to Follow-up|9
6046041|NCT00404547|9645243|FG000|Overall Study|Lack of compliance|5
6046042|NCT00404547|9645244|FG001|Overall Study|Lack of compliance|1
6046043|NCT00404547|9645243|FG000|Overall Study|Other|4
6046044|NCT00404547|9645244|FG001|Overall Study|Other|0
6046045|NCT00404547|9645243|FG000|Overall Study|Reason not stated|3
6046046|NCT00404547|9645244|FG001|Overall Study|Reason not stated|6
6046047|NCT00404651|9645254|FG000|Overall Study|Serious Adverse Event|0
6046048|NCT00404651|9645255|FG001|Overall Study|Serious Adverse Event|0
6046049|NCT00404651|9645256|FG002|Overall Study|Serious Adverse Event|2
6046050|NCT00404651|9645257|FG003|Overall Study|Serious Adverse Event|0
6046051|NCT00404651|9645254|FG000|Overall Study|Protocol Violation|10
6046052|NCT00404651|9645255|FG001|Overall Study|Protocol Violation|5
6046053|NCT00404651|9645256|FG002|Overall Study|Protocol Violation|14
6046054|NCT00404651|9645257|FG003|Overall Study|Protocol Violation|5
6046055|NCT00404651|9645254|FG000|Overall Study|Lost to Follow-up|15
6046056|NCT00404651|9645255|FG001|Overall Study|Lost to Follow-up|11
6046057|NCT00404651|9645256|FG002|Overall Study|Lost to Follow-up|13
6046058|NCT00404651|9645257|FG003|Overall Study|Lost to Follow-up|10
6046059|NCT00404651|9645254|FG000|Overall Study|Withdrawal by Subject|14
6046060|NCT00404651|9645255|FG001|Overall Study|Withdrawal by Subject|12
6046061|NCT00404651|9645256|FG002|Overall Study|Withdrawal by Subject|16
6046062|NCT00404651|9645257|FG003|Overall Study|Withdrawal by Subject|6
5992733|NCT03175198|9585257|FG000|Overall Study|Adverse Event|480
5992734|NCT03175198|9585257|FG000|Overall Study|No actual visit|120
5992735|NCT03175198|9585257|FG000|Overall Study|Registration rule not followed|4
5992736|NCT03175198|9585257|FG000|Overall Study|Patients received Prazaxa treatment before|5
5992737|NCT03175198|9585257|FG000|Overall Study|Other personal reason|509
5992738|NCT03175198|9585257|FG000|Overall Study|To take a contraindication/careful administration drug|8
5992739|NCT03175198|9585257|FG000|Overall Study|Lost to follow-up (changing hospital)|373
5992740|NCT03175198|9585257|FG000|Overall Study|Lost to follow-up (unknown reason)|146
5992741|NCT03175198|9585257|FG000|Overall Study|To conduct invasive treatment of operation|53
5992742|NCT03175198|9585257|FG000|Overall Study|Improvement of nonvalvular atrial fibrillation|629
6068521|NCT00539279|9671212|FG000|Post-Treatment Assessment|Lost to Follow-up|12
6068522|NCT00539279|9671213|FG001|Post-Treatment Assessment|Lost to Follow-up|9
6068523|NCT00539279|9671212|FG000|6-Month Follow-Up Assessment|Lost to Follow-up|1
6309349|NCT02637856|10037906|FG001|Main Study (Baseline to Week 100)|Withdrawal by Subject|0
6309350|NCT02637856|10037905|FG000|Main Study (Baseline to Week 100)|Protocol Deviation|2
6309351|NCT02637856|10037906|FG001|Main Study (Baseline to Week 100)|Protocol Deviation|0
6309352|NCT02637856|10037905|FG000|Main Study (Baseline to Week 100)|Continued on Commercial Ocrevus|164
6068524|NCT00539279|9671213|FG001|6-Month Follow-Up Assessment|Lost to Follow-up|7
6068525|NCT00539305|9671221|FG000|Overall Study|Adverse Event|1
6068526|NCT00539305|9671222|FG001|Overall Study|Adverse Event|0
6068527|NCT00539305|9671221|FG000|Overall Study|Substance Use|0
5992743|NCT03158727|9585263|FG000|Overall Study|Withdrawal by Subject|2
5992744|NCT03158727|9585264|FG001|Overall Study|Withdrawal by Subject|6
5992745|NCT03158727|9585263|FG000|Overall Study|Death|11
5992746|NCT03158727|9585264|FG001|Overall Study|Death|12
5992747|NCT03158727|9585263|FG000|Overall Study|Lost to Follow-up|1
5992748|NCT03158727|9585264|FG001|Overall Study|Lost to Follow-up|0
5992749|NCT03158727|9585263|FG000|Overall Study|Participant doesn't want to come back to the hospital for the visit|2
5992750|NCT03158727|9585264|FG001|Overall Study|Participant doesn't want to come back to the hospital for the visit|0
5992751|NCT03158727|9585263|FG000|Overall Study|Visit 11 not done by mistake|0
6068528|NCT00539305|9671222|FG001|Overall Study|Substance Use|1
6068529|NCT00539305|9671221|FG000|Overall Study|Withdrawal by Subject|0
6068530|NCT00539305|9671222|FG001|Overall Study|Withdrawal by Subject|1
5992752|NCT03158727|9585264|FG001|Overall Study|Visit 11 not done by mistake|1
5992753|NCT03158727|9585263|FG000|Overall Study|Enrolled, not treated|1
5992754|NCT03158727|9585264|FG001|Overall Study|Enrolled, not treated|0
5992755|NCT03075826|9585270|FG000|Overall Study|Withdrawal by Subject|1
5992756|NCT03075826|9585270|FG000|Overall Study|Received less than 3 cycles of study drug|5
5992757|NCT02993731|9585276|FG000|Overall Study|Study Termination|101
5992758|NCT02993731|9585277|FG001|Overall Study|Study Termination|105
6309353|NCT02637856|10037906|FG001|Main Study (Baseline to Week 100)|Continued on Commercial Ocrevus|0
6309354|NCT02637856|10037905|FG000|Main Study (Baseline to Week 100)|Failed Drug Test|1
6068531|NCT00539500|9671228|FG000|Overall Study|Disease Progression|1
6068532|NCT00539500|9671228|FG000|Overall Study|Lost to Follow-up|2
6068533|NCT00539513|9671234|FG000|Overall Study|Withdrawal by Subject|2
6068534|NCT00539513|9671235|FG001|Overall Study|Withdrawal by Subject|1
5992759|NCT02831764|9585295|FG000|Overall Study|Protocol specific withdrawal criteria|0
5992760|NCT02831764|9585296|FG001|Overall Study|Protocol specific withdrawal criteria|2
5992761|NCT02831764|9585295|FG000|Overall Study|Withdrawal by Subject|7
5992762|NCT02831764|9585296|FG001|Overall Study|Withdrawal by Subject|6
5992763|NCT02831764|9585295|FG000|Overall Study|Physician Decision|2
6068535|NCT00539513|9671234|FG000|Overall Study|Lost to Follow-up|0
6068536|NCT00539513|9671235|FG001|Overall Study|Lost to Follow-up|1
6068537|NCT00539734|9671271|FG000|Overall Study|Protocol Violation|1
6068538|NCT00539864|9671277|FG000|Overall Study|Lost to Follow-up|0
6068539|NCT00539864|9671278|FG001|Overall Study|Lost to Follow-up|1
6068540|NCT00539864|9671277|FG000|Overall Study|Withdrawal by Subject|1
6068541|NCT00539864|9671278|FG001|Overall Study|Withdrawal by Subject|1
5992764|NCT02831764|9585296|FG001|Overall Study|Physician Decision|2
5992765|NCT02831764|9585295|FG000|Overall Study|Lost to Follow-up|6
5992766|NCT02831764|9585296|FG001|Overall Study|Lost to Follow-up|5
5992767|NCT02831764|9585295|FG000|Overall Study|Adverse Event|8
5992768|NCT02831764|9585296|FG001|Overall Study|Adverse Event|5
5992769|NCT02831764|9585295|FG000|Overall Study|Lack of Efficacy|2
5992770|NCT02831764|9585296|FG001|Overall Study|Lack of Efficacy|2
5992771|NCT02831764|9585295|FG000|Overall Study|Protocol Violation|5
5992772|NCT02831764|9585296|FG001|Overall Study|Protocol Violation|2
5992773|NCT02831764|9585295|FG000|Overall Study|Ongoing at the time of the analysis|330
5992774|NCT02831764|9585296|FG001|Overall Study|Ongoing at the time of the analysis|335
5992775|NCT02586025|9585312|FG000|Neoadjuvant Treatment|Did Not Receive Study Drug|1
5992776|NCT02586025|9585313|FG001|Neoadjuvant Treatment|Did Not Receive Study Drug|0
5992777|NCT02586025|9585312|FG000|Neoadjuvant Treatment|Death|1
5992778|NCT02586025|9585313|FG001|Neoadjuvant Treatment|Death|0
5992779|NCT02586025|9585312|FG000|Neoadjuvant Treatment|Adverse Event|1
5992780|NCT02586025|9585313|FG001|Neoadjuvant Treatment|Adverse Event|0
5992781|NCT02586025|9585312|FG000|Neoadjuvant Treatment|Withdrawal by Subject|4
5992782|NCT02586025|9585313|FG001|Neoadjuvant Treatment|Withdrawal by Subject|3
6068542|NCT00539994|9671296|FG000|Overall Study|Lost to Follow-up|2
6309355|NCT02637856|10037906|FG001|Main Study (Baseline to Week 100)|Failed Drug Test|0
6309356|NCT02637856|10037905|FG000|Main Study (Baseline to Week 100)|Incarceration|1
6309357|NCT02637856|10037906|FG001|Main Study (Baseline to Week 100)|Incarceration|0
6309358|NCT02637856|10037905|FG000|Main Study (Baseline to Week 100)|Pregnancy Attempts|2
6309359|NCT02637856|10037906|FG001|Main Study (Baseline to Week 100)|Pregnancy Attempts|0
6309360|NCT02637856|10037905|FG000|Main Study (Baseline to Week 100)|Site Closing|6
6309361|NCT02637856|10037906|FG001|Main Study (Baseline to Week 100)|Site Closing|0
6309362|NCT02637856|10037905|FG000|Sub-Study (Week 72 to Week 100)|Non-safety reason (moved out of state)|0
6309363|NCT02637856|10037906|FG001|Sub-Study (Week 72 to Week 100)|Non-safety reason (moved out of state)|1
6309364|NCT02637856|10037905|FG000|Sub-Study (Week 72 to Week 100)|Lost to Follow-up|0
6309365|NCT02637856|10037906|FG001|Sub-Study (Week 72 to Week 100)|Lost to Follow-up|3
6309366|NCT02637895|10037914|FG000|Overall Study|Lost to Follow-up|4
6309367|NCT02637895|10037915|FG001|Overall Study|Lost to Follow-up|0
5992783|NCT02586025|9585312|FG000|Neoadjuvant Treatment|Physician Decision|2
5992784|NCT02586025|9585313|FG001|Neoadjuvant Treatment|Physician Decision|1
5992785|NCT02586025|9585312|FG000|Neoadjuvant Treatment|Progressive Disease|2
5992786|NCT02586025|9585313|FG001|Neoadjuvant Treatment|Progressive Disease|3
5992787|NCT02586025|9585312|FG000|Adjuvant Treatment|Remain in Adjuvant Treatment|133
5992788|NCT02586025|9585313|FG001|Adjuvant Treatment|Remain in Adjuvant Treatment|61
5992789|NCT02586025|9585312|FG000|Adjuvant Treatment|Withdrawal by Subject|5
5992790|NCT02586025|9585313|FG001|Adjuvant Treatment|Withdrawal by Subject|3
5992791|NCT02586025|9585312|FG000|Adjuvant Treatment|Physician Decision|0
5992792|NCT02586025|9585313|FG001|Adjuvant Treatment|Physician Decision|1
5992793|NCT02586025|9585312|FG000|Adjuvant Treatment|Recurrent Disease|1
5992794|NCT02586025|9585313|FG001|Adjuvant Treatment|Recurrent Disease|4
5992795|NCT02586025|9585312|FG000|Treatment-Free Follow-Up|Remain in Treatment-Free Follow-Up|56
5992796|NCT02586025|9585313|FG001|Treatment-Free Follow-Up|Remain in Treatment-Free Follow-Up|35
5992797|NCT02520011|9585322|FG000|Overall Study|Adverse Event|0
5992798|NCT02520011|9585323|FG001|Overall Study|Adverse Event|1
5992799|NCT02520011|9585324|FG002|Overall Study|Adverse Event|2
5992800|NCT02520011|9585322|FG000|Overall Study|Death|0
5992801|NCT02520011|9585323|FG001|Overall Study|Death|8
5992802|NCT02520011|9585324|FG002|Overall Study|Death|1
5992803|NCT02520011|9585322|FG000|Overall Study|Lack of Efficacy|4
5992804|NCT02520011|9585323|FG001|Overall Study|Lack of Efficacy|26
5992805|NCT02520011|9585324|FG002|Overall Study|Lack of Efficacy|4
5992806|NCT02520011|9585322|FG000|Overall Study|Physician Decision|0
5992807|NCT02520011|9585323|FG001|Overall Study|Physician Decision|2
5992808|NCT02520011|9585324|FG002|Overall Study|Physician Decision|0
5992809|NCT02520011|9585322|FG000|Overall Study|Withdrawal by Subject|1
5992810|NCT02520011|9585323|FG001|Overall Study|Withdrawal by Subject|3
5992811|NCT02520011|9585324|FG002|Overall Study|Withdrawal by Subject|0
5992812|NCT02520011|9585322|FG000|Overall Study|Protocol Deviation|0
5992813|NCT02520011|9585323|FG001|Overall Study|Protocol Deviation|1
6309368|NCT02637895|10037914|FG000|Overall Study|Protocol Violation|0
5992814|NCT02520011|9585324|FG002|Overall Study|Protocol Deviation|0
5992815|NCT02520011|9585322|FG000|Overall Study|Patient went to hospice|0
5992816|NCT02520011|9585323|FG001|Overall Study|Patient went to hospice|1
5992817|NCT02520011|9585324|FG002|Overall Study|Patient went to hospice|0
5992818|NCT02520011|9585322|FG000|Overall Study|Progressive disease following response|0
5992819|NCT02520011|9585323|FG001|Overall Study|Progressive disease following response|4
5992820|NCT02520011|9585324|FG002|Overall Study|Progressive disease following response|2
5992821|NCT02279719|9585361|FG000|Overall Study|Patients randomized but never treated|0
5992822|NCT02279719|9585362|FG001|Overall Study|Patients randomized but never treated|0
5992823|NCT02279719|9585363|FG002|Overall Study|Patients randomized but never treated|0
5992824|NCT02279719|9585364|FG003|Overall Study|Patients randomized but never treated|0
5992825|NCT02279719|9585365|FG004|Overall Study|Patients randomized but never treated|3
5992826|NCT02279719|9585366|FG005|Overall Study|Patients randomized but never treated|0
5992827|NCT02279719|9585367|FG006|Overall Study|Patients randomized but never treated|3
5992828|NCT02178956|9585402|FG000|Overall Study|Lost to Follow-up|4
5992829|NCT02178956|9585403|FG001|Overall Study|Lost to Follow-up|4
5992830|NCT02178956|9585402|FG000|Overall Study|Sponsor terminated study|49
6068543|NCT00539994|9671297|FG001|Overall Study|Lost to Follow-up|1
6068544|NCT00539994|9671298|FG002|Overall Study|Lost to Follow-up|0
6068545|NCT00539994|9671296|FG000|Overall Study|Withdrawal by Subject|1
6068546|NCT00539994|9671297|FG001|Overall Study|Withdrawal by Subject|0
6068547|NCT00539994|9671298|FG002|Overall Study|Withdrawal by Subject|1
6068548|NCT00539994|9671296|FG000|Overall Study|Physician Decision|0
6068549|NCT00539994|9671297|FG001|Overall Study|Physician Decision|0
6068550|NCT00539994|9671298|FG002|Overall Study|Physician Decision|1
6068551|NCT00540046|9671325|FG000|Overall Study|Lost to Follow-up|33
6068552|NCT00540046|9671326|FG001|Overall Study|Lost to Follow-up|23
6068553|NCT00540124|9671337|FG000|Overall Study|Adverse Event|0
6068554|NCT00540124|9671338|FG001|Overall Study|Adverse Event|2
6068555|NCT00540124|9671339|FG002|Overall Study|Adverse Event|1
6068556|NCT00540124|9671337|FG000|Overall Study|Entry Criteria Not Met|2
6068557|NCT00540124|9671338|FG001|Overall Study|Entry Criteria Not Met|0
6068558|NCT00540124|9671339|FG002|Overall Study|Entry Criteria Not Met|0
6068559|NCT00540124|9671337|FG000|Overall Study|Lack of Efficacy|1
6068560|NCT00540124|9671338|FG001|Overall Study|Lack of Efficacy|0
6068561|NCT00540124|9671339|FG002|Overall Study|Lack of Efficacy|0
6068562|NCT00540124|9671337|FG000|Overall Study|Withdrawal by Subject|1
6068563|NCT00540124|9671338|FG001|Overall Study|Withdrawal by Subject|1
6068564|NCT00540124|9671339|FG002|Overall Study|Withdrawal by Subject|0
6068565|NCT00540228|9671352|FG000|Overall Study|Adverse Event|2
6068566|NCT00540228|9671353|FG001|Overall Study|Adverse Event|0
6068567|NCT00540228|9671354|FG002|Overall Study|Adverse Event|0
6068568|NCT00540228|9671355|FG003|Overall Study|Adverse Event|0
6068569|NCT00540228|9671356|FG004|Overall Study|Adverse Event|0
6068570|NCT00540228|9671352|FG000|Overall Study|Lost to Follow-up|1
6068571|NCT00540228|9671353|FG001|Overall Study|Lost to Follow-up|1
6068572|NCT00540228|9671354|FG002|Overall Study|Lost to Follow-up|0
6068573|NCT00540228|9671355|FG003|Overall Study|Lost to Follow-up|0
6068574|NCT00540228|9671356|FG004|Overall Study|Lost to Follow-up|0
6068575|NCT00540293|9671368|FG000|Overall Study|Adverse event related to study drug|10
6068576|NCT00540293|9671368|FG000|Overall Study|Adverse event not related to study drug|7
6068577|NCT00540293|9671368|FG000|Overall Study|Withdrawal by Subject|6
6068578|NCT00540293|9671368|FG000|Overall Study|Protocol violation, & subject schedule|12
6068579|NCT00540423|9671380|FG000|Double-Blind Treatment Period|Adverse Event|0
6068580|NCT00540423|9671381|FG001|Double-Blind Treatment Period|Adverse Event|1
6068581|NCT00540423|9671382|FG002|Double-Blind Treatment Period|Adverse Event|0
6068582|NCT00540423|9671380|FG000|Open-Label Treatment Period|Lack of Efficacy|0
6068583|NCT00540423|9671381|FG001|Open-Label Treatment Period|Lack of Efficacy|0
6068584|NCT00540423|9671382|FG002|Open-Label Treatment Period|Lack of Efficacy|2
6068585|NCT00540436|9671400|FG000|First 12-Week Treatment Period|Adverse Event|1
6068586|NCT00540436|9671400|FG000|First 12-Week Treatment Period|Withdrawal by Subject|1
6068587|NCT00540436|9671400|FG000|First 12-Week Treatment Period|Initiation of prohibited medication|1
6068588|NCT00540436|9671400|FG000|Second 12-Week Treatment Period|Adverse Event|1
6068589|NCT00540449|9671406|FG000|Overall Study|Adverse Event|12
6068590|NCT00540449|9671407|FG001|Overall Study|Adverse Event|32
6068591|NCT00540449|9671406|FG000|Overall Study|Sponsor's Decision|1
6068592|NCT00540449|9671407|FG001|Overall Study|Sponsor's Decision|1
6068593|NCT00540449|9671406|FG000|Overall Study|Subject Ineligible To Continue The Trial|2
6068594|NCT00540449|9671407|FG001|Overall Study|Subject Ineligible To Continue The Trial|1
6068595|NCT00540449|9671406|FG000|Overall Study|Lost to Follow-up|19
6068596|NCT00540449|9671407|FG001|Overall Study|Lost to Follow-up|17
6068597|NCT00540449|9671406|FG000|Overall Study|Subject Non-Compliant|7
6068598|NCT00540449|9671407|FG001|Overall Study|Subject Non-Compliant|5
6068599|NCT00540449|9671406|FG000|Overall Study|Subject Reached A Virologic Endpoint|32
6068600|NCT00540449|9671407|FG001|Overall Study|Subject Reached A Virologic Endpoint|8
6068601|NCT00540449|9671406|FG000|Overall Study|Withdrawal by Subject|10
6068602|NCT00540449|9671407|FG001|Overall Study|Withdrawal by Subject|10
6068603|NCT00540449|9671406|FG000|Overall Study|Other|1
6068604|NCT00540449|9671407|FG001|Overall Study|Other|4
6068605|NCT00540514|9671415|FG000|Overall Study|Still on treatment|3
6068606|NCT00540514|9671416|FG001|Overall Study|Still on treatment|0
6068607|NCT00540514|9671415|FG000|Overall Study|Unacceptable Toxicity|61
6068608|NCT00540514|9671416|FG001|Overall Study|Unacceptable Toxicity|62
6068609|NCT00540514|9671415|FG000|Overall Study|Adverse Event|20
6068610|NCT00540514|9671416|FG001|Overall Study|Adverse Event|24
6068611|NCT00540514|9671415|FG000|Overall Study|Physician Decision|86
6068612|NCT00540514|9671416|FG001|Overall Study|Physician Decision|99
6068613|NCT00540514|9671415|FG000|Overall Study|Protocol Deviation|3
6068614|NCT00540514|9671416|FG001|Overall Study|Protocol Deviation|4
6068615|NCT00540514|9671415|FG000|Overall Study|Lost to Follow-up|1
6068616|NCT00540514|9671416|FG001|Overall Study|Lost to Follow-up|1
6068617|NCT00540514|9671415|FG000|Overall Study|Withdrawal by Subject|65
6068618|NCT00540514|9671416|FG001|Overall Study|Withdrawal by Subject|67
6068619|NCT00540514|9671415|FG000|Overall Study|Excluded prior to treatment|7
6068620|NCT00540514|9671416|FG001|Overall Study|Excluded prior to treatment|7
6068621|NCT00540514|9671415|FG000|Overall Study|Paclitaxel not available|0
6068622|NCT00540514|9671416|FG001|Overall Study|Paclitaxel not available|2
6068623|NCT00540592|9671437|FG000|Overall Study|Adverse Event|0
6068624|NCT00540592|9671438|FG001|Overall Study|Adverse Event|1
6068625|NCT00540592|9671439|FG002|Overall Study|Adverse Event|0
6068626|NCT00540592|9671440|FG003|Overall Study|Adverse Event|0
6068627|NCT00540592|9671441|FG004|Overall Study|Adverse Event|1
6068628|NCT00540592|9671442|FG005|Overall Study|Adverse Event|0
6068629|NCT00540592|9671443|FG006|Overall Study|Adverse Event|0
6068630|NCT00540592|9671444|FG007|Overall Study|Adverse Event|1
6068631|NCT00540592|9671445|FG008|Overall Study|Adverse Event|1
6068632|NCT00540592|9671446|FG009|Overall Study|Adverse Event|2
6068633|NCT00540592|9671437|FG000|Overall Study|Lost to Follow-up|2
6068634|NCT00540592|9671438|FG001|Overall Study|Lost to Follow-up|0
6068635|NCT00540592|9671439|FG002|Overall Study|Lost to Follow-up|0
6068636|NCT00540592|9671440|FG003|Overall Study|Lost to Follow-up|0
6068637|NCT00540592|9671441|FG004|Overall Study|Lost to Follow-up|0
6068638|NCT00540592|9671442|FG005|Overall Study|Lost to Follow-up|0
6068639|NCT00540592|9671443|FG006|Overall Study|Lost to Follow-up|0
6068640|NCT00540592|9671444|FG007|Overall Study|Lost to Follow-up|0
6068641|NCT00540592|9671445|FG008|Overall Study|Lost to Follow-up|0
6068642|NCT00540592|9671446|FG009|Overall Study|Lost to Follow-up|0
6068643|NCT00540592|9671437|FG000|Overall Study|Withdrawal by Subject|0
6068644|NCT00540592|9671438|FG001|Overall Study|Withdrawal by Subject|0
6068645|NCT00540592|9671439|FG002|Overall Study|Withdrawal by Subject|1
6068646|NCT00540592|9671440|FG003|Overall Study|Withdrawal by Subject|1
6068647|NCT00540592|9671441|FG004|Overall Study|Withdrawal by Subject|0
6068648|NCT00540592|9671442|FG005|Overall Study|Withdrawal by Subject|0
6068649|NCT00540592|9671443|FG006|Overall Study|Withdrawal by Subject|0
6068650|NCT00540592|9671444|FG007|Overall Study|Withdrawal by Subject|0
6068651|NCT00540592|9671445|FG008|Overall Study|Withdrawal by Subject|0
6068652|NCT00540592|9671446|FG009|Overall Study|Withdrawal by Subject|0
6068653|NCT00540644|9671470|FG000|Overall Study|Adverse Event|3
6068654|NCT00540644|9671471|FG001|Overall Study|Adverse Event|1
6068655|NCT00540644|9671470|FG000|Overall Study|Disease Progression|3
6068656|NCT00540644|9671471|FG001|Overall Study|Disease Progression|1
6068657|NCT00540644|9671470|FG000|Overall Study|Physician Decision|0
6068658|NCT00540644|9671471|FG001|Overall Study|Physician Decision|5
6068659|NCT00540644|9671470|FG000|Overall Study|Withdrawal by Subject|2
6068660|NCT00540644|9671471|FG001|Overall Study|Withdrawal by Subject|2
6068661|NCT00540644|9671470|FG000|Overall Study|Noncomplilance|1
6068662|NCT00540644|9671471|FG001|Overall Study|Noncomplilance|0
6068663|NCT00541034|9671504|FG000|Overall Study|Non-Compliance|3
6087166|NCT00666835|9697339|FG001|Overall Study|Hemoglobulin concentration|3
6087167|NCT00666835|9697338|FG000|Overall Study|Planned operation|2
6087168|NCT00666835|9697339|FG001|Overall Study|Planned operation|0
6087169|NCT00666835|9697338|FG000|Overall Study|Physician Decision|1
6087170|NCT00666835|9697339|FG001|Overall Study|Physician Decision|2
6087171|NCT00666926|9697359|FG000|Overall Study|Adverse Event|0
6087172|NCT00666926|9697360|FG001|Overall Study|Adverse Event|0
6087173|NCT00666926|9697361|FG002|Overall Study|Adverse Event|0
6087174|NCT00666926|9697362|FG003|Overall Study|Adverse Event|0
6087175|NCT00666926|9697363|FG004|Overall Study|Adverse Event|0
6087176|NCT00666926|9697364|FG005|Overall Study|Adverse Event|0
6087177|NCT00666926|9697365|FG006|Overall Study|Adverse Event|0
6087178|NCT00666926|9697366|FG007|Overall Study|Adverse Event|0
6087179|NCT00666926|9697367|FG008|Overall Study|Adverse Event|0
6087180|NCT00666926|9697368|FG009|Overall Study|Adverse Event|2
6087181|NCT00666926|9697369|FG010|Overall Study|Adverse Event|2
6087182|NCT00666926|9697370|FG011|Overall Study|Adverse Event|2
6087183|NCT00666926|9697371|FG012|Overall Study|Adverse Event|0
6087184|NCT00666926|9697372|FG013|Overall Study|Adverse Event|1
6087185|NCT00666926|9697373|FG014|Overall Study|Adverse Event|0
6087186|NCT00666926|9697374|FG015|Overall Study|Adverse Event|0
6087187|NCT00666926|9697359|FG000|Overall Study|Laboratory abnormality|0
6087188|NCT00666926|9697360|FG001|Overall Study|Laboratory abnormality|0
6087189|NCT00666926|9697361|FG002|Overall Study|Laboratory abnormality|0
6087190|NCT00666926|9697362|FG003|Overall Study|Laboratory abnormality|0
6087191|NCT00666926|9697363|FG004|Overall Study|Laboratory abnormality|0
6087192|NCT00666926|9697364|FG005|Overall Study|Laboratory abnormality|0
6087193|NCT00666926|9697365|FG006|Overall Study|Laboratory abnormality|0
6087194|NCT00666926|9697366|FG007|Overall Study|Laboratory abnormality|0
6087195|NCT00666926|9697367|FG008|Overall Study|Laboratory abnormality|0
6087196|NCT00666926|9697368|FG009|Overall Study|Laboratory abnormality|0
6087197|NCT00666926|9697369|FG010|Overall Study|Laboratory abnormality|1
6087198|NCT00666926|9697370|FG011|Overall Study|Laboratory abnormality|0
6087199|NCT00666926|9697371|FG012|Overall Study|Laboratory abnormality|0
6087200|NCT00666926|9697372|FG013|Overall Study|Laboratory abnormality|0
6087201|NCT00666926|9697373|FG014|Overall Study|Laboratory abnormality|0
6087202|NCT00666926|9697374|FG015|Overall Study|Laboratory abnormality|1
6087203|NCT00666926|9697359|FG000|Overall Study|Lack of Efficacy|0
6087204|NCT00666926|9697360|FG001|Overall Study|Lack of Efficacy|0
6087205|NCT00666926|9697361|FG002|Overall Study|Lack of Efficacy|0
6087206|NCT00666926|9697362|FG003|Overall Study|Lack of Efficacy|0
6087207|NCT00666926|9697363|FG004|Overall Study|Lack of Efficacy|0
6087208|NCT00666926|9697364|FG005|Overall Study|Lack of Efficacy|1
6087209|NCT00666926|9697365|FG006|Overall Study|Lack of Efficacy|0
6087210|NCT00666926|9697366|FG007|Overall Study|Lack of Efficacy|0
6068664|NCT00541099|9671508|FG000|Overall Study|Ineligible|3
6068665|NCT00541229|9671529|FG000|Treatment Period I (Week 1)|Physician Decision|0
6068666|NCT00541229|9671530|FG001|Treatment Period I (Week 1)|Physician Decision|0
6068667|NCT00541229|9671531|FG002|Treatment Period I (Week 1)|Physician Decision|1
6068668|NCT00541229|9671532|FG003|Treatment Period I (Week 1)|Physician Decision|0
6068669|NCT00541229|9671533|FG004|Treatment Period I (Week 1)|Physician Decision|0
6068670|NCT00541229|9671534|FG005|Treatment Period I (Week 1)|Physician Decision|0
6068671|NCT00541229|9671529|FG000|Treatment Period I (Week 1)|Withdrawal by Subject|0
6068672|NCT00541229|9671530|FG001|Treatment Period I (Week 1)|Withdrawal by Subject|0
6068673|NCT00541229|9671531|FG002|Treatment Period I (Week 1)|Withdrawal by Subject|0
6068674|NCT00541229|9671532|FG003|Treatment Period I (Week 1)|Withdrawal by Subject|0
6068675|NCT00541229|9671533|FG004|Treatment Period I (Week 1)|Withdrawal by Subject|0
6068676|NCT00541229|9671534|FG005|Treatment Period I (Week 1)|Withdrawal by Subject|1
6068677|NCT00541229|9671529|FG000|Treatment Period I (Week 1)|Protocol Specified Criteria|0
6068678|NCT00541229|9671530|FG001|Treatment Period I (Week 1)|Protocol Specified Criteria|0
6068679|NCT00541229|9671531|FG002|Treatment Period I (Week 1)|Protocol Specified Criteria|0
6068680|NCT00541229|9671532|FG003|Treatment Period I (Week 1)|Protocol Specified Criteria|0
6068681|NCT00541229|9671533|FG004|Treatment Period I (Week 1)|Protocol Specified Criteria|0
6068682|NCT00541229|9671534|FG005|Treatment Period I (Week 1)|Protocol Specified Criteria|1
6068683|NCT00541229|9671529|FG000|Treatment Period I (Week 1)|Study Terminated by Sponsor|0
6068684|NCT00541229|9671530|FG001|Treatment Period I (Week 1)|Study Terminated by Sponsor|1
6068685|NCT00541229|9671531|FG002|Treatment Period I (Week 1)|Study Terminated by Sponsor|2
6068686|NCT00541229|9671532|FG003|Treatment Period I (Week 1)|Study Terminated by Sponsor|1
6068687|NCT00541229|9671533|FG004|Treatment Period I (Week 1)|Study Terminated by Sponsor|0
5992831|NCT02178956|9585403|FG001|Overall Study|Sponsor terminated study|58
5992832|NCT02178956|9585402|FG000|Overall Study|Withdrawal by Subject|15
5992833|NCT02178956|9585403|FG001|Overall Study|Withdrawal by Subject|11
5992834|NCT02178956|9585402|FG000|Overall Study|Various Reasons|3
5992835|NCT02178956|9585403|FG001|Overall Study|Various Reasons|5
5992836|NCT02167945|9585413|FG000|Overall Study|Adverse Event|16
5992837|NCT02167945|9585413|FG000|Overall Study|Withdrew Consent|42
5992838|NCT02167945|9585413|FG000|Overall Study|Lost to Follow-up|122
5992839|NCT02167945|9585413|FG000|Overall Study|COVID-19 logistical restrictions|6
5992840|NCT02167945|9585413|FG000|Overall Study|Other, not specified|63
5992841|NCT02097420|9585425|FG000|Overall Study|Death|4
5992842|NCT02097420|9585425|FG000|Overall Study|Device explanted|3
5992843|NCT02097420|9585425|FG000|Overall Study|Not reached 12-month visit|7
6046063|NCT00404755|9645267|FG000|Phase I (Bupropion)|Adverse Event|3
6046064|NCT00404755|9645267|FG000|Phase I (Bupropion)|Other|1
6046065|NCT00404755|9645267|FG000|Phase II (Escitalopram)|Lost to Follow-up|2
6046066|NCT00404768|9645279|FG000|Part A and B|Withdrawn due to labor progression|1
6046067|NCT00404768|9645280|FG001|Part A and B|Withdrawn due to labor progression|0
5992844|NCT01925131|9585482|FG000|Overall Study|Death|0
5992845|NCT01925131|9585483|FG001|Overall Study|Death|0
5992846|NCT01925131|9585484|FG002|Overall Study|Death|1
5992847|NCT01925131|9585485|FG003|Overall Study|Death|0
5992848|NCT01925131|9585486|FG004|Overall Study|Death|0
5992849|NCT01925131|9585487|FG005|Overall Study|Death|0
5992850|NCT01925131|9585482|FG000|Overall Study|Progression/Relapse|1
5992851|NCT01925131|9585483|FG001|Overall Study|Progression/Relapse|1
5992852|NCT01925131|9585484|FG002|Overall Study|Progression/Relapse|4
5992853|NCT01925131|9585485|FG003|Overall Study|Progression/Relapse|0
5992854|NCT01925131|9585486|FG004|Overall Study|Progression/Relapse|0
5992855|NCT01925131|9585487|FG005|Overall Study|Progression/Relapse|1
6068688|NCT00541229|9671534|FG005|Treatment Period I (Week 1)|Study Terminated by Sponsor|0
6068689|NCT00541229|9671529|FG000|Washout Period I (Week 2-5)|Adverse Event|1
6068690|NCT00541229|9671530|FG001|Washout Period I (Week 2-5)|Adverse Event|0
6068691|NCT00541229|9671531|FG002|Washout Period I (Week 2-5)|Adverse Event|1
6068692|NCT00541229|9671532|FG003|Washout Period I (Week 2-5)|Adverse Event|0
6068693|NCT00541229|9671533|FG004|Washout Period I (Week 2-5)|Adverse Event|0
6068694|NCT00541229|9671534|FG005|Washout Period I (Week 2-5)|Adverse Event|0
6068695|NCT00541229|9671529|FG000|Washout Period I (Week 2-5)|Physician Decision|0
6068696|NCT00541229|9671530|FG001|Washout Period I (Week 2-5)|Physician Decision|0
6068697|NCT00541229|9671531|FG002|Washout Period I (Week 2-5)|Physician Decision|0
6068698|NCT00541229|9671532|FG003|Washout Period I (Week 2-5)|Physician Decision|1
6068699|NCT00541229|9671533|FG004|Washout Period I (Week 2-5)|Physician Decision|0
6068700|NCT00541229|9671534|FG005|Washout Period I (Week 2-5)|Physician Decision|0
6068701|NCT00541229|9671529|FG000|Washout Period I (Week 2-5)|Protocol Violation|0
6068702|NCT00541229|9671530|FG001|Washout Period I (Week 2-5)|Protocol Violation|0
6068703|NCT00541229|9671531|FG002|Washout Period I (Week 2-5)|Protocol Violation|0
6068704|NCT00541229|9671532|FG003|Washout Period I (Week 2-5)|Protocol Violation|0
6068705|NCT00541229|9671533|FG004|Washout Period I (Week 2-5)|Protocol Violation|0
6068706|NCT00541229|9671534|FG005|Washout Period I (Week 2-5)|Protocol Violation|1
6068707|NCT00541229|9671529|FG000|Washout Period I (Week 2-5)|Study Terminated by Sponsor|3
6068708|NCT00541229|9671530|FG001|Washout Period I (Week 2-5)|Study Terminated by Sponsor|2
6068709|NCT00541229|9671531|FG002|Washout Period I (Week 2-5)|Study Terminated by Sponsor|3
6068710|NCT00541229|9671532|FG003|Washout Period I (Week 2-5)|Study Terminated by Sponsor|3
6068711|NCT00541229|9671533|FG004|Washout Period I (Week 2-5)|Study Terminated by Sponsor|1
6068712|NCT00541229|9671534|FG005|Washout Period I (Week 2-5)|Study Terminated by Sponsor|4
6068713|NCT00541229|9671529|FG000|Treatment Period II (Week 6)|Protocol Violation|0
6068714|NCT00541229|9671530|FG001|Treatment Period II (Week 6)|Protocol Violation|0
6068715|NCT00541229|9671531|FG002|Treatment Period II (Week 6)|Protocol Violation|0
6068716|NCT00541229|9671532|FG003|Treatment Period II (Week 6)|Protocol Violation|0
6068717|NCT00541229|9671533|FG004|Treatment Period II (Week 6)|Protocol Violation|1
6068718|NCT00541229|9671534|FG005|Treatment Period II (Week 6)|Protocol Violation|1
6068719|NCT00541229|9671529|FG000|Treatment Period II (Week 6)|Study Terminated by Sponsor|2
6068720|NCT00541229|9671530|FG001|Treatment Period II (Week 6)|Study Terminated by Sponsor|1
6068721|NCT00541229|9671531|FG002|Treatment Period II (Week 6)|Study Terminated by Sponsor|1
6068722|NCT00541229|9671532|FG003|Treatment Period II (Week 6)|Study Terminated by Sponsor|1
6068723|NCT00541229|9671533|FG004|Treatment Period II (Week 6)|Study Terminated by Sponsor|1
6068724|NCT00541229|9671534|FG005|Treatment Period II (Week 6)|Study Terminated by Sponsor|2
5992856|NCT01925131|9585482|FG000|Overall Study|Patient Refusal|1
5992857|NCT01925131|9585483|FG001|Overall Study|Patient Refusal|0
6068725|NCT00541229|9671529|FG000|Washout Period II (Week 7-10)|Protocol Violation|1
6068726|NCT00541229|9671530|FG001|Washout Period II (Week 7-10)|Protocol Violation|0
6068727|NCT00541229|9671531|FG002|Washout Period II (Week 7-10)|Protocol Violation|0
6068728|NCT00541229|9671532|FG003|Washout Period II (Week 7-10)|Protocol Violation|0
6068729|NCT00541229|9671533|FG004|Washout Period II (Week 7-10)|Protocol Violation|0
6068730|NCT00541229|9671534|FG005|Washout Period II (Week 7-10)|Protocol Violation|0
6068731|NCT00541229|9671529|FG000|Washout Period II (Week 7-10)|Withdrawal by Subject|0
6068732|NCT00541229|9671530|FG001|Washout Period II (Week 7-10)|Withdrawal by Subject|0
6068733|NCT00541229|9671531|FG002|Washout Period II (Week 7-10)|Withdrawal by Subject|0
6068734|NCT00541229|9671532|FG003|Washout Period II (Week 7-10)|Withdrawal by Subject|0
6068735|NCT00541229|9671533|FG004|Washout Period II (Week 7-10)|Withdrawal by Subject|1
6068736|NCT00541229|9671534|FG005|Washout Period II (Week 7-10)|Withdrawal by Subject|0
6068737|NCT00541229|9671529|FG000|Washout Period II (Week 7-10)|Study Terminated by Sponsor|3
6068738|NCT00541229|9671530|FG001|Washout Period II (Week 7-10)|Study Terminated by Sponsor|4
6068739|NCT00541229|9671531|FG002|Washout Period II (Week 7-10)|Study Terminated by Sponsor|2
6068740|NCT00541229|9671532|FG003|Washout Period II (Week 7-10)|Study Terminated by Sponsor|4
6068741|NCT00541229|9671533|FG004|Washout Period II (Week 7-10)|Study Terminated by Sponsor|3
6068742|NCT00541229|9671534|FG005|Washout Period II (Week 7-10)|Study Terminated by Sponsor|3
6068743|NCT00541229|9671529|FG000|Treatment Period III (Week 11)|Adverse Event|0
6068744|NCT00541229|9671530|FG001|Treatment Period III (Week 11)|Adverse Event|0
6068745|NCT00541229|9671531|FG002|Treatment Period III (Week 11)|Adverse Event|0
6068746|NCT00541229|9671532|FG003|Treatment Period III (Week 11)|Adverse Event|0
6068747|NCT00541229|9671533|FG004|Treatment Period III (Week 11)|Adverse Event|1
6068748|NCT00541229|9671534|FG005|Treatment Period III (Week 11)|Adverse Event|0
6068749|NCT00541229|9671529|FG000|Treatment Period III (Week 11)|Protocol Specified Criteria|0
6068750|NCT00541229|9671530|FG001|Treatment Period III (Week 11)|Protocol Specified Criteria|0
6068751|NCT00541229|9671531|FG002|Treatment Period III (Week 11)|Protocol Specified Criteria|0
6068752|NCT00541229|9671532|FG003|Treatment Period III (Week 11)|Protocol Specified Criteria|0
6068753|NCT00541229|9671533|FG004|Treatment Period III (Week 11)|Protocol Specified Criteria|0
6068754|NCT00541229|9671534|FG005|Treatment Period III (Week 11)|Protocol Specified Criteria|1
6068755|NCT00541229|9671529|FG000|Treatment Period III (Week 11)|Study Terminated by Sponsor|0
6068756|NCT00541229|9671530|FG001|Treatment Period III (Week 11)|Study Terminated by Sponsor|0
6068757|NCT00541229|9671531|FG002|Treatment Period III (Week 11)|Study Terminated by Sponsor|1
6068758|NCT00541229|9671532|FG003|Treatment Period III (Week 11)|Study Terminated by Sponsor|0
6068759|NCT00541229|9671533|FG004|Treatment Period III (Week 11)|Study Terminated by Sponsor|0
6068760|NCT00541229|9671534|FG005|Treatment Period III (Week 11)|Study Terminated by Sponsor|0
6068761|NCT00541307|9671551|FG000|Overall Study|Death|5
6068762|NCT00541307|9671551|FG000|Overall Study|Physician Decision|3
6068763|NCT00541307|9671551|FG000|Overall Study|Withdrawal by Subject|6
6068764|NCT00541307|9671551|FG000|Overall Study|Lost to Follow-up|4
6068765|NCT00541307|9671551|FG000|Overall Study|Subject returned early (outside window)|1
6068766|NCT00541307|9671551|FG000|Overall Study|Surgical Bypass|5
6068767|NCT00541346|9671555|FG000|Follow-up|Adverse Event|1
6068768|NCT00541385|9671561|FG000|Overall Study|Adverse Event|6
6068769|NCT00541385|9671562|FG001|Overall Study|Adverse Event|3
6068770|NCT00541385|9671561|FG000|Overall Study|Withdrawal by Subject|2
6068771|NCT00541385|9671562|FG001|Overall Study|Withdrawal by Subject|2
6068772|NCT00541385|9671561|FG000|Overall Study|Lost to Follow-up|6
6068773|NCT00541385|9671562|FG001|Overall Study|Lost to Follow-up|1
6068774|NCT00541385|9671561|FG000|Overall Study|Parasite reappearance/malaria|67
6068775|NCT00541385|9671562|FG001|Overall Study|Parasite reappearance/malaria|32
6068776|NCT00541450|9671570|FG000|Phase A|Adverse Event|3
6068777|NCT00541450|9671571|FG001|Phase A|Adverse Event|0
6068778|NCT00541450|9671570|FG000|Phase A|Creatinine/CrCl -Increase in creatinine|0
6068779|NCT00541450|9671571|FG001|Phase A|Creatinine/CrCl -Increase in creatinine|2
6068780|NCT00541450|9671570|FG000|Phase A|Hyperglycemia|0
6068781|NCT00541450|9671571|FG001|Phase A|Hyperglycemia|1
6068782|NCT00541450|9671570|FG000|Phase A|Lost to Follow-up|6
6068783|NCT00541450|9671571|FG001|Phase A|Lost to Follow-up|4
6068784|NCT00541450|9671570|FG000|Phase A|Physician Decision|2
6068785|NCT00541450|9671571|FG001|Phase A|Physician Decision|0
6068786|NCT00541450|9671570|FG000|Phase A|Protocol Violation|2
6068787|NCT00541450|9671571|FG001|Phase A|Protocol Violation|3
6068788|NCT00541450|9671570|FG000|Phase A|Withdrawal by Subject|7
6068789|NCT00541450|9671571|FG001|Phase A|Withdrawal by Subject|7
6068790|NCT00541450|9671570|FG000|Phase B|Adverse Event|6
6068791|NCT00541450|9671571|FG001|Phase B|Adverse Event|6
6068792|NCT00541450|9671570|FG000|Phase B|Hyperglycemia|10
6068793|NCT00541450|9671571|FG001|Phase B|Hyperglycemia|9
6068794|NCT00541450|9671570|FG000|Phase B|Lost to Follow-up|6
6068795|NCT00541450|9671571|FG001|Phase B|Lost to Follow-up|4
6068796|NCT00541450|9671570|FG000|Phase B|Physician Decision|4
6068797|NCT00541450|9671571|FG001|Phase B|Physician Decision|2
6068798|NCT00541450|9671570|FG000|Phase B|Pregnancy|0
6068799|NCT00541450|9671571|FG001|Phase B|Pregnancy|1
6068800|NCT00541450|9671570|FG000|Phase B|Protocol Violation|3
6068801|NCT00541450|9671571|FG001|Phase B|Protocol Violation|3
6068802|NCT00541450|9671570|FG000|Phase B|Withdrawal by Subject|8
6068803|NCT00541450|9671571|FG001|Phase B|Withdrawal by Subject|6
6068804|NCT00541658|9671588|FG000|Overall Study|Adverse Event|28
6068805|NCT00541658|9671589|FG001|Overall Study|Adverse Event|37
6068806|NCT00541658|9671590|FG002|Overall Study|Adverse Event|25
6068807|NCT00541658|9671588|FG000|Overall Study|Physician Decision|0
6068808|NCT00541658|9671589|FG001|Overall Study|Physician Decision|0
6068809|NCT00541658|9671590|FG002|Overall Study|Physician Decision|4
6068810|NCT00541658|9671588|FG000|Overall Study|Lost to Follow-up|3
6068811|NCT00541658|9671589|FG001|Overall Study|Lost to Follow-up|3
6068812|NCT00541658|9671590|FG002|Overall Study|Lost to Follow-up|6
6068813|NCT00541658|9671588|FG000|Overall Study|Protocol Violation|0
6068814|NCT00541658|9671589|FG001|Overall Study|Protocol Violation|1
6068815|NCT00541658|9671590|FG002|Overall Study|Protocol Violation|1
6068816|NCT00541658|9671588|FG000|Overall Study|Withdrawal by Subject|28
6068817|NCT00541658|9671589|FG001|Overall Study|Withdrawal by Subject|32
6068818|NCT00541658|9671590|FG002|Overall Study|Withdrawal by Subject|32
6309369|NCT02637895|10037915|FG001|Overall Study|Protocol Violation|1
6309370|NCT02637895|10037914|FG000|Overall Study|Lack of Efficacy|1
6068819|NCT00541658|9671588|FG000|Overall Study|Took No Study Drug|1
6068820|NCT00541658|9671589|FG001|Overall Study|Took No Study Drug|0
6068821|NCT00541658|9671590|FG002|Overall Study|Took No Study Drug|0
6068822|NCT00541775|9671612|FG000|Overall Study|Adverse Event|3
6068823|NCT00541775|9671613|FG001|Overall Study|Adverse Event|2
6068824|NCT00541775|9671614|FG002|Overall Study|Adverse Event|1
6068825|NCT00541775|9671612|FG000|Overall Study|Lack of Efficacy|0
6068826|NCT00541775|9671613|FG001|Overall Study|Lack of Efficacy|0
6068827|NCT00541775|9671614|FG002|Overall Study|Lack of Efficacy|3
6068828|NCT00541775|9671612|FG000|Overall Study|Lost to Follow-up|0
6068829|NCT00541775|9671613|FG001|Overall Study|Lost to Follow-up|0
6068830|NCT00541775|9671614|FG002|Overall Study|Lost to Follow-up|2
6309371|NCT02637895|10037915|FG001|Overall Study|Lack of Efficacy|0
6068831|NCT00541775|9671612|FG000|Overall Study|Protocol Violation|1
6068832|NCT00541775|9671613|FG001|Overall Study|Protocol Violation|0
6068833|NCT00541775|9671614|FG002|Overall Study|Protocol Violation|0
6309372|NCT02637895|10037914|FG000|Overall Study|Withdrawal by Subject|1
6068834|NCT00541775|9671612|FG000|Overall Study|Withdrawal by Subject and Other|5
6068835|NCT00541775|9671613|FG001|Overall Study|Withdrawal by Subject and Other|0
6068836|NCT00541775|9671614|FG002|Overall Study|Withdrawal by Subject and Other|2
6068837|NCT00541866|9671627|FG000|Overall Study|Adverse Event|3
6068838|NCT00541866|9671628|FG001|Overall Study|Adverse Event|0
6068839|NCT00541866|9671629|FG002|Overall Study|Adverse Event|0
6068840|NCT00541866|9671630|FG003|Overall Study|Adverse Event|0
6068841|NCT00541866|9671631|FG004|Overall Study|Adverse Event|0
6068842|NCT00541866|9671627|FG000|Overall Study|Death|1
6068843|NCT00541866|9671628|FG001|Overall Study|Death|0
6068844|NCT00541866|9671629|FG002|Overall Study|Death|0
6068845|NCT00541866|9671630|FG003|Overall Study|Death|0
6068846|NCT00541866|9671631|FG004|Overall Study|Death|0
6068847|NCT00541866|9671627|FG000|Overall Study|Lack of Efficacy|19
6068848|NCT00541866|9671628|FG001|Overall Study|Lack of Efficacy|15
6068849|NCT00541866|9671629|FG002|Overall Study|Lack of Efficacy|10
6068850|NCT00541866|9671630|FG003|Overall Study|Lack of Efficacy|12
6068851|NCT00541866|9671631|FG004|Overall Study|Lack of Efficacy|14
6068852|NCT00541866|9671627|FG000|Overall Study|Not Reported or Other|11
6068853|NCT00541866|9671628|FG001|Overall Study|Not Reported or Other|3
6068854|NCT00541866|9671629|FG002|Overall Study|Not Reported or Other|3
6068855|NCT00541866|9671630|FG003|Overall Study|Not Reported or Other|3
6068856|NCT00541866|9671631|FG004|Overall Study|Not Reported or Other|1
6068857|NCT00541866|9671627|FG000|Overall Study|Physician Decision|0
6068858|NCT00541866|9671628|FG001|Overall Study|Physician Decision|0
6068859|NCT00541866|9671629|FG002|Overall Study|Physician Decision|2
6068860|NCT00541866|9671630|FG003|Overall Study|Physician Decision|1
6068861|NCT00541866|9671631|FG004|Overall Study|Physician Decision|0
6068862|NCT00541931|9671661|FG000|Overall Study|Adverse Event|1
6068863|NCT00541931|9671662|FG001|Overall Study|Adverse Event|0
6068864|NCT00541931|9671661|FG000|Overall Study|Lost to Follow-up|3
6068865|NCT00541931|9671662|FG001|Overall Study|Lost to Follow-up|3
6068866|NCT00541931|9671661|FG000|Overall Study|Withdrawal by Subject|1
6068867|NCT00541931|9671662|FG001|Overall Study|Withdrawal by Subject|0
6068868|NCT00541931|9671661|FG000|Overall Study|Transportation Issue|0
6068869|NCT00541931|9671662|FG001|Overall Study|Transportation Issue|1
6068870|NCT00541970|9671674|FG000|Month 7|Protocol Violation|9
6068871|NCT00541970|9671675|FG001|Month 7|Protocol Violation|13
6068872|NCT00541970|9671676|FG002|Month 7|Protocol Violation|11
6068873|NCT00541970|9671677|FG003|Month 7|Protocol Violation|5
6068874|NCT00541970|9671674|FG000|Month 12|Adverse Event|0
6068875|NCT00541970|9671675|FG001|Month 12|Adverse Event|1
6068876|NCT00541970|9671676|FG002|Month 12|Adverse Event|1
6068877|NCT00541970|9671677|FG003|Month 12|Adverse Event|1
6068878|NCT00541970|9671674|FG000|Month 12|Protocol Violation|12
6068879|NCT00541970|9671675|FG001|Month 12|Protocol Violation|21
6068880|NCT00541970|9671676|FG002|Month 12|Protocol Violation|20
6068881|NCT00541970|9671677|FG003|Month 12|Protocol Violation|15
6068882|NCT00541970|9671674|FG000|Month 18|Adverse Event|0
6068883|NCT00541970|9671675|FG001|Month 18|Adverse Event|1
6068884|NCT00541970|9671676|FG002|Month 18|Adverse Event|1
6068885|NCT00541970|9671677|FG003|Month 18|Adverse Event|1
6068886|NCT00541970|9671674|FG000|Month 18|Protocol Violation|14
6068887|NCT00541970|9671675|FG001|Month 18|Protocol Violation|23
6068888|NCT00541970|9671676|FG002|Month 18|Protocol Violation|24
6068889|NCT00541970|9671677|FG003|Month 18|Protocol Violation|16
6068890|NCT00541970|9671674|FG000|Month 24|Adverse Event|0
6068891|NCT00541970|9671675|FG001|Month 24|Adverse Event|1
6068892|NCT00541970|9671676|FG002|Month 24|Adverse Event|1
6068893|NCT00541970|9671677|FG003|Month 24|Adverse Event|1
6068894|NCT00541970|9671674|FG000|Month 24|Protocol Violation|29
6068895|NCT00541970|9671675|FG001|Month 24|Protocol Violation|31
6068896|NCT00541970|9671676|FG002|Month 24|Protocol Violation|31
6068897|NCT00541970|9671677|FG003|Month 24|Protocol Violation|21
6068898|NCT00541970|9671674|FG000|Month 36|Protocol Violation|61
6068899|NCT00541970|9671675|FG001|Month 36|Protocol Violation|66
6068900|NCT00541970|9671676|FG002|Month 36|Protocol Violation|66
6068901|NCT00541970|9671677|FG003|Month 36|Protocol Violation|60
6068902|NCT00541970|9671674|FG000|Month 48|Withdrawal by Subject|2
6068903|NCT00541970|9671675|FG001|Month 48|Withdrawal by Subject|4
6068904|NCT00541970|9671676|FG002|Month 48|Withdrawal by Subject|4
6068905|NCT00541970|9671677|FG003|Month 48|Withdrawal by Subject|2
6068906|NCT00541970|9671674|FG000|Month 48|Other|3
6068907|NCT00541970|9671675|FG001|Month 48|Other|1
6068908|NCT00541970|9671676|FG002|Month 48|Other|1
6068909|NCT00541970|9671677|FG003|Month 48|Other|0
6068910|NCT00541970|9671674|FG000|Month 48|Lost to Follow-up|66
6068911|NCT00541970|9671675|FG001|Month 48|Lost to Follow-up|68
6068912|NCT00541970|9671676|FG002|Month 48|Lost to Follow-up|68
6068913|NCT00541970|9671677|FG003|Month 48|Lost to Follow-up|73
6068914|NCT00541970|9671674|FG000|Month 60|Protocol Violation|78
5992858|NCT01925131|9585484|FG002|Overall Study|Patient Refusal|0
5992859|NCT01925131|9585485|FG003|Overall Study|Patient Refusal|0
5992860|NCT01925131|9585486|FG004|Overall Study|Patient Refusal|0
5992861|NCT01925131|9585487|FG005|Overall Study|Patient Refusal|0
5992862|NCT01925131|9585482|FG000|Overall Study|Adverse Event|0
5992863|NCT01925131|9585483|FG001|Overall Study|Adverse Event|0
5992864|NCT01925131|9585484|FG002|Overall Study|Adverse Event|2
5992865|NCT01925131|9585485|FG003|Overall Study|Adverse Event|0
5992866|NCT01925131|9585486|FG004|Overall Study|Adverse Event|1
5992867|NCT01925131|9585487|FG005|Overall Study|Adverse Event|3
5992868|NCT01925131|9585482|FG000|Overall Study|Other - Not Protocol Specified|3
5992869|NCT01925131|9585483|FG001|Overall Study|Other - Not Protocol Specified|1
6068915|NCT00541970|9671675|FG001|Month 60|Protocol Violation|77
6068916|NCT00541970|9671676|FG002|Month 60|Protocol Violation|82
6068917|NCT00541970|9671677|FG003|Month 60|Protocol Violation|72
6068918|NCT00542178|9671693|FG000|Overall Study|did not complete year 4 follow-up|75
6068919|NCT00542178|9671694|FG001|Overall Study|did not complete year 4 follow-up|80
6068920|NCT00542178|9671695|FG002|Overall Study|did not complete year 4 follow-up|74
6068921|NCT00542178|9671696|FG003|Overall Study|did not complete year 4 follow-up|62
6068922|NCT00542178|9671697|FG004|Overall Study|did not complete year 4 follow-up|64
6068923|NCT00542178|9671698|FG005|Overall Study|did not complete year 4 follow-up|89
6068924|NCT00542178|9671699|FG006|Overall Study|did not complete year 4 follow-up|87
6068925|NCT00542178|9671700|FG007|Overall Study|did not complete year 4 follow-up|85
6068926|NCT00542191|9671714|FG000|Overall Study|Death|3
6068927|NCT00542269|9671721|FG000|Overall Study|Adverse Event|10
6068928|NCT00542269|9671722|FG001|Overall Study|Adverse Event|4
6068929|NCT00542269|9671723|FG002|Overall Study|Adverse Event|5
6068930|NCT00542269|9671721|FG000|Overall Study|Protocol Violation|1
6068931|NCT00542269|9671722|FG001|Overall Study|Protocol Violation|1
6068932|NCT00542269|9671723|FG002|Overall Study|Protocol Violation|0
6068933|NCT00542269|9671721|FG000|Overall Study|Withdrawal by Subject|1
6068934|NCT00542269|9671722|FG001|Overall Study|Withdrawal by Subject|0
6068935|NCT00542269|9671723|FG002|Overall Study|Withdrawal by Subject|0
6068936|NCT00542269|9671721|FG000|Overall Study|Administrative problems|1
6068937|NCT00542269|9671722|FG001|Overall Study|Administrative problems|1
6068938|NCT00542269|9671723|FG002|Overall Study|Administrative problems|1
6068939|NCT00542321|9671739|FG000|Overall Study|Death|0
6068940|NCT00542321|9671740|FG001|Overall Study|Death|1
6068941|NCT00542386|9671752|FG000|Overall Study|Adverse Event|1
6068942|NCT00542386|9671753|FG001|Overall Study|Adverse Event|7
6068943|NCT00542386|9671754|FG002|Overall Study|Adverse Event|7
6068944|NCT00542386|9671755|FG003|Overall Study|Adverse Event|8
6068945|NCT00542386|9671756|FG004|Overall Study|Adverse Event|13
6068946|NCT00542386|9671757|FG005|Overall Study|Adverse Event|4
6068947|NCT00542386|9671752|FG000|Overall Study|Death|0
6068948|NCT00542386|9671753|FG001|Overall Study|Death|0
6068949|NCT00542386|9671754|FG002|Overall Study|Death|1
6068950|NCT00542386|9671755|FG003|Overall Study|Death|2
6068951|NCT00542386|9671756|FG004|Overall Study|Death|1
6068952|NCT00542386|9671757|FG005|Overall Study|Death|2
6068953|NCT00542386|9671752|FG000|Overall Study|Lack of Efficacy|32
6068954|NCT00542386|9671753|FG001|Overall Study|Lack of Efficacy|12
6068955|NCT00542386|9671754|FG002|Overall Study|Lack of Efficacy|10
6068956|NCT00542386|9671755|FG003|Overall Study|Lack of Efficacy|13
6068957|NCT00542386|9671756|FG004|Overall Study|Lack of Efficacy|7
6068958|NCT00542386|9671757|FG005|Overall Study|Lack of Efficacy|31
6068959|NCT00542386|9671752|FG000|Overall Study|Physician Decision|1
6068960|NCT00542386|9671753|FG001|Overall Study|Physician Decision|0
6146193|NCT01075984|9780817|FG004|Treatment Phase|Protocol Violation|3
6146194|NCT01075984|9780813|FG000|Treatment Phase|Withdrawal by Subject|0
6146195|NCT01075984|9780814|FG001|Treatment Phase|Withdrawal by Subject|0
6146196|NCT01075984|9780815|FG002|Treatment Phase|Withdrawal by Subject|2
6146197|NCT01075984|9780816|FG003|Treatment Phase|Withdrawal by Subject|0
6146198|NCT01075984|9780817|FG004|Treatment Phase|Withdrawal by Subject|15
6146199|NCT01075984|9780813|FG000|Treatment Phase|Treatment Failure|0
6068961|NCT00542386|9671754|FG002|Overall Study|Physician Decision|0
6068962|NCT00542386|9671755|FG003|Overall Study|Physician Decision|1
6068963|NCT00542386|9671756|FG004|Overall Study|Physician Decision|0
6068964|NCT00542386|9671757|FG005|Overall Study|Physician Decision|0
6068965|NCT00542386|9671752|FG000|Overall Study|Protocol Violation|0
6068966|NCT00542386|9671753|FG001|Overall Study|Protocol Violation|0
6068967|NCT00542386|9671754|FG002|Overall Study|Protocol Violation|1
6068968|NCT00542386|9671755|FG003|Overall Study|Protocol Violation|0
6068969|NCT00542386|9671756|FG004|Overall Study|Protocol Violation|0
6068970|NCT00542386|9671757|FG005|Overall Study|Protocol Violation|4
6068971|NCT00542386|9671752|FG000|Overall Study|Withdrawal by Subject|5
6068972|NCT00542386|9671753|FG001|Overall Study|Withdrawal by Subject|8
6068973|NCT00542386|9671754|FG002|Overall Study|Withdrawal by Subject|10
6068974|NCT00542386|9671755|FG003|Overall Study|Withdrawal by Subject|11
6068975|NCT00542386|9671756|FG004|Overall Study|Withdrawal by Subject|15
6068976|NCT00542386|9671757|FG005|Overall Study|Withdrawal by Subject|7
6068977|NCT00542386|9671752|FG000|Overall Study|Other Reasons|4
6068978|NCT00542386|9671753|FG001|Overall Study|Other Reasons|1
6068979|NCT00542386|9671754|FG002|Overall Study|Other Reasons|4
6068980|NCT00542386|9671755|FG003|Overall Study|Other Reasons|3
6068981|NCT00542386|9671756|FG004|Overall Study|Other Reasons|4
6068982|NCT00542386|9671757|FG005|Overall Study|Other Reasons|2
6068983|NCT00542425|9671776|FG000|Initial 24 Weeks|Administrative reasons|0
6068984|NCT00542425|9671777|FG001|Initial 24 Weeks|Administrative reasons|0
6068985|NCT00542425|9671778|FG002|Initial 24 Weeks|Administrative reasons|1
6068986|NCT00542425|9671779|FG003|Initial 24 Weeks|Administrative reasons|1
6068987|NCT00542425|9671780|FG004|Initial 24 Weeks|Administrative reasons|0
6068988|NCT00542425|9671776|FG000|Initial 24 Weeks|Adverse Event|0
6068989|NCT00542425|9671777|FG001|Initial 24 Weeks|Adverse Event|1
6068990|NCT00542425|9671778|FG002|Initial 24 Weeks|Adverse Event|1
6146200|NCT01075984|9780814|FG001|Treatment Phase|Treatment Failure|0
6068991|NCT00542425|9671779|FG003|Initial 24 Weeks|Adverse Event|3
6068992|NCT00542425|9671780|FG004|Initial 24 Weeks|Adverse Event|2
6068993|NCT00542425|9671776|FG000|Initial 24 Weeks|Inability to complete procedures|0
6068994|NCT00542425|9671777|FG001|Initial 24 Weeks|Inability to complete procedures|3
6068995|NCT00542425|9671778|FG002|Initial 24 Weeks|Inability to complete procedures|2
6068996|NCT00542425|9671779|FG003|Initial 24 Weeks|Inability to complete procedures|1
6068997|NCT00542425|9671780|FG004|Initial 24 Weeks|Inability to complete procedures|2
6068998|NCT00542425|9671776|FG000|Initial 24 Weeks|Lost to Follow-up|2
6068999|NCT00542425|9671777|FG001|Initial 24 Weeks|Lost to Follow-up|2
6069000|NCT00542425|9671778|FG002|Initial 24 Weeks|Lost to Follow-up|1
6069001|NCT00542425|9671779|FG003|Initial 24 Weeks|Lost to Follow-up|0
6069002|NCT00542425|9671780|FG004|Initial 24 Weeks|Lost to Follow-up|0
6069003|NCT00542425|9671776|FG000|Initial 24 Weeks|Non-compliance|0
6069004|NCT00542425|9671777|FG001|Initial 24 Weeks|Non-compliance|0
6069005|NCT00542425|9671778|FG002|Initial 24 Weeks|Non-compliance|0
6069006|NCT00542425|9671779|FG003|Initial 24 Weeks|Non-compliance|1
6069007|NCT00542425|9671780|FG004|Initial 24 Weeks|Non-compliance|1
6069008|NCT00542425|9671776|FG000|Initial 24 Weeks|Protocol Violation|0
6069009|NCT00542425|9671777|FG001|Initial 24 Weeks|Protocol Violation|0
6069010|NCT00542425|9671778|FG002|Initial 24 Weeks|Protocol Violation|0
6069011|NCT00542425|9671779|FG003|Initial 24 Weeks|Protocol Violation|1
6069012|NCT00542425|9671780|FG004|Initial 24 Weeks|Protocol Violation|0
6069013|NCT00542425|9671776|FG000|Initial 24 Weeks|Refusal of treatment|2
6069014|NCT00542425|9671777|FG001|Initial 24 Weeks|Refusal of treatment|2
6069015|NCT00542425|9671778|FG002|Initial 24 Weeks|Refusal of treatment|1
6069016|NCT00542425|9671779|FG003|Initial 24 Weeks|Refusal of treatment|4
6069017|NCT00542425|9671780|FG004|Initial 24 Weeks|Refusal of treatment|1
6069018|NCT00542425|9671776|FG000|Initial 24 Weeks|Other|0
6069019|NCT00542425|9671777|FG001|Initial 24 Weeks|Other|2
6069020|NCT00542425|9671778|FG002|Initial 24 Weeks|Other|1
6069021|NCT00542425|9671779|FG003|Initial 24 Weeks|Other|0
6069022|NCT00542425|9671780|FG004|Initial 24 Weeks|Other|0
6069023|NCT00542425|9671776|FG000|Extended 24 Weeks of Treatment|Adverse Event|0
6069024|NCT00542425|9671777|FG001|Extended 24 Weeks of Treatment|Adverse Event|0
6069025|NCT00542425|9671778|FG002|Extended 24 Weeks of Treatment|Adverse Event|1
6069026|NCT00542425|9671779|FG003|Extended 24 Weeks of Treatment|Adverse Event|1
6069027|NCT00542425|9671780|FG004|Extended 24 Weeks of Treatment|Adverse Event|0
6069028|NCT00542425|9671776|FG000|Extended 24 Weeks of Treatment|Protocol Violation|0
6069029|NCT00542425|9671777|FG001|Extended 24 Weeks of Treatment|Protocol Violation|0
6069030|NCT00542425|9671778|FG002|Extended 24 Weeks of Treatment|Protocol Violation|1
6069031|NCT00542425|9671779|FG003|Extended 24 Weeks of Treatment|Protocol Violation|0
6069032|NCT00542425|9671780|FG004|Extended 24 Weeks of Treatment|Protocol Violation|0
6069033|NCT00542425|9671776|FG000|Extended 24 Weeks of Treatment|Refusal of treatment|0
6069034|NCT00542425|9671777|FG001|Extended 24 Weeks of Treatment|Refusal of treatment|1
6069035|NCT00542425|9671778|FG002|Extended 24 Weeks of Treatment|Refusal of treatment|0
6069036|NCT00542425|9671779|FG003|Extended 24 Weeks of Treatment|Refusal of treatment|0
6069037|NCT00542425|9671780|FG004|Extended 24 Weeks of Treatment|Refusal of treatment|0
6069038|NCT00542425|9671776|FG000|Extended 24 Weeks of Treatment|Other|1
6069039|NCT00542425|9671777|FG001|Extended 24 Weeks of Treatment|Other|1
6069040|NCT00542425|9671778|FG002|Extended 24 Weeks of Treatment|Other|0
6069041|NCT00542425|9671779|FG003|Extended 24 Weeks of Treatment|Other|0
6069042|NCT00542425|9671780|FG004|Extended 24 Weeks of Treatment|Other|1
6069043|NCT00542789|9671811|FG000|Overall Study|Adverse Event|18
6069044|NCT00542789|9671812|FG001|Overall Study|Adverse Event|17
6069045|NCT00542789|9671811|FG000|Overall Study|Withdrawal by Subject|7
6069046|NCT00542789|9671812|FG001|Overall Study|Withdrawal by Subject|3
6069047|NCT00542789|9671811|FG000|Overall Study|Protocol Violation|8
6069048|NCT00542789|9671812|FG001|Overall Study|Protocol Violation|1
6069049|NCT00542789|9671811|FG000|Overall Study|Recurrence of Gastric Ulcer|8
6069050|NCT00542789|9671812|FG001|Overall Study|Recurrence of Gastric Ulcer|57
6069051|NCT00542815|9671821|FG000|Overall Study|Adverse Event|19
6069052|NCT00542815|9671822|FG001|Overall Study|Adverse Event|6
6069053|NCT00542815|9671823|FG002|Overall Study|Adverse Event|9
6069054|NCT00542815|9671821|FG000|Overall Study|Death|10
6069055|NCT00542815|9671822|FG001|Overall Study|Death|7
6069056|NCT00542815|9671823|FG002|Overall Study|Death|3
6069057|NCT00542815|9671821|FG000|Overall Study|Lack of Efficacy|9
6069058|NCT00542815|9671822|FG001|Overall Study|Lack of Efficacy|2
6069059|NCT00542815|9671823|FG002|Overall Study|Lack of Efficacy|0
6069060|NCT00542815|9671821|FG000|Overall Study|Physician Decision|2
6069061|NCT00542815|9671822|FG001|Overall Study|Physician Decision|1
6069062|NCT00542815|9671823|FG002|Overall Study|Physician Decision|0
6069063|NCT00542815|9671821|FG000|Overall Study|Protocol Violation|1
6069064|NCT00542815|9671822|FG001|Overall Study|Protocol Violation|1
6069065|NCT00542815|9671823|FG002|Overall Study|Protocol Violation|2
6069066|NCT00542815|9671821|FG000|Overall Study|Withdrawal by Subject|41
6069067|NCT00542815|9671822|FG001|Overall Study|Withdrawal by Subject|5
6069068|NCT00542815|9671823|FG002|Overall Study|Withdrawal by Subject|8
6069069|NCT00542815|9671821|FG000|Overall Study|Other reasons|24
6069070|NCT00542815|9671822|FG001|Overall Study|Other reasons|10
6069071|NCT00542815|9671823|FG002|Overall Study|Other reasons|10
6069072|NCT00542828|9671831|FG000|Overall Study|Physician Decision|1
6069073|NCT00542828|9671831|FG000|Overall Study|Need for Prohibited Treatment|3
6069074|NCT00542828|9671831|FG000|Overall Study|Study Prematurely Discontinued|7
6069075|NCT00542828|9671831|FG000|Overall Study|Did Not Receive Thymoglobulin Treatment|2
6069076|NCT00542880|9671837|FG000|Period 1|Eligibility criteria not fulfilled|2
6069077|NCT00542880|9671838|FG001|Period 1|Eligibility criteria not fulfilled|6
6069078|NCT00542880|9671837|FG000|Period 1|Adverse Event|2
6069079|NCT00542880|9671838|FG001|Period 1|Adverse Event|2
6069080|NCT00542880|9671837|FG000|Period 1|Development of study-specific criteria|1
6069081|NCT00542880|9671838|FG001|Period 1|Development of study-specific criteria|2
6069082|NCT00542880|9671837|FG000|Period 1|Withdrawal by Subject|1
6069083|NCT00542880|9671838|FG001|Period 1|Withdrawal by Subject|1
6069084|NCT00542880|9671837|FG000|Period 1|Protocol Violation|0
6069085|NCT00542880|9671838|FG001|Period 1|Protocol Violation|1
6069086|NCT00542880|9671837|FG000|Period 2|Adverse Event|5
6069087|NCT00542880|9671838|FG001|Period 2|Adverse Event|7
6069088|NCT00542880|9671837|FG000|Period 2|Eligibility not fulfilled|0
6069089|NCT00542880|9671838|FG001|Period 2|Eligibility not fulfilled|1
6069090|NCT00542880|9671837|FG000|Period 2|Discontinuation criteria|2
6069091|NCT00542880|9671838|FG001|Period 2|Discontinuation criteria|0
6069092|NCT00542880|9671837|FG000|Period 2|Severe non-compliance|0
6069093|NCT00542880|9671838|FG001|Period 2|Severe non-compliance|1
6069094|NCT00542880|9671837|FG000|Period 2|Other|0
6069095|NCT00542880|9671838|FG001|Period 2|Other|1
6069096|NCT00542880|9671837|FG000|Period 3|Adverse Event|0
6069097|NCT00542880|9671838|FG001|Period 3|Adverse Event|2
6069098|NCT00542919|9671848|FG000|Overall Study|Adverse Event|1
6069099|NCT00542919|9671849|FG001|Overall Study|Adverse Event|5
6069100|NCT00542919|9671850|FG002|Overall Study|Adverse Event|1
6069101|NCT00542919|9671848|FG000|Overall Study|Withdrawal by Subject|1
6069102|NCT00542919|9671849|FG001|Overall Study|Withdrawal by Subject|0
6069103|NCT00542919|9671850|FG002|Overall Study|Withdrawal by Subject|3
6069104|NCT00542919|9671848|FG000|Overall Study|Physician Decision|2
6069105|NCT00542919|9671849|FG001|Overall Study|Physician Decision|2
6069106|NCT00542919|9671850|FG002|Overall Study|Physician Decision|1
6069107|NCT00542919|9671848|FG000|Overall Study|Sponsor Decision|1
6069108|NCT00542919|9671849|FG001|Overall Study|Sponsor Decision|0
6069109|NCT00542919|9671850|FG002|Overall Study|Sponsor Decision|0
6069110|NCT00542919|9671848|FG000|Overall Study|Lost to Follow-up|2
6069111|NCT00542919|9671849|FG001|Overall Study|Lost to Follow-up|0
6069112|NCT00542919|9671850|FG002|Overall Study|Lost to Follow-up|1
6069113|NCT00542997|9671877|FG000|Wash in / Wash Out Period|Withdrawal by Subject|2
6069114|NCT00542997|9671877|FG000|Wash in / Wash Out Period|Adverse Event|3
6069115|NCT00542997|9671877|FG000|Efficacy Period|Adverse Event|3
6069116|NCT00543062|9671884|FG000|Overall Study|Withdrawal by Subject|1
6069117|NCT00543062|9671885|FG001|Overall Study|Withdrawal by Subject|0
6069118|NCT00543062|9671886|FG002|Overall Study|Withdrawal by Subject|2
6069119|NCT00543062|9671887|FG003|Overall Study|Withdrawal by Subject|0
6069120|NCT00543062|9671884|FG000|Overall Study|Adverse Event|0
6069121|NCT00543062|9671885|FG001|Overall Study|Adverse Event|1
6069122|NCT00543062|9671886|FG002|Overall Study|Adverse Event|1
6069123|NCT00543062|9671887|FG003|Overall Study|Adverse Event|1
6069124|NCT00543062|9671884|FG000|Overall Study|Protocol Violation|1
6069125|NCT00543062|9671885|FG001|Overall Study|Protocol Violation|0
6069126|NCT00543062|9671886|FG002|Overall Study|Protocol Violation|0
6069127|NCT00543062|9671887|FG003|Overall Study|Protocol Violation|0
6069128|NCT00543140|9671924|FG000|Overall Study|Lost to Follow-up|33
6069129|NCT00543140|9671924|FG000|Overall Study|Withdrawal by Subject|13
6069130|NCT00543140|9671924|FG000|Overall Study|Protocol Violation|10
6069131|NCT00543140|9671924|FG000|Overall Study|Insufficient weight loss|10
6069132|NCT00543140|9671924|FG000|Overall Study|SAE leading to explant of SAGB|3
6069133|NCT00543140|9671924|FG000|Overall Study|Death|1
6069134|NCT00543140|9671924|FG000|Overall Study|Subject moved|1
6069135|NCT00543140|9671924|FG000|Overall Study|Conversion to different procedure|1
6069136|NCT00543296|9671928|FG000|Overall Study|Physician Decision|7
6069137|NCT00543309|9671935|FG000|Overall Study|Physician Decision|0
6069138|NCT00543309|9671936|FG001|Overall Study|Physician Decision|1
6069139|NCT00543309|9671937|FG002|Overall Study|Physician Decision|0
6069140|NCT00543387|9671955|FG000|Panel 1 + Panel 2|Adverse Event|0
6069141|NCT00543387|9671956|FG001|Panel 1 + Panel 2|Adverse Event|1
6069142|NCT00543387|9671957|FG002|Panel 1 + Panel 2|Adverse Event|0
6069143|NCT00543387|9671958|FG003|Panel 1 + Panel 2|Adverse Event|0
6069144|NCT00543387|9671959|FG004|Panel 1 + Panel 2|Adverse Event|0
6069145|NCT00543387|9671960|FG005|Panel 1 + Panel 2|Adverse Event|0
6069146|NCT00543387|9671961|FG006|Panel 1 + Panel 2|Adverse Event|0
6069147|NCT00543387|9671962|FG007|Panel 1 + Panel 2|Adverse Event|1
6069148|NCT00543387|9671963|FG008|Panel 1 + Panel 2|Adverse Event|1
6069149|NCT00543387|9671964|FG009|Panel 1 + Panel 2|Adverse Event|0
6069150|NCT00543387|9671965|FG010|Panel 1 + Panel 2|Adverse Event|0
6069151|NCT00543387|9671955|FG000|Panel 1 + Panel 2|Physician Decision|0
6069152|NCT00543387|9671956|FG001|Panel 1 + Panel 2|Physician Decision|0
6069153|NCT00543387|9671957|FG002|Panel 1 + Panel 2|Physician Decision|1
6069154|NCT00543387|9671958|FG003|Panel 1 + Panel 2|Physician Decision|0
6069155|NCT00543387|9671959|FG004|Panel 1 + Panel 2|Physician Decision|0
6069156|NCT00543387|9671960|FG005|Panel 1 + Panel 2|Physician Decision|0
6069157|NCT00543387|9671961|FG006|Panel 1 + Panel 2|Physician Decision|0
6069158|NCT00543387|9671962|FG007|Panel 1 + Panel 2|Physician Decision|1
6069159|NCT00543387|9671963|FG008|Panel 1 + Panel 2|Physician Decision|0
6069160|NCT00543387|9671964|FG009|Panel 1 + Panel 2|Physician Decision|0
6069161|NCT00543387|9671965|FG010|Panel 1 + Panel 2|Physician Decision|0
6069162|NCT00543387|9671955|FG000|Panel 1 + Panel 2|Progressive Disease (PD)|3
6069163|NCT00543387|9671956|FG001|Panel 1 + Panel 2|Progressive Disease (PD)|2
6069164|NCT00543387|9671957|FG002|Panel 1 + Panel 2|Progressive Disease (PD)|2
6069165|NCT00543387|9671958|FG003|Panel 1 + Panel 2|Progressive Disease (PD)|3
6069166|NCT00543387|9671959|FG004|Panel 1 + Panel 2|Progressive Disease (PD)|3
6069167|NCT00543387|9671960|FG005|Panel 1 + Panel 2|Progressive Disease (PD)|3
6069168|NCT00543387|9671961|FG006|Panel 1 + Panel 2|Progressive Disease (PD)|5
6069169|NCT00543387|9671962|FG007|Panel 1 + Panel 2|Progressive Disease (PD)|4
6069170|NCT00543387|9671963|FG008|Panel 1 + Panel 2|Progressive Disease (PD)|4
6069171|NCT00543387|9671964|FG009|Panel 1 + Panel 2|Progressive Disease (PD)|0
6069172|NCT00543387|9671965|FG010|Panel 1 + Panel 2|Progressive Disease (PD)|0
6069173|NCT00543387|9671955|FG000|Panel 1 + Panel 2|Withdrawal by Subject|0
6069174|NCT00543387|9671956|FG001|Panel 1 + Panel 2|Withdrawal by Subject|0
6069175|NCT00543387|9671957|FG002|Panel 1 + Panel 2|Withdrawal by Subject|0
6069176|NCT00543387|9671958|FG003|Panel 1 + Panel 2|Withdrawal by Subject|0
6069177|NCT00543387|9671959|FG004|Panel 1 + Panel 2|Withdrawal by Subject|0
6069178|NCT00543387|9671960|FG005|Panel 1 + Panel 2|Withdrawal by Subject|0
6069179|NCT00543387|9671961|FG006|Panel 1 + Panel 2|Withdrawal by Subject|1
6069180|NCT00543387|9671962|FG007|Panel 1 + Panel 2|Withdrawal by Subject|0
6069181|NCT00543387|9671963|FG008|Panel 1 + Panel 2|Withdrawal by Subject|0
6069182|NCT00543387|9671964|FG009|Panel 1 + Panel 2|Withdrawal by Subject|0
6069183|NCT00543387|9671965|FG010|Panel 1 + Panel 2|Withdrawal by Subject|0
6069184|NCT00543387|9671955|FG000|Crossover Participants|Progressive Disease|0
6069185|NCT00543387|9671956|FG001|Crossover Participants|Progressive Disease|0
6069186|NCT00543387|9671957|FG002|Crossover Participants|Progressive Disease|0
6069187|NCT00543387|9671958|FG003|Crossover Participants|Progressive Disease|0
6069188|NCT00543387|9671959|FG004|Crossover Participants|Progressive Disease|0
6069189|NCT00543387|9671960|FG005|Crossover Participants|Progressive Disease|0
6069190|NCT00543387|9671961|FG006|Crossover Participants|Progressive Disease|0
6069191|NCT00543387|9671962|FG007|Crossover Participants|Progressive Disease|0
6069192|NCT00543387|9671963|FG008|Crossover Participants|Progressive Disease|0
6069193|NCT00543387|9671964|FG009|Crossover Participants|Progressive Disease|1
6069194|NCT00543387|9671965|FG010|Crossover Participants|Progressive Disease|2
6069195|NCT00543387|9671955|FG000|Crossover Participants|Study Terminated by Sponsor|0
6069196|NCT00543387|9671956|FG001|Crossover Participants|Study Terminated by Sponsor|0
6069197|NCT00543387|9671957|FG002|Crossover Participants|Study Terminated by Sponsor|0
6087211|NCT00666926|9697367|FG008|Overall Study|Lack of Efficacy|0
5992870|NCT01925131|9585484|FG002|Overall Study|Other - Not Protocol Specified|2
5992871|NCT01925131|9585485|FG003|Overall Study|Other - Not Protocol Specified|5
5992872|NCT01925131|9585486|FG004|Overall Study|Other - Not Protocol Specified|10
5992873|NCT01925131|9585487|FG005|Overall Study|Other - Not Protocol Specified|6
5992874|NCT01776307|9585506|FG000|Overall Study|Not dosed|0
5992875|NCT01776307|9585507|FG001|Overall Study|Not dosed|0
5992876|NCT01776307|9585508|FG002|Overall Study|Not dosed|1
5992877|NCT01535274|9585552|FG000|Overall Study|Determined to be ineligible|0
5992878|NCT01535274|9585553|FG001|Overall Study|Determined to be ineligible|1
5992879|NCT01535274|9585552|FG000|Overall Study|Misallocated to propofol intervention|0
5992880|NCT01535274|9585553|FG001|Overall Study|Misallocated to propofol intervention|1
5992881|NCT00539981|9585567|FG000|Overall Study|Adverse events (AE)|3
5992882|NCT00539981|9585568|FG001|Overall Study|Adverse events (AE)|3
5992883|NCT00539981|9585567|FG000|Overall Study|Lost to Follow-up|260
5992884|NCT00539981|9585568|FG001|Overall Study|Lost to Follow-up|251
5992885|NCT00539981|9585567|FG000|Overall Study|Withdrew consent|22
5992886|NCT00539981|9585568|FG001|Overall Study|Withdrew consent|14
5992887|NCT00539981|9585567|FG000|Overall Study|Death|1
5992888|NCT00539981|9585568|FG001|Overall Study|Death|1
5992889|NCT00539981|9585567|FG000|Overall Study|Other reason-unspecified|9
5992890|NCT00539981|9585568|FG001|Overall Study|Other reason-unspecified|13
6046068|NCT00404768|9645281|FG002|Part A and B|Withdrawn due to labor progression|0
6046069|NCT00404768|9645282|FG003|Part A and B|Withdrawn due to labor progression|0
6046070|NCT00404768|9645279|FG000|Part A and B|Withdrawn as delivery imminemnt|0
6046071|NCT00404768|9645280|FG001|Part A and B|Withdrawn as delivery imminemnt|1
6046072|NCT00404768|9645281|FG002|Part A and B|Withdrawn as delivery imminemnt|0
6046073|NCT00404768|9645282|FG003|Part A and B|Withdrawn as delivery imminemnt|0
6046074|NCT00404768|9645279|FG000|Part C|Adverse Event|0
6069198|NCT00543387|9671958|FG003|Crossover Participants|Study Terminated by Sponsor|0
6069199|NCT00543387|9671959|FG004|Crossover Participants|Study Terminated by Sponsor|0
6069200|NCT00543387|9671960|FG005|Crossover Participants|Study Terminated by Sponsor|0
6069201|NCT00543387|9671961|FG006|Crossover Participants|Study Terminated by Sponsor|0
6069202|NCT00543387|9671962|FG007|Crossover Participants|Study Terminated by Sponsor|0
6069203|NCT00543387|9671963|FG008|Crossover Participants|Study Terminated by Sponsor|0
6069204|NCT00543387|9671964|FG009|Crossover Participants|Study Terminated by Sponsor|0
6069205|NCT00543387|9671965|FG010|Crossover Participants|Study Terminated by Sponsor|1
6069206|NCT00543439|9672009|FG000|Period 1|Adverse Event|0
6069207|NCT00543439|9672010|FG001|Period 1|Adverse Event|2
6069208|NCT00543439|9672011|FG002|Period 1|Adverse Event|1
6069209|NCT00543439|9672009|FG000|Period 1|Withdrawal by Subject|1
6069210|NCT00543439|9672010|FG001|Period 1|Withdrawal by Subject|1
6146201|NCT01075984|9780815|FG002|Treatment Phase|Treatment Failure|1
6146202|NCT01075984|9780816|FG003|Treatment Phase|Treatment Failure|0
6146203|NCT01075984|9780817|FG004|Treatment Phase|Treatment Failure|5
6146204|NCT01075984|9780813|FG000|Treatment Phase|Progression of disease|0
6069211|NCT00543439|9672011|FG002|Period 1|Withdrawal by Subject|0
6069212|NCT00543439|9672009|FG000|Period 1|Physician Decision|0
6069213|NCT00543439|9672010|FG001|Period 1|Physician Decision|0
6069214|NCT00543439|9672011|FG002|Period 1|Physician Decision|1
6069215|NCT00543439|9672009|FG000|Period 2|Protocol Violation|1
6069216|NCT00543439|9672010|FG001|Period 2|Protocol Violation|0
6069217|NCT00543439|9672011|FG002|Period 2|Protocol Violation|1
6069218|NCT00543439|9672009|FG000|Period 2|Adverse Event|0
6069219|NCT00543439|9672010|FG001|Period 2|Adverse Event|1
6069220|NCT00543439|9672011|FG002|Period 2|Adverse Event|1
6069221|NCT00543543|9672032|FG000|Base Study|Adverse Event|1
6069222|NCT00543543|9672033|FG001|Base Study|Adverse Event|11
6069223|NCT00543543|9672034|FG002|Base Study|Adverse Event|0
6069224|NCT00543543|9672035|FG003|Base Study|Adverse Event|5
6069225|NCT00543543|9672032|FG000|Base Study|Lost to Follow-up|12
6069226|NCT00543543|9672033|FG001|Base Study|Lost to Follow-up|749
6069227|NCT00543543|9672034|FG002|Base Study|Lost to Follow-up|9
6069228|NCT00543543|9672035|FG003|Base Study|Lost to Follow-up|701
6069229|NCT00543543|9672032|FG000|Base Study|Physician Decision|0
6069230|NCT00543543|9672033|FG001|Base Study|Physician Decision|4
6069231|NCT00543543|9672034|FG002|Base Study|Physician Decision|0
6069232|NCT00543543|9672035|FG003|Base Study|Physician Decision|7
6069233|NCT00543543|9672032|FG000|Base Study|Protocol Violation|0
6069234|NCT00543543|9672033|FG001|Base Study|Protocol Violation|6
6069235|NCT00543543|9672034|FG002|Base Study|Protocol Violation|0
6069236|NCT00543543|9672035|FG003|Base Study|Protocol Violation|6
5992891|NCT04732338|9585588|FG000|Overall Study|Lost to Follow-up|3
5992892|NCT04732338|9585589|FG001|Overall Study|Lost to Follow-up|3
6046075|NCT00404768|9645280|FG001|Part C|Adverse Event|0
6046076|NCT00404768|9645281|FG002|Part C|Adverse Event|0
6046077|NCT00404768|9645282|FG003|Part C|Adverse Event|3
6046078|NCT00404768|9645279|FG000|Part C|Lost to Follow-up|0
6046079|NCT00404768|9645280|FG001|Part C|Lost to Follow-up|0
6069237|NCT00543543|9672032|FG000|Base Study|Withdrawal by Subject|7
6046080|NCT00404768|9645281|FG002|Part C|Lost to Follow-up|3
6046081|NCT00404768|9645282|FG003|Part C|Lost to Follow-up|1
6046082|NCT00404768|9645279|FG000|Part C|Withdrawal by Subject|0
6046083|NCT00404768|9645280|FG001|Part C|Withdrawal by Subject|0
6069238|NCT00543543|9672033|FG001|Base Study|Withdrawal by Subject|482
6069239|NCT00543543|9672034|FG002|Base Study|Withdrawal by Subject|5
6069240|NCT00543543|9672035|FG003|Base Study|Withdrawal by Subject|503
6069241|NCT00543543|9672032|FG000|Extension Study|Adverse Event|0
6069242|NCT00543543|9672033|FG001|Extension Study|Adverse Event|0
6069243|NCT00543543|9672034|FG002|Extension Study|Adverse Event|0
6069244|NCT00543543|9672035|FG003|Extension Study|Adverse Event|5
6069245|NCT00543543|9672032|FG000|Extension Study|Lost to Follow-up|0
6046084|NCT00404768|9645281|FG002|Part C|Withdrawal by Subject|2
6069246|NCT00543543|9672033|FG001|Extension Study|Lost to Follow-up|0
6069247|NCT00543543|9672034|FG002|Extension Study|Lost to Follow-up|0
6069248|NCT00543543|9672035|FG003|Extension Study|Lost to Follow-up|77
6069249|NCT00543543|9672032|FG000|Extension Study|Physician Decision|0
6069250|NCT00543543|9672033|FG001|Extension Study|Physician Decision|0
6069251|NCT00543543|9672034|FG002|Extension Study|Physician Decision|0
6069252|NCT00543543|9672035|FG003|Extension Study|Physician Decision|7
6069253|NCT00543543|9672032|FG000|Extension Study|Pregnancy|0
6069254|NCT00543543|9672033|FG001|Extension Study|Pregnancy|0
6069255|NCT00543543|9672034|FG002|Extension Study|Pregnancy|0
6069256|NCT00543543|9672035|FG003|Extension Study|Pregnancy|6
6069257|NCT00543543|9672032|FG000|Extension Study|Protocol Violation|0
6069258|NCT00543543|9672033|FG001|Extension Study|Protocol Violation|0
6069259|NCT00543543|9672034|FG002|Extension Study|Protocol Violation|0
6069260|NCT00543543|9672035|FG003|Extension Study|Protocol Violation|11
6069261|NCT00543543|9672032|FG000|Extension Study|Withdrawal by Subject|0
6069262|NCT00543543|9672033|FG001|Extension Study|Withdrawal by Subject|0
6069263|NCT00543543|9672034|FG002|Extension Study|Withdrawal by Subject|0
6069264|NCT00543543|9672035|FG003|Extension Study|Withdrawal by Subject|120
6069265|NCT00543569|9672054|FG000|Overall Study|Death|2
6069266|NCT00543569|9672055|FG001|Overall Study|Death|2
6069267|NCT00543569|9672056|FG002|Overall Study|Death|3
6069268|NCT00543569|9672057|FG003|Overall Study|Death|1
6069269|NCT00543569|9672054|FG000|Overall Study|Lost to Follow-up|0
6069270|NCT00543569|9672055|FG001|Overall Study|Lost to Follow-up|0
6069271|NCT00543569|9672056|FG002|Overall Study|Lost to Follow-up|1
6069272|NCT00543569|9672057|FG003|Overall Study|Lost to Follow-up|1
6069273|NCT00543569|9672054|FG000|Overall Study|Miscellaneous Reasons|7
6069274|NCT00543569|9672055|FG001|Overall Study|Miscellaneous Reasons|3
6069275|NCT00543569|9672056|FG002|Overall Study|Miscellaneous Reasons|11
6069276|NCT00543569|9672057|FG003|Overall Study|Miscellaneous Reasons|4
6069277|NCT00543569|9672054|FG000|Overall Study|Randomized but never received study drug|3
6069278|NCT00543569|9672055|FG001|Overall Study|Randomized but never received study drug|3
6069279|NCT00543569|9672056|FG002|Overall Study|Randomized but never received study drug|5
6069280|NCT00543569|9672057|FG003|Overall Study|Randomized but never received study drug|3
6069281|NCT00543725|9672069|FG000|Overall Study|Adverse Event|18
6069282|NCT00543725|9672070|FG001|Overall Study|Adverse Event|27
5992893|NCT04728802|9585597|FG000|Overall Study|Withdrawal by Subject|4
5992894|NCT04728802|9585598|FG001|Overall Study|Withdrawal by Subject|20
5992895|NCT04728802|9585597|FG000|Overall Study|Physician Decision|7
5992896|NCT04728802|9585598|FG001|Overall Study|Physician Decision|7
5992897|NCT04728802|9585597|FG000|Overall Study|Protocol Violation|10
5992898|NCT04728802|9585598|FG001|Overall Study|Protocol Violation|4
5992899|NCT04728802|9585597|FG000|Overall Study|Transfer|1
5992900|NCT04728802|9585598|FG001|Overall Study|Transfer|0
5992901|NCT04728802|9585597|FG000|Overall Study|Death|4
5992902|NCT04728802|9585598|FG001|Overall Study|Death|5
6069283|NCT00543725|9672069|FG000|Overall Study|Sponsor's Decision|0
6069284|NCT00543725|9672070|FG001|Overall Study|Sponsor's Decision|1
5992903|NCT04728802|9585597|FG000|Overall Study|Other|3
5992904|NCT04728802|9585598|FG001|Overall Study|Other|0
5992908|NCT04716426|9585634|FG000|Overall Study|Vaccination|1
5992909|NCT04716426|9585635|FG001|Overall Study|Vaccination|1
5992910|NCT04716426|9585634|FG000|Overall Study|Contamination|1
5992911|NCT04716426|9585635|FG001|Overall Study|Contamination|0
5992912|NCT04698993|9585656|FG000|Overall Study|PCR results not accessible|2
5992913|NCT04698993|9585657|FG001|Overall Study|PCR results not accessible|7
5992914|NCT04698993|9585656|FG000|Overall Study|incomplete documentation of kit assessment prior to testing|1
5992915|NCT04698993|9585657|FG001|Overall Study|incomplete documentation of kit assessment prior to testing|0
5992916|NCT04674644|9585684|FG000|Overall Study|with missing data|37
5992917|NCT04668989|9585702|FG000|First Intervention|Covid-19 related self-isolation|0
5992918|NCT04668989|9585703|FG001|First Intervention|Covid-19 related self-isolation|1
5992919|NCT04668989|9585702|FG000|Second Intervention|Adverse Event|0
5992920|NCT04668989|9585703|FG001|Second Intervention|Adverse Event|1
5992921|NCT04646109|9585769|FG000|Overall Study|Mutation disrupting ivermectin metabolism was found in 6 patients|0
5992922|NCT04646109|9585770|FG001|Overall Study|Mutation disrupting ivermectin metabolism was found in 6 patients|6
5992923|NCT04633642|9585805|FG000|Overall Study|Chronic renal disease, critical limb ischemia and heart attack|1
5992924|NCT04633642|9585806|FG001|Overall Study|Chronic renal disease, critical limb ischemia and heart attack|2
5992925|NCT04615507|9585861|FG000|Period 1|Covid-19 exposure|2
5992926|NCT04615507|9585862|FG001|Period 1|Covid-19 exposure|1
5992927|NCT04615507|9585861|FG000|Period 2|Covid-19 exposure|0
5992928|NCT04615507|9585862|FG001|Period 2|Covid-19 exposure|1
6069285|NCT00543725|9672069|FG000|Overall Study|Subject Non-Compliant|4
6146205|NCT01075984|9780814|FG001|Treatment Phase|Progression of disease|0
6146206|NCT01075984|9780815|FG002|Treatment Phase|Progression of disease|0
6146207|NCT01075984|9780816|FG003|Treatment Phase|Progression of disease|0
6146208|NCT01075984|9780817|FG004|Treatment Phase|Progression of disease|2
6146209|NCT01075984|9780813|FG000|Follow-up Phase|Protocol Violation|0
6146210|NCT01075984|9780814|FG001|Follow-up Phase|Protocol Violation|0
6146211|NCT01075984|9780815|FG002|Follow-up Phase|Protocol Violation|1
6146212|NCT01075984|9780816|FG003|Follow-up Phase|Protocol Violation|0
6146213|NCT01075984|9780817|FG004|Follow-up Phase|Protocol Violation|3
6146214|NCT01075984|9780813|FG000|Follow-up Phase|Adverse Event|0
6146215|NCT01075984|9780814|FG001|Follow-up Phase|Adverse Event|0
6146216|NCT01075984|9780815|FG002|Follow-up Phase|Adverse Event|0
6146217|NCT01075984|9780816|FG003|Follow-up Phase|Adverse Event|2
6146218|NCT01075984|9780817|FG004|Follow-up Phase|Adverse Event|27
6146219|NCT01075984|9780813|FG000|Follow-up Phase|Administrative|0
6146220|NCT01075984|9780814|FG001|Follow-up Phase|Administrative|0
6146221|NCT01075984|9780815|FG002|Follow-up Phase|Administrative|0
6146222|NCT01075984|9780816|FG003|Follow-up Phase|Administrative|0
6146223|NCT01075984|9780817|FG004|Follow-up Phase|Administrative|1
6146224|NCT01075984|9780813|FG000|Follow-up Phase|Withdrawal by Subject|0
6069286|NCT00543725|9672070|FG001|Overall Study|Subject Non-Compliant|4
6069287|NCT00543725|9672069|FG000|Overall Study|Subject Ineligible To Continue The Trial|2
6069288|NCT00543725|9672070|FG001|Overall Study|Subject Ineligible To Continue The Trial|0
6069289|NCT00543725|9672069|FG000|Overall Study|Subject Reached A Virologic Endpoint|22
6069290|NCT00543725|9672070|FG001|Overall Study|Subject Reached A Virologic Endpoint|14
6069291|NCT00543725|9672069|FG000|Overall Study|Protocol Violation|0
6069292|NCT00543725|9672070|FG001|Overall Study|Protocol Violation|1
6069293|NCT00543725|9672069|FG000|Overall Study|Withdrawal by Subject|4
6069294|NCT00543725|9672070|FG001|Overall Study|Withdrawal by Subject|13
6069295|NCT00543725|9672069|FG000|Overall Study|Lost to Follow-up|15
6069296|NCT00543725|9672070|FG001|Overall Study|Lost to Follow-up|11
6069297|NCT00543725|9672069|FG000|Overall Study|Other|3
6069298|NCT00543725|9672070|FG001|Overall Study|Other|3
6069299|NCT00543803|9672089|FG000|Overall Study|Adverse Event|14
6069300|NCT00543803|9672089|FG000|Overall Study|Lack of Efficacy|22
6069301|NCT00543803|9672089|FG000|Overall Study|Lost to Follow-up|20
6069302|NCT00543803|9672089|FG000|Overall Study|Other|86
6069303|NCT00543855|9672099|FG000|Overall Study|Adverse Event|3
6069304|NCT00543855|9672100|FG001|Overall Study|Adverse Event|1
6069305|NCT00543855|9672101|FG002|Overall Study|Adverse Event|3
6069306|NCT00543855|9672102|FG003|Overall Study|Adverse Event|4
6069307|NCT00543855|9672099|FG000|Overall Study|Lost to Follow-up|0
6069308|NCT00543855|9672100|FG001|Overall Study|Lost to Follow-up|0
6069309|NCT00543855|9672101|FG002|Overall Study|Lost to Follow-up|1
6069310|NCT00543855|9672102|FG003|Overall Study|Lost to Follow-up|0
6069311|NCT00543855|9672099|FG000|Overall Study|Withdrawal by Subject|0
6069312|NCT00543855|9672100|FG001|Overall Study|Withdrawal by Subject|1
6069313|NCT00543855|9672101|FG002|Overall Study|Withdrawal by Subject|2
6069314|NCT00543855|9672102|FG003|Overall Study|Withdrawal by Subject|0
6069315|NCT00543855|9672099|FG000|Overall Study|Protocol Violation|1
6069316|NCT00543855|9672100|FG001|Overall Study|Protocol Violation|0
6069317|NCT00543855|9672101|FG002|Overall Study|Protocol Violation|0
6069318|NCT00543855|9672102|FG003|Overall Study|Protocol Violation|0
6069319|NCT00543985|9672112|FG000|Overall Study|Withdrawal by Subject|4
6069320|NCT00544167|9672133|FG000|Overall Study|Adverse Event|21
6069321|NCT00544167|9672133|FG000|Overall Study|Physician Decision|8
6069322|NCT00544440|9672137|FG000|Overall Study|Other|1
6069323|NCT00544440|9672137|FG000|Overall Study|Adverse Event|1
6069324|NCT00544440|9672137|FG000|Overall Study|Withdrawal by Subject|2
6069325|NCT00544440|9672137|FG000|Overall Study|Subject Non-compliance|1
6069326|NCT00544440|9672137|FG000|Overall Study|Progressive Disease|47
6069327|NCT00544440|9672137|FG000|Overall Study|Other|5
6069328|NCT00544544|9672141|FG000|Overall Study|Withdrawal by Subject|1
6069329|NCT00544544|9672141|FG000|Overall Study|Adverse Event|1
6069330|NCT00544544|9672141|FG000|Overall Study|Lost to Follow-up|1
6069331|NCT00544557|9672145|FG000|Overall Study|Adverse Event|140
6069332|NCT00544557|9672145|FG000|Overall Study|Lack of Efficacy|196
6069333|NCT00544557|9672145|FG000|Overall Study|Other|98
6069334|NCT00544648|9672151|FG000|Overall Study|Withdrawal by Subject|1
6069335|NCT00544648|9672152|FG001|Overall Study|Withdrawal by Subject|0
6069336|NCT00544648|9672151|FG000|Overall Study|Adverse Event|1
6069337|NCT00544648|9672152|FG001|Overall Study|Adverse Event|1
6069338|NCT00544648|9672151|FG000|Overall Study|progression of disease|1
6069339|NCT00544648|9672152|FG001|Overall Study|progression of disease|0
6069340|NCT00544817|9672177|FG000|Combined Modality|Lack of Efficacy|2
6069341|NCT00544817|9672177|FG000|Combined Modality|Worsening Neurologic Symptoms|2
6146225|NCT01075984|9780814|FG001|Follow-up Phase|Withdrawal by Subject|0
6069342|NCT00544817|9672177|FG000|Combined Modality|Adverse Event|2
6069343|NCT00544817|9672177|FG000|Combined Modality|Intercurrent Illness - Pneumonia|1
6069344|NCT00544817|9672177|FG000|No Treatment Interval|Lack of Efficacy|8
6069345|NCT00544817|9672177|FG000|No Treatment Interval|Physician Decision|3
6069346|NCT00544817|9672177|FG000|No Treatment Interval|Adverse Event|1
6069347|NCT00544817|9672177|FG000|Follow-up Systemic Therapy|Lack of Efficacy|15
6069348|NCT00544817|9672177|FG000|Follow-up Systemic Therapy|Physician Decision|3
6069349|NCT00544817|9672177|FG000|Follow-up Systemic Therapy|Intercurrent Illness - Pneumonia|1
6069350|NCT00544869|9672184|FG000|Overall Study|Rsolution of congenitive symptoms|3
6069351|NCT00544869|9672185|FG001|Overall Study|Rsolution of congenitive symptoms|0
6069352|NCT00544869|9672186|FG002|Overall Study|Rsolution of congenitive symptoms|0
6069353|NCT00544869|9672184|FG000|Overall Study|Adverse Event|6
6069354|NCT00544869|9672185|FG001|Overall Study|Adverse Event|1
6069355|NCT00544869|9672186|FG002|Overall Study|Adverse Event|0
6069356|NCT00544869|9672184|FG000|Overall Study|Lack of Efficacy|1
6069357|NCT00544869|9672185|FG001|Overall Study|Lack of Efficacy|1
6069358|NCT00544869|9672186|FG002|Overall Study|Lack of Efficacy|0
6069359|NCT00544869|9672184|FG000|Overall Study|Physician Decision|2
6069360|NCT00544869|9672185|FG001|Overall Study|Physician Decision|0
6069361|NCT00544869|9672186|FG002|Overall Study|Physician Decision|0
6069362|NCT00544882|9672196|FG000|Cycle 1: Run-in Cycle|Withdrawal by Subject|2
6069363|NCT00544882|9672197|FG001|Cycle 1: Run-in Cycle|Withdrawal by Subject|0
6069364|NCT00544882|9672198|FG002|Cycle 1: Run-in Cycle|Withdrawal by Subject|0
6069365|NCT00544882|9672196|FG000|Cycle 1: Run-in Cycle|Adverse Event|1
6069366|NCT00544882|9672197|FG001|Cycle 1: Run-in Cycle|Adverse Event|0
6069367|NCT00544882|9672198|FG002|Cycle 1: Run-in Cycle|Adverse Event|0
6069368|NCT00544882|9672196|FG000|Cycle 2: Randomized Treatment Cycle|Withdrawal by Subject|0
6069369|NCT00544882|9672197|FG001|Cycle 2: Randomized Treatment Cycle|Withdrawal by Subject|1
6069370|NCT00544882|9672198|FG002|Cycle 2: Randomized Treatment Cycle|Withdrawal by Subject|0
6069371|NCT00544882|9672196|FG000|Cycle 2: Randomized Treatment Cycle|Noncompliance|0
6069372|NCT00544882|9672197|FG001|Cycle 2: Randomized Treatment Cycle|Noncompliance|0
6069373|NCT00544882|9672198|FG002|Cycle 2: Randomized Treatment Cycle|Noncompliance|1
6069374|NCT00544882|9672196|FG000|Cycle 3: Follow-up|Noncompliance|0
6069375|NCT00544882|9672197|FG001|Cycle 3: Follow-up|Noncompliance|1
6069376|NCT00544882|9672198|FG002|Cycle 3: Follow-up|Noncompliance|0
6069377|NCT00544882|9672196|FG000|Cycle 3: Follow-up|Pregnancy|0
6069378|NCT00544882|9672197|FG001|Cycle 3: Follow-up|Pregnancy|1
6069379|NCT00544882|9672198|FG002|Cycle 3: Follow-up|Pregnancy|0
6069380|NCT00545051|9672219|FG000|Overall Study|Adverse Event|7
6069381|NCT00545051|9672220|FG001|Overall Study|Adverse Event|3
6069382|NCT00545051|9672219|FG000|Overall Study|Death|1
6069383|NCT00545051|9672220|FG001|Overall Study|Death|0
6069384|NCT00545051|9672219|FG000|Overall Study|Violation of inclusion/exclusion|0
6069385|NCT00545051|9672220|FG001|Overall Study|Violation of inclusion/exclusion|2
6069386|NCT00545051|9672219|FG000|Overall Study|Protocol Violation|1
6146226|NCT01075984|9780815|FG002|Follow-up Phase|Withdrawal by Subject|0
6069387|NCT00545051|9672220|FG001|Overall Study|Protocol Violation|0
6069388|NCT00545051|9672219|FG000|Overall Study|Withdrawal by Subject|0
6069389|NCT00545051|9672220|FG001|Overall Study|Withdrawal by Subject|1
6069390|NCT00545051|9672219|FG000|Overall Study|Administrative reasons|0
6069391|NCT00545051|9672220|FG001|Overall Study|Administrative reasons|1
6069392|NCT00545064|9672226|FG000|Overall Study|Lost to Follow-up|3
6069393|NCT00545064|9672226|FG000|Overall Study|Withdrawal by Subject|2
6069394|NCT00545064|9672226|FG000|Overall Study|did not complete course of treatment|1
6069395|NCT00545064|9672226|FG000|Overall Study|cancel all appointments, no rebooking|1
6069396|NCT00545064|9672226|FG000|Overall Study|inclement weather|1
6069397|NCT00545077|9672234|FG000|Overall Study|Treatment not received|5
6069398|NCT00545077|9672235|FG001|Overall Study|Treatment not received|1
6069399|NCT00545077|9672234|FG000|Overall Study|Disease Progression|131
6069400|NCT00545077|9672235|FG001|Overall Study|Disease Progression|98
6069401|NCT00545077|9672234|FG000|Overall Study|Withdrawal by Subject|3
6069402|NCT00545077|9672235|FG001|Overall Study|Withdrawal by Subject|14
6069403|NCT00545077|9672234|FG000|Overall Study|Physician Decision|6
6069404|NCT00545077|9672235|FG001|Overall Study|Physician Decision|3
6069405|NCT00545077|9672234|FG000|Overall Study|Lost to Follow-up|2
6069406|NCT00545077|9672235|FG001|Overall Study|Lost to Follow-up|0
6069407|NCT00545077|9672234|FG000|Overall Study|Protocol Violation|1
6069408|NCT00545077|9672235|FG001|Overall Study|Protocol Violation|0
6069409|NCT00545077|9672234|FG000|Overall Study|Adverse Event|0
6069410|NCT00545077|9672235|FG001|Overall Study|Adverse Event|31
6069411|NCT00545077|9672234|FG000|Overall Study|Death|0
6069412|NCT00545077|9672235|FG001|Overall Study|Death|8
6069413|NCT00545103|9672245|FG000|Overall Study|Lack of Efficacy|48
6069414|NCT00545103|9672246|FG001|Overall Study|Lack of Efficacy|45
6069415|NCT00545103|9672247|FG002|Overall Study|Lack of Efficacy|31
6069416|NCT00545103|9672248|FG003|Overall Study|Lack of Efficacy|27
6069417|NCT00545103|9672245|FG000|Overall Study|Withdrawal by Subject|6
6069418|NCT00545103|9672246|FG001|Overall Study|Withdrawal by Subject|10
6069419|NCT00545103|9672247|FG002|Overall Study|Withdrawal by Subject|18
6069420|NCT00545103|9672248|FG003|Overall Study|Withdrawal by Subject|22
6069421|NCT00545103|9672245|FG000|Overall Study|Adverse Event|11
6069422|NCT00545103|9672246|FG001|Overall Study|Adverse Event|12
6069423|NCT00545103|9672247|FG002|Overall Study|Adverse Event|17
6069424|NCT00545103|9672248|FG003|Overall Study|Adverse Event|10
6069425|NCT00545103|9672245|FG000|Overall Study|Lost to Follow-up|4
6069426|NCT00545103|9672246|FG001|Overall Study|Lost to Follow-up|6
6069427|NCT00545103|9672247|FG002|Overall Study|Lost to Follow-up|3
6069428|NCT00545103|9672248|FG003|Overall Study|Lost to Follow-up|4
6069429|NCT00545103|9672245|FG000|Overall Study|Protocol Violation|1
6069430|NCT00545103|9672246|FG001|Overall Study|Protocol Violation|2
6069431|NCT00545103|9672247|FG002|Overall Study|Protocol Violation|3
6069432|NCT00545103|9672248|FG003|Overall Study|Protocol Violation|0
6069433|NCT00545103|9672245|FG000|Overall Study|Suspected recurrence of diverticulitis|1
6069434|NCT00545103|9672246|FG001|Overall Study|Suspected recurrence of diverticulitis|0
6069435|NCT00545103|9672247|FG002|Overall Study|Suspected recurrence of diverticulitis|0
6069436|NCT00545103|9672248|FG003|Overall Study|Suspected recurrence of diverticulitis|3
6069437|NCT00545103|9672245|FG000|Overall Study|Difficult to open package|0
6069438|NCT00545103|9672246|FG001|Overall Study|Difficult to open package|0
6069439|NCT00545103|9672247|FG002|Overall Study|Difficult to open package|0
6069440|NCT00545103|9672248|FG003|Overall Study|Difficult to open package|1
6069441|NCT00545103|9672245|FG000|Overall Study|Investigational product not taken|1
6069442|NCT00545103|9672246|FG001|Overall Study|Investigational product not taken|0
6069443|NCT00545103|9672247|FG002|Overall Study|Investigational product not taken|0
6069444|NCT00545103|9672248|FG003|Overall Study|Investigational product not taken|1
6069445|NCT00545103|9672245|FG000|Overall Study|Wish to start a family|0
6069446|NCT00545103|9672246|FG001|Overall Study|Wish to start a family|0
6069447|NCT00545103|9672247|FG002|Overall Study|Wish to start a family|0
6069448|NCT00545103|9672248|FG003|Overall Study|Wish to start a family|1
6069449|NCT00545103|9672245|FG000|Overall Study|Diverticulitis crisis|0
6069450|NCT00545103|9672246|FG001|Overall Study|Diverticulitis crisis|0
6069451|NCT00545103|9672247|FG002|Overall Study|Diverticulitis crisis|0
6069452|NCT00545103|9672248|FG003|Overall Study|Diverticulitis crisis|1
6069453|NCT00545103|9672245|FG000|Overall Study|Personal reasons|1
6069454|NCT00545103|9672246|FG001|Overall Study|Personal reasons|0
6069455|NCT00545103|9672247|FG002|Overall Study|Personal reasons|0
6069456|NCT00545103|9672248|FG003|Overall Study|Personal reasons|0
6069457|NCT00545103|9672245|FG000|Overall Study|Subject's decision|1
6069458|NCT00545103|9672246|FG001|Overall Study|Subject's decision|0
6069459|NCT00545103|9672247|FG002|Overall Study|Subject's decision|0
6069460|NCT00545103|9672248|FG003|Overall Study|Subject's decision|0
6069461|NCT00545103|9672245|FG000|Overall Study|Noncompliance|0
6069462|NCT00545103|9672246|FG001|Overall Study|Noncompliance|1
6069463|NCT00545103|9672247|FG002|Overall Study|Noncompliance|0
6069464|NCT00545103|9672248|FG003|Overall Study|Noncompliance|0
6069465|NCT00545103|9672245|FG000|Overall Study|Investigator decision|0
6069466|NCT00545103|9672246|FG001|Overall Study|Investigator decision|0
6069467|NCT00545103|9672247|FG002|Overall Study|Investigator decision|1
6069468|NCT00545103|9672248|FG003|Overall Study|Investigator decision|0
6069469|NCT00545103|9672245|FG000|Overall Study|Subject moved|0
6069470|NCT00545103|9672246|FG001|Overall Study|Subject moved|1
6069471|NCT00545103|9672247|FG002|Overall Study|Subject moved|0
6069472|NCT00545103|9672248|FG003|Overall Study|Subject moved|0
6069473|NCT00545103|9672245|FG000|Overall Study|Use of prohibited medication|0
6069474|NCT00545103|9672246|FG001|Overall Study|Use of prohibited medication|0
6069475|NCT00545103|9672247|FG002|Overall Study|Use of prohibited medication|1
6069476|NCT00545103|9672248|FG003|Overall Study|Use of prohibited medication|0
6069477|NCT00545103|9672245|FG000|Overall Study|Does not want to take study drug anymore|1
6069478|NCT00545103|9672246|FG001|Overall Study|Does not want to take study drug anymore|0
6069479|NCT00545103|9672247|FG002|Overall Study|Does not want to take study drug anymore|1
6069480|NCT00545103|9672248|FG003|Overall Study|Does not want to take study drug anymore|0
6069481|NCT00545103|9672245|FG000|Overall Study|Subject met endpoint under protocol v. 1|0
6069482|NCT00545103|9672246|FG001|Overall Study|Subject met endpoint under protocol v. 1|0
6069483|NCT00545103|9672247|FG002|Overall Study|Subject met endpoint under protocol v. 1|1
6069484|NCT00545103|9672248|FG003|Overall Study|Subject met endpoint under protocol v. 1|0
6069485|NCT00545103|9672245|FG000|Overall Study|Death|0
6069486|NCT00545103|9672246|FG001|Overall Study|Death|1
6069487|NCT00545103|9672247|FG002|Overall Study|Death|0
6069488|NCT00545103|9672248|FG003|Overall Study|Death|0
6069489|NCT00545168|9672265|FG000|Overall Study|Lost to Follow-up|5
6069490|NCT00545168|9672266|FG001|Overall Study|Lost to Follow-up|5
6069491|NCT00545168|9672267|FG002|Overall Study|Lost to Follow-up|5
6069492|NCT00545168|9672265|FG000|Overall Study|Withdrawal by Subject|9
6069493|NCT00545168|9672266|FG001|Overall Study|Withdrawal by Subject|0
6069494|NCT00545168|9672267|FG002|Overall Study|Withdrawal by Subject|13
6069495|NCT00545168|9672265|FG000|Overall Study|Protocol Violation|1
6069496|NCT00545168|9672266|FG001|Overall Study|Protocol Violation|0
6069497|NCT00545168|9672267|FG002|Overall Study|Protocol Violation|1
6069498|NCT00545168|9672265|FG000|Overall Study|Visit for Day 21 was not done in error|1
6069499|NCT00545168|9672266|FG001|Overall Study|Visit for Day 21 was not done in error|0
6069500|NCT00545168|9672267|FG002|Overall Study|Visit for Day 21 was not done in error|2
6069501|NCT00545233|9672287|FG000|Overall Study|Adverse Event|10
6069502|NCT00545233|9672288|FG001|Overall Study|Adverse Event|5
6069503|NCT00545233|9672287|FG000|Overall Study|Violation of Selection Criteria at Entry|5
6069504|NCT00545233|9672288|FG001|Overall Study|Violation of Selection Criteria at Entry|1
6069505|NCT00545233|9672287|FG000|Overall Study|Protocol Violation|2
6069506|NCT00545233|9672288|FG001|Overall Study|Protocol Violation|0
6069507|NCT00545233|9672287|FG000|Overall Study|Refused Treatment|9
6069508|NCT00545233|9672288|FG001|Overall Study|Refused Treatment|7
6069509|NCT00545233|9672287|FG000|Overall Study|Failure to Return|4
6069510|NCT00545233|9672288|FG001|Overall Study|Failure to Return|6
6069511|NCT00545233|9672287|FG000|Overall Study|Insufficient response|14
6069512|NCT00545233|9672288|FG001|Overall Study|Insufficient response|15
6069513|NCT00545233|9672287|FG000|Overall Study|Physician Decision|2
6069514|NCT00545233|9672288|FG001|Overall Study|Physician Decision|1
6069515|NCT00545272|9672301|FG000|Overall Study|Protocol deviation|0
6069516|NCT00545272|9672302|FG001|Overall Study|Protocol deviation|1
6069517|NCT00545272|9672303|FG002|Overall Study|Protocol deviation|0
6069518|NCT00545272|9672304|FG003|Overall Study|Protocol deviation|1
6069519|NCT00545272|9672305|FG004|Overall Study|Protocol deviation|0
6069520|NCT00545272|9672306|FG005|Overall Study|Protocol deviation|1
6069521|NCT00545272|9672301|FG000|Overall Study|Adverse Event|0
5992905|NCT04725500|9585619|FG000|Screening|Screen Failure|26
5992906|NCT04725500|9585619|FG000|Screening|Withdrawal by Subject|1
5992907|NCT04725500|9585619|FG000|2 Week Take Home|Screen Fail|5
6069522|NCT00545272|9672302|FG001|Overall Study|Adverse Event|0
6069523|NCT00545272|9672303|FG002|Overall Study|Adverse Event|1
6069524|NCT00545272|9672304|FG003|Overall Study|Adverse Event|0
6069525|NCT00545272|9672305|FG004|Overall Study|Adverse Event|0
6069526|NCT00545272|9672306|FG005|Overall Study|Adverse Event|1
6069527|NCT00545272|9672301|FG000|Overall Study|Abnormal laboratory value(s)|0
6069528|NCT00545272|9672302|FG001|Overall Study|Abnormal laboratory value(s)|0
6069529|NCT00545272|9672303|FG002|Overall Study|Abnormal laboratory value(s)|0
6069530|NCT00545272|9672304|FG003|Overall Study|Abnormal laboratory value(s)|0
6069531|NCT00545272|9672305|FG004|Overall Study|Abnormal laboratory value(s)|0
6069532|NCT00545272|9672306|FG005|Overall Study|Abnormal laboratory value(s)|1
6069533|NCT00545272|9672301|FG000|Overall Study|Abnormal test procedure result(s)|0
6069534|NCT00545272|9672302|FG001|Overall Study|Abnormal test procedure result(s)|0
6069535|NCT00545272|9672303|FG002|Overall Study|Abnormal test procedure result(s)|0
6069536|NCT00545272|9672304|FG003|Overall Study|Abnormal test procedure result(s)|0
6069537|NCT00545272|9672305|FG004|Overall Study|Abnormal test procedure result(s)|1
6069538|NCT00545272|9672306|FG005|Overall Study|Abnormal test procedure result(s)|0
6069539|NCT00545272|9672301|FG000|Overall Study|Lost to Follow-up|0
6069540|NCT00545272|9672302|FG001|Overall Study|Lost to Follow-up|0
6069541|NCT00545272|9672303|FG002|Overall Study|Lost to Follow-up|0
6069542|NCT00545272|9672304|FG003|Overall Study|Lost to Follow-up|0
6069543|NCT00545272|9672305|FG004|Overall Study|Lost to Follow-up|1
6069544|NCT00545272|9672306|FG005|Overall Study|Lost to Follow-up|0
6069545|NCT00545298|9672323|FG000|Overall Study|Issues with Standard of Care|2
6069546|NCT00545298|9672324|FG001|Overall Study|Issues with Standard of Care|0
6069547|NCT00545298|9672325|FG002|Overall Study|Issues with Standard of Care|1
6069548|NCT00545363|9672338|FG000|Overall Study|Adverse Event|6
6069549|NCT00545363|9672339|FG001|Overall Study|Adverse Event|7
6069550|NCT00545363|9672338|FG000|Overall Study|Withdrawal by Subject|6
6069551|NCT00545363|9672339|FG001|Overall Study|Withdrawal by Subject|5
6069552|NCT00545363|9672338|FG000|Overall Study|Non-compliance|3
6069553|NCT00545363|9672339|FG001|Overall Study|Non-compliance|1
6069554|NCT00545363|9672338|FG000|Overall Study|Did not meet entry criteria|1
6069555|NCT00545363|9672339|FG001|Overall Study|Did not meet entry criteria|1
6069556|NCT00545363|9672338|FG000|Overall Study|Lost to Follow-up|2
6069557|NCT00545363|9672339|FG001|Overall Study|Lost to Follow-up|0
6069558|NCT00545363|9672338|FG000|Overall Study|Other|1
6069559|NCT00545363|9672339|FG001|Overall Study|Other|1
6069560|NCT00545402|9672347|FG000|Overall Study|Discontinuation of treatment|17
6069561|NCT00545402|9672348|FG001|Overall Study|Discontinuation of treatment|9
6069562|NCT00545402|9672347|FG000|Overall Study|Use of unauthorized immunosuppressant|8
6069563|NCT00545402|9672348|FG001|Overall Study|Use of unauthorized immunosuppressant|7
6069564|NCT00545402|9672347|FG000|Overall Study|Death|5
6069565|NCT00545402|9672348|FG001|Overall Study|Death|7
6069566|NCT00545402|9672347|FG000|Overall Study|Graft loss|2
6069567|NCT00545402|9672348|FG001|Overall Study|Graft loss|4
6069568|NCT00545402|9672347|FG000|Overall Study|Withdrawal by Subject|0
6069569|NCT00545402|9672348|FG001|Overall Study|Withdrawal by Subject|1
6069570|NCT00545402|9672347|FG000|Overall Study|Protocol Violation|1
5992929|NCT04615507|9585861|FG000|Period 2|Protocol Violation|1
5992930|NCT04615507|9585862|FG001|Period 2|Protocol Violation|0
5992931|NCT04615507|9585861|FG000|Period 2|Withdrawal by Subject|1
5992932|NCT04615507|9585862|FG001|Period 2|Withdrawal by Subject|0
5992933|NCT04615507|9585861|FG000|Period 2|Adverse Event|0
5992934|NCT04615507|9585862|FG001|Period 2|Adverse Event|1
5992935|NCT04615507|9585861|FG000|Period 3|Covid-19 exposure|0
5992936|NCT04615507|9585862|FG001|Period 3|Covid-19 exposure|1
6046085|NCT00404768|9645282|FG003|Part C|Withdrawal by Subject|1
6046086|NCT00404768|9645279|FG000|Part C|Early withdrawal from study medication|0
6046087|NCT00404768|9645280|FG001|Part C|Early withdrawal from study medication|0
6046088|NCT00404768|9645281|FG002|Part C|Early withdrawal from study medication|1
6046089|NCT00404768|9645282|FG003|Part C|Early withdrawal from study medication|0
6046090|NCT00404768|9645279|FG000|Part C|Participant did not respond to therapy|0
6046091|NCT00404768|9645280|FG001|Part C|Participant did not respond to therapy|0
6046092|NCT00404768|9645281|FG002|Part C|Participant did not respond to therapy|1
6046093|NCT00404768|9645282|FG003|Part C|Participant did not respond to therapy|1
6046094|NCT00404768|9645279|FG000|Part C|Physician withdrew the study medication|0
6069571|NCT00545402|9672348|FG001|Overall Study|Protocol Violation|0
6069572|NCT00545402|9672347|FG000|Overall Study|Reason not specified|1
6046095|NCT00404768|9645280|FG001|Part C|Physician withdrew the study medication|0
6069573|NCT00545402|9672348|FG001|Overall Study|Reason not specified|1
6069574|NCT00545441|9672356|FG000|Overall Study|Fistula draining at 6 months|2
6069575|NCT00545441|9672357|FG001|Overall Study|Fistula draining at 6 months|4
6069576|NCT00545441|9672356|FG000|Overall Study|Lost to Follow-up|9
6069577|NCT00545441|9672357|FG001|Overall Study|Lost to Follow-up|5
6069578|NCT00545441|9672356|FG000|Overall Study|Technical failure|0
6069579|NCT00545441|9672357|FG001|Overall Study|Technical failure|1
6069580|NCT00545441|9672356|FG000|Overall Study|Withdrawal by Subject|1
6069581|NCT00545441|9672357|FG001|Overall Study|Withdrawal by Subject|1
5992937|NCT04608500|9585875|FG000|Overall Study|Adverse Event|2
5992938|NCT04608500|9585876|FG001|Overall Study|Adverse Event|0
5992939|NCT04608500|9585875|FG000|Overall Study|Lost to Follow-up|15
5992940|NCT04608500|9585876|FG001|Overall Study|Lost to Follow-up|9
5992941|NCT04608500|9585875|FG000|Overall Study|Participant request|11
5992942|NCT04608500|9585876|FG001|Overall Study|Participant request|7
5992943|NCT04608500|9585875|FG000|Overall Study|Protocol Violation|1
6069582|NCT00545441|9672356|FG000|Overall Study|Persistence or recurrence of fistula|5
6069583|NCT00545441|9672357|FG001|Overall Study|Persistence or recurrence of fistula|2
6069584|NCT00545441|9672356|FG000|Overall Study|Patients were not treated|1
6069585|NCT00545441|9672357|FG001|Overall Study|Patients were not treated|3
6069586|NCT00545532|9672365|FG000|Overall Study|Withdrawal by Subject|1
6069587|NCT00545532|9672366|FG001|Overall Study|Withdrawal by Subject|3
6069588|NCT00545532|9672365|FG000|Overall Study|Lost to Follow-up|5
6069589|NCT00545532|9672366|FG001|Overall Study|Lost to Follow-up|6
6069590|NCT00545532|9672365|FG000|Overall Study|Death|0
6069591|NCT00545532|9672366|FG001|Overall Study|Death|1
6069592|NCT00545571|9672374|FG000|Overall Study|Administrative Reasons|1
6069593|NCT00545571|9672374|FG000|Overall Study|Adverse Event|2
6069594|NCT00545571|9672374|FG000|Overall Study|Death|5
6069595|NCT00545571|9672374|FG000|Overall Study|Lack of Efficacy|1
6069596|NCT00545571|9672374|FG000|Overall Study|Protocol Violation|2
6069597|NCT00545571|9672374|FG000|Overall Study|Refused Treatment|1
6069598|NCT00545571|9672374|FG000|Overall Study|Screen Failure|16
6069599|NCT00545571|9672374|FG000|Overall Study|Transfusion|12
6069600|NCT00545571|9672374|FG000|Overall Study|Early Termination of Study|24
6069601|NCT00545571|9672374|FG000|Overall Study|Kidney Transplantation|3
6069602|NCT00545584|9672381|FG000|Overall Study|Only one reason for discontinuation|62
6069603|NCT00545584|9672382|FG001|Overall Study|Only one reason for discontinuation|61
6069604|NCT00545584|9672383|FG002|Overall Study|Only one reason for discontinuation|48
6069605|NCT00545584|9672381|FG000|Overall Study|Two or more reasons for discontinuation|17
6069606|NCT00545584|9672382|FG001|Overall Study|Two or more reasons for discontinuation|19
6069607|NCT00545584|9672383|FG002|Overall Study|Two or more reasons for discontinuation|8
6069608|NCT00545688|9672421|FG000|Neo-Adjuvant Treatment Period|Protocol Violation|1
6069609|NCT00545688|9672422|FG001|Neo-Adjuvant Treatment Period|Protocol Violation|2
6069610|NCT00545688|9672423|FG002|Neo-Adjuvant Treatment Period|Protocol Violation|1
6069611|NCT00545688|9672424|FG003|Neo-Adjuvant Treatment Period|Protocol Violation|1
6069612|NCT00545688|9672421|FG000|Neo-Adjuvant Treatment Period|Refused Treatment|1
6069613|NCT00545688|9672422|FG001|Neo-Adjuvant Treatment Period|Refused Treatment|1
6069614|NCT00545688|9672423|FG002|Neo-Adjuvant Treatment Period|Refused Treatment|4
6069615|NCT00545688|9672424|FG003|Neo-Adjuvant Treatment Period|Refused Treatment|1
6069616|NCT00545688|9672421|FG000|Neo-Adjuvant Treatment Period|Lost to Follow-up|1
6069617|NCT00545688|9672422|FG001|Neo-Adjuvant Treatment Period|Lost to Follow-up|0
6069618|NCT00545688|9672423|FG002|Neo-Adjuvant Treatment Period|Lost to Follow-up|0
6069619|NCT00545688|9672424|FG003|Neo-Adjuvant Treatment Period|Lost to Follow-up|0
6069620|NCT00545688|9672421|FG000|Neo-Adjuvant Treatment Period|Death|0
6069621|NCT00545688|9672422|FG001|Neo-Adjuvant Treatment Period|Death|1
6069622|NCT00545688|9672423|FG002|Neo-Adjuvant Treatment Period|Death|0
6069623|NCT00545688|9672424|FG003|Neo-Adjuvant Treatment Period|Death|0
6069624|NCT00545688|9672421|FG000|Neo-Adjuvant Treatment Period|Disease Progression|0
6069625|NCT00545688|9672422|FG001|Neo-Adjuvant Treatment Period|Disease Progression|1
6069626|NCT00545688|9672423|FG002|Neo-Adjuvant Treatment Period|Disease Progression|7
6069627|NCT00545688|9672424|FG003|Neo-Adjuvant Treatment Period|Disease Progression|2
6069628|NCT00545688|9672421|FG000|Neo-Adjuvant Treatment Period|Unknown Reason|1
6069629|NCT00545688|9672422|FG001|Neo-Adjuvant Treatment Period|Unknown Reason|0
6069630|NCT00545688|9672423|FG002|Neo-Adjuvant Treatment Period|Unknown Reason|0
6069631|NCT00545688|9672424|FG003|Neo-Adjuvant Treatment Period|Unknown Reason|0
6069632|NCT00545688|9672421|FG000|Neo-Adjuvant Treatment Period|Adverse Event|0
6069633|NCT00545688|9672422|FG001|Neo-Adjuvant Treatment Period|Adverse Event|0
6069634|NCT00545688|9672423|FG002|Neo-Adjuvant Treatment Period|Adverse Event|2
6069635|NCT00545688|9672424|FG003|Neo-Adjuvant Treatment Period|Adverse Event|2
6069636|NCT00545688|9672421|FG000|Adjuvant Treatment Period|Disease Progression|3
6069637|NCT00545688|9672422|FG001|Adjuvant Treatment Period|Disease Progression|3
6069638|NCT00545688|9672423|FG002|Adjuvant Treatment Period|Disease Progression|0
6069639|NCT00545688|9672424|FG003|Adjuvant Treatment Period|Disease Progression|7
6069640|NCT00545688|9672421|FG000|Adjuvant Treatment Period|Refused Treatment|1
5992944|NCT04608500|9585876|FG001|Overall Study|Protocol Violation|0
5992945|NCT04608500|9585875|FG000|Overall Study|Other|6
5992946|NCT04608500|9585876|FG001|Overall Study|Other|2
5992949|NCT04590027|9585914|FG000|Overall Study|Lost to Follow-up|17
6069641|NCT00545688|9672422|FG001|Adjuvant Treatment Period|Refused Treatment|1
6069642|NCT00545688|9672423|FG002|Adjuvant Treatment Period|Refused Treatment|1
6069643|NCT00545688|9672424|FG003|Adjuvant Treatment Period|Refused Treatment|5
6069644|NCT00545688|9672421|FG000|Adjuvant Treatment Period|Lost to Follow-up|1
6069645|NCT00545688|9672422|FG001|Adjuvant Treatment Period|Lost to Follow-up|0
6069646|NCT00545688|9672423|FG002|Adjuvant Treatment Period|Lost to Follow-up|1
6069647|NCT00545688|9672424|FG003|Adjuvant Treatment Period|Lost to Follow-up|0
6069648|NCT00545688|9672421|FG000|Adjuvant Treatment Period|Adverse Event|0
6069649|NCT00545688|9672422|FG001|Adjuvant Treatment Period|Adverse Event|3
6069650|NCT00545688|9672423|FG002|Adjuvant Treatment Period|Adverse Event|2
6069651|NCT00545688|9672424|FG003|Adjuvant Treatment Period|Adverse Event|2
6069652|NCT00545688|9672421|FG000|Adjuvant Treatment Period|Unknown Reason|0
6069653|NCT00545688|9672422|FG001|Adjuvant Treatment Period|Unknown Reason|1
6069654|NCT00545688|9672423|FG002|Adjuvant Treatment Period|Unknown Reason|0
6069655|NCT00545688|9672424|FG003|Adjuvant Treatment Period|Unknown Reason|0
6069656|NCT00545688|9672421|FG000|Follow-Up Period|Death|4
6069657|NCT00545688|9672422|FG001|Follow-Up Period|Death|2
6069658|NCT00545688|9672423|FG002|Follow-Up Period|Death|2
6069659|NCT00545688|9672424|FG003|Follow-Up Period|Death|6
6069660|NCT00545688|9672421|FG000|Follow-Up Period|Disease Progression|6
6069661|NCT00545688|9672422|FG001|Follow-Up Period|Disease Progression|5
6069662|NCT00545688|9672423|FG002|Follow-Up Period|Disease Progression|9
6069663|NCT00545688|9672424|FG003|Follow-Up Period|Disease Progression|9
6069664|NCT00545688|9672421|FG000|Follow-Up Period|Refused Treatment|6
6069665|NCT00545688|9672422|FG001|Follow-Up Period|Refused Treatment|2
6069666|NCT00545688|9672423|FG002|Follow-Up Period|Refused Treatment|0
6069667|NCT00545688|9672424|FG003|Follow-Up Period|Refused Treatment|2
6069668|NCT00545688|9672421|FG000|Follow-Up Period|Lost to Follow-up|3
6069669|NCT00545688|9672422|FG001|Follow-Up Period|Lost to Follow-up|3
6069670|NCT00545688|9672423|FG002|Follow-Up Period|Lost to Follow-up|3
6069671|NCT00545688|9672424|FG003|Follow-Up Period|Lost to Follow-up|1
6069672|NCT00545688|9672421|FG000|Follow-Up Period|Unspecified Reason|2
6069673|NCT00545688|9672422|FG001|Follow-Up Period|Unspecified Reason|5
6069674|NCT00545688|9672423|FG002|Follow-Up Period|Unspecified Reason|6
6069675|NCT00545688|9672424|FG003|Follow-Up Period|Unspecified Reason|8
6069676|NCT00545688|9672421|FG000|Follow-Up Period|Violation of Selection Criteria at Entry|0
6069677|NCT00545688|9672422|FG001|Follow-Up Period|Violation of Selection Criteria at Entry|2
6069678|NCT00545688|9672423|FG002|Follow-Up Period|Violation of Selection Criteria at Entry|0
6069679|NCT00545688|9672424|FG003|Follow-Up Period|Violation of Selection Criteria at Entry|1
6069680|NCT00545714|9672437|FG000|Induction Phase (6 Months)|Physician Decision|3
6069681|NCT00545714|9672437|FG000|Induction Phase (6 Months)|Unacceptable Toxicity|6
6069682|NCT00545714|9672437|FG000|Induction Phase (6 Months)|Disease Progression|1
6069683|NCT00545714|9672437|FG000|Induction Phase (6 Months)|Eligibility Criteria Violation|2
6069684|NCT00545714|9672437|FG000|Maintenance Phase (36 Months)|Unacceptable Toxicity|16
6069685|NCT00545714|9672437|FG000|Maintenance Phase (36 Months)|Disease Progression|9
6069686|NCT00545714|9672437|FG000|Maintenance Phase (36 Months)|Physician Decision|1
6069687|NCT00545714|9672437|FG000|Maintenance Phase (36 Months)|Protocol Violation|1
6069688|NCT00545714|9672437|FG000|Maintenance Phase (36 Months)|Withdrawal by Subject|3
6069689|NCT00545714|9672437|FG000|Maintenance Phase (36 Months)|Death|2
6069690|NCT00545740|9672445|FG000|Overall Study|Lack of Efficacy|34
6069691|NCT00545740|9672446|FG001|Overall Study|Lack of Efficacy|35
5992947|NCT04605588|9585888|FG000|Overall Study|Withdrawal by Subject|1
5992948|NCT04605588|9585889|FG001|Overall Study|Withdrawal by Subject|0
5992950|NCT04590027|9585915|FG001|Overall Study|Lost to Follow-up|14
5992951|NCT04590027|9585914|FG000|Overall Study|Protocol Violation|0
5992952|NCT04590027|9585915|FG001|Overall Study|Protocol Violation|3
6046096|NCT00404768|9645281|FG002|Part C|Physician withdrew the study medication|1
6046097|NCT00404768|9645282|FG003|Part C|Physician withdrew the study medication|0
6046098|NCT00404768|9645279|FG000|Part C|Participant delivered baby|0
6046099|NCT00404768|9645280|FG001|Part C|Participant delivered baby|0
6046100|NCT00404768|9645281|FG002|Part C|Participant delivered baby|0
6046101|NCT00404768|9645282|FG003|Part C|Participant delivered baby|1
6046102|NCT00404768|9645279|FG000|Part C|Unsatisfactory uterine response to IP|0
6046103|NCT00404768|9645280|FG001|Part C|Unsatisfactory uterine response to IP|0
6046104|NCT00404768|9645281|FG002|Part C|Unsatisfactory uterine response to IP|0
6046105|NCT00404768|9645282|FG003|Part C|Unsatisfactory uterine response to IP|1
6046106|NCT00404768|9645279|FG000|Part C|Active labor|0
6046107|NCT00404768|9645280|FG001|Part C|Active labor|0
6046108|NCT00404768|9645281|FG002|Part C|Active labor|0
6046109|NCT00404768|9645282|FG003|Part C|Active labor|1
6046110|NCT00404768|9645279|FG000|Part C|Lack of Efficacy|0
6046111|NCT00404768|9645280|FG001|Part C|Lack of Efficacy|0
6046112|NCT00404768|9645281|FG002|Part C|Lack of Efficacy|0
6046113|NCT00404768|9645282|FG003|Part C|Lack of Efficacy|2
6046114|NCT00404768|9645279|FG000|Part C|Treatment failure|0
6046115|NCT00404768|9645280|FG001|Part C|Treatment failure|0
6046116|NCT00404768|9645281|FG002|Part C|Treatment failure|0
6046117|NCT00404768|9645282|FG003|Part C|Treatment failure|1
6046118|NCT00404768|9645279|FG000|Part C|Investigator discretion|0
6046119|NCT00404768|9645280|FG001|Part C|Investigator discretion|0
6046120|NCT00404768|9645281|FG002|Part C|Investigator discretion|0
6046121|NCT00404768|9645282|FG003|Part C|Investigator discretion|1
6046122|NCT00404768|9645279|FG000|Part C|Researcher suspended study medication|0
6046123|NCT00404768|9645280|FG001|Part C|Researcher suspended study medication|0
6046124|NCT00404768|9645281|FG002|Part C|Researcher suspended study medication|0
6046125|NCT00404768|9645282|FG003|Part C|Researcher suspended study medication|1
6046126|NCT00404820|9645299|FG000|Overall Study|Adverse Event|4
6046127|NCT00404820|9645300|FG001|Overall Study|Adverse Event|16
6046128|NCT00404820|9645299|FG000|Overall Study|Withdrawal by Subject|5
6046129|NCT00404820|9645300|FG001|Overall Study|Withdrawal by Subject|3
6046130|NCT00404820|9645299|FG000|Overall Study|Lost to Follow-up|7
6046131|NCT00404820|9645300|FG001|Overall Study|Lost to Follow-up|3
6069692|NCT00545740|9672447|FG002|Overall Study|Lack of Efficacy|47
6069693|NCT00545740|9672448|FG003|Overall Study|Lack of Efficacy|36
6069694|NCT00545740|9672445|FG000|Overall Study|Withdrawal by Subject|17
6069695|NCT00545740|9672446|FG001|Overall Study|Withdrawal by Subject|15
6069696|NCT00545740|9672447|FG002|Overall Study|Withdrawal by Subject|16
6069697|NCT00545740|9672448|FG003|Overall Study|Withdrawal by Subject|18
6069698|NCT00545740|9672445|FG000|Overall Study|Adverse Event|10
6069699|NCT00545740|9672446|FG001|Overall Study|Adverse Event|18
6069700|NCT00545740|9672447|FG002|Overall Study|Adverse Event|19
6069701|NCT00545740|9672448|FG003|Overall Study|Adverse Event|9
6069702|NCT00545740|9672445|FG000|Overall Study|Lost to Follow-up|7
6069703|NCT00545740|9672446|FG001|Overall Study|Lost to Follow-up|5
6069704|NCT00545740|9672447|FG002|Overall Study|Lost to Follow-up|5
6069705|NCT00545740|9672448|FG003|Overall Study|Lost to Follow-up|6
6069706|NCT00545740|9672445|FG000|Overall Study|Protocol Violation|1
6069707|NCT00545740|9672446|FG001|Overall Study|Protocol Violation|3
6069708|NCT00545740|9672447|FG002|Overall Study|Protocol Violation|1
6069709|NCT00545740|9672448|FG003|Overall Study|Protocol Violation|0
6069710|NCT00545740|9672445|FG000|Overall Study|Non-compliance|0
6069711|NCT00545740|9672446|FG001|Overall Study|Non-compliance|2
6069712|NCT00545740|9672447|FG002|Overall Study|Non-compliance|1
6069713|NCT00545740|9672448|FG003|Overall Study|Non-compliance|0
6069714|NCT00545740|9672445|FG000|Overall Study|Moved|2
6069715|NCT00545740|9672446|FG001|Overall Study|Moved|0
6069716|NCT00545740|9672447|FG002|Overall Study|Moved|1
6069717|NCT00545740|9672448|FG003|Overall Study|Moved|0
6069718|NCT00545740|9672445|FG000|Overall Study|Diverticulitis attack|0
6069719|NCT00545740|9672446|FG001|Overall Study|Diverticulitis attack|0
6069720|NCT00545740|9672447|FG002|Overall Study|Diverticulitis attack|1
6069721|NCT00545740|9672448|FG003|Overall Study|Diverticulitis attack|1
6069722|NCT00545740|9672445|FG000|Overall Study|Suspected Diverticulitis Recurrence|1
6069723|NCT00545740|9672446|FG001|Overall Study|Suspected Diverticulitis Recurrence|1
6069724|NCT00545740|9672447|FG002|Overall Study|Suspected Diverticulitis Recurrence|1
6069725|NCT00545740|9672448|FG003|Overall Study|Suspected Diverticulitis Recurrence|1
6069726|NCT00545740|9672445|FG000|Overall Study|Site closure|1
6069727|NCT00545740|9672446|FG001|Overall Study|Site closure|0
6069728|NCT00545740|9672447|FG002|Overall Study|Site closure|0
6069729|NCT00545740|9672448|FG003|Overall Study|Site closure|0
6069730|NCT00545740|9672445|FG000|Overall Study|Missed visit|1
6069731|NCT00545740|9672446|FG001|Overall Study|Missed visit|0
6069732|NCT00545740|9672447|FG002|Overall Study|Missed visit|0
6069733|NCT00545740|9672448|FG003|Overall Study|Missed visit|0
6069734|NCT00545740|9672445|FG000|Overall Study|Physician Decision|0
6069735|NCT00545740|9672446|FG001|Overall Study|Physician Decision|0
6069736|NCT00545740|9672447|FG002|Overall Study|Physician Decision|3
6069737|NCT00545740|9672448|FG003|Overall Study|Physician Decision|0
6069738|NCT00545740|9672445|FG000|Overall Study|Accepted only monthly telephone calls|1
6069739|NCT00545740|9672446|FG001|Overall Study|Accepted only monthly telephone calls|0
6069740|NCT00545740|9672447|FG002|Overall Study|Accepted only monthly telephone calls|0
6069741|NCT00545740|9672448|FG003|Overall Study|Accepted only monthly telephone calls|0
6069742|NCT00545740|9672445|FG000|Overall Study|Sponsor decision|0
6069743|NCT00545740|9672446|FG001|Overall Study|Sponsor decision|1
6069744|NCT00545740|9672447|FG002|Overall Study|Sponsor decision|0
6069745|NCT00545740|9672448|FG003|Overall Study|Sponsor decision|0
6069746|NCT00545740|9672445|FG000|Overall Study|Lack of time|0
6069747|NCT00545740|9672446|FG001|Overall Study|Lack of time|1
6069748|NCT00545740|9672447|FG002|Overall Study|Lack of time|0
6069749|NCT00545740|9672448|FG003|Overall Study|Lack of time|0
6069750|NCT00545740|9672445|FG000|Overall Study|Non-adherence to visits|0
6069751|NCT00545740|9672446|FG001|Overall Study|Non-adherence to visits|1
6069752|NCT00545740|9672447|FG002|Overall Study|Non-adherence to visits|0
6069753|NCT00545740|9672448|FG003|Overall Study|Non-adherence to visits|0
6069754|NCT00545740|9672445|FG000|Overall Study|Patient difficulties|0
6069755|NCT00545740|9672446|FG001|Overall Study|Patient difficulties|1
6069756|NCT00545740|9672447|FG002|Overall Study|Patient difficulties|0
6069757|NCT00545740|9672448|FG003|Overall Study|Patient difficulties|0
6069758|NCT00545740|9672445|FG000|Overall Study|Husband against study|0
6069759|NCT00545740|9672446|FG001|Overall Study|Husband against study|0
6069760|NCT00545740|9672447|FG002|Overall Study|Husband against study|1
6069761|NCT00545740|9672448|FG003|Overall Study|Husband against study|0
6069762|NCT00545753|9672461|FG000|Overall Study|Withdrawal by Subject|0
6069763|NCT00545753|9672462|FG001|Overall Study|Withdrawal by Subject|1
6069764|NCT00545753|9672463|FG002|Overall Study|Withdrawal by Subject|10
6069765|NCT00545753|9672461|FG000|Overall Study|Lost to Follow-up|13
6069766|NCT00545753|9672462|FG001|Overall Study|Lost to Follow-up|3
6069767|NCT00545753|9672463|FG002|Overall Study|Lost to Follow-up|12
6069768|NCT00545753|9672461|FG000|Overall Study|Protocol Violation|3
6069769|NCT00545753|9672462|FG001|Overall Study|Protocol Violation|1
6069770|NCT00545753|9672463|FG002|Overall Study|Protocol Violation|4
6069771|NCT00545779|9672472|FG000|Overall Study|Violation of selection criteria at entry|8
6069772|NCT00545779|9672472|FG000|Overall Study|Other protocol violation|1
6069773|NCT00545779|9672472|FG000|Overall Study|Did not cooperate|7
6069774|NCT00545779|9672472|FG000|Overall Study|Withdrawal by Subject|20
6069775|NCT00545779|9672472|FG000|Overall Study|Adverse Event/intercurrent illness|5
6069776|NCT00545779|9672472|FG000|Overall Study|Failure to return|3
6069777|NCT00545792|9672476|FG000|Overall Study|Withdrawal by Subject|1
6069778|NCT00545818|9672482|FG000|Overall Study|Protocol Violation|1
6069779|NCT00545818|9672483|FG001|Overall Study|Protocol Violation|0
6069780|NCT00545818|9672482|FG000|Overall Study|Adverse Event|1
6069781|NCT00545818|9672483|FG001|Overall Study|Adverse Event|1
6069782|NCT00545818|9672482|FG000|Overall Study|Lost to Follow-up|1
6069783|NCT00545818|9672483|FG001|Overall Study|Lost to Follow-up|6
6069784|NCT00545948|9672492|FG000|Overall Study|Not Treated|1
6069785|NCT00545948|9672493|FG001|Overall Study|Not Treated|1
6069786|NCT00545948|9672494|FG002|Overall Study|Not Treated|7
6069787|NCT00546000|9672512|FG000|Overall Study|Adverse Event|1
6069788|NCT00546000|9672512|FG000|Overall Study|Lost to Follow-up|1
6069789|NCT00546000|9672512|FG000|Overall Study|Baseline HPA Axis Supression|2
6069790|NCT00546078|9672518|FG000|Overall Study|Lost to Follow-up|1
6069791|NCT00546078|9672519|FG001|Overall Study|Lost to Follow-up|3
6069792|NCT00546078|9672518|FG000|Overall Study|Withdrawal by Subject|2
6069793|NCT00546078|9672519|FG001|Overall Study|Withdrawal by Subject|3
6069794|NCT00546078|9672518|FG000|Overall Study|Other reason|1
6069795|NCT00546078|9672519|FG001|Overall Study|Other reason|1
6069796|NCT00546117|9672531|FG000|Overall Study|Withdrawal by Subject|3
6069797|NCT00546117|9672532|FG001|Overall Study|Withdrawal by Subject|0
6069798|NCT00546117|9672531|FG000|Overall Study|Inability to schedule follow-up visit|1
6069799|NCT00546117|9672532|FG001|Overall Study|Inability to schedule follow-up visit|0
6069800|NCT00546260|9672550|FG000|Overall Study|Drug not given pre diagnostic angiogr|8
6069801|NCT00546260|9672551|FG001|Overall Study|Drug not given pre diagnostic angiogr|2
6069802|NCT00546351|9672557|FG000|Overall Study|Adverse Event|76
6309373|NCT02637895|10037915|FG001|Overall Study|Withdrawal by Subject|1
6309374|NCT02637895|10037914|FG000|Overall Study|Abnormal baseline lab|0
6309375|NCT02637895|10037915|FG001|Overall Study|Abnormal baseline lab|1
6309376|NCT02638012|10037935|FG000|Overall Study|Lost to Follow-up|1
6309377|NCT02638103|10037952|FG000|Overall Study|Adverse Event|13
6309378|NCT02638103|10037953|FG001|Overall Study|Adverse Event|12
6069803|NCT00546351|9672557|FG000|Overall Study|Lack of Efficacy|15
5992953|NCT04578457|9585925|FG000|Hearing Aid Without NR Enabled (0)|Withdrawal by Subject|2
5992954|NCT04578457|9585925|FG000|Hearing Aid With NR (1)|Withdrawal by Subject|2
5992955|NCT04578457|9585925|FG000|Hearing Aid With NR (2)|Withdrawal by Subject|2
5992956|NCT04578457|9585925|FG000|Hearing Aid With NR (4)|Withdrawal by Subject|2
6046132|NCT00404820|9645299|FG000|Overall Study|Administrative problems|2
6046133|NCT00404820|9645300|FG001|Overall Study|Administrative problems|0
6046134|NCT00404820|9645299|FG000|Overall Study|Death|1
6046135|NCT00404820|9645300|FG001|Overall Study|Death|0
6069804|NCT00546351|9672557|FG000|Overall Study|Withdrawal by Subject|109
6069805|NCT00546351|9672557|FG000|Overall Study|Lost to Follow-up|9
6069806|NCT00546351|9672557|FG000|Overall Study|Protocol Deviation|1
6069807|NCT00546351|9672557|FG000|Overall Study|Unsatisfactory compliance|9
6069808|NCT00546351|9672557|FG000|Overall Study|Other reasons for premature termination|17
6069809|NCT00546364|9672564|FG000|Overall Study|Disease progression|5
6069810|NCT00546364|9672565|FG001|Overall Study|Disease progression|11
6069811|NCT00546364|9672566|FG002|Overall Study|Disease progression|8
6069812|NCT00546364|9672564|FG000|Overall Study|Completed and off treatment|1
6146227|NCT01075984|9780816|FG003|Follow-up Phase|Withdrawal by Subject|0
6309379|NCT02638103|10037954|FG002|Overall Study|Adverse Event|19
6309380|NCT02638103|10037955|FG003|Overall Study|Adverse Event|12
6046136|NCT00404820|9645299|FG000|Overall Study|Other|0
6046137|NCT00404820|9645300|FG001|Overall Study|Other|2
5992957|NCT04577183|9585937|FG000|Overall Study|Death|1
5992958|NCT04577183|9585937|FG000|Overall Study|Withdrawal by Subject|3
5992959|NCT04577183|9585937|FG000|Overall Study|Early termination|2
6046138|NCT00404924|9645308|FG000|Overall Study|Adverse Event|75
6046139|NCT00404924|9645309|FG001|Overall Study|Adverse Event|16
6046140|NCT00404924|9645308|FG000|Overall Study|Condition under investigation worsened|475
6069813|NCT00546364|9672565|FG001|Overall Study|Completed and off treatment|0
6069814|NCT00546364|9672566|FG002|Overall Study|Completed and off treatment|2
6069815|NCT00546364|9672564|FG000|Overall Study|Administrative reason by sponsor|1
6069816|NCT00546364|9672565|FG001|Overall Study|Administrative reason by sponsor|0
6069817|NCT00546364|9672566|FG002|Overall Study|Administrative reason by sponsor|0
6069818|NCT00546364|9672564|FG000|Overall Study|Poor compliance/noncompliance|0
6069819|NCT00546364|9672565|FG001|Overall Study|Poor compliance/noncompliance|0
6069820|NCT00546364|9672566|FG002|Overall Study|Poor compliance/noncompliance|1
6069821|NCT00546364|9672564|FG000|Overall Study|No longer meets study criteria|1
6069822|NCT00546364|9672565|FG001|Overall Study|No longer meets study criteria|1
6069823|NCT00546364|9672566|FG002|Overall Study|No longer meets study criteria|0
6069824|NCT00546364|9672564|FG000|Overall Study|Withdrawal by Subject|5
6069825|NCT00546364|9672565|FG001|Overall Study|Withdrawal by Subject|6
6069826|NCT00546364|9672566|FG002|Overall Study|Withdrawal by Subject|3
6069827|NCT00546364|9672564|FG000|Overall Study|Prior taxotere|1
6069828|NCT00546364|9672565|FG001|Overall Study|Prior taxotere|0
6069829|NCT00546364|9672566|FG002|Overall Study|Prior taxotere|0
6069830|NCT00546364|9672564|FG000|Overall Study|Mixed response|1
6069831|NCT00546364|9672565|FG001|Overall Study|Mixed response|0
6069832|NCT00546364|9672566|FG002|Overall Study|Mixed response|0
6069833|NCT00546364|9672564|FG000|Overall Study|Palliative treatment|1
6069834|NCT00546364|9672565|FG001|Overall Study|Palliative treatment|0
6069835|NCT00546364|9672566|FG002|Overall Study|Palliative treatment|1
6069836|NCT00546364|9672564|FG000|Overall Study|Target lesions resected|1
6069837|NCT00546364|9672565|FG001|Overall Study|Target lesions resected|0
6069838|NCT00546364|9672566|FG002|Overall Study|Target lesions resected|0
6069839|NCT00546364|9672564|FG000|Overall Study|Physician Decision|0
6069840|NCT00546364|9672565|FG001|Overall Study|Physician Decision|0
6069841|NCT00546364|9672566|FG002|Overall Study|Physician Decision|1
6069842|NCT00546364|9672564|FG000|Overall Study|Sponsor decision|0
6069843|NCT00546364|9672565|FG001|Overall Study|Sponsor decision|0
6069844|NCT00546364|9672566|FG002|Overall Study|Sponsor decision|1
6069845|NCT00546377|9672574|FG000|Overall Study|Deemed ineligible|1
6069846|NCT00546377|9672574|FG000|Overall Study|Adverse Event|6
6087212|NCT00666926|9697368|FG009|Overall Study|Lack of Efficacy|0
6087213|NCT00666926|9697369|FG010|Overall Study|Lack of Efficacy|0
6087214|NCT00666926|9697370|FG011|Overall Study|Lack of Efficacy|1
6087215|NCT00666926|9697371|FG012|Overall Study|Lack of Efficacy|0
6087216|NCT00666926|9697372|FG013|Overall Study|Lack of Efficacy|0
6087217|NCT00666926|9697373|FG014|Overall Study|Lack of Efficacy|0
6087218|NCT00666926|9697374|FG015|Overall Study|Lack of Efficacy|0
6087219|NCT00666926|9697359|FG000|Overall Study|Lost to Follow-up|0
6087220|NCT00666926|9697360|FG001|Overall Study|Lost to Follow-up|0
6087221|NCT00666926|9697361|FG002|Overall Study|Lost to Follow-up|0
6087222|NCT00666926|9697362|FG003|Overall Study|Lost to Follow-up|1
6087223|NCT00666926|9697363|FG004|Overall Study|Lost to Follow-up|0
6087224|NCT00666926|9697364|FG005|Overall Study|Lost to Follow-up|0
6087225|NCT00666926|9697365|FG006|Overall Study|Lost to Follow-up|0
6087226|NCT00666926|9697366|FG007|Overall Study|Lost to Follow-up|0
6087227|NCT00666926|9697367|FG008|Overall Study|Lost to Follow-up|0
6087228|NCT00666926|9697368|FG009|Overall Study|Lost to Follow-up|0
6087229|NCT00666926|9697369|FG010|Overall Study|Lost to Follow-up|0
6087230|NCT00666926|9697370|FG011|Overall Study|Lost to Follow-up|0
6087231|NCT00666926|9697371|FG012|Overall Study|Lost to Follow-up|0
6087232|NCT00666926|9697372|FG013|Overall Study|Lost to Follow-up|0
6087233|NCT00666926|9697373|FG014|Overall Study|Lost to Follow-up|0
6087234|NCT00666926|9697374|FG015|Overall Study|Lost to Follow-up|0
6087235|NCT00666926|9697359|FG000|Overall Study|Other|2
6087236|NCT00666926|9697360|FG001|Overall Study|Other|4
6087237|NCT00666926|9697361|FG002|Overall Study|Other|3
6087238|NCT00666926|9697362|FG003|Overall Study|Other|3
6087239|NCT00666926|9697363|FG004|Overall Study|Other|3
6087240|NCT00666926|9697364|FG005|Overall Study|Other|3
6046141|NCT00404924|9645309|FG001|Overall Study|Condition under investigation worsened|264
6046142|NCT00404924|9645308|FG000|Overall Study|Lost to Follow-up|1
6046143|NCT00404924|9645309|FG001|Overall Study|Lost to Follow-up|1
6046144|NCT00404924|9645308|FG000|Overall Study|Withdrawal by Subject|26
6046145|NCT00404924|9645309|FG001|Overall Study|Withdrawal by Subject|13
6046146|NCT00404924|9645308|FG000|Overall Study|Other|25
6046147|NCT00404924|9645309|FG001|Overall Study|Other|11
6087241|NCT00666926|9697365|FG006|Overall Study|Other|4
6087242|NCT00666926|9697366|FG007|Overall Study|Other|0
6087243|NCT00666926|9697367|FG008|Overall Study|Other|3
6087244|NCT00666926|9697368|FG009|Overall Study|Other|5
6046148|NCT00404924|9645308|FG000|Overall Study|Randomised but not received treatment|1
6046149|NCT00404924|9645309|FG001|Overall Study|Randomised but not received treatment|1
6087245|NCT00666926|9697369|FG010|Overall Study|Other|3
6087246|NCT00666926|9697370|FG011|Overall Study|Other|26
6087247|NCT00666926|9697371|FG012|Overall Study|Other|3
6087248|NCT00666926|9697372|FG013|Overall Study|Other|2
5992960|NCT04574999|9585943|FG000|Overall Study|Adverse Event|1
5992961|NCT04574999|9585944|FG001|Overall Study|Adverse Event|0
5992962|NCT04574999|9585943|FG000|Overall Study|Lack of Efficacy|2
5992963|NCT04574999|9585944|FG001|Overall Study|Lack of Efficacy|3
5992964|NCT04574999|9585943|FG000|Overall Study|Protocol Violation|1
5992965|NCT04574999|9585944|FG001|Overall Study|Protocol Violation|0
5992966|NCT04574999|9585943|FG000|Overall Study|Withdrawal by Subject|2
5992967|NCT04574999|9585944|FG001|Overall Study|Withdrawal by Subject|2
5992968|NCT04574999|9585943|FG000|Overall Study|Lost to Follow-up|1
6069847|NCT00546481|9672594|FG000|Correction Phase (CERA or Epoetin Beta)|Protocol Violation|1
6069848|NCT00546481|9672595|FG001|Correction Phase (CERA or Epoetin Beta)|Protocol Violation|0
6069849|NCT00546481|9672596|FG002|Correction Phase (CERA or Epoetin Beta)|Protocol Violation|0
6069850|NCT00546481|9672594|FG000|Correction Phase (CERA or Epoetin Beta)|Withdrawal by Subject|1
6069851|NCT00546481|9672595|FG001|Correction Phase (CERA or Epoetin Beta)|Withdrawal by Subject|3
6069852|NCT00546481|9672596|FG002|Correction Phase (CERA or Epoetin Beta)|Withdrawal by Subject|0
6069853|NCT00546481|9672594|FG000|Correction Phase (CERA or Epoetin Beta)|Lack of Efficacy|1
6069854|NCT00546481|9672595|FG001|Correction Phase (CERA or Epoetin Beta)|Lack of Efficacy|0
6069855|NCT00546481|9672596|FG002|Correction Phase (CERA or Epoetin Beta)|Lack of Efficacy|0
6069856|NCT00546481|9672594|FG000|Correction Phase (CERA or Epoetin Beta)|Kidney transplantation|2
6069857|NCT00546481|9672595|FG001|Correction Phase (CERA or Epoetin Beta)|Kidney transplantation|0
6069858|NCT00546481|9672596|FG002|Correction Phase (CERA or Epoetin Beta)|Kidney transplantation|0
6069859|NCT00546481|9672594|FG000|Correction Phase (CERA or Epoetin Beta)|Lost to Follow-up|1
6069860|NCT00546481|9672595|FG001|Correction Phase (CERA or Epoetin Beta)|Lost to Follow-up|1
6069861|NCT00546481|9672596|FG002|Correction Phase (CERA or Epoetin Beta)|Lost to Follow-up|0
6069862|NCT00546481|9672594|FG000|Correction Phase (CERA or Epoetin Beta)|RBC transfusion|0
6069863|NCT00546481|9672595|FG001|Correction Phase (CERA or Epoetin Beta)|RBC transfusion|1
5992969|NCT04574999|9585944|FG001|Overall Study|Lost to Follow-up|0
6069864|NCT00546481|9672596|FG002|Correction Phase (CERA or Epoetin Beta)|RBC transfusion|0
6069865|NCT00546481|9672594|FG000|Maintenance Phase (CERA)|Withdrawal by Subject|0
5992970|NCT04574999|9585943|FG000|Overall Study|Personal problems|1
5992971|NCT04574999|9585944|FG001|Overall Study|Personal problems|0
5992972|NCT04574999|9585943|FG000|Overall Study|Previous planned surgery|1
6069866|NCT00546481|9672595|FG001|Maintenance Phase (CERA)|Withdrawal by Subject|0
6069867|NCT00546481|9672596|FG002|Maintenance Phase (CERA)|Withdrawal by Subject|2
6069868|NCT00546481|9672594|FG000|Maintenance Phase (CERA)|Kidney transplantation|0
6069869|NCT00546481|9672595|FG001|Maintenance Phase (CERA)|Kidney transplantation|0
6069870|NCT00546481|9672596|FG002|Maintenance Phase (CERA)|Kidney transplantation|1
6069871|NCT00546481|9672594|FG000|Maintenance Phase (CERA)|Other Reason|0
6069872|NCT00546481|9672595|FG001|Maintenance Phase (CERA)|Other Reason|0
6069873|NCT00546481|9672596|FG002|Maintenance Phase (CERA)|Other Reason|1
6069874|NCT00546572|9672606|FG000|Vax 1 / Year 0|Randomized, not treated|1
6069875|NCT00546572|9672607|FG001|Vax 1 / Year 0|Randomized, not treated|1
6069876|NCT00546572|9672606|FG000|Vax 1 / Year 0|Withdrawal by Subject|3
6069877|NCT00546572|9672607|FG001|Vax 1 / Year 0|Withdrawal by Subject|2
6069878|NCT00546572|9672606|FG000|Vax 1 / Year 0|Protocol Violation|3
5992973|NCT04574999|9585944|FG001|Overall Study|Previous planned surgery|0
6046150|NCT00405067|9645318|FG000|Overall Study|Adverse Event|4
6046151|NCT00405067|9645319|FG001|Overall Study|Adverse Event|9
6046152|NCT00405067|9645320|FG002|Overall Study|Adverse Event|4
6046153|NCT00405067|9645318|FG000|Overall Study|Lost to Follow-up|0
6046154|NCT00405067|9645319|FG001|Overall Study|Lost to Follow-up|0
6046155|NCT00405067|9645320|FG002|Overall Study|Lost to Follow-up|1
6046156|NCT00405275|9645330|FG000|Overall Study|Death|1
6046157|NCT00405275|9645331|FG001|Overall Study|Death|0
6046158|NCT00405275|9645330|FG000|Overall Study|Lost to Follow-up|5
6046159|NCT00405275|9645331|FG001|Overall Study|Lost to Follow-up|1
6069879|NCT00546572|9672607|FG001|Vax 1 / Year 0|Protocol Violation|4
6069880|NCT00546572|9672606|FG000|Vax 1 / Year 0|Death|2
6069881|NCT00546572|9672607|FG001|Vax 1 / Year 0|Death|2
6069882|NCT00546572|9672606|FG000|Vax 1 / Year 0|Adverse Event|0
6069883|NCT00546572|9672607|FG001|Vax 1 / Year 0|Adverse Event|1
6069884|NCT00546572|9672606|FG000|Vax 1 / Year 0|Lost to Follow-up|0
6069885|NCT00546572|9672607|FG001|Vax 1 / Year 0|Lost to Follow-up|1
6069886|NCT00546572|9672606|FG000|Vax 1 / Year 0|6-Month Contact; withdraw before Vax 2|64
6069887|NCT00546572|9672607|FG001|Vax 1 / Year 0|6-Month Contact; withdraw before Vax 2|59
6069888|NCT00546572|9672606|FG000|Vax 2 / Year 1|Other|1
6069889|NCT00546572|9672607|FG001|Vax 2 / Year 1|Other|1
6069890|NCT00546572|9672606|FG000|Vax 2 / Year 1|Adverse Event|1
6069891|NCT00546572|9672607|FG001|Vax 2 / Year 1|Adverse Event|0
6069892|NCT00546572|9672606|FG000|Vax 2 / Year 1|Vax 2; withdraw before 6-Month Contact|2
6069893|NCT00546572|9672607|FG001|Vax 2 / Year 1|Vax 2; withdraw before 6-Month Contact|1
6069894|NCT00546637|9672626|FG000|Overall Study|Adverse Event|46
6069895|NCT00546637|9672627|FG001|Overall Study|Adverse Event|20
6069896|NCT00546637|9672626|FG000|Overall Study|Lack of Efficacy|5
6069897|NCT00546637|9672627|FG001|Overall Study|Lack of Efficacy|5
6069898|NCT00546637|9672626|FG000|Overall Study|Lost to Follow-up|2
6069899|NCT00546637|9672627|FG001|Overall Study|Lost to Follow-up|2
6069900|NCT00546637|9672626|FG000|Overall Study|Other|10
6069901|NCT00546637|9672627|FG001|Overall Study|Other|12
6069902|NCT00546637|9672626|FG000|Overall Study|Withdrawal by Subject|7
6069903|NCT00546637|9672627|FG001|Overall Study|Withdrawal by Subject|9
6069904|NCT00546637|9672626|FG000|Overall Study|Randomized, but not treated|3
6069905|NCT00546637|9672627|FG001|Overall Study|Randomized, but not treated|1
6069906|NCT00546715|9672637|FG000|Overall Study|Withdrawal by Subject|0
6069907|NCT00546715|9672638|FG001|Overall Study|Withdrawal by Subject|1
6069908|NCT00546715|9672639|FG002|Overall Study|Withdrawal by Subject|0
6069909|NCT00546715|9672640|FG003|Overall Study|Withdrawal by Subject|0
6069910|NCT00546819|9672661|FG000|Overall Study|Adverse Event|2
6069911|NCT00546819|9672662|FG001|Overall Study|Adverse Event|3
6069912|NCT00546819|9672661|FG000|Overall Study|Lost to Follow-up|2
6069913|NCT00546819|9672662|FG001|Overall Study|Lost to Follow-up|1
6069914|NCT00546819|9672661|FG000|Overall Study|Withdrawal by Subject|4
6069915|NCT00546819|9672662|FG001|Overall Study|Withdrawal by Subject|2
6069916|NCT00546871|9672668|FG000|Part 1 - IV Infusions of IGIV, PK|Withdrawal by Subject|1
6069917|NCT00546871|9672669|FG001|Part 1 - IV Infusions of IGIV, PK|Withdrawal by Subject|0
6069918|NCT00546871|9672668|FG000|Part 2 - Subcutaneous (SC) IGIV, PK|Withdrawal by Subject|1
6069919|NCT00546871|9672669|FG001|Part 2 - Subcutaneous (SC) IGIV, PK|Withdrawal by Subject|2
6069920|NCT00546871|9672668|FG000|Part 2 - Subcutaneous (SC) IGIV, PK|Family Emergency|0
6069921|NCT00546871|9672669|FG001|Part 2 - Subcutaneous (SC) IGIV, PK|Family Emergency|1
6069922|NCT00546871|9672668|FG000|Study Extension Period|Protocol Violation|1
6069923|NCT00546871|9672669|FG001|Study Extension Period|Protocol Violation|0
5992974|NCT04572997|9585950|FG000|Overall Study|Adverse Event|1
6046160|NCT00405275|9645330|FG000|Overall Study|Withdrawal by Subject|7
6046161|NCT00405275|9645331|FG001|Overall Study|Withdrawal by Subject|9
6046162|NCT00405275|9645330|FG000|Overall Study|Unwilling to continue|10
6046163|NCT00405275|9645331|FG001|Overall Study|Unwilling to continue|9
6046164|NCT00405392|9645352|FG000|Overall Study|Adverse Event|15
6046165|NCT00405392|9645353|FG001|Overall Study|Adverse Event|14
6046166|NCT00405392|9645352|FG000|Overall Study|Did not meet Eligibility criteria|7
6046167|NCT00405392|9645353|FG001|Overall Study|Did not meet Eligibility criteria|2
6046168|NCT00405392|9645352|FG000|Overall Study|Withdrawal by Subject|4
6046169|NCT00405392|9645353|FG001|Overall Study|Withdrawal by Subject|3
6046170|NCT00405392|9645352|FG000|Overall Study|Lost to Follow-up|1
6046171|NCT00405392|9645353|FG001|Overall Study|Lost to Follow-up|2
6046172|NCT00405392|9645352|FG000|Overall Study|Data missing|2
6046173|NCT00405392|9645353|FG001|Overall Study|Data missing|0
6046174|NCT00405392|9645352|FG000|Overall Study|Non-compliance|0
6046175|NCT00405392|9645353|FG001|Overall Study|Non-compliance|1
6046176|NCT00405392|9645352|FG000|Overall Study|Other|1
6046177|NCT00405392|9645353|FG001|Overall Study|Other|5
6046178|NCT00405548|9645379|FG000|Overall Study|Cognitive Memory problems on study day|1
6046179|NCT00405548|9645380|FG001|Overall Study|Cognitive Memory problems on study day|0
6046180|NCT00405548|9645379|FG000|Overall Study|Amyloidosis on study echo-exclusionary|0
6046181|NCT00405548|9645380|FG001|Overall Study|Amyloidosis on study echo-exclusionary|1
6069924|NCT00546871|9672668|FG000|Study Extension Period|Withdrawal by Subject|0
6069925|NCT00546871|9672669|FG001|Study Extension Period|Withdrawal by Subject|1
6069926|NCT00546910|9672718|FG000|Overall Study|Adverse Event|2
6069927|NCT00546910|9672719|FG001|Overall Study|Adverse Event|3
6069928|NCT00546910|9672718|FG000|Overall Study|Lack of Efficacy|5
6046182|NCT00405548|9645379|FG000|Overall Study|Unable to self-administer shots|1
6046183|NCT00405548|9645380|FG001|Overall Study|Unable to self-administer shots|0
6046184|NCT00405548|9645379|FG000|Overall Study|Venous access failed during study day|1
6046185|NCT00405548|9645380|FG001|Overall Study|Venous access failed during study day|0
6069929|NCT00546910|9672719|FG001|Overall Study|Lack of Efficacy|7
6069930|NCT00546910|9672718|FG000|Overall Study|Physician Decision|0
6069931|NCT00546910|9672719|FG001|Overall Study|Physician Decision|1
6069932|NCT00546910|9672718|FG000|Overall Study|Withdrawal by Subject|2
6069933|NCT00546910|9672719|FG001|Overall Study|Withdrawal by Subject|0
5992975|NCT04542694|9586029|FG000|Overall Study|The need for prohibited therapy|2
5992976|NCT04542694|9586030|FG001|Overall Study|The need for prohibited therapy|0
5992977|NCT04542694|9586029|FG000|Overall Study|Adverse Event|1
5992978|NCT04542694|9586030|FG001|Overall Study|Adverse Event|0
5992979|NCT04542694|9586029|FG000|Overall Study|Protocol Violation|1
5992980|NCT04542694|9586030|FG001|Overall Study|Protocol Violation|0
5992981|NCT04534491|9586072|FG000|Overall Study|Not completed end-of-study interview|24
5992982|NCT04534491|9586072|FG000|Overall Study|Non-users|70
5992983|NCT04534491|9586072|FG000|Overall Study|Non-verifiable users|58
5992998|NCT04093258|9586126|FG000|Period 2|Subject no longer meets the eligibility criteria|1
5992999|NCT04093258|9586127|FG001|Period 2|Subject no longer meets the eligibility criteria|0
5993000|NCT03993379|9586141|FG000|Overall Study|The study was terminated early due to business decision.|0
5993001|NCT03993379|9586142|FG001|Overall Study|The study was terminated early due to business decision.|2
5993002|NCT03993379|9586143|FG002|Overall Study|The study was terminated early due to business decision.|0
5993003|NCT03993379|9586144|FG003|Overall Study|The study was terminated early due to business decision.|0
5993004|NCT03993379|9586141|FG000|Overall Study|Withdrawal by Subject|0
5993005|NCT03993379|9586142|FG001|Overall Study|Withdrawal by Subject|1
5993006|NCT03993379|9586143|FG002|Overall Study|Withdrawal by Subject|0
5993007|NCT03993379|9586144|FG003|Overall Study|Withdrawal by Subject|0
5993008|NCT03956615|9586154|FG000|Overall Study|No multiple myeloma confirmed|2
5993009|NCT03956615|9586154|FG000|Overall Study|Assessment of membrane-expressed ideotypic paraprotein not possible due to low CD38 signals|1
5993010|NCT03956615|9586154|FG000|Overall Study|No expression of ideotypic paraprotein on membrane|2
5993011|NCT03956615|9586154|FG000|Overall Study|Not selected for sdAb generation, due to limitation of total number to 3|2
5993012|NCT03803059|9586158|FG000|Overall Study|Protocol Violation|2
5993013|NCT03803059|9586158|FG000|Overall Study|Lost to Follow-up|1
5993014|NCT03723590|9586163|FG000|Overall Study|Withdrawal by Subject|3
5993015|NCT03430895|9586186|FG000|Overall Study|Not Treated|2
5993016|NCT03230838|9586209|FG000|Overall Study|Withdrawal by Subject|3
5993017|NCT03230838|9586210|FG001|Overall Study|Withdrawal by Subject|0
5993018|NCT03230838|9586209|FG000|Overall Study|Temperature excursion|1
5993019|NCT03230838|9586210|FG001|Overall Study|Temperature excursion|0
5993020|NCT03183778|9586216|FG000|Overall Study|Withdrawn by Investigator (potassium in normal range)|1
5993021|NCT02700698|9586242|FG000|Overall Study|Withdrawal by Subject|1
5993022|NCT02700698|9586243|FG001|Overall Study|Withdrawal by Subject|0
5993023|NCT02698865|9586260|FG000|Overall Study|Other|11
5993024|NCT02698865|9586261|FG001|Overall Study|Other|11
5993025|NCT02698865|9586260|FG000|Overall Study|Withdrawal by Subject|20
5993026|NCT02698865|9586261|FG001|Overall Study|Withdrawal by Subject|16
5993027|NCT02698865|9586260|FG000|Overall Study|Physician Decision|0
5993028|NCT02698865|9586261|FG001|Overall Study|Physician Decision|4
5993029|NCT02698865|9586260|FG000|Overall Study|Lost to Follow-up|4
5993030|NCT02698865|9586261|FG001|Overall Study|Lost to Follow-up|2
5993031|NCT02660086|9586269|FG000|Overall Study- 12-month|Withdrawal by Subject|5
5993032|NCT02660086|9586270|FG001|Overall Study- 12-month|Withdrawal by Subject|5
5993033|NCT02660086|9586269|FG000|Overall Study- 12-month|Left full-time employment|12
5993034|NCT02660086|9586270|FG001|Overall Study- 12-month|Left full-time employment|20
5993035|NCT02660086|9586269|FG000|Overall Study- 12-month|Missed 12-month follow-up visit|8
5993036|NCT02660086|9586270|FG001|Overall Study- 12-month|Missed 12-month follow-up visit|4
5993037|NCT02660086|9586269|FG000|Overall Study- 12-month|Became ineligible: new job in cafeteria|1
5993038|NCT02660086|9586270|FG001|Overall Study- 12-month|Became ineligible: new job in cafeteria|0
5993039|NCT02660086|9586269|FG000|Overall Study: 24-month Follow-up|Left employment after 12 months|17
5993040|NCT02660086|9586270|FG001|Overall Study: 24-month Follow-up|Left employment after 12 months|8
5993041|NCT02660086|9586269|FG000|Overall Study: 24-month Follow-up|Missed 24-month follow-up|9
5993042|NCT02660086|9586270|FG001|Overall Study: 24-month Follow-up|Missed 24-month follow-up|16
5993043|NCT02129647|9586280|FG000|Overall Study|Adverse Event|2
5993044|NCT02129647|9586280|FG000|Overall Study|surgical intervention for clinically progressive disease|1
5993045|NCT01959139|9586292|FG000|Phase II|Disease progression|0
5993046|NCT01959139|9586293|FG001|Phase II|Disease progression|0
5993047|NCT01959139|9586294|FG002|Phase II|Disease progression|26
5993048|NCT01959139|9586295|FG003|Phase II|Disease progression|34
5993049|NCT01959139|9586292|FG000|Phase II|Adverse Event|0
5993050|NCT01959139|9586293|FG001|Phase II|Adverse Event|0
5993051|NCT01959139|9586294|FG002|Phase II|Adverse Event|10
5993052|NCT01959139|9586295|FG003|Phase II|Adverse Event|11
5993053|NCT01959139|9586292|FG000|Phase II|Patient Refusal|0
5993054|NCT01959139|9586293|FG001|Phase II|Patient Refusal|0
5993055|NCT01959139|9586294|FG002|Phase II|Patient Refusal|5
5993056|NCT01959139|9586295|FG003|Phase II|Patient Refusal|4
5993057|NCT01959139|9586292|FG000|Phase II|Death|0
5993058|NCT01959139|9586293|FG001|Phase II|Death|0
5993059|NCT01959139|9586294|FG002|Phase II|Death|3
5993060|NCT01959139|9586295|FG003|Phase II|Death|1
5993061|NCT01959139|9586292|FG000|Phase II|Other/Unknown|0
5993062|NCT01959139|9586293|FG001|Phase II|Other/Unknown|0
5993063|NCT01959139|9586294|FG002|Phase II|Other/Unknown|8
5993064|NCT01959139|9586295|FG003|Phase II|Other/Unknown|5
5993065|NCT01959139|9586292|FG000|Phase II|On treatment|0
5993066|NCT01959139|9586293|FG001|Phase II|On treatment|0
5993067|NCT01959139|9586294|FG002|Phase II|On treatment|4
5993068|NCT01959139|9586295|FG003|Phase II|On treatment|0
6069934|NCT00547118|9672731|FG000|Overall Study|Did not qualify prior to starting drug|1
6069935|NCT00547118|9672732|FG001|Overall Study|Did not qualify prior to starting drug|1
6069936|NCT00547118|9672731|FG000|Overall Study|Study suspended|7
6069937|NCT00547118|9672732|FG001|Overall Study|Study suspended|8
6069938|NCT00547157|9672742|FG000|Overall Study|Other|1
6069939|NCT00547157|9672743|FG001|Overall Study|Other|0
6069940|NCT00547157|9672742|FG000|Overall Study|Death|38
6069941|NCT00547157|9672743|FG001|Overall Study|Death|18
6069942|NCT00547157|9672742|FG000|Overall Study|Withdrawal by Subject|3
6069943|NCT00547157|9672743|FG001|Overall Study|Withdrawal by Subject|1
6069944|NCT00547157|9672742|FG000|Overall Study|Administrative decision|3
6069945|NCT00547157|9672743|FG001|Overall Study|Administrative decision|2
6069946|NCT00547157|9672742|FG000|Overall Study|Lost to Follow-up|4
6069947|NCT00547157|9672743|FG001|Overall Study|Lost to Follow-up|2
5992984|NCT04533204|9586094|FG000|Overall Study|Unable to understand training instructions|1
5992985|NCT04533204|9586095|FG001|Overall Study|Unable to understand training instructions|1
5992986|NCT04532164|9586101|FG000|Overall Study|Adverse Event|1
5992987|NCT04532164|9586101|FG000|Overall Study|Protocol Violation|5
5992988|NCT04532164|9586101|FG000|Overall Study|Lost to Follow-up|1
5992989|NCT04532164|9586101|FG000|Overall Study|Found to be Ineligible|3
5992990|NCT04532164|9586101|FG000|Overall Study|Withdrawal by Subject|14
5992991|NCT04531813|9586106|FG000|Overall Study|Protocol Violation|1
5992992|NCT04531813|9586106|FG000|Overall Study|Withdrawal by Subject|1
5992993|NCT04531527|9586110|FG000|Overall Study|Found to be Ineligible|3
5993069|NCT01597778|9586312|FG000|Overall Study|Death|7
5993070|NCT01597778|9586313|FG001|Overall Study|Death|10
5993071|NCT01597778|9586312|FG000|Overall Study|Withdrawal by Subject|3
5993072|NCT01597778|9586313|FG001|Overall Study|Withdrawal by Subject|4
5993073|NCT01597778|9586312|FG000|Overall Study|Adverse Event|1
5993074|NCT01597778|9586313|FG001|Overall Study|Adverse Event|1
5993075|NCT01597778|9586312|FG000|Overall Study|Protocol Violation|1
5993076|NCT01597778|9586313|FG001|Overall Study|Protocol Violation|11
5993077|NCT01597778|9586312|FG000|Overall Study|Transplanted off protocol|2
5993078|NCT01597778|9586313|FG001|Overall Study|Transplanted off protocol|3
5993079|NCT01522976|9586322|FG000|Overall Study|Ineligible|4
5993080|NCT01522976|9586323|FG001|Overall Study|Ineligible|0
5993081|NCT01522976|9586324|FG002|Overall Study|Ineligible|1
5993082|NCT01522976|9586322|FG000|Overall Study|Death|7
5993083|NCT01522976|9586323|FG001|Overall Study|Death|6
5993084|NCT01522976|9586324|FG002|Overall Study|Death|2
5993085|NCT01522976|9586322|FG000|Overall Study|Still on treatment|9
5993086|NCT01522976|9586323|FG001|Overall Study|Still on treatment|9
5993087|NCT01522976|9586324|FG002|Overall Study|Still on treatment|6
5993088|NCT01522976|9586322|FG000|Overall Study|Disease progression|28
5993089|NCT01522976|9586323|FG001|Overall Study|Disease progression|30
5993090|NCT01522976|9586324|FG002|Overall Study|Disease progression|25
5993091|NCT01522976|9586322|FG000|Overall Study|Adverse Event|17
5993092|NCT01522976|9586323|FG001|Overall Study|Adverse Event|7
5993093|NCT01522976|9586324|FG002|Overall Study|Adverse Event|18
5993094|NCT01522976|9586322|FG000|Overall Study|Refusal unrelated to adverse event|10
5993095|NCT01522976|9586323|FG001|Overall Study|Refusal unrelated to adverse event|13
5993096|NCT01522976|9586324|FG002|Overall Study|Refusal unrelated to adverse event|14
5993097|NCT01522976|9586322|FG000|Overall Study|Not protocol specified|22
5993098|NCT01522976|9586323|FG001|Overall Study|Not protocol specified|27
5993099|NCT01522976|9586324|FG002|Overall Study|Not protocol specified|27
5993100|NCT01286272|9586337|FG000|Overall Study|Ineligible after beginning treatment|1
5993101|NCT01286272|9586338|FG001|Overall Study|Ineligible after beginning treatment|3
5993102|NCT00879086|9586355|FG000|Overall Study|Adverse Event|3
5993103|NCT00879086|9586356|FG001|Overall Study|Adverse Event|15
5993104|NCT00879086|9586355|FG000|Overall Study|Participant choice|2
5993105|NCT00879086|9586356|FG001|Overall Study|Participant choice|2
5993106|NCT00879086|9586355|FG000|Overall Study|Progression of disease|40
5993107|NCT00879086|9586356|FG001|Overall Study|Progression of disease|26
5993108|NCT00879086|9586355|FG000|Overall Study|Withdrawal of consent|2
5993109|NCT00879086|9586356|FG001|Overall Study|Withdrawal of consent|1
6069948|NCT00547248|9672753|FG000|Overall Study|Protocol Violation|0
5993110|NCT00879086|9586355|FG000|Overall Study|Other|4
5993111|NCT00879086|9586356|FG001|Overall Study|Other|6
5993112|NCT00879086|9586355|FG000|Overall Study|Death|1
5993113|NCT00879086|9586356|FG001|Overall Study|Death|2
5993114|NCT00864227|9586362|FG000|Overall Study|Withdrawal by Subject|1
5993115|NCT00864227|9586362|FG000|Overall Study|Disease Relapse/Progression|3
5993116|NCT00731731|9586369|FG000|Overall Study|Protocol Violation|0
5993117|NCT00731731|9586370|FG001|Overall Study|Protocol Violation|0
5993118|NCT00731731|9586371|FG002|Overall Study|Protocol Violation|1
5993119|NCT00731731|9586369|FG000|Overall Study|Cancel prior to treatment|0
5993120|NCT00731731|9586370|FG001|Overall Study|Cancel prior to treatment|0
5993121|NCT00731731|9586371|FG002|Overall Study|Cancel prior to treatment|2
5993122|NCT00685360|9586387|FG000|Overall Study|Lost to Follow-up|0
5993123|NCT00685360|9586388|FG001|Overall Study|Lost to Follow-up|1
5993124|NCT00685360|9586389|FG002|Overall Study|Lost to Follow-up|2
5993125|NCT00685360|9586387|FG000|Overall Study|Adverse Event|4
6069949|NCT00547248|9672754|FG001|Overall Study|Protocol Violation|0
6069950|NCT00547248|9672755|FG002|Overall Study|Protocol Violation|1
6069951|NCT00547248|9672756|FG003|Overall Study|Protocol Violation|1
5992994|NCT04531540|9586114|FG000|Overall Study|Adverse Event|1
5992995|NCT04531540|9586114|FG000|Overall Study|Protocol Violation|3
5992996|NCT04531540|9586114|FG000|Overall Study|Withdrawal by Subject|4
5992997|NCT04531540|9586114|FG000|Overall Study|Found to be Ineligible|1
5993126|NCT00685360|9586388|FG001|Overall Study|Adverse Event|6
5993127|NCT00685360|9586389|FG002|Overall Study|Adverse Event|4
5993128|NCT00685360|9586387|FG000|Overall Study|Subject Met (Protocol Specified) Withdrawal Criteria|1
5993129|NCT00685360|9586388|FG001|Overall Study|Subject Met (Protocol Specified) Withdrawal Criteria|0
5993130|NCT00685360|9586389|FG002|Overall Study|Subject Met (Protocol Specified) Withdrawal Criteria|2
5993131|NCT00685360|9586387|FG000|Overall Study|Subject was Withdrawn From Participation by the Investigator|0
5993132|NCT00685360|9586388|FG001|Overall Study|Subject was Withdrawn From Participation by the Investigator|4
5993133|NCT00685360|9586389|FG002|Overall Study|Subject was Withdrawn From Participation by the Investigator|1
5993134|NCT00685360|9586387|FG000|Overall Study|Subject Withdrew Consent to Participate|13
5993135|NCT00685360|9586388|FG001|Overall Study|Subject Withdrew Consent to Participate|2
5993136|NCT00685360|9586389|FG002|Overall Study|Subject Withdrew Consent to Participate|5
5993137|NCT00685360|9586387|FG000|Overall Study|Protocol Deviation|0
5993138|NCT00685360|9586388|FG001|Overall Study|Protocol Deviation|1
5993139|NCT00685360|9586389|FG002|Overall Study|Protocol Deviation|1
5993140|NCT00299728|9586399|FG000|Overall Study|Lost to Follow-up|0
5993141|NCT00299728|9586400|FG001|Overall Study|Lost to Follow-up|1
5993142|NCT00299728|9586399|FG000|Overall Study|Withdrawal by Subject|0
5993143|NCT00299728|9586400|FG001|Overall Study|Withdrawal by Subject|1
5993144|NCT00299728|9586399|FG000|Overall Study|Progressive disease|0
5993145|NCT00299728|9586400|FG001|Overall Study|Progressive disease|1
5993146|NCT00070499|9586415|FG000|Overall Study|Adverse Event|6
5993147|NCT00070499|9586416|FG001|Overall Study|Adverse Event|6
5993148|NCT00070499|9586417|FG002|Overall Study|Adverse Event|19
5993149|NCT00070499|9586418|FG003|Overall Study|Adverse Event|15
5993150|NCT00070499|9586415|FG000|Overall Study|Refusal unrelated to adverse effects|7
5993151|NCT00070499|9586416|FG001|Overall Study|Refusal unrelated to adverse effects|5
5993152|NCT00070499|9586417|FG002|Overall Study|Refusal unrelated to adverse effects|5
5993153|NCT00070499|9586418|FG003|Overall Study|Refusal unrelated to adverse effects|8
5993154|NCT00070499|9586415|FG000|Overall Study|Progression/relapse|4
5993155|NCT00070499|9586416|FG001|Overall Study|Progression/relapse|2
5993156|NCT00070499|9586417|FG002|Overall Study|Progression/relapse|1
5993157|NCT00070499|9586418|FG003|Overall Study|Progression/relapse|4
5993158|NCT00070499|9586415|FG000|Overall Study|Death|1
5993159|NCT00070499|9586416|FG001|Overall Study|Death|1
5993160|NCT00070499|9586417|FG002|Overall Study|Death|1
5993161|NCT00070499|9586418|FG003|Overall Study|Death|2
5993162|NCT00070499|9586415|FG000|Overall Study|Other - not protocol specified|7
5993163|NCT00070499|9586416|FG001|Overall Study|Other - not protocol specified|3
5993164|NCT00070499|9586417|FG002|Overall Study|Other - not protocol specified|12
5993165|NCT00070499|9586418|FG003|Overall Study|Other - not protocol specified|20
5993166|NCT00070499|9586415|FG000|Overall Study|Still on protocol treatment|10
5993167|NCT00070499|9586416|FG001|Overall Study|Still on protocol treatment|4
5993168|NCT00070499|9586417|FG002|Overall Study|Still on protocol treatment|79
5993169|NCT00070499|9586418|FG003|Overall Study|Still on protocol treatment|57
5993170|NCT00070499|9586415|FG000|Overall Study|Did not start treatment|1
5993171|NCT00070499|9586416|FG001|Overall Study|Did not start treatment|0
5993172|NCT00070499|9586417|FG002|Overall Study|Did not start treatment|0
5993173|NCT00070499|9586418|FG003|Overall Study|Did not start treatment|2
5993174|NCT00070499|9586415|FG000|Overall Study|Not eligible|2
5993175|NCT00070499|9586416|FG001|Overall Study|Not eligible|5
5993176|NCT00070499|9586417|FG002|Overall Study|Not eligible|3
5993177|NCT00070499|9586418|FG003|Overall Study|Not eligible|2
6046186|NCT00405548|9645379|FG000|Overall Study|Withdrawal by Subject|1
6046187|NCT00405548|9645380|FG001|Overall Study|Withdrawal by Subject|0
6046188|NCT00405587|9645390|FG000|Overall Study|Death|0
6046189|NCT00405587|9645391|FG001|Overall Study|Death|0
6046190|NCT00405587|9645392|FG002|Overall Study|Death|0
6046191|NCT00405587|9645393|FG003|Overall Study|Death|1
6046192|NCT00405587|9645390|FG000|Overall Study|Disease Progression|22
6046193|NCT00405587|9645391|FG001|Overall Study|Disease Progression|23
6046194|NCT00405587|9645392|FG002|Overall Study|Disease Progression|21
6046195|NCT00405587|9645393|FG003|Overall Study|Disease Progression|17
6046196|NCT00405587|9645390|FG000|Overall Study|Physician Decision|3
6046197|NCT00405587|9645391|FG001|Overall Study|Physician Decision|2
6046198|NCT00405587|9645392|FG002|Overall Study|Physician Decision|0
6046199|NCT00405587|9645393|FG003|Overall Study|Physician Decision|0
6046200|NCT00405587|9645390|FG000|Overall Study|Adverse Event|1
6046201|NCT00405587|9645391|FG001|Overall Study|Adverse Event|0
6046202|NCT00405587|9645392|FG002|Overall Study|Adverse Event|0
6046203|NCT00405587|9645393|FG003|Overall Study|Adverse Event|0
6046204|NCT00405587|9645390|FG000|Overall Study|Lost to Follow-up|0
6046205|NCT00405587|9645391|FG001|Overall Study|Lost to Follow-up|1
6046206|NCT00405587|9645392|FG002|Overall Study|Lost to Follow-up|1
6046207|NCT00405587|9645393|FG003|Overall Study|Lost to Follow-up|0
6046208|NCT00405587|9645390|FG000|Overall Study|Radiation induced necrosis|0
6046209|NCT00405587|9645391|FG001|Overall Study|Radiation induced necrosis|1
6046210|NCT00405587|9645392|FG002|Overall Study|Radiation induced necrosis|0
6046211|NCT00405587|9645393|FG003|Overall Study|Radiation induced necrosis|0
5993178|NCT04330157|9586457|FG000|Overall Study|Protocol Violation|4
5993179|NCT04330157|9586457|FG000|Overall Study|Not extubated within 24 h postoperatively|3
5993185|NCT04160988|9586499|FG000|Overall Study|poor image quality|28
5993186|NCT04079114|9586508|FG000|Overall Study|Study prematuely terminated.|166
5993187|NCT04461795|9586633|FG000|Overall Study|Lost to Follow-up|2
5993188|NCT04461795|9586633|FG000|Overall Study|Withdrawal by Subject|2
5993189|NCT04461795|9586633|FG000|Overall Study|Protocol Specified Withdrawal Criterion Met|1
5993190|NCT04035473|9586654|FG000|Screening/Baseline|Death|0
5993191|NCT04035473|9586655|FG001|Screening/Baseline|Death|1
5993192|NCT04035473|9586654|FG000|Screening/Baseline|Adverse Event|0
5993193|NCT04035473|9586655|FG001|Screening/Baseline|Adverse Event|1
5993194|NCT04035473|9586654|FG000|Follow-up Period|Adverse Event|2
5993195|NCT04035473|9586655|FG001|Follow-up Period|Adverse Event|0
5993196|NCT03796676|9586664|FG000|Overall Study|Adverse Event|2
5993197|NCT03796676|9586665|FG001|Overall Study|Adverse Event|1
5993198|NCT03796676|9586666|FG002|Overall Study|Adverse Event|2
5993199|NCT03796676|9586664|FG000|Overall Study|Lost to Follow-up|2
5993200|NCT03796676|9586665|FG001|Overall Study|Lost to Follow-up|1
5993201|NCT03796676|9586666|FG002|Overall Study|Lost to Follow-up|0
5993202|NCT03796676|9586664|FG000|Overall Study|Protocol Violation|0
5993203|NCT03796676|9586665|FG001|Overall Study|Protocol Violation|0
5993204|NCT03796676|9586666|FG002|Overall Study|Protocol Violation|1
5993205|NCT03796676|9586664|FG000|Overall Study|Withdrawal by Subject|1
5993206|NCT03796676|9586665|FG001|Overall Study|Withdrawal by Subject|1
5993207|NCT03796676|9586666|FG002|Overall Study|Withdrawal by Subject|0
5993208|NCT03796676|9586664|FG000|Overall Study|Participant did not complete Week 16 due to COVID-19 impact|1
5993209|NCT03796676|9586665|FG001|Overall Study|Participant did not complete Week 16 due to COVID-19 impact|0
5993210|NCT03796676|9586666|FG002|Overall Study|Participant did not complete Week 16 due to COVID-19 impact|0
5993211|NCT03215810|9586686|FG000|Overall Study|Still responding to nivolumab|1
5993212|NCT03215810|9586686|FG000|Overall Study|Insufficient TIL growth|1
5993213|NCT03215810|9586686|FG000|Overall Study|Decline in performance status|1
5993214|NCT03215810|9586686|FG000|Overall Study|Withdrawal by Subject|1
5993215|NCT02989857|9586692|FG000|Randomization Phase|Adverse Event|8
5993216|NCT02989857|9586693|FG001|Randomization Phase|Adverse Event|4
5993217|NCT02989857|9586694|FG002|Randomization Phase|Adverse Event|0
5993218|NCT02989857|9586692|FG000|Randomization Phase|Death|6
5993219|NCT02989857|9586693|FG001|Randomization Phase|Death|0
5993220|NCT02989857|9586694|FG002|Randomization Phase|Death|0
5993221|NCT02989857|9586692|FG000|Randomization Phase|Progressive Disease|98
5993222|NCT02989857|9586693|FG001|Randomization Phase|Progressive Disease|51
5993223|NCT02989857|9586694|FG002|Randomization Phase|Progressive Disease|0
5993224|NCT02989857|9586692|FG000|Randomization Phase|Withdrawal by Subject|6
5993225|NCT02989857|9586693|FG001|Randomization Phase|Withdrawal by Subject|2
5993226|NCT02989857|9586694|FG002|Randomization Phase|Withdrawal by Subject|0
5993227|NCT02989857|9586692|FG000|Randomization Phase|Withdrawal of Consent|2
5993228|NCT02989857|9586693|FG001|Randomization Phase|Withdrawal of Consent|1
5993229|NCT02989857|9586694|FG002|Randomization Phase|Withdrawal of Consent|0
5993230|NCT02989857|9586692|FG000|Randomization Phase|Reason not specified|3
5993231|NCT02989857|9586693|FG001|Randomization Phase|Reason not specified|1
5993232|NCT02989857|9586694|FG002|Randomization Phase|Reason not specified|0
5993233|NCT02989857|9586692|FG000|Randomization Phase|Not Treated|3
5993234|NCT02989857|9586693|FG001|Randomization Phase|Not Treated|2
5993235|NCT02989857|9586694|FG002|Randomization Phase|Not Treated|0
5993236|NCT02989857|9586692|FG000|Cross Over Phase|Adverse Event|0
5993237|NCT02989857|9586693|FG001|Cross Over Phase|Adverse Event|0
5993238|NCT02989857|9586694|FG002|Cross Over Phase|Adverse Event|2
5993239|NCT02989857|9586692|FG000|Cross Over Phase|Physician Decision|0
5993240|NCT02989857|9586693|FG001|Cross Over Phase|Physician Decision|0
5993241|NCT02989857|9586694|FG002|Cross Over Phase|Physician Decision|2
5993242|NCT02989857|9586692|FG000|Cross Over Phase|Progressive Disease|0
5993243|NCT02989857|9586693|FG001|Cross Over Phase|Progressive Disease|0
5993244|NCT02989857|9586694|FG002|Cross Over Phase|Progressive Disease|36
5993245|NCT02989857|9586692|FG000|Cross Over Phase|Withdrawal by Consent|0
5993246|NCT02989857|9586693|FG001|Cross Over Phase|Withdrawal by Consent|0
5993247|NCT02989857|9586694|FG002|Cross Over Phase|Withdrawal by Consent|3
5993248|NCT02983799|9586706|FG000|Overall Study|Withdrawn from study before data cut-off|28
5993249|NCT02983799|9586707|FG001|Overall Study|Withdrawn from study before data cut-off|12
5993250|NCT02983799|9586708|FG002|Overall Study|Withdrawn from study before data cut-off|23
5993251|NCT02983799|9586709|FG003|Overall Study|Withdrawn from study before data cut-off|25
5993252|NCT02983799|9586710|FG004|Overall Study|Withdrawn from study before data cut-off|1
5993253|NCT02983799|9586706|FG000|Overall Study|Death|20
5993254|NCT02983799|9586707|FG001|Overall Study|Death|5
5993255|NCT02983799|9586708|FG002|Overall Study|Death|23
5993256|NCT02983799|9586709|FG003|Overall Study|Death|47
5993257|NCT02983799|9586710|FG004|Overall Study|Death|7
5993258|NCT02983799|9586706|FG000|Overall Study|Withdrawal by Subject|1
5993259|NCT02983799|9586707|FG001|Overall Study|Withdrawal by Subject|0
5993260|NCT02983799|9586708|FG002|Overall Study|Withdrawal by Subject|3
5993261|NCT02983799|9586709|FG003|Overall Study|Withdrawal by Subject|4
5993262|NCT02983799|9586710|FG004|Overall Study|Withdrawal by Subject|1
5993263|NCT02983799|9586706|FG000|Overall Study|Protocol Violation|0
5993264|NCT02983799|9586707|FG001|Overall Study|Protocol Violation|1
5993180|NCT04317690|9586471|FG000|Overall Study|did not have complete information for primary outcome|0
5993181|NCT04317690|9586472|FG001|Overall Study|did not have complete information for primary outcome|4
5993182|NCT04317690|9586473|FG002|Overall Study|did not have complete information for primary outcome|0
5993183|NCT04317690|9586474|FG003|Overall Study|did not have complete information for primary outcome|2
5993184|NCT04317690|9586475|FG004|Overall Study|did not have complete information for primary outcome|0
5993265|NCT02983799|9586708|FG002|Overall Study|Protocol Violation|0
5993266|NCT02983799|9586709|FG003|Overall Study|Protocol Violation|0
5993267|NCT02983799|9586710|FG004|Overall Study|Protocol Violation|1
5993268|NCT02983799|9586706|FG000|Overall Study|Lost to Follow-up|1
5993269|NCT02983799|9586707|FG001|Overall Study|Lost to Follow-up|0
5993270|NCT02983799|9586708|FG002|Overall Study|Lost to Follow-up|1
5993271|NCT02983799|9586709|FG003|Overall Study|Lost to Follow-up|0
5993272|NCT02983799|9586710|FG004|Overall Study|Lost to Follow-up|0
6069952|NCT00547248|9672753|FG000|Overall Study|Migrated/moved from study area|0
6069953|NCT00547248|9672754|FG001|Overall Study|Migrated/moved from study area|0
5993273|NCT02971683|9586728|FG000|Overall Study|Other reasons|0
5993274|NCT02971683|9586729|FG001|Overall Study|Other reasons|1
5993275|NCT02971683|9586728|FG000|Overall Study|Poor/Non-Compliance|0
5993276|NCT02971683|9586729|FG001|Overall Study|Poor/Non-Compliance|1
5993277|NCT02971683|9586728|FG000|Overall Study|Lost to Follow-up|1
5993278|NCT02971683|9586729|FG001|Overall Study|Lost to Follow-up|0
5993279|NCT02971683|9586728|FG000|Overall Study|Participant withdrew consent|1
5993280|NCT02971683|9586729|FG001|Overall Study|Participant withdrew consent|1
5993281|NCT02971683|9586728|FG000|Overall Study|Participant request to discontinue study treatment|1
5993282|NCT02971683|9586729|FG001|Overall Study|Participant request to discontinue study treatment|1
5993283|NCT02971683|9586728|FG000|Overall Study|Adverse Event|1
5993284|NCT02971683|9586729|FG001|Overall Study|Adverse Event|2
5993285|NCT02971683|9586728|FG000|Overall Study|Lack of Efficacy|2
5993286|NCT02971683|9586729|FG001|Overall Study|Lack of Efficacy|2
5993287|NCT02631577|9586741|FG000|Overall Study|Death|1
5993288|NCT02631577|9586742|FG001|Overall Study|Death|7
5993289|NCT02631577|9586741|FG000|Overall Study|Withdrawal by Subject|0
5993290|NCT02631577|9586742|FG001|Overall Study|Withdrawal by Subject|3
5993291|NCT02300233|9586769|FG000|Overall Study|Adverse Event or Serious Adverse Event|3
5993292|NCT02300233|9586770|FG001|Overall Study|Adverse Event or Serious Adverse Event|1
5993293|NCT02300233|9586771|FG002|Overall Study|Adverse Event or Serious Adverse Event|14
5993294|NCT02300233|9586769|FG000|Overall Study|Withdrawal by Subject|1
5993295|NCT02300233|9586770|FG001|Overall Study|Withdrawal by Subject|0
5993296|NCT02300233|9586771|FG002|Overall Study|Withdrawal by Subject|3
5993297|NCT02300233|9586769|FG000|Overall Study|Investigator Judgement|0
5993298|NCT02300233|9586770|FG001|Overall Study|Investigator Judgement|0
5993299|NCT02300233|9586771|FG002|Overall Study|Investigator Judgement|1
5993300|NCT02300233|9586769|FG000|Overall Study|Reason Not Specified|0
5993301|NCT02300233|9586770|FG001|Overall Study|Reason Not Specified|0
5993302|NCT02300233|9586771|FG002|Overall Study|Reason Not Specified|5
5993303|NCT02211209|9586782|FG000|Overall Study|Investigator judgment|0
5993304|NCT02211209|9586783|FG001|Overall Study|Investigator judgment|1
5993305|NCT02211209|9586782|FG000|Overall Study|Voluntary withdrawal|1
5993306|NCT02211209|9586783|FG001|Overall Study|Voluntary withdrawal|4
5993307|NCT02211209|9586782|FG000|Overall Study|Adverse Event or Serious Adverse Event|0
5993308|NCT02211209|9586783|FG001|Overall Study|Adverse Event or Serious Adverse Event|9
5993309|NCT02211209|9586782|FG000|Overall Study|Reason Not Specified|1
5993310|NCT02211209|9586783|FG001|Overall Study|Reason Not Specified|0
5993311|NCT02125461|9586791|FG000|Overall Study|Withdrawal by Subject|30
5993312|NCT02125461|9586792|FG001|Overall Study|Withdrawal by Subject|16
5993313|NCT02125461|9586791|FG000|Overall Study|Lost to Follow-up|8
5993314|NCT02125461|9586792|FG001|Overall Study|Lost to Follow-up|3
5993315|NCT02125461|9586791|FG000|Overall Study|Death|260
5993316|NCT02125461|9586792|FG001|Overall Study|Death|149
5993317|NCT02125461|9586791|FG000|Overall Study|Missing Termination Reason|0
5993318|NCT02125461|9586792|FG001|Overall Study|Missing Termination Reason|1
5993319|NCT02000115|9586801|FG000|Overall Study|Death|56
5993320|NCT02000115|9586802|FG001|Overall Study|Death|45
5993321|NCT02000115|9586803|FG002|Overall Study|Death|0
5993322|NCT02000115|9586804|FG003|Overall Study|Death|0
5993323|NCT02000115|9586801|FG000|Overall Study|Missed Visit|6
5993324|NCT02000115|9586802|FG001|Overall Study|Missed Visit|8
5993325|NCT02000115|9586803|FG002|Overall Study|Missed Visit|1
5993326|NCT02000115|9586804|FG003|Overall Study|Missed Visit|0
5993327|NCT02000115|9586801|FG000|Overall Study|Protocol Violation|2
5993328|NCT02000115|9586802|FG001|Overall Study|Protocol Violation|1
5993329|NCT02000115|9586803|FG002|Overall Study|Protocol Violation|0
5993330|NCT02000115|9586804|FG003|Overall Study|Protocol Violation|0
5993331|NCT02000115|9586801|FG000|Overall Study|Physician Decision|2
5993332|NCT02000115|9586802|FG001|Overall Study|Physician Decision|0
5993333|NCT02000115|9586803|FG002|Overall Study|Physician Decision|0
5993334|NCT02000115|9586804|FG003|Overall Study|Physician Decision|0
5993335|NCT02000115|9586801|FG000|Overall Study|Withdrawal by Subject|11
5993336|NCT02000115|9586802|FG001|Overall Study|Withdrawal by Subject|11
6069954|NCT00547248|9672755|FG002|Overall Study|Migrated/moved from study area|2
5993337|NCT02000115|9586803|FG002|Overall Study|Withdrawal by Subject|0
5993338|NCT02000115|9586804|FG003|Overall Study|Withdrawal by Subject|0
5993339|NCT02000115|9586801|FG000|Overall Study|Lost to Follow-up|0
5993340|NCT02000115|9586802|FG001|Overall Study|Lost to Follow-up|1
5993341|NCT02000115|9586803|FG002|Overall Study|Lost to Follow-up|0
5993342|NCT02000115|9586804|FG003|Overall Study|Lost to Follow-up|0
5993343|NCT02000115|9586801|FG000|Overall Study|Non-compliance|2
5993344|NCT02000115|9586802|FG001|Overall Study|Non-compliance|1
5993345|NCT02000115|9586803|FG002|Overall Study|Non-compliance|0
5993346|NCT02000115|9586804|FG003|Overall Study|Non-compliance|0
5993347|NCT02000115|9586801|FG000|Overall Study|Withdrawn on day of randomization|0
5993348|NCT02000115|9586802|FG001|Overall Study|Withdrawn on day of randomization|1
5993349|NCT02000115|9586803|FG002|Overall Study|Withdrawn on day of randomization|0
5993350|NCT02000115|9586804|FG003|Overall Study|Withdrawn on day of randomization|0
5993351|NCT02000115|9586801|FG000|Overall Study|Still on Study|0
5993352|NCT02000115|9586802|FG001|Overall Study|Still on Study|0
5993353|NCT02000115|9586803|FG002|Overall Study|Still on Study|0
5993354|NCT02000115|9586804|FG003|Overall Study|Still on Study|53
5993355|NCT01695317|9586828|FG000|Period 1 in the Cross-over Design|Withdrawal by Subject|2
5993356|NCT01695317|9586829|FG001|Period 1 in the Cross-over Design|Withdrawal by Subject|1
5993357|NCT01695317|9586828|FG000|Cross-over to Period 2|Withdrawal by Subject|4
5993358|NCT01695317|9586829|FG001|Cross-over to Period 2|Withdrawal by Subject|34
5993359|NCT01127451|9586860|FG000|Overall Study|Other|2
5993360|NCT01127451|9586861|FG001|Overall Study|Other|1
5993361|NCT01127451|9586860|FG000|Overall Study|Completed 1 Year Follow-up after last dose of study drug|14
5993362|NCT01127451|9586861|FG001|Overall Study|Completed 1 Year Follow-up after last dose of study drug|12
6069955|NCT00547248|9672756|FG003|Overall Study|Migrated/moved from study area|0
5993363|NCT01127451|9586860|FG000|Overall Study|Death|22
5993364|NCT01127451|9586861|FG001|Overall Study|Death|17
5993365|NCT01127451|9586860|FG000|Overall Study|Lost to Follow-up|3
5993366|NCT01127451|9586861|FG001|Overall Study|Lost to Follow-up|0
5993367|NCT01127451|9586860|FG000|Overall Study|Administrative Reason by Sponsor|2
5993368|NCT01127451|9586861|FG001|Overall Study|Administrative Reason by Sponsor|2
6046212|NCT00405587|9645390|FG000|Overall Study|Withdrawal by Subject|0
6046213|NCT00405587|9645391|FG001|Overall Study|Withdrawal by Subject|0
6046214|NCT00405587|9645392|FG002|Overall Study|Withdrawal by Subject|0
6046215|NCT00405587|9645393|FG003|Overall Study|Withdrawal by Subject|2
6046216|NCT00405587|9645390|FG000|Overall Study|Participant not dosed|0
6046217|NCT00405587|9645391|FG001|Overall Study|Participant not dosed|1
6046218|NCT00405587|9645392|FG002|Overall Study|Participant not dosed|0
6046219|NCT00405587|9645393|FG003|Overall Study|Participant not dosed|0
6046220|NCT00405639|9645431|FG000|Overall Study|Withdrawal by Subject|1
6046221|NCT00405639|9645432|FG001|Overall Study|Withdrawal by Subject|0
6046222|NCT00405639|9645431|FG000|Overall Study|Adverse Event|1
6046223|NCT00405639|9645432|FG001|Overall Study|Adverse Event|0
6046224|NCT00405639|9645431|FG000|Overall Study|Seizure prior to receiving BNP|1
6046225|NCT00405639|9645432|FG001|Overall Study|Seizure prior to receiving BNP|0
6046226|NCT00405652|9645438|FG000|Overall Study|Adverse Event|4
6046227|NCT00405756|9645455|FG000|Double-blind Treatment|Ongoing in Double-blind Treatment|45
6046228|NCT00405756|9645456|FG001|Double-blind Treatment|Ongoing in Double-blind Treatment|24
6069956|NCT00547248|9672753|FG000|Overall Study|Withdrawal by Subject|0
6069957|NCT00547248|9672754|FG001|Overall Study|Withdrawal by Subject|0
6069958|NCT00547248|9672755|FG002|Overall Study|Withdrawal by Subject|7
6069959|NCT00547248|9672756|FG003|Overall Study|Withdrawal by Subject|1
6069960|NCT00547365|9672769|FG000|Overall Study|Physician Decision|1
6046229|NCT00405756|9645457|FG002|Double-blind Treatment|Ongoing in Double-blind Treatment|18
6046230|NCT00405756|9645455|FG000|Double-blind Treatment|Adverse Event|31
6046231|NCT00405756|9645456|FG001|Double-blind Treatment|Adverse Event|27
6046232|NCT00405756|9645457|FG002|Double-blind Treatment|Adverse Event|12
6046233|NCT00405756|9645455|FG000|Double-blind Treatment|Disease Progression|47
6046234|NCT00405756|9645456|FG001|Double-blind Treatment|Disease Progression|81
6046235|NCT00405756|9645457|FG002|Double-blind Treatment|Disease Progression|102
6046236|NCT00405756|9645455|FG000|Double-blind Treatment|Lack of Efficacy|1
6046237|NCT00405756|9645456|FG001|Double-blind Treatment|Lack of Efficacy|4
6046238|NCT00405756|9645457|FG002|Double-blind Treatment|Lack of Efficacy|2
6046239|NCT00405756|9645455|FG000|Double-blind Treatment|Withdrawal by Subject|15
6046240|NCT00405756|9645456|FG001|Double-blind Treatment|Withdrawal by Subject|9
6046241|NCT00405756|9645457|FG002|Double-blind Treatment|Withdrawal by Subject|10
6046242|NCT00405756|9645455|FG000|Double-blind Treatment|Lost to Follow-up|1
6046243|NCT00405756|9645456|FG001|Double-blind Treatment|Lost to Follow-up|0
6046244|NCT00405756|9645457|FG002|Double-blind Treatment|Lost to Follow-up|0
6046245|NCT00405756|9645455|FG000|Double-blind Treatment|Death|4
6046246|NCT00405756|9645456|FG001|Double-blind Treatment|Death|4
6046247|NCT00405756|9645457|FG002|Double-blind Treatment|Death|4
6046248|NCT00405756|9645455|FG000|Double-blind Treatment|Protocol Violation|1
6046249|NCT00405756|9645456|FG001|Double-blind Treatment|Protocol Violation|0
6046250|NCT00405756|9645457|FG002|Double-blind Treatment|Protocol Violation|2
6046251|NCT00405756|9645455|FG000|Double-blind Treatment|Other|7
6069961|NCT00547365|9672769|FG000|Overall Study|Lost to Follow-up|1
6069962|NCT00547365|9672769|FG000|Overall Study|Protocol Violation|2
5993369|NCT04559698|9586893|FG000|Overall Study|Lost to Follow-up|14
5993370|NCT04559698|9586894|FG001|Overall Study|Lost to Follow-up|15
5993371|NCT04559698|9586893|FG000|Overall Study|Withdrawal by Subject|0
5993372|NCT04559698|9586894|FG001|Overall Study|Withdrawal by Subject|1
5993373|NCT04492475|9586902|FG000|Overall Study|Enrolled but not treated|8
5993374|NCT04492475|9586903|FG001|Overall Study|Enrolled but not treated|8
5993375|NCT04492475|9586902|FG000|Overall Study|Withdrawal by Subject|4
5993376|NCT04492475|9586903|FG001|Overall Study|Withdrawal by Subject|0
5993377|NCT04492475|9586902|FG000|Overall Study|Became ineligible after enrollment|2
5993378|NCT04492475|9586903|FG001|Overall Study|Became ineligible after enrollment|0
5993379|NCT04401579|9586918|FG000|Overall Study|Death|23
5993380|NCT04401579|9586919|FG001|Overall Study|Death|36
5993381|NCT04401579|9586918|FG000|Overall Study|Lost to Follow-up|40
5993382|NCT04401579|9586919|FG001|Overall Study|Lost to Follow-up|41
5993383|NCT04401579|9586918|FG000|Overall Study|Withdrawal by Subject|8
5993384|NCT04401579|9586919|FG001|Overall Study|Withdrawal by Subject|16
5993385|NCT04401579|9586918|FG000|Overall Study|Physician Decision|1
5993386|NCT04401579|9586919|FG001|Overall Study|Physician Decision|2
5993387|NCT04401579|9586918|FG000|Overall Study|Became ineligible after enrollment|1
5993388|NCT04401579|9586919|FG001|Overall Study|Became ineligible after enrollment|1
5993389|NCT04401579|9586918|FG000|Overall Study|Enrolled but treatment not administered|7
5993390|NCT04401579|9586919|FG001|Overall Study|Enrolled but treatment not administered|9
5993391|NCT04401579|9586918|FG000|Overall Study|Adverse Event|2
5993392|NCT04401579|9586919|FG001|Overall Study|Adverse Event|1
5993393|NCT04401579|9586918|FG000|Overall Study|Scheduling error|1
5993394|NCT04401579|9586919|FG001|Overall Study|Scheduling error|2
5993395|NCT04401579|9586918|FG000|Overall Study|Transferred to another hospital|1
5993396|NCT04401579|9586919|FG001|Overall Study|Transferred to another hospital|2
5993397|NCT04321460|9586927|FG000|Overall Study|Participants who had no defecation or no data about it|1
5993398|NCT04321460|9586928|FG001|Overall Study|Participants who had no defecation or no data about it|1
5993399|NCT04280705|9586936|FG000|Overall Study|Enrolled but not treated|4
5993400|NCT04280705|9586937|FG001|Overall Study|Enrolled but not treated|10
5993401|NCT04280705|9586936|FG000|Overall Study|Physician Decision|1
5993402|NCT04280705|9586937|FG001|Overall Study|Physician Decision|0
5993403|NCT04280705|9586936|FG000|Overall Study|Withdrawal by Subject|7
5993404|NCT04280705|9586937|FG001|Overall Study|Withdrawal by Subject|9
5993405|NCT04280705|9586936|FG000|Overall Study|Adverse Event|0
5993406|NCT04280705|9586937|FG001|Overall Study|Adverse Event|4
5993407|NCT04280705|9586936|FG000|Overall Study|Transferred to another hospital|1
5993408|NCT04280705|9586937|FG001|Overall Study|Transferred to another hospital|1
5993409|NCT04208750|9586945|FG000|Overall Study|Lost to Follow-up|16
5993410|NCT04208750|9586946|FG001|Overall Study|Lost to Follow-up|15
5993411|NCT03713281|9586952|FG000|Overall Study|Lens handling difficuluties|2
5993412|NCT03713281|9586952|FG000|Overall Study|Subject was not dispensed enough lenses|1
5993413|NCT03608254|9586956|FG000|Overall Study|Blood sampling was not completed for 2 participants.|2
5993414|NCT03608254|9586956|FG000|Overall Study|One participant chose not to consume the entire 12-ounce dose of watermelon juice.|1
5993415|NCT03512275|9586962|FG000|Overall Study|Withdrawal by Subject|1
5993416|NCT03512275|9586963|FG001|Overall Study|Withdrawal by Subject|3
5993417|NCT03512275|9586962|FG000|Overall Study|Physician Decision|0
5993418|NCT03512275|9586963|FG001|Overall Study|Physician Decision|1
5993419|NCT03512275|9586962|FG000|Overall Study|Lost to Follow-up|0
5993420|NCT03512275|9586963|FG001|Overall Study|Lost to Follow-up|3
5993421|NCT03512275|9586962|FG000|Overall Study|Other|1
5993422|NCT03512275|9586963|FG001|Overall Study|Other|0
5993423|NCT03414983|9586971|FG000|Pre-Treatment|Other reasons|1
5993424|NCT03414983|9586972|FG001|Pre-Treatment|Other reasons|0
5993425|NCT03414983|9586971|FG000|Pre-Treatment|Participant no longer meets study criteria|2
5993426|NCT03414983|9586972|FG001|Pre-Treatment|Participant no longer meets study criteria|3
5993427|NCT03414983|9586971|FG000|Pre-Treatment|Participant withdrew consent|1
5993428|NCT03414983|9586972|FG001|Pre-Treatment|Participant withdrew consent|3
5993429|NCT03414983|9586971|FG000|Treatment|Participant withdrew consent|4
5993430|NCT03414983|9586972|FG001|Treatment|Participant withdrew consent|3
5993431|NCT03414983|9586971|FG000|Treatment|Participant request to discontinue study treatment|8
5993432|NCT03414983|9586972|FG001|Treatment|Participant request to discontinue study treatment|10
5993433|NCT03414983|9586971|FG000|Treatment|Adverse Event Unrelated to Study Drug|5
5993434|NCT03414983|9586972|FG001|Treatment|Adverse Event Unrelated to Study Drug|2
5993435|NCT03414983|9586971|FG000|Treatment|Death|0
5993436|NCT03414983|9586972|FG001|Treatment|Death|2
5993437|NCT03414983|9586971|FG000|Treatment|Study Drug Toxicity|11
5993438|NCT03414983|9586972|FG001|Treatment|Study Drug Toxicity|4
5993439|NCT03414983|9586971|FG000|Treatment|Disease Progression|72
5993440|NCT03414983|9586972|FG001|Treatment|Disease Progression|27
5993441|NCT03414983|9586971|FG000|Treatment|Not reported|1
5993442|NCT03414983|9586972|FG001|Treatment|Not reported|0
5993443|NCT03414983|9586971|FG000|Treatment|Other reasons|3
5993444|NCT03414983|9586972|FG001|Treatment|Other reasons|2
5993445|NCT03414983|9586971|FG000|Treatment|Completed treatment as per protocol|8
5993446|NCT03414983|9586972|FG001|Treatment|Completed treatment as per protocol|0
5993447|NCT03414983|9586971|FG000|Treatment|Poor/non-compliance|2
5993448|NCT03414983|9586972|FG001|Treatment|Poor/non-compliance|0
5993449|NCT03414983|9586971|FG000|Treatment|Maximum clinical benefit|5
5993450|NCT03414983|9586972|FG001|Treatment|Maximum clinical benefit|9
6069963|NCT00547365|9672769|FG000|Overall Study|death (not related to study)|4
6069964|NCT00547378|9672777|FG000|Randomized Cohort|Withdrawal by Subject|7
6069965|NCT00547378|9672778|FG001|Randomized Cohort|Withdrawal by Subject|5
6069966|NCT00547378|9672779|FG002|Randomized Cohort|Withdrawal by Subject|0
6069967|NCT00547378|9672777|FG000|Randomized Cohort|Death|0
6069968|NCT00547378|9672778|FG001|Randomized Cohort|Death|1
6069969|NCT00547378|9672779|FG002|Randomized Cohort|Death|0
6069970|NCT00547378|9672777|FG000|Randomized Cohort|Lost to Follow-up|1
6069971|NCT00547378|9672778|FG001|Randomized Cohort|Lost to Follow-up|0
6069972|NCT00547378|9672779|FG002|Randomized Cohort|Lost to Follow-up|0
6069973|NCT00547378|9672777|FG000|Randomized Cohort|Adverse Event|1
6069974|NCT00547378|9672778|FG001|Randomized Cohort|Adverse Event|0
5993451|NCT03414983|9586971|FG000|Treatment|Lost to Follow-up|0
5993452|NCT03414983|9586972|FG001|Treatment|Lost to Follow-up|1
5993453|NCT03383692|9586980|FG000|Overall Study|Progressive disease as per RECIST|3
5993454|NCT03383692|9586981|FG001|Overall Study|Progressive disease as per RECIST|3
5993455|NCT03383692|9586980|FG000|Overall Study|Clinical progression|0
5993456|NCT03383692|9586981|FG001|Overall Study|Clinical progression|1
5993457|NCT03383692|9586980|FG000|Overall Study|Adverse Event|3
5993458|NCT03383692|9586981|FG001|Overall Study|Adverse Event|0
5993459|NCT03371251|9586995|FG000|Overall Study|Withdrawal by Subject|1
5993460|NCT03371251|9586996|FG001|Overall Study|Withdrawal by Subject|0
5993461|NCT03371251|9586997|FG002|Overall Study|Withdrawal by Subject|1
5993462|NCT03371251|9586998|FG003|Overall Study|Withdrawal by Subject|0
5993463|NCT03371251|9586999|FG004|Overall Study|Withdrawal by Subject|2
5993464|NCT03371251|9587000|FG005|Overall Study|Withdrawal by Subject|2
5993465|NCT03371251|9586995|FG000|Overall Study|Phase 1b: Pregnancy, Phase 2: fear of COVID-19 or local restrictions|1
5993466|NCT03371251|9586996|FG001|Overall Study|Phase 1b: Pregnancy, Phase 2: fear of COVID-19 or local restrictions|0
5993467|NCT03371251|9586997|FG002|Overall Study|Phase 1b: Pregnancy, Phase 2: fear of COVID-19 or local restrictions|0
5993468|NCT03371251|9586998|FG003|Overall Study|Phase 1b: Pregnancy, Phase 2: fear of COVID-19 or local restrictions|0
5993469|NCT03371251|9586999|FG004|Overall Study|Phase 1b: Pregnancy, Phase 2: fear of COVID-19 or local restrictions|2
5993470|NCT03371251|9587000|FG005|Overall Study|Phase 1b: Pregnancy, Phase 2: fear of COVID-19 or local restrictions|3
5993471|NCT03371251|9586995|FG000|Overall Study|Adverse Event|0
5993472|NCT03371251|9586996|FG001|Overall Study|Adverse Event|0
5993473|NCT03371251|9586997|FG002|Overall Study|Adverse Event|0
5993474|NCT03371251|9586998|FG003|Overall Study|Adverse Event|0
6069975|NCT00547378|9672779|FG002|Randomized Cohort|Adverse Event|0
6069976|NCT00547378|9672777|FG000|Randomized Cohort|Other reasons|2
6069977|NCT00547378|9672778|FG001|Randomized Cohort|Other reasons|0
6069978|NCT00547378|9672779|FG002|Randomized Cohort|Other reasons|0
6069979|NCT00547378|9672777|FG000|All Implanted Cohort|Withdrawal by Subject|5
6069980|NCT00547378|9672778|FG001|All Implanted Cohort|Withdrawal by Subject|4
6069981|NCT00547378|9672779|FG002|All Implanted Cohort|Withdrawal by Subject|27
6069982|NCT00547378|9672777|FG000|All Implanted Cohort|Adverse Event|4
6069983|NCT00547378|9672778|FG001|All Implanted Cohort|Adverse Event|10
6069984|NCT00547378|9672779|FG002|All Implanted Cohort|Adverse Event|17
6069985|NCT00547378|9672777|FG000|All Implanted Cohort|Lost to Follow-up|0
6069986|NCT00547378|9672778|FG001|All Implanted Cohort|Lost to Follow-up|1
6069987|NCT00547378|9672779|FG002|All Implanted Cohort|Lost to Follow-up|14
6069988|NCT00547378|9672777|FG000|All Implanted Cohort|Death|3
6069989|NCT00547378|9672778|FG001|All Implanted Cohort|Death|1
6069990|NCT00547378|9672779|FG002|All Implanted Cohort|Death|4
6069991|NCT00547378|9672777|FG000|All Implanted Cohort|Physician Decision|0
6069992|NCT00547378|9672778|FG001|All Implanted Cohort|Physician Decision|2
6069993|NCT00547378|9672779|FG002|All Implanted Cohort|Physician Decision|6
6069994|NCT00547378|9672777|FG000|All Implanted Cohort|Site closure|2
6069995|NCT00547378|9672778|FG001|All Implanted Cohort|Site closure|0
6069996|NCT00547378|9672779|FG002|All Implanted Cohort|Site closure|1
6069997|NCT00547378|9672777|FG000|All Implanted Cohort|Other reasons|1
6069998|NCT00547378|9672778|FG001|All Implanted Cohort|Other reasons|0
6069999|NCT00547378|9672779|FG002|All Implanted Cohort|Other reasons|1
6070000|NCT00547521|9672789|FG000|Short Term Study (4 Months)|Adverse Event|1
6070001|NCT00547521|9672790|FG001|Short Term Study (4 Months)|Adverse Event|0
6070002|NCT00547521|9672789|FG000|Short Term Study (4 Months)|Lack of Efficacy|0
6070003|NCT00547521|9672790|FG001|Short Term Study (4 Months)|Lack of Efficacy|2
6070004|NCT00547521|9672789|FG000|Short Term Study (4 Months)|Withdrawal of consent|0
6070005|NCT00547521|9672790|FG001|Short Term Study (4 Months)|Withdrawal of consent|1
6070006|NCT00547521|9672789|FG000|Short Term Study (4 Months)|primary endpoint evaluation not complete|0
6070007|NCT00547521|9672790|FG001|Short Term Study (4 Months)|primary endpoint evaluation not complete|1
6070008|NCT00547521|9672789|FG000|Long Term Extension (LTE) Study|Lack of Efficacy|0
6070009|NCT00547521|9672790|FG001|Long Term Extension (LTE) Study|Lack of Efficacy|14
6070010|NCT00547521|9672789|FG000|Long Term Extension (LTE) Study|Adverse Event|0
5993475|NCT03371251|9586999|FG004|Overall Study|Adverse Event|1
6070011|NCT00547521|9672790|FG001|Long Term Extension (LTE) Study|Adverse Event|9
6070012|NCT00547521|9672789|FG000|Long Term Extension (LTE) Study|Lost to Follow-up|0
6070013|NCT00547521|9672790|FG001|Long Term Extension (LTE) Study|Lost to Follow-up|3
6070014|NCT00547521|9672789|FG000|Long Term Extension (LTE) Study|Withdrawal by Subject|0
5993476|NCT03371251|9587000|FG005|Overall Study|Adverse Event|0
5993477|NCT03371251|9586995|FG000|Overall Study|Decision by Sponsor|0
5993478|NCT03371251|9586996|FG001|Overall Study|Decision by Sponsor|0
5993479|NCT03371251|9586997|FG002|Overall Study|Decision by Sponsor|0
5993480|NCT03371251|9586998|FG003|Overall Study|Decision by Sponsor|0
5993481|NCT03371251|9586999|FG004|Overall Study|Decision by Sponsor|2
5993482|NCT03371251|9587000|FG005|Overall Study|Decision by Sponsor|0
5993483|NCT03307785|9587040|FG000|Part A: Up to 28.5 Months|Disease progression|2
5993484|NCT03307785|9587041|FG001|Part A: Up to 28.5 Months|Disease progression|0
5993485|NCT03307785|9587042|FG002|Part A: Up to 28.5 Months|Disease progression|0
5993486|NCT03307785|9587043|FG003|Part A: Up to 28.5 Months|Disease progression|0
5993487|NCT03307785|9587044|FG004|Part A: Up to 28.5 Months|Disease progression|0
5993488|NCT03307785|9587045|FG005|Part A: Up to 28.5 Months|Disease progression|0
5993489|NCT03307785|9587046|FG006|Part A: Up to 28.5 Months|Disease progression|0
5993490|NCT03307785|9587047|FG007|Part A: Up to 28.5 Months|Disease progression|0
5993491|NCT03307785|9587048|FG008|Part A: Up to 28.5 Months|Disease progression|0
5993492|NCT03307785|9587049|FG009|Part A: Up to 28.5 Months|Disease progression|0
5993493|NCT03307785|9587050|FG010|Part A: Up to 28.5 Months|Disease progression|0
5993494|NCT03307785|9587040|FG000|Part A: Up to 28.5 Months|Withdrawal by Subject|7
5993495|NCT03307785|9587041|FG001|Part A: Up to 28.5 Months|Withdrawal by Subject|1
5993496|NCT03307785|9587042|FG002|Part A: Up to 28.5 Months|Withdrawal by Subject|0
5993497|NCT03307785|9587043|FG003|Part A: Up to 28.5 Months|Withdrawal by Subject|0
5993498|NCT03307785|9587044|FG004|Part A: Up to 28.5 Months|Withdrawal by Subject|0
5993499|NCT03307785|9587045|FG005|Part A: Up to 28.5 Months|Withdrawal by Subject|0
5993500|NCT03307785|9587046|FG006|Part A: Up to 28.5 Months|Withdrawal by Subject|0
5993501|NCT03307785|9587047|FG007|Part A: Up to 28.5 Months|Withdrawal by Subject|0
5993502|NCT03307785|9587048|FG008|Part A: Up to 28.5 Months|Withdrawal by Subject|0
5993503|NCT03307785|9587049|FG009|Part A: Up to 28.5 Months|Withdrawal by Subject|0
5993504|NCT03307785|9587050|FG010|Part A: Up to 28.5 Months|Withdrawal by Subject|0
5993505|NCT03307785|9587040|FG000|Part A: Up to 28.5 Months|Death|4
5993506|NCT03307785|9587041|FG001|Part A: Up to 28.5 Months|Death|4
5993507|NCT03307785|9587042|FG002|Part A: Up to 28.5 Months|Death|0
5993508|NCT03307785|9587043|FG003|Part A: Up to 28.5 Months|Death|0
5993509|NCT03307785|9587044|FG004|Part A: Up to 28.5 Months|Death|0
5993510|NCT03307785|9587045|FG005|Part A: Up to 28.5 Months|Death|0
5993511|NCT03307785|9587046|FG006|Part A: Up to 28.5 Months|Death|0
5993512|NCT03307785|9587047|FG007|Part A: Up to 28.5 Months|Death|0
5993513|NCT03307785|9587048|FG008|Part A: Up to 28.5 Months|Death|0
5993514|NCT03307785|9587049|FG009|Part A: Up to 28.5 Months|Death|0
5993515|NCT03307785|9587050|FG010|Part A: Up to 28.5 Months|Death|0
5993516|NCT03307785|9587040|FG000|Part A: Up to 28.5 Months|Physician Decision|3
5993517|NCT03307785|9587041|FG001|Part A: Up to 28.5 Months|Physician Decision|1
5993518|NCT03307785|9587042|FG002|Part A: Up to 28.5 Months|Physician Decision|0
5993519|NCT03307785|9587043|FG003|Part A: Up to 28.5 Months|Physician Decision|0
5993520|NCT03307785|9587044|FG004|Part A: Up to 28.5 Months|Physician Decision|0
5993521|NCT03307785|9587045|FG005|Part A: Up to 28.5 Months|Physician Decision|0
5993522|NCT03307785|9587046|FG006|Part A: Up to 28.5 Months|Physician Decision|0
5993523|NCT03307785|9587047|FG007|Part A: Up to 28.5 Months|Physician Decision|0
5993524|NCT03307785|9587048|FG008|Part A: Up to 28.5 Months|Physician Decision|0
5993525|NCT03307785|9587049|FG009|Part A: Up to 28.5 Months|Physician Decision|0
5993526|NCT03307785|9587050|FG010|Part A: Up to 28.5 Months|Physician Decision|0
5993527|NCT03307785|9587040|FG000|Part B: Up to 28.5 Months|Disease progression|0
5993528|NCT03307785|9587041|FG001|Part B: Up to 28.5 Months|Disease progression|0
5993529|NCT03307785|9587042|FG002|Part B: Up to 28.5 Months|Disease progression|1
5993530|NCT03307785|9587043|FG003|Part B: Up to 28.5 Months|Disease progression|0
5993531|NCT03307785|9587044|FG004|Part B: Up to 28.5 Months|Disease progression|0
5993532|NCT03307785|9587045|FG005|Part B: Up to 28.5 Months|Disease progression|0
5993533|NCT03307785|9587046|FG006|Part B: Up to 28.5 Months|Disease progression|0
5993534|NCT03307785|9587047|FG007|Part B: Up to 28.5 Months|Disease progression|0
5993535|NCT03307785|9587048|FG008|Part B: Up to 28.5 Months|Disease progression|0
5993536|NCT03307785|9587049|FG009|Part B: Up to 28.5 Months|Disease progression|0
5993537|NCT03307785|9587050|FG010|Part B: Up to 28.5 Months|Disease progression|0
5993538|NCT03307785|9587040|FG000|Part B: Up to 28.5 Months|Physician Decision|0
5993539|NCT03307785|9587041|FG001|Part B: Up to 28.5 Months|Physician Decision|0
5993540|NCT03307785|9587042|FG002|Part B: Up to 28.5 Months|Physician Decision|1
5993541|NCT03307785|9587043|FG003|Part B: Up to 28.5 Months|Physician Decision|0
5993542|NCT03307785|9587044|FG004|Part B: Up to 28.5 Months|Physician Decision|0
5993543|NCT03307785|9587045|FG005|Part B: Up to 28.5 Months|Physician Decision|0
5993544|NCT03307785|9587046|FG006|Part B: Up to 28.5 Months|Physician Decision|0
5993545|NCT03307785|9587047|FG007|Part B: Up to 28.5 Months|Physician Decision|0
5993546|NCT03307785|9587048|FG008|Part B: Up to 28.5 Months|Physician Decision|0
5993547|NCT03307785|9587049|FG009|Part B: Up to 28.5 Months|Physician Decision|0
5993548|NCT03307785|9587050|FG010|Part B: Up to 28.5 Months|Physician Decision|0
5993549|NCT03307785|9587040|FG000|Part B: Up to 28.5 Months|Death|0
5993550|NCT03307785|9587041|FG001|Part B: Up to 28.5 Months|Death|0
5993551|NCT03307785|9587042|FG002|Part B: Up to 28.5 Months|Death|7
5993552|NCT03307785|9587043|FG003|Part B: Up to 28.5 Months|Death|0
5993553|NCT03307785|9587044|FG004|Part B: Up to 28.5 Months|Death|0
5993554|NCT03307785|9587045|FG005|Part B: Up to 28.5 Months|Death|0
5993555|NCT03307785|9587046|FG006|Part B: Up to 28.5 Months|Death|0
5993556|NCT03307785|9587047|FG007|Part B: Up to 28.5 Months|Death|0
5993557|NCT03307785|9587048|FG008|Part B: Up to 28.5 Months|Death|0
5993558|NCT03307785|9587049|FG009|Part B: Up to 28.5 Months|Death|0
5993559|NCT03307785|9587050|FG010|Part B: Up to 28.5 Months|Death|0
5993560|NCT03307785|9587040|FG000|Part B: Up to 28.5 Months|Withdrawal by Subject|0
5993561|NCT03307785|9587041|FG001|Part B: Up to 28.5 Months|Withdrawal by Subject|0
5993562|NCT03307785|9587042|FG002|Part B: Up to 28.5 Months|Withdrawal by Subject|1
5993563|NCT03307785|9587043|FG003|Part B: Up to 28.5 Months|Withdrawal by Subject|0
5993564|NCT03307785|9587044|FG004|Part B: Up to 28.5 Months|Withdrawal by Subject|0
5993565|NCT03307785|9587045|FG005|Part B: Up to 28.5 Months|Withdrawal by Subject|0
5993566|NCT03307785|9587046|FG006|Part B: Up to 28.5 Months|Withdrawal by Subject|0
5993567|NCT03307785|9587047|FG007|Part B: Up to 28.5 Months|Withdrawal by Subject|0
5993568|NCT03307785|9587048|FG008|Part B: Up to 28.5 Months|Withdrawal by Subject|0
5993569|NCT03307785|9587049|FG009|Part B: Up to 28.5 Months|Withdrawal by Subject|0
5993570|NCT03307785|9587050|FG010|Part B: Up to 28.5 Months|Withdrawal by Subject|0
5993571|NCT03307785|9587040|FG000|Part B: Up to 28.5 Months|Ongoing With Treatment in the Study|0
5993572|NCT03307785|9587041|FG001|Part B: Up to 28.5 Months|Ongoing With Treatment in the Study|0
5993573|NCT03307785|9587042|FG002|Part B: Up to 28.5 Months|Ongoing With Treatment in the Study|4
5993574|NCT03307785|9587043|FG003|Part B: Up to 28.5 Months|Ongoing With Treatment in the Study|0
5993575|NCT03307785|9587044|FG004|Part B: Up to 28.5 Months|Ongoing With Treatment in the Study|0
5993576|NCT03307785|9587045|FG005|Part B: Up to 28.5 Months|Ongoing With Treatment in the Study|0
5993577|NCT03307785|9587046|FG006|Part B: Up to 28.5 Months|Ongoing With Treatment in the Study|0
5993578|NCT03307785|9587047|FG007|Part B: Up to 28.5 Months|Ongoing With Treatment in the Study|0
5993579|NCT03307785|9587048|FG008|Part B: Up to 28.5 Months|Ongoing With Treatment in the Study|0
5993580|NCT03307785|9587049|FG009|Part B: Up to 28.5 Months|Ongoing With Treatment in the Study|0
5993581|NCT03307785|9587050|FG010|Part B: Up to 28.5 Months|Ongoing With Treatment in the Study|0
5993582|NCT03307785|9587040|FG000|Part C: Up to 22.5 Months|Disease progression|0
5993583|NCT03307785|9587041|FG001|Part C: Up to 22.5 Months|Disease progression|0
5993584|NCT03307785|9587042|FG002|Part C: Up to 22.5 Months|Disease progression|0
5993585|NCT03307785|9587043|FG003|Part C: Up to 22.5 Months|Disease progression|0
5993586|NCT03307785|9587044|FG004|Part C: Up to 22.5 Months|Disease progression|1
5993587|NCT03307785|9587045|FG005|Part C: Up to 22.5 Months|Disease progression|0
5993588|NCT03307785|9587046|FG006|Part C: Up to 22.5 Months|Disease progression|0
5993589|NCT03307785|9587047|FG007|Part C: Up to 22.5 Months|Disease progression|0
5993590|NCT03307785|9587048|FG008|Part C: Up to 22.5 Months|Disease progression|0
5993591|NCT03307785|9587049|FG009|Part C: Up to 22.5 Months|Disease progression|0
5993592|NCT03307785|9587050|FG010|Part C: Up to 22.5 Months|Disease progression|0
5993593|NCT03307785|9587040|FG000|Part C: Up to 22.5 Months|Physician Decision|0
5993594|NCT03307785|9587041|FG001|Part C: Up to 22.5 Months|Physician Decision|0
5993595|NCT03307785|9587042|FG002|Part C: Up to 22.5 Months|Physician Decision|0
5993596|NCT03307785|9587043|FG003|Part C: Up to 22.5 Months|Physician Decision|3
5993597|NCT03307785|9587044|FG004|Part C: Up to 22.5 Months|Physician Decision|1
5993598|NCT03307785|9587045|FG005|Part C: Up to 22.5 Months|Physician Decision|0
5993599|NCT03307785|9587046|FG006|Part C: Up to 22.5 Months|Physician Decision|0
5993600|NCT03307785|9587047|FG007|Part C: Up to 22.5 Months|Physician Decision|0
5993601|NCT03307785|9587048|FG008|Part C: Up to 22.5 Months|Physician Decision|0
5993602|NCT03307785|9587049|FG009|Part C: Up to 22.5 Months|Physician Decision|0
5993603|NCT03307785|9587050|FG010|Part C: Up to 22.5 Months|Physician Decision|0
5993604|NCT03307785|9587040|FG000|Part C: Up to 22.5 Months|Death|0
5993605|NCT03307785|9587041|FG001|Part C: Up to 22.5 Months|Death|0
5993606|NCT03307785|9587042|FG002|Part C: Up to 22.5 Months|Death|0
5993607|NCT03307785|9587043|FG003|Part C: Up to 22.5 Months|Death|1
5993608|NCT03307785|9587044|FG004|Part C: Up to 22.5 Months|Death|4
5993609|NCT03307785|9587045|FG005|Part C: Up to 22.5 Months|Death|0
5993610|NCT03307785|9587046|FG006|Part C: Up to 22.5 Months|Death|0
5993611|NCT03307785|9587047|FG007|Part C: Up to 22.5 Months|Death|0
5993612|NCT03307785|9587048|FG008|Part C: Up to 22.5 Months|Death|0
5993613|NCT03307785|9587049|FG009|Part C: Up to 22.5 Months|Death|0
5993614|NCT03307785|9587050|FG010|Part C: Up to 22.5 Months|Death|0
5993615|NCT03307785|9587040|FG000|Part C: Up to 22.5 Months|Withdrawal by Subject|0
5993616|NCT03307785|9587041|FG001|Part C: Up to 22.5 Months|Withdrawal by Subject|0
5993617|NCT03307785|9587042|FG002|Part C: Up to 22.5 Months|Withdrawal by Subject|0
5993618|NCT03307785|9587043|FG003|Part C: Up to 22.5 Months|Withdrawal by Subject|1
5993619|NCT03307785|9587044|FG004|Part C: Up to 22.5 Months|Withdrawal by Subject|0
5993620|NCT03307785|9587045|FG005|Part C: Up to 22.5 Months|Withdrawal by Subject|0
5993621|NCT03307785|9587046|FG006|Part C: Up to 22.5 Months|Withdrawal by Subject|0
5993622|NCT03307785|9587047|FG007|Part C: Up to 22.5 Months|Withdrawal by Subject|0
5993623|NCT03307785|9587048|FG008|Part C: Up to 22.5 Months|Withdrawal by Subject|0
5993624|NCT03307785|9587049|FG009|Part C: Up to 22.5 Months|Withdrawal by Subject|0
5993625|NCT03307785|9587050|FG010|Part C: Up to 22.5 Months|Withdrawal by Subject|0
5993626|NCT03307785|9587040|FG000|Part C: Up to 22.5 Months|Ongoing With Treatment in the Study|0
5993627|NCT03307785|9587041|FG001|Part C: Up to 22.5 Months|Ongoing With Treatment in the Study|0
5993628|NCT03307785|9587042|FG002|Part C: Up to 22.5 Months|Ongoing With Treatment in the Study|0
6070015|NCT00547521|9672790|FG001|Long Term Extension (LTE) Study|Withdrawal by Subject|2
6070016|NCT00547521|9672789|FG000|Long Term Extension (LTE) Study|Other|0
6070017|NCT00547521|9672790|FG001|Long Term Extension (LTE) Study|Other|2
6070018|NCT00547521|9672789|FG000|Long Term Extension (LTE) Study|Poor/Non-Compliance|0
6070019|NCT00547521|9672790|FG001|Long Term Extension (LTE) Study|Poor/Non-Compliance|1
6070020|NCT00547534|9672803|FG000|Overall Study|Adverse Event|7
6070021|NCT00547534|9672803|FG000|Overall Study|Disease Progression|4
6070022|NCT00547703|9672840|FG000|Overall Study|Lost to Follow-up|1
6070023|NCT00547703|9672841|FG001|Overall Study|Lost to Follow-up|0
6070024|NCT00547911|9672874|FG000|Overall Study|Adverse Event|0
6070025|NCT00547911|9672875|FG001|Overall Study|Adverse Event|0
5993629|NCT03307785|9587043|FG003|Part C: Up to 22.5 Months|Ongoing With Treatment in the Study|1
5993630|NCT03307785|9587044|FG004|Part C: Up to 22.5 Months|Ongoing With Treatment in the Study|1
5993631|NCT03307785|9587045|FG005|Part C: Up to 22.5 Months|Ongoing With Treatment in the Study|0
5993632|NCT03307785|9587046|FG006|Part C: Up to 22.5 Months|Ongoing With Treatment in the Study|0
5993633|NCT03307785|9587047|FG007|Part C: Up to 22.5 Months|Ongoing With Treatment in the Study|0
5993634|NCT03307785|9587048|FG008|Part C: Up to 22.5 Months|Ongoing With Treatment in the Study|0
5993635|NCT03307785|9587049|FG009|Part C: Up to 22.5 Months|Ongoing With Treatment in the Study|0
5993636|NCT03307785|9587050|FG010|Part C: Up to 22.5 Months|Ongoing With Treatment in the Study|0
5993637|NCT03307785|9587040|FG000|Part D: Up to 9.5 Months|Physician Decision|0
5993638|NCT03307785|9587041|FG001|Part D: Up to 9.5 Months|Physician Decision|0
5993639|NCT03307785|9587042|FG002|Part D: Up to 9.5 Months|Physician Decision|0
5993640|NCT03307785|9587043|FG003|Part D: Up to 9.5 Months|Physician Decision|0
5993641|NCT03307785|9587044|FG004|Part D: Up to 9.5 Months|Physician Decision|0
5993642|NCT03307785|9587045|FG005|Part D: Up to 9.5 Months|Physician Decision|1
5993643|NCT03307785|9587046|FG006|Part D: Up to 9.5 Months|Physician Decision|0
5993644|NCT03307785|9587047|FG007|Part D: Up to 9.5 Months|Physician Decision|0
5993645|NCT03307785|9587048|FG008|Part D: Up to 9.5 Months|Physician Decision|0
5993646|NCT03307785|9587049|FG009|Part D: Up to 9.5 Months|Physician Decision|0
5993647|NCT03307785|9587050|FG010|Part D: Up to 9.5 Months|Physician Decision|0
5993648|NCT03307785|9587040|FG000|Part D: Up to 9.5 Months|Death|0
5993649|NCT03307785|9587041|FG001|Part D: Up to 9.5 Months|Death|0
5993650|NCT03307785|9587042|FG002|Part D: Up to 9.5 Months|Death|0
5993651|NCT03307785|9587043|FG003|Part D: Up to 9.5 Months|Death|0
5993652|NCT03307785|9587044|FG004|Part D: Up to 9.5 Months|Death|0
5993653|NCT03307785|9587045|FG005|Part D: Up to 9.5 Months|Death|1
5993654|NCT03307785|9587046|FG006|Part D: Up to 9.5 Months|Death|0
5993655|NCT03307785|9587047|FG007|Part D: Up to 9.5 Months|Death|0
5993656|NCT03307785|9587048|FG008|Part D: Up to 9.5 Months|Death|0
5993657|NCT03307785|9587049|FG009|Part D: Up to 9.5 Months|Death|0
5993658|NCT03307785|9587050|FG010|Part D: Up to 9.5 Months|Death|0
5993659|NCT03307785|9587040|FG000|Part D: Up to 9.5 Months|Withdrawal by Subject|0
5993660|NCT03307785|9587041|FG001|Part D: Up to 9.5 Months|Withdrawal by Subject|0
5993661|NCT03307785|9587042|FG002|Part D: Up to 9.5 Months|Withdrawal by Subject|0
5993662|NCT03307785|9587043|FG003|Part D: Up to 9.5 Months|Withdrawal by Subject|0
5993663|NCT03307785|9587044|FG004|Part D: Up to 9.5 Months|Withdrawal by Subject|0
5993664|NCT03307785|9587045|FG005|Part D: Up to 9.5 Months|Withdrawal by Subject|1
5993665|NCT03307785|9587046|FG006|Part D: Up to 9.5 Months|Withdrawal by Subject|0
5993666|NCT03307785|9587047|FG007|Part D: Up to 9.5 Months|Withdrawal by Subject|0
5993667|NCT03307785|9587048|FG008|Part D: Up to 9.5 Months|Withdrawal by Subject|0
5993668|NCT03307785|9587049|FG009|Part D: Up to 9.5 Months|Withdrawal by Subject|0
5993669|NCT03307785|9587050|FG010|Part D: Up to 9.5 Months|Withdrawal by Subject|0
5993670|NCT03307785|9587040|FG000|Part E: Up to 4.4 Months|Death|0
5993671|NCT03307785|9587041|FG001|Part E: Up to 4.4 Months|Death|0
5993672|NCT03307785|9587042|FG002|Part E: Up to 4.4 Months|Death|0
5993673|NCT03307785|9587043|FG003|Part E: Up to 4.4 Months|Death|0
5993674|NCT03307785|9587044|FG004|Part E: Up to 4.4 Months|Death|0
5993675|NCT03307785|9587045|FG005|Part E: Up to 4.4 Months|Death|0
5993676|NCT03307785|9587046|FG006|Part E: Up to 4.4 Months|Death|1
5993677|NCT03307785|9587047|FG007|Part E: Up to 4.4 Months|Death|0
5993678|NCT03307785|9587048|FG008|Part E: Up to 4.4 Months|Death|0
5993679|NCT03307785|9587049|FG009|Part E: Up to 4.4 Months|Death|0
5993680|NCT03307785|9587050|FG010|Part E: Up to 4.4 Months|Death|0
5993681|NCT03307785|9587040|FG000|Part E: Up to 4.4 Months|Physician Decision|0
5993682|NCT03307785|9587041|FG001|Part E: Up to 4.4 Months|Physician Decision|0
5993683|NCT03307785|9587042|FG002|Part E: Up to 4.4 Months|Physician Decision|0
5993684|NCT03307785|9587043|FG003|Part E: Up to 4.4 Months|Physician Decision|0
5993685|NCT03307785|9587044|FG004|Part E: Up to 4.4 Months|Physician Decision|0
5993686|NCT03307785|9587045|FG005|Part E: Up to 4.4 Months|Physician Decision|0
5993687|NCT03307785|9587046|FG006|Part E: Up to 4.4 Months|Physician Decision|1
6070026|NCT00547911|9672876|FG002|Overall Study|Adverse Event|0
6070027|NCT00547911|9672877|FG003|Overall Study|Adverse Event|1
5993688|NCT03307785|9587047|FG007|Part E: Up to 4.4 Months|Physician Decision|0
5993689|NCT03307785|9587048|FG008|Part E: Up to 4.4 Months|Physician Decision|0
5993690|NCT03307785|9587049|FG009|Part E: Up to 4.4 Months|Physician Decision|0
5993691|NCT03307785|9587050|FG010|Part E: Up to 4.4 Months|Physician Decision|0
5993692|NCT03307785|9587040|FG000|Part F: Up to 3.5 Months|Physician Decision|0
5993693|NCT03307785|9587041|FG001|Part F: Up to 3.5 Months|Physician Decision|0
5993694|NCT03307785|9587042|FG002|Part F: Up to 3.5 Months|Physician Decision|0
5993695|NCT03307785|9587043|FG003|Part F: Up to 3.5 Months|Physician Decision|0
5993696|NCT03307785|9587044|FG004|Part F: Up to 3.5 Months|Physician Decision|0
5993697|NCT03307785|9587045|FG005|Part F: Up to 3.5 Months|Physician Decision|0
5993698|NCT03307785|9587046|FG006|Part F: Up to 3.5 Months|Physician Decision|0
5993699|NCT03307785|9587047|FG007|Part F: Up to 3.5 Months|Physician Decision|1
5993700|NCT03307785|9587048|FG008|Part F: Up to 3.5 Months|Physician Decision|0
5993701|NCT03307785|9587049|FG009|Part F: Up to 3.5 Months|Physician Decision|0
5993702|NCT03307785|9587050|FG010|Part F: Up to 3.5 Months|Physician Decision|0
6046252|NCT00405756|9645456|FG001|Double-blind Treatment|Other|4
6046253|NCT00405756|9645457|FG002|Double-blind Treatment|Other|4
6046254|NCT00405756|9645455|FG000|Open-label Extension|Ongoing in Open Label Period|7
6046255|NCT00405756|9645456|FG001|Open-label Extension|Ongoing in Open Label Period|15
6046256|NCT00405756|9645457|FG002|Open-label Extension|Ongoing in Open Label Period|25
6046257|NCT00405756|9645455|FG000|Open-label Extension|Adverse Event|1
6046258|NCT00405756|9645456|FG001|Open-label Extension|Adverse Event|3
6046259|NCT00405756|9645457|FG002|Open-label Extension|Adverse Event|7
6046260|NCT00405756|9645455|FG000|Open-label Extension|Disease Progression|8
6046261|NCT00405756|9645456|FG001|Open-label Extension|Disease Progression|23
6046262|NCT00405756|9645457|FG002|Open-label Extension|Disease Progression|26
6046263|NCT00405756|9645455|FG000|Open-label Extension|Withdrawal by Subject|2
6046264|NCT00405756|9645456|FG001|Open-label Extension|Withdrawal by Subject|3
6046265|NCT00405756|9645457|FG002|Open-label Extension|Withdrawal by Subject|3
6046266|NCT00405756|9645455|FG000|Open-label Extension|Death|1
6046267|NCT00405756|9645456|FG001|Open-label Extension|Death|2
6046268|NCT00405756|9645457|FG002|Open-label Extension|Death|4
6046269|NCT00405756|9645455|FG000|Open-label Extension|Other|0
6046270|NCT00405756|9645456|FG001|Open-label Extension|Other|1
6046271|NCT00405756|9645457|FG002|Open-label Extension|Other|7
6046272|NCT00405756|9645455|FG000|Follow-up|Ongoing in Follow-up Period|52
6046273|NCT00405756|9645456|FG001|Follow-up|Ongoing in Follow-up Period|51
6046274|NCT00405756|9645457|FG002|Follow-up|Ongoing in Follow-up Period|60
6046275|NCT00405756|9645455|FG000|Follow-up|Death|21
6046276|NCT00405756|9645456|FG001|Follow-up|Death|31
6046277|NCT00405756|9645457|FG002|Follow-up|Death|24
6046278|NCT00405756|9645455|FG000|Follow-up|Lost to Follow-up|2
6046279|NCT00405756|9645456|FG001|Follow-up|Lost to Follow-up|8
6046280|NCT00405756|9645457|FG002|Follow-up|Lost to Follow-up|4
6046281|NCT00405821|9645467|FG000|Overall Study|Death|5
6046282|NCT00405821|9645468|FG001|Overall Study|Death|7
6046283|NCT00405821|9645467|FG000|Overall Study|Lost to Follow-up|7
6046284|NCT00405821|9645468|FG001|Overall Study|Lost to Follow-up|7
6046285|NCT00405821|9645467|FG000|Overall Study|Protocol Violation|1
6046286|NCT00405821|9645468|FG001|Overall Study|Protocol Violation|0
6046287|NCT00405821|9645467|FG000|Overall Study|initiated ART|9
6046288|NCT00405821|9645468|FG001|Overall Study|initiated ART|8
6046289|NCT00405912|9645477|FG000|Overall Study|Withdrawal by Subject|12
6046290|NCT00405912|9645478|FG001|Overall Study|Withdrawal by Subject|11
6046291|NCT00405912|9645479|FG002|Overall Study|Withdrawal by Subject|12
6046292|NCT00405912|9645477|FG000|Overall Study|Lost to Follow-up|4
6046293|NCT00405912|9645478|FG001|Overall Study|Lost to Follow-up|8
6046294|NCT00405912|9645479|FG002|Overall Study|Lost to Follow-up|4
6046295|NCT00406029|9645501|FG000|Overall Study|Adverse Event|12
6046296|NCT00406029|9645502|FG001|Overall Study|Adverse Event|2
6046297|NCT00406029|9645503|FG002|Overall Study|Adverse Event|5
6046298|NCT00406029|9645504|FG003|Overall Study|Adverse Event|10
6046299|NCT00406029|9645505|FG004|Overall Study|Adverse Event|7
6046300|NCT00406029|9645501|FG000|Overall Study|Withdrawal by Subject|3
6046301|NCT00406029|9645502|FG001|Overall Study|Withdrawal by Subject|4
6046302|NCT00406029|9645503|FG002|Overall Study|Withdrawal by Subject|2
6046303|NCT00406029|9645504|FG003|Overall Study|Withdrawal by Subject|2
6046304|NCT00406029|9645505|FG004|Overall Study|Withdrawal by Subject|0
6046305|NCT00406029|9645501|FG000|Overall Study|Protocol Violation|1
6046306|NCT00406029|9645502|FG001|Overall Study|Protocol Violation|2
6309381|NCT02638103|10037952|FG000|Overall Study|Withdrawal by Subject|43
6046307|NCT00406029|9645503|FG002|Overall Study|Protocol Violation|0
6046308|NCT00406029|9645504|FG003|Overall Study|Protocol Violation|2
6046309|NCT00406029|9645505|FG004|Overall Study|Protocol Violation|0
6046310|NCT00406029|9645501|FG000|Overall Study|Did Not Meet Eligibility Criteria|0
6046311|NCT00406029|9645502|FG001|Overall Study|Did Not Meet Eligibility Criteria|0
6046312|NCT00406029|9645503|FG002|Overall Study|Did Not Meet Eligibility Criteria|1
6046313|NCT00406029|9645504|FG003|Overall Study|Did Not Meet Eligibility Criteria|0
6046314|NCT00406029|9645505|FG004|Overall Study|Did Not Meet Eligibility Criteria|0
6046315|NCT00406029|9645501|FG000|Overall Study|Randomized in Error|0
6046316|NCT00406029|9645502|FG001|Overall Study|Randomized in Error|0
6046317|NCT00406029|9645503|FG002|Overall Study|Randomized in Error|2
6046318|NCT00406029|9645504|FG003|Overall Study|Randomized in Error|3
6046319|NCT00406029|9645505|FG004|Overall Study|Randomized in Error|1
6046320|NCT00406315|9645554|FG000|Overall Study|Death|1
6046321|NCT00406315|9645554|FG000|Overall Study|Adverse Event|39
6046322|NCT00406315|9645554|FG000|Overall Study|Laboratory Abnormality|4
6046323|NCT00406315|9645554|FG000|Overall Study|Lack of Efficacy|13
6309382|NCT02638103|10037953|FG001|Overall Study|Withdrawal by Subject|53
6309383|NCT02638103|10037954|FG002|Overall Study|Withdrawal by Subject|30
6309384|NCT02638103|10037955|FG003|Overall Study|Withdrawal by Subject|61
6309385|NCT02638103|10037952|FG000|Overall Study|Protocol Violation|1
5993703|NCT03090737|9587071|FG000|Overall Study|Participant withdrew consent|4
5993704|NCT03090737|9587071|FG000|Overall Study|Death|27
5993705|NCT03043872|9587087|FG000|Overall Study|Withdrawal by Subject|6
5993706|NCT03043872|9587088|FG001|Overall Study|Withdrawal by Subject|6
5993707|NCT03043872|9587089|FG002|Overall Study|Withdrawal by Subject|15
5993708|NCT03043872|9587087|FG000|Overall Study|Lost to Follow-up|2
5993709|NCT03043872|9587088|FG001|Overall Study|Lost to Follow-up|1
5993710|NCT03043872|9587089|FG002|Overall Study|Lost to Follow-up|1
5993711|NCT03043872|9587087|FG000|Overall Study|Death|270
5993712|NCT03043872|9587088|FG001|Overall Study|Death|269
5993713|NCT03043872|9587089|FG002|Overall Study|Death|296
5993714|NCT01984346|9587126|FG000|Overall Study|Physician Decision|4
5993715|NCT01984346|9587127|FG001|Overall Study|Physician Decision|2
5993716|NCT01984346|9587126|FG000|Overall Study|Withdrawal by Subject|2
6309386|NCT02638103|10037953|FG001|Overall Study|Protocol Violation|2
5993717|NCT01984346|9587127|FG001|Overall Study|Withdrawal by Subject|2
5993718|NCT01984346|9587126|FG000|Overall Study|Enrollment Closed|8
5993719|NCT01984346|9587127|FG001|Overall Study|Enrollment Closed|1
5993720|NCT01984346|9587126|FG000|Overall Study|Insurance Coverage|1
5993721|NCT01984346|9587127|FG001|Overall Study|Insurance Coverage|0
5993722|NCT01984346|9587126|FG000|Overall Study|Intra-operative Exclusion|2
5993723|NCT01984346|9587127|FG001|Overall Study|Intra-operative Exclusion|0
5993724|NCT01750281|9587136|FG000|Overall Study|Discontinued Selumetinib/Placebo|37
5993725|NCT01750281|9587137|FG001|Overall Study|Discontinued Selumetinib/Placebo|77
5993726|NCT01750281|9587138|FG002|Overall Study|Discontinued Selumetinib/Placebo|75
5993727|NCT01750281|9587136|FG000|Overall Study|Ongoing Selumetinib/Pbo at data cut-off|6
5993728|NCT01750281|9587137|FG001|Overall Study|Ongoing Selumetinib/Pbo at data cut-off|7
5993729|NCT01750281|9587138|FG002|Overall Study|Ongoing Selumetinib/Pbo at data cut-off|9
5993730|NCT01750281|9587136|FG000|Overall Study|Did not receive treatment|0
5993731|NCT01750281|9587137|FG001|Overall Study|Did not receive treatment|1
5993732|NCT01750281|9587138|FG002|Overall Study|Did not receive treatment|0
5993733|NCT01252953|9587157|FG000|Overall Study|Withdrawal by Subject|16
5993734|NCT01252953|9587158|FG001|Overall Study|Withdrawal by Subject|17
5993735|NCT01252953|9587157|FG000|Overall Study|Lost to Follow-up|22
5993736|NCT01252953|9587158|FG001|Overall Study|Lost to Follow-up|21
5993737|NCT01012609|9587167|FG000|Overall Study|Withdrawal by Subject|1
5993738|NCT01012609|9587168|FG001|Overall Study|Withdrawal by Subject|1
5993739|NCT00920387|9587177|FG000|Stage 1|Adverse Event|1
5993740|NCT00920387|9587178|FG001|Stage 1|Adverse Event|0
5993741|NCT00920387|9587179|FG002|Stage 1|Adverse Event|0
5993742|NCT00494234|9587188|FG000|Overall Study|Lack of Efficacy|12
5993743|NCT00494234|9587189|FG001|Overall Study|Lack of Efficacy|9
5993744|NCT00494234|9587188|FG000|Overall Study|Withdrawal by Subject|1
5993745|NCT00494234|9587189|FG001|Overall Study|Withdrawal by Subject|0
5993746|NCT00494234|9587188|FG000|Overall Study|Death|2
5993747|NCT00494234|9587189|FG001|Overall Study|Death|1
5993748|NCT00403559|9587220|FG000|Overall Study|Adverse Event|0
5993749|NCT00403559|9587221|FG001|Overall Study|Adverse Event|1
5993750|NCT00403559|9587220|FG000|Overall Study|Lost to Follow-up|3
5993751|NCT00403559|9587221|FG001|Overall Study|Lost to Follow-up|3
5993752|NCT00403559|9587220|FG000|Overall Study|Withdrawal by Subject|1
5993753|NCT00403559|9587221|FG001|Overall Study|Withdrawal by Subject|0
6046324|NCT00406315|9645554|FG000|Overall Study|Other|33
6046325|NCT00406315|9645554|FG000|Overall Study|Lost to Follow-up|21
6046326|NCT00406315|9645554|FG000|Overall Study|Withdrawal by Subject|30
6046327|NCT00406354|9645561|FG000|All Randomized Patients|Protocol Violation|0
6046328|NCT00406354|9645562|FG001|All Randomized Patients|Protocol Violation|0
6046329|NCT00406354|9645563|FG002|All Randomized Patients|Protocol Violation|1
6046330|NCT00406354|9645561|FG000|All Randomized and Treated Patients|Lack of Efficacy|7
6046331|NCT00406354|9645562|FG001|All Randomized and Treated Patients|Lack of Efficacy|4
6046332|NCT00406354|9645563|FG002|All Randomized and Treated Patients|Lack of Efficacy|17
6046333|NCT00406354|9645561|FG000|All Randomized and Treated Patients|Adverse Event|6
6046334|NCT00406354|9645562|FG001|All Randomized and Treated Patients|Adverse Event|2
6046335|NCT00406354|9645563|FG002|All Randomized and Treated Patients|Adverse Event|1
6046336|NCT00406354|9645561|FG000|All Randomized and Treated Patients|Parent/Caregiver Decision|2
6046337|NCT00406354|9645562|FG001|All Randomized and Treated Patients|Parent/Caregiver Decision|6
6046338|NCT00406354|9645563|FG002|All Randomized and Treated Patients|Parent/Caregiver Decision|1
6046339|NCT00406354|9645561|FG000|All Randomized and Treated Patients|Withdrawal by Subject|1
6046340|NCT00406354|9645562|FG001|All Randomized and Treated Patients|Withdrawal by Subject|1
6046341|NCT00406354|9645563|FG002|All Randomized and Treated Patients|Withdrawal by Subject|2
6046342|NCT00406354|9645561|FG000|All Randomized and Treated Patients|Physician Decision|0
6046343|NCT00406354|9645562|FG001|All Randomized and Treated Patients|Physician Decision|0
6046344|NCT00406354|9645563|FG002|All Randomized and Treated Patients|Physician Decision|1
6046345|NCT00406367|9645573|FG000|Main Period - 6 to 20 Weeks|Withdrawal Criteria Occurred|4
6046346|NCT00406367|9645574|FG001|Main Period - 6 to 20 Weeks|Withdrawal Criteria Occurred|0
6046347|NCT00406367|9645573|FG000|Main Period - 6 to 20 Weeks|Consent Withdrawn|1
5993754|NCT04702984|9587262|FG000|Overall Study|Adverse Event Unrelated to the Study Device|1
5993755|NCT04633564|9587270|FG000|Period 1|Adverse Event|28
5993756|NCT04633564|9587271|FG001|Period 1|Adverse Event|19
5993757|NCT04633564|9587270|FG000|Period 1|Death|8
5993758|NCT04633564|9587271|FG001|Period 1|Death|7
5993759|NCT04633564|9587270|FG000|Period 1|Lost to Follow-up|3
5993760|NCT04633564|9587271|FG001|Period 1|Lost to Follow-up|5
5993761|NCT04633564|9587270|FG000|Period 1|Physician Decision|4
5993762|NCT04633564|9587271|FG001|Period 1|Physician Decision|12
5993763|NCT04633564|9587270|FG000|Period 1|Protocol Violation|0
5993764|NCT04633564|9587271|FG001|Period 1|Protocol Violation|1
5993765|NCT04633564|9587270|FG000|Period 1|Withdrawal by Subject|10
5993766|NCT04633564|9587271|FG001|Period 1|Withdrawal by Subject|8
5993767|NCT04633564|9587270|FG000|Period 1|Progressive disease|47
5993768|NCT04633564|9587271|FG001|Period 1|Progressive disease|51
5993769|NCT04633564|9587270|FG000|Period 1|Terminated by Sponsor|8
5993770|NCT04633564|9587271|FG001|Period 1|Terminated by Sponsor|6
5993771|NCT04633564|9587270|FG000|Period 2|Adverse Event|3
5993772|NCT04633564|9587271|FG001|Period 2|Adverse Event|4
5993773|NCT04633564|9587270|FG000|Period 2|Death|0
5993774|NCT04633564|9587271|FG001|Period 2|Death|2
5993775|NCT04633564|9587270|FG000|Period 2|Lost to Follow-up|0
5993776|NCT04633564|9587271|FG001|Period 2|Lost to Follow-up|1
5993777|NCT04633564|9587270|FG000|Period 2|Physician Decision|2
5993778|NCT04633564|9587271|FG001|Period 2|Physician Decision|4
5993779|NCT04633564|9587270|FG000|Period 2|Withdrawal by Subject|5
5993780|NCT04633564|9587271|FG001|Period 2|Withdrawal by Subject|1
5993781|NCT04633564|9587270|FG000|Period 2|Progressive Disease|74
5993782|NCT04633564|9587271|FG001|Period 2|Progressive Disease|82
5993783|NCT04633564|9587270|FG000|Period 2|Terminated by Sponsor|9
5993784|NCT04633564|9587271|FG001|Period 2|Terminated by Sponsor|3
5993785|NCT04191148|9587292|FG000|Overall Study|Withdrawal by Subject|1
5993786|NCT04191148|9587293|FG001|Overall Study|Withdrawal by Subject|0
5993787|NCT04191148|9587292|FG000|Overall Study|Adverse Event|1
5993788|NCT04191148|9587293|FG001|Overall Study|Adverse Event|0
5993789|NCT04022733|9587334|FG000|Overall Study|conversion to open surgery|3
5993790|NCT04022733|9587335|FG001|Overall Study|conversion to open surgery|2
5993791|NCT04022733|9587334|FG000|Overall Study|bradycardia|0
5993792|NCT04022733|9587335|FG001|Overall Study|bradycardia|1
5993793|NCT04021524|9587343|FG000|Overall Study|Change in surgical intervention|0
5993794|NCT04021524|9587344|FG001|Overall Study|Change in surgical intervention|1
5993795|NCT03605680|9587368|FG000|SB Placebo Run-in Period (1 Week)|Adverse Event|6
5993796|NCT03605680|9587369|FG001|SB Placebo Run-in Period (1 Week)|Adverse Event|0
5993797|NCT03605680|9587370|FG002|SB Placebo Run-in Period (1 Week)|Adverse Event|0
5993798|NCT03605680|9587371|FG003|SB Placebo Run-in Period (1 Week)|Adverse Event|0
5993799|NCT03605680|9587368|FG000|SB Placebo Run-in Period (1 Week)|Lack of Efficacy|1
5993800|NCT03605680|9587369|FG001|SB Placebo Run-in Period (1 Week)|Lack of Efficacy|0
5993801|NCT03605680|9587370|FG002|SB Placebo Run-in Period (1 Week)|Lack of Efficacy|0
5993802|NCT03605680|9587371|FG003|SB Placebo Run-in Period (1 Week)|Lack of Efficacy|0
5993803|NCT03605680|9587368|FG000|SB Placebo Run-in Period (1 Week)|Lost to Follow-up|9
5993804|NCT03605680|9587369|FG001|SB Placebo Run-in Period (1 Week)|Lost to Follow-up|0
5993805|NCT03605680|9587370|FG002|SB Placebo Run-in Period (1 Week)|Lost to Follow-up|0
5993806|NCT03605680|9587371|FG003|SB Placebo Run-in Period (1 Week)|Lost to Follow-up|0
5993807|NCT03605680|9587368|FG000|SB Placebo Run-in Period (1 Week)|Non-compliance With Study Drug|3
5993808|NCT03605680|9587369|FG001|SB Placebo Run-in Period (1 Week)|Non-compliance With Study Drug|0
5993809|NCT03605680|9587370|FG002|SB Placebo Run-in Period (1 Week)|Non-compliance With Study Drug|0
5993810|NCT03605680|9587371|FG003|SB Placebo Run-in Period (1 Week)|Non-compliance With Study Drug|0
5993811|NCT03605680|9587368|FG000|SB Placebo Run-in Period (1 Week)|Protocol Deviation|13
5993812|NCT03605680|9587369|FG001|SB Placebo Run-in Period (1 Week)|Protocol Deviation|0
5993813|NCT03605680|9587370|FG002|SB Placebo Run-in Period (1 Week)|Protocol Deviation|0
5993814|NCT03605680|9587371|FG003|SB Placebo Run-in Period (1 Week)|Protocol Deviation|0
5993815|NCT03605680|9587368|FG000|SB Placebo Run-in Period (1 Week)|Withdrawal by Subject|12
5993816|NCT03605680|9587369|FG001|SB Placebo Run-in Period (1 Week)|Withdrawal by Subject|0
5993817|NCT03605680|9587370|FG002|SB Placebo Run-in Period (1 Week)|Withdrawal by Subject|0
5993818|NCT03605680|9587371|FG003|SB Placebo Run-in Period (1 Week)|Withdrawal by Subject|0
5993819|NCT03605680|9587368|FG000|SB Placebo Run-in Period (1 Week)|Site Terminated by Sponsor|1
5993820|NCT03605680|9587369|FG001|SB Placebo Run-in Period (1 Week)|Site Terminated by Sponsor|0
5993821|NCT03605680|9587370|FG002|SB Placebo Run-in Period (1 Week)|Site Terminated by Sponsor|0
5993822|NCT03605680|9587371|FG003|SB Placebo Run-in Period (1 Week)|Site Terminated by Sponsor|0
5993823|NCT03605680|9587368|FG000|SB Placebo Run-in Period (1 Week)|Physician Decision|6
5993824|NCT03605680|9587369|FG001|SB Placebo Run-in Period (1 Week)|Physician Decision|0
5993825|NCT03605680|9587370|FG002|SB Placebo Run-in Period (1 Week)|Physician Decision|0
5993826|NCT03605680|9587371|FG003|SB Placebo Run-in Period (1 Week)|Physician Decision|0
5993827|NCT03605680|9587368|FG000|SB Placebo Run-in Period (1 Week)|Reason not Specified|87
5993828|NCT03605680|9587369|FG001|SB Placebo Run-in Period (1 Week)|Reason not Specified|0
5993829|NCT03605680|9587370|FG002|SB Placebo Run-in Period (1 Week)|Reason not Specified|0
5993830|NCT03605680|9587371|FG003|SB Placebo Run-in Period (1 Week)|Reason not Specified|0
6046348|NCT00406367|9645574|FG001|Main Period - 6 to 20 Weeks|Consent Withdrawn|0
5993831|NCT03605680|9587368|FG000|Double-blind Treatment Period (6 Weeks)|Randomized but Not Treated in Double-Blind Treatment Period|0
5993832|NCT03605680|9587369|FG001|Double-blind Treatment Period (6 Weeks)|Randomized but Not Treated in Double-Blind Treatment Period|5
5993833|NCT03605680|9587370|FG002|Double-blind Treatment Period (6 Weeks)|Randomized but Not Treated in Double-Blind Treatment Period|7
5993834|NCT03605680|9587371|FG003|Double-blind Treatment Period (6 Weeks)|Randomized but Not Treated in Double-Blind Treatment Period|8
5993835|NCT03605680|9587368|FG000|Double-blind Treatment Period (6 Weeks)|Adverse Event|0
5993836|NCT03605680|9587369|FG001|Double-blind Treatment Period (6 Weeks)|Adverse Event|8
5993837|NCT03605680|9587370|FG002|Double-blind Treatment Period (6 Weeks)|Adverse Event|8
5993838|NCT03605680|9587371|FG003|Double-blind Treatment Period (6 Weeks)|Adverse Event|3
5993839|NCT03605680|9587368|FG000|Double-blind Treatment Period (6 Weeks)|Lack of Efficacy|0
5993840|NCT03605680|9587369|FG001|Double-blind Treatment Period (6 Weeks)|Lack of Efficacy|0
5993841|NCT03605680|9587370|FG002|Double-blind Treatment Period (6 Weeks)|Lack of Efficacy|0
5993842|NCT03605680|9587371|FG003|Double-blind Treatment Period (6 Weeks)|Lack of Efficacy|1
5993843|NCT03605680|9587368|FG000|Double-blind Treatment Period (6 Weeks)|Lost to Follow-up|0
5993844|NCT03605680|9587369|FG001|Double-blind Treatment Period (6 Weeks)|Lost to Follow-up|3
5993845|NCT03605680|9587370|FG002|Double-blind Treatment Period (6 Weeks)|Lost to Follow-up|4
5993846|NCT03605680|9587371|FG003|Double-blind Treatment Period (6 Weeks)|Lost to Follow-up|3
5993847|NCT03605680|9587368|FG000|Double-blind Treatment Period (6 Weeks)|Non-compliance with Study Drug|0
5993848|NCT03605680|9587369|FG001|Double-blind Treatment Period (6 Weeks)|Non-compliance with Study Drug|3
5993849|NCT03605680|9587370|FG002|Double-blind Treatment Period (6 Weeks)|Non-compliance with Study Drug|1
5993850|NCT03605680|9587371|FG003|Double-blind Treatment Period (6 Weeks)|Non-compliance with Study Drug|2
5993851|NCT03605680|9587368|FG000|Double-blind Treatment Period (6 Weeks)|Protocol Deviation|0
5993852|NCT03605680|9587369|FG001|Double-blind Treatment Period (6 Weeks)|Protocol Deviation|14
5993853|NCT03605680|9587370|FG002|Double-blind Treatment Period (6 Weeks)|Protocol Deviation|7
5993854|NCT03605680|9587371|FG003|Double-blind Treatment Period (6 Weeks)|Protocol Deviation|5
5993855|NCT03605680|9587368|FG000|Double-blind Treatment Period (6 Weeks)|Withdrawal by Subject|0
5993856|NCT03605680|9587369|FG001|Double-blind Treatment Period (6 Weeks)|Withdrawal by Subject|4
5993857|NCT03605680|9587370|FG002|Double-blind Treatment Period (6 Weeks)|Withdrawal by Subject|4
5993858|NCT03605680|9587371|FG003|Double-blind Treatment Period (6 Weeks)|Withdrawal by Subject|7
5993859|NCT03605680|9587368|FG000|Double-blind Treatment Period (6 Weeks)|Physician Decision|0
5993860|NCT03605680|9587369|FG001|Double-blind Treatment Period (6 Weeks)|Physician Decision|1
5993861|NCT03605680|9587370|FG002|Double-blind Treatment Period (6 Weeks)|Physician Decision|2
5993862|NCT03605680|9587371|FG003|Double-blind Treatment Period (6 Weeks)|Physician Decision|0
5993863|NCT03605680|9587368|FG000|Double-blind Treatment Period (6 Weeks)|Reason not Specified|0
5993864|NCT03605680|9587369|FG001|Double-blind Treatment Period (6 Weeks)|Reason not Specified|5
5993865|NCT03605680|9587370|FG002|Double-blind Treatment Period (6 Weeks)|Reason not Specified|4
5993866|NCT03605680|9587371|FG003|Double-blind Treatment Period (6 Weeks)|Reason not Specified|3
5993867|NCT03605680|9587368|FG000|Double-blind Treatment Period (6 Weeks)|Reason due to COVID-19|0
5993868|NCT03605680|9587369|FG001|Double-blind Treatment Period (6 Weeks)|Reason due to COVID-19|1
5993869|NCT03605680|9587370|FG002|Double-blind Treatment Period (6 Weeks)|Reason due to COVID-19|2
5993870|NCT03605680|9587371|FG003|Double-blind Treatment Period (6 Weeks)|Reason due to COVID-19|3
6046349|NCT00406367|9645573|FG000|Main Period - 6 to 20 Weeks|Lost to Follow-up|0
6046350|NCT00406367|9645574|FG001|Main Period - 6 to 20 Weeks|Lost to Follow-up|1
6046351|NCT00406367|9645573|FG000|Main Period - 6 to 20 Weeks|Dosing Error At Visit 2 (Baseline)|0
6046352|NCT00406367|9645574|FG001|Main Period - 6 to 20 Weeks|Dosing Error At Visit 2 (Baseline)|1
6046353|NCT00406367|9645573|FG000|Open-Label Ext. Period - up to 68 Weeks|Lost to Follow-up|2
6046354|NCT00406367|9645574|FG001|Open-Label Ext. Period - up to 68 Weeks|Lost to Follow-up|0
6046355|NCT00406367|9645573|FG000|Open-Label Ext. Period - up to 68 Weeks|Consent Withdrawn|6
6046356|NCT00406367|9645574|FG001|Open-Label Ext. Period - up to 68 Weeks|Consent Withdrawn|0
6046357|NCT00406367|9645573|FG000|Open-Label Ext. Period - up to 68 Weeks|Withdrawal Criteria Occurred|4
6046358|NCT00406367|9645574|FG001|Open-Label Ext. Period - up to 68 Weeks|Withdrawal Criteria Occurred|0
6046359|NCT00406367|9645573|FG000|Open-Label Ext. Period - up to 68 Weeks|Lack of Efficacy|4
6046360|NCT00406367|9645574|FG001|Open-Label Ext. Period - up to 68 Weeks|Lack of Efficacy|0
6046361|NCT00406367|9645573|FG000|Open-Label Ext. Period - up to 68 Weeks|Subjects Needed Further Injection|1
6046362|NCT00406367|9645574|FG001|Open-Label Ext. Period - up to 68 Weeks|Subjects Needed Further Injection|0
6046363|NCT00406367|9645573|FG000|Open-Label Ext. Period - up to 68 Weeks|Subject Received Botox Injection|1
6046364|NCT00406367|9645574|FG001|Open-Label Ext. Period - up to 68 Weeks|Subject Received Botox Injection|0
6046365|NCT00406367|9645573|FG000|Open-Label Ext. Period - up to 68 Weeks|Injection in Wrong Muscle|1
6046366|NCT00406367|9645574|FG001|Open-Label Ext. Period - up to 68 Weeks|Injection in Wrong Muscle|0
6046367|NCT00406367|9645573|FG000|Open-Label Ext. Period - up to 68 Weeks|OLEX Drug Given at Baseline|1
6046368|NCT00406367|9645574|FG001|Open-Label Ext. Period - up to 68 Weeks|OLEX Drug Given at Baseline|0
6046369|NCT00406393|9645582|FG000|Overall Study|Did not undergo transplantation|2
6046370|NCT00406393|9645583|FG001|Overall Study|Did not undergo transplantation|1
6046371|NCT00406419|9645592|FG000|Overall Study|Death|3
6046372|NCT00406419|9645593|FG001|Overall Study|Death|1
6046373|NCT00406419|9645594|FG002|Overall Study|Death|4
5993871|NCT03485950|9587382|FG000|Overall Study|Adverse Event|1
5993872|NCT03485950|9587383|FG001|Overall Study|Adverse Event|0
5993873|NCT03485950|9587382|FG000|Overall Study|Death|3
5993874|NCT03485950|9587383|FG001|Overall Study|Death|2
5993875|NCT03485950|9587382|FG000|Overall Study|Withdrawal by Subject|3
5993876|NCT03485950|9587383|FG001|Overall Study|Withdrawal by Subject|0
5993877|NCT03404518|9587391|FG000|Overall Study|Lost to Follow-up|28
5993878|NCT03404518|9587392|FG001|Overall Study|Lost to Follow-up|30
5993879|NCT03404518|9587391|FG000|Overall Study|Protocol Violation|13
5993880|NCT03404518|9587392|FG001|Overall Study|Protocol Violation|6
5993881|NCT03402841|9587398|FG000|Overall Study|Withdrawal by Subject|4
5993882|NCT03402841|9587398|FG000|Overall Study|Lost to Follow-up|3
5993883|NCT03402841|9587398|FG000|Overall Study|Death|85
5993884|NCT03289143|9587426|FG000|Overall Study|Caregiver Unavailability|1
5993885|NCT03289143|9587427|FG001|Overall Study|Caregiver Unavailability|1
5993886|NCT03289143|9587428|FG002|Overall Study|Caregiver Unavailability|0
5993887|NCT03289143|9587429|FG003|Overall Study|Caregiver Unavailability|0
5993888|NCT03289143|9587426|FG000|Overall Study|Research Department Closure|0
5993889|NCT03289143|9587427|FG001|Overall Study|Research Department Closure|0
5993890|NCT03289143|9587428|FG002|Overall Study|Research Department Closure|1
5993891|NCT03289143|9587429|FG003|Overall Study|Research Department Closure|0
5993892|NCT03289143|9587426|FG000|Overall Study|Caregiver and Participant Withdrew Consent|0
5993893|NCT03289143|9587427|FG001|Overall Study|Caregiver and Participant Withdrew Consent|0
5993894|NCT03289143|9587428|FG002|Overall Study|Caregiver and Participant Withdrew Consent|1
5993895|NCT03289143|9587429|FG003|Overall Study|Caregiver and Participant Withdrew Consent|0
5993896|NCT03289143|9587426|FG000|Overall Study|Medical Monitor Decision|1
5993897|NCT03289143|9587427|FG001|Overall Study|Medical Monitor Decision|0
5993898|NCT03289143|9587428|FG002|Overall Study|Medical Monitor Decision|0
5993899|NCT03289143|9587429|FG003|Overall Study|Medical Monitor Decision|0
5993900|NCT03289143|9587426|FG000|Overall Study|Participant Non-Compliance|0
5993901|NCT03289143|9587427|FG001|Overall Study|Participant Non-Compliance|0
5993902|NCT03289143|9587428|FG002|Overall Study|Participant Non-Compliance|1
5993903|NCT03289143|9587429|FG003|Overall Study|Participant Non-Compliance|0
5993904|NCT03289143|9587426|FG000|Overall Study|Drug Interrupted for Too Long Due to Prohibited Med|0
5993905|NCT03289143|9587427|FG001|Overall Study|Drug Interrupted for Too Long Due to Prohibited Med|0
5993906|NCT03289143|9587428|FG002|Overall Study|Drug Interrupted for Too Long Due to Prohibited Med|1
5993907|NCT03289143|9587429|FG003|Overall Study|Drug Interrupted for Too Long Due to Prohibited Med|0
5993908|NCT03289143|9587426|FG000|Overall Study|Participant Non Compliance With Concomitant Medications|0
5993909|NCT03289143|9587427|FG001|Overall Study|Participant Non Compliance With Concomitant Medications|0
5993910|NCT03289143|9587428|FG002|Overall Study|Participant Non Compliance With Concomitant Medications|1
5993911|NCT03289143|9587429|FG003|Overall Study|Participant Non Compliance With Concomitant Medications|0
5993912|NCT03289143|9587426|FG000|Overall Study|Caregiver Passed Away|1
5993913|NCT03289143|9587427|FG001|Overall Study|Caregiver Passed Away|0
5993914|NCT03289143|9587428|FG002|Overall Study|Caregiver Passed Away|0
5993915|NCT03289143|9587429|FG003|Overall Study|Caregiver Passed Away|0
5993916|NCT03289143|9587426|FG000|Overall Study|Physician Decision|0
5993917|NCT03289143|9587427|FG001|Overall Study|Physician Decision|2
5993918|NCT03289143|9587428|FG002|Overall Study|Physician Decision|2
5993919|NCT03289143|9587429|FG003|Overall Study|Physician Decision|2
5993920|NCT03289143|9587426|FG000|Overall Study|Protocol Deviation|2
6070028|NCT00547911|9672878|FG004|Overall Study|Adverse Event|0
6070029|NCT00547911|9672879|FG005|Overall Study|Adverse Event|0
6070030|NCT00548145|9672909|FG000|Overall Study|Death|0
6070031|NCT00548145|9672910|FG001|Overall Study|Death|1
5993921|NCT03289143|9587427|FG001|Overall Study|Protocol Deviation|1
5993922|NCT03289143|9587428|FG002|Overall Study|Protocol Deviation|3
5993923|NCT03289143|9587429|FG003|Overall Study|Protocol Deviation|1
5993924|NCT03289143|9587426|FG000|Overall Study|Study Terminated By Sponsor|101
5993925|NCT03289143|9587427|FG001|Overall Study|Study Terminated By Sponsor|75
6070032|NCT00548145|9672909|FG000|Overall Study|Withdrawal by Subject|0
6070033|NCT00548145|9672910|FG001|Overall Study|Withdrawal by Subject|2
6070034|NCT00548145|9672909|FG000|Overall Study|Physician Decision|1
6070035|NCT00548145|9672910|FG001|Overall Study|Physician Decision|1
5993926|NCT03289143|9587428|FG002|Overall Study|Study Terminated By Sponsor|100
5993927|NCT03289143|9587429|FG003|Overall Study|Study Terminated By Sponsor|69
5993928|NCT03289143|9587426|FG000|Overall Study|Withdrawal by Subject|14
5993929|NCT03289143|9587427|FG001|Overall Study|Withdrawal by Subject|6
5993930|NCT03289143|9587428|FG002|Overall Study|Withdrawal by Subject|14
5993931|NCT03289143|9587429|FG003|Overall Study|Withdrawal by Subject|12
5993932|NCT03289143|9587426|FG000|Overall Study|Adverse Event|10
5993933|NCT03289143|9587427|FG001|Overall Study|Adverse Event|7
5993934|NCT03289143|9587428|FG002|Overall Study|Adverse Event|6
5993935|NCT03289143|9587429|FG003|Overall Study|Adverse Event|5
5993936|NCT03289143|9587426|FG000|Overall Study|Death|2
5993937|NCT03289143|9587427|FG001|Overall Study|Death|0
5993938|NCT03289143|9587428|FG002|Overall Study|Death|2
5993939|NCT03289143|9587429|FG003|Overall Study|Death|1
5993940|NCT03289143|9587426|FG000|Overall Study|Lost to Follow-up|2
5993941|NCT03289143|9587427|FG001|Overall Study|Lost to Follow-up|1
5993942|NCT03289143|9587428|FG002|Overall Study|Lost to Follow-up|1
5993943|NCT03289143|9587429|FG003|Overall Study|Lost to Follow-up|0
6070036|NCT00548184|9672925|FG000|Overall Study|Adverse Event|3
5993944|NCT03289143|9587426|FG000|Overall Study|Participant No Longer Has Study Partner|0
5993945|NCT03289143|9587427|FG001|Overall Study|Participant No Longer Has Study Partner|0
5993946|NCT03289143|9587428|FG002|Overall Study|Participant No Longer Has Study Partner|0
5993947|NCT03289143|9587429|FG003|Overall Study|Participant No Longer Has Study Partner|1
5993948|NCT03289143|9587426|FG000|Overall Study|Withdrawal by Caregiver|0
5993949|NCT03289143|9587427|FG001|Overall Study|Withdrawal by Caregiver|1
5993950|NCT03289143|9587428|FG002|Overall Study|Withdrawal by Caregiver|0
5993951|NCT03289143|9587429|FG003|Overall Study|Withdrawal by Caregiver|0
5993952|NCT03289143|9587426|FG000|Overall Study|Caregiver Passed Away & Family Moved Out of State|0
5993953|NCT03289143|9587427|FG001|Overall Study|Caregiver Passed Away & Family Moved Out of State|0
5993954|NCT03289143|9587428|FG002|Overall Study|Caregiver Passed Away & Family Moved Out of State|1
5993955|NCT03289143|9587429|FG003|Overall Study|Caregiver Passed Away & Family Moved Out of State|0
5993956|NCT03289143|9587426|FG000|Overall Study|Absence of Consistent and Reliable Caregiver|0
5993957|NCT03289143|9587427|FG001|Overall Study|Absence of Consistent and Reliable Caregiver|0
5993958|NCT03289143|9587428|FG002|Overall Study|Absence of Consistent and Reliable Caregiver|0
5993959|NCT03289143|9587429|FG003|Overall Study|Absence of Consistent and Reliable Caregiver|1
6046374|NCT00406419|9645592|FG000|Overall Study|Protocol Violation|6
6046375|NCT00406419|9645593|FG001|Overall Study|Protocol Violation|2
6046376|NCT00406419|9645594|FG002|Overall Study|Protocol Violation|5
6046377|NCT00406419|9645592|FG000|Overall Study|Study Terminated by Sponsor|260
6046378|NCT00406419|9645593|FG001|Overall Study|Study Terminated by Sponsor|288
6046379|NCT00406419|9645594|FG002|Overall Study|Study Terminated by Sponsor|282
6046380|NCT00406419|9645592|FG000|Overall Study|Withdrawal by Subject|17
6046381|NCT00406419|9645593|FG001|Overall Study|Withdrawal by Subject|24
6046382|NCT00406419|9645594|FG002|Overall Study|Withdrawal by Subject|26
6046383|NCT00406419|9645592|FG000|Overall Study|Lack of Efficacy|12
6046384|NCT00406419|9645593|FG001|Overall Study|Lack of Efficacy|1
6046385|NCT00406419|9645594|FG002|Overall Study|Lack of Efficacy|6
6046386|NCT00406419|9645592|FG000|Overall Study|Non-Compliance with Study Drug|5
6046387|NCT00406419|9645593|FG001|Overall Study|Non-Compliance with Study Drug|6
6046388|NCT00406419|9645594|FG002|Overall Study|Non-Compliance with Study Drug|3
6046389|NCT00406419|9645592|FG000|Overall Study|Adverse Event|10
6046390|NCT00406419|9645593|FG001|Overall Study|Adverse Event|12
6046391|NCT00406419|9645594|FG002|Overall Study|Adverse Event|16
6046392|NCT00406419|9645592|FG000|Overall Study|Lost to Follow-up|11
6046393|NCT00406419|9645593|FG001|Overall Study|Lost to Follow-up|10
6046394|NCT00406419|9645594|FG002|Overall Study|Lost to Follow-up|5
6046395|NCT00406640|9645604|FG000|Acute Phase|Adverse Event|18
6046396|NCT00406640|9645605|FG001|Acute Phase|Adverse Event|13
6046397|NCT00406640|9645604|FG000|Acute Phase|Failed to Return|5
6046398|NCT00406640|9645605|FG001|Acute Phase|Failed to Return|1
6046399|NCT00406640|9645604|FG000|Acute Phase|Physician Decision|0
6046400|NCT00406640|9645605|FG001|Acute Phase|Physician Decision|1
6046401|NCT00406640|9645604|FG000|Acute Phase|Lost to Follow-up|7
6046402|NCT00406640|9645605|FG001|Acute Phase|Lost to Follow-up|4
6046403|NCT00406640|9645604|FG000|Acute Phase|Protocol deviation|4
6046404|NCT00406640|9645605|FG001|Acute Phase|Protocol deviation|10
6046405|NCT00406640|9645604|FG000|Acute Phase|Protocol Violation|3
6046406|NCT00406640|9645605|FG001|Acute Phase|Protocol Violation|2
6046407|NCT00406640|9645604|FG000|Acute Phase|Withdrawal by Subject|11
6046408|NCT00406640|9645605|FG001|Acute Phase|Withdrawal by Subject|9
6046409|NCT00406640|9645604|FG000|Acute Phase|Lack of Efficacy|3
6046410|NCT00406640|9645605|FG001|Acute Phase|Lack of Efficacy|3
6070037|NCT00548184|9672925|FG000|Overall Study|took other drug|1
6070038|NCT00548184|9672925|FG000|Overall Study|Found Her2 negative|1
6070039|NCT00548249|9672945|FG000|Overall Study|Hemoglobin (Hgb) decrease >=1.0 g/dL|3
6070040|NCT00548249|9672946|FG001|Overall Study|Hemoglobin (Hgb) decrease >=1.0 g/dL|4
6070041|NCT00548249|9672947|FG002|Overall Study|Hemoglobin (Hgb) decrease >=1.0 g/dL|4
6070042|NCT00548249|9672948|FG003|Overall Study|Hemoglobin (Hgb) decrease >=1.0 g/dL|2
6070043|NCT00548249|9672949|FG004|Overall Study|Hemoglobin (Hgb) decrease >=1.0 g/dL|4
6070044|NCT00548249|9672945|FG000|Overall Study|Transferrin Saturation (TSAT) <20%|5
6070045|NCT00548249|9672946|FG001|Overall Study|Transferrin Saturation (TSAT) <20%|1
6070046|NCT00548249|9672947|FG002|Overall Study|Transferrin Saturation (TSAT) <20%|3
6070047|NCT00548249|9672948|FG003|Overall Study|Transferrin Saturation (TSAT) <20%|1
6070048|NCT00548249|9672949|FG004|Overall Study|Transferrin Saturation (TSAT) <20%|2
6070049|NCT00548249|9672945|FG000|Overall Study|Protocol Violation|1
6070050|NCT00548249|9672946|FG001|Overall Study|Protocol Violation|1
6070051|NCT00548249|9672947|FG002|Overall Study|Protocol Violation|4
6046411|NCT00406640|9645604|FG000|DB Continuation Phase for Responders|Adverse Event|11
6046412|NCT00406640|9645605|FG001|DB Continuation Phase for Responders|Adverse Event|11
6046413|NCT00406640|9645604|FG000|DB Continuation Phase for Responders|Death|1
6046414|NCT00406640|9645605|FG001|DB Continuation Phase for Responders|Death|0
6046415|NCT00406640|9645604|FG000|DB Continuation Phase for Responders|Failed to Return|0
6046416|NCT00406640|9645605|FG001|DB Continuation Phase for Responders|Failed to Return|2
6046417|NCT00406640|9645604|FG000|DB Continuation Phase for Responders|Physician Decision|2
6046418|NCT00406640|9645605|FG001|DB Continuation Phase for Responders|Physician Decision|3
6046419|NCT00406640|9645604|FG000|DB Continuation Phase for Responders|Lost to Follow-up|1
6046420|NCT00406640|9645605|FG001|DB Continuation Phase for Responders|Lost to Follow-up|7
5993960|NCT03156504|9587444|FG000|Overall Study|Withdrawal by Subject|1
5993961|NCT03006926|9587450|FG000|Overall Study|Death|0
5993962|NCT03006926|9587451|FG001|Overall Study|Death|33
5993963|NCT03006926|9587450|FG000|Overall Study|Ongoing Survival Follow-up|0
5993964|NCT03006926|9587451|FG001|Overall Study|Ongoing Survival Follow-up|26
5993965|NCT03006926|9587450|FG000|Overall Study|Ongoing-on Treatment|0
5993966|NCT03006926|9587451|FG001|Overall Study|Ongoing-on Treatment|36
5993967|NCT03006926|9587450|FG000|Overall Study|Lost to Follow-up|0
5993968|NCT03006926|9587451|FG001|Overall Study|Lost to Follow-up|1
5993969|NCT03006926|9587450|FG000|Overall Study|Withdrawal by Subject|0
5993970|NCT03006926|9587451|FG001|Overall Study|Withdrawal by Subject|2
5993971|NCT02993926|9587459|FG000|Enantone Treatment Phase|Adverse Event|1
5993972|NCT02993926|9587460|FG001|Enantone Treatment Phase|Adverse Event|0
5993973|NCT02993926|9587461|FG002|Enantone Treatment Phase|Adverse Event|0
5993974|NCT02993926|9587459|FG000|Enantone Treatment Phase|Changed CPP Therapy to Another GnRHa|26
5993975|NCT02993926|9587460|FG001|Enantone Treatment Phase|Changed CPP Therapy to Another GnRHa|0
5993976|NCT02993926|9587461|FG002|Enantone Treatment Phase|Changed CPP Therapy to Another GnRHa|0
5993977|NCT02993926|9587459|FG000|Enantone Treatment Phase|Investigator Judgment|1
5993978|NCT02993926|9587460|FG001|Enantone Treatment Phase|Investigator Judgment|0
5993979|NCT02993926|9587461|FG002|Enantone Treatment Phase|Investigator Judgment|0
5993980|NCT02993926|9587459|FG000|Enantone Treatment Phase|Reason Not Specified|4
5993981|NCT02993926|9587460|FG001|Enantone Treatment Phase|Reason Not Specified|0
5993982|NCT02993926|9587461|FG002|Enantone Treatment Phase|Reason Not Specified|0
5993983|NCT02932579|9587473|FG000|Overall Study|Withdrawal by Subject|4
5993984|NCT02932579|9587474|FG001|Overall Study|Withdrawal by Subject|1
5993985|NCT02928224|9587484|FG000|Overall Study|Randomized, Not Treated|0
5993986|NCT02928224|9587485|FG001|Overall Study|Randomized, Not Treated|2
5993987|NCT02928224|9587486|FG002|Overall Study|Randomized, Not Treated|4
5993988|NCT02928224|9587487|FG003|Overall Study|Randomized, Not Treated|28
5993989|NCT02928224|9587484|FG000|Overall Study|Treatment Ongoing|6
5993990|NCT02928224|9587485|FG001|Overall Study|Treatment Ongoing|78
5993991|NCT02928224|9587486|FG002|Overall Study|Treatment Ongoing|78
5993992|NCT02928224|9587487|FG003|Overall Study|Treatment Ongoing|37
5993993|NCT02928224|9587484|FG000|Overall Study|Progressive Disease|23
5993994|NCT02928224|9587485|FG001|Overall Study|Progressive Disease|104
5993995|NCT02928224|9587486|FG002|Overall Study|Progressive Disease|101
5993996|NCT02928224|9587487|FG003|Overall Study|Progressive Disease|103
5993997|NCT02928224|9587484|FG000|Overall Study|Adverse Event|2
6070052|NCT00548249|9672948|FG003|Overall Study|Protocol Violation|0
6070053|NCT00548249|9672949|FG004|Overall Study|Protocol Violation|3
6070054|NCT00548249|9672945|FG000|Overall Study|Miscellaneous|2
6070055|NCT00548249|9672946|FG001|Overall Study|Miscellaneous|3
6070056|NCT00548249|9672947|FG002|Overall Study|Miscellaneous|2
6070057|NCT00548249|9672948|FG003|Overall Study|Miscellaneous|0
6070058|NCT00548249|9672949|FG004|Overall Study|Miscellaneous|2
6070059|NCT00548249|9672945|FG000|Overall Study|Pre-dialysis (Pre-HD) TSAT >=50%|0
6070060|NCT00548249|9672946|FG001|Overall Study|Pre-dialysis (Pre-HD) TSAT >=50%|0
6070061|NCT00548249|9672947|FG002|Overall Study|Pre-dialysis (Pre-HD) TSAT >=50%|2
6070062|NCT00548249|9672948|FG003|Overall Study|Pre-dialysis (Pre-HD) TSAT >=50%|1
6070063|NCT00548249|9672949|FG004|Overall Study|Pre-dialysis (Pre-HD) TSAT >=50%|4
6070064|NCT00548249|9672945|FG000|Overall Study|Adverse Event|2
6070065|NCT00548249|9672946|FG001|Overall Study|Adverse Event|2
6070066|NCT00548249|9672947|FG002|Overall Study|Adverse Event|0
6070067|NCT00548249|9672948|FG003|Overall Study|Adverse Event|1
6070068|NCT00548249|9672949|FG004|Overall Study|Adverse Event|1
6070069|NCT00548249|9672945|FG000|Overall Study|Post-dialysis high TSAT or low UIBC|0
6070070|NCT00548249|9672946|FG001|Overall Study|Post-dialysis high TSAT or low UIBC|0
6070071|NCT00548249|9672947|FG002|Overall Study|Post-dialysis high TSAT or low UIBC|1
6070072|NCT00548249|9672948|FG003|Overall Study|Post-dialysis high TSAT or low UIBC|3
6070073|NCT00548249|9672949|FG004|Overall Study|Post-dialysis high TSAT or low UIBC|2
6070074|NCT00548249|9672945|FG000|Overall Study|Erythropoietin (ESA)Dose Change Required|0
6070075|NCT00548249|9672946|FG001|Overall Study|Erythropoietin (ESA)Dose Change Required|0
6070076|NCT00548249|9672947|FG002|Overall Study|Erythropoietin (ESA)Dose Change Required|1
6087249|NCT00666926|9697373|FG014|Overall Study|Other|4
5993998|NCT02928224|9587485|FG001|Overall Study|Adverse Event|11
5993999|NCT02928224|9587486|FG002|Overall Study|Adverse Event|11
5994000|NCT02928224|9587487|FG003|Overall Study|Adverse Event|10
5994001|NCT02928224|9587484|FG000|Overall Study|Changes in Patient's Condition|3
5994002|NCT02928224|9587485|FG001|Overall Study|Changes in Patient's Condition|9
5994003|NCT02928224|9587486|FG002|Overall Study|Changes in Patient's Condition|9
5994004|NCT02928224|9587487|FG003|Overall Study|Changes in Patient's Condition|13
5994005|NCT02928224|9587484|FG000|Overall Study|Death|1
5994006|NCT02928224|9587485|FG001|Overall Study|Death|7
5994007|NCT02928224|9587486|FG002|Overall Study|Death|5
6227279|NCT01716520|9900043|FG002|Washout Period 1 (10 to 14 Days)|Adverse Event|0
5994008|NCT02928224|9587487|FG003|Overall Study|Death|11
6227280|NCT01716520|9900044|FG003|Washout Period 1 (10 to 14 Days)|Adverse Event|0
6227281|NCT01716520|9900045|FG004|Washout Period 1 (10 to 14 Days)|Adverse Event|0
6227282|NCT01716520|9900046|FG005|Washout Period 1 (10 to 14 Days)|Adverse Event|0
6227283|NCT01716520|9900041|FG000|Washout Period 1 (10 to 14 Days)|Lack of Efficacy|0
6227284|NCT01716520|9900042|FG001|Washout Period 1 (10 to 14 Days)|Lack of Efficacy|0
5994009|NCT02928224|9587484|FG000|Overall Study|Withdrawal by Subject|1
5994010|NCT02928224|9587485|FG001|Overall Study|Withdrawal by Subject|4
5994011|NCT02928224|9587486|FG002|Overall Study|Withdrawal by Subject|3
5994012|NCT02928224|9587487|FG003|Overall Study|Withdrawal by Subject|9
5994013|NCT02928224|9587484|FG000|Overall Study|Dose Interruptions>28|1
5994014|NCT02928224|9587485|FG001|Overall Study|Dose Interruptions>28|2
5994015|NCT02928224|9587486|FG002|Overall Study|Dose Interruptions>28|2
5994016|NCT02928224|9587487|FG003|Overall Study|Dose Interruptions>28|4
5994017|NCT02928224|9587484|FG000|Overall Study|Patient Decision to Discontinue Drug|0
5994018|NCT02928224|9587485|FG001|Overall Study|Patient Decision to Discontinue Drug|2
5994019|NCT02928224|9587486|FG002|Overall Study|Patient Decision to Discontinue Drug|2
5994020|NCT02928224|9587487|FG003|Overall Study|Patient Decision to Discontinue Drug|4
5994021|NCT02928224|9587484|FG000|Overall Study|Physician Decision|0
5994022|NCT02928224|9587485|FG001|Overall Study|Physician Decision|2
5994023|NCT02928224|9587486|FG002|Overall Study|Physician Decision|4
5994024|NCT02928224|9587487|FG003|Overall Study|Physician Decision|2
5994025|NCT02928224|9587484|FG000|Overall Study|not listed|0
5994026|NCT02928224|9587485|FG001|Overall Study|not listed|3
5994027|NCT02928224|9587486|FG002|Overall Study|not listed|1
5994028|NCT02928224|9587487|FG003|Overall Study|not listed|0
5994029|NCT02852967|9587512|FG000|Overall Study|Adverse Event|3
5994030|NCT02852967|9587513|FG001|Overall Study|Adverse Event|1
5994031|NCT02852967|9587514|FG002|Overall Study|Adverse Event|0
5994032|NCT02852967|9587515|FG003|Overall Study|Adverse Event|1
5994033|NCT02852967|9587516|FG004|Overall Study|Adverse Event|0
5994034|NCT02852967|9587512|FG000|Overall Study|Death|1
5994035|NCT02852967|9587513|FG001|Overall Study|Death|0
5994036|NCT02852967|9587514|FG002|Overall Study|Death|0
5994037|NCT02852967|9587515|FG003|Overall Study|Death|0
5994038|NCT02852967|9587516|FG004|Overall Study|Death|0
5994039|NCT02852967|9587512|FG000|Overall Study|Lost to Follow-up|1
5994040|NCT02852967|9587513|FG001|Overall Study|Lost to Follow-up|2
5994041|NCT02852967|9587514|FG002|Overall Study|Lost to Follow-up|3
5994042|NCT02852967|9587515|FG003|Overall Study|Lost to Follow-up|4
5994043|NCT02852967|9587516|FG004|Overall Study|Lost to Follow-up|4
5994044|NCT02852967|9587512|FG000|Overall Study|Withdrawal by Subject|6
5994045|NCT02852967|9587513|FG001|Overall Study|Withdrawal by Subject|12
5994046|NCT02852967|9587514|FG002|Overall Study|Withdrawal by Subject|7
5994047|NCT02852967|9587515|FG003|Overall Study|Withdrawal by Subject|10
5994048|NCT02852967|9587516|FG004|Overall Study|Withdrawal by Subject|10
5994049|NCT02852967|9587512|FG000|Overall Study|SAE|0
5994050|NCT02852967|9587513|FG001|Overall Study|SAE|0
5994051|NCT02852967|9587514|FG002|Overall Study|SAE|0
5994052|NCT02852967|9587515|FG003|Overall Study|SAE|3
5994053|NCT02852967|9587516|FG004|Overall Study|SAE|0
5994054|NCT02852967|9587512|FG000|Overall Study|Elevated Liver Enzymes|2
5994055|NCT02852967|9587513|FG001|Overall Study|Elevated Liver Enzymes|0
5994056|NCT02852967|9587514|FG002|Overall Study|Elevated Liver Enzymes|0
5994057|NCT02852967|9587515|FG003|Overall Study|Elevated Liver Enzymes|2
5994058|NCT02852967|9587516|FG004|Overall Study|Elevated Liver Enzymes|2
5994059|NCT02852967|9587512|FG000|Overall Study|Physician Decision|0
5994060|NCT02852967|9587513|FG001|Overall Study|Physician Decision|0
5994061|NCT02852967|9587514|FG002|Overall Study|Physician Decision|0
5994062|NCT02852967|9587515|FG003|Overall Study|Physician Decision|1
5994063|NCT02852967|9587516|FG004|Overall Study|Physician Decision|0
5994064|NCT02852967|9587512|FG000|Overall Study|Lack of Efficacy|0
5994065|NCT02852967|9587513|FG001|Overall Study|Lack of Efficacy|1
5994066|NCT02852967|9587514|FG002|Overall Study|Lack of Efficacy|0
5994067|NCT02852967|9587515|FG003|Overall Study|Lack of Efficacy|0
5994068|NCT02852967|9587516|FG004|Overall Study|Lack of Efficacy|0
5994069|NCT02852967|9587512|FG000|Overall Study|Non-compliance|0
5994070|NCT02852967|9587513|FG001|Overall Study|Non-compliance|0
5994071|NCT02852967|9587514|FG002|Overall Study|Non-compliance|1
5994072|NCT02852967|9587515|FG003|Overall Study|Non-compliance|1
5994073|NCT02852967|9587516|FG004|Overall Study|Non-compliance|0
5994074|NCT02852967|9587512|FG000|Overall Study|Dispensing Drug Violation|0
5994075|NCT02852967|9587513|FG001|Overall Study|Dispensing Drug Violation|0
5994076|NCT02852967|9587514|FG002|Overall Study|Dispensing Drug Violation|1
5994077|NCT02852967|9587515|FG003|Overall Study|Dispensing Drug Violation|0
5994078|NCT02852967|9587516|FG004|Overall Study|Dispensing Drug Violation|0
5994079|NCT02852967|9587512|FG000|Overall Study|Inclusion/Exclusion Violation|1
5994080|NCT02852967|9587513|FG001|Overall Study|Inclusion/Exclusion Violation|0
5994081|NCT02852967|9587514|FG002|Overall Study|Inclusion/Exclusion Violation|0
6070077|NCT00548249|9672948|FG003|Overall Study|Erythropoietin (ESA)Dose Change Required|2
5994082|NCT02852967|9587515|FG003|Overall Study|Inclusion/Exclusion Violation|0
5994083|NCT02852967|9587516|FG004|Overall Study|Inclusion/Exclusion Violation|0
5994084|NCT02810418|9587543|FG000|Arm A Dose Escalation|Adverse Event|2
5994085|NCT02810418|9587544|FG001|Arm A Dose Escalation|Adverse Event|1
5994086|NCT02810418|9587545|FG002|Arm A Dose Escalation|Adverse Event|0
5994087|NCT02810418|9587546|FG003|Arm A Dose Escalation|Adverse Event|0
5994088|NCT02810418|9587547|FG004|Arm A Dose Escalation|Adverse Event|0
5994089|NCT02810418|9587548|FG005|Arm A Dose Escalation|Adverse Event|0
5994090|NCT02810418|9587549|FG006|Arm A Dose Escalation|Adverse Event|0
5994091|NCT02810418|9587543|FG000|Dose Expansion|Adverse Event|0
5994092|NCT02810418|9587544|FG001|Dose Expansion|Adverse Event|1
5994093|NCT02810418|9587545|FG002|Dose Expansion|Adverse Event|1
5994094|NCT02810418|9587546|FG003|Dose Expansion|Adverse Event|0
5994095|NCT02810418|9587547|FG004|Dose Expansion|Adverse Event|0
5994096|NCT02810418|9587548|FG005|Dose Expansion|Adverse Event|0
5994097|NCT02810418|9587549|FG006|Dose Expansion|Adverse Event|0
5994098|NCT02810418|9587543|FG000|Dose Expansion|Physician Decision|0
5994099|NCT02810418|9587544|FG001|Dose Expansion|Physician Decision|0
5994100|NCT02810418|9587545|FG002|Dose Expansion|Physician Decision|2
5994101|NCT02810418|9587546|FG003|Dose Expansion|Physician Decision|0
5994102|NCT02810418|9587547|FG004|Dose Expansion|Physician Decision|0
5994103|NCT02810418|9587548|FG005|Dose Expansion|Physician Decision|0
5994104|NCT02810418|9587549|FG006|Dose Expansion|Physician Decision|0
5994105|NCT02810418|9587543|FG000|Arm B Dose Escalation|Adverse Event|0
5994106|NCT02810418|9587544|FG001|Arm B Dose Escalation|Adverse Event|0
5994107|NCT02810418|9587545|FG002|Arm B Dose Escalation|Adverse Event|0
5994108|NCT02810418|9587546|FG003|Arm B Dose Escalation|Adverse Event|0
5994109|NCT02810418|9587547|FG004|Arm B Dose Escalation|Adverse Event|1
5994110|NCT02810418|9587548|FG005|Arm B Dose Escalation|Adverse Event|2
5994111|NCT02810418|9587549|FG006|Arm B Dose Escalation|Adverse Event|0
5994112|NCT02781584|9587630|FG000|Pre-treatment Phase|Investigator's Discretion|0
5994113|NCT02781584|9587631|FG001|Pre-treatment Phase|Investigator's Discretion|0
5994114|NCT02781584|9587632|FG002|Pre-treatment Phase|Investigator's Discretion|0
5994115|NCT02781584|9587633|FG003|Pre-treatment Phase|Investigator's Discretion|0
5994116|NCT02781584|9587634|FG004|Pre-treatment Phase|Investigator's Discretion|0
6070078|NCT00548249|9672949|FG004|Overall Study|Erythropoietin (ESA)Dose Change Required|2
6070079|NCT00548249|9672945|FG000|Overall Study|Hemoglobin (Hgb) >= 12.6 g/dL|1
6070080|NCT00548249|9672946|FG001|Overall Study|Hemoglobin (Hgb) >= 12.6 g/dL|1
5994117|NCT02781584|9587635|FG005|Pre-treatment Phase|Investigator's Discretion|0
5994118|NCT02781584|9587636|FG006|Pre-treatment Phase|Investigator's Discretion|0
5994119|NCT02781584|9587637|FG007|Pre-treatment Phase|Investigator's Discretion|0
5994120|NCT02781584|9587638|FG008|Pre-treatment Phase|Investigator's Discretion|0
5994121|NCT02781584|9587639|FG009|Pre-treatment Phase|Investigator's Discretion|0
5994122|NCT02781584|9587640|FG010|Pre-treatment Phase|Investigator's Discretion|0
5994123|NCT02781584|9587641|FG011|Pre-treatment Phase|Investigator's Discretion|2
5994124|NCT02781584|9587642|FG012|Pre-treatment Phase|Investigator's Discretion|1
5994125|NCT02781584|9587630|FG000|Pre-treatment Phase|Adverse Event|0
5994126|NCT02781584|9587631|FG001|Pre-treatment Phase|Adverse Event|0
5994127|NCT02781584|9587632|FG002|Pre-treatment Phase|Adverse Event|0
5994128|NCT02781584|9587633|FG003|Pre-treatment Phase|Adverse Event|0
5994129|NCT02781584|9587634|FG004|Pre-treatment Phase|Adverse Event|0
5994130|NCT02781584|9587635|FG005|Pre-treatment Phase|Adverse Event|0
5994131|NCT02781584|9587636|FG006|Pre-treatment Phase|Adverse Event|0
5994132|NCT02781584|9587637|FG007|Pre-treatment Phase|Adverse Event|0
5994133|NCT02781584|9587638|FG008|Pre-treatment Phase|Adverse Event|0
5994134|NCT02781584|9587639|FG009|Pre-treatment Phase|Adverse Event|0
5994135|NCT02781584|9587640|FG010|Pre-treatment Phase|Adverse Event|0
5994136|NCT02781584|9587641|FG011|Pre-treatment Phase|Adverse Event|1
5994137|NCT02781584|9587642|FG012|Pre-treatment Phase|Adverse Event|0
5994138|NCT02781584|9587630|FG000|Treatment Phase|Withdrew Consent|0
5994139|NCT02781584|9587631|FG001|Treatment Phase|Withdrew Consent|0
5994140|NCT02781584|9587632|FG002|Treatment Phase|Withdrew Consent|0
5994141|NCT02781584|9587633|FG003|Treatment Phase|Withdrew Consent|0
5994142|NCT02781584|9587634|FG004|Treatment Phase|Withdrew Consent|0
5994143|NCT02781584|9587635|FG005|Treatment Phase|Withdrew Consent|1
5994144|NCT02781584|9587636|FG006|Treatment Phase|Withdrew Consent|0
5994145|NCT02781584|9587637|FG007|Treatment Phase|Withdrew Consent|0
5994146|NCT02781584|9587638|FG008|Treatment Phase|Withdrew Consent|0
5994147|NCT02781584|9587639|FG009|Treatment Phase|Withdrew Consent|0
5994148|NCT02781584|9587640|FG010|Treatment Phase|Withdrew Consent|1
5994149|NCT02781584|9587641|FG011|Treatment Phase|Withdrew Consent|2
5994150|NCT02781584|9587642|FG012|Treatment Phase|Withdrew Consent|0
5994151|NCT02781584|9587630|FG000|Treatment Phase|Adverse Event|0
5994152|NCT02781584|9587631|FG001|Treatment Phase|Adverse Event|0
5994153|NCT02781584|9587632|FG002|Treatment Phase|Adverse Event|0
5994154|NCT02781584|9587633|FG003|Treatment Phase|Adverse Event|0
5994155|NCT02781584|9587634|FG004|Treatment Phase|Adverse Event|0
5994156|NCT02781584|9587635|FG005|Treatment Phase|Adverse Event|0
5994157|NCT02781584|9587636|FG006|Treatment Phase|Adverse Event|0
5994158|NCT02781584|9587637|FG007|Treatment Phase|Adverse Event|1
5994159|NCT02781584|9587638|FG008|Treatment Phase|Adverse Event|0
5994160|NCT02781584|9587639|FG009|Treatment Phase|Adverse Event|0
5994161|NCT02781584|9587640|FG010|Treatment Phase|Adverse Event|0
5994162|NCT02781584|9587641|FG011|Treatment Phase|Adverse Event|0
5994163|NCT02781584|9587642|FG012|Treatment Phase|Adverse Event|0
5994164|NCT02714062|9587677|FG000|Overall Study|Adverse Event|0
5994165|NCT02714062|9587678|FG001|Overall Study|Adverse Event|0
5994166|NCT02714062|9587679|FG002|Overall Study|Adverse Event|2
5994167|NCT02714062|9587677|FG000|Overall Study|Withdrawal by Subject|1
5994168|NCT02714062|9587678|FG001|Overall Study|Withdrawal by Subject|0
5994169|NCT02714062|9587679|FG002|Overall Study|Withdrawal by Subject|1
5994170|NCT02714062|9587677|FG000|Overall Study|Protocol Violation|0
5994171|NCT02714062|9587678|FG001|Overall Study|Protocol Violation|1
5994172|NCT02714062|9587679|FG002|Overall Study|Protocol Violation|0
5994173|NCT02707055|9587691|FG000|Phase 1|Withdrawal by Subject|1
5994174|NCT02707055|9587692|FG001|Phase 1|Withdrawal by Subject|2
5994175|NCT02707055|9587691|FG000|Phase 1|Physician Decision|0
5994176|NCT02707055|9587692|FG001|Phase 1|Physician Decision|1
5994177|NCT02707055|9587691|FG000|Phase 2|Adverse Event|1
5994178|NCT02707055|9587692|FG001|Phase 2|Adverse Event|2
5994179|NCT02656290|9587702|FG000|Overall Study|Subjects Remain On Study|26
5994180|NCT02652130|9587706|FG000|Overall Study|Death|1
5994181|NCT02616393|9587713|FG000|Overall Study|Death|5
5994182|NCT02616393|9587714|FG001|Overall Study|Death|12
5994183|NCT02616393|9587715|FG002|Overall Study|Death|1
5994184|NCT02616393|9587713|FG000|Overall Study|Termination by Sponsor|4
5994185|NCT02616393|9587714|FG001|Overall Study|Termination by Sponsor|5
5994186|NCT02616393|9587715|FG002|Overall Study|Termination by Sponsor|2
5994187|NCT02616393|9587713|FG000|Overall Study|Other|3
5994188|NCT02616393|9587714|FG001|Overall Study|Other|0
5994189|NCT02616393|9587715|FG002|Overall Study|Other|0
5994190|NCT02616393|9587713|FG000|Overall Study|Withdrawal by Subject|1
5994191|NCT02616393|9587714|FG001|Overall Study|Withdrawal by Subject|1
5994192|NCT02616393|9587715|FG002|Overall Study|Withdrawal by Subject|0
5994193|NCT02616393|9587713|FG000|Overall Study|Lost to Follow-up|0
5994194|NCT02616393|9587714|FG001|Overall Study|Lost to Follow-up|2
5994195|NCT02616393|9587715|FG002|Overall Study|Lost to Follow-up|0
5994196|NCT02602288|9587741|FG000|End of Treatment/3 Month Follow-up|Lost to Follow-up|14
5994197|NCT02602288|9587742|FG001|End of Treatment/3 Month Follow-up|Lost to Follow-up|10
5994198|NCT02602288|9587741|FG000|End of Treatment/3 Month Follow-up|Withdrawal by Subject|2
5994199|NCT02602288|9587742|FG001|End of Treatment/3 Month Follow-up|Withdrawal by Subject|2
5994200|NCT02602288|9587741|FG000|End of Treatment/3 Month Follow-up|Withdrawn - refused treatment|9
5994201|NCT02602288|9587742|FG001|End of Treatment/3 Month Follow-up|Withdrawn - refused treatment|6
5994202|NCT02602288|9587741|FG000|12 Month Follow-up|Lost to Follow-up|0
5994203|NCT02602288|9587742|FG001|12 Month Follow-up|Lost to Follow-up|4
5994204|NCT02602288|9587741|FG000|12 Month Follow-up|Withdrawal by Subject|2
5994205|NCT02602288|9587742|FG001|12 Month Follow-up|Withdrawal by Subject|0
5994206|NCT02577523|9587750|FG000|Overall Study|Adverse Event|1
5994207|NCT02577523|9587751|FG001|Overall Study|Adverse Event|1
5994208|NCT02577523|9587750|FG000|Overall Study|Lack of Efficacy|1
5994209|NCT02577523|9587751|FG001|Overall Study|Lack of Efficacy|1
6070081|NCT00548249|9672947|FG002|Overall Study|Hemoglobin (Hgb) >= 12.6 g/dL|1
6070082|NCT00548249|9672948|FG003|Overall Study|Hemoglobin (Hgb) >= 12.6 g/dL|1
6070083|NCT00548249|9672949|FG004|Overall Study|Hemoglobin (Hgb) >= 12.6 g/dL|0
6070084|NCT00548249|9672945|FG000|Overall Study|Prolonged hospitalization|0
6070085|NCT00548249|9672946|FG001|Overall Study|Prolonged hospitalization|0
6070086|NCT00548249|9672947|FG002|Overall Study|Prolonged hospitalization|2
6070087|NCT00548249|9672948|FG003|Overall Study|Prolonged hospitalization|1
6070088|NCT00548249|9672949|FG004|Overall Study|Prolonged hospitalization|0
6070089|NCT00548249|9672945|FG000|Overall Study|Withdrawal by Subject|2
6070090|NCT00548249|9672946|FG001|Overall Study|Withdrawal by Subject|0
6070091|NCT00548249|9672947|FG002|Overall Study|Withdrawal by Subject|0
6070092|NCT00548249|9672948|FG003|Overall Study|Withdrawal by Subject|0
6070093|NCT00548249|9672949|FG004|Overall Study|Withdrawal by Subject|0
6070094|NCT00548249|9672945|FG000|Overall Study|Corrected Q-wave T-wave (QTc) increase|0
6070095|NCT00548249|9672946|FG001|Overall Study|Corrected Q-wave T-wave (QTc) increase|1
6070096|NCT00548249|9672947|FG002|Overall Study|Corrected Q-wave T-wave (QTc) increase|0
6070097|NCT00548249|9672948|FG003|Overall Study|Corrected Q-wave T-wave (QTc) increase|0
6070098|NCT00548249|9672949|FG004|Overall Study|Corrected Q-wave T-wave (QTc) increase|1
6070099|NCT00548249|9672945|FG000|Overall Study|Sponsor's request|0
6070100|NCT00548249|9672946|FG001|Overall Study|Sponsor's request|0
6070101|NCT00548249|9672947|FG002|Overall Study|Sponsor's request|0
6070102|NCT00548249|9672948|FG003|Overall Study|Sponsor's request|1
6070103|NCT00548249|9672949|FG004|Overall Study|Sponsor's request|0
6070104|NCT00548262|9672961|FG000|Overall Study|Death|21
6070105|NCT00548262|9672961|FG000|Overall Study|Adverse Event|2
6070106|NCT00548262|9672961|FG000|Overall Study|Lack of Efficacy|4
6070107|NCT00548262|9672961|FG000|Overall Study|Lost to Follow-up|1
6070108|NCT00548262|9672961|FG000|Overall Study|Other|3
6070109|NCT00548262|9672961|FG000|Overall Study|Withdrawal by Subject|1
6070110|NCT00548340|9672968|FG000|Overall Study|Protocol Violation|2
6070111|NCT00548340|9672969|FG001|Overall Study|Protocol Violation|3
5994210|NCT02577523|9587750|FG000|Overall Study|Withdrawal by Subject|1
5994211|NCT02577523|9587751|FG001|Overall Study|Withdrawal by Subject|0
6046421|NCT00406640|9645604|FG000|DB Continuation Phase for Responders|non-compliance|7
6046422|NCT00406640|9645605|FG001|DB Continuation Phase for Responders|non-compliance|5
6046423|NCT00406640|9645604|FG000|DB Continuation Phase for Responders|Protocol Violation|2
6046424|NCT00406640|9645605|FG001|DB Continuation Phase for Responders|Protocol Violation|2
6046425|NCT00406640|9645604|FG000|DB Continuation Phase for Responders|Withdrawal by Subject|8
6070112|NCT00548340|9672970|FG002|Overall Study|Protocol Violation|3
6070113|NCT00548340|9672968|FG000|Overall Study|Adverse Event|2
6070114|NCT00548340|9672969|FG001|Overall Study|Adverse Event|2
6070115|NCT00548340|9672970|FG002|Overall Study|Adverse Event|2
6070116|NCT00548340|9672968|FG000|Overall Study|Lost to Follow-up|1
6046426|NCT00406640|9645605|FG001|DB Continuation Phase for Responders|Withdrawal by Subject|6
6070117|NCT00548340|9672969|FG001|Overall Study|Lost to Follow-up|1
6070118|NCT00548340|9672970|FG002|Overall Study|Lost to Follow-up|0
5994212|NCT02563002|9587759|FG000|Overall Study|Death|62
5994213|NCT02563002|9587760|FG001|Overall Study|Death|75
5994214|NCT02563002|9587759|FG000|Overall Study|Lost to Follow-up|1
5994215|NCT02563002|9587760|FG001|Overall Study|Lost to Follow-up|0
5994216|NCT02563002|9587759|FG000|Overall Study|Withdrawal by Subject|0
5994217|NCT02563002|9587760|FG001|Overall Study|Withdrawal by Subject|9
5994218|NCT02563002|9587759|FG000|Overall Study|Ongoing|90
5994219|NCT02563002|9587760|FG001|Overall Study|Ongoing|70
5994220|NCT02427958|9587778|FG000|Overall Study|Pretreatment Event (PTE) or AE|3
5994221|NCT02427958|9587778|FG000|Overall Study|Lost to Follow-up|6
5994222|NCT02427958|9587778|FG000|Overall Study|Withdrawal by Subject|14
5994223|NCT02427958|9587778|FG000|Overall Study|Lack of Efficacy|1
5994224|NCT02425826|9587784|FG000|Placebo-controlled Phase (Week 0 - 16)|Adverse Event|5
5994225|NCT02425826|9587785|FG001|Placebo-controlled Phase (Week 0 - 16)|Adverse Event|2
5994226|NCT02425826|9587786|FG002|Placebo-controlled Phase (Week 0 - 16)|Adverse Event|0
5994227|NCT02425826|9587784|FG000|Placebo-controlled Phase (Week 0 - 16)|Lack of Efficacy|0
5994228|NCT02425826|9587785|FG001|Placebo-controlled Phase (Week 0 - 16)|Lack of Efficacy|1
5994229|NCT02425826|9587786|FG002|Placebo-controlled Phase (Week 0 - 16)|Lack of Efficacy|0
5994230|NCT02425826|9587784|FG000|Placebo-controlled Phase (Week 0 - 16)|Withdrawal by Subject|9
5994231|NCT02425826|9587785|FG001|Placebo-controlled Phase (Week 0 - 16)|Withdrawal by Subject|1
5994232|NCT02425826|9587786|FG002|Placebo-controlled Phase (Week 0 - 16)|Withdrawal by Subject|0
5994233|NCT02425826|9587784|FG000|Placebo-controlled Phase (Week 0 - 16)|Lost to Follow-up|10
5994234|NCT02425826|9587785|FG001|Placebo-controlled Phase (Week 0 - 16)|Lost to Follow-up|4
5994235|NCT02425826|9587786|FG002|Placebo-controlled Phase (Week 0 - 16)|Lost to Follow-up|0
5994236|NCT02425826|9587784|FG000|Placebo-controlled Phase (Week 0 - 16)|Other|3
5994237|NCT02425826|9587785|FG001|Placebo-controlled Phase (Week 0 - 16)|Other|1
5994238|NCT02425826|9587786|FG002|Placebo-controlled Phase (Week 0 - 16)|Other|0
5994239|NCT02425826|9587784|FG000|Apremilast Extension Phase (Weeks 16-52)|Adverse Event|7
5994240|NCT02425826|9587785|FG001|Apremilast Extension Phase (Weeks 16-52)|Adverse Event|0
5994241|NCT02425826|9587786|FG002|Apremilast Extension Phase (Weeks 16-52)|Adverse Event|2
5994242|NCT02425826|9587784|FG000|Apremilast Extension Phase (Weeks 16-52)|Lost to Follow-up|8
5994243|NCT02425826|9587785|FG001|Apremilast Extension Phase (Weeks 16-52)|Lost to Follow-up|0
5994244|NCT02425826|9587786|FG002|Apremilast Extension Phase (Weeks 16-52)|Lost to Follow-up|6
5994245|NCT02425826|9587784|FG000|Apremilast Extension Phase (Weeks 16-52)|Withdrawal by Subject|12
5994246|NCT02425826|9587785|FG001|Apremilast Extension Phase (Weeks 16-52)|Withdrawal by Subject|0
5994247|NCT02425826|9587786|FG002|Apremilast Extension Phase (Weeks 16-52)|Withdrawal by Subject|4
5994248|NCT02425826|9587784|FG000|Apremilast Extension Phase (Weeks 16-52)|Lack of Efficacy|8
5994249|NCT02425826|9587785|FG001|Apremilast Extension Phase (Weeks 16-52)|Lack of Efficacy|0
5994250|NCT02425826|9587786|FG002|Apremilast Extension Phase (Weeks 16-52)|Lack of Efficacy|1
5994251|NCT02425826|9587784|FG000|Apremilast Extension Phase (Weeks 16-52)|miscellaneous|0
5994252|NCT02425826|9587785|FG001|Apremilast Extension Phase (Weeks 16-52)|miscellaneous|0
5994253|NCT02425826|9587786|FG002|Apremilast Extension Phase (Weeks 16-52)|miscellaneous|1
5994254|NCT02000622|9587856|FG000|Overall Study|Withdrawal by Subject|5
5994255|NCT02000622|9587857|FG001|Overall Study|Withdrawal by Subject|7
5994256|NCT02000622|9587856|FG000|Overall Study|Lost to Follow-up|4
5994257|NCT02000622|9587857|FG001|Overall Study|Lost to Follow-up|0
5994258|NCT02000622|9587856|FG000|Overall Study|Death|159
5994259|NCT02000622|9587857|FG001|Overall Study|Death|73
5994260|NCT02000622|9587856|FG000|Overall Study|Withdrawn due to site closure|1
5994261|NCT02000622|9587857|FG001|Overall Study|Withdrawn due to site closure|0
5994262|NCT01933932|9587865|FG000|Overall Study|Death|173
5994263|NCT01933932|9587866|FG001|Overall Study|Death|163
5994264|NCT01933932|9587865|FG000|Overall Study|Withdrawal by Subject|11
5994265|NCT01933932|9587866|FG001|Overall Study|Withdrawal by Subject|14
5994266|NCT01933932|9587865|FG000|Overall Study|Eligibility criteria not fulfilled|0
5994267|NCT01933932|9587866|FG001|Overall Study|Eligibility criteria not fulfilled|1
5994268|NCT01927068|9587874|FG000|Overall Study|Death|37
5994269|NCT01927068|9587875|FG001|Overall Study|Death|3
5994270|NCT01927068|9587874|FG000|Overall Study|Withdrawal by Subject|50
5994271|NCT01927068|9587875|FG001|Overall Study|Withdrawal by Subject|3
5994272|NCT01927068|9587874|FG000|Overall Study|Lost to Follow-up|10
5994273|NCT01927068|9587875|FG001|Overall Study|Lost to Follow-up|2
5994274|NCT01927068|9587874|FG000|Overall Study|Physician Decision|9
5994275|NCT01927068|9587875|FG001|Overall Study|Physician Decision|0
5994276|NCT01927068|9587874|FG000|Overall Study|Missed last follow-up visit|2
5994277|NCT01927068|9587875|FG001|Overall Study|Missed last follow-up visit|0
5994278|NCT01813435|9587893|FG000|Overall Study|did not finish experimental regimen|1902
5994279|NCT01813435|9587894|FG001|Overall Study|did not finish experimental regimen|770
5994280|NCT01813435|9587893|FG000|Overall Study|Lost to Follow-up|268
5994281|NCT01813435|9587894|FG001|Overall Study|Lost to Follow-up|237
5994282|NCT01690299|9587908|FG000|Placebo-controlled Phase (Weeks 0-16)|Adverse Event|2
5994283|NCT01690299|9587909|FG001|Placebo-controlled Phase (Weeks 0-16)|Adverse Event|2
5994284|NCT01690299|9587910|FG002|Placebo-controlled Phase (Weeks 0-16)|Adverse Event|1
5994285|NCT01690299|9587911|FG003|Placebo-controlled Phase (Weeks 0-16)|Adverse Event|0
5994286|NCT01690299|9587912|FG004|Placebo-controlled Phase (Weeks 0-16)|Adverse Event|0
5994287|NCT01690299|9587913|FG005|Placebo-controlled Phase (Weeks 0-16)|Adverse Event|0
5994288|NCT01690299|9587908|FG000|Placebo-controlled Phase (Weeks 0-16)|Lack of Efficacy|4
5994289|NCT01690299|9587909|FG001|Placebo-controlled Phase (Weeks 0-16)|Lack of Efficacy|0
5994290|NCT01690299|9587910|FG002|Placebo-controlled Phase (Weeks 0-16)|Lack of Efficacy|0
5994291|NCT01690299|9587911|FG003|Placebo-controlled Phase (Weeks 0-16)|Lack of Efficacy|0
5994292|NCT01690299|9587912|FG004|Placebo-controlled Phase (Weeks 0-16)|Lack of Efficacy|0
5994293|NCT01690299|9587913|FG005|Placebo-controlled Phase (Weeks 0-16)|Lack of Efficacy|0
5994294|NCT01690299|9587908|FG000|Placebo-controlled Phase (Weeks 0-16)|Withdrawal by Subject|1
5994295|NCT01690299|9587909|FG001|Placebo-controlled Phase (Weeks 0-16)|Withdrawal by Subject|3
5994296|NCT01690299|9587910|FG002|Placebo-controlled Phase (Weeks 0-16)|Withdrawal by Subject|0
5994297|NCT01690299|9587911|FG003|Placebo-controlled Phase (Weeks 0-16)|Withdrawal by Subject|0
5994298|NCT01690299|9587912|FG004|Placebo-controlled Phase (Weeks 0-16)|Withdrawal by Subject|0
5994299|NCT01690299|9587913|FG005|Placebo-controlled Phase (Weeks 0-16)|Withdrawal by Subject|0
5994300|NCT01690299|9587908|FG000|Placebo-controlled Phase (Weeks 0-16)|Other|2
5994301|NCT01690299|9587909|FG001|Placebo-controlled Phase (Weeks 0-16)|Other|1
5994302|NCT01690299|9587910|FG002|Placebo-controlled Phase (Weeks 0-16)|Other|1
5994303|NCT01690299|9587911|FG003|Placebo-controlled Phase (Weeks 0-16)|Other|0
5994304|NCT01690299|9587912|FG004|Placebo-controlled Phase (Weeks 0-16)|Other|0
5994305|NCT01690299|9587913|FG005|Placebo-controlled Phase (Weeks 0-16)|Other|0
5994306|NCT01690299|9587908|FG000|Apremilast Extension Phase (Weeks16-104)|Adverse Event|0
5994307|NCT01690299|9587909|FG001|Apremilast Extension Phase (Weeks16-104)|Adverse Event|0
5994308|NCT01690299|9587910|FG002|Apremilast Extension Phase (Weeks16-104)|Adverse Event|0
5994309|NCT01690299|9587911|FG003|Apremilast Extension Phase (Weeks16-104)|Adverse Event|3
5994310|NCT01690299|9587912|FG004|Apremilast Extension Phase (Weeks16-104)|Adverse Event|4
5994311|NCT01690299|9587913|FG005|Apremilast Extension Phase (Weeks16-104)|Adverse Event|3
5994312|NCT01690299|9587908|FG000|Apremilast Extension Phase (Weeks16-104)|Lack of Efficacy|0
5994313|NCT01690299|9587909|FG001|Apremilast Extension Phase (Weeks16-104)|Lack of Efficacy|0
5994314|NCT01690299|9587910|FG002|Apremilast Extension Phase (Weeks16-104)|Lack of Efficacy|0
5994315|NCT01690299|9587911|FG003|Apremilast Extension Phase (Weeks16-104)|Lack of Efficacy|9
5994316|NCT01690299|9587912|FG004|Apremilast Extension Phase (Weeks16-104)|Lack of Efficacy|10
5994317|NCT01690299|9587913|FG005|Apremilast Extension Phase (Weeks16-104)|Lack of Efficacy|8
5994318|NCT01690299|9587908|FG000|Apremilast Extension Phase (Weeks16-104)|Non-compliance With Study Drug|0
5994319|NCT01690299|9587909|FG001|Apremilast Extension Phase (Weeks16-104)|Non-compliance With Study Drug|0
5994320|NCT01690299|9587910|FG002|Apremilast Extension Phase (Weeks16-104)|Non-compliance With Study Drug|0
5994321|NCT01690299|9587911|FG003|Apremilast Extension Phase (Weeks16-104)|Non-compliance With Study Drug|0
5994322|NCT01690299|9587912|FG004|Apremilast Extension Phase (Weeks16-104)|Non-compliance With Study Drug|1
5994323|NCT01690299|9587913|FG005|Apremilast Extension Phase (Weeks16-104)|Non-compliance With Study Drug|1
5994324|NCT01690299|9587908|FG000|Apremilast Extension Phase (Weeks16-104)|Withdrawal by Subject|0
5994325|NCT01690299|9587909|FG001|Apremilast Extension Phase (Weeks16-104)|Withdrawal by Subject|0
5994326|NCT01690299|9587910|FG002|Apremilast Extension Phase (Weeks16-104)|Withdrawal by Subject|0
5994327|NCT01690299|9587911|FG003|Apremilast Extension Phase (Weeks16-104)|Withdrawal by Subject|8
5994328|NCT01690299|9587912|FG004|Apremilast Extension Phase (Weeks16-104)|Withdrawal by Subject|5
5994329|NCT01690299|9587913|FG005|Apremilast Extension Phase (Weeks16-104)|Withdrawal by Subject|11
5994330|NCT01690299|9587908|FG000|Apremilast Extension Phase (Weeks16-104)|Lost to Follow-up|0
5994331|NCT01690299|9587909|FG001|Apremilast Extension Phase (Weeks16-104)|Lost to Follow-up|0
5994332|NCT01690299|9587910|FG002|Apremilast Extension Phase (Weeks16-104)|Lost to Follow-up|0
5994333|NCT01690299|9587911|FG003|Apremilast Extension Phase (Weeks16-104)|Lost to Follow-up|6
5994334|NCT01690299|9587912|FG004|Apremilast Extension Phase (Weeks16-104)|Lost to Follow-up|13
5994335|NCT01690299|9587913|FG005|Apremilast Extension Phase (Weeks16-104)|Lost to Follow-up|6
5994336|NCT01690299|9587908|FG000|Apremilast Extension Phase (Weeks16-104)|Protocol Violation|0
5994337|NCT01690299|9587909|FG001|Apremilast Extension Phase (Weeks16-104)|Protocol Violation|0
5994338|NCT01690299|9587910|FG002|Apremilast Extension Phase (Weeks16-104)|Protocol Violation|0
5994339|NCT01690299|9587911|FG003|Apremilast Extension Phase (Weeks16-104)|Protocol Violation|0
5994340|NCT01690299|9587912|FG004|Apremilast Extension Phase (Weeks16-104)|Protocol Violation|0
5994341|NCT01690299|9587913|FG005|Apremilast Extension Phase (Weeks16-104)|Protocol Violation|1
5994342|NCT01452152|9587967|FG000|Overall Study|Study termination by sponsor|5
5994343|NCT01452152|9587968|FG001|Overall Study|Study termination by sponsor|0
5994344|NCT01452152|9587969|FG002|Overall Study|Study termination by sponsor|4
5994345|NCT01420926|9587979|FG000|Overall Study|Adverse Event|6
5994346|NCT01420926|9587980|FG001|Overall Study|Adverse Event|4
5994347|NCT01420926|9587979|FG000|Overall Study|Death|18
5994348|NCT01420926|9587980|FG001|Overall Study|Death|17
5994349|NCT01420926|9587979|FG000|Overall Study|Withdrawal by Subject|11
5994350|NCT01420926|9587980|FG001|Overall Study|Withdrawal by Subject|16
5994351|NCT01420926|9587979|FG000|Overall Study|Non-protocol treatment|17
5994352|NCT01420926|9587980|FG001|Overall Study|Non-protocol treatment|20
5994353|NCT01420926|9587979|FG000|Overall Study|Physician Decision|7
5994354|NCT01420926|9587980|FG001|Overall Study|Physician Decision|5
5994355|NCT01420926|9587979|FG000|Overall Study|Continues on active treatment|1
5994356|NCT01420926|9587980|FG001|Overall Study|Continues on active treatment|3
5994357|NCT01386385|9587991|FG000|Phase I 40mg: Concurrent CRT|Progression/relapse|1
5994358|NCT01386385|9587992|FG001|Phase I 40mg: Concurrent CRT|Progression/relapse|0
5994359|NCT01386385|9587993|FG002|Phase I 40mg: Concurrent CRT|Progression/relapse|0
5994360|NCT01386385|9587994|FG003|Phase I 40mg: Concurrent CRT|Progression/relapse|0
5994361|NCT01386385|9587995|FG004|Phase I 40mg: Concurrent CRT|Progression/relapse|0
5994362|NCT01386385|9587996|FG005|Phase I 40mg: Concurrent CRT|Progression/relapse|0
5994363|NCT01386385|9587997|FG006|Phase I 40mg: Concurrent CRT|Progression/relapse|0
5994364|NCT01386385|9587998|FG007|Phase I 40mg: Concurrent CRT|Progression/relapse|0
5994365|NCT01386385|9587991|FG000|Phase I 40mg: Concurrent CRT|Other- not protocol specified|1
5994366|NCT01386385|9587992|FG001|Phase I 40mg: Concurrent CRT|Other- not protocol specified|0
5994367|NCT01386385|9587993|FG002|Phase I 40mg: Concurrent CRT|Other- not protocol specified|0
5994368|NCT01386385|9587994|FG003|Phase I 40mg: Concurrent CRT|Other- not protocol specified|0
5994369|NCT01386385|9587995|FG004|Phase I 40mg: Concurrent CRT|Other- not protocol specified|0
5994370|NCT01386385|9587996|FG005|Phase I 40mg: Concurrent CRT|Other- not protocol specified|0
5994371|NCT01386385|9587997|FG006|Phase I 40mg: Concurrent CRT|Other- not protocol specified|0
5994372|NCT01386385|9587998|FG007|Phase I 40mg: Concurrent CRT|Other- not protocol specified|0
5994373|NCT01386385|9587991|FG000|Phase I 80mg: Concurrent CRT|Adverse Event|0
5994374|NCT01386385|9587992|FG001|Phase I 80mg: Concurrent CRT|Adverse Event|0
5994375|NCT01386385|9587993|FG002|Phase I 80mg: Concurrent CRT|Adverse Event|2
5994376|NCT01386385|9587994|FG003|Phase I 80mg: Concurrent CRT|Adverse Event|0
5994377|NCT01386385|9587995|FG004|Phase I 80mg: Concurrent CRT|Adverse Event|0
5994378|NCT01386385|9587996|FG005|Phase I 80mg: Concurrent CRT|Adverse Event|0
5994379|NCT01386385|9587997|FG006|Phase I 80mg: Concurrent CRT|Adverse Event|0
5994380|NCT01386385|9587998|FG007|Phase I 80mg: Concurrent CRT|Adverse Event|0
5994381|NCT01386385|9587991|FG000|Phase I 120mg: Concurrent CRT|Refusal unrelated to AE|0
5994382|NCT01386385|9587992|FG001|Phase I 120mg: Concurrent CRT|Refusal unrelated to AE|0
5994383|NCT01386385|9587993|FG002|Phase I 120mg: Concurrent CRT|Refusal unrelated to AE|0
5994384|NCT01386385|9587994|FG003|Phase I 120mg: Concurrent CRT|Refusal unrelated to AE|0
5994385|NCT01386385|9587995|FG004|Phase I 120mg: Concurrent CRT|Refusal unrelated to AE|1
5994386|NCT01386385|9587996|FG005|Phase I 120mg: Concurrent CRT|Refusal unrelated to AE|0
5994387|NCT01386385|9587997|FG006|Phase I 120mg: Concurrent CRT|Refusal unrelated to AE|0
5994388|NCT01386385|9587998|FG007|Phase I 120mg: Concurrent CRT|Refusal unrelated to AE|0
5994389|NCT01386385|9587991|FG000|Phase II Concurrent CRT|Adverse Event|0
5994390|NCT01386385|9587992|FG001|Phase II Concurrent CRT|Adverse Event|0
5994391|NCT01386385|9587993|FG002|Phase II Concurrent CRT|Adverse Event|0
6070119|NCT00548340|9672968|FG000|Overall Study|Withdrawal by Subject|2
6070120|NCT00548340|9672969|FG001|Overall Study|Withdrawal by Subject|4
6070121|NCT00548340|9672970|FG002|Overall Study|Withdrawal by Subject|3
5994392|NCT01386385|9587994|FG003|Phase II Concurrent CRT|Adverse Event|0
5994393|NCT01386385|9587995|FG004|Phase II Concurrent CRT|Adverse Event|0
5994394|NCT01386385|9587996|FG005|Phase II Concurrent CRT|Adverse Event|0
5994395|NCT01386385|9587997|FG006|Phase II Concurrent CRT|Adverse Event|3
5994396|NCT01386385|9587998|FG007|Phase II Concurrent CRT|Adverse Event|3
5994397|NCT01386385|9587991|FG000|Phase II Concurrent CRT|Refusal unrelated to AE|0
5994398|NCT01386385|9587992|FG001|Phase II Concurrent CRT|Refusal unrelated to AE|0
5994399|NCT01386385|9587993|FG002|Phase II Concurrent CRT|Refusal unrelated to AE|0
5994400|NCT01386385|9587994|FG003|Phase II Concurrent CRT|Refusal unrelated to AE|0
5994401|NCT01386385|9587995|FG004|Phase II Concurrent CRT|Refusal unrelated to AE|0
5994402|NCT01386385|9587996|FG005|Phase II Concurrent CRT|Refusal unrelated to AE|0
5994403|NCT01386385|9587997|FG006|Phase II Concurrent CRT|Refusal unrelated to AE|3
5994404|NCT01386385|9587998|FG007|Phase II Concurrent CRT|Refusal unrelated to AE|0
5994405|NCT01386385|9587991|FG000|Phase II: Consolidation Therapy|Adverse Event|0
5994406|NCT01386385|9587992|FG001|Phase II: Consolidation Therapy|Adverse Event|0
5994407|NCT01386385|9587993|FG002|Phase II: Consolidation Therapy|Adverse Event|0
5994408|NCT01386385|9587994|FG003|Phase II: Consolidation Therapy|Adverse Event|0
5994409|NCT01386385|9587995|FG004|Phase II: Consolidation Therapy|Adverse Event|0
6070122|NCT00548340|9672968|FG000|Overall Study|Other|1
6070123|NCT00548340|9672969|FG001|Overall Study|Other|1
6070124|NCT00548340|9672970|FG002|Overall Study|Other|1
6070125|NCT00548405|9672981|FG000|Overall Study|Adverse Event|6
6070126|NCT00548405|9672982|FG001|Overall Study|Adverse Event|2
6070127|NCT00548405|9672983|FG002|Overall Study|Adverse Event|0
6070128|NCT00548405|9672981|FG000|Overall Study|Lack of Efficacy|6
6070129|NCT00548405|9672982|FG001|Overall Study|Lack of Efficacy|0
6070130|NCT00548405|9672983|FG002|Overall Study|Lack of Efficacy|0
6070131|NCT00548405|9672981|FG000|Overall Study|Physician Decision|3
5994410|NCT01386385|9587996|FG005|Phase II: Consolidation Therapy|Adverse Event|0
5994411|NCT01386385|9587997|FG006|Phase II: Consolidation Therapy|Adverse Event|2
5994412|NCT01386385|9587998|FG007|Phase II: Consolidation Therapy|Adverse Event|1
5994413|NCT01386385|9587991|FG000|Phase II: Consolidation Therapy|Refusal unrelated to AE|0
5994414|NCT01386385|9587992|FG001|Phase II: Consolidation Therapy|Refusal unrelated to AE|0
5994415|NCT01386385|9587993|FG002|Phase II: Consolidation Therapy|Refusal unrelated to AE|0
5994416|NCT01386385|9587994|FG003|Phase II: Consolidation Therapy|Refusal unrelated to AE|0
5994417|NCT01386385|9587995|FG004|Phase II: Consolidation Therapy|Refusal unrelated to AE|0
5994418|NCT01386385|9587996|FG005|Phase II: Consolidation Therapy|Refusal unrelated to AE|0
6070132|NCT00548405|9672982|FG001|Overall Study|Physician Decision|4
5994419|NCT01386385|9587997|FG006|Phase II: Consolidation Therapy|Refusal unrelated to AE|2
5994420|NCT01386385|9587998|FG007|Phase II: Consolidation Therapy|Refusal unrelated to AE|0
5994421|NCT01386385|9587991|FG000|Phase II: Consolidation Therapy|Progression/relapse|0
5994422|NCT01386385|9587992|FG001|Phase II: Consolidation Therapy|Progression/relapse|0
5994423|NCT01386385|9587993|FG002|Phase II: Consolidation Therapy|Progression/relapse|0
5994424|NCT01386385|9587994|FG003|Phase II: Consolidation Therapy|Progression/relapse|0
5994425|NCT01386385|9587995|FG004|Phase II: Consolidation Therapy|Progression/relapse|0
6070133|NCT00548405|9672983|FG002|Overall Study|Physician Decision|1
6070134|NCT00548405|9672981|FG000|Overall Study|Pregnancy|1
6070135|NCT00548405|9672982|FG001|Overall Study|Pregnancy|0
6070136|NCT00548405|9672983|FG002|Overall Study|Pregnancy|0
6070137|NCT00548405|9672981|FG000|Overall Study|Protocol Violation|1
5994426|NCT01386385|9587996|FG005|Phase II: Consolidation Therapy|Progression/relapse|0
5994427|NCT01386385|9587997|FG006|Phase II: Consolidation Therapy|Progression/relapse|1
5994428|NCT01386385|9587998|FG007|Phase II: Consolidation Therapy|Progression/relapse|1
5994429|NCT01358877|9588021|FG000|Overall Study|Death|80
5994430|NCT01358877|9588022|FG001|Overall Study|Death|89
5994431|NCT01358877|9588021|FG000|Overall Study|Ongoing follow-up for post-recurrence|87
5994432|NCT01358877|9588022|FG001|Overall Study|Ongoing follow-up for post-recurrence|108
5994433|NCT01358877|9588021|FG000|Overall Study|Ongoing follow-up for IDFS event|2084
5994434|NCT01358877|9588022|FG001|Overall Study|Ongoing follow-up for IDFS event|2073
5994435|NCT01358877|9588021|FG000|Overall Study|Ongoing follow-up for overall survival|7
5994436|NCT01358877|9588022|FG001|Overall Study|Ongoing follow-up for overall survival|5
5994437|NCT01358877|9588021|FG000|Overall Study|Other|142
5994438|NCT01358877|9588022|FG001|Overall Study|Other|129
5994439|NCT01267955|9588033|FG000|Stage 1 (6 Months)|Death|3
5994440|NCT01267955|9588033|FG000|Stage 2 (6 Months)|Death|5
5994441|NCT01267955|9588033|FG000|Stage 2 (6 Months)|Protocol Violation|1
6046427|NCT00406640|9645604|FG000|DB Continuation Phase for Responders|Lack of Efficacy|1
6046428|NCT00406640|9645605|FG001|DB Continuation Phase for Responders|Lack of Efficacy|1
6046429|NCT00406640|9645604|FG000|OL Extension Phase for Non-Responders|Adverse Event|6
6046430|NCT00406640|9645605|FG001|OL Extension Phase for Non-Responders|Adverse Event|6
6046431|NCT00406640|9645604|FG000|OL Extension Phase for Non-Responders|Failed to Return|1
6046432|NCT00406640|9645605|FG001|OL Extension Phase for Non-Responders|Failed to Return|0
6046433|NCT00406640|9645604|FG000|OL Extension Phase for Non-Responders|Physician Decision|1
6046434|NCT00406640|9645605|FG001|OL Extension Phase for Non-Responders|Physician Decision|0
6046435|NCT00406640|9645604|FG000|OL Extension Phase for Non-Responders|Lost to Follow-up|2
6046436|NCT00406640|9645605|FG001|OL Extension Phase for Non-Responders|Lost to Follow-up|3
6046437|NCT00406640|9645604|FG000|OL Extension Phase for Non-Responders|non-compliance|3
6046438|NCT00406640|9645605|FG001|OL Extension Phase for Non-Responders|non-compliance|2
6046439|NCT00406640|9645604|FG000|OL Extension Phase for Non-Responders|Withdrawal by Subject|3
6046440|NCT00406640|9645605|FG001|OL Extension Phase for Non-Responders|Withdrawal by Subject|6
6046441|NCT00406640|9645604|FG000|OL Extension Phase for Non-Responders|Lack of Efficacy|6
6046442|NCT00406640|9645605|FG001|OL Extension Phase for Non-Responders|Lack of Efficacy|7
6046443|NCT00406653|9645621|FG000|Induction Period|Adverse Event|1
6046444|NCT00406653|9645622|FG001|Induction Period|Adverse Event|10
6046445|NCT00406653|9645623|FG002|Induction Period|Adverse Event|4
6046446|NCT00406653|9645624|FG003|Induction Period|Adverse Event|11
6046447|NCT00406653|9645625|FG004|Induction Period|Adverse Event|0
6046448|NCT00406653|9645626|FG005|Induction Period|Adverse Event|0
6046449|NCT00406653|9645627|FG006|Induction Period|Adverse Event|0
6046450|NCT00406653|9645621|FG000|Induction Period|Lack of Efficacy|11
6046451|NCT00406653|9645622|FG001|Induction Period|Lack of Efficacy|14
6046452|NCT00406653|9645623|FG002|Induction Period|Lack of Efficacy|8
6046453|NCT00406653|9645624|FG003|Induction Period|Lack of Efficacy|10
6046454|NCT00406653|9645625|FG004|Induction Period|Lack of Efficacy|0
6046455|NCT00406653|9645626|FG005|Induction Period|Lack of Efficacy|0
6046456|NCT00406653|9645627|FG006|Induction Period|Lack of Efficacy|0
6046457|NCT00406653|9645621|FG000|Induction Period|Lost to Follow-up|0
6046458|NCT00406653|9645622|FG001|Induction Period|Lost to Follow-up|2
6046459|NCT00406653|9645623|FG002|Induction Period|Lost to Follow-up|0
6046460|NCT00406653|9645624|FG003|Induction Period|Lost to Follow-up|0
6046461|NCT00406653|9645625|FG004|Induction Period|Lost to Follow-up|0
6046462|NCT00406653|9645626|FG005|Induction Period|Lost to Follow-up|0
6046463|NCT00406653|9645627|FG006|Induction Period|Lost to Follow-up|0
6046464|NCT00406653|9645621|FG000|Induction Period|Withdrawal of Consent|2
6046465|NCT00406653|9645622|FG001|Induction Period|Withdrawal of Consent|5
6046466|NCT00406653|9645623|FG002|Induction Period|Withdrawal of Consent|1
6046467|NCT00406653|9645624|FG003|Induction Period|Withdrawal of Consent|2
6046468|NCT00406653|9645625|FG004|Induction Period|Withdrawal of Consent|0
6046469|NCT00406653|9645626|FG005|Induction Period|Withdrawal of Consent|0
6046470|NCT00406653|9645627|FG006|Induction Period|Withdrawal of Consent|0
6046471|NCT00406653|9645621|FG000|Induction Period|Subject No Longer Meets Study Criteria|0
6046472|NCT00406653|9645622|FG001|Induction Period|Subject No Longer Meets Study Criteria|0
6046473|NCT00406653|9645623|FG002|Induction Period|Subject No Longer Meets Study Criteria|0
6046474|NCT00406653|9645624|FG003|Induction Period|Subject No Longer Meets Study Criteria|2
6046475|NCT00406653|9645625|FG004|Induction Period|Subject No Longer Meets Study Criteria|0
6070138|NCT00548405|9672982|FG001|Overall Study|Protocol Violation|0
5994442|NCT01232283|9588044|FG000|Placebo Controlled Phase (Weeks 0-16)|Adverse Event|12
5994443|NCT01232283|9588045|FG001|Placebo Controlled Phase (Weeks 0-16)|Adverse Event|8
5994444|NCT01232283|9588046|FG002|Placebo Controlled Phase (Weeks 0-16)|Adverse Event|0
5994445|NCT01232283|9588047|FG003|Placebo Controlled Phase (Weeks 0-16)|Adverse Event|0
5994446|NCT01232283|9588048|FG004|Placebo Controlled Phase (Weeks 0-16)|Adverse Event|0
5994447|NCT01232283|9588049|FG005|Placebo Controlled Phase (Weeks 0-16)|Adverse Event|0
5994448|NCT01232283|9588050|FG006|Placebo Controlled Phase (Weeks 0-16)|Adverse Event|0
5994449|NCT01232283|9588051|FG007|Placebo Controlled Phase (Weeks 0-16)|Adverse Event|0
5994450|NCT01232283|9588052|FG008|Placebo Controlled Phase (Weeks 0-16)|Adverse Event|0
5994451|NCT01232283|9588053|FG009|Placebo Controlled Phase (Weeks 0-16)|Adverse Event|0
5994452|NCT01232283|9588044|FG000|Placebo Controlled Phase (Weeks 0-16)|Lack of Efficacy|3
5994453|NCT01232283|9588045|FG001|Placebo Controlled Phase (Weeks 0-16)|Lack of Efficacy|2
5994454|NCT01232283|9588046|FG002|Placebo Controlled Phase (Weeks 0-16)|Lack of Efficacy|0
5994455|NCT01232283|9588047|FG003|Placebo Controlled Phase (Weeks 0-16)|Lack of Efficacy|0
5994456|NCT01232283|9588048|FG004|Placebo Controlled Phase (Weeks 0-16)|Lack of Efficacy|0
5994457|NCT01232283|9588049|FG005|Placebo Controlled Phase (Weeks 0-16)|Lack of Efficacy|0
5994458|NCT01232283|9588050|FG006|Placebo Controlled Phase (Weeks 0-16)|Lack of Efficacy|0
5994459|NCT01232283|9588051|FG007|Placebo Controlled Phase (Weeks 0-16)|Lack of Efficacy|0
5994460|NCT01232283|9588052|FG008|Placebo Controlled Phase (Weeks 0-16)|Lack of Efficacy|0
5994461|NCT01232283|9588053|FG009|Placebo Controlled Phase (Weeks 0-16)|Lack of Efficacy|0
5994462|NCT01232283|9588044|FG000|Placebo Controlled Phase (Weeks 0-16)|Noncompliance with study drug|1
5994463|NCT01232283|9588045|FG001|Placebo Controlled Phase (Weeks 0-16)|Noncompliance with study drug|0
5994464|NCT01232283|9588046|FG002|Placebo Controlled Phase (Weeks 0-16)|Noncompliance with study drug|0
5994465|NCT01232283|9588047|FG003|Placebo Controlled Phase (Weeks 0-16)|Noncompliance with study drug|0
5994466|NCT01232283|9588048|FG004|Placebo Controlled Phase (Weeks 0-16)|Noncompliance with study drug|0
5994467|NCT01232283|9588049|FG005|Placebo Controlled Phase (Weeks 0-16)|Noncompliance with study drug|0
5994468|NCT01232283|9588050|FG006|Placebo Controlled Phase (Weeks 0-16)|Noncompliance with study drug|0
5994469|NCT01232283|9588051|FG007|Placebo Controlled Phase (Weeks 0-16)|Noncompliance with study drug|0
5994470|NCT01232283|9588052|FG008|Placebo Controlled Phase (Weeks 0-16)|Noncompliance with study drug|0
5994471|NCT01232283|9588053|FG009|Placebo Controlled Phase (Weeks 0-16)|Noncompliance with study drug|0
5994472|NCT01232283|9588044|FG000|Placebo Controlled Phase (Weeks 0-16)|Withdrawal by Subject|9
5994473|NCT01232283|9588045|FG001|Placebo Controlled Phase (Weeks 0-16)|Withdrawal by Subject|7
5994474|NCT01232283|9588046|FG002|Placebo Controlled Phase (Weeks 0-16)|Withdrawal by Subject|0
5994475|NCT01232283|9588047|FG003|Placebo Controlled Phase (Weeks 0-16)|Withdrawal by Subject|0
5994476|NCT01232283|9588048|FG004|Placebo Controlled Phase (Weeks 0-16)|Withdrawal by Subject|0
5994477|NCT01232283|9588049|FG005|Placebo Controlled Phase (Weeks 0-16)|Withdrawal by Subject|0
5994478|NCT01232283|9588050|FG006|Placebo Controlled Phase (Weeks 0-16)|Withdrawal by Subject|0
5994479|NCT01232283|9588051|FG007|Placebo Controlled Phase (Weeks 0-16)|Withdrawal by Subject|0
5994480|NCT01232283|9588052|FG008|Placebo Controlled Phase (Weeks 0-16)|Withdrawal by Subject|0
5994481|NCT01232283|9588053|FG009|Placebo Controlled Phase (Weeks 0-16)|Withdrawal by Subject|0
5994482|NCT01232283|9588044|FG000|Placebo Controlled Phase (Weeks 0-16)|Lost to Follow-up|6
5994483|NCT01232283|9588045|FG001|Placebo Controlled Phase (Weeks 0-16)|Lost to Follow-up|6
5994484|NCT01232283|9588046|FG002|Placebo Controlled Phase (Weeks 0-16)|Lost to Follow-up|0
5994485|NCT01232283|9588047|FG003|Placebo Controlled Phase (Weeks 0-16)|Lost to Follow-up|0
5994486|NCT01232283|9588048|FG004|Placebo Controlled Phase (Weeks 0-16)|Lost to Follow-up|0
5994487|NCT01232283|9588049|FG005|Placebo Controlled Phase (Weeks 0-16)|Lost to Follow-up|0
5994488|NCT01232283|9588050|FG006|Placebo Controlled Phase (Weeks 0-16)|Lost to Follow-up|0
5994489|NCT01232283|9588051|FG007|Placebo Controlled Phase (Weeks 0-16)|Lost to Follow-up|0
5994490|NCT01232283|9588052|FG008|Placebo Controlled Phase (Weeks 0-16)|Lost to Follow-up|0
5994491|NCT01232283|9588053|FG009|Placebo Controlled Phase (Weeks 0-16)|Lost to Follow-up|0
5994492|NCT01232283|9588044|FG000|Placebo Controlled Phase (Weeks 0-16)|Protocol Violation|3
5994493|NCT01232283|9588045|FG001|Placebo Controlled Phase (Weeks 0-16)|Protocol Violation|2
5994494|NCT01232283|9588046|FG002|Placebo Controlled Phase (Weeks 0-16)|Protocol Violation|0
5994495|NCT01232283|9588047|FG003|Placebo Controlled Phase (Weeks 0-16)|Protocol Violation|0
5994496|NCT01232283|9588048|FG004|Placebo Controlled Phase (Weeks 0-16)|Protocol Violation|0
5994497|NCT01232283|9588049|FG005|Placebo Controlled Phase (Weeks 0-16)|Protocol Violation|0
5994498|NCT01232283|9588050|FG006|Placebo Controlled Phase (Weeks 0-16)|Protocol Violation|0
5994499|NCT01232283|9588051|FG007|Placebo Controlled Phase (Weeks 0-16)|Protocol Violation|0
5994500|NCT01232283|9588052|FG008|Placebo Controlled Phase (Weeks 0-16)|Protocol Violation|0
5994501|NCT01232283|9588053|FG009|Placebo Controlled Phase (Weeks 0-16)|Protocol Violation|0
5994502|NCT01232283|9588044|FG000|Placebo Controlled Phase (Weeks 0-16)|Other|2
5994503|NCT01232283|9588045|FG001|Placebo Controlled Phase (Weeks 0-16)|Other|1
5994504|NCT01232283|9588046|FG002|Placebo Controlled Phase (Weeks 0-16)|Other|0
5994505|NCT01232283|9588047|FG003|Placebo Controlled Phase (Weeks 0-16)|Other|0
5994506|NCT01232283|9588048|FG004|Placebo Controlled Phase (Weeks 0-16)|Other|0
5994507|NCT01232283|9588049|FG005|Placebo Controlled Phase (Weeks 0-16)|Other|0
5994508|NCT01232283|9588050|FG006|Placebo Controlled Phase (Weeks 0-16)|Other|0
6070139|NCT00548405|9672983|FG002|Overall Study|Protocol Violation|0
5994509|NCT01232283|9588051|FG007|Placebo Controlled Phase (Weeks 0-16)|Other|0
5994510|NCT01232283|9588052|FG008|Placebo Controlled Phase (Weeks 0-16)|Other|0
5994511|NCT01232283|9588053|FG009|Placebo Controlled Phase (Weeks 0-16)|Other|0
5994512|NCT01232283|9588044|FG000|Maintenance Phase (Weeks16-32)|Adverse Event|0
5994513|NCT01232283|9588045|FG001|Maintenance Phase (Weeks16-32)|Adverse Event|0
5994514|NCT01232283|9588046|FG002|Maintenance Phase (Weeks16-32)|Adverse Event|8
5994515|NCT01232283|9588047|FG003|Maintenance Phase (Weeks16-32)|Adverse Event|2
5994516|NCT01232283|9588048|FG004|Maintenance Phase (Weeks16-32)|Adverse Event|0
5994517|NCT01232283|9588049|FG005|Maintenance Phase (Weeks16-32)|Adverse Event|0
5994518|NCT01232283|9588050|FG006|Maintenance Phase (Weeks16-32)|Adverse Event|0
5994519|NCT01232283|9588051|FG007|Maintenance Phase (Weeks16-32)|Adverse Event|0
5994520|NCT01232283|9588052|FG008|Maintenance Phase (Weeks16-32)|Adverse Event|0
5994521|NCT01232283|9588053|FG009|Maintenance Phase (Weeks16-32)|Adverse Event|0
5994522|NCT01232283|9588044|FG000|Maintenance Phase (Weeks16-32)|Lack of Efficacy|0
5994523|NCT01232283|9588045|FG001|Maintenance Phase (Weeks16-32)|Lack of Efficacy|0
5994524|NCT01232283|9588046|FG002|Maintenance Phase (Weeks16-32)|Lack of Efficacy|19
5994525|NCT01232283|9588047|FG003|Maintenance Phase (Weeks16-32)|Lack of Efficacy|3
5994526|NCT01232283|9588048|FG004|Maintenance Phase (Weeks16-32)|Lack of Efficacy|0
5994527|NCT01232283|9588049|FG005|Maintenance Phase (Weeks16-32)|Lack of Efficacy|0
5994528|NCT01232283|9588050|FG006|Maintenance Phase (Weeks16-32)|Lack of Efficacy|0
5994529|NCT01232283|9588051|FG007|Maintenance Phase (Weeks16-32)|Lack of Efficacy|0
5994530|NCT01232283|9588052|FG008|Maintenance Phase (Weeks16-32)|Lack of Efficacy|0
5994531|NCT01232283|9588053|FG009|Maintenance Phase (Weeks16-32)|Lack of Efficacy|0
5994532|NCT01232283|9588044|FG000|Maintenance Phase (Weeks16-32)|Non-compliance with study drug|0
5994533|NCT01232283|9588045|FG001|Maintenance Phase (Weeks16-32)|Non-compliance with study drug|0
5994534|NCT01232283|9588046|FG002|Maintenance Phase (Weeks16-32)|Non-compliance with study drug|1
5994535|NCT01232283|9588047|FG003|Maintenance Phase (Weeks16-32)|Non-compliance with study drug|0
5994536|NCT01232283|9588048|FG004|Maintenance Phase (Weeks16-32)|Non-compliance with study drug|0
5994537|NCT01232283|9588049|FG005|Maintenance Phase (Weeks16-32)|Non-compliance with study drug|0
5994538|NCT01232283|9588050|FG006|Maintenance Phase (Weeks16-32)|Non-compliance with study drug|0
5994539|NCT01232283|9588051|FG007|Maintenance Phase (Weeks16-32)|Non-compliance with study drug|0
5994540|NCT01232283|9588052|FG008|Maintenance Phase (Weeks16-32)|Non-compliance with study drug|0
5994541|NCT01232283|9588053|FG009|Maintenance Phase (Weeks16-32)|Non-compliance with study drug|0
5994542|NCT01232283|9588044|FG000|Maintenance Phase (Weeks16-32)|Withdrawal by Subject|0
5994543|NCT01232283|9588045|FG001|Maintenance Phase (Weeks16-32)|Withdrawal by Subject|0
5994544|NCT01232283|9588046|FG002|Maintenance Phase (Weeks16-32)|Withdrawal by Subject|7
5994545|NCT01232283|9588047|FG003|Maintenance Phase (Weeks16-32)|Withdrawal by Subject|1
5994546|NCT01232283|9588048|FG004|Maintenance Phase (Weeks16-32)|Withdrawal by Subject|0
5994547|NCT01232283|9588049|FG005|Maintenance Phase (Weeks16-32)|Withdrawal by Subject|0
5994548|NCT01232283|9588050|FG006|Maintenance Phase (Weeks16-32)|Withdrawal by Subject|0
5994549|NCT01232283|9588051|FG007|Maintenance Phase (Weeks16-32)|Withdrawal by Subject|0
5994550|NCT01232283|9588052|FG008|Maintenance Phase (Weeks16-32)|Withdrawal by Subject|0
5994551|NCT01232283|9588053|FG009|Maintenance Phase (Weeks16-32)|Withdrawal by Subject|0
5994552|NCT01232283|9588044|FG000|Maintenance Phase (Weeks16-32)|Lost to Follow-up|0
5994553|NCT01232283|9588045|FG001|Maintenance Phase (Weeks16-32)|Lost to Follow-up|0
5994554|NCT01232283|9588046|FG002|Maintenance Phase (Weeks16-32)|Lost to Follow-up|3
5994555|NCT01232283|9588047|FG003|Maintenance Phase (Weeks16-32)|Lost to Follow-up|2
5994556|NCT01232283|9588048|FG004|Maintenance Phase (Weeks16-32)|Lost to Follow-up|0
5994557|NCT01232283|9588049|FG005|Maintenance Phase (Weeks16-32)|Lost to Follow-up|0
5994558|NCT01232283|9588050|FG006|Maintenance Phase (Weeks16-32)|Lost to Follow-up|0
5994559|NCT01232283|9588051|FG007|Maintenance Phase (Weeks16-32)|Lost to Follow-up|0
5994560|NCT01232283|9588052|FG008|Maintenance Phase (Weeks16-32)|Lost to Follow-up|0
5994561|NCT01232283|9588053|FG009|Maintenance Phase (Weeks16-32)|Lost to Follow-up|0
5994562|NCT01232283|9588044|FG000|Maintenance Phase (Weeks16-32)|Other|0
5994563|NCT01232283|9588045|FG001|Maintenance Phase (Weeks16-32)|Other|0
5994564|NCT01232283|9588046|FG002|Maintenance Phase (Weeks16-32)|Other|2
5994565|NCT01232283|9588047|FG003|Maintenance Phase (Weeks16-32)|Other|0
5994566|NCT01232283|9588048|FG004|Maintenance Phase (Weeks16-32)|Other|0
5994567|NCT01232283|9588049|FG005|Maintenance Phase (Weeks16-32)|Other|0
5994568|NCT01232283|9588050|FG006|Maintenance Phase (Weeks16-32)|Other|0
5994569|NCT01232283|9588051|FG007|Maintenance Phase (Weeks16-32)|Other|0
5994570|NCT01232283|9588052|FG008|Maintenance Phase (Weeks16-32)|Other|0
5994571|NCT01232283|9588053|FG009|Maintenance Phase (Weeks16-32)|Other|0
5994572|NCT01232283|9588044|FG000|Randomized Withdrawal Phase(Weeks 32-52)|Adverse Event|0
5994573|NCT01232283|9588045|FG001|Randomized Withdrawal Phase(Weeks 32-52)|Adverse Event|0
5994574|NCT01232283|9588046|FG002|Randomized Withdrawal Phase(Weeks 32-52)|Adverse Event|0
5994575|NCT01232283|9588047|FG003|Randomized Withdrawal Phase(Weeks 32-52)|Adverse Event|0
5994576|NCT01232283|9588048|FG004|Randomized Withdrawal Phase(Weeks 32-52)|Adverse Event|2
5994577|NCT01232283|9588049|FG005|Randomized Withdrawal Phase(Weeks 32-52)|Adverse Event|1
5994578|NCT01232283|9588050|FG006|Randomized Withdrawal Phase(Weeks 32-52)|Adverse Event|0
5994579|NCT01232283|9588051|FG007|Randomized Withdrawal Phase(Weeks 32-52)|Adverse Event|1
5994580|NCT01232283|9588052|FG008|Randomized Withdrawal Phase(Weeks 32-52)|Adverse Event|0
6070140|NCT00548405|9672981|FG000|Overall Study|Withdrawal by Subject|36
5994581|NCT01232283|9588053|FG009|Randomized Withdrawal Phase(Weeks 32-52)|Adverse Event|0
5994582|NCT01232283|9588044|FG000|Randomized Withdrawal Phase(Weeks 32-52)|Lack of Efficacy|0
5994583|NCT01232283|9588045|FG001|Randomized Withdrawal Phase(Weeks 32-52)|Lack of Efficacy|0
5994584|NCT01232283|9588046|FG002|Randomized Withdrawal Phase(Weeks 32-52)|Lack of Efficacy|0
5994585|NCT01232283|9588047|FG003|Randomized Withdrawal Phase(Weeks 32-52)|Lack of Efficacy|0
5994586|NCT01232283|9588048|FG004|Randomized Withdrawal Phase(Weeks 32-52)|Lack of Efficacy|4
5994587|NCT01232283|9588049|FG005|Randomized Withdrawal Phase(Weeks 32-52)|Lack of Efficacy|0
5994588|NCT01232283|9588050|FG006|Randomized Withdrawal Phase(Weeks 32-52)|Lack of Efficacy|13
5994589|NCT01232283|9588051|FG007|Randomized Withdrawal Phase(Weeks 32-52)|Lack of Efficacy|5
5994590|NCT01232283|9588052|FG008|Randomized Withdrawal Phase(Weeks 32-52)|Lack of Efficacy|0
5994591|NCT01232283|9588053|FG009|Randomized Withdrawal Phase(Weeks 32-52)|Lack of Efficacy|0
5994592|NCT01232283|9588044|FG000|Randomized Withdrawal Phase(Weeks 32-52)|Withdrawal by Subject|0
5994593|NCT01232283|9588045|FG001|Randomized Withdrawal Phase(Weeks 32-52)|Withdrawal by Subject|0
5994594|NCT01232283|9588046|FG002|Randomized Withdrawal Phase(Weeks 32-52)|Withdrawal by Subject|0
5994595|NCT01232283|9588047|FG003|Randomized Withdrawal Phase(Weeks 32-52)|Withdrawal by Subject|0
5994596|NCT01232283|9588048|FG004|Randomized Withdrawal Phase(Weeks 32-52)|Withdrawal by Subject|3
5994597|NCT01232283|9588049|FG005|Randomized Withdrawal Phase(Weeks 32-52)|Withdrawal by Subject|3
5994598|NCT01232283|9588050|FG006|Randomized Withdrawal Phase(Weeks 32-52)|Withdrawal by Subject|3
5994599|NCT01232283|9588051|FG007|Randomized Withdrawal Phase(Weeks 32-52)|Withdrawal by Subject|4
5994600|NCT01232283|9588052|FG008|Randomized Withdrawal Phase(Weeks 32-52)|Withdrawal by Subject|0
5994601|NCT01232283|9588053|FG009|Randomized Withdrawal Phase(Weeks 32-52)|Withdrawal by Subject|0
5994602|NCT01232283|9588044|FG000|Randomized Withdrawal Phase(Weeks 32-52)|Death|0
5994603|NCT01232283|9588045|FG001|Randomized Withdrawal Phase(Weeks 32-52)|Death|0
5994604|NCT01232283|9588046|FG002|Randomized Withdrawal Phase(Weeks 32-52)|Death|0
5994605|NCT01232283|9588047|FG003|Randomized Withdrawal Phase(Weeks 32-52)|Death|0
5994606|NCT01232283|9588048|FG004|Randomized Withdrawal Phase(Weeks 32-52)|Death|1
5994607|NCT01232283|9588049|FG005|Randomized Withdrawal Phase(Weeks 32-52)|Death|0
5994608|NCT01232283|9588050|FG006|Randomized Withdrawal Phase(Weeks 32-52)|Death|0
5994609|NCT01232283|9588051|FG007|Randomized Withdrawal Phase(Weeks 32-52)|Death|0
5994610|NCT01232283|9588052|FG008|Randomized Withdrawal Phase(Weeks 32-52)|Death|0
5994611|NCT01232283|9588053|FG009|Randomized Withdrawal Phase(Weeks 32-52)|Death|0
5994612|NCT01232283|9588044|FG000|Randomized Withdrawal Phase(Weeks 32-52)|Lost to Follow-up|0
5994613|NCT01232283|9588045|FG001|Randomized Withdrawal Phase(Weeks 32-52)|Lost to Follow-up|0
5994614|NCT01232283|9588046|FG002|Randomized Withdrawal Phase(Weeks 32-52)|Lost to Follow-up|0
5994615|NCT01232283|9588047|FG003|Randomized Withdrawal Phase(Weeks 32-52)|Lost to Follow-up|0
5994616|NCT01232283|9588048|FG004|Randomized Withdrawal Phase(Weeks 32-52)|Lost to Follow-up|2
5994617|NCT01232283|9588049|FG005|Randomized Withdrawal Phase(Weeks 32-52)|Lost to Follow-up|0
5994618|NCT01232283|9588050|FG006|Randomized Withdrawal Phase(Weeks 32-52)|Lost to Follow-up|1
5994619|NCT01232283|9588051|FG007|Randomized Withdrawal Phase(Weeks 32-52)|Lost to Follow-up|1
5994620|NCT01232283|9588052|FG008|Randomized Withdrawal Phase(Weeks 32-52)|Lost to Follow-up|0
5994621|NCT01232283|9588053|FG009|Randomized Withdrawal Phase(Weeks 32-52)|Lost to Follow-up|0
5994622|NCT01232283|9588044|FG000|Randomized Withdrawal Phase(Weeks 32-52)|Protocol Violation|0
5994623|NCT01232283|9588045|FG001|Randomized Withdrawal Phase(Weeks 32-52)|Protocol Violation|0
5994624|NCT01232283|9588046|FG002|Randomized Withdrawal Phase(Weeks 32-52)|Protocol Violation|0
5994625|NCT01232283|9588047|FG003|Randomized Withdrawal Phase(Weeks 32-52)|Protocol Violation|0
5994626|NCT01232283|9588048|FG004|Randomized Withdrawal Phase(Weeks 32-52)|Protocol Violation|0
5994627|NCT01232283|9588049|FG005|Randomized Withdrawal Phase(Weeks 32-52)|Protocol Violation|0
5994628|NCT01232283|9588050|FG006|Randomized Withdrawal Phase(Weeks 32-52)|Protocol Violation|0
5994629|NCT01232283|9588051|FG007|Randomized Withdrawal Phase(Weeks 32-52)|Protocol Violation|1
5994630|NCT01232283|9588052|FG008|Randomized Withdrawal Phase(Weeks 32-52)|Protocol Violation|0
6070141|NCT00548405|9672982|FG001|Overall Study|Withdrawal by Subject|12
6070142|NCT00548405|9672983|FG002|Overall Study|Withdrawal by Subject|5
6070143|NCT00548405|9672981|FG000|Overall Study|Lost to Follow-up|1
6070144|NCT00548405|9672982|FG001|Overall Study|Lost to Follow-up|1
6070145|NCT00548405|9672983|FG002|Overall Study|Lost to Follow-up|2
6070146|NCT00548405|9672981|FG000|Overall Study|Death|0
6070147|NCT00548405|9672982|FG001|Overall Study|Death|1
6070148|NCT00548405|9672983|FG002|Overall Study|Death|1
6070149|NCT00548405|9672981|FG000|Overall Study|Sponsor decision|1
6070150|NCT00548405|9672982|FG001|Overall Study|Sponsor decision|0
6070151|NCT00548405|9672983|FG002|Overall Study|Sponsor decision|0
6070152|NCT00548405|9672981|FG000|Overall Study|Randomized but not treated|1
6070153|NCT00548405|9672982|FG001|Overall Study|Randomized but not treated|0
6070154|NCT00548405|9672983|FG002|Overall Study|Randomized but not treated|0
6070155|NCT00548548|9673006|FG000|Overall Study|Death|345
6070156|NCT00548548|9673007|FG001|Overall Study|Death|348
6070157|NCT00548548|9673006|FG000|Overall Study|Lost to Follow-up|17
6070158|NCT00548548|9673007|FG001|Overall Study|Lost to Follow-up|18
6070159|NCT00548717|9673037|FG000|Overall Study|Death|5
6070160|NCT00548717|9673038|FG001|Overall Study|Death|2
6070161|NCT00548717|9673037|FG000|Overall Study|Relapse|3
6070162|NCT00548717|9673038|FG001|Overall Study|Relapse|0
6070163|NCT00548717|9673037|FG000|Overall Study|Alternative treatment for GVHD|1
5994631|NCT01232283|9588053|FG009|Randomized Withdrawal Phase(Weeks 32-52)|Protocol Violation|0
5994632|NCT01232283|9588044|FG000|Randomized Withdrawal Phase(Weeks 32-52)|Other|0
5994633|NCT01232283|9588045|FG001|Randomized Withdrawal Phase(Weeks 32-52)|Other|0
5994634|NCT01232283|9588046|FG002|Randomized Withdrawal Phase(Weeks 32-52)|Other|0
5994635|NCT01232283|9588047|FG003|Randomized Withdrawal Phase(Weeks 32-52)|Other|0
5994636|NCT01232283|9588048|FG004|Randomized Withdrawal Phase(Weeks 32-52)|Other|0
5994637|NCT01232283|9588049|FG005|Randomized Withdrawal Phase(Weeks 32-52)|Other|1
5994638|NCT01232283|9588050|FG006|Randomized Withdrawal Phase(Weeks 32-52)|Other|0
5994639|NCT01232283|9588051|FG007|Randomized Withdrawal Phase(Weeks 32-52)|Other|0
5994640|NCT01232283|9588052|FG008|Randomized Withdrawal Phase(Weeks 32-52)|Other|0
5994641|NCT01232283|9588053|FG009|Randomized Withdrawal Phase(Weeks 32-52)|Other|0
5994642|NCT01232283|9588044|FG000|Long-Term Extension Phase (Weeks 52-260)|Adverse Event|0
5994643|NCT01232283|9588045|FG001|Long-Term Extension Phase (Weeks 52-260)|Adverse Event|0
5994644|NCT01232283|9588046|FG002|Long-Term Extension Phase (Weeks 52-260)|Adverse Event|0
5994645|NCT01232283|9588047|FG003|Long-Term Extension Phase (Weeks 52-260)|Adverse Event|0
5994646|NCT01232283|9588048|FG004|Long-Term Extension Phase (Weeks 52-260)|Adverse Event|0
5994647|NCT01232283|9588049|FG005|Long-Term Extension Phase (Weeks 52-260)|Adverse Event|0
5994648|NCT01232283|9588050|FG006|Long-Term Extension Phase (Weeks 52-260)|Adverse Event|0
5994649|NCT01232283|9588051|FG007|Long-Term Extension Phase (Weeks 52-260)|Adverse Event|0
5994650|NCT01232283|9588052|FG008|Long-Term Extension Phase (Weeks 52-260)|Adverse Event|11
5994651|NCT01232283|9588053|FG009|Long-Term Extension Phase (Weeks 52-260)|Adverse Event|6
5994652|NCT01232283|9588044|FG000|Long-Term Extension Phase (Weeks 52-260)|Lack of Efficacy|0
5994653|NCT01232283|9588045|FG001|Long-Term Extension Phase (Weeks 52-260)|Lack of Efficacy|0
5994654|NCT01232283|9588046|FG002|Long-Term Extension Phase (Weeks 52-260)|Lack of Efficacy|0
5994655|NCT01232283|9588047|FG003|Long-Term Extension Phase (Weeks 52-260)|Lack of Efficacy|0
5994656|NCT01232283|9588048|FG004|Long-Term Extension Phase (Weeks 52-260)|Lack of Efficacy|0
5994657|NCT01232283|9588049|FG005|Long-Term Extension Phase (Weeks 52-260)|Lack of Efficacy|0
5994658|NCT01232283|9588050|FG006|Long-Term Extension Phase (Weeks 52-260)|Lack of Efficacy|0
5994659|NCT01232283|9588051|FG007|Long-Term Extension Phase (Weeks 52-260)|Lack of Efficacy|0
5994660|NCT01232283|9588052|FG008|Long-Term Extension Phase (Weeks 52-260)|Lack of Efficacy|46
5994661|NCT01232283|9588053|FG009|Long-Term Extension Phase (Weeks 52-260)|Lack of Efficacy|30
5994662|NCT01232283|9588044|FG000|Long-Term Extension Phase (Weeks 52-260)|Non-compliance|0
5994663|NCT01232283|9588045|FG001|Long-Term Extension Phase (Weeks 52-260)|Non-compliance|0
5994664|NCT01232283|9588046|FG002|Long-Term Extension Phase (Weeks 52-260)|Non-compliance|0
5994665|NCT01232283|9588047|FG003|Long-Term Extension Phase (Weeks 52-260)|Non-compliance|0
5994666|NCT01232283|9588048|FG004|Long-Term Extension Phase (Weeks 52-260)|Non-compliance|0
5994667|NCT01232283|9588049|FG005|Long-Term Extension Phase (Weeks 52-260)|Non-compliance|0
5994668|NCT01232283|9588050|FG006|Long-Term Extension Phase (Weeks 52-260)|Non-compliance|0
5994669|NCT01232283|9588051|FG007|Long-Term Extension Phase (Weeks 52-260)|Non-compliance|0
5994670|NCT01232283|9588052|FG008|Long-Term Extension Phase (Weeks 52-260)|Non-compliance|3
5994671|NCT01232283|9588053|FG009|Long-Term Extension Phase (Weeks 52-260)|Non-compliance|2
5994672|NCT01232283|9588044|FG000|Long-Term Extension Phase (Weeks 52-260)|Withdrawal by Subject|0
5994673|NCT01232283|9588045|FG001|Long-Term Extension Phase (Weeks 52-260)|Withdrawal by Subject|0
5994674|NCT01232283|9588046|FG002|Long-Term Extension Phase (Weeks 52-260)|Withdrawal by Subject|0
5994675|NCT01232283|9588047|FG003|Long-Term Extension Phase (Weeks 52-260)|Withdrawal by Subject|0
5994676|NCT01232283|9588048|FG004|Long-Term Extension Phase (Weeks 52-260)|Withdrawal by Subject|0
5994677|NCT01232283|9588049|FG005|Long-Term Extension Phase (Weeks 52-260)|Withdrawal by Subject|0
5994678|NCT01232283|9588050|FG006|Long-Term Extension Phase (Weeks 52-260)|Withdrawal by Subject|0
5994679|NCT01232283|9588051|FG007|Long-Term Extension Phase (Weeks 52-260)|Withdrawal by Subject|0
5994680|NCT01232283|9588052|FG008|Long-Term Extension Phase (Weeks 52-260)|Withdrawal by Subject|30
5994681|NCT01232283|9588053|FG009|Long-Term Extension Phase (Weeks 52-260)|Withdrawal by Subject|14
5994682|NCT01232283|9588044|FG000|Long-Term Extension Phase (Weeks 52-260)|Lost to Follow-up|0
5994683|NCT01232283|9588045|FG001|Long-Term Extension Phase (Weeks 52-260)|Lost to Follow-up|0
5994684|NCT01232283|9588046|FG002|Long-Term Extension Phase (Weeks 52-260)|Lost to Follow-up|0
5994685|NCT01232283|9588047|FG003|Long-Term Extension Phase (Weeks 52-260)|Lost to Follow-up|0
5994686|NCT01232283|9588048|FG004|Long-Term Extension Phase (Weeks 52-260)|Lost to Follow-up|0
5994687|NCT01232283|9588049|FG005|Long-Term Extension Phase (Weeks 52-260)|Lost to Follow-up|0
5994688|NCT01232283|9588050|FG006|Long-Term Extension Phase (Weeks 52-260)|Lost to Follow-up|0
5994689|NCT01232283|9588051|FG007|Long-Term Extension Phase (Weeks 52-260)|Lost to Follow-up|0
5994690|NCT01232283|9588052|FG008|Long-Term Extension Phase (Weeks 52-260)|Lost to Follow-up|9
5994691|NCT01232283|9588053|FG009|Long-Term Extension Phase (Weeks 52-260)|Lost to Follow-up|6
5994692|NCT01232283|9588044|FG000|Long-Term Extension Phase (Weeks 52-260)|Death|0
5994693|NCT01232283|9588045|FG001|Long-Term Extension Phase (Weeks 52-260)|Death|0
5994694|NCT01232283|9588046|FG002|Long-Term Extension Phase (Weeks 52-260)|Death|0
5994695|NCT01232283|9588047|FG003|Long-Term Extension Phase (Weeks 52-260)|Death|0
5994696|NCT01232283|9588048|FG004|Long-Term Extension Phase (Weeks 52-260)|Death|0
5994697|NCT01232283|9588049|FG005|Long-Term Extension Phase (Weeks 52-260)|Death|0
5994698|NCT01232283|9588050|FG006|Long-Term Extension Phase (Weeks 52-260)|Death|0
5994699|NCT01232283|9588051|FG007|Long-Term Extension Phase (Weeks 52-260)|Death|0
5994700|NCT01232283|9588052|FG008|Long-Term Extension Phase (Weeks 52-260)|Death|1
5994701|NCT01232283|9588053|FG009|Long-Term Extension Phase (Weeks 52-260)|Death|0
5994702|NCT01232283|9588044|FG000|Long-Term Extension Phase (Weeks 52-260)|Protocol Violation|0
5994703|NCT01232283|9588045|FG001|Long-Term Extension Phase (Weeks 52-260)|Protocol Violation|0
5994704|NCT01232283|9588046|FG002|Long-Term Extension Phase (Weeks 52-260)|Protocol Violation|0
5994705|NCT01232283|9588047|FG003|Long-Term Extension Phase (Weeks 52-260)|Protocol Violation|0
5994706|NCT01232283|9588048|FG004|Long-Term Extension Phase (Weeks 52-260)|Protocol Violation|0
5994707|NCT01232283|9588049|FG005|Long-Term Extension Phase (Weeks 52-260)|Protocol Violation|0
5994708|NCT01232283|9588050|FG006|Long-Term Extension Phase (Weeks 52-260)|Protocol Violation|0
5994709|NCT01232283|9588051|FG007|Long-Term Extension Phase (Weeks 52-260)|Protocol Violation|0
5994710|NCT01232283|9588052|FG008|Long-Term Extension Phase (Weeks 52-260)|Protocol Violation|1
5994711|NCT01232283|9588053|FG009|Long-Term Extension Phase (Weeks 52-260)|Protocol Violation|0
5994712|NCT01232283|9588044|FG000|Long-Term Extension Phase (Weeks 52-260)|Miscellaneous|0
5994713|NCT01232283|9588045|FG001|Long-Term Extension Phase (Weeks 52-260)|Miscellaneous|0
5994714|NCT01232283|9588046|FG002|Long-Term Extension Phase (Weeks 52-260)|Miscellaneous|0
5994715|NCT01232283|9588047|FG003|Long-Term Extension Phase (Weeks 52-260)|Miscellaneous|0
5994716|NCT01232283|9588048|FG004|Long-Term Extension Phase (Weeks 52-260)|Miscellaneous|0
5994717|NCT01232283|9588049|FG005|Long-Term Extension Phase (Weeks 52-260)|Miscellaneous|0
5994718|NCT01232283|9588050|FG006|Long-Term Extension Phase (Weeks 52-260)|Miscellaneous|0
5994719|NCT01232283|9588051|FG007|Long-Term Extension Phase (Weeks 52-260)|Miscellaneous|0
5994720|NCT01232283|9588052|FG008|Long-Term Extension Phase (Weeks 52-260)|Miscellaneous|7
5994721|NCT01232283|9588053|FG009|Long-Term Extension Phase (Weeks 52-260)|Miscellaneous|3
5994722|NCT01231516|9588077|FG000|Double-blind Phase (Up to Week [Wk] 48)|Adverse Event|4
5994723|NCT01231516|9588078|FG001|Double-blind Phase (Up to Week [Wk] 48)|Adverse Event|11
6070164|NCT00548717|9673038|FG001|Overall Study|Alternative treatment for GVHD|0
6070165|NCT00548808|9673049|FG000|Overall Study|Lost to Follow-up|9
6070166|NCT00548808|9673050|FG001|Overall Study|Lost to Follow-up|3
6070167|NCT00548808|9673049|FG000|Overall Study|Protocol Violation|8
6070168|NCT00548808|9673050|FG001|Overall Study|Protocol Violation|8
6070169|NCT00548808|9673049|FG000|Overall Study|Withdrawal by Subject|8
6070170|NCT00548808|9673050|FG001|Overall Study|Withdrawal by Subject|4
6070171|NCT00548808|9673049|FG000|Overall Study|Physician Decision|6
6070172|NCT00548808|9673050|FG001|Overall Study|Physician Decision|3
6070173|NCT00548808|9673049|FG000|Overall Study|Adverse Event|4
6070174|NCT00548808|9673050|FG001|Overall Study|Adverse Event|5
6070175|NCT00548808|9673049|FG000|Overall Study|Death|2
6070176|NCT00548808|9673050|FG001|Overall Study|Death|0
6070177|NCT00548808|9673049|FG000|Overall Study|Entry Criteria Not Met|2
6070178|NCT00548808|9673050|FG001|Overall Study|Entry Criteria Not Met|2
6070179|NCT00548808|9673049|FG000|Overall Study|Lack of Efficacy|2
6309387|NCT02638103|10037954|FG002|Overall Study|Protocol Violation|1
6309388|NCT02638103|10037955|FG003|Overall Study|Protocol Violation|4
6309389|NCT02638103|10037952|FG000|Overall Study|Pregnancy|2
6309390|NCT02638103|10037953|FG001|Overall Study|Pregnancy|3
6309391|NCT02638103|10037954|FG002|Overall Study|Pregnancy|0
6309392|NCT02638103|10037955|FG003|Overall Study|Pregnancy|1
6309393|NCT02638103|10037952|FG000|Overall Study|Non-compliance to Study Procedures|2
6309394|NCT02638103|10037953|FG001|Overall Study|Non-compliance to Study Procedures|1
6309395|NCT02638103|10037954|FG002|Overall Study|Non-compliance to Study Procedures|1
6309396|NCT02638103|10037955|FG003|Overall Study|Non-compliance to Study Procedures|1
6309397|NCT02638103|10037952|FG000|Overall Study|Lost to Follow-up|26
6309398|NCT02638103|10037953|FG001|Overall Study|Lost to Follow-up|33
6309399|NCT02638103|10037954|FG002|Overall Study|Lost to Follow-up|20
6309400|NCT02638103|10037955|FG003|Overall Study|Lost to Follow-up|37
6309401|NCT02638103|10037952|FG000|Overall Study|Lack of Efficacy|14
6309402|NCT02638103|10037953|FG001|Overall Study|Lack of Efficacy|10
6309403|NCT02638103|10037954|FG002|Overall Study|Lack of Efficacy|12
6309404|NCT02638103|10037955|FG003|Overall Study|Lack of Efficacy|22
6309405|NCT02638103|10037952|FG000|Overall Study|Other than specified|5
6309406|NCT02638103|10037953|FG001|Overall Study|Other than specified|4
6309407|NCT02638103|10037954|FG002|Overall Study|Other than specified|2
6309408|NCT02638103|10037955|FG003|Overall Study|Other than specified|4
6309409|NCT02638259|10037995|FG000|Treatment Period 1|Adverse Event|1
5994724|NCT01231516|9588077|FG000|Double-blind Phase (Up to Week [Wk] 48)|Lack of Efficacy|20
5994725|NCT01231516|9588078|FG001|Double-blind Phase (Up to Week [Wk] 48)|Lack of Efficacy|42
5994726|NCT01231516|9588077|FG000|Double-blind Phase (Up to Week [Wk] 48)|Protocol Violation|9
5994727|NCT01231516|9588078|FG001|Double-blind Phase (Up to Week [Wk] 48)|Protocol Violation|6
5994728|NCT01231516|9588077|FG000|Double-blind Phase (Up to Week [Wk] 48)|Met Protocol-Defined Stopping Criteria|5
5994729|NCT01231516|9588078|FG001|Double-blind Phase (Up to Week [Wk] 48)|Met Protocol-Defined Stopping Criteria|3
5994730|NCT01231516|9588077|FG000|Double-blind Phase (Up to Week [Wk] 48)|Lost to Follow-up|5
5994731|NCT01231516|9588078|FG001|Double-blind Phase (Up to Week [Wk] 48)|Lost to Follow-up|10
5994732|NCT01231516|9588077|FG000|Double-blind Phase (Up to Week [Wk] 48)|Physician Decision|1
5994733|NCT01231516|9588078|FG001|Double-blind Phase (Up to Week [Wk] 48)|Physician Decision|1
5994734|NCT01231516|9588077|FG000|Double-blind Phase (Up to Week [Wk] 48)|Withdrawal by Subject|11
6309410|NCT02638259|10037996|FG001|Treatment Period 1|Adverse Event|5
6309411|NCT02638259|10037995|FG000|Treatment Period 1|Death|0
6309412|NCT02638259|10037996|FG001|Treatment Period 1|Death|1
6309413|NCT02638259|10037995|FG000|Treatment Period 1|Lack of Efficacy|0
6309414|NCT02638259|10037996|FG001|Treatment Period 1|Lack of Efficacy|1
6309415|NCT02638259|10037995|FG000|Treatment Period 1|Protocol Violation|0
6309416|NCT02638259|10037996|FG001|Treatment Period 1|Protocol Violation|3
5994735|NCT01231516|9588078|FG001|Double-blind Phase (Up to Week [Wk] 48)|Withdrawal by Subject|5
5994736|NCT01231516|9588077|FG000|Double-blind Phase (Up to Week [Wk] 48)|Site Closed|3
5994737|NCT01231516|9588078|FG001|Double-blind Phase (Up to Week [Wk] 48)|Site Closed|1
5994738|NCT01231516|9588077|FG000|Double-blind Phase (Up to Week [Wk] 48)|Randomized, but did not receive treatment|3
5994739|NCT01231516|9588078|FG001|Double-blind Phase (Up to Week [Wk] 48)|Randomized, but did not receive treatment|2
5994740|NCT01231516|9588077|FG000|Open-label Phase:From Wk 48 up to Wk 480|Physician Decision|5
5994741|NCT01231516|9588078|FG001|Open-label Phase:From Wk 48 up to Wk 480|Physician Decision|0
5994742|NCT01231516|9588077|FG000|Open-label Phase:From Wk 48 up to Wk 480|Lack of Efficacy|27
5994743|NCT01231516|9588078|FG001|Open-label Phase:From Wk 48 up to Wk 480|Lack of Efficacy|11
5994744|NCT01231516|9588077|FG000|Open-label Phase:From Wk 48 up to Wk 480|Protocol Violation|10
5994745|NCT01231516|9588078|FG001|Open-label Phase:From Wk 48 up to Wk 480|Protocol Violation|0
5994746|NCT01231516|9588077|FG000|Open-label Phase:From Wk 48 up to Wk 480|Withdrawal by Subject|6
5994747|NCT01231516|9588078|FG001|Open-label Phase:From Wk 48 up to Wk 480|Withdrawal by Subject|3
5994748|NCT01231516|9588077|FG000|Open-label Phase:From Wk 48 up to Wk 480|Met protocol-defined stopping criteria|2
5994749|NCT01231516|9588078|FG001|Open-label Phase:From Wk 48 up to Wk 480|Met protocol-defined stopping criteria|0
5994750|NCT01231516|9588077|FG000|Open-label Phase:From Wk 48 up to Wk 480|Adverse Event|6
5994751|NCT01231516|9588078|FG001|Open-label Phase:From Wk 48 up to Wk 480|Adverse Event|1
5994752|NCT01231516|9588077|FG000|Open-label Phase:From Wk 48 up to Wk 480|Lost to Follow-up|12
5994753|NCT01231516|9588078|FG001|Open-label Phase:From Wk 48 up to Wk 480|Lost to Follow-up|2
5994754|NCT01194219|9588097|FG000|Placebo-Controlled Phase Weeks 0-16|Adverse Event|23
5994755|NCT01194219|9588098|FG001|Placebo-Controlled Phase Weeks 0-16|Adverse Event|5
5994756|NCT01194219|9588099|FG002|Placebo-Controlled Phase Weeks 0-16|Adverse Event|0
5994757|NCT01194219|9588100|FG003|Placebo-Controlled Phase Weeks 0-16|Adverse Event|0
5994758|NCT01194219|9588101|FG004|Placebo-Controlled Phase Weeks 0-16|Adverse Event|0
5994759|NCT01194219|9588102|FG005|Placebo-Controlled Phase Weeks 0-16|Adverse Event|0
5994760|NCT01194219|9588103|FG006|Placebo-Controlled Phase Weeks 0-16|Adverse Event|0
5994761|NCT01194219|9588104|FG007|Placebo-Controlled Phase Weeks 0-16|Adverse Event|0
5994762|NCT01194219|9588105|FG008|Placebo-Controlled Phase Weeks 0-16|Adverse Event|0
5994763|NCT01194219|9588106|FG009|Placebo-Controlled Phase Weeks 0-16|Adverse Event|0
5994764|NCT01194219|9588097|FG000|Placebo-Controlled Phase Weeks 0-16|Lack of Efficacy|2
5994765|NCT01194219|9588098|FG001|Placebo-Controlled Phase Weeks 0-16|Lack of Efficacy|7
5994766|NCT01194219|9588099|FG002|Placebo-Controlled Phase Weeks 0-16|Lack of Efficacy|0
5994767|NCT01194219|9588100|FG003|Placebo-Controlled Phase Weeks 0-16|Lack of Efficacy|0
5994768|NCT01194219|9588101|FG004|Placebo-Controlled Phase Weeks 0-16|Lack of Efficacy|0
5994769|NCT01194219|9588102|FG005|Placebo-Controlled Phase Weeks 0-16|Lack of Efficacy|0
6309417|NCT02638259|10037995|FG000|Treatment Period 1|Withdrawal by Subject|4
6309418|NCT02638259|10037996|FG001|Treatment Period 1|Withdrawal by Subject|6
6309419|NCT02638259|10037995|FG000|Treatment Period 1|Withdrawn per sponsor decision|0
5994770|NCT01194219|9588103|FG006|Placebo-Controlled Phase Weeks 0-16|Lack of Efficacy|0
5994771|NCT01194219|9588104|FG007|Placebo-Controlled Phase Weeks 0-16|Lack of Efficacy|0
5994772|NCT01194219|9588105|FG008|Placebo-Controlled Phase Weeks 0-16|Lack of Efficacy|0
5994773|NCT01194219|9588106|FG009|Placebo-Controlled Phase Weeks 0-16|Lack of Efficacy|0
5994774|NCT01194219|9588097|FG000|Placebo-Controlled Phase Weeks 0-16|Noncompliance with study drug|7
5994775|NCT01194219|9588098|FG001|Placebo-Controlled Phase Weeks 0-16|Noncompliance with study drug|0
6309420|NCT02638259|10037996|FG001|Treatment Period 1|Withdrawn per sponsor decision|2
6309421|NCT02638259|10037995|FG000|Treatment Period 2|Adverse Event|5
6309422|NCT02638259|10037996|FG001|Treatment Period 2|Adverse Event|4
6309423|NCT02638259|10037995|FG000|Treatment Period 2|Withdrawal by Subject|1
6309424|NCT02638259|10037996|FG001|Treatment Period 2|Withdrawal by Subject|7
6309425|NCT02638337|10038008|FG000|Overall Study|Adverse Event|6
6309426|NCT02638337|10038009|FG001|Overall Study|Adverse Event|10
6309427|NCT02638337|10038008|FG000|Overall Study|Protocol Violation|3
6309428|NCT02638337|10038009|FG001|Overall Study|Protocol Violation|0
6309429|NCT02638337|10038008|FG000|Overall Study|Withdrawal by Subject|13
6309430|NCT02638337|10038009|FG001|Overall Study|Withdrawal by Subject|16
6309431|NCT02638337|10038008|FG000|Overall Study|Lost to Follow-up|7
6309432|NCT02638337|10038009|FG001|Overall Study|Lost to Follow-up|7
6309433|NCT02638337|10038008|FG000|Overall Study|Other - Miscellaneous|4
6309434|NCT02638337|10038009|FG001|Overall Study|Other - Miscellaneous|3
6309435|NCT02638493|10038018|FG000|Overall Study|Inability to provide semen samples|2
6309436|NCT02638493|10038019|FG001|Overall Study|Inability to provide semen samples|0
6309437|NCT02638493|10038020|FG002|Overall Study|Inability to provide semen samples|0
6309438|NCT02638623|10038041|FG000|Overall Study|Surgery timing|5
6309439|NCT02638623|10038042|FG001|Overall Study|Surgery timing|6
6309440|NCT02638623|10038041|FG000|Overall Study|Not given intervention|2
6309441|NCT02638623|10038042|FG001|Overall Study|Not given intervention|0
6309442|NCT02638948|10038052|FG000|Overall Study|Withdrawal by Subject|4
6309443|NCT02638948|10038053|FG001|Overall Study|Withdrawal by Subject|5
6309444|NCT02638948|10038054|FG002|Overall Study|Withdrawal by Subject|3
5994776|NCT01194219|9588099|FG002|Placebo-Controlled Phase Weeks 0-16|Noncompliance with study drug|0
5994777|NCT01194219|9588100|FG003|Placebo-Controlled Phase Weeks 0-16|Noncompliance with study drug|0
5994778|NCT01194219|9588101|FG004|Placebo-Controlled Phase Weeks 0-16|Noncompliance with study drug|0
5994779|NCT01194219|9588102|FG005|Placebo-Controlled Phase Weeks 0-16|Noncompliance with study drug|0
5994780|NCT01194219|9588103|FG006|Placebo-Controlled Phase Weeks 0-16|Noncompliance with study drug|0
5994781|NCT01194219|9588104|FG007|Placebo-Controlled Phase Weeks 0-16|Noncompliance with study drug|0
5994782|NCT01194219|9588105|FG008|Placebo-Controlled Phase Weeks 0-16|Noncompliance with study drug|0
5994783|NCT01194219|9588106|FG009|Placebo-Controlled Phase Weeks 0-16|Noncompliance with study drug|0
5994784|NCT01194219|9588097|FG000|Placebo-Controlled Phase Weeks 0-16|Withdrawal by Subject|12
5994785|NCT01194219|9588098|FG001|Placebo-Controlled Phase Weeks 0-16|Withdrawal by Subject|9
5994786|NCT01194219|9588099|FG002|Placebo-Controlled Phase Weeks 0-16|Withdrawal by Subject|0
5994787|NCT01194219|9588100|FG003|Placebo-Controlled Phase Weeks 0-16|Withdrawal by Subject|0
5994788|NCT01194219|9588101|FG004|Placebo-Controlled Phase Weeks 0-16|Withdrawal by Subject|0
5994789|NCT01194219|9588102|FG005|Placebo-Controlled Phase Weeks 0-16|Withdrawal by Subject|0
5994790|NCT01194219|9588103|FG006|Placebo-Controlled Phase Weeks 0-16|Withdrawal by Subject|0
5994791|NCT01194219|9588104|FG007|Placebo-Controlled Phase Weeks 0-16|Withdrawal by Subject|0
5994792|NCT01194219|9588105|FG008|Placebo-Controlled Phase Weeks 0-16|Withdrawal by Subject|0
5994793|NCT01194219|9588106|FG009|Placebo-Controlled Phase Weeks 0-16|Withdrawal by Subject|0
5994794|NCT01194219|9588097|FG000|Placebo-Controlled Phase Weeks 0-16|Death|0
5994795|NCT01194219|9588098|FG001|Placebo-Controlled Phase Weeks 0-16|Death|1
5994796|NCT01194219|9588099|FG002|Placebo-Controlled Phase Weeks 0-16|Death|0
5994797|NCT01194219|9588100|FG003|Placebo-Controlled Phase Weeks 0-16|Death|0
5994798|NCT01194219|9588101|FG004|Placebo-Controlled Phase Weeks 0-16|Death|0
5994799|NCT01194219|9588102|FG005|Placebo-Controlled Phase Weeks 0-16|Death|0
5994800|NCT01194219|9588103|FG006|Placebo-Controlled Phase Weeks 0-16|Death|0
5994801|NCT01194219|9588104|FG007|Placebo-Controlled Phase Weeks 0-16|Death|0
5994802|NCT01194219|9588105|FG008|Placebo-Controlled Phase Weeks 0-16|Death|0
5994803|NCT01194219|9588106|FG009|Placebo-Controlled Phase Weeks 0-16|Death|0
5994804|NCT01194219|9588097|FG000|Placebo-Controlled Phase Weeks 0-16|Lost to Follow-up|7
5994805|NCT01194219|9588098|FG001|Placebo-Controlled Phase Weeks 0-16|Lost to Follow-up|9
5994806|NCT01194219|9588099|FG002|Placebo-Controlled Phase Weeks 0-16|Lost to Follow-up|0
5994807|NCT01194219|9588100|FG003|Placebo-Controlled Phase Weeks 0-16|Lost to Follow-up|0
5994808|NCT01194219|9588101|FG004|Placebo-Controlled Phase Weeks 0-16|Lost to Follow-up|0
5994809|NCT01194219|9588102|FG005|Placebo-Controlled Phase Weeks 0-16|Lost to Follow-up|0
5994810|NCT01194219|9588103|FG006|Placebo-Controlled Phase Weeks 0-16|Lost to Follow-up|0
5994811|NCT01194219|9588104|FG007|Placebo-Controlled Phase Weeks 0-16|Lost to Follow-up|0
5994812|NCT01194219|9588105|FG008|Placebo-Controlled Phase Weeks 0-16|Lost to Follow-up|0
5994813|NCT01194219|9588106|FG009|Placebo-Controlled Phase Weeks 0-16|Lost to Follow-up|0
5994814|NCT01194219|9588097|FG000|Placebo-Controlled Phase Weeks 0-16|Protocol Violation|7
5994815|NCT01194219|9588098|FG001|Placebo-Controlled Phase Weeks 0-16|Protocol Violation|1
5994816|NCT01194219|9588099|FG002|Placebo-Controlled Phase Weeks 0-16|Protocol Violation|0
5994817|NCT01194219|9588100|FG003|Placebo-Controlled Phase Weeks 0-16|Protocol Violation|0
5994818|NCT01194219|9588101|FG004|Placebo-Controlled Phase Weeks 0-16|Protocol Violation|0
5994819|NCT01194219|9588102|FG005|Placebo-Controlled Phase Weeks 0-16|Protocol Violation|0
5994820|NCT01194219|9588103|FG006|Placebo-Controlled Phase Weeks 0-16|Protocol Violation|0
5994821|NCT01194219|9588104|FG007|Placebo-Controlled Phase Weeks 0-16|Protocol Violation|0
5994822|NCT01194219|9588105|FG008|Placebo-Controlled Phase Weeks 0-16|Protocol Violation|0
5994823|NCT01194219|9588106|FG009|Placebo-Controlled Phase Weeks 0-16|Protocol Violation|0
5994824|NCT01194219|9588097|FG000|Placebo-Controlled Phase Weeks 0-16|Miscellaneous|1
5994825|NCT01194219|9588098|FG001|Placebo-Controlled Phase Weeks 0-16|Miscellaneous|1
5994826|NCT01194219|9588099|FG002|Placebo-Controlled Phase Weeks 0-16|Miscellaneous|0
5994827|NCT01194219|9588100|FG003|Placebo-Controlled Phase Weeks 0-16|Miscellaneous|0
5994828|NCT01194219|9588101|FG004|Placebo-Controlled Phase Weeks 0-16|Miscellaneous|0
5994829|NCT01194219|9588102|FG005|Placebo-Controlled Phase Weeks 0-16|Miscellaneous|0
5994830|NCT01194219|9588103|FG006|Placebo-Controlled Phase Weeks 0-16|Miscellaneous|0
5994831|NCT01194219|9588104|FG007|Placebo-Controlled Phase Weeks 0-16|Miscellaneous|0
5994832|NCT01194219|9588105|FG008|Placebo-Controlled Phase Weeks 0-16|Miscellaneous|0
5994833|NCT01194219|9588106|FG009|Placebo-Controlled Phase Weeks 0-16|Miscellaneous|0
5994834|NCT01194219|9588097|FG000|Maintenance Phase Weeks16-32|Adverse Event|0
5994835|NCT01194219|9588098|FG001|Maintenance Phase Weeks16-32|Adverse Event|0
5994836|NCT01194219|9588099|FG002|Maintenance Phase Weeks16-32|Adverse Event|8
5994837|NCT01194219|9588100|FG003|Maintenance Phase Weeks16-32|Adverse Event|9
5994838|NCT01194219|9588101|FG004|Maintenance Phase Weeks16-32|Adverse Event|0
5994839|NCT01194219|9588102|FG005|Maintenance Phase Weeks16-32|Adverse Event|0
5994840|NCT01194219|9588103|FG006|Maintenance Phase Weeks16-32|Adverse Event|0
5994841|NCT01194219|9588104|FG007|Maintenance Phase Weeks16-32|Adverse Event|0
5994842|NCT01194219|9588105|FG008|Maintenance Phase Weeks16-32|Adverse Event|0
5994843|NCT01194219|9588106|FG009|Maintenance Phase Weeks16-32|Adverse Event|0
5994844|NCT01194219|9588097|FG000|Maintenance Phase Weeks16-32|Lack of Efficacy|0
5994845|NCT01194219|9588098|FG001|Maintenance Phase Weeks16-32|Lack of Efficacy|0
5994846|NCT01194219|9588099|FG002|Maintenance Phase Weeks16-32|Lack of Efficacy|37
5994847|NCT01194219|9588100|FG003|Maintenance Phase Weeks16-32|Lack of Efficacy|15
5994848|NCT01194219|9588101|FG004|Maintenance Phase Weeks16-32|Lack of Efficacy|0
5994849|NCT01194219|9588102|FG005|Maintenance Phase Weeks16-32|Lack of Efficacy|0
5994850|NCT01194219|9588103|FG006|Maintenance Phase Weeks16-32|Lack of Efficacy|0
5994851|NCT01194219|9588104|FG007|Maintenance Phase Weeks16-32|Lack of Efficacy|0
5994852|NCT01194219|9588105|FG008|Maintenance Phase Weeks16-32|Lack of Efficacy|0
5994853|NCT01194219|9588106|FG009|Maintenance Phase Weeks16-32|Lack of Efficacy|0
5994854|NCT01194219|9588097|FG000|Maintenance Phase Weeks16-32|Non-compliance with Study Drug|0
5994855|NCT01194219|9588098|FG001|Maintenance Phase Weeks16-32|Non-compliance with Study Drug|0
5994856|NCT01194219|9588099|FG002|Maintenance Phase Weeks16-32|Non-compliance with Study Drug|2
5994857|NCT01194219|9588100|FG003|Maintenance Phase Weeks16-32|Non-compliance with Study Drug|1
5994858|NCT01194219|9588101|FG004|Maintenance Phase Weeks16-32|Non-compliance with Study Drug|0
5994859|NCT01194219|9588102|FG005|Maintenance Phase Weeks16-32|Non-compliance with Study Drug|0
5994860|NCT01194219|9588103|FG006|Maintenance Phase Weeks16-32|Non-compliance with Study Drug|0
5994861|NCT01194219|9588104|FG007|Maintenance Phase Weeks16-32|Non-compliance with Study Drug|0
5994862|NCT01194219|9588105|FG008|Maintenance Phase Weeks16-32|Non-compliance with Study Drug|0
5994863|NCT01194219|9588106|FG009|Maintenance Phase Weeks16-32|Non-compliance with Study Drug|0
5994864|NCT01194219|9588097|FG000|Maintenance Phase Weeks16-32|Withdrawal by Subject|0
5994865|NCT01194219|9588098|FG001|Maintenance Phase Weeks16-32|Withdrawal by Subject|0
5994866|NCT01194219|9588099|FG002|Maintenance Phase Weeks16-32|Withdrawal by Subject|12
5994867|NCT01194219|9588100|FG003|Maintenance Phase Weeks16-32|Withdrawal by Subject|3
5994868|NCT01194219|9588101|FG004|Maintenance Phase Weeks16-32|Withdrawal by Subject|0
5994869|NCT01194219|9588102|FG005|Maintenance Phase Weeks16-32|Withdrawal by Subject|0
5994870|NCT01194219|9588103|FG006|Maintenance Phase Weeks16-32|Withdrawal by Subject|0
5994871|NCT01194219|9588104|FG007|Maintenance Phase Weeks16-32|Withdrawal by Subject|0
5994872|NCT01194219|9588105|FG008|Maintenance Phase Weeks16-32|Withdrawal by Subject|0
5994873|NCT01194219|9588106|FG009|Maintenance Phase Weeks16-32|Withdrawal by Subject|0
5994874|NCT01194219|9588097|FG000|Maintenance Phase Weeks16-32|Lost to Follow-up|0
5994875|NCT01194219|9588098|FG001|Maintenance Phase Weeks16-32|Lost to Follow-up|0
5994876|NCT01194219|9588099|FG002|Maintenance Phase Weeks16-32|Lost to Follow-up|9
5994877|NCT01194219|9588100|FG003|Maintenance Phase Weeks16-32|Lost to Follow-up|0
5994878|NCT01194219|9588101|FG004|Maintenance Phase Weeks16-32|Lost to Follow-up|0
5994879|NCT01194219|9588102|FG005|Maintenance Phase Weeks16-32|Lost to Follow-up|0
5994880|NCT01194219|9588103|FG006|Maintenance Phase Weeks16-32|Lost to Follow-up|0
5994881|NCT01194219|9588104|FG007|Maintenance Phase Weeks16-32|Lost to Follow-up|0
5994882|NCT01194219|9588105|FG008|Maintenance Phase Weeks16-32|Lost to Follow-up|0
5994883|NCT01194219|9588106|FG009|Maintenance Phase Weeks16-32|Lost to Follow-up|0
5994884|NCT01194219|9588097|FG000|Maintenance Phase Weeks16-32|Protocol Violation|0
5994885|NCT01194219|9588098|FG001|Maintenance Phase Weeks16-32|Protocol Violation|0
5994886|NCT01194219|9588099|FG002|Maintenance Phase Weeks16-32|Protocol Violation|0
5994887|NCT01194219|9588100|FG003|Maintenance Phase Weeks16-32|Protocol Violation|1
5994888|NCT01194219|9588101|FG004|Maintenance Phase Weeks16-32|Protocol Violation|0
5994889|NCT01194219|9588102|FG005|Maintenance Phase Weeks16-32|Protocol Violation|0
5994890|NCT01194219|9588103|FG006|Maintenance Phase Weeks16-32|Protocol Violation|0
5994891|NCT01194219|9588104|FG007|Maintenance Phase Weeks16-32|Protocol Violation|0
5994892|NCT01194219|9588105|FG008|Maintenance Phase Weeks16-32|Protocol Violation|0
5994893|NCT01194219|9588106|FG009|Maintenance Phase Weeks16-32|Protocol Violation|0
5994894|NCT01194219|9588097|FG000|Maintenance Phase Weeks16-32|Other|0
5994895|NCT01194219|9588098|FG001|Maintenance Phase Weeks16-32|Other|0
5994896|NCT01194219|9588099|FG002|Maintenance Phase Weeks16-32|Other|2
5994897|NCT01194219|9588100|FG003|Maintenance Phase Weeks16-32|Other|1
5994898|NCT01194219|9588101|FG004|Maintenance Phase Weeks16-32|Other|0
5994899|NCT01194219|9588102|FG005|Maintenance Phase Weeks16-32|Other|0
5994900|NCT01194219|9588103|FG006|Maintenance Phase Weeks16-32|Other|0
5994901|NCT01194219|9588104|FG007|Maintenance Phase Weeks16-32|Other|0
5994902|NCT01194219|9588105|FG008|Maintenance Phase Weeks16-32|Other|0
5994903|NCT01194219|9588106|FG009|Maintenance Phase Weeks16-32|Other|0
6070180|NCT00548808|9673050|FG001|Overall Study|Lack of Efficacy|0
6070181|NCT00548808|9673049|FG000|Overall Study|Sponsor Decision|1
6070182|NCT00548808|9673050|FG001|Overall Study|Sponsor Decision|1
6070183|NCT00548847|9673056|FG000|Overall Study|Disease progression|7
6070184|NCT00549055|9673079|FG000|Overall Study|Adverse Event|4
6070185|NCT00549055|9673079|FG000|Overall Study|Lack of Efficacy|18
6070186|NCT00549055|9673079|FG000|Overall Study|Stabilization|5
5994904|NCT01194219|9588097|FG000|Randomized Withdrawal Phase-Weeks 32-52|Adverse Event|0
6070187|NCT00549055|9673079|FG000|Overall Study|Progression to fibrosis|2
6070188|NCT00549055|9673079|FG000|Overall Study|Decrease of size|1
6070189|NCT00549055|9673079|FG000|Overall Study|Active choroidal neovascula increased|1
6070190|NCT00549055|9673079|FG000|Overall Study|Vitreous hemorrhage|1
6070191|NCT00549055|9673079|FG000|Overall Study|Growth choroidal neovascularisation|1
6070192|NCT00549055|9673079|FG000|Overall Study|Choroidal neovascularization|1
6070193|NCT00549055|9673079|FG000|Overall Study|Very low visual acuity (VA)|1
6070194|NCT00549198|9673094|FG000|Overall Study|Adverse Event|28
6070195|NCT00549198|9673095|FG001|Overall Study|Adverse Event|26
6070196|NCT00549198|9673094|FG000|Overall Study|Insufficient Viral Load Response|4
5994905|NCT01194219|9588098|FG001|Randomized Withdrawal Phase-Weeks 32-52|Adverse Event|0
5994906|NCT01194219|9588099|FG002|Randomized Withdrawal Phase-Weeks 32-52|Adverse Event|0
5994907|NCT01194219|9588100|FG003|Randomized Withdrawal Phase-Weeks 32-52|Adverse Event|0
5994908|NCT01194219|9588101|FG004|Randomized Withdrawal Phase-Weeks 32-52|Adverse Event|0
5994909|NCT01194219|9588102|FG005|Randomized Withdrawal Phase-Weeks 32-52|Adverse Event|1
5994910|NCT01194219|9588103|FG006|Randomized Withdrawal Phase-Weeks 32-52|Adverse Event|6
5994911|NCT01194219|9588104|FG007|Randomized Withdrawal Phase-Weeks 32-52|Adverse Event|5
5994912|NCT01194219|9588105|FG008|Randomized Withdrawal Phase-Weeks 32-52|Adverse Event|0
5994913|NCT01194219|9588106|FG009|Randomized Withdrawal Phase-Weeks 32-52|Adverse Event|0
5994914|NCT01194219|9588097|FG000|Randomized Withdrawal Phase-Weeks 32-52|Lack of Efficacy|0
6146228|NCT01075984|9780817|FG004|Follow-up Phase|Withdrawal by Subject|10
6146229|NCT01075984|9780813|FG000|Follow-up Phase|Progression of disease|0
6146230|NCT01075984|9780814|FG001|Follow-up Phase|Progression of disease|0
6146231|NCT01075984|9780815|FG002|Follow-up Phase|Progression of disease|0
6146232|NCT01075984|9780816|FG003|Follow-up Phase|Progression of disease|0
6146233|NCT01075984|9780817|FG004|Follow-up Phase|Progression of disease|2
6146234|NCT01075984|9780813|FG000|Follow-up Phase|Treatment failure|0
5994915|NCT01194219|9588098|FG001|Randomized Withdrawal Phase-Weeks 32-52|Lack of Efficacy|0
5994916|NCT01194219|9588099|FG002|Randomized Withdrawal Phase-Weeks 32-52|Lack of Efficacy|0
5994917|NCT01194219|9588100|FG003|Randomized Withdrawal Phase-Weeks 32-52|Lack of Efficacy|0
5994918|NCT01194219|9588101|FG004|Randomized Withdrawal Phase-Weeks 32-52|Lack of Efficacy|1
5994919|NCT01194219|9588102|FG005|Randomized Withdrawal Phase-Weeks 32-52|Lack of Efficacy|1
5994920|NCT01194219|9588103|FG006|Randomized Withdrawal Phase-Weeks 32-52|Lack of Efficacy|35
5994921|NCT01194219|9588104|FG007|Randomized Withdrawal Phase-Weeks 32-52|Lack of Efficacy|33
6146235|NCT01075984|9780814|FG001|Follow-up Phase|Treatment failure|0
6146236|NCT01075984|9780815|FG002|Follow-up Phase|Treatment failure|0
6146237|NCT01075984|9780816|FG003|Follow-up Phase|Treatment failure|0
6146238|NCT01075984|9780817|FG004|Follow-up Phase|Treatment failure|4
6146239|NCT01076010|9780832|FG000|Overall Study|Death|15
5994922|NCT01194219|9588105|FG008|Randomized Withdrawal Phase-Weeks 32-52|Lack of Efficacy|0
5994923|NCT01194219|9588106|FG009|Randomized Withdrawal Phase-Weeks 32-52|Lack of Efficacy|0
5994924|NCT01194219|9588097|FG000|Randomized Withdrawal Phase-Weeks 32-52|Non-compliance with Study Drug|0
5994925|NCT01194219|9588098|FG001|Randomized Withdrawal Phase-Weeks 32-52|Non-compliance with Study Drug|0
5994926|NCT01194219|9588099|FG002|Randomized Withdrawal Phase-Weeks 32-52|Non-compliance with Study Drug|0
5994927|NCT01194219|9588100|FG003|Randomized Withdrawal Phase-Weeks 32-52|Non-compliance with Study Drug|0
5994928|NCT01194219|9588101|FG004|Randomized Withdrawal Phase-Weeks 32-52|Non-compliance with Study Drug|1
5994929|NCT01194219|9588102|FG005|Randomized Withdrawal Phase-Weeks 32-52|Non-compliance with Study Drug|0
5994930|NCT01194219|9588103|FG006|Randomized Withdrawal Phase-Weeks 32-52|Non-compliance with Study Drug|2
5994931|NCT01194219|9588104|FG007|Randomized Withdrawal Phase-Weeks 32-52|Non-compliance with Study Drug|0
5994932|NCT01194219|9588105|FG008|Randomized Withdrawal Phase-Weeks 32-52|Non-compliance with Study Drug|0
5994933|NCT01194219|9588106|FG009|Randomized Withdrawal Phase-Weeks 32-52|Non-compliance with Study Drug|0
5994934|NCT01194219|9588097|FG000|Randomized Withdrawal Phase-Weeks 32-52|Withdrawal by Subject|0
5994935|NCT01194219|9588098|FG001|Randomized Withdrawal Phase-Weeks 32-52|Withdrawal by Subject|0
5994936|NCT01194219|9588099|FG002|Randomized Withdrawal Phase-Weeks 32-52|Withdrawal by Subject|0
5994937|NCT01194219|9588100|FG003|Randomized Withdrawal Phase-Weeks 32-52|Withdrawal by Subject|0
5994938|NCT01194219|9588101|FG004|Randomized Withdrawal Phase-Weeks 32-52|Withdrawal by Subject|1
5994939|NCT01194219|9588102|FG005|Randomized Withdrawal Phase-Weeks 32-52|Withdrawal by Subject|0
5994940|NCT01194219|9588103|FG006|Randomized Withdrawal Phase-Weeks 32-52|Withdrawal by Subject|12
5994941|NCT01194219|9588104|FG007|Randomized Withdrawal Phase-Weeks 32-52|Withdrawal by Subject|6
5994942|NCT01194219|9588105|FG008|Randomized Withdrawal Phase-Weeks 32-52|Withdrawal by Subject|0
5994943|NCT01194219|9588106|FG009|Randomized Withdrawal Phase-Weeks 32-52|Withdrawal by Subject|0
5994944|NCT01194219|9588097|FG000|Randomized Withdrawal Phase-Weeks 32-52|Lost to Follow-up|0
5994945|NCT01194219|9588098|FG001|Randomized Withdrawal Phase-Weeks 32-52|Lost to Follow-up|0
5994946|NCT01194219|9588099|FG002|Randomized Withdrawal Phase-Weeks 32-52|Lost to Follow-up|0
5994947|NCT01194219|9588100|FG003|Randomized Withdrawal Phase-Weeks 32-52|Lost to Follow-up|0
5994948|NCT01194219|9588101|FG004|Randomized Withdrawal Phase-Weeks 32-52|Lost to Follow-up|1
5994949|NCT01194219|9588102|FG005|Randomized Withdrawal Phase-Weeks 32-52|Lost to Follow-up|2
5994950|NCT01194219|9588103|FG006|Randomized Withdrawal Phase-Weeks 32-52|Lost to Follow-up|5
5994951|NCT01194219|9588104|FG007|Randomized Withdrawal Phase-Weeks 32-52|Lost to Follow-up|0
5994952|NCT01194219|9588105|FG008|Randomized Withdrawal Phase-Weeks 32-52|Lost to Follow-up|0
5994953|NCT01194219|9588106|FG009|Randomized Withdrawal Phase-Weeks 32-52|Lost to Follow-up|0
5994954|NCT01194219|9588097|FG000|Randomized Withdrawal Phase-Weeks 32-52|Protocol Violation|0
5994955|NCT01194219|9588098|FG001|Randomized Withdrawal Phase-Weeks 32-52|Protocol Violation|0
5994956|NCT01194219|9588099|FG002|Randomized Withdrawal Phase-Weeks 32-52|Protocol Violation|0
5994957|NCT01194219|9588100|FG003|Randomized Withdrawal Phase-Weeks 32-52|Protocol Violation|0
5994958|NCT01194219|9588101|FG004|Randomized Withdrawal Phase-Weeks 32-52|Protocol Violation|0
5994959|NCT01194219|9588102|FG005|Randomized Withdrawal Phase-Weeks 32-52|Protocol Violation|0
5994960|NCT01194219|9588103|FG006|Randomized Withdrawal Phase-Weeks 32-52|Protocol Violation|0
5994961|NCT01194219|9588104|FG007|Randomized Withdrawal Phase-Weeks 32-52|Protocol Violation|1
6146240|NCT01076010|9780833|FG001|Overall Study|Death|1
5994962|NCT01194219|9588105|FG008|Randomized Withdrawal Phase-Weeks 32-52|Protocol Violation|0
5994963|NCT01194219|9588106|FG009|Randomized Withdrawal Phase-Weeks 32-52|Protocol Violation|0
5994964|NCT01194219|9588097|FG000|Randomized Withdrawal Phase-Weeks 32-52|Other|0
5994965|NCT01194219|9588098|FG001|Randomized Withdrawal Phase-Weeks 32-52|Other|0
5994966|NCT01194219|9588099|FG002|Randomized Withdrawal Phase-Weeks 32-52|Other|0
5994967|NCT01194219|9588100|FG003|Randomized Withdrawal Phase-Weeks 32-52|Other|0
5994968|NCT01194219|9588101|FG004|Randomized Withdrawal Phase-Weeks 32-52|Other|0
5994969|NCT01194219|9588102|FG005|Randomized Withdrawal Phase-Weeks 32-52|Other|0
5994970|NCT01194219|9588103|FG006|Randomized Withdrawal Phase-Weeks 32-52|Other|1
5994971|NCT01194219|9588104|FG007|Randomized Withdrawal Phase-Weeks 32-52|Other|0
5994972|NCT01194219|9588105|FG008|Randomized Withdrawal Phase-Weeks 32-52|Other|0
5994973|NCT01194219|9588106|FG009|Randomized Withdrawal Phase-Weeks 32-52|Other|0
5994974|NCT01194219|9588097|FG000|Long-Term Extension Weeks 52 to 260|Adverse Event|0
5994975|NCT01194219|9588098|FG001|Long-Term Extension Weeks 52 to 260|Adverse Event|0
5994976|NCT01194219|9588099|FG002|Long-Term Extension Weeks 52 to 260|Adverse Event|0
5994977|NCT01194219|9588100|FG003|Long-Term Extension Weeks 52 to 260|Adverse Event|0
5994978|NCT01194219|9588101|FG004|Long-Term Extension Weeks 52 to 260|Adverse Event|0
5994979|NCT01194219|9588102|FG005|Long-Term Extension Weeks 52 to 260|Adverse Event|0
5994980|NCT01194219|9588103|FG006|Long-Term Extension Weeks 52 to 260|Adverse Event|0
5994981|NCT01194219|9588104|FG007|Long-Term Extension Weeks 52 to 260|Adverse Event|0
5994982|NCT01194219|9588105|FG008|Long-Term Extension Weeks 52 to 260|Adverse Event|25
5994983|NCT01194219|9588106|FG009|Long-Term Extension Weeks 52 to 260|Adverse Event|14
5994984|NCT01194219|9588097|FG000|Long-Term Extension Weeks 52 to 260|Lack of Efficacy|0
5994985|NCT01194219|9588098|FG001|Long-Term Extension Weeks 52 to 260|Lack of Efficacy|0
5994986|NCT01194219|9588099|FG002|Long-Term Extension Weeks 52 to 260|Lack of Efficacy|0
5994987|NCT01194219|9588100|FG003|Long-Term Extension Weeks 52 to 260|Lack of Efficacy|0
5994988|NCT01194219|9588101|FG004|Long-Term Extension Weeks 52 to 260|Lack of Efficacy|0
5994989|NCT01194219|9588102|FG005|Long-Term Extension Weeks 52 to 260|Lack of Efficacy|0
5994990|NCT01194219|9588103|FG006|Long-Term Extension Weeks 52 to 260|Lack of Efficacy|0
5994991|NCT01194219|9588104|FG007|Long-Term Extension Weeks 52 to 260|Lack of Efficacy|0
5994992|NCT01194219|9588105|FG008|Long-Term Extension Weeks 52 to 260|Lack of Efficacy|81
5994993|NCT01194219|9588106|FG009|Long-Term Extension Weeks 52 to 260|Lack of Efficacy|49
5994994|NCT01194219|9588097|FG000|Long-Term Extension Weeks 52 to 260|Noncompliance with IP|0
5994995|NCT01194219|9588098|FG001|Long-Term Extension Weeks 52 to 260|Noncompliance with IP|0
5994996|NCT01194219|9588099|FG002|Long-Term Extension Weeks 52 to 260|Noncompliance with IP|0
5994997|NCT01194219|9588100|FG003|Long-Term Extension Weeks 52 to 260|Noncompliance with IP|0
5994998|NCT01194219|9588101|FG004|Long-Term Extension Weeks 52 to 260|Noncompliance with IP|0
5994999|NCT01194219|9588102|FG005|Long-Term Extension Weeks 52 to 260|Noncompliance with IP|0
5995000|NCT01194219|9588103|FG006|Long-Term Extension Weeks 52 to 260|Noncompliance with IP|0
5995001|NCT01194219|9588104|FG007|Long-Term Extension Weeks 52 to 260|Noncompliance with IP|0
5995002|NCT01194219|9588105|FG008|Long-Term Extension Weeks 52 to 260|Noncompliance with IP|9
5995003|NCT01194219|9588106|FG009|Long-Term Extension Weeks 52 to 260|Noncompliance with IP|4
5995004|NCT01194219|9588097|FG000|Long-Term Extension Weeks 52 to 260|Withdrawal by Subject|0
5995005|NCT01194219|9588098|FG001|Long-Term Extension Weeks 52 to 260|Withdrawal by Subject|0
5995006|NCT01194219|9588099|FG002|Long-Term Extension Weeks 52 to 260|Withdrawal by Subject|0
5995007|NCT01194219|9588100|FG003|Long-Term Extension Weeks 52 to 260|Withdrawal by Subject|0
5995008|NCT01194219|9588101|FG004|Long-Term Extension Weeks 52 to 260|Withdrawal by Subject|0
5995009|NCT01194219|9588102|FG005|Long-Term Extension Weeks 52 to 260|Withdrawal by Subject|0
5995010|NCT01194219|9588103|FG006|Long-Term Extension Weeks 52 to 260|Withdrawal by Subject|0
5995011|NCT01194219|9588104|FG007|Long-Term Extension Weeks 52 to 260|Withdrawal by Subject|0
5995012|NCT01194219|9588105|FG008|Long-Term Extension Weeks 52 to 260|Withdrawal by Subject|66
5995013|NCT01194219|9588106|FG009|Long-Term Extension Weeks 52 to 260|Withdrawal by Subject|32
5995014|NCT01194219|9588097|FG000|Long-Term Extension Weeks 52 to 260|Death|0
5995015|NCT01194219|9588098|FG001|Long-Term Extension Weeks 52 to 260|Death|0
5995016|NCT01194219|9588099|FG002|Long-Term Extension Weeks 52 to 260|Death|0
5995017|NCT01194219|9588100|FG003|Long-Term Extension Weeks 52 to 260|Death|0
5995018|NCT01194219|9588101|FG004|Long-Term Extension Weeks 52 to 260|Death|0
5995019|NCT01194219|9588102|FG005|Long-Term Extension Weeks 52 to 260|Death|0
5995020|NCT01194219|9588103|FG006|Long-Term Extension Weeks 52 to 260|Death|0
5995021|NCT01194219|9588104|FG007|Long-Term Extension Weeks 52 to 260|Death|0
5995022|NCT01194219|9588105|FG008|Long-Term Extension Weeks 52 to 260|Death|1
5995023|NCT01194219|9588106|FG009|Long-Term Extension Weeks 52 to 260|Death|1
5995024|NCT01194219|9588097|FG000|Long-Term Extension Weeks 52 to 260|Lost to Follow-up|0
5995025|NCT01194219|9588098|FG001|Long-Term Extension Weeks 52 to 260|Lost to Follow-up|0
5995026|NCT01194219|9588099|FG002|Long-Term Extension Weeks 52 to 260|Lost to Follow-up|0
5995027|NCT01194219|9588100|FG003|Long-Term Extension Weeks 52 to 260|Lost to Follow-up|0
5995028|NCT01194219|9588101|FG004|Long-Term Extension Weeks 52 to 260|Lost to Follow-up|0
6070197|NCT00549198|9673095|FG001|Overall Study|Insufficient Viral Load Response|2
6070198|NCT00549198|9673094|FG000|Overall Study|Protocol-defined Virological Failure|7
6070199|NCT00549198|9673095|FG001|Overall Study|Protocol-defined Virological Failure|0
6070200|NCT00549198|9673094|FG000|Overall Study|Non-compliance|2
6070201|NCT00549198|9673095|FG001|Overall Study|Non-compliance|4
6070202|NCT00549198|9673094|FG000|Overall Study|Lost to Follow-up|7
5995029|NCT01194219|9588102|FG005|Long-Term Extension Weeks 52 to 260|Lost to Follow-up|0
5995030|NCT01194219|9588103|FG006|Long-Term Extension Weeks 52 to 260|Lost to Follow-up|0
5995031|NCT01194219|9588104|FG007|Long-Term Extension Weeks 52 to 260|Lost to Follow-up|0
5995032|NCT01194219|9588105|FG008|Long-Term Extension Weeks 52 to 260|Lost to Follow-up|24
5995033|NCT01194219|9588106|FG009|Long-Term Extension Weeks 52 to 260|Lost to Follow-up|10
5995034|NCT01194219|9588097|FG000|Long-Term Extension Weeks 52 to 260|Protocol Violation|0
5995035|NCT01194219|9588098|FG001|Long-Term Extension Weeks 52 to 260|Protocol Violation|0
6070203|NCT00549198|9673095|FG001|Overall Study|Lost to Follow-up|8
6070204|NCT00549198|9673094|FG000|Overall Study|Treatment Eligibility Criteria Not Met|3
6070205|NCT00549198|9673095|FG001|Overall Study|Treatment Eligibility Criteria Not Met|0
6070206|NCT00549198|9673094|FG000|Overall Study|Protocol Violation|7
6070207|NCT00549198|9673095|FG001|Overall Study|Protocol Violation|2
6070208|NCT00549198|9673094|FG000|Overall Study|Investigator Decision|4
6070209|NCT00549198|9673095|FG001|Overall Study|Investigator Decision|3
6070210|NCT00549198|9673094|FG000|Overall Study|Withdrawal by Subject|7
6070211|NCT00549198|9673095|FG001|Overall Study|Withdrawal by Subject|7
6070212|NCT00549198|9673094|FG000|Overall Study|Disease Progression|1
6070213|NCT00549198|9673095|FG001|Overall Study|Disease Progression|0
6070214|NCT00549198|9673094|FG000|Overall Study|Participant Moved|2
6070215|NCT00549198|9673095|FG001|Overall Study|Participant Moved|0
6070216|NCT00549198|9673094|FG000|Overall Study|Participant not able to perform Week 96|1
6070217|NCT00549198|9673095|FG001|Overall Study|Participant not able to perform Week 96|0
6070218|NCT00549198|9673094|FG000|Overall Study|Participant moved.Week 96 visit, no scan|1
6070219|NCT00549198|9673095|FG001|Overall Study|Participant moved.Week 96 visit, no scan|0
6070220|NCT00549198|9673094|FG000|Overall Study|Prohibited Medication|1
6070221|NCT00549198|9673095|FG001|Overall Study|Prohibited Medication|2
6070222|NCT00549198|9673094|FG000|Overall Study|Participant planning pregnancy|1
6070223|NCT00549198|9673095|FG001|Overall Study|Participant planning pregnancy|0
6070224|NCT00549198|9673094|FG000|Overall Study|Participant overweight, no scan possible|1
6070225|NCT00549198|9673095|FG001|Overall Study|Participant overweight, no scan possible|0
6070226|NCT00549198|9673094|FG000|Overall Study|No scan facilities|0
6070227|NCT00549198|9673095|FG001|Overall Study|No scan facilities|2
6070228|NCT00549198|9673094|FG000|Overall Study|Pregnancy|0
6070229|NCT00549198|9673095|FG001|Overall Study|Pregnancy|3
6070230|NCT00549198|9673094|FG000|Overall Study|Not Exposed to Study Drug|3
6070231|NCT00549198|9673095|FG001|Overall Study|Not Exposed to Study Drug|4
6070232|NCT00549302|9673103|FG000|Double-Blind|Death|2
6070233|NCT00549302|9673104|FG001|Double-Blind|Death|9
6070234|NCT00549302|9673105|FG002|Double-Blind|Death|0
6070235|NCT00549302|9673103|FG000|Double-Blind|Adverse Event|3
6070236|NCT00549302|9673104|FG001|Double-Blind|Adverse Event|16
6070237|NCT00549302|9673105|FG002|Double-Blind|Adverse Event|0
6070238|NCT00549302|9673103|FG000|Double-Blind|Withdrawal by Subject|3
6070239|NCT00549302|9673104|FG001|Double-Blind|Withdrawal by Subject|8
6070240|NCT00549302|9673105|FG002|Double-Blind|Withdrawal by Subject|0
6070241|NCT00549302|9673103|FG000|Double-Blind|Investigator Decision|1
6070242|NCT00549302|9673104|FG001|Double-Blind|Investigator Decision|5
6070243|NCT00549302|9673105|FG002|Double-Blind|Investigator Decision|0
6070244|NCT00549302|9673103|FG000|Double-Blind|Sponsor Decision|0
6070245|NCT00549302|9673104|FG001|Double-Blind|Sponsor Decision|1
6070246|NCT00549302|9673105|FG002|Double-Blind|Sponsor Decision|0
6070247|NCT00549302|9673103|FG000|Double-Blind|Lost to Follow-up|1
6070248|NCT00549302|9673104|FG001|Double-Blind|Lost to Follow-up|2
6070249|NCT00549302|9673105|FG002|Double-Blind|Lost to Follow-up|0
6070250|NCT00549302|9673103|FG000|Double-Blind|New Drug Pulmonary Atrial Hypertension|1
6070251|NCT00549302|9673104|FG001|Double-Blind|New Drug Pulmonary Atrial Hypertension|10
6070252|NCT00549302|9673105|FG002|Double-Blind|New Drug Pulmonary Atrial Hypertension|0
6070253|NCT00549302|9673103|FG000|Double-Blind|New condition or starts new therapy|0
6070254|NCT00549302|9673104|FG001|Double-Blind|New condition or starts new therapy|2
6070255|NCT00549302|9673105|FG002|Double-Blind|New condition or starts new therapy|0
6070256|NCT00549302|9673103|FG000|Open-Label|Adverse Event|0
6070257|NCT00549302|9673104|FG001|Open-Label|Adverse Event|0
6070258|NCT00549302|9673105|FG002|Open-Label|Adverse Event|11
6070259|NCT00549302|9673103|FG000|Open-Label|Death|0
6070260|NCT00549302|9673104|FG001|Open-Label|Death|0
6070261|NCT00549302|9673105|FG002|Open-Label|Death|40
6070262|NCT00549302|9673103|FG000|Open-Label|Investigator Decision|0
6070263|NCT00549302|9673104|FG001|Open-Label|Investigator Decision|0
6070264|NCT00549302|9673105|FG002|Open-Label|Investigator Decision|5
6070265|NCT00549302|9673103|FG000|Open-Label|Lost to Follow-up|0
6070266|NCT00549302|9673104|FG001|Open-Label|Lost to Follow-up|0
6070267|NCT00549302|9673105|FG002|Open-Label|Lost to Follow-up|2
6070268|NCT00549302|9673103|FG000|Open-Label|Other|0
6070269|NCT00549302|9673104|FG001|Open-Label|Other|0
6070270|NCT00549302|9673105|FG002|Open-Label|Other|3
6070271|NCT00549302|9673103|FG000|Open-Label|New drug pulmonary atrial hypertension|0
6070272|NCT00549302|9673104|FG001|Open-Label|New drug pulmonary atrial hypertension|0
6070273|NCT00549302|9673105|FG002|Open-Label|New drug pulmonary atrial hypertension|2
6070274|NCT00549302|9673103|FG000|Open-Label|Withdrawal by Subject|0
6070275|NCT00549302|9673104|FG001|Open-Label|Withdrawal by Subject|0
6070276|NCT00549302|9673105|FG002|Open-Label|Withdrawal by Subject|6
6070277|NCT00549445|9673126|FG000|Overall Study|Sputum & Blood Samples Not Available|15
5995036|NCT01194219|9588099|FG002|Long-Term Extension Weeks 52 to 260|Protocol Violation|0
5995037|NCT01194219|9588100|FG003|Long-Term Extension Weeks 52 to 260|Protocol Violation|0
5995038|NCT01194219|9588101|FG004|Long-Term Extension Weeks 52 to 260|Protocol Violation|0
5995039|NCT01194219|9588102|FG005|Long-Term Extension Weeks 52 to 260|Protocol Violation|0
5995040|NCT01194219|9588103|FG006|Long-Term Extension Weeks 52 to 260|Protocol Violation|0
5995041|NCT01194219|9588104|FG007|Long-Term Extension Weeks 52 to 260|Protocol Violation|0
5995042|NCT01194219|9588105|FG008|Long-Term Extension Weeks 52 to 260|Protocol Violation|3
5995043|NCT01194219|9588106|FG009|Long-Term Extension Weeks 52 to 260|Protocol Violation|0
5995044|NCT01194219|9588097|FG000|Long-Term Extension Weeks 52 to 260|Miscellaneous|0
5995045|NCT01194219|9588098|FG001|Long-Term Extension Weeks 52 to 260|Miscellaneous|0
5995046|NCT01194219|9588099|FG002|Long-Term Extension Weeks 52 to 260|Miscellaneous|0
5995047|NCT01194219|9588100|FG003|Long-Term Extension Weeks 52 to 260|Miscellaneous|0
5995048|NCT01194219|9588101|FG004|Long-Term Extension Weeks 52 to 260|Miscellaneous|0
5995049|NCT01194219|9588102|FG005|Long-Term Extension Weeks 52 to 260|Miscellaneous|0
5995050|NCT01194219|9588103|FG006|Long-Term Extension Weeks 52 to 260|Miscellaneous|0
5995051|NCT01194219|9588104|FG007|Long-Term Extension Weeks 52 to 260|Miscellaneous|0
5995052|NCT01194219|9588105|FG008|Long-Term Extension Weeks 52 to 260|Miscellaneous|11
5995053|NCT01194219|9588106|FG009|Long-Term Extension Weeks 52 to 260|Miscellaneous|2
5995054|NCT01193842|9588134|FG000|Phase I: VR-DA-EPOCH, DL 2|Ineligible|0
5995055|NCT01193842|9588135|FG001|Phase I: VR-DA-EPOCH, DL 2|Ineligible|1
5995056|NCT01193842|9588136|FG002|Phase I: VR-DA-EPOCH, DL 2|Ineligible|0
5995057|NCT01193842|9588137|FG003|Phase I: VR-DA-EPOCH, DL 2|Ineligible|0
5995058|NCT01193842|9588138|FG004|Phase I: VR-DA-EPOCH, DL 2|Ineligible|0
5995059|NCT01193842|9588134|FG000|Phase I: VR-DA-EPOCH, DL 1 (De-escalate)|Ineligible|1
5995060|NCT01193842|9588135|FG001|Phase I: VR-DA-EPOCH, DL 1 (De-escalate)|Ineligible|0
5995061|NCT01193842|9588136|FG002|Phase I: VR-DA-EPOCH, DL 1 (De-escalate)|Ineligible|0
5995062|NCT01193842|9588137|FG003|Phase I: VR-DA-EPOCH, DL 1 (De-escalate)|Ineligible|0
5995063|NCT01193842|9588138|FG004|Phase I: VR-DA-EPOCH, DL 1 (De-escalate)|Ineligible|0
5995064|NCT01193842|9588134|FG000|Phase I: VR-CHOP, DL 1|Noncompliant (Cycle 1 not complete)|0
5995065|NCT01193842|9588135|FG001|Phase I: VR-CHOP, DL 1|Noncompliant (Cycle 1 not complete)|0
5995066|NCT01193842|9588136|FG002|Phase I: VR-CHOP, DL 1|Noncompliant (Cycle 1 not complete)|1
5995067|NCT01193842|9588137|FG003|Phase I: VR-CHOP, DL 1|Noncompliant (Cycle 1 not complete)|0
5995068|NCT01193842|9588138|FG004|Phase I: VR-CHOP, DL 1|Noncompliant (Cycle 1 not complete)|0
5995069|NCT01193842|9588134|FG000|Phase II: Randomized Groups|Death|0
5995070|NCT01193842|9588135|FG001|Phase II: Randomized Groups|Death|0
5995071|NCT01193842|9588136|FG002|Phase II: Randomized Groups|Death|0
5995072|NCT01193842|9588137|FG003|Phase II: Randomized Groups|Death|1
5995073|NCT01193842|9588138|FG004|Phase II: Randomized Groups|Death|1
5995074|NCT01193842|9588134|FG000|Phase II: Randomized Groups|Adverse Event|0
5995075|NCT01193842|9588135|FG001|Phase II: Randomized Groups|Adverse Event|0
5995076|NCT01193842|9588136|FG002|Phase II: Randomized Groups|Adverse Event|0
5995077|NCT01193842|9588137|FG003|Phase II: Randomized Groups|Adverse Event|5
5995078|NCT01193842|9588138|FG004|Phase II: Randomized Groups|Adverse Event|3
5995079|NCT01193842|9588134|FG000|Phase II: Randomized Groups|Withdrawal by Subject|0
5995080|NCT01193842|9588135|FG001|Phase II: Randomized Groups|Withdrawal by Subject|0
5995081|NCT01193842|9588136|FG002|Phase II: Randomized Groups|Withdrawal by Subject|0
5995082|NCT01193842|9588137|FG003|Phase II: Randomized Groups|Withdrawal by Subject|1
5995083|NCT01193842|9588138|FG004|Phase II: Randomized Groups|Withdrawal by Subject|2
5995084|NCT01193842|9588134|FG000|Phase II: Randomized Groups|Ineligible|0
5995085|NCT01193842|9588135|FG001|Phase II: Randomized Groups|Ineligible|0
5995086|NCT01193842|9588136|FG002|Phase II: Randomized Groups|Ineligible|0
5995087|NCT01193842|9588137|FG003|Phase II: Randomized Groups|Ineligible|0
5995088|NCT01193842|9588138|FG004|Phase II: Randomized Groups|Ineligible|1
5995089|NCT01193842|9588134|FG000|Phase II: Randomized Groups|Disease progression/relapse on treatment|0
6070278|NCT00549445|9673127|FG001|Overall Study|Sputum & Blood Samples Not Available|17
5995090|NCT01193842|9588135|FG001|Phase II: Randomized Groups|Disease progression/relapse on treatment|0
5995091|NCT01193842|9588136|FG002|Phase II: Randomized Groups|Disease progression/relapse on treatment|0
5995092|NCT01193842|9588137|FG003|Phase II: Randomized Groups|Disease progression/relapse on treatment|5
5995093|NCT01193842|9588138|FG004|Phase II: Randomized Groups|Disease progression/relapse on treatment|3
5995094|NCT00855803|9588155|FG000|Overall Study|Death|2
5995095|NCT00855803|9588155|FG000|Overall Study|Lost to Follow-up|2
5995096|NCT00855803|9588155|FG000|Overall Study|Technical inability to undergo procedure|2
5995097|NCT00855803|9588155|FG000|Overall Study|Not evaluable at 3 month timepoint|2
5995098|NCT00855803|9588155|FG000|Overall Study|Withdrawal by Subject|3
5995099|NCT00855803|9588155|FG000|Overall Study|Physician Decision|3
5995100|NCT00740116|9588165|FG000|Overall Study|Withdrawal by Subject|1
5995101|NCT00740116|9588166|FG001|Overall Study|Withdrawal by Subject|1
5995102|NCT00740116|9588165|FG000|Overall Study|Protocol Violation|1
5995103|NCT00740116|9588166|FG001|Overall Study|Protocol Violation|4
5995104|NCT00565617|9588174|FG000|Overall Study|Withdrawal by Subject|1
5995105|NCT00470704|9588180|FG000|Overall Study|Withdrawal by Subject|4
5995106|NCT00470704|9588181|FG001|Overall Study|Withdrawal by Subject|3
5995107|NCT00470704|9588180|FG000|Overall Study|Relapse/Progression|37
5995108|NCT00470704|9588181|FG001|Overall Study|Relapse/Progression|42
5995109|NCT00470704|9588180|FG000|Overall Study|toxicity|0
5995110|NCT00470704|9588181|FG001|Overall Study|toxicity|1
5995111|NCT00142584|9588209|FG000|Overall Study|Sponsor Termination of Study, etc.|72
5995112|NCT00142584|9588210|FG001|Overall Study|Sponsor Termination of Study, etc.|16
5995113|NCT00142584|9588209|FG000|Overall Study|Withdrawal by Subject|30
5995114|NCT00142584|9588210|FG001|Overall Study|Withdrawal by Subject|16
5995115|NCT00142584|9588209|FG000|Overall Study|Lost to Follow-up|22
5995116|NCT00142584|9588210|FG001|Overall Study|Lost to Follow-up|12
5995117|NCT00142584|9588209|FG000|Overall Study|Adverse Event|14
5995118|NCT00142584|9588210|FG001|Overall Study|Adverse Event|5
5995119|NCT00142584|9588209|FG000|Overall Study|Protocol Violation|4
5995120|NCT00142584|9588210|FG001|Overall Study|Protocol Violation|7
5995121|NCT00142584|9588209|FG000|Overall Study|Treatment Failure|2
6146241|NCT01076010|9780834|FG002|Overall Study|Death|0
6146242|NCT01076010|9780832|FG000|Overall Study|Adverse Event|7
5995122|NCT00142584|9588210|FG001|Overall Study|Treatment Failure|0
6046476|NCT00406653|9645626|FG005|Induction Period|Subject No Longer Meets Study Criteria|0
6046477|NCT00406653|9645627|FG006|Induction Period|Subject No Longer Meets Study Criteria|0
6046478|NCT00406653|9645621|FG000|Induction Period|Pregnancy|1
6046479|NCT00406653|9645622|FG001|Induction Period|Pregnancy|0
6046480|NCT00406653|9645623|FG002|Induction Period|Pregnancy|0
6046481|NCT00406653|9645624|FG003|Induction Period|Pregnancy|0
6046482|NCT00406653|9645625|FG004|Induction Period|Pregnancy|0
6046483|NCT00406653|9645626|FG005|Induction Period|Pregnancy|0
6046484|NCT00406653|9645627|FG006|Induction Period|Pregnancy|0
6046485|NCT00406653|9645621|FG000|Induction Period|Declined participation but followup done|0
6046486|NCT00406653|9645622|FG001|Induction Period|Declined participation but followup done|2
6046487|NCT00406653|9645623|FG002|Induction Period|Declined participation but followup done|1
6046488|NCT00406653|9645624|FG003|Induction Period|Declined participation but followup done|1
6046489|NCT00406653|9645625|FG004|Induction Period|Declined participation but followup done|0
6046490|NCT00406653|9645626|FG005|Induction Period|Declined participation but followup done|0
6046491|NCT00406653|9645627|FG006|Induction Period|Declined participation but followup done|0
6046492|NCT00406653|9645621|FG000|Induction Period|Given prohibited drug|0
6046493|NCT00406653|9645622|FG001|Induction Period|Given prohibited drug|1
6046494|NCT00406653|9645623|FG002|Induction Period|Given prohibited drug|2
6046495|NCT00406653|9645624|FG003|Induction Period|Given prohibited drug|0
6046496|NCT00406653|9645625|FG004|Induction Period|Given prohibited drug|0
6046497|NCT00406653|9645626|FG005|Induction Period|Given prohibited drug|0
6046498|NCT00406653|9645627|FG006|Induction Period|Given prohibited drug|0
6046499|NCT00406653|9645621|FG000|Induction Period|Incarcerated|0
6046500|NCT00406653|9645622|FG001|Induction Period|Incarcerated|0
6046501|NCT00406653|9645623|FG002|Induction Period|Incarcerated|1
6046502|NCT00406653|9645624|FG003|Induction Period|Incarcerated|0
6046503|NCT00406653|9645625|FG004|Induction Period|Incarcerated|0
6046504|NCT00406653|9645626|FG005|Induction Period|Incarcerated|0
6046505|NCT00406653|9645627|FG006|Induction Period|Incarcerated|0
6046506|NCT00406653|9645621|FG000|Induction Period|Patient relocated|0
6046507|NCT00406653|9645622|FG001|Induction Period|Patient relocated|0
6046508|NCT00406653|9645623|FG002|Induction Period|Patient relocated|1
6046509|NCT00406653|9645624|FG003|Induction Period|Patient relocated|0
6046510|NCT00406653|9645625|FG004|Induction Period|Patient relocated|0
6046511|NCT00406653|9645626|FG005|Induction Period|Patient relocated|0
6046512|NCT00406653|9645627|FG006|Induction Period|Patient relocated|0
6046513|NCT00406653|9645621|FG000|Maintenance Period|Adverse Event|0
6046514|NCT00406653|9645622|FG001|Maintenance Period|Adverse Event|0
6046515|NCT00406653|9645623|FG002|Maintenance Period|Adverse Event|0
6046516|NCT00406653|9645624|FG003|Maintenance Period|Adverse Event|0
6046517|NCT00406653|9645625|FG004|Maintenance Period|Adverse Event|1
6046518|NCT00406653|9645626|FG005|Maintenance Period|Adverse Event|1
6046519|NCT00406653|9645627|FG006|Maintenance Period|Adverse Event|0
6046520|NCT00406653|9645621|FG000|Maintenance Period|Lack of Efficacy|0
6046521|NCT00406653|9645622|FG001|Maintenance Period|Lack of Efficacy|0
6046522|NCT00406653|9645623|FG002|Maintenance Period|Lack of Efficacy|0
6070279|NCT00549549|9673137|FG000|Overall Study|Adverse Event|5
6070280|NCT00549549|9673138|FG001|Overall Study|Adverse Event|3
6070281|NCT00549549|9673139|FG002|Overall Study|Adverse Event|1
6070282|NCT00549549|9673140|FG003|Overall Study|Adverse Event|9
6070283|NCT00549549|9673137|FG000|Overall Study|Lack of Efficacy|9
6070284|NCT00549549|9673138|FG001|Overall Study|Lack of Efficacy|6
6070285|NCT00549549|9673139|FG002|Overall Study|Lack of Efficacy|4
6070286|NCT00549549|9673140|FG003|Overall Study|Lack of Efficacy|2
6070287|NCT00549549|9673137|FG000|Overall Study|Lost to Follow-up|1
6070288|NCT00549549|9673138|FG001|Overall Study|Lost to Follow-up|0
6070289|NCT00549549|9673139|FG002|Overall Study|Lost to Follow-up|1
6070290|NCT00549549|9673140|FG003|Overall Study|Lost to Follow-up|2
6046523|NCT00406653|9645624|FG003|Maintenance Period|Lack of Efficacy|0
6046524|NCT00406653|9645625|FG004|Maintenance Period|Lack of Efficacy|20
6046525|NCT00406653|9645626|FG005|Maintenance Period|Lack of Efficacy|26
6046526|NCT00406653|9645627|FG006|Maintenance Period|Lack of Efficacy|0
6046527|NCT00406653|9645621|FG000|Maintenance Period|Lost to Follow-up|0
6046528|NCT00406653|9645622|FG001|Maintenance Period|Lost to Follow-up|0
6046529|NCT00406653|9645623|FG002|Maintenance Period|Lost to Follow-up|0
6046530|NCT00406653|9645624|FG003|Maintenance Period|Lost to Follow-up|0
6070291|NCT00549549|9673137|FG000|Overall Study|Withdrawal by Subject|0
5995123|NCT04551898|9588240|FG000|Overall Study|Participant randomized but did not receive study drug|0
5995124|NCT04551898|9588241|FG001|Overall Study|Participant randomized but did not receive study drug|1
5995125|NCT04551898|9588242|FG002|Overall Study|Participant randomized but did not receive study drug|3
5995126|NCT04551898|9588243|FG003|Overall Study|Participant randomized but did not receive study drug|1
5995127|NCT04551898|9588240|FG000|Overall Study|Withdrawal by Subject|5
5995128|NCT04551898|9588241|FG001|Overall Study|Withdrawal by Subject|1
5995129|NCT04551898|9588242|FG002|Overall Study|Withdrawal by Subject|2
5995130|NCT04551898|9588243|FG003|Overall Study|Withdrawal by Subject|2
6070292|NCT00549549|9673138|FG001|Overall Study|Withdrawal by Subject|4
6070293|NCT00549549|9673139|FG002|Overall Study|Withdrawal by Subject|1
6070294|NCT00549549|9673140|FG003|Overall Study|Withdrawal by Subject|0
6070295|NCT00549549|9673137|FG000|Overall Study|Other|9
6070296|NCT00549549|9673138|FG001|Overall Study|Other|9
6070297|NCT00549549|9673139|FG002|Overall Study|Other|9
6070298|NCT00549549|9673140|FG003|Overall Study|Other|11
6070299|NCT00549549|9673137|FG000|Overall Study|Randomized but not treated|0
5995131|NCT04551898|9588240|FG000|Overall Study|Lost to Follow-up|2
6070300|NCT00549549|9673138|FG001|Overall Study|Randomized but not treated|0
6070301|NCT00549549|9673139|FG002|Overall Study|Randomized but not treated|1
6070302|NCT00549549|9673140|FG003|Overall Study|Randomized but not treated|1
6070303|NCT00549562|9673150|FG000|Overall Study|Adverse Event|1
6070304|NCT00549562|9673150|FG000|Overall Study|Lack of Efficacy|1
6070305|NCT00549601|9673157|FG000|Randomized|Protocol Violation|0
6070306|NCT00549601|9673158|FG001|Randomized|Protocol Violation|0
6070307|NCT00549601|9673159|FG002|Randomized|Protocol Violation|1
6070308|NCT00549601|9673157|FG000|Randomized|Withdrawal by Subject|0
6070309|NCT00549601|9673158|FG001|Randomized|Withdrawal by Subject|1
6070310|NCT00549601|9673159|FG002|Randomized|Withdrawal by Subject|1
6070311|NCT00549601|9673157|FG000|Received Study Drug|Adverse Event|2
6070312|NCT00549601|9673158|FG001|Received Study Drug|Adverse Event|5
6070313|NCT00549601|9673159|FG002|Received Study Drug|Adverse Event|1
6070314|NCT00549601|9673157|FG000|Received Study Drug|Death|0
6070315|NCT00549601|9673158|FG001|Received Study Drug|Death|1
6070316|NCT00549601|9673159|FG002|Received Study Drug|Death|0
6070317|NCT00549601|9673157|FG000|Received Study Drug|Lost to Follow-up|0
6070318|NCT00549601|9673158|FG001|Received Study Drug|Lost to Follow-up|1
6070319|NCT00549601|9673159|FG002|Received Study Drug|Lost to Follow-up|1
6070320|NCT00549601|9673157|FG000|Received Study Drug|Protocol Violation|3
6070321|NCT00549601|9673158|FG001|Received Study Drug|Protocol Violation|4
6070322|NCT00549601|9673159|FG002|Received Study Drug|Protocol Violation|1
6070323|NCT00549601|9673157|FG000|Received Study Drug|Withdrawal by Subject|2
6070324|NCT00549601|9673158|FG001|Received Study Drug|Withdrawal by Subject|0
6070325|NCT00549601|9673159|FG002|Received Study Drug|Withdrawal by Subject|1
6070326|NCT00549640|9673171|FG000|Overall Study|Withdrawal by Subject|6
6070327|NCT00549640|9673172|FG001|Overall Study|Withdrawal by Subject|12
6070328|NCT00549640|9673171|FG000|Overall Study|Adverse Event|5
6070329|NCT00549640|9673172|FG001|Overall Study|Adverse Event|0
6070330|NCT00549640|9673171|FG000|Overall Study|Lost to Follow-up|7
6070331|NCT00549640|9673172|FG001|Overall Study|Lost to Follow-up|4
6070332|NCT00549718|9673182|FG000|Overall Study|Insufficient clinical response|20
6070333|NCT00549718|9673183|FG001|Overall Study|Insufficient clinical response|7
5995132|NCT04551898|9588241|FG001|Overall Study|Lost to Follow-up|1
5995133|NCT04551898|9588242|FG002|Overall Study|Lost to Follow-up|2
5995134|NCT04551898|9588243|FG003|Overall Study|Lost to Follow-up|2
5995135|NCT04551898|9588240|FG000|Overall Study|Death|1
5995136|NCT04551898|9588241|FG001|Overall Study|Death|0
5995137|NCT04551898|9588242|FG002|Overall Study|Death|0
5995138|NCT04551898|9588243|FG003|Overall Study|Death|0
5995139|NCT04551898|9588240|FG000|Overall Study|Incorrectly randomized and screen failed due to administrative error|0
5995140|NCT04551898|9588241|FG001|Overall Study|Incorrectly randomized and screen failed due to administrative error|0
5995141|NCT04551898|9588242|FG002|Overall Study|Incorrectly randomized and screen failed due to administrative error|1
5995142|NCT04551898|9588243|FG003|Overall Study|Incorrectly randomized and screen failed due to administrative error|0
5995143|NCT04402866|9588265|FG000|Overall Study|Discontinued Prior to Treatment|0
5995144|NCT04402866|9588266|FG001|Overall Study|Discontinued Prior to Treatment|0
5995145|NCT04402866|9588267|FG002|Overall Study|Discontinued Prior to Treatment|0
5995146|NCT04402866|9588268|FG003|Overall Study|Discontinued Prior to Treatment|0
5995147|NCT04402866|9588269|FG004|Overall Study|Discontinued Prior to Treatment|2
5995148|NCT04402866|9588270|FG005|Overall Study|Discontinued Prior to Treatment|3
5995149|NCT04402866|9588265|FG000|Overall Study|Adverse Event|2
5995150|NCT04402866|9588266|FG001|Overall Study|Adverse Event|1
5995151|NCT04402866|9588267|FG002|Overall Study|Adverse Event|0
5995152|NCT04402866|9588268|FG003|Overall Study|Adverse Event|0
5995153|NCT04402866|9588269|FG004|Overall Study|Adverse Event|13
6070334|NCT00549718|9673184|FG002|Overall Study|Insufficient clinical response|18
6070335|NCT00549718|9673185|FG003|Overall Study|Insufficient clinical response|32
6070336|NCT00549718|9673182|FG000|Overall Study|Adverse Event|6
6070337|NCT00549718|9673183|FG001|Overall Study|Adverse Event|8
6070338|NCT00549718|9673184|FG002|Overall Study|Adverse Event|7
6070339|NCT00549718|9673185|FG003|Overall Study|Adverse Event|3
6070340|NCT00549718|9673182|FG000|Overall Study|Lost to Follow-up|4
5995154|NCT04402866|9588270|FG005|Overall Study|Adverse Event|8
5995155|NCT04402866|9588265|FG000|Overall Study|Miscellaneous|0
5995156|NCT04402866|9588266|FG001|Overall Study|Miscellaneous|0
5995157|NCT04402866|9588267|FG002|Overall Study|Miscellaneous|1
5995158|NCT04402866|9588268|FG003|Overall Study|Miscellaneous|0
5995159|NCT04402866|9588269|FG004|Overall Study|Miscellaneous|0
5995160|NCT04402866|9588270|FG005|Overall Study|Miscellaneous|0
5995161|NCT04402866|9588265|FG000|Overall Study|Lost to Follow-up|0
5995162|NCT04402866|9588266|FG001|Overall Study|Lost to Follow-up|0
5995163|NCT04402866|9588267|FG002|Overall Study|Lost to Follow-up|0
5995164|NCT04402866|9588268|FG003|Overall Study|Lost to Follow-up|0
5995165|NCT04402866|9588269|FG004|Overall Study|Lost to Follow-up|0
5995166|NCT04402866|9588270|FG005|Overall Study|Lost to Follow-up|1
5995167|NCT04402866|9588265|FG000|Overall Study|Withdrawal by Subject|0
5995168|NCT04402866|9588266|FG001|Overall Study|Withdrawal by Subject|0
5995169|NCT04402866|9588267|FG002|Overall Study|Withdrawal by Subject|0
5995170|NCT04402866|9588268|FG003|Overall Study|Withdrawal by Subject|0
6070341|NCT00549718|9673183|FG001|Overall Study|Lost to Follow-up|2
6070342|NCT00549718|9673184|FG002|Overall Study|Lost to Follow-up|0
6070343|NCT00549718|9673185|FG003|Overall Study|Lost to Follow-up|6
5995171|NCT04402866|9588269|FG004|Overall Study|Withdrawal by Subject|0
5995172|NCT04402866|9588270|FG005|Overall Study|Withdrawal by Subject|2
6046531|NCT00406653|9645625|FG004|Maintenance Period|Lost to Follow-up|2
6070344|NCT00549718|9673182|FG000|Overall Study|Withdrawal by Subject|9
6070345|NCT00549718|9673183|FG001|Overall Study|Withdrawal by Subject|18
6070346|NCT00549718|9673184|FG002|Overall Study|Withdrawal by Subject|12
6070347|NCT00549718|9673185|FG003|Overall Study|Withdrawal by Subject|13
6070348|NCT00549718|9673182|FG000|Overall Study|Administrative|2
6070349|NCT00549718|9673183|FG001|Overall Study|Administrative|2
6070350|NCT00549718|9673184|FG002|Overall Study|Administrative|2
6070351|NCT00549718|9673185|FG003|Overall Study|Administrative|1
6070352|NCT00549757|9673197|FG000|Active Treatment Phase: Max. 50 Months|Adverse Event|590
6070353|NCT00549757|9673198|FG001|Active Treatment Phase: Max. 50 Months|Adverse Event|462
6070354|NCT00549757|9673197|FG000|Active Treatment Phase: Max. 50 Months|Abnormal laboratory value(s)|98
6070355|NCT00549757|9673198|FG001|Active Treatment Phase: Max. 50 Months|Abnormal laboratory value(s)|58
6070356|NCT00549757|9673197|FG000|Active Treatment Phase: Max. 50 Months|Abnormal test procedure result(s)|7
6070357|NCT00549757|9673198|FG001|Active Treatment Phase: Max. 50 Months|Abnormal test procedure result(s)|7
6070358|NCT00549757|9673197|FG000|Active Treatment Phase: Max. 50 Months|Unsatisfactory therapeutic effect|47
6070359|NCT00549757|9673198|FG001|Active Treatment Phase: Max. 50 Months|Unsatisfactory therapeutic effect|53
6070360|NCT00549757|9673197|FG000|Active Treatment Phase: Max. 50 Months|Subject withdrew consent|38
6070361|NCT00549757|9673198|FG001|Active Treatment Phase: Max. 50 Months|Subject withdrew consent|38
6070362|NCT00549757|9673197|FG000|Active Treatment Phase: Max. 50 Months|Lost to Follow-up|41
6070363|NCT00549757|9673198|FG001|Active Treatment Phase: Max. 50 Months|Lost to Follow-up|29
6070364|NCT00549757|9673197|FG000|Active Treatment Phase: Max. 50 Months|Administrative problems|2857
6070365|NCT00549757|9673198|FG001|Active Treatment Phase: Max. 50 Months|Administrative problems|3019
6070366|NCT00549757|9673197|FG000|Active Treatment Phase: Max. 50 Months|Death|188
6070367|NCT00549757|9673198|FG001|Active Treatment Phase: Max. 50 Months|Death|200
6070368|NCT00549757|9673197|FG000|Active Treatment Phase: Max. 50 Months|Patient's request|353
6070369|NCT00549757|9673198|FG001|Active Treatment Phase: Max. 50 Months|Patient's request|380
6070370|NCT00549757|9673197|FG000|Active Treatment Phase: Max. 50 Months|Incorrect Entry|69
6070371|NCT00549757|9673198|FG001|Active Treatment Phase: Max. 50 Months|Incorrect Entry|55
6070372|NCT00549757|9673197|FG000|Active Treatment Phase: Max. 50 Months|Missing data|8
6070373|NCT00549757|9673198|FG001|Active Treatment Phase: Max. 50 Months|Missing data|9
6070374|NCT00549757|9673197|FG000|Extension Period (in Average 9 Months)|Death|143
6070375|NCT00549757|9673198|FG001|Extension Period (in Average 9 Months)|Death|136
6070376|NCT00549757|9673197|FG000|Extension Period (in Average 9 Months)|Lost to Follow-up|52
6070377|NCT00549757|9673198|FG001|Extension Period (in Average 9 Months)|Lost to Follow-up|47
6070378|NCT00549757|9673197|FG000|Extension Period (in Average 9 Months)|Withdrawal by Subject|9
6070379|NCT00549757|9673198|FG001|Extension Period (in Average 9 Months)|Withdrawal by Subject|16
6070380|NCT00549757|9673197|FG000|Extension Period (in Average 9 Months)|Patient's request|421
6070381|NCT00549757|9673198|FG001|Extension Period (in Average 9 Months)|Patient's request|436
6070382|NCT00549770|9673218|FG000|Overall Study|Protocol deviation|1
6070383|NCT00549770|9673219|FG001|Overall Study|Protocol deviation|1
6070384|NCT00549770|9673220|FG002|Overall Study|Protocol deviation|1
6070385|NCT00549770|9673221|FG003|Overall Study|Protocol deviation|2
6070386|NCT00549770|9673222|FG004|Overall Study|Protocol deviation|2
6046532|NCT00406653|9645626|FG005|Maintenance Period|Lost to Follow-up|1
6046533|NCT00406653|9645627|FG006|Maintenance Period|Lost to Follow-up|0
6070387|NCT00549770|9673223|FG005|Overall Study|Protocol deviation|2
6070388|NCT00549770|9673224|FG006|Overall Study|Protocol deviation|1
6070389|NCT00549770|9673225|FG007|Overall Study|Protocol deviation|2
6070390|NCT00549770|9673218|FG000|Overall Study|Administrative problems|0
6070391|NCT00549770|9673219|FG001|Overall Study|Administrative problems|1
6070392|NCT00549770|9673220|FG002|Overall Study|Administrative problems|0
6070393|NCT00549770|9673221|FG003|Overall Study|Administrative problems|0
6070394|NCT00549770|9673222|FG004|Overall Study|Administrative problems|0
6046534|NCT00406653|9645621|FG000|Maintenance Period|Withdrawal of Consent|0
6070395|NCT00549770|9673223|FG005|Overall Study|Administrative problems|0
6070396|NCT00549770|9673224|FG006|Overall Study|Administrative problems|0
6070397|NCT00549770|9673225|FG007|Overall Study|Administrative problems|1
6070398|NCT00549770|9673218|FG000|Overall Study|Lost to Follow-up|0
6070399|NCT00549770|9673219|FG001|Overall Study|Lost to Follow-up|0
6070400|NCT00549770|9673220|FG002|Overall Study|Lost to Follow-up|2
6070401|NCT00549770|9673221|FG003|Overall Study|Lost to Follow-up|2
6070402|NCT00549770|9673222|FG004|Overall Study|Lost to Follow-up|3
6070403|NCT00549770|9673223|FG005|Overall Study|Lost to Follow-up|2
6070404|NCT00549770|9673224|FG006|Overall Study|Lost to Follow-up|0
6070405|NCT00549770|9673225|FG007|Overall Study|Lost to Follow-up|0
5995173|NCT04327388|9588283|FG000|Overall Study|Adverse Event|17
5995174|NCT04327388|9588284|FG001|Overall Study|Adverse Event|18
5995175|NCT04327388|9588285|FG002|Overall Study|Adverse Event|9
5995176|NCT04327388|9588283|FG000|Overall Study|Other|1
5995177|NCT04327388|9588284|FG001|Overall Study|Other|2
5995178|NCT04327388|9588285|FG002|Overall Study|Other|0
5995179|NCT04327388|9588283|FG000|Overall Study|Randomized and not treated|2
5995180|NCT04327388|9588284|FG001|Overall Study|Randomized and not treated|0
5995181|NCT04327388|9588285|FG002|Overall Study|Randomized and not treated|2
5995182|NCT03860259|9588295|FG000|Overall Study|Lost to Follow-up|5
5995183|NCT03860259|9588296|FG001|Overall Study|Lost to Follow-up|5
5995184|NCT03860259|9588295|FG000|Overall Study|Protocol Violation|1
5995185|NCT03860259|9588296|FG001|Overall Study|Protocol Violation|0
6046535|NCT00406653|9645622|FG001|Maintenance Period|Withdrawal of Consent|0
6046536|NCT00406653|9645623|FG002|Maintenance Period|Withdrawal of Consent|0
6046537|NCT00406653|9645624|FG003|Maintenance Period|Withdrawal of Consent|0
6046538|NCT00406653|9645625|FG004|Maintenance Period|Withdrawal of Consent|2
6046539|NCT00406653|9645626|FG005|Maintenance Period|Withdrawal of Consent|0
6046540|NCT00406653|9645627|FG006|Maintenance Period|Withdrawal of Consent|0
6046541|NCT00406653|9645621|FG000|Maintenance Period|Pregnancy|0
6046542|NCT00406653|9645622|FG001|Maintenance Period|Pregnancy|0
6046543|NCT00406653|9645623|FG002|Maintenance Period|Pregnancy|0
6046544|NCT00406653|9645624|FG003|Maintenance Period|Pregnancy|0
6046545|NCT00406653|9645625|FG004|Maintenance Period|Pregnancy|0
6046546|NCT00406653|9645626|FG005|Maintenance Period|Pregnancy|1
6070406|NCT00549770|9673218|FG000|Overall Study|Withdrawal by Subject|4
6070407|NCT00549770|9673219|FG001|Overall Study|Withdrawal by Subject|6
6070408|NCT00549770|9673220|FG002|Overall Study|Withdrawal by Subject|4
6070409|NCT00549770|9673221|FG003|Overall Study|Withdrawal by Subject|5
6070410|NCT00549770|9673222|FG004|Overall Study|Withdrawal by Subject|6
6070411|NCT00549770|9673223|FG005|Overall Study|Withdrawal by Subject|6
6070412|NCT00549770|9673224|FG006|Overall Study|Withdrawal by Subject|4
6070413|NCT00549770|9673225|FG007|Overall Study|Withdrawal by Subject|9
6070414|NCT00549770|9673218|FG000|Overall Study|Lack of Efficacy|1
6070415|NCT00549770|9673219|FG001|Overall Study|Lack of Efficacy|0
6070416|NCT00549770|9673220|FG002|Overall Study|Lack of Efficacy|2
6070417|NCT00549770|9673221|FG003|Overall Study|Lack of Efficacy|3
6070418|NCT00549770|9673222|FG004|Overall Study|Lack of Efficacy|5
6070419|NCT00549770|9673223|FG005|Overall Study|Lack of Efficacy|1
6070420|NCT00549770|9673224|FG006|Overall Study|Lack of Efficacy|3
6070421|NCT00549770|9673225|FG007|Overall Study|Lack of Efficacy|8
6070422|NCT00549770|9673218|FG000|Overall Study|Abnormal test procedure results|0
6070423|NCT00549770|9673219|FG001|Overall Study|Abnormal test procedure results|0
6070424|NCT00549770|9673220|FG002|Overall Study|Abnormal test procedure results|0
6070425|NCT00549770|9673221|FG003|Overall Study|Abnormal test procedure results|2
6046547|NCT00406653|9645627|FG006|Maintenance Period|Pregnancy|0
6046548|NCT00406653|9645621|FG000|Maintenance Period|Administrative Reason By Sponsor|0
6046549|NCT00406653|9645622|FG001|Maintenance Period|Administrative Reason By Sponsor|0
6046550|NCT00406653|9645623|FG002|Maintenance Period|Administrative Reason By Sponsor|0
6046551|NCT00406653|9645624|FG003|Maintenance Period|Administrative Reason By Sponsor|0
6046552|NCT00406653|9645625|FG004|Maintenance Period|Administrative Reason By Sponsor|4
6046553|NCT00406653|9645626|FG005|Maintenance Period|Administrative Reason By Sponsor|7
6046554|NCT00406653|9645627|FG006|Maintenance Period|Administrative Reason By Sponsor|0
6046555|NCT00406653|9645621|FG000|Maintenance Period|Error in disease score evaluation|0
6046556|NCT00406653|9645622|FG001|Maintenance Period|Error in disease score evaluation|0
6046557|NCT00406653|9645623|FG002|Maintenance Period|Error in disease score evaluation|0
6046558|NCT00406653|9645624|FG003|Maintenance Period|Error in disease score evaluation|0
6046559|NCT00406653|9645625|FG004|Maintenance Period|Error in disease score evaluation|1
6046560|NCT00406653|9645626|FG005|Maintenance Period|Error in disease score evaluation|0
6046561|NCT00406653|9645627|FG006|Maintenance Period|Error in disease score evaluation|0
6046562|NCT00406653|9645621|FG000|Open-Label Period|Death|0
6070426|NCT00549770|9673222|FG004|Overall Study|Abnormal test procedure results|0
6070427|NCT00549770|9673223|FG005|Overall Study|Abnormal test procedure results|1
6070428|NCT00549770|9673224|FG006|Overall Study|Abnormal test procedure results|1
6070429|NCT00549770|9673225|FG007|Overall Study|Abnormal test procedure results|1
6046563|NCT00406653|9645622|FG001|Open-Label Period|Death|0
6046564|NCT00406653|9645623|FG002|Open-Label Period|Death|0
6046565|NCT00406653|9645624|FG003|Open-Label Period|Death|0
6070430|NCT00549770|9673218|FG000|Overall Study|Abnormal laboratory values|0
6070431|NCT00549770|9673219|FG001|Overall Study|Abnormal laboratory values|0
5995186|NCT03446573|9588318|FG000|Overall Study|Withdrawal by Subject|7
5995187|NCT03446573|9588319|FG001|Overall Study|Withdrawal by Subject|16
5995188|NCT03446573|9588318|FG000|Overall Study|Physician Decision|1
5995189|NCT03446573|9588319|FG001|Overall Study|Physician Decision|1
5995190|NCT03446573|9588318|FG000|Overall Study|Lost to Follow-up|3
5995191|NCT03446573|9588319|FG001|Overall Study|Lost to Follow-up|5
5995192|NCT03446573|9588318|FG000|Overall Study|Protocol Violation|3
5995193|NCT03446573|9588319|FG001|Overall Study|Protocol Violation|2
5995194|NCT03446573|9588318|FG000|Overall Study|Lack of Efficacy|0
6070432|NCT00549770|9673220|FG002|Overall Study|Abnormal laboratory values|0
6070433|NCT00549770|9673221|FG003|Overall Study|Abnormal laboratory values|0
6070434|NCT00549770|9673222|FG004|Overall Study|Abnormal laboratory values|0
5995195|NCT03446573|9588319|FG001|Overall Study|Lack of Efficacy|3
5995196|NCT03446573|9588318|FG000|Overall Study|Adverse Event|13
5995197|NCT03446573|9588319|FG001|Overall Study|Adverse Event|2
5995198|NCT03446573|9588318|FG000|Overall Study|Ongoing at the time of interim analysis|342
5995199|NCT03446573|9588319|FG001|Overall Study|Ongoing at the time of interim analysis|343
5995200|NCT03388138|9588330|FG000|Overall Study|Protocol Violation|1
5995201|NCT03388138|9588331|FG001|Overall Study|Protocol Violation|0
5995202|NCT02981082|9588397|FG000|Overall Study|Withdrawal by Subject|2
5995203|NCT02981082|9588398|FG001|Overall Study|Withdrawal by Subject|0
5995204|NCT02981082|9588397|FG000|Overall Study|Met stopping rule of low absolute lymphocyte count (<0.5L) at two visits|1
5995205|NCT02981082|9588398|FG001|Overall Study|Met stopping rule of low absolute lymphocyte count (<0.5L) at two visits|0
5995206|NCT02981082|9588397|FG000|Overall Study|Adverse Event|0
5995207|NCT02981082|9588398|FG001|Overall Study|Adverse Event|1
5995208|NCT02924129|9588406|FG000|Overall Study|Adverse Event Unrelated to Device or Stimulation|2
5995209|NCT02924129|9588407|FG001|Overall Study|Adverse Event Unrelated to Device or Stimulation|1
5995210|NCT02924129|9588406|FG000|Overall Study|Withdrawal by Subject|2
5995211|NCT02924129|9588407|FG001|Overall Study|Withdrawal by Subject|2
5995212|NCT02924129|9588406|FG000|Overall Study|Physician Decision|1
5995213|NCT02924129|9588407|FG001|Overall Study|Physician Decision|0
5995214|NCT02924129|9588406|FG000|Overall Study|Missed Visit|0
5995215|NCT02924129|9588407|FG001|Overall Study|Missed Visit|1
5995216|NCT02831673|9588415|FG000|Overall Study|Adverse Event|6
5995217|NCT02831673|9588416|FG001|Overall Study|Adverse Event|4
5995218|NCT02831673|9588415|FG000|Overall Study|Lack of Efficacy|3
5995219|NCT02831673|9588416|FG001|Overall Study|Lack of Efficacy|1
5995220|NCT02831673|9588415|FG000|Overall Study|Protocol Violation|5
5995221|NCT02831673|9588416|FG001|Overall Study|Protocol Violation|4
5995222|NCT02831673|9588415|FG000|Overall Study|Protocol Withdrawal Criterion Met|1
5995223|NCT02831673|9588416|FG001|Overall Study|Protocol Withdrawal Criterion Met|6
5995224|NCT02831673|9588415|FG000|Overall Study|Lost to Follow-up|9
5995225|NCT02831673|9588416|FG001|Overall Study|Lost to Follow-up|6
5995226|NCT02831673|9588415|FG000|Overall Study|Physician Decision|6
5995227|NCT02831673|9588416|FG001|Overall Study|Physician Decision|3
5995228|NCT02831673|9588415|FG000|Overall Study|Withdrawal by Subject|6
5995229|NCT02831673|9588416|FG001|Overall Study|Withdrawal by Subject|4
5995230|NCT02831673|9588415|FG000|Overall Study|Ongoing at Week 48 primary analysis.|320
5995231|NCT02831673|9588416|FG001|Overall Study|Ongoing at Week 48 primary analysis.|330
5995232|NCT02741700|9588424|FG000|Overall Study|Lost to Follow-up|17
5995233|NCT02741700|9588425|FG001|Overall Study|Lost to Follow-up|8
5995234|NCT02741700|9588424|FG000|Overall Study|Withdrawal by Subject|2
5995235|NCT02741700|9588425|FG001|Overall Study|Withdrawal by Subject|5
5995236|NCT02741700|9588424|FG000|Overall Study|Physician Decision|3
5995237|NCT02741700|9588425|FG001|Overall Study|Physician Decision|0
5995238|NCT02741700|9588424|FG000|Overall Study|Moved out of State|0
5995239|NCT02741700|9588425|FG001|Overall Study|Moved out of State|1
5995240|NCT02741700|9588424|FG000|Overall Study|Death|4
5995241|NCT02741700|9588425|FG001|Overall Study|Death|5
5995242|NCT02635776|9588433|FG000|Overall Study|Physician Decision|1
5995243|NCT02635776|9588434|FG001|Overall Study|Physician Decision|0
5995244|NCT02635776|9588433|FG000|Overall Study|Adverse Event|51
5995245|NCT02635776|9588434|FG001|Overall Study|Adverse Event|3
5995246|NCT02635776|9588433|FG000|Overall Study|Withdrawal by Subject|41
5995247|NCT02635776|9588434|FG001|Overall Study|Withdrawal by Subject|7
5995248|NCT02635776|9588433|FG000|Overall Study|Lost to Follow-up|4
5995249|NCT02635776|9588434|FG001|Overall Study|Lost to Follow-up|0
5995250|NCT02635776|9588433|FG000|Overall Study|Other reasons|5
5995251|NCT02635776|9588434|FG001|Overall Study|Other reasons|1
5995252|NCT02609724|9588445|FG000|Overall Study|Death|2
5995253|NCT02609724|9588446|FG001|Overall Study|Death|0
5995254|NCT02609724|9588447|FG002|Overall Study|Death|1
5995255|NCT02609724|9588445|FG000|Overall Study|Withdrawal by Subject|1
5995256|NCT02609724|9588446|FG001|Overall Study|Withdrawal by Subject|2
5995257|NCT02609724|9588447|FG002|Overall Study|Withdrawal by Subject|3
5995258|NCT02609724|9588445|FG000|Overall Study|Illness|2
5995259|NCT02609724|9588446|FG001|Overall Study|Illness|1
5995260|NCT02609724|9588447|FG002|Overall Study|Illness|0
6070435|NCT00549770|9673223|FG005|Overall Study|Abnormal laboratory values|1
5995261|NCT02359994|9588457|FG000|Overall Population Study|Adverse Event|1
5995262|NCT02359994|9588458|FG001|Overall Population Study|Adverse Event|1
5995263|NCT02359994|9588457|FG000|Overall Population Study|Death|1
5995264|NCT02359994|9588458|FG001|Overall Population Study|Death|5
6070436|NCT00549770|9673224|FG006|Overall Study|Abnormal laboratory values|0
5995265|NCT02359994|9588457|FG000|Overall Population Study|Lost to Follow-up|1
5995266|NCT02359994|9588458|FG001|Overall Population Study|Lost to Follow-up|1
5995267|NCT02359994|9588457|FG000|Overall Population Study|Withdrawal by Subject|1
5995268|NCT02359994|9588458|FG001|Overall Population Study|Withdrawal by Subject|0
5995269|NCT02359994|9588457|FG000|Overall Population Study|Canceled appointment and followed up with their primary care physician instead.|1
5995270|NCT02359994|9588458|FG001|Overall Population Study|Canceled appointment and followed up with their primary care physician instead.|0
5995271|NCT02359994|9588457|FG000|Overall Population Study|Remained in the long term care facility to which the subject was discharged.|0
5995272|NCT02359994|9588458|FG001|Overall Population Study|Remained in the long term care facility to which the subject was discharged.|1
5995273|NCT02359994|9588457|FG000|Extended Oncology 24-Month Survival|Death|19
5995274|NCT02359994|9588458|FG001|Extended Oncology 24-Month Survival|Death|21
5995275|NCT02359994|9588457|FG000|Extended Oncology 24-Month Survival|Lost to Follow-up|1
5995276|NCT02359994|9588458|FG001|Extended Oncology 24-Month Survival|Lost to Follow-up|0
5995277|NCT02336230|9588464|FG000|Overall Study|Adverse Event|1
5995278|NCT02336230|9588464|FG000|Overall Study|Withdrawal of consent|1
5995279|NCT02336230|9588464|FG000|Overall Study|Death|9
5995280|NCT02336230|9588464|FG000|Overall Study|Dose not received due to shipping delay|1
5995281|NCT02336230|9588464|FG000|Overall Study|Discontinuation of MSC infusion|1
5995282|NCT02032823|9588470|FG000|Overall Study|Death|59
5995283|NCT02032823|9588471|FG001|Overall Study|Death|86
5995284|NCT02032823|9588470|FG000|Overall Study|Lost to Follow-up|12
5995285|NCT02032823|9588471|FG001|Overall Study|Lost to Follow-up|15
5995286|NCT02032823|9588470|FG000|Overall Study|Withdrawal by Subject|65
6070437|NCT00549770|9673225|FG007|Overall Study|Abnormal laboratory values|0
6070438|NCT00549770|9673218|FG000|Overall Study|Adverse Event|1
5995287|NCT02032823|9588471|FG001|Overall Study|Withdrawal by Subject|49
5995288|NCT02032823|9588470|FG000|Overall Study|Ongoing study at data cut-off|782
5995289|NCT02032823|9588471|FG001|Overall Study|Ongoing study at data cut-off|760
5995290|NCT02032823|9588470|FG000|Overall Study|Other (e.g investigators decision, protocol deviation, randomised by mistake)|3
5995291|NCT02032823|9588471|FG001|Overall Study|Other (e.g investigators decision, protocol deviation, randomised by mistake)|5
5995292|NCT01557751|9588477|FG000|Overall Study|Physician Decision|3
5995293|NCT00378482|9588494|FG000|Overall Study|Lost to Follow-up|1
5995294|NCT00378482|9588494|FG000|Overall Study|Lack of Efficacy|8
5995295|NCT00378482|9588494|FG000|Overall Study|Subject or physician decision, or subject relocation to another city or region.|9
5995296|NCT00378482|9588494|FG000|Overall Study|Withdrawal by Subject|4
5995297|NCT00378482|9588494|FG000|Overall Study|Adverse Event|9
6046566|NCT00406653|9645625|FG004|Open-Label Period|Death|0
6046567|NCT00406653|9645626|FG005|Open-Label Period|Death|0
6046568|NCT00406653|9645627|FG006|Open-Label Period|Death|1
6046569|NCT00406653|9645621|FG000|Open-Label Period|Adverse Event|0
6046570|NCT00406653|9645622|FG001|Open-Label Period|Adverse Event|0
6046571|NCT00406653|9645623|FG002|Open-Label Period|Adverse Event|0
6046572|NCT00406653|9645624|FG003|Open-Label Period|Adverse Event|0
6046573|NCT00406653|9645625|FG004|Open-Label Period|Adverse Event|0
6046574|NCT00406653|9645626|FG005|Open-Label Period|Adverse Event|0
6046575|NCT00406653|9645627|FG006|Open-Label Period|Adverse Event|18
6046576|NCT00406653|9645621|FG000|Open-Label Period|Lack of Efficacy|0
6046577|NCT00406653|9645622|FG001|Open-Label Period|Lack of Efficacy|0
6046578|NCT00406653|9645623|FG002|Open-Label Period|Lack of Efficacy|0
6046579|NCT00406653|9645624|FG003|Open-Label Period|Lack of Efficacy|0
6046580|NCT00406653|9645625|FG004|Open-Label Period|Lack of Efficacy|0
6070439|NCT00549770|9673219|FG001|Overall Study|Adverse Event|3
6070440|NCT00549770|9673220|FG002|Overall Study|Adverse Event|1
6070441|NCT00549770|9673221|FG003|Overall Study|Adverse Event|2
6070442|NCT00549770|9673222|FG004|Overall Study|Adverse Event|1
6070443|NCT00549770|9673223|FG005|Overall Study|Adverse Event|0
6070444|NCT00549770|9673224|FG006|Overall Study|Adverse Event|5
6070445|NCT00549770|9673225|FG007|Overall Study|Adverse Event|4
6070446|NCT00549900|9673256|FG000|Overall Study|Adverse Event|1
6070447|NCT00549939|9673263|FG000|12-week Double Blind Treatment Period|Adverse Event|1
6070448|NCT00549939|9673264|FG001|12-week Double Blind Treatment Period|Adverse Event|1
6070449|NCT00549939|9673265|FG002|12-week Double Blind Treatment Period|Adverse Event|2
6070450|NCT00549939|9673263|FG000|12-week Double Blind Treatment Period|Too many blood draws|0
6070451|NCT00549939|9673264|FG001|12-week Double Blind Treatment Period|Too many blood draws|1
6070452|NCT00549939|9673265|FG002|12-week Double Blind Treatment Period|Too many blood draws|0
6070453|NCT00549939|9673263|FG000|40-week Open Label Treatment Period|Adverse Event|0
6070454|NCT00549939|9673264|FG001|40-week Open Label Treatment Period|Adverse Event|2
6070455|NCT00549939|9673265|FG002|40-week Open Label Treatment Period|Adverse Event|1
6070456|NCT00549939|9673263|FG000|40-week Open Label Treatment Period|Lack of Efficacy|0
6070457|NCT00549939|9673264|FG001|40-week Open Label Treatment Period|Lack of Efficacy|1
6070458|NCT00549939|9673265|FG002|40-week Open Label Treatment Period|Lack of Efficacy|0
6070459|NCT00549939|9673263|FG000|40-week Open Label Treatment Period|Protocol Violation|0
6046581|NCT00406653|9645626|FG005|Open-Label Period|Lack of Efficacy|0
6046582|NCT00406653|9645627|FG006|Open-Label Period|Lack of Efficacy|160
6070460|NCT00549939|9673264|FG001|40-week Open Label Treatment Period|Protocol Violation|1
6046583|NCT00406653|9645621|FG000|Open-Label Period|Lost to Follow-up|0
6046584|NCT00406653|9645622|FG001|Open-Label Period|Lost to Follow-up|0
5995298|NCT03790917|9588520|FG000|Overall Study|Death|1
5995299|NCT05017493|9588536|FG000|Overall Study|Withdrawal by Subject|26
5995300|NCT05017493|9588537|FG001|Overall Study|Withdrawal by Subject|0
5995301|NCT05017493|9588536|FG000|Overall Study|Physician Decision|15
5995302|NCT05017493|9588537|FG001|Overall Study|Physician Decision|0
5995303|NCT05017493|9588536|FG000|Overall Study|Protocol Violation|81
5995304|NCT05017493|9588537|FG001|Overall Study|Protocol Violation|0
5995305|NCT04348500|9588570|FG000|Overall Study|Death|2
5995306|NCT04348500|9588571|FG001|Overall Study|Death|2
6070461|NCT00549939|9673265|FG002|40-week Open Label Treatment Period|Protocol Violation|0
6070462|NCT00549939|9673263|FG000|40-week Open Label Treatment Period|Other|0
6070463|NCT00549939|9673264|FG001|40-week Open Label Treatment Period|Other|1
6070464|NCT00549939|9673265|FG002|40-week Open Label Treatment Period|Other|4
6070465|NCT00550043|9673280|FG000|Overall Study|Adverse Event|0
6070466|NCT00550043|9673281|FG001|Overall Study|Adverse Event|0
6070467|NCT00550043|9673282|FG002|Overall Study|Adverse Event|0
6070468|NCT00550043|9673283|FG003|Overall Study|Adverse Event|1
6070469|NCT00550043|9673284|FG004|Overall Study|Adverse Event|1
6070470|NCT00550043|9673280|FG000|Overall Study|Subject Withdrew Consent|0
6070471|NCT00550043|9673281|FG001|Overall Study|Subject Withdrew Consent|2
6070472|NCT00550043|9673282|FG002|Overall Study|Subject Withdrew Consent|1
6070473|NCT00550043|9673283|FG003|Overall Study|Subject Withdrew Consent|0
6070474|NCT00550043|9673284|FG004|Overall Study|Subject Withdrew Consent|0
6070475|NCT00550043|9673280|FG000|Overall Study|Other Reasons- Unspecified|0
6070476|NCT00550043|9673281|FG001|Overall Study|Other Reasons- Unspecified|1
6070477|NCT00550043|9673282|FG002|Overall Study|Other Reasons- Unspecified|0
6070478|NCT00550043|9673283|FG003|Overall Study|Other Reasons- Unspecified|1
6070479|NCT00550043|9673284|FG004|Overall Study|Other Reasons- Unspecified|0
6070480|NCT00550147|9673296|FG000|OROS Methylphenidate Monotherapy|significant improvement at visit 5|4
6070481|NCT00550147|9673296|FG000|OROS Methylphenidate Monotherapy|Withdrawal by Subject|2
6070482|NCT00550147|9673296|FG000|Quetiapine Addition Treatment Period|Adverse Event|3
6070483|NCT00550147|9673296|FG000|Quetiapine Addition Treatment Period|Noncompliance|2
6070484|NCT00550147|9673296|FG000|Quetiapine Addition Treatment Period|Moved out of state|1
6070485|NCT00550173|9673312|FG000|Overall Study|Death|45
6070486|NCT00550173|9673313|FG001|Overall Study|Death|38
6070487|NCT00550173|9673314|FG002|Overall Study|Death|50
6070488|NCT00550173|9673312|FG000|Overall Study|Physician Decision|1
6070489|NCT00550173|9673313|FG001|Overall Study|Physician Decision|2
6070490|NCT00550173|9673314|FG002|Overall Study|Physician Decision|2
6070491|NCT00550173|9673312|FG000|Overall Study|Withdrawal by Subject|9
6070492|NCT00550173|9673313|FG001|Overall Study|Withdrawal by Subject|12
6070493|NCT00550173|9673314|FG002|Overall Study|Withdrawal by Subject|17
6070494|NCT00550173|9673312|FG000|Overall Study|Sponsor Decision|13
6070495|NCT00550173|9673313|FG001|Overall Study|Sponsor Decision|7
6070496|NCT00550173|9673314|FG002|Overall Study|Sponsor Decision|1
6070497|NCT00550173|9673312|FG000|Overall Study|Lost to Follow-up|4
6070498|NCT00550173|9673313|FG001|Overall Study|Lost to Follow-up|4
6070499|NCT00550173|9673314|FG002|Overall Study|Lost to Follow-up|3
6070500|NCT00550238|9673323|FG000|Overall Study|Adverse Event|88
6070501|NCT00550238|9673323|FG000|Overall Study|Death|34
6070502|NCT00550238|9673323|FG000|Overall Study|Disease progression|46
6070503|NCT00550238|9673323|FG000|Overall Study|Withdrawal by Subject|167
6070504|NCT00550238|9673323|FG000|Overall Study|Physician Decision|31
6070505|NCT00550238|9673323|FG000|Overall Study|Patient noncompliance|25
6070506|NCT00550238|9673323|FG000|Overall Study|Lost to Follow-up|13
6070507|NCT00550238|9673323|FG000|Overall Study|Sponsor decision|55
6070508|NCT00550407|9673362|FG000|8-16 Week Preliminary (Open-Label) Phase|Adverse Event|55
6070509|NCT00550407|9673363|FG001|8-16 Week Preliminary (Open-Label) Phase|Adverse Event|0
6070510|NCT00550407|9673364|FG002|8-16 Week Preliminary (Open-Label) Phase|Adverse Event|0
6070511|NCT00550407|9673362|FG000|8-16 Week Preliminary (Open-Label) Phase|Lack of Efficacy|39
6070512|NCT00550407|9673363|FG001|8-16 Week Preliminary (Open-Label) Phase|Lack of Efficacy|0
6070513|NCT00550407|9673364|FG002|8-16 Week Preliminary (Open-Label) Phase|Lack of Efficacy|0
6070514|NCT00550407|9673362|FG000|8-16 Week Preliminary (Open-Label) Phase|Protocol Violation|1
6070515|NCT00550407|9673363|FG001|8-16 Week Preliminary (Open-Label) Phase|Protocol Violation|0
6070516|NCT00550407|9673364|FG002|8-16 Week Preliminary (Open-Label) Phase|Protocol Violation|0
6070517|NCT00550407|9673362|FG000|8-16 Week Preliminary (Open-Label) Phase|Defined Stopping Criteria Reached|1
6070518|NCT00550407|9673363|FG001|8-16 Week Preliminary (Open-Label) Phase|Defined Stopping Criteria Reached|0
6070519|NCT00550407|9673364|FG002|8-16 Week Preliminary (Open-Label) Phase|Defined Stopping Criteria Reached|0
6070520|NCT00550407|9673362|FG000|8-16 Week Preliminary (Open-Label) Phase|Lost to Follow-up|1
6070521|NCT00550407|9673363|FG001|8-16 Week Preliminary (Open-Label) Phase|Lost to Follow-up|0
6070522|NCT00550407|9673364|FG002|8-16 Week Preliminary (Open-Label) Phase|Lost to Follow-up|0
6070523|NCT00550407|9673362|FG000|8-16 Week Preliminary (Open-Label) Phase|Investigator Discretion|8
6070524|NCT00550407|9673363|FG001|8-16 Week Preliminary (Open-Label) Phase|Investigator Discretion|0
6070525|NCT00550407|9673364|FG002|8-16 Week Preliminary (Open-Label) Phase|Investigator Discretion|0
6070526|NCT00550407|9673362|FG000|8-16 Week Preliminary (Open-Label) Phase|Withdrew Consent|6
6070527|NCT00550407|9673363|FG001|8-16 Week Preliminary (Open-Label) Phase|Withdrew Consent|0
6070528|NCT00550407|9673364|FG002|8-16 Week Preliminary (Open-Label) Phase|Withdrew Consent|0
5995307|NCT04348500|9588570|FG000|Overall Study|Withdrawn by subject due to dementia|0
5995308|NCT04348500|9588571|FG001|Overall Study|Withdrawn by subject due to dementia|1
6046585|NCT00406653|9645623|FG002|Open-Label Period|Lost to Follow-up|0
6046586|NCT00406653|9645624|FG003|Open-Label Period|Lost to Follow-up|0
6046587|NCT00406653|9645625|FG004|Open-Label Period|Lost to Follow-up|0
6046588|NCT00406653|9645626|FG005|Open-Label Period|Lost to Follow-up|0
6046589|NCT00406653|9645627|FG006|Open-Label Period|Lost to Follow-up|6
6046590|NCT00406653|9645621|FG000|Open-Label Period|Withdrawal of Consent|0
6046591|NCT00406653|9645622|FG001|Open-Label Period|Withdrawal of Consent|0
6046592|NCT00406653|9645623|FG002|Open-Label Period|Withdrawal of Consent|0
6046593|NCT00406653|9645624|FG003|Open-Label Period|Withdrawal of Consent|0
6046594|NCT00406653|9645625|FG004|Open-Label Period|Withdrawal of Consent|0
6046595|NCT00406653|9645626|FG005|Open-Label Period|Withdrawal of Consent|0
6046596|NCT00406653|9645627|FG006|Open-Label Period|Withdrawal of Consent|11
6046597|NCT00406653|9645621|FG000|Open-Label Period|Subject No Longer Meets Study Criteria|0
6046598|NCT00406653|9645622|FG001|Open-Label Period|Subject No Longer Meets Study Criteria|0
6046599|NCT00406653|9645623|FG002|Open-Label Period|Subject No Longer Meets Study Criteria|0
6046600|NCT00406653|9645624|FG003|Open-Label Period|Subject No Longer Meets Study Criteria|0
6046601|NCT00406653|9645625|FG004|Open-Label Period|Subject No Longer Meets Study Criteria|0
6046602|NCT00406653|9645626|FG005|Open-Label Period|Subject No Longer Meets Study Criteria|0
6046603|NCT00406653|9645627|FG006|Open-Label Period|Subject No Longer Meets Study Criteria|1
6046604|NCT00406653|9645621|FG000|Open-Label Period|Pregnancy|0
6046605|NCT00406653|9645622|FG001|Open-Label Period|Pregnancy|0
6046606|NCT00406653|9645623|FG002|Open-Label Period|Pregnancy|0
6046607|NCT00406653|9645624|FG003|Open-Label Period|Pregnancy|0
6046608|NCT00406653|9645625|FG004|Open-Label Period|Pregnancy|0
6046609|NCT00406653|9645626|FG005|Open-Label Period|Pregnancy|0
6046610|NCT00406653|9645627|FG006|Open-Label Period|Pregnancy|2
6046611|NCT00406653|9645621|FG000|Open-Label Period|Administrative Reason By Sponsor|0
6046612|NCT00406653|9645622|FG001|Open-Label Period|Administrative Reason By Sponsor|0
6046613|NCT00406653|9645623|FG002|Open-Label Period|Administrative Reason By Sponsor|0
6046614|NCT00406653|9645624|FG003|Open-Label Period|Administrative Reason By Sponsor|0
6046615|NCT00406653|9645625|FG004|Open-Label Period|Administrative Reason By Sponsor|0
6046616|NCT00406653|9645626|FG005|Open-Label Period|Administrative Reason By Sponsor|0
6046617|NCT00406653|9645627|FG006|Open-Label Period|Administrative Reason By Sponsor|115
6046618|NCT00406653|9645621|FG000|Open-Label Period|Declined participation but followup done|0
6046619|NCT00406653|9645622|FG001|Open-Label Period|Declined participation but followup done|0
6046620|NCT00406653|9645623|FG002|Open-Label Period|Declined participation but followup done|0
6046621|NCT00406653|9645624|FG003|Open-Label Period|Declined participation but followup done|0
6046622|NCT00406653|9645625|FG004|Open-Label Period|Declined participation but followup done|0
6046623|NCT00406653|9645626|FG005|Open-Label Period|Declined participation but followup done|0
6046624|NCT00406653|9645627|FG006|Open-Label Period|Declined participation but followup done|8
6046625|NCT00406653|9645621|FG000|Open-Label Period|Discontinued by Sponsor|0
6046626|NCT00406653|9645622|FG001|Open-Label Period|Discontinued by Sponsor|0
6046627|NCT00406653|9645623|FG002|Open-Label Period|Discontinued by Sponsor|0
6046628|NCT00406653|9645624|FG003|Open-Label Period|Discontinued by Sponsor|0
6046629|NCT00406653|9645625|FG004|Open-Label Period|Discontinued by Sponsor|0
6046630|NCT00406653|9645626|FG005|Open-Label Period|Discontinued by Sponsor|0
6046631|NCT00406653|9645627|FG006|Open-Label Period|Discontinued by Sponsor|1
6046632|NCT00406653|9645621|FG000|Open-Label Period|Refused followup|0
6046633|NCT00406653|9645622|FG001|Open-Label Period|Refused followup|0
6046634|NCT00406653|9645623|FG002|Open-Label Period|Refused followup|0
6046635|NCT00406653|9645624|FG003|Open-Label Period|Refused followup|0
6046636|NCT00406653|9645625|FG004|Open-Label Period|Refused followup|0
6046637|NCT00406653|9645626|FG005|Open-Label Period|Refused followup|0
6046638|NCT00406653|9645627|FG006|Open-Label Period|Refused followup|1
6046639|NCT00406692|9645647|FG000|Overall Study|Withdrawal by Subject|4
6046640|NCT00406692|9645647|FG000|Overall Study|Physician Decision|1
6046641|NCT00406692|9645647|FG000|Overall Study|Adverse Event|1
6046642|NCT00406692|9645647|FG000|Overall Study|Lack of Efficacy|1
6046643|NCT00406718|9645654|FG000|Overall Study|Withdrawal by Subject|2
6046644|NCT00406718|9645655|FG001|Overall Study|Withdrawal by Subject|9
6046645|NCT00406718|9645656|FG002|Overall Study|Withdrawal by Subject|4
6046646|NCT00406718|9645654|FG000|Overall Study|Lost to Follow-up|2
6046647|NCT00406718|9645655|FG001|Overall Study|Lost to Follow-up|5
6046648|NCT00406718|9645656|FG002|Overall Study|Lost to Follow-up|4
6046649|NCT00406848|9645668|FG000|Overall Study|Withdrawal by Subject|27
6046650|NCT00406848|9645669|FG001|Overall Study|Withdrawal by Subject|22
6046651|NCT00406848|9645668|FG000|Overall Study|Adverse Event|38
6046652|NCT00406848|9645669|FG001|Overall Study|Adverse Event|7
6046653|NCT00406848|9645668|FG000|Overall Study|Lack of Efficacy|9
6046654|NCT00406848|9645669|FG001|Overall Study|Lack of Efficacy|14
6046655|NCT00406848|9645668|FG000|Overall Study|Protocol Violation|10
6046656|NCT00406848|9645669|FG001|Overall Study|Protocol Violation|6
6046657|NCT00406848|9645668|FG000|Overall Study|Lost to Follow-up|6
6046658|NCT00406848|9645669|FG001|Overall Study|Lost to Follow-up|2
6046659|NCT00406848|9645668|FG000|Overall Study|Physician Decision|2
5995309|NCT03799198|9588614|FG000|Overall Study|Lost to Follow-up|4
5995310|NCT03799198|9588615|FG001|Overall Study|Lost to Follow-up|8
5995311|NCT03799198|9588614|FG000|Overall Study|Death|0
5995312|NCT03799198|9588615|FG001|Overall Study|Death|1
5995313|NCT03770728|9588625|FG000|Overall Study|Adverse Event|1
5995314|NCT03770728|9588626|FG001|Overall Study|Adverse Event|0
6070529|NCT00550407|9673362|FG000|8-16 Week Preliminary (Open-Label) Phase|Continuation Criteria Not Met|1
6070530|NCT00550407|9673363|FG001|8-16 Week Preliminary (Open-Label) Phase|Continuation Criteria Not Met|0
6070531|NCT00550407|9673364|FG002|8-16 Week Preliminary (Open-Label) Phase|Continuation Criteria Not Met|0
6070532|NCT00550407|9673362|FG000|26-Week Randomized Phase|Adverse Event|0
6070533|NCT00550407|9673363|FG001|26-Week Randomized Phase|Adverse Event|5
6070534|NCT00550407|9673364|FG002|26-Week Randomized Phase|Adverse Event|2
6070535|NCT00550407|9673362|FG000|26-Week Randomized Phase|Lack of Efficacy|0
6070536|NCT00550407|9673363|FG001|26-Week Randomized Phase|Lack of Efficacy|36
6070537|NCT00550407|9673364|FG002|26-Week Randomized Phase|Lack of Efficacy|19
6070538|NCT00550407|9673362|FG000|26-Week Randomized Phase|Investigator Discretion|0
6070539|NCT00550407|9673363|FG001|26-Week Randomized Phase|Investigator Discretion|1
6070540|NCT00550407|9673364|FG002|26-Week Randomized Phase|Investigator Discretion|0
6070541|NCT00550407|9673362|FG000|26-Week Randomized Phase|Withdrawal by Subject|0
6070542|NCT00550407|9673363|FG001|26-Week Randomized Phase|Withdrawal by Subject|1
6070543|NCT00550407|9673364|FG002|26-Week Randomized Phase|Withdrawal by Subject|3
6070544|NCT00550420|9673372|FG000|Overall Study|Adverse Event|28
6070545|NCT00550420|9673372|FG000|Overall Study|Lost to Follow-up|8
6070546|NCT00550420|9673372|FG000|Overall Study|Protocol Violation|11
6070547|NCT00550420|9673372|FG000|Overall Study|Withdrawal by Subject|30
6070548|NCT00550420|9673372|FG000|Overall Study|Still in study at termination|206
6070549|NCT00550420|9673372|FG000|Overall Study|Missing|2
6070550|NCT00550420|9673372|FG000|Overall Study|Prolonged QT Interval Electrocardiogram|12
6070551|NCT00550420|9673372|FG000|Overall Study|Investigators opinion|1
6070552|NCT00550420|9673372|FG000|Overall Study|Lack of curative effect|1
6070553|NCT00550420|9673372|FG000|Overall Study|Unethical stop of enrollment|2
6070554|NCT00550420|9673372|FG000|Overall Study|Caregiver's decision to withdraw|1
6070555|NCT00550420|9673372|FG000|Overall Study|Out of Electrocardiogram criteria|1
6070556|NCT00550420|9673372|FG000|Overall Study|Exclusion criteria|1
6070557|NCT00550420|9673372|FG000|Overall Study|Prohibited medicine|1
6070558|NCT00550446|9673385|FG000|Up To Week 12|Adverse Event|2
6070559|NCT00550446|9673386|FG001|Up To Week 12|Adverse Event|2
6070560|NCT00550446|9673387|FG002|Up To Week 12|Adverse Event|0
6070561|NCT00550446|9673388|FG003|Up To Week 12|Adverse Event|0
6070562|NCT00550446|9673389|FG004|Up To Week 12|Adverse Event|2
6070563|NCT00550446|9673390|FG005|Up To Week 12|Adverse Event|2
6070564|NCT00550446|9673391|FG006|Up To Week 12|Adverse Event|1
6070565|NCT00550446|9673392|FG007|Up To Week 12|Adverse Event|0
6070566|NCT00550446|9673393|FG008|Up To Week 12|Adverse Event|0
6070567|NCT00550446|9673394|FG009|Up To Week 12|Adverse Event|0
6070568|NCT00550446|9673395|FG010|Up To Week 12|Adverse Event|0
6070569|NCT00550446|9673385|FG000|Up To Week 12|Lack of Efficacy|3
6070570|NCT00550446|9673386|FG001|Up To Week 12|Lack of Efficacy|1
6070571|NCT00550446|9673387|FG002|Up To Week 12|Lack of Efficacy|0
5995315|NCT03770728|9588627|FG002|Overall Study|Adverse Event|1
5995316|NCT03770728|9588628|FG003|Overall Study|Adverse Event|0
5995317|NCT03770728|9588625|FG000|Overall Study|Poor compliance to protocol|0
5995318|NCT03770728|9588626|FG001|Overall Study|Poor compliance to protocol|0
5995319|NCT03770728|9588627|FG002|Overall Study|Poor compliance to protocol|1
5995320|NCT03770728|9588628|FG003|Overall Study|Poor compliance to protocol|0
5995321|NCT03770728|9588625|FG000|Overall Study|Withdrawal by Subject|13
5995322|NCT03770728|9588626|FG001|Overall Study|Withdrawal by Subject|8
5995323|NCT03770728|9588627|FG002|Overall Study|Withdrawal by Subject|9
5995324|NCT03770728|9588628|FG003|Overall Study|Withdrawal by Subject|13
5995325|NCT03770728|9588625|FG000|Overall Study|Other than specified|24
5995326|NCT03770728|9588626|FG001|Overall Study|Other than specified|23
5995327|NCT03770728|9588627|FG002|Overall Study|Other than specified|21
5995328|NCT03770728|9588628|FG003|Overall Study|Other than specified|22
5995329|NCT03760146|9588646|FG000|Overall Study|Adverse Event|11
5995330|NCT03760146|9588647|FG001|Overall Study|Adverse Event|8
5995331|NCT03760146|9588648|FG002|Overall Study|Adverse Event|0
5995332|NCT03760146|9588649|FG003|Overall Study|Adverse Event|0
5995333|NCT03760146|9588650|FG004|Overall Study|Adverse Event|0
5995334|NCT03760146|9588651|FG005|Overall Study|Adverse Event|0
6070572|NCT00550446|9673388|FG003|Up To Week 12|Lack of Efficacy|1
6070573|NCT00550446|9673389|FG004|Up To Week 12|Lack of Efficacy|0
6070574|NCT00550446|9673390|FG005|Up To Week 12|Lack of Efficacy|3
6070575|NCT00550446|9673391|FG006|Up To Week 12|Lack of Efficacy|3
6070576|NCT00550446|9673392|FG007|Up To Week 12|Lack of Efficacy|0
6070577|NCT00550446|9673393|FG008|Up To Week 12|Lack of Efficacy|0
6070578|NCT00550446|9673394|FG009|Up To Week 12|Lack of Efficacy|0
6070579|NCT00550446|9673395|FG010|Up To Week 12|Lack of Efficacy|0
6070580|NCT00550446|9673385|FG000|Up To Week 12|Lost to Follow-up|0
6070581|NCT00550446|9673386|FG001|Up To Week 12|Lost to Follow-up|1
5995335|NCT03760146|9588646|FG000|Overall Study|Death|1
5995336|NCT03760146|9588647|FG001|Overall Study|Death|0
5995337|NCT03760146|9588648|FG002|Overall Study|Death|0
5995338|NCT03760146|9588649|FG003|Overall Study|Death|0
5995339|NCT03760146|9588650|FG004|Overall Study|Death|0
5995340|NCT03760146|9588651|FG005|Overall Study|Death|0
5995341|NCT03760146|9588646|FG000|Overall Study|Lost to Follow-up|41
5995342|NCT03760146|9588647|FG001|Overall Study|Lost to Follow-up|28
5995343|NCT03760146|9588648|FG002|Overall Study|Lost to Follow-up|9
5995344|NCT03760146|9588649|FG003|Overall Study|Lost to Follow-up|2
5995345|NCT03760146|9588650|FG004|Overall Study|Lost to Follow-up|14
5995346|NCT03760146|9588651|FG005|Overall Study|Lost to Follow-up|8
5995347|NCT03760146|9588646|FG000|Overall Study|No longer met eligibility criteria|3
5995348|NCT03760146|9588647|FG001|Overall Study|No longer met eligibility criteria|9
5995349|NCT03760146|9588648|FG002|Overall Study|No longer met eligibility criteria|0
5995350|NCT03760146|9588649|FG003|Overall Study|No longer met eligibility criteria|0
5995351|NCT03760146|9588650|FG004|Overall Study|No longer met eligibility criteria|1
5995352|NCT03760146|9588651|FG005|Overall Study|No longer met eligibility criteria|0
5995353|NCT03760146|9588646|FG000|Overall Study|Protocol Violation|21
5995354|NCT03760146|9588647|FG001|Overall Study|Protocol Violation|13
5995355|NCT03760146|9588648|FG002|Overall Study|Protocol Violation|1
5995356|NCT03760146|9588649|FG003|Overall Study|Protocol Violation|0
6070582|NCT00550446|9673387|FG002|Up To Week 12|Lost to Follow-up|0
6070583|NCT00550446|9673388|FG003|Up To Week 12|Lost to Follow-up|0
6070584|NCT00550446|9673389|FG004|Up To Week 12|Lost to Follow-up|1
6070585|NCT00550446|9673390|FG005|Up To Week 12|Lost to Follow-up|1
6070586|NCT00550446|9673391|FG006|Up To Week 12|Lost to Follow-up|2
6070587|NCT00550446|9673392|FG007|Up To Week 12|Lost to Follow-up|0
6070588|NCT00550446|9673393|FG008|Up To Week 12|Lost to Follow-up|0
6070589|NCT00550446|9673394|FG009|Up To Week 12|Lost to Follow-up|0
6070590|NCT00550446|9673395|FG010|Up To Week 12|Lost to Follow-up|0
6070591|NCT00550446|9673385|FG000|Up To Week 12|Withdrawal by Subject|2
6070592|NCT00550446|9673386|FG001|Up To Week 12|Withdrawal by Subject|0
6070593|NCT00550446|9673387|FG002|Up To Week 12|Withdrawal by Subject|3
6070594|NCT00550446|9673388|FG003|Up To Week 12|Withdrawal by Subject|2
6070595|NCT00550446|9673389|FG004|Up To Week 12|Withdrawal by Subject|0
6070596|NCT00550446|9673390|FG005|Up To Week 12|Withdrawal by Subject|1
6070597|NCT00550446|9673391|FG006|Up To Week 12|Withdrawal by Subject|3
6070598|NCT00550446|9673392|FG007|Up To Week 12|Withdrawal by Subject|0
6070599|NCT00550446|9673393|FG008|Up To Week 12|Withdrawal by Subject|0
6070600|NCT00550446|9673394|FG009|Up To Week 12|Withdrawal by Subject|0
6070601|NCT00550446|9673395|FG010|Up To Week 12|Withdrawal by Subject|0
6070602|NCT00550446|9673385|FG000|Up To Week 12|Other|3
6070603|NCT00550446|9673386|FG001|Up To Week 12|Other|0
6070604|NCT00550446|9673387|FG002|Up To Week 12|Other|0
6070605|NCT00550446|9673388|FG003|Up To Week 12|Other|0
5995357|NCT03760146|9588650|FG004|Overall Study|Protocol Violation|1
6070606|NCT00550446|9673389|FG004|Up To Week 12|Other|0
6070607|NCT00550446|9673390|FG005|Up To Week 12|Other|1
6070608|NCT00550446|9673391|FG006|Up To Week 12|Other|4
6070609|NCT00550446|9673392|FG007|Up To Week 12|Other|0
6070610|NCT00550446|9673393|FG008|Up To Week 12|Other|0
6070611|NCT00550446|9673394|FG009|Up To Week 12|Other|0
6070612|NCT00550446|9673395|FG010|Up To Week 12|Other|0
6070613|NCT00550446|9673385|FG000|Up To Week 12|Randomized not treated|0
6070614|NCT00550446|9673386|FG001|Up To Week 12|Randomized not treated|1
6070615|NCT00550446|9673387|FG002|Up To Week 12|Randomized not treated|1
6070616|NCT00550446|9673388|FG003|Up To Week 12|Randomized not treated|0
6070617|NCT00550446|9673389|FG004|Up To Week 12|Randomized not treated|0
6070618|NCT00550446|9673390|FG005|Up To Week 12|Randomized not treated|0
6070619|NCT00550446|9673391|FG006|Up To Week 12|Randomized not treated|0
6070620|NCT00550446|9673392|FG007|Up To Week 12|Randomized not treated|0
6070621|NCT00550446|9673393|FG008|Up To Week 12|Randomized not treated|0
6070622|NCT00550446|9673394|FG009|Up To Week 12|Randomized not treated|0
6070623|NCT00550446|9673395|FG010|Up To Week 12|Randomized not treated|0
6070624|NCT00550446|9673385|FG000|Post Week 12|Adverse Event|2
6070625|NCT00550446|9673386|FG001|Post Week 12|Adverse Event|1
6070626|NCT00550446|9673387|FG002|Post Week 12|Adverse Event|1
6070627|NCT00550446|9673388|FG003|Post Week 12|Adverse Event|1
6070628|NCT00550446|9673389|FG004|Post Week 12|Adverse Event|1
6070629|NCT00550446|9673390|FG005|Post Week 12|Adverse Event|1
6070630|NCT00550446|9673391|FG006|Post Week 12|Adverse Event|0
6070631|NCT00550446|9673392|FG007|Post Week 12|Adverse Event|0
6070632|NCT00550446|9673393|FG008|Post Week 12|Adverse Event|0
5995358|NCT03760146|9588651|FG005|Overall Study|Protocol Violation|0
5995359|NCT03760146|9588646|FG000|Overall Study|Withdrawal by Subject|19
6070633|NCT00550446|9673394|FG009|Post Week 12|Adverse Event|4
6070634|NCT00550446|9673395|FG010|Post Week 12|Adverse Event|0
6070635|NCT00550446|9673385|FG000|Post Week 12|Lack of Efficacy|0
6070636|NCT00550446|9673386|FG001|Post Week 12|Lack of Efficacy|0
6070637|NCT00550446|9673387|FG002|Post Week 12|Lack of Efficacy|1
6070638|NCT00550446|9673388|FG003|Post Week 12|Lack of Efficacy|0
6070639|NCT00550446|9673389|FG004|Post Week 12|Lack of Efficacy|0
6070640|NCT00550446|9673390|FG005|Post Week 12|Lack of Efficacy|0
6070641|NCT00550446|9673391|FG006|Post Week 12|Lack of Efficacy|0
6070642|NCT00550446|9673392|FG007|Post Week 12|Lack of Efficacy|1
6070643|NCT00550446|9673393|FG008|Post Week 12|Lack of Efficacy|1
6070644|NCT00550446|9673394|FG009|Post Week 12|Lack of Efficacy|2
5995360|NCT03760146|9588647|FG001|Overall Study|Withdrawal by Subject|20
6070645|NCT00550446|9673395|FG010|Post Week 12|Lack of Efficacy|1
5995361|NCT03760146|9588648|FG002|Overall Study|Withdrawal by Subject|1
6070646|NCT00550446|9673385|FG000|Post Week 12|Lost to Follow-up|0
6070647|NCT00550446|9673386|FG001|Post Week 12|Lost to Follow-up|0
6070648|NCT00550446|9673387|FG002|Post Week 12|Lost to Follow-up|1
6070649|NCT00550446|9673388|FG003|Post Week 12|Lost to Follow-up|1
6070650|NCT00550446|9673389|FG004|Post Week 12|Lost to Follow-up|0
6070651|NCT00550446|9673390|FG005|Post Week 12|Lost to Follow-up|0
6070652|NCT00550446|9673391|FG006|Post Week 12|Lost to Follow-up|1
6070653|NCT00550446|9673392|FG007|Post Week 12|Lost to Follow-up|0
6070654|NCT00550446|9673393|FG008|Post Week 12|Lost to Follow-up|0
6070655|NCT00550446|9673394|FG009|Post Week 12|Lost to Follow-up|0
6070656|NCT00550446|9673395|FG010|Post Week 12|Lost to Follow-up|0
6070657|NCT00550446|9673385|FG000|Post Week 12|Withdrawal by Subject|0
6070658|NCT00550446|9673386|FG001|Post Week 12|Withdrawal by Subject|0
6070659|NCT00550446|9673387|FG002|Post Week 12|Withdrawal by Subject|0
6070660|NCT00550446|9673388|FG003|Post Week 12|Withdrawal by Subject|0
6070661|NCT00550446|9673389|FG004|Post Week 12|Withdrawal by Subject|1
6070662|NCT00550446|9673390|FG005|Post Week 12|Withdrawal by Subject|0
6070663|NCT00550446|9673391|FG006|Post Week 12|Withdrawal by Subject|0
6070664|NCT00550446|9673392|FG007|Post Week 12|Withdrawal by Subject|0
6070665|NCT00550446|9673393|FG008|Post Week 12|Withdrawal by Subject|0
5995362|NCT03760146|9588649|FG003|Overall Study|Withdrawal by Subject|0
5995363|NCT03760146|9588650|FG004|Overall Study|Withdrawal by Subject|1
5995364|NCT03760146|9588651|FG005|Overall Study|Withdrawal by Subject|0
5995365|NCT03760081|9588671|FG000|Overall Study|Miscellaneous|0
5995366|NCT03760081|9588672|FG001|Overall Study|Miscellaneous|1
5995367|NCT03760081|9588671|FG000|Overall Study|Progressive Disease|5
5995368|NCT03760081|9588672|FG001|Overall Study|Progressive Disease|10
5995369|NCT03760081|9588671|FG000|Overall Study|Death|1
5995370|NCT03760081|9588672|FG001|Overall Study|Death|1
5995371|NCT03737110|9588682|FG000|Run-in (RI) Period|Lack of Efficacy|3
5995372|NCT03737110|9588683|FG001|Run-in (RI) Period|Lack of Efficacy|0
5995373|NCT03737110|9588684|FG002|Run-in (RI) Period|Lack of Efficacy|0
5995374|NCT03737110|9588682|FG000|Run-in (RI) Period|Did Not Meet Clinical Response Criteria|3
5995375|NCT03737110|9588683|FG001|Run-in (RI) Period|Did Not Meet Clinical Response Criteria|0
5995376|NCT03737110|9588684|FG002|Run-in (RI) Period|Did Not Meet Clinical Response Criteria|0
5995377|NCT03737110|9588682|FG000|Run-in (RI) Period|Adverse Event|4
5995378|NCT03737110|9588683|FG001|Run-in (RI) Period|Adverse Event|0
5995379|NCT03737110|9588684|FG002|Run-in (RI) Period|Adverse Event|0
5995380|NCT03737110|9588682|FG000|Randomized Withdrawal (RW) Period|Completed, Not Continuing into LTE|0
5995381|NCT03737110|9588683|FG001|Randomized Withdrawal (RW) Period|Completed, Not Continuing into LTE|1
5995382|NCT03737110|9588684|FG002|Randomized Withdrawal (RW) Period|Completed, Not Continuing into LTE|0
5995383|NCT03737110|9588682|FG000|Randomized Withdrawal (RW) Period|Withdrawal by Subject|0
5995384|NCT03737110|9588683|FG001|Randomized Withdrawal (RW) Period|Withdrawal by Subject|0
5995385|NCT03737110|9588684|FG002|Randomized Withdrawal (RW) Period|Withdrawal by Subject|1
5995386|NCT03713684|9588706|FG000|Overall Study|Adverse Event|1
5995387|NCT03713684|9588707|FG001|Overall Study|Adverse Event|3
5995388|NCT03713684|9588708|FG002|Overall Study|Adverse Event|1
5995389|NCT03713684|9588709|FG003|Overall Study|Adverse Event|0
5995390|NCT03713684|9588706|FG000|Overall Study|Poor compliance to protocol|2
5995391|NCT03713684|9588707|FG001|Overall Study|Poor compliance to protocol|1
5995392|NCT03713684|9588708|FG002|Overall Study|Poor compliance to protocol|0
5995393|NCT03713684|9588709|FG003|Overall Study|Poor compliance to protocol|1
5995394|NCT03713684|9588706|FG000|Overall Study|Withdrawal by Subject|14
5995395|NCT03713684|9588707|FG001|Overall Study|Withdrawal by Subject|6
5995396|NCT03713684|9588708|FG002|Overall Study|Withdrawal by Subject|14
5995397|NCT03713684|9588709|FG003|Overall Study|Withdrawal by Subject|16
5995398|NCT03713684|9588706|FG000|Overall Study|Other than specified|69
5995399|NCT03713684|9588707|FG001|Overall Study|Other than specified|77
5995400|NCT03713684|9588708|FG002|Overall Study|Other than specified|73
5995401|NCT03713684|9588709|FG003|Overall Study|Other than specified|70
5995402|NCT03644550|9588719|FG000|Overall Study|Withdrawal by Subject|3
5995403|NCT03644550|9588719|FG000|Overall Study|Progressive disease|15
5995404|NCT03557970|9588726|FG000|Overall Study|Study closure|1
5995405|NCT03557970|9588727|FG001|Overall Study|Study closure|0
5995406|NCT03557970|9588726|FG000|Overall Study|Physician Decision|0
5995407|NCT03557970|9588727|FG001|Overall Study|Physician Decision|1
5995408|NCT03557970|9588726|FG000|Overall Study|Death|0
5995409|NCT03557970|9588727|FG001|Overall Study|Death|1
5995410|NCT03022461|9588746|FG000|Overall Study|Death|3
6046660|NCT00406848|9645669|FG001|Overall Study|Physician Decision|2
6046661|NCT00406848|9645668|FG000|Overall Study|Sponsor Decision|1
6046662|NCT00406848|9645669|FG001|Overall Study|Sponsor Decision|1
6046663|NCT00407030|9645681|FG000|Main Period - 8 to 20 Weeks|Adverse Event|2
6046664|NCT00407030|9645682|FG001|Main Period - 8 to 20 Weeks|Adverse Event|1
6046665|NCT00407030|9645683|FG002|Main Period - 8 to 20 Weeks|Adverse Event|0
6046666|NCT00407030|9645681|FG000|Main Period - 8 to 20 Weeks|Lack of Efficacy|0
6046667|NCT00407030|9645682|FG001|Main Period - 8 to 20 Weeks|Lack of Efficacy|0
6046668|NCT00407030|9645683|FG002|Main Period - 8 to 20 Weeks|Lack of Efficacy|3
6046669|NCT00407030|9645681|FG000|Main Period - 8 to 20 Weeks|Lost to Follow-up|1
5995411|NCT02964039|9588762|FG000|Overall Study|Medical reason unrelated to study participation|1
5995412|NCT02964039|9588763|FG001|Overall Study|Medical reason unrelated to study participation|0
5995413|NCT02964039|9588764|FG002|Overall Study|Medical reason unrelated to study participation|3
5995414|NCT02964039|9588762|FG000|Overall Study|Research shutdown due to pandemic|2
5995415|NCT02964039|9588763|FG001|Overall Study|Research shutdown due to pandemic|0
5995416|NCT02964039|9588764|FG002|Overall Study|Research shutdown due to pandemic|1
5995417|NCT02964039|9588762|FG000|Overall Study|Withdrawal by Subject|0
5995418|NCT02964039|9588763|FG001|Overall Study|Withdrawal by Subject|1
5995419|NCT02964039|9588764|FG002|Overall Study|Withdrawal by Subject|0
5995420|NCT02964039|9588762|FG000|Overall Study|Lost to Follow-up|1
5995421|NCT02964039|9588763|FG001|Overall Study|Lost to Follow-up|0
5995422|NCT02964039|9588764|FG002|Overall Study|Lost to Follow-up|1
5995423|NCT02930889|9588772|FG000|Overall Study|Lost to Follow-up|2
5995424|NCT02930889|9588772|FG000|Overall Study|Withdrawal by Subject|6
5995425|NCT02930889|9588772|FG000|Overall Study|Did not meet inclusion/exclusion criteria|8
5995426|NCT02919618|9588776|FG000|Overall Study|Death|1
5995427|NCT02844946|9588793|FG000|Overall Study|Lost to Follow-up|7
5995428|NCT02844946|9588794|FG001|Overall Study|Lost to Follow-up|0
5995429|NCT02564796|9588811|FG000|Overall Study|Physician Decision|2
5995430|NCT02564796|9588812|FG001|Overall Study|Physician Decision|2
5995431|NCT02562716|9588820|FG000|Overall Study|Adverse Event|7
5995432|NCT02562716|9588821|FG001|Overall Study|Adverse Event|14
5995433|NCT02562716|9588820|FG000|Overall Study|Withdrawal unrelated to AE|7
5995434|NCT02562716|9588821|FG001|Overall Study|Withdrawal unrelated to AE|1
5995435|NCT02562716|9588820|FG000|Overall Study|Progression|8
5995436|NCT02562716|9588821|FG001|Overall Study|Progression|10
5995437|NCT02562716|9588820|FG000|Overall Study|Death|2
5995438|NCT02562716|9588821|FG001|Overall Study|Death|1
5995439|NCT02562716|9588820|FG000|Overall Study|Not protocol specified|4
5995440|NCT02562716|9588821|FG001|Overall Study|Not protocol specified|2
6046670|NCT00407030|9645682|FG001|Main Period - 8 to 20 Weeks|Lost to Follow-up|1
6046671|NCT00407030|9645683|FG002|Main Period - 8 to 20 Weeks|Lost to Follow-up|1
6046672|NCT00407030|9645681|FG000|Main Period - 8 to 20 Weeks|Consent Withdrawn|1
6046673|NCT00407030|9645682|FG001|Main Period - 8 to 20 Weeks|Consent Withdrawn|1
6046674|NCT00407030|9645683|FG002|Main Period - 8 to 20 Weeks|Consent Withdrawn|1
6309445|NCT02638948|10038055|FG003|Overall Study|Withdrawal by Subject|1
6309446|NCT02638948|10038052|FG000|Overall Study|Administrative Reason by Sponsor|0
6309447|NCT02638948|10038053|FG001|Overall Study|Administrative Reason by Sponsor|1
6046675|NCT00407030|9645681|FG000|Main Period - 8 to 20 Weeks|Withdrawal Criteria Occurred|0
6046676|NCT00407030|9645682|FG001|Main Period - 8 to 20 Weeks|Withdrawal Criteria Occurred|0
6046677|NCT00407030|9645683|FG002|Main Period - 8 to 20 Weeks|Withdrawal Criteria Occurred|1
6046678|NCT00407030|9645681|FG000|Main Period - 8 to 20 Weeks|Patient Decision|1
6046679|NCT00407030|9645682|FG001|Main Period - 8 to 20 Weeks|Patient Decision|0
6046680|NCT00407030|9645683|FG002|Main Period - 8 to 20 Weeks|Patient Decision|0
6046681|NCT00407030|9645681|FG000|Extension Period - up to 68 Weeks|Withdrawal Criteria Occurred|4
6046682|NCT00407030|9645682|FG001|Extension Period - up to 68 Weeks|Withdrawal Criteria Occurred|5
6046683|NCT00407030|9645683|FG002|Extension Period - up to 68 Weeks|Withdrawal Criteria Occurred|0
6046684|NCT00407030|9645681|FG000|Extension Period - up to 68 Weeks|Lack of Efficacy|11
6046685|NCT00407030|9645682|FG001|Extension Period - up to 68 Weeks|Lack of Efficacy|11
6309448|NCT02638948|10038054|FG002|Overall Study|Administrative Reason by Sponsor|0
6309449|NCT02638948|10038055|FG003|Overall Study|Administrative Reason by Sponsor|4
6309450|NCT02638948|10038052|FG000|Overall Study|Adverse Event|0
6309451|NCT02638948|10038053|FG001|Overall Study|Adverse Event|0
6309452|NCT02638948|10038054|FG002|Overall Study|Adverse Event|1
6309453|NCT02638948|10038055|FG003|Overall Study|Adverse Event|1
6309454|NCT02638948|10038052|FG000|Overall Study|Lack of Efficacy|1
6309455|NCT02638948|10038053|FG001|Overall Study|Lack of Efficacy|1
6309456|NCT02638948|10038054|FG002|Overall Study|Lack of Efficacy|0
6309457|NCT02638948|10038055|FG003|Overall Study|Lack of Efficacy|0
6309458|NCT02638948|10038052|FG000|Overall Study|Lost to Follow-up|0
6309459|NCT02638948|10038053|FG001|Overall Study|Lost to Follow-up|0
6309460|NCT02638948|10038054|FG002|Overall Study|Lost to Follow-up|1
6046686|NCT00407030|9645683|FG002|Extension Period - up to 68 Weeks|Lack of Efficacy|0
6046687|NCT00407030|9645681|FG000|Extension Period - up to 68 Weeks|Adverse Event|1
6046688|NCT00407030|9645682|FG001|Extension Period - up to 68 Weeks|Adverse Event|0
6046689|NCT00407030|9645683|FG002|Extension Period - up to 68 Weeks|Adverse Event|0
6046690|NCT00407030|9645681|FG000|Extension Period - up to 68 Weeks|Consent Withdrawn|4
6046691|NCT00407030|9645682|FG001|Extension Period - up to 68 Weeks|Consent Withdrawn|4
6046692|NCT00407030|9645683|FG002|Extension Period - up to 68 Weeks|Consent Withdrawn|0
6046693|NCT00407030|9645681|FG000|Extension Period - up to 68 Weeks|Lost to Follow-up|5
6046694|NCT00407030|9645682|FG001|Extension Period - up to 68 Weeks|Lost to Follow-up|5
6046695|NCT00407030|9645683|FG002|Extension Period - up to 68 Weeks|Lost to Follow-up|0
6046696|NCT00407030|9645681|FG000|Extension Period - up to 68 Weeks|Patient Decision|1
6046697|NCT00407030|9645682|FG001|Extension Period - up to 68 Weeks|Patient Decision|2
6309461|NCT02638948|10038055|FG003|Overall Study|Lost to Follow-up|1
6309462|NCT02638948|10038052|FG000|Overall Study|Poor/Non-Compliance|0
6309463|NCT02638948|10038053|FG001|Overall Study|Poor/Non-Compliance|2
6309464|NCT02638948|10038054|FG002|Overall Study|Poor/Non-Compliance|1
5995441|NCT01472081|9588840|FG000|Overall Study|Continuing treatment at time of analysis|1
5995442|NCT01472081|9588841|FG001|Overall Study|Continuing treatment at time of analysis|4
5995443|NCT01472081|9588842|FG002|Overall Study|Continuing treatment at time of analysis|1
5995444|NCT01472081|9588843|FG003|Overall Study|Continuing treatment at time of analysis|8
5995445|NCT01472081|9588844|FG004|Overall Study|Continuing treatment at time of analysis|9
5995446|NCT01472081|9588845|FG005|Overall Study|Continuing treatment at time of analysis|0
5995447|NCT01472081|9588840|FG000|Overall Study|Disease Progression|4
5995448|NCT01472081|9588841|FG001|Overall Study|Disease Progression|10
5995449|NCT01472081|9588842|FG002|Overall Study|Disease Progression|12
5995450|NCT01472081|9588843|FG003|Overall Study|Disease Progression|31
5995451|NCT01472081|9588844|FG004|Overall Study|Disease Progression|22
5995452|NCT01472081|9588845|FG005|Overall Study|Disease Progression|3
5995453|NCT01472081|9588840|FG000|Overall Study|Study drug toxicity|2
5995454|NCT01472081|9588841|FG001|Overall Study|Study drug toxicity|9
5995455|NCT01472081|9588842|FG002|Overall Study|Study drug toxicity|4
5995456|NCT01472081|9588843|FG003|Overall Study|Study drug toxicity|6
5995457|NCT01472081|9588844|FG004|Overall Study|Study drug toxicity|13
5995458|NCT01472081|9588845|FG005|Overall Study|Study drug toxicity|2
5995459|NCT01472081|9588840|FG000|Overall Study|Death|0
5995460|NCT01472081|9588841|FG001|Overall Study|Death|0
5995461|NCT01472081|9588842|FG002|Overall Study|Death|0
5995462|NCT01472081|9588843|FG003|Overall Study|Death|0
5995463|NCT01472081|9588844|FG004|Overall Study|Death|1
5995464|NCT01472081|9588845|FG005|Overall Study|Death|0
5995465|NCT01472081|9588840|FG000|Overall Study|Adverse Event unrelated to study drug|0
5995466|NCT01472081|9588841|FG001|Overall Study|Adverse Event unrelated to study drug|0
5995467|NCT01472081|9588842|FG002|Overall Study|Adverse Event unrelated to study drug|0
5995468|NCT01472081|9588843|FG003|Overall Study|Adverse Event unrelated to study drug|0
5995469|NCT01472081|9588844|FG004|Overall Study|Adverse Event unrelated to study drug|1
5995470|NCT01472081|9588845|FG005|Overall Study|Adverse Event unrelated to study drug|0
5995471|NCT01472081|9588840|FG000|Overall Study|Withdrawal by Subject|0
5995472|NCT01472081|9588841|FG001|Overall Study|Withdrawal by Subject|0
5995473|NCT01472081|9588842|FG002|Overall Study|Withdrawal by Subject|0
5995474|NCT01472081|9588843|FG003|Overall Study|Withdrawal by Subject|0
5995475|NCT01472081|9588844|FG004|Overall Study|Withdrawal by Subject|0
5995476|NCT01472081|9588845|FG005|Overall Study|Withdrawal by Subject|1
5995477|NCT01472081|9588840|FG000|Overall Study|Poor/non-compliance|0
5995478|NCT01472081|9588841|FG001|Overall Study|Poor/non-compliance|0
5995479|NCT01472081|9588842|FG002|Overall Study|Poor/non-compliance|1
5995480|NCT01472081|9588843|FG003|Overall Study|Poor/non-compliance|0
5995481|NCT01472081|9588844|FG004|Overall Study|Poor/non-compliance|1
5995482|NCT01472081|9588845|FG005|Overall Study|Poor/non-compliance|0
5995483|NCT01472081|9588840|FG000|Overall Study|No longer meets study criteria|0
5995484|NCT01472081|9588841|FG001|Overall Study|No longer meets study criteria|0
5995485|NCT01472081|9588842|FG002|Overall Study|No longer meets study criteria|1
5995486|NCT01472081|9588843|FG003|Overall Study|No longer meets study criteria|0
5995487|NCT01472081|9588844|FG004|Overall Study|No longer meets study criteria|0
5995488|NCT01472081|9588845|FG005|Overall Study|No longer meets study criteria|0
5995489|NCT01472081|9588840|FG000|Overall Study|Subject request to discontinue treatment|0
5995490|NCT01472081|9588841|FG001|Overall Study|Subject request to discontinue treatment|3
5995491|NCT01472081|9588842|FG002|Overall Study|Subject request to discontinue treatment|1
5995492|NCT01472081|9588843|FG003|Overall Study|Subject request to discontinue treatment|1
5995493|NCT01472081|9588844|FG004|Overall Study|Subject request to discontinue treatment|0
5995494|NCT01472081|9588845|FG005|Overall Study|Subject request to discontinue treatment|0
5995495|NCT01309672|9588858|FG000|Overall Study|Lack of Efficacy|20
5995496|NCT01309672|9588858|FG000|Overall Study|Other|9
5995497|NCT01309672|9588858|FG000|Overall Study|Adverse Event|5
5995498|NCT01309672|9588858|FG000|Overall Study|Withdrawal by Subject|3
5995499|NCT00774345|9588875|FG000|Pre-treatment|Other reasons|2
5995500|NCT00774345|9588876|FG001|Pre-treatment|Other reasons|0
5995501|NCT00774345|9588875|FG000|Treatment|Adverse Event|61
5995502|NCT00774345|9588876|FG001|Treatment|Adverse Event|15
5995503|NCT00774345|9588875|FG000|Treatment|Progressive Disease without histologic transformation|51
5995504|NCT00774345|9588876|FG001|Treatment|Progressive Disease without histologic transformation|111
5995505|NCT00774345|9588875|FG000|Treatment|Progressive Disease with histologic transformation|4
5995506|NCT00774345|9588876|FG001|Treatment|Progressive Disease with histologic transformation|2
5995507|NCT00774345|9588875|FG000|Treatment|Withdrawal by Subject|5
5995508|NCT00774345|9588876|FG001|Treatment|Withdrawal by Subject|2
5995509|NCT00774345|9588875|FG000|Treatment|Lost to Follow-up|1
5995510|NCT00774345|9588876|FG001|Treatment|Lost to Follow-up|1
5995511|NCT00774345|9588875|FG000|Treatment|Death|4
5995512|NCT00774345|9588876|FG001|Treatment|Death|0
5995513|NCT00774345|9588875|FG000|Treatment|Other Reasons|32
5995514|NCT00774345|9588876|FG001|Treatment|Other Reasons|26
5995515|NCT00000135|9588960|FG000|Overall Study|Death|27
5995516|NCT00000135|9588961|FG001|Overall Study|Death|14
5995517|NCT00000378|9589009|FG000|Overall Study|Lack of Efficacy|16
5995518|NCT00000378|9589010|FG001|Overall Study|Lack of Efficacy|14
5995519|NCT00000620|9589057|FG000|Overall Study|Death|86
5995520|NCT00000620|9589058|FG001|Overall Study|Death|67
5995521|NCT00000620|9589059|FG002|Overall Study|Death|112
5995522|NCT00000620|9589060|FG003|Overall Study|Death|126
5995523|NCT00000620|9589061|FG004|Overall Study|Death|64
5995524|NCT00000620|9589062|FG005|Overall Study|Death|77
5995525|NCT00000620|9589063|FG006|Overall Study|Death|91
5995526|NCT00000620|9589064|FG007|Overall Study|Death|95
5995527|NCT00000620|9589057|FG000|Overall Study|Lost to Follow-up|14
5995528|NCT00000620|9589058|FG001|Overall Study|Lost to Follow-up|14
5995529|NCT00000620|9589059|FG002|Overall Study|Lost to Follow-up|14
5995530|NCT00000620|9589060|FG003|Overall Study|Lost to Follow-up|14
5995531|NCT00000620|9589061|FG004|Overall Study|Lost to Follow-up|15
5995532|NCT00000620|9589062|FG005|Overall Study|Lost to Follow-up|15
5995533|NCT00000620|9589063|FG006|Overall Study|Lost to Follow-up|13
5995534|NCT00000620|9589064|FG007|Overall Study|Lost to Follow-up|14
5995535|NCT00000620|9589057|FG000|Overall Study|Withdrawal by Subject|40
5995536|NCT00000620|9589058|FG001|Overall Study|Withdrawal by Subject|27
5995537|NCT00000620|9589059|FG002|Overall Study|Withdrawal by Subject|28
5995538|NCT00000620|9589060|FG003|Overall Study|Withdrawal by Subject|27
5995539|NCT00000620|9589061|FG004|Overall Study|Withdrawal by Subject|30
5995540|NCT00000620|9589062|FG005|Overall Study|Withdrawal by Subject|32
5995541|NCT00000620|9589063|FG006|Overall Study|Withdrawal by Subject|32
5995542|NCT00000620|9589064|FG007|Overall Study|Withdrawal by Subject|21
5995543|NCT00000620|9589057|FG000|Overall Study|missed closeout visit|22
5995544|NCT00000620|9589058|FG001|Overall Study|missed closeout visit|28
5995545|NCT00000620|9589059|FG002|Overall Study|missed closeout visit|16
5995546|NCT00000620|9589060|FG003|Overall Study|missed closeout visit|11
5995547|NCT00000620|9589061|FG004|Overall Study|missed closeout visit|26
5995548|NCT00000620|9589062|FG005|Overall Study|missed closeout visit|28
5995549|NCT00000620|9589063|FG006|Overall Study|missed closeout visit|13
5995550|NCT00000620|9589064|FG007|Overall Study|missed closeout visit|16
5995551|NCT00001213|9589080|FG000|Overall Study|Death|18
5995552|NCT00001262|9589087|FG000|Overall Study|Death|10
5995553|NCT00001262|9589088|FG001|Overall Study|Death|11
5995554|NCT00001262|9589089|FG002|Overall Study|Death|0
5995555|NCT00001262|9589087|FG000|Overall Study|Withdrawal by Subject|0
5995556|NCT00001262|9589088|FG001|Overall Study|Withdrawal by Subject|3
6070666|NCT00550446|9673394|FG009|Post Week 12|Withdrawal by Subject|0
6070667|NCT00550446|9673395|FG010|Post Week 12|Withdrawal by Subject|0
6070668|NCT00550446|9673385|FG000|Post Week 12|Other|1
6070669|NCT00550446|9673386|FG001|Post Week 12|Other|1
5995557|NCT00001262|9589089|FG002|Overall Study|Withdrawal by Subject|0
5995558|NCT00001566|9589110|FG000|Overall Study|patients' choice to discontinue protocol|3
5995559|NCT00001566|9589110|FG000|Overall Study|stopped after C3 due to symptomatic PD|1
5995560|NCT00001566|9589110|FG000|Overall Study|Death|13
5995561|NCT00001566|9589110|FG000|Overall Study|Lost to Follow-up|1
5995562|NCT00001566|9589110|FG000|Overall Study|unable to complete initial apheresis|1
5995563|NCT00001575|9589114|FG000|Overall Study|Screening failures-Ph I portion|22
5995564|NCT00001575|9589114|FG000|Overall Study|Withdrawn/deaths|23
5995565|NCT00001596|9589129|FG000|Overall Study|Death|1
5995566|NCT00001596|9589130|FG001|Overall Study|Death|0
5995567|NCT00001596|9589129|FG000|Overall Study|Withdrawal by Subject|3
5995568|NCT00001596|9589130|FG001|Overall Study|Withdrawal by Subject|1
5995569|NCT00001596|9589129|FG000|Overall Study|Study Termination|12
5995570|NCT00001596|9589130|FG001|Overall Study|Study Termination|9
5995571|NCT00001596|9589129|FG000|Overall Study|Adverse Event|1
5995572|NCT00001596|9589130|FG001|Overall Study|Adverse Event|0
5995573|NCT00001703|9589145|FG000|Overall Study|progressed disease|2
5995574|NCT00001703|9589145|FG000|Overall Study|No evidence of disease|1
5995575|NCT00001703|9589145|FG000|Overall Study|recurrent disease|2
5995576|NCT00001723|9589151|FG000|Overall Study|Lack of Efficacy|6
5995577|NCT00001723|9589152|FG001|Overall Study|Lack of Efficacy|7
5995578|NCT00001723|9589151|FG000|Overall Study|Lack of family interest|4
5995579|NCT00001723|9589152|FG001|Overall Study|Lack of family interest|5
5995580|NCT00001723|9589151|FG000|Overall Study|Lost to Follow-up|2
5995581|NCT00001723|9589152|FG001|Overall Study|Lost to Follow-up|2
5995582|NCT00001723|9589151|FG000|Overall Study|medication intolerance|1
5995583|NCT00001723|9589152|FG001|Overall Study|medication intolerance|2
5995584|NCT00001832|9589176|FG000|Apheresis Period|not able to manufacture treatment cells|60
5995585|NCT00001832|9589177|FG001|Apheresis Period|not able to manufacture treatment cells|0
5995586|NCT00001832|9589178|FG002|Apheresis Period|not able to manufacture treatment cells|0
5995587|NCT00001832|9589179|FG003|Apheresis Period|not able to manufacture treatment cells|0
5995588|NCT00001832|9589180|FG004|Apheresis Period|not able to manufacture treatment cells|0
5995589|NCT00001832|9589181|FG005|Apheresis Period|not able to manufacture treatment cells|0
5995590|NCT00001832|9589182|FG006|Apheresis Period|not able to manufacture treatment cells|0
5995591|NCT00001832|9589183|FG007|Apheresis Period|not able to manufacture treatment cells|0
5995592|NCT00001832|9589184|FG008|Apheresis Period|not able to manufacture treatment cells|0
5995593|NCT00001832|9589185|FG009|Apheresis Period|not able to manufacture treatment cells|0
5995594|NCT00001832|9589186|FG010|Apheresis Period|not able to manufacture treatment cells|0
5995595|NCT00001832|9589187|FG011|Apheresis Period|not able to manufacture treatment cells|0
5995596|NCT00001832|9589188|FG012|Apheresis Period|not able to manufacture treatment cells|0
5995597|NCT00001832|9589189|FG013|Apheresis Period|not able to manufacture treatment cells|0
5995598|NCT00001832|9589190|FG014|Apheresis Period|not able to manufacture treatment cells|0
6070670|NCT00550446|9673387|FG002|Post Week 12|Other|0
5995599|NCT00001832|9589176|FG000|Treatment Period|Death during treatment|0
5995600|NCT00001832|9589177|FG001|Treatment Period|Death during treatment|0
5995601|NCT00001832|9589178|FG002|Treatment Period|Death during treatment|0
5995602|NCT00001832|9589179|FG003|Treatment Period|Death during treatment|0
5995603|NCT00001832|9589180|FG004|Treatment Period|Death during treatment|0
5995604|NCT00001832|9589181|FG005|Treatment Period|Death during treatment|1
5995605|NCT00001832|9589182|FG006|Treatment Period|Death during treatment|0
5995606|NCT00001832|9589183|FG007|Treatment Period|Death during treatment|0
5995607|NCT00001832|9589184|FG008|Treatment Period|Death during treatment|0
5995608|NCT00001832|9589185|FG009|Treatment Period|Death during treatment|0
5995609|NCT00001832|9589186|FG010|Treatment Period|Death during treatment|0
5995610|NCT00001832|9589187|FG011|Treatment Period|Death during treatment|0
5995611|NCT00001832|9589188|FG012|Treatment Period|Death during treatment|0
5995612|NCT00001832|9589189|FG013|Treatment Period|Death during treatment|0
5995613|NCT00001832|9589190|FG014|Treatment Period|Death during treatment|0
5995614|NCT00001832|9589176|FG000|Treatment Period|Not treated|0
5995615|NCT00001832|9589177|FG001|Treatment Period|Not treated|0
5995616|NCT00001832|9589178|FG002|Treatment Period|Not treated|0
5995617|NCT00001832|9589179|FG003|Treatment Period|Not treated|0
5995618|NCT00001832|9589180|FG004|Treatment Period|Not treated|0
5995619|NCT00001832|9589181|FG005|Treatment Period|Not treated|0
5995620|NCT00001832|9589182|FG006|Treatment Period|Not treated|0
5995621|NCT00001832|9589183|FG007|Treatment Period|Not treated|1
5995622|NCT00001832|9589184|FG008|Treatment Period|Not treated|0
5995623|NCT00001832|9589185|FG009|Treatment Period|Not treated|0
5995624|NCT00001832|9589186|FG010|Treatment Period|Not treated|0
5995625|NCT00001832|9589187|FG011|Treatment Period|Not treated|0
5995626|NCT00001832|9589188|FG012|Treatment Period|Not treated|0
5995627|NCT00001832|9589189|FG013|Treatment Period|Not treated|0
5995628|NCT00001832|9589190|FG014|Treatment Period|Not treated|0
5995629|NCT00001849|9589220|FG000|Overall Study|Death|4
5995630|NCT00001849|9589220|FG000|Overall Study|Lost to Follow-up|2
5995631|NCT00001849|9589220|FG000|Overall Study|Withdrawal by Subject|2
5995632|NCT00001849|9589220|FG000|Overall Study|tumor remained occult|6
5995633|NCT00001880|9589233|FG000|Overall Study|Death|14
5995634|NCT00001941|9589237|FG000|Overall Study|not treated- rapidly progressing disease|0
5995635|NCT00001941|9589238|FG001|Overall Study|not treated- rapidly progressing disease|0
5995636|NCT00001941|9589239|FG002|Overall Study|not treated- rapidly progressing disease|0
5995637|NCT00001941|9589240|FG003|Overall Study|not treated- rapidly progressing disease|0
5995638|NCT00001941|9589241|FG004|Overall Study|not treated- rapidly progressing disease|1
5995639|NCT00001959|9589246|FG000|Overall Study|newly diagnosed colon cancer|1
5995640|NCT00001959|9589246|FG000|Overall Study|disabling sedation|1
5995641|NCT00001959|9589246|FG000|Overall Study|non-compliance|1
5995642|NCT00001962|9589250|FG000|Overall Study|Lack of Efficacy|18
5995643|NCT00001962|9589250|FG000|Overall Study|Lack of Accrual|6
5995644|NCT00001962|9589250|FG000|Overall Study|Death|1
5995645|NCT00001962|9589250|FG000|Overall Study|Lost to Follow-up|2
5995646|NCT00001962|9589250|FG000|Overall Study|Adverse Event|1
5995647|NCT00002525|9589260|FG000|Overall Study|Adverse Event|36
5995648|NCT00002525|9589261|FG001|Overall Study|Adverse Event|0
5995649|NCT00002525|9589260|FG000|Overall Study|Death|5
5995650|NCT00002525|9589261|FG001|Overall Study|Death|0
5995651|NCT00002525|9589260|FG000|Overall Study|Withdrawal by Subject|11
5995652|NCT00002525|9589261|FG001|Overall Study|Withdrawal by Subject|0
5995653|NCT00002525|9589260|FG000|Overall Study|Start non-protocol therapy|1
5995654|NCT00002525|9589261|FG001|Overall Study|Start non-protocol therapy|0
5995655|NCT00002525|9589260|FG000|Overall Study|Other complicating disease|1
5995656|NCT00002525|9589261|FG001|Overall Study|Other complicating disease|0
5995657|NCT00002525|9589260|FG000|Overall Study|Duke's A, B1, D disease|92
5995658|NCT00002525|9589261|FG001|Overall Study|Duke's A, B1, D disease|0
5995659|NCT00002525|9589260|FG000|Overall Study|Error|6
5995660|NCT00002525|9589261|FG001|Overall Study|Error|0
5995661|NCT00002525|9589260|FG000|Overall Study|Other|26
5995662|NCT00002525|9589261|FG001|Overall Study|Other|0
5995663|NCT00002525|9589260|FG000|Overall Study|Never start protocol therapy|8
5995664|NCT00002525|9589261|FG001|Overall Study|Never start protocol therapy|0
5995665|NCT00002540|9589271|FG000|Overall Study|Cancer Before Rand. (Prostate Screening)|0
5995666|NCT00002540|9589272|FG001|Overall Study|Cancer Before Rand. (Prostate Screening)|25
5995667|NCT00002540|9589271|FG000|Overall Study|Died Before Randomization|2
5995668|NCT00002540|9589272|FG001|Overall Study|Died Before Randomization|6
5995669|NCT00002540|9589271|FG000|Overall Study|Died Before ASU (Control)|202
5995670|NCT00002540|9589272|FG001|Overall Study|Died Before ASU (Control)|0
5995671|NCT00002540|9589271|FG000|Overall Study|Refused ASU (Control)|597
5995672|NCT00002540|9589272|FG001|Overall Study|Refused ASU (Control)|0
5995673|NCT00002540|9589271|FG000|Overall Study|Refused Screen (Prostate Screening)|0
5995674|NCT00002540|9589272|FG001|Overall Study|Refused Screen (Prostate Screening)|2433
5995675|NCT00002558|9589280|FG000|Overall Study|Withdrawal by Subject|0
5995676|NCT00002558|9589281|FG001|Overall Study|Withdrawal by Subject|1
5995677|NCT00002597|9589289|FG000|Overall Study|Protocol Violation|19
5995678|NCT00002597|9589290|FG001|Overall Study|Protocol Violation|17
5995679|NCT00002597|9589289|FG000|Overall Study|Withdrawal by Subject|7
5995680|NCT00002597|9589290|FG001|Overall Study|Withdrawal by Subject|6
5995681|NCT00002651|9589304|FG000|Induction|Adverse Event|44
5995682|NCT00002651|9589305|FG001|Induction|Adverse Event|0
5995683|NCT00002651|9589306|FG002|Induction|Adverse Event|0
5995684|NCT00002651|9589304|FG000|Induction|Refusal unrelated to adverse event|50
5995685|NCT00002651|9589305|FG001|Induction|Refusal unrelated to adverse event|0
5995686|NCT00002651|9589306|FG002|Induction|Refusal unrelated to adverse event|0
5995687|NCT00002651|9589304|FG000|Induction|Progression/relapse|274
5995688|NCT00002651|9589305|FG001|Induction|Progression/relapse|0
5995689|NCT00002651|9589306|FG002|Induction|Progression/relapse|0
5995690|NCT00002651|9589304|FG000|Induction|Death|62
5995691|NCT00002651|9589305|FG001|Induction|Death|0
5995692|NCT00002651|9589306|FG002|Induction|Death|0
5995693|NCT00002651|9589304|FG000|Induction|Other|823
5995694|NCT00002651|9589305|FG001|Induction|Other|0
5995695|NCT00002651|9589306|FG002|Induction|Other|0
5995696|NCT00002651|9589304|FG000|Induction|not eligible|90
5995697|NCT00002651|9589305|FG001|Induction|not eligible|0
5995698|NCT00002651|9589306|FG002|Induction|not eligible|0
5995699|NCT00002651|9589304|FG000|Consolidation and Randomization|Adverse Event|0
5995700|NCT00002651|9589305|FG001|Consolidation and Randomization|Adverse Event|36
5995701|NCT00002651|9589306|FG002|Consolidation and Randomization|Adverse Event|14
5995702|NCT00002651|9589304|FG000|Consolidation and Randomization|Refusal unrelated to adverse event|0
5995703|NCT00002651|9589305|FG001|Consolidation and Randomization|Refusal unrelated to adverse event|53
5995704|NCT00002651|9589306|FG002|Consolidation and Randomization|Refusal unrelated to adverse event|75
5995705|NCT00002651|9589304|FG000|Consolidation and Randomization|Progression/relapse|0
5995706|NCT00002651|9589305|FG001|Consolidation and Randomization|Progression/relapse|295
5995707|NCT00002651|9589306|FG002|Consolidation and Randomization|Progression/relapse|298
5995708|NCT00002651|9589304|FG000|Consolidation and Randomization|Death|0
5995709|NCT00002651|9589305|FG001|Consolidation and Randomization|Death|38
5995710|NCT00002651|9589306|FG002|Consolidation and Randomization|Death|48
5995711|NCT00002651|9589304|FG000|Consolidation and Randomization|Other|0
5995712|NCT00002651|9589305|FG001|Consolidation and Randomization|Other|314
5995713|NCT00002651|9589306|FG002|Consolidation and Randomization|Other|313
5995714|NCT00002651|9589304|FG000|Consolidation and Randomization|not eligible|0
5995715|NCT00002651|9589305|FG001|Consolidation and Randomization|not eligible|102
5995716|NCT00002651|9589306|FG002|Consolidation and Randomization|not eligible|112
5995717|NCT00002766|9589316|FG000|Overall Study|Withdrawal by Subject|0
5995718|NCT00002766|9589317|FG001|Overall Study|Withdrawal by Subject|1
5995719|NCT00002766|9589316|FG000|Overall Study|Patient Not Treated|1
5995720|NCT00002766|9589317|FG001|Overall Study|Patient Not Treated|2
5995721|NCT00002766|9589316|FG000|Overall Study|Adverse Event|1
5995722|NCT00002766|9589317|FG001|Overall Study|Adverse Event|1
5995723|NCT00002766|9589316|FG000|Overall Study|Protocol Violation|1
5995724|NCT00002766|9589317|FG001|Overall Study|Protocol Violation|0
6070671|NCT00550446|9673388|FG003|Post Week 12|Other|1
6070672|NCT00550446|9673389|FG004|Post Week 12|Other|0
6070673|NCT00550446|9673390|FG005|Post Week 12|Other|0
6070674|NCT00550446|9673391|FG006|Post Week 12|Other|1
6070675|NCT00550446|9673392|FG007|Post Week 12|Other|0
6070676|NCT00550446|9673393|FG008|Post Week 12|Other|1
6070677|NCT00550446|9673394|FG009|Post Week 12|Other|1
6070678|NCT00550446|9673395|FG010|Post Week 12|Other|0
6070679|NCT00550459|9673435|FG000|Overall Study|Adverse Event|0
6070680|NCT00550459|9673436|FG001|Overall Study|Adverse Event|2
6070681|NCT00550459|9673435|FG000|Overall Study|Withdrawal by Subject|1
5995725|NCT00002842|9589323|FG000|Overall Study|ineligible for surgical resection|27
5995726|NCT00002850|9589330|FG000|Overall Study|Death|4
5995727|NCT00002850|9589331|FG001|Overall Study|Death|1
5995728|NCT00002850|9589332|FG002|Overall Study|Death|3
5995729|NCT00002850|9589330|FG000|Overall Study|Protocol Violation|1
5995730|NCT00002850|9589331|FG001|Overall Study|Protocol Violation|0
5995731|NCT00002850|9589332|FG002|Overall Study|Protocol Violation|1
5995732|NCT00002850|9589330|FG000|Overall Study|Withdrawal by Subject|0
5995733|NCT00002850|9589331|FG001|Overall Study|Withdrawal by Subject|1
5995734|NCT00002850|9589332|FG002|Overall Study|Withdrawal by Subject|0
6046698|NCT00407030|9645683|FG002|Extension Period - up to 68 Weeks|Patient Decision|0
6046699|NCT00407030|9645681|FG000|Extension Period - up to 68 Weeks|Physician Decision|1
6046700|NCT00407030|9645682|FG001|Extension Period - up to 68 Weeks|Physician Decision|2
6046701|NCT00407030|9645683|FG002|Extension Period - up to 68 Weeks|Physician Decision|0
6046702|NCT00407511|9645731|FG000|Overall Study|Adverse Event|9
6046703|NCT00407511|9645731|FG000|Overall Study|Lost to Follow-up|4
6046704|NCT00407511|9645731|FG000|Overall Study|Other|5
6046705|NCT00407511|9645731|FG000|Overall Study|Withdrawal by Subject|4
6046706|NCT00407537|9645737|FG000|Overall Study|Death|5
6046707|NCT00407537|9645738|FG001|Overall Study|Death|2
6046708|NCT00407537|9645737|FG000|Overall Study|Adverse Event|36
6046709|NCT00407537|9645738|FG001|Overall Study|Adverse Event|0
6046710|NCT00407537|9645737|FG000|Overall Study|Lost to Follow-up|12
6046711|NCT00407537|9645738|FG001|Overall Study|Lost to Follow-up|19
6046712|NCT00407537|9645737|FG000|Overall Study|Other|6
6046713|NCT00407537|9645738|FG001|Overall Study|Other|7
6070682|NCT00550459|9673436|FG001|Overall Study|Withdrawal by Subject|1
6070683|NCT00550537|9673442|FG000|Overall Study|Death|18
6070684|NCT00550537|9673442|FG000|Overall Study|Adverse Event|20
6070685|NCT00550537|9673442|FG000|Overall Study|Disease progression before|46
6070686|NCT00550537|9673442|FG000|Overall Study|Withdrawal by Subject|7
5995735|NCT03666988|9589346|FG000|Part 1 (Up to 28 Months)|Adverse Event|0
5995736|NCT03666988|9589347|FG001|Part 1 (Up to 28 Months)|Adverse Event|1
5995737|NCT03666988|9589348|FG002|Part 1 (Up to 28 Months)|Adverse Event|3
5995738|NCT03666988|9589349|FG003|Part 1 (Up to 28 Months)|Adverse Event|0
5995739|NCT03666988|9589350|FG004|Part 1 (Up to 28 Months)|Adverse Event|0
5995740|NCT03666988|9589351|FG005|Part 1 (Up to 28 Months)|Adverse Event|0
5995741|NCT03666988|9589346|FG000|Part 1 (Up to 28 Months)|Other|0
5995742|NCT03666988|9589347|FG001|Part 1 (Up to 28 Months)|Other|1
5995743|NCT03666988|9589348|FG002|Part 1 (Up to 28 Months)|Other|1
5995744|NCT03666988|9589349|FG003|Part 1 (Up to 28 Months)|Other|0
5995745|NCT03666988|9589350|FG004|Part 1 (Up to 28 Months)|Other|0
5995746|NCT03666988|9589351|FG005|Part 1 (Up to 28 Months)|Other|0
5995747|NCT03666988|9589346|FG000|Part 1 (Up to 28 Months)|Disease Progression|2
5995748|NCT03666988|9589347|FG001|Part 1 (Up to 28 Months)|Disease Progression|14
5995749|NCT03666988|9589348|FG002|Part 1 (Up to 28 Months)|Disease Progression|7
5995750|NCT03666988|9589349|FG003|Part 1 (Up to 28 Months)|Disease Progression|0
5995751|NCT03666988|9589350|FG004|Part 1 (Up to 28 Months)|Disease Progression|0
5995752|NCT03666988|9589351|FG005|Part 1 (Up to 28 Months)|Disease Progression|0
5995753|NCT03666988|9589346|FG000|Part 1 (Up to 28 Months)|Physician Decision|0
5995754|NCT03666988|9589347|FG001|Part 1 (Up to 28 Months)|Physician Decision|0
5995755|NCT03666988|9589348|FG002|Part 1 (Up to 28 Months)|Physician Decision|1
5995756|NCT03666988|9589349|FG003|Part 1 (Up to 28 Months)|Physician Decision|0
5995757|NCT03666988|9589350|FG004|Part 1 (Up to 28 Months)|Physician Decision|0
5995758|NCT03666988|9589351|FG005|Part 1 (Up to 28 Months)|Physician Decision|0
5995759|NCT03666988|9589346|FG000|Part 1 (Up to 28 Months)|Withdrawal by Subject|1
5995760|NCT03666988|9589347|FG001|Part 1 (Up to 28 Months)|Withdrawal by Subject|0
5995761|NCT03666988|9589348|FG002|Part 1 (Up to 28 Months)|Withdrawal by Subject|0
5995762|NCT03666988|9589349|FG003|Part 1 (Up to 28 Months)|Withdrawal by Subject|0
5995763|NCT03666988|9589350|FG004|Part 1 (Up to 28 Months)|Withdrawal by Subject|0
5995764|NCT03666988|9589351|FG005|Part 1 (Up to 28 Months)|Withdrawal by Subject|0
5995765|NCT03552029|9589371|FG000|Overall Study|Death|3
5995766|NCT03552029|9589372|FG001|Overall Study|Death|0
5995767|NCT03552029|9589371|FG000|Overall Study|Adverse Event|1
5995768|NCT03552029|9589372|FG001|Overall Study|Adverse Event|0
5995769|NCT03552029|9589371|FG000|Overall Study|Lack of Efficacy|0
5995770|NCT03552029|9589372|FG001|Overall Study|Lack of Efficacy|2
5995771|NCT03552029|9589371|FG000|Overall Study|Physician Decision|0
5995772|NCT03552029|9589372|FG001|Overall Study|Physician Decision|1
5995773|NCT03552029|9589371|FG000|Overall Study|Study terminated by Sponsor|0
5995774|NCT03552029|9589372|FG001|Overall Study|Study terminated by Sponsor|1
5995775|NCT03552029|9589371|FG000|Overall Study|Other|0
5995776|NCT03552029|9589372|FG001|Overall Study|Other|2
5995777|NCT03549104|9589380|FG000|Overall Study|Physician Decision|2
5995778|NCT03549104|9589381|FG001|Overall Study|Physician Decision|0
5995779|NCT03549104|9589380|FG000|Overall Study|Withdrawal by Subject|5
5995780|NCT03549104|9589381|FG001|Overall Study|Withdrawal by Subject|2
5995781|NCT03549104|9589380|FG000|Overall Study|Covid shelter in place|1
5995782|NCT03549104|9589381|FG001|Overall Study|Covid shelter in place|2
5995783|NCT03462719|9589389|FG000|Overall Study|Withdrawal by Subject|2
5995784|NCT03462719|9589390|FG001|Overall Study|Withdrawal by Subject|3
5995785|NCT03462719|9589389|FG000|Overall Study|Ongoing|93
5995786|NCT03462719|9589390|FG001|Overall Study|Ongoing|91
5995787|NCT03412565|9589400|FG000|Overall Study|Other|0
5995788|NCT03412565|9589401|FG001|Overall Study|Other|0
5995789|NCT03412565|9589402|FG002|Overall Study|Other|0
5995790|NCT03412565|9589403|FG003|Overall Study|Other|3
5995791|NCT03412565|9589400|FG000|Overall Study|Withdrawal by Subject|0
5995792|NCT03412565|9589401|FG001|Overall Study|Withdrawal by Subject|0
5995793|NCT03412565|9589402|FG002|Overall Study|Withdrawal by Subject|1
5995794|NCT03412565|9589403|FG003|Overall Study|Withdrawal by Subject|5
5995795|NCT03412565|9589400|FG000|Overall Study|Physician Decision|0
5995796|NCT03412565|9589401|FG001|Overall Study|Physician Decision|1
5995797|NCT03412565|9589402|FG002|Overall Study|Physician Decision|0
5995798|NCT03412565|9589403|FG003|Overall Study|Physician Decision|1
5995799|NCT03412565|9589400|FG000|Overall Study|Death|1
5995800|NCT03412565|9589401|FG001|Overall Study|Death|2
5995801|NCT03412565|9589402|FG002|Overall Study|Death|2
5995802|NCT03412565|9589403|FG003|Overall Study|Death|4
5995803|NCT03412565|9589400|FG000|Overall Study|Still ongoing|0
5995804|NCT03412565|9589401|FG001|Overall Study|Still ongoing|62
5995805|NCT03412565|9589402|FG002|Overall Study|Still ongoing|59
5995806|NCT03412565|9589403|FG003|Overall Study|Still ongoing|41
5995807|NCT03332589|9589421|FG000|Overall Study|Lack of Efficacy|2
5995808|NCT03332589|9589422|FG001|Overall Study|Lack of Efficacy|0
5995809|NCT03332589|9589423|FG002|Overall Study|Lack of Efficacy|0
5995810|NCT03332589|9589421|FG000|Overall Study|Adverse Event|1
5995811|NCT03332589|9589422|FG001|Overall Study|Adverse Event|0
5995812|NCT03332589|9589423|FG002|Overall Study|Adverse Event|0
5995813|NCT03332589|9589421|FG000|Overall Study|Death|1
5995814|NCT03332589|9589422|FG001|Overall Study|Death|0
5995815|NCT03332589|9589423|FG002|Overall Study|Death|0
5995816|NCT03277105|9589433|FG000|Overall Study|Death|77
5995817|NCT03277105|9589434|FG001|Overall Study|Death|73
5995818|NCT03277105|9589433|FG000|Overall Study|Lost to Follow-up|0
5995819|NCT03277105|9589434|FG001|Overall Study|Lost to Follow-up|3
5995820|NCT03277105|9589433|FG000|Overall Study|Withdrawal by Subject|10
5995821|NCT03277105|9589434|FG001|Overall Study|Withdrawal by Subject|9
5995822|NCT03277105|9589433|FG000|Overall Study|Other|1
5995823|NCT03277105|9589434|FG001|Overall Study|Other|3
5995824|NCT03277105|9589433|FG000|Overall Study|Ongoing|171
5995825|NCT03277105|9589434|FG001|Overall Study|Ongoing|175
5995826|NCT03201965|9589443|FG000|Overall Study|Death|5
5995827|NCT03201965|9589444|FG001|Overall Study|Death|27
5995828|NCT03201965|9589445|FG002|Overall Study|Death|27
5995829|NCT03201965|9589443|FG000|Overall Study|Lost to Follow-up|0
5995830|NCT03201965|9589444|FG001|Overall Study|Lost to Follow-up|1
5995831|NCT03201965|9589445|FG002|Overall Study|Lost to Follow-up|0
5995832|NCT03201965|9589443|FG000|Overall Study|Withdrawal by Subject|3
5995833|NCT03201965|9589444|FG001|Overall Study|Withdrawal by Subject|13
5995834|NCT03201965|9589445|FG002|Overall Study|Withdrawal by Subject|4
5995835|NCT03201965|9589443|FG000|Overall Study|Ongoing|20
5995836|NCT03201965|9589444|FG001|Overall Study|Ongoing|152
5995837|NCT03201965|9589445|FG002|Overall Study|Ongoing|164
6046714|NCT00407537|9645737|FG000|Overall Study|Withdrawal by Subject|34
6046715|NCT00407537|9645738|FG001|Overall Study|Withdrawal by Subject|16
6046716|NCT00407550|9645746|FG000|Overall Study|Adverse Event|0
6046717|NCT00407550|9645747|FG001|Overall Study|Adverse Event|1
6046718|NCT00407550|9645746|FG000|Overall Study|Withdrawal by Subject|0
6046719|NCT00407550|9645747|FG001|Overall Study|Withdrawal by Subject|2
6046720|NCT00407550|9645746|FG000|Overall Study|Death|1
6046721|NCT00407550|9645747|FG001|Overall Study|Death|0
6046722|NCT00407550|9645746|FG000|Overall Study|Insurance or Other medical condition|2
6046723|NCT00407550|9645747|FG001|Overall Study|Insurance or Other medical condition|1
6046724|NCT00407563|9645753|FG000|Overall Study|Patient continues on treatment|1
6046725|NCT00407745|9645764|FG000|Overall Study|Lack of Efficacy|1
6070687|NCT00550537|9673442|FG000|Overall Study|Change in treatment plan|4
6070688|NCT00550537|9673442|FG000|Overall Study|Other complicating ilness|3
6070689|NCT00550537|9673442|FG000|Overall Study|Declining performance status|2
6070690|NCT00550537|9673442|FG000|Overall Study|Treated closer to home|4
6070691|NCT00550550|9673453|FG000|Overall Study|Adverse Event|13
6046726|NCT00407745|9645765|FG001|Overall Study|Lack of Efficacy|2
6046727|NCT00407745|9645764|FG000|Overall Study|Withdrawal by Subject|3
6046728|NCT00407745|9645765|FG001|Overall Study|Withdrawal by Subject|3
6046729|NCT00407745|9645764|FG000|Overall Study|Protocol Violation|5
6046730|NCT00407745|9645765|FG001|Overall Study|Protocol Violation|3
6046731|NCT00407745|9645764|FG000|Overall Study|Adverse Event|8
6046732|NCT00407745|9645765|FG001|Overall Study|Adverse Event|8
6046733|NCT00407745|9645764|FG000|Overall Study|Other|2
6046734|NCT00407745|9645765|FG001|Overall Study|Other|0
6046735|NCT00407745|9645764|FG000|Overall Study|Randomized, unknown if treated|0
6046736|NCT00407745|9645765|FG001|Overall Study|Randomized, unknown if treated|1
6046737|NCT00407758|9645771|FG000|Overall Study|ineligible -improper prior treatment|1
6046738|NCT00407797|9645775|FG000|Overall Study|Lost to Follow-up|2
6046739|NCT00407797|9645775|FG000|Overall Study|Adverse Event|6
6046740|NCT00407797|9645775|FG000|Overall Study|Other|7
6046741|NCT00407797|9645775|FG000|Overall Study|Withdrawal by Subject|3
6046742|NCT00408317|9645800|FG000|First Intervention Period|Adverse Event|0
6046743|NCT00408317|9645801|FG001|First Intervention Period|Adverse Event|1
6046744|NCT00408317|9645800|FG000|Second Intervention Period|Adverse Event|2
6046745|NCT00408317|9645801|FG001|Second Intervention Period|Adverse Event|0
6046746|NCT00408317|9645800|FG000|Second Intervention Period|Protocol Violation|0
6046747|NCT00408317|9645801|FG001|Second Intervention Period|Protocol Violation|1
6046748|NCT00408317|9645800|FG000|Second Intervention Period|Withdrawal of consent|0
6046749|NCT00408317|9645801|FG001|Second Intervention Period|Withdrawal of consent|1
6046750|NCT00408408|9645813|FG000|Overall Study|No follow up data|2
6046751|NCT00408408|9645814|FG001|Overall Study|No follow up data|3
6046752|NCT00408408|9645815|FG002|Overall Study|No follow up data|0
6046753|NCT00408408|9645816|FG003|Overall Study|No follow up data|7
6046754|NCT00408408|9645817|FG004|Overall Study|No follow up data|5
6046755|NCT00408408|9645818|FG005|Overall Study|No follow up data|3
6046756|NCT00408421|9645834|FG000|Treatment Initial Randomization|Adverse Event|5
6046757|NCT00408421|9645835|FG001|Treatment Initial Randomization|Adverse Event|9
6046758|NCT00408421|9645836|FG002|Treatment Initial Randomization|Adverse Event|0
6046759|NCT00408421|9645834|FG000|Treatment Initial Randomization|Lack of Efficacy|2
6046760|NCT00408421|9645835|FG001|Treatment Initial Randomization|Lack of Efficacy|2
6046761|NCT00408421|9645836|FG002|Treatment Initial Randomization|Lack of Efficacy|0
6046762|NCT00408421|9645834|FG000|Treatment Initial Randomization|Lost to Follow-up|0
6046763|NCT00408421|9645835|FG001|Treatment Initial Randomization|Lost to Follow-up|3
6046764|NCT00408421|9645836|FG002|Treatment Initial Randomization|Lost to Follow-up|0
6046765|NCT00408421|9645834|FG000|Treatment Initial Randomization|Physician Decision|1
6046766|NCT00408421|9645835|FG001|Treatment Initial Randomization|Physician Decision|0
6046767|NCT00408421|9645836|FG002|Treatment Initial Randomization|Physician Decision|0
6046768|NCT00408421|9645834|FG000|Treatment Initial Randomization|Protocol Violation|0
6070692|NCT00550550|9673454|FG001|Overall Study|Adverse Event|5
6070693|NCT00550550|9673453|FG000|Overall Study|Treatment Failure|0
6046769|NCT00408421|9645835|FG001|Treatment Initial Randomization|Protocol Violation|1
6046770|NCT00408421|9645836|FG002|Treatment Initial Randomization|Protocol Violation|0
5995838|NCT03091192|9589454|FG000|Overall Study|Study terminated by sponsor|21
5995839|NCT03091192|9589455|FG001|Overall Study|Study terminated by sponsor|14
5995840|NCT03091192|9589454|FG000|Overall Study|Death|9
5995841|NCT03091192|9589455|FG001|Overall Study|Death|13
5995842|NCT03091192|9589454|FG000|Overall Study|Withdrawal by Subject|2
5995843|NCT03091192|9589455|FG001|Overall Study|Withdrawal by Subject|0
5995844|NCT03091192|9589454|FG000|Overall Study|Lost to Follow-up|1
5995845|NCT03091192|9589455|FG001|Overall Study|Lost to Follow-up|0
5995846|NCT02717611|9589461|FG000|Overall Study|Death|13
5995847|NCT02717611|9589461|FG000|Overall Study|Withdrawal by Subject|6
5995848|NCT02717611|9589461|FG000|Overall Study|Active, not recruiting|40
5995849|NCT02717611|9589461|FG000|Overall Study|Complicating disease|1
5995850|NCT02489318|9589467|FG000|Randomized|Withdrawal by Subject|0
5995851|NCT02489318|9589468|FG001|Randomized|Withdrawal by Subject|1
5995852|NCT02489318|9589467|FG000|Treated|Adverse Event|19
5995853|NCT02489318|9589468|FG001|Treated|Adverse Event|62
5995854|NCT02489318|9589467|FG000|Treated|Death|13
5995855|NCT02489318|9589468|FG001|Treated|Death|11
5995856|NCT02489318|9589467|FG000|Treated|Physician Decision|4
5995857|NCT02489318|9589468|FG001|Treated|Physician Decision|6
5995858|NCT02489318|9589467|FG000|Treated|Protocol Violation|1
5995859|NCT02489318|9589468|FG001|Treated|Protocol Violation|2
5995860|NCT02489318|9589467|FG000|Treated|Withdrawal by Subject|37
5995861|NCT02489318|9589468|FG001|Treated|Withdrawal by Subject|36
5995862|NCT02489318|9589467|FG000|Treated|Other: Progressive Disease|245
5995863|NCT02489318|9589468|FG001|Treated|Other: Progressive Disease|138
5995864|NCT02489318|9589467|FG000|Treated|Other|0
5995865|NCT02489318|9589468|FG001|Treated|Other|2
5995866|NCT02489318|9589467|FG000|Treated|Ongoing|0
5995867|NCT02489318|9589468|FG001|Treated|Ongoing|267
5995868|NCT02301156|9589477|FG000|Overall Study|Adverse Event|13
5995869|NCT02301156|9589478|FG001|Overall Study|Adverse Event|14
5995870|NCT02301156|9589477|FG000|Overall Study|Death|1
5995871|NCT02301156|9589478|FG001|Overall Study|Death|5
5995872|NCT02301156|9589477|FG000|Overall Study|Investigator Decision (includes non-compliance with study drug, investigator determined suitability)|2
5995873|NCT02301156|9589478|FG001|Overall Study|Investigator Decision (includes non-compliance with study drug, investigator determined suitability)|2
5995874|NCT02301156|9589477|FG000|Overall Study|Site Terminated by Sponsor at the End of Study|27
5995875|NCT02301156|9589478|FG001|Overall Study|Site Terminated by Sponsor at the End of Study|16
5995876|NCT02301156|9589477|FG000|Overall Study|Withdrawal of Consent by Subject|4
5995877|NCT02301156|9589478|FG001|Overall Study|Withdrawal of Consent by Subject|12
5995878|NCT02301156|9589477|FG000|Overall Study|Reason not Specified|6
5995879|NCT02301156|9589478|FG001|Overall Study|Reason not Specified|3
5995880|NCT02296125|9589486|FG000|Overall Study|Withdrawal by Subject|18
5995881|NCT02296125|9589487|FG001|Overall Study|Withdrawal by Subject|8
5995882|NCT02296125|9589488|FG002|Overall Study|Withdrawal by Subject|6
5995883|NCT02296125|9589489|FG003|Overall Study|Withdrawal by Subject|2
5995884|NCT02296125|9589486|FG000|Overall Study|Adverse Event|41
5995885|NCT02296125|9589487|FG001|Overall Study|Adverse Event|52
5995886|NCT02296125|9589488|FG002|Overall Study|Adverse Event|9
5995887|NCT02296125|9589489|FG003|Overall Study|Adverse Event|4
5995888|NCT02296125|9589486|FG000|Overall Study|Severe non-compliance to protocol|0
5995889|NCT02296125|9589487|FG001|Overall Study|Severe non-compliance to protocol|1
5995890|NCT02296125|9589488|FG002|Overall Study|Severe non-compliance to protocol|0
5995891|NCT02296125|9589489|FG003|Overall Study|Severe non-compliance to protocol|0
5995892|NCT02296125|9589486|FG000|Overall Study|Condition under investigation worsened|153
5995893|NCT02296125|9589487|FG001|Overall Study|Condition under investigation worsened|199
5995894|NCT02296125|9589488|FG002|Overall Study|Condition under investigation worsened|39
5995895|NCT02296125|9589489|FG003|Overall Study|Condition under investigation worsened|56
5995896|NCT02296125|9589486|FG000|Overall Study|Any reason not specifically recorded|6
5995897|NCT02296125|9589487|FG001|Overall Study|Any reason not specifically recorded|4
5995898|NCT02296125|9589488|FG002|Overall Study|Any reason not specifically recorded|2
5995899|NCT02296125|9589489|FG003|Overall Study|Any reason not specifically recorded|0
5995900|NCT02277444|9589500|FG000|Overall Study|Adverse Event|10
5995901|NCT02277444|9589500|FG000|Overall Study|Withdrawal by Subject|3
5995902|NCT02277444|9589500|FG000|Overall Study|Other|1
5995903|NCT02277444|9589500|FG000|Overall Study|Enrolled and not Treated|3
5995904|NCT02277444|9589500|FG000|Overall Study|Ongoing|113
5995905|NCT02257736|9589506|FG000|Overall Study|Progressive disease|365
5995906|NCT02257736|9589507|FG001|Overall Study|Progressive disease|327
5995907|NCT02257736|9589506|FG000|Overall Study|Adverse Event|45
5995908|NCT02257736|9589507|FG001|Overall Study|Adverse Event|56
5995909|NCT02257736|9589506|FG000|Overall Study|Withdrawal by Subject|21
5995910|NCT02257736|9589507|FG001|Overall Study|Withdrawal by Subject|38
5995911|NCT02257736|9589506|FG000|Overall Study|Death|11
5995912|NCT02257736|9589507|FG001|Overall Study|Death|6
5995913|NCT02257736|9589506|FG000|Overall Study|Physician Decision|5
5995914|NCT02257736|9589507|FG001|Overall Study|Physician Decision|9
5995915|NCT02257736|9589506|FG000|Overall Study|Non-Compliance with study drug|1
5995916|NCT02257736|9589507|FG001|Overall Study|Non-Compliance with study drug|2
5995917|NCT02257736|9589506|FG000|Overall Study|Protocol Violation|1
5995918|NCT02257736|9589507|FG001|Overall Study|Protocol Violation|0
6070694|NCT00550550|9673454|FG001|Overall Study|Treatment Failure|1
5995919|NCT02257736|9589506|FG000|Overall Study|Other|1
5995920|NCT02257736|9589507|FG001|Overall Study|Other|7
5995921|NCT02257736|9589506|FG000|Overall Study|Randomized, not treated|1
5995922|NCT02257736|9589507|FG001|Overall Study|Randomized, not treated|2
5995923|NCT02252172|9589515|FG000|Overall Study|Lost to Follow-up|3
5995924|NCT02252172|9589516|FG001|Overall Study|Lost to Follow-up|1
5995925|NCT02252172|9589515|FG000|Overall Study|Ongoing|276
5995926|NCT02252172|9589516|FG001|Overall Study|Ongoing|298
6070695|NCT00550550|9673453|FG000|Overall Study|Lost to Follow-up|4
5995927|NCT02195479|9589524|FG000|Overall Study|Lost to Follow-up|3
5995928|NCT02195479|9589525|FG001|Overall Study|Lost to Follow-up|0
5995929|NCT02195479|9589524|FG000|Overall Study|Death|48
5995930|NCT02195479|9589525|FG001|Overall Study|Death|45
5995931|NCT02195479|9589524|FG000|Overall Study|Physician Decision|1
5995932|NCT02195479|9589525|FG001|Overall Study|Physician Decision|0
5995933|NCT02195479|9589524|FG000|Overall Study|Withdrawal by Subject|11
5995934|NCT02195479|9589525|FG001|Overall Study|Withdrawal by Subject|6
5995935|NCT02195479|9589524|FG000|Overall Study|Other|2
5995936|NCT02195479|9589525|FG001|Overall Study|Other|2
5995937|NCT02195479|9589524|FG000|Overall Study|Ongoing|291
5995938|NCT02195479|9589525|FG001|Overall Study|Ongoing|297
5995939|NCT02136134|9589533|FG000|Overall Study|Death|35
5995940|NCT02136134|9589534|FG001|Overall Study|Death|29
5995941|NCT02136134|9589533|FG000|Overall Study|Withdrawal by Subject|14
5995942|NCT02136134|9589534|FG001|Overall Study|Withdrawal by Subject|4
5995943|NCT02136134|9589533|FG000|Overall Study|Other|3
5995944|NCT02136134|9589534|FG001|Overall Study|Other|3
5995945|NCT02136134|9589533|FG000|Overall Study|Ongoing|185
5995946|NCT02136134|9589534|FG001|Overall Study|Ongoing|207
5995947|NCT02136134|9589533|FG000|Overall Study|Subjects randomized but not treated|10
5995948|NCT02136134|9589534|FG001|Overall Study|Subjects randomized but not treated|8
5995949|NCT02087423|9589543|FG000|Overall Study|Withdrawal by Subject|20
5995950|NCT02087423|9589544|FG001|Overall Study|Withdrawal by Subject|20
5995951|NCT02087423|9589545|FG002|Overall Study|Withdrawal by Subject|3
5995952|NCT02087423|9589543|FG000|Overall Study|Death|68
5995953|NCT02087423|9589544|FG001|Overall Study|Death|207
5995954|NCT02087423|9589545|FG002|Overall Study|Death|40
5995955|NCT02087423|9589543|FG000|Overall Study|Lost to Follow-up|0
5995956|NCT02087423|9589544|FG001|Overall Study|Lost to Follow-up|2
5995957|NCT02087423|9589545|FG002|Overall Study|Lost to Follow-up|0
5995958|NCT02087423|9589543|FG000|Overall Study|Terminated from study at final DCO|23
5995959|NCT02087423|9589544|FG001|Overall Study|Terminated from study at final DCO|36
5995960|NCT02087423|9589545|FG002|Overall Study|Terminated from study at final DCO|25
5995961|NCT02076009|9589557|FG000|Overall Study|Death|44
5995962|NCT02076009|9589558|FG001|Overall Study|Death|30
5995963|NCT02076009|9589557|FG000|Overall Study|Withdrawal by Subject|9
5995964|NCT02076009|9589558|FG001|Overall Study|Withdrawal by Subject|3
5995965|NCT02076009|9589557|FG000|Overall Study|Lost to Follow-up|1
5995966|NCT02076009|9589558|FG001|Overall Study|Lost to Follow-up|1
5995967|NCT02076009|9589557|FG000|Overall Study|Progressive disease|1
5995968|NCT02076009|9589558|FG001|Overall Study|Progressive disease|0
5995969|NCT02076009|9589557|FG000|Overall Study|Ongoing|226
5995970|NCT02076009|9589558|FG001|Overall Study|Ongoing|249
5995971|NCT02076009|9589557|FG000|Overall Study|Subjects randomized but not treated|2
5995972|NCT02076009|9589558|FG001|Overall Study|Subjects randomized but not treated|3
5995973|NCT01946204|9589566|FG000|Overall Study|Death|38
5995974|NCT01946204|9589567|FG001|Overall Study|Death|59
5995975|NCT01946204|9589566|FG000|Overall Study|Withdrawal by Subject|37
5995976|NCT01946204|9589567|FG001|Overall Study|Withdrawal by Subject|50
5995977|NCT01946204|9589566|FG000|Overall Study|Lost to Follow-up|3
5995978|NCT01946204|9589567|FG001|Overall Study|Lost to Follow-up|7
5995979|NCT01946204|9589566|FG000|Overall Study|Ongoing|316
5995980|NCT01946204|9589567|FG001|Overall Study|Ongoing|687
5995981|NCT01946204|9589566|FG000|Overall Study|Other|7
5995982|NCT01946204|9589567|FG001|Overall Study|Other|3
5995983|NCT01626079|9589576|FG000|Overall Study|Death|117
5995984|NCT01626079|9589577|FG001|Overall Study|Death|153
5995985|NCT01626079|9589578|FG002|Overall Study|Death|39
5995986|NCT01626079|9589576|FG000|Overall Study|Withdrawal by Subject|15
5995987|NCT01626079|9589577|FG001|Overall Study|Withdrawal by Subject|39
5995988|NCT01626079|9589578|FG002|Overall Study|Withdrawal by Subject|5
5995989|NCT01626079|9589576|FG000|Overall Study|Lost to Follow-up|5
5995990|NCT01626079|9589577|FG001|Overall Study|Lost to Follow-up|4
5995991|NCT01626079|9589578|FG002|Overall Study|Lost to Follow-up|2
5995992|NCT01626079|9589576|FG000|Overall Study|Missed Visits|13
5995993|NCT01626079|9589577|FG001|Overall Study|Missed Visits|5
5995994|NCT01626079|9589578|FG002|Overall Study|Missed Visits|6
5995995|NCT01615029|9589594|FG000|Overall Study|Adverse Event|0
5995996|NCT01615029|9589595|FG001|Overall Study|Adverse Event|0
5995997|NCT01615029|9589596|FG002|Overall Study|Adverse Event|0
5995998|NCT01615029|9589597|FG003|Overall Study|Adverse Event|0
5995999|NCT01615029|9589598|FG004|Overall Study|Adverse Event|1
5996000|NCT01615029|9589594|FG000|Overall Study|Death|0
5996001|NCT01615029|9589595|FG001|Overall Study|Death|0
5996002|NCT01615029|9589596|FG002|Overall Study|Death|0
5996003|NCT01615029|9589597|FG003|Overall Study|Death|0
5996004|NCT01615029|9589598|FG004|Overall Study|Death|1
5996005|NCT01615029|9589594|FG000|Overall Study|Lost to Follow-up|0
6070696|NCT00550550|9673454|FG001|Overall Study|Lost to Follow-up|0
5996006|NCT01615029|9589595|FG001|Overall Study|Lost to Follow-up|0
5996007|NCT01615029|9589596|FG002|Overall Study|Lost to Follow-up|0
6070697|NCT00550550|9673453|FG000|Overall Study|Withdrawal by Subject|10
6070698|NCT00550550|9673454|FG001|Overall Study|Withdrawal by Subject|8
6070699|NCT00550550|9673453|FG000|Overall Study|Protocol Violation|5
6070700|NCT00550550|9673454|FG001|Overall Study|Protocol Violation|14
6070701|NCT00550550|9673453|FG000|Overall Study|Did Not Meet Protocol Eligibility|1
6070702|NCT00550550|9673454|FG001|Overall Study|Did Not Meet Protocol Eligibility|1
6070703|NCT00550550|9673453|FG000|Overall Study|Randomized But Not Treated|1
6070704|NCT00550550|9673454|FG001|Overall Study|Randomized But Not Treated|0
5996008|NCT01615029|9589597|FG003|Overall Study|Lost to Follow-up|0
5996009|NCT01615029|9589598|FG004|Overall Study|Lost to Follow-up|1
5996010|NCT01615029|9589594|FG000|Overall Study|Progressive disease|2
5996011|NCT01615029|9589595|FG001|Overall Study|Progressive disease|1
5996012|NCT01615029|9589596|FG002|Overall Study|Progressive disease|1
5996013|NCT01615029|9589597|FG003|Overall Study|Progressive disease|1
5996014|NCT01615029|9589598|FG004|Overall Study|Progressive disease|5
5996015|NCT01615029|9589594|FG000|Overall Study|Physician Decision|0
5996016|NCT01615029|9589595|FG001|Overall Study|Physician Decision|0
5996017|NCT01615029|9589596|FG002|Overall Study|Physician Decision|0
5996018|NCT01615029|9589597|FG003|Overall Study|Physician Decision|0
5996019|NCT01615029|9589598|FG004|Overall Study|Physician Decision|1
5996020|NCT01615029|9589594|FG000|Overall Study|Ongoing|1
5996021|NCT01615029|9589595|FG001|Overall Study|Ongoing|2
5996022|NCT01615029|9589596|FG002|Overall Study|Ongoing|3
5996023|NCT01615029|9589597|FG003|Overall Study|Ongoing|2
5996024|NCT01615029|9589598|FG004|Overall Study|Ongoing|23
5996025|NCT01590628|9589621|FG000|Overall Study|Death|2
5996026|NCT01590628|9589622|FG001|Overall Study|Death|0
5996027|NCT01533714|9589638|FG000|Overall Study|Adverse Event|0
5996028|NCT01533714|9589639|FG001|Overall Study|Adverse Event|1
5996029|NCT01533714|9589640|FG002|Overall Study|Adverse Event|2
5996030|NCT01533714|9589641|FG003|Overall Study|Adverse Event|2
5996031|NCT01533714|9589642|FG004|Overall Study|Adverse Event|2
5996032|NCT01533714|9589643|FG005|Overall Study|Adverse Event|1
5996033|NCT01533714|9589638|FG000|Overall Study|Lack of Efficacy|0
5996034|NCT01533714|9589639|FG001|Overall Study|Lack of Efficacy|0
5996035|NCT01533714|9589640|FG002|Overall Study|Lack of Efficacy|0
5996036|NCT01533714|9589641|FG003|Overall Study|Lack of Efficacy|0
5996037|NCT01533714|9589642|FG004|Overall Study|Lack of Efficacy|0
5996038|NCT01533714|9589643|FG005|Overall Study|Lack of Efficacy|1
5996039|NCT01533714|9589638|FG000|Overall Study|Withdrawal by Subject|0
5996040|NCT01533714|9589639|FG001|Overall Study|Withdrawal by Subject|1
5996041|NCT01533714|9589640|FG002|Overall Study|Withdrawal by Subject|0
5996042|NCT01533714|9589641|FG003|Overall Study|Withdrawal by Subject|1
5996043|NCT01533714|9589642|FG004|Overall Study|Withdrawal by Subject|1
5996044|NCT01533714|9589643|FG005|Overall Study|Withdrawal by Subject|0
5996045|NCT01533714|9589638|FG000|Overall Study|Exclusion criteria|0
5996046|NCT01533714|9589639|FG001|Overall Study|Exclusion criteria|1
5996047|NCT01533714|9589640|FG002|Overall Study|Exclusion criteria|0
5996048|NCT01533714|9589641|FG003|Overall Study|Exclusion criteria|0
5996049|NCT01533714|9589642|FG004|Overall Study|Exclusion criteria|0
5996050|NCT01533714|9589643|FG005|Overall Study|Exclusion criteria|0
5996051|NCT01533714|9589638|FG000|Overall Study|Positive for purified protein derivative|0
5996052|NCT01533714|9589639|FG001|Overall Study|Positive for purified protein derivative|0
5996053|NCT01533714|9589640|FG002|Overall Study|Positive for purified protein derivative|1
5996054|NCT01533714|9589641|FG003|Overall Study|Positive for purified protein derivative|0
5996055|NCT01533714|9589642|FG004|Overall Study|Positive for purified protein derivative|1
5996056|NCT01533714|9589643|FG005|Overall Study|Positive for purified protein derivative|0
6070705|NCT00550615|9673468|FG000|Overall Study|Withdrawal by Subject|0
6070706|NCT00550615|9673469|FG001|Overall Study|Withdrawal by Subject|0
6070707|NCT00550615|9673470|FG002|Overall Study|Withdrawal by Subject|2
6070708|NCT00550615|9673471|FG003|Overall Study|Withdrawal by Subject|3
6070709|NCT00550615|9673468|FG000|Overall Study|Not evaluable|0
6070710|NCT00550615|9673469|FG001|Overall Study|Not evaluable|0
6070711|NCT00550615|9673470|FG002|Overall Study|Not evaluable|2
6070712|NCT00550615|9673471|FG003|Overall Study|Not evaluable|7
6070713|NCT00550680|9673481|FG000|Overall Study|Administrative Reasons|1
6070714|NCT00550680|9673481|FG000|Overall Study|Adverse Event|5
6070715|NCT00550680|9673481|FG000|Overall Study|Death|3
6070716|NCT00550680|9673481|FG000|Overall Study|Early Improvement|1
6070717|NCT00550680|9673481|FG000|Overall Study|Lost to Follow-up|3
5996057|NCT01533714|9589638|FG000|Overall Study|Withdrawal criteria|0
6070718|NCT00550680|9673481|FG000|Overall Study|Lack of Efficacy|1
6070719|NCT00550680|9673481|FG000|Overall Study|Other|10
6070720|NCT00550680|9673481|FG000|Overall Study|Protocol Violation|7
6070721|NCT00550680|9673481|FG000|Overall Study|Refused Treatment|19
5996058|NCT01533714|9589639|FG001|Overall Study|Withdrawal criteria|0
5996059|NCT01533714|9589640|FG002|Overall Study|Withdrawal criteria|1
5996060|NCT01533714|9589641|FG003|Overall Study|Withdrawal criteria|0
5996061|NCT01533714|9589642|FG004|Overall Study|Withdrawal criteria|3
6070722|NCT00550680|9673481|FG000|Overall Study|Screen Failure|6
6070723|NCT00550732|9673485|FG000|Overall Study|Death|4
6070724|NCT00550732|9673485|FG000|Overall Study|Withdrawal by Subject|2
6070725|NCT00550732|9673485|FG000|Overall Study|Physician Decision|2
6070726|NCT00550732|9673485|FG000|Overall Study|Lost to Follow-up|1
5996062|NCT01533714|9589643|FG005|Overall Study|Withdrawal criteria|1
5996063|NCT01533714|9589638|FG000|Overall Study|Ineligibility reason|0
5996064|NCT01533714|9589639|FG001|Overall Study|Ineligibility reason|0
5996065|NCT01533714|9589640|FG002|Overall Study|Ineligibility reason|0
6070727|NCT00550732|9673485|FG000|Overall Study|Palliative care|1
6070728|NCT00550732|9673485|FG000|Overall Study|Adverse Event|1
6070729|NCT00550745|9673492|FG000|Overall Study|Death|20
6070730|NCT00550745|9673493|FG001|Overall Study|Death|16
6070731|NCT00550745|9673492|FG000|Overall Study|Lost to Follow-up|45
6070732|NCT00550745|9673493|FG001|Overall Study|Lost to Follow-up|30
6070733|NCT00550745|9673492|FG000|Overall Study|Physician Decision|0
6070734|NCT00550745|9673493|FG001|Overall Study|Physician Decision|2
6070735|NCT00550745|9673492|FG000|Overall Study|Protocol Violation|4
6070736|NCT00550745|9673493|FG001|Overall Study|Protocol Violation|2
6070737|NCT00550745|9673492|FG000|Overall Study|Withdrawal by Subject|17
6070738|NCT00550745|9673493|FG001|Overall Study|Withdrawal by Subject|10
5996066|NCT01533714|9589641|FG003|Overall Study|Ineligibility reason|1
5996067|NCT01533714|9589642|FG004|Overall Study|Ineligibility reason|0
5996068|NCT01533714|9589643|FG005|Overall Study|Ineligibility reason|0
5996069|NCT01314118|9589657|FG000|Overall Study|Adverse Event|9
5996070|NCT01314118|9589657|FG000|Overall Study|Progressive disease|27
5996071|NCT01314118|9589657|FG000|Overall Study|Physician Decision|11
5996072|NCT01314118|9589657|FG000|Overall Study|Death|4
5996073|NCT01314118|9589657|FG000|Overall Study|Protocol Violation|5
5996074|NCT01314118|9589657|FG000|Overall Study|Withdrawal by Subject|11
5996075|NCT01314118|9589657|FG000|Overall Study|Other|2
5996076|NCT01314118|9589657|FG000|Overall Study|Ongoing|62
5996077|NCT01171898|9589665|FG000|Overall Study|Death|0
6309465|NCT02638948|10038055|FG003|Overall Study|Poor/Non-Compliance|0
6309466|NCT02638948|10038052|FG000|Overall Study|Participant no longer met study criteria|0
6309467|NCT02638948|10038053|FG001|Overall Study|Participant no longer met study criteria|1
6309468|NCT02638948|10038054|FG002|Overall Study|Participant no longer met study criteria|0
6309469|NCT02638948|10038055|FG003|Overall Study|Participant no longer met study criteria|0
6309470|NCT02638948|10038052|FG000|Overall Study|Other than specified above|4
6309471|NCT02638948|10038053|FG001|Overall Study|Other than specified above|1
6309472|NCT02638948|10038054|FG002|Overall Study|Other than specified above|1
5996078|NCT01171898|9589666|FG001|Overall Study|Death|0
5996079|NCT01171898|9589667|FG002|Overall Study|Death|2
5996080|NCT01171898|9589668|FG003|Overall Study|Death|0
5996081|NCT01171898|9589665|FG000|Overall Study|Lost to Follow-up|0
5996082|NCT01171898|9589666|FG001|Overall Study|Lost to Follow-up|1
5996083|NCT01171898|9589667|FG002|Overall Study|Lost to Follow-up|1
5996084|NCT01171898|9589668|FG003|Overall Study|Lost to Follow-up|1
5996085|NCT01171898|9589665|FG000|Overall Study|Withdrawal by Subject|1
5996086|NCT01171898|9589666|FG001|Overall Study|Withdrawal by Subject|4
5996087|NCT01171898|9589667|FG002|Overall Study|Withdrawal by Subject|6
5996088|NCT01171898|9589668|FG003|Overall Study|Withdrawal by Subject|3
5996089|NCT01171898|9589665|FG000|Overall Study|Terminated by Sponsor|1
5996090|NCT01171898|9589666|FG001|Overall Study|Terminated by Sponsor|0
5996091|NCT01171898|9589667|FG002|Overall Study|Terminated by Sponsor|0
5996092|NCT01171898|9589668|FG003|Overall Study|Terminated by Sponsor|0
5996093|NCT01171898|9589665|FG000|Overall Study|Ongoing|1
5996094|NCT01171898|9589666|FG001|Overall Study|Ongoing|9
5996095|NCT01171898|9589667|FG002|Overall Study|Ongoing|3
5996096|NCT01171898|9589668|FG003|Overall Study|Ongoing|0
5996097|NCT01171898|9589665|FG000|Overall Study|Other|1
5996098|NCT01171898|9589666|FG001|Overall Study|Other|5
5996099|NCT01171898|9589667|FG002|Overall Study|Other|0
5996100|NCT01171898|9589668|FG003|Overall Study|Other|2
6046771|NCT00408421|9645834|FG000|Treatment Initial Randomization|Withdrawal by Subject|7
6046772|NCT00408421|9645835|FG001|Treatment Initial Randomization|Withdrawal by Subject|7
6046773|NCT00408421|9645836|FG002|Treatment Initial Randomization|Withdrawal by Subject|0
6046774|NCT00408421|9645834|FG000|Treatment Initial Randomization|Entry Criteria Not Met|1
6046775|NCT00408421|9645835|FG001|Treatment Initial Randomization|Entry Criteria Not Met|0
6046776|NCT00408421|9645836|FG002|Treatment Initial Randomization|Entry Criteria Not Met|0
6070739|NCT00550745|9673492|FG000|Overall Study|Screen failure|1
6070740|NCT00550745|9673493|FG001|Overall Study|Screen failure|0
6070741|NCT00550771|9673501|FG000|Overall Study|Adverse Event|11
6070742|NCT00550771|9673502|FG001|Overall Study|Adverse Event|3
6070743|NCT00550771|9673501|FG000|Overall Study|Discontinued for study-related reasons|0
6070744|NCT00550771|9673502|FG001|Overall Study|Discontinued for study-related reasons|1
6070745|NCT00550771|9673501|FG000|Overall Study|Physician Decision|2
6070746|NCT00550771|9673502|FG001|Overall Study|Physician Decision|0
6070747|NCT00550771|9673501|FG000|Overall Study|Withdrawal by Subject|0
6070748|NCT00550771|9673502|FG001|Overall Study|Withdrawal by Subject|1
6309473|NCT02638948|10038055|FG003|Overall Study|Other than specified above|1
6046777|NCT00408421|9645834|FG000|Treatment Initial Randomization|Sponsor Decision|1
6046778|NCT00408421|9645835|FG001|Treatment Initial Randomization|Sponsor Decision|0
6046779|NCT00408421|9645836|FG002|Treatment Initial Randomization|Sponsor Decision|0
6070749|NCT00550771|9673501|FG000|Overall Study|Protocol Violation|4
6070750|NCT00550771|9673502|FG001|Overall Study|Protocol Violation|5
6070751|NCT00550836|9673510|FG000|Overall Study|Withdrawal by Subject|3
6070752|NCT00550836|9673511|FG001|Overall Study|Withdrawal by Subject|9
6070753|NCT00550953|9673536|FG000|Overall Study|Adverse Event|4
5996101|NCT00002931|9589681|FG000|Overall Study|rapidly progressing disease during|2
5996102|NCT00003138|9589687|FG000|Step 1|Reasons off treatment not documented|60
5996103|NCT00003138|9589688|FG001|Step 1|Reasons off treatment not documented|57
5996104|NCT00003138|9589687|FG000|Step 1|Never started treatment|1
5996105|NCT00003138|9589688|FG001|Step 1|Never started treatment|0
5996106|NCT00003138|9589687|FG000|Step 2 (Cross Over)|Reasons off treatment not documented|26
5996107|NCT00003138|9589688|FG001|Step 2 (Cross Over)|Reasons off treatment not documented|0
5996108|NCT00003138|9589687|FG000|Step 3 (EPO 150 Units/kg and G-CSF)|Off treatment reasons not documented|12
5996109|NCT00003138|9589688|FG001|Step 3 (EPO 150 Units/kg and G-CSF)|Off treatment reasons not documented|19
5996110|NCT00003138|9589687|FG000|Step 3 (EPO 150 Units/kg and G-CSF)|Never started treatment|0
5996111|NCT00003138|9589688|FG001|Step 3 (EPO 150 Units/kg and G-CSF)|Never started treatment|1
5996112|NCT00003138|9589687|FG000|Step 4 (EPO 300 Units/kg and G-CSF)|Off treatment reasons not documented|6
5996113|NCT00003138|9589688|FG001|Step 4 (EPO 300 Units/kg and G-CSF)|Off treatment reasons not documented|7
5996114|NCT00003199|9589697|FG000|Overall Study|Refused Post-Transplant Immunotherapy|5
5996115|NCT00003199|9589697|FG000|Overall Study|Lack of insurance clearance|2
5996116|NCT00003199|9589697|FG000|Overall Study|Screen fail|15
5996117|NCT00003222|9589703|FG000|Overall Study|Physician Decision|0
5996118|NCT00003222|9589704|FG001|Overall Study|Physician Decision|1
6046780|NCT00408421|9645834|FG000|Treatment Re-Randomization|Adverse Event|2
6046781|NCT00408421|9645835|FG001|Treatment Re-Randomization|Adverse Event|2
6046782|NCT00408421|9645836|FG002|Treatment Re-Randomization|Adverse Event|4
6046783|NCT00408421|9645834|FG000|Treatment Re-Randomization|Lack of Efficacy|1
6046784|NCT00408421|9645835|FG001|Treatment Re-Randomization|Lack of Efficacy|0
6046785|NCT00408421|9645836|FG002|Treatment Re-Randomization|Lack of Efficacy|0
6046786|NCT00408421|9645834|FG000|Treatment Re-Randomization|Lost to Follow-up|0
6046787|NCT00408421|9645835|FG001|Treatment Re-Randomization|Lost to Follow-up|0
6046788|NCT00408421|9645836|FG002|Treatment Re-Randomization|Lost to Follow-up|1
6046789|NCT00408421|9645834|FG000|Treatment Re-Randomization|Physician Decision|1
6046790|NCT00408421|9645835|FG001|Treatment Re-Randomization|Physician Decision|3
6046791|NCT00408421|9645836|FG002|Treatment Re-Randomization|Physician Decision|0
6046792|NCT00408421|9645834|FG000|Treatment Re-Randomization|Protocol Violation|1
6046793|NCT00408421|9645835|FG001|Treatment Re-Randomization|Protocol Violation|1
6046794|NCT00408421|9645836|FG002|Treatment Re-Randomization|Protocol Violation|0
6046795|NCT00408421|9645834|FG000|Treatment Re-Randomization|Withdrawal by Subject|2
6046796|NCT00408421|9645835|FG001|Treatment Re-Randomization|Withdrawal by Subject|1
6046797|NCT00408421|9645836|FG002|Treatment Re-Randomization|Withdrawal by Subject|0
6046798|NCT00408434|9645851|FG000|Overall Study|Adverse Event|0
6046799|NCT00408434|9645852|FG001|Overall Study|Adverse Event|0
6046800|NCT00408434|9645853|FG002|Overall Study|Adverse Event|1
6046801|NCT00408434|9645854|FG003|Overall Study|Adverse Event|0
6046802|NCT00408434|9645855|FG004|Overall Study|Adverse Event|0
6046803|NCT00408434|9645856|FG005|Overall Study|Adverse Event|0
6046804|NCT00408434|9645857|FG006|Overall Study|Adverse Event|0
6046805|NCT00408434|9645851|FG000|Overall Study|Progressive disease|6
6046806|NCT00408434|9645852|FG001|Overall Study|Progressive disease|3
6046807|NCT00408434|9645853|FG002|Overall Study|Progressive disease|4
6046808|NCT00408434|9645854|FG003|Overall Study|Progressive disease|3
6046809|NCT00408434|9645855|FG004|Overall Study|Progressive disease|3
6046810|NCT00408434|9645856|FG005|Overall Study|Progressive disease|1
6046811|NCT00408434|9645857|FG006|Overall Study|Progressive disease|4
6046812|NCT00408434|9645851|FG000|Overall Study|Other|0
6046813|NCT00408434|9645852|FG001|Overall Study|Other|0
6046814|NCT00408434|9645853|FG002|Overall Study|Other|1
6046815|NCT00408434|9645854|FG003|Overall Study|Other|0
6046816|NCT00408434|9645855|FG004|Overall Study|Other|2
6046817|NCT00408434|9645856|FG005|Overall Study|Other|1
6046818|NCT00408434|9645857|FG006|Overall Study|Other|0
6046819|NCT00408434|9645851|FG000|Overall Study|Terminated by Investigator|0
6046820|NCT00408434|9645852|FG001|Overall Study|Terminated by Investigator|0
6046821|NCT00408434|9645853|FG002|Overall Study|Terminated by Investigator|0
6046822|NCT00408434|9645854|FG003|Overall Study|Terminated by Investigator|0
6046823|NCT00408434|9645855|FG004|Overall Study|Terminated by Investigator|1
6046824|NCT00408434|9645856|FG005|Overall Study|Terminated by Investigator|1
6046825|NCT00408434|9645857|FG006|Overall Study|Terminated by Investigator|0
6046826|NCT00408499|9645878|FG000|Phase 1: Dose Levels 1-4|Adverse Event|0
6046827|NCT00408499|9645879|FG001|Phase 1: Dose Levels 1-4|Adverse Event|0
6046828|NCT00408499|9645880|FG002|Phase 1: Dose Levels 1-4|Adverse Event|1
6046829|NCT00408499|9645881|FG003|Phase 1: Dose Levels 1-4|Adverse Event|0
6046830|NCT00408499|9645882|FG004|Phase 1: Dose Levels 1-4|Adverse Event|0
6046831|NCT00408499|9645878|FG000|Phase 1: Dose Levels 1-4|Withdrawal by Subject|1
6046832|NCT00408499|9645879|FG001|Phase 1: Dose Levels 1-4|Withdrawal by Subject|1
6046833|NCT00408499|9645880|FG002|Phase 1: Dose Levels 1-4|Withdrawal by Subject|0
6046834|NCT00408499|9645881|FG003|Phase 1: Dose Levels 1-4|Withdrawal by Subject|0
6046835|NCT00408499|9645882|FG004|Phase 1: Dose Levels 1-4|Withdrawal by Subject|0
6046836|NCT00408499|9645878|FG000|Phase 1: Dose Levels 1-4|Physician Decision|1
6046837|NCT00408499|9645879|FG001|Phase 1: Dose Levels 1-4|Physician Decision|1
6046838|NCT00408499|9645880|FG002|Phase 1: Dose Levels 1-4|Physician Decision|0
6046839|NCT00408499|9645881|FG003|Phase 1: Dose Levels 1-4|Physician Decision|0
5996119|NCT04848662|9589739|FG000|Period 2 (Second Treatment Intervention)|Physician Decision|1
5996120|NCT04848662|9589740|FG001|Period 2 (Second Treatment Intervention)|Physician Decision|0
5996121|NCT03969719|9589753|FG000|Overall Study|Other reasons not specified|1
5996122|NCT03969719|9589754|FG001|Overall Study|Other reasons not specified|1
5996123|NCT03969719|9589755|FG002|Overall Study|Other reasons not specified|3
5996124|NCT03969719|9589753|FG000|Overall Study|Withdrawal by Subject|2
5996125|NCT03969719|9589754|FG001|Overall Study|Withdrawal by Subject|3
5996126|NCT03969719|9589755|FG002|Overall Study|Withdrawal by Subject|2
5996127|NCT03969719|9589753|FG000|Overall Study|Protocol Violation|1
5996128|NCT03969719|9589754|FG001|Overall Study|Protocol Violation|2
5996129|NCT03969719|9589755|FG002|Overall Study|Protocol Violation|0
5996130|NCT03969719|9589753|FG000|Overall Study|Adverse Event|0
5996131|NCT03969719|9589754|FG001|Overall Study|Adverse Event|2
5996132|NCT03969719|9589755|FG002|Overall Study|Adverse Event|0
5996133|NCT03969719|9589753|FG000|Overall Study|Lost to Follow-up|0
5996134|NCT03969719|9589754|FG001|Overall Study|Lost to Follow-up|1
5996135|NCT03969719|9589755|FG002|Overall Study|Lost to Follow-up|0
5996136|NCT03883477|9589765|FG000|Overall Study|Death|1
5996137|NCT03883477|9589766|FG001|Overall Study|Death|0
5996138|NCT03883477|9589765|FG000|Overall Study|Protocol Violation|0
5996139|NCT03883477|9589766|FG001|Overall Study|Protocol Violation|1
5996140|NCT03809611|9589795|FG000|Overall Study|Withdrawal by Subject|1
5996141|NCT03809611|9589796|FG001|Overall Study|Withdrawal by Subject|1
5996142|NCT03721705|9589805|FG000|Overall Study|Adverse Event|2
5996143|NCT03721705|9589806|FG001|Overall Study|Adverse Event|0
5996144|NCT03721705|9589805|FG000|Overall Study|Withdrawal by Subject|4
5996145|NCT03721705|9589806|FG001|Overall Study|Withdrawal by Subject|10
5996146|NCT03721705|9589805|FG000|Overall Study|No Suitable Study Partner|1
5996147|NCT03721705|9589806|FG001|Overall Study|No Suitable Study Partner|0
5996148|NCT03721705|9589805|FG000|Overall Study|Early Termination Due to Coronavirus Disease 2019 (COVID-19)|3
5996149|NCT03721705|9589806|FG001|Overall Study|Early Termination Due to Coronavirus Disease 2019 (COVID-19)|7
5996150|NCT03721705|9589805|FG000|Overall Study|Death|0
5996151|NCT03721705|9589806|FG001|Overall Study|Death|1
5996152|NCT03505671|9589814|FG000|Overall Study|Withdrawal by Subject|2
5996153|NCT03505671|9589815|FG001|Overall Study|Withdrawal by Subject|1
5996154|NCT03505671|9589814|FG000|Overall Study|Lost to Follow-up|1
5996155|NCT03505671|9589815|FG001|Overall Study|Lost to Follow-up|0
5996156|NCT03505021|9589823|FG000|Overall Study|Protocol Violation|1
5996157|NCT03505021|9589824|FG001|Overall Study|Protocol Violation|0
5996158|NCT03505021|9589823|FG000|Overall Study|Death|9
5996159|NCT03505021|9589824|FG001|Overall Study|Death|8
5996160|NCT03505021|9589823|FG000|Overall Study|Consent withdrawn by subject|6
5996161|NCT03505021|9589824|FG001|Overall Study|Consent withdrawn by subject|1
5996162|NCT03505021|9589823|FG000|Overall Study|Lost to Follow-up|5
5996163|NCT03505021|9589824|FG001|Overall Study|Lost to Follow-up|3
5996164|NCT03505021|9589823|FG000|Overall Study|Adverse Event|26
5996165|NCT03505021|9589824|FG001|Overall Study|Adverse Event|9
5996166|NCT03505021|9589823|FG000|Overall Study|Disease progression|33
5996167|NCT03505021|9589824|FG001|Overall Study|Disease progression|17
5996168|NCT03505021|9589823|FG000|Overall Study|Other|11
5996169|NCT03505021|9589824|FG001|Overall Study|Other|5
5996170|NCT03505021|9589823|FG000|Overall Study|Personal reason|21
5996171|NCT03505021|9589824|FG001|Overall Study|Personal reason|12
5996172|NCT03366194|9589853|FG000|Overall Study|Lost to Follow-up|2
5996173|NCT03213158|9589867|FG000|Overall Study|Withdrawal by Subject|1
5996174|NCT03213158|9589867|FG000|Overall Study|Physician Decision|2
5996175|NCT03203473|9589871|FG000|Induction Phase|Never started primary treatment|2
5996176|NCT03203473|9589872|FG001|Induction Phase|Never started primary treatment|0
5996177|NCT03203473|9589873|FG002|Induction Phase|Never started primary treatment|0
5996178|NCT03203473|9589871|FG000|Induction Phase|Withdrew from study due to progressive disease|7
5996179|NCT03203473|9589872|FG001|Induction Phase|Withdrew from study due to progressive disease|0
5996180|NCT03203473|9589873|FG002|Induction Phase|Withdrew from study due to progressive disease|0
5996181|NCT03203473|9589871|FG000|Induction Phase|Withdrew from study due to toxicity|7
5996182|NCT03203473|9589872|FG001|Induction Phase|Withdrew from study due to toxicity|0
5996183|NCT03203473|9589873|FG002|Induction Phase|Withdrew from study due to toxicity|0
5996184|NCT03203473|9589871|FG000|Arm Allocation Phase|Still on Arm A-observation|0
5996185|NCT03203473|9589872|FG001|Arm Allocation Phase|Still on Arm A-observation|7
5996186|NCT03203473|9589873|FG002|Arm Allocation Phase|Still on Arm A-observation|0
5996187|NCT03203473|9589871|FG000|Arm Allocation Phase|started salvage therapy|0
5996188|NCT03203473|9589872|FG001|Arm Allocation Phase|started salvage therapy|5
5996189|NCT03203473|9589873|FG002|Arm Allocation Phase|started salvage therapy|0
5996190|NCT03203473|9589871|FG000|Arm Allocation Phase|Disease progression|0
5996191|NCT03203473|9589872|FG001|Arm Allocation Phase|Disease progression|0
5996192|NCT03203473|9589873|FG002|Arm Allocation Phase|Disease progression|37
5996193|NCT03203473|9589871|FG000|Arm Allocation Phase|Adverse Event|0
5996194|NCT03203473|9589872|FG001|Arm Allocation Phase|Adverse Event|0
5996195|NCT03203473|9589873|FG002|Arm Allocation Phase|Adverse Event|11
5996196|NCT03203473|9589871|FG000|Arm Allocation Phase|Physician Decision|0
5996197|NCT03203473|9589872|FG001|Arm Allocation Phase|Physician Decision|0
5996198|NCT03203473|9589873|FG002|Arm Allocation Phase|Physician Decision|3
5996199|NCT03203473|9589871|FG000|Arm Allocation Phase|Death|0
5996200|NCT03203473|9589872|FG001|Arm Allocation Phase|Death|0
5996201|NCT03203473|9589873|FG002|Arm Allocation Phase|Death|1
5996202|NCT03203473|9589871|FG000|Arm Allocation Phase|Developed 2nd cancer|0
5996203|NCT03203473|9589872|FG001|Arm Allocation Phase|Developed 2nd cancer|0
5996204|NCT03203473|9589873|FG002|Arm Allocation Phase|Developed 2nd cancer|1
5996205|NCT03203473|9589871|FG000|Arm Allocation Phase|Intercurrent illness|0
5996206|NCT03203473|9589872|FG001|Arm Allocation Phase|Intercurrent illness|0
5996207|NCT03203473|9589873|FG002|Arm Allocation Phase|Intercurrent illness|1
5996208|NCT03203473|9589871|FG000|Arm Allocation Phase|Still on arm-B treatment|0
5996209|NCT03203473|9589872|FG001|Arm Allocation Phase|Still on arm-B treatment|0
5996210|NCT03203473|9589873|FG002|Arm Allocation Phase|Still on arm-B treatment|3
5996211|NCT03180736|9589886|FG000|Overall Study|Adverse Event|3
5996212|NCT03180736|9589887|FG001|Overall Study|Adverse Event|4
5996213|NCT03180736|9589886|FG000|Overall Study|Death|10
5996214|NCT03180736|9589887|FG001|Overall Study|Death|7
5996215|NCT03180736|9589886|FG000|Overall Study|Withdrawal by Subject|5
5996216|NCT03180736|9589887|FG001|Overall Study|Withdrawal by Subject|12
5996217|NCT03180736|9589886|FG000|Overall Study|Lost to Follow-up|1
5996218|NCT03180736|9589887|FG001|Overall Study|Lost to Follow-up|0
5996219|NCT03180736|9589886|FG000|Overall Study|Lack of Efficacy|66
5996220|NCT03180736|9589887|FG001|Overall Study|Lack of Efficacy|87
5996221|NCT03180736|9589886|FG000|Overall Study|Physician Decision|4
5996222|NCT03180736|9589887|FG001|Overall Study|Physician Decision|7
5996223|NCT03180736|9589886|FG000|Overall Study|randomized but not treated|2
5996224|NCT03180736|9589887|FG001|Overall Study|randomized but not treated|3
5996225|NCT03051659|9589900|FG000|Treatment Period|Withdrawal by Subject|0
5996226|NCT03051659|9589901|FG001|Treatment Period|Withdrawal by Subject|2
5996227|NCT03051659|9589900|FG000|Survival Follow-up|Lost to Follow-up|23
5996228|NCT03051659|9589901|FG001|Survival Follow-up|Lost to Follow-up|22
5996229|NCT02949219|9589924|FG000|Overall Study|Withdrawal by Subject|1
5996230|NCT02886884|9589932|FG000|Follow-up|Withdrawal by Subject|0
5996231|NCT02886884|9589933|FG001|Follow-up|Withdrawal by Subject|0
5996232|NCT02886884|9589934|FG002|Follow-up|Withdrawal by Subject|0
5996233|NCT02886884|9589935|FG003|Follow-up|Withdrawal by Subject|1
5996234|NCT02717832|9589963|FG000|Overall Study|Inability to place IV|3
6070754|NCT00550953|9673537|FG001|Overall Study|Adverse Event|3
6070755|NCT00550953|9673536|FG000|Overall Study|Not able to visit the site|2
6070756|NCT00550953|9673537|FG001|Overall Study|Not able to visit the site|3
6070757|NCT00551031|9673548|FG000|Overall Study|Adverse Event|0
6070758|NCT00551031|9673549|FG001|Overall Study|Adverse Event|1
6070759|NCT00551031|9673550|FG002|Overall Study|Adverse Event|0
6070760|NCT00551031|9673551|FG003|Overall Study|Adverse Event|0
6070761|NCT00551031|9673552|FG004|Overall Study|Adverse Event|0
6070762|NCT00551031|9673548|FG000|Overall Study|Protocol Violation|1
6070763|NCT00551031|9673549|FG001|Overall Study|Protocol Violation|1
6070764|NCT00551031|9673550|FG002|Overall Study|Protocol Violation|0
6070765|NCT00551031|9673551|FG003|Overall Study|Protocol Violation|0
6070766|NCT00551031|9673552|FG004|Overall Study|Protocol Violation|0
6070767|NCT00551031|9673548|FG000|Overall Study|Lost to Follow-up|0
6070768|NCT00551031|9673549|FG001|Overall Study|Lost to Follow-up|1
6070769|NCT00551031|9673550|FG002|Overall Study|Lost to Follow-up|0
6070770|NCT00551031|9673551|FG003|Overall Study|Lost to Follow-up|1
6070771|NCT00551031|9673552|FG004|Overall Study|Lost to Follow-up|1
6070772|NCT00551031|9673548|FG000|Overall Study|Withdrawal by Subject|0
6070773|NCT00551031|9673549|FG001|Overall Study|Withdrawal by Subject|4
6070774|NCT00551031|9673550|FG002|Overall Study|Withdrawal by Subject|1
6070775|NCT00551031|9673551|FG003|Overall Study|Withdrawal by Subject|2
6070776|NCT00551031|9673552|FG004|Overall Study|Withdrawal by Subject|0
6070777|NCT00551031|9673548|FG000|Overall Study|Serious Adverse Event|0
6070778|NCT00551031|9673549|FG001|Overall Study|Serious Adverse Event|2
6070779|NCT00551031|9673550|FG002|Overall Study|Serious Adverse Event|1
6070780|NCT00551031|9673551|FG003|Overall Study|Serious Adverse Event|0
6070781|NCT00551031|9673552|FG004|Overall Study|Serious Adverse Event|0
6070782|NCT00551031|9673548|FG000|Overall Study|Did not receive vaccine|1
6070783|NCT00551031|9673549|FG001|Overall Study|Did not receive vaccine|2
6070784|NCT00551031|9673550|FG002|Overall Study|Did not receive vaccine|0
6070785|NCT00551031|9673551|FG003|Overall Study|Did not receive vaccine|0
5996235|NCT02677324|9589968|FG000|Overall Study|Disease Progression|6
5996236|NCT02677324|9589968|FG000|Overall Study|Inability to Swallow pills|1
5996237|NCT02677324|9589968|FG000|Overall Study|Non-compliance|1
5996238|NCT02677324|9589968|FG000|Overall Study|Lack of Efficacy|1
5996239|NCT02677324|9589968|FG000|Overall Study|Medical insurance coverage|1
5996240|NCT02677324|9589968|FG000|Overall Study|Adverse Event|1
5996241|NCT02677324|9589968|FG000|Overall Study|IgM Myeloma diagnosis|1
5996242|NCT02563028|9589974|FG000|Overall Study|Lack of equipment|1
5996243|NCT02563028|9589974|FG000|Overall Study|Unable to elicit VEP post induction|1
5996244|NCT02552212|9589980|FG000|Double-Blind Period (Week 0 - 52)|Adverse Event|6
5996245|NCT02552212|9589981|FG001|Double-Blind Period (Week 0 - 52)|Adverse Event|3
5996246|NCT02552212|9589982|FG002|Double-Blind Period (Week 0 - 52)|Adverse Event|0
6070786|NCT00551031|9673552|FG004|Overall Study|Did not receive vaccine|0
6070787|NCT00551135|9673572|FG000|Overall Study|Adverse Event|1
6070788|NCT00551135|9673573|FG001|Overall Study|Adverse Event|0
6070789|NCT00551135|9673574|FG002|Overall Study|Adverse Event|1
6070790|NCT00551135|9673575|FG003|Overall Study|Adverse Event|1
6070791|NCT00551135|9673572|FG000|Overall Study|Lost to Follow-up|0
6070792|NCT00551135|9673573|FG001|Overall Study|Lost to Follow-up|0
6070793|NCT00551135|9673574|FG002|Overall Study|Lost to Follow-up|0
6070794|NCT00551135|9673575|FG003|Overall Study|Lost to Follow-up|1
6070795|NCT00551135|9673572|FG000|Overall Study|Other|3
6070796|NCT00551135|9673573|FG001|Overall Study|Other|2
6070797|NCT00551135|9673574|FG002|Overall Study|Other|1
6070798|NCT00551135|9673575|FG003|Overall Study|Other|2
6070799|NCT00551135|9673572|FG000|Overall Study|Withdrawal by Subject|1
6070800|NCT00551135|9673573|FG001|Overall Study|Withdrawal by Subject|0
6070801|NCT00551135|9673574|FG002|Overall Study|Withdrawal by Subject|3
6070802|NCT00551135|9673575|FG003|Overall Study|Withdrawal by Subject|1
6070803|NCT00551161|9673585|FG000|Overall Study|Withdrawal by Subject|1
6070804|NCT00551213|9673610|FG000|Overall Study|Adverse Event|6
6070805|NCT00551213|9673611|FG001|Overall Study|Adverse Event|3
6070806|NCT00551213|9673610|FG000|Overall Study|Progressive Disease|41
6070807|NCT00551213|9673611|FG001|Overall Study|Progressive Disease|12
6070808|NCT00551213|9673610|FG000|Overall Study|Withdrawal by Subject|2
6070809|NCT00551213|9673611|FG001|Overall Study|Withdrawal by Subject|0
6070810|NCT00551213|9673610|FG000|Overall Study|Not Treated|1
6070811|NCT00551213|9673611|FG001|Overall Study|Not Treated|2
6070812|NCT00551291|9673617|FG000|Overall Study|Physician Decision|1
6070813|NCT00551369|9673621|FG000|Overall Study|Protocol Violation|5
6070814|NCT00551369|9673621|FG000|Overall Study|Withdrawal by Subject|1
6070815|NCT00551369|9673621|FG000|Overall Study|Not treated per protocol and re|1
6070816|NCT00551421|9673625|FG000|Amended Protocol (Cetuximab-refr. mCRC)|Withdrawal by Subject|1
6070817|NCT00551460|9673630|FG000|Overall Study|Adverse Event|1
6070818|NCT00551460|9673630|FG000|Overall Study|Withdrawal by Subject|1
6070819|NCT00551460|9673630|FG000|Overall Study|Physician Decision|1
6070820|NCT00551460|9673630|FG000|Overall Study|Death|7
6070821|NCT00551460|9673630|FG000|Overall Study|Ineligible|4
6070822|NCT00551460|9673630|FG000|Overall Study|Not analyzable (did not start treatment)|4
6070823|NCT00551525|9673634|FG000|Overall Study|Protocol Violation|5
6070824|NCT00551642|9673640|FG000|Treatment Period|Protocol Deviation|6
6070825|NCT00551642|9673641|FG001|Treatment Period|Protocol Deviation|11
6070826|NCT00551642|9673640|FG000|Treatment Period|Delivery device failure|1
6070827|NCT00551642|9673641|FG001|Treatment Period|Delivery device failure|3
6070828|NCT00551642|9673640|FG000|Treatment Period|Physician Decision|0
6070829|NCT00551642|9673641|FG001|Treatment Period|Physician Decision|1
6070830|NCT00551642|9673640|FG000|Treatment Period|Death|33
6070831|NCT00551642|9673641|FG001|Treatment Period|Death|31
6070832|NCT00551642|9673640|FG000|Treatment Period|Inclusion/Exclusion criteria|4
6070833|NCT00551642|9673641|FG001|Treatment Period|Inclusion/Exclusion criteria|4
6070834|NCT00551642|9673640|FG000|Treatment Period|Adverse Event|15
5996247|NCT02552212|9589980|FG000|Double-Blind Period (Week 0 - 52)|Lack of Efficacy|2
5996248|NCT02552212|9589981|FG001|Double-Blind Period (Week 0 - 52)|Lack of Efficacy|2
5996249|NCT02552212|9589982|FG002|Double-Blind Period (Week 0 - 52)|Lack of Efficacy|0
5996250|NCT02552212|9589980|FG000|Double-Blind Period (Week 0 - 52)|Protocol Violation|1
5996251|NCT02552212|9589981|FG001|Double-Blind Period (Week 0 - 52)|Protocol Violation|1
5996252|NCT02552212|9589982|FG002|Double-Blind Period (Week 0 - 52)|Protocol Violation|0
5996253|NCT02552212|9589980|FG000|Double-Blind Period (Week 0 - 52)|Lost to Follow-up|1
5996254|NCT02552212|9589981|FG001|Double-Blind Period (Week 0 - 52)|Lost to Follow-up|0
5996255|NCT02552212|9589982|FG002|Double-Blind Period (Week 0 - 52)|Lost to Follow-up|0
5996256|NCT02552212|9589980|FG000|Double-Blind Period (Week 0 - 52)|Withdrawal by Subject|3
5996257|NCT02552212|9589981|FG001|Double-Blind Period (Week 0 - 52)|Withdrawal by Subject|7
5996258|NCT02552212|9589982|FG002|Double-Blind Period (Week 0 - 52)|Withdrawal by Subject|0
5996259|NCT02552212|9589980|FG000|Double-Blind Period (Week 0 - 52)|Study non-compliance|1
5996260|NCT02552212|9589981|FG001|Double-Blind Period (Week 0 - 52)|Study non-compliance|1
5996261|NCT02552212|9589982|FG002|Double-Blind Period (Week 0 - 52)|Study non-compliance|0
5996262|NCT02552212|9589980|FG000|Double-Blind Period (Week 0 - 52)|Patient's decision|0
5996263|NCT02552212|9589981|FG001|Double-Blind Period (Week 0 - 52)|Patient's decision|1
5996264|NCT02552212|9589982|FG002|Double-Blind Period (Week 0 - 52)|Patient's decision|0
5996265|NCT02552212|9589980|FG000|Double-Blind Period (Week 0 - 52)|As per suggestion|0
5996266|NCT02552212|9589981|FG001|Double-Blind Period (Week 0 - 52)|As per suggestion|1
5996267|NCT02552212|9589982|FG002|Double-Blind Period (Week 0 - 52)|As per suggestion|0
5996268|NCT02552212|9589980|FG000|Double-Blind Period (Week 0 - 52)|Not eligible|0
5996269|NCT02552212|9589981|FG001|Double-Blind Period (Week 0 - 52)|Not eligible|1
5996270|NCT02552212|9589982|FG002|Double-Blind Period (Week 0 - 52)|Not eligible|0
6070835|NCT00551642|9673641|FG001|Treatment Period|Adverse Event|12
6070836|NCT00551642|9673640|FG000|Treatment Period|Withdrawal by Subject|2
6070837|NCT00551642|9673641|FG001|Treatment Period|Withdrawal by Subject|1
6087250|NCT00666926|9697374|FG015|Overall Study|Other|4
6087251|NCT00666926|9697359|FG000|Overall Study|Withdrawal by Subject|0
6087252|NCT00666926|9697360|FG001|Overall Study|Withdrawal by Subject|0
6087253|NCT00666926|9697361|FG002|Overall Study|Withdrawal by Subject|0
6087254|NCT00666926|9697362|FG003|Overall Study|Withdrawal by Subject|0
6087255|NCT00666926|9697363|FG004|Overall Study|Withdrawal by Subject|0
6087256|NCT00666926|9697364|FG005|Overall Study|Withdrawal by Subject|0
6087257|NCT00666926|9697365|FG006|Overall Study|Withdrawal by Subject|0
6087258|NCT00666926|9697366|FG007|Overall Study|Withdrawal by Subject|1
5996271|NCT02552212|9589980|FG000|Double-Blind Period (Week 0 - 52)|Missing/Unspecified|1
5996272|NCT02552212|9589981|FG001|Double-Blind Period (Week 0 - 52)|Missing/Unspecified|0
5996273|NCT02552212|9589982|FG002|Double-Blind Period (Week 0 - 52)|Missing/Unspecified|0
5996274|NCT02552212|9589980|FG000|SFE Period (Week 52 - 156)|Adverse Event|0
5996275|NCT02552212|9589981|FG001|SFE Period (Week 52 - 156)|Adverse Event|0
5996276|NCT02552212|9589982|FG002|SFE Period (Week 52 - 156)|Adverse Event|5
5996277|NCT02552212|9589980|FG000|SFE Period (Week 52 - 156)|Lack of Efficacy|0
5996278|NCT02552212|9589981|FG001|SFE Period (Week 52 - 156)|Lack of Efficacy|0
5996279|NCT02552212|9589982|FG002|SFE Period (Week 52 - 156)|Lack of Efficacy|4
5996280|NCT02552212|9589980|FG000|SFE Period (Week 52 - 156)|Lost to Follow-up|0
5996281|NCT02552212|9589981|FG001|SFE Period (Week 52 - 156)|Lost to Follow-up|0
5996282|NCT02552212|9589982|FG002|SFE Period (Week 52 - 156)|Lost to Follow-up|2
5996283|NCT02552212|9589980|FG000|SFE Period (Week 52 - 156)|Withdrawal by Subject|0
5996284|NCT02552212|9589981|FG001|SFE Period (Week 52 - 156)|Withdrawal by Subject|0
5996285|NCT02552212|9589982|FG002|SFE Period (Week 52 - 156)|Withdrawal by Subject|18
5996286|NCT02552212|9589980|FG000|SFE Period (Week 52 - 156)|Return to standard-of-care /OL CZP|0
5996287|NCT02552212|9589981|FG001|SFE Period (Week 52 - 156)|Return to standard-of-care /OL CZP|0
5996288|NCT02552212|9589982|FG002|SFE Period (Week 52 - 156)|Return to standard-of-care /OL CZP|1
5996289|NCT02552212|9589980|FG000|SFE Period (Week 52 - 156)|Patient's personal reason|0
5996290|NCT02552212|9589981|FG001|SFE Period (Week 52 - 156)|Patient's personal reason|0
5996291|NCT02552212|9589982|FG002|SFE Period (Week 52 - 156)|Patient's personal reason|1
5996292|NCT02552212|9589980|FG000|SFE Period (Week 52 - 156)|Investigator decision|0
5996293|NCT02552212|9589981|FG001|SFE Period (Week 52 - 156)|Investigator decision|0
5996294|NCT02552212|9589982|FG002|SFE Period (Week 52 - 156)|Investigator decision|1
5996295|NCT02552212|9589980|FG000|SFE Period (Week 52 - 156)|Subject withdrew consent due to traveling to site|0
5996296|NCT02552212|9589981|FG001|SFE Period (Week 52 - 156)|Subject withdrew consent due to traveling to site|0
5996297|NCT02552212|9589982|FG002|SFE Period (Week 52 - 156)|Subject withdrew consent due to traveling to site|1
5996298|NCT02552212|9589980|FG000|SFE Period (Week 52 - 156)|Compassionate access|0
5996299|NCT02552212|9589981|FG001|SFE Period (Week 52 - 156)|Compassionate access|0
5996300|NCT02552212|9589982|FG002|SFE Period (Week 52 - 156)|Compassionate access|2
5996301|NCT02552212|9589980|FG000|SFE Period (Week 52 - 156)|Patient travelling for study unable to continue|0
5996302|NCT02552212|9589981|FG001|SFE Period (Week 52 - 156)|Patient travelling for study unable to continue|0
5996303|NCT02552212|9589982|FG002|SFE Period (Week 52 - 156)|Patient travelling for study unable to continue|1
5996304|NCT02552212|9589980|FG000|SFE Period (Week 52 - 156)|Decision of Patient|0
5996305|NCT02552212|9589981|FG001|SFE Period (Week 52 - 156)|Decision of Patient|0
5996306|NCT02552212|9589982|FG002|SFE Period (Week 52 - 156)|Decision of Patient|1
6046840|NCT00408499|9645882|FG004|Phase 1: Dose Levels 1-4|Physician Decision|0
6046841|NCT00408499|9645878|FG000|Phase II- MTD Expansion|Adverse Event|0
6046842|NCT00408499|9645879|FG001|Phase II- MTD Expansion|Adverse Event|0
6046843|NCT00408499|9645880|FG002|Phase II- MTD Expansion|Adverse Event|0
6046844|NCT00408499|9645881|FG003|Phase II- MTD Expansion|Adverse Event|0
6046845|NCT00408499|9645882|FG004|Phase II- MTD Expansion|Adverse Event|9
6046846|NCT00408499|9645878|FG000|Phase II- MTD Expansion|Death|0
6046847|NCT00408499|9645879|FG001|Phase II- MTD Expansion|Death|0
6046848|NCT00408499|9645880|FG002|Phase II- MTD Expansion|Death|0
6046849|NCT00408499|9645881|FG003|Phase II- MTD Expansion|Death|0
6046850|NCT00408499|9645882|FG004|Phase II- MTD Expansion|Death|2
6046851|NCT00408499|9645878|FG000|Phase II- MTD Expansion|Physician Decision|0
6046852|NCT00408499|9645879|FG001|Phase II- MTD Expansion|Physician Decision|0
6046853|NCT00408499|9645880|FG002|Phase II- MTD Expansion|Physician Decision|0
6046854|NCT00408499|9645881|FG003|Phase II- MTD Expansion|Physician Decision|0
6046855|NCT00408499|9645882|FG004|Phase II- MTD Expansion|Physician Decision|1
6046856|NCT00408499|9645878|FG000|Phase II- MTD Expansion|Withdrawal by Subject|0
6046857|NCT00408499|9645879|FG001|Phase II- MTD Expansion|Withdrawal by Subject|0
6046858|NCT00408499|9645880|FG002|Phase II- MTD Expansion|Withdrawal by Subject|0
6046859|NCT00408499|9645881|FG003|Phase II- MTD Expansion|Withdrawal by Subject|0
6046860|NCT00408499|9645882|FG004|Phase II- MTD Expansion|Withdrawal by Subject|5
6046861|NCT00408499|9645878|FG000|Phase II- MTD Expansion|treatment delay|0
6046862|NCT00408499|9645879|FG001|Phase II- MTD Expansion|treatment delay|0
6046863|NCT00408499|9645880|FG002|Phase II- MTD Expansion|treatment delay|0
6046864|NCT00408499|9645881|FG003|Phase II- MTD Expansion|treatment delay|0
6046865|NCT00408499|9645882|FG004|Phase II- MTD Expansion|treatment delay|3
6046866|NCT00408629|9645938|FG000|Overall Study|Adverse Event|13
6046867|NCT00408629|9645939|FG001|Overall Study|Adverse Event|27
6046868|NCT00408629|9645938|FG000|Overall Study|Withdrawal by Subject|8
6046869|NCT00408629|9645939|FG001|Overall Study|Withdrawal by Subject|4
6046870|NCT00408629|9645938|FG000|Overall Study|Lost to Follow-up|1
6046871|NCT00408629|9645939|FG001|Overall Study|Lost to Follow-up|1
6046872|NCT00408629|9645938|FG000|Overall Study|Lack of Efficacy|63
6046873|NCT00408629|9645939|FG001|Overall Study|Lack of Efficacy|73
6046874|NCT00408629|9645938|FG000|Overall Study|Protocol Violation|1
6046875|NCT00408629|9645939|FG001|Overall Study|Protocol Violation|5
6046876|NCT00408629|9645938|FG000|Overall Study|Miscellaneous|11
6046877|NCT00408629|9645939|FG001|Overall Study|Miscellaneous|15
6046878|NCT00408681|9645946|FG000|Overall Study|Lack of Efficacy|2
6046879|NCT00408681|9645946|FG000|Overall Study|Adverse Event|7
5996307|NCT02411448|9590019|FG000|Overall Study|Withdrawal by Subject|1
5996308|NCT02411448|9590020|FG001|Overall Study|Withdrawal by Subject|14
5996309|NCT02411448|9590021|FG002|Overall Study|Withdrawal by Subject|9
5996310|NCT02411448|9590019|FG000|Overall Study|Other|0
5996311|NCT02411448|9590020|FG001|Overall Study|Other|2
5996312|NCT02411448|9590021|FG002|Overall Study|Other|0
5996313|NCT02411448|9590019|FG000|Overall Study|Did not receive study treatment|0
5996314|NCT02411448|9590020|FG001|Overall Study|Did not receive study treatment|3
5996315|NCT02411448|9590021|FG002|Overall Study|Did not receive study treatment|0
5996316|NCT02411448|9590019|FG000|Overall Study|Alive on study treatment|3
5996317|NCT02411448|9590020|FG001|Overall Study|Alive on study treatment|64
5996318|NCT02411448|9590021|FG002|Overall Study|Alive on study treatment|43
5996319|NCT02371369|9590035|FG000|Part 1|Physician Decision|0
5996320|NCT02371369|9590036|FG001|Part 1|Physician Decision|3
5996321|NCT02371369|9590035|FG000|Part 1|Adverse Event|8
5996322|NCT02371369|9590036|FG001|Part 1|Adverse Event|0
5996323|NCT02371369|9590035|FG000|Part 1|Withdrawal by Subject|1
5996324|NCT02371369|9590036|FG001|Part 1|Withdrawal by Subject|6
5996325|NCT02371369|9590035|FG000|Part 1|Disease progression|0
5996326|NCT02371369|9590036|FG001|Part 1|Disease progression|1
5996327|NCT02371369|9590035|FG000|Part 1|Protocol Violation|0
5996328|NCT02371369|9590036|FG001|Part 1|Protocol Violation|1
5996329|NCT02371369|9590035|FG000|Part 2|Adverse Event|6
5996330|NCT02371369|9590036|FG001|Part 2|Adverse Event|5
5996331|NCT02371369|9590035|FG000|Part 2|Withdrawal by Subject|16
5996332|NCT02371369|9590036|FG001|Part 2|Withdrawal by Subject|6
5996333|NCT02371369|9590035|FG000|Part 2|Investigator decision|1
5996334|NCT02371369|9590036|FG001|Part 2|Investigator decision|2
5996335|NCT02371369|9590035|FG000|Part 2|Death|0
5996336|NCT02371369|9590036|FG001|Part 2|Death|1
5996337|NCT02371369|9590035|FG000|Part 2|Disease progression|1
5996338|NCT02371369|9590036|FG001|Part 2|Disease progression|0
5996339|NCT02371369|9590035|FG000|Part 2|Subject Noncompliance|1
5996340|NCT02371369|9590036|FG001|Part 2|Subject Noncompliance|0
5996341|NCT02371369|9590035|FG000|Part 2|Lost to Follow-up|1
5996342|NCT02371369|9590036|FG001|Part 2|Lost to Follow-up|1
5996343|NCT02371369|9590035|FG000|Part 2|Subject transitioned to commercial supply|6
5996344|NCT02371369|9590036|FG001|Part 2|Subject transitioned to commercial supply|4
5996345|NCT02371369|9590035|FG000|Part 2|Subject transitioned to another DS pexidartinib protocol|15
5996346|NCT02371369|9590036|FG001|Part 2|Subject transitioned to another DS pexidartinib protocol|9
5996347|NCT02371369|9590035|FG000|Part 2|Surgical resection of tumor|1
5996348|NCT02371369|9590036|FG001|Part 2|Surgical resection of tumor|1
5996349|NCT02371369|9590035|FG000|Part 2|Other|0
5996350|NCT02371369|9590036|FG001|Part 2|Other|1
5996351|NCT02282917|9590058|FG000|Overall Study|Withdrawal by Subject|1
5996352|NCT02282917|9590058|FG000|Overall Study|Screen Failure/Not Eligible|1
5996353|NCT01849783|9590062|FG000|Overall Study|Adverse Event|5
5996354|NCT01849783|9590062|FG000|Overall Study|Death|2
5996355|NCT01849783|9590062|FG000|Overall Study|Physician Decision|1
5996356|NCT01849783|9590062|FG000|Overall Study|Withdrawal by Subject|1
5996357|NCT01849783|9590062|FG000|Overall Study|Unable to comply|2
5996358|NCT01849783|9590062|FG000|Overall Study|Disease progression|11
5996359|NCT01737021|9590083|FG000|Overall Study|Lost to Follow-up|5
5996360|NCT01737021|9590084|FG001|Overall Study|Lost to Follow-up|3
5996361|NCT01333943|9590101|FG000|Overall Study|Known neuropathy|1
5996362|NCT01333943|9590102|FG001|Overall Study|Known neuropathy|0
5996363|NCT01090024|9590117|FG000|Period 1|Met exclusion criteria|0
5996364|NCT01090024|9590118|FG001|Period 1|Met exclusion criteria|0
5996365|NCT01090024|9590119|FG002|Period 1|Met exclusion criteria|0
5996366|NCT01090024|9590120|FG003|Period 1|Met exclusion criteria|0
5996367|NCT01090024|9590121|FG004|Period 1|Met exclusion criteria|0
5996368|NCT01090024|9590122|FG005|Period 1|Met exclusion criteria|0
5996369|NCT01090024|9590123|FG006|Period 1|Met exclusion criteria|0
5996370|NCT01090024|9590124|FG007|Period 1|Met exclusion criteria|0
5996371|NCT01090024|9590125|FG008|Period 1|Met exclusion criteria|0
5996372|NCT01090024|9590126|FG009|Period 1|Met exclusion criteria|0
5996373|NCT01090024|9590127|FG010|Period 1|Met exclusion criteria|0
5996374|NCT01090024|9590128|FG011|Period 1|Met exclusion criteria|0
5996375|NCT01090024|9590129|FG012|Period 1|Met exclusion criteria|0
5996376|NCT01090024|9590130|FG013|Period 1|Met exclusion criteria|0
5996377|NCT01090024|9590131|FG014|Period 1|Met exclusion criteria|1
5996378|NCT01090024|9590132|FG015|Period 1|Met exclusion criteria|0
5996379|NCT01090024|9590133|FG016|Period 1|Met exclusion criteria|0
5996380|NCT01090024|9590134|FG017|Period 1|Met exclusion criteria|0
5996381|NCT01090024|9590117|FG000|Period 1|Adverse Event|0
5996382|NCT01090024|9590118|FG001|Period 1|Adverse Event|0
5996383|NCT01090024|9590119|FG002|Period 1|Adverse Event|0
5996384|NCT01090024|9590120|FG003|Period 1|Adverse Event|0
5996385|NCT01090024|9590121|FG004|Period 1|Adverse Event|0
5996386|NCT01090024|9590122|FG005|Period 1|Adverse Event|0
5996387|NCT01090024|9590123|FG006|Period 1|Adverse Event|0
5996388|NCT01090024|9590124|FG007|Period 1|Adverse Event|0
5996389|NCT01090024|9590125|FG008|Period 1|Adverse Event|0
5996390|NCT01090024|9590126|FG009|Period 1|Adverse Event|1
5996391|NCT01090024|9590127|FG010|Period 1|Adverse Event|0
5996392|NCT01090024|9590128|FG011|Period 1|Adverse Event|1
5996393|NCT01090024|9590129|FG012|Period 1|Adverse Event|0
5996394|NCT01090024|9590130|FG013|Period 1|Adverse Event|0
5996395|NCT01090024|9590131|FG014|Period 1|Adverse Event|0
6070838|NCT00551759|9673679|FG000|Overall Study|Adverse Event|7
6070839|NCT00551759|9673679|FG000|Overall Study|Death|5
6070840|NCT00551759|9673679|FG000|Overall Study|Ineligible|1
6070841|NCT00552058|9673685|FG000|Overall Study|Adverse Event|8
6070842|NCT00552058|9673686|FG001|Overall Study|Adverse Event|7
6070843|NCT00552058|9673685|FG000|Overall Study|Lack of Efficacy|1
5996396|NCT01090024|9590132|FG015|Period 1|Adverse Event|0
5996397|NCT01090024|9590133|FG016|Period 1|Adverse Event|0
5996398|NCT01090024|9590134|FG017|Period 1|Adverse Event|1
5996399|NCT01090024|9590117|FG000|Period 1|Withdrawal by Subject|0
5996400|NCT01090024|9590118|FG001|Period 1|Withdrawal by Subject|0
5996401|NCT01090024|9590119|FG002|Period 1|Withdrawal by Subject|0
5996402|NCT01090024|9590120|FG003|Period 1|Withdrawal by Subject|1
5996403|NCT01090024|9590121|FG004|Period 1|Withdrawal by Subject|0
5996404|NCT01090024|9590122|FG005|Period 1|Withdrawal by Subject|0
5996405|NCT01090024|9590123|FG006|Period 1|Withdrawal by Subject|0
5996406|NCT01090024|9590124|FG007|Period 1|Withdrawal by Subject|0
5996407|NCT01090024|9590125|FG008|Period 1|Withdrawal by Subject|0
5996408|NCT01090024|9590126|FG009|Period 1|Withdrawal by Subject|0
5996409|NCT01090024|9590127|FG010|Period 1|Withdrawal by Subject|0
5996410|NCT01090024|9590128|FG011|Period 1|Withdrawal by Subject|0
5996411|NCT01090024|9590129|FG012|Period 1|Withdrawal by Subject|0
5996412|NCT01090024|9590130|FG013|Period 1|Withdrawal by Subject|0
5996413|NCT01090024|9590131|FG014|Period 1|Withdrawal by Subject|0
5996414|NCT01090024|9590132|FG015|Period 1|Withdrawal by Subject|0
5996415|NCT01090024|9590133|FG016|Period 1|Withdrawal by Subject|0
5996416|NCT01090024|9590134|FG017|Period 1|Withdrawal by Subject|0
6070844|NCT00552058|9673686|FG001|Overall Study|Lack of Efficacy|5
6070845|NCT00552058|9673685|FG000|Overall Study|Lost to Follow-up|1
6070846|NCT00552058|9673686|FG001|Overall Study|Lost to Follow-up|0
6070847|NCT00552058|9673685|FG000|Overall Study|Withdrawal by Subject|4
6070848|NCT00552058|9673686|FG001|Overall Study|Withdrawal by Subject|4
6070849|NCT00552058|9673685|FG000|Overall Study|Other: Protocol Violation|0
6070850|NCT00552058|9673686|FG001|Overall Study|Other: Protocol Violation|1
6070851|NCT00552058|9673685|FG000|Overall Study|Other: Non Compliance|1
6070852|NCT00552058|9673686|FG001|Overall Study|Other: Non Compliance|2
6070853|NCT00552058|9673685|FG000|Overall Study|Other: Crossed Over to a Follow-up Study|0
6070854|NCT00552058|9673686|FG001|Overall Study|Other: Crossed Over to a Follow-up Study|1
6070855|NCT00552058|9673685|FG000|Overall Study|Other: Low CDAI score, entry violation|0
6070856|NCT00552058|9673686|FG001|Overall Study|Other: Low CDAI score, entry violation|1
6070857|NCT00552058|9673685|FG000|Overall Study|Other: Positive Stool Result|0
6070858|NCT00552058|9673686|FG001|Overall Study|Other: Positive Stool Result|1
6070859|NCT00552058|9673685|FG000|Overall Study|Other: Randomized in error|0
6070860|NCT00552058|9673686|FG001|Overall Study|Other: Randomized in error|1
6070861|NCT00552058|9673685|FG000|Overall Study|Other: Sponsors Decision|0
6070862|NCT00552058|9673686|FG001|Overall Study|Other: Sponsors Decision|1
6070863|NCT00552058|9673685|FG000|Overall Study|Other: Early Roll Over|1
6070864|NCT00552058|9673686|FG001|Overall Study|Other: Early Roll Over|0
6070865|NCT00552071|9673694|FG000|Overall Study|Adverse Event|1
6070866|NCT00552071|9673695|FG001|Overall Study|Adverse Event|0
6070867|NCT00552071|9673694|FG000|Overall Study|Lack of Efficacy|1
6070868|NCT00552071|9673695|FG001|Overall Study|Lack of Efficacy|0
6070869|NCT00552071|9673694|FG000|Overall Study|Physician Decision|1
6070870|NCT00552071|9673695|FG001|Overall Study|Physician Decision|0
6070871|NCT00552071|9673694|FG000|Overall Study|Pregnancy|1
6070872|NCT00552071|9673695|FG001|Overall Study|Pregnancy|0
6070873|NCT00552071|9673694|FG000|Overall Study|Death|0
6070874|NCT00552071|9673695|FG001|Overall Study|Death|1
6070875|NCT00552071|9673694|FG000|Overall Study|Withdrawal by Subject|0
6070876|NCT00552071|9673695|FG001|Overall Study|Withdrawal by Subject|1
6070877|NCT00552084|9673705|FG000|Overall Study|Adverse Event|2
6070878|NCT00552084|9673706|FG001|Overall Study|Adverse Event|3
6070879|NCT00552084|9673705|FG000|Overall Study|Withdrawal by Subject|4
6070880|NCT00552084|9673706|FG001|Overall Study|Withdrawal by Subject|5
6070881|NCT00552084|9673705|FG000|Overall Study|Protocol Violation|1
6070882|NCT00552084|9673706|FG001|Overall Study|Protocol Violation|0
6070883|NCT00552084|9673705|FG000|Overall Study|change in anti-arrythmic drug|1
6070884|NCT00552084|9673706|FG001|Overall Study|change in anti-arrythmic drug|1
6070885|NCT00552110|9673717|FG000|Overall Study|Serious or Life-Threatening AE|0
6070886|NCT00552110|9673718|FG001|Overall Study|Serious or Life-Threatening AE|0
5996417|NCT01090024|9590117|FG000|Period 1|Lost to Follow-up|0
5996418|NCT01090024|9590118|FG001|Period 1|Lost to Follow-up|1
5996419|NCT01090024|9590119|FG002|Period 1|Lost to Follow-up|0
5996420|NCT01090024|9590120|FG003|Period 1|Lost to Follow-up|0
5996421|NCT01090024|9590121|FG004|Period 1|Lost to Follow-up|0
5996422|NCT01090024|9590122|FG005|Period 1|Lost to Follow-up|0
5996423|NCT01090024|9590123|FG006|Period 1|Lost to Follow-up|0
5996424|NCT01090024|9590124|FG007|Period 1|Lost to Follow-up|0
5996425|NCT01090024|9590125|FG008|Period 1|Lost to Follow-up|0
5996426|NCT01090024|9590126|FG009|Period 1|Lost to Follow-up|0
5996427|NCT01090024|9590127|FG010|Period 1|Lost to Follow-up|0
6070887|NCT00552110|9673719|FG002|Overall Study|Serious or Life-Threatening AE|1
6070888|NCT00552110|9673720|FG003|Overall Study|Serious or Life-Threatening AE|0
6070889|NCT00552110|9673721|FG004|Overall Study|Serious or Life-Threatening AE|0
6070890|NCT00552110|9673717|FG000|Overall Study|Lack of Efficacy|1
5996428|NCT01090024|9590128|FG011|Period 1|Lost to Follow-up|0
5996429|NCT01090024|9590129|FG012|Period 1|Lost to Follow-up|0
5996430|NCT01090024|9590130|FG013|Period 1|Lost to Follow-up|0
5996431|NCT01090024|9590131|FG014|Period 1|Lost to Follow-up|0
5996432|NCT01090024|9590132|FG015|Period 1|Lost to Follow-up|0
5996433|NCT01090024|9590133|FG016|Period 1|Lost to Follow-up|0
5996434|NCT01090024|9590134|FG017|Period 1|Lost to Follow-up|0
5996435|NCT01090024|9590117|FG000|Period 2|Lost to Follow-up|0
5996436|NCT01090024|9590118|FG001|Period 2|Lost to Follow-up|0
5996437|NCT01090024|9590119|FG002|Period 2|Lost to Follow-up|0
5996438|NCT01090024|9590120|FG003|Period 2|Lost to Follow-up|1
5996439|NCT01090024|9590121|FG004|Period 2|Lost to Follow-up|0
5996440|NCT01090024|9590122|FG005|Period 2|Lost to Follow-up|0
5996441|NCT01090024|9590123|FG006|Period 2|Lost to Follow-up|0
5996442|NCT01090024|9590124|FG007|Period 2|Lost to Follow-up|0
5996443|NCT01090024|9590125|FG008|Period 2|Lost to Follow-up|0
5996444|NCT01090024|9590126|FG009|Period 2|Lost to Follow-up|0
5996445|NCT01090024|9590127|FG010|Period 2|Lost to Follow-up|0
5996446|NCT01090024|9590128|FG011|Period 2|Lost to Follow-up|0
5996447|NCT01090024|9590129|FG012|Period 2|Lost to Follow-up|0
5996448|NCT01090024|9590130|FG013|Period 2|Lost to Follow-up|0
5996449|NCT01090024|9590131|FG014|Period 2|Lost to Follow-up|0
5996450|NCT01090024|9590132|FG015|Period 2|Lost to Follow-up|0
5996451|NCT01090024|9590133|FG016|Period 2|Lost to Follow-up|0
5996452|NCT01090024|9590134|FG017|Period 2|Lost to Follow-up|0
6070891|NCT00552110|9673718|FG001|Overall Study|Lack of Efficacy|0
6070892|NCT00552110|9673719|FG002|Overall Study|Lack of Efficacy|0
6070893|NCT00552110|9673720|FG003|Overall Study|Lack of Efficacy|1
6070894|NCT00552110|9673721|FG004|Overall Study|Lack of Efficacy|4
6070895|NCT00552110|9673717|FG000|Overall Study|Withdrawal by Subject|0
6070896|NCT00552110|9673718|FG001|Overall Study|Withdrawal by Subject|2
6070897|NCT00552110|9673719|FG002|Overall Study|Withdrawal by Subject|0
6070898|NCT00552110|9673720|FG003|Overall Study|Withdrawal by Subject|3
6070899|NCT00552110|9673721|FG004|Overall Study|Withdrawal by Subject|2
6070900|NCT00552110|9673717|FG000|Overall Study|Lost to Follow-up|0
6070901|NCT00552110|9673718|FG001|Overall Study|Lost to Follow-up|0
6070902|NCT00552110|9673719|FG002|Overall Study|Lost to Follow-up|0
6070903|NCT00552110|9673720|FG003|Overall Study|Lost to Follow-up|1
6070904|NCT00552110|9673721|FG004|Overall Study|Lost to Follow-up|1
6070905|NCT00552110|9673717|FG000|Overall Study|Failed to Comply With Study Requirements|1
6070906|NCT00552110|9673718|FG001|Overall Study|Failed to Comply With Study Requirements|1
6070907|NCT00552110|9673719|FG002|Overall Study|Failed to Comply With Study Requirements|1
6070908|NCT00552110|9673720|FG003|Overall Study|Failed to Comply With Study Requirements|0
6070909|NCT00552110|9673721|FG004|Overall Study|Failed to Comply With Study Requirements|1
6070910|NCT00552110|9673717|FG000|Overall Study|Withdrawn per Sponsor|0
6070911|NCT00552110|9673718|FG001|Overall Study|Withdrawn per Sponsor|1
6070912|NCT00552110|9673719|FG002|Overall Study|Withdrawn per Sponsor|0
6070913|NCT00552110|9673720|FG003|Overall Study|Withdrawn per Sponsor|0
6070914|NCT00552110|9673721|FG004|Overall Study|Withdrawn per Sponsor|1
6070915|NCT00552110|9673717|FG000|Overall Study|Use of Prohibited Medication|1
6070916|NCT00552110|9673718|FG001|Overall Study|Use of Prohibited Medication|1
6070917|NCT00552110|9673719|FG002|Overall Study|Use of Prohibited Medication|0
6070918|NCT00552110|9673720|FG003|Overall Study|Use of Prohibited Medication|0
6070919|NCT00552110|9673721|FG004|Overall Study|Use of Prohibited Medication|0
6070920|NCT00552110|9673717|FG000|Overall Study|Delay of Study due to Relabeling|0
6070921|NCT00552110|9673718|FG001|Overall Study|Delay of Study due to Relabeling|0
6070922|NCT00552110|9673719|FG002|Overall Study|Delay of Study due to Relabeling|0
6070923|NCT00552110|9673720|FG003|Overall Study|Delay of Study due to Relabeling|1
6070924|NCT00552110|9673721|FG004|Overall Study|Delay of Study due to Relabeling|0
6070925|NCT00552110|9673717|FG000|Overall Study|Increased Blood Pressure at Visit 2|0
6070926|NCT00552110|9673718|FG001|Overall Study|Increased Blood Pressure at Visit 2|0
6070927|NCT00552110|9673719|FG002|Overall Study|Increased Blood Pressure at Visit 2|0
6070928|NCT00552110|9673720|FG003|Overall Study|Increased Blood Pressure at Visit 2|1
6070929|NCT00552110|9673721|FG004|Overall Study|Increased Blood Pressure at Visit 2|0
6070930|NCT00552110|9673717|FG000|Overall Study|Nonserious Adverse Event (AE)|1
6070931|NCT00552110|9673718|FG001|Overall Study|Nonserious Adverse Event (AE)|0
6070932|NCT00552110|9673719|FG002|Overall Study|Nonserious Adverse Event (AE)|0
6070933|NCT00552110|9673720|FG003|Overall Study|Nonserious Adverse Event (AE)|1
6070934|NCT00552110|9673721|FG004|Overall Study|Nonserious Adverse Event (AE)|0
5996453|NCT01090024|9590117|FG000|Period 2|Adverse Event|1
5996454|NCT01090024|9590118|FG001|Period 2|Adverse Event|0
5996455|NCT01090024|9590119|FG002|Period 2|Adverse Event|0
5996456|NCT01090024|9590120|FG003|Period 2|Adverse Event|0
5996457|NCT01090024|9590121|FG004|Period 2|Adverse Event|0
5996458|NCT01090024|9590122|FG005|Period 2|Adverse Event|0
5996459|NCT01090024|9590123|FG006|Period 2|Adverse Event|0
5996460|NCT01090024|9590124|FG007|Period 2|Adverse Event|0
5996461|NCT01090024|9590125|FG008|Period 2|Adverse Event|0
5996462|NCT01090024|9590126|FG009|Period 2|Adverse Event|0
5996463|NCT01090024|9590127|FG010|Period 2|Adverse Event|0
6070935|NCT00552175|9673736|FG000|Overall Study|Lack of Efficacy|2
6070936|NCT00552175|9673737|FG001|Overall Study|Lack of Efficacy|0
6070937|NCT00552175|9673738|FG002|Overall Study|Lack of Efficacy|1
5996464|NCT01090024|9590128|FG011|Period 2|Adverse Event|0
5996465|NCT01090024|9590129|FG012|Period 2|Adverse Event|0
6070938|NCT00552175|9673736|FG000|Overall Study|Adverse Event|9
6070939|NCT00552175|9673737|FG001|Overall Study|Adverse Event|9
6070940|NCT00552175|9673738|FG002|Overall Study|Adverse Event|10
6070941|NCT00552175|9673736|FG000|Overall Study|Withdrawal by Subject|2
6070942|NCT00552175|9673737|FG001|Overall Study|Withdrawal by Subject|2
6070943|NCT00552175|9673738|FG002|Overall Study|Withdrawal by Subject|1
5996466|NCT01090024|9590130|FG013|Period 2|Adverse Event|0
5996467|NCT01090024|9590131|FG014|Period 2|Adverse Event|0
5996468|NCT01090024|9590132|FG015|Period 2|Adverse Event|0
5996469|NCT01090024|9590133|FG016|Period 2|Adverse Event|0
5996470|NCT01090024|9590134|FG017|Period 2|Adverse Event|0
5996471|NCT01090024|9590117|FG000|Period 3|Withdrawal by Subject|0
5996472|NCT01090024|9590118|FG001|Period 3|Withdrawal by Subject|0
5996473|NCT01090024|9590119|FG002|Period 3|Withdrawal by Subject|0
5996474|NCT01090024|9590120|FG003|Period 3|Withdrawal by Subject|0
5996475|NCT01090024|9590121|FG004|Period 3|Withdrawal by Subject|0
5996476|NCT01090024|9590122|FG005|Period 3|Withdrawal by Subject|0
5996477|NCT01090024|9590123|FG006|Period 3|Withdrawal by Subject|0
6070944|NCT00552175|9673736|FG000|Overall Study|Lost to Follow-up|0
6070945|NCT00552175|9673737|FG001|Overall Study|Lost to Follow-up|0
6070946|NCT00552175|9673738|FG002|Overall Study|Lost to Follow-up|1
6070947|NCT00552175|9673736|FG000|Overall Study|Entry Criteria Not Met|1
6070948|NCT00552175|9673737|FG001|Overall Study|Entry Criteria Not Met|1
6070949|NCT00552175|9673738|FG002|Overall Study|Entry Criteria Not Met|0
6070950|NCT00552175|9673736|FG000|Overall Study|Reason Not Specified|3
6070951|NCT00552175|9673737|FG001|Overall Study|Reason Not Specified|1
6070952|NCT00552175|9673738|FG002|Overall Study|Reason Not Specified|1
6070953|NCT00552188|9673749|FG000|Overall Study|Adverse Event|0
6070954|NCT00552188|9673750|FG001|Overall Study|Adverse Event|2
6070955|NCT00552188|9673749|FG000|Overall Study|Lost to Follow-up|2
6070956|NCT00552188|9673750|FG001|Overall Study|Lost to Follow-up|1
5996478|NCT01090024|9590124|FG007|Period 3|Withdrawal by Subject|0
5996479|NCT01090024|9590125|FG008|Period 3|Withdrawal by Subject|0
5996480|NCT01090024|9590126|FG009|Period 3|Withdrawal by Subject|0
5996481|NCT01090024|9590127|FG010|Period 3|Withdrawal by Subject|0
5996482|NCT01090024|9590128|FG011|Period 3|Withdrawal by Subject|0
6070957|NCT00552188|9673749|FG000|Overall Study|Withdrawal of consent|0
6070958|NCT00552188|9673750|FG001|Overall Study|Withdrawal of consent|1
6070959|NCT00552188|9673749|FG000|Overall Study|Subject returned to home country|0
6070960|NCT00552188|9673750|FG001|Overall Study|Subject returned to home country|1
6070961|NCT00552240|9673758|FG000|Overall Study|Adverse Event|9
6070962|NCT00552240|9673759|FG001|Overall Study|Adverse Event|9
6070963|NCT00552240|9673758|FG000|Overall Study|Protocol Violation|1
6070964|NCT00552240|9673759|FG001|Overall Study|Protocol Violation|1
5996483|NCT01090024|9590129|FG012|Period 3|Withdrawal by Subject|0
5996484|NCT01090024|9590130|FG013|Period 3|Withdrawal by Subject|0
5996485|NCT01090024|9590131|FG014|Period 3|Withdrawal by Subject|0
5996486|NCT01090024|9590132|FG015|Period 3|Withdrawal by Subject|1
5996487|NCT01090024|9590133|FG016|Period 3|Withdrawal by Subject|0
5996488|NCT01090024|9590134|FG017|Period 3|Withdrawal by Subject|0
5996489|NCT01090024|9590117|FG000|Period 3|Protocol Violation|0
5996490|NCT01090024|9590118|FG001|Period 3|Protocol Violation|0
5996491|NCT01090024|9590119|FG002|Period 3|Protocol Violation|0
5996492|NCT01090024|9590120|FG003|Period 3|Protocol Violation|0
5996493|NCT01090024|9590121|FG004|Period 3|Protocol Violation|0
5996494|NCT01090024|9590122|FG005|Period 3|Protocol Violation|0
5996495|NCT01090024|9590123|FG006|Period 3|Protocol Violation|0
5996496|NCT01090024|9590124|FG007|Period 3|Protocol Violation|0
5996497|NCT01090024|9590125|FG008|Period 3|Protocol Violation|1
5996498|NCT01090024|9590126|FG009|Period 3|Protocol Violation|0
5996499|NCT01090024|9590127|FG010|Period 3|Protocol Violation|0
5996500|NCT01090024|9590128|FG011|Period 3|Protocol Violation|0
5996501|NCT01090024|9590129|FG012|Period 3|Protocol Violation|0
5996502|NCT01090024|9590130|FG013|Period 3|Protocol Violation|0
5996503|NCT01090024|9590131|FG014|Period 3|Protocol Violation|0
5996504|NCT01090024|9590132|FG015|Period 3|Protocol Violation|0
5996505|NCT01090024|9590133|FG016|Period 3|Protocol Violation|0
5996506|NCT01090024|9590134|FG017|Period 3|Protocol Violation|0
5996507|NCT01090024|9590117|FG000|Period 3|Adverse Event|0
5996508|NCT01090024|9590118|FG001|Period 3|Adverse Event|0
5996509|NCT01090024|9590119|FG002|Period 3|Adverse Event|0
5996510|NCT01090024|9590120|FG003|Period 3|Adverse Event|0
5996511|NCT01090024|9590121|FG004|Period 3|Adverse Event|0
5996512|NCT01090024|9590122|FG005|Period 3|Adverse Event|1
5996513|NCT01090024|9590123|FG006|Period 3|Adverse Event|0
5996514|NCT01090024|9590124|FG007|Period 3|Adverse Event|0
6070965|NCT00552240|9673758|FG000|Overall Study|Lost to Follow-up|5
6070966|NCT00552240|9673759|FG001|Overall Study|Lost to Follow-up|6
6070967|NCT00552240|9673758|FG000|Overall Study|Withdrawal by Subject|2
6070968|NCT00552240|9673759|FG001|Overall Study|Withdrawal by Subject|2
6070969|NCT00552240|9673758|FG000|Overall Study|Lack of Efficacy|6
5996515|NCT01090024|9590125|FG008|Period 3|Adverse Event|0
5996516|NCT01090024|9590126|FG009|Period 3|Adverse Event|0
5996517|NCT01090024|9590127|FG010|Period 3|Adverse Event|0
5996518|NCT01090024|9590128|FG011|Period 3|Adverse Event|0
5996519|NCT01090024|9590129|FG012|Period 3|Adverse Event|0
5996520|NCT01090024|9590130|FG013|Period 3|Adverse Event|0
5996521|NCT01090024|9590131|FG014|Period 3|Adverse Event|0
5996522|NCT01090024|9590132|FG015|Period 3|Adverse Event|0
5996523|NCT01090024|9590133|FG016|Period 3|Adverse Event|0
5996524|NCT01090024|9590134|FG017|Period 3|Adverse Event|0
5996525|NCT00980538|9590144|FG000|Overall Study|Lost to Follow-up|20
5996526|NCT00980538|9590144|FG000|Overall Study|Sponsor's Decision|4
5996527|NCT00980538|9590144|FG000|Overall Study|Participant/Legal Representative Withdrew Consent/Assent|34
5996528|NCT00980538|9590144|FG000|Overall Study|Adverse Event/HIV-Related Event/Cutaneous Event/Rash|12
5996529|NCT00980538|9590144|FG000|Overall Study|Switch to Commercially Available Medication|25
5996530|NCT00980538|9590144|FG000|Overall Study|Participant Non-Compliant|9
5996531|NCT00980538|9590144|FG000|Overall Study|Investigator no Longer Thinks Participant Benefits from the ETR Treatment|9
5996532|NCT00980538|9590144|FG000|Overall Study|Participant Ineligible to Continue the Trial|6
5996533|NCT00980538|9590144|FG000|Overall Study|Other|60
5996534|NCT00980538|9590144|FG000|Overall Study|Other|1
5996535|NCT00943722|9590153|FG000|Base Study|Adverse Event|0
5996536|NCT00943722|9590154|FG001|Base Study|Adverse Event|0
5996537|NCT00943722|9590155|FG002|Base Study|Adverse Event|0
5996538|NCT00943722|9590156|FG003|Base Study|Adverse Event|1
5996539|NCT00943722|9590157|FG004|Base Study|Adverse Event|0
5996540|NCT00943722|9590158|FG005|Base Study|Adverse Event|0
5996541|NCT00943722|9590159|FG006|Base Study|Adverse Event|0
5996542|NCT00943722|9590153|FG000|Base Study|Lost to Follow-up|12
5996543|NCT00943722|9590154|FG001|Base Study|Lost to Follow-up|8
5996544|NCT00943722|9590155|FG002|Base Study|Lost to Follow-up|10
5996545|NCT00943722|9590156|FG003|Base Study|Lost to Follow-up|8
5996546|NCT00943722|9590157|FG004|Base Study|Lost to Follow-up|11
5996547|NCT00943722|9590158|FG005|Base Study|Lost to Follow-up|0
5996548|NCT00943722|9590159|FG006|Base Study|Lost to Follow-up|0
5996549|NCT00943722|9590153|FG000|Base Study|Physician Decision|1
5996550|NCT00943722|9590154|FG001|Base Study|Physician Decision|0
5996551|NCT00943722|9590155|FG002|Base Study|Physician Decision|0
5996552|NCT00943722|9590156|FG003|Base Study|Physician Decision|0
5996553|NCT00943722|9590157|FG004|Base Study|Physician Decision|1
5996554|NCT00943722|9590158|FG005|Base Study|Physician Decision|0
5996555|NCT00943722|9590159|FG006|Base Study|Physician Decision|0
5996556|NCT00943722|9590153|FG000|Base Study|Pregnancy|0
5996557|NCT00943722|9590154|FG001|Base Study|Pregnancy|0
5996558|NCT00943722|9590155|FG002|Base Study|Pregnancy|1
5996559|NCT00943722|9590156|FG003|Base Study|Pregnancy|0
5996560|NCT00943722|9590157|FG004|Base Study|Pregnancy|2
5996561|NCT00943722|9590158|FG005|Base Study|Pregnancy|0
5996562|NCT00943722|9590159|FG006|Base Study|Pregnancy|0
5996563|NCT00943722|9590153|FG000|Base Study|Protocol Violation|0
5996564|NCT00943722|9590154|FG001|Base Study|Protocol Violation|1
5996565|NCT00943722|9590155|FG002|Base Study|Protocol Violation|0
5996566|NCT00943722|9590156|FG003|Base Study|Protocol Violation|0
5996567|NCT00943722|9590157|FG004|Base Study|Protocol Violation|2
5996568|NCT00943722|9590158|FG005|Base Study|Protocol Violation|0
5996569|NCT00943722|9590159|FG006|Base Study|Protocol Violation|0
5996570|NCT00943722|9590153|FG000|Base Study|Withdrawal by Subject|12
5996571|NCT00943722|9590154|FG001|Base Study|Withdrawal by Subject|13
5996572|NCT00943722|9590155|FG002|Base Study|Withdrawal by Subject|2
5996573|NCT00943722|9590156|FG003|Base Study|Withdrawal by Subject|13
5996574|NCT00943722|9590157|FG004|Base Study|Withdrawal by Subject|8
5996575|NCT00943722|9590158|FG005|Base Study|Withdrawal by Subject|0
5996576|NCT00943722|9590159|FG006|Base Study|Withdrawal by Subject|0
5996577|NCT00943722|9590153|FG000|Base Study|Month 12 visit not completed|0
5996578|NCT00943722|9590154|FG001|Base Study|Month 12 visit not completed|0
5996579|NCT00943722|9590155|FG002|Base Study|Month 12 visit not completed|0
5996580|NCT00943722|9590156|FG003|Base Study|Month 12 visit not completed|0
5996581|NCT00943722|9590157|FG004|Base Study|Month 12 visit not completed|2
5996582|NCT00943722|9590158|FG005|Base Study|Month 12 visit not completed|0
5996583|NCT00943722|9590159|FG006|Base Study|Month 12 visit not completed|0
5996584|NCT00943722|9590153|FG000|First Extension Study: EXT 1|Adverse Event|0
5996585|NCT00943722|9590154|FG001|First Extension Study: EXT 1|Adverse Event|0
5996586|NCT00943722|9590155|FG002|First Extension Study: EXT 1|Adverse Event|0
5996587|NCT00943722|9590156|FG003|First Extension Study: EXT 1|Adverse Event|0
5996588|NCT00943722|9590157|FG004|First Extension Study: EXT 1|Adverse Event|0
5996589|NCT00943722|9590158|FG005|First Extension Study: EXT 1|Adverse Event|1
5996590|NCT00943722|9590159|FG006|First Extension Study: EXT 1|Adverse Event|0
5996591|NCT00943722|9590153|FG000|First Extension Study: EXT 1|Lost to Follow-up|0
5996592|NCT00943722|9590154|FG001|First Extension Study: EXT 1|Lost to Follow-up|0
5996593|NCT00943722|9590155|FG002|First Extension Study: EXT 1|Lost to Follow-up|0
5996594|NCT00943722|9590156|FG003|First Extension Study: EXT 1|Lost to Follow-up|0
5996595|NCT00943722|9590157|FG004|First Extension Study: EXT 1|Lost to Follow-up|0
5996596|NCT00943722|9590158|FG005|First Extension Study: EXT 1|Lost to Follow-up|38
5996597|NCT00943722|9590159|FG006|First Extension Study: EXT 1|Lost to Follow-up|10
5996598|NCT00943722|9590153|FG000|First Extension Study: EXT 1|Withdrawal by Subject|0
5996599|NCT00943722|9590154|FG001|First Extension Study: EXT 1|Withdrawal by Subject|0
5996600|NCT00943722|9590155|FG002|First Extension Study: EXT 1|Withdrawal by Subject|0
5996601|NCT00943722|9590156|FG003|First Extension Study: EXT 1|Withdrawal by Subject|0
5996602|NCT00943722|9590157|FG004|First Extension Study: EXT 1|Withdrawal by Subject|0
5996603|NCT00943722|9590158|FG005|First Extension Study: EXT 1|Withdrawal by Subject|32
5996604|NCT00943722|9590159|FG006|First Extension Study: EXT 1|Withdrawal by Subject|10
5996605|NCT00943722|9590153|FG000|First Extension Study: EXT 1|Disposition Unknown|0
5996606|NCT00943722|9590154|FG001|First Extension Study: EXT 1|Disposition Unknown|0
5996607|NCT00943722|9590155|FG002|First Extension Study: EXT 1|Disposition Unknown|0
5996608|NCT00943722|9590156|FG003|First Extension Study: EXT 1|Disposition Unknown|0
5996609|NCT00943722|9590157|FG004|First Extension Study: EXT 1|Disposition Unknown|0
5996610|NCT00943722|9590158|FG005|First Extension Study: EXT 1|Disposition Unknown|44
5996611|NCT00943722|9590159|FG006|First Extension Study: EXT 1|Disposition Unknown|21
5996612|NCT00943722|9590153|FG000|Second Extension Study: EXT 2|Adverse Event|0
5996613|NCT00943722|9590154|FG001|Second Extension Study: EXT 2|Adverse Event|0
5996614|NCT00943722|9590155|FG002|Second Extension Study: EXT 2|Adverse Event|0
5996615|NCT00943722|9590156|FG003|Second Extension Study: EXT 2|Adverse Event|0
5996616|NCT00943722|9590157|FG004|Second Extension Study: EXT 2|Adverse Event|0
5996617|NCT00943722|9590158|FG005|Second Extension Study: EXT 2|Adverse Event|1
5996618|NCT00943722|9590159|FG006|Second Extension Study: EXT 2|Adverse Event|0
5996619|NCT00943722|9590153|FG000|Second Extension Study: EXT 2|Lost to Follow-up|0
5996620|NCT00943722|9590154|FG001|Second Extension Study: EXT 2|Lost to Follow-up|0
5996621|NCT00943722|9590155|FG002|Second Extension Study: EXT 2|Lost to Follow-up|0
5996622|NCT00943722|9590156|FG003|Second Extension Study: EXT 2|Lost to Follow-up|0
5996623|NCT00943722|9590157|FG004|Second Extension Study: EXT 2|Lost to Follow-up|0
5996624|NCT00943722|9590158|FG005|Second Extension Study: EXT 2|Lost to Follow-up|111
5996625|NCT00943722|9590159|FG006|Second Extension Study: EXT 2|Lost to Follow-up|46
5996626|NCT00943722|9590153|FG000|Second Extension Study: EXT 2|Physician Decision|0
5996627|NCT00943722|9590154|FG001|Second Extension Study: EXT 2|Physician Decision|0
5996628|NCT00943722|9590155|FG002|Second Extension Study: EXT 2|Physician Decision|0
5996629|NCT00943722|9590156|FG003|Second Extension Study: EXT 2|Physician Decision|0
5996630|NCT00943722|9590157|FG004|Second Extension Study: EXT 2|Physician Decision|0
5996631|NCT00943722|9590158|FG005|Second Extension Study: EXT 2|Physician Decision|1
5996632|NCT00943722|9590159|FG006|Second Extension Study: EXT 2|Physician Decision|3
5996633|NCT00943722|9590153|FG000|Second Extension Study: EXT 2|Pregnancy|0
5996634|NCT00943722|9590154|FG001|Second Extension Study: EXT 2|Pregnancy|0
5996635|NCT00943722|9590155|FG002|Second Extension Study: EXT 2|Pregnancy|0
5996636|NCT00943722|9590156|FG003|Second Extension Study: EXT 2|Pregnancy|0
5996637|NCT00943722|9590157|FG004|Second Extension Study: EXT 2|Pregnancy|0
5996638|NCT00943722|9590158|FG005|Second Extension Study: EXT 2|Pregnancy|1
5996639|NCT00943722|9590159|FG006|Second Extension Study: EXT 2|Pregnancy|0
5996640|NCT00943722|9590153|FG000|Second Extension Study: EXT 2|Withdrawal by Subject|0
5996641|NCT00943722|9590154|FG001|Second Extension Study: EXT 2|Withdrawal by Subject|0
5996642|NCT00943722|9590155|FG002|Second Extension Study: EXT 2|Withdrawal by Subject|0
5996643|NCT00943722|9590156|FG003|Second Extension Study: EXT 2|Withdrawal by Subject|0
5996644|NCT00943722|9590157|FG004|Second Extension Study: EXT 2|Withdrawal by Subject|0
5996645|NCT00943722|9590158|FG005|Second Extension Study: EXT 2|Withdrawal by Subject|137
5996646|NCT00943722|9590159|FG006|Second Extension Study: EXT 2|Withdrawal by Subject|50
5996647|NCT00676663|9590184|FG000|Overall Study|Death|43
5996648|NCT00676663|9590185|FG001|Overall Study|Death|27
5996649|NCT00676663|9590184|FG000|Overall Study|Withdrew Consent|1
5996650|NCT00676663|9590185|FG001|Overall Study|Withdrew Consent|8
5996651|NCT00676663|9590184|FG000|Overall Study|Lost to Follow-up|1
5996652|NCT00676663|9590185|FG001|Overall Study|Lost to Follow-up|3
5996653|NCT00573131|9590195|FG000|Overall Study|Withdrawal by Subject|10
5996654|NCT00573131|9590196|FG001|Overall Study|Withdrawal by Subject|8
5996655|NCT00479765|9590202|FG000|Overall Study|study terminated|4
6046880|NCT00408694|9645951|FG000|Overall Study|Ineligible|1
6046881|NCT00408694|9645951|FG000|Overall Study|No protocol treatment|1
6070970|NCT00552240|9673759|FG001|Overall Study|Lack of Efficacy|0
6070971|NCT00552240|9673758|FG000|Overall Study|Other|1
6070972|NCT00552240|9673759|FG001|Overall Study|Other|0
6070973|NCT00552279|9673767|FG000|Overall Study|Adverse Event|0
6070974|NCT00552279|9673768|FG001|Overall Study|Adverse Event|1
6070975|NCT00552279|9673767|FG000|Overall Study|Withdrawal by Subject|12
6070976|NCT00552279|9673768|FG001|Overall Study|Withdrawal by Subject|1
6070977|NCT00552279|9673767|FG000|Overall Study|Lost to Follow-up|1
6070978|NCT00552279|9673768|FG001|Overall Study|Lost to Follow-up|0
6070979|NCT00552279|9673767|FG000|Overall Study|Other|1
6070980|NCT00552279|9673768|FG001|Overall Study|Other|1
6070981|NCT00552305|9673774|FG000|Overall Study|Adverse Event|43
6070982|NCT00552305|9673774|FG000|Overall Study|Lack of Efficacy|120
6070983|NCT00552305|9673774|FG000|Overall Study|Lost to Follow-up|4
6070984|NCT00552305|9673774|FG000|Overall Study|Protocol Violation|3
6070985|NCT00552305|9673774|FG000|Overall Study|Withdrawal by Subject|44
6070986|NCT00552305|9673774|FG000|Overall Study|Lack of efficacy/withdrew consent|1
6070987|NCT00552305|9673774|FG000|Overall Study|Lack of efficacy (LoE)/adverse event|3
6070988|NCT00552305|9673774|FG000|Overall Study|Adverse event (AE)/withdrew (WD) consent|2
6070989|NCT00552305|9673774|FG000|Overall Study|Unsatisfactory compliance|11
6070990|NCT00552305|9673774|FG000|Overall Study|Poor compliance/lost to follow-up|1
6046882|NCT00408876|9645959|FG000|Overall Study|Adverse Event|9
6046883|NCT00408876|9645960|FG001|Overall Study|Adverse Event|17
6046884|NCT00408876|9645961|FG002|Overall Study|Adverse Event|27
6070991|NCT00552305|9673774|FG000|Overall Study|AE/Other: prohibited drug required|1
6070992|NCT00552305|9673774|FG000|Overall Study|LoE/WD consent/Other: cannot make visits|1
6070993|NCT00552305|9673774|FG000|Overall Study|Other: Site closed|4
6070994|NCT00552305|9673774|FG000|Overall Study|Other: Personal problems|1
6070995|NCT00552305|9673774|FG000|Overall Study|Other: Unable to attend visits|1
6070996|NCT00552305|9673774|FG000|Overall Study|Other: Subject underwent surgery|4
6070997|NCT00552305|9673774|FG000|Overall Study|Other: Subject became pregnant|1
6070998|NCT00552305|9673774|FG000|Overall Study|Other: Health problems, not drug related|1
6070999|NCT00552305|9673774|FG000|Overall Study|Other: Subject moved from area|2
6071000|NCT00552305|9673774|FG000|Overall Study|Other: Subject incarcerated|1
6071001|NCT00552305|9673774|FG000|Overall Study|Other: Subject went to rehab|1
6071002|NCT00552344|9673778|FG000|Overall Study|Lack of Efficacy|55
6071003|NCT00552344|9673778|FG000|Overall Study|Loss of efficacy|75
6071004|NCT00552344|9673778|FG000|Overall Study|Lost to Follow-up|8
5996656|NCT04617860|9590219|FG000|Overall Study|Adverse Event|0
5996657|NCT04617860|9590220|FG001|Overall Study|Adverse Event|2
5996658|NCT04617860|9590221|FG002|Overall Study|Adverse Event|2
5996659|NCT04617860|9590219|FG000|Overall Study|Withdrawal by Subject|0
5996660|NCT04617860|9590220|FG001|Overall Study|Withdrawal by Subject|0
5996661|NCT04617860|9590221|FG002|Overall Study|Withdrawal by Subject|2
5996662|NCT04617860|9590219|FG000|Overall Study|Physician Decision|0
5996663|NCT04617860|9590220|FG001|Overall Study|Physician Decision|1
5996664|NCT04617860|9590221|FG002|Overall Study|Physician Decision|0
5996665|NCT04617860|9590219|FG000|Overall Study|Sponsor Decision|0
5996666|NCT04617860|9590220|FG001|Overall Study|Sponsor Decision|3
5996667|NCT04617860|9590221|FG002|Overall Study|Sponsor Decision|1
5996668|NCT04617860|9590219|FG000|Overall Study|Termination of Study by Sponsor|8
5996669|NCT04617860|9590220|FG001|Overall Study|Termination of Study by Sponsor|4
5996670|NCT04617860|9590221|FG002|Overall Study|Termination of Study by Sponsor|13
5996671|NCT04617847|9590233|FG000|Overall Study|Withdrawal by Subject|1
5996672|NCT04617847|9590234|FG001|Overall Study|Withdrawal by Subject|0
5996673|NCT04617847|9590233|FG000|Overall Study|Adverse Event|0
5996674|NCT04617847|9590234|FG001|Overall Study|Adverse Event|2
5996675|NCT04617847|9590233|FG000|Overall Study|Death|0
5996676|NCT04617847|9590234|FG001|Overall Study|Death|1
5996677|NCT04617847|9590233|FG000|Overall Study|Termination of Study by Sponsor|2
5996678|NCT04617847|9590234|FG001|Overall Study|Termination of Study by Sponsor|21
6046885|NCT00408876|9645962|FG003|Overall Study|Adverse Event|10
6046886|NCT00408876|9645959|FG000|Overall Study|Withdrawal by Subject|3
6046887|NCT00408876|9645960|FG001|Overall Study|Withdrawal by Subject|6
6046888|NCT00408876|9645961|FG002|Overall Study|Withdrawal by Subject|6
6046889|NCT00408876|9645962|FG003|Overall Study|Withdrawal by Subject|14
6046890|NCT00408876|9645959|FG000|Overall Study|Lack of Efficacy|2
6046891|NCT00408876|9645960|FG001|Overall Study|Lack of Efficacy|4
6046892|NCT00408876|9645961|FG002|Overall Study|Lack of Efficacy|5
6046893|NCT00408876|9645962|FG003|Overall Study|Lack of Efficacy|6
6046894|NCT00408876|9645959|FG000|Overall Study|Lost to Follow-up|1
6046895|NCT00408876|9645960|FG001|Overall Study|Lost to Follow-up|6
6046896|NCT00408876|9645961|FG002|Overall Study|Lost to Follow-up|5
6046897|NCT00408876|9645962|FG003|Overall Study|Lost to Follow-up|2
6046898|NCT00408876|9645959|FG000|Overall Study|Protocol Violation|0
6046899|NCT00408876|9645960|FG001|Overall Study|Protocol Violation|3
6046900|NCT00408876|9645961|FG002|Overall Study|Protocol Violation|4
6046901|NCT00408876|9645962|FG003|Overall Study|Protocol Violation|3
6046902|NCT00408876|9645959|FG000|Overall Study|Physician Decision|1
6046903|NCT00408876|9645960|FG001|Overall Study|Physician Decision|0
6046904|NCT00408876|9645961|FG002|Overall Study|Physician Decision|3
6046905|NCT00408876|9645962|FG003|Overall Study|Physician Decision|0
6046906|NCT00408902|9645972|FG000|Overall Study|Lack of Efficacy|7
6046907|NCT00408902|9645972|FG000|Overall Study|Adverse Event|3
6046908|NCT00408928|9645977|FG000|Overall Study|Withdrawal by Subject|1
6046909|NCT00408928|9645977|FG000|Overall Study|Death|1
6046910|NCT00408928|9645977|FG000|Overall Study|Infection indistinguishable from GVHD|1
6046911|NCT00408993|9645983|FG000|Overall Study|Adverse Event|15
6046912|NCT00408993|9645984|FG001|Overall Study|Adverse Event|4
6046913|NCT00408993|9645983|FG000|Overall Study|Protocol Violation|1
6046914|NCT00408993|9645984|FG001|Overall Study|Protocol Violation|6
6046915|NCT00408993|9645983|FG000|Overall Study|Lack of Efficacy|1
6046916|NCT00408993|9645984|FG001|Overall Study|Lack of Efficacy|4
6046917|NCT00408993|9645983|FG000|Overall Study|Withdrawal by Subject|2
6046918|NCT00408993|9645984|FG001|Overall Study|Withdrawal by Subject|3
6046919|NCT00409006|9645996|FG000|Overall Study|Death|15
6046920|NCT00409006|9645997|FG001|Overall Study|Death|6
6046921|NCT00409006|9645996|FG000|Overall Study|Lost to Follow-up|1
6046922|NCT00409006|9645997|FG001|Overall Study|Lost to Follow-up|2
6046923|NCT00409006|9645996|FG000|Overall Study|Withdrawal by Subject|3
6046924|NCT00409006|9645997|FG001|Overall Study|Withdrawal by Subject|2
6046925|NCT00409006|9645996|FG000|Overall Study|Physician Decision|1
6046926|NCT00409006|9645997|FG001|Overall Study|Physician Decision|2
6046927|NCT00409175|9646005|FG000|Overall Study|Adverse Event|4
6046928|NCT00409175|9646006|FG001|Overall Study|Adverse Event|3
6046929|NCT00409175|9646005|FG000|Overall Study|Withdrawal by Subject|1
6046930|NCT00409175|9646006|FG001|Overall Study|Withdrawal by Subject|2
6046931|NCT00409175|9646005|FG000|Overall Study|Negative genotype|0
6071005|NCT00552344|9673778|FG000|Overall Study|Withdrawal by Subject|48
6071006|NCT00552344|9673778|FG000|Overall Study|SAE, non-fatal|6
6071007|NCT00552344|9673778|FG000|Overall Study|AE, non-serious non-fatal|38
6071008|NCT00552344|9673778|FG000|Overall Study|SAE,non-fatal+AE,non-serious non-fatal|62
6071009|NCT00552344|9673778|FG000|Overall Study|SAE, fatal + AE, non-serious non-fatal|1
6071010|NCT00552344|9673778|FG000|Overall Study|Other Reason|22
6071011|NCT00552396|9673790|FG000|Overall Study|protocol withdrawal criteria|3
6071012|NCT00552396|9673791|FG001|Overall Study|protocol withdrawal criteria|3
6071013|NCT00552396|9673792|FG002|Overall Study|protocol withdrawal criteria|3
6071014|NCT00552396|9673793|FG003|Overall Study|protocol withdrawal criteria|6
6071015|NCT00552396|9673794|FG004|Overall Study|protocol withdrawal criteria|3
6071016|NCT00552396|9673795|FG005|Overall Study|protocol withdrawal criteria|3
6071017|NCT00552396|9673796|FG006|Overall Study|protocol withdrawal criteria|9
6071018|NCT00552578|9673854|FG000|Overall Study|Lost to Follow-up|1
5996679|NCT04426318|9590244|FG000|Overall Study|failed attention checks and had their data removed from analyses|2
5996680|NCT04426318|9590245|FG001|Overall Study|failed attention checks and had their data removed from analyses|2
5996681|NCT04063657|9590257|FG000|Overall Study|Lost to Follow-up|1
5996682|NCT04063657|9590258|FG001|Overall Study|Lost to Follow-up|0
5996683|NCT03882047|9590271|FG000|Overall Study|Adverse Event|0
5996684|NCT03882047|9590272|FG001|Overall Study|Adverse Event|2
5996685|NCT03882047|9590273|FG002|Overall Study|Adverse Event|2
5996686|NCT03882047|9590271|FG000|Overall Study|Treatment Failure|3
5996687|NCT03882047|9590272|FG001|Overall Study|Treatment Failure|3
5996688|NCT03882047|9590273|FG002|Overall Study|Treatment Failure|12
5996689|NCT03882047|9590271|FG000|Overall Study|Lost to Follow-up|0
5996690|NCT03882047|9590272|FG001|Overall Study|Lost to Follow-up|1
5996691|NCT03882047|9590273|FG002|Overall Study|Lost to Follow-up|0
5996692|NCT03882047|9590271|FG000|Overall Study|Did Not Wish to Continue|1
5996693|NCT03882047|9590272|FG001|Overall Study|Did Not Wish to Continue|4
5996694|NCT03882047|9590273|FG002|Overall Study|Did Not Wish to Continue|1
5996695|NCT03882047|9590271|FG000|Overall Study|Noncompliance With Protocol|2
5996696|NCT03882047|9590272|FG001|Overall Study|Noncompliance With Protocol|0
5996697|NCT03882047|9590273|FG002|Overall Study|Noncompliance With Protocol|0
5996698|NCT03882047|9590271|FG000|Overall Study|Did Not Meet Eligibility|0
5996699|NCT03882047|9590272|FG001|Overall Study|Did Not Meet Eligibility|0
5996700|NCT03882047|9590273|FG002|Overall Study|Did Not Meet Eligibility|1
5996701|NCT03879772|9590286|FG000|Overall Study|Adverse Event|2
5996702|NCT03879772|9590287|FG001|Overall Study|Adverse Event|2
5996703|NCT03879772|9590288|FG002|Overall Study|Adverse Event|3
5996704|NCT03879772|9590289|FG003|Overall Study|Adverse Event|4
5996705|NCT03879772|9590290|FG004|Overall Study|Adverse Event|3
5996706|NCT03879772|9590286|FG000|Overall Study|Treatment Failure|1
5996707|NCT03879772|9590287|FG001|Overall Study|Treatment Failure|0
5996708|NCT03879772|9590288|FG002|Overall Study|Treatment Failure|0
5996709|NCT03879772|9590289|FG003|Overall Study|Treatment Failure|2
5996710|NCT03879772|9590290|FG004|Overall Study|Treatment Failure|1
5996711|NCT03879772|9590286|FG000|Overall Study|Lost to Follow-up|0
5996712|NCT03879772|9590287|FG001|Overall Study|Lost to Follow-up|0
5996713|NCT03879772|9590288|FG002|Overall Study|Lost to Follow-up|0
5996714|NCT03879772|9590289|FG003|Overall Study|Lost to Follow-up|0
5996715|NCT03879772|9590290|FG004|Overall Study|Lost to Follow-up|1
5996716|NCT03879772|9590286|FG000|Overall Study|Withdrawal by Subject|0
5996717|NCT03879772|9590287|FG001|Overall Study|Withdrawal by Subject|1
5996718|NCT03879772|9590288|FG002|Overall Study|Withdrawal by Subject|3
5996719|NCT03879772|9590289|FG003|Overall Study|Withdrawal by Subject|1
5996720|NCT03879772|9590290|FG004|Overall Study|Withdrawal by Subject|1
5996721|NCT03879772|9590286|FG000|Overall Study|Protocol Violation|0
5996722|NCT03879772|9590287|FG001|Overall Study|Protocol Violation|0
5996723|NCT03879772|9590288|FG002|Overall Study|Protocol Violation|3
5996724|NCT03879772|9590289|FG003|Overall Study|Protocol Violation|1
5996725|NCT03879772|9590290|FG004|Overall Study|Protocol Violation|2
5996726|NCT03879772|9590286|FG000|Overall Study|Did Not Meet Entry Requirements|1
5996727|NCT03879772|9590287|FG001|Overall Study|Did Not Meet Entry Requirements|0
5996728|NCT03879772|9590288|FG002|Overall Study|Did Not Meet Entry Requirements|1
5996729|NCT03879772|9590289|FG003|Overall Study|Did Not Meet Entry Requirements|0
5996730|NCT03879772|9590290|FG004|Overall Study|Did Not Meet Entry Requirements|0
5996731|NCT03861559|9590304|FG000|Overall Study|Adverse Event|0
5996732|NCT03861559|9590305|FG001|Overall Study|Adverse Event|2
5996733|NCT03861559|9590304|FG000|Overall Study|Treatment failure|0
5996734|NCT03861559|9590305|FG001|Overall Study|Treatment failure|2
6071019|NCT00552578|9673855|FG001|Overall Study|Lost to Follow-up|1
6071020|NCT00552617|9673871|FG000|Overall Study|Not Treated|0
6071021|NCT00552617|9673872|FG001|Overall Study|Not Treated|0
6071022|NCT00552617|9673873|FG002|Overall Study|Not Treated|1
5996735|NCT03861559|9590304|FG000|Overall Study|Noncompliance|1
5996736|NCT03861559|9590305|FG001|Overall Study|Noncompliance|1
5996737|NCT03861559|9590304|FG000|Overall Study|Did not meet eligibility requirements|1
5996738|NCT03861559|9590305|FG001|Overall Study|Did not meet eligibility requirements|0
5996739|NCT03855228|9590315|FG000|Overall Study|Adverse Event|2
5996740|NCT03855228|9590316|FG001|Overall Study|Adverse Event|4
5996741|NCT03855228|9590317|FG002|Overall Study|Adverse Event|4
5996742|NCT03855228|9590318|FG003|Overall Study|Adverse Event|8
6071023|NCT00552617|9673874|FG003|Overall Study|Not Treated|0
5996743|NCT03855228|9590315|FG000|Overall Study|Treatment Failure|1
5996744|NCT03855228|9590316|FG001|Overall Study|Treatment Failure|2
5996745|NCT03855228|9590317|FG002|Overall Study|Treatment Failure|1
5996746|NCT03855228|9590318|FG003|Overall Study|Treatment Failure|8
5996747|NCT03855228|9590315|FG000|Overall Study|Lost to Follow-up|0
5996748|NCT03855228|9590316|FG001|Overall Study|Lost to Follow-up|0
5996749|NCT03855228|9590317|FG002|Overall Study|Lost to Follow-up|0
5996750|NCT03855228|9590318|FG003|Overall Study|Lost to Follow-up|1
5996751|NCT03855228|9590315|FG000|Overall Study|Protocol Violation|0
5996752|NCT03855228|9590316|FG001|Overall Study|Protocol Violation|1
5996753|NCT03855228|9590317|FG002|Overall Study|Protocol Violation|2
5996754|NCT03855228|9590318|FG003|Overall Study|Protocol Violation|1
5996755|NCT03855228|9590315|FG000|Overall Study|Did Not Meet Entry Requirements|0
5996756|NCT03855228|9590316|FG001|Overall Study|Did Not Meet Entry Requirements|2
5996757|NCT03855228|9590317|FG002|Overall Study|Did Not Meet Entry Requirements|1
5996758|NCT03855228|9590318|FG003|Overall Study|Did Not Meet Entry Requirements|1
5996759|NCT03855189|9590331|FG000|Overall Study|Adverse Event|5
5996760|NCT03855189|9590332|FG001|Overall Study|Adverse Event|2
5996761|NCT03855189|9590333|FG002|Overall Study|Adverse Event|4
5996762|NCT03855189|9590331|FG000|Overall Study|Treatment Failure|1
5996763|NCT03855189|9590332|FG001|Overall Study|Treatment Failure|1
5996764|NCT03855189|9590333|FG002|Overall Study|Treatment Failure|2
5996765|NCT03855189|9590331|FG000|Overall Study|Noncompliance with Protocol|0
5996766|NCT03855189|9590332|FG001|Overall Study|Noncompliance with Protocol|1
5996767|NCT03855189|9590333|FG002|Overall Study|Noncompliance with Protocol|0
5996768|NCT03855189|9590331|FG000|Overall Study|Did Not Return|4
5996769|NCT03855189|9590332|FG001|Overall Study|Did Not Return|3
5996770|NCT03855189|9590333|FG002|Overall Study|Did Not Return|0
6046932|NCT00409175|9646006|FG001|Overall Study|Negative genotype|1
6046933|NCT00409175|9646005|FG000|Overall Study|Liver transplantation|13
6046934|NCT00409175|9646006|FG001|Overall Study|Liver transplantation|13
6046935|NCT00409188|9646014|FG000|Overall Study|Ongoing at data cut-off|383
6046936|NCT00409188|9646015|FG001|Overall Study|Ongoing at data cut-off|175
6046937|NCT00409409|9646038|FG000|Overall Study|Adverse Event|7
6071024|NCT00552617|9673875|FG004|Overall Study|Not Treated|0
6071025|NCT00552617|9673876|FG005|Overall Study|Not Treated|0
6071026|NCT00552617|9673877|FG006|Overall Study|Not Treated|0
6071027|NCT00552617|9673878|FG007|Overall Study|Not Treated|0
6071028|NCT00552617|9673879|FG008|Overall Study|Not Treated|0
6071029|NCT00552617|9673880|FG009|Overall Study|Not Treated|1
6071030|NCT00552617|9673871|FG000|Overall Study|Lost to Follow-up|0
6071031|NCT00552617|9673872|FG001|Overall Study|Lost to Follow-up|0
6046938|NCT00409409|9646039|FG001|Overall Study|Adverse Event|2
6046939|NCT00409409|9646038|FG000|Overall Study|Withdrawal by Subject|1
6046940|NCT00409409|9646039|FG001|Overall Study|Withdrawal by Subject|1
6046941|NCT00409409|9646038|FG000|Overall Study|Any other reason not above-mentioned|0
6046942|NCT00409409|9646039|FG001|Overall Study|Any other reason not above-mentioned|1
6046943|NCT00409578|9646074|FG000|Overall Study|Adverse Event|27
6046944|NCT00409578|9646075|FG001|Overall Study|Adverse Event|37
6046945|NCT00409578|9646076|FG002|Overall Study|Adverse Event|25
6046946|NCT00409578|9646077|FG003|Overall Study|Adverse Event|33
6046947|NCT00409578|9646074|FG000|Overall Study|Abnormal laboratory value(s)|2
6046948|NCT00409578|9646075|FG001|Overall Study|Abnormal laboratory value(s)|2
6046949|NCT00409578|9646076|FG002|Overall Study|Abnormal laboratory value(s)|2
6046950|NCT00409578|9646077|FG003|Overall Study|Abnormal laboratory value(s)|4
6046951|NCT00409578|9646074|FG000|Overall Study|Lack of Efficacy|0
6046952|NCT00409578|9646075|FG001|Overall Study|Lack of Efficacy|0
6046953|NCT00409578|9646076|FG002|Overall Study|Lack of Efficacy|0
6046954|NCT00409578|9646077|FG003|Overall Study|Lack of Efficacy|2
6046955|NCT00409578|9646074|FG000|Overall Study|Subject no longer requires study drug|0
6046956|NCT00409578|9646075|FG001|Overall Study|Subject no longer requires study drug|0
6046957|NCT00409578|9646076|FG002|Overall Study|Subject no longer requires study drug|0
6071032|NCT00552617|9673873|FG002|Overall Study|Lost to Follow-up|0
6071033|NCT00552617|9673874|FG003|Overall Study|Lost to Follow-up|1
6071034|NCT00552617|9673875|FG004|Overall Study|Lost to Follow-up|0
6071035|NCT00552617|9673876|FG005|Overall Study|Lost to Follow-up|2
6071036|NCT00552617|9673877|FG006|Overall Study|Lost to Follow-up|0
6071037|NCT00552617|9673878|FG007|Overall Study|Lost to Follow-up|0
6071038|NCT00552617|9673879|FG008|Overall Study|Lost to Follow-up|2
6071039|NCT00552617|9673880|FG009|Overall Study|Lost to Follow-up|0
6071040|NCT00552669|9673904|FG000|Overall Study|Death|3
6046958|NCT00409578|9646077|FG003|Overall Study|Subject no longer requires study drug|1
6046959|NCT00409578|9646074|FG000|Overall Study|Withdrawal by Subject|8
6046960|NCT00409578|9646075|FG001|Overall Study|Withdrawal by Subject|15
6046961|NCT00409578|9646076|FG002|Overall Study|Withdrawal by Subject|16
6046962|NCT00409578|9646077|FG003|Overall Study|Withdrawal by Subject|17
6046963|NCT00409578|9646074|FG000|Overall Study|Lost to Follow-up|2
6046964|NCT00409578|9646075|FG001|Overall Study|Lost to Follow-up|0
6046965|NCT00409578|9646076|FG002|Overall Study|Lost to Follow-up|2
6046966|NCT00409578|9646077|FG003|Overall Study|Lost to Follow-up|2
6046967|NCT00409578|9646074|FG000|Overall Study|Administrative problems|8
6071041|NCT00552669|9673905|FG001|Overall Study|Death|7
6071042|NCT00552760|9673922|FG000|Overall Study|Adverse Event|3
6071043|NCT00552760|9673923|FG001|Overall Study|Adverse Event|5
6071044|NCT00552760|9673922|FG000|Overall Study|Relapsed- Depressed Event|10
5996771|NCT03764631|9590343|FG000|Overall Study|Personal Reasons|3
5996772|NCT03764631|9590344|FG001|Overall Study|Personal Reasons|2
5996773|NCT03764631|9590343|FG000|Overall Study|Switching Therapy|3
5996774|NCT03764631|9590344|FG001|Overall Study|Switching Therapy|3
5996775|NCT03764631|9590343|FG000|Overall Study|Adverse Event|0
5996776|NCT03764631|9590344|FG001|Overall Study|Adverse Event|1
5996777|NCT03764631|9590343|FG000|Overall Study|Lost to Follow-up|33
5996778|NCT03764631|9590344|FG001|Overall Study|Lost to Follow-up|41
5996779|NCT03764631|9590343|FG000|Overall Study|No data as study site was closed|2
5996780|NCT03764631|9590344|FG001|Overall Study|No data as study site was closed|6
5996781|NCT03764072|9590356|FG000|Overall Study|Withdrawal of consent (due to lack of efficacy)|0
5996782|NCT03764072|9590357|FG001|Overall Study|Withdrawal of consent (due to lack of efficacy)|0
5996783|NCT03764072|9590358|FG002|Overall Study|Withdrawal of consent (due to lack of efficacy)|1
5996784|NCT03764072|9590359|FG003|Overall Study|Withdrawal of consent (due to lack of efficacy)|0
5996785|NCT03764072|9590360|FG004|Overall Study|Withdrawal of consent (due to lack of efficacy)|0
5996786|NCT03764072|9590361|FG005|Overall Study|Withdrawal of consent (due to lack of efficacy)|0
5996787|NCT03764072|9590356|FG000|Overall Study|Withdrawal of consent (for other reason)|0
5996788|NCT03764072|9590357|FG001|Overall Study|Withdrawal of consent (for other reason)|0
5996789|NCT03764072|9590358|FG002|Overall Study|Withdrawal of consent (for other reason)|0
5996790|NCT03764072|9590359|FG003|Overall Study|Withdrawal of consent (for other reason)|0
5996791|NCT03764072|9590360|FG004|Overall Study|Withdrawal of consent (for other reason)|0
5996792|NCT03764072|9590361|FG005|Overall Study|Withdrawal of consent (for other reason)|1
5996793|NCT03764072|9590356|FG000|Overall Study|Lost to Follow-up|0
5996794|NCT03764072|9590357|FG001|Overall Study|Lost to Follow-up|0
5996795|NCT03764072|9590358|FG002|Overall Study|Lost to Follow-up|0
5996796|NCT03764072|9590359|FG003|Overall Study|Lost to Follow-up|0
5996797|NCT03764072|9590360|FG004|Overall Study|Lost to Follow-up|1
5996798|NCT03764072|9590361|FG005|Overall Study|Lost to Follow-up|0
5996799|NCT03578809|9590393|FG000|Overall Study|Death|0
5996800|NCT03578809|9590394|FG001|Overall Study|Death|2
5996801|NCT03578809|9590395|FG002|Overall Study|Death|0
5996802|NCT03578809|9590396|FG003|Overall Study|Death|1
5996803|NCT03578809|9590393|FG000|Overall Study|Lost to Follow-up|0
5996804|NCT03578809|9590394|FG001|Overall Study|Lost to Follow-up|1
5996805|NCT03578809|9590395|FG002|Overall Study|Lost to Follow-up|0
5996806|NCT03578809|9590396|FG003|Overall Study|Lost to Follow-up|0
5996807|NCT03578809|9590393|FG000|Overall Study|Withdrawal by Subject|3
5996808|NCT03578809|9590394|FG001|Overall Study|Withdrawal by Subject|5
5996809|NCT03578809|9590395|FG002|Overall Study|Withdrawal by Subject|2
5996810|NCT03578809|9590396|FG003|Overall Study|Withdrawal by Subject|0
5996811|NCT03578809|9590393|FG000|Overall Study|Other|3
5996812|NCT03578809|9590394|FG001|Overall Study|Other|6
5996813|NCT03578809|9590395|FG002|Overall Study|Other|2
5996814|NCT03578809|9590396|FG003|Overall Study|Other|8
5996815|NCT03571204|9590412|FG000|Overall Study|Stopped due to COVID-19 pandemic|1
5996816|NCT03571204|9590413|FG001|Overall Study|Stopped due to COVID-19 pandemic|1
5996817|NCT03571204|9590414|FG002|Overall Study|Stopped due to COVID-19 pandemic|0
5996818|NCT03571204|9590412|FG000|Overall Study|Physician Decision|0
5996819|NCT03571204|9590413|FG001|Overall Study|Physician Decision|1
5996820|NCT03571204|9590414|FG002|Overall Study|Physician Decision|0
5996821|NCT03523091|9590425|FG000|Overall Study|Lower dose due to elevated post void residual (PVR)|1
5996822|NCT03523091|9590426|FG001|Overall Study|Lower dose due to elevated post void residual (PVR)|0
5996823|NCT03523091|9590425|FG000|Overall Study|Withdrawal by Subject|0
5996824|NCT03523091|9590426|FG001|Overall Study|Withdrawal by Subject|3
5996825|NCT03523091|9590425|FG000|Overall Study|Increase Botox dose|0
5996826|NCT03523091|9590426|FG001|Overall Study|Increase Botox dose|1
5996827|NCT03391960|9590454|FG000|Overall Study|Protocol Violation|0
5996828|NCT03391960|9590455|FG001|Overall Study|Protocol Violation|
5996829|NCT03362190|9590474|FG000|Overall Study|Adverse Event|0
5996830|NCT03362190|9590475|FG001|Overall Study|Adverse Event|0
5996831|NCT03362190|9590476|FG002|Overall Study|Adverse Event|0
5996832|NCT03362190|9590477|FG003|Overall Study|Adverse Event|1
5996833|NCT03362190|9590474|FG000|Overall Study|Withdrawal by Subject|0
5996834|NCT03362190|9590475|FG001|Overall Study|Withdrawal by Subject|0
5996835|NCT03362190|9590476|FG002|Overall Study|Withdrawal by Subject|0
5996836|NCT03362190|9590477|FG003|Overall Study|Withdrawal by Subject|1
5996837|NCT03252522|9590492|FG000|Overall Study|Adverse Event|3
5996838|NCT03252522|9590493|FG001|Overall Study|Adverse Event|1
5996839|NCT03252522|9590494|FG002|Overall Study|Adverse Event|0
5996840|NCT03252522|9590492|FG000|Overall Study|Unable to swallow pills|4
5996841|NCT03252522|9590493|FG001|Overall Study|Unable to swallow pills|1
5996842|NCT03252522|9590494|FG002|Overall Study|Unable to swallow pills|0
5996843|NCT03252522|9590492|FG000|Overall Study|Commenced stimulant medication|1
5996844|NCT03252522|9590493|FG001|Overall Study|Commenced stimulant medication|1
5996845|NCT03252522|9590494|FG002|Overall Study|Commenced stimulant medication|0
5996846|NCT03252522|9590492|FG000|Overall Study|Protocol Violation|1
5996847|NCT03252522|9590493|FG001|Overall Study|Protocol Violation|0
5996848|NCT03252522|9590494|FG002|Overall Study|Protocol Violation|0
5996849|NCT03235544|9590509|FG000|Overall Study|Participants Still Ongoing in the Study|1
5996850|NCT03235544|9590510|FG001|Overall Study|Participants Still Ongoing in the Study|13
5996851|NCT03235544|9590511|FG002|Overall Study|Participants Still Ongoing in the Study|19
5996852|NCT03235544|9590512|FG003|Overall Study|Participants Still Ongoing in the Study|55
5996853|NCT03235544|9590509|FG000|Overall Study|Death|11
5996854|NCT03235544|9590510|FG001|Overall Study|Death|23
5996855|NCT03235544|9590511|FG002|Overall Study|Death|11
5996856|NCT03235544|9590512|FG003|Overall Study|Death|20
5996857|NCT03235544|9590509|FG000|Overall Study|Lost to Follow-up|0
5996858|NCT03235544|9590510|FG001|Overall Study|Lost to Follow-up|1
5996859|NCT03235544|9590511|FG002|Overall Study|Lost to Follow-up|0
5996860|NCT03235544|9590512|FG003|Overall Study|Lost to Follow-up|1
5996861|NCT03235544|9590509|FG000|Overall Study|Withdrawal by Participant|0
5996862|NCT03235544|9590510|FG001|Overall Study|Withdrawal by Participant|0
5996863|NCT03235544|9590511|FG002|Overall Study|Withdrawal by Participant|1
5996864|NCT03235544|9590512|FG003|Overall Study|Withdrawal by Participant|0
5996865|NCT03235544|9590509|FG000|Overall Study|Reason not Specified|0
5996866|NCT03235544|9590510|FG001|Overall Study|Reason not Specified|4
5996867|NCT03235544|9590511|FG002|Overall Study|Reason not Specified|0
5996868|NCT03235544|9590512|FG003|Overall Study|Reason not Specified|1
5996869|NCT03225833|9590529|FG000|Overall Study|Adverse Event|0
5996870|NCT03225833|9590530|FG001|Overall Study|Adverse Event|1
5996871|NCT03225833|9590531|FG002|Overall Study|Adverse Event|2
5996872|NCT03225833|9590532|FG003|Overall Study|Adverse Event|0
5996873|NCT03225833|9590533|FG004|Overall Study|Adverse Event|0
5996874|NCT03225833|9590534|FG005|Overall Study|Adverse Event|2
5996875|NCT03225833|9590529|FG000|Overall Study|Withdrawal by Subject|1
5996876|NCT03225833|9590530|FG001|Overall Study|Withdrawal by Subject|0
5996877|NCT03225833|9590531|FG002|Overall Study|Withdrawal by Subject|0
5996878|NCT03225833|9590532|FG003|Overall Study|Withdrawal by Subject|0
5996879|NCT03225833|9590533|FG004|Overall Study|Withdrawal by Subject|1
5996880|NCT03225833|9590534|FG005|Overall Study|Withdrawal by Subject|0
5996881|NCT03225833|9590529|FG000|Overall Study|Termination of Study by Sponsor|4
5996882|NCT03225833|9590530|FG001|Overall Study|Termination of Study by Sponsor|0
5996883|NCT03225833|9590531|FG002|Overall Study|Termination of Study by Sponsor|0
5996884|NCT03225833|9590532|FG003|Overall Study|Termination of Study by Sponsor|0
5996885|NCT03225833|9590533|FG004|Overall Study|Termination of Study by Sponsor|0
5996886|NCT03225833|9590534|FG005|Overall Study|Termination of Study by Sponsor|7
5996887|NCT03225833|9590529|FG000|Overall Study|Sponsor Decision|0
5996888|NCT03225833|9590530|FG001|Overall Study|Sponsor Decision|0
5996889|NCT03225833|9590531|FG002|Overall Study|Sponsor Decision|0
5996890|NCT03225833|9590532|FG003|Overall Study|Sponsor Decision|0
5996891|NCT03225833|9590533|FG004|Overall Study|Sponsor Decision|0
5996892|NCT03225833|9590534|FG005|Overall Study|Sponsor Decision|1
5996893|NCT03167242|9590565|FG000|Overall Study|Patient/Guardian Decision|0
5996894|NCT03167242|9590566|FG001|Overall Study|Patient/Guardian Decision|1
5996895|NCT03167242|9590567|FG002|Overall Study|Patient/Guardian Decision|2
5996896|NCT03167242|9590568|FG003|Overall Study|Patient/Guardian Decision|1
5996897|NCT03167242|9590569|FG004|Overall Study|Patient/Guardian Decision|1
5996898|NCT03167242|9590570|FG005|Overall Study|Patient/Guardian Decision|1
5996899|NCT03167242|9590571|FG006|Overall Study|Patient/Guardian Decision|0
5996900|NCT03167242|9590572|FG007|Overall Study|Patient/Guardian Decision|0
5996901|NCT03167242|9590573|FG008|Overall Study|Patient/Guardian Decision|0
5996902|NCT03167242|9590574|FG009|Overall Study|Patient/Guardian Decision|0
5996903|NCT03167242|9590575|FG010|Overall Study|Patient/Guardian Decision|1
5996904|NCT03167242|9590576|FG011|Overall Study|Patient/Guardian Decision|0
5996905|NCT03167242|9590565|FG000|Overall Study|Lost to Follow-up|0
5996906|NCT03167242|9590566|FG001|Overall Study|Lost to Follow-up|0
5996907|NCT03167242|9590567|FG002|Overall Study|Lost to Follow-up|1
5996908|NCT03167242|9590568|FG003|Overall Study|Lost to Follow-up|0
5996909|NCT03167242|9590569|FG004|Overall Study|Lost to Follow-up|0
5996910|NCT03167242|9590570|FG005|Overall Study|Lost to Follow-up|1
5996911|NCT03167242|9590571|FG006|Overall Study|Lost to Follow-up|2
5996912|NCT03167242|9590572|FG007|Overall Study|Lost to Follow-up|1
5996913|NCT03167242|9590573|FG008|Overall Study|Lost to Follow-up|0
5996914|NCT03167242|9590574|FG009|Overall Study|Lost to Follow-up|0
5996915|NCT03167242|9590575|FG010|Overall Study|Lost to Follow-up|1
5996916|NCT03167242|9590576|FG011|Overall Study|Lost to Follow-up|1
5996917|NCT03167242|9590565|FG000|Overall Study|Reason not provided|0
5996918|NCT03167242|9590566|FG001|Overall Study|Reason not provided|0
5996919|NCT03167242|9590567|FG002|Overall Study|Reason not provided|0
5996920|NCT03167242|9590568|FG003|Overall Study|Reason not provided|0
5996921|NCT03167242|9590569|FG004|Overall Study|Reason not provided|0
5996922|NCT03167242|9590570|FG005|Overall Study|Reason not provided|0
5996923|NCT03167242|9590571|FG006|Overall Study|Reason not provided|0
5996924|NCT03167242|9590572|FG007|Overall Study|Reason not provided|0
5996925|NCT03167242|9590573|FG008|Overall Study|Reason not provided|1
5996926|NCT03167242|9590574|FG009|Overall Study|Reason not provided|0
5996927|NCT03167242|9590575|FG010|Overall Study|Reason not provided|0
5996928|NCT03167242|9590576|FG011|Overall Study|Reason not provided|0
5996929|NCT03137537|9590614|FG000|Overall Study|Adverse Event|0
5996930|NCT03137537|9590615|FG001|Overall Study|Adverse Event|1
5996931|NCT03126019|9590623|FG000|Overall Study|Participants Still Ongoing in the Study|17
5996932|NCT03126019|9590624|FG001|Overall Study|Participants Still Ongoing in the Study|87
5996933|NCT03126019|9590623|FG000|Overall Study|Death|2
5996934|NCT03126019|9590624|FG001|Overall Study|Death|7
5996935|NCT03126019|9590623|FG000|Overall Study|Lost to Follow-up|2
5996936|NCT03126019|9590624|FG001|Overall Study|Lost to Follow-up|3
5996937|NCT03126019|9590623|FG000|Overall Study|Withdrawal by Participant|1
5996938|NCT03126019|9590624|FG001|Overall Study|Withdrawal by Participant|3
5996939|NCT03126019|9590623|FG000|Overall Study|Reason not Specified|1
5996940|NCT03126019|9590624|FG001|Overall Study|Reason not Specified|3
5996941|NCT03113383|9590631|FG000|Overall Study|Death|4
5996942|NCT03113383|9590632|FG001|Overall Study|Death|0
5996943|NCT02978326|9590663|FG000|Part B (Up to 45 Days)|Adverse Event|0
5996944|NCT02978326|9590664|FG001|Part B (Up to 45 Days)|Adverse Event|0
5996945|NCT02978326|9590665|FG002|Part B (Up to 45 Days)|Adverse Event|1
5996946|NCT02978326|9590663|FG000|Part B (Up to 45 Days)|Lost to Follow-up|0
5996947|NCT02978326|9590664|FG001|Part B (Up to 45 Days)|Lost to Follow-up|3
5996948|NCT02978326|9590665|FG002|Part B (Up to 45 Days)|Lost to Follow-up|0
5996949|NCT02978326|9590663|FG000|Part B (Up to 45 Days)|Non-compliance|0
5996950|NCT02978326|9590664|FG001|Part B (Up to 45 Days)|Non-compliance|2
5996951|NCT02978326|9590665|FG002|Part B (Up to 45 Days)|Non-compliance|0
5996952|NCT02978326|9590663|FG000|Part B (Up to 45 Days)|Withdrawal by Subject|0
5996953|NCT02978326|9590664|FG001|Part B (Up to 45 Days)|Withdrawal by Subject|2
5996954|NCT02978326|9590665|FG002|Part B (Up to 45 Days)|Withdrawal by Subject|3
5996955|NCT02970929|9590675|FG000|Overall Study|Adverse Event|18
5996956|NCT02970929|9590675|FG000|Overall Study|Lack of Efficacy|8
5996957|NCT02970929|9590675|FG000|Overall Study|NON-COMPLIANCE WITH STUDY DRUG|1
5996958|NCT02970929|9590675|FG000|Overall Study|INVESTIGATOR CONSIDERS SUBJECT CLINICALLY UNSTABLE, NOT APPROPRIATE FOR DISCHARGE TO AN OUTPATIENT|1
5996959|NCT02970929|9590675|FG000|Overall Study|SPONSOR REQUEST THAT SUBJECT BE WITHDRAWN DUE TO POSITIVE DRUG RESULTS AND FOR THE SUBJECT'S SAFETY|1
5996960|NCT02970929|9590675|FG000|Overall Study|LOST TO FOLLOWUP|6
5996961|NCT02970929|9590675|FG000|Overall Study|MOVED OUT OF STATE|1
5996962|NCT02970929|9590675|FG000|Overall Study|Withdrawal by Subject|16
5996963|NCT02797951|9590709|FG000|Overall Study|Adverse Event|4
5996964|NCT02797951|9590709|FG000|Overall Study|Death|1
5996965|NCT02797951|9590709|FG000|Overall Study|Lack of Efficacy|19
5996966|NCT02797951|9590709|FG000|Overall Study|Lost to Follow-up|4
5996967|NCT02797951|9590709|FG000|Overall Study|Physician Decision|6
5996968|NCT02797951|9590709|FG000|Overall Study|Withdrawal by Subject|15
5996969|NCT02748057|9590724|FG000|Overall Study|Adverse Event|1
5996970|NCT02748057|9590725|FG001|Overall Study|Adverse Event|0
5996971|NCT02748057|9590724|FG000|Overall Study|Physician Decision|0
5996972|NCT02748057|9590725|FG001|Overall Study|Physician Decision|1
5996973|NCT02748057|9590724|FG000|Overall Study|Protocol Violation|2
5996974|NCT02748057|9590725|FG001|Overall Study|Protocol Violation|1
5996975|NCT02748057|9590724|FG000|Overall Study|Participant Moved|1
5996976|NCT02748057|9590725|FG001|Overall Study|Participant Moved|0
5996977|NCT02748057|9590724|FG000|Overall Study|Withdrawal by Subject|1
5996978|NCT02748057|9590725|FG001|Overall Study|Withdrawal by Subject|0
5996979|NCT02741271|9590733|FG000|Overall Study|Lost to Follow-up|2
5996980|NCT02741271|9590734|FG001|Overall Study|Lost to Follow-up|0
5996981|NCT02741271|9590733|FG000|Overall Study|Withdrawal by Parent/Guardian|0
5996982|NCT02741271|9590734|FG001|Overall Study|Withdrawal by Parent/Guardian|2
5996983|NCT02741245|9590747|FG000|Overall Study|Adverse Event|0
5996984|NCT02741245|9590748|FG001|Overall Study|Adverse Event|0
5996985|NCT02741245|9590749|FG002|Overall Study|Adverse Event|0
5996986|NCT02741245|9590750|FG003|Overall Study|Adverse Event|2
5996987|NCT02741245|9590751|FG004|Overall Study|Adverse Event|2
5996988|NCT02741245|9590747|FG000|Overall Study|Protocol Violation|0
5996989|NCT02741245|9590748|FG001|Overall Study|Protocol Violation|1
5996990|NCT02741245|9590749|FG002|Overall Study|Protocol Violation|0
5996991|NCT02741245|9590750|FG003|Overall Study|Protocol Violation|1
5996992|NCT02741245|9590751|FG004|Overall Study|Protocol Violation|0
5996993|NCT02741245|9590747|FG000|Overall Study|Withdrawal by Subject|0
5996994|NCT02741245|9590748|FG001|Overall Study|Withdrawal by Subject|0
5996995|NCT02741245|9590749|FG002|Overall Study|Withdrawal by Subject|0
5996996|NCT02741245|9590750|FG003|Overall Study|Withdrawal by Subject|1
5996997|NCT02741245|9590751|FG004|Overall Study|Withdrawal by Subject|0
5996998|NCT02688608|9590763|FG000|Overall Study|Lost to Follow-up|1
5996999|NCT02675231|9590770|FG000|Overall Study|Withdrawal by Subject|1
5997000|NCT02675231|9590771|FG001|Overall Study|Withdrawal by Subject|3
5997001|NCT02675231|9590772|FG002|Overall Study|Withdrawal by Subject|1
5997002|NCT02675231|9590770|FG000|Overall Study|Lost to Follow-up|2
5997003|NCT02675231|9590771|FG001|Overall Study|Lost to Follow-up|2
5997004|NCT02675231|9590772|FG002|Overall Study|Lost to Follow-up|2
5997005|NCT02675231|9590770|FG000|Overall Study|On study treatment/follow up|23
5997006|NCT02675231|9590771|FG001|Overall Study|On study treatment/follow up|31
5997007|NCT02675231|9590772|FG002|Overall Study|On study treatment/follow up|23
5997008|NCT02605967|9590792|FG000|Overall Study|subject / guardian decision|1
5997009|NCT02605967|9590793|FG001|Overall Study|subject / guardian decision|2
5997010|NCT02605967|9590792|FG000|Overall Study|Physician Decision|10
5997011|NCT02605967|9590793|FG001|Overall Study|Physician Decision|1
5997012|NCT02605967|9590792|FG000|Overall Study|Death|4
5997013|NCT02605967|9590793|FG001|Overall Study|Death|2
5997014|NCT02605967|9590792|FG000|Overall Study|Adverse Event|1
5997015|NCT02605967|9590793|FG001|Overall Study|Adverse Event|0
5997016|NCT02605967|9590792|FG000|Overall Study|progressive disease|66
5997017|NCT02605967|9590793|FG001|Overall Study|progressive disease|35
5997018|NCT02584634|9590805|FG000|Overall Study|Adverse Event|3
5997019|NCT02584634|9590806|FG001|Overall Study|Adverse Event|3
5997020|NCT02584634|9590805|FG000|Overall Study|Death|0
5997021|NCT02584634|9590806|FG001|Overall Study|Death|1
5997022|NCT02584634|9590805|FG000|Overall Study|Lost to Follow-up|0
5997023|NCT02584634|9590806|FG001|Overall Study|Lost to Follow-up|1
5997024|NCT02584634|9590805|FG000|Overall Study|Physician Decision|1
5997025|NCT02584634|9590806|FG001|Overall Study|Physician Decision|1
5997026|NCT02584634|9590805|FG000|Overall Study|Progressive disease|7
5997027|NCT02584634|9590806|FG001|Overall Study|Progressive disease|14
5997028|NCT02584634|9590805|FG000|Overall Study|Withdrawal by Subject|1
5997029|NCT02584634|9590806|FG001|Overall Study|Withdrawal by Subject|1
5997030|NCT02584634|9590805|FG000|Overall Study|Other|0
5997031|NCT02584634|9590806|FG001|Overall Study|Other|2
5997032|NCT02584634|9590805|FG000|Overall Study|Ongoing|0
5997033|NCT02584634|9590806|FG001|Overall Study|Ongoing|8
6046968|NCT00409578|9646075|FG001|Overall Study|Administrative problems|9
6046969|NCT00409578|9646076|FG002|Overall Study|Administrative problems|2
6046970|NCT00409578|9646077|FG003|Overall Study|Administrative problems|4
6046971|NCT00409578|9646074|FG000|Overall Study|Death|2
6046972|NCT00409578|9646075|FG001|Overall Study|Death|4
6046973|NCT00409578|9646076|FG002|Overall Study|Death|4
6046974|NCT00409578|9646077|FG003|Overall Study|Death|2
6046975|NCT00409578|9646074|FG000|Overall Study|Protocol Violation|3
6046976|NCT00409578|9646075|FG001|Overall Study|Protocol Violation|2
6046977|NCT00409578|9646076|FG002|Overall Study|Protocol Violation|3
6046978|NCT00409578|9646077|FG003|Overall Study|Protocol Violation|1
6046979|NCT00409578|9646074|FG000|Overall Study|Missing|0
6046980|NCT00409578|9646075|FG001|Overall Study|Missing|1
6046981|NCT00409578|9646076|FG002|Overall Study|Missing|0
6046982|NCT00409578|9646077|FG003|Overall Study|Missing|1
6046983|NCT00409617|9646087|FG000|Overall Study|Adverse Event|57
6046984|NCT00409617|9646087|FG000|Overall Study|Lack of Efficacy|54
6046985|NCT00409617|9646087|FG000|Overall Study|Lost to Follow-up|2
6046986|NCT00409617|9646087|FG000|Overall Study|Protocol Violation|24
6046987|NCT00409617|9646087|FG000|Overall Study|Withdrawal by Subject|8
6046988|NCT00409617|9646087|FG000|Overall Study|Administrative reasons|1
6046989|NCT00409617|9646087|FG000|Overall Study|Not described|14
6046990|NCT00409682|9646094|FG000|Open-label Induction Period|Adverse Event|1
6046991|NCT00409682|9646095|FG001|Open-label Induction Period|Adverse Event|0
6046992|NCT00409682|9646096|FG002|Open-label Induction Period|Adverse Event|0
6046993|NCT00409682|9646094|FG000|Open-label Induction Period|Lack of Efficacy|1
6046994|NCT00409682|9646095|FG001|Open-label Induction Period|Lack of Efficacy|0
6046995|NCT00409682|9646096|FG002|Open-label Induction Period|Lack of Efficacy|0
6046996|NCT00409682|9646094|FG000|Open-label Induction Period|Protocol Violation|1
6046997|NCT00409682|9646095|FG001|Open-label Induction Period|Protocol Violation|0
6046998|NCT00409682|9646096|FG002|Open-label Induction Period|Protocol Violation|0
6046999|NCT00409682|9646094|FG000|Open-label Induction Period|Subject did not satisfy entry criteria|1
6047000|NCT00409682|9646095|FG001|Open-label Induction Period|Subject did not satisfy entry criteria|0
6047001|NCT00409682|9646096|FG002|Open-label Induction Period|Subject did not satisfy entry criteria|0
6047002|NCT00409682|9646094|FG000|EOW Double-blind Maintenance Period|Adverse Event|0
6047003|NCT00409682|9646095|FG001|EOW Double-blind Maintenance Period|Adverse Event|10
6047004|NCT00409682|9646096|FG002|EOW Double-blind Maintenance Period|Adverse Event|12
6047005|NCT00409682|9646094|FG000|EOW Double-blind Maintenance Period|Lack of Efficacy|0
6047006|NCT00409682|9646095|FG001|EOW Double-blind Maintenance Period|Lack of Efficacy|18
6047007|NCT00409682|9646096|FG002|EOW Double-blind Maintenance Period|Lack of Efficacy|11
6047008|NCT00409682|9646094|FG000|EOW Double-blind Maintenance Period|Lost to Follow-up|0
6047009|NCT00409682|9646095|FG001|EOW Double-blind Maintenance Period|Lost to Follow-up|1
6047010|NCT00409682|9646096|FG002|EOW Double-blind Maintenance Period|Lost to Follow-up|0
6047011|NCT00409682|9646094|FG000|EOW Double-blind Maintenance Period|Withdrawal by Subject|0
6047012|NCT00409682|9646095|FG001|EOW Double-blind Maintenance Period|Withdrawal by Subject|4
6047013|NCT00409682|9646096|FG002|EOW Double-blind Maintenance Period|Withdrawal by Subject|2
6047014|NCT00409682|9646094|FG000|EOW Double-blind Maintenance Period|Protocol Violation|0
6047015|NCT00409682|9646095|FG001|EOW Double-blind Maintenance Period|Protocol Violation|4
6047016|NCT00409682|9646096|FG002|EOW Double-blind Maintenance Period|Protocol Violation|1
6071045|NCT00552760|9673923|FG001|Overall Study|Relapsed- Depressed Event|16
6071046|NCT00552760|9673922|FG000|Overall Study|Relapse- Manic Event|3
6071047|NCT00552760|9673923|FG001|Overall Study|Relapse- Manic Event|3
6071048|NCT00552760|9673922|FG000|Overall Study|Relapsed- Mixed Event|3
6047017|NCT00409682|9646094|FG000|EOW Double-blind Maintenance Period|Non-compliance|0
6047018|NCT00409682|9646095|FG001|EOW Double-blind Maintenance Period|Non-compliance|0
6047019|NCT00409682|9646096|FG002|EOW Double-blind Maintenance Period|Non-compliance|1
6047020|NCT00409708|9646105|FG000|Treatment|Abnormal test procedure result(s)|1
6047021|NCT00409708|9646106|FG001|Treatment|Abnormal test procedure result(s)|0
6047022|NCT00409708|9646105|FG000|Treatment|Lack of Efficacy|0
6047023|NCT00409708|9646106|FG001|Treatment|Lack of Efficacy|1
6047024|NCT00409708|9646105|FG000|Treatment|Protocol Violation|6
6047025|NCT00409708|9646106|FG001|Treatment|Protocol Violation|2
6047026|NCT00409708|9646105|FG000|Treatment|Withdrawal by Subject|3
6047027|NCT00409708|9646106|FG001|Treatment|Withdrawal by Subject|8
6047028|NCT00409708|9646105|FG000|Treatment|Lost to Follow-up|0
6047029|NCT00409708|9646106|FG001|Treatment|Lost to Follow-up|6
6047030|NCT00409708|9646105|FG000|Treatment|Administrative problems|5
5997034|NCT02553265|9590828|FG000|Enrollment|Death|0
5997035|NCT02553265|9590829|FG001|Enrollment|Death|0
5997036|NCT02553265|9590830|FG002|Enrollment|Death|1
5997037|NCT02553265|9590828|FG000|First Intervention (28 Days)|Adverse Event|1
5997038|NCT02553265|9590829|FG001|First Intervention (28 Days)|Adverse Event|0
5997039|NCT02553265|9590830|FG002|First Intervention (28 Days)|Adverse Event|0
5997040|NCT02553265|9590828|FG000|First Intervention (28 Days)|Withdrawal by Subject|0
5997041|NCT02553265|9590829|FG001|First Intervention (28 Days)|Withdrawal by Subject|0
5997042|NCT02553265|9590830|FG002|First Intervention (28 Days)|Withdrawal by Subject|1
5997043|NCT02553265|9590828|FG000|Second Intervention (28 Days)|Adverse Event|1
5997044|NCT02553265|9590829|FG001|Second Intervention (28 Days)|Adverse Event|0
5997045|NCT02553265|9590830|FG002|Second Intervention (28 Days)|Adverse Event|0
5997046|NCT02553265|9590828|FG000|Third Intervention (28 Days)|Adverse Event|1
5997047|NCT02553265|9590829|FG001|Third Intervention (28 Days)|Adverse Event|0
5997048|NCT02553265|9590830|FG002|Third Intervention (28 Days)|Adverse Event|0
5997049|NCT02553265|9590828|FG000|Third Intervention (28 Days)|Lost to Follow-up|0
5997050|NCT02553265|9590829|FG001|Third Intervention (28 Days)|Lost to Follow-up|0
5997051|NCT02553265|9590830|FG002|Third Intervention (28 Days)|Lost to Follow-up|1
5997052|NCT02550288|9590846|FG000|Overall Study|Adverse Event|0
5997053|NCT02550288|9590847|FG001|Overall Study|Adverse Event|1
5997054|NCT02550288|9590848|FG002|Overall Study|Adverse Event|0
5997055|NCT02550288|9590849|FG003|Overall Study|Adverse Event|0
5997056|NCT02550288|9590850|FG004|Overall Study|Adverse Event|0
5997057|NCT02550288|9590846|FG000|Overall Study|Physician Decision|0
5997058|NCT02550288|9590847|FG001|Overall Study|Physician Decision|0
5997059|NCT02550288|9590848|FG002|Overall Study|Physician Decision|0
5997060|NCT02550288|9590849|FG003|Overall Study|Physician Decision|1
5997061|NCT02550288|9590850|FG004|Overall Study|Physician Decision|0
5997062|NCT02550288|9590846|FG000|Overall Study|Protocol Violation|2
5997063|NCT02550288|9590847|FG001|Overall Study|Protocol Violation|2
5997064|NCT02550288|9590848|FG002|Overall Study|Protocol Violation|1
5997065|NCT02550288|9590849|FG003|Overall Study|Protocol Violation|0
5997066|NCT02550288|9590850|FG004|Overall Study|Protocol Violation|3
5997067|NCT02550288|9590846|FG000|Overall Study|Participant moved|0
5997068|NCT02550288|9590847|FG001|Overall Study|Participant moved|0
5997069|NCT02550288|9590848|FG002|Overall Study|Participant moved|0
5997070|NCT02550288|9590849|FG003|Overall Study|Participant moved|1
5997071|NCT02550288|9590850|FG004|Overall Study|Participant moved|0
5997072|NCT02550288|9590846|FG000|Overall Study|Withdrawal by Subject|0
5997073|NCT02550288|9590847|FG001|Overall Study|Withdrawal by Subject|0
5997074|NCT02550288|9590848|FG002|Overall Study|Withdrawal by Subject|0
5997075|NCT02550288|9590849|FG003|Overall Study|Withdrawal by Subject|1
5997076|NCT02550288|9590850|FG004|Overall Study|Withdrawal by Subject|0
5997077|NCT02510040|9590865|FG000|Overall Study|Deemed no longer eligible|18
5997078|NCT02510040|9590866|FG001|Overall Study|Deemed no longer eligible|3
5997079|NCT02510040|9590867|FG002|Overall Study|Deemed no longer eligible|1
5997080|NCT02499328|9590895|FG000|Overall Study|Withdrawal by Subject|1
5997081|NCT02499328|9590896|FG001|Overall Study|Withdrawal by Subject|1
5997082|NCT02499328|9590897|FG002|Overall Study|Withdrawal by Subject|5
5997083|NCT02499328|9590898|FG003|Overall Study|Withdrawal by Subject|3
5997084|NCT02499328|9590899|FG004|Overall Study|Withdrawal by Subject|5
5997085|NCT02499328|9590900|FG005|Overall Study|Withdrawal by Subject|0
5997086|NCT02499328|9590901|FG006|Overall Study|Withdrawal by Subject|0
5997087|NCT02499328|9590902|FG007|Overall Study|Withdrawal by Subject|0
5997088|NCT02499328|9590903|FG008|Overall Study|Withdrawal by Subject|2
5997089|NCT02499328|9590904|FG009|Overall Study|Withdrawal by Subject|2
5997090|NCT02499328|9590905|FG010|Overall Study|Withdrawal by Subject|0
5997091|NCT02499328|9590906|FG011|Overall Study|Withdrawal by Subject|3
5997092|NCT02499328|9590907|FG012|Overall Study|Withdrawal by Subject|7
5997093|NCT02499328|9590908|FG013|Overall Study|Withdrawal by Subject|3
5997094|NCT02499328|9590909|FG014|Overall Study|Withdrawal by Subject|1
5997095|NCT02499328|9590910|FG015|Overall Study|Withdrawal by Subject|0
5997096|NCT02499328|9590911|FG016|Overall Study|Withdrawal by Subject|0
5997097|NCT02499328|9590912|FG017|Overall Study|Withdrawal by Subject|3
5997098|NCT02499328|9590913|FG018|Overall Study|Withdrawal by Subject|0
5997099|NCT02499328|9590895|FG000|Overall Study|Lost to Follow-up|0
5997100|NCT02499328|9590896|FG001|Overall Study|Lost to Follow-up|1
5997101|NCT02499328|9590897|FG002|Overall Study|Lost to Follow-up|1
5997102|NCT02499328|9590898|FG003|Overall Study|Lost to Follow-up|2
5997103|NCT02499328|9590899|FG004|Overall Study|Lost to Follow-up|0
5997104|NCT02499328|9590900|FG005|Overall Study|Lost to Follow-up|0
5997105|NCT02499328|9590901|FG006|Overall Study|Lost to Follow-up|0
5997106|NCT02499328|9590902|FG007|Overall Study|Lost to Follow-up|2
5997107|NCT02499328|9590903|FG008|Overall Study|Lost to Follow-up|3
5997108|NCT02499328|9590904|FG009|Overall Study|Lost to Follow-up|0
5997109|NCT02499328|9590905|FG010|Overall Study|Lost to Follow-up|0
5997110|NCT02499328|9590906|FG011|Overall Study|Lost to Follow-up|0
5997111|NCT02499328|9590907|FG012|Overall Study|Lost to Follow-up|0
5997112|NCT02499328|9590908|FG013|Overall Study|Lost to Follow-up|0
5997113|NCT02499328|9590909|FG014|Overall Study|Lost to Follow-up|0
5997114|NCT02499328|9590910|FG015|Overall Study|Lost to Follow-up|0
5997115|NCT02499328|9590911|FG016|Overall Study|Lost to Follow-up|0
5997116|NCT02499328|9590912|FG017|Overall Study|Lost to Follow-up|0
5997117|NCT02499328|9590913|FG018|Overall Study|Lost to Follow-up|1
5997118|NCT02499328|9590895|FG000|Overall Study|Death|0
5997119|NCT02499328|9590896|FG001|Overall Study|Death|3
5997120|NCT02499328|9590897|FG002|Overall Study|Death|3
5997121|NCT02499328|9590898|FG003|Overall Study|Death|2
5997122|NCT02499328|9590899|FG004|Overall Study|Death|4
5997123|NCT02499328|9590900|FG005|Overall Study|Death|7
5997124|NCT02499328|9590901|FG006|Overall Study|Death|3
5997125|NCT02499328|9590902|FG007|Overall Study|Death|0
5997126|NCT02499328|9590903|FG008|Overall Study|Death|2
5997127|NCT02499328|9590904|FG009|Overall Study|Death|6
5997128|NCT02499328|9590905|FG010|Overall Study|Death|6
5997129|NCT02499328|9590906|FG011|Overall Study|Death|20
5997130|NCT02499328|9590907|FG012|Overall Study|Death|9
6071049|NCT00552760|9673923|FG001|Overall Study|Relapsed- Mixed Event|5
6071050|NCT00552760|9673922|FG000|Overall Study|Protocol Violation|0
6071051|NCT00552760|9673923|FG001|Overall Study|Protocol Violation|1
6071052|NCT00552760|9673922|FG000|Overall Study|Lost to Follow-up|1
6071053|NCT00552760|9673923|FG001|Overall Study|Lost to Follow-up|1
6071054|NCT00552760|9673922|FG000|Overall Study|Non-compliance|1
6071055|NCT00552760|9673923|FG001|Overall Study|Non-compliance|1
6071056|NCT00552760|9673922|FG000|Overall Study|Medical Condition|1
6071057|NCT00552760|9673923|FG001|Overall Study|Medical Condition|1
6071058|NCT00552760|9673922|FG000|Overall Study|Withdrawal by Subject|3
6071059|NCT00552760|9673923|FG001|Overall Study|Withdrawal by Subject|0
6071060|NCT00552760|9673922|FG000|Overall Study|Medication Change|1
6071061|NCT00552760|9673923|FG001|Overall Study|Medication Change|0
6071062|NCT00552929|9673952|FG000|Overall Study|Lost to Follow-up|0
6071063|NCT00552929|9673953|FG001|Overall Study|Lost to Follow-up|0
6071064|NCT00552929|9673954|FG002|Overall Study|Lost to Follow-up|0
6071065|NCT00552929|9673955|FG003|Overall Study|Lost to Follow-up|0
6071066|NCT00552929|9673956|FG004|Overall Study|Lost to Follow-up|0
6071067|NCT00552929|9673957|FG005|Overall Study|Lost to Follow-up|0
6071068|NCT00552929|9673958|FG006|Overall Study|Lost to Follow-up|0
6071069|NCT00552929|9673959|FG007|Overall Study|Lost to Follow-up|0
6071070|NCT00552929|9673960|FG008|Overall Study|Lost to Follow-up|1
6071071|NCT00552929|9673961|FG009|Overall Study|Lost to Follow-up|0
6071072|NCT00552929|9673952|FG000|Overall Study|Not Eligible|0
6071073|NCT00552929|9673953|FG001|Overall Study|Not Eligible|0
6071074|NCT00552929|9673954|FG002|Overall Study|Not Eligible|0
6071075|NCT00552929|9673955|FG003|Overall Study|Not Eligible|0
6071076|NCT00552929|9673956|FG004|Overall Study|Not Eligible|0
6071077|NCT00552929|9673957|FG005|Overall Study|Not Eligible|1
6071078|NCT00552929|9673958|FG006|Overall Study|Not Eligible|0
6071079|NCT00552929|9673959|FG007|Overall Study|Not Eligible|0
6071080|NCT00552929|9673960|FG008|Overall Study|Not Eligible|0
6071081|NCT00552929|9673961|FG009|Overall Study|Not Eligible|0
6071082|NCT00553059|9673985|FG000|Overall Study|Deemed ineligible|1
6071083|NCT00553059|9673986|FG001|Overall Study|Deemed ineligible|1
6071084|NCT00553059|9673985|FG000|Overall Study|Drug supply not available|0
6071085|NCT00553059|9673986|FG001|Overall Study|Drug supply not available|1
6071086|NCT00553150|9674002|FG000|Overall Study|Withdrawal by Subject|0
6071087|NCT00553150|9674003|FG001|Overall Study|Withdrawal by Subject|0
6071088|NCT00553150|9674004|FG002|Overall Study|Withdrawal by Subject|0
6071089|NCT00553150|9674005|FG003|Overall Study|Withdrawal by Subject|2
6071090|NCT00553150|9674002|FG000|Overall Study|Protocol Violation|0
6071091|NCT00553150|9674003|FG001|Overall Study|Protocol Violation|0
6071092|NCT00553150|9674004|FG002|Overall Study|Protocol Violation|0
6071093|NCT00553150|9674005|FG003|Overall Study|Protocol Violation|1
6071094|NCT00553150|9674002|FG000|Overall Study|Ineligible|0
6071095|NCT00553150|9674003|FG001|Overall Study|Ineligible|0
6071096|NCT00553150|9674004|FG002|Overall Study|Ineligible|0
6071097|NCT00553150|9674005|FG003|Overall Study|Ineligible|1
6071098|NCT00553202|9674027|FG000|Overall Study|Death|16
6071099|NCT00553202|9674027|FG000|Overall Study|Lost to Follow-up|1
6071100|NCT00553202|9674027|FG000|Overall Study|Physician Decision|28
6071101|NCT00553202|9674027|FG000|Overall Study|Withdrawal by Subject|1
6071102|NCT00553202|9674027|FG000|Overall Study|No donor identified|16
6071103|NCT00553202|9674027|FG000|Overall Study|Fails to meet organ function|6
6071104|NCT00553254|9674034|FG000|Overall Study|Death|3
6071105|NCT00553254|9674035|FG001|Overall Study|Death|6
6071106|NCT00553254|9674036|FG002|Overall Study|Death|25
6071107|NCT00553254|9674034|FG000|Overall Study|Lost to Follow-up|0
6071108|NCT00553254|9674035|FG001|Overall Study|Lost to Follow-up|0
6071109|NCT00553254|9674036|FG002|Overall Study|Lost to Follow-up|2
6071110|NCT00553254|9674034|FG000|Overall Study|Withdrawal by Subject|2
6071111|NCT00553254|9674035|FG001|Overall Study|Withdrawal by Subject|0
6071112|NCT00553254|9674036|FG002|Overall Study|Withdrawal by Subject|2
6071113|NCT00553254|9674034|FG000|Overall Study|Study terminated by Sponsor|0
5997131|NCT02499328|9590908|FG013|Overall Study|Death|7
5997132|NCT02499328|9590909|FG014|Overall Study|Death|3
6071114|NCT00553254|9674035|FG001|Overall Study|Study terminated by Sponsor|0
6071115|NCT00553254|9674036|FG002|Overall Study|Study terminated by Sponsor|1
5997133|NCT02499328|9590910|FG015|Overall Study|Death|1
5997134|NCT02499328|9590911|FG016|Overall Study|Death|1
5997135|NCT02499328|9590912|FG017|Overall Study|Death|16
5997136|NCT02499328|9590913|FG018|Overall Study|Death|5
6071116|NCT00553254|9674034|FG000|Overall Study|Other|1
6071117|NCT00553254|9674035|FG001|Overall Study|Other|0
5997137|NCT02499328|9590895|FG000|Overall Study|"Other"|2
5997138|NCT02499328|9590896|FG001|Overall Study|"Other"|2
5997139|NCT02499328|9590897|FG002|Overall Study|"Other"|1
5997140|NCT02499328|9590898|FG003|Overall Study|"Other"|3
5997141|NCT02499328|9590899|FG004|Overall Study|"Other"|6
5997142|NCT02499328|9590900|FG005|Overall Study|"Other"|2
5997143|NCT02499328|9590901|FG006|Overall Study|"Other"|3
5997144|NCT02499328|9590902|FG007|Overall Study|"Other"|4
5997145|NCT02499328|9590903|FG008|Overall Study|"Other"|6
5997146|NCT02499328|9590904|FG009|Overall Study|"Other"|16
5997147|NCT02499328|9590905|FG010|Overall Study|"Other"|13
5997148|NCT02499328|9590906|FG011|Overall Study|"Other"|31
5997149|NCT02499328|9590907|FG012|Overall Study|"Other"|8
5997150|NCT02499328|9590908|FG013|Overall Study|"Other"|7
5997151|NCT02499328|9590909|FG014|Overall Study|"Other"|6
5997152|NCT02499328|9590910|FG015|Overall Study|"Other"|0
5997153|NCT02499328|9590911|FG016|Overall Study|"Other"|0
5997154|NCT02499328|9590912|FG017|Overall Study|"Other"|34
5997155|NCT02499328|9590913|FG018|Overall Study|"Other"|43
5997156|NCT02499328|9590895|FG000|Overall Study|Disease Progression|0
5997157|NCT02499328|9590896|FG001|Overall Study|Disease Progression|0
5997158|NCT02499328|9590897|FG002|Overall Study|Disease Progression|0
5997159|NCT02499328|9590898|FG003|Overall Study|Disease Progression|0
5997160|NCT02499328|9590899|FG004|Overall Study|Disease Progression|0
5997161|NCT02499328|9590900|FG005|Overall Study|Disease Progression|0
5997162|NCT02499328|9590901|FG006|Overall Study|Disease Progression|1
5997163|NCT02499328|9590902|FG007|Overall Study|Disease Progression|0
5997164|NCT02499328|9590903|FG008|Overall Study|Disease Progression|1
5997165|NCT02499328|9590904|FG009|Overall Study|Disease Progression|0
5997166|NCT02499328|9590905|FG010|Overall Study|Disease Progression|1
6071118|NCT00553254|9674036|FG002|Overall Study|Other|13
5997167|NCT02499328|9590906|FG011|Overall Study|Disease Progression|0
5997168|NCT02499328|9590907|FG012|Overall Study|Disease Progression|0
5997169|NCT02499328|9590908|FG013|Overall Study|Disease Progression|0
5997170|NCT02499328|9590909|FG014|Overall Study|Disease Progression|0
5997171|NCT02499328|9590910|FG015|Overall Study|Disease Progression|0
5997172|NCT02499328|9590911|FG016|Overall Study|Disease Progression|0
5997173|NCT02499328|9590912|FG017|Overall Study|Disease Progression|2
5997174|NCT02499328|9590913|FG018|Overall Study|Disease Progression|0
5997175|NCT02499328|9590895|FG000|Overall Study|Adverse Event|1
5997176|NCT02499328|9590896|FG001|Overall Study|Adverse Event|0
5997177|NCT02499328|9590897|FG002|Overall Study|Adverse Event|0
5997178|NCT02499328|9590898|FG003|Overall Study|Adverse Event|1
5997179|NCT02499328|9590899|FG004|Overall Study|Adverse Event|0
5997180|NCT02499328|9590900|FG005|Overall Study|Adverse Event|0
5997181|NCT02499328|9590901|FG006|Overall Study|Adverse Event|0
5997182|NCT02499328|9590902|FG007|Overall Study|Adverse Event|0
5997183|NCT02499328|9590903|FG008|Overall Study|Adverse Event|0
5997184|NCT02499328|9590904|FG009|Overall Study|Adverse Event|0
5997185|NCT02499328|9590905|FG010|Overall Study|Adverse Event|0
5997186|NCT02499328|9590906|FG011|Overall Study|Adverse Event|0
5997187|NCT02499328|9590907|FG012|Overall Study|Adverse Event|1
5997188|NCT02499328|9590908|FG013|Overall Study|Adverse Event|0
5997189|NCT02499328|9590909|FG014|Overall Study|Adverse Event|0
5997190|NCT02499328|9590910|FG015|Overall Study|Adverse Event|0
5997191|NCT02499328|9590911|FG016|Overall Study|Adverse Event|0
5997192|NCT02499328|9590912|FG017|Overall Study|Adverse Event|0
5997193|NCT02499328|9590913|FG018|Overall Study|Adverse Event|0
5997194|NCT02460224|9591034|FG000|Overall Study|Adverse Event|0
5997195|NCT02460224|9591035|FG001|Overall Study|Adverse Event|0
5997196|NCT02460224|9591036|FG002|Overall Study|Adverse Event|0
5997197|NCT02460224|9591037|FG003|Overall Study|Adverse Event|0
5997198|NCT02460224|9591038|FG004|Overall Study|Adverse Event|0
5997199|NCT02460224|9591039|FG005|Overall Study|Adverse Event|0
5997200|NCT02460224|9591040|FG006|Overall Study|Adverse Event|1
5997201|NCT02460224|9591041|FG007|Overall Study|Adverse Event|0
5997202|NCT02460224|9591042|FG008|Overall Study|Adverse Event|0
5997203|NCT02460224|9591043|FG009|Overall Study|Adverse Event|0
5997204|NCT02460224|9591044|FG010|Overall Study|Adverse Event|0
5997205|NCT02460224|9591045|FG011|Overall Study|Adverse Event|0
5997206|NCT02460224|9591046|FG012|Overall Study|Adverse Event|1
5997207|NCT02460224|9591047|FG013|Overall Study|Adverse Event|0
5997208|NCT02460224|9591048|FG014|Overall Study|Adverse Event|0
5997209|NCT02460224|9591049|FG015|Overall Study|Adverse Event|0
5997210|NCT02460224|9591050|FG016|Overall Study|Adverse Event|1
5997211|NCT02460224|9591051|FG017|Overall Study|Adverse Event|0
5997212|NCT02460224|9591052|FG018|Overall Study|Adverse Event|1
6071119|NCT00553267|9674051|FG000|Overall Study|Adverse Event|8
5997213|NCT02460224|9591053|FG019|Overall Study|Adverse Event|0
5997214|NCT02460224|9591054|FG020|Overall Study|Adverse Event|1
5997215|NCT02460224|9591055|FG021|Overall Study|Adverse Event|1
5997216|NCT02460224|9591056|FG022|Overall Study|Adverse Event|1
5997217|NCT02460224|9591057|FG023|Overall Study|Adverse Event|0
5997218|NCT02460224|9591058|FG024|Overall Study|Adverse Event|0
5997219|NCT02460224|9591059|FG025|Overall Study|Adverse Event|0
5997220|NCT02460224|9591060|FG026|Overall Study|Adverse Event|11
5997221|NCT02460224|9591061|FG027|Overall Study|Adverse Event|1
5997222|NCT02460224|9591062|FG028|Overall Study|Adverse Event|6
5997223|NCT02460224|9591034|FG000|Overall Study|Death|0
5997224|NCT02460224|9591035|FG001|Overall Study|Death|0
5997225|NCT02460224|9591036|FG002|Overall Study|Death|0
5997226|NCT02460224|9591037|FG003|Overall Study|Death|0
5997227|NCT02460224|9591038|FG004|Overall Study|Death|0
5997228|NCT02460224|9591039|FG005|Overall Study|Death|2
5997229|NCT02460224|9591040|FG006|Overall Study|Death|1
5997230|NCT02460224|9591041|FG007|Overall Study|Death|0
5997231|NCT02460224|9591042|FG008|Overall Study|Death|0
5997232|NCT02460224|9591043|FG009|Overall Study|Death|1
5997233|NCT02460224|9591044|FG010|Overall Study|Death|0
5997234|NCT02460224|9591045|FG011|Overall Study|Death|0
5997235|NCT02460224|9591046|FG012|Overall Study|Death|0
5997236|NCT02460224|9591047|FG013|Overall Study|Death|1
5997237|NCT02460224|9591048|FG014|Overall Study|Death|0
5997238|NCT02460224|9591049|FG015|Overall Study|Death|0
5997239|NCT02460224|9591050|FG016|Overall Study|Death|2
5997240|NCT02460224|9591051|FG017|Overall Study|Death|1
5997241|NCT02460224|9591052|FG018|Overall Study|Death|0
5997242|NCT02460224|9591053|FG019|Overall Study|Death|2
5997243|NCT02460224|9591054|FG020|Overall Study|Death|0
5997244|NCT02460224|9591055|FG021|Overall Study|Death|0
5997245|NCT02460224|9591056|FG022|Overall Study|Death|0
5997246|NCT02460224|9591057|FG023|Overall Study|Death|0
5997247|NCT02460224|9591058|FG024|Overall Study|Death|1
5997248|NCT02460224|9591059|FG025|Overall Study|Death|1
5997249|NCT02460224|9591060|FG026|Overall Study|Death|5
5997250|NCT02460224|9591061|FG027|Overall Study|Death|0
5997251|NCT02460224|9591062|FG028|Overall Study|Death|1
5997252|NCT02460224|9591034|FG000|Overall Study|Lost to Follow-up|0
5997253|NCT02460224|9591035|FG001|Overall Study|Lost to Follow-up|0
5997254|NCT02460224|9591036|FG002|Overall Study|Lost to Follow-up|0
5997255|NCT02460224|9591037|FG003|Overall Study|Lost to Follow-up|0
5997256|NCT02460224|9591038|FG004|Overall Study|Lost to Follow-up|0
5997257|NCT02460224|9591039|FG005|Overall Study|Lost to Follow-up|0
5997258|NCT02460224|9591040|FG006|Overall Study|Lost to Follow-up|0
5997259|NCT02460224|9591041|FG007|Overall Study|Lost to Follow-up|0
5997260|NCT02460224|9591042|FG008|Overall Study|Lost to Follow-up|0
5997261|NCT02460224|9591043|FG009|Overall Study|Lost to Follow-up|0
5997262|NCT02460224|9591044|FG010|Overall Study|Lost to Follow-up|0
5997263|NCT02460224|9591045|FG011|Overall Study|Lost to Follow-up|0
5997264|NCT02460224|9591046|FG012|Overall Study|Lost to Follow-up|0
5997265|NCT02460224|9591047|FG013|Overall Study|Lost to Follow-up|0
5997266|NCT02460224|9591048|FG014|Overall Study|Lost to Follow-up|0
5997267|NCT02460224|9591049|FG015|Overall Study|Lost to Follow-up|0
5997268|NCT02460224|9591050|FG016|Overall Study|Lost to Follow-up|0
5997269|NCT02460224|9591051|FG017|Overall Study|Lost to Follow-up|0
5997270|NCT02460224|9591052|FG018|Overall Study|Lost to Follow-up|0
5997271|NCT02460224|9591053|FG019|Overall Study|Lost to Follow-up|0
5997272|NCT02460224|9591054|FG020|Overall Study|Lost to Follow-up|0
5997273|NCT02460224|9591055|FG021|Overall Study|Lost to Follow-up|0
5997274|NCT02460224|9591056|FG022|Overall Study|Lost to Follow-up|1
5997275|NCT02460224|9591057|FG023|Overall Study|Lost to Follow-up|0
5997276|NCT02460224|9591058|FG024|Overall Study|Lost to Follow-up|0
5997277|NCT02460224|9591059|FG025|Overall Study|Lost to Follow-up|0
5997278|NCT02460224|9591060|FG026|Overall Study|Lost to Follow-up|0
5997279|NCT02460224|9591061|FG027|Overall Study|Lost to Follow-up|0
5997280|NCT02460224|9591062|FG028|Overall Study|Lost to Follow-up|0
5997281|NCT02460224|9591034|FG000|Overall Study|Physician Decision|0
5997282|NCT02460224|9591035|FG001|Overall Study|Physician Decision|1
5997283|NCT02460224|9591036|FG002|Overall Study|Physician Decision|0
5997284|NCT02460224|9591037|FG003|Overall Study|Physician Decision|0
5997285|NCT02460224|9591038|FG004|Overall Study|Physician Decision|1
5997286|NCT02460224|9591039|FG005|Overall Study|Physician Decision|0
5997287|NCT02460224|9591040|FG006|Overall Study|Physician Decision|0
5997288|NCT02460224|9591041|FG007|Overall Study|Physician Decision|1
5997289|NCT02460224|9591042|FG008|Overall Study|Physician Decision|0
5997290|NCT02460224|9591043|FG009|Overall Study|Physician Decision|0
5997291|NCT02460224|9591044|FG010|Overall Study|Physician Decision|0
5997292|NCT02460224|9591045|FG011|Overall Study|Physician Decision|1
5997293|NCT02460224|9591046|FG012|Overall Study|Physician Decision|0
5997294|NCT02460224|9591047|FG013|Overall Study|Physician Decision|1
5997295|NCT02460224|9591048|FG014|Overall Study|Physician Decision|0
5997296|NCT02460224|9591049|FG015|Overall Study|Physician Decision|0
5997297|NCT02460224|9591050|FG016|Overall Study|Physician Decision|2
5997298|NCT02460224|9591051|FG017|Overall Study|Physician Decision|1
5997299|NCT02460224|9591052|FG018|Overall Study|Physician Decision|1
5997300|NCT02460224|9591053|FG019|Overall Study|Physician Decision|2
5997301|NCT02460224|9591054|FG020|Overall Study|Physician Decision|1
5997302|NCT02460224|9591055|FG021|Overall Study|Physician Decision|1
5997303|NCT02460224|9591056|FG022|Overall Study|Physician Decision|0
5997304|NCT02460224|9591057|FG023|Overall Study|Physician Decision|0
5997305|NCT02460224|9591058|FG024|Overall Study|Physician Decision|1
5997306|NCT02460224|9591059|FG025|Overall Study|Physician Decision|0
5997307|NCT02460224|9591060|FG026|Overall Study|Physician Decision|14
5997308|NCT02460224|9591061|FG027|Overall Study|Physician Decision|1
5997309|NCT02460224|9591062|FG028|Overall Study|Physician Decision|6
5997310|NCT02460224|9591034|FG000|Overall Study|Progressive disease|15
5997311|NCT02460224|9591035|FG001|Overall Study|Progressive disease|11
5997312|NCT02460224|9591036|FG002|Overall Study|Progressive disease|5
5997313|NCT02460224|9591037|FG003|Overall Study|Progressive disease|6
5997314|NCT02460224|9591038|FG004|Overall Study|Progressive disease|3
5997315|NCT02460224|9591039|FG005|Overall Study|Progressive disease|26
5997316|NCT02460224|9591040|FG006|Overall Study|Progressive disease|28
5997317|NCT02460224|9591041|FG007|Overall Study|Progressive disease|4
5997318|NCT02460224|9591042|FG008|Overall Study|Progressive disease|5
5997319|NCT02460224|9591043|FG009|Overall Study|Progressive disease|9
5997320|NCT02460224|9591044|FG010|Overall Study|Progressive disease|5
5997321|NCT02460224|9591045|FG011|Overall Study|Progressive disease|4
5997322|NCT02460224|9591046|FG012|Overall Study|Progressive disease|5
5997323|NCT02460224|9591047|FG013|Overall Study|Progressive disease|4
5997324|NCT02460224|9591048|FG014|Overall Study|Progressive disease|5
5997325|NCT02460224|9591049|FG015|Overall Study|Progressive disease|5
5997326|NCT02460224|9591050|FG016|Overall Study|Progressive disease|15
5997327|NCT02460224|9591051|FG017|Overall Study|Progressive disease|3
5997328|NCT02460224|9591052|FG018|Overall Study|Progressive disease|8
5997329|NCT02460224|9591053|FG019|Overall Study|Progressive disease|3
5997330|NCT02460224|9591054|FG020|Overall Study|Progressive disease|4
5997331|NCT02460224|9591055|FG021|Overall Study|Progressive disease|9
5997332|NCT02460224|9591056|FG022|Overall Study|Progressive disease|4
5997333|NCT02460224|9591057|FG023|Overall Study|Progressive disease|11
5997334|NCT02460224|9591058|FG024|Overall Study|Progressive disease|4
5997335|NCT02460224|9591059|FG025|Overall Study|Progressive disease|5
5997336|NCT02460224|9591060|FG026|Overall Study|Progressive disease|85
5997337|NCT02460224|9591061|FG027|Overall Study|Progressive disease|17
5997338|NCT02460224|9591062|FG028|Overall Study|Progressive disease|77
5997339|NCT02460224|9591034|FG000|Overall Study|Subject/guardian decision|2
5997340|NCT02460224|9591035|FG001|Overall Study|Subject/guardian decision|0
5997341|NCT02460224|9591036|FG002|Overall Study|Subject/guardian decision|1
5997342|NCT02460224|9591037|FG003|Overall Study|Subject/guardian decision|0
5997343|NCT02460224|9591038|FG004|Overall Study|Subject/guardian decision|2
5997344|NCT02460224|9591039|FG005|Overall Study|Subject/guardian decision|2
5997345|NCT02460224|9591040|FG006|Overall Study|Subject/guardian decision|0
5997346|NCT02460224|9591041|FG007|Overall Study|Subject/guardian decision|0
5997347|NCT02460224|9591042|FG008|Overall Study|Subject/guardian decision|1
5997348|NCT02460224|9591043|FG009|Overall Study|Subject/guardian decision|1
5997349|NCT02460224|9591044|FG010|Overall Study|Subject/guardian decision|0
5997350|NCT02460224|9591045|FG011|Overall Study|Subject/guardian decision|1
5997351|NCT02460224|9591046|FG012|Overall Study|Subject/guardian decision|0
5997352|NCT02460224|9591047|FG013|Overall Study|Subject/guardian decision|0
5997353|NCT02460224|9591048|FG014|Overall Study|Subject/guardian decision|0
5997354|NCT02460224|9591049|FG015|Overall Study|Subject/guardian decision|1
5997355|NCT02460224|9591050|FG016|Overall Study|Subject/guardian decision|0
5997356|NCT02460224|9591051|FG017|Overall Study|Subject/guardian decision|1
5997357|NCT02460224|9591052|FG018|Overall Study|Subject/guardian decision|2
5997358|NCT02460224|9591053|FG019|Overall Study|Subject/guardian decision|0
5997359|NCT02460224|9591054|FG020|Overall Study|Subject/guardian decision|0
5997360|NCT02460224|9591055|FG021|Overall Study|Subject/guardian decision|1
5997361|NCT02460224|9591056|FG022|Overall Study|Subject/guardian decision|0
5997362|NCT02460224|9591057|FG023|Overall Study|Subject/guardian decision|0
5997363|NCT02460224|9591058|FG024|Overall Study|Subject/guardian decision|0
5997364|NCT02460224|9591059|FG025|Overall Study|Subject/guardian decision|0
5997365|NCT02460224|9591060|FG026|Overall Study|Subject/guardian decision|6
5997366|NCT02460224|9591061|FG027|Overall Study|Subject/guardian decision|2
5997367|NCT02460224|9591062|FG028|Overall Study|Subject/guardian decision|3
5997368|NCT02460159|9591136|FG000|Overall Study|Adverse Event|4
5997369|NCT02460159|9591137|FG001|Overall Study|Adverse Event|1
5997370|NCT02460159|9591136|FG000|Overall Study|Withdrawal by Subject|2
5997371|NCT02460159|9591137|FG001|Overall Study|Withdrawal by Subject|0
5997372|NCT02457910|9591149|FG000|Overall Study|Withdrawal by Subject|0
5997373|NCT02457910|9591150|FG001|Overall Study|Withdrawal by Subject|0
5997374|NCT02457910|9591151|FG002|Overall Study|Withdrawal by Subject|0
5997375|NCT02457910|9591152|FG003|Overall Study|Withdrawal by Subject|0
5997376|NCT02457910|9591153|FG004|Overall Study|Withdrawal by Subject|0
5997377|NCT02457910|9591154|FG005|Overall Study|Withdrawal by Subject|1
5997378|NCT02457910|9591149|FG000|Overall Study|Adverse Event|0
5997379|NCT02457910|9591150|FG001|Overall Study|Adverse Event|2
5997380|NCT02457910|9591151|FG002|Overall Study|Adverse Event|1
5997381|NCT02457910|9591152|FG003|Overall Study|Adverse Event|1
5997382|NCT02457910|9591153|FG004|Overall Study|Adverse Event|1
5997383|NCT02457910|9591154|FG005|Overall Study|Adverse Event|3
5997384|NCT02457910|9591149|FG000|Overall Study|Disease progression|3
5997385|NCT02457910|9591150|FG001|Overall Study|Disease progression|3
5997386|NCT02457910|9591151|FG002|Overall Study|Disease progression|1
5997387|NCT02457910|9591152|FG003|Overall Study|Disease progression|1
5997388|NCT02457910|9591153|FG004|Overall Study|Disease progression|4
5997389|NCT02457910|9591154|FG005|Overall Study|Disease progression|6
5997390|NCT02457910|9591149|FG000|Overall Study|Other complicating illness|0
5997391|NCT02457910|9591150|FG001|Overall Study|Other complicating illness|0
5997392|NCT02457910|9591151|FG002|Overall Study|Other complicating illness|0
5997393|NCT02457910|9591152|FG003|Overall Study|Other complicating illness|0
5997394|NCT02457910|9591153|FG004|Overall Study|Other complicating illness|0
5997395|NCT02457910|9591154|FG005|Overall Study|Other complicating illness|1
5997396|NCT02457910|9591149|FG000|Overall Study|Death|0
5997397|NCT02457910|9591150|FG001|Overall Study|Death|0
5997398|NCT02457910|9591151|FG002|Overall Study|Death|1
5997399|NCT02457910|9591152|FG003|Overall Study|Death|0
5997400|NCT02457910|9591153|FG004|Overall Study|Death|0
6071120|NCT00553267|9674052|FG001|Overall Study|Adverse Event|10
6071121|NCT00553267|9674053|FG002|Overall Study|Adverse Event|5
6071122|NCT00553267|9674051|FG000|Overall Study|Non compliant with protocol|3
6071123|NCT00553267|9674052|FG001|Overall Study|Non compliant with protocol|3
6071124|NCT00553267|9674053|FG002|Overall Study|Non compliant with protocol|2
5997401|NCT02457910|9591154|FG005|Overall Study|Death|0
5997402|NCT02407236|9591179|FG000|Induction Study (8 Weeks)|Adverse Event|3
5997403|NCT02407236|9591180|FG001|Induction Study (8 Weeks)|Adverse Event|0
5997404|NCT02407236|9591181|FG002|Induction Study (8 Weeks)|Adverse Event|1
5997405|NCT02407236|9591182|FG003|Induction Study (8 Weeks)|Adverse Event|0
5997406|NCT02407236|9591183|FG004|Induction Study (8 Weeks)|Adverse Event|0
5997407|NCT02407236|9591184|FG005|Induction Study (8 Weeks)|Adverse Event|0
5997408|NCT02407236|9591185|FG006|Induction Study (8 Weeks)|Adverse Event|0
5997409|NCT02407236|9591186|FG007|Induction Study (8 Weeks)|Adverse Event|0
5997410|NCT02407236|9591179|FG000|Induction Study (8 Weeks)|Death|0
5997411|NCT02407236|9591180|FG001|Induction Study (8 Weeks)|Death|0
5997412|NCT02407236|9591181|FG002|Induction Study (8 Weeks)|Death|1
5997413|NCT02407236|9591182|FG003|Induction Study (8 Weeks)|Death|0
5997414|NCT02407236|9591183|FG004|Induction Study (8 Weeks)|Death|0
5997415|NCT02407236|9591184|FG005|Induction Study (8 Weeks)|Death|0
5997416|NCT02407236|9591185|FG006|Induction Study (8 Weeks)|Death|0
5997417|NCT02407236|9591186|FG007|Induction Study (8 Weeks)|Death|0
5997418|NCT02407236|9591179|FG000|Induction Study (8 Weeks)|Withdrawal by Subject|17
5997419|NCT02407236|9591180|FG001|Induction Study (8 Weeks)|Withdrawal by Subject|9
5997420|NCT02407236|9591181|FG002|Induction Study (8 Weeks)|Withdrawal by Subject|7
5997421|NCT02407236|9591182|FG003|Induction Study (8 Weeks)|Withdrawal by Subject|0
5997422|NCT02407236|9591183|FG004|Induction Study (8 Weeks)|Withdrawal by Subject|0
5997423|NCT02407236|9591184|FG005|Induction Study (8 Weeks)|Withdrawal by Subject|0
5997424|NCT02407236|9591185|FG006|Induction Study (8 Weeks)|Withdrawal by Subject|0
5997425|NCT02407236|9591186|FG007|Induction Study (8 Weeks)|Withdrawal by Subject|0
5997426|NCT02407236|9591179|FG000|Induction Study (8 Weeks)|Lost to Follow-up|0
5997427|NCT02407236|9591180|FG001|Induction Study (8 Weeks)|Lost to Follow-up|0
5997428|NCT02407236|9591181|FG002|Induction Study (8 Weeks)|Lost to Follow-up|1
5997429|NCT02407236|9591182|FG003|Induction Study (8 Weeks)|Lost to Follow-up|0
5997430|NCT02407236|9591183|FG004|Induction Study (8 Weeks)|Lost to Follow-up|0
5997431|NCT02407236|9591184|FG005|Induction Study (8 Weeks)|Lost to Follow-up|0
5997432|NCT02407236|9591185|FG006|Induction Study (8 Weeks)|Lost to Follow-up|0
5997433|NCT02407236|9591186|FG007|Induction Study (8 Weeks)|Lost to Follow-up|0
5997434|NCT02407236|9591179|FG000|Induction Study (8 Weeks)|Physician Decision|1
5997435|NCT02407236|9591180|FG001|Induction Study (8 Weeks)|Physician Decision|1
5997436|NCT02407236|9591181|FG002|Induction Study (8 Weeks)|Physician Decision|0
5997437|NCT02407236|9591182|FG003|Induction Study (8 Weeks)|Physician Decision|0
5997438|NCT02407236|9591183|FG004|Induction Study (8 Weeks)|Physician Decision|0
5997439|NCT02407236|9591184|FG005|Induction Study (8 Weeks)|Physician Decision|0
5997440|NCT02407236|9591185|FG006|Induction Study (8 Weeks)|Physician Decision|0
5997441|NCT02407236|9591186|FG007|Induction Study (8 Weeks)|Physician Decision|0
5997442|NCT02407236|9591179|FG000|Induction Study (8 Weeks)|Other|2
5997443|NCT02407236|9591180|FG001|Induction Study (8 Weeks)|Other|1
5997444|NCT02407236|9591181|FG002|Induction Study (8 Weeks)|Other|5
5997445|NCT02407236|9591182|FG003|Induction Study (8 Weeks)|Other|0
5997446|NCT02407236|9591183|FG004|Induction Study (8 Weeks)|Other|0
5997447|NCT02407236|9591184|FG005|Induction Study (8 Weeks)|Other|0
5997448|NCT02407236|9591185|FG006|Induction Study (8 Weeks)|Other|0
5997449|NCT02407236|9591186|FG007|Induction Study (8 Weeks)|Other|0
5997450|NCT02407236|9591179|FG000|Maintenance Study (44 Weeks)|Lost to Follow-up|0
5997451|NCT02407236|9591180|FG001|Maintenance Study (44 Weeks)|Lost to Follow-up|0
5997452|NCT02407236|9591181|FG002|Maintenance Study (44 Weeks)|Lost to Follow-up|0
5997453|NCT02407236|9591182|FG003|Maintenance Study (44 Weeks)|Lost to Follow-up|1
5997454|NCT02407236|9591183|FG004|Maintenance Study (44 Weeks)|Lost to Follow-up|0
5997455|NCT02407236|9591184|FG005|Maintenance Study (44 Weeks)|Lost to Follow-up|1
5997456|NCT02407236|9591185|FG006|Maintenance Study (44 Weeks)|Lost to Follow-up|0
5997457|NCT02407236|9591186|FG007|Maintenance Study (44 Weeks)|Lost to Follow-up|1
5997458|NCT02407236|9591179|FG000|Maintenance Study (44 Weeks)|Death|0
5997459|NCT02407236|9591180|FG001|Maintenance Study (44 Weeks)|Death|0
5997460|NCT02407236|9591181|FG002|Maintenance Study (44 Weeks)|Death|0
5997461|NCT02407236|9591182|FG003|Maintenance Study (44 Weeks)|Death|0
5997462|NCT02407236|9591183|FG004|Maintenance Study (44 Weeks)|Death|0
5997463|NCT02407236|9591184|FG005|Maintenance Study (44 Weeks)|Death|0
5997464|NCT02407236|9591185|FG006|Maintenance Study (44 Weeks)|Death|0
5997465|NCT02407236|9591186|FG007|Maintenance Study (44 Weeks)|Death|1
5997466|NCT02407236|9591179|FG000|Maintenance Study (44 Weeks)|Withdraw of consent|0
5997467|NCT02407236|9591180|FG001|Maintenance Study (44 Weeks)|Withdraw of consent|0
5997468|NCT02407236|9591181|FG002|Maintenance Study (44 Weeks)|Withdraw of consent|0
5997469|NCT02407236|9591182|FG003|Maintenance Study (44 Weeks)|Withdraw of consent|8
5997470|NCT02407236|9591183|FG004|Maintenance Study (44 Weeks)|Withdraw of consent|10
5997471|NCT02407236|9591184|FG005|Maintenance Study (44 Weeks)|Withdraw of consent|5
6071125|NCT00553267|9674051|FG000|Overall Study|Lost to Follow-up|0
6071126|NCT00553267|9674052|FG001|Overall Study|Lost to Follow-up|0
6071127|NCT00553267|9674053|FG002|Overall Study|Lost to Follow-up|1
6071128|NCT00553267|9674051|FG000|Overall Study|Consent withdrawn|2
5997472|NCT02407236|9591185|FG006|Maintenance Study (44 Weeks)|Withdraw of consent|7
5997473|NCT02407236|9591186|FG007|Maintenance Study (44 Weeks)|Withdraw of consent|5
5997474|NCT02407236|9591179|FG000|Maintenance Study (44 Weeks)|Sponsor decision|0
5997475|NCT02407236|9591180|FG001|Maintenance Study (44 Weeks)|Sponsor decision|0
5997476|NCT02407236|9591181|FG002|Maintenance Study (44 Weeks)|Sponsor decision|0
5997477|NCT02407236|9591182|FG003|Maintenance Study (44 Weeks)|Sponsor decision|1
5997478|NCT02407236|9591183|FG004|Maintenance Study (44 Weeks)|Sponsor decision|0
5997479|NCT02407236|9591184|FG005|Maintenance Study (44 Weeks)|Sponsor decision|1
5997480|NCT02407236|9591185|FG006|Maintenance Study (44 Weeks)|Sponsor decision|0
5997481|NCT02407236|9591186|FG007|Maintenance Study (44 Weeks)|Sponsor decision|0
5997482|NCT02407236|9591179|FG000|Maintenance Study (44 Weeks)|Other|0
5997483|NCT02407236|9591180|FG001|Maintenance Study (44 Weeks)|Other|0
5997484|NCT02407236|9591181|FG002|Maintenance Study (44 Weeks)|Other|0
5997485|NCT02407236|9591182|FG003|Maintenance Study (44 Weeks)|Other|0
5997486|NCT02407236|9591183|FG004|Maintenance Study (44 Weeks)|Other|1
5997487|NCT02407236|9591184|FG005|Maintenance Study (44 Weeks)|Other|1
5997488|NCT02407236|9591185|FG006|Maintenance Study (44 Weeks)|Other|2
5997489|NCT02407236|9591186|FG007|Maintenance Study (44 Weeks)|Other|1
5997490|NCT02320396|9591206|FG000|Overall Study|Adverse Event|2
5997491|NCT02320396|9591207|FG001|Overall Study|Adverse Event|2
5997492|NCT02320396|9591206|FG000|Overall Study|Pregnancy|0
5997493|NCT02320396|9591207|FG001|Overall Study|Pregnancy|1
5997494|NCT02320396|9591206|FG000|Overall Study|Protocol Violation|0
5997495|NCT02320396|9591207|FG001|Overall Study|Protocol Violation|1
5997496|NCT02320396|9591206|FG000|Overall Study|Withdrawal by Subject|2
5997497|NCT02320396|9591207|FG001|Overall Study|Withdrawal by Subject|0
5997498|NCT02282345|9591215|FG000|Overall Study|Progression|0
5997499|NCT02282345|9591216|FG001|Overall Study|Progression|1
5997500|NCT02230410|9591225|FG000|Overall Study|Screen Failure|3
5997501|NCT02053246|9591229|FG000|Overall Study|Withdrawal by Subject|3
5997502|NCT02053246|9591229|FG000|Overall Study|Physician Decision|1
5997503|NCT01980940|9591241|FG000|Overall Study|Protocol Violation|0
5997504|NCT01980940|9591242|FG001|Overall Study|Protocol Violation|0
5997505|NCT01980940|9591243|FG002|Overall Study|Protocol Violation|0
5997506|NCT01980940|9591244|FG003|Overall Study|Protocol Violation|0
5997507|NCT01980940|9591245|FG004|Overall Study|Protocol Violation|0
5997508|NCT01980940|9591246|FG005|Overall Study|Protocol Violation|2
5997509|NCT01980940|9591247|FG006|Overall Study|Protocol Violation|0
5997510|NCT01980940|9591248|FG007|Overall Study|Protocol Violation|0
5997511|NCT01918033|9591279|FG000|Overall Study|Adverse Event|1
5997512|NCT01918033|9591280|FG001|Overall Study|Adverse Event|0
5997513|NCT01918033|9591281|FG002|Overall Study|Adverse Event|2
5997514|NCT01918033|9591279|FG000|Overall Study|Lost to Follow-up|0
5997515|NCT01918033|9591280|FG001|Overall Study|Lost to Follow-up|1
5997516|NCT01918033|9591281|FG002|Overall Study|Lost to Follow-up|0
5997517|NCT01918033|9591279|FG000|Overall Study|Protocol Violation|2
5997518|NCT01918033|9591280|FG001|Overall Study|Protocol Violation|0
6071129|NCT00553267|9674052|FG001|Overall Study|Consent withdrawn|3
6071130|NCT00553267|9674053|FG002|Overall Study|Consent withdrawn|1
6071131|NCT00553267|9674051|FG000|Overall Study|Specified category|1
6071132|NCT00553267|9674052|FG001|Overall Study|Specified category|2
6071133|NCT00553267|9674053|FG002|Overall Study|Specified category|1
6071134|NCT00553280|9674061|FG000|Overall Study|Adverse Event|19
6071135|NCT00553280|9674061|FG000|Overall Study|Lack of Efficacy|3
6071136|NCT00553280|9674061|FG000|Overall Study|Withdrawal by Subject|3
6071137|NCT00553280|9674061|FG000|Overall Study|Physician Decision|1
6071138|NCT00553319|9674068|FG000|Overall Study|Lost to Follow-up|10
6071139|NCT00553319|9674069|FG001|Overall Study|Lost to Follow-up|9
6071140|NCT00553319|9674070|FG002|Overall Study|Lost to Follow-up|5
6071141|NCT00553319|9674068|FG000|Overall Study|wanted treatment elsewhere|2
6071142|NCT00553319|9674069|FG001|Overall Study|wanted treatment elsewhere|1
6071143|NCT00553319|9674070|FG002|Overall Study|wanted treatment elsewhere|1
6071144|NCT00553319|9674068|FG000|Overall Study|non-compliance|0
6071145|NCT00553319|9674069|FG001|Overall Study|non-compliance|0
6071146|NCT00553319|9674070|FG002|Overall Study|non-compliance|2
6071147|NCT00553319|9674068|FG000|Overall Study|incarceration|1
6071148|NCT00553319|9674069|FG001|Overall Study|incarceration|0
6071149|NCT00553319|9674070|FG002|Overall Study|incarceration|0
6071150|NCT00553319|9674068|FG000|Overall Study|moved|1
6071151|NCT00553319|9674069|FG001|Overall Study|moved|0
5997519|NCT01918033|9591281|FG002|Overall Study|Protocol Violation|1
5997520|NCT01918033|9591279|FG000|Overall Study|Withdrawal by Subject|2
5997521|NCT01918033|9591280|FG001|Overall Study|Withdrawal by Subject|1
6071152|NCT00553319|9674070|FG002|Overall Study|moved|1
6071153|NCT00553332|9674078|FG000|Overall Study|ineligible, incorrect diagnosis|1
6071154|NCT00553358|9674085|FG000|Overall Study|Randomized but did not receive treatment|3
6071155|NCT00553358|9674086|FG001|Overall Study|Randomized but did not receive treatment|3
5997522|NCT01918033|9591281|FG002|Overall Study|Withdrawal by Subject|0
5997523|NCT01916980|9591291|FG000|Overall Study|Adverse Event|4
5997524|NCT01916980|9591292|FG001|Overall Study|Adverse Event|2
5997525|NCT01916980|9591291|FG000|Overall Study|Lack of Efficacy|2
5997526|NCT01916980|9591292|FG001|Overall Study|Lack of Efficacy|2
5997527|NCT01916980|9591291|FG000|Overall Study|Withdrawal by Subject|1
5997528|NCT01916980|9591292|FG001|Overall Study|Withdrawal by Subject|0
5997529|NCT01916967|9591301|FG000|Overall Study|Adverse Event|0
5997530|NCT01916967|9591302|FG001|Overall Study|Adverse Event|0
5997531|NCT01916967|9591303|FG002|Overall Study|Adverse Event|2
5997532|NCT01916967|9591301|FG000|Overall Study|Lack of Efficacy|0
5997533|NCT01916967|9591302|FG001|Overall Study|Lack of Efficacy|0
5997534|NCT01916967|9591303|FG002|Overall Study|Lack of Efficacy|6
6071156|NCT00553358|9674087|FG002|Overall Study|Randomized but did not receive treatment|1
6071157|NCT00553358|9674085|FG000|Overall Study|Lost to Follow-up|22
6071158|NCT00553358|9674086|FG001|Overall Study|Lost to Follow-up|26
6071159|NCT00553358|9674087|FG002|Overall Study|Lost to Follow-up|18
6071160|NCT00553358|9674085|FG000|Overall Study|Withdrew completely|23
6071161|NCT00553358|9674086|FG001|Overall Study|Withdrew completely|33
6071162|NCT00553358|9674087|FG002|Overall Study|Withdrew completely|34
6071163|NCT00553358|9674085|FG000|Overall Study|Died during clinical follow-up|25
6071164|NCT00553358|9674086|FG001|Overall Study|Died during clinical follow-up|29
6071165|NCT00553358|9674087|FG002|Overall Study|Died during clinical follow-up|32
6071166|NCT00553358|9674085|FG000|Overall Study|Not dead but were last followed-up prior to 9 years + 6 months after randomization|4
6071167|NCT00553358|9674086|FG001|Overall Study|Not dead but were last followed-up prior to 9 years + 6 months after randomization|2
6071168|NCT00553358|9674087|FG002|Overall Study|Not dead but were last followed-up prior to 9 years + 6 months after randomization|2
6071169|NCT00553358|9674085|FG000|Overall Study|Died after clinical follow-up ended|1
6071170|NCT00553358|9674086|FG001|Overall Study|Died after clinical follow-up ended|2
6071171|NCT00553358|9674087|FG002|Overall Study|Died after clinical follow-up ended|0
6071172|NCT00553358|9674085|FG000|Overall Study|Withdrew (survival only) - alive at end of survival follow-up|1
6071173|NCT00553358|9674086|FG001|Overall Study|Withdrew (survival only) - alive at end of survival follow-up|1
6071174|NCT00553358|9674087|FG002|Overall Study|Withdrew (survival only) - alive at end of survival follow-up|1
6071175|NCT00553436|9674110|FG000|Overall Study|Conversion to another procedure|1
6071176|NCT00553462|9674114|FG000|Overall Study|Adverse Event|4
6071177|NCT00553462|9674114|FG000|Overall Study|Progression|4
6071178|NCT00553462|9674114|FG000|Overall Study|Withdrawal by Subject|5
6071179|NCT00553462|9674114|FG000|Overall Study|Physician Decision|1
6071180|NCT00553475|9674121|FG000|Overall Study|Adverse Event|7
6071181|NCT00553475|9674122|FG001|Overall Study|Adverse Event|17
6071182|NCT00553475|9674123|FG002|Overall Study|Adverse Event|13
6071183|NCT00553475|9674121|FG000|Overall Study|Lack of Efficacy|7
6071184|NCT00553475|9674122|FG001|Overall Study|Lack of Efficacy|1
6071185|NCT00553475|9674123|FG002|Overall Study|Lack of Efficacy|0
6071186|NCT00553475|9674121|FG000|Overall Study|Withdrawal by Subject|1
6071187|NCT00553475|9674122|FG001|Overall Study|Withdrawal by Subject|1
6071188|NCT00553475|9674123|FG002|Overall Study|Withdrawal by Subject|0
6071189|NCT00553475|9674121|FG000|Overall Study|Physician Decision|1
6071190|NCT00553475|9674122|FG001|Overall Study|Physician Decision|0
6071191|NCT00553475|9674123|FG002|Overall Study|Physician Decision|0
6071192|NCT00553475|9674121|FG000|Overall Study|Due to moving|0
6071193|NCT00553475|9674122|FG001|Overall Study|Due to moving|1
6071194|NCT00553475|9674123|FG002|Overall Study|Due to moving|0
6071195|NCT00553501|9674133|FG000|Overall Study|Adverse Event|2
6071196|NCT00553501|9674133|FG000|Overall Study|Death|1
6071197|NCT00553501|9674133|FG000|Overall Study|Progression|1
6071198|NCT00553514|9674142|FG000|Overall Study|Protocol deviation|0
6071199|NCT00553514|9674143|FG001|Overall Study|Protocol deviation|0
6071200|NCT00553514|9674144|FG002|Overall Study|Protocol deviation|0
6071201|NCT00553514|9674145|FG003|Overall Study|Protocol deviation|1
6071202|NCT00553514|9674146|FG004|Overall Study|Protocol deviation|0
6071203|NCT00553514|9674142|FG000|Overall Study|Lack of ovarian response|4
6071204|NCT00553514|9674143|FG001|Overall Study|Lack of ovarian response|5
6071205|NCT00553514|9674144|FG002|Overall Study|Lack of ovarian response|5
6071206|NCT00553514|9674145|FG003|Overall Study|Lack of ovarian response|5
6071207|NCT00553514|9674146|FG004|Overall Study|Lack of ovarian response|6
6071208|NCT00553514|9674142|FG000|Overall Study|Ovarian hyperstimulation syndrome risk|3
6071209|NCT00553514|9674143|FG001|Overall Study|Ovarian hyperstimulation syndrome risk|0
6071210|NCT00553514|9674144|FG002|Overall Study|Ovarian hyperstimulation syndrome risk|1
6071211|NCT00553514|9674145|FG003|Overall Study|Ovarian hyperstimulation syndrome risk|0
6071212|NCT00553514|9674146|FG004|Overall Study|Ovarian hyperstimulation syndrome risk|0
6071213|NCT00553514|9674142|FG000|Overall Study|Risk of multiple pregnancy|0
6071214|NCT00553514|9674143|FG001|Overall Study|Risk of multiple pregnancy|2
6071215|NCT00553514|9674144|FG002|Overall Study|Risk of multiple pregnancy|0
6071216|NCT00553514|9674145|FG003|Overall Study|Risk of multiple pregnancy|1
6071217|NCT00553514|9674146|FG004|Overall Study|Risk of multiple pregnancy|0
6071218|NCT00553514|9674142|FG000|Overall Study|Other|1
6071219|NCT00553514|9674143|FG001|Overall Study|Other|1
6071220|NCT00553514|9674144|FG002|Overall Study|Other|0
6071221|NCT00553514|9674145|FG003|Overall Study|Other|0
6071222|NCT00553514|9674146|FG004|Overall Study|Other|1
6071223|NCT00553540|9674160|FG000|Overall Study|discharged after first visit|2
5997535|NCT01916967|9591301|FG000|Overall Study|Physician Decision|0
5997536|NCT01916967|9591302|FG001|Overall Study|Physician Decision|0
5997537|NCT01916967|9591303|FG002|Overall Study|Physician Decision|1
5997538|NCT01916967|9591301|FG000|Overall Study|Protocol Violation|0
5997539|NCT01916967|9591302|FG001|Overall Study|Protocol Violation|1
5997540|NCT01916967|9591303|FG002|Overall Study|Protocol Violation|0
5997541|NCT01910402|9591315|FG000|Randomized Phase|Adverse Event|10
5997542|NCT01910402|9591316|FG001|Randomized Phase|Adverse Event|18
5997543|NCT01910402|9591315|FG000|Randomized Phase|Physician Decision|1
5997544|NCT01910402|9591316|FG001|Randomized Phase|Physician Decision|0
5997545|NCT01910402|9591315|FG000|Randomized Phase|Lack of Efficacy|5
6071224|NCT00553540|9674161|FG001|Overall Study|discharged after first visit|5
5997546|NCT01910402|9591316|FG001|Randomized Phase|Lack of Efficacy|4
5997547|NCT01910402|9591315|FG000|Randomized Phase|Lost to Follow-up|11
5997548|NCT01910402|9591316|FG001|Randomized Phase|Lost to Follow-up|13
5997549|NCT01910402|9591315|FG000|Randomized Phase|Protocol Violation|10
5997550|NCT01910402|9591316|FG001|Randomized Phase|Protocol Violation|13
5997551|NCT01910402|9591315|FG000|Randomized Phase|Withdrawal by Subject|5
5997552|NCT01910402|9591316|FG001|Randomized Phase|Withdrawal by Subject|7
5997553|NCT01910402|9591315|FG000|Continuation Phase|Ongoing|84
5997554|NCT01910402|9591316|FG001|Continuation Phase|Ongoing|0
5997555|NCT01910402|9591315|FG000|Continuation Phase|Adverse Event|1
5997556|NCT01910402|9591316|FG001|Continuation Phase|Adverse Event|0
6071225|NCT00553605|9674169|FG000|Overall Study|Did not meet entrance criteria|1
6071226|NCT00553605|9674170|FG001|Overall Study|Did not meet entrance criteria|3
6071227|NCT00553605|9674169|FG000|Overall Study|Did not receive full dose|1
6071228|NCT00553605|9674170|FG001|Overall Study|Did not receive full dose|0
6071229|NCT00553605|9674169|FG000|Overall Study|Randomized but not treated|2
6071230|NCT00553605|9674170|FG001|Overall Study|Randomized but not treated|0
6071231|NCT00553631|9674178|FG000|Overall Study|Withdrawal by Subject|0
6071232|NCT00553631|9674179|FG001|Overall Study|Withdrawal by Subject|1
6071233|NCT00553631|9674178|FG000|Overall Study|Lost to Follow-up|1
6071234|NCT00553631|9674179|FG001|Overall Study|Lost to Follow-up|0
6071235|NCT00553644|9674185|FG000|Overall Study|Adverse Event|17
6071236|NCT00553644|9674185|FG000|Overall Study|Withdrawal by Subject|4
6071237|NCT00553644|9674185|FG000|Overall Study|Physician Decision|1
6071238|NCT00553644|9674185|FG000|Overall Study|Alternative therapy|6
6071239|NCT00553696|9674193|FG000|Overall Study|Adverse Event|2
6071240|NCT00553696|9674194|FG001|Overall Study|Adverse Event|4
6071241|NCT00553696|9674195|FG002|Overall Study|Adverse Event|0
6071242|NCT00553696|9674196|FG003|Overall Study|Adverse Event|1
6071243|NCT00553696|9674193|FG000|Overall Study|Global deterioration of health status|0
6071244|NCT00553696|9674194|FG001|Overall Study|Global deterioration of health status|2
6071245|NCT00553696|9674195|FG002|Overall Study|Global deterioration of health status|0
6071246|NCT00553696|9674196|FG003|Overall Study|Global deterioration of health status|0
6071247|NCT00553696|9674193|FG000|Overall Study|Objective progression or relapse|2
6071248|NCT00553696|9674194|FG001|Overall Study|Objective progression or relapse|9
6071249|NCT00553696|9674195|FG002|Overall Study|Objective progression or relapse|6
6071250|NCT00553696|9674196|FG003|Overall Study|Objective progression or relapse|0
6071251|NCT00553696|9674193|FG000|Overall Study|Withdrawal by Subject|0
6071252|NCT00553696|9674194|FG001|Overall Study|Withdrawal by Subject|1
6071253|NCT00553696|9674195|FG002|Overall Study|Withdrawal by Subject|0
6071254|NCT00553696|9674196|FG003|Overall Study|Withdrawal by Subject|0
6071255|NCT00553787|9674219|FG000|Overall Study|Adverse Event|34
6071256|NCT00553787|9674220|FG001|Overall Study|Adverse Event|21
6071257|NCT00553787|9674221|FG002|Overall Study|Adverse Event|67
6071258|NCT00553787|9674219|FG000|Overall Study|Lost to Follow-up|132
6071259|NCT00553787|9674220|FG001|Overall Study|Lost to Follow-up|44
6071260|NCT00553787|9674221|FG002|Overall Study|Lost to Follow-up|78
6071261|NCT00553787|9674219|FG000|Overall Study|Withdrawal by Subject|151
6071262|NCT00553787|9674220|FG001|Overall Study|Withdrawal by Subject|40
6071263|NCT00553787|9674221|FG002|Overall Study|Withdrawal by Subject|83
6071264|NCT00553787|9674219|FG000|Overall Study|Lack of Efficacy|31
6071265|NCT00553787|9674220|FG001|Overall Study|Lack of Efficacy|1
6071266|NCT00553787|9674221|FG002|Overall Study|Lack of Efficacy|3
6071267|NCT00553787|9674219|FG000|Overall Study|Pregnancy|0
6071268|NCT00553787|9674220|FG001|Overall Study|Pregnancy|1
6071269|NCT00553787|9674221|FG002|Overall Study|Pregnancy|2
6071270|NCT00553787|9674219|FG000|Overall Study|non compliance|4
6071271|NCT00553787|9674220|FG001|Overall Study|non compliance|0
6071272|NCT00553787|9674221|FG002|Overall Study|non compliance|11
6071273|NCT00553787|9674219|FG000|Overall Study|Requirement for restricted medication|8
6071274|NCT00553787|9674220|FG001|Overall Study|Requirement for restricted medication|7
6071275|NCT00553787|9674221|FG002|Overall Study|Requirement for restricted medication|5
6071276|NCT00553787|9674219|FG000|Overall Study|Other|18
6071277|NCT00553787|9674220|FG001|Overall Study|Other|10
6071278|NCT00553787|9674221|FG002|Overall Study|Other|13
6071279|NCT00554099|9674253|FG000|Treatment Period (12 Weeks)|Adverse Event|3
6071280|NCT00554099|9674254|FG001|Treatment Period (12 Weeks)|Adverse Event|5
6071281|NCT00554099|9674255|FG002|Treatment Period (12 Weeks)|Adverse Event|1
6071282|NCT00554099|9674253|FG000|Treatment Period (12 Weeks)|Physician Decision|3
5997557|NCT01910402|9591315|FG000|Continuation Phase|Protocol Violation|3
6071283|NCT00554099|9674254|FG001|Treatment Period (12 Weeks)|Physician Decision|0
6071284|NCT00554099|9674255|FG002|Treatment Period (12 Weeks)|Physician Decision|0
6071285|NCT00554099|9674253|FG000|Treatment Period (12 Weeks)|Lost to Follow-up|1
5997558|NCT01910402|9591316|FG001|Continuation Phase|Protocol Violation|0
6071286|NCT00554099|9674254|FG001|Treatment Period (12 Weeks)|Lost to Follow-up|0
6071287|NCT00554099|9674255|FG002|Treatment Period (12 Weeks)|Lost to Follow-up|2
6087259|NCT00666926|9697367|FG008|Overall Study|Withdrawal by Subject|0
5997559|NCT01910402|9591315|FG000|Continuation Phase|Withdrawal by Subject|2
6071288|NCT00554099|9674253|FG000|Treatment Period (12 Weeks)|Recurrent diverticulitis,surgery require|1
6071289|NCT00554099|9674254|FG001|Treatment Period (12 Weeks)|Recurrent diverticulitis,surgery require|2
6071290|NCT00554099|9674255|FG002|Treatment Period (12 Weeks)|Recurrent diverticulitis,surgery require|0
6071291|NCT00554099|9674253|FG000|Treatment Period (12 Weeks)|Protocol Violation|0
6071292|NCT00554099|9674254|FG001|Treatment Period (12 Weeks)|Protocol Violation|0
6071293|NCT00554099|9674255|FG002|Treatment Period (12 Weeks)|Protocol Violation|2
6071294|NCT00554099|9674253|FG000|Treatment Period (12 Weeks)|Withdrawal by Subject|4
6071295|NCT00554099|9674254|FG001|Treatment Period (12 Weeks)|Withdrawal by Subject|1
6071296|NCT00554099|9674255|FG002|Treatment Period (12 Weeks)|Withdrawal by Subject|4
6071297|NCT00554099|9674253|FG000|Non-Treatment Phase (9 Months)|Lost to Follow-up|1
6071298|NCT00554099|9674254|FG001|Non-Treatment Phase (9 Months)|Lost to Follow-up|2
6071299|NCT00554099|9674255|FG002|Non-Treatment Phase (9 Months)|Lost to Follow-up|0
6071300|NCT00554099|9674253|FG000|Non-Treatment Phase (9 Months)|Relapse|2
6071301|NCT00554099|9674254|FG001|Non-Treatment Phase (9 Months)|Relapse|1
6071302|NCT00554099|9674255|FG002|Non-Treatment Phase (9 Months)|Relapse|1
6071303|NCT00554099|9674253|FG000|Non-Treatment Phase (9 Months)|Withdrawal by Subject|4
6071304|NCT00554099|9674254|FG001|Non-Treatment Phase (9 Months)|Withdrawal by Subject|2
6071305|NCT00554099|9674255|FG002|Non-Treatment Phase (9 Months)|Withdrawal by Subject|2
6071306|NCT00554216|9674266|FG000|Overall Study|Lost to Follow-up|92
6071307|NCT00554216|9674267|FG001|Overall Study|Lost to Follow-up|31
6071308|NCT00554216|9674268|FG002|Overall Study|Lost to Follow-up|63
6071309|NCT00554216|9674266|FG000|Overall Study|Adverse Event|16
6071310|NCT00554216|9674267|FG001|Overall Study|Adverse Event|16
6071311|NCT00554216|9674268|FG002|Overall Study|Adverse Event|36
6071312|NCT00554216|9674266|FG000|Overall Study|Withdrawal by Subject|92
6071313|NCT00554216|9674267|FG001|Overall Study|Withdrawal by Subject|31
6071314|NCT00554216|9674268|FG002|Overall Study|Withdrawal by Subject|43
6071315|NCT00554216|9674266|FG000|Overall Study|Non compliance|10
6071316|NCT00554216|9674267|FG001|Overall Study|Non compliance|4
6071317|NCT00554216|9674268|FG002|Overall Study|Non compliance|5
6071318|NCT00554216|9674266|FG000|Overall Study|Pregnancy|2
6071319|NCT00554216|9674267|FG001|Overall Study|Pregnancy|1
6071320|NCT00554216|9674268|FG002|Overall Study|Pregnancy|14
6071321|NCT00554216|9674266|FG000|Overall Study|Restricted med|3
6071322|NCT00554216|9674267|FG001|Overall Study|Restricted med|1
6071323|NCT00554216|9674268|FG002|Overall Study|Restricted med|1
6071324|NCT00554216|9674266|FG000|Overall Study|Other|12
6071325|NCT00554216|9674267|FG001|Overall Study|Other|7
6071326|NCT00554216|9674268|FG002|Overall Study|Other|10
6071327|NCT00554216|9674266|FG000|Overall Study|Lack of Efficacy|15
6071328|NCT00554216|9674267|FG001|Overall Study|Lack of Efficacy|3
6071329|NCT00554216|9674268|FG002|Overall Study|Lack of Efficacy|0
6071330|NCT00554229|9674278|FG000|Overall Study|Lost to Follow-up|3
6071331|NCT00554229|9674279|FG001|Overall Study|Lost to Follow-up|6
6071332|NCT00554229|9674278|FG000|Overall Study|Withdrawal by Subject|29
6071333|NCT00554229|9674279|FG001|Overall Study|Withdrawal by Subject|37
6071334|NCT00554229|9674278|FG000|Overall Study|Adverse Event|71
6071335|NCT00554229|9674279|FG001|Overall Study|Adverse Event|39
6071336|NCT00554229|9674278|FG000|Overall Study|Protocol Violation|3
6071337|NCT00554229|9674279|FG001|Overall Study|Protocol Violation|3
6071338|NCT00554229|9674278|FG000|Overall Study|Reason not otherwise captured, eg; death|119
5997560|NCT01910402|9591316|FG001|Continuation Phase|Withdrawal by Subject|0
5997561|NCT01870401|9591335|FG000|Overall Study|Death|48
5997562|NCT01870401|9591336|FG001|Overall Study|Death|24
5997563|NCT01870401|9591335|FG000|Overall Study|Withdrawal by Subject|39
5997564|NCT01870401|9591336|FG001|Overall Study|Withdrawal by Subject|26
5997565|NCT01870401|9591335|FG000|Overall Study|Lost to Follow-up|19
5997566|NCT01870401|9591336|FG001|Overall Study|Lost to Follow-up|14
5997567|NCT01870401|9591335|FG000|Overall Study|Other|9
5997568|NCT01870401|9591336|FG001|Overall Study|Other|7
5997569|NCT01870401|9591335|FG000|Overall Study|On-going in the Study|35
5997570|NCT01870401|9591336|FG001|Overall Study|On-going in the Study|25
6146243|NCT01076010|9780833|FG001|Overall Study|Adverse Event|2
6146244|NCT01076010|9780834|FG002|Overall Study|Adverse Event|0
6146245|NCT01076010|9780832|FG000|Overall Study|Progressive disease|90
6146246|NCT01076010|9780833|FG001|Overall Study|Progressive disease|30
6146247|NCT01076010|9780834|FG002|Overall Study|Progressive disease|1
6146248|NCT01076010|9780832|FG000|Overall Study|Lack of Efficacy|4
5997571|NCT01867606|9591346|FG000|Overall Study|Withdrawal by Subject|10
5997572|NCT01867606|9591347|FG001|Overall Study|Withdrawal by Subject|14
5997573|NCT01867606|9591346|FG000|Overall Study|Protocol Violation|0
5997574|NCT01867606|9591347|FG001|Overall Study|Protocol Violation|1
5997575|NCT01857063|9591361|FG000|Period 1 (7 Days)|Adverse Event|0
5997576|NCT01857063|9591362|FG001|Period 1 (7 Days)|Adverse Event|1
5997577|NCT01857063|9591361|FG000|Period 1 (7 Days)|Physician Decision|1
5997578|NCT01857063|9591362|FG001|Period 1 (7 Days)|Physician Decision|0
6071339|NCT00554229|9674279|FG001|Overall Study|Reason not otherwise captured, eg; death|140
6071340|NCT00554229|9674278|FG000|Overall Study|Randomised but no treatment received|1
6146249|NCT01076010|9780833|FG001|Overall Study|Lack of Efficacy|0
6146250|NCT01076010|9780834|FG002|Overall Study|Lack of Efficacy|0
6193346|NCT01437397|9850970|FG004|Overall Study|Adverse Event|21
5997579|NCT01857063|9591361|FG000|Period 1 (7 Days)|Withdrawal by Subject|1
5997580|NCT01857063|9591362|FG001|Period 1 (7 Days)|Withdrawal by Subject|3
5997581|NCT01857063|9591361|FG000|Period 2 (7 Days)|Adverse Event|2
5997582|NCT01857063|9591362|FG001|Period 2 (7 Days)|Adverse Event|1
5997583|NCT01857063|9591361|FG000|Period 2 (7 Days)|Physician Decision|1
5997584|NCT01857063|9591362|FG001|Period 2 (7 Days)|Physician Decision|1
5997585|NCT01857063|9591361|FG000|Period 2 (7 Days)|Withdrawal by Subject|1
5997586|NCT01857063|9591362|FG001|Period 2 (7 Days)|Withdrawal by Subject|0
5997587|NCT01852812|9591375|FG000|Overall Study|Adverse Event|0
5997588|NCT01852812|9591376|FG001|Overall Study|Adverse Event|0
5997589|NCT01852812|9591377|FG002|Overall Study|Adverse Event|1
5997590|NCT01852812|9591375|FG000|Overall Study|Non-compliance With Study Drug|0
5997591|NCT01852812|9591376|FG001|Overall Study|Non-compliance With Study Drug|1
5997592|NCT01852812|9591377|FG002|Overall Study|Non-compliance With Study Drug|0
5997593|NCT01828021|9591385|FG000|Overall Study|Adverse Event|5
5997594|NCT01828021|9591385|FG000|Overall Study|Lack of Efficacy|17
5997595|NCT01828021|9591385|FG000|Overall Study|Withdrawal by Subject|2
5997596|NCT01828021|9591385|FG000|Overall Study|Ileal obstruction, unrelated|1
5997597|NCT01709318|9591396|FG000|Overall Study|Adverse Event|3
5997598|NCT01709318|9591397|FG001|Overall Study|Adverse Event|4
5997599|NCT01709318|9591398|FG002|Overall Study|Adverse Event|2
5997600|NCT01709318|9591399|FG003|Overall Study|Adverse Event|2
5997601|NCT01709318|9591400|FG004|Overall Study|Adverse Event|0
5997602|NCT01709318|9591401|FG005|Overall Study|Adverse Event|1
5997603|NCT01709318|9591402|FG006|Overall Study|Adverse Event|2
5997604|NCT01709318|9591396|FG000|Overall Study|Lost to Follow-up|2
5997605|NCT01709318|9591397|FG001|Overall Study|Lost to Follow-up|0
5997606|NCT01709318|9591398|FG002|Overall Study|Lost to Follow-up|0
5997607|NCT01709318|9591399|FG003|Overall Study|Lost to Follow-up|0
5997608|NCT01709318|9591400|FG004|Overall Study|Lost to Follow-up|1
6071341|NCT00554229|9674279|FG001|Overall Study|Randomised but no treatment received|0
6071342|NCT00554515|9674300|FG000|Overall Study|Withdrawal by Subject|3
6071343|NCT00554515|9674300|FG000|Overall Study|Disease progression|52
6071344|NCT00554515|9674300|FG000|Overall Study|Physician Decision|18
6071345|NCT00554515|9674300|FG000|Overall Study|Withdrawal by Subject|11
6071346|NCT00554515|9674300|FG000|Overall Study|Adverse Event|9
6071347|NCT00554515|9674300|FG000|Overall Study|Death|2
6071348|NCT00554515|9674300|FG000|Overall Study|Achieved Stable Disease|7
6071349|NCT00554515|9674300|FG000|Overall Study|Other|1
6071350|NCT00554515|9674300|FG000|Overall Study|Misc|15
6071351|NCT00554619|9674325|FG000|Overall Study|Adverse Event|1
6071352|NCT00554619|9674325|FG000|Overall Study|Physician Decision|1
6071353|NCT00554619|9674325|FG000|Overall Study|Liver Function Test Abnormality|1
6071354|NCT00554788|9674346|FG000|Overall Study|Adverse Event|0
6071355|NCT00554788|9674347|FG001|Overall Study|Adverse Event|1
6071356|NCT00554788|9674348|FG002|Overall Study|Adverse Event|2
6071357|NCT00554788|9674346|FG000|Overall Study|Lost to Follow-up|4
6071358|NCT00554788|9674347|FG001|Overall Study|Lost to Follow-up|3
5997609|NCT01709318|9591401|FG005|Overall Study|Lost to Follow-up|1
5997610|NCT01709318|9591402|FG006|Overall Study|Lost to Follow-up|1
5997611|NCT01709318|9591396|FG000|Overall Study|Non-compliance with Study Drug|0
5997612|NCT01709318|9591397|FG001|Overall Study|Non-compliance with Study Drug|2
5997613|NCT01709318|9591398|FG002|Overall Study|Non-compliance with Study Drug|1
5997614|NCT01709318|9591399|FG003|Overall Study|Non-compliance with Study Drug|1
5997615|NCT01709318|9591400|FG004|Overall Study|Non-compliance with Study Drug|0
5997616|NCT01709318|9591401|FG005|Overall Study|Non-compliance with Study Drug|0
5997617|NCT01709318|9591402|FG006|Overall Study|Non-compliance with Study Drug|2
5997618|NCT01709318|9591396|FG000|Overall Study|Physician Decision|0
5997619|NCT01709318|9591397|FG001|Overall Study|Physician Decision|0
5997620|NCT01709318|9591398|FG002|Overall Study|Physician Decision|0
5997621|NCT01709318|9591399|FG003|Overall Study|Physician Decision|0
5997622|NCT01709318|9591400|FG004|Overall Study|Physician Decision|0
5997623|NCT01709318|9591401|FG005|Overall Study|Physician Decision|0
5997624|NCT01709318|9591402|FG006|Overall Study|Physician Decision|1
5997625|NCT01709318|9591396|FG000|Overall Study|Pregnancy|0
5997626|NCT01709318|9591397|FG001|Overall Study|Pregnancy|0
5997627|NCT01709318|9591398|FG002|Overall Study|Pregnancy|0
5997628|NCT01709318|9591399|FG003|Overall Study|Pregnancy|0
5997629|NCT01709318|9591400|FG004|Overall Study|Pregnancy|1
5997630|NCT01709318|9591401|FG005|Overall Study|Pregnancy|0
5997631|NCT01709318|9591402|FG006|Overall Study|Pregnancy|0
5997632|NCT01709318|9591396|FG000|Overall Study|Protocol Violation|0
5997633|NCT01709318|9591397|FG001|Overall Study|Protocol Violation|0
5997634|NCT01709318|9591398|FG002|Overall Study|Protocol Violation|0
5997635|NCT01709318|9591399|FG003|Overall Study|Protocol Violation|0
5997636|NCT01709318|9591400|FG004|Overall Study|Protocol Violation|2
5997637|NCT01709318|9591401|FG005|Overall Study|Protocol Violation|0
5997638|NCT01709318|9591402|FG006|Overall Study|Protocol Violation|1
5997639|NCT01709318|9591396|FG000|Overall Study|Technical Problems|1
5997640|NCT01709318|9591397|FG001|Overall Study|Technical Problems|0
5997641|NCT01709318|9591398|FG002|Overall Study|Technical Problems|0
5997642|NCT01709318|9591399|FG003|Overall Study|Technical Problems|0
5997643|NCT01709318|9591400|FG004|Overall Study|Technical Problems|0
5997644|NCT01709318|9591401|FG005|Overall Study|Technical Problems|0
6071359|NCT00554788|9674348|FG002|Overall Study|Lost to Follow-up|3
6071360|NCT00554788|9674346|FG000|Overall Study|Physician Decision|1
6071361|NCT00554788|9674347|FG001|Overall Study|Physician Decision|1
5997645|NCT01709318|9591402|FG006|Overall Study|Technical Problems|0
5997646|NCT01709318|9591396|FG000|Overall Study|Withdrawal by Subject|3
5997647|NCT01709318|9591397|FG001|Overall Study|Withdrawal by Subject|0
5997648|NCT01709318|9591398|FG002|Overall Study|Withdrawal by Subject|3
6071362|NCT00554788|9674348|FG002|Overall Study|Physician Decision|3
6071363|NCT00554788|9674346|FG000|Overall Study|Withdrawal by Subject|0
6071364|NCT00554788|9674347|FG001|Overall Study|Withdrawal by Subject|0
6071365|NCT00554788|9674348|FG002|Overall Study|Withdrawal by Subject|1
6071366|NCT00554788|9674346|FG000|Overall Study|Refusal of further protocol therapy|0
6071367|NCT00554788|9674347|FG001|Overall Study|Refusal of further protocol therapy|1
6071368|NCT00554788|9674348|FG002|Overall Study|Refusal of further protocol therapy|1
6071369|NCT00554788|9674346|FG000|Overall Study|Progressive disease|0
6071370|NCT00554788|9674347|FG001|Overall Study|Progressive disease|0
6071371|NCT00554788|9674348|FG002|Overall Study|Progressive disease|3
6071372|NCT00554788|9674346|FG000|Overall Study|Ineligible|2
6071373|NCT00554788|9674347|FG001|Overall Study|Ineligible|0
6071374|NCT00554788|9674348|FG002|Overall Study|Ineligible|1
6071375|NCT00554801|9674359|FG000|Overall Study|left area before completion|5
6071376|NCT00554801|9674360|FG001|Overall Study|left area before completion|0
6071377|NCT00554801|9674359|FG000|Overall Study|Withdrawal by Subject|14
6071378|NCT00554801|9674360|FG001|Overall Study|Withdrawal by Subject|0
6071379|NCT00555061|9674408|FG000|Overall Study|Adverse Event|3
6071380|NCT00555061|9674408|FG000|Overall Study|Protocol Violation|1
6071381|NCT00555061|9674408|FG000|Overall Study|Lost to Follow-up|2
6071382|NCT00555061|9674408|FG000|Overall Study|Withdrawal by Subject|2
6071383|NCT00555061|9674408|FG000|Overall Study|Participant enrolled, but never treated|1
6071384|NCT00555217|9674431|FG000|Overall Study|Withdrawal by Subject|35
6071385|NCT00555217|9674432|FG001|Overall Study|Withdrawal by Subject|31
6071386|NCT00555217|9674431|FG000|Overall Study|Lost to Follow-up|19
6071387|NCT00555217|9674432|FG001|Overall Study|Lost to Follow-up|20
6071388|NCT00555217|9674431|FG000|Overall Study|close out sites|21
6071389|NCT00555217|9674432|FG001|Overall Study|close out sites|17
6071390|NCT00555321|9674443|FG000|Treatment Phase up to 12-months|Adverse Event|6
6071391|NCT00555321|9674444|FG001|Treatment Phase up to 12-months|Adverse Event|7
6071392|NCT00555321|9674445|FG002|Treatment Phase up to 12-months|Adverse Event|11
6071393|NCT00555321|9674446|FG003|Treatment Phase up to 12-months|Adverse Event|7
6071394|NCT00555321|9674447|FG004|Treatment Phase up to 12-months|Adverse Event|18
6071395|NCT00555321|9674443|FG000|Treatment Phase up to 12-months|Withdrawal by Subject|1
6071396|NCT00555321|9674444|FG001|Treatment Phase up to 12-months|Withdrawal by Subject|0
6071397|NCT00555321|9674445|FG002|Treatment Phase up to 12-months|Withdrawal by Subject|1
6071398|NCT00555321|9674446|FG003|Treatment Phase up to 12-months|Withdrawal by Subject|0
6071399|NCT00555321|9674447|FG004|Treatment Phase up to 12-months|Withdrawal by Subject|0
6071400|NCT00555321|9674443|FG000|Treatment Phase up to 12-months|Death|2
6071401|NCT00555321|9674444|FG001|Treatment Phase up to 12-months|Death|1
6071402|NCT00555321|9674445|FG002|Treatment Phase up to 12-months|Death|4
6071403|NCT00555321|9674446|FG003|Treatment Phase up to 12-months|Death|0
6071404|NCT00555321|9674447|FG004|Treatment Phase up to 12-months|Death|0
6071405|NCT00555321|9674443|FG000|Treatment Phase up to 12-months|Lack of Efficacy|9
5997649|NCT01709318|9591399|FG003|Overall Study|Withdrawal by Subject|3
5997650|NCT01709318|9591400|FG004|Overall Study|Withdrawal by Subject|0
5997651|NCT01709318|9591401|FG005|Overall Study|Withdrawal by Subject|2
5997652|NCT01709318|9591402|FG006|Overall Study|Withdrawal by Subject|4
5997653|NCT01709318|9591396|FG000|Overall Study|Other Protocol Specified Criteria|0
5997654|NCT01709318|9591397|FG001|Overall Study|Other Protocol Specified Criteria|1
5997655|NCT01709318|9591398|FG002|Overall Study|Other Protocol Specified Criteria|0
5997656|NCT01709318|9591399|FG003|Overall Study|Other Protocol Specified Criteria|0
5997657|NCT01709318|9591400|FG004|Overall Study|Other Protocol Specified Criteria|0
5997658|NCT01709318|9591401|FG005|Overall Study|Other Protocol Specified Criteria|0
5997659|NCT01709318|9591402|FG006|Overall Study|Other Protocol Specified Criteria|0
5997660|NCT01698918|9591418|FG000|First Line Treatment (Core+Extension)|Adverse Event|33
5997661|NCT01698918|9591418|FG000|First Line Treatment (Core+Extension)|Withdrawal by Subject|11
5997662|NCT01698918|9591418|FG000|First Line Treatment (Core+Extension)|Death|2
5997663|NCT01698918|9591418|FG000|First Line Treatment (Core+Extension)|Disease progression|120
6047031|NCT00409708|9646106|FG001|Treatment|Administrative problems|0
6047032|NCT00409708|9646105|FG000|Washout|Lack of Efficacy|9
6047033|NCT00409708|9646106|FG001|Washout|Lack of Efficacy|1
6047034|NCT00409708|9646105|FG000|Washout|Protocol Violation|0
6047035|NCT00409708|9646106|FG001|Washout|Protocol Violation|1
6047036|NCT00409708|9646105|FG000|Washout|Withdrawal by Subject|11
6047037|NCT00409708|9646106|FG001|Washout|Withdrawal by Subject|5
6047038|NCT00409708|9646105|FG000|Washout|Lost to Follow-up|1
6047039|NCT00409708|9646106|FG001|Washout|Lost to Follow-up|3
6047040|NCT00409747|9646112|FG000|Overall Study|Withdrawal by Subject|1
6047041|NCT00409786|9646116|FG000|Overall Study|Withdrawal by Subject|3
6047042|NCT00409838|9646126|FG000|Short-term Period|Adverse Event|0
6047043|NCT00409838|9646127|FG001|Short-term Period|Adverse Event|1
6047044|NCT00409838|9646126|FG000|Short-term Period|Lost to Follow-up|0
6047045|NCT00409838|9646127|FG001|Short-term Period|Lost to Follow-up|1
6047046|NCT00409838|9646126|FG000|Short-term Period|Withdrawal by Subject|2
6047047|NCT00409838|9646127|FG001|Short-term Period|Withdrawal by Subject|3
5997664|NCT01698918|9591418|FG000|First Line Treatment (Core+Extension)|Physician Decision|7
5997665|NCT01698918|9591418|FG000|Second Line Treatment (Core+Extension)|Adverse Event|3
5997666|NCT01698918|9591418|FG000|Second Line Treatment (Core+Extension)|Withdrawal by Subject|1
5997667|NCT01698918|9591418|FG000|Second Line Treatment (Core+Extension)|Death|1
5997668|NCT01698918|9591418|FG000|Second Line Treatment (Core+Extension)|Disease progression|38
5997669|NCT01698918|9591418|FG000|Second Line Treatment (Core+Extension)|Physician Decision|3
5997670|NCT01673620|9591432|FG000|Overall Study|Adverse Event|1
5997671|NCT01673620|9591433|FG001|Overall Study|Adverse Event|0
5997672|NCT01660243|9591443|FG000|Overall Study|Adverse Event|1
5997673|NCT01660243|9591444|FG001|Overall Study|Adverse Event|0
5997674|NCT01660243|9591445|FG002|Overall Study|Adverse Event|1
5997675|NCT01660243|9591446|FG003|Overall Study|Adverse Event|0
5997676|NCT01660243|9591443|FG000|Overall Study|Unable to visit clinic to obtain study drug due to hospitalization|1
5997677|NCT01660243|9591444|FG001|Overall Study|Unable to visit clinic to obtain study drug due to hospitalization|0
5997678|NCT01660243|9591445|FG002|Overall Study|Unable to visit clinic to obtain study drug due to hospitalization|0
5997679|NCT01660243|9591446|FG003|Overall Study|Unable to visit clinic to obtain study drug due to hospitalization|0
5997680|NCT01660243|9591443|FG000|Overall Study|Subject was noncompliant with study drug after experiencing AEs; was not discontinued due to the AEs|0
5997681|NCT01660243|9591444|FG001|Overall Study|Subject was noncompliant with study drug after experiencing AEs; was not discontinued due to the AEs|0
5997682|NCT01660243|9591445|FG002|Overall Study|Subject was noncompliant with study drug after experiencing AEs; was not discontinued due to the AEs|1
5997683|NCT01660243|9591446|FG003|Overall Study|Subject was noncompliant with study drug after experiencing AEs; was not discontinued due to the AEs|0
5997684|NCT01660243|9591443|FG000|Overall Study|Randomization error|0
5997685|NCT01660243|9591444|FG001|Overall Study|Randomization error|0
5997686|NCT01660243|9591445|FG002|Overall Study|Randomization error|0
5997687|NCT01660243|9591446|FG003|Overall Study|Randomization error|1
5997688|NCT01617187|9591460|FG000|Randomization Through Start Treatment|Not Treated: Administrative Reason|0
5997689|NCT01617187|9591461|FG001|Randomization Through Start Treatment|Not Treated: Administrative Reason|0
5997690|NCT01617187|9591462|FG002|Randomization Through Start Treatment|Not Treated: Administrative Reason|0
5997691|NCT01617187|9591463|FG003|Randomization Through Start Treatment|Not Treated: Administrative Reason|1
5997692|NCT01617187|9591460|FG000|Randomization Through Start Treatment|Not Treated: Adverse Event|0
5997693|NCT01617187|9591461|FG001|Randomization Through Start Treatment|Not Treated: Adverse Event|0
5997694|NCT01617187|9591462|FG002|Randomization Through Start Treatment|Not Treated: Adverse Event|0
5997695|NCT01617187|9591463|FG003|Randomization Through Start Treatment|Not Treated: Adverse Event|1
5997696|NCT01617187|9591460|FG000|Randomization Through Start Treatment|Not Treated: Completed study in database|1
5997697|NCT01617187|9591461|FG001|Randomization Through Start Treatment|Not Treated: Completed study in database|0
5997698|NCT01617187|9591462|FG002|Randomization Through Start Treatment|Not Treated: Completed study in database|0
5997699|NCT01617187|9591463|FG003|Randomization Through Start Treatment|Not Treated: Completed study in database|0
5997700|NCT01617187|9591460|FG000|Treatment Through Study Completion|Adverse Event|1
5997701|NCT01617187|9591461|FG001|Treatment Through Study Completion|Adverse Event|1
5997702|NCT01617187|9591462|FG002|Treatment Through Study Completion|Adverse Event|0
5997703|NCT01617187|9591463|FG003|Treatment Through Study Completion|Adverse Event|1
5997704|NCT01617187|9591460|FG000|Treatment Through Study Completion|Lost to Follow-up|4
5997705|NCT01617187|9591461|FG001|Treatment Through Study Completion|Lost to Follow-up|2
5997706|NCT01617187|9591462|FG002|Treatment Through Study Completion|Lost to Follow-up|2
5997707|NCT01617187|9591463|FG003|Treatment Through Study Completion|Lost to Follow-up|2
5997708|NCT01617187|9591460|FG000|Treatment Through Study Completion|Withdrawal by Subject|5
5997709|NCT01617187|9591461|FG001|Treatment Through Study Completion|Withdrawal by Subject|8
5997710|NCT01617187|9591462|FG002|Treatment Through Study Completion|Withdrawal by Subject|3
5997711|NCT01617187|9591463|FG003|Treatment Through Study Completion|Withdrawal by Subject|6
5997712|NCT01617187|9591460|FG000|Treatment Through Study Completion|Protocol Violation|1
5997713|NCT01617187|9591461|FG001|Treatment Through Study Completion|Protocol Violation|0
5997714|NCT01617187|9591462|FG002|Treatment Through Study Completion|Protocol Violation|0
5997715|NCT01617187|9591463|FG003|Treatment Through Study Completion|Protocol Violation|1
5997716|NCT01611883|9591475|FG000|Overall Study|Adverse Event|1
5997717|NCT01611883|9591476|FG001|Overall Study|Adverse Event|1
5997718|NCT01572675|9591484|FG000|Overall Study|End of prescribed treatment|140
5997719|NCT01572675|9591485|FG001|Overall Study|End of prescribed treatment|118
5997720|NCT01572675|9591484|FG000|Overall Study|Recovery|16
5997721|NCT01572675|9591485|FG001|Overall Study|Recovery|23
5997722|NCT01572675|9591484|FG000|Overall Study|Lack of Efficacy|31
5997723|NCT01572675|9591485|FG001|Overall Study|Lack of Efficacy|31
5997724|NCT01572675|9591484|FG000|Overall Study|Intolerance|6
5997725|NCT01572675|9591485|FG001|Overall Study|Intolerance|5
5997726|NCT01572675|9591484|FG000|Overall Study|Improved symptoms|8
5997727|NCT01572675|9591485|FG001|Overall Study|Improved symptoms|2
5997728|NCT01572675|9591484|FG000|Overall Study|Surgical intervention|3
5997729|NCT01572675|9591485|FG001|Overall Study|Surgical intervention|6
5997730|NCT01572675|9591484|FG000|Overall Study|Withdrawal by Subject|5
5997731|NCT01572675|9591485|FG001|Overall Study|Withdrawal by Subject|1
5997732|NCT01572675|9591484|FG000|Overall Study|Physician Decision|2
5997733|NCT01572675|9591485|FG001|Overall Study|Physician Decision|2
5997734|NCT01572675|9591484|FG000|Overall Study|Death unrelated to coxibs|1
5997735|NCT01572675|9591485|FG001|Overall Study|Death unrelated to coxibs|1
5997736|NCT01572675|9591484|FG000|Overall Study|Other disease detected|1
5997737|NCT01572675|9591485|FG001|Overall Study|Other disease detected|1
5997738|NCT01572675|9591484|FG000|Overall Study|Unknown reason|1
5997739|NCT01572675|9591485|FG001|Overall Study|Unknown reason|1
5997740|NCT01572675|9591484|FG000|Overall Study|Rheumatologist new evaluation|0
5997741|NCT01572675|9591485|FG001|Overall Study|Rheumatologist new evaluation|1
5997742|NCT01572675|9591484|FG000|Overall Study|Missing data|1
5997743|NCT01572675|9591485|FG001|Overall Study|Missing data|4
5997744|NCT01572675|9591484|FG000|Overall Study|Lost to Follow-up|22
5997745|NCT01572675|9591485|FG001|Overall Study|Lost to Follow-up|27
5997746|NCT01554163|9591506|FG000|Overall Study|Adverse Event|3
5997747|NCT01554163|9591507|FG001|Overall Study|Adverse Event|0
5997748|NCT01554163|9591506|FG000|Overall Study|Lack of Efficacy|1
5997749|NCT01554163|9591507|FG001|Overall Study|Lack of Efficacy|0
5997750|NCT01554163|9591506|FG000|Overall Study|Lost to Follow-up|1
5997751|NCT01554163|9591507|FG001|Overall Study|Lost to Follow-up|0
5997752|NCT01554163|9591506|FG000|Overall Study|Non-Compliance With Study Drug|1
5997753|NCT01554163|9591507|FG001|Overall Study|Non-Compliance With Study Drug|1
5997754|NCT01554163|9591506|FG000|Overall Study|Protocol Violation|0
5997755|NCT01554163|9591507|FG001|Overall Study|Protocol Violation|4
5997756|NCT01554163|9591506|FG000|Overall Study|Withdrawal by Subject|1
5997757|NCT01554163|9591507|FG001|Overall Study|Withdrawal by Subject|5
5997758|NCT01554163|9591506|FG000|Overall Study|Not Treated|1
5997759|NCT01554163|9591507|FG001|Overall Study|Not Treated|0
5997760|NCT01502371|9591518|FG000|Overall Study|Withdrawal by Subject|1
5997761|NCT01502371|9591519|FG001|Overall Study|Withdrawal by Subject|2
5997762|NCT01502371|9591520|FG002|Overall Study|Withdrawal by Subject|1
5997763|NCT01502371|9591521|FG003|Overall Study|Withdrawal by Subject|1
5997764|NCT01502371|9591522|FG004|Overall Study|Withdrawal by Subject|1
5997765|NCT01502371|9591518|FG000|Overall Study|Adverse Event|2
5997766|NCT01502371|9591519|FG001|Overall Study|Adverse Event|1
5997767|NCT01502371|9591520|FG002|Overall Study|Adverse Event|0
5997768|NCT01502371|9591521|FG003|Overall Study|Adverse Event|4
5997769|NCT01502371|9591522|FG004|Overall Study|Adverse Event|3
5997770|NCT01502371|9591518|FG000|Overall Study|Treatment Failure|22
5997771|NCT01502371|9591519|FG001|Overall Study|Treatment Failure|20
5997772|NCT01502371|9591520|FG002|Overall Study|Treatment Failure|12
5997773|NCT01502371|9591521|FG003|Overall Study|Treatment Failure|19
5997774|NCT01502371|9591522|FG004|Overall Study|Treatment Failure|30
5997775|NCT01502371|9591518|FG000|Overall Study|Lack of Efficacy|3
5997776|NCT01502371|9591519|FG001|Overall Study|Lack of Efficacy|3
5997777|NCT01502371|9591520|FG002|Overall Study|Lack of Efficacy|2
5997778|NCT01502371|9591521|FG003|Overall Study|Lack of Efficacy|2
5997779|NCT01502371|9591522|FG004|Overall Study|Lack of Efficacy|4
5997780|NCT01502371|9591518|FG000|Overall Study|Physician Decision|3
5997781|NCT01502371|9591519|FG001|Overall Study|Physician Decision|0
5997782|NCT01502371|9591520|FG002|Overall Study|Physician Decision|0
5997783|NCT01502371|9591521|FG003|Overall Study|Physician Decision|0
5997784|NCT01502371|9591522|FG004|Overall Study|Physician Decision|1
5997785|NCT01502371|9591518|FG000|Overall Study|Noncompliance with Study Drug|0
5997786|NCT01502371|9591519|FG001|Overall Study|Noncompliance with Study Drug|0
5997787|NCT01502371|9591520|FG002|Overall Study|Noncompliance with Study Drug|1
5997788|NCT01502371|9591521|FG003|Overall Study|Noncompliance with Study Drug|2
5997789|NCT01502371|9591522|FG004|Overall Study|Noncompliance with Study Drug|1
5997790|NCT01502371|9591518|FG000|Overall Study|Technical Problems|1
5997791|NCT01502371|9591519|FG001|Overall Study|Technical Problems|0
5997792|NCT01502371|9591520|FG002|Overall Study|Technical Problems|2
5997793|NCT01502371|9591521|FG003|Overall Study|Technical Problems|4
5997794|NCT01502371|9591522|FG004|Overall Study|Technical Problems|1
5997795|NCT01502371|9591518|FG000|Overall Study|Protocol Violation|9
5997796|NCT01502371|9591519|FG001|Overall Study|Protocol Violation|5
5997797|NCT01502371|9591520|FG002|Overall Study|Protocol Violation|6
5997798|NCT01502371|9591521|FG003|Overall Study|Protocol Violation|5
5997799|NCT01502371|9591522|FG004|Overall Study|Protocol Violation|10
5997800|NCT01502371|9591518|FG000|Overall Study|Excluded Medication|0
5997801|NCT01502371|9591519|FG001|Overall Study|Excluded Medication|1
5997802|NCT01502371|9591520|FG002|Overall Study|Excluded Medication|1
5997803|NCT01502371|9591521|FG003|Overall Study|Excluded Medication|0
5997804|NCT01502371|9591522|FG004|Overall Study|Excluded Medication|1
5997805|NCT01490190|9591535|FG000|Overall Study|Withdrawal by Subject|9
5997806|NCT01490190|9591535|FG000|Overall Study|Adverse Event|17
5997807|NCT01490190|9591535|FG000|Overall Study|Protocol Violation|5
5997808|NCT01490190|9591535|FG000|Overall Study|Lost to Follow-up|13
5997809|NCT01490190|9591535|FG000|Overall Study|Relocation|1
5997810|NCT01490190|9591535|FG000|Overall Study|Inconvenience|1
5997811|NCT01490190|9591535|FG000|Overall Study|Ring expulsion|2
5997812|NCT01471340|9591541|FG000|Overall Study|Death|5
5997813|NCT01471340|9591542|FG001|Overall Study|Death|4
5997814|NCT01471340|9591541|FG000|Overall Study|Lost to Follow-up|0
5997815|NCT01471340|9591542|FG001|Overall Study|Lost to Follow-up|1
5997816|NCT01471340|9591541|FG000|Overall Study|Investigational site closure|0
5997817|NCT01471340|9591542|FG001|Overall Study|Investigational site closure|1
5997818|NCT01471340|9591541|FG000|Overall Study|Invalid informed consent|1
5997819|NCT01471340|9591542|FG001|Overall Study|Invalid informed consent|0
5997820|NCT01462370|9591548|FG000|Overall Study|Lack of Qualifying Event|1
5997821|NCT01462370|9591549|FG001|Overall Study|Lack of Qualifying Event|1
5997822|NCT01462370|9591548|FG000|Overall Study|Physician Decision|0
5997823|NCT01462370|9591549|FG001|Overall Study|Physician Decision|1
5997824|NCT01462370|9591548|FG000|Overall Study|Withdrawal by Subject|0
5997825|NCT01462370|9591549|FG001|Overall Study|Withdrawal by Subject|3
5997826|NCT01436253|9591555|FG000|Overall Study|Lost to Follow-up|182
5997827|NCT01436253|9591555|FG000|Overall Study|Not meeting all eligibility criteria|117
5997828|NCT01381679|9591589|FG000|Overall Study|Adverse Event|3
5997829|NCT01381679|9591589|FG000|Overall Study|Lost to Follow-up|885
5997830|NCT01370603|9591595|FG000|Period 1|Adverse Event|5
5997831|NCT01370603|9591596|FG001|Period 1|Adverse Event|3
5997832|NCT01370603|9591595|FG000|Period 1|Lost to Follow-up|2
5997833|NCT01370603|9591596|FG001|Period 1|Lost to Follow-up|0
5997834|NCT01370603|9591595|FG000|Period 1|Protocol Violation|2
5997835|NCT01370603|9591596|FG001|Period 1|Protocol Violation|2
5997836|NCT01370603|9591595|FG000|Period 1|Withdrawal by Subject|5
5997837|NCT01370603|9591596|FG001|Period 1|Withdrawal by Subject|5
5997838|NCT01370603|9591595|FG000|Crossover Washout|Adverse Event|2
5997839|NCT01370603|9591596|FG001|Crossover Washout|Adverse Event|1
5997840|NCT01370603|9591595|FG000|Crossover Washout|Lost to Follow-up|2
5997841|NCT01370603|9591596|FG001|Crossover Washout|Lost to Follow-up|0
5997842|NCT01370603|9591595|FG000|Crossover Washout|Protocol Violation|1
5997843|NCT01370603|9591596|FG001|Crossover Washout|Protocol Violation|0
5997844|NCT01370603|9591595|FG000|Crossover Washout|Withdrawal by Subject|4
5997845|NCT01370603|9591596|FG001|Crossover Washout|Withdrawal by Subject|1
5997846|NCT01370603|9591595|FG000|Crossover Washout|Non-compliance with Study Drug|0
5997847|NCT01370603|9591596|FG001|Crossover Washout|Non-compliance with Study Drug|2
5997848|NCT01370603|9591595|FG000|Period 2|Adverse Event|1
5997849|NCT01370603|9591596|FG001|Period 2|Adverse Event|4
5997850|NCT01370603|9591595|FG000|Period 2|Lost to Follow-up|1
5997851|NCT01370603|9591596|FG001|Period 2|Lost to Follow-up|0
5997852|NCT01370603|9591595|FG000|Period 2|Withdrawal by Subject|1
5997853|NCT01370603|9591596|FG001|Period 2|Withdrawal by Subject|0
5997854|NCT01370590|9591604|FG000|Period 1|Adverse Event|8
5997855|NCT01370590|9591605|FG001|Period 1|Adverse Event|4
5997856|NCT01370590|9591604|FG000|Period 1|Lost to Follow-up|2
5997857|NCT01370590|9591605|FG001|Period 1|Lost to Follow-up|2
5997858|NCT01370590|9591604|FG000|Period 1|Protocol Violation|2
5997859|NCT01370590|9591605|FG001|Period 1|Protocol Violation|2
5997860|NCT01370590|9591604|FG000|Period 1|Withdrawal by Subject|4
5997861|NCT01370590|9591605|FG001|Period 1|Withdrawal by Subject|2
5997862|NCT01370590|9591604|FG000|Period 1|Could not access randomization system|0
5997863|NCT01370590|9591605|FG001|Period 1|Could not access randomization system|1
6071406|NCT00555321|9674444|FG001|Treatment Phase up to 12-months|Lack of Efficacy|8
6071407|NCT00555321|9674445|FG002|Treatment Phase up to 12-months|Lack of Efficacy|5
6071408|NCT00555321|9674446|FG003|Treatment Phase up to 12-months|Lack of Efficacy|0
6071409|NCT00555321|9674447|FG004|Treatment Phase up to 12-months|Lack of Efficacy|0
6071410|NCT00555321|9674443|FG000|Treatment Phase up to 12-months|Other Reason|1
6071411|NCT00555321|9674444|FG001|Treatment Phase up to 12-months|Other Reason|3
6071412|NCT00555321|9674445|FG002|Treatment Phase up to 12-months|Other Reason|2
6071413|NCT00555321|9674446|FG003|Treatment Phase up to 12-months|Other Reason|0
6071414|NCT00555321|9674447|FG004|Treatment Phase up to 12-months|Other Reason|0
6071415|NCT00555321|9674443|FG000|Treatment Phase up to 12-months|Never treated|2
6071416|NCT00555321|9674444|FG001|Treatment Phase up to 12-months|Never treated|3
6071417|NCT00555321|9674445|FG002|Treatment Phase up to 12-months|Never treated|1
6071418|NCT00555321|9674446|FG003|Treatment Phase up to 12-months|Never treated|0
6071419|NCT00555321|9674447|FG004|Treatment Phase up to 12-months|Never treated|4
6071420|NCT00555321|9674443|FG000|Long-term Extension Phase|Adverse Event|2
6071421|NCT00555321|9674444|FG001|Long-term Extension Phase|Adverse Event|5
6071422|NCT00555321|9674445|FG002|Long-term Extension Phase|Adverse Event|2
6071423|NCT00555321|9674446|FG003|Long-term Extension Phase|Adverse Event|1
6071424|NCT00555321|9674447|FG004|Long-term Extension Phase|Adverse Event|0
6071425|NCT00555321|9674443|FG000|Long-term Extension Phase|Withdrawal by Subject|2
6071426|NCT00555321|9674444|FG001|Long-term Extension Phase|Withdrawal by Subject|1
6071427|NCT00555321|9674445|FG002|Long-term Extension Phase|Withdrawal by Subject|2
6071428|NCT00555321|9674446|FG003|Long-term Extension Phase|Withdrawal by Subject|3
6071429|NCT00555321|9674447|FG004|Long-term Extension Phase|Withdrawal by Subject|2
6071430|NCT00555321|9674443|FG000|Long-term Extension Phase|Administrative reason by sponsor|23
5997864|NCT01370590|9591604|FG000|Crossover Washout Period|Adverse Event|1
5997865|NCT01370590|9591605|FG001|Crossover Washout Period|Adverse Event|4
5997866|NCT01370590|9591604|FG000|Crossover Washout Period|Lost to Follow-up|2
5997867|NCT01370590|9591605|FG001|Crossover Washout Period|Lost to Follow-up|0
5997868|NCT01370590|9591604|FG000|Crossover Washout Period|Non-compliance with Study Drug|1
5997869|NCT01370590|9591605|FG001|Crossover Washout Period|Non-compliance with Study Drug|0
5997870|NCT01370590|9591604|FG000|Crossover Washout Period|Withdrawal by Subject|2
5997871|NCT01370590|9591605|FG001|Crossover Washout Period|Withdrawal by Subject|2
5997872|NCT01370590|9591604|FG000|Period 2|Adverse Event|0
5997873|NCT01370590|9591605|FG001|Period 2|Adverse Event|1
5997874|NCT01370590|9591604|FG000|Period 2|Withdrawal by Subject|1
5997875|NCT01370590|9591605|FG001|Period 2|Withdrawal by Subject|1
5997876|NCT01349907|9591617|FG000|Overall Study|Adverse Event|37
5997877|NCT01349907|9591618|FG001|Overall Study|Adverse Event|11
5997878|NCT01349907|9591617|FG000|Overall Study|Treatment failure|13
6309474|NCT02639052|10038077|FG000|Overall Study|Lost to Follow-up|1
6309475|NCT02639182|10038085|FG000|Overall Study|Disease Progression|50
6071431|NCT00555321|9674444|FG001|Long-term Extension Phase|Administrative reason by sponsor|21
6071432|NCT00555321|9674445|FG002|Long-term Extension Phase|Administrative reason by sponsor|18
6071433|NCT00555321|9674446|FG003|Long-term Extension Phase|Administrative reason by sponsor|31
6071434|NCT00555321|9674447|FG004|Long-term Extension Phase|Administrative reason by sponsor|23
6071435|NCT00555321|9674443|FG000|Long-term Extension Phase|Death|2
6071436|NCT00555321|9674444|FG001|Long-term Extension Phase|Death|0
6071437|NCT00555321|9674445|FG002|Long-term Extension Phase|Death|0
6071438|NCT00555321|9674446|FG003|Long-term Extension Phase|Death|3
6071439|NCT00555321|9674447|FG004|Long-term Extension Phase|Death|0
6071440|NCT00555321|9674443|FG000|Long-term Extension Phase|Participant did not meet study criteria|0
6071441|NCT00555321|9674444|FG001|Long-term Extension Phase|Participant did not meet study criteria|0
6071442|NCT00555321|9674445|FG002|Long-term Extension Phase|Participant did not meet study criteria|0
6071443|NCT00555321|9674446|FG003|Long-term Extension Phase|Participant did not meet study criteria|0
6071444|NCT00555321|9674447|FG004|Long-term Extension Phase|Participant did not meet study criteria|1
6071445|NCT00555321|9674443|FG000|Long-term Extension Phase|Other Reason|1
6071446|NCT00555321|9674444|FG001|Long-term Extension Phase|Other Reason|0
6071447|NCT00555321|9674445|FG002|Long-term Extension Phase|Other Reason|2
6071448|NCT00555321|9674446|FG003|Long-term Extension Phase|Other Reason|0
6071449|NCT00555321|9674447|FG004|Long-term Extension Phase|Other Reason|0
6071450|NCT00555425|9674476|FG000|Overall Study|Missed Medication > 1 wk|34
6071451|NCT00555425|9674477|FG001|Overall Study|Missed Medication > 1 wk|15
6071452|NCT00555425|9674476|FG000|Overall Study|Missed 3 physician management visits|1
6071453|NCT00555425|9674477|FG001|Overall Study|Missed 3 physician management visits|0
6071454|NCT00555425|9674476|FG000|Overall Study|Met criteria for protective transfer|16
6071455|NCT00555425|9674477|FG001|Overall Study|Met criteria for protective transfer|3
6071456|NCT00555425|9674476|FG000|Overall Study|Became pregnant and transferred care|0
6071457|NCT00555425|9674477|FG001|Overall Study|Became pregnant and transferred care|1
6071458|NCT00555438|9674483|FG000|10 Days Post-operative|Death|4
6071459|NCT00555438|9674483|FG000|Between 10 Days and 30 Days Postoperativ|Death|5
6071460|NCT00555477|9674498|FG000|Overall Study|Adverse Event|0
6071461|NCT00555477|9674499|FG001|Overall Study|Adverse Event|9
6071462|NCT00555477|9674498|FG000|Overall Study|Withdrawal by Subject|1
6309476|NCT02639182|10038086|FG001|Overall Study|Disease Progression|49
5997879|NCT01349907|9591618|FG001|Overall Study|Treatment failure|4
5997880|NCT01349907|9591617|FG000|Overall Study|Lost to Follow-up|25
5997881|NCT01349907|9591618|FG001|Overall Study|Lost to Follow-up|6
5997882|NCT01349907|9591617|FG000|Overall Study|Withdrawal by Subject|30
5997883|NCT01349907|9591618|FG001|Overall Study|Withdrawal by Subject|8
5997884|NCT01349907|9591617|FG000|Overall Study|Protocol Violation|33
5997885|NCT01349907|9591618|FG001|Overall Study|Protocol Violation|13
5997886|NCT01349907|9591617|FG000|Overall Study|Administrative|1
5997887|NCT01349907|9591618|FG001|Overall Study|Administrative|1
5997888|NCT01345786|9591628|FG000|Overall Study|Adverse Event|0
5997889|NCT01345786|9591629|FG001|Overall Study|Adverse Event|1
5997890|NCT01345786|9591630|FG002|Overall Study|Adverse Event|3
5997891|NCT01345786|9591631|FG003|Overall Study|Adverse Event|1
5997892|NCT01345786|9591628|FG000|Overall Study|Subject withdrew consent|2
5997893|NCT01345786|9591629|FG001|Overall Study|Subject withdrew consent|2
5997894|NCT01345786|9591630|FG002|Overall Study|Subject withdrew consent|1
5997895|NCT01345786|9591631|FG003|Overall Study|Subject withdrew consent|0
5997896|NCT01345786|9591628|FG000|Overall Study|Noncompliance with protocol|1
5997897|NCT01345786|9591629|FG001|Overall Study|Noncompliance with protocol|0
5997898|NCT01345786|9591630|FG002|Overall Study|Noncompliance with protocol|1
5997899|NCT01345786|9591631|FG003|Overall Study|Noncompliance with protocol|0
5997900|NCT01345786|9591628|FG000|Overall Study|Administrative|3
5997901|NCT01345786|9591629|FG001|Overall Study|Administrative|5
5997902|NCT01345786|9591630|FG002|Overall Study|Administrative|0
5997903|NCT01345786|9591631|FG003|Overall Study|Administrative|0
5997904|NCT01345786|9591628|FG000|Overall Study|Lost to Follow-up|0
5997905|NCT01345786|9591629|FG001|Overall Study|Lost to Follow-up|0
5997906|NCT01345786|9591630|FG002|Overall Study|Lost to Follow-up|0
5997907|NCT01345786|9591631|FG003|Overall Study|Lost to Follow-up|2
5997908|NCT01306929|9591641|FG000|Overall Study|Withdrawal by Subject|23
5997909|NCT01306929|9591641|FG000|Overall Study|Adverse Event|21
5997910|NCT01306929|9591641|FG000|Overall Study|Physician Decision|13
5997911|NCT01306929|9591641|FG000|Overall Study|Death|8
5997912|NCT01306929|9591641|FG000|Overall Study|Withdrawal by parent/guardian|5
5997913|NCT01306929|9591641|FG000|Overall Study|Protocol Violation|3
5997914|NCT01306929|9591641|FG000|Overall Study|Non-compliance with study drug|2
5997915|NCT01306929|9591641|FG000|Overall Study|Lost to Follow-up|2
5997916|NCT01306929|9591641|FG000|Overall Study|Various|17
5997917|NCT01294696|9591647|FG000|Overall Study|Screening failures|7
5997918|NCT01294696|9591647|FG000|Overall Study|Protocol Violation|8
5997919|NCT01294696|9591647|FG000|Overall Study|Missing BPI Response|7
5997920|NCT01294696|9591647|FG000|Overall Study|Site closure|52
5997921|NCT01277822|9591654|FG000|Overall Study|Adverse Event|2
6309477|NCT02639182|10038085|FG000|Overall Study|Adverse Event|7
6309478|NCT02639182|10038086|FG001|Overall Study|Adverse Event|5
6309479|NCT02639182|10038085|FG000|Overall Study|Physician Decision|3
6309480|NCT02639182|10038086|FG001|Overall Study|Physician Decision|3
6309481|NCT02639182|10038085|FG000|Overall Study|Withdrew Consent|5
6309482|NCT02639182|10038086|FG001|Overall Study|Withdrew Consent|4
6309483|NCT02639182|10038085|FG000|Overall Study|Lost to Follow-up|0
6309484|NCT02639182|10038086|FG001|Overall Study|Lost to Follow-up|1
6309485|NCT02639182|10038085|FG000|Overall Study|Study Closure|1
6309486|NCT02639182|10038086|FG001|Overall Study|Study Closure|2
6309487|NCT02639182|10038085|FG000|Overall Study|Sponsor Ended Study|0
6309488|NCT02639182|10038086|FG001|Overall Study|Sponsor Ended Study|1
6309489|NCT02639182|10038085|FG000|Overall Study|Randomized But Did Not Receive Study Drug|1
6309490|NCT02639182|10038086|FG001|Overall Study|Randomized But Did Not Receive Study Drug|1
6309491|NCT02639247|10038094|FG000|Overall Study|Lost to Follow-up|2
5997922|NCT01277822|9591655|FG001|Overall Study|Adverse Event|1
5997923|NCT01277822|9591654|FG000|Overall Study|Withdrawal by Subject|6
5997924|NCT01277822|9591655|FG001|Overall Study|Withdrawal by Subject|7
5997925|NCT01277822|9591654|FG000|Overall Study|Physician Decision|1
5997926|NCT01277822|9591655|FG001|Overall Study|Physician Decision|1
5997927|NCT01277822|9591654|FG000|Overall Study|Protocol Violation|1
5997928|NCT01277822|9591655|FG001|Overall Study|Protocol Violation|0
5997929|NCT01277822|9591654|FG000|Overall Study|Lost to Follow-up|2
5997930|NCT01277822|9591655|FG001|Overall Study|Lost to Follow-up|1
5997931|NCT01277822|9591654|FG000|Overall Study|Contraindicated medication used|2
5997932|NCT01277822|9591655|FG001|Overall Study|Contraindicated medication used|1
5997933|NCT01277822|9591654|FG000|Overall Study|Participant moved|1
5997934|NCT01277822|9591655|FG001|Overall Study|Participant moved|0
5997935|NCT01244763|9591667|FG000|Overall Study|Adverse Event|1
5997936|NCT01244763|9591668|FG001|Overall Study|Adverse Event|0
5997937|NCT01244763|9591669|FG002|Overall Study|Adverse Event|0
5997938|NCT01244763|9591670|FG003|Overall Study|Adverse Event|0
5997939|NCT01244763|9591671|FG004|Overall Study|Adverse Event|0
5997940|NCT01244763|9591672|FG005|Overall Study|Adverse Event|1
5997941|NCT01244763|9591667|FG000|Overall Study|Death|1
5997942|NCT01244763|9591668|FG001|Overall Study|Death|0
5997943|NCT01244763|9591669|FG002|Overall Study|Death|1
5997944|NCT01244763|9591670|FG003|Overall Study|Death|0
5997945|NCT01244763|9591671|FG004|Overall Study|Death|2
5997946|NCT01244763|9591672|FG005|Overall Study|Death|0
5997947|NCT01244763|9591667|FG000|Overall Study|Physician Decision|0
5997948|NCT01244763|9591668|FG001|Overall Study|Physician Decision|0
5997949|NCT01244763|9591669|FG002|Overall Study|Physician Decision|1
5997950|NCT01244763|9591670|FG003|Overall Study|Physician Decision|0
5997951|NCT01244763|9591671|FG004|Overall Study|Physician Decision|0
5997952|NCT01244763|9591672|FG005|Overall Study|Physician Decision|0
5997953|NCT01244763|9591667|FG000|Overall Study|Withdrawal by Subject|1
5997954|NCT01244763|9591668|FG001|Overall Study|Withdrawal by Subject|2
6071463|NCT00555477|9674499|FG001|Overall Study|Withdrawal by Subject|2
6071464|NCT00555477|9674498|FG000|Overall Study|Physician Decision|1
6071465|NCT00555477|9674499|FG001|Overall Study|Physician Decision|2
6071466|NCT00555568|9674507|FG000|Overall Study|Lost to Follow-up|26
6071467|NCT00555568|9674508|FG001|Overall Study|Lost to Follow-up|16
6071468|NCT00555568|9674509|FG002|Overall Study|Lost to Follow-up|16
6071469|NCT00555620|9674527|FG000|Overall Study|Death|0
6071470|NCT00555620|9674528|FG001|Overall Study|Death|1
6071471|NCT00555620|9674529|FG002|Overall Study|Death|0
6071472|NCT00555620|9674530|FG003|Overall Study|Death|0
6071473|NCT00555620|9674531|FG004|Overall Study|Death|0
6071474|NCT00555620|9674532|FG005|Overall Study|Death|1
6071475|NCT00555620|9674527|FG000|Overall Study|Study terminated by sponsor|0
6071476|NCT00555620|9674528|FG001|Overall Study|Study terminated by sponsor|0
6071477|NCT00555620|9674529|FG002|Overall Study|Study terminated by sponsor|1
6071478|NCT00555620|9674530|FG003|Overall Study|Study terminated by sponsor|0
6071479|NCT00555620|9674531|FG004|Overall Study|Study terminated by sponsor|0
6071480|NCT00555620|9674532|FG005|Overall Study|Study terminated by sponsor|0
6071481|NCT00555620|9674527|FG000|Overall Study|Adverse Event|0
6071482|NCT00555620|9674528|FG001|Overall Study|Adverse Event|0
6071483|NCT00555620|9674529|FG002|Overall Study|Adverse Event|1
6071484|NCT00555620|9674530|FG003|Overall Study|Adverse Event|5
6071485|NCT00555620|9674531|FG004|Overall Study|Adverse Event|0
6071486|NCT00555620|9674532|FG005|Overall Study|Adverse Event|1
6071487|NCT00555620|9674527|FG000|Overall Study|Objective progression or relapse|6
6071488|NCT00555620|9674528|FG001|Overall Study|Objective progression or relapse|5
6071489|NCT00555620|9674529|FG002|Overall Study|Objective progression or relapse|12
6309492|NCT02639247|10038095|FG001|Overall Study|Lost to Follow-up|1
6309493|NCT02639247|10038094|FG000|Overall Study|Death|2
5997955|NCT01244763|9591669|FG002|Overall Study|Withdrawal by Subject|0
5997956|NCT01244763|9591670|FG003|Overall Study|Withdrawal by Subject|1
5997957|NCT01244763|9591671|FG004|Overall Study|Withdrawal by Subject|1
5997958|NCT01244763|9591672|FG005|Overall Study|Withdrawal by Subject|2
5997959|NCT01244763|9591667|FG000|Overall Study|Lost to Follow-up|0
5997960|NCT01244763|9591668|FG001|Overall Study|Lost to Follow-up|1
5997961|NCT01244763|9591669|FG002|Overall Study|Lost to Follow-up|0
6309494|NCT02639247|10038095|FG001|Overall Study|Death|0
6309495|NCT02639247|10038094|FG000|Overall Study|Withdrew Consent|0
5997962|NCT01244763|9591670|FG003|Overall Study|Lost to Follow-up|0
5997963|NCT01244763|9591671|FG004|Overall Study|Lost to Follow-up|0
5997964|NCT01244763|9591672|FG005|Overall Study|Lost to Follow-up|0
5997965|NCT01244763|9591667|FG000|Overall Study|Enrolled into the Extension Study|0
5997966|NCT01244763|9591668|FG001|Overall Study|Enrolled into the Extension Study|0
5997967|NCT01244763|9591669|FG002|Overall Study|Enrolled into the Extension Study|0
5997968|NCT01244763|9591670|FG003|Overall Study|Enrolled into the Extension Study|0
5997969|NCT01244763|9591671|FG004|Overall Study|Enrolled into the Extension Study|0
6071490|NCT00555620|9674530|FG003|Overall Study|Objective progression or relapse|17
6071491|NCT00555620|9674531|FG004|Overall Study|Objective progression or relapse|3
6071492|NCT00555620|9674532|FG005|Overall Study|Objective progression or relapse|16
6071493|NCT00555620|9674527|FG000|Overall Study|Participant refused treatment|0
6071494|NCT00555620|9674528|FG001|Overall Study|Participant refused treatment|1
6071495|NCT00555620|9674529|FG002|Overall Study|Participant refused treatment|1
6071496|NCT00555620|9674530|FG003|Overall Study|Participant refused treatment|0
6071497|NCT00555620|9674531|FG004|Overall Study|Participant refused treatment|0
6071498|NCT00555620|9674532|FG005|Overall Study|Participant refused treatment|1
6071499|NCT00555620|9674527|FG000|Overall Study|Other|0
6071500|NCT00555620|9674528|FG001|Overall Study|Other|0
6071501|NCT00555620|9674529|FG002|Overall Study|Other|0
6071502|NCT00555620|9674530|FG003|Overall Study|Other|1
6071503|NCT00555620|9674531|FG004|Overall Study|Other|0
6071504|NCT00555620|9674532|FG005|Overall Study|Other|3
6071505|NCT00555672|9674552|FG000|Overall Study|Death|0
6071506|NCT00555672|9674553|FG001|Overall Study|Death|2
6071507|NCT00555672|9674552|FG000|Overall Study|Adverse Event|8
6071508|NCT00555672|9674553|FG001|Overall Study|Adverse Event|2
6071509|NCT00555672|9674552|FG000|Overall Study|Objective progression or relapse|11
6071510|NCT00555672|9674553|FG001|Overall Study|Objective progression or relapse|5
6071511|NCT00555672|9674552|FG000|Overall Study|Other|3
6071512|NCT00555672|9674553|FG001|Overall Study|Other|1
6071513|NCT00555672|9674552|FG000|Overall Study|Participant refused|2
6071514|NCT00555672|9674553|FG001|Overall Study|Participant refused|0
6071515|NCT00555906|9674590|FG000|Phase 1|Objective Progression or Relapse|3
6071516|NCT00555906|9674591|FG001|Phase 1|Objective Progression or Relapse|5
6071517|NCT00555906|9674592|FG002|Phase 1|Objective Progression or Relapse|3
6071518|NCT00555906|9674593|FG003|Phase 1|Objective Progression or Relapse|1
6071519|NCT00555906|9674594|FG004|Phase 1|Objective Progression or Relapse|0
6071520|NCT00555906|9674590|FG000|Phase 1|Global Deterioration of Health Status|0
6071521|NCT00555906|9674591|FG001|Phase 1|Global Deterioration of Health Status|1
6071522|NCT00555906|9674592|FG002|Phase 1|Global Deterioration of Health Status|1
6071523|NCT00555906|9674593|FG003|Phase 1|Global Deterioration of Health Status|1
6071524|NCT00555906|9674594|FG004|Phase 1|Global Deterioration of Health Status|0
6071525|NCT00555906|9674590|FG000|Phase 1|Adverse Event|0
6071526|NCT00555906|9674591|FG001|Phase 1|Adverse Event|0
6071527|NCT00555906|9674592|FG002|Phase 1|Adverse Event|3
6071528|NCT00555906|9674593|FG003|Phase 1|Adverse Event|2
6071529|NCT00555906|9674594|FG004|Phase 1|Adverse Event|0
6071530|NCT00555906|9674590|FG000|Phase 1|Withdrawal by Subject|0
6071531|NCT00555906|9674591|FG001|Phase 1|Withdrawal by Subject|0
6071532|NCT00555906|9674592|FG002|Phase 1|Withdrawal by Subject|0
6071533|NCT00555906|9674593|FG003|Phase 1|Withdrawal by Subject|1
6071534|NCT00555906|9674594|FG004|Phase 1|Withdrawal by Subject|0
6071535|NCT00555906|9674590|FG000|Phase 2|Adverse Event|0
6071536|NCT00555906|9674591|FG001|Phase 2|Adverse Event|0
6071537|NCT00555906|9674592|FG002|Phase 2|Adverse Event|0
6071538|NCT00555906|9674593|FG003|Phase 2|Adverse Event|0
6071539|NCT00555906|9674594|FG004|Phase 2|Adverse Event|4
6071540|NCT00555906|9674590|FG000|Phase 2|Global Deterioration of Health Status|0
6071541|NCT00555906|9674591|FG001|Phase 2|Global Deterioration of Health Status|0
6071542|NCT00555906|9674592|FG002|Phase 2|Global Deterioration of Health Status|0
6071543|NCT00555906|9674593|FG003|Phase 2|Global Deterioration of Health Status|0
6071544|NCT00555906|9674594|FG004|Phase 2|Global Deterioration of Health Status|2
6071545|NCT00555906|9674590|FG000|Phase 2|Objective Progression or Relapse|0
6071546|NCT00555906|9674591|FG001|Phase 2|Objective Progression or Relapse|0
6071547|NCT00555906|9674592|FG002|Phase 2|Objective Progression or Relapse|0
6071548|NCT00555906|9674593|FG003|Phase 2|Objective Progression or Relapse|0
6071549|NCT00555906|9674594|FG004|Phase 2|Objective Progression or Relapse|16
6071550|NCT00555906|9674590|FG000|Phase 2|Withdrawal by Subject|0
6071551|NCT00555906|9674591|FG001|Phase 2|Withdrawal by Subject|0
6071552|NCT00555906|9674592|FG002|Phase 2|Withdrawal by Subject|0
6071553|NCT00555906|9674593|FG003|Phase 2|Withdrawal by Subject|0
6071554|NCT00555906|9674594|FG004|Phase 2|Withdrawal by Subject|2
6071555|NCT00555906|9674590|FG000|Phase 2|Other|0
6071556|NCT00555906|9674591|FG001|Phase 2|Other|0
5997970|NCT01244763|9591672|FG005|Overall Study|Enrolled into the Extension Study|1
6047048|NCT00409838|9646126|FG000|Short-term Period|Never Treated|1
6047049|NCT00409838|9646127|FG001|Short-term Period|Never Treated|0
6071557|NCT00555906|9674592|FG002|Phase 2|Other|0
6071558|NCT00555906|9674593|FG003|Phase 2|Other|0
6071559|NCT00555906|9674594|FG004|Phase 2|Other|6
6071560|NCT00555906|9674590|FG000|Phase 2|Randomized but not Treated|0
6071561|NCT00555906|9674591|FG001|Phase 2|Randomized but not Treated|0
6071562|NCT00555906|9674592|FG002|Phase 2|Randomized but not Treated|0
6071563|NCT00555906|9674593|FG003|Phase 2|Randomized but not Treated|0
6071564|NCT00555906|9674594|FG004|Phase 2|Randomized but not Treated|2
5997971|NCT01208207|9591689|FG000|Part I|Adverse Event|19
5997972|NCT01208207|9591690|FG001|Part I|Adverse Event|2
5997973|NCT01208207|9591691|FG002|Part I|Adverse Event|6
5997974|NCT01208207|9591692|FG003|Part I|Adverse Event|0
5997975|NCT01208207|9591693|FG004|Part I|Adverse Event|0
5997976|NCT01208207|9591694|FG005|Part I|Adverse Event|0
5997977|NCT01208207|9591695|FG006|Part I|Adverse Event|0
5997978|NCT01208207|9591689|FG000|Part I|Lack of Efficacy|21
5997979|NCT01208207|9591690|FG001|Part I|Lack of Efficacy|3
5997980|NCT01208207|9591691|FG002|Part I|Lack of Efficacy|2
5997981|NCT01208207|9591692|FG003|Part I|Lack of Efficacy|0
5997982|NCT01208207|9591693|FG004|Part I|Lack of Efficacy|0
5997983|NCT01208207|9591694|FG005|Part I|Lack of Efficacy|0
5997984|NCT01208207|9591695|FG006|Part I|Lack of Efficacy|0
5997985|NCT01208207|9591689|FG000|Part I|Lost to Follow-up|6
5997986|NCT01208207|9591690|FG001|Part I|Lost to Follow-up|1
5997987|NCT01208207|9591691|FG002|Part I|Lost to Follow-up|0
5997988|NCT01208207|9591692|FG003|Part I|Lost to Follow-up|0
5997989|NCT01208207|9591693|FG004|Part I|Lost to Follow-up|0
5997990|NCT01208207|9591694|FG005|Part I|Lost to Follow-up|0
5997991|NCT01208207|9591695|FG006|Part I|Lost to Follow-up|0
5997992|NCT01208207|9591689|FG000|Part I|Non-Compliance With Study Drug|1
5997993|NCT01208207|9591690|FG001|Part I|Non-Compliance With Study Drug|0
5997994|NCT01208207|9591691|FG002|Part I|Non-Compliance With Study Drug|1
5997995|NCT01208207|9591692|FG003|Part I|Non-Compliance With Study Drug|0
5997996|NCT01208207|9591693|FG004|Part I|Non-Compliance With Study Drug|0
5997997|NCT01208207|9591694|FG005|Part I|Non-Compliance With Study Drug|0
5997998|NCT01208207|9591695|FG006|Part I|Non-Compliance With Study Drug|0
5997999|NCT01208207|9591689|FG000|Part I|Physician Decision|0
5998000|NCT01208207|9591690|FG001|Part I|Physician Decision|1
5998001|NCT01208207|9591691|FG002|Part I|Physician Decision|0
6071565|NCT00555971|9674611|FG000|Overall Study|Adverse Event|1
6071566|NCT00555971|9674612|FG001|Overall Study|Adverse Event|1
6071567|NCT00556322|9674646|FG000|Overall Study|Insufficient therapeutic response|158
6071568|NCT00556322|9674647|FG001|Overall Study|Insufficient therapeutic response|168
6071569|NCT00556322|9674646|FG000|Overall Study|Adverse Event|7
6071570|NCT00556322|9674647|FG001|Overall Study|Adverse Event|4
6071571|NCT00556322|9674646|FG000|Overall Study|Other|4
6071572|NCT00556322|9674647|FG001|Overall Study|Other|1
6071573|NCT00556322|9674646|FG000|Overall Study|Lost to Follow-up|5
6071574|NCT00556322|9674647|FG001|Overall Study|Lost to Follow-up|3
6071575|NCT00556322|9674646|FG000|Overall Study|Withdrawal by Subject|19
6071576|NCT00556322|9674647|FG001|Overall Study|Withdrawal by Subject|7
6071577|NCT00556322|9674646|FG000|Overall Study|Protocol Violation|5
6071578|NCT00556322|9674647|FG001|Overall Study|Protocol Violation|1
6071579|NCT00556322|9674646|FG000|Overall Study|Ongoing at data cutoff|3
6071580|NCT00556322|9674647|FG001|Overall Study|Ongoing at data cutoff|5
6071581|NCT00556322|9674646|FG000|Overall Study|Death|20
6071582|NCT00556322|9674647|FG001|Overall Study|Death|14
6071583|NCT00556374|9674658|FG000|Overall Study|Withdrawal by Subject|190
6071584|NCT00556374|9674659|FG001|Overall Study|Withdrawal by Subject|172
6071585|NCT00556374|9674658|FG000|Overall Study|Death|50
6071586|NCT00556374|9674659|FG001|Overall Study|Death|43
6071587|NCT00556374|9674658|FG000|Overall Study|Lost to Follow-up|7
6071588|NCT00556374|9674659|FG001|Overall Study|Lost to Follow-up|5
6071589|NCT00556426|9674665|FG000|Overall Study|Withdrawal by Subject|3
6071590|NCT00556426|9674665|FG000|Overall Study|Death|6
6071591|NCT00556439|9674674|FG000|Study Entry to Week 12|Lack of Efficacy|5
6071592|NCT00556439|9674675|FG001|Study Entry to Week 12|Lack of Efficacy|0
6071593|NCT00556439|9674676|FG002|Study Entry to Week 12|Lack of Efficacy|6
6071594|NCT00556439|9674677|FG003|Study Entry to Week 12|Lack of Efficacy|0
6071595|NCT00556439|9674674|FG000|Study Entry to Week 12|Physician Decision|1
6071596|NCT00556439|9674675|FG001|Study Entry to Week 12|Physician Decision|0
6071597|NCT00556439|9674676|FG002|Study Entry to Week 12|Physician Decision|0
6071598|NCT00556439|9674677|FG003|Study Entry to Week 12|Physician Decision|0
6071599|NCT00556439|9674674|FG000|Study Entry to Week 12|Withdrawal by Subject|1
6071600|NCT00556439|9674675|FG001|Study Entry to Week 12|Withdrawal by Subject|0
6071601|NCT00556439|9674676|FG002|Study Entry to Week 12|Withdrawal by Subject|1
6071602|NCT00556439|9674677|FG003|Study Entry to Week 12|Withdrawal by Subject|0
6071603|NCT00556439|9674674|FG000|Study Entry to Week 12|Recurrent infection|1
6071604|NCT00556439|9674675|FG001|Study Entry to Week 12|Recurrent infection|0
6071605|NCT00556439|9674676|FG002|Study Entry to Week 12|Recurrent infection|0
6071606|NCT00556439|9674677|FG003|Study Entry to Week 12|Recurrent infection|0
6071607|NCT00556439|9674674|FG000|Study Entry to Week 12|Malignancy|0
6071608|NCT00556439|9674675|FG001|Study Entry to Week 12|Malignancy|0
6071609|NCT00556439|9674676|FG002|Study Entry to Week 12|Malignancy|1
6071610|NCT00556439|9674677|FG003|Study Entry to Week 12|Malignancy|0
6071611|NCT00556439|9674674|FG000|After Week 12 (Randomized Study Period)|Withdrawal by Subject|1
6071612|NCT00556439|9674675|FG001|After Week 12 (Randomized Study Period)|Withdrawal by Subject|3
5998002|NCT01208207|9591692|FG003|Part I|Physician Decision|0
5998003|NCT01208207|9591693|FG004|Part I|Physician Decision|0
5998004|NCT01208207|9591694|FG005|Part I|Physician Decision|0
5998005|NCT01208207|9591695|FG006|Part I|Physician Decision|0
5998006|NCT01208207|9591689|FG000|Part I|Progressive Disease|1
5998007|NCT01208207|9591690|FG001|Part I|Progressive Disease|0
5998008|NCT01208207|9591691|FG002|Part I|Progressive Disease|0
6087260|NCT00666926|9697368|FG009|Overall Study|Withdrawal by Subject|3
5998009|NCT01208207|9591692|FG003|Part I|Progressive Disease|0
5998010|NCT01208207|9591693|FG004|Part I|Progressive Disease|0
5998011|NCT01208207|9591694|FG005|Part I|Progressive Disease|0
5998012|NCT01208207|9591695|FG006|Part I|Progressive Disease|0
5998013|NCT01208207|9591689|FG000|Part I|Protocol Violation|8
5998014|NCT01208207|9591690|FG001|Part I|Protocol Violation|0
5998015|NCT01208207|9591691|FG002|Part I|Protocol Violation|2
5998016|NCT01208207|9591692|FG003|Part I|Protocol Violation|0
5998017|NCT01208207|9591693|FG004|Part I|Protocol Violation|0
5998018|NCT01208207|9591694|FG005|Part I|Protocol Violation|0
5998019|NCT01208207|9591695|FG006|Part I|Protocol Violation|0
5998020|NCT01208207|9591689|FG000|Part I|Withdrawal by Subject|14
5998021|NCT01208207|9591690|FG001|Part I|Withdrawal by Subject|4
5998022|NCT01208207|9591691|FG002|Part I|Withdrawal by Subject|4
5998023|NCT01208207|9591692|FG003|Part I|Withdrawal by Subject|0
5998024|NCT01208207|9591693|FG004|Part I|Withdrawal by Subject|0
5998025|NCT01208207|9591694|FG005|Part I|Withdrawal by Subject|0
5998026|NCT01208207|9591695|FG006|Part I|Withdrawal by Subject|0
5998027|NCT01208207|9591689|FG000|Part II|Withdrawal by Subject|0
5998028|NCT01208207|9591690|FG001|Part II|Withdrawal by Subject|0
5998029|NCT01208207|9591691|FG002|Part II|Withdrawal by Subject|0
5998030|NCT01208207|9591692|FG003|Part II|Withdrawal by Subject|10
5998031|NCT01208207|9591693|FG004|Part II|Withdrawal by Subject|9
5998032|NCT01208207|9591694|FG005|Part II|Withdrawal by Subject|3
5998033|NCT01208207|9591695|FG006|Part II|Withdrawal by Subject|5
5998034|NCT01208207|9591689|FG000|Part II|Adverse Event|0
5998035|NCT01208207|9591690|FG001|Part II|Adverse Event|0
6071613|NCT00556439|9674676|FG002|After Week 12 (Randomized Study Period)|Withdrawal by Subject|0
6071614|NCT00556439|9674677|FG003|After Week 12 (Randomized Study Period)|Withdrawal by Subject|0
6071615|NCT00556439|9674674|FG000|After Week 12 (Randomized Study Period)|Physician Decision|1
6071616|NCT00556439|9674675|FG001|After Week 12 (Randomized Study Period)|Physician Decision|0
6071617|NCT00556439|9674676|FG002|After Week 12 (Randomized Study Period)|Physician Decision|0
6071618|NCT00556439|9674677|FG003|After Week 12 (Randomized Study Period)|Physician Decision|0
6071619|NCT00556439|9674674|FG000|After Week 12 (Randomized Study Period)|Malignancy|0
6071620|NCT00556439|9674675|FG001|After Week 12 (Randomized Study Period)|Malignancy|1
6071621|NCT00556439|9674676|FG002|After Week 12 (Randomized Study Period)|Malignancy|0
6071622|NCT00556439|9674677|FG003|After Week 12 (Randomized Study Period)|Malignancy|1
6071623|NCT00556439|9674674|FG000|After Week 12 (Randomized Study Period)|Severe infection|1
6071624|NCT00556439|9674675|FG001|After Week 12 (Randomized Study Period)|Severe infection|0
6071625|NCT00556439|9674676|FG002|After Week 12 (Randomized Study Period)|Severe infection|0
6071626|NCT00556439|9674677|FG003|After Week 12 (Randomized Study Period)|Severe infection|0
6071627|NCT00556673|9674746|FG000|Overall Study|Protocol deviation|3
6071628|NCT00556673|9674747|FG001|Overall Study|Protocol deviation|2
6071629|NCT00556712|9674757|FG000|Overall Study|Adverse Event|7
6071630|NCT00556712|9674758|FG001|Overall Study|Adverse Event|19
6071631|NCT00556712|9674757|FG000|Overall Study|Death|5
6071632|NCT00556712|9674758|FG001|Overall Study|Death|10
6071633|NCT00556712|9674757|FG000|Overall Study|Progressive Disease|383
6071634|NCT00556712|9674758|FG001|Overall Study|Progressive Disease|320
6071635|NCT00556712|9674757|FG000|Overall Study|Protocol Violation|3
6071636|NCT00556712|9674758|FG001|Overall Study|Protocol Violation|2
6071637|NCT00556712|9674757|FG000|Overall Study|Refused Treatment|17
6071638|NCT00556712|9674758|FG001|Overall Study|Refused Treatment|16
6071639|NCT00556712|9674757|FG000|Overall Study|Failure to Return|2
6071640|NCT00556712|9674758|FG001|Overall Study|Failure to Return|3
6071641|NCT00556712|9674757|FG000|Overall Study|Other|2
6071642|NCT00556712|9674758|FG001|Overall Study|Other|2
6071643|NCT00556712|9674757|FG000|Overall Study|Ongoing at Data Cutoff|32
6071644|NCT00556712|9674758|FG001|Overall Study|Ongoing at Data Cutoff|66
6071645|NCT00556894|9674784|FG000|Overall Study|Adverse Event|2
6071646|NCT00556894|9674785|FG001|Overall Study|Adverse Event|3
6071647|NCT00556894|9674786|FG002|Overall Study|Adverse Event|3
6071648|NCT00556894|9674784|FG000|Overall Study|Death|1
6071649|NCT00556894|9674785|FG001|Overall Study|Death|0
6071650|NCT00556894|9674786|FG002|Overall Study|Death|0
6071651|NCT00556894|9674784|FG000|Overall Study|regulatory decision in Bulgaria|10
6071652|NCT00556894|9674785|FG001|Overall Study|regulatory decision in Bulgaria|14
6071653|NCT00556894|9674786|FG002|Overall Study|regulatory decision in Bulgaria|13
6071654|NCT00556894|9674784|FG000|Overall Study|Change in therapy|2
6071655|NCT00556894|9674785|FG001|Overall Study|Change in therapy|1
5998036|NCT01208207|9591691|FG002|Part II|Adverse Event|0
5998037|NCT01208207|9591692|FG003|Part II|Adverse Event|5
6071656|NCT00556894|9674786|FG002|Overall Study|Change in therapy|2
6071657|NCT00556894|9674784|FG000|Overall Study|Withdrawal by Subject|1
6071658|NCT00556894|9674785|FG001|Overall Study|Withdrawal by Subject|1
6071659|NCT00556894|9674786|FG002|Overall Study|Withdrawal by Subject|1
6146251|NCT01076010|9780832|FG000|Overall Study|Treatment Interruption for > 2 Weeks|0
5998038|NCT01208207|9591693|FG004|Part II|Adverse Event|9
5998039|NCT01208207|9591694|FG005|Part II|Adverse Event|4
5998040|NCT01208207|9591695|FG006|Part II|Adverse Event|2
5998041|NCT01208207|9591689|FG000|Part II|Lack of Efficacy|0
5998042|NCT01208207|9591690|FG001|Part II|Lack of Efficacy|0
5998043|NCT01208207|9591691|FG002|Part II|Lack of Efficacy|0
5998044|NCT01208207|9591692|FG003|Part II|Lack of Efficacy|6
5998045|NCT01208207|9591693|FG004|Part II|Lack of Efficacy|4
5998046|NCT01208207|9591694|FG005|Part II|Lack of Efficacy|3
5998047|NCT01208207|9591695|FG006|Part II|Lack of Efficacy|3
5998048|NCT01208207|9591689|FG000|Part II|Lost to Follow-up|0
5998049|NCT01208207|9591690|FG001|Part II|Lost to Follow-up|0
5998050|NCT01208207|9591691|FG002|Part II|Lost to Follow-up|0
5998051|NCT01208207|9591692|FG003|Part II|Lost to Follow-up|4
5998052|NCT01208207|9591693|FG004|Part II|Lost to Follow-up|0
5998053|NCT01208207|9591694|FG005|Part II|Lost to Follow-up|2
5998054|NCT01208207|9591695|FG006|Part II|Lost to Follow-up|1
5998055|NCT01208207|9591689|FG000|Part II|Non-Compliance With Study Drug|0
5998056|NCT01208207|9591690|FG001|Part II|Non-Compliance With Study Drug|0
5998057|NCT01208207|9591691|FG002|Part II|Non-Compliance With Study Drug|0
5998058|NCT01208207|9591692|FG003|Part II|Non-Compliance With Study Drug|4
5998059|NCT01208207|9591693|FG004|Part II|Non-Compliance With Study Drug|1
5998060|NCT01208207|9591694|FG005|Part II|Non-Compliance With Study Drug|1
5998061|NCT01208207|9591695|FG006|Part II|Non-Compliance With Study Drug|0
5998062|NCT01208207|9591689|FG000|Part II|Physician Decision|0
5998063|NCT01208207|9591690|FG001|Part II|Physician Decision|0
5998064|NCT01208207|9591691|FG002|Part II|Physician Decision|0
5998065|NCT01208207|9591692|FG003|Part II|Physician Decision|1
5998066|NCT01208207|9591693|FG004|Part II|Physician Decision|0
5998067|NCT01208207|9591694|FG005|Part II|Physician Decision|2
5998068|NCT01208207|9591695|FG006|Part II|Physician Decision|0
5998069|NCT01208207|9591689|FG000|Part II|Protocol Violation|0
5998070|NCT01208207|9591690|FG001|Part II|Protocol Violation|0
5998071|NCT01208207|9591691|FG002|Part II|Protocol Violation|0
5998072|NCT01208207|9591692|FG003|Part II|Protocol Violation|1
5998073|NCT01208207|9591693|FG004|Part II|Protocol Violation|0
5998074|NCT01208207|9591694|FG005|Part II|Protocol Violation|0
5998075|NCT01208207|9591695|FG006|Part II|Protocol Violation|0
5998076|NCT01208207|9591689|FG000|Part II|Technical Problems|0
5998077|NCT01208207|9591690|FG001|Part II|Technical Problems|0
5998078|NCT01208207|9591691|FG002|Part II|Technical Problems|0
5998079|NCT01208207|9591692|FG003|Part II|Technical Problems|1
5998080|NCT01208207|9591693|FG004|Part II|Technical Problems|0
5998081|NCT01208207|9591694|FG005|Part II|Technical Problems|1
5998082|NCT01208207|9591695|FG006|Part II|Technical Problems|0
5998083|NCT01208181|9591720|FG000|Part 1|Withdrawal by Subject|11
5998084|NCT01208181|9591721|FG001|Part 1|Withdrawal by Subject|10
5998085|NCT01208181|9591722|FG002|Part 1|Withdrawal by Subject|0
5998086|NCT01208181|9591723|FG003|Part 1|Withdrawal by Subject|0
5998087|NCT01208181|9591724|FG004|Part 1|Withdrawal by Subject|0
5998088|NCT01208181|9591720|FG000|Part 1|Technical problem|5
5998089|NCT01208181|9591721|FG001|Part 1|Technical problem|0
6071660|NCT00556933|9674798|FG000|Single vs. Divided-dose rATG Induction|Protocol Violation|2
6071661|NCT00556933|9674799|FG001|Single vs. Divided-dose rATG Induction|Protocol Violation|3
6071662|NCT00556933|9674800|FG002|Single vs. Divided-dose rATG Induction|Protocol Violation|3
6071663|NCT00556933|9674801|FG003|Single vs. Divided-dose rATG Induction|Protocol Violation|0
6071664|NCT00556933|9674798|FG000|Single vs. Divided-dose rATG Induction|Withdrawal by Subject|0
6071665|NCT00556933|9674799|FG001|Single vs. Divided-dose rATG Induction|Withdrawal by Subject|0
6071666|NCT00556933|9674800|FG002|Single vs. Divided-dose rATG Induction|Withdrawal by Subject|1
6071667|NCT00556933|9674801|FG003|Single vs. Divided-dose rATG Induction|Withdrawal by Subject|0
6071668|NCT00556933|9674798|FG000|Single vs. Divided-dose rATG Induction|Pancreas transplantation|0
6071669|NCT00556933|9674799|FG001|Single vs. Divided-dose rATG Induction|Pancreas transplantation|2
6071670|NCT00556933|9674800|FG002|Single vs. Divided-dose rATG Induction|Pancreas transplantation|2
6071671|NCT00556933|9674801|FG003|Single vs. Divided-dose rATG Induction|Pancreas transplantation|2
6071672|NCT00556933|9674798|FG000|Single vs. Divided-dose rATG Induction|Death|0
6071673|NCT00556933|9674799|FG001|Single vs. Divided-dose rATG Induction|Death|1
6071674|NCT00556933|9674800|FG002|Single vs. Divided-dose rATG Induction|Death|0
6071675|NCT00556933|9674801|FG003|Single vs. Divided-dose rATG Induction|Death|0
6071676|NCT00556933|9674798|FG000|Single vs. Divided-dose rATG Induction|Lost to Follow-up|0
6071677|NCT00556933|9674799|FG001|Single vs. Divided-dose rATG Induction|Lost to Follow-up|1
6071678|NCT00556933|9674800|FG002|Single vs. Divided-dose rATG Induction|Lost to Follow-up|0
6071679|NCT00556933|9674801|FG003|Single vs. Divided-dose rATG Induction|Lost to Follow-up|0
6071680|NCT00556933|9674798|FG000|Single vs. Divided-dose rATG Induction|Kidney graft primary non-function|0
6071681|NCT00556933|9674799|FG001|Single vs. Divided-dose rATG Induction|Kidney graft primary non-function|1
6071682|NCT00556933|9674800|FG002|Single vs. Divided-dose rATG Induction|Kidney graft primary non-function|0
6071683|NCT00556933|9674801|FG003|Single vs. Divided-dose rATG Induction|Kidney graft primary non-function|0
6071684|NCT00556933|9674798|FG000|CNI Withdrawal vs. Minimization|Pancreas transplantation|1
6071685|NCT00556933|9674799|FG001|CNI Withdrawal vs. Minimization|Pancreas transplantation|1
6071686|NCT00556933|9674800|FG002|CNI Withdrawal vs. Minimization|Pancreas transplantation|0
6071687|NCT00556933|9674801|FG003|CNI Withdrawal vs. Minimization|Pancreas transplantation|0
6071688|NCT00556933|9674798|FG000|CNI Withdrawal vs. Minimization|Lost to Follow-up|0
6071689|NCT00556933|9674799|FG001|CNI Withdrawal vs. Minimization|Lost to Follow-up|1
6071690|NCT00556933|9674800|FG002|CNI Withdrawal vs. Minimization|Lost to Follow-up|0
5998090|NCT01208181|9591722|FG002|Part 1|Technical problem|0
5998091|NCT01208181|9591723|FG003|Part 1|Technical problem|0
5998092|NCT01208181|9591724|FG004|Part 1|Technical problem|0
5998093|NCT01208181|9591720|FG000|Part 1|Protocol Violation|10
5998094|NCT01208181|9591721|FG001|Part 1|Protocol Violation|5
5998095|NCT01208181|9591722|FG002|Part 1|Protocol Violation|0
5998096|NCT01208181|9591723|FG003|Part 1|Protocol Violation|0
5998097|NCT01208181|9591724|FG004|Part 1|Protocol Violation|0
5998098|NCT01208181|9591720|FG000|Part 1|Physician Decision|4
5998099|NCT01208181|9591721|FG001|Part 1|Physician Decision|0
5998100|NCT01208181|9591722|FG002|Part 1|Physician Decision|0
5998101|NCT01208181|9591723|FG003|Part 1|Physician Decision|0
5998102|NCT01208181|9591724|FG004|Part 1|Physician Decision|0
5998103|NCT01208181|9591720|FG000|Part 1|Non-compliance with study drug|1
5998104|NCT01208181|9591721|FG001|Part 1|Non-compliance with study drug|1
5998105|NCT01208181|9591722|FG002|Part 1|Non-compliance with study drug|0
5998106|NCT01208181|9591723|FG003|Part 1|Non-compliance with study drug|0
5998107|NCT01208181|9591724|FG004|Part 1|Non-compliance with study drug|0
5998108|NCT01208181|9591720|FG000|Part 1|Lost to Follow-up|5
5998109|NCT01208181|9591721|FG001|Part 1|Lost to Follow-up|3
5998110|NCT01208181|9591722|FG002|Part 1|Lost to Follow-up|0
6071691|NCT00556933|9674801|FG003|CNI Withdrawal vs. Minimization|Lost to Follow-up|1
6071692|NCT00556933|9674798|FG000|CNI Withdrawal vs. Minimization|Withdrawal by Subject|0
6071693|NCT00556933|9674799|FG001|CNI Withdrawal vs. Minimization|Withdrawal by Subject|1
6071694|NCT00556933|9674800|FG002|CNI Withdrawal vs. Minimization|Withdrawal by Subject|1
6071695|NCT00556933|9674801|FG003|CNI Withdrawal vs. Minimization|Withdrawal by Subject|0
6071696|NCT00556933|9674798|FG000|CNI Withdrawal vs. Minimization|Graft loss|0
6071697|NCT00556933|9674799|FG001|CNI Withdrawal vs. Minimization|Graft loss|1
6071698|NCT00556933|9674800|FG002|CNI Withdrawal vs. Minimization|Graft loss|2
6071699|NCT00556933|9674801|FG003|CNI Withdrawal vs. Minimization|Graft loss|0
6071700|NCT00556933|9674798|FG000|CNI Withdrawal vs. Minimization|Death|0
6071701|NCT00556933|9674799|FG001|CNI Withdrawal vs. Minimization|Death|0
6071702|NCT00556933|9674800|FG002|CNI Withdrawal vs. Minimization|Death|0
6071703|NCT00556933|9674801|FG003|CNI Withdrawal vs. Minimization|Death|1
6071704|NCT00556998|9674828|FG000|Voriconazole Intravenous (IV)|Adverse Event|1
6071705|NCT00556998|9674828|FG000|Voriconazole Intravenous (IV)|Other|4
6071706|NCT00556998|9674828|FG000|Voriconazole Oral|Adverse Event|1
6071707|NCT00556998|9674828|FG000|Voriconazole Oral|Intolerant of oral treatment|1
6071708|NCT00557076|9674838|FG000|Overall Study|Unblinding|0
6071709|NCT00557076|9674839|FG001|Overall Study|Unblinding|1
6071710|NCT00557245|9674848|FG000|Overall Study|Lost to Follow-up|7
6071711|NCT00557245|9674849|FG001|Overall Study|Lost to Follow-up|8
6071712|NCT00557245|9674850|FG002|Overall Study|Lost to Follow-up|10
6071713|NCT00557245|9674848|FG000|Overall Study|Ineligible|5
6071714|NCT00557245|9674849|FG001|Overall Study|Ineligible|4
6071715|NCT00557245|9674850|FG002|Overall Study|Ineligible|2
6071716|NCT00557310|9674870|FG000|Main Study (0 - 18 Months)|Adverse Event|4
6071717|NCT00557310|9674870|FG000|Main Study (0 - 18 Months)|Withdrawal by Subject|1
6071718|NCT00557310|9674870|FG000|Extension Phase (18 - 24 Months)|Adverse Event|1
6071719|NCT00557310|9674870|FG000|Extension Phase (18 - 24 Months)|Lost to Follow-up|1
6071720|NCT00557310|9674870|FG000|Extension Phase (18 - 24 Months)|Physician Decision|2
6071721|NCT00557310|9674870|FG000|Extension Phase (18 - 24 Months)|Protocol Violation|1
6071722|NCT00557323|9674874|FG000|Overall Study|Death|3
6071723|NCT00557323|9674874|FG000|Overall Study|Withdrawal by Subject|2
6071724|NCT00557323|9674874|FG000|Overall Study|Administrative change|2
6071725|NCT00557440|9674910|FG000|Treatment Period 1|Adverse Event|0
6071726|NCT00557440|9674911|FG001|Treatment Period 1|Adverse Event|0
6071727|NCT00557440|9674912|FG002|Treatment Period 1|Adverse Event|1
6071728|NCT00557466|9674926|FG000|Overall Study|Adverse Event|3
6071729|NCT00557466|9674927|FG001|Overall Study|Adverse Event|1
6071730|NCT00557466|9674928|FG002|Overall Study|Adverse Event|4
6071731|NCT00557466|9674929|FG003|Overall Study|Adverse Event|1
6071732|NCT00557466|9674930|FG004|Overall Study|Adverse Event|2
6071733|NCT00557466|9674931|FG005|Overall Study|Adverse Event|4
6071734|NCT00557466|9674926|FG000|Overall Study|Abnormal laboratory value(s)|1
6071735|NCT00557466|9674927|FG001|Overall Study|Abnormal laboratory value(s)|2
6071736|NCT00557466|9674928|FG002|Overall Study|Abnormal laboratory value(s)|0
6071737|NCT00557466|9674929|FG003|Overall Study|Abnormal laboratory value(s)|0
6071738|NCT00557466|9674930|FG004|Overall Study|Abnormal laboratory value(s)|0
6071739|NCT00557466|9674931|FG005|Overall Study|Abnormal laboratory value(s)|0
6071740|NCT00557466|9674926|FG000|Overall Study|Protocol deviation|0
6071741|NCT00557466|9674927|FG001|Overall Study|Protocol deviation|1
6071742|NCT00557466|9674928|FG002|Overall Study|Protocol deviation|0
6071743|NCT00557466|9674929|FG003|Overall Study|Protocol deviation|2
6071744|NCT00557466|9674930|FG004|Overall Study|Protocol deviation|0
6071745|NCT00557466|9674931|FG005|Overall Study|Protocol deviation|0
6071746|NCT00557466|9674926|FG000|Overall Study|Subject withdrew consent|0
6071747|NCT00557466|9674927|FG001|Overall Study|Subject withdrew consent|0
6071748|NCT00557466|9674928|FG002|Overall Study|Subject withdrew consent|0
6071749|NCT00557466|9674929|FG003|Overall Study|Subject withdrew consent|0
5998111|NCT01208181|9591723|FG003|Part 1|Lost to Follow-up|0
5998112|NCT01208181|9591724|FG004|Part 1|Lost to Follow-up|1
6071750|NCT00557466|9674930|FG004|Overall Study|Subject withdrew consent|1
6071751|NCT00557466|9674931|FG005|Overall Study|Subject withdrew consent|2
6071752|NCT00557466|9674926|FG000|Overall Study|Administrative problems|0
6071753|NCT00557466|9674927|FG001|Overall Study|Administrative problems|1
6071754|NCT00557466|9674928|FG002|Overall Study|Administrative problems|1
5998113|NCT01208181|9591720|FG000|Part 1|Lack of Efficacy|37
5998114|NCT01208181|9591721|FG001|Part 1|Lack of Efficacy|12
5998115|NCT01208181|9591722|FG002|Part 1|Lack of Efficacy|0
5998116|NCT01208181|9591723|FG003|Part 1|Lack of Efficacy|0
5998117|NCT01208181|9591724|FG004|Part 1|Lack of Efficacy|17
5998118|NCT01208181|9591720|FG000|Part 1|Adverse Event|26
5998119|NCT01208181|9591721|FG001|Part 1|Adverse Event|24
5998120|NCT01208181|9591722|FG002|Part 1|Adverse Event|0
5998121|NCT01208181|9591723|FG003|Part 1|Adverse Event|0
5998122|NCT01208181|9591724|FG004|Part 1|Adverse Event|4
5998123|NCT01208181|9591720|FG000|Part 2|Adverse Event|0
5998124|NCT01208181|9591721|FG001|Part 2|Adverse Event|0
5998125|NCT01208181|9591722|FG002|Part 2|Adverse Event|6
5998126|NCT01208181|9591723|FG003|Part 2|Adverse Event|7
5998127|NCT01208181|9591724|FG004|Part 2|Adverse Event|0
5998128|NCT01208181|9591720|FG000|Part 2|Withdrawal by Subject|0
5998129|NCT01208181|9591721|FG001|Part 2|Withdrawal by Subject|0
5998130|NCT01208181|9591722|FG002|Part 2|Withdrawal by Subject|1
5998131|NCT01208181|9591723|FG003|Part 2|Withdrawal by Subject|1
5998132|NCT01208181|9591724|FG004|Part 2|Withdrawal by Subject|0
5998133|NCT01208181|9591720|FG000|Part 2|Protocol Violation|0
5998134|NCT01208181|9591721|FG001|Part 2|Protocol Violation|0
5998135|NCT01208181|9591722|FG002|Part 2|Protocol Violation|1
5998136|NCT01208181|9591723|FG003|Part 2|Protocol Violation|0
5998137|NCT01208181|9591724|FG004|Part 2|Protocol Violation|0
5998138|NCT01208181|9591720|FG000|Part 2|Physician Decision|0
5998139|NCT01208181|9591721|FG001|Part 2|Physician Decision|0
5998140|NCT01208181|9591722|FG002|Part 2|Physician Decision|1
5998141|NCT01208181|9591723|FG003|Part 2|Physician Decision|2
5998142|NCT01208181|9591724|FG004|Part 2|Physician Decision|0
5998143|NCT01208181|9591720|FG000|Part 2|Non-compliance with study drug|0
6071755|NCT00557466|9674929|FG003|Overall Study|Administrative problems|0
6071756|NCT00557466|9674930|FG004|Overall Study|Administrative problems|0
6071757|NCT00557466|9674931|FG005|Overall Study|Administrative problems|0
6071758|NCT00557466|9674926|FG000|Overall Study|Abnormal test procedure results|0
6071759|NCT00557466|9674927|FG001|Overall Study|Abnormal test procedure results|0
6071760|NCT00557466|9674928|FG002|Overall Study|Abnormal test procedure results|1
6071761|NCT00557466|9674929|FG003|Overall Study|Abnormal test procedure results|0
6071762|NCT00557466|9674930|FG004|Overall Study|Abnormal test procedure results|0
6071763|NCT00557466|9674931|FG005|Overall Study|Abnormal test procedure results|0
6071764|NCT00557466|9674926|FG000|Overall Study|Lost to Follow-up|0
6071765|NCT00557466|9674927|FG001|Overall Study|Lost to Follow-up|0
6071766|NCT00557466|9674928|FG002|Overall Study|Lost to Follow-up|0
6071767|NCT00557466|9674929|FG003|Overall Study|Lost to Follow-up|1
6071768|NCT00557466|9674930|FG004|Overall Study|Lost to Follow-up|0
6071769|NCT00557466|9674931|FG005|Overall Study|Lost to Follow-up|0
6071770|NCT00557492|9674945|FG000|Overall Study|Change in health insurance|1
6071771|NCT00557505|9674958|FG000|Overall Study|Death|0
6071772|NCT00557505|9674959|FG001|Overall Study|Death|0
6071773|NCT00557505|9674960|FG002|Overall Study|Death|0
6071774|NCT00557505|9674961|FG003|Overall Study|Death|0
6071775|NCT00557505|9674962|FG004|Overall Study|Death|0
6071776|NCT00557505|9674963|FG005|Overall Study|Death|0
6071777|NCT00557505|9674964|FG006|Overall Study|Death|0
6071778|NCT00557505|9674965|FG007|Overall Study|Death|0
6071779|NCT00557505|9674966|FG008|Overall Study|Death|1
6071780|NCT00557505|9674958|FG000|Overall Study|Adverse Event|0
6071781|NCT00557505|9674959|FG001|Overall Study|Adverse Event|0
6071782|NCT00557505|9674960|FG002|Overall Study|Adverse Event|1
6071783|NCT00557505|9674961|FG003|Overall Study|Adverse Event|0
6071784|NCT00557505|9674962|FG004|Overall Study|Adverse Event|0
6071785|NCT00557505|9674963|FG005|Overall Study|Adverse Event|0
6071786|NCT00557505|9674964|FG006|Overall Study|Adverse Event|1
6071787|NCT00557505|9674965|FG007|Overall Study|Adverse Event|0
6071788|NCT00557505|9674966|FG008|Overall Study|Adverse Event|0
6071789|NCT00557505|9674958|FG000|Overall Study|Global deterioration of health|1
6071790|NCT00557505|9674959|FG001|Overall Study|Global deterioration of health|0
6071791|NCT00557505|9674960|FG002|Overall Study|Global deterioration of health|0
6071792|NCT00557505|9674961|FG003|Overall Study|Global deterioration of health|0
6071793|NCT00557505|9674962|FG004|Overall Study|Global deterioration of health|0
6071794|NCT00557505|9674963|FG005|Overall Study|Global deterioration of health|0
6071795|NCT00557505|9674964|FG006|Overall Study|Global deterioration of health|0
6071796|NCT00557505|9674965|FG007|Overall Study|Global deterioration of health|0
6071797|NCT00557505|9674966|FG008|Overall Study|Global deterioration of health|0
6071798|NCT00557505|9674958|FG000|Overall Study|Objective progression or relapse|2
6071799|NCT00557505|9674959|FG001|Overall Study|Objective progression or relapse|3
5998144|NCT01208181|9591721|FG001|Part 2|Non-compliance with study drug|0
5998145|NCT01208181|9591722|FG002|Part 2|Non-compliance with study drug|1
5998146|NCT01208181|9591723|FG003|Part 2|Non-compliance with study drug|1
5998147|NCT01208181|9591724|FG004|Part 2|Non-compliance with study drug|0
5998148|NCT01208181|9591720|FG000|Part 2|Lost to Follow-up|0
5998149|NCT01208181|9591721|FG001|Part 2|Lost to Follow-up|0
5998150|NCT01208181|9591722|FG002|Part 2|Lost to Follow-up|1
5998151|NCT01208181|9591723|FG003|Part 2|Lost to Follow-up|2
6071800|NCT00557505|9674960|FG002|Overall Study|Objective progression or relapse|3
6071801|NCT00557505|9674961|FG003|Overall Study|Objective progression or relapse|2
6071802|NCT00557505|9674962|FG004|Overall Study|Objective progression or relapse|2
6071803|NCT00557505|9674963|FG005|Overall Study|Objective progression or relapse|3
5998152|NCT01208181|9591724|FG004|Part 2|Lost to Follow-up|0
5998153|NCT01208181|9591720|FG000|Part 2|Lack of Efficacy|0
5998154|NCT01208181|9591721|FG001|Part 2|Lack of Efficacy|0
5998155|NCT01208181|9591722|FG002|Part 2|Lack of Efficacy|5
5998156|NCT01208181|9591723|FG003|Part 2|Lack of Efficacy|7
6071804|NCT00557505|9674964|FG006|Overall Study|Objective progression or relapse|2
6071805|NCT00557505|9674965|FG007|Overall Study|Objective progression or relapse|5
6071806|NCT00557505|9674966|FG008|Overall Study|Objective progression or relapse|15
6071807|NCT00557505|9674958|FG000|Overall Study|Withdrawal by Subject|0
6071808|NCT00557505|9674959|FG001|Overall Study|Withdrawal by Subject|0
6071809|NCT00557505|9674960|FG002|Overall Study|Withdrawal by Subject|0
6071810|NCT00557505|9674961|FG003|Overall Study|Withdrawal by Subject|1
6071811|NCT00557505|9674962|FG004|Overall Study|Withdrawal by Subject|0
6071812|NCT00557505|9674963|FG005|Overall Study|Withdrawal by Subject|0
6071813|NCT00557505|9674964|FG006|Overall Study|Withdrawal by Subject|0
6071814|NCT00557505|9674965|FG007|Overall Study|Withdrawal by Subject|0
6071815|NCT00557505|9674966|FG008|Overall Study|Withdrawal by Subject|1
6071816|NCT00557622|9674991|FG000|4-Week Run-in Phase|Withdrawal by Subject|1
6071817|NCT00557622|9674992|FG001|4-Week Run-in Phase|Withdrawal by Subject|0
6071818|NCT00557622|9674991|FG000|4-Week Run-in Phase|Protocol-defined stopping criteria|1
6071819|NCT00557622|9674992|FG001|4-Week Run-in Phase|Protocol-defined stopping criteria|0
6071820|NCT00557622|9674991|FG000|12-Week Treatment Phase|Lost to Follow-up|0
6071821|NCT00557622|9674992|FG001|12-Week Treatment Phase|Lost to Follow-up|1
6071822|NCT00557830|9675001|FG000|Screening Treatment Phase|Withdrawal by Subject|1
6071823|NCT00557830|9675002|FG001|Screening Treatment Phase|Withdrawal by Subject|0
6071824|NCT00557830|9675003|FG002|Screening Treatment Phase|Withdrawal by Subject|0
6071825|NCT00557830|9675001|FG000|Screening Treatment Phase|Adverse Event|2
6071826|NCT00557830|9675002|FG001|Screening Treatment Phase|Adverse Event|0
6071827|NCT00557830|9675003|FG002|Screening Treatment Phase|Adverse Event|0
6071828|NCT00557830|9675001|FG000|Screening Treatment Phase|Unable to tolerate standard dose|3
6071829|NCT00557830|9675002|FG001|Screening Treatment Phase|Unable to tolerate standard dose|0
6071830|NCT00557830|9675003|FG002|Screening Treatment Phase|Unable to tolerate standard dose|0
6071831|NCT00557856|9675011|FG000|Part 1: Dose Escalation Phase|objective progression or relapse|3
6071832|NCT00557856|9675012|FG001|Part 1: Dose Escalation Phase|objective progression or relapse|5
6071833|NCT00557856|9675013|FG002|Part 1: Dose Escalation Phase|objective progression or relapse|3
6071834|NCT00557856|9675014|FG003|Part 1: Dose Escalation Phase|objective progression or relapse|1
6071835|NCT00557856|9675015|FG004|Part 1: Dose Escalation Phase|objective progression or relapse|3
6071836|NCT00557856|9675016|FG005|Part 1: Dose Escalation Phase|objective progression or relapse|2
6071837|NCT00557856|9675017|FG006|Part 1: Dose Escalation Phase|objective progression or relapse|5
6071838|NCT00557856|9675018|FG007|Part 1: Dose Escalation Phase|objective progression or relapse|3
6071839|NCT00557856|9675019|FG008|Part 1: Dose Escalation Phase|objective progression or relapse|0
6071840|NCT00557856|9675011|FG000|Part 1: Dose Escalation Phase|Withdrawal by Subject|1
6071841|NCT00557856|9675012|FG001|Part 1: Dose Escalation Phase|Withdrawal by Subject|0
6071842|NCT00557856|9675013|FG002|Part 1: Dose Escalation Phase|Withdrawal by Subject|1
6071843|NCT00557856|9675014|FG003|Part 1: Dose Escalation Phase|Withdrawal by Subject|0
5998157|NCT01208181|9591724|FG004|Part 2|Lack of Efficacy|0
6071844|NCT00557856|9675015|FG004|Part 1: Dose Escalation Phase|Withdrawal by Subject|0
6071845|NCT00557856|9675016|FG005|Part 1: Dose Escalation Phase|Withdrawal by Subject|0
6071846|NCT00557856|9675017|FG006|Part 1: Dose Escalation Phase|Withdrawal by Subject|0
6071847|NCT00557856|9675018|FG007|Part 1: Dose Escalation Phase|Withdrawal by Subject|0
6071848|NCT00557856|9675019|FG008|Part 1: Dose Escalation Phase|Withdrawal by Subject|0
6071849|NCT00557856|9675011|FG000|Part 1: Dose Escalation Phase|Adverse Event|1
6071850|NCT00557856|9675012|FG001|Part 1: Dose Escalation Phase|Adverse Event|0
6071851|NCT00557856|9675013|FG002|Part 1: Dose Escalation Phase|Adverse Event|1
6071852|NCT00557856|9675014|FG003|Part 1: Dose Escalation Phase|Adverse Event|1
6071853|NCT00557856|9675015|FG004|Part 1: Dose Escalation Phase|Adverse Event|1
6071854|NCT00557856|9675016|FG005|Part 1: Dose Escalation Phase|Adverse Event|3
6071855|NCT00557856|9675017|FG006|Part 1: Dose Escalation Phase|Adverse Event|1
6071856|NCT00557856|9675018|FG007|Part 1: Dose Escalation Phase|Adverse Event|2
6071857|NCT00557856|9675019|FG008|Part 1: Dose Escalation Phase|Adverse Event|0
6071858|NCT00557856|9675011|FG000|Part 1: Dose Escalation Phase|Other|0
5998158|NCT01206517|9591747|FG000|Overall Study|Withdrawal by Subject|0
5998159|NCT01206517|9591748|FG001|Overall Study|Withdrawal by Subject|0
5998160|NCT01206517|9591749|FG002|Overall Study|Withdrawal by Subject|2
5998161|NCT01206517|9591750|FG003|Overall Study|Withdrawal by Subject|0
5998162|NCT01206517|9591751|FG004|Overall Study|Withdrawal by Subject|1
5998163|NCT01206517|9591752|FG005|Overall Study|Withdrawal by Subject|0
5998164|NCT01190267|9591765|FG000|Overall Study|Adverse Event|10
6071859|NCT00557856|9675012|FG001|Part 1: Dose Escalation Phase|Other|0
5998165|NCT01190267|9591766|FG001|Overall Study|Adverse Event|0
5998166|NCT01190267|9591765|FG000|Overall Study|Treatment Failure|8
5998167|NCT01190267|9591766|FG001|Overall Study|Treatment Failure|2
5998168|NCT01190267|9591765|FG000|Overall Study|Lost to Follow-up|2
5998169|NCT01190267|9591766|FG001|Overall Study|Lost to Follow-up|0
5998170|NCT01190267|9591765|FG000|Overall Study|Withdrawal by Subject|13
5998171|NCT01190267|9591766|FG001|Overall Study|Withdrawal by Subject|1
6071860|NCT00557856|9675013|FG002|Part 1: Dose Escalation Phase|Other|1
6071861|NCT00557856|9675014|FG003|Part 1: Dose Escalation Phase|Other|1
6071862|NCT00557856|9675015|FG004|Part 1: Dose Escalation Phase|Other|0
6071863|NCT00557856|9675016|FG005|Part 1: Dose Escalation Phase|Other|0
6071864|NCT00557856|9675017|FG006|Part 1: Dose Escalation Phase|Other|0
6071865|NCT00557856|9675018|FG007|Part 1: Dose Escalation Phase|Other|1
5998172|NCT01190267|9591765|FG000|Overall Study|Protocol Violation|8
5998173|NCT01190267|9591766|FG001|Overall Study|Protocol Violation|1
6071866|NCT00557856|9675019|FG008|Part 1: Dose Escalation Phase|Other|0
6071867|NCT00557856|9675011|FG000|Part 1: Dose Escalation Phase|Death|0
6071868|NCT00557856|9675012|FG001|Part 1: Dose Escalation Phase|Death|0
6071869|NCT00557856|9675013|FG002|Part 1: Dose Escalation Phase|Death|0
6071870|NCT00557856|9675014|FG003|Part 1: Dose Escalation Phase|Death|0
6071871|NCT00557856|9675015|FG004|Part 1: Dose Escalation Phase|Death|0
6071872|NCT00557856|9675016|FG005|Part 1: Dose Escalation Phase|Death|1
6071873|NCT00557856|9675017|FG006|Part 1: Dose Escalation Phase|Death|0
6071874|NCT00557856|9675018|FG007|Part 1: Dose Escalation Phase|Death|0
6071875|NCT00557856|9675019|FG008|Part 1: Dose Escalation Phase|Death|0
6071876|NCT00557856|9675011|FG000|Part 1: Dose Escalation Phase|global deterioration of health status|0
6071877|NCT00557856|9675012|FG001|Part 1: Dose Escalation Phase|global deterioration of health status|0
6071878|NCT00557856|9675013|FG002|Part 1: Dose Escalation Phase|global deterioration of health status|0
6071879|NCT00557856|9675014|FG003|Part 1: Dose Escalation Phase|global deterioration of health status|0
6071880|NCT00557856|9675015|FG004|Part 1: Dose Escalation Phase|global deterioration of health status|0
6071881|NCT00557856|9675016|FG005|Part 1: Dose Escalation Phase|global deterioration of health status|2
6071882|NCT00557856|9675017|FG006|Part 1: Dose Escalation Phase|global deterioration of health status|1
6071883|NCT00557856|9675018|FG007|Part 1: Dose Escalation Phase|global deterioration of health status|0
6071884|NCT00557856|9675019|FG008|Part 1: Dose Escalation Phase|global deterioration of health status|0
6071885|NCT00557856|9675011|FG000|Part 1: Dose Escalation Phase|randomized but not treated|2
6071886|NCT00557856|9675012|FG001|Part 1: Dose Escalation Phase|randomized but not treated|0
6071887|NCT00557856|9675013|FG002|Part 1: Dose Escalation Phase|randomized but not treated|0
6071888|NCT00557856|9675014|FG003|Part 1: Dose Escalation Phase|randomized but not treated|0
6071889|NCT00557856|9675015|FG004|Part 1: Dose Escalation Phase|randomized but not treated|0
6071890|NCT00557856|9675016|FG005|Part 1: Dose Escalation Phase|randomized but not treated|0
6071891|NCT00557856|9675017|FG006|Part 1: Dose Escalation Phase|randomized but not treated|0
6071892|NCT00557856|9675018|FG007|Part 1: Dose Escalation Phase|randomized but not treated|0
6071893|NCT00557856|9675019|FG008|Part 1: Dose Escalation Phase|randomized but not treated|0
6071894|NCT00557856|9675011|FG000|Part 2: Exploratory Phase|objective progression or relapse|0
6087261|NCT00666926|9697369|FG010|Overall Study|Withdrawal by Subject|0
5998174|NCT01190254|9591775|FG000|Overall Study|Adverse Event|3
5998175|NCT01190254|9591776|FG001|Overall Study|Adverse Event|6
5998176|NCT01190254|9591777|FG002|Overall Study|Adverse Event|8
5998177|NCT01190254|9591775|FG000|Overall Study|Lack of Efficacy|7
5998178|NCT01190254|9591776|FG001|Overall Study|Lack of Efficacy|4
5998179|NCT01190254|9591777|FG002|Overall Study|Lack of Efficacy|5
5998180|NCT01190254|9591775|FG000|Overall Study|Lost to Follow-up|4
5998181|NCT01190254|9591776|FG001|Overall Study|Lost to Follow-up|2
5998182|NCT01190254|9591777|FG002|Overall Study|Lost to Follow-up|0
5998183|NCT01190254|9591775|FG000|Overall Study|Withdrawal by Subject|4
5998184|NCT01190254|9591776|FG001|Overall Study|Withdrawal by Subject|5
5998185|NCT01190254|9591777|FG002|Overall Study|Withdrawal by Subject|7
5998186|NCT01190254|9591775|FG000|Overall Study|Protocol Violation|2
5998187|NCT01190254|9591776|FG001|Overall Study|Protocol Violation|0
5998188|NCT01190254|9591777|FG002|Overall Study|Protocol Violation|2
5998189|NCT01190254|9591775|FG000|Overall Study|Did not meet protocol eligibility|1
5998190|NCT01190254|9591776|FG001|Overall Study|Did not meet protocol eligibility|0
5998191|NCT01190254|9591777|FG002|Overall Study|Did not meet protocol eligibility|0
5998192|NCT01154036|9591788|FG000|Phase I|Physician Decision|0
5998193|NCT01154036|9591789|FG001|Phase I|Physician Decision|1
5998194|NCT01154036|9591790|FG002|Phase I|Physician Decision|0
5998195|NCT01154036|9591791|FG003|Phase I|Physician Decision|0
5998196|NCT01154036|9591792|FG004|Phase I|Physician Decision|0
5998197|NCT01154036|9591793|FG005|Phase I|Physician Decision|0
5998198|NCT01154036|9591794|FG006|Phase I|Physician Decision|0
5998199|NCT01154036|9591795|FG007|Phase I|Physician Decision|0
5998200|NCT01154036|9591788|FG000|Phase I|Lost to Follow-up|0
5998201|NCT01154036|9591789|FG001|Phase I|Lost to Follow-up|3
5998202|NCT01154036|9591790|FG002|Phase I|Lost to Follow-up|6
5998203|NCT01154036|9591791|FG003|Phase I|Lost to Follow-up|0
5998204|NCT01154036|9591792|FG004|Phase I|Lost to Follow-up|0
5998205|NCT01154036|9591793|FG005|Phase I|Lost to Follow-up|0
5998206|NCT01154036|9591794|FG006|Phase I|Lost to Follow-up|0
5998207|NCT01154036|9591795|FG007|Phase I|Lost to Follow-up|0
5998208|NCT01154036|9591788|FG000|Phase I|Protocol Violation|0
5998209|NCT01154036|9591789|FG001|Phase I|Protocol Violation|3
5998210|NCT01154036|9591790|FG002|Phase I|Protocol Violation|9
5998211|NCT01154036|9591791|FG003|Phase I|Protocol Violation|0
5998212|NCT01154036|9591792|FG004|Phase I|Protocol Violation|0
5998213|NCT01154036|9591793|FG005|Phase I|Protocol Violation|0
5998214|NCT01154036|9591794|FG006|Phase I|Protocol Violation|0
5998215|NCT01154036|9591795|FG007|Phase I|Protocol Violation|0
5998216|NCT01154036|9591788|FG000|Phase I|Withdrawal by Subject|2
5998217|NCT01154036|9591789|FG001|Phase I|Withdrawal by Subject|10
5998218|NCT01154036|9591790|FG002|Phase I|Withdrawal by Subject|29
5998219|NCT01154036|9591791|FG003|Phase I|Withdrawal by Subject|0
5998220|NCT01154036|9591792|FG004|Phase I|Withdrawal by Subject|0
5998221|NCT01154036|9591793|FG005|Phase I|Withdrawal by Subject|0
5998222|NCT01154036|9591794|FG006|Phase I|Withdrawal by Subject|0
5998223|NCT01154036|9591795|FG007|Phase I|Withdrawal by Subject|0
6071895|NCT00557856|9675012|FG001|Part 2: Exploratory Phase|objective progression or relapse|0
6071896|NCT00557856|9675013|FG002|Part 2: Exploratory Phase|objective progression or relapse|0
6071897|NCT00557856|9675014|FG003|Part 2: Exploratory Phase|objective progression or relapse|0
6071898|NCT00557856|9675015|FG004|Part 2: Exploratory Phase|objective progression or relapse|0
6071899|NCT00557856|9675016|FG005|Part 2: Exploratory Phase|objective progression or relapse|0
6071900|NCT00557856|9675017|FG006|Part 2: Exploratory Phase|objective progression or relapse|0
6071901|NCT00557856|9675018|FG007|Part 2: Exploratory Phase|objective progression or relapse|0
6071902|NCT00557856|9675019|FG008|Part 2: Exploratory Phase|objective progression or relapse|15
6071903|NCT00557856|9675011|FG000|Part 2: Exploratory Phase|Withdrawal by Subject|0
6071904|NCT00557856|9675012|FG001|Part 2: Exploratory Phase|Withdrawal by Subject|0
6071905|NCT00557856|9675013|FG002|Part 2: Exploratory Phase|Withdrawal by Subject|0
6071906|NCT00557856|9675014|FG003|Part 2: Exploratory Phase|Withdrawal by Subject|0
6071907|NCT00557856|9675015|FG004|Part 2: Exploratory Phase|Withdrawal by Subject|0
6071908|NCT00557856|9675016|FG005|Part 2: Exploratory Phase|Withdrawal by Subject|0
6071909|NCT00557856|9675017|FG006|Part 2: Exploratory Phase|Withdrawal by Subject|0
6071910|NCT00557856|9675018|FG007|Part 2: Exploratory Phase|Withdrawal by Subject|0
6071911|NCT00557856|9675019|FG008|Part 2: Exploratory Phase|Withdrawal by Subject|1
6071912|NCT00557856|9675011|FG000|Part 2: Exploratory Phase|Adverse Event|0
5998224|NCT01154036|9591788|FG000|Phase I|Adverse Event|1
5998225|NCT01154036|9591789|FG001|Phase I|Adverse Event|11
5998226|NCT01154036|9591790|FG002|Phase I|Adverse Event|12
5998227|NCT01154036|9591791|FG003|Phase I|Adverse Event|0
5998228|NCT01154036|9591792|FG004|Phase I|Adverse Event|0
5998229|NCT01154036|9591793|FG005|Phase I|Adverse Event|0
5998230|NCT01154036|9591794|FG006|Phase I|Adverse Event|0
5998231|NCT01154036|9591795|FG007|Phase I|Adverse Event|0
5998232|NCT01154036|9591788|FG000|Phase II|Adverse Event|0
5998233|NCT01154036|9591789|FG001|Phase II|Adverse Event|0
5998234|NCT01154036|9591790|FG002|Phase II|Adverse Event|0
5998235|NCT01154036|9591791|FG003|Phase II|Adverse Event|0
5998236|NCT01154036|9591792|FG004|Phase II|Adverse Event|1
5998237|NCT01154036|9591793|FG005|Phase II|Adverse Event|1
5998238|NCT01154036|9591794|FG006|Phase II|Adverse Event|1
5998239|NCT01154036|9591795|FG007|Phase II|Adverse Event|1
5998240|NCT01154036|9591788|FG000|Phase II|Physician Decision|0
5998241|NCT01154036|9591789|FG001|Phase II|Physician Decision|0
5998242|NCT01154036|9591790|FG002|Phase II|Physician Decision|0
5998243|NCT01154036|9591791|FG003|Phase II|Physician Decision|0
5998244|NCT01154036|9591792|FG004|Phase II|Physician Decision|0
5998245|NCT01154036|9591793|FG005|Phase II|Physician Decision|0
5998246|NCT01154036|9591794|FG006|Phase II|Physician Decision|1
5998247|NCT01154036|9591795|FG007|Phase II|Physician Decision|0
5998248|NCT01154036|9591788|FG000|Phase II|Lost to Follow-up|0
5998249|NCT01154036|9591789|FG001|Phase II|Lost to Follow-up|0
5998250|NCT01154036|9591790|FG002|Phase II|Lost to Follow-up|0
5998251|NCT01154036|9591791|FG003|Phase II|Lost to Follow-up|1
5998252|NCT01154036|9591792|FG004|Phase II|Lost to Follow-up|2
5998253|NCT01154036|9591793|FG005|Phase II|Lost to Follow-up|0
5998254|NCT01154036|9591794|FG006|Phase II|Lost to Follow-up|2
5998255|NCT01154036|9591795|FG007|Phase II|Lost to Follow-up|1
5998256|NCT01154036|9591788|FG000|Phase II|Protocol Violation|0
5998257|NCT01154036|9591789|FG001|Phase II|Protocol Violation|0
5998258|NCT01154036|9591790|FG002|Phase II|Protocol Violation|0
5998259|NCT01154036|9591791|FG003|Phase II|Protocol Violation|0
5998260|NCT01154036|9591792|FG004|Phase II|Protocol Violation|1
5998261|NCT01154036|9591793|FG005|Phase II|Protocol Violation|2
5998262|NCT01154036|9591794|FG006|Phase II|Protocol Violation|0
5998263|NCT01154036|9591795|FG007|Phase II|Protocol Violation|0
5998264|NCT01154036|9591788|FG000|Phase II|Withdrawal by Subject|0
5998265|NCT01154036|9591789|FG001|Phase II|Withdrawal by Subject|0
5998266|NCT01154036|9591790|FG002|Phase II|Withdrawal by Subject|0
5998267|NCT01154036|9591791|FG003|Phase II|Withdrawal by Subject|0
5998268|NCT01154036|9591792|FG004|Phase II|Withdrawal by Subject|4
5998269|NCT01154036|9591793|FG005|Phase II|Withdrawal by Subject|2
5998270|NCT01154036|9591794|FG006|Phase II|Withdrawal by Subject|5
5998271|NCT01154036|9591795|FG007|Phase II|Withdrawal by Subject|4
5998272|NCT01098071|9591826|FG000|Overall Study|Surgery (adenoidectomy)|2
5998273|NCT01098071|9591826|FG000|Overall Study|Lost to Follow-up|13
5998274|NCT01070966|9591839|FG000|Participants for Safety Evaluation|Violation of inclusion criteria|59
5998275|NCT01070966|9591839|FG000|Participants for Safety Evaluation|Off-label use|9
5998276|NCT01070966|9591839|FG000|Participants for Safety Evaluation|Duplicate Participants|4
5998277|NCT01070966|9591839|FG000|Participants for Safety Evaluation|Violation inclusion criteria/off label|3
5998278|NCT01070966|9591839|FG000|Participants for Safety Evaluation|TMT given before date of contract|3
5998279|NCT01070966|9591839|FG000|Participants for Efficacy Evaluation|Lack of tmt period (<28 days)|61
5998280|NCT01070966|9591839|FG000|Participants for Efficacy Evaluation|No efficacy evaluation|19
5998281|NCT01070966|9591839|FG000|Participants for Efficacy Evaluation|Efficacy evaluation window violation|2
5998282|NCT01070953|9591850|FG000|Participants for Safety Evaluation|Violation of inclusion criteria|612
5998283|NCT01070953|9591850|FG000|Participants for Safety Evaluation|Off-label use|283
5998284|NCT01070953|9591850|FG000|Participants for Safety Evaluation|Duplicated participants|22
5998285|NCT01070953|9591850|FG000|Participants for Safety Evaluation|Treatment prior to date of contract|8
5998286|NCT01070953|9591850|FG000|Participants for Safety Evaluation|Uncontracted participants|4
5998287|NCT01070953|9591850|FG000|Participants for Safety Evaluation|Violation of inclusions & off label use|1
5998288|NCT01070953|9591850|FG000|Participants for Safety Evaluation|Duplicated participants & off-label use|1
6071913|NCT00557856|9675012|FG001|Part 2: Exploratory Phase|Adverse Event|0
6071914|NCT00557856|9675013|FG002|Part 2: Exploratory Phase|Adverse Event|0
6071915|NCT00557856|9675014|FG003|Part 2: Exploratory Phase|Adverse Event|0
6071916|NCT00557856|9675015|FG004|Part 2: Exploratory Phase|Adverse Event|0
6071917|NCT00557856|9675016|FG005|Part 2: Exploratory Phase|Adverse Event|0
6071918|NCT00557856|9675017|FG006|Part 2: Exploratory Phase|Adverse Event|0
6071919|NCT00557856|9675018|FG007|Part 2: Exploratory Phase|Adverse Event|0
6071920|NCT00557856|9675019|FG008|Part 2: Exploratory Phase|Adverse Event|4
6071921|NCT00557856|9675011|FG000|Part 2: Exploratory Phase|Other|0
6071922|NCT00557856|9675012|FG001|Part 2: Exploratory Phase|Other|0
6071923|NCT00557856|9675013|FG002|Part 2: Exploratory Phase|Other|0
6071924|NCT00557856|9675014|FG003|Part 2: Exploratory Phase|Other|0
6071925|NCT00557856|9675015|FG004|Part 2: Exploratory Phase|Other|0
6071926|NCT00557856|9675016|FG005|Part 2: Exploratory Phase|Other|0
6071927|NCT00557856|9675017|FG006|Part 2: Exploratory Phase|Other|0
6071928|NCT00557856|9675018|FG007|Part 2: Exploratory Phase|Other|0
6071929|NCT00557856|9675019|FG008|Part 2: Exploratory Phase|Other|1
6071930|NCT00557856|9675011|FG000|Part 2: Exploratory Phase|Death|0
6071931|NCT00557856|9675012|FG001|Part 2: Exploratory Phase|Death|0
5998289|NCT01070953|9591850|FG000|Participants for Efficacy Evaluation|No efficacy evaluation|119
5998290|NCT01070953|9591850|FG000|Participants for Efficacy Evaluation|Lack of treatment period (<28 days)|106
5998291|NCT01070953|9591850|FG000|Participants for Efficacy Evaluation|Unknown date of efficacy evaluation|2
5998292|NCT01030341|9591860|FG000|Overall Study|Withdrawal by Subject|1
5998293|NCT01030341|9591860|FG000|Overall Study|Lost to Follow-up|2
5998294|NCT00979901|9591868|FG000|Overall Study|Adverse Event|1
5998295|NCT00979901|9591869|FG001|Overall Study|Adverse Event|3
5998296|NCT00979901|9591870|FG002|Overall Study|Adverse Event|9
5998297|NCT00979901|9591871|FG003|Overall Study|Adverse Event|2
5998298|NCT00979901|9591868|FG000|Overall Study|Lack of Efficacy|8
5998299|NCT00979901|9591869|FG001|Overall Study|Lack of Efficacy|4
5998300|NCT00979901|9591870|FG002|Overall Study|Lack of Efficacy|9
5998301|NCT00979901|9591871|FG003|Overall Study|Lack of Efficacy|0
5998302|NCT00979901|9591868|FG000|Overall Study|Lost to Follow-up|1
5998303|NCT00979901|9591869|FG001|Overall Study|Lost to Follow-up|1
5998304|NCT00979901|9591870|FG002|Overall Study|Lost to Follow-up|2
5998305|NCT00979901|9591871|FG003|Overall Study|Lost to Follow-up|0
5998306|NCT00979901|9591868|FG000|Overall Study|Protocol Violation|2
5998307|NCT00979901|9591869|FG001|Overall Study|Protocol Violation|2
5998308|NCT00979901|9591870|FG002|Overall Study|Protocol Violation|7
5998309|NCT00979901|9591871|FG003|Overall Study|Protocol Violation|1
5998310|NCT00979901|9591868|FG000|Overall Study|Withdrawal by Subject|2
5998311|NCT00979901|9591869|FG001|Overall Study|Withdrawal by Subject|1
5998312|NCT00979901|9591870|FG002|Overall Study|Withdrawal by Subject|1
5998313|NCT00979901|9591871|FG003|Overall Study|Withdrawal by Subject|1
5998314|NCT00979901|9591868|FG000|Overall Study|Noncompliance|1
5998315|NCT00979901|9591869|FG001|Overall Study|Noncompliance|0
5998316|NCT00979901|9591870|FG002|Overall Study|Noncompliance|0
5998317|NCT00979901|9591871|FG003|Overall Study|Noncompliance|0
5998318|NCT00979901|9591868|FG000|Overall Study|out-of-state|1
5998319|NCT00979901|9591869|FG001|Overall Study|out-of-state|0
5998320|NCT00979901|9591870|FG002|Overall Study|out-of-state|0
5998321|NCT00979901|9591871|FG003|Overall Study|out-of-state|0
5998322|NCT00979901|9591868|FG000|Overall Study|vacation|1
6071932|NCT00557856|9675013|FG002|Part 2: Exploratory Phase|Death|0
6071933|NCT00557856|9675014|FG003|Part 2: Exploratory Phase|Death|0
6071934|NCT00557856|9675015|FG004|Part 2: Exploratory Phase|Death|0
6071935|NCT00557856|9675016|FG005|Part 2: Exploratory Phase|Death|0
6071936|NCT00557856|9675017|FG006|Part 2: Exploratory Phase|Death|0
6071937|NCT00557856|9675018|FG007|Part 2: Exploratory Phase|Death|0
6071938|NCT00557856|9675019|FG008|Part 2: Exploratory Phase|Death|2
6071939|NCT00557856|9675011|FG000|Part 2: Exploratory Phase|global deterioration of health status|0
6071940|NCT00557856|9675012|FG001|Part 2: Exploratory Phase|global deterioration of health status|0
6071941|NCT00557856|9675013|FG002|Part 2: Exploratory Phase|global deterioration of health status|0
5998323|NCT00979901|9591869|FG001|Overall Study|vacation|0
5998324|NCT00979901|9591870|FG002|Overall Study|vacation|0
5998325|NCT00979901|9591871|FG003|Overall Study|vacation|0
5998326|NCT00979901|9591868|FG000|Overall Study|elevated lab values pre-randomization|1
5998327|NCT00979901|9591869|FG001|Overall Study|elevated lab values pre-randomization|0
5998328|NCT00979901|9591870|FG002|Overall Study|elevated lab values pre-randomization|0
6071942|NCT00557856|9675014|FG003|Part 2: Exploratory Phase|global deterioration of health status|0
5998329|NCT00979901|9591871|FG003|Overall Study|elevated lab values pre-randomization|0
5998330|NCT00979901|9591868|FG000|Overall Study|Discontinued in Error|0
5998331|NCT00979901|9591869|FG001|Overall Study|Discontinued in Error|1
5998332|NCT00979901|9591870|FG002|Overall Study|Discontinued in Error|0
5998333|NCT00979901|9591871|FG003|Overall Study|Discontinued in Error|0
5998334|NCT00979901|9591868|FG000|Overall Study|Left Country|0
5998335|NCT00979901|9591869|FG001|Overall Study|Left Country|0
5998336|NCT00979901|9591870|FG002|Overall Study|Left Country|1
5998337|NCT00979901|9591871|FG003|Overall Study|Left Country|0
5998338|NCT00979901|9591868|FG000|Overall Study|Treatment Group Terminated by Sponsor|0
5998339|NCT00979901|9591869|FG001|Overall Study|Treatment Group Terminated by Sponsor|0
5998340|NCT00979901|9591870|FG002|Overall Study|Treatment Group Terminated by Sponsor|0
5998341|NCT00979901|9591871|FG003|Overall Study|Treatment Group Terminated by Sponsor|112
5998342|NCT00963599|9591884|FG000|Overall Study|Adverse Event|2
5998343|NCT00963599|9591885|FG001|Overall Study|Adverse Event|0
5998344|NCT00963599|9591886|FG002|Overall Study|Adverse Event|1
5998345|NCT00963599|9591887|FG003|Overall Study|Adverse Event|2
5998346|NCT00963599|9591884|FG000|Overall Study|Lack of Efficacy|0
5998347|NCT00963599|9591885|FG001|Overall Study|Lack of Efficacy|2
5998348|NCT00963599|9591886|FG002|Overall Study|Lack of Efficacy|1
5998349|NCT00963599|9591887|FG003|Overall Study|Lack of Efficacy|4
5998350|NCT00963599|9591884|FG000|Overall Study|Lost to Follow-up|0
5998351|NCT00963599|9591885|FG001|Overall Study|Lost to Follow-up|1
5998352|NCT00963599|9591886|FG002|Overall Study|Lost to Follow-up|1
5998353|NCT00963599|9591887|FG003|Overall Study|Lost to Follow-up|1
5998354|NCT00963599|9591884|FG000|Overall Study|Protocol Violation|2
5998355|NCT00963599|9591885|FG001|Overall Study|Protocol Violation|2
5998356|NCT00963599|9591886|FG002|Overall Study|Protocol Violation|3
5998357|NCT00963599|9591887|FG003|Overall Study|Protocol Violation|4
5998358|NCT00963599|9591884|FG000|Overall Study|Withdrawal by Subject|2
5998359|NCT00963599|9591885|FG001|Overall Study|Withdrawal by Subject|1
5998360|NCT00963599|9591886|FG002|Overall Study|Withdrawal by Subject|3
5998361|NCT00963599|9591887|FG003|Overall Study|Withdrawal by Subject|3
5998362|NCT00953680|9591902|FG000|Period 1|Withdrawal by Subject|0
5998363|NCT00953680|9591903|FG001|Period 1|Withdrawal by Subject|1
5998364|NCT00943852|9591916|FG000|Washout Period After Period 1 Treatment|BP too low for dosing at the next period|0
5998365|NCT00943852|9591917|FG001|Washout Period After Period 1 Treatment|BP too low for dosing at the next period|0
5998366|NCT00943852|9591918|FG002|Washout Period After Period 1 Treatment|BP too low for dosing at the next period|0
5998367|NCT00943852|9591919|FG003|Washout Period After Period 1 Treatment|BP too low for dosing at the next period|1
5998368|NCT00943852|9591920|FG004|Washout Period After Period 1 Treatment|BP too low for dosing at the next period|0
5998369|NCT00943852|9591921|FG005|Washout Period After Period 1 Treatment|BP too low for dosing at the next period|0
5998370|NCT00943852|9591922|FG006|Washout Period After Period 1 Treatment|BP too low for dosing at the next period|0
6071943|NCT00557856|9675015|FG004|Part 2: Exploratory Phase|global deterioration of health status|0
6071944|NCT00557856|9675016|FG005|Part 2: Exploratory Phase|global deterioration of health status|0
6071945|NCT00557856|9675017|FG006|Part 2: Exploratory Phase|global deterioration of health status|0
6071946|NCT00557856|9675018|FG007|Part 2: Exploratory Phase|global deterioration of health status|0
6071947|NCT00557856|9675019|FG008|Part 2: Exploratory Phase|global deterioration of health status|1
6071948|NCT00558025|9675062|FG000|Overall Study|Adverse Event|1
6071949|NCT00558025|9675063|FG001|Overall Study|Adverse Event|1
6071950|NCT00558025|9675062|FG000|Overall Study|Withdrawal by Subject|2
6071951|NCT00558025|9675063|FG001|Overall Study|Withdrawal by Subject|2
6071952|NCT00558025|9675062|FG000|Overall Study|Protocol Violation|1
6071953|NCT00558025|9675063|FG001|Overall Study|Protocol Violation|0
6071954|NCT00558064|9675071|FG000|Overall Study|Adverse Event|3
6071955|NCT00558064|9675072|FG001|Overall Study|Adverse Event|2
6071956|NCT00558064|9675071|FG000|Overall Study|Lack of Efficacy|0
6071957|NCT00558064|9675072|FG001|Overall Study|Lack of Efficacy|1
6071958|NCT00558064|9675071|FG000|Overall Study|Protocol Violation|1
6071959|NCT00558064|9675072|FG001|Overall Study|Protocol Violation|0
6071960|NCT00558064|9675071|FG000|Overall Study|Lost to Follow-up|0
6071961|NCT00558064|9675072|FG001|Overall Study|Lost to Follow-up|1
6071962|NCT00558064|9675071|FG000|Overall Study|Withdrawal by Subject|0
6071963|NCT00558064|9675072|FG001|Overall Study|Withdrawal by Subject|1
6071964|NCT00558064|9675071|FG000|Overall Study|No visit within allowance period|1
6071965|NCT00558064|9675072|FG001|Overall Study|No visit within allowance period|0
6071966|NCT00558103|9675083|FG000|Randomized Treatment Phase|Lost to Follow-up|2
6071967|NCT00558103|9675084|FG001|Randomized Treatment Phase|Lost to Follow-up|2
6071968|NCT00558103|9675085|FG002|Randomized Treatment Phase|Lost to Follow-up|2
6071969|NCT00558103|9675086|FG003|Randomized Treatment Phase|Lost to Follow-up|1
6071970|NCT00558103|9675087|FG004|Randomized Treatment Phase|Lost to Follow-up|3
6071971|NCT00558103|9675088|FG005|Randomized Treatment Phase|Lost to Follow-up|0
6071972|NCT00558103|9675083|FG000|Randomized Treatment Phase|Withdrawal by Subject|2
6071973|NCT00558103|9675084|FG001|Randomized Treatment Phase|Withdrawal by Subject|2
6047050|NCT00409838|9646126|FG000|Long-term Extension Period|Adverse Event|10
6071974|NCT00558103|9675085|FG002|Randomized Treatment Phase|Withdrawal by Subject|0
6071975|NCT00558103|9675086|FG003|Randomized Treatment Phase|Withdrawal by Subject|0
6071976|NCT00558103|9675087|FG004|Randomized Treatment Phase|Withdrawal by Subject|1
6071977|NCT00558103|9675088|FG005|Randomized Treatment Phase|Withdrawal by Subject|0
5998371|NCT00943852|9591923|FG007|Washout Period After Period 1 Treatment|BP too low for dosing at the next period|0
5998372|NCT00943852|9591924|FG008|Washout Period After Period 1 Treatment|BP too low for dosing at the next period|0
5998373|NCT00943852|9591925|FG009|Washout Period After Period 1 Treatment|BP too low for dosing at the next period|0
5998374|NCT00943852|9591916|FG000|Washout Period After Period 2 Treatment|Trial stopped early|0
5998375|NCT00943852|9591917|FG001|Washout Period After Period 2 Treatment|Trial stopped early|0
5998376|NCT00943852|9591918|FG002|Washout Period After Period 2 Treatment|Trial stopped early|0
5998377|NCT00943852|9591919|FG003|Washout Period After Period 2 Treatment|Trial stopped early|0
5998378|NCT00943852|9591920|FG004|Washout Period After Period 2 Treatment|Trial stopped early|0
5998379|NCT00943852|9591921|FG005|Washout Period After Period 2 Treatment|Trial stopped early|1
5998380|NCT00943852|9591922|FG006|Washout Period After Period 2 Treatment|Trial stopped early|0
5998381|NCT00943852|9591923|FG007|Washout Period After Period 2 Treatment|Trial stopped early|0
5998382|NCT00943852|9591924|FG008|Washout Period After Period 2 Treatment|Trial stopped early|0
5998383|NCT00943852|9591925|FG009|Washout Period After Period 2 Treatment|Trial stopped early|0
5998384|NCT00943852|9591916|FG000|Washout Period After Period 3 Treatment|Did not meet criteria for next period|0
5998385|NCT00943852|9591917|FG001|Washout Period After Period 3 Treatment|Did not meet criteria for next period|0
5998386|NCT00943852|9591918|FG002|Washout Period After Period 3 Treatment|Did not meet criteria for next period|0
5998387|NCT00943852|9591919|FG003|Washout Period After Period 3 Treatment|Did not meet criteria for next period|0
5998388|NCT00943852|9591920|FG004|Washout Period After Period 3 Treatment|Did not meet criteria for next period|0
5998389|NCT00943852|9591921|FG005|Washout Period After Period 3 Treatment|Did not meet criteria for next period|0
5998390|NCT00943852|9591922|FG006|Washout Period After Period 3 Treatment|Did not meet criteria for next period|1
5998391|NCT00943852|9591923|FG007|Washout Period After Period 3 Treatment|Did not meet criteria for next period|0
5998392|NCT00943852|9591924|FG008|Washout Period After Period 3 Treatment|Did not meet criteria for next period|0
5998393|NCT00943852|9591925|FG009|Washout Period After Period 3 Treatment|Did not meet criteria for next period|0
5998394|NCT00943852|9591916|FG000|Washout Period After Period 4 Treatment|Not taking medication per protocol|0
5998395|NCT00943852|9591917|FG001|Washout Period After Period 4 Treatment|Not taking medication per protocol|0
6047051|NCT00409838|9646127|FG001|Long-term Extension Period|Adverse Event|0
6071978|NCT00558103|9675083|FG000|Randomized Treatment Phase|Disease Progression|1
6071979|NCT00558103|9675084|FG001|Randomized Treatment Phase|Disease Progression|0
6071980|NCT00558103|9675085|FG002|Randomized Treatment Phase|Disease Progression|1
6071981|NCT00558103|9675086|FG003|Randomized Treatment Phase|Disease Progression|0
6071982|NCT00558103|9675087|FG004|Randomized Treatment Phase|Disease Progression|0
6071983|NCT00558103|9675088|FG005|Randomized Treatment Phase|Disease Progression|0
6071984|NCT00558103|9675083|FG000|Randomized Treatment Phase|Adverse Event|0
6071985|NCT00558103|9675084|FG001|Randomized Treatment Phase|Adverse Event|0
6071986|NCT00558103|9675085|FG002|Randomized Treatment Phase|Adverse Event|0
6071987|NCT00558103|9675086|FG003|Randomized Treatment Phase|Adverse Event|1
6071988|NCT00558103|9675087|FG004|Randomized Treatment Phase|Adverse Event|1
6071989|NCT00558103|9675088|FG005|Randomized Treatment Phase|Adverse Event|0
6071990|NCT00558103|9675083|FG000|Monotherapy Extension Phase|Protocol Violation|0
6071991|NCT00558103|9675084|FG001|Monotherapy Extension Phase|Protocol Violation|0
6071992|NCT00558103|9675085|FG002|Monotherapy Extension Phase|Protocol Violation|0
6071993|NCT00558103|9675086|FG003|Monotherapy Extension Phase|Protocol Violation|0
6071994|NCT00558103|9675087|FG004|Monotherapy Extension Phase|Protocol Violation|0
6071995|NCT00558103|9675088|FG005|Monotherapy Extension Phase|Protocol Violation|1
6071996|NCT00558103|9675083|FG000|Monotherapy Extension Phase|Disease Progression|0
6071997|NCT00558103|9675084|FG001|Monotherapy Extension Phase|Disease Progression|0
6071998|NCT00558103|9675085|FG002|Monotherapy Extension Phase|Disease Progression|0
6071999|NCT00558103|9675086|FG003|Monotherapy Extension Phase|Disease Progression|0
6072000|NCT00558103|9675087|FG004|Monotherapy Extension Phase|Disease Progression|0
6072001|NCT00558103|9675088|FG005|Monotherapy Extension Phase|Disease Progression|8
6072002|NCT00558259|9675110|FG000|Overall Study|Adverse Event|50
6072003|NCT00558259|9675111|FG001|Overall Study|Adverse Event|81
6072004|NCT00558259|9675110|FG000|Overall Study|Protocol Violation|9
6072005|NCT00558259|9675111|FG001|Overall Study|Protocol Violation|5
6072006|NCT00558259|9675110|FG000|Overall Study|Withdrawal by Subject|12
6072007|NCT00558259|9675111|FG001|Overall Study|Withdrawal by Subject|13
6072008|NCT00558272|9675119|FG000|Overall Study|Adverse Event|10
6072009|NCT00558272|9675120|FG001|Overall Study|Adverse Event|0
6072010|NCT00558272|9675119|FG000|Overall Study|Death|1
6072011|NCT00558272|9675120|FG001|Overall Study|Death|0
6072012|NCT00558272|9675119|FG000|Overall Study|Dev. of study specific discon. criteria|1
6072013|NCT00558272|9675120|FG001|Overall Study|Dev. of study specific discon. criteria|0
6072014|NCT00558272|9675119|FG000|Overall Study|AZ study team decision|0
6072015|NCT00558272|9675120|FG001|Overall Study|AZ study team decision|1
6072016|NCT00558272|9675119|FG000|Overall Study|Incorrectly enrolled|1
6072017|NCT00558272|9675120|FG001|Overall Study|Incorrectly enrolled|0
6072018|NCT00558272|9675119|FG000|Overall Study|Withdrawal by Subject|0
6072019|NCT00558272|9675120|FG001|Overall Study|Withdrawal by Subject|1
6072020|NCT00558285|9675131|FG000|Overall Study|Adverse Event|1
6072021|NCT00558285|9675132|FG001|Overall Study|Adverse Event|1
6072022|NCT00558285|9675133|FG002|Overall Study|Adverse Event|4
5998396|NCT00943852|9591918|FG002|Washout Period After Period 4 Treatment|Not taking medication per protocol|0
5998397|NCT00943852|9591919|FG003|Washout Period After Period 4 Treatment|Not taking medication per protocol|0
5998398|NCT00943852|9591920|FG004|Washout Period After Period 4 Treatment|Not taking medication per protocol|0
5998399|NCT00943852|9591921|FG005|Washout Period After Period 4 Treatment|Not taking medication per protocol|0
5998400|NCT00943852|9591922|FG006|Washout Period After Period 4 Treatment|Not taking medication per protocol|0
6072023|NCT00558285|9675134|FG003|Overall Study|Adverse Event|1
6072024|NCT00558285|9675135|FG004|Overall Study|Adverse Event|2
6072025|NCT00558285|9675131|FG000|Overall Study|Abnormal test procedure result(s)|1
6072026|NCT00558285|9675132|FG001|Overall Study|Abnormal test procedure result(s)|0
6072027|NCT00558285|9675133|FG002|Overall Study|Abnormal test procedure result(s)|0
6072028|NCT00558285|9675134|FG003|Overall Study|Abnormal test procedure result(s)|0
6072029|NCT00558285|9675135|FG004|Overall Study|Abnormal test procedure result(s)|0
6072030|NCT00558285|9675131|FG000|Overall Study|Subject withdrew consent|2
6072031|NCT00558285|9675132|FG001|Overall Study|Subject withdrew consent|0
6072032|NCT00558285|9675133|FG002|Overall Study|Subject withdrew consent|1
6072033|NCT00558285|9675134|FG003|Overall Study|Subject withdrew consent|1
6072034|NCT00558285|9675135|FG004|Overall Study|Subject withdrew consent|1
6072035|NCT00558285|9675131|FG000|Overall Study|Lost to Follow-up|1
6072036|NCT00558285|9675132|FG001|Overall Study|Lost to Follow-up|1
6072037|NCT00558285|9675133|FG002|Overall Study|Lost to Follow-up|0
6072038|NCT00558285|9675134|FG003|Overall Study|Lost to Follow-up|0
6072039|NCT00558285|9675135|FG004|Overall Study|Lost to Follow-up|0
6072040|NCT00558285|9675131|FG000|Overall Study|Administrative problems|0
6072041|NCT00558285|9675132|FG001|Overall Study|Administrative problems|0
6072042|NCT00558285|9675133|FG002|Overall Study|Administrative problems|0
6072043|NCT00558285|9675134|FG003|Overall Study|Administrative problems|1
6072044|NCT00558285|9675135|FG004|Overall Study|Administrative problems|1
6072045|NCT00558285|9675131|FG000|Overall Study|Protocol deviation|1
6072046|NCT00558285|9675132|FG001|Overall Study|Protocol deviation|1
6072047|NCT00558285|9675133|FG002|Overall Study|Protocol deviation|0
6072048|NCT00558285|9675134|FG003|Overall Study|Protocol deviation|1
6072049|NCT00558285|9675135|FG004|Overall Study|Protocol deviation|0
6072050|NCT00558363|9675149|FG000|Overall Study|Physician Decision|18
6072051|NCT00558363|9675150|FG001|Overall Study|Physician Decision|4
6072052|NCT00558363|9675149|FG000|Overall Study|Withdrawal by Subject|11
6072053|NCT00558363|9675150|FG001|Overall Study|Withdrawal by Subject|4
6072054|NCT00558363|9675149|FG000|Overall Study|Adverse Event|5
6072055|NCT00558363|9675150|FG001|Overall Study|Adverse Event|5
6072056|NCT00558363|9675149|FG000|Overall Study|Lack of Efficacy|2
6072057|NCT00558363|9675150|FG001|Overall Study|Lack of Efficacy|2
6072058|NCT00558363|9675149|FG000|Overall Study|Protocol Violation|2
6072059|NCT00558363|9675150|FG001|Overall Study|Protocol Violation|1
6072060|NCT00558363|9675149|FG000|Overall Study|Lost to Follow-up|0
6072061|NCT00558363|9675150|FG001|Overall Study|Lost to Follow-up|1
6072062|NCT00558363|9675149|FG000|Overall Study|Met Protocol-defined Stopping Criteria|32
6072063|NCT00558363|9675150|FG001|Overall Study|Met Protocol-defined Stopping Criteria|16
6072064|NCT00558363|9675149|FG000|Overall Study|Randomized in Error|1
6072065|NCT00558363|9675150|FG001|Overall Study|Randomized in Error|2
6072066|NCT00558363|9675149|FG000|Overall Study|Hospitalized; Unable to Continue|0
6072067|NCT00558363|9675150|FG001|Overall Study|Hospitalized; Unable to Continue|1
6072068|NCT00558428|9675160|FG000|Overall Study|Adverse Event|6
6072069|NCT00558428|9675161|FG001|Overall Study|Adverse Event|22
6072070|NCT00558428|9675162|FG002|Overall Study|Adverse Event|3
6072071|NCT00558428|9675163|FG003|Overall Study|Adverse Event|4
6072072|NCT00558428|9675160|FG000|Overall Study|Lost to Follow-up|0
6072073|NCT00558428|9675161|FG001|Overall Study|Lost to Follow-up|1
6072074|NCT00558428|9675162|FG002|Overall Study|Lost to Follow-up|0
6072075|NCT00558428|9675163|FG003|Overall Study|Lost to Follow-up|0
6072076|NCT00558428|9675160|FG000|Overall Study|Lack of Efficacy|0
6072077|NCT00558428|9675161|FG001|Overall Study|Lack of Efficacy|0
6072078|NCT00558428|9675162|FG002|Overall Study|Lack of Efficacy|1
6072079|NCT00558428|9675163|FG003|Overall Study|Lack of Efficacy|2
6072080|NCT00558428|9675160|FG000|Overall Study|Non compliant with protocol|1
6072081|NCT00558428|9675161|FG001|Overall Study|Non compliant with protocol|0
6072082|NCT00558428|9675162|FG002|Overall Study|Non compliant with protocol|0
6072083|NCT00558428|9675163|FG003|Overall Study|Non compliant with protocol|3
6072084|NCT00558428|9675160|FG000|Overall Study|Consent withdrawn|2
6072085|NCT00558428|9675161|FG001|Overall Study|Consent withdrawn|1
6072086|NCT00558428|9675162|FG002|Overall Study|Consent withdrawn|0
6072087|NCT00558428|9675163|FG003|Overall Study|Consent withdrawn|1
6072088|NCT00558428|9675160|FG000|Overall Study|Other|3
6072089|NCT00558428|9675161|FG001|Overall Study|Other|0
5998401|NCT00943852|9591923|FG007|Washout Period After Period 4 Treatment|Not taking medication per protocol|1
5998402|NCT00943852|9591924|FG008|Washout Period After Period 4 Treatment|Not taking medication per protocol|0
5998403|NCT00943852|9591925|FG009|Washout Period After Period 4 Treatment|Not taking medication per protocol|0
5998404|NCT00943852|9591916|FG000|Washout Period After Period 4 Treatment|Trial stopped early|1
5998405|NCT00943852|9591917|FG001|Washout Period After Period 4 Treatment|Trial stopped early|0
5998406|NCT00943852|9591918|FG002|Washout Period After Period 4 Treatment|Trial stopped early|1
5998407|NCT00943852|9591919|FG003|Washout Period After Period 4 Treatment|Trial stopped early|1
5998408|NCT00943852|9591920|FG004|Washout Period After Period 4 Treatment|Trial stopped early|0
5998409|NCT00943852|9591921|FG005|Washout Period After Period 4 Treatment|Trial stopped early|0
6072090|NCT00558428|9675162|FG002|Overall Study|Other|0
6072091|NCT00558428|9675163|FG003|Overall Study|Other|1
6072092|NCT00558467|9675175|FG000|Overall Study|Adverse Event|1
6072093|NCT00558467|9675176|FG001|Overall Study|Adverse Event|2
6072094|NCT00558467|9675175|FG000|Overall Study|Lack of Efficacy|0
6072095|NCT00558467|9675176|FG001|Overall Study|Lack of Efficacy|1
6072096|NCT00558467|9675175|FG000|Overall Study|Patient moving out of state|0
6072097|NCT00558467|9675176|FG001|Overall Study|Patient moving out of state|1
6072098|NCT00558519|9675182|FG000|Overall Study|Ph+|20
6072099|NCT00558519|9675182|FG000|Overall Study|Ineligible|1
6072100|NCT00558519|9675182|FG000|Overall Study|Insufficient data|1
6072101|NCT00558519|9675182|FG000|Overall Study|Never received treatment|1
6072102|NCT00558636|9675216|FG000|Treatment|Adverse Event|9
6072103|NCT00558636|9675217|FG001|Treatment|Adverse Event|2
6072104|NCT00558636|9675216|FG000|Treatment|Withdrawal by Subject|2
6072105|NCT00558636|9675217|FG001|Treatment|Withdrawal by Subject|0
6072106|NCT00558636|9675216|FG000|Treatment|Premature termination of the study|35
6072107|NCT00558636|9675217|FG001|Treatment|Premature termination of the study|37
6072108|NCT00558636|9675216|FG000|Treatment|Disease progression|1
6072109|NCT00558636|9675217|FG001|Treatment|Disease progression|5
6072110|NCT00558636|9675216|FG000|Follow-up|Premature termination of the study|12
6072111|NCT00558636|9675217|FG001|Follow-up|Premature termination of the study|7
6072112|NCT00558701|9675225|FG000|Overall Study|Protocol Deviations|1
6072113|NCT00558701|9675226|FG001|Overall Study|Protocol Deviations|4
6072114|NCT00558753|9675234|FG000|Overall Study|Lost to Follow-up|5
6072115|NCT00558753|9675235|FG001|Overall Study|Lost to Follow-up|7
6072116|NCT00558831|9675257|FG000|Overall Study|Lost to Follow-up|1
6072117|NCT00558896|9675292|FG000|Overall Study|Adverse Event|1
6072118|NCT00558896|9675293|FG001|Overall Study|Adverse Event|1
6072119|NCT00558896|9675294|FG002|Overall Study|Adverse Event|1
6072120|NCT00558896|9675295|FG003|Overall Study|Adverse Event|3
6072121|NCT00558896|9675296|FG004|Overall Study|Adverse Event|4
6072122|NCT00558896|9675297|FG005|Overall Study|Adverse Event|10
6072123|NCT00558896|9675298|FG006|Overall Study|Adverse Event|3
6072124|NCT00558896|9675292|FG000|Overall Study|Death|3
6072125|NCT00558896|9675293|FG001|Overall Study|Death|0
6072126|NCT00558896|9675294|FG002|Overall Study|Death|2
6072127|NCT00558896|9675295|FG003|Overall Study|Death|3
6072128|NCT00558896|9675296|FG004|Overall Study|Death|2
6072129|NCT00558896|9675297|FG005|Overall Study|Death|2
6072130|NCT00558896|9675298|FG006|Overall Study|Death|6
6072131|NCT00558896|9675292|FG000|Overall Study|Withdrawal by Subject|2
6072132|NCT00558896|9675293|FG001|Overall Study|Withdrawal by Subject|1
6072133|NCT00558896|9675294|FG002|Overall Study|Withdrawal by Subject|1
6072134|NCT00558896|9675295|FG003|Overall Study|Withdrawal by Subject|1
6072135|NCT00558896|9675296|FG004|Overall Study|Withdrawal by Subject|1
6072136|NCT00558896|9675297|FG005|Overall Study|Withdrawal by Subject|5
6072137|NCT00558896|9675298|FG006|Overall Study|Withdrawal by Subject|5
6072138|NCT00558896|9675292|FG000|Overall Study|Alternative Treatment|2
6072139|NCT00558896|9675293|FG001|Overall Study|Alternative Treatment|2
6072140|NCT00558896|9675294|FG002|Overall Study|Alternative Treatment|0
6072141|NCT00558896|9675295|FG003|Overall Study|Alternative Treatment|2
6072142|NCT00558896|9675296|FG004|Overall Study|Alternative Treatment|6
6072143|NCT00558896|9675297|FG005|Overall Study|Alternative Treatment|7
6072144|NCT00558896|9675298|FG006|Overall Study|Alternative Treatment|1
6072145|NCT00558896|9675292|FG000|Overall Study|Physician discretion|3
6072146|NCT00558896|9675293|FG001|Overall Study|Physician discretion|2
6072147|NCT00558896|9675294|FG002|Overall Study|Physician discretion|1
6072148|NCT00558896|9675295|FG003|Overall Study|Physician discretion|2
5998410|NCT00943852|9591922|FG006|Washout Period After Period 4 Treatment|Trial stopped early|1
5998411|NCT00943852|9591923|FG007|Washout Period After Period 4 Treatment|Trial stopped early|0
5998412|NCT00943852|9591924|FG008|Washout Period After Period 4 Treatment|Trial stopped early|0
5998413|NCT00943852|9591925|FG009|Washout Period After Period 4 Treatment|Trial stopped early|0
5998414|NCT00927953|9591937|FG000|Overall Study|Death|2
5998415|NCT00927953|9591938|FG001|Overall Study|Death|1
5998416|NCT00909389|9591945|FG000|Overall Study|Adverse Event|6
5998417|NCT00909389|9591945|FG000|Overall Study|Death|4
5998418|NCT00909389|9591945|FG000|Overall Study|Poor Compliance|16
5998419|NCT00909389|9591945|FG000|Overall Study|Lost to Follow-up|4
5998420|NCT00909389|9591945|FG000|Overall Study|No Information|103
5998421|NCT00820027|9591953|FG000|Overall Study|Adverse Event|15
5998422|NCT00820027|9591954|FG001|Overall Study|Adverse Event|8
5998423|NCT00820027|9591955|FG002|Overall Study|Adverse Event|10
5998424|NCT00820027|9591956|FG003|Overall Study|Adverse Event|5
5998425|NCT00820027|9591953|FG000|Overall Study|Lack of Efficacy|2
5998426|NCT00820027|9591954|FG001|Overall Study|Lack of Efficacy|1
5998427|NCT00820027|9591955|FG002|Overall Study|Lack of Efficacy|2
5998428|NCT00820027|9591956|FG003|Overall Study|Lack of Efficacy|2
5998429|NCT00820027|9591953|FG000|Overall Study|Physician Decision|0
5998430|NCT00820027|9591954|FG001|Overall Study|Physician Decision|1
5998431|NCT00820027|9591955|FG002|Overall Study|Physician Decision|1
5998432|NCT00820027|9591956|FG003|Overall Study|Physician Decision|0
5998433|NCT00820027|9591953|FG000|Overall Study|Protocol Violation|3
5998434|NCT00820027|9591954|FG001|Overall Study|Protocol Violation|0
5998435|NCT00820027|9591955|FG002|Overall Study|Protocol Violation|4
5998436|NCT00820027|9591956|FG003|Overall Study|Protocol Violation|0
5998437|NCT00820027|9591953|FG000|Overall Study|Withdrawal by Subject|6
5998438|NCT00820027|9591954|FG001|Overall Study|Withdrawal by Subject|4
5998439|NCT00820027|9591955|FG002|Overall Study|Withdrawal by Subject|4
5998440|NCT00820027|9591956|FG003|Overall Study|Withdrawal by Subject|6
5998441|NCT00788710|9591970|FG000|Overall Study|Adverse Event|1
5998442|NCT00788710|9591971|FG001|Overall Study|Adverse Event|3
5998443|NCT00788710|9591972|FG002|Overall Study|Adverse Event|4
5998444|NCT00788710|9591970|FG000|Overall Study|Lack of Efficacy|0
5998445|NCT00788710|9591971|FG001|Overall Study|Lack of Efficacy|0
5998446|NCT00788710|9591972|FG002|Overall Study|Lack of Efficacy|1
5998447|NCT00788710|9591970|FG000|Overall Study|Lost to Follow-up|0
5998448|NCT00788710|9591971|FG001|Overall Study|Lost to Follow-up|1
5998449|NCT00788710|9591972|FG002|Overall Study|Lost to Follow-up|0
5998450|NCT00788710|9591970|FG000|Overall Study|Physician Decision|2
5998451|NCT00788710|9591971|FG001|Overall Study|Physician Decision|1
5998452|NCT00788710|9591972|FG002|Overall Study|Physician Decision|0
5998453|NCT00788710|9591970|FG000|Overall Study|Protocol Violation|0
5998454|NCT00788710|9591971|FG001|Overall Study|Protocol Violation|1
5998455|NCT00788710|9591972|FG002|Overall Study|Protocol Violation|1
5998456|NCT00788710|9591970|FG000|Overall Study|Withdrawal by Subject|2
5998457|NCT00788710|9591971|FG001|Overall Study|Withdrawal by Subject|2
5998458|NCT00788710|9591972|FG002|Overall Study|Withdrawal by Subject|0
5998459|NCT00783224|9591984|FG000|Overall Study|Adverse Event|0
5998460|NCT00783224|9591985|FG001|Overall Study|Adverse Event|0
5998461|NCT00783224|9591986|FG002|Overall Study|Adverse Event|1
5998462|NCT00783224|9591987|FG003|Overall Study|Adverse Event|0
5998463|NCT00783224|9591984|FG000|Overall Study|Discarded the Investigational Drug Used|0
5998464|NCT00783224|9591985|FG001|Overall Study|Discarded the Investigational Drug Used|0
5998465|NCT00783224|9591986|FG002|Overall Study|Discarded the Investigational Drug Used|0
5998466|NCT00783224|9591987|FG003|Overall Study|Discarded the Investigational Drug Used|1
5998467|NCT00783224|9591984|FG000|Overall Study|Inappropriate as a study subject|0
5998468|NCT00783224|9591985|FG001|Overall Study|Inappropriate as a study subject|0
5998469|NCT00783224|9591986|FG002|Overall Study|Inappropriate as a study subject|0
5998470|NCT00783224|9591987|FG003|Overall Study|Inappropriate as a study subject|1
5998471|NCT00778700|9592016|FG000|Overall Study|Adverse Event|6
5998472|NCT00778700|9592017|FG001|Overall Study|Adverse Event|1
5998473|NCT00778700|9592018|FG002|Overall Study|Adverse Event|3
5998474|NCT00778700|9592019|FG003|Overall Study|Adverse Event|5
5998475|NCT00778700|9592016|FG000|Overall Study|Protocol Violation|1
5998476|NCT00778700|9592017|FG001|Overall Study|Protocol Violation|1
5998477|NCT00778700|9592018|FG002|Overall Study|Protocol Violation|0
5998478|NCT00778700|9592019|FG003|Overall Study|Protocol Violation|0
5998479|NCT00778700|9592016|FG000|Overall Study|Subject Withdrew Consent|6
5998480|NCT00778700|9592017|FG001|Overall Study|Subject Withdrew Consent|4
5998481|NCT00778700|9592018|FG002|Overall Study|Subject Withdrew Consent|1
5998482|NCT00778700|9592019|FG003|Overall Study|Subject Withdrew Consent|4
5998483|NCT00778700|9592016|FG000|Overall Study|Lost to Follow-up|3
5998484|NCT00778700|9592017|FG001|Overall Study|Lost to Follow-up|1
5998485|NCT00778700|9592018|FG002|Overall Study|Lost to Follow-up|0
5998486|NCT00778700|9592019|FG003|Overall Study|Lost to Follow-up|1
5998487|NCT00778700|9592016|FG000|Overall Study|Reason not Specified|2
5998488|NCT00778700|9592017|FG001|Overall Study|Reason not Specified|0
5998489|NCT00778700|9592018|FG002|Overall Study|Reason not Specified|1
5998490|NCT00778700|9592019|FG003|Overall Study|Reason not Specified|3
5998491|NCT00778700|9592016|FG000|Overall Study|Other|0
5998492|NCT00778700|9592017|FG001|Overall Study|Other|0
5998493|NCT00778700|9592018|FG002|Overall Study|Other|1
5998494|NCT00778700|9592019|FG003|Overall Study|Other|0
6072149|NCT00558896|9675296|FG004|Overall Study|Physician discretion|1
6072150|NCT00558896|9675297|FG005|Overall Study|Physician discretion|3
6072151|NCT00558896|9675298|FG006|Overall Study|Physician discretion|3
6072152|NCT00558896|9675292|FG000|Overall Study|Continues on treatment|10
6072153|NCT00558896|9675293|FG001|Overall Study|Continues on treatment|1
6072154|NCT00558896|9675294|FG002|Overall Study|Continues on treatment|0
6072155|NCT00558896|9675295|FG003|Overall Study|Continues on treatment|1
6072156|NCT00558896|9675296|FG004|Overall Study|Continues on treatment|9
6072157|NCT00558896|9675297|FG005|Overall Study|Continues on treatment|25
6072158|NCT00558896|9675298|FG006|Overall Study|Continues on treatment|6
6072159|NCT00559104|9675320|FG000|Overall Study|Lack of Efficacy|9
5998495|NCT00764478|9592036|FG000|Overall Study|Adverse Event|1
5998496|NCT00764478|9592037|FG001|Overall Study|Adverse Event|1
5998497|NCT00764478|9592038|FG002|Overall Study|Adverse Event|1
5998498|NCT00764478|9592036|FG000|Overall Study|Withdrawal by Subject|7
5998499|NCT00764478|9592037|FG001|Overall Study|Withdrawal by Subject|12
5998500|NCT00764478|9592038|FG002|Overall Study|Withdrawal by Subject|1
5998501|NCT00764478|9592036|FG000|Overall Study|Lost to Follow-up|7
5998502|NCT00764478|9592037|FG001|Overall Study|Lost to Follow-up|8
5998503|NCT00764478|9592038|FG002|Overall Study|Lost to Follow-up|5
5998504|NCT00764478|9592036|FG000|Overall Study|Protocol Violation|0
5998505|NCT00764478|9592037|FG001|Overall Study|Protocol Violation|1
6072160|NCT00559104|9675321|FG001|Overall Study|Lack of Efficacy|0
5998506|NCT00764478|9592038|FG002|Overall Study|Protocol Violation|1
5998507|NCT00761527|9592046|FG000|Overall Study|Adverse Event|3
5998508|NCT00761527|9592046|FG000|Overall Study|Poor Compliance|8
5998509|NCT00761527|9592046|FG000|Overall Study|Lost to Follow-up|9
5998510|NCT00761527|9592046|FG000|Overall Study|Unknown reason|2
5998511|NCT00757627|9592050|FG000|Overall Study|Adverse Event|15
5998512|NCT00757627|9592050|FG000|Overall Study|Lack of Efficacy|10
5998513|NCT00757627|9592050|FG000|Overall Study|Lost to Follow-up|28
5998514|NCT00757627|9592050|FG000|Overall Study|Withdrawal by Subject|27
5998515|NCT00757627|9592050|FG000|Overall Study|Other|1
5998516|NCT00756938|9592062|FG000|12-week Base Study|Protocol-specific Criteria Met|1
5998517|NCT00756938|9592063|FG001|12-week Base Study|Protocol-specific Criteria Met|0
5998518|NCT00756938|9592064|FG002|12-week Base Study|Protocol-specific Criteria Met|1
5998519|NCT00756938|9592065|FG003|12-week Base Study|Protocol-specific Criteria Met|0
5998520|NCT00756938|9592062|FG000|12-week Base Study|Protocol Violation|0
5998521|NCT00756938|9592063|FG001|12-week Base Study|Protocol Violation|0
5998522|NCT00756938|9592064|FG002|12-week Base Study|Protocol Violation|1
5998523|NCT00756938|9592065|FG003|12-week Base Study|Protocol Violation|0
5998524|NCT00756938|9592062|FG000|12-week Base Study|Lost to Follow-up|1
5998525|NCT00756938|9592063|FG001|12-week Base Study|Lost to Follow-up|0
5998526|NCT00756938|9592064|FG002|12-week Base Study|Lost to Follow-up|0
5998527|NCT00756938|9592065|FG003|12-week Base Study|Lost to Follow-up|0
5998528|NCT00756938|9592062|FG000|Optional Extension|Lack of Efficacy|0
5998529|NCT00756938|9592063|FG001|Optional Extension|Lack of Efficacy|0
5998530|NCT00756938|9592064|FG002|Optional Extension|Lack of Efficacy|0
5998531|NCT00756938|9592065|FG003|Optional Extension|Lack of Efficacy|1
5998532|NCT00756938|9592062|FG000|Optional Extension|End of Study|0
5998533|NCT00756938|9592063|FG001|Optional Extension|End of Study|0
5998534|NCT00756938|9592064|FG002|Optional Extension|End of Study|0
5998535|NCT00756938|9592065|FG003|Optional Extension|End of Study|11
5998536|NCT00756938|9592062|FG000|Optional Extension|Protocol-specific criteria met|0
5998537|NCT00756938|9592063|FG001|Optional Extension|Protocol-specific criteria met|0
5998538|NCT00756938|9592064|FG002|Optional Extension|Protocol-specific criteria met|0
5998539|NCT00756938|9592065|FG003|Optional Extension|Protocol-specific criteria met|9
5998540|NCT00756938|9592062|FG000|Optional Extension|Physician Decision|0
5998541|NCT00756938|9592063|FG001|Optional Extension|Physician Decision|0
5998542|NCT00756938|9592064|FG002|Optional Extension|Physician Decision|0
5998543|NCT00756938|9592065|FG003|Optional Extension|Physician Decision|3
5998544|NCT00756938|9592062|FG000|Optional Extension|Lost to Follow-up|0
5998545|NCT00756938|9592063|FG001|Optional Extension|Lost to Follow-up|0
5998546|NCT00756938|9592064|FG002|Optional Extension|Lost to Follow-up|0
5998547|NCT00756938|9592065|FG003|Optional Extension|Lost to Follow-up|1
5998548|NCT00756938|9592062|FG000|Optional Extension|Protocol Violation|0
5998549|NCT00756938|9592063|FG001|Optional Extension|Protocol Violation|0
5998550|NCT00756938|9592064|FG002|Optional Extension|Protocol Violation|0
5998551|NCT00756938|9592065|FG003|Optional Extension|Protocol Violation|1
5998552|NCT00756938|9592062|FG000|Optional Extension|Withdrawal by Subject|0
5998553|NCT00756938|9592063|FG001|Optional Extension|Withdrawal by Subject|0
5998554|NCT00756938|9592064|FG002|Optional Extension|Withdrawal by Subject|0
5998555|NCT00756938|9592065|FG003|Optional Extension|Withdrawal by Subject|10
5998556|NCT00756938|9592062|FG000|Optional Extension|Adverse Event|0
5998557|NCT00756938|9592063|FG001|Optional Extension|Adverse Event|0
5998558|NCT00756938|9592064|FG002|Optional Extension|Adverse Event|0
5998559|NCT00756938|9592065|FG003|Optional Extension|Adverse Event|1
5998560|NCT00746590|9592083|FG000|Overall Study|Death|1
5998561|NCT00730132|9592087|FG000|Overall Study|Protocol Violation|154
5998562|NCT00730132|9592087|FG000|Overall Study|Death|1
5998563|NCT00728416|9592096|FG000|Overall Study|Adverse Event|1
5998564|NCT00728416|9592097|FG001|Overall Study|Adverse Event|1
5998565|NCT00728416|9592096|FG000|Overall Study|Treatment Failure|0
5998566|NCT00728416|9592097|FG001|Overall Study|Treatment Failure|1
5998567|NCT00728416|9592096|FG000|Overall Study|Withdrawal by Subject|1
5998568|NCT00728416|9592097|FG001|Overall Study|Withdrawal by Subject|0
5998569|NCT00704535|9592124|FG000|Overall Study|Adverse Event|2
5998570|NCT00704535|9592124|FG000|Overall Study|Death|2
5998571|NCT00704535|9592124|FG000|Overall Study|Lost to Follow-up|8
5998572|NCT00704535|9592124|FG000|Overall Study|Protocol Violation|10
5998573|NCT00704535|9592124|FG000|Overall Study|Completed status not on Case Report Form|124
5998574|NCT00694369|9592133|FG000|Overall Study|Adverse Event|0
5998575|NCT00694369|9592134|FG001|Overall Study|Adverse Event|1
5998576|NCT00694369|9592135|FG002|Overall Study|Adverse Event|0
5998577|NCT00694369|9592136|FG003|Overall Study|Adverse Event|1
5998578|NCT00694369|9592137|FG004|Overall Study|Adverse Event|3
5998579|NCT00694369|9592133|FG000|Overall Study|Lost to Follow-up|0
5998580|NCT00694369|9592134|FG001|Overall Study|Lost to Follow-up|0
5998581|NCT00694369|9592135|FG002|Overall Study|Lost to Follow-up|1
6072161|NCT00559273|9675329|FG000|Correction Period (20 Weeks)|Death|3
5998582|NCT00694369|9592136|FG003|Overall Study|Lost to Follow-up|1
5998583|NCT00694369|9592137|FG004|Overall Study|Lost to Follow-up|0
5998584|NCT00694369|9592133|FG000|Overall Study|Physician Decision|0
5998585|NCT00694369|9592134|FG001|Overall Study|Physician Decision|0
5998586|NCT00694369|9592135|FG002|Overall Study|Physician Decision|0
5998587|NCT00694369|9592136|FG003|Overall Study|Physician Decision|0
5998588|NCT00694369|9592137|FG004|Overall Study|Physician Decision|1
5998589|NCT00694369|9592133|FG000|Overall Study|Protocol Violation|0
5998590|NCT00694369|9592134|FG001|Overall Study|Protocol Violation|1
5998591|NCT00694369|9592135|FG002|Overall Study|Protocol Violation|0
5998592|NCT00694369|9592136|FG003|Overall Study|Protocol Violation|0
5998593|NCT00694369|9592137|FG004|Overall Study|Protocol Violation|0
5998594|NCT00694369|9592133|FG000|Overall Study|Withdrawal by Subject|1
5998595|NCT00694369|9592134|FG001|Overall Study|Withdrawal by Subject|1
5998596|NCT00694369|9592135|FG002|Overall Study|Withdrawal by Subject|1
5998597|NCT00694369|9592136|FG003|Overall Study|Withdrawal by Subject|1
5998598|NCT00694369|9592137|FG004|Overall Study|Withdrawal by Subject|2
5998599|NCT00667823|9592162|FG000|Overall Study|Lost to Follow-up|5
5998600|NCT00667823|9592162|FG000|Overall Study|Adverse Event|7
5998601|NCT00667823|9592162|FG000|Overall Study|Death|182
5998602|NCT00667823|9592162|FG000|Overall Study|Withdrawal by Subject|12
5998603|NCT00667823|9592162|FG000|Overall Study|Other|8
5998604|NCT00667823|9592162|FG000|Overall Study|Missing (completion page missing)|2
5998605|NCT00652327|9592168|FG000|Overall Study|Adverse Event|0
5998606|NCT00652327|9592169|FG001|Overall Study|Adverse Event|2
5998607|NCT00652327|9592168|FG000|Overall Study|Lost to Follow-up|0
5998608|NCT00652327|9592169|FG001|Overall Study|Lost to Follow-up|3
5998609|NCT00604500|9592175|FG000|Overall Study|Adverse Event|2
5998610|NCT00604500|9592175|FG000|Overall Study|Protocol Violation|2
5998611|NCT00604500|9592175|FG000|Overall Study|Treatment Failure|1
5998612|NCT00604500|9592175|FG000|Overall Study|Withdrawal by Subject|4
5998613|NCT00604500|9592175|FG000|Overall Study|Administrative|1
5998614|NCT00604500|9592175|FG000|Overall Study|Did not meet protocol eligibility|1
5998615|NCT00568178|9592181|FG000|Double Blind Base Study|Adverse Event|0
5998616|NCT00568178|9592182|FG001|Double Blind Base Study|Adverse Event|2
5998617|NCT00568178|9592183|FG002|Double Blind Base Study|Adverse Event|1
5998618|NCT00568178|9592184|FG003|Double Blind Base Study|Adverse Event|2
5998619|NCT00568178|9592185|FG004|Double Blind Base Study|Adverse Event|0
5998620|NCT00568178|9592186|FG005|Double Blind Base Study|Adverse Event|0
5998621|NCT00568178|9592181|FG000|Double Blind Base Study|Lost to Follow-up|1
5998622|NCT00568178|9592182|FG001|Double Blind Base Study|Lost to Follow-up|0
5998623|NCT00568178|9592183|FG002|Double Blind Base Study|Lost to Follow-up|0
5998624|NCT00568178|9592184|FG003|Double Blind Base Study|Lost to Follow-up|1
5998625|NCT00568178|9592185|FG004|Double Blind Base Study|Lost to Follow-up|0
5998626|NCT00568178|9592186|FG005|Double Blind Base Study|Lost to Follow-up|0
5998627|NCT00568178|9592181|FG000|Double Blind Base Study|Physician Decision|1
5998628|NCT00568178|9592182|FG001|Double Blind Base Study|Physician Decision|1
5998629|NCT00568178|9592183|FG002|Double Blind Base Study|Physician Decision|0
5998630|NCT00568178|9592184|FG003|Double Blind Base Study|Physician Decision|1
5998631|NCT00568178|9592185|FG004|Double Blind Base Study|Physician Decision|0
5998632|NCT00568178|9592186|FG005|Double Blind Base Study|Physician Decision|0
5998633|NCT00568178|9592181|FG000|Double Blind Base Study|Protocol Violation|3
5998634|NCT00568178|9592182|FG001|Double Blind Base Study|Protocol Violation|2
5998635|NCT00568178|9592183|FG002|Double Blind Base Study|Protocol Violation|0
5998636|NCT00568178|9592184|FG003|Double Blind Base Study|Protocol Violation|0
5998637|NCT00568178|9592185|FG004|Double Blind Base Study|Protocol Violation|0
5998638|NCT00568178|9592186|FG005|Double Blind Base Study|Protocol Violation|0
5998639|NCT00568178|9592181|FG000|Double Blind Base Study|Withdrawal by Subject|1
5998640|NCT00568178|9592182|FG001|Double Blind Base Study|Withdrawal by Subject|1
5998641|NCT00568178|9592183|FG002|Double Blind Base Study|Withdrawal by Subject|0
5998642|NCT00568178|9592184|FG003|Double Blind Base Study|Withdrawal by Subject|0
5998643|NCT00568178|9592185|FG004|Double Blind Base Study|Withdrawal by Subject|0
5998644|NCT00568178|9592186|FG005|Double Blind Base Study|Withdrawal by Subject|0
5998645|NCT00568178|9592181|FG000|Double Blind Base Study|Progressive Disease|0
5998646|NCT00568178|9592182|FG001|Double Blind Base Study|Progressive Disease|0
5998647|NCT00568178|9592183|FG002|Double Blind Base Study|Progressive Disease|0
5998648|NCT00568178|9592184|FG003|Double Blind Base Study|Progressive Disease|1
5998649|NCT00568178|9592185|FG004|Double Blind Base Study|Progressive Disease|0
5998650|NCT00568178|9592186|FG005|Double Blind Base Study|Progressive Disease|0
5998651|NCT00568178|9592181|FG000|Open Label Extension|Adverse Event|0
5998652|NCT00568178|9592182|FG001|Open Label Extension|Adverse Event|0
5998653|NCT00568178|9592183|FG002|Open Label Extension|Adverse Event|0
5998654|NCT00568178|9592184|FG003|Open Label Extension|Adverse Event|0
5998655|NCT00568178|9592185|FG004|Open Label Extension|Adverse Event|11
5998656|NCT00568178|9592186|FG005|Open Label Extension|Adverse Event|8
5998657|NCT00568178|9592181|FG000|Open Label Extension|Protocol Violation|0
5998658|NCT00568178|9592182|FG001|Open Label Extension|Protocol Violation|0
5998659|NCT00568178|9592183|FG002|Open Label Extension|Protocol Violation|0
5998660|NCT00568178|9592184|FG003|Open Label Extension|Protocol Violation|0
5998661|NCT00568178|9592185|FG004|Open Label Extension|Protocol Violation|1
5998662|NCT00568178|9592186|FG005|Open Label Extension|Protocol Violation|0
5998663|NCT00568178|9592181|FG000|Open Label Extension|Lost to Follow-up|0
5998664|NCT00568178|9592182|FG001|Open Label Extension|Lost to Follow-up|0
5998665|NCT00568178|9592183|FG002|Open Label Extension|Lost to Follow-up|0
5998666|NCT00568178|9592184|FG003|Open Label Extension|Lost to Follow-up|0
5998667|NCT00568178|9592185|FG004|Open Label Extension|Lost to Follow-up|6
5998668|NCT00568178|9592186|FG005|Open Label Extension|Lost to Follow-up|11
5998669|NCT00568178|9592181|FG000|Open Label Extension|Physician Decision|0
5998670|NCT00568178|9592182|FG001|Open Label Extension|Physician Decision|0
5998671|NCT00568178|9592183|FG002|Open Label Extension|Physician Decision|0
5998672|NCT00568178|9592184|FG003|Open Label Extension|Physician Decision|0
5998673|NCT00568178|9592185|FG004|Open Label Extension|Physician Decision|9
5998674|NCT00568178|9592186|FG005|Open Label Extension|Physician Decision|8
5998675|NCT00568178|9592181|FG000|Open Label Extension|Pregnancy|0
5998676|NCT00568178|9592182|FG001|Open Label Extension|Pregnancy|0
5998677|NCT00568178|9592183|FG002|Open Label Extension|Pregnancy|0
5998678|NCT00568178|9592184|FG003|Open Label Extension|Pregnancy|0
5998679|NCT00568178|9592185|FG004|Open Label Extension|Pregnancy|0
5998680|NCT00568178|9592186|FG005|Open Label Extension|Pregnancy|1
5998681|NCT00568178|9592181|FG000|Open Label Extension|Progressive Disease|0
5998682|NCT00568178|9592182|FG001|Open Label Extension|Progressive Disease|0
5998683|NCT00568178|9592183|FG002|Open Label Extension|Progressive Disease|0
5998684|NCT00568178|9592184|FG003|Open Label Extension|Progressive Disease|0
5998685|NCT00568178|9592185|FG004|Open Label Extension|Progressive Disease|3
5998686|NCT00568178|9592186|FG005|Open Label Extension|Progressive Disease|1
5998687|NCT00568178|9592181|FG000|Open Label Extension|Termination of Trial|0
5998688|NCT00568178|9592182|FG001|Open Label Extension|Termination of Trial|0
5998689|NCT00568178|9592183|FG002|Open Label Extension|Termination of Trial|0
5998690|NCT00568178|9592184|FG003|Open Label Extension|Termination of Trial|0
5998691|NCT00568178|9592185|FG004|Open Label Extension|Termination of Trial|45
5998692|NCT00568178|9592186|FG005|Open Label Extension|Termination of Trial|47
5998693|NCT00568178|9592181|FG000|Open Label Extension|Withdrawal by Subject|0
5998694|NCT00568178|9592182|FG001|Open Label Extension|Withdrawal by Subject|0
5998695|NCT00568178|9592183|FG002|Open Label Extension|Withdrawal by Subject|0
5998696|NCT00568178|9592184|FG003|Open Label Extension|Withdrawal by Subject|0
5998697|NCT00568178|9592185|FG004|Open Label Extension|Withdrawal by Subject|4
5998698|NCT00568178|9592186|FG005|Open Label Extension|Withdrawal by Subject|4
5998699|NCT00545844|9592200|FG000|Overall Study|Lost to Follow-up|9
5998700|NCT00545844|9592200|FG000|Overall Study|Protocol Violation|1
5998701|NCT00545844|9592200|FG000|Overall Study|Withdrawal by Subject|2
5998702|NCT00511433|9592208|FG000|Overall Study|Adverse Event|5
5998703|NCT00511433|9592209|FG001|Overall Study|Adverse Event|0
5998704|NCT00511433|9592208|FG000|Overall Study|Other Reason|1
5998705|NCT00511433|9592209|FG001|Overall Study|Other Reason|1
5998706|NCT00511355|9592219|FG000|Overall Study|Adverse Event|4
5998707|NCT00511355|9592220|FG001|Overall Study|Adverse Event|4
5998708|NCT00511355|9592219|FG000|Overall Study|Pregnancy Wish|1
5998709|NCT00511355|9592220|FG001|Overall Study|Pregnancy Wish|0
5998710|NCT00511355|9592219|FG000|Overall Study|Lost to Follow-up|2
5998711|NCT00511355|9592220|FG001|Overall Study|Lost to Follow-up|1
5998712|NCT00511355|9592219|FG000|Overall Study|Other Reason|0
5998713|NCT00511355|9592220|FG001|Overall Study|Other Reason|1
5998714|NCT00511355|9592219|FG000|Overall Study|Pre-treatment (serious) adverse event|0
5998715|NCT00511355|9592220|FG001|Overall Study|Pre-treatment (serious) adverse event|1
5998716|NCT00511355|9592219|FG000|Overall Study|Withdrawal of informed consent|0
5998717|NCT00511355|9592220|FG001|Overall Study|Withdrawal of informed consent|1
5998718|NCT00511355|9592219|FG000|Overall Study|Other reason pre-treatment|0
5998719|NCT00511355|9592220|FG001|Overall Study|Other reason pre-treatment|1
5998720|NCT00511342|9592230|FG000|Overall Study|Unacceptable vaginal bleeding|2
5998721|NCT00511342|9592231|FG001|Overall Study|Unacceptable vaginal bleeding|1
5998722|NCT00511342|9592230|FG000|Overall Study|Other Adverse Event (AE)/ Serious AE|8
5998723|NCT00511342|9592231|FG001|Overall Study|Other Adverse Event (AE)/ Serious AE|12
5998724|NCT00511342|9592230|FG000|Overall Study|Pregnancy|0
5998725|NCT00511342|9592231|FG001|Overall Study|Pregnancy|1
5998726|NCT00511342|9592230|FG000|Overall Study|Pregnancy wish|0
5998727|NCT00511342|9592231|FG001|Overall Study|Pregnancy wish|1
5998728|NCT00511342|9592230|FG000|Overall Study|Lost to Follow-up|1
5998729|NCT00511342|9592231|FG001|Overall Study|Lost to Follow-up|5
5998730|NCT00511342|9592230|FG000|Overall Study|Other Reason|2
5998731|NCT00511342|9592231|FG001|Overall Study|Other Reason|2
5998732|NCT00511199|9592239|FG000|Overall Study|Unacceptable Vaginal Bleeding|63
5998733|NCT00511199|9592240|FG001|Overall Study|Unacceptable Vaginal Bleeding|4
5998734|NCT00511199|9592239|FG000|Overall Study|Other Adverse Event (AE)/ Serious AE|227
5998735|NCT00511199|9592240|FG001|Overall Study|Other Adverse Event (AE)/ Serious AE|52
5998736|NCT00511199|9592239|FG000|Overall Study|Withdrawal of Informed Consent|19
5998737|NCT00511199|9592240|FG001|Overall Study|Withdrawal of Informed Consent|4
5998738|NCT00511199|9592239|FG000|Overall Study|Pregnancy|6
5998739|NCT00511199|9592240|FG001|Overall Study|Pregnancy|3
5998740|NCT00511199|9592239|FG000|Overall Study|Pregnancy Wish|16
5998741|NCT00511199|9592240|FG001|Overall Study|Pregnancy Wish|8
5998742|NCT00511199|9592239|FG000|Overall Study|Lost to Follow-up|40
5998743|NCT00511199|9592240|FG001|Overall Study|Lost to Follow-up|17
5998744|NCT00511199|9592239|FG000|Overall Study|Other Reason|78
5998745|NCT00511199|9592240|FG001|Overall Study|Other Reason|37
5998746|NCT00491504|9592252|FG000|Overall Study|Adverse Event|0
5998747|NCT00491504|9592253|FG001|Overall Study|Adverse Event|1
5998748|NCT00491504|9592254|FG002|Overall Study|Adverse Event|0
5998749|NCT00491504|9592255|FG003|Overall Study|Adverse Event|0
5998750|NCT00491504|9592252|FG000|Overall Study|Withdrawal by Subject|0
5998751|NCT00491504|9592253|FG001|Overall Study|Withdrawal by Subject|0
5998752|NCT00491504|9592254|FG002|Overall Study|Withdrawal by Subject|1
5998753|NCT00491504|9592255|FG003|Overall Study|Withdrawal by Subject|2
5998754|NCT00491504|9592252|FG000|Overall Study|Protocol Violation|0
5998755|NCT00491504|9592253|FG001|Overall Study|Protocol Violation|0
5998756|NCT00491504|9592254|FG002|Overall Study|Protocol Violation|3
5998757|NCT00491504|9592255|FG003|Overall Study|Protocol Violation|2
5998758|NCT00468312|9592265|FG000|Overall Study|Adverse Event|2
5998759|NCT00468312|9592266|FG001|Overall Study|Adverse Event|1
5998760|NCT00468312|9592265|FG000|Overall Study|Lack of Efficacy|0
5998761|NCT00468312|9592266|FG001|Overall Study|Lack of Efficacy|1
5998762|NCT00468312|9592265|FG000|Overall Study|Withdrawal by Subject|0
5998763|NCT00468312|9592266|FG001|Overall Study|Withdrawal by Subject|1
5998764|NCT00468312|9592265|FG000|Overall Study|Protocol Violation|2
5998765|NCT00468312|9592266|FG001|Overall Study|Protocol Violation|1
5998766|NCT00468312|9592265|FG000|Overall Study|Did not meet protocol eligibility|0
5998767|NCT00468312|9592266|FG001|Overall Study|Did not meet protocol eligibility|1
5998768|NCT00453063|9592274|FG000|Overall Study|Adverse Event|1
5998769|NCT00453063|9592275|FG001|Overall Study|Adverse Event|2
5998770|NCT00453063|9592274|FG000|Overall Study|Withdrawal by Subject|1
5998771|NCT00453063|9592275|FG001|Overall Study|Withdrawal by Subject|1
5998772|NCT00453063|9592274|FG000|Overall Study|Protocol Violation|1
5998773|NCT00453063|9592275|FG001|Overall Study|Protocol Violation|0
5998774|NCT00447603|9592281|FG000|Screening|Withdrawal by Subject|1
5998775|NCT00447603|9592282|FG001|Screening|Withdrawal by Subject|0
5998776|NCT00447603|9592283|FG002|Screening|Withdrawal by Subject|0
5998777|NCT00447603|9592281|FG000|Screening|Protocol Violation|1
5998778|NCT00447603|9592282|FG001|Screening|Protocol Violation|0
5998779|NCT00447603|9592283|FG002|Screening|Protocol Violation|0
5998780|NCT00447603|9592281|FG000|Screening|Screen Failure|4
5998781|NCT00447603|9592282|FG001|Screening|Screen Failure|0
5998782|NCT00447603|9592283|FG002|Screening|Screen Failure|0
5998783|NCT00447603|9592281|FG000|Screening|Study Terminated by Sponsor|15
5998784|NCT00447603|9592282|FG001|Screening|Study Terminated by Sponsor|0
5998785|NCT00447603|9592283|FG002|Screening|Study Terminated by Sponsor|0
5998786|NCT00447603|9592281|FG000|Filter Period|Adverse Event|0
5998787|NCT00447603|9592282|FG001|Filter Period|Adverse Event|0
5998788|NCT00447603|9592283|FG002|Filter Period|Adverse Event|1
5998789|NCT00447603|9592281|FG000|Filter Period|Screen Failure|0
5998790|NCT00447603|9592282|FG001|Filter Period|Screen Failure|3
5998791|NCT00447603|9592283|FG002|Filter Period|Screen Failure|4
5998792|NCT00447603|9592281|FG000|Filter Period|Study terminated by Sponsor|0
5998793|NCT00447603|9592282|FG001|Filter Period|Study terminated by Sponsor|1
5998794|NCT00447603|9592283|FG002|Filter Period|Study terminated by Sponsor|10
5998795|NCT00442351|9592293|FG000|Overall Study|Administrative|6
5998796|NCT00442351|9592294|FG001|Overall Study|Administrative|5
5998797|NCT00442351|9592293|FG000|Overall Study|Did not meet protocol eligibility|1
5998798|NCT00442351|9592294|FG001|Overall Study|Did not meet protocol eligibility|0
5998799|NCT00442351|9592293|FG000|Overall Study|Other|0
5998800|NCT00442351|9592294|FG001|Overall Study|Other|1
5998801|NCT00423488|9592302|FG000|Overall Study|No evidence of study drug intake|2
5998802|NCT00423488|9592303|FG001|Overall Study|No evidence of study drug intake|1
5998803|NCT00423488|9592302|FG000|Overall Study|No post baseline data|3
5998804|NCT00423488|9592303|FG001|Overall Study|No post baseline data|0
5998805|NCT00413972|9592313|FG000|Overall Study|Adverse Event|2
5998806|NCT00413972|9592314|FG001|Overall Study|Adverse Event|1
5998807|NCT00413972|9592315|FG002|Overall Study|Adverse Event|0
5998808|NCT00413972|9592316|FG003|Overall Study|Adverse Event|0
5998809|NCT00413972|9592313|FG000|Overall Study|Lost to Follow-up|1
5998810|NCT00413972|9592314|FG001|Overall Study|Lost to Follow-up|2
5998811|NCT00413972|9592315|FG002|Overall Study|Lost to Follow-up|1
5998812|NCT00413972|9592316|FG003|Overall Study|Lost to Follow-up|0
5998813|NCT00413972|9592313|FG000|Overall Study|Withdrawal by Subject|4
5998814|NCT00413972|9592314|FG001|Overall Study|Withdrawal by Subject|5
5998815|NCT00413972|9592315|FG002|Overall Study|Withdrawal by Subject|7
5998816|NCT00413972|9592316|FG003|Overall Study|Withdrawal by Subject|2
5998817|NCT00413972|9592313|FG000|Overall Study|Protocol Violation|0
5998818|NCT00413972|9592314|FG001|Overall Study|Protocol Violation|0
5998819|NCT00413972|9592315|FG002|Overall Study|Protocol Violation|2
5998820|NCT00413972|9592316|FG003|Overall Study|Protocol Violation|0
5998821|NCT00413972|9592313|FG000|Overall Study|Other|0
5998822|NCT00413972|9592314|FG001|Overall Study|Other|0
5998823|NCT00413972|9592315|FG002|Overall Study|Other|0
5998824|NCT00413972|9592316|FG003|Overall Study|Other|1
5998825|NCT00413062|9592328|FG000|Overall Study|Adverse event/serious adverse event|289
5998826|NCT00413062|9592329|FG001|Overall Study|Adverse event/serious adverse event|56
5998827|NCT00413062|9592328|FG000|Overall Study|Pre-treatment (serious) adverse event|1
5998828|NCT00413062|9592329|FG001|Overall Study|Pre-treatment (serious) adverse event|0
5998829|NCT00413062|9592328|FG000|Overall Study|Withdrawal of informed consent|111
5998830|NCT00413062|9592329|FG001|Overall Study|Withdrawal of informed consent|36
5998831|NCT00413062|9592328|FG000|Overall Study|Pregnancy|15
5998832|NCT00413062|9592329|FG001|Overall Study|Pregnancy|5
5998833|NCT00413062|9592328|FG000|Overall Study|Pregnancy wish|17
5998834|NCT00413062|9592329|FG001|Overall Study|Pregnancy wish|6
5998835|NCT00413062|9592328|FG000|Overall Study|Lost to Follow-up|175
5998836|NCT00413062|9592329|FG001|Overall Study|Lost to Follow-up|73
5998837|NCT00413062|9592328|FG000|Overall Study|Other reason|70
5998838|NCT00413062|9592329|FG001|Overall Study|Other reason|34
5998839|NCT00391170|9592339|FG000|Overall Study|Withdrawal by Subject|1
5998840|NCT00391170|9592340|FG001|Overall Study|Withdrawal by Subject|0
5998841|NCT00391170|9592339|FG000|Overall Study|Adverse Event|3
5998842|NCT00391170|9592340|FG001|Overall Study|Adverse Event|2
5998843|NCT00391170|9592339|FG000|Overall Study|Physician Decision|2
5998844|NCT00391170|9592340|FG001|Overall Study|Physician Decision|2
5998845|NCT00319449|9592374|FG000|Overall Study|Subject did not wish to continue|1
5998846|NCT00319449|9592375|FG001|Overall Study|Subject did not wish to continue|0
5998847|NCT00319449|9592374|FG000|Overall Study|Noncompliance with the protocol|1
5998848|NCT00319449|9592375|FG001|Overall Study|Noncompliance with the protocol|0
5998849|NCT00289887|9592387|FG000|Overall Study|Adverse Event|3
5998850|NCT00289887|9592388|FG001|Overall Study|Adverse Event|3
5998851|NCT00289887|9592387|FG000|Overall Study|Lack of Efficacy|3
5998852|NCT00289887|9592388|FG001|Overall Study|Lack of Efficacy|11
5998853|NCT00289887|9592387|FG000|Overall Study|Lost to Follow-up|3
5998854|NCT00289887|9592388|FG001|Overall Study|Lost to Follow-up|3
5998855|NCT00289887|9592387|FG000|Overall Study|Protocol Violation|3
5998856|NCT00289887|9592388|FG001|Overall Study|Protocol Violation|1
5998857|NCT00289887|9592387|FG000|Overall Study|Withdrawal by Subject|3
5998858|NCT00289887|9592388|FG001|Overall Study|Withdrawal by Subject|8
5998859|NCT00289887|9592387|FG000|Overall Study|Other|7
5998860|NCT00289887|9592388|FG001|Overall Study|Other|3
5998861|NCT00281320|9592396|FG000|Overall Study|Adverse Event|12
5998862|NCT00281320|9592397|FG001|Overall Study|Adverse Event|9
5998863|NCT00281320|9592396|FG000|Overall Study|Lack of Efficacy|4
5998864|NCT00281320|9592397|FG001|Overall Study|Lack of Efficacy|3
5998865|NCT00281320|9592396|FG000|Overall Study|Withdrawal by Subject|5
5998866|NCT00281320|9592397|FG001|Overall Study|Withdrawal by Subject|6
5998867|NCT00281320|9592396|FG000|Overall Study|Lost to Follow-up|1
5998868|NCT00281320|9592397|FG001|Overall Study|Lost to Follow-up|2
5998869|NCT00281320|9592396|FG000|Overall Study|Other|3
5998870|NCT00281320|9592397|FG001|Overall Study|Other|1
5998871|NCT00276016|9592415|FG000|Intervention 1|Withdrawal by Subject|0
5998872|NCT00276016|9592416|FG001|Intervention 1|Withdrawal by Subject|1
5998873|NCT00276016|9592417|FG002|Intervention 1|Withdrawal by Subject|0
5998874|NCT00276016|9592418|FG003|Intervention 1|Withdrawal by Subject|0
5998875|NCT00276016|9592419|FG004|Intervention 1|Withdrawal by Subject|0
5998876|NCT00276016|9592420|FG005|Intervention 1|Withdrawal by Subject|0
5998877|NCT00265343|9592431|FG000|Overall Study|Adverse Event|10
5998878|NCT00265343|9592432|FG001|Overall Study|Adverse Event|7
5998879|NCT00265343|9592431|FG000|Overall Study|Withdrawal by Subject|3
5998880|NCT00265343|9592432|FG001|Overall Study|Withdrawal by Subject|9
5998881|NCT00265343|9592431|FG000|Overall Study|Other|8
5998882|NCT00265343|9592432|FG001|Overall Study|Other|3
5998883|NCT00264147|9592443|FG000|Treatment I Period|Adverse Event|3
5998884|NCT00264147|9592444|FG001|Treatment I Period|Adverse Event|6
5998885|NCT00264147|9592445|FG002|Treatment I Period|Adverse Event|3
5998886|NCT00264147|9592446|FG003|Treatment I Period|Adverse Event|5
5998887|NCT00264147|9592447|FG004|Treatment I Period|Adverse Event|7
5998888|NCT00264147|9592448|FG005|Treatment I Period|Adverse Event|0
5998889|NCT00264147|9592443|FG000|Treatment I Period|Laboratory Adverse Event|0
5998890|NCT00264147|9592444|FG001|Treatment I Period|Laboratory Adverse Event|0
5998891|NCT00264147|9592445|FG002|Treatment I Period|Laboratory Adverse Event|0
5998892|NCT00264147|9592446|FG003|Treatment I Period|Laboratory Adverse Event|1
5998893|NCT00264147|9592447|FG004|Treatment I Period|Laboratory Adverse Event|0
5998894|NCT00264147|9592448|FG005|Treatment I Period|Laboratory Adverse Event|0
5998895|NCT00264147|9592443|FG000|Treatment I Period|Lack of Efficacy|6
5998896|NCT00264147|9592444|FG001|Treatment I Period|Lack of Efficacy|2
5998897|NCT00264147|9592445|FG002|Treatment I Period|Lack of Efficacy|8
5998898|NCT00264147|9592446|FG003|Treatment I Period|Lack of Efficacy|0
5998899|NCT00264147|9592447|FG004|Treatment I Period|Lack of Efficacy|1
5998900|NCT00264147|9592448|FG005|Treatment I Period|Lack of Efficacy|0
5998901|NCT00264147|9592443|FG000|Treatment I Period|Lost to Follow-up|1
5998902|NCT00264147|9592444|FG001|Treatment I Period|Lost to Follow-up|0
5998903|NCT00264147|9592445|FG002|Treatment I Period|Lost to Follow-up|0
5998904|NCT00264147|9592446|FG003|Treatment I Period|Lost to Follow-up|1
5998905|NCT00264147|9592447|FG004|Treatment I Period|Lost to Follow-up|1
5998906|NCT00264147|9592448|FG005|Treatment I Period|Lost to Follow-up|0
5998907|NCT00264147|9592443|FG000|Treatment I Period|Protocol Violation|2
5998908|NCT00264147|9592444|FG001|Treatment I Period|Protocol Violation|2
5998909|NCT00264147|9592445|FG002|Treatment I Period|Protocol Violation|0
5998910|NCT00264147|9592446|FG003|Treatment I Period|Protocol Violation|0
5998911|NCT00264147|9592447|FG004|Treatment I Period|Protocol Violation|0
5998912|NCT00264147|9592448|FG005|Treatment I Period|Protocol Violation|0
5998913|NCT00264147|9592443|FG000|Treatment I Period|Withdrawal by Subject|2
5998914|NCT00264147|9592444|FG001|Treatment I Period|Withdrawal by Subject|0
5998915|NCT00264147|9592445|FG002|Treatment I Period|Withdrawal by Subject|0
5998916|NCT00264147|9592446|FG003|Treatment I Period|Withdrawal by Subject|2
5998917|NCT00264147|9592447|FG004|Treatment I Period|Withdrawal by Subject|2
5998918|NCT00264147|9592448|FG005|Treatment I Period|Withdrawal by Subject|0
6072162|NCT00559273|9675330|FG001|Correction Period (20 Weeks)|Death|4
6072163|NCT00559273|9675329|FG000|Correction Period (20 Weeks)|Adverse Event|2
6072164|NCT00559273|9675330|FG001|Correction Period (20 Weeks)|Adverse Event|1
6072165|NCT00559273|9675329|FG000|Correction Period (20 Weeks)|Withdrawal by Subject|2
6072166|NCT00559273|9675330|FG001|Correction Period (20 Weeks)|Withdrawal by Subject|6
5998919|NCT00264147|9592443|FG000|Treatment I Period|Patient out of town for an extended time|0
5998920|NCT00264147|9592444|FG001|Treatment I Period|Patient out of town for an extended time|1
5998921|NCT00264147|9592445|FG002|Treatment I Period|Patient out of town for an extended time|0
5998922|NCT00264147|9592446|FG003|Treatment I Period|Patient out of town for an extended time|0
5998923|NCT00264147|9592447|FG004|Treatment I Period|Patient out of town for an extended time|0
6072167|NCT00559273|9675329|FG000|Correction Period (20 Weeks)|Participant treated by another center|0
6072168|NCT00559273|9675330|FG001|Correction Period (20 Weeks)|Participant treated by another center|1
6072169|NCT00559273|9675329|FG000|Correction Period (20 Weeks)|Did not received study treatment|2
6072170|NCT00559273|9675330|FG001|Correction Period (20 Weeks)|Did not received study treatment|0
6072171|NCT00559273|9675329|FG000|Evaluation Period (8 Weeks)|Death|1
6072172|NCT00559273|9675330|FG001|Evaluation Period (8 Weeks)|Death|3
6072173|NCT00559273|9675329|FG000|Evaluation Period (8 Weeks)|Adverse Event|0
6072174|NCT00559273|9675330|FG001|Evaluation Period (8 Weeks)|Adverse Event|1
6072175|NCT00559273|9675329|FG000|Evaluation Period (8 Weeks)|Withdrawal by Subject|2
6072176|NCT00559273|9675330|FG001|Evaluation Period (8 Weeks)|Withdrawal by Subject|0
6072177|NCT00559273|9675329|FG000|Evaluation Period (8 Weeks)|Physician Decision|0
6072178|NCT00559273|9675330|FG001|Evaluation Period (8 Weeks)|Physician Decision|1
6072179|NCT00559364|9675338|FG000|Overall Study|Inclusion/exclusion criteria failure|1
6072180|NCT00559364|9675339|FG001|Overall Study|Inclusion/exclusion criteria failure|0
6072181|NCT00559377|9675345|FG000|Overall Study|Withdrawal by Subject|9
6072182|NCT00559507|9675361|FG000|Overall Study|Not treated, patient ineligible|3
6072183|NCT00559585|9675367|FG000|Double Blind ST Period Main Study|Adverse Event|17
6072184|NCT00559585|9675368|FG001|Double Blind ST Period Main Study|Adverse Event|25
6072185|NCT00559585|9675367|FG000|Double Blind ST Period Main Study|Withdrawal by Subject|11
6072186|NCT00559585|9675368|FG001|Double Blind ST Period Main Study|Withdrawal by Subject|5
6072187|NCT00559585|9675367|FG000|Double Blind ST Period Main Study|Lost to Follow-up|0
6072188|NCT00559585|9675368|FG001|Double Blind ST Period Main Study|Lost to Follow-up|6
6072189|NCT00559585|9675367|FG000|Double Blind ST Period Main Study|Administrative Reason By Sponsor|1
6072190|NCT00559585|9675368|FG001|Double Blind ST Period Main Study|Administrative Reason By Sponsor|0
6072191|NCT00559585|9675367|FG000|Double Blind ST Period Main Study|Death|1
6072192|NCT00559585|9675368|FG001|Double Blind ST Period Main Study|Death|1
6072193|NCT00559585|9675367|FG000|Double Blind ST Period Main Study|No Longer Meets Study Criteria|2
6072194|NCT00559585|9675368|FG001|Double Blind ST Period Main Study|No Longer Meets Study Criteria|1
6072195|NCT00559585|9675367|FG000|Double Blind ST Period Main Study|Lack of Efficacy|6
6072196|NCT00559585|9675368|FG001|Double Blind ST Period Main Study|Lack of Efficacy|1
6072197|NCT00559585|9675367|FG000|Double Blind ST Period Main Study|Poor/Non-Compliance|3
6072198|NCT00559585|9675368|FG001|Double Blind ST Period Main Study|Poor/Non-Compliance|0
6072199|NCT00559585|9675367|FG000|Double Blind ST Period Main Study|Missed Doses|0
6072200|NCT00559585|9675368|FG001|Double Blind ST Period Main Study|Missed Doses|1
6072201|NCT00559585|9675367|FG000|Double Blind ST Period Main Study|Incomplete Breast Exam|0
6072202|NCT00559585|9675368|FG001|Double Blind ST Period Main Study|Incomplete Breast Exam|1
6072203|NCT00559585|9675367|FG000|Double Blind ST Period Main Study|Suspended Drug Due To Surgery|0
6072204|NCT00559585|9675368|FG001|Double Blind ST Period Main Study|Suspended Drug Due To Surgery|1
6072205|NCT00559585|9675367|FG000|Double Blind ST Period Main Study|Early Discontinuation|0
6072206|NCT00559585|9675368|FG001|Double Blind ST Period Main Study|Early Discontinuation|1
6072207|NCT00559585|9675367|FG000|Double Blind ST Period Main Study|Participant Weight Gain|1
6072208|NCT00559585|9675368|FG001|Double Blind ST Period Main Study|Participant Weight Gain|0
6072209|NCT00559585|9675367|FG000|Double Blind ST Period Main Study|Participant Withdrew-Recurrent Infection|0
6072210|NCT00559585|9675368|FG001|Double Blind ST Period Main Study|Participant Withdrew-Recurrent Infection|1
6072211|NCT00559585|9675367|FG000|Double Blind ST Period Main Study|Investigator Decision|0
6072212|NCT00559585|9675368|FG001|Double Blind ST Period Main Study|Investigator Decision|1
6072213|NCT00559585|9675367|FG000|Double Blind ST Period Main Study|Ongoing Infection Risk|1
6072214|NCT00559585|9675368|FG001|Double Blind ST Period Main Study|Ongoing Infection Risk|0
6072215|NCT00559585|9675367|FG000|Anti-TNF Sub-Study in ST Period|Lack of Efficacy|1
6072216|NCT00559585|9675368|FG001|Anti-TNF Sub-Study in ST Period|Lack of Efficacy|1
6072217|NCT00559585|9675367|FG000|Open Label LT Period Main + Sub-Study|Adverse Event|100
6072218|NCT00559585|9675368|FG001|Open Label LT Period Main + Sub-Study|Adverse Event|0
5998924|NCT00264147|9592448|FG005|Treatment I Period|Patient out of town for an extended time|0
5998925|NCT00264147|9592443|FG000|Treatment I Period|Unblinded due to Serious Adverse Event|0
5998926|NCT00264147|9592444|FG001|Treatment I Period|Unblinded due to Serious Adverse Event|0
5998927|NCT00264147|9592445|FG002|Treatment I Period|Unblinded due to Serious Adverse Event|1
6072219|NCT00559585|9675367|FG000|Open Label LT Period Main + Sub-Study|Withdrawal by Subject|81
6072220|NCT00559585|9675368|FG001|Open Label LT Period Main + Sub-Study|Withdrawal by Subject|0
6072221|NCT00559585|9675367|FG000|Open Label LT Period Main + Sub-Study|Pregnancy|16
6072222|NCT00559585|9675368|FG001|Open Label LT Period Main + Sub-Study|Pregnancy|0
6072223|NCT00559585|9675367|FG000|Open Label LT Period Main + Sub-Study|Lost to Follow-up|32
6072224|NCT00559585|9675368|FG001|Open Label LT Period Main + Sub-Study|Lost to Follow-up|0
6072225|NCT00559585|9675367|FG000|Open Label LT Period Main + Sub-Study|Administrative reason by Sponsor|9
5998928|NCT00264147|9592446|FG003|Treatment I Period|Unblinded due to Serious Adverse Event|0
5998929|NCT00264147|9592447|FG004|Treatment I Period|Unblinded due to Serious Adverse Event|0
5998930|NCT00264147|9592448|FG005|Treatment I Period|Unblinded due to Serious Adverse Event|0
5998931|NCT00264147|9592443|FG000|Treatment I Period|Reassigned to Treatment II Period|84
5998932|NCT00264147|9592444|FG001|Treatment I Period|Reassigned to Treatment II Period|72
5998933|NCT00264147|9592445|FG002|Treatment I Period|Reassigned to Treatment II Period|65
5998934|NCT00264147|9592446|FG003|Treatment I Period|Reassigned to Treatment II Period|63
5998935|NCT00264147|9592447|FG004|Treatment I Period|Reassigned to Treatment II Period|45
5998936|NCT00264147|9592448|FG005|Treatment I Period|Reassigned to Treatment II Period|0
5998937|NCT00264147|9592443|FG000|Treatment II Period|Adverse Event|0
5998938|NCT00264147|9592444|FG001|Treatment II Period|Adverse Event|0
5998939|NCT00264147|9592445|FG002|Treatment II Period|Adverse Event|0
5998940|NCT00264147|9592446|FG003|Treatment II Period|Adverse Event|0
5998941|NCT00264147|9592447|FG004|Treatment II Period|Adverse Event|9
5998942|NCT00264147|9592448|FG005|Treatment II Period|Adverse Event|9
5998943|NCT00264147|9592443|FG000|Treatment II Period|Laboratory Adverse Event|0
5998944|NCT00264147|9592444|FG001|Treatment II Period|Laboratory Adverse Event|0
5998945|NCT00264147|9592445|FG002|Treatment II Period|Laboratory Adverse Event|0
5998946|NCT00264147|9592446|FG003|Treatment II Period|Laboratory Adverse Event|0
5998947|NCT00264147|9592447|FG004|Treatment II Period|Laboratory Adverse Event|0
5998948|NCT00264147|9592448|FG005|Treatment II Period|Laboratory Adverse Event|1
5998949|NCT00264147|9592443|FG000|Treatment II Period|Lack of Efficacy|0
5998950|NCT00264147|9592444|FG001|Treatment II Period|Lack of Efficacy|0
5998951|NCT00264147|9592445|FG002|Treatment II Period|Lack of Efficacy|0
5998952|NCT00264147|9592446|FG003|Treatment II Period|Lack of Efficacy|0
5998953|NCT00264147|9592447|FG004|Treatment II Period|Lack of Efficacy|20
5998954|NCT00264147|9592448|FG005|Treatment II Period|Lack of Efficacy|19
5998955|NCT00264147|9592443|FG000|Treatment II Period|Lost to Follow-up|0
5998956|NCT00264147|9592444|FG001|Treatment II Period|Lost to Follow-up|0
5998957|NCT00264147|9592445|FG002|Treatment II Period|Lost to Follow-up|0
5998958|NCT00264147|9592446|FG003|Treatment II Period|Lost to Follow-up|0
5998959|NCT00264147|9592447|FG004|Treatment II Period|Lost to Follow-up|1
5998960|NCT00264147|9592448|FG005|Treatment II Period|Lost to Follow-up|1
5998961|NCT00264147|9592443|FG000|Treatment II Period|Withdrawal by Subject|0
5998962|NCT00264147|9592444|FG001|Treatment II Period|Withdrawal by Subject|0
5998963|NCT00264147|9592445|FG002|Treatment II Period|Withdrawal by Subject|0
5998964|NCT00264147|9592446|FG003|Treatment II Period|Withdrawal by Subject|0
6072226|NCT00559585|9675368|FG001|Open Label LT Period Main + Sub-Study|Administrative reason by Sponsor|0
6072227|NCT00559585|9675367|FG000|Open Label LT Period Main + Sub-Study|Death|20
6072228|NCT00559585|9675368|FG001|Open Label LT Period Main + Sub-Study|Death|0
6072229|NCT00559585|9675367|FG000|Open Label LT Period Main + Sub-Study|No longer met criteria|1
6072230|NCT00559585|9675368|FG001|Open Label LT Period Main + Sub-Study|No longer met criteria|0
6072231|NCT00559585|9675367|FG000|Open Label LT Period Main + Sub-Study|Lack of Efficacy|89
6072232|NCT00559585|9675368|FG001|Open Label LT Period Main + Sub-Study|Lack of Efficacy|0
6072233|NCT00559585|9675367|FG000|Open Label LT Period Main + Sub-Study|Poor/non-compliance|8
6072234|NCT00559585|9675368|FG001|Open Label LT Period Main + Sub-Study|Poor/non-compliance|0
6072235|NCT00559585|9675367|FG000|Open Label LT Period Main + Sub-Study|non-specified|71
6072236|NCT00559585|9675368|FG001|Open Label LT Period Main + Sub-Study|non-specified|0
6072237|NCT00559585|9675367|FG000|Open Label LT Period Main + Sub-Study|no end of study status page|1
6072238|NCT00559585|9675368|FG001|Open Label LT Period Main + Sub-Study|no end of study status page|0
6072239|NCT00559637|9675385|FG000|Overall Study|Adverse Event|22
6072240|NCT00559637|9675385|FG000|Overall Study|Withdrawal by Subject|4
6072241|NCT00559637|9675385|FG000|Overall Study|Protocol Violation|6
6072242|NCT00559637|9675385|FG000|Overall Study|Withdrawal criteria fulfilled|4
5998965|NCT00264147|9592447|FG004|Treatment II Period|Withdrawal by Subject|3
5998966|NCT00264147|9592448|FG005|Treatment II Period|Withdrawal by Subject|2
5998967|NCT00264147|9592443|FG000|Treatment II Period|Pre-scheduled total hip replacement|0
5998968|NCT00264147|9592444|FG001|Treatment II Period|Pre-scheduled total hip replacement|0
5998969|NCT00264147|9592445|FG002|Treatment II Period|Pre-scheduled total hip replacement|0
5998970|NCT00264147|9592446|FG003|Treatment II Period|Pre-scheduled total hip replacement|0
5998971|NCT00264147|9592447|FG004|Treatment II Period|Pre-scheduled total hip replacement|0
5998972|NCT00264147|9592448|FG005|Treatment II Period|Pre-scheduled total hip replacement|1
5998973|NCT00202878|9592464|FG000|Overall Study|Death|964
5998974|NCT00202878|9592465|FG001|Overall Study|Death|968
5998975|NCT00202878|9592464|FG000|Overall Study|Only Vital Status Known|357
5998976|NCT00202878|9592465|FG001|Overall Study|Only Vital Status Known|356
5998977|NCT00202878|9592464|FG000|Overall Study|Lost to Follow-up|44
5998978|NCT00202878|9592465|FG001|Overall Study|Lost to Follow-up|49
5998979|NCT00202878|9592464|FG000|Overall Study|Site Closure|39
5998980|NCT00202878|9592465|FG001|Overall Study|Site Closure|36
5998981|NCT00202878|9592464|FG000|Overall Study|Withdrawal by Subject|795
5998982|NCT00202878|9592465|FG001|Overall Study|Withdrawal by Subject|808
6072243|NCT00559637|9675385|FG000|Overall Study|Failure to return|6
5998983|NCT00174265|9592473|FG000|Overall Study|Adverse Event|7
5998984|NCT00174265|9592474|FG001|Overall Study|Adverse Event|4
5998985|NCT00174265|9592473|FG000|Overall Study|Lack of Efficacy|2
5998986|NCT00174265|9592474|FG001|Overall Study|Lack of Efficacy|2
5998987|NCT00174265|9592473|FG000|Overall Study|Withdrawal by Subject|3
5998988|NCT00174265|9592474|FG001|Overall Study|Withdrawal by Subject|5
5998989|NCT00174265|9592473|FG000|Overall Study|Lost to Follow-up|1
5998990|NCT00174265|9592474|FG001|Overall Study|Lost to Follow-up|0
5998991|NCT00174265|9592473|FG000|Overall Study|Other (Not specified)|16
5998992|NCT00174265|9592474|FG001|Overall Study|Other (Not specified)|10
5998993|NCT00159783|9592483|FG000|Overall Study|Adverse Event|5
5998994|NCT00159783|9592484|FG001|Overall Study|Adverse Event|7
5998995|NCT00159783|9592485|FG002|Overall Study|Adverse Event|9
5998996|NCT00159783|9592483|FG000|Overall Study|Lack of Efficacy|1
5998997|NCT00159783|9592484|FG001|Overall Study|Lack of Efficacy|2
5998998|NCT00159783|9592485|FG002|Overall Study|Lack of Efficacy|3
5998999|NCT00159783|9592483|FG000|Overall Study|Withdrawal by Subject|7
5999000|NCT00159783|9592484|FG001|Overall Study|Withdrawal by Subject|11
5999001|NCT00159783|9592485|FG002|Overall Study|Withdrawal by Subject|12
5999002|NCT00159783|9592483|FG000|Overall Study|Lost to Follow-up|6
5999003|NCT00159783|9592484|FG001|Overall Study|Lost to Follow-up|5
5999004|NCT00159783|9592485|FG002|Overall Study|Lost to Follow-up|11
5999005|NCT00159783|9592483|FG000|Overall Study|Other|0
5999006|NCT00159783|9592484|FG001|Overall Study|Other|2
5999007|NCT00159783|9592485|FG002|Overall Study|Other|4
5999008|NCT00092677|9592507|FG000|Overall Study|Lost to Follow-up|0
5999009|NCT00092677|9592508|FG001|Overall Study|Lost to Follow-up|2
5999010|NCT00092677|9592507|FG000|Overall Study|Adminstrative|5
5999011|NCT00092677|9592508|FG001|Overall Study|Adminstrative|9
5999012|NCT00090259|9592516|FG000|Overall Study|Lost to Follow-up|30
5999013|NCT00090259|9592517|FG001|Overall Study|Lost to Follow-up|26
5999014|NCT00090259|9592516|FG000|Overall Study|Withdrawal by Subject|21
5999015|NCT00090259|9592517|FG001|Overall Study|Withdrawal by Subject|15
5999016|NCT00090259|9592516|FG000|Overall Study|Investigator site closed|11
5999017|NCT00090259|9592517|FG001|Overall Study|Investigator site closed|7
5999018|NCT00003298|9592523|FG000|Step 1 (Neoadjuvant Therapy)|Ineligible for step 1|1
5999019|NCT00003298|9592523|FG000|Step 1 (Neoadjuvant Therapy)|Adverse Event|3
5999020|NCT00003298|9592523|FG000|Surgery|Unresectable at surgery|3
5999021|NCT00003298|9592523|FG000|Surgery|Progression before surgery|2
5999022|NCT00003298|9592523|FG000|Surgery|Unevaluable and off study|2
5999023|NCT00003298|9592523|FG000|Re-register to Step 2 After Surgery|Less than 15 nodes examined|7
5999024|NCT00003298|9592523|FG000|Re-register to Step 2 After Surgery|Positive margins|5
5999025|NCT00003298|9592523|FG000|Re-register to Step 2 After Surgery|Other complications|2
5999026|NCT00003298|9592523|FG000|Re-register to Step 2 After Surgery|Reason unknown|1
5999027|NCT00003298|9592523|FG000|Re-register to Step 2 After Surgery|Ineligible due to tumor staging|3
5999028|NCT00003298|9592523|FG000|Step 2 (Adjuvant Therapy)|Ineligible|1
5999029|NCT00003298|9592523|FG000|Step 2 (Adjuvant Therapy)|Death|1
5999030|NCT00003298|9592523|FG000|Step 2 (Adjuvant Therapy)|Progression before starting treatment|1
5999031|NCT00003298|9592523|FG000|Step 2 (Adjuvant Therapy)|Excessive complication|1
5999032|NCT00003298|9592523|FG000|Step 2 (Adjuvant Therapy)|Withdrawal by Subject|2
5999033|NCT00003377|9592533|FG000|Period I|Dose Limiting Toxicity(DLT)|0
5999034|NCT00003377|9592534|FG001|Period I|Dose Limiting Toxicity(DLT)|0
5999035|NCT00003377|9592535|FG002|Period I|Dose Limiting Toxicity(DLT)|1
5999036|NCT00003377|9592536|FG003|Period I|Dose Limiting Toxicity(DLT)|1
5999037|NCT00003377|9592537|FG004|Period I|Dose Limiting Toxicity(DLT)|0
5999038|NCT00003377|9592533|FG000|Period II|Ureteral stent complications|0
5999039|NCT00003377|9592534|FG001|Period II|Ureteral stent complications|0
5999040|NCT00003377|9592535|FG002|Period II|Ureteral stent complications|0
5999041|NCT00003377|9592536|FG003|Period II|Ureteral stent complications|0
5999042|NCT00003377|9592537|FG004|Period II|Ureteral stent complications|1
5999043|NCT00003389|9592552|FG000|Overall Study|Disease progression|6
5999044|NCT00003389|9592553|FG001|Overall Study|Disease progression|1
5999045|NCT00003389|9592552|FG000|Overall Study|Adverse Event|13
5999046|NCT00003389|9592553|FG001|Overall Study|Adverse Event|2
5999047|NCT00003389|9592552|FG000|Overall Study|Death|0
5999048|NCT00003389|9592553|FG001|Overall Study|Death|3
5999049|NCT00003389|9592552|FG000|Overall Study|Withdrawal by Subject|12
5999050|NCT00003389|9592553|FG001|Overall Study|Withdrawal by Subject|5
5999051|NCT00003389|9592552|FG000|Overall Study|Alternative therapy|2
5999052|NCT00003389|9592553|FG001|Overall Study|Alternative therapy|1
5999053|NCT00003389|9592552|FG000|Overall Study|Complicating disease|1
5999054|NCT00003389|9592553|FG001|Overall Study|Complicating disease|0
5999055|NCT00003389|9592552|FG000|Overall Study|Off-treatment reason missing|31
5999056|NCT00003389|9592553|FG001|Overall Study|Off-treatment reason missing|21
5999057|NCT00003389|9592552|FG000|Overall Study|Ineligible|33
5999058|NCT00003389|9592553|FG001|Overall Study|Ineligible|27
5999059|NCT00003456|9592568|FG000|Overall Study|Not evaluable|8
5999060|NCT00003457|9592572|FG000|Overall Study|Not evaluable|9
5999061|NCT00003470|9592592|FG000|Overall Study|Not evaluable|6
5999062|NCT00003471|9592596|FG000|Overall Study|Not evaluable|4
5999063|NCT00003472|9592600|FG000|Overall Study|Not evaluable|3
5999064|NCT00003473|9592604|FG000|Overall Study|Three patients were not evaluable.|3
5999065|NCT00003474|9592608|FG000|Overall Study|Not Evaluable|14
5999066|NCT00003475|9592612|FG000|Overall Study|Not evaluable|13
6047052|NCT00409838|9646126|FG000|Long-term Extension Period|Death|1
6047053|NCT00409838|9646127|FG001|Long-term Extension Period|Death|0
6047054|NCT00409838|9646126|FG000|Long-term Extension Period|Lack of Efficacy|2
6047055|NCT00409838|9646127|FG001|Long-term Extension Period|Lack of Efficacy|0
6047056|NCT00409838|9646126|FG000|Long-term Extension Period|Withdrawal by Subject|3
6047057|NCT00409838|9646127|FG001|Long-term Extension Period|Withdrawal by Subject|0
6047058|NCT00409838|9646126|FG000|Long-term Extension Period|Poor compliance/noncompliance|1
6047059|NCT00409838|9646127|FG001|Long-term Extension Period|Poor compliance/noncompliance|0
6047060|NCT00409838|9646126|FG000|Long-term Extension Period|Pregnancy|1
6047061|NCT00409838|9646127|FG001|Long-term Extension Period|Pregnancy|0
6047062|NCT00410046|9646150|FG000|Overall Study|Adverse Event|3
6047063|NCT00410046|9646150|FG000|Overall Study|Withdrawal by Subject|1
6047064|NCT00410046|9646150|FG000|Overall Study|Lost to Follow-up|1
6047065|NCT00410072|9646161|FG000|Day 1 to Week 48|Adverse Event|1
6047066|NCT00410072|9646162|FG001|Day 1 to Week 48|Adverse Event|2
6047067|NCT00410072|9646161|FG000|Day 1 to Week 48|Lost to Follow-up|5
6047068|NCT00410072|9646162|FG001|Day 1 to Week 48|Lost to Follow-up|2
6047069|NCT00410072|9646161|FG000|Day 1 to Week 48|Other|0
6047070|NCT00410072|9646162|FG001|Day 1 to Week 48|Other|1
6047071|NCT00410072|9646161|FG000|Day 1 to Week 48|poor compliance/noncompliance|0
6047072|NCT00410072|9646162|FG001|Day 1 to Week 48|poor compliance/noncompliance|3
6047073|NCT00410072|9646161|FG000|Day 1 to Week 48|Pregnancy|0
6047074|NCT00410072|9646162|FG001|Day 1 to Week 48|Pregnancy|2
6047075|NCT00410072|9646161|FG000|Day 1 to Week 48|Withdrawal by Subject|0
6047076|NCT00410072|9646162|FG001|Day 1 to Week 48|Withdrawal by Subject|2
6047077|NCT00410072|9646161|FG000|After Week 48 to Week 96|Adverse Event|1
6047078|NCT00410072|9646162|FG001|After Week 48 to Week 96|Adverse Event|2
6047079|NCT00410072|9646161|FG000|After Week 48 to Week 96|Death|0
6047080|NCT00410072|9646162|FG001|After Week 48 to Week 96|Death|1
6047081|NCT00410072|9646161|FG000|After Week 48 to Week 96|Lack of Efficacy|1
6047082|NCT00410072|9646162|FG001|After Week 48 to Week 96|Lack of Efficacy|0
6047083|NCT00410072|9646161|FG000|After Week 48 to Week 96|Lost to Follow-up|2
6047084|NCT00410072|9646162|FG001|After Week 48 to Week 96|Lost to Follow-up|4
6047085|NCT00410072|9646161|FG000|After Week 48 to Week 96|Other|2
6047086|NCT00410072|9646162|FG001|After Week 48 to Week 96|Other|0
6047087|NCT00410072|9646161|FG000|After Week 48 to Week 96|Poor compliance/noncompliance|0
6047088|NCT00410072|9646162|FG001|After Week 48 to Week 96|Poor compliance/noncompliance|1
6047089|NCT00410072|9646161|FG000|After Week 48 to Week 96|Pregnancy|0
6047090|NCT00410072|9646162|FG001|After Week 48 to Week 96|Pregnancy|2
6047091|NCT00410072|9646161|FG000|After Week 48 to Week 96|Withdrawal by Subject|0
6047092|NCT00410072|9646162|FG001|After Week 48 to Week 96|Withdrawal by Subject|1
6047093|NCT00410124|9646170|FG000|Core Phase Double Blind (15 Months)|Adverse Event|36
6047094|NCT00410124|9646171|FG001|Core Phase Double Blind (15 Months)|Adverse Event|2
6047095|NCT00410124|9646170|FG000|Core Phase Double Blind (15 Months)|Abnormal Laboratory Value|1
6047096|NCT00410124|9646171|FG001|Core Phase Double Blind (15 Months)|Abnormal Laboratory Value|0
6047097|NCT00410124|9646170|FG000|Core Phase Double Blind (15 Months)|Protocol Violation|2
6047098|NCT00410124|9646171|FG001|Core Phase Double Blind (15 Months)|Protocol Violation|1
6047099|NCT00410124|9646170|FG000|Core Phase Double Blind (15 Months)|Withdrawal by Subject|13
6047100|NCT00410124|9646171|FG001|Core Phase Double Blind (15 Months)|Withdrawal by Subject|2
6047101|NCT00410124|9646170|FG000|Core Phase Double Blind (15 Months)|Lost to Follow-up|4
6047102|NCT00410124|9646171|FG001|Core Phase Double Blind (15 Months)|Lost to Follow-up|0
6047103|NCT00410124|9646170|FG000|Core Phase Double Blind (15 Months)|Administrative Problems|2
6047104|NCT00410124|9646171|FG001|Core Phase Double Blind (15 Months)|Administrative Problems|0
6047105|NCT00410124|9646170|FG000|Core Phase Double Blind (15 Months)|Death|7
6047106|NCT00410124|9646171|FG001|Core Phase Double Blind (15 Months)|Death|4
6047107|NCT00410124|9646170|FG000|Core Phase Double Blind (15 Months)|Disease Progression|137
6047108|NCT00410124|9646171|FG001|Core Phase Double Blind (15 Months)|Disease Progression|124
6072244|NCT00559637|9675385|FG000|Overall Study|Insufficient response|3
6072245|NCT00559637|9675385|FG000|Overall Study|Started requiring dialysis after month 7|2
6072246|NCT00559637|9675385|FG000|Overall Study|Suspected lung cancer|1
6072247|NCT00559637|9675385|FG000|Overall Study|Participation in another study|1
6072248|NCT00559637|9675385|FG000|Overall Study|Delayed administration of C.E.R.A|1
6072249|NCT00559637|9675385|FG000|Overall Study|Change of center|1
6072250|NCT00559637|9675385|FG000|Overall Study|Change of home|1
6072251|NCT00559637|9675385|FG000|Overall Study|Inclusion or exclusion criteria violated|2
6072252|NCT00559754|9675389|FG000|Overall Study|Disease progression|1
6072253|NCT00559754|9675389|FG000|Overall Study|Adverse Event|5
6072254|NCT00559754|9675389|FG000|Overall Study|Protocol Violation|1
6072255|NCT00559754|9675389|FG000|Overall Study|Investigator criteria|2
6072256|NCT00559754|9675389|FG000|Overall Study|Withdrawal by Subject|2
6072257|NCT00559845|9675393|FG000|Overall Study|Withdrew Consent|1
6047109|NCT00410124|9646170|FG000|Extension Phase - Open Label (45 Months)|Adverse Event|7
6047110|NCT00410124|9646171|FG001|Extension Phase - Open Label (45 Months)|Adverse Event|19
6047111|NCT00410124|9646170|FG000|Extension Phase - Open Label (45 Months)|Abnormal Laboratory Values|0
6047112|NCT00410124|9646171|FG001|Extension Phase - Open Label (45 Months)|Abnormal Laboratory Values|1
6047113|NCT00410124|9646170|FG000|Extension Phase - Open Label (45 Months)|Abnormal Test Procedures|0
5999067|NCT00003476|9592617|FG000|Overall Study|Not evaluable|1
5999068|NCT00003477|9592621|FG000|Overall Study|Not evalauable|4
5999069|NCT00003483|9592625|FG000|Overall Study|Not evaluable|1
5999070|NCT00003487|9592629|FG000|Overall Study|Not evaluable|2
5999071|NCT00003492|9592633|FG000|Overall Study|Not evaluable|6
5999072|NCT00003498|9592637|FG000|Overall Study|Not evaluable.|4
5999073|NCT00003499|9592641|FG000|Overall Study|Not evaluable|8
5999074|NCT00003508|9592645|FG000|Overall Study|Not evaluable|5
5999075|NCT00003509|9592649|FG000|Overall Study|Not evaluable|5
5999076|NCT00003511|9592653|FG000|Overall Study|Not evaluable|4
5999077|NCT00003526|9592657|FG000|Overall Study|Not evaluable|6
5999078|NCT00003531|9592661|FG000|Overall Study|Not evaluable|10
5999079|NCT00003535|9592665|FG000|Overall Study|Not evaluable|5
5999080|NCT00003537|9592669|FG000|Overall Study|Not evalauable|1
5999081|NCT00003590|9592673|FG000|Overall Study|Ineligible Patient|1
5999082|NCT00003590|9592673|FG000|Overall Study|Adverse Event|7
5999083|NCT00003590|9592673|FG000|Overall Study|Withdrawal by Subject|1
5999084|NCT00003590|9592673|FG000|Overall Study|Lack of Efficacy|11
5999085|NCT00003590|9592673|FG000|Overall Study|Death|1
5999086|NCT00003590|9592673|FG000|Overall Study|Physician Decision|1
5999087|NCT00003631|9592680|FG000|Overall Study|Patient not treated|1
5999088|NCT00003631|9592681|FG001|Overall Study|Patient not treated|0
5999089|NCT00003631|9592682|FG002|Overall Study|Patient not treated|1
5999090|NCT00003631|9592680|FG000|Overall Study|Protocol Violation|1
5999091|NCT00003631|9592681|FG001|Overall Study|Protocol Violation|0
5999092|NCT00003631|9592682|FG002|Overall Study|Protocol Violation|0
5999093|NCT00003631|9592680|FG000|Overall Study|Adverse Event|1
5999094|NCT00003631|9592681|FG001|Overall Study|Adverse Event|1
5999095|NCT00003631|9592682|FG002|Overall Study|Adverse Event|5
5999096|NCT00003631|9592680|FG000|Overall Study|Death|0
5999097|NCT00003631|9592681|FG001|Overall Study|Death|0
5999098|NCT00003631|9592682|FG002|Overall Study|Death|1
5999099|NCT00003631|9592680|FG000|Overall Study|Evaluable for toxicity only|0
5999100|NCT00003631|9592681|FG001|Overall Study|Evaluable for toxicity only|0
5999101|NCT00003631|9592682|FG002|Overall Study|Evaluable for toxicity only|2
5999102|NCT00003641|9592692|FG000|Overall Study|Withdrawal by Subject|0
5999103|NCT00003641|9592693|FG001|Overall Study|Withdrawal by Subject|100
5999104|NCT00003641|9592692|FG000|Overall Study|Adverse Event|0
5999105|NCT00003641|9592693|FG001|Overall Study|Adverse Event|38
5999106|NCT00003641|9592692|FG000|Overall Study|Disease progression|0
5999107|NCT00003641|9592693|FG001|Overall Study|Disease progression|2
5999108|NCT00003641|9592692|FG000|Overall Study|Unknown/missing|0
5999109|NCT00003641|9592693|FG001|Overall Study|Unknown/missing|22
5999110|NCT00003641|9592692|FG000|Overall Study|Should not receive interferon therapy|2
5999111|NCT00003641|9592693|FG001|Overall Study|Should not receive interferon therapy|0
5999112|NCT00003641|9592692|FG000|Overall Study|Never started interferon|567
5999113|NCT00003641|9592693|FG001|Overall Study|Never started interferon|12
5999114|NCT00003645|9592712|FG000|Overall Study|Death|4
5999115|NCT00003645|9592713|FG001|Overall Study|Death|1
5999116|NCT00003645|9592712|FG000|Overall Study|Lost to Follow-up|7
5999117|NCT00003645|9592713|FG001|Overall Study|Lost to Follow-up|8
5999118|NCT00003645|9592712|FG000|Overall Study|Withdrawal by Subject|1
5999119|NCT00003645|9592713|FG001|Overall Study|Withdrawal by Subject|3
5999120|NCT00003659|9592721|FG000|Overall Study|Withdrawal by Subject|3
5999121|NCT00003702|9592727|FG000|Overall Study|Ineligible cell types|2
5999122|NCT00003702|9592728|FG001|Overall Study|Ineligible cell types|2
5999123|NCT00003702|9592727|FG000|Overall Study|Did not meet criteria for persistence|8
5999124|NCT00003702|9592728|FG001|Overall Study|Did not meet criteria for persistence|5
5999125|NCT00003702|9592727|FG000|Overall Study|WHO score > 6|2
5999126|NCT00003702|9592728|FG001|Overall Study|WHO score > 6|1
5999127|NCT00003702|9592727|FG000|Overall Study|Inadequate documentation of disease|1
5999128|NCT00003702|9592728|FG001|Overall Study|Inadequate documentation of disease|3
5999129|NCT00003782|9592738|FG000|Overall Study|No follow up data|30
5999130|NCT00003782|9592739|FG001|Overall Study|No follow up data|31
5999131|NCT00003782|9592740|FG002|Overall Study|No follow up data|26
5999132|NCT00003830|9592778|FG000|Overall Study|No follow up data|3
5999133|NCT00003830|9592779|FG001|Overall Study|No follow up data|0
5999134|NCT00003830|9592778|FG000|Overall Study|Sentinel node positive patients|829
5999135|NCT00003830|9592779|FG001|Overall Study|Sentinel node positive patients|793
5999136|NCT00003869|9592789|FG000|Overall Study|Adverse Event|14
5999137|NCT00003869|9592790|FG001|Overall Study|Adverse Event|3
5999138|NCT00003869|9592789|FG000|Overall Study|Withdrawal by Subject|21
5999139|NCT00003869|9592790|FG001|Overall Study|Withdrawal by Subject|3
5999140|NCT00003869|9592789|FG000|Overall Study|Death|1
5999141|NCT00003869|9592790|FG001|Overall Study|Death|2
5999142|NCT00003869|9592789|FG000|Overall Study|Alternative treatmnt, medical problems|5
5999143|NCT00003869|9592790|FG001|Overall Study|Alternative treatmnt, medical problems|4
5999144|NCT00003875|9592796|FG000|Overall Study|Screen Failed|1
5999145|NCT00003895|9592802|FG000|Overall Study|Adverse Event|4
5999146|NCT00003895|9592803|FG001|Overall Study|Adverse Event|0
5999147|NCT00003895|9592802|FG000|Overall Study|Lack of Efficacy|1
5999148|NCT00003895|9592803|FG001|Overall Study|Lack of Efficacy|1
5999149|NCT00003895|9592802|FG000|Overall Study|Patient Vacation|2
5999150|NCT00003895|9592803|FG001|Overall Study|Patient Vacation|0
5999151|NCT00003895|9592802|FG000|Overall Study|Withdrawal by Subject|0
5999152|NCT00003895|9592803|FG001|Overall Study|Withdrawal by Subject|3
5999153|NCT00003896|9592809|FG000|Overall Study|Adverse Event|16
5999154|NCT00003896|9592809|FG000|Overall Study|Withdrawal by Subject|1
5999155|NCT00003896|9592809|FG000|Overall Study|Lack of Efficacy|1
5999156|NCT00003896|9592809|FG000|Overall Study|Death|3
5999157|NCT00003896|9592809|FG000|Overall Study|not protocol specified|3
5999158|NCT00003896|9592809|FG000|Overall Study|ineligible|5
5999159|NCT00003901|9592814|FG000|Overall Study|Adverse Event|1
5999160|NCT00003901|9592814|FG000|Overall Study|Withdrawal by Subject|1
5999161|NCT00003901|9592814|FG000|Overall Study|Ineligible|6
5999162|NCT00003901|9592814|FG000|Overall Study|CT Scan not within protocol requirement|2
5999163|NCT00003901|9592814|FG000|Overall Study|Chest X-Ray not done prior registration|1
5999164|NCT00003901|9592814|FG000|Overall Study|Medical problems|6
5999165|NCT00003907|9592823|FG000|Overall Study|Adverse Event|2
5999166|NCT00003907|9592824|FG001|Overall Study|Adverse Event|11
5999167|NCT00003907|9592823|FG000|Overall Study|Death|2
5999168|NCT00003907|9592824|FG001|Overall Study|Death|0
5999169|NCT00003907|9592823|FG000|Overall Study|Withdrawal by Subject|1
5999170|NCT00003907|9592824|FG001|Overall Study|Withdrawal by Subject|3
5999171|NCT00003907|9592823|FG000|Overall Study|Progressive disease|4
5999172|NCT00003907|9592824|FG001|Overall Study|Progressive disease|4
5999173|NCT00003907|9592823|FG000|Overall Study|Complicating disease|1
5999174|NCT00003907|9592824|FG001|Overall Study|Complicating disease|0
6072258|NCT00559845|9675393|FG000|Overall Study|Disease Progression|1
6072259|NCT00559845|9675393|FG000|Overall Study|Adverse Event|3
6072260|NCT00559845|9675393|FG000|Overall Study|Did Not Attend Cycle 6 Hospital Visit|1
6072261|NCT00559845|9675393|FG000|Overall Study|Premature Surgery-Investigator Decision|1
5999175|NCT00003907|9592823|FG000|Overall Study|Other|1
6072262|NCT00559949|9675397|FG000|Overall Study|Progressive Disease during cycle 1|1
6072263|NCT00559949|9675397|FG000|Overall Study|Adverse Event|1
6072264|NCT00559949|9675397|FG000|Overall Study|Withdrawal by Subject|4
6072265|NCT00559949|9675397|FG000|Overall Study|No disease evaluation per protocol|1
6072266|NCT00559962|9675409|FG000|Overall Study|Adverse Event|1
6072267|NCT00559962|9675410|FG001|Overall Study|Adverse Event|7
6072268|NCT00559962|9675411|FG002|Overall Study|Adverse Event|8
6072269|NCT00559962|9675412|FG003|Overall Study|Adverse Event|5
6072270|NCT00559962|9675413|FG004|Overall Study|Adverse Event|11
6072271|NCT00559962|9675414|FG005|Overall Study|Adverse Event|4
6072272|NCT00559962|9675415|FG006|Overall Study|Adverse Event|4
6072273|NCT00559962|9675416|FG007|Overall Study|Adverse Event|2
6072274|NCT00559962|9675409|FG000|Overall Study|Lost to Follow-up|0
6072275|NCT00559962|9675410|FG001|Overall Study|Lost to Follow-up|1
6072276|NCT00559962|9675411|FG002|Overall Study|Lost to Follow-up|0
6072277|NCT00559962|9675412|FG003|Overall Study|Lost to Follow-up|0
6072278|NCT00559962|9675413|FG004|Overall Study|Lost to Follow-up|0
6072279|NCT00559962|9675414|FG005|Overall Study|Lost to Follow-up|0
6072280|NCT00559962|9675415|FG006|Overall Study|Lost to Follow-up|0
6072281|NCT00559962|9675416|FG007|Overall Study|Lost to Follow-up|0
5999176|NCT00003907|9592824|FG001|Overall Study|Other|3
5999177|NCT00003907|9592823|FG000|Overall Study|ineligible or not treated|2
5999178|NCT00003907|9592824|FG001|Overall Study|ineligible or not treated|2
5999179|NCT00004031|9592839|FG000|Overall Study|Adverse Event|5
5999180|NCT00004031|9592840|FG001|Overall Study|Adverse Event|0
5999181|NCT00004031|9592839|FG000|Overall Study|Refusal unrelated to adverse events|2
5999182|NCT00004031|9592840|FG001|Overall Study|Refusal unrelated to adverse events|11
5999183|NCT00004031|9592839|FG000|Overall Study|Progression/relapse|9
5999184|NCT00004031|9592840|FG001|Overall Study|Progression/relapse|4
5999185|NCT00004031|9592839|FG000|Overall Study|Death|3
5999186|NCT00004031|9592840|FG001|Overall Study|Death|1
5999187|NCT00004031|9592839|FG000|Overall Study|Other- not protocol specified|3
5999188|NCT00004031|9592840|FG001|Overall Study|Other- not protocol specified|3
5999189|NCT00004031|9592839|FG000|Overall Study|Reason under review|3
5999190|NCT00004031|9592840|FG001|Overall Study|Reason under review|2
5999191|NCT00004088|9592857|FG000|Overall Study|No C2 given due to study on hold by IRB|4
5999192|NCT00004088|9592857|FG000|Overall Study|Withdrawal by Subject|1
5999193|NCT00004088|9592857|FG000|Overall Study|Protocol Violation|3
5999194|NCT00004088|9592857|FG000|Overall Study|Physician Decision|1
5999195|NCT00004124|9592872|FG000|Overall Study|Received no protocol therapy|12
6072282|NCT00559962|9675409|FG000|Overall Study|Withdrawal by Subject|1
6072283|NCT00559962|9675410|FG001|Overall Study|Withdrawal by Subject|1
6072284|NCT00559962|9675411|FG002|Overall Study|Withdrawal by Subject|2
5999196|NCT00004124|9592873|FG001|Overall Study|Received no protocol therapy|20
5999197|NCT00004228|9592896|FG000|Overall Study|Adverse Event|0
5999198|NCT00004228|9592897|FG001|Overall Study|Adverse Event|1
5999199|NCT00004228|9592898|FG002|Overall Study|Adverse Event|0
5999200|NCT00004228|9592899|FG003|Overall Study|Adverse Event|0
5999201|NCT00004228|9592900|FG004|Overall Study|Adverse Event|1
5999202|NCT00004228|9592901|FG005|Overall Study|Adverse Event|0
6072285|NCT00559962|9675412|FG003|Overall Study|Withdrawal by Subject|0
6072286|NCT00559962|9675413|FG004|Overall Study|Withdrawal by Subject|3
6072287|NCT00559962|9675414|FG005|Overall Study|Withdrawal by Subject|1
6072288|NCT00559962|9675415|FG006|Overall Study|Withdrawal by Subject|0
5999203|NCT00004228|9592902|FG006|Overall Study|Adverse Event|0
5999204|NCT00004228|9592896|FG000|Overall Study|Death|0
6072289|NCT00559962|9675416|FG007|Overall Study|Withdrawal by Subject|2
5999205|NCT00004228|9592897|FG001|Overall Study|Death|1
5999206|NCT00004228|9592898|FG002|Overall Study|Death|2
5999207|NCT00004228|9592899|FG003|Overall Study|Death|0
5999208|NCT00004228|9592900|FG004|Overall Study|Death|1
5999209|NCT00004228|9592901|FG005|Overall Study|Death|0
5999210|NCT00004228|9592902|FG006|Overall Study|Death|0
5999211|NCT00004228|9592896|FG000|Overall Study|Lack of Efficacy|1
5999212|NCT00004228|9592897|FG001|Overall Study|Lack of Efficacy|6
5999213|NCT00004228|9592898|FG002|Overall Study|Lack of Efficacy|5
5999214|NCT00004228|9592899|FG003|Overall Study|Lack of Efficacy|3
5999215|NCT00004228|9592900|FG004|Overall Study|Lack of Efficacy|9
5999216|NCT00004228|9592901|FG005|Overall Study|Lack of Efficacy|8
5999217|NCT00004228|9592902|FG006|Overall Study|Lack of Efficacy|4
5999218|NCT00004228|9592896|FG000|Overall Study|Lost to Follow-up|0
5999219|NCT00004228|9592897|FG001|Overall Study|Lost to Follow-up|0
5999220|NCT00004228|9592898|FG002|Overall Study|Lost to Follow-up|1
5999221|NCT00004228|9592899|FG003|Overall Study|Lost to Follow-up|0
5999222|NCT00004228|9592900|FG004|Overall Study|Lost to Follow-up|0
5999223|NCT00004228|9592901|FG005|Overall Study|Lost to Follow-up|0
5999224|NCT00004228|9592902|FG006|Overall Study|Lost to Follow-up|0
5999225|NCT00004228|9592896|FG000|Overall Study|Physician Decision|1
5999226|NCT00004228|9592897|FG001|Overall Study|Physician Decision|0
5999227|NCT00004228|9592898|FG002|Overall Study|Physician Decision|3
5999228|NCT00004228|9592899|FG003|Overall Study|Physician Decision|2
5999229|NCT00004228|9592900|FG004|Overall Study|Physician Decision|1
5999230|NCT00004228|9592901|FG005|Overall Study|Physician Decision|1
5999231|NCT00004228|9592902|FG006|Overall Study|Physician Decision|1
5999232|NCT00004228|9592896|FG000|Overall Study|Protocol Violation|0
5999233|NCT00004228|9592897|FG001|Overall Study|Protocol Violation|5
5999234|NCT00004228|9592898|FG002|Overall Study|Protocol Violation|2
5999235|NCT00004228|9592899|FG003|Overall Study|Protocol Violation|1
5999236|NCT00004228|9592900|FG004|Overall Study|Protocol Violation|1
5999237|NCT00004228|9592901|FG005|Overall Study|Protocol Violation|2
5999238|NCT00004228|9592902|FG006|Overall Study|Protocol Violation|0
5999239|NCT00004228|9592896|FG000|Overall Study|Withdrawal by Subject|3
5999240|NCT00004228|9592897|FG001|Overall Study|Withdrawal by Subject|0
5999241|NCT00004228|9592898|FG002|Overall Study|Withdrawal by Subject|1
5999242|NCT00004228|9592899|FG003|Overall Study|Withdrawal by Subject|0
5999243|NCT00004228|9592900|FG004|Overall Study|Withdrawal by Subject|2
5999244|NCT00004228|9592901|FG005|Overall Study|Withdrawal by Subject|1
5999245|NCT00004228|9592902|FG006|Overall Study|Withdrawal by Subject|2
5999246|NCT00004228|9592896|FG000|Overall Study|Other|0
5999247|NCT00004228|9592897|FG001|Overall Study|Other|0
5999248|NCT00004228|9592898|FG002|Overall Study|Other|1
5999249|NCT00004228|9592899|FG003|Overall Study|Other|0
5999250|NCT00004228|9592900|FG004|Overall Study|Other|0
5999251|NCT00004228|9592901|FG005|Overall Study|Other|0
5999252|NCT00004228|9592902|FG006|Overall Study|Other|0
6072290|NCT00559962|9675409|FG000|Overall Study|Inclusion/exclusion criteria not met|0
6072291|NCT00559962|9675410|FG001|Overall Study|Inclusion/exclusion criteria not met|0
6072292|NCT00559962|9675411|FG002|Overall Study|Inclusion/exclusion criteria not met|0
6072293|NCT00559962|9675412|FG003|Overall Study|Inclusion/exclusion criteria not met|0
6072294|NCT00559962|9675413|FG004|Overall Study|Inclusion/exclusion criteria not met|0
6072295|NCT00559962|9675414|FG005|Overall Study|Inclusion/exclusion criteria not met|0
6072296|NCT00559962|9675415|FG006|Overall Study|Inclusion/exclusion criteria not met|1
6072297|NCT00559962|9675416|FG007|Overall Study|Inclusion/exclusion criteria not met|0
6072298|NCT00559988|9675437|FG000|Overall Study|Death|147
6072299|NCT00559988|9675438|FG001|Overall Study|Death|140
6072300|NCT00559988|9675437|FG000|Overall Study|Withdrawal by Subject|152
6072301|NCT00559988|9675438|FG001|Overall Study|Withdrawal by Subject|139
6072302|NCT00559988|9675437|FG000|Overall Study|Lost to Follow-up|42
6072303|NCT00559988|9675438|FG001|Overall Study|Lost to Follow-up|56
6072304|NCT00559988|9675437|FG000|Overall Study|ICD device explanted|10
6072305|NCT00559988|9675438|FG001|Overall Study|ICD device explanted|17
6072306|NCT00560066|9675446|FG000|Overall Study|Death|2
6072307|NCT00560066|9675447|FG001|Overall Study|Death|1
6072308|NCT00560066|9675446|FG000|Overall Study|Withdrawal by Subject|0
6072309|NCT00560066|9675447|FG001|Overall Study|Withdrawal by Subject|3
6072310|NCT00560066|9675446|FG000|Overall Study|Lost to Follow-up|4
6072311|NCT00560066|9675447|FG001|Overall Study|Lost to Follow-up|10
6072312|NCT00560066|9675446|FG000|Overall Study|Protocol Violation|0
6072313|NCT00560066|9675447|FG001|Overall Study|Protocol Violation|1
6072314|NCT00560066|9675446|FG000|Overall Study|Administrative reason|0
5999253|NCT00004228|9592896|FG000|Overall Study|ineligible|4
5999254|NCT00004228|9592897|FG001|Overall Study|ineligible|2
6072315|NCT00560066|9675447|FG001|Overall Study|Administrative reason|5
6072316|NCT00560066|9675446|FG000|Overall Study|Missing primary reason|0
6072317|NCT00560066|9675447|FG001|Overall Study|Missing primary reason|2
6072318|NCT00560105|9675460|FG000|Overall Study|musculoskeletal chest discomfort with us|1
6072319|NCT00560105|9675461|FG001|Overall Study|musculoskeletal chest discomfort with us|2
5999255|NCT00004228|9592898|FG002|Overall Study|ineligible|4
5999256|NCT00004228|9592899|FG003|Overall Study|ineligible|1
5999257|NCT00004228|9592900|FG004|Overall Study|ineligible|1
5999258|NCT00004228|9592901|FG005|Overall Study|ineligible|2
5999259|NCT00004228|9592902|FG006|Overall Study|ineligible|5
5999260|NCT00004259|9592923|FG000|Overall Study|Protocol Violation|1
5999261|NCT00004259|9592924|FG001|Overall Study|Protocol Violation|2
5999262|NCT00004259|9592925|FG002|Overall Study|Protocol Violation|0
5999263|NCT00004259|9592926|FG003|Overall Study|Protocol Violation|0
5999264|NCT00004259|9592923|FG000|Overall Study|Withdrawal by Subject|0
5999265|NCT00004259|9592924|FG001|Overall Study|Withdrawal by Subject|2
5999266|NCT00004259|9592925|FG002|Overall Study|Withdrawal by Subject|0
5999267|NCT00004259|9592926|FG003|Overall Study|Withdrawal by Subject|0
5999268|NCT00004412|9592942|FG000|Randomized Period|Moved to Crossover Period|3
5999269|NCT00004412|9592943|FG001|Randomized Period|Moved to Crossover Period|0
5999270|NCT00004412|9592944|FG002|Randomized Period|Moved to Crossover Period|0
5999271|NCT00004445|9592954|FG000|Overall Study|Physician Decision|2
5999272|NCT00004445|9592954|FG000|Overall Study|Withdrawal by Subject|1
5999273|NCT00004562|9592983|FG000|Overall Study|Lost to Follow-up|102
5999274|NCT00004562|9592984|FG001|Overall Study|Lost to Follow-up|91
5999275|NCT00004563|9592992|FG000|Overall Study|Withdrawal by Subject|20
5999276|NCT00004563|9592993|FG001|Overall Study|Withdrawal by Subject|16
5999277|NCT00004563|9592992|FG000|Overall Study|Lack of Efficacy|3
5999278|NCT00004563|9592993|FG001|Overall Study|Lack of Efficacy|5
5999279|NCT00004563|9592992|FG000|Overall Study|Death|2
5999280|NCT00004563|9592993|FG001|Overall Study|Death|3
5999281|NCT00004635|9593001|FG000|Period One|refused|2
5999282|NCT00004635|9593002|FG001|Period One|refused|1
5999283|NCT00004635|9593001|FG000|Period One|Withdrawal by Subject|1
5999284|NCT00004635|9593002|FG001|Period One|Withdrawal by Subject|1
6072320|NCT00560235|9675470|FG000|Phase 1|Discontinued|8
6072321|NCT00560235|9675471|FG001|Phase 1|Discontinued|0
6072322|NCT00560235|9675472|FG002|Phase 1|Discontinued|0
5999285|NCT00004635|9593001|FG000|Period One|Protocol Violation|1
5999286|NCT00004635|9593002|FG001|Period One|Protocol Violation|0
5999287|NCT00004635|9593001|FG000|Period One|PSA did not go <5 ng/mL|1
5999288|NCT00004635|9593002|FG001|Period One|PSA did not go <5 ng/mL|0
5999289|NCT00004635|9593001|FG000|Period One|second malignancy|1
5999290|NCT00004635|9593002|FG001|Period One|second malignancy|0
5999291|NCT00004635|9593001|FG000|Period One|progressed|0
5999292|NCT00004635|9593002|FG001|Period One|progressed|2
5999293|NCT00004635|9593001|FG000|Period One|health problem|0
5999294|NCT00004635|9593002|FG001|Period One|health problem|1
5999295|NCT00004635|9593001|FG000|Period One|discrepancy in data entry|0
5999296|NCT00004635|9593002|FG001|Period One|discrepancy in data entry|1
5999297|NCT00004635|9593001|FG000|Period Two|progression|2
5999298|NCT00004635|9593002|FG001|Period Two|progression|3
5999299|NCT00004635|9593001|FG000|Period Two|Adverse Event|1
5999300|NCT00004635|9593002|FG001|Period Two|Adverse Event|0
5999301|NCT00004635|9593001|FG000|Period Two|refused|0
5999302|NCT00004635|9593002|FG001|Period Two|refused|2
5999303|NCT00004635|9593001|FG000|Period Two|health problem|1
5999304|NCT00004635|9593002|FG001|Period Two|health problem|1
5999305|NCT00004635|9593001|FG000|Period Two|travel issues|0
5999306|NCT00004635|9593002|FG001|Period Two|travel issues|1
5999307|NCT00004635|9593001|FG000|Period Two|secondary malignancy|1
5999308|NCT00004635|9593002|FG001|Period Two|secondary malignancy|1
5999309|NCT00004635|9593001|FG000|Period Two|Lost to Follow-up|1
5999310|NCT00004635|9593002|FG001|Period Two|Lost to Follow-up|0
5999311|NCT00004635|9593001|FG000|Period Two|discrepancy in data entry|0
5999312|NCT00004635|9593002|FG001|Period Two|discrepancy in data entry|1
5999313|NCT00004732|9593013|FG000|Overall Study|Withdrawal by Subject|36
5999314|NCT00004732|9593014|FG001|Overall Study|Withdrawal by Subject|64
5999315|NCT00004732|9593013|FG000|Overall Study|Lost to Follow-up|33
5999316|NCT00004732|9593014|FG001|Overall Study|Lost to Follow-up|47
5999317|NCT00004859|9593024|FG000|Overall Study|Lack of Efficacy|43
5999318|NCT00004859|9593025|FG001|Overall Study|Lack of Efficacy|113
5999319|NCT00004859|9593024|FG000|Overall Study|Adverse Event|31
5999320|NCT00004859|9593025|FG001|Overall Study|Adverse Event|93
5999321|NCT00004859|9593024|FG000|Overall Study|Death|5
5999322|NCT00004859|9593025|FG001|Overall Study|Death|5
5999323|NCT00004859|9593024|FG000|Overall Study|Withdrawal by Subject|7
5999324|NCT00004859|9593025|FG001|Overall Study|Withdrawal by Subject|33
5999325|NCT00004859|9593024|FG000|Overall Study|Protocol Violation|2
5999326|NCT00004859|9593025|FG001|Overall Study|Protocol Violation|2
5999327|NCT00004859|9593024|FG000|Overall Study|other disease|0
5999328|NCT00004859|9593025|FG001|Overall Study|other disease|3
5999329|NCT00004859|9593024|FG000|Overall Study|error|3
5999330|NCT00004859|9593025|FG001|Overall Study|error|1
5999331|NCT00004859|9593024|FG000|Overall Study|missing data|14
5999332|NCT00004859|9593025|FG001|Overall Study|missing data|11
5999333|NCT00004859|9593024|FG000|Overall Study|Other|13
6072323|NCT00560235|9675470|FG000|Phase 1B|Discontinued|0
5999334|NCT00004859|9593025|FG001|Overall Study|Other|21
5999335|NCT00004888|9593035|FG000|Overall Study|Adverse Event|5
5999336|NCT00004888|9593036|FG001|Overall Study|Adverse Event|10
5999337|NCT00004888|9593035|FG000|Overall Study|Withdrawal by Subject|0
5999338|NCT00004888|9593036|FG001|Overall Study|Withdrawal by Subject|3
5999339|NCT00004888|9593035|FG000|Overall Study|Physician Decision|1
5999340|NCT00004888|9593036|FG001|Overall Study|Physician Decision|1
5999341|NCT00004888|9593035|FG000|Overall Study|Progressive Disease|4
5999342|NCT00004888|9593036|FG001|Overall Study|Progressive Disease|9
5999343|NCT00004888|9593035|FG000|Overall Study|Death without progressive disease|0
6072324|NCT00560235|9675471|FG001|Phase 1B|Discontinued|19
5999344|NCT00004888|9593036|FG001|Overall Study|Death without progressive disease|1
5999345|NCT00004888|9593035|FG000|Overall Study|Toxic death|1
5999346|NCT00004888|9593036|FG001|Overall Study|Toxic death|0
5999347|NCT00004978|9593044|FG000|Overall Study|Death|107
5999348|NCT00004978|9593045|FG001|Overall Study|Death|116
5999349|NCT00004978|9593044|FG000|Overall Study|Lost to Follow-up|101
5999350|NCT00004978|9593045|FG001|Overall Study|Lost to Follow-up|108
5999351|NCT00004978|9593044|FG000|Overall Study|Withdrawal by Subject|17
5999352|NCT00004978|9593045|FG001|Overall Study|Withdrawal by Subject|26
5999353|NCT00004978|9593044|FG000|Overall Study|site closure - not in analysis cohort|19
5999354|NCT00004978|9593045|FG001|Overall Study|site closure - not in analysis cohort|20
5999355|NCT00004980|9593053|FG000|Overall Study|Withdrawal by Subject|1
5999356|NCT00004980|9593054|FG001|Overall Study|Withdrawal by Subject|0
5999357|NCT00004980|9593053|FG000|Overall Study|memory difficulties|1
5999358|NCT00004980|9593054|FG001|Overall Study|memory difficulties|1
5999359|NCT00004980|9593053|FG000|Overall Study|Physician Decision|0
5999360|NCT00004980|9593054|FG001|Overall Study|Physician Decision|1
5999361|NCT00005044|9593062|FG000|Overall Study|Protocol Violation|37
6309496|NCT02639247|10038095|FG001|Overall Study|Withdrew Consent|1
6309497|NCT02639247|10038094|FG000|Overall Study|Protocol Violation|1
5999362|NCT00005044|9593063|FG001|Overall Study|Protocol Violation|46
5999363|NCT00005044|9593062|FG000|Overall Study|Withdrawal by Subject|1
5999364|NCT00005044|9593063|FG001|Overall Study|Withdrawal by Subject|5
5999365|NCT00005044|9593062|FG000|Overall Study|No protocol treatment|0
5999366|NCT00005044|9593063|FG001|Overall Study|No protocol treatment|1
5999367|NCT00005047|9593073|FG000|Overall Study|Withdrawal by Subject|12
5999368|NCT00005047|9593074|FG001|Overall Study|Withdrawal by Subject|0
5999369|NCT00005047|9593075|FG002|Overall Study|Withdrawal by Subject|0
5999370|NCT00005047|9593076|FG003|Overall Study|Withdrawal by Subject|0
5999371|NCT00005047|9593073|FG000|Overall Study|Adverse Event|5
5999372|NCT00005047|9593074|FG001|Overall Study|Adverse Event|0
5999373|NCT00005047|9593075|FG002|Overall Study|Adverse Event|0
5999374|NCT00005047|9593076|FG003|Overall Study|Adverse Event|0
5999375|NCT00005047|9593073|FG000|Overall Study|Lost to Follow-up|1
5999376|NCT00005047|9593074|FG001|Overall Study|Lost to Follow-up|0
5999377|NCT00005047|9593075|FG002|Overall Study|Lost to Follow-up|0
5999378|NCT00005047|9593076|FG003|Overall Study|Lost to Follow-up|0
5999379|NCT00005047|9593073|FG000|Overall Study|Lack of Efficacy|1
5999380|NCT00005047|9593074|FG001|Overall Study|Lack of Efficacy|0
5999381|NCT00005047|9593075|FG002|Overall Study|Lack of Efficacy|0
5999382|NCT00005047|9593076|FG003|Overall Study|Lack of Efficacy|0
5999383|NCT00005879|9593104|FG000|Overall Study|Withdrawal by Subject|8
5999384|NCT00005879|9593105|FG001|Overall Study|Withdrawal by Subject|10
5999385|NCT00005906|9593120|FG000|Overall Study|Lack of Efficacy|3
5999386|NCT00005908|9593124|FG000|Overall Study|Withdrawal by Subject|1
5999387|NCT00005908|9593125|FG001|Overall Study|Withdrawal by Subject|0
6072325|NCT00560235|9675472|FG002|Phase 1B|Discontinued|0
6072326|NCT00560235|9675470|FG000|Phase 2|Discontinued|0
6072327|NCT00560235|9675471|FG001|Phase 2|Discontinued|0
6072328|NCT00560235|9675472|FG002|Phase 2|Discontinued|96
6309498|NCT02639247|10038095|FG001|Overall Study|Protocol Violation|0
5999388|NCT00005937|9593134|FG000|Overall Study|Lack of Efficacy|5
5999389|NCT00005947|9593140|FG000|Overall Study|Death|54
5999390|NCT00005947|9593141|FG001|Overall Study|Death|40
5999391|NCT00005947|9593140|FG000|Overall Study|Patient Refused to Continue|2
5999392|NCT00005947|9593141|FG001|Overall Study|Patient Refused to Continue|1
5999393|NCT00005947|9593140|FG000|Overall Study|Site Closure|1
5999394|NCT00005947|9593141|FG001|Overall Study|Site Closure|0
5999395|NCT00005957|9593151|FG000|Overall Study|No treated|3
5999396|NCT00005957|9593152|FG001|Overall Study|No treated|9
5999397|NCT00005957|9593151|FG000|Overall Study|Crossover to the other arm|5
5999398|NCT00005957|9593152|FG001|Overall Study|Crossover to the other arm|19
5999399|NCT00006011|9593161|FG000|Overall Study|Disease progression|13
5999400|NCT00006011|9593162|FG001|Overall Study|Disease progression|6
5999401|NCT00006011|9593163|FG002|Overall Study|Disease progression|26
5999402|NCT00006011|9593161|FG000|Overall Study|Refused further treatment|15
5999403|NCT00006011|9593162|FG001|Overall Study|Refused further treatment|13
5999404|NCT00006011|9593163|FG002|Overall Study|Refused further treatment|26
5999405|NCT00006011|9593161|FG000|Overall Study|Adverse Event|15
5999406|NCT00006011|9593162|FG001|Overall Study|Adverse Event|39
5999407|NCT00006011|9593163|FG002|Overall Study|Adverse Event|5
5999408|NCT00006011|9593161|FG000|Overall Study|Death|0
5999409|NCT00006011|9593162|FG001|Overall Study|Death|1
5999410|NCT00006011|9593163|FG002|Overall Study|Death|2
5999411|NCT00006011|9593161|FG000|Overall Study|Other|4
5999412|NCT00006011|9593162|FG001|Overall Study|Other|2
5999413|NCT00006011|9593163|FG002|Overall Study|Other|5
5999414|NCT00006011|9593161|FG000|Overall Study|Ineligible|18
5999415|NCT00006011|9593162|FG001|Overall Study|Ineligible|16
5999416|NCT00006011|9593163|FG002|Overall Study|Ineligible|9
6072329|NCT00560235|9675470|FG000|Phase 2|Ongoing at Date of Cut-Off|0
6072330|NCT00560235|9675471|FG001|Phase 2|Ongoing at Date of Cut-Off|0
5999417|NCT00006046|9593174|FG000|Overall Study|Adverse Event|3
5999418|NCT00006046|9593175|FG001|Overall Study|Adverse Event|0
5999419|NCT00006046|9593176|FG002|Overall Study|Adverse Event|0
5999420|NCT00006046|9593177|FG003|Overall Study|Adverse Event|0
6072331|NCT00560235|9675472|FG002|Phase 2|Ongoing at Date of Cut-Off|1
6072332|NCT00560313|9675490|FG000|Overall Study|Adverse Events or Death|2
6072333|NCT00560313|9675490|FG000|Overall Study|Withdrawal by Subject|2
6072334|NCT00560313|9675490|FG000|Overall Study|Lost to Follow-up|1
5999421|NCT00006046|9593178|FG004|Overall Study|Adverse Event|0
5999422|NCT00006046|9593174|FG000|Overall Study|Disease Progression|2
5999423|NCT00006046|9593175|FG001|Overall Study|Disease Progression|0
5999424|NCT00006046|9593176|FG002|Overall Study|Disease Progression|0
5999425|NCT00006046|9593177|FG003|Overall Study|Disease Progression|0
5999426|NCT00006046|9593178|FG004|Overall Study|Disease Progression|0
5999427|NCT00006164|9593242|FG000|Overall Study|Withdrew or lost to follow-up|70
5999428|NCT00006164|9593243|FG001|Overall Study|Withdrew or lost to follow-up|81
6047114|NCT00410124|9646171|FG001|Extension Phase - Open Label (45 Months)|Abnormal Test Procedures|1
6047115|NCT00410124|9646170|FG000|Extension Phase - Open Label (45 Months)|Withdrawal by Subject|1
6047116|NCT00410124|9646171|FG001|Extension Phase - Open Label (45 Months)|Withdrawal by Subject|1
6047117|NCT00410124|9646170|FG000|Extension Phase - Open Label (45 Months)|Death|2
6047118|NCT00410124|9646171|FG001|Extension Phase - Open Label (45 Months)|Death|10
6047119|NCT00410124|9646170|FG000|Extension Phase - Open Label (45 Months)|Disease Progression|56
6047120|NCT00410124|9646171|FG001|Extension Phase - Open Label (45 Months)|Disease Progression|78
6047121|NCT00410124|9646170|FG000|Extension Phase - Open Label (45 Months)|Patient no longer required study drug|1
6047122|NCT00410124|9646171|FG001|Extension Phase - Open Label (45 Months)|Patient no longer required study drug|0
6047123|NCT00410124|9646170|FG000|Extension Phase - Open Label (45 Months)|Final Primary Analysis|0
6047124|NCT00410124|9646171|FG001|Extension Phase - Open Label (45 Months)|Final Primary Analysis|1
6047125|NCT00410163|9646192|FG000|Treatment and Follow-up Phase (2 Years)|Adverse Event|4
6047126|NCT00410163|9646193|FG001|Treatment and Follow-up Phase (2 Years)|Adverse Event|2
6047127|NCT00410163|9646192|FG000|Treatment and Follow-up Phase (2 Years)|Death|1
6047128|NCT00410163|9646193|FG001|Treatment and Follow-up Phase (2 Years)|Death|1
6047129|NCT00410163|9646192|FG000|Treatment and Follow-up Phase (2 Years)|Withdrawal by Subject|2
6047130|NCT00410163|9646193|FG001|Treatment and Follow-up Phase (2 Years)|Withdrawal by Subject|1
6047131|NCT00410163|9646192|FG000|Treatment and Follow-up Phase (2 Years)|Lack of Efficacy|0
6047132|NCT00410163|9646193|FG001|Treatment and Follow-up Phase (2 Years)|Lack of Efficacy|4
6047133|NCT00410163|9646192|FG000|Treatment and Follow-up Phase (2 Years)|Participant Had No Response|2
6047134|NCT00410163|9646193|FG001|Treatment and Follow-up Phase (2 Years)|Participant Had No Response|1
6047135|NCT00410163|9646192|FG000|Treatment and Follow-up Phase (2 Years)|Participant Had Stable Disease|1
6047136|NCT00410163|9646193|FG001|Treatment and Follow-up Phase (2 Years)|Participant Had Stable Disease|0
6047137|NCT00410163|9646192|FG000|Treatment and Follow-up Phase (2 Years)|Participant Received New Therapy|1
6047138|NCT00410163|9646193|FG001|Treatment and Follow-up Phase (2 Years)|Participant Received New Therapy|1
6047139|NCT00410163|9646192|FG000|Treatment and Follow-up Phase (2 Years)|Participant Had Bone Marrow Transplant|1
6047140|NCT00410163|9646193|FG001|Treatment and Follow-up Phase (2 Years)|Participant Had Bone Marrow Transplant|0
6047141|NCT00410163|9646192|FG000|Treatment and Follow-up Phase (2 Years)|Investigator Decision|0
6047142|NCT00410163|9646193|FG001|Treatment and Follow-up Phase (2 Years)|Investigator Decision|1
6047143|NCT00410163|9646192|FG000|Extended Follow-up (FU) Phase (2-5 Years|Lost to Follow-up|3
6047144|NCT00410163|9646193|FG001|Extended Follow-up (FU) Phase (2-5 Years|Lost to Follow-up|1
6047145|NCT00410163|9646192|FG000|Extended Follow-up (FU) Phase (2-5 Years|Death|1
6047146|NCT00410163|9646193|FG001|Extended Follow-up (FU) Phase (2-5 Years|Death|1
6047147|NCT00410163|9646192|FG000|Extended Follow-up (FU) Phase (2-5 Years|Medical Reasons|1
6047148|NCT00410163|9646193|FG001|Extended Follow-up (FU) Phase (2-5 Years|Medical Reasons|0
6047149|NCT00410163|9646192|FG000|Extended Follow-up (FU) Phase (2-5 Years|New Anti-CLL Treatment|4
6047150|NCT00410163|9646193|FG001|Extended Follow-up (FU) Phase (2-5 Years|New Anti-CLL Treatment|8
6047151|NCT00410163|9646192|FG000|Extended Follow-up (FU) Phase (2-5 Years|Secondary Acute Myeloid Leukemia|1
6047152|NCT00410163|9646193|FG001|Extended Follow-up (FU) Phase (2-5 Years|Secondary Acute Myeloid Leukemia|0
6047153|NCT00410202|9646210|FG000|On-Treatment|Continuing treatment|69
6047154|NCT00410202|9646211|FG001|On-Treatment|Continuing treatment|71
6047155|NCT00410202|9646212|FG002|On-Treatment|Continuing treatment|66
6047156|NCT00410202|9646210|FG000|On-Treatment|Adverse Event|1
6072335|NCT00560313|9675490|FG000|Overall Study|Protocol Violation|1
6072336|NCT00560352|9675512|FG000|Overall Study|Adverse event unrelated to study drug|2
6072337|NCT00560352|9675513|FG001|Overall Study|Adverse event unrelated to study drug|1
6072338|NCT00560352|9675514|FG002|Overall Study|Adverse event unrelated to study drug|1
6072339|NCT00560352|9675512|FG000|Overall Study|Study drug toxicity|3
6072340|NCT00560352|9675513|FG001|Overall Study|Study drug toxicity|0
6072341|NCT00560352|9675514|FG002|Overall Study|Study drug toxicity|1
6072342|NCT00560352|9675512|FG000|Overall Study|Disease progression|0
6072343|NCT00560352|9675513|FG001|Overall Study|Disease progression|1
6072344|NCT00560352|9675514|FG002|Overall Study|Disease progression|1
6072345|NCT00560352|9675512|FG000|Overall Study|Withdrawal by Subject|1
6072346|NCT00560352|9675513|FG001|Overall Study|Withdrawal by Subject|1
6072347|NCT00560352|9675514|FG002|Overall Study|Withdrawal by Subject|1
6072348|NCT00560352|9675512|FG000|Overall Study|Maximum clinical benefit|1
6072349|NCT00560352|9675513|FG001|Overall Study|Maximum clinical benefit|0
6072350|NCT00560352|9675514|FG002|Overall Study|Maximum clinical benefit|0
6072351|NCT00560391|9675531|FG000|Overall Study|Still on treatment|0
6072352|NCT00560391|9675532|FG001|Overall Study|Still on treatment|0
5999429|NCT04323800|9593268|FG000|Overall Study|Withdrawal by Subject|4
5999430|NCT04323800|9593269|FG001|Overall Study|Withdrawal by Subject|4
6072353|NCT00560391|9675533|FG002|Overall Study|Still on treatment|0
6072354|NCT00560391|9675534|FG003|Overall Study|Still on treatment|1
6072355|NCT00560391|9675535|FG004|Overall Study|Still on treatment|2
6072356|NCT00560404|9675550|FG000|Overall Study|Adverse Event|2
5999431|NCT04323800|9593268|FG000|Overall Study|Incomplete transfusion|1
5999432|NCT04323800|9593269|FG001|Overall Study|Incomplete transfusion|0
5999433|NCT04323800|9593268|FG000|Overall Study|Other|0
5999434|NCT04323800|9593269|FG001|Overall Study|Other|1
5999435|NCT04323800|9593268|FG000|Overall Study|Positive RT-PCR at transfusion|1
5999436|NCT04323800|9593269|FG001|Overall Study|Positive RT-PCR at transfusion|1
5999488|NCT03447314|9593358|FG000|Part 1 (Up to 27 Months)|Death|6
5999489|NCT03447314|9593359|FG001|Part 1 (Up to 27 Months)|Death|5
6072357|NCT00560404|9675551|FG001|Overall Study|Adverse Event|3
6072358|NCT00560404|9675550|FG000|Overall Study|Death|3
6072359|NCT00560404|9675551|FG001|Overall Study|Death|3
5999490|NCT03447314|9593360|FG002|Part 1 (Up to 27 Months)|Death|3
5999491|NCT03447314|9593361|FG003|Part 1 (Up to 27 Months)|Death|3
5999492|NCT03447314|9593362|FG004|Part 1 (Up to 27 Months)|Death|0
5999493|NCT03447314|9593363|FG005|Part 1 (Up to 27 Months)|Death|4
5999494|NCT03447314|9593364|FG006|Part 1 (Up to 27 Months)|Death|3
5999495|NCT03447314|9593365|FG007|Part 1 (Up to 27 Months)|Death|0
5999496|NCT03447314|9593366|FG008|Part 1 (Up to 27 Months)|Death|0
5999497|NCT03447314|9593367|FG009|Part 1 (Up to 27 Months)|Death|0
5999498|NCT03447314|9593368|FG010|Part 1 (Up to 27 Months)|Death|4
5999499|NCT03447314|9593369|FG011|Part 1 (Up to 27 Months)|Death|2
5999500|NCT03447314|9593370|FG012|Part 1 (Up to 27 Months)|Death|0
5999501|NCT03447314|9593371|FG013|Part 1 (Up to 27 Months)|Death|0
5999502|NCT03447314|9593372|FG014|Part 1 (Up to 27 Months)|Death|0
5999503|NCT03447314|9593373|FG015|Part 1 (Up to 27 Months)|Death|0
5999504|NCT03447314|9593374|FG016|Part 1 (Up to 27 Months)|Death|0
5999505|NCT03447314|9593375|FG017|Part 1 (Up to 27 Months)|Death|0
5999506|NCT03447314|9593358|FG000|Part 1 (Up to 27 Months)|Ongoing in the study|2
5999507|NCT03447314|9593359|FG001|Part 1 (Up to 27 Months)|Ongoing in the study|1
5999508|NCT03447314|9593360|FG002|Part 1 (Up to 27 Months)|Ongoing in the study|3
5999509|NCT03447314|9593361|FG003|Part 1 (Up to 27 Months)|Ongoing in the study|1
5999510|NCT03447314|9593362|FG004|Part 1 (Up to 27 Months)|Ongoing in the study|2
5999511|NCT03447314|9593363|FG005|Part 1 (Up to 27 Months)|Ongoing in the study|1
5999512|NCT03447314|9593364|FG006|Part 1 (Up to 27 Months)|Ongoing in the study|2
5999513|NCT03447314|9593365|FG007|Part 1 (Up to 27 Months)|Ongoing in the study|0
5999514|NCT03447314|9593366|FG008|Part 1 (Up to 27 Months)|Ongoing in the study|0
5999515|NCT03447314|9593367|FG009|Part 1 (Up to 27 Months)|Ongoing in the study|0
5999516|NCT03447314|9593368|FG010|Part 1 (Up to 27 Months)|Ongoing in the study|3
5999517|NCT03447314|9593369|FG011|Part 1 (Up to 27 Months)|Ongoing in the study|4
5999518|NCT03447314|9593370|FG012|Part 1 (Up to 27 Months)|Ongoing in the study|0
5999519|NCT03447314|9593371|FG013|Part 1 (Up to 27 Months)|Ongoing in the study|0
5999520|NCT03447314|9593372|FG014|Part 1 (Up to 27 Months)|Ongoing in the study|0
5999521|NCT03447314|9593373|FG015|Part 1 (Up to 27 Months)|Ongoing in the study|0
5999522|NCT03447314|9593374|FG016|Part 1 (Up to 27 Months)|Ongoing in the study|0
5999523|NCT03447314|9593375|FG017|Part 1 (Up to 27 Months)|Ongoing in the study|0
5999524|NCT03447314|9593358|FG000|Part 1 (Up to 27 Months)|Withdrawal by Subject|1
5999525|NCT03447314|9593359|FG001|Part 1 (Up to 27 Months)|Withdrawal by Subject|0
5999526|NCT03447314|9593360|FG002|Part 1 (Up to 27 Months)|Withdrawal by Subject|1
5999527|NCT03447314|9593361|FG003|Part 1 (Up to 27 Months)|Withdrawal by Subject|0
5999528|NCT03447314|9593362|FG004|Part 1 (Up to 27 Months)|Withdrawal by Subject|0
5999529|NCT03447314|9593363|FG005|Part 1 (Up to 27 Months)|Withdrawal by Subject|1
5999530|NCT03447314|9593364|FG006|Part 1 (Up to 27 Months)|Withdrawal by Subject|0
5999531|NCT03447314|9593365|FG007|Part 1 (Up to 27 Months)|Withdrawal by Subject|0
5999532|NCT03447314|9593366|FG008|Part 1 (Up to 27 Months)|Withdrawal by Subject|0
5999533|NCT03447314|9593367|FG009|Part 1 (Up to 27 Months)|Withdrawal by Subject|0
5999534|NCT03447314|9593368|FG010|Part 1 (Up to 27 Months)|Withdrawal by Subject|0
5999535|NCT03447314|9593369|FG011|Part 1 (Up to 27 Months)|Withdrawal by Subject|0
5999536|NCT03447314|9593370|FG012|Part 1 (Up to 27 Months)|Withdrawal by Subject|0
5999537|NCT03447314|9593371|FG013|Part 1 (Up to 27 Months)|Withdrawal by Subject|0
5999538|NCT03447314|9593372|FG014|Part 1 (Up to 27 Months)|Withdrawal by Subject|0
5999539|NCT03447314|9593373|FG015|Part 1 (Up to 27 Months)|Withdrawal by Subject|0
5999540|NCT03447314|9593374|FG016|Part 1 (Up to 27 Months)|Withdrawal by Subject|0
5999541|NCT03447314|9593375|FG017|Part 1 (Up to 27 Months)|Withdrawal by Subject|0
5999542|NCT03447314|9593358|FG000|Part 1 (Up to 27 Months)|Disease progression|0
5999543|NCT03447314|9593359|FG001|Part 1 (Up to 27 Months)|Disease progression|0
5999544|NCT03447314|9593360|FG002|Part 1 (Up to 27 Months)|Disease progression|1
5999545|NCT03447314|9593361|FG003|Part 1 (Up to 27 Months)|Disease progression|0
5999546|NCT03447314|9593362|FG004|Part 1 (Up to 27 Months)|Disease progression|0
5999547|NCT03447314|9593363|FG005|Part 1 (Up to 27 Months)|Disease progression|0
5999548|NCT03447314|9593364|FG006|Part 1 (Up to 27 Months)|Disease progression|0
5999549|NCT03447314|9593365|FG007|Part 1 (Up to 27 Months)|Disease progression|0
6072360|NCT00560404|9675550|FG000|Overall Study|Protocol Violation|12
6072361|NCT00560404|9675551|FG001|Overall Study|Protocol Violation|7
6072362|NCT00560404|9675550|FG000|Overall Study|Administrative Reasons|1
6072363|NCT00560404|9675551|FG001|Overall Study|Administrative Reasons|1
5999437|NCT04110145|9593289|FG000|Double-Blind Treatment Period (4 Weeks)|Site Terminated by the Sponsor|0
5999438|NCT04110145|9593290|FG001|Double-Blind Treatment Period (4 Weeks)|Site Terminated by the Sponsor|0
5999439|NCT04110145|9593291|FG002|Double-Blind Treatment Period (4 Weeks)|Site Terminated by the Sponsor|0
5999440|NCT04110145|9593292|FG003|Double-Blind Treatment Period (4 Weeks)|Site Terminated by the Sponsor|1
5999441|NCT04110145|9593293|FG004|Double-Blind Treatment Period (4 Weeks)|Site Terminated by the Sponsor|0
5999442|NCT03986866|9593307|FG000|Overall Study|Withdrawal by Subject|0
5999443|NCT03986866|9593308|FG001|Overall Study|Withdrawal by Subject|3
6072364|NCT00560404|9675550|FG000|Overall Study|Withdrew Consent|4
5999444|NCT03986866|9593307|FG000|Overall Study|patient required admission so no longer fit study exclusion criteria of ambulatory surgery|2
5999445|NCT03986866|9593308|FG001|Overall Study|patient required admission so no longer fit study exclusion criteria of ambulatory surgery|2
5999446|NCT03636269|9593316|FG000|Period 1: Double-blind Phase|Adverse Event|13
5999447|NCT03636269|9593317|FG001|Period 1: Double-blind Phase|Adverse Event|7
5999448|NCT03636269|9593318|FG002|Period 1: Double-blind Phase|Adverse Event|0
5999449|NCT03636269|9593316|FG000|Period 1: Double-blind Phase|Lack of Efficacy|1
5999450|NCT03636269|9593317|FG001|Period 1: Double-blind Phase|Lack of Efficacy|0
5999451|NCT03636269|9593318|FG002|Period 1: Double-blind Phase|Lack of Efficacy|0
5999452|NCT03636269|9593316|FG000|Period 1: Double-blind Phase|Eligibility (inclusion/exclusion criteria)|2
5999453|NCT03636269|9593317|FG001|Period 1: Double-blind Phase|Eligibility (inclusion/exclusion criteria)|0
5999454|NCT03636269|9593318|FG002|Period 1: Double-blind Phase|Eligibility (inclusion/exclusion criteria)|0
5999455|NCT03636269|9593316|FG000|Period 1: Double-blind Phase|Withdrawal by Subject|5
5999456|NCT03636269|9593317|FG001|Period 1: Double-blind Phase|Withdrawal by Subject|1
5999457|NCT03636269|9593318|FG002|Period 1: Double-blind Phase|Withdrawal by Subject|0
5999458|NCT03636269|9593316|FG000|Period 1: Double-blind Phase|Other|6
5999459|NCT03636269|9593317|FG001|Period 1: Double-blind Phase|Other|3
5999460|NCT03636269|9593318|FG002|Period 1: Double-blind Phase|Other|0
5999461|NCT03636269|9593316|FG000|Period 1: Double-blind Phase|Lost to Follow-up|1
5999462|NCT03636269|9593317|FG001|Period 1: Double-blind Phase|Lost to Follow-up|0
5999463|NCT03636269|9593318|FG002|Period 1: Double-blind Phase|Lost to Follow-up|0
5999464|NCT03636269|9593316|FG000|Period 1: Double-blind Phase|Subject non-compliance|1
5999465|NCT03636269|9593317|FG001|Period 1: Double-blind Phase|Subject non-compliance|2
5999466|NCT03636269|9593318|FG002|Period 1: Double-blind Phase|Subject non-compliance|0
5999467|NCT03636269|9593316|FG000|Period 2: Open-label Phase|Adverse Event|0
5999468|NCT03636269|9593317|FG001|Period 2: Open-label Phase|Adverse Event|0
5999469|NCT03636269|9593318|FG002|Period 2: Open-label Phase|Adverse Event|21
5999470|NCT03636269|9593316|FG000|Period 2: Open-label Phase|Lack of Efficacy|0
5999471|NCT03636269|9593317|FG001|Period 2: Open-label Phase|Lack of Efficacy|0
5999472|NCT03636269|9593318|FG002|Period 2: Open-label Phase|Lack of Efficacy|2
5999473|NCT03636269|9593316|FG000|Period 2: Open-label Phase|Eligibility (inclusion/exclusion criteria)|0
5999474|NCT03636269|9593317|FG001|Period 2: Open-label Phase|Eligibility (inclusion/exclusion criteria)|0
5999475|NCT03636269|9593318|FG002|Period 2: Open-label Phase|Eligibility (inclusion/exclusion criteria)|2
5999476|NCT03636269|9593316|FG000|Period 2: Open-label Phase|Withdrawal by Subject|0
5999477|NCT03636269|9593317|FG001|Period 2: Open-label Phase|Withdrawal by Subject|0
5999478|NCT03636269|9593318|FG002|Period 2: Open-label Phase|Withdrawal by Subject|11
5999479|NCT03636269|9593316|FG000|Period 2: Open-label Phase|Administrative|0
5999480|NCT03636269|9593317|FG001|Period 2: Open-label Phase|Administrative|0
5999481|NCT03636269|9593318|FG002|Period 2: Open-label Phase|Administrative|36
5999482|NCT03636269|9593316|FG000|Period 2: Open-label Phase|Other|0
5999483|NCT03636269|9593317|FG001|Period 2: Open-label Phase|Other|0
5999484|NCT03636269|9593318|FG002|Period 2: Open-label Phase|Other|9
5999485|NCT03636269|9593316|FG000|Period 2: Open-label Phase|Sponsor stopping study|0
5999486|NCT03636269|9593317|FG001|Period 2: Open-label Phase|Sponsor stopping study|0
5999487|NCT03636269|9593318|FG002|Period 2: Open-label Phase|Sponsor stopping study|313
5999550|NCT03447314|9593366|FG008|Part 1 (Up to 27 Months)|Disease progression|0
5999551|NCT03447314|9593367|FG009|Part 1 (Up to 27 Months)|Disease progression|0
5999552|NCT03447314|9593368|FG010|Part 1 (Up to 27 Months)|Disease progression|0
5999553|NCT03447314|9593369|FG011|Part 1 (Up to 27 Months)|Disease progression|0
5999554|NCT03447314|9593370|FG012|Part 1 (Up to 27 Months)|Disease progression|0
5999555|NCT03447314|9593371|FG013|Part 1 (Up to 27 Months)|Disease progression|0
5999556|NCT03447314|9593372|FG014|Part 1 (Up to 27 Months)|Disease progression|0
5999557|NCT03447314|9593373|FG015|Part 1 (Up to 27 Months)|Disease progression|0
5999558|NCT03447314|9593374|FG016|Part 1 (Up to 27 Months)|Disease progression|0
5999559|NCT03447314|9593375|FG017|Part 1 (Up to 27 Months)|Disease progression|0
5999560|NCT03447314|9593358|FG000|Part 1 (Up to 27 Months)|Lost to Follow-up|0
5999561|NCT03447314|9593359|FG001|Part 1 (Up to 27 Months)|Lost to Follow-up|0
5999562|NCT03447314|9593360|FG002|Part 1 (Up to 27 Months)|Lost to Follow-up|1
5999563|NCT03447314|9593361|FG003|Part 1 (Up to 27 Months)|Lost to Follow-up|0
5999564|NCT03447314|9593362|FG004|Part 1 (Up to 27 Months)|Lost to Follow-up|0
5999565|NCT03447314|9593363|FG005|Part 1 (Up to 27 Months)|Lost to Follow-up|0
5999566|NCT03447314|9593364|FG006|Part 1 (Up to 27 Months)|Lost to Follow-up|0
6072365|NCT00560404|9675551|FG001|Overall Study|Withdrew Consent|0
6072366|NCT00560404|9675550|FG000|Overall Study|Failure to return|1
5999567|NCT03447314|9593365|FG007|Part 1 (Up to 27 Months)|Lost to Follow-up|0
5999568|NCT03447314|9593366|FG008|Part 1 (Up to 27 Months)|Lost to Follow-up|0
5999569|NCT03447314|9593367|FG009|Part 1 (Up to 27 Months)|Lost to Follow-up|0
5999570|NCT03447314|9593368|FG010|Part 1 (Up to 27 Months)|Lost to Follow-up|0
5999571|NCT03447314|9593369|FG011|Part 1 (Up to 27 Months)|Lost to Follow-up|0
5999572|NCT03447314|9593370|FG012|Part 1 (Up to 27 Months)|Lost to Follow-up|0
5999573|NCT03447314|9593371|FG013|Part 1 (Up to 27 Months)|Lost to Follow-up|0
5999574|NCT03447314|9593372|FG014|Part 1 (Up to 27 Months)|Lost to Follow-up|0
5999575|NCT03447314|9593373|FG015|Part 1 (Up to 27 Months)|Lost to Follow-up|0
5999576|NCT03447314|9593374|FG016|Part 1 (Up to 27 Months)|Lost to Follow-up|0
5999577|NCT03447314|9593375|FG017|Part 1 (Up to 27 Months)|Lost to Follow-up|0
5999578|NCT03320330|9593432|FG000|Overall Study|Lack of Efficacy|5
5999579|NCT03320330|9593433|FG001|Overall Study|Lack of Efficacy|5
5999580|NCT03320330|9593434|FG002|Overall Study|Lack of Efficacy|14
5999581|NCT03320330|9593432|FG000|Overall Study|Physician Decision|1
5999582|NCT03320330|9593433|FG001|Overall Study|Physician Decision|0
5999583|NCT03320330|9593434|FG002|Overall Study|Physician Decision|0
5999584|NCT03271151|9593445|FG000|Overall Study|Lost to Follow-up|1
5999585|NCT03271151|9593446|FG001|Overall Study|Lost to Follow-up|3
5999586|NCT03271151|9593445|FG000|Overall Study|Withdrawal by Subject|1
5999587|NCT03271151|9593446|FG001|Overall Study|Withdrawal by Subject|0
5999588|NCT03141177|9593455|FG000|Overall Study|Death|62
5999589|NCT03141177|9593456|FG001|Overall Study|Death|13
5999590|NCT03141177|9593457|FG002|Overall Study|Death|84
5999591|NCT03141177|9593455|FG000|Overall Study|Participant withdrew consent|9
5999592|NCT03141177|9593456|FG001|Overall Study|Participant withdrew consent|2
5999593|NCT03141177|9593457|FG002|Overall Study|Participant withdrew consent|13
5999594|NCT03141177|9593455|FG000|Overall Study|Not reported|1
5999595|NCT03141177|9593456|FG001|Overall Study|Not reported|0
5999596|NCT03141177|9593457|FG002|Overall Study|Not reported|1
5999597|NCT03141177|9593455|FG000|Overall Study|Lost to Follow-up|2
5999598|NCT03141177|9593456|FG001|Overall Study|Lost to Follow-up|1
5999599|NCT03141177|9593457|FG002|Overall Study|Lost to Follow-up|1
5999600|NCT03141177|9593455|FG000|Overall Study|Other reasons|4
5999601|NCT03141177|9593456|FG001|Overall Study|Other reasons|0
6072367|NCT00560404|9675551|FG001|Overall Study|Failure to return|2
6072368|NCT00560404|9675550|FG000|Overall Study|Other withdrawal reason|13
6072369|NCT00560404|9675551|FG001|Overall Study|Other withdrawal reason|5
6072370|NCT00560417|9675559|FG000|Overall Study|Adverse Event|3
6072371|NCT00560417|9675560|FG001|Overall Study|Adverse Event|2
6072372|NCT00560417|9675559|FG000|Overall Study|Entry Criteria Not Met|1
5999602|NCT03141177|9593457|FG002|Overall Study|Other reasons|11
5999603|NCT03141177|9593455|FG000|Overall Study|Participants did not start treatment period|3
5999604|NCT03141177|9593456|FG001|Overall Study|Participants did not start treatment period|0
5999605|NCT03141177|9593457|FG002|Overall Study|Participants did not start treatment period|8
5999606|NCT03117049|9593468|FG000|Overall Study|Continued the follow-up period|109
5999607|NCT03117049|9593469|FG001|Overall Study|Continued the follow-up period|129
5999608|NCT03117049|9593468|FG000|Overall Study|Died|82
5999609|NCT03117049|9593469|FG001|Overall Study|Died|93
5999610|NCT03117049|9593468|FG000|Overall Study|Consent withdrawal|7
5999611|NCT03117049|9593469|FG001|Overall Study|Consent withdrawal|6
5999612|NCT03117049|9593468|FG000|Overall Study|Missing contact|3
5999613|NCT03117049|9593469|FG001|Overall Study|Missing contact|3
5999614|NCT03023813|9593478|FG000|Overall Study|Lost to Follow-up|1
5999615|NCT03023813|9593479|FG001|Overall Study|Lost to Follow-up|2
5999616|NCT03023813|9593480|FG002|Overall Study|Lost to Follow-up|0
5999617|NCT02993822|9593493|FG000|Overall Study|Lack of Efficacy|1
5999618|NCT02993822|9593494|FG001|Overall Study|Lack of Efficacy|1
5999619|NCT02993822|9593495|FG002|Overall Study|Lack of Efficacy|0
5999620|NCT02993822|9593496|FG003|Overall Study|Lack of Efficacy|0
5999621|NCT02993822|9593493|FG000|Overall Study|Protocol Violation|1
5999622|NCT02993822|9593494|FG001|Overall Study|Protocol Violation|0
5999623|NCT02993822|9593495|FG002|Overall Study|Protocol Violation|0
5999624|NCT02993822|9593496|FG003|Overall Study|Protocol Violation|0
5999625|NCT02993822|9593493|FG000|Overall Study|Unable to attend follow-up due to illness|0
5999626|NCT02993822|9593494|FG001|Overall Study|Unable to attend follow-up due to illness|0
5999627|NCT02993822|9593495|FG002|Overall Study|Unable to attend follow-up due to illness|0
5999628|NCT02993822|9593496|FG003|Overall Study|Unable to attend follow-up due to illness|1
5999629|NCT02993822|9593493|FG000|Overall Study|Adverse Event|3
5999630|NCT02993822|9593494|FG001|Overall Study|Adverse Event|1
5999631|NCT02993822|9593495|FG002|Overall Study|Adverse Event|7
5999632|NCT02993822|9593496|FG003|Overall Study|Adverse Event|0
5999633|NCT02993822|9593493|FG000|Overall Study|Withdrawal by Subject|4
5999634|NCT02993822|9593494|FG001|Overall Study|Withdrawal by Subject|2
5999635|NCT02993822|9593495|FG002|Overall Study|Withdrawal by Subject|2
5999636|NCT02993822|9593496|FG003|Overall Study|Withdrawal by Subject|3
5999637|NCT02993822|9593493|FG000|Overall Study|Lost to Follow-up|1
5999638|NCT02993822|9593494|FG001|Overall Study|Lost to Follow-up|0
5999639|NCT02993822|9593495|FG002|Overall Study|Lost to Follow-up|1
6072373|NCT00560417|9675560|FG001|Overall Study|Entry Criteria Not Met|0
5999640|NCT02993822|9593496|FG003|Overall Study|Lost to Follow-up|0
5999641|NCT02753127|9593521|FG000|Overall Study|Lost to Follow-up|13
6072374|NCT00560417|9675559|FG000|Overall Study|Lost to Follow-up|0
5999642|NCT02753127|9593522|FG001|Overall Study|Lost to Follow-up|11
5999643|NCT02753127|9593521|FG000|Overall Study|Withdrawal by Subject|37
5999644|NCT02753127|9593522|FG001|Overall Study|Withdrawal by Subject|47
5999645|NCT02753127|9593521|FG000|Overall Study|Other|3
5999646|NCT02753127|9593522|FG001|Overall Study|Other|8
5999647|NCT02753127|9593521|FG000|Overall Study|Hospice|0
5999648|NCT02753127|9593522|FG001|Overall Study|Hospice|2
5999649|NCT02460198|9593547|FG000|Overall Study|Adverse Event|1
5999650|NCT02460198|9593548|FG001|Overall Study|Adverse Event|3
5999651|NCT02460198|9593547|FG000|Overall Study|Death|36
5999652|NCT02460198|9593548|FG001|Overall Study|Death|28
5999653|NCT02460198|9593547|FG000|Overall Study|Lost to Follow-up|1
5999654|NCT02460198|9593548|FG001|Overall Study|Lost to Follow-up|1
5999655|NCT02460198|9593547|FG000|Overall Study|Transferred to Extension Study|15
5999656|NCT02460198|9593548|FG001|Overall Study|Transferred to Extension Study|15
5999657|NCT02460198|9593547|FG000|Overall Study|Withdrawal by Subject|2
5999658|NCT02460198|9593548|FG001|Overall Study|Withdrawal by Subject|4
5999659|NCT02460198|9593547|FG000|Overall Study|Site Terminated By Sponsor|0
5999660|NCT02460198|9593548|FG001|Overall Study|Site Terminated By Sponsor|1
5999661|NCT02460198|9593547|FG000|Overall Study|Did Not Continue on Extension Study|6
5999662|NCT02460198|9593548|FG001|Overall Study|Did Not Continue on Extension Study|11
5999663|NCT01892722|9593612|FG000|Overall Study|Protocol deviation|0
5999664|NCT01892722|9593613|FG001|Overall Study|Protocol deviation|1
5999665|NCT01892722|9593612|FG000|Overall Study|Administrative problems|0
5999666|NCT01892722|9593613|FG001|Overall Study|Administrative problems|1
5999667|NCT01892722|9593612|FG000|Overall Study|Patient/guardian decision|0
5999668|NCT01892722|9593613|FG001|Overall Study|Patient/guardian decision|2
5999669|NCT01892722|9593612|FG000|Overall Study|Physician Decision|1
5999670|NCT01892722|9593613|FG001|Overall Study|Physician Decision|2
5999671|NCT01892722|9593612|FG000|Overall Study|Adverse Event|3
5999672|NCT01892722|9593613|FG001|Overall Study|Adverse Event|2
5999673|NCT01892722|9593612|FG000|Overall Study|Lack of Efficacy|0
5999674|NCT01892722|9593613|FG001|Overall Study|Lack of Efficacy|7
5999675|NCT01892722|9593612|FG000|Overall Study|Withdrawal by Subject|3
5999676|NCT01892722|9593613|FG001|Overall Study|Withdrawal by Subject|5
6047157|NCT00410202|9646211|FG001|On-Treatment|Adverse Event|3
6047158|NCT00410202|9646212|FG002|On-Treatment|Adverse Event|2
6047159|NCT00410202|9646210|FG000|On-Treatment|Death|1
6047160|NCT00410202|9646211|FG001|On-Treatment|Death|0
6047161|NCT00410202|9646212|FG002|On-Treatment|Death|0
6047162|NCT00410202|9646210|FG000|On-Treatment|Lost to Follow-up|1
6047163|NCT00410202|9646211|FG001|On-Treatment|Lost to Follow-up|0
6047164|NCT00410202|9646212|FG002|On-Treatment|Lost to Follow-up|1
6047165|NCT00410202|9646210|FG000|On-Treatment|Lack of Efficacy|1
6047166|NCT00410202|9646211|FG001|On-Treatment|Lack of Efficacy|4
6047167|NCT00410202|9646212|FG002|On-Treatment|Lack of Efficacy|0
6047168|NCT00410202|9646210|FG000|On-Treatment|Withdrawal by Subject|2
6047169|NCT00410202|9646211|FG001|On-Treatment|Withdrawal by Subject|1
6047170|NCT00410202|9646212|FG002|On-Treatment|Withdrawal by Subject|1
6047171|NCT00410202|9646210|FG000|On-Treatment|Other Reason|0
6047172|NCT00410202|9646211|FG001|On-Treatment|Other Reason|0
6047173|NCT00410202|9646212|FG002|On-Treatment|Other Reason|1
6047174|NCT00410202|9646210|FG000|Off-treatment Follow up|Continuing off-treatment follow up|10
6047175|NCT00410202|9646211|FG001|Off-treatment Follow up|Continuing off-treatment follow up|8
6047176|NCT00410202|9646212|FG002|Off-treatment Follow up|Continuing off-treatment follow up|11
6047177|NCT00410202|9646210|FG000|Off-treatment Follow up|Follow up not required per protocol|3
6047178|NCT00410202|9646211|FG001|Off-treatment Follow up|Follow up not required per protocol|0
6047179|NCT00410202|9646212|FG002|Off-treatment Follow up|Follow up not required per protocol|1
6047180|NCT00410202|9646210|FG000|Off-treatment Follow up|Lost to Follow-up|1
6047181|NCT00410202|9646211|FG001|Off-treatment Follow up|Lost to Follow-up|0
6047182|NCT00410202|9646212|FG002|Off-treatment Follow up|Lost to Follow-up|0
6047183|NCT00410384|9646233|FG000|Overall Study|Withdrawal by Subject|28
6047184|NCT00410384|9646234|FG001|Overall Study|Withdrawal by Subject|17
6047185|NCT00410384|9646235|FG002|Overall Study|Withdrawal by Subject|20
6047186|NCT00410384|9646233|FG000|Overall Study|Adverse Event|23
6047187|NCT00410384|9646234|FG001|Overall Study|Adverse Event|18
6047188|NCT00410384|9646235|FG002|Overall Study|Adverse Event|23
6047189|NCT00410384|9646233|FG000|Overall Study|Lack of Efficacy|20
6047190|NCT00410384|9646234|FG001|Overall Study|Lack of Efficacy|12
6047191|NCT00410384|9646235|FG002|Overall Study|Lack of Efficacy|17
6047192|NCT00410384|9646233|FG000|Overall Study|Lack of Compliance|2
6047193|NCT00410384|9646234|FG001|Overall Study|Lack of Compliance|2
6047194|NCT00410384|9646235|FG002|Overall Study|Lack of Compliance|2
6047195|NCT00410384|9646233|FG000|Overall Study|Lost to Follow-up|4
6047196|NCT00410384|9646234|FG001|Overall Study|Lost to Follow-up|6
6047197|NCT00410384|9646235|FG002|Overall Study|Lost to Follow-up|6
6047198|NCT00410384|9646233|FG000|Overall Study|Protocol Violation|6
6047199|NCT00410384|9646234|FG001|Overall Study|Protocol Violation|6
6047200|NCT00410384|9646235|FG002|Overall Study|Protocol Violation|6
6047201|NCT00410384|9646233|FG000|Overall Study|Physician Decision|3
6047202|NCT00410384|9646234|FG001|Overall Study|Physician Decision|3
6047203|NCT00410384|9646235|FG002|Overall Study|Physician Decision|4
6047204|NCT00410384|9646233|FG000|Overall Study|Other|3
6047205|NCT00410384|9646234|FG001|Overall Study|Other|8
6047206|NCT00410384|9646235|FG002|Overall Study|Other|4
5999677|NCT01516216|9593621|FG000|Overall Study|Adverse Event|2
5999678|NCT01516216|9593622|FG001|Overall Study|Adverse Event|4
5999679|NCT01516216|9593621|FG000|Overall Study|Disease Progression|38
5999680|NCT01516216|9593622|FG001|Overall Study|Disease Progression|34
5999681|NCT01516216|9593621|FG000|Overall Study|Withdrawal by Subject|9
5999682|NCT01516216|9593622|FG001|Overall Study|Withdrawal by Subject|11
5999683|NCT01516216|9593621|FG000|Overall Study|Potentially Curative Resection|6
5999684|NCT01516216|9593622|FG001|Overall Study|Potentially Curative Resection|12
5999685|NCT01516216|9593621|FG000|Overall Study|Nonadherence|2
5999686|NCT01516216|9593622|FG001|Overall Study|Nonadherence|3
5999687|NCT01516216|9593621|FG000|Overall Study|Physician Decision|6
5999688|NCT01516216|9593622|FG001|Overall Study|Physician Decision|3
5999689|NCT01516216|9593621|FG000|Overall Study|Prolonged Treatment Delay|5
5999690|NCT01516216|9593622|FG001|Overall Study|Prolonged Treatment Delay|1
5999691|NCT01516216|9593621|FG000|Overall Study|Intercurrent Illness|1
5999692|NCT01516216|9593622|FG001|Overall Study|Intercurrent Illness|0
5999693|NCT01516216|9593621|FG000|Overall Study|Death|1
5999694|NCT01516216|9593622|FG001|Overall Study|Death|1
5999695|NCT00381641|9593638|FG000|Overall Study|Withdrawal by Subject|0
5999696|NCT00381641|9593639|FG001|Overall Study|Withdrawal by Subject|2
5999697|NCT00006184|9593651|FG000|Overall Study|Death|1
5999698|NCT00006184|9593652|FG001|Overall Study|Death|0
5999699|NCT00006237|9593664|FG000|Overall Study|Adverse Event|39
5999700|NCT00006237|9593665|FG001|Overall Study|Adverse Event|29
5999701|NCT00006237|9593664|FG000|Overall Study|Death|1
5999702|NCT00006237|9593665|FG001|Overall Study|Death|0
5999703|NCT00006237|9593664|FG000|Overall Study|Refusal unrelated to adverse effects|8
5999704|NCT00006237|9593665|FG001|Overall Study|Refusal unrelated to adverse effects|4
5999705|NCT00006237|9593664|FG000|Overall Study|Progression/relapse|54
5999706|NCT00006237|9593665|FG001|Overall Study|Progression/relapse|2
5999707|NCT00006237|9593664|FG000|Overall Study|Not eligible|9
5999708|NCT00006237|9593665|FG001|Overall Study|Not eligible|20
5999709|NCT00006237|9593664|FG000|Overall Study|Withdrawal by Subject|0
5999710|NCT00006237|9593665|FG001|Overall Study|Withdrawal by Subject|1
5999711|NCT00006237|9593664|FG000|Overall Study|Not protocol specified|14
5999712|NCT00006237|9593665|FG001|Overall Study|Not protocol specified|5
5999713|NCT00006289|9593680|FG000|First Intervention (5 Weeks)|Adverse Event|1
5999714|NCT00006289|9593681|FG001|First Intervention (5 Weeks)|Adverse Event|0
5999715|NCT00006289|9593680|FG000|Second Intervention (5 Weeks)|Protocol Violation|1
5999716|NCT00006289|9593681|FG001|Second Intervention (5 Weeks)|Protocol Violation|1
5999717|NCT00006305|9593701|FG000|Overall Study|Withdrawal by Subject|17
5999718|NCT00006305|9593702|FG001|Overall Study|Withdrawal by Subject|10
5999719|NCT00006305|9593703|FG002|Overall Study|Withdrawal by Subject|15
5999720|NCT00006305|9593704|FG003|Overall Study|Withdrawal by Subject|14
5999721|NCT00006389|9593714|FG000|Overall Study|Adverse Event|1
5999722|NCT00006392|9593723|FG000|Overall Study|Ineligible|11
5999723|NCT00006392|9593724|FG001|Overall Study|Ineligible|3
5999724|NCT00006392|9593725|FG002|Overall Study|Ineligible|5
5999725|NCT00006392|9593726|FG003|Overall Study|Ineligible|5
5999726|NCT00006392|9593723|FG000|Overall Study|Poor data/ppt mgmt, regulatory problems|156
5999727|NCT00006392|9593724|FG001|Overall Study|Poor data/ppt mgmt, regulatory problems|155
5999728|NCT00006392|9593725|FG002|Overall Study|Poor data/ppt mgmt, regulatory problems|155
5999729|NCT00006392|9593726|FG003|Overall Study|Poor data/ppt mgmt, regulatory problems|155
5999730|NCT00006409|9593751|FG000|Baseline|Protocol Violation|48
5999731|NCT00006409|9593752|FG001|Baseline|Protocol Violation|70
5999732|NCT00006409|9593753|FG002|Baseline|Protocol Violation|0
5999733|NCT00006409|9593754|FG003|Baseline|Protocol Violation|0
5999734|NCT00006409|9593755|FG004|Baseline|Protocol Violation|0
5999735|NCT00006409|9593756|FG005|Baseline|Protocol Violation|0
5999736|NCT00006409|9593751|FG000|Post-2 Year Intervention|Protocol Violation|0
5999737|NCT00006409|9593752|FG001|Post-2 Year Intervention|Protocol Violation|0
5999738|NCT00006409|9593753|FG002|Post-2 Year Intervention|Protocol Violation|251
5999739|NCT00006409|9593754|FG003|Post-2 Year Intervention|Protocol Violation|168
5999740|NCT00006409|9593755|FG004|Post-2 Year Intervention|Protocol Violation|0
5999741|NCT00006409|9593756|FG005|Post-2 Year Intervention|Protocol Violation|0
5999742|NCT00006409|9593751|FG000|Post-3 Year Intervention|Protocol Violation|0
5999743|NCT00006409|9593752|FG001|Post-3 Year Intervention|Protocol Violation|0
5999744|NCT00006409|9593753|FG002|Post-3 Year Intervention|Protocol Violation|0
5999745|NCT00006409|9593754|FG003|Post-3 Year Intervention|Protocol Violation|0
5999746|NCT00006409|9593755|FG004|Post-3 Year Intervention|Protocol Violation|62
5999747|NCT00006409|9593756|FG005|Post-3 Year Intervention|Protocol Violation|62
5999748|NCT00006489|9593783|FG000|Overall Study|Adverse Event|3
5999749|NCT00006489|9593784|FG001|Overall Study|Adverse Event|2
5999750|NCT00006489|9593785|FG002|Overall Study|Adverse Event|4
5999751|NCT00006489|9593786|FG003|Overall Study|Adverse Event|3
5999752|NCT00006489|9593783|FG000|Overall Study|Withdrawal by Subject|10
5999753|NCT00006489|9593784|FG001|Overall Study|Withdrawal by Subject|9
5999754|NCT00006489|9593785|FG002|Overall Study|Withdrawal by Subject|9
5999755|NCT00006489|9593786|FG003|Overall Study|Withdrawal by Subject|6
5999756|NCT00006489|9593783|FG000|Overall Study|Scheduling Conflict|0
5999757|NCT00006489|9593784|FG001|Overall Study|Scheduling Conflict|3
5999758|NCT00006489|9593785|FG002|Overall Study|Scheduling Conflict|2
5999759|NCT00006489|9593786|FG003|Overall Study|Scheduling Conflict|1
5999760|NCT00006489|9593783|FG000|Overall Study|Death|0
5999761|NCT00006489|9593784|FG001|Overall Study|Death|0
5999762|NCT00006489|9593785|FG002|Overall Study|Death|0
5999763|NCT00006489|9593786|FG003|Overall Study|Death|1
5999764|NCT00006604|9593803|FG000|Overall Study|Met study objective - no further FU|1
5999765|NCT00006604|9593804|FG001|Overall Study|Met study objective - no further FU|0
5999766|NCT00006604|9593805|FG002|Overall Study|Met study objective - no further FU|0
5999767|NCT00006604|9593806|FG003|Overall Study|Met study objective - no further FU|0
5999768|NCT00006604|9593807|FG004|Overall Study|Met study objective - no further FU|0
5999769|NCT00006604|9593808|FG005|Overall Study|Met study objective - no further FU|0
5999770|NCT00006604|9593809|FG006|Overall Study|Met study objective - no further FU|0
5999771|NCT00006604|9593810|FG007|Overall Study|Met study objective - no further FU|0
5999772|NCT00006604|9593811|FG008|Overall Study|Met study objective - no further FU|0
5999773|NCT00006604|9593812|FG009|Overall Study|Met study objective - no further FU|0
5999774|NCT00006604|9593813|FG010|Overall Study|Met study objective - no further FU|0
5999775|NCT00006604|9593814|FG011|Overall Study|Met study objective - no further FU|0
5999776|NCT00006604|9593815|FG012|Overall Study|Met study objective - no further FU|0
5999777|NCT00006604|9593816|FG013|Overall Study|Met study objective - no further FU|0
5999778|NCT00006604|9593817|FG014|Overall Study|Met study objective - no further FU|1
5999779|NCT00006604|9593818|FG015|Overall Study|Met study objective - no further FU|1
5999780|NCT00006604|9593819|FG016|Overall Study|Met study objective - no further FU|0
5999781|NCT00006604|9593803|FG000|Overall Study|Randomization entry error-no RX, no FU|0
5999782|NCT00006604|9593804|FG001|Overall Study|Randomization entry error-no RX, no FU|0
5999783|NCT00006604|9593805|FG002|Overall Study|Randomization entry error-no RX, no FU|0
5999784|NCT00006604|9593806|FG003|Overall Study|Randomization entry error-no RX, no FU|0
5999785|NCT00006604|9593807|FG004|Overall Study|Randomization entry error-no RX, no FU|0
5999786|NCT00006604|9593808|FG005|Overall Study|Randomization entry error-no RX, no FU|0
5999787|NCT00006604|9593809|FG006|Overall Study|Randomization entry error-no RX, no FU|0
5999788|NCT00006604|9593810|FG007|Overall Study|Randomization entry error-no RX, no FU|0
5999789|NCT00006604|9593811|FG008|Overall Study|Randomization entry error-no RX, no FU|0
5999790|NCT00006604|9593812|FG009|Overall Study|Randomization entry error-no RX, no FU|0
5999791|NCT00006604|9593813|FG010|Overall Study|Randomization entry error-no RX, no FU|0
5999792|NCT00006604|9593814|FG011|Overall Study|Randomization entry error-no RX, no FU|1
5999793|NCT00006604|9593815|FG012|Overall Study|Randomization entry error-no RX, no FU|0
5999794|NCT00006604|9593816|FG013|Overall Study|Randomization entry error-no RX, no FU|0
5999795|NCT00006604|9593817|FG014|Overall Study|Randomization entry error-no RX, no FU|0
5999796|NCT00006604|9593818|FG015|Overall Study|Randomization entry error-no RX, no FU|0
5999797|NCT00006604|9593819|FG016|Overall Study|Randomization entry error-no RX, no FU|0
5999798|NCT00006604|9593803|FG000|Overall Study|Death|0
5999799|NCT00006604|9593804|FG001|Overall Study|Death|0
5999800|NCT00006604|9593805|FG002|Overall Study|Death|0
5999801|NCT00006604|9593806|FG003|Overall Study|Death|0
5999802|NCT00006604|9593807|FG004|Overall Study|Death|0
5999803|NCT00006604|9593808|FG005|Overall Study|Death|0
5999804|NCT00006604|9593809|FG006|Overall Study|Death|0
5999805|NCT00006604|9593810|FG007|Overall Study|Death|0
5999806|NCT00006604|9593811|FG008|Overall Study|Death|0
5999807|NCT00006604|9593812|FG009|Overall Study|Death|1
5999808|NCT00006604|9593813|FG010|Overall Study|Death|1
5999809|NCT00006604|9593814|FG011|Overall Study|Death|1
5999810|NCT00006604|9593815|FG012|Overall Study|Death|0
5999811|NCT00006604|9593816|FG013|Overall Study|Death|0
5999812|NCT00006604|9593817|FG014|Overall Study|Death|0
5999813|NCT00006604|9593818|FG015|Overall Study|Death|0
5999814|NCT00006604|9593819|FG016|Overall Study|Death|0
5999815|NCT00006604|9593803|FG000|Overall Study|Severe debilitation, unable to continue|0
5999816|NCT00006604|9593804|FG001|Overall Study|Severe debilitation, unable to continue|0
5999817|NCT00006604|9593805|FG002|Overall Study|Severe debilitation, unable to continue|0
5999818|NCT00006604|9593806|FG003|Overall Study|Severe debilitation, unable to continue|0
5999819|NCT00006604|9593807|FG004|Overall Study|Severe debilitation, unable to continue|0
5999820|NCT00006604|9593808|FG005|Overall Study|Severe debilitation, unable to continue|0
5999821|NCT00006604|9593809|FG006|Overall Study|Severe debilitation, unable to continue|3
5999822|NCT00006604|9593810|FG007|Overall Study|Severe debilitation, unable to continue|0
5999823|NCT00006604|9593811|FG008|Overall Study|Severe debilitation, unable to continue|0
5999824|NCT00006604|9593812|FG009|Overall Study|Severe debilitation, unable to continue|5
5999825|NCT00006604|9593813|FG010|Overall Study|Severe debilitation, unable to continue|0
5999826|NCT00006604|9593814|FG011|Overall Study|Severe debilitation, unable to continue|2
5999827|NCT00006604|9593815|FG012|Overall Study|Severe debilitation, unable to continue|1
5999828|NCT00006604|9593816|FG013|Overall Study|Severe debilitation, unable to continue|0
5999829|NCT00006604|9593817|FG014|Overall Study|Severe debilitation, unable to continue|2
5999830|NCT00006604|9593818|FG015|Overall Study|Severe debilitation, unable to continue|0
5999831|NCT00006604|9593819|FG016|Overall Study|Severe debilitation, unable to continue|0
5999832|NCT00006604|9593803|FG000|Overall Study|Subj/Parent not able to get to clinic|0
5999833|NCT00006604|9593804|FG001|Overall Study|Subj/Parent not able to get to clinic|0
5999834|NCT00006604|9593805|FG002|Overall Study|Subj/Parent not able to get to clinic|0
5999835|NCT00006604|9593806|FG003|Overall Study|Subj/Parent not able to get to clinic|1
5999836|NCT00006604|9593807|FG004|Overall Study|Subj/Parent not able to get to clinic|1
6072375|NCT00560417|9675560|FG001|Overall Study|Lost to Follow-up|1
6072376|NCT00560417|9675559|FG000|Overall Study|Physician Decision|2
6072377|NCT00560417|9675560|FG001|Overall Study|Physician Decision|6
6072378|NCT00560417|9675559|FG000|Overall Study|Protocol Violation|6
6072379|NCT00560417|9675560|FG001|Overall Study|Protocol Violation|5
6072380|NCT00560417|9675559|FG000|Overall Study|Sponsor Decision|2
6072381|NCT00560417|9675560|FG001|Overall Study|Sponsor Decision|0
6072382|NCT00560417|9675559|FG000|Overall Study|Withdrawal by Subject|3
6072383|NCT00560417|9675560|FG001|Overall Study|Withdrawal by Subject|3
6072384|NCT00560508|9675568|FG000|12 Week Double-blind Period|Adverse Event|3
6072385|NCT00560508|9675569|FG001|12 Week Double-blind Period|Adverse Event|2
6072386|NCT00560508|9675568|FG000|12 Week Double-blind Period|Protocol Violation|1
6072387|NCT00560508|9675569|FG001|12 Week Double-blind Period|Protocol Violation|0
6072388|NCT00560508|9675568|FG000|12 Week Double-blind Period|Withdrawal by Subject|1
6072389|NCT00560508|9675569|FG001|12 Week Double-blind Period|Withdrawal by Subject|1
6072390|NCT00560508|9675568|FG000|52-week Open-label Period Pramipexole ER|Adverse Event|6
6072391|NCT00560508|9675569|FG001|52-week Open-label Period Pramipexole ER|Adverse Event|6
6072392|NCT00560508|9675568|FG000|52-week Open-label Period Pramipexole ER|Lack of Efficacy|1
6072393|NCT00560508|9675569|FG001|52-week Open-label Period Pramipexole ER|Lack of Efficacy|1
6072394|NCT00560508|9675568|FG000|52-week Open-label Period Pramipexole ER|Withdrawal by Subject|0
5999837|NCT00006604|9593808|FG005|Overall Study|Subj/Parent not able to get to clinic|0
5999838|NCT00006604|9593809|FG006|Overall Study|Subj/Parent not able to get to clinic|1
5999839|NCT00006604|9593810|FG007|Overall Study|Subj/Parent not able to get to clinic|0
5999840|NCT00006604|9593811|FG008|Overall Study|Subj/Parent not able to get to clinic|0
5999841|NCT00006604|9593812|FG009|Overall Study|Subj/Parent not able to get to clinic|1
5999842|NCT00006604|9593813|FG010|Overall Study|Subj/Parent not able to get to clinic|2
5999843|NCT00006604|9593814|FG011|Overall Study|Subj/Parent not able to get to clinic|1
5999844|NCT00006604|9593815|FG012|Overall Study|Subj/Parent not able to get to clinic|1
5999845|NCT00006604|9593816|FG013|Overall Study|Subj/Parent not able to get to clinic|1
5999846|NCT00006604|9593817|FG014|Overall Study|Subj/Parent not able to get to clinic|3
5999847|NCT00006604|9593818|FG015|Overall Study|Subj/Parent not able to get to clinic|0
5999848|NCT00006604|9593819|FG016|Overall Study|Subj/Parent not able to get to clinic|0
5999849|NCT00006604|9593803|FG000|Overall Study|Site closing|0
5999850|NCT00006604|9593804|FG001|Overall Study|Site closing|0
5999851|NCT00006604|9593805|FG002|Overall Study|Site closing|1
5999852|NCT00006604|9593806|FG003|Overall Study|Site closing|1
5999853|NCT00006604|9593807|FG004|Overall Study|Site closing|0
5999854|NCT00006604|9593808|FG005|Overall Study|Site closing|0
5999855|NCT00006604|9593809|FG006|Overall Study|Site closing|0
5999856|NCT00006604|9593810|FG007|Overall Study|Site closing|1
5999857|NCT00006604|9593811|FG008|Overall Study|Site closing|0
5999858|NCT00006604|9593812|FG009|Overall Study|Site closing|0
5999859|NCT00006604|9593813|FG010|Overall Study|Site closing|0
5999860|NCT00006604|9593814|FG011|Overall Study|Site closing|1
5999861|NCT00006604|9593815|FG012|Overall Study|Site closing|1
5999862|NCT00006604|9593816|FG013|Overall Study|Site closing|1
5999863|NCT00006604|9593817|FG014|Overall Study|Site closing|0
5999864|NCT00006604|9593818|FG015|Overall Study|Site closing|0
5999865|NCT00006604|9593819|FG016|Overall Study|Site closing|1
5999866|NCT00006604|9593803|FG000|Overall Study|Withdrawal by Subject|1
5999867|NCT00006604|9593804|FG001|Overall Study|Withdrawal by Subject|0
5999868|NCT00006604|9593805|FG002|Overall Study|Withdrawal by Subject|2
5999869|NCT00006604|9593806|FG003|Overall Study|Withdrawal by Subject|0
5999870|NCT00006604|9593807|FG004|Overall Study|Withdrawal by Subject|1
5999871|NCT00006604|9593808|FG005|Overall Study|Withdrawal by Subject|2
5999872|NCT00006604|9593809|FG006|Overall Study|Withdrawal by Subject|2
5999873|NCT00006604|9593810|FG007|Overall Study|Withdrawal by Subject|0
5999874|NCT00006604|9593811|FG008|Overall Study|Withdrawal by Subject|1
5999875|NCT00006604|9593812|FG009|Overall Study|Withdrawal by Subject|3
5999876|NCT00006604|9593813|FG010|Overall Study|Withdrawal by Subject|2
5999877|NCT00006604|9593814|FG011|Overall Study|Withdrawal by Subject|0
5999878|NCT00006604|9593815|FG012|Overall Study|Withdrawal by Subject|1
5999879|NCT00006604|9593816|FG013|Overall Study|Withdrawal by Subject|2
5999880|NCT00006604|9593817|FG014|Overall Study|Withdrawal by Subject|1
5999881|NCT00006604|9593818|FG015|Overall Study|Withdrawal by Subject|0
5999882|NCT00006604|9593819|FG016|Overall Study|Withdrawal by Subject|1
5999883|NCT00006604|9593803|FG000|Overall Study|Subj/parent not willing to adhere to req|0
6072395|NCT00560508|9675569|FG001|52-week Open-label Period Pramipexole ER|Withdrawal by Subject|3
6072396|NCT00560508|9675568|FG000|52-week Open-label Period Pramipexole ER|Other reason - investigator's judgement|1
6072397|NCT00560508|9675569|FG001|52-week Open-label Period Pramipexole ER|Other reason - investigator's judgement|1
6072398|NCT00560573|9675589|FG000|Overall Study|Death|4
6072399|NCT00560573|9675590|FG001|Overall Study|Death|1
6072400|NCT00560573|9675591|FG002|Overall Study|Death|4
5999884|NCT00006604|9593804|FG001|Overall Study|Subj/parent not willing to adhere to req|0
5999885|NCT00006604|9593805|FG002|Overall Study|Subj/parent not willing to adhere to req|1
5999886|NCT00006604|9593806|FG003|Overall Study|Subj/parent not willing to adhere to req|3
5999887|NCT00006604|9593807|FG004|Overall Study|Subj/parent not willing to adhere to req|0
6047207|NCT00410410|9646249|FG000|Induction Period (IP)|Death|1
5999888|NCT00006604|9593808|FG005|Overall Study|Subj/parent not willing to adhere to req|0
5999889|NCT00006604|9593809|FG006|Overall Study|Subj/parent not willing to adhere to req|3
5999890|NCT00006604|9593810|FG007|Overall Study|Subj/parent not willing to adhere to req|1
5999891|NCT00006604|9593811|FG008|Overall Study|Subj/parent not willing to adhere to req|0
5999892|NCT00006604|9593812|FG009|Overall Study|Subj/parent not willing to adhere to req|6
5999893|NCT00006604|9593813|FG010|Overall Study|Subj/parent not willing to adhere to req|3
5999894|NCT00006604|9593814|FG011|Overall Study|Subj/parent not willing to adhere to req|0
5999895|NCT00006604|9593815|FG012|Overall Study|Subj/parent not willing to adhere to req|0
5999896|NCT00006604|9593816|FG013|Overall Study|Subj/parent not willing to adhere to req|2
5999897|NCT00006604|9593817|FG014|Overall Study|Subj/parent not willing to adhere to req|3
5999898|NCT00006604|9593818|FG015|Overall Study|Subj/parent not willing to adhere to req|3
5999899|NCT00006604|9593819|FG016|Overall Study|Subj/parent not willing to adhere to req|4
5999900|NCT00006604|9593803|FG000|Overall Study|Lost to Follow-up|0
5999901|NCT00006604|9593804|FG001|Overall Study|Lost to Follow-up|0
5999902|NCT00006604|9593805|FG002|Overall Study|Lost to Follow-up|0
5999903|NCT00006604|9593806|FG003|Overall Study|Lost to Follow-up|0
5999904|NCT00006604|9593807|FG004|Overall Study|Lost to Follow-up|0
5999905|NCT00006604|9593808|FG005|Overall Study|Lost to Follow-up|0
5999906|NCT00006604|9593809|FG006|Overall Study|Lost to Follow-up|0
5999907|NCT00006604|9593810|FG007|Overall Study|Lost to Follow-up|1
5999908|NCT00006604|9593811|FG008|Overall Study|Lost to Follow-up|0
5999909|NCT00006604|9593812|FG009|Overall Study|Lost to Follow-up|2
5999910|NCT00006604|9593813|FG010|Overall Study|Lost to Follow-up|0
5999911|NCT00006604|9593814|FG011|Overall Study|Lost to Follow-up|0
5999912|NCT00006604|9593815|FG012|Overall Study|Lost to Follow-up|0
5999913|NCT00006604|9593816|FG013|Overall Study|Lost to Follow-up|0
5999914|NCT00006604|9593817|FG014|Overall Study|Lost to Follow-up|0
5999915|NCT00006604|9593818|FG015|Overall Study|Lost to Follow-up|1
5999916|NCT00006604|9593819|FG016|Overall Study|Lost to Follow-up|3
5999917|NCT00006604|9593803|FG000|Overall Study|Other Reason|0
5999918|NCT00006604|9593804|FG001|Overall Study|Other Reason|0
5999919|NCT00006604|9593805|FG002|Overall Study|Other Reason|0
5999920|NCT00006604|9593806|FG003|Overall Study|Other Reason|0
5999921|NCT00006604|9593807|FG004|Overall Study|Other Reason|0
5999922|NCT00006604|9593808|FG005|Overall Study|Other Reason|1
5999923|NCT00006604|9593809|FG006|Overall Study|Other Reason|0
5999924|NCT00006604|9593810|FG007|Overall Study|Other Reason|0
5999925|NCT00006604|9593811|FG008|Overall Study|Other Reason|0
5999926|NCT00006604|9593812|FG009|Overall Study|Other Reason|1
5999927|NCT00006604|9593813|FG010|Overall Study|Other Reason|0
5999928|NCT00006604|9593814|FG011|Overall Study|Other Reason|0
5999929|NCT00006604|9593815|FG012|Overall Study|Other Reason|0
5999930|NCT00006604|9593816|FG013|Overall Study|Other Reason|0
5999931|NCT00006604|9593817|FG014|Overall Study|Other Reason|0
5999932|NCT00006604|9593818|FG015|Overall Study|Other Reason|0
5999933|NCT00006604|9593819|FG016|Overall Study|Other Reason|0
5999934|NCT00006721|9593845|FG000|Overall Study|Adverse Event|0
5999935|NCT00006721|9593846|FG001|Overall Study|Adverse Event|4
5999936|NCT00006721|9593847|FG002|Overall Study|Adverse Event|4
5999937|NCT00006721|9593845|FG000|Overall Study|Refusal Unrelated to Adverse Event|1
5999938|NCT00006721|9593846|FG001|Overall Study|Refusal Unrelated to Adverse Event|0
5999939|NCT00006721|9593847|FG002|Overall Study|Refusal Unrelated to Adverse Event|8
5999940|NCT00006721|9593845|FG000|Overall Study|Progression/Relapse|0
5999941|NCT00006721|9593846|FG001|Overall Study|Progression/Relapse|1
5999942|NCT00006721|9593847|FG002|Overall Study|Progression/Relapse|2
5999943|NCT00006721|9593845|FG000|Overall Study|Death|0
5999944|NCT00006721|9593846|FG001|Overall Study|Death|1
5999945|NCT00006721|9593847|FG002|Overall Study|Death|2
5999946|NCT00006721|9593845|FG000|Overall Study|Other - Not Protocol Specified|0
5999947|NCT00006721|9593846|FG001|Overall Study|Other - Not Protocol Specified|7
5999948|NCT00006721|9593847|FG002|Overall Study|Other - Not Protocol Specified|7
5999949|NCT00006721|9593845|FG000|Overall Study|Ineligible|2
5999950|NCT00006721|9593846|FG001|Overall Study|Ineligible|12
5999951|NCT00006721|9593847|FG002|Overall Study|Ineligible|10
5999952|NCT00006721|9593845|FG000|Overall Study|Eligible but no Treatment Received|1
5999953|NCT00006721|9593846|FG001|Overall Study|Eligible but no Treatment Received|0
5999954|NCT00006721|9593847|FG002|Overall Study|Eligible but no Treatment Received|0
5999955|NCT00006903|9593859|FG000|Overall Study|Still receiving treatment|0
5999956|NCT00006903|9593860|FG001|Overall Study|Still receiving treatment|0
5999957|NCT00006903|9593861|FG002|Overall Study|Still receiving treatment|1
5999958|NCT00006903|9593859|FG000|Overall Study|Refused further treatment|0
5999959|NCT00006903|9593860|FG001|Overall Study|Refused further treatment|2
5999960|NCT00006903|9593861|FG002|Overall Study|Refused further treatment|1
5999961|NCT00006903|9593859|FG000|Overall Study|Adverse Event|0
5999962|NCT00006903|9593860|FG001|Overall Study|Adverse Event|0
5999963|NCT00006903|9593861|FG002|Overall Study|Adverse Event|1
5999964|NCT00006903|9593859|FG000|Overall Study|Death|0
5999965|NCT00006903|9593860|FG001|Overall Study|Death|1
5999966|NCT00006903|9593861|FG002|Overall Study|Death|0
5999967|NCT00006903|9593859|FG000|Overall Study|Patient never treated|0
5999968|NCT00006903|9593860|FG001|Overall Study|Patient never treated|0
5999969|NCT00006903|9593861|FG002|Overall Study|Patient never treated|1
5999970|NCT00006903|9593859|FG000|Overall Study|Ineligible|10
5999971|NCT00006903|9593860|FG001|Overall Study|Ineligible|1
5999972|NCT00006903|9593861|FG002|Overall Study|Ineligible|2
5999973|NCT00007020|9593869|FG000|Overall Study|Death|16
5999974|NCT00007020|9593869|FG000|Overall Study|Lost to Follow-up|13
5999975|NCT00007020|9593869|FG000|Overall Study|Pt withdrawn (worsening cholestasis)|1
5999976|NCT00007020|9593869|FG000|Overall Study|Pt withdrawn (liver transplant)|4
5999977|NCT00007020|9593869|FG000|Overall Study|Pt cared for by outside physician|4
5999978|NCT00007020|9593869|FG000|Overall Study|No evidence of treatment|6
5999979|NCT00007345|9593877|FG000|Overall Study|Refused further treatment|0
5999980|NCT00007345|9593878|FG001|Overall Study|Refused further treatment|7
5999981|NCT00007345|9593877|FG000|Overall Study|Switched to alternative treatment|0
5999982|NCT00007345|9593878|FG001|Overall Study|Switched to alternative treatment|3
5999983|NCT00007345|9593877|FG000|Overall Study|Intercurrent illness|1
5999984|NCT00007345|9593878|FG001|Overall Study|Intercurrent illness|0
6072401|NCT00560573|9675592|FG003|Overall Study|Death|5
6072402|NCT00560573|9675593|FG004|Overall Study|Death|1
5999985|NCT00007345|9593877|FG000|Overall Study|Death on study|1
5999986|NCT00007345|9593878|FG001|Overall Study|Death on study|1
5999987|NCT00007475|9593887|FG000|Overall Study|Withdrawal by Subject|1
5999988|NCT00007475|9593888|FG001|Overall Study|Withdrawal by Subject|0
5999989|NCT00007475|9593889|FG002|Overall Study|Withdrawal by Subject|0
5999990|NCT00007475|9593890|FG003|Overall Study|Withdrawal by Subject|0
5999991|NCT00007475|9593887|FG000|Overall Study|Adverse Event|3
5999992|NCT00007475|9593888|FG001|Overall Study|Adverse Event|0
5999993|NCT00007475|9593889|FG002|Overall Study|Adverse Event|0
5999994|NCT00007475|9593890|FG003|Overall Study|Adverse Event|0
5999995|NCT00008138|9593909|FG000|Neoadjuvant Chemotherapy|Adverse Event|3
5999996|NCT00008138|9593909|FG000|Neoadjuvant Chemotherapy|Withdrawal by Subject|3
5999997|NCT00008138|9593909|FG000|Neoadjuvant Chemotherapy|Lack of Efficacy|6
5999998|NCT00008138|9593909|FG000|Neoadjuvant Chemotherapy|not protocol specified|8
5999999|NCT00008138|9593909|FG000|Interval Debulking|Withdrawal by Subject|2
6000000|NCT00008138|9593909|FG000|Post-Cytoreduction Chemotherapy|Adverse Event|6
6000001|NCT00008138|9593909|FG000|Post-Cytoreduction Chemotherapy|Progression|1
6000002|NCT00008138|9593909|FG000|Post-Cytoreduction Chemotherapy|not protocol specified|1
6000003|NCT00008385|9593916|FG000|Overall Study|Off treatment reasons not reported|79
6000004|NCT00008385|9593917|FG001|Overall Study|Off treatment reasons not reported|70
6000005|NCT00008385|9593916|FG000|Overall Study|Progressive disease|52
6000006|NCT00008385|9593917|FG001|Overall Study|Progressive disease|117
6000007|NCT00008385|9593916|FG000|Overall Study|Adverse Event|8
6000008|NCT00008385|9593917|FG001|Overall Study|Adverse Event|20
6000009|NCT00008385|9593916|FG000|Overall Study|Death|12
6000010|NCT00008385|9593917|FG001|Overall Study|Death|18
6000011|NCT00008385|9593916|FG000|Overall Study|Withdrawal by Subject|67
6000012|NCT00008385|9593917|FG001|Overall Study|Withdrawal by Subject|157
6000013|NCT00008385|9593916|FG000|Overall Study|Start non-protocol therapy|3
6072403|NCT00560573|9675594|FG005|Overall Study|Death|10
6072404|NCT00560573|9675589|FG000|Overall Study|Lost to Follow-up|0
6072405|NCT00560573|9675590|FG001|Overall Study|Lost to Follow-up|0
6072406|NCT00560573|9675591|FG002|Overall Study|Lost to Follow-up|0
6072407|NCT00560573|9675592|FG003|Overall Study|Lost to Follow-up|1
6072408|NCT00560573|9675593|FG004|Overall Study|Lost to Follow-up|1
6072409|NCT00560573|9675594|FG005|Overall Study|Lost to Follow-up|0
6072410|NCT00560573|9675589|FG000|Overall Study|Withdrawal by Subject|0
6072411|NCT00560573|9675590|FG001|Overall Study|Withdrawal by Subject|0
6072412|NCT00560573|9675591|FG002|Overall Study|Withdrawal by Subject|0
6072413|NCT00560573|9675592|FG003|Overall Study|Withdrawal by Subject|1
6072414|NCT00560573|9675593|FG004|Overall Study|Withdrawal by Subject|1
6072415|NCT00560573|9675594|FG005|Overall Study|Withdrawal by Subject|0
6072416|NCT00560573|9675589|FG000|Overall Study|Other|2
6072417|NCT00560573|9675590|FG001|Overall Study|Other|2
6072418|NCT00560573|9675591|FG002|Overall Study|Other|2
6072419|NCT00560573|9675592|FG003|Overall Study|Other|3
6072420|NCT00560573|9675593|FG004|Overall Study|Other|3
6072421|NCT00560573|9675594|FG005|Overall Study|Other|3
6072422|NCT00560573|9675589|FG000|Overall Study|Enrolled, not treated|0
6072423|NCT00560573|9675590|FG001|Overall Study|Enrolled, not treated|0
6072424|NCT00560573|9675591|FG002|Overall Study|Enrolled, not treated|0
6072425|NCT00560573|9675592|FG003|Overall Study|Enrolled, not treated|0
6072426|NCT00560573|9675593|FG004|Overall Study|Enrolled, not treated|1
6072427|NCT00560573|9675594|FG005|Overall Study|Enrolled, not treated|0
6072428|NCT00560703|9675635|FG000|Overall Study|Adverse Event|0
6072429|NCT00560703|9675636|FG001|Overall Study|Adverse Event|2
6072430|NCT00560703|9675635|FG000|Overall Study|Protocol Violation|0
6072431|NCT00560703|9675636|FG001|Overall Study|Protocol Violation|2
6000014|NCT00008385|9593917|FG001|Overall Study|Start non-protocol therapy|1
6000015|NCT00008385|9593916|FG000|Overall Study|Other complicating disease|17
6000016|NCT00008385|9593917|FG001|Overall Study|Other complicating disease|30
6000017|NCT00008385|9593916|FG000|Overall Study|Maximum dose reached|0
6072432|NCT00560703|9675635|FG000|Overall Study|Withdrawal by Subject|0
6072433|NCT00560703|9675636|FG001|Overall Study|Withdrawal by Subject|1
6146252|NCT01076010|9780833|FG001|Overall Study|Treatment Interruption for > 2 Weeks|1
6072434|NCT00560703|9675635|FG000|Overall Study|non-compliance|0
6072435|NCT00560703|9675636|FG001|Overall Study|non-compliance|1
6072436|NCT00560755|9675642|FG000|Overall Study|Protocol Violation|15
6000018|NCT00008385|9593917|FG001|Overall Study|Maximum dose reached|2
6000019|NCT00008385|9593916|FG000|Overall Study|Other|105
6000020|NCT00008385|9593917|FG001|Overall Study|Other|212
6000021|NCT00008385|9593916|FG000|Overall Study|Not start protocol therapy|44
6000022|NCT00008385|9593917|FG001|Overall Study|Not start protocol therapy|175
6000023|NCT00009737|9593925|FG000|Overall Study|Adverse Event|112
6000024|NCT00009737|9593926|FG001|Overall Study|Adverse Event|75
6000025|NCT00009737|9593925|FG000|Overall Study|Death|4
6000026|NCT00009737|9593926|FG001|Overall Study|Death|6
6000027|NCT00009737|9593925|FG000|Overall Study|Lack of Efficacy|17
6000028|NCT00009737|9593926|FG001|Overall Study|Lack of Efficacy|15
6000029|NCT00009737|9593925|FG000|Overall Study|Violation of Selection Criteria at Entry|13
6000030|NCT00009737|9593926|FG001|Overall Study|Violation of Selection Criteria at Entry|9
6000031|NCT00009737|9593925|FG000|Overall Study|Other Protocol Violation|1
6000032|NCT00009737|9593926|FG001|Overall Study|Other Protocol Violation|0
6000033|NCT00009737|9593925|FG000|Overall Study|Refused Treatment|15
6000034|NCT00009737|9593926|FG001|Overall Study|Refused Treatment|16
6000035|NCT00009737|9593925|FG000|Overall Study|Lost to Follow-up|1
6000036|NCT00009737|9593926|FG001|Overall Study|Lost to Follow-up|1
6000037|NCT00009737|9593925|FG000|Overall Study|Administrative/Other Reasons|7
6000038|NCT00009737|9593926|FG001|Overall Study|Administrative/Other Reasons|1
6000039|NCT00009945|9593934|FG000|Overall Study|no follow up data|7
6000040|NCT00009945|9593935|FG001|Overall Study|no follow up data|5
6000041|NCT00010257|9593943|FG000|Overall Study|Withdrawal by Subject|1
6000042|NCT00010257|9593944|FG001|Overall Study|Withdrawal by Subject|0
6000043|NCT00010374|9593950|FG000|Overall Study|False positive phrenic nerve test|1
6000044|NCT00010803|9593961|FG000|Overall Study|Withdrawal by Subject|97
6000045|NCT00010803|9593962|FG001|Overall Study|Withdrawal by Subject|98
6000046|NCT00012012|9593996|FG000|Overall Study|Protocol Violation|1
6000047|NCT00012012|9593997|FG001|Overall Study|Protocol Violation|1
6000048|NCT00012012|9593996|FG000|Overall Study|Withdrawal by Subject|0
6000049|NCT00012012|9593997|FG001|Overall Study|Withdrawal by Subject|2
6000050|NCT00013611|9594036|FG000|Overall Study|Lost to Follow-up|91
6000051|NCT00013611|9594037|FG001|Overall Study|Lost to Follow-up|100
6000052|NCT00014495|9594060|FG000|Overall Study|Death|0
6000053|NCT00014495|9594061|FG001|Overall Study|Death|0
6000054|NCT00014495|9594062|FG002|Overall Study|Death|1
6000055|NCT00014495|9594063|FG003|Overall Study|Death|0
6000056|NCT00014495|9594060|FG000|Overall Study|Clinical deterioration|0
6000057|NCT00014495|9594061|FG001|Overall Study|Clinical deterioration|0
6000058|NCT00014495|9594062|FG002|Overall Study|Clinical deterioration|0
6000059|NCT00014495|9594063|FG003|Overall Study|Clinical deterioration|1
6000060|NCT00014911|9594070|FG000|Overall Study|Adverse Event|1
6000061|NCT00014911|9594070|FG000|Overall Study|Lost to Follow-up|1
6000062|NCT00014911|9594070|FG000|Overall Study|Withdrawal by Subject|6
6000063|NCT00014911|9594070|FG000|Overall Study|Unknown Reasons|2
6000064|NCT00014911|9594070|FG000|Overall Study|Immunosuppression-related Side Effects|1
6000065|NCT00015457|9594074|FG000|First Intervention|Adverse Event|0
6000066|NCT00015457|9594075|FG001|First Intervention|Adverse Event|2
6000067|NCT00015457|9594074|FG000|First Intervention|Lack of Efficacy|0
6000068|NCT00015457|9594075|FG001|First Intervention|Lack of Efficacy|1
6000069|NCT00015457|9594074|FG000|Second Intervention|Withdrawal by Subject|1
6000070|NCT00015457|9594075|FG001|Second Intervention|Withdrawal by Subject|0
6000071|NCT00016354|9594085|FG000|Overall Study|Lack of Efficacy|0
6000072|NCT00016354|9594086|FG001|Overall Study|Lack of Efficacy|0
6000073|NCT00016354|9594087|FG002|Overall Study|Lack of Efficacy|0
6000074|NCT00016354|9594088|FG003|Overall Study|Lack of Efficacy|0
6000075|NCT00016354|9594089|FG004|Overall Study|Lack of Efficacy|0
6000076|NCT00016354|9594090|FG005|Overall Study|Lack of Efficacy|0
6000077|NCT00016354|9594091|FG006|Overall Study|Lack of Efficacy|0
6000078|NCT00016354|9594092|FG007|Overall Study|Lack of Efficacy|1
6000079|NCT00019604|9594121|FG000|Overall Study|Death|1
6000080|NCT00019604|9594121|FG000|Overall Study|Progressive disease|23
6000081|NCT00019604|9594121|FG000|Overall Study|Refused treatment|1
6000082|NCT00019604|9594121|FG000|Overall Study|Carcinoid tumor, not treatable|1
6000083|NCT00019604|9594121|FG000|Overall Study|Going to have liver transplant|1
6000084|NCT00019604|9594121|FG000|Overall Study|Move to a different study|1
6000085|NCT00019604|9594121|FG000|Overall Study|Non compliant on systemic CH|1
6000086|NCT00019604|9594121|FG000|Overall Study|Non compliant|1
6000087|NCT00019604|9594121|FG000|Overall Study|Resectable disease|1
6000088|NCT00019604|9594121|FG000|Overall Study|Started new chemo regimen|1
6000089|NCT00019604|9594121|FG000|Overall Study|Pt going to immunotherapy study|1
6000090|NCT00019604|9594121|FG000|Overall Study|Too much disease|1
6000091|NCT00019604|9594121|FG000|Overall Study|Unable to evaluate|1
6000092|NCT00019604|9594121|FG000|Overall Study|Details for other not available|4
6000093|NCT00021229|9594137|FG000|Overall Study|Adverse Event|10
6000094|NCT00021229|9594138|FG001|Overall Study|Adverse Event|5
6000095|NCT00021229|9594139|FG002|Overall Study|Adverse Event|2
6000096|NCT00021229|9594137|FG000|Overall Study|Death|0
6000097|NCT00021229|9594138|FG001|Overall Study|Death|1
6000098|NCT00021229|9594139|FG002|Overall Study|Death|0
6000099|NCT00021229|9594137|FG000|Overall Study|Withdrawal by Subject|7
6000100|NCT00021229|9594138|FG001|Overall Study|Withdrawal by Subject|7
6000101|NCT00021229|9594139|FG002|Overall Study|Withdrawal by Subject|1
6000102|NCT00021229|9594137|FG000|Overall Study|Progressive Disease|15
6000103|NCT00021229|9594138|FG001|Overall Study|Progressive Disease|19
6000104|NCT00021229|9594139|FG002|Overall Study|Progressive Disease|12
6000105|NCT00021229|9594137|FG000|Overall Study|Protocol Violation|1
6000106|NCT00021229|9594138|FG001|Overall Study|Protocol Violation|1
6000107|NCT00021229|9594139|FG002|Overall Study|Protocol Violation|0
6000108|NCT00021229|9594137|FG000|Overall Study|Physician Decision|0
6000109|NCT00021229|9594138|FG001|Overall Study|Physician Decision|0
6000110|NCT00021229|9594139|FG002|Overall Study|Physician Decision|1
6000111|NCT00021229|9594137|FG000|Overall Study|Punctate hemmorrhage post RT|2
6000112|NCT00021229|9594138|FG001|Overall Study|Punctate hemmorrhage post RT|0
6000113|NCT00021229|9594139|FG002|Overall Study|Punctate hemmorrhage post RT|0
6000114|NCT00021255|9594152|FG000|Overall Study|Death|1
6000115|NCT00021255|9594153|FG001|Overall Study|Death|0
6000116|NCT00021255|9594154|FG002|Overall Study|Death|2
6000117|NCT00021255|9594152|FG000|Overall Study|Breast cancer relapse|5
6000118|NCT00021255|9594153|FG001|Overall Study|Breast cancer relapse|18
6000119|NCT00021255|9594154|FG002|Overall Study|Breast cancer relapse|11
6000120|NCT00021255|9594152|FG000|Overall Study|Second primary malignancy|0
6000121|NCT00021255|9594153|FG001|Overall Study|Second primary malignancy|4
6000122|NCT00021255|9594154|FG002|Overall Study|Second primary malignancy|1
6000123|NCT00021255|9594152|FG000|Overall Study|Withdrawal by Subject|41
6000124|NCT00021255|9594153|FG001|Overall Study|Withdrawal by Subject|64
6000125|NCT00021255|9594154|FG002|Overall Study|Withdrawal by Subject|26
6000126|NCT00021255|9594152|FG000|Overall Study|Lost to Follow-up|0
6000127|NCT00021255|9594153|FG001|Overall Study|Lost to Follow-up|2
6000128|NCT00021255|9594154|FG002|Overall Study|Lost to Follow-up|3
6000129|NCT00021255|9594152|FG000|Overall Study|Cardiac toxicity|0
6000130|NCT00021255|9594153|FG001|Overall Study|Cardiac toxicity|61
6000131|NCT00021255|9594154|FG002|Overall Study|Cardiac toxicity|32
6000132|NCT00021255|9594152|FG000|Overall Study|Herceptin toxicity|0
6000133|NCT00021255|9594153|FG001|Overall Study|Herceptin toxicity|22
6000134|NCT00021255|9594154|FG002|Overall Study|Herceptin toxicity|6
6000135|NCT00021255|9594152|FG000|Overall Study|Adverse Event|46
6000136|NCT00021255|9594153|FG001|Overall Study|Adverse Event|30
6000137|NCT00021255|9594154|FG002|Overall Study|Adverse Event|18
6000138|NCT00021255|9594152|FG000|Overall Study|Protocol Violation|0
6000139|NCT00021255|9594153|FG001|Overall Study|Protocol Violation|2
6000140|NCT00021255|9594154|FG002|Overall Study|Protocol Violation|0
6000141|NCT00021255|9594152|FG000|Overall Study|Other than specified above|0
6000142|NCT00021255|9594153|FG001|Overall Study|Other than specified above|38
6000143|NCT00021255|9594154|FG002|Overall Study|Other than specified above|19
6000144|NCT00021255|9594152|FG000|Overall Study|Missing|0
6000145|NCT00021255|9594153|FG001|Overall Study|Missing|27
6000146|NCT00021255|9594154|FG002|Overall Study|Missing|13
6000147|NCT00021255|9594152|FG000|Overall Study|Randomized but not treated|28
6000148|NCT00021255|9594153|FG001|Overall Study|Randomized but not treated|2
6000149|NCT00021255|9594154|FG002|Overall Study|Randomized but not treated|18
6000150|NCT00021541|9594164|FG000|Period 1-First Treatment|Withdrawal by Subject|3
6000151|NCT00021541|9594165|FG001|Period 1-First Treatment|Withdrawal by Subject|3
6000152|NCT00021541|9594164|FG000|Period 1-First Treatment|Adverse Event|2
6000153|NCT00021541|9594165|FG001|Period 1-First Treatment|Adverse Event|1
6000154|NCT00021541|9594164|FG000|Period 1-First Treatment|non-adherence|3
6000155|NCT00021541|9594165|FG001|Period 1-First Treatment|non-adherence|0
6000156|NCT00021541|9594164|FG000|Period 1-First Treatment|Death|1
6000157|NCT00021541|9594165|FG001|Period 1-First Treatment|Death|0
6000158|NCT00021541|9594164|FG000|Period 1-First Treatment|Pts that did not progress|2
6000159|NCT00021541|9594165|FG001|Period 1-First Treatment|Pts that did not progress|2
6000160|NCT00021541|9594164|FG000|Period 1-First Treatment|Ineligible|0
6000161|NCT00021541|9594165|FG001|Period 1-First Treatment|Ineligible|2
6000162|NCT00021541|9594164|FG000|Period 2-crossover|refused phase B|2
6000163|NCT00021541|9594165|FG001|Period 2-crossover|refused phase B|2
6000164|NCT00021541|9594164|FG000|Period 2-crossover|Withdrawal by Subject|3
6000165|NCT00021541|9594165|FG001|Period 2-crossover|Withdrawal by Subject|4
6000166|NCT00021541|9594164|FG000|Period 2-crossover|Adverse Event|2
6000167|NCT00021541|9594165|FG001|Period 2-crossover|Adverse Event|2
6000168|NCT00021541|9594164|FG000|Period 2-crossover|non-adherence|1
6000169|NCT00021541|9594165|FG001|Period 2-crossover|non-adherence|0
6000170|NCT00021541|9594164|FG000|Period 2-crossover|Pts that did not progress|2
6000171|NCT00021541|9594165|FG001|Period 2-crossover|Pts that did not progress|3
6000172|NCT00022516|9594179|FG000|Overall Study|Adverse Event|0
6000173|NCT00022516|9594180|FG001|Overall Study|Adverse Event|59
6000174|NCT00022516|9594179|FG000|Overall Study|Lack of Efficacy|0
6000175|NCT00022516|9594180|FG001|Overall Study|Lack of Efficacy|27
6000176|NCT00022516|9594179|FG000|Overall Study|Physician Decision|0
6000177|NCT00022516|9594180|FG001|Overall Study|Physician Decision|1
6000178|NCT00022516|9594179|FG000|Overall Study|Protocol Violation|1
6000179|NCT00022516|9594180|FG001|Overall Study|Protocol Violation|3
6000180|NCT00022516|9594179|FG000|Overall Study|Withdrawal by Subject|2
6000181|NCT00022516|9594180|FG001|Overall Study|Withdrawal by Subject|113
6000182|NCT00022516|9594179|FG000|Overall Study|Incomplete documentation|0
6000183|NCT00022516|9594180|FG001|Overall Study|Incomplete documentation|27
6000184|NCT00022633|9594188|FG000|Overall Study|Adverse Event|11
6000185|NCT00022633|9594189|FG001|Overall Study|Adverse Event|1
6000186|NCT00022633|9594188|FG000|Overall Study|Refusal unrelated to adverse event|1
6000187|NCT00022633|9594189|FG001|Overall Study|Refusal unrelated to adverse event|0
6000188|NCT00022633|9594188|FG000|Overall Study|Progression/relapse|9
6000189|NCT00022633|9594189|FG001|Overall Study|Progression/relapse|2
6000190|NCT00022633|9594188|FG000|Overall Study|Death|4
6000191|NCT00022633|9594189|FG001|Overall Study|Death|0
6000192|NCT00022633|9594188|FG000|Overall Study|Other - not protocol specified|3
6000193|NCT00022633|9594189|FG001|Overall Study|Other - not protocol specified|2
6000194|NCT00022633|9594188|FG000|Overall Study|Ineligible|4
6000195|NCT00022633|9594189|FG001|Overall Study|Ineligible|0
6000196|NCT00022659|9594194|FG000|Overall Study|Ineligible: wrong primary|1
6000197|NCT00022659|9594194|FG000|Overall Study|Never treated|1
6000198|NCT00022672|9594204|FG000|Main Phase: 24 Months|Adverse Event|6
6000199|NCT00022672|9594205|FG001|Main Phase: 24 Months|Adverse Event|0
6000200|NCT00022672|9594204|FG000|Main Phase: 24 Months|Death|0
6000201|NCT00022672|9594205|FG001|Main Phase: 24 Months|Death|3
6000202|NCT00022672|9594204|FG000|Main Phase: 24 Months|Insufficient Therapeutic Response|75
6000203|NCT00022672|9594205|FG001|Main Phase: 24 Months|Insufficient Therapeutic Response|91
6000204|NCT00022672|9594204|FG000|Main Phase: 24 Months|Violation of Selection Criteria at Entry|0
6000205|NCT00022672|9594205|FG001|Main Phase: 24 Months|Violation of Selection Criteria at Entry|1
6000206|NCT00022672|9594204|FG000|Main Phase: 24 Months|Other Protocol Violation|1
6000207|NCT00022672|9594205|FG001|Main Phase: 24 Months|Other Protocol Violation|0
6000208|NCT00022672|9594204|FG000|Main Phase: 24 Months|Refused Treatment|3
6000209|NCT00022672|9594205|FG001|Main Phase: 24 Months|Refused Treatment|4
6000210|NCT00022672|9594204|FG000|Main Phase: 24 Months|Failure to Return|1
6000211|NCT00022672|9594205|FG001|Main Phase: 24 Months|Failure to Return|1
6000212|NCT00022672|9594204|FG000|Main Phase: 24 Months|Other|1
6000213|NCT00022672|9594205|FG001|Main Phase: 24 Months|Other|0
6000214|NCT00022672|9594204|FG000|Extension Phase|Adverse Event|1
6000215|NCT00022672|9594205|FG001|Extension Phase|Adverse Event|3
6000216|NCT00022672|9594204|FG000|Extension Phase|Death|0
6000217|NCT00022672|9594205|FG001|Extension Phase|Death|1
6000218|NCT00022672|9594204|FG000|Extension Phase|Insufficient Therapeutic Response|1
6000219|NCT00022672|9594205|FG001|Extension Phase|Insufficient Therapeutic Response|44
6000220|NCT00022672|9594204|FG000|Extension Phase|Refused Treatment|0
6000221|NCT00022672|9594205|FG001|Extension Phase|Refused Treatment|2
6000222|NCT00022672|9594204|FG000|Extension Phase|Other|1
6000223|NCT00022672|9594205|FG001|Extension Phase|Other|1
6000224|NCT00022698|9594214|FG000|Overall Study|Adverse Event|5
6000225|NCT00022698|9594215|FG001|Overall Study|Adverse Event|9
6000226|NCT00022698|9594214|FG000|Overall Study|Death|0
6000227|NCT00022698|9594215|FG001|Overall Study|Death|2
6000228|NCT00022698|9594214|FG000|Overall Study|Failure to return|0
6000229|NCT00022698|9594215|FG001|Overall Study|Failure to return|1
6000230|NCT00022698|9594214|FG000|Overall Study|Refused treatment|0
6000231|NCT00022698|9594215|FG001|Overall Study|Refused treatment|2
6000232|NCT00022698|9594214|FG000|Overall Study|Insufficient therapeutic response|2
6000233|NCT00022698|9594215|FG001|Overall Study|Insufficient therapeutic response|14
6000234|NCT00022698|9594214|FG000|Overall Study|Administrative /other|1
6000235|NCT00022698|9594215|FG001|Overall Study|Administrative /other|7
6000236|NCT00022763|9594225|FG000|Overall Study|Adverse Event|1
6000237|NCT00022763|9594226|FG001|Overall Study|Adverse Event|2
6000238|NCT00022763|9594225|FG000|Overall Study|Injection Site Reactions|0
6000239|NCT00022763|9594226|FG001|Overall Study|Injection Site Reactions|2
6000240|NCT00022763|9594225|FG000|Overall Study|Death|0
6000241|NCT00022763|9594226|FG001|Overall Study|Death|1
6000242|NCT00022763|9594225|FG000|Overall Study|Lost to Follow-up|0
6000243|NCT00022763|9594226|FG001|Overall Study|Lost to Follow-up|3
6000244|NCT00022763|9594225|FG000|Overall Study|Withdrawal by Subject|4
6000245|NCT00022763|9594226|FG001|Overall Study|Withdrawal by Subject|7
6000246|NCT00022763|9594225|FG000|Overall Study|Insufficient Therapy|1
6000247|NCT00022763|9594226|FG001|Overall Study|Insufficient Therapy|0
6000248|NCT00022763|9594225|FG000|Overall Study|Admin|3
6000249|NCT00022763|9594226|FG001|Overall Study|Admin|2
6000250|NCT00023322|9594240|FG000|Overall Study|Lost to Follow-up|1
6000251|NCT00023452|9594246|FG000|Overall Study|Ineligible for Study|163
6000252|NCT00023452|9594247|FG001|Overall Study|Ineligible for Study|159
6000253|NCT00023452|9594246|FG000|Overall Study|Out of Window|129
6000254|NCT00023452|9594247|FG001|Overall Study|Out of Window|69
6000255|NCT00023452|9594246|FG000|Overall Study|Death|2
6000256|NCT00023452|9594247|FG001|Overall Study|Death|0
6000257|NCT00023452|9594246|FG000|Overall Study|Withdrawal by Subject|66
6000258|NCT00023452|9594247|FG001|Overall Study|Withdrawal by Subject|54
6000259|NCT00023452|9594246|FG000|Overall Study|Adverse Event|139
6072437|NCT00560755|9675642|FG000|Overall Study|Withdrawal by Subject|26
6072438|NCT00560755|9675642|FG000|Overall Study|Lost to Follow-up|9
6000260|NCT00023452|9594247|FG001|Overall Study|Adverse Event|196
6000261|NCT00023452|9594246|FG000|Overall Study|Lost to Follow-up|293
6000262|NCT00023452|9594247|FG001|Overall Study|Lost to Follow-up|60
6000263|NCT00023452|9594246|FG000|Overall Study|Physician Decision|49
6000264|NCT00023452|9594247|FG001|Overall Study|Physician Decision|21
6000265|NCT00023452|9594246|FG000|Overall Study|Refused Treatment (continued follow-up)|225
6000266|NCT00023452|9594247|FG001|Overall Study|Refused Treatment (continued follow-up)|224
6000267|NCT00023452|9594246|FG000|Overall Study|Pregnant|53
6072439|NCT00560755|9675642|FG000|Overall Study|Adverse Event|8
6072440|NCT00560755|9675642|FG000|Overall Study|Physician Decision|2
6000268|NCT00023452|9594247|FG001|Overall Study|Pregnant|20
6000269|NCT00023452|9594246|FG000|Overall Study|Other|204
6000270|NCT00023452|9594247|FG001|Overall Study|Other|69
6000271|NCT00023595|9594262|FG000|5 Year Follow up|Lost to Follow-up|2
6000272|NCT00023595|9594263|FG001|5 Year Follow up|Lost to Follow-up|2
6000273|NCT00023595|9594264|FG002|5 Year Follow up|Lost to Follow-up|1
6000274|NCT00023595|9594265|FG003|5 Year Follow up|Lost to Follow-up|7
6000275|NCT00023595|9594266|FG004|5 Year Follow up|Lost to Follow-up|3
6000276|NCT00023595|9594262|FG000|10 Year Follow up|Lost to Follow-up|12
6000277|NCT00023595|9594263|FG001|10 Year Follow up|Lost to Follow-up|10
6000278|NCT00023595|9594264|FG002|10 Year Follow up|Lost to Follow-up|3
6000279|NCT00023595|9594265|FG003|10 Year Follow up|Lost to Follow-up|0
6000280|NCT00023595|9594266|FG004|10 Year Follow up|Lost to Follow-up|0
6000281|NCT00023673|9594292|FG000|Overall Study|Ineligible / no protocol treatment|0
6000282|NCT00023673|9594293|FG001|Overall Study|Ineligible / no protocol treatment|0
6000283|NCT00023673|9594294|FG002|Overall Study|Ineligible / no protocol treatment|0
6000284|NCT00023673|9594295|FG003|Overall Study|Ineligible / no protocol treatment|1
6000285|NCT00023673|9594292|FG000|Overall Study|Patient withdrew consent|0
6000286|NCT00023673|9594293|FG001|Overall Study|Patient withdrew consent|0
6000287|NCT00023673|9594294|FG002|Overall Study|Patient withdrew consent|0
6000288|NCT00023673|9594295|FG003|Overall Study|Patient withdrew consent|1
6000289|NCT00023712|9594307|FG000|Overall Study|Not platinum sensitive|1
6000290|NCT00023712|9594308|FG001|Overall Study|Not platinum sensitive|0
6000291|NCT00023712|9594307|FG000|Overall Study|Never treated|1
6000292|NCT00023712|9594308|FG001|Overall Study|Never treated|1
6000293|NCT00023764|9594324|FG000|Overall Study|Other|1
6000294|NCT00023764|9594324|FG000|Overall Study|Adverse Event|4
6000295|NCT00023764|9594324|FG000|Overall Study|Withdrawal by Subject|1
6000296|NCT00023764|9594324|FG000|Overall Study|Progression of disease|6
6000297|NCT00023764|9594324|FG000|Overall Study|patient received other treatment|1
6000298|NCT00023764|9594324|FG000|Overall Study|delay in obtaining staging images|1
6000299|NCT00024167|9594345|FG000|Overall Study|Death|53
6000300|NCT00024167|9594346|FG001|Overall Study|Death|47
6000301|NCT00024258|9594353|FG000|Overall Study|Withdrawal by Subject|1
6000302|NCT00024258|9594353|FG000|Overall Study|Disease Progression|8
6000303|NCT00025155|9594357|FG000|Overall Study|Ineligible: Wrong primary cancer site|1
6000304|NCT00025155|9594357|FG000|Overall Study|Ineligible: Second primary cancer site|1
6000305|NCT00025233|9594366|FG000|Overall Study|Ineligible: wrong cell type|1
6000306|NCT00025233|9594366|FG000|Overall Study|Ineligible: wrong primary|1
6000307|NCT00025233|9594366|FG000|Overall Study|Ineligible: improper prior treatment|1
6000308|NCT00025233|9594366|FG000|Overall Study|Never treated|1
6000309|NCT00025259|9594383|FG000|Overall Study|Death|1
6000310|NCT00025259|9594384|FG001|Overall Study|Death|3
6000311|NCT00025259|9594385|FG002|Overall Study|Death|0
6000312|NCT00025259|9594386|FG003|Overall Study|Death|3
6000313|NCT00025259|9594387|FG004|Overall Study|Death|0
6000314|NCT00025259|9594388|FG005|Overall Study|Death|1
6000315|NCT00025259|9594389|FG006|Overall Study|Death|2
6000316|NCT00025259|9594383|FG000|Overall Study|Lack of Efficacy|2
6000317|NCT00025259|9594384|FG001|Overall Study|Lack of Efficacy|46
6000318|NCT00025259|9594385|FG002|Overall Study|Lack of Efficacy|60
6000319|NCT00025259|9594386|FG003|Overall Study|Lack of Efficacy|78
6000320|NCT00025259|9594387|FG004|Overall Study|Lack of Efficacy|11
6000321|NCT00025259|9594388|FG005|Overall Study|Lack of Efficacy|30
6000322|NCT00025259|9594389|FG006|Overall Study|Lack of Efficacy|38
6000323|NCT00025259|9594383|FG000|Overall Study|Lost to Follow-up|2
6000324|NCT00025259|9594384|FG001|Overall Study|Lost to Follow-up|9
6000325|NCT00025259|9594385|FG002|Overall Study|Lost to Follow-up|13
6000326|NCT00025259|9594386|FG003|Overall Study|Lost to Follow-up|13
6000327|NCT00025259|9594387|FG004|Overall Study|Lost to Follow-up|1
6000328|NCT00025259|9594388|FG005|Overall Study|Lost to Follow-up|3
6000329|NCT00025259|9594389|FG006|Overall Study|Lost to Follow-up|1
6000330|NCT00025259|9594383|FG000|Overall Study|Physician Decision|12
6000331|NCT00025259|9594384|FG001|Overall Study|Physician Decision|1
6000332|NCT00025259|9594385|FG002|Overall Study|Physician Decision|0
6000333|NCT00025259|9594386|FG003|Overall Study|Physician Decision|5
6000334|NCT00025259|9594387|FG004|Overall Study|Physician Decision|4
6000335|NCT00025259|9594388|FG005|Overall Study|Physician Decision|2
6000336|NCT00025259|9594389|FG006|Overall Study|Physician Decision|1
6000337|NCT00025259|9594383|FG000|Overall Study|Protocol Violation|3
6000338|NCT00025259|9594384|FG001|Overall Study|Protocol Violation|2
6000339|NCT00025259|9594385|FG002|Overall Study|Protocol Violation|2
6000340|NCT00025259|9594386|FG003|Overall Study|Protocol Violation|1
6000341|NCT00025259|9594387|FG004|Overall Study|Protocol Violation|2
6000342|NCT00025259|9594388|FG005|Overall Study|Protocol Violation|1
6000343|NCT00025259|9594389|FG006|Overall Study|Protocol Violation|3
6000344|NCT00025259|9594383|FG000|Overall Study|Withdrawal by Subject|9
6000345|NCT00025259|9594384|FG001|Overall Study|Withdrawal by Subject|27
6000346|NCT00025259|9594385|FG002|Overall Study|Withdrawal by Subject|6
6000347|NCT00025259|9594386|FG003|Overall Study|Withdrawal by Subject|14
6000348|NCT00025259|9594387|FG004|Overall Study|Withdrawal by Subject|11
6000349|NCT00025259|9594388|FG005|Overall Study|Withdrawal by Subject|8
6000350|NCT00025259|9594389|FG006|Overall Study|Withdrawal by Subject|3
6000351|NCT00025259|9594383|FG000|Overall Study|Ineligible|14
6000352|NCT00025259|9594384|FG001|Overall Study|Ineligible|1
6000353|NCT00025259|9594385|FG002|Overall Study|Ineligible|0
6000354|NCT00025259|9594386|FG003|Overall Study|Ineligible|0
6000355|NCT00025259|9594387|FG004|Overall Study|Ineligible|6
6000356|NCT00025259|9594388|FG005|Overall Study|Ineligible|0
6000357|NCT00025259|9594389|FG006|Overall Study|Ineligible|1
6000358|NCT00025259|9594383|FG000|Overall Study|Randomization error|1
6000359|NCT00025259|9594384|FG001|Overall Study|Randomization error|0
6000360|NCT00025259|9594385|FG002|Overall Study|Randomization error|0
6000361|NCT00025259|9594386|FG003|Overall Study|Randomization error|0
6000362|NCT00025259|9594387|FG004|Overall Study|Randomization error|1
6000363|NCT00025259|9594388|FG005|Overall Study|Randomization error|7
6000364|NCT00025259|9594389|FG006|Overall Study|Randomization error|2
6000365|NCT00025259|9594383|FG000|Overall Study|Adverse Event|1
6000366|NCT00025259|9594384|FG001|Overall Study|Adverse Event|0
6000367|NCT00025259|9594385|FG002|Overall Study|Adverse Event|0
6000368|NCT00025259|9594386|FG003|Overall Study|Adverse Event|0
6000369|NCT00025259|9594387|FG004|Overall Study|Adverse Event|0
6000370|NCT00025259|9594388|FG005|Overall Study|Adverse Event|0
6000371|NCT00025259|9594389|FG006|Overall Study|Adverse Event|0
6000372|NCT00025506|9594408|FG000|Overall Study|Ineligible: clerical error|1
6000373|NCT00025506|9594408|FG000|Overall Study|Ineligible: wrong cell type|5
6000374|NCT00025506|9594408|FG000|Overall Study|Ineligible: inadequate pathology|2
6000375|NCT00025506|9594408|FG000|Overall Study|Never Treated|2
6000376|NCT00025662|9594417|FG000|Overall Study|Withdrawal by Subject|2
6000377|NCT00025662|9594417|FG000|Overall Study|Technical failure of manipulation|1
6000378|NCT00025883|9594423|FG000|Overall Study|had atypical progeriod lipodystrophy|4
6000379|NCT00025883|9594423|FG000|Overall Study|no baseline data|1
6000380|NCT00025883|9594423|FG000|Overall Study|Death|1
6000381|NCT00025883|9594423|FG000|Overall Study|Adverse Event|1
6000382|NCT00025883|9594423|FG000|Overall Study|didn't reach 6 months of Metreleptin|10
6000383|NCT00026208|9594430|FG000|Overall Study|Complications of auto accident|1
6000384|NCT00026208|9594431|FG001|Overall Study|Complications of auto accident|0
6000385|NCT00026494|9594454|FG000|Overall Study|Withdrawal by Subject|1
6000386|NCT00026494|9594455|FG001|Overall Study|Withdrawal by Subject|0
6000387|NCT00026494|9594456|FG002|Overall Study|Withdrawal by Subject|1
6000388|NCT00026494|9594457|FG003|Overall Study|Withdrawal by Subject|0
6000389|NCT00026494|9594454|FG000|Overall Study|Patient non-compliance|1
6000390|NCT00026494|9594455|FG001|Overall Study|Patient non-compliance|0
6000391|NCT00026494|9594456|FG002|Overall Study|Patient non-compliance|0
6000392|NCT00026494|9594457|FG003|Overall Study|Patient non-compliance|0
6000393|NCT00026494|9594454|FG000|Overall Study|Patient not treated|0
6000394|NCT00026494|9594455|FG001|Overall Study|Patient not treated|0
6000395|NCT00026494|9594456|FG002|Overall Study|Patient not treated|2
6000396|NCT00026494|9594457|FG003|Overall Study|Patient not treated|0
6000397|NCT00026494|9594454|FG000|Overall Study|Clinical progression|0
6000398|NCT00026494|9594455|FG001|Overall Study|Clinical progression|0
6000399|NCT00026494|9594456|FG002|Overall Study|Clinical progression|3
6000400|NCT00026494|9594457|FG003|Overall Study|Clinical progression|0
6000401|NCT00026793|9594467|FG000|Overall Study|Death on study due to underlying disease|4
6000402|NCT00026793|9594467|FG000|Overall Study|Physician Decision|2
6000403|NCT00026793|9594467|FG000|Overall Study|Off study|2
6000404|NCT00027027|9594476|FG000|Overall Study|Adverse Event|0
6000405|NCT00027027|9594477|FG001|Overall Study|Adverse Event|0
6000406|NCT00027027|9594478|FG002|Overall Study|Adverse Event|1
6000407|NCT00027027|9594479|FG003|Overall Study|Adverse Event|0
6000408|NCT00027027|9594480|FG004|Overall Study|Adverse Event|1
6000409|NCT00027027|9594476|FG000|Overall Study|Admitted for Signs of PD|0
6000410|NCT00027027|9594477|FG001|Overall Study|Admitted for Signs of PD|0
6000411|NCT00027027|9594478|FG002|Overall Study|Admitted for Signs of PD|0
6000412|NCT00027027|9594479|FG003|Overall Study|Admitted for Signs of PD|0
6000413|NCT00027027|9594480|FG004|Overall Study|Admitted for Signs of PD|1
6000414|NCT00027027|9594476|FG000|Overall Study|Clinical Symptoms Progression not PD|1
6000415|NCT00027027|9594477|FG001|Overall Study|Clinical Symptoms Progression not PD|0
6000416|NCT00027027|9594478|FG002|Overall Study|Clinical Symptoms Progression not PD|0
6000417|NCT00027027|9594479|FG003|Overall Study|Clinical Symptoms Progression not PD|0
6000418|NCT00027027|9594480|FG004|Overall Study|Clinical Symptoms Progression not PD|0
6000419|NCT00027027|9594476|FG000|Overall Study|PD Requiring Surgery|0
6000420|NCT00027027|9594477|FG001|Overall Study|PD Requiring Surgery|0
6000421|NCT00027027|9594478|FG002|Overall Study|PD Requiring Surgery|1
6000422|NCT00027027|9594479|FG003|Overall Study|PD Requiring Surgery|0
6000423|NCT00027027|9594480|FG004|Overall Study|PD Requiring Surgery|0
6000424|NCT00027027|9594476|FG000|Overall Study|Physician Decision Due To PD|2
6000425|NCT00027027|9594477|FG001|Overall Study|Physician Decision Due To PD|3
6000426|NCT00027027|9594478|FG002|Overall Study|Physician Decision Due To PD|2
6000427|NCT00027027|9594479|FG003|Overall Study|Physician Decision Due To PD|3
6000428|NCT00027027|9594480|FG004|Overall Study|Physician Decision Due To PD|5
6000429|NCT00027027|9594476|FG000|Overall Study|Withdrawal by Subject|0
6000430|NCT00027027|9594477|FG001|Overall Study|Withdrawal by Subject|0
6000431|NCT00027027|9594478|FG002|Overall Study|Withdrawal by Subject|0
6000432|NCT00027027|9594479|FG003|Overall Study|Withdrawal by Subject|0
6000433|NCT00027027|9594480|FG004|Overall Study|Withdrawal by Subject|1
6000434|NCT00027378|9594498|FG000|Overall Study|Physician Decision|0
6000435|NCT00027378|9594499|FG001|Overall Study|Physician Decision|3
6000436|NCT00027560|9594505|FG000|Overall Study|Withdrawal by Subject|1
6000437|NCT00027846|9594514|FG000|Overall Study|Lost to Follow-up|0
6000438|NCT00027846|9594515|FG001|Overall Study|Lost to Follow-up|41
6000439|NCT00027846|9594516|FG002|Overall Study|Lost to Follow-up|9
6000440|NCT00027846|9594514|FG000|Overall Study|Withdrawal by Subject|0
6000441|NCT00027846|9594515|FG001|Overall Study|Withdrawal by Subject|14
6000442|NCT00027846|9594516|FG002|Overall Study|Withdrawal by Subject|7
6000443|NCT00027846|9594514|FG000|Overall Study|Ineligible for study|2
6000444|NCT00027846|9594515|FG001|Overall Study|Ineligible for study|6
6000445|NCT00027846|9594516|FG002|Overall Study|Ineligible for study|14
6000446|NCT00027846|9594514|FG000|Overall Study|Entry into another COG therapeutic study|0
6072441|NCT00560794|9675647|FG000|Overall Study|Adverse Event|2
6000447|NCT00027846|9594515|FG001|Overall Study|Entry into another COG therapeutic study|5
6000448|NCT00027846|9594516|FG002|Overall Study|Entry into another COG therapeutic study|2
6000449|NCT00027846|9594514|FG000|Overall Study|Neuraxis dissemination during/after ther|0
6000450|NCT00027846|9594515|FG001|Overall Study|Neuraxis dissemination during/after ther|2
6000451|NCT00027846|9594516|FG002|Overall Study|Neuraxis dissemination during/after ther|5
6000452|NCT00028002|9594526|FG000|Overall Study|Withdrawal by Subject|3
6000453|NCT00028002|9594526|FG000|Overall Study|Ineligible|8
6000454|NCT00028769|9594544|FG000|Overall Study|Adverse Event|2
6000455|NCT00028769|9594544|FG000|Overall Study|Refusal Unrelated to Adverse Events|1
6000456|NCT00028769|9594544|FG000|Overall Study|Progression or Death|31
6000457|NCT00028769|9594544|FG000|Overall Study|Other - Not Protocol Specified|1
6000458|NCT00028769|9594544|FG000|Overall Study|Ineligible|5
6000459|NCT00028769|9594544|FG000|Overall Study|Not Analyzable|1
6047208|NCT00410410|9646250|FG001|Induction Period (IP)|Death|0
6047209|NCT00410410|9646251|FG002|Induction Period (IP)|Death|0
6047210|NCT00410410|9646252|FG003|Induction Period (IP)|Death|0
6047211|NCT00410410|9646253|FG004|Induction Period (IP)|Death|0
6047212|NCT00410410|9646254|FG005|Induction Period (IP)|Death|0
6047213|NCT00410410|9646255|FG006|Induction Period (IP)|Death|0
6047214|NCT00410410|9646256|FG007|Induction Period (IP)|Death|0
6047215|NCT00410410|9646257|FG008|Induction Period (IP)|Death|0
6047216|NCT00410410|9646249|FG000|Induction Period (IP)|Adverse Event|3
6047217|NCT00410410|9646250|FG001|Induction Period (IP)|Adverse Event|4
6047218|NCT00410410|9646251|FG002|Induction Period (IP)|Adverse Event|2
6047219|NCT00410410|9646252|FG003|Induction Period (IP)|Adverse Event|4
6047220|NCT00410410|9646253|FG004|Induction Period (IP)|Adverse Event|1
6047221|NCT00410410|9646254|FG005|Induction Period (IP)|Adverse Event|0
6047222|NCT00410410|9646255|FG006|Induction Period (IP)|Adverse Event|0
6047223|NCT00410410|9646256|FG007|Induction Period (IP)|Adverse Event|0
6047224|NCT00410410|9646257|FG008|Induction Period (IP)|Adverse Event|0
6047225|NCT00410410|9646249|FG000|Induction Period (IP)|Lack of Efficacy|26
6047226|NCT00410410|9646250|FG001|Induction Period (IP)|Lack of Efficacy|24
6047227|NCT00410410|9646251|FG002|Induction Period (IP)|Lack of Efficacy|8
6047228|NCT00410410|9646252|FG003|Induction Period (IP)|Lack of Efficacy|8
6047229|NCT00410410|9646253|FG004|Induction Period (IP)|Lack of Efficacy|7
6047230|NCT00410410|9646254|FG005|Induction Period (IP)|Lack of Efficacy|7
6047231|NCT00410410|9646255|FG006|Induction Period (IP)|Lack of Efficacy|0
6047232|NCT00410410|9646256|FG007|Induction Period (IP)|Lack of Efficacy|0
6047233|NCT00410410|9646257|FG008|Induction Period (IP)|Lack of Efficacy|0
6047234|NCT00410410|9646249|FG000|Induction Period (IP)|Lost to Follow-up|2
6047235|NCT00410410|9646250|FG001|Induction Period (IP)|Lost to Follow-up|2
6047236|NCT00410410|9646251|FG002|Induction Period (IP)|Lost to Follow-up|2
6047237|NCT00410410|9646252|FG003|Induction Period (IP)|Lost to Follow-up|3
6047238|NCT00410410|9646253|FG004|Induction Period (IP)|Lost to Follow-up|0
6047239|NCT00410410|9646254|FG005|Induction Period (IP)|Lost to Follow-up|1
6047240|NCT00410410|9646255|FG006|Induction Period (IP)|Lost to Follow-up|0
6047241|NCT00410410|9646256|FG007|Induction Period (IP)|Lost to Follow-up|0
6047242|NCT00410410|9646257|FG008|Induction Period (IP)|Lost to Follow-up|0
6047243|NCT00410410|9646249|FG000|Induction Period (IP)|Withdrawal by Subject|3
6047244|NCT00410410|9646250|FG001|Induction Period (IP)|Withdrawal by Subject|5
6047245|NCT00410410|9646251|FG002|Induction Period (IP)|Withdrawal by Subject|3
6047246|NCT00410410|9646252|FG003|Induction Period (IP)|Withdrawal by Subject|5
6047247|NCT00410410|9646253|FG004|Induction Period (IP)|Withdrawal by Subject|2
6047248|NCT00410410|9646254|FG005|Induction Period (IP)|Withdrawal by Subject|0
6047249|NCT00410410|9646255|FG006|Induction Period (IP)|Withdrawal by Subject|0
6047250|NCT00410410|9646256|FG007|Induction Period (IP)|Withdrawal by Subject|0
6047251|NCT00410410|9646257|FG008|Induction Period (IP)|Withdrawal by Subject|0
6047252|NCT00410410|9646249|FG000|Induction Period (IP)|Subject No Longer Meets Study Criteria|0
6047253|NCT00410410|9646250|FG001|Induction Period (IP)|Subject No Longer Meets Study Criteria|0
6047254|NCT00410410|9646251|FG002|Induction Period (IP)|Subject No Longer Meets Study Criteria|1
6047255|NCT00410410|9646252|FG003|Induction Period (IP)|Subject No Longer Meets Study Criteria|0
6047256|NCT00410410|9646253|FG004|Induction Period (IP)|Subject No Longer Meets Study Criteria|0
6047257|NCT00410410|9646254|FG005|Induction Period (IP)|Subject No Longer Meets Study Criteria|0
6047258|NCT00410410|9646255|FG006|Induction Period (IP)|Subject No Longer Meets Study Criteria|0
6047259|NCT00410410|9646256|FG007|Induction Period (IP)|Subject No Longer Meets Study Criteria|0
6072442|NCT00560794|9675647|FG000|Overall Study|Patient was not Compliant|1
6000460|NCT00029146|9594559|FG000|Overall Study|Lost to Follow-up|2
6000461|NCT00029146|9594560|FG001|Overall Study|Lost to Follow-up|1
6000462|NCT00030823|9594610|FG000|Overall Study|Withdrawal by Subject|1
6000463|NCT00030901|9594616|FG000|Initial Registration|Ineligible|167
6000464|NCT00030901|9594617|FG001|Initial Registration|Ineligible|0
6000465|NCT00030901|9594618|FG002|Initial Registration|Ineligible|0
6000466|NCT00030901|9594616|FG000|Randomization|Adverse Event|0
6000467|NCT00030901|9594617|FG001|Randomization|Adverse Event|11
6000468|NCT00030901|9594618|FG002|Randomization|Adverse Event|7
6000469|NCT00030901|9594616|FG000|Randomization|Refusal Unrelated to Adverse Event|0
6000470|NCT00030901|9594617|FG001|Randomization|Refusal Unrelated to Adverse Event|16
6000471|NCT00030901|9594618|FG002|Randomization|Refusal Unrelated to Adverse Event|10
6000472|NCT00030901|9594616|FG000|Randomization|Progression/Relapse|0
6000473|NCT00030901|9594617|FG001|Randomization|Progression/Relapse|22
6000474|NCT00030901|9594618|FG002|Randomization|Progression/Relapse|21
6000475|NCT00030901|9594616|FG000|Randomization|Death|0
6000476|NCT00030901|9594617|FG001|Randomization|Death|1
6000477|NCT00030901|9594618|FG002|Randomization|Death|3
6000478|NCT00030901|9594616|FG000|Randomization|Other|0
6000479|NCT00030901|9594617|FG001|Randomization|Other|36
6000480|NCT00030901|9594618|FG002|Randomization|Other|33
6000481|NCT00030901|9594616|FG000|Randomization|Ineligible|0
6000482|NCT00030901|9594617|FG001|Randomization|Ineligible|15
6000483|NCT00030901|9594618|FG002|Randomization|Ineligible|14
6000484|NCT00031447|9594630|FG000|Overall Study|Lost to Follow-up|0
6000485|NCT00031447|9594631|FG001|Overall Study|Lost to Follow-up|1
6000486|NCT00031447|9594630|FG000|Overall Study|Non-compliant|1
6000487|NCT00031447|9594631|FG001|Overall Study|Non-compliant|1
6000488|NCT00031447|9594630|FG000|Overall Study|Re-activation of Disease|2
6000489|NCT00031447|9594631|FG001|Overall Study|Re-activation of Disease|1
6000490|NCT00031447|9594630|FG000|Overall Study|Disruption of blinded study drug supply|7
6000491|NCT00031447|9594631|FG001|Overall Study|Disruption of blinded study drug supply|4
6000492|NCT00031460|9594639|FG000|Overall Study|Lost to Follow-up|0
6000493|NCT00031460|9594640|FG001|Overall Study|Lost to Follow-up|1
6000494|NCT00031460|9594639|FG000|Overall Study|Withdrawal by Subject|1
6000495|NCT00031460|9594640|FG001|Overall Study|Withdrawal by Subject|1
6000496|NCT00031460|9594639|FG000|Overall Study|Non-Compliant|1
6000497|NCT00031460|9594640|FG001|Overall Study|Non-Compliant|1
6000498|NCT00031460|9594639|FG000|Overall Study|Death|0
6000499|NCT00031460|9594640|FG001|Overall Study|Death|1
6000500|NCT00031460|9594639|FG000|Overall Study|Reactivation of Disease|5
6000501|NCT00031460|9594640|FG001|Overall Study|Reactivation of Disease|9
6000502|NCT00031460|9594639|FG000|Overall Study|Disruption of blinded drug supply|2
6000503|NCT00031460|9594640|FG001|Overall Study|Disruption of blinded drug supply|0
6000504|NCT00031460|9594639|FG000|Overall Study|Confirmed unevaluable|0
6000505|NCT00031460|9594640|FG001|Overall Study|Confirmed unevaluable|1
6000506|NCT00031486|9594648|FG000|Overall Study|Adverse Event|1
6000507|NCT00031486|9594649|FG001|Overall Study|Adverse Event|0
6000508|NCT00031486|9594648|FG000|Overall Study|Lost to Follow-up|0
6000509|NCT00031486|9594649|FG001|Overall Study|Lost to Follow-up|1
6000510|NCT00031486|9594648|FG000|Overall Study|Withdrawal by Subject|3
6000511|NCT00031486|9594649|FG001|Overall Study|Withdrawal by Subject|2
6000512|NCT00031486|9594648|FG000|Overall Study|Death|0
6000513|NCT00031486|9594649|FG001|Overall Study|Death|3
6000514|NCT00031486|9594648|FG000|Overall Study|Non-compliant|0
6000515|NCT00031486|9594649|FG001|Overall Study|Non-compliant|4
6000516|NCT00031486|9594648|FG000|Overall Study|Did not meet eligibility requirement|2
6000517|NCT00031486|9594649|FG001|Overall Study|Did not meet eligibility requirement|1
6000518|NCT00031486|9594648|FG000|Overall Study|Other|1
6000519|NCT00031486|9594649|FG001|Overall Study|Other|1
6000520|NCT00031551|9594659|FG000|Overall Study|Withdrew due to chemotherapy effects|2
6000521|NCT00031551|9594660|FG001|Overall Study|Withdrew due to chemotherapy effects|0
6000522|NCT00031590|9594670|FG000|Overall Study|Adverse Event|1
6000523|NCT00031590|9594670|FG000|Overall Study|Withdrawal by parents|2
6000524|NCT00031694|9594675|FG000|Overall Study|Adverse Event|12
6000525|NCT00031694|9594675|FG000|Overall Study|Death|2
6000526|NCT00031694|9594675|FG000|Overall Study|Withdrawal by Subject|5
6000527|NCT00032487|9594682|FG000|Overall Study|Withdrawal by Subject|67
6000528|NCT00032487|9594683|FG001|Overall Study|Withdrawal by Subject|43
6000529|NCT00032487|9594682|FG000|Overall Study|Adverse Event|3
6000530|NCT00032487|9594683|FG001|Overall Study|Adverse Event|7
6000531|NCT00032487|9594682|FG000|Overall Study|Lost to Follow-up|57
6000532|NCT00032487|9594683|FG001|Overall Study|Lost to Follow-up|58
6000533|NCT00032487|9594682|FG000|Overall Study|Had other reason|12
6000534|NCT00032487|9594683|FG001|Overall Study|Had other reason|12
6000535|NCT00033371|9594709|FG000|Overall Study|Adverse Event|1
6000536|NCT00033371|9594710|FG001|Overall Study|Adverse Event|5
6000537|NCT00033371|9594709|FG000|Overall Study|Lost to Follow-up|2
6000538|NCT00033371|9594710|FG001|Overall Study|Lost to Follow-up|1
6000539|NCT00033371|9594709|FG000|Overall Study|Withdrawal by Subject|3
6000540|NCT00033371|9594710|FG001|Overall Study|Withdrawal by Subject|3
6000541|NCT00033371|9594709|FG000|Overall Study|Disease Progression|0
6000542|NCT00033371|9594710|FG001|Overall Study|Disease Progression|1
6000543|NCT00033514|9594722|FG000|Overall Study|Lost to Follow-up|1
6000544|NCT00033514|9594723|FG001|Overall Study|Lost to Follow-up|1
6000545|NCT00033514|9594722|FG000|Overall Study|Withdrawal by Subject|0
6000546|NCT00033514|9594723|FG001|Overall Study|Withdrawal by Subject|3
6000547|NCT00033540|9594730|FG000|Overall Study|Adverse Event|14
6000548|NCT00033540|9594730|FG000|Overall Study|Death|1
6000549|NCT00033540|9594730|FG000|Overall Study|Progression|26
6000550|NCT00033540|9594730|FG000|Overall Study|Withdrawal by Subject|6
6000551|NCT00033540|9594730|FG000|Overall Study|Other|5
6000552|NCT00033540|9594730|FG000|Overall Study|Ineligible|3
6072443|NCT00560794|9675647|FG000|Overall Study|Minimal Residual Disease Relapse|1
6072444|NCT00560794|9675647|FG000|Overall Study|Hematological Relapse|1
6072445|NCT00560794|9675647|FG000|Overall Study|Received Bone Marrow Transplant|6
6072446|NCT00560833|9675658|FG000|Overall Study|Adverse Event|16
6072447|NCT00560833|9675659|FG001|Overall Study|Adverse Event|10
6072448|NCT00560833|9675660|FG002|Overall Study|Adverse Event|25
6072449|NCT00560833|9675661|FG003|Overall Study|Adverse Event|23
6072450|NCT00560833|9675662|FG004|Overall Study|Adverse Event|35
6072451|NCT00560833|9675658|FG000|Overall Study|Lost to Follow-up|0
6072452|NCT00560833|9675659|FG001|Overall Study|Lost to Follow-up|0
6072453|NCT00560833|9675660|FG002|Overall Study|Lost to Follow-up|1
6072454|NCT00560833|9675661|FG003|Overall Study|Lost to Follow-up|0
6072455|NCT00560833|9675662|FG004|Overall Study|Lost to Follow-up|0
6072456|NCT00560833|9675658|FG000|Overall Study|Lack of Efficacy|22
6072457|NCT00560833|9675659|FG001|Overall Study|Lack of Efficacy|9
6072458|NCT00560833|9675660|FG002|Overall Study|Lack of Efficacy|6
6072459|NCT00560833|9675661|FG003|Overall Study|Lack of Efficacy|4
6072460|NCT00560833|9675662|FG004|Overall Study|Lack of Efficacy|4
6072461|NCT00560833|9675658|FG000|Overall Study|Participant uncooperative|5
6072462|NCT00560833|9675659|FG001|Overall Study|Participant uncooperative|5
6000553|NCT00033540|9594730|FG000|Overall Study|Never received treatment|2
6000554|NCT00033631|9594737|FG000|Overall Study|Protocol Violation|14
6000555|NCT00033631|9594738|FG001|Overall Study|Protocol Violation|11
6000556|NCT00033631|9594737|FG000|Overall Study|Withdrawal by Subject|4
6000557|NCT00033631|9594738|FG001|Overall Study|Withdrawal by Subject|4
6000558|NCT00033657|9594747|FG000|Neoadjuvant Chemotherapy|Lack of Efficacy|1
6000559|NCT00033657|9594748|FG001|Neoadjuvant Chemotherapy|Lack of Efficacy|2
6000560|NCT00033657|9594747|FG000|Neoadjuvant Chemotherapy|Adverse Event|0
6000561|NCT00033657|9594748|FG001|Neoadjuvant Chemotherapy|Adverse Event|2
6000562|NCT00033657|9594747|FG000|Neoadjuvant Chemotherapy|Death|1
6000563|NCT00033657|9594748|FG001|Neoadjuvant Chemotherapy|Death|1
6000564|NCT00033657|9594747|FG000|Neoadjuvant Chemotherapy|Withdrawal by Subject|1
6000565|NCT00033657|9594748|FG001|Neoadjuvant Chemotherapy|Withdrawal by Subject|0
6000566|NCT00033657|9594747|FG000|Neoadjuvant Chemotherapy|other complicating disease|0
6000567|NCT00033657|9594748|FG001|Neoadjuvant Chemotherapy|other complicating disease|1
6000568|NCT00033657|9594747|FG000|Neoadjuvant Chemotherapy|Ineligible|8
6000569|NCT00033657|9594748|FG001|Neoadjuvant Chemotherapy|Ineligible|4
6000570|NCT00033657|9594747|FG000|Neoadjuvant Chemotherapy|Not started protocol therapy|3
6000571|NCT00033657|9594748|FG001|Neoadjuvant Chemotherapy|Not started protocol therapy|1
6000572|NCT00033657|9594747|FG000|Surgical Resection|not complete resection|0
6000573|NCT00033657|9594748|FG001|Surgical Resection|not complete resection|3
6000574|NCT00033657|9594747|FG000|Adjuvant Chemotherapy|Lack of Efficacy|3
6000575|NCT00033657|9594748|FG001|Adjuvant Chemotherapy|Lack of Efficacy|1
6000576|NCT00033657|9594747|FG000|Adjuvant Chemotherapy|Adverse Event|7
6000577|NCT00033657|9594748|FG001|Adjuvant Chemotherapy|Adverse Event|10
6000578|NCT00033657|9594747|FG000|Adjuvant Chemotherapy|Death|2
6000579|NCT00033657|9594748|FG001|Adjuvant Chemotherapy|Death|1
6000580|NCT00033657|9594747|FG000|Adjuvant Chemotherapy|Withdrawal by Subject|5
6000581|NCT00033657|9594748|FG001|Adjuvant Chemotherapy|Withdrawal by Subject|3
6000582|NCT00033657|9594747|FG000|Adjuvant Chemotherapy|alternative therapy|1
6000583|NCT00033657|9594748|FG001|Adjuvant Chemotherapy|alternative therapy|0
6000584|NCT00033657|9594747|FG000|Adjuvant Chemotherapy|Other|0
6000585|NCT00033657|9594748|FG001|Adjuvant Chemotherapy|Other|2
6000586|NCT00035555|9594772|FG000|Overall Study|Adverse Event|5
6000587|NCT00035555|9594773|FG001|Overall Study|Adverse Event|8
6000588|NCT00035555|9594774|FG002|Overall Study|Adverse Event|9
6000589|NCT00035555|9594772|FG000|Overall Study|Allograft loss|1
6000590|NCT00035555|9594773|FG001|Overall Study|Allograft loss|1
6000591|NCT00035555|9594774|FG002|Overall Study|Allograft loss|2
6000592|NCT00035555|9594772|FG000|Overall Study|Death|0
6000593|NCT00035555|9594773|FG001|Overall Study|Death|0
6000594|NCT00035555|9594774|FG002|Overall Study|Death|2
6000595|NCT00035555|9594772|FG000|Overall Study|Lost to Follow-up|0
6000596|NCT00035555|9594773|FG001|Overall Study|Lost to Follow-up|0
6000597|NCT00035555|9594774|FG002|Overall Study|Lost to Follow-up|1
6000598|NCT00035555|9594772|FG000|Overall Study|Noncompliance|0
6000599|NCT00035555|9594773|FG001|Overall Study|Noncompliance|1
6000600|NCT00035555|9594774|FG002|Overall Study|Noncompliance|1
6000601|NCT00035555|9594772|FG000|Overall Study|Prohibited medication|1
6000602|NCT00035555|9594773|FG001|Overall Study|Prohibited medication|1
6072463|NCT00560833|9675660|FG002|Overall Study|Participant uncooperative|4
6072464|NCT00560833|9675661|FG003|Overall Study|Participant uncooperative|4
6072465|NCT00560833|9675662|FG004|Overall Study|Participant uncooperative|2
6072466|NCT00560833|9675658|FG000|Overall Study|Other|1
6000603|NCT00035555|9594774|FG002|Overall Study|Prohibited medication|0
6000604|NCT00035555|9594772|FG000|Overall Study|Treatment failure/lack of efficacy|7
6072467|NCT00560833|9675659|FG001|Overall Study|Other|1
6072468|NCT00560833|9675660|FG002|Overall Study|Other|3
6000605|NCT00035555|9594773|FG001|Overall Study|Treatment failure/lack of efficacy|5
6000606|NCT00035555|9594774|FG002|Overall Study|Treatment failure/lack of efficacy|3
6000607|NCT00035555|9594772|FG000|Overall Study|Withdrawal by Subject|2
6000608|NCT00035555|9594773|FG001|Overall Study|Withdrawal by Subject|0
6000609|NCT00035555|9594774|FG002|Overall Study|Withdrawal by Subject|2
6000610|NCT00035555|9594772|FG000|Overall Study|Investigator deemed not a good candidate|0
6000611|NCT00035555|9594773|FG001|Overall Study|Investigator deemed not a good candidate|0
6000612|NCT00035555|9594774|FG002|Overall Study|Investigator deemed not a good candidate|1
6000613|NCT00035555|9594772|FG000|Overall Study|Received cyclosporin in error|0
6000614|NCT00035555|9594773|FG001|Overall Study|Received cyclosporin in error|0
6000615|NCT00035555|9594774|FG002|Overall Study|Received cyclosporin in error|1
6000616|NCT00035815|9594785|FG000|Overall Study|Withdrawal by Subject|17
6000617|NCT00035815|9594786|FG001|Overall Study|Withdrawal by Subject|11
6000618|NCT00035932|9594795|FG000|Overall Study|Adverse Event|10
6000619|NCT00035932|9594796|FG001|Overall Study|Adverse Event|9
6000620|NCT00035932|9594797|FG002|Overall Study|Adverse Event|9
6000621|NCT00035932|9594795|FG000|Overall Study|Death|0
6000622|NCT00035932|9594796|FG001|Overall Study|Death|0
6000623|NCT00035932|9594797|FG002|Overall Study|Death|1
6000624|NCT00035932|9594795|FG000|Overall Study|Disease Progression / Relapse|1
6000625|NCT00035932|9594796|FG001|Overall Study|Disease Progression / Relapse|1
6000626|NCT00035932|9594797|FG002|Overall Study|Disease Progression / Relapse|0
6000627|NCT00035932|9594795|FG000|Overall Study|Lost to Follow-up|4
6072469|NCT00560833|9675661|FG003|Overall Study|Other|0
6072470|NCT00560833|9675662|FG004|Overall Study|Other|0
6072471|NCT00560833|9675658|FG000|Overall Study|Never received drug|0
6072472|NCT00560833|9675659|FG001|Overall Study|Never received drug|1
6072473|NCT00560833|9675660|FG002|Overall Study|Never received drug|0
6072474|NCT00560833|9675661|FG003|Overall Study|Never received drug|0
6072475|NCT00560833|9675662|FG004|Overall Study|Never received drug|1
6072476|NCT00560885|9675684|FG000|Overall Study|Death|7
6072477|NCT00560885|9675684|FG000|Overall Study|Withdrawal by Subject|1
6072478|NCT00560937|9675690|FG000|Overall Study|Withdrawal by Subject|0
6072479|NCT00560937|9675691|FG001|Overall Study|Withdrawal by Subject|1
6072480|NCT00560937|9675690|FG000|Overall Study|Physician Decision|1
6072481|NCT00560937|9675691|FG001|Overall Study|Physician Decision|1
6072482|NCT00560950|9675699|FG000|Overall Study|Lost to Follow-up|1
6072483|NCT00560950|9675700|FG001|Overall Study|Lost to Follow-up|0
6072484|NCT00561015|9675723|FG000|Overall Study|Adverse Event|0
6072485|NCT00561015|9675724|FG001|Overall Study|Adverse Event|0
6072486|NCT00561015|9675725|FG002|Overall Study|Adverse Event|0
6072487|NCT00561015|9675726|FG003|Overall Study|Adverse Event|0
6072488|NCT00561015|9675727|FG004|Overall Study|Adverse Event|1
6072489|NCT00561015|9675728|FG005|Overall Study|Adverse Event|0
6072490|NCT00561015|9675723|FG000|Overall Study|Lost to Follow-up|2
6072491|NCT00561015|9675724|FG001|Overall Study|Lost to Follow-up|0
6072492|NCT00561015|9675725|FG002|Overall Study|Lost to Follow-up|0
6072493|NCT00561015|9675726|FG003|Overall Study|Lost to Follow-up|1
6072494|NCT00561015|9675727|FG004|Overall Study|Lost to Follow-up|0
6072495|NCT00561015|9675728|FG005|Overall Study|Lost to Follow-up|3
6072496|NCT00561015|9675723|FG000|Overall Study|Participant non-compliance|2
6072497|NCT00561015|9675724|FG001|Overall Study|Participant non-compliance|0
6072498|NCT00561015|9675725|FG002|Overall Study|Participant non-compliance|0
6072499|NCT00561015|9675726|FG003|Overall Study|Participant non-compliance|0
6072500|NCT00561015|9675727|FG004|Overall Study|Participant non-compliance|0
6072501|NCT00561015|9675728|FG005|Overall Study|Participant non-compliance|0
6072502|NCT00561080|9675749|FG000|Vaccination Period (up to Month 4)|Adverse Event|0
6072503|NCT00561080|9675750|FG001|Vaccination Period (up to Month 4)|Adverse Event|4
6072504|NCT00561080|9675751|FG002|Vaccination Period (up to Month 4)|Adverse Event|6
6072505|NCT00561080|9675749|FG000|Vaccination Period (up to Month 4)|Definitive Contra-indication|0
6072506|NCT00561080|9675750|FG001|Vaccination Period (up to Month 4)|Definitive Contra-indication|2
6072507|NCT00561080|9675751|FG002|Vaccination Period (up to Month 4)|Definitive Contra-indication|3
6072508|NCT00561080|9675749|FG000|Vaccination Period (up to Month 4)|Protocol Violation|0
6072509|NCT00561080|9675750|FG001|Vaccination Period (up to Month 4)|Protocol Violation|1
6072510|NCT00561080|9675751|FG002|Vaccination Period (up to Month 4)|Protocol Violation|3
6072511|NCT00561080|9675749|FG000|Vaccination Period (up to Month 4)|Withdrawal by Subject|3
6072512|NCT00561080|9675750|FG001|Vaccination Period (up to Month 4)|Withdrawal by Subject|16
6072513|NCT00561080|9675751|FG002|Vaccination Period (up to Month 4)|Withdrawal by Subject|13
6072514|NCT00561080|9675749|FG000|Vaccination Period (up to Month 4)|Lost to Follow-up|0
6072515|NCT00561080|9675750|FG001|Vaccination Period (up to Month 4)|Lost to Follow-up|1
6072516|NCT00561080|9675751|FG002|Vaccination Period (up to Month 4)|Lost to Follow-up|0
6000628|NCT00035932|9594796|FG001|Overall Study|Lost to Follow-up|4
6000629|NCT00035932|9594797|FG002|Overall Study|Lost to Follow-up|3
6000630|NCT00035932|9594795|FG000|Overall Study|Noncompliance|6
6000631|NCT00035932|9594796|FG001|Overall Study|Noncompliance|7
6000632|NCT00035932|9594797|FG002|Overall Study|Noncompliance|6
6000633|NCT00035932|9594795|FG000|Overall Study|Protocol Violation While on Study|0
6072517|NCT00561080|9675749|FG000|Vaccination Period (up to Month 4)|Other|0
6072518|NCT00561080|9675750|FG001|Vaccination Period (up to Month 4)|Other|2
6000634|NCT00035932|9594796|FG001|Overall Study|Protocol Violation While on Study|1
6000635|NCT00035932|9594797|FG002|Overall Study|Protocol Violation While on Study|2
6000636|NCT00035932|9594795|FG000|Overall Study|Withdrawal by Subject|1
6000637|NCT00035932|9594796|FG001|Overall Study|Withdrawal by Subject|5
6000638|NCT00035932|9594797|FG002|Overall Study|Withdrawal by Subject|0
6000639|NCT00035932|9594795|FG000|Overall Study|Study Termination by Sponsor|1
6000640|NCT00035932|9594796|FG001|Overall Study|Study Termination by Sponsor|0
6000641|NCT00035932|9594797|FG002|Overall Study|Study Termination by Sponsor|0
6000642|NCT00035932|9594795|FG000|Overall Study|Lack of Efficacy|33
6000643|NCT00035932|9594796|FG001|Overall Study|Lack of Efficacy|33
6000644|NCT00035932|9594797|FG002|Overall Study|Lack of Efficacy|28
6000645|NCT00036270|9594812|FG000|Randomized to Study Treatment|Withdrawal by Subject|6
6000646|NCT00036270|9594813|FG001|Randomized to Study Treatment|Withdrawal by Subject|7
6000647|NCT00036270|9594812|FG000|Study Treatment to 5 Year Report|Ongoing|1081
6000648|NCT00036270|9594813|FG001|Study Treatment to 5 Year Report|Ongoing|736
6000649|NCT00036270|9594812|FG000|Study Treatment to 5 Year Report|Disease- Free Survival (DFS) event|507
6000650|NCT00036270|9594813|FG001|Study Treatment to 5 Year Report|Disease- Free Survival (DFS) event|447
6000651|NCT00036270|9594812|FG000|Study Treatment to 5 Year Report|Adverse Event|501
6000652|NCT00036270|9594813|FG001|Study Treatment to 5 Year Report|Adverse Event|782
6000653|NCT00036270|9594812|FG000|Study Treatment to 5 Year Report|Other|277
6000654|NCT00036270|9594813|FG001|Study Treatment to 5 Year Report|Other|288
6000655|NCT00036270|9594812|FG000|Study Treatment to 5 Year Report|Treatment refusal|113
6000656|NCT00036270|9594813|FG001|Study Treatment to 5 Year Report|Treatment refusal|208
6000657|NCT00036270|9594812|FG000|Study Treatment to 5 Year Report|Randomized but not treated|46
6000658|NCT00036270|9594813|FG001|Study Treatment to 5 Year Report|Randomized but not treated|54
6000659|NCT00036270|9594812|FG000|Study Treatment to 5 Year Report|Protocol Violation|23
6000660|NCT00036270|9594813|FG001|Study Treatment to 5 Year Report|Protocol Violation|91
6000661|NCT00036270|9594812|FG000|Study Treatment to 5 Year Report|Intercurrent illness|17
6000662|NCT00036270|9594813|FG001|Study Treatment to 5 Year Report|Intercurrent illness|29
6000663|NCT00036270|9594812|FG000|Study Treatment to 5 Year Report|Too early switch|0
6000664|NCT00036270|9594813|FG001|Study Treatment to 5 Year Report|Too early switch|103
6000665|NCT00036270|9594812|FG000|Study Treatment to 5 Year Report|No/too late switch/refusal to switch|0
6000666|NCT00036270|9594813|FG001|Study Treatment to 5 Year Report|No/too late switch/refusal to switch|750
6000667|NCT00037830|9594832|FG000|Overall Study|Adverse Event|2
6000668|NCT00037830|9594833|FG001|Overall Study|Adverse Event|0
6000669|NCT00037830|9594834|FG002|Overall Study|Adverse Event|0
6000670|NCT00037830|9594832|FG000|Overall Study|Withdrawal by Subject|4
6000671|NCT00037830|9594833|FG001|Overall Study|Withdrawal by Subject|5
6000672|NCT00037830|9594834|FG002|Overall Study|Withdrawal by Subject|1
6000673|NCT00037830|9594832|FG000|Overall Study|Protocol Violation|2
6000674|NCT00037830|9594833|FG001|Overall Study|Protocol Violation|2
6000675|NCT00037830|9594834|FG002|Overall Study|Protocol Violation|0
6000676|NCT00037830|9594832|FG000|Overall Study|Unrelated Medical Problem|2
6000677|NCT00037830|9594833|FG001|Overall Study|Unrelated Medical Problem|0
6000678|NCT00037830|9594834|FG002|Overall Study|Unrelated Medical Problem|0
6000679|NCT00038103|9594844|FG000|Overall Study|Adverse Event|5
6000680|NCT00038103|9594845|FG001|Overall Study|Adverse Event|6
6000681|NCT00038103|9594844|FG000|Overall Study|Lack of Efficacy|48
6000682|NCT00038103|9594845|FG001|Overall Study|Lack of Efficacy|41
6000683|NCT00038103|9594844|FG000|Overall Study|Withdrawal by Subject|0
6000684|NCT00038103|9594845|FG001|Overall Study|Withdrawal by Subject|3
6000685|NCT00038103|9594844|FG000|Overall Study|Lost to Follow-up|0
6000686|NCT00038103|9594845|FG001|Overall Study|Lost to Follow-up|3
6000687|NCT00038103|9594844|FG000|Overall Study|Protocol Violation|0
6000688|NCT00038103|9594845|FG001|Overall Study|Protocol Violation|2
6000689|NCT00038103|9594844|FG000|Overall Study|Sponsor Decision|0
6000690|NCT00038103|9594845|FG001|Overall Study|Sponsor Decision|1
6000691|NCT00038103|9594844|FG000|Overall Study|Randomized/never treated|2
6000692|NCT00038103|9594845|FG001|Overall Study|Randomized/never treated|0
6000693|NCT00038467|9594853|FG000|Overall Study|Adverse Event|170
6000694|NCT00038467|9594854|FG001|Overall Study|Adverse Event|145
6000695|NCT00038467|9594853|FG000|Overall Study|Withdrawal by Subject|150
6000696|NCT00038467|9594854|FG001|Overall Study|Withdrawal by Subject|107
6000697|NCT00038467|9594853|FG000|Overall Study|Protocol Violation|19
6000698|NCT00038467|9594854|FG001|Overall Study|Protocol Violation|22
6000699|NCT00038467|9594853|FG000|Overall Study|Death|22
6000700|NCT00038467|9594854|FG001|Overall Study|Death|16
6000701|NCT00038467|9594853|FG000|Overall Study|Lost to Follow-up|15
6000702|NCT00038467|9594854|FG001|Overall Study|Lost to Follow-up|10
6000703|NCT00038467|9594853|FG000|Overall Study|Recurrence|109
6000704|NCT00038467|9594854|FG001|Overall Study|Recurrence|179
6000705|NCT00038467|9594853|FG000|Overall Study|Randomized, but not treated|31
6000706|NCT00038467|9594854|FG001|Overall Study|Randomized, but not treated|35
6000707|NCT00038467|9594853|FG000|Overall Study|Other|26
6000708|NCT00038467|9594854|FG001|Overall Study|Other|28
6000709|NCT00038649|9594864|FG000|Overall Study|Adverse Event|9
6000710|NCT00038948|9594874|FG000|Overall Study|Adverse Event|131
6000711|NCT00038948|9594875|FG001|Overall Study|Adverse Event|43
6000712|NCT00038948|9594874|FG000|Overall Study|Lost to Follow-up|4
6000713|NCT00038948|9594875|FG001|Overall Study|Lost to Follow-up|4
6000714|NCT00038948|9594874|FG000|Overall Study|Nonmedical event|5
6000715|NCT00038948|9594875|FG001|Overall Study|Nonmedical event|7
6000716|NCT00038948|9594874|FG000|Overall Study|Withdrawal by Subject|23
6000717|NCT00038948|9594875|FG001|Overall Study|Withdrawal by Subject|10
6000718|NCT00038948|9594874|FG000|Overall Study|Protocol Violation|3
6000719|NCT00038948|9594875|FG001|Overall Study|Protocol Violation|7
6000720|NCT00038948|9594874|FG000|Overall Study|Lack of Efficacy|3
6000721|NCT00038948|9594875|FG001|Overall Study|Lack of Efficacy|6
6000722|NCT00039130|9594887|FG000|Overall Study|Adverse Event|11
6000723|NCT00039130|9594887|FG000|Overall Study|Death|9
6000724|NCT00039130|9594887|FG000|Overall Study|Withdrawal by Subject|3
6000725|NCT00039130|9594887|FG000|Overall Study|Progression|2
6000726|NCT00039130|9594887|FG000|Overall Study|Subsequent treatment|2
6000727|NCT00039130|9594887|FG000|Overall Study|Physician Decision|3
6000728|NCT00039377|9594895|FG000|Initial Registration|Adverse Event|2
6000729|NCT00039377|9594896|FG001|Initial Registration|Adverse Event|0
6000730|NCT00039377|9594897|FG002|Initial Registration|Adverse Event|0
6000731|NCT00039377|9594898|FG003|Initial Registration|Adverse Event|0
6000732|NCT00039377|9594895|FG000|Initial Registration|Relapsed|6
6000733|NCT00039377|9594896|FG001|Initial Registration|Relapsed|0
6072519|NCT00561080|9675751|FG002|Vaccination Period (up to Month 4)|Other|1
6072520|NCT00561080|9675749|FG000|12-month Post Last Dose Follow-up|Adverse Event|3
6072521|NCT00561080|9675750|FG001|12-month Post Last Dose Follow-up|Adverse Event|3
6072522|NCT00561080|9675751|FG002|12-month Post Last Dose Follow-up|Adverse Event|1
6072523|NCT00561080|9675749|FG000|12-month Post Last Dose Follow-up|Protocol Violation|0
6072524|NCT00561080|9675750|FG001|12-month Post Last Dose Follow-up|Protocol Violation|0
6072525|NCT00561080|9675751|FG002|12-month Post Last Dose Follow-up|Protocol Violation|4
6072526|NCT00561080|9675749|FG000|12-month Post Last Dose Follow-up|Withdrawal by Subject|2
6072527|NCT00561080|9675750|FG001|12-month Post Last Dose Follow-up|Withdrawal by Subject|6
6072528|NCT00561080|9675751|FG002|12-month Post Last Dose Follow-up|Withdrawal by Subject|5
6072529|NCT00561080|9675749|FG000|12-month Post Last Dose Follow-up|Lost to Follow-up|2
6072530|NCT00561080|9675750|FG001|12-month Post Last Dose Follow-up|Lost to Follow-up|0
6072531|NCT00561080|9675751|FG002|12-month Post Last Dose Follow-up|Lost to Follow-up|0
6072532|NCT00561340|9675772|FG000|Overall Study|refused to drink pediasure|6
6072533|NCT00561340|9675773|FG001|Overall Study|refused to drink pediasure|0
6072534|NCT00561353|9675789|FG000|Overall Study|Subject reached a virologic endpoint|2
6072535|NCT00561353|9675790|FG001|Overall Study|Subject reached a virologic endpoint|1
6072536|NCT00561353|9675791|FG002|Overall Study|Subject reached a virologic endpoint|1
6072537|NCT00561353|9675792|FG003|Overall Study|Subject reached a virologic endpoint|4
6072538|NCT00561353|9675793|FG004|Overall Study|Subject reached a virologic endpoint|1
6072539|NCT00561353|9675794|FG005|Overall Study|Subject reached a virologic endpoint|3
6072540|NCT00561353|9675795|FG006|Overall Study|Subject reached a virologic endpoint|4
6072541|NCT00561353|9675796|FG007|Overall Study|Subject reached a virologic endpoint|4
6072542|NCT00561353|9675797|FG008|Overall Study|Subject reached a virologic endpoint|5
6072543|NCT00561353|9675798|FG009|Overall Study|Subject reached a virologic endpoint|0
6072544|NCT00561353|9675789|FG000|Overall Study|Subject ineligible to continue the trial|0
6072545|NCT00561353|9675790|FG001|Overall Study|Subject ineligible to continue the trial|0
6072546|NCT00561353|9675791|FG002|Overall Study|Subject ineligible to continue the trial|0
6072547|NCT00561353|9675792|FG003|Overall Study|Subject ineligible to continue the trial|0
6072548|NCT00561353|9675793|FG004|Overall Study|Subject ineligible to continue the trial|0
6072549|NCT00561353|9675794|FG005|Overall Study|Subject ineligible to continue the trial|1
6072550|NCT00561353|9675795|FG006|Overall Study|Subject ineligible to continue the trial|1
6072551|NCT00561353|9675796|FG007|Overall Study|Subject ineligible to continue the trial|0
6072552|NCT00561353|9675797|FG008|Overall Study|Subject ineligible to continue the trial|2
6072553|NCT00561353|9675798|FG009|Overall Study|Subject ineligible to continue the trial|1
6072554|NCT00561353|9675789|FG000|Overall Study|Other|1
6072555|NCT00561353|9675790|FG001|Overall Study|Other|0
6072556|NCT00561353|9675791|FG002|Overall Study|Other|1
6072557|NCT00561353|9675792|FG003|Overall Study|Other|0
6072558|NCT00561353|9675793|FG004|Overall Study|Other|0
6072559|NCT00561353|9675794|FG005|Overall Study|Other|2
6072560|NCT00561353|9675795|FG006|Overall Study|Other|0
6072561|NCT00561353|9675796|FG007|Overall Study|Other|0
6072562|NCT00561353|9675797|FG008|Overall Study|Other|0
6072563|NCT00561353|9675798|FG009|Overall Study|Other|0
6072564|NCT00561353|9675789|FG000|Overall Study|Adverse Event|0
6072565|NCT00561353|9675790|FG001|Overall Study|Adverse Event|0
6072566|NCT00561353|9675791|FG002|Overall Study|Adverse Event|0
6072567|NCT00561353|9675792|FG003|Overall Study|Adverse Event|2
6072568|NCT00561353|9675793|FG004|Overall Study|Adverse Event|0
6072569|NCT00561353|9675794|FG005|Overall Study|Adverse Event|0
6072570|NCT00561353|9675795|FG006|Overall Study|Adverse Event|1
6072571|NCT00561353|9675796|FG007|Overall Study|Adverse Event|0
6072572|NCT00561353|9675797|FG008|Overall Study|Adverse Event|0
6072573|NCT00561353|9675798|FG009|Overall Study|Adverse Event|1
6072574|NCT00561353|9675789|FG000|Overall Study|Lost to Follow-up|2
6072575|NCT00561353|9675790|FG001|Overall Study|Lost to Follow-up|0
6000734|NCT00039377|9594897|FG002|Initial Registration|Relapsed|0
6000735|NCT00039377|9594898|FG003|Initial Registration|Relapsed|0
6000736|NCT00039377|9594895|FG000|Initial Registration|Received non-protocol therapy|11
6072576|NCT00561353|9675791|FG002|Overall Study|Lost to Follow-up|1
6072577|NCT00561353|9675792|FG003|Overall Study|Lost to Follow-up|0
6072578|NCT00561353|9675793|FG004|Overall Study|Lost to Follow-up|0
6072579|NCT00561353|9675794|FG005|Overall Study|Lost to Follow-up|0
6072580|NCT00561353|9675795|FG006|Overall Study|Lost to Follow-up|0
6072581|NCT00561353|9675796|FG007|Overall Study|Lost to Follow-up|0
6000737|NCT00039377|9594896|FG001|Initial Registration|Received non-protocol therapy|0
6000738|NCT00039377|9594897|FG002|Initial Registration|Received non-protocol therapy|0
6000739|NCT00039377|9594898|FG003|Initial Registration|Received non-protocol therapy|0
6000740|NCT00039377|9594895|FG000|Initial Registration|Withdrawal by Subject|3
6000741|NCT00039377|9594896|FG001|Initial Registration|Withdrawal by Subject|0
6000742|NCT00039377|9594897|FG002|Initial Registration|Withdrawal by Subject|0
6000743|NCT00039377|9594898|FG003|Initial Registration|Withdrawal by Subject|0
6000744|NCT00039741|9594910|FG000|Overall Study|Death|0
6000745|NCT00039741|9594911|FG001|Overall Study|Death|1
6000746|NCT00039741|9594912|FG002|Overall Study|Death|0
6000747|NCT00039741|9594913|FG003|Overall Study|Death|0
6000748|NCT00039741|9594910|FG000|Overall Study|Lost to Follow-up|3
6000749|NCT00039741|9594911|FG001|Overall Study|Lost to Follow-up|1
6000750|NCT00039741|9594912|FG002|Overall Study|Lost to Follow-up|5
6000751|NCT00039741|9594913|FG003|Overall Study|Lost to Follow-up|2
6000752|NCT00039741|9594910|FG000|Overall Study|Confounding medical condition|1
6000753|NCT00039741|9594911|FG001|Overall Study|Confounding medical condition|0
6000754|NCT00039741|9594912|FG002|Overall Study|Confounding medical condition|0
6000755|NCT00039741|9594913|FG003|Overall Study|Confounding medical condition|0
6000756|NCT00039741|9594910|FG000|Overall Study|Not able to get to clinic|5
6000757|NCT00039741|9594911|FG001|Overall Study|Not able to get to clinic|2
6000758|NCT00039741|9594912|FG002|Overall Study|Not able to get to clinic|0
6000759|NCT00039741|9594913|FG003|Overall Study|Not able to get to clinic|3
6000760|NCT00039741|9594910|FG000|Overall Study|Moved|3
6000761|NCT00039741|9594911|FG001|Overall Study|Moved|2
6000762|NCT00039741|9594912|FG002|Overall Study|Moved|3
6000763|NCT00039741|9594913|FG003|Overall Study|Moved|6
6000764|NCT00039741|9594910|FG000|Overall Study|Non-compliance with protocol|1
6000765|NCT00039741|9594911|FG001|Overall Study|Non-compliance with protocol|0
6000766|NCT00039741|9594912|FG002|Overall Study|Non-compliance with protocol|1
6000767|NCT00039741|9594913|FG003|Overall Study|Non-compliance with protocol|0
6000768|NCT00039741|9594910|FG000|Overall Study|Withdrew consent|0
6000769|NCT00039741|9594911|FG001|Overall Study|Withdrew consent|5
6000770|NCT00039741|9594912|FG002|Overall Study|Withdrew consent|0
6000771|NCT00039741|9594913|FG003|Overall Study|Withdrew consent|1
6000772|NCT00039741|9594910|FG000|Overall Study|Missed final visit|2
6000773|NCT00039741|9594911|FG001|Overall Study|Missed final visit|1
6000774|NCT00039741|9594912|FG002|Overall Study|Missed final visit|2
6000775|NCT00039741|9594913|FG003|Overall Study|Missed final visit|2
6000776|NCT00039871|9594923|FG000|Overall Study|Adverse Event|165
6000777|NCT00039871|9594923|FG000|Overall Study|Lost to Follow-up|18
6000778|NCT00039871|9594923|FG000|Overall Study|Protocol Violation|24
6000779|NCT00039871|9594923|FG000|Overall Study|Withdrawal by Subject|97
6000780|NCT00039871|9594923|FG000|Overall Study|Did not meet eligibility criteria|11
6000781|NCT00039871|9594923|FG000|Overall Study|Administrative|1
6000782|NCT00039871|9594923|FG000|Overall Study|Discontinued at Week 12 per protocol|1061
6000783|NCT00039871|9594923|FG000|Overall Study|Never entered follow-up|7
6000784|NCT00040365|9594927|FG000|Overall Study|Death|1
6000785|NCT00040365|9594927|FG000|Overall Study|Progressive disease|7
6000786|NCT00040365|9594927|FG000|Overall Study|Lost to Follow-up|3
6000787|NCT00040664|9594940|FG000|Overall Study|Adverse Event|12
6000788|NCT00040664|9594941|FG001|Overall Study|Adverse Event|3
6000789|NCT00040664|9594942|FG002|Overall Study|Adverse Event|2
6000790|NCT00040664|9594943|FG003|Overall Study|Adverse Event|7
6000791|NCT00040664|9594940|FG000|Overall Study|Lack of Efficacy|9
6000792|NCT00040664|9594941|FG001|Overall Study|Lack of Efficacy|2
6000793|NCT00040664|9594942|FG002|Overall Study|Lack of Efficacy|3
6000794|NCT00040664|9594943|FG003|Overall Study|Lack of Efficacy|4
6000795|NCT00040664|9594940|FG000|Overall Study|Insufficient CD4 response|1
6000796|NCT00040664|9594941|FG001|Overall Study|Insufficient CD4 response|0
6000797|NCT00040664|9594942|FG002|Overall Study|Insufficient CD4 response|1
6000798|NCT00040664|9594943|FG003|Overall Study|Insufficient CD4 response|0
6000799|NCT00040664|9594940|FG000|Overall Study|Lost to Follow-up|4
6000800|NCT00040664|9594941|FG001|Overall Study|Lost to Follow-up|2
6000801|NCT00040664|9594942|FG002|Overall Study|Lost to Follow-up|0
6000802|NCT00040664|9594943|FG003|Overall Study|Lost to Follow-up|2
6000803|NCT00040664|9594940|FG000|Overall Study|Protocol Violation|2
6000804|NCT00040664|9594941|FG001|Overall Study|Protocol Violation|1
6000805|NCT00040664|9594942|FG002|Overall Study|Protocol Violation|0
6000806|NCT00040664|9594943|FG003|Overall Study|Protocol Violation|1
6000807|NCT00040664|9594940|FG000|Overall Study|Withdrawal by Subject|7
6000808|NCT00040664|9594941|FG001|Overall Study|Withdrawal by Subject|0
6000809|NCT00040664|9594942|FG002|Overall Study|Withdrawal by Subject|3
6000810|NCT00040664|9594943|FG003|Overall Study|Withdrawal by Subject|4
6000811|NCT00040664|9594940|FG000|Overall Study|Pregnancy|3
6000812|NCT00040664|9594941|FG001|Overall Study|Pregnancy|0
6000813|NCT00040664|9594942|FG002|Overall Study|Pregnancy|0
6000814|NCT00040664|9594943|FG003|Overall Study|Pregnancy|3
6072582|NCT00561353|9675797|FG008|Overall Study|Lost to Follow-up|0
6000815|NCT00040664|9594940|FG000|Overall Study|Medication adherence/compliance problems|8
6000816|NCT00040664|9594941|FG001|Overall Study|Medication adherence/compliance problems|2
6000817|NCT00040664|9594942|FG002|Overall Study|Medication adherence/compliance problems|1
6000818|NCT00040664|9594943|FG003|Overall Study|Medication adherence/compliance problems|5
6000819|NCT00040664|9594940|FG000|Overall Study|Poor taste|2
6000820|NCT00040664|9594941|FG001|Overall Study|Poor taste|0
6000821|NCT00040664|9594942|FG002|Overall Study|Poor taste|2
6000822|NCT00040664|9594943|FG003|Overall Study|Poor taste|0
6000823|NCT00040664|9594940|FG000|Overall Study|Pharmacokinetic target not achieved|2
6000824|NCT00040664|9594941|FG001|Overall Study|Pharmacokinetic target not achieved|1
6000825|NCT00040664|9594942|FG002|Overall Study|Pharmacokinetic target not achieved|0
6000826|NCT00040664|9594943|FG003|Overall Study|Pharmacokinetic target not achieved|1
6000827|NCT00040664|9594940|FG000|Overall Study|Change of formulation|2
6000828|NCT00040664|9594941|FG001|Overall Study|Change of formulation|2
6000829|NCT00040664|9594942|FG002|Overall Study|Change of formulation|0
6000830|NCT00040664|9594943|FG003|Overall Study|Change of formulation|0
6000831|NCT00040664|9594940|FG000|Overall Study|Non-viability of oral suspension|1
6000832|NCT00040664|9594941|FG001|Overall Study|Non-viability of oral suspension|0
6000833|NCT00040664|9594942|FG002|Overall Study|Non-viability of oral suspension|1
6000834|NCT00040664|9594943|FG003|Overall Study|Non-viability of oral suspension|0
6000835|NCT00040742|9594965|FG000|Overall Study|Death|0
6072583|NCT00561353|9675798|FG009|Overall Study|Lost to Follow-up|0
6072584|NCT00561353|9675789|FG000|Overall Study|Withdrawal by Subject|0
6072585|NCT00561353|9675790|FG001|Overall Study|Withdrawal by Subject|2
6072586|NCT00561353|9675791|FG002|Overall Study|Withdrawal by Subject|0
6072587|NCT00561353|9675792|FG003|Overall Study|Withdrawal by Subject|0
6072588|NCT00561353|9675793|FG004|Overall Study|Withdrawal by Subject|0
6072589|NCT00561353|9675794|FG005|Overall Study|Withdrawal by Subject|0
6072590|NCT00561353|9675795|FG006|Overall Study|Withdrawal by Subject|0
6072591|NCT00561353|9675796|FG007|Overall Study|Withdrawal by Subject|0
6072592|NCT00561353|9675797|FG008|Overall Study|Withdrawal by Subject|0
6072593|NCT00561353|9675798|FG009|Overall Study|Withdrawal by Subject|0
6072594|NCT00561392|9675860|FG000|Overall Study|Adverse Event|38
6072595|NCT00561392|9675860|FG000|Overall Study|Lack of Efficacy|2
6072596|NCT00561392|9675860|FG000|Overall Study|Protocol Violation|1
6072597|NCT00561392|9675860|FG000|Overall Study|Withdrawal by Subject|8
6072598|NCT00561392|9675860|FG000|Overall Study|Administrative problems|4
6072599|NCT00561470|9675883|FG000|Overall Study|Adverse Event|74
6072600|NCT00561470|9675884|FG001|Overall Study|Adverse Event|163
6072601|NCT00561470|9675883|FG000|Overall Study|Disease progression|437
6072602|NCT00561470|9675884|FG001|Overall Study|Disease progression|305
6072603|NCT00561470|9675883|FG000|Overall Study|poor compliance to protocol|4
6072604|NCT00561470|9675884|FG001|Overall Study|poor compliance to protocol|4
6072605|NCT00561470|9675883|FG000|Overall Study|Lost to Follow-up|2
6072606|NCT00561470|9675884|FG001|Overall Study|Lost to Follow-up|0
6072607|NCT00561470|9675883|FG000|Overall Study|Physician Decision|21
6072608|NCT00561470|9675884|FG001|Overall Study|Physician Decision|20
6072609|NCT00561470|9675883|FG000|Overall Study|Consent Withdrawn|2
6072610|NCT00561470|9675884|FG001|Overall Study|Consent Withdrawn|6
6072611|NCT00561470|9675883|FG000|Overall Study|Subject request|43
6072612|NCT00561470|9675884|FG001|Overall Study|Subject request|77
6072613|NCT00561470|9675883|FG000|Overall Study|Metastatic surgery|10
6072614|NCT00561470|9675884|FG001|Overall Study|Metastatic surgery|12
6072615|NCT00561470|9675883|FG000|Overall Study|Unauthorized procedure|3
6072616|NCT00561470|9675884|FG001|Overall Study|Unauthorized procedure|1
6072617|NCT00561470|9675883|FG000|Overall Study|Randomized but not treated|5
6072618|NCT00561470|9675884|FG001|Overall Study|Randomized but not treated|5
6072619|NCT00561470|9675883|FG000|Overall Study|Missed visit window|1
6072620|NCT00561470|9675884|FG001|Overall Study|Missed visit window|4
6072621|NCT00561470|9675883|FG000|Overall Study|Planning surgery|1
6072622|NCT00561470|9675884|FG001|Overall Study|Planning surgery|1
6072623|NCT00561470|9675883|FG000|Overall Study|Ongoing Treatment|11
6072624|NCT00561470|9675884|FG001|Overall Study|Ongoing Treatment|14
6072625|NCT00561574|9675894|FG000|Overall Study|Adverse Event|21
6072626|NCT00561574|9675895|FG001|Overall Study|Adverse Event|24
6072627|NCT00561574|9675894|FG000|Overall Study|Lack of Efficacy|11
6072628|NCT00561574|9675895|FG001|Overall Study|Lack of Efficacy|21
6072629|NCT00561574|9675894|FG000|Overall Study|Withdrawal by Subject|4
6072630|NCT00561574|9675895|FG001|Overall Study|Withdrawal by Subject|4
6072631|NCT00561574|9675894|FG000|Overall Study|Reason Unrelated to Trial|6
6072632|NCT00561574|9675895|FG001|Overall Study|Reason Unrelated to Trial|2
6072633|NCT00561574|9675894|FG000|Overall Study|Lost to Follow-up|1
6072634|NCT00561574|9675895|FG001|Overall Study|Lost to Follow-up|0
6000836|NCT00040742|9594966|FG001|Overall Study|Death|0
6000837|NCT00040742|9594967|FG002|Overall Study|Death|1
6072635|NCT00561574|9675894|FG000|Overall Study|Other|5
6072636|NCT00561574|9675895|FG001|Overall Study|Other|7
6072637|NCT00561652|9675914|FG000|Overall Study|Withdrawal by Subject|0
6072638|NCT00561652|9675915|FG001|Overall Study|Withdrawal by Subject|1
6072639|NCT00561678|9675923|FG000|Overall Study|Withdrawal by Subject|4
6000838|NCT00040742|9594968|FG003|Overall Study|Death|0
6000839|NCT00040742|9594965|FG000|Overall Study|Adverse Event|15
6072640|NCT00561678|9675924|FG001|Overall Study|Withdrawal by Subject|3
6072641|NCT00561678|9675923|FG000|Overall Study|surgery cancelled|1
6000840|NCT00040742|9594966|FG001|Overall Study|Adverse Event|16
6000841|NCT00040742|9594967|FG002|Overall Study|Adverse Event|21
6000842|NCT00040742|9594968|FG003|Overall Study|Adverse Event|9
6000843|NCT00040742|9594965|FG000|Overall Study|Withdrawal by Subject|7
6000844|NCT00040742|9594966|FG001|Overall Study|Withdrawal by Subject|15
6000845|NCT00040742|9594967|FG002|Overall Study|Withdrawal by Subject|10
6000846|NCT00040742|9594968|FG003|Overall Study|Withdrawal by Subject|13
6000847|NCT00040742|9594965|FG000|Overall Study|Chemotoxicity|4
6000848|NCT00040742|9594966|FG001|Overall Study|Chemotoxicity|3
6000849|NCT00040742|9594967|FG002|Overall Study|Chemotoxicity|5
6000850|NCT00040742|9594968|FG003|Overall Study|Chemotoxicity|2
6000851|NCT00040742|9594965|FG000|Overall Study|Incomplete Forms|6
6000852|NCT00040742|9594966|FG001|Overall Study|Incomplete Forms|10
6000853|NCT00040742|9594967|FG002|Overall Study|Incomplete Forms|4
6000854|NCT00040742|9594968|FG003|Overall Study|Incomplete Forms|5
6000855|NCT00040742|9594965|FG000|Overall Study|Other medical|7
6000856|NCT00040742|9594966|FG001|Overall Study|Other medical|5
6000857|NCT00040742|9594967|FG002|Overall Study|Other medical|5
6000858|NCT00040742|9594968|FG003|Overall Study|Other medical|5
6000859|NCT00041067|9595010|FG000|Overall Study|Adverse Event|20
6000860|NCT00041067|9595010|FG000|Overall Study|Progression|19
6000861|NCT00041067|9595010|FG000|Overall Study|Patient refusal|12
6000862|NCT00041067|9595010|FG000|Overall Study|Other reasons|23
6000863|NCT00041067|9595010|FG000|Overall Study|Ineligible|2
6000864|NCT00041080|9595017|FG000|Overall Study|Adverse Event|21
6000865|NCT00041080|9595018|FG001|Overall Study|Adverse Event|1
6000866|NCT00041080|9595017|FG000|Overall Study|Withdrawal by Subject|6
6000867|NCT00041080|9595018|FG001|Overall Study|Withdrawal by Subject|6
6000868|NCT00041080|9595017|FG000|Overall Study|Concommitant Illness/Other|1
6000869|NCT00041080|9595018|FG001|Overall Study|Concommitant Illness/Other|2
6000870|NCT00041080|9595017|FG000|Overall Study|Did not start therapy|1
6000871|NCT00041080|9595018|FG001|Overall Study|Did not start therapy|1
6000872|NCT00041080|9595017|FG000|Overall Study|Ineligible|1
6000873|NCT00041080|9595018|FG001|Overall Study|Ineligible|0
6000874|NCT00041132|9595045|FG000|Overall Study|Adverse Event|19
6000875|NCT00041132|9595045|FG000|Overall Study|Death|1
6000876|NCT00041132|9595045|FG000|Overall Study|Not Eligible|7
6000877|NCT00041132|9595045|FG000|Overall Study|Withdrawal by Subject|1
6000878|NCT00041132|9595045|FG000|Overall Study|Physician Decision|2
6000879|NCT00041470|9595049|FG000|Overall Study|Loss of Funding|38
6000880|NCT00041756|9595067|FG000|Overall Study|Adverse Event|4
6072642|NCT00561678|9675924|FG001|Overall Study|surgery cancelled|1
6072643|NCT00561678|9675923|FG000|Overall Study|surgery rescheduled to different site|2
6072644|NCT00561678|9675924|FG001|Overall Study|surgery rescheduled to different site|2
6072645|NCT00561678|9675923|FG000|Overall Study|anesthesia provider refusal|1
6072646|NCT00561678|9675924|FG001|Overall Study|anesthesia provider refusal|0
6072647|NCT00561730|9675930|FG000|Overall Study|Adverse Event|2
6072648|NCT00561730|9675930|FG000|Overall Study|Handling of the drug|1
6072649|NCT00561730|9675930|FG000|Overall Study|Lost to Follow-up|5
6072650|NCT00561730|9675930|FG000|Overall Study|Not specified reasons|1
6072651|NCT00561821|9675940|FG000|Overall Study|Not treated|0
6072652|NCT00561821|9675941|FG001|Overall Study|Not treated|0
6072653|NCT00561821|9675942|FG002|Overall Study|Not treated|1
6072654|NCT00561821|9675943|FG003|Overall Study|Not treated|0
6072655|NCT00561821|9675940|FG000|Overall Study|Withdrawal by Subject|0
6072656|NCT00561821|9675941|FG001|Overall Study|Withdrawal by Subject|1
6072657|NCT00561821|9675942|FG002|Overall Study|Withdrawal by Subject|0
6072658|NCT00561821|9675943|FG003|Overall Study|Withdrawal by Subject|2
6072659|NCT00561821|9675940|FG000|Overall Study|Reasons not related to trial|2
6072660|NCT00561821|9675941|FG001|Overall Study|Reasons not related to trial|1
6072661|NCT00561821|9675942|FG002|Overall Study|Reasons not related to trial|0
6072662|NCT00561821|9675943|FG003|Overall Study|Reasons not related to trial|0
6072663|NCT00561821|9675940|FG000|Overall Study|Other (reason not specified)|1
6072664|NCT00561821|9675941|FG001|Overall Study|Other (reason not specified)|1
6072665|NCT00561821|9675942|FG002|Overall Study|Other (reason not specified)|0
6072666|NCT00561821|9675943|FG003|Overall Study|Other (reason not specified)|0
6072667|NCT00561821|9675940|FG000|Overall Study|Adverse Event|2
6072668|NCT00561821|9675941|FG001|Overall Study|Adverse Event|3
6072669|NCT00561821|9675942|FG002|Overall Study|Adverse Event|1
6072670|NCT00561821|9675943|FG003|Overall Study|Adverse Event|1
6072671|NCT00561925|9675960|FG000|14 Day Lead-In Period|Adverse Event|38
6072672|NCT00561925|9675961|FG001|14 Day Lead-In Period|Adverse Event|0
6072673|NCT00561925|9675962|FG002|14 Day Lead-In Period|Adverse Event|0
6000881|NCT00041756|9595068|FG001|Overall Study|Adverse Event|10
6000882|NCT00041756|9595069|FG002|Overall Study|Adverse Event|6
6000883|NCT00041756|9595070|FG003|Overall Study|Adverse Event|11
6072674|NCT00561925|9675963|FG003|14 Day Lead-In Period|Adverse Event|0
6072675|NCT00561925|9675964|FG004|14 Day Lead-In Period|Adverse Event|0
6072676|NCT00561925|9675960|FG000|14 Day Lead-In Period|In/Exclusion criteria|4
6072677|NCT00561925|9675961|FG001|14 Day Lead-In Period|In/Exclusion criteria|0
6000884|NCT00041756|9595071|FG004|Overall Study|Adverse Event|34
6000885|NCT00041756|9595067|FG000|Overall Study|Protocol Violation|1
6000886|NCT00041756|9595068|FG001|Overall Study|Protocol Violation|1
6000887|NCT00041756|9595069|FG002|Overall Study|Protocol Violation|2
6000888|NCT00041756|9595070|FG003|Overall Study|Protocol Violation|2
6000889|NCT00041756|9595071|FG004|Overall Study|Protocol Violation|1
6000890|NCT00041756|9595067|FG000|Overall Study|Withdrawal by Subject|3
6000891|NCT00041756|9595068|FG001|Overall Study|Withdrawal by Subject|3
6000892|NCT00041756|9595069|FG002|Overall Study|Withdrawal by Subject|4
6000893|NCT00041756|9595070|FG003|Overall Study|Withdrawal by Subject|2
6072678|NCT00561925|9675962|FG002|14 Day Lead-In Period|In/Exclusion criteria|0
6072679|NCT00561925|9675963|FG003|14 Day Lead-In Period|In/Exclusion criteria|0
6072680|NCT00561925|9675964|FG004|14 Day Lead-In Period|In/Exclusion criteria|0
6072681|NCT00561925|9675960|FG000|14 Day Lead-In Period|Lost to Follow-up|4
6072682|NCT00561925|9675961|FG001|14 Day Lead-In Period|Lost to Follow-up|0
6072683|NCT00561925|9675962|FG002|14 Day Lead-In Period|Lost to Follow-up|0
6072684|NCT00561925|9675963|FG003|14 Day Lead-In Period|Lost to Follow-up|0
6072685|NCT00561925|9675964|FG004|14 Day Lead-In Period|Lost to Follow-up|0
6072686|NCT00561925|9675960|FG000|14 Day Lead-In Period|Withdrawal by Subject|4
6072687|NCT00561925|9675961|FG001|14 Day Lead-In Period|Withdrawal by Subject|0
6072688|NCT00561925|9675962|FG002|14 Day Lead-In Period|Withdrawal by Subject|0
6072689|NCT00561925|9675963|FG003|14 Day Lead-In Period|Withdrawal by Subject|0
6072690|NCT00561925|9675964|FG004|14 Day Lead-In Period|Withdrawal by Subject|0
6072691|NCT00561925|9675960|FG000|14 Day Lead-In Period|Other|5
6072692|NCT00561925|9675961|FG001|14 Day Lead-In Period|Other|0
6000894|NCT00041756|9595071|FG004|Overall Study|Withdrawal by Subject|3
6000895|NCT00041756|9595067|FG000|Overall Study|Lost to Follow-up|0
6000896|NCT00041756|9595068|FG001|Overall Study|Lost to Follow-up|1
6000897|NCT00041756|9595069|FG002|Overall Study|Lost to Follow-up|0
6000898|NCT00041756|9595070|FG003|Overall Study|Lost to Follow-up|1
6000899|NCT00041756|9595071|FG004|Overall Study|Lost to Follow-up|0
6000900|NCT00041756|9595067|FG000|Overall Study|Unable to meet protocol criteria|0
6000901|NCT00041756|9595068|FG001|Overall Study|Unable to meet protocol criteria|0
6000902|NCT00041756|9595069|FG002|Overall Study|Unable to meet protocol criteria|1
6000903|NCT00041756|9595070|FG003|Overall Study|Unable to meet protocol criteria|0
6000904|NCT00041756|9595071|FG004|Overall Study|Unable to meet protocol criteria|1
6000905|NCT00041756|9595067|FG000|Overall Study|Data Monitoring Committee Recommendation|0
6000906|NCT00041756|9595068|FG001|Overall Study|Data Monitoring Committee Recommendation|0
6000907|NCT00041756|9595069|FG002|Overall Study|Data Monitoring Committee Recommendation|0
6000908|NCT00041756|9595070|FG003|Overall Study|Data Monitoring Committee Recommendation|0
6000909|NCT00041756|9595071|FG004|Overall Study|Data Monitoring Committee Recommendation|21
6000910|NCT00042432|9595103|FG000|Overall Study|Adverse Event|4
6000911|NCT00042432|9595104|FG001|Overall Study|Adverse Event|1
6000912|NCT00042432|9595103|FG000|Overall Study|Withdrawal by Subject|1
6000913|NCT00042432|9595104|FG001|Overall Study|Withdrawal by Subject|3
6000914|NCT00042432|9595103|FG000|Overall Study|Death|0
6000915|NCT00042432|9595104|FG001|Overall Study|Death|2
6000916|NCT00042432|9595103|FG000|Overall Study|Ineligibility determined|1
6000917|NCT00042432|9595104|FG001|Overall Study|Ineligibility determined|0
6000918|NCT00042432|9595103|FG000|Overall Study|Initiation of maintenance dialysis|1
6000919|NCT00042432|9595104|FG001|Overall Study|Initiation of maintenance dialysis|1
6000920|NCT00042432|9595103|FG000|Overall Study|Other|2
6000921|NCT00042432|9595104|FG001|Overall Study|Other|0
6000922|NCT00042666|9595110|FG000|Overall Study|Adverse Event|2
6000923|NCT00042666|9595110|FG000|Overall Study|Death|4
6000924|NCT00042666|9595110|FG000|Overall Study|Protocol Violation|1
6000925|NCT00042666|9595110|FG000|Overall Study|Participant/Physician Perception|1
6000926|NCT00042666|9595110|FG000|Overall Study|Progressive Disease|41
6000927|NCT00042666|9595110|FG000|Overall Study|Other|1
6000928|NCT00042666|9595110|FG000|Overall Study|Other|4
6000929|NCT00042939|9595117|FG000|Overall Study|Adverse Event|6
6000930|NCT00042939|9595118|FG001|Overall Study|Adverse Event|7
6000931|NCT00042939|9595117|FG000|Overall Study|Death|3
6000932|NCT00042939|9595118|FG001|Overall Study|Death|2
6000933|NCT00042939|9595117|FG000|Overall Study|Withdrawal by Subject|3
6000934|NCT00042939|9595118|FG001|Overall Study|Withdrawal by Subject|4
6000935|NCT00042939|9595117|FG000|Overall Study|Other disease|1
6000936|NCT00042939|9595118|FG001|Overall Study|Other disease|0
6000937|NCT00042939|9595117|FG000|Overall Study|Ineligible|2
6000938|NCT00042939|9595118|FG001|Overall Study|Ineligible|2
6000939|NCT00042939|9595117|FG000|Overall Study|Deterioration of health|3
6000940|NCT00042939|9595118|FG001|Overall Study|Deterioration of health|4
6000941|NCT00042939|9595117|FG000|Overall Study|QOL diminished|1
6000942|NCT00042939|9595118|FG001|Overall Study|QOL diminished|0
6000943|NCT00042939|9595117|FG000|Overall Study|Rising ca 19-9|1
6000944|NCT00042939|9595118|FG001|Overall Study|Rising ca 19-9|0
6000945|NCT00042939|9595117|FG000|Overall Study|Patient non-compliance|1
6000946|NCT00042939|9595118|FG001|Overall Study|Patient non-compliance|0
6000947|NCT00042939|9595117|FG000|Overall Study|Still on treatment|1
6000948|NCT00042939|9595118|FG001|Overall Study|Still on treatment|0
6000949|NCT00042939|9595117|FG000|Overall Study|Treatment break > 4 weeks|0
6000950|NCT00042939|9595118|FG001|Overall Study|Treatment break > 4 weeks|1
6000951|NCT00042939|9595117|FG000|Overall Study|Did not start treatment|2
6072693|NCT00561925|9675962|FG002|14 Day Lead-In Period|Other|0
6072694|NCT00561925|9675963|FG003|14 Day Lead-In Period|Other|0
6072695|NCT00561925|9675964|FG004|14 Day Lead-In Period|Other|0
6000952|NCT00042939|9595118|FG001|Overall Study|Did not start treatment|1
6000953|NCT00042991|9595131|FG000|Overall Study|Adverse Event|1
6000954|NCT00042991|9595132|FG001|Overall Study|Adverse Event|4
6000955|NCT00042991|9595133|FG002|Overall Study|Adverse Event|2
6000956|NCT00042991|9595134|FG003|Overall Study|Adverse Event|0
6000957|NCT00042991|9595135|FG004|Overall Study|Adverse Event|0
6000958|NCT00042991|9595136|FG005|Overall Study|Adverse Event|1
6000959|NCT00042991|9595137|FG006|Overall Study|Adverse Event|0
6000960|NCT00042991|9595131|FG000|Overall Study|Withdrawal by Subject|0
6000961|NCT00042991|9595132|FG001|Overall Study|Withdrawal by Subject|7
6000962|NCT00042991|9595133|FG002|Overall Study|Withdrawal by Subject|2
6000963|NCT00042991|9595134|FG003|Overall Study|Withdrawal by Subject|0
6000964|NCT00042991|9595135|FG004|Overall Study|Withdrawal by Subject|1
6000965|NCT00042991|9595136|FG005|Overall Study|Withdrawal by Subject|0
6000966|NCT00042991|9595137|FG006|Overall Study|Withdrawal by Subject|0
6000967|NCT00042991|9595131|FG000|Overall Study|Disease Progression|5
6000968|NCT00042991|9595132|FG001|Overall Study|Disease Progression|29
6000969|NCT00042991|9595133|FG002|Overall Study|Disease Progression|2
6000970|NCT00042991|9595134|FG003|Overall Study|Disease Progression|2
6000971|NCT00042991|9595135|FG004|Overall Study|Disease Progression|1
6000972|NCT00042991|9595136|FG005|Overall Study|Disease Progression|4
6000973|NCT00042991|9595137|FG006|Overall Study|Disease Progression|2
6000974|NCT00042991|9595131|FG000|Overall Study|Alternative Therapy|0
6072696|NCT00561925|9675960|FG000|144-week Double-blind, Double-dummy|Adverse Event|0
6072697|NCT00561925|9675961|FG001|144-week Double-blind, Double-dummy|Adverse Event|48
6072698|NCT00561925|9675962|FG002|144-week Double-blind, Double-dummy|Adverse Event|43
6072699|NCT00561925|9675963|FG003|144-week Double-blind, Double-dummy|Adverse Event|0
6072700|NCT00561925|9675964|FG004|144-week Double-blind, Double-dummy|Adverse Event|0
6072701|NCT00561925|9675960|FG000|144-week Double-blind, Double-dummy|Protocol Violation|0
6072702|NCT00561925|9675961|FG001|144-week Double-blind, Double-dummy|Protocol Violation|15
6072703|NCT00561925|9675962|FG002|144-week Double-blind, Double-dummy|Protocol Violation|9
6072704|NCT00561925|9675963|FG003|144-week Double-blind, Double-dummy|Protocol Violation|0
6072705|NCT00561925|9675964|FG004|144-week Double-blind, Double-dummy|Protocol Violation|0
6072706|NCT00561925|9675960|FG000|144-week Double-blind, Double-dummy|Lost to Follow-up|0
6072707|NCT00561925|9675961|FG001|144-week Double-blind, Double-dummy|Lost to Follow-up|15
6072708|NCT00561925|9675962|FG002|144-week Double-blind, Double-dummy|Lost to Follow-up|12
6072709|NCT00561925|9675963|FG003|144-week Double-blind, Double-dummy|Lost to Follow-up|0
6072710|NCT00561925|9675964|FG004|144-week Double-blind, Double-dummy|Lost to Follow-up|0
6072711|NCT00561925|9675960|FG000|144-week Double-blind, Double-dummy|Withdrawal by Subject|0
6072712|NCT00561925|9675961|FG001|144-week Double-blind, Double-dummy|Withdrawal by Subject|19
6072713|NCT00561925|9675962|FG002|144-week Double-blind, Double-dummy|Withdrawal by Subject|7
6072714|NCT00561925|9675963|FG003|144-week Double-blind, Double-dummy|Withdrawal by Subject|0
6072715|NCT00561925|9675964|FG004|144-week Double-blind, Double-dummy|Withdrawal by Subject|0
6072716|NCT00561925|9675960|FG000|144-week Double-blind, Double-dummy|Lack of Efficacy|0
6072717|NCT00561925|9675961|FG001|144-week Double-blind, Double-dummy|Lack of Efficacy|36
6072718|NCT00561925|9675962|FG002|144-week Double-blind, Double-dummy|Lack of Efficacy|33
6072719|NCT00561925|9675963|FG003|144-week Double-blind, Double-dummy|Lack of Efficacy|0
6072720|NCT00561925|9675964|FG004|144-week Double-blind, Double-dummy|Lack of Efficacy|0
6072721|NCT00561925|9675960|FG000|144-week Double-blind, Double-dummy|Pregnancy|0
6072722|NCT00561925|9675961|FG001|144-week Double-blind, Double-dummy|Pregnancy|1
6072723|NCT00561925|9675962|FG002|144-week Double-blind, Double-dummy|Pregnancy|9
6072724|NCT00561925|9675963|FG003|144-week Double-blind, Double-dummy|Pregnancy|0
6072725|NCT00561925|9675964|FG004|144-week Double-blind, Double-dummy|Pregnancy|0
6072726|NCT00561925|9675960|FG000|144-week Double-blind, Double-dummy|Death|0
6072727|NCT00561925|9675961|FG001|144-week Double-blind, Double-dummy|Death|6
6072728|NCT00561925|9675962|FG002|144-week Double-blind, Double-dummy|Death|3
6072729|NCT00561925|9675963|FG003|144-week Double-blind, Double-dummy|Death|0
6072730|NCT00561925|9675964|FG004|144-week Double-blind, Double-dummy|Death|0
6072731|NCT00561925|9675960|FG000|144-week Double-blind, Double-dummy|Not treated with study drug|0
6072732|NCT00561925|9675961|FG001|144-week Double-blind, Double-dummy|Not treated with study drug|2
6072733|NCT00561925|9675962|FG002|144-week Double-blind, Double-dummy|Not treated with study drug|0
6072734|NCT00561925|9675963|FG003|144-week Double-blind, Double-dummy|Not treated with study drug|0
6072735|NCT00561925|9675964|FG004|144-week Double-blind, Double-dummy|Not treated with study drug|0
6072736|NCT00561925|9675960|FG000|144-week Double-blind, Double-dummy|Other|0
6072737|NCT00561925|9675961|FG001|144-week Double-blind, Double-dummy|Other|8
6072738|NCT00561925|9675962|FG002|144-week Double-blind, Double-dummy|Other|11
6072739|NCT00561925|9675963|FG003|144-week Double-blind, Double-dummy|Other|0
6072740|NCT00561925|9675964|FG004|144-week Double-blind, Double-dummy|Other|0
6072741|NCT00561925|9675960|FG000|Open-Label Extension Period|Declined entry into extension period|0
6072742|NCT00561925|9675961|FG001|Open-Label Extension Period|Declined entry into extension period|0
6072743|NCT00561925|9675962|FG002|Open-Label Extension Period|Declined entry into extension period|0
6087262|NCT00666926|9697370|FG011|Overall Study|Withdrawal by Subject|3
6000975|NCT00042991|9595132|FG001|Overall Study|Alternative Therapy|0
6000976|NCT00042991|9595133|FG002|Overall Study|Alternative Therapy|0
6000977|NCT00042991|9595134|FG003|Overall Study|Alternative Therapy|0
6000978|NCT00042991|9595135|FG004|Overall Study|Alternative Therapy|1
6000979|NCT00042991|9595136|FG005|Overall Study|Alternative Therapy|0
6000980|NCT00042991|9595137|FG006|Overall Study|Alternative Therapy|0
6000981|NCT00043186|9595164|FG000|Overall Study|Physician Decision|0
6000982|NCT00043186|9595165|FG001|Overall Study|Physician Decision|0
6000983|NCT00043186|9595166|FG002|Overall Study|Physician Decision|3
6000984|NCT00043186|9595167|FG003|Overall Study|Physician Decision|0
6000985|NCT00043186|9595168|FG004|Overall Study|Physician Decision|1
6000986|NCT00043186|9595169|FG005|Overall Study|Physician Decision|0
6000987|NCT00043186|9595170|FG006|Overall Study|Physician Decision|0
6000988|NCT00043186|9595171|FG007|Overall Study|Physician Decision|1
6000989|NCT00043186|9595172|FG008|Overall Study|Physician Decision|1
6000990|NCT00043186|9595164|FG000|Overall Study|Adverse Event|2
6000991|NCT00043186|9595165|FG001|Overall Study|Adverse Event|2
6000992|NCT00043186|9595166|FG002|Overall Study|Adverse Event|2
6000993|NCT00043186|9595167|FG003|Overall Study|Adverse Event|3
6000994|NCT00043186|9595168|FG004|Overall Study|Adverse Event|2
6000995|NCT00043186|9595169|FG005|Overall Study|Adverse Event|1
6000996|NCT00043186|9595170|FG006|Overall Study|Adverse Event|2
6000997|NCT00043186|9595171|FG007|Overall Study|Adverse Event|1
6000998|NCT00043186|9595172|FG008|Overall Study|Adverse Event|3
6000999|NCT00043186|9595164|FG000|Overall Study|Withdrawal by Subject|11
6001000|NCT00043186|9595165|FG001|Overall Study|Withdrawal by Subject|8
6001001|NCT00043186|9595166|FG002|Overall Study|Withdrawal by Subject|11
6001002|NCT00043186|9595167|FG003|Overall Study|Withdrawal by Subject|13
6001003|NCT00043186|9595168|FG004|Overall Study|Withdrawal by Subject|14
6001004|NCT00043186|9595169|FG005|Overall Study|Withdrawal by Subject|6
6001005|NCT00043186|9595170|FG006|Overall Study|Withdrawal by Subject|12
6001006|NCT00043186|9595171|FG007|Overall Study|Withdrawal by Subject|9
6001007|NCT00043186|9595172|FG008|Overall Study|Withdrawal by Subject|10
6001008|NCT00043186|9595164|FG000|Overall Study|Death|0
6001009|NCT00043186|9595165|FG001|Overall Study|Death|0
6001010|NCT00043186|9595166|FG002|Overall Study|Death|1
6072744|NCT00561925|9675963|FG003|Open-Label Extension Period|Declined entry into extension period|43
6072745|NCT00561925|9675964|FG004|Open-Label Extension Period|Declined entry into extension period|50
6072746|NCT00561951|9675985|FG000|Overall Study|Adverse Event|11
6072747|NCT00561951|9675986|FG001|Overall Study|Adverse Event|14
6072748|NCT00561951|9675987|FG002|Overall Study|Adverse Event|14
6072749|NCT00561951|9675985|FG000|Overall Study|Lack of Efficacy|5
6072750|NCT00561951|9675986|FG001|Overall Study|Lack of Efficacy|3
6072751|NCT00561951|9675987|FG002|Overall Study|Lack of Efficacy|2
6072752|NCT00561951|9675985|FG000|Overall Study|Lost to Follow-up|1
6072753|NCT00561951|9675986|FG001|Overall Study|Lost to Follow-up|1
6072754|NCT00561951|9675987|FG002|Overall Study|Lost to Follow-up|0
6072755|NCT00561951|9675985|FG000|Overall Study|Withdrawal by Subject|10
6072756|NCT00561951|9675986|FG001|Overall Study|Withdrawal by Subject|9
6072757|NCT00561951|9675987|FG002|Overall Study|Withdrawal by Subject|10
6072758|NCT00561951|9675985|FG000|Overall Study|Protocol Violation|4
6072759|NCT00561951|9675986|FG001|Overall Study|Protocol Violation|3
6072760|NCT00561951|9675987|FG002|Overall Study|Protocol Violation|4
6072761|NCT00561951|9675985|FG000|Overall Study|Physician Decision|1
6072762|NCT00561951|9675986|FG001|Overall Study|Physician Decision|0
6072763|NCT00561951|9675987|FG002|Overall Study|Physician Decision|0
6072764|NCT00561951|9675985|FG000|Overall Study|Pregnancy|0
6072765|NCT00561951|9675986|FG001|Overall Study|Pregnancy|1
6072766|NCT00561951|9675987|FG002|Overall Study|Pregnancy|0
6072767|NCT00561951|9675985|FG000|Overall Study|Meet Withdrawal Criterion|0
6072768|NCT00561951|9675986|FG001|Overall Study|Meet Withdrawal Criterion|1
6072769|NCT00561951|9675987|FG002|Overall Study|Meet Withdrawal Criterion|1
6072770|NCT00561951|9675985|FG000|Overall Study|Adverse Event Occured Before Treatment|1
6072771|NCT00561951|9675986|FG001|Overall Study|Adverse Event Occured Before Treatment|2
6072772|NCT00561951|9675987|FG002|Overall Study|Adverse Event Occured Before Treatment|1
6072773|NCT00561977|9675998|FG000|Overall Study|Withdrawal by Subject|0
6072774|NCT00561977|9675999|FG001|Overall Study|Withdrawal by Subject|2
6072775|NCT00561977|9676000|FG002|Overall Study|Withdrawal by Subject|1
6072776|NCT00561977|9675998|FG000|Overall Study|Pregnancy|0
6072777|NCT00561977|9675999|FG001|Overall Study|Pregnancy|1
6072778|NCT00561977|9676000|FG002|Overall Study|Pregnancy|1
6072779|NCT00562094|9676008|FG000|Overall Study|Lost to Follow-up|62
6072780|NCT00562120|9676016|FG000|First Intervention Period|Adverse Event|1
6072781|NCT00562120|9676017|FG001|First Intervention Period|Adverse Event|0
6072782|NCT00562120|9676018|FG002|First Intervention Period|Adverse Event|0
6072783|NCT00562120|9676019|FG003|First Intervention Period|Adverse Event|0
6072784|NCT00562120|9676016|FG000|First Intervention Period|Randomized but not Treated|1
6001011|NCT00043186|9595167|FG003|Overall Study|Death|0
6001012|NCT00043186|9595168|FG004|Overall Study|Death|0
6001013|NCT00043186|9595169|FG005|Overall Study|Death|0
6001014|NCT00043186|9595170|FG006|Overall Study|Death|2
6001015|NCT00043186|9595171|FG007|Overall Study|Death|0
6072785|NCT00562120|9676017|FG001|First Intervention Period|Randomized but not Treated|0
6072786|NCT00562120|9676018|FG002|First Intervention Period|Randomized but not Treated|0
6072787|NCT00562120|9676019|FG003|First Intervention Period|Randomized but not Treated|0
6072788|NCT00562159|9676031|FG000|Overall Study|Adverse Event|11
6072789|NCT00562159|9676032|FG001|Overall Study|Adverse Event|8
6072790|NCT00562159|9676031|FG000|Overall Study|Lost to Follow-up|5
6072791|NCT00562159|9676032|FG001|Overall Study|Lost to Follow-up|4
6072792|NCT00562159|9676031|FG000|Overall Study|Withdrawal by Subject|9
6001016|NCT00043186|9595172|FG008|Overall Study|Death|0
6001017|NCT00043186|9595164|FG000|Overall Study|Disease progression|1
6001018|NCT00043186|9595165|FG001|Overall Study|Disease progression|0
6001019|NCT00043186|9595166|FG002|Overall Study|Disease progression|0
6001020|NCT00043186|9595167|FG003|Overall Study|Disease progression|3
6001021|NCT00043186|9595168|FG004|Overall Study|Disease progression|0
6001022|NCT00043186|9595169|FG005|Overall Study|Disease progression|0
6001023|NCT00043186|9595170|FG006|Overall Study|Disease progression|0
6001024|NCT00043186|9595171|FG007|Overall Study|Disease progression|4
6001025|NCT00043186|9595172|FG008|Overall Study|Disease progression|0
6001026|NCT00043186|9595164|FG000|Overall Study|Ineligibility determined|0
6001027|NCT00043186|9595165|FG001|Overall Study|Ineligibility determined|0
6001028|NCT00043186|9595166|FG002|Overall Study|Ineligibility determined|0
6001029|NCT00043186|9595167|FG003|Overall Study|Ineligibility determined|0
6001030|NCT00043186|9595168|FG004|Overall Study|Ineligibility determined|0
6001031|NCT00043186|9595169|FG005|Overall Study|Ineligibility determined|0
6001032|NCT00043186|9595170|FG006|Overall Study|Ineligibility determined|0
6001033|NCT00043186|9595171|FG007|Overall Study|Ineligibility determined|0
6001034|NCT00043186|9595172|FG008|Overall Study|Ineligibility determined|1
6001035|NCT00043186|9595164|FG000|Overall Study|Lost to Follow-up|3
6001036|NCT00043186|9595165|FG001|Overall Study|Lost to Follow-up|5
6001037|NCT00043186|9595166|FG002|Overall Study|Lost to Follow-up|1
6001038|NCT00043186|9595167|FG003|Overall Study|Lost to Follow-up|1
6001039|NCT00043186|9595168|FG004|Overall Study|Lost to Follow-up|1
6001040|NCT00043186|9595169|FG005|Overall Study|Lost to Follow-up|1
6001041|NCT00043186|9595170|FG006|Overall Study|Lost to Follow-up|1
6001042|NCT00043186|9595171|FG007|Overall Study|Lost to Follow-up|1
6001043|NCT00043186|9595172|FG008|Overall Study|Lost to Follow-up|2
6001044|NCT00043186|9595164|FG000|Overall Study|Noncompliance|0
6001045|NCT00043186|9595165|FG001|Overall Study|Noncompliance|0
6001046|NCT00043186|9595166|FG002|Overall Study|Noncompliance|1
6001047|NCT00043186|9595167|FG003|Overall Study|Noncompliance|1
6001048|NCT00043186|9595168|FG004|Overall Study|Noncompliance|0
6001049|NCT00043186|9595169|FG005|Overall Study|Noncompliance|0
6001050|NCT00043186|9595170|FG006|Overall Study|Noncompliance|0
6001051|NCT00043186|9595171|FG007|Overall Study|Noncompliance|0
6001052|NCT00043186|9595172|FG008|Overall Study|Noncompliance|0
6001053|NCT00043186|9595164|FG000|Overall Study|Other|0
6001054|NCT00043186|9595165|FG001|Overall Study|Other|0
6001055|NCT00043186|9595166|FG002|Overall Study|Other|1
6001056|NCT00043186|9595167|FG003|Overall Study|Other|1
6001057|NCT00043186|9595168|FG004|Overall Study|Other|0
6001058|NCT00043186|9595169|FG005|Overall Study|Other|0
6001059|NCT00043186|9595170|FG006|Overall Study|Other|0
6001060|NCT00043186|9595171|FG007|Overall Study|Other|0
6001061|NCT00043186|9595172|FG008|Overall Study|Other|0
6001062|NCT00043550|9595196|FG000|Overall Study|Withdrawal by Subject|22
6001063|NCT00043550|9595197|FG001|Overall Study|Withdrawal by Subject|12
6001064|NCT00043550|9595198|FG002|Overall Study|Withdrawal by Subject|20
6001065|NCT00043979|9595208|FG000|Period 1|recipient with progressive disease|7
6001066|NCT00043979|9595209|FG001|Period 1|recipient with progressive disease|4
6001067|NCT00043979|9595210|FG002|Period 1|recipient with progressive disease|3
6001068|NCT00044083|9595252|FG000|First Intervention (One Week)- HV's|Adverse Event|1
6001069|NCT00044083|9595253|FG001|First Intervention (One Week)- HV's|Adverse Event|0
6001070|NCT00044083|9595252|FG000|First Intervention (One Week)- HV's|Not follow directions|2
6001071|NCT00044083|9595253|FG001|First Intervention (One Week)- HV's|Not follow directions|2
6001072|NCT00044083|9595252|FG000|First Intervention (One Week)- HV's|Withdrawal by Subject|5
6001073|NCT00044083|9595253|FG001|First Intervention (One Week)- HV's|Withdrawal by Subject|3
6001074|NCT00044083|9595252|FG000|First Intervention (One Week)- HV's|Pregnancy|1
6001075|NCT00044083|9595253|FG001|First Intervention (One Week)- HV's|Pregnancy|0
6001076|NCT00044083|9595252|FG000|First Intervention (One Week)- HV's|Used illegal drugs|1
6001077|NCT00044083|9595253|FG001|First Intervention (One Week)- HV's|Used illegal drugs|0
6001078|NCT00044083|9595252|FG000|First Intervention (One Week)- HV's|Abnormal MRI|0
6001079|NCT00044083|9595253|FG001|First Intervention (One Week)- HV's|Abnormal MRI|1
6001080|NCT00044083|9595252|FG000|First Intervention (One Week)- HV's|Drank while on protocol|0
6001081|NCT00044083|9595253|FG001|First Intervention (One Week)- HV's|Drank while on protocol|1
6001082|NCT00044083|9595252|FG000|First Intervention (One Week) Patients|Not follow directions|0
6072793|NCT00562159|9676032|FG001|Overall Study|Withdrawal by Subject|8
6001083|NCT00044083|9595253|FG001|First Intervention (One Week) Patients|Not follow directions|2
6001084|NCT00044083|9595252|FG000|First Intervention (One Week) Patients|Used illegal drug|1
6001085|NCT00044083|9595253|FG001|First Intervention (One Week) Patients|Used illegal drug|0
6001086|NCT00044083|9595252|FG000|Second Intervention (One Week) Patients|Withdrawal by Subject|0
6001087|NCT00044083|9595253|FG001|Second Intervention (One Week) Patients|Withdrawal by Subject|1
6001088|NCT00044213|9595290|FG000|Overall Study|Withdrawal by Subject|50
6001089|NCT00044213|9595291|FG001|Overall Study|Withdrawal by Subject|65
6001090|NCT00044213|9595292|FG002|Overall Study|Withdrawal by Subject|91
6001091|NCT00044213|9595293|FG003|Overall Study|Withdrawal by Subject|83
6072794|NCT00562159|9676031|FG000|Overall Study|Protocol Violation|12
6001092|NCT00044213|9595290|FG000|Overall Study|Death|42
6001093|NCT00044213|9595291|FG001|Overall Study|Death|42
6001094|NCT00044213|9595292|FG002|Overall Study|Death|42
6072795|NCT00562159|9676032|FG001|Overall Study|Protocol Violation|12
6001095|NCT00044213|9595293|FG003|Overall Study|Death|49
6001096|NCT00044213|9595290|FG000|Overall Study|Lost to Follow-up|8
6001097|NCT00044213|9595291|FG001|Overall Study|Lost to Follow-up|5
6001098|NCT00044213|9595292|FG002|Overall Study|Lost to Follow-up|5
6001099|NCT00044213|9595293|FG003|Overall Study|Lost to Follow-up|4
6001100|NCT00044512|9595303|FG000|Follow Up|Lost to Follow-up|2
6001101|NCT00045032|9595319|FG000|Overall Study|Adverse Event/Intercurrent Illness|2
6001102|NCT00045032|9595320|FG001|Overall Study|Adverse Event/Intercurrent Illness|2
6001103|NCT00045032|9595321|FG002|Overall Study|Adverse Event/Intercurrent Illness|7
6001104|NCT00045032|9595319|FG000|Overall Study|Death|22
6001105|NCT00045032|9595320|FG001|Overall Study|Death|24
6001106|NCT00045032|9595321|FG002|Overall Study|Death|17
6001107|NCT00045032|9595319|FG000|Overall Study|Insufficient Therapeutic Response|542
6001108|NCT00045032|9595320|FG001|Overall Study|Insufficient Therapeutic Response|437
6001109|NCT00045032|9595321|FG002|Overall Study|Insufficient Therapeutic Response|445
6001110|NCT00045032|9595319|FG000|Overall Study|Violation of Selection Criteria at Entry|3
6001111|NCT00045032|9595320|FG001|Overall Study|Violation of Selection Criteria at Entry|6
6001112|NCT00045032|9595321|FG002|Overall Study|Violation of Selection Criteria at Entry|6
6001113|NCT00045032|9595319|FG000|Overall Study|Other Protocol Violation|2
6001114|NCT00045032|9595320|FG001|Overall Study|Other Protocol Violation|0
6001115|NCT00045032|9595321|FG002|Overall Study|Other Protocol Violation|1
6001116|NCT00045032|9595319|FG000|Overall Study|Refused/Did Not Cooperate/Withdrew|142
6001117|NCT00045032|9595320|FG001|Overall Study|Refused/Did Not Cooperate/Withdrew|93
6001118|NCT00045032|9595321|FG002|Overall Study|Refused/Did Not Cooperate/Withdrew|84
6001119|NCT00045032|9595319|FG000|Overall Study|Failure to Return|57
6001120|NCT00045032|9595320|FG001|Overall Study|Failure to Return|62
6072796|NCT00562159|9676031|FG000|Overall Study|Did not meet protocol eligibility|1
6072797|NCT00562159|9676032|FG001|Overall Study|Did not meet protocol eligibility|1
6072798|NCT00562302|9676041|FG000|Overall Study|Lost to Follow-up|3
6072799|NCT00562302|9676042|FG001|Overall Study|Lost to Follow-up|3
6072800|NCT00562302|9676041|FG000|Overall Study|Adverse Event|0
6072801|NCT00562302|9676042|FG001|Overall Study|Adverse Event|6
6072802|NCT00562302|9676041|FG000|Overall Study|Non-compliance|1
6072803|NCT00562302|9676042|FG001|Overall Study|Non-compliance|2
6072804|NCT00562302|9676041|FG000|Overall Study|Withdrawal by Subject|7
6072805|NCT00562302|9676042|FG001|Overall Study|Withdrawal by Subject|8
6072806|NCT00562302|9676041|FG000|Overall Study|Death|1
6072807|NCT00562302|9676042|FG001|Overall Study|Death|2
6072808|NCT00562302|9676041|FG000|Overall Study|Lung resection prior to study completion|7
6072809|NCT00562302|9676042|FG001|Overall Study|Lung resection prior to study completion|7
6072810|NCT00562302|9676041|FG000|Overall Study|Not stated|1
6072811|NCT00562302|9676042|FG001|Overall Study|Not stated|4
6087263|NCT00666926|9697371|FG012|Overall Study|Withdrawal by Subject|0
6087264|NCT00666926|9697372|FG013|Overall Study|Withdrawal by Subject|1
6087265|NCT00666926|9697373|FG014|Overall Study|Withdrawal by Subject|3
6087266|NCT00666926|9697374|FG015|Overall Study|Withdrawal by Subject|3
6087267|NCT00666926|9697359|FG000|Overall Study|Death|0
6087268|NCT00666926|9697360|FG001|Overall Study|Death|0
6087269|NCT00666926|9697361|FG002|Overall Study|Death|0
6087270|NCT00666926|9697362|FG003|Overall Study|Death|0
6087271|NCT00666926|9697363|FG004|Overall Study|Death|0
6087272|NCT00666926|9697364|FG005|Overall Study|Death|0
6087273|NCT00666926|9697365|FG006|Overall Study|Death|0
6087274|NCT00666926|9697366|FG007|Overall Study|Death|0
6087275|NCT00666926|9697367|FG008|Overall Study|Death|0
6087276|NCT00666926|9697368|FG009|Overall Study|Death|0
6087277|NCT00666926|9697369|FG010|Overall Study|Death|0
6087278|NCT00666926|9697370|FG011|Overall Study|Death|1
6087279|NCT00666926|9697371|FG012|Overall Study|Death|0
6087280|NCT00666926|9697372|FG013|Overall Study|Death|0
6087281|NCT00666926|9697373|FG014|Overall Study|Death|0
6087282|NCT00666926|9697374|FG015|Overall Study|Death|0
6087283|NCT00666965|9697429|FG000|Overall Study|Adverse Event|0
6087284|NCT00666965|9697430|FG001|Overall Study|Adverse Event|2
6087285|NCT00666965|9697431|FG002|Overall Study|Adverse Event|1
6087286|NCT00666965|9697432|FG003|Overall Study|Adverse Event|9
6087287|NCT00666965|9697429|FG000|Overall Study|Lack of Efficacy|1
6087288|NCT00666965|9697430|FG001|Overall Study|Lack of Efficacy|1
6087289|NCT00666965|9697431|FG002|Overall Study|Lack of Efficacy|0
6087290|NCT00666965|9697432|FG003|Overall Study|Lack of Efficacy|0
6087291|NCT00666965|9697429|FG000|Overall Study|Protocol Violation|0
6087292|NCT00666965|9697430|FG001|Overall Study|Protocol Violation|0
6087293|NCT00666965|9697431|FG002|Overall Study|Protocol Violation|0
6087294|NCT00666965|9697432|FG003|Overall Study|Protocol Violation|2
6001121|NCT00045032|9595321|FG002|Overall Study|Failure to Return|61
6001122|NCT00045032|9595319|FG000|Overall Study|Other|93
6001123|NCT00045032|9595320|FG001|Overall Study|Other|84
6001124|NCT00045032|9595321|FG002|Overall Study|Other|105
6087295|NCT00666965|9697429|FG000|Overall Study|Discontinuation criteria|2
6087296|NCT00666965|9697430|FG001|Overall Study|Discontinuation criteria|1
6087297|NCT00666965|9697431|FG002|Overall Study|Discontinuation criteria|1
6087298|NCT00666965|9697432|FG003|Overall Study|Discontinuation criteria|2
6087299|NCT00666965|9697429|FG000|Overall Study|Withdrawal by Subject|0
6087300|NCT00666965|9697430|FG001|Overall Study|Withdrawal by Subject|0
6087301|NCT00666965|9697431|FG002|Overall Study|Withdrawal by Subject|0
6087302|NCT00666965|9697432|FG003|Overall Study|Withdrawal by Subject|2
6001125|NCT00045110|9595334|FG000|100mg Phase 1 Dose Escalalation|did not initiate treatment|0
6001126|NCT00045110|9595335|FG001|100mg Phase 1 Dose Escalalation|did not initiate treatment|2
6001127|NCT00045110|9595336|FG002|100mg Phase 1 Dose Escalalation|did not initiate treatment|1
6001128|NCT00045110|9595334|FG000|100mg Phase 1 Dose Escalalation|prior treatment history|0
6001129|NCT00045110|9595335|FG001|100mg Phase 1 Dose Escalalation|prior treatment history|4
6001130|NCT00045110|9595336|FG002|100mg Phase 1 Dose Escalalation|prior treatment history|0
6001131|NCT00045110|9595334|FG000|100mg Phase 1 Dose Escalalation|ineligible histology|0
6001132|NCT00045110|9595335|FG001|100mg Phase 1 Dose Escalalation|ineligible histology|0
6001133|NCT00045110|9595336|FG002|100mg Phase 1 Dose Escalalation|ineligible histology|1
6001134|NCT00045162|9595355|FG000|Overall Study|Ineligible|12
6001135|NCT00045162|9595356|FG001|Overall Study|Ineligible|8
6001136|NCT00045162|9595355|FG000|Overall Study|Not treated|7
6001137|NCT00045162|9595356|FG001|Overall Study|Not treated|2
6001138|NCT00045162|9595355|FG000|Overall Study|Adverse Event|55
6001139|NCT00045162|9595356|FG001|Overall Study|Adverse Event|50
6001140|NCT00045162|9595355|FG000|Overall Study|Lack of Efficacy|32
6001141|NCT00045162|9595356|FG001|Overall Study|Lack of Efficacy|29
6001142|NCT00045162|9595355|FG000|Overall Study|Death|10
6001143|NCT00045162|9595356|FG001|Overall Study|Death|10
6001144|NCT00045162|9595355|FG000|Overall Study|Withdrawal by Subject|5
6001145|NCT00045162|9595356|FG001|Overall Study|Withdrawal by Subject|3
6001146|NCT00045162|9595355|FG000|Overall Study|Other|21
6001147|NCT00045162|9595356|FG001|Overall Study|Other|16
6001148|NCT00045305|9595362|FG000|Overall Study|Lack of Efficacy|6
6001149|NCT00045305|9595362|FG000|Overall Study|Adverse Event|3
6001150|NCT00045305|9595362|FG000|Overall Study|Death|3
6001151|NCT00045305|9595362|FG000|Overall Study|site error|2
6001152|NCT00045630|9595374|FG000|Overall Study|Adverse Event|1
6001153|NCT00045630|9595374|FG000|Overall Study|Refusal unrelated to adverse event|1
6001154|NCT00045630|9595374|FG000|Overall Study|Progression/relapse|1
6001155|NCT00045630|9595374|FG000|Overall Study|Death|1
6001156|NCT00045630|9595374|FG000|Overall Study|Ineligible|2
6001157|NCT00045708|9595381|FG000|Phase 1|early progressive disease|0
6001158|NCT00045708|9595382|FG001|Phase 1|early progressive disease|1
6001159|NCT00045708|9595383|FG002|Phase 1|early progressive disease|0
6001160|NCT00045734|9595400|FG000|Overall Study|Protocol Violation|1
6001161|NCT00045942|9595413|FG000|PKC412A2104 (Core)|Withdrawal by Subject|1
6001162|NCT00045942|9595414|FG001|PKC412A2104 (Core)|Withdrawal by Subject|0
6001163|NCT00045942|9595415|FG002|PKC412A2104 (Core)|Withdrawal by Subject|0
6001164|NCT00045942|9595416|FG003|PKC412A2104 (Core)|Withdrawal by Subject|0
6001165|NCT00045942|9595417|FG004|PKC412A2104 (Core)|Withdrawal by Subject|0
6001166|NCT00045942|9595418|FG005|PKC412A2104 (Core)|Withdrawal by Subject|0
6001167|NCT00045942|9595419|FG006|PKC412A2104 (Core)|Withdrawal by Subject|0
6001168|NCT00045942|9595420|FG007|PKC412A2104 (Core)|Withdrawal by Subject|0
6001169|NCT00045942|9595421|FG008|PKC412A2104 (Core)|Withdrawal by Subject|0
6001170|NCT00045942|9595413|FG000|PKC412A2104 (Core)|Adverse Event|5
6001171|NCT00045942|9595414|FG001|PKC412A2104 (Core)|Adverse Event|0
6001172|NCT00045942|9595415|FG002|PKC412A2104 (Core)|Adverse Event|0
6001173|NCT00045942|9595416|FG003|PKC412A2104 (Core)|Adverse Event|0
6001174|NCT00045942|9595417|FG004|PKC412A2104 (Core)|Adverse Event|0
6001175|NCT00045942|9595418|FG005|PKC412A2104 (Core)|Adverse Event|0
6001176|NCT00045942|9595419|FG006|PKC412A2104 (Core)|Adverse Event|0
6001177|NCT00045942|9595420|FG007|PKC412A2104 (Core)|Adverse Event|0
6001178|NCT00045942|9595421|FG008|PKC412A2104 (Core)|Adverse Event|0
6001179|NCT00045942|9595413|FG000|PKC412A2104 (Core)|Lack of Efficacy|13
6001180|NCT00045942|9595414|FG001|PKC412A2104 (Core)|Lack of Efficacy|0
6001181|NCT00045942|9595415|FG002|PKC412A2104 (Core)|Lack of Efficacy|0
6001182|NCT00045942|9595416|FG003|PKC412A2104 (Core)|Lack of Efficacy|0
6001183|NCT00045942|9595417|FG004|PKC412A2104 (Core)|Lack of Efficacy|0
6001184|NCT00045942|9595418|FG005|PKC412A2104 (Core)|Lack of Efficacy|0
6001185|NCT00045942|9595419|FG006|PKC412A2104 (Core)|Lack of Efficacy|0
6001186|NCT00045942|9595420|FG007|PKC412A2104 (Core)|Lack of Efficacy|0
6001187|NCT00045942|9595421|FG008|PKC412A2104 (Core)|Lack of Efficacy|0
6001188|NCT00045942|9595413|FG000|PKC412A2104 (Core)|Death|1
6001189|NCT00045942|9595414|FG001|PKC412A2104 (Core)|Death|0
6001190|NCT00045942|9595415|FG002|PKC412A2104 (Core)|Death|0
6001191|NCT00045942|9595416|FG003|PKC412A2104 (Core)|Death|0
6001192|NCT00045942|9595417|FG004|PKC412A2104 (Core)|Death|0
6001193|NCT00045942|9595418|FG005|PKC412A2104 (Core)|Death|0
6001194|NCT00045942|9595419|FG006|PKC412A2104 (Core)|Death|0
6001195|NCT00045942|9595420|FG007|PKC412A2104 (Core)|Death|0
6001196|NCT00045942|9595421|FG008|PKC412A2104 (Core)|Death|0
6001197|NCT00045942|9595413|FG000|PKC412A2104E1|Withdrawal by Subject|0
6001198|NCT00045942|9595414|FG001|PKC412A2104E1|Withdrawal by Subject|0
6001199|NCT00045942|9595415|FG002|PKC412A2104E1|Withdrawal by Subject|2
6001200|NCT00045942|9595416|FG003|PKC412A2104E1|Withdrawal by Subject|5
6001201|NCT00045942|9595417|FG004|PKC412A2104E1|Withdrawal by Subject|2
6001202|NCT00045942|9595418|FG005|PKC412A2104E1|Withdrawal by Subject|0
6001203|NCT00045942|9595419|FG006|PKC412A2104E1|Withdrawal by Subject|0
6001204|NCT00045942|9595420|FG007|PKC412A2104E1|Withdrawal by Subject|0
6001205|NCT00045942|9595421|FG008|PKC412A2104E1|Withdrawal by Subject|0
6001206|NCT00045942|9595413|FG000|PKC412A2104E1|Condition no longer requires study drug|0
6001207|NCT00045942|9595414|FG001|PKC412A2104E1|Condition no longer requires study drug|1
6001208|NCT00045942|9595415|FG002|PKC412A2104E1|Condition no longer requires study drug|1
6001209|NCT00045942|9595416|FG003|PKC412A2104E1|Condition no longer requires study drug|0
6001210|NCT00045942|9595417|FG004|PKC412A2104E1|Condition no longer requires study drug|1
6001211|NCT00045942|9595418|FG005|PKC412A2104E1|Condition no longer requires study drug|0
6001212|NCT00045942|9595419|FG006|PKC412A2104E1|Condition no longer requires study drug|0
6001213|NCT00045942|9595420|FG007|PKC412A2104E1|Condition no longer requires study drug|0
6001214|NCT00045942|9595421|FG008|PKC412A2104E1|Condition no longer requires study drug|0
6001215|NCT00045942|9595413|FG000|PKC412A2104E1|Lack of Efficacy|0
6001216|NCT00045942|9595414|FG001|PKC412A2104E1|Lack of Efficacy|11
6001217|NCT00045942|9595415|FG002|PKC412A2104E1|Lack of Efficacy|11
6001218|NCT00045942|9595416|FG003|PKC412A2104E1|Lack of Efficacy|23
6001219|NCT00045942|9595417|FG004|PKC412A2104E1|Lack of Efficacy|17
6001220|NCT00045942|9595418|FG005|PKC412A2104E1|Lack of Efficacy|0
6001221|NCT00045942|9595419|FG006|PKC412A2104E1|Lack of Efficacy|0
6001222|NCT00045942|9595420|FG007|PKC412A2104E1|Lack of Efficacy|0
6001223|NCT00045942|9595421|FG008|PKC412A2104E1|Lack of Efficacy|0
6001224|NCT00045942|9595413|FG000|PKC412A2104E1|Abnormal laboratory value|0
6001225|NCT00045942|9595414|FG001|PKC412A2104E1|Abnormal laboratory value|1
6001226|NCT00045942|9595415|FG002|PKC412A2104E1|Abnormal laboratory value|0
6001227|NCT00045942|9595416|FG003|PKC412A2104E1|Abnormal laboratory value|0
6001228|NCT00045942|9595417|FG004|PKC412A2104E1|Abnormal laboratory value|0
6001229|NCT00045942|9595418|FG005|PKC412A2104E1|Abnormal laboratory value|0
6001230|NCT00045942|9595419|FG006|PKC412A2104E1|Abnormal laboratory value|0
6001231|NCT00045942|9595420|FG007|PKC412A2104E1|Abnormal laboratory value|0
6001232|NCT00045942|9595421|FG008|PKC412A2104E1|Abnormal laboratory value|0
6001233|NCT00045942|9595413|FG000|PKC412A2104E1|Adverse Event|0
6001234|NCT00045942|9595414|FG001|PKC412A2104E1|Adverse Event|1
6001235|NCT00045942|9595415|FG002|PKC412A2104E1|Adverse Event|1
6001236|NCT00045942|9595416|FG003|PKC412A2104E1|Adverse Event|3
6001237|NCT00045942|9595417|FG004|PKC412A2104E1|Adverse Event|6
6001238|NCT00045942|9595418|FG005|PKC412A2104E1|Adverse Event|0
6001239|NCT00045942|9595419|FG006|PKC412A2104E1|Adverse Event|0
6001240|NCT00045942|9595420|FG007|PKC412A2104E1|Adverse Event|0
6001241|NCT00045942|9595421|FG008|PKC412A2104E1|Adverse Event|0
6001242|NCT00045942|9595413|FG000|PKC412A2104E1|Death|0
6001243|NCT00045942|9595414|FG001|PKC412A2104E1|Death|4
6001244|NCT00045942|9595415|FG002|PKC412A2104E1|Death|1
6001245|NCT00045942|9595416|FG003|PKC412A2104E1|Death|1
6001246|NCT00045942|9595417|FG004|PKC412A2104E1|Death|1
6001247|NCT00045942|9595418|FG005|PKC412A2104E1|Death|0
6001248|NCT00045942|9595419|FG006|PKC412A2104E1|Death|0
6001249|NCT00045942|9595420|FG007|PKC412A2104E1|Death|0
6001250|NCT00045942|9595421|FG008|PKC412A2104E1|Death|0
6001251|NCT00045942|9595413|FG000|PKC412A2104E1|Enrolled into PKC412A2104E2|0
6001252|NCT00045942|9595414|FG001|PKC412A2104E1|Enrolled into PKC412A2104E2|0
6001253|NCT00045942|9595415|FG002|PKC412A2104E1|Enrolled into PKC412A2104E2|1
6001254|NCT00045942|9595416|FG003|PKC412A2104E1|Enrolled into PKC412A2104E2|1
6001255|NCT00045942|9595417|FG004|PKC412A2104E1|Enrolled into PKC412A2104E2|0
6001256|NCT00045942|9595418|FG005|PKC412A2104E1|Enrolled into PKC412A2104E2|0
6001257|NCT00045942|9595419|FG006|PKC412A2104E1|Enrolled into PKC412A2104E2|0
6001258|NCT00045942|9595420|FG007|PKC412A2104E1|Enrolled into PKC412A2104E2|0
6001259|NCT00045942|9595421|FG008|PKC412A2104E1|Enrolled into PKC412A2104E2|0
6001260|NCT00045942|9595413|FG000|PKC412A2104E2|Lost to Follow-up|0
6001261|NCT00045942|9595414|FG001|PKC412A2104E2|Lost to Follow-up|0
6001262|NCT00045942|9595415|FG002|PKC412A2104E2|Lost to Follow-up|0
6001263|NCT00045942|9595416|FG003|PKC412A2104E2|Lost to Follow-up|0
6001264|NCT00045942|9595417|FG004|PKC412A2104E2|Lost to Follow-up|0
6072812|NCT00562354|9676060|FG000|Overall Study|Physician Decision|0
6072813|NCT00562354|9676061|FG001|Overall Study|Physician Decision|1
6072814|NCT00562354|9676060|FG000|Overall Study|Lost to Follow-up|0
6072815|NCT00562354|9676061|FG001|Overall Study|Lost to Follow-up|1
6072816|NCT00562484|9676071|FG000|Overall Study|Adverse Event|6
6072817|NCT00562484|9676072|FG001|Overall Study|Adverse Event|1
6072818|NCT00562484|9676071|FG000|Overall Study|Protocol Violation|11
6072819|NCT00562484|9676072|FG001|Overall Study|Protocol Violation|2
6072820|NCT00562484|9676071|FG000|Overall Study|Withdrawal by Subject|12
6072821|NCT00562484|9676072|FG001|Overall Study|Withdrawal by Subject|9
6072822|NCT00562484|9676071|FG000|Overall Study|Moved away from the study area|20
6001265|NCT00045942|9595418|FG005|PKC412A2104E2|Lost to Follow-up|0
6001266|NCT00045942|9595419|FG006|PKC412A2104E2|Lost to Follow-up|0
6001267|NCT00045942|9595420|FG007|PKC412A2104E2|Lost to Follow-up|3
6001268|NCT00045942|9595421|FG008|PKC412A2104E2|Lost to Follow-up|0
6001269|NCT00045942|9595413|FG000|PKC412A2104E2|Withdrawal by Subject|0
6001270|NCT00045942|9595414|FG001|PKC412A2104E2|Withdrawal by Subject|0
6001271|NCT00045942|9595415|FG002|PKC412A2104E2|Withdrawal by Subject|0
6001272|NCT00045942|9595416|FG003|PKC412A2104E2|Withdrawal by Subject|0
6001273|NCT00045942|9595417|FG004|PKC412A2104E2|Withdrawal by Subject|0
6001274|NCT00045942|9595418|FG005|PKC412A2104E2|Withdrawal by Subject|1
6072823|NCT00562484|9676072|FG001|Overall Study|Moved away from the study area|9
6072824|NCT00562484|9676071|FG000|Overall Study|Lost to Follow-up|132
6001275|NCT00045942|9595419|FG006|PKC412A2104E2|Withdrawal by Subject|0
6001276|NCT00045942|9595420|FG007|PKC412A2104E2|Withdrawal by Subject|1
6001277|NCT00045942|9595421|FG008|PKC412A2104E2|Withdrawal by Subject|0
6001278|NCT00045942|9595413|FG000|PKC412A2104E2|Lack of Efficacy|0
6072825|NCT00562484|9676072|FG001|Overall Study|Lost to Follow-up|71
6001279|NCT00045942|9595414|FG001|PKC412A2104E2|Lack of Efficacy|0
6001280|NCT00045942|9595415|FG002|PKC412A2104E2|Lack of Efficacy|0
6001281|NCT00045942|9595416|FG003|PKC412A2104E2|Lack of Efficacy|0
6001282|NCT00045942|9595417|FG004|PKC412A2104E2|Lack of Efficacy|0
6001283|NCT00045942|9595418|FG005|PKC412A2104E2|Lack of Efficacy|3
6001284|NCT00045942|9595419|FG006|PKC412A2104E2|Lack of Efficacy|2
6001285|NCT00045942|9595420|FG007|PKC412A2104E2|Lack of Efficacy|2
6001286|NCT00045942|9595421|FG008|PKC412A2104E2|Lack of Efficacy|6
6001287|NCT00045942|9595413|FG000|PKC412A2104E2|Adverse Event|0
6001288|NCT00045942|9595414|FG001|PKC412A2104E2|Adverse Event|0
6001289|NCT00045942|9595415|FG002|PKC412A2104E2|Adverse Event|0
6001290|NCT00045942|9595416|FG003|PKC412A2104E2|Adverse Event|0
6001291|NCT00045942|9595417|FG004|PKC412A2104E2|Adverse Event|0
6001292|NCT00045942|9595418|FG005|PKC412A2104E2|Adverse Event|4
6001293|NCT00045942|9595419|FG006|PKC412A2104E2|Adverse Event|3
6001294|NCT00045942|9595420|FG007|PKC412A2104E2|Adverse Event|1
6001295|NCT00045942|9595421|FG008|PKC412A2104E2|Adverse Event|0
6001296|NCT00045942|9595413|FG000|PKC412A2104E2|Death|0
6001297|NCT00045942|9595414|FG001|PKC412A2104E2|Death|0
6001298|NCT00045942|9595415|FG002|PKC412A2104E2|Death|0
6001299|NCT00045942|9595416|FG003|PKC412A2104E2|Death|0
6001300|NCT00045942|9595417|FG004|PKC412A2104E2|Death|0
6001301|NCT00045942|9595418|FG005|PKC412A2104E2|Death|1
6001302|NCT00045942|9595419|FG006|PKC412A2104E2|Death|2
6001303|NCT00045942|9595420|FG007|PKC412A2104E2|Death|0
6001304|NCT00045942|9595421|FG008|PKC412A2104E2|Death|0
6001305|NCT00046839|9595488|FG000|Overall Study|Ineligible / No protocol treatment|0
6001306|NCT00046839|9595489|FG001|Overall Study|Ineligible / No protocol treatment|2
6001307|NCT00046839|9595488|FG000|Overall Study|Withdrawal of consent|1
6001308|NCT00046839|9595489|FG001|Overall Study|Withdrawal of consent|0
6001309|NCT00046891|9595498|FG000|Overall Study|Cancels|5
6001310|NCT00046891|9595499|FG001|Overall Study|Cancels|9
6001311|NCT00046891|9595498|FG000|Overall Study|Ineligible|1
6001312|NCT00046891|9595499|FG001|Overall Study|Ineligible|1
6001313|NCT00046891|9595498|FG000|Overall Study|Withdrawal by Subject|18
6001314|NCT00046891|9595499|FG001|Overall Study|Withdrawal by Subject|15
6001315|NCT00046891|9595498|FG000|Overall Study|Adverse Event|5
6072826|NCT00562484|9676071|FG000|Overall Study|Reason not provided or not specified|25
6072827|NCT00562484|9676072|FG001|Overall Study|Reason not provided or not specified|12
6072828|NCT00562588|9676080|FG000|Overall Study|Adverse Event|40
6072829|NCT00562588|9676081|FG001|Overall Study|Adverse Event|58
6072830|NCT00562588|9676080|FG000|Overall Study|Protocol Violation|30
6072831|NCT00562588|9676081|FG001|Overall Study|Protocol Violation|26
6072832|NCT00562588|9676080|FG000|Overall Study|Lost to Follow-up|12
6072833|NCT00562588|9676081|FG001|Overall Study|Lost to Follow-up|4
6072834|NCT00562588|9676080|FG000|Overall Study|Withdrawal by Subject|10
6072835|NCT00562588|9676081|FG001|Overall Study|Withdrawal by Subject|9
6072836|NCT00562588|9676080|FG000|Overall Study|Other|0
6072837|NCT00562588|9676081|FG001|Overall Study|Other|2
6072838|NCT00562627|9676090|FG000|Overall Study|Protocol Violation|1
6072839|NCT00562627|9676091|FG001|Overall Study|Protocol Violation|1
6072840|NCT00562627|9676092|FG002|Overall Study|Protocol Violation|1
6072841|NCT00562718|9676100|FG000|Overall Study|Death|1
6072842|NCT00562718|9676100|FG000|Overall Study|Withdrawal by Subject|3
6072843|NCT00562718|9676100|FG000|Overall Study|Adverse Event|4
6072844|NCT00562718|9676100|FG000|Overall Study|Lack of Efficacy|2
6072845|NCT00562718|9676100|FG000|Overall Study|not stated|1
6072846|NCT00562861|9676106|FG000|Overall Study|Adverse Event|1
6072847|NCT00562861|9676107|FG001|Overall Study|Adverse Event|1
6072848|NCT00562861|9676106|FG000|Overall Study|Lack of Efficacy|5
6072849|NCT00562861|9676107|FG001|Overall Study|Lack of Efficacy|5
6072850|NCT00562861|9676106|FG000|Overall Study|noncompliance, moved|7
6072851|NCT00562861|9676107|FG001|Overall Study|noncompliance, moved|2
6072852|NCT00562861|9676106|FG000|Overall Study|Lost to Follow-up|7
6072853|NCT00562861|9676107|FG001|Overall Study|Lost to Follow-up|3
6072854|NCT00562965|9676115|FG000|Overall Study|Withdrawal by Subject|0
6072855|NCT00562965|9676116|FG001|Overall Study|Withdrawal by Subject|1
6072856|NCT00562965|9676115|FG000|Overall Study|Death|2
6072857|NCT00562965|9676116|FG001|Overall Study|Death|4
6072858|NCT00562965|9676115|FG000|Overall Study|Lost to Follow-up|1
6072859|NCT00562965|9676116|FG001|Overall Study|Lost to Follow-up|0
6072860|NCT00562965|9676115|FG000|Overall Study|Other|0
6001316|NCT00046891|9595499|FG001|Overall Study|Adverse Event|5
6001317|NCT00046930|9595515|FG000|Overall Study|Ineligible|12
6001318|NCT00046930|9595516|FG001|Overall Study|Ineligible|4
6001319|NCT00047008|9595527|FG000|Overall Study|Withdrawn consent|2
6001320|NCT00047008|9595528|FG001|Overall Study|Withdrawn consent|3
6001321|NCT00047008|9595527|FG000|Overall Study|Ineligible|9
6001322|NCT00047008|9595528|FG001|Overall Study|Ineligible|8
6001323|NCT00047320|9595538|FG000|Overall Study|Lack of Efficacy|8
6072861|NCT00562965|9676116|FG001|Overall Study|Other|1
6072862|NCT00562978|9676124|FG000|Overall Study|Patient had imaging dose only|1
6072863|NCT00562978|9676125|FG001|Overall Study|Patient had imaging dose only|11
6072864|NCT00563186|9676133|FG000|Overall Study|LOS<48 hours|97
6001324|NCT00047320|9595538|FG000|Overall Study|Lost to Follow-up|1
6001325|NCT00047320|9595538|FG000|Overall Study|Physician Decision|8
6001326|NCT00047320|9595538|FG000|Overall Study|Withdrawal by Subject|9
6001327|NCT00047320|9595538|FG000|Overall Study|Ineligible|2
6001328|NCT00047385|9595544|FG000|Overall Study|Death before any screening|2
6001329|NCT00047385|9595545|FG001|Overall Study|Death before any screening|5
6001330|NCT00047385|9595544|FG000|Overall Study|Lung Cancer diagnosed before screening|5
6001331|NCT00047385|9595545|FG001|Overall Study|Lung Cancer diagnosed before screening|3
6001332|NCT00047385|9595544|FG000|Overall Study|Eligible for screening but had no screen|260
6001333|NCT00047385|9595545|FG001|Overall Study|Eligible for screening but had no screen|492
6001334|NCT00047463|9595553|FG000|Overall Study|Withdrawal by Subject|0
6001335|NCT00047463|9595554|FG001|Overall Study|Withdrawal by Subject|3
6001336|NCT00047879|9595584|FG000|Overall Study|Progressive disease|4
6001337|NCT00047879|9595585|FG001|Overall Study|Progressive disease|3
6001338|NCT00048035|9595597|FG000|Core Period|Early Withdrawals|4
6001339|NCT00048035|9595598|FG001|Core Period|Early Withdrawals|2
6001340|NCT00048035|9595599|FG002|Core Period|Early Withdrawals|1
6001341|NCT00048035|9595600|FG003|Core Period|Early Withdrawals|1
6001342|NCT00048035|9595601|FG004|Core Period|Early Withdrawals|1
6001343|NCT00048035|9595602|FG005|Core Period|Early Withdrawals|1
6001344|NCT00048035|9595603|FG006|Core Period|Early Withdrawals|0
6001345|NCT00048035|9595604|FG007|Core Period|Early Withdrawals|0
6001346|NCT00048035|9595597|FG000|Extension Year 1|Early Withdrawals|0
6001347|NCT00048035|9595598|FG001|Extension Year 1|Early Withdrawals|0
6001348|NCT00048035|9595599|FG002|Extension Year 1|Early Withdrawals|0
6001349|NCT00048035|9595600|FG003|Extension Year 1|Early Withdrawals|0
6001350|NCT00048035|9595601|FG004|Extension Year 1|Early Withdrawals|0
6001351|NCT00048035|9595602|FG005|Extension Year 1|Early Withdrawals|0
6001352|NCT00048035|9595603|FG006|Extension Year 1|Early Withdrawals|11
6001353|NCT00048035|9595604|FG007|Extension Year 1|Early Withdrawals|11
6001354|NCT00048035|9595597|FG000|Extension Year 2|Early Withdrawals|0
6001355|NCT00048035|9595598|FG001|Extension Year 2|Early Withdrawals|0
6072865|NCT00563186|9676134|FG001|Overall Study|LOS<48 hours|74
6001356|NCT00048035|9595599|FG002|Extension Year 2|Early Withdrawals|0
6001357|NCT00048035|9595600|FG003|Extension Year 2|Early Withdrawals|0
6001358|NCT00048035|9595601|FG004|Extension Year 2|Early Withdrawals|0
6001359|NCT00048035|9595602|FG005|Extension Year 2|Early Withdrawals|0
6001360|NCT00048035|9595603|FG006|Extension Year 2|Early Withdrawals|3
6001361|NCT00048035|9595604|FG007|Extension Year 2|Early Withdrawals|3
6001362|NCT00048048|9595628|FG000|Core Treatment|Withdrawal by Subject|0
6001363|NCT00048048|9595629|FG001|Core Treatment|Withdrawal by Subject|0
6001364|NCT00048048|9595630|FG002|Core Treatment|Withdrawal by Subject|1
6001365|NCT00048048|9595631|FG003|Core Treatment|Withdrawal by Subject|0
6001366|NCT00048048|9595632|FG004|Core Treatment|Withdrawal by Subject|0
6001367|NCT00048048|9595633|FG005|Core Treatment|Withdrawal by Subject|0
6001368|NCT00048048|9595634|FG006|Core Treatment|Withdrawal by Subject|0
6001369|NCT00048048|9595635|FG007|Core Treatment|Withdrawal by Subject|0
6001370|NCT00048048|9595636|FG008|Core Treatment|Withdrawal by Subject|0
6001371|NCT00048048|9595637|FG009|Core Treatment|Withdrawal by Subject|0
6001372|NCT00048048|9595638|FG010|Core Treatment|Withdrawal by Subject|0
6001373|NCT00048048|9595639|FG011|Core Treatment|Withdrawal by Subject|0
6001374|NCT00048048|9595628|FG000|Core Treatment|Adverse Event|0
6001375|NCT00048048|9595629|FG001|Core Treatment|Adverse Event|0
6001376|NCT00048048|9595630|FG002|Core Treatment|Adverse Event|0
6001377|NCT00048048|9595631|FG003|Core Treatment|Adverse Event|0
6001378|NCT00048048|9595632|FG004|Core Treatment|Adverse Event|0
6001379|NCT00048048|9595633|FG005|Core Treatment|Adverse Event|0
6001380|NCT00048048|9595634|FG006|Core Treatment|Adverse Event|0
6001381|NCT00048048|9595635|FG007|Core Treatment|Adverse Event|1
6001382|NCT00048048|9595636|FG008|Core Treatment|Adverse Event|0
6001383|NCT00048048|9595637|FG009|Core Treatment|Adverse Event|0
6001384|NCT00048048|9595638|FG010|Core Treatment|Adverse Event|0
6001385|NCT00048048|9595639|FG011|Core Treatment|Adverse Event|0
6001386|NCT00048048|9595628|FG000|Extension Year 1|Early withdrawals|0
6001387|NCT00048048|9595629|FG001|Extension Year 1|Early withdrawals|0
6001388|NCT00048048|9595630|FG002|Extension Year 1|Early withdrawals|0
6001389|NCT00048048|9595631|FG003|Extension Year 1|Early withdrawals|0
6001390|NCT00048048|9595632|FG004|Extension Year 1|Early withdrawals|0
6001391|NCT00048048|9595633|FG005|Extension Year 1|Early withdrawals|0
6001392|NCT00048048|9595634|FG006|Extension Year 1|Early withdrawals|0
6001393|NCT00048048|9595635|FG007|Extension Year 1|Early withdrawals|0
6001394|NCT00048048|9595636|FG008|Extension Year 1|Early withdrawals|0
6001395|NCT00048048|9595637|FG009|Extension Year 1|Early withdrawals|2
6001396|NCT00048048|9595638|FG010|Extension Year 1|Early withdrawals|2
6001397|NCT00048048|9595639|FG011|Extension Year 1|Early withdrawals|4
6001398|NCT00048048|9595628|FG000|Extension Year 2|Early withdrawals|0
6001399|NCT00048048|9595629|FG001|Extension Year 2|Early withdrawals|0
6001400|NCT00048048|9595630|FG002|Extension Year 2|Early withdrawals|0
6001401|NCT00048048|9595631|FG003|Extension Year 2|Early withdrawals|0
6001402|NCT00048048|9595632|FG004|Extension Year 2|Early withdrawals|0
6001403|NCT00048048|9595633|FG005|Extension Year 2|Early withdrawals|0
6001404|NCT00048048|9595634|FG006|Extension Year 2|Early withdrawals|0
6001405|NCT00048048|9595635|FG007|Extension Year 2|Early withdrawals|0
6001406|NCT00048048|9595636|FG008|Extension Year 2|Early withdrawals|0
6001407|NCT00048048|9595637|FG009|Extension Year 2|Early withdrawals|0
6001408|NCT00048048|9595638|FG010|Extension Year 2|Early withdrawals|4
6001409|NCT00048048|9595639|FG011|Extension Year 2|Early withdrawals|2
6001410|NCT00048061|9595670|FG000|Overall Study|Adverse Event|41
6001411|NCT00048061|9595671|FG001|Overall Study|Adverse Event|32
6001412|NCT00048061|9595672|FG002|Overall Study|Adverse Event|44
6001413|NCT00048061|9595673|FG003|Overall Study|Adverse Event|37
6001414|NCT00048061|9595670|FG000|Overall Study|Lost to Follow-up|3
6001415|NCT00048061|9595671|FG001|Overall Study|Lost to Follow-up|2
6001416|NCT00048061|9595672|FG002|Overall Study|Lost to Follow-up|4
6001417|NCT00048061|9595673|FG003|Overall Study|Lost to Follow-up|5
6001418|NCT00048061|9595670|FG000|Overall Study|Withdrawal by Subject|20
6001419|NCT00048061|9595671|FG001|Overall Study|Withdrawal by Subject|29
6072866|NCT00563186|9676133|FG000|Overall Study|Incomplete data|1
6072867|NCT00563186|9676134|FG001|Overall Study|Incomplete data|1
6072868|NCT00563316|9676154|FG000|Overall Study|Adverse Event|2
6072869|NCT00563316|9676154|FG000|Overall Study|Physician Decision|1
6072870|NCT00563316|9676154|FG000|Overall Study|Lost to Follow-up|2
6072871|NCT00563316|9676154|FG000|Overall Study|Death|1
6072872|NCT00563316|9676154|FG000|Overall Study|On-going in study as of 16 July 2009.|5
6072873|NCT00563316|9676154|FG000|Overall Study|Other|1
6072874|NCT00563368|9676169|FG000|Overall Study|Lost to Follow-up|14
6072875|NCT00563368|9676170|FG001|Overall Study|Lost to Follow-up|14
6072876|NCT00563368|9676171|FG002|Overall Study|Lost to Follow-up|12
6072877|NCT00563368|9676172|FG003|Overall Study|Lost to Follow-up|6
6072878|NCT00563368|9676173|FG004|Overall Study|Lost to Follow-up|9
6072879|NCT00563368|9676174|FG005|Overall Study|Lost to Follow-up|8
6072880|NCT00563368|9676175|FG006|Overall Study|Lost to Follow-up|9
6072881|NCT00563368|9676169|FG000|Overall Study|Adverse Event|3
6072882|NCT00563368|9676170|FG001|Overall Study|Adverse Event|4
6072883|NCT00563368|9676171|FG002|Overall Study|Adverse Event|5
6072884|NCT00563368|9676172|FG003|Overall Study|Adverse Event|9
6072885|NCT00563368|9676173|FG004|Overall Study|Adverse Event|6
6072886|NCT00563368|9676174|FG005|Overall Study|Adverse Event|10
6072887|NCT00563368|9676175|FG006|Overall Study|Adverse Event|17
6072888|NCT00563368|9676169|FG000|Overall Study|Withdrawal by Subject|11
6072889|NCT00563368|9676170|FG001|Overall Study|Withdrawal by Subject|6
6072890|NCT00563368|9676171|FG002|Overall Study|Withdrawal by Subject|5
6072891|NCT00563368|9676172|FG003|Overall Study|Withdrawal by Subject|7
6072892|NCT00563368|9676173|FG004|Overall Study|Withdrawal by Subject|8
6072893|NCT00563368|9676174|FG005|Overall Study|Withdrawal by Subject|5
6072894|NCT00563368|9676175|FG006|Overall Study|Withdrawal by Subject|4
6072895|NCT00563368|9676169|FG000|Overall Study|protocol non-compliance|1
6072896|NCT00563368|9676170|FG001|Overall Study|protocol non-compliance|1
6072897|NCT00563368|9676171|FG002|Overall Study|protocol non-compliance|2
6072898|NCT00563368|9676172|FG003|Overall Study|protocol non-compliance|1
6072899|NCT00563368|9676173|FG004|Overall Study|protocol non-compliance|0
6072900|NCT00563368|9676174|FG005|Overall Study|protocol non-compliance|1
6072901|NCT00563368|9676175|FG006|Overall Study|protocol non-compliance|3
6072902|NCT00563368|9676169|FG000|Overall Study|Pregnancy|1
6072903|NCT00563368|9676170|FG001|Overall Study|Pregnancy|0
6072904|NCT00563368|9676171|FG002|Overall Study|Pregnancy|1
6072905|NCT00563368|9676172|FG003|Overall Study|Pregnancy|2
6072906|NCT00563368|9676173|FG004|Overall Study|Pregnancy|1
6072907|NCT00563368|9676174|FG005|Overall Study|Pregnancy|2
6072908|NCT00563368|9676175|FG006|Overall Study|Pregnancy|0
6072909|NCT00563368|9676169|FG000|Overall Study|requirement for restricted medication|0
6072910|NCT00563368|9676170|FG001|Overall Study|requirement for restricted medication|0
6072911|NCT00563368|9676171|FG002|Overall Study|requirement for restricted medication|2
6072912|NCT00563368|9676172|FG003|Overall Study|requirement for restricted medication|0
6072913|NCT00563368|9676173|FG004|Overall Study|requirement for restricted medication|0
6072914|NCT00563368|9676174|FG005|Overall Study|requirement for restricted medication|0
6072915|NCT00563368|9676175|FG006|Overall Study|requirement for restricted medication|0
6072916|NCT00563368|9676169|FG000|Overall Study|Other|5
6072917|NCT00563368|9676170|FG001|Overall Study|Other|5
6072918|NCT00563368|9676171|FG002|Overall Study|Other|3
6072919|NCT00563368|9676172|FG003|Overall Study|Other|4
6072920|NCT00563368|9676173|FG004|Overall Study|Other|4
6072921|NCT00563368|9676174|FG005|Overall Study|Other|4
6072922|NCT00563368|9676175|FG006|Overall Study|Other|0
6072923|NCT00563381|9676193|FG000|Overall Study|Adverse Event|264
6072924|NCT00563381|9676194|FG001|Overall Study|Adverse Event|292
6072925|NCT00563381|9676193|FG000|Overall Study|Protocol Violation|66
6072926|NCT00563381|9676194|FG001|Overall Study|Protocol Violation|74
6072927|NCT00563381|9676193|FG000|Overall Study|Lost to Follow-up|7
6072928|NCT00563381|9676194|FG001|Overall Study|Lost to Follow-up|15
6072929|NCT00563381|9676193|FG000|Overall Study|Withdrawal by Subject|192
6001420|NCT00048061|9595672|FG002|Overall Study|Withdrawal by Subject|29
6001421|NCT00048061|9595673|FG003|Overall Study|Withdrawal by Subject|32
6001422|NCT00048061|9595670|FG000|Overall Study|Did not follow-up|5
6001423|NCT00048061|9595671|FG001|Overall Study|Did not follow-up|5
6072930|NCT00563381|9676194|FG001|Overall Study|Withdrawal by Subject|209
6072931|NCT00563381|9676193|FG000|Overall Study|Lack of Efficacy|32
6072932|NCT00563381|9676194|FG001|Overall Study|Lack of Efficacy|24
6072933|NCT00563381|9676193|FG000|Overall Study|Individual different reasons|24
6072934|NCT00563381|9676194|FG001|Overall Study|Individual different reasons|34
6001424|NCT00048061|9595672|FG002|Overall Study|Did not follow-up|4
6001425|NCT00048061|9595673|FG003|Overall Study|Did not follow-up|5
6001426|NCT00048061|9595670|FG000|Overall Study|Early improvement|6
6001427|NCT00048061|9595671|FG001|Overall Study|Early improvement|5
6001428|NCT00048061|9595672|FG002|Overall Study|Early improvement|3
6001429|NCT00048061|9595673|FG003|Overall Study|Early improvement|0
6001430|NCT00048074|9595686|FG000|Overall Study|Adverse Event|46
6001431|NCT00048074|9595687|FG001|Overall Study|Adverse Event|41
6001432|NCT00048074|9595688|FG002|Overall Study|Adverse Event|53
6001433|NCT00048074|9595686|FG000|Overall Study|Death|3
6001434|NCT00048074|9595687|FG001|Overall Study|Death|3
6001435|NCT00048074|9595688|FG002|Overall Study|Death|2
6001436|NCT00048074|9595686|FG000|Overall Study|Lost to Follow-up|2
6001437|NCT00048074|9595687|FG001|Overall Study|Lost to Follow-up|6
6001438|NCT00048074|9595688|FG002|Overall Study|Lost to Follow-up|6
6001439|NCT00048074|9595686|FG000|Overall Study|Withdrawal by Subject|28
6001440|NCT00048074|9595687|FG001|Overall Study|Withdrawal by Subject|30
6001441|NCT00048074|9595688|FG002|Overall Study|Withdrawal by Subject|35
6001442|NCT00048074|9595686|FG000|Overall Study|Protocol Violation|1
6001443|NCT00048074|9595687|FG001|Overall Study|Protocol Violation|3
6001444|NCT00048074|9595688|FG002|Overall Study|Protocol Violation|0
6001445|NCT00048074|9595686|FG000|Overall Study|Study participation was terminated|0
6001446|NCT00048074|9595687|FG001|Overall Study|Study participation was terminated|1
6001447|NCT00048074|9595688|FG002|Overall Study|Study participation was terminated|0
6001448|NCT00048074|9595686|FG000|Overall Study|Husband ill|0
6001449|NCT00048074|9595687|FG001|Overall Study|Husband ill|1
6001450|NCT00048074|9595688|FG002|Overall Study|Husband ill|0
6001451|NCT00048074|9595686|FG000|Overall Study|Poor compliance|0
6001452|NCT00048074|9595687|FG001|Overall Study|Poor compliance|1
6001453|NCT00048074|9595688|FG002|Overall Study|Poor compliance|0
6001454|NCT00048074|9595686|FG000|Overall Study|Out of station|0
6001455|NCT00048074|9595687|FG001|Overall Study|Out of station|1
6001456|NCT00048074|9595688|FG002|Overall Study|Out of station|1
6001457|NCT00048074|9595686|FG000|Overall Study|Social reasons|1
6001458|NCT00048074|9595687|FG001|Overall Study|Social reasons|0
6001459|NCT00048074|9595688|FG002|Overall Study|Social reasons|0
6001460|NCT00048165|9595698|FG000|Completed 6 Months Study|Administration/Other|8
6001461|NCT00048165|9595699|FG001|Completed 6 Months Study|Administration/Other|8
6001462|NCT00048165|9595698|FG000|Completed 6 Months Study|Abnormality of laboratory test|1
6001463|NCT00048165|9595699|FG001|Completed 6 Months Study|Abnormality of laboratory test|0
6001464|NCT00048165|9595698|FG000|Completed 6 Months Study|Adverse event/intermittent illness|14
6001465|NCT00048165|9595699|FG001|Completed 6 Months Study|Adverse event/intermittent illness|11
6001466|NCT00048165|9595698|FG000|Completed 6 Months Study|Death|12
6001467|NCT00048165|9595699|FG001|Completed 6 Months Study|Death|6
6001468|NCT00048165|9595698|FG000|Completed 6 Months Study|Insufficient therapy|1
6001469|NCT00048165|9595699|FG001|Completed 6 Months Study|Insufficient therapy|4
6001470|NCT00048165|9595698|FG000|Completed 6 Months Study|Other violation|4
6001471|NCT00048165|9595699|FG001|Completed 6 Months Study|Other violation|6
6001472|NCT00048165|9595698|FG000|Completed 6 Months Study|Refused treatment|5
6001473|NCT00048165|9595699|FG001|Completed 6 Months Study|Refused treatment|5
6001474|NCT00048165|9595698|FG000|Completed 6 Months Study|Violation criteria|0
6001475|NCT00048165|9595699|FG001|Completed 6 Months Study|Violation criteria|2
6001476|NCT00048165|9595698|FG000|Completed 6 Months Study|Did not receive study drug|6
6001477|NCT00048165|9595699|FG001|Completed 6 Months Study|Did not receive study drug|6
6001478|NCT00048165|9595698|FG000|Completed 12 Months Study|Administration/Other|0
6072935|NCT00563706|9676209|FG000|DB Treatment Period (Day 1 up to Day 28)|Adverse Event|4
6072936|NCT00563706|9676210|FG001|DB Treatment Period (Day 1 up to Day 28)|Adverse Event|1
6072937|NCT00563706|9676211|FG002|DB Treatment Period (Day 1 up to Day 28)|Adverse Event|1
6072938|NCT00563706|9676212|FG003|DB Treatment Period (Day 1 up to Day 28)|Adverse Event|1
6072939|NCT00563706|9676213|FG004|DB Treatment Period (Day 1 up to Day 28)|Adverse Event|0
6072940|NCT00563706|9676214|FG005|DB Treatment Period (Day 1 up to Day 28)|Adverse Event|0
6072941|NCT00563706|9676215|FG006|DB Treatment Period (Day 1 up to Day 28)|Adverse Event|0
6072942|NCT00563706|9676216|FG007|DB Treatment Period (Day 1 up to Day 28)|Adverse Event|1
6072943|NCT00563706|9676217|FG008|DB Treatment Period (Day 1 up to Day 28)|Adverse Event|5
6072944|NCT00563706|9676209|FG000|DB Treatment Period (Day 1 up to Day 28)|Lack of Efficacy|2
6072945|NCT00563706|9676210|FG001|DB Treatment Period (Day 1 up to Day 28)|Lack of Efficacy|1
6072946|NCT00563706|9676211|FG002|DB Treatment Period (Day 1 up to Day 28)|Lack of Efficacy|2
6072947|NCT00563706|9676212|FG003|DB Treatment Period (Day 1 up to Day 28)|Lack of Efficacy|4
6072948|NCT00563706|9676213|FG004|DB Treatment Period (Day 1 up to Day 28)|Lack of Efficacy|1
6072949|NCT00563706|9676214|FG005|DB Treatment Period (Day 1 up to Day 28)|Lack of Efficacy|2
6072950|NCT00563706|9676215|FG006|DB Treatment Period (Day 1 up to Day 28)|Lack of Efficacy|2
6072951|NCT00563706|9676216|FG007|DB Treatment Period (Day 1 up to Day 28)|Lack of Efficacy|5
6001479|NCT00048165|9595699|FG001|Completed 12 Months Study|Administration/Other|2
6001480|NCT00048165|9595698|FG000|Completed 12 Months Study|Death|2
6001481|NCT00048165|9595699|FG001|Completed 12 Months Study|Death|1
6001482|NCT00048165|9595698|FG000|Completed 12 Months Study|Did not co-operate/Withdrew|1
6001483|NCT00048165|9595699|FG001|Completed 12 Months Study|Did not co-operate/Withdrew|0
6001484|NCT00048347|9595707|FG000|Overall Study|Screen failure|2
6001485|NCT00048542|9595715|FG000|Double-Blind Phase|Withdrawal by Subject|0
6001486|NCT00048542|9595716|FG001|Double-Blind Phase|Withdrawal by Subject|1
6001487|NCT00048542|9595717|FG002|Double-Blind Phase|Withdrawal by Subject|0
6001488|NCT00048542|9595718|FG003|Double-Blind Phase|Withdrawal by Subject|0
6001489|NCT00048542|9595719|FG004|Double-Blind Phase|Withdrawal by Subject|0
6001490|NCT00048542|9595720|FG005|Double-Blind Phase|Withdrawal by Subject|0
6001491|NCT00048542|9595721|FG006|Double-Blind Phase|Withdrawal by Subject|0
6001492|NCT00048542|9595722|FG007|Double-Blind Phase|Withdrawal by Subject|0
6001493|NCT00048542|9595715|FG000|Double-Blind Phase|Protocol Violation|0
6001494|NCT00048542|9595716|FG001|Double-Blind Phase|Protocol Violation|0
6001495|NCT00048542|9595717|FG002|Double-Blind Phase|Protocol Violation|1
6001496|NCT00048542|9595718|FG003|Double-Blind Phase|Protocol Violation|0
6001497|NCT00048542|9595719|FG004|Double-Blind Phase|Protocol Violation|0
6001498|NCT00048542|9595720|FG005|Double-Blind Phase|Protocol Violation|0
6001499|NCT00048542|9595721|FG006|Double-Blind Phase|Protocol Violation|0
6001500|NCT00048542|9595722|FG007|Double-Blind Phase|Protocol Violation|0
6001501|NCT00048542|9595715|FG000|Double-Blind Phase|Sponsor request or decision|2
6001502|NCT00048542|9595716|FG001|Double-Blind Phase|Sponsor request or decision|0
6001503|NCT00048542|9595717|FG002|Double-Blind Phase|Sponsor request or decision|0
6001504|NCT00048542|9595718|FG003|Double-Blind Phase|Sponsor request or decision|0
6001505|NCT00048542|9595719|FG004|Double-Blind Phase|Sponsor request or decision|0
6001506|NCT00048542|9595720|FG005|Double-Blind Phase|Sponsor request or decision|0
6001507|NCT00048542|9595721|FG006|Double-Blind Phase|Sponsor request or decision|0
6001508|NCT00048542|9595722|FG007|Double-Blind Phase|Sponsor request or decision|0
6001509|NCT00048542|9595715|FG000|Double-Blind Phase|Randomized in error|1
6001510|NCT00048542|9595716|FG001|Double-Blind Phase|Randomized in error|0
6001511|NCT00048542|9595717|FG002|Double-Blind Phase|Randomized in error|0
6001512|NCT00048542|9595718|FG003|Double-Blind Phase|Randomized in error|0
6001513|NCT00048542|9595719|FG004|Double-Blind Phase|Randomized in error|0
6001514|NCT00048542|9595720|FG005|Double-Blind Phase|Randomized in error|0
6001515|NCT00048542|9595721|FG006|Double-Blind Phase|Randomized in error|0
6001516|NCT00048542|9595722|FG007|Double-Blind Phase|Randomized in error|0
6001517|NCT00048542|9595715|FG000|Open-Label Extension BSA Phase|Withdrawal by Subject|0
6001518|NCT00048542|9595716|FG001|Open-Label Extension BSA Phase|Withdrawal by Subject|0
6001519|NCT00048542|9595717|FG002|Open-Label Extension BSA Phase|Withdrawal by Subject|0
6001520|NCT00048542|9595718|FG003|Open-Label Extension BSA Phase|Withdrawal by Subject|0
6001521|NCT00048542|9595719|FG004|Open-Label Extension BSA Phase|Withdrawal by Subject|3
6001522|NCT00048542|9595720|FG005|Open-Label Extension BSA Phase|Withdrawal by Subject|6
6001523|NCT00048542|9595721|FG006|Open-Label Extension BSA Phase|Withdrawal by Subject|0
6001524|NCT00048542|9595722|FG007|Open-Label Extension BSA Phase|Withdrawal by Subject|0
6001525|NCT00048542|9595715|FG000|Open-Label Extension BSA Phase|Protocol Violation|0
6001526|NCT00048542|9595716|FG001|Open-Label Extension BSA Phase|Protocol Violation|0
6001527|NCT00048542|9595717|FG002|Open-Label Extension BSA Phase|Protocol Violation|0
6001528|NCT00048542|9595718|FG003|Open-Label Extension BSA Phase|Protocol Violation|0
6001529|NCT00048542|9595719|FG004|Open-Label Extension BSA Phase|Protocol Violation|0
6001530|NCT00048542|9595720|FG005|Open-Label Extension BSA Phase|Protocol Violation|1
6001531|NCT00048542|9595721|FG006|Open-Label Extension BSA Phase|Protocol Violation|0
6001532|NCT00048542|9595722|FG007|Open-Label Extension BSA Phase|Protocol Violation|0
6001533|NCT00048542|9595715|FG000|Open-Label Extension BSA Phase|Sponsor request or decision|0
6001534|NCT00048542|9595716|FG001|Open-Label Extension BSA Phase|Sponsor request or decision|0
6001535|NCT00048542|9595717|FG002|Open-Label Extension BSA Phase|Sponsor request or decision|0
6001536|NCT00048542|9595718|FG003|Open-Label Extension BSA Phase|Sponsor request or decision|0
6001537|NCT00048542|9595719|FG004|Open-Label Extension BSA Phase|Sponsor request or decision|5
6072952|NCT00563706|9676217|FG008|DB Treatment Period (Day 1 up to Day 28)|Lack of Efficacy|1
6072953|NCT00563706|9676209|FG000|DB Treatment Period (Day 1 up to Day 28)|Withdrawal by Subject|9
6072954|NCT00563706|9676210|FG001|DB Treatment Period (Day 1 up to Day 28)|Withdrawal by Subject|3
6072955|NCT00563706|9676211|FG002|DB Treatment Period (Day 1 up to Day 28)|Withdrawal by Subject|2
6072956|NCT00563706|9676212|FG003|DB Treatment Period (Day 1 up to Day 28)|Withdrawal by Subject|5
6072957|NCT00563706|9676213|FG004|DB Treatment Period (Day 1 up to Day 28)|Withdrawal by Subject|4
6072958|NCT00563706|9676214|FG005|DB Treatment Period (Day 1 up to Day 28)|Withdrawal by Subject|3
6072959|NCT00563706|9676215|FG006|DB Treatment Period (Day 1 up to Day 28)|Withdrawal by Subject|1
6072960|NCT00563706|9676216|FG007|DB Treatment Period (Day 1 up to Day 28)|Withdrawal by Subject|6
6072961|NCT00563706|9676217|FG008|DB Treatment Period (Day 1 up to Day 28)|Withdrawal by Subject|3
6072962|NCT00563706|9676209|FG000|DB Treatment Period (Day 1 up to Day 28)|Discontinuation of Study by Sponsor|2
6072963|NCT00563706|9676210|FG001|DB Treatment Period (Day 1 up to Day 28)|Discontinuation of Study by Sponsor|0
6072964|NCT00563706|9676211|FG002|DB Treatment Period (Day 1 up to Day 28)|Discontinuation of Study by Sponsor|0
6072965|NCT00563706|9676212|FG003|DB Treatment Period (Day 1 up to Day 28)|Discontinuation of Study by Sponsor|0
6072966|NCT00563706|9676213|FG004|DB Treatment Period (Day 1 up to Day 28)|Discontinuation of Study by Sponsor|0
6087303|NCT00667095|9697464|FG000|Overall Study|Withdrawal by Subject|0
6001538|NCT00048542|9595720|FG005|Open-Label Extension BSA Phase|Sponsor request or decision|1
6001539|NCT00048542|9595721|FG006|Open-Label Extension BSA Phase|Sponsor request or decision|0
6001540|NCT00048542|9595722|FG007|Open-Label Extension BSA Phase|Sponsor request or decision|0
6001541|NCT00048542|9595715|FG000|Open-Label Extension BSA Phase|Adverse Event|0
6001542|NCT00048542|9595716|FG001|Open-Label Extension BSA Phase|Adverse Event|0
6001543|NCT00048542|9595717|FG002|Open-Label Extension BSA Phase|Adverse Event|0
6001544|NCT00048542|9595718|FG003|Open-Label Extension BSA Phase|Adverse Event|0
6001545|NCT00048542|9595719|FG004|Open-Label Extension BSA Phase|Adverse Event|1
6001546|NCT00048542|9595720|FG005|Open-Label Extension BSA Phase|Adverse Event|1
6001547|NCT00048542|9595721|FG006|Open-Label Extension BSA Phase|Adverse Event|0
6001548|NCT00048542|9595722|FG007|Open-Label Extension BSA Phase|Adverse Event|0
6001549|NCT00048542|9595715|FG000|Open-Label Extension BSA Phase|Lack of Efficacy|0
6001550|NCT00048542|9595716|FG001|Open-Label Extension BSA Phase|Lack of Efficacy|0
6001551|NCT00048542|9595717|FG002|Open-Label Extension BSA Phase|Lack of Efficacy|0
6001552|NCT00048542|9595718|FG003|Open-Label Extension BSA Phase|Lack of Efficacy|0
6001553|NCT00048542|9595719|FG004|Open-Label Extension BSA Phase|Lack of Efficacy|3
6001554|NCT00048542|9595720|FG005|Open-Label Extension BSA Phase|Lack of Efficacy|1
6001555|NCT00048542|9595721|FG006|Open-Label Extension BSA Phase|Lack of Efficacy|0
6001556|NCT00048542|9595722|FG007|Open-Label Extension BSA Phase|Lack of Efficacy|0
6001557|NCT00048542|9595715|FG000|Open-Label Extension Fixed Dose Phase|Withdrawal by Subject|0
6001558|NCT00048542|9595716|FG001|Open-Label Extension Fixed Dose Phase|Withdrawal by Subject|0
6001559|NCT00048542|9595717|FG002|Open-Label Extension Fixed Dose Phase|Withdrawal by Subject|0
6001560|NCT00048542|9595718|FG003|Open-Label Extension Fixed Dose Phase|Withdrawal by Subject|0
6001561|NCT00048542|9595719|FG004|Open-Label Extension Fixed Dose Phase|Withdrawal by Subject|0
6001562|NCT00048542|9595720|FG005|Open-Label Extension Fixed Dose Phase|Withdrawal by Subject|0
6001563|NCT00048542|9595721|FG006|Open-Label Extension Fixed Dose Phase|Withdrawal by Subject|6
6001564|NCT00048542|9595722|FG007|Open-Label Extension Fixed Dose Phase|Withdrawal by Subject|3
6001565|NCT00048542|9595715|FG000|Open-Label Extension Fixed Dose Phase|Protocol Violation|0
6001566|NCT00048542|9595716|FG001|Open-Label Extension Fixed Dose Phase|Protocol Violation|0
6001567|NCT00048542|9595717|FG002|Open-Label Extension Fixed Dose Phase|Protocol Violation|0
6001568|NCT00048542|9595718|FG003|Open-Label Extension Fixed Dose Phase|Protocol Violation|0
6001569|NCT00048542|9595719|FG004|Open-Label Extension Fixed Dose Phase|Protocol Violation|0
6001570|NCT00048542|9595720|FG005|Open-Label Extension Fixed Dose Phase|Protocol Violation|0
6001571|NCT00048542|9595721|FG006|Open-Label Extension Fixed Dose Phase|Protocol Violation|1
6001572|NCT00048542|9595722|FG007|Open-Label Extension Fixed Dose Phase|Protocol Violation|1
6001573|NCT00048542|9595715|FG000|Open-Label Extension Fixed Dose Phase|Sponsor request or decision|0
6001574|NCT00048542|9595716|FG001|Open-Label Extension Fixed Dose Phase|Sponsor request or decision|0
6001575|NCT00048542|9595717|FG002|Open-Label Extension Fixed Dose Phase|Sponsor request or decision|0
6001576|NCT00048542|9595718|FG003|Open-Label Extension Fixed Dose Phase|Sponsor request or decision|0
6001577|NCT00048542|9595719|FG004|Open-Label Extension Fixed Dose Phase|Sponsor request or decision|0
6072967|NCT00563706|9676214|FG005|DB Treatment Period (Day 1 up to Day 28)|Discontinuation of Study by Sponsor|0
6072968|NCT00563706|9676215|FG006|DB Treatment Period (Day 1 up to Day 28)|Discontinuation of Study by Sponsor|0
6072969|NCT00563706|9676216|FG007|DB Treatment Period (Day 1 up to Day 28)|Discontinuation of Study by Sponsor|1
6072970|NCT00563706|9676217|FG008|DB Treatment Period (Day 1 up to Day 28)|Discontinuation of Study by Sponsor|0
6072971|NCT00563706|9676209|FG000|DB Treatment Period (Day 1 up to Day 28)|Other|0
6072972|NCT00563706|9676210|FG001|DB Treatment Period (Day 1 up to Day 28)|Other|0
6072973|NCT00563706|9676211|FG002|DB Treatment Period (Day 1 up to Day 28)|Other|0
6072974|NCT00563706|9676212|FG003|DB Treatment Period (Day 1 up to Day 28)|Other|0
6072975|NCT00563706|9676213|FG004|DB Treatment Period (Day 1 up to Day 28)|Other|0
6072976|NCT00563706|9676214|FG005|DB Treatment Period (Day 1 up to Day 28)|Other|0
6072977|NCT00563706|9676215|FG006|DB Treatment Period (Day 1 up to Day 28)|Other|0
6072978|NCT00563706|9676216|FG007|DB Treatment Period (Day 1 up to Day 28)|Other|1
6072979|NCT00563706|9676217|FG008|DB Treatment Period (Day 1 up to Day 28)|Other|2
6072980|NCT00563784|9676237|FG000|Overall Study|Withdrawal by Subject|2
6072981|NCT00563784|9676237|FG000|Overall Study|Screen Failures|20
6072982|NCT00563797|9676243|FG000|Overall Study|Lost to Follow-up|7
6072983|NCT00563797|9676244|FG001|Overall Study|Lost to Follow-up|2
6072984|NCT00564018|9676255|FG000|Overall Study|Withdrawal by Subject|2
6072985|NCT00564018|9676256|FG001|Overall Study|Withdrawal by Subject|3
6072986|NCT00564018|9676257|FG002|Overall Study|Withdrawal by Subject|1
6072987|NCT00564070|9676267|FG000|Overall Study|Lost to Follow-up|9
6072988|NCT00564070|9676268|FG001|Overall Study|Lost to Follow-up|7
6072989|NCT00564070|9676267|FG000|Overall Study|Worsening depression, referred to care|3
6072990|NCT00564070|9676268|FG001|Overall Study|Worsening depression, referred to care|0
6072991|NCT00564278|9676280|FG000|Overall Study|Lost to Follow-up|35
6072992|NCT00564278|9676281|FG001|Overall Study|Lost to Follow-up|33
6072993|NCT00564278|9676280|FG000|Overall Study|Physician Decision|1
6072994|NCT00564278|9676281|FG001|Overall Study|Physician Decision|2
6072995|NCT00564278|9676280|FG000|Overall Study|Withdrawal by Subject|11
6072996|NCT00564278|9676281|FG001|Overall Study|Withdrawal by Subject|7
6072997|NCT00564395|9676287|FG000|First Intervention (10 Days)|Withdrawal by Subject|1
6072998|NCT00564395|9676288|FG001|First Intervention (10 Days)|Withdrawal by Subject|0
6001578|NCT00048542|9595720|FG005|Open-Label Extension Fixed Dose Phase|Sponsor request or decision|0
6001579|NCT00048542|9595721|FG006|Open-Label Extension Fixed Dose Phase|Sponsor request or decision|6
6001580|NCT00048542|9595722|FG007|Open-Label Extension Fixed Dose Phase|Sponsor request or decision|7
6001581|NCT00048542|9595715|FG000|Open-Label Extension Fixed Dose Phase|Adverse Event|0
6001582|NCT00048542|9595716|FG001|Open-Label Extension Fixed Dose Phase|Adverse Event|0
6001583|NCT00048542|9595717|FG002|Open-Label Extension Fixed Dose Phase|Adverse Event|0
6001584|NCT00048542|9595718|FG003|Open-Label Extension Fixed Dose Phase|Adverse Event|0
6001585|NCT00048542|9595719|FG004|Open-Label Extension Fixed Dose Phase|Adverse Event|0
6001586|NCT00048542|9595720|FG005|Open-Label Extension Fixed Dose Phase|Adverse Event|0
6001587|NCT00048542|9595721|FG006|Open-Label Extension Fixed Dose Phase|Adverse Event|2
6001588|NCT00048542|9595722|FG007|Open-Label Extension Fixed Dose Phase|Adverse Event|2
6001589|NCT00048542|9595715|FG000|Open-Label Extension Fixed Dose Phase|Lack of Efficacy|0
6072999|NCT00564395|9676287|FG000|First Intervention (10 Days)|Trouble with the CGM tracing|1
6073000|NCT00564395|9676288|FG001|First Intervention (10 Days)|Trouble with the CGM tracing|2
6073001|NCT00564486|9676330|FG000|Overall Study|Adverse Event|0
6073002|NCT00564486|9676331|FG001|Overall Study|Adverse Event|1
6073003|NCT00564486|9676332|FG002|Overall Study|Adverse Event|0
6073004|NCT00564486|9676333|FG003|Overall Study|Adverse Event|0
6073005|NCT00564486|9676330|FG000|Overall Study|Withdrawal by Subject|4
6073006|NCT00564486|9676331|FG001|Overall Study|Withdrawal by Subject|0
6073007|NCT00564486|9676332|FG002|Overall Study|Withdrawal by Subject|0
6073008|NCT00564486|9676333|FG003|Overall Study|Withdrawal by Subject|5
6073009|NCT00564486|9676330|FG000|Overall Study|Subject refused to have blood drawn|0
6073010|NCT00564486|9676331|FG001|Overall Study|Subject refused to have blood drawn|0
6073011|NCT00564486|9676332|FG002|Overall Study|Subject refused to have blood drawn|1
6073012|NCT00564486|9676333|FG003|Overall Study|Subject refused to have blood drawn|0
6073013|NCT00564486|9676330|FG000|Overall Study|Lost to Follow-up|3
6073014|NCT00564486|9676331|FG001|Overall Study|Lost to Follow-up|0
6073015|NCT00564486|9676332|FG002|Overall Study|Lost to Follow-up|2
6073016|NCT00564486|9676333|FG003|Overall Study|Lost to Follow-up|2
6073017|NCT00564629|9676349|FG000|Overall Study|Vomited within 2 hours of receiving drug|15
6073018|NCT00564629|9676350|FG001|Overall Study|Vomited within 2 hours of receiving drug|9
6073019|NCT00564733|9676372|FG000|Overall Study|Withdrawal by Subject|4
6073020|NCT00564733|9676372|FG000|Overall Study|Ineligible|5
6073021|NCT00564850|9676376|FG000|Overall Study|Protocol Violation|2
6073022|NCT00564889|9676380|FG000|Overall Study|Death|7
6073023|NCT00564889|9676380|FG000|Overall Study|Adverse Event|12
6073024|NCT00564889|9676380|FG000|Overall Study|Alternative treatment|3
6073025|NCT00564889|9676380|FG000|Overall Study|Disease progression|3
6073026|NCT00564889|9676380|FG000|Overall Study|Other, not specified|4
6073027|NCT00564902|9676387|FG000|Overall Study|Withdrawal by Subject|0
6073028|NCT00564902|9676388|FG001|Overall Study|Withdrawal by Subject|3
6073029|NCT00564902|9676389|FG002|Overall Study|Withdrawal by Subject|4
6073030|NCT00564902|9676387|FG000|Overall Study|Death|1
6073031|NCT00564902|9676388|FG001|Overall Study|Death|1
6073032|NCT00564902|9676389|FG002|Overall Study|Death|0
6073033|NCT00565058|9676417|FG000|Overall Study|Adverse Event|1
6073034|NCT00565058|9676418|FG001|Overall Study|Adverse Event|0
6073035|NCT00565136|9676443|FG000|Overall Study|Lost to Follow-up|1
6073036|NCT00565136|9676443|FG000|Overall Study|Withdrawal by Subject|1
6073037|NCT00565136|9676443|FG000|Overall Study|Protocol Violation|1
6073038|NCT00565409|9676459|FG000|Period 1 Open Label|Adverse Event|17
6073039|NCT00565409|9676460|FG001|Period 1 Open Label|Adverse Event|0
6073040|NCT00565409|9676461|FG002|Period 1 Open Label|Adverse Event|0
6073041|NCT00565409|9676462|FG003|Period 1 Open Label|Adverse Event|0
6073042|NCT00565409|9676459|FG000|Period 1 Open Label|Death|2
6073043|NCT00565409|9676460|FG001|Period 1 Open Label|Death|0
6073044|NCT00565409|9676461|FG002|Period 1 Open Label|Death|0
6073045|NCT00565409|9676462|FG003|Period 1 Open Label|Death|0
6073046|NCT00565409|9676459|FG000|Period 1 Open Label|Lost to Follow-up|1
6073047|NCT00565409|9676460|FG001|Period 1 Open Label|Lost to Follow-up|0
6073048|NCT00565409|9676461|FG002|Period 1 Open Label|Lost to Follow-up|0
6073049|NCT00565409|9676462|FG003|Period 1 Open Label|Lost to Follow-up|0
6073050|NCT00565409|9676459|FG000|Period 1 Open Label|Other|21
6073051|NCT00565409|9676460|FG001|Period 1 Open Label|Other|0
6073052|NCT00565409|9676461|FG002|Period 1 Open Label|Other|0
6073053|NCT00565409|9676462|FG003|Period 1 Open Label|Other|0
6073054|NCT00565409|9676459|FG000|Period 1 Open Label|Protocol Violation|14
6073055|NCT00565409|9676460|FG001|Period 1 Open Label|Protocol Violation|0
6073056|NCT00565409|9676461|FG002|Period 1 Open Label|Protocol Violation|0
6073057|NCT00565409|9676462|FG003|Period 1 Open Label|Protocol Violation|0
6073058|NCT00565409|9676459|FG000|Period 1 Open Label|Unsatisfactory Response-Efficacy|22
6073059|NCT00565409|9676460|FG001|Period 1 Open Label|Unsatisfactory Response-Efficacy|0
6073060|NCT00565409|9676461|FG002|Period 1 Open Label|Unsatisfactory Response-Efficacy|0
6073061|NCT00565409|9676462|FG003|Period 1 Open Label|Unsatisfactory Response-Efficacy|0
6073062|NCT00565409|9676459|FG000|Period 1 Open Label|no conclusion of participation record|1
6073063|NCT00565409|9676460|FG001|Period 1 Open Label|no conclusion of participation record|0
6073064|NCT00565409|9676461|FG002|Period 1 Open Label|no conclusion of participation record|0
6073065|NCT00565409|9676462|FG003|Period 1 Open Label|no conclusion of participation record|0
6073066|NCT00565409|9676459|FG000|After Period 1, Prior to Period 2|did not meet criteria|152
6073067|NCT00565409|9676460|FG001|After Period 1, Prior to Period 2|did not meet criteria|0
6073068|NCT00565409|9676461|FG002|After Period 1, Prior to Period 2|did not meet criteria|0
6073069|NCT00565409|9676462|FG003|After Period 1, Prior to Period 2|did not meet criteria|0
6073070|NCT00565409|9676459|FG000|Period 2 Double-Blind|Adverse Event|0
6001590|NCT00048542|9595716|FG001|Open-Label Extension Fixed Dose Phase|Lack of Efficacy|0
6001591|NCT00048542|9595717|FG002|Open-Label Extension Fixed Dose Phase|Lack of Efficacy|0
6001592|NCT00048542|9595718|FG003|Open-Label Extension Fixed Dose Phase|Lack of Efficacy|0
6001593|NCT00048542|9595719|FG004|Open-Label Extension Fixed Dose Phase|Lack of Efficacy|0
6001594|NCT00048542|9595720|FG005|Open-Label Extension Fixed Dose Phase|Lack of Efficacy|0
6001595|NCT00048542|9595721|FG006|Open-Label Extension Fixed Dose Phase|Lack of Efficacy|2
6001596|NCT00048542|9595722|FG007|Open-Label Extension Fixed Dose Phase|Lack of Efficacy|1
6001597|NCT00048542|9595715|FG000|Open-Label Extension Fixed Dose Phase|Lost to Follow-up|0
6001598|NCT00048542|9595716|FG001|Open-Label Extension Fixed Dose Phase|Lost to Follow-up|0
6001599|NCT00048542|9595717|FG002|Open-Label Extension Fixed Dose Phase|Lost to Follow-up|0
6001600|NCT00048542|9595718|FG003|Open-Label Extension Fixed Dose Phase|Lost to Follow-up|0
6001601|NCT00048542|9595719|FG004|Open-Label Extension Fixed Dose Phase|Lost to Follow-up|0
6001602|NCT00048542|9595720|FG005|Open-Label Extension Fixed Dose Phase|Lost to Follow-up|0
6001603|NCT00048542|9595721|FG006|Open-Label Extension Fixed Dose Phase|Lost to Follow-up|5
6001604|NCT00048542|9595722|FG007|Open-Label Extension Fixed Dose Phase|Lost to Follow-up|8
6047260|NCT00410410|9646257|FG008|Induction Period (IP)|Subject No Longer Meets Study Criteria|0
6047261|NCT00410410|9646249|FG000|Induction Period (IP)|Administrative Reason By Sponsor|0
6047262|NCT00410410|9646250|FG001|Induction Period (IP)|Administrative Reason By Sponsor|0
6047263|NCT00410410|9646251|FG002|Induction Period (IP)|Administrative Reason By Sponsor|0
6047264|NCT00410410|9646252|FG003|Induction Period (IP)|Administrative Reason By Sponsor|0
6047265|NCT00410410|9646253|FG004|Induction Period (IP)|Administrative Reason By Sponsor|22
6047266|NCT00410410|9646254|FG005|Induction Period (IP)|Administrative Reason By Sponsor|21
6047267|NCT00410410|9646255|FG006|Induction Period (IP)|Administrative Reason By Sponsor|0
6073071|NCT00565409|9676460|FG001|Period 2 Double-Blind|Adverse Event|7
6073072|NCT00565409|9676461|FG002|Period 2 Double-Blind|Adverse Event|4
6073073|NCT00565409|9676462|FG003|Period 2 Double-Blind|Adverse Event|5
6073074|NCT00565409|9676459|FG000|Period 2 Double-Blind|Death|0
6073075|NCT00565409|9676460|FG001|Period 2 Double-Blind|Death|2
6073076|NCT00565409|9676461|FG002|Period 2 Double-Blind|Death|0
6073077|NCT00565409|9676462|FG003|Period 2 Double-Blind|Death|0
6073078|NCT00565409|9676459|FG000|Period 2 Double-Blind|Protocol Violation|0
6073079|NCT00565409|9676460|FG001|Period 2 Double-Blind|Protocol Violation|4
6073080|NCT00565409|9676461|FG002|Period 2 Double-Blind|Protocol Violation|6
6073081|NCT00565409|9676462|FG003|Period 2 Double-Blind|Protocol Violation|2
6073082|NCT00565409|9676459|FG000|Period 2 Double-Blind|Lost to Follow-up|0
6073083|NCT00565409|9676460|FG001|Period 2 Double-Blind|Lost to Follow-up|0
6073084|NCT00565409|9676461|FG002|Period 2 Double-Blind|Lost to Follow-up|1
6073085|NCT00565409|9676462|FG003|Period 2 Double-Blind|Lost to Follow-up|0
6073086|NCT00565409|9676459|FG000|Period 2 Double-Blind|Other|0
6073087|NCT00565409|9676460|FG001|Period 2 Double-Blind|Other|4
6073088|NCT00565409|9676461|FG002|Period 2 Double-Blind|Other|5
6073089|NCT00565409|9676462|FG003|Period 2 Double-Blind|Other|9
6073090|NCT00565409|9676459|FG000|Period 2 Double-Blind|Unsatisfactory Response-Efficacy|0
6073091|NCT00565409|9676460|FG001|Period 2 Double-Blind|Unsatisfactory Response-Efficacy|4
6073092|NCT00565409|9676461|FG002|Period 2 Double-Blind|Unsatisfactory Response-Efficacy|11
6073093|NCT00565409|9676462|FG003|Period 2 Double-Blind|Unsatisfactory Response-Efficacy|43
6073094|NCT00565448|9676474|FG000|Overall Study|Adverse Event|1
6073095|NCT00565448|9676475|FG001|Overall Study|Adverse Event|2
6073096|NCT00565448|9676474|FG000|Overall Study|Disease progression|1
6073097|NCT00565448|9676475|FG001|Overall Study|Disease progression|0
6073098|NCT00565448|9676474|FG000|Overall Study|Withdrawal by Subject|1
6073099|NCT00565448|9676475|FG001|Overall Study|Withdrawal by Subject|0
6073100|NCT00565604|9676484|FG000|Overall Study|Failure to treat|2
6073101|NCT00565604|9676484|FG000|Overall Study|Lost to Follow-up|2
6073102|NCT00565721|9676507|FG000|Overall Study|Screen Failure|2
6073103|NCT00565721|9676507|FG000|Overall Study|Lost to Follow-up|6
6073104|NCT00565721|9676507|FG000|Overall Study|Technical Problems|1
6073105|NCT00565721|9676507|FG000|Overall Study|Physician Decision|2
6073106|NCT00565721|9676507|FG000|Overall Study|Other reasons|6
6073107|NCT00565747|9676528|FG000|Overall Study|No embryo transfer|67
6073108|NCT00565747|9676529|FG001|Overall Study|No embryo transfer|73
6073109|NCT00565773|9676535|FG000|Overall Study|Withdrawal by Subject|1
6073110|NCT00565773|9676535|FG000|Overall Study|Physician Decision|1
6073111|NCT00565812|9676542|FG000|Overall Study|Death|2
6073112|NCT00565812|9676543|FG001|Overall Study|Death|1
6047268|NCT00410410|9646256|FG007|Induction Period (IP)|Administrative Reason By Sponsor|0
6073113|NCT00565812|9676544|FG002|Overall Study|Death|3
6073114|NCT00565812|9676542|FG000|Overall Study|Did not Meet Entrance Criteria|1
6073115|NCT00565812|9676543|FG001|Overall Study|Did not Meet Entrance Criteria|0
6073116|NCT00565812|9676544|FG002|Overall Study|Did not Meet Entrance Criteria|1
6073117|NCT00565812|9676542|FG000|Overall Study|Lost to Follow-up|10
6073118|NCT00565812|9676543|FG001|Overall Study|Lost to Follow-up|8
6073119|NCT00565812|9676544|FG002|Overall Study|Lost to Follow-up|8
6073120|NCT00565812|9676542|FG000|Overall Study|Withdrawal by Subject|58
6073121|NCT00565812|9676543|FG001|Overall Study|Withdrawal by Subject|47
6073122|NCT00565812|9676544|FG002|Overall Study|Withdrawal by Subject|48
6073123|NCT00565812|9676542|FG000|Overall Study|Work Schedule|5
6073124|NCT00565812|9676543|FG001|Overall Study|Work Schedule|3
6073125|NCT00565812|9676544|FG002|Overall Study|Work Schedule|1
6001605|NCT00048568|9595753|FG000|Double-Blind Period Days 1 to 169|Adverse Event|11
6001606|NCT00048568|9595754|FG001|Double-Blind Period Days 1 to 169|Adverse Event|3
6001607|NCT00048568|9595755|FG002|Double-Blind Period Days 1 to 169|Adverse Event|0
6001608|NCT00048568|9595753|FG000|Double-Blind Period Days 1 to 169|Lack of Efficacy|11
6001609|NCT00048568|9595754|FG001|Double-Blind Period Days 1 to 169|Lack of Efficacy|33
6001610|NCT00048568|9595755|FG002|Double-Blind Period Days 1 to 169|Lack of Efficacy|0
6001611|NCT00048568|9595753|FG000|Double-Blind Period Days 1 to 169|Lost to Follow-up|1
6001612|NCT00048568|9595754|FG001|Double-Blind Period Days 1 to 169|Lost to Follow-up|1
6001613|NCT00048568|9595755|FG002|Double-Blind Period Days 1 to 169|Lost to Follow-up|0
6001614|NCT00048568|9595753|FG000|Double-Blind Period Days 1 to 169|Withdrawal by Subject|7
6001615|NCT00048568|9595754|FG001|Double-Blind Period Days 1 to 169|Withdrawal by Subject|4
6001616|NCT00048568|9595755|FG002|Double-Blind Period Days 1 to 169|Withdrawal by Subject|0
6001617|NCT00048568|9595753|FG000|Double-Blind Period Days 1 to 169|Unknown Reasons|2
6001618|NCT00048568|9595754|FG001|Double-Blind Period Days 1 to 169|Unknown Reasons|4
6001619|NCT00048568|9595755|FG002|Double-Blind Period Days 1 to 169|Unknown Reasons|0
6001620|NCT00048568|9595753|FG000|Double-Blind Period Days 170 to 365|Death|1
6001621|NCT00048568|9595754|FG001|Double-Blind Period Days 170 to 365|Death|1
6001622|NCT00048568|9595755|FG002|Double-Blind Period Days 170 to 365|Death|0
6001623|NCT00048568|9595753|FG000|Double-Blind Period Days 170 to 365|Adverse Event|7
6001624|NCT00048568|9595754|FG001|Double-Blind Period Days 170 to 365|Adverse Event|1
6001625|NCT00048568|9595755|FG002|Double-Blind Period Days 170 to 365|Adverse Event|0
6001626|NCT00048568|9595753|FG000|Double-Blind Period Days 170 to 365|Lack of Efficacy|2
6001627|NCT00048568|9595754|FG001|Double-Blind Period Days 170 to 365|Lack of Efficacy|7
6001628|NCT00048568|9595755|FG002|Double-Blind Period Days 170 to 365|Lack of Efficacy|0
6001629|NCT00048568|9595753|FG000|Double-Blind Period Days 170 to 365|Withdrawal by Subject|3
6001630|NCT00048568|9595754|FG001|Double-Blind Period Days 170 to 365|Withdrawal by Subject|1
6001631|NCT00048568|9595755|FG002|Double-Blind Period Days 170 to 365|Withdrawal by Subject|0
6001632|NCT00048568|9595753|FG000|Double-Blind Period Days 170 to 365|Poor/Non-Compliance|0
6001633|NCT00048568|9595754|FG001|Double-Blind Period Days 170 to 365|Poor/Non-Compliance|1
6001634|NCT00048568|9595755|FG002|Double-Blind Period Days 170 to 365|Poor/Non-Compliance|0
6001635|NCT00048568|9595753|FG000|Double-Blind Period Days 170 to 365|Pregnancy|2
6001636|NCT00048568|9595754|FG001|Double-Blind Period Days 170 to 365|Pregnancy|0
6001637|NCT00048568|9595755|FG002|Double-Blind Period Days 170 to 365|Pregnancy|0
6001638|NCT00048568|9595753|FG000|Double-Blind Period Days 170 to 365|No Longer Met Study Criteria|1
6001639|NCT00048568|9595754|FG001|Double-Blind Period Days 170 to 365|No Longer Met Study Criteria|1
6001640|NCT00048568|9595755|FG002|Double-Blind Period Days 170 to 365|No Longer Met Study Criteria|0
6001641|NCT00048568|9595753|FG000|Open-Label Period|Death|0
6001642|NCT00048568|9595754|FG001|Open-Label Period|Death|0
6001643|NCT00048568|9595755|FG002|Open-Label Period|Death|13
6001644|NCT00048568|9595753|FG000|Open-Label Period|Adverse Event|0
6001645|NCT00048568|9595754|FG001|Open-Label Period|Adverse Event|0
6001646|NCT00048568|9595755|FG002|Open-Label Period|Adverse Event|49
6001647|NCT00048568|9595753|FG000|Open-Label Period|Lack of Efficacy|0
6001648|NCT00048568|9595754|FG001|Open-Label Period|Lack of Efficacy|0
6073126|NCT00565812|9676542|FG000|Overall Study|Protocol Violation|2
6073127|NCT00565812|9676543|FG001|Overall Study|Protocol Violation|6
6073128|NCT00565812|9676544|FG002|Overall Study|Protocol Violation|4
6073129|NCT00565812|9676542|FG000|Overall Study|Adverse Event|41
6073130|NCT00565812|9676543|FG001|Overall Study|Adverse Event|54
6073131|NCT00565812|9676544|FG002|Overall Study|Adverse Event|40
6073132|NCT00565812|9676542|FG000|Overall Study|Jury Duty|1
6073133|NCT00565812|9676543|FG001|Overall Study|Jury Duty|0
6073134|NCT00565812|9676544|FG002|Overall Study|Jury Duty|0
6073135|NCT00565812|9676542|FG000|Overall Study|Relocated Out of Area|5
6073136|NCT00565812|9676543|FG001|Overall Study|Relocated Out of Area|8
6073137|NCT00565812|9676544|FG002|Overall Study|Relocated Out of Area|9
6073138|NCT00565812|9676542|FG000|Overall Study|Sponsor Decision|1
6073139|NCT00565812|9676543|FG001|Overall Study|Sponsor Decision|5
6073140|NCT00565812|9676544|FG002|Overall Study|Sponsor Decision|1
6073141|NCT00565812|9676542|FG000|Overall Study|Domestic Reasons|7
6073142|NCT00565812|9676543|FG001|Overall Study|Domestic Reasons|1
6073143|NCT00565812|9676544|FG002|Overall Study|Domestic Reasons|3
6073144|NCT00565812|9676542|FG000|Overall Study|Research Site Closure|6
6073145|NCT00565812|9676543|FG001|Overall Study|Research Site Closure|1
6073146|NCT00565812|9676544|FG002|Overall Study|Research Site Closure|8
6073147|NCT00565812|9676542|FG000|Overall Study|Surgical Intervention|0
6073148|NCT00565812|9676543|FG001|Overall Study|Surgical Intervention|1
6073149|NCT00565812|9676544|FG002|Overall Study|Surgical Intervention|2
6073150|NCT00565812|9676542|FG000|Overall Study|Low Compliance|1
6001649|NCT00048568|9595755|FG002|Open-Label Period|Lack of Efficacy|32
6001650|NCT00048568|9595753|FG000|Open-Label Period|Withdrawal by Subject|0
6001651|NCT00048568|9595754|FG001|Open-Label Period|Withdrawal by Subject|0
6073151|NCT00565812|9676543|FG001|Overall Study|Low Compliance|0
6073152|NCT00565812|9676544|FG002|Overall Study|Low Compliance|1
6073153|NCT00565812|9676542|FG000|Overall Study|Follow-up Visit Not Completed|2
6073154|NCT00565812|9676543|FG001|Overall Study|Follow-up Visit Not Completed|0
6073155|NCT00565812|9676544|FG002|Overall Study|Follow-up Visit Not Completed|1
6073156|NCT00565812|9676542|FG000|Overall Study|Physician Decision|2
6073157|NCT00565812|9676543|FG001|Overall Study|Physician Decision|0
6001652|NCT00048568|9595755|FG002|Open-Label Period|Withdrawal by Subject|26
6001653|NCT00048568|9595753|FG000|Open-Label Period|Pregnancy|0
6001654|NCT00048568|9595754|FG001|Open-Label Period|Pregnancy|0
6001655|NCT00048568|9595755|FG002|Open-Label Period|Pregnancy|5
6001656|NCT00048568|9595753|FG000|Open-Label Period|No Longer Met Study Criteria|0
6001657|NCT00048568|9595754|FG001|Open-Label Period|No Longer Met Study Criteria|0
6001658|NCT00048568|9595755|FG002|Open-Label Period|No Longer Met Study Criteria|2
6001659|NCT00048568|9595753|FG000|Open-Label Period|Administrative Decision By Sponsor|0
6073158|NCT00565812|9676544|FG002|Overall Study|Physician Decision|0
6073159|NCT00566020|9676576|FG000|6-week Dosage Adjustment Phase|Adverse Event|5
6073160|NCT00566020|9676577|FG001|6-week Dosage Adjustment Phase|Adverse Event|0
6073161|NCT00566020|9676576|FG000|6-week Dosage Adjustment Phase|Lack of Efficacy|2
6073162|NCT00566020|9676577|FG001|6-week Dosage Adjustment Phase|Lack of Efficacy|0
6073163|NCT00566020|9676576|FG000|46-week Long-term Administration Phase|Adverse Event|0
6073164|NCT00566020|9676577|FG001|46-week Long-term Administration Phase|Adverse Event|7
6073165|NCT00566020|9676576|FG000|46-week Long-term Administration Phase|Physician Decision|0
6073166|NCT00566020|9676577|FG001|46-week Long-term Administration Phase|Physician Decision|7
6073167|NCT00566020|9676576|FG000|46-week Long-term Administration Phase|Lost to Follow-up|0
6073168|NCT00566020|9676577|FG001|46-week Long-term Administration Phase|Lost to Follow-up|2
6073169|NCT00566020|9676576|FG000|46-week Long-term Administration Phase|Protocol-defined Stopping Criteria|0
6073170|NCT00566020|9676577|FG001|46-week Long-term Administration Phase|Protocol-defined Stopping Criteria|1
6073171|NCT00566098|9676582|FG000|Collection of MILs|Withdrawal by Subject|1
6073172|NCT00566098|9676582|FG000|Collection of MILs|Relapsed|1
6073173|NCT00566098|9676582|FG000|Generation of MILs Product|Relapsed|1
6073174|NCT00566098|9676582|FG000|Administration of ASCT+MILs|Death|10
6073175|NCT00566098|9676582|FG000|Administration of ASCT+MILs|Lack of Efficacy|8
6073176|NCT00566111|9676589|FG000|Overall Study|Adverse Event|0
6073177|NCT00566111|9676590|FG001|Overall Study|Adverse Event|2
6073178|NCT00566228|9676607|FG000|Overall Study|Withdrawal by Subject|1
6073179|NCT00566228|9676608|FG001|Overall Study|Withdrawal by Subject|0
6073180|NCT00566228|9676607|FG000|Overall Study|Attempt to mobilize stem cells failed|2
6073181|NCT00566228|9676608|FG001|Overall Study|Attempt to mobilize stem cells failed|2
6073182|NCT00566228|9676607|FG000|Overall Study|Unable to collect sufficient CD34 cells|3
6073183|NCT00566228|9676608|FG001|Overall Study|Unable to collect sufficient CD34 cells|2
6073184|NCT00566228|9676607|FG000|Overall Study|progressed before infusion could occur|0
6073185|NCT00566228|9676608|FG001|Overall Study|progressed before infusion could occur|1
6073186|NCT00566254|9676616|FG000|Overall Study|Adverse Event|3
6073187|NCT00566254|9676617|FG001|Overall Study|Adverse Event|1
6073188|NCT00566254|9676616|FG000|Overall Study|Protocol Violation|1
6073189|NCT00566254|9676617|FG001|Overall Study|Protocol Violation|3
6073190|NCT00566254|9676616|FG000|Overall Study|Withdrawal by Subject|1
6073191|NCT00566254|9676617|FG001|Overall Study|Withdrawal by Subject|2
6073192|NCT00566254|9676616|FG000|Overall Study|Lack of Efficacy|5
6073193|NCT00566254|9676617|FG001|Overall Study|Lack of Efficacy|6
6073194|NCT00566254|9676616|FG000|Overall Study|Other|0
6073195|NCT00566254|9676617|FG001|Overall Study|Other|2
6073196|NCT00566501|9676625|FG000|Overall Study|Adverse Event|68
6073197|NCT00566501|9676626|FG001|Overall Study|Adverse Event|59
6073198|NCT00566501|9676625|FG000|Overall Study|Medication Non-compliance|5
6073199|NCT00566501|9676626|FG001|Overall Study|Medication Non-compliance|0
6073200|NCT00566501|9676625|FG000|Overall Study|Protocol Violation|2
6073201|NCT00566501|9676626|FG001|Overall Study|Protocol Violation|2
6073202|NCT00566501|9676625|FG000|Overall Study|Request of Investigator or Sponsor|6
6073203|NCT00566501|9676626|FG001|Overall Study|Request of Investigator or Sponsor|7
6073204|NCT00566501|9676625|FG000|Overall Study|Withdrawal by Subject|33
6073205|NCT00566501|9676626|FG001|Overall Study|Withdrawal by Subject|30
6073206|NCT00566501|9676625|FG000|Overall Study|Lack of Efficacy|8
6073207|NCT00566501|9676626|FG001|Overall Study|Lack of Efficacy|3
6073208|NCT00566501|9676625|FG000|Overall Study|Other|25
6073209|NCT00566501|9676626|FG001|Overall Study|Other|21
6073210|NCT00566527|9676635|FG000|Overall Study|Reason not provided|3
6001660|NCT00048568|9595754|FG001|Open-Label Period|Administrative Decision By Sponsor|0
6001661|NCT00048568|9595755|FG002|Open-Label Period|Administrative Decision By Sponsor|1
6001662|NCT00048568|9595753|FG000|Open-Label Period|Unknown Reasons|0
6001663|NCT00048568|9595754|FG001|Open-Label Period|Unknown Reasons|0
6001664|NCT00048568|9595755|FG002|Open-Label Period|Unknown Reasons|25
6001665|NCT00048568|9595753|FG000|Open-Label Period|Lost to Follow-up|0
6001666|NCT00048568|9595754|FG001|Open-Label Period|Lost to Follow-up|0
6001667|NCT00048568|9595755|FG002|Open-Label Period|Lost to Follow-up|7
6001668|NCT00048581|9595778|FG000|Double-Blind Period|Adverse Event|9
6073211|NCT00566527|9676636|FG001|Overall Study|Reason not provided|11
6073212|NCT00566527|9676637|FG002|Overall Study|Reason not provided|10
6073213|NCT00566527|9676635|FG000|Overall Study|Adverse Event|2
6073214|NCT00566527|9676636|FG001|Overall Study|Adverse Event|0
6073215|NCT00566527|9676637|FG002|Overall Study|Adverse Event|1
6073216|NCT00566527|9676635|FG000|Overall Study|Physician Decision|3
6073217|NCT00566527|9676636|FG001|Overall Study|Physician Decision|8
6073218|NCT00566527|9676637|FG002|Overall Study|Physician Decision|20
6073219|NCT00566527|9676635|FG000|Overall Study|Lost to Follow-up|3
6073220|NCT00566527|9676636|FG001|Overall Study|Lost to Follow-up|4
6073221|NCT00566527|9676637|FG002|Overall Study|Lost to Follow-up|4
6001669|NCT00048581|9595779|FG001|Double-Blind Period|Adverse Event|5
6001670|NCT00048581|9595780|FG002|Double-Blind Period|Adverse Event|0
6001671|NCT00048581|9595778|FG000|Double-Blind Period|Lack of Efficacy|14
6001672|NCT00048581|9595779|FG001|Double-Blind Period|Lack of Efficacy|27
6001673|NCT00048581|9595780|FG002|Double-Blind Period|Lack of Efficacy|0
6001674|NCT00048581|9595778|FG000|Double-Blind Period|Lost to Follow-up|5
6001675|NCT00048581|9595779|FG001|Double-Blind Period|Lost to Follow-up|0
6001676|NCT00048581|9595780|FG002|Double-Blind Period|Lost to Follow-up|0
6001677|NCT00048581|9595778|FG000|Double-Blind Period|Withdrawal by Subject|5
6001678|NCT00048581|9595779|FG001|Double-Blind Period|Withdrawal by Subject|2
6001679|NCT00048581|9595780|FG002|Double-Blind Period|Withdrawal by Subject|0
6001680|NCT00048581|9595778|FG000|Double-Blind Period|Participant Has History of Lymphopenia|1
6001681|NCT00048581|9595779|FG001|Double-Blind Period|Participant Has History of Lymphopenia|0
6001682|NCT00048581|9595780|FG002|Double-Blind Period|Participant Has History of Lymphopenia|0
6001683|NCT00048581|9595778|FG000|Double-Blind Period|Investigator Decision|1
6001684|NCT00048581|9595779|FG001|Double-Blind Period|Investigator Decision|0
6001685|NCT00048581|9595780|FG002|Double-Blind Period|Investigator Decision|0
6001686|NCT00048581|9595778|FG000|Open-Label Period|Death|0
6001687|NCT00048581|9595779|FG001|Open-Label Period|Death|0
6001688|NCT00048581|9595780|FG002|Open-Label Period|Death|4
6001689|NCT00048581|9595778|FG000|Open-Label Period|Adverse Event|0
6001690|NCT00048581|9595779|FG001|Open-Label Period|Adverse Event|0
6001691|NCT00048581|9595780|FG002|Open-Label Period|Adverse Event|37
6001692|NCT00048581|9595778|FG000|Open-Label Period|Lack of Efficacy|0
6001693|NCT00048581|9595779|FG001|Open-Label Period|Lack of Efficacy|0
6001694|NCT00048581|9595780|FG002|Open-Label Period|Lack of Efficacy|69
6001695|NCT00048581|9595778|FG000|Open-Label Period|Lost to Follow-up|0
6001696|NCT00048581|9595779|FG001|Open-Label Period|Lost to Follow-up|0
6001697|NCT00048581|9595780|FG002|Open-Label Period|Lost to Follow-up|14
6001698|NCT00048581|9595778|FG000|Open-Label Period|Withdrawal by Subject|0
6001699|NCT00048581|9595779|FG001|Open-Label Period|Withdrawal by Subject|0
6001700|NCT00048581|9595780|FG002|Open-Label Period|Withdrawal by Subject|20
6001701|NCT00048581|9595778|FG000|Open-Label Period|No Longer Meets Study Criteria|0
6001702|NCT00048581|9595779|FG001|Open-Label Period|No Longer Meets Study Criteria|0
6001703|NCT00048581|9595780|FG002|Open-Label Period|No Longer Meets Study Criteria|2
6001704|NCT00048581|9595778|FG000|Open-Label Period|Poor/Non-compliance|0
6001705|NCT00048581|9595779|FG001|Open-Label Period|Poor/Non-compliance|0
6001706|NCT00048581|9595780|FG002|Open-Label Period|Poor/Non-compliance|5
6001707|NCT00048581|9595778|FG000|Open-Label Period|Pregnancy|0
6001708|NCT00048581|9595779|FG001|Open-Label Period|Pregnancy|0
6001709|NCT00048581|9595780|FG002|Open-Label Period|Pregnancy|7
6001710|NCT00048581|9595778|FG000|Open-Label Period|Study Site Closure|0
6001711|NCT00048581|9595779|FG001|Open-Label Period|Study Site Closure|0
6001712|NCT00048581|9595780|FG002|Open-Label Period|Study Site Closure|2
6001713|NCT00048581|9595778|FG000|Open-Label Period|Continue ABA With Primary Rheumatologist|0
6001714|NCT00048581|9595779|FG001|Open-Label Period|Continue ABA With Primary Rheumatologist|0
6001715|NCT00048581|9595780|FG002|Open-Label Period|Continue ABA With Primary Rheumatologist|3
6001716|NCT00048581|9595778|FG000|Open-Label Period|Problem With Transportation To Site|0
6001717|NCT00048581|9595779|FG001|Open-Label Period|Problem With Transportation To Site|0
6001718|NCT00048581|9595780|FG002|Open-Label Period|Problem With Transportation To Site|1
6001719|NCT00048581|9595778|FG000|Open-Label Period|Primary Investigator Retired|0
6001720|NCT00048581|9595779|FG001|Open-Label Period|Primary Investigator Retired|0
6001721|NCT00048581|9595780|FG002|Open-Label Period|Primary Investigator Retired|2
6001722|NCT00048581|9595778|FG000|Open-Label Period|Study Ended By Sponsor|0
6001723|NCT00048581|9595779|FG001|Open-Label Period|Study Ended By Sponsor|0
6001724|NCT00048581|9595780|FG002|Open-Label Period|Study Ended By Sponsor|1
6001725|NCT00048724|9595795|FG000|Overall Study|Adverse Event|53
6001726|NCT00048724|9595796|FG001|Overall Study|Adverse Event|12
6001727|NCT00048724|9595795|FG000|Overall Study|Withdrawal by Subject|34
6001728|NCT00048724|9595796|FG001|Overall Study|Withdrawal by Subject|54
6001729|NCT00048724|9595795|FG000|Overall Study|Lost to Follow-up|5
6001730|NCT00048724|9595796|FG001|Overall Study|Lost to Follow-up|5
6001731|NCT00048724|9595795|FG000|Overall Study|Protocol-defined Clinical Event|17
6001732|NCT00048724|9595796|FG001|Overall Study|Protocol-defined Clinical Event|32
6001733|NCT00048724|9595795|FG000|Overall Study|Noncompliance With Protocol|4
6001734|NCT00048724|9595796|FG001|Overall Study|Noncompliance With Protocol|12
6001735|NCT00048724|9595795|FG000|Overall Study|Did Not Meet Protocol Eligibility|2
6001736|NCT00048724|9595796|FG001|Overall Study|Did Not Meet Protocol Eligibility|2
6001737|NCT00048724|9595795|FG000|Overall Study|Administrative|1
6001738|NCT00048724|9595796|FG001|Overall Study|Administrative|1
6001739|NCT00048932|9595825|FG000|Double Blind Period (DB)|Administrative Reason By Sponsor|1
6001740|NCT00048932|9595826|FG001|Double Blind Period (DB)|Administrative Reason By Sponsor|0
6001741|NCT00048932|9595827|FG002|Double Blind Period (DB)|Administrative Reason By Sponsor|0
6001742|NCT00048932|9595825|FG000|Double Blind Period (DB)|Adverse Event|51
6001743|NCT00048932|9595826|FG001|Double Blind Period (DB)|Adverse Event|19
6001744|NCT00048932|9595827|FG002|Double Blind Period (DB)|Adverse Event|0
6001745|NCT00048932|9595825|FG000|Double Blind Period (DB)|Death|5
6001746|NCT00048932|9595826|FG001|Double Blind Period (DB)|Death|3
6001747|NCT00048932|9595827|FG002|Double Blind Period (DB)|Death|0
6001748|NCT00048932|9595825|FG000|Double Blind Period (DB)|Lack of Efficacy|26
6001749|NCT00048932|9595826|FG001|Double Blind Period (DB)|Lack of Efficacy|44
6001750|NCT00048932|9595827|FG002|Double Blind Period (DB)|Lack of Efficacy|0
6001751|NCT00048932|9595825|FG000|Double Blind Period (DB)|Lost to Follow-up|3
6001752|NCT00048932|9595826|FG001|Double Blind Period (DB)|Lost to Follow-up|4
6001753|NCT00048932|9595827|FG002|Double Blind Period (DB)|Lost to Follow-up|0
6001754|NCT00048932|9595825|FG000|Double Blind Period (DB)|Relocation|1
6001755|NCT00048932|9595826|FG001|Double Blind Period (DB)|Relocation|0
6001756|NCT00048932|9595827|FG002|Double Blind Period (DB)|Relocation|0
6001757|NCT00048932|9595825|FG000|Double Blind Period (DB)|Uncontrolled hypertension|0
6001758|NCT00048932|9595826|FG001|Double Blind Period (DB)|Uncontrolled hypertension|1
6001759|NCT00048932|9595827|FG002|Double Blind Period (DB)|Uncontrolled hypertension|0
6001760|NCT00048932|9595825|FG000|Double Blind Period (DB)|Missed 2 doses while undergoing work-up|1
6001761|NCT00048932|9595826|FG001|Double Blind Period (DB)|Missed 2 doses while undergoing work-up|0
6001762|NCT00048932|9595827|FG002|Double Blind Period (DB)|Missed 2 doses while undergoing work-up|0
6001763|NCT00048932|9595825|FG000|Double Blind Period (DB)|Pregnancy|1
6001764|NCT00048932|9595826|FG001|Double Blind Period (DB)|Pregnancy|0
6073222|NCT00566527|9676635|FG000|Overall Study|Withdrawal by Subject|6
6073223|NCT00566527|9676636|FG001|Overall Study|Withdrawal by Subject|43
6073224|NCT00566527|9676637|FG002|Overall Study|Withdrawal by Subject|43
6073225|NCT00566631|9676660|FG000|Part 1: Core Treatment Phase|Lack of Efficacy|18
6073226|NCT00566631|9676660|FG000|Part 1: Core Treatment Phase|Physician Decision|1
6073227|NCT00566631|9676660|FG000|Part 1: Core Treatment Phase|Adverse Event|9
6073228|NCT00566631|9676660|FG000|Part 1: Core Treatment Phase|Lost to Follow-up|4
6073229|NCT00566631|9676660|FG000|Part 1: Core Treatment Phase|Withdrawal by Subject|26
6073230|NCT00566631|9676660|FG000|Part 1: Core Treatment Phase|Moved to a penitentiary hospital|1
6073231|NCT00566631|9676660|FG000|Part 1: Core Treatment Phase|Met exclusion criteria|1
6073232|NCT00566631|9676660|FG000|Between Treatment and Extension Phase|Participants not willing to participate|95
6073233|NCT00566631|9676660|FG000|Part 2: Extension Phase|Lack of Efficacy|25
6073234|NCT00566631|9676660|FG000|Part 2: Extension Phase|Withdrawal by Subject|34
6073235|NCT00566631|9676660|FG000|Part 2: Extension Phase|Adverse Event|11
6073236|NCT00566631|9676660|FG000|Part 2: Extension Phase|Lost to Follow-up|6
6073237|NCT00566631|9676660|FG000|Part 2: Extension Phase|Death|1
6073238|NCT00566631|9676660|FG000|Part 2: Extension Phase|Other|5
6073239|NCT00566696|9676664|FG000|Overall Study|Met Exclusion Criteria|2
6073240|NCT00566696|9676664|FG000|Overall Study|Muromonab not available|1
6073241|NCT00566696|9676664|FG000|Overall Study|Health Status Change|1
6073242|NCT00566696|9676664|FG000|Overall Study|Physician Decision|1
6073243|NCT00566696|9676664|FG000|Overall Study|Non-Patient Donors|37
6073244|NCT00566709|9676670|FG000|Overall Study|Protocol Violation|5
6073245|NCT00566709|9676671|FG001|Overall Study|Protocol Violation|0
6073246|NCT00566722|9676680|FG000|Overall Study|Adverse Event|0
6073247|NCT00566722|9676681|FG001|Overall Study|Adverse Event|1
6073248|NCT00566722|9676682|FG002|Overall Study|Adverse Event|0
6073249|NCT00566722|9676680|FG000|Overall Study|Withdrawal by Subject|0
6073250|NCT00566722|9676681|FG001|Overall Study|Withdrawal by Subject|0
6073251|NCT00566722|9676682|FG002|Overall Study|Withdrawal by Subject|1
6073252|NCT00566722|9676680|FG000|Overall Study|Lost to Follow-up|1
6073253|NCT00566722|9676681|FG001|Overall Study|Lost to Follow-up|1
6073254|NCT00566722|9676682|FG002|Overall Study|Lost to Follow-up|1
6073255|NCT00566722|9676680|FG000|Overall Study|Lack of Efficacy|1
6073256|NCT00566722|9676681|FG001|Overall Study|Lack of Efficacy|2
6073257|NCT00566722|9676682|FG002|Overall Study|Lack of Efficacy|4
6073258|NCT00566722|9676680|FG000|Overall Study|Did not meet exclusion criteria|0
6073259|NCT00566722|9676681|FG001|Overall Study|Did not meet exclusion criteria|0
6073260|NCT00566722|9676682|FG002|Overall Study|Did not meet exclusion criteria|2
6073261|NCT00566722|9676680|FG000|Overall Study|Serious adverse event|0
6073262|NCT00566722|9676681|FG001|Overall Study|Serious adverse event|1
6073263|NCT00566722|9676682|FG002|Overall Study|Serious adverse event|0
6073264|NCT00566722|9676680|FG000|Overall Study|Noncompliant with drug administration|0
6073265|NCT00566722|9676681|FG001|Overall Study|Noncompliant with drug administration|0
6073266|NCT00566722|9676682|FG002|Overall Study|Noncompliant with drug administration|1
6073267|NCT00566735|9676695|FG000|Overall Study|Withdrawal by Subject|0
6073268|NCT00566735|9676696|FG001|Overall Study|Withdrawal by Subject|1
6073269|NCT00566735|9676695|FG000|Overall Study|Refused neuropsychological testing|2
6073270|NCT00566735|9676696|FG001|Overall Study|Refused neuropsychological testing|5
6073271|NCT00566735|9676695|FG000|Overall Study|Switched into a manic episode|0
6073272|NCT00566735|9676696|FG001|Overall Study|Switched into a manic episode|1
6073273|NCT00566852|9676713|FG000|Overall Study|Protocol Violation|22
6001765|NCT00048932|9595827|FG002|Double Blind Period (DB)|Pregnancy|0
6001766|NCT00048932|9595825|FG000|Double Blind Period (DB)|No Longer Meets Study Criteria|8
6001767|NCT00048932|9595826|FG001|Double Blind Period (DB)|No Longer Meets Study Criteria|2
6073274|NCT00566852|9676714|FG001|Overall Study|Protocol Violation|24
6073275|NCT00566852|9676713|FG000|Overall Study|Death|95
6073276|NCT00566852|9676714|FG001|Overall Study|Death|78
6073277|NCT00566852|9676713|FG000|Overall Study|Withdrawal by Subject|30
6073278|NCT00566852|9676714|FG001|Overall Study|Withdrawal by Subject|25
6001768|NCT00048932|9595827|FG002|Double Blind Period (DB)|No Longer Meets Study Criteria|0
6001769|NCT00048932|9595825|FG000|Double Blind Period (DB)|Withdrawal by Subject|24
6001770|NCT00048932|9595826|FG001|Double Blind Period (DB)|Withdrawal by Subject|10
6001771|NCT00048932|9595827|FG002|Double Blind Period (DB)|Withdrawal by Subject|0
6001772|NCT00048932|9595825|FG000|Double Blind Period (DB)|Poor/Non-Compliance|2
6001773|NCT00048932|9595826|FG001|Double Blind Period (DB)|Poor/Non-Compliance|4
6001774|NCT00048932|9595827|FG002|Double Blind Period (DB)|Poor/Non-Compliance|0
6001775|NCT00048932|9595825|FG000|Open Label Period (OL)|Death|0
6001776|NCT00048932|9595826|FG001|Open Label Period (OL)|Death|0
6001777|NCT00048932|9595827|FG002|Open Label Period (OL)|Death|25
6001778|NCT00048932|9595825|FG000|Open Label Period (OL)|Adverse Event|0
6001779|NCT00048932|9595826|FG001|Open Label Period (OL)|Adverse Event|0
6001780|NCT00048932|9595827|FG002|Open Label Period (OL)|Adverse Event|103
6001781|NCT00048932|9595825|FG000|Open Label Period (OL)|Lack of Efficacy|0
6001782|NCT00048932|9595826|FG001|Open Label Period (OL)|Lack of Efficacy|0
6001783|NCT00048932|9595827|FG002|Open Label Period (OL)|Lack of Efficacy|81
6001784|NCT00048932|9595825|FG000|Open Label Period (OL)|Lost to Follow-up|0
6001785|NCT00048932|9595826|FG001|Open Label Period (OL)|Lost to Follow-up|0
6001786|NCT00048932|9595827|FG002|Open Label Period (OL)|Lost to Follow-up|27
6001787|NCT00048932|9595825|FG000|Open Label Period (OL)|Withdrawal by Subject|0
6001788|NCT00048932|9595826|FG001|Open Label Period (OL)|Withdrawal by Subject|0
6001789|NCT00048932|9595827|FG002|Open Label Period (OL)|Withdrawal by Subject|117
6001790|NCT00048932|9595825|FG000|Open Label Period (OL)|No Longer Meets Study Criteria|0
6001791|NCT00048932|9595826|FG001|Open Label Period (OL)|No Longer Meets Study Criteria|0
6001792|NCT00048932|9595827|FG002|Open Label Period (OL)|No Longer Meets Study Criteria|5
6001793|NCT00048932|9595825|FG000|Open Label Period (OL)|Poor/Non-Compliance|0
6001794|NCT00048932|9595826|FG001|Open Label Period (OL)|Poor/Non-Compliance|0
6001795|NCT00048932|9595827|FG002|Open Label Period (OL)|Poor/Non-Compliance|13
6001796|NCT00048932|9595825|FG000|Open Label Period (OL)|Pregnancy|0
6001797|NCT00048932|9595826|FG001|Open Label Period (OL)|Pregnancy|0
6001798|NCT00048932|9595827|FG002|Open Label Period (OL)|Pregnancy|6
6001799|NCT00048932|9595825|FG000|Open Label Period (OL)|Administrative Reason By Sponsor|0
6001800|NCT00048932|9595826|FG001|Open Label Period (OL)|Administrative Reason By Sponsor|0
6001801|NCT00048932|9595827|FG002|Open Label Period (OL)|Administrative Reason By Sponsor|20
6001802|NCT00048932|9595825|FG000|Open Label Period (OL)|Investigator Retiring|0
6001803|NCT00048932|9595826|FG001|Open Label Period (OL)|Investigator Retiring|0
6001804|NCT00048932|9595827|FG002|Open Label Period (OL)|Investigator Retiring|2
6001805|NCT00048932|9595825|FG000|Open Label Period (OL)|Participant Transportation Issues|0
6001806|NCT00048932|9595826|FG001|Open Label Period (OL)|Participant Transportation Issues|0
6001807|NCT00048932|9595827|FG002|Open Label Period (OL)|Participant Transportation Issues|1
6001808|NCT00048932|9595825|FG000|Open Label Period (OL)|Participant Relocated|0
6001809|NCT00048932|9595826|FG001|Open Label Period (OL)|Participant Relocated|0
6001810|NCT00048932|9595827|FG002|Open Label Period (OL)|Participant Relocated|6
6001811|NCT00048932|9595825|FG000|Open Label Period (OL)|Investigator Dosing the Trial|0
6001812|NCT00048932|9595826|FG001|Open Label Period (OL)|Investigator Dosing the Trial|0
6001813|NCT00048932|9595827|FG002|Open Label Period (OL)|Investigator Dosing the Trial|1
6001814|NCT00048932|9595825|FG000|Open Label Period (OL)|Site Closure|0
6001815|NCT00048932|9595826|FG001|Open Label Period (OL)|Site Closure|0
6001816|NCT00048932|9595827|FG002|Open Label Period (OL)|Site Closure|3
6001817|NCT00048932|9595825|FG000|Open Label Period (OL)|Trial Terminated|0
6001818|NCT00048932|9595826|FG001|Open Label Period (OL)|Trial Terminated|0
6073279|NCT00566852|9676713|FG000|Overall Study|Patient refusal|37
6073280|NCT00566852|9676714|FG001|Overall Study|Patient refusal|37
6073281|NCT00566852|9676713|FG000|Overall Study|Not tested due to disability|6
6073282|NCT00566852|9676714|FG001|Overall Study|Not tested due to disability|12
6073283|NCT00566852|9676713|FG000|Overall Study|Missing reason not specified|1
6073284|NCT00566852|9676714|FG001|Overall Study|Missing reason not specified|2
6073285|NCT00566852|9676713|FG000|Overall Study|Missing reason not reported|16
6073286|NCT00566852|9676714|FG001|Overall Study|Missing reason not reported|20
6073287|NCT00566982|9676763|FG000|Overall Study|Adverse Event|6
6073288|NCT00566982|9676764|FG001|Overall Study|Adverse Event|48
6073289|NCT00566982|9676763|FG000|Overall Study|Withdrawal by Subject|1
6073290|NCT00566982|9676764|FG001|Overall Study|Withdrawal by Subject|14
6073291|NCT00566982|9676763|FG000|Overall Study|Protocol Violation|1
6073292|NCT00566982|9676764|FG001|Overall Study|Protocol Violation|4
6073293|NCT00566982|9676763|FG000|Overall Study|Lost to Follow-up|0
6073294|NCT00566982|9676764|FG001|Overall Study|Lost to Follow-up|1
6073295|NCT00566982|9676763|FG000|Overall Study|Other-family problems & doctor's request|0
6073296|NCT00566982|9676764|FG001|Overall Study|Other-family problems & doctor's request|2
6073297|NCT00567112|9676782|FG000|Treatment Period 2 (3 Days)|Protocol Violation|0
6073298|NCT00567112|9676783|FG001|Treatment Period 2 (3 Days)|Protocol Violation|1
6001819|NCT00048932|9595827|FG002|Open Label Period (OL)|Trial Terminated|1
6001820|NCT00048932|9595825|FG000|Open Label Period (OL)|Difficult IV Access with Participant|0
6001821|NCT00048932|9595826|FG001|Open Label Period (OL)|Difficult IV Access with Participant|0
6001822|NCT00048932|9595827|FG002|Open Label Period (OL)|Difficult IV Access with Participant|1
6001823|NCT00048932|9595825|FG000|Open Label Period (OL)|Patient Decision|0
6001824|NCT00048932|9595826|FG001|Open Label Period (OL)|Patient Decision|0
6001825|NCT00048932|9595827|FG002|Open Label Period (OL)|Patient Decision|4
6001826|NCT00048932|9595825|FG000|Open Label Period (OL)|Participant Received Wrong Medication|0
6001827|NCT00048932|9595826|FG001|Open Label Period (OL)|Participant Received Wrong Medication|0
6001828|NCT00048932|9595827|FG002|Open Label Period (OL)|Participant Received Wrong Medication|1
6001829|NCT00048932|9595825|FG000|Open Label Period (OL)|Participant Desires Pregnancy|0
6001830|NCT00048932|9595826|FG001|Open Label Period (OL)|Participant Desires Pregnancy|0
6001831|NCT00048932|9595827|FG002|Open Label Period (OL)|Participant Desires Pregnancy|2
6001832|NCT00048932|9595825|FG000|Open Label Period (OL)|Participant Missed Consecutive Doses|0
6001833|NCT00048932|9595826|FG001|Open Label Period (OL)|Participant Missed Consecutive Doses|0
6001834|NCT00048932|9595827|FG002|Open Label Period (OL)|Participant Missed Consecutive Doses|5
6001835|NCT00048932|9595825|FG000|Open Label Period (OL)|Medication Lost Efficacy|0
6001836|NCT00048932|9595826|FG001|Open Label Period (OL)|Medication Lost Efficacy|0
6001837|NCT00048932|9595827|FG002|Open Label Period (OL)|Medication Lost Efficacy|1
6001838|NCT00048932|9595825|FG000|Open Label Period (OL)|Investigator Decision|0
6001839|NCT00048932|9595826|FG001|Open Label Period (OL)|Investigator Decision|0
6001840|NCT00048932|9595827|FG002|Open Label Period (OL)|Investigator Decision|4
6001841|NCT00048932|9595825|FG000|Open Label Period (OL)|Site Staff Issues|0
6001842|NCT00048932|9595826|FG001|Open Label Period (OL)|Site Staff Issues|0
6001843|NCT00048932|9595827|FG002|Open Label Period (OL)|Site Staff Issues|2
6001844|NCT00048932|9595825|FG000|Open Label Period (OL)|Site Not Participating in Open Label|0
6001845|NCT00048932|9595826|FG001|Open Label Period (OL)|Site Not Participating in Open Label|0
6001846|NCT00048932|9595827|FG002|Open Label Period (OL)|Site Not Participating in Open Label|9
6001847|NCT00048932|9595825|FG000|Open Label Period (OL)|Participant Surgery|0
6001848|NCT00048932|9595826|FG001|Open Label Period (OL)|Participant Surgery|0
6001849|NCT00048932|9595827|FG002|Open Label Period (OL)|Participant Surgery|1
6001850|NCT00048997|9595838|FG000|Overall Study|Protocol Violation|7
6001851|NCT00048997|9595839|FG001|Overall Study|Protocol Violation|2
6001852|NCT00048997|9595838|FG000|Overall Study|Withdrawal by Subject|6
6001853|NCT00048997|9595839|FG001|Overall Study|Withdrawal by Subject|1
6001854|NCT00049127|9595858|FG000|Overall Study|Withdrawal by Subject|0
6001855|NCT00049127|9595859|FG001|Overall Study|Withdrawal by Subject|0
6001856|NCT00049127|9595860|FG002|Overall Study|Withdrawal by Subject|1
6001857|NCT00049127|9595861|FG003|Overall Study|Withdrawal by Subject|0
6001858|NCT00049127|9595862|FG004|Overall Study|Withdrawal by Subject|0
6001859|NCT00049257|9595874|FG000|Carboplatin, Paclitaxel|Withdrawal by Subject|10
6001860|NCT00049257|9595874|FG000|Carboplatin, Paclitaxel|Lost to Follow-up|1
6001861|NCT00049257|9595874|FG000|Carboplatin, Paclitaxel|Death|2
6001862|NCT00049257|9595874|FG000|Follow-up Period for Survival Status|Lost to Follow-up|4
6001863|NCT00049322|9595880|FG000|Overall Study|disease burden|0
6001864|NCT00049322|9595881|FG001|Overall Study|disease burden|3
6001865|NCT00049322|9595880|FG000|Overall Study|Adverse Event|1
6001866|NCT00049322|9595881|FG001|Overall Study|Adverse Event|0
6001867|NCT00049322|9595880|FG000|Overall Study|refused angio|0
6001868|NCT00049322|9595881|FG001|Overall Study|refused angio|3
6001869|NCT00049517|9595895|FG000|Induction|Disease progression|0
6001870|NCT00049517|9595896|FG001|Induction|Disease progression|0
6001871|NCT00049517|9595897|FG002|Induction|Disease progression|0
6001872|NCT00049517|9595898|FG003|Induction|Disease progression|0
6001873|NCT00049517|9595899|FG004|Induction|Disease progression|18
6001874|NCT00049517|9595900|FG005|Induction|Disease progression|11
6001875|NCT00049517|9595895|FG000|Induction|Adverse Event|0
6001876|NCT00049517|9595896|FG001|Induction|Adverse Event|0
6001877|NCT00049517|9595897|FG002|Induction|Adverse Event|0
6001878|NCT00049517|9595898|FG003|Induction|Adverse Event|0
6001879|NCT00049517|9595899|FG004|Induction|Adverse Event|5
6001880|NCT00049517|9595900|FG005|Induction|Adverse Event|7
6001881|NCT00049517|9595895|FG000|Induction|Death|0
6001882|NCT00049517|9595896|FG001|Induction|Death|0
6001883|NCT00049517|9595897|FG002|Induction|Death|0
6001884|NCT00049517|9595898|FG003|Induction|Death|0
6001885|NCT00049517|9595899|FG004|Induction|Death|9
6001886|NCT00049517|9595900|FG005|Induction|Death|6
6001887|NCT00049517|9595895|FG000|Induction|Withdrawal by Subject|0
6001888|NCT00049517|9595896|FG001|Induction|Withdrawal by Subject|0
6001889|NCT00049517|9595897|FG002|Induction|Withdrawal by Subject|0
6001890|NCT00049517|9595898|FG003|Induction|Withdrawal by Subject|0
6001891|NCT00049517|9595899|FG004|Induction|Withdrawal by Subject|1
6001892|NCT00049517|9595900|FG005|Induction|Withdrawal by Subject|3
6001893|NCT00049517|9595895|FG000|Induction|Alternative therapy|0
6001894|NCT00049517|9595896|FG001|Induction|Alternative therapy|0
6001895|NCT00049517|9595897|FG002|Induction|Alternative therapy|0
6001896|NCT00049517|9595898|FG003|Induction|Alternative therapy|0
6001897|NCT00049517|9595899|FG004|Induction|Alternative therapy|2
6001898|NCT00049517|9595900|FG005|Induction|Alternative therapy|2
6001899|NCT00049517|9595895|FG000|Induction|Other complicating disease|0
6001900|NCT00049517|9595896|FG001|Induction|Other complicating disease|0
6001901|NCT00049517|9595897|FG002|Induction|Other complicating disease|0
6001902|NCT00049517|9595898|FG003|Induction|Other complicating disease|0
6001903|NCT00049517|9595899|FG004|Induction|Other complicating disease|3
6001904|NCT00049517|9595900|FG005|Induction|Other complicating disease|0
6001905|NCT00049517|9595895|FG000|Induction|Reasons not reported|0
6001906|NCT00049517|9595896|FG001|Induction|Reasons not reported|0
6001907|NCT00049517|9595897|FG002|Induction|Reasons not reported|0
6001908|NCT00049517|9595898|FG003|Induction|Reasons not reported|0
6001909|NCT00049517|9595899|FG004|Induction|Reasons not reported|22
6001910|NCT00049517|9595900|FG005|Induction|Reasons not reported|25
6001911|NCT00049517|9595895|FG000|Conditioning/Transplant|Disease progression|14
6001912|NCT00049517|9595896|FG001|Conditioning/Transplant|Disease progression|6
6001913|NCT00049517|9595897|FG002|Conditioning/Transplant|Disease progression|10
6001914|NCT00049517|9595898|FG003|Conditioning/Transplant|Disease progression|6
6001915|NCT00049517|9595899|FG004|Conditioning/Transplant|Disease progression|0
6001916|NCT00049517|9595900|FG005|Conditioning/Transplant|Disease progression|0
6001917|NCT00049517|9595895|FG000|Conditioning/Transplant|Adverse Event|2
6001918|NCT00049517|9595896|FG001|Conditioning/Transplant|Adverse Event|1
6001919|NCT00049517|9595897|FG002|Conditioning/Transplant|Adverse Event|4
6001920|NCT00049517|9595898|FG003|Conditioning/Transplant|Adverse Event|8
6001921|NCT00049517|9595899|FG004|Conditioning/Transplant|Adverse Event|0
6001922|NCT00049517|9595900|FG005|Conditioning/Transplant|Adverse Event|0
6001923|NCT00049517|9595895|FG000|Conditioning/Transplant|Death|1
6001924|NCT00049517|9595896|FG001|Conditioning/Transplant|Death|0
6001925|NCT00049517|9595897|FG002|Conditioning/Transplant|Death|0
6001926|NCT00049517|9595898|FG003|Conditioning/Transplant|Death|2
6001927|NCT00049517|9595899|FG004|Conditioning/Transplant|Death|0
6001928|NCT00049517|9595900|FG005|Conditioning/Transplant|Death|0
6001929|NCT00049517|9595895|FG000|Conditioning/Transplant|Withdrawal by Subject|4
6001930|NCT00049517|9595896|FG001|Conditioning/Transplant|Withdrawal by Subject|8
6001931|NCT00049517|9595897|FG002|Conditioning/Transplant|Withdrawal by Subject|4
6001932|NCT00049517|9595898|FG003|Conditioning/Transplant|Withdrawal by Subject|7
6001933|NCT00049517|9595899|FG004|Conditioning/Transplant|Withdrawal by Subject|0
6001934|NCT00049517|9595900|FG005|Conditioning/Transplant|Withdrawal by Subject|0
6001935|NCT00049517|9595895|FG000|Conditioning/Transplant|Alternative therapy|4
6001936|NCT00049517|9595896|FG001|Conditioning/Transplant|Alternative therapy|4
6001937|NCT00049517|9595897|FG002|Conditioning/Transplant|Alternative therapy|2
6001938|NCT00049517|9595898|FG003|Conditioning/Transplant|Alternative therapy|1
6001939|NCT00049517|9595899|FG004|Conditioning/Transplant|Alternative therapy|1
6001940|NCT00049517|9595900|FG005|Conditioning/Transplant|Alternative therapy|0
6001941|NCT00049517|9595895|FG000|Conditioning/Transplant|Other complicating disease|2
6001942|NCT00049517|9595896|FG001|Conditioning/Transplant|Other complicating disease|0
6001943|NCT00049517|9595897|FG002|Conditioning/Transplant|Other complicating disease|0
6001944|NCT00049517|9595898|FG003|Conditioning/Transplant|Other complicating disease|4
6001945|NCT00049517|9595899|FG004|Conditioning/Transplant|Other complicating disease|0
6001946|NCT00049517|9595900|FG005|Conditioning/Transplant|Other complicating disease|1
6001947|NCT00049517|9595895|FG000|Conditioning/Transplant|Reasons not reported|25
6001948|NCT00049517|9595896|FG001|Conditioning/Transplant|Reasons not reported|31
6001949|NCT00049517|9595897|FG002|Conditioning/Transplant|Reasons not reported|18
6001950|NCT00049517|9595898|FG003|Conditioning/Transplant|Reasons not reported|15
6001951|NCT00049517|9595899|FG004|Conditioning/Transplant|Reasons not reported|5
6001952|NCT00049517|9595900|FG005|Conditioning/Transplant|Reasons not reported|5
6001953|NCT00049530|9595908|FG000|Overall Study|Lack of Efficacy|25
6001954|NCT00049530|9595908|FG000|Overall Study|Adverse Event|2
6001955|NCT00049530|9595908|FG000|Overall Study|Death|1
6001956|NCT00049530|9595908|FG000|Overall Study|symptomatic deterioration|1
6001957|NCT00049530|9595908|FG000|Overall Study|ineligible|3
6001958|NCT00049543|9595914|FG000|Overall Study|still on treatment|2
6001959|NCT00049543|9595915|FG001|Overall Study|still on treatment|9
6001960|NCT00049673|9595923|FG000|Overall Study|No receive treatment/lost to follow-up|1
6001961|NCT00049673|9595924|FG001|Overall Study|No receive treatment/lost to follow-up|3
6001962|NCT00049842|9595932|FG000|Treatment Phase|Adverse Event|47
6001963|NCT00049842|9595933|FG001|Treatment Phase|Adverse Event|12
6001964|NCT00049842|9595932|FG000|Treatment Phase|Withdrawal by Subject|35
6001965|NCT00049842|9595933|FG001|Treatment Phase|Withdrawal by Subject|46
6001966|NCT00049842|9595932|FG000|Treatment Phase|Non-compliance with protocol|7
6001967|NCT00049842|9595933|FG001|Treatment Phase|Non-compliance with protocol|8
6001968|NCT00049842|9595932|FG000|Treatment Phase|Lost to Follow-up|4
6001969|NCT00049842|9595933|FG001|Treatment Phase|Lost to Follow-up|8
6001970|NCT00049842|9595932|FG000|Treatment Phase|Administrative|0
6001971|NCT00049842|9595933|FG001|Treatment Phase|Administrative|3
6001972|NCT00049842|9595932|FG000|Treatment Phase|Did not meet protocol eligibility|0
6001973|NCT00049842|9595933|FG001|Treatment Phase|Did not meet protocol eligibility|1
6001974|NCT00049842|9595932|FG000|Follow-up Phase|Adverse Event|6
6001975|NCT00049842|9595933|FG001|Follow-up Phase|Adverse Event|1
6001976|NCT00049842|9595932|FG000|Follow-up Phase|Other|1
6001977|NCT00049842|9595933|FG001|Follow-up Phase|Other|4
6001978|NCT00050011|9595941|FG000|Overall Study|Adverse Event|41
6001979|NCT00050011|9595942|FG001|Overall Study|Adverse Event|46
6001980|NCT00050011|9595941|FG000|Overall Study|Abnormal laboratory value(s)|1
6001981|NCT00050011|9595942|FG001|Overall Study|Abnormal laboratory value(s)|1
6001982|NCT00050011|9595941|FG000|Overall Study|Abnormal test procedure results|0
6001983|NCT00050011|9595942|FG001|Overall Study|Abnormal test procedure results|1
6001984|NCT00050011|9595941|FG000|Overall Study|Lack of Efficacy|16
6001985|NCT00050011|9595942|FG001|Overall Study|Lack of Efficacy|21
6001986|NCT00050011|9595941|FG000|Overall Study|Participant condition no longer required|1
6001987|NCT00050011|9595942|FG001|Overall Study|Participant condition no longer required|0
6001988|NCT00050011|9595941|FG000|Overall Study|Protocol Violation|4
6001989|NCT00050011|9595942|FG001|Overall Study|Protocol Violation|10
6001990|NCT00050011|9595941|FG000|Overall Study|Withdrawal by Subject|34
6001991|NCT00050011|9595942|FG001|Overall Study|Withdrawal by Subject|26
6001992|NCT00050011|9595941|FG000|Overall Study|Lost to Follow-up|7
6001993|NCT00050011|9595942|FG001|Overall Study|Lost to Follow-up|9
6001994|NCT00050011|9595941|FG000|Overall Study|Administrative problems|10
6001995|NCT00050011|9595942|FG001|Overall Study|Administrative problems|6
6001996|NCT00050011|9595941|FG000|Overall Study|Death|7
6001997|NCT00050011|9595942|FG001|Overall Study|Death|4
6001998|NCT00050011|9595941|FG000|Overall Study|Unknown - Reason is missing|0
6001999|NCT00050011|9595942|FG001|Overall Study|Unknown - Reason is missing|2
6002000|NCT00050167|9595972|FG000|Overall Study|not eligible not invasive|1
6002001|NCT00050167|9595973|FG001|Overall Study|not eligible not invasive|1
6002002|NCT00050622|9595979|FG000|Overall Study|Adverse Event|1
6002003|NCT00050778|9596006|FG000|Overall Study|Adverse Event|13
6002004|NCT00050778|9596007|FG001|Overall Study|Adverse Event|3
6002005|NCT00050778|9596008|FG002|Overall Study|Adverse Event|2
6002006|NCT00050778|9596006|FG000|Overall Study|Death|0
6002007|NCT00050778|9596007|FG001|Overall Study|Death|1
6002008|NCT00050778|9596008|FG002|Overall Study|Death|1
6002009|NCT00050778|9596006|FG000|Overall Study|Lack of Efficacy|16
6002010|NCT00050778|9596007|FG001|Overall Study|Lack of Efficacy|2
6002011|NCT00050778|9596008|FG002|Overall Study|Lack of Efficacy|2
6002012|NCT00050778|9596006|FG000|Overall Study|Lost to Follow-up|0
6002013|NCT00050778|9596007|FG001|Overall Study|Lost to Follow-up|2
6002014|NCT00050778|9596008|FG002|Overall Study|Lost to Follow-up|4
6002015|NCT00050778|9596006|FG000|Overall Study|Physician Decision|3
6002016|NCT00050778|9596007|FG001|Overall Study|Physician Decision|0
6002017|NCT00050778|9596008|FG002|Overall Study|Physician Decision|2
6002018|NCT00050778|9596006|FG000|Overall Study|Protocol Violation|2
6002019|NCT00050778|9596007|FG001|Overall Study|Protocol Violation|0
6002020|NCT00050778|9596008|FG002|Overall Study|Protocol Violation|1
6002021|NCT00050778|9596006|FG000|Overall Study|Withdrawal by Subject|6
6002022|NCT00050778|9596007|FG001|Overall Study|Withdrawal by Subject|8
6002023|NCT00050778|9596008|FG002|Overall Study|Withdrawal by Subject|4
6002024|NCT00050778|9596006|FG000|Overall Study|Randomized but not treated|4
6002025|NCT00050778|9596007|FG001|Overall Study|Randomized but not treated|5
6002026|NCT00050778|9596008|FG002|Overall Study|Randomized but not treated|2
6087304|NCT00667095|9697465|FG001|Overall Study|Withdrawal by Subject|1
6002027|NCT00050778|9596006|FG000|Overall Study|Familial and personal reasons|1
6002028|NCT00050778|9596007|FG001|Overall Study|Familial and personal reasons|0
6002029|NCT00050778|9596008|FG002|Overall Study|Familial and personal reasons|0
6002030|NCT00050960|9596020|FG000|Overall Study|Progressive Disease|137
6002031|NCT00050960|9596021|FG001|Overall Study|Progressive Disease|93
6002032|NCT00050960|9596020|FG000|Overall Study|Stable Disease|19
6002033|NCT00050960|9596021|FG001|Overall Study|Stable Disease|48
6002034|NCT00050960|9596020|FG000|Overall Study|Partial Response|14
6002035|NCT00050960|9596021|FG001|Overall Study|Partial Response|19
6002036|NCT00050960|9596020|FG000|Overall Study|Complete Response|0
6002037|NCT00050960|9596021|FG001|Overall Study|Complete Response|2
6002038|NCT00050960|9596020|FG000|Overall Study|Adverse Event|62
6002039|NCT00050960|9596021|FG001|Overall Study|Adverse Event|61
6002040|NCT00050960|9596020|FG000|Overall Study|Lost to Follow-up|0
6002041|NCT00050960|9596021|FG001|Overall Study|Lost to Follow-up|1
6002042|NCT00050960|9596020|FG000|Overall Study|Withdrawal by Subject|23
6002043|NCT00050960|9596021|FG001|Overall Study|Withdrawal by Subject|18
6002044|NCT00050960|9596020|FG000|Overall Study|Administrative|31
6002045|NCT00050960|9596021|FG001|Overall Study|Administrative|46
6002046|NCT00050960|9596020|FG000|Overall Study|Non-compliance|3
6002047|NCT00050960|9596021|FG001|Overall Study|Non-compliance|1
6002048|NCT00050960|9596020|FG000|Overall Study|Death|13
6002049|NCT00050960|9596021|FG001|Overall Study|Death|15
6002050|NCT00051025|9596033|FG000|Overall Study|Progressive Disease|1
6002051|NCT00051025|9596034|FG001|Overall Study|Progressive Disease|1
6002052|NCT00051025|9596033|FG000|Overall Study|Adverse Event|1
6002053|NCT00051025|9596034|FG001|Overall Study|Adverse Event|1
6002054|NCT00051025|9596033|FG000|Overall Study|Withdrawal by Subject|0
6002055|NCT00051025|9596034|FG001|Overall Study|Withdrawal by Subject|1
6002056|NCT00051025|9596033|FG000|Overall Study|Death|0
6002057|NCT00051025|9596034|FG001|Overall Study|Death|1
6002058|NCT00051311|9596046|FG000|Overall Study|Starting new study|0
6002059|NCT00051311|9596047|FG001|Overall Study|Starting new study|1
6002060|NCT00051311|9596046|FG000|Overall Study|Pt. to pursue treatment for progressive disease|0
6002061|NCT00051311|9596047|FG001|Overall Study|Pt. to pursue treatment for progressive disease|1
6002062|NCT00051311|9596046|FG000|Overall Study|Death of recipient|8
6002063|NCT00051311|9596047|FG001|Overall Study|Death of recipient|8
6002064|NCT00051311|9596046|FG000|Overall Study|Recipient taken off study|4
6002065|NCT00051311|9596047|FG001|Overall Study|Recipient taken off study|4
6002066|NCT00051363|9596053|FG000|Overall Study|Dropped Post-Rand for Any Reason|102
6002067|NCT00051363|9596054|FG001|Overall Study|Dropped Post-Rand for Any Reason|126
6002068|NCT00051363|9596053|FG000|Overall Study|Disqualified Post-Rand for Any Reason|9
6002069|NCT00051363|9596054|FG001|Overall Study|Disqualified Post-Rand for Any Reason|11
6002070|NCT00051363|9596053|FG000|Overall Study|Death|2
6002071|NCT00051363|9596054|FG001|Overall Study|Death|2
6002072|NCT00051363|9596053|FG000|Overall Study|Excluded Pre-Randomization|2
6002073|NCT00051363|9596054|FG001|Overall Study|Excluded Pre-Randomization|5
6002074|NCT00051558|9596062|FG000|Overall Study|Adverse Event|30
6002075|NCT00051558|9596063|FG001|Overall Study|Adverse Event|18
6002076|NCT00051558|9596062|FG000|Overall Study|Withdrawal by Subject|29
6002077|NCT00051558|9596063|FG001|Overall Study|Withdrawal by Subject|42
6002078|NCT00051558|9596062|FG000|Overall Study|Death|9
6002079|NCT00051558|9596063|FG001|Overall Study|Death|15
6002080|NCT00051558|9596062|FG000|Overall Study|Lost to Follow-up|4
6002081|NCT00051558|9596063|FG001|Overall Study|Lost to Follow-up|13
6002082|NCT00051558|9596062|FG000|Overall Study|Protocol Violation|3
6002083|NCT00051558|9596063|FG001|Overall Study|Protocol Violation|4
6002084|NCT00051558|9596062|FG000|Overall Study|Protocol Entry Criteria Unmet|1
6002085|NCT00051558|9596063|FG001|Overall Study|Protocol Entry Criteria Unmet|2
6002086|NCT00051558|9596062|FG000|Overall Study|Sponsor Decision|6
6002087|NCT00051558|9596063|FG001|Overall Study|Sponsor Decision|1
6002088|NCT00051558|9596062|FG000|Overall Study|Other|2
6002089|NCT00051558|9596063|FG001|Overall Study|Other|1
6002090|NCT00051558|9596062|FG000|Overall Study|Significant Lab Value|2
6002091|NCT00051558|9596063|FG001|Overall Study|Significant Lab Value|0
6002092|NCT00051558|9596062|FG000|Overall Study|Physician Decision|5
6002093|NCT00051558|9596063|FG001|Overall Study|Physician Decision|0
6002094|NCT00051636|9596071|FG000|Period 1 - Core|Adverse Event|2
6002095|NCT00051636|9596072|FG001|Period 1 - Core|Adverse Event|2
6002096|NCT00051636|9596071|FG000|Period 1 - Core|Protocol Violation|1
6002097|NCT00051636|9596072|FG001|Period 1 - Core|Protocol Violation|0
6002098|NCT00051636|9596071|FG000|Period 1 - Core|Withdrawal by Subject|1
6002099|NCT00051636|9596072|FG001|Period 1 - Core|Withdrawal by Subject|2
6002100|NCT00051636|9596071|FG000|Period 1 - Core|Lost to Follow-up|0
6002101|NCT00051636|9596072|FG001|Period 1 - Core|Lost to Follow-up|2
6002102|NCT00051636|9596071|FG000|Period 2- Extended Observation Period|Lost to Follow-up|5
6002103|NCT00051636|9596072|FG001|Period 2- Extended Observation Period|Lost to Follow-up|4
6002104|NCT00051636|9596071|FG000|Period 2- Extended Observation Period|withdrew for nonclinical reason|12
6002105|NCT00051636|9596072|FG001|Period 2- Extended Observation Period|withdrew for nonclinical reason|7
6002106|NCT00051636|9596071|FG000|Period 2- Extended Observation Period|Clinical reasons other than Paget's|9
6002107|NCT00051636|9596072|FG001|Period 2- Extended Observation Period|Clinical reasons other than Paget's|2
6002108|NCT00051636|9596071|FG000|Period 2- Extended Observation Period|Death|4
6002109|NCT00051636|9596072|FG001|Period 2- Extended Observation Period|Death|5
6002110|NCT00051636|9596071|FG000|Period 2- Extended Observation Period|Amendment 6 Informed Consent Not Signed|40
6002111|NCT00051636|9596072|FG001|Period 2- Extended Observation Period|Amendment 6 Informed Consent Not Signed|12
6002112|NCT00052715|9596120|FG000|Overall Study|wrong histology|1
6002113|NCT00052962|9596135|FG000|Overall Study|Not evaluable|0
6002114|NCT00052962|9596136|FG001|Overall Study|Not evaluable|2
6002115|NCT00052962|9596135|FG000|Overall Study|Not randomized/not evaluable|1
6002116|NCT00052962|9596136|FG001|Overall Study|Not randomized/not evaluable|0
6002117|NCT00053352|9596148|FG000|Overall Study|Lost to Follow-up|0
6002118|NCT00053352|9596149|FG001|Overall Study|Lost to Follow-up|1
6002119|NCT00053352|9596148|FG000|Overall Study|Physician Decision|11
6002120|NCT00053352|9596149|FG001|Overall Study|Physician Decision|1
6002121|NCT00053352|9596148|FG000|Overall Study|Withdrawal by Subject|1
6002122|NCT00053352|9596149|FG001|Overall Study|Withdrawal by Subject|0
6002123|NCT00053352|9596148|FG000|Overall Study|Ineligible|8
6002124|NCT00053352|9596149|FG001|Overall Study|Ineligible|8
6002125|NCT00053352|9596148|FG000|Overall Study|Disease at new site|1
6002126|NCT00053352|9596149|FG001|Overall Study|Disease at new site|0
6002127|NCT00053365|9596156|FG000|Overall Study|Incorrect cell type|1
6002128|NCT00053365|9596156|FG000|Overall Study|Platinum-sensitive interval >12 months|1
6002129|NCT00053365|9596156|FG000|Overall Study|Never treated|4
6002130|NCT00053417|9596166|FG000|Overall Study|Adverse Event|1
6002131|NCT00053417|9596167|FG001|Overall Study|Adverse Event|0
6002132|NCT00053417|9596168|FG002|Overall Study|Adverse Event|1
6002133|NCT00053417|9596169|FG003|Overall Study|Adverse Event|5
6002134|NCT00053417|9596166|FG000|Overall Study|Non-Compliance|0
6002135|NCT00053417|9596167|FG001|Overall Study|Non-Compliance|0
6002136|NCT00053417|9596168|FG002|Overall Study|Non-Compliance|0
6002137|NCT00053417|9596169|FG003|Overall Study|Non-Compliance|1
6002138|NCT00053417|9596166|FG000|Overall Study|Withdrawal by Subject|0
6002139|NCT00053417|9596167|FG001|Overall Study|Withdrawal by Subject|1
6002140|NCT00053417|9596168|FG002|Overall Study|Withdrawal by Subject|0
6002141|NCT00053417|9596169|FG003|Overall Study|Withdrawal by Subject|0
6002142|NCT00053417|9596166|FG000|Overall Study|Lost to Follow-up|1
6002143|NCT00053417|9596167|FG001|Overall Study|Lost to Follow-up|1
6002144|NCT00053417|9596168|FG002|Overall Study|Lost to Follow-up|0
6002145|NCT00053417|9596169|FG003|Overall Study|Lost to Follow-up|0
6002146|NCT00053846|9596254|FG000|Overall Study|Changed mind|8
6002147|NCT00053846|9596255|FG001|Overall Study|Changed mind|13
6002148|NCT00053846|9596254|FG000|Overall Study|Became too ill|8
6002149|NCT00053846|9596255|FG001|Overall Study|Became too ill|7
6002150|NCT00053846|9596254|FG000|Overall Study|Expired|5
6002151|NCT00053846|9596255|FG001|Overall Study|Expired|0
6002152|NCT00053846|9596254|FG000|Overall Study|Became ineligible|3
6002153|NCT00053846|9596255|FG001|Overall Study|Became ineligible|1
6002154|NCT00053846|9596254|FG000|Overall Study|Did not return data|1
6002155|NCT00053846|9596255|FG001|Overall Study|Did not return data|2
6002156|NCT00053846|9596254|FG000|Overall Study|Quit due to side effects|1
6002157|NCT00053846|9596255|FG001|Overall Study|Quit due to side effects|3
6002158|NCT00053846|9596254|FG000|Overall Study|Pills too large|0
6002159|NCT00053846|9596255|FG001|Overall Study|Pills too large|1
6002160|NCT00053898|9596263|FG000|Overall Study|No follow-up data from any source|9
6002161|NCT00053898|9596264|FG001|Overall Study|No follow-up data from any source|12
6002162|NCT00053898|9596263|FG000|Overall Study|Follow-up from telephone contact only|5
6002163|NCT00053898|9596264|FG001|Overall Study|Follow-up from telephone contact only|1
6002164|NCT00054132|9596281|FG000|Overall Study|Not Treated|1
6002165|NCT00054275|9596286|FG000|Overall Study|Withdrawal by Subject|4
6002166|NCT00054275|9596286|FG000|Overall Study|Adverse Event|5
6002167|NCT00054275|9596286|FG000|Overall Study|Progressive disease in cycle 1|1
6002168|NCT00054275|9596286|FG000|Overall Study|Physician Decision|1
6002169|NCT00054327|9596296|FG000|Overall Study|Engraftment failure|1
6002170|NCT00054327|9596297|FG001|Overall Study|Engraftment failure|0
6002171|NCT00054327|9596298|FG002|Overall Study|Engraftment failure|0
6002172|NCT00054327|9596299|FG003|Overall Study|Engraftment failure|0
6002173|NCT00054327|9596300|FG004|Overall Study|Engraftment failure|0
6002174|NCT00054327|9596301|FG005|Overall Study|Engraftment failure|0
6002175|NCT00054639|9596328|FG000|Overall Study|Lack of Efficacy|1
6002176|NCT00054639|9596328|FG000|Overall Study|Physician Decision|1
6002177|NCT00054691|9596341|FG000|Overall Study|Unmeasurable Disease|2
6002178|NCT00054691|9596341|FG000|Overall Study|Noncompliant|1
6002179|NCT00054704|9596347|FG000|Overall Study|Lack of Efficacy|2
6002180|NCT00054704|9596348|FG001|Overall Study|Lack of Efficacy|3
6002181|NCT00054704|9596347|FG000|Overall Study|Adverse Event|3
6002182|NCT00054704|9596348|FG001|Overall Study|Adverse Event|1
6002183|NCT00054704|9596347|FG000|Overall Study|Lost to Follow-up|0
6002184|NCT00054704|9596348|FG001|Overall Study|Lost to Follow-up|1
6002185|NCT00054717|9596356|FG000|Overall Study|Randomized but not treated|2
6002186|NCT00054717|9596357|FG001|Overall Study|Randomized but not treated|8
6002187|NCT00054717|9596356|FG000|Overall Study|Adverse Event|70
6002188|NCT00054717|9596357|FG001|Overall Study|Adverse Event|22
6002189|NCT00054717|9596356|FG000|Overall Study|Protocol Violation|18
6002190|NCT00054717|9596357|FG001|Overall Study|Protocol Violation|19
6002191|NCT00054717|9596356|FG000|Overall Study|Lost to Follow-up|23
6002192|NCT00054717|9596357|FG001|Overall Study|Lost to Follow-up|13
6002193|NCT00054717|9596356|FG000|Overall Study|Withdrawal by Subject|32
6002194|NCT00054717|9596357|FG001|Overall Study|Withdrawal by Subject|20
6002195|NCT00054717|9596356|FG000|Overall Study|Other reason not defined above|117
6002196|NCT00054717|9596357|FG001|Overall Study|Other reason not defined above|217
6002197|NCT00055471|9596391|FG000|Period 1: Dose Escalation Period|Adverse Event|0
6002198|NCT00055471|9596392|FG001|Period 1: Dose Escalation Period|Adverse Event|1
6002199|NCT00055471|9596393|FG002|Period 1: Dose Escalation Period|Adverse Event|2
6002200|NCT00055471|9596391|FG000|Period 1: Dose Escalation Period|Erroneously reported discont. criteria|0
6002201|NCT00055471|9596392|FG001|Period 1: Dose Escalation Period|Erroneously reported discont. criteria|0
6002202|NCT00055471|9596393|FG002|Period 1: Dose Escalation Period|Erroneously reported discont. criteria|1
6002203|NCT00055471|9596391|FG000|Period 1: Dose Escalation Period|Disease progression|0
6002204|NCT00055471|9596392|FG001|Period 1: Dose Escalation Period|Disease progression|1
6002205|NCT00055471|9596393|FG002|Period 1: Dose Escalation Period|Disease progression|0
6002206|NCT00055497|9596405|FG000|Overall Study|Adverse Event|1
6002207|NCT00055497|9596406|FG001|Overall Study|Adverse Event|1
6002208|NCT00055497|9596407|FG002|Overall Study|Adverse Event|1
6002209|NCT00055497|9596408|FG003|Overall Study|Adverse Event|28
6002210|NCT00055497|9596405|FG000|Overall Study|Withdrawal by Subject|3
6002211|NCT00055497|9596406|FG001|Overall Study|Withdrawal by Subject|1
6073299|NCT00567112|9676784|FG002|Treatment Period 2 (3 Days)|Protocol Violation|0
6073300|NCT00567112|9676782|FG000|Washout Period 3 (3 Days)|Lost to Follow-up|2
6073301|NCT00567112|9676783|FG001|Washout Period 3 (3 Days)|Lost to Follow-up|0
6073302|NCT00567112|9676784|FG002|Washout Period 3 (3 Days)|Lost to Follow-up|0
6073303|NCT00567112|9676782|FG000|Washout Period 3 (3 Days)|Protocol Violation|1
6073304|NCT00567112|9676783|FG001|Washout Period 3 (3 Days)|Protocol Violation|0
6073305|NCT00567112|9676784|FG002|Washout Period 3 (3 Days)|Protocol Violation|0
6073306|NCT00567164|9676796|FG000|Overall Study|Withdrawal by Subject|171
6073307|NCT00567164|9676797|FG001|Overall Study|Withdrawal by Subject|21
6073308|NCT00567164|9676798|FG002|Overall Study|Withdrawal by Subject|17
6073309|NCT00567164|9676796|FG000|Overall Study|Protocol Violation|23
6073310|NCT00567164|9676797|FG001|Overall Study|Protocol Violation|4
6073311|NCT00567164|9676798|FG002|Overall Study|Protocol Violation|2
6073312|NCT00567164|9676796|FG000|Overall Study|Adverse Event|92
6073313|NCT00567164|9676797|FG001|Overall Study|Adverse Event|13
6002212|NCT00055497|9596407|FG002|Overall Study|Withdrawal by Subject|1
6002213|NCT00055497|9596408|FG003|Overall Study|Withdrawal by Subject|15
6002214|NCT00055497|9596405|FG000|Overall Study|Lost to Follow-up|0
6073314|NCT00567164|9676798|FG002|Overall Study|Adverse Event|9
6073315|NCT00567164|9676796|FG000|Overall Study|Death|0
6073316|NCT00567164|9676797|FG001|Overall Study|Death|0
6073317|NCT00567164|9676798|FG002|Overall Study|Death|1
6002215|NCT00055497|9596406|FG001|Overall Study|Lost to Follow-up|1
6002216|NCT00055497|9596407|FG002|Overall Study|Lost to Follow-up|0
6002217|NCT00055497|9596408|FG003|Overall Study|Lost to Follow-up|5
6002218|NCT00055497|9596405|FG000|Overall Study|Protocol Violation|0
6002219|NCT00055497|9596406|FG001|Overall Study|Protocol Violation|0
6002220|NCT00055497|9596407|FG002|Overall Study|Protocol Violation|0
6002221|NCT00055497|9596408|FG003|Overall Study|Protocol Violation|3
6002222|NCT00055497|9596405|FG000|Overall Study|Lack of Efficacy|1
6002223|NCT00055497|9596406|FG001|Overall Study|Lack of Efficacy|0
6002224|NCT00055497|9596407|FG002|Overall Study|Lack of Efficacy|0
6002225|NCT00055497|9596408|FG003|Overall Study|Lack of Efficacy|27
6002226|NCT00055497|9596405|FG000|Overall Study|Administrative Reasons|0
6002227|NCT00055497|9596406|FG001|Overall Study|Administrative Reasons|0
6002228|NCT00055497|9596407|FG002|Overall Study|Administrative Reasons|0
6002229|NCT00055497|9596408|FG003|Overall Study|Administrative Reasons|1
6002230|NCT00055497|9596405|FG000|Overall Study|Other|0
6002231|NCT00055497|9596406|FG001|Overall Study|Other|0
6002232|NCT00055497|9596407|FG002|Overall Study|Other|0
6002233|NCT00055497|9596408|FG003|Overall Study|Other|11
6002234|NCT00055601|9596425|FG000|Overall Study|Protocol Violation|1
6002235|NCT00055601|9596426|FG001|Overall Study|Protocol Violation|1
6002236|NCT00055601|9596425|FG000|Overall Study|No protocol treatment received|1
6002237|NCT00055601|9596426|FG001|Overall Study|No protocol treatment received|1
6002238|NCT00056160|9596440|FG000|Up to Unblinding (07 Jun 2005)|Adverse Event|35
6002239|NCT00056160|9596441|FG001|Up to Unblinding (07 Jun 2005)|Adverse Event|18
6002240|NCT00056160|9596440|FG000|Up to Unblinding (07 Jun 2005)|Progression of disease|57
6002241|NCT00056160|9596441|FG001|Up to Unblinding (07 Jun 2005)|Progression of disease|124
6002242|NCT00056160|9596440|FG000|Up to Unblinding (07 Jun 2005)|Lack of Efficacy|3
6002243|NCT00056160|9596441|FG001|Up to Unblinding (07 Jun 2005)|Lack of Efficacy|5
6002244|NCT00056160|9596440|FG000|Up to Unblinding (07 Jun 2005)|Withdrawal by Subject|8
6309499|NCT02639338|10038112|FG000|Overall Study|Lost to Follow-up|2
6309500|NCT02639338|10038113|FG001|Overall Study|Lost to Follow-up|2
6002245|NCT00056160|9596441|FG001|Up to Unblinding (07 Jun 2005)|Withdrawal by Subject|8
6002246|NCT00056160|9596440|FG000|Up to Unblinding (07 Jun 2005)|Death|2
6002247|NCT00056160|9596441|FG001|Up to Unblinding (07 Jun 2005)|Death|1
6002248|NCT00056160|9596440|FG000|Up to Unblinding (07 Jun 2005)|Other|8
6002249|NCT00056160|9596441|FG001|Up to Unblinding (07 Jun 2005)|Other|7
6002250|NCT00056160|9596440|FG000|Extended Follow-up Cutoff (23 Jul 2008)|Adverse Event|44
6002251|NCT00056160|9596441|FG001|Extended Follow-up Cutoff (23 Jul 2008)|Adverse Event|0
6002252|NCT00056160|9596440|FG000|Extended Follow-up Cutoff (23 Jul 2008)|Progression of disease|87
6002253|NCT00056160|9596441|FG001|Extended Follow-up Cutoff (23 Jul 2008)|Progression of disease|0
6002254|NCT00056160|9596440|FG000|Extended Follow-up Cutoff (23 Jul 2008)|Lack of Efficacy|3
6002255|NCT00056160|9596441|FG001|Extended Follow-up Cutoff (23 Jul 2008)|Lack of Efficacy|0
6002256|NCT00056160|9596440|FG000|Extended Follow-up Cutoff (23 Jul 2008)|Withdrawal by Subject|11
6002257|NCT00056160|9596441|FG001|Extended Follow-up Cutoff (23 Jul 2008)|Withdrawal by Subject|0
6002258|NCT00056160|9596440|FG000|Extended Follow-up Cutoff (23 Jul 2008)|Death|5
6002259|NCT00056160|9596441|FG001|Extended Follow-up Cutoff (23 Jul 2008)|Death|0
6002260|NCT00056160|9596440|FG000|Extended Follow-up Cutoff (23 Jul 2008)|Other|21
6002261|NCT00056160|9596441|FG001|Extended Follow-up Cutoff (23 Jul 2008)|Other|0
6002262|NCT00056160|9596440|FG000|Final Follow-up|Transferred into expanded access study.|3
6002263|NCT00056160|9596441|FG001|Final Follow-up|Transferred into expanded access study.|0
6002264|NCT00056160|9596440|FG000|Final Follow-up|Transferred into RevAssist Program|2
6002265|NCT00056160|9596441|FG001|Final Follow-up|Transferred into RevAssist Program|0
6002266|NCT00056160|9596440|FG000|Final Follow-up|Adverse Event|1
6002267|NCT00056160|9596441|FG001|Final Follow-up|Adverse Event|0
6002268|NCT00056316|9596449|FG000|Overall Study|Withdrawal by Subject|2
6002269|NCT00056316|9596450|FG001|Overall Study|Withdrawal by Subject|2
6002270|NCT00056316|9596449|FG000|Overall Study|Death/NH placement of pt|1
6002271|NCT00056316|9596450|FG001|Overall Study|Death/NH placement of pt|1
6002272|NCT00056407|9596458|FG000|Overall Study|Adverse Event|282
6002273|NCT00056407|9596459|FG001|Overall Study|Adverse Event|364
6002274|NCT00056407|9596458|FG000|Overall Study|Withdrawal by Subject|377
6002275|NCT00056407|9596459|FG001|Overall Study|Withdrawal by Subject|361
6002276|NCT00056407|9596458|FG000|Overall Study|Lost to Follow-up|123
6002277|NCT00056407|9596459|FG001|Overall Study|Lost to Follow-up|113
6002278|NCT00056407|9596458|FG000|Overall Study|Protocol Violation|104
6002279|NCT00056407|9596459|FG001|Overall Study|Protocol Violation|95
6002280|NCT00056407|9596458|FG000|Overall Study|Diagnosed with Prostate Cancer|202
6002281|NCT00056407|9596459|FG001|Overall Study|Diagnosed with Prostate Cancer|166
6002282|NCT00056407|9596458|FG000|Overall Study|"Listed as Other on Case Report Form"|98
6002283|NCT00056407|9596459|FG001|Overall Study|"Listed as Other on Case Report Form"|60
6002284|NCT00056407|9596458|FG000|Overall Study|Missing|25
6002285|NCT00056407|9596459|FG001|Overall Study|Missing|34
6002286|NCT00056862|9596499|FG000|Overall Study|Protocol Violation|1
6002287|NCT00056862|9596500|FG001|Overall Study|Protocol Violation|0
6002288|NCT00057330|9596508|FG000|Overall Study|Adverse Event|9
6002289|NCT00057330|9596509|FG001|Overall Study|Adverse Event|12
6002290|NCT00057330|9596508|FG000|Overall Study|Death|1
6002291|NCT00057330|9596509|FG001|Overall Study|Death|0
6002292|NCT00057330|9596508|FG000|Overall Study|Protocol Violation|1
6002293|NCT00057330|9596509|FG001|Overall Study|Protocol Violation|1
6002294|NCT00057330|9596508|FG000|Overall Study|Withdrawal by Subject|115
6002295|NCT00057330|9596509|FG001|Overall Study|Withdrawal by Subject|84
6002296|NCT00057330|9596508|FG000|Overall Study|Lost to Follow-up|745
6002297|NCT00057330|9596509|FG001|Overall Study|Lost to Follow-up|617
6002298|NCT00057330|9596508|FG000|Overall Study|Physician Decision|1
6002299|NCT00057330|9596509|FG001|Overall Study|Physician Decision|0
6002300|NCT00057330|9596508|FG000|Overall Study|Other|260
6002301|NCT00057330|9596509|FG001|Overall Study|Other|206
6002302|NCT00057746|9596558|FG000|Overall Study|Withdrawal by Subject|0
6002303|NCT00057746|9596559|FG001|Overall Study|Withdrawal by Subject|0
6002304|NCT00057746|9596560|FG002|Overall Study|Withdrawal by Subject|1
6002305|NCT00057811|9596574|FG000|Overall Study|Lack of Efficacy|1
6002306|NCT00057811|9596575|FG001|Overall Study|Lack of Efficacy|4
6002307|NCT00057811|9596574|FG000|Overall Study|Physician Decision|1
6002308|NCT00057811|9596575|FG001|Overall Study|Physician Decision|0
6002309|NCT00057811|9596574|FG000|Overall Study|Withdrawal by Subject|3
6002310|NCT00057811|9596575|FG001|Overall Study|Withdrawal by Subject|4
6002311|NCT00057811|9596574|FG000|Overall Study|Ineligible|4
6002312|NCT00057811|9596575|FG001|Overall Study|Ineligible|2
6002313|NCT00057811|9596574|FG000|Overall Study|Inevaluable|1
6002314|NCT00057811|9596575|FG001|Overall Study|Inevaluable|2
6002315|NCT00057837|9596583|FG000|Overall Study|Progression/relapse|12
6002316|NCT00057837|9596584|FG001|Overall Study|Progression/relapse|14
6002317|NCT00057837|9596583|FG000|Overall Study|Adverse Event|2
6002318|NCT00057837|9596584|FG001|Overall Study|Adverse Event|12
6002319|NCT00057837|9596583|FG000|Overall Study|Death|5
6002320|NCT00057837|9596584|FG001|Overall Study|Death|4
6002321|NCT00057837|9596583|FG000|Overall Study|Withdrawal by Subject|5
6002322|NCT00057837|9596584|FG001|Overall Study|Withdrawal by Subject|3
6002323|NCT00057837|9596583|FG000|Overall Study|Alternative therapy|0
6002324|NCT00057837|9596584|FG001|Overall Study|Alternative therapy|1
6002325|NCT00057837|9596583|FG000|Overall Study|Other complicating disease|2
6002326|NCT00057837|9596584|FG001|Overall Study|Other complicating disease|1
6002327|NCT00057837|9596583|FG000|Overall Study|Physician Decision|1
6002328|NCT00057837|9596584|FG001|Overall Study|Physician Decision|0
6002329|NCT00057837|9596583|FG000|Overall Study|Ineligible|3
6002330|NCT00057837|9596584|FG001|Overall Study|Ineligible|3
6002331|NCT00057837|9596583|FG000|Overall Study|Never started treatment|1
6002332|NCT00057837|9596584|FG001|Overall Study|Never started treatment|1
6002333|NCT00057863|9596590|FG000|Overall Study|Death|1
6002334|NCT00057863|9596590|FG000|Overall Study|Withdrawal by Subject|2
6002335|NCT00057876|9596596|FG000|Overall Study|Adverse Event|8
6002336|NCT00057876|9596597|FG001|Overall Study|Adverse Event|8
6002337|NCT00057876|9596596|FG000|Overall Study|Death|2
6002338|NCT00057876|9596597|FG001|Overall Study|Death|1
6002339|NCT00057876|9596596|FG000|Overall Study|Withdrawal by Subject|5
6002340|NCT00057876|9596597|FG001|Overall Study|Withdrawal by Subject|6
6002341|NCT00057876|9596596|FG000|Overall Study|Lack of Efficacy|10
6002342|NCT00057876|9596597|FG001|Overall Study|Lack of Efficacy|8
6002343|NCT00057876|9596596|FG000|Overall Study|Ineligible|1
6002344|NCT00057876|9596597|FG001|Overall Study|Ineligible|2
6002345|NCT00057876|9596596|FG000|Overall Study|other reason|2
6002346|NCT00057876|9596597|FG001|Overall Study|other reason|2
6002347|NCT00057876|9596596|FG000|Overall Study|other complicating disease|1
6002348|NCT00057876|9596597|FG001|Overall Study|other complicating disease|0
6002349|NCT00057941|9596605|FG000|Overall Study|Death|1
6002350|NCT00057941|9596606|FG001|Overall Study|Death|2
6002351|NCT00057941|9596605|FG000|Overall Study|Adverse Event|7
6002352|NCT00057941|9596606|FG001|Overall Study|Adverse Event|9
6002353|NCT00057941|9596605|FG000|Overall Study|Lack of Efficacy|54
6002354|NCT00057941|9596606|FG001|Overall Study|Lack of Efficacy|53
6002355|NCT00057941|9596605|FG000|Overall Study|Withdrawal by Subject|6
6002356|NCT00057941|9596606|FG001|Overall Study|Withdrawal by Subject|1
6002357|NCT00057941|9596605|FG000|Overall Study|still on treatment|3
6002358|NCT00057941|9596606|FG001|Overall Study|still on treatment|1
6002359|NCT00057941|9596605|FG000|Overall Study|insurance, symptomatic deterioration|1
6002360|NCT00057941|9596606|FG001|Overall Study|insurance, symptomatic deterioration|3
6002361|NCT00057941|9596605|FG000|Overall Study|Ineligible|2
6002362|NCT00057941|9596606|FG001|Overall Study|Ineligible|5
6002363|NCT00057954|9596612|FG000|Overall Study|Death|1
6002364|NCT00057954|9596612|FG000|Overall Study|Disease progression|1
6002365|NCT00058058|9596624|FG000|Overall Study|Withdrawal by Subject|4
6002366|NCT00058058|9596624|FG000|Overall Study|Ineligible|20
6002367|NCT00058058|9596624|FG000|Overall Study|Claustrophobic|5
6073318|NCT00567164|9676796|FG000|Overall Study|Lost to Follow-up|202
6002368|NCT00058058|9596624|FG000|Overall Study|technical issues|6
6002369|NCT00058058|9596624|FG000|Overall Study|Poor positioning, illness,pain|3
6002370|NCT00058123|9596629|FG000|Overall Study|Wrong histology|9
6002371|NCT00058123|9596629|FG000|Overall Study|Received >3 prior treatments|1
6002372|NCT00058214|9596634|FG000|Overall Study|Adverse Event|1
6002373|NCT00058422|9596659|FG000|Overall Study|Not treated|2
6002374|NCT00058539|9596663|FG000|Overall Study|Disease progression|24
6002375|NCT00058539|9596663|FG000|Overall Study|Adverse Event|3
6002376|NCT00058539|9596663|FG000|Overall Study|Withdrawal by Subject|5
6002377|NCT00058539|9596663|FG000|Overall Study|Physician Decision|9
6002378|NCT00058539|9596663|FG000|Overall Study|Death|1
6002379|NCT00058552|9596669|FG000|Overall Study|Died prior to receiving treatment|4
6002380|NCT00058552|9596670|FG001|Overall Study|Died prior to receiving treatment|2
6002381|NCT00058552|9596669|FG000|Overall Study|Disease progression|52
6002382|NCT00058552|9596670|FG001|Overall Study|Disease progression|44
6002383|NCT00058552|9596669|FG000|Overall Study|Adverse Event|4
6002384|NCT00058552|9596670|FG001|Overall Study|Adverse Event|2
6002385|NCT00058552|9596669|FG000|Overall Study|Withdrawal by Subject|3
6002386|NCT00058552|9596670|FG001|Overall Study|Withdrawal by Subject|5
6002387|NCT00058552|9596669|FG000|Overall Study|Physician Decision|2
6002388|NCT00058552|9596670|FG001|Overall Study|Physician Decision|5
6002389|NCT00058552|9596669|FG000|Overall Study|Clinical disease progression|0
6002390|NCT00058552|9596670|FG001|Overall Study|Clinical disease progression|4
6002391|NCT00058825|9596678|FG000|Overall Study|Relapse|9
6002392|NCT00058825|9596678|FG000|Overall Study|Progressive Disease|5
6002393|NCT00058825|9596678|FG000|Overall Study|Graft Failure|5
6002394|NCT00058825|9596678|FG000|Overall Study|Death|3
6002395|NCT00059202|9596686|FG000|Overall Study|Withdrawal by Subject|5
6002396|NCT00059202|9596687|FG001|Overall Study|Withdrawal by Subject|9
6002397|NCT00059202|9596686|FG000|Overall Study|Protocol Violation|1
6002398|NCT00059202|9596687|FG001|Overall Study|Protocol Violation|3
6002399|NCT00059202|9596686|FG000|Overall Study|drug toxicity|0
6002400|NCT00059202|9596687|FG001|Overall Study|drug toxicity|3
6002401|NCT00059215|9596700|FG000|Overall Study|Adverse Event|5
6002402|NCT00059215|9596701|FG001|Overall Study|Adverse Event|5
6002403|NCT00059215|9596702|FG002|Overall Study|Adverse Event|9
6002404|NCT00059215|9596703|FG003|Overall Study|Adverse Event|9
6002405|NCT00059215|9596700|FG000|Overall Study|Death|0
6002406|NCT00059215|9596701|FG001|Overall Study|Death|0
6002407|NCT00059215|9596702|FG002|Overall Study|Death|3
6002408|NCT00059215|9596703|FG003|Overall Study|Death|0
6002409|NCT00059215|9596700|FG000|Overall Study|Lost to Follow-up|1
6002410|NCT00059215|9596701|FG001|Overall Study|Lost to Follow-up|2
6002411|NCT00059215|9596702|FG002|Overall Study|Lost to Follow-up|0
6002412|NCT00059215|9596703|FG003|Overall Study|Lost to Follow-up|0
6002413|NCT00059215|9596700|FG000|Overall Study|Withdrawal by Subject|4
6002414|NCT00059215|9596701|FG001|Overall Study|Withdrawal by Subject|4
6002415|NCT00059215|9596702|FG002|Overall Study|Withdrawal by Subject|1
6002416|NCT00059215|9596703|FG003|Overall Study|Withdrawal by Subject|3
6002417|NCT00059215|9596700|FG000|Overall Study|Protocol Violation|1
6002418|NCT00059215|9596701|FG001|Overall Study|Protocol Violation|0
6002419|NCT00059215|9596702|FG002|Overall Study|Protocol Violation|1
6002420|NCT00059215|9596703|FG003|Overall Study|Protocol Violation|0
6002421|NCT00059215|9596700|FG000|Overall Study|Protocol entry criteria not met|1
6002422|NCT00059215|9596701|FG001|Overall Study|Protocol entry criteria not met|1
6002423|NCT00059215|9596702|FG002|Overall Study|Protocol entry criteria not met|0
6002424|NCT00059215|9596703|FG003|Overall Study|Protocol entry criteria not met|2
6002425|NCT00059215|9596700|FG000|Overall Study|Physician Decision|1
6002426|NCT00059215|9596701|FG001|Overall Study|Physician Decision|2
6002427|NCT00059215|9596702|FG002|Overall Study|Physician Decision|1
6002428|NCT00059215|9596703|FG003|Overall Study|Physician Decision|1
6073319|NCT00567164|9676797|FG001|Overall Study|Lost to Follow-up|23
6073320|NCT00567164|9676798|FG002|Overall Study|Lost to Follow-up|21
6073321|NCT00567164|9676796|FG000|Overall Study|Pregnancy|20
6073322|NCT00567164|9676797|FG001|Overall Study|Pregnancy|4
6073323|NCT00567164|9676798|FG002|Overall Study|Pregnancy|6
6073324|NCT00567164|9676796|FG000|Overall Study|Primary Reason coded as 'Other'|37
6073325|NCT00567164|9676797|FG001|Overall Study|Primary Reason coded as 'Other'|8
6073326|NCT00567164|9676798|FG002|Overall Study|Primary Reason coded as 'Other'|16
6073327|NCT00567164|9676796|FG000|Overall Study|Missing|1
6073328|NCT00567164|9676797|FG001|Overall Study|Missing|0
6073329|NCT00567164|9676798|FG002|Overall Study|Missing|0
6073330|NCT00567190|9676812|FG000|Overall Study|Death|235
6073331|NCT00567190|9676813|FG001|Overall Study|Death|280
6073332|NCT00567190|9676812|FG000|Overall Study|Withdrew Consent or Lost to Follow-up|48
6073333|NCT00567190|9676813|FG001|Overall Study|Withdrew Consent or Lost to Follow-up|53
6073334|NCT00567255|9676839|FG000|Overall Study|Adverse Event|241
6073335|NCT00567255|9676840|FG001|Overall Study|Adverse Event|68
6073336|NCT00567255|9676839|FG000|Overall Study|Lost to Follow-up|77
6073337|NCT00567255|9676840|FG001|Overall Study|Lost to Follow-up|48
6073338|NCT00567255|9676839|FG000|Overall Study|Withdrawal by Subject|75
6073339|NCT00567255|9676840|FG001|Overall Study|Withdrawal by Subject|56
6073340|NCT00567255|9676839|FG000|Overall Study|Lack of Efficacy|19
6002429|NCT00059332|9596725|FG000|Overall Study|Withdrawal by Subject|2
6002430|NCT00059332|9596726|FG001|Overall Study|Withdrawal by Subject|1
6002431|NCT00059332|9596725|FG000|Overall Study|Lost to Follow-up|1
6002432|NCT00059332|9596726|FG001|Overall Study|Lost to Follow-up|1
6047269|NCT00410410|9646257|FG008|Induction Period (IP)|Administrative Reason By Sponsor|0
6047270|NCT00410410|9646249|FG000|Induction Period (IP)|Other|0
6047271|NCT00410410|9646250|FG001|Induction Period (IP)|Other|0
6047272|NCT00410410|9646251|FG002|Induction Period (IP)|Other|1
6073341|NCT00567255|9676840|FG001|Overall Study|Lack of Efficacy|33
6073342|NCT00567255|9676839|FG000|Overall Study|Protocol Violation|20
6073343|NCT00567255|9676840|FG001|Overall Study|Protocol Violation|8
6073344|NCT00567255|9676839|FG000|Overall Study|Pregnancy|6
6073345|NCT00567255|9676840|FG001|Overall Study|Pregnancy|0
6073346|NCT00567255|9676839|FG000|Overall Study|Drug noncompliance,moved,other|25
6002433|NCT00059787|9596772|FG000|Overall Study|Adverse Event|13
6002434|NCT00059787|9596772|FG000|Overall Study|disease progression|2
6002435|NCT00059787|9596772|FG000|Overall Study|ineligible|1
6002436|NCT00059787|9596772|FG000|Overall Study|Other|4
6002437|NCT00059839|9596779|FG000|Overall Study|Death|1
6002438|NCT00059839|9596780|FG001|Overall Study|Death|1
6002439|NCT00059839|9596779|FG000|Overall Study|Lack of Efficacy|6
6002440|NCT00059839|9596780|FG001|Overall Study|Lack of Efficacy|5
6002441|NCT00059839|9596779|FG000|Overall Study|Lost to Follow-up|2
6002442|NCT00059839|9596780|FG001|Overall Study|Lost to Follow-up|0
6002443|NCT00059839|9596779|FG000|Overall Study|Physician Decision|1
6002444|NCT00059839|9596780|FG001|Overall Study|Physician Decision|2
6002445|NCT00059839|9596779|FG000|Overall Study|Withdrawal by Subject|1
6002446|NCT00059839|9596780|FG001|Overall Study|Withdrawal by Subject|6
6002447|NCT00059839|9596779|FG000|Overall Study|Ineligible|1
6002448|NCT00059839|9596780|FG001|Overall Study|Ineligible|3
6002449|NCT00060840|9596833|FG000|Overall Study|Change in surgical plan|2
6002450|NCT00060840|9596834|FG001|Overall Study|Change in surgical plan|6
6002451|NCT00060840|9596833|FG000|Overall Study|Death|0
6002452|NCT00060840|9596834|FG001|Overall Study|Death|1
6002453|NCT00060840|9596833|FG000|Overall Study|Withdrawal by Subject|0
6002454|NCT00060840|9596834|FG001|Overall Study|Withdrawal by Subject|1
6002455|NCT00060840|9596833|FG000|Overall Study|Subinvestigator unavailable|0
6002456|NCT00060840|9596834|FG001|Overall Study|Subinvestigator unavailable|1
6002457|NCT00060840|9596833|FG000|Overall Study|Physician Decision|1
6002458|NCT00060840|9596834|FG001|Overall Study|Physician Decision|0
6002459|NCT00060840|9596833|FG000|Overall Study|Other|1
6002460|NCT00060840|9596834|FG001|Overall Study|Other|0
6002461|NCT00060944|9596842|FG000|Overall Study|Adverse Event|12
6002462|NCT00060944|9596843|FG001|Overall Study|Adverse Event|10
6002463|NCT00060944|9596842|FG000|Overall Study|Death|2
6002464|NCT00060944|9596843|FG001|Overall Study|Death|3
6002465|NCT00060944|9596842|FG000|Overall Study|Withdrawal by Subject|18
6002466|NCT00060944|9596843|FG001|Overall Study|Withdrawal by Subject|5
6002467|NCT00060944|9596842|FG000|Overall Study|Disease Progression|93
6002468|NCT00060944|9596843|FG001|Overall Study|Disease Progression|94
6002469|NCT00060944|9596842|FG000|Overall Study|Lost to Follow-up|1
6002470|NCT00060944|9596843|FG001|Overall Study|Lost to Follow-up|0
6002471|NCT00060944|9596842|FG000|Overall Study|Subject Ineligible To Continue|2
6002472|NCT00060944|9596843|FG001|Overall Study|Subject Ineligible To Continue|1
6002473|NCT00060944|9596842|FG000|Overall Study|Treatment Switch|0
6002474|NCT00060944|9596843|FG001|Overall Study|Treatment Switch|13
6002475|NCT00060944|9596842|FG000|Overall Study|Other|2
6002476|NCT00060944|9596843|FG001|Overall Study|Other|4
6002477|NCT00060944|9596842|FG000|Overall Study|randomized but not treated|6
6002478|NCT00060944|9596843|FG001|Overall Study|randomized but not treated|4
6002479|NCT00061048|9596849|FG000|Overall Study|Adverse Event|2
6002480|NCT00061048|9596849|FG000|Overall Study|disease progression|20
6002481|NCT00061633|9596864|FG000|Overall Study|Adverse Event|1
6002482|NCT00061633|9596865|FG001|Overall Study|Adverse Event|2
6002483|NCT00061633|9596864|FG000|Overall Study|Withdrawal by Subject|2
6002484|NCT00061633|9596865|FG001|Overall Study|Withdrawal by Subject|2
6002485|NCT00061633|9596864|FG000|Overall Study|Lost to Follow-up|1
6002486|NCT00061633|9596865|FG001|Overall Study|Lost to Follow-up|4
6002487|NCT00061633|9596864|FG000|Overall Study|Other|1
6002488|NCT00061633|9596865|FG001|Overall Study|Other|1
6002489|NCT00061633|9596864|FG000|Overall Study|Never received study treatment|0
6002490|NCT00061633|9596865|FG001|Overall Study|Never received study treatment|2
6002491|NCT00061932|9596877|FG000|Overall Study|Withdrawal by Subject|13
6002492|NCT00061932|9596878|FG001|Overall Study|Withdrawal by Subject|4
6002493|NCT00062010|9596885|FG000|Overall Study|Ineligible|3
6002494|NCT00062166|9596889|FG000|Overall Study|Withdrawal by Subject|6
6002495|NCT00062374|9596894|FG000|Overall Study|Not treated|12
6002496|NCT00062439|9596898|FG000|Induction Chemotherapy + Radiotherapy|Ineligible|1
6002497|NCT00062439|9596898|FG000|Induction Chemotherapy + Radiotherapy|Refused protocol treatment|1
6002498|NCT00062439|9596898|FG000|Induction Chemotherapy + Radiotherapy|Adverse Event|3
6002499|NCT00062439|9596898|FG000|Induction Chemotherapy + Radiotherapy|Lack of Efficacy|3
6002500|NCT00062439|9596898|FG000|Post Chemoradiation Assessment|Death|1
6002501|NCT00062439|9596898|FG000|Post Chemoradiation Assessment|Disease progression|2
6002502|NCT00062439|9596898|FG000|Post Chemoradiation Assessment|Withdrawal by Subject|1
6002503|NCT00062439|9596898|FG000|Post Chemoradiation Assessment|Physician Decision|1
6002504|NCT00062439|9596898|FG000|Post Chemoradiation Assessment|Not eligible to continue to surgery|4
6002505|NCT00062439|9596898|FG000|Surgery|Physician Decision|4
6002506|NCT00062439|9596898|FG000|Surgery|Death|1
6002507|NCT00062439|9596898|FG000|Surgery|Adverse Event|2
6002508|NCT00062439|9596898|FG000|Consolidation Chemotherapy|Adverse Event|2
6002509|NCT00062647|9596909|FG000|Overall Study|Death|2
6002510|NCT00062647|9596910|FG001|Overall Study|Death|2
6002511|NCT00062647|9596909|FG000|Overall Study|Adverse Event|1
6002512|NCT00062647|9596910|FG001|Overall Study|Adverse Event|1
6002513|NCT00062647|9596909|FG000|Overall Study|Withdrawal by Subject|2
6002514|NCT00062647|9596910|FG001|Overall Study|Withdrawal by Subject|1
6002515|NCT00062647|9596909|FG000|Overall Study|Protocol Violation|1
6002516|NCT00062647|9596910|FG001|Overall Study|Protocol Violation|0
6002517|NCT00062647|9596909|FG000|Overall Study|Lost to Follow-up|1
6073347|NCT00567255|9676840|FG001|Overall Study|Drug noncompliance,moved,other|15
6073348|NCT00567268|9676846|FG000|Overall Study|Protocol Violation|7
6073349|NCT00567268|9676846|FG000|Overall Study|Lost to Follow-up|36
6002518|NCT00062647|9596910|FG001|Overall Study|Lost to Follow-up|2
6002519|NCT00062647|9596909|FG000|Overall Study|Failed continuation criteria|4
6002520|NCT00062647|9596910|FG001|Overall Study|Failed continuation criteria|2
6002521|NCT00062647|9596909|FG000|Overall Study|Other|4
6002522|NCT00062647|9596910|FG001|Overall Study|Other|4
6002523|NCT00062647|9596909|FG000|Overall Study|Never received study treatment|1
6002524|NCT00062647|9596910|FG001|Overall Study|Never received study treatment|1
6002525|NCT00062868|9596957|FG000|Dose Level 1|Death|2
6002526|NCT00062868|9596958|FG001|Dose Level 1|Death|0
6002527|NCT00062868|9596959|FG002|Dose Level 1|Death|0
6002528|NCT00062868|9596960|FG003|Dose Level 1|Death|2
6002529|NCT00062868|9596961|FG004|Dose Level 1|Death|0
6002530|NCT00062868|9596962|FG005|Dose Level 1|Death|0
6002531|NCT00062868|9596963|FG006|Dose Level 1|Death|3
6002532|NCT00062868|9596964|FG007|Dose Level 1|Death|0
6002533|NCT00062868|9596965|FG008|Dose Level 1|Death|0
6002534|NCT00062868|9596966|FG009|Dose Level 1|Death|0
6002535|NCT00062868|9596967|FG010|Dose Level 1|Death|0
6002536|NCT00062868|9596968|FG011|Dose Level 1|Death|0
6002537|NCT00062868|9596969|FG012|Dose Level 1|Death|0
6002538|NCT00062868|9596970|FG013|Dose Level 1|Death|0
6002539|NCT00062868|9596971|FG014|Dose Level 1|Death|0
6002540|NCT00062868|9596972|FG015|Dose Level 1|Death|0
6002541|NCT00062868|9596973|FG016|Dose Level 1|Death|0
6002542|NCT00062868|9596974|FG017|Dose Level 1|Death|0
6002543|NCT00062868|9596975|FG018|Dose Level 1|Death|7
6002544|NCT00062868|9596976|FG019|Dose Level 1|Death|0
6002545|NCT00062868|9596977|FG020|Dose Level 1|Death|1
6002546|NCT00062868|9596957|FG000|Dose Level 1|Lost to Follow-up|0
6002547|NCT00062868|9596958|FG001|Dose Level 1|Lost to Follow-up|0
6002548|NCT00062868|9596959|FG002|Dose Level 1|Lost to Follow-up|0
6002549|NCT00062868|9596960|FG003|Dose Level 1|Lost to Follow-up|0
6002550|NCT00062868|9596961|FG004|Dose Level 1|Lost to Follow-up|0
6002551|NCT00062868|9596962|FG005|Dose Level 1|Lost to Follow-up|0
6002552|NCT00062868|9596963|FG006|Dose Level 1|Lost to Follow-up|0
6002553|NCT00062868|9596964|FG007|Dose Level 1|Lost to Follow-up|0
6002554|NCT00062868|9596965|FG008|Dose Level 1|Lost to Follow-up|0
6002555|NCT00062868|9596966|FG009|Dose Level 1|Lost to Follow-up|0
6002556|NCT00062868|9596967|FG010|Dose Level 1|Lost to Follow-up|0
6002557|NCT00062868|9596968|FG011|Dose Level 1|Lost to Follow-up|0
6002558|NCT00062868|9596969|FG012|Dose Level 1|Lost to Follow-up|1
6002559|NCT00062868|9596970|FG013|Dose Level 1|Lost to Follow-up|0
6002560|NCT00062868|9596971|FG014|Dose Level 1|Lost to Follow-up|0
6002561|NCT00062868|9596972|FG015|Dose Level 1|Lost to Follow-up|0
6002562|NCT00062868|9596973|FG016|Dose Level 1|Lost to Follow-up|0
6002563|NCT00062868|9596974|FG017|Dose Level 1|Lost to Follow-up|0
6002564|NCT00062868|9596975|FG018|Dose Level 1|Lost to Follow-up|2
6002565|NCT00062868|9596976|FG019|Dose Level 1|Lost to Follow-up|0
6002566|NCT00062868|9596977|FG020|Dose Level 1|Lost to Follow-up|1
6002567|NCT00062868|9596957|FG000|Dose Level 2|Death|0
6002568|NCT00062868|9596958|FG001|Dose Level 2|Death|3
6073350|NCT00567268|9676846|FG000|Overall Study|No Visit After First Day of Treatment|2
6073351|NCT00567268|9676846|FG000|Overall Study|No Drug Administration|4
6073352|NCT00567268|9676846|FG000|Overall Study|"Safety Evaluation Not Assessable"|1
6073353|NCT00567359|9676903|FG000|Overall Study|Withdrawal by Subject|1
6073354|NCT00567398|9676909|FG000|Overall Study|Adverse Event|6
6073355|NCT00567398|9676910|FG001|Overall Study|Adverse Event|14
6073356|NCT00567398|9676909|FG000|Overall Study|Physician Decision|0
6073357|NCT00567398|9676910|FG001|Overall Study|Physician Decision|4
6073358|NCT00567398|9676909|FG000|Overall Study|Withdrawal by Subject|0
6073359|NCT00567398|9676910|FG001|Overall Study|Withdrawal by Subject|2
6073360|NCT00567398|9676909|FG000|Overall Study|Renal Transplantation|0
6002569|NCT00062868|9596959|FG002|Dose Level 2|Death|0
6002570|NCT00062868|9596960|FG003|Dose Level 2|Death|0
6002571|NCT00062868|9596961|FG004|Dose Level 2|Death|2
6002572|NCT00062868|9596962|FG005|Dose Level 2|Death|0
6002573|NCT00062868|9596963|FG006|Dose Level 2|Death|0
6002574|NCT00062868|9596964|FG007|Dose Level 2|Death|0
6002575|NCT00062868|9596965|FG008|Dose Level 2|Death|0
6002576|NCT00062868|9596966|FG009|Dose Level 2|Death|0
6002577|NCT00062868|9596967|FG010|Dose Level 2|Death|1
6002578|NCT00062868|9596968|FG011|Dose Level 2|Death|0
6073361|NCT00567398|9676910|FG001|Overall Study|Renal Transplantation|3
6073362|NCT00567398|9676909|FG000|Overall Study|Other|1
6073363|NCT00567398|9676910|FG001|Overall Study|Other|0
6073364|NCT00567476|9676918|FG000|Overall Study|Adverse Event|2
6002579|NCT00062868|9596969|FG012|Dose Level 2|Death|0
6002580|NCT00062868|9596970|FG013|Dose Level 2|Death|0
6002581|NCT00062868|9596971|FG014|Dose Level 2|Death|0
6002582|NCT00062868|9596972|FG015|Dose Level 2|Death|0
6002583|NCT00062868|9596973|FG016|Dose Level 2|Death|2
6002584|NCT00062868|9596974|FG017|Dose Level 2|Death|0
6002585|NCT00062868|9596975|FG018|Dose Level 2|Death|0
6002586|NCT00062868|9596976|FG019|Dose Level 2|Death|0
6002587|NCT00062868|9596977|FG020|Dose Level 2|Death|0
6002588|NCT00062868|9596957|FG000|Dose Level 2|Lost to Follow-up|0
6002589|NCT00062868|9596958|FG001|Dose Level 2|Lost to Follow-up|0
6002590|NCT00062868|9596959|FG002|Dose Level 2|Lost to Follow-up|0
6002591|NCT00062868|9596960|FG003|Dose Level 2|Lost to Follow-up|0
6002592|NCT00062868|9596961|FG004|Dose Level 2|Lost to Follow-up|0
6002593|NCT00062868|9596962|FG005|Dose Level 2|Lost to Follow-up|0
6002594|NCT00062868|9596963|FG006|Dose Level 2|Lost to Follow-up|0
6002595|NCT00062868|9596964|FG007|Dose Level 2|Lost to Follow-up|0
6002596|NCT00062868|9596965|FG008|Dose Level 2|Lost to Follow-up|0
6002597|NCT00062868|9596966|FG009|Dose Level 2|Lost to Follow-up|0
6002598|NCT00062868|9596967|FG010|Dose Level 2|Lost to Follow-up|0
6002599|NCT00062868|9596968|FG011|Dose Level 2|Lost to Follow-up|0
6002600|NCT00062868|9596969|FG012|Dose Level 2|Lost to Follow-up|0
6002601|NCT00062868|9596970|FG013|Dose Level 2|Lost to Follow-up|1
6002602|NCT00062868|9596971|FG014|Dose Level 2|Lost to Follow-up|0
6002603|NCT00062868|9596972|FG015|Dose Level 2|Lost to Follow-up|0
6002604|NCT00062868|9596973|FG016|Dose Level 2|Lost to Follow-up|1
6002605|NCT00062868|9596974|FG017|Dose Level 2|Lost to Follow-up|0
6002606|NCT00062868|9596975|FG018|Dose Level 2|Lost to Follow-up|0
6002607|NCT00062868|9596976|FG019|Dose Level 2|Lost to Follow-up|0
6002608|NCT00062868|9596977|FG020|Dose Level 2|Lost to Follow-up|0
6002609|NCT00062868|9596957|FG000|Dose Level 3|Death|0
6002610|NCT00062868|9596958|FG001|Dose Level 3|Death|0
6002611|NCT00062868|9596959|FG002|Dose Level 3|Death|0
6002612|NCT00062868|9596960|FG003|Dose Level 3|Death|0
6002613|NCT00062868|9596961|FG004|Dose Level 3|Death|0
6002614|NCT00062868|9596962|FG005|Dose Level 3|Death|0
6002615|NCT00062868|9596963|FG006|Dose Level 3|Death|0
6002616|NCT00062868|9596964|FG007|Dose Level 3|Death|0
6002617|NCT00062868|9596965|FG008|Dose Level 3|Death|0
6002618|NCT00062868|9596966|FG009|Dose Level 3|Death|0
6002619|NCT00062868|9596967|FG010|Dose Level 3|Death|0
6002620|NCT00062868|9596968|FG011|Dose Level 3|Death|1
6002621|NCT00062868|9596969|FG012|Dose Level 3|Death|0
6002622|NCT00062868|9596970|FG013|Dose Level 3|Death|0
6002623|NCT00062868|9596971|FG014|Dose Level 3|Death|0
6002624|NCT00062868|9596972|FG015|Dose Level 3|Death|0
6002625|NCT00062868|9596973|FG016|Dose Level 3|Death|0
6002626|NCT00062868|9596974|FG017|Dose Level 3|Death|1
6002627|NCT00062868|9596975|FG018|Dose Level 3|Death|0
6002628|NCT00062868|9596976|FG019|Dose Level 3|Death|0
6002629|NCT00062868|9596977|FG020|Dose Level 3|Death|0
6002630|NCT00062868|9596957|FG000|Dose Level 3|Lost to Follow-up|0
6002631|NCT00062868|9596958|FG001|Dose Level 3|Lost to Follow-up|0
6002632|NCT00062868|9596959|FG002|Dose Level 3|Lost to Follow-up|0
6002633|NCT00062868|9596960|FG003|Dose Level 3|Lost to Follow-up|0
6002634|NCT00062868|9596961|FG004|Dose Level 3|Lost to Follow-up|0
6002635|NCT00062868|9596962|FG005|Dose Level 3|Lost to Follow-up|0
6002636|NCT00062868|9596963|FG006|Dose Level 3|Lost to Follow-up|0
6002637|NCT00062868|9596964|FG007|Dose Level 3|Lost to Follow-up|0
6002638|NCT00062868|9596965|FG008|Dose Level 3|Lost to Follow-up|0
6002639|NCT00062868|9596966|FG009|Dose Level 3|Lost to Follow-up|0
6002640|NCT00062868|9596967|FG010|Dose Level 3|Lost to Follow-up|0
6002641|NCT00062868|9596968|FG011|Dose Level 3|Lost to Follow-up|0
6002642|NCT00062868|9596969|FG012|Dose Level 3|Lost to Follow-up|0
6002643|NCT00062868|9596970|FG013|Dose Level 3|Lost to Follow-up|0
6002644|NCT00062868|9596971|FG014|Dose Level 3|Lost to Follow-up|1
6002645|NCT00062868|9596972|FG015|Dose Level 3|Lost to Follow-up|0
6002646|NCT00062868|9596973|FG016|Dose Level 3|Lost to Follow-up|0
6002647|NCT00062868|9596974|FG017|Dose Level 3|Lost to Follow-up|0
6002648|NCT00062868|9596975|FG018|Dose Level 3|Lost to Follow-up|0
6002649|NCT00062868|9596976|FG019|Dose Level 3|Lost to Follow-up|0
6002650|NCT00062868|9596977|FG020|Dose Level 3|Lost to Follow-up|0
6002651|NCT00062868|9596957|FG000|Dose Level 3|Withdrew|0
6002652|NCT00062868|9596958|FG001|Dose Level 3|Withdrew|0
6002653|NCT00062868|9596959|FG002|Dose Level 3|Withdrew|2
6002654|NCT00062868|9596960|FG003|Dose Level 3|Withdrew|0
6002655|NCT00062868|9596961|FG004|Dose Level 3|Withdrew|0
6002656|NCT00062868|9596962|FG005|Dose Level 3|Withdrew|0
6002657|NCT00062868|9596963|FG006|Dose Level 3|Withdrew|0
6002658|NCT00062868|9596964|FG007|Dose Level 3|Withdrew|0
6002659|NCT00062868|9596965|FG008|Dose Level 3|Withdrew|0
6002660|NCT00062868|9596966|FG009|Dose Level 3|Withdrew|0
6002661|NCT00062868|9596967|FG010|Dose Level 3|Withdrew|0
6002662|NCT00062868|9596968|FG011|Dose Level 3|Withdrew|0
6002663|NCT00062868|9596969|FG012|Dose Level 3|Withdrew|0
6002664|NCT00062868|9596970|FG013|Dose Level 3|Withdrew|0
6002665|NCT00062868|9596971|FG014|Dose Level 3|Withdrew|0
6002666|NCT00062868|9596972|FG015|Dose Level 3|Withdrew|0
6002667|NCT00062868|9596973|FG016|Dose Level 3|Withdrew|0
6002668|NCT00062868|9596974|FG017|Dose Level 3|Withdrew|0
6002669|NCT00062868|9596975|FG018|Dose Level 3|Withdrew|0
6002670|NCT00062868|9596976|FG019|Dose Level 3|Withdrew|0
6002671|NCT00062868|9596977|FG020|Dose Level 3|Withdrew|0
6002672|NCT00063154|9597021|FG000|Overall Study|Disease progression|27
6002673|NCT00063154|9597021|FG000|Overall Study|Adverse Event|2
6002674|NCT00063154|9597021|FG000|Overall Study|Physician Decision|10
6002675|NCT00063154|9597021|FG000|Overall Study|Death|3
6002676|NCT00063154|9597021|FG000|Overall Study|Reason unspecified|1
6002677|NCT00063154|9597021|FG000|Overall Study|Did not receive treatment|8
6002678|NCT00063258|9597031|FG000|Overall Study|Physician Decision|2
6002679|NCT00063258|9597032|FG001|Overall Study|Physician Decision|0
6002680|NCT00063258|9597031|FG000|Overall Study|Lack of Efficacy|2
6002681|NCT00063258|9597032|FG001|Overall Study|Lack of Efficacy|0
6002682|NCT00063882|9597084|FG000|Overall Study|Protocol Violation|3
6002683|NCT00063882|9597085|FG001|Overall Study|Protocol Violation|3
6002684|NCT00063882|9597084|FG000|Overall Study|Withdrawal by Subject|2
6002685|NCT00063882|9597085|FG001|Overall Study|Withdrawal by Subject|1
6002686|NCT00063934|9597091|FG000|Overall Study|Ineligible|1
6002687|NCT00063986|9597095|FG000|Overall Study|Withdrawal by Subject|1
6002688|NCT00063986|9597095|FG000|Overall Study|Ineligible|1
6002689|NCT00063986|9597095|FG000|Overall Study|Intra-operatively ineligible|4
6002690|NCT00063999|9597101|FG000|Overall Study|Withdrawal by Subject|1
6002691|NCT00063999|9597102|FG001|Overall Study|Withdrawal by Subject|0
6002692|NCT00063999|9597101|FG000|Overall Study|Ineligible|44
6002693|NCT00063999|9597102|FG001|Overall Study|Ineligible|24
6002694|NCT00064025|9597115|FG000|Overall Study|Ineligible|4
6002695|NCT00064025|9597115|FG000|Overall Study|Inevaluable|3
6002696|NCT00064077|9597138|FG000|Overall Study|Improper prior treatment|1
6002697|NCT00064077|9597139|FG001|Overall Study|Improper prior treatment|0
6002698|NCT00064077|9597140|FG002|Overall Study|Improper prior treatment|0
6002699|NCT00064077|9597141|FG003|Overall Study|Improper prior treatment|0
6002700|NCT00064077|9597138|FG000|Overall Study|Poor risk|2
6002701|NCT00064077|9597139|FG001|Overall Study|Poor risk|0
6073365|NCT00567476|9676919|FG001|Overall Study|Adverse Event|0
6073366|NCT00567476|9676918|FG000|Overall Study|Pregnancy|1
6073367|NCT00567476|9676919|FG001|Overall Study|Pregnancy|0
6073368|NCT00567476|9676918|FG000|Overall Study|Protocol Violation|4
6002702|NCT00064077|9597140|FG002|Overall Study|Poor risk|1
6002703|NCT00064077|9597141|FG003|Overall Study|Poor risk|1
6002704|NCT00064077|9597138|FG000|Overall Study|Pathology|10
6002705|NCT00064077|9597139|FG001|Overall Study|Pathology|7
6002706|NCT00064077|9597140|FG002|Overall Study|Pathology|3
6002707|NCT00064077|9597141|FG003|Overall Study|Pathology|4
6002708|NCT00064077|9597138|FG000|Overall Study|No surgery|0
6002709|NCT00064077|9597139|FG001|Overall Study|No surgery|0
6002710|NCT00064077|9597140|FG002|Overall Study|No surgery|1
6002711|NCT00064077|9597141|FG003|Overall Study|No surgery|0
6002712|NCT00064077|9597138|FG000|Overall Study|No tumor|0
6002713|NCT00064077|9597139|FG001|Overall Study|No tumor|0
6002714|NCT00064077|9597140|FG002|Overall Study|No tumor|1
6002715|NCT00064077|9597141|FG003|Overall Study|No tumor|0
6002716|NCT00064077|9597138|FG000|Overall Study|Other reasons|2
6002717|NCT00064077|9597139|FG001|Overall Study|Other reasons|2
6002718|NCT00064077|9597140|FG002|Overall Study|Other reasons|1
6002719|NCT00064077|9597141|FG003|Overall Study|Other reasons|2
6002720|NCT00064259|9597151|FG000|Overall Study|Adverse Event|1
6002721|NCT00064259|9597152|FG001|Overall Study|Adverse Event|0
6002722|NCT00064259|9597153|FG002|Overall Study|Adverse Event|0
6002723|NCT00064259|9597154|FG003|Overall Study|Adverse Event|1
6002724|NCT00064298|9597161|FG000|Overall Study|Withdrawal by Subject|2
6002725|NCT00064298|9597162|FG001|Overall Study|Withdrawal by Subject|1
6002726|NCT00064298|9597161|FG000|Overall Study|Lost to Follow-up|2
6002727|NCT00064298|9597162|FG001|Overall Study|Lost to Follow-up|2
6002728|NCT00064298|9597161|FG000|Overall Study|Death|0
6002729|NCT00064298|9597162|FG001|Overall Study|Death|1
6002730|NCT00064298|9597161|FG000|Overall Study|Disease Progression|2
6002731|NCT00064298|9597162|FG001|Overall Study|Disease Progression|1
6002732|NCT00064337|9597168|FG000|PBSCC or Induction/PBSCC|Not protocol-specified|7
6002733|NCT00064337|9597168|FG000|PBSCC or Induction/PBSCC|Adverse Event|6
6002734|NCT00064337|9597168|FG000|PBSCC or Induction/PBSCC|Progression|3
6002735|NCT00064337|9597168|FG000|PBSCC or Induction/PBSCC|Patient Refusal|2
6002736|NCT00064337|9597168|FG000|PBSCC or Induction/PBSCC|Death|2
6002737|NCT00064337|9597168|FG000|Transplant|Adverse Event|9
6002738|NCT00064337|9597168|FG000|Transplant|Not protocol-specified|5
6002739|NCT00064337|9597168|FG000|Transplant|Death|3
6002740|NCT00064337|9597168|FG000|Transplant|Patient Refusal|2
6002741|NCT00064337|9597168|FG000|Transplant|Progression|2
6002742|NCT00064337|9597168|FG000|Maintenance|Adverse Event|3
6002743|NCT00064337|9597168|FG000|Maintenance|Progression|2
6002744|NCT00064337|9597168|FG000|Maintenance|On treatment at time of analysis|2
6002745|NCT00064337|9597168|FG000|Maintenance|Not protocol-specified|2
6002746|NCT00064337|9597168|FG000|Maintenance|Death|1
6002747|NCT00064350|9597178|FG000|Induction Treatment|Disease Progression|5
6002748|NCT00064350|9597179|FG001|Induction Treatment|Disease Progression|1
6002749|NCT00064350|9597180|FG002|Induction Treatment|Disease Progression|110
6002750|NCT00064350|9597178|FG000|Induction Treatment|Adverse Event|0
6002751|NCT00064350|9597179|FG001|Induction Treatment|Adverse Event|2
6073369|NCT00567476|9676919|FG001|Overall Study|Protocol Violation|1
6002752|NCT00064350|9597180|FG002|Induction Treatment|Adverse Event|49
6002753|NCT00064350|9597178|FG000|Induction Treatment|Death|0
6002754|NCT00064350|9597179|FG001|Induction Treatment|Death|0
6002755|NCT00064350|9597180|FG002|Induction Treatment|Death|9
6002756|NCT00064350|9597178|FG000|Induction Treatment|Withdrawal by Subject|0
6002757|NCT00064350|9597179|FG001|Induction Treatment|Withdrawal by Subject|0
6002758|NCT00064350|9597180|FG002|Induction Treatment|Withdrawal by Subject|21
6002759|NCT00064350|9597178|FG000|Induction Treatment|Ineligible or never started treatment|3
6002760|NCT00064350|9597179|FG001|Induction Treatment|Ineligible or never started treatment|6
6002761|NCT00064350|9597180|FG002|Induction Treatment|Ineligible or never started treatment|34
6002762|NCT00064350|9597178|FG000|Induction Treatment|Other|0
6002763|NCT00064350|9597179|FG001|Induction Treatment|Other|0
6002764|NCT00064350|9597180|FG002|Induction Treatment|Other|13
6073370|NCT00567476|9676918|FG000|Overall Study|Lost to Follow-up|0
6002765|NCT00064350|9597178|FG000|Randomization|Adverse Event|8
6002766|NCT00064350|9597179|FG001|Randomization|Adverse Event|3
6002767|NCT00064350|9597180|FG002|Randomization|Adverse Event|0
6002768|NCT00064350|9597178|FG000|Randomization|Death|3
6002769|NCT00064350|9597179|FG001|Randomization|Death|0
6002770|NCT00064350|9597180|FG002|Randomization|Death|0
6002771|NCT00064350|9597178|FG000|Randomization|Withdrawal by Subject|1
6002772|NCT00064350|9597179|FG001|Randomization|Withdrawal by Subject|0
6002773|NCT00064350|9597180|FG002|Randomization|Withdrawal by Subject|0
6002774|NCT00064350|9597178|FG000|Randomization|Ineligible or never started treatment|9
6002775|NCT00064350|9597179|FG001|Randomization|Ineligible or never started treatment|15
6002776|NCT00064350|9597180|FG002|Randomization|Ineligible or never started treatment|0
6002777|NCT00064350|9597178|FG000|Randomization|Other|5
6002778|NCT00064350|9597179|FG001|Randomization|Other|0
6002779|NCT00064350|9597180|FG002|Randomization|Other|0
6002780|NCT00064350|9597178|FG000|Cross-Over|Adverse Event|0
6002781|NCT00064350|9597179|FG001|Cross-Over|Adverse Event|1
6002782|NCT00064350|9597180|FG002|Cross-Over|Adverse Event|0
6002783|NCT00064350|9597178|FG000|Cross-Over|Death|1
6002784|NCT00064350|9597179|FG001|Cross-Over|Death|3
6002785|NCT00064350|9597180|FG002|Cross-Over|Death|0
6002786|NCT00064350|9597178|FG000|Cross-Over|Withdrawal by Subject|2
6002787|NCT00064350|9597179|FG001|Cross-Over|Withdrawal by Subject|2
6002788|NCT00064350|9597180|FG002|Cross-Over|Withdrawal by Subject|0
6002789|NCT00064350|9597178|FG000|Cross-Over|Ineligible or never started treatment|3
6002790|NCT00064350|9597179|FG001|Cross-Over|Ineligible or never started treatment|6
6002791|NCT00064350|9597180|FG002|Cross-Over|Ineligible or never started treatment|0
6002792|NCT00064350|9597178|FG000|Cross-Over|Other|0
6002793|NCT00064350|9597179|FG001|Cross-Over|Other|2
6002794|NCT00064350|9597180|FG002|Cross-Over|Other|0
6002795|NCT00064662|9597191|FG000|Overall Study|Death|1
6002796|NCT00064662|9597192|FG001|Overall Study|Death|1
6002797|NCT00064662|9597191|FG000|Overall Study|Lost to Follow-up|57
6002798|NCT00064662|9597192|FG001|Overall Study|Lost to Follow-up|44
6002799|NCT00064662|9597191|FG000|Overall Study|Withdrawal by Subject|14
6002800|NCT00064662|9597192|FG001|Overall Study|Withdrawal by Subject|14
6002801|NCT00064662|9597191|FG000|Overall Study|Administratively withdrawn|2
6002802|NCT00064662|9597192|FG001|Overall Study|Administratively withdrawn|2
6002803|NCT00064701|9597201|FG000|One Year Post-transplant|Did not receive study drug|7
6002804|NCT00064701|9597202|FG001|One Year Post-transplant|Did not receive study drug|12
6002805|NCT00064701|9597203|FG002|One Year Post-transplant|Did not receive study drug|11
6002806|NCT00064701|9597201|FG000|One Year Post-transplant|Adverse Event|23
6002807|NCT00064701|9597202|FG001|One Year Post-transplant|Adverse Event|19
6002808|NCT00064701|9597203|FG002|One Year Post-transplant|Adverse Event|37
6002809|NCT00064701|9597201|FG000|One Year Post-transplant|Rejection|0
6002810|NCT00064701|9597202|FG001|One Year Post-transplant|Rejection|1
6002811|NCT00064701|9597203|FG002|One Year Post-transplant|Rejection|16
6002812|NCT00064701|9597201|FG000|One Year Post-transplant|Non-compliance|4
6002813|NCT00064701|9597202|FG001|One Year Post-transplant|Non-compliance|2
6002814|NCT00064701|9597203|FG002|One Year Post-transplant|Non-compliance|5
6002815|NCT00064701|9597201|FG000|One Year Post-transplant|Graft Failure|3
6002816|NCT00064701|9597202|FG001|One Year Post-transplant|Graft Failure|2
6002817|NCT00064701|9597203|FG002|One Year Post-transplant|Graft Failure|1
6002818|NCT00064701|9597201|FG000|One Year Post-transplant|Withdrawal by Subject|0
6002819|NCT00064701|9597202|FG001|One Year Post-transplant|Withdrawal by Subject|4
6002820|NCT00064701|9597203|FG002|One Year Post-transplant|Withdrawal by Subject|1
6002821|NCT00064701|9597201|FG000|One Year Post-transplant|Lost to Follow-up|1
6002822|NCT00064701|9597202|FG001|One Year Post-transplant|Lost to Follow-up|0
6002823|NCT00064701|9597203|FG002|One Year Post-transplant|Lost to Follow-up|0
6002824|NCT00064701|9597201|FG000|One Year Post-transplant|Converted to rapamycin|1
6002825|NCT00064701|9597202|FG001|One Year Post-transplant|Converted to rapamycin|0
6002826|NCT00064701|9597203|FG002|One Year Post-transplant|Converted to rapamycin|0
6002827|NCT00064701|9597201|FG000|One Year Post-transplant|Acute tubular necrosis|1
6002828|NCT00064701|9597202|FG001|One Year Post-transplant|Acute tubular necrosis|0
6002829|NCT00064701|9597203|FG002|One Year Post-transplant|Acute tubular necrosis|0
6002830|NCT00064701|9597201|FG000|One Year Post-transplant|Incorrect study drug dispensed|0
6002831|NCT00064701|9597202|FG001|One Year Post-transplant|Incorrect study drug dispensed|1
6002832|NCT00064701|9597203|FG002|One Year Post-transplant|Incorrect study drug dispensed|0
6002833|NCT00064701|9597201|FG000|One Year Post-transplant|Crossover secondary to possible toxicity|0
6002834|NCT00064701|9597202|FG001|One Year Post-transplant|Crossover secondary to possible toxicity|1
6002835|NCT00064701|9597203|FG002|One Year Post-transplant|Crossover secondary to possible toxicity|0
6002836|NCT00064701|9597201|FG000|One Year Post-transplant|Poor absorption|0
6002837|NCT00064701|9597202|FG001|One Year Post-transplant|Poor absorption|1
6002838|NCT00064701|9597203|FG002|One Year Post-transplant|Poor absorption|0
6002839|NCT00064701|9597201|FG000|One Year Post-transplant|Pancreas transplant|0
6002840|NCT00064701|9597202|FG001|One Year Post-transplant|Pancreas transplant|0
6002841|NCT00064701|9597203|FG002|One Year Post-transplant|Pancreas transplant|1
6002842|NCT00064701|9597201|FG000|Clinical Continuation Phase|Adverse Event|12
6002843|NCT00064701|9597202|FG001|Clinical Continuation Phase|Adverse Event|21
6002844|NCT00064701|9597203|FG002|Clinical Continuation Phase|Adverse Event|14
6002845|NCT00064701|9597201|FG000|Clinical Continuation Phase|Non-compliance|8
6002846|NCT00064701|9597202|FG001|Clinical Continuation Phase|Non-compliance|6
6002847|NCT00064701|9597203|FG002|Clinical Continuation Phase|Non-compliance|7
6002848|NCT00064701|9597201|FG000|Clinical Continuation Phase|Withdrawal by Subject|22
6002849|NCT00064701|9597202|FG001|Clinical Continuation Phase|Withdrawal by Subject|3
6002850|NCT00064701|9597203|FG002|Clinical Continuation Phase|Withdrawal by Subject|22
6002851|NCT00064701|9597201|FG000|Clinical Continuation Phase|Lost to Follow-up|6
6002852|NCT00064701|9597202|FG001|Clinical Continuation Phase|Lost to Follow-up|3
6002853|NCT00064701|9597203|FG002|Clinical Continuation Phase|Lost to Follow-up|6
6002854|NCT00064701|9597201|FG000|Clinical Continuation Phase|Graft Failure|5
6002855|NCT00064701|9597202|FG001|Clinical Continuation Phase|Graft Failure|5
6002856|NCT00064701|9597203|FG002|Clinical Continuation Phase|Graft Failure|2
6002857|NCT00064701|9597201|FG000|Clinical Continuation Phase|Rejection|1
6002858|NCT00064701|9597202|FG001|Clinical Continuation Phase|Rejection|2
6002859|NCT00064701|9597203|FG002|Clinical Continuation Phase|Rejection|2
6002860|NCT00064701|9597201|FG000|Clinical Continuation Phase|Sponsor discontinued study|113
6002861|NCT00064701|9597202|FG001|Clinical Continuation Phase|Sponsor discontinued study|129
6002862|NCT00064701|9597203|FG002|Clinical Continuation Phase|Sponsor discontinued study|79
6002863|NCT00064701|9597201|FG000|Clinical Continuation Phase|Immunosuppressive treatment crossover|0
6002864|NCT00064701|9597202|FG001|Clinical Continuation Phase|Immunosuppressive treatment crossover|3
6002865|NCT00064701|9597203|FG002|Clinical Continuation Phase|Immunosuppressive treatment crossover|6
6002866|NCT00064701|9597201|FG000|Clinical Continuation Phase|Physician Decision|1
6002867|NCT00064701|9597202|FG001|Clinical Continuation Phase|Physician Decision|3
6002868|NCT00064701|9597203|FG002|Clinical Continuation Phase|Physician Decision|0
6002869|NCT00064701|9597201|FG000|Clinical Continuation Phase|Unable to return to site for study visit|1
6073371|NCT00567476|9676919|FG001|Overall Study|Lost to Follow-up|1
6073372|NCT00567476|9676918|FG000|Overall Study|Administrative issues|1
6002870|NCT00064701|9597202|FG001|Clinical Continuation Phase|Unable to return to site for study visit|0
6002871|NCT00064701|9597203|FG002|Clinical Continuation Phase|Unable to return to site for study visit|1
6002872|NCT00064701|9597201|FG000|Clinical Continuation Phase|Pancreas transplant|1
6002873|NCT00064701|9597202|FG001|Clinical Continuation Phase|Pancreas transplant|0
6002874|NCT00064701|9597203|FG002|Clinical Continuation Phase|Pancreas transplant|0
6002875|NCT00064701|9597201|FG000|Clinical Continuation Phase|Ran out of study drug due to Hurricane|0
6002876|NCT00064701|9597202|FG001|Clinical Continuation Phase|Ran out of study drug due to Hurricane|1
6002877|NCT00064701|9597203|FG002|Clinical Continuation Phase|Ran out of study drug due to Hurricane|0
6002878|NCT00064701|9597201|FG000|Clinical Continuation Phase|Discharged to nursing home|0
6002879|NCT00064701|9597202|FG001|Clinical Continuation Phase|Discharged to nursing home|1
6002880|NCT00064701|9597203|FG002|Clinical Continuation Phase|Discharged to nursing home|0
6002881|NCT00064701|9597201|FG000|Clinical Continuation Phase|Incorrect study drug dispensed|0
6002882|NCT00064701|9597202|FG001|Clinical Continuation Phase|Incorrect study drug dispensed|1
6002883|NCT00064701|9597203|FG002|Clinical Continuation Phase|Incorrect study drug dispensed|0
6002884|NCT00064701|9597201|FG000|Clinical Continuation Phase|Patient opted out|0
6002885|NCT00064701|9597202|FG001|Clinical Continuation Phase|Patient opted out|0
6002886|NCT00064701|9597203|FG002|Clinical Continuation Phase|Patient opted out|1
6002887|NCT00064753|9597213|FG000|Overall Study|Death|251
6002888|NCT00064753|9597214|FG001|Overall Study|Death|242
6002889|NCT00064753|9597213|FG000|Overall Study|Withdrawal by Subject|198
6002890|NCT00064753|9597214|FG001|Overall Study|Withdrawal by Subject|171
6002891|NCT00064753|9597213|FG000|Overall Study|Lost to Follow-up|225
6002892|NCT00064753|9597214|FG001|Overall Study|Lost to Follow-up|235
6002893|NCT00064792|9597222|FG000|Overall Study|Withdrawal by Subject|2
6073373|NCT00567476|9676919|FG001|Overall Study|Administrative issues|0
6073374|NCT00567476|9676918|FG000|Overall Study|Medical Decision|0
6073375|NCT00567476|9676919|FG001|Overall Study|Medical Decision|1
6073376|NCT00567476|9676918|FG000|Overall Study|Non-adherence to protocol|0
6073377|NCT00567476|9676919|FG001|Overall Study|Non-adherence to protocol|1
6073378|NCT00567489|9676927|FG000|Overall Study|Adverse Event|6
6073379|NCT00567489|9676928|FG001|Overall Study|Adverse Event|14
6073380|NCT00567489|9676927|FG000|Overall Study|Physician Decision|0
6073381|NCT00567489|9676928|FG001|Overall Study|Physician Decision|4
6073382|NCT00567489|9676927|FG000|Overall Study|Withdrawal by Subject|0
6073383|NCT00567489|9676928|FG001|Overall Study|Withdrawal by Subject|2
6073384|NCT00567489|9676927|FG000|Overall Study|Renal Transplantation|0
6073385|NCT00567489|9676928|FG001|Overall Study|Renal Transplantation|3
6073386|NCT00567489|9676927|FG000|Overall Study|Other|1
6073387|NCT00567489|9676928|FG001|Overall Study|Other|0
6073388|NCT00567502|9676938|FG000|Overall Study|Lost to Follow-up|91
6073389|NCT00567502|9676939|FG001|Overall Study|Lost to Follow-up|14
6073390|NCT00567502|9676940|FG002|Overall Study|Lost to Follow-up|351
6073391|NCT00567502|9676941|FG003|Overall Study|Lost to Follow-up|2
6073392|NCT00567502|9676938|FG000|Overall Study|Death|65
6073393|NCT00567502|9676939|FG001|Overall Study|Death|16
6002894|NCT00064792|9597223|FG001|Overall Study|Withdrawal by Subject|0
6073394|NCT00567502|9676940|FG002|Overall Study|Death|360
6073395|NCT00567502|9676941|FG003|Overall Study|Death|5
6073396|NCT00567502|9676938|FG000|Overall Study|Other|64
6073397|NCT00567502|9676939|FG001|Overall Study|Other|2
6002895|NCT00064792|9597222|FG000|Overall Study|Adverse Event|3
6073398|NCT00567502|9676940|FG002|Overall Study|Other|134
6002896|NCT00064792|9597223|FG001|Overall Study|Adverse Event|0
6002897|NCT00064987|9597240|FG000|Overall Study|Physician Decision|3
6002898|NCT00064987|9597241|FG001|Overall Study|Physician Decision|0
6002899|NCT00065065|9597249|FG000|Overall Study|Adverse Event|3
6002900|NCT00065065|9597250|FG001|Overall Study|Adverse Event|2
6002901|NCT00065065|9597249|FG000|Overall Study|Withdrawal by Subject|1
6002902|NCT00065065|9597250|FG001|Overall Study|Withdrawal by Subject|5
6002903|NCT00065065|9597249|FG000|Overall Study|Lack of Efficacy|4
6002904|NCT00065065|9597250|FG001|Overall Study|Lack of Efficacy|11
6002905|NCT00065065|9597249|FG000|Overall Study|Other|2
6002906|NCT00065065|9597250|FG001|Overall Study|Other|2
6002907|NCT00065156|9597258|FG000|Overall Study|Adverse Event|37
6002908|NCT00065156|9597258|FG000|Overall Study|Lack of Efficacy|52
6002909|NCT00065156|9597258|FG000|Overall Study|Withdrawal by Subject|8
6002910|NCT00065156|9597258|FG000|Overall Study|Lost to Follow-up|1
6002911|NCT00065156|9597258|FG000|Overall Study|Death|11
6002912|NCT00065156|9597258|FG000|Overall Study|Study Closed by Sponsor|2
6002913|NCT00065156|9597258|FG000|Overall Study|Disease Progression|7
6002914|NCT00065156|9597258|FG000|Overall Study|Investigator Decision|2
6002915|NCT00065156|9597258|FG000|Overall Study|Non-Compliance|2
6002916|NCT00065156|9597258|FG000|Overall Study|Loss of Response|1
6002917|NCT00065156|9597258|FG000|Overall Study|Secondary Malign Disease|1
6002918|NCT00065182|9597264|FG000|Overall Study|Adverse Event|24
6002919|NCT00065182|9597265|FG001|Overall Study|Adverse Event|17
6002920|NCT00065182|9597264|FG000|Overall Study|Lost to Follow-up|0
6002921|NCT00065182|9597265|FG001|Overall Study|Lost to Follow-up|4
6002922|NCT00065182|9597264|FG000|Overall Study|Protocol Violation|3
6002923|NCT00065182|9597265|FG001|Overall Study|Protocol Violation|4
6002924|NCT00065182|9597264|FG000|Overall Study|Serious adverse events (SAE)|1
6002925|NCT00065182|9597265|FG001|Overall Study|Serious adverse events (SAE)|0
6002926|NCT00065182|9597264|FG000|Overall Study|Sponsor Decision|11
6002927|NCT00065182|9597265|FG001|Overall Study|Sponsor Decision|7
6002928|NCT00065182|9597264|FG000|Overall Study|Withdrawal by Subject|8
6002929|NCT00065182|9597265|FG001|Overall Study|Withdrawal by Subject|3
6002930|NCT00065182|9597264|FG000|Overall Study|No clinical benefit|1
6002931|NCT00065182|9597265|FG001|Overall Study|No clinical benefit|0
6002932|NCT00065182|9597264|FG000|Overall Study|Death|0
6002933|NCT00065182|9597265|FG001|Overall Study|Death|1
6002934|NCT00065182|9597264|FG000|Overall Study|Decline in Status|0
6309501|NCT02639338|10038112|FG000|Overall Study|Withdrew Consent|1
6002935|NCT00065182|9597265|FG001|Overall Study|Decline in Status|1
6002936|NCT00065260|9597273|FG000|Overall Study|Death|0
6002937|NCT00065260|9597274|FG001|Overall Study|Death|1
6002938|NCT00065429|9597287|FG000|Phase I - May 2001 - Oct 2002|Lost to Follow-up|0
6002939|NCT00065429|9597288|FG001|Phase I - May 2001 - Oct 2002|Lost to Follow-up|0
6002940|NCT00065429|9597289|FG002|Phase I - May 2001 - Oct 2002|Lost to Follow-up|0
6002941|NCT00065429|9597290|FG003|Phase I - May 2001 - Oct 2002|Lost to Follow-up|0
6002942|NCT00065429|9597291|FG004|Phase I - May 2001 - Oct 2002|Lost to Follow-up|0
6002943|NCT00065429|9597292|FG005|Phase I - May 2001 - Oct 2002|Lost to Follow-up|1
6002944|NCT00065429|9597293|FG006|Phase I - May 2001 - Oct 2002|Lost to Follow-up|0
6002945|NCT00065429|9597287|FG000|Phase I - May 2001 - Oct 2002|Withdrawal by Subject|0
6002946|NCT00065429|9597288|FG001|Phase I - May 2001 - Oct 2002|Withdrawal by Subject|0
6002947|NCT00065429|9597289|FG002|Phase I - May 2001 - Oct 2002|Withdrawal by Subject|1
6002948|NCT00065429|9597290|FG003|Phase I - May 2001 - Oct 2002|Withdrawal by Subject|0
6002949|NCT00065429|9597291|FG004|Phase I - May 2001 - Oct 2002|Withdrawal by Subject|0
6002950|NCT00065429|9597292|FG005|Phase I - May 2001 - Oct 2002|Withdrawal by Subject|0
6002951|NCT00065429|9597293|FG006|Phase I - May 2001 - Oct 2002|Withdrawal by Subject|0
6002952|NCT00065429|9597287|FG000|Phase I - May 2001 - Oct 2002|Physician Decision|1
6002953|NCT00065429|9597288|FG001|Phase I - May 2001 - Oct 2002|Physician Decision|0
6002954|NCT00065429|9597289|FG002|Phase I - May 2001 - Oct 2002|Physician Decision|0
6002955|NCT00065429|9597290|FG003|Phase I - May 2001 - Oct 2002|Physician Decision|0
6002956|NCT00065429|9597291|FG004|Phase I - May 2001 - Oct 2002|Physician Decision|0
6002957|NCT00065429|9597292|FG005|Phase I - May 2001 - Oct 2002|Physician Decision|0
6002958|NCT00065429|9597293|FG006|Phase I - May 2001 - Oct 2002|Physician Decision|0
6002959|NCT00065429|9597287|FG000|Phase I - May 2001 - Oct 2002|Death|0
6002960|NCT00065429|9597288|FG001|Phase I - May 2001 - Oct 2002|Death|0
6002961|NCT00065429|9597289|FG002|Phase I - May 2001 - Oct 2002|Death|0
6002962|NCT00065429|9597290|FG003|Phase I - May 2001 - Oct 2002|Death|0
6002963|NCT00065429|9597291|FG004|Phase I - May 2001 - Oct 2002|Death|1
6002964|NCT00065429|9597292|FG005|Phase I - May 2001 - Oct 2002|Death|0
6002965|NCT00065429|9597293|FG006|Phase I - May 2001 - Oct 2002|Death|0
6002966|NCT00065429|9597287|FG000|Phase I - May 2001 - Oct 2002|Adverse Event|0
6002967|NCT00065429|9597288|FG001|Phase I - May 2001 - Oct 2002|Adverse Event|0
6002968|NCT00065429|9597289|FG002|Phase I - May 2001 - Oct 2002|Adverse Event|0
6002969|NCT00065429|9597290|FG003|Phase I - May 2001 - Oct 2002|Adverse Event|1
6002970|NCT00065429|9597291|FG004|Phase I - May 2001 - Oct 2002|Adverse Event|0
6002971|NCT00065429|9597292|FG005|Phase I - May 2001 - Oct 2002|Adverse Event|1
6002972|NCT00065429|9597293|FG006|Phase I - May 2001 - Oct 2002|Adverse Event|2
6002973|NCT00065429|9597287|FG000|Phase II - Apr 2003 - Aug 2008|Lack of Efficacy|0
6002974|NCT00065429|9597288|FG001|Phase II - Apr 2003 - Aug 2008|Lack of Efficacy|0
6002975|NCT00065429|9597289|FG002|Phase II - Apr 2003 - Aug 2008|Lack of Efficacy|0
6002976|NCT00065429|9597290|FG003|Phase II - Apr 2003 - Aug 2008|Lack of Efficacy|0
6002977|NCT00065429|9597291|FG004|Phase II - Apr 2003 - Aug 2008|Lack of Efficacy|4
6002978|NCT00065429|9597292|FG005|Phase II - Apr 2003 - Aug 2008|Lack of Efficacy|0
6002979|NCT00065429|9597293|FG006|Phase II - Apr 2003 - Aug 2008|Lack of Efficacy|0
6002980|NCT00065429|9597287|FG000|Phase II - Apr 2003 - Aug 2008|Adverse Event|0
6002981|NCT00065429|9597288|FG001|Phase II - Apr 2003 - Aug 2008|Adverse Event|0
6002982|NCT00065429|9597289|FG002|Phase II - Apr 2003 - Aug 2008|Adverse Event|0
6002983|NCT00065429|9597290|FG003|Phase II - Apr 2003 - Aug 2008|Adverse Event|0
6002984|NCT00065429|9597291|FG004|Phase II - Apr 2003 - Aug 2008|Adverse Event|2
6002985|NCT00065429|9597292|FG005|Phase II - Apr 2003 - Aug 2008|Adverse Event|0
6002986|NCT00065429|9597293|FG006|Phase II - Apr 2003 - Aug 2008|Adverse Event|0
6002987|NCT00065442|9597306|FG000|Overall Study|Lost to Follow-up|1
6002988|NCT00065442|9597307|FG001|Overall Study|Lost to Follow-up|1
6002989|NCT00065442|9597306|FG000|Overall Study|Death|121
6002990|NCT00065442|9597307|FG001|Overall Study|Death|210
6002991|NCT00065442|9597306|FG000|Overall Study|Withdrawal by Subject|3
6002992|NCT00065442|9597307|FG001|Overall Study|Withdrawal by Subject|9
6002993|NCT00065468|9597316|FG000|Overall Study|Death|172
6002994|NCT00065468|9597317|FG001|Overall Study|Death|169
6002995|NCT00065468|9597318|FG002|Overall Study|Death|171
6002996|NCT00065468|9597316|FG000|Overall Study|Withdrawal by Subject|3
6002997|NCT00065468|9597317|FG001|Overall Study|Withdrawal by Subject|4
6002998|NCT00065468|9597318|FG002|Overall Study|Withdrawal by Subject|5
6002999|NCT00065468|9597316|FG000|Overall Study|Lost to Follow-up|5
6003000|NCT00065468|9597317|FG001|Overall Study|Lost to Follow-up|3
6003001|NCT00065468|9597318|FG002|Overall Study|Lost to Follow-up|2
6003002|NCT00065468|9597316|FG000|Overall Study|Discontinuation of study by Sponsor|13
6003003|NCT00065468|9597317|FG001|Overall Study|Discontinuation of study by Sponsor|9
6003004|NCT00065468|9597318|FG002|Overall Study|Discontinuation of study by Sponsor|13
6003005|NCT00065468|9597316|FG000|Overall Study|Disease progression|0
6003006|NCT00065468|9597317|FG001|Overall Study|Disease progression|0
6003007|NCT00065468|9597318|FG002|Overall Study|Disease progression|1
6003008|NCT00065468|9597316|FG000|Overall Study|Other|14
6003009|NCT00065468|9597317|FG001|Overall Study|Other|24
6003010|NCT00065468|9597318|FG002|Overall Study|Other|18
6003011|NCT00065507|9597328|FG000|Overall Study|Death|16
6003012|NCT00065507|9597329|FG001|Overall Study|Death|17
6003013|NCT00065507|9597328|FG000|Overall Study|Adverse Event|4
6003014|NCT00065507|9597329|FG001|Overall Study|Adverse Event|3
6003015|NCT00065507|9597328|FG000|Overall Study|Lack of Efficacy|0
6003016|NCT00065507|9597329|FG001|Overall Study|Lack of Efficacy|6
6003017|NCT00065507|9597328|FG000|Overall Study|Poor/Non-compliance|3
6003018|NCT00065507|9597329|FG001|Overall Study|Poor/Non-compliance|2
6003019|NCT00065507|9597328|FG000|Overall Study|Lost to Follow-up|3
6003020|NCT00065507|9597329|FG001|Overall Study|Lost to Follow-up|0
6003021|NCT00065507|9597328|FG000|Overall Study|Subject Withdrew Consent|2
6003022|NCT00065507|9597329|FG001|Overall Study|Subject Withdrew Consent|1
6003023|NCT00065507|9597328|FG000|Overall Study|Subject No Longer Meets Study Criteria|1
6003024|NCT00065507|9597329|FG001|Overall Study|Subject No Longer Meets Study Criteria|0
6003025|NCT00066066|9597360|FG000|Overall Study|Lost to Follow-up|6
6003026|NCT00066066|9597361|FG001|Overall Study|Lost to Follow-up|4
6003027|NCT00066066|9597362|FG002|Overall Study|Lost to Follow-up|7
6003028|NCT00066066|9597363|FG003|Overall Study|Lost to Follow-up|4
6003029|NCT00066066|9597364|FG004|Overall Study|Lost to Follow-up|3
6003030|NCT00066066|9597365|FG005|Overall Study|Lost to Follow-up|5
6003031|NCT00066170|9597383|FG000|Overall Study|Adverse Event|2
6003032|NCT00066170|9597384|FG001|Overall Study|Adverse Event|4
6003033|NCT00066170|9597385|FG002|Overall Study|Adverse Event|1
6003034|NCT00066170|9597386|FG003|Overall Study|Adverse Event|7
6003035|NCT00066170|9597383|FG000|Overall Study|Serious Adverse Event|0
6003036|NCT00066170|9597384|FG001|Overall Study|Serious Adverse Event|0
6003037|NCT00066170|9597385|FG002|Overall Study|Serious Adverse Event|1
6003038|NCT00066170|9597386|FG003|Overall Study|Serious Adverse Event|1
6003039|NCT00066170|9597383|FG000|Overall Study|Lost to Follow-up|0
6003040|NCT00066170|9597384|FG001|Overall Study|Lost to Follow-up|1
6003041|NCT00066170|9597385|FG002|Overall Study|Lost to Follow-up|0
6003042|NCT00066170|9597386|FG003|Overall Study|Lost to Follow-up|0
6003043|NCT00066170|9597383|FG000|Overall Study|Non-Compliance with Trial Medicine|1
6003044|NCT00066170|9597384|FG001|Overall Study|Non-Compliance with Trial Medicine|0
6003045|NCT00066170|9597385|FG002|Overall Study|Non-Compliance with Trial Medicine|0
6003046|NCT00066170|9597386|FG003|Overall Study|Non-Compliance with Trial Medicine|1
6003047|NCT00066170|9597383|FG000|Overall Study|Protocol Violation|3
6003048|NCT00066170|9597384|FG001|Overall Study|Protocol Violation|0
6003049|NCT00066170|9597385|FG002|Overall Study|Protocol Violation|0
6003050|NCT00066170|9597386|FG003|Overall Study|Protocol Violation|0
6003051|NCT00066170|9597383|FG000|Overall Study|Other|1
6003052|NCT00066170|9597384|FG001|Overall Study|Other|5
6003053|NCT00066170|9597385|FG002|Overall Study|Other|2
6003054|NCT00066170|9597386|FG003|Overall Study|Other|0
6003055|NCT00066222|9597396|FG000|Overall Study|No protocol treatment received|1
6003056|NCT00066365|9597402|FG000|Overall Study|Adverse Event|1
6003057|NCT00066365|9597403|FG001|Overall Study|Adverse Event|0
6003058|NCT00066365|9597402|FG000|Overall Study|Lack of Efficacy|15
6003059|NCT00066365|9597403|FG001|Overall Study|Lack of Efficacy|12
6003060|NCT00066365|9597402|FG000|Overall Study|Physician Decision|1
6003061|NCT00066365|9597403|FG001|Overall Study|Physician Decision|0
6003062|NCT00066365|9597402|FG000|Overall Study|No viable tumor after 1 cycle of therapy|2
6003063|NCT00066365|9597403|FG001|Overall Study|No viable tumor after 1 cycle of therapy|0
6003064|NCT00066365|9597402|FG000|Overall Study|Ineligible|4
6003065|NCT00066365|9597403|FG001|Overall Study|Ineligible|2
6003066|NCT00066469|9597411|FG000|Overall Study|Death|3
6003067|NCT00066469|9597411|FG000|Overall Study|Lack of Efficacy|9
6003068|NCT00066469|9597411|FG000|Overall Study|Lost to Follow-up|1
6003069|NCT00066469|9597411|FG000|Overall Study|Physician Decision|1
6003070|NCT00066469|9597411|FG000|Overall Study|Withdrawal by Subject|1
6003071|NCT00066469|9597411|FG000|Overall Study|ineligible|1
6003072|NCT00066573|9597417|FG000|Overall Study|Did not received protocol treatment|28
6003073|NCT00066573|9597418|FG001|Overall Study|Did not received protocol treatment|28
6003074|NCT00066690|9597436|FG000|Overall Study|Adverse Event|145
6003075|NCT00066690|9597437|FG001|Overall Study|Adverse Event|58
6003076|NCT00066690|9597438|FG002|Overall Study|Adverse Event|126
6003077|NCT00066690|9597436|FG000|Overall Study|Death|3
6003078|NCT00066690|9597437|FG001|Overall Study|Death|0
6003079|NCT00066690|9597438|FG002|Overall Study|Death|2
6003080|NCT00066690|9597436|FG000|Overall Study|Lack of Efficacy|114
6003081|NCT00066690|9597437|FG001|Overall Study|Lack of Efficacy|110
6003082|NCT00066690|9597438|FG002|Overall Study|Lack of Efficacy|76
6003083|NCT00066690|9597436|FG000|Overall Study|Lost to Follow-up|40
6003084|NCT00066690|9597437|FG001|Overall Study|Lost to Follow-up|21
6003085|NCT00066690|9597438|FG002|Overall Study|Lost to Follow-up|29
6003086|NCT00066690|9597436|FG000|Overall Study|Withdrawal by Subject|50
6003087|NCT00066690|9597437|FG001|Overall Study|Withdrawal by Subject|55
6003088|NCT00066690|9597438|FG002|Overall Study|Withdrawal by Subject|49
6003089|NCT00066690|9597436|FG000|Overall Study|Treatment Ongoing|246
6003090|NCT00066690|9597437|FG001|Overall Study|Treatment Ongoing|278
6003091|NCT00066690|9597438|FG002|Overall Study|Treatment Ongoing|282
6003092|NCT00066703|9597451|FG000|Overall Study|Adverse Event|80
6003093|NCT00066703|9597452|FG001|Overall Study|Adverse Event|111
6003094|NCT00066703|9597451|FG000|Overall Study|Death|3
6003095|NCT00066703|9597452|FG001|Overall Study|Death|0
6003096|NCT00066703|9597451|FG000|Overall Study|Lack of Efficacy|114
6003097|NCT00066703|9597452|FG001|Overall Study|Lack of Efficacy|69
6003098|NCT00066703|9597451|FG000|Overall Study|Lost to Follow-up|31
6003099|NCT00066703|9597452|FG001|Overall Study|Lost to Follow-up|28
6003100|NCT00066703|9597451|FG000|Overall Study|Withdrawal by Subject|38
6003101|NCT00066703|9597452|FG001|Overall Study|Withdrawal by Subject|63
6003102|NCT00066703|9597451|FG000|Overall Study|Treatment ongoing|346
6003103|NCT00066703|9597452|FG001|Overall Study|Treatment ongoing|311
6003104|NCT00066729|9597458|FG000|Overall Study|Lost to Follow-up|1
6003105|NCT00066729|9597458|FG000|Overall Study|Disease progression|1
6003106|NCT00066742|9597462|FG000|Induction Chemoradiotherapy|Did not receive any protocol treatment|1
6003107|NCT00066742|9597462|FG000|Induction Chemoradiotherapy|Adverse Event|21
6003108|NCT00066742|9597462|FG000|Induction Chemoradiotherapy|Withdrawal by Subject|2
6003109|NCT00066742|9597462|FG000|Induction Chemoradiotherapy|not protocol specified|2
6003110|NCT00066742|9597462|FG000|Induction Chemoradiotherapy|Ineligible|3
6003111|NCT00066742|9597462|FG000|Consolidation Chemotherapy|not protocol specified|1
6003112|NCT00066742|9597462|FG000|Consolidation Chemotherapy|Ineligible|2
6003113|NCT00067002|9597496|FG000|Overall Study|Early Death|1
6003114|NCT00067002|9597497|FG001|Overall Study|Early Death|2
6003115|NCT00067002|9597496|FG000|Overall Study|Delayed|1
6003116|NCT00067002|9597497|FG001|Overall Study|Delayed|1
6003117|NCT00067002|9597496|FG000|Overall Study|Graft Failure|5
6003118|NCT00067002|9597497|FG001|Overall Study|Graft Failure|6
6003119|NCT00067470|9597529|FG000|Overall Study|Withdrawal by Subject|0
6003120|NCT00067470|9597530|FG001|Overall Study|Withdrawal by Subject|1
6003121|NCT00067990|9597551|FG000|Overall Study|Death|5
6003122|NCT00067990|9597552|FG001|Overall Study|Death|7
6003123|NCT00067990|9597551|FG000|Overall Study|ESRD, Non IF/TA|1
6003124|NCT00067990|9597552|FG001|Overall Study|ESRD, Non IF/TA|3
6003125|NCT00067990|9597551|FG000|Overall Study|Withdrawal by Subject|4
6003126|NCT00067990|9597552|FG001|Overall Study|Withdrawal by Subject|12
6003127|NCT00068107|9597558|FG000|Overall Study|end-stage renal disease|6
6003128|NCT00068107|9597558|FG000|Overall Study|Death|2
6003129|NCT00068107|9597558|FG000|Overall Study|Withdrawal by Subject|1
6003130|NCT00068237|9597565|FG000|Overall Study|Ineligible|3
6003131|NCT00068237|9597565|FG000|Overall Study|No protocol treatment received|2
6003132|NCT00068250|9597572|FG000|Phase I: Dose Level 2|Protocol Violation|0
6003133|NCT00068250|9597573|FG001|Phase I: Dose Level 2|Protocol Violation|1
6003134|NCT00068250|9597574|FG002|Phase I: Dose Level 2|Protocol Violation|0
6003135|NCT00068250|9597575|FG003|Phase I: Dose Level 2|Protocol Violation|0
6003136|NCT00068380|9597613|FG000|Overall Study|Withdrawal by Subject|3
6003137|NCT00068380|9597613|FG000|Overall Study|Adverse Event|2
6003138|NCT00068393|9597617|FG000|Overall Study|Adverse Event|2
6003139|NCT00068393|9597617|FG000|Overall Study|Death|3
6003140|NCT00068393|9597617|FG000|Overall Study|Withdrawal by Subject|3
6003141|NCT00068393|9597617|FG000|Overall Study|Alternative treatment|1
6003142|NCT00068393|9597617|FG000|Overall Study|Quality of life worsening|1
6003143|NCT00068406|9597621|FG000|Overall Study|Ineligible-improper pre-protocol treatm|1
6003144|NCT00068406|9597621|FG000|Overall Study|Ineligible-Inadequate Pathology|2
6003145|NCT00068419|9597625|FG000|Overall Study|Adverse Event|3
6003146|NCT00068419|9597625|FG000|Overall Study|Lack of Efficacy|24
6003147|NCT00068419|9597625|FG000|Overall Study|Lost to Follow-up|1
6003148|NCT00068419|9597625|FG000|Overall Study|Physician Decision|7
6003149|NCT00068419|9597625|FG000|Overall Study|Withdrawal by Subject|14
6003150|NCT00068419|9597625|FG000|Overall Study|Ineligible|11
6003151|NCT00068445|9597631|FG000|Randomization|Cancel|1
6003152|NCT00068445|9597632|FG001|Randomization|Cancel|3
6003153|NCT00068445|9597631|FG000|Randomization|Ineligible|1
6073399|NCT00567502|9676941|FG003|Overall Study|Other|6
6073400|NCT00567502|9676938|FG000|Overall Study|Participant request|12
6073401|NCT00567502|9676939|FG001|Overall Study|Participant request|1
6073402|NCT00567502|9676940|FG002|Overall Study|Participant request|33
6073403|NCT00567502|9676941|FG003|Overall Study|Participant request|1
6073404|NCT00567502|9676938|FG000|Overall Study|Sponsor request|9
6073405|NCT00567502|9676939|FG001|Overall Study|Sponsor request|0
6073406|NCT00567502|9676940|FG002|Overall Study|Sponsor request|30
6073407|NCT00567502|9676941|FG003|Overall Study|Sponsor request|1
6003154|NCT00068445|9597632|FG001|Randomization|Ineligible|1
6003155|NCT00068445|9597631|FG000|Treatment|Refused Further Treatment|13
6003156|NCT00068445|9597632|FG001|Treatment|Refused Further Treatment|10
6003157|NCT00068445|9597631|FG000|Treatment|Adverse Event|7
6003158|NCT00068445|9597632|FG001|Treatment|Adverse Event|1
6003159|NCT00068445|9597631|FG000|Treatment|Other (Specifics not available)|9
6003160|NCT00068445|9597632|FG001|Treatment|Other (Specifics not available)|5
6003161|NCT00068588|9597645|FG000|Overall Study|Adverse Event|0
6003162|NCT00068588|9597646|FG001|Overall Study|Adverse Event|0
6003163|NCT00068588|9597647|FG002|Overall Study|Adverse Event|2
6003164|NCT00068588|9597645|FG000|Overall Study|Withdrawal by Subject|0
6003165|NCT00068588|9597646|FG001|Overall Study|Withdrawal by Subject|0
6003166|NCT00068588|9597647|FG002|Overall Study|Withdrawal by Subject|1
6003167|NCT00068588|9597645|FG000|Overall Study|Poor KPS|0
6003168|NCT00068588|9597646|FG001|Overall Study|Poor KPS|0
6003169|NCT00068588|9597647|FG002|Overall Study|Poor KPS|1
6003170|NCT00068601|9597656|FG000|Overall Study|Ineligible|11
6003171|NCT00068601|9597657|FG001|Overall Study|Ineligible|13
6003172|NCT00068601|9597656|FG000|Overall Study|Not evaluable: withdrew consent|5
6003173|NCT00068601|9597657|FG001|Overall Study|Not evaluable: withdrew consent|4
6003174|NCT00068601|9597656|FG000|Overall Study|Not evaluable: hysterectomy/oophorectomy|2
6003175|NCT00068601|9597657|FG001|Overall Study|Not evaluable: hysterectomy/oophorectomy|4
6003176|NCT00068601|9597656|FG000|Overall Study|Death|11
6003177|NCT00068601|9597657|FG001|Overall Study|Death|3
6003178|NCT00068601|9597656|FG000|Overall Study|Lost to Follow-up|3
6003179|NCT00068601|9597657|FG001|Overall Study|Lost to Follow-up|2
6003180|NCT00068601|9597656|FG000|Overall Study|Missing primary outcome data|30
6003181|NCT00068601|9597657|FG001|Overall Study|Missing primary outcome data|34
6003182|NCT00068692|9597666|FG000|Step 1: Registration|Disese progression/relapse|5
6003183|NCT00068692|9597667|FG001|Step 1: Registration|Disese progression/relapse|0
6003184|NCT00068692|9597668|FG002|Step 1: Registration|Disese progression/relapse|0
6003185|NCT00068692|9597669|FG003|Step 1: Registration|Disese progression/relapse|0
6003186|NCT00068692|9597670|FG004|Step 1: Registration|Disese progression/relapse|0
6003187|NCT00068692|9597671|FG005|Step 1: Registration|Disese progression/relapse|0
6003188|NCT00068692|9597672|FG006|Step 1: Registration|Disese progression/relapse|0
6003189|NCT00068692|9597673|FG007|Step 1: Registration|Disese progression/relapse|0
6003190|NCT00068692|9597666|FG000|Step 1: Registration|Adverse Event|7
6003191|NCT00068692|9597667|FG001|Step 1: Registration|Adverse Event|0
6003192|NCT00068692|9597668|FG002|Step 1: Registration|Adverse Event|0
6003193|NCT00068692|9597669|FG003|Step 1: Registration|Adverse Event|0
6003194|NCT00068692|9597670|FG004|Step 1: Registration|Adverse Event|0
6003195|NCT00068692|9597671|FG005|Step 1: Registration|Adverse Event|0
6003196|NCT00068692|9597672|FG006|Step 1: Registration|Adverse Event|0
6003197|NCT00068692|9597673|FG007|Step 1: Registration|Adverse Event|0
6003198|NCT00068692|9597666|FG000|Step 1: Registration|Death|1
6003199|NCT00068692|9597667|FG001|Step 1: Registration|Death|0
6003200|NCT00068692|9597668|FG002|Step 1: Registration|Death|0
6003201|NCT00068692|9597669|FG003|Step 1: Registration|Death|0
6003202|NCT00068692|9597670|FG004|Step 1: Registration|Death|0
6003203|NCT00068692|9597671|FG005|Step 1: Registration|Death|0
6003204|NCT00068692|9597672|FG006|Step 1: Registration|Death|0
6073408|NCT00567502|9676938|FG000|Overall Study|Never Initiated Treatment|0
6073409|NCT00567502|9676939|FG001|Overall Study|Never Initiated Treatment|0
6003205|NCT00068692|9597673|FG007|Step 1: Registration|Death|0
6003206|NCT00068692|9597666|FG000|Step 1: Registration|Withdrawal by Subject|11
6003207|NCT00068692|9597667|FG001|Step 1: Registration|Withdrawal by Subject|0
6003208|NCT00068692|9597668|FG002|Step 1: Registration|Withdrawal by Subject|0
6003209|NCT00068692|9597669|FG003|Step 1: Registration|Withdrawal by Subject|0
6003210|NCT00068692|9597670|FG004|Step 1: Registration|Withdrawal by Subject|0
6003211|NCT00068692|9597671|FG005|Step 1: Registration|Withdrawal by Subject|0
6003212|NCT00068692|9597672|FG006|Step 1: Registration|Withdrawal by Subject|0
6003213|NCT00068692|9597673|FG007|Step 1: Registration|Withdrawal by Subject|0
6003214|NCT00068692|9597666|FG000|Step 1: Registration|Alternative therapy|2
6003215|NCT00068692|9597667|FG001|Step 1: Registration|Alternative therapy|0
6003216|NCT00068692|9597668|FG002|Step 1: Registration|Alternative therapy|0
6003217|NCT00068692|9597669|FG003|Step 1: Registration|Alternative therapy|0
6003218|NCT00068692|9597670|FG004|Step 1: Registration|Alternative therapy|0
6003219|NCT00068692|9597671|FG005|Step 1: Registration|Alternative therapy|0
6003220|NCT00068692|9597672|FG006|Step 1: Registration|Alternative therapy|0
6003221|NCT00068692|9597673|FG007|Step 1: Registration|Alternative therapy|0
6003222|NCT00068692|9597666|FG000|Step 1: Registration|Complicating disease|2
6003223|NCT00068692|9597667|FG001|Step 1: Registration|Complicating disease|0
6003224|NCT00068692|9597668|FG002|Step 1: Registration|Complicating disease|0
6003225|NCT00068692|9597669|FG003|Step 1: Registration|Complicating disease|0
6003226|NCT00068692|9597670|FG004|Step 1: Registration|Complicating disease|0
6003227|NCT00068692|9597671|FG005|Step 1: Registration|Complicating disease|0
6003228|NCT00068692|9597672|FG006|Step 1: Registration|Complicating disease|0
6003229|NCT00068692|9597673|FG007|Step 1: Registration|Complicating disease|0
6003230|NCT00068692|9597666|FG000|Step 1: Registration|Protocol Violation|1
6003231|NCT00068692|9597667|FG001|Step 1: Registration|Protocol Violation|0
6003232|NCT00068692|9597668|FG002|Step 1: Registration|Protocol Violation|0
6003233|NCT00068692|9597669|FG003|Step 1: Registration|Protocol Violation|0
6003234|NCT00068692|9597670|FG004|Step 1: Registration|Protocol Violation|0
6003235|NCT00068692|9597671|FG005|Step 1: Registration|Protocol Violation|0
6003236|NCT00068692|9597672|FG006|Step 1: Registration|Protocol Violation|0
6003237|NCT00068692|9597673|FG007|Step 1: Registration|Protocol Violation|0
6003238|NCT00068692|9597666|FG000|Step 1: Registration|Not eligible|6
6003239|NCT00068692|9597667|FG001|Step 1: Registration|Not eligible|0
6003240|NCT00068692|9597668|FG002|Step 1: Registration|Not eligible|0
6003241|NCT00068692|9597669|FG003|Step 1: Registration|Not eligible|0
6003242|NCT00068692|9597670|FG004|Step 1: Registration|Not eligible|0
6003243|NCT00068692|9597671|FG005|Step 1: Registration|Not eligible|0
6003244|NCT00068692|9597672|FG006|Step 1: Registration|Not eligible|0
6003245|NCT00068692|9597673|FG007|Step 1: Registration|Not eligible|0
6003246|NCT00068692|9597666|FG000|Step 1: Registration|Other|2
6003247|NCT00068692|9597667|FG001|Step 1: Registration|Other|0
6003248|NCT00068692|9597668|FG002|Step 1: Registration|Other|0
6003249|NCT00068692|9597669|FG003|Step 1: Registration|Other|0
6003250|NCT00068692|9597670|FG004|Step 1: Registration|Other|0
6003251|NCT00068692|9597671|FG005|Step 1: Registration|Other|0
6003252|NCT00068692|9597672|FG006|Step 1: Registration|Other|0
6003253|NCT00068692|9597673|FG007|Step 1: Registration|Other|0
6003254|NCT00068692|9597666|FG000|Step 1: Registration|Not start protocol therapy|3
6003255|NCT00068692|9597667|FG001|Step 1: Registration|Not start protocol therapy|0
6003256|NCT00068692|9597668|FG002|Step 1: Registration|Not start protocol therapy|0
6003257|NCT00068692|9597669|FG003|Step 1: Registration|Not start protocol therapy|0
6003258|NCT00068692|9597670|FG004|Step 1: Registration|Not start protocol therapy|0
6003259|NCT00068692|9597671|FG005|Step 1: Registration|Not start protocol therapy|0
6003260|NCT00068692|9597672|FG006|Step 1: Registration|Not start protocol therapy|0
6003261|NCT00068692|9597673|FG007|Step 1: Registration|Not start protocol therapy|0
6003262|NCT00068692|9597666|FG000|Step 1: Registration|Registered but not randomized|0
6003263|NCT00068692|9597667|FG001|Step 1: Registration|Registered but not randomized|1
6003264|NCT00068692|9597668|FG002|Step 1: Registration|Registered but not randomized|0
6003265|NCT00068692|9597669|FG003|Step 1: Registration|Registered but not randomized|0
6003266|NCT00068692|9597670|FG004|Step 1: Registration|Registered but not randomized|0
6003267|NCT00068692|9597671|FG005|Step 1: Registration|Registered but not randomized|0
6003268|NCT00068692|9597672|FG006|Step 1: Registration|Registered but not randomized|0
6003269|NCT00068692|9597673|FG007|Step 1: Registration|Registered but not randomized|0
6003270|NCT00068692|9597666|FG000|Step 2: Randomization|Disesae progression/replase|0
6003271|NCT00068692|9597667|FG001|Step 2: Randomization|Disesae progression/replase|0
6003272|NCT00068692|9597668|FG002|Step 2: Randomization|Disesae progression/replase|1
6003273|NCT00068692|9597669|FG003|Step 2: Randomization|Disesae progression/replase|1
6003274|NCT00068692|9597670|FG004|Step 2: Randomization|Disesae progression/replase|0
6003275|NCT00068692|9597671|FG005|Step 2: Randomization|Disesae progression/replase|0
6003276|NCT00068692|9597672|FG006|Step 2: Randomization|Disesae progression/replase|0
6003277|NCT00068692|9597673|FG007|Step 2: Randomization|Disesae progression/replase|0
6003278|NCT00068692|9597666|FG000|Step 2: Randomization|Adverse Event|0
6003279|NCT00068692|9597667|FG001|Step 2: Randomization|Adverse Event|0
6003280|NCT00068692|9597668|FG002|Step 2: Randomization|Adverse Event|4
6003281|NCT00068692|9597669|FG003|Step 2: Randomization|Adverse Event|2
6003282|NCT00068692|9597670|FG004|Step 2: Randomization|Adverse Event|2
6003283|NCT00068692|9597671|FG005|Step 2: Randomization|Adverse Event|3
6003284|NCT00068692|9597672|FG006|Step 2: Randomization|Adverse Event|4
6003285|NCT00068692|9597673|FG007|Step 2: Randomization|Adverse Event|4
6003286|NCT00068692|9597666|FG000|Step 2: Randomization|Death|0
6003287|NCT00068692|9597667|FG001|Step 2: Randomization|Death|0
6003288|NCT00068692|9597668|FG002|Step 2: Randomization|Death|0
6003289|NCT00068692|9597669|FG003|Step 2: Randomization|Death|0
6003290|NCT00068692|9597670|FG004|Step 2: Randomization|Death|1
6003291|NCT00068692|9597671|FG005|Step 2: Randomization|Death|0
6003292|NCT00068692|9597672|FG006|Step 2: Randomization|Death|0
6003293|NCT00068692|9597673|FG007|Step 2: Randomization|Death|1
6003294|NCT00068692|9597666|FG000|Step 2: Randomization|Withdrawal by Subject|0
6003295|NCT00068692|9597667|FG001|Step 2: Randomization|Withdrawal by Subject|0
6003296|NCT00068692|9597668|FG002|Step 2: Randomization|Withdrawal by Subject|4
6003297|NCT00068692|9597669|FG003|Step 2: Randomization|Withdrawal by Subject|6
6003298|NCT00068692|9597670|FG004|Step 2: Randomization|Withdrawal by Subject|3
6003299|NCT00068692|9597671|FG005|Step 2: Randomization|Withdrawal by Subject|2
6003300|NCT00068692|9597672|FG006|Step 2: Randomization|Withdrawal by Subject|0
6003301|NCT00068692|9597673|FG007|Step 2: Randomization|Withdrawal by Subject|3
6003302|NCT00068692|9597666|FG000|Step 2: Randomization|alternative therapy|0
6003303|NCT00068692|9597667|FG001|Step 2: Randomization|alternative therapy|0
6003304|NCT00068692|9597668|FG002|Step 2: Randomization|alternative therapy|0
6003305|NCT00068692|9597669|FG003|Step 2: Randomization|alternative therapy|1
6003306|NCT00068692|9597670|FG004|Step 2: Randomization|alternative therapy|1
6003307|NCT00068692|9597671|FG005|Step 2: Randomization|alternative therapy|0
6003308|NCT00068692|9597672|FG006|Step 2: Randomization|alternative therapy|0
6003309|NCT00068692|9597673|FG007|Step 2: Randomization|alternative therapy|0
6003310|NCT00068692|9597666|FG000|Step 2: Randomization|Physician Decision|0
6003311|NCT00068692|9597667|FG001|Step 2: Randomization|Physician Decision|0
6003312|NCT00068692|9597668|FG002|Step 2: Randomization|Physician Decision|0
6003313|NCT00068692|9597669|FG003|Step 2: Randomization|Physician Decision|1
6003314|NCT00068692|9597670|FG004|Step 2: Randomization|Physician Decision|1
6003315|NCT00068692|9597671|FG005|Step 2: Randomization|Physician Decision|0
6003316|NCT00068692|9597672|FG006|Step 2: Randomization|Physician Decision|0
6003317|NCT00068692|9597673|FG007|Step 2: Randomization|Physician Decision|0
6003318|NCT00068692|9597666|FG000|Step 2: Randomization|Other|0
6003319|NCT00068692|9597667|FG001|Step 2: Randomization|Other|0
6003320|NCT00068692|9597668|FG002|Step 2: Randomization|Other|0
6003321|NCT00068692|9597669|FG003|Step 2: Randomization|Other|1
6003322|NCT00068692|9597670|FG004|Step 2: Randomization|Other|0
6003323|NCT00068692|9597671|FG005|Step 2: Randomization|Other|1
6003324|NCT00068692|9597672|FG006|Step 2: Randomization|Other|0
6003325|NCT00068692|9597673|FG007|Step 2: Randomization|Other|0
6003326|NCT00068692|9597666|FG000|Step 2: Randomization|never start protocol therapy|0
6003327|NCT00068692|9597667|FG001|Step 2: Randomization|never start protocol therapy|0
6003328|NCT00068692|9597668|FG002|Step 2: Randomization|never start protocol therapy|1
6003329|NCT00068692|9597669|FG003|Step 2: Randomization|never start protocol therapy|0
6003330|NCT00068692|9597670|FG004|Step 2: Randomization|never start protocol therapy|1
6003331|NCT00068692|9597671|FG005|Step 2: Randomization|never start protocol therapy|0
6003332|NCT00068692|9597672|FG006|Step 2: Randomization|never start protocol therapy|0
6003333|NCT00068692|9597673|FG007|Step 2: Randomization|never start protocol therapy|0
6003334|NCT00068822|9597703|FG000|First Randomized Intervention|Lost to Follow-up|1
6003335|NCT00068822|9597704|FG001|First Randomized Intervention|Lost to Follow-up|2
6003336|NCT00069095|9597716|FG000|Primary Treatment Phase|Ongoing|0
6003337|NCT00069095|9597717|FG001|Primary Treatment Phase|Ongoing|0
6003338|NCT00069095|9597718|FG002|Primary Treatment Phase|Ongoing|5
6003339|NCT00069095|9597719|FG003|Primary Treatment Phase|Ongoing|7
6003340|NCT00069095|9597720|FG004|Primary Treatment Phase|Ongoing|7
6003341|NCT00069095|9597721|FG005|Primary Treatment Phase|Ongoing|4
6003342|NCT00069095|9597716|FG000|Primary Treatment Phase|Admin/Other|29
6003343|NCT00069095|9597717|FG001|Primary Treatment Phase|Admin/Other|38
6003344|NCT00069095|9597718|FG002|Primary Treatment Phase|Admin/Other|31
6003345|NCT00069095|9597719|FG003|Primary Treatment Phase|Admin/Other|45
6003346|NCT00069095|9597720|FG004|Primary Treatment Phase|Admin/Other|48
6003347|NCT00069095|9597721|FG005|Primary Treatment Phase|Admin/Other|42
6073410|NCT00567502|9676940|FG002|Overall Study|Never Initiated Treatment|0
6073411|NCT00567502|9676941|FG003|Overall Study|Never Initiated Treatment|72
6073412|NCT00567541|9676964|FG000|Overall Study|Adverse Event|0
6073413|NCT00567541|9676965|FG001|Overall Study|Adverse Event|1
6073414|NCT00567593|9676971|FG000|Overall Study|Adverse Event|1
6073415|NCT00567593|9676971|FG000|Overall Study|Physician Decision|1
6073416|NCT00567879|9677002|FG000|Overall Study|Adverse Event|2
6073417|NCT00567879|9677003|FG001|Overall Study|Adverse Event|0
6073418|NCT00567879|9677004|FG002|Overall Study|Adverse Event|1
6073419|NCT00567879|9677005|FG003|Overall Study|Adverse Event|0
6073420|NCT00567879|9677006|FG004|Overall Study|Adverse Event|1
6073421|NCT00567879|9677007|FG005|Overall Study|Adverse Event|0
6073422|NCT00567879|9677002|FG000|Overall Study|Abnormal test procedure(s)|0
6073423|NCT00567879|9677003|FG001|Overall Study|Abnormal test procedure(s)|0
6073424|NCT00567879|9677004|FG002|Overall Study|Abnormal test procedure(s)|1
6073425|NCT00567879|9677005|FG003|Overall Study|Abnormal test procedure(s)|0
6073426|NCT00567879|9677006|FG004|Overall Study|Abnormal test procedure(s)|0
6073427|NCT00567879|9677007|FG005|Overall Study|Abnormal test procedure(s)|0
6073428|NCT00567879|9677002|FG000|Overall Study|Withdrawal by Subject|0
6073429|NCT00567879|9677003|FG001|Overall Study|Withdrawal by Subject|0
6073430|NCT00567879|9677004|FG002|Overall Study|Withdrawal by Subject|3
6073431|NCT00567879|9677005|FG003|Overall Study|Withdrawal by Subject|1
6003348|NCT00069095|9597716|FG000|Primary Treatment Phase|Adverse Event|99
6003349|NCT00069095|9597717|FG001|Primary Treatment Phase|Adverse Event|92
6003350|NCT00069095|9597718|FG002|Primary Treatment Phase|Adverse Event|71
6003351|NCT00069095|9597719|FG003|Primary Treatment Phase|Adverse Event|72
6003352|NCT00069095|9597720|FG004|Primary Treatment Phase|Adverse Event|109
6003353|NCT00069095|9597721|FG005|Primary Treatment Phase|Adverse Event|101
6003354|NCT00069095|9597716|FG000|Primary Treatment Phase|Death|14
6003355|NCT00069095|9597717|FG001|Primary Treatment Phase|Death|8
6003356|NCT00069095|9597718|FG002|Primary Treatment Phase|Death|2
6003357|NCT00069095|9597719|FG003|Primary Treatment Phase|Death|5
6003358|NCT00069095|9597720|FG004|Primary Treatment Phase|Death|8
6003359|NCT00069095|9597721|FG005|Primary Treatment Phase|Death|8
6003360|NCT00069095|9597716|FG000|Primary Treatment Phase|Failure to return|5
6003361|NCT00069095|9597717|FG001|Primary Treatment Phase|Failure to return|5
6003362|NCT00069095|9597718|FG002|Primary Treatment Phase|Failure to return|0
6003363|NCT00069095|9597719|FG003|Primary Treatment Phase|Failure to return|0
6003364|NCT00069095|9597720|FG004|Primary Treatment Phase|Failure to return|0
6003365|NCT00069095|9597721|FG005|Primary Treatment Phase|Failure to return|2
6003366|NCT00069095|9597716|FG000|Primary Treatment Phase|Insufficient Therapeutic Response|131
6003367|NCT00069095|9597717|FG001|Primary Treatment Phase|Insufficient Therapeutic Response|127
6003368|NCT00069095|9597718|FG002|Primary Treatment Phase|Insufficient Therapeutic Response|175
6003369|NCT00069095|9597719|FG003|Primary Treatment Phase|Insufficient Therapeutic Response|154
6003370|NCT00069095|9597720|FG004|Primary Treatment Phase|Insufficient Therapeutic Response|101
6003371|NCT00069095|9597721|FG005|Primary Treatment Phase|Insufficient Therapeutic Response|102
6003372|NCT00069095|9597716|FG000|Primary Treatment Phase|Refused treatment|15
6003373|NCT00069095|9597717|FG001|Primary Treatment Phase|Refused treatment|26
6003374|NCT00069095|9597718|FG002|Primary Treatment Phase|Refused treatment|17
6003375|NCT00069095|9597719|FG003|Primary Treatment Phase|Refused treatment|31
6003376|NCT00069095|9597720|FG004|Primary Treatment Phase|Refused treatment|24
6003377|NCT00069095|9597721|FG005|Primary Treatment Phase|Refused treatment|27
6003378|NCT00069095|9597716|FG000|Primary Treatment Phase|Withdrew|2
6003379|NCT00069095|9597717|FG001|Primary Treatment Phase|Withdrew|3
6003380|NCT00069095|9597718|FG002|Primary Treatment Phase|Withdrew|8
6003381|NCT00069095|9597719|FG003|Primary Treatment Phase|Withdrew|2
6003382|NCT00069095|9597720|FG004|Primary Treatment Phase|Withdrew|4
6003383|NCT00069095|9597721|FG005|Primary Treatment Phase|Withdrew|9
6003384|NCT00069095|9597716|FG000|Primary Treatment Phase|Other Violation|0
6003385|NCT00069095|9597717|FG001|Primary Treatment Phase|Other Violation|1
6003386|NCT00069095|9597718|FG002|Primary Treatment Phase|Other Violation|1
6003387|NCT00069095|9597719|FG003|Primary Treatment Phase|Other Violation|1
6003388|NCT00069095|9597720|FG004|Primary Treatment Phase|Other Violation|0
6003389|NCT00069095|9597721|FG005|Primary Treatment Phase|Other Violation|1
6003390|NCT00069095|9597716|FG000|Primary Treatment Phase|Violation criteria|0
6003391|NCT00069095|9597717|FG001|Primary Treatment Phase|Violation criteria|2
6003392|NCT00069095|9597718|FG002|Primary Treatment Phase|Violation criteria|4
6003393|NCT00069095|9597719|FG003|Primary Treatment Phase|Violation criteria|3
6003394|NCT00069095|9597720|FG004|Primary Treatment Phase|Violation criteria|1
6003395|NCT00069095|9597721|FG005|Primary Treatment Phase|Violation criteria|5
6003396|NCT00069095|9597716|FG000|Post-study Treatment Phase|Missing reason|1
6003397|NCT00069095|9597717|FG001|Post-study Treatment Phase|Missing reason|3
6003398|NCT00069095|9597718|FG002|Post-study Treatment Phase|Missing reason|12
6003399|NCT00069095|9597719|FG003|Post-study Treatment Phase|Missing reason|8
6003400|NCT00069095|9597720|FG004|Post-study Treatment Phase|Missing reason|18
6003401|NCT00069095|9597721|FG005|Post-study Treatment Phase|Missing reason|17
6003402|NCT00069095|9597716|FG000|Post-study Treatment Phase|Adverse Event|2
6003403|NCT00069095|9597717|FG001|Post-study Treatment Phase|Adverse Event|3
6003404|NCT00069095|9597718|FG002|Post-study Treatment Phase|Adverse Event|1
6003405|NCT00069095|9597719|FG003|Post-study Treatment Phase|Adverse Event|0
6003406|NCT00069095|9597720|FG004|Post-study Treatment Phase|Adverse Event|5
6003407|NCT00069095|9597721|FG005|Post-study Treatment Phase|Adverse Event|1
6003408|NCT00069095|9597716|FG000|Post-study Treatment Phase|Eligible for surgery|2
6003409|NCT00069095|9597717|FG001|Post-study Treatment Phase|Eligible for surgery|0
6003410|NCT00069095|9597718|FG002|Post-study Treatment Phase|Eligible for surgery|0
6073432|NCT00567879|9677006|FG004|Overall Study|Withdrawal by Subject|0
6073433|NCT00567879|9677007|FG005|Overall Study|Withdrawal by Subject|0
6073434|NCT00567879|9677002|FG000|Overall Study|New cancer therapy|0
6073435|NCT00567879|9677003|FG001|Overall Study|New cancer therapy|0
6073436|NCT00567879|9677004|FG002|Overall Study|New cancer therapy|1
6073437|NCT00567879|9677005|FG003|Overall Study|New cancer therapy|0
6073438|NCT00567879|9677006|FG004|Overall Study|New cancer therapy|0
6073439|NCT00567879|9677007|FG005|Overall Study|New cancer therapy|0
6073440|NCT00567879|9677002|FG000|Overall Study|Disease progression|5
6073441|NCT00567879|9677003|FG001|Overall Study|Disease progression|7
6073442|NCT00567879|9677004|FG002|Overall Study|Disease progression|15
6073443|NCT00567879|9677005|FG003|Overall Study|Disease progression|5
6073444|NCT00567879|9677006|FG004|Overall Study|Disease progression|11
6073445|NCT00567879|9677007|FG005|Overall Study|Disease progression|3
6073446|NCT00567892|9677027|FG000|First Treatment (2 or 4 Weeks)|Withdrawal by Subject|0
6073447|NCT00567892|9677028|FG001|First Treatment (2 or 4 Weeks)|Withdrawal by Subject|0
6003411|NCT00069095|9597719|FG003|Post-study Treatment Phase|Eligible for surgery|0
6003412|NCT00069095|9597720|FG004|Post-study Treatment Phase|Eligible for surgery|0
6003413|NCT00069095|9597721|FG005|Post-study Treatment Phase|Eligible for surgery|0
6003414|NCT00069095|9597716|FG000|Post-study Treatment Phase|Insufficient therapeutic response|1
6003415|NCT00069095|9597717|FG001|Post-study Treatment Phase|Insufficient therapeutic response|4
6003416|NCT00069095|9597718|FG002|Post-study Treatment Phase|Insufficient therapeutic response|5
6073448|NCT00567892|9677029|FG002|First Treatment (2 or 4 Weeks)|Withdrawal by Subject|1
6271848|NCT02168387|9973864|FG000|Overall Study|Death|1
6003417|NCT00069095|9597719|FG003|Post-study Treatment Phase|Insufficient therapeutic response|6
6003418|NCT00069095|9597720|FG004|Post-study Treatment Phase|Insufficient therapeutic response|7
6003419|NCT00069095|9597721|FG005|Post-study Treatment Phase|Insufficient therapeutic response|9
6003420|NCT00069095|9597716|FG000|Post-study Treatment Phase|Participant refusal/Admin reasons|1
6003421|NCT00069095|9597717|FG001|Post-study Treatment Phase|Participant refusal/Admin reasons|0
6003422|NCT00069095|9597718|FG002|Post-study Treatment Phase|Participant refusal/Admin reasons|0
6003423|NCT00069095|9597719|FG003|Post-study Treatment Phase|Participant refusal/Admin reasons|0
6003424|NCT00069095|9597720|FG004|Post-study Treatment Phase|Participant refusal/Admin reasons|0
6003425|NCT00069095|9597721|FG005|Post-study Treatment Phase|Participant refusal/Admin reasons|1
6003426|NCT00069095|9597716|FG000|Post-study Treatment Phase|Participant had complete response|1
6003427|NCT00069095|9597717|FG001|Post-study Treatment Phase|Participant had complete response|1
6003428|NCT00069095|9597718|FG002|Post-study Treatment Phase|Participant had complete response|0
6003429|NCT00069095|9597719|FG003|Post-study Treatment Phase|Participant had complete response|0
6003430|NCT00069095|9597720|FG004|Post-study Treatment Phase|Participant had complete response|0
6003431|NCT00069095|9597721|FG005|Post-study Treatment Phase|Participant had complete response|0
6003432|NCT00069095|9597716|FG000|Post-study Treatment Phase|More than 21 days delay between cycles|0
6003433|NCT00069095|9597717|FG001|Post-study Treatment Phase|More than 21 days delay between cycles|1
6003434|NCT00069095|9597718|FG002|Post-study Treatment Phase|More than 21 days delay between cycles|0
6003435|NCT00069095|9597719|FG003|Post-study Treatment Phase|More than 21 days delay between cycles|0
6003436|NCT00069095|9597720|FG004|Post-study Treatment Phase|More than 21 days delay between cycles|0
6003437|NCT00069095|9597721|FG005|Post-study Treatment Phase|More than 21 days delay between cycles|0
6003438|NCT00069095|9597716|FG000|Post-study Treatment Phase|Investigator decision (enough treatment)|0
6003439|NCT00069095|9597717|FG001|Post-study Treatment Phase|Investigator decision (enough treatment)|1
6003440|NCT00069095|9597718|FG002|Post-study Treatment Phase|Investigator decision (enough treatment)|1
6003441|NCT00069095|9597719|FG003|Post-study Treatment Phase|Investigator decision (enough treatment)|0
6003442|NCT00069095|9597720|FG004|Post-study Treatment Phase|Investigator decision (enough treatment)|1
6003443|NCT00069095|9597721|FG005|Post-study Treatment Phase|Investigator decision (enough treatment)|0
6003444|NCT00069095|9597716|FG000|Post-study Treatment Phase|Participant withdrew consent|0
6003445|NCT00069095|9597717|FG001|Post-study Treatment Phase|Participant withdrew consent|0
6003446|NCT00069095|9597718|FG002|Post-study Treatment Phase|Participant withdrew consent|1
6003447|NCT00069095|9597719|FG003|Post-study Treatment Phase|Participant withdrew consent|0
6003448|NCT00069095|9597720|FG004|Post-study Treatment Phase|Participant withdrew consent|0
6003449|NCT00069095|9597721|FG005|Post-study Treatment Phase|Participant withdrew consent|0
6003450|NCT00069095|9597716|FG000|Post-study Treatment Phase|Participant will start new treatment|0
6003451|NCT00069095|9597717|FG001|Post-study Treatment Phase|Participant will start new treatment|0
6003452|NCT00069095|9597718|FG002|Post-study Treatment Phase|Participant will start new treatment|1
6003453|NCT00069095|9597719|FG003|Post-study Treatment Phase|Participant will start new treatment|0
6003454|NCT00069095|9597720|FG004|Post-study Treatment Phase|Participant will start new treatment|0
6003455|NCT00069095|9597721|FG005|Post-study Treatment Phase|Participant will start new treatment|0
6003456|NCT00069095|9597716|FG000|Post-study Treatment Phase|Participant wanted break from treatment|0
6003457|NCT00069095|9597717|FG001|Post-study Treatment Phase|Participant wanted break from treatment|0
6003458|NCT00069095|9597718|FG002|Post-study Treatment Phase|Participant wanted break from treatment|0
6003459|NCT00069095|9597719|FG003|Post-study Treatment Phase|Participant wanted break from treatment|1
6003460|NCT00069095|9597720|FG004|Post-study Treatment Phase|Participant wanted break from treatment|0
6003461|NCT00069095|9597721|FG005|Post-study Treatment Phase|Participant wanted break from treatment|0
6003462|NCT00069095|9597716|FG000|Post-study Treatment Phase|Participant completed treatment|0
6003463|NCT00069095|9597717|FG001|Post-study Treatment Phase|Participant completed treatment|0
6003464|NCT00069095|9597718|FG002|Post-study Treatment Phase|Participant completed treatment|0
6003465|NCT00069095|9597719|FG003|Post-study Treatment Phase|Participant completed treatment|1
6003466|NCT00069095|9597720|FG004|Post-study Treatment Phase|Participant completed treatment|0
6003467|NCT00069095|9597721|FG005|Post-study Treatment Phase|Participant completed treatment|0
6003468|NCT00069095|9597716|FG000|Post-study Treatment Phase|Surgery|0
6003469|NCT00069095|9597717|FG001|Post-study Treatment Phase|Surgery|0
6003470|NCT00069095|9597718|FG002|Post-study Treatment Phase|Surgery|0
6003471|NCT00069095|9597719|FG003|Post-study Treatment Phase|Surgery|1
6003472|NCT00069095|9597720|FG004|Post-study Treatment Phase|Surgery|1
6003473|NCT00069095|9597721|FG005|Post-study Treatment Phase|Surgery|0
6003474|NCT00069095|9597716|FG000|Post-study Treatment Phase|Death|0
6003475|NCT00069095|9597717|FG001|Post-study Treatment Phase|Death|0
6003476|NCT00069095|9597718|FG002|Post-study Treatment Phase|Death|0
6003477|NCT00069095|9597719|FG003|Post-study Treatment Phase|Death|0
6003478|NCT00069095|9597720|FG004|Post-study Treatment Phase|Death|1
6003479|NCT00069095|9597721|FG005|Post-study Treatment Phase|Death|0
6003480|NCT00069095|9597716|FG000|Post-study Treatment Phase|Participant had progressive disease|0
6003481|NCT00069095|9597717|FG001|Post-study Treatment Phase|Participant had progressive disease|0
6003482|NCT00069095|9597718|FG002|Post-study Treatment Phase|Participant had progressive disease|0
6003483|NCT00069095|9597719|FG003|Post-study Treatment Phase|Participant had progressive disease|0
6003484|NCT00069095|9597720|FG004|Post-study Treatment Phase|Participant had progressive disease|1
6003485|NCT00069095|9597721|FG005|Post-study Treatment Phase|Participant had progressive disease|0
6003486|NCT00069095|9597716|FG000|Post-study Treatment Phase|Participant/Physician decision to stop|0
6003487|NCT00069095|9597717|FG001|Post-study Treatment Phase|Participant/Physician decision to stop|0
6003488|NCT00069095|9597718|FG002|Post-study Treatment Phase|Participant/Physician decision to stop|0
6003489|NCT00069095|9597719|FG003|Post-study Treatment Phase|Participant/Physician decision to stop|0
6003490|NCT00069095|9597720|FG004|Post-study Treatment Phase|Participant/Physician decision to stop|1
6003491|NCT00069095|9597721|FG005|Post-study Treatment Phase|Participant/Physician decision to stop|0
6003492|NCT00069095|9597716|FG000|Post-study Treatment Phase|Preplanned 6 cycles after surgery|0
6003493|NCT00069095|9597717|FG001|Post-study Treatment Phase|Preplanned 6 cycles after surgery|0
6003494|NCT00069095|9597718|FG002|Post-study Treatment Phase|Preplanned 6 cycles after surgery|0
6003495|NCT00069095|9597719|FG003|Post-study Treatment Phase|Preplanned 6 cycles after surgery|0
6003496|NCT00069095|9597720|FG004|Post-study Treatment Phase|Preplanned 6 cycles after surgery|1
6003497|NCT00069095|9597721|FG005|Post-study Treatment Phase|Preplanned 6 cycles after surgery|0
6003498|NCT00069095|9597716|FG000|Post-study Treatment Phase|Investigator decision|0
6003499|NCT00069095|9597717|FG001|Post-study Treatment Phase|Investigator decision|0
6003500|NCT00069095|9597718|FG002|Post-study Treatment Phase|Investigator decision|0
6003501|NCT00069095|9597719|FG003|Post-study Treatment Phase|Investigator decision|0
6003502|NCT00069095|9597720|FG004|Post-study Treatment Phase|Investigator decision|0
6003503|NCT00069095|9597721|FG005|Post-study Treatment Phase|Investigator decision|1
6003504|NCT00069095|9597716|FG000|Follow-up Phase|Death|174
6003505|NCT00069095|9597717|FG001|Follow-up Phase|Death|206
6003506|NCT00069095|9597718|FG002|Follow-up Phase|Death|120
6003507|NCT00069095|9597719|FG003|Follow-up Phase|Death|112
6003508|NCT00069095|9597720|FG004|Follow-up Phase|Death|92
6003509|NCT00069095|9597721|FG005|Follow-up Phase|Death|101
6003510|NCT00069108|9597735|FG000|Overall Study|Withdrawal by Subject|5
6003511|NCT00069108|9597736|FG001|Overall Study|Withdrawal by Subject|9
6003512|NCT00069108|9597735|FG000|Overall Study|Adverse Event|64
6003513|NCT00069108|9597736|FG001|Overall Study|Adverse Event|42
6003514|NCT00069108|9597735|FG000|Overall Study|Death|6
6003515|NCT00069108|9597736|FG001|Overall Study|Death|6
6003516|NCT00069108|9597735|FG000|Overall Study|Administration|15
6003517|NCT00069108|9597736|FG001|Overall Study|Administration|4
6003518|NCT00069108|9597735|FG000|Overall Study|Insufficient therapy|117
6003519|NCT00069108|9597736|FG001|Overall Study|Insufficient therapy|144
6003520|NCT00069108|9597735|FG000|Overall Study|Violation criteria|1
6003521|NCT00069108|9597736|FG001|Overall Study|Violation criteria|4
6003522|NCT00069108|9597735|FG000|Overall Study|Refused treatment|5
6003523|NCT00069108|9597736|FG001|Overall Study|Refused treatment|10
6003524|NCT00069121|9597745|FG000|Overall Study|Death|286
6003525|NCT00069121|9597746|FG001|Overall Study|Death|242
6003526|NCT00069121|9597745|FG000|Overall Study|Withdrawal by Subject|18
6003527|NCT00069121|9597746|FG001|Overall Study|Withdrawal by Subject|20
6003528|NCT00069121|9597745|FG000|Overall Study|Lost to Follow-up|63
6003529|NCT00069121|9597746|FG001|Overall Study|Lost to Follow-up|63
6003530|NCT00069264|9597768|FG000|Overall Study|Adverse Event|3
6003531|NCT00069264|9597768|FG000|Overall Study|Progressive Disease|23
6003532|NCT00069264|9597768|FG000|Overall Study|Withdrawal by Subject|3
6003533|NCT00069264|9597768|FG000|Overall Study|Discon Therapy|3
6003534|NCT00069277|9597772|FG000|Overall Study|Adverse Event|3
6003535|NCT00069277|9597772|FG000|Overall Study|Withdrawal by Subject|1
6003536|NCT00069277|9597772|FG000|Overall Study|Progressive Disease|15
6003537|NCT00069277|9597772|FG000|Overall Study|Physician Decision|2
6047273|NCT00410410|9646252|FG003|Induction Period (IP)|Other|0
6047274|NCT00410410|9646253|FG004|Induction Period (IP)|Other|0
6047275|NCT00410410|9646254|FG005|Induction Period (IP)|Other|0
6047276|NCT00410410|9646255|FG006|Induction Period (IP)|Other|0
6047277|NCT00410410|9646256|FG007|Induction Period (IP)|Other|0
6047278|NCT00410410|9646257|FG008|Induction Period (IP)|Other|0
6047279|NCT00410410|9646249|FG000|Maintenance Period (MP)|Death|0
6047280|NCT00410410|9646250|FG001|Maintenance Period (MP)|Death|0
6047281|NCT00410410|9646251|FG002|Maintenance Period (MP)|Death|0
6047282|NCT00410410|9646252|FG003|Maintenance Period (MP)|Death|0
6047283|NCT00410410|9646253|FG004|Maintenance Period (MP)|Death|0
6047284|NCT00410410|9646254|FG005|Maintenance Period (MP)|Death|0
6047285|NCT00410410|9646255|FG006|Maintenance Period (MP)|Death|1
6047286|NCT00410410|9646256|FG007|Maintenance Period (MP)|Death|0
6047287|NCT00410410|9646257|FG008|Maintenance Period (MP)|Death|0
6047288|NCT00410410|9646249|FG000|Maintenance Period (MP)|Adverse Event|0
6047289|NCT00410410|9646250|FG001|Maintenance Period (MP)|Adverse Event|0
6047290|NCT00410410|9646251|FG002|Maintenance Period (MP)|Adverse Event|0
6047291|NCT00410410|9646252|FG003|Maintenance Period (MP)|Adverse Event|0
6047292|NCT00410410|9646253|FG004|Maintenance Period (MP)|Adverse Event|0
6047293|NCT00410410|9646254|FG005|Maintenance Period (MP)|Adverse Event|0
6047294|NCT00410410|9646255|FG006|Maintenance Period (MP)|Adverse Event|1
6047295|NCT00410410|9646256|FG007|Maintenance Period (MP)|Adverse Event|3
6047296|NCT00410410|9646257|FG008|Maintenance Period (MP)|Adverse Event|0
6047297|NCT00410410|9646249|FG000|Maintenance Period (MP)|Lack of Efficacy|0
6047298|NCT00410410|9646250|FG001|Maintenance Period (MP)|Lack of Efficacy|0
6047299|NCT00410410|9646251|FG002|Maintenance Period (MP)|Lack of Efficacy|0
6003538|NCT00069576|9597782|FG000|Original Trial|Lost to Follow-up|25
6003539|NCT00069576|9597783|FG001|Original Trial|Lost to Follow-up|33
6003540|NCT00069576|9597782|FG000|Follow-up Study at 5-10 Years|Not eligible or did not consent|196
6003541|NCT00069576|9597783|FG001|Follow-up Study at 5-10 Years|Not eligible or did not consent|204
6003542|NCT00069641|9597792|FG000|Overall Study|Death|1
6003543|NCT00069641|9597793|FG001|Overall Study|Death|0
6003544|NCT00069641|9597794|FG002|Overall Study|Death|1
6003545|NCT00069784|9597805|FG000|Overall Study|Adverse Event|105
6003546|NCT00069784|9597806|FG001|Overall Study|Adverse Event|0
6003547|NCT00069784|9597805|FG000|Overall Study|Withdrawal by Subject|1090
6003548|NCT00069784|9597806|FG001|Overall Study|Withdrawal by Subject|0
6003549|NCT00069784|9597805|FG000|Overall Study|Other|17
6003550|NCT00069784|9597806|FG001|Overall Study|Other|0
6003551|NCT00069823|9597814|FG000|Overall Study|Did not have follow-up diary cards|6
6003552|NCT00069823|9597815|FG001|Overall Study|Did not have follow-up diary cards|3
6003553|NCT00069953|9597821|FG000|Overall Study|Protocol Violation|2
6003554|NCT00070109|9597847|FG000|Overall Study|Death|1
6003555|NCT00070109|9597848|FG001|Overall Study|Death|1
6003556|NCT00070109|9597849|FG002|Overall Study|Death|0
6003557|NCT00070109|9597850|FG003|Overall Study|Death|0
6003558|NCT00070109|9597851|FG004|Overall Study|Death|1
6003559|NCT00070109|9597847|FG000|Overall Study|Lack of Efficacy|6
6003560|NCT00070109|9597848|FG001|Overall Study|Lack of Efficacy|4
6003561|NCT00070109|9597849|FG002|Overall Study|Lack of Efficacy|5
6003562|NCT00070109|9597850|FG003|Overall Study|Lack of Efficacy|15
6003563|NCT00070109|9597851|FG004|Overall Study|Lack of Efficacy|5
6003564|NCT00070109|9597847|FG000|Overall Study|Physician Decision|1
6003565|NCT00070109|9597848|FG001|Overall Study|Physician Decision|0
6003566|NCT00070109|9597849|FG002|Overall Study|Physician Decision|0
6003567|NCT00070109|9597850|FG003|Overall Study|Physician Decision|0
6003568|NCT00070109|9597851|FG004|Overall Study|Physician Decision|0
6003569|NCT00070109|9597847|FG000|Overall Study|Withdrawal by Subject|0
6003570|NCT00070109|9597848|FG001|Overall Study|Withdrawal by Subject|1
6003571|NCT00070109|9597849|FG002|Overall Study|Withdrawal by Subject|1
6003572|NCT00070109|9597850|FG003|Overall Study|Withdrawal by Subject|0
6003573|NCT00070109|9597851|FG004|Overall Study|Withdrawal by Subject|0
6003574|NCT00070109|9597847|FG000|Overall Study|Adverse Event|0
6003575|NCT00070109|9597848|FG001|Overall Study|Adverse Event|0
6003576|NCT00070109|9597849|FG002|Overall Study|Adverse Event|2
6003577|NCT00070109|9597850|FG003|Overall Study|Adverse Event|4
6003578|NCT00070109|9597851|FG004|Overall Study|Adverse Event|2
6003579|NCT00070109|9597847|FG000|Overall Study|removed from prot thpy prior to chemo|0
6003580|NCT00070109|9597848|FG001|Overall Study|removed from prot thpy prior to chemo|0
6003581|NCT00070109|9597849|FG002|Overall Study|removed from prot thpy prior to chemo|0
6003582|NCT00070109|9597850|FG003|Overall Study|removed from prot thpy prior to chemo|1
6003583|NCT00070109|9597851|FG004|Overall Study|removed from prot thpy prior to chemo|0
6003584|NCT00070291|9597874|FG000|Step 1|Withdrawal by Subject|1
6003585|NCT00070291|9597874|FG000|Step 1|Adverse Event|1
6003586|NCT00070291|9597874|FG000|Step 2|Adverse Event|1
6003587|NCT00070317|9597878|FG000|Overall Study|Inevaluable (Never Treated)|1
6003588|NCT00070317|9597878|FG000|Overall Study|Ineligible Wrong Cell type/primary/stage|3
6003589|NCT00070317|9597878|FG000|Overall Study|Ineligible required test not done|1
6003590|NCT00070317|9597878|FG000|Overall Study|Ineligible-Improper prior treatment|2
6003591|NCT00070317|9597878|FG000|Overall Study|Ineligible-Inadequate pathology|6
6003592|NCT00070941|9597885|FG000|Overall Study|Adverse Event|10
6003593|NCT00070941|9597886|FG001|Overall Study|Adverse Event|8
6003594|NCT00070941|9597887|FG002|Overall Study|Adverse Event|4
6003595|NCT00071006|9597895|FG000|Overall Study|Lack of Efficacy|7
6003596|NCT00071006|9597895|FG000|Overall Study|Adverse Event|1
6003597|NCT00071006|9597895|FG000|Overall Study|Withdrawal by Subject|1
6003598|NCT00071006|9597895|FG000|Overall Study|Other|3
6003599|NCT00071032|9597901|FG000|Overall Study|Lost to Follow-up|1
6003600|NCT00071032|9597902|FG001|Overall Study|Lost to Follow-up|1
6003601|NCT00071032|9597901|FG000|Overall Study|Withdrawal by Subject|8
6003602|NCT00071032|9597902|FG001|Overall Study|Withdrawal by Subject|6
6003603|NCT00071032|9597901|FG000|Overall Study|Missing Primary Outcome|0
6003604|NCT00071032|9597902|FG001|Overall Study|Missing Primary Outcome|1
6003605|NCT00071058|9597909|FG000|Overall Study|brain tumor-removed from study|1
6003606|NCT00071110|9597916|FG000|Overall Study|Protocol Violation|0
6003607|NCT00071110|9597917|FG001|Overall Study|Protocol Violation|4
6003608|NCT00071396|9597923|FG000|Overall Study|Withdrawal by Subject|1
6003609|NCT00071396|9597923|FG000|Overall Study|Physician Decision|2
6003610|NCT00071487|9597931|FG000|52-Week Double-Blind Period|Adverse Event|5
6003611|NCT00071487|9597932|FG001|52-Week Double-Blind Period|Adverse Event|8
6003612|NCT00071487|9597933|FG002|52-Week Double-Blind Period|Adverse Event|4
6003613|NCT00071487|9597934|FG003|52-Week Double-Blind Period|Adverse Event|8
6003614|NCT00071487|9597931|FG000|52-Week Double-Blind Period|Lack of Efficacy|1
6003615|NCT00071487|9597932|FG001|52-Week Double-Blind Period|Lack of Efficacy|2
6003616|NCT00071487|9597933|FG002|52-Week Double-Blind Period|Lack of Efficacy|0
6003617|NCT00071487|9597934|FG003|52-Week Double-Blind Period|Lack of Efficacy|1
6003618|NCT00071487|9597931|FG000|52-Week Double-Blind Period|Withdrawal by Subject|7
6003619|NCT00071487|9597932|FG001|52-Week Double-Blind Period|Withdrawal by Subject|11
6003620|NCT00071487|9597933|FG002|52-Week Double-Blind Period|Withdrawal by Subject|7
6003621|NCT00071487|9597934|FG003|52-Week Double-Blind Period|Withdrawal by Subject|7
6003622|NCT00071487|9597931|FG000|52-Week Double-Blind Period|Physician Decision|1
6003623|NCT00071487|9597932|FG001|52-Week Double-Blind Period|Physician Decision|0
6003624|NCT00071487|9597933|FG002|52-Week Double-Blind Period|Physician Decision|0
6003625|NCT00071487|9597934|FG003|52-Week Double-Blind Period|Physician Decision|0
6003626|NCT00071487|9597931|FG000|52-Week Double-Blind Period|Lost to Follow-up|0
6003627|NCT00071487|9597932|FG001|52-Week Double-Blind Period|Lost to Follow-up|0
6003628|NCT00071487|9597933|FG002|52-Week Double-Blind Period|Lost to Follow-up|2
6003629|NCT00071487|9597934|FG003|52-Week Double-Blind Period|Lost to Follow-up|2
6003630|NCT00071487|9597931|FG000|52-Week Double-Blind Period|Pregnancy|0
6003631|NCT00071487|9597932|FG001|52-Week Double-Blind Period|Pregnancy|1
6271849|NCT02168387|9973865|FG001|Overall Study|Death|0
6003632|NCT00071487|9597933|FG002|52-Week Double-Blind Period|Pregnancy|0
6003633|NCT00071487|9597934|FG003|52-Week Double-Blind Period|Pregnancy|0
6003634|NCT00071487|9597931|FG000|52-Week Double-Blind Period|Protocol Violation|0
6003635|NCT00071487|9597932|FG001|52-Week Double-Blind Period|Protocol Violation|1
6003636|NCT00071487|9597933|FG002|52-Week Double-Blind Period|Protocol Violation|1
6003637|NCT00071487|9597934|FG003|52-Week Double-Blind Period|Protocol Violation|0
6003638|NCT00071487|9597931|FG000|52-Week Double-Blind Period|Death|0
6003639|NCT00071487|9597932|FG001|52-Week Double-Blind Period|Death|1
6003640|NCT00071487|9597933|FG002|52-Week Double-Blind Period|Death|0
6003641|NCT00071487|9597934|FG003|52-Week Double-Blind Period|Death|0
6003642|NCT00071487|9597931|FG000|52-Week Double-Blind Period|Lack of Compliance|6
6003643|NCT00071487|9597932|FG001|52-Week Double-Blind Period|Lack of Compliance|3
6003644|NCT00071487|9597933|FG002|52-Week Double-Blind Period|Lack of Compliance|3
6003645|NCT00071487|9597934|FG003|52-Week Double-Blind Period|Lack of Compliance|3
6003646|NCT00071487|9597931|FG000|24-Week Open-Label Extension Period|Adverse Event|0
6003647|NCT00071487|9597932|FG001|24-Week Open-Label Extension Period|Adverse Event|0
6003648|NCT00071487|9597933|FG002|24-Week Open-Label Extension Period|Adverse Event|1
6003649|NCT00071487|9597934|FG003|24-Week Open-Label Extension Period|Adverse Event|6
6003650|NCT00071487|9597931|FG000|24-Week Open-Label Extension Period|Lack of Efficacy|0
6003651|NCT00071487|9597932|FG001|24-Week Open-Label Extension Period|Lack of Efficacy|0
6003652|NCT00071487|9597933|FG002|24-Week Open-Label Extension Period|Lack of Efficacy|0
6003653|NCT00071487|9597934|FG003|24-Week Open-Label Extension Period|Lack of Efficacy|3
6003654|NCT00071487|9597931|FG000|24-Week Open-Label Extension Period|Withdrawal by Subject|0
6003655|NCT00071487|9597932|FG001|24-Week Open-Label Extension Period|Withdrawal by Subject|0
6003656|NCT00071487|9597933|FG002|24-Week Open-Label Extension Period|Withdrawal by Subject|0
6003657|NCT00071487|9597934|FG003|24-Week Open-Label Extension Period|Withdrawal by Subject|9
6003658|NCT00071487|9597931|FG000|24-Week Open-Label Extension Period|Pregnancy|0
6003659|NCT00071487|9597932|FG001|24-Week Open-Label Extension Period|Pregnancy|0
6003660|NCT00071487|9597933|FG002|24-Week Open-Label Extension Period|Pregnancy|0
6003661|NCT00071487|9597934|FG003|24-Week Open-Label Extension Period|Pregnancy|1
6003662|NCT00071487|9597931|FG000|24-Week Open-Label Extension Period|Lost to Follow-up|0
6003663|NCT00071487|9597932|FG001|24-Week Open-Label Extension Period|Lost to Follow-up|0
6003664|NCT00071487|9597933|FG002|24-Week Open-Label Extension Period|Lost to Follow-up|0
6003665|NCT00071487|9597934|FG003|24-Week Open-Label Extension Period|Lost to Follow-up|2
6003666|NCT00071487|9597931|FG000|24-Week Open-Label Extension Period|Lack of Compliance|0
6003667|NCT00071487|9597932|FG001|24-Week Open-Label Extension Period|Lack of Compliance|0
6003668|NCT00071487|9597933|FG002|24-Week Open-Label Extension Period|Lack of Compliance|0
6003669|NCT00071487|9597934|FG003|24-Week Open-Label Extension Period|Lack of Compliance|2
6003670|NCT00071513|9597948|FG000|Intervention Component|Withdrawal by Subject|2
6003671|NCT00071513|9597949|FG001|Intervention Component|Withdrawal by Subject|3
6073449|NCT00567892|9677030|FG003|First Treatment (2 or 4 Weeks)|Withdrawal by Subject|4
6073450|NCT00567892|9677027|FG000|Second Treatment (2 or 4 Weeks)|Withdrawal by Subject|0
6073451|NCT00567892|9677028|FG001|Second Treatment (2 or 4 Weeks)|Withdrawal by Subject|0
6073452|NCT00567892|9677029|FG002|Second Treatment (2 or 4 Weeks)|Withdrawal by Subject|0
6073453|NCT00567892|9677030|FG003|Second Treatment (2 or 4 Weeks)|Withdrawal by Subject|1
6073454|NCT00567996|9677045|FG000|Overall Study|Adverse Event|18
6073455|NCT00567996|9677046|FG001|Overall Study|Adverse Event|16
6073456|NCT00567996|9677047|FG002|Overall Study|Adverse Event|13
6073457|NCT00567996|9677045|FG000|Overall Study|Protocol Deviation|9
6073458|NCT00567996|9677046|FG001|Overall Study|Protocol Deviation|11
6073459|NCT00567996|9677047|FG002|Overall Study|Protocol Deviation|13
6073460|NCT00567996|9677045|FG000|Overall Study|Withdrawal by Subject|8
6073461|NCT00567996|9677046|FG001|Overall Study|Withdrawal by Subject|12
6073462|NCT00567996|9677047|FG002|Overall Study|Withdrawal by Subject|22
6073463|NCT00567996|9677045|FG000|Overall Study|Abnormal Lab value(s)|2
6073464|NCT00567996|9677046|FG001|Overall Study|Abnormal Lab value(s)|1
6073465|NCT00567996|9677047|FG002|Overall Study|Abnormal Lab value(s)|2
6073466|NCT00567996|9677045|FG000|Overall Study|Abnormal test procedure result(s)|2
6073467|NCT00567996|9677046|FG001|Overall Study|Abnormal test procedure result(s)|1
6003672|NCT00071513|9597948|FG000|Follow-up Assessment|Withdrawal by Subject|6
6003673|NCT00071513|9597949|FG001|Follow-up Assessment|Withdrawal by Subject|6
6003674|NCT00071760|9597966|FG000|Overall Study|Adverse Event|3
6003675|NCT00071760|9597966|FG000|Overall Study|Lost to Follow-up|4
6073468|NCT00567996|9677047|FG002|Overall Study|Abnormal test procedure result(s)|1
6073469|NCT00567996|9677045|FG000|Overall Study|Lost to Follow-up|2
6073470|NCT00567996|9677046|FG001|Overall Study|Lost to Follow-up|5
6073471|NCT00567996|9677047|FG002|Overall Study|Lost to Follow-up|2
6073472|NCT00567996|9677045|FG000|Overall Study|Unsatisfactory therapeutic effect|1
6073473|NCT00567996|9677046|FG001|Overall Study|Unsatisfactory therapeutic effect|2
6073474|NCT00567996|9677047|FG002|Overall Study|Unsatisfactory therapeutic effect|15
6003676|NCT00071760|9597966|FG000|Overall Study|Protocol Violation|1
6003677|NCT00071760|9597966|FG000|Overall Study|Withdrawal by Subject|3
6003678|NCT00071760|9597966|FG000|Overall Study|Insufficient Viral Load Response|3
6003679|NCT00071760|9597966|FG000|Overall Study|Pulmonary Tuberculosis|1
6003680|NCT00071760|9597966|FG000|Overall Study|Unavailability of RTV|8
6003681|NCT00071760|9597966|FG000|Overall Study|Relocation|1
6003682|NCT00071760|9597966|FG000|Overall Study|Investigator's Recommendation (Rec.)|4
6003683|NCT00071760|9597966|FG000|Overall Study|Study Team Rec./Resistance|1
6003684|NCT00071760|9597966|FG000|Overall Study|Ongoing|25
6003685|NCT00071799|9597978|FG000|Overall Study|Adverse Event|19
6003686|NCT00071799|9597979|FG001|Overall Study|Adverse Event|10
6003687|NCT00071799|9597978|FG000|Overall Study|Protocol Violation|1
6003688|NCT00071799|9597979|FG001|Overall Study|Protocol Violation|7
6073475|NCT00567996|9677045|FG000|Overall Study|Administrative problems|1
6271850|NCT02168439|9973873|FG000|Overall Study|Protocol Violation|0
6003689|NCT00071799|9597978|FG000|Overall Study|Lost to Follow-up|1
6003690|NCT00071799|9597979|FG001|Overall Study|Lost to Follow-up|1
6003691|NCT00071799|9597978|FG000|Overall Study|Withdrawal by Subject|15
6003692|NCT00071799|9597979|FG001|Overall Study|Withdrawal by Subject|37
6003693|NCT00071799|9597978|FG000|Overall Study|Physician Decision|0
6003694|NCT00071799|9597979|FG001|Overall Study|Physician Decision|2
6003695|NCT00071799|9597978|FG000|Overall Study|Lack of Efficacy|11
6003696|NCT00071799|9597979|FG001|Overall Study|Lack of Efficacy|18
6003697|NCT00071799|9597978|FG000|Overall Study|Disease Progression|23
6003698|NCT00071799|9597979|FG001|Overall Study|Disease Progression|20
6003699|NCT00071799|9597978|FG000|Overall Study|Different Central+Local Pathology Review|0
6003700|NCT00071799|9597979|FG001|Overall Study|Different Central+Local Pathology Review|1
6003701|NCT00071799|9597978|FG000|Overall Study|Not Documented|0
6003702|NCT00071799|9597979|FG001|Overall Study|Not Documented|2
6003703|NCT00071812|9597995|FG000|24-Week Double-Blind Period|Adverse Event|2
6003704|NCT00071812|9597996|FG001|24-Week Double-Blind Period|Adverse Event|3
6003705|NCT00071812|9597997|FG002|24-Week Double-Blind Period|Adverse Event|4
6003706|NCT00071812|9597998|FG003|24-Week Double-Blind Period|Adverse Event|4
6003707|NCT00071812|9597995|FG000|24-Week Double-Blind Period|Lack of Efficacy|3
6003708|NCT00071812|9597996|FG001|24-Week Double-Blind Period|Lack of Efficacy|1
6003709|NCT00071812|9597997|FG002|24-Week Double-Blind Period|Lack of Efficacy|2
6003710|NCT00071812|9597998|FG003|24-Week Double-Blind Period|Lack of Efficacy|1
6003711|NCT00071812|9597995|FG000|24-Week Double-Blind Period|Lost to Follow-up|0
6003712|NCT00071812|9597996|FG001|24-Week Double-Blind Period|Lost to Follow-up|1
6003713|NCT00071812|9597997|FG002|24-Week Double-Blind Period|Lost to Follow-up|1
6003714|NCT00071812|9597998|FG003|24-Week Double-Blind Period|Lost to Follow-up|0
6003715|NCT00071812|9597995|FG000|24-Week Double-Blind Period|Withdrawal by Subject|5
6003716|NCT00071812|9597996|FG001|24-Week Double-Blind Period|Withdrawal by Subject|1
6003717|NCT00071812|9597997|FG002|24-Week Double-Blind Period|Withdrawal by Subject|1
6003718|NCT00071812|9597998|FG003|24-Week Double-Blind Period|Withdrawal by Subject|5
6003719|NCT00071812|9597995|FG000|24-Week Double-Blind Period|Protocol Violation|0
6003720|NCT00071812|9597996|FG001|24-Week Double-Blind Period|Protocol Violation|0
6003721|NCT00071812|9597997|FG002|24-Week Double-Blind Period|Protocol Violation|0
6003722|NCT00071812|9597998|FG003|24-Week Double-Blind Period|Protocol Violation|1
6003723|NCT00071812|9597995|FG000|24-Week Open-Label Extension Period|Adverse Event|0
6003724|NCT00071812|9597996|FG001|24-Week Open-Label Extension Period|Adverse Event|0
6003725|NCT00071812|9597997|FG002|24-Week Open-Label Extension Period|Adverse Event|0
6003726|NCT00071812|9597998|FG003|24-Week Open-Label Extension Period|Adverse Event|7
6003727|NCT00071812|9597995|FG000|24-Week Open-Label Extension Period|Lack of Efficacy|0
6003728|NCT00071812|9597996|FG001|24-Week Open-Label Extension Period|Lack of Efficacy|0
6003729|NCT00071812|9597997|FG002|24-Week Open-Label Extension Period|Lack of Efficacy|0
6003730|NCT00071812|9597998|FG003|24-Week Open-Label Extension Period|Lack of Efficacy|17
6003731|NCT00071812|9597995|FG000|24-Week Open-Label Extension Period|Lost to Follow-up|0
6003732|NCT00071812|9597996|FG001|24-Week Open-Label Extension Period|Lost to Follow-up|0
6003733|NCT00071812|9597997|FG002|24-Week Open-Label Extension Period|Lost to Follow-up|0
6003734|NCT00071812|9597998|FG003|24-Week Open-Label Extension Period|Lost to Follow-up|2
6003735|NCT00071812|9597995|FG000|24-Week Open-Label Extension Period|Withdrawal by Subject|0
6003736|NCT00071812|9597996|FG001|24-Week Open-Label Extension Period|Withdrawal by Subject|0
6003737|NCT00071812|9597997|FG002|24-Week Open-Label Extension Period|Withdrawal by Subject|0
6003738|NCT00071812|9597998|FG003|24-Week Open-Label Extension Period|Withdrawal by Subject|12
6003739|NCT00071812|9597995|FG000|24-Week Open-Label Extension Period|Lack of Compliance|0
6003740|NCT00071812|9597996|FG001|24-Week Open-Label Extension Period|Lack of Compliance|0
6003741|NCT00071812|9597997|FG002|24-Week Open-Label Extension Period|Lack of Compliance|1
6003742|NCT00071812|9597998|FG003|24-Week Open-Label Extension Period|Lack of Compliance|2
6003743|NCT00071981|9598023|FG000|Overall Study|Lack of Efficacy|37
6003744|NCT00071981|9598024|FG001|Overall Study|Lack of Efficacy|29
6073476|NCT00567996|9677046|FG001|Overall Study|Administrative problems|1
6003745|NCT00071981|9598025|FG002|Overall Study|Lack of Efficacy|30
6003746|NCT00071981|9598026|FG003|Overall Study|Lack of Efficacy|43
6003747|NCT00071981|9598023|FG000|Overall Study|Adverse Event|4
6003748|NCT00071981|9598024|FG001|Overall Study|Adverse Event|4
6003749|NCT00071981|9598025|FG002|Overall Study|Adverse Event|3
6003750|NCT00071981|9598026|FG003|Overall Study|Adverse Event|1
6003751|NCT00071981|9598023|FG000|Overall Study|Death|0
6003752|NCT00071981|9598024|FG001|Overall Study|Death|0
6003753|NCT00071981|9598025|FG002|Overall Study|Death|1
6003754|NCT00071981|9598026|FG003|Overall Study|Death|1
6003755|NCT00071981|9598023|FG000|Overall Study|Withdrawal by Subject|3
6003756|NCT00071981|9598024|FG001|Overall Study|Withdrawal by Subject|1
6003757|NCT00071981|9598025|FG002|Overall Study|Withdrawal by Subject|0
6003758|NCT00071981|9598026|FG003|Overall Study|Withdrawal by Subject|0
6003759|NCT00071981|9598023|FG000|Overall Study|No protocol therapy|2
6003760|NCT00071981|9598024|FG001|Overall Study|No protocol therapy|5
6003761|NCT00071981|9598025|FG002|Overall Study|No protocol therapy|1
6003762|NCT00071981|9598026|FG003|Overall Study|No protocol therapy|0
6003763|NCT00071981|9598023|FG000|Overall Study|others (not specified in the study)|0
6003764|NCT00071981|9598024|FG001|Overall Study|others (not specified in the study)|2
6003765|NCT00071981|9598025|FG002|Overall Study|others (not specified in the study)|2
6003766|NCT00071981|9598026|FG003|Overall Study|others (not specified in the study)|0
6003767|NCT00072176|9598038|FG000|Overall Study|Withdrawal by Subject|1
6003768|NCT00072176|9598039|FG001|Overall Study|Withdrawal by Subject|0
6003769|NCT00072176|9598038|FG000|Overall Study|Protocol Violation|0
6003770|NCT00072176|9598039|FG001|Overall Study|Protocol Violation|1
6003771|NCT00072189|9598045|FG000|Overall Study|Withdrawal by Subject|1
6003772|NCT00072280|9598051|FG000|Treatment|Found ineligible|1
6003773|NCT00072280|9598052|FG001|Treatment|Found ineligible|2
6003774|NCT00072280|9598051|FG000|Follow-up|Early termination of study|2
6003775|NCT00072280|9598052|FG001|Follow-up|Early termination of study|2
6003776|NCT00072293|9598059|FG000|Overall Study|Lost to Follow-up|1
6003777|NCT00072293|9598060|FG001|Overall Study|Lost to Follow-up|1
6003778|NCT00072293|9598059|FG000|Overall Study|Withdrawal by Subject|0
6003779|NCT00072293|9598060|FG001|Overall Study|Withdrawal by Subject|1
6003780|NCT00072384|9598066|FG000|Overall Study|Physician Decision|1
6003781|NCT00072384|9598066|FG000|Overall Study|Ineligible|8
6003782|NCT00072475|9598076|FG000|Overall Study|Adverse Event|44
6003783|NCT00072475|9598076|FG000|Overall Study|Death|3
6003784|NCT00072475|9598076|FG000|Overall Study|Withdrawal by Subject|46
6003785|NCT00072475|9598076|FG000|Overall Study|Patient/Investigator Decision|4
6003786|NCT00073008|9598099|FG000|Overall Study|Missing|6
6003787|NCT00073008|9598100|FG001|Overall Study|Missing|6
6003788|NCT00073008|9598099|FG000|Overall Study|Withdrawal by Subject|2
6003789|NCT00073008|9598100|FG001|Overall Study|Withdrawal by Subject|2
6003790|NCT00073008|9598099|FG000|Overall Study|Lost to Follow-up|1
6003791|NCT00073008|9598100|FG001|Overall Study|Lost to Follow-up|3
6003792|NCT00073008|9598099|FG000|Overall Study|Death|46
6003793|NCT00073008|9598100|FG001|Overall Study|Death|47
6003794|NCT00073008|9598099|FG000|Overall Study|"Other selected on Case Report Form"|7
6003795|NCT00073008|9598100|FG001|Overall Study|"Other selected on Case Report Form"|5
6003796|NCT00073021|9598108|FG000|Overall Study|Protocol Violation|2
6003797|NCT00073021|9598109|FG001|Overall Study|Protocol Violation|1
6003798|NCT00073021|9598108|FG000|Overall Study|Adverse Event|4
6003799|NCT00073021|9598109|FG001|Overall Study|Adverse Event|4
6003800|NCT00073021|9598108|FG000|Overall Study|Withdrawal by Subject|6
6003801|NCT00073021|9598109|FG001|Overall Study|Withdrawal by Subject|5
6003802|NCT00073021|9598108|FG000|Overall Study|Physician Decision|3
6003803|NCT00073021|9598109|FG001|Overall Study|Physician Decision|1
6003804|NCT00073021|9598108|FG000|Overall Study|Lack of Efficacy|11
6003805|NCT00073021|9598109|FG001|Overall Study|Lack of Efficacy|5
6003806|NCT00073307|9598121|FG000|Double-Blind (DB, as of ~31May2005)|Adverse Event|22
6003807|NCT00073307|9598122|FG001|Double-Blind (DB, as of ~31May2005)|Adverse Event|17
6003808|NCT00073307|9598123|FG002|Double-Blind (DB, as of ~31May2005)|Adverse Event|0
6003809|NCT00073307|9598121|FG000|Double-Blind (DB, as of ~31May2005)|Lost to Follow-up|1
6003810|NCT00073307|9598122|FG001|Double-Blind (DB, as of ~31May2005)|Lost to Follow-up|6
6003811|NCT00073307|9598123|FG002|Double-Blind (DB, as of ~31May2005)|Lost to Follow-up|0
6003812|NCT00073307|9598121|FG000|Double-Blind (DB, as of ~31May2005)|Withdrawal by Subject|6
6003813|NCT00073307|9598122|FG001|Double-Blind (DB, as of ~31May2005)|Withdrawal by Subject|11
6003814|NCT00073307|9598123|FG002|Double-Blind (DB, as of ~31May2005)|Withdrawal by Subject|0
6003815|NCT00073307|9598121|FG000|Double-Blind (DB, as of ~31May2005)|Protocol Violation|1
6003816|NCT00073307|9598122|FG001|Double-Blind (DB, as of ~31May2005)|Protocol Violation|1
6003817|NCT00073307|9598123|FG002|Double-Blind (DB, as of ~31May2005)|Protocol Violation|0
6003818|NCT00073307|9598121|FG000|Double-Blind (DB, as of ~31May2005)|Non-compliant with Study medication|1
6003819|NCT00073307|9598122|FG001|Double-Blind (DB, as of ~31May2005)|Non-compliant with Study medication|2
6003820|NCT00073307|9598123|FG002|Double-Blind (DB, as of ~31May2005)|Non-compliant with Study medication|0
6003821|NCT00073307|9598121|FG000|Double-Blind (DB, as of ~31May2005)|Unknown reason.|1
6003822|NCT00073307|9598122|FG001|Double-Blind (DB, as of ~31May2005)|Unknown reason.|0
6003823|NCT00073307|9598123|FG002|Double-Blind (DB, as of ~31May2005)|Unknown reason.|0
6003824|NCT00073307|9598121|FG000|Double-Blind (DB, as of ~31May2005)|Protocol driven decision point|0
6047300|NCT00410410|9646252|FG003|Maintenance Period (MP)|Lack of Efficacy|0
6003825|NCT00073307|9598122|FG001|Double-Blind (DB, as of ~31May2005)|Protocol driven decision point|1
6003826|NCT00073307|9598123|FG002|Double-Blind (DB, as of ~31May2005)|Protocol driven decision point|0
6003827|NCT00073307|9598121|FG000|Double-Blind (DB, as of ~31May2005)|entered Open Label (OL); Sorafenib only|165
6003828|NCT00073307|9598122|FG001|Double-Blind (DB, as of ~31May2005)|entered Open Label (OL); Sorafenib only|114
6003829|NCT00073307|9598123|FG002|Double-Blind (DB, as of ~31May2005)|entered Open Label (OL); Sorafenib only|0
6003830|NCT00073307|9598121|FG000|Double-Blind (DB, as of ~31May2005)|Subject did not receive treatment|0
6003831|NCT00073307|9598122|FG001|Double-Blind (DB, as of ~31May2005)|Subject did not receive treatment|1
6003832|NCT00073307|9598123|FG002|Double-Blind (DB, as of ~31May2005)|Subject did not receive treatment|0
6003833|NCT00073307|9598121|FG000|Open Label-Sorafenib Only [30Jun2008]|Adverse Event|17
6003834|NCT00073307|9598122|FG001|Open Label-Sorafenib Only [30Jun2008]|Adverse Event|0
6003835|NCT00073307|9598123|FG002|Open Label-Sorafenib Only [30Jun2008]|Adverse Event|19
6003836|NCT00073307|9598121|FG000|Open Label-Sorafenib Only [30Jun2008]|Lost to Follow-up|2
6003837|NCT00073307|9598122|FG001|Open Label-Sorafenib Only [30Jun2008]|Lost to Follow-up|0
6003838|NCT00073307|9598123|FG002|Open Label-Sorafenib Only [30Jun2008]|Lost to Follow-up|2
6003839|NCT00073307|9598121|FG000|Open Label-Sorafenib Only [30Jun2008]|Withdrawal by Subject|19
6003840|NCT00073307|9598122|FG001|Open Label-Sorafenib Only [30Jun2008]|Withdrawal by Subject|0
6003841|NCT00073307|9598123|FG002|Open Label-Sorafenib Only [30Jun2008]|Withdrawal by Subject|9
6003842|NCT00073307|9598121|FG000|Open Label-Sorafenib Only [30Jun2008]|Study terminated by Sponsor|37
6003843|NCT00073307|9598122|FG001|Open Label-Sorafenib Only [30Jun2008]|Study terminated by Sponsor|0
6003844|NCT00073307|9598123|FG002|Open Label-Sorafenib Only [30Jun2008]|Study terminated by Sponsor|28
6003845|NCT00073307|9598121|FG000|Open Label-Sorafenib Only [30Jun2008]|Per Investigator, not protocol driven|1
6003846|NCT00073307|9598122|FG001|Open Label-Sorafenib Only [30Jun2008]|Per Investigator, not protocol driven|0
6003847|NCT00073307|9598123|FG002|Open Label-Sorafenib Only [30Jun2008]|Per Investigator, not protocol driven|1
6003848|NCT00073307|9598121|FG000|Open Label-Sorafenib Only [30Jun2008]|Switched to commercial drug|1
6003849|NCT00073307|9598122|FG001|Open Label-Sorafenib Only [30Jun2008]|Switched to commercial drug|0
6073477|NCT00567996|9677047|FG002|Overall Study|Administrative problems|0
6073478|NCT00567996|9677045|FG000|Overall Study|Death|1
6073479|NCT00567996|9677046|FG001|Overall Study|Death|0
6073480|NCT00567996|9677047|FG002|Overall Study|Death|2
6073481|NCT00567996|9677045|FG000|Overall Study|Patient's inability to use the device|0
6073482|NCT00567996|9677046|FG001|Overall Study|Patient's inability to use the device|1
6003850|NCT00073307|9598123|FG002|Open Label-Sorafenib Only [30Jun2008]|Switched to commercial drug|1
6003851|NCT00073307|9598121|FG000|Open Label-Sorafenib Only [30Jun2008]|Switched to commercial drug (code error)|0
6003852|NCT00073307|9598122|FG001|Open Label-Sorafenib Only [30Jun2008]|Switched to commercial drug (code error)|0
6003853|NCT00073307|9598123|FG002|Open Label-Sorafenib Only [30Jun2008]|Switched to commercial drug (code error)|3
6003854|NCT00073307|9598121|FG000|Open Label-Sorafenib Only [30Jun2008]|Missing|3
6003855|NCT00073307|9598122|FG001|Open Label-Sorafenib Only [30Jun2008]|Missing|0
6003856|NCT00073307|9598123|FG002|Open Label-Sorafenib Only [30Jun2008]|Missing|1
6003857|NCT00073307|9598121|FG000|Open Label-Sorafenib Only [30Jun2008]|No record of treatment discontinuation|19
6003858|NCT00073307|9598122|FG001|Open Label-Sorafenib Only [30Jun2008]|No record of treatment discontinuation|0
6003859|NCT00073307|9598123|FG002|Open Label-Sorafenib Only [30Jun2008]|No record of treatment discontinuation|9
6003860|NCT00073307|9598121|FG000|Open Label-Sorafenib Only [30Jun2008]|Did not enter OL/ Sorafenib only phase|35
6003861|NCT00073307|9598122|FG001|Open Label-Sorafenib Only [30Jun2008]|Did not enter OL/ Sorafenib only phase|0
6003862|NCT00073307|9598123|FG002|Open Label-Sorafenib Only [30Jun2008]|Did not enter OL/ Sorafenib only phase|83
6003863|NCT00073528|9598147|FG000|Overall Study|Death|488
6003864|NCT00073528|9598148|FG001|Overall Study|Death|473
6003865|NCT00073528|9598147|FG000|Overall Study|Lost to Follow-up|52
6003866|NCT00073528|9598148|FG001|Overall Study|Lost to Follow-up|45
6003867|NCT00073528|9598147|FG000|Overall Study|Withdrawal by Subject|50
6003868|NCT00073528|9598148|FG001|Overall Study|Withdrawal by Subject|45
6003869|NCT00073528|9598147|FG000|Overall Study|Study terminated by Sponsor|10
6003870|NCT00073528|9598148|FG001|Overall Study|Study terminated by Sponsor|29
6003871|NCT00073528|9598147|FG000|Overall Study|Other|18
6003872|NCT00073528|9598148|FG001|Overall Study|Other|19
6003873|NCT00073528|9598147|FG000|Overall Study|Other|9
6003874|NCT00073528|9598148|FG001|Overall Study|Other|12
6003875|NCT00073528|9598147|FG000|Overall Study|Protocol Violation|3
6003876|NCT00073528|9598148|FG001|Overall Study|Protocol Violation|5
6003877|NCT00073749|9598161|FG000|Overall Study|Disease Progression|2
6003878|NCT00073749|9598162|FG001|Overall Study|Disease Progression|0
6003879|NCT00073749|9598163|FG002|Overall Study|Disease Progression|3
6003880|NCT00073749|9598164|FG003|Overall Study|Disease Progression|2
6003881|NCT00073749|9598165|FG004|Overall Study|Disease Progression|3
6073483|NCT00567996|9677047|FG002|Overall Study|Patient's inability to use the device|0
6073484|NCT00568061|9677071|FG000|Overall Study|Inclusion / exclusion criteria|5
6073485|NCT00568061|9677072|FG001|Overall Study|Inclusion / exclusion criteria|1
6073486|NCT00568061|9677071|FG000|Overall Study|Adverse Event|0
6073487|NCT00568061|9677072|FG001|Overall Study|Adverse Event|1
6073488|NCT00568126|9677090|FG000|Overall Study|Adverse Event|3
6073489|NCT00568126|9677091|FG001|Overall Study|Adverse Event|0
6073490|NCT00568126|9677090|FG000|Overall Study|Withdrawal by Subject|2
6003882|NCT00073749|9598166|FG005|Overall Study|Disease Progression|1
6003883|NCT00073749|9598167|FG006|Overall Study|Disease Progression|3
6003884|NCT00073749|9598161|FG000|Overall Study|Death|0
6003885|NCT00073749|9598162|FG001|Overall Study|Death|1
6003886|NCT00073749|9598163|FG002|Overall Study|Death|1
6003887|NCT00073749|9598164|FG003|Overall Study|Death|0
6003888|NCT00073749|9598165|FG004|Overall Study|Death|0
6003889|NCT00073749|9598166|FG005|Overall Study|Death|0
6003890|NCT00073749|9598167|FG006|Overall Study|Death|29
6003891|NCT00073749|9598161|FG000|Overall Study|Adverse Event|0
6003892|NCT00073749|9598162|FG001|Overall Study|Adverse Event|3
6003893|NCT00073749|9598163|FG002|Overall Study|Adverse Event|6
6003894|NCT00073749|9598164|FG003|Overall Study|Adverse Event|4
6003895|NCT00073749|9598165|FG004|Overall Study|Adverse Event|2
6003896|NCT00073749|9598166|FG005|Overall Study|Adverse Event|1
6003897|NCT00073749|9598167|FG006|Overall Study|Adverse Event|0
6003898|NCT00073749|9598161|FG000|Overall Study|Physician Decision|0
6003899|NCT00073749|9598162|FG001|Overall Study|Physician Decision|0
6003900|NCT00073749|9598163|FG002|Overall Study|Physician Decision|1
6003901|NCT00073749|9598164|FG003|Overall Study|Physician Decision|0
6003902|NCT00073749|9598165|FG004|Overall Study|Physician Decision|0
6003903|NCT00073749|9598166|FG005|Overall Study|Physician Decision|2
6003904|NCT00073749|9598167|FG006|Overall Study|Physician Decision|0
6003905|NCT00073749|9598161|FG000|Overall Study|Withdrawal by Subject|0
6003906|NCT00073749|9598162|FG001|Overall Study|Withdrawal by Subject|1
6003907|NCT00073749|9598163|FG002|Overall Study|Withdrawal by Subject|0
6003908|NCT00073749|9598164|FG003|Overall Study|Withdrawal by Subject|0
6003909|NCT00073749|9598165|FG004|Overall Study|Withdrawal by Subject|1
6003910|NCT00073749|9598166|FG005|Overall Study|Withdrawal by Subject|0
6003911|NCT00073749|9598167|FG006|Overall Study|Withdrawal by Subject|2
6003912|NCT00073749|9598161|FG000|Overall Study|Discontinuation of Study by Sponsor|0
6003913|NCT00073749|9598162|FG001|Overall Study|Discontinuation of Study by Sponsor|0
6003914|NCT00073749|9598163|FG002|Overall Study|Discontinuation of Study by Sponsor|0
6003915|NCT00073749|9598164|FG003|Overall Study|Discontinuation of Study by Sponsor|0
6003916|NCT00073749|9598165|FG004|Overall Study|Discontinuation of Study by Sponsor|0
6003917|NCT00073749|9598166|FG005|Overall Study|Discontinuation of Study by Sponsor|0
6003918|NCT00073749|9598167|FG006|Overall Study|Discontinuation of Study by Sponsor|4
6003919|NCT00073749|9598161|FG000|Overall Study|Lost to Follow-up|0
6003920|NCT00073749|9598162|FG001|Overall Study|Lost to Follow-up|0
6003921|NCT00073749|9598163|FG002|Overall Study|Lost to Follow-up|0
6003922|NCT00073749|9598164|FG003|Overall Study|Lost to Follow-up|0
6003923|NCT00073749|9598165|FG004|Overall Study|Lost to Follow-up|0
6003924|NCT00073749|9598166|FG005|Overall Study|Lost to Follow-up|0
6003925|NCT00073749|9598167|FG006|Overall Study|Lost to Follow-up|2
6003926|NCT00073749|9598161|FG000|Overall Study|Other|0
6003927|NCT00073749|9598162|FG001|Overall Study|Other|0
6003928|NCT00073749|9598163|FG002|Overall Study|Other|0
6003929|NCT00073749|9598164|FG003|Overall Study|Other|0
6003930|NCT00073749|9598165|FG004|Overall Study|Other|0
6003931|NCT00073749|9598166|FG005|Overall Study|Other|2
6003932|NCT00073749|9598167|FG006|Overall Study|Other|0
6003933|NCT00073918|9598186|FG000|Overall Study|Eligibility requirement not met - HAMA+|1
6003934|NCT00073918|9598186|FG000|Overall Study|Rapid disease progression|2
6003935|NCT00073918|9598186|FG000|Overall Study|Eligibility requirement not met-low CD20|1
6003936|NCT00073983|9598196|FG000|Overall Study|not evaluable|1
6003937|NCT00074152|9598208|FG000|Overall Study|Death|21
6003938|NCT00074152|9598209|FG001|Overall Study|Death|9
6003939|NCT00074152|9598208|FG000|Overall Study|Lack of Efficacy|34
6003940|NCT00074152|9598209|FG001|Overall Study|Lack of Efficacy|24
6003941|NCT00074282|9598228|FG000|Step 1|Adverse Event|32
6003942|NCT00074282|9598229|FG001|Step 1|Adverse Event|0
6003943|NCT00074282|9598230|FG002|Step 1|Adverse Event|0
6003944|NCT00074282|9598228|FG000|Step 1|Death|6
6003945|NCT00074282|9598229|FG001|Step 1|Death|0
6003946|NCT00074282|9598230|FG002|Step 1|Death|0
6003947|NCT00074282|9598228|FG000|Step 1|Withdrawal by Subject|7
6003948|NCT00074282|9598229|FG001|Step 1|Withdrawal by Subject|0
6003949|NCT00074282|9598230|FG002|Step 1|Withdrawal by Subject|0
6003950|NCT00074282|9598228|FG000|Step 1|Disease progression|2
6003951|NCT00074282|9598229|FG001|Step 1|Disease progression|0
6073491|NCT00568126|9677091|FG001|Overall Study|Withdrawal by Subject|3
6073492|NCT00568126|9677090|FG000|Overall Study|Lost to Follow-up|4
6073493|NCT00568126|9677091|FG001|Overall Study|Lost to Follow-up|3
6073494|NCT00568126|9677090|FG000|Overall Study|Lack of Efficacy|0
6073495|NCT00568126|9677091|FG001|Overall Study|Lack of Efficacy|1
6003952|NCT00074282|9598230|FG002|Step 1|Disease progression|0
6003953|NCT00074282|9598228|FG000|Step 1|Alternative therapy|2
6003954|NCT00074282|9598229|FG001|Step 1|Alternative therapy|0
6003955|NCT00074282|9598230|FG002|Step 1|Alternative therapy|0
6003956|NCT00074282|9598228|FG000|Step 1|Other complicating disease|2
6003957|NCT00074282|9598229|FG001|Step 1|Other complicating disease|0
6003958|NCT00074282|9598230|FG002|Step 1|Other complicating disease|0
6003959|NCT00074282|9598228|FG000|Step 1|Physician Decision|1
6003960|NCT00074282|9598229|FG001|Step 1|Physician Decision|0
6003961|NCT00074282|9598230|FG002|Step 1|Physician Decision|0
6073496|NCT00568126|9677090|FG000|Overall Study|Physician Decision|2
6003962|NCT00074282|9598228|FG000|Step 1|Ineligible|4
6003963|NCT00074282|9598229|FG001|Step 1|Ineligible|0
6003964|NCT00074282|9598230|FG002|Step 1|Ineligible|0
6003965|NCT00074282|9598228|FG000|Step 1|Never started treatment|2
6003966|NCT00074282|9598229|FG001|Step 1|Never started treatment|0
6003967|NCT00074282|9598230|FG002|Step 1|Never started treatment|0
6003968|NCT00074282|9598228|FG000|Step 2|Adverse Event|0
6003969|NCT00074282|9598229|FG001|Step 2|Adverse Event|2
6003970|NCT00074282|9598230|FG002|Step 2|Adverse Event|12
6003971|NCT00074282|9598228|FG000|Step 2|Disease progression|0
6003972|NCT00074282|9598229|FG001|Step 2|Disease progression|0
6003973|NCT00074282|9598230|FG002|Step 2|Disease progression|5
6003974|NCT00074282|9598228|FG000|Step 2|Death|0
6003975|NCT00074282|9598229|FG001|Step 2|Death|0
6003976|NCT00074282|9598230|FG002|Step 2|Death|3
6003977|NCT00074282|9598228|FG000|Step 2|Withdrawal by Subject|0
6003978|NCT00074282|9598229|FG001|Step 2|Withdrawal by Subject|0
6003979|NCT00074282|9598230|FG002|Step 2|Withdrawal by Subject|2
6003980|NCT00074282|9598228|FG000|Step 2|Physician Decision|0
6003981|NCT00074282|9598229|FG001|Step 2|Physician Decision|0
6003982|NCT00074282|9598230|FG002|Step 2|Physician Decision|1
6003983|NCT00074282|9598228|FG000|Step 2|Ineligible|0
6003984|NCT00074282|9598229|FG001|Step 2|Ineligible|0
6003985|NCT00074282|9598230|FG002|Step 2|Ineligible|1
6003986|NCT00074412|9598256|FG000|Overall Study|Death|30
6003987|NCT00074412|9598257|FG001|Overall Study|Death|26
6003988|NCT00074412|9598256|FG000|Overall Study|Lost to Follow-up|52
6003989|NCT00074412|9598257|FG001|Overall Study|Lost to Follow-up|58
6003990|NCT00074490|9598269|FG000|Overall Study|Progressive malignancy|0
6003991|NCT00074490|9598270|FG001|Overall Study|Progressive malignancy|7
6003992|NCT00074490|9598271|FG002|Overall Study|Progressive malignancy|0
6003993|NCT00074490|9598272|FG003|Overall Study|Progressive malignancy|0
6003994|NCT00074490|9598273|FG004|Overall Study|Progressive malignancy|3
6003995|NCT00074490|9598274|FG005|Overall Study|Progressive malignancy|0
6003996|NCT00074581|9598289|FG000|Overall Study|Death|15
6003997|NCT00074581|9598290|FG001|Overall Study|Death|16
6003998|NCT00074581|9598289|FG000|Overall Study|Withdrawal by Subject|50
6003999|NCT00074581|9598290|FG001|Overall Study|Withdrawal by Subject|49
6004000|NCT00074581|9598289|FG000|Overall Study|Unable to adhere to visit schedule|13
6004001|NCT00074581|9598290|FG001|Overall Study|Unable to adhere to visit schedule|14
6004002|NCT00074581|9598289|FG000|Overall Study|Relocated|14
6004003|NCT00074581|9598290|FG001|Overall Study|Relocated|9
6004004|NCT00074581|9598289|FG000|Overall Study|Were withdrawn by investigator|5
6004005|NCT00074581|9598290|FG001|Overall Study|Were withdrawn by investigator|2
6004006|NCT00074581|9598289|FG000|Overall Study|Lost to Follow-up|16
6004007|NCT00074581|9598290|FG001|Overall Study|Lost to Follow-up|11
6004008|NCT00074581|9598289|FG000|Overall Study|Ended relationship w. index participant|117
6004009|NCT00074581|9598290|FG001|Overall Study|Ended relationship w. index participant|106
6073497|NCT00568126|9677091|FG001|Overall Study|Physician Decision|2
6073498|NCT00568321|9677100|FG000|Overall Study|Adverse Event|1
6073499|NCT00568321|9677101|FG001|Overall Study|Adverse Event|0
6073500|NCT00568321|9677102|FG002|Overall Study|Adverse Event|0
6073501|NCT00568321|9677100|FG000|Overall Study|Lack of Efficacy|8
6073502|NCT00568321|9677101|FG001|Overall Study|Lack of Efficacy|5
6073503|NCT00568321|9677102|FG002|Overall Study|Lack of Efficacy|6
6073504|NCT00568321|9677100|FG000|Overall Study|Lost to Follow-up|0
6073505|NCT00568321|9677101|FG001|Overall Study|Lost to Follow-up|0
6073506|NCT00568321|9677102|FG002|Overall Study|Lost to Follow-up|1
6073507|NCT00568321|9677100|FG000|Overall Study|Withdrawal by Subject|2
6073508|NCT00568321|9677101|FG001|Overall Study|Withdrawal by Subject|0
6073509|NCT00568321|9677102|FG002|Overall Study|Withdrawal by Subject|0
6073510|NCT00568321|9677100|FG000|Overall Study|Protocol Violation|0
6073511|NCT00568321|9677101|FG001|Overall Study|Protocol Violation|0
6073512|NCT00568321|9677102|FG002|Overall Study|Protocol Violation|1
6073513|NCT00568321|9677100|FG000|Overall Study|Randomized, not treated|2
6073514|NCT00568321|9677101|FG001|Overall Study|Randomized, not treated|0
6073515|NCT00568321|9677102|FG002|Overall Study|Randomized, not treated|1
6073516|NCT00568334|9677114|FG000|Overall Study|Withdrawal by Subject|0
6073517|NCT00568334|9677115|FG001|Overall Study|Withdrawal by Subject|1
6073518|NCT00568334|9677114|FG000|Overall Study|Lost to Follow-up|1
6073519|NCT00568334|9677115|FG001|Overall Study|Lost to Follow-up|0
6073520|NCT00568399|9677130|FG000|Overall Study|Death|2
6073521|NCT00568399|9677130|FG000|Overall Study|Adverse Event|5
6004010|NCT00074581|9598289|FG000|Overall Study|Other|14
6004011|NCT00074581|9598290|FG001|Overall Study|Other|19
6004012|NCT00074711|9598298|FG000|Overall Study|Withdrawal by Subject|1
6004013|NCT00074711|9598299|FG001|Overall Study|Withdrawal by Subject|1
6004014|NCT00074711|9598298|FG000|Overall Study|Lost to Follow-up|10
6004015|NCT00074711|9598299|FG001|Overall Study|Lost to Follow-up|8
6004016|NCT00074711|9598298|FG000|Overall Study|Participant stopped study drug|4
6004017|NCT00074711|9598299|FG001|Overall Study|Participant stopped study drug|6
6004018|NCT00074958|9598327|FG000|Overall Study|Adverse Event|1
6004019|NCT00074984|9598333|FG000|Overall Study|Death|1
6004020|NCT00074984|9598334|FG001|Overall Study|Death|2
6004021|NCT00074984|9598333|FG000|Overall Study|Withdrawal by Subject|2
6004022|NCT00074984|9598334|FG001|Overall Study|Withdrawal by Subject|3
6004023|NCT00074984|9598333|FG000|Overall Study|Patient Withdrawn Per Protocol|0
6004024|NCT00074984|9598334|FG001|Overall Study|Patient Withdrawn Per Protocol|3
6004025|NCT00075023|9598343|FG000|Pilot Study|Physician Decision|1
6073522|NCT00568399|9677130|FG000|Overall Study|Withdrawal by Subject|8
6004026|NCT00075023|9598344|FG001|Pilot Study|Physician Decision|2
6004027|NCT00075023|9598343|FG000|Pilot Study|Withdrawal by Subject|1
6004028|NCT00075023|9598344|FG001|Pilot Study|Withdrawal by Subject|0
6004029|NCT00075218|9598363|FG000|Double-Blind Treatment|Adverse Event|23
6004030|NCT00075218|9598364|FG001|Double-Blind Treatment|Adverse Event|4
6004031|NCT00075218|9598365|FG002|Double-Blind Treatment|Adverse Event|0
6004032|NCT00075218|9598363|FG000|Double-Blind Treatment|Withdrawal by Subject|7
6004033|NCT00075218|9598364|FG001|Double-Blind Treatment|Withdrawal by Subject|4
6004034|NCT00075218|9598365|FG002|Double-Blind Treatment|Withdrawal by Subject|0
6004035|NCT00075218|9598363|FG000|Double-Blind Treatment|Lost to Follow-up|1
6004036|NCT00075218|9598364|FG001|Double-Blind Treatment|Lost to Follow-up|0
6004037|NCT00075218|9598365|FG002|Double-Blind Treatment|Lost to Follow-up|0
6004038|NCT00075218|9598363|FG000|Double-Blind Treatment|Lack of Efficacy|58
6004039|NCT00075218|9598364|FG001|Double-Blind Treatment|Lack of Efficacy|6
6004040|NCT00075218|9598365|FG002|Double-Blind Treatment|Lack of Efficacy|0
6004041|NCT00075218|9598363|FG000|Double-Blind Treatment|Decision of Sponsor|0
6004042|NCT00075218|9598364|FG001|Double-Blind Treatment|Decision of Sponsor|1
6004043|NCT00075218|9598365|FG002|Double-Blind Treatment|Decision of Sponsor|0
6004044|NCT00075218|9598363|FG000|Double-Blind Treatment|No study medication taken|2
6004045|NCT00075218|9598364|FG001|Double-Blind Treatment|No study medication taken|0
6004046|NCT00075218|9598365|FG002|Double-Blind Treatment|No study medication taken|0
6004047|NCT00075218|9598363|FG000|Open-Label Treatment|Lack of Efficacy|0
6004048|NCT00075218|9598364|FG001|Open-Label Treatment|Lack of Efficacy|0
6004049|NCT00075218|9598365|FG002|Open-Label Treatment|Lack of Efficacy|174
6004050|NCT00075218|9598363|FG000|Open-Label Treatment|Adverse Event|0
6004051|NCT00075218|9598364|FG001|Open-Label Treatment|Adverse Event|0
6004052|NCT00075218|9598365|FG002|Open-Label Treatment|Adverse Event|51
6004053|NCT00075218|9598363|FG000|Open-Label Treatment|Withdrawal by Subject|0
6004054|NCT00075218|9598364|FG001|Open-Label Treatment|Withdrawal by Subject|0
6004055|NCT00075218|9598365|FG002|Open-Label Treatment|Withdrawal by Subject|12
6004056|NCT00075218|9598363|FG000|Open-Label Treatment|Decision of Sponsor|0
6004057|NCT00075218|9598364|FG001|Open-Label Treatment|Decision of Sponsor|0
6004058|NCT00075218|9598365|FG002|Open-Label Treatment|Decision of Sponsor|8
6004059|NCT00075218|9598363|FG000|Open-Label Treatment|Protocol Violation|0
6004060|NCT00075218|9598364|FG001|Open-Label Treatment|Protocol Violation|0
6004061|NCT00075218|9598365|FG002|Open-Label Treatment|Protocol Violation|1
6004062|NCT00075218|9598363|FG000|Open-Label Treatment|enrolled in a separate continuation|0
6004063|NCT00075218|9598364|FG001|Open-Label Treatment|enrolled in a separate continuation|0
6004064|NCT00075218|9598365|FG002|Open-Label Treatment|enrolled in a separate continuation|9
6004065|NCT00075270|9598374|FG000|Overall Study|Withdrawal by Subject|28
6004066|NCT00075270|9598375|FG001|Overall Study|Withdrawal by Subject|21
6004067|NCT00075270|9598374|FG000|Overall Study|Lost to Follow-up|25
6004068|NCT00075270|9598375|FG001|Overall Study|Lost to Follow-up|28
6004069|NCT00075270|9598374|FG000|Overall Study|Protocol Violation|0
6004070|NCT00075270|9598375|FG001|Overall Study|Protocol Violation|2
6004071|NCT00075270|9598374|FG000|Overall Study|Death|198
6004072|NCT00075270|9598375|FG001|Overall Study|Death|215
6004073|NCT00075270|9598374|FG000|Overall Study|Other/Unknown|9
6004074|NCT00075270|9598375|FG001|Overall Study|Other/Unknown|5
6004075|NCT00075270|9598374|FG000|Overall Study|Missing|26
6004076|NCT00075270|9598375|FG001|Overall Study|Missing|13
6004077|NCT00075400|9598386|FG000|Overall Study|Ineligible: wrong primary|1
6004078|NCT00075400|9598386|FG000|Overall Study|Never treated|2
6004079|NCT00075478|9598397|FG000|Overall Study|not eligible|1
6004080|NCT00075478|9598398|FG001|Overall Study|not eligible|0
6004081|NCT00075478|9598397|FG000|Overall Study|Physician Decision|0
6073523|NCT00568451|9677138|FG000|Overall Study|Disease Progression|0
6073524|NCT00568451|9677139|FG001|Overall Study|Disease Progression|0
6073525|NCT00568451|9677140|FG002|Overall Study|Disease Progression|2
6073526|NCT00568451|9677141|FG003|Overall Study|Disease Progression|7
6087305|NCT00667225|9697482|FG000|Overall Study|Subject had no more lesions to treat.|1
6087306|NCT00667225|9697483|FG001|Overall Study|Subject had no more lesions to treat.|0
6087307|NCT00667225|9697482|FG000|Overall Study|Lost to Follow-up|0
6087308|NCT00667225|9697483|FG001|Overall Study|Lost to Follow-up|1
6087309|NCT00667277|9697489|FG000|Overall Study|Withdrawal by Subject|2
6087310|NCT00667342|9697496|FG000|Overall Study|Protocol Violation|1
6087311|NCT00667342|9697497|FG001|Overall Study|Protocol Violation|0
6004082|NCT00075478|9598398|FG001|Overall Study|Physician Decision|1
6004083|NCT00075504|9598406|FG000|Overall Study|Withdrawal by Subject|9
6004084|NCT00075504|9598407|FG001|Overall Study|Withdrawal by Subject|7
6004085|NCT00075582|9598415|FG000|Overall Study|Adverse Event|3
6004086|NCT00075582|9598416|FG001|Overall Study|Adverse Event|1
6087312|NCT00667342|9697498|FG002|Overall Study|Protocol Violation|0
6004087|NCT00075582|9598415|FG000|Overall Study|Lack of Efficacy|4
6004088|NCT00075582|9598416|FG001|Overall Study|Lack of Efficacy|8
6004089|NCT00075582|9598415|FG000|Overall Study|Physician Decision|5
6004090|NCT00075582|9598416|FG001|Overall Study|Physician Decision|8
6004091|NCT00075582|9598415|FG000|Overall Study|Withdrawal by Subject|2
6004092|NCT00075582|9598416|FG001|Overall Study|Withdrawal by Subject|2
6004093|NCT00075582|9598415|FG000|Overall Study|Ineligible for study|36
6004094|NCT00075582|9598416|FG001|Overall Study|Ineligible for study|16
6004095|NCT00075725|9598438|FG000|Overall Study|Adverse Event|6
6004096|NCT00075725|9598439|FG001|Overall Study|Adverse Event|6
6004097|NCT00075725|9598440|FG002|Overall Study|Adverse Event|20
6004098|NCT00075725|9598441|FG003|Overall Study|Adverse Event|8
6004099|NCT00075725|9598442|FG004|Overall Study|Adverse Event|4
6004100|NCT00075725|9598443|FG005|Overall Study|Adverse Event|38
6004101|NCT00075725|9598444|FG006|Overall Study|Adverse Event|3
6004102|NCT00075725|9598445|FG007|Overall Study|Adverse Event|51
6004103|NCT00075725|9598446|FG008|Overall Study|Adverse Event|15
6004104|NCT00075725|9598447|FG009|Overall Study|Adverse Event|4
6004105|NCT00075725|9598448|FG010|Overall Study|Adverse Event|2
6004106|NCT00075725|9598449|FG011|Overall Study|Adverse Event|2
6004107|NCT00075725|9598438|FG000|Overall Study|Death|3
6004108|NCT00075725|9598439|FG001|Overall Study|Death|5
6004109|NCT00075725|9598440|FG002|Overall Study|Death|10
6004110|NCT00075725|9598441|FG003|Overall Study|Death|2
6004111|NCT00075725|9598442|FG004|Overall Study|Death|3
6004112|NCT00075725|9598443|FG005|Overall Study|Death|25
6004113|NCT00075725|9598444|FG006|Overall Study|Death|4
6004114|NCT00075725|9598445|FG007|Overall Study|Death|22
6004115|NCT00075725|9598446|FG008|Overall Study|Death|14
6004116|NCT00075725|9598447|FG009|Overall Study|Death|4
6004117|NCT00075725|9598448|FG010|Overall Study|Death|3
6004118|NCT00075725|9598449|FG011|Overall Study|Death|0
6004119|NCT00075725|9598438|FG000|Overall Study|Lost to Follow-up|1
6004120|NCT00075725|9598439|FG001|Overall Study|Lost to Follow-up|1
6004121|NCT00075725|9598440|FG002|Overall Study|Lost to Follow-up|4
6004122|NCT00075725|9598441|FG003|Overall Study|Lost to Follow-up|1
6004123|NCT00075725|9598442|FG004|Overall Study|Lost to Follow-up|0
6004124|NCT00075725|9598443|FG005|Overall Study|Lost to Follow-up|13
6004125|NCT00075725|9598444|FG006|Overall Study|Lost to Follow-up|2
6004126|NCT00075725|9598445|FG007|Overall Study|Lost to Follow-up|4
6004127|NCT00075725|9598446|FG008|Overall Study|Lost to Follow-up|1
6004128|NCT00075725|9598447|FG009|Overall Study|Lost to Follow-up|0
6004129|NCT00075725|9598448|FG010|Overall Study|Lost to Follow-up|0
6004130|NCT00075725|9598449|FG011|Overall Study|Lost to Follow-up|0
6004131|NCT00075725|9598438|FG000|Overall Study|Physician Decision|2
6004132|NCT00075725|9598439|FG001|Overall Study|Physician Decision|6
6004133|NCT00075725|9598440|FG002|Overall Study|Physician Decision|5
6004134|NCT00075725|9598441|FG003|Overall Study|Physician Decision|8
6004135|NCT00075725|9598442|FG004|Overall Study|Physician Decision|4
6004136|NCT00075725|9598443|FG005|Overall Study|Physician Decision|19
6004137|NCT00075725|9598444|FG006|Overall Study|Physician Decision|3
6004138|NCT00075725|9598445|FG007|Overall Study|Physician Decision|17
6004139|NCT00075725|9598446|FG008|Overall Study|Physician Decision|5
6004140|NCT00075725|9598447|FG009|Overall Study|Physician Decision|0
6004141|NCT00075725|9598448|FG010|Overall Study|Physician Decision|1
6004142|NCT00075725|9598449|FG011|Overall Study|Physician Decision|0
6004143|NCT00075725|9598438|FG000|Overall Study|Pregnancy|0
6004144|NCT00075725|9598439|FG001|Overall Study|Pregnancy|0
6004145|NCT00075725|9598440|FG002|Overall Study|Pregnancy|0
6004146|NCT00075725|9598441|FG003|Overall Study|Pregnancy|0
6004147|NCT00075725|9598442|FG004|Overall Study|Pregnancy|0
6004148|NCT00075725|9598443|FG005|Overall Study|Pregnancy|1
6004149|NCT00075725|9598444|FG006|Overall Study|Pregnancy|0
6004150|NCT00075725|9598445|FG007|Overall Study|Pregnancy|1
6004151|NCT00075725|9598446|FG008|Overall Study|Pregnancy|0
6004152|NCT00075725|9598447|FG009|Overall Study|Pregnancy|0
6004153|NCT00075725|9598448|FG010|Overall Study|Pregnancy|0
6004154|NCT00075725|9598449|FG011|Overall Study|Pregnancy|0
6004155|NCT00075725|9598438|FG000|Overall Study|Protocol Violation|1
6004156|NCT00075725|9598439|FG001|Overall Study|Protocol Violation|1
6004157|NCT00075725|9598440|FG002|Overall Study|Protocol Violation|0
6004158|NCT00075725|9598441|FG003|Overall Study|Protocol Violation|3
6004159|NCT00075725|9598442|FG004|Overall Study|Protocol Violation|3
6004160|NCT00075725|9598443|FG005|Overall Study|Protocol Violation|2
6004161|NCT00075725|9598444|FG006|Overall Study|Protocol Violation|1
6004162|NCT00075725|9598445|FG007|Overall Study|Protocol Violation|2
6004163|NCT00075725|9598446|FG008|Overall Study|Protocol Violation|3
6004164|NCT00075725|9598447|FG009|Overall Study|Protocol Violation|0
6004165|NCT00075725|9598448|FG010|Overall Study|Protocol Violation|0
6004166|NCT00075725|9598449|FG011|Overall Study|Protocol Violation|1
6004167|NCT00075725|9598438|FG000|Overall Study|Withdrawal by Subject|12
6004168|NCT00075725|9598439|FG001|Overall Study|Withdrawal by Subject|3
6004169|NCT00075725|9598440|FG002|Overall Study|Withdrawal by Subject|6
6004170|NCT00075725|9598441|FG003|Overall Study|Withdrawal by Subject|10
6004171|NCT00075725|9598442|FG004|Overall Study|Withdrawal by Subject|6
6004172|NCT00075725|9598443|FG005|Overall Study|Withdrawal by Subject|27
6004173|NCT00075725|9598444|FG006|Overall Study|Withdrawal by Subject|7
6004174|NCT00075725|9598445|FG007|Overall Study|Withdrawal by Subject|31
6004175|NCT00075725|9598446|FG008|Overall Study|Withdrawal by Subject|10
6004176|NCT00075725|9598447|FG009|Overall Study|Withdrawal by Subject|2
6004177|NCT00075725|9598448|FG010|Overall Study|Withdrawal by Subject|0
6004178|NCT00075725|9598449|FG011|Overall Study|Withdrawal by Subject|0
6004179|NCT00075725|9598438|FG000|Overall Study|Disease Progression, all other reasons|17
6004180|NCT00075725|9598439|FG001|Overall Study|Disease Progression, all other reasons|5
6004181|NCT00075725|9598440|FG002|Overall Study|Disease Progression, all other reasons|33
6004182|NCT00075725|9598441|FG003|Overall Study|Disease Progression, all other reasons|6
6004183|NCT00075725|9598442|FG004|Overall Study|Disease Progression, all other reasons|21
6004184|NCT00075725|9598443|FG005|Overall Study|Disease Progression, all other reasons|59
6004185|NCT00075725|9598444|FG006|Overall Study|Disease Progression, all other reasons|20
6004186|NCT00075725|9598445|FG007|Overall Study|Disease Progression, all other reasons|46
6004187|NCT00075725|9598446|FG008|Overall Study|Disease Progression, all other reasons|21
6004188|NCT00075725|9598447|FG009|Overall Study|Disease Progression, all other reasons|4
6004189|NCT00075725|9598448|FG010|Overall Study|Disease Progression, all other reasons|0
6004190|NCT00075725|9598449|FG011|Overall Study|Disease Progression, all other reasons|5
6004191|NCT00075725|9598438|FG000|Overall Study|Patient off treatment|0
6004192|NCT00075725|9598439|FG001|Overall Study|Patient off treatment|0
6004193|NCT00075725|9598440|FG002|Overall Study|Patient off treatment|1
6004194|NCT00075725|9598441|FG003|Overall Study|Patient off treatment|2
6004195|NCT00075725|9598442|FG004|Overall Study|Patient off treatment|1
6004196|NCT00075725|9598443|FG005|Overall Study|Patient off treatment|0
6004197|NCT00075725|9598444|FG006|Overall Study|Patient off treatment|0
6004198|NCT00075725|9598445|FG007|Overall Study|Patient off treatment|2
6004199|NCT00075725|9598446|FG008|Overall Study|Patient off treatment|1
6004200|NCT00075725|9598447|FG009|Overall Study|Patient off treatment|0
6073527|NCT00568555|9677154|FG000|Overall Study|Withdrawal by Subject|1
6073528|NCT00568555|9677155|FG001|Overall Study|Withdrawal by Subject|1
6073529|NCT00568685|9677175|FG000|Overall Study|Adverse Event|2
6073530|NCT00568685|9677176|FG001|Overall Study|Adverse Event|3
6073531|NCT00568685|9677177|FG002|Overall Study|Adverse Event|3
6073532|NCT00568685|9677175|FG000|Overall Study|Withdrawal by Subject|7
6073533|NCT00568685|9677176|FG001|Overall Study|Withdrawal by Subject|2
6073534|NCT00568685|9677177|FG002|Overall Study|Withdrawal by Subject|2
6073535|NCT00568685|9677175|FG000|Overall Study|Protocol Violation|1
6073536|NCT00568685|9677176|FG001|Overall Study|Protocol Violation|0
6073537|NCT00568685|9677177|FG002|Overall Study|Protocol Violation|0
6073538|NCT00568776|9677193|FG000|Overall Study|Adverse Event|8
6073539|NCT00568776|9677194|FG001|Overall Study|Adverse Event|8
6073540|NCT00568776|9677195|FG002|Overall Study|Adverse Event|10
6073541|NCT00568776|9677196|FG003|Overall Study|Adverse Event|8
6073542|NCT00568776|9677193|FG000|Overall Study|Death|0
6073543|NCT00568776|9677194|FG001|Overall Study|Death|1
6073544|NCT00568776|9677195|FG002|Overall Study|Death|4
6073545|NCT00568776|9677196|FG003|Overall Study|Death|3
6073546|NCT00568776|9677193|FG000|Overall Study|Physician Decision|0
6073547|NCT00568776|9677194|FG001|Overall Study|Physician Decision|2
6073548|NCT00568776|9677195|FG002|Overall Study|Physician Decision|0
6073549|NCT00568776|9677196|FG003|Overall Study|Physician Decision|0
6073550|NCT00568776|9677193|FG000|Overall Study|Lack of Efficacy|2
6073551|NCT00568776|9677194|FG001|Overall Study|Lack of Efficacy|2
6073552|NCT00568776|9677195|FG002|Overall Study|Lack of Efficacy|2
6073553|NCT00568776|9677196|FG003|Overall Study|Lack of Efficacy|4
6073554|NCT00568776|9677193|FG000|Overall Study|Lost to Follow-up|1
6073555|NCT00568776|9677194|FG001|Overall Study|Lost to Follow-up|1
6073556|NCT00568776|9677195|FG002|Overall Study|Lost to Follow-up|1
6073557|NCT00568776|9677196|FG003|Overall Study|Lost to Follow-up|1
6073558|NCT00568776|9677193|FG000|Overall Study|Protocol Violation|1
6073559|NCT00568776|9677194|FG001|Overall Study|Protocol Violation|0
6073560|NCT00568776|9677195|FG002|Overall Study|Protocol Violation|1
6073561|NCT00568776|9677196|FG003|Overall Study|Protocol Violation|1
6073562|NCT00568776|9677193|FG000|Overall Study|Withdrawal by Subject|13
6073563|NCT00568776|9677194|FG001|Overall Study|Withdrawal by Subject|15
6073564|NCT00568776|9677195|FG002|Overall Study|Withdrawal by Subject|13
6073565|NCT00568776|9677196|FG003|Overall Study|Withdrawal by Subject|7
6073566|NCT00568776|9677193|FG000|Overall Study|Loss of Caregiver|0
6073567|NCT00568776|9677194|FG001|Overall Study|Loss of Caregiver|2
6073568|NCT00568776|9677195|FG002|Overall Study|Loss of Caregiver|1
6073569|NCT00568776|9677196|FG003|Overall Study|Loss of Caregiver|2
6073570|NCT00568776|9677193|FG000|Overall Study|Sponsor Decision|2
6073571|NCT00568776|9677194|FG001|Overall Study|Sponsor Decision|2
6073572|NCT00568776|9677195|FG002|Overall Study|Sponsor Decision|41
6073573|NCT00568776|9677196|FG003|Overall Study|Sponsor Decision|42
6073574|NCT00568776|9677193|FG000|Overall Study|Miscellaeneous|3
6073575|NCT00568776|9677194|FG001|Overall Study|Miscellaeneous|3
6073576|NCT00568776|9677195|FG002|Overall Study|Miscellaeneous|1
6073577|NCT00568776|9677196|FG003|Overall Study|Miscellaeneous|4
6087313|NCT00667342|9697496|FG000|Overall Study|Withdrawal by Subject|1
6087314|NCT00667342|9697497|FG001|Overall Study|Withdrawal by Subject|0
6087315|NCT00667342|9697498|FG002|Overall Study|Withdrawal by Subject|0
6087316|NCT00667342|9697496|FG000|Overall Study|Physician Decision|3
6087317|NCT00667342|9697497|FG001|Overall Study|Physician Decision|0
6087318|NCT00667342|9697498|FG002|Overall Study|Physician Decision|0
6087319|NCT00667342|9697496|FG000|Overall Study|Relapse or tumor progression|9
6087320|NCT00667342|9697497|FG001|Overall Study|Relapse or tumor progression|0
6087321|NCT00667342|9697498|FG002|Overall Study|Relapse or tumor progression|7
6087322|NCT00667342|9697496|FG000|Overall Study|Adverse Event|0
6087323|NCT00667342|9697497|FG001|Overall Study|Adverse Event|0
6087324|NCT00667342|9697498|FG002|Overall Study|Adverse Event|1
6087325|NCT00667342|9697496|FG000|Overall Study|Ineligible|0
6087326|NCT00667342|9697497|FG001|Overall Study|Ineligible|0
6087327|NCT00667342|9697498|FG002|Overall Study|Ineligible|1
6087328|NCT00667355|9697512|FG000|Overall Study|Adverse Event|5
6073578|NCT04274192|9677208|FG000|Overall Study|Protocol Violation|1
6073579|NCT04274192|9677209|FG001|Overall Study|Protocol Violation|0
6073580|NCT04110314|9677227|FG000|Overall Study|Did not meet inclusion criteria|35255
6073581|NCT04110314|9677228|FG001|Overall Study|Did not meet inclusion criteria|35104
6073582|NCT04110314|9677229|FG002|Overall Study|Did not meet inclusion criteria|35636
6073583|NCT04110314|9677230|FG003|Overall Study|Did not meet inclusion criteria|35135
6073584|NCT04110314|9677231|FG004|Overall Study|Did not meet inclusion criteria|35247
6073585|NCT04110314|9677232|FG005|Overall Study|Did not meet inclusion criteria|35727
6073586|NCT04086472|9677249|FG000|Overall Study|Lost to Follow-up|1
6073587|NCT04086472|9677250|FG001|Overall Study|Lost to Follow-up|0
6073588|NCT04086472|9677251|FG002|Overall Study|Lost to Follow-up|0
6073589|NCT04086472|9677252|FG003|Overall Study|Lost to Follow-up|0
6073590|NCT04086472|9677253|FG004|Overall Study|Lost to Follow-up|1
6073591|NCT04086472|9677249|FG000|Overall Study|Physician Decision|0
6073592|NCT04086472|9677250|FG001|Overall Study|Physician Decision|1
6073593|NCT04086472|9677251|FG002|Overall Study|Physician Decision|1
6073594|NCT04086472|9677252|FG003|Overall Study|Physician Decision|0
6073595|NCT04086472|9677253|FG004|Overall Study|Physician Decision|0
6073596|NCT04086472|9677249|FG000|Overall Study|Withdrawal by Subject|1
6073597|NCT04086472|9677250|FG001|Overall Study|Withdrawal by Subject|1
6073598|NCT04086472|9677251|FG002|Overall Study|Withdrawal by Subject|1
6073599|NCT04086472|9677252|FG003|Overall Study|Withdrawal by Subject|0
6073600|NCT04086472|9677253|FG004|Overall Study|Withdrawal by Subject|0
6073601|NCT04086472|9677249|FG000|Overall Study|Various reasons|2
6073602|NCT04086472|9677250|FG001|Overall Study|Various reasons|0
6073603|NCT04086472|9677251|FG002|Overall Study|Various reasons|0
6073604|NCT04086472|9677252|FG003|Overall Study|Various reasons|3
6073605|NCT04086472|9677253|FG004|Overall Study|Various reasons|1
6073606|NCT03961204|9677274|FG000|Overall Study|Withdrawal by Subject|2
6073607|NCT03961204|9677274|FG000|Overall Study|Lost to Follow-up|3
6073608|NCT03961204|9677274|FG000|Overall Study|Other|1
6073609|NCT03961204|9677274|FG000|Overall Study|Missing|1
6073610|NCT03895840|9677278|FG000|Overall Study|Withdrawal by Subject|21
6073611|NCT03818399|9677282|FG000|Overall Study|Lost to Follow-up|11
6073612|NCT03818399|9677282|FG000|Overall Study|Withdrawal by Subject|1
6073613|NCT03818399|9677282|FG000|Overall Study|Protocol Violation|2
6073614|NCT03603496|9677288|FG000|Overall Study|Death|19
6073615|NCT03603496|9677289|FG001|Overall Study|Death|24
6073616|NCT03603496|9677288|FG000|Overall Study|Lost to Follow-up|141
6073617|NCT03603496|9677289|FG001|Overall Study|Lost to Follow-up|141
6073618|NCT03603496|9677288|FG000|Overall Study|Withdrawal by Subject|26
6073619|NCT03603496|9677289|FG001|Overall Study|Withdrawal by Subject|20
6073620|NCT03480802|9677297|FG000|Overall Study|Lost to Follow-up|5
6073621|NCT03480802|9677298|FG001|Overall Study|Lost to Follow-up|1
6073622|NCT03480802|9677297|FG000|Overall Study|Withdrawal by Subject|2
6073623|NCT03480802|9677298|FG001|Overall Study|Withdrawal by Subject|1
6073624|NCT03480802|9677297|FG000|Overall Study|Relocated|0
6073625|NCT03480802|9677298|FG001|Overall Study|Relocated|1
6073626|NCT03472521|9677308|FG000|Overall Study|Lost to Follow-up|3
6073627|NCT03472521|9677309|FG001|Overall Study|Lost to Follow-up|2
6073628|NCT03472521|9677308|FG000|Overall Study|Discontinued intervention|3
6073629|NCT03472521|9677309|FG001|Overall Study|Discontinued intervention|1
6073630|NCT02664441|9677340|FG000|Randomization|Withdrawal by Subject|0
6073631|NCT02664441|9677341|FG001|Randomization|Withdrawal by Subject|1
6073632|NCT02664441|9677340|FG000|36-week Randomized Trial|Adverse Event|2
6073633|NCT02664441|9677341|FG001|36-week Randomized Trial|Adverse Event|0
6073634|NCT02664441|9677340|FG000|36-week Randomized Trial|Lost to Follow-up|1
6073635|NCT02664441|9677341|FG001|36-week Randomized Trial|Lost to Follow-up|0
6073636|NCT02664441|9677340|FG000|36-week Randomized Trial|Withdrawal by Subject|0
6073637|NCT02664441|9677341|FG001|36-week Randomized Trial|Withdrawal by Subject|3
6073638|NCT02664441|9677340|FG000|18-week Open Label Extension|Adverse Event|1
6073639|NCT02664441|9677341|FG001|18-week Open Label Extension|Adverse Event|0
6073640|NCT02664441|9677340|FG000|18-week Open Label Extension|Physician Decision|1
6073641|NCT02664441|9677341|FG001|18-week Open Label Extension|Physician Decision|0
6073642|NCT02664441|9677340|FG000|18-week Open Label Extension|Death|1
6073643|NCT02664441|9677341|FG001|18-week Open Label Extension|Death|0
6073644|NCT02664441|9677340|FG000|18-week Open Label Extension|Lost to Follow-up|0
6073645|NCT02664441|9677341|FG001|18-week Open Label Extension|Lost to Follow-up|1
6073646|NCT02513472|9677361|FG000|Overall Study|Radiological Disease Progression|45
6073647|NCT02513472|9677362|FG001|Overall Study|Radiological Disease Progression|57
6073648|NCT02513472|9677361|FG000|Overall Study|Clinical Disease Progression|5
6073649|NCT02513472|9677362|FG001|Overall Study|Clinical Disease Progression|13
6073650|NCT02513472|9677361|FG000|Overall Study|Adverse Event|8
6073651|NCT02513472|9677362|FG001|Overall Study|Adverse Event|11
6073652|NCT02513472|9677361|FG000|Overall Study|Withdrawal by Subject|0
6073653|NCT02513472|9677362|FG001|Overall Study|Withdrawal by Subject|4
6073654|NCT02513472|9677361|FG000|Overall Study|Subject Choice|2
6073655|NCT02513472|9677362|FG001|Overall Study|Subject Choice|7
6073656|NCT02513472|9677361|FG000|Overall Study|Treatment Completed as per Protocol|3
6073657|NCT02513472|9677362|FG001|Overall Study|Treatment Completed as per Protocol|3
6073658|NCT02513472|9677361|FG000|Overall Study|Other|3
6073659|NCT02513472|9677362|FG001|Overall Study|Other|6
6073660|NCT01855412|9677404|FG000|Overall Study|Death|77
6073661|NCT01855412|9677405|FG001|Overall Study|Death|123
6073662|NCT01855412|9677406|FG002|Overall Study|Death|30
6073663|NCT01855412|9677404|FG000|Overall Study|Lost to Follow-up|28
6073664|NCT01855412|9677405|FG001|Overall Study|Lost to Follow-up|46
6073665|NCT01855412|9677406|FG002|Overall Study|Lost to Follow-up|15
6073666|NCT01855412|9677404|FG000|Overall Study|Withdrawal by Subject|77
6073667|NCT01855412|9677405|FG001|Overall Study|Withdrawal by Subject|123
6073668|NCT01855412|9677406|FG002|Overall Study|Withdrawal by Subject|24
6073669|NCT01855412|9677404|FG000|Overall Study|Physician Decision|25
6004201|NCT00075725|9598448|FG010|Overall Study|Patient off treatment|0
6004202|NCT00075725|9598449|FG011|Overall Study|Patient off treatment|0
6004203|NCT00075725|9598438|FG000|Overall Study|Ineligible or wrong diagnosis|8
6004204|NCT00075725|9598439|FG001|Overall Study|Ineligible or wrong diagnosis|3
6004205|NCT00075725|9598440|FG002|Overall Study|Ineligible or wrong diagnosis|3
6004206|NCT00075725|9598441|FG003|Overall Study|Ineligible or wrong diagnosis|10
6004207|NCT00075725|9598442|FG004|Overall Study|Ineligible or wrong diagnosis|3
6004208|NCT00075725|9598443|FG005|Overall Study|Ineligible or wrong diagnosis|17
6004209|NCT00075725|9598444|FG006|Overall Study|Ineligible or wrong diagnosis|6
6004210|NCT00075725|9598445|FG007|Overall Study|Ineligible or wrong diagnosis|9
6004211|NCT00075725|9598446|FG008|Overall Study|Ineligible or wrong diagnosis|10
6004212|NCT00075725|9598447|FG009|Overall Study|Ineligible or wrong diagnosis|1
6004213|NCT00075725|9598448|FG010|Overall Study|Ineligible or wrong diagnosis|2
6004214|NCT00075725|9598449|FG011|Overall Study|Ineligible or wrong diagnosis|4
6004215|NCT00075725|9598438|FG000|Overall Study|Pt/Guardian refused RT therapy|1
6004216|NCT00075725|9598439|FG001|Overall Study|Pt/Guardian refused RT therapy|0
6004217|NCT00075725|9598440|FG002|Overall Study|Pt/Guardian refused RT therapy|1
6004218|NCT00075725|9598441|FG003|Overall Study|Pt/Guardian refused RT therapy|2
6004219|NCT00075725|9598442|FG004|Overall Study|Pt/Guardian refused RT therapy|1
6073670|NCT01855412|9677405|FG001|Overall Study|Physician Decision|31
6073671|NCT01855412|9677406|FG002|Overall Study|Physician Decision|3
6073672|NCT01855412|9677404|FG000|Overall Study|Site Closure|4
6073673|NCT01855412|9677405|FG001|Overall Study|Site Closure|18
6073674|NCT01855412|9677406|FG002|Overall Study|Site Closure|1
6073675|NCT01855412|9677404|FG000|Overall Study|Reason not Specified|1
6073676|NCT01855412|9677405|FG001|Overall Study|Reason not Specified|2
6073677|NCT01855412|9677406|FG002|Overall Study|Reason not Specified|3
6073678|NCT01559935|9677420|FG000|Car Phase|Toxicity|4
6073679|NCT01559935|9677420|FG000|Car Phase|Death|1
6073680|NCT01559935|9677420|FG000|Car Phase|Lack of Efficacy|2
6073681|NCT01559935|9677420|FG000|Car Phase|Lost to Follow-up|1
6073682|NCT01559935|9677420|FG000|Car Phase|Physician Decision|1
6073683|NCT01559935|9677420|FG000|Car Phase|Withdrawal by Subject|2
6073684|NCT01559935|9677420|FG000|Car Phase|Per protocol|1
6073685|NCT01559935|9677420|FG000|Car Phase|Insurance|1
6073686|NCT01559935|9677420|FG000|Car Phase|non-compliance|1
6073687|NCT01559935|9677420|FG000|BiRD Phase|Toxicity|1
6073688|NCT01559935|9677420|FG000|BiRD Phase|Lack of Efficacy|1
6073689|NCT01559935|9677420|FG000|BiRD Phase|Withdrawal by Subject|2
6073690|NCT01559935|9677420|FG000|Maintenance Phase|Remains on study|28
6073691|NCT01559935|9677420|FG000|Maintenance Phase|Toxicity|1
6073692|NCT01559935|9677420|FG000|Maintenance Phase|Lack of Efficacy|18
6073693|NCT01559935|9677420|FG000|Maintenance Phase|Withdrawal by Subject|5
6073694|NCT01559935|9677420|FG000|Maintenance Phase|Non-compliance|2
6073695|NCT01067144|9677435|FG000|Treatment|Did not receive allocated intervention|4
6073696|NCT01067144|9677436|FG001|Treatment|Did not receive allocated intervention|7
6073697|NCT01067144|9677435|FG000|Follow-up|Lost to Follow-up|22
6073698|NCT01067144|9677436|FG001|Follow-up|Lost to Follow-up|12
6073699|NCT01067144|9677435|FG000|Follow-up|Censored owing to second surgery|19
6073700|NCT01067144|9677436|FG001|Follow-up|Censored owing to second surgery|28
6073701|NCT01067144|9677435|FG000|Follow-up|Withdrawal by Subject|18
6073702|NCT01067144|9677436|FG001|Follow-up|Withdrawal by Subject|14
6073703|NCT01067144|9677435|FG000|Follow-up|Surgery cancelled|0
6309502|NCT02639338|10038113|FG001|Overall Study|Withdrew Consent|2
6309503|NCT02639338|10038112|FG000|Overall Study|Death|1
6309504|NCT02639338|10038113|FG001|Overall Study|Death|0
6309505|NCT02639338|10038112|FG000|Overall Study|Randomized but Not Treated|0
6309506|NCT02639338|10038113|FG001|Overall Study|Randomized but Not Treated|1
6309507|NCT02640053|10038184|FG000|Overall Study|Withdrawal by Subject|2
6004220|NCT00075725|9598443|FG005|Overall Study|Pt/Guardian refused RT therapy|0
6004221|NCT00075725|9598444|FG006|Overall Study|Pt/Guardian refused RT therapy|0
6073704|NCT01067144|9677436|FG001|Follow-up|Surgery cancelled|1
6073705|NCT01067144|9677435|FG000|Follow-up|Death|0
6073706|NCT01067144|9677436|FG001|Follow-up|Death|1
6073707|NCT00777036|9677445|FG000|On Treatment|Reason Not Specified|4
6073708|NCT00777036|9677446|FG001|On Treatment|Reason Not Specified|7
6073709|NCT00777036|9677447|FG002|On Treatment|Reason Not Specified|12
6073710|NCT00777036|9677445|FG000|On Treatment|Failure to Meet Study Criteria|0
6073711|NCT00777036|9677446|FG001|On Treatment|Failure to Meet Study Criteria|1
6073712|NCT00777036|9677447|FG002|On Treatment|Failure to Meet Study Criteria|0
6309508|NCT02640053|10038185|FG001|Overall Study|Withdrawal by Subject|1
6309509|NCT02640053|10038184|FG000|Overall Study|Adverse Event|1
6073713|NCT00777036|9677445|FG000|On Treatment|Non-compliance with Study Drug|1
6073714|NCT00777036|9677446|FG001|On Treatment|Non-compliance with Study Drug|0
6004222|NCT00075725|9598445|FG007|Overall Study|Pt/Guardian refused RT therapy|0
6004223|NCT00075725|9598446|FG008|Overall Study|Pt/Guardian refused RT therapy|0
6004224|NCT00075725|9598447|FG009|Overall Study|Pt/Guardian refused RT therapy|0
6004225|NCT00075725|9598448|FG010|Overall Study|Pt/Guardian refused RT therapy|0
6004226|NCT00075725|9598449|FG011|Overall Study|Pt/Guardian refused RT therapy|0
6004227|NCT00075725|9598438|FG000|Overall Study|Pt non compliant with therapy|2
6004228|NCT00075725|9598439|FG001|Overall Study|Pt non compliant with therapy|1
6004229|NCT00075725|9598440|FG002|Overall Study|Pt non compliant with therapy|1
6004230|NCT00075725|9598441|FG003|Overall Study|Pt non compliant with therapy|0
6004231|NCT00075725|9598442|FG004|Overall Study|Pt non compliant with therapy|2
6004232|NCT00075725|9598443|FG005|Overall Study|Pt non compliant with therapy|14
6004233|NCT00075725|9598444|FG006|Overall Study|Pt non compliant with therapy|2
6004234|NCT00075725|9598445|FG007|Overall Study|Pt non compliant with therapy|5
6004235|NCT00075725|9598446|FG008|Overall Study|Pt non compliant with therapy|3
6004236|NCT00075725|9598447|FG009|Overall Study|Pt non compliant with therapy|0
6004237|NCT00075725|9598448|FG010|Overall Study|Pt non compliant with therapy|0
6004238|NCT00075725|9598449|FG011|Overall Study|Pt non compliant with therapy|0
6004239|NCT00075725|9598438|FG000|Overall Study|Pt age out of range for treatment|0
6004240|NCT00075725|9598439|FG001|Overall Study|Pt age out of range for treatment|1
6004241|NCT00075725|9598440|FG002|Overall Study|Pt age out of range for treatment|0
6004242|NCT00075725|9598441|FG003|Overall Study|Pt age out of range for treatment|0
6004243|NCT00075725|9598442|FG004|Overall Study|Pt age out of range for treatment|0
6004244|NCT00075725|9598443|FG005|Overall Study|Pt age out of range for treatment|1
6004245|NCT00075725|9598444|FG006|Overall Study|Pt age out of range for treatment|0
6004246|NCT00075725|9598445|FG007|Overall Study|Pt age out of range for treatment|1
6004247|NCT00075725|9598446|FG008|Overall Study|Pt age out of range for treatment|0
6004248|NCT00075725|9598447|FG009|Overall Study|Pt age out of range for treatment|0
6004249|NCT00075725|9598448|FG010|Overall Study|Pt age out of range for treatment|0
6004250|NCT00075725|9598449|FG011|Overall Study|Pt age out of range for treatment|0
6004251|NCT00075725|9598438|FG000|Overall Study|Insurance issues|0
6004252|NCT00075725|9598439|FG001|Overall Study|Insurance issues|1
6004253|NCT00075725|9598440|FG002|Overall Study|Insurance issues|0
6004254|NCT00075725|9598441|FG003|Overall Study|Insurance issues|1
6004255|NCT00075725|9598442|FG004|Overall Study|Insurance issues|1
6004256|NCT00075725|9598443|FG005|Overall Study|Insurance issues|1
6004257|NCT00075725|9598444|FG006|Overall Study|Insurance issues|0
6004258|NCT00075725|9598445|FG007|Overall Study|Insurance issues|1
6004259|NCT00075725|9598446|FG008|Overall Study|Insurance issues|0
6004260|NCT00075725|9598447|FG009|Overall Study|Insurance issues|0
6004261|NCT00075725|9598448|FG010|Overall Study|Insurance issues|0
6004262|NCT00075725|9598449|FG011|Overall Study|Insurance issues|0
6004263|NCT00075725|9598438|FG000|Overall Study|MRD positive after extended ind|0
6004264|NCT00075725|9598439|FG001|Overall Study|MRD positive after extended ind|1
6004265|NCT00075725|9598440|FG002|Overall Study|MRD positive after extended ind|1
6004266|NCT00075725|9598441|FG003|Overall Study|MRD positive after extended ind|0
6004267|NCT00075725|9598442|FG004|Overall Study|MRD positive after extended ind|1
6004268|NCT00075725|9598443|FG005|Overall Study|MRD positive after extended ind|2
6004269|NCT00075725|9598444|FG006|Overall Study|MRD positive after extended ind|0
6004270|NCT00075725|9598445|FG007|Overall Study|MRD positive after extended ind|1
6004271|NCT00075725|9598446|FG008|Overall Study|MRD positive after extended ind|0
6004272|NCT00075725|9598447|FG009|Overall Study|MRD positive after extended ind|0
6004273|NCT00075725|9598448|FG010|Overall Study|MRD positive after extended ind|0
6004274|NCT00075725|9598449|FG011|Overall Study|MRD positive after extended ind|0
6004275|NCT00075725|9598438|FG000|Overall Study|Pt has very high risk ALL characteristic|15
6004276|NCT00075725|9598439|FG001|Overall Study|Pt has very high risk ALL characteristic|11
6004277|NCT00075725|9598440|FG002|Overall Study|Pt has very high risk ALL characteristic|26
6004278|NCT00075725|9598441|FG003|Overall Study|Pt has very high risk ALL characteristic|18
6004279|NCT00075725|9598442|FG004|Overall Study|Pt has very high risk ALL characteristic|11
6004280|NCT00075725|9598443|FG005|Overall Study|Pt has very high risk ALL characteristic|75
6004281|NCT00075725|9598444|FG006|Overall Study|Pt has very high risk ALL characteristic|23
6004282|NCT00075725|9598445|FG007|Overall Study|Pt has very high risk ALL characteristic|74
6004283|NCT00075725|9598446|FG008|Overall Study|Pt has very high risk ALL characteristic|29
6004284|NCT00075725|9598447|FG009|Overall Study|Pt has very high risk ALL characteristic|1
6004285|NCT00075725|9598448|FG010|Overall Study|Pt has very high risk ALL characteristic|0
6004286|NCT00075725|9598449|FG011|Overall Study|Pt has very high risk ALL characteristic|3
6004287|NCT00075725|9598438|FG000|Overall Study|Inevaluable|1
6004288|NCT00075725|9598439|FG001|Overall Study|Inevaluable|1
6004289|NCT00075725|9598440|FG002|Overall Study|Inevaluable|4
6004290|NCT00075725|9598441|FG003|Overall Study|Inevaluable|2
6004291|NCT00075725|9598442|FG004|Overall Study|Inevaluable|2
6004292|NCT00075725|9598443|FG005|Overall Study|Inevaluable|9
6004293|NCT00075725|9598444|FG006|Overall Study|Inevaluable|1
6004294|NCT00075725|9598445|FG007|Overall Study|Inevaluable|11
6004295|NCT00075725|9598446|FG008|Overall Study|Inevaluable|2
6004296|NCT00075725|9598447|FG009|Overall Study|Inevaluable|0
6004297|NCT00075725|9598448|FG010|Overall Study|Inevaluable|1
6004298|NCT00075725|9598449|FG011|Overall Study|Inevaluable|0
6004299|NCT00075725|9598438|FG000|Overall Study|Other|4
6004300|NCT00075725|9598439|FG001|Overall Study|Other|2
6004301|NCT00075725|9598440|FG002|Overall Study|Other|1
6004302|NCT00075725|9598441|FG003|Overall Study|Other|1
6004303|NCT00075725|9598442|FG004|Overall Study|Other|1
6004304|NCT00075725|9598443|FG005|Overall Study|Other|4
6004305|NCT00075725|9598444|FG006|Overall Study|Other|2
6004306|NCT00075725|9598445|FG007|Overall Study|Other|9
6004307|NCT00075725|9598446|FG008|Overall Study|Other|2
6004308|NCT00075725|9598447|FG009|Overall Study|Other|1
6004309|NCT00075725|9598448|FG010|Overall Study|Other|0
6004310|NCT00075725|9598449|FG011|Overall Study|Other|3
6004311|NCT00075725|9598438|FG000|Overall Study|Pt trying to find a BM donor|0
6004312|NCT00075725|9598439|FG001|Overall Study|Pt trying to find a BM donor|1
6004313|NCT00075725|9598440|FG002|Overall Study|Pt trying to find a BM donor|0
6004314|NCT00075725|9598441|FG003|Overall Study|Pt trying to find a BM donor|0
6004315|NCT00075725|9598442|FG004|Overall Study|Pt trying to find a BM donor|0
6004316|NCT00075725|9598443|FG005|Overall Study|Pt trying to find a BM donor|0
6004317|NCT00075725|9598444|FG006|Overall Study|Pt trying to find a BM donor|0
6004318|NCT00075725|9598445|FG007|Overall Study|Pt trying to find a BM donor|0
6004319|NCT00075725|9598446|FG008|Overall Study|Pt trying to find a BM donor|0
6004320|NCT00075725|9598447|FG009|Overall Study|Pt trying to find a BM donor|0
6004321|NCT00075725|9598448|FG010|Overall Study|Pt trying to find a BM donor|0
6004322|NCT00075725|9598449|FG011|Overall Study|Pt trying to find a BM donor|0
6004323|NCT00075725|9598438|FG000|Overall Study|Clinic chart lost unable to recreate|0
6004324|NCT00075725|9598439|FG001|Overall Study|Clinic chart lost unable to recreate|0
6004325|NCT00075725|9598440|FG002|Overall Study|Clinic chart lost unable to recreate|1
6004326|NCT00075725|9598441|FG003|Overall Study|Clinic chart lost unable to recreate|0
6004327|NCT00075725|9598442|FG004|Overall Study|Clinic chart lost unable to recreate|0
6004328|NCT00075725|9598443|FG005|Overall Study|Clinic chart lost unable to recreate|0
6004329|NCT00075725|9598444|FG006|Overall Study|Clinic chart lost unable to recreate|0
6004330|NCT00075725|9598445|FG007|Overall Study|Clinic chart lost unable to recreate|0
6004331|NCT00075725|9598446|FG008|Overall Study|Clinic chart lost unable to recreate|0
6004332|NCT00075725|9598447|FG009|Overall Study|Clinic chart lost unable to recreate|0
6004333|NCT00075725|9598448|FG010|Overall Study|Clinic chart lost unable to recreate|0
6004334|NCT00075725|9598449|FG011|Overall Study|Clinic chart lost unable to recreate|0
6004335|NCT00075725|9598438|FG000|Overall Study|Unsuccessful institutional transfer|0
6004336|NCT00075725|9598439|FG001|Overall Study|Unsuccessful institutional transfer|0
6004337|NCT00075725|9598440|FG002|Overall Study|Unsuccessful institutional transfer|2
6004338|NCT00075725|9598441|FG003|Overall Study|Unsuccessful institutional transfer|0
6004339|NCT00075725|9598442|FG004|Overall Study|Unsuccessful institutional transfer|0
6004340|NCT00075725|9598443|FG005|Overall Study|Unsuccessful institutional transfer|0
6004341|NCT00075725|9598444|FG006|Overall Study|Unsuccessful institutional transfer|0
6004342|NCT00075725|9598445|FG007|Overall Study|Unsuccessful institutional transfer|0
6004343|NCT00075725|9598446|FG008|Overall Study|Unsuccessful institutional transfer|0
6004344|NCT00075725|9598447|FG009|Overall Study|Unsuccessful institutional transfer|1
6004345|NCT00075725|9598448|FG010|Overall Study|Unsuccessful institutional transfer|0
6004346|NCT00075725|9598449|FG011|Overall Study|Unsuccessful institutional transfer|0
6004347|NCT00075725|9598438|FG000|Overall Study|specimen(s) not submitted|0
6004348|NCT00075725|9598439|FG001|Overall Study|specimen(s) not submitted|0
6004349|NCT00075725|9598440|FG002|Overall Study|specimen(s) not submitted|2
6004350|NCT00075725|9598441|FG003|Overall Study|specimen(s) not submitted|0
6004351|NCT00075725|9598442|FG004|Overall Study|specimen(s) not submitted|0
6004352|NCT00075725|9598443|FG005|Overall Study|specimen(s) not submitted|0
6004353|NCT00075725|9598444|FG006|Overall Study|specimen(s) not submitted|0
6004354|NCT00075725|9598445|FG007|Overall Study|specimen(s) not submitted|0
6004355|NCT00075725|9598446|FG008|Overall Study|specimen(s) not submitted|0
6004356|NCT00075725|9598447|FG009|Overall Study|specimen(s) not submitted|0
6004357|NCT00075725|9598448|FG010|Overall Study|specimen(s) not submitted|0
6004358|NCT00075725|9598449|FG011|Overall Study|specimen(s) not submitted|0
6004359|NCT00075725|9598438|FG000|Overall Study|Pt went to transplant|0
6004360|NCT00075725|9598439|FG001|Overall Study|Pt went to transplant|0
6004361|NCT00075725|9598440|FG002|Overall Study|Pt went to transplant|0
6004362|NCT00075725|9598441|FG003|Overall Study|Pt went to transplant|1
6004363|NCT00075725|9598442|FG004|Overall Study|Pt went to transplant|0
6004364|NCT00075725|9598443|FG005|Overall Study|Pt went to transplant|1
6004365|NCT00075725|9598444|FG006|Overall Study|Pt went to transplant|0
6004366|NCT00075725|9598445|FG007|Overall Study|Pt went to transplant|0
6004367|NCT00075725|9598446|FG008|Overall Study|Pt went to transplant|0
6004368|NCT00075725|9598447|FG009|Overall Study|Pt went to transplant|0
6004369|NCT00075725|9598448|FG010|Overall Study|Pt went to transplant|0
6004370|NCT00075725|9598449|FG011|Overall Study|Pt went to transplant|0
6004371|NCT00075725|9598438|FG000|Overall Study|Pt received additional steroids|0
6004372|NCT00075725|9598439|FG001|Overall Study|Pt received additional steroids|0
6004373|NCT00075725|9598440|FG002|Overall Study|Pt received additional steroids|0
6004374|NCT00075725|9598441|FG003|Overall Study|Pt received additional steroids|1
6004375|NCT00075725|9598442|FG004|Overall Study|Pt received additional steroids|0
6004376|NCT00075725|9598443|FG005|Overall Study|Pt received additional steroids|0
6004377|NCT00075725|9598444|FG006|Overall Study|Pt received additional steroids|0
6004378|NCT00075725|9598445|FG007|Overall Study|Pt received additional steroids|0
6004379|NCT00075725|9598446|FG008|Overall Study|Pt received additional steroids|0
6004380|NCT00075725|9598447|FG009|Overall Study|Pt received additional steroids|0
6004381|NCT00075725|9598448|FG010|Overall Study|Pt received additional steroids|0
6004382|NCT00075725|9598449|FG011|Overall Study|Pt received additional steroids|0
6004383|NCT00075725|9598438|FG000|Overall Study|Pt relocated|0
6004384|NCT00075725|9598439|FG001|Overall Study|Pt relocated|0
6004385|NCT00075725|9598440|FG002|Overall Study|Pt relocated|0
6004386|NCT00075725|9598441|FG003|Overall Study|Pt relocated|2
6004387|NCT00075725|9598442|FG004|Overall Study|Pt relocated|0
6004388|NCT00075725|9598443|FG005|Overall Study|Pt relocated|1
6004389|NCT00075725|9598444|FG006|Overall Study|Pt relocated|1
6004390|NCT00075725|9598445|FG007|Overall Study|Pt relocated|2
6004391|NCT00075725|9598446|FG008|Overall Study|Pt relocated|1
6004392|NCT00075725|9598447|FG009|Overall Study|Pt relocated|0
6004393|NCT00075725|9598448|FG010|Overall Study|Pt relocated|0
6004394|NCT00075725|9598449|FG011|Overall Study|Pt relocated|0
6004395|NCT00075725|9598438|FG000|Overall Study|Institution Terminated|0
6004396|NCT00075725|9598439|FG001|Overall Study|Institution Terminated|0
6004397|NCT00075725|9598440|FG002|Overall Study|Institution Terminated|0
6004398|NCT00075725|9598441|FG003|Overall Study|Institution Terminated|0
6004399|NCT00075725|9598442|FG004|Overall Study|Institution Terminated|1
6004400|NCT00075725|9598443|FG005|Overall Study|Institution Terminated|0
6004401|NCT00075725|9598444|FG006|Overall Study|Institution Terminated|0
6004402|NCT00075725|9598445|FG007|Overall Study|Institution Terminated|3
6004403|NCT00075725|9598446|FG008|Overall Study|Institution Terminated|0
6004404|NCT00075725|9598447|FG009|Overall Study|Institution Terminated|0
6004405|NCT00075725|9598448|FG010|Overall Study|Institution Terminated|0
6004406|NCT00075725|9598449|FG011|Overall Study|Institution Terminated|0
6004407|NCT00075725|9598438|FG000|Overall Study|Study Closure|1
6004408|NCT00075725|9598439|FG001|Overall Study|Study Closure|0
6004409|NCT00075725|9598440|FG002|Overall Study|Study Closure|0
6004410|NCT00075725|9598441|FG003|Overall Study|Study Closure|0
6004411|NCT00075725|9598442|FG004|Overall Study|Study Closure|1
6004412|NCT00075725|9598443|FG005|Overall Study|Study Closure|3
6073715|NCT00777036|9677447|FG002|On Treatment|Non-compliance with Study Drug|0
6073716|NCT00777036|9677445|FG000|On Treatment|Maximum Clinical Benefit|2
6073717|NCT00777036|9677446|FG001|On Treatment|Maximum Clinical Benefit|0
6073718|NCT00777036|9677447|FG002|On Treatment|Maximum Clinical Benefit|1
6073719|NCT00777036|9677445|FG000|On Treatment|Withdrawal by Subject|3
6073720|NCT00777036|9677446|FG001|On Treatment|Withdrawal by Subject|2
6073721|NCT00777036|9677447|FG002|On Treatment|Withdrawal by Subject|3
6073722|NCT00777036|9677445|FG000|On Treatment|Death|0
6073723|NCT00777036|9677446|FG001|On Treatment|Death|2
6073724|NCT00777036|9677447|FG002|On Treatment|Death|0
6073725|NCT00777036|9677445|FG000|On Treatment|Study Drug Toxicity|0
6073726|NCT00777036|9677446|FG001|On Treatment|Study Drug Toxicity|0
6073727|NCT00777036|9677447|FG002|On Treatment|Study Drug Toxicity|1
6073728|NCT00777036|9677445|FG000|On Treatment|Progressive Disease|5
6073729|NCT00777036|9677446|FG001|On Treatment|Progressive Disease|4
6073730|NCT00777036|9677447|FG002|On Treatment|Progressive Disease|6
6073731|NCT00777036|9677445|FG000|Follow-Up|Lost to Follow-up|1
6073732|NCT00777036|9677446|FG001|Follow-Up|Lost to Follow-up|0
6073733|NCT00777036|9677447|FG002|Follow-Up|Lost to Follow-up|0
6073734|NCT00777036|9677445|FG000|Follow-Up|Reason Not Specified|2
6073735|NCT00777036|9677446|FG001|Follow-Up|Reason Not Specified|0
6073736|NCT00777036|9677447|FG002|Follow-Up|Reason Not Specified|0
6073737|NCT00777036|9677445|FG000|Follow-Up|Withdrawal by Subject|1
6073738|NCT00777036|9677446|FG001|Follow-Up|Withdrawal by Subject|0
6073739|NCT00777036|9677447|FG002|Follow-Up|Withdrawal by Subject|4
6073740|NCT00777036|9677445|FG000|Follow-Up|Death|1
6073741|NCT00777036|9677446|FG001|Follow-Up|Death|8
6073742|NCT00777036|9677447|FG002|Follow-Up|Death|0
6073743|NCT00600483|9677464|FG000|Overall Study|Lost to Follow-up|26
6073744|NCT00600483|9677465|FG001|Overall Study|Lost to Follow-up|47
6073745|NCT00600483|9677464|FG000|Overall Study|Randomized but not treated|10
6073746|NCT00600483|9677465|FG001|Overall Study|Randomized but not treated|0
6073747|NCT00568958|9677482|FG000|Allocation|Withdrawal by Subject|7
6073748|NCT00568958|9677483|FG001|Allocation|Withdrawal by Subject|3
6073749|NCT00568958|9677482|FG000|Allocation|Physician Decision|2
6073750|NCT00568958|9677483|FG001|Allocation|Physician Decision|0
6073751|NCT00568958|9677482|FG000|Follow-Up|Withdrawal by Subject|6
6004413|NCT00075725|9598444|FG006|Overall Study|Study Closure|0
6004414|NCT00075725|9598445|FG007|Overall Study|Study Closure|1
6004415|NCT00075725|9598446|FG008|Overall Study|Study Closure|0
6004416|NCT00075725|9598447|FG009|Overall Study|Study Closure|0
6004417|NCT00075725|9598448|FG010|Overall Study|Study Closure|0
6004418|NCT00075725|9598449|FG011|Overall Study|Study Closure|0
6004419|NCT00075725|9598438|FG000|Overall Study|Other complications|0
6004420|NCT00075725|9598439|FG001|Overall Study|Other complications|0
6004421|NCT00075725|9598440|FG002|Overall Study|Other complications|0
6004422|NCT00075725|9598441|FG003|Overall Study|Other complications|0
6073752|NCT00568958|9677483|FG001|Follow-Up|Withdrawal by Subject|6
6004423|NCT00075725|9598442|FG004|Overall Study|Other complications|0
6073753|NCT00568958|9677482|FG000|Follow-Up|Physician Decision|1
6073754|NCT00568958|9677483|FG001|Follow-Up|Physician Decision|1
6073755|NCT00568958|9677482|FG000|Follow-Up|Family Emergency|1
6004424|NCT00075725|9598443|FG005|Overall Study|Other complications|1
6004425|NCT00075725|9598444|FG006|Overall Study|Other complications|0
6004426|NCT00075725|9598445|FG007|Overall Study|Other complications|0
6004427|NCT00075725|9598446|FG008|Overall Study|Other complications|0
6004428|NCT00075725|9598447|FG009|Overall Study|Other complications|0
6004429|NCT00075725|9598448|FG010|Overall Study|Other complications|0
6004430|NCT00075725|9598449|FG011|Overall Study|Other complications|0
6004431|NCT00075725|9598438|FG000|Overall Study|Pt care terminated due to pt behavior|0
6004432|NCT00075725|9598439|FG001|Overall Study|Pt care terminated due to pt behavior|0
6004433|NCT00075725|9598440|FG002|Overall Study|Pt care terminated due to pt behavior|0
6004434|NCT00075725|9598441|FG003|Overall Study|Pt care terminated due to pt behavior|0
6004435|NCT00075725|9598442|FG004|Overall Study|Pt care terminated due to pt behavior|0
6004436|NCT00075725|9598443|FG005|Overall Study|Pt care terminated due to pt behavior|0
6004437|NCT00075725|9598444|FG006|Overall Study|Pt care terminated due to pt behavior|0
6004438|NCT00075725|9598445|FG007|Overall Study|Pt care terminated due to pt behavior|1
6073756|NCT00568958|9677483|FG001|Follow-Up|Family Emergency|0
6073757|NCT00568958|9677482|FG000|Follow-Up|Adverse Event|1
6004439|NCT00075725|9598446|FG008|Overall Study|Pt care terminated due to pt behavior|0
6004440|NCT00075725|9598447|FG009|Overall Study|Pt care terminated due to pt behavior|0
6004441|NCT00075725|9598448|FG010|Overall Study|Pt care terminated due to pt behavior|0
6004442|NCT00075725|9598449|FG011|Overall Study|Pt care terminated due to pt behavior|0
6004443|NCT00075725|9598438|FG000|Overall Study|Pt incarcerated|0
6004444|NCT00075725|9598439|FG001|Overall Study|Pt incarcerated|0
6004445|NCT00075725|9598440|FG002|Overall Study|Pt incarcerated|0
6004446|NCT00075725|9598441|FG003|Overall Study|Pt incarcerated|0
6004447|NCT00075725|9598442|FG004|Overall Study|Pt incarcerated|0
6004448|NCT00075725|9598443|FG005|Overall Study|Pt incarcerated|0
6004449|NCT00075725|9598444|FG006|Overall Study|Pt incarcerated|0
6004450|NCT00075725|9598445|FG007|Overall Study|Pt incarcerated|1
6004451|NCT00075725|9598446|FG008|Overall Study|Pt incarcerated|0
6004452|NCT00075725|9598447|FG009|Overall Study|Pt incarcerated|0
6004453|NCT00075725|9598448|FG010|Overall Study|Pt incarcerated|0
6004454|NCT00075725|9598449|FG011|Overall Study|Pt incarcerated|0
6004455|NCT00075764|9598482|FG000|Overall Study|Adverse Event|5
6004456|NCT00075764|9598483|FG001|Overall Study|Adverse Event|12
6004457|NCT00075764|9598482|FG000|Overall Study|Death|4
6004458|NCT00075764|9598483|FG001|Overall Study|Death|8
6004459|NCT00075764|9598482|FG000|Overall Study|Withdrawal by Subject|28
6004460|NCT00075764|9598483|FG001|Overall Study|Withdrawal by Subject|18
6004461|NCT00075764|9598482|FG000|Overall Study|Progression|269
6004462|NCT00075764|9598483|FG001|Overall Study|Progression|274
6004463|NCT00075764|9598482|FG000|Overall Study|Still on treatment|8
6004464|NCT00075764|9598483|FG001|Overall Study|Still on treatment|15
6004465|NCT00075764|9598482|FG000|Overall Study|Delinquent|4
6004466|NCT00075764|9598483|FG001|Overall Study|Delinquent|2
6004467|NCT00075764|9598482|FG000|Overall Study|Not protocol specified|27
6004468|NCT00075764|9598483|FG001|Overall Study|Not protocol specified|19
6004469|NCT00075764|9598482|FG000|Overall Study|Under review|0
6004470|NCT00075764|9598483|FG001|Overall Study|Under review|1
6004471|NCT00075816|9598502|FG000|Overall Study|Did not undergo transplantation|14
6004472|NCT00075816|9598503|FG001|Overall Study|Did not undergo transplantation|11
6004473|NCT00075881|9598531|FG000|Overall Study|Lack of Efficacy|18
6004474|NCT00075881|9598531|FG000|Overall Study|Adverse Event|7
6004475|NCT00075881|9598531|FG000|Overall Study|Death|1
6004476|NCT00075881|9598531|FG000|Overall Study|Withdrawal by Subject|2
6004477|NCT00075881|9598531|FG000|Overall Study|Protocol Violation|4
6004478|NCT00075881|9598531|FG000|Overall Study|other complicating disease|3
6004479|NCT00075881|9598531|FG000|Overall Study|other|4
6004480|NCT00075881|9598531|FG000|Overall Study|missing data|2
6004481|NCT00075881|9598531|FG000|Overall Study|Ineligible|1
6004482|NCT00075881|9598531|FG000|Overall Study|never start protocol therapy|1
6004483|NCT00075946|9598541|FG000|Overall Study|Path ineligible: undetermined histology|0
6004484|NCT00075946|9598542|FG001|Overall Study|Path ineligible: undetermined histology|0
6004485|NCT00075946|9598543|FG002|Overall Study|Path ineligible: undetermined histology|0
6004486|NCT00075946|9598544|FG003|Overall Study|Path ineligible: undetermined histology|0
6004487|NCT00075946|9598545|FG004|Overall Study|Path ineligible: undetermined histology|6
6004488|NCT00075946|9598541|FG000|Overall Study|Did not achieve response after induction|0
6004489|NCT00075946|9598542|FG001|Overall Study|Did not achieve response after induction|0
6004490|NCT00075946|9598543|FG002|Overall Study|Did not achieve response after induction|0
6004491|NCT00075946|9598544|FG003|Overall Study|Did not achieve response after induction|0
6004492|NCT00075946|9598545|FG004|Overall Study|Did not achieve response after induction|182
6004493|NCT00075946|9598541|FG000|Overall Study|Incorrectly randomized (no response)|5
6004494|NCT00075946|9598542|FG001|Overall Study|Incorrectly randomized (no response)|5
6004495|NCT00075946|9598543|FG002|Overall Study|Incorrectly randomized (no response)|5
6004496|NCT00075946|9598544|FG003|Overall Study|Incorrectly randomized (no response)|1
6004497|NCT00075946|9598545|FG004|Overall Study|Incorrectly randomized (no response)|0
6004498|NCT00075946|9598541|FG000|Overall Study|Still on treatment at time of analysis|52
6004499|NCT00075946|9598542|FG001|Overall Study|Still on treatment at time of analysis|19
6073758|NCT00568958|9677483|FG001|Follow-Up|Adverse Event|0
6004500|NCT00075946|9598543|FG002|Overall Study|Still on treatment at time of analysis|3
6004501|NCT00075946|9598544|FG003|Overall Study|Still on treatment at time of analysis|9
6004502|NCT00075946|9598545|FG004|Overall Study|Still on treatment at time of analysis|0
6004503|NCT00075946|9598541|FG000|Overall Study|Adverse Event|2
6004504|NCT00075946|9598542|FG001|Overall Study|Adverse Event|10
6004505|NCT00075946|9598543|FG002|Overall Study|Adverse Event|0
6004506|NCT00075946|9598544|FG003|Overall Study|Adverse Event|2
6004507|NCT00075946|9598545|FG004|Overall Study|Adverse Event|0
6004508|NCT00075946|9598541|FG000|Overall Study|Death|0
6004509|NCT00075946|9598542|FG001|Overall Study|Death|1
6004510|NCT00075946|9598543|FG002|Overall Study|Death|0
6004511|NCT00075946|9598544|FG003|Overall Study|Death|0
6004512|NCT00075946|9598545|FG004|Overall Study|Death|0
6004513|NCT00075946|9598541|FG000|Overall Study|Withdrawal by Subject|23
6004514|NCT00075946|9598542|FG001|Overall Study|Withdrawal by Subject|58
6004515|NCT00075946|9598543|FG002|Overall Study|Withdrawal by Subject|4
6004516|NCT00075946|9598544|FG003|Overall Study|Withdrawal by Subject|9
6004517|NCT00075946|9598545|FG004|Overall Study|Withdrawal by Subject|0
6004518|NCT00075946|9598541|FG000|Overall Study|Alternative therapy|16
6004519|NCT00075946|9598542|FG001|Overall Study|Alternative therapy|2
6004520|NCT00075946|9598543|FG002|Overall Study|Alternative therapy|5
6004521|NCT00075946|9598544|FG003|Overall Study|Alternative therapy|0
6004522|NCT00075946|9598545|FG004|Overall Study|Alternative therapy|0
6004523|NCT00075946|9598541|FG000|Overall Study|Other complicating disease|7
6004524|NCT00075946|9598542|FG001|Overall Study|Other complicating disease|13
6004525|NCT00075946|9598543|FG002|Overall Study|Other complicating disease|1
6004526|NCT00075946|9598544|FG003|Overall Study|Other complicating disease|4
6004527|NCT00075946|9598545|FG004|Overall Study|Other complicating disease|0
6004528|NCT00075946|9598541|FG000|Overall Study|No response to retreatment|23
6004529|NCT00075946|9598542|FG001|Overall Study|No response to retreatment|0
6004530|NCT00075946|9598543|FG002|Overall Study|No response to retreatment|2
6004531|NCT00075946|9598544|FG003|Overall Study|No response to retreatment|0
6004532|NCT00075946|9598545|FG004|Overall Study|No response to retreatment|0
6004533|NCT00075946|9598541|FG000|Overall Study|Time to progression less than 6 months|15
6004534|NCT00075946|9598542|FG001|Overall Study|Time to progression less than 6 months|30
6004535|NCT00075946|9598543|FG002|Overall Study|Time to progression less than 6 months|8
6004536|NCT00075946|9598544|FG003|Overall Study|Time to progression less than 6 months|3
6004537|NCT00075946|9598545|FG004|Overall Study|Time to progression less than 6 months|0
6004538|NCT00075946|9598541|FG000|Overall Study|Other|5
6004539|NCT00075946|9598542|FG001|Overall Study|Other|13
6004540|NCT00075946|9598543|FG002|Overall Study|Other|0
6004541|NCT00075946|9598544|FG003|Overall Study|Other|2
6004542|NCT00075946|9598545|FG004|Overall Study|Other|0
6004543|NCT00076011|9598556|FG000|Overall Study|Death|1
6004544|NCT00076011|9598556|FG000|Overall Study|Adverse Event|10
6073759|NCT00569166|9677509|FG000|Overall Study|Withdrawal by Subject|7
6073760|NCT00569166|9677510|FG001|Overall Study|Withdrawal by Subject|5
6073761|NCT00569166|9677511|FG002|Overall Study|Withdrawal by Subject|3
6073762|NCT00569166|9677509|FG000|Overall Study|Lost to Follow-up|2
6073763|NCT00569166|9677510|FG001|Overall Study|Lost to Follow-up|1
6073764|NCT00569166|9677511|FG002|Overall Study|Lost to Follow-up|1
6073765|NCT00569231|9677532|FG000|Overall Study|Study unrelated surgery|1
6073766|NCT00569231|9677532|FG000|Overall Study|Airfare expense|2
6073767|NCT00569231|9677532|FG000|Overall Study|Withdrawal by Subject|1
6073768|NCT00569231|9677532|FG000|Overall Study|Car accident injury|1
6073769|NCT00569231|9677532|FG000|Overall Study|Non-compliance|2
6073770|NCT00569270|9677536|FG000|Period: First Intervention|Protocol Violation|0
6073771|NCT00569270|9677537|FG001|Period: First Intervention|Protocol Violation|1
6073772|NCT00569374|9677556|FG000|Overall Study|Withdrawal by Subject|4
6073773|NCT00569582|9677569|FG000|Overall Study|Withdrawal by Subject|5
6073774|NCT00569582|9677569|FG000|Overall Study|Death|2
6073775|NCT00569582|9677569|FG000|Overall Study|Adverse Event|7
6073776|NCT00569582|9677569|FG000|Overall Study|Subject was too ill to travel.|1
6073777|NCT00569582|9677569|FG000|Overall Study|Subject was non-compliant.|1
6073778|NCT00569777|9677583|FG000|Overall Study|Withdrawal by Subject|4
6073779|NCT00569777|9677584|FG001|Overall Study|Withdrawal by Subject|0
6073780|NCT00569777|9677583|FG000|Overall Study|Adverse Event|3
6073781|NCT00569777|9677584|FG001|Overall Study|Adverse Event|0
6073782|NCT00569777|9677583|FG000|Overall Study|Lost to Follow-up|1
6073783|NCT00569777|9677584|FG001|Overall Study|Lost to Follow-up|0
6073784|NCT00569777|9677583|FG000|Overall Study|scheduled eye surgery|0
6073785|NCT00569777|9677584|FG001|Overall Study|scheduled eye surgery|1
6073786|NCT00569777|9677583|FG000|Overall Study|did not meet exclusion criteria|1
6004545|NCT00076011|9598556|FG000|Overall Study|Lack of Efficacy|25
6004546|NCT00076011|9598556|FG000|Overall Study|Withdrawal by Subject|1
6004547|NCT00076011|9598556|FG000|Overall Study|Study terminated by sponsor|3
6004548|NCT00076011|9598556|FG000|Overall Study|Other|11
6004549|NCT00076011|9598556|FG000|Overall Study|Ongoing|1
6004550|NCT00076024|9598563|FG000|Phase 1, Lead-in|Lack of Efficacy|4
6004551|NCT00076024|9598564|FG001|Phase 1, Lead-in|Lack of Efficacy|0
6004552|NCT00076024|9598565|FG002|Phase 1, Lead-in|Lack of Efficacy|0
6004553|NCT00076024|9598566|FG003|Phase 1, Lead-in|Lack of Efficacy|0
6004554|NCT00076024|9598563|FG000|Phase 1, Lead-in|Adverse Event|1
6004555|NCT00076024|9598564|FG001|Phase 1, Lead-in|Adverse Event|0
6004556|NCT00076024|9598565|FG002|Phase 1, Lead-in|Adverse Event|0
6004557|NCT00076024|9598566|FG003|Phase 1, Lead-in|Adverse Event|0
6004558|NCT00076024|9598563|FG000|Phase 1, Lead-in|Clinical progression|1
6004559|NCT00076024|9598564|FG001|Phase 1, Lead-in|Clinical progression|0
6004560|NCT00076024|9598565|FG002|Phase 1, Lead-in|Clinical progression|0
6004561|NCT00076024|9598566|FG003|Phase 1, Lead-in|Clinical progression|0
6004562|NCT00076024|9598563|FG000|Phase 2, Double-blind|Lack of Efficacy|0
6004563|NCT00076024|9598564|FG001|Phase 2, Double-blind|Lack of Efficacy|59
6004564|NCT00076024|9598565|FG002|Phase 2, Double-blind|Lack of Efficacy|40
6004565|NCT00076024|9598566|FG003|Phase 2, Double-blind|Lack of Efficacy|0
6004566|NCT00076024|9598563|FG000|Phase 2, Double-blind|Withdrawal by Subject|0
6004567|NCT00076024|9598564|FG001|Phase 2, Double-blind|Withdrawal by Subject|13
6004568|NCT00076024|9598565|FG002|Phase 2, Double-blind|Withdrawal by Subject|4
6004569|NCT00076024|9598566|FG003|Phase 2, Double-blind|Withdrawal by Subject|0
6004570|NCT00076024|9598563|FG000|Phase 2, Double-blind|Adverse Event|0
6004571|NCT00076024|9598564|FG001|Phase 2, Double-blind|Adverse Event|25
6004572|NCT00076024|9598565|FG002|Phase 2, Double-blind|Adverse Event|6
6004573|NCT00076024|9598566|FG003|Phase 2, Double-blind|Adverse Event|0
6004574|NCT00076024|9598563|FG000|Phase 2, Double-blind|Un-specified|0
6004575|NCT00076024|9598564|FG001|Phase 2, Double-blind|Un-specified|14
6004576|NCT00076024|9598565|FG002|Phase 2, Double-blind|Un-specified|6
6004577|NCT00076024|9598566|FG003|Phase 2, Double-blind|Un-specified|0
6004578|NCT00076024|9598563|FG000|Phase 2, Double-blind|Randomized but not treated|0
6004579|NCT00076024|9598564|FG001|Phase 2, Double-blind|Randomized but not treated|1
6004580|NCT00076024|9598565|FG002|Phase 2, Double-blind|Randomized but not treated|0
6004581|NCT00076024|9598566|FG003|Phase 2, Double-blind|Randomized but not treated|0
6004582|NCT00076024|9598563|FG000|Phase 2, Open-label|Adverse Event|0
6004583|NCT00076024|9598564|FG001|Phase 2, Open-label|Adverse Event|0
6004584|NCT00076024|9598565|FG002|Phase 2, Open-label|Adverse Event|0
6004585|NCT00076024|9598566|FG003|Phase 2, Open-label|Adverse Event|2
6004586|NCT00076024|9598563|FG000|Phase 2, Open-label|Lack of Efficacy|0
6004587|NCT00076024|9598564|FG001|Phase 2, Open-label|Lack of Efficacy|0
6004588|NCT00076024|9598565|FG002|Phase 2, Open-label|Lack of Efficacy|0
6004589|NCT00076024|9598566|FG003|Phase 2, Open-label|Lack of Efficacy|11
6004590|NCT00076024|9598563|FG000|Phase 2, Open-label|Withdrawal by Subject|0
6004591|NCT00076024|9598564|FG001|Phase 2, Open-label|Withdrawal by Subject|0
6004592|NCT00076024|9598565|FG002|Phase 2, Open-label|Withdrawal by Subject|0
6004593|NCT00076024|9598566|FG003|Phase 2, Open-label|Withdrawal by Subject|1
6004594|NCT00076024|9598563|FG000|Phase 2, Open-label|Other|0
6004595|NCT00076024|9598564|FG001|Phase 2, Open-label|Other|0
6004596|NCT00076024|9598565|FG002|Phase 2, Open-label|Other|0
6004597|NCT00076024|9598566|FG003|Phase 2, Open-label|Other|2
6004598|NCT00076102|9598584|FG000|Overall Study|Clinical progression|1
6004599|NCT00076102|9598584|FG000|Overall Study|Progression in pre-existing brain tumor|1
6004600|NCT00076102|9598584|FG000|Overall Study|plexiform neurofibroma surgery|1
6004601|NCT00076102|9598584|FG000|Overall Study|refusal of further therapy|2
6004602|NCT00076336|9598627|FG000|Overall Study|Death|13
6004603|NCT00076336|9598628|FG001|Overall Study|Death|17
6004604|NCT00076336|9598627|FG000|Overall Study|Adverse Event|4
6004605|NCT00076336|9598628|FG001|Overall Study|Adverse Event|4
6004606|NCT00076336|9598627|FG000|Overall Study|Lost to Follow-up|4
6004607|NCT00076336|9598628|FG001|Overall Study|Lost to Follow-up|4
6004608|NCT00076336|9598627|FG000|Overall Study|Non-Compliance|2
6004609|NCT00076336|9598628|FG001|Overall Study|Non-Compliance|0
6004610|NCT00076336|9598627|FG000|Overall Study|Creatinine Clearance < 30 or Dialysis|0
6004611|NCT00076336|9598628|FG001|Overall Study|Creatinine Clearance < 30 or Dialysis|1
6004612|NCT00076336|9598627|FG000|Overall Study|Patient, Investigator, Sponsor request|8
6004613|NCT00076336|9598628|FG001|Overall Study|Patient, Investigator, Sponsor request|6
6004614|NCT00076336|9598627|FG000|Overall Study|Liver Transplantation|3
6004615|NCT00076336|9598628|FG001|Overall Study|Liver Transplantation|3
6004616|NCT00076336|9598627|FG000|Overall Study|Virologic Breakthrough|14
6004617|NCT00076336|9598628|FG001|Overall Study|Virologic Breakthrough|16
6004618|NCT00076336|9598627|FG000|Overall Study|Treatment failure|4
6004619|NCT00076336|9598628|FG001|Overall Study|Treatment failure|5
6004620|NCT00076570|9598636|FG000|Overall Study|Drug intolerance|8
6004621|NCT00076570|9598637|FG001|Overall Study|Drug intolerance|8
6004622|NCT00076752|9598677|FG000|Overall Study|Death|2
6004623|NCT00076752|9598677|FG000|Overall Study|Withdrawal per PI, PI put study on hold|1
6004624|NCT00076804|9598684|FG000|Overall Study|Death|9
6004625|NCT00076804|9598685|FG001|Overall Study|Death|20
6004626|NCT00076804|9598684|FG000|Overall Study|Lost to Follow-up|9
6004627|NCT00076804|9598685|FG001|Overall Study|Lost to Follow-up|9
6004628|NCT00076804|9598684|FG000|Overall Study|Withdrawal by Subject|10
6004629|NCT00076804|9598685|FG001|Overall Study|Withdrawal by Subject|8
6004630|NCT00076804|9598684|FG000|Overall Study|Early study Closure|32
6004631|NCT00076804|9598685|FG001|Overall Study|Early study Closure|32
6004632|NCT00076999|9598695|FG000|Overall Study|Adverse Event|2
6004633|NCT00076999|9598696|FG001|Overall Study|Adverse Event|8
6004634|NCT00076999|9598697|FG002|Overall Study|Adverse Event|6
6004635|NCT00076999|9598698|FG003|Overall Study|Adverse Event|0
6004636|NCT00076999|9598699|FG004|Overall Study|Adverse Event|2
6004637|NCT00076999|9598695|FG000|Overall Study|Protocol Violation|0
6004638|NCT00076999|9598696|FG001|Overall Study|Protocol Violation|3
6004639|NCT00076999|9598697|FG002|Overall Study|Protocol Violation|4
6004640|NCT00076999|9598698|FG003|Overall Study|Protocol Violation|0
6004641|NCT00076999|9598699|FG004|Overall Study|Protocol Violation|9
6004642|NCT00076999|9598695|FG000|Overall Study|Lost to Follow-up|2
6004643|NCT00076999|9598696|FG001|Overall Study|Lost to Follow-up|1
6004644|NCT00076999|9598697|FG002|Overall Study|Lost to Follow-up|0
6004645|NCT00076999|9598698|FG003|Overall Study|Lost to Follow-up|0
6004646|NCT00076999|9598699|FG004|Overall Study|Lost to Follow-up|0
6004647|NCT00076999|9598695|FG000|Overall Study|Withdrawal by Subject|0
6004648|NCT00076999|9598696|FG001|Overall Study|Withdrawal by Subject|4
6004649|NCT00076999|9598697|FG002|Overall Study|Withdrawal by Subject|3
6004650|NCT00076999|9598698|FG003|Overall Study|Withdrawal by Subject|0
6004651|NCT00076999|9598699|FG004|Overall Study|Withdrawal by Subject|1
6004652|NCT00076999|9598695|FG000|Overall Study|Other reason (not specified)|8
6004653|NCT00076999|9598696|FG001|Overall Study|Other reason (not specified)|8
6004654|NCT00076999|9598697|FG002|Overall Study|Other reason (not specified)|4
6004655|NCT00076999|9598698|FG003|Overall Study|Other reason (not specified)|1
6004656|NCT00076999|9598699|FG004|Overall Study|Other reason (not specified)|13
6004657|NCT00077064|9598714|FG000|Overall Study|Adverse Event|0
6004658|NCT00077064|9598715|FG001|Overall Study|Adverse Event|4
6004659|NCT00077064|9598714|FG000|Overall Study|Patient refusal|0
6004660|NCT00077064|9598715|FG001|Overall Study|Patient refusal|2
6004661|NCT00077207|9598722|FG000|Overall Study|Adverse Event|5
6004662|NCT00077207|9598722|FG000|Overall Study|Lack of Efficacy|12
6004663|NCT00077207|9598722|FG000|Overall Study|Physician Decision|6
6004664|NCT00077207|9598722|FG000|Overall Study|Withdrawal by Subject|6
6004665|NCT00077207|9598722|FG000|Overall Study|Ineligible|1
6004666|NCT00077376|9598727|FG000|Overall Study|Adverse Event|8
6004667|NCT00077376|9598727|FG000|Overall Study|Withdrawal by Subject|2
6004668|NCT00077376|9598727|FG000|Overall Study|Death|1
6004669|NCT00077376|9598727|FG000|Overall Study|Physician Decision|1
6004670|NCT00077376|9598727|FG000|Overall Study|Alternative therapy|5
6004671|NCT00077376|9598727|FG000|Overall Study|Complicating disease|1
6004672|NCT00077376|9598727|FG000|Overall Study|Still on treatment|1
6004673|NCT00077376|9598727|FG000|Overall Study|Symptomatic deterioration|1
6004674|NCT00077376|9598727|FG000|Overall Study|Surgery|1
6004675|NCT00077376|9598727|FG000|Overall Study|Insurance ran out|1
6004676|NCT00077610|9598734|FG000|Overall Study|Adverse Event|9
6004677|NCT00077610|9598735|FG001|Overall Study|Adverse Event|7
6004678|NCT00077610|9598736|FG002|Overall Study|Adverse Event|1
6004679|NCT00077610|9598734|FG000|Overall Study|Lost to Follow-up|0
6004680|NCT00077610|9598735|FG001|Overall Study|Lost to Follow-up|1
6004681|NCT00077610|9598736|FG002|Overall Study|Lost to Follow-up|2
6004682|NCT00077610|9598734|FG000|Overall Study|Withdrawal by Subject|4
6004683|NCT00077610|9598735|FG001|Overall Study|Withdrawal by Subject|10
6004684|NCT00077610|9598736|FG002|Overall Study|Withdrawal by Subject|6
6004685|NCT00077610|9598734|FG000|Overall Study|Death|17
6004686|NCT00077610|9598735|FG001|Overall Study|Death|13
6004687|NCT00077610|9598736|FG002|Overall Study|Death|13
6004688|NCT00077610|9598734|FG000|Overall Study|Renal transplant|12
6004689|NCT00077610|9598735|FG001|Overall Study|Renal transplant|15
6004690|NCT00077610|9598736|FG002|Overall Study|Renal transplant|11
6004691|NCT00077610|9598734|FG000|Overall Study|Withdrew from dialysis care|5
6004692|NCT00077610|9598735|FG001|Overall Study|Withdrew from dialysis care|0
6004693|NCT00077610|9598736|FG002|Overall Study|Withdrew from dialysis care|3
6004694|NCT00077610|9598734|FG000|Overall Study|Insufficient Therapeutic Response|1
6004695|NCT00077610|9598735|FG001|Overall Study|Insufficient Therapeutic Response|0
6004696|NCT00077610|9598736|FG002|Overall Study|Insufficient Therapeutic Response|0
6004697|NCT00077610|9598734|FG000|Overall Study|Multiple blood transfusions|0
6004698|NCT00077610|9598735|FG001|Overall Study|Multiple blood transfusions|0
6004699|NCT00077610|9598736|FG002|Overall Study|Multiple blood transfusions|1
6004700|NCT00077610|9598734|FG000|Overall Study|Principal Investigator's decision|1
6004701|NCT00077610|9598735|FG001|Overall Study|Principal Investigator's decision|0
6004702|NCT00077610|9598736|FG002|Overall Study|Principal Investigator's decision|1
6004703|NCT00077610|9598734|FG000|Overall Study|Worsening of health condition|1
6004704|NCT00077610|9598735|FG001|Overall Study|Worsening of health condition|1
6004705|NCT00077610|9598736|FG002|Overall Study|Worsening of health condition|0
6004706|NCT00077610|9598734|FG000|Overall Study|Given Epogen in hospital|1
6004707|NCT00077610|9598735|FG001|Overall Study|Given Epogen in hospital|0
6004708|NCT00077610|9598736|FG002|Overall Study|Given Epogen in hospital|0
6004709|NCT00077610|9598734|FG000|Overall Study|Transferred to other unit|0
6004710|NCT00077610|9598735|FG001|Overall Study|Transferred to other unit|0
6004711|NCT00077610|9598736|FG002|Overall Study|Transferred to other unit|1
6004712|NCT00077610|9598734|FG000|Overall Study|Transferred to nursing home|0
6004713|NCT00077610|9598735|FG001|Overall Study|Transferred to nursing home|0
6004714|NCT00077610|9598736|FG002|Overall Study|Transferred to nursing home|1
6073787|NCT00569777|9677584|FG001|Overall Study|did not meet exclusion criteria|2
6004715|NCT00077610|9598734|FG000|Overall Study|Transfer to satellite unit|1
6004716|NCT00077610|9598735|FG001|Overall Study|Transfer to satellite unit|0
6073788|NCT00569777|9677583|FG000|Overall Study|pregnant|1
6004717|NCT00077610|9598736|FG002|Overall Study|Transfer to satellite unit|0
6073789|NCT00569777|9677584|FG001|Overall Study|pregnant|0
6004718|NCT00077610|9598734|FG000|Overall Study|Transfer to other center for surgery|1
6004719|NCT00077610|9598735|FG001|Overall Study|Transfer to other center for surgery|0
6004720|NCT00077610|9598736|FG002|Overall Study|Transfer to other center for surgery|0
6004721|NCT00077610|9598734|FG000|Overall Study|Change in dialysis modality|1
6004722|NCT00077610|9598735|FG001|Overall Study|Change in dialysis modality|0
6004723|NCT00077610|9598736|FG002|Overall Study|Change in dialysis modality|0
6004724|NCT00077610|9598734|FG000|Overall Study|Relocation|0
6004725|NCT00077610|9598735|FG001|Overall Study|Relocation|8
6004726|NCT00077610|9598736|FG002|Overall Study|Relocation|5
6004727|NCT00077610|9598734|FG000|Overall Study|Financial issues|0
6004728|NCT00077610|9598735|FG001|Overall Study|Financial issues|1
6004729|NCT00077610|9598736|FG002|Overall Study|Financial issues|0
6004730|NCT00077610|9598734|FG000|Overall Study|Sponsors decision to withdraw|0
6004731|NCT00077610|9598735|FG001|Overall Study|Sponsors decision to withdraw|0
6004732|NCT00077610|9598736|FG002|Overall Study|Sponsors decision to withdraw|1
6004733|NCT00077623|9598752|FG000|Overall Study|Adverse Event|1
6004734|NCT00077623|9598753|FG001|Overall Study|Adverse Event|0
6004735|NCT00077623|9598754|FG002|Overall Study|Adverse Event|1
6004736|NCT00077623|9598752|FG000|Overall Study|Withdrawal by Subject|2
6004737|NCT00077623|9598753|FG001|Overall Study|Withdrawal by Subject|10
6004738|NCT00077623|9598754|FG002|Overall Study|Withdrawal by Subject|1
6004739|NCT00077623|9598752|FG000|Overall Study|Other-Non safety reason|18
6004740|NCT00077623|9598753|FG001|Overall Study|Other-Non safety reason|15
6004741|NCT00077623|9598754|FG002|Overall Study|Other-Non safety reason|19
6004742|NCT00077623|9598752|FG000|Overall Study|Insufficient therapeutic response|2
6004743|NCT00077623|9598753|FG001|Overall Study|Insufficient therapeutic response|0
6004744|NCT00077623|9598754|FG002|Overall Study|Insufficient therapeutic response|0
6004745|NCT00077623|9598752|FG000|Overall Study|Death|12
6004746|NCT00077623|9598753|FG001|Overall Study|Death|18
6004747|NCT00077623|9598754|FG002|Overall Study|Death|11
6004748|NCT00077623|9598752|FG000|Overall Study|Failure to return|1
6004749|NCT00077623|9598753|FG001|Overall Study|Failure to return|0
6004750|NCT00077623|9598754|FG002|Overall Study|Failure to return|0
6004751|NCT00077636|9598764|FG000|Overall Study|Refused Treatment|9
6004752|NCT00077636|9598765|FG001|Overall Study|Refused Treatment|31
6004753|NCT00077636|9598764|FG000|Overall Study|Admin|3
6004754|NCT00077636|9598765|FG001|Overall Study|Admin|3
6004755|NCT00077636|9598764|FG000|Overall Study|Withdrawal by Subject|2
6004756|NCT00077636|9598765|FG001|Overall Study|Withdrawal by Subject|2
6004757|NCT00077636|9598764|FG000|Overall Study|Adverse Event|17
6004758|NCT00077636|9598765|FG001|Overall Study|Adverse Event|34
6004759|NCT00077636|9598764|FG000|Overall Study|Protocol Violation|0
6004760|NCT00077636|9598765|FG001|Overall Study|Protocol Violation|2
6004761|NCT00077636|9598764|FG000|Overall Study|Lost to Follow-up|10
6004762|NCT00077636|9598765|FG001|Overall Study|Lost to Follow-up|18
6004763|NCT00077636|9598764|FG000|Overall Study|Abnormality Of Laboratory Test|3
6073790|NCT00569803|9677598|FG000|Overall Study|Lost to Follow-up|1
6073791|NCT00569803|9677599|FG001|Overall Study|Lost to Follow-up|0
6073792|NCT00569803|9677600|FG002|Overall Study|Lost to Follow-up|0
6073793|NCT00569803|9677601|FG003|Overall Study|Lost to Follow-up|0
6073794|NCT00569803|9677602|FG004|Overall Study|Lost to Follow-up|0
6073795|NCT00569803|9677603|FG005|Overall Study|Lost to Follow-up|0
6073796|NCT00569803|9677604|FG006|Overall Study|Lost to Follow-up|0
6073797|NCT00569803|9677605|FG007|Overall Study|Lost to Follow-up|0
6073798|NCT00569803|9677598|FG000|Overall Study|injection syringe leaked during dosing|0
6073799|NCT00569803|9677599|FG001|Overall Study|injection syringe leaked during dosing|0
6073800|NCT00569803|9677600|FG002|Overall Study|injection syringe leaked during dosing|0
6073801|NCT00569803|9677601|FG003|Overall Study|injection syringe leaked during dosing|1
6073802|NCT00569803|9677602|FG004|Overall Study|injection syringe leaked during dosing|0
6073803|NCT00569803|9677603|FG005|Overall Study|injection syringe leaked during dosing|0
6073804|NCT00569803|9677604|FG006|Overall Study|injection syringe leaked during dosing|0
6073805|NCT00569803|9677605|FG007|Overall Study|injection syringe leaked during dosing|0
6073806|NCT00569803|9677598|FG000|Overall Study|Withdrawal by Subject|0
6073807|NCT00569803|9677599|FG001|Overall Study|Withdrawal by Subject|0
6073808|NCT00569803|9677600|FG002|Overall Study|Withdrawal by Subject|0
6073809|NCT00569803|9677601|FG003|Overall Study|Withdrawal by Subject|0
6073810|NCT00569803|9677602|FG004|Overall Study|Withdrawal by Subject|0
6073811|NCT00569803|9677603|FG005|Overall Study|Withdrawal by Subject|0
6073812|NCT00569803|9677604|FG006|Overall Study|Withdrawal by Subject|0
6073813|NCT00569803|9677605|FG007|Overall Study|Withdrawal by Subject|1
6073814|NCT00569946|9677631|FG000|Overall Study|Adverse Event|16
6073815|NCT00569946|9677631|FG000|Overall Study|Objective Progression or Relapse|42
6073816|NCT00569946|9677631|FG000|Overall Study|Global Deterioration of Health Status|1
6073817|NCT00570037|9677637|FG000|Overall Study|Could not reach for 6-8 week contact|44
6073818|NCT00570037|9677638|FG001|Overall Study|Could not reach for 6-8 week contact|69
6073819|NCT00570063|9677646|FG000|Overall Study|Adverse Event|4
6073820|NCT00570063|9677647|FG001|Overall Study|Adverse Event|1
6004764|NCT00077636|9598765|FG001|Overall Study|Abnormality Of Laboratory Test|2
6004765|NCT00077649|9598776|FG000|Overall Study|Adverse Event|5
6004766|NCT00077649|9598777|FG001|Overall Study|Adverse Event|1
6004767|NCT00077649|9598778|FG002|Overall Study|Adverse Event|7
6004768|NCT00077649|9598779|FG003|Overall Study|Adverse Event|9
6004769|NCT00077649|9598776|FG000|Overall Study|Lack of Efficacy|5
6004770|NCT00077649|9598777|FG001|Overall Study|Lack of Efficacy|3
6004771|NCT00077649|9598778|FG002|Overall Study|Lack of Efficacy|3
6004772|NCT00077649|9598779|FG003|Overall Study|Lack of Efficacy|2
6004773|NCT00077649|9598776|FG000|Overall Study|Withdrawal by Subject|0
6004774|NCT00077649|9598777|FG001|Overall Study|Withdrawal by Subject|1
6004775|NCT00077649|9598778|FG002|Overall Study|Withdrawal by Subject|1
6004776|NCT00077649|9598779|FG003|Overall Study|Withdrawal by Subject|2
6004777|NCT00077649|9598776|FG000|Overall Study|Lost to Follow-up|2
6004778|NCT00077649|9598777|FG001|Overall Study|Lost to Follow-up|2
6004779|NCT00077649|9598778|FG002|Overall Study|Lost to Follow-up|3
6004780|NCT00077649|9598779|FG003|Overall Study|Lost to Follow-up|2
6004781|NCT00077649|9598776|FG000|Overall Study|Abnormality of Laboratory Test|1
6004782|NCT00077649|9598777|FG001|Overall Study|Abnormality of Laboratory Test|2
6004783|NCT00077649|9598778|FG002|Overall Study|Abnormality of Laboratory Test|1
6004784|NCT00077649|9598779|FG003|Overall Study|Abnormality of Laboratory Test|2
6004785|NCT00077649|9598776|FG000|Overall Study|Randomized but never dosed|1
6004786|NCT00077649|9598777|FG001|Overall Study|Randomized but never dosed|0
6004787|NCT00077649|9598778|FG002|Overall Study|Randomized but never dosed|0
6004788|NCT00077649|9598779|FG003|Overall Study|Randomized but never dosed|0
6004789|NCT00077675|9598795|FG000|Overall Study|Adverse Event|1
6004790|NCT00077675|9598796|FG001|Overall Study|Adverse Event|2
6004791|NCT00077675|9598795|FG000|Overall Study|Lost to Follow-up|6
6004792|NCT00077675|9598796|FG001|Overall Study|Lost to Follow-up|3
6004793|NCT00077675|9598795|FG000|Overall Study|Withdrawal by Subject|1
6004794|NCT00077675|9598796|FG001|Overall Study|Withdrawal by Subject|0
6004795|NCT00077675|9598795|FG000|Overall Study|Other|0
6004796|NCT00077675|9598796|FG001|Overall Study|Other|1
6004797|NCT00077675|9598795|FG000|Overall Study|Never received study treatment|3
6004798|NCT00077675|9598796|FG001|Overall Study|Never received study treatment|3
6004799|NCT00077766|9598804|FG000|Overall Study|Adverse Event|1
6004800|NCT00077766|9598805|FG001|Overall Study|Adverse Event|1
6004801|NCT00077766|9598804|FG000|Overall Study|Withdrawal by Subject|4
6004802|NCT00077766|9598805|FG001|Overall Study|Withdrawal by Subject|3
6004803|NCT00077766|9598804|FG000|Overall Study|Death|12
6004804|NCT00077766|9598805|FG001|Overall Study|Death|10
6004805|NCT00077766|9598804|FG000|Overall Study|Lost to Follow-up|2
6004806|NCT00077766|9598805|FG001|Overall Study|Lost to Follow-up|0
6004807|NCT00077766|9598804|FG000|Overall Study|Protocol Violation|1
6004808|NCT00077766|9598805|FG001|Overall Study|Protocol Violation|0
6004809|NCT00077766|9598804|FG000|Overall Study|Kidney Transplantation|9
6004810|NCT00077766|9598805|FG001|Overall Study|Kidney Transplantation|5
6004811|NCT00077766|9598804|FG000|Overall Study|Transplantation|5
6004812|NCT00077766|9598805|FG001|Overall Study|Transplantation|1
6004813|NCT00077766|9598804|FG000|Overall Study|Investigators Discretion|1
6004814|NCT00077766|9598805|FG001|Overall Study|Investigators Discretion|0
6004815|NCT00077766|9598804|FG000|Overall Study|Participant's decision|1
6004816|NCT00077766|9598805|FG001|Overall Study|Participant's decision|0
6004817|NCT00077766|9598804|FG000|Overall Study|Dialysis Discontinued|1
6004818|NCT00077766|9598805|FG001|Overall Study|Dialysis Discontinued|0
6004819|NCT00077766|9598804|FG000|Overall Study|Dialysis|0
6004820|NCT00077766|9598805|FG001|Overall Study|Dialysis|1
6004821|NCT00077766|9598804|FG000|Overall Study|Enrolled in Nocturnal Hemodialysis Study|0
6004822|NCT00077766|9598805|FG001|Overall Study|Enrolled in Nocturnal Hemodialysis Study|1
6004823|NCT00077766|9598804|FG000|Overall Study|Started Nocturnal Dialysis|0
6004824|NCT00077766|9598805|FG001|Overall Study|Started Nocturnal Dialysis|1
6004825|NCT00077766|9598804|FG000|Overall Study|Stop Dialysis|0
6004826|NCT00077766|9598805|FG001|Overall Study|Stop Dialysis|1
6004827|NCT00077766|9598804|FG000|Overall Study|Participants Vacation|2
6004828|NCT00077766|9598805|FG001|Overall Study|Participants Vacation|1
6004829|NCT00077857|9598814|FG000|Overall Study|Adverse Event|30
6004830|NCT00077857|9598815|FG001|Overall Study|Adverse Event|32
6004831|NCT00077857|9598814|FG000|Overall Study|Death|7
6004832|NCT00077857|9598815|FG001|Overall Study|Death|3
6004833|NCT00077857|9598814|FG000|Overall Study|Insufficient therapeutic response|112
6004834|NCT00077857|9598815|FG001|Overall Study|Insufficient therapeutic response|128
6004835|NCT00077857|9598814|FG000|Overall Study|Violation of selection criteria at entry|3
6004836|NCT00077857|9598815|FG001|Overall Study|Violation of selection criteria at entry|1
6004837|NCT00077857|9598814|FG000|Overall Study|Other protocol violation|0
6004838|NCT00077857|9598815|FG001|Overall Study|Other protocol violation|1
6004839|NCT00077857|9598814|FG000|Overall Study|Refused treatment|29
6004840|NCT00077857|9598815|FG001|Overall Study|Refused treatment|21
6004841|NCT00077857|9598814|FG000|Overall Study|Failure to return|5
6004842|NCT00077857|9598815|FG001|Overall Study|Failure to return|5
6004843|NCT00077857|9598814|FG000|Overall Study|Other|15
6004844|NCT00077857|9598815|FG001|Overall Study|Other|13
6073821|NCT00570063|9677646|FG000|Overall Study|Lack of Efficacy|0
6073822|NCT00570063|9677647|FG001|Overall Study|Lack of Efficacy|1
6073823|NCT00570063|9677646|FG000|Overall Study|Withdrawal by Subject|4
6047301|NCT00410410|9646253|FG004|Maintenance Period (MP)|Lack of Efficacy|0
6047302|NCT00410410|9646254|FG005|Maintenance Period (MP)|Lack of Efficacy|0
6047303|NCT00410410|9646255|FG006|Maintenance Period (MP)|Lack of Efficacy|25
6047304|NCT00410410|9646256|FG007|Maintenance Period (MP)|Lack of Efficacy|24
6047305|NCT00410410|9646257|FG008|Maintenance Period (MP)|Lack of Efficacy|0
6047306|NCT00410410|9646249|FG000|Maintenance Period (MP)|Lost to Follow-up|0
6047307|NCT00410410|9646250|FG001|Maintenance Period (MP)|Lost to Follow-up|0
6004845|NCT00077974|9598825|FG000|Overall Study|Adverse Event|22
6004846|NCT00077974|9598825|FG000|Overall Study|Protocol Violation|1
6004847|NCT00077974|9598825|FG000|Overall Study|Withdrawal by Subject|3
6004848|NCT00077974|9598825|FG000|Overall Study|Lack of Efficacy|76
6004849|NCT00077974|9598825|FG000|Overall Study|Decision of Sponsor|2
6004850|NCT00078312|9598838|FG000|Overall Study|Adverse Event|43
6004851|NCT00078312|9598838|FG000|Overall Study|Lack of Efficacy|15
6004852|NCT00078312|9598838|FG000|Overall Study|Lost to Follow-up|41
6004853|NCT00078312|9598838|FG000|Overall Study|Physician Decision|9
6004854|NCT00078312|9598838|FG000|Overall Study|Protocol Violation|3
6004855|NCT00078312|9598838|FG000|Overall Study|Withdrawal by Subject|33
6004856|NCT00078312|9598838|FG000|Overall Study|Miscellaneous|33
6004857|NCT00078325|9598845|FG000|Overall Study|Adverse Event|15
6004858|NCT00078325|9598846|FG001|Overall Study|Adverse Event|10
6004859|NCT00078325|9598847|FG002|Overall Study|Adverse Event|5
6004860|NCT00078325|9598845|FG000|Overall Study|Protocol Violation|2
6004861|NCT00078325|9598846|FG001|Overall Study|Protocol Violation|2
6004862|NCT00078325|9598847|FG002|Overall Study|Protocol Violation|0
6004863|NCT00078325|9598845|FG000|Overall Study|Withdrawal by Subject|1
6004864|NCT00078325|9598846|FG001|Overall Study|Withdrawal by Subject|5
6004865|NCT00078325|9598847|FG002|Overall Study|Withdrawal by Subject|3
6004866|NCT00078325|9598845|FG000|Overall Study|Lost to Follow-up|0
6004867|NCT00078325|9598846|FG001|Overall Study|Lost to Follow-up|1
6004868|NCT00078325|9598847|FG002|Overall Study|Lost to Follow-up|1
6004869|NCT00078325|9598845|FG000|Overall Study|Physician Decision|2
6004870|NCT00078325|9598846|FG001|Overall Study|Physician Decision|0
6004871|NCT00078325|9598847|FG002|Overall Study|Physician Decision|1
6004872|NCT00078325|9598845|FG000|Overall Study|Miscellaneous|1
6004873|NCT00078325|9598846|FG001|Overall Study|Miscellaneous|1
6004874|NCT00078325|9598847|FG002|Overall Study|Miscellaneous|1
6004875|NCT00078338|9598857|FG000|Overall Study|Adverse Event|31
6004876|NCT00078338|9598858|FG001|Overall Study|Adverse Event|24
6004877|NCT00078338|9598857|FG000|Overall Study|Lost to Follow-up|17
6004878|NCT00078338|9598858|FG001|Overall Study|Lost to Follow-up|2
6004879|NCT00078338|9598857|FG000|Overall Study|Protocol Violation|2
6004880|NCT00078338|9598858|FG001|Overall Study|Protocol Violation|2
6004881|NCT00078338|9598857|FG000|Overall Study|Disease Progression|4
6004882|NCT00078338|9598858|FG001|Overall Study|Disease Progression|7
6004883|NCT00078338|9598857|FG000|Overall Study|Other|28
6004884|NCT00078338|9598858|FG001|Overall Study|Other|16
6004885|NCT00078338|9598857|FG000|Overall Study|Subjects randomized, but not treated|3
6004886|NCT00078338|9598858|FG001|Overall Study|Subjects randomized, but not treated|3
6004887|NCT00078377|9598867|FG000|Overall Study|Adverse Event|2
6004888|NCT00078377|9598868|FG001|Overall Study|Adverse Event|5
6004889|NCT00078377|9598869|FG002|Overall Study|Adverse Event|1
6004890|NCT00078377|9598867|FG000|Overall Study|Lack of Efficacy|2
6004891|NCT00078377|9598868|FG001|Overall Study|Lack of Efficacy|0
6004892|NCT00078377|9598869|FG002|Overall Study|Lack of Efficacy|2
6004893|NCT00078377|9598867|FG000|Overall Study|Lost to Follow-up|0
6004894|NCT00078377|9598868|FG001|Overall Study|Lost to Follow-up|1
6004895|NCT00078377|9598869|FG002|Overall Study|Lost to Follow-up|1
6004896|NCT00078377|9598867|FG000|Overall Study|Physician Decision|2
6004897|NCT00078377|9598868|FG001|Overall Study|Physician Decision|0
6004898|NCT00078377|9598869|FG002|Overall Study|Physician Decision|0
6004899|NCT00078377|9598867|FG000|Overall Study|Withdrawal by Subject|3
6004900|NCT00078377|9598868|FG001|Overall Study|Withdrawal by Subject|4
6004901|NCT00078377|9598869|FG002|Overall Study|Withdrawal by Subject|4
6004902|NCT00078377|9598867|FG000|Overall Study|Miscellaneous|2
6004903|NCT00078377|9598868|FG001|Overall Study|Miscellaneous|6
6004904|NCT00078377|9598869|FG002|Overall Study|Miscellaneous|1
6004905|NCT00078767|9598934|FG000|Overall Study|Withdrawal by Subject|1
6004906|NCT00078767|9598935|FG001|Overall Study|Withdrawal by Subject|1
6004907|NCT00078819|9598943|FG000|Double-blind Treatment Period: Week 1-12|Adverse Event|0
6004908|NCT00078819|9598944|FG001|Double-blind Treatment Period: Week 1-12|Adverse Event|1
6004909|NCT00078819|9598945|FG002|Double-blind Treatment Period: Week 1-12|Adverse Event|0
6004910|NCT00078819|9598946|FG003|Double-blind Treatment Period: Week 1-12|Adverse Event|0
6004911|NCT00078819|9598943|FG000|Double-blind Treatment Period: Week 1-12|Withdrawal by Subject|1
6004912|NCT00078819|9598944|FG001|Double-blind Treatment Period: Week 1-12|Withdrawal by Subject|0
6004913|NCT00078819|9598945|FG002|Double-blind Treatment Period: Week 1-12|Withdrawal by Subject|0
6004914|NCT00078819|9598946|FG003|Double-blind Treatment Period: Week 1-12|Withdrawal by Subject|0
6004915|NCT00078819|9598943|FG000|Open-label Treatment Period: Weeks 13-36|Lost to Follow-up|1
6004916|NCT00078819|9598944|FG001|Open-label Treatment Period: Weeks 13-36|Lost to Follow-up|1
6004917|NCT00078819|9598945|FG002|Open-label Treatment Period: Weeks 13-36|Lost to Follow-up|0
6004918|NCT00078819|9598946|FG003|Open-label Treatment Period: Weeks 13-36|Lost to Follow-up|0
6004919|NCT00078819|9598943|FG000|Open-label Treatment Period: Weeks 13-36|Adverse Event|3
6004920|NCT00078819|9598944|FG001|Open-label Treatment Period: Weeks 13-36|Adverse Event|2
6004921|NCT00078819|9598945|FG002|Open-label Treatment Period: Weeks 13-36|Adverse Event|0
6004922|NCT00078819|9598946|FG003|Open-label Treatment Period: Weeks 13-36|Adverse Event|0
6004923|NCT00078819|9598943|FG000|Open-label Treatment Period: Weeks 13-36|Withdrawal by Subject|2
6004924|NCT00078819|9598944|FG001|Open-label Treatment Period: Weeks 13-36|Withdrawal by Subject|2
6004925|NCT00078819|9598945|FG002|Open-label Treatment Period: Weeks 13-36|Withdrawal by Subject|0
6004926|NCT00078819|9598946|FG003|Open-label Treatment Period: Weeks 13-36|Withdrawal by Subject|0
6004927|NCT00078819|9598943|FG000|Open-label Treatment Period: Weeks 13-36|Incomplete Responders|34
6004928|NCT00078819|9598944|FG001|Open-label Treatment Period: Weeks 13-36|Incomplete Responders|25
6004929|NCT00078819|9598945|FG002|Open-label Treatment Period: Weeks 13-36|Incomplete Responders|0
6004930|NCT00078819|9598946|FG003|Open-label Treatment Period: Weeks 13-36|Incomplete Responders|0
6004931|NCT00078819|9598943|FG000|Withdrawal Period: Weeks 37-48|Entered Retreatment|0
6004932|NCT00078819|9598944|FG001|Withdrawal Period: Weeks 37-48|Entered Retreatment|0
6004933|NCT00078819|9598945|FG002|Withdrawal Period: Weeks 37-48|Entered Retreatment|29
6004934|NCT00078819|9598946|FG003|Withdrawal Period: Weeks 37-48|Entered Retreatment|13
6004935|NCT00078819|9598943|FG000|Withdrawal Period: Weeks 37-48|Lost to Follow-up|0
6004936|NCT00078819|9598944|FG001|Withdrawal Period: Weeks 37-48|Lost to Follow-up|0
6004937|NCT00078819|9598945|FG002|Withdrawal Period: Weeks 37-48|Lost to Follow-up|0
6004938|NCT00078819|9598946|FG003|Withdrawal Period: Weeks 37-48|Lost to Follow-up|1
6004939|NCT00078949|9598976|FG000|Overall Study|No treated|4
6004940|NCT00078949|9598977|FG001|Overall Study|No treated|5
6004941|NCT00078949|9598978|FG002|Overall Study|No treated|3
6004942|NCT00078949|9598979|FG003|Overall Study|No treated|3
6004943|NCT00079040|9599000|FG000|Overall Study|Withdrew before treatment|1
6004944|NCT00079040|9599000|FG000|Overall Study|Ineligible|1
6004945|NCT00079183|9599004|FG000|Overall Study|Withdrawal by Subject|4
6004946|NCT00079183|9599004|FG000|Overall Study|Study medication non-compliance|2
6004947|NCT00079183|9599004|FG000|Overall Study|Specimen collection non-compliance|1
6004948|NCT00079274|9599016|FG000|Overall Study|Withdrawal by Subject|111
6004949|NCT00079274|9599017|FG001|Overall Study|Withdrawal by Subject|10
6004950|NCT00079274|9599018|FG002|Overall Study|Withdrawal by Subject|12
6004951|NCT00079274|9599019|FG003|Overall Study|Withdrawal by Subject|163
6004952|NCT00079274|9599020|FG004|Overall Study|Withdrawal by Subject|7
6004953|NCT00079274|9599021|FG005|Overall Study|Withdrawal by Subject|8
6004954|NCT00079274|9599022|FG006|Overall Study|Withdrawal by Subject|0
6004955|NCT00079274|9599016|FG000|Overall Study|Adverse Event|130
6004956|NCT00079274|9599017|FG001|Overall Study|Adverse Event|8
6004957|NCT00079274|9599018|FG002|Overall Study|Adverse Event|8
6004958|NCT00079274|9599019|FG003|Overall Study|Adverse Event|184
6004959|NCT00079274|9599020|FG004|Overall Study|Adverse Event|7
6004960|NCT00079274|9599021|FG005|Overall Study|Adverse Event|8
6004961|NCT00079274|9599022|FG006|Overall Study|Adverse Event|0
6004962|NCT00079274|9599016|FG000|Overall Study|Recurrence|21
6004963|NCT00079274|9599017|FG001|Overall Study|Recurrence|0
6004964|NCT00079274|9599018|FG002|Overall Study|Recurrence|1
6004965|NCT00079274|9599019|FG003|Overall Study|Recurrence|15
6004966|NCT00079274|9599020|FG004|Overall Study|Recurrence|0
6004967|NCT00079274|9599021|FG005|Overall Study|Recurrence|2
6004968|NCT00079274|9599022|FG006|Overall Study|Recurrence|0
6004969|NCT00079274|9599016|FG000|Overall Study|Alternate Treatment|6
6004970|NCT00079274|9599017|FG001|Overall Study|Alternate Treatment|1
6004971|NCT00079274|9599018|FG002|Overall Study|Alternate Treatment|0
6004972|NCT00079274|9599019|FG003|Overall Study|Alternate Treatment|3
6004973|NCT00079274|9599020|FG004|Overall Study|Alternate Treatment|0
6004974|NCT00079274|9599021|FG005|Overall Study|Alternate Treatment|0
6004975|NCT00079274|9599022|FG006|Overall Study|Alternate Treatment|0
6004976|NCT00079274|9599016|FG000|Overall Study|Other Medical Problems|6
6004977|NCT00079274|9599017|FG001|Overall Study|Other Medical Problems|1
6004978|NCT00079274|9599018|FG002|Overall Study|Other Medical Problems|0
6004979|NCT00079274|9599019|FG003|Overall Study|Other Medical Problems|7
6004980|NCT00079274|9599020|FG004|Overall Study|Other Medical Problems|0
6004981|NCT00079274|9599021|FG005|Overall Study|Other Medical Problems|0
6004982|NCT00079274|9599022|FG006|Overall Study|Other Medical Problems|0
6004983|NCT00079274|9599016|FG000|Overall Study|Death|4
6004984|NCT00079274|9599017|FG001|Overall Study|Death|0
6004985|NCT00079274|9599018|FG002|Overall Study|Death|1
6004986|NCT00079274|9599019|FG003|Overall Study|Death|15
6004987|NCT00079274|9599020|FG004|Overall Study|Death|0
6073824|NCT00570063|9677647|FG001|Overall Study|Withdrawal by Subject|3
6073825|NCT00570063|9677646|FG000|Overall Study|Sponsor's Decision|7
6073826|NCT00570063|9677647|FG001|Overall Study|Sponsor's Decision|3
6073827|NCT00570128|9677664|FG000|Overall Study|Adverse Event|1
6073828|NCT00570128|9677665|FG001|Overall Study|Adverse Event|0
6073829|NCT00570128|9677664|FG000|Overall Study|Lost to Follow-up|1
6073830|NCT00570128|9677665|FG001|Overall Study|Lost to Follow-up|0
6073831|NCT00570128|9677664|FG000|Overall Study|Withdrawal by Subject|2
6073832|NCT00570128|9677665|FG001|Overall Study|Withdrawal by Subject|0
6073833|NCT00570141|9677671|FG000|Overall Study|Adverse Event|1
6073834|NCT00570141|9677671|FG000|Overall Study|Missed visits|1
6073835|NCT00570141|9677671|FG000|Overall Study|Lost to Follow-up|1
6073836|NCT00570232|9677675|FG000|Overall Study|Adverse Event|10
6073837|NCT00570232|9677675|FG000|Overall Study|discontinued due to medical condition|3
6073838|NCT00570232|9677675|FG000|Overall Study|discontinued due to recurrence|8
6004988|NCT00079274|9599021|FG005|Overall Study|Death|0
6073839|NCT00570232|9677675|FG000|Overall Study|discontinued due to noncompliance|2
6004989|NCT00079274|9599022|FG006|Overall Study|Death|0
6004990|NCT00079274|9599016|FG000|Overall Study|Cytogenetic resistance|0
6004991|NCT00079274|9599017|FG001|Overall Study|Cytogenetic resistance|0
6004992|NCT00079274|9599018|FG002|Overall Study|Cytogenetic resistance|0
6004993|NCT00079274|9599019|FG003|Overall Study|Cytogenetic resistance|2
6004994|NCT00079274|9599020|FG004|Overall Study|Cytogenetic resistance|0
6004995|NCT00079274|9599021|FG005|Overall Study|Cytogenetic resistance|0
6004996|NCT00079274|9599022|FG006|Overall Study|Cytogenetic resistance|0
6004997|NCT00079274|9599016|FG000|Overall Study|Other|43
6004998|NCT00079274|9599017|FG001|Overall Study|Other|7
6004999|NCT00079274|9599018|FG002|Overall Study|Other|5
6005000|NCT00079274|9599019|FG003|Overall Study|Other|55
6005001|NCT00079274|9599020|FG004|Overall Study|Other|1
6005002|NCT00079274|9599021|FG005|Overall Study|Other|2
6005003|NCT00079274|9599022|FG006|Overall Study|Other|0
6005004|NCT00079339|9599046|FG000|Overall Study|Adverse Event|1
6005005|NCT00079339|9599047|FG001|Overall Study|Adverse Event|7
6005006|NCT00079339|9599048|FG002|Overall Study|Adverse Event|2
6005007|NCT00079339|9599046|FG000|Overall Study|Death|1
6005008|NCT00079339|9599047|FG001|Overall Study|Death|0
6005009|NCT00079339|9599048|FG002|Overall Study|Death|0
6005010|NCT00079339|9599046|FG000|Overall Study|Non-compliance|0
6005011|NCT00079339|9599047|FG001|Overall Study|Non-compliance|0
6005012|NCT00079339|9599048|FG002|Overall Study|Non-compliance|1
6005013|NCT00079339|9599046|FG000|Overall Study|Withdrawal by Subject|0
6005014|NCT00079339|9599047|FG001|Overall Study|Withdrawal by Subject|4
6005015|NCT00079339|9599048|FG002|Overall Study|Withdrawal by Subject|1
6005016|NCT00079339|9599046|FG000|Overall Study|Disease progression|3
6005017|NCT00079339|9599047|FG001|Overall Study|Disease progression|28
6005018|NCT00079339|9599048|FG002|Overall Study|Disease progression|2
6073840|NCT00570310|9677681|FG000|Overall Study|Adverse Event|1
6073841|NCT00570310|9677682|FG001|Overall Study|Adverse Event|2
6073842|NCT00570310|9677681|FG000|Overall Study|Lack of Efficacy|1
6073843|NCT00570310|9677682|FG001|Overall Study|Lack of Efficacy|4
6073844|NCT00570323|9677690|FG000|Started Treatment After Randomization|Withdrawal by Subject|0
6073845|NCT00570323|9677691|FG001|Started Treatment After Randomization|Withdrawal by Subject|1
6073846|NCT00570323|9677690|FG000|Started Treatment After Randomization|Protocol Violation|1
6073847|NCT00570323|9677691|FG001|Started Treatment After Randomization|Protocol Violation|0
6073848|NCT00570323|9677690|FG000|Started Treatment After Randomization|Physician Decision|1
6073849|NCT00570323|9677691|FG001|Started Treatment After Randomization|Physician Decision|0
6073850|NCT00570323|9677690|FG000|Complete Study After Start|Lost to Follow-up|0
6073851|NCT00570323|9677691|FG001|Complete Study After Start|Lost to Follow-up|1
6073852|NCT00570323|9677690|FG000|Complete Study After Start|Withdrawal by Subject|2
6073853|NCT00570323|9677691|FG001|Complete Study After Start|Withdrawal by Subject|0
6073854|NCT00570323|9677690|FG000|Complete Study After Start|Physician Decision|1
6073855|NCT00570323|9677691|FG001|Complete Study After Start|Physician Decision|0
6073856|NCT00570401|9677721|FG000|Overall Study|Adverse Event|2
6073857|NCT00570492|9677727|FG000|16-week Single-blind Baseline Period|Didn't Meet Inclusion/Exclusion Criteria|98
6073858|NCT00570492|9677728|FG001|16-week Single-blind Baseline Period|Didn't Meet Inclusion/Exclusion Criteria|0
6073859|NCT00570492|9677729|FG002|16-week Single-blind Baseline Period|Didn't Meet Inclusion/Exclusion Criteria|0
6073860|NCT00570492|9677727|FG000|16-week Single-blind Baseline Period|Didn't Meet Randomization Criteria|263
6073861|NCT00570492|9677728|FG001|16-week Single-blind Baseline Period|Didn't Meet Randomization Criteria|0
6073862|NCT00570492|9677729|FG002|16-week Single-blind Baseline Period|Didn't Meet Randomization Criteria|0
6073863|NCT00570492|9677727|FG000|16-week Single-blind Baseline Period|Withdrawal by Subject|56
6073864|NCT00570492|9677728|FG001|16-week Single-blind Baseline Period|Withdrawal by Subject|0
6073865|NCT00570492|9677729|FG002|16-week Single-blind Baseline Period|Withdrawal by Subject|0
6073866|NCT00570492|9677727|FG000|16-week Single-blind Baseline Period|Protocol Violation|15
6073867|NCT00570492|9677728|FG001|16-week Single-blind Baseline Period|Protocol Violation|0
6073868|NCT00570492|9677729|FG002|16-week Single-blind Baseline Period|Protocol Violation|0
6073869|NCT00570492|9677727|FG000|16-week Single-blind Baseline Period|Lost to Follow-up|2
6073870|NCT00570492|9677728|FG001|16-week Single-blind Baseline Period|Lost to Follow-up|0
6073871|NCT00570492|9677729|FG002|16-week Single-blind Baseline Period|Lost to Follow-up|0
6073872|NCT00570492|9677727|FG000|16-week Single-blind Baseline Period|Adverse Event|1
6073873|NCT00570492|9677728|FG001|16-week Single-blind Baseline Period|Adverse Event|0
6073874|NCT00570492|9677729|FG002|16-week Single-blind Baseline Period|Adverse Event|0
6073875|NCT00570492|9677727|FG000|16-week Single-blind Baseline Period|Randomized but Did'nt Receive Treatment|1
6073876|NCT00570492|9677728|FG001|16-week Single-blind Baseline Period|Randomized but Did'nt Receive Treatment|0
6073877|NCT00570492|9677729|FG002|16-week Single-blind Baseline Period|Randomized but Did'nt Receive Treatment|0
6073878|NCT00570492|9677727|FG000|52-week Double-blind Treatment Period|Withdrawal by Subject|0
6073879|NCT00570492|9677728|FG001|52-week Double-blind Treatment Period|Withdrawal by Subject|20
6073880|NCT00570492|9677729|FG002|52-week Double-blind Treatment Period|Withdrawal by Subject|20
6073881|NCT00570492|9677727|FG000|52-week Double-blind Treatment Period|Protocol Violation|0
6073882|NCT00570492|9677728|FG001|52-week Double-blind Treatment Period|Protocol Violation|12
6073883|NCT00570492|9677729|FG002|52-week Double-blind Treatment Period|Protocol Violation|15
6073884|NCT00570492|9677727|FG000|52-week Double-blind Treatment Period|Lost to Follow-up|0
6073885|NCT00570492|9677728|FG001|52-week Double-blind Treatment Period|Lost to Follow-up|5
6073886|NCT00570492|9677729|FG002|52-week Double-blind Treatment Period|Lost to Follow-up|7
6087329|NCT00667355|9697512|FG000|Overall Study|Lost to Follow-up|1
6005019|NCT00079391|9599061|FG000|Overall Study|Withdrawal by Subject|1
6005020|NCT00079417|9599067|FG000|Overall Study|Physician Decision|2
6005021|NCT00079417|9599067|FG000|Overall Study|Ineligible|7
6005022|NCT00079677|9599073|FG000|Overall Study|Adverse Event|5
6005023|NCT00079677|9599074|FG001|Overall Study|Adverse Event|6
6005024|NCT00079677|9599073|FG000|Overall Study|Lack of Efficacy|1
6005025|NCT00079677|9599074|FG001|Overall Study|Lack of Efficacy|0
6005026|NCT00079677|9599073|FG000|Overall Study|Lost to Follow-up|2
6005027|NCT00079677|9599074|FG001|Overall Study|Lost to Follow-up|2
6005028|NCT00079677|9599073|FG000|Overall Study|Physician Decision|3
6005029|NCT00079677|9599074|FG001|Overall Study|Physician Decision|0
6005030|NCT00079677|9599073|FG000|Overall Study|Protocol Violation|2
6005031|NCT00079677|9599074|FG001|Overall Study|Protocol Violation|3
6005032|NCT00079677|9599073|FG000|Overall Study|Withdrawal by Subject|5
6005033|NCT00079677|9599074|FG001|Overall Study|Withdrawal by Subject|3
6005034|NCT00079677|9599073|FG000|Overall Study|Miscellaneous|2
6005035|NCT00079677|9599074|FG001|Overall Study|Miscellaneous|0
6005036|NCT00079781|9599083|FG000|Pre-implant Period|Withdrawal by Subject|2
6005037|NCT00079781|9599084|FG001|Pre-implant Period|Withdrawal by Subject|0
6005038|NCT00079781|9599085|FG002|Pre-implant Period|Withdrawal by Subject|0
6005039|NCT00079781|9599083|FG000|Pre-implant Period|Did not meet I/E criteria|1
6005040|NCT00079781|9599084|FG001|Pre-implant Period|Did not meet I/E criteria|1
6005041|NCT00079781|9599085|FG002|Pre-implant Period|Did not meet I/E criteria|1
6005042|NCT00079781|9599083|FG000|Follow-up Period|Withdrawal by Subject|3
6005043|NCT00079781|9599084|FG001|Follow-up Period|Withdrawal by Subject|0
6005044|NCT00079781|9599085|FG002|Follow-up Period|Withdrawal by Subject|1
6005045|NCT00079781|9599083|FG000|Follow-up Period|Lost to Follow-up|1
6005046|NCT00079781|9599084|FG001|Follow-up Period|Lost to Follow-up|0
6005047|NCT00079781|9599085|FG002|Follow-up Period|Lost to Follow-up|0
6005048|NCT00079781|9599083|FG000|Follow-up Period|Death|0
6005049|NCT00079781|9599084|FG001|Follow-up Period|Death|0
6005050|NCT00079781|9599085|FG002|Follow-up Period|Death|1
6005051|NCT00079937|9599093|FG000|Overall Study|Adverse Event|2
6005052|NCT00079937|9599094|FG001|Overall Study|Adverse Event|1
6005053|NCT00079937|9599093|FG000|Overall Study|Unsatisfactory therapeutic effect|1
6005054|NCT00079937|9599094|FG001|Overall Study|Unsatisfactory therapeutic effect|2
6005055|NCT00079937|9599093|FG000|Overall Study|Subject no longer requires study drug|3
6005056|NCT00079937|9599094|FG001|Overall Study|Subject no longer requires study drug|0
6005057|NCT00079937|9599093|FG000|Overall Study|Protocol Violation|8
6005058|NCT00079937|9599094|FG001|Overall Study|Protocol Violation|6
6005059|NCT00079937|9599093|FG000|Overall Study|Withdrawal by Subject|21
6005060|NCT00079937|9599094|FG001|Overall Study|Withdrawal by Subject|7
6005061|NCT00079937|9599093|FG000|Overall Study|Lost to Follow-up|12
6005062|NCT00079937|9599094|FG001|Overall Study|Lost to Follow-up|5
6005063|NCT00079937|9599093|FG000|Overall Study|Administrative problems|22
6005064|NCT00079937|9599094|FG001|Overall Study|Administrative problems|11
6005065|NCT00080119|9599104|FG000|Overall Study|Discontinued because of study closure|0
6005066|NCT00080119|9599105|FG001|Overall Study|Discontinued because of study closure|0
6005067|NCT00080119|9599106|FG002|Overall Study|Discontinued because of study closure|130
6005068|NCT00080119|9599107|FG003|Overall Study|Discontinued because of study closure|141
6005069|NCT00080119|9599104|FG000|Overall Study|Unable to get to clinic|24
6005070|NCT00080119|9599105|FG001|Overall Study|Unable to get to clinic|24
6005071|NCT00080119|9599106|FG002|Overall Study|Unable to get to clinic|7
6005072|NCT00080119|9599107|FG003|Overall Study|Unable to get to clinic|1
6005073|NCT00080119|9599104|FG000|Overall Study|Consent withdrawn|13
6005074|NCT00080119|9599105|FG001|Overall Study|Consent withdrawn|17
6005075|NCT00080119|9599106|FG002|Overall Study|Consent withdrawn|4
6005076|NCT00080119|9599107|FG003|Overall Study|Consent withdrawn|6
6073887|NCT00570492|9677727|FG000|52-week Double-blind Treatment Period|Adverse Event|0
6073888|NCT00570492|9677728|FG001|52-week Double-blind Treatment Period|Adverse Event|5
6073889|NCT00570492|9677729|FG002|52-week Double-blind Treatment Period|Adverse Event|5
6073890|NCT00570492|9677727|FG000|52-week Double-blind Treatment Period|Physician Decision|0
6073891|NCT00570492|9677728|FG001|52-week Double-blind Treatment Period|Physician Decision|2
6073892|NCT00570492|9677729|FG002|52-week Double-blind Treatment Period|Physician Decision|4
6073893|NCT00570492|9677727|FG000|52-week Double-blind Treatment Period|Lack of Efficacy|0
6073894|NCT00570492|9677728|FG001|52-week Double-blind Treatment Period|Lack of Efficacy|3
6073895|NCT00570492|9677729|FG002|52-week Double-blind Treatment Period|Lack of Efficacy|0
6073896|NCT00570492|9677727|FG000|52-week Double-blind Treatment Period|Reached Protocol-defined Stop Criteria|0
6073897|NCT00570492|9677728|FG001|52-week Double-blind Treatment Period|Reached Protocol-defined Stop Criteria|3
6073898|NCT00570492|9677729|FG002|52-week Double-blind Treatment Period|Reached Protocol-defined Stop Criteria|0
6073899|NCT00570505|9677735|FG000|Overall Study|Adverse Event|7
6073900|NCT00570505|9677735|FG000|Overall Study|Withdrawal by Subject|7
6073901|NCT00570505|9677735|FG000|Overall Study|Lost to Follow-up|23
6073902|NCT00570505|9677735|FG000|Overall Study|Other loss to follow-up|4
6073903|NCT00570661|9677739|FG000|Overall Study|Disease worsening|5
6073904|NCT00570661|9677739|FG000|Overall Study|Unmet criterion of sufficient therapeutic response|1
6073905|NCT00570661|9677739|FG000|Overall Study|Adverse Event|1
6005077|NCT00080119|9599104|FG000|Overall Study|Unwilling to adhere to study requirement|3
6005078|NCT00080119|9599105|FG001|Overall Study|Unwilling to adhere to study requirement|2
6047308|NCT00410410|9646251|FG002|Maintenance Period (MP)|Lost to Follow-up|0
6005079|NCT00080119|9599106|FG002|Overall Study|Unwilling to adhere to study requirement|5
6005080|NCT00080119|9599107|FG003|Overall Study|Unwilling to adhere to study requirement|1
6005081|NCT00080119|9599104|FG000|Overall Study|Lost to Follow-up|16
6005082|NCT00080119|9599105|FG001|Overall Study|Lost to Follow-up|19
6005083|NCT00080119|9599106|FG002|Overall Study|Lost to Follow-up|19
6005084|NCT00080119|9599107|FG003|Overall Study|Lost to Follow-up|14
6005085|NCT00080223|9599119|FG000|Overall Study|Adverse Event|23
6005086|NCT00080223|9599119|FG000|Overall Study|Death|21
6005087|NCT00080223|9599119|FG000|Overall Study|Withdrawal by Subject|13
6005088|NCT00080223|9599119|FG000|Overall Study|Lung Transplantation|9
6005089|NCT00080223|9599119|FG000|Overall Study|Non-compliance With Study Treatment|7
6005090|NCT00080223|9599119|FG000|Overall Study|Participant unwilling to continue|2
6005091|NCT00080223|9599119|FG000|Overall Study|Physician Decision|1
6005092|NCT00080288|9599125|FG000|Overall Study|Adverse Event|7
6005093|NCT00080288|9599126|FG001|Overall Study|Adverse Event|4
6005094|NCT00080288|9599125|FG000|Overall Study|Lost to Follow-up|3
6005095|NCT00080288|9599126|FG001|Overall Study|Lost to Follow-up|5
6005096|NCT00080288|9599125|FG000|Overall Study|Physician Decision|6
6005097|NCT00080288|9599126|FG001|Overall Study|Physician Decision|2
6005098|NCT00080288|9599125|FG000|Overall Study|Withdrawal by Subject|3
6005099|NCT00080288|9599126|FG001|Overall Study|Withdrawal by Subject|16
6005100|NCT00080288|9599125|FG000|Overall Study|Miscellaneous|11
6005101|NCT00080288|9599126|FG001|Overall Study|Miscellaneous|11
6005102|NCT00080301|9599134|FG000|Overall Study|Randomized but Never Treated|5
6005103|NCT00080301|9599135|FG001|Overall Study|Randomized but Never Treated|10
6005104|NCT00080301|9599134|FG000|Overall Study|Still on Treatment as of CSR date|0
6005105|NCT00080301|9599135|FG001|Overall Study|Still on Treatment as of CSR date|1
6005106|NCT00080483|9599155|FG000|Overall Study|Lost to Follow-up|1
6005107|NCT00080483|9599156|FG001|Overall Study|Lost to Follow-up|1
6005108|NCT00080483|9599155|FG000|Overall Study|Physician Decision|1
6005109|NCT00080483|9599156|FG001|Overall Study|Physician Decision|1
6005110|NCT00080899|9599166|FG000|Overall Study|Adverse Event|1
6005111|NCT00080938|9599179|FG000|Overall Study|Adverse Event|3
6005112|NCT00080938|9599179|FG000|Overall Study|Withdrawal by Subject|6
6005113|NCT00080938|9599179|FG000|Overall Study|Death|2
6005114|NCT00080938|9599179|FG000|Overall Study|Lack of Efficacy|7
6005115|NCT00080938|9599179|FG000|Overall Study|other disease|1
6005116|NCT00080938|9599179|FG000|Overall Study|Not started protocol therapy|1
6005117|NCT00080938|9599179|FG000|Overall Study|Ineligible|4
6005118|NCT00081159|9599185|FG000|Overall Study|Withdrawal by Subject|0
6005119|NCT00081159|9599186|FG001|Overall Study|Withdrawal by Subject|3
6005120|NCT00081159|9599185|FG000|Overall Study|Myelosuppression prior to treatment|0
6005121|NCT00081159|9599186|FG001|Overall Study|Myelosuppression prior to treatment|1
6005122|NCT00081159|9599185|FG000|Overall Study|Lost to Follow-up|2
6005123|NCT00081159|9599186|FG001|Overall Study|Lost to Follow-up|1
6005124|NCT00081263|9599194|FG000|Overall Study|clerical error|1
6005125|NCT00081263|9599195|FG001|Overall Study|clerical error|0
6005126|NCT00081263|9599194|FG000|Overall Study|wrong cell type|7
6005127|NCT00081263|9599195|FG001|Overall Study|wrong cell type|5
6005128|NCT00081263|9599194|FG000|Overall Study|improper pre-protocol therapy|0
6005129|NCT00081263|9599195|FG001|Overall Study|improper pre-protocol therapy|1
6005130|NCT00081263|9599194|FG000|Overall Study|Inadequate pathology|0
6005131|NCT00081263|9599195|FG001|Overall Study|Inadequate pathology|1
6005132|NCT00081263|9599194|FG000|Overall Study|Never treated|4
6005133|NCT00081263|9599195|FG001|Overall Study|Never treated|5
6005134|NCT00081263|9599194|FG000|Overall Study|Inadequate data|5
6005135|NCT00081263|9599195|FG001|Overall Study|Inadequate data|10
6005136|NCT00081289|9599203|FG000|Overall Study|Accrued prior to chemotherapy amendment|18
6005137|NCT00081289|9599204|FG001|Overall Study|Accrued prior to chemotherapy amendment|17
6005138|NCT00081289|9599203|FG000|Overall Study|Ineligible / no protocol treatment|3
6005139|NCT00081289|9599204|FG001|Overall Study|Ineligible / no protocol treatment|4
6005140|NCT00081458|9599228|FG000|Overall Study|Adverse Event|1
6005141|NCT00081458|9599229|FG001|Overall Study|Adverse Event|5
6005142|NCT00081458|9599230|FG002|Overall Study|Adverse Event|2
6005143|NCT00081458|9599228|FG000|Overall Study|Withdrawal by Subject|0
6005144|NCT00081458|9599229|FG001|Overall Study|Withdrawal by Subject|3
6005145|NCT00081458|9599230|FG002|Overall Study|Withdrawal by Subject|1
6005146|NCT00081458|9599228|FG000|Overall Study|Randomized but not dosed|0
6005147|NCT00081458|9599229|FG001|Overall Study|Randomized but not dosed|0
6005148|NCT00081458|9599230|FG002|Overall Study|Randomized but not dosed|1
6005149|NCT00081497|9599241|FG000|Overall Study|Adverse Event|2
6005150|NCT00081497|9599242|FG001|Overall Study|Adverse Event|0
6005151|NCT00081497|9599241|FG000|Overall Study|Death|0
6005152|NCT00081497|9599242|FG001|Overall Study|Death|1
6005153|NCT00081497|9599241|FG000|Overall Study|Withdrawal by Subject|1
6005154|NCT00081497|9599242|FG001|Overall Study|Withdrawal by Subject|0
6005155|NCT00081497|9599241|FG000|Overall Study|Non-compliance|0
6005156|NCT00081497|9599242|FG001|Overall Study|Non-compliance|1
6005157|NCT00081653|9599256|FG000|Overall Study|Adverse Event|23
6005158|NCT00081653|9599257|FG001|Overall Study|Adverse Event|17
6005159|NCT00081653|9599256|FG000|Overall Study|Lost to Follow-up|2
6005160|NCT00081653|9599257|FG001|Overall Study|Lost to Follow-up|4
6005161|NCT00081653|9599256|FG000|Overall Study|Refused Treatment|18
6005162|NCT00081653|9599257|FG001|Overall Study|Refused Treatment|14
6005163|NCT00081653|9599256|FG000|Overall Study|Low bone mineral density|1
6005164|NCT00081653|9599257|FG001|Overall Study|Low bone mineral density|0
6005165|NCT00081653|9599256|FG000|Overall Study|Bone loss|2
6005166|NCT00081653|9599257|FG001|Overall Study|Bone loss|0
6005167|NCT00081653|9599256|FG000|Overall Study|Participant leaving country|1
6005168|NCT00081653|9599257|FG001|Overall Study|Participant leaving country|0
6005169|NCT00081653|9599256|FG000|Overall Study|Loss of bone mass|0
6005170|NCT00081653|9599257|FG001|Overall Study|Loss of bone mass|2
6005171|NCT00081731|9599266|FG000|Overall Study|scientific integrity issue|8
6005172|NCT00081731|9599267|FG001|Overall Study|scientific integrity issue|8
6005173|NCT00081770|9599276|FG000|Overall Study|Adverse Event|130
6005174|NCT00081770|9599277|FG001|Overall Study|Adverse Event|98
6005175|NCT00081770|9599278|FG002|Overall Study|Adverse Event|136
6005176|NCT00081770|9599276|FG000|Overall Study|Lack of Efficacy|262
6005177|NCT00081770|9599277|FG001|Overall Study|Lack of Efficacy|357
6005178|NCT00081770|9599278|FG002|Overall Study|Lack of Efficacy|211
6005179|NCT00081770|9599276|FG000|Overall Study|Lost to Follow-up|45
6005180|NCT00081770|9599277|FG001|Overall Study|Lost to Follow-up|34
6005181|NCT00081770|9599278|FG002|Overall Study|Lost to Follow-up|45
6005182|NCT00081770|9599276|FG000|Overall Study|Protocol Violation|15
6005183|NCT00081770|9599277|FG001|Overall Study|Protocol Violation|10
6005184|NCT00081770|9599278|FG002|Overall Study|Protocol Violation|10
6005185|NCT00081770|9599276|FG000|Overall Study|Withdrawal by Subject|45
6005186|NCT00081770|9599277|FG001|Overall Study|Withdrawal by Subject|40
6005187|NCT00081770|9599278|FG002|Overall Study|Withdrawal by Subject|42
6005188|NCT00081770|9599276|FG000|Overall Study|Did not meet protocol eligibility|2
6005189|NCT00081770|9599277|FG001|Overall Study|Did not meet protocol eligibility|0
6005190|NCT00081770|9599278|FG002|Overall Study|Did not meet protocol eligibility|3
6005191|NCT00081770|9599276|FG000|Overall Study|Administrative|1
6005192|NCT00081770|9599277|FG001|Overall Study|Administrative|0
6005193|NCT00081770|9599278|FG002|Overall Study|Administrative|1
6005194|NCT00081770|9599276|FG000|Overall Study|Other|2
6005195|NCT00081770|9599277|FG001|Overall Study|Other|7
6005196|NCT00081770|9599278|FG002|Overall Study|Other|8
6005197|NCT00082173|9599303|FG000|Overall Study|Withdrawal by Subject|3
6005198|NCT00082173|9599304|FG001|Overall Study|Withdrawal by Subject|5
6005199|NCT00082173|9599303|FG000|Overall Study|Lost to Follow-up|1
6005200|NCT00082173|9599304|FG001|Overall Study|Lost to Follow-up|0
6005201|NCT00082173|9599303|FG000|Overall Study|Adverse Event|1
6005202|NCT00082173|9599304|FG001|Overall Study|Adverse Event|0
6005203|NCT00082173|9599303|FG000|Overall Study|Culture negative or resistant at baselin|5
6005204|NCT00082173|9599304|FG001|Overall Study|Culture negative or resistant at baselin|6
6005205|NCT00082355|9599337|FG000|Initial Results of Thrombolytic Therapy|died of causes unrelated to protocol|1
6005206|NCT00082355|9599337|FG000|Initial Results of Thrombolytic Therapy|Withdrawal by Subject|1
6005207|NCT00082355|9599337|FG000|5 Year Recurrent Thromboembolism Rate|will be completed 2014|28
6005208|NCT00082368|9599341|FG000|Overall Study|Not treated-pt had poor IV access|1
6005209|NCT00082381|9599347|FG000|Overall Study|Adverse Event|27
6005210|NCT00082381|9599348|FG001|Overall Study|Adverse Event|2
6005211|NCT00082381|9599347|FG000|Overall Study|Lost to Follow-up|5
6005212|NCT00082381|9599348|FG001|Overall Study|Lost to Follow-up|7
6005213|NCT00082381|9599347|FG000|Overall Study|Patient Decision|8
6005214|NCT00082381|9599348|FG001|Overall Study|Patient Decision|4
6005215|NCT00082381|9599347|FG000|Overall Study|Physician Decision|1
6005216|NCT00082381|9599348|FG001|Overall Study|Physician Decision|2
6005217|NCT00082381|9599347|FG000|Overall Study|Protocol Violation|10
6005218|NCT00082381|9599348|FG001|Overall Study|Protocol Violation|11
6005219|NCT00082381|9599347|FG000|Overall Study|Loss of Glucose Control|4
6005220|NCT00082381|9599348|FG001|Overall Study|Loss of Glucose Control|0
6073906|NCT00570674|9677744|FG000|Overall Study|Withdrawal by Subject|0
6073907|NCT00570674|9677745|FG001|Overall Study|Withdrawal by Subject|0
6073908|NCT00570674|9677746|FG002|Overall Study|Withdrawal by Subject|1
6073909|NCT00570674|9677747|FG003|Overall Study|Withdrawal by Subject|0
6073910|NCT00570674|9677748|FG004|Overall Study|Withdrawal by Subject|0
6073911|NCT00570674|9677749|FG005|Overall Study|Withdrawal by Subject|0
6073912|NCT00570674|9677750|FG006|Overall Study|Withdrawal by Subject|0
6073913|NCT00570687|9677763|FG000|Washout 3 (7-21 Days) - Orig Protocol|Sponsor Decision|0
6073914|NCT00570687|9677764|FG001|Washout 3 (7-21 Days) - Orig Protocol|Sponsor Decision|0
6073915|NCT00570687|9677765|FG002|Washout 3 (7-21 Days) - Orig Protocol|Sponsor Decision|0
6073916|NCT00570687|9677766|FG003|Washout 3 (7-21 Days) - Orig Protocol|Sponsor Decision|0
6005221|NCT00082407|9599356|FG000|Overall Study|Adverse Event|20
6005222|NCT00082407|9599357|FG001|Overall Study|Adverse Event|0
6005223|NCT00082407|9599356|FG000|Overall Study|Protocol Violation|14
6005224|NCT00082407|9599357|FG001|Overall Study|Protocol Violation|12
6005225|NCT00082407|9599356|FG000|Overall Study|Patient Decision|13
6005226|NCT00082407|9599357|FG001|Overall Study|Patient Decision|6
6005227|NCT00082407|9599356|FG000|Overall Study|Physician Decision|5
6005228|NCT00082407|9599357|FG001|Overall Study|Physician Decision|3
6005229|NCT00082407|9599356|FG000|Overall Study|Loss of Glucose Control|2
6005230|NCT00082407|9599357|FG001|Overall Study|Loss of Glucose Control|2
6005231|NCT00082407|9599356|FG000|Overall Study|Death|2
6005232|NCT00082407|9599357|FG001|Overall Study|Death|1
6073917|NCT00570687|9677767|FG004|Washout 3 (7-21 Days) - Orig Protocol|Sponsor Decision|3
6005233|NCT00082407|9599356|FG000|Overall Study|Lost to Follow-up|0
6073918|NCT00570687|9677768|FG005|Washout 3 (7-21 Days) - Orig Protocol|Sponsor Decision|3
6073919|NCT00570687|9677769|FG006|Washout 3 (7-21 Days) - Orig Protocol|Sponsor Decision|2
6073920|NCT00570687|9677770|FG007|Washout 3 (7-21 Days) - Orig Protocol|Sponsor Decision|3
6005234|NCT00082407|9599357|FG001|Overall Study|Lost to Follow-up|3
6005235|NCT00082433|9599365|FG000|Overall Study|Adverse Event|12
6005236|NCT00082433|9599366|FG001|Overall Study|Adverse Event|17
6005237|NCT00082433|9599365|FG000|Overall Study|Death|8
6005238|NCT00082433|9599366|FG001|Overall Study|Death|18
6005239|NCT00082433|9599365|FG000|Overall Study|Disease Progression/Relapse|270
6005240|NCT00082433|9599366|FG001|Overall Study|Disease Progression/Relapse|388
6005241|NCT00082433|9599365|FG000|Overall Study|Physician Decision|50
6005242|NCT00082433|9599366|FG001|Overall Study|Physician Decision|61
6005243|NCT00082433|9599365|FG000|Overall Study|Lost to Follow-up|1
6005244|NCT00082433|9599366|FG001|Overall Study|Lost to Follow-up|2
6005245|NCT00082433|9599365|FG000|Overall Study|Study Drug Toxicity|179
6005246|NCT00082433|9599366|FG001|Overall Study|Study Drug Toxicity|66
6005247|NCT00082433|9599365|FG000|Overall Study|Withdrawal by Subject|55
6005248|NCT00082433|9599366|FG001|Overall Study|Withdrawal by Subject|30
6005249|NCT00082433|9599365|FG000|Overall Study|Still On Treatment|2
6005250|NCT00082433|9599366|FG001|Overall Study|Still On Treatment|1
6005251|NCT00082433|9599365|FG000|Overall Study|Not Treated|12
6005252|NCT00082433|9599366|FG001|Overall Study|Not Treated|11
6005253|NCT00082433|9599365|FG000|Overall Study|Ineligible|2
6005254|NCT00082433|9599366|FG001|Overall Study|Ineligible|1
6073921|NCT00570687|9677771|FG008|Washout 3 (7-21 Days) - Orig Protocol|Sponsor Decision|2
6073922|NCT00570687|9677772|FG009|Washout 3 (7-21 Days) - Orig Protocol|Sponsor Decision|3
6073923|NCT00570687|9677763|FG000|Washout 4 (7-21 Days) - Orig Protocol|Sponsor Decision|0
6073924|NCT00570687|9677764|FG001|Washout 4 (7-21 Days) - Orig Protocol|Sponsor Decision|0
6073925|NCT00570687|9677765|FG002|Washout 4 (7-21 Days) - Orig Protocol|Sponsor Decision|0
6073926|NCT00570687|9677766|FG003|Washout 4 (7-21 Days) - Orig Protocol|Sponsor Decision|0
6073927|NCT00570687|9677767|FG004|Washout 4 (7-21 Days) - Orig Protocol|Sponsor Decision|0
6073928|NCT00570687|9677768|FG005|Washout 4 (7-21 Days) - Orig Protocol|Sponsor Decision|0
6073929|NCT00570687|9677769|FG006|Washout 4 (7-21 Days) - Orig Protocol|Sponsor Decision|0
6073930|NCT00570687|9677770|FG007|Washout 4 (7-21 Days) - Orig Protocol|Sponsor Decision|0
6073931|NCT00570687|9677771|FG008|Washout 4 (7-21 Days) - Orig Protocol|Sponsor Decision|1
6073932|NCT00570687|9677772|FG009|Washout 4 (7-21 Days) - Orig Protocol|Sponsor Decision|0
6073933|NCT00570687|9677763|FG000|Washout 5 (7-21 Days) - Orig Protocol|Sponsor Decision|0
6073934|NCT00570687|9677764|FG001|Washout 5 (7-21 Days) - Orig Protocol|Sponsor Decision|0
6073935|NCT00570687|9677765|FG002|Washout 5 (7-21 Days) - Orig Protocol|Sponsor Decision|0
6073936|NCT00570687|9677766|FG003|Washout 5 (7-21 Days) - Orig Protocol|Sponsor Decision|0
6073937|NCT00570687|9677767|FG004|Washout 5 (7-21 Days) - Orig Protocol|Sponsor Decision|0
6073938|NCT00570687|9677768|FG005|Washout 5 (7-21 Days) - Orig Protocol|Sponsor Decision|0
6073939|NCT00570687|9677769|FG006|Washout 5 (7-21 Days) - Orig Protocol|Sponsor Decision|1
6073940|NCT00570687|9677770|FG007|Washout 5 (7-21 Days) - Orig Protocol|Sponsor Decision|0
6073941|NCT00570687|9677771|FG008|Washout 5 (7-21 Days) - Orig Protocol|Sponsor Decision|0
6073942|NCT00570687|9677772|FG009|Washout 5 (7-21 Days) - Orig Protocol|Sponsor Decision|0
6073943|NCT00570713|9677792|FG000|Overall Study|Adverse Event|16
6073944|NCT00570713|9677793|FG001|Overall Study|Adverse Event|9
6073945|NCT00570713|9677792|FG000|Overall Study|Death|7
6073946|NCT00570713|9677793|FG001|Overall Study|Death|7
6073947|NCT00570713|9677792|FG000|Overall Study|Lack of Efficacy|40
6073948|NCT00570713|9677793|FG001|Overall Study|Lack of Efficacy|49
6073949|NCT00570713|9677792|FG000|Overall Study|Physician Decision|2
6073950|NCT00570713|9677793|FG001|Overall Study|Physician Decision|2
6073951|NCT00570713|9677792|FG000|Overall Study|Withdrawal by Subject|3
6073952|NCT00570713|9677793|FG001|Overall Study|Withdrawal by Subject|3
6073953|NCT00570713|9677792|FG000|Overall Study|Discontinuation of Study by the Sponsor|10
6073954|NCT00570713|9677793|FG001|Overall Study|Discontinuation of Study by the Sponsor|7
6073955|NCT00570739|9677803|FG000|Overall Study|Adverse Event|8
6073956|NCT00570739|9677804|FG001|Overall Study|Adverse Event|6
6073957|NCT00570739|9677805|FG002|Overall Study|Adverse Event|2
6073958|NCT00570739|9677806|FG003|Overall Study|Adverse Event|2
6073959|NCT00570739|9677803|FG000|Overall Study|Lost to Follow-up|4
6073960|NCT00570739|9677804|FG001|Overall Study|Lost to Follow-up|5
6073961|NCT00570739|9677805|FG002|Overall Study|Lost to Follow-up|4
6073962|NCT00570739|9677806|FG003|Overall Study|Lost to Follow-up|1
6073963|NCT00570739|9677803|FG000|Overall Study|Physician Decision|1
6073964|NCT00570739|9677804|FG001|Overall Study|Physician Decision|1
6073965|NCT00570739|9677805|FG002|Overall Study|Physician Decision|0
6073966|NCT00570739|9677806|FG003|Overall Study|Physician Decision|0
6073967|NCT00570739|9677803|FG000|Overall Study|Withdrawal by Subject|7
6073968|NCT00570739|9677804|FG001|Overall Study|Withdrawal by Subject|7
6073969|NCT00570739|9677805|FG002|Overall Study|Withdrawal by Subject|3
6073970|NCT00570739|9677806|FG003|Overall Study|Withdrawal by Subject|5
6073971|NCT00570739|9677803|FG000|Overall Study|Required restricted medication|0
6005255|NCT00082433|9599365|FG000|Overall Study|Noncompliance|2
6005256|NCT00082433|9599366|FG001|Overall Study|Noncompliance|1
6005257|NCT00082433|9599365|FG000|Overall Study|New primary cancer|1
6073972|NCT00570739|9677804|FG001|Overall Study|Required restricted medication|0
6073973|NCT00570739|9677805|FG002|Overall Study|Required restricted medication|1
6073974|NCT00570739|9677806|FG003|Overall Study|Required restricted medication|0
6073975|NCT00570739|9677803|FG000|Overall Study|Met discontinuation criteria|1
6073976|NCT00570739|9677804|FG001|Overall Study|Met discontinuation criteria|0
6073977|NCT00570739|9677805|FG002|Overall Study|Met discontinuation criteria|1
6073978|NCT00570739|9677806|FG003|Overall Study|Met discontinuation criteria|1
6073979|NCT00570739|9677803|FG000|Overall Study|Other|0
6073980|NCT00570739|9677804|FG001|Overall Study|Other|2
6073981|NCT00570739|9677805|FG002|Overall Study|Other|5
6073982|NCT00570739|9677806|FG003|Overall Study|Other|3
6073983|NCT00570765|9677839|FG000|DB Phase|Withdrawal by Subject|1
6073984|NCT00570765|9677840|FG001|DB Phase|Withdrawal by Subject|0
6073985|NCT00570765|9677841|FG002|DB Phase|Withdrawal by Subject|0
6073986|NCT00570765|9677842|FG003|DB Phase|Withdrawal by Subject|0
6073987|NCT00570765|9677839|FG000|DB Phase|Protocol Violation|0
6073988|NCT00570765|9677840|FG001|DB Phase|Protocol Violation|1
6073989|NCT00570765|9677841|FG002|DB Phase|Protocol Violation|0
6073990|NCT00570765|9677842|FG003|DB Phase|Protocol Violation|0
6073991|NCT00570765|9677839|FG000|DB Phase|Adverse Event|3
6073992|NCT00570765|9677840|FG001|DB Phase|Adverse Event|6
6073993|NCT00570765|9677841|FG002|DB Phase|Adverse Event|0
6073994|NCT00570765|9677842|FG003|DB Phase|Adverse Event|0
6073995|NCT00570765|9677839|FG000|DB Phase|Did Not Receive Study Drug|0
6073996|NCT00570765|9677840|FG001|DB Phase|Did Not Receive Study Drug|0
6073997|NCT00570765|9677841|FG002|DB Phase|Did Not Receive Study Drug|1
6073998|NCT00570765|9677842|FG003|DB Phase|Did Not Receive Study Drug|0
6073999|NCT00570765|9677839|FG000|LTSE Phase|Withdrawal by Subject|0
6074000|NCT00570765|9677840|FG001|LTSE Phase|Withdrawal by Subject|0
6074001|NCT00570765|9677841|FG002|LTSE Phase|Withdrawal by Subject|0
6074002|NCT00570765|9677842|FG003|LTSE Phase|Withdrawal by Subject|1
6074003|NCT00570765|9677839|FG000|LTSE Phase|Adverse Event|0
6074004|NCT00570765|9677840|FG001|LTSE Phase|Adverse Event|0
6074005|NCT00570765|9677841|FG002|LTSE Phase|Adverse Event|0
6074006|NCT00570765|9677842|FG003|LTSE Phase|Adverse Event|7
6074007|NCT00570765|9677839|FG000|LTSE Phase|Physician Decision|0
6074008|NCT00570765|9677840|FG001|LTSE Phase|Physician Decision|0
6074009|NCT00570765|9677841|FG002|LTSE Phase|Physician Decision|0
6074010|NCT00570765|9677842|FG003|LTSE Phase|Physician Decision|4
6074011|NCT00570778|9677853|FG000|Overall Study|Protocol deviation|2
6074012|NCT00570778|9677854|FG001|Overall Study|Protocol deviation|1
6074013|NCT00570778|9677855|FG002|Overall Study|Protocol deviation|2
6074014|NCT00570778|9677856|FG003|Overall Study|Protocol deviation|2
6074015|NCT00570778|9677853|FG000|Overall Study|Adverse Event|0
6074016|NCT00570778|9677854|FG001|Overall Study|Adverse Event|1
6074017|NCT00570778|9677855|FG002|Overall Study|Adverse Event|4
6074018|NCT00570778|9677856|FG003|Overall Study|Adverse Event|1
6074019|NCT00570778|9677853|FG000|Overall Study|Subject withdrew consent|0
6074020|NCT00570778|9677854|FG001|Overall Study|Subject withdrew consent|1
6074021|NCT00570778|9677855|FG002|Overall Study|Subject withdrew consent|0
6074022|NCT00570778|9677856|FG003|Overall Study|Subject withdrew consent|1
6074023|NCT00570778|9677853|FG000|Overall Study|Abnormal test procedure|1
6074024|NCT00570778|9677854|FG001|Overall Study|Abnormal test procedure|0
6074025|NCT00570778|9677855|FG002|Overall Study|Abnormal test procedure|0
6074026|NCT00570778|9677856|FG003|Overall Study|Abnormal test procedure|0
6074027|NCT00570778|9677853|FG000|Overall Study|Unsatisfactory therapeutic effect|1
6074028|NCT00570778|9677854|FG001|Overall Study|Unsatisfactory therapeutic effect|0
6074029|NCT00570778|9677855|FG002|Overall Study|Unsatisfactory therapeutic effect|0
6074030|NCT00570778|9677856|FG003|Overall Study|Unsatisfactory therapeutic effect|0
6074031|NCT00570778|9677853|FG000|Overall Study|Lost to Follow-up|0
6074032|NCT00570778|9677854|FG001|Overall Study|Lost to Follow-up|0
6074033|NCT00570778|9677855|FG002|Overall Study|Lost to Follow-up|1
6074034|NCT00570778|9677856|FG003|Overall Study|Lost to Follow-up|0
6074035|NCT00570778|9677853|FG000|Overall Study|Subject no longer requires study drug|0
6074036|NCT00570778|9677854|FG001|Overall Study|Subject no longer requires study drug|1
6074037|NCT00570778|9677855|FG002|Overall Study|Subject no longer requires study drug|0
6074038|NCT00570778|9677856|FG003|Overall Study|Subject no longer requires study drug|0
6074039|NCT00570908|9677866|FG000|Overall Study|Adverse Event|5
6074040|NCT00570908|9677866|FG000|Overall Study|Withdrawal by Subject|2
6074041|NCT00570921|9677870|FG000|Overall Study|Protocol Violation|1
6074042|NCT00570921|9677870|FG000|Overall Study|Physician Decision|1
6074043|NCT00571038|9677885|FG000|Overall Study|Lost to Follow-up|1
6074044|NCT00571038|9677886|FG001|Overall Study|Lost to Follow-up|4
6074045|NCT00571038|9677885|FG000|Overall Study|Death|7
6074046|NCT00571038|9677886|FG001|Overall Study|Death|5
6074047|NCT00571038|9677885|FG000|Overall Study|Withdrawal by Subject|1
6074048|NCT00571038|9677886|FG001|Overall Study|Withdrawal by Subject|3
6074049|NCT00571038|9677885|FG000|Overall Study|Moved out of state|2
6074050|NCT00571038|9677886|FG001|Overall Study|Moved out of state|2
6074051|NCT00571064|9677892|FG000|Overall Study|Adverse Event|13
6074052|NCT00571064|9677892|FG000|Overall Study|Protocol Violation|4
6074053|NCT00571064|9677892|FG000|Overall Study|Withdrawal by Subject|2
6074054|NCT00571064|9677892|FG000|Overall Study|Other|2
6074055|NCT00571103|9677897|FG000|Overall Study|Withdrawal by Subject|1
6074056|NCT00571103|9677897|FG000|Overall Study|Lost to Follow-up|1
6074057|NCT00571519|9677949|FG000|Overall Study|Subject withdrew consent|0
6074058|NCT00571519|9677950|FG001|Overall Study|Subject withdrew consent|1
6005258|NCT00082433|9599366|FG001|Overall Study|New primary cancer|0
6005259|NCT00082433|9599365|FG000|Overall Study|Impending surgery|0
6005260|NCT00082433|9599366|FG001|Overall Study|Impending surgery|1
6005261|NCT00082628|9599374|FG000|Treatment Period I (Week 1 to Week 12)|Subjects Did Not Receive Study Drug|0
6005262|NCT00082628|9599375|FG001|Treatment Period I (Week 1 to Week 12)|Subjects Did Not Receive Study Drug|1
6005263|NCT00082628|9599376|FG002|Treatment Period I (Week 1 to Week 12)|Subjects Did Not Receive Study Drug|0
6005264|NCT00082628|9599377|FG003|Treatment Period I (Week 1 to Week 12)|Subjects Did Not Receive Study Drug|0
6005265|NCT00082628|9599378|FG004|Treatment Period I (Week 1 to Week 12)|Subjects Did Not Receive Study Drug|0
6005266|NCT00082628|9599374|FG000|Treatment Period I (Week 1 to Week 12)|Subjects Without Post-Baseline Assessmen|2
6005267|NCT00082628|9599375|FG001|Treatment Period I (Week 1 to Week 12)|Subjects Without Post-Baseline Assessmen|1
6005268|NCT00082628|9599376|FG002|Treatment Period I (Week 1 to Week 12)|Subjects Without Post-Baseline Assessmen|0
6005269|NCT00082628|9599377|FG003|Treatment Period I (Week 1 to Week 12)|Subjects Without Post-Baseline Assessmen|0
6005270|NCT00082628|9599378|FG004|Treatment Period I (Week 1 to Week 12)|Subjects Without Post-Baseline Assessmen|0
6005271|NCT00082628|9599374|FG000|Treatment Period I (Week 1 to Week 12)|Subjects Did Not Complete Week 12|5
6005272|NCT00082628|9599375|FG001|Treatment Period I (Week 1 to Week 12)|Subjects Did Not Complete Week 12|43
6005273|NCT00082628|9599376|FG002|Treatment Period I (Week 1 to Week 12)|Subjects Did Not Complete Week 12|0
6005274|NCT00082628|9599377|FG003|Treatment Period I (Week 1 to Week 12)|Subjects Did Not Complete Week 12|0
6005275|NCT00082628|9599378|FG004|Treatment Period I (Week 1 to Week 12)|Subjects Did Not Complete Week 12|0
6005276|NCT00082628|9599374|FG000|Treatment Period I (Week 1 to Week 12)|Did not continue to Period II|1
6005277|NCT00082628|9599375|FG001|Treatment Period I (Week 1 to Week 12)|Did not continue to Period II|15
6005278|NCT00082628|9599376|FG002|Treatment Period I (Week 1 to Week 12)|Did not continue to Period II|0
6005279|NCT00082628|9599377|FG003|Treatment Period I (Week 1 to Week 12)|Did not continue to Period II|0
6005280|NCT00082628|9599378|FG004|Treatment Period I (Week 1 to Week 12)|Did not continue to Period II|0
6005281|NCT00082628|9599374|FG000|Treatment Period II: Week 12 to Week 36|Lost to Follow-up|0
6005282|NCT00082628|9599375|FG001|Treatment Period II: Week 12 to Week 36|Lost to Follow-up|0
6005283|NCT00082628|9599376|FG002|Treatment Period II: Week 12 to Week 36|Lost to Follow-up|0
6005284|NCT00082628|9599377|FG003|Treatment Period II: Week 12 to Week 36|Lost to Follow-up|0
6005285|NCT00082628|9599378|FG004|Treatment Period II: Week 12 to Week 36|Lost to Follow-up|1
6047309|NCT00410410|9646252|FG003|Maintenance Period (MP)|Lost to Follow-up|0
6047310|NCT00410410|9646253|FG004|Maintenance Period (MP)|Lost to Follow-up|0
6047311|NCT00410410|9646254|FG005|Maintenance Period (MP)|Lost to Follow-up|0
6047312|NCT00410410|9646255|FG006|Maintenance Period (MP)|Lost to Follow-up|1
6074059|NCT00571519|9677951|FG002|Overall Study|Subject withdrew consent|0
6074060|NCT00571519|9677952|FG003|Overall Study|Subject withdrew consent|2
6074061|NCT00571519|9677953|FG004|Overall Study|Subject withdrew consent|1
6074062|NCT00571519|9677954|FG005|Overall Study|Subject withdrew consent|1
6074063|NCT00571519|9677955|FG006|Overall Study|Subject withdrew consent|2
6074064|NCT00571519|9677949|FG000|Overall Study|Hyperglycemia meeting discontinuation criteria|1
6074065|NCT00571519|9677950|FG001|Overall Study|Hyperglycemia meeting discontinuation criteria|0
6074066|NCT00571519|9677951|FG002|Overall Study|Hyperglycemia meeting discontinuation criteria|1
6074067|NCT00571519|9677952|FG003|Overall Study|Hyperglycemia meeting discontinuation criteria|1
6074068|NCT00571519|9677953|FG004|Overall Study|Hyperglycemia meeting discontinuation criteria|0
6074069|NCT00571519|9677954|FG005|Overall Study|Hyperglycemia meeting discontinuation criteria|0
6074070|NCT00571519|9677955|FG006|Overall Study|Hyperglycemia meeting discontinuation criteria|0
6074071|NCT00571519|9677949|FG000|Overall Study|Therapeutic failure/lack of efficacy|0
6074072|NCT00571519|9677950|FG001|Overall Study|Therapeutic failure/lack of efficacy|1
6074073|NCT00571519|9677951|FG002|Overall Study|Therapeutic failure/lack of efficacy|0
6074074|NCT00571519|9677952|FG003|Overall Study|Therapeutic failure/lack of efficacy|0
6074075|NCT00571519|9677953|FG004|Overall Study|Therapeutic failure/lack of efficacy|0
6074076|NCT00571519|9677954|FG005|Overall Study|Therapeutic failure/lack of efficacy|0
6074077|NCT00571519|9677955|FG006|Overall Study|Therapeutic failure/lack of efficacy|0
6074078|NCT00571519|9677949|FG000|Overall Study|Termination of study by Sponsor|2
6074079|NCT00571519|9677950|FG001|Overall Study|Termination of study by Sponsor|7
6074080|NCT00571519|9677951|FG002|Overall Study|Termination of study by Sponsor|10
6074081|NCT00571519|9677952|FG003|Overall Study|Termination of study by Sponsor|24
6074082|NCT00571519|9677953|FG004|Overall Study|Termination of study by Sponsor|8
6074083|NCT00571519|9677954|FG005|Overall Study|Termination of study by Sponsor|9
6074084|NCT00571519|9677955|FG006|Overall Study|Termination of study by Sponsor|22
6074085|NCT00571519|9677949|FG000|Overall Study|Per medical monitor regarding thyroid-stimulating hormone level|0
6074086|NCT00571519|9677950|FG001|Overall Study|Per medical monitor regarding thyroid-stimulating hormone level|0
6074087|NCT00571519|9677951|FG002|Overall Study|Per medical monitor regarding thyroid-stimulating hormone level|1
6047313|NCT00410410|9646256|FG007|Maintenance Period (MP)|Lost to Follow-up|2
6047314|NCT00410410|9646257|FG008|Maintenance Period (MP)|Lost to Follow-up|0
6047315|NCT00410410|9646249|FG000|Maintenance Period (MP)|Withdrawal by Subject|0
6047316|NCT00410410|9646250|FG001|Maintenance Period (MP)|Withdrawal by Subject|0
6047317|NCT00410410|9646251|FG002|Maintenance Period (MP)|Withdrawal by Subject|0
6047318|NCT00410410|9646252|FG003|Maintenance Period (MP)|Withdrawal by Subject|0
6047319|NCT00410410|9646253|FG004|Maintenance Period (MP)|Withdrawal by Subject|0
6005286|NCT00082628|9599374|FG000|Treatment Period II: Week 12 to Week 36|Withdrawal by Subject|0
6005287|NCT00082628|9599375|FG001|Treatment Period II: Week 12 to Week 36|Withdrawal by Subject|0
6005288|NCT00082628|9599376|FG002|Treatment Period II: Week 12 to Week 36|Withdrawal by Subject|0
6005289|NCT00082628|9599377|FG003|Treatment Period II: Week 12 to Week 36|Withdrawal by Subject|1
6005290|NCT00082628|9599378|FG004|Treatment Period II: Week 12 to Week 36|Withdrawal by Subject|0
6005291|NCT00082628|9599374|FG000|Treatment Period II: Week 12 to Week 36|Subjects Did Not Complete Week 36|0
6005292|NCT00082628|9599375|FG001|Treatment Period II: Week 12 to Week 36|Subjects Did Not Complete Week 36|0
6005293|NCT00082628|9599376|FG002|Treatment Period II: Week 12 to Week 36|Subjects Did Not Complete Week 36|15
6005294|NCT00082628|9599377|FG003|Treatment Period II: Week 12 to Week 36|Subjects Did Not Complete Week 36|15
6005295|NCT00082628|9599378|FG004|Treatment Period II: Week 12 to Week 36|Subjects Did Not Complete Week 36|17
6005296|NCT00082758|9599403|FG000|Overall Study|Adverse Event|0
6005297|NCT00082758|9599404|FG001|Overall Study|Adverse Event|2
6005298|NCT00082758|9599405|FG002|Overall Study|Adverse Event|0
6005299|NCT00082758|9599403|FG000|Overall Study|Lack of Efficacy|12
6005300|NCT00082758|9599404|FG001|Overall Study|Lack of Efficacy|13
6005301|NCT00082758|9599405|FG002|Overall Study|Lack of Efficacy|0
6005302|NCT00082758|9599403|FG000|Overall Study|Physician Decision|0
6005303|NCT00082758|9599404|FG001|Overall Study|Physician Decision|1
6005304|NCT00082758|9599405|FG002|Overall Study|Physician Decision|0
6005305|NCT00082758|9599403|FG000|Overall Study|Withdrawal by Subject|3
6005306|NCT00082758|9599404|FG001|Overall Study|Withdrawal by Subject|0
6005307|NCT00082758|9599405|FG002|Overall Study|Withdrawal by Subject|0
6005308|NCT00082758|9599403|FG000|Overall Study|Protocol Violation|0
6005309|NCT00082758|9599404|FG001|Overall Study|Protocol Violation|1
6005310|NCT00082758|9599405|FG002|Overall Study|Protocol Violation|0
6005311|NCT00082810|9599413|FG000|Overall Study|Adverse Event|3
6005312|NCT00082810|9599413|FG000|Overall Study|Progressive disease|24
6005313|NCT00082810|9599413|FG000|Overall Study|Withdrawal by Subject|4
6005314|NCT00082888|9599421|FG000|Overall Study|Ineligible|1
6005315|NCT00082888|9599422|FG001|Overall Study|Ineligible|0
6005316|NCT00082888|9599423|FG002|Overall Study|Ineligible|0
6005317|NCT00083226|9599455|FG000|Overall Study|Lack of Efficacy|19
6005318|NCT00083226|9599455|FG000|Overall Study|Adverse Event|9
6005319|NCT00083226|9599455|FG000|Overall Study|Death|4
6005320|NCT00083226|9599455|FG000|Overall Study|Withdrawal by Subject|4
6074088|NCT00571519|9677952|FG003|Overall Study|Per medical monitor regarding thyroid-stimulating hormone level|0
6074089|NCT00571519|9677953|FG004|Overall Study|Per medical monitor regarding thyroid-stimulating hormone level|0
6074090|NCT00571519|9677954|FG005|Overall Study|Per medical monitor regarding thyroid-stimulating hormone level|0
6074091|NCT00571519|9677955|FG006|Overall Study|Per medical monitor regarding thyroid-stimulating hormone level|0
6074092|NCT00571649|9677973|FG000|Treatment Period|Adverse Event|438
6074093|NCT00571649|9677974|FG001|Treatment Period|Adverse Event|385
6074094|NCT00571649|9677973|FG000|Treatment Period|Clinical endpoint reached|50
6074095|NCT00571649|9677974|FG001|Treatment Period|Clinical endpoint reached|56
6074096|NCT00571649|9677973|FG000|Treatment Period|Withdrawal by Subject|285
6074097|NCT00571649|9677974|FG001|Treatment Period|Withdrawal by Subject|255
6074098|NCT00571649|9677973|FG000|Treatment Period|Death|76
6074099|NCT00571649|9677974|FG001|Treatment Period|Death|59
6074100|NCT00571649|9677973|FG000|Treatment Period|Physician Decision|8
6074101|NCT00571649|9677974|FG001|Treatment Period|Physician Decision|9
6074102|NCT00571649|9677973|FG000|Treatment Period|Lost to Follow-up|43
6074103|NCT00571649|9677974|FG001|Treatment Period|Lost to Follow-up|41
6074104|NCT00571649|9677973|FG000|Treatment Period|Non-compliant with study medication|88
6074105|NCT00571649|9677974|FG001|Treatment Period|Non-compliant with study medication|89
6074106|NCT00571649|9677973|FG000|Treatment Period|Patient convenience|11
6074107|NCT00571649|9677974|FG001|Treatment Period|Patient convenience|13
6074108|NCT00571649|9677973|FG000|Treatment Period|Protocol Violation|90
6074109|NCT00571649|9677974|FG001|Treatment Period|Protocol Violation|92
6074110|NCT00571649|9677973|FG000|Treatment Period|Technical problems|3
6074111|NCT00571649|9677974|FG001|Treatment Period|Technical problems|5
6074112|NCT00571649|9677973|FG000|Follow-up Period|Adverse Event|46
6074113|NCT00571649|9677974|FG001|Follow-up Period|Adverse Event|40
6074114|NCT00571649|9677973|FG000|Follow-up Period|Clinical endpoint reached|5
6074115|NCT00571649|9677974|FG001|Follow-up Period|Clinical endpoint reached|2
6074116|NCT00571649|9677973|FG000|Follow-up Period|Withdrawal by Subject|119
6074117|NCT00571649|9677974|FG001|Follow-up Period|Withdrawal by Subject|115
6074118|NCT00571649|9677973|FG000|Follow-up Period|Death|132
6074119|NCT00571649|9677974|FG001|Follow-up Period|Death|133
6074120|NCT00571649|9677973|FG000|Follow-up Period|Physician Decision|7
6074121|NCT00571649|9677974|FG001|Follow-up Period|Physician Decision|13
6074122|NCT00571649|9677973|FG000|Follow-up Period|Lost to Follow-up|95
6074123|NCT00571649|9677974|FG001|Follow-up Period|Lost to Follow-up|92
6005321|NCT00083226|9599455|FG000|Overall Study|Other|2
6005322|NCT00083226|9599455|FG000|Overall Study|ineligible or not receiving treatment|4
6005323|NCT00083616|9599472|FG000|Overall Study|Disease Progression|16
6005324|NCT00083616|9599472|FG000|Overall Study|Lost to Follow-up|1
6074124|NCT00571649|9677973|FG000|Follow-up Period|Patient convenience|136
6074125|NCT00571649|9677974|FG001|Follow-up Period|Patient convenience|121
6074126|NCT00571649|9677973|FG000|Follow-up Period|Protocol Violation|5
6074127|NCT00571649|9677974|FG001|Follow-up Period|Protocol Violation|12
6005325|NCT00083616|9599472|FG000|Overall Study|Physician Decision|2
6005326|NCT00083616|9599472|FG000|Overall Study|Withdrawal by Subject|3
6005327|NCT00083616|9599472|FG000|Overall Study|Ineligibility determined|2
6005328|NCT00083616|9599472|FG000|Overall Study|Non-compliance|1
6005329|NCT00083616|9599472|FG000|Overall Study|Other|6
6005330|NCT00083889|9599482|FG000|Overall Study|Adverse Event|76
6005331|NCT00083889|9599483|FG001|Overall Study|Adverse Event|86
6005332|NCT00083889|9599482|FG000|Overall Study|Protocol Violation|2
6005333|NCT00083889|9599483|FG001|Overall Study|Protocol Violation|2
6005334|NCT00083889|9599482|FG000|Overall Study|Withdrawal by Subject|22
6005335|NCT00083889|9599483|FG001|Overall Study|Withdrawal by Subject|24
6005336|NCT00083889|9599482|FG000|Overall Study|Lack of Efficacy|240
6005337|NCT00083889|9599483|FG001|Overall Study|Lack of Efficacy|219
6005338|NCT00083889|9599482|FG000|Overall Study|Decision of sponsor|32
6005339|NCT00083889|9599483|FG001|Overall Study|Decision of sponsor|4
6005340|NCT00083889|9599482|FG000|Overall Study|Randomized: did not take study drug|0
6005341|NCT00083889|9599483|FG001|Overall Study|Randomized: did not take study drug|15
6005342|NCT00083889|9599482|FG000|Overall Study|Completed on marketed sunitinub|3
6005343|NCT00083889|9599483|FG001|Overall Study|Completed on marketed sunitinub|0
6005344|NCT00083889|9599482|FG000|Overall Study|Crossover to SU011248|0
6005345|NCT00083889|9599483|FG001|Overall Study|Crossover to SU011248|25
6005346|NCT00084084|9599492|FG000|Phase 1 (Treatment With Replagal RB)|Lost to Follow-up|1
6005347|NCT00084084|9599492|FG000|Phase 2 (Transition to Replagal AF)|Failure to visit clinic as scheduled|1
6005348|NCT00084136|9599500|FG000|PI Comparison|Death|10
6005349|NCT00084136|9599501|FG001|PI Comparison|Death|9
6005350|NCT00084136|9599502|FG002|PI Comparison|Death|0
6005351|NCT00084136|9599500|FG000|PI Comparison|Lost to Follow-up|11
6005352|NCT00084136|9599501|FG001|PI Comparison|Lost to Follow-up|8
6005353|NCT00084136|9599502|FG002|PI Comparison|Lost to Follow-up|0
6005354|NCT00084136|9599500|FG000|PI Comparison|Withdrawal by Subject|33
6005355|NCT00084136|9599501|FG001|PI Comparison|Withdrawal by Subject|30
6005356|NCT00084136|9599502|FG002|PI Comparison|Withdrawal by Subject|0
6005357|NCT00084136|9599500|FG000|PI Comparison|Clinic site closed|1
6005358|NCT00084136|9599501|FG001|PI Comparison|Clinic site closed|0
6005359|NCT00084136|9599502|FG002|PI Comparison|Clinic site closed|0
6005360|NCT00084136|9599500|FG000|NRTI Comparison|Death|20
6005361|NCT00084136|9599501|FG001|NRTI Comparison|Death|0
6005362|NCT00084136|9599502|FG002|NRTI Comparison|Death|18
6005363|NCT00084136|9599500|FG000|NRTI Comparison|Lost to Follow-up|14
6005364|NCT00084136|9599501|FG001|NRTI Comparison|Lost to Follow-up|0
6005365|NCT00084136|9599502|FG002|NRTI Comparison|Lost to Follow-up|12
6005366|NCT00084136|9599500|FG000|NRTI Comparison|Withdrawal by Subject|54
6005367|NCT00084136|9599501|FG001|NRTI Comparison|Withdrawal by Subject|0
6005368|NCT00084136|9599502|FG002|NRTI Comparison|Withdrawal by Subject|38
6005369|NCT00084136|9599500|FG000|NRTI Comparison|Clinic site closed|12
6005370|NCT00084136|9599501|FG001|NRTI Comparison|Clinic site closed|0
6005371|NCT00084136|9599502|FG002|NRTI Comparison|Clinic site closed|14
6005372|NCT00084136|9599500|FG000|NRTI Comparison|Not reason above|1
6005373|NCT00084136|9599501|FG001|NRTI Comparison|Not reason above|0
6005374|NCT00084136|9599502|FG002|NRTI Comparison|Not reason above|0
6005375|NCT00084266|9599526|FG000|Overall Study|Death|42
6005376|NCT00084266|9599527|FG001|Overall Study|Death|39
6005377|NCT00084266|9599526|FG000|Overall Study|Adverse Event|8
6005378|NCT00084266|9599527|FG001|Overall Study|Adverse Event|5
6005379|NCT00084266|9599526|FG000|Overall Study|Lack of Efficacy|2
6005380|NCT00084266|9599527|FG001|Overall Study|Lack of Efficacy|4
6005381|NCT00084266|9599526|FG000|Overall Study|Lost to Follow-up|5
6005382|NCT00084266|9599527|FG001|Overall Study|Lost to Follow-up|3
6005383|NCT00084266|9599526|FG000|Overall Study|Participant not willing to participate|3
6005384|NCT00084266|9599527|FG001|Overall Study|Participant not willing to participate|8
6005385|NCT00084266|9599526|FG000|Overall Study|Other|360
6005386|NCT00084266|9599527|FG001|Overall Study|Other|344
6005387|NCT00084266|9599526|FG000|Overall Study|Randomized not treated|21
6005388|NCT00084266|9599527|FG001|Overall Study|Randomized not treated|20
6005389|NCT00084318|9599535|FG000|Overall Study|Withdrawal by Subject|5
6005390|NCT00084318|9599536|FG001|Overall Study|Withdrawal by Subject|2
6005391|NCT00084318|9599535|FG000|Overall Study|Protocol Violation|15
6005392|NCT00084318|9599536|FG001|Overall Study|Protocol Violation|11
6005393|NCT00084318|9599535|FG000|Overall Study|No protocol treatment|2
6005394|NCT00084318|9599536|FG001|Overall Study|No protocol treatment|0
6005395|NCT00084487|9599559|FG000|Overall Study|Death|1
6005396|NCT00084617|9599572|FG000|Overall Study|Withdrawal by Subject|7
6005397|NCT00084617|9599572|FG000|Overall Study|Lack of Efficacy|1
6005398|NCT00084617|9599572|FG000|Overall Study|Protocol Violation|1
6005399|NCT00084682|9599576|FG000|Overall Study|Withdrawal by Subject|1
6005400|NCT00084747|9599581|FG000|Overall Study|Relapsed|8
6005401|NCT00084747|9599581|FG000|Overall Study|Death|3
6005402|NCT00084747|9599581|FG000|Overall Study|Withdrawal by Subject|2
6005403|NCT00084838|9599586|FG000|Overall Study|Death|1
6005404|NCT00084838|9599586|FG000|Overall Study|Adverse Event|2
6005405|NCT00084838|9599586|FG000|Overall Study|Withdrawal by Subject|1
6005406|NCT00084838|9599586|FG000|Overall Study|Progressive Disease|4
6005407|NCT00084838|9599586|FG000|Overall Study|Pt Non-Compliance|1
6005408|NCT00084838|9599586|FG000|Overall Study|Ineligible|4
6005409|NCT00084864|9599596|FG000|Overall Study|Adverse Event|1
6005410|NCT00084864|9599597|FG001|Overall Study|Adverse Event|0
6005411|NCT00084864|9599598|FG002|Overall Study|Adverse Event|0
6005412|NCT00084864|9599599|FG003|Overall Study|Adverse Event|0
6005413|NCT00084929|9599609|FG000|Overall Study|ineligible - medical contraindication|1
6005414|NCT00084929|9599609|FG000|Overall Study|ineligible - Pre-scheduled procedure not|1
6005415|NCT00084929|9599609|FG000|Overall Study|Ineligible - Medical history|6
6005416|NCT00084929|9599609|FG000|Overall Study|Withdrawal by Subject|10
6005417|NCT00084929|9599609|FG000|Overall Study|Missing/incomplete CTC exam|9
6005418|NCT00084929|9599609|FG000|Overall Study|Missing Reference Standard (Colonoscopy)|42
6005419|NCT00085098|9599619|FG000|Overall Study|Withdrawal by Subject|0
6005420|NCT00085098|9599620|FG001|Overall Study|Withdrawal by Subject|1
6005421|NCT00085098|9599619|FG000|Overall Study|Ineligible|1
6005422|NCT00085098|9599620|FG001|Overall Study|Ineligible|1
6005423|NCT00085423|9599657|FG000|Overall Study|Withdrawal by Subject|1
6005424|NCT00085423|9599657|FG000|Overall Study|screen failure|1
6005425|NCT00085540|9599668|FG000|Overall Study|Withdrawal by Subject|0
6005426|NCT00085540|9599669|FG001|Overall Study|Withdrawal by Subject|1
6005427|NCT00085540|9599668|FG000|Overall Study|Protocol Violation|0
6005428|NCT00085540|9599669|FG001|Overall Study|Protocol Violation|1
6005429|NCT00085566|9599678|FG000|Overall Study|Adverse Event|0
6005430|NCT00085566|9599679|FG001|Overall Study|Adverse Event|0
6074128|NCT00571662|9677980|FG000|Overall Study|Withdrawal by Subject|2
6074129|NCT00571662|9677980|FG000|Overall Study|psychiatric instability|1
6074130|NCT00571662|9677980|FG000|Overall Study|Adverse Event|5
6074131|NCT00571688|9677988|FG000|Overall Study|Lost to Follow-up|3
6074132|NCT00571688|9677989|FG001|Overall Study|Lost to Follow-up|6
6074133|NCT00571688|9677988|FG000|Overall Study|subject did not tolerate Consta|1
6074134|NCT00571688|9677989|FG001|Overall Study|subject did not tolerate Consta|0
6074135|NCT00571688|9677988|FG000|Overall Study|subject moved out of the area|1
6074136|NCT00571688|9677989|FG001|Overall Study|subject moved out of the area|0
6074137|NCT00571701|9677997|FG000|First Intervention 12 Months|Withdrawal by Subject|2
6074138|NCT00571701|9677998|FG001|First Intervention 12 Months|Withdrawal by Subject|1
6074139|NCT00571701|9677997|FG000|First Intervention 12 Months|Death|1
6074140|NCT00571701|9677998|FG001|First Intervention 12 Months|Death|0
6074141|NCT00571701|9677997|FG000|Second Intervention 12 Months|Adverse Event|0
6074142|NCT00571701|9677998|FG001|Second Intervention 12 Months|Adverse Event|1
6074143|NCT00571701|9677997|FG000|Second Intervention 12 Months|Withdrawal by Subject|3
6074144|NCT00571701|9677998|FG001|Second Intervention 12 Months|Withdrawal by Subject|0
6074145|NCT00571948|9678024|FG000|Overall Study|Lost to Follow-up|2
6074146|NCT00571948|9678025|FG001|Overall Study|Lost to Follow-up|0
6074147|NCT00571948|9678024|FG000|Overall Study|Withdrawal by Subject|1
6074148|NCT00571948|9678025|FG001|Overall Study|Withdrawal by Subject|2
6074149|NCT00571948|9678024|FG000|Overall Study|Protocol Violation|3
6074150|NCT00571948|9678025|FG001|Overall Study|Protocol Violation|3
6074151|NCT00571948|9678024|FG000|Overall Study|infant refused study meal|3
6074152|NCT00571948|9678025|FG001|Overall Study|infant refused study meal|4
6074153|NCT00571948|9678024|FG000|Overall Study|Parent were afraid of blood colection|2
6074154|NCT00571948|9678025|FG001|Overall Study|Parent were afraid of blood colection|5
6074155|NCT00572039|9678051|FG000|Overall Study|Withdrawal by Subject|9
6074156|NCT00572039|9678052|FG001|Overall Study|Withdrawal by Subject|6
6074157|NCT00572039|9678051|FG000|Overall Study|Death|2
6074158|NCT00572039|9678052|FG001|Overall Study|Death|3
6074159|NCT00572039|9678051|FG000|Overall Study|Ill|5
6074160|NCT00572039|9678052|FG001|Overall Study|Ill|1
6074161|NCT00572156|9678075|FG000|Overall Study|Adverse Event|3
6074162|NCT00572156|9678076|FG001|Overall Study|Adverse Event|1
6074163|NCT00572156|9678077|FG002|Overall Study|Adverse Event|5
6074164|NCT00572156|9678078|FG003|Overall Study|Adverse Event|1
6074165|NCT00572156|9678075|FG000|Overall Study|Lost to Follow-up|1
6074166|NCT00572156|9678076|FG001|Overall Study|Lost to Follow-up|1
6074167|NCT00572156|9678077|FG002|Overall Study|Lost to Follow-up|1
6074168|NCT00572156|9678078|FG003|Overall Study|Lost to Follow-up|0
6074169|NCT00572156|9678075|FG000|Overall Study|Protocol Violation|1
6074170|NCT00572156|9678076|FG001|Overall Study|Protocol Violation|2
6074171|NCT00572156|9678077|FG002|Overall Study|Protocol Violation|0
6074172|NCT00572156|9678078|FG003|Overall Study|Protocol Violation|2
6074173|NCT00572156|9678075|FG000|Overall Study|Patient/Parent Decision|1
6074174|NCT00572156|9678076|FG001|Overall Study|Patient/Parent Decision|6
6074175|NCT00572156|9678077|FG002|Overall Study|Patient/Parent Decision|4
6074176|NCT00572156|9678078|FG003|Overall Study|Patient/Parent Decision|3
6074177|NCT00572156|9678075|FG000|Overall Study|Sponsor Decision|20
6074178|NCT00572156|9678076|FG001|Overall Study|Sponsor Decision|16
6074179|NCT00572156|9678077|FG002|Overall Study|Sponsor Decision|17
6074180|NCT00572156|9678078|FG003|Overall Study|Sponsor Decision|19
6074181|NCT00572195|9678088|FG000|Overall Study|Withdrawal by Subject|50
6074182|NCT00572195|9678088|FG000|Overall Study|Death|9
6005431|NCT00085566|9599680|FG002|Overall Study|Adverse Event|10
6005432|NCT00085566|9599678|FG000|Overall Study|Patient Not treated|0
6005433|NCT00085566|9599679|FG001|Overall Study|Patient Not treated|0
6005434|NCT00085566|9599680|FG002|Overall Study|Patient Not treated|3
6005435|NCT00085566|9599678|FG000|Overall Study|Clinical progression|0
6005436|NCT00085566|9599679|FG001|Overall Study|Clinical progression|0
6005437|NCT00085566|9599680|FG002|Overall Study|Clinical progression|1
6005438|NCT00085644|9599690|FG000|Double-Blind Period|Adverse Event|5
6005439|NCT00085644|9599691|FG001|Double-Blind Period|Adverse Event|2
6005440|NCT00085644|9599692|FG002|Double-Blind Period|Adverse Event|0
6005441|NCT00085644|9599690|FG000|Double-Blind Period|Withdrawal by Subject|3
6005442|NCT00085644|9599691|FG001|Double-Blind Period|Withdrawal by Subject|0
6005443|NCT00085644|9599692|FG002|Double-Blind Period|Withdrawal by Subject|0
6005444|NCT00085644|9599690|FG000|Double-Blind Period|Lost to Follow-up|2
6005445|NCT00085644|9599691|FG001|Double-Blind Period|Lost to Follow-up|1
6005446|NCT00085644|9599692|FG002|Double-Blind Period|Lost to Follow-up|0
6005447|NCT00085644|9599690|FG000|Double-Blind Period|Lack/loss of efficacy|2
6005448|NCT00085644|9599691|FG001|Double-Blind Period|Lack/loss of efficacy|2
6005449|NCT00085644|9599692|FG002|Double-Blind Period|Lack/loss of efficacy|0
6005450|NCT00085644|9599690|FG000|Double-Blind Period|Contemplating pregnancy|1
6005451|NCT00085644|9599691|FG001|Double-Blind Period|Contemplating pregnancy|0
6005452|NCT00085644|9599692|FG002|Double-Blind Period|Contemplating pregnancy|0
6005453|NCT00085644|9599690|FG000|Double-Blind Period|Undiagnosed pre-existing condition|0
6005454|NCT00085644|9599691|FG001|Double-Blind Period|Undiagnosed pre-existing condition|1
6005455|NCT00085644|9599692|FG002|Double-Blind Period|Undiagnosed pre-existing condition|0
6005456|NCT00085644|9599690|FG000|Open-Label Period|Adverse Event|0
6005457|NCT00085644|9599691|FG001|Open-Label Period|Adverse Event|0
6005458|NCT00085644|9599692|FG002|Open-Label Period|Adverse Event|38
6005459|NCT00085644|9599690|FG000|Open-Label Period|Withdrawal by Subject|0
6005460|NCT00085644|9599691|FG001|Open-Label Period|Withdrawal by Subject|0
6005461|NCT00085644|9599692|FG002|Open-Label Period|Withdrawal by Subject|29
6005462|NCT00085644|9599690|FG000|Open-Label Period|Lost to Follow-up|0
6005463|NCT00085644|9599691|FG001|Open-Label Period|Lost to Follow-up|0
6005464|NCT00085644|9599692|FG002|Open-Label Period|Lost to Follow-up|13
6005465|NCT00085644|9599690|FG000|Open-Label Period|Lack of Efficacy|0
6005466|NCT00085644|9599691|FG001|Open-Label Period|Lack of Efficacy|0
6005467|NCT00085644|9599692|FG002|Open-Label Period|Lack of Efficacy|15
6005468|NCT00085644|9599690|FG000|Open-Label Period|Pregnancy|0
6005469|NCT00085644|9599691|FG001|Open-Label Period|Pregnancy|0
6005470|NCT00085644|9599692|FG002|Open-Label Period|Pregnancy|3
6005471|NCT00085644|9599690|FG000|Open-Label Period|Contemplating pregnancy|0
6005472|NCT00085644|9599691|FG001|Open-Label Period|Contemplating pregnancy|0
6005473|NCT00085644|9599692|FG002|Open-Label Period|Contemplating pregnancy|3
6005474|NCT00085644|9599690|FG000|Open-Label Period|Protocol Violation|0
6005475|NCT00085644|9599691|FG001|Open-Label Period|Protocol Violation|0
6005476|NCT00085644|9599692|FG002|Open-Label Period|Protocol Violation|4
6005477|NCT00085644|9599690|FG000|Open-Label Period|Personal reason|0
6005478|NCT00085644|9599691|FG001|Open-Label Period|Personal reason|0
6005479|NCT00085644|9599692|FG002|Open-Label Period|Personal reason|4
6005480|NCT00085709|9599701|FG000|Overall Study|Adverse Event|8
6005481|NCT00085709|9599702|FG001|Overall Study|Adverse Event|0
6005482|NCT00085709|9599701|FG000|Overall Study|Death|8
6005483|NCT00085709|9599702|FG001|Overall Study|Death|2
6005484|NCT00085709|9599701|FG000|Overall Study|Refusal unrelated to adverse events|1
6005485|NCT00085709|9599702|FG001|Overall Study|Refusal unrelated to adverse events|2
6005486|NCT00085709|9599701|FG000|Overall Study|Progression|3
6005487|NCT00085709|9599702|FG001|Overall Study|Progression|4
6005488|NCT00085709|9599701|FG000|Overall Study|Not protocol specified|12
6005489|NCT00085709|9599702|FG001|Overall Study|Not protocol specified|22
6005490|NCT00085709|9599701|FG000|Overall Study|Not eligible|19
6005491|NCT00085709|9599702|FG001|Overall Study|Not eligible|19
6005492|NCT00085709|9599701|FG000|Overall Study|Withdrawal by Subject|2
6005493|NCT00085709|9599702|FG001|Overall Study|Withdrawal by Subject|1
6005494|NCT00085917|9599727|FG000|Overall Study|Adverse Event|4
6005495|NCT00085917|9599728|FG001|Overall Study|Adverse Event|3
6005496|NCT00086047|9599736|FG000|Overall Study|Lost to Follow-up|7
6005497|NCT00086047|9599737|FG001|Overall Study|Lost to Follow-up|6
6005498|NCT00086047|9599736|FG000|Overall Study|Physician Decision|0
6005499|NCT00086047|9599737|FG001|Overall Study|Physician Decision|1
6005500|NCT00086190|9599755|FG000|Overall Study|Adverse Event|6
6005501|NCT00086190|9599756|FG001|Overall Study|Adverse Event|2
6005502|NCT00086190|9599757|FG002|Overall Study|Adverse Event|2
6005503|NCT00086190|9599755|FG000|Overall Study|Withdrawal by Subject|0
6005504|NCT00086190|9599756|FG001|Overall Study|Withdrawal by Subject|2
6005505|NCT00086190|9599757|FG002|Overall Study|Withdrawal by Subject|2
6005506|NCT00086190|9599755|FG000|Overall Study|Protocol Violation|1
6005507|NCT00086190|9599756|FG001|Overall Study|Protocol Violation|0
6005508|NCT00086190|9599757|FG002|Overall Study|Protocol Violation|0
6005509|NCT00086190|9599755|FG000|Overall Study|Moved|1
6005510|NCT00086190|9599756|FG001|Overall Study|Moved|0
6005511|NCT00086190|9599757|FG002|Overall Study|Moved|0
6005512|NCT00086190|9599755|FG000|Overall Study|Worsening depression|0
6005513|NCT00086190|9599756|FG001|Overall Study|Worsening depression|0
6005514|NCT00086190|9599757|FG002|Overall Study|Worsening depression|2
6005515|NCT00086281|9599780|FG000|Phase 1|Adverse Event|0
6005516|NCT00086281|9599781|FG001|Phase 1|Adverse Event|0
6005517|NCT00086281|9599782|FG002|Phase 1|Adverse Event|0
6005518|NCT00086281|9599783|FG003|Phase 1|Adverse Event|0
6005519|NCT00086281|9599784|FG004|Phase 1|Adverse Event|0
6005520|NCT00086281|9599785|FG005|Phase 1|Adverse Event|0
6005521|NCT00086281|9599786|FG006|Phase 1|Adverse Event|0
6005522|NCT00086281|9599787|FG007|Phase 1|Adverse Event|0
6005523|NCT00086281|9599788|FG008|Phase 1|Adverse Event|0
6005524|NCT00086281|9599789|FG009|Phase 1|Adverse Event|1
6005525|NCT00086281|9599790|FG010|Phase 1|Adverse Event|2
6005526|NCT00086281|9599791|FG011|Phase 1|Adverse Event|1
6005527|NCT00086281|9599792|FG012|Phase 1|Adverse Event|1
6005528|NCT00086281|9599793|FG013|Phase 1|Adverse Event|1
6005529|NCT00086281|9599794|FG014|Phase 1|Adverse Event|2
6005530|NCT00086281|9599780|FG000|Phase 1|Protocol Violation|0
6005531|NCT00086281|9599781|FG001|Phase 1|Protocol Violation|0
6005532|NCT00086281|9599782|FG002|Phase 1|Protocol Violation|0
6005533|NCT00086281|9599783|FG003|Phase 1|Protocol Violation|0
6005534|NCT00086281|9599784|FG004|Phase 1|Protocol Violation|0
6005535|NCT00086281|9599785|FG005|Phase 1|Protocol Violation|0
6005536|NCT00086281|9599786|FG006|Phase 1|Protocol Violation|0
6005537|NCT00086281|9599787|FG007|Phase 1|Protocol Violation|0
6005538|NCT00086281|9599788|FG008|Phase 1|Protocol Violation|0
6005539|NCT00086281|9599789|FG009|Phase 1|Protocol Violation|0
6005540|NCT00086281|9599790|FG010|Phase 1|Protocol Violation|1
6005541|NCT00086281|9599791|FG011|Phase 1|Protocol Violation|0
6005542|NCT00086281|9599792|FG012|Phase 1|Protocol Violation|0
6005543|NCT00086281|9599793|FG013|Phase 1|Protocol Violation|0
6005544|NCT00086281|9599794|FG014|Phase 1|Protocol Violation|0
6005545|NCT00086281|9599780|FG000|Phase 1|Serious Adverse Event|0
6005546|NCT00086281|9599781|FG001|Phase 1|Serious Adverse Event|0
6005547|NCT00086281|9599782|FG002|Phase 1|Serious Adverse Event|0
6005548|NCT00086281|9599783|FG003|Phase 1|Serious Adverse Event|0
6005549|NCT00086281|9599784|FG004|Phase 1|Serious Adverse Event|0
6005550|NCT00086281|9599785|FG005|Phase 1|Serious Adverse Event|0
6005551|NCT00086281|9599786|FG006|Phase 1|Serious Adverse Event|0
6005552|NCT00086281|9599787|FG007|Phase 1|Serious Adverse Event|0
6005553|NCT00086281|9599788|FG008|Phase 1|Serious Adverse Event|0
6005554|NCT00086281|9599789|FG009|Phase 1|Serious Adverse Event|0
6005555|NCT00086281|9599790|FG010|Phase 1|Serious Adverse Event|0
6005556|NCT00086281|9599791|FG011|Phase 1|Serious Adverse Event|0
6005557|NCT00086281|9599792|FG012|Phase 1|Serious Adverse Event|0
6005558|NCT00086281|9599793|FG013|Phase 1|Serious Adverse Event|0
6005559|NCT00086281|9599794|FG014|Phase 1|Serious Adverse Event|1
6005560|NCT00086281|9599780|FG000|Phase 2|Adverse Event|0
6005561|NCT00086281|9599781|FG001|Phase 2|Adverse Event|0
6005562|NCT00086281|9599782|FG002|Phase 2|Adverse Event|0
6005563|NCT00086281|9599783|FG003|Phase 2|Adverse Event|0
6005564|NCT00086281|9599784|FG004|Phase 2|Adverse Event|0
6005565|NCT00086281|9599785|FG005|Phase 2|Adverse Event|0
6005566|NCT00086281|9599786|FG006|Phase 2|Adverse Event|0
6005567|NCT00086281|9599787|FG007|Phase 2|Adverse Event|0
6005568|NCT00086281|9599788|FG008|Phase 2|Adverse Event|0
6005569|NCT00086281|9599789|FG009|Phase 2|Adverse Event|0
6005570|NCT00086281|9599790|FG010|Phase 2|Adverse Event|0
6005571|NCT00086281|9599791|FG011|Phase 2|Adverse Event|0
6005572|NCT00086281|9599792|FG012|Phase 2|Adverse Event|1
6005573|NCT00086281|9599793|FG013|Phase 2|Adverse Event|1
6005574|NCT00086281|9599794|FG014|Phase 2|Adverse Event|0
6047320|NCT00410410|9646254|FG005|Maintenance Period (MP)|Withdrawal by Subject|0
6047321|NCT00410410|9646255|FG006|Maintenance Period (MP)|Withdrawal by Subject|1
6047322|NCT00410410|9646256|FG007|Maintenance Period (MP)|Withdrawal by Subject|1
6047323|NCT00410410|9646257|FG008|Maintenance Period (MP)|Withdrawal by Subject|0
6047324|NCT00410410|9646249|FG000|Maintenance Period (MP)|Administrative Reason By Sponsor|0
6047325|NCT00410410|9646250|FG001|Maintenance Period (MP)|Administrative Reason By Sponsor|0
6047326|NCT00410410|9646251|FG002|Maintenance Period (MP)|Administrative Reason By Sponsor|0
6047327|NCT00410410|9646252|FG003|Maintenance Period (MP)|Administrative Reason By Sponsor|0
6047328|NCT00410410|9646253|FG004|Maintenance Period (MP)|Administrative Reason By Sponsor|0
6047329|NCT00410410|9646254|FG005|Maintenance Period (MP)|Administrative Reason By Sponsor|0
6047330|NCT00410410|9646255|FG006|Maintenance Period (MP)|Administrative Reason By Sponsor|21
6047331|NCT00410410|9646256|FG007|Maintenance Period (MP)|Administrative Reason By Sponsor|25
6047332|NCT00410410|9646257|FG008|Maintenance Period (MP)|Administrative Reason By Sponsor|0
6047333|NCT00410410|9646249|FG000|Open-Label Period (OL)|Death|0
6047334|NCT00410410|9646250|FG001|Open-Label Period (OL)|Death|0
6047335|NCT00410410|9646251|FG002|Open-Label Period (OL)|Death|0
6047336|NCT00410410|9646252|FG003|Open-Label Period (OL)|Death|0
6047337|NCT00410410|9646253|FG004|Open-Label Period (OL)|Death|0
6047338|NCT00410410|9646254|FG005|Open-Label Period (OL)|Death|0
6047339|NCT00410410|9646255|FG006|Open-Label Period (OL)|Death|0
6047340|NCT00410410|9646256|FG007|Open-Label Period (OL)|Death|0
6047341|NCT00410410|9646257|FG008|Open-Label Period (OL)|Death|1
6047342|NCT00410410|9646249|FG000|Open-Label Period (OL)|Adverse Event|0
6047343|NCT00410410|9646250|FG001|Open-Label Period (OL)|Adverse Event|0
6047344|NCT00410410|9646251|FG002|Open-Label Period (OL)|Adverse Event|0
6047345|NCT00410410|9646252|FG003|Open-Label Period (OL)|Adverse Event|0
6047346|NCT00410410|9646253|FG004|Open-Label Period (OL)|Adverse Event|0
6047347|NCT00410410|9646254|FG005|Open-Label Period (OL)|Adverse Event|0
6047348|NCT00410410|9646255|FG006|Open-Label Period (OL)|Adverse Event|0
6047349|NCT00410410|9646256|FG007|Open-Label Period (OL)|Adverse Event|0
6047350|NCT00410410|9646257|FG008|Open-Label Period (OL)|Adverse Event|10
6047351|NCT00410410|9646249|FG000|Open-Label Period (OL)|Lack of Efficacy|0
6047352|NCT00410410|9646250|FG001|Open-Label Period (OL)|Lack of Efficacy|0
6047353|NCT00410410|9646251|FG002|Open-Label Period (OL)|Lack of Efficacy|0
6047354|NCT00410410|9646252|FG003|Open-Label Period (OL)|Lack of Efficacy|0
6005575|NCT00086307|9599807|FG000|Overall Study|Lack of Efficacy|1
6005576|NCT00086307|9599808|FG001|Overall Study|Lack of Efficacy|1
6005577|NCT00086307|9599809|FG002|Overall Study|Lack of Efficacy|2
6005578|NCT00086307|9599807|FG000|Overall Study|Shortness of breath and muscle spasms|1
6005579|NCT00086307|9599808|FG001|Overall Study|Shortness of breath and muscle spasms|0
6005580|NCT00086307|9599809|FG002|Overall Study|Shortness of breath and muscle spasms|0
6005581|NCT00086307|9599807|FG000|Overall Study|Nausea and headaches|0
6005582|NCT00086307|9599808|FG001|Overall Study|Nausea and headaches|0
6005583|NCT00086307|9599809|FG002|Overall Study|Nausea and headaches|1
6005584|NCT00086307|9599807|FG000|Overall Study|Constipation and sleepiness|0
6005585|NCT00086307|9599808|FG001|Overall Study|Constipation and sleepiness|0
6005586|NCT00086307|9599809|FG002|Overall Study|Constipation and sleepiness|1
6005587|NCT00086307|9599807|FG000|Overall Study|Suicidal ideation|0
6005588|NCT00086307|9599808|FG001|Overall Study|Suicidal ideation|0
6005589|NCT00086307|9599809|FG002|Overall Study|Suicidal ideation|1
6005590|NCT00086307|9599807|FG000|Overall Study|Fatigue and difficulty falling asleep|0
6005591|NCT00086307|9599808|FG001|Overall Study|Fatigue and difficulty falling asleep|0
6005592|NCT00086307|9599809|FG002|Overall Study|Fatigue and difficulty falling asleep|1
6005593|NCT00086307|9599807|FG000|Overall Study|Withdrawal by Subject|0
6005594|NCT00086307|9599808|FG001|Overall Study|Withdrawal by Subject|0
6005595|NCT00086307|9599809|FG002|Overall Study|Withdrawal by Subject|2
6005596|NCT00086346|9599819|FG000|Randomization|Did not receive test article|4
6005597|NCT00086346|9599820|FG001|Randomization|Did not receive test article|4
6005598|NCT00086346|9599819|FG000|Patients Dosed With Test Article|Adverse Event|94
6005599|NCT00086346|9599820|FG001|Patients Dosed With Test Article|Adverse Event|11
6005600|NCT00086346|9599819|FG000|Patients Dosed With Test Article|Lost to Follow-up|1
6005601|NCT00086346|9599820|FG001|Patients Dosed With Test Article|Lost to Follow-up|3
6005602|NCT00086346|9599819|FG000|Patients Dosed With Test Article|Nonmedical event|7
6005603|NCT00086346|9599820|FG001|Patients Dosed With Test Article|Nonmedical event|3
6005604|NCT00086346|9599819|FG000|Patients Dosed With Test Article|Withdrawal by Subject|16
6005605|NCT00086346|9599820|FG001|Patients Dosed With Test Article|Withdrawal by Subject|3
6005606|NCT00086346|9599819|FG000|Patients Dosed With Test Article|Protocol Violation|11
6005607|NCT00086346|9599820|FG001|Patients Dosed With Test Article|Protocol Violation|3
6005608|NCT00086346|9599819|FG000|Patients Dosed With Test Article|Lack of Efficacy|11
6005609|NCT00086346|9599820|FG001|Patients Dosed With Test Article|Lack of Efficacy|0
6005610|NCT00086385|9599830|FG000|Overall Study|Death|2
6005611|NCT00086385|9599831|FG001|Overall Study|Death|2
6005612|NCT00086385|9599832|FG002|Overall Study|Death|1
6005613|NCT00086385|9599833|FG003|Overall Study|Death|1
6005614|NCT00086411|9599847|FG000|Overall Study|Lost to Follow-up|11
6005615|NCT00086411|9599848|FG001|Overall Study|Lost to Follow-up|11
6005616|NCT00086411|9599849|FG002|Overall Study|Lost to Follow-up|13
6005617|NCT00086411|9599850|FG003|Overall Study|Lost to Follow-up|12
6005618|NCT00086502|9599872|FG000|Overall Study|Adverse Event|11
6005619|NCT00086502|9599873|FG001|Overall Study|Adverse Event|2
6005620|NCT00086502|9599872|FG000|Overall Study|Lack of Efficacy|0
6005621|NCT00086502|9599873|FG001|Overall Study|Lack of Efficacy|2
6005622|NCT00086502|9599872|FG000|Overall Study|Lost to Follow-up|3
6005623|NCT00086502|9599873|FG001|Overall Study|Lost to Follow-up|1
6005624|NCT00086502|9599872|FG000|Overall Study|Physician Decision|1
6005625|NCT00086502|9599873|FG001|Overall Study|Physician Decision|1
6005626|NCT00086502|9599872|FG000|Overall Study|Pregnancy|0
6005627|NCT00086502|9599873|FG001|Overall Study|Pregnancy|1
6005628|NCT00086502|9599872|FG000|Overall Study|Protocol Violation|3
6005629|NCT00086502|9599873|FG001|Overall Study|Protocol Violation|3
6005630|NCT00086502|9599872|FG000|Overall Study|Withdrawal by Subject|5
6005631|NCT00086502|9599873|FG001|Overall Study|Withdrawal by Subject|6
6005632|NCT00086502|9599872|FG000|Overall Study|Patient Moved|1
6005633|NCT00086502|9599873|FG001|Overall Study|Patient Moved|1
6005634|NCT00086502|9599872|FG000|Overall Study|Protocol Discontinuation Criteria|1
6005635|NCT00086502|9599873|FG001|Overall Study|Protocol Discontinuation Criteria|3
6005636|NCT00086502|9599872|FG000|Overall Study|Patient Accidentally Unblinded|1
6005637|NCT00086502|9599873|FG001|Overall Study|Patient Accidentally Unblinded|0
6005638|NCT00086515|9599881|FG000|Phase A (Weeks 0-24)|Adverse Event|17
6005639|NCT00086515|9599882|FG001|Phase A (Weeks 0-24)|Adverse Event|9
6005640|NCT00086515|9599881|FG000|Phase A (Weeks 0-24)|Lack of Efficacy|7
6005641|NCT00086515|9599882|FG001|Phase A (Weeks 0-24)|Lack of Efficacy|13
6005642|NCT00086515|9599881|FG000|Phase A (Weeks 0-24)|Lost to Follow-up|4
6005643|NCT00086515|9599882|FG001|Phase A (Weeks 0-24)|Lost to Follow-up|5
6005644|NCT00086515|9599881|FG000|Phase A (Weeks 0-24)|Protocol Violation|3
6005645|NCT00086515|9599882|FG001|Phase A (Weeks 0-24)|Protocol Violation|1
6005646|NCT00086515|9599881|FG000|Phase A (Weeks 0-24)|Withdrawal by Subject|10
6005647|NCT00086515|9599882|FG001|Phase A (Weeks 0-24)|Withdrawal by Subject|10
6005648|NCT00086515|9599881|FG000|Phase A (Weeks 0-24)|Patient Moved|2
6005649|NCT00086515|9599882|FG001|Phase A (Weeks 0-24)|Patient Moved|3
6005650|NCT00086515|9599881|FG000|Phase A (Weeks 0-24)|Protocol-Spec lab discon criteria|4
6005651|NCT00086515|9599882|FG001|Phase A (Weeks 0-24)|Protocol-Spec lab discon criteria|3
6005652|NCT00086515|9599881|FG000|Phase A (Weeks 0-24)|Poor compliance|1
6005653|NCT00086515|9599882|FG001|Phase A (Weeks 0-24)|Poor compliance|0
6005654|NCT00086515|9599881|FG000|Phase A (Weeks 0-24)|Patient needed prohibited treatment|0
6005655|NCT00086515|9599882|FG001|Phase A (Weeks 0-24)|Patient needed prohibited treatment|1
6005656|NCT00086515|9599881|FG000|Phase A (Weeks 0-24)|Personal Circumstance|1
6005657|NCT00086515|9599882|FG001|Phase A (Weeks 0-24)|Personal Circumstance|0
6005658|NCT00086515|9599881|FG000|Phase A to Phase B Transition Period|Adverse Event|2
6005659|NCT00086515|9599882|FG001|Phase A to Phase B Transition Period|Adverse Event|1
6005660|NCT00086515|9599881|FG000|Phase A to Phase B Transition Period|Lack of Efficacy|2
6005661|NCT00086515|9599882|FG001|Phase A to Phase B Transition Period|Lack of Efficacy|2
6005662|NCT00086515|9599881|FG000|Phase A to Phase B Transition Period|Withdrawal by Subject|1
6005663|NCT00086515|9599882|FG001|Phase A to Phase B Transition Period|Withdrawal by Subject|0
6005664|NCT00086515|9599881|FG000|Phase A to Phase B Transition Period|Protocol Violation|0
6005665|NCT00086515|9599882|FG001|Phase A to Phase B Transition Period|Protocol Violation|1
6005666|NCT00086515|9599881|FG000|Phase A to Phase B Transition Period|Patient received Phase A rescue therapy|16
6005667|NCT00086515|9599882|FG001|Phase A to Phase B Transition Period|Patient received Phase A rescue therapy|23
6005668|NCT00086515|9599881|FG000|Phase A to Phase B Transition Period|Protocol-Spec lab discon criteria|1
6005669|NCT00086515|9599882|FG001|Phase A to Phase B Transition Period|Protocol-Spec lab discon criteria|1
6005670|NCT00086515|9599881|FG000|Phase A to Phase B Transition Period|Poor compliance|1
6005671|NCT00086515|9599882|FG001|Phase A to Phase B Transition Period|Poor compliance|0
6005672|NCT00086515|9599881|FG000|Phase A to Phase B Transition Period|Patient needed prohibited treatment|1
6005673|NCT00086515|9599882|FG001|Phase A to Phase B Transition Period|Patient needed prohibited treatment|0
6005674|NCT00086515|9599881|FG000|Phase B (Weeks 24-104)|Adverse Event|16
6005675|NCT00086515|9599882|FG001|Phase B (Weeks 24-104)|Adverse Event|10
6005676|NCT00086515|9599881|FG000|Phase B (Weeks 24-104)|Lack of Efficacy|94
6005677|NCT00086515|9599882|FG001|Phase B (Weeks 24-104)|Lack of Efficacy|19
6005678|NCT00086515|9599881|FG000|Phase B (Weeks 24-104)|Lost to Follow-up|13
6005679|NCT00086515|9599882|FG001|Phase B (Weeks 24-104)|Lost to Follow-up|4
6005680|NCT00086515|9599881|FG000|Phase B (Weeks 24-104)|Physician Decision|3
6005681|NCT00086515|9599882|FG001|Phase B (Weeks 24-104)|Physician Decision|0
6005682|NCT00086515|9599881|FG000|Phase B (Weeks 24-104)|Protocol Violation|1
6005683|NCT00086515|9599882|FG001|Phase B (Weeks 24-104)|Protocol Violation|0
6005684|NCT00086515|9599881|FG000|Phase B (Weeks 24-104)|Withdrawal by Subject|15
6005685|NCT00086515|9599882|FG001|Phase B (Weeks 24-104)|Withdrawal by Subject|5
6005686|NCT00086515|9599881|FG000|Phase B (Weeks 24-104)|Patient Moved|2
6005687|NCT00086515|9599882|FG001|Phase B (Weeks 24-104)|Patient Moved|2
6005688|NCT00086515|9599881|FG000|Phase B (Weeks 24-104)|Protocol-Specific discontinuation|5
6005689|NCT00086515|9599882|FG001|Phase B (Weeks 24-104)|Protocol-Specific discontinuation|3
6005690|NCT00086515|9599881|FG000|Phase B (Weeks 24-104)|Protocol-Specific lab discon criteria|36
6005691|NCT00086515|9599882|FG001|Phase B (Weeks 24-104)|Protocol-Specific lab discon criteria|10
6005692|NCT00086515|9599881|FG000|Phase B (Weeks 24-104)|Patient Died|3
6005693|NCT00086515|9599882|FG001|Phase B (Weeks 24-104)|Patient Died|1
6005694|NCT00086515|9599881|FG000|Phase B (Weeks 24-104)|Patient needed prohibited treatment|0
6005695|NCT00086515|9599882|FG001|Phase B (Weeks 24-104)|Patient needed prohibited treatment|1
6005696|NCT00086515|9599881|FG000|Phase B (Weeks 24-104)|Personal Circumstance|1
6005697|NCT00086515|9599882|FG001|Phase B (Weeks 24-104)|Personal Circumstance|0
6005698|NCT00086515|9599881|FG000|Phase B (Weeks 24-104)|Discontinued in error|1
6005699|NCT00086515|9599882|FG001|Phase B (Weeks 24-104)|Discontinued in error|0
6005700|NCT00086580|9599890|FG000|Treatment Period|Disease progression|9
6005701|NCT00086580|9599891|FG001|Treatment Period|Disease progression|8
6005702|NCT00086580|9599890|FG000|Treatment Period|Unable to comply with protocol|3
6005703|NCT00086580|9599891|FG001|Treatment Period|Unable to comply with protocol|1
6005704|NCT00086580|9599890|FG000|Treatment Period|Withdrawal by Subject|7
6005705|NCT00086580|9599891|FG001|Treatment Period|Withdrawal by Subject|8
6005706|NCT00086580|9599890|FG000|Treatment Period|Physician Decision|13
6005707|NCT00086580|9599891|FG001|Treatment Period|Physician Decision|7
6005708|NCT00086580|9599890|FG000|Treatment Period|AE - not treatment related|7
6005709|NCT00086580|9599891|FG001|Treatment Period|AE - not treatment related|7
6005710|NCT00086580|9599890|FG000|Treatment Period|Toxicity - treatment related|15
6005711|NCT00086580|9599891|FG001|Treatment Period|Toxicity - treatment related|15
6005712|NCT00086580|9599890|FG000|Treatment Period|Anemia or thrombocytopenia|1
6005713|NCT00086580|9599891|FG001|Treatment Period|Anemia or thrombocytopenia|4
6005714|NCT00086580|9599890|FG000|Treatment Period|Death|5
6005715|NCT00086580|9599891|FG001|Treatment Period|Death|7
6005716|NCT00086580|9599890|FG000|Treatment Period|Other|5
6005717|NCT00086580|9599891|FG001|Treatment Period|Other|3
6005718|NCT00086580|9599890|FG000|Follow-up Period|Disease progression|72
6005719|NCT00086580|9599891|FG001|Follow-up Period|Disease progression|99
6005720|NCT00086580|9599890|FG000|Follow-up Period|Unable to comply with protocol|5
6005721|NCT00086580|9599891|FG001|Follow-up Period|Unable to comply with protocol|0
6005722|NCT00086580|9599890|FG000|Follow-up Period|Withdrawal by Subject|6
6005723|NCT00086580|9599891|FG001|Follow-up Period|Withdrawal by Subject|6
6005724|NCT00086580|9599890|FG000|Follow-up Period|Physician Decision|0
6005725|NCT00086580|9599891|FG001|Follow-up Period|Physician Decision|1
6005726|NCT00086580|9599890|FG000|Follow-up Period|AE - not related|1
6005727|NCT00086580|9599891|FG001|Follow-up Period|AE - not related|0
6005728|NCT00086580|9599890|FG000|Follow-up Period|Death|13
6005729|NCT00086580|9599891|FG001|Follow-up Period|Death|7
6005730|NCT00086580|9599890|FG000|Follow-up Period|Other|7
6005731|NCT00086580|9599891|FG001|Follow-up Period|Other|6
6005732|NCT00086580|9599890|FG000|Observation Period|Unable to comply with protocol|1
6005733|NCT00086580|9599891|FG001|Observation Period|Unable to comply with protocol|1
6005734|NCT00086580|9599890|FG000|Observation Period|Withdrawal by Subject|4
6005735|NCT00086580|9599891|FG001|Observation Period|Withdrawal by Subject|2
6005736|NCT00086580|9599890|FG000|Observation Period|Death|33
6005737|NCT00086580|9599891|FG001|Observation Period|Death|55
6005738|NCT00086580|9599890|FG000|Observation Period|Other|8
6005739|NCT00086580|9599891|FG001|Observation Period|Other|7
6005740|NCT00086619|9599899|FG000|Overall Study|Withdrawal by Subject|6
6005741|NCT00086619|9599900|FG001|Overall Study|Withdrawal by Subject|6
6005742|NCT00086619|9599899|FG000|Overall Study|Adverse Event|8
6005743|NCT00086619|9599900|FG001|Overall Study|Adverse Event|10
6005744|NCT00086619|9599899|FG000|Overall Study|Protocol Violation|1
6005745|NCT00086619|9599900|FG001|Overall Study|Protocol Violation|1
6005746|NCT00086684|9599909|FG000|Overall Study|Adverse Event|12
6005747|NCT00086684|9599910|FG001|Overall Study|Adverse Event|17
6005748|NCT00086684|9599911|FG002|Overall Study|Adverse Event|14
6005749|NCT00086684|9599909|FG000|Overall Study|Lack of Efficacy|6
6005750|NCT00086684|9599910|FG001|Overall Study|Lack of Efficacy|6
6005751|NCT00086684|9599911|FG002|Overall Study|Lack of Efficacy|5
6005752|NCT00086684|9599909|FG000|Overall Study|Lost to Follow-up|15
6005753|NCT00086684|9599910|FG001|Overall Study|Lost to Follow-up|8
6005754|NCT00086684|9599911|FG002|Overall Study|Lost to Follow-up|10
6074183|NCT00572195|9678088|FG000|Overall Study|Adverse Event|4
6074184|NCT00572195|9678088|FG000|Overall Study|Lost to Follow-up|5
6074185|NCT00572455|9678115|FG000|Stage I (14 Days)|Adverse Event|0
6074186|NCT00572455|9678116|FG001|Stage I (14 Days)|Adverse Event|0
6074187|NCT00572455|9678117|FG002|Stage I (14 Days)|Adverse Event|0
6074188|NCT00572455|9678118|FG003|Stage I (14 Days)|Adverse Event|0
6074189|NCT00572455|9678119|FG004|Stage I (14 Days)|Adverse Event|0
6074190|NCT00572455|9678120|FG005|Stage I (14 Days)|Adverse Event|3
6074191|NCT00572455|9678121|FG006|Stage I (14 Days)|Adverse Event|0
6074192|NCT00572455|9678122|FG007|Stage I (14 Days)|Adverse Event|0
6074193|NCT00572455|9678123|FG008|Stage I (14 Days)|Adverse Event|0
6074194|NCT00572455|9678124|FG009|Stage I (14 Days)|Adverse Event|0
6074195|NCT00572455|9678125|FG010|Stage I (14 Days)|Adverse Event|0
6074196|NCT00572455|9678126|FG011|Stage I (14 Days)|Adverse Event|0
6074197|NCT00572455|9678127|FG012|Stage I (14 Days)|Adverse Event|0
6074198|NCT00572455|9678128|FG013|Stage I (14 Days)|Adverse Event|0
6074199|NCT00572455|9678115|FG000|Stage I (14 Days)|Other|0
6074200|NCT00572455|9678116|FG001|Stage I (14 Days)|Other|0
6074201|NCT00572455|9678117|FG002|Stage I (14 Days)|Other|0
6074202|NCT00572455|9678118|FG003|Stage I (14 Days)|Other|0
6074203|NCT00572455|9678119|FG004|Stage I (14 Days)|Other|1
6074204|NCT00572455|9678120|FG005|Stage I (14 Days)|Other|0
6074205|NCT00572455|9678121|FG006|Stage I (14 Days)|Other|0
6074206|NCT00572455|9678122|FG007|Stage I (14 Days)|Other|0
6074207|NCT00572455|9678123|FG008|Stage I (14 Days)|Other|0
6074208|NCT00572455|9678124|FG009|Stage I (14 Days)|Other|0
6074209|NCT00572455|9678125|FG010|Stage I (14 Days)|Other|0
6074210|NCT00572455|9678126|FG011|Stage I (14 Days)|Other|0
6074211|NCT00572455|9678127|FG012|Stage I (14 Days)|Other|0
6074212|NCT00572455|9678128|FG013|Stage I (14 Days)|Other|0
6074213|NCT00572455|9678115|FG000|Stage II (28 Days)|Adverse Event|0
6074214|NCT00572455|9678116|FG001|Stage II (28 Days)|Adverse Event|0
6074215|NCT00572455|9678117|FG002|Stage II (28 Days)|Adverse Event|0
6074216|NCT00572455|9678118|FG003|Stage II (28 Days)|Adverse Event|0
6074217|NCT00572455|9678119|FG004|Stage II (28 Days)|Adverse Event|0
6074218|NCT00572455|9678120|FG005|Stage II (28 Days)|Adverse Event|0
6074219|NCT00572455|9678121|FG006|Stage II (28 Days)|Adverse Event|0
6074220|NCT00572455|9678122|FG007|Stage II (28 Days)|Adverse Event|0
6074221|NCT00572455|9678123|FG008|Stage II (28 Days)|Adverse Event|1
6074222|NCT00572455|9678124|FG009|Stage II (28 Days)|Adverse Event|3
6074223|NCT00572455|9678125|FG010|Stage II (28 Days)|Adverse Event|3
6074224|NCT00572455|9678126|FG011|Stage II (28 Days)|Adverse Event|4
6074225|NCT00572455|9678127|FG012|Stage II (28 Days)|Adverse Event|5
6074226|NCT00572455|9678128|FG013|Stage II (28 Days)|Adverse Event|1
6074227|NCT00572455|9678115|FG000|Stage II (28 Days)|Death|0
6074228|NCT00572455|9678116|FG001|Stage II (28 Days)|Death|0
6074229|NCT00572455|9678117|FG002|Stage II (28 Days)|Death|0
6074230|NCT00572455|9678118|FG003|Stage II (28 Days)|Death|0
6074231|NCT00572455|9678119|FG004|Stage II (28 Days)|Death|0
6074232|NCT00572455|9678120|FG005|Stage II (28 Days)|Death|0
6074233|NCT00572455|9678121|FG006|Stage II (28 Days)|Death|0
6074234|NCT00572455|9678122|FG007|Stage II (28 Days)|Death|0
6074235|NCT00572455|9678123|FG008|Stage II (28 Days)|Death|1
6005755|NCT00086684|9599909|FG000|Overall Study|Protocol Violation|8
6005756|NCT00086684|9599910|FG001|Overall Study|Protocol Violation|3
6005757|NCT00086684|9599911|FG002|Overall Study|Protocol Violation|0
6005758|NCT00086684|9599909|FG000|Overall Study|Withdrawal by Subject|0
6074236|NCT00572455|9678124|FG009|Stage II (28 Days)|Death|0
6074237|NCT00572455|9678125|FG010|Stage II (28 Days)|Death|0
6074238|NCT00572455|9678126|FG011|Stage II (28 Days)|Death|0
6074239|NCT00572455|9678127|FG012|Stage II (28 Days)|Death|0
6074240|NCT00572455|9678128|FG013|Stage II (28 Days)|Death|0
6074241|NCT00572455|9678115|FG000|Stage II (28 Days)|Withdrawal by Subject|0
6074242|NCT00572455|9678116|FG001|Stage II (28 Days)|Withdrawal by Subject|0
6005759|NCT00086684|9599910|FG001|Overall Study|Withdrawal by Subject|4
6005760|NCT00086684|9599911|FG002|Overall Study|Withdrawal by Subject|10
6005761|NCT00086684|9599909|FG000|Overall Study|NONCOMPLIANCE|5
6074243|NCT00572455|9678117|FG002|Stage II (28 Days)|Withdrawal by Subject|0
6074244|NCT00572455|9678118|FG003|Stage II (28 Days)|Withdrawal by Subject|0
6074245|NCT00572455|9678119|FG004|Stage II (28 Days)|Withdrawal by Subject|0
6074246|NCT00572455|9678120|FG005|Stage II (28 Days)|Withdrawal by Subject|0
6074247|NCT00572455|9678121|FG006|Stage II (28 Days)|Withdrawal by Subject|0
6074248|NCT00572455|9678122|FG007|Stage II (28 Days)|Withdrawal by Subject|1
6074249|NCT00572455|9678123|FG008|Stage II (28 Days)|Withdrawal by Subject|0
6074250|NCT00572455|9678124|FG009|Stage II (28 Days)|Withdrawal by Subject|0
6074251|NCT00572455|9678125|FG010|Stage II (28 Days)|Withdrawal by Subject|2
6074252|NCT00572455|9678126|FG011|Stage II (28 Days)|Withdrawal by Subject|0
6074253|NCT00572455|9678127|FG012|Stage II (28 Days)|Withdrawal by Subject|0
6074254|NCT00572455|9678128|FG013|Stage II (28 Days)|Withdrawal by Subject|0
6074255|NCT00572455|9678115|FG000|Stage II (28 Days)|Other|0
6074256|NCT00572455|9678116|FG001|Stage II (28 Days)|Other|0
6074257|NCT00572455|9678117|FG002|Stage II (28 Days)|Other|0
6074258|NCT00572455|9678118|FG003|Stage II (28 Days)|Other|0
6074259|NCT00572455|9678119|FG004|Stage II (28 Days)|Other|0
6074260|NCT00572455|9678120|FG005|Stage II (28 Days)|Other|0
6074261|NCT00572455|9678121|FG006|Stage II (28 Days)|Other|0
6074262|NCT00572455|9678122|FG007|Stage II (28 Days)|Other|0
6074263|NCT00572455|9678123|FG008|Stage II (28 Days)|Other|1
6074264|NCT00572455|9678124|FG009|Stage II (28 Days)|Other|0
6074265|NCT00572455|9678125|FG010|Stage II (28 Days)|Other|0
6074266|NCT00572455|9678126|FG011|Stage II (28 Days)|Other|0
6074267|NCT00572455|9678127|FG012|Stage II (28 Days)|Other|0
6074268|NCT00572455|9678128|FG013|Stage II (28 Days)|Other|0
6074269|NCT00572455|9678115|FG000|Stage II (28 Days)|Randomized, but not treated|0
6074270|NCT00572455|9678116|FG001|Stage II (28 Days)|Randomized, but not treated|0
6074271|NCT00572455|9678117|FG002|Stage II (28 Days)|Randomized, but not treated|0
6074272|NCT00572455|9678118|FG003|Stage II (28 Days)|Randomized, but not treated|0
6074273|NCT00572455|9678119|FG004|Stage II (28 Days)|Randomized, but not treated|0
6074274|NCT00572455|9678120|FG005|Stage II (28 Days)|Randomized, but not treated|0
6074275|NCT00572455|9678121|FG006|Stage II (28 Days)|Randomized, but not treated|0
6074276|NCT00572455|9678122|FG007|Stage II (28 Days)|Randomized, but not treated|0
6074277|NCT00572455|9678123|FG008|Stage II (28 Days)|Randomized, but not treated|0
6074278|NCT00572455|9678124|FG009|Stage II (28 Days)|Randomized, but not treated|0
6074279|NCT00572455|9678125|FG010|Stage II (28 Days)|Randomized, but not treated|0
6074280|NCT00572455|9678126|FG011|Stage II (28 Days)|Randomized, but not treated|0
6074281|NCT00572455|9678127|FG012|Stage II (28 Days)|Randomized, but not treated|0
6074282|NCT00572455|9678128|FG013|Stage II (28 Days)|Randomized, but not treated|1
6074283|NCT00572533|9678169|FG000|Overall Study|Death|4
6074284|NCT00572533|9678170|FG001|Overall Study|Death|1
6074285|NCT00572533|9678169|FG000|Overall Study|Received Kidney Transplant|2
6074286|NCT00572533|9678170|FG001|Overall Study|Received Kidney Transplant|1
6074287|NCT00572533|9678169|FG000|Overall Study|Social Issues|1
6074288|NCT00572533|9678170|FG001|Overall Study|Social Issues|0
6074289|NCT00572533|9678169|FG000|Overall Study|Transfer out of Facility|0
6074290|NCT00572533|9678170|FG001|Overall Study|Transfer out of Facility|1
6074291|NCT00572572|9678178|FG000|Overall Study|Withdrawal by Subject|3
6074292|NCT00572572|9678179|FG001|Overall Study|Withdrawal by Subject|6
6074293|NCT00572624|9678187|FG000|Overall Study|Lost to Follow-up|10
6074294|NCT00572624|9678188|FG001|Overall Study|Lost to Follow-up|4
6074295|NCT00572624|9678187|FG000|Overall Study|Wanted to do a different diet program|1
6074296|NCT00572624|9678188|FG001|Overall Study|Wanted to do a different diet program|0
6074297|NCT00572624|9678187|FG000|Overall Study|Medication change|1
6005762|NCT00086684|9599910|FG001|Overall Study|NONCOMPLIANCE|7
6005763|NCT00086684|9599911|FG002|Overall Study|NONCOMPLIANCE|6
6005764|NCT00086684|9599909|FG000|Overall Study|STUDY TERMINATED BY SPONSOR|0
6005765|NCT00086684|9599910|FG001|Overall Study|STUDY TERMINATED BY SPONSOR|1
6005766|NCT00086684|9599911|FG002|Overall Study|STUDY TERMINATED BY SPONSOR|0
6005767|NCT00086684|9599909|FG000|Overall Study|WITHDRAWAL OF CONSENT|5
6005768|NCT00086684|9599910|FG001|Overall Study|WITHDRAWAL OF CONSENT|7
6005769|NCT00086684|9599911|FG002|Overall Study|WITHDRAWAL OF CONSENT|5
6005770|NCT00086684|9599909|FG000|Overall Study|Other|4
6005771|NCT00086684|9599910|FG001|Overall Study|Other|2
6005772|NCT00086684|9599911|FG002|Overall Study|Other|3
6005773|NCT00086996|9599930|FG000|Overall Study|Adverse Event|29
6005774|NCT00086996|9599930|FG000|Overall Study|Death|4
6074298|NCT00572624|9678188|FG001|Overall Study|Medication change|0
6074299|NCT00572624|9678187|FG000|Overall Study|Started a new job-- no time for study|1
6005775|NCT00086996|9599930|FG000|Overall Study|progression/relapse|7
6005776|NCT00086996|9599930|FG000|Overall Study|Withdrawal by Subject|13
6005777|NCT00086996|9599930|FG000|Overall Study|Other|6
6005778|NCT00086996|9599930|FG000|Overall Study|not eligible|5
6074300|NCT00572624|9678188|FG001|Overall Study|Started a new job-- no time for study|0
6074301|NCT00572624|9678187|FG000|Overall Study|Admitted to being a smoker|1
6074302|NCT00572624|9678188|FG001|Overall Study|Admitted to being a smoker|0
6074303|NCT00572624|9678187|FG000|Overall Study|Refused to do the stress test|1
6074304|NCT00572624|9678188|FG001|Overall Study|Refused to do the stress test|0
6074305|NCT00572624|9678187|FG000|Overall Study|Problem with vascular access|1
6005779|NCT00087126|9599943|FG000|Overall Study|Ineligible - second primary|1
6005780|NCT00087126|9599943|FG000|Overall Study|Never treated|1
6005781|NCT00087139|9599955|FG000|Overall Study|Adverse Event|18
6005782|NCT00087139|9599956|FG001|Overall Study|Adverse Event|17
6005783|NCT00087139|9599957|FG002|Overall Study|Adverse Event|13
6005784|NCT00087139|9599955|FG000|Overall Study|Death|2
6005785|NCT00087139|9599956|FG001|Overall Study|Death|1
6005786|NCT00087139|9599957|FG002|Overall Study|Death|0
6005787|NCT00087139|9599955|FG000|Overall Study|Withdrawal by Subject|3
6005788|NCT00087139|9599956|FG001|Overall Study|Withdrawal by Subject|2
6005789|NCT00087139|9599957|FG002|Overall Study|Withdrawal by Subject|2
6005790|NCT00087139|9599955|FG000|Overall Study|Physician Decision|1
6005791|NCT00087139|9599956|FG001|Overall Study|Physician Decision|1
6005792|NCT00087139|9599957|FG002|Overall Study|Physician Decision|1
6005793|NCT00087139|9599955|FG000|Overall Study|Disease progression|9
6005794|NCT00087139|9599956|FG001|Overall Study|Disease progression|19
6005795|NCT00087139|9599957|FG002|Overall Study|Disease progression|12
6005796|NCT00087139|9599955|FG000|Overall Study|Ineligible|4
6005797|NCT00087139|9599956|FG001|Overall Study|Ineligible|7
6005798|NCT00087139|9599957|FG002|Overall Study|Ineligible|4
6005799|NCT00087139|9599955|FG000|Overall Study|Symptomatic deterioration|1
6005800|NCT00087139|9599956|FG001|Overall Study|Symptomatic deterioration|1
6005801|NCT00087139|9599957|FG002|Overall Study|Symptomatic deterioration|3
6005802|NCT00087139|9599955|FG000|Overall Study|Use of coumadin|1
6005803|NCT00087139|9599956|FG001|Overall Study|Use of coumadin|0
6005804|NCT00087139|9599957|FG002|Overall Study|Use of coumadin|0
6005805|NCT00087139|9599955|FG000|Overall Study|Response achieved|0
6005806|NCT00087139|9599956|FG001|Overall Study|Response achieved|1
6005807|NCT00087139|9599957|FG002|Overall Study|Response achieved|0
6005808|NCT00087139|9599955|FG000|Overall Study|Extradural disease|0
6005809|NCT00087139|9599956|FG001|Overall Study|Extradural disease|0
6005810|NCT00087139|9599957|FG002|Overall Study|Extradural disease|1
6005811|NCT00087152|9599963|FG000|Overall Study|Ineligible|6
6005812|NCT00087438|9599968|FG000|Overall Study|Ineligible / No protocol treatment|4
6005813|NCT00087490|9599976|FG000|Overall Study|Death|6
6005814|NCT00087490|9599977|FG001|Overall Study|Death|4
6005815|NCT00087490|9599976|FG000|Overall Study|Adverse Event|3
6005816|NCT00087490|9599977|FG001|Overall Study|Adverse Event|8
6005817|NCT00087490|9599976|FG000|Overall Study|Lack of Efficacy|0
6005818|NCT00087490|9599977|FG001|Overall Study|Lack of Efficacy|2
6005819|NCT00087490|9599976|FG000|Overall Study|Protocol Violation or (/) Unspecified|214
6005820|NCT00087490|9599977|FG001|Overall Study|Protocol Violation or (/) Unspecified|201
6005821|NCT00087490|9599976|FG000|Overall Study|Lost to Follow-Up/participant withdrawal|28
6005822|NCT00087490|9599977|FG001|Overall Study|Lost to Follow-Up/participant withdrawal|36
6005823|NCT00087490|9599976|FG000|Overall Study|Randomized but not treated|7
6005824|NCT00087490|9599977|FG001|Overall Study|Randomized but not treated|18
6005825|NCT00087516|9599986|FG000|Overall Study|Adverse Event|10
6005826|NCT00087516|9599987|FG001|Overall Study|Adverse Event|10
6005827|NCT00087516|9599988|FG002|Overall Study|Adverse Event|3
6005828|NCT00087516|9599989|FG003|Overall Study|Adverse Event|6
6005829|NCT00087516|9599986|FG000|Overall Study|Lack of Efficacy|82
6005830|NCT00087516|9599987|FG001|Overall Study|Lack of Efficacy|80
6005831|NCT00087516|9599988|FG002|Overall Study|Lack of Efficacy|39
6005832|NCT00087516|9599989|FG003|Overall Study|Lack of Efficacy|29
6005833|NCT00087516|9599986|FG000|Overall Study|Lost to Follow-up|8
6005834|NCT00087516|9599987|FG001|Overall Study|Lost to Follow-up|6
6005835|NCT00087516|9599988|FG002|Overall Study|Lost to Follow-up|5
6005836|NCT00087516|9599989|FG003|Overall Study|Lost to Follow-up|5
6005837|NCT00087516|9599986|FG000|Overall Study|Protocol Violation|4
6005838|NCT00087516|9599987|FG001|Overall Study|Protocol Violation|8
6005839|NCT00087516|9599988|FG002|Overall Study|Protocol Violation|3
6005840|NCT00087516|9599989|FG003|Overall Study|Protocol Violation|6
6005841|NCT00087516|9599986|FG000|Overall Study|Withdrawal by Subject|16
6005842|NCT00087516|9599987|FG001|Overall Study|Withdrawal by Subject|27
6005843|NCT00087516|9599988|FG002|Overall Study|Withdrawal by Subject|11
6005844|NCT00087516|9599989|FG003|Overall Study|Withdrawal by Subject|12
6005845|NCT00087516|9599986|FG000|Overall Study|Site terminated|0
6005846|NCT00087516|9599987|FG001|Overall Study|Site terminated|2
6005847|NCT00087516|9599988|FG002|Overall Study|Site terminated|1
6005848|NCT00087516|9599989|FG003|Overall Study|Site terminated|0
6005849|NCT00087516|9599986|FG000|Overall Study|Protocol specified discontinuation|35
6005850|NCT00087516|9599987|FG001|Overall Study|Protocol specified discontinuation|33
6005851|NCT00087516|9599988|FG002|Overall Study|Protocol specified discontinuation|33
6005852|NCT00087516|9599989|FG003|Overall Study|Protocol specified discontinuation|26
6005853|NCT00087516|9599986|FG000|Overall Study|Patient moved|3
6005854|NCT00087516|9599987|FG001|Overall Study|Patient moved|2
6005855|NCT00087516|9599988|FG002|Overall Study|Patient moved|1
6005856|NCT00087516|9599989|FG003|Overall Study|Patient moved|0
6005857|NCT00087516|9599986|FG000|Overall Study|Patient was non-compliant|3
6005858|NCT00087516|9599987|FG001|Overall Study|Patient was non-compliant|1
6005859|NCT00087516|9599988|FG002|Overall Study|Patient was non-compliant|0
6005860|NCT00087516|9599989|FG003|Overall Study|Patient was non-compliant|0
6005861|NCT00087516|9599986|FG000|Overall Study|Recommendation of Primary Care Physician|0
6005862|NCT00087516|9599987|FG001|Overall Study|Recommendation of Primary Care Physician|0
6005863|NCT00087516|9599988|FG002|Overall Study|Recommendation of Primary Care Physician|0
6005864|NCT00087516|9599989|FG003|Overall Study|Recommendation of Primary Care Physician|1
6005865|NCT00087516|9599986|FG000|Overall Study|Other|0
6005866|NCT00087516|9599987|FG001|Overall Study|Other|0
6005867|NCT00087516|9599988|FG002|Overall Study|Other|1
6005868|NCT00087516|9599989|FG003|Overall Study|Other|0
6005869|NCT00087529|9600005|FG000|Overall Study|Death|1
6005870|NCT00087529|9600006|FG001|Overall Study|Death|0
6005871|NCT00087529|9600005|FG000|Overall Study|Adverse Event|0
6005872|NCT00087529|9600006|FG001|Overall Study|Adverse Event|8
6005873|NCT00087529|9600005|FG000|Overall Study|Pregnancy|0
6005874|NCT00087529|9600006|FG001|Overall Study|Pregnancy|1
6005875|NCT00087529|9600005|FG000|Overall Study|Lost to Follow-up|2
6005876|NCT00087529|9600006|FG001|Overall Study|Lost to Follow-up|3
6005877|NCT00087529|9600005|FG000|Overall Study|Participant Decision|14
6005878|NCT00087529|9600006|FG001|Overall Study|Participant Decision|37
6005879|NCT00087529|9600005|FG000|Overall Study|Physician Decision|4
6005880|NCT00087529|9600006|FG001|Overall Study|Physician Decision|8
6005881|NCT00087529|9600005|FG000|Overall Study|Initiation of Excluded Therapy|0
6005882|NCT00087529|9600006|FG001|Overall Study|Initiation of Excluded Therapy|1
6005883|NCT00087529|9600005|FG000|Overall Study|Participant Noncompliance|0
6005884|NCT00087529|9600006|FG001|Overall Study|Participant Noncompliance|1
6005885|NCT00087529|9600005|FG000|Overall Study|Disease Progression|5
6005886|NCT00087529|9600006|FG001|Overall Study|Disease Progression|4
6005887|NCT00087529|9600005|FG000|Overall Study|Did Not Continue to Safety Follow-Up|5
6005888|NCT00087529|9600006|FG001|Overall Study|Did Not Continue to Safety Follow-Up|5
6005889|NCT00087555|9600015|FG000|Overall Study|Adverse Event|3
6005890|NCT00087555|9600016|FG001|Overall Study|Adverse Event|6
6005891|NCT00087555|9600017|FG002|Overall Study|Adverse Event|14
6005892|NCT00087555|9600015|FG000|Overall Study|Lost to Follow-up|0
6005893|NCT00087555|9600016|FG001|Overall Study|Lost to Follow-up|1
6005894|NCT00087555|9600017|FG002|Overall Study|Lost to Follow-up|1
6005895|NCT00087555|9600015|FG000|Overall Study|Non - Compliance|1
6005896|NCT00087555|9600016|FG001|Overall Study|Non - Compliance|0
6005897|NCT00087555|9600017|FG002|Overall Study|Non - Compliance|0
6005898|NCT00087555|9600015|FG000|Overall Study|Protocol Violation|0
6005899|NCT00087555|9600016|FG001|Overall Study|Protocol Violation|0
6005900|NCT00087555|9600017|FG002|Overall Study|Protocol Violation|2
6005901|NCT00087555|9600015|FG000|Overall Study|Screen Failure|1
6005902|NCT00087555|9600016|FG001|Overall Study|Screen Failure|1
6005903|NCT00087555|9600017|FG002|Overall Study|Screen Failure|0
6005904|NCT00087555|9600015|FG000|Overall Study|Pregnancy|0
6005905|NCT00087555|9600016|FG001|Overall Study|Pregnancy|1
6005906|NCT00087555|9600017|FG002|Overall Study|Pregnancy|1
6005907|NCT00087555|9600015|FG000|Overall Study|Withdrawal by Subject|3
6005908|NCT00087555|9600016|FG001|Overall Study|Withdrawal by Subject|2
6005909|NCT00087555|9600017|FG002|Overall Study|Withdrawal by Subject|1
6005910|NCT00087555|9600015|FG000|Overall Study|Lack of Efficacy|2
6005911|NCT00087555|9600016|FG001|Overall Study|Lack of Efficacy|0
6005912|NCT00087555|9600017|FG002|Overall Study|Lack of Efficacy|1
6005913|NCT00087555|9600015|FG000|Overall Study|Non Compliance|0
6005914|NCT00087555|9600016|FG001|Overall Study|Non Compliance|0
6005915|NCT00087555|9600017|FG002|Overall Study|Non Compliance|1
6005916|NCT00087555|9600015|FG000|Overall Study|Chronic Migraine Headaches (Med History)|1
6005917|NCT00087555|9600016|FG001|Overall Study|Chronic Migraine Headaches (Med History)|0
6005918|NCT00087555|9600017|FG002|Overall Study|Chronic Migraine Headaches (Med History)|0
6005919|NCT00087555|9600015|FG000|Overall Study|Patient wanted to go back on Med|1
6005920|NCT00087555|9600016|FG001|Overall Study|Patient wanted to go back on Med|0
6005921|NCT00087555|9600017|FG002|Overall Study|Patient wanted to go back on Med|0
6005922|NCT00087568|9600027|FG000|Overall Study|Adverse Event|4
6005923|NCT00087568|9600028|FG001|Overall Study|Adverse Event|0
6005924|NCT00087568|9600027|FG000|Overall Study|Withdrawal by Subject|1
6005925|NCT00087568|9600028|FG001|Overall Study|Withdrawal by Subject|1
6005926|NCT00087568|9600027|FG000|Overall Study|Lost to Follow-up|1
6005927|NCT00087568|9600028|FG001|Overall Study|Lost to Follow-up|0
6005928|NCT00087568|9600027|FG000|Overall Study|Lack of Efficacy|24
6005929|NCT00087568|9600028|FG001|Overall Study|Lack of Efficacy|1
6005930|NCT00087594|9600036|FG000|Overall Study|Adverse Event|2
6005931|NCT00087594|9600037|FG001|Overall Study|Adverse Event|3
6005932|NCT00087594|9600036|FG000|Overall Study|Lost to Follow-up|0
6005933|NCT00087594|9600037|FG001|Overall Study|Lost to Follow-up|2
6005934|NCT00087594|9600036|FG000|Overall Study|Withdrawal by Subject|4
6005935|NCT00087594|9600037|FG001|Overall Study|Withdrawal by Subject|2
6005936|NCT00087594|9600036|FG000|Overall Study|Lack of Efficacy|2
6005937|NCT00087594|9600037|FG001|Overall Study|Lack of Efficacy|5
6005938|NCT00087607|9600045|FG000|Overall Study|Adverse Event|14
6005939|NCT00087607|9600046|FG001|Overall Study|Adverse Event|24
6005940|NCT00087607|9600045|FG000|Overall Study|Death|0
6005941|NCT00087607|9600046|FG001|Overall Study|Death|1
6005942|NCT00087607|9600045|FG000|Overall Study|Insufficient Therapeutic Response|53
6005943|NCT00087607|9600046|FG001|Overall Study|Insufficient Therapeutic Response|42
6005944|NCT00087607|9600045|FG000|Overall Study|Failure to return|21
6005945|NCT00087607|9600046|FG001|Overall Study|Failure to return|17
6005946|NCT00087607|9600045|FG000|Overall Study|Withdrew Consent|12
6005947|NCT00087607|9600046|FG001|Overall Study|Withdrew Consent|16
6005948|NCT00087607|9600045|FG000|Overall Study|Administrative|12
6005949|NCT00087607|9600046|FG001|Overall Study|Administrative|12
6005950|NCT00087607|9600045|FG000|Overall Study|Refused Treatment|5
6005951|NCT00087607|9600046|FG001|Overall Study|Refused Treatment|7
6005952|NCT00087607|9600045|FG000|Overall Study|Other Protocol Violation|5
6005953|NCT00087607|9600046|FG001|Overall Study|Other Protocol Violation|2
6005954|NCT00087607|9600045|FG000|Overall Study|Violation of Selection Criteria at Entry|0
6005955|NCT00087607|9600046|FG001|Overall Study|Violation of Selection Criteria at Entry|1
6005956|NCT00087646|9600069|FG000|Overall Study|Adverse Event|37
6005957|NCT00087646|9600070|FG001|Overall Study|Adverse Event|6
6005958|NCT00087646|9600071|FG002|Overall Study|Adverse Event|18
6005959|NCT00087646|9600072|FG003|Overall Study|Adverse Event|20
6005960|NCT00087646|9600069|FG000|Overall Study|Death|0
6005961|NCT00087646|9600070|FG001|Overall Study|Death|1
6005962|NCT00087646|9600071|FG002|Overall Study|Death|0
6005963|NCT00087646|9600072|FG003|Overall Study|Death|0
6005964|NCT00087646|9600069|FG000|Overall Study|Withdrawal by Subject|6
6005965|NCT00087646|9600070|FG001|Overall Study|Withdrawal by Subject|1
6005966|NCT00087646|9600071|FG002|Overall Study|Withdrawal by Subject|2
6005967|NCT00087646|9600072|FG003|Overall Study|Withdrawal by Subject|2
6005968|NCT00087646|9600069|FG000|Overall Study|Insufficient therapeutic response|64
6005969|NCT00087646|9600070|FG001|Overall Study|Insufficient therapeutic response|24
6005970|NCT00087646|9600071|FG002|Overall Study|Insufficient therapeutic response|38
6005971|NCT00087646|9600072|FG003|Overall Study|Insufficient therapeutic response|51
6005972|NCT00087646|9600069|FG000|Overall Study|Refused Treatment/Did Not Cooperate|13
6005973|NCT00087646|9600070|FG001|Overall Study|Refused Treatment/Did Not Cooperate|6
6005974|NCT00087646|9600071|FG002|Overall Study|Refused Treatment/Did Not Cooperate|4
6005975|NCT00087646|9600072|FG003|Overall Study|Refused Treatment/Did Not Cooperate|5
6005976|NCT00087646|9600069|FG000|Overall Study|Failure to Return|5
6005977|NCT00087646|9600070|FG001|Overall Study|Failure to Return|2
6005978|NCT00087646|9600071|FG002|Overall Study|Failure to Return|2
6005979|NCT00087646|9600072|FG003|Overall Study|Failure to Return|3
6005980|NCT00087646|9600069|FG000|Overall Study|Administrative/Other|6
6005981|NCT00087646|9600070|FG001|Overall Study|Administrative/Other|1
6005982|NCT00087646|9600071|FG002|Overall Study|Administrative/Other|1
6005983|NCT00087646|9600072|FG003|Overall Study|Administrative/Other|2
6005984|NCT00087646|9600069|FG000|Overall Study|Other Protocol Violation|3
6005985|NCT00087646|9600070|FG001|Overall Study|Other Protocol Violation|1
6005986|NCT00087646|9600071|FG002|Overall Study|Other Protocol Violation|0
6005987|NCT00087646|9600072|FG003|Overall Study|Other Protocol Violation|0
6005988|NCT00087646|9600069|FG000|Overall Study|Violation of Selection Criteria at Entry|1
6005989|NCT00087646|9600070|FG001|Overall Study|Violation of Selection Criteria at Entry|0
6005990|NCT00087646|9600071|FG002|Overall Study|Violation of Selection Criteria at Entry|0
6005991|NCT00087646|9600072|FG003|Overall Study|Violation of Selection Criteria at Entry|1
6005992|NCT00087685|9600091|FG000|Overall Study|Adverse Event|5
6005993|NCT00087685|9600091|FG000|Overall Study|Non-Compliance|1
6005994|NCT00087685|9600091|FG000|Overall Study|Progressive Disease|5
6005995|NCT00087685|9600091|FG000|Overall Study|Withdrawal by Subject|3
6005996|NCT00087698|9600095|FG000|Overall Study|Lack of Efficacy, Progressive Disease|14
6005997|NCT00087698|9600095|FG000|Overall Study|Death from Other Causes|3
6005998|NCT00087698|9600095|FG000|Overall Study|Adverse Event|4
6005999|NCT00087698|9600095|FG000|Overall Study|Withdrawal by Subject|4
6006000|NCT00087698|9600095|FG000|Overall Study|Lack of Efficacy, Physician Perception|3
6006001|NCT00087698|9600095|FG000|Overall Study|Protocol Entry Criteria Not Met|2
6006002|NCT00087698|9600095|FG000|Overall Study|Clinical Relapse|1
6006003|NCT00087698|9600095|FG000|Overall Study|Death from Study Disease|2
6006004|NCT00087698|9600095|FG000|Overall Study|Death from Study Drug Toxicity|2
6006005|NCT00087698|9600095|FG000|Overall Study|Protocol Violation|1
6006006|NCT00088153|9600101|FG000|Overall Study|Physician Decision|3
6006007|NCT00088153|9600102|FG001|Overall Study|Physician Decision|3
6006008|NCT00088153|9600101|FG000|Overall Study|Withdrawal by Subject|10
6006009|NCT00088153|9600102|FG001|Overall Study|Withdrawal by Subject|10
6074306|NCT00572624|9678188|FG001|Overall Study|Problem with vascular access|0
6074307|NCT00572624|9678187|FG000|Overall Study|Health issues unrelated to the study|1
6074308|NCT00572624|9678188|FG001|Overall Study|Health issues unrelated to the study|0
6074309|NCT00572728|9678194|FG000|Overall Study|Withdrawal by Subject|10
6074310|NCT00572728|9678194|FG000|Overall Study|Ineligible|3
6074311|NCT00572728|9678194|FG000|Overall Study|Enrolled under Amendment 4|5
6074312|NCT00572728|9678194|FG000|Overall Study|Offstudy due to complicating disease|1
6074313|NCT00572728|9678194|FG000|Overall Study|FLT1 not completed|4
6074314|NCT00572728|9678194|FG000|Overall Study|First Chemotherapy not initiated|2
6074315|NCT00572728|9678194|FG000|Overall Study|FLT2 not completed|5
6074316|NCT00572728|9678194|FG000|Overall Study|Second chemotherapy not initiated|1
6074317|NCT00572728|9678194|FG000|Overall Study|FLT2 after second chemotherapy initiated|7
6074318|NCT00572728|9678194|FG000|Overall Study|Pathology missing|1
6074319|NCT00572832|9678202|FG000|Overall Study|Lost to Follow-up|0
6074320|NCT00572832|9678203|FG001|Overall Study|Lost to Follow-up|11
6074321|NCT00572832|9678202|FG000|Overall Study|Pregnancy|0
6074322|NCT00572832|9678203|FG001|Overall Study|Pregnancy|1
6006010|NCT00088153|9600101|FG000|Overall Study|Lost to Follow-up|11
6074323|NCT00572910|9678224|FG000|Overall Study|Adverse Event|1
6074324|NCT00572910|9678225|FG001|Overall Study|Adverse Event|2
6006011|NCT00088153|9600102|FG001|Overall Study|Lost to Follow-up|12
6074325|NCT00572910|9678226|FG002|Overall Study|Adverse Event|0
6074326|NCT00572910|9678227|FG003|Overall Study|Adverse Event|2
6074327|NCT00572910|9678228|FG004|Overall Study|Adverse Event|0
6074328|NCT00572910|9678229|FG005|Overall Study|Adverse Event|0
6074329|NCT00572910|9678230|FG006|Overall Study|Adverse Event|4
6074330|NCT00572910|9678231|FG007|Overall Study|Adverse Event|2
6074331|NCT00572910|9678232|FG008|Overall Study|Adverse Event|1
6074332|NCT00572910|9678233|FG009|Overall Study|Adverse Event|3
6074333|NCT00572910|9678234|FG010|Overall Study|Adverse Event|2
6074334|NCT00572910|9678224|FG000|Overall Study|Lost to Follow-up|0
6074335|NCT00572910|9678225|FG001|Overall Study|Lost to Follow-up|1
6074336|NCT00572910|9678226|FG002|Overall Study|Lost to Follow-up|1
6074337|NCT00572910|9678227|FG003|Overall Study|Lost to Follow-up|2
6074338|NCT00572910|9678228|FG004|Overall Study|Lost to Follow-up|1
6074339|NCT00572910|9678229|FG005|Overall Study|Lost to Follow-up|0
6074340|NCT00572910|9678230|FG006|Overall Study|Lost to Follow-up|0
6074341|NCT00572910|9678231|FG007|Overall Study|Lost to Follow-up|0
6074342|NCT00572910|9678232|FG008|Overall Study|Lost to Follow-up|0
6074343|NCT00572910|9678233|FG009|Overall Study|Lost to Follow-up|1
6074344|NCT00572910|9678234|FG010|Overall Study|Lost to Follow-up|0
6074345|NCT00572910|9678224|FG000|Overall Study|Withdrawal by Subject|3
6074346|NCT00572910|9678225|FG001|Overall Study|Withdrawal by Subject|0
6074347|NCT00572910|9678226|FG002|Overall Study|Withdrawal by Subject|1
6074348|NCT00572910|9678227|FG003|Overall Study|Withdrawal by Subject|0
6074349|NCT00572910|9678228|FG004|Overall Study|Withdrawal by Subject|1
6074350|NCT00572910|9678229|FG005|Overall Study|Withdrawal by Subject|3
6074351|NCT00572910|9678230|FG006|Overall Study|Withdrawal by Subject|0
6074352|NCT00572910|9678231|FG007|Overall Study|Withdrawal by Subject|2
6074353|NCT00572910|9678232|FG008|Overall Study|Withdrawal by Subject|2
6074354|NCT00572910|9678233|FG009|Overall Study|Withdrawal by Subject|2
6074355|NCT00572910|9678234|FG010|Overall Study|Withdrawal by Subject|1
6074356|NCT00573066|9678282|FG000|Overall Study|Exclusion criteria|18
6074357|NCT00573066|9678282|FG000|Overall Study|IV malfunction|1
6074358|NCT00573066|9678282|FG000|Overall Study|Postoperative bleeding|1
6074359|NCT00573144|9678288|FG000|Overall Study|Withdrawal by Subject|2
6074360|NCT00573144|9678289|FG001|Overall Study|Withdrawal by Subject|3
6074361|NCT00573170|9678295|FG000|First Treatment Period|Did Not Treat Attack 1|0
6074362|NCT00573170|9678296|FG001|First Treatment Period|Did Not Treat Attack 1|0
6074363|NCT00573170|9678297|FG002|First Treatment Period|Did Not Treat Attack 1|0
6074364|NCT00573170|9678298|FG003|First Treatment Period|Did Not Treat Attack 1|0
6074365|NCT00573170|9678299|FG004|First Treatment Period|Did Not Treat Attack 1|1
6074366|NCT00573170|9678300|FG005|First Treatment Period|Did Not Treat Attack 1|0
6074367|NCT00573170|9678295|FG000|First Washout Period|Adverse Event|1
6074368|NCT00573170|9678296|FG001|First Washout Period|Adverse Event|1
6074369|NCT00573170|9678297|FG002|First Washout Period|Adverse Event|0
6074370|NCT00573170|9678298|FG003|First Washout Period|Adverse Event|0
6074371|NCT00573170|9678299|FG004|First Washout Period|Adverse Event|0
6074372|NCT00573170|9678300|FG005|First Washout Period|Adverse Event|1
6074373|NCT00573170|9678295|FG000|First Washout Period|Lack of Efficacy|0
6074374|NCT00573170|9678296|FG001|First Washout Period|Lack of Efficacy|0
6074375|NCT00573170|9678297|FG002|First Washout Period|Lack of Efficacy|0
6074376|NCT00573170|9678298|FG003|First Washout Period|Lack of Efficacy|0
6074377|NCT00573170|9678299|FG004|First Washout Period|Lack of Efficacy|0
6074378|NCT00573170|9678300|FG005|First Washout Period|Lack of Efficacy|1
6074379|NCT00573170|9678295|FG000|First Washout Period|Lost to Follow-up|1
6074380|NCT00573170|9678296|FG001|First Washout Period|Lost to Follow-up|1
6074381|NCT00573170|9678297|FG002|First Washout Period|Lost to Follow-up|0
6074382|NCT00573170|9678298|FG003|First Washout Period|Lost to Follow-up|2
6074383|NCT00573170|9678299|FG004|First Washout Period|Lost to Follow-up|0
6074384|NCT00573170|9678300|FG005|First Washout Period|Lost to Follow-up|2
6074385|NCT00573170|9678295|FG000|First Washout Period|Withdrawal by Subject|2
6074386|NCT00573170|9678296|FG001|First Washout Period|Withdrawal by Subject|0
6074387|NCT00573170|9678297|FG002|First Washout Period|Withdrawal by Subject|0
6074388|NCT00573170|9678298|FG003|First Washout Period|Withdrawal by Subject|2
6074389|NCT00573170|9678299|FG004|First Washout Period|Withdrawal by Subject|3
6074390|NCT00573170|9678300|FG005|First Washout Period|Withdrawal by Subject|3
6074391|NCT00573170|9678295|FG000|First Washout Period|Other|4
6074392|NCT00573170|9678296|FG001|First Washout Period|Other|0
6074393|NCT00573170|9678297|FG002|First Washout Period|Other|1
6074394|NCT00573170|9678298|FG003|First Washout Period|Other|1
6074395|NCT00573170|9678299|FG004|First Washout Period|Other|0
6074396|NCT00573170|9678300|FG005|First Washout Period|Other|0
6074397|NCT00573170|9678295|FG000|Second Washout Period|Adverse Event|1
6074398|NCT00573170|9678296|FG001|Second Washout Period|Adverse Event|0
6074399|NCT00573170|9678297|FG002|Second Washout Period|Adverse Event|0
6074400|NCT00573170|9678298|FG003|Second Washout Period|Adverse Event|0
6074401|NCT00573170|9678299|FG004|Second Washout Period|Adverse Event|1
6074402|NCT00573170|9678300|FG005|Second Washout Period|Adverse Event|0
6074403|NCT00573170|9678295|FG000|Second Washout Period|Protocol Violation|2
6074404|NCT00573170|9678296|FG001|Second Washout Period|Protocol Violation|1
6074405|NCT00573170|9678297|FG002|Second Washout Period|Protocol Violation|1
6074406|NCT00573170|9678298|FG003|Second Washout Period|Protocol Violation|0
6074407|NCT00573170|9678299|FG004|Second Washout Period|Protocol Violation|0
6006012|NCT00088166|9600110|FG000|Overall Study|Adverse Event|11
6006013|NCT00088166|9600111|FG001|Overall Study|Adverse Event|9
6006014|NCT00088166|9600110|FG000|Overall Study|Death|3
6006015|NCT00088166|9600111|FG001|Overall Study|Death|1
6006016|NCT00088166|9600110|FG000|Overall Study|Lost to Follow-up|0
6006017|NCT00088166|9600111|FG001|Overall Study|Lost to Follow-up|1
6006018|NCT00088166|9600110|FG000|Overall Study|Physician Decision|4
6006019|NCT00088166|9600111|FG001|Overall Study|Physician Decision|1
6006020|NCT00088166|9600110|FG000|Overall Study|Protocol Violation|1
6006021|NCT00088166|9600111|FG001|Overall Study|Protocol Violation|5
6006022|NCT00088166|9600110|FG000|Overall Study|Patient deterioration|29
6006023|NCT00088166|9600111|FG001|Overall Study|Patient deterioration|39
6006024|NCT00088166|9600110|FG000|Overall Study|Withdrawal by Subject|5
6006025|NCT00088166|9600111|FG001|Overall Study|Withdrawal by Subject|5
6006026|NCT00088205|9600117|FG000|Overall Study|Adverse Event|4
6006027|NCT00088205|9600117|FG000|Overall Study|Progressive Disease|51
6006028|NCT00088205|9600117|FG000|Overall Study|Physician Decision|1
6006029|NCT00088205|9600117|FG000|Overall Study|Death Due to Study Disease|4
6006030|NCT00088374|9600130|FG000|Overall Study|patient did not receive any 17AAG|1
6006031|NCT00088374|9600130|FG000|Overall Study|patient received <1 cycle only of 17AAG|1
6006032|NCT00088413|9600138|FG000|Overall Study|Limited supply of trmt drug (PANVAC-f)|0
6006033|NCT00088413|9600139|FG001|Overall Study|Limited supply of trmt drug (PANVAC-f)|0
6006034|NCT00088413|9600140|FG002|Overall Study|Limited supply of trmt drug (PANVAC-f)|1
6006035|NCT00088413|9600141|FG003|Overall Study|Limited supply of trmt drug (PANVAC-f)|0
6006036|NCT00088413|9600138|FG000|Overall Study|Adverse Events/Side Effects|0
6006037|NCT00088413|9600139|FG001|Overall Study|Adverse Events/Side Effects|1
6006038|NCT00088413|9600140|FG002|Overall Study|Adverse Events/Side Effects|1
6006039|NCT00088413|9600141|FG003|Overall Study|Adverse Events/Side Effects|0
6006040|NCT00088413|9600138|FG000|Overall Study|Refused trmt Off-study per pt wishes|0
6006041|NCT00088413|9600139|FG001|Overall Study|Refused trmt Off-study per pt wishes|1
6006042|NCT00088413|9600140|FG002|Overall Study|Refused trmt Off-study per pt wishes|1
6006043|NCT00088413|9600141|FG003|Overall Study|Refused trmt Off-study per pt wishes|0
6006044|NCT00088413|9600138|FG000|Overall Study|Off study due to missing a vaccine dose|1
6006045|NCT00088413|9600139|FG001|Overall Study|Off study due to missing a vaccine dose|0
6006046|NCT00088413|9600140|FG002|Overall Study|Off study due to missing a vaccine dose|0
6006047|NCT00088413|9600141|FG003|Overall Study|Off study due to missing a vaccine dose|0
6006048|NCT00088413|9600138|FG000|Overall Study|Death|0
6006049|NCT00088413|9600139|FG001|Overall Study|Death|1
6006050|NCT00088413|9600140|FG002|Overall Study|Death|0
6006051|NCT00088413|9600141|FG003|Overall Study|Death|0
6006052|NCT00088413|9600138|FG000|Overall Study|Progressive disease|9
6006053|NCT00088413|9600139|FG001|Overall Study|Progressive disease|11
6006054|NCT00088413|9600140|FG002|Overall Study|Progressive disease|8
6006055|NCT00088413|9600141|FG003|Overall Study|Progressive disease|14
6006056|NCT00088413|9600138|FG000|Overall Study|Other|0
6006057|NCT00088413|9600139|FG001|Overall Study|Other|1
6006058|NCT00088413|9600140|FG002|Overall Study|Other|0
6006059|NCT00088413|9600141|FG003|Overall Study|Other|0
6006060|NCT00088413|9600138|FG000|Overall Study|Patient unevaluable due to adverse event|0
6006061|NCT00088413|9600139|FG001|Overall Study|Patient unevaluable due to adverse event|0
6006062|NCT00088413|9600140|FG002|Overall Study|Patient unevaluable due to adverse event|1
6006063|NCT00088413|9600141|FG003|Overall Study|Patient unevaluable due to adverse event|0
6006064|NCT00088452|9600156|FG000|Overall Study|Did not receive intervention|1
6006065|NCT00088452|9600157|FG001|Overall Study|Did not receive intervention|0
6006066|NCT00088452|9600158|FG002|Overall Study|Did not receive intervention|1
6006067|NCT00088465|9600166|FG000|Overall Study|Withdrawal by Subject|290
6006068|NCT00088465|9600166|FG000|Overall Study|Adverse Event|77
6006069|NCT00088465|9600166|FG000|Overall Study|Lost to Follow-up|57
6006070|NCT00088465|9600166|FG000|Overall Study|Physician Decision|45
6006071|NCT00088465|9600166|FG000|Overall Study|Sponsor Decision|37
6006072|NCT00088465|9600166|FG000|Overall Study|Lack of Efficacy|27
6006073|NCT00088465|9600166|FG000|Overall Study|Protocol Violation|17
6006074|NCT00088465|9600166|FG000|Overall Study|Death|11
6006075|NCT00088530|9600172|FG000|Overall Study|Progressive/Relapsed Disease|28
6006076|NCT00088530|9600173|FG001|Overall Study|Progressive/Relapsed Disease|39
6006077|NCT00088530|9600172|FG000|Overall Study|Adverse Event|15
6074408|NCT00573170|9678300|FG005|Second Washout Period|Protocol Violation|0
6074409|NCT00573170|9678295|FG000|Second Washout Period|Withdrawal by Subject|1
6074410|NCT00573170|9678296|FG001|Second Washout Period|Withdrawal by Subject|1
6074411|NCT00573170|9678297|FG002|Second Washout Period|Withdrawal by Subject|2
6074412|NCT00573170|9678298|FG003|Second Washout Period|Withdrawal by Subject|0
6074413|NCT00573170|9678299|FG004|Second Washout Period|Withdrawal by Subject|1
6074414|NCT00573170|9678300|FG005|Second Washout Period|Withdrawal by Subject|0
6074415|NCT00573170|9678295|FG000|Second Washout Period|Lost to Follow-up|0
6074416|NCT00573170|9678296|FG001|Second Washout Period|Lost to Follow-up|0
6074417|NCT00573170|9678297|FG002|Second Washout Period|Lost to Follow-up|0
6074418|NCT00573170|9678298|FG003|Second Washout Period|Lost to Follow-up|1
6074419|NCT00573170|9678299|FG004|Second Washout Period|Lost to Follow-up|0
6006078|NCT00088530|9600173|FG001|Overall Study|Adverse Event|9
6074420|NCT00573170|9678300|FG005|Second Washout Period|Lost to Follow-up|0
6006079|NCT00088530|9600172|FG000|Overall Study|Withdrawal by Subject|2
6006080|NCT00088530|9600173|FG001|Overall Study|Withdrawal by Subject|5
6006081|NCT00088530|9600172|FG000|Overall Study|Lost to Follow-up|2
6006082|NCT00088530|9600173|FG001|Overall Study|Lost to Follow-up|0
6006083|NCT00088530|9600172|FG000|Overall Study|Physician Decision|2
6006084|NCT00088530|9600173|FG001|Overall Study|Physician Decision|0
6006085|NCT00088530|9600172|FG000|Overall Study|Sponsor decision|0
6006086|NCT00088530|9600173|FG001|Overall Study|Sponsor decision|1
6006087|NCT00088530|9600172|FG000|Overall Study|Patient never treated|1
6006088|NCT00088530|9600173|FG001|Overall Study|Patient never treated|0
6006089|NCT00088595|9600179|FG000|Overall Study|Adverse Event|11
6006090|NCT00088595|9600179|FG000|Overall Study|Withdrawal by Subject|8
6006091|NCT00088595|9600179|FG000|Overall Study|Ongoing (After Core)|7
6006092|NCT00088595|9600179|FG000|Overall Study|New Cancer Therapy|2
6006093|NCT00088881|9600221|FG000|Step 1 - R-CHOP|Patient ineligible|9
6006094|NCT00088881|9600221|FG000|Step 1 - R-CHOP|Adverse Event|1
6006095|NCT00088881|9600221|FG000|Step 1 - R-CHOP|Withdrawal by Subject|2
6006096|NCT00088881|9600221|FG000|Step 1 - R-CHOP|Physician Decision|1
6006097|NCT00088881|9600221|FG000|Step 1 - R-CHOP|Insurance company refused to cover|1
6006098|NCT00088881|9600221|FG000|Step 2 - Zevalin™ Radioimmunotherapy|Patient ineligible|8
6006099|NCT00088881|9600221|FG000|Step 2 - Zevalin™ Radioimmunotherapy|Other|3
6006100|NCT00088907|9600229|FG000|Randomized Study (Step 1)|Lack of Efficacy|55
6006101|NCT00088907|9600230|FG001|Randomized Study (Step 1)|Lack of Efficacy|62
6006102|NCT00088907|9600229|FG000|Randomized Study (Step 1)|Adverse Event|14
6006103|NCT00088907|9600230|FG001|Randomized Study (Step 1)|Adverse Event|19
6006104|NCT00088907|9600229|FG000|Randomized Study (Step 1)|Death|11
6006105|NCT00088907|9600230|FG001|Randomized Study (Step 1)|Death|12
6006106|NCT00088907|9600229|FG000|Randomized Study (Step 1)|Withdrawal by Subject|10
6006107|NCT00088907|9600230|FG001|Randomized Study (Step 1)|Withdrawal by Subject|15
6006108|NCT00088907|9600229|FG000|Randomized Study (Step 1)|complicating disease|3
6006109|NCT00088907|9600230|FG001|Randomized Study (Step 1)|complicating disease|1
6006110|NCT00088907|9600229|FG000|Randomized Study (Step 1)|unknown/not specify|24
6006111|NCT00088907|9600230|FG001|Randomized Study (Step 1)|unknown/not specify|13
6006112|NCT00088907|9600229|FG000|Randomized Study (Step 1)|ineligible or not start protocol therapy|19
6006113|NCT00088907|9600230|FG001|Randomized Study (Step 1)|ineligible or not start protocol therapy|12
6006114|NCT00088907|9600229|FG000|Single Gefitinib Treatment (Step 2)|Lack of Efficacy|16
6006115|NCT00088907|9600230|FG001|Single Gefitinib Treatment (Step 2)|Lack of Efficacy|0
6006116|NCT00088907|9600229|FG000|Single Gefitinib Treatment (Step 2)|Death|1
6006117|NCT00088907|9600230|FG001|Single Gefitinib Treatment (Step 2)|Death|0
6006118|NCT00088907|9600229|FG000|Single Gefitinib Treatment (Step 2)|unknown/not specify|2
6006119|NCT00088907|9600230|FG001|Single Gefitinib Treatment (Step 2)|unknown/not specify|0
6006120|NCT00088907|9600229|FG000|Single Gefitinib Treatment (Step 2)|not start protocol therapy|5
6006121|NCT00088907|9600230|FG001|Single Gefitinib Treatment (Step 2)|not start protocol therapy|0
6006122|NCT00089076|9600254|FG000|Overall Study|Alternate Therapy|1
6006123|NCT00089076|9600254|FG000|Overall Study|Withdrawal by Subject|2
6006124|NCT00089076|9600254|FG000|Overall Study|Progression|7
6006125|NCT00089284|9600267|FG000|Overall Study|Adverse event before starting treatment|0
6006126|NCT00089284|9600268|FG001|Overall Study|Adverse event before starting treatment|0
6006127|NCT00089284|9600269|FG002|Overall Study|Adverse event before starting treatment|0
6006128|NCT00089284|9600270|FG003|Overall Study|Adverse event before starting treatment|0
6006129|NCT00089284|9600271|FG004|Overall Study|Adverse event before starting treatment|0
6006130|NCT00089284|9600272|FG005|Overall Study|Adverse event before starting treatment|0
6006131|NCT00089284|9600273|FG006|Overall Study|Adverse event before starting treatment|1
6006132|NCT00089297|9600295|FG000|Overall Study|Adverse Event|9
6006133|NCT00089297|9600295|FG000|Overall Study|Death|1
6006134|NCT00089297|9600295|FG000|Overall Study|Withdrawal by Subject|12
6006135|NCT00089297|9600295|FG000|Overall Study|Disease progression|2
6006136|NCT00089297|9600295|FG000|Overall Study|Ineligible|11
6006137|NCT00089297|9600295|FG000|Overall Study|Secondary malignancy|1
6006138|NCT00089297|9600295|FG000|Overall Study|IRB approval not ready|1
6006139|NCT00089297|9600295|FG000|Overall Study|Non-compliance|1
6006140|NCT00089479|9600301|FG000|Overall Study|Death|108
6006141|NCT00089479|9600302|FG001|Overall Study|Death|75
6006142|NCT00089479|9600301|FG000|Overall Study|Withdrawal by Subject|86
6006143|NCT00089479|9600302|FG001|Overall Study|Withdrawal by Subject|107
6006144|NCT00089479|9600301|FG000|Overall Study|Lost to Follow-up|137
6006145|NCT00089479|9600302|FG001|Overall Study|Lost to Follow-up|107
6006146|NCT00089505|9600312|FG000|Overall Study|Death|4
6006147|NCT00089505|9600313|FG001|Overall Study|Death|1
6006148|NCT00089505|9600314|FG002|Overall Study|Death|5
6006149|NCT00089505|9600315|FG003|Overall Study|Death|8
6006150|NCT00089505|9600312|FG000|Overall Study|Withdrawal by Subject|3
6006151|NCT00089505|9600313|FG001|Overall Study|Withdrawal by Subject|0
6006152|NCT00089505|9600314|FG002|Overall Study|Withdrawal by Subject|6
6006153|NCT00089505|9600315|FG003|Overall Study|Withdrawal by Subject|6
6006154|NCT00089505|9600312|FG000|Overall Study|Lost to Follow-up|1
6006155|NCT00089505|9600313|FG001|Overall Study|Lost to Follow-up|1
6006156|NCT00089505|9600314|FG002|Overall Study|Lost to Follow-up|9
6006157|NCT00089505|9600315|FG003|Overall Study|Lost to Follow-up|7
6006158|NCT00089505|9600312|FG000|Overall Study|Physician Decision|1
6006159|NCT00089505|9600313|FG001|Overall Study|Physician Decision|0
6006160|NCT00089505|9600314|FG002|Overall Study|Physician Decision|0
6006161|NCT00089505|9600315|FG003|Overall Study|Physician Decision|0
6006162|NCT00089505|9600312|FG000|Overall Study|Protocol Violation|0
6006163|NCT00089505|9600313|FG001|Overall Study|Protocol Violation|0
6006164|NCT00089505|9600314|FG002|Overall Study|Protocol Violation|1
6006165|NCT00089505|9600315|FG003|Overall Study|Protocol Violation|0
6006166|NCT00089544|9600327|FG000|Overall Study|Ineligible|1
6006167|NCT00089544|9600328|FG001|Overall Study|Ineligible|0
6006168|NCT00089583|9600336|FG000|Overall Study|Adverse Event|0
6006169|NCT00089583|9600337|FG001|Overall Study|Adverse Event|3
6006170|NCT00089583|9600336|FG000|Overall Study|Insufficient Viral Load Response|5
6006171|NCT00089583|9600337|FG001|Overall Study|Insufficient Viral Load Response|5
6006172|NCT00089583|9600336|FG000|Overall Study|Withdrawal by Subject|0
6006173|NCT00089583|9600337|FG001|Overall Study|Withdrawal by Subject|4
6006174|NCT00089583|9600336|FG000|Overall Study|Participant (Par) Didn't Take Medication|1
6006175|NCT00089583|9600337|FG001|Overall Study|Participant (Par) Didn't Take Medication|0
6006176|NCT00089583|9600336|FG000|Overall Study|Participant Refused Study Medication|0
6006177|NCT00089583|9600337|FG001|Overall Study|Participant Refused Study Medication|2
6006178|NCT00089583|9600336|FG000|Overall Study|Non-Compliance|0
6006179|NCT00089583|9600337|FG001|Overall Study|Non-Compliance|4
6006180|NCT00089583|9600336|FG000|Overall Study|Poor Medical Compliance/Adherence Issues|0
6006181|NCT00089583|9600337|FG001|Overall Study|Poor Medical Compliance/Adherence Issues|3
6006182|NCT00089583|9600336|FG000|Overall Study|Participant Management Criteria Met|0
6006183|NCT00089583|9600337|FG001|Overall Study|Participant Management Criteria Met|1
6006184|NCT00089583|9600336|FG000|Overall Study|Reason Not Provided|0
6006185|NCT00089583|9600337|FG001|Overall Study|Reason Not Provided|1
6006186|NCT00089583|9600336|FG000|Overall Study|Protocol Violation|0
6006187|NCT00089583|9600337|FG001|Overall Study|Protocol Violation|3
6006188|NCT00089583|9600336|FG000|Overall Study|Principal Investigator Decision|0
6006189|NCT00089583|9600337|FG001|Overall Study|Principal Investigator Decision|10
6006190|NCT00089583|9600336|FG000|Overall Study|Start of Disallowed Medication|0
6006191|NCT00089583|9600337|FG001|Overall Study|Start of Disallowed Medication|1
6006192|NCT00089583|9600336|FG000|Overall Study|Necessity to Use Prohibited Drug|1
6006193|NCT00089583|9600337|FG001|Overall Study|Necessity to Use Prohibited Drug|0
6006194|NCT00089583|9600336|FG000|Overall Study|Participant Incarcerated|0
6006195|NCT00089583|9600337|FG001|Overall Study|Participant Incarcerated|1
6006196|NCT00089609|9600351|FG000|Overall Study|Withdrawal by Subject|3
6006197|NCT00089609|9600352|FG001|Overall Study|Withdrawal by Subject|1
6006198|NCT00089635|9600361|FG000|Overall Study|Adverse Event|2
6006199|NCT00089635|9600361|FG000|Overall Study|Death|17
6006200|NCT00089635|9600361|FG000|Overall Study|Disease Progression|12
6006201|NCT00089635|9600361|FG000|Overall Study|Lost to Follow-up|3
6006202|NCT00089635|9600361|FG000|Overall Study|Withdrawal by Subject|6
6006203|NCT00089635|9600361|FG000|Overall Study|Ineligibility determined|1
6006204|NCT00089635|9600361|FG000|Overall Study|Other|2
6006205|NCT00089648|9600365|FG000|Overall Study|Adverse Event|7
6006206|NCT00089648|9600365|FG000|Overall Study|Withdrawal by Subject|1
6006207|NCT00089648|9600365|FG000|Overall Study|Lack of Efficacy|33
6006208|NCT00089661|9600371|FG000|Overall Study|Adverse Event|0
6006209|NCT00089661|9600372|FG001|Overall Study|Adverse Event|2
6006210|NCT00089661|9600371|FG000|Overall Study|Death|1
6006211|NCT00089661|9600372|FG001|Overall Study|Death|0
6006212|NCT00089661|9600371|FG000|Overall Study|Lost to Follow-up|0
6006213|NCT00089661|9600372|FG001|Overall Study|Lost to Follow-up|3
6006214|NCT00089661|9600371|FG000|Overall Study|Withdrawal by Subject|11
6006215|NCT00089661|9600372|FG001|Overall Study|Withdrawal by Subject|9
6006216|NCT00089661|9600371|FG000|Overall Study|Disease progression|1
6006217|NCT00089661|9600372|FG001|Overall Study|Disease progression|3
6006218|NCT00089661|9600371|FG000|Overall Study|Ineligibility determined|4
6006219|NCT00089661|9600372|FG001|Overall Study|Ineligibility determined|4
6006220|NCT00089661|9600371|FG000|Overall Study|Noncompliance|2
6006221|NCT00089661|9600372|FG001|Overall Study|Noncompliance|4
6006222|NCT00089661|9600371|FG000|Overall Study|Other|2
6006223|NCT00089661|9600372|FG001|Overall Study|Other|1
6006224|NCT00089674|9600380|FG000|Overall Study|Physician Decision|4
6006225|NCT00089674|9600381|FG001|Overall Study|Physician Decision|2
6006226|NCT00089674|9600380|FG000|Overall Study|Adverse Event|23
6006227|NCT00089674|9600381|FG001|Overall Study|Adverse Event|29
6006228|NCT00089674|9600380|FG000|Overall Study|Withdrawal by Subject|143
6006229|NCT00089674|9600381|FG001|Overall Study|Withdrawal by Subject|127
6006230|NCT00089674|9600380|FG000|Overall Study|Death|43
6006231|NCT00089674|9600381|FG001|Overall Study|Death|43
6006232|NCT00089674|9600380|FG000|Overall Study|Disease progression|21
6006233|NCT00089674|9600381|FG001|Overall Study|Disease progression|23
6006234|NCT00089674|9600380|FG000|Overall Study|Ineligibility determined|8
6006235|NCT00089674|9600381|FG001|Overall Study|Ineligibility determined|10
6006236|NCT00089674|9600380|FG000|Overall Study|Lost to Follow-up|21
6006237|NCT00089674|9600381|FG001|Overall Study|Lost to Follow-up|17
6006238|NCT00089674|9600380|FG000|Overall Study|Noncompliance|7
6006239|NCT00089674|9600381|FG001|Overall Study|Noncompliance|3
6006240|NCT00089674|9600380|FG000|Overall Study|Other|5
6006241|NCT00089674|9600381|FG001|Overall Study|Other|9
6006242|NCT00089674|9600380|FG000|Overall Study|Requirement for alternative therapy|14
6006243|NCT00089674|9600381|FG001|Overall Study|Requirement for alternative therapy|4
6006244|NCT00089778|9600401|FG000|Overall Study|Protocol Violation|0
6006245|NCT00089778|9600402|FG001|Overall Study|Protocol Violation|0
6006246|NCT00089778|9600403|FG002|Overall Study|Protocol Violation|1
6006247|NCT00089843|9600417|FG000|Overall Study|Withdrawal by Subject|1
6006248|NCT00089843|9600418|FG001|Overall Study|Withdrawal by Subject|4
6006249|NCT00089843|9600419|FG002|Overall Study|Withdrawal by Subject|5
6006250|NCT00089843|9600420|FG003|Overall Study|Withdrawal by Subject|6
6006251|NCT00089843|9600417|FG000|Overall Study|Physician Decision|1
6006252|NCT00089843|9600418|FG001|Overall Study|Physician Decision|0
6006253|NCT00089843|9600419|FG002|Overall Study|Physician Decision|0
6006254|NCT00089843|9600420|FG003|Overall Study|Physician Decision|1
6006255|NCT00089973|9600430|FG000|Overall Study|Adverse Event|3
6006256|NCT00089973|9600430|FG000|Overall Study|Withdrawal by Subject|1
6006257|NCT00089973|9600430|FG000|Overall Study|Disease progression|45
6006258|NCT00089973|9600430|FG000|Overall Study|Death|1
6006259|NCT00089986|9600437|FG000|Overall Study|Adverse Event|6
6006260|NCT00089986|9600438|FG001|Overall Study|Adverse Event|9
6006261|NCT00089986|9600439|FG002|Overall Study|Adverse Event|6
6006262|NCT00089986|9600437|FG000|Overall Study|Lost to Follow-up|3
6006263|NCT00089986|9600438|FG001|Overall Study|Lost to Follow-up|1
6006264|NCT00089986|9600439|FG002|Overall Study|Lost to Follow-up|1
6006265|NCT00089986|9600437|FG000|Overall Study|Protocol Violation|0
6006266|NCT00089986|9600438|FG001|Overall Study|Protocol Violation|1
6006267|NCT00089986|9600439|FG002|Overall Study|Protocol Violation|0
6006268|NCT00089986|9600437|FG000|Overall Study|Patient transferred to another hospital|2
6006269|NCT00089986|9600438|FG001|Overall Study|Patient transferred to another hospital|1
6006270|NCT00089986|9600439|FG002|Overall Study|Patient transferred to another hospital|0
6006271|NCT00089986|9600437|FG000|Overall Study|Subject withdrew but agreed follow up|1
6006272|NCT00089986|9600438|FG001|Overall Study|Subject withdrew but agreed follow up|2
6006273|NCT00089986|9600439|FG002|Overall Study|Subject withdrew but agreed follow up|0
6006274|NCT00089986|9600437|FG000|Overall Study|Hemohlobin stopping rule|0
6006275|NCT00089986|9600438|FG001|Overall Study|Hemohlobin stopping rule|1
6006276|NCT00089986|9600439|FG002|Overall Study|Hemohlobin stopping rule|0
6006277|NCT00089986|9600437|FG000|Overall Study|Investigator decision to withdrew|0
6006278|NCT00089986|9600438|FG001|Overall Study|Investigator decision to withdrew|1
6006279|NCT00089986|9600439|FG002|Overall Study|Investigator decision to withdrew|0
6006280|NCT00089986|9600437|FG000|Overall Study|Enrollment in another study|0
6006281|NCT00089986|9600438|FG001|Overall Study|Enrollment in another study|1
6006282|NCT00089986|9600439|FG002|Overall Study|Enrollment in another study|0
6006283|NCT00089986|9600437|FG000|Overall Study|Family decision|0
6006284|NCT00089986|9600438|FG001|Overall Study|Family decision|1
6006285|NCT00089986|9600439|FG002|Overall Study|Family decision|0
6006286|NCT00089986|9600437|FG000|Overall Study|Do not resuscitate (DNR)|0
6006287|NCT00089986|9600438|FG001|Overall Study|Do not resuscitate (DNR)|0
6006288|NCT00089986|9600439|FG002|Overall Study|Do not resuscitate (DNR)|1
6006289|NCT00089986|9600437|FG000|Overall Study|Withdrawal by Subject|3
6006290|NCT00089986|9600438|FG001|Overall Study|Withdrawal by Subject|6
6006291|NCT00089986|9600439|FG002|Overall Study|Withdrawal by Subject|2
6006292|NCT00089999|9600449|FG000|Overall Study|Adverse Event|4
6006293|NCT00089999|9600450|FG001|Overall Study|Adverse Event|7
6006294|NCT00089999|9600449|FG000|Overall Study|Withdrawal by Subject|0
6006295|NCT00089999|9600450|FG001|Overall Study|Withdrawal by Subject|4
6006296|NCT00089999|9600449|FG000|Overall Study|Lost to Follow-up|2
6006297|NCT00089999|9600450|FG001|Overall Study|Lost to Follow-up|1
6006298|NCT00089999|9600449|FG000|Overall Study|Radiological Progression of Cancer|52
6006299|NCT00089999|9600450|FG001|Overall Study|Radiological Progression of Cancer|44
6006300|NCT00089999|9600449|FG000|Overall Study|Symptomatic Progression of Cancer|2
6006301|NCT00089999|9600450|FG001|Overall Study|Symptomatic Progression of Cancer|5
6006302|NCT00089999|9600449|FG000|Overall Study|Death|3
6006303|NCT00089999|9600450|FG001|Overall Study|Death|3
6006304|NCT00089999|9600449|FG000|Overall Study|Poor General Condition|1
6006305|NCT00089999|9600450|FG001|Overall Study|Poor General Condition|0
6006306|NCT00089999|9600449|FG000|Overall Study|Clinical Progression|1
6006307|NCT00089999|9600450|FG001|Overall Study|Clinical Progression|2
6006308|NCT00089999|9600449|FG000|Overall Study|Physician Decision|2
6006309|NCT00089999|9600450|FG001|Overall Study|Physician Decision|2
6006310|NCT00089999|9600449|FG000|Overall Study|Patient Underwent Surgery|2
6006311|NCT00089999|9600450|FG001|Overall Study|Patient Underwent Surgery|0
6006312|NCT00089999|9600449|FG000|Overall Study|Skin Nodule Over Right Mastectomy|0
6006313|NCT00089999|9600450|FG001|Overall Study|Skin Nodule Over Right Mastectomy|1
6006314|NCT00090103|9600481|FG000|Four-Year Double-Blind Treatment Period|Adverse Event|211
6006315|NCT00090103|9600482|FG001|Four-Year Double-Blind Treatment Period|Adverse Event|185
6006316|NCT00090103|9600483|FG002|Four-Year Double-Blind Treatment Period|Adverse Event|210
6006317|NCT00090103|9600481|FG000|Four-Year Double-Blind Treatment Period|Withdrawal by Subject|114
6074421|NCT00573170|9678295|FG000|Second Washout Period|Other|1
6006318|NCT00090103|9600482|FG001|Four-Year Double-Blind Treatment Period|Withdrawal by Subject|160
6006319|NCT00090103|9600483|FG002|Four-Year Double-Blind Treatment Period|Withdrawal by Subject|148
6006320|NCT00090103|9600481|FG000|Four-Year Double-Blind Treatment Period|Lost to Follow-up|53
6006321|NCT00090103|9600482|FG001|Four-Year Double-Blind Treatment Period|Lost to Follow-up|48
6006322|NCT00090103|9600483|FG002|Four-Year Double-Blind Treatment Period|Lost to Follow-up|58
6006323|NCT00090103|9600481|FG000|Four-Year Double-Blind Treatment Period|Protocol Violation|29
6006324|NCT00090103|9600482|FG001|Four-Year Double-Blind Treatment Period|Protocol Violation|29
6006325|NCT00090103|9600483|FG002|Four-Year Double-Blind Treatment Period|Protocol Violation|34
6006326|NCT00090103|9600481|FG000|Four-Year Double-Blind Treatment Period|Lack of Efficacy|53
6006327|NCT00090103|9600482|FG001|Four-Year Double-Blind Treatment Period|Lack of Efficacy|71
6006328|NCT00090103|9600483|FG002|Four-Year Double-Blind Treatment Period|Lack of Efficacy|104
6006329|NCT00090103|9600481|FG000|Four-Year Double-Blind Treatment Period|Participant Relocated|7
6006330|NCT00090103|9600482|FG001|Four-Year Double-Blind Treatment Period|Participant Relocated|2
6006331|NCT00090103|9600483|FG002|Four-Year Double-Blind Treatment Period|Participant Relocated|8
6006332|NCT00090103|9600481|FG000|Four-Year Double-Blind Treatment Period|Site Closed/Sponsor Termination|7
6006333|NCT00090103|9600482|FG001|Four-Year Double-Blind Treatment Period|Site Closed/Sponsor Termination|7
6006334|NCT00090103|9600483|FG002|Four-Year Double-Blind Treatment Period|Site Closed/Sponsor Termination|4
6006335|NCT00090103|9600481|FG000|Four-Year Double-Blind Treatment Period|Non-compliant/Medication Interruption|6
6006336|NCT00090103|9600482|FG001|Four-Year Double-Blind Treatment Period|Non-compliant/Medication Interruption|4
6006337|NCT00090103|9600483|FG002|Four-Year Double-Blind Treatment Period|Non-compliant/Medication Interruption|7
6006338|NCT00090103|9600481|FG000|Four-Year Double-Blind Treatment Period|Prostate Surgery/TURP/Alt. Therapy|3
6006339|NCT00090103|9600482|FG001|Four-Year Double-Blind Treatment Period|Prostate Surgery/TURP/Alt. Therapy|7
6006340|NCT00090103|9600483|FG002|Four-Year Double-Blind Treatment Period|Prostate Surgery/TURP/Alt. Therapy|19
6006341|NCT00090103|9600481|FG000|Four-Year Double-Blind Treatment Period|Participant Decision/Withdrawn|2
6006342|NCT00090103|9600482|FG001|Four-Year Double-Blind Treatment Period|Participant Decision/Withdrawn|0
6006343|NCT00090103|9600483|FG002|Four-Year Double-Blind Treatment Period|Participant Decision/Withdrawn|4
6006344|NCT00090103|9600481|FG000|Four-Year Double-Blind Treatment Period|Acute Urinary Retention (AUR)|2
6006345|NCT00090103|9600482|FG001|Four-Year Double-Blind Treatment Period|Acute Urinary Retention (AUR)|3
6006346|NCT00090103|9600483|FG002|Four-Year Double-Blind Treatment Period|Acute Urinary Retention (AUR)|6
6006347|NCT00090103|9600481|FG000|Four-Year Double-Blind Treatment Period|Prohibited Medication|2
6006348|NCT00090103|9600482|FG001|Four-Year Double-Blind Treatment Period|Prohibited Medication|2
6006349|NCT00090103|9600483|FG002|Four-Year Double-Blind Treatment Period|Prohibited Medication|8
6006350|NCT00090103|9600481|FG000|Four-Year Double-Blind Treatment Period|Investigator Departure|2
6006351|NCT00090103|9600482|FG001|Four-Year Double-Blind Treatment Period|Investigator Departure|0
6006352|NCT00090103|9600483|FG002|Four-Year Double-Blind Treatment Period|Investigator Departure|0
6006353|NCT00090103|9600481|FG000|Four-Year Double-Blind Treatment Period|Alcohol Dependent|1
6006354|NCT00090103|9600482|FG001|Four-Year Double-Blind Treatment Period|Alcohol Dependent|0
6006355|NCT00090103|9600483|FG002|Four-Year Double-Blind Treatment Period|Alcohol Dependent|0
6006356|NCT00090103|9600481|FG000|Four-Year Double-Blind Treatment Period|Screen Failure|1
6006357|NCT00090103|9600482|FG001|Four-Year Double-Blind Treatment Period|Screen Failure|0
6006358|NCT00090103|9600483|FG002|Four-Year Double-Blind Treatment Period|Screen Failure|0
6006359|NCT00090103|9600481|FG000|Four-Year Double-Blind Treatment Period|No Improvement|1
6006360|NCT00090103|9600482|FG001|Four-Year Double-Blind Treatment Period|No Improvement|0
6006361|NCT00090103|9600483|FG002|Four-Year Double-Blind Treatment Period|No Improvement|0
6006362|NCT00090103|9600481|FG000|Four-Year Double-Blind Treatment Period|BPH/BPH symptoms worse/urinary incont.|1
6006363|NCT00090103|9600482|FG001|Four-Year Double-Blind Treatment Period|BPH/BPH symptoms worse/urinary incont.|0
6006364|NCT00090103|9600483|FG002|Four-Year Double-Blind Treatment Period|BPH/BPH symptoms worse/urinary incont.|5
6006365|NCT00090103|9600481|FG000|Four-Year Double-Blind Treatment Period|Financial Problems|1
6006366|NCT00090103|9600482|FG001|Four-Year Double-Blind Treatment Period|Financial Problems|0
6006367|NCT00090103|9600483|FG002|Four-Year Double-Blind Treatment Period|Financial Problems|0
6006368|NCT00090103|9600481|FG000|Four-Year Double-Blind Treatment Period|Loss of Libido|1
6006369|NCT00090103|9600482|FG001|Four-Year Double-Blind Treatment Period|Loss of Libido|0
6006370|NCT00090103|9600483|FG002|Four-Year Double-Blind Treatment Period|Loss of Libido|0
6006371|NCT00090103|9600481|FG000|Four-Year Double-Blind Treatment Period|Angina Pectoris|0
6006372|NCT00090103|9600482|FG001|Four-Year Double-Blind Treatment Period|Angina Pectoris|2
6006373|NCT00090103|9600483|FG002|Four-Year Double-Blind Treatment Period|Angina Pectoris|0
6006374|NCT00090103|9600481|FG000|Four-Year Double-Blind Treatment Period|Loss of Contact|0
6006375|NCT00090103|9600482|FG001|Four-Year Double-Blind Treatment Period|Loss of Contact|1
6006376|NCT00090103|9600483|FG002|Four-Year Double-Blind Treatment Period|Loss of Contact|0
6006377|NCT00090103|9600481|FG000|Four-Year Double-Blind Treatment Period|Neoplasm of Bladder/Prostate|0
6006378|NCT00090103|9600482|FG001|Four-Year Double-Blind Treatment Period|Neoplasm of Bladder/Prostate|1
6006379|NCT00090103|9600483|FG002|Four-Year Double-Blind Treatment Period|Neoplasm of Bladder/Prostate|1
6006380|NCT00090103|9600481|FG000|Four-Year Double-Blind Treatment Period|Cardiologist/Neurologist Decision|0
6006381|NCT00090103|9600482|FG001|Four-Year Double-Blind Treatment Period|Cardiologist/Neurologist Decision|2
6006382|NCT00090103|9600483|FG002|Four-Year Double-Blind Treatment Period|Cardiologist/Neurologist Decision|0
6006383|NCT00090103|9600481|FG000|Four-Year Double-Blind Treatment Period|Renal Insufficiency|0
6006384|NCT00090103|9600482|FG001|Four-Year Double-Blind Treatment Period|Renal Insufficiency|1
6006385|NCT00090103|9600483|FG002|Four-Year Double-Blind Treatment Period|Renal Insufficiency|0
6006386|NCT00090103|9600481|FG000|Four-Year Double-Blind Treatment Period|Back Pain|0
6006387|NCT00090103|9600482|FG001|Four-Year Double-Blind Treatment Period|Back Pain|1
6006388|NCT00090103|9600483|FG002|Four-Year Double-Blind Treatment Period|Back Pain|0
6006389|NCT00090103|9600481|FG000|Four-Year Double-Blind Treatment Period|Scheduling Issues|0
6006390|NCT00090103|9600482|FG001|Four-Year Double-Blind Treatment Period|Scheduling Issues|1
6006391|NCT00090103|9600483|FG002|Four-Year Double-Blind Treatment Period|Scheduling Issues|0
6006392|NCT00090103|9600481|FG000|Four-Year Double-Blind Treatment Period|Any Appreciable Improvement|0
6006393|NCT00090103|9600482|FG001|Four-Year Double-Blind Treatment Period|Any Appreciable Improvement|1
6006394|NCT00090103|9600483|FG002|Four-Year Double-Blind Treatment Period|Any Appreciable Improvement|0
6006395|NCT00090103|9600481|FG000|Four-Year Double-Blind Treatment Period|Investigator Decision|0
6006396|NCT00090103|9600482|FG001|Four-Year Double-Blind Treatment Period|Investigator Decision|1
6006397|NCT00090103|9600483|FG002|Four-Year Double-Blind Treatment Period|Investigator Decision|3
6006398|NCT00090103|9600481|FG000|Four-Year Double-Blind Treatment Period|Enrollment Error|0
6006399|NCT00090103|9600482|FG001|Four-Year Double-Blind Treatment Period|Enrollment Error|0
6006400|NCT00090103|9600483|FG002|Four-Year Double-Blind Treatment Period|Enrollment Error|2
6006401|NCT00090103|9600481|FG000|Four-Year Double-Blind Treatment Period|Urinary Tract Infection (UTI)|0
6006402|NCT00090103|9600482|FG001|Four-Year Double-Blind Treatment Period|Urinary Tract Infection (UTI)|0
6006403|NCT00090103|9600483|FG002|Four-Year Double-Blind Treatment Period|Urinary Tract Infection (UTI)|1
6006404|NCT00090103|9600481|FG000|Four-Year Double-Blind Treatment Period|Prostate Specific Antigen Rising|0
6006405|NCT00090103|9600482|FG001|Four-Year Double-Blind Treatment Period|Prostate Specific Antigen Rising|1
6006406|NCT00090103|9600483|FG002|Four-Year Double-Blind Treatment Period|Prostate Specific Antigen Rising|0
6006407|NCT00090103|9600481|FG000|16-Week Safety Follow-up Period|Adverse Event|34
6006408|NCT00090103|9600482|FG001|16-Week Safety Follow-up Period|Adverse Event|39
6006409|NCT00090103|9600483|FG002|16-Week Safety Follow-up Period|Adverse Event|44
6006410|NCT00090103|9600481|FG000|16-Week Safety Follow-up Period|Withdrawal by Subject|185
6006411|NCT00090103|9600482|FG001|16-Week Safety Follow-up Period|Withdrawal by Subject|212
6006412|NCT00090103|9600483|FG002|16-Week Safety Follow-up Period|Withdrawal by Subject|229
6006413|NCT00090103|9600481|FG000|16-Week Safety Follow-up Period|Lost to Follow-up|101
6006414|NCT00090103|9600482|FG001|16-Week Safety Follow-up Period|Lost to Follow-up|97
6006415|NCT00090103|9600483|FG002|16-Week Safety Follow-up Period|Lost to Follow-up|111
6006416|NCT00090103|9600481|FG000|16-Week Safety Follow-up Period|Protocol Violation|18
6006417|NCT00090103|9600482|FG001|16-Week Safety Follow-up Period|Protocol Violation|18
6006418|NCT00090103|9600483|FG002|16-Week Safety Follow-up Period|Protocol Violation|17
6006419|NCT00090103|9600481|FG000|16-Week Safety Follow-up Period|Site Closed/Sponsor Termination|8
6006420|NCT00090103|9600482|FG001|16-Week Safety Follow-up Period|Site Closed/Sponsor Termination|5
6006421|NCT00090103|9600483|FG002|16-Week Safety Follow-up Period|Site Closed/Sponsor Termination|4
6006422|NCT00090103|9600481|FG000|16-Week Safety Follow-up Period|Non-compliant/Medication Interruption|8
6006423|NCT00090103|9600482|FG001|16-Week Safety Follow-up Period|Non-compliant/Medication Interruption|6
6006424|NCT00090103|9600483|FG002|16-Week Safety Follow-up Period|Non-compliant/Medication Interruption|4
6006425|NCT00090103|9600481|FG000|16-Week Safety Follow-up Period|Loss of Contact|4
6006426|NCT00090103|9600482|FG001|16-Week Safety Follow-up Period|Loss of Contact|0
6006427|NCT00090103|9600483|FG002|16-Week Safety Follow-up Period|Loss of Contact|2
6006428|NCT00090103|9600481|FG000|16-Week Safety Follow-up Period|Disease Progression/Treatment Failure|3
6006429|NCT00090103|9600482|FG001|16-Week Safety Follow-up Period|Disease Progression/Treatment Failure|1
6006430|NCT00090103|9600483|FG002|16-Week Safety Follow-up Period|Disease Progression/Treatment Failure|1
6006431|NCT00090103|9600481|FG000|16-Week Safety Follow-up Period|Participant relocated|2
6006432|NCT00090103|9600482|FG001|16-Week Safety Follow-up Period|Participant relocated|3
6006433|NCT00090103|9600483|FG002|16-Week Safety Follow-up Period|Participant relocated|1
6074422|NCT00573170|9678296|FG001|Second Washout Period|Other|2
6074423|NCT00573170|9678297|FG002|Second Washout Period|Other|1
6074424|NCT00573170|9678298|FG003|Second Washout Period|Other|4
6074425|NCT00573170|9678299|FG004|Second Washout Period|Other|6
6074426|NCT00573170|9678300|FG005|Second Washout Period|Other|2
6074427|NCT00573170|9678295|FG000|Third Treatment Period|Withdrawal by Subject|1
6074428|NCT00573170|9678296|FG001|Third Treatment Period|Withdrawal by Subject|0
6074429|NCT00573170|9678297|FG002|Third Treatment Period|Withdrawal by Subject|0
6074430|NCT00573170|9678298|FG003|Third Treatment Period|Withdrawal by Subject|0
6074431|NCT00573170|9678299|FG004|Third Treatment Period|Withdrawal by Subject|0
6074432|NCT00573170|9678300|FG005|Third Treatment Period|Withdrawal by Subject|0
6074433|NCT00573170|9678295|FG000|Third Treatment Period|Lost to Follow-up|0
6074434|NCT00573170|9678296|FG001|Third Treatment Period|Lost to Follow-up|0
6074435|NCT00573170|9678297|FG002|Third Treatment Period|Lost to Follow-up|0
6074436|NCT00573170|9678298|FG003|Third Treatment Period|Lost to Follow-up|0
6074437|NCT00573170|9678299|FG004|Third Treatment Period|Lost to Follow-up|0
6074438|NCT00573170|9678300|FG005|Third Treatment Period|Lost to Follow-up|2
6074439|NCT00573183|9678319|FG000|Overall Study|Lost to Follow-up|52
6006434|NCT00090103|9600481|FG000|16-Week Safety Follow-up Period|Participant Decision/Withdrawn|2
6006435|NCT00090103|9600482|FG001|16-Week Safety Follow-up Period|Participant Decision/Withdrawn|1
6006436|NCT00090103|9600483|FG002|16-Week Safety Follow-up Period|Participant Decision/Withdrawn|2
6006437|NCT00090103|9600481|FG000|16-Week Safety Follow-up Period|Prohibited Medication|2
6006438|NCT00090103|9600482|FG001|16-Week Safety Follow-up Period|Prohibited Medication|3
6006439|NCT00090103|9600483|FG002|16-Week Safety Follow-up Period|Prohibited Medication|5
6006440|NCT00090103|9600481|FG000|16-Week Safety Follow-up Period|Alcohol Dependent|1
6006441|NCT00090103|9600482|FG001|16-Week Safety Follow-up Period|Alcohol Dependent|0
6006442|NCT00090103|9600483|FG002|16-Week Safety Follow-up Period|Alcohol Dependent|1
6006443|NCT00090103|9600481|FG000|16-Week Safety Follow-up Period|Prostate surgery/TURP/Alt. therapy|1
6006444|NCT00090103|9600482|FG001|16-Week Safety Follow-up Period|Prostate surgery/TURP/Alt. therapy|5
6006445|NCT00090103|9600483|FG002|16-Week Safety Follow-up Period|Prostate surgery/TURP/Alt. therapy|13
6006446|NCT00090103|9600481|FG000|16-Week Safety Follow-up Period|Loss of Libido|1
6006447|NCT00090103|9600482|FG001|16-Week Safety Follow-up Period|Loss of Libido|0
6006448|NCT00090103|9600483|FG002|16-Week Safety Follow-up Period|Loss of Libido|0
6006449|NCT00090103|9600481|FG000|16-Week Safety Follow-up Period|Enrollment Error|1
6006450|NCT00090103|9600482|FG001|16-Week Safety Follow-up Period|Enrollment Error|0
6006451|NCT00090103|9600483|FG002|16-Week Safety Follow-up Period|Enrollment Error|2
6006452|NCT00090103|9600481|FG000|16-Week Safety Follow-up Period|Neoplasm of Bladder/Prostate Cancer|1
6006453|NCT00090103|9600482|FG001|16-Week Safety Follow-up Period|Neoplasm of Bladder/Prostate Cancer|3
6006454|NCT00090103|9600483|FG002|16-Week Safety Follow-up Period|Neoplasm of Bladder/Prostate Cancer|6
6006455|NCT00090103|9600481|FG000|16-Week Safety Follow-up Period|Death|1
6006456|NCT00090103|9600482|FG001|16-Week Safety Follow-up Period|Death|0
6006457|NCT00090103|9600483|FG002|16-Week Safety Follow-up Period|Death|1
6006458|NCT00090103|9600481|FG000|16-Week Safety Follow-up Period|Gyneomastia|1
6006459|NCT00090103|9600482|FG001|16-Week Safety Follow-up Period|Gyneomastia|0
6006460|NCT00090103|9600483|FG002|16-Week Safety Follow-up Period|Gyneomastia|0
6006461|NCT00090103|9600481|FG000|16-Week Safety Follow-up Period|Acute Urinary Retention (AUR)|0
6006462|NCT00090103|9600482|FG001|16-Week Safety Follow-up Period|Acute Urinary Retention (AUR)|5
6006463|NCT00090103|9600483|FG002|16-Week Safety Follow-up Period|Acute Urinary Retention (AUR)|4
6006464|NCT00090103|9600481|FG000|16-Week Safety Follow-up Period|BPH/BPH symptoms worse/urinary incont.|0
6006465|NCT00090103|9600482|FG001|16-Week Safety Follow-up Period|BPH/BPH symptoms worse/urinary incont.|2
6006466|NCT00090103|9600483|FG002|16-Week Safety Follow-up Period|BPH/BPH symptoms worse/urinary incont.|3
6006467|NCT00090103|9600481|FG000|16-Week Safety Follow-up Period|Angina Pectoris|0
6006468|NCT00090103|9600482|FG001|16-Week Safety Follow-up Period|Angina Pectoris|1
6006469|NCT00090103|9600483|FG002|16-Week Safety Follow-up Period|Angina Pectoris|0
6006470|NCT00090103|9600481|FG000|16-Week Safety Follow-up Period|Back Pain|0
6006471|NCT00090103|9600482|FG001|16-Week Safety Follow-up Period|Back Pain|1
6006472|NCT00090103|9600483|FG002|16-Week Safety Follow-up Period|Back Pain|0
6006473|NCT00090103|9600481|FG000|16-Week Safety Follow-up Period|Scheduling Issues|0
6006474|NCT00090103|9600482|FG001|16-Week Safety Follow-up Period|Scheduling Issues|2
6006475|NCT00090103|9600483|FG002|16-Week Safety Follow-up Period|Scheduling Issues|4
6006476|NCT00090103|9600481|FG000|16-Week Safety Follow-up Period|Investigator/Sponsor Decision|0
6006477|NCT00090103|9600482|FG001|16-Week Safety Follow-up Period|Investigator/Sponsor Decision|2
6006478|NCT00090103|9600483|FG002|16-Week Safety Follow-up Period|Investigator/Sponsor Decision|3
6006479|NCT00090103|9600481|FG000|16-Week Safety Follow-up Period|Depression|0
6006480|NCT00090103|9600482|FG001|16-Week Safety Follow-up Period|Depression|1
6006481|NCT00090103|9600483|FG002|16-Week Safety Follow-up Period|Depression|0
6006482|NCT00090103|9600481|FG000|16-Week Safety Follow-up Period|Diabetes Uncontrolled|0
6006483|NCT00090103|9600482|FG001|16-Week Safety Follow-up Period|Diabetes Uncontrolled|1
6006484|NCT00090103|9600483|FG002|16-Week Safety Follow-up Period|Diabetes Uncontrolled|0
6006485|NCT00090103|9600481|FG000|16-Week Safety Follow-up Period|Jailed|0
6006486|NCT00090103|9600482|FG001|16-Week Safety Follow-up Period|Jailed|1
6006487|NCT00090103|9600483|FG002|16-Week Safety Follow-up Period|Jailed|0
6006488|NCT00090103|9600481|FG000|16-Week Safety Follow-up Period|Other|0
6006489|NCT00090103|9600482|FG001|16-Week Safety Follow-up Period|Other|1
6006490|NCT00090103|9600483|FG002|16-Week Safety Follow-up Period|Other|0
6006491|NCT00090220|9600493|FG000|Base Study Vaccination Period|Randomized not Vaccinated|1
6006492|NCT00090220|9600494|FG001|Base Study Vaccination Period|Randomized not Vaccinated|1
6006493|NCT00090220|9600495|FG002|Base Study Vaccination Period|Randomized not Vaccinated|0
6006494|NCT00090220|9600496|FG003|Base Study Vaccination Period|Randomized not Vaccinated|0
6006495|NCT00090220|9600497|FG004|Base Study Vaccination Period|Randomized not Vaccinated|0
6006496|NCT00090220|9600498|FG005|Base Study Vaccination Period|Randomized not Vaccinated|0
6006497|NCT00090220|9600493|FG000|Base Study Vaccination Period|Adverse Event|6
6006498|NCT00090220|9600494|FG001|Base Study Vaccination Period|Adverse Event|1
6006499|NCT00090220|9600495|FG002|Base Study Vaccination Period|Adverse Event|0
6006500|NCT00090220|9600496|FG003|Base Study Vaccination Period|Adverse Event|0
6006501|NCT00090220|9600497|FG004|Base Study Vaccination Period|Adverse Event|0
6006502|NCT00090220|9600498|FG005|Base Study Vaccination Period|Adverse Event|0
6006503|NCT00090220|9600493|FG000|Base Study Vaccination Period|Lost to Follow-up|24
6006504|NCT00090220|9600494|FG001|Base Study Vaccination Period|Lost to Follow-up|28
6006505|NCT00090220|9600495|FG002|Base Study Vaccination Period|Lost to Follow-up|0
6006506|NCT00090220|9600496|FG003|Base Study Vaccination Period|Lost to Follow-up|0
6006507|NCT00090220|9600497|FG004|Base Study Vaccination Period|Lost to Follow-up|0
6006508|NCT00090220|9600498|FG005|Base Study Vaccination Period|Lost to Follow-up|0
6006509|NCT00090220|9600493|FG000|Base Study Vaccination Period|Withdrawal by Subject|23
6006510|NCT00090220|9600494|FG001|Base Study Vaccination Period|Withdrawal by Subject|27
6006511|NCT00090220|9600495|FG002|Base Study Vaccination Period|Withdrawal by Subject|0
6006512|NCT00090220|9600496|FG003|Base Study Vaccination Period|Withdrawal by Subject|0
6006513|NCT00090220|9600497|FG004|Base Study Vaccination Period|Withdrawal by Subject|0
6006514|NCT00090220|9600498|FG005|Base Study Vaccination Period|Withdrawal by Subject|0
6006515|NCT00090220|9600493|FG000|Base Study Vaccination Period|Patient Moved|6
6006516|NCT00090220|9600494|FG001|Base Study Vaccination Period|Patient Moved|2
6006517|NCT00090220|9600495|FG002|Base Study Vaccination Period|Patient Moved|0
6006518|NCT00090220|9600496|FG003|Base Study Vaccination Period|Patient Moved|0
6006519|NCT00090220|9600497|FG004|Base Study Vaccination Period|Patient Moved|0
6006520|NCT00090220|9600498|FG005|Base Study Vaccination Period|Patient Moved|0
6006521|NCT00090220|9600493|FG000|Base Study Vaccination Period|Other|4
6006522|NCT00090220|9600494|FG001|Base Study Vaccination Period|Other|4
6006523|NCT00090220|9600495|FG002|Base Study Vaccination Period|Other|0
6006524|NCT00090220|9600496|FG003|Base Study Vaccination Period|Other|0
6006525|NCT00090220|9600497|FG004|Base Study Vaccination Period|Other|0
6006526|NCT00090220|9600498|FG005|Base Study Vaccination Period|Other|0
6006527|NCT00090220|9600493|FG000|Base Study Follow-up Period|Adverse Event|6
6006528|NCT00090220|9600494|FG001|Base Study Follow-up Period|Adverse Event|1
6006529|NCT00090220|9600495|FG002|Base Study Follow-up Period|Adverse Event|0
6006530|NCT00090220|9600496|FG003|Base Study Follow-up Period|Adverse Event|0
6006531|NCT00090220|9600497|FG004|Base Study Follow-up Period|Adverse Event|0
6006532|NCT00090220|9600498|FG005|Base Study Follow-up Period|Adverse Event|0
6006533|NCT00090220|9600493|FG000|Base Study Follow-up Period|Lost to Follow-up|88
6006534|NCT00090220|9600494|FG001|Base Study Follow-up Period|Lost to Follow-up|78
6006535|NCT00090220|9600495|FG002|Base Study Follow-up Period|Lost to Follow-up|0
6006536|NCT00090220|9600496|FG003|Base Study Follow-up Period|Lost to Follow-up|0
6006537|NCT00090220|9600497|FG004|Base Study Follow-up Period|Lost to Follow-up|0
6006538|NCT00090220|9600498|FG005|Base Study Follow-up Period|Lost to Follow-up|0
6006539|NCT00090220|9600493|FG000|Base Study Follow-up Period|Withdrawal by Subject|27
6006540|NCT00090220|9600494|FG001|Base Study Follow-up Period|Withdrawal by Subject|36
6006541|NCT00090220|9600495|FG002|Base Study Follow-up Period|Withdrawal by Subject|0
6006542|NCT00090220|9600496|FG003|Base Study Follow-up Period|Withdrawal by Subject|0
6006543|NCT00090220|9600497|FG004|Base Study Follow-up Period|Withdrawal by Subject|0
6006544|NCT00090220|9600498|FG005|Base Study Follow-up Period|Withdrawal by Subject|0
6006545|NCT00090220|9600493|FG000|Base Study Follow-up Period|Patient Moved|20
6006546|NCT00090220|9600494|FG001|Base Study Follow-up Period|Patient Moved|28
6006547|NCT00090220|9600495|FG002|Base Study Follow-up Period|Patient Moved|0
6006548|NCT00090220|9600496|FG003|Base Study Follow-up Period|Patient Moved|0
6006549|NCT00090220|9600497|FG004|Base Study Follow-up Period|Patient Moved|0
6006550|NCT00090220|9600498|FG005|Base Study Follow-up Period|Patient Moved|0
6006551|NCT00090220|9600493|FG000|Base Study Follow-up Period|Other|19
6006552|NCT00090220|9600494|FG001|Base Study Follow-up Period|Other|21
6006553|NCT00090220|9600495|FG002|Base Study Follow-up Period|Other|0
6006554|NCT00090220|9600496|FG003|Base Study Follow-up Period|Other|0
6006555|NCT00090220|9600497|FG004|Base Study Follow-up Period|Other|0
6006556|NCT00090220|9600498|FG005|Base Study Follow-up Period|Other|0
6006557|NCT00090220|9600493|FG000|Extension 1 (EXT1)|Adverse Event|0
6006558|NCT00090220|9600494|FG001|Extension 1 (EXT1)|Adverse Event|0
6006559|NCT00090220|9600495|FG002|Extension 1 (EXT1)|Adverse Event|4
6006560|NCT00090220|9600496|FG003|Extension 1 (EXT1)|Adverse Event|0
6006561|NCT00090220|9600497|FG004|Extension 1 (EXT1)|Adverse Event|0
6006562|NCT00090220|9600498|FG005|Extension 1 (EXT1)|Adverse Event|0
6006563|NCT00090220|9600493|FG000|Extension 1 (EXT1)|Lost to Follow-up|0
6006564|NCT00090220|9600494|FG001|Extension 1 (EXT1)|Lost to Follow-up|0
6006565|NCT00090220|9600495|FG002|Extension 1 (EXT1)|Lost to Follow-up|22
6006566|NCT00090220|9600496|FG003|Extension 1 (EXT1)|Lost to Follow-up|0
6006567|NCT00090220|9600497|FG004|Extension 1 (EXT1)|Lost to Follow-up|0
6006568|NCT00090220|9600498|FG005|Extension 1 (EXT1)|Lost to Follow-up|0
6006569|NCT00090220|9600493|FG000|Extension 1 (EXT1)|Moved|0
6006570|NCT00090220|9600494|FG001|Extension 1 (EXT1)|Moved|0
6006571|NCT00090220|9600495|FG002|Extension 1 (EXT1)|Moved|2
6006572|NCT00090220|9600496|FG003|Extension 1 (EXT1)|Moved|1
6006573|NCT00090220|9600497|FG004|Extension 1 (EXT1)|Moved|0
6006574|NCT00090220|9600498|FG005|Extension 1 (EXT1)|Moved|0
6006575|NCT00090220|9600493|FG000|Extension 1 (EXT1)|Withdrawal by Subject|0
6006576|NCT00090220|9600494|FG001|Extension 1 (EXT1)|Withdrawal by Subject|0
6006577|NCT00090220|9600495|FG002|Extension 1 (EXT1)|Withdrawal by Subject|25
6006578|NCT00090220|9600496|FG003|Extension 1 (EXT1)|Withdrawal by Subject|0
6006579|NCT00090220|9600497|FG004|Extension 1 (EXT1)|Withdrawal by Subject|0
6006580|NCT00090220|9600498|FG005|Extension 1 (EXT1)|Withdrawal by Subject|0
6006581|NCT00090220|9600493|FG000|Extension 1 (EXT1)|Protocol Violation|0
6006582|NCT00090220|9600494|FG001|Extension 1 (EXT1)|Protocol Violation|0
6006583|NCT00090220|9600495|FG002|Extension 1 (EXT1)|Protocol Violation|0
6006584|NCT00090220|9600496|FG003|Extension 1 (EXT1)|Protocol Violation|1
6006585|NCT00090220|9600497|FG004|Extension 1 (EXT1)|Protocol Violation|0
6006586|NCT00090220|9600498|FG005|Extension 1 (EXT1)|Protocol Violation|0
6006587|NCT00090220|9600493|FG000|Extension 1 (EXT1)|Other reason|0
6006588|NCT00090220|9600494|FG001|Extension 1 (EXT1)|Other reason|0
6006589|NCT00090220|9600495|FG002|Extension 1 (EXT1)|Other reason|2
6006590|NCT00090220|9600496|FG003|Extension 1 (EXT1)|Other reason|0
6006591|NCT00090220|9600497|FG004|Extension 1 (EXT1)|Other reason|0
6006592|NCT00090220|9600498|FG005|Extension 1 (EXT1)|Other reason|0
6006593|NCT00090220|9600493|FG000|Long-term Follow-up (EXT2)|Lost to Follow-up|0
6006594|NCT00090220|9600494|FG001|Long-term Follow-up (EXT2)|Lost to Follow-up|0
6006595|NCT00090220|9600495|FG002|Long-term Follow-up (EXT2)|Lost to Follow-up|0
6006596|NCT00090220|9600496|FG003|Long-term Follow-up (EXT2)|Lost to Follow-up|0
6006597|NCT00090220|9600497|FG004|Long-term Follow-up (EXT2)|Lost to Follow-up|38
6006598|NCT00090220|9600498|FG005|Long-term Follow-up (EXT2)|Lost to Follow-up|23
6006599|NCT00090220|9600493|FG000|Long-term Follow-up (EXT2)|Death|0
6006600|NCT00090220|9600494|FG001|Long-term Follow-up (EXT2)|Death|0
6006601|NCT00090220|9600495|FG002|Long-term Follow-up (EXT2)|Death|0
6006602|NCT00090220|9600496|FG003|Long-term Follow-up (EXT2)|Death|0
6006603|NCT00090220|9600497|FG004|Long-term Follow-up (EXT2)|Death|1
6006604|NCT00090220|9600498|FG005|Long-term Follow-up (EXT2)|Death|1
6006605|NCT00090220|9600493|FG000|Long-term Follow-up (EXT2)|Withdrawal by Subject|0
6006606|NCT00090220|9600494|FG001|Long-term Follow-up (EXT2)|Withdrawal by Subject|0
6006607|NCT00090220|9600495|FG002|Long-term Follow-up (EXT2)|Withdrawal by Subject|0
6006608|NCT00090220|9600496|FG003|Long-term Follow-up (EXT2)|Withdrawal by Subject|0
6006609|NCT00090220|9600497|FG004|Long-term Follow-up (EXT2)|Withdrawal by Subject|4
6006610|NCT00090220|9600498|FG005|Long-term Follow-up (EXT2)|Withdrawal by Subject|4
6006611|NCT00090220|9600493|FG000|Long-term Follow-up (EXT2)|Other|0
6006612|NCT00090220|9600494|FG001|Long-term Follow-up (EXT2)|Other|0
6006613|NCT00090220|9600495|FG002|Long-term Follow-up (EXT2)|Other|0
6006614|NCT00090220|9600496|FG003|Long-term Follow-up (EXT2)|Other|0
6006615|NCT00090220|9600497|FG004|Long-term Follow-up (EXT2)|Other|1
6006616|NCT00090220|9600498|FG005|Long-term Follow-up (EXT2)|Other|0
6006617|NCT00090233|9600517|FG000|Overall Study|Randomized Not Vaccinated (Visit 1)|609
6006618|NCT00090233|9600518|FG001|Overall Study|Randomized Not Vaccinated (Visit 1)|627
6006619|NCT00090233|9600517|FG000|Overall Study|Adverse Event|214
6006620|NCT00090233|9600518|FG001|Overall Study|Adverse Event|198
6006621|NCT00090233|9600517|FG000|Overall Study|Lost to Follow-up|68
6006622|NCT00090233|9600518|FG001|Overall Study|Lost to Follow-up|95
6006623|NCT00090233|9600517|FG000|Overall Study|Protocol Violation|960
6006624|NCT00090233|9600518|FG001|Overall Study|Protocol Violation|1022
6006625|NCT00090233|9600517|FG000|Overall Study|Withdrawal by Subject|182
6006626|NCT00090233|9600518|FG001|Overall Study|Withdrawal by Subject|211
6006627|NCT00090233|9600517|FG000|Overall Study|Moved|203
6006628|NCT00090233|9600518|FG001|Overall Study|Moved|189
6006629|NCT00090233|9600517|FG000|Overall Study|Other|1211
6006630|NCT00090233|9600518|FG001|Overall Study|Other|1160
6006631|NCT00090233|9600517|FG000|Overall Study|Data not available at data cut-off point|1552
6006632|NCT00090233|9600518|FG001|Overall Study|Data not available at data cut-off point|1563
6006633|NCT00090285|9600530|FG000|Base Study Vaccination Period|Randomized Not Vaccinated|7
6006634|NCT00090285|9600531|FG001|Base Study Vaccination Period|Randomized Not Vaccinated|3
6006635|NCT00090285|9600532|FG002|Base Study Vaccination Period|Randomized Not Vaccinated|0
6006636|NCT00090285|9600533|FG003|Base Study Vaccination Period|Randomized Not Vaccinated|0
6006637|NCT00090285|9600534|FG004|Base Study Vaccination Period|Randomized Not Vaccinated|0
6006638|NCT00090285|9600535|FG005|Base Study Vaccination Period|Randomized Not Vaccinated|0
6006639|NCT00090285|9600530|FG000|Base Study Vaccination Period|Adverse Event|2
6006640|NCT00090285|9600531|FG001|Base Study Vaccination Period|Adverse Event|4
6006641|NCT00090285|9600532|FG002|Base Study Vaccination Period|Adverse Event|0
6006642|NCT00090285|9600533|FG003|Base Study Vaccination Period|Adverse Event|0
6006643|NCT00090285|9600534|FG004|Base Study Vaccination Period|Adverse Event|0
6006644|NCT00090285|9600535|FG005|Base Study Vaccination Period|Adverse Event|0
6006645|NCT00090285|9600530|FG000|Base Study Vaccination Period|Lost to Follow-up|111
6006646|NCT00090285|9600531|FG001|Base Study Vaccination Period|Lost to Follow-up|112
6006647|NCT00090285|9600532|FG002|Base Study Vaccination Period|Lost to Follow-up|0
6006648|NCT00090285|9600533|FG003|Base Study Vaccination Period|Lost to Follow-up|0
6006649|NCT00090285|9600534|FG004|Base Study Vaccination Period|Lost to Follow-up|0
6006650|NCT00090285|9600535|FG005|Base Study Vaccination Period|Lost to Follow-up|0
6006651|NCT00090285|9600530|FG000|Base Study Vaccination Period|Protocol Violation|2
6006652|NCT00090285|9600531|FG001|Base Study Vaccination Period|Protocol Violation|3
6006653|NCT00090285|9600532|FG002|Base Study Vaccination Period|Protocol Violation|0
6006654|NCT00090285|9600533|FG003|Base Study Vaccination Period|Protocol Violation|0
6006655|NCT00090285|9600534|FG004|Base Study Vaccination Period|Protocol Violation|0
6006656|NCT00090285|9600535|FG005|Base Study Vaccination Period|Protocol Violation|0
6006657|NCT00090285|9600530|FG000|Base Study Vaccination Period|Withdrawal by Subject|64
6006658|NCT00090285|9600531|FG001|Base Study Vaccination Period|Withdrawal by Subject|69
6006659|NCT00090285|9600532|FG002|Base Study Vaccination Period|Withdrawal by Subject|0
6006660|NCT00090285|9600533|FG003|Base Study Vaccination Period|Withdrawal by Subject|0
6006661|NCT00090285|9600534|FG004|Base Study Vaccination Period|Withdrawal by Subject|0
6006662|NCT00090285|9600535|FG005|Base Study Vaccination Period|Withdrawal by Subject|0
6006663|NCT00090285|9600530|FG000|Base Study Vaccination Period|Uncooperative|2
6006664|NCT00090285|9600531|FG001|Base Study Vaccination Period|Uncooperative|2
6006665|NCT00090285|9600532|FG002|Base Study Vaccination Period|Uncooperative|0
6006666|NCT00090285|9600533|FG003|Base Study Vaccination Period|Uncooperative|0
6006667|NCT00090285|9600534|FG004|Base Study Vaccination Period|Uncooperative|0
6006668|NCT00090285|9600535|FG005|Base Study Vaccination Period|Uncooperative|0
6006669|NCT00090285|9600530|FG000|Base Study Vaccination Period|Moved|20
6006670|NCT00090285|9600531|FG001|Base Study Vaccination Period|Moved|21
6006671|NCT00090285|9600532|FG002|Base Study Vaccination Period|Moved|0
6006672|NCT00090285|9600533|FG003|Base Study Vaccination Period|Moved|0
6006673|NCT00090285|9600534|FG004|Base Study Vaccination Period|Moved|0
6006674|NCT00090285|9600535|FG005|Base Study Vaccination Period|Moved|0
6006675|NCT00090285|9600530|FG000|Base Study Vaccination Period|Site Terminated|1
6006676|NCT00090285|9600531|FG001|Base Study Vaccination Period|Site Terminated|0
6006677|NCT00090285|9600532|FG002|Base Study Vaccination Period|Site Terminated|0
6006678|NCT00090285|9600533|FG003|Base Study Vaccination Period|Site Terminated|0
6006679|NCT00090285|9600534|FG004|Base Study Vaccination Period|Site Terminated|0
6006680|NCT00090285|9600535|FG005|Base Study Vaccination Period|Site Terminated|0
6006681|NCT00090285|9600530|FG000|Base Study Vaccination Period|Other|2
6006682|NCT00090285|9600531|FG001|Base Study Vaccination Period|Other|2
6006683|NCT00090285|9600532|FG002|Base Study Vaccination Period|Other|0
6006684|NCT00090285|9600533|FG003|Base Study Vaccination Period|Other|0
6006685|NCT00090285|9600534|FG004|Base Study Vaccination Period|Other|0
6006686|NCT00090285|9600535|FG005|Base Study Vaccination Period|Other|0
6006687|NCT00090285|9600530|FG000|Base Study Vaccination Period|Subject Incarcerated|2
6006688|NCT00090285|9600531|FG001|Base Study Vaccination Period|Subject Incarcerated|2
6006689|NCT00090285|9600532|FG002|Base Study Vaccination Period|Subject Incarcerated|0
6006690|NCT00090285|9600533|FG003|Base Study Vaccination Period|Subject Incarcerated|0
6006691|NCT00090285|9600534|FG004|Base Study Vaccination Period|Subject Incarcerated|0
6006692|NCT00090285|9600535|FG005|Base Study Vaccination Period|Subject Incarcerated|0
6006693|NCT00090285|9600530|FG000|Base Study Vaccination Period|HIV positive|1
6006694|NCT00090285|9600531|FG001|Base Study Vaccination Period|HIV positive|1
6006695|NCT00090285|9600532|FG002|Base Study Vaccination Period|HIV positive|0
6006696|NCT00090285|9600533|FG003|Base Study Vaccination Period|HIV positive|0
6006697|NCT00090285|9600534|FG004|Base Study Vaccination Period|HIV positive|0
6006698|NCT00090285|9600535|FG005|Base Study Vaccination Period|HIV positive|0
6006699|NCT00090285|9600530|FG000|Base Study Follow-up Period|Adverse Event|3
6006700|NCT00090285|9600531|FG001|Base Study Follow-up Period|Adverse Event|10
6006701|NCT00090285|9600532|FG002|Base Study Follow-up Period|Adverse Event|0
6006702|NCT00090285|9600533|FG003|Base Study Follow-up Period|Adverse Event|0
6006703|NCT00090285|9600534|FG004|Base Study Follow-up Period|Adverse Event|0
6006704|NCT00090285|9600535|FG005|Base Study Follow-up Period|Adverse Event|0
6006705|NCT00090285|9600530|FG000|Base Study Follow-up Period|Lost to Follow-up|232
6006706|NCT00090285|9600531|FG001|Base Study Follow-up Period|Lost to Follow-up|226
6006707|NCT00090285|9600532|FG002|Base Study Follow-up Period|Lost to Follow-up|0
6006708|NCT00090285|9600533|FG003|Base Study Follow-up Period|Lost to Follow-up|0
6006709|NCT00090285|9600534|FG004|Base Study Follow-up Period|Lost to Follow-up|0
6006710|NCT00090285|9600535|FG005|Base Study Follow-up Period|Lost to Follow-up|0
6006711|NCT00090285|9600530|FG000|Base Study Follow-up Period|Withdrawal by Subject|53
6006712|NCT00090285|9600531|FG001|Base Study Follow-up Period|Withdrawal by Subject|64
6006713|NCT00090285|9600532|FG002|Base Study Follow-up Period|Withdrawal by Subject|0
6006714|NCT00090285|9600533|FG003|Base Study Follow-up Period|Withdrawal by Subject|0
6006715|NCT00090285|9600534|FG004|Base Study Follow-up Period|Withdrawal by Subject|0
6006716|NCT00090285|9600535|FG005|Base Study Follow-up Period|Withdrawal by Subject|0
6006717|NCT00090285|9600530|FG000|Base Study Follow-up Period|Moved|41
6006718|NCT00090285|9600531|FG001|Base Study Follow-up Period|Moved|36
6006719|NCT00090285|9600532|FG002|Base Study Follow-up Period|Moved|0
6006720|NCT00090285|9600533|FG003|Base Study Follow-up Period|Moved|0
6006721|NCT00090285|9600534|FG004|Base Study Follow-up Period|Moved|0
6006722|NCT00090285|9600535|FG005|Base Study Follow-up Period|Moved|0
6006723|NCT00090285|9600530|FG000|Base Study Follow-up Period|Other|2
6006724|NCT00090285|9600531|FG001|Base Study Follow-up Period|Other|0
6006725|NCT00090285|9600532|FG002|Base Study Follow-up Period|Other|0
6006726|NCT00090285|9600533|FG003|Base Study Follow-up Period|Other|0
6006727|NCT00090285|9600534|FG004|Base Study Follow-up Period|Other|0
6006728|NCT00090285|9600535|FG005|Base Study Follow-up Period|Other|0
6006729|NCT00090285|9600530|FG000|Base Study Follow-up Period|Protocol Violation|1
6006730|NCT00090285|9600531|FG001|Base Study Follow-up Period|Protocol Violation|0
6006731|NCT00090285|9600532|FG002|Base Study Follow-up Period|Protocol Violation|0
6006732|NCT00090285|9600533|FG003|Base Study Follow-up Period|Protocol Violation|0
6006733|NCT00090285|9600534|FG004|Base Study Follow-up Period|Protocol Violation|0
6006734|NCT00090285|9600535|FG005|Base Study Follow-up Period|Protocol Violation|0
6006735|NCT00090285|9600530|FG000|Base Study Follow-up Period|Uncooperative|3
6006736|NCT00090285|9600531|FG001|Base Study Follow-up Period|Uncooperative|4
6006737|NCT00090285|9600532|FG002|Base Study Follow-up Period|Uncooperative|0
6006738|NCT00090285|9600533|FG003|Base Study Follow-up Period|Uncooperative|0
6006739|NCT00090285|9600534|FG004|Base Study Follow-up Period|Uncooperative|0
6006740|NCT00090285|9600535|FG005|Base Study Follow-up Period|Uncooperative|0
6006741|NCT00090285|9600530|FG000|Base Study Follow-up Period|Subject Incarcerated|0
6006742|NCT00090285|9600531|FG001|Base Study Follow-up Period|Subject Incarcerated|2
6006743|NCT00090285|9600532|FG002|Base Study Follow-up Period|Subject Incarcerated|0
6006744|NCT00090285|9600533|FG003|Base Study Follow-up Period|Subject Incarcerated|0
6006745|NCT00090285|9600534|FG004|Base Study Follow-up Period|Subject Incarcerated|0
6006746|NCT00090285|9600535|FG005|Base Study Follow-up Period|Subject Incarcerated|0
6006747|NCT00090285|9600530|FG000|Extension 1|Adverse Event|0
6006748|NCT00090285|9600531|FG001|Extension 1|Adverse Event|0
6006749|NCT00090285|9600532|FG002|Extension 1|Adverse Event|2
6006750|NCT00090285|9600533|FG003|Extension 1|Adverse Event|0
6006751|NCT00090285|9600534|FG004|Extension 1|Adverse Event|0
6006752|NCT00090285|9600535|FG005|Extension 1|Adverse Event|0
6006753|NCT00090285|9600530|FG000|Extension 1|Lost to Follow-up|0
6006754|NCT00090285|9600531|FG001|Extension 1|Lost to Follow-up|0
6006755|NCT00090285|9600532|FG002|Extension 1|Lost to Follow-up|35
6006756|NCT00090285|9600533|FG003|Extension 1|Lost to Follow-up|0
6006757|NCT00090285|9600534|FG004|Extension 1|Lost to Follow-up|0
6006758|NCT00090285|9600535|FG005|Extension 1|Lost to Follow-up|0
6006759|NCT00090285|9600530|FG000|Extension 1|Withdrawal by Subject|0
6006760|NCT00090285|9600531|FG001|Extension 1|Withdrawal by Subject|0
6006761|NCT00090285|9600532|FG002|Extension 1|Withdrawal by Subject|13
6006762|NCT00090285|9600533|FG003|Extension 1|Withdrawal by Subject|1
6006763|NCT00090285|9600534|FG004|Extension 1|Withdrawal by Subject|0
6006764|NCT00090285|9600535|FG005|Extension 1|Withdrawal by Subject|0
6006765|NCT00090285|9600530|FG000|Extension 1|Other|0
6006766|NCT00090285|9600531|FG001|Extension 1|Other|0
6006767|NCT00090285|9600532|FG002|Extension 1|Other|4
6006768|NCT00090285|9600533|FG003|Extension 1|Other|0
6006769|NCT00090285|9600534|FG004|Extension 1|Other|0
6006770|NCT00090285|9600535|FG005|Extension 1|Other|0
6006771|NCT00090285|9600530|FG000|Extension 1|Moved|0
6006772|NCT00090285|9600531|FG001|Extension 1|Moved|0
6006773|NCT00090285|9600532|FG002|Extension 1|Moved|3
6006774|NCT00090285|9600533|FG003|Extension 1|Moved|0
6006775|NCT00090285|9600534|FG004|Extension 1|Moved|0
6006776|NCT00090285|9600535|FG005|Extension 1|Moved|0
6006777|NCT00090285|9600530|FG000|Long-term Follow-up (EXT2)|Adverse Event|0
6006778|NCT00090285|9600531|FG001|Long-term Follow-up (EXT2)|Adverse Event|0
6006779|NCT00090285|9600532|FG002|Long-term Follow-up (EXT2)|Adverse Event|0
6006780|NCT00090285|9600533|FG003|Long-term Follow-up (EXT2)|Adverse Event|0
6006781|NCT00090285|9600534|FG004|Long-term Follow-up (EXT2)|Adverse Event|5
6006782|NCT00090285|9600535|FG005|Long-term Follow-up (EXT2)|Adverse Event|2
6006783|NCT00090285|9600530|FG000|Long-term Follow-up (EXT2)|Lost to Follow-up|0
6006784|NCT00090285|9600531|FG001|Long-term Follow-up (EXT2)|Lost to Follow-up|0
6006785|NCT00090285|9600532|FG002|Long-term Follow-up (EXT2)|Lost to Follow-up|0
6006786|NCT00090285|9600533|FG003|Long-term Follow-up (EXT2)|Lost to Follow-up|0
6006787|NCT00090285|9600534|FG004|Long-term Follow-up (EXT2)|Lost to Follow-up|156
6006788|NCT00090285|9600535|FG005|Long-term Follow-up (EXT2)|Lost to Follow-up|143
6006789|NCT00090285|9600530|FG000|Long-term Follow-up (EXT2)|Withdrawal by Subject|0
6006790|NCT00090285|9600531|FG001|Long-term Follow-up (EXT2)|Withdrawal by Subject|0
6006791|NCT00090285|9600532|FG002|Long-term Follow-up (EXT2)|Withdrawal by Subject|0
6006792|NCT00090285|9600533|FG003|Long-term Follow-up (EXT2)|Withdrawal by Subject|0
6006793|NCT00090285|9600534|FG004|Long-term Follow-up (EXT2)|Withdrawal by Subject|60
6006794|NCT00090285|9600535|FG005|Long-term Follow-up (EXT2)|Withdrawal by Subject|53
6006795|NCT00090285|9600530|FG000|Long-term Follow-up (EXT2)|Physician Decision|0
6006796|NCT00090285|9600531|FG001|Long-term Follow-up (EXT2)|Physician Decision|0
6006797|NCT00090285|9600532|FG002|Long-term Follow-up (EXT2)|Physician Decision|0
6006798|NCT00090285|9600533|FG003|Long-term Follow-up (EXT2)|Physician Decision|0
6006799|NCT00090285|9600534|FG004|Long-term Follow-up (EXT2)|Physician Decision|6
6006800|NCT00090285|9600535|FG005|Long-term Follow-up (EXT2)|Physician Decision|5
6006801|NCT00090363|9600553|FG000|Overall Study|Lost to Follow-up|1
6006802|NCT00090363|9600554|FG001|Overall Study|Lost to Follow-up|2
6006803|NCT00090363|9600555|FG002|Overall Study|Lost to Follow-up|1
6006804|NCT00090363|9600553|FG000|Overall Study|Withdrawal by Subject|7
6006805|NCT00090363|9600554|FG001|Overall Study|Withdrawal by Subject|7
6006806|NCT00090363|9600555|FG002|Overall Study|Withdrawal by Subject|6
6006807|NCT00090363|9600553|FG000|Overall Study|Study-specific discontinuation criteria|75
6006808|NCT00090363|9600554|FG001|Overall Study|Study-specific discontinuation criteria|74
6006809|NCT00090363|9600555|FG002|Overall Study|Study-specific discontinuation criteria|62
6006810|NCT00090363|9600553|FG000|Overall Study|Eligibility criteria not fulfilled|0
6006811|NCT00090363|9600554|FG001|Overall Study|Eligibility criteria not fulfilled|0
6006812|NCT00090363|9600555|FG002|Overall Study|Eligibility criteria not fulfilled|1
6006813|NCT00090363|9600553|FG000|Overall Study|Consent expired|7
6006814|NCT00090363|9600554|FG001|Overall Study|Consent expired|10
6006815|NCT00090363|9600555|FG002|Overall Study|Consent expired|9
6006816|NCT00090363|9600553|FG000|Overall Study|Reasons not specified|2
6006817|NCT00090363|9600554|FG001|Overall Study|Reasons not specified|1
6006818|NCT00090363|9600555|FG002|Overall Study|Reasons not specified|1
6074440|NCT00573183|9678320|FG001|Overall Study|Lost to Follow-up|50
6074441|NCT00573183|9678319|FG000|Overall Study|Withdrawal by Subject|8
6006819|NCT00090363|9600553|FG000|Overall Study|Continuing on study off treatment|14
6074442|NCT00573183|9678320|FG001|Overall Study|Withdrawal by Subject|2
6006820|NCT00090363|9600554|FG001|Overall Study|Continuing on study off treatment|13
6006821|NCT00090363|9600555|FG002|Overall Study|Continuing on study off treatment|16
6006822|NCT00090402|9600566|FG000|Overall Study|Death|1
6006823|NCT00090402|9600567|FG001|Overall Study|Death|1
6006824|NCT00090402|9600568|FG002|Overall Study|Death|0
6006825|NCT00090402|9600566|FG000|Overall Study|subject moved|0
6074443|NCT00573183|9678319|FG000|Overall Study|Death|0
6006826|NCT00090402|9600567|FG001|Overall Study|subject moved|1
6006827|NCT00090402|9600568|FG002|Overall Study|subject moved|0
6006828|NCT00090402|9600566|FG000|Overall Study|stopped taking study medication|1
6006829|NCT00090402|9600567|FG001|Overall Study|stopped taking study medication|0
6006830|NCT00090402|9600568|FG002|Overall Study|stopped taking study medication|1
6006831|NCT00090493|9600579|FG000|Overall Study|Physician Decision|2
6006832|NCT00090519|9600585|FG000|Overall Study|Adverse Event|5
6006833|NCT00090519|9600586|FG001|Overall Study|Adverse Event|4
6006834|NCT00090519|9600585|FG000|Overall Study|Death|9
6006835|NCT00090519|9600586|FG001|Overall Study|Death|9
6006836|NCT00090519|9600585|FG000|Overall Study|Lost to Follow-up|26
6006837|NCT00090519|9600586|FG001|Overall Study|Lost to Follow-up|29
6006838|NCT00090519|9600585|FG000|Overall Study|Withdrawal by Subject|28
6006839|NCT00090519|9600586|FG001|Overall Study|Withdrawal by Subject|29
6006840|NCT00090519|9600585|FG000|Overall Study|Physician Decision|2
6006841|NCT00090519|9600586|FG001|Overall Study|Physician Decision|3
6006842|NCT00090519|9600585|FG000|Overall Study|Sponsor Decision|3
6006843|NCT00090519|9600586|FG001|Overall Study|Sponsor Decision|1
6006844|NCT00090545|9600594|FG000|Overall Study|Disease progression on study|21
6006845|NCT00090545|9600595|FG001|Overall Study|Disease progression on study|17
6006846|NCT00090545|9600594|FG000|Overall Study|Refused further treatment|1
6006847|NCT00090545|9600595|FG001|Overall Study|Refused further treatment|4
6006848|NCT00090545|9600594|FG000|Overall Study|Death|0
6006849|NCT00090545|9600595|FG001|Overall Study|Death|1
6006850|NCT00090545|9600594|FG000|Overall Study|Adverse Event|0
6006851|NCT00090545|9600595|FG001|Overall Study|Adverse Event|2
6006852|NCT00090584|9600605|FG000|Baseline to 10 Weeks|Lost to Follow-up|15
6006853|NCT00090584|9600606|FG001|Baseline to 10 Weeks|Lost to Follow-up|12
6006854|NCT00090584|9600605|FG000|Baseline to 8 Months|Lost to Follow-up|44
6006855|NCT00090584|9600606|FG001|Baseline to 8 Months|Lost to Follow-up|41
6006856|NCT00090610|9600622|FG000|Overall Study|Withdrawal by Subject|1
6006857|NCT00090610|9600623|FG001|Overall Study|Withdrawal by Subject|1
6006858|NCT00090753|9600631|FG000|First Treatment Period|Adverse Event|20
6006859|NCT00090753|9600632|FG001|First Treatment Period|Adverse Event|8
6006860|NCT00090753|9600631|FG000|First Treatment Period|Death|88
6006861|NCT00090753|9600632|FG001|First Treatment Period|Death|62
6006862|NCT00090753|9600631|FG000|First Treatment Period|Lack of Efficacy|2
6006863|NCT00090753|9600632|FG001|First Treatment Period|Lack of Efficacy|1
6006864|NCT00090753|9600631|FG000|First Treatment Period|Refused Treatment|32
6006865|NCT00090753|9600632|FG001|First Treatment Period|Refused Treatment|25
6006866|NCT00090753|9600631|FG000|First Treatment Period|Lost to Follow-up|4
6006867|NCT00090753|9600632|FG001|First Treatment Period|Lost to Follow-up|4
6006868|NCT00090753|9600631|FG000|First Treatment Period|Renal Transplant|70
6006869|NCT00090753|9600632|FG001|First Treatment Period|Renal Transplant|50
6006870|NCT00090753|9600631|FG000|First Treatment Period|Mircera Commercialization|1
6006871|NCT00090753|9600632|FG001|First Treatment Period|Mircera Commercialization|0
6006872|NCT00090753|9600631|FG000|First Treatment Period|Other Unrelated to Safety and Efficacy|39
6006873|NCT00090753|9600632|FG001|First Treatment Period|Other Unrelated to Safety and Efficacy|28
6006874|NCT00090753|9600631|FG000|Extended Treatment Period|Adverse Event|11
6006875|NCT00090753|9600632|FG001|Extended Treatment Period|Adverse Event|0
6006876|NCT00090753|9600631|FG000|Extended Treatment Period|Death|58
6006877|NCT00090753|9600632|FG001|Extended Treatment Period|Death|30
6006878|NCT00090753|9600631|FG000|Extended Treatment Period|Lack of Efficacy|1
6006879|NCT00090753|9600632|FG001|Extended Treatment Period|Lack of Efficacy|0
6006880|NCT00090753|9600631|FG000|Extended Treatment Period|Refused Treatment|18
6006881|NCT00090753|9600632|FG001|Extended Treatment Period|Refused Treatment|12
6006882|NCT00090753|9600631|FG000|Extended Treatment Period|Lost to Follow-up|3
6006883|NCT00090753|9600632|FG001|Extended Treatment Period|Lost to Follow-up|1
6006884|NCT00090753|9600631|FG000|Extended Treatment Period|Renal Transplant|15
6006885|NCT00090753|9600632|FG001|Extended Treatment Period|Renal Transplant|12
6006886|NCT00090753|9600631|FG000|Extended Treatment Period|Mircera Commercialization|188
6006887|NCT00090753|9600632|FG001|Extended Treatment Period|Mircera Commercialization|93
6006888|NCT00090753|9600631|FG000|Extended Treatment Period|Other Unrelated to Safety and Efficacy|65
6006889|NCT00090753|9600632|FG001|Extended Treatment Period|Other Unrelated to Safety and Efficacy|43
6006890|NCT00090766|9600641|FG000|Overall Study|Nephrectomy Planned|0
6006891|NCT00090766|9600642|FG001|Overall Study|Nephrectomy Planned|0
6006892|NCT00090766|9600643|FG002|Overall Study|Nephrectomy Planned|1
6006893|NCT00090766|9600641|FG000|Overall Study|Death|1
6006894|NCT00090766|9600642|FG001|Overall Study|Death|0
6006895|NCT00090766|9600643|FG002|Overall Study|Death|0
6006896|NCT00090766|9600641|FG000|Overall Study|Admin|0
6006897|NCT00090766|9600642|FG001|Overall Study|Admin|2
6006898|NCT00090766|9600643|FG002|Overall Study|Admin|0
6006899|NCT00090766|9600641|FG000|Overall Study|Lost to Follow-up|2
6006900|NCT00090766|9600642|FG001|Overall Study|Lost to Follow-up|0
6006901|NCT00090766|9600643|FG002|Overall Study|Lost to Follow-up|2
6006902|NCT00090779|9600655|FG000|Step 1|Withdrawal by Subject|4
6006903|NCT00090779|9600656|FG001|Step 1|Withdrawal by Subject|2
6006904|NCT00090779|9600655|FG000|Step 1|Lost to Follow-up|3
6006905|NCT00090779|9600656|FG001|Step 1|Lost to Follow-up|2
6006906|NCT00090779|9600655|FG000|Step 1|Death|0
6006907|NCT00090779|9600656|FG001|Step 1|Death|2
6006908|NCT00090779|9600655|FG000|Step 1|Physician Decision|1
6006909|NCT00090779|9600656|FG001|Step 1|Physician Decision|0
6006910|NCT00090779|9600655|FG000|Step 1|Pregnancy|1
6006911|NCT00090779|9600656|FG001|Step 1|Pregnancy|0
6006912|NCT00090779|9600655|FG000|Step 1|Non-compliance to study requirements|0
6006913|NCT00090779|9600656|FG001|Step 1|Non-compliance to study requirements|1
6006914|NCT00090779|9600655|FG000|Step 1|Subject relocated|2
6006915|NCT00090779|9600656|FG001|Step 1|Subject relocated|8
6006916|NCT00090779|9600655|FG000|Step 2|Off study per study closure|6
6006917|NCT00090779|9600656|FG001|Step 2|Off study per study closure|16
6006918|NCT00090779|9600655|FG000|Step 2|Subject relocated|0
6006919|NCT00090779|9600656|FG001|Step 2|Subject relocated|1
6006920|NCT00090779|9600655|FG000|Step 2|Non-compliance to study requirements|0
6006921|NCT00090779|9600656|FG001|Step 2|Non-compliance to study requirements|1
6006922|NCT00090779|9600655|FG000|Step 3|Initiation of ART and off extended study|3
6006923|NCT00090779|9600656|FG001|Step 3|Initiation of ART and off extended study|2
6006924|NCT00090779|9600655|FG000|Step 3|Off extended study due to study closure|4
6006925|NCT00090779|9600656|FG001|Step 3|Off extended study due to study closure|3
6006926|NCT00090857|9600674|FG000|Overall Study|Lost to Follow-up|0
6006927|NCT00090857|9600675|FG001|Overall Study|Lost to Follow-up|1
6006928|NCT00090857|9600674|FG000|Overall Study|Withdrawal by Subject|2
6006929|NCT00090857|9600675|FG001|Overall Study|Withdrawal by Subject|0
6006930|NCT00090857|9600674|FG000|Overall Study|Adverse Event|2
6006931|NCT00090857|9600675|FG001|Overall Study|Adverse Event|2
6006932|NCT00090987|9600681|FG000|Overall Study|Adverse Event|5
6006933|NCT00090987|9600681|FG000|Overall Study|Lack of Efficacy|7
6006934|NCT00090987|9600681|FG000|Overall Study|Withdrawal by Subject|3
6006935|NCT00090987|9600681|FG000|Overall Study|alternative therapy|1
6006936|NCT00090987|9600681|FG000|Overall Study|Non-compliance|4
6006937|NCT00090987|9600681|FG000|Overall Study|Incarcerated|1
6006938|NCT00091026|9600687|FG000|Overall Study|Patient deemed non eligible-never receiv|1
6006939|NCT00091026|9600688|FG001|Overall Study|Patient deemed non eligible-never receiv|0
6006940|NCT00091026|9600687|FG000|Overall Study|Patient withdrew and never received trea|0
6006941|NCT00091026|9600688|FG001|Overall Study|Patient withdrew and never received trea|2
6006942|NCT00091026|9600687|FG000|Overall Study|Unknown-never received treatment|0
6006943|NCT00091026|9600688|FG001|Overall Study|Unknown-never received treatment|1
6006944|NCT00091169|9600696|FG000|Overall Study|Disease progression|3
6006945|NCT00091169|9600697|FG001|Overall Study|Disease progression|1
6006946|NCT00091169|9600696|FG000|Overall Study|Adverse Event|11
6006947|NCT00091169|9600697|FG001|Overall Study|Adverse Event|17
6006948|NCT00091169|9600696|FG000|Overall Study|Death|4
6006949|NCT00091169|9600697|FG001|Overall Study|Death|1
6006950|NCT00091169|9600696|FG000|Overall Study|Withdrawal by Subject|10
6006951|NCT00091169|9600697|FG001|Overall Study|Withdrawal by Subject|13
6006952|NCT00091169|9600696|FG000|Overall Study|Other|3
6006953|NCT00091169|9600697|FG001|Overall Study|Other|4
6006954|NCT00091169|9600696|FG000|Overall Study|Not start protocol therapy|26
6006955|NCT00091169|9600697|FG001|Overall Study|Not start protocol therapy|17
6006956|NCT00091390|9600714|FG000|Overall Study|Protocol Violation|1
6006957|NCT00091390|9600714|FG000|Overall Study|No protocol treatment|3
6006958|NCT00091442|9600720|FG000|Overall Study|Progressive Disease|220
6006959|NCT00091442|9600721|FG001|Overall Study|Progressive Disease|189
6006960|NCT00091442|9600720|FG000|Overall Study|Physician Decision|61
6006961|NCT00091442|9600721|FG001|Overall Study|Physician Decision|58
6006962|NCT00091442|9600720|FG000|Overall Study|Withdrawal by Subject|38
6006963|NCT00091442|9600721|FG001|Overall Study|Withdrawal by Subject|46
6006964|NCT00091442|9600720|FG000|Overall Study|Adverse Event|29
6006965|NCT00091442|9600721|FG001|Overall Study|Adverse Event|48
6006966|NCT00091442|9600720|FG000|Overall Study|2cycles therapy beyond Complete response|9
6006967|NCT00091442|9600721|FG001|Overall Study|2cycles therapy beyond Complete response|16
6006968|NCT00091442|9600720|FG000|Overall Study|Death|9
6006969|NCT00091442|9600721|FG001|Overall Study|Death|7
6006970|NCT00091442|9600720|FG000|Overall Study|Lost to Follow-up|1
6006971|NCT00091442|9600721|FG001|Overall Study|Lost to Follow-up|3
6006972|NCT00091442|9600720|FG000|Overall Study|Other|2
6006973|NCT00091442|9600721|FG001|Overall Study|Other|6
6006974|NCT00091572|9600738|FG000|Overall Study|Lost to Follow-up|1
6006975|NCT00091572|9600739|FG001|Overall Study|Lost to Follow-up|1
6006976|NCT00091572|9600738|FG000|Overall Study|Subject's Refusal unrelated to toxicity|14
6006977|NCT00091572|9600739|FG001|Overall Study|Subject's Refusal unrelated to toxicity|22
6006978|NCT00091572|9600738|FG000|Overall Study|Death not due to malignancy/toxicity|1
6006979|NCT00091572|9600739|FG001|Overall Study|Death not due to malignancy/toxicity|3
6006980|NCT00091572|9600738|FG000|Overall Study|Medical Decision unrelated toxicity/PD|10
6006981|NCT00091572|9600739|FG001|Overall Study|Medical Decision unrelated toxicity/PD|22
6006982|NCT00091572|9600738|FG000|Overall Study|Other Reason|6
6006983|NCT00091572|9600739|FG001|Overall Study|Other Reason|13
6006984|NCT00091572|9600738|FG000|Overall Study|Ongoing (still on treatment)|8
6006985|NCT00091572|9600739|FG001|Overall Study|Ongoing (still on treatment)|12
6006986|NCT00091572|9600738|FG000|Overall Study|Major Protocol Violation|2
6006987|NCT00091572|9600739|FG001|Overall Study|Major Protocol Violation|0
6006988|NCT00091572|9600738|FG000|Overall Study|Toxicity (Related AE)|53
6006989|NCT00091572|9600739|FG001|Overall Study|Toxicity (Related AE)|9
6006990|NCT00091793|9600747|FG000|Overall Study|Adverse Event|1
6006991|NCT00091793|9600748|FG001|Overall Study|Adverse Event|2
6006992|NCT00091793|9600747|FG000|Overall Study|Withdrawal by Subject|10
6006993|NCT00091793|9600748|FG001|Overall Study|Withdrawal by Subject|15
6006994|NCT00091793|9600747|FG000|Overall Study|Ineligibility determined|2
6006995|NCT00091793|9600748|FG001|Overall Study|Ineligibility determined|0
6006996|NCT00091793|9600747|FG000|Overall Study|Lost to Follow-up|7
6006997|NCT00091793|9600748|FG001|Overall Study|Lost to Follow-up|5
6006998|NCT00091793|9600747|FG000|Overall Study|Noncompliance|2
6006999|NCT00091793|9600748|FG001|Overall Study|Noncompliance|0
6007000|NCT00091793|9600747|FG000|Overall Study|Other|2
6007001|NCT00091793|9600748|FG001|Overall Study|Other|0
6007002|NCT00091819|9600756|FG000|Overall Study|Adverse Event|1
6007003|NCT00091819|9600757|FG001|Overall Study|Adverse Event|1
6007004|NCT00091819|9600756|FG000|Overall Study|Death|4
6007005|NCT00091819|9600757|FG001|Overall Study|Death|5
6007006|NCT00091819|9600756|FG000|Overall Study|Lost to Follow-up|26
6007007|NCT00091819|9600757|FG001|Overall Study|Lost to Follow-up|23
6007008|NCT00091819|9600756|FG000|Overall Study|Withdrawal by Subject|5
6007009|NCT00091819|9600757|FG001|Overall Study|Withdrawal by Subject|8
6007010|NCT00091819|9600756|FG000|Overall Study|Protocol Violation|1
6007011|NCT00091819|9600757|FG001|Overall Study|Protocol Violation|2
6007012|NCT00091819|9600756|FG000|Overall Study|Other|2
6007013|NCT00091819|9600757|FG001|Overall Study|Other|3
6007014|NCT00091819|9600756|FG000|Overall Study|Never received study treatment|3
6007015|NCT00091819|9600757|FG001|Overall Study|Never received study treatment|4
6007016|NCT00091832|9600769|FG000|Overall Study|Physician Decision|1
6007017|NCT00091832|9600770|FG001|Overall Study|Physician Decision|0
6007018|NCT00091832|9600771|FG002|Overall Study|Physician Decision|0
6007019|NCT00091832|9600772|FG003|Overall Study|Physician Decision|0
6007020|NCT00091832|9600773|FG004|Overall Study|Physician Decision|0
6007021|NCT00091832|9600774|FG005|Overall Study|Physician Decision|0
6007022|NCT00091832|9600769|FG000|Overall Study|Adverse Event|0
6074444|NCT00573183|9678320|FG001|Overall Study|Death|1
6074445|NCT00573183|9678319|FG000|Overall Study|Adverse Event|2
6074446|NCT00573183|9678320|FG001|Overall Study|Adverse Event|0
6074447|NCT00573183|9678319|FG000|Overall Study|Incarceration|5
6074448|NCT00573183|9678320|FG001|Overall Study|Incarceration|8
6074449|NCT00573183|9678319|FG000|Overall Study|Other|5
6074450|NCT00573183|9678320|FG001|Overall Study|Other|2
6074451|NCT00573248|9678330|FG000|Overall Study|scheduling conflicts|15
6074452|NCT00573248|9678331|FG001|Overall Study|scheduling conflicts|11
6074453|NCT00573313|9678361|FG000|Overall Study|Protocol Violation|5
6074454|NCT00573313|9678362|FG001|Overall Study|Protocol Violation|0
6074455|NCT00573313|9678363|FG002|Overall Study|Protocol Violation|6
6074456|NCT00573313|9678364|FG003|Overall Study|Protocol Violation|0
6074457|NCT00573430|9678374|FG000|Overall Study|Incorrect enrollment of randomization|0
6074458|NCT00573430|9678375|FG001|Overall Study|Incorrect enrollment of randomization|4
6074459|NCT00573430|9678376|FG002|Overall Study|Incorrect enrollment of randomization|3
6074460|NCT00573430|9678374|FG000|Overall Study|Adverse Event|0
6074461|NCT00573430|9678375|FG001|Overall Study|Adverse Event|0
6074462|NCT00573430|9678376|FG002|Overall Study|Adverse Event|2
6074463|NCT00573430|9678374|FG000|Overall Study|Withdrawal by Subject|1
6074464|NCT00573430|9678375|FG001|Overall Study|Withdrawal by Subject|0
6074465|NCT00573430|9678376|FG002|Overall Study|Withdrawal by Subject|1
6074466|NCT00573430|9678374|FG000|Overall Study|Protocol Violation|0
6074467|NCT00573430|9678375|FG001|Overall Study|Protocol Violation|1
6074468|NCT00573430|9678376|FG002|Overall Study|Protocol Violation|1
6074469|NCT00573430|9678374|FG000|Overall Study|Eligibility criteria not fulfilled|0
6074470|NCT00573430|9678375|FG001|Overall Study|Eligibility criteria not fulfilled|0
6074471|NCT00573430|9678376|FG002|Overall Study|Eligibility criteria not fulfilled|3
6074472|NCT00573443|9678387|FG000|Double-Blind Phase|Lost to Follow-up|1
6074473|NCT00573443|9678388|FG001|Double-Blind Phase|Lost to Follow-up|3
6074474|NCT00573443|9678389|FG002|Double-Blind Phase|Lost to Follow-up|2
6074475|NCT00573443|9678387|FG000|Double-Blind Phase|Exacerbation of MS symptoms|1
6074476|NCT00573443|9678388|FG001|Double-Blind Phase|Exacerbation of MS symptoms|0
6074477|NCT00573443|9678389|FG002|Double-Blind Phase|Exacerbation of MS symptoms|1
6074478|NCT00573443|9678387|FG000|Double-Blind Phase|Adverse Event|1
6074479|NCT00573443|9678388|FG001|Double-Blind Phase|Adverse Event|5
6074480|NCT00573443|9678389|FG002|Double-Blind Phase|Adverse Event|0
6074481|NCT00573443|9678387|FG000|Double-Blind Phase|Serious Adverse Event (AE)|2
6074482|NCT00573443|9678388|FG001|Double-Blind Phase|Serious Adverse Event (AE)|3
6074483|NCT00573443|9678389|FG002|Double-Blind Phase|Serious Adverse Event (AE)|1
6074484|NCT00573443|9678387|FG000|Double-Blind Phase|Medication refusal due to AE|2
6074485|NCT00573443|9678388|FG001|Double-Blind Phase|Medication refusal due to AE|2
6074486|NCT00573443|9678389|FG002|Double-Blind Phase|Medication refusal due to AE|0
6007023|NCT00091832|9600770|FG001|Overall Study|Adverse Event|0
6007024|NCT00091832|9600771|FG002|Overall Study|Adverse Event|0
6007025|NCT00091832|9600772|FG003|Overall Study|Adverse Event|1
6074487|NCT00573443|9678387|FG000|Double-Blind Phase|Withdrawal by Subject|2
6007026|NCT00091832|9600773|FG004|Overall Study|Adverse Event|3
6007027|NCT00091832|9600774|FG005|Overall Study|Adverse Event|0
6007028|NCT00091832|9600769|FG000|Overall Study|Withdrawal by Subject|4
6007029|NCT00091832|9600770|FG001|Overall Study|Withdrawal by Subject|5
6007030|NCT00091832|9600771|FG002|Overall Study|Withdrawal by Subject|0
6007031|NCT00091832|9600772|FG003|Overall Study|Withdrawal by Subject|1
6007032|NCT00091832|9600773|FG004|Overall Study|Withdrawal by Subject|3
6007033|NCT00091832|9600774|FG005|Overall Study|Withdrawal by Subject|1
6007034|NCT00091832|9600769|FG000|Overall Study|Death|6
6007035|NCT00091832|9600770|FG001|Overall Study|Death|4
6007036|NCT00091832|9600771|FG002|Overall Study|Death|5
6007037|NCT00091832|9600772|FG003|Overall Study|Death|8
6007038|NCT00091832|9600773|FG004|Overall Study|Death|5
6007039|NCT00091832|9600774|FG005|Overall Study|Death|6
6007040|NCT00091832|9600769|FG000|Overall Study|Disease Progression|2
6007041|NCT00091832|9600770|FG001|Overall Study|Disease Progression|0
6007042|NCT00091832|9600771|FG002|Overall Study|Disease Progression|0
6007043|NCT00091832|9600772|FG003|Overall Study|Disease Progression|1
6007044|NCT00091832|9600773|FG004|Overall Study|Disease Progression|1
6007045|NCT00091832|9600774|FG005|Overall Study|Disease Progression|2
6007046|NCT00091832|9600769|FG000|Overall Study|Ineligibility Determined|0
6007047|NCT00091832|9600770|FG001|Overall Study|Ineligibility Determined|0
6007048|NCT00091832|9600771|FG002|Overall Study|Ineligibility Determined|1
6007049|NCT00091832|9600772|FG003|Overall Study|Ineligibility Determined|0
6007050|NCT00091832|9600773|FG004|Overall Study|Ineligibility Determined|1
6007051|NCT00091832|9600774|FG005|Overall Study|Ineligibility Determined|0
6007052|NCT00091832|9600769|FG000|Overall Study|Lost to Follow-up|1
6007053|NCT00091832|9600770|FG001|Overall Study|Lost to Follow-up|0
6007054|NCT00091832|9600771|FG002|Overall Study|Lost to Follow-up|3
6007055|NCT00091832|9600772|FG003|Overall Study|Lost to Follow-up|3
6007056|NCT00091832|9600773|FG004|Overall Study|Lost to Follow-up|2
6007057|NCT00091832|9600774|FG005|Overall Study|Lost to Follow-up|1
6007058|NCT00091832|9600769|FG000|Overall Study|Noncompliance|0
6007059|NCT00091832|9600770|FG001|Overall Study|Noncompliance|1
6007060|NCT00091832|9600771|FG002|Overall Study|Noncompliance|0
6007061|NCT00091832|9600772|FG003|Overall Study|Noncompliance|0
6007062|NCT00091832|9600773|FG004|Overall Study|Noncompliance|0
6007063|NCT00091832|9600774|FG005|Overall Study|Noncompliance|0
6007064|NCT00091832|9600769|FG000|Overall Study|Other|0
6007065|NCT00091832|9600770|FG001|Overall Study|Other|1
6007066|NCT00091832|9600771|FG002|Overall Study|Other|2
6007067|NCT00091832|9600772|FG003|Overall Study|Other|0
6007068|NCT00091832|9600773|FG004|Overall Study|Other|0
6007069|NCT00091832|9600774|FG005|Overall Study|Other|0
6007070|NCT00091832|9600769|FG000|Overall Study|Protocol Violation|0
6007071|NCT00091832|9600770|FG001|Overall Study|Protocol Violation|0
6007072|NCT00091832|9600771|FG002|Overall Study|Protocol Violation|1
6007073|NCT00091832|9600772|FG003|Overall Study|Protocol Violation|0
6007074|NCT00091832|9600773|FG004|Overall Study|Protocol Violation|0
6007075|NCT00091832|9600774|FG005|Overall Study|Protocol Violation|1
6007076|NCT00091949|9600790|FG000|Overall Study|Withdrawal by Subject|117
6007077|NCT00091949|9600791|FG001|Overall Study|Withdrawal by Subject|110
6007078|NCT00091949|9600790|FG000|Overall Study|Lost to Follow-up|58
6007079|NCT00091949|9600791|FG001|Overall Study|Lost to Follow-up|41
6007080|NCT00092417|9600815|FG000|Overall Study|Lost to Follow-up|2
6007081|NCT00092417|9600816|FG001|Overall Study|Lost to Follow-up|0
6007082|NCT00092417|9600815|FG000|Overall Study|Withdrawal by Subject|2
6007083|NCT00092417|9600816|FG001|Overall Study|Withdrawal by Subject|1
6007084|NCT00092417|9600815|FG000|Overall Study|Other|1
6007085|NCT00092417|9600816|FG001|Overall Study|Other|0
6007086|NCT00092443|9600824|FG000|Overall Study|Adverse Event|9
6007087|NCT00092443|9600825|FG001|Overall Study|Adverse Event|13
6007088|NCT00092443|9600824|FG000|Overall Study|Lost to Follow-up|7
6007089|NCT00092443|9600825|FG001|Overall Study|Lost to Follow-up|3
6007090|NCT00092443|9600824|FG000|Overall Study|Protocol Violation|11
6007091|NCT00092443|9600825|FG001|Overall Study|Protocol Violation|9
6007092|NCT00092443|9600824|FG000|Overall Study|Withdrawal by Subject|9
6007093|NCT00092443|9600825|FG001|Overall Study|Withdrawal by Subject|11
6007094|NCT00092443|9600824|FG000|Overall Study|Moved|5
6007095|NCT00092443|9600825|FG001|Overall Study|Moved|5
6007096|NCT00092443|9600824|FG000|Overall Study|Other|17
6007097|NCT00092443|9600825|FG001|Overall Study|Other|13
6047355|NCT00410410|9646253|FG004|Open-Label Period (OL)|Lack of Efficacy|0
6047356|NCT00410410|9646254|FG005|Open-Label Period (OL)|Lack of Efficacy|0
6047357|NCT00410410|9646255|FG006|Open-Label Period (OL)|Lack of Efficacy|0
6047358|NCT00410410|9646256|FG007|Open-Label Period (OL)|Lack of Efficacy|0
6047359|NCT00410410|9646257|FG008|Open-Label Period (OL)|Lack of Efficacy|161
6047360|NCT00410410|9646249|FG000|Open-Label Period (OL)|Lost to Follow-up|0
6047361|NCT00410410|9646250|FG001|Open-Label Period (OL)|Lost to Follow-up|0
6047362|NCT00410410|9646251|FG002|Open-Label Period (OL)|Lost to Follow-up|0
6047363|NCT00410410|9646252|FG003|Open-Label Period (OL)|Lost to Follow-up|0
6047364|NCT00410410|9646253|FG004|Open-Label Period (OL)|Lost to Follow-up|0
6047365|NCT00410410|9646254|FG005|Open-Label Period (OL)|Lost to Follow-up|0
6047366|NCT00410410|9646255|FG006|Open-Label Period (OL)|Lost to Follow-up|0
6047367|NCT00410410|9646256|FG007|Open-Label Period (OL)|Lost to Follow-up|0
6047368|NCT00410410|9646257|FG008|Open-Label Period (OL)|Lost to Follow-up|4
6047369|NCT00410410|9646249|FG000|Open-Label Period (OL)|Withdrawal by Subject|0
6047370|NCT00410410|9646250|FG001|Open-Label Period (OL)|Withdrawal by Subject|0
6047371|NCT00410410|9646251|FG002|Open-Label Period (OL)|Withdrawal by Subject|0
6047372|NCT00410410|9646252|FG003|Open-Label Period (OL)|Withdrawal by Subject|0
6047373|NCT00410410|9646253|FG004|Open-Label Period (OL)|Withdrawal by Subject|0
6047374|NCT00410410|9646254|FG005|Open-Label Period (OL)|Withdrawal by Subject|0
6047375|NCT00410410|9646255|FG006|Open-Label Period (OL)|Withdrawal by Subject|0
6007098|NCT00092456|9600845|FG000|Overall Study|Adverse Event|0
6007099|NCT00092456|9600846|FG001|Overall Study|Adverse Event|0
6007100|NCT00092456|9600847|FG002|Overall Study|Adverse Event|1
6007101|NCT00092456|9600848|FG003|Overall Study|Adverse Event|1
6007102|NCT00092456|9600845|FG000|Overall Study|Lost to Follow-up|2
6007103|NCT00092456|9600846|FG001|Overall Study|Lost to Follow-up|2
6007104|NCT00092456|9600847|FG002|Overall Study|Lost to Follow-up|1
6007105|NCT00092456|9600848|FG003|Overall Study|Lost to Follow-up|2
6007106|NCT00092456|9600845|FG000|Overall Study|Protocol Violation|5
6007107|NCT00092456|9600846|FG001|Overall Study|Protocol Violation|7
6007108|NCT00092456|9600847|FG002|Overall Study|Protocol Violation|8
6007109|NCT00092456|9600848|FG003|Overall Study|Protocol Violation|6
6007110|NCT00092456|9600845|FG000|Overall Study|Withdrawal by Subject|13
6007111|NCT00092456|9600846|FG001|Overall Study|Withdrawal by Subject|5
6007112|NCT00092456|9600847|FG002|Overall Study|Withdrawal by Subject|16
6007113|NCT00092456|9600848|FG003|Overall Study|Withdrawal by Subject|6
6007114|NCT00092456|9600845|FG000|Overall Study|Moved|1
6007115|NCT00092456|9600846|FG001|Overall Study|Moved|1
6007116|NCT00092456|9600847|FG002|Overall Study|Moved|0
6007117|NCT00092456|9600848|FG003|Overall Study|Moved|1
6007118|NCT00092456|9600845|FG000|Overall Study|Other|4
6007119|NCT00092456|9600846|FG001|Overall Study|Other|2
6007120|NCT00092456|9600847|FG002|Overall Study|Other|3
6007121|NCT00092456|9600848|FG003|Overall Study|Other|0
6007122|NCT00092495|9600862|FG000|Base Study Vaccination Period|Randomized Not Vaccinated|1
6007123|NCT00092495|9600863|FG001|Base Study Vaccination Period|Randomized Not Vaccinated|1
6007124|NCT00092495|9600864|FG002|Base Study Vaccination Period|Randomized Not Vaccinated|0
6007125|NCT00092495|9600865|FG003|Base Study Vaccination Period|Randomized Not Vaccinated|4
6007126|NCT00092495|9600866|FG004|Base Study Vaccination Period|Randomized Not Vaccinated|0
6007127|NCT00092495|9600862|FG000|Base Study Vaccination Period|Extended|0
6007128|NCT00092495|9600863|FG001|Base Study Vaccination Period|Extended|0
6007129|NCT00092495|9600864|FG002|Base Study Vaccination Period|Extended|0
6007130|NCT00092495|9600865|FG003|Base Study Vaccination Period|Extended|1
6007131|NCT00092495|9600866|FG004|Base Study Vaccination Period|Extended|0
6007132|NCT00092495|9600862|FG000|Base Study Vaccination Period|*Clinical AE|1
6007133|NCT00092495|9600863|FG001|Base Study Vaccination Period|*Clinical AE|0
6007134|NCT00092495|9600864|FG002|Base Study Vaccination Period|*Clinical AE|1
6007135|NCT00092495|9600865|FG003|Base Study Vaccination Period|*Clinical AE|2
6007136|NCT00092495|9600866|FG004|Base Study Vaccination Period|*Clinical AE|0
6007137|NCT00092495|9600862|FG000|Base Study Vaccination Period|*Other reasons|1
6007138|NCT00092495|9600863|FG001|Base Study Vaccination Period|*Other reasons|0
6007139|NCT00092495|9600864|FG002|Base Study Vaccination Period|*Other reasons|0
6007140|NCT00092495|9600865|FG003|Base Study Vaccination Period|*Other reasons|1
6007141|NCT00092495|9600866|FG004|Base Study Vaccination Period|*Other reasons|0
6007142|NCT00092495|9600862|FG000|Base Study Vaccination Period|*Pregnancy|0
6007143|NCT00092495|9600863|FG001|Base Study Vaccination Period|*Pregnancy|2
6007144|NCT00092495|9600864|FG002|Base Study Vaccination Period|*Pregnancy|5
6007145|NCT00092495|9600865|FG003|Base Study Vaccination Period|*Pregnancy|7
6007146|NCT00092495|9600866|FG004|Base Study Vaccination Period|*Pregnancy|0
6007147|NCT00092495|9600862|FG000|Base Study Vaccination Period|Adverse Event|1
6007148|NCT00092495|9600863|FG001|Base Study Vaccination Period|Adverse Event|0
6007149|NCT00092495|9600864|FG002|Base Study Vaccination Period|Adverse Event|0
6007150|NCT00092495|9600865|FG003|Base Study Vaccination Period|Adverse Event|3
6007151|NCT00092495|9600866|FG004|Base Study Vaccination Period|Adverse Event|0
6007152|NCT00092495|9600862|FG000|Base Study Vaccination Period|Lost to Follow-up|16
6007153|NCT00092495|9600863|FG001|Base Study Vaccination Period|Lost to Follow-up|6
6007154|NCT00092495|9600864|FG002|Base Study Vaccination Period|Lost to Follow-up|11
6007155|NCT00092495|9600865|FG003|Base Study Vaccination Period|Lost to Follow-up|36
6007156|NCT00092495|9600866|FG004|Base Study Vaccination Period|Lost to Follow-up|0
6007157|NCT00092495|9600862|FG000|Base Study Vaccination Period|Moved|3
6007158|NCT00092495|9600863|FG001|Base Study Vaccination Period|Moved|1
6007159|NCT00092495|9600864|FG002|Base Study Vaccination Period|Moved|2
6007160|NCT00092495|9600865|FG003|Base Study Vaccination Period|Moved|2
6007161|NCT00092495|9600866|FG004|Base Study Vaccination Period|Moved|0
6007162|NCT00092495|9600862|FG000|Base Study Vaccination Period|Other|1
6007163|NCT00092495|9600863|FG001|Base Study Vaccination Period|Other|1
6007164|NCT00092495|9600864|FG002|Base Study Vaccination Period|Other|0
6007165|NCT00092495|9600865|FG003|Base Study Vaccination Period|Other|2
6007166|NCT00092495|9600866|FG004|Base Study Vaccination Period|Other|0
6007167|NCT00092495|9600862|FG000|Base Study Vaccination Period|Pregnancy|2
6007168|NCT00092495|9600863|FG001|Base Study Vaccination Period|Pregnancy|0
6007169|NCT00092495|9600864|FG002|Base Study Vaccination Period|Pregnancy|0
6007170|NCT00092495|9600865|FG003|Base Study Vaccination Period|Pregnancy|0
6007171|NCT00092495|9600866|FG004|Base Study Vaccination Period|Pregnancy|0
6007172|NCT00092495|9600862|FG000|Base Study Vaccination Period|Parent Withdrew Consent|1
6007173|NCT00092495|9600863|FG001|Base Study Vaccination Period|Parent Withdrew Consent|1
6007174|NCT00092495|9600864|FG002|Base Study Vaccination Period|Parent Withdrew Consent|1
6007175|NCT00092495|9600865|FG003|Base Study Vaccination Period|Parent Withdrew Consent|5
6007176|NCT00092495|9600866|FG004|Base Study Vaccination Period|Parent Withdrew Consent|0
6007177|NCT00092495|9600862|FG000|Base Study Vaccination Period|Protocol Violation|1
6007178|NCT00092495|9600863|FG001|Base Study Vaccination Period|Protocol Violation|0
6007179|NCT00092495|9600864|FG002|Base Study Vaccination Period|Protocol Violation|0
6007180|NCT00092495|9600865|FG003|Base Study Vaccination Period|Protocol Violation|0
6007181|NCT00092495|9600866|FG004|Base Study Vaccination Period|Protocol Violation|0
6007182|NCT00092495|9600862|FG000|Base Study Vaccination Period|Withdrawal by Subject|9
6007183|NCT00092495|9600863|FG001|Base Study Vaccination Period|Withdrawal by Subject|10
6007184|NCT00092495|9600864|FG002|Base Study Vaccination Period|Withdrawal by Subject|14
6007185|NCT00092495|9600865|FG003|Base Study Vaccination Period|Withdrawal by Subject|25
6007186|NCT00092495|9600866|FG004|Base Study Vaccination Period|Withdrawal by Subject|0
6007187|NCT00092495|9600862|FG000|Base Study Follow-up Period|Extended|0
6007188|NCT00092495|9600863|FG001|Base Study Follow-up Period|Extended|0
6007189|NCT00092495|9600864|FG002|Base Study Follow-up Period|Extended|1
6007190|NCT00092495|9600865|FG003|Base Study Follow-up Period|Extended|2
6007191|NCT00092495|9600866|FG004|Base Study Follow-up Period|Extended|0
6007192|NCT00092495|9600862|FG000|Base Study Follow-up Period|Lost to Follow-up|1
6007193|NCT00092495|9600863|FG001|Base Study Follow-up Period|Lost to Follow-up|3
6007194|NCT00092495|9600864|FG002|Base Study Follow-up Period|Lost to Follow-up|3
6007195|NCT00092495|9600865|FG003|Base Study Follow-up Period|Lost to Follow-up|12
6007196|NCT00092495|9600866|FG004|Base Study Follow-up Period|Lost to Follow-up|0
6007197|NCT00092495|9600862|FG000|Base Study Follow-up Period|Withdrawal by Subject|2
6007198|NCT00092495|9600863|FG001|Base Study Follow-up Period|Withdrawal by Subject|0
6007199|NCT00092495|9600864|FG002|Base Study Follow-up Period|Withdrawal by Subject|0
6007200|NCT00092495|9600865|FG003|Base Study Follow-up Period|Withdrawal by Subject|0
6007201|NCT00092495|9600866|FG004|Base Study Follow-up Period|Withdrawal by Subject|0
6007202|NCT00092521|9600882|FG000|Vaccination (Day 1 Through Month 7)|Randomized Not Vaccinated|6
6007203|NCT00092521|9600883|FG001|Vaccination (Day 1 Through Month 7)|Randomized Not Vaccinated|0
6007204|NCT00092521|9600884|FG002|Vaccination (Day 1 Through Month 7)|Randomized Not Vaccinated|7
6007205|NCT00092521|9600885|FG003|Vaccination (Day 1 Through Month 7)|Randomized Not Vaccinated|0
6007206|NCT00092521|9600882|FG000|Vaccination (Day 1 Through Month 7)|Adverse Event|1
6007207|NCT00092521|9600883|FG001|Vaccination (Day 1 Through Month 7)|Adverse Event|0
6007208|NCT00092521|9600884|FG002|Vaccination (Day 1 Through Month 7)|Adverse Event|7
6007209|NCT00092521|9600885|FG003|Vaccination (Day 1 Through Month 7)|Adverse Event|0
6007210|NCT00092521|9600882|FG000|Vaccination (Day 1 Through Month 7)|Death|0
6007211|NCT00092521|9600883|FG001|Vaccination (Day 1 Through Month 7)|Death|0
6007212|NCT00092521|9600884|FG002|Vaccination (Day 1 Through Month 7)|Death|1
6007213|NCT00092521|9600885|FG003|Vaccination (Day 1 Through Month 7)|Death|0
6007214|NCT00092521|9600882|FG000|Vaccination (Day 1 Through Month 7)|Lost to Follow-up|51
6007215|NCT00092521|9600883|FG001|Vaccination (Day 1 Through Month 7)|Lost to Follow-up|6
6007216|NCT00092521|9600884|FG002|Vaccination (Day 1 Through Month 7)|Lost to Follow-up|44
6007217|NCT00092521|9600885|FG003|Vaccination (Day 1 Through Month 7)|Lost to Follow-up|0
6007218|NCT00092521|9600882|FG000|Vaccination (Day 1 Through Month 7)|Pregnancy|5
6007219|NCT00092521|9600883|FG001|Vaccination (Day 1 Through Month 7)|Pregnancy|0
6007220|NCT00092521|9600884|FG002|Vaccination (Day 1 Through Month 7)|Pregnancy|7
6007221|NCT00092521|9600885|FG003|Vaccination (Day 1 Through Month 7)|Pregnancy|0
6007222|NCT00092521|9600882|FG000|Vaccination (Day 1 Through Month 7)|Withdrawal by Subject|59
6007223|NCT00092521|9600883|FG001|Vaccination (Day 1 Through Month 7)|Withdrawal by Subject|7
6007224|NCT00092521|9600884|FG002|Vaccination (Day 1 Through Month 7)|Withdrawal by Subject|62
6007225|NCT00092521|9600885|FG003|Vaccination (Day 1 Through Month 7)|Withdrawal by Subject|0
6007226|NCT00092521|9600882|FG000|Vaccination (Day 1 Through Month 7)|Moved|14
6007227|NCT00092521|9600883|FG001|Vaccination (Day 1 Through Month 7)|Moved|1
6007228|NCT00092521|9600884|FG002|Vaccination (Day 1 Through Month 7)|Moved|18
6007229|NCT00092521|9600885|FG003|Vaccination (Day 1 Through Month 7)|Moved|0
6007230|NCT00092521|9600882|FG000|Vaccination (Day 1 Through Month 7)|Unblinded|2
6007231|NCT00092521|9600883|FG001|Vaccination (Day 1 Through Month 7)|Unblinded|0
6007232|NCT00092521|9600884|FG002|Vaccination (Day 1 Through Month 7)|Unblinded|0
6007233|NCT00092521|9600885|FG003|Vaccination (Day 1 Through Month 7)|Unblinded|0
6007234|NCT00092521|9600882|FG000|Vaccination (Day 1 Through Month 7)|New Medical History (Not AE)|2
6007235|NCT00092521|9600883|FG001|Vaccination (Day 1 Through Month 7)|New Medical History (Not AE)|0
6007236|NCT00092521|9600884|FG002|Vaccination (Day 1 Through Month 7)|New Medical History (Not AE)|0
6007237|NCT00092521|9600885|FG003|Vaccination (Day 1 Through Month 7)|New Medical History (Not AE)|0
6007238|NCT00092521|9600882|FG000|Follow-Up (After Month 7)|Subjects Continuing|34
6007239|NCT00092521|9600883|FG001|Follow-Up (After Month 7)|Subjects Continuing|4
6007240|NCT00092521|9600884|FG002|Follow-Up (After Month 7)|Subjects Continuing|35
6007241|NCT00092521|9600885|FG003|Follow-Up (After Month 7)|Subjects Continuing|0
6007242|NCT00092521|9600882|FG000|Follow-Up (After Month 7)|Subjects in Extension|13
6007243|NCT00092521|9600883|FG001|Follow-Up (After Month 7)|Subjects in Extension|109
6007244|NCT00092521|9600884|FG002|Follow-Up (After Month 7)|Subjects in Extension|412
6007245|NCT00092521|9600885|FG003|Follow-Up (After Month 7)|Subjects in Extension|0
6007246|NCT00092521|9600882|FG000|Follow-Up (After Month 7)|Adverse Event|1
6007247|NCT00092521|9600883|FG001|Follow-Up (After Month 7)|Adverse Event|0
6007248|NCT00092521|9600884|FG002|Follow-Up (After Month 7)|Adverse Event|0
6007249|NCT00092521|9600885|FG003|Follow-Up (After Month 7)|Adverse Event|0
6007250|NCT00092521|9600882|FG000|Follow-Up (After Month 7)|Death|2
6007251|NCT00092521|9600883|FG001|Follow-Up (After Month 7)|Death|0
6007252|NCT00092521|9600884|FG002|Follow-Up (After Month 7)|Death|1
6007253|NCT00092521|9600885|FG003|Follow-Up (After Month 7)|Death|0
6007254|NCT00092521|9600882|FG000|Follow-Up (After Month 7)|Lost to Follow-up|113
6007255|NCT00092521|9600883|FG001|Follow-Up (After Month 7)|Lost to Follow-up|14
6007256|NCT00092521|9600884|FG002|Follow-Up (After Month 7)|Lost to Follow-up|108
6007257|NCT00092521|9600885|FG003|Follow-Up (After Month 7)|Lost to Follow-up|0
6007258|NCT00092521|9600882|FG000|Follow-Up (After Month 7)|Protocol Violation|1
6007259|NCT00092521|9600883|FG001|Follow-Up (After Month 7)|Protocol Violation|1
6007260|NCT00092521|9600884|FG002|Follow-Up (After Month 7)|Protocol Violation|5
6007261|NCT00092521|9600885|FG003|Follow-Up (After Month 7)|Protocol Violation|0
6007262|NCT00092521|9600882|FG000|Follow-Up (After Month 7)|Withdrawal by Subject|40
6007263|NCT00092521|9600883|FG001|Follow-Up (After Month 7)|Withdrawal by Subject|6
6007264|NCT00092521|9600884|FG002|Follow-Up (After Month 7)|Withdrawal by Subject|51
6007265|NCT00092521|9600885|FG003|Follow-Up (After Month 7)|Withdrawal by Subject|0
6007266|NCT00092521|9600882|FG000|Follow-Up (After Month 7)|Moved|32
6007267|NCT00092521|9600883|FG001|Follow-Up (After Month 7)|Moved|2
6007268|NCT00092521|9600884|FG002|Follow-Up (After Month 7)|Moved|28
6007269|NCT00092521|9600885|FG003|Follow-Up (After Month 7)|Moved|0
6007270|NCT00092521|9600882|FG000|Follow-Up (After Month 7)|Site Terminated|3
6007271|NCT00092521|9600883|FG001|Follow-Up (After Month 7)|Site Terminated|0
6007272|NCT00092521|9600884|FG002|Follow-Up (After Month 7)|Site Terminated|3
6007273|NCT00092521|9600885|FG003|Follow-Up (After Month 7)|Site Terminated|0
6007274|NCT00092521|9600882|FG000|Follow-Up (After Month 7)|Travel|2
6007275|NCT00092521|9600883|FG001|Follow-Up (After Month 7)|Travel|0
6007276|NCT00092521|9600884|FG002|Follow-Up (After Month 7)|Travel|0
6007277|NCT00092521|9600885|FG003|Follow-Up (After Month 7)|Travel|0
6007278|NCT00092521|9600882|FG000|Follow-Up (After Month 7)|Visits Compressed|5
6007279|NCT00092521|9600883|FG001|Follow-Up (After Month 7)|Visits Compressed|0
6007280|NCT00092521|9600884|FG002|Follow-Up (After Month 7)|Visits Compressed|5
6007281|NCT00092521|9600885|FG003|Follow-Up (After Month 7)|Visits Compressed|0
6007282|NCT00092521|9600882|FG000|Extension Study (Group 4)|Excluded ineligible for extension|0
6007283|NCT00092521|9600883|FG001|Extension Study (Group 4)|Excluded ineligible for extension|0
6007284|NCT00092521|9600884|FG002|Extension Study (Group 4)|Excluded ineligible for extension|0
6007285|NCT00092521|9600885|FG003|Extension Study (Group 4)|Excluded ineligible for extension|23
6007286|NCT00092521|9600882|FG000|Extension Study (Group 4)|Adverse Event|0
6007287|NCT00092521|9600883|FG001|Extension Study (Group 4)|Adverse Event|0
6007288|NCT00092521|9600884|FG002|Extension Study (Group 4)|Adverse Event|0
6007289|NCT00092521|9600885|FG003|Extension Study (Group 4)|Adverse Event|2
6007290|NCT00092521|9600882|FG000|Extension Study (Group 4)|Lost to Follow-up|0
6007291|NCT00092521|9600883|FG001|Extension Study (Group 4)|Lost to Follow-up|0
6007292|NCT00092521|9600884|FG002|Extension Study (Group 4)|Lost to Follow-up|0
6007293|NCT00092521|9600885|FG003|Extension Study (Group 4)|Lost to Follow-up|87
6007294|NCT00092521|9600882|FG000|Extension Study (Group 4)|Pregnancy|0
6007295|NCT00092521|9600883|FG001|Extension Study (Group 4)|Pregnancy|0
6007296|NCT00092521|9600884|FG002|Extension Study (Group 4)|Pregnancy|0
6007297|NCT00092521|9600885|FG003|Extension Study (Group 4)|Pregnancy|4
6007298|NCT00092521|9600882|FG000|Extension Study (Group 4)|Protocol Violation|0
6007299|NCT00092521|9600883|FG001|Extension Study (Group 4)|Protocol Violation|0
6007300|NCT00092521|9600884|FG002|Extension Study (Group 4)|Protocol Violation|0
6007301|NCT00092521|9600885|FG003|Extension Study (Group 4)|Protocol Violation|2
6007302|NCT00092521|9600882|FG000|Extension Study (Group 4)|Withdrawal by Subject|0
6007303|NCT00092521|9600883|FG001|Extension Study (Group 4)|Withdrawal by Subject|0
6074488|NCT00573443|9678388|FG001|Double-Blind Phase|Withdrawal by Subject|2
6074489|NCT00573443|9678389|FG002|Double-Blind Phase|Withdrawal by Subject|7
6074490|NCT00573443|9678387|FG000|Double-Blind Phase|Protocol Violation|0
6074491|NCT00573443|9678388|FG001|Double-Blind Phase|Protocol Violation|2
6074492|NCT00573443|9678389|FG002|Double-Blind Phase|Protocol Violation|1
6074493|NCT00573443|9678387|FG000|Double-Blind Phase|Other|0
6074494|NCT00573443|9678388|FG001|Double-Blind Phase|Other|2
6074495|NCT00573443|9678389|FG002|Double-Blind Phase|Other|3
6074496|NCT00573443|9678387|FG000|Open-Label Extension Phase|Lost to Follow-up|1
6074497|NCT00573443|9678388|FG001|Open-Label Extension Phase|Lost to Follow-up|0
6074498|NCT00573443|9678389|FG002|Open-Label Extension Phase|Lost to Follow-up|0
6074499|NCT00573443|9678387|FG000|Open-Label Extension Phase|Exacerbation of MS symptoms|2
6074500|NCT00573443|9678388|FG001|Open-Label Extension Phase|Exacerbation of MS symptoms|0
6074501|NCT00573443|9678389|FG002|Open-Label Extension Phase|Exacerbation of MS symptoms|0
6074502|NCT00573443|9678387|FG000|Open-Label Extension Phase|Adverse Event|3
6074503|NCT00573443|9678388|FG001|Open-Label Extension Phase|Adverse Event|0
6074504|NCT00573443|9678389|FG002|Open-Label Extension Phase|Adverse Event|0
6074505|NCT00573443|9678387|FG000|Open-Label Extension Phase|Serious Adverse Event|5
6074506|NCT00573443|9678388|FG001|Open-Label Extension Phase|Serious Adverse Event|0
6074507|NCT00573443|9678389|FG002|Open-Label Extension Phase|Serious Adverse Event|0
6074508|NCT00573443|9678387|FG000|Open-Label Extension Phase|Withdrawal by Subject|3
6074509|NCT00573443|9678388|FG001|Open-Label Extension Phase|Withdrawal by Subject|0
6074510|NCT00573443|9678389|FG002|Open-Label Extension Phase|Withdrawal by Subject|0
6271851|NCT02168439|9973874|FG001|Overall Study|Protocol Violation|2
6074511|NCT00573443|9678387|FG000|Open-Label Extension Phase|Protocol Violation|2
6074512|NCT00573443|9678388|FG001|Open-Label Extension Phase|Protocol Violation|0
6007304|NCT00092521|9600884|FG002|Extension Study (Group 4)|Withdrawal by Subject|0
6007305|NCT00092521|9600885|FG003|Extension Study (Group 4)|Withdrawal by Subject|46
6007306|NCT00092521|9600882|FG000|Extension Study (Group 4)|Moved|0
6007307|NCT00092521|9600883|FG001|Extension Study (Group 4)|Moved|0
6007308|NCT00092521|9600884|FG002|Extension Study (Group 4)|Moved|0
6007309|NCT00092521|9600885|FG003|Extension Study (Group 4)|Moved|16
6007310|NCT00092521|9600882|FG000|Extension Study (Group 4)|Site Terminated|0
6007311|NCT00092521|9600883|FG001|Extension Study (Group 4)|Site Terminated|0
6007312|NCT00092521|9600884|FG002|Extension Study (Group 4)|Site Terminated|0
6007313|NCT00092521|9600885|FG003|Extension Study (Group 4)|Site Terminated|4
6007314|NCT00092521|9600882|FG000|Extension Study (Group 4)|Unable/unwilling to return|0
6007315|NCT00092521|9600883|FG001|Extension Study (Group 4)|Unable/unwilling to return|0
6007316|NCT00092521|9600884|FG002|Extension Study (Group 4)|Unable/unwilling to return|0
6007317|NCT00092521|9600885|FG003|Extension Study (Group 4)|Unable/unwilling to return|25
6007318|NCT00092534|9600895|FG000|Base Study Vaccination Period|Randomized not Vaccinated|5
6007319|NCT00092534|9600896|FG001|Base Study Vaccination Period|Randomized not Vaccinated|5
6007320|NCT00092534|9600897|FG002|Base Study Vaccination Period|Randomized not Vaccinated|0
6007321|NCT00092534|9600898|FG003|Base Study Vaccination Period|Randomized not Vaccinated|0
6007322|NCT00092534|9600899|FG004|Base Study Vaccination Period|Randomized not Vaccinated|0
6007323|NCT00092534|9600895|FG000|Base Study Vaccination Period|Adverse Event|3
6007324|NCT00092534|9600896|FG001|Base Study Vaccination Period|Adverse Event|1
6007325|NCT00092534|9600897|FG002|Base Study Vaccination Period|Adverse Event|0
6007326|NCT00092534|9600898|FG003|Base Study Vaccination Period|Adverse Event|0
6007327|NCT00092534|9600899|FG004|Base Study Vaccination Period|Adverse Event|0
6007328|NCT00092534|9600895|FG000|Base Study Vaccination Period|Death|5
6007329|NCT00092534|9600896|FG001|Base Study Vaccination Period|Death|4
6007330|NCT00092534|9600897|FG002|Base Study Vaccination Period|Death|0
6007331|NCT00092534|9600898|FG003|Base Study Vaccination Period|Death|0
6007332|NCT00092534|9600899|FG004|Base Study Vaccination Period|Death|0
6007333|NCT00092534|9600895|FG000|Base Study Vaccination Period|Lost to Follow-up|41
6007334|NCT00092534|9600896|FG001|Base Study Vaccination Period|Lost to Follow-up|37
6007335|NCT00092534|9600897|FG002|Base Study Vaccination Period|Lost to Follow-up|0
6007336|NCT00092534|9600898|FG003|Base Study Vaccination Period|Lost to Follow-up|0
6007337|NCT00092534|9600899|FG004|Base Study Vaccination Period|Lost to Follow-up|0
6007338|NCT00092534|9600895|FG000|Base Study Vaccination Period|Physician Decision|1
6007339|NCT00092534|9600896|FG001|Base Study Vaccination Period|Physician Decision|0
6007340|NCT00092534|9600897|FG002|Base Study Vaccination Period|Physician Decision|0
6007341|NCT00092534|9600898|FG003|Base Study Vaccination Period|Physician Decision|0
6007342|NCT00092534|9600899|FG004|Base Study Vaccination Period|Physician Decision|0
6007343|NCT00092534|9600895|FG000|Base Study Vaccination Period|Pregnancy|9
6007344|NCT00092534|9600896|FG001|Base Study Vaccination Period|Pregnancy|7
6007345|NCT00092534|9600897|FG002|Base Study Vaccination Period|Pregnancy|0
6007346|NCT00092534|9600898|FG003|Base Study Vaccination Period|Pregnancy|0
6007347|NCT00092534|9600899|FG004|Base Study Vaccination Period|Pregnancy|0
6007348|NCT00092534|9600895|FG000|Base Study Vaccination Period|Protocol Violation|2
6007349|NCT00092534|9600896|FG001|Base Study Vaccination Period|Protocol Violation|1
6007350|NCT00092534|9600897|FG002|Base Study Vaccination Period|Protocol Violation|0
6007351|NCT00092534|9600898|FG003|Base Study Vaccination Period|Protocol Violation|0
6007352|NCT00092534|9600899|FG004|Base Study Vaccination Period|Protocol Violation|0
6007353|NCT00092534|9600895|FG000|Base Study Vaccination Period|Withdrawal by Subject|85
6007354|NCT00092534|9600896|FG001|Base Study Vaccination Period|Withdrawal by Subject|58
6007355|NCT00092534|9600897|FG002|Base Study Vaccination Period|Withdrawal by Subject|0
6007356|NCT00092534|9600898|FG003|Base Study Vaccination Period|Withdrawal by Subject|0
6007357|NCT00092534|9600899|FG004|Base Study Vaccination Period|Withdrawal by Subject|0
6007358|NCT00092534|9600895|FG000|Base Study Vaccination Period|Moved|14
6007359|NCT00092534|9600896|FG001|Base Study Vaccination Period|Moved|12
6007360|NCT00092534|9600897|FG002|Base Study Vaccination Period|Moved|0
6007361|NCT00092534|9600898|FG003|Base Study Vaccination Period|Moved|0
6007362|NCT00092534|9600899|FG004|Base Study Vaccination Period|Moved|0
6007363|NCT00092534|9600895|FG000|Base Study Vaccination Period|New Medical History (Not AEs)|5
6007364|NCT00092534|9600896|FG001|Base Study Vaccination Period|New Medical History (Not AEs)|0
6007365|NCT00092534|9600897|FG002|Base Study Vaccination Period|New Medical History (Not AEs)|0
6007366|NCT00092534|9600898|FG003|Base Study Vaccination Period|New Medical History (Not AEs)|0
6007367|NCT00092534|9600899|FG004|Base Study Vaccination Period|New Medical History (Not AEs)|0
6074513|NCT00573443|9678389|FG002|Open-Label Extension Phase|Protocol Violation|0
6074514|NCT00573443|9678387|FG000|Open-Label Extension Phase|Other|2
6007368|NCT00092534|9600895|FG000|Base Study Vaccination Period|Travel|1
6007369|NCT00092534|9600896|FG001|Base Study Vaccination Period|Travel|0
6007370|NCT00092534|9600897|FG002|Base Study Vaccination Period|Travel|0
6007371|NCT00092534|9600898|FG003|Base Study Vaccination Period|Travel|0
6007372|NCT00092534|9600899|FG004|Base Study Vaccination Period|Travel|0
6007373|NCT00092534|9600895|FG000|Base Study Vaccination Period|Site Closed|0
6007374|NCT00092534|9600896|FG001|Base Study Vaccination Period|Site Closed|1
6007375|NCT00092534|9600897|FG002|Base Study Vaccination Period|Site Closed|0
6007376|NCT00092534|9600898|FG003|Base Study Vaccination Period|Site Closed|0
6074515|NCT00573443|9678388|FG001|Open-Label Extension Phase|Other|0
6007377|NCT00092534|9600899|FG004|Base Study Vaccination Period|Site Closed|0
6007378|NCT00092534|9600895|FG000|Base Study Follow-Up Period|Adverse Event|2
6007379|NCT00092534|9600896|FG001|Base Study Follow-Up Period|Adverse Event|4
6007380|NCT00092534|9600897|FG002|Base Study Follow-Up Period|Adverse Event|0
6007381|NCT00092534|9600898|FG003|Base Study Follow-Up Period|Adverse Event|0
6007382|NCT00092534|9600899|FG004|Base Study Follow-Up Period|Adverse Event|0
6007383|NCT00092534|9600895|FG000|Base Study Follow-Up Period|Death|2
6007384|NCT00092534|9600896|FG001|Base Study Follow-Up Period|Death|1
6007385|NCT00092534|9600897|FG002|Base Study Follow-Up Period|Death|0
6007386|NCT00092534|9600898|FG003|Base Study Follow-Up Period|Death|0
6007387|NCT00092534|9600899|FG004|Base Study Follow-Up Period|Death|0
6007388|NCT00092534|9600895|FG000|Base Study Follow-Up Period|Lost to Follow-up|120
6007389|NCT00092534|9600896|FG001|Base Study Follow-Up Period|Lost to Follow-up|146
6007390|NCT00092534|9600897|FG002|Base Study Follow-Up Period|Lost to Follow-up|0
6007391|NCT00092534|9600898|FG003|Base Study Follow-Up Period|Lost to Follow-up|0
6007392|NCT00092534|9600899|FG004|Base Study Follow-Up Period|Lost to Follow-up|0
6007393|NCT00092534|9600895|FG000|Base Study Follow-Up Period|Pregnancy|6
6007394|NCT00092534|9600896|FG001|Base Study Follow-Up Period|Pregnancy|10
6007395|NCT00092534|9600897|FG002|Base Study Follow-Up Period|Pregnancy|0
6007396|NCT00092534|9600898|FG003|Base Study Follow-Up Period|Pregnancy|0
6007397|NCT00092534|9600899|FG004|Base Study Follow-Up Period|Pregnancy|0
6007398|NCT00092534|9600895|FG000|Base Study Follow-Up Period|Protocol Violation|1
6074516|NCT00573443|9678389|FG002|Open-Label Extension Phase|Other|0
6074517|NCT00573469|9678401|FG000|Overall Study|Adverse Event|1
6074518|NCT00573469|9678402|FG001|Overall Study|Adverse Event|1
6007399|NCT00092534|9600896|FG001|Base Study Follow-Up Period|Protocol Violation|2
6007400|NCT00092534|9600897|FG002|Base Study Follow-Up Period|Protocol Violation|0
6007401|NCT00092534|9600898|FG003|Base Study Follow-Up Period|Protocol Violation|0
6007402|NCT00092534|9600899|FG004|Base Study Follow-Up Period|Protocol Violation|0
6007403|NCT00092534|9600895|FG000|Base Study Follow-Up Period|Withdrawal by Subject|71
6007404|NCT00092534|9600896|FG001|Base Study Follow-Up Period|Withdrawal by Subject|62
6007405|NCT00092534|9600897|FG002|Base Study Follow-Up Period|Withdrawal by Subject|0
6007406|NCT00092534|9600898|FG003|Base Study Follow-Up Period|Withdrawal by Subject|0
6074519|NCT00573469|9678403|FG002|Overall Study|Adverse Event|1
6007407|NCT00092534|9600899|FG004|Base Study Follow-Up Period|Withdrawal by Subject|0
6007408|NCT00092534|9600895|FG000|Base Study Follow-Up Period|Moved|62
6007409|NCT00092534|9600896|FG001|Base Study Follow-Up Period|Moved|58
6007410|NCT00092534|9600897|FG002|Base Study Follow-Up Period|Moved|0
6007411|NCT00092534|9600898|FG003|Base Study Follow-Up Period|Moved|0
6007412|NCT00092534|9600899|FG004|Base Study Follow-Up Period|Moved|0
6007413|NCT00092534|9600895|FG000|Base Study Follow-Up Period|Travel|10
6007414|NCT00092534|9600896|FG001|Base Study Follow-Up Period|Travel|7
6007415|NCT00092534|9600897|FG002|Base Study Follow-Up Period|Travel|0
6007416|NCT00092534|9600898|FG003|Base Study Follow-Up Period|Travel|0
6007417|NCT00092534|9600899|FG004|Base Study Follow-Up Period|Travel|0
6007418|NCT00092534|9600895|FG000|Base Study Follow-Up Period|Site Closed|0
6007419|NCT00092534|9600896|FG001|Base Study Follow-Up Period|Site Closed|2
6007420|NCT00092534|9600897|FG002|Base Study Follow-Up Period|Site Closed|0
6007421|NCT00092534|9600898|FG003|Base Study Follow-Up Period|Site Closed|0
6007422|NCT00092534|9600899|FG004|Base Study Follow-Up Period|Site Closed|0
6007423|NCT00092534|9600895|FG000|Base Study Follow-Up Period|Subjects continuing|27
6007424|NCT00092534|9600896|FG001|Base Study Follow-Up Period|Subjects continuing|31
6007425|NCT00092534|9600897|FG002|Base Study Follow-Up Period|Subjects continuing|0
6007426|NCT00092534|9600898|FG003|Base Study Follow-Up Period|Subjects continuing|0
6007427|NCT00092534|9600899|FG004|Base Study Follow-Up Period|Subjects continuing|0
6007428|NCT00092534|9600895|FG000|Base Study Follow-Up Period|Subjects in extension|15
6007429|NCT00092534|9600896|FG001|Base Study Follow-Up Period|Subjects in extension|371
6007430|NCT00092534|9600897|FG002|Base Study Follow-Up Period|Subjects in extension|0
6007431|NCT00092534|9600898|FG003|Base Study Follow-Up Period|Subjects in extension|0
6007432|NCT00092534|9600899|FG004|Base Study Follow-Up Period|Subjects in extension|0
6007433|NCT00092534|9600895|FG000|Base Study EXT|Lost to Follow-up|0
6007434|NCT00092534|9600896|FG001|Base Study EXT|Lost to Follow-up|0
6007435|NCT00092534|9600897|FG002|Base Study EXT|Lost to Follow-up|41
6007436|NCT00092534|9600898|FG003|Base Study EXT|Lost to Follow-up|0
6007437|NCT00092534|9600899|FG004|Base Study EXT|Lost to Follow-up|0
6074520|NCT00573469|9678401|FG000|Overall Study|Withdrawal by Subject|0
6074521|NCT00573469|9678402|FG001|Overall Study|Withdrawal by Subject|2
6074522|NCT00573469|9678403|FG002|Overall Study|Withdrawal by Subject|0
6074523|NCT00573469|9678401|FG000|Overall Study|Other|5
6074524|NCT00573469|9678402|FG001|Overall Study|Other|1
6074525|NCT00573469|9678403|FG002|Overall Study|Other|3
6074526|NCT00573534|9678420|FG000|Overall Study|oppositional behavior|3
6074527|NCT00573755|9678427|FG000|Overall Study|Still receiving treatment|1
6007438|NCT00092534|9600895|FG000|Base Study EXT|Physician Decision|0
6007439|NCT00092534|9600896|FG001|Base Study EXT|Physician Decision|0
6007440|NCT00092534|9600897|FG002|Base Study EXT|Physician Decision|1
6074528|NCT00573755|9678428|FG001|Overall Study|Still receiving treatment|0
6007441|NCT00092534|9600898|FG003|Base Study EXT|Physician Decision|0
6007442|NCT00092534|9600899|FG004|Base Study EXT|Physician Decision|0
6007443|NCT00092534|9600895|FG000|Base Study EXT|Pregnancy|0
6007444|NCT00092534|9600896|FG001|Base Study EXT|Pregnancy|0
6007445|NCT00092534|9600897|FG002|Base Study EXT|Pregnancy|12
6007446|NCT00092534|9600898|FG003|Base Study EXT|Pregnancy|0
6007447|NCT00092534|9600899|FG004|Base Study EXT|Pregnancy|0
6007448|NCT00092534|9600895|FG000|Base Study EXT|Withdrawal by Subject|0
6074529|NCT00573768|9678437|FG000|Overall Study|Adverse Event|1
6074530|NCT00573768|9678438|FG001|Overall Study|Adverse Event|1
6074531|NCT00573768|9678439|FG002|Overall Study|Adverse Event|2
6074532|NCT00573768|9678437|FG000|Overall Study|Protocol Violation|1
6074533|NCT00573768|9678438|FG001|Overall Study|Protocol Violation|0
6007449|NCT00092534|9600896|FG001|Base Study EXT|Withdrawal by Subject|0
6007450|NCT00092534|9600897|FG002|Base Study EXT|Withdrawal by Subject|18
6007451|NCT00092534|9600898|FG003|Base Study EXT|Withdrawal by Subject|0
6007452|NCT00092534|9600899|FG004|Base Study EXT|Withdrawal by Subject|0
6007453|NCT00092534|9600895|FG000|Base Study EXT|Participant moved|0
6007454|NCT00092534|9600896|FG001|Base Study EXT|Participant moved|0
6007455|NCT00092534|9600897|FG002|Base Study EXT|Participant moved|6
6007456|NCT00092534|9600898|FG003|Base Study EXT|Participant moved|0
6007457|NCT00092534|9600899|FG004|Base Study EXT|Participant moved|0
6007458|NCT00092534|9600895|FG000|Base Study EXT|Travel|0
6007459|NCT00092534|9600896|FG001|Base Study EXT|Travel|0
6007460|NCT00092534|9600897|FG002|Base Study EXT|Travel|2
6007461|NCT00092534|9600898|FG003|Base Study EXT|Travel|0
6007462|NCT00092534|9600899|FG004|Base Study EXT|Travel|0
6007463|NCT00092534|9600895|FG000|Base Study EXT|Site closed|0
6007464|NCT00092534|9600896|FG001|Base Study EXT|Site closed|0
6007465|NCT00092534|9600897|FG002|Base Study EXT|Site closed|21
6007466|NCT00092534|9600898|FG003|Base Study EXT|Site closed|0
6007467|NCT00092534|9600899|FG004|Base Study EXT|Site closed|0
6007468|NCT00092534|9600895|FG000|Base Study EXT|Study ended|0
6007469|NCT00092534|9600896|FG001|Base Study EXT|Study ended|0
6007470|NCT00092534|9600897|FG002|Base Study EXT|Study ended|29
6007471|NCT00092534|9600898|FG003|Base Study EXT|Study ended|0
6007472|NCT00092534|9600899|FG004|Base Study EXT|Study ended|0
6007473|NCT00092534|9600895|FG000|Base Study EXT|Protocol Violation|0
6007474|NCT00092534|9600896|FG001|Base Study EXT|Protocol Violation|0
6007475|NCT00092534|9600897|FG002|Base Study EXT|Protocol Violation|15
6007476|NCT00092534|9600898|FG003|Base Study EXT|Protocol Violation|0
6007477|NCT00092534|9600899|FG004|Base Study EXT|Protocol Violation|0
6007478|NCT00092534|9600895|FG000|Long-Term Follow-Up (LTFU) Study|Withdrawal by Subject|0
6007479|NCT00092534|9600896|FG001|Long-Term Follow-Up (LTFU) Study|Withdrawal by Subject|0
6007480|NCT00092534|9600897|FG002|Long-Term Follow-Up (LTFU) Study|Withdrawal by Subject|0
6007481|NCT00092534|9600898|FG003|Long-Term Follow-Up (LTFU) Study|Withdrawal by Subject|1
6007482|NCT00092534|9600899|FG004|Long-Term Follow-Up (LTFU) Study|Withdrawal by Subject|0
6007483|NCT00092547|9600911|FG000|Base Vaccine Phase (Day 1 to Month 7)|Not Vaccinated|5
6007484|NCT00092547|9600912|FG001|Base Vaccine Phase (Day 1 to Month 7)|Not Vaccinated|1
6007485|NCT00092547|9600913|FG002|Base Vaccine Phase (Day 1 to Month 7)|Not Vaccinated|0
6007486|NCT00092547|9600911|FG000|Base Vaccine Phase (Day 1 to Month 7)|Adverse Event|4
6007487|NCT00092547|9600912|FG001|Base Vaccine Phase (Day 1 to Month 7)|Adverse Event|1
6007488|NCT00092547|9600913|FG002|Base Vaccine Phase (Day 1 to Month 7)|Adverse Event|0
6007489|NCT00092547|9600911|FG000|Base Vaccine Phase (Day 1 to Month 7)|Lost to Follow-up|18
6007490|NCT00092547|9600912|FG001|Base Vaccine Phase (Day 1 to Month 7)|Lost to Follow-up|7
6007491|NCT00092547|9600913|FG002|Base Vaccine Phase (Day 1 to Month 7)|Lost to Follow-up|0
6007492|NCT00092547|9600911|FG000|Base Vaccine Phase (Day 1 to Month 7)|Withdrawal by Subject|28
6007493|NCT00092547|9600912|FG001|Base Vaccine Phase (Day 1 to Month 7)|Withdrawal by Subject|21
6007494|NCT00092547|9600913|FG002|Base Vaccine Phase (Day 1 to Month 7)|Withdrawal by Subject|0
6007495|NCT00092547|9600911|FG000|Base Vaccine Phase (Day 1 to Month 7)|Moved|3
6007496|NCT00092547|9600912|FG001|Base Vaccine Phase (Day 1 to Month 7)|Moved|1
6007497|NCT00092547|9600913|FG002|Base Vaccine Phase (Day 1 to Month 7)|Moved|0
6007498|NCT00092547|9600911|FG000|Base Vaccine Phase (Day 1 to Month 7)|per sponsor request: (noncompliant)|0
6074534|NCT00573768|9678439|FG002|Overall Study|Protocol Violation|1
6074535|NCT00573768|9678437|FG000|Overall Study|Withdrawal by Subject|0
6074536|NCT00573768|9678438|FG001|Overall Study|Withdrawal by Subject|1
6074537|NCT00573768|9678439|FG002|Overall Study|Withdrawal by Subject|0
6074538|NCT00573768|9678437|FG000|Overall Study|Lost to Follow-up|0
6074539|NCT00573768|9678438|FG001|Overall Study|Lost to Follow-up|0
6074540|NCT00573768|9678439|FG002|Overall Study|Lost to Follow-up|1
6074541|NCT00573794|9678447|FG000|Overall Study|Adverse Event|81
6074542|NCT00573794|9678447|FG000|Overall Study|Withdrew Consent|90
6074543|NCT00573794|9678447|FG000|Overall Study|Lost to Follow-up|13
6074544|NCT00573794|9678447|FG000|Overall Study|Protocol Violation|6
6074545|NCT00573794|9678447|FG000|Overall Study|Lack of Efficacy|94
6007499|NCT00092547|9600912|FG001|Base Vaccine Phase (Day 1 to Month 7)|per sponsor request: (noncompliant)|1
6074546|NCT00573794|9678447|FG000|Overall Study|Other|46
6007500|NCT00092547|9600913|FG002|Base Vaccine Phase (Day 1 to Month 7)|per sponsor request: (noncompliant)|0
6007501|NCT00092547|9600911|FG000|Base Vaccine Phase (Day 1 to Month 7)|Did not meet local regulations|0
6007502|NCT00092547|9600912|FG001|Base Vaccine Phase (Day 1 to Month 7)|Did not meet local regulations|1
6007503|NCT00092547|9600913|FG002|Base Vaccine Phase (Day 1 to Month 7)|Did not meet local regulations|0
6007504|NCT00092547|9600911|FG000|Base Vaccine Phase (Day 1 to Month 7)|Refused Vaccination|5
6007505|NCT00092547|9600912|FG001|Base Vaccine Phase (Day 1 to Month 7)|Refused Vaccination|3
6074547|NCT00573833|9678451|FG000|Overall Study|Not Treated|2
6074548|NCT00573859|9678455|FG000|Medication Versus Placebo|Scheduling conflicts|12
6007506|NCT00092547|9600913|FG002|Base Vaccine Phase (Day 1 to Month 7)|Refused Vaccination|0
6007507|NCT00092547|9600911|FG000|Base Follow-up Phase (Month 7 to 18)|Subject moved|1
6007508|NCT00092547|9600912|FG001|Base Follow-up Phase (Month 7 to 18)|Subject moved|5
6007509|NCT00092547|9600913|FG002|Base Follow-up Phase (Month 7 to 18)|Subject moved|0
6007510|NCT00092547|9600911|FG000|Base Follow-up Phase (Month 7 to 18)|Withdrawal by Subject|4
6007511|NCT00092547|9600912|FG001|Base Follow-up Phase (Month 7 to 18)|Withdrawal by Subject|2
6007512|NCT00092547|9600913|FG002|Base Follow-up Phase (Month 7 to 18)|Withdrawal by Subject|0
6007513|NCT00092547|9600911|FG000|Base Follow-up Phase (Month 7 to 18)|Lost to Follow-up|13
6007514|NCT00092547|9600912|FG001|Base Follow-up Phase (Month 7 to 18)|Lost to Follow-up|7
6074549|NCT00573859|9678455|FG000|Smoking Versus Abstinence|Scheduling conflicts|12
6074550|NCT00574119|9678494|FG000|Overall Study|Adverse Event|1
6074551|NCT00574119|9678494|FG000|Overall Study|Protocol Violation|1
6074552|NCT00574119|9678494|FG000|Overall Study|Withdrawal by Subject|1
6074553|NCT00574119|9678494|FG000|Overall Study|Physician Decision|1
6074554|NCT00574145|9678500|FG000|Overall Study|Withdrawal by Subject|2
6074555|NCT00574145|9678501|FG001|Overall Study|Withdrawal by Subject|1
6074556|NCT00574249|9678521|FG000|Overall Study|Adverse Event|6
6074557|NCT00574249|9678522|FG001|Overall Study|Adverse Event|18
6074558|NCT00574249|9678521|FG000|Overall Study|Lack of Efficacy|5
6007515|NCT00092547|9600913|FG002|Base Follow-up Phase (Month 7 to 18)|Lost to Follow-up|0
6007516|NCT00092547|9600911|FG000|Base Follow-up Phase (Month 7 to 18)|Protocol Violation|1
6007517|NCT00092547|9600912|FG001|Base Follow-up Phase (Month 7 to 18)|Protocol Violation|0
6007518|NCT00092547|9600913|FG002|Base Follow-up Phase (Month 7 to 18)|Protocol Violation|0
6007519|NCT00092547|9600911|FG000|Base Follow-up Phase (Month 7 to 18)|Physician Decision|1
6007520|NCT00092547|9600912|FG001|Base Follow-up Phase (Month 7 to 18)|Physician Decision|0
6007521|NCT00092547|9600913|FG002|Base Follow-up Phase (Month 7 to 18)|Physician Decision|0
6007522|NCT00092547|9600911|FG000|Base Follow-up Phase (Month 18 to 30)|Subject moved|4
6007523|NCT00092547|9600912|FG001|Base Follow-up Phase (Month 18 to 30)|Subject moved|2
6007524|NCT00092547|9600913|FG002|Base Follow-up Phase (Month 18 to 30)|Subject moved|0
6007525|NCT00092547|9600911|FG000|Base Follow-up Phase (Month 18 to 30)|Withdrawal by Subject|1
6007526|NCT00092547|9600912|FG001|Base Follow-up Phase (Month 18 to 30)|Withdrawal by Subject|3
6007527|NCT00092547|9600913|FG002|Base Follow-up Phase (Month 18 to 30)|Withdrawal by Subject|0
6007528|NCT00092547|9600911|FG000|Base Follow-up Phase (Month 18 to 30)|Lost to Follow-up|2
6007529|NCT00092547|9600912|FG001|Base Follow-up Phase (Month 18 to 30)|Lost to Follow-up|0
6007530|NCT00092547|9600913|FG002|Base Follow-up Phase (Month 18 to 30)|Lost to Follow-up|0
6007531|NCT00092547|9600911|FG000|Base Follow-up Phase (Month 18 to 30)|Protocol Violation|1
6007532|NCT00092547|9600912|FG001|Base Follow-up Phase (Month 18 to 30)|Protocol Violation|0
6007533|NCT00092547|9600913|FG002|Base Follow-up Phase (Month 18 to 30)|Protocol Violation|0
6007534|NCT00092547|9600911|FG000|Extension Vaccine Phase (Month 30 to 37)|Subject moved|3
6007535|NCT00092547|9600912|FG001|Extension Vaccine Phase (Month 30 to 37)|Subject moved|0
6007536|NCT00092547|9600913|FG002|Extension Vaccine Phase (Month 30 to 37)|Subject moved|0
6007537|NCT00092547|9600911|FG000|Extension Vaccine Phase (Month 30 to 37)|Withdrawal by Subject|6
6007538|NCT00092547|9600912|FG001|Extension Vaccine Phase (Month 30 to 37)|Withdrawal by Subject|0
6007539|NCT00092547|9600913|FG002|Extension Vaccine Phase (Month 30 to 37)|Withdrawal by Subject|9
6007540|NCT00092547|9600911|FG000|Extension Vaccine Phase (Month 30 to 37)|Lost to Follow-up|14
6007541|NCT00092547|9600912|FG001|Extension Vaccine Phase (Month 30 to 37)|Lost to Follow-up|0
6007542|NCT00092547|9600913|FG002|Extension Vaccine Phase (Month 30 to 37)|Lost to Follow-up|7
6007543|NCT00092547|9600911|FG000|Long-term Follow-up (Month 42 Visit)|Adverse Event|1
6007544|NCT00092547|9600912|FG001|Long-term Follow-up (Month 42 Visit)|Adverse Event|0
6007545|NCT00092547|9600913|FG002|Long-term Follow-up (Month 42 Visit)|Adverse Event|0
6074559|NCT00574249|9678522|FG001|Overall Study|Lack of Efficacy|3
6074560|NCT00574249|9678521|FG000|Overall Study|Lost to Follow-up|4
6074561|NCT00574249|9678522|FG001|Overall Study|Lost to Follow-up|3
6074562|NCT00574249|9678521|FG000|Overall Study|Protocol Violation|5
6074563|NCT00574249|9678522|FG001|Overall Study|Protocol Violation|2
6074564|NCT00574249|9678521|FG000|Overall Study|History of carcinoma|1
6074565|NCT00574249|9678522|FG001|Overall Study|History of carcinoma|0
6074566|NCT00574249|9678521|FG000|Overall Study|Withdrawal by Subject|3
6074567|NCT00574249|9678522|FG001|Overall Study|Withdrawal by Subject|0
6074568|NCT00574249|9678521|FG000|Overall Study|Physician Decision|1
6074569|NCT00574249|9678522|FG001|Overall Study|Physician Decision|0
6074570|NCT00574249|9678521|FG000|Overall Study|Pregnancy|1
6074571|NCT00574249|9678522|FG001|Overall Study|Pregnancy|0
6074572|NCT00574249|9678521|FG000|Overall Study|Excluded by company|0
6074573|NCT00574249|9678522|FG001|Overall Study|Excluded by company|1
6074574|NCT00574249|9678521|FG000|Overall Study|PPD test taken twice|0
6074575|NCT00574249|9678522|FG001|Overall Study|PPD test taken twice|1
6074576|NCT00574275|9678530|FG000|Overall Study|Randomized but not treated|2
6074577|NCT00574275|9678531|FG001|Overall Study|Randomized but not treated|3
6074578|NCT00574275|9678530|FG000|Overall Study|Adverse Event|32
6074579|NCT00574275|9678531|FG001|Overall Study|Adverse Event|76
6074580|NCT00574275|9678530|FG000|Overall Study|Disease progression|160
6074581|NCT00574275|9678531|FG001|Overall Study|Disease progression|146
6074582|NCT00574275|9678530|FG000|Overall Study|Lost to Follow-up|2
6074583|NCT00574275|9678531|FG001|Overall Study|Lost to Follow-up|1
6007546|NCT00093015|9600926|FG000|Overall Study|Withdrawal by Subject|194
6007547|NCT00093015|9600927|FG001|Overall Study|Withdrawal by Subject|171
6007548|NCT00093015|9600926|FG000|Overall Study|Lost to Follow-up|96
6007549|NCT00093015|9600927|FG001|Overall Study|Lost to Follow-up|108
6007550|NCT00093015|9600926|FG000|Overall Study|Death|375
6007551|NCT00093015|9600927|FG001|Overall Study|Death|385
6007552|NCT00093145|9600958|FG000|Overall Study|Unacceptable Toxicity Only|2
6007553|NCT00093145|9600958|FG000|Overall Study|Physician Decision|5
6007554|NCT00093145|9600958|FG000|Overall Study|Withdrawal by Subject|9
6007555|NCT00093145|9600958|FG000|Overall Study|Other|1
6074584|NCT00574275|9678530|FG000|Overall Study|Study stopped based on DMC decision|62
6074585|NCT00574275|9678531|FG001|Overall Study|Study stopped based on DMC decision|23
6074586|NCT00574275|9678530|FG000|Overall Study|Withdrawal by Subject|15
6074587|NCT00574275|9678531|FG001|Overall Study|Withdrawal by Subject|17
6007556|NCT00093470|9600968|FG000|Overall Study|Disease progression|39
6007557|NCT00093470|9600969|FG001|Overall Study|Disease progression|0
6007558|NCT00093470|9600968|FG000|Overall Study|Adverse Event|15
6007559|NCT00093470|9600969|FG001|Overall Study|Adverse Event|0
6007560|NCT00093470|9600968|FG000|Overall Study|Death|2
6007561|NCT00093470|9600969|FG001|Overall Study|Death|0
6007562|NCT00093470|9600968|FG000|Overall Study|Withdrawal by Subject|8
6007563|NCT00093470|9600969|FG001|Overall Study|Withdrawal by Subject|0
6007564|NCT00093470|9600968|FG000|Overall Study|Alternative therapy|2
6007565|NCT00093470|9600969|FG001|Overall Study|Alternative therapy|0
6007566|NCT00093470|9600968|FG000|Overall Study|Other complicating disease|3
6007567|NCT00093470|9600969|FG001|Overall Study|Other complicating disease|0
6007568|NCT00093470|9600968|FG000|Overall Study|Physician Decision|2
6007569|NCT00093470|9600969|FG001|Overall Study|Physician Decision|0
6007570|NCT00093470|9600968|FG000|Overall Study|Never started treatment|1
6007571|NCT00093470|9600969|FG001|Overall Study|Never started treatment|0
6007572|NCT00093470|9600968|FG000|Overall Study|ANC < 1000 on day 1 of cycle 1|1
6007573|NCT00093470|9600969|FG001|Overall Study|ANC < 1000 on day 1 of cycle 1|0
6007574|NCT00093496|9600977|FG000|Overall Study|Protocol Violation|1
6007575|NCT00093496|9600978|FG001|Overall Study|Protocol Violation|3
6007576|NCT00093795|9601001|FG000|Overall Study|No follow up data|20
6007577|NCT00093795|9601002|FG001|Overall Study|No follow up data|16
6007578|NCT00093795|9601003|FG002|Overall Study|No follow up data|17
6074588|NCT00574275|9678530|FG000|Overall Study|Error calculating tumor measurement|1
6074589|NCT00574275|9678531|FG001|Overall Study|Error calculating tumor measurement|0
6074590|NCT00574275|9678530|FG000|Overall Study|Physician Decision|1
6074591|NCT00574275|9678531|FG001|Overall Study|Physician Decision|1
6074592|NCT00574275|9678530|FG000|Overall Study|Protocol Violation|0
6074593|NCT00574275|9678531|FG001|Overall Study|Protocol Violation|1
6074594|NCT00574275|9678530|FG000|Overall Study|Patient and Investigator decision|0
6074595|NCT00574275|9678531|FG001|Overall Study|Patient and Investigator decision|1
6074596|NCT00574275|9678530|FG000|Overall Study|Insurance change|0
6074597|NCT00574275|9678531|FG001|Overall Study|Insurance change|1
6074598|NCT00574275|9678530|FG000|Overall Study|Operation for curative intent|0
6074599|NCT00574275|9678531|FG001|Overall Study|Operation for curative intent|1
6074600|NCT00574288|9678544|FG000|Overall Study|Adverse Event|2
6074601|NCT00574288|9678545|FG001|Overall Study|Adverse Event|0
6074602|NCT00574288|9678546|FG002|Overall Study|Adverse Event|0
6074603|NCT00574288|9678547|FG003|Overall Study|Adverse Event|0
6074604|NCT00574288|9678548|FG004|Overall Study|Adverse Event|1
6074605|NCT00574288|9678549|FG005|Overall Study|Adverse Event|0
6074606|NCT00574288|9678550|FG006|Overall Study|Adverse Event|0
6074607|NCT00574288|9678544|FG000|Overall Study|Death|0
6074608|NCT00574288|9678545|FG001|Overall Study|Death|0
6074609|NCT00574288|9678546|FG002|Overall Study|Death|0
6074610|NCT00574288|9678547|FG003|Overall Study|Death|0
6074611|NCT00574288|9678548|FG004|Overall Study|Death|0
6074612|NCT00574288|9678549|FG005|Overall Study|Death|25
6074613|NCT00574288|9678550|FG006|Overall Study|Death|21
6074614|NCT00574288|9678544|FG000|Overall Study|Lost to Follow-up|0
6074615|NCT00574288|9678545|FG001|Overall Study|Lost to Follow-up|0
6074616|NCT00574288|9678546|FG002|Overall Study|Lost to Follow-up|0
6074617|NCT00574288|9678547|FG003|Overall Study|Lost to Follow-up|0
6074618|NCT00574288|9678548|FG004|Overall Study|Lost to Follow-up|0
6074619|NCT00574288|9678549|FG005|Overall Study|Lost to Follow-up|1
6074620|NCT00574288|9678550|FG006|Overall Study|Lost to Follow-up|2
6074621|NCT00574288|9678544|FG000|Overall Study|Study Terminated By Sponsor|0
6074622|NCT00574288|9678545|FG001|Overall Study|Study Terminated By Sponsor|0
6074623|NCT00574288|9678546|FG002|Overall Study|Study Terminated By Sponsor|0
6074624|NCT00574288|9678547|FG003|Overall Study|Study Terminated By Sponsor|0
6074625|NCT00574288|9678548|FG004|Overall Study|Study Terminated By Sponsor|0
6007579|NCT00093808|9601011|FG000|Overall Study|Cancel participation before receiving tx|1
6007580|NCT00093808|9601011|FG000|Overall Study|Protocol Violation|1
6007581|NCT00094055|9601035|FG000|Overall Study|Adverse Event|11
6007582|NCT00094055|9601035|FG000|Overall Study|Death|4
6007583|NCT00094055|9601035|FG000|Overall Study|Lack of Efficacy|17
6074626|NCT00574288|9678549|FG005|Overall Study|Study Terminated By Sponsor|0
6074627|NCT00574288|9678550|FG006|Overall Study|Study Terminated By Sponsor|5
6074628|NCT00574288|9678544|FG000|Overall Study|Progressive Disease|17
6074629|NCT00574288|9678545|FG001|Overall Study|Progressive Disease|2
6007584|NCT00094055|9601035|FG000|Overall Study|Lost to Follow-up|2
6007585|NCT00094055|9601035|FG000|Overall Study|progressive disease|2
6007586|NCT00094055|9601035|FG000|Overall Study|clinical progression|1
6007587|NCT00094055|9601035|FG000|Overall Study|roll-over to another study|14
6007588|NCT00094055|9601035|FG000|Overall Study|Withdrawal by Subject|9
6007589|NCT00094094|9601039|FG000|Overall Study|Death|2
6007590|NCT00094094|9601039|FG000|Overall Study|Lack of Efficacy|23
6007591|NCT00094094|9601039|FG000|Overall Study|Adverse Event|7
6007592|NCT00094107|9601043|FG000|Overall Study|Lack of Efficacy|23
6007593|NCT00094107|9601043|FG000|Overall Study|Death|5
6007594|NCT00094107|9601043|FG000|Overall Study|Adverse Event|3
6007595|NCT00094107|9601043|FG000|Overall Study|Withdrawal due to Disease Progression|1
6007596|NCT00094172|9601049|FG000|Overall Study|Adverse Event|0
6007597|NCT00094172|9601050|FG001|Overall Study|Adverse Event|1
6007598|NCT00094172|9601049|FG000|Overall Study|Lost to Follow-up|2
6007599|NCT00094172|9601050|FG001|Overall Study|Lost to Follow-up|0
6007600|NCT00094172|9601049|FG000|Overall Study|Protocol Violation|0
6007601|NCT00094172|9601050|FG001|Overall Study|Protocol Violation|1
6007602|NCT00094172|9601049|FG000|Overall Study|Withdrawal by Subject|10
6007603|NCT00094172|9601050|FG001|Overall Study|Withdrawal by Subject|5
6007604|NCT00094172|9601049|FG000|Overall Study|Primary endpoint met.|1
6007605|NCT00094172|9601050|FG001|Overall Study|Primary endpoint met.|0
6007606|NCT00094172|9601049|FG000|Overall Study|Started other MS therapy due to disease|1
6007607|NCT00094172|9601050|FG001|Overall Study|Started other MS therapy due to disease|0
6007608|NCT00094302|9601079|FG000|Overall Study|Lost to Follow-up|43
6007609|NCT00094302|9601080|FG001|Overall Study|Lost to Follow-up|41
6007610|NCT00094302|9601079|FG000|Overall Study|Physician Decision|5
6007611|NCT00094302|9601080|FG001|Overall Study|Physician Decision|8
6007612|NCT00094302|9601079|FG000|Overall Study|Withdrawal by Subject|103
6007613|NCT00094302|9601080|FG001|Overall Study|Withdrawal by Subject|111
6007614|NCT00094302|9601079|FG000|Overall Study|Death|266
6007615|NCT00094302|9601080|FG001|Overall Study|Death|246
6007616|NCT00094328|9601086|FG000|Overall Study|Lost to Follow-up|1
6007617|NCT00094445|9601090|FG000|Overall Study|Withdrawal by Subject|3
6007618|NCT00094445|9601090|FG000|Overall Study|Lost to Follow-up|1
6007619|NCT00094445|9601090|FG000|Overall Study|Progressive Disease|2
6007620|NCT00094458|9601097|FG000|Main Study: Through Week 30|Eligibility criteria not met|3
6007621|NCT00094458|9601098|FG001|Main Study: Through Week 30|Eligibility criteria not met|8
6007622|NCT00094458|9601099|FG002|Main Study: Through Week 30|Eligibility criteria not met|2
6007623|NCT00094458|9601100|FG003|Main Study: Through Week 30|Eligibility criteria not met|0
6007624|NCT00094458|9601101|FG004|Main Study: Through Week 30|Eligibility criteria not met|0
6007625|NCT00094458|9601102|FG005|Main Study: Through Week 30|Eligibility criteria not met|0
6007626|NCT00094458|9601097|FG000|Main Study: Through Week 30|Lost to Follow-up|5
6007627|NCT00094458|9601098|FG001|Main Study: Through Week 30|Lost to Follow-up|5
6007628|NCT00094458|9601099|FG002|Main Study: Through Week 30|Lost to Follow-up|2
6007629|NCT00094458|9601100|FG003|Main Study: Through Week 30|Lost to Follow-up|0
6007630|NCT00094458|9601101|FG004|Main Study: Through Week 30|Lost to Follow-up|0
6007631|NCT00094458|9601102|FG005|Main Study: Through Week 30|Lost to Follow-up|0
6007632|NCT00094458|9601097|FG000|Main Study: Through Week 30|Withdrawal by Subject|18
6007633|NCT00094458|9601098|FG001|Main Study: Through Week 30|Withdrawal by Subject|9
6007634|NCT00094458|9601099|FG002|Main Study: Through Week 30|Withdrawal by Subject|7
6007635|NCT00094458|9601100|FG003|Main Study: Through Week 30|Withdrawal by Subject|0
6007636|NCT00094458|9601101|FG004|Main Study: Through Week 30|Withdrawal by Subject|0
6007637|NCT00094458|9601102|FG005|Main Study: Through Week 30|Withdrawal by Subject|0
6007638|NCT00094458|9601097|FG000|Main Study: Through Week 30|Adverse Event|38
6007639|NCT00094458|9601098|FG001|Main Study: Through Week 30|Adverse Event|20
6007640|NCT00094458|9601099|FG002|Main Study: Through Week 30|Adverse Event|28
6007641|NCT00094458|9601100|FG003|Main Study: Through Week 30|Adverse Event|0
6007642|NCT00094458|9601101|FG004|Main Study: Through Week 30|Adverse Event|0
6007643|NCT00094458|9601102|FG005|Main Study: Through Week 30|Adverse Event|0
6007644|NCT00094458|9601097|FG000|Main Study: Through Week 30|Death|1
6007645|NCT00094458|9601098|FG001|Main Study: Through Week 30|Death|0
6007646|NCT00094458|9601099|FG002|Main Study: Through Week 30|Death|0
6007647|NCT00094458|9601100|FG003|Main Study: Through Week 30|Death|0
6007648|NCT00094458|9601101|FG004|Main Study: Through Week 30|Death|0
6007649|NCT00094458|9601102|FG005|Main Study: Through Week 30|Death|0
6007650|NCT00094458|9601097|FG000|Main Study: Through Week 30|Other|19
6007651|NCT00094458|9601098|FG001|Main Study: Through Week 30|Other|16
6007652|NCT00094458|9601099|FG002|Main Study: Through Week 30|Other|9
6007653|NCT00094458|9601100|FG003|Main Study: Through Week 30|Other|0
6007654|NCT00094458|9601101|FG004|Main Study: Through Week 30|Other|0
6007655|NCT00094458|9601102|FG005|Main Study: Through Week 30|Other|0
6007656|NCT00094458|9601097|FG000|Study Extension: Week 30 Through Week 50|Lost to Follow-up|2
6007657|NCT00094458|9601098|FG001|Study Extension: Week 30 Through Week 50|Lost to Follow-up|1
6007658|NCT00094458|9601099|FG002|Study Extension: Week 30 Through Week 50|Lost to Follow-up|4
6007659|NCT00094458|9601100|FG003|Study Extension: Week 30 Through Week 50|Lost to Follow-up|0
6007660|NCT00094458|9601101|FG004|Study Extension: Week 30 Through Week 50|Lost to Follow-up|0
6007661|NCT00094458|9601102|FG005|Study Extension: Week 30 Through Week 50|Lost to Follow-up|0
6007662|NCT00094458|9601097|FG000|Study Extension: Week 30 Through Week 50|Withdrawal by Subject|2
6007663|NCT00094458|9601098|FG001|Study Extension: Week 30 Through Week 50|Withdrawal by Subject|0
6007664|NCT00094458|9601099|FG002|Study Extension: Week 30 Through Week 50|Withdrawal by Subject|4
6007665|NCT00094458|9601100|FG003|Study Extension: Week 30 Through Week 50|Withdrawal by Subject|0
6007666|NCT00094458|9601101|FG004|Study Extension: Week 30 Through Week 50|Withdrawal by Subject|0
6007667|NCT00094458|9601102|FG005|Study Extension: Week 30 Through Week 50|Withdrawal by Subject|0
6007668|NCT00094458|9601097|FG000|Study Extension: Week 30 Through Week 50|Adverse Event|3
6007669|NCT00094458|9601098|FG001|Study Extension: Week 30 Through Week 50|Adverse Event|9
6007670|NCT00094458|9601099|FG002|Study Extension: Week 30 Through Week 50|Adverse Event|7
6007671|NCT00094458|9601100|FG003|Study Extension: Week 30 Through Week 50|Adverse Event|0
6007672|NCT00094458|9601101|FG004|Study Extension: Week 30 Through Week 50|Adverse Event|0
6007673|NCT00094458|9601102|FG005|Study Extension: Week 30 Through Week 50|Adverse Event|0
6007674|NCT00094458|9601097|FG000|Study Extension: Week 30 Through Week 50|Other|1
6074630|NCT00574288|9678546|FG002|Overall Study|Progressive Disease|3
6074631|NCT00574288|9678547|FG003|Overall Study|Progressive Disease|2
6074632|NCT00574288|9678548|FG004|Overall Study|Progressive Disease|1
6074633|NCT00574288|9678549|FG005|Overall Study|Progressive Disease|0
6074634|NCT00574288|9678550|FG006|Overall Study|Progressive Disease|0
6074635|NCT00574288|9678544|FG000|Overall Study|Other|1
6007675|NCT00094458|9601098|FG001|Study Extension: Week 30 Through Week 50|Other|2
6007676|NCT00094458|9601099|FG002|Study Extension: Week 30 Through Week 50|Other|3
6007677|NCT00094458|9601100|FG003|Study Extension: Week 30 Through Week 50|Other|0
6007678|NCT00094458|9601101|FG004|Study Extension: Week 30 Through Week 50|Other|0
6007679|NCT00094458|9601102|FG005|Study Extension: Week 30 Through Week 50|Other|0
6007680|NCT00094458|9601097|FG000|OLE: Open-Label Extension|Adverse Event|0
6007681|NCT00094458|9601098|FG001|OLE: Open-Label Extension|Adverse Event|0
6007682|NCT00094458|9601099|FG002|OLE: Open-Label Extension|Adverse Event|0
6007683|NCT00094458|9601100|FG003|OLE: Open-Label Extension|Adverse Event|0
6007684|NCT00094458|9601101|FG004|OLE: Open-Label Extension|Adverse Event|3
6007685|NCT00094458|9601102|FG005|OLE: Open-Label Extension|Adverse Event|4
6007686|NCT00094458|9601097|FG000|OLE: Open-Label Extension|Inadequate therapeutic effect|0
6007687|NCT00094458|9601098|FG001|OLE: Open-Label Extension|Inadequate therapeutic effect|0
6007688|NCT00094458|9601099|FG002|OLE: Open-Label Extension|Inadequate therapeutic effect|0
6007689|NCT00094458|9601100|FG003|OLE: Open-Label Extension|Inadequate therapeutic effect|1
6007690|NCT00094458|9601101|FG004|OLE: Open-Label Extension|Inadequate therapeutic effect|1
6007691|NCT00094458|9601102|FG005|OLE: Open-Label Extension|Inadequate therapeutic effect|0
6007692|NCT00094458|9601097|FG000|OLE: Open-Label Extension|Patient decision|0
6007693|NCT00094458|9601098|FG001|OLE: Open-Label Extension|Patient decision|0
6007694|NCT00094458|9601099|FG002|OLE: Open-Label Extension|Patient decision|0
6074636|NCT00574288|9678545|FG001|Overall Study|Other|1
6074637|NCT00574288|9678546|FG002|Overall Study|Other|0
6074638|NCT00574288|9678547|FG003|Overall Study|Other|0
6074639|NCT00574288|9678548|FG004|Overall Study|Other|0
6074640|NCT00574288|9678549|FG005|Overall Study|Other|0
6074641|NCT00574288|9678550|FG006|Overall Study|Other|0
6074642|NCT00574405|9678585|FG000|Overall Study|Withdrawal by Subject|3
6074643|NCT00574405|9678586|FG001|Overall Study|Withdrawal by Subject|2
6074644|NCT00574795|9678654|FG000|Infant Series|Withdrawal by Subject|2
6074645|NCT00574795|9678654|FG000|Infant Series|Protocol Violation|2
6074646|NCT00574795|9678654|FG000|Infant Series|Adverse Event|1
6074647|NCT00574795|9678654|FG000|After Infant Series|Withdrawal by Subject|1
6074648|NCT00574795|9678654|FG000|After Infant Series|Adverse Event|2
6074649|NCT00574795|9678654|FG000|Toddler Dose|Withdrawal by Subject|1
6074650|NCT00574847|9678684|FG000|Overall Study|Adverse Event|2
6074651|NCT00574847|9678685|FG001|Overall Study|Adverse Event|0
6074652|NCT00574847|9678684|FG000|Overall Study|Death|1
6074653|NCT00574847|9678685|FG001|Overall Study|Death|0
6074654|NCT00574847|9678684|FG000|Overall Study|Withdrawal by Subject|2
6074655|NCT00574847|9678685|FG001|Overall Study|Withdrawal by Subject|2
6074656|NCT00574847|9678684|FG000|Overall Study|Physician Decision|1
6074657|NCT00574847|9678685|FG001|Overall Study|Physician Decision|0
6074658|NCT00574847|9678684|FG000|Overall Study|Did not receive medication (declined)|2
6074659|NCT00574847|9678685|FG001|Overall Study|Did not receive medication (declined)|5
6074660|NCT00574873|9678693|FG000|Overall Study|Withdrawal by Subject|18
6074661|NCT00574873|9678694|FG001|Overall Study|Withdrawal by Subject|19
6074662|NCT00574873|9678693|FG000|Overall Study|Investigator request|18
6074663|NCT00574873|9678694|FG001|Overall Study|Investigator request|8
6074664|NCT00574873|9678693|FG000|Overall Study|Death|15
6074665|NCT00574873|9678694|FG001|Overall Study|Death|14
6074666|NCT00574873|9678693|FG000|Overall Study|Lost to Follow-up|14
6074667|NCT00574873|9678694|FG001|Overall Study|Lost to Follow-up|5
6074668|NCT00574873|9678693|FG000|Overall Study|Other|40
6074669|NCT00574873|9678694|FG001|Overall Study|Other|4
6074670|NCT00574873|9678693|FG000|Overall Study|Discontinuation of study by sponsor|5
6074671|NCT00574873|9678694|FG001|Overall Study|Discontinuation of study by sponsor|199
6074672|NCT00574873|9678693|FG000|Overall Study|Blank, site closed per local regulations|2
6074673|NCT00574873|9678694|FG001|Overall Study|Blank, site closed per local regulations|2
6074674|NCT00574873|9678693|FG000|Overall Study|Extension Study|126
6074675|NCT00574873|9678694|FG001|Overall Study|Extension Study|0
6074676|NCT00574912|9678700|FG000|Overall Study|Could not place IV lines.|3
6074677|NCT00574912|9678700|FG000|Overall Study|scheduling conflicts|3
6074678|NCT00574912|9678700|FG000|Overall Study|Physician Decision|2
6074679|NCT00574951|9678712|FG000|Overall Study|Ineligible - improper prior treatment|1
6007695|NCT00094458|9601100|FG003|OLE: Open-Label Extension|Patient decision|0
6007696|NCT00094458|9601101|FG004|OLE: Open-Label Extension|Patient decision|1
6007697|NCT00094458|9601102|FG005|OLE: Open-Label Extension|Patient decision|0
6007698|NCT00094536|9601125|FG000|Inclusion Exclusion Evaluation|Did not qualify for study treatment|24
6007699|NCT00094536|9601125|FG000|Treatment and Follow-up|Adverse Event|4
6007700|NCT00094536|9601125|FG000|Treatment and Follow-up|Lack of Efficacy|9
6007701|NCT00094536|9601125|FG000|Treatment and Follow-up|Lost to Follow-up|7
6007702|NCT00094536|9601125|FG000|Treatment and Follow-up|Withdrawal by Subject|1
6007703|NCT00094536|9601125|FG000|Treatment and Follow-up|Subject non-compliance|9
6007704|NCT00094536|9601125|FG000|Treatment and Follow-up|Unable to attend visits|1
6007705|NCT00094575|9601131|FG000|Overall Study|Death|146
6007706|NCT00094575|9601132|FG001|Overall Study|Death|146
6007707|NCT00094653|9601143|FG000|Overall Study|Death|306
6007708|NCT00094653|9601144|FG001|Overall Study|Death|100
6007709|NCT00094653|9601145|FG002|Overall Study|Death|119
6007710|NCT00094653|9601143|FG000|Overall Study|Subject Withdrew Consent|10
6007711|NCT00094653|9601144|FG001|Overall Study|Subject Withdrew Consent|2
6007712|NCT00094653|9601145|FG002|Overall Study|Subject Withdrew Consent|3
6007713|NCT00094653|9601143|FG000|Overall Study|Other|2
6007714|NCT00094653|9601144|FG001|Overall Study|Other|2
6007715|NCT00094653|9601145|FG002|Overall Study|Other|2
6007716|NCT00094653|9601143|FG000|Overall Study|Lost to Follow-up|3
6007717|NCT00094653|9601144|FG001|Overall Study|Lost to Follow-up|2
6007718|NCT00094653|9601145|FG002|Overall Study|Lost to Follow-up|1
6007719|NCT00094653|9601143|FG000|Overall Study|Protocol Violation|0
6007720|NCT00094653|9601144|FG001|Overall Study|Protocol Violation|0
6007721|NCT00094653|9601145|FG002|Overall Study|Protocol Violation|1
6007722|NCT00094757|9601157|FG000|Overall Study|Adverse Event|11
6007723|NCT00094757|9601158|FG001|Overall Study|Adverse Event|9
6007724|NCT00094757|9601159|FG002|Overall Study|Adverse Event|6
6007725|NCT00094757|9601157|FG000|Overall Study|Lack of Efficacy|11
6007726|NCT00094757|9601158|FG001|Overall Study|Lack of Efficacy|15
6007727|NCT00094757|9601159|FG002|Overall Study|Lack of Efficacy|8
6007728|NCT00094757|9601157|FG000|Overall Study|Lost to Follow-up|3
6007729|NCT00094757|9601158|FG001|Overall Study|Lost to Follow-up|5
6007730|NCT00094757|9601159|FG002|Overall Study|Lost to Follow-up|6
6007731|NCT00094757|9601157|FG000|Overall Study|Patient Moved|2
6007732|NCT00094757|9601158|FG001|Overall Study|Patient Moved|1
6007733|NCT00094757|9601159|FG002|Overall Study|Patient Moved|1
6007734|NCT00094757|9601157|FG000|Overall Study|Protocol Violation|8
6007735|NCT00094757|9601158|FG001|Overall Study|Protocol Violation|5
6007736|NCT00094757|9601159|FG002|Overall Study|Protocol Violation|3
6007737|NCT00094757|9601157|FG000|Overall Study|Withdrawal by Subject|14
6007738|NCT00094757|9601158|FG001|Overall Study|Withdrawal by Subject|21
6007739|NCT00094757|9601159|FG002|Overall Study|Withdrawal by Subject|5
6007740|NCT00094757|9601157|FG000|Overall Study|Other|3
6007741|NCT00094757|9601158|FG001|Overall Study|Other|3
6007742|NCT00094757|9601159|FG002|Overall Study|Other|1
6007743|NCT00094757|9601157|FG000|Overall Study|Protocol specified discontinuation|1
6007744|NCT00094757|9601158|FG001|Overall Study|Protocol specified discontinuation|3
6007745|NCT00094757|9601159|FG002|Overall Study|Protocol specified discontinuation|0
6007746|NCT00094770|9601169|FG000|Year 1 ( Week 0 to Week 52)|Adverse Event|25
6007747|NCT00094770|9601170|FG001|Year 1 ( Week 0 to Week 52)|Adverse Event|26
6007748|NCT00094770|9601169|FG000|Year 1 ( Week 0 to Week 52)|Lack of Efficacy|86
6007749|NCT00094770|9601170|FG001|Year 1 ( Week 0 to Week 52)|Lack of Efficacy|58
6007750|NCT00094770|9601169|FG000|Year 1 ( Week 0 to Week 52)|Lost to Follow-up|19
6007751|NCT00094770|9601170|FG001|Year 1 ( Week 0 to Week 52)|Lost to Follow-up|10
6007752|NCT00094770|9601169|FG000|Year 1 ( Week 0 to Week 52)|Protocol Violation|10
6007753|NCT00094770|9601170|FG001|Year 1 ( Week 0 to Week 52)|Protocol Violation|10
6007754|NCT00094770|9601169|FG000|Year 1 ( Week 0 to Week 52)|Protocol Specified Discontinuation|19
6007755|NCT00094770|9601170|FG001|Year 1 ( Week 0 to Week 52)|Protocol Specified Discontinuation|25
6007756|NCT00094770|9601169|FG000|Year 1 ( Week 0 to Week 52)|Patient Moved|6
6007757|NCT00094770|9601170|FG001|Year 1 ( Week 0 to Week 52)|Patient Moved|2
6007758|NCT00094770|9601169|FG000|Year 1 ( Week 0 to Week 52)|Withdrawal by Subject|25
6007759|NCT00094770|9601170|FG001|Year 1 ( Week 0 to Week 52)|Withdrawal by Subject|28
6007760|NCT00094770|9601169|FG000|Year 1 ( Week 0 to Week 52)|Site Terminated|2
6007761|NCT00094770|9601170|FG001|Year 1 ( Week 0 to Week 52)|Site Terminated|2
6007762|NCT00094770|9601169|FG000|Year 1 ( Week 0 to Week 52)|Other|10
6007763|NCT00094770|9601170|FG001|Year 1 ( Week 0 to Week 52)|Other|11
6007764|NCT00094770|9601169|FG000|Year 2 (Week 0 to Week 104)|Adverse Event|35
6007765|NCT00094770|9601170|FG001|Year 2 (Week 0 to Week 104)|Adverse Event|36
6007766|NCT00094770|9601169|FG000|Year 2 (Week 0 to Week 104)|Lack of Efficacy|180
6007767|NCT00094770|9601170|FG001|Year 2 (Week 0 to Week 104)|Lack of Efficacy|162
6007768|NCT00094770|9601169|FG000|Year 2 (Week 0 to Week 104)|Lost to Follow-up|25
6007769|NCT00094770|9601170|FG001|Year 2 (Week 0 to Week 104)|Lost to Follow-up|15
6007770|NCT00094770|9601169|FG000|Year 2 (Week 0 to Week 104)|Protocol Violation|13
6007771|NCT00094770|9601170|FG001|Year 2 (Week 0 to Week 104)|Protocol Violation|12
6007772|NCT00094770|9601169|FG000|Year 2 (Week 0 to Week 104)|Protocol Specified Discontinuation|29
6007773|NCT00094770|9601170|FG001|Year 2 (Week 0 to Week 104)|Protocol Specified Discontinuation|30
6007774|NCT00094770|9601169|FG000|Year 2 (Week 0 to Week 104)|Patient Moved|6
6007775|NCT00094770|9601170|FG001|Year 2 (Week 0 to Week 104)|Patient Moved|2
6007776|NCT00094770|9601169|FG000|Year 2 (Week 0 to Week 104)|Withdrawal by Subject|28
6007777|NCT00094770|9601170|FG001|Year 2 (Week 0 to Week 104)|Withdrawal by Subject|38
6007778|NCT00094770|9601169|FG000|Year 2 (Week 0 to Week 104)|Site Terminated|2
6007779|NCT00094770|9601170|FG001|Year 2 (Week 0 to Week 104)|Site Terminated|2
6007780|NCT00094770|9601169|FG000|Year 2 (Week 0 to Week 104)|Other|15
6007781|NCT00094770|9601170|FG001|Year 2 (Week 0 to Week 104)|Other|23
6007782|NCT00094809|9601178|FG000|Overall Study|Protocol deviation|2
6007783|NCT00094809|9601179|FG001|Overall Study|Protocol deviation|2
6007784|NCT00094809|9601178|FG000|Overall Study|Noncompliance|1
6007785|NCT00094809|9601179|FG001|Overall Study|Noncompliance|0
6007786|NCT00094809|9601178|FG000|Overall Study|Adverse Event|3
6007787|NCT00094809|9601179|FG001|Overall Study|Adverse Event|1
6007788|NCT00094809|9601178|FG000|Overall Study|Withdrawal by Subject|8
6007789|NCT00094809|9601179|FG001|Overall Study|Withdrawal by Subject|9
6007790|NCT00094809|9601178|FG000|Overall Study|Disease progression|3
6007791|NCT00094809|9601179|FG001|Overall Study|Disease progression|3
6007792|NCT00094809|9601178|FG000|Overall Study|Physician Decision|3
6007793|NCT00094809|9601179|FG001|Overall Study|Physician Decision|5
6007794|NCT00094809|9601178|FG000|Overall Study|Lost to Follow-up|6
6007795|NCT00094809|9601179|FG001|Overall Study|Lost to Follow-up|6
6007796|NCT00094809|9601178|FG000|Overall Study|Death|19
6007797|NCT00094809|9601179|FG001|Overall Study|Death|25
6007798|NCT00094809|9601178|FG000|Overall Study|Protocol-specified criteria|1
6007799|NCT00094809|9601179|FG001|Overall Study|Protocol-specified criteria|1
6007800|NCT00094809|9601178|FG000|Overall Study|Other|2
6007801|NCT00094809|9601179|FG001|Overall Study|Other|4
6007802|NCT00094809|9601178|FG000|Overall Study|Informed consent signed after treatment|1
6007803|NCT00094809|9601179|FG001|Overall Study|Informed consent signed after treatment|0
6007804|NCT00094809|9601178|FG000|Overall Study|Study drug not received|2
6007805|NCT00094809|9601179|FG001|Overall Study|Study drug not received|8
6007806|NCT00094809|9601178|FG000|Overall Study|Other|1
6007807|NCT00094809|9601179|FG001|Overall Study|Other|1
6007808|NCT00094835|9601192|FG000|Overall Study|Physician Decision|1
6007809|NCT00094835|9601193|FG001|Overall Study|Physician Decision|0
6007810|NCT00094835|9601194|FG002|Overall Study|Physician Decision|0
6007811|NCT00094835|9601195|FG003|Overall Study|Physician Decision|0
6007812|NCT00094835|9601196|FG004|Overall Study|Physician Decision|0
6007813|NCT00094835|9601197|FG005|Overall Study|Physician Decision|1
6007814|NCT00094835|9601198|FG006|Overall Study|Physician Decision|0
6007815|NCT00094835|9601192|FG000|Overall Study|Withdrawal by Subject|0
6007816|NCT00094835|9601193|FG001|Overall Study|Withdrawal by Subject|0
6007817|NCT00094835|9601194|FG002|Overall Study|Withdrawal by Subject|0
6007818|NCT00094835|9601195|FG003|Overall Study|Withdrawal by Subject|0
6007819|NCT00094835|9601196|FG004|Overall Study|Withdrawal by Subject|0
6007820|NCT00094835|9601197|FG005|Overall Study|Withdrawal by Subject|0
6007821|NCT00094835|9601198|FG006|Overall Study|Withdrawal by Subject|1
6007822|NCT00094835|9601192|FG000|Overall Study|Lost to Follow-up|0
6007823|NCT00094835|9601193|FG001|Overall Study|Lost to Follow-up|0
6007824|NCT00094835|9601194|FG002|Overall Study|Lost to Follow-up|0
6007825|NCT00094835|9601195|FG003|Overall Study|Lost to Follow-up|0
6007826|NCT00094835|9601196|FG004|Overall Study|Lost to Follow-up|1
6007827|NCT00094835|9601197|FG005|Overall Study|Lost to Follow-up|0
6007828|NCT00094835|9601198|FG006|Overall Study|Lost to Follow-up|0
6007829|NCT00094835|9601192|FG000|Overall Study|Death|1
6007830|NCT00094835|9601193|FG001|Overall Study|Death|0
6007831|NCT00094835|9601194|FG002|Overall Study|Death|0
6007832|NCT00094835|9601195|FG003|Overall Study|Death|0
6007833|NCT00094835|9601196|FG004|Overall Study|Death|1
6007834|NCT00094835|9601197|FG005|Overall Study|Death|0
6007835|NCT00094835|9601198|FG006|Overall Study|Death|0
6007836|NCT00094835|9601192|FG000|Overall Study|Non-compliance|1
6007837|NCT00094835|9601193|FG001|Overall Study|Non-compliance|2
6007838|NCT00094835|9601194|FG002|Overall Study|Non-compliance|2
6007839|NCT00094835|9601195|FG003|Overall Study|Non-compliance|0
6007840|NCT00094835|9601196|FG004|Overall Study|Non-compliance|2
6007841|NCT00094835|9601197|FG005|Overall Study|Non-compliance|2
6007842|NCT00094835|9601198|FG006|Overall Study|Non-compliance|1
6007843|NCT00094835|9601192|FG000|Overall Study|Other|1
6007844|NCT00094835|9601193|FG001|Overall Study|Other|1
6007845|NCT00094835|9601194|FG002|Overall Study|Other|1
6007846|NCT00094835|9601195|FG003|Overall Study|Other|1
6007847|NCT00094835|9601196|FG004|Overall Study|Other|0
6007848|NCT00094835|9601197|FG005|Overall Study|Other|0
6007849|NCT00094835|9601198|FG006|Overall Study|Other|0
6007850|NCT00094861|9601221|FG000|Overall Study|Adverse Event|5
6007851|NCT00094861|9601222|FG001|Overall Study|Adverse Event|2
6007852|NCT00094861|9601221|FG000|Overall Study|Withdrawal by Subject|5
6007853|NCT00094861|9601222|FG001|Overall Study|Withdrawal by Subject|3
6007854|NCT00094861|9601221|FG000|Overall Study|Physician Decision|1
6007855|NCT00094861|9601222|FG001|Overall Study|Physician Decision|1
6007856|NCT00094861|9601221|FG000|Overall Study|Lost to Follow-up|0
6007857|NCT00094861|9601222|FG001|Overall Study|Lost to Follow-up|1
6007858|NCT00094861|9601221|FG000|Overall Study|Death|4
6007859|NCT00094861|9601222|FG001|Overall Study|Death|2
6007860|NCT00094861|9601221|FG000|Overall Study|Other|3
6007861|NCT00094861|9601222|FG001|Overall Study|Other|0
6007862|NCT00095056|9601243|FG000|Phase A (Weeks 0-12)|Adverse Event|1
6007863|NCT00095056|9601244|FG001|Phase A (Weeks 0-12)|Adverse Event|1
6007864|NCT00095056|9601243|FG000|Phase A (Weeks 0-12)|Withdrawal by Subject|3
6007865|NCT00095056|9601244|FG001|Phase A (Weeks 0-12)|Withdrawal by Subject|0
6007866|NCT00095056|9601243|FG000|Phase A (Weeks 0-12)|Death|1
6007867|NCT00095056|9601244|FG001|Phase A (Weeks 0-12)|Death|0
6007868|NCT00095056|9601243|FG000|Phase A (Weeks 0-12)|Protocol specific criteria|2
6007869|NCT00095056|9601244|FG001|Phase A (Weeks 0-12)|Protocol specific criteria|0
6007870|NCT00095056|9601243|FG000|Phase B (Weeks 12-54)|Adverse Event|2
6007871|NCT00095056|9601244|FG001|Phase B (Weeks 12-54)|Adverse Event|2
6007872|NCT00095056|9601243|FG000|Phase B (Weeks 12-54)|Lost to Follow-up|1
6007873|NCT00095056|9601244|FG001|Phase B (Weeks 12-54)|Lost to Follow-up|0
6007874|NCT00095056|9601243|FG000|Phase B (Weeks 12-54)|Withdrawal by Subject|2
6007875|NCT00095056|9601244|FG001|Phase B (Weeks 12-54)|Withdrawal by Subject|1
6007876|NCT00095056|9601243|FG000|Phase B (Weeks 12-54)|Patient Moved|1
6007877|NCT00095056|9601244|FG001|Phase B (Weeks 12-54)|Patient Moved|0
6007878|NCT00095056|9601243|FG000|Phase B (Weeks 12-54)|Death|3
6007879|NCT00095056|9601244|FG001|Phase B (Weeks 12-54)|Death|1
6007880|NCT00095056|9601243|FG000|Phase B (Weeks 12-54)|Protocol specific criteria|1
6007881|NCT00095056|9601244|FG001|Phase B (Weeks 12-54)|Protocol specific criteria|0
6007882|NCT00095056|9601243|FG000|Phase B (Weeks 12-54)|Protocol Violation|0
6007883|NCT00095056|9601244|FG001|Phase B (Weeks 12-54)|Protocol Violation|1
6074680|NCT00575042|9678753|FG000|Overall Study|Adverse Event|2
6074681|NCT00575042|9678753|FG000|Overall Study|Lost to Follow-up|1
6074682|NCT00575094|9678758|FG000|Overall Study|Adverse Event|2
6074683|NCT00575094|9678758|FG000|Overall Study|Withdrawal by Subject|1
6074684|NCT00575328|9678795|FG000|Overall Study|Adverse Event|1
6007884|NCT00095121|9601252|FG000|Double-Blind (Study Weeks 0 Through 48)|Adverse Event|1
6007885|NCT00095121|9601253|FG001|Double-Blind (Study Weeks 0 Through 48)|Adverse Event|0
6007886|NCT00095121|9601252|FG000|Double-Blind (Study Weeks 0 Through 48)|Not Compliant|2
6007887|NCT00095121|9601253|FG001|Double-Blind (Study Weeks 0 Through 48)|Not Compliant|0
6007888|NCT00095147|9601272|FG000|Double-blind Period 1 (Days 1-197)|Death|1
6007889|NCT00095147|9601273|FG001|Double-blind Period 1 (Days 1-197)|Death|0
6007890|NCT00095147|9601274|FG002|Double-blind Period 1 (Days 1-197)|Death|0
6007891|NCT00095147|9601275|FG003|Double-blind Period 1 (Days 1-197)|Death|0
6007892|NCT00095147|9601276|FG004|Double-blind Period 1 (Days 1-197)|Death|0
6007893|NCT00095147|9601272|FG000|Double-blind Period 1 (Days 1-197)|Adverse Event|2
6007894|NCT00095147|9601273|FG001|Double-blind Period 1 (Days 1-197)|Adverse Event|8
6007895|NCT00095147|9601274|FG002|Double-blind Period 1 (Days 1-197)|Adverse Event|1
6007896|NCT00095147|9601275|FG003|Double-blind Period 1 (Days 1-197)|Adverse Event|0
6007897|NCT00095147|9601276|FG004|Double-blind Period 1 (Days 1-197)|Adverse Event|0
6007898|NCT00095147|9601272|FG000|Double-blind Period 1 (Days 1-197)|Lack of Efficacy|2
6007899|NCT00095147|9601273|FG001|Double-blind Period 1 (Days 1-197)|Lack of Efficacy|2
6007900|NCT00095147|9601274|FG002|Double-blind Period 1 (Days 1-197)|Lack of Efficacy|1
6007901|NCT00095147|9601275|FG003|Double-blind Period 1 (Days 1-197)|Lack of Efficacy|0
6007902|NCT00095147|9601276|FG004|Double-blind Period 1 (Days 1-197)|Lack of Efficacy|0
6007903|NCT00095147|9601272|FG000|Double-blind Period 1 (Days 1-197)|Lost to Follow-up|2
6007904|NCT00095147|9601273|FG001|Double-blind Period 1 (Days 1-197)|Lost to Follow-up|2
6007905|NCT00095147|9601274|FG002|Double-blind Period 1 (Days 1-197)|Lost to Follow-up|0
6007906|NCT00095147|9601275|FG003|Double-blind Period 1 (Days 1-197)|Lost to Follow-up|0
6007907|NCT00095147|9601276|FG004|Double-blind Period 1 (Days 1-197)|Lost to Follow-up|0
6007908|NCT00095147|9601272|FG000|Double-blind Period 1 (Days 1-197)|Withdrawal of consent|1
6007909|NCT00095147|9601273|FG001|Double-blind Period 1 (Days 1-197)|Withdrawal of consent|0
6007910|NCT00095147|9601274|FG002|Double-blind Period 1 (Days 1-197)|Withdrawal of consent|1
6007911|NCT00095147|9601275|FG003|Double-blind Period 1 (Days 1-197)|Withdrawal of consent|0
6007912|NCT00095147|9601276|FG004|Double-blind Period 1 (Days 1-197)|Withdrawal of consent|0
6007913|NCT00095147|9601272|FG000|Double-blind Period 1 (Days 1-197)|Pregnancy|1
6007914|NCT00095147|9601273|FG001|Double-blind Period 1 (Days 1-197)|Pregnancy|1
6007915|NCT00095147|9601274|FG002|Double-blind Period 1 (Days 1-197)|Pregnancy|0
6007916|NCT00095147|9601275|FG003|Double-blind Period 1 (Days 1-197)|Pregnancy|0
6007917|NCT00095147|9601276|FG004|Double-blind Period 1 (Days 1-197)|Pregnancy|0
6007918|NCT00095147|9601272|FG000|Double-blind Period 2 (Days 198-365)|Death|0
6007919|NCT00095147|9601273|FG001|Double-blind Period 2 (Days 198-365)|Death|1
6007920|NCT00095147|9601274|FG002|Double-blind Period 2 (Days 198-365)|Death|0
6007921|NCT00095147|9601275|FG003|Double-blind Period 2 (Days 198-365)|Death|1
6007922|NCT00095147|9601276|FG004|Double-blind Period 2 (Days 198-365)|Death|0
6007923|NCT00095147|9601272|FG000|Double-blind Period 2 (Days 198-365)|Adverse Event|2
6007924|NCT00095147|9601273|FG001|Double-blind Period 2 (Days 198-365)|Adverse Event|4
6007925|NCT00095147|9601274|FG002|Double-blind Period 2 (Days 198-365)|Adverse Event|0
6007926|NCT00095147|9601275|FG003|Double-blind Period 2 (Days 198-365)|Adverse Event|0
6007927|NCT00095147|9601276|FG004|Double-blind Period 2 (Days 198-365)|Adverse Event|0
6007928|NCT00095147|9601272|FG000|Double-blind Period 2 (Days 198-365)|Lack of Efficacy|2
6007929|NCT00095147|9601273|FG001|Double-blind Period 2 (Days 198-365)|Lack of Efficacy|4
6007930|NCT00095147|9601274|FG002|Double-blind Period 2 (Days 198-365)|Lack of Efficacy|0
6007931|NCT00095147|9601275|FG003|Double-blind Period 2 (Days 198-365)|Lack of Efficacy|1
6007932|NCT00095147|9601276|FG004|Double-blind Period 2 (Days 198-365)|Lack of Efficacy|0
6074685|NCT00575328|9678796|FG001|Overall Study|Adverse Event|1
6007933|NCT00095147|9601272|FG000|Double-blind Period 2 (Days 198-365)|Withdrawal of consent|3
6007934|NCT00095147|9601273|FG001|Double-blind Period 2 (Days 198-365)|Withdrawal of consent|2
6007935|NCT00095147|9601274|FG002|Double-blind Period 2 (Days 198-365)|Withdrawal of consent|0
6007936|NCT00095147|9601275|FG003|Double-blind Period 2 (Days 198-365)|Withdrawal of consent|0
6007937|NCT00095147|9601276|FG004|Double-blind Period 2 (Days 198-365)|Withdrawal of consent|0
6007938|NCT00095147|9601272|FG000|Double-blind Period 2 (Days 198-365)|Participant relocation|1
6007939|NCT00095147|9601273|FG001|Double-blind Period 2 (Days 198-365)|Participant relocation|0
6007940|NCT00095147|9601274|FG002|Double-blind Period 2 (Days 198-365)|Participant relocation|0
6007941|NCT00095147|9601275|FG003|Double-blind Period 2 (Days 198-365)|Participant relocation|1
6007942|NCT00095147|9601276|FG004|Double-blind Period 2 (Days 198-365)|Participant relocation|0
6007943|NCT00095147|9601272|FG000|Long-term Extension Period|Death|0
6007944|NCT00095147|9601273|FG001|Long-term Extension Period|Death|0
6007945|NCT00095147|9601274|FG002|Long-term Extension Period|Death|0
6007946|NCT00095147|9601275|FG003|Long-term Extension Period|Death|0
6007947|NCT00095147|9601276|FG004|Long-term Extension Period|Death|3
6007948|NCT00095147|9601272|FG000|Long-term Extension Period|Adverse Event|0
6007949|NCT00095147|9601273|FG001|Long-term Extension Period|Adverse Event|0
6007950|NCT00095147|9601274|FG002|Long-term Extension Period|Adverse Event|0
6007951|NCT00095147|9601275|FG003|Long-term Extension Period|Adverse Event|0
6007952|NCT00095147|9601276|FG004|Long-term Extension Period|Adverse Event|11
6007953|NCT00095147|9601272|FG000|Long-term Extension Period|Lack of Efficacy|0
6007954|NCT00095147|9601273|FG001|Long-term Extension Period|Lack of Efficacy|0
6007955|NCT00095147|9601274|FG002|Long-term Extension Period|Lack of Efficacy|0
6007956|NCT00095147|9601275|FG003|Long-term Extension Period|Lack of Efficacy|0
6007957|NCT00095147|9601276|FG004|Long-term Extension Period|Lack of Efficacy|9
6007958|NCT00095147|9601272|FG000|Long-term Extension Period|Lost to Follow-up|0
6007959|NCT00095147|9601273|FG001|Long-term Extension Period|Lost to Follow-up|0
6007960|NCT00095147|9601274|FG002|Long-term Extension Period|Lost to Follow-up|0
6007961|NCT00095147|9601275|FG003|Long-term Extension Period|Lost to Follow-up|0
6007962|NCT00095147|9601276|FG004|Long-term Extension Period|Lost to Follow-up|6
6007963|NCT00095147|9601272|FG000|Long-term Extension Period|Withdrawal of consent|0
6007964|NCT00095147|9601273|FG001|Long-term Extension Period|Withdrawal of consent|0
6007965|NCT00095147|9601274|FG002|Long-term Extension Period|Withdrawal of consent|0
6007966|NCT00095147|9601275|FG003|Long-term Extension Period|Withdrawal of consent|0
6007967|NCT00095147|9601276|FG004|Long-term Extension Period|Withdrawal of consent|12
6007968|NCT00095147|9601272|FG000|Long-term Extension Period|Pregnancy|0
6007969|NCT00095147|9601273|FG001|Long-term Extension Period|Pregnancy|0
6007970|NCT00095147|9601274|FG002|Long-term Extension Period|Pregnancy|0
6007971|NCT00095147|9601275|FG003|Long-term Extension Period|Pregnancy|0
6007972|NCT00095147|9601276|FG004|Long-term Extension Period|Pregnancy|1
6007973|NCT00095147|9601272|FG000|Long-term Extension Period|No longer meets study criteria|0
6007974|NCT00095147|9601273|FG001|Long-term Extension Period|No longer meets study criteria|0
6007975|NCT00095147|9601274|FG002|Long-term Extension Period|No longer meets study criteria|0
6007976|NCT00095147|9601275|FG003|Long-term Extension Period|No longer meets study criteria|0
6007977|NCT00095147|9601276|FG004|Long-term Extension Period|No longer meets study criteria|1
6007978|NCT00095147|9601272|FG000|Long-term Extension Period|Participant chose to use Revellex|0
6007979|NCT00095147|9601273|FG001|Long-term Extension Period|Participant chose to use Revellex|0
6007980|NCT00095147|9601274|FG002|Long-term Extension Period|Participant chose to use Revellex|0
6007981|NCT00095147|9601275|FG003|Long-term Extension Period|Participant chose to use Revellex|0
6007982|NCT00095147|9601276|FG004|Long-term Extension Period|Participant chose to use Revellex|1
6007983|NCT00095147|9601272|FG000|Long-term Extension Period|Leaving country|0
6007984|NCT00095147|9601273|FG001|Long-term Extension Period|Leaving country|0
6007985|NCT00095147|9601274|FG002|Long-term Extension Period|Leaving country|0
6007986|NCT00095147|9601275|FG003|Long-term Extension Period|Leaving country|0
6007987|NCT00095147|9601276|FG004|Long-term Extension Period|Leaving country|1
6007988|NCT00095173|9601294|FG000|Open-Label Lead-In Phase (Period A)|Adverse Event|1
6007989|NCT00095173|9601295|FG001|Open-Label Lead-In Phase (Period A)|Adverse Event|0
6007990|NCT00095173|9601296|FG002|Open-Label Lead-In Phase (Period A)|Adverse Event|0
6007991|NCT00095173|9601297|FG003|Open-Label Lead-In Phase (Period A)|Adverse Event|0
6007992|NCT00095173|9601298|FG004|Open-Label Lead-In Phase (Period A)|Adverse Event|0
6007993|NCT00095173|9601299|FG005|Open-Label Lead-In Phase (Period A)|Adverse Event|0
6007994|NCT00095173|9601294|FG000|Open-Label Lead-In Phase (Period A)|Lack of Efficacy|17
6007995|NCT00095173|9601295|FG001|Open-Label Lead-In Phase (Period A)|Lack of Efficacy|0
6007996|NCT00095173|9601296|FG002|Open-Label Lead-In Phase (Period A)|Lack of Efficacy|0
6007997|NCT00095173|9601297|FG003|Open-Label Lead-In Phase (Period A)|Lack of Efficacy|0
6007998|NCT00095173|9601298|FG004|Open-Label Lead-In Phase (Period A)|Lack of Efficacy|0
6007999|NCT00095173|9601299|FG005|Open-Label Lead-In Phase (Period A)|Lack of Efficacy|0
6008000|NCT00095173|9601294|FG000|Open-Label Lead-In Phase (Period A)|Withdrawal by Subject|1
6008001|NCT00095173|9601295|FG001|Open-Label Lead-In Phase (Period A)|Withdrawal by Subject|0
6008002|NCT00095173|9601296|FG002|Open-Label Lead-In Phase (Period A)|Withdrawal by Subject|0
6008003|NCT00095173|9601297|FG003|Open-Label Lead-In Phase (Period A)|Withdrawal by Subject|0
6008004|NCT00095173|9601298|FG004|Open-Label Lead-In Phase (Period A)|Withdrawal by Subject|0
6008005|NCT00095173|9601299|FG005|Open-Label Lead-In Phase (Period A)|Withdrawal by Subject|0
6008006|NCT00095173|9601294|FG000|Open-Label Lead-In Phase (Period A)|Other|1
6008007|NCT00095173|9601295|FG001|Open-Label Lead-In Phase (Period A)|Other|0
6008008|NCT00095173|9601296|FG002|Open-Label Lead-In Phase (Period A)|Other|0
6008009|NCT00095173|9601297|FG003|Open-Label Lead-In Phase (Period A)|Other|0
6008010|NCT00095173|9601298|FG004|Open-Label Lead-In Phase (Period A)|Other|0
6008011|NCT00095173|9601299|FG005|Open-Label Lead-In Phase (Period A)|Other|0
6008012|NCT00095173|9601294|FG000|Double-Blind Phase (Period B)|Lack of Efficacy|0
6008013|NCT00095173|9601295|FG001|Double-Blind Phase (Period B)|Lack of Efficacy|10
6008014|NCT00095173|9601296|FG002|Double-Blind Phase (Period B)|Lack of Efficacy|31
6008015|NCT00095173|9601297|FG003|Double-Blind Phase (Period B)|Lack of Efficacy|0
6008016|NCT00095173|9601298|FG004|Double-Blind Phase (Period B)|Lack of Efficacy|0
6008017|NCT00095173|9601299|FG005|Double-Blind Phase (Period B)|Lack of Efficacy|0
6008018|NCT00095173|9601294|FG000|Double-Blind Phase (Period B)|Withdrawal by Subject|0
6008019|NCT00095173|9601295|FG001|Double-Blind Phase (Period B)|Withdrawal by Subject|1
6008020|NCT00095173|9601296|FG002|Double-Blind Phase (Period B)|Withdrawal by Subject|0
6008021|NCT00095173|9601297|FG003|Double-Blind Phase (Period B)|Withdrawal by Subject|0
6008022|NCT00095173|9601298|FG004|Double-Blind Phase (Period B)|Withdrawal by Subject|0
6008023|NCT00095173|9601299|FG005|Double-Blind Phase (Period B)|Withdrawal by Subject|0
6008024|NCT00095173|9601294|FG000|Open-Label Extension Phase (Period C)|Death|0
6008025|NCT00095173|9601295|FG001|Open-Label Extension Phase (Period C)|Death|0
6008026|NCT00095173|9601296|FG002|Open-Label Extension Phase (Period C)|Death|0
6008027|NCT00095173|9601297|FG003|Open-Label Extension Phase (Period C)|Death|0
6008028|NCT00095173|9601298|FG004|Open-Label Extension Phase (Period C)|Death|0
6008029|NCT00095173|9601299|FG005|Open-Label Extension Phase (Period C)|Death|1
6008030|NCT00095173|9601294|FG000|Open-Label Extension Phase (Period C)|Adverse Event|0
6008031|NCT00095173|9601295|FG001|Open-Label Extension Phase (Period C)|Adverse Event|0
6008032|NCT00095173|9601296|FG002|Open-Label Extension Phase (Period C)|Adverse Event|0
6008033|NCT00095173|9601297|FG003|Open-Label Extension Phase (Period C)|Adverse Event|1
6008034|NCT00095173|9601298|FG004|Open-Label Extension Phase (Period C)|Adverse Event|2
6008035|NCT00095173|9601299|FG005|Open-Label Extension Phase (Period C)|Adverse Event|3
6008036|NCT00095173|9601294|FG000|Open-Label Extension Phase (Period C)|Lack of Efficacy|0
6008037|NCT00095173|9601295|FG001|Open-Label Extension Phase (Period C)|Lack of Efficacy|0
6008038|NCT00095173|9601296|FG002|Open-Label Extension Phase (Period C)|Lack of Efficacy|0
6008039|NCT00095173|9601297|FG003|Open-Label Extension Phase (Period C)|Lack of Efficacy|11
6008040|NCT00095173|9601298|FG004|Open-Label Extension Phase (Period C)|Lack of Efficacy|5
6008041|NCT00095173|9601299|FG005|Open-Label Extension Phase (Period C)|Lack of Efficacy|8
6008042|NCT00095173|9601294|FG000|Open-Label Extension Phase (Period C)|Lost to Follow-up|0
6008043|NCT00095173|9601295|FG001|Open-Label Extension Phase (Period C)|Lost to Follow-up|0
6008044|NCT00095173|9601296|FG002|Open-Label Extension Phase (Period C)|Lost to Follow-up|0
6008045|NCT00095173|9601297|FG003|Open-Label Extension Phase (Period C)|Lost to Follow-up|2
6008046|NCT00095173|9601298|FG004|Open-Label Extension Phase (Period C)|Lost to Follow-up|5
6008047|NCT00095173|9601299|FG005|Open-Label Extension Phase (Period C)|Lost to Follow-up|6
6008048|NCT00095173|9601294|FG000|Open-Label Extension Phase (Period C)|Withdrawal by Subject|0
6008049|NCT00095173|9601295|FG001|Open-Label Extension Phase (Period C)|Withdrawal by Subject|0
6008050|NCT00095173|9601296|FG002|Open-Label Extension Phase (Period C)|Withdrawal by Subject|0
6008051|NCT00095173|9601297|FG003|Open-Label Extension Phase (Period C)|Withdrawal by Subject|4
6008052|NCT00095173|9601298|FG004|Open-Label Extension Phase (Period C)|Withdrawal by Subject|6
6008053|NCT00095173|9601299|FG005|Open-Label Extension Phase (Period C)|Withdrawal by Subject|0
6008054|NCT00095173|9601294|FG000|Open-Label Extension Phase (Period C)|No Longer Meets Study Criteria|0
6008055|NCT00095173|9601295|FG001|Open-Label Extension Phase (Period C)|No Longer Meets Study Criteria|0
6008056|NCT00095173|9601296|FG002|Open-Label Extension Phase (Period C)|No Longer Meets Study Criteria|0
6008057|NCT00095173|9601297|FG003|Open-Label Extension Phase (Period C)|No Longer Meets Study Criteria|0
6008058|NCT00095173|9601298|FG004|Open-Label Extension Phase (Period C)|No Longer Meets Study Criteria|1
6008059|NCT00095173|9601299|FG005|Open-Label Extension Phase (Period C)|No Longer Meets Study Criteria|1
6008060|NCT00095173|9601294|FG000|Open-Label Extension Phase (Period C)|Poor/Non-Compliance|0
6074686|NCT00575328|9678795|FG000|Overall Study|Lost to Follow-up|2
6008061|NCT00095173|9601295|FG001|Open-Label Extension Phase (Period C)|Poor/Non-Compliance|0
6008062|NCT00095173|9601296|FG002|Open-Label Extension Phase (Period C)|Poor/Non-Compliance|0
6008063|NCT00095173|9601297|FG003|Open-Label Extension Phase (Period C)|Poor/Non-Compliance|0
6008064|NCT00095173|9601298|FG004|Open-Label Extension Phase (Period C)|Poor/Non-Compliance|2
6008065|NCT00095173|9601299|FG005|Open-Label Extension Phase (Period C)|Poor/Non-Compliance|2
6008066|NCT00095173|9601294|FG000|Open-Label Extension Phase (Period C)|Pregnancy|0
6008067|NCT00095173|9601295|FG001|Open-Label Extension Phase (Period C)|Pregnancy|0
6008068|NCT00095173|9601296|FG002|Open-Label Extension Phase (Period C)|Pregnancy|0
6008069|NCT00095173|9601297|FG003|Open-Label Extension Phase (Period C)|Pregnancy|1
6008070|NCT00095173|9601298|FG004|Open-Label Extension Phase (Period C)|Pregnancy|2
6008071|NCT00095173|9601299|FG005|Open-Label Extension Phase (Period C)|Pregnancy|3
6074687|NCT00575328|9678796|FG001|Overall Study|Lost to Follow-up|1
6074688|NCT00575380|9678813|FG000|Overall Study|Withdrawal by Subject|1
6008072|NCT00095173|9601294|FG000|Open-Label Extension Phase (Period C)|Other|0
6008073|NCT00095173|9601295|FG001|Open-Label Extension Phase (Period C)|Other|0
6008074|NCT00095173|9601296|FG002|Open-Label Extension Phase (Period C)|Other|0
6008075|NCT00095173|9601297|FG003|Open-Label Extension Phase (Period C)|Other|4
6008076|NCT00095173|9601298|FG004|Open-Label Extension Phase (Period C)|Other|6
6008077|NCT00095173|9601299|FG005|Open-Label Extension Phase (Period C)|Other|8
6008078|NCT00095199|9601317|FG000|Overall Study|Adverse Event|40
6008079|NCT00095199|9601318|FG001|Overall Study|Adverse Event|22
6008080|NCT00095199|9601319|FG002|Overall Study|Adverse Event|26
6008081|NCT00095199|9601320|FG003|Overall Study|Adverse Event|11
6008082|NCT00095199|9601317|FG000|Overall Study|Progressive disease|213
6008083|NCT00095199|9601318|FG001|Overall Study|Progressive disease|179
6008084|NCT00095199|9601319|FG002|Overall Study|Progressive disease|105
6008085|NCT00095199|9601320|FG003|Overall Study|Progressive disease|98
6008086|NCT00095199|9601317|FG000|Overall Study|Death|10
6008087|NCT00095199|9601318|FG001|Overall Study|Death|6
6008088|NCT00095199|9601319|FG002|Overall Study|Death|11
6008089|NCT00095199|9601320|FG003|Overall Study|Death|9
6008090|NCT00095199|9601317|FG000|Overall Study|Withdrawal by Subject|21
6008091|NCT00095199|9601318|FG001|Overall Study|Withdrawal by Subject|16
6008092|NCT00095199|9601319|FG002|Overall Study|Withdrawal by Subject|13
6008093|NCT00095199|9601320|FG003|Overall Study|Withdrawal by Subject|22
6008094|NCT00095199|9601317|FG000|Overall Study|Protocol Violation|4
6008095|NCT00095199|9601318|FG001|Overall Study|Protocol Violation|4
6008096|NCT00095199|9601319|FG002|Overall Study|Protocol Violation|2
6008097|NCT00095199|9601320|FG003|Overall Study|Protocol Violation|0
6008098|NCT00095199|9601317|FG000|Overall Study|Liver function test results elevated|0
6008099|NCT00095199|9601318|FG001|Overall Study|Liver function test results elevated|0
6008100|NCT00095199|9601319|FG002|Overall Study|Liver function test results elevated|1
6008101|NCT00095199|9601320|FG003|Overall Study|Liver function test results elevated|1
6008102|NCT00095199|9601317|FG000|Overall Study|Surgery needed could not start in 7 days|0
6008103|NCT00095199|9601318|FG001|Overall Study|Surgery needed could not start in 7 days|0
6008104|NCT00095199|9601319|FG002|Overall Study|Surgery needed could not start in 7 days|1
6008105|NCT00095199|9601320|FG003|Overall Study|Surgery needed could not start in 7 days|0
6008106|NCT00095199|9601317|FG000|Overall Study|Physician Decision|5
6008107|NCT00095199|9601318|FG001|Overall Study|Physician Decision|6
6008108|NCT00095199|9601319|FG002|Overall Study|Physician Decision|1
6008109|NCT00095199|9601320|FG003|Overall Study|Physician Decision|1
6008110|NCT00095199|9601317|FG000|Overall Study|Not eligible|1
6008111|NCT00095199|9601318|FG001|Overall Study|Not eligible|7
6008112|NCT00095199|9601319|FG002|Overall Study|Not eligible|0
6008113|NCT00095199|9601320|FG003|Overall Study|Not eligible|1
6008114|NCT00095199|9601317|FG000|Overall Study|Started Palliative Radiotherapy|1
6008115|NCT00095199|9601318|FG001|Overall Study|Started Palliative Radiotherapy|0
6008116|NCT00095199|9601319|FG002|Overall Study|Started Palliative Radiotherapy|0
6008117|NCT00095199|9601320|FG003|Overall Study|Started Palliative Radiotherapy|0
6008118|NCT00095199|9601317|FG000|Overall Study|Started radiotherapy regimen|0
6008119|NCT00095199|9601318|FG001|Overall Study|Started radiotherapy regimen|1
6008120|NCT00095199|9601319|FG002|Overall Study|Started radiotherapy regimen|0
6074689|NCT00575380|9678814|FG001|Overall Study|Withdrawal by Subject|0
6074690|NCT00575380|9678813|FG000|Overall Study|Adverse Event|0
6008121|NCT00095199|9601320|FG003|Overall Study|Started radiotherapy regimen|0
6008122|NCT00095199|9601317|FG000|Overall Study|Primary tumor removed in other surgery|0
6008123|NCT00095199|9601318|FG001|Overall Study|Primary tumor removed in other surgery|1
6008124|NCT00095199|9601319|FG002|Overall Study|Primary tumor removed in other surgery|0
6008125|NCT00095199|9601320|FG003|Overall Study|Primary tumor removed in other surgery|0
6008126|NCT00095199|9601317|FG000|Overall Study|Data inadvertently lost by site|1
6008127|NCT00095199|9601318|FG001|Overall Study|Data inadvertently lost by site|0
6008128|NCT00095199|9601319|FG002|Overall Study|Data inadvertently lost by site|0
6008129|NCT00095199|9601320|FG003|Overall Study|Data inadvertently lost by site|0
6008130|NCT00095212|9601337|FG000|Overall Study|Withdrawal by Subject|1
6008131|NCT00095212|9601338|FG001|Overall Study|Withdrawal by Subject|3
6008132|NCT00095238|9601346|FG000|Overall Study|Lack of Efficacy|9
6008133|NCT00095238|9601347|FG001|Overall Study|Lack of Efficacy|9
6008134|NCT00095238|9601346|FG000|Overall Study|Adverse Event|331
6008135|NCT00095238|9601347|FG001|Overall Study|Adverse Event|287
6008136|NCT00095238|9601346|FG000|Overall Study|Subject Withdrew Consent|208
6008137|NCT00095238|9601347|FG001|Overall Study|Subject Withdrew Consent|223
6008138|NCT00095238|9601346|FG000|Overall Study|Death|154
6008139|NCT00095238|9601347|FG001|Overall Study|Death|170
6008140|NCT00095238|9601346|FG000|Overall Study|Lost to Follow-up|19
6008141|NCT00095238|9601347|FG001|Overall Study|Lost to Follow-up|24
6008142|NCT00095238|9601346|FG000|Overall Study|Noncompliance|44
6008143|NCT00095238|9601347|FG001|Overall Study|Noncompliance|45
6008144|NCT00095238|9601346|FG000|Overall Study|No longer met study criteria|4
6008145|NCT00095238|9601347|FG001|Overall Study|No longer met study criteria|5
6008146|NCT00095238|9601346|FG000|Overall Study|Study terminated by sponsor|0
6008147|NCT00095238|9601347|FG001|Overall Study|Study terminated by sponsor|1
6008148|NCT00095238|9601346|FG000|Overall Study|Missing|1
6008149|NCT00095238|9601347|FG001|Overall Study|Missing|0
6008150|NCT00095238|9601346|FG000|Overall Study|Other Reasons|87
6074691|NCT00575380|9678814|FG001|Overall Study|Adverse Event|1
6008151|NCT00095238|9601347|FG001|Overall Study|Other Reasons|88
6008152|NCT00095303|9601387|FG000|Main Study|Lost to Follow-up|91
6008153|NCT00095303|9601388|FG001|Main Study|Lost to Follow-up|87
6008154|NCT00095303|9601387|FG000|Follow Up Study|Lost to Follow-up|59
6008155|NCT00095303|9601388|FG001|Follow Up Study|Lost to Follow-up|58
6008156|NCT00095498|9601397|FG000|Overall Study|Physician Decision|9
6008157|NCT00095498|9601398|FG001|Overall Study|Physician Decision|10
6008158|NCT00095498|9601399|FG002|Overall Study|Physician Decision|8
6008159|NCT00095498|9601397|FG000|Overall Study|Adverse Event|1
6008160|NCT00095498|9601398|FG001|Overall Study|Adverse Event|0
6008161|NCT00095498|9601399|FG002|Overall Study|Adverse Event|1
6008162|NCT00095498|9601397|FG000|Overall Study|Withdrawal by Subject|15
6008163|NCT00095498|9601398|FG001|Overall Study|Withdrawal by Subject|16
6008164|NCT00095498|9601399|FG002|Overall Study|Withdrawal by Subject|15
6008165|NCT00095498|9601397|FG000|Overall Study|Disease progression|0
6008166|NCT00095498|9601398|FG001|Overall Study|Disease progression|1
6008167|NCT00095498|9601399|FG002|Overall Study|Disease progression|1
6008168|NCT00095498|9601397|FG000|Overall Study|Ineligibility determined|3
6008169|NCT00095498|9601398|FG001|Overall Study|Ineligibility determined|0
6008170|NCT00095498|9601399|FG002|Overall Study|Ineligibility determined|2
6008171|NCT00095498|9601397|FG000|Overall Study|Lost to Follow-up|1
6008172|NCT00095498|9601398|FG001|Overall Study|Lost to Follow-up|1
6008173|NCT00095498|9601399|FG002|Overall Study|Lost to Follow-up|2
6008174|NCT00095498|9601397|FG000|Overall Study|Noncompliance|1
6008175|NCT00095498|9601398|FG001|Overall Study|Noncompliance|0
6008176|NCT00095498|9601399|FG002|Overall Study|Noncompliance|1
6008177|NCT00095498|9601397|FG000|Overall Study|Other|6
6008178|NCT00095498|9601398|FG001|Overall Study|Other|7
6008179|NCT00095498|9601399|FG002|Overall Study|Other|6
6008180|NCT00095498|9601397|FG000|Overall Study|Protocol Violation|0
6008181|NCT00095498|9601398|FG001|Overall Study|Protocol Violation|0
6008182|NCT00095498|9601399|FG002|Overall Study|Protocol Violation|1
6074692|NCT00575380|9678813|FG000|Overall Study|Various|0
6074693|NCT00575380|9678814|FG001|Overall Study|Various|2
6087330|NCT00667355|9697512|FG000|Overall Study|Other reason was not specified|5
6087331|NCT00667368|9697518|FG000|Overall Study|Lost to Follow-up|176
6087332|NCT00667368|9697519|FG001|Overall Study|Lost to Follow-up|155
6087333|NCT00667368|9697518|FG000|Overall Study|Discontinued early|24
6008183|NCT00095498|9601397|FG000|Overall Study|Requirement for alternative therapy|1
6008184|NCT00095498|9601398|FG001|Overall Study|Requirement for alternative therapy|0
6008185|NCT00095498|9601399|FG002|Overall Study|Requirement for alternative therapy|2
6008186|NCT00095576|9601413|FG000|Overall Study|Adverse Event|5
6008187|NCT00095576|9601414|FG001|Overall Study|Adverse Event|3
6008188|NCT00095576|9601413|FG000|Overall Study|Lost to Follow-up|233
6008189|NCT00095576|9601414|FG001|Overall Study|Lost to Follow-up|229
6008190|NCT00095576|9601413|FG000|Overall Study|Protocol Violation|1
6008191|NCT00095576|9601414|FG001|Overall Study|Protocol Violation|0
6008192|NCT00095576|9601413|FG000|Overall Study|Withdrawal by Subject|34
6008193|NCT00095576|9601414|FG001|Overall Study|Withdrawal by Subject|47
6008194|NCT00095576|9601413|FG000|Overall Study|Option to switch to a rollover study|1097
6008195|NCT00095576|9601414|FG001|Overall Study|Option to switch to a rollover study|1099
6008196|NCT00095576|9601413|FG000|Overall Study|Site terminated|75
6008197|NCT00095576|9601414|FG001|Overall Study|Site terminated|67
6008198|NCT00095576|9601413|FG000|Overall Study|Subject moved|30
6008199|NCT00095576|9601414|FG001|Overall Study|Subject moved|36
6008200|NCT00095628|9601420|FG000|Overall Study|Disease progression prior to treatment|1
6008201|NCT00095836|9601424|FG000|Overall Study|Lost to Follow-up|1
6008202|NCT00095836|9601424|FG000|Overall Study|Adverse Event|1
6008203|NCT00095836|9601424|FG000|Overall Study|Death|2
6008204|NCT00095940|9601444|FG000|Lapatinib Continuation/Phase II|Disease Progression|1
6008205|NCT00095940|9601445|FG001|Lapatinib Continuation/Phase II|Disease Progression|1
6008206|NCT00095940|9601446|FG002|Lapatinib Continuation/Phase II|Disease Progression|15
6008207|NCT00095940|9601447|FG003|Lapatinib Continuation/Phase II|Disease Progression|0
6008208|NCT00095940|9601448|FG004|Lapatinib Continuation/Phase II|Disease Progression|0
6008209|NCT00095940|9601449|FG005|Lapatinib Continuation/Phase II|Disease Progression|13
6008210|NCT00095940|9601450|FG006|Lapatinib Continuation/Phase II|Disease Progression|2
6008211|NCT00095940|9601451|FG007|Lapatinib Continuation/Phase II|Disease Progression|1
6008212|NCT00095940|9601452|FG008|Lapatinib Continuation/Phase II|Disease Progression|12
6087334|NCT00667368|9697519|FG001|Overall Study|Discontinued early|17
6087335|NCT00667394|9697536|FG000|Overall Study|Adverse Event|3
6087336|NCT00667394|9697537|FG001|Overall Study|Adverse Event|0
6087337|NCT00667394|9697536|FG000|Overall Study|Progressive disease|1
6087338|NCT00667394|9697537|FG001|Overall Study|Progressive disease|0
6087339|NCT00667420|9697543|FG000|Overall Study|Adverse Event|2
6008213|NCT00095940|9601444|FG000|Lapatinib Continuation/Phase II|Withdrawal by Subject|1
6008214|NCT00095940|9601445|FG001|Lapatinib Continuation/Phase II|Withdrawal by Subject|1
6008215|NCT00095940|9601446|FG002|Lapatinib Continuation/Phase II|Withdrawal by Subject|1
6087340|NCT00667420|9697543|FG000|Overall Study|Lack of Efficacy|5
6087341|NCT00667420|9697543|FG000|Overall Study|Physician Decision|1
6008216|NCT00095940|9601447|FG003|Lapatinib Continuation/Phase II|Withdrawal by Subject|0
6008217|NCT00095940|9601448|FG004|Lapatinib Continuation/Phase II|Withdrawal by Subject|0
6008218|NCT00095940|9601449|FG005|Lapatinib Continuation/Phase II|Withdrawal by Subject|0
6087342|NCT00667420|9697543|FG000|Overall Study|Withdrawal by Subject|2
6008219|NCT00095940|9601450|FG006|Lapatinib Continuation/Phase II|Withdrawal by Subject|0
6008220|NCT00095940|9601451|FG007|Lapatinib Continuation/Phase II|Withdrawal by Subject|0
6008221|NCT00095940|9601452|FG008|Lapatinib Continuation/Phase II|Withdrawal by Subject|1
6008222|NCT00095940|9601444|FG000|Lapatinib Continuation/Phase II|Adverse Event|0
6008223|NCT00095940|9601445|FG001|Lapatinib Continuation/Phase II|Adverse Event|0
6008224|NCT00095940|9601446|FG002|Lapatinib Continuation/Phase II|Adverse Event|0
6008225|NCT00095940|9601447|FG003|Lapatinib Continuation/Phase II|Adverse Event|0
6008226|NCT00095940|9601448|FG004|Lapatinib Continuation/Phase II|Adverse Event|0
6008227|NCT00095940|9601449|FG005|Lapatinib Continuation/Phase II|Adverse Event|0
6008228|NCT00095940|9601450|FG006|Lapatinib Continuation/Phase II|Adverse Event|0
6008229|NCT00095940|9601451|FG007|Lapatinib Continuation/Phase II|Adverse Event|1
6008230|NCT00095940|9601452|FG008|Lapatinib Continuation/Phase II|Adverse Event|0
6008231|NCT00095979|9601470|FG000|Overall Study|Ineligible: Second primary cancer site|2
6008232|NCT00096018|9601481|FG000|Overall Study|Became Ineligible (not treated)|0
6008233|NCT00096018|9601482|FG001|Overall Study|Became Ineligible (not treated)|3
6008234|NCT00096018|9601481|FG000|Overall Study|Miscellaneous (not treated)|0
6008235|NCT00096018|9601482|FG001|Overall Study|Miscellaneous (not treated)|2
6008236|NCT00096018|9601481|FG000|Overall Study|Adverse Event|0
6008237|NCT00096018|9601482|FG001|Overall Study|Adverse Event|5
6008238|NCT00096018|9601481|FG000|Overall Study|Death|0
6008239|NCT00096018|9601482|FG001|Overall Study|Death|1
6008240|NCT00096018|9601481|FG000|Overall Study|Withdrawal by Subject|0
6008241|NCT00096018|9601482|FG001|Overall Study|Withdrawal by Subject|2
6008242|NCT00096018|9601481|FG000|Overall Study|Miscellaneous|2
6008243|NCT00096018|9601482|FG001|Overall Study|Miscellaneous|1
6008244|NCT00096031|9601488|FG000|Overall Study|Adverse Event|3
6008245|NCT00096031|9601488|FG000|Overall Study|Lack of Efficacy|42
6008246|NCT00096031|9601488|FG000|Overall Study|Death|4
6008247|NCT00096031|9601488|FG000|Overall Study|Withdrawal by Subject|1
6008248|NCT00096031|9601488|FG000|Overall Study|Ineligible|8
6008249|NCT00096031|9601488|FG000|Overall Study|Not protocol specified|5
6008250|NCT00096044|9601492|FG000|Overall Study|Withdrawal by Subject|9
6008251|NCT00096044|9601492|FG000|Overall Study|Adverse Event|21
6008252|NCT00096044|9601492|FG000|Overall Study|Disease Progression|4
6008253|NCT00096135|9601506|FG000|Overall Study|Physician Decision|20
6008254|NCT00096135|9601507|FG001|Overall Study|Physician Decision|4
6008255|NCT00096135|9601506|FG000|Overall Study|Refusal of further protocol therapy|4
6008256|NCT00096135|9601507|FG001|Overall Study|Refusal of further protocol therapy|1
6008257|NCT00096135|9601506|FG000|Overall Study|Progressive disease, Marrow,CNS, Relapse|22
6008258|NCT00096135|9601507|FG001|Overall Study|Progressive disease, Marrow,CNS, Relapse|7
6008259|NCT00096135|9601506|FG000|Overall Study|Other, specify|15
6008260|NCT00096135|9601507|FG001|Overall Study|Other, specify|3
6008261|NCT00096135|9601506|FG000|Overall Study|Ineligible|2
6008262|NCT00096135|9601507|FG001|Overall Study|Ineligible|0
6008263|NCT00096174|9601530|FG000|Overall Study|Lack of Efficacy|9
6008264|NCT00096174|9601530|FG000|Overall Study|Adverse Event|15
6008265|NCT00096174|9601530|FG000|Overall Study|Death|6
6008266|NCT00096174|9601530|FG000|Overall Study|Withdrawal by Subject|15
6008267|NCT00096174|9601530|FG000|Overall Study|Not started protocol therapy|3
6008268|NCT00096174|9601530|FG000|Overall Study|Ineligible|6
6008269|NCT00096174|9601530|FG000|Overall Study|other reason|8
6008270|NCT00096226|9601534|FG000|Overall Study|Ineligible|2
6008271|NCT00096226|9601534|FG000|Overall Study|Protocol treatment not started|1
6008272|NCT00096265|9601541|FG000|Overall Study|Ineligible|1
6008273|NCT00096265|9601542|FG001|Overall Study|Ineligible|0
6008274|NCT00096265|9601543|FG002|Overall Study|Ineligible|0
6008275|NCT00096278|9601554|FG000|Overall Study|No follow-up data|15
6008276|NCT00096278|9601555|FG001|Overall Study|No follow-up data|18
6008277|NCT00096278|9601554|FG000|Overall Study|Patient not at risk for primary endpoint|3
6008278|NCT00096278|9601555|FG001|Overall Study|Patient not at risk for primary endpoint|2
6008279|NCT00096356|9601565|FG000|Overall Study|Adverse Event|11
6008280|NCT00096356|9601566|FG001|Overall Study|Adverse Event|9
6008281|NCT00096356|9601565|FG000|Overall Study|Physician Decision|5
6008282|NCT00096356|9601566|FG001|Overall Study|Physician Decision|3
6008283|NCT00096356|9601565|FG000|Overall Study|Withdrawal by Subject|17
6008284|NCT00096356|9601566|FG001|Overall Study|Withdrawal by Subject|23
6008285|NCT00096356|9601565|FG000|Overall Study|Lack of Efficacy|1
6008286|NCT00096356|9601566|FG001|Overall Study|Lack of Efficacy|0
6008287|NCT00096356|9601565|FG000|Overall Study|multiple reasons|10
6008288|NCT00096356|9601566|FG001|Overall Study|multiple reasons|18
6008289|NCT00096382|9601575|FG000|Overall Study|Not treated|1
6008290|NCT00096382|9601576|FG001|Overall Study|Not treated|0
6008291|NCT00096382|9601575|FG000|Overall Study|Death during treatment|1
6008292|NCT00096382|9601576|FG001|Overall Study|Death during treatment|0
6008293|NCT00096447|9601582|FG000|Overall Study|Never treated|1
6008294|NCT00096486|9601604|FG000|Overall Study|Withdrawal by Subject|0
6008295|NCT00096486|9601605|FG001|Overall Study|Withdrawal by Subject|0
6008296|NCT00096486|9601606|FG002|Overall Study|Withdrawal by Subject|1
6008297|NCT00096486|9601607|FG003|Overall Study|Withdrawal by Subject|1
6008298|NCT00096486|9601604|FG000|Overall Study|Not Treated|0
6008299|NCT00096486|9601605|FG001|Overall Study|Not Treated|0
6008300|NCT00096486|9601606|FG002|Overall Study|Not Treated|1
6008301|NCT00096486|9601607|FG003|Overall Study|Not Treated|1
6008302|NCT00096538|9601617|FG000|Overall Study|Withdrawal by Subject|1
6008303|NCT00096785|9601627|FG000|Overall Study|Lost to Follow-up|1
6008304|NCT00096785|9601628|FG001|Overall Study|Lost to Follow-up|0
6008305|NCT00096785|9601627|FG000|Overall Study|Withdrawal by Subject|0
6008306|NCT00096785|9601628|FG001|Overall Study|Withdrawal by Subject|1
6008307|NCT00096785|9601627|FG000|Overall Study|Relocated|1
6008308|NCT00096785|9601628|FG001|Overall Study|Relocated|0
6008309|NCT00096941|9601634|FG000|Overall Study|disease progression|3
6008310|NCT00096954|9601640|FG000|Overall Study|Adverse Event|3
6008311|NCT00096954|9601641|FG001|Overall Study|Adverse Event|1
6008312|NCT00096954|9601640|FG000|Overall Study|Withdrawal by Subject|9
6008313|NCT00096954|9601641|FG001|Overall Study|Withdrawal by Subject|8
6008314|NCT00096954|9601640|FG000|Overall Study|Physician Decision|1
6008315|NCT00096954|9601641|FG001|Overall Study|Physician Decision|1
6008316|NCT00096954|9601640|FG000|Overall Study|Sponsors Decision|1
6008317|NCT00096954|9601641|FG001|Overall Study|Sponsors Decision|1
6008318|NCT00096954|9601640|FG000|Overall Study|Pregnancy|1
6008319|NCT00096954|9601641|FG001|Overall Study|Pregnancy|1
6008320|NCT00096954|9601640|FG000|Overall Study|Initiation of immunotherapy|1
6008321|NCT00096954|9601641|FG001|Overall Study|Initiation of immunotherapy|0
6008322|NCT00096954|9601640|FG000|Overall Study|Non-compliance|0
6008323|NCT00096954|9601641|FG001|Overall Study|Non-compliance|3
6008324|NCT00096954|9601640|FG000|Overall Study|Lost to Follow-up|8
6008325|NCT00096954|9601641|FG001|Overall Study|Lost to Follow-up|5
6008326|NCT00096993|9601649|FG000|Overall Study|Death|1
6008327|NCT00096993|9601650|FG001|Overall Study|Death|0
6008328|NCT00096993|9601649|FG000|Overall Study|Disease progression|56
6008329|NCT00096993|9601650|FG001|Overall Study|Disease progression|53
6008330|NCT00096993|9601649|FG000|Overall Study|Adverse Event|2
6008331|NCT00096993|9601650|FG001|Overall Study|Adverse Event|8
6008332|NCT00096993|9601649|FG000|Overall Study|Subject's decision|3
6008333|NCT00096993|9601650|FG001|Overall Study|Subject's decision|1
6008334|NCT00096993|9601649|FG000|Overall Study|Physician Decision|2
6008335|NCT00096993|9601650|FG001|Overall Study|Physician Decision|1
6008336|NCT00096993|9601649|FG000|Overall Study|Non-compliance|0
6008337|NCT00096993|9601650|FG001|Overall Study|Non-compliance|1
6008338|NCT00096993|9601649|FG000|Overall Study|Other unspecified|1
6008339|NCT00096993|9601650|FG001|Overall Study|Other unspecified|1
6008340|NCT00097370|9601664|FG000|Stage 1|Adverse Event|3
6008341|NCT00097370|9601664|FG000|Stage 1|Withdrawal by Subject|1
6008342|NCT00097370|9601664|FG000|Stage 1|Lack of Efficacy|2
6008343|NCT00097370|9601664|FG000|Stage 2|Adverse Event|5
6008344|NCT00097370|9601664|FG000|Stage 2|Withdrawal by Subject|1
6008345|NCT00097370|9601664|FG000|Stage 2|Lack of Efficacy|3
6008346|NCT00097370|9601664|FG000|Stage 2|Pregnancy|1
6008347|NCT00097370|9601664|FG000|Stage 2|Sponsor Terminated Study|2
6008348|NCT00097370|9601664|FG000|Stage 2|Lost to Follow-up|1
6008349|NCT00097370|9601664|FG000|Stage 3|Adverse Event|2
6008350|NCT00097370|9601664|FG000|Stage 3|Withdrawal by Subject|3
6008351|NCT00097370|9601664|FG000|Stage 3|Lack of Efficacy|1
6008352|NCT00097370|9601664|FG000|Stage 3|Sponsor Terminated Study|52
6008353|NCT00097370|9601664|FG000|Stage 3|Lost to Follow-up|1
6008354|NCT00097500|9601679|FG000|On-drug Period (Week 0 to Week 52)|Withdrawal of consent|1
6008355|NCT00097500|9601680|FG001|On-drug Period (Week 0 to Week 52)|Withdrawal of consent|1
6008356|NCT00097500|9601679|FG000|On-drug Period (Week 0 to Week 52)|Adverse Event|5
6008357|NCT00097500|9601680|FG001|On-drug Period (Week 0 to Week 52)|Adverse Event|0
6008358|NCT00097500|9601679|FG000|On-drug Period (Week 0 to Week 52)|Physician Decision|0
6008359|NCT00097500|9601680|FG001|On-drug Period (Week 0 to Week 52)|Physician Decision|1
6008360|NCT00097500|9601679|FG000|On-drug Period (Week 0 to Week 52)|Lost to Follow-up|0
6008361|NCT00097500|9601680|FG001|On-drug Period (Week 0 to Week 52)|Lost to Follow-up|1
6008362|NCT00097500|9601679|FG000|Off-drug Period (Week 52 to Week 64)|Withdrawal of consent|2
6008363|NCT00097500|9601680|FG001|Off-drug Period (Week 52 to Week 64)|Withdrawal of consent|1
6008364|NCT00097500|9601679|FG000|Off-drug Period (Week 52 to Week 64)|Physician Decision|0
6008365|NCT00097500|9601680|FG001|Off-drug Period (Week 52 to Week 64)|Physician Decision|1
6008366|NCT00097500|9601679|FG000|Off-drug Period (Week 52 to Week 64)|Loss of glucose control|3
6008367|NCT00097500|9601680|FG001|Off-drug Period (Week 52 to Week 64)|Loss of glucose control|2
6008368|NCT00097539|9601693|FG000|Overall Study|Status Unknown (Or no final evaluation)|11959
6008369|NCT00097539|9601694|FG001|Overall Study|Status Unknown (Or no final evaluation)|3948
6008370|NCT00097539|9601695|FG002|Overall Study|Status Unknown (Or no final evaluation)|5646
6008371|NCT00097539|9601696|FG003|Overall Study|Status Unknown (Or no final evaluation)|2170
6008372|NCT00097539|9601697|FG004|Overall Study|Status Unknown (Or no final evaluation)|1106
6008373|NCT00097539|9601698|FG005|Overall Study|Status Unknown (Or no final evaluation)|3546
6008374|NCT00097539|9601699|FG006|Overall Study|Status Unknown (Or no final evaluation)|108
6008375|NCT00097539|9601693|FG000|Overall Study|Withdrawal by Subject|925
6008376|NCT00097539|9601694|FG001|Overall Study|Withdrawal by Subject|323
6008377|NCT00097539|9601695|FG002|Overall Study|Withdrawal by Subject|346
6008378|NCT00097539|9601696|FG003|Overall Study|Withdrawal by Subject|217
6008379|NCT00097539|9601697|FG004|Overall Study|Withdrawal by Subject|68
6008380|NCT00097539|9601698|FG005|Overall Study|Withdrawal by Subject|229
6008381|NCT00097539|9601699|FG006|Overall Study|Withdrawal by Subject|3
6008382|NCT00097539|9601693|FG000|Overall Study|Participant Non-compliant|2140
6008383|NCT00097539|9601694|FG001|Overall Study|Participant Non-compliant|567
6008384|NCT00097539|9601695|FG002|Overall Study|Participant Non-compliant|1067
6008385|NCT00097539|9601696|FG003|Overall Study|Participant Non-compliant|353
6008386|NCT00097539|9601697|FG004|Overall Study|Participant Non-compliant|136
6008387|NCT00097539|9601698|FG005|Overall Study|Participant Non-compliant|543
6008388|NCT00097539|9601699|FG006|Overall Study|Participant Non-compliant|18
6008389|NCT00097539|9601693|FG000|Overall Study|Lack of Efficacy|249
6074694|NCT00575510|9678823|FG000|Overall Study|Lost to Follow-up|4
6074695|NCT00575510|9678824|FG001|Overall Study|Lost to Follow-up|6
6008390|NCT00097539|9601694|FG001|Overall Study|Lack of Efficacy|122
6008391|NCT00097539|9601695|FG002|Overall Study|Lack of Efficacy|202
6008392|NCT00097539|9601696|FG003|Overall Study|Lack of Efficacy|105
6008393|NCT00097539|9601697|FG004|Overall Study|Lack of Efficacy|45
6008394|NCT00097539|9601698|FG005|Overall Study|Lack of Efficacy|228
6008395|NCT00097539|9601699|FG006|Overall Study|Lack of Efficacy|5
6008396|NCT00097539|9601693|FG000|Overall Study|Adverse Event|78
6008397|NCT00097539|9601694|FG001|Overall Study|Adverse Event|133
6008398|NCT00097539|9601695|FG002|Overall Study|Adverse Event|37
6008399|NCT00097539|9601696|FG003|Overall Study|Adverse Event|27
6008400|NCT00097539|9601697|FG004|Overall Study|Adverse Event|30
6008401|NCT00097539|9601698|FG005|Overall Study|Adverse Event|59
6008402|NCT00097539|9601699|FG006|Overall Study|Adverse Event|1
6008403|NCT00097539|9601693|FG000|Overall Study|Death|2
6008404|NCT00097539|9601694|FG001|Overall Study|Death|7
6008405|NCT00097539|9601695|FG002|Overall Study|Death|0
6008406|NCT00097539|9601696|FG003|Overall Study|Death|0
6008407|NCT00097539|9601697|FG004|Overall Study|Death|1
6008408|NCT00097539|9601698|FG005|Overall Study|Death|3
6008409|NCT00097539|9601699|FG006|Overall Study|Death|0
6008410|NCT00097539|9601693|FG000|Overall Study|Reasons Other Than Above|3602
6008411|NCT00097539|9601694|FG001|Overall Study|Reasons Other Than Above|1382
6008412|NCT00097539|9601695|FG002|Overall Study|Reasons Other Than Above|1757
6008413|NCT00097539|9601696|FG003|Overall Study|Reasons Other Than Above|692
6008414|NCT00097539|9601697|FG004|Overall Study|Reasons Other Than Above|361
6008415|NCT00097539|9601698|FG005|Overall Study|Reasons Other Than Above|1244
6008416|NCT00097539|9601699|FG006|Overall Study|Reasons Other Than Above|34
6008417|NCT00097539|9601693|FG000|Overall Study|Reason not Specified|111
6008418|NCT00097539|9601694|FG001|Overall Study|Reason not Specified|49
6008419|NCT00097539|9601695|FG002|Overall Study|Reason not Specified|53
6074696|NCT00575510|9678825|FG002|Overall Study|Lost to Follow-up|9
6074697|NCT00575510|9678823|FG000|Overall Study|Withdrawal by Subject|1
6074698|NCT00575510|9678824|FG001|Overall Study|Withdrawal by Subject|0
6074699|NCT00575510|9678825|FG002|Overall Study|Withdrawal by Subject|0
6074700|NCT00575510|9678823|FG000|Overall Study|Clinic Called Patient|7
6074701|NCT00575510|9678824|FG001|Overall Study|Clinic Called Patient|7
6008420|NCT00097539|9601696|FG003|Overall Study|Reason not Specified|21
6008421|NCT00097539|9601697|FG004|Overall Study|Reason not Specified|11
6008422|NCT00097539|9601698|FG005|Overall Study|Reason not Specified|40
6074702|NCT00575510|9678825|FG002|Overall Study|Clinic Called Patient|7
6074703|NCT00575510|9678823|FG000|Overall Study|Pregnancy|0
6074704|NCT00575510|9678824|FG001|Overall Study|Pregnancy|0
6074705|NCT00575510|9678825|FG002|Overall Study|Pregnancy|1
6074706|NCT00575588|9678836|FG000|Overall Study|Adverse Event|11
6074707|NCT00575588|9678837|FG001|Overall Study|Adverse Event|13
6074708|NCT00575588|9678836|FG000|Overall Study|Withdrawal by Subject|27
6074709|NCT00575588|9678837|FG001|Overall Study|Withdrawal by Subject|31
6074710|NCT00575588|9678836|FG000|Overall Study|Lost to Follow-up|1
6074711|NCT00575588|9678837|FG001|Overall Study|Lost to Follow-up|3
6074712|NCT00575588|9678836|FG000|Overall Study|Death|4
6074713|NCT00575588|9678837|FG001|Overall Study|Death|2
6074714|NCT00575588|9678836|FG000|Overall Study|Incorrect enrollment|8
6074715|NCT00575588|9678837|FG001|Overall Study|Incorrect enrollment|4
6074716|NCT00575588|9678836|FG000|Overall Study|Study specific discontinuation criteria|203
6074717|NCT00575588|9678837|FG001|Overall Study|Study specific discontinuation criteria|218
6008423|NCT00097539|9601699|FG006|Overall Study|Reason not Specified|2
6008424|NCT00097591|9601717|FG000|Overall Study|Withdrawal of consent|342
6008425|NCT00097591|9601718|FG001|Overall Study|Withdrawal of consent|323
6008426|NCT00097591|9601717|FG000|Overall Study|Less than 6 months on study drug|9
6008427|NCT00097591|9601718|FG001|Overall Study|Less than 6 months on study drug|7
6008428|NCT00097591|9601717|FG000|Overall Study|Unable to attend termination visit|53
6008429|NCT00097591|9601718|FG001|Overall Study|Unable to attend termination visit|51
6008430|NCT00097591|9601717|FG000|Overall Study|Lost to follow up|6
6008431|NCT00097591|9601718|FG001|Overall Study|Lost to follow up|10
6074718|NCT00575588|9678836|FG000|Overall Study|Severe non-compliance to protocol|5
6074719|NCT00575588|9678837|FG001|Overall Study|Severe non-compliance to protocol|7
6074720|NCT00575588|9678836|FG000|Overall Study|Safety reasons|2
6074721|NCT00575588|9678837|FG001|Overall Study|Safety reasons|1
6008432|NCT00097591|9601717|FG000|Overall Study|Other|0
6008433|NCT00097591|9601718|FG001|Overall Study|Other|3
6008434|NCT00097721|9601767|FG000|Overall Study|Adverse Event|8
6008435|NCT00097721|9601768|FG001|Overall Study|Adverse Event|1
6008436|NCT00097721|9601767|FG000|Overall Study|Withdrawal by Subject|6
6008437|NCT00097721|9601768|FG001|Overall Study|Withdrawal by Subject|1
6008438|NCT00097721|9601767|FG000|Overall Study|Progressive Disease|55
6074722|NCT00575588|9678836|FG000|Overall Study|Elevated triglyceride|1
6074723|NCT00575588|9678837|FG001|Overall Study|Elevated triglyceride|0
6008439|NCT00097721|9601768|FG001|Overall Study|Progressive Disease|27
6008440|NCT00097721|9601767|FG000|Overall Study|Physician Decision|1
6008441|NCT00097721|9601768|FG001|Overall Study|Physician Decision|3
6008442|NCT00097721|9601767|FG000|Overall Study|Reason not given|1
6008443|NCT00097721|9601768|FG001|Overall Study|Reason not given|1
6008444|NCT00097773|9601778|FG000|Overall Study|Lost to Follow-up|2
6008445|NCT00097773|9601779|FG001|Overall Study|Lost to Follow-up|2
6008446|NCT00097773|9601780|FG002|Overall Study|Lost to Follow-up|0
6008447|NCT00097773|9601781|FG003|Overall Study|Lost to Follow-up|1
6008448|NCT00097773|9601778|FG000|Overall Study|Physician Decision|2
6008449|NCT00097773|9601779|FG001|Overall Study|Physician Decision|2
6008450|NCT00097773|9601780|FG002|Overall Study|Physician Decision|3
6008451|NCT00097773|9601781|FG003|Overall Study|Physician Decision|1
6008452|NCT00097773|9601778|FG000|Overall Study|Withdrawal by Subject|3
6008453|NCT00097773|9601779|FG001|Overall Study|Withdrawal by Subject|3
6008454|NCT00097773|9601780|FG002|Overall Study|Withdrawal by Subject|3
6008455|NCT00097773|9601781|FG003|Overall Study|Withdrawal by Subject|1
6008456|NCT00097773|9601778|FG000|Overall Study|Adverse Event|0
6008457|NCT00097773|9601779|FG001|Overall Study|Adverse Event|1
6008458|NCT00097773|9601780|FG002|Overall Study|Adverse Event|0
6008459|NCT00097773|9601781|FG003|Overall Study|Adverse Event|0
6008460|NCT00097773|9601778|FG000|Overall Study|Other|1
6008461|NCT00097773|9601779|FG001|Overall Study|Other|0
6008462|NCT00097773|9601780|FG002|Overall Study|Other|2
6008463|NCT00097773|9601781|FG003|Overall Study|Other|0
6008464|NCT00097786|9601800|FG000|Overall Study|lost to follow-up for all-cause death|296
6008465|NCT00097786|9601801|FG001|Overall Study|lost to follow-up for all-cause death|292
6008466|NCT00097786|9601802|FG002|Overall Study|lost to follow-up for all-cause death|313
6008467|NCT00097786|9601803|FG003|Overall Study|lost to follow-up for all-cause death|310
6008468|NCT00097981|9601815|FG000|Overall Study|Adverse Event|31
6008469|NCT00097981|9601816|FG001|Overall Study|Adverse Event|44
6008470|NCT00097981|9601815|FG000|Overall Study|Withdrawal by Subject|10
6008471|NCT00097981|9601816|FG001|Overall Study|Withdrawal by Subject|8
6008472|NCT00097981|9601815|FG000|Overall Study|Protocol Violation|1
6008473|NCT00097981|9601816|FG001|Overall Study|Protocol Violation|1
6008474|NCT00097981|9601815|FG000|Overall Study|Death|2
6008475|NCT00097981|9601816|FG001|Overall Study|Death|4
6008476|NCT00097981|9601815|FG000|Overall Study|Physician Decision|7
6008477|NCT00097981|9601816|FG001|Overall Study|Physician Decision|1
6008478|NCT00097981|9601815|FG000|Overall Study|Disease Progression|8
6008479|NCT00097981|9601816|FG001|Overall Study|Disease Progression|2
6008480|NCT00097981|9601815|FG000|Overall Study|Transplant planned|28
6008481|NCT00097981|9601816|FG001|Overall Study|Transplant planned|27
6008482|NCT00097981|9601815|FG000|Overall Study|Other|19
6008483|NCT00097981|9601816|FG001|Overall Study|Other|13
6008484|NCT00098020|9601822|FG000|Overall Study|Adverse Event|2
6008485|NCT00098020|9601822|FG000|Overall Study|Lost to Follow-up|1
6008486|NCT00098020|9601822|FG000|Overall Study|elevated liver enzymes|1
6008487|NCT00098020|9601822|FG000|Overall Study|Low urine PCR|1
6008488|NCT00098020|9601822|FG000|Overall Study|Low epidermal growth factor receptor|1
6008489|NCT00098254|9601840|FG000|Overall Study|Adverse Event|2
6008490|NCT00098254|9601840|FG000|Overall Study|Death|1
6008491|NCT00098293|9601847|FG000|Double-blind (DB) Phase|Adverse Event|14
6008492|NCT00098293|9601848|FG001|Double-blind (DB) Phase|Adverse Event|27
6008493|NCT00098293|9601849|FG002|Double-blind (DB) Phase|Adverse Event|60
6008494|NCT00098293|9601850|FG003|Double-blind (DB) Phase|Adverse Event|0
6008495|NCT00098293|9601851|FG004|Double-blind (DB) Phase|Adverse Event|0
6008496|NCT00098293|9601847|FG000|Double-blind (DB) Phase|Pregnancy|0
6008497|NCT00098293|9601848|FG001|Double-blind (DB) Phase|Pregnancy|7
6008498|NCT00098293|9601849|FG002|Double-blind (DB) Phase|Pregnancy|9
6008499|NCT00098293|9601850|FG003|Double-blind (DB) Phase|Pregnancy|0
6008500|NCT00098293|9601851|FG004|Double-blind (DB) Phase|Pregnancy|0
6008501|NCT00098293|9601847|FG000|Double-blind (DB) Phase|Participant Defaulted|11
6074724|NCT00575588|9678836|FG000|Overall Study|Patient moved|1
6074725|NCT00575588|9678837|FG001|Overall Study|Patient moved|3
6074726|NCT00575588|9678836|FG000|Overall Study|Impossible to determine HbA1c|0
6074727|NCT00575588|9678837|FG001|Overall Study|Impossible to determine HbA1c|1
6074728|NCT00575666|9678845|FG000|Overall Study|Withdrawal by Subject|3
6074729|NCT00575666|9678846|FG001|Overall Study|Withdrawal by Subject|2
6074730|NCT00575666|9678845|FG000|Overall Study|Physician Decision|1
6074731|NCT00575666|9678846|FG001|Overall Study|Physician Decision|1
6008502|NCT00098293|9601848|FG001|Double-blind (DB) Phase|Participant Defaulted|40
6008503|NCT00098293|9601849|FG002|Double-blind (DB) Phase|Participant Defaulted|36
6008504|NCT00098293|9601850|FG003|Double-blind (DB) Phase|Participant Defaulted|0
6008505|NCT00098293|9601851|FG004|Double-blind (DB) Phase|Participant Defaulted|0
6008506|NCT00098293|9601847|FG000|Double-blind (DB) Phase|Lack of Efficacy|11
6008507|NCT00098293|9601848|FG001|Double-blind (DB) Phase|Lack of Efficacy|64
6074732|NCT00576056|9678860|FG000|Overall Study|Adverse Event|1
6008508|NCT00098293|9601849|FG002|Double-blind (DB) Phase|Lack of Efficacy|30
6008509|NCT00098293|9601850|FG003|Double-blind (DB) Phase|Lack of Efficacy|0
6008510|NCT00098293|9601851|FG004|Double-blind (DB) Phase|Lack of Efficacy|0
6008511|NCT00098293|9601847|FG000|Double-blind (DB) Phase|Death|1
6008512|NCT00098293|9601848|FG001|Double-blind (DB) Phase|Death|2
6008513|NCT00098293|9601849|FG002|Double-blind (DB) Phase|Death|2
6074733|NCT00576056|9678860|FG000|Overall Study|Death|1
6074734|NCT00576056|9678860|FG000|Overall Study|Lack of Efficacy|1
6074735|NCT00576056|9678860|FG000|Overall Study|Withdrawal by Subject|2
6074736|NCT00576056|9678860|FG000|Overall Study|did not meet eligibility criteria|8
6074737|NCT00576056|9678860|FG000|Overall Study|Physician Decision|1
6074738|NCT00576199|9678868|FG000|Overall Study|Adverse Event|12
6074739|NCT00576199|9678868|FG000|Overall Study|Insufficient Therapeutic Response|14
6008514|NCT00098293|9601850|FG003|Double-blind (DB) Phase|Death|0
6008515|NCT00098293|9601851|FG004|Double-blind (DB) Phase|Death|0
6008516|NCT00098293|9601847|FG000|Double-blind (DB) Phase|Randomized, Not Treated|3
6008517|NCT00098293|9601848|FG001|Double-blind (DB) Phase|Randomized, Not Treated|8
6008518|NCT00098293|9601849|FG002|Double-blind (DB) Phase|Randomized, Not Treated|11
6008519|NCT00098293|9601850|FG003|Double-blind (DB) Phase|Randomized, Not Treated|0
6008520|NCT00098293|9601851|FG004|Double-blind (DB) Phase|Randomized, Not Treated|0
6008521|NCT00098293|9601847|FG000|Double-blind (DB) Phase|Protocol Violation|2
6008522|NCT00098293|9601848|FG001|Double-blind (DB) Phase|Protocol Violation|18
6008523|NCT00098293|9601849|FG002|Double-blind (DB) Phase|Protocol Violation|22
6008524|NCT00098293|9601850|FG003|Double-blind (DB) Phase|Protocol Violation|0
6008525|NCT00098293|9601851|FG004|Double-blind (DB) Phase|Protocol Violation|0
6008526|NCT00098293|9601847|FG000|Double-blind (DB) Phase|Terminated by sponsor|135
6008527|NCT00098293|9601848|FG001|Double-blind (DB) Phase|Terminated by sponsor|0
6008528|NCT00098293|9601849|FG002|Double-blind (DB) Phase|Terminated by sponsor|0
6008529|NCT00098293|9601850|FG003|Double-blind (DB) Phase|Terminated by sponsor|0
6008530|NCT00098293|9601851|FG004|Double-blind (DB) Phase|Terminated by sponsor|0
6008531|NCT00098293|9601847|FG000|Between DB and OL Phase|Did Not Enter Open-label Phase|0
6008532|NCT00098293|9601848|FG001|Between DB and OL Phase|Did Not Enter Open-label Phase|0
6008533|NCT00098293|9601849|FG002|Between DB and OL Phase|Did Not Enter Open-label Phase|3
6008534|NCT00098293|9601850|FG003|Between DB and OL Phase|Did Not Enter Open-label Phase|0
6008535|NCT00098293|9601851|FG004|Between DB and OL Phase|Did Not Enter Open-label Phase|0
6008536|NCT00098293|9601847|FG000|Open-label (OL) Phase|Adverse Event|0
6008537|NCT00098293|9601848|FG001|Open-label (OL) Phase|Adverse Event|3
6008538|NCT00098293|9601849|FG002|Open-label (OL) Phase|Adverse Event|7
6008539|NCT00098293|9601850|FG003|Open-label (OL) Phase|Adverse Event|6
6008540|NCT00098293|9601851|FG004|Open-label (OL) Phase|Adverse Event|0
6008541|NCT00098293|9601847|FG000|Open-label (OL) Phase|Lack of Efficacy|0
6008542|NCT00098293|9601848|FG001|Open-label (OL) Phase|Lack of Efficacy|7
6008543|NCT00098293|9601849|FG002|Open-label (OL) Phase|Lack of Efficacy|2
6008544|NCT00098293|9601850|FG003|Open-label (OL) Phase|Lack of Efficacy|20
6008545|NCT00098293|9601851|FG004|Open-label (OL) Phase|Lack of Efficacy|0
6008546|NCT00098293|9601847|FG000|Open-label (OL) Phase|Pregnancy|0
6008547|NCT00098293|9601848|FG001|Open-label (OL) Phase|Pregnancy|1
6008548|NCT00098293|9601849|FG002|Open-label (OL) Phase|Pregnancy|0
6008549|NCT00098293|9601850|FG003|Open-label (OL) Phase|Pregnancy|3
6008550|NCT00098293|9601851|FG004|Open-label (OL) Phase|Pregnancy|0
6008551|NCT00098293|9601847|FG000|Open-label (OL) Phase|Protocol Violation|0
6008552|NCT00098293|9601848|FG001|Open-label (OL) Phase|Protocol Violation|6
6008553|NCT00098293|9601849|FG002|Open-label (OL) Phase|Protocol Violation|13
6008554|NCT00098293|9601850|FG003|Open-label (OL) Phase|Protocol Violation|16
6008555|NCT00098293|9601851|FG004|Open-label (OL) Phase|Protocol Violation|0
6008556|NCT00098293|9601847|FG000|Open-label (OL) Phase|Participant Defaulted|0
6008557|NCT00098293|9601848|FG001|Open-label (OL) Phase|Participant Defaulted|6
6008558|NCT00098293|9601849|FG002|Open-label (OL) Phase|Participant Defaulted|16
6008559|NCT00098293|9601850|FG003|Open-label (OL) Phase|Participant Defaulted|20
6008560|NCT00098293|9601851|FG004|Open-label (OL) Phase|Participant Defaulted|0
6008561|NCT00098293|9601847|FG000|Open-label (OL) Phase|Death|0
6008562|NCT00098293|9601848|FG001|Open-label (OL) Phase|Death|2
6008563|NCT00098293|9601849|FG002|Open-label (OL) Phase|Death|3
6008564|NCT00098293|9601850|FG003|Open-label (OL) Phase|Death|0
6008565|NCT00098293|9601851|FG004|Open-label (OL) Phase|Death|0
6008566|NCT00098293|9601847|FG000|Supplemental Phase (SP)|Death|0
6008567|NCT00098293|9601848|FG001|Supplemental Phase (SP)|Death|0
6008568|NCT00098293|9601849|FG002|Supplemental Phase (SP)|Death|0
6074740|NCT00576199|9678868|FG000|Overall Study|Refused Treatment|2
6074741|NCT00576199|9678868|FG000|Overall Study|Reason Unspecified|2
6074742|NCT00576303|9678881|FG000|Dose Titration Period|Early withdrawal|17
6074743|NCT00576303|9678881|FG000|Efficacy Evaluation Period|Early withdrawal|5
6074744|NCT00576303|9678881|FG000|Long Term Safety Period|Early withdrawal|16
6074745|NCT00576316|9678885|FG000|Overall Study|Adverse Event|9
6074746|NCT00576316|9678885|FG000|Overall Study|Withdrawal by Subject|2
6074747|NCT00576316|9678885|FG000|Overall Study|Protocol Violation|9
6074748|NCT00576381|9678889|FG000|Overall Study|Reoperation|3
6008569|NCT00098293|9601850|FG003|Supplemental Phase (SP)|Death|0
6008570|NCT00098293|9601851|FG004|Supplemental Phase (SP)|Death|1
6008571|NCT00098293|9601847|FG000|Supplemental Phase (SP)|Lost to Follow-up|0
6008572|NCT00098293|9601848|FG001|Supplemental Phase (SP)|Lost to Follow-up|0
6008573|NCT00098293|9601849|FG002|Supplemental Phase (SP)|Lost to Follow-up|0
6008574|NCT00098293|9601850|FG003|Supplemental Phase (SP)|Lost to Follow-up|0
6008575|NCT00098293|9601851|FG004|Supplemental Phase (SP)|Lost to Follow-up|2
6008576|NCT00098293|9601847|FG000|Supplemental Phase (SP)|Withdrawal by Subject|0
6074749|NCT00576381|9678889|FG000|Overall Study|Adverse Event|4
6074750|NCT00576420|9678896|FG000|Overall Study|Death|0
6074751|NCT00576420|9678897|FG001|Overall Study|Death|0
6008577|NCT00098293|9601848|FG001|Supplemental Phase (SP)|Withdrawal by Subject|0
6008578|NCT00098293|9601849|FG002|Supplemental Phase (SP)|Withdrawal by Subject|0
6008579|NCT00098293|9601850|FG003|Supplemental Phase (SP)|Withdrawal by Subject|0
6008580|NCT00098293|9601851|FG004|Supplemental Phase (SP)|Withdrawal by Subject|8
6008581|NCT00098293|9601847|FG000|Supplemental Phase (SP)|Other|0
6008582|NCT00098293|9601848|FG001|Supplemental Phase (SP)|Other|0
6008583|NCT00098293|9601849|FG002|Supplemental Phase (SP)|Other|0
6008584|NCT00098293|9601850|FG003|Supplemental Phase (SP)|Other|0
6008585|NCT00098293|9601851|FG004|Supplemental Phase (SP)|Other|22
6008586|NCT00098306|9601865|FG000|Double Blind|Randomized, not treated|9
6008587|NCT00098306|9601866|FG001|Double Blind|Randomized, not treated|5
6008588|NCT00098306|9601867|FG002|Double Blind|Randomized, not treated|2
6008589|NCT00098306|9601868|FG003|Double Blind|Randomized, not treated|0
6008590|NCT00098306|9601869|FG004|Double Blind|Randomized, not treated|0
6008591|NCT00098306|9601870|FG005|Double Blind|Randomized, not treated|0
6008592|NCT00098306|9601871|FG006|Double Blind|Randomized, not treated|0
6008593|NCT00098306|9601865|FG000|Double Blind|Ongoing at cut-off date|151
6008594|NCT00098306|9601866|FG001|Double Blind|Ongoing at cut-off date|166
6008595|NCT00098306|9601867|FG002|Double Blind|Ongoing at cut-off date|72
6008596|NCT00098306|9601868|FG003|Double Blind|Ongoing at cut-off date|0
6008597|NCT00098306|9601869|FG004|Double Blind|Ongoing at cut-off date|0
6008598|NCT00098306|9601870|FG005|Double Blind|Ongoing at cut-off date|0
6008599|NCT00098306|9601871|FG006|Double Blind|Ongoing at cut-off date|0
6008600|NCT00098306|9601865|FG000|Double Blind|Adverse Event|11
6008601|NCT00098306|9601866|FG001|Double Blind|Adverse Event|10
6008602|NCT00098306|9601867|FG002|Double Blind|Adverse Event|6
6008603|NCT00098306|9601868|FG003|Double Blind|Adverse Event|0
6008604|NCT00098306|9601869|FG004|Double Blind|Adverse Event|0
6008605|NCT00098306|9601870|FG005|Double Blind|Adverse Event|0
6008606|NCT00098306|9601871|FG006|Double Blind|Adverse Event|0
6008607|NCT00098306|9601865|FG000|Double Blind|Lack of Efficacy|43
6008608|NCT00098306|9601866|FG001|Double Blind|Lack of Efficacy|34
6008609|NCT00098306|9601867|FG002|Double Blind|Lack of Efficacy|17
6008610|NCT00098306|9601868|FG003|Double Blind|Lack of Efficacy|0
6008611|NCT00098306|9601869|FG004|Double Blind|Lack of Efficacy|0
6008612|NCT00098306|9601870|FG005|Double Blind|Lack of Efficacy|0
6008613|NCT00098306|9601871|FG006|Double Blind|Lack of Efficacy|0
6008614|NCT00098306|9601865|FG000|Double Blind|Death|1
6008615|NCT00098306|9601866|FG001|Double Blind|Death|4
6008616|NCT00098306|9601867|FG002|Double Blind|Death|1
6008617|NCT00098306|9601868|FG003|Double Blind|Death|0
6074752|NCT00576420|9678898|FG002|Overall Study|Death|1
6074753|NCT00576472|9678962|FG000|MPH In-Lab Phase|Declined participation in medication pha|0
6074754|NCT00576472|9678963|FG001|MPH In-Lab Phase|Declined participation in medication pha|0
6074755|NCT00576472|9678964|FG002|MPH In-Lab Phase|Declined participation in medication pha|0
6074756|NCT00576472|9678965|FG003|MPH In-Lab Phase|Declined participation in medication pha|75
6074757|NCT00576472|9678966|FG004|MPH In-Lab Phase|Declined participation in medication pha|0
6074758|NCT00576472|9678967|FG005|MPH In-Lab Phase|Declined participation in medication pha|0
6074759|NCT00576472|9678968|FG006|MPH In-Lab Phase|Declined participation in medication pha|0
6074760|NCT00576472|9678969|FG007|MPH In-Lab Phase|Declined participation in medication pha|0
6074761|NCT00576472|9678970|FG008|MPH In-Lab Phase|Declined participation in medication pha|0
6074762|NCT00576472|9678971|FG009|MPH In-Lab Phase|Declined participation in medication pha|0
6074763|NCT00576472|9678972|FG010|MPH In-Lab Phase|Declined participation in medication pha|0
6074764|NCT00576472|9678973|FG011|MPH In-Lab Phase|Declined participation in medication pha|0
6074765|NCT00576472|9678974|FG012|MPH In-Lab Phase|Declined participation in medication pha|0
6074766|NCT00576472|9678975|FG013|MPH In-Lab Phase|Declined participation in medication pha|0
6074767|NCT00576472|9678976|FG014|MPH In-Lab Phase|Declined participation in medication pha|0
6074768|NCT00576472|9678962|FG000|MPH In-Lab Phase|Lost to Follow-up|0
6074769|NCT00576472|9678963|FG001|MPH In-Lab Phase|Lost to Follow-up|0
6074770|NCT00576472|9678964|FG002|MPH In-Lab Phase|Lost to Follow-up|0
6074771|NCT00576472|9678965|FG003|MPH In-Lab Phase|Lost to Follow-up|1
6074772|NCT00576472|9678966|FG004|MPH In-Lab Phase|Lost to Follow-up|0
6074773|NCT00576472|9678967|FG005|MPH In-Lab Phase|Lost to Follow-up|0
6074774|NCT00576472|9678968|FG006|MPH In-Lab Phase|Lost to Follow-up|0
6074775|NCT00576472|9678969|FG007|MPH In-Lab Phase|Lost to Follow-up|0
6074776|NCT00576472|9678970|FG008|MPH In-Lab Phase|Lost to Follow-up|0
6074777|NCT00576472|9678971|FG009|MPH In-Lab Phase|Lost to Follow-up|0
6074778|NCT00576472|9678972|FG010|MPH In-Lab Phase|Lost to Follow-up|0
6074779|NCT00576472|9678973|FG011|MPH In-Lab Phase|Lost to Follow-up|0
6008618|NCT00098306|9601869|FG004|Double Blind|Death|0
6008619|NCT00098306|9601870|FG005|Double Blind|Death|0
6008620|NCT00098306|9601871|FG006|Double Blind|Death|0
6074780|NCT00576472|9678974|FG012|MPH In-Lab Phase|Lost to Follow-up|0
6074781|NCT00576472|9678975|FG013|MPH In-Lab Phase|Lost to Follow-up|0
6074782|NCT00576472|9678976|FG014|MPH In-Lab Phase|Lost to Follow-up|0
6074783|NCT00576472|9678962|FG000|MPH In-Lab Phase|Patients did not qualify - IQ < 50|0
6008621|NCT00098306|9601865|FG000|Double Blind|Participant defaulted|19
6008622|NCT00098306|9601866|FG001|Double Blind|Participant defaulted|18
6008623|NCT00098306|9601867|FG002|Double Blind|Participant defaulted|11
6008624|NCT00098306|9601868|FG003|Double Blind|Participant defaulted|0
6008625|NCT00098306|9601869|FG004|Double Blind|Participant defaulted|0
6008626|NCT00098306|9601870|FG005|Double Blind|Participant defaulted|0
6008627|NCT00098306|9601871|FG006|Double Blind|Participant defaulted|0
6008628|NCT00098306|9601865|FG000|Double Blind|Un-specified|7
6008629|NCT00098306|9601866|FG001|Double Blind|Un-specified|3
6008630|NCT00098306|9601867|FG002|Double Blind|Un-specified|11
6008631|NCT00098306|9601868|FG003|Double Blind|Un-specified|0
6008632|NCT00098306|9601869|FG004|Double Blind|Un-specified|0
6008633|NCT00098306|9601870|FG005|Double Blind|Un-specified|0
6008634|NCT00098306|9601871|FG006|Double Blind|Un-specified|0
6008635|NCT00098306|9601865|FG000|Open Label|Lack of Efficacy|0
6008636|NCT00098306|9601866|FG001|Open Label|Lack of Efficacy|0
6008637|NCT00098306|9601867|FG002|Open Label|Lack of Efficacy|0
6008638|NCT00098306|9601868|FG003|Open Label|Lack of Efficacy|13
6008639|NCT00098306|9601869|FG004|Open Label|Lack of Efficacy|0
6008640|NCT00098306|9601870|FG005|Open Label|Lack of Efficacy|0
6008641|NCT00098306|9601871|FG006|Open Label|Lack of Efficacy|0
6008642|NCT00098306|9601865|FG000|Open Label|Adverse Event|0
6008643|NCT00098306|9601866|FG001|Open Label|Adverse Event|0
6008644|NCT00098306|9601867|FG002|Open Label|Adverse Event|0
6008645|NCT00098306|9601868|FG003|Open Label|Adverse Event|2
6008646|NCT00098306|9601869|FG004|Open Label|Adverse Event|0
6008647|NCT00098306|9601870|FG005|Open Label|Adverse Event|0
6008648|NCT00098306|9601871|FG006|Open Label|Adverse Event|0
6008649|NCT00098306|9601865|FG000|Open Label|Death|0
6008650|NCT00098306|9601866|FG001|Open Label|Death|0
6008651|NCT00098306|9601867|FG002|Open Label|Death|0
6008652|NCT00098306|9601868|FG003|Open Label|Death|4
6008653|NCT00098306|9601869|FG004|Open Label|Death|0
6008654|NCT00098306|9601870|FG005|Open Label|Death|0
6008655|NCT00098306|9601871|FG006|Open Label|Death|0
6008656|NCT00098306|9601865|FG000|Open Label|Participant defaulted|0
6008657|NCT00098306|9601866|FG001|Open Label|Participant defaulted|0
6008658|NCT00098306|9601867|FG002|Open Label|Participant defaulted|0
6008659|NCT00098306|9601868|FG003|Open Label|Participant defaulted|24
6008660|NCT00098306|9601869|FG004|Open Label|Participant defaulted|0
6008661|NCT00098306|9601870|FG005|Open Label|Participant defaulted|0
6008662|NCT00098306|9601871|FG006|Open Label|Participant defaulted|0
6008663|NCT00098306|9601865|FG000|Open Label|Un-specified|0
6008664|NCT00098306|9601866|FG001|Open Label|Un-specified|0
6008665|NCT00098306|9601867|FG002|Open Label|Un-specified|0
6008666|NCT00098306|9601868|FG003|Open Label|Un-specified|15
6008667|NCT00098306|9601869|FG004|Open Label|Un-specified|0
6008668|NCT00098306|9601870|FG005|Open Label|Un-specified|0
6008669|NCT00098306|9601871|FG006|Open Label|Un-specified|0
6008670|NCT00098306|9601865|FG000|Open Label|Ongoing at cut-off date|0
6008671|NCT00098306|9601866|FG001|Open Label|Ongoing at cut-off date|0
6008672|NCT00098306|9601867|FG002|Open Label|Ongoing at cut-off date|0
6008673|NCT00098306|9601868|FG003|Open Label|Ongoing at cut-off date|269
6008674|NCT00098306|9601869|FG004|Open Label|Ongoing at cut-off date|62
6008675|NCT00098306|9601870|FG005|Open Label|Ongoing at cut-off date|0
6008676|NCT00098306|9601871|FG006|Open Label|Ongoing at cut-off date|0
6008677|NCT00098306|9601865|FG000|Observational Phase|Death|0
6008678|NCT00098306|9601866|FG001|Observational Phase|Death|0
6008679|NCT00098306|9601867|FG002|Observational Phase|Death|0
6008680|NCT00098306|9601868|FG003|Observational Phase|Death|0
6008681|NCT00098306|9601869|FG004|Observational Phase|Death|0
6008682|NCT00098306|9601870|FG005|Observational Phase|Death|5
6008683|NCT00098306|9601871|FG006|Observational Phase|Death|4
6008684|NCT00098306|9601865|FG000|Observational Phase|Participant defaulted|0
6008685|NCT00098306|9601866|FG001|Observational Phase|Participant defaulted|0
6008686|NCT00098306|9601867|FG002|Observational Phase|Participant defaulted|0
6008687|NCT00098306|9601868|FG003|Observational Phase|Participant defaulted|0
6008688|NCT00098306|9601869|FG004|Observational Phase|Participant defaulted|0
6008689|NCT00098306|9601870|FG005|Observational Phase|Participant defaulted|34
6008690|NCT00098306|9601871|FG006|Observational Phase|Participant defaulted|18
6008691|NCT00098306|9601865|FG000|Observational Phase|Un-specified|0
6008692|NCT00098306|9601866|FG001|Observational Phase|Un-specified|0
6008693|NCT00098306|9601867|FG002|Observational Phase|Un-specified|0
6008694|NCT00098306|9601868|FG003|Observational Phase|Un-specified|0
6008695|NCT00098306|9601869|FG004|Observational Phase|Un-specified|0
6008696|NCT00098306|9601870|FG005|Observational Phase|Un-specified|7
6008697|NCT00098306|9601871|FG006|Observational Phase|Un-specified|4
6008698|NCT00098345|9601884|FG000|Overall Study|Adverse Event|7
6008699|NCT00098345|9601884|FG000|Overall Study|Withdrawal by Subject|2
6008700|NCT00098345|9601884|FG000|Overall Study|progression|4
6008701|NCT00098722|9601911|FG000|Double Blind Phase|Adverse Event|7
6008702|NCT00098722|9601912|FG001|Double Blind Phase|Adverse Event|7
6008703|NCT00098722|9601913|FG002|Double Blind Phase|Adverse Event|3
6008704|NCT00098722|9601914|FG003|Double Blind Phase|Adverse Event|0
6008705|NCT00098722|9601915|FG004|Double Blind Phase|Adverse Event|0
6008706|NCT00098722|9601916|FG005|Double Blind Phase|Adverse Event|0
6008707|NCT00098722|9601917|FG006|Double Blind Phase|Adverse Event|0
6008708|NCT00098722|9601911|FG000|Double Blind Phase|Death|2
6008709|NCT00098722|9601912|FG001|Double Blind Phase|Death|5
6008710|NCT00098722|9601913|FG002|Double Blind Phase|Death|0
6008711|NCT00098722|9601914|FG003|Double Blind Phase|Death|0
6008712|NCT00098722|9601915|FG004|Double Blind Phase|Death|0
6008713|NCT00098722|9601916|FG005|Double Blind Phase|Death|0
6008714|NCT00098722|9601917|FG006|Double Blind Phase|Death|0
6008715|NCT00098722|9601911|FG000|Double Blind Phase|Lack of Efficacy|21
6008716|NCT00098722|9601912|FG001|Double Blind Phase|Lack of Efficacy|23
6074784|NCT00576472|9678963|FG001|MPH In-Lab Phase|Patients did not qualify - IQ < 50|0
6074785|NCT00576472|9678964|FG002|MPH In-Lab Phase|Patients did not qualify - IQ < 50|0
6074786|NCT00576472|9678965|FG003|MPH In-Lab Phase|Patients did not qualify - IQ < 50|4
6074787|NCT00576472|9678966|FG004|MPH In-Lab Phase|Patients did not qualify - IQ < 50|0
6074788|NCT00576472|9678967|FG005|MPH In-Lab Phase|Patients did not qualify - IQ < 50|0
6074789|NCT00576472|9678968|FG006|MPH In-Lab Phase|Patients did not qualify - IQ < 50|0
6074790|NCT00576472|9678969|FG007|MPH In-Lab Phase|Patients did not qualify - IQ < 50|0
6074791|NCT00576472|9678970|FG008|MPH In-Lab Phase|Patients did not qualify - IQ < 50|0
6074792|NCT00576472|9678971|FG009|MPH In-Lab Phase|Patients did not qualify - IQ < 50|0
6074793|NCT00576472|9678972|FG010|MPH In-Lab Phase|Patients did not qualify - IQ < 50|0
6074794|NCT00576472|9678973|FG011|MPH In-Lab Phase|Patients did not qualify - IQ < 50|0
6074795|NCT00576472|9678974|FG012|MPH In-Lab Phase|Patients did not qualify - IQ < 50|0
6008717|NCT00098722|9601913|FG002|Double Blind Phase|Lack of Efficacy|15
6008718|NCT00098722|9601914|FG003|Double Blind Phase|Lack of Efficacy|0
6008719|NCT00098722|9601915|FG004|Double Blind Phase|Lack of Efficacy|0
6008720|NCT00098722|9601916|FG005|Double Blind Phase|Lack of Efficacy|0
6008721|NCT00098722|9601917|FG006|Double Blind Phase|Lack of Efficacy|0
6008722|NCT00098722|9601911|FG000|Double Blind Phase|Participant defaulted|16
6008723|NCT00098722|9601912|FG001|Double Blind Phase|Participant defaulted|11
6008724|NCT00098722|9601913|FG002|Double Blind Phase|Participant defaulted|9
6008725|NCT00098722|9601914|FG003|Double Blind Phase|Participant defaulted|0
6008726|NCT00098722|9601915|FG004|Double Blind Phase|Participant defaulted|0
6008727|NCT00098722|9601916|FG005|Double Blind Phase|Participant defaulted|0
6008728|NCT00098722|9601917|FG006|Double Blind Phase|Participant defaulted|0
6008729|NCT00098722|9601911|FG000|Double Blind Phase|Pregnancy|1
6008730|NCT00098722|9601912|FG001|Double Blind Phase|Pregnancy|0
6008731|NCT00098722|9601913|FG002|Double Blind Phase|Pregnancy|0
6008732|NCT00098722|9601914|FG003|Double Blind Phase|Pregnancy|0
6008733|NCT00098722|9601915|FG004|Double Blind Phase|Pregnancy|0
6008734|NCT00098722|9601916|FG005|Double Blind Phase|Pregnancy|0
6008735|NCT00098722|9601917|FG006|Double Blind Phase|Pregnancy|0
6008736|NCT00098722|9601911|FG000|Double Blind Phase|Randomized, not treated|4
6008737|NCT00098722|9601912|FG001|Double Blind Phase|Randomized, not treated|3
6008738|NCT00098722|9601913|FG002|Double Blind Phase|Randomized, not treated|3
6008739|NCT00098722|9601914|FG003|Double Blind Phase|Randomized, not treated|0
6008740|NCT00098722|9601915|FG004|Double Blind Phase|Randomized, not treated|0
6008741|NCT00098722|9601916|FG005|Double Blind Phase|Randomized, not treated|0
6008742|NCT00098722|9601917|FG006|Double Blind Phase|Randomized, not treated|0
6008743|NCT00098722|9601911|FG000|Double Blind Phase|Ongoing at cut-off date|128
6008744|NCT00098722|9601912|FG001|Double Blind Phase|Ongoing at cut-off date|137
6008745|NCT00098722|9601913|FG002|Double Blind Phase|Ongoing at cut-off date|57
6008746|NCT00098722|9601914|FG003|Double Blind Phase|Ongoing at cut-off date|0
6008747|NCT00098722|9601915|FG004|Double Blind Phase|Ongoing at cut-off date|0
6008748|NCT00098722|9601916|FG005|Double Blind Phase|Ongoing at cut-off date|0
6008749|NCT00098722|9601917|FG006|Double Blind Phase|Ongoing at cut-off date|0
6008750|NCT00098722|9601911|FG000|Double Blind Phase|Other|7
6074796|NCT00576472|9678975|FG013|MPH In-Lab Phase|Patients did not qualify - IQ < 50|0
6074797|NCT00576472|9678976|FG014|MPH In-Lab Phase|Patients did not qualify - IQ < 50|0
6074798|NCT00576472|9678962|FG000|MPH In-Lab Phase|No attention/academic problems|0
6074799|NCT00576472|9678963|FG001|MPH In-Lab Phase|No attention/academic problems|0
6074800|NCT00576472|9678964|FG002|MPH In-Lab Phase|No attention/academic problems|0
6074801|NCT00576472|9678965|FG003|MPH In-Lab Phase|No attention/academic problems|245
6074802|NCT00576472|9678966|FG004|MPH In-Lab Phase|No attention/academic problems|0
6074803|NCT00576472|9678967|FG005|MPH In-Lab Phase|No attention/academic problems|0
6074804|NCT00576472|9678968|FG006|MPH In-Lab Phase|No attention/academic problems|0
6074805|NCT00576472|9678969|FG007|MPH In-Lab Phase|No attention/academic problems|0
6074806|NCT00576472|9678970|FG008|MPH In-Lab Phase|No attention/academic problems|0
6074807|NCT00576472|9678971|FG009|MPH In-Lab Phase|No attention/academic problems|0
6074808|NCT00576472|9678972|FG010|MPH In-Lab Phase|No attention/academic problems|0
6074809|NCT00576472|9678973|FG011|MPH In-Lab Phase|No attention/academic problems|0
6074810|NCT00576472|9678974|FG012|MPH In-Lab Phase|No attention/academic problems|0
6074811|NCT00576472|9678975|FG013|MPH In-Lab Phase|No attention/academic problems|0
6074812|NCT00576472|9678976|FG014|MPH In-Lab Phase|No attention/academic problems|0
6074813|NCT00576472|9678962|FG000|MPH In-Lab Phase|Psychiatric exclusion|0
6074814|NCT00576472|9678963|FG001|MPH In-Lab Phase|Psychiatric exclusion|0
6074815|NCT00576472|9678964|FG002|MPH In-Lab Phase|Psychiatric exclusion|0
6074816|NCT00576472|9678965|FG003|MPH In-Lab Phase|Psychiatric exclusion|10
6074817|NCT00576472|9678966|FG004|MPH In-Lab Phase|Psychiatric exclusion|0
6074818|NCT00576472|9678967|FG005|MPH In-Lab Phase|Psychiatric exclusion|0
6008751|NCT00098722|9601912|FG001|Double Blind Phase|Other|8
6008752|NCT00098722|9601913|FG002|Double Blind Phase|Other|7
6008753|NCT00098722|9601914|FG003|Double Blind Phase|Other|0
6008754|NCT00098722|9601915|FG004|Double Blind Phase|Other|0
6074819|NCT00576472|9678968|FG006|MPH In-Lab Phase|Psychiatric exclusion|0
6008755|NCT00098722|9601916|FG005|Double Blind Phase|Other|0
6008756|NCT00098722|9601917|FG006|Double Blind Phase|Other|0
6008757|NCT00098722|9601911|FG000|Open Label Phase|Adverse Event|0
6008758|NCT00098722|9601912|FG001|Open Label Phase|Adverse Event|0
6008759|NCT00098722|9601913|FG002|Open Label Phase|Adverse Event|0
6008760|NCT00098722|9601914|FG003|Open Label Phase|Adverse Event|5
6008761|NCT00098722|9601915|FG004|Open Label Phase|Adverse Event|0
6008762|NCT00098722|9601916|FG005|Open Label Phase|Adverse Event|0
6008763|NCT00098722|9601917|FG006|Open Label Phase|Adverse Event|0
6008764|NCT00098722|9601911|FG000|Open Label Phase|Death|0
6008765|NCT00098722|9601912|FG001|Open Label Phase|Death|0
6008766|NCT00098722|9601913|FG002|Open Label Phase|Death|0
6008767|NCT00098722|9601914|FG003|Open Label Phase|Death|2
6008768|NCT00098722|9601915|FG004|Open Label Phase|Death|0
6008769|NCT00098722|9601916|FG005|Open Label Phase|Death|0
6008770|NCT00098722|9601917|FG006|Open Label Phase|Death|0
6008771|NCT00098722|9601911|FG000|Open Label Phase|Lack of Efficacy|0
6008772|NCT00098722|9601912|FG001|Open Label Phase|Lack of Efficacy|0
6008773|NCT00098722|9601913|FG002|Open Label Phase|Lack of Efficacy|0
6008774|NCT00098722|9601914|FG003|Open Label Phase|Lack of Efficacy|8
6008775|NCT00098722|9601915|FG004|Open Label Phase|Lack of Efficacy|0
6008776|NCT00098722|9601916|FG005|Open Label Phase|Lack of Efficacy|0
6008777|NCT00098722|9601917|FG006|Open Label Phase|Lack of Efficacy|0
6008778|NCT00098722|9601911|FG000|Open Label Phase|Pregnancy|0
6008779|NCT00098722|9601912|FG001|Open Label Phase|Pregnancy|0
6008780|NCT00098722|9601913|FG002|Open Label Phase|Pregnancy|0
6008781|NCT00098722|9601914|FG003|Open Label Phase|Pregnancy|1
6008782|NCT00098722|9601915|FG004|Open Label Phase|Pregnancy|0
6008783|NCT00098722|9601916|FG005|Open Label Phase|Pregnancy|0
6008784|NCT00098722|9601917|FG006|Open Label Phase|Pregnancy|0
6008785|NCT00098722|9601911|FG000|Open Label Phase|Participant defaulted|0
6008786|NCT00098722|9601912|FG001|Open Label Phase|Participant defaulted|0
6008787|NCT00098722|9601913|FG002|Open Label Phase|Participant defaulted|0
6008788|NCT00098722|9601914|FG003|Open Label Phase|Participant defaulted|18
6008789|NCT00098722|9601915|FG004|Open Label Phase|Participant defaulted|0
6008790|NCT00098722|9601916|FG005|Open Label Phase|Participant defaulted|0
6008791|NCT00098722|9601917|FG006|Open Label Phase|Participant defaulted|0
6008792|NCT00098722|9601911|FG000|Open Label Phase|Ongoing at cut-off date|0
6008793|NCT00098722|9601912|FG001|Open Label Phase|Ongoing at cut-off date|0
6008794|NCT00098722|9601913|FG002|Open Label Phase|Ongoing at cut-off date|0
6008795|NCT00098722|9601914|FG003|Open Label Phase|Ongoing at cut-off date|220
6008796|NCT00098722|9601915|FG004|Open Label Phase|Ongoing at cut-off date|50
6008797|NCT00098722|9601916|FG005|Open Label Phase|Ongoing at cut-off date|0
6008798|NCT00098722|9601917|FG006|Open Label Phase|Ongoing at cut-off date|0
6008799|NCT00098722|9601911|FG000|Open Label Phase|Other|0
6008800|NCT00098722|9601912|FG001|Open Label Phase|Other|0
6008801|NCT00098722|9601913|FG002|Open Label Phase|Other|0
6008802|NCT00098722|9601914|FG003|Open Label Phase|Other|18
6008803|NCT00098722|9601915|FG004|Open Label Phase|Other|0
6008804|NCT00098722|9601916|FG005|Open Label Phase|Other|0
6008805|NCT00098722|9601917|FG006|Open Label Phase|Other|0
6008806|NCT00098722|9601911|FG000|Observation Phase|Death|0
6008807|NCT00098722|9601912|FG001|Observation Phase|Death|0
6008808|NCT00098722|9601913|FG002|Observation Phase|Death|0
6008809|NCT00098722|9601914|FG003|Observation Phase|Death|0
6008810|NCT00098722|9601915|FG004|Observation Phase|Death|0
6008811|NCT00098722|9601916|FG005|Observation Phase|Death|5
6008812|NCT00098722|9601917|FG006|Observation Phase|Death|3
6008813|NCT00098722|9601911|FG000|Observation Phase|Lack of Efficacy|0
6008814|NCT00098722|9601912|FG001|Observation Phase|Lack of Efficacy|0
6008815|NCT00098722|9601913|FG002|Observation Phase|Lack of Efficacy|0
6008816|NCT00098722|9601914|FG003|Observation Phase|Lack of Efficacy|0
6008817|NCT00098722|9601915|FG004|Observation Phase|Lack of Efficacy|0
6008818|NCT00098722|9601916|FG005|Observation Phase|Lack of Efficacy|2
6008819|NCT00098722|9601917|FG006|Observation Phase|Lack of Efficacy|0
6008820|NCT00098722|9601911|FG000|Observation Phase|Participant defaulted|0
6008821|NCT00098722|9601912|FG001|Observation Phase|Participant defaulted|0
6008822|NCT00098722|9601913|FG002|Observation Phase|Participant defaulted|0
6008823|NCT00098722|9601914|FG003|Observation Phase|Participant defaulted|0
6008824|NCT00098722|9601915|FG004|Observation Phase|Participant defaulted|0
6008825|NCT00098722|9601916|FG005|Observation Phase|Participant defaulted|17
6008826|NCT00098722|9601917|FG006|Observation Phase|Participant defaulted|4
6008827|NCT00098722|9601911|FG000|Observation Phase|Other|0
6008828|NCT00098722|9601912|FG001|Observation Phase|Other|0
6008829|NCT00098722|9601913|FG002|Observation Phase|Other|0
6008830|NCT00098722|9601914|FG003|Observation Phase|Other|0
6008831|NCT00098722|9601915|FG004|Observation Phase|Other|0
6008832|NCT00098722|9601916|FG005|Observation Phase|Other|21
6008833|NCT00098722|9601917|FG006|Observation Phase|Other|10
6008834|NCT00098748|9601932|FG000|Assigned to Study Treatment|Randomized, but not treated|0
6008835|NCT00098748|9601933|FG001|Assigned to Study Treatment|Randomized, but not treated|2
6008836|NCT00098748|9601934|FG002|Assigned to Study Treatment|Randomized, but not treated|2
6008837|NCT00098748|9601932|FG000|Received Study Treatment|Death|2
6008838|NCT00098748|9601933|FG001|Received Study Treatment|Death|1
6008839|NCT00098748|9601934|FG002|Received Study Treatment|Death|2
6008840|NCT00098748|9601932|FG000|Received Study Treatment|Adverse Event|1
6008841|NCT00098748|9601933|FG001|Received Study Treatment|Adverse Event|2
6008842|NCT00098748|9601934|FG002|Received Study Treatment|Adverse Event|5
6008843|NCT00098748|9601932|FG000|Received Study Treatment|Lack of Efficacy|40
6008844|NCT00098748|9601933|FG001|Received Study Treatment|Lack of Efficacy|27
6008845|NCT00098748|9601934|FG002|Received Study Treatment|Lack of Efficacy|27
6008846|NCT00098748|9601932|FG000|Received Study Treatment|Other|2
6008847|NCT00098748|9601933|FG001|Received Study Treatment|Other|2
6008848|NCT00098748|9601934|FG002|Received Study Treatment|Other|6
6008849|NCT00098748|9601932|FG000|Received Study Treatment|Subject defaulted|3
6008850|NCT00098748|9601933|FG001|Received Study Treatment|Subject defaulted|4
6008851|NCT00098748|9601934|FG002|Received Study Treatment|Subject defaulted|4
6008852|NCT00098748|9601932|FG000|Continued on Open-Label Treatment|Adverse Event|0
6008853|NCT00098748|9601933|FG001|Continued on Open-Label Treatment|Adverse Event|1
6008854|NCT00098748|9601934|FG002|Continued on Open-Label Treatment|Adverse Event|0
6008855|NCT00098748|9601932|FG000|Continued on Open-Label Treatment|Lack of Efficacy|1
6008856|NCT00098748|9601933|FG001|Continued on Open-Label Treatment|Lack of Efficacy|2
6008857|NCT00098748|9601934|FG002|Continued on Open-Label Treatment|Lack of Efficacy|0
6008858|NCT00098748|9601932|FG000|Continued on Open-Label Treatment|Other reason includes protocol violation|6
6008859|NCT00098748|9601933|FG001|Continued on Open-Label Treatment|Other reason includes protocol violation|7
6008860|NCT00098748|9601934|FG002|Continued on Open-Label Treatment|Other reason includes protocol violation|0
6008861|NCT00098748|9601932|FG000|Continued on Open-Label Treatment|Lost to Follow-up|1
6008862|NCT00098748|9601933|FG001|Continued on Open-Label Treatment|Lost to Follow-up|1
6008863|NCT00098748|9601934|FG002|Continued on Open-Label Treatment|Lost to Follow-up|0
6008864|NCT00098748|9601932|FG000|Continued on Open-Label Treatment|Withdrawal by Subject|0
6008865|NCT00098748|9601933|FG001|Continued on Open-Label Treatment|Withdrawal by Subject|4
6008866|NCT00098748|9601934|FG002|Continued on Open-Label Treatment|Withdrawal by Subject|0
6008867|NCT00098774|9601942|FG000|Overall Study|Adverse Event|2
6008868|NCT00098774|9601942|FG000|Overall Study|Disease Progression|9
6008869|NCT00098774|9601942|FG000|Overall Study|Withdrawal by Subject|1
6008870|NCT00098774|9601942|FG000|Overall Study|Failed (to respond) during induction|4
6008871|NCT00098774|9601942|FG000|Overall Study|Physician Decision|2
6008872|NCT00098787|9601949|FG000|Overall Study|Never started treatment|3
6008873|NCT00098787|9601950|FG001|Overall Study|Never started treatment|2
6008874|NCT00098787|9601951|FG002|Overall Study|Never started treatment|1
6008875|NCT00098787|9601949|FG000|Overall Study|Ineligible|9
6008876|NCT00098787|9601950|FG001|Overall Study|Ineligible|7
6008877|NCT00098787|9601951|FG002|Overall Study|Ineligible|3
6008878|NCT00098787|9601949|FG000|Overall Study|Disease progression|28
6008879|NCT00098787|9601950|FG001|Overall Study|Disease progression|17
6008880|NCT00098787|9601951|FG002|Overall Study|Disease progression|23
6008881|NCT00098787|9601949|FG000|Overall Study|Adverse Event|8
6008882|NCT00098787|9601950|FG001|Overall Study|Adverse Event|17
6008883|NCT00098787|9601951|FG002|Overall Study|Adverse Event|8
6008884|NCT00098787|9601949|FG000|Overall Study|Death|6
6008885|NCT00098787|9601950|FG001|Overall Study|Death|1
6008886|NCT00098787|9601951|FG002|Overall Study|Death|0
6008887|NCT00098787|9601949|FG000|Overall Study|Withdrawal by Subject|4
6008888|NCT00098787|9601950|FG001|Overall Study|Withdrawal by Subject|12
6008889|NCT00098787|9601951|FG002|Overall Study|Withdrawal by Subject|6
6008890|NCT00098787|9601949|FG000|Overall Study|Alternative therapy|8
6008891|NCT00098787|9601950|FG001|Overall Study|Alternative therapy|13
6008892|NCT00098787|9601951|FG002|Overall Study|Alternative therapy|13
6008893|NCT00098787|9601949|FG000|Overall Study|Other|7
6008894|NCT00098787|9601950|FG001|Overall Study|Other|6
6008895|NCT00098787|9601951|FG002|Overall Study|Other|9
6047376|NCT00410410|9646256|FG007|Open-Label Period (OL)|Withdrawal by Subject|0
6047377|NCT00410410|9646257|FG008|Open-Label Period (OL)|Withdrawal by Subject|20
6047378|NCT00410410|9646249|FG000|Open-Label Period (OL)|Pregnancy|0
6047379|NCT00410410|9646250|FG001|Open-Label Period (OL)|Pregnancy|0
6047380|NCT00410410|9646251|FG002|Open-Label Period (OL)|Pregnancy|0
6047381|NCT00410410|9646252|FG003|Open-Label Period (OL)|Pregnancy|0
6047382|NCT00410410|9646253|FG004|Open-Label Period (OL)|Pregnancy|0
6047383|NCT00410410|9646254|FG005|Open-Label Period (OL)|Pregnancy|0
6047384|NCT00410410|9646255|FG006|Open-Label Period (OL)|Pregnancy|0
6047385|NCT00410410|9646256|FG007|Open-Label Period (OL)|Pregnancy|0
6047386|NCT00410410|9646257|FG008|Open-Label Period (OL)|Pregnancy|1
6047387|NCT00410410|9646249|FG000|Open-Label Period (OL)|Administrative Reason By Sponsor|0
6047388|NCT00410410|9646250|FG001|Open-Label Period (OL)|Administrative Reason By Sponsor|0
6047389|NCT00410410|9646251|FG002|Open-Label Period (OL)|Administrative Reason By Sponsor|0
6047390|NCT00410410|9646252|FG003|Open-Label Period (OL)|Administrative Reason By Sponsor|0
6047391|NCT00410410|9646253|FG004|Open-Label Period (OL)|Administrative Reason By Sponsor|0
6047392|NCT00410410|9646254|FG005|Open-Label Period (OL)|Administrative Reason By Sponsor|0
6047393|NCT00410410|9646255|FG006|Open-Label Period (OL)|Administrative Reason By Sponsor|0
6047394|NCT00410410|9646256|FG007|Open-Label Period (OL)|Administrative Reason By Sponsor|0
6047395|NCT00410410|9646257|FG008|Open-Label Period (OL)|Administrative Reason By Sponsor|145
6047396|NCT00410410|9646249|FG000|Open-Label Period (OL)|Other|0
6047397|NCT00410410|9646250|FG001|Open-Label Period (OL)|Other|0
6047398|NCT00410410|9646251|FG002|Open-Label Period (OL)|Other|0
6047399|NCT00410410|9646252|FG003|Open-Label Period (OL)|Other|0
6047400|NCT00410410|9646253|FG004|Open-Label Period (OL)|Other|0
6047401|NCT00410410|9646254|FG005|Open-Label Period (OL)|Other|0
6047402|NCT00410410|9646255|FG006|Open-Label Period (OL)|Other|0
6047403|NCT00410410|9646256|FG007|Open-Label Period (OL)|Other|0
6047404|NCT00410410|9646257|FG008|Open-Label Period (OL)|Other|7
6049106|NCT00421304|9648322|FG000|Overall Study|Mistakenly randomized, chose not to participate in study|1
6008896|NCT00098813|9601959|FG000|Overall Study|Death|8
6008897|NCT00098813|9601959|FG000|Overall Study|Protocol Violation|1
6008898|NCT00098813|9601959|FG000|Overall Study|Withdrawal by Subject|7
6008899|NCT00098813|9601959|FG000|Overall Study|Progression of Disease|1
6008900|NCT00098813|9601959|FG000|Overall Study|Other complicating disease|1
6008901|NCT00098813|9601959|FG000|Overall Study|Reversal of RAI resistance|1
6008902|NCT00098839|9601965|FG000|Overall Study|Adverse Event|5
6008903|NCT00098839|9601966|FG001|Overall Study|Adverse Event|2
6008904|NCT00098839|9601965|FG000|Overall Study|Death|1
6008905|NCT00098839|9601966|FG001|Overall Study|Death|2
6008906|NCT00098839|9601965|FG000|Overall Study|Physician Decision|4
6008907|NCT00098839|9601966|FG001|Overall Study|Physician Decision|14
6008908|NCT00098839|9601965|FG000|Overall Study|Withdrawal by Subject|1
6008909|NCT00098839|9601966|FG001|Overall Study|Withdrawal by Subject|0
6008910|NCT00098839|9601965|FG000|Overall Study|Refusal of further protocol therapy|3
6008911|NCT00098839|9601966|FG001|Overall Study|Refusal of further protocol therapy|1
6008912|NCT00098839|9601965|FG000|Overall Study|Relapse|6
6008913|NCT00098839|9601966|FG001|Overall Study|Relapse|3
6008914|NCT00098839|9601965|FG000|Overall Study|M2/M3 marrow on Day 15 of Block 2|10
6008915|NCT00098839|9601966|FG001|Overall Study|M2/M3 marrow on Day 15 of Block 2|11
6008916|NCT00098839|9601965|FG000|Overall Study|Ineligible|2
6008917|NCT00098839|9601966|FG001|Overall Study|Ineligible|0
6008918|NCT00098865|9601973|FG000|Overall Study|Progressive Disease|6
6008919|NCT00098865|9601973|FG000|Overall Study|Adverse Event|2
6008920|NCT00098865|9601973|FG000|Overall Study|Alternative Therapy|1
6008921|NCT00099268|9601996|FG000|Overall Study|Withdrawal by Subject|46
6008922|NCT00099268|9601997|FG001|Overall Study|Withdrawal by Subject|28
6008923|NCT00099268|9601996|FG000|Overall Study|Adverse Event|19
6008924|NCT00099268|9601997|FG001|Overall Study|Adverse Event|19
6008925|NCT00099268|9601996|FG000|Overall Study|Protocol Violation|9
6008926|NCT00099268|9601997|FG001|Overall Study|Protocol Violation|8
6008927|NCT00099268|9601996|FG000|Overall Study|Lost to Follow-up|6
6008928|NCT00099268|9601997|FG001|Overall Study|Lost to Follow-up|4
6008929|NCT00099268|9601996|FG000|Overall Study|Lack of Efficacy|5
6008930|NCT00099268|9601997|FG001|Overall Study|Lack of Efficacy|18
6008931|NCT00099268|9601996|FG000|Overall Study|Administrative problems|4
6008932|NCT00099268|9601997|FG001|Overall Study|Administrative problems|4
6008933|NCT00099268|9601996|FG000|Overall Study|Death|3
6008934|NCT00099268|9601997|FG001|Overall Study|Death|1
6008935|NCT00099359|9602006|FG000|Overall Study|Death|11
6008936|NCT00099359|9602007|FG001|Overall Study|Death|15
6008937|NCT00099359|9602008|FG002|Overall Study|Death|17
6008938|NCT00099359|9602006|FG000|Overall Study|Withdrawal by Subject|19
6008939|NCT00099359|9602007|FG001|Overall Study|Withdrawal by Subject|19
6008940|NCT00099359|9602008|FG002|Overall Study|Withdrawal by Subject|23
6008941|NCT00099359|9602006|FG000|Overall Study|Lost to Follow-up|15
6008942|NCT00099359|9602007|FG001|Overall Study|Lost to Follow-up|24
6008943|NCT00099359|9602008|FG002|Overall Study|Lost to Follow-up|24
6008944|NCT00099359|9602006|FG000|Overall Study|moved out of area|9
6008945|NCT00099359|9602007|FG001|Overall Study|moved out of area|7
6008946|NCT00099359|9602008|FG002|Overall Study|moved out of area|4
6008947|NCT00099632|9602043|FG000|Overall Study|Lost to Follow-up|1
6008948|NCT00099632|9602044|FG001|Overall Study|Lost to Follow-up|0
6008949|NCT00099632|9602045|FG002|Overall Study|Lost to Follow-up|3
6008950|NCT00099632|9602046|FG003|Overall Study|Lost to Follow-up|1
6008951|NCT00099632|9602047|FG004|Overall Study|Lost to Follow-up|1
6008952|NCT00099632|9602048|FG005|Overall Study|Lost to Follow-up|0
6008953|NCT00099632|9602043|FG000|Overall Study|Withdrawal by Subject|0
6008954|NCT00099632|9602044|FG001|Overall Study|Withdrawal by Subject|1
6008955|NCT00099632|9602045|FG002|Overall Study|Withdrawal by Subject|0
6008956|NCT00099632|9602046|FG003|Overall Study|Withdrawal by Subject|0
6008957|NCT00099632|9602047|FG004|Overall Study|Withdrawal by Subject|0
6008958|NCT00099632|9602048|FG005|Overall Study|Withdrawal by Subject|1
6008959|NCT00099632|9602043|FG000|Overall Study|Protocol Violation|0
6008960|NCT00099632|9602044|FG001|Overall Study|Protocol Violation|0
6008961|NCT00099632|9602045|FG002|Overall Study|Protocol Violation|0
6008962|NCT00099632|9602046|FG003|Overall Study|Protocol Violation|0
6008963|NCT00099632|9602047|FG004|Overall Study|Protocol Violation|0
6008964|NCT00099632|9602048|FG005|Overall Study|Protocol Violation|1
6008965|NCT00099983|9602064|FG000|Overall Study|Lost to Follow-up|2
6008966|NCT00099983|9602065|FG001|Overall Study|Lost to Follow-up|3
6008967|NCT00099983|9602064|FG000|Overall Study|Missing Source Documents|14
6008968|NCT00099983|9602065|FG001|Overall Study|Missing Source Documents|15
6008969|NCT00099983|9602064|FG000|Overall Study|Withdrawal by Subject|3
6008970|NCT00099983|9602065|FG001|Overall Study|Withdrawal by Subject|2
6008971|NCT00099983|9602064|FG000|Overall Study|Adverse Event|1
6008972|NCT00099983|9602065|FG001|Overall Study|Adverse Event|1
6008973|NCT00099983|9602064|FG000|Overall Study|Lack of Efficacy|0
6008974|NCT00099983|9602065|FG001|Overall Study|Lack of Efficacy|1
6008975|NCT00099983|9602064|FG000|Overall Study|Unable to return for appointments|1
6008976|NCT00099983|9602065|FG001|Overall Study|Unable to return for appointments|1
6008977|NCT00099983|9602064|FG000|Overall Study|Moved|1
6008978|NCT00099983|9602065|FG001|Overall Study|Moved|0
6008979|NCT00099983|9602064|FG000|Overall Study|Other psychiatric problem|1
6008980|NCT00099983|9602065|FG001|Overall Study|Other psychiatric problem|0
6008981|NCT00099983|9602064|FG000|Overall Study|Incarcerated|0
6008982|NCT00099983|9602065|FG001|Overall Study|Incarcerated|1
6074820|NCT00576472|9678969|FG007|MPH In-Lab Phase|Psychiatric exclusion|0
6074821|NCT00576472|9678970|FG008|MPH In-Lab Phase|Psychiatric exclusion|0
6008983|NCT00099983|9602064|FG000|Overall Study|Intolerant of burden of visits|0
6008984|NCT00099983|9602065|FG001|Overall Study|Intolerant of burden of visits|1
6008985|NCT00099983|9602064|FG000|Overall Study|Other issue|1
6008986|NCT00099983|9602065|FG001|Overall Study|Other issue|0
6008987|NCT00100048|9602076|FG000|Cohort I & II-Combination Therapy Phase|Never Treated|2
6008988|NCT00100048|9602077|FG001|Cohort I & II-Combination Therapy Phase|Never Treated|0
6008989|NCT00100048|9602078|FG002|Cohort I & II-Combination Therapy Phase|Never Treated|0
6008990|NCT00100048|9602079|FG003|Cohort I & II-Combination Therapy Phase|Never Treated|0
6008991|NCT00100048|9602080|FG004|Cohort I & II-Combination Therapy Phase|Never Treated|0
6008992|NCT00100048|9602081|FG005|Cohort I & II-Combination Therapy Phase|Never Treated|1
6008993|NCT00100048|9602076|FG000|Cohort I & II-Combination Therapy Phase|Adverse Event|0
6008994|NCT00100048|9602077|FG001|Cohort I & II-Combination Therapy Phase|Adverse Event|1
6008995|NCT00100048|9602078|FG002|Cohort I & II-Combination Therapy Phase|Adverse Event|2
6008996|NCT00100048|9602079|FG003|Cohort I & II-Combination Therapy Phase|Adverse Event|0
6008997|NCT00100048|9602080|FG004|Cohort I & II-Combination Therapy Phase|Adverse Event|0
6008998|NCT00100048|9602081|FG005|Cohort I & II-Combination Therapy Phase|Adverse Event|1
6008999|NCT00100048|9602076|FG000|Cohort I & II-Combination Therapy Phase|Lack of Efficacy|1
6009000|NCT00100048|9602077|FG001|Cohort I & II-Combination Therapy Phase|Lack of Efficacy|3
6009001|NCT00100048|9602078|FG002|Cohort I & II-Combination Therapy Phase|Lack of Efficacy|0
6009002|NCT00100048|9602079|FG003|Cohort I & II-Combination Therapy Phase|Lack of Efficacy|0
6009003|NCT00100048|9602080|FG004|Cohort I & II-Combination Therapy Phase|Lack of Efficacy|0
6009004|NCT00100048|9602081|FG005|Cohort I & II-Combination Therapy Phase|Lack of Efficacy|2
6009005|NCT00100048|9602076|FG000|Cohort I & II-Combination Therapy Phase|Lost to Follow-up|2
6009006|NCT00100048|9602077|FG001|Cohort I & II-Combination Therapy Phase|Lost to Follow-up|1
6009007|NCT00100048|9602078|FG002|Cohort I & II-Combination Therapy Phase|Lost to Follow-up|3
6009008|NCT00100048|9602079|FG003|Cohort I & II-Combination Therapy Phase|Lost to Follow-up|2
6009009|NCT00100048|9602080|FG004|Cohort I & II-Combination Therapy Phase|Lost to Follow-up|0
6009010|NCT00100048|9602081|FG005|Cohort I & II-Combination Therapy Phase|Lost to Follow-up|3
6009011|NCT00100048|9602076|FG000|Cohort I & II-Combination Therapy Phase|Withdrawal by Subject|1
6009012|NCT00100048|9602077|FG001|Cohort I & II-Combination Therapy Phase|Withdrawal by Subject|2
6009013|NCT00100048|9602078|FG002|Cohort I & II-Combination Therapy Phase|Withdrawal by Subject|2
6009014|NCT00100048|9602079|FG003|Cohort I & II-Combination Therapy Phase|Withdrawal by Subject|5
6009015|NCT00100048|9602080|FG004|Cohort I & II-Combination Therapy Phase|Withdrawal by Subject|0
6009016|NCT00100048|9602081|FG005|Cohort I & II-Combination Therapy Phase|Withdrawal by Subject|4
6009017|NCT00100048|9602076|FG000|Cohort I & II-Combination Therapy Phase|Other Reason|7
6009018|NCT00100048|9602077|FG001|Cohort I & II-Combination Therapy Phase|Other Reason|1
6009019|NCT00100048|9602078|FG002|Cohort I & II-Combination Therapy Phase|Other Reason|4
6009020|NCT00100048|9602079|FG003|Cohort I & II-Combination Therapy Phase|Other Reason|2
6009021|NCT00100048|9602080|FG004|Cohort I & II-Combination Therapy Phase|Other Reason|0
6009022|NCT00100048|9602081|FG005|Cohort I & II-Combination Therapy Phase|Other Reason|0
6009023|NCT00100048|9602076|FG000|Cohort I & II-Combination Therapy Phase|Completed Base Study, Did Not Continue|1
6009024|NCT00100048|9602077|FG001|Cohort I & II-Combination Therapy Phase|Completed Base Study, Did Not Continue|1
6009025|NCT00100048|9602078|FG002|Cohort I & II-Combination Therapy Phase|Completed Base Study, Did Not Continue|2
6009026|NCT00100048|9602079|FG003|Cohort I & II-Combination Therapy Phase|Completed Base Study, Did Not Continue|0
6009027|NCT00100048|9602080|FG004|Cohort I & II-Combination Therapy Phase|Completed Base Study, Did Not Continue|0
6009028|NCT00100048|9602081|FG005|Cohort I & II-Combination Therapy Phase|Completed Base Study, Did Not Continue|2
6009029|NCT00100048|9602076|FG000|Cohort I & II-Combination Therapy Phase|Laboratory Adverse Experience|0
6009030|NCT00100048|9602077|FG001|Cohort I & II-Combination Therapy Phase|Laboratory Adverse Experience|0
6009031|NCT00100048|9602078|FG002|Cohort I & II-Combination Therapy Phase|Laboratory Adverse Experience|0
6009032|NCT00100048|9602079|FG003|Cohort I & II-Combination Therapy Phase|Laboratory Adverse Experience|1
6009033|NCT00100048|9602080|FG004|Cohort I & II-Combination Therapy Phase|Laboratory Adverse Experience|0
6009034|NCT00100048|9602081|FG005|Cohort I & II-Combination Therapy Phase|Laboratory Adverse Experience|0
6009035|NCT00100178|9602125|FG000|Overall Study|Lost to Follow-up|0
6009036|NCT00100178|9602126|FG001|Overall Study|Lost to Follow-up|6
6009037|NCT00100178|9602127|FG002|Overall Study|Lost to Follow-up|5
6009038|NCT00100178|9602125|FG000|Overall Study|Adverse Event|2
6009039|NCT00100178|9602126|FG001|Overall Study|Adverse Event|2
6009040|NCT00100178|9602127|FG002|Overall Study|Adverse Event|1
6009041|NCT00100178|9602125|FG000|Overall Study|Withdrawal by Subject|1
6009042|NCT00100178|9602126|FG001|Overall Study|Withdrawal by Subject|1
6009043|NCT00100178|9602127|FG002|Overall Study|Withdrawal by Subject|1
6009044|NCT00100178|9602125|FG000|Overall Study|Physician Decision|6
6009045|NCT00100178|9602126|FG001|Overall Study|Physician Decision|1
6009046|NCT00100178|9602127|FG002|Overall Study|Physician Decision|3
6074822|NCT00576472|9678971|FG009|MPH In-Lab Phase|Psychiatric exclusion|0
6074823|NCT00576472|9678972|FG010|MPH In-Lab Phase|Psychiatric exclusion|0
6074824|NCT00576472|9678973|FG011|MPH In-Lab Phase|Psychiatric exclusion|0
6074825|NCT00576472|9678974|FG012|MPH In-Lab Phase|Psychiatric exclusion|0
6009047|NCT00100789|9602166|FG000|Overall Study|Adverse Event|10
6009048|NCT00100789|9602166|FG000|Overall Study|Withdrawal by Subject|1
6009049|NCT00100789|9602166|FG000|Overall Study|Progression/relapse|42
6009050|NCT00100789|9602166|FG000|Overall Study|Death|2
6009051|NCT00100789|9602166|FG000|Overall Study|Not protocol specified|5
6009052|NCT00100789|9602166|FG000|Overall Study|Ineligible|3
6009053|NCT00100789|9602166|FG000|Overall Study|Never received treatment|1
6009054|NCT00100802|9602171|FG000|Overall Study|Adverse Event|9
6009055|NCT00100802|9602171|FG000|Overall Study|Death|1
6009056|NCT00100802|9602171|FG000|Overall Study|Lack of Efficacy|47
6009057|NCT00100802|9602171|FG000|Overall Study|Physician Decision|5
6009058|NCT00100802|9602171|FG000|Overall Study|Protocol Violation|1
6009059|NCT00100802|9602171|FG000|Overall Study|Withdrawal by Subject|5
6009060|NCT00100802|9602171|FG000|Overall Study|Ineligible|12
6009061|NCT00100815|9602175|FG000|Overall Study|Progression|24
6009062|NCT00100815|9602175|FG000|Overall Study|Adverse Event|18
6009063|NCT00100815|9602175|FG000|Overall Study|Death|4
6009064|NCT00100815|9602175|FG000|Overall Study|Other|3
6009065|NCT00100932|9602185|FG000|Overall Study|Adverse Event|11
6009066|NCT00100932|9602186|FG001|Overall Study|Adverse Event|2
6009067|NCT00100932|9602185|FG000|Overall Study|Withdrawal by Subject|6
6009068|NCT00100932|9602186|FG001|Overall Study|Withdrawal by Subject|0
6009069|NCT00100932|9602185|FG000|Overall Study|Progressive Disease|44
6009070|NCT00100932|9602186|FG001|Overall Study|Progressive Disease|18
6009071|NCT00100932|9602185|FG000|Overall Study|Physician Decision|7
6009072|NCT00100932|9602186|FG001|Overall Study|Physician Decision|5
6009073|NCT00100932|9602185|FG000|Overall Study|Other|5
6009074|NCT00100932|9602186|FG001|Overall Study|Other|2
6009075|NCT00101010|9602192|FG000|Overall Study|Physician Decision|1
6009076|NCT00101101|9602205|FG000|Overall Study|never received vaccine|20
6009077|NCT00101166|9602209|FG000|Overall Study|progressive disease|10
6009078|NCT00101192|9602213|FG000|Overall Study|Ineligible|6
6009079|NCT00101192|9602213|FG000|Overall Study|Inevaluable|1
6009080|NCT00101283|9602219|FG000|Overall Study|Withdrawal by Subject|0
6009081|NCT00101283|9602220|FG001|Overall Study|Withdrawal by Subject|1
6009082|NCT00101283|9602219|FG000|Overall Study|Insurance Refusal|0
6009083|NCT00101283|9602220|FG001|Overall Study|Insurance Refusal|1
6009084|NCT00101283|9602219|FG000|Overall Study|Prostate Cancer Recurrence|0
6074826|NCT00576472|9678975|FG013|MPH In-Lab Phase|Psychiatric exclusion|0
6074827|NCT00576472|9678976|FG014|MPH In-Lab Phase|Psychiatric exclusion|0
6074828|NCT00576472|9678962|FG000|MPH Cross Over Phase|Withdrawal by Subject|0
6074829|NCT00576472|9678963|FG001|MPH Cross Over Phase|Withdrawal by Subject|0
6074830|NCT00576472|9678964|FG002|MPH Cross Over Phase|Withdrawal by Subject|0
6074831|NCT00576472|9678965|FG003|MPH Cross Over Phase|Withdrawal by Subject|0
6074832|NCT00576472|9678966|FG004|MPH Cross Over Phase|Withdrawal by Subject|0
6074833|NCT00576472|9678967|FG005|MPH Cross Over Phase|Withdrawal by Subject|0
6074834|NCT00576472|9678968|FG006|MPH Cross Over Phase|Withdrawal by Subject|6
6074835|NCT00576472|9678969|FG007|MPH Cross Over Phase|Withdrawal by Subject|0
6074836|NCT00576472|9678970|FG008|MPH Cross Over Phase|Withdrawal by Subject|0
6074837|NCT00576472|9678971|FG009|MPH Cross Over Phase|Withdrawal by Subject|0
6074838|NCT00576472|9678972|FG010|MPH Cross Over Phase|Withdrawal by Subject|0
6074839|NCT00576472|9678973|FG011|MPH Cross Over Phase|Withdrawal by Subject|0
6074840|NCT00576472|9678974|FG012|MPH Cross Over Phase|Withdrawal by Subject|0
6074841|NCT00576472|9678975|FG013|MPH Cross Over Phase|Withdrawal by Subject|0
6074842|NCT00576472|9678976|FG014|MPH Cross Over Phase|Withdrawal by Subject|0
6074843|NCT00576472|9678962|FG000|MPH Cross Over Phase|Ineligible due to disease|0
6074844|NCT00576472|9678963|FG001|MPH Cross Over Phase|Ineligible due to disease|0
6074845|NCT00576472|9678964|FG002|MPH Cross Over Phase|Ineligible due to disease|0
6074846|NCT00576472|9678965|FG003|MPH Cross Over Phase|Ineligible due to disease|0
6074847|NCT00576472|9678966|FG004|MPH Cross Over Phase|Ineligible due to disease|0
6074848|NCT00576472|9678967|FG005|MPH Cross Over Phase|Ineligible due to disease|0
6074849|NCT00576472|9678968|FG006|MPH Cross Over Phase|Ineligible due to disease|2
6074850|NCT00576472|9678969|FG007|MPH Cross Over Phase|Ineligible due to disease|0
6009085|NCT00101283|9602220|FG001|Overall Study|Prostate Cancer Recurrence|1
6009086|NCT00101400|9602235|FG000|Survival Follow-Up|Alive|7
6047405|NCT00410514|9646313|FG000|Overall Study|Adverse Event|2
6047406|NCT00410514|9646314|FG001|Overall Study|Adverse Event|2
6047407|NCT00410514|9646315|FG002|Overall Study|Adverse Event|2
6047408|NCT00410514|9646313|FG000|Overall Study|Protocol Violation|0
6047409|NCT00410514|9646314|FG001|Overall Study|Protocol Violation|1
6047410|NCT00410514|9646315|FG002|Overall Study|Protocol Violation|1
6074851|NCT00576472|9678970|FG008|MPH Cross Over Phase|Ineligible due to disease|0
6047411|NCT00410514|9646313|FG000|Overall Study|Lost to Follow-up|0
6047412|NCT00410514|9646314|FG001|Overall Study|Lost to Follow-up|0
6047413|NCT00410514|9646315|FG002|Overall Study|Lost to Follow-up|2
6047414|NCT00410514|9646313|FG000|Overall Study|Non-compliant with study procedures|0
6047415|NCT00410514|9646314|FG001|Overall Study|Non-compliant with study procedures|0
6047416|NCT00410514|9646315|FG002|Overall Study|Non-compliant with study procedures|2
6047417|NCT00410605|9646323|FG000|Overall Study|Adverse Event|12
6074852|NCT00576472|9678971|FG009|MPH Cross Over Phase|Ineligible due to disease|0
6074853|NCT00576472|9678972|FG010|MPH Cross Over Phase|Ineligible due to disease|0
6074854|NCT00576472|9678973|FG011|MPH Cross Over Phase|Ineligible due to disease|0
6009087|NCT00101452|9602246|FG000|Overall Study|Adverse Event|2
6009088|NCT00101452|9602247|FG001|Overall Study|Adverse Event|0
6009089|NCT00101452|9602248|FG002|Overall Study|Adverse Event|1
6009090|NCT00101452|9602246|FG000|Overall Study|Lost to Follow-up|13
6009091|NCT00101452|9602247|FG001|Overall Study|Lost to Follow-up|8
6009092|NCT00101452|9602248|FG002|Overall Study|Lost to Follow-up|14
6009093|NCT00101452|9602246|FG000|Overall Study|Withdrawal by Subject|10
6009094|NCT00101452|9602247|FG001|Overall Study|Withdrawal by Subject|14
6009095|NCT00101452|9602248|FG002|Overall Study|Withdrawal by Subject|9
6009096|NCT00101452|9602246|FG000|Overall Study|Baseline Fail|2
6009097|NCT00101452|9602247|FG001|Overall Study|Baseline Fail|1
6009098|NCT00101452|9602248|FG002|Overall Study|Baseline Fail|2
6009099|NCT00101452|9602246|FG000|Overall Study|Physician Decision|0
6009100|NCT00101452|9602247|FG001|Overall Study|Physician Decision|3
6009101|NCT00101452|9602248|FG002|Overall Study|Physician Decision|2
6009102|NCT00101452|9602246|FG000|Overall Study|Protocol Violation|2
6009103|NCT00101452|9602247|FG001|Overall Study|Protocol Violation|1
6074855|NCT00576472|9678974|FG012|MPH Cross Over Phase|Ineligible due to disease|0
6074856|NCT00576472|9678975|FG013|MPH Cross Over Phase|Ineligible due to disease|0
6074857|NCT00576472|9678976|FG014|MPH Cross Over Phase|Ineligible due to disease|0
6074858|NCT00576472|9678962|FG000|MPH Cross Over Phase|Physician Decision|0
6074859|NCT00576472|9678963|FG001|MPH Cross Over Phase|Physician Decision|0
6074860|NCT00576472|9678964|FG002|MPH Cross Over Phase|Physician Decision|0
6074861|NCT00576472|9678965|FG003|MPH Cross Over Phase|Physician Decision|0
6074862|NCT00576472|9678966|FG004|MPH Cross Over Phase|Physician Decision|0
6074863|NCT00576472|9678967|FG005|MPH Cross Over Phase|Physician Decision|0
6074864|NCT00576472|9678968|FG006|MPH Cross Over Phase|Physician Decision|4
6074865|NCT00576472|9678969|FG007|MPH Cross Over Phase|Physician Decision|0
6074866|NCT00576472|9678970|FG008|MPH Cross Over Phase|Physician Decision|0
6074867|NCT00576472|9678971|FG009|MPH Cross Over Phase|Physician Decision|0
6074868|NCT00576472|9678972|FG010|MPH Cross Over Phase|Physician Decision|0
6074869|NCT00576472|9678973|FG011|MPH Cross Over Phase|Physician Decision|0
6074870|NCT00576472|9678974|FG012|MPH Cross Over Phase|Physician Decision|0
6074871|NCT00576472|9678975|FG013|MPH Cross Over Phase|Physician Decision|0
6074872|NCT00576472|9678976|FG014|MPH Cross Over Phase|Physician Decision|0
6074873|NCT00576472|9678962|FG000|MPH Cross Over Phase|Did not complete cross over phase|0
6074874|NCT00576472|9678963|FG001|MPH Cross Over Phase|Did not complete cross over phase|0
6074875|NCT00576472|9678964|FG002|MPH Cross Over Phase|Did not complete cross over phase|0
6074876|NCT00576472|9678965|FG003|MPH Cross Over Phase|Did not complete cross over phase|0
6074877|NCT00576472|9678966|FG004|MPH Cross Over Phase|Did not complete cross over phase|0
6074878|NCT00576472|9678967|FG005|MPH Cross Over Phase|Did not complete cross over phase|0
6074879|NCT00576472|9678968|FG006|MPH Cross Over Phase|Did not complete cross over phase|0
6074880|NCT00576472|9678969|FG007|MPH Cross Over Phase|Did not complete cross over phase|0
6074881|NCT00576472|9678970|FG008|MPH Cross Over Phase|Did not complete cross over phase|2
6074882|NCT00576472|9678971|FG009|MPH Cross Over Phase|Did not complete cross over phase|0
6074883|NCT00576472|9678972|FG010|MPH Cross Over Phase|Did not complete cross over phase|1
6074884|NCT00576472|9678973|FG011|MPH Cross Over Phase|Did not complete cross over phase|1
6074885|NCT00576472|9678974|FG012|MPH Cross Over Phase|Did not complete cross over phase|0
6074886|NCT00576472|9678975|FG013|MPH Cross Over Phase|Did not complete cross over phase|0
6074887|NCT00576472|9678976|FG014|MPH Cross Over Phase|Did not complete cross over phase|0
6074888|NCT00576472|9678962|FG000|MPH Home Maintenance Phase|Did not meet response criteria|0
6074889|NCT00576472|9678963|FG001|MPH Home Maintenance Phase|Did not meet response criteria|0
6074890|NCT00576472|9678964|FG002|MPH Home Maintenance Phase|Did not meet response criteria|0
6074891|NCT00576472|9678965|FG003|MPH Home Maintenance Phase|Did not meet response criteria|0
6074892|NCT00576472|9678966|FG004|MPH Home Maintenance Phase|Did not meet response criteria|0
6074893|NCT00576472|9678967|FG005|MPH Home Maintenance Phase|Did not meet response criteria|0
6074894|NCT00576472|9678968|FG006|MPH Home Maintenance Phase|Did not meet response criteria|0
6074895|NCT00576472|9678969|FG007|MPH Home Maintenance Phase|Did not meet response criteria|0
6074896|NCT00576472|9678970|FG008|MPH Home Maintenance Phase|Did not meet response criteria|0
6074897|NCT00576472|9678971|FG009|MPH Home Maintenance Phase|Did not meet response criteria|0
6074898|NCT00576472|9678972|FG010|MPH Home Maintenance Phase|Did not meet response criteria|0
6074899|NCT00576472|9678973|FG011|MPH Home Maintenance Phase|Did not meet response criteria|0
6074900|NCT00576472|9678974|FG012|MPH Home Maintenance Phase|Did not meet response criteria|0
6074901|NCT00576472|9678975|FG013|MPH Home Maintenance Phase|Did not meet response criteria|16
6074902|NCT00576472|9678976|FG014|MPH Home Maintenance Phase|Did not meet response criteria|0
6074903|NCT00576472|9678962|FG000|MPH Home Maintenance Phase|Declined to participate|0
6074904|NCT00576472|9678963|FG001|MPH Home Maintenance Phase|Declined to participate|0
6009104|NCT00101452|9602248|FG002|Overall Study|Protocol Violation|3
6009105|NCT00101452|9602246|FG000|Overall Study|Other|15
6009106|NCT00101452|9602247|FG001|Overall Study|Other|16
6074905|NCT00576472|9678964|FG002|MPH Home Maintenance Phase|Declined to participate|0
6074906|NCT00576472|9678965|FG003|MPH Home Maintenance Phase|Declined to participate|0
6074907|NCT00576472|9678966|FG004|MPH Home Maintenance Phase|Declined to participate|0
6074908|NCT00576472|9678967|FG005|MPH Home Maintenance Phase|Declined to participate|0
6009107|NCT00101452|9602248|FG002|Overall Study|Other|12
6009108|NCT00101582|9602262|FG000|Overall Study|Ineligibility determined|0
6009109|NCT00101582|9602263|FG001|Overall Study|Ineligibility determined|1
6009110|NCT00101582|9602262|FG000|Overall Study|Adverse Event|1
6009111|NCT00101582|9602263|FG001|Overall Study|Adverse Event|4
6009112|NCT00101582|9602262|FG000|Overall Study|Withdrawal by Subject|6
6009113|NCT00101582|9602263|FG001|Overall Study|Withdrawal by Subject|4
6009114|NCT00101582|9602262|FG000|Overall Study|Physician Decision|1
6009115|NCT00101582|9602263|FG001|Overall Study|Physician Decision|0
6009116|NCT00101582|9602262|FG000|Overall Study|Death|3
6009117|NCT00101582|9602263|FG001|Overall Study|Death|5
6009118|NCT00101582|9602262|FG000|Overall Study|Other|0
6009119|NCT00101582|9602263|FG001|Overall Study|Other|1
6009120|NCT00101686|9602313|FG000|Overall Study|Progressive Disease|37
6009121|NCT00101686|9602314|FG001|Overall Study|Progressive Disease|28
6009122|NCT00101686|9602315|FG002|Overall Study|Progressive Disease|37
6009123|NCT00101686|9602316|FG003|Overall Study|Progressive Disease|38
6009124|NCT00101686|9602317|FG004|Overall Study|Progressive Disease|28
6009125|NCT00101686|9602318|FG005|Overall Study|Progressive Disease|25
6009126|NCT00101686|9602319|FG006|Overall Study|Progressive Disease|5
6009127|NCT00101686|9602320|FG007|Overall Study|Progressive Disease|7
6009128|NCT00101686|9602321|FG008|Overall Study|Progressive Disease|10
6009129|NCT00101686|9602322|FG009|Overall Study|Progressive Disease|8
6009130|NCT00101686|9602313|FG000|Overall Study|initiation other anti-cancer treatment|4
6009131|NCT00101686|9602314|FG001|Overall Study|initiation other anti-cancer treatment|3
6009132|NCT00101686|9602315|FG002|Overall Study|initiation other anti-cancer treatment|4
6009133|NCT00101686|9602316|FG003|Overall Study|initiation other anti-cancer treatment|3
6009134|NCT00101686|9602317|FG004|Overall Study|initiation other anti-cancer treatment|1
6009135|NCT00101686|9602318|FG005|Overall Study|initiation other anti-cancer treatment|1
6009136|NCT00101686|9602319|FG006|Overall Study|initiation other anti-cancer treatment|2
6009137|NCT00101686|9602320|FG007|Overall Study|initiation other anti-cancer treatment|2
6009138|NCT00101686|9602321|FG008|Overall Study|initiation other anti-cancer treatment|3
6009139|NCT00101686|9602322|FG009|Overall Study|initiation other anti-cancer treatment|3
6009140|NCT00101686|9602313|FG000|Overall Study|>3 week delay treatment due toxicity|6
6009141|NCT00101686|9602314|FG001|Overall Study|>3 week delay treatment due toxicity|2
6009142|NCT00101686|9602315|FG002|Overall Study|>3 week delay treatment due toxicity|1
6009143|NCT00101686|9602316|FG003|Overall Study|>3 week delay treatment due toxicity|2
6009144|NCT00101686|9602317|FG004|Overall Study|>3 week delay treatment due toxicity|7
6009145|NCT00101686|9602318|FG005|Overall Study|>3 week delay treatment due toxicity|3
6009146|NCT00101686|9602319|FG006|Overall Study|>3 week delay treatment due toxicity|2
6009147|NCT00101686|9602320|FG007|Overall Study|>3 week delay treatment due toxicity|1
6009148|NCT00101686|9602321|FG008|Overall Study|>3 week delay treatment due toxicity|3
6009149|NCT00101686|9602322|FG009|Overall Study|>3 week delay treatment due toxicity|0
6009150|NCT00101686|9602313|FG000|Overall Study|unacceptable toxicity|3
6009151|NCT00101686|9602314|FG001|Overall Study|unacceptable toxicity|9
6009152|NCT00101686|9602315|FG002|Overall Study|unacceptable toxicity|10
6009153|NCT00101686|9602316|FG003|Overall Study|unacceptable toxicity|6
6009154|NCT00101686|9602317|FG004|Overall Study|unacceptable toxicity|16
6009155|NCT00101686|9602318|FG005|Overall Study|unacceptable toxicity|10
6009156|NCT00101686|9602319|FG006|Overall Study|unacceptable toxicity|4
6009157|NCT00101686|9602320|FG007|Overall Study|unacceptable toxicity|2
6009158|NCT00101686|9602321|FG008|Overall Study|unacceptable toxicity|1
6009159|NCT00101686|9602322|FG009|Overall Study|unacceptable toxicity|4
6009160|NCT00101686|9602313|FG000|Overall Study|Randomized but did not receive treament|1
6009161|NCT00101686|9602314|FG001|Overall Study|Randomized but did not receive treament|6
6009162|NCT00101686|9602315|FG002|Overall Study|Randomized but did not receive treament|2
6009163|NCT00101686|9602316|FG003|Overall Study|Randomized but did not receive treament|2
6009164|NCT00101686|9602317|FG004|Overall Study|Randomized but did not receive treament|2
6009165|NCT00101686|9602318|FG005|Overall Study|Randomized but did not receive treament|2
6009166|NCT00101686|9602319|FG006|Overall Study|Randomized but did not receive treament|0
6009167|NCT00101686|9602320|FG007|Overall Study|Randomized but did not receive treament|1
6009168|NCT00101686|9602321|FG008|Overall Study|Randomized but did not receive treament|0
6009169|NCT00101686|9602322|FG009|Overall Study|Randomized but did not receive treament|1
6009170|NCT00101686|9602313|FG000|Overall Study|intercurrent non-cancer related illness|0
6009171|NCT00101686|9602314|FG001|Overall Study|intercurrent non-cancer related illness|0
6009172|NCT00101686|9602315|FG002|Overall Study|intercurrent non-cancer related illness|2
6009173|NCT00101686|9602316|FG003|Overall Study|intercurrent non-cancer related illness|0
6009174|NCT00101686|9602317|FG004|Overall Study|intercurrent non-cancer related illness|1
6009175|NCT00101686|9602318|FG005|Overall Study|intercurrent non-cancer related illness|3
6009176|NCT00101686|9602319|FG006|Overall Study|intercurrent non-cancer related illness|1
6009177|NCT00101686|9602320|FG007|Overall Study|intercurrent non-cancer related illness|0
6009178|NCT00101686|9602321|FG008|Overall Study|intercurrent non-cancer related illness|1
6009179|NCT00101686|9602322|FG009|Overall Study|intercurrent non-cancer related illness|1
6009180|NCT00101686|9602313|FG000|Overall Study|Physician Decision|10
6009181|NCT00101686|9602314|FG001|Overall Study|Physician Decision|13
6074909|NCT00576472|9678968|FG006|MPH Home Maintenance Phase|Declined to participate|0
6074910|NCT00576472|9678969|FG007|MPH Home Maintenance Phase|Declined to participate|0
6009182|NCT00101686|9602315|FG002|Overall Study|Physician Decision|6
6009183|NCT00101686|9602316|FG003|Overall Study|Physician Decision|7
6009184|NCT00101686|9602317|FG004|Overall Study|Physician Decision|8
6009185|NCT00101686|9602318|FG005|Overall Study|Physician Decision|9
6009186|NCT00101686|9602319|FG006|Overall Study|Physician Decision|5
6009187|NCT00101686|9602320|FG007|Overall Study|Physician Decision|5
6009188|NCT00101686|9602321|FG008|Overall Study|Physician Decision|1
6009189|NCT00101686|9602322|FG009|Overall Study|Physician Decision|1
6009190|NCT00101686|9602313|FG000|Overall Study|Other|1
6009191|NCT00101686|9602314|FG001|Overall Study|Other|4
6009192|NCT00101686|9602315|FG002|Overall Study|Other|1
6009193|NCT00101686|9602316|FG003|Overall Study|Other|6
6009194|NCT00101686|9602317|FG004|Overall Study|Other|2
6009195|NCT00101686|9602318|FG005|Overall Study|Other|12
6009196|NCT00101686|9602319|FG006|Overall Study|Other|1
6009197|NCT00101686|9602320|FG007|Overall Study|Other|5
6009198|NCT00101686|9602321|FG008|Overall Study|Other|3
6009199|NCT00101686|9602322|FG009|Overall Study|Other|3
6009200|NCT00101686|9602313|FG000|Overall Study|Withdrawal by Subject|9
6009201|NCT00101686|9602314|FG001|Overall Study|Withdrawal by Subject|8
6009202|NCT00101686|9602315|FG002|Overall Study|Withdrawal by Subject|6
6009203|NCT00101686|9602316|FG003|Overall Study|Withdrawal by Subject|8
6009204|NCT00101686|9602317|FG004|Overall Study|Withdrawal by Subject|8
6009205|NCT00101686|9602318|FG005|Overall Study|Withdrawal by Subject|7
6009206|NCT00101686|9602319|FG006|Overall Study|Withdrawal by Subject|7
6009207|NCT00101686|9602320|FG007|Overall Study|Withdrawal by Subject|7
6009208|NCT00101686|9602321|FG008|Overall Study|Withdrawal by Subject|8
6009209|NCT00101686|9602322|FG009|Overall Study|Withdrawal by Subject|9
6009210|NCT00101868|9602358|FG000|Overall Study|Death|10
6009211|NCT00101868|9602359|FG001|Overall Study|Death|10
6009212|NCT00101868|9602358|FG000|Overall Study|Withdrawal by Subject|8
6009213|NCT00101868|9602359|FG001|Overall Study|Withdrawal by Subject|9
6009214|NCT00101868|9602358|FG000|Overall Study|Protocol Violation|3
6009215|NCT00101868|9602359|FG001|Overall Study|Protocol Violation|0
6009216|NCT00101868|9602358|FG000|Overall Study|Lost to Follow-up|8
6009217|NCT00101868|9602359|FG001|Overall Study|Lost to Follow-up|13
6009218|NCT00101907|9602373|FG000|Overall Study|Adverse Event|1
6009219|NCT00101907|9602374|FG001|Overall Study|Adverse Event|0
6009220|NCT00101907|9602375|FG002|Overall Study|Adverse Event|0
6009221|NCT00101907|9602376|FG003|Overall Study|Adverse Event|0
6009222|NCT00101907|9602377|FG004|Overall Study|Adverse Event|0
6009223|NCT00101907|9602378|FG005|Overall Study|Adverse Event|0
6009224|NCT00101907|9602373|FG000|Overall Study|Death|0
6009225|NCT00101907|9602374|FG001|Overall Study|Death|1
6009226|NCT00101907|9602375|FG002|Overall Study|Death|0
6009227|NCT00101907|9602376|FG003|Overall Study|Death|0
6009228|NCT00101907|9602377|FG004|Overall Study|Death|3
6009229|NCT00101907|9602378|FG005|Overall Study|Death|0
6009230|NCT00101907|9602373|FG000|Overall Study|Physician Decision|0
6009231|NCT00101907|9602374|FG001|Overall Study|Physician Decision|0
6009232|NCT00101907|9602375|FG002|Overall Study|Physician Decision|0
6009233|NCT00101907|9602376|FG003|Overall Study|Physician Decision|1
6009234|NCT00101907|9602377|FG004|Overall Study|Physician Decision|1
6009235|NCT00101907|9602378|FG005|Overall Study|Physician Decision|0
6009236|NCT00101907|9602373|FG000|Overall Study|Withdrawal by Subject|1
6009237|NCT00101907|9602374|FG001|Overall Study|Withdrawal by Subject|0
6009238|NCT00101907|9602375|FG002|Overall Study|Withdrawal by Subject|1
6009239|NCT00101907|9602376|FG003|Overall Study|Withdrawal by Subject|0
6009240|NCT00101907|9602377|FG004|Overall Study|Withdrawal by Subject|1
6009241|NCT00101907|9602378|FG005|Overall Study|Withdrawal by Subject|0
6009242|NCT00102063|9602412|FG000|Overall Study|Lack of Efficacy|5
6009243|NCT00102063|9602413|FG001|Overall Study|Lack of Efficacy|1
6009244|NCT00102063|9602414|FG002|Overall Study|Lack of Efficacy|1
6009245|NCT00102063|9602412|FG000|Overall Study|Adverse Event|7
6009246|NCT00102063|9602413|FG001|Overall Study|Adverse Event|4
6009247|NCT00102063|9602414|FG002|Overall Study|Adverse Event|2
6009248|NCT00102063|9602412|FG000|Overall Study|Withdrawal by Subject|4
6009249|NCT00102063|9602413|FG001|Overall Study|Withdrawal by Subject|12
6009250|NCT00102063|9602414|FG002|Overall Study|Withdrawal by Subject|5
6009251|NCT00102063|9602412|FG000|Overall Study|Lost to Follow-up|0
6009252|NCT00102063|9602413|FG001|Overall Study|Lost to Follow-up|0
6009253|NCT00102063|9602414|FG002|Overall Study|Lost to Follow-up|1
6009254|NCT00102063|9602412|FG000|Overall Study|Protocol Violation|0
6009255|NCT00102063|9602413|FG001|Overall Study|Protocol Violation|1
6009256|NCT00102063|9602414|FG002|Overall Study|Protocol Violation|1
6009257|NCT00102440|9602425|FG000|Overall Study|Lost to Follow-up|25
6009258|NCT00102440|9602426|FG001|Overall Study|Lost to Follow-up|18
6009259|NCT00102440|9602427|FG002|Overall Study|Lost to Follow-up|21
6009260|NCT00102440|9602425|FG000|Overall Study|Adverse Event|16
6009261|NCT00102440|9602426|FG001|Overall Study|Adverse Event|23
6009262|NCT00102440|9602427|FG002|Overall Study|Adverse Event|8
6009263|NCT00102440|9602425|FG000|Overall Study|Gout Flare|10
6009264|NCT00102440|9602426|FG001|Overall Study|Gout Flare|28
6009265|NCT00102440|9602427|FG002|Overall Study|Gout Flare|9
6009266|NCT00102440|9602425|FG000|Overall Study|Personal Reason(s)|19
6009267|NCT00102440|9602426|FG001|Overall Study|Personal Reason(s)|13
6009268|NCT00102440|9602427|FG002|Overall Study|Personal Reason(s)|13
6009269|NCT00102440|9602425|FG000|Overall Study|Other|11
6009270|NCT00102440|9602426|FG001|Overall Study|Other|14
6009271|NCT00102440|9602427|FG002|Overall Study|Other|14
6009272|NCT00102440|9602425|FG000|Overall Study|Protocol Violation|7
6009273|NCT00102440|9602426|FG001|Overall Study|Protocol Violation|2
6009274|NCT00102440|9602427|FG002|Overall Study|Protocol Violation|1
6009275|NCT00102531|9602441|FG000|Overall Study|Adverse Event|0
6009276|NCT00102531|9602442|FG001|Overall Study|Adverse Event|1
6009277|NCT00102531|9602441|FG000|Overall Study|Disease Progression|5
6009278|NCT00102531|9602442|FG001|Overall Study|Disease Progression|9
6009279|NCT00102531|9602441|FG000|Overall Study|Physician Decision|0
6009280|NCT00102531|9602442|FG001|Overall Study|Physician Decision|1
6009281|NCT00102596|9602448|FG000|Part A|Screen failures|6
6009282|NCT00102596|9602449|FG001|Part A|Screen failures|0
6009283|NCT00102596|9602448|FG000|Part A|Adverse Event|1
6009284|NCT00102596|9602449|FG001|Part A|Adverse Event|0
6009285|NCT00102687|9602459|FG000|Initial Period|Withdrawal by Subject|6
6009286|NCT00102687|9602460|FG001|Initial Period|Withdrawal by Subject|3
6009287|NCT00102687|9602461|FG002|Initial Period|Withdrawal by Subject|5
6009288|NCT00102687|9602462|FG003|Initial Period|Withdrawal by Subject|0
6009289|NCT00102687|9602463|FG004|Initial Period|Withdrawal by Subject|0
6009290|NCT00102687|9602459|FG000|Initial Period|Adverse Event|4
6009291|NCT00102687|9602460|FG001|Initial Period|Adverse Event|7
6009292|NCT00102687|9602461|FG002|Initial Period|Adverse Event|9
6009293|NCT00102687|9602462|FG003|Initial Period|Adverse Event|0
6009294|NCT00102687|9602463|FG004|Initial Period|Adverse Event|0
6009295|NCT00102687|9602459|FG000|Initial Period|Transformation to AML (blast > 30%)|1
6009296|NCT00102687|9602460|FG001|Initial Period|Transformation to AML (blast > 30%)|3
6009297|NCT00102687|9602461|FG002|Initial Period|Transformation to AML (blast > 30%)|0
6009298|NCT00102687|9602462|FG003|Initial Period|Transformation to AML (blast > 30%)|0
6009299|NCT00102687|9602463|FG004|Initial Period|Transformation to AML (blast > 30%)|0
6009300|NCT00102687|9602459|FG000|Initial Period|Protocol Violation|0
6009301|NCT00102687|9602460|FG001|Initial Period|Protocol Violation|0
6009302|NCT00102687|9602461|FG002|Initial Period|Protocol Violation|2
6009303|NCT00102687|9602462|FG003|Initial Period|Protocol Violation|0
6009304|NCT00102687|9602463|FG004|Initial Period|Protocol Violation|0
6009305|NCT00102687|9602459|FG000|Initial Period|Physician Decision|2
6009306|NCT00102687|9602460|FG001|Initial Period|Physician Decision|9
6009307|NCT00102687|9602461|FG002|Initial Period|Physician Decision|6
6009308|NCT00102687|9602462|FG003|Initial Period|Physician Decision|0
6009309|NCT00102687|9602463|FG004|Initial Period|Physician Decision|0
6009310|NCT00102687|9602459|FG000|Initial Period|Sponsor's decision|0
6009311|NCT00102687|9602460|FG001|Initial Period|Sponsor's decision|1
6009312|NCT00102687|9602461|FG002|Initial Period|Sponsor's decision|1
6009313|NCT00102687|9602462|FG003|Initial Period|Sponsor's decision|0
6009314|NCT00102687|9602463|FG004|Initial Period|Sponsor's decision|0
6009315|NCT00102687|9602459|FG000|Initial Period|Failed Treatments (relapse,disease prog)|4
6009316|NCT00102687|9602460|FG001|Initial Period|Failed Treatments (relapse,disease prog)|4
6009317|NCT00102687|9602461|FG002|Initial Period|Failed Treatments (relapse,disease prog)|2
6074911|NCT00576472|9678970|FG008|MPH Home Maintenance Phase|Declined to participate|0
6074912|NCT00576472|9678971|FG009|MPH Home Maintenance Phase|Declined to participate|0
6074913|NCT00576472|9678972|FG010|MPH Home Maintenance Phase|Declined to participate|0
6074914|NCT00576472|9678973|FG011|MPH Home Maintenance Phase|Declined to participate|0
6074915|NCT00576472|9678974|FG012|MPH Home Maintenance Phase|Declined to participate|0
6074916|NCT00576472|9678975|FG013|MPH Home Maintenance Phase|Declined to participate|7
6074917|NCT00576472|9678976|FG014|MPH Home Maintenance Phase|Declined to participate|0
6074918|NCT00576472|9678962|FG000|MPH Home Maintenance Phase|Insufficient data|0
6074919|NCT00576472|9678963|FG001|MPH Home Maintenance Phase|Insufficient data|0
6074920|NCT00576472|9678964|FG002|MPH Home Maintenance Phase|Insufficient data|0
6074921|NCT00576472|9678965|FG003|MPH Home Maintenance Phase|Insufficient data|0
6074922|NCT00576472|9678966|FG004|MPH Home Maintenance Phase|Insufficient data|0
6074923|NCT00576472|9678967|FG005|MPH Home Maintenance Phase|Insufficient data|0
6074924|NCT00576472|9678968|FG006|MPH Home Maintenance Phase|Insufficient data|0
6074925|NCT00576472|9678969|FG007|MPH Home Maintenance Phase|Insufficient data|0
6074926|NCT00576472|9678970|FG008|MPH Home Maintenance Phase|Insufficient data|0
6074927|NCT00576472|9678971|FG009|MPH Home Maintenance Phase|Insufficient data|0
6074928|NCT00576472|9678972|FG010|MPH Home Maintenance Phase|Insufficient data|0
6074929|NCT00576472|9678973|FG011|MPH Home Maintenance Phase|Insufficient data|0
6074930|NCT00576472|9678974|FG012|MPH Home Maintenance Phase|Insufficient data|0
6074931|NCT00576472|9678975|FG013|MPH Home Maintenance Phase|Insufficient data|4
6074932|NCT00576472|9678976|FG014|MPH Home Maintenance Phase|Insufficient data|0
6074933|NCT00576472|9678962|FG000|MPH Home Maintenance Phase|Side effects|0
6074934|NCT00576472|9678963|FG001|MPH Home Maintenance Phase|Side effects|0
6074935|NCT00576472|9678964|FG002|MPH Home Maintenance Phase|Side effects|0
6074936|NCT00576472|9678965|FG003|MPH Home Maintenance Phase|Side effects|0
6074937|NCT00576472|9678966|FG004|MPH Home Maintenance Phase|Side effects|0
6074938|NCT00576472|9678967|FG005|MPH Home Maintenance Phase|Side effects|0
6009318|NCT00102687|9602462|FG003|Initial Period|Failed Treatments (relapse,disease prog)|0
6009319|NCT00102687|9602463|FG004|Initial Period|Failed Treatments (relapse,disease prog)|0
6009320|NCT00102687|9602459|FG000|Initial Period|Death|1
6009321|NCT00102687|9602460|FG001|Initial Period|Death|1
6009322|NCT00102687|9602461|FG002|Initial Period|Death|1
6009323|NCT00102687|9602462|FG003|Initial Period|Death|0
6009324|NCT00102687|9602463|FG004|Initial Period|Death|0
6009325|NCT00102687|9602459|FG000|Maintenance Period|Withdrawal by Subject|4
6009326|NCT00102687|9602460|FG001|Maintenance Period|Withdrawal by Subject|0
6009327|NCT00102687|9602461|FG002|Maintenance Period|Withdrawal by Subject|2
6009328|NCT00102687|9602462|FG003|Maintenance Period|Withdrawal by Subject|3
6009329|NCT00102687|9602463|FG004|Maintenance Period|Withdrawal by Subject|1
6009330|NCT00102687|9602459|FG000|Maintenance Period|Adverse Event|1
6009331|NCT00102687|9602460|FG001|Maintenance Period|Adverse Event|0
6009332|NCT00102687|9602461|FG002|Maintenance Period|Adverse Event|0
6009333|NCT00102687|9602462|FG003|Maintenance Period|Adverse Event|1
6009334|NCT00102687|9602463|FG004|Maintenance Period|Adverse Event|3
6009335|NCT00102687|9602459|FG000|Maintenance Period|Transformation to AML (blast > 30%)|0
6009336|NCT00102687|9602460|FG001|Maintenance Period|Transformation to AML (blast > 30%)|1
6009337|NCT00102687|9602461|FG002|Maintenance Period|Transformation to AML (blast > 30%)|0
6009338|NCT00102687|9602462|FG003|Maintenance Period|Transformation to AML (blast > 30%)|2
6009339|NCT00102687|9602463|FG004|Maintenance Period|Transformation to AML (blast > 30%)|0
6009340|NCT00102687|9602459|FG000|Maintenance Period|Failed Treatment (relapse,disease prog)|1
6009341|NCT00102687|9602460|FG001|Maintenance Period|Failed Treatment (relapse,disease prog)|1
6009342|NCT00102687|9602461|FG002|Maintenance Period|Failed Treatment (relapse,disease prog)|1
6009343|NCT00102687|9602462|FG003|Maintenance Period|Failed Treatment (relapse,disease prog)|3
6009344|NCT00102687|9602463|FG004|Maintenance Period|Failed Treatment (relapse,disease prog)|4
6009345|NCT00102687|9602459|FG000|Maintenance Period|Death|0
6009346|NCT00102687|9602460|FG001|Maintenance Period|Death|0
6009347|NCT00102687|9602461|FG002|Maintenance Period|Death|0
6009348|NCT00102687|9602462|FG003|Maintenance Period|Death|1
6009349|NCT00102687|9602463|FG004|Maintenance Period|Death|1
6009350|NCT00102687|9602459|FG000|Maintenance Period|Physician Decision|1
6009351|NCT00102687|9602460|FG001|Maintenance Period|Physician Decision|2
6009352|NCT00102687|9602461|FG002|Maintenance Period|Physician Decision|3
6009353|NCT00102687|9602462|FG003|Maintenance Period|Physician Decision|0
6009354|NCT00102687|9602463|FG004|Maintenance Period|Physician Decision|4
6009355|NCT00102804|9602481|FG000|Overall Study|Progressive Disease (PD)|307
6009356|NCT00102804|9602482|FG001|Overall Study|Progressive Disease (PD)|196
6009357|NCT00102804|9602481|FG000|Overall Study|Withdrawal by Subject|46
6009358|NCT00102804|9602482|FG001|Overall Study|Withdrawal by Subject|7
6009359|NCT00102804|9602481|FG000|Overall Study|Adverse Event|37
6009360|NCT00102804|9602482|FG001|Overall Study|Adverse Event|3
6009361|NCT00102804|9602481|FG000|Overall Study|Physician Decision|24
6009362|NCT00102804|9602482|FG001|Overall Study|Physician Decision|6
6009363|NCT00102804|9602481|FG000|Overall Study|Death|5
6009364|NCT00102804|9602482|FG001|Overall Study|Death|6
6009365|NCT00102804|9602481|FG000|Overall Study|Enrollment Criteria Not Met|6
6009366|NCT00102804|9602482|FG001|Overall Study|Enrollment Criteria Not Met|0
6009367|NCT00102804|9602481|FG000|Overall Study|Lost to Follow-up|4
6009368|NCT00102804|9602482|FG001|Overall Study|Lost to Follow-up|1
6009369|NCT00102804|9602481|FG000|Overall Study|Protocol Violation|2
6009370|NCT00102804|9602482|FG001|Overall Study|Protocol Violation|1
6009371|NCT00102804|9602481|FG000|Overall Study|Satisfactory Response|2
6009372|NCT00102804|9602482|FG001|Overall Study|Satisfactory Response|0
6009373|NCT00102804|9602481|FG000|Overall Study|Sponsor Decision|1
6009374|NCT00102804|9602482|FG001|Overall Study|Sponsor Decision|0
6009375|NCT00102804|9602481|FG000|Overall Study|Alive, Receiving Treatment|7
6009376|NCT00102804|9602482|FG001|Overall Study|Alive, Receiving Treatment|2
6009377|NCT00102960|9602491|FG000|Overall Study|Death|23
6009378|NCT00102960|9602492|FG001|Overall Study|Death|11
6009379|NCT00102960|9602493|FG002|Overall Study|Death|11
6009380|NCT00102960|9602491|FG000|Overall Study|Lost to Follow-up|6
6009381|NCT00102960|9602492|FG001|Overall Study|Lost to Follow-up|12
6009382|NCT00102960|9602493|FG002|Overall Study|Lost to Follow-up|16
6009383|NCT00102960|9602491|FG000|Overall Study|Withdrawal by Subject|1
6009384|NCT00102960|9602492|FG001|Overall Study|Withdrawal by Subject|0
6009385|NCT00102960|9602493|FG002|Overall Study|Withdrawal by Subject|1
6009386|NCT00103012|9602508|FG000|Overall Study|Withdrawal by Subject|2
6009387|NCT00103012|9602509|FG001|Overall Study|Withdrawal by Subject|1
6009388|NCT00103012|9602510|FG002|Overall Study|Withdrawal by Subject|2
6009389|NCT00103012|9602508|FG000|Overall Study|Pregnancy|1
6009390|NCT00103012|9602509|FG001|Overall Study|Pregnancy|0
6009391|NCT00103012|9602510|FG002|Overall Study|Pregnancy|0
6009392|NCT00103012|9602508|FG000|Overall Study|Adverse Event|0
6009393|NCT00103012|9602509|FG001|Overall Study|Adverse Event|0
6009394|NCT00103012|9602510|FG002|Overall Study|Adverse Event|1
6009395|NCT00103012|9602508|FG000|Overall Study|Subject non-compliant with medications|0
6009396|NCT00103012|9602509|FG001|Overall Study|Subject non-compliant with medications|0
6009397|NCT00103012|9602510|FG002|Overall Study|Subject non-compliant with medications|1
6009398|NCT00103142|9602524|FG000|Overall Study|Adverse Event|1
6009399|NCT00103142|9602525|FG001|Overall Study|Adverse Event|0
6009400|NCT00103142|9602524|FG000|Overall Study|Progression of disease|2
6009401|NCT00103142|9602525|FG001|Overall Study|Progression of disease|1
6009402|NCT00103207|9602537|FG000|Overall Study|Adverse Event|3
6009403|NCT00103207|9602537|FG000|Overall Study|Death|1
6009404|NCT00103207|9602537|FG000|Overall Study|Withdrawal by Subject|2
6009405|NCT00103207|9602537|FG000|Overall Study|Other complicating disease|1
6009406|NCT00103207|9602537|FG000|Overall Study|Ineligible|4
6009407|NCT00103207|9602537|FG000|Overall Study|Diagnosis of BAC not confirmed|27
6009408|NCT00103259|9602545|FG000|Overall Study|Death|3
6009409|NCT00103259|9602546|FG001|Overall Study|Death|2
6009410|NCT00103259|9602545|FG000|Overall Study|Withdrawal by Subject|2
6009411|NCT00103259|9602546|FG001|Overall Study|Withdrawal by Subject|3
6009412|NCT00103259|9602545|FG000|Overall Study|alternative therapy|1
6009413|NCT00103259|9602546|FG001|Overall Study|alternative therapy|0
6009414|NCT00103259|9602545|FG000|Overall Study|other (reasons were not specified)|2
6009415|NCT00103259|9602546|FG001|Overall Study|other (reasons were not specified)|1
6009416|NCT00103259|9602545|FG000|Overall Study|ineligible/no protocol therapy|4
6009417|NCT00103259|9602546|FG001|Overall Study|ineligible/no protocol therapy|6
6009418|NCT00103285|9602554|FG000|Induction|Adverse Event|14
6009419|NCT00103285|9602555|FG001|Induction|Adverse Event|0
6009420|NCT00103285|9602556|FG002|Induction|Adverse Event|0
6009421|NCT00103285|9602557|FG003|Induction|Adverse Event|0
6009422|NCT00103285|9602558|FG004|Induction|Adverse Event|0
6009423|NCT00103285|9602559|FG005|Induction|Adverse Event|0
6009424|NCT00103285|9602560|FG006|Induction|Adverse Event|0
6009425|NCT00103285|9602561|FG007|Induction|Adverse Event|0
6009426|NCT00103285|9602554|FG000|Induction|Death|24
6009427|NCT00103285|9602555|FG001|Induction|Death|0
6009428|NCT00103285|9602556|FG002|Induction|Death|0
6009429|NCT00103285|9602557|FG003|Induction|Death|0
6009430|NCT00103285|9602558|FG004|Induction|Death|0
6009431|NCT00103285|9602559|FG005|Induction|Death|0
6009432|NCT00103285|9602560|FG006|Induction|Death|0
6009433|NCT00103285|9602561|FG007|Induction|Death|0
6009434|NCT00103285|9602554|FG000|Induction|Physician Decision|103
6009435|NCT00103285|9602555|FG001|Induction|Physician Decision|0
6009436|NCT00103285|9602556|FG002|Induction|Physician Decision|0
6009437|NCT00103285|9602557|FG003|Induction|Physician Decision|0
6009438|NCT00103285|9602558|FG004|Induction|Physician Decision|0
6009439|NCT00103285|9602559|FG005|Induction|Physician Decision|0
6009440|NCT00103285|9602560|FG006|Induction|Physician Decision|0
6009441|NCT00103285|9602561|FG007|Induction|Physician Decision|0
6009442|NCT00103285|9602554|FG000|Induction|Withdrawal by Subject|1
6009443|NCT00103285|9602555|FG001|Induction|Withdrawal by Subject|0
6009444|NCT00103285|9602556|FG002|Induction|Withdrawal by Subject|0
6009445|NCT00103285|9602557|FG003|Induction|Withdrawal by Subject|0
6009446|NCT00103285|9602558|FG004|Induction|Withdrawal by Subject|0
6009447|NCT00103285|9602559|FG005|Induction|Withdrawal by Subject|0
6009448|NCT00103285|9602560|FG006|Induction|Withdrawal by Subject|0
6009449|NCT00103285|9602561|FG007|Induction|Withdrawal by Subject|0
6009450|NCT00103285|9602554|FG000|Induction|Ineligible|43
6009451|NCT00103285|9602555|FG001|Induction|Ineligible|0
6009452|NCT00103285|9602556|FG002|Induction|Ineligible|0
6009453|NCT00103285|9602557|FG003|Induction|Ineligible|0
6009454|NCT00103285|9602558|FG004|Induction|Ineligible|0
6009455|NCT00103285|9602559|FG005|Induction|Ineligible|0
6074939|NCT00576472|9678968|FG006|MPH Home Maintenance Phase|Side effects|0
6074940|NCT00576472|9678969|FG007|MPH Home Maintenance Phase|Side effects|0
6074941|NCT00576472|9678970|FG008|MPH Home Maintenance Phase|Side effects|0
6074942|NCT00576472|9678971|FG009|MPH Home Maintenance Phase|Side effects|0
6074943|NCT00576472|9678972|FG010|MPH Home Maintenance Phase|Side effects|0
6074944|NCT00576472|9678973|FG011|MPH Home Maintenance Phase|Side effects|0
6074945|NCT00576472|9678974|FG012|MPH Home Maintenance Phase|Side effects|0
6074946|NCT00576472|9678975|FG013|MPH Home Maintenance Phase|Side effects|0
6074947|NCT00576472|9678976|FG014|MPH Home Maintenance Phase|Side effects|8
6074948|NCT00576472|9678962|FG000|MPH Home Maintenance Phase|Withdrawal by Subject|0
6074949|NCT00576472|9678963|FG001|MPH Home Maintenance Phase|Withdrawal by Subject|0
6074950|NCT00576472|9678964|FG002|MPH Home Maintenance Phase|Withdrawal by Subject|0
6074951|NCT00576472|9678965|FG003|MPH Home Maintenance Phase|Withdrawal by Subject|0
6074952|NCT00576472|9678966|FG004|MPH Home Maintenance Phase|Withdrawal by Subject|0
6074953|NCT00576472|9678967|FG005|MPH Home Maintenance Phase|Withdrawal by Subject|0
6074954|NCT00576472|9678968|FG006|MPH Home Maintenance Phase|Withdrawal by Subject|0
6074955|NCT00576472|9678969|FG007|MPH Home Maintenance Phase|Withdrawal by Subject|0
6074956|NCT00576472|9678970|FG008|MPH Home Maintenance Phase|Withdrawal by Subject|0
6074957|NCT00576472|9678971|FG009|MPH Home Maintenance Phase|Withdrawal by Subject|0
6074958|NCT00576472|9678972|FG010|MPH Home Maintenance Phase|Withdrawal by Subject|0
6074959|NCT00576472|9678973|FG011|MPH Home Maintenance Phase|Withdrawal by Subject|0
6074960|NCT00576472|9678974|FG012|MPH Home Maintenance Phase|Withdrawal by Subject|0
6074961|NCT00576472|9678975|FG013|MPH Home Maintenance Phase|Withdrawal by Subject|0
6074962|NCT00576472|9678976|FG014|MPH Home Maintenance Phase|Withdrawal by Subject|6
6074963|NCT00576472|9678962|FG000|MPH Home Maintenance Phase|Medical reasons|0
6146253|NCT01076010|9780834|FG002|Overall Study|Treatment Interruption for > 2 Weeks|0
6009456|NCT00103285|9602560|FG006|Induction|Ineligible|0
6009457|NCT00103285|9602561|FG007|Induction|Ineligible|0
6009458|NCT00103285|9602554|FG000|Induction|Refusal|906
6009459|NCT00103285|9602555|FG001|Induction|Refusal|0
6009460|NCT00103285|9602556|FG002|Induction|Refusal|0
6009461|NCT00103285|9602557|FG003|Induction|Refusal|0
6009462|NCT00103285|9602558|FG004|Induction|Refusal|0
6009463|NCT00103285|9602559|FG005|Induction|Refusal|0
6009464|NCT00103285|9602560|FG006|Induction|Refusal|0
6009465|NCT00103285|9602561|FG007|Induction|Refusal|0
6009466|NCT00103285|9602554|FG000|Induction|Other|258
6009467|NCT00103285|9602555|FG001|Induction|Other|0
6009468|NCT00103285|9602556|FG002|Induction|Other|0
6009469|NCT00103285|9602557|FG003|Induction|Other|0
6009470|NCT00103285|9602558|FG004|Induction|Other|0
6074964|NCT00576472|9678963|FG001|MPH Home Maintenance Phase|Medical reasons|0
6074965|NCT00576472|9678964|FG002|MPH Home Maintenance Phase|Medical reasons|0
6074966|NCT00576472|9678965|FG003|MPH Home Maintenance Phase|Medical reasons|0
6074967|NCT00576472|9678966|FG004|MPH Home Maintenance Phase|Medical reasons|0
6074968|NCT00576472|9678967|FG005|MPH Home Maintenance Phase|Medical reasons|0
6074969|NCT00576472|9678968|FG006|MPH Home Maintenance Phase|Medical reasons|0
6074970|NCT00576472|9678969|FG007|MPH Home Maintenance Phase|Medical reasons|0
6009471|NCT00103285|9602559|FG005|Induction|Other|0
6009472|NCT00103285|9602560|FG006|Induction|Other|0
6009473|NCT00103285|9602561|FG007|Induction|Other|0
6009474|NCT00103285|9602554|FG000|Response Assignment|Adverse Event|0
6009475|NCT00103285|9602555|FG001|Response Assignment|Adverse Event|8
6009476|NCT00103285|9602556|FG002|Response Assignment|Adverse Event|3
6009477|NCT00103285|9602557|FG003|Response Assignment|Adverse Event|2
6009478|NCT00103285|9602558|FG004|Response Assignment|Adverse Event|3
6009479|NCT00103285|9602559|FG005|Response Assignment|Adverse Event|1
6009480|NCT00103285|9602560|FG006|Response Assignment|Adverse Event|1
6009481|NCT00103285|9602561|FG007|Response Assignment|Adverse Event|2
6009482|NCT00103285|9602554|FG000|Response Assignment|Death|0
6009483|NCT00103285|9602555|FG001|Response Assignment|Death|5
6009484|NCT00103285|9602556|FG002|Response Assignment|Death|2
6009485|NCT00103285|9602557|FG003|Response Assignment|Death|2
6009486|NCT00103285|9602558|FG004|Response Assignment|Death|3
6009487|NCT00103285|9602559|FG005|Response Assignment|Death|1
6009488|NCT00103285|9602560|FG006|Response Assignment|Death|0
6009489|NCT00103285|9602561|FG007|Response Assignment|Death|8
6009490|NCT00103285|9602554|FG000|Response Assignment|Lost to Follow-up|0
6009491|NCT00103285|9602555|FG001|Response Assignment|Lost to Follow-up|9
6009492|NCT00103285|9602556|FG002|Response Assignment|Lost to Follow-up|5
6009493|NCT00103285|9602557|FG003|Response Assignment|Lost to Follow-up|5
6009494|NCT00103285|9602558|FG004|Response Assignment|Lost to Follow-up|1
6009495|NCT00103285|9602559|FG005|Response Assignment|Lost to Follow-up|2
6009496|NCT00103285|9602560|FG006|Response Assignment|Lost to Follow-up|2
6009497|NCT00103285|9602561|FG007|Response Assignment|Lost to Follow-up|5
6009498|NCT00103285|9602554|FG000|Response Assignment|Physician Decision|0
6009499|NCT00103285|9602555|FG001|Response Assignment|Physician Decision|13
6009500|NCT00103285|9602556|FG002|Response Assignment|Physician Decision|14
6009501|NCT00103285|9602557|FG003|Response Assignment|Physician Decision|9
6009502|NCT00103285|9602558|FG004|Response Assignment|Physician Decision|13
6009503|NCT00103285|9602559|FG005|Response Assignment|Physician Decision|7
6009504|NCT00103285|9602560|FG006|Response Assignment|Physician Decision|4
6009505|NCT00103285|9602561|FG007|Response Assignment|Physician Decision|35
6009506|NCT00103285|9602554|FG000|Response Assignment|Protocol Violation|0
6009507|NCT00103285|9602555|FG001|Response Assignment|Protocol Violation|2
6009508|NCT00103285|9602556|FG002|Response Assignment|Protocol Violation|0
6009509|NCT00103285|9602557|FG003|Response Assignment|Protocol Violation|0
6009510|NCT00103285|9602558|FG004|Response Assignment|Protocol Violation|0
6009511|NCT00103285|9602559|FG005|Response Assignment|Protocol Violation|0
6009512|NCT00103285|9602560|FG006|Response Assignment|Protocol Violation|0
6074971|NCT00576472|9678970|FG008|MPH Home Maintenance Phase|Medical reasons|0
6074972|NCT00576472|9678971|FG009|MPH Home Maintenance Phase|Medical reasons|0
6074973|NCT00576472|9678972|FG010|MPH Home Maintenance Phase|Medical reasons|0
6074974|NCT00576472|9678973|FG011|MPH Home Maintenance Phase|Medical reasons|0
6074975|NCT00576472|9678974|FG012|MPH Home Maintenance Phase|Medical reasons|0
6074976|NCT00576472|9678975|FG013|MPH Home Maintenance Phase|Medical reasons|0
6074977|NCT00576472|9678976|FG014|MPH Home Maintenance Phase|Medical reasons|6
6074978|NCT00576472|9678962|FG000|MPH Home Maintenance Phase|Lost to Follow-up|0
6074979|NCT00576472|9678963|FG001|MPH Home Maintenance Phase|Lost to Follow-up|0
6074980|NCT00576472|9678964|FG002|MPH Home Maintenance Phase|Lost to Follow-up|0
6074981|NCT00576472|9678965|FG003|MPH Home Maintenance Phase|Lost to Follow-up|0
6074982|NCT00576472|9678966|FG004|MPH Home Maintenance Phase|Lost to Follow-up|0
6074983|NCT00576472|9678967|FG005|MPH Home Maintenance Phase|Lost to Follow-up|0
6074984|NCT00576472|9678968|FG006|MPH Home Maintenance Phase|Lost to Follow-up|0
6074985|NCT00576472|9678969|FG007|MPH Home Maintenance Phase|Lost to Follow-up|0
6074986|NCT00576472|9678970|FG008|MPH Home Maintenance Phase|Lost to Follow-up|0
6009513|NCT00103285|9602561|FG007|Response Assignment|Protocol Violation|0
6009514|NCT00103285|9602554|FG000|Response Assignment|Withdrawal by Subject|0
6009515|NCT00103285|9602555|FG001|Response Assignment|Withdrawal by Subject|4
6009516|NCT00103285|9602556|FG002|Response Assignment|Withdrawal by Subject|1
6074987|NCT00576472|9678971|FG009|MPH Home Maintenance Phase|Lost to Follow-up|0
6074988|NCT00576472|9678972|FG010|MPH Home Maintenance Phase|Lost to Follow-up|0
6009517|NCT00103285|9602557|FG003|Response Assignment|Withdrawal by Subject|1
6009518|NCT00103285|9602558|FG004|Response Assignment|Withdrawal by Subject|2
6009519|NCT00103285|9602559|FG005|Response Assignment|Withdrawal by Subject|2
6009520|NCT00103285|9602560|FG006|Response Assignment|Withdrawal by Subject|0
6009521|NCT00103285|9602561|FG007|Response Assignment|Withdrawal by Subject|2
6009522|NCT00103285|9602554|FG000|Response Assignment|Ineligible|0
6009523|NCT00103285|9602555|FG001|Response Assignment|Ineligible|8
6009524|NCT00103285|9602556|FG002|Response Assignment|Ineligible|6
6009525|NCT00103285|9602557|FG003|Response Assignment|Ineligible|2
6009526|NCT00103285|9602558|FG004|Response Assignment|Ineligible|0
6009527|NCT00103285|9602559|FG005|Response Assignment|Ineligible|3
6009528|NCT00103285|9602560|FG006|Response Assignment|Ineligible|1
6009529|NCT00103285|9602561|FG007|Response Assignment|Ineligible|5
6009530|NCT00103285|9602554|FG000|Response Assignment|Refusal|0
6009531|NCT00103285|9602555|FG001|Response Assignment|Refusal|53
6009532|NCT00103285|9602556|FG002|Response Assignment|Refusal|5
6009533|NCT00103285|9602557|FG003|Response Assignment|Refusal|3
6009534|NCT00103285|9602558|FG004|Response Assignment|Refusal|25
6009535|NCT00103285|9602559|FG005|Response Assignment|Refusal|15
6009536|NCT00103285|9602560|FG006|Response Assignment|Refusal|30
6009537|NCT00103285|9602561|FG007|Response Assignment|Refusal|10
6009538|NCT00103285|9602554|FG000|Response Assignment|Other|0
6009539|NCT00103285|9602555|FG001|Response Assignment|Other|30
6009540|NCT00103285|9602556|FG002|Response Assignment|Other|48
6009541|NCT00103285|9602557|FG003|Response Assignment|Other|38
6009542|NCT00103285|9602558|FG004|Response Assignment|Other|37
6009543|NCT00103285|9602559|FG005|Response Assignment|Other|17
6009544|NCT00103285|9602560|FG006|Response Assignment|Other|11
6009545|NCT00103285|9602561|FG007|Response Assignment|Other|53
6009546|NCT00103311|9602588|FG000|Overall Study|Lost to Follow-up|1
6009547|NCT00103311|9602589|FG001|Overall Study|Lost to Follow-up|0
6009548|NCT00103311|9602588|FG000|Overall Study|Withdrawal by Subject|2
6009549|NCT00103311|9602589|FG001|Overall Study|Withdrawal by Subject|1
6009550|NCT00103311|9602588|FG000|Overall Study|Adverse Event|1
6009551|NCT00103311|9602589|FG001|Overall Study|Adverse Event|0
6009552|NCT00103402|9602616|FG000|Overall Study|Adverse Event|3
6009553|NCT00103402|9602617|FG001|Overall Study|Adverse Event|4
6009554|NCT00103402|9602616|FG000|Overall Study|Lost to Follow-up|8
6009555|NCT00103402|9602617|FG001|Overall Study|Lost to Follow-up|7
6009556|NCT00103402|9602616|FG000|Overall Study|Dissatisfied/No longer interested|6
6009557|NCT00103402|9602617|FG001|Overall Study|Dissatisfied/No longer interested|6
6009558|NCT00103402|9602616|FG000|Overall Study|Personal constraints/Other|5
6009559|NCT00103402|9602617|FG001|Overall Study|Personal constraints/Other|0
6009560|NCT00103506|9602625|FG000|Overall Study|Study closed by sponsor|34
6009561|NCT00103506|9602626|FG001|Overall Study|Study closed by sponsor|37
6009562|NCT00103506|9602625|FG000|Overall Study|Death|257
6009563|NCT00103506|9602626|FG001|Overall Study|Death|253
6009564|NCT00103506|9602625|FG000|Overall Study|Lost to Follow-up|13
6009565|NCT00103506|9602626|FG001|Overall Study|Lost to Follow-up|13
6009566|NCT00103506|9602625|FG000|Overall Study|Withdrawal by Subject|18
6074989|NCT00576472|9678973|FG011|MPH Home Maintenance Phase|Lost to Follow-up|0
6074990|NCT00576472|9678974|FG012|MPH Home Maintenance Phase|Lost to Follow-up|0
6074991|NCT00576472|9678975|FG013|MPH Home Maintenance Phase|Lost to Follow-up|0
6074992|NCT00576472|9678976|FG014|MPH Home Maintenance Phase|Lost to Follow-up|3
6074993|NCT00576576|9679007|FG000|Overall Study|Lost to Follow-up|6
6074994|NCT00576576|9679007|FG000|Overall Study|Protocol Violation|1
6074995|NCT00576628|9679011|FG000|Overall Study|Adverse Event|11
6074996|NCT00576628|9679011|FG000|Overall Study|Death|2
6074997|NCT00576628|9679011|FG000|Overall Study|Failure to return|1
6074998|NCT00576628|9679011|FG000|Overall Study|Refused Treatment|8
6074999|NCT00576628|9679011|FG000|Overall Study|Pregnancy|1
6075000|NCT00576628|9679011|FG000|Overall Study|RBC transfusion|1
6075001|NCT00576628|9679011|FG000|Overall Study|Progression of Kidney Disease|1
6075002|NCT00576628|9679011|FG000|Overall Study|Progression of Renal Failure|1
6075003|NCT00576628|9679011|FG000|Overall Study|The patient move into other town|1
6075004|NCT00576628|9679011|FG000|Overall Study|Transplantation|1
6075005|NCT00576628|9679011|FG000|Overall Study|Dialysis|15
6075006|NCT00576693|9679022|FG000|Overall Study|Lost to Follow-up|7
6075007|NCT00576693|9679023|FG001|Overall Study|Lost to Follow-up|11
6075008|NCT00576693|9679022|FG000|Overall Study|Withdrawal by Subject|3
6075009|NCT00576693|9679023|FG001|Overall Study|Withdrawal by Subject|13
6075010|NCT00576732|9679032|FG000|DOUBLE BLIND|Adverse Event|0
6075011|NCT00576732|9679033|FG001|DOUBLE BLIND|Adverse Event|0
6075012|NCT00576732|9679034|FG002|DOUBLE BLIND|Adverse Event|1
6075013|NCT00576732|9679035|FG003|DOUBLE BLIND|Adverse Event|0
6075014|NCT00576732|9679036|FG004|DOUBLE BLIND|Adverse Event|0
6075015|NCT00576732|9679037|FG005|DOUBLE BLIND|Adverse Event|0
6075016|NCT00576732|9679032|FG000|DOUBLE BLIND|Lost to Follow-up|0
6009567|NCT00103506|9602626|FG001|Overall Study|Withdrawal by Subject|21
6009568|NCT00103610|9602634|FG000|Overall Study|Entered Rescue Procedure|10
6009569|NCT00103610|9602635|FG001|Overall Study|Entered Rescue Procedure|52
6009570|NCT00103610|9602634|FG000|Overall Study|Death|16
6009571|NCT00103610|9602635|FG001|Overall Study|Death|12
6009572|NCT00103610|9602634|FG000|Overall Study|Elective Withdrawal|4
6009573|NCT00103610|9602635|FG001|Overall Study|Elective Withdrawal|0
6009574|NCT00103610|9602634|FG000|Overall Study|Lost to Follow-up|3
6009575|NCT00103610|9602635|FG001|Overall Study|Lost to Follow-up|1
6009576|NCT00103610|9602634|FG000|Overall Study|Adverse Event|2
6009577|NCT00103610|9602635|FG001|Overall Study|Adverse Event|2
6009578|NCT00103610|9602634|FG000|Overall Study|Other|2
6009579|NCT00103610|9602635|FG001|Overall Study|Other|7
6075017|NCT00576732|9679033|FG001|DOUBLE BLIND|Lost to Follow-up|1
6075018|NCT00576732|9679034|FG002|DOUBLE BLIND|Lost to Follow-up|1
6075019|NCT00576732|9679035|FG003|DOUBLE BLIND|Lost to Follow-up|0
6075020|NCT00576732|9679036|FG004|DOUBLE BLIND|Lost to Follow-up|0
6075021|NCT00576732|9679037|FG005|DOUBLE BLIND|Lost to Follow-up|0
6075022|NCT00576732|9679032|FG000|DOUBLE BLIND|Withdrawal by Subject|1
6075023|NCT00576732|9679033|FG001|DOUBLE BLIND|Withdrawal by Subject|1
6009580|NCT00103610|9602634|FG000|Overall Study|Failed mobilization|1
6009581|NCT00103610|9602635|FG001|Overall Study|Failed mobilization|5
6009582|NCT00103610|9602634|FG000|Overall Study|Noncompliance|0
6009583|NCT00103610|9602635|FG001|Overall Study|Noncompliance|1
6009584|NCT00103662|9602644|FG000|Overall Study|Entered Rescue Procedure|0
6009585|NCT00103662|9602645|FG001|Overall Study|Entered Rescue Procedure|7
6009586|NCT00103662|9602644|FG000|Overall Study|Death|7
6009587|NCT00103662|9602645|FG001|Overall Study|Death|7
6009588|NCT00103662|9602644|FG000|Overall Study|Elective Withdrawal|5
6009589|NCT00103662|9602645|FG001|Overall Study|Elective Withdrawal|5
6009590|NCT00103662|9602644|FG000|Overall Study|Lost to Follow-up|0
6009591|NCT00103662|9602645|FG001|Overall Study|Lost to Follow-up|1
6009592|NCT00103662|9602644|FG000|Overall Study|Other|6
6009593|NCT00103662|9602645|FG001|Overall Study|Other|9
6009594|NCT00103662|9602644|FG000|Overall Study|Failed mobilization|0
6009595|NCT00103662|9602645|FG001|Overall Study|Failed mobilization|4
6009596|NCT00103662|9602644|FG000|Overall Study|Intercurrent illness|1
6009597|NCT00103662|9602645|FG001|Overall Study|Intercurrent illness|0
6009598|NCT00103740|9602653|FG000|Period 1 - Core|Adverse Event|1
6009599|NCT00103740|9602654|FG001|Period 1 - Core|Adverse Event|0
6009600|NCT00103740|9602653|FG000|Period 1 - Core|Protocol Violation|3
6009601|NCT00103740|9602654|FG001|Period 1 - Core|Protocol Violation|2
6009602|NCT00103740|9602653|FG000|Period 1 - Core|Patient withdrew consent|3
6009603|NCT00103740|9602654|FG001|Period 1 - Core|Patient withdrew consent|2
6009604|NCT00103740|9602653|FG000|Period 2 - Extended Observation Period|Lost to Follow-up|7
6009605|NCT00103740|9602654|FG001|Period 2 - Extended Observation Period|Lost to Follow-up|6
6009606|NCT00103740|9602653|FG000|Period 2 - Extended Observation Period|Withdrew for nonclinical reason|21
6009607|NCT00103740|9602654|FG001|Period 2 - Extended Observation Period|Withdrew for nonclinical reason|13
6009608|NCT00103740|9602653|FG000|Period 2 - Extended Observation Period|Clinical reason other than Paget's|5
6009609|NCT00103740|9602654|FG001|Period 2 - Extended Observation Period|Clinical reason other than Paget's|6
6009610|NCT00103740|9602653|FG000|Period 2 - Extended Observation Period|Death|6
6009611|NCT00103740|9602654|FG001|Period 2 - Extended Observation Period|Death|2
6009612|NCT00103740|9602653|FG000|Period 2 - Extended Observation Period|Amendment 6 informed consent not signed|30
6009613|NCT00103740|9602654|FG001|Period 2 - Extended Observation Period|Amendment 6 informed consent not signed|9
6009614|NCT00103857|9602676|FG000|54-Week Base Study|Adverse Event|12
6009615|NCT00103857|9602677|FG001|54-Week Base Study|Adverse Event|9
6009616|NCT00103857|9602678|FG002|54-Week Base Study|Adverse Event|11
6009617|NCT00103857|9602679|FG003|54-Week Base Study|Adverse Event|6
6009618|NCT00103857|9602680|FG004|54-Week Base Study|Adverse Event|5
6009619|NCT00103857|9602681|FG005|54-Week Base Study|Adverse Event|11
6009620|NCT00103857|9602682|FG006|54-Week Base Study|Adverse Event|3
6009621|NCT00103857|9602676|FG000|54-Week Base Study|Death|0
6009622|NCT00103857|9602677|FG001|54-Week Base Study|Death|0
6009623|NCT00103857|9602678|FG002|54-Week Base Study|Death|0
6009624|NCT00103857|9602679|FG003|54-Week Base Study|Death|0
6009625|NCT00103857|9602680|FG004|54-Week Base Study|Death|1
6009626|NCT00103857|9602681|FG005|54-Week Base Study|Death|1
6009627|NCT00103857|9602682|FG006|54-Week Base Study|Death|0
6009628|NCT00103857|9602676|FG000|54-Week Base Study|Lack of Efficacy|11
6009629|NCT00103857|9602677|FG001|54-Week Base Study|Lack of Efficacy|14
6009630|NCT00103857|9602678|FG002|54-Week Base Study|Lack of Efficacy|8
6009631|NCT00103857|9602679|FG003|54-Week Base Study|Lack of Efficacy|4
6009632|NCT00103857|9602680|FG004|54-Week Base Study|Lack of Efficacy|3
6009633|NCT00103857|9602681|FG005|54-Week Base Study|Lack of Efficacy|14
6009634|NCT00103857|9602682|FG006|54-Week Base Study|Lack of Efficacy|19
6009635|NCT00103857|9602676|FG000|54-Week Base Study|Lost to Follow-up|5
6009636|NCT00103857|9602677|FG001|54-Week Base Study|Lost to Follow-up|4
6009637|NCT00103857|9602678|FG002|54-Week Base Study|Lost to Follow-up|7
6009638|NCT00103857|9602679|FG003|54-Week Base Study|Lost to Follow-up|5
6009639|NCT00103857|9602680|FG004|54-Week Base Study|Lost to Follow-up|10
6009640|NCT00103857|9602681|FG005|54-Week Base Study|Lost to Follow-up|9
6009641|NCT00103857|9602682|FG006|54-Week Base Study|Lost to Follow-up|3
6009642|NCT00103857|9602676|FG000|54-Week Base Study|Physician Decision|1
6009643|NCT00103857|9602677|FG001|54-Week Base Study|Physician Decision|1
6009644|NCT00103857|9602678|FG002|54-Week Base Study|Physician Decision|0
6009645|NCT00103857|9602679|FG003|54-Week Base Study|Physician Decision|0
6009646|NCT00103857|9602680|FG004|54-Week Base Study|Physician Decision|1
6009647|NCT00103857|9602681|FG005|54-Week Base Study|Physician Decision|0
6009648|NCT00103857|9602682|FG006|54-Week Base Study|Physician Decision|0
6009649|NCT00103857|9602676|FG000|54-Week Base Study|Pregnancy|1
6009650|NCT00103857|9602677|FG001|54-Week Base Study|Pregnancy|0
6009651|NCT00103857|9602678|FG002|54-Week Base Study|Pregnancy|0
6009652|NCT00103857|9602679|FG003|54-Week Base Study|Pregnancy|0
6009653|NCT00103857|9602680|FG004|54-Week Base Study|Pregnancy|1
6009654|NCT00103857|9602681|FG005|54-Week Base Study|Pregnancy|0
6009655|NCT00103857|9602682|FG006|54-Week Base Study|Pregnancy|1
6009656|NCT00103857|9602676|FG000|54-Week Base Study|Protocol Violation|6
6009657|NCT00103857|9602677|FG001|54-Week Base Study|Protocol Violation|4
6009658|NCT00103857|9602678|FG002|54-Week Base Study|Protocol Violation|2
6009659|NCT00103857|9602679|FG003|54-Week Base Study|Protocol Violation|4
6009660|NCT00103857|9602680|FG004|54-Week Base Study|Protocol Violation|0
6009661|NCT00103857|9602681|FG005|54-Week Base Study|Protocol Violation|3
6009662|NCT00103857|9602682|FG006|54-Week Base Study|Protocol Violation|3
6009663|NCT00103857|9602676|FG000|54-Week Base Study|Withdrawal by Subject|17
6009664|NCT00103857|9602677|FG001|54-Week Base Study|Withdrawal by Subject|16
6009665|NCT00103857|9602678|FG002|54-Week Base Study|Withdrawal by Subject|16
6009666|NCT00103857|9602679|FG003|54-Week Base Study|Withdrawal by Subject|15
6009667|NCT00103857|9602680|FG004|54-Week Base Study|Withdrawal by Subject|10
6009668|NCT00103857|9602681|FG005|54-Week Base Study|Withdrawal by Subject|15
6009669|NCT00103857|9602682|FG006|54-Week Base Study|Withdrawal by Subject|4
6009670|NCT00103857|9602676|FG000|54-Week Base Study|protocol discontinuation criteria|2
6009671|NCT00103857|9602677|FG001|54-Week Base Study|protocol discontinuation criteria|5
6009672|NCT00103857|9602678|FG002|54-Week Base Study|protocol discontinuation criteria|2
6009673|NCT00103857|9602679|FG003|54-Week Base Study|protocol discontinuation criteria|6
6009674|NCT00103857|9602680|FG004|54-Week Base Study|protocol discontinuation criteria|5
6009675|NCT00103857|9602681|FG005|54-Week Base Study|protocol discontinuation criteria|3
6009676|NCT00103857|9602682|FG006|54-Week Base Study|protocol discontinuation criteria|5
6009677|NCT00103857|9602676|FG000|54-Week Base Study|patient moved|0
6009678|NCT00103857|9602677|FG001|54-Week Base Study|patient moved|1
6009679|NCT00103857|9602678|FG002|54-Week Base Study|patient moved|1
6009680|NCT00103857|9602679|FG003|54-Week Base Study|patient moved|2
6009681|NCT00103857|9602680|FG004|54-Week Base Study|patient moved|3
6009682|NCT00103857|9602681|FG005|54-Week Base Study|patient moved|1
6009683|NCT00103857|9602682|FG006|54-Week Base Study|patient moved|0
6009684|NCT00103857|9602676|FG000|54-Week Base Study|non-compliance with study procedures|1
6009685|NCT00103857|9602677|FG001|54-Week Base Study|non-compliance with study procedures|2
6009686|NCT00103857|9602678|FG002|54-Week Base Study|non-compliance with study procedures|0
6009687|NCT00103857|9602679|FG003|54-Week Base Study|non-compliance with study procedures|0
6009688|NCT00103857|9602680|FG004|54-Week Base Study|non-compliance with study procedures|0
6009689|NCT00103857|9602681|FG005|54-Week Base Study|non-compliance with study procedures|2
6009690|NCT00103857|9602682|FG006|54-Week Base Study|non-compliance with study procedures|0
6009691|NCT00103857|9602676|FG000|54-Week Base Study|patient incarcerated|0
6009692|NCT00103857|9602677|FG001|54-Week Base Study|patient incarcerated|0
6009693|NCT00103857|9602678|FG002|54-Week Base Study|patient incarcerated|0
6009694|NCT00103857|9602679|FG003|54-Week Base Study|patient incarcerated|0
6009695|NCT00103857|9602680|FG004|54-Week Base Study|patient incarcerated|1
6009696|NCT00103857|9602681|FG005|54-Week Base Study|patient incarcerated|1
6009697|NCT00103857|9602682|FG006|54-Week Base Study|patient incarcerated|0
6009698|NCT00103857|9602676|FG000|54-Week Base Study|laboratory reporting error|0
6009699|NCT00103857|9602677|FG001|54-Week Base Study|laboratory reporting error|0
6009700|NCT00103857|9602678|FG002|54-Week Base Study|laboratory reporting error|0
6009701|NCT00103857|9602679|FG003|54-Week Base Study|laboratory reporting error|0
6009702|NCT00103857|9602680|FG004|54-Week Base Study|laboratory reporting error|1
6009703|NCT00103857|9602681|FG005|54-Week Base Study|laboratory reporting error|0
6009704|NCT00103857|9602682|FG006|54-Week Base Study|laboratory reporting error|0
6075024|NCT00576732|9679034|FG002|DOUBLE BLIND|Withdrawal by Subject|3
6075025|NCT00576732|9679035|FG003|DOUBLE BLIND|Withdrawal by Subject|0
6075026|NCT00576732|9679036|FG004|DOUBLE BLIND|Withdrawal by Subject|0
6075027|NCT00576732|9679037|FG005|DOUBLE BLIND|Withdrawal by Subject|0
6075028|NCT00576732|9679032|FG000|DOUBLE BLIND|OTHER|0
6075029|NCT00576732|9679033|FG001|DOUBLE BLIND|OTHER|2
6075030|NCT00576732|9679034|FG002|DOUBLE BLIND|OTHER|1
6075031|NCT00576732|9679035|FG003|DOUBLE BLIND|OTHER|0
6075032|NCT00576732|9679036|FG004|DOUBLE BLIND|OTHER|0
6075033|NCT00576732|9679037|FG005|DOUBLE BLIND|OTHER|0
6075034|NCT00576732|9679032|FG000|DOUBLE BLIND|Lack of Efficacy|6
6075035|NCT00576732|9679033|FG001|DOUBLE BLIND|Lack of Efficacy|1
6075036|NCT00576732|9679034|FG002|DOUBLE BLIND|Lack of Efficacy|0
6075037|NCT00576732|9679035|FG003|DOUBLE BLIND|Lack of Efficacy|0
6075038|NCT00576732|9679036|FG004|DOUBLE BLIND|Lack of Efficacy|0
6075039|NCT00576732|9679037|FG005|DOUBLE BLIND|Lack of Efficacy|0
6075040|NCT00576732|9679032|FG000|DOUBLE BLIND|Protocol Violation|1
6075041|NCT00576732|9679033|FG001|DOUBLE BLIND|Protocol Violation|0
6075042|NCT00576732|9679034|FG002|DOUBLE BLIND|Protocol Violation|0
6075043|NCT00576732|9679035|FG003|DOUBLE BLIND|Protocol Violation|0
6075044|NCT00576732|9679036|FG004|DOUBLE BLIND|Protocol Violation|0
6075045|NCT00576732|9679037|FG005|DOUBLE BLIND|Protocol Violation|0
6075046|NCT00576732|9679032|FG000|OPEN LABEL|Adverse Event|0
6075047|NCT00576732|9679033|FG001|OPEN LABEL|Adverse Event|0
6075048|NCT00576732|9679034|FG002|OPEN LABEL|Adverse Event|0
6075049|NCT00576732|9679035|FG003|OPEN LABEL|Adverse Event|4
6075050|NCT00576732|9679036|FG004|OPEN LABEL|Adverse Event|0
6075051|NCT00576732|9679037|FG005|OPEN LABEL|Adverse Event|1
6075052|NCT00576732|9679032|FG000|OPEN LABEL|Lost to Follow-up|0
6075053|NCT00576732|9679033|FG001|OPEN LABEL|Lost to Follow-up|0
6075054|NCT00576732|9679034|FG002|OPEN LABEL|Lost to Follow-up|0
6075055|NCT00576732|9679035|FG003|OPEN LABEL|Lost to Follow-up|2
6009705|NCT00103857|9602676|FG000|54-Week Base Study|site error|0
6009706|NCT00103857|9602677|FG001|54-Week Base Study|site error|0
6009707|NCT00103857|9602678|FG002|54-Week Base Study|site error|0
6075056|NCT00576732|9679036|FG004|OPEN LABEL|Lost to Follow-up|1
6075057|NCT00576732|9679037|FG005|OPEN LABEL|Lost to Follow-up|1
6075058|NCT00576732|9679032|FG000|OPEN LABEL|Withdrawal by Subject|0
6075059|NCT00576732|9679033|FG001|OPEN LABEL|Withdrawal by Subject|0
6075060|NCT00576732|9679034|FG002|OPEN LABEL|Withdrawal by Subject|0
6009708|NCT00103857|9602679|FG003|54-Week Base Study|site error|0
6009709|NCT00103857|9602680|FG004|54-Week Base Study|site error|0
6009710|NCT00103857|9602681|FG005|54-Week Base Study|site error|1
6009711|NCT00103857|9602682|FG006|54-Week Base Study|site error|0
6009712|NCT00103857|9602676|FG000|54-Week Base Study|patient intolerance to rescue therapy|1
6009713|NCT00103857|9602677|FG001|54-Week Base Study|patient intolerance to rescue therapy|0
6009714|NCT00103857|9602678|FG002|54-Week Base Study|patient intolerance to rescue therapy|0
6009715|NCT00103857|9602679|FG003|54-Week Base Study|patient intolerance to rescue therapy|0
6009716|NCT00103857|9602680|FG004|54-Week Base Study|patient intolerance to rescue therapy|0
6009717|NCT00103857|9602681|FG005|54-Week Base Study|patient intolerance to rescue therapy|0
6009718|NCT00103857|9602682|FG006|54-Week Base Study|patient intolerance to rescue therapy|0
6009719|NCT00103857|9602676|FG000|50-Week Extension Study|Adverse Event|2
6009720|NCT00103857|9602677|FG001|50-Week Extension Study|Adverse Event|3
6009721|NCT00103857|9602678|FG002|50-Week Extension Study|Adverse Event|2
6009722|NCT00103857|9602679|FG003|50-Week Extension Study|Adverse Event|0
6009723|NCT00103857|9602680|FG004|50-Week Extension Study|Adverse Event|1
6009724|NCT00103857|9602681|FG005|50-Week Extension Study|Adverse Event|1
6009725|NCT00103857|9602682|FG006|50-Week Extension Study|Adverse Event|0
6009726|NCT00103857|9602676|FG000|50-Week Extension Study|Death|0
6009727|NCT00103857|9602677|FG001|50-Week Extension Study|Death|0
6009728|NCT00103857|9602678|FG002|50-Week Extension Study|Death|0
6009729|NCT00103857|9602679|FG003|50-Week Extension Study|Death|1
6009730|NCT00103857|9602680|FG004|50-Week Extension Study|Death|0
6009731|NCT00103857|9602681|FG005|50-Week Extension Study|Death|1
6009732|NCT00103857|9602682|FG006|50-Week Extension Study|Death|0
6009733|NCT00103857|9602676|FG000|50-Week Extension Study|Lack of Efficacy|26
6009734|NCT00103857|9602677|FG001|50-Week Extension Study|Lack of Efficacy|15
6009735|NCT00103857|9602678|FG002|50-Week Extension Study|Lack of Efficacy|13
6009736|NCT00103857|9602679|FG003|50-Week Extension Study|Lack of Efficacy|16
6009737|NCT00103857|9602680|FG004|50-Week Extension Study|Lack of Efficacy|8
6009738|NCT00103857|9602681|FG005|50-Week Extension Study|Lack of Efficacy|8
6009739|NCT00103857|9602682|FG006|50-Week Extension Study|Lack of Efficacy|0
6009740|NCT00103857|9602676|FG000|50-Week Extension Study|Lost to Follow-up|4
6009741|NCT00103857|9602677|FG001|50-Week Extension Study|Lost to Follow-up|0
6009742|NCT00103857|9602678|FG002|50-Week Extension Study|Lost to Follow-up|1
6009743|NCT00103857|9602679|FG003|50-Week Extension Study|Lost to Follow-up|4
6009744|NCT00103857|9602680|FG004|50-Week Extension Study|Lost to Follow-up|3
6009745|NCT00103857|9602681|FG005|50-Week Extension Study|Lost to Follow-up|3
6009746|NCT00103857|9602682|FG006|50-Week Extension Study|Lost to Follow-up|0
6009747|NCT00103857|9602676|FG000|50-Week Extension Study|Physician Decision|0
6009748|NCT00103857|9602677|FG001|50-Week Extension Study|Physician Decision|1
6009749|NCT00103857|9602678|FG002|50-Week Extension Study|Physician Decision|1
6075061|NCT00576732|9679035|FG003|OPEN LABEL|Withdrawal by Subject|1
6075062|NCT00576732|9679036|FG004|OPEN LABEL|Withdrawal by Subject|0
6075063|NCT00576732|9679037|FG005|OPEN LABEL|Withdrawal by Subject|1
6075064|NCT00576732|9679032|FG000|OPEN LABEL|OTHER|0
6075065|NCT00576732|9679033|FG001|OPEN LABEL|OTHER|0
6075066|NCT00576732|9679034|FG002|OPEN LABEL|OTHER|0
6075067|NCT00576732|9679035|FG003|OPEN LABEL|OTHER|0
6075068|NCT00576732|9679036|FG004|OPEN LABEL|OTHER|0
6075069|NCT00576732|9679037|FG005|OPEN LABEL|OTHER|2
6075070|NCT00576732|9679032|FG000|OPEN LABEL|Lack of Efficacy|0
6075071|NCT00576732|9679033|FG001|OPEN LABEL|Lack of Efficacy|0
6075072|NCT00576732|9679034|FG002|OPEN LABEL|Lack of Efficacy|0
6075073|NCT00576732|9679035|FG003|OPEN LABEL|Lack of Efficacy|2
6075074|NCT00576732|9679036|FG004|OPEN LABEL|Lack of Efficacy|2
6075075|NCT00576732|9679037|FG005|OPEN LABEL|Lack of Efficacy|3
6075076|NCT00576732|9679032|FG000|OPEN LABEL|Protocol Violation|0
6075077|NCT00576732|9679033|FG001|OPEN LABEL|Protocol Violation|0
6075078|NCT00576732|9679034|FG002|OPEN LABEL|Protocol Violation|0
6075079|NCT00576732|9679035|FG003|OPEN LABEL|Protocol Violation|2
6075080|NCT00576732|9679036|FG004|OPEN LABEL|Protocol Violation|1
6075081|NCT00576732|9679037|FG005|OPEN LABEL|Protocol Violation|0
6075082|NCT00576758|9679051|FG000|Induction Treatment Period|Adverse event or Intercurrent illness|3
6075083|NCT00576758|9679052|FG001|Induction Treatment Period|Adverse event or Intercurrent illness|3
6075084|NCT00576758|9679051|FG000|Induction Treatment Period|Insufficient therapeutic response|2
6075085|NCT00576758|9679052|FG001|Induction Treatment Period|Insufficient therapeutic response|0
6075086|NCT00576758|9679051|FG000|Induction Treatment Period|Violation of selection criteria at entry|1
6075087|NCT00576758|9679052|FG001|Induction Treatment Period|Violation of selection criteria at entry|1
6075088|NCT00576758|9679051|FG000|Induction Treatment Period|Death|1
6075089|NCT00576758|9679052|FG001|Induction Treatment Period|Death|0
6075090|NCT00576758|9679051|FG000|Induction Treatment Period|Refused treatment/ Did not Cooperate|0
6075091|NCT00576758|9679052|FG001|Induction Treatment Period|Refused treatment/ Did not Cooperate|1
6075092|NCT00576758|9679051|FG000|Induction Treatment Period|Withdrew consent|1
6075093|NCT00576758|9679052|FG001|Induction Treatment Period|Withdrew consent|0
6075094|NCT00576758|9679051|FG000|Extension Treatment Period|Adverse event or Intercurrent illness|6
6009750|NCT00103857|9602679|FG003|50-Week Extension Study|Physician Decision|0
6075095|NCT00576758|9679052|FG001|Extension Treatment Period|Adverse event or Intercurrent illness|7
6075096|NCT00576758|9679051|FG000|Extension Treatment Period|Death|1
6075097|NCT00576758|9679052|FG001|Extension Treatment Period|Death|1
6009751|NCT00103857|9602680|FG004|50-Week Extension Study|Physician Decision|0
6009752|NCT00103857|9602681|FG005|50-Week Extension Study|Physician Decision|0
6009753|NCT00103857|9602682|FG006|50-Week Extension Study|Physician Decision|0
6009754|NCT00103857|9602676|FG000|50-Week Extension Study|Pregnancy|0
6009755|NCT00103857|9602677|FG001|50-Week Extension Study|Pregnancy|0
6009756|NCT00103857|9602678|FG002|50-Week Extension Study|Pregnancy|1
6009757|NCT00103857|9602679|FG003|50-Week Extension Study|Pregnancy|0
6009758|NCT00103857|9602680|FG004|50-Week Extension Study|Pregnancy|1
6009759|NCT00103857|9602681|FG005|50-Week Extension Study|Pregnancy|0
6009760|NCT00103857|9602682|FG006|50-Week Extension Study|Pregnancy|0
6009761|NCT00103857|9602676|FG000|50-Week Extension Study|Protocol Violation|1
6009762|NCT00103857|9602677|FG001|50-Week Extension Study|Protocol Violation|1
6009763|NCT00103857|9602678|FG002|50-Week Extension Study|Protocol Violation|1
6009764|NCT00103857|9602679|FG003|50-Week Extension Study|Protocol Violation|2
6009765|NCT00103857|9602680|FG004|50-Week Extension Study|Protocol Violation|0
6009766|NCT00103857|9602681|FG005|50-Week Extension Study|Protocol Violation|1
6009767|NCT00103857|9602682|FG006|50-Week Extension Study|Protocol Violation|0
6009768|NCT00103857|9602676|FG000|50-Week Extension Study|Withdrawal by Subject|2
6009769|NCT00103857|9602677|FG001|50-Week Extension Study|Withdrawal by Subject|5
6009770|NCT00103857|9602678|FG002|50-Week Extension Study|Withdrawal by Subject|2
6009771|NCT00103857|9602679|FG003|50-Week Extension Study|Withdrawal by Subject|8
6009772|NCT00103857|9602680|FG004|50-Week Extension Study|Withdrawal by Subject|3
6009773|NCT00103857|9602681|FG005|50-Week Extension Study|Withdrawal by Subject|3
6009774|NCT00103857|9602682|FG006|50-Week Extension Study|Withdrawal by Subject|0
6009775|NCT00103857|9602676|FG000|50-Week Extension Study|protocol discontinuation criteria|2
6009776|NCT00103857|9602677|FG001|50-Week Extension Study|protocol discontinuation criteria|2
6009777|NCT00103857|9602678|FG002|50-Week Extension Study|protocol discontinuation criteria|3
6009778|NCT00103857|9602679|FG003|50-Week Extension Study|protocol discontinuation criteria|2
6009779|NCT00103857|9602680|FG004|50-Week Extension Study|protocol discontinuation criteria|3
6009780|NCT00103857|9602681|FG005|50-Week Extension Study|protocol discontinuation criteria|3
6009781|NCT00103857|9602682|FG006|50-Week Extension Study|protocol discontinuation criteria|0
6009782|NCT00103857|9602676|FG000|50-Week Extension Study|non-compliance with study procedures|1
6009783|NCT00103857|9602677|FG001|50-Week Extension Study|non-compliance with study procedures|0
6009784|NCT00103857|9602678|FG002|50-Week Extension Study|non-compliance with study procedures|0
6009785|NCT00103857|9602679|FG003|50-Week Extension Study|non-compliance with study procedures|1
6009786|NCT00103857|9602680|FG004|50-Week Extension Study|non-compliance with study procedures|1
6009787|NCT00103857|9602681|FG005|50-Week Extension Study|non-compliance with study procedures|0
6009788|NCT00103857|9602682|FG006|50-Week Extension Study|non-compliance with study procedures|0
6009789|NCT00103857|9602676|FG000|50-Week Extension Study|patient moved|0
6009790|NCT00103857|9602677|FG001|50-Week Extension Study|patient moved|0
6009791|NCT00103857|9602678|FG002|50-Week Extension Study|patient moved|1
6009792|NCT00103857|9602679|FG003|50-Week Extension Study|patient moved|2
6009793|NCT00103857|9602680|FG004|50-Week Extension Study|patient moved|0
6009794|NCT00103857|9602681|FG005|50-Week Extension Study|patient moved|0
6009795|NCT00103857|9602682|FG006|50-Week Extension Study|patient moved|0
6009796|NCT00103857|9602676|FG000|50-Week Extension Study|patient scheduled for elective surgery|0
6009797|NCT00103857|9602677|FG001|50-Week Extension Study|patient scheduled for elective surgery|0
6009798|NCT00103857|9602678|FG002|50-Week Extension Study|patient scheduled for elective surgery|1
6009799|NCT00103857|9602679|FG003|50-Week Extension Study|patient scheduled for elective surgery|0
6009800|NCT00103857|9602680|FG004|50-Week Extension Study|patient scheduled for elective surgery|0
6009801|NCT00103857|9602681|FG005|50-Week Extension Study|patient scheduled for elective surgery|0
6009802|NCT00103857|9602682|FG006|50-Week Extension Study|patient scheduled for elective surgery|0
6009803|NCT00103857|9602676|FG000|50-Week Extension Study|reason unspecified|0
6009804|NCT00103857|9602677|FG001|50-Week Extension Study|reason unspecified|0
6009805|NCT00103857|9602678|FG002|50-Week Extension Study|reason unspecified|0
6009806|NCT00103857|9602679|FG003|50-Week Extension Study|reason unspecified|0
6009807|NCT00103857|9602680|FG004|50-Week Extension Study|reason unspecified|1
6009808|NCT00103857|9602681|FG005|50-Week Extension Study|reason unspecified|0
6009809|NCT00103857|9602682|FG006|50-Week Extension Study|reason unspecified|0
6009810|NCT00104052|9602697|FG000|Overall Study|Adverse Event|1
6009811|NCT00104052|9602697|FG000|Overall Study|Lack of Efficacy|26
6009812|NCT00104052|9602697|FG000|Overall Study|Discontinuation unrelated to treatment|2
6009813|NCT00104104|9602703|FG000|Overall Study|Adverse Event|8
6009814|NCT00104104|9602704|FG001|Overall Study|Adverse Event|8
6009815|NCT00104104|9602703|FG000|Overall Study|Abnormal laboratory value(s)|20
6009816|NCT00104104|9602704|FG001|Overall Study|Abnormal laboratory value(s)|14
6009817|NCT00104104|9602703|FG000|Overall Study|Lack of Efficacy|0
6009818|NCT00104104|9602704|FG001|Overall Study|Lack of Efficacy|3
6009819|NCT00104104|9602703|FG000|Overall Study|Condition no longer requires study drug|7
6009820|NCT00104104|9602704|FG001|Overall Study|Condition no longer requires study drug|4
6009821|NCT00104104|9602703|FG000|Overall Study|Protocol Violation|5
6009822|NCT00104104|9602704|FG001|Overall Study|Protocol Violation|2
6009823|NCT00104104|9602703|FG000|Overall Study|Withdrawal by Subject|11
6009824|NCT00104104|9602704|FG001|Overall Study|Withdrawal by Subject|15
6009825|NCT00104104|9602703|FG000|Overall Study|Lost to Follow-up|3
6009826|NCT00104104|9602704|FG001|Overall Study|Lost to Follow-up|7
6009827|NCT00104104|9602703|FG000|Overall Study|Administrative problems|12
6009828|NCT00104104|9602704|FG001|Overall Study|Administrative problems|13
6009829|NCT00104104|9602703|FG000|Overall Study|Death|9
6009830|NCT00104104|9602704|FG001|Overall Study|Death|6
6009831|NCT00104247|9602721|FG000|Overall Study|Withdrawal by Subject|1
6009832|NCT00104247|9602722|FG001|Overall Study|Withdrawal by Subject|0
6009833|NCT00104247|9602721|FG000|Overall Study|Noncompliant with dosing|0
6009834|NCT00104247|9602722|FG001|Overall Study|Noncompliant with dosing|1
6009835|NCT00104299|9602730|FG000|Overall Study|Adverse Event|3
6009836|NCT00104299|9602731|FG001|Overall Study|Adverse Event|1
6009837|NCT00104299|9602730|FG000|Overall Study|Death|2
6075098|NCT00576758|9679051|FG000|Extension Treatment Period|Refused treatment/did not cooperate|2
6075099|NCT00576758|9679052|FG001|Extension Treatment Period|Refused treatment/did not cooperate|1
6075100|NCT00576758|9679051|FG000|Extension Treatment Period|Insufficient therapeutic response|30
6075101|NCT00576758|9679052|FG001|Extension Treatment Period|Insufficient therapeutic response|33
6075102|NCT00576758|9679051|FG000|Extension Treatment Period|Administrative/Other|3
6075103|NCT00576758|9679052|FG001|Extension Treatment Period|Administrative/Other|1
6075104|NCT00576758|9679051|FG000|Follow-up Period|Administrative/Other|6
6075105|NCT00576758|9679052|FG001|Follow-up Period|Administrative/Other|8
6075106|NCT00576758|9679051|FG000|Follow-up Period|Death|3
6075107|NCT00576758|9679052|FG001|Follow-up Period|Death|3
6075108|NCT00576758|9679051|FG000|Follow-up Period|Insufficient therapeutic response|16
6075109|NCT00576758|9679052|FG001|Follow-up Period|Insufficient therapeutic response|5
6075110|NCT00576758|9679051|FG000|Follow-up Period|Withdrew consent|2
6075111|NCT00576758|9679052|FG001|Follow-up Period|Withdrew consent|1
6075112|NCT00576823|9679062|FG000|12-week Efficacy Phase|Parent's schedule issue|1
6075113|NCT00576823|9679063|FG001|12-week Efficacy Phase|Parent's schedule issue|0
6075114|NCT00576823|9679064|FG002|12-week Efficacy Phase|Parent's schedule issue|0
6075115|NCT00576823|9679062|FG000|40-week Safety Extension Phase|Lack of Efficacy|1
6075116|NCT00576823|9679063|FG001|40-week Safety Extension Phase|Lack of Efficacy|0
6075117|NCT00576823|9679064|FG002|40-week Safety Extension Phase|Lack of Efficacy|0
6075118|NCT00576901|9679075|FG000|Overall Study|Withdrawal by Subject|1
6075119|NCT00576901|9679075|FG000|Overall Study|Disease course|1
6075120|NCT00576901|9679075|FG000|Overall Study|Protocol Violation|1
6075121|NCT00576927|9679081|FG000|Clinical Assessment|Lack of Efficacy|24
6075122|NCT00576927|9679081|FG000|Clinical Assessment|Death|1
6075123|NCT00576927|9679081|FG000|Clinical Assessment|Withdrawal by Subject|10
6075124|NCT00576927|9679081|FG000|Clinical Assessment|Physician Decision|1
6075125|NCT00576927|9679081|FG000|Baseline|Physician Decision|9
6075126|NCT00576927|9679081|FG000|Baseline|Medication Change by PCP of subject|1
6075127|NCT00576927|9679081|FG000|Baseline|Withdrawal by Subject|3
6075128|NCT00576927|9679081|FG000|Sleep Hygiene Behavioral Intervention|Responded to intervention|4
6075129|NCT00576927|9679081|FG000|Sleep Hygiene Behavioral Intervention|Death|1
6075130|NCT00576927|9679081|FG000|Sleep Hygiene Behavioral Intervention|Medication Change by PCP for subject|1
6075131|NCT00576927|9679081|FG000|Sleep Hygiene Behavioral Intervention|Withdrawal by Subject|1
6075132|NCT00576927|9679081|FG000|Sleep Hygiene With the Placebo|Withdrawal by Subject|1
6075133|NCT00577005|9679089|FG000|Overall Study|Lost to Follow-up|3
6075134|NCT00577005|9679090|FG001|Overall Study|Lost to Follow-up|2
6075135|NCT00577005|9679089|FG000|Overall Study|Withdrawal by Subject|2
6075136|NCT00577005|9679090|FG001|Overall Study|Withdrawal by Subject|1
6075137|NCT00577031|9679099|FG000|Overall Study|Adverse Event|52
6075138|NCT00577031|9679099|FG000|Overall Study|Progression of disease|93
6075139|NCT00577031|9679099|FG000|Overall Study|Protocol Violation|5
6075140|NCT00577031|9679099|FG000|Overall Study|Participant withdrew consent|13
6075141|NCT00577031|9679099|FG000|Overall Study|Participant non-compliance|5
6075142|NCT00577031|9679099|FG000|Overall Study|Need for surgery|17
6075143|NCT00577031|9679099|FG000|Overall Study|Medical decision|14
6075144|NCT00577031|9679099|FG000|Overall Study|Death|6
6075145|NCT00577096|9679123|FG000|Short Term Participation|withdrew from multiple myeloma treatment|3
6075146|NCT00577096|9679124|FG001|Short Term Participation|withdrew from multiple myeloma treatment|2
6075147|NCT00577096|9679123|FG000|Short Term Participation|Withdrawal by Subject|3
6075148|NCT00577096|9679124|FG001|Short Term Participation|Withdrawal by Subject|5
6075149|NCT00577096|9679123|FG000|Short Term Participation|Death|1
6075150|NCT00577096|9679124|FG001|Short Term Participation|Death|1
6075151|NCT00577122|9679132|FG000|Overall Study|Adverse Event|0
6075152|NCT00577122|9679133|FG001|Overall Study|Adverse Event|2
6075153|NCT00577122|9679132|FG000|Overall Study|Progression, relapse during active trt|6
6075154|NCT00577122|9679133|FG001|Overall Study|Progression, relapse during active trt|8
6075155|NCT00577122|9679132|FG000|Overall Study|Prog, refract disease during active trt|8
6075156|NCT00577122|9679133|FG001|Overall Study|Prog, refract disease during active trt|5
6075157|NCT00577122|9679132|FG000|Overall Study|Alternative Therapy|0
6075158|NCT00577122|9679133|FG001|Overall Study|Alternative Therapy|1
6075159|NCT00577382|9679159|FG000|Overall Study|Adverse Event|0
6075160|NCT00577382|9679160|FG001|Overall Study|Adverse Event|6
6075161|NCT00577382|9679159|FG000|Overall Study|Withdrawal by Subject|0
6075162|NCT00577382|9679160|FG001|Overall Study|Withdrawal by Subject|1
6009838|NCT00104299|9602731|FG001|Overall Study|Death|2
6009839|NCT00104299|9602730|FG000|Overall Study|Withdrawal by Subject|2
6009840|NCT00104299|9602731|FG001|Overall Study|Withdrawal by Subject|6
6009841|NCT00104299|9602730|FG000|Overall Study|Physician Decision|1
6009842|NCT00104299|9602731|FG001|Overall Study|Physician Decision|1
6009843|NCT00104299|9602730|FG000|Overall Study|To have renal transplant|1
6009844|NCT00104299|9602731|FG001|Overall Study|To have renal transplant|0
6009845|NCT00104416|9602739|FG000|Double-Blind Phase|Adverse Event|2
6009846|NCT00104416|9602740|FG001|Double-Blind Phase|Adverse Event|1
6009847|NCT00104416|9602741|FG002|Double-Blind Phase|Adverse Event|0
6009848|NCT00104416|9602742|FG003|Double-Blind Phase|Adverse Event|0
6075163|NCT00577382|9679159|FG000|Overall Study|Progressive Disease|17
6075164|NCT00577382|9679160|FG001|Overall Study|Progressive Disease|19
6075165|NCT00577382|9679159|FG000|Overall Study|Intercurrent Illness|1
6075166|NCT00577382|9679160|FG001|Overall Study|Intercurrent Illness|2
6075167|NCT00577382|9679159|FG000|Overall Study|Death|1
6075168|NCT00577382|9679160|FG001|Overall Study|Death|1
6075169|NCT00577382|9679159|FG000|Overall Study|Lost to Follow-up|2
6075170|NCT00577382|9679160|FG001|Overall Study|Lost to Follow-up|2
6075171|NCT00577408|9679168|FG000|Overall Study|Stopped attending study visits|9
6075172|NCT00577408|9679169|FG001|Overall Study|Stopped attending study visits|11
6075173|NCT00577408|9679168|FG000|Overall Study|Continued opioid use|3
6075174|NCT00577408|9679169|FG001|Overall Study|Continued opioid use|2
6075175|NCT00577408|9679168|FG000|Overall Study|Non-compliance with study meds|0
6075176|NCT00577408|9679169|FG001|Overall Study|Non-compliance with study meds|3
6075177|NCT00577408|9679168|FG000|Overall Study|Refused Oral Naltrexone|0
6075178|NCT00577408|9679169|FG001|Overall Study|Refused Oral Naltrexone|1
6075179|NCT00577408|9679168|FG000|Overall Study|Moved out of state|0
6075180|NCT00577408|9679169|FG001|Overall Study|Moved out of state|1
6075181|NCT00577408|9679168|FG000|Overall Study|Scheduling Issues|0
6075182|NCT00577408|9679169|FG001|Overall Study|Scheduling Issues|3
6075183|NCT00577408|9679168|FG000|Overall Study|Death|0
6075184|NCT00577408|9679169|FG001|Overall Study|Death|1
6075185|NCT00577408|9679168|FG000|Overall Study|Psychiatric hospitalization|0
6075186|NCT00577408|9679169|FG001|Overall Study|Psychiatric hospitalization|1
6075187|NCT00577460|9679178|FG000|Overall Study|Adverse Event|11
6075188|NCT00577460|9679179|FG001|Overall Study|Adverse Event|7
6075189|NCT00577460|9679180|FG002|Overall Study|Adverse Event|14
6075190|NCT00577460|9679178|FG000|Overall Study|Protocol Violation|0
6075191|NCT00577460|9679179|FG001|Overall Study|Protocol Violation|1
6075192|NCT00577460|9679180|FG002|Overall Study|Protocol Violation|1
6075193|NCT00577460|9679178|FG000|Overall Study|Lost to Follow-up|0
6075194|NCT00577460|9679179|FG001|Overall Study|Lost to Follow-up|3
6075195|NCT00577460|9679180|FG002|Overall Study|Lost to Follow-up|4
6075196|NCT00577460|9679178|FG000|Overall Study|Withdrawal by Subject|5
6075197|NCT00577460|9679179|FG001|Overall Study|Withdrawal by Subject|5
6075198|NCT00577460|9679180|FG002|Overall Study|Withdrawal by Subject|6
6075199|NCT00577460|9679178|FG000|Overall Study|Other|0
6075200|NCT00577460|9679179|FG001|Overall Study|Other|3
6075201|NCT00577460|9679180|FG002|Overall Study|Other|2
6075202|NCT00577473|9679197|FG000|Overall Study|Protocol Violation|1
6075203|NCT00577473|9679198|FG001|Overall Study|Protocol Violation|4
6075204|NCT00577473|9679197|FG000|Overall Study|Adverse Event|8
6075205|NCT00577473|9679198|FG001|Overall Study|Adverse Event|5
6075206|NCT00577473|9679197|FG000|Overall Study|Withdrawal by Subject|2
6075207|NCT00577473|9679198|FG001|Overall Study|Withdrawal by Subject|6
6075208|NCT00577473|9679197|FG000|Overall Study|Physician Decision|2
6075209|NCT00577473|9679198|FG001|Overall Study|Physician Decision|2
6075210|NCT00577473|9679197|FG000|Overall Study|Lack of Efficacy|8
6075211|NCT00577473|9679198|FG001|Overall Study|Lack of Efficacy|7
6075212|NCT00577629|9679221|FG000|Treatment Period|Death|1
6075213|NCT00577629|9679221|FG000|Long Term Follow-Up|Death|15
6075214|NCT00577629|9679221|FG000|Long Term Follow-Up|Lost to Follow-up|5
6075215|NCT00577629|9679221|FG000|Long Term Follow-Up|Withdrawal by Subject|4
6075216|NCT00577629|9679221|FG000|Long Term Follow-Up|Physician Decision|1
6075217|NCT00577642|9679227|FG000|Overall Study|Clinical Disease Progression|1
6075218|NCT00577655|9679233|FG000|Overall Study|Patient Request|0
6075219|NCT00577655|9679234|FG001|Overall Study|Patient Request|2
6075220|NCT00577655|9679233|FG000|Overall Study|Protocol Violation|0
6075221|NCT00577655|9679234|FG001|Overall Study|Protocol Violation|1
6075222|NCT00577655|9679233|FG000|Overall Study|Lost to Follow-up|1
6075223|NCT00577655|9679234|FG001|Overall Study|Lost to Follow-up|1
6075224|NCT00577707|9679241|FG000|Overall Study|Withdrawal by Subject|3
6075225|NCT00577720|9679249|FG000|Overall Study|Adverse Event|2
6075226|NCT00577720|9679250|FG001|Overall Study|Adverse Event|1
6075227|NCT00577720|9679251|FG002|Overall Study|Adverse Event|0
6075228|NCT00577720|9679252|FG003|Overall Study|Adverse Event|4
6075229|NCT00577720|9679249|FG000|Overall Study|Lost to Follow-up|0
6075230|NCT00577720|9679250|FG001|Overall Study|Lost to Follow-up|0
6075231|NCT00577720|9679251|FG002|Overall Study|Lost to Follow-up|1
6009849|NCT00104416|9602743|FG004|Double-Blind Phase|Adverse Event|0
6009850|NCT00104416|9602739|FG000|Double-Blind Phase|Lost to Follow-up|0
6075232|NCT00577720|9679252|FG003|Overall Study|Lost to Follow-up|0
6075233|NCT00577720|9679249|FG000|Overall Study|Protocol Violation|0
6075234|NCT00577720|9679250|FG001|Overall Study|Protocol Violation|0
6075235|NCT00577720|9679251|FG002|Overall Study|Protocol Violation|0
6075236|NCT00577720|9679252|FG003|Overall Study|Protocol Violation|1
6075237|NCT00577720|9679249|FG000|Overall Study|Withdrawal by Subject|2
6009851|NCT00104416|9602740|FG001|Double-Blind Phase|Lost to Follow-up|1
6009852|NCT00104416|9602741|FG002|Double-Blind Phase|Lost to Follow-up|0
6009853|NCT00104416|9602742|FG003|Double-Blind Phase|Lost to Follow-up|0
6009854|NCT00104416|9602743|FG004|Double-Blind Phase|Lost to Follow-up|0
6009855|NCT00104416|9602739|FG000|Double-Blind Phase|Protocol Violation|0
6009856|NCT00104416|9602740|FG001|Double-Blind Phase|Protocol Violation|1
6009857|NCT00104416|9602741|FG002|Double-Blind Phase|Protocol Violation|0
6009858|NCT00104416|9602742|FG003|Double-Blind Phase|Protocol Violation|0
6009859|NCT00104416|9602743|FG004|Double-Blind Phase|Protocol Violation|0
6009860|NCT00104416|9602739|FG000|Double-Blind Phase|Withdrawal by Subject|2
6009861|NCT00104416|9602740|FG001|Double-Blind Phase|Withdrawal by Subject|3
6009862|NCT00104416|9602741|FG002|Double-Blind Phase|Withdrawal by Subject|0
6009863|NCT00104416|9602742|FG003|Double-Blind Phase|Withdrawal by Subject|0
6009864|NCT00104416|9602743|FG004|Double-Blind Phase|Withdrawal by Subject|0
6009865|NCT00104416|9602739|FG000|Double-Blind Phase|Pregnancy|1
6075238|NCT00577720|9679250|FG001|Overall Study|Withdrawal by Subject|0
6075239|NCT00577720|9679251|FG002|Overall Study|Withdrawal by Subject|0
6075240|NCT00577720|9679252|FG003|Overall Study|Withdrawal by Subject|2
6075241|NCT00577824|9679265|FG000|Overall Study|Adverse Event|6
6075242|NCT00577824|9679266|FG001|Overall Study|Adverse Event|18
6075243|NCT00577824|9679267|FG002|Overall Study|Adverse Event|1
6075244|NCT00577824|9679265|FG000|Overall Study|Patient decision|0
6075245|NCT00577824|9679266|FG001|Overall Study|Patient decision|1
6075246|NCT00577824|9679267|FG002|Overall Study|Patient decision|1
6075247|NCT00577824|9679265|FG000|Overall Study|Protocol Violation|1
6075248|NCT00577824|9679266|FG001|Overall Study|Protocol Violation|1
6075249|NCT00577824|9679267|FG002|Overall Study|Protocol Violation|0
6075250|NCT00577863|9679277|FG000|Overall Study|Adverse Event|4
6075251|NCT00577863|9679278|FG001|Overall Study|Adverse Event|2
6075252|NCT00577863|9679277|FG000|Overall Study|Death|1
6075253|NCT00577863|9679278|FG001|Overall Study|Death|0
6075254|NCT00577863|9679277|FG000|Overall Study|Lost to Follow-up|2
6075255|NCT00577863|9679278|FG001|Overall Study|Lost to Follow-up|2
6075256|NCT00577863|9679277|FG000|Overall Study|Entry Criteria Exclusion|1
6075257|NCT00577863|9679278|FG001|Overall Study|Entry Criteria Exclusion|0
6075258|NCT00577863|9679277|FG000|Overall Study|Withdrawal by Subject|0
6075259|NCT00577863|9679278|FG001|Overall Study|Withdrawal by Subject|2
6075260|NCT00577863|9679277|FG000|Overall Study|Sponsor Decision|2
6075261|NCT00577863|9679278|FG001|Overall Study|Sponsor Decision|7
6075262|NCT00577863|9679277|FG000|Overall Study|Did Not Receive at Least One Injection|0
6075263|NCT00577863|9679278|FG001|Overall Study|Did Not Receive at Least One Injection|1
6075264|NCT00577889|9679287|FG000|Overall Study|Withdrawal by Subject|1
6075265|NCT00577889|9679288|FG001|Overall Study|Withdrawal by Subject|0
6075266|NCT00577889|9679289|FG002|Overall Study|Withdrawal by Subject|0
6075267|NCT00577993|9679300|FG000|Overall Study|Adverse Event|1
6075268|NCT00577993|9679301|FG001|Overall Study|Adverse Event|0
6075269|NCT00577993|9679302|FG002|Overall Study|Adverse Event|0
6075270|NCT00577993|9679300|FG000|Overall Study|Death|0
6075271|NCT00577993|9679301|FG001|Overall Study|Death|1
6075272|NCT00577993|9679302|FG002|Overall Study|Death|1
6075273|NCT00577993|9679300|FG000|Overall Study|Lack of Efficacy|0
6075274|NCT00577993|9679301|FG001|Overall Study|Lack of Efficacy|1
6075275|NCT00577993|9679302|FG002|Overall Study|Lack of Efficacy|0
6075276|NCT00577993|9679300|FG000|Overall Study|Protocol Violation|2
6075277|NCT00577993|9679301|FG001|Overall Study|Protocol Violation|3
6075278|NCT00577993|9679302|FG002|Overall Study|Protocol Violation|0
6075279|NCT00577993|9679300|FG000|Overall Study|Withdrawal by Subject|1
6075280|NCT00577993|9679301|FG001|Overall Study|Withdrawal by Subject|0
6075281|NCT00577993|9679302|FG002|Overall Study|Withdrawal by Subject|2
6075282|NCT00577993|9679300|FG000|Overall Study|Conversion|2
6075283|NCT00577993|9679301|FG001|Overall Study|Conversion|5
6075284|NCT00577993|9679302|FG002|Overall Study|Conversion|0
6075285|NCT00577993|9679300|FG000|Overall Study|Uninsured|1
6075286|NCT00577993|9679301|FG001|Overall Study|Uninsured|0
6075287|NCT00577993|9679302|FG002|Overall Study|Uninsured|0
6075288|NCT00578136|9679315|FG000|Overall Study|Not given intervention|1
6075289|NCT00578136|9679316|FG001|Overall Study|Not given intervention|1
6075290|NCT00578175|9679325|FG000|Overall Study|Adverse Event|0
6075291|NCT00578175|9679326|FG001|Overall Study|Adverse Event|1
6075292|NCT00578175|9679327|FG002|Overall Study|Adverse Event|1
6075293|NCT00578175|9679325|FG000|Overall Study|Other reasons|70
6009866|NCT00104416|9602740|FG001|Double-Blind Phase|Pregnancy|0
6009867|NCT00104416|9602741|FG002|Double-Blind Phase|Pregnancy|0
6075294|NCT00578175|9679326|FG001|Overall Study|Other reasons|42
6075295|NCT00578175|9679327|FG002|Overall Study|Other reasons|23
6075296|NCT00578227|9679353|FG000|Overall Study|Lost to Follow-up|0
6009868|NCT00104416|9602742|FG003|Double-Blind Phase|Pregnancy|0
6075297|NCT00578227|9679354|FG001|Overall Study|Lost to Follow-up|1
6075298|NCT00578227|9679355|FG002|Overall Study|Lost to Follow-up|1
6075299|NCT00578227|9679353|FG000|Overall Study|Withdrawal by Subject|5
6075300|NCT00578227|9679354|FG001|Overall Study|Withdrawal by Subject|1
6075301|NCT00578227|9679355|FG002|Overall Study|Withdrawal by Subject|3
6075302|NCT00578292|9679374|FG000|Overall Study|Death|1
6075303|NCT00578292|9679374|FG000|Overall Study|Graft failure|2
6075304|NCT00578318|9679399|FG000|Overall Study|Lost to Follow-up|2
6075305|NCT00578318|9679400|FG001|Overall Study|Lost to Follow-up|0
6009869|NCT00104416|9602743|FG004|Double-Blind Phase|Pregnancy|0
6009870|NCT00104416|9602739|FG000|Double-Blind Phase|Participant Did Not Take Drug|3
6009871|NCT00104416|9602740|FG001|Double-Blind Phase|Participant Did Not Take Drug|4
6009872|NCT00104416|9602741|FG002|Double-Blind Phase|Participant Did Not Take Drug|0
6009873|NCT00104416|9602742|FG003|Double-Blind Phase|Participant Did Not Take Drug|0
6009874|NCT00104416|9602743|FG004|Double-Blind Phase|Participant Did Not Take Drug|0
6009875|NCT00104416|9602739|FG000|Continuation Phase|Adverse Event|0
6009876|NCT00104416|9602740|FG001|Continuation Phase|Adverse Event|0
6009877|NCT00104416|9602741|FG002|Continuation Phase|Adverse Event|2
6009878|NCT00104416|9602742|FG003|Continuation Phase|Adverse Event|0
6009879|NCT00104416|9602743|FG004|Continuation Phase|Adverse Event|2
6009880|NCT00104416|9602739|FG000|Continuation Phase|Lost to Follow-up|0
6009881|NCT00104416|9602740|FG001|Continuation Phase|Lost to Follow-up|0
6009882|NCT00104416|9602741|FG002|Continuation Phase|Lost to Follow-up|1
6009883|NCT00104416|9602742|FG003|Continuation Phase|Lost to Follow-up|0
6009884|NCT00104416|9602743|FG004|Continuation Phase|Lost to Follow-up|1
6009885|NCT00104416|9602739|FG000|Continuation Phase|Withdrawal by Subject|0
6009886|NCT00104416|9602740|FG001|Continuation Phase|Withdrawal by Subject|0
6009887|NCT00104416|9602741|FG002|Continuation Phase|Withdrawal by Subject|2
6009888|NCT00104416|9602742|FG003|Continuation Phase|Withdrawal by Subject|1
6009889|NCT00104416|9602743|FG004|Continuation Phase|Withdrawal by Subject|1
6009890|NCT00104416|9602739|FG000|Continuation Phase|Pregnancy|0
6009891|NCT00104416|9602740|FG001|Continuation Phase|Pregnancy|0
6009892|NCT00104416|9602741|FG002|Continuation Phase|Pregnancy|1
6009893|NCT00104416|9602742|FG003|Continuation Phase|Pregnancy|1
6009894|NCT00104416|9602743|FG004|Continuation Phase|Pregnancy|0
6009895|NCT00104416|9602739|FG000|Continuation Phase|Non-compliance|0
6009896|NCT00104416|9602740|FG001|Continuation Phase|Non-compliance|0
6009897|NCT00104416|9602741|FG002|Continuation Phase|Non-compliance|0
6009898|NCT00104416|9602742|FG003|Continuation Phase|Non-compliance|0
6009899|NCT00104416|9602743|FG004|Continuation Phase|Non-compliance|1
6009900|NCT00104520|9602757|FG000|Overall Study|Unrelated adverse event|34
6009901|NCT00104520|9602758|FG001|Overall Study|Unrelated adverse event|47
6009902|NCT00104520|9602757|FG000|Overall Study|Study drug intolerance|0
6009903|NCT00104520|9602758|FG001|Overall Study|Study drug intolerance|1
6009904|NCT00104520|9602757|FG000|Overall Study|Related adverse event|13
6009905|NCT00104520|9602758|FG001|Overall Study|Related adverse event|15
6009906|NCT00104520|9602757|FG000|Overall Study|Lost to Follow-up|1
6009907|NCT00104520|9602758|FG001|Overall Study|Lost to Follow-up|0
6075306|NCT00578318|9679399|FG000|Overall Study|Physician Decision|1
6075307|NCT00578318|9679400|FG001|Overall Study|Physician Decision|0
6075308|NCT00578344|9679415|FG000|Overall Study|Insurance problems|1
6075309|NCT00578344|9679415|FG000|Overall Study|Graft failure|1
6075310|NCT00578448|9679440|FG000|Day 1 up to 3 Years of Planned Study|Death|1
6075311|NCT00578448|9679440|FG000|Day 1 up to 3 Years of Planned Study|Adverse Event|1
6075312|NCT00578448|9679440|FG000|Day 1 up to 3 Years of Planned Study|started marketed Cellcept and Prograf|1
6075313|NCT00578448|9679440|FG000|1 Year Long Term Extension (LTE)|Adverse Event|1
6075314|NCT00578565|9679467|FG000|Overall Study|Adverse Event|3
6075315|NCT00578643|9679481|FG000|Overall Study|Death|1
6075316|NCT00578643|9679481|FG000|Overall Study|Lost to Follow-up|1
6075317|NCT00578786|9679506|FG000|Overall Study|Adverse Event|27
6075318|NCT00578786|9679507|FG001|Overall Study|Adverse Event|37
6075319|NCT00578786|9679508|FG002|Overall Study|Adverse Event|17
6075320|NCT00578786|9679506|FG000|Overall Study|Lack of Efficacy|2
6075321|NCT00578786|9679507|FG001|Overall Study|Lack of Efficacy|5
6075322|NCT00578786|9679508|FG002|Overall Study|Lack of Efficacy|2
6075323|NCT00578786|9679506|FG000|Overall Study|Early Escape from Prior Study|2
6075324|NCT00578786|9679507|FG001|Overall Study|Early Escape from Prior Study|1
6075325|NCT00578786|9679508|FG002|Overall Study|Early Escape from Prior Study|2
6075326|NCT00578786|9679506|FG000|Overall Study|Withdrawal by Subject|7
6075327|NCT00578786|9679507|FG001|Overall Study|Withdrawal by Subject|8
6075328|NCT00578786|9679508|FG002|Overall Study|Withdrawal by Subject|5
6075329|NCT00578786|9679506|FG000|Overall Study|Protocol Violation|0
6075330|NCT00578786|9679507|FG001|Overall Study|Protocol Violation|3
6075331|NCT00578786|9679508|FG002|Overall Study|Protocol Violation|1
6075332|NCT00578786|9679506|FG000|Overall Study|Physician Decision|1
6075333|NCT00578786|9679507|FG001|Overall Study|Physician Decision|0
6009908|NCT00104520|9602757|FG000|Overall Study|Noncompliance|0
6009909|NCT00104520|9602758|FG001|Overall Study|Noncompliance|2
6009910|NCT00104520|9602757|FG000|Overall Study|Personal/administrative|1
6009911|NCT00104520|9602758|FG001|Overall Study|Personal/administrative|1
6009912|NCT00104520|9602757|FG000|Overall Study|Other|1
6009913|NCT00104520|9602758|FG001|Overall Study|Other|5
6075334|NCT00578786|9679508|FG002|Overall Study|Physician Decision|1
6075335|NCT00578786|9679506|FG000|Overall Study|Sponsor Decision|0
6075336|NCT00578786|9679507|FG001|Overall Study|Sponsor Decision|0
6075337|NCT00578786|9679508|FG002|Overall Study|Sponsor Decision|1
6075338|NCT00578786|9679506|FG000|Overall Study|Lost to Follow-up|0
6075339|NCT00578786|9679507|FG001|Overall Study|Lost to Follow-up|4
6146254|NCT01076010|9780832|FG000|Overall Study|Significant Surgical Procedure|0
6009914|NCT00104572|9602767|FG000|Overall Study|Withdrawal by Subject|3
6075340|NCT00578786|9679508|FG002|Overall Study|Lost to Follow-up|0
6075341|NCT00578786|9679506|FG000|Overall Study|Pregnancy|0
6075342|NCT00578786|9679507|FG001|Overall Study|Pregnancy|1
6009915|NCT00104572|9602768|FG001|Overall Study|Withdrawal by Subject|3
6009916|NCT00104572|9602769|FG002|Overall Study|Withdrawal by Subject|0
6009917|NCT00104637|9602777|FG000|Period 1: ( TREATMENT: 4 Weeks)|Adverse Event|1
6009918|NCT00104637|9602778|FG001|Period 1: ( TREATMENT: 4 Weeks)|Adverse Event|0
6009919|NCT00104650|9602790|FG000|Treatment Period (25 Weeks)|Physician Decision|0
6009920|NCT00104650|9602791|FG001|Treatment Period (25 Weeks)|Physician Decision|0
6009921|NCT00104650|9602792|FG002|Treatment Period (25 Weeks)|Physician Decision|1
6009922|NCT00104650|9602790|FG000|Treatment Period (25 Weeks)|Withdrawal by Subject|2
6009923|NCT00104650|9602791|FG001|Treatment Period (25 Weeks)|Withdrawal by Subject|1
6009924|NCT00104650|9602792|FG002|Treatment Period (25 Weeks)|Withdrawal by Subject|1
6009925|NCT00104650|9602790|FG000|Treatment Period (25 Weeks)|Death|7
6009926|NCT00104650|9602791|FG001|Treatment Period (25 Weeks)|Death|5
6009927|NCT00104650|9602792|FG002|Treatment Period (25 Weeks)|Death|6
6075343|NCT00578786|9679508|FG002|Overall Study|Pregnancy|0
6075344|NCT00578786|9679506|FG000|Overall Study|Not Otherwise Specified|0
6075345|NCT00578786|9679507|FG001|Overall Study|Not Otherwise Specified|4
6075346|NCT00578786|9679508|FG002|Overall Study|Not Otherwise Specified|1
6075347|NCT00578786|9679506|FG000|Overall Study|Qualified but Not Enrolled in Extension|0
6075348|NCT00578786|9679507|FG001|Overall Study|Qualified but Not Enrolled in Extension|3
6075349|NCT00578786|9679508|FG002|Overall Study|Qualified but Not Enrolled in Extension|0
6075350|NCT00578812|9679528|FG000|Overall Study|Not treated|6
6075351|NCT00578812|9679529|FG001|Overall Study|Not treated|7
6075352|NCT00578864|9679538|FG000|Overall Study|Death|1
6075353|NCT00578864|9679539|FG001|Overall Study|Death|0
6075354|NCT00578877|9679547|FG000|Overall Study|Lost to Follow-up|8
6075355|NCT00578877|9679548|FG001|Overall Study|Lost to Follow-up|10
6075356|NCT00578877|9679547|FG000|Overall Study|early discontinue|61
6075357|NCT00578877|9679548|FG001|Overall Study|early discontinue|101
6075358|NCT00578877|9679547|FG000|Overall Study|did not provide follow-up data|12
6075359|NCT00578877|9679548|FG001|Overall Study|did not provide follow-up data|17
6075360|NCT00578942|9679576|FG000|Overall Study|Lost to Follow-up|1
6075361|NCT00579059|9679596|FG000|Overall Study|Study Canceled at 1 Year|21
6075362|NCT00579059|9679597|FG001|Overall Study|Study Canceled at 1 Year|10
6075363|NCT00579098|9679605|FG000|Overall Study|Lost to Follow-up|2
6075364|NCT00579098|9679606|FG001|Overall Study|Lost to Follow-up|0
6075365|NCT00579098|9679605|FG000|Overall Study|Adverse Event|2
6075366|NCT00579098|9679606|FG001|Overall Study|Adverse Event|3
6075367|NCT00579098|9679605|FG000|Overall Study|Withdrawal by Subject|2
6075368|NCT00579098|9679606|FG001|Overall Study|Withdrawal by Subject|3
6075369|NCT00579098|9679605|FG000|Overall Study|AF returned after ablation|3
6075370|NCT00579098|9679606|FG001|Overall Study|AF returned after ablation|2
6075371|NCT00579345|9679646|FG000|Overall Study|Withdrawal by Subject|2
6075372|NCT00579345|9679647|FG001|Overall Study|Withdrawal by Subject|0
6075373|NCT00579345|9679648|FG002|Overall Study|Withdrawal by Subject|0
6075374|NCT00579345|9679649|FG003|Overall Study|Withdrawal by Subject|0
6075375|NCT00579345|9679650|FG004|Overall Study|Withdrawal by Subject|0
6075376|NCT00579345|9679651|FG005|Overall Study|Withdrawal by Subject|0
6075377|NCT00579345|9679652|FG006|Overall Study|Withdrawal by Subject|0
6075378|NCT00579345|9679653|FG007|Overall Study|Withdrawal by Subject|1
6075379|NCT00579345|9679646|FG000|Overall Study|Lost to Follow-up|1
6075380|NCT00579345|9679647|FG001|Overall Study|Lost to Follow-up|0
6075381|NCT00579345|9679648|FG002|Overall Study|Lost to Follow-up|0
6075382|NCT00579345|9679649|FG003|Overall Study|Lost to Follow-up|0
6075383|NCT00579345|9679650|FG004|Overall Study|Lost to Follow-up|0
6075384|NCT00579345|9679651|FG005|Overall Study|Lost to Follow-up|0
6075385|NCT00579345|9679652|FG006|Overall Study|Lost to Follow-up|0
6075386|NCT00579345|9679653|FG007|Overall Study|Lost to Follow-up|0
6075387|NCT00579345|9679646|FG000|Overall Study|Adverse Event|0
6075388|NCT00579345|9679647|FG001|Overall Study|Adverse Event|0
6075389|NCT00579345|9679648|FG002|Overall Study|Adverse Event|1
6075390|NCT00579345|9679649|FG003|Overall Study|Adverse Event|0
6075391|NCT00579345|9679650|FG004|Overall Study|Adverse Event|0
6075392|NCT00579345|9679651|FG005|Overall Study|Adverse Event|0
6075393|NCT00579345|9679652|FG006|Overall Study|Adverse Event|0
6075394|NCT00579345|9679653|FG007|Overall Study|Adverse Event|0
6075395|NCT00579345|9679646|FG000|Overall Study|Protocol Violation|1
6075396|NCT00579345|9679647|FG001|Overall Study|Protocol Violation|0
6075397|NCT00579345|9679648|FG002|Overall Study|Protocol Violation|0
6009928|NCT00104650|9602790|FG000|Treatment Period (25 Weeks)|Disease progression|2
6075398|NCT00579345|9679649|FG003|Overall Study|Protocol Violation|0
6075399|NCT00579345|9679650|FG004|Overall Study|Protocol Violation|0
6075400|NCT00579345|9679651|FG005|Overall Study|Protocol Violation|0
6075401|NCT00579345|9679652|FG006|Overall Study|Protocol Violation|0
6075402|NCT00579345|9679653|FG007|Overall Study|Protocol Violation|1
6075403|NCT00579345|9679646|FG000|Overall Study|Death|1
6075404|NCT00579345|9679647|FG001|Overall Study|Death|1
6075405|NCT00579345|9679648|FG002|Overall Study|Death|1
6075406|NCT00579345|9679649|FG003|Overall Study|Death|1
6009929|NCT00104650|9602791|FG001|Treatment Period (25 Weeks)|Disease progression|3
6047418|NCT00410605|9646323|FG000|Overall Study|Physician Decision|3
6075407|NCT00579345|9679650|FG004|Overall Study|Death|0
6075408|NCT00579345|9679651|FG005|Overall Study|Death|0
6075409|NCT00579345|9679652|FG006|Overall Study|Death|0
6075410|NCT00579345|9679653|FG007|Overall Study|Death|0
6075411|NCT00579501|9679690|FG000|Overall Study|Death|1
6009930|NCT00104650|9602792|FG002|Treatment Period (25 Weeks)|Disease progression|2
6009931|NCT00104650|9602790|FG000|Treatment Period (25 Weeks)|Ineligibility determined|0
6009932|NCT00104650|9602791|FG001|Treatment Period (25 Weeks)|Ineligibility determined|1
6009933|NCT00104650|9602792|FG002|Treatment Period (25 Weeks)|Ineligibility determined|0
6009934|NCT00104650|9602790|FG000|Treatment Period (25 Weeks)|Other|1
6009935|NCT00104650|9602791|FG001|Treatment Period (25 Weeks)|Other|0
6009936|NCT00104650|9602792|FG002|Treatment Period (25 Weeks)|Other|0
6009937|NCT00104650|9602790|FG000|Treatment Period (25 Weeks)|Protocol deviation|0
6009938|NCT00104650|9602791|FG001|Treatment Period (25 Weeks)|Protocol deviation|1
6009939|NCT00104650|9602792|FG002|Treatment Period (25 Weeks)|Protocol deviation|0
6009940|NCT00104650|9602790|FG000|Follow-up Period|Physician Decision|1
6009941|NCT00104650|9602791|FG001|Follow-up Period|Physician Decision|1
6009942|NCT00104650|9602792|FG002|Follow-up Period|Physician Decision|0
6009943|NCT00104650|9602790|FG000|Follow-up Period|Adverse Event|1
6009944|NCT00104650|9602791|FG001|Follow-up Period|Adverse Event|0
6009945|NCT00104650|9602792|FG002|Follow-up Period|Adverse Event|1
6009946|NCT00104650|9602790|FG000|Follow-up Period|Withdrawal by Subject|0
6009947|NCT00104650|9602791|FG001|Follow-up Period|Withdrawal by Subject|3
6009948|NCT00104650|9602792|FG002|Follow-up Period|Withdrawal by Subject|3
6009949|NCT00104650|9602790|FG000|Follow-up Period|Death|6
6009950|NCT00104650|9602791|FG001|Follow-up Period|Death|6
6009951|NCT00104650|9602792|FG002|Follow-up Period|Death|4
6009952|NCT00104650|9602790|FG000|Follow-up Period|Disease progression|3
6009953|NCT00104650|9602791|FG001|Follow-up Period|Disease progression|1
6009954|NCT00104650|9602792|FG002|Follow-up Period|Disease progression|0
6009955|NCT00104650|9602790|FG000|Follow-up Period|Lost to Follow-up|0
6075412|NCT00579501|9679690|FG000|Overall Study|End of neoadjuvant therapy|25
6075413|NCT00579501|9679690|FG000|Overall Study|toxicity|1
6075414|NCT00579501|9679690|FG000|Overall Study|Secondary lesion|1
6075415|NCT00579501|9679690|FG000|Overall Study|Radiation therapy before surgery|1
6075416|NCT00579553|9679696|FG000|Overall Study|Lost to Follow-up|16
6075417|NCT00579553|9679697|FG001|Overall Study|Lost to Follow-up|13
6075418|NCT00579670|9679708|FG000|Overall Study|Death|1
6075419|NCT00579670|9679709|FG001|Overall Study|Death|0
6075420|NCT00579670|9679710|FG002|Overall Study|Death|0
6075421|NCT00579670|9679711|FG003|Overall Study|Death|0
6075422|NCT00579670|9679712|FG004|Overall Study|Death|0
6075423|NCT00579670|9679708|FG000|Overall Study|Adverse Event|1
6075424|NCT00579670|9679709|FG001|Overall Study|Adverse Event|0
6075425|NCT00579670|9679710|FG002|Overall Study|Adverse Event|1
6075426|NCT00579670|9679711|FG003|Overall Study|Adverse Event|2
6075427|NCT00579670|9679712|FG004|Overall Study|Adverse Event|0
6075428|NCT00579670|9679708|FG000|Overall Study|Lack of Efficacy|0
6075429|NCT00579670|9679709|FG001|Overall Study|Lack of Efficacy|0
6075430|NCT00579670|9679710|FG002|Overall Study|Lack of Efficacy|1
6075431|NCT00579670|9679711|FG003|Overall Study|Lack of Efficacy|14
6075432|NCT00579670|9679712|FG004|Overall Study|Lack of Efficacy|0
6075433|NCT00579670|9679708|FG000|Overall Study|Lost to Follow-up|0
6075434|NCT00579670|9679709|FG001|Overall Study|Lost to Follow-up|1
6075435|NCT00579670|9679710|FG002|Overall Study|Lost to Follow-up|0
6075436|NCT00579670|9679711|FG003|Overall Study|Lost to Follow-up|4
6075437|NCT00579670|9679712|FG004|Overall Study|Lost to Follow-up|0
6075438|NCT00579670|9679708|FG000|Overall Study|Other|0
6075439|NCT00579670|9679709|FG001|Overall Study|Other|0
6075440|NCT00579670|9679710|FG002|Overall Study|Other|1
6075441|NCT00579670|9679711|FG003|Overall Study|Other|2
6075442|NCT00579670|9679712|FG004|Overall Study|Other|0
6075443|NCT00579670|9679708|FG000|Overall Study|Withdrawal by Subject|0
6075444|NCT00579670|9679709|FG001|Overall Study|Withdrawal by Subject|0
6075445|NCT00579670|9679710|FG002|Overall Study|Withdrawal by Subject|1
6075446|NCT00579670|9679711|FG003|Overall Study|Withdrawal by Subject|0
6075447|NCT00579670|9679712|FG004|Overall Study|Withdrawal by Subject|0
6075448|NCT00579982|9679759|FG000|Overall Study|Adverse Event|4
6075449|NCT00579982|9679759|FG000|Overall Study|Protocol Violation|4
6075450|NCT00580034|9679763|FG000|Overall Study|Toxicity|10
6075451|NCT00580034|9679764|FG001|Overall Study|Toxicity|0
6075452|NCT00580047|9679771|FG000|Overall Study|Lost to Follow-up|1
6009956|NCT00104650|9602791|FG001|Follow-up Period|Lost to Follow-up|1
6009957|NCT00104650|9602792|FG002|Follow-up Period|Lost to Follow-up|2
6009958|NCT00104650|9602790|FG000|Follow-up Period|Other|0
6009959|NCT00104650|9602791|FG001|Follow-up Period|Other|1
6009960|NCT00104650|9602792|FG002|Follow-up Period|Other|0
6075453|NCT00580047|9679772|FG001|Overall Study|Lost to Follow-up|1
6075454|NCT00580047|9679773|FG002|Overall Study|Lost to Follow-up|0
6075455|NCT00580047|9679771|FG000|Overall Study|Withdrawal by Subject|1
6075456|NCT00580047|9679772|FG001|Overall Study|Withdrawal by Subject|1
6075457|NCT00580047|9679773|FG002|Overall Study|Withdrawal by Subject|2
6009961|NCT00104676|9602802|FG000|Overall Study|Death|3
6075458|NCT00580047|9679771|FG000|Overall Study|Withdrawal by Subject|1
6075459|NCT00580047|9679772|FG001|Overall Study|Withdrawal by Subject|0
6075460|NCT00580047|9679773|FG002|Overall Study|Withdrawal by Subject|0
6075461|NCT00580606|9679833|FG000|Open Label (OL)|Lack of Efficacy at Week 116 OFC|2
6075462|NCT00580606|9679834|FG001|Open Label (OL)|Lack of Efficacy at Week 116 OFC|1
6075463|NCT00580606|9679833|FG000|Open Label (OL)|Withdrawal by Subject|4
6075464|NCT00580606|9679834|FG001|Open Label (OL)|Withdrawal by Subject|6
6075465|NCT00580606|9679833|FG000|Open Label (OL)|Dosing Symptoms|0
6009962|NCT00104676|9602803|FG001|Overall Study|Death|2
6009963|NCT00104676|9602802|FG000|Overall Study|Withdrawal by Subject|0
6009964|NCT00104676|9602803|FG001|Overall Study|Withdrawal by Subject|2
6009965|NCT00104676|9602802|FG000|Overall Study|treatment interruption|4
6009966|NCT00104676|9602803|FG001|Overall Study|treatment interruption|10
6009967|NCT00104871|9602815|FG000|Overall Study|Not evaluable|1
6009968|NCT00104884|9602819|FG000|Overall Study|Disease progression|4
6009969|NCT00105066|9602863|FG000|Overall Study|Adverse Event|2
6009970|NCT00105066|9602864|FG001|Overall Study|Adverse Event|5
6009971|NCT00105079|9602872|FG000|Overall Study|Adverse Event|5
6009972|NCT00105079|9602873|FG001|Overall Study|Adverse Event|12
6009973|NCT00105079|9602872|FG000|Overall Study|Death|3
6009974|NCT00105079|9602873|FG001|Overall Study|Death|1
6075466|NCT00580606|9679834|FG001|Open Label (OL)|Dosing Symptoms|1
6075467|NCT00580606|9679833|FG000|Open Label (OL)|Lost to Follow-up|0
6075468|NCT00580606|9679834|FG001|Open Label (OL)|Lost to Follow-up|1
6075469|NCT00580606|9679833|FG000|Open Label (OL)|Pregnancy|0
6075470|NCT00580606|9679834|FG001|Open Label (OL)|Pregnancy|1
6075471|NCT00580606|9679833|FG000|Open Label (OL)|Non-compliance|2
6075472|NCT00580606|9679834|FG001|Open Label (OL)|Non-compliance|0
6075473|NCT00580606|9679833|FG000|Open Label (OL)|Physician Decision|1
6075474|NCT00580606|9679834|FG001|Open Label (OL)|Physician Decision|1
6075475|NCT00580606|9679833|FG000|Open Label (OL)|Needed Prohibited Medication|0
6075476|NCT00580606|9679834|FG001|Open Label (OL)|Needed Prohibited Medication|1
6087343|NCT00667446|9697550|FG000|Treatment Period (36 Months)|Ready to enter puberty based on age|13
6087344|NCT00667446|9697551|FG001|Treatment Period (36 Months)|Ready to enter puberty based on age|15
6087345|NCT00667446|9697550|FG000|Treatment Period (36 Months)|Other|2
6087346|NCT00667446|9697551|FG001|Treatment Period (36 Months)|Other|2
6087347|NCT00667446|9697550|FG000|Treatment Period (36 Months)|Personal reasons|2
6087348|NCT00667446|9697551|FG001|Treatment Period (36 Months)|Personal reasons|2
6087349|NCT00667446|9697550|FG000|Treatment Period (36 Months)|Withdrawal by Subject|0
6087350|NCT00667446|9697551|FG001|Treatment Period (36 Months)|Withdrawal by Subject|4
6087351|NCT00667446|9697550|FG000|Treatment Period (36 Months)|Not Adequately Suppressed on Therapy|3
6087352|NCT00667446|9697551|FG001|Treatment Period (36 Months)|Not Adequately Suppressed on Therapy|0
6087353|NCT00667446|9697550|FG000|Treatment Period (36 Months)|Lost to Follow-up|1
6087354|NCT00667446|9697551|FG001|Treatment Period (36 Months)|Lost to Follow-up|0
6087355|NCT00667446|9697550|FG000|Treatment Period (36 Months)|Protocol Violation|1
6087356|NCT00667446|9697551|FG001|Treatment Period (36 Months)|Protocol Violation|1
6087357|NCT00667446|9697550|FG000|Treatment Period (36 Months)|Therapeutic Failure|1
6087358|NCT00667446|9697551|FG001|Treatment Period (36 Months)|Therapeutic Failure|1
6087359|NCT00667446|9697550|FG000|Safety Follow-up Period (12 Weeks)|No Longer Needed Treatment|0
6087360|NCT00667446|9697551|FG001|Safety Follow-up Period (12 Weeks)|No Longer Needed Treatment|1
6087361|NCT00667459|9697559|FG000|Overall Study|Death|0
6087362|NCT00667459|9697560|FG001|Overall Study|Death|2
6087363|NCT00667459|9697559|FG000|Overall Study|Lost to Follow-up|8
6087364|NCT00667459|9697560|FG001|Overall Study|Lost to Follow-up|43
6009975|NCT00105079|9602872|FG000|Overall Study|Lost to Follow-up|12
6009976|NCT00105079|9602873|FG001|Overall Study|Lost to Follow-up|12
6009977|NCT00105079|9602872|FG000|Overall Study|Lack of Efficacy|9
6009978|NCT00105079|9602873|FG001|Overall Study|Lack of Efficacy|3
6009979|NCT00105079|9602872|FG000|Overall Study|Refused treatment|6
6009980|NCT00105079|9602873|FG001|Overall Study|Refused treatment|4
6009981|NCT00105079|9602872|FG000|Overall Study|Violation of selection criteria at entry|0
6009982|NCT00105079|9602873|FG001|Overall Study|Violation of selection criteria at entry|2
6009983|NCT00105079|9602872|FG000|Overall Study|Protocol Violation|1
6009984|NCT00105079|9602873|FG001|Overall Study|Protocol Violation|0
6009985|NCT00105079|9602872|FG000|Overall Study|Other|3
6009986|NCT00105079|9602873|FG001|Overall Study|Other|1
6009987|NCT00105157|9602883|FG000|Double-Blind (DB)|Never Treated|1
6009988|NCT00105157|9602884|FG001|Double-Blind (DB)|Never Treated|0
6009989|NCT00105157|9602885|FG002|Double-Blind (DB)|Never Treated|0
6009990|NCT00105157|9602886|FG003|Double-Blind (DB)|Never Treated|0
6087365|NCT00667563|9697572|FG000|Overall Study|Protocol Violation|24
6087366|NCT00667576|9697581|FG000|Overall Study|Withdrawal by Subject|1
6087367|NCT00667576|9697582|FG001|Overall Study|Withdrawal by Subject|0
6087368|NCT00667576|9697583|FG002|Overall Study|Withdrawal by Subject|1
6009991|NCT00105157|9602883|FG000|Double-Blind (DB)|Adverse Event|2
6009992|NCT00105157|9602884|FG001|Double-Blind (DB)|Adverse Event|0
6009993|NCT00105157|9602885|FG002|Double-Blind (DB)|Adverse Event|1
6087369|NCT00667576|9697584|FG003|Overall Study|Withdrawal by Subject|1
6087370|NCT00667576|9697585|FG004|Overall Study|Withdrawal by Subject|1
6087371|NCT00667576|9697581|FG000|Overall Study|Adverse Event|1
6087372|NCT00667576|9697582|FG001|Overall Study|Adverse Event|1
6087373|NCT00667576|9697583|FG002|Overall Study|Adverse Event|0
6087374|NCT00667576|9697584|FG003|Overall Study|Adverse Event|0
6087375|NCT00667576|9697585|FG004|Overall Study|Adverse Event|0
6087376|NCT00667576|9697581|FG000|Overall Study|Lost to Follow-up|0
6087377|NCT00667576|9697582|FG001|Overall Study|Lost to Follow-up|0
6087378|NCT00667576|9697583|FG002|Overall Study|Lost to Follow-up|1
6087379|NCT00667576|9697584|FG003|Overall Study|Lost to Follow-up|0
6087380|NCT00667576|9697585|FG004|Overall Study|Lost to Follow-up|0
6087381|NCT00667576|9697581|FG000|Overall Study|Protocol Violation|0
6009994|NCT00105157|9602886|FG003|Double-Blind (DB)|Adverse Event|1
6009995|NCT00105157|9602883|FG000|Double-Blind (DB)|Lack of Efficacy|11
6009996|NCT00105157|9602884|FG001|Double-Blind (DB)|Lack of Efficacy|14
6009997|NCT00105157|9602885|FG002|Double-Blind (DB)|Lack of Efficacy|11
6009998|NCT00105157|9602886|FG003|Double-Blind (DB)|Lack of Efficacy|38
6009999|NCT00105157|9602883|FG000|Open-Label Continuation of DB|Adverse Event|3
6010000|NCT00105157|9602884|FG001|Open-Label Continuation of DB|Adverse Event|1
6010001|NCT00105157|9602885|FG002|Open-Label Continuation of DB|Adverse Event|0
6010002|NCT00105157|9602886|FG003|Open-Label Continuation of DB|Adverse Event|0
6010003|NCT00105157|9602883|FG000|Open-Label Continuation of DB|Lack of Efficacy|1
6010004|NCT00105157|9602884|FG001|Open-Label Continuation of DB|Lack of Efficacy|4
6075477|NCT00580723|9679874|FG000|Overall Study|Did not want to participate in extension|3
6075478|NCT00580723|9679874|FG000|Overall Study|Lost to Follow-up|5
6075479|NCT00580788|9679882|FG000|Overall Study|Adverse Event|0
6075480|NCT00580788|9679883|FG001|Overall Study|Adverse Event|0
6075481|NCT00580788|9679884|FG002|Overall Study|Adverse Event|0
6075482|NCT00580788|9679885|FG003|Overall Study|Adverse Event|1
6075483|NCT00580801|9679905|FG000|Overall Study|Physician Decision|1
6075484|NCT00580801|9679906|FG001|Overall Study|Physician Decision|0
6075485|NCT00580801|9679907|FG002|Overall Study|Physician Decision|0
6075486|NCT00580801|9679905|FG000|Overall Study|Adverse Event|2
6075487|NCT00580801|9679906|FG001|Overall Study|Adverse Event|0
6075488|NCT00580801|9679907|FG002|Overall Study|Adverse Event|0
6075489|NCT00580801|9679905|FG000|Overall Study|Lost to Follow-up|2
6075490|NCT00580801|9679906|FG001|Overall Study|Lost to Follow-up|0
6075491|NCT00580801|9679907|FG002|Overall Study|Lost to Follow-up|0
6075492|NCT00580801|9679905|FG000|Overall Study|Reached a virologic endpoint|0
6075493|NCT00580801|9679906|FG001|Overall Study|Reached a virologic endpoint|1
6075494|NCT00580801|9679907|FG002|Overall Study|Reached a virologic endpoint|2
6075495|NCT00580801|9679905|FG000|Overall Study|Participant non-compliant|0
6075496|NCT00580801|9679906|FG001|Overall Study|Participant non-compliant|0
6075497|NCT00580801|9679907|FG002|Overall Study|Participant non-compliant|1
6075498|NCT00580801|9679905|FG000|Overall Study|Travel|1
6075499|NCT00580801|9679906|FG001|Overall Study|Travel|0
6075500|NCT00580801|9679907|FG002|Overall Study|Travel|0
6075501|NCT00580840|9679915|FG000|Run-in|Adverse Event|17
6075502|NCT00580840|9679916|FG001|Run-in|Adverse Event|0
6075503|NCT00580840|9679917|FG002|Run-in|Adverse Event|0
6075504|NCT00580840|9679918|FG003|Run-in|Adverse Event|0
6075505|NCT00580840|9679915|FG000|Run-in|Lack of Efficacy|93
6075506|NCT00580840|9679916|FG001|Run-in|Lack of Efficacy|0
6075507|NCT00580840|9679917|FG002|Run-in|Lack of Efficacy|0
6075508|NCT00580840|9679918|FG003|Run-in|Lack of Efficacy|0
6075509|NCT00580840|9679915|FG000|Run-in|Loss of Efficacy|1
6075510|NCT00580840|9679916|FG001|Run-in|Loss of Efficacy|0
6075511|NCT00580840|9679917|FG002|Run-in|Loss of Efficacy|0
6075512|NCT00580840|9679918|FG003|Run-in|Loss of Efficacy|0
6075513|NCT00580840|9679915|FG000|Run-in|Lost to Follow-up|4
6075514|NCT00580840|9679916|FG001|Run-in|Lost to Follow-up|0
6075515|NCT00580840|9679917|FG002|Run-in|Lost to Follow-up|0
6075516|NCT00580840|9679918|FG003|Run-in|Lost to Follow-up|0
6075517|NCT00580840|9679915|FG000|Run-in|Withdrawal by Subject|5
6075518|NCT00580840|9679916|FG001|Run-in|Withdrawal by Subject|0
6075519|NCT00580840|9679917|FG002|Run-in|Withdrawal by Subject|0
6075520|NCT00580840|9679918|FG003|Run-in|Withdrawal by Subject|0
6075521|NCT00580840|9679915|FG000|Run-in|Other: Per Sponsor Request|2
6075522|NCT00580840|9679916|FG001|Run-in|Other: Per Sponsor Request|0
6075523|NCT00580840|9679917|FG002|Run-in|Other: Per Sponsor Request|0
6075524|NCT00580840|9679918|FG003|Run-in|Other: Per Sponsor Request|0
6075525|NCT00580840|9679915|FG000|Run-in|Other: Did Not Meet Joint Count Criteria|1
6075526|NCT00580840|9679916|FG001|Run-in|Other: Did Not Meet Joint Count Criteria|0
6075527|NCT00580840|9679917|FG002|Run-in|Other: Did Not Meet Joint Count Criteria|0
6075528|NCT00580840|9679918|FG003|Run-in|Other: Did Not Meet Joint Count Criteria|0
6075529|NCT00580840|9679915|FG000|Run-in|Other: Exclusionary Lab Value|1
6075530|NCT00580840|9679916|FG001|Run-in|Other: Exclusionary Lab Value|0
6075531|NCT00580840|9679917|FG002|Run-in|Other: Exclusionary Lab Value|0
6010005|NCT00105157|9602885|FG002|Open-Label Continuation of DB|Lack of Efficacy|3
6010006|NCT00105157|9602886|FG003|Open-Label Continuation of DB|Lack of Efficacy|1
6075532|NCT00580840|9679918|FG003|Run-in|Other: Exclusionary Lab Value|0
6075533|NCT00580840|9679915|FG000|Double-Blind|Adverse Event|0
6075534|NCT00580840|9679916|FG001|Double-Blind|Adverse Event|3
6075535|NCT00580840|9679917|FG002|Double-Blind|Adverse Event|4
6075536|NCT00580840|9679918|FG003|Double-Blind|Adverse Event|1
6075537|NCT00580840|9679915|FG000|Double-Blind|Loss of Efficacy|0
6075538|NCT00580840|9679916|FG001|Double-Blind|Loss of Efficacy|1
6075539|NCT00580840|9679917|FG002|Double-Blind|Loss of Efficacy|2
6075540|NCT00580840|9679918|FG003|Double-Blind|Loss of Efficacy|10
6075541|NCT00580840|9679915|FG000|Double-Blind|Lost to Follow-up|0
6075542|NCT00580840|9679916|FG001|Double-Blind|Lost to Follow-up|1
6075543|NCT00580840|9679917|FG002|Double-Blind|Lost to Follow-up|0
6075544|NCT00580840|9679918|FG003|Double-Blind|Lost to Follow-up|2
6075545|NCT00580840|9679915|FG000|Double-Blind|Withdrawal by Subject|0
6075546|NCT00580840|9679916|FG001|Double-Blind|Withdrawal by Subject|1
6075547|NCT00580840|9679917|FG002|Double-Blind|Withdrawal by Subject|2
6075548|NCT00580840|9679918|FG003|Double-Blind|Withdrawal by Subject|2
6075549|NCT00580840|9679915|FG000|Double-Blind|Other: Discontinued Methotrexate|0
6010007|NCT00105157|9602883|FG000|Open-Label Continuation of DB|Lost to Follow-up|1
6010008|NCT00105157|9602884|FG001|Open-Label Continuation of DB|Lost to Follow-up|1
6010009|NCT00105157|9602885|FG002|Open-Label Continuation of DB|Lost to Follow-up|1
6010010|NCT00105157|9602886|FG003|Open-Label Continuation of DB|Lost to Follow-up|0
6010011|NCT00105157|9602883|FG000|Open-Label Continuation of DB|Withdrawal by Subject|0
6010012|NCT00105157|9602884|FG001|Open-Label Continuation of DB|Withdrawal by Subject|1
6010013|NCT00105157|9602885|FG002|Open-Label Continuation of DB|Withdrawal by Subject|3
6010014|NCT00105157|9602886|FG003|Open-Label Continuation of DB|Withdrawal by Subject|0
6010015|NCT00105157|9602883|FG000|Open-Label Continuation of DB|Patient did not continue in extension|1
6010016|NCT00105157|9602884|FG001|Open-Label Continuation of DB|Patient did not continue in extension|0
6010017|NCT00105157|9602885|FG002|Open-Label Continuation of DB|Patient did not continue in extension|0
6010018|NCT00105157|9602886|FG003|Open-Label Continuation of DB|Patient did not continue in extension|0
6010019|NCT00105157|9602883|FG000|Open-Label Continuation of DB|Patient moved/site stopped trial|1
6010020|NCT00105157|9602884|FG001|Open-Label Continuation of DB|Patient moved/site stopped trial|3
6010021|NCT00105157|9602885|FG002|Open-Label Continuation of DB|Patient moved/site stopped trial|2
6010022|NCT00105157|9602886|FG003|Open-Label Continuation of DB|Patient moved/site stopped trial|0
6010023|NCT00105157|9602883|FG000|Open-Label Post Virologic Failure(OLPVF)|Adverse Event|0
6010024|NCT00105157|9602884|FG001|Open-Label Post Virologic Failure(OLPVF)|Adverse Event|0
6010025|NCT00105157|9602885|FG002|Open-Label Post Virologic Failure(OLPVF)|Adverse Event|0
6010026|NCT00105157|9602886|FG003|Open-Label Post Virologic Failure(OLPVF)|Adverse Event|1
6010027|NCT00105157|9602883|FG000|Open-Label Post Virologic Failure(OLPVF)|Lack of Efficacy|7
6010028|NCT00105157|9602884|FG001|Open-Label Post Virologic Failure(OLPVF)|Lack of Efficacy|6
6010029|NCT00105157|9602885|FG002|Open-Label Post Virologic Failure(OLPVF)|Lack of Efficacy|5
6010030|NCT00105157|9602886|FG003|Open-Label Post Virologic Failure(OLPVF)|Lack of Efficacy|10
6010031|NCT00105157|9602883|FG000|Open-Label Post Virologic Failure(OLPVF)|Lost to Follow-up|1
6010032|NCT00105157|9602884|FG001|Open-Label Post Virologic Failure(OLPVF)|Lost to Follow-up|0
6010033|NCT00105157|9602885|FG002|Open-Label Post Virologic Failure(OLPVF)|Lost to Follow-up|0
6010034|NCT00105157|9602886|FG003|Open-Label Post Virologic Failure(OLPVF)|Lost to Follow-up|1
6010035|NCT00105157|9602883|FG000|Open-Label Post Virologic Failure(OLPVF)|Withdrawal by Subject|0
6010036|NCT00105157|9602884|FG001|Open-Label Post Virologic Failure(OLPVF)|Withdrawal by Subject|0
6010037|NCT00105157|9602885|FG002|Open-Label Post Virologic Failure(OLPVF)|Withdrawal by Subject|0
6010038|NCT00105157|9602886|FG003|Open-Label Post Virologic Failure(OLPVF)|Withdrawal by Subject|5
6010039|NCT00105157|9602883|FG000|Open-Label Post Virologic Failure(OLPVF)|Patient moved/Site stopped trial|1
6010040|NCT00105157|9602884|FG001|Open-Label Post Virologic Failure(OLPVF)|Patient moved/Site stopped trial|0
6010041|NCT00105157|9602885|FG002|Open-Label Post Virologic Failure(OLPVF)|Patient moved/Site stopped trial|1
6010042|NCT00105157|9602886|FG003|Open-Label Post Virologic Failure(OLPVF)|Patient moved/Site stopped trial|1
6010043|NCT00105183|9602897|FG000|Overall Study|Death|19
6010044|NCT00105183|9602898|FG001|Overall Study|Death|13
6010045|NCT00105183|9602899|FG002|Overall Study|Death|15
6010046|NCT00105183|9602897|FG000|Overall Study|Withdrawal by Subject|1
6010047|NCT00105183|9602898|FG001|Overall Study|Withdrawal by Subject|1
6010048|NCT00105183|9602899|FG002|Overall Study|Withdrawal by Subject|4
6010049|NCT00105183|9602897|FG000|Overall Study|Physician Decision|1
6010050|NCT00105183|9602898|FG001|Overall Study|Physician Decision|2
6010051|NCT00105183|9602899|FG002|Overall Study|Physician Decision|3
6010052|NCT00105183|9602897|FG000|Overall Study|Lost to Follow-up|0
6010053|NCT00105183|9602898|FG001|Overall Study|Lost to Follow-up|1
6010054|NCT00105183|9602899|FG002|Overall Study|Lost to Follow-up|1
6010055|NCT00105183|9602897|FG000|Overall Study|Other reason|1
6010056|NCT00105183|9602898|FG001|Overall Study|Other reason|2
6010057|NCT00105183|9602899|FG002|Overall Study|Other reason|0
6010058|NCT00105196|9602909|FG000|Overall Study|Lack of Efficacy|2
6010059|NCT00105196|9602910|FG001|Overall Study|Lack of Efficacy|3
6010060|NCT00105196|9602909|FG000|Overall Study|Adverse Event|11
6010061|NCT00105196|9602910|FG001|Overall Study|Adverse Event|3
6010062|NCT00105196|9602909|FG000|Overall Study|Withdrawal by Subject|6
6010063|NCT00105196|9602910|FG001|Overall Study|Withdrawal by Subject|6
6010064|NCT00105196|9602909|FG000|Overall Study|Lost to Follow-up|3
6010065|NCT00105196|9602910|FG001|Overall Study|Lost to Follow-up|2
6010066|NCT00105196|9602909|FG000|Overall Study|Poor/noncompliance|3
6010067|NCT00105196|9602910|FG001|Overall Study|Poor/noncompliance|4
6010068|NCT00105196|9602909|FG000|Overall Study|Protocol Violation|5
6010069|NCT00105196|9602910|FG001|Overall Study|Protocol Violation|2
6010070|NCT00105196|9602909|FG000|Overall Study|pending surgery|0
6010071|NCT00105196|9602910|FG001|Overall Study|pending surgery|1
6010072|NCT00105196|9602909|FG000|Overall Study|marijuana use|0
6010073|NCT00105196|9602910|FG001|Overall Study|marijuana use|1
6010074|NCT00105196|9602909|FG000|Overall Study|Subject became unblinded|0
6010075|NCT00105196|9602910|FG001|Overall Study|Subject became unblinded|1
6010076|NCT00105235|9602916|FG000|Overall Study|Death|4
6010077|NCT00105235|9602916|FG000|Overall Study|Physician Decision|1
6010078|NCT00105235|9602916|FG000|Overall Study|Withdrawal by Subject|2
6010079|NCT00105443|9602926|FG000|Double-Blind Treatment|Adverse Event|1
6010080|NCT00105443|9602927|FG001|Double-Blind Treatment|Adverse Event|0
6010081|NCT00105443|9602928|FG002|Double-Blind Treatment|Adverse Event|0
6010082|NCT00105443|9602929|FG003|Double-Blind Treatment|Adverse Event|0
6010083|NCT00105443|9602926|FG000|Double-Blind Treatment|Lost to Follow-up|0
6010084|NCT00105443|9602927|FG001|Double-Blind Treatment|Lost to Follow-up|0
6010085|NCT00105443|9602928|FG002|Double-Blind Treatment|Lost to Follow-up|1
6010086|NCT00105443|9602929|FG003|Double-Blind Treatment|Lost to Follow-up|0
6010087|NCT00105443|9602926|FG000|Double-Blind Treatment|Withdrawal by Subject|8
6010088|NCT00105443|9602927|FG001|Double-Blind Treatment|Withdrawal by Subject|0
6010089|NCT00105443|9602928|FG002|Double-Blind Treatment|Withdrawal by Subject|7
6010090|NCT00105443|9602929|FG003|Double-Blind Treatment|Withdrawal by Subject|0
6010091|NCT00105443|9602926|FG000|Double-Blind Treatment|Physician Decision|1
6010092|NCT00105443|9602927|FG001|Double-Blind Treatment|Physician Decision|0
6010093|NCT00105443|9602928|FG002|Double-Blind Treatment|Physician Decision|2
6010094|NCT00105443|9602929|FG003|Double-Blind Treatment|Physician Decision|0
6010095|NCT00105443|9602926|FG000|Double-Blind Treatment|Radiological and symptomatic progression|4
6010096|NCT00105443|9602927|FG001|Double-Blind Treatment|Radiological and symptomatic progression|0
6010097|NCT00105443|9602928|FG002|Double-Blind Treatment|Radiological and symptomatic progression|1
6010098|NCT00105443|9602929|FG003|Double-Blind Treatment|Radiological and symptomatic progression|0
6010099|NCT00105443|9602926|FG000|Follow-up and/or Open Label Nexavar|Death|180
6010100|NCT00105443|9602927|FG001|Follow-up and/or Open Label Nexavar|Death|7
6010101|NCT00105443|9602928|FG002|Follow-up and/or Open Label Nexavar|Death|219
6010102|NCT00105443|9602929|FG003|Follow-up and/or Open Label Nexavar|Death|4
6010103|NCT00105443|9602926|FG000|Follow-up and/or Open Label Nexavar|Lost to Follow-up|14
6010104|NCT00105443|9602927|FG001|Follow-up and/or Open Label Nexavar|Lost to Follow-up|0
6010105|NCT00105443|9602928|FG002|Follow-up and/or Open Label Nexavar|Lost to Follow-up|10
6010106|NCT00105443|9602929|FG003|Follow-up and/or Open Label Nexavar|Lost to Follow-up|0
6010107|NCT00105443|9602926|FG000|Follow-up and/or Open Label Nexavar|Withdrawal by Subject|24
6010108|NCT00105443|9602927|FG001|Follow-up and/or Open Label Nexavar|Withdrawal by Subject|3
6010109|NCT00105443|9602928|FG002|Follow-up and/or Open Label Nexavar|Withdrawal by Subject|13
6010110|NCT00105443|9602929|FG003|Follow-up and/or Open Label Nexavar|Withdrawal by Subject|4
6010111|NCT00105443|9602926|FG000|Follow-up and/or Open Label Nexavar|Adverse Event|0
6010112|NCT00105443|9602927|FG001|Follow-up and/or Open Label Nexavar|Adverse Event|14
6010113|NCT00105443|9602928|FG002|Follow-up and/or Open Label Nexavar|Adverse Event|0
6010114|NCT00105443|9602929|FG003|Follow-up and/or Open Label Nexavar|Adverse Event|16
6010115|NCT00105443|9602926|FG000|Follow-up and/or Open Label Nexavar|Physician Decision|1
6010116|NCT00105443|9602927|FG001|Follow-up and/or Open Label Nexavar|Physician Decision|0
6010117|NCT00105443|9602928|FG002|Follow-up and/or Open Label Nexavar|Physician Decision|1
6010118|NCT00105443|9602929|FG003|Follow-up and/or Open Label Nexavar|Physician Decision|0
6010119|NCT00105443|9602926|FG000|Follow-up and/or Open Label Nexavar|Protocol Violation|0
6010120|NCT00105443|9602927|FG001|Follow-up and/or Open Label Nexavar|Protocol Violation|2
6010121|NCT00105443|9602928|FG002|Follow-up and/or Open Label Nexavar|Protocol Violation|0
6010122|NCT00105443|9602929|FG003|Follow-up and/or Open Label Nexavar|Protocol Violation|0
6010123|NCT00105443|9602926|FG000|Follow-up and/or Open Label Nexavar|Progression by clinical judgment|0
6010124|NCT00105443|9602927|FG001|Follow-up and/or Open Label Nexavar|Progression by clinical judgment|2
6010125|NCT00105443|9602928|FG002|Follow-up and/or Open Label Nexavar|Progression by clinical judgment|0
6010126|NCT00105443|9602929|FG003|Follow-up and/or Open Label Nexavar|Progression by clinical judgment|5
6010127|NCT00105443|9602926|FG000|Follow-up and/or Open Label Nexavar|Progression, measurement proven|0
6010128|NCT00105443|9602927|FG001|Follow-up and/or Open Label Nexavar|Progression, measurement proven|3
6010129|NCT00105443|9602928|FG002|Follow-up and/or Open Label Nexavar|Progression, measurement proven|0
6010130|NCT00105443|9602929|FG003|Follow-up and/or Open Label Nexavar|Progression, measurement proven|3
6010131|NCT00105443|9602926|FG000|Follow-up and/or Open Label Nexavar|Disease progression, recurrence, relapse|6
6010132|NCT00105443|9602927|FG001|Follow-up and/or Open Label Nexavar|Disease progression, recurrence, relapse|0
6010133|NCT00105443|9602928|FG002|Follow-up and/or Open Label Nexavar|Disease progression, recurrence, relapse|1
6010134|NCT00105443|9602929|FG003|Follow-up and/or Open Label Nexavar|Disease progression, recurrence, relapse|0
6010135|NCT00105443|9602926|FG000|Follow-up and/or Open Label Nexavar|Endpoint record not completed|2
6010136|NCT00105443|9602927|FG001|Follow-up and/or Open Label Nexavar|Endpoint record not completed|2
6010137|NCT00105443|9602928|FG002|Follow-up and/or Open Label Nexavar|Endpoint record not completed|1
6010138|NCT00105443|9602929|FG003|Follow-up and/or Open Label Nexavar|Endpoint record not completed|2
6010139|NCT00105443|9602926|FG000|Follow-up and/or Open Label Nexavar|Planned switch to OL; record incomplete|1
6010140|NCT00105443|9602927|FG001|Follow-up and/or Open Label Nexavar|Planned switch to OL; record incomplete|0
6010141|NCT00105443|9602928|FG002|Follow-up and/or Open Label Nexavar|Planned switch to OL; record incomplete|0
6010142|NCT00105443|9602929|FG003|Follow-up and/or Open Label Nexavar|Planned switch to OL; record incomplete|0
6010143|NCT00105443|9602926|FG000|Follow-up and/or Open Label Nexavar|Non-compliant with study medication|0
6010144|NCT00105443|9602927|FG001|Follow-up and/or Open Label Nexavar|Non-compliant with study medication|0
6010145|NCT00105443|9602928|FG002|Follow-up and/or Open Label Nexavar|Non-compliant with study medication|0
6010146|NCT00105443|9602929|FG003|Follow-up and/or Open Label Nexavar|Non-compliant with study medication|1
6010147|NCT00105443|9602926|FG000|Follow-up and/or Open Label Nexavar|Reached ECOG 4|0
6010148|NCT00105443|9602927|FG001|Follow-up and/or Open Label Nexavar|Reached ECOG 4|1
6010149|NCT00105443|9602928|FG002|Follow-up and/or Open Label Nexavar|Reached ECOG 4|0
6010150|NCT00105443|9602929|FG003|Follow-up and/or Open Label Nexavar|Reached ECOG 4|1
6010151|NCT00105443|9602926|FG000|Follow-up and/or Open Label Nexavar|Switch to commercial drug|0
6010152|NCT00105443|9602927|FG001|Follow-up and/or Open Label Nexavar|Switch to commercial drug|23
6010153|NCT00105443|9602928|FG002|Follow-up and/or Open Label Nexavar|Switch to commercial drug|0
6010154|NCT00105443|9602929|FG003|Follow-up and/or Open Label Nexavar|Switch to commercial drug|11
6010155|NCT00105469|9602940|FG000|Overall Study|Adverse Event|9
6010156|NCT00105469|9602941|FG001|Overall Study|Adverse Event|8
6010157|NCT00105469|9602940|FG000|Overall Study|Protocol Violation|4
6010158|NCT00105469|9602941|FG001|Overall Study|Protocol Violation|0
6010159|NCT00105469|9602940|FG000|Overall Study|Withdrawal by Subject|2
6010160|NCT00105469|9602941|FG001|Overall Study|Withdrawal by Subject|3
6010161|NCT00105469|9602940|FG000|Overall Study|Lost to Follow-up|1
6010162|NCT00105469|9602941|FG001|Overall Study|Lost to Follow-up|0
6010163|NCT00105469|9602940|FG000|Overall Study|Lack of Efficacy|2
6010164|NCT00105469|9602941|FG001|Overall Study|Lack of Efficacy|0
6010165|NCT00105469|9602940|FG000|Overall Study|Other Reason|4
6010166|NCT00105469|9602941|FG001|Overall Study|Other Reason|0
6010167|NCT00105482|9602949|FG000|Overall Study|Adverse Event|1
6010168|NCT00105482|9602950|FG001|Overall Study|Adverse Event|1
6010169|NCT00105482|9602949|FG000|Overall Study|Lost to Follow-up|26
6010170|NCT00105482|9602950|FG001|Overall Study|Lost to Follow-up|17
6010171|NCT00105482|9602949|FG000|Overall Study|Withdrawal by Subject|0
6010172|NCT00105482|9602950|FG001|Overall Study|Withdrawal by Subject|1
6010173|NCT00105482|9602949|FG000|Overall Study|Lost Interest|29
6010174|NCT00105482|9602950|FG001|Overall Study|Lost Interest|32
6010175|NCT00105482|9602949|FG000|Overall Study|Scheduling Conflict|2
6010176|NCT00105482|9602950|FG001|Overall Study|Scheduling Conflict|3
6010177|NCT00105482|9602949|FG000|Overall Study|Withdrawn by PI|1
6010178|NCT00105482|9602950|FG001|Overall Study|Withdrawn by PI|1
6010179|NCT00105508|9602958|FG000|Overall Study|Prephase Dropout|1
6010180|NCT00105508|9602959|FG001|Overall Study|Prephase Dropout|0
6010181|NCT00105508|9602958|FG000|Overall Study|Adverse Event|16
6010182|NCT00105508|9602959|FG001|Overall Study|Adverse Event|19
6010183|NCT00105508|9602958|FG000|Overall Study|Insufficient Efficacy|1
6010184|NCT00105508|9602959|FG001|Overall Study|Insufficient Efficacy|0
6010185|NCT00105508|9602958|FG000|Overall Study|Withdrawal by Subject|10
6010186|NCT00105508|9602959|FG001|Overall Study|Withdrawal by Subject|6
6010187|NCT00105508|9602958|FG000|Overall Study|Lost to Follow-up|3
6010188|NCT00105508|9602959|FG001|Overall Study|Lost to Follow-up|0
6010189|NCT00105508|9602958|FG000|Overall Study|Protocol Violation|1
6010190|NCT00105508|9602959|FG001|Overall Study|Protocol Violation|2
6010191|NCT00105508|9602958|FG000|Overall Study|Other|8
6010192|NCT00105508|9602959|FG001|Overall Study|Other|9
6010193|NCT00105521|9602969|FG000|Overall Study|Other|1
6010194|NCT00105521|9602970|FG001|Overall Study|Other|1
6010195|NCT00105521|9602971|FG002|Overall Study|Other|2
6010196|NCT00105521|9602972|FG003|Overall Study|Other|0
6010197|NCT00105521|9602969|FG000|Overall Study|Adverse Event|10
6010198|NCT00105521|9602970|FG001|Overall Study|Adverse Event|4
6010199|NCT00105521|9602971|FG002|Overall Study|Adverse Event|10
6010200|NCT00105521|9602972|FG003|Overall Study|Adverse Event|8
6010201|NCT00105521|9602969|FG000|Overall Study|Withdrawal by Subject|1
6010202|NCT00105521|9602970|FG001|Overall Study|Withdrawal by Subject|0
6010203|NCT00105521|9602971|FG002|Overall Study|Withdrawal by Subject|1
6010204|NCT00105521|9602972|FG003|Overall Study|Withdrawal by Subject|4
6010205|NCT00105521|9602969|FG000|Overall Study|Lack of Efficacy|0
6010206|NCT00105521|9602970|FG001|Overall Study|Lack of Efficacy|0
6010207|NCT00105521|9602971|FG002|Overall Study|Lack of Efficacy|0
6010208|NCT00105521|9602972|FG003|Overall Study|Lack of Efficacy|1
6010209|NCT00105521|9602969|FG000|Overall Study|Protocol Violation|3
6010210|NCT00105521|9602970|FG001|Overall Study|Protocol Violation|5
6010211|NCT00105521|9602971|FG002|Overall Study|Protocol Violation|4
6010212|NCT00105521|9602972|FG003|Overall Study|Protocol Violation|4
6010213|NCT00105521|9602969|FG000|Overall Study|Lost to Follow-up|0
6010214|NCT00105521|9602970|FG001|Overall Study|Lost to Follow-up|1
6010215|NCT00105521|9602971|FG002|Overall Study|Lost to Follow-up|0
6010216|NCT00105521|9602972|FG003|Overall Study|Lost to Follow-up|0
6010217|NCT00105534|9602984|FG000|Overall Study|Adverse Event|2
6010218|NCT00105534|9602985|FG001|Overall Study|Adverse Event|5
6010219|NCT00105534|9602984|FG000|Overall Study|Protocol Violation|1
6010220|NCT00105534|9602985|FG001|Overall Study|Protocol Violation|4
6010221|NCT00105534|9602984|FG000|Overall Study|Withdrawal by Subject|6
6010222|NCT00105534|9602985|FG001|Overall Study|Withdrawal by Subject|6
6010223|NCT00105534|9602984|FG000|Overall Study|Lost to Follow-up|5
6010224|NCT00105534|9602985|FG001|Overall Study|Lost to Follow-up|1
6010225|NCT00105534|9602984|FG000|Overall Study|Lack of Efficacy|7
6010226|NCT00105534|9602985|FG001|Overall Study|Lack of Efficacy|15
6010227|NCT00105534|9602984|FG000|Overall Study|Treatment unmasked|1
6010228|NCT00105534|9602985|FG001|Overall Study|Treatment unmasked|0
6010229|NCT00105534|9602984|FG000|Overall Study|Other Reason|0
6010230|NCT00105534|9602985|FG001|Overall Study|Other Reason|2
6010231|NCT00105586|9602993|FG000|Overall Study|Adverse Event|4
6010232|NCT00105586|9602994|FG001|Overall Study|Adverse Event|3
6010233|NCT00105586|9602993|FG000|Overall Study|Physician Decision|13
6087382|NCT00667576|9697582|FG001|Overall Study|Protocol Violation|0
6010234|NCT00105586|9602994|FG001|Overall Study|Physician Decision|13
6075550|NCT00580840|9679916|FG001|Double-Blind|Other: Discontinued Methotrexate|1
6075551|NCT00580840|9679917|FG002|Double-Blind|Other: Discontinued Methotrexate|0
6075552|NCT00580840|9679918|FG003|Double-Blind|Other: Discontinued Methotrexate|0
6075553|NCT00580840|9679915|FG000|Double-Blind|Other: Forbidden Medication|0
6075554|NCT00580840|9679916|FG001|Double-Blind|Other: Forbidden Medication|0
6075555|NCT00580840|9679917|FG002|Double-Blind|Other: Forbidden Medication|1
6075556|NCT00580840|9679918|FG003|Double-Blind|Other: Forbidden Medication|0
6075557|NCT00580866|9679943|FG000|Overall Study|Lost to Follow-up|2
6075558|NCT00580866|9679944|FG001|Overall Study|Lost to Follow-up|2
6010235|NCT00105989|9603002|FG000|Acute - Open Label: Week 0-10|Adverse Event|33
6010236|NCT00105989|9603003|FG001|Acute - Open Label: Week 0-10|Adverse Event|0
6010237|NCT00105989|9603002|FG000|Acute - Open Label: Week 0-10|Withdrawal by Subject|24
6010238|NCT00105989|9603003|FG001|Acute - Open Label: Week 0-10|Withdrawal by Subject|0
6010239|NCT00105989|9603002|FG000|Acute - Open Label: Week 0-10|Lack of Efficacy|17
6010240|NCT00105989|9603003|FG001|Acute - Open Label: Week 0-10|Lack of Efficacy|0
6010241|NCT00105989|9603002|FG000|Acute - Open Label: Week 0-10|Protocol Response Criteria Not Met|14
6010242|NCT00105989|9603003|FG001|Acute - Open Label: Week 0-10|Protocol Response Criteria Not Met|0
6010243|NCT00105989|9603002|FG000|Acute - Open Label: Week 0-10|Protocol Violation|8
6010244|NCT00105989|9603003|FG001|Acute - Open Label: Week 0-10|Protocol Violation|0
6010245|NCT00105989|9603002|FG000|Acute - Open Label: Week 0-10|Lost to Follow-up|4
6010246|NCT00105989|9603003|FG001|Acute - Open Label: Week 0-10|Lost to Follow-up|0
6010247|NCT00105989|9603002|FG000|Acute - Open Label: Week 0-10|Physician Decision|0
6010248|NCT00105989|9603003|FG001|Acute - Open Label: Week 0-10|Physician Decision|0
6010249|NCT00105989|9603002|FG000|Acute - Open Label: Week 0-10|Death|1
6010250|NCT00105989|9603003|FG001|Acute - Open Label: Week 0-10|Death|0
6010251|NCT00105989|9603002|FG000|Acute - Open Label: Week 0-10|Recurrence Criteria Met|0
6010252|NCT00105989|9603003|FG001|Acute - Open Label: Week 0-10|Recurrence Criteria Met|0
6010253|NCT00105989|9603002|FG000|Acute - Open Label: Week 0-10|Unspecified - no reason reported|0
6010254|NCT00105989|9603003|FG001|Acute - Open Label: Week 0-10|Unspecified - no reason reported|0
6010255|NCT00105989|9603002|FG000|Continuation - Open Label:Week 10-34|Adverse Event|25
6010256|NCT00105989|9603003|FG001|Continuation - Open Label:Week 10-34|Adverse Event|0
6010257|NCT00105989|9603002|FG000|Continuation - Open Label:Week 10-34|Withdrawal by Subject|50
6010258|NCT00105989|9603003|FG001|Continuation - Open Label:Week 10-34|Withdrawal by Subject|0
6010259|NCT00105989|9603002|FG000|Continuation - Open Label:Week 10-34|Lack of Efficacy|15
6010260|NCT00105989|9603003|FG001|Continuation - Open Label:Week 10-34|Lack of Efficacy|0
6010261|NCT00105989|9603002|FG000|Continuation - Open Label:Week 10-34|Protocol Response Criteria Not Met|16
6010262|NCT00105989|9603003|FG001|Continuation - Open Label:Week 10-34|Protocol Response Criteria Not Met|0
6010263|NCT00105989|9603002|FG000|Continuation - Open Label:Week 10-34|Protocol Violation|5
6010264|NCT00105989|9603003|FG001|Continuation - Open Label:Week 10-34|Protocol Violation|0
6010265|NCT00105989|9603002|FG000|Continuation - Open Label:Week 10-34|Lost to Follow-up|9
6010266|NCT00105989|9603003|FG001|Continuation - Open Label:Week 10-34|Lost to Follow-up|0
6010267|NCT00105989|9603002|FG000|Continuation - Open Label:Week 10-34|Physician Decision|3
6010268|NCT00105989|9603003|FG001|Continuation - Open Label:Week 10-34|Physician Decision|0
6010269|NCT00105989|9603002|FG000|Continuation - Open Label:Week 10-34|Death|0
6010270|NCT00105989|9603003|FG001|Continuation - Open Label:Week 10-34|Death|0
6010271|NCT00105989|9603002|FG000|Continuation - Open Label:Week 10-34|Recurrence Criteria Met|2
6010272|NCT00105989|9603003|FG001|Continuation - Open Label:Week 10-34|Recurrence Criteria Met|0
6010273|NCT00105989|9603002|FG000|Continuation - Open Label:Week 10-34|Unspecified - no reason reported|0
6010274|NCT00105989|9603003|FG001|Continuation - Open Label:Week 10-34|Unspecified - no reason reported|0
6010275|NCT00105989|9603002|FG000|Maintenance - Double-Blind:Week 34-86|Adverse Event|6
6010276|NCT00105989|9603003|FG001|Maintenance - Double-Blind:Week 34-86|Adverse Event|3
6010277|NCT00105989|9603002|FG000|Maintenance - Double-Blind:Week 34-86|Withdrawal by Subject|17
6010278|NCT00105989|9603003|FG001|Maintenance - Double-Blind:Week 34-86|Withdrawal by Subject|18
6010279|NCT00105989|9603002|FG000|Maintenance - Double-Blind:Week 34-86|Lack of Efficacy|0
6010280|NCT00105989|9603003|FG001|Maintenance - Double-Blind:Week 34-86|Lack of Efficacy|0
6010281|NCT00105989|9603002|FG000|Maintenance - Double-Blind:Week 34-86|Protocol Response Criteria Not Met|0
6010282|NCT00105989|9603003|FG001|Maintenance - Double-Blind:Week 34-86|Protocol Response Criteria Not Met|0
6010283|NCT00105989|9603002|FG000|Maintenance - Double-Blind:Week 34-86|Protocol Violation|5
6010284|NCT00105989|9603003|FG001|Maintenance - Double-Blind:Week 34-86|Protocol Violation|4
6010285|NCT00105989|9603002|FG000|Maintenance - Double-Blind:Week 34-86|Lost to Follow-up|4
6010286|NCT00105989|9603003|FG001|Maintenance - Double-Blind:Week 34-86|Lost to Follow-up|0
6010287|NCT00105989|9603002|FG000|Maintenance - Double-Blind:Week 34-86|Physician Decision|4
6010288|NCT00105989|9603003|FG001|Maintenance - Double-Blind:Week 34-86|Physician Decision|1
6010289|NCT00105989|9603002|FG000|Maintenance - Double-Blind:Week 34-86|Death|0
6010290|NCT00105989|9603003|FG001|Maintenance - Double-Blind:Week 34-86|Death|0
6010291|NCT00105989|9603002|FG000|Maintenance - Double-Blind:Week 34-86|Recurrence Criteria Met|14
6010292|NCT00105989|9603003|FG001|Maintenance - Double-Blind:Week 34-86|Recurrence Criteria Met|43
6010293|NCT00105989|9603002|FG000|Maintenance - Double-Blind:Week 34-86|Unspecified - no reason reported|0
6075559|NCT00580970|9679961|FG000|Pre-treatment|Non-compliance|1
6075560|NCT00580970|9679961|FG000|Treatment (Lovastatin)|Non-compliance|6
6087383|NCT00667576|9697583|FG002|Overall Study|Protocol Violation|0
6010294|NCT00105989|9603003|FG001|Maintenance - Double-Blind:Week 34-86|Unspecified - no reason reported|0
6010295|NCT00106002|9603019|FG000|Overall Study|Did not take any study drug|1
6010296|NCT00106002|9603019|FG000|Overall Study|Ineligible after Registration|1
6010297|NCT00106028|9603025|FG000|Overall Study|Adverse Event|3
6010298|NCT00106028|9603026|FG001|Overall Study|Adverse Event|2
6010299|NCT00106028|9603025|FG000|Overall Study|Protocol Violation|1
6010300|NCT00106028|9603026|FG001|Overall Study|Protocol Violation|1
6010301|NCT00106028|9603025|FG000|Overall Study|Withdrawal by Subject|2
6010302|NCT00106028|9603026|FG001|Overall Study|Withdrawal by Subject|8
6010303|NCT00106028|9603025|FG000|Overall Study|Lost to Follow-up|0
6010304|NCT00106028|9603026|FG001|Overall Study|Lost to Follow-up|1
6010305|NCT00106080|9603036|FG000|Overall Study|Withdrew/Loss to follow-up|43
6010306|NCT00106080|9603037|FG001|Overall Study|Withdrew/Loss to follow-up|27
6010307|NCT00106184|9603061|FG000|Overall Study|Withdrawal by Subject|3
6010308|NCT00106184|9603062|FG001|Overall Study|Withdrawal by Subject|2
6047419|NCT00410605|9646323|FG000|Overall Study|Withdrawal by Subject|5
6047420|NCT00410605|9646323|FG000|Overall Study|Started Non-Protocol Therapy|3
6047421|NCT00410605|9646323|FG000|Overall Study|Stopped treatmen to collect stem cells|1
6047422|NCT00410605|9646323|FG000|Overall Study|Transferred to another Institution|1
6047423|NCT00410761|9646329|FG000|Overall Study|Adverse Event|29
6047424|NCT00410761|9646330|FG001|Overall Study|Adverse Event|3
6047425|NCT00410761|9646329|FG000|Overall Study|objective disease progression|71
6047426|NCT00410761|9646330|FG001|Overall Study|objective disease progression|55
6047427|NCT00410761|9646329|FG000|Overall Study|Withdrawal by Subject|8
6047428|NCT00410761|9646330|FG001|Overall Study|Withdrawal by Subject|4
6047429|NCT00410761|9646329|FG000|Overall Study|Other|12
6047430|NCT00410761|9646330|FG001|Overall Study|Other|9
6047431|NCT00410761|9646329|FG000|Overall Study|Never received randomised treatment|0
6047432|NCT00410761|9646330|FG001|Overall Study|Never received randomised treatment|1
6047433|NCT00410813|9646338|FG000|Overall Study|Adverse Event|6
6047434|NCT00410813|9646339|FG001|Overall Study|Adverse Event|11
6047435|NCT00410813|9646338|FG000|Overall Study|Progression|32
6047436|NCT00410813|9646339|FG001|Overall Study|Progression|21
6047437|NCT00410813|9646338|FG000|Overall Study|Not protocol specified|3
6047438|NCT00410813|9646339|FG001|Overall Study|Not protocol specified|4
6047439|NCT00410813|9646338|FG000|Overall Study|Ineligible|2
6047440|NCT00410813|9646339|FG001|Overall Study|Ineligible|4
6047441|NCT00410813|9646338|FG000|Overall Study|Death|0
6047442|NCT00410813|9646339|FG001|Overall Study|Death|2
6047443|NCT00411151|9646395|FG000|Overall Study|Death|38
6047444|NCT00411151|9646395|FG000|Overall Study|Withdrawal by Subject|2
6047445|NCT00411151|9646395|FG000|Overall Study|Lost to Follow-up|2
6075561|NCT00580970|9679961|FG000|Treatment (Lovastatin)|Intolerance of Lovastatin|7
6075562|NCT00580970|9679961|FG000|Treatment (Lovastatin)|Physician Decision|4
6075563|NCT00580970|9679961|FG000|Treatment (Lovastatin)|Development of metastatic second primary|1
6075564|NCT00580970|9679961|FG000|Treatment (Lovastatin)|Death|1
6075565|NCT00580983|9679965|FG000|Overall Study|Did not complete 12 mon post RT studies|7
6075566|NCT00581100|9679982|FG000|Overall Study|Death|1
6075567|NCT00581100|9679983|FG001|Overall Study|Death|0
6075568|NCT00581100|9679982|FG000|Overall Study|Adverse Event|2
6075569|NCT00581100|9679983|FG001|Overall Study|Adverse Event|1
6075570|NCT00581100|9679982|FG000|Overall Study|Withdrawal by Subject|1
6075571|NCT00581100|9679983|FG001|Overall Study|Withdrawal by Subject|4
6075572|NCT00581100|9679982|FG000|Overall Study|Other|3
6075573|NCT00581100|9679983|FG001|Overall Study|Other|0
6075574|NCT00581308|9680005|FG000|Pre Discharge|Lost to Follow-up|1
6075575|NCT00581308|9680005|FG000|Pre Discharge|Device Removed|1
6075576|NCT00581308|9680005|FG000|Month 1|Lost to Follow-up|3
6075577|NCT00581308|9680005|FG000|Month 1|Withdrawal by Subject|2
6075578|NCT00581308|9680005|FG000|Month 1|Device Removed|2
6075579|NCT00581308|9680005|FG000|Month 1|Uknown|1
6075580|NCT00581308|9680005|FG000|Month 6|Lost to Follow-up|1
6075581|NCT00581308|9680005|FG000|Month 6|Withdrawal by Subject|2
6075582|NCT00581308|9680005|FG000|Month 12|Death|1
6075583|NCT00581308|9680005|FG000|Month 12|Lost to Follow-up|14
6075584|NCT00581308|9680005|FG000|Month 12|Withdrawal by Subject|3
6047446|NCT00411151|9646395|FG000|Overall Study|Protocol Violation|1
6047447|NCT00411151|9646395|FG000|Overall Study|Trial prematurely closed|4
6047448|NCT00411216|9646401|FG000|Overall Study|Ten participants were entered into the c|0
6047449|NCT00411216|9646402|FG001|Overall Study|Ten participants were entered into the c|2
6075585|NCT00581308|9680005|FG000|Month 12|Device Removed|1
6075586|NCT00581308|9680005|FG000|Month 12|Other|1
6047450|NCT00411450|9646422|FG000|Overall Study|Ongoing at time of data cut-off.|3
6047451|NCT00411554|9646442|FG000|Overall Study|Adverse Event|2
6047452|NCT00411554|9646443|FG001|Overall Study|Adverse Event|4
6047453|NCT00411554|9646442|FG000|Overall Study|Lack of Efficacy|2
6047454|NCT00411554|9646443|FG001|Overall Study|Lack of Efficacy|5
6047455|NCT00411554|9646442|FG000|Overall Study|Withdrawal by Subject|3
6047456|NCT00411554|9646443|FG001|Overall Study|Withdrawal by Subject|0
6047457|NCT00411554|9646442|FG000|Overall Study|Patient Moved|1
6047458|NCT00411554|9646443|FG001|Overall Study|Patient Moved|0
6075587|NCT00581360|9680021|FG000|Overall Study|Withdrawal by Subject|1
6075588|NCT00581542|9680053|FG000|Overall Study|they met an exclusion criteria|2
6075589|NCT00581542|9680054|FG001|Overall Study|they met an exclusion criteria|2
6075590|NCT00581542|9680053|FG000|Overall Study|Lost to Follow-up|9
6010309|NCT00106249|9603072|FG000|Overall Study|Lost to Follow-up|3
6010310|NCT00106249|9603073|FG001|Overall Study|Lost to Follow-up|2
6010311|NCT00106353|9603081|FG000|Part 1|Disease progression|3
6010312|NCT00106353|9603082|FG001|Part 1|Disease progression|4
6010313|NCT00106353|9603083|FG002|Part 1|Disease progression|1
6010314|NCT00106353|9603084|FG003|Part 1|Disease progression|3
6010315|NCT00106353|9603085|FG004|Part 1|Disease progression|0
6010316|NCT00106353|9603086|FG005|Part 1|Disease progression|0
6010317|NCT00106353|9603087|FG006|Part 1|Disease progression|0
6010318|NCT00106353|9603081|FG000|Part 1|Withdrawal by Subject|0
6010319|NCT00106353|9603082|FG001|Part 1|Withdrawal by Subject|0
6010320|NCT00106353|9603083|FG002|Part 1|Withdrawal by Subject|1
6010321|NCT00106353|9603084|FG003|Part 1|Withdrawal by Subject|2
6010322|NCT00106353|9603085|FG004|Part 1|Withdrawal by Subject|0
6010323|NCT00106353|9603086|FG005|Part 1|Withdrawal by Subject|0
6010324|NCT00106353|9603087|FG006|Part 1|Withdrawal by Subject|0
6010325|NCT00106353|9603081|FG000|Part 1|Symptomatic deterioration|0
6010326|NCT00106353|9603082|FG001|Part 1|Symptomatic deterioration|0
6010327|NCT00106353|9603083|FG002|Part 1|Symptomatic deterioration|1
6010328|NCT00106353|9603084|FG003|Part 1|Symptomatic deterioration|0
6010329|NCT00106353|9603085|FG004|Part 1|Symptomatic deterioration|0
6010330|NCT00106353|9603086|FG005|Part 1|Symptomatic deterioration|0
6010331|NCT00106353|9603087|FG006|Part 1|Symptomatic deterioration|0
6010332|NCT00106353|9603081|FG000|Part 1|Entered follow-up phase|1
6010333|NCT00106353|9603082|FG001|Part 1|Entered follow-up phase|1
6010334|NCT00106353|9603083|FG002|Part 1|Entered follow-up phase|0
6010335|NCT00106353|9603084|FG003|Part 1|Entered follow-up phase|1
6010336|NCT00106353|9603085|FG004|Part 1|Entered follow-up phase|0
6010337|NCT00106353|9603086|FG005|Part 1|Entered follow-up phase|0
6010338|NCT00106353|9603087|FG006|Part 1|Entered follow-up phase|0
6010339|NCT00106353|9603081|FG000|Part 1|Adverse Event|0
6010340|NCT00106353|9603082|FG001|Part 1|Adverse Event|0
6010341|NCT00106353|9603083|FG002|Part 1|Adverse Event|0
6010342|NCT00106353|9603084|FG003|Part 1|Adverse Event|1
6010343|NCT00106353|9603085|FG004|Part 1|Adverse Event|0
6010344|NCT00106353|9603086|FG005|Part 1|Adverse Event|0
6010345|NCT00106353|9603087|FG006|Part 1|Adverse Event|0
6010346|NCT00106353|9603081|FG000|Part 2|Disease progression|0
6010347|NCT00106353|9603082|FG001|Part 2|Disease progression|0
6010348|NCT00106353|9603083|FG002|Part 2|Disease progression|0
6010349|NCT00106353|9603084|FG003|Part 2|Disease progression|0
6010350|NCT00106353|9603085|FG004|Part 2|Disease progression|8
6010351|NCT00106353|9603086|FG005|Part 2|Disease progression|14
6010352|NCT00106353|9603087|FG006|Part 2|Disease progression|13
6010353|NCT00106353|9603081|FG000|Part 2|Death|0
6010354|NCT00106353|9603082|FG001|Part 2|Death|0
6010355|NCT00106353|9603083|FG002|Part 2|Death|0
6010356|NCT00106353|9603084|FG003|Part 2|Death|0
6010357|NCT00106353|9603085|FG004|Part 2|Death|3
6010358|NCT00106353|9603086|FG005|Part 2|Death|0
6010359|NCT00106353|9603087|FG006|Part 2|Death|1
6010360|NCT00106353|9603081|FG000|Part 2|Symptomatic deterioration|0
6010361|NCT00106353|9603082|FG001|Part 2|Symptomatic deterioration|0
6010362|NCT00106353|9603083|FG002|Part 2|Symptomatic deterioration|0
6010363|NCT00106353|9603084|FG003|Part 2|Symptomatic deterioration|0
6010364|NCT00106353|9603085|FG004|Part 2|Symptomatic deterioration|3
6010365|NCT00106353|9603086|FG005|Part 2|Symptomatic deterioration|0
6010366|NCT00106353|9603087|FG006|Part 2|Symptomatic deterioration|0
6010367|NCT00106353|9603081|FG000|Part 2|Adverse Event|0
6010368|NCT00106353|9603082|FG001|Part 2|Adverse Event|0
6010369|NCT00106353|9603083|FG002|Part 2|Adverse Event|0
6010370|NCT00106353|9603084|FG003|Part 2|Adverse Event|0
6010371|NCT00106353|9603085|FG004|Part 2|Adverse Event|0
6010372|NCT00106353|9603086|FG005|Part 2|Adverse Event|2
6010373|NCT00106353|9603087|FG006|Part 2|Adverse Event|1
6010374|NCT00106353|9603081|FG000|Part 2|Other|0
6010375|NCT00106353|9603082|FG001|Part 2|Other|0
6010376|NCT00106353|9603083|FG002|Part 2|Other|0
6010377|NCT00106353|9603084|FG003|Part 2|Other|0
6010378|NCT00106353|9603085|FG004|Part 2|Other|1
6010379|NCT00106353|9603086|FG005|Part 2|Other|1
6010380|NCT00106353|9603087|FG006|Part 2|Other|1
6010381|NCT00106353|9603081|FG000|Part 2|Withdrawal by Subject|0
6010382|NCT00106353|9603082|FG001|Part 2|Withdrawal by Subject|0
6010383|NCT00106353|9603083|FG002|Part 2|Withdrawal by Subject|0
6010384|NCT00106353|9603084|FG003|Part 2|Withdrawal by Subject|0
6010385|NCT00106353|9603085|FG004|Part 2|Withdrawal by Subject|1
6010386|NCT00106353|9603086|FG005|Part 2|Withdrawal by Subject|0
6010387|NCT00106353|9603087|FG006|Part 2|Withdrawal by Subject|0
6010388|NCT00106353|9603081|FG000|Part 2|Physician Decision|0
6010389|NCT00106353|9603082|FG001|Part 2|Physician Decision|0
6010390|NCT00106353|9603083|FG002|Part 2|Physician Decision|0
6010391|NCT00106353|9603084|FG003|Part 2|Physician Decision|0
6010392|NCT00106353|9603085|FG004|Part 2|Physician Decision|0
6010393|NCT00106353|9603086|FG005|Part 2|Physician Decision|1
6010394|NCT00106353|9603087|FG006|Part 2|Physician Decision|0
6010395|NCT00106639|9603142|FG000|Overall Study|Adverse Event|3
6010396|NCT00106639|9603143|FG001|Overall Study|Adverse Event|4
6010397|NCT00106639|9603144|FG002|Overall Study|Adverse Event|1
6010398|NCT00106639|9603142|FG000|Overall Study|Protocol Violation|0
6010399|NCT00106639|9603143|FG001|Overall Study|Protocol Violation|1
6010400|NCT00106639|9603144|FG002|Overall Study|Protocol Violation|0
6010401|NCT00106639|9603142|FG000|Overall Study|Withdrawal by Subject|0
6010402|NCT00106639|9603143|FG001|Overall Study|Withdrawal by Subject|1
6010403|NCT00106639|9603144|FG002|Overall Study|Withdrawal by Subject|0
6010404|NCT00106639|9603142|FG000|Overall Study|Participant defaulted|0
6010405|NCT00106639|9603143|FG001|Overall Study|Participant defaulted|1
6010406|NCT00106639|9603144|FG002|Overall Study|Participant defaulted|1
6010407|NCT00106704|9603155|FG000|Overall Study|Adverse Event|10
6010408|NCT00106704|9603156|FG001|Overall Study|Adverse Event|7
6010409|NCT00106704|9603155|FG000|Overall Study|Death|2
6010410|NCT00106704|9603156|FG001|Overall Study|Death|1
6010411|NCT00106704|9603155|FG000|Overall Study|Lack of Efficacy|67
6010412|NCT00106704|9603156|FG001|Overall Study|Lack of Efficacy|69
6010413|NCT00106704|9603155|FG000|Overall Study|Lost to Follow-up|7
6010414|NCT00106704|9603156|FG001|Overall Study|Lost to Follow-up|3
6010415|NCT00106704|9603155|FG000|Overall Study|Pregnancy|1
6010416|NCT00106704|9603156|FG001|Overall Study|Pregnancy|0
6010417|NCT00106704|9603155|FG000|Overall Study|Protocol Violation|4
6010418|NCT00106704|9603156|FG001|Overall Study|Protocol Violation|7
6010419|NCT00106704|9603155|FG000|Overall Study|Withdrawal by Subject|14
6010420|NCT00106704|9603156|FG001|Overall Study|Withdrawal by Subject|21
6010421|NCT00106704|9603155|FG000|Overall Study|Patient moved|1
6010422|NCT00106704|9603156|FG001|Overall Study|Patient moved|0
6010423|NCT00106704|9603155|FG000|Overall Study|Site terminated|0
6010424|NCT00106704|9603156|FG001|Overall Study|Site terminated|1
6010425|NCT00106704|9603155|FG000|Overall Study|Planned major surgery|1
6010426|NCT00106704|9603156|FG001|Overall Study|Planned major surgery|0
6010427|NCT00106704|9603155|FG000|Overall Study|Patient Received Glycemic Medication|22
6010428|NCT00106704|9603156|FG001|Overall Study|Patient Received Glycemic Medication|41
6010429|NCT00106704|9603155|FG000|Overall Study|Unable to re-enter US|1
6010430|NCT00106704|9603156|FG001|Overall Study|Unable to re-enter US|0
6010431|NCT00106704|9603155|FG000|Overall Study|Laboratory test|1
6010432|NCT00106704|9603156|FG001|Overall Study|Laboratory test|1
6010433|NCT00106964|9603174|FG000|Overall Study|Lost to Follow-up|8
6010434|NCT00106964|9603175|FG001|Overall Study|Lost to Follow-up|6
6010435|NCT00106964|9603176|FG002|Overall Study|Lost to Follow-up|2
6010436|NCT00106964|9603174|FG000|Overall Study|Pregnancy|2
6010437|NCT00106964|9603175|FG001|Overall Study|Pregnancy|3
6010438|NCT00106964|9603176|FG002|Overall Study|Pregnancy|2
6010439|NCT00106964|9603174|FG000|Overall Study|Death|1
6010440|NCT00106964|9603175|FG001|Overall Study|Death|1
6010441|NCT00106964|9603176|FG002|Overall Study|Death|0
6010442|NCT00106964|9603174|FG000|Overall Study|Incarceration|0
6010443|NCT00106964|9603175|FG001|Overall Study|Incarceration|1
6010444|NCT00106964|9603176|FG002|Overall Study|Incarceration|0
6010445|NCT00106964|9603174|FG000|Overall Study|Site Funding Terminated|0
6010446|NCT00106964|9603175|FG001|Overall Study|Site Funding Terminated|1
6010447|NCT00106964|9603176|FG002|Overall Study|Site Funding Terminated|1
6010448|NCT00106964|9603174|FG000|Overall Study|Failure to adhere|2
6010449|NCT00106964|9603175|FG001|Overall Study|Failure to adhere|0
6010450|NCT00106964|9603176|FG002|Overall Study|Failure to adhere|0
6010451|NCT00106964|9603174|FG000|Overall Study|Did not meet eligibility criteria|0
6010452|NCT00106964|9603175|FG001|Overall Study|Did not meet eligibility criteria|2
6010453|NCT00106964|9603176|FG002|Overall Study|Did not meet eligibility criteria|2
6010454|NCT00106964|9603174|FG000|Overall Study|Required disallowed medication|0
6010455|NCT00106964|9603175|FG001|Overall Study|Required disallowed medication|1
6010456|NCT00106964|9603176|FG002|Overall Study|Required disallowed medication|0
6010457|NCT00107042|9603195|FG000|Overall Study|Lost to Follow-up|9
6010458|NCT00107042|9603196|FG001|Overall Study|Lost to Follow-up|7
6010459|NCT00107042|9603195|FG000|Overall Study|Withdrawal by Subject|6
6010460|NCT00107042|9603196|FG001|Overall Study|Withdrawal by Subject|1
6010461|NCT00107042|9603195|FG000|Overall Study|Moved out of area|5
6010462|NCT00107042|9603196|FG001|Overall Study|Moved out of area|3
6010463|NCT00107042|9603195|FG000|Overall Study|Pregnancy|1
6010464|NCT00107042|9603196|FG001|Overall Study|Pregnancy|1
6010465|NCT00107042|9603195|FG000|Overall Study|Inadvertent enrollment|0
6010466|NCT00107042|9603196|FG001|Overall Study|Inadvertent enrollment|1
6010467|NCT00107042|9603195|FG000|Overall Study|vaccinated outside window|1
6010468|NCT00107042|9603196|FG001|Overall Study|vaccinated outside window|1
6010469|NCT00107042|9603195|FG000|Overall Study|Disallowed medications|0
6010470|NCT00107042|9603196|FG001|Overall Study|Disallowed medications|2
6010471|NCT00107120|9603246|FG000|Overall Study|Adverse Event|4
6010472|NCT00107120|9603247|FG001|Overall Study|Adverse Event|1
6010473|NCT00107120|9603246|FG000|Overall Study|Lack of Efficacy|5
6010474|NCT00107120|9603247|FG001|Overall Study|Lack of Efficacy|5
6010475|NCT00107120|9603246|FG000|Overall Study|Protocol Violation|3
6010476|NCT00107120|9603247|FG001|Overall Study|Protocol Violation|0
6010477|NCT00107120|9603246|FG000|Overall Study|Withdrawal by Subject|8
6010478|NCT00107120|9603247|FG001|Overall Study|Withdrawal by Subject|9
6010479|NCT00107120|9603246|FG000|Overall Study|Lost to Follow-up|8
6010480|NCT00107120|9603247|FG001|Overall Study|Lost to Follow-up|6
6010481|NCT00107120|9603246|FG000|Overall Study|Pregnancy|0
6010482|NCT00107120|9603247|FG001|Overall Study|Pregnancy|1
6010483|NCT00107120|9603246|FG000|Overall Study|moving away from site|1
6010484|NCT00107120|9603247|FG001|Overall Study|moving away from site|1
6010485|NCT00107120|9603246|FG000|Overall Study|death of parent|0
6010486|NCT00107120|9603247|FG001|Overall Study|death of parent|1
6010487|NCT00107172|9603255|FG000|Overall Study|Withdrawal by Subject|1
6010488|NCT00107172|9603256|FG001|Overall Study|Withdrawal by Subject|0
6010489|NCT00107172|9603255|FG000|Overall Study|Death|0
6010490|NCT00107172|9603256|FG001|Overall Study|Death|2
6010491|NCT00107172|9603255|FG000|Overall Study|Other Reason|4
6010492|NCT00107172|9603256|FG001|Overall Study|Other Reason|3
6010493|NCT00107198|9603262|FG000|Overall Study|Lack of Efficacy|28
6010494|NCT00107198|9603262|FG000|Overall Study|Lost to Follow-up|12
6010495|NCT00107198|9603262|FG000|Overall Study|Protocol Violation|1
6010496|NCT00107198|9603262|FG000|Overall Study|Withdrawal by Subject|6
6010497|NCT00107198|9603262|FG000|Overall Study|Ineligible|5
6010498|NCT00107276|9603266|FG000|Overall Study|Progression|46
6010499|NCT00107276|9603266|FG000|Overall Study|Adverse Event|6
6010500|NCT00107276|9603266|FG000|Overall Study|M.D. decision|2
6010501|NCT00107276|9603266|FG000|Overall Study|Patient refusal|1
6010502|NCT00107276|9603266|FG000|Overall Study|Death|1
6010503|NCT00107276|9603266|FG000|Overall Study|Ineligible|16
6010504|NCT00107380|9603271|FG000|Overall Study|Adverse Event|7
6010505|NCT00107380|9603271|FG000|Overall Study|Refusal Unrelated to Adverse Event|7
6010506|NCT00107380|9603271|FG000|Overall Study|Progression/relapse|4
6010507|NCT00107380|9603271|FG000|Overall Study|Death|3
6010508|NCT00107380|9603271|FG000|Overall Study|Other - not protocol specified|7
6010509|NCT00107380|9603271|FG000|Overall Study|Ineligible|2
6010510|NCT00107653|9603291|FG000|Overall Study|Adverse Event|24
6010511|NCT00107653|9603292|FG001|Overall Study|Adverse Event|43
6010512|NCT00107653|9603291|FG000|Overall Study|Insufficient Therapeutic Response|25
6010513|NCT00107653|9603292|FG001|Overall Study|Insufficient Therapeutic Response|11
6010514|NCT00107653|9603291|FG000|Overall Study|Violation of Selection Criteria at Entry|1
6010515|NCT00107653|9603292|FG001|Overall Study|Violation of Selection Criteria at Entry|1
6010516|NCT00107653|9603291|FG000|Overall Study|Protocol Violation|1
6010517|NCT00107653|9603292|FG001|Overall Study|Protocol Violation|0
6010518|NCT00107653|9603291|FG000|Overall Study|Withdrawal by Subject|12
6010519|NCT00107653|9603292|FG001|Overall Study|Withdrawal by Subject|13
6010520|NCT00107653|9603291|FG000|Overall Study|Lost to Follow-up|13
6010521|NCT00107653|9603292|FG001|Overall Study|Lost to Follow-up|5
6010522|NCT00107653|9603291|FG000|Overall Study|Administrative Reasons|3
6010523|NCT00107653|9603292|FG001|Overall Study|Administrative Reasons|3
6010524|NCT00107783|9603313|FG000|Overall Study|Adverse Event|0
6010525|NCT00107783|9603314|FG001|Overall Study|Adverse Event|2
6010526|NCT00107783|9603313|FG000|Overall Study|Death|0
6010527|NCT00107783|9603314|FG001|Overall Study|Death|1
6010528|NCT00107783|9603313|FG000|Overall Study|Withdrawal by Subject|2
6010529|NCT00107783|9603314|FG001|Overall Study|Withdrawal by Subject|0
6010530|NCT00107783|9603313|FG000|Overall Study|Second hip replacement|1
6010531|NCT00107783|9603314|FG001|Overall Study|Second hip replacement|1
6010532|NCT00107900|9603326|FG000|Overall Study|Adverse Event|3
6010533|NCT00107900|9603327|FG001|Overall Study|Adverse Event|2
6010534|NCT00107900|9603328|FG002|Overall Study|Adverse Event|10
6010535|NCT00107900|9603329|FG003|Overall Study|Adverse Event|3
6010536|NCT00107900|9603330|FG004|Overall Study|Adverse Event|5
6010537|NCT00107900|9603331|FG005|Overall Study|Adverse Event|3
6010538|NCT00107900|9603326|FG000|Overall Study|Death|0
6010539|NCT00107900|9603327|FG001|Overall Study|Death|0
6010540|NCT00107900|9603328|FG002|Overall Study|Death|0
6010541|NCT00107900|9603329|FG003|Overall Study|Death|0
6010542|NCT00107900|9603330|FG004|Overall Study|Death|1
6010543|NCT00107900|9603331|FG005|Overall Study|Death|0
6010544|NCT00107900|9603326|FG000|Overall Study|Lost to Follow-up|4
6075591|NCT00581542|9680054|FG001|Overall Study|Lost to Follow-up|21
6075592|NCT00581555|9680064|FG000|Overall Study|Adverse Event|4
6075593|NCT00581555|9680065|FG001|Overall Study|Adverse Event|3
6075594|NCT00581555|9680064|FG000|Overall Study|Physician Decision|3
6075595|NCT00581555|9680065|FG001|Overall Study|Physician Decision|2
6075596|NCT00581555|9680064|FG000|Overall Study|Withdrawal by Subject|18
6010545|NCT00107900|9603327|FG001|Overall Study|Lost to Follow-up|1
6010546|NCT00107900|9603328|FG002|Overall Study|Lost to Follow-up|3
6010547|NCT00107900|9603329|FG003|Overall Study|Lost to Follow-up|2
6010548|NCT00107900|9603330|FG004|Overall Study|Lost to Follow-up|5
6010549|NCT00107900|9603331|FG005|Overall Study|Lost to Follow-up|5
6075597|NCT00581555|9680065|FG001|Overall Study|Withdrawal by Subject|9
6010550|NCT00107900|9603326|FG000|Overall Study|Protocol Violation|1
6010551|NCT00107900|9603327|FG001|Overall Study|Protocol Violation|0
6010552|NCT00107900|9603328|FG002|Overall Study|Protocol Violation|5
6010553|NCT00107900|9603329|FG003|Overall Study|Protocol Violation|5
6010554|NCT00107900|9603330|FG004|Overall Study|Protocol Violation|7
6010555|NCT00107900|9603331|FG005|Overall Study|Protocol Violation|0
6010556|NCT00107900|9603326|FG000|Overall Study|Withdrawal by Subject|1
6010557|NCT00107900|9603327|FG001|Overall Study|Withdrawal by Subject|0
6010558|NCT00107900|9603328|FG002|Overall Study|Withdrawal by Subject|5
6010559|NCT00107900|9603329|FG003|Overall Study|Withdrawal by Subject|0
6010560|NCT00107900|9603330|FG004|Overall Study|Withdrawal by Subject|1
6010561|NCT00107900|9603331|FG005|Overall Study|Withdrawal by Subject|1
6075598|NCT00581555|9680064|FG000|Overall Study|Lost to Follow-up|2
6010562|NCT00107900|9603326|FG000|Overall Study|Administrative Reasons|1
6075599|NCT00581555|9680065|FG001|Overall Study|Lost to Follow-up|2
6010563|NCT00107900|9603327|FG001|Overall Study|Administrative Reasons|0
6075600|NCT00581555|9680064|FG000|Overall Study|Other reasons|16
6010564|NCT00107900|9603328|FG002|Overall Study|Administrative Reasons|2
6010565|NCT00107900|9603329|FG003|Overall Study|Administrative Reasons|2
6010566|NCT00107900|9603330|FG004|Overall Study|Administrative Reasons|2
6010567|NCT00107900|9603331|FG005|Overall Study|Administrative Reasons|0
6010568|NCT00107952|9603347|FG000|Overall Study|Death|75
6010569|NCT00107952|9603348|FG001|Overall Study|Death|61
6010570|NCT00107952|9603347|FG000|Overall Study|Lost to Follow-up|0
6010571|NCT00107952|9603348|FG001|Overall Study|Lost to Follow-up|3
6010572|NCT00107952|9603347|FG000|Overall Study|Withdrawal by Subject|9
6010573|NCT00107952|9603348|FG001|Overall Study|Withdrawal by Subject|6
6010574|NCT00107952|9603347|FG000|Overall Study|Other|2
6010575|NCT00107952|9603348|FG001|Overall Study|Other|5
6010576|NCT00107952|9603347|FG000|Overall Study|Never received study treatment|9
6010577|NCT00107952|9603348|FG001|Overall Study|Never received study treatment|6
6010578|NCT00107978|9603356|FG000|Overall Study|Adverse Event|1
6010579|NCT00107978|9603357|FG001|Overall Study|Adverse Event|5
6010580|NCT00107978|9603356|FG000|Overall Study|Death|3
6010581|NCT00107978|9603357|FG001|Overall Study|Death|3
6010582|NCT00107978|9603356|FG000|Overall Study|Lost to Follow-up|20
6010583|NCT00107978|9603357|FG001|Overall Study|Lost to Follow-up|28
6010584|NCT00107978|9603356|FG000|Overall Study|Withdrawal by Subject|4
6010585|NCT00107978|9603357|FG001|Overall Study|Withdrawal by Subject|9
6010586|NCT00107978|9603356|FG000|Overall Study|Protocol Violation|0
6010587|NCT00107978|9603357|FG001|Overall Study|Protocol Violation|1
6010588|NCT00107978|9603356|FG000|Overall Study|Other|5
6010589|NCT00107978|9603357|FG001|Overall Study|Other|4
6010590|NCT00107991|9603363|FG000|Eligibility Assessment|Disease not severe enough|7
6010591|NCT00107991|9603363|FG000|Eligibility Assessment|Unwilling to participate|7
6010592|NCT00107991|9603363|FG000|Eligibility Assessment|Positive purified protein derivative|4
6010593|NCT00107991|9603363|FG000|Eligibility Assessment|Abnormal labs|2
6010594|NCT00107991|9603363|FG000|Eligibility Assessment|Ongoing treatment with antibiotics|1
6010595|NCT00107991|9603363|FG000|Eligibility Assessment|chronic uncontrolled asthma|1
6010596|NCT00107991|9603363|FG000|Eligibility Assessment|hx of alcohol abuse in past 12 months|1
6010597|NCT00107991|9603363|FG000|12 Week Treatment Period|Lack of Efficacy|2
6010598|NCT00107991|9603363|FG000|12 Week Treatment Period|Adverse Event|1
6010599|NCT00107991|9603363|FG000|12 Week Treatment Period|Protocol Violation|1
6010600|NCT00107991|9603363|FG000|12 Week Treatment Period|Incarcerated|1
6010601|NCT00107991|9603363|FG000|18-Week Post Treatment Assessment|Adverse Event|2
6010602|NCT00108069|9603369|FG000|Overall Study|Never rec'd study drug|0
6010603|NCT00108069|9603370|FG001|Overall Study|Never rec'd study drug|1
6010604|NCT00108069|9603369|FG000|Overall Study|Adverse Event|1
6010605|NCT00108069|9603370|FG001|Overall Study|Adverse Event|1
6010606|NCT00108069|9603369|FG000|Overall Study|Withdrawal by Subject|1
6010607|NCT00108069|9603370|FG001|Overall Study|Withdrawal by Subject|0
6010608|NCT00108069|9603369|FG000|Overall Study|Death|1
6010609|NCT00108069|9603370|FG001|Overall Study|Death|0
6010610|NCT00108069|9603369|FG000|Overall Study|Progessive disease|27
6010611|NCT00108069|9603370|FG001|Overall Study|Progessive disease|11
6010612|NCT00108082|9603385|FG000|Overall Study|Adverse Event|14
6010613|NCT00108082|9603386|FG001|Overall Study|Adverse Event|12
6010614|NCT00108082|9603387|FG002|Overall Study|Adverse Event|17
6010615|NCT00108082|9603385|FG000|Overall Study|Lost to Follow-up|6
6010616|NCT00108082|9603386|FG001|Overall Study|Lost to Follow-up|3
6010617|NCT00108082|9603387|FG002|Overall Study|Lost to Follow-up|7
6075601|NCT00581555|9680065|FG001|Overall Study|Other reasons|4
6075602|NCT00581776|9680080|FG000|Overall Study|Disease progression or no response|3
6075603|NCT00581828|9680084|FG000|Overall Study|Protocol Violation|1
6075604|NCT00581893|9680099|FG000|Second Intervention (1 Month)|Lost to Follow-up|3
6075605|NCT00581893|9680100|FG001|Second Intervention (1 Month)|Lost to Follow-up|2
6075606|NCT00581919|9680106|FG000|Overall Study|Adverse Event|8
6075607|NCT00581919|9680106|FG000|Overall Study|Death|1
6075608|NCT00581919|9680106|FG000|Overall Study|Disease Progression|10
6075609|NCT00581919|9680106|FG000|Overall Study|Physician Decision|1
6075610|NCT00581919|9680106|FG000|Overall Study|Other Complicating Disease|1
6075611|NCT00581919|9680106|FG000|Overall Study|Started Non-Protocol Therapy|2
6075612|NCT00581919|9680106|FG000|Overall Study|Withdrawal by Subject|1
6075613|NCT00581945|9680113|FG000|Overall Study|Adverse Event|4
6075614|NCT00581945|9680114|FG001|Overall Study|Adverse Event|4
6010618|NCT00108082|9603385|FG000|Overall Study|Consent Withdrawn|3
6010619|NCT00108082|9603386|FG001|Overall Study|Consent Withdrawn|3
6010620|NCT00108082|9603387|FG002|Overall Study|Consent Withdrawn|5
6010621|NCT00108082|9603385|FG000|Overall Study|Protocol Violation|1
6010622|NCT00108082|9603386|FG001|Overall Study|Protocol Violation|2
6010623|NCT00108082|9603387|FG002|Overall Study|Protocol Violation|0
6010624|NCT00108082|9603385|FG000|Overall Study|Lack of Efficacy|3
6010625|NCT00108082|9603386|FG001|Overall Study|Lack of Efficacy|1
6010626|NCT00108082|9603387|FG002|Overall Study|Lack of Efficacy|2
6010627|NCT00108082|9603385|FG000|Overall Study|Amendment 4: > Month 12|5
6010628|NCT00108082|9603386|FG001|Overall Study|Amendment 4: > Month 12|7
6010629|NCT00108082|9603387|FG002|Overall Study|Amendment 4: > Month 12|5
6010630|NCT00108082|9603385|FG000|Overall Study|Woman of Child-bearing Potential|2
6010631|NCT00108082|9603386|FG001|Overall Study|Woman of Child-bearing Potential|0
6010632|NCT00108082|9603387|FG002|Overall Study|Woman of Child-bearing Potential|2
6075615|NCT00581945|9680113|FG000|Overall Study|Unsatisfactory therapeutic effect|2
6010633|NCT00108082|9603385|FG000|Overall Study|Incorrectly Randomized|0
6010634|NCT00108082|9603386|FG001|Overall Study|Incorrectly Randomized|0
6010635|NCT00108082|9603387|FG002|Overall Study|Incorrectly Randomized|2
6010636|NCT00108082|9603385|FG000|Overall Study|Non-compliance|1
6010637|NCT00108082|9603386|FG001|Overall Study|Non-compliance|0
6010638|NCT00108082|9603387|FG002|Overall Study|Non-compliance|2
6010639|NCT00108082|9603385|FG000|Overall Study|Stopped Study Medication|0
6010640|NCT00108082|9603386|FG001|Overall Study|Stopped Study Medication|0
6010641|NCT00108082|9603387|FG002|Overall Study|Stopped Study Medication|1
6010642|NCT00108082|9603385|FG000|Overall Study|Site Closed Study|0
6010643|NCT00108082|9603386|FG001|Overall Study|Site Closed Study|2
6010644|NCT00108082|9603387|FG002|Overall Study|Site Closed Study|0
6010645|NCT00108082|9603385|FG000|Overall Study|Protocol Amendment|0
6010646|NCT00108082|9603386|FG001|Overall Study|Protocol Amendment|1
6010647|NCT00108082|9603387|FG002|Overall Study|Protocol Amendment|0
6010648|NCT00108082|9603385|FG000|Overall Study|Study Medication Not Tapered|0
6010649|NCT00108082|9603386|FG001|Overall Study|Study Medication Not Tapered|1
6010650|NCT00108082|9603387|FG002|Overall Study|Study Medication Not Tapered|0
6010651|NCT00108082|9603385|FG000|Overall Study|Subject Left Site Location|1
6010652|NCT00108082|9603386|FG001|Overall Study|Subject Left Site Location|0
6010653|NCT00108082|9603387|FG002|Overall Study|Subject Left Site Location|0
6010654|NCT00108082|9603385|FG000|Overall Study|Investigator Not at Site|1
6010655|NCT00108082|9603386|FG001|Overall Study|Investigator Not at Site|0
6010656|NCT00108082|9603387|FG002|Overall Study|Investigator Not at Site|0
6010657|NCT00108082|9603385|FG000|Overall Study|Blood Pressure Not Controlled|1
6010658|NCT00108082|9603386|FG001|Overall Study|Blood Pressure Not Controlled|0
6010659|NCT00108082|9603387|FG002|Overall Study|Blood Pressure Not Controlled|0
6010660|NCT00108160|9603397|FG000|Overall Study|Lost to Follow-up|25
6010661|NCT00108160|9603398|FG001|Overall Study|Lost to Follow-up|12
6010662|NCT00108160|9603397|FG000|Overall Study|Death|1
6010663|NCT00108160|9603398|FG001|Overall Study|Death|2
6010664|NCT00108160|9603397|FG000|Overall Study|Withdrawal by Subject|4
6010665|NCT00108160|9603398|FG001|Overall Study|Withdrawal by Subject|2
6010666|NCT00108160|9603397|FG000|Overall Study|Protocol Violation|9
6010667|NCT00108160|9603398|FG001|Overall Study|Protocol Violation|5
6010668|NCT00108355|9603438|FG000|Overall Study|Peritonitis at index paracentesis|1
6010669|NCT00108355|9603439|FG001|Overall Study|Peritonitis at index paracentesis|1
6010670|NCT00108355|9603438|FG000|Overall Study|Loculated ascites, limiting paracentesis|1
6010671|NCT00108355|9603439|FG001|Overall Study|Loculated ascites, limiting paracentesis|1
6010672|NCT00108485|9603447|FG000|Overall Study|Withdrawal by Subject|3
6010673|NCT00108485|9603448|FG001|Overall Study|Withdrawal by Subject|0
6010674|NCT00108485|9603447|FG000|Overall Study|Lost to Follow-up|0
6010675|NCT00108485|9603448|FG001|Overall Study|Lost to Follow-up|2
6010676|NCT00108628|9603474|FG000|Overall Study|Withdrawal by Subject|17
6010677|NCT00108628|9603475|FG001|Overall Study|Withdrawal by Subject|9
6010678|NCT00108628|9603474|FG000|Overall Study|Lack of Efficacy|2
6010679|NCT00108628|9603475|FG001|Overall Study|Lack of Efficacy|1
6010680|NCT00108628|9603474|FG000|Overall Study|Death|1
6010681|NCT00108628|9603475|FG001|Overall Study|Death|0
6010682|NCT00108732|9603481|FG000|Step 1 (Vaccinia/Fowlpox/GM-CSF)|Adverse Event|1
6010683|NCT00108732|9603481|FG000|Step 1 (Vaccinia/Fowlpox/GM-CSF)|Withdrawal by Subject|2
6010684|NCT00108732|9603481|FG000|Step 1 (Vaccinia/Fowlpox/GM-CSF)|Ineligible|10
6010685|NCT00108732|9603481|FG000|Step 1 (Vaccinia/Fowlpox/GM-CSF)|Non-compliance|1
6010686|NCT00108732|9603481|FG000|Step 2 (Androgen Ablation and Vaccine)|Adverse Event|3
6010687|NCT00108732|9603481|FG000|Step 2 (Androgen Ablation and Vaccine)|Withdrawal by Subject|1
6010688|NCT00108732|9603481|FG000|Step 2 (Androgen Ablation and Vaccine)|Other|1
6010689|NCT00108745|9603488|FG000|Overall Study|Withdrawal by Subject|19
6010690|NCT00108745|9603489|FG001|Overall Study|Withdrawal by Subject|12
6010691|NCT00108745|9603490|FG002|Overall Study|Withdrawal by Subject|12
6010692|NCT00108745|9603488|FG000|Overall Study|Never Treated|8
6010693|NCT00108745|9603489|FG001|Overall Study|Never Treated|10
6010694|NCT00108745|9603490|FG002|Overall Study|Never Treated|12
6010695|NCT00108745|9603488|FG000|Overall Study|Ineligible|7
6010696|NCT00108745|9603489|FG001|Overall Study|Ineligible|13
6010697|NCT00108745|9603490|FG002|Overall Study|Ineligible|13
6010698|NCT00108862|9603500|FG000|Overall Study|Death|31
6010699|NCT00108862|9603501|FG001|Overall Study|Death|37
6010700|NCT00108862|9603500|FG000|Overall Study|Withdrawal by Subject|10
6010701|NCT00108862|9603501|FG001|Overall Study|Withdrawal by Subject|6
6010702|NCT00108862|9603500|FG000|Overall Study|Lost to Follow-up|27
6010703|NCT00108862|9603501|FG001|Overall Study|Lost to Follow-up|19
6010704|NCT00108953|9603509|FG000|Follow-up|Death|18
6010705|NCT00108953|9603510|FG001|Follow-up|Death|26
6010706|NCT00108953|9603509|FG000|Follow-up|Lost to Follow-up|1
6010707|NCT00108953|9603510|FG001|Follow-up|Lost to Follow-up|1
6010708|NCT00108953|9603509|FG000|Follow-up|Study terminated by sponsor|10
6010709|NCT00108953|9603510|FG001|Follow-up|Study terminated by sponsor|6
6010710|NCT00109031|9603532|FG000|Overall Study|Adverse Event|0
6010711|NCT00109031|9603533|FG001|Overall Study|Adverse Event|0
6010712|NCT00109031|9603534|FG002|Overall Study|Adverse Event|1
6010713|NCT00109031|9603535|FG003|Overall Study|Adverse Event|0
6010714|NCT00109031|9603532|FG000|Overall Study|Withdrawal by Subject|0
6010715|NCT00109031|9603533|FG001|Overall Study|Withdrawal by Subject|1
6010716|NCT00109031|9603534|FG002|Overall Study|Withdrawal by Subject|0
6010717|NCT00109031|9603535|FG003|Overall Study|Withdrawal by Subject|0
6010718|NCT00109031|9603532|FG000|Overall Study|Physician Decision|0
6010719|NCT00109031|9603533|FG001|Overall Study|Physician Decision|1
6010720|NCT00109031|9603534|FG002|Overall Study|Physician Decision|0
6010721|NCT00109031|9603535|FG003|Overall Study|Physician Decision|0
6010722|NCT00109031|9603532|FG000|Overall Study|Protocol Violation|0
6075616|NCT00581945|9680114|FG001|Overall Study|Unsatisfactory therapeutic effect|0
6075617|NCT00581945|9680113|FG000|Overall Study|Withdrawal by Subject|2
6075618|NCT00581945|9680114|FG001|Overall Study|Withdrawal by Subject|6
6010723|NCT00109031|9603533|FG001|Overall Study|Protocol Violation|0
6010724|NCT00109031|9603534|FG002|Overall Study|Protocol Violation|1
6010725|NCT00109031|9603535|FG003|Overall Study|Protocol Violation|0
6010726|NCT00109343|9603548|FG000|Overall Study|Adverse Event|1
6010727|NCT00109343|9603549|FG001|Overall Study|Adverse Event|0
6010728|NCT00109343|9603550|FG002|Overall Study|Adverse Event|2
6010729|NCT00109343|9603548|FG000|Overall Study|Lack of Efficacy|1
6010730|NCT00109343|9603549|FG001|Overall Study|Lack of Efficacy|0
6010731|NCT00109343|9603550|FG002|Overall Study|Lack of Efficacy|0
6010732|NCT00109343|9603548|FG000|Overall Study|Lost to Follow-up|35
6010733|NCT00109343|9603549|FG001|Overall Study|Lost to Follow-up|20
6010734|NCT00109343|9603550|FG002|Overall Study|Lost to Follow-up|14
6010735|NCT00109343|9603548|FG000|Overall Study|Protocol Violation|1
6010736|NCT00109343|9603549|FG001|Overall Study|Protocol Violation|2
6010737|NCT00109343|9603550|FG002|Overall Study|Protocol Violation|2
6010738|NCT00109343|9603548|FG000|Overall Study|Withdrawal by Subject|15
6010739|NCT00109343|9603549|FG001|Overall Study|Withdrawal by Subject|11
6010740|NCT00109343|9603550|FG002|Overall Study|Withdrawal by Subject|10
6010741|NCT00109343|9603548|FG000|Overall Study|Subject Moved|6
6010742|NCT00109343|9603549|FG001|Overall Study|Subject Moved|2
6010743|NCT00109343|9603550|FG002|Overall Study|Subject Moved|1
6010744|NCT00109343|9603548|FG000|Overall Study|Other|5
6010745|NCT00109343|9603549|FG001|Overall Study|Other|2
6010746|NCT00109343|9603550|FG002|Overall Study|Other|1
6010747|NCT00109577|9603572|FG000|Overall Study|Withdrawal by Subject|3
6010748|NCT00109577|9603573|FG001|Overall Study|Withdrawal by Subject|3
6010749|NCT00109590|9603582|FG000|Overall Study|Lost to Follow-up|1
6010750|NCT00109590|9603583|FG001|Overall Study|Lost to Follow-up|0
6010751|NCT00109590|9603584|FG002|Overall Study|Lost to Follow-up|1
6010752|NCT00109590|9603582|FG000|Overall Study|Never Started Treatment|1
6010753|NCT00109590|9603583|FG001|Overall Study|Never Started Treatment|2
6010754|NCT00109590|9603584|FG002|Overall Study|Never Started Treatment|3
6010755|NCT00109707|9603609|FG000|Overall Study|Discontinued in core study without entering the extension study|215
6010756|NCT00109707|9603610|FG001|Overall Study|Discontinued in core study without entering the extension study|122
6010757|NCT00109707|9603611|FG002|Overall Study|Discontinued in core study without entering the extension study|34
6010758|NCT00109707|9603609|FG000|Overall Study|Abnormal laboratory values|1
6010759|NCT00109707|9603610|FG001|Overall Study|Abnormal laboratory values|0
6010760|NCT00109707|9603611|FG002|Overall Study|Abnormal laboratory values|0
6010761|NCT00109707|9603609|FG000|Overall Study|Administrative problems|2
6010762|NCT00109707|9603610|FG001|Overall Study|Administrative problems|0
6010763|NCT00109707|9603611|FG002|Overall Study|Administrative problems|1
6010764|NCT00109707|9603609|FG000|Overall Study|Adverse Event|10
6010765|NCT00109707|9603610|FG001|Overall Study|Adverse Event|2
6010766|NCT00109707|9603611|FG002|Overall Study|Adverse Event|3
6010767|NCT00109707|9603609|FG000|Overall Study|Death|4
6010768|NCT00109707|9603610|FG001|Overall Study|Death|0
6010769|NCT00109707|9603611|FG002|Overall Study|Death|0
6010770|NCT00109707|9603609|FG000|Overall Study|Disease progression|12
6010771|NCT00109707|9603610|FG001|Overall Study|Disease progression|4
6010772|NCT00109707|9603611|FG002|Overall Study|Disease progression|3
6010773|NCT00109707|9603609|FG000|Overall Study|Lost to Follow-up|3
6010774|NCT00109707|9603610|FG001|Overall Study|Lost to Follow-up|0
6010775|NCT00109707|9603611|FG002|Overall Study|Lost to Follow-up|0
6010776|NCT00109707|9603609|FG000|Overall Study|Protocol Violation|1
6010777|NCT00109707|9603610|FG001|Overall Study|Protocol Violation|0
6010778|NCT00109707|9603611|FG002|Overall Study|Protocol Violation|0
6010779|NCT00109707|9603609|FG000|Overall Study|Patient withdrew consent|6
6010780|NCT00109707|9603610|FG001|Overall Study|Patient withdrew consent|1
6010781|NCT00109707|9603611|FG002|Overall Study|Patient withdrew consent|0
6010782|NCT00109733|9603625|FG000|Overall Study|Protocol Violation|0
6010783|NCT00109733|9603626|FG001|Overall Study|Protocol Violation|1
6010784|NCT00109733|9603625|FG000|Overall Study|Stopped taking study drug|1
6075619|NCT00581945|9680113|FG000|Overall Study|Death|1
6010785|NCT00109733|9603626|FG001|Overall Study|Stopped taking study drug|1
6010786|NCT00109733|9603625|FG000|Overall Study|Non-compliant|0
6010787|NCT00109733|9603626|FG001|Overall Study|Non-compliant|1
6010788|NCT00109733|9603625|FG000|Overall Study|Could not commit time for study|1
6010789|NCT00109733|9603626|FG001|Overall Study|Could not commit time for study|1
6010790|NCT00109772|9603634|FG000|Double-blind Treatment|Adverse Event|14
6010791|NCT00109772|9603635|FG001|Double-blind Treatment|Adverse Event|5
6010792|NCT00109772|9603634|FG000|Double-blind Treatment|Lack of Efficacy|1
6010793|NCT00109772|9603635|FG001|Double-blind Treatment|Lack of Efficacy|0
6010794|NCT00109772|9603634|FG000|Double-blind Treatment|Withdrawal by Subject|2
6010795|NCT00109772|9603635|FG001|Double-blind Treatment|Withdrawal by Subject|1
6010796|NCT00109772|9603634|FG000|Double-blind Treatment|Lost to Follow-up|2
6010797|NCT00109772|9603635|FG001|Double-blind Treatment|Lost to Follow-up|3
6010798|NCT00109772|9603634|FG000|Double-blind Treatment|Protocol Violation|0
6010799|NCT00109772|9603635|FG001|Double-blind Treatment|Protocol Violation|1
6010800|NCT00109772|9603634|FG000|Double-blind Treatment|Other|0
6010801|NCT00109772|9603635|FG001|Double-blind Treatment|Other|4
6010802|NCT00109772|9603634|FG000|Double-blind Treatment|Withdrew prior to treatment|3
6010803|NCT00109772|9603635|FG001|Double-blind Treatment|Withdrew prior to treatment|1
6010804|NCT00109772|9603634|FG000|Open-label Extension|Adverse Event|10
6010805|NCT00109772|9603635|FG001|Open-label Extension|Adverse Event|19
6010806|NCT00109772|9603634|FG000|Open-label Extension|Lack of Efficacy|19
6010807|NCT00109772|9603635|FG001|Open-label Extension|Lack of Efficacy|11
6010808|NCT00109772|9603634|FG000|Open-label Extension|Withdrawal by Subject|9
6010809|NCT00109772|9603635|FG001|Open-label Extension|Withdrawal by Subject|6
6010810|NCT00109772|9603634|FG000|Open-label Extension|Lost to Follow-up|1
6010811|NCT00109772|9603635|FG001|Open-label Extension|Lost to Follow-up|0
6010812|NCT00109772|9603634|FG000|Open-label Extension|Death|0
6010813|NCT00109772|9603635|FG001|Open-label Extension|Death|1
6010814|NCT00109772|9603634|FG000|Open-label Extension|Protocol Violation|2
6010815|NCT00109772|9603635|FG001|Open-label Extension|Protocol Violation|2
6010816|NCT00109772|9603634|FG000|Open-label Extension|Other|4
6010817|NCT00109772|9603635|FG001|Open-label Extension|Other|10
6010818|NCT00109837|9603641|FG000|Overall Study|Adverse Event|2
6010819|NCT00109837|9603641|FG000|Overall Study|Refusal unrelated to adverse effects|1
6010820|NCT00109837|9603641|FG000|Overall Study|Death|1
6010821|NCT00109837|9603641|FG000|Overall Study|BCR/ABL+ or Ph+|17
6010822|NCT00109837|9603641|FG000|Overall Study|Not treated|1
6010823|NCT00109837|9603641|FG000|Overall Study|Ineligible|1
6010824|NCT00109850|9603649|FG000|Overall Study|Adverse Event|1
6010825|NCT00109850|9603649|FG000|Overall Study|Death|2
6010826|NCT00109850|9603649|FG000|Overall Study|Ineligible|1
6010827|NCT00109928|9603657|FG000|Overall Study|Adverse Event|2
6010828|NCT00109928|9603657|FG000|Overall Study|Progression|6
6010829|NCT00109928|9603657|FG000|Overall Study|Death|2
6010830|NCT00109928|9603657|FG000|Overall Study|not protocol specified|2
6010831|NCT00109928|9603657|FG000|Overall Study|not eligible|1
6010832|NCT00109967|9603664|FG000|Overall Study|Cancel Prior to Treatment|2
6010833|NCT00109967|9603665|FG001|Overall Study|Cancel Prior to Treatment|0
6010834|NCT00109967|9603664|FG000|Overall Study|Adverse Event|12
6010835|NCT00109967|9603665|FG001|Overall Study|Adverse Event|1
6010836|NCT00109967|9603664|FG000|Overall Study|Withdrawal by Subject|5
6010837|NCT00109967|9603665|FG001|Overall Study|Withdrawal by Subject|0
6010838|NCT00109967|9603664|FG000|Overall Study|Physician Decision|1
6010839|NCT00109967|9603665|FG001|Overall Study|Physician Decision|3
6010840|NCT00109967|9603664|FG000|Overall Study|Death|0
6010841|NCT00109967|9603665|FG001|Overall Study|Death|2
6010842|NCT00110019|9603673|FG000|Overall Study|Lack of Efficacy|253
6010843|NCT00110019|9603674|FG001|Overall Study|Lack of Efficacy|285
6010844|NCT00110019|9603673|FG000|Overall Study|Adverse Event|61
6010845|NCT00110019|9603674|FG001|Overall Study|Adverse Event|40
6010846|NCT00110019|9603673|FG000|Overall Study|Death|13
6010847|NCT00110019|9603674|FG001|Overall Study|Death|15
6010848|NCT00110019|9603673|FG000|Overall Study|Withdrawal by Subject|21
6010849|NCT00110019|9603674|FG001|Overall Study|Withdrawal by Subject|9
6010850|NCT00110019|9603673|FG000|Overall Study|alternative therapy|5
6010851|NCT00110019|9603674|FG001|Overall Study|alternative therapy|1
6010852|NCT00110019|9603673|FG000|Overall Study|complicating disease|1
6010853|NCT00110019|9603674|FG001|Overall Study|complicating disease|1
6010854|NCT00110019|9603673|FG000|Overall Study|symptom deterioration|13
6010855|NCT00110019|9603674|FG001|Overall Study|symptom deterioration|16
6010856|NCT00110019|9603673|FG000|Overall Study|Not start protocol therapy|17
6010857|NCT00110019|9603674|FG001|Overall Study|Not start protocol therapy|16
6010858|NCT00110019|9603673|FG000|Overall Study|other reasons|22
6010859|NCT00110019|9603674|FG001|Overall Study|other reasons|30
6010860|NCT00110084|9603680|FG000|Overall Study|Adverse Event|9
6010861|NCT00110084|9603680|FG000|Overall Study|Death|1
6010862|NCT00110084|9603680|FG000|Overall Study|Patient Refusal|10
6010863|NCT00110084|9603680|FG000|Overall Study|Alternate Therapy|5
6010864|NCT00110084|9603680|FG000|Overall Study|Intercurrent Illness|1
6010865|NCT00110084|9603680|FG000|Overall Study|Other|2
6010866|NCT00110149|9603689|FG000|Overall Study|Physician Decision|3
6010867|NCT00110214|9603696|FG000|Overall Study|Never started treatment|21
6010868|NCT00110214|9603697|FG001|Overall Study|Never started treatment|20
6010869|NCT00110214|9603696|FG000|Overall Study|Disease progression or death|260
6010870|NCT00110214|9603697|FG001|Overall Study|Disease progression or death|151
6010871|NCT00110214|9603696|FG000|Overall Study|Adverse Event|115
6010872|NCT00110214|9603697|FG001|Overall Study|Adverse Event|192
6010873|NCT00110214|9603696|FG000|Overall Study|Refused further treatment|52
6010874|NCT00110214|9603697|FG001|Overall Study|Refused further treatment|65
6010875|NCT00110214|9603696|FG000|Overall Study|Other (not specified)|61
6010876|NCT00110214|9603697|FG001|Overall Study|Other (not specified)|75
6010877|NCT00110266|9603703|FG000|Overall Study|Adverse Event|27
6010878|NCT00110266|9603703|FG000|Overall Study|Abnormal laboratory value|15
6010879|NCT00110266|9603703|FG000|Overall Study|Withdrawal by Subject|16
6010880|NCT00110266|9603703|FG000|Overall Study|Death|17
6010881|NCT00110266|9603703|FG000|Overall Study|Unsatisfactory therapeutic effect|2
6010882|NCT00110266|9603703|FG000|Overall Study|Participant condition no longer requires study drug|1
6010883|NCT00110305|9603712|FG000|Overall Study|Adverse Event|46
6010884|NCT00110305|9603713|FG001|Overall Study|Adverse Event|13
6010885|NCT00110305|9603712|FG000|Overall Study|Sponsors Decision|1
6010886|NCT00110305|9603713|FG001|Overall Study|Sponsors Decision|0
6010887|NCT00110305|9603712|FG000|Overall Study|Subject Non-Compliant|9
6010888|NCT00110305|9603713|FG001|Overall Study|Subject Non-Compliant|2
6010889|NCT00110305|9603712|FG000|Overall Study|Subject Ineligible To Continue The Trial|2
6010890|NCT00110305|9603713|FG001|Overall Study|Subject Ineligible To Continue The Trial|1
6010891|NCT00110305|9603712|FG000|Overall Study|Subject Reached A Virologic Endpoint|21
6010892|NCT00110305|9603713|FG001|Overall Study|Subject Reached A Virologic Endpoint|3
6010893|NCT00110305|9603712|FG000|Overall Study|Protocol Violation|0
6010894|NCT00110305|9603713|FG001|Overall Study|Protocol Violation|1
6010895|NCT00110305|9603712|FG000|Overall Study|Withdrawal by Subject|7
6010896|NCT00110305|9603713|FG001|Overall Study|Withdrawal by Subject|7
6010897|NCT00110305|9603712|FG000|Overall Study|Lost to Follow-up|20
6010898|NCT00110305|9603713|FG001|Overall Study|Lost to Follow-up|3
6010899|NCT00110305|9603712|FG000|Overall Study|Other|8
6010900|NCT00110305|9603713|FG001|Overall Study|Other|2
6010901|NCT00110357|9603732|FG000|Overall Study|Deterioration without progression|2
6010902|NCT00110357|9603733|FG001|Overall Study|Deterioration without progression|0
6010903|NCT00110357|9603732|FG000|Overall Study|Disease progression/relapse|20
6010904|NCT00110357|9603733|FG001|Overall Study|Disease progression/relapse|15
6010905|NCT00110357|9603732|FG000|Overall Study|Study Closure|1
6010906|NCT00110357|9603733|FG001|Overall Study|Study Closure|0
6010907|NCT00110357|9603732|FG000|Overall Study|Study Drug Toxicity|1
6010908|NCT00110357|9603733|FG001|Overall Study|Study Drug Toxicity|3
6010909|NCT00110357|9603732|FG000|Overall Study|Withdrawal by Subject|3
6010910|NCT00110357|9603733|FG001|Overall Study|Withdrawal by Subject|1
6010911|NCT00110396|9603766|FG000|Overall Study|Adverse Event|15
6010912|NCT00110396|9603766|FG000|Overall Study|Lost to Follow-up|1
6010913|NCT00110396|9603766|FG000|Overall Study|Administration of plasmapheresis|1
6010914|NCT00110396|9603766|FG000|Overall Study|Initiated mitoxantrone therapy|1
6010915|NCT00110396|9603766|FG000|Overall Study|Lack of Efficacy|1
6010916|NCT00110396|9603766|FG000|Overall Study|Decided not to continue treatment|1
6010917|NCT00110396|9603766|FG000|Overall Study|Patient non-compliance|1
6010918|NCT00110396|9603766|FG000|Overall Study|Patient refused to continue|1
6075620|NCT00581945|9680114|FG001|Overall Study|Death|0
6075621|NCT00582010|9680127|FG000|Overall Study|Death|0
6075622|NCT00582010|9680128|FG001|Overall Study|Death|1
6075623|NCT00582114|9680140|FG000|Overall Study|Death|4
6075624|NCT00582114|9680141|FG001|Overall Study|Death|4
6075625|NCT00582114|9680140|FG000|Overall Study|Kidney Transplant|3
6075626|NCT00582114|9680141|FG001|Overall Study|Kidney Transplant|1
6075627|NCT00582114|9680140|FG000|Overall Study|Lost to Follow-up|7
6075628|NCT00582114|9680141|FG001|Overall Study|Lost to Follow-up|6
6075629|NCT00582114|9680140|FG000|Overall Study|Withdrawal by Subject|8
6075630|NCT00582114|9680141|FG001|Overall Study|Withdrawal by Subject|16
6075631|NCT00582114|9680140|FG000|Overall Study|Adverse Event|1
6075632|NCT00582114|9680141|FG001|Overall Study|Adverse Event|1
6075633|NCT00582114|9680140|FG000|Overall Study|Physician Decision|0
6075634|NCT00582114|9680141|FG001|Overall Study|Physician Decision|6
6075635|NCT00582114|9680140|FG000|Overall Study|Stopped by data safety monitoring board|19
6075636|NCT00582114|9680141|FG001|Overall Study|Stopped by data safety monitoring board|20
6075637|NCT00582166|9680147|FG000|Overall Study|Death|1
6075638|NCT00582166|9680147|FG000|Overall Study|Ineligible pathology|1
6075639|NCT00582309|9680158|FG000|Overall Study|Protocol Violation|0
6075640|NCT00582309|9680159|FG001|Overall Study|Protocol Violation|0
6075641|NCT00582309|9680160|FG002|Overall Study|Protocol Violation|2
6075642|NCT00582426|9680183|FG000|Overall Study|Lost to Follow-up|0
6075643|NCT00582426|9680184|FG001|Overall Study|Lost to Follow-up|2
6075644|NCT00582426|9680183|FG000|Overall Study|Adverse Event|4
6075645|NCT00582426|9680184|FG001|Overall Study|Adverse Event|2
6075646|NCT00582426|9680183|FG000|Overall Study|Protocol Violation|6
6010919|NCT00110396|9603766|FG000|Overall Study|Patient refused to participate|1
6010920|NCT00110396|9603766|FG000|Overall Study|Patient will|1
6010921|NCT00110396|9603766|FG000|Overall Study|Patient's decision|1
6010922|NCT00110396|9603766|FG000|Overall Study|Participation in MS vaccine study|1
6010923|NCT00110396|9603766|FG000|Overall Study|Pregnancy|1
6010924|NCT00110396|9603766|FG000|Overall Study|Pregnancy (Protocol violation)|2
6010925|NCT00110396|9603766|FG000|Overall Study|Protocol Violation|2
6010926|NCT00110396|9603766|FG000|Overall Study|Patient refused to come back|1
6010927|NCT00110396|9603766|FG000|Overall Study|The patient has refused|2
6010928|NCT00110396|9603766|FG000|Overall Study|The patient has refused to visit site|1
6010929|NCT00110396|9603766|FG000|Overall Study|Patient is to be administered copaxone|1
6075647|NCT00582426|9680184|FG001|Overall Study|Protocol Violation|2
6075648|NCT00582426|9680183|FG000|Overall Study|Death|4
6010930|NCT00110617|9603789|FG000|Overall Study|Adverse Event|2
6010931|NCT00110617|9603790|FG001|Overall Study|Adverse Event|4
6010932|NCT00110617|9603789|FG000|Overall Study|Abnormal Laboratory Value|4
6010933|NCT00110617|9603790|FG001|Overall Study|Abnormal Laboratory Value|2
6010934|NCT00110617|9603789|FG000|Overall Study|Lack of Efficacy|1
6075649|NCT00582426|9680184|FG001|Overall Study|Death|3
6010935|NCT00110617|9603790|FG001|Overall Study|Lack of Efficacy|0
6010936|NCT00110617|9603789|FG000|Overall Study|Patient no longer requires study drug|1
6010937|NCT00110617|9603790|FG001|Overall Study|Patient no longer requires study drug|0
6010938|NCT00110617|9603789|FG000|Overall Study|Protocol Violation|5
6010939|NCT00110617|9603790|FG001|Overall Study|Protocol Violation|0
6010940|NCT00110617|9603789|FG000|Overall Study|Withdrawal by Subject|10
6010941|NCT00110617|9603790|FG001|Overall Study|Withdrawal by Subject|4
6010942|NCT00110617|9603789|FG000|Overall Study|Lost to Follow-up|9
6010943|NCT00110617|9603790|FG001|Overall Study|Lost to Follow-up|1
6010944|NCT00110617|9603789|FG000|Overall Study|Administrative problems|6
6010945|NCT00110617|9603790|FG001|Overall Study|Administrative problems|5
6010946|NCT00110617|9603789|FG000|Overall Study|Death|1
6010947|NCT00110617|9603790|FG001|Overall Study|Death|1
6010948|NCT00110617|9603789|FG000|Overall Study|Did not receive study drug|0
6010949|NCT00110617|9603790|FG001|Overall Study|Did not receive study drug|12
6010950|NCT00110812|9603801|FG000|Main Study|Death|0
6010951|NCT00110812|9603802|FG001|Main Study|Death|0
6010952|NCT00110812|9603803|FG002|Main Study|Death|2
6010953|NCT00110812|9603801|FG000|Main Study|Withdrawal by Subject|0
6010954|NCT00110812|9603802|FG001|Main Study|Withdrawal by Subject|0
6010955|NCT00110812|9603803|FG002|Main Study|Withdrawal by Subject|1
6010956|NCT00110812|9603801|FG000|Main Study|Lost to Follow-up|8
6010957|NCT00110812|9603802|FG001|Main Study|Lost to Follow-up|11
6010958|NCT00110812|9603803|FG002|Main Study|Lost to Follow-up|10
6010959|NCT00110812|9603801|FG000|Extended Follow-up|Death|1
6010960|NCT00110812|9603802|FG001|Extended Follow-up|Death|0
6010961|NCT00110812|9603803|FG002|Extended Follow-up|Death|3
6010962|NCT00110812|9603801|FG000|Extended Follow-up|Withdrawal by Subject|0
6010963|NCT00110812|9603802|FG001|Extended Follow-up|Withdrawal by Subject|1
6010964|NCT00110812|9603803|FG002|Extended Follow-up|Withdrawal by Subject|0
6010965|NCT00110812|9603801|FG000|Extended Follow-up|Lost to Follow-up|1
6010966|NCT00110812|9603802|FG001|Extended Follow-up|Lost to Follow-up|3
6010967|NCT00110812|9603803|FG002|Extended Follow-up|Lost to Follow-up|1
6010968|NCT00110890|9603818|FG000|Overall Study|Adverse Event|30
6010969|NCT00110890|9603819|FG001|Overall Study|Adverse Event|7
6010970|NCT00110890|9603818|FG000|Overall Study|Death|16
6010971|NCT00110890|9603819|FG001|Overall Study|Death|9
6010972|NCT00110890|9603818|FG000|Overall Study|Lost to Follow-up|3
6010973|NCT00110890|9603819|FG001|Overall Study|Lost to Follow-up|1
6010974|NCT00110890|9603818|FG000|Overall Study|Physician Decision|4
6010975|NCT00110890|9603819|FG001|Overall Study|Physician Decision|5
6010976|NCT00110890|9603818|FG000|Overall Study|Withdrawal by Subject|17
6010977|NCT00110890|9603819|FG001|Overall Study|Withdrawal by Subject|5
6010978|NCT00110890|9603818|FG000|Overall Study|Protocol Deviation|1
6010979|NCT00110890|9603819|FG001|Overall Study|Protocol Deviation|0
6010980|NCT00110890|9603818|FG000|Overall Study|Noncompliance|10
6010981|NCT00110890|9603819|FG001|Overall Study|Noncompliance|0
6010982|NCT00110890|9603818|FG000|Overall Study|Kidney Transplant|16
6010983|NCT00110890|9603819|FG001|Overall Study|Kidney Transplant|12
6010984|NCT00110890|9603818|FG000|Overall Study|Invest. Product Commercially Available|217
6010985|NCT00110890|9603819|FG001|Overall Study|Invest. Product Commercially Available|110
6010986|NCT00110890|9603818|FG000|Overall Study|Other|34
6010987|NCT00110890|9603819|FG001|Overall Study|Other|23
6010988|NCT00110890|9603818|FG000|Overall Study|Ineligibility determined|3
6010989|NCT00110890|9603819|FG001|Overall Study|Ineligibility determined|0
6010990|NCT00110890|9603818|FG000|Overall Study|Requirement for alternative therapy|0
6010991|NCT00110890|9603819|FG001|Overall Study|Requirement for alternative therapy|1
6010992|NCT00110890|9603818|FG000|Overall Study|Disease progression|0
6010993|NCT00110890|9603819|FG001|Overall Study|Disease progression|1
6010994|NCT00110890|9603818|FG000|Overall Study|Parathyroidectomy|0
6010995|NCT00110890|9603819|FG001|Overall Study|Parathyroidectomy|1
6010996|NCT00110890|9603818|FG000|Overall Study|Did not enter follow-up phase|10
6010997|NCT00110890|9603819|FG001|Overall Study|Did not enter follow-up phase|4
6010998|NCT00110994|9603827|FG000|Double-blind (DB) Treatment|Adverse Event|3
6010999|NCT00110994|9603828|FG001|Double-blind (DB) Treatment|Adverse Event|0
6011000|NCT00110994|9603827|FG000|Double-blind (DB) Treatment|Death|1
6011001|NCT00110994|9603828|FG001|Double-blind (DB) Treatment|Death|0
6011002|NCT00110994|9603827|FG000|Double-blind (DB) Treatment|Withdrawal by Subject|0
6011003|NCT00110994|9603828|FG001|Double-blind (DB) Treatment|Withdrawal by Subject|2
6011004|NCT00110994|9603827|FG000|Double-blind (DB) Treatment|Progression by clinical judgement|2
6011005|NCT00110994|9603828|FG001|Double-blind (DB) Treatment|Progression by clinical judgement|1
6011006|NCT00110994|9603827|FG000|Double-blind (DB) Treatment|Radiological and symptomatic progression|34
6011007|NCT00110994|9603828|FG001|Double-blind (DB) Treatment|Radiological and symptomatic progression|41
6011008|NCT00110994|9603827|FG000|Double-blind (DB) Treatment|other reasons|2
6011009|NCT00110994|9603828|FG001|Double-blind (DB) Treatment|other reasons|3
6011010|NCT00110994|9603827|FG000|Active Follow-up|Disease progression/recurrence/replace|1
6011011|NCT00110994|9603828|FG001|Active Follow-up|Disease progression/recurrence/replace|0
6011012|NCT00110994|9603827|FG000|Active Follow-up|Other reasons|0
6011013|NCT00110994|9603828|FG001|Active Follow-up|Other reasons|2
6011014|NCT00110994|9603827|FG000|Long Term Follow-up|Death|19
6011015|NCT00110994|9603828|FG001|Long Term Follow-up|Death|17
6011016|NCT00111007|9603836|FG000|Double-blind (DB) Treatment|Adverse Event|12
6011017|NCT00111007|9603837|FG001|Double-blind (DB) Treatment|Adverse Event|4
6011018|NCT00111007|9603836|FG000|Double-blind (DB) Treatment|Death|5
6011019|NCT00111007|9603837|FG001|Double-blind (DB) Treatment|Death|2
6011020|NCT00111007|9603836|FG000|Double-blind (DB) Treatment|Protocol Violation|0
6011021|NCT00111007|9603837|FG001|Double-blind (DB) Treatment|Protocol Violation|1
6011022|NCT00111007|9603836|FG000|Double-blind (DB) Treatment|Withdrawal by Subject|6
6011023|NCT00111007|9603837|FG001|Double-blind (DB) Treatment|Withdrawal by Subject|8
6011024|NCT00111007|9603836|FG000|Double-blind (DB) Treatment|Disease progression/recurrence/relapse|1
6011025|NCT00111007|9603837|FG001|Double-blind (DB) Treatment|Disease progression/recurrence/relapse|0
6011026|NCT00111007|9603836|FG000|Double-blind (DB) Treatment|Relapse|1
6011027|NCT00111007|9603837|FG001|Double-blind (DB) Treatment|Relapse|0
6011028|NCT00111007|9603836|FG000|Double-blind (DB) Treatment|Progression by clinical judgement|0
6011029|NCT00111007|9603837|FG001|Double-blind (DB) Treatment|Progression by clinical judgement|2
6011030|NCT00111007|9603836|FG000|Double-blind (DB) Treatment|Radiological and symptomatic progression|83
6011031|NCT00111007|9603837|FG001|Double-blind (DB) Treatment|Radiological and symptomatic progression|93
6011032|NCT00111007|9603836|FG000|Double-blind (DB) Treatment|Primary reason with other category|0
6011033|NCT00111007|9603837|FG001|Double-blind (DB) Treatment|Primary reason with other category|1
6011034|NCT00111007|9603836|FG000|Active Follow-up|Adverse Event|1
6011035|NCT00111007|9603837|FG001|Active Follow-up|Adverse Event|0
6011036|NCT00111007|9603836|FG000|Active Follow-up|Death|2
6011037|NCT00111007|9603837|FG001|Active Follow-up|Death|0
6011038|NCT00111007|9603836|FG000|Active Follow-up|Disease progression/recurrence/relapse|3
6011039|NCT00111007|9603837|FG001|Active Follow-up|Disease progression/recurrence/relapse|2
6011040|NCT00111007|9603836|FG000|Long Term Follow-up|Death|34
6011041|NCT00111007|9603837|FG001|Long Term Follow-up|Death|39
6011042|NCT00111007|9603836|FG000|Long Term Follow-up|Lost to Follow-up|1
6011043|NCT00111007|9603837|FG001|Long Term Follow-up|Lost to Follow-up|1
6011044|NCT00111007|9603836|FG000|Long Term Follow-up|Withdrawal by Subject|0
6011045|NCT00111007|9603837|FG001|Long Term Follow-up|Withdrawal by Subject|1
6011046|NCT00111007|9603836|FG000|Long Term Follow-up|Disease progression/recurrence/relapse|2
6011047|NCT00111007|9603837|FG001|Long Term Follow-up|Disease progression/recurrence/relapse|1
6011048|NCT00111007|9603836|FG000|Long Term Follow-up|Missing|10
6011049|NCT00111007|9603837|FG001|Long Term Follow-up|Missing|3
6011050|NCT00111228|9603846|FG000|Overall Study|Withdrawal by Subject|5
6011051|NCT00111228|9603847|FG001|Overall Study|Withdrawal by Subject|1
6011052|NCT00111228|9603848|FG002|Overall Study|Withdrawal by Subject|0
6011053|NCT00111241|9603858|FG000|Overall Study|Lost to Follow-up|1
6011054|NCT00111241|9603859|FG001|Overall Study|Lost to Follow-up|0
6011055|NCT00111241|9603858|FG000|Overall Study|Withdrawal by Subject|4
6011056|NCT00111241|9603859|FG001|Overall Study|Withdrawal by Subject|0
6011057|NCT00111241|9603858|FG000|Overall Study|Protocol Violation|9
6011058|NCT00111241|9603859|FG001|Overall Study|Protocol Violation|8
6011059|NCT00111241|9603858|FG000|Overall Study|Adverse Event|1
6011060|NCT00111241|9603859|FG001|Overall Study|Adverse Event|0
6011061|NCT00111475|9603877|FG000|Overall Study|Lost to Follow-up|0
6011062|NCT00111475|9603878|FG001|Overall Study|Lost to Follow-up|0
6011063|NCT00111475|9603879|FG002|Overall Study|Lost to Follow-up|0
6011064|NCT00111475|9603880|FG003|Overall Study|Lost to Follow-up|0
6011065|NCT00111475|9603881|FG004|Overall Study|Lost to Follow-up|0
6011066|NCT00111475|9603882|FG005|Overall Study|Lost to Follow-up|1
6011067|NCT00111475|9603883|FG006|Overall Study|Lost to Follow-up|0
6011068|NCT00111475|9603884|FG007|Overall Study|Lost to Follow-up|0
6011069|NCT00111475|9603885|FG008|Overall Study|Lost to Follow-up|0
6011070|NCT00111475|9603886|FG009|Overall Study|Lost to Follow-up|0
6011071|NCT00111761|9603921|FG000|Part 1|Physician Decision|0
6011072|NCT00111761|9603922|FG001|Part 1|Physician Decision|1
6011073|NCT00111761|9603921|FG000|Part 1|Death|0
6011074|NCT00111761|9603922|FG001|Part 1|Death|2
6011075|NCT00111761|9603921|FG000|Part 1|Other|0
6011076|NCT00111761|9603922|FG001|Part 1|Other|1
6011077|NCT00111761|9603921|FG000|Part 1|Withdrawal by Subject|0
6011078|NCT00111761|9603922|FG001|Part 1|Withdrawal by Subject|1
6011079|NCT00111761|9603921|FG000|Part 2|Adverse Event|1
6011080|NCT00111761|9603922|FG001|Part 2|Adverse Event|0
6011081|NCT00111761|9603921|FG000|Part 2|Physician Decision|1
6011082|NCT00111761|9603922|FG001|Part 2|Physician Decision|0
6011083|NCT00111761|9603921|FG000|Part 2|Death|1
6011084|NCT00111761|9603922|FG001|Part 2|Death|0
6011085|NCT00111761|9603921|FG000|Part 2|Disease progression|3
6011086|NCT00111761|9603922|FG001|Part 2|Disease progression|0
6011087|NCT00111761|9603921|FG000|Part 2|Protocol-specified criteria|1
6011088|NCT00111761|9603922|FG001|Part 2|Protocol-specified criteria|0
6011089|NCT00111761|9603921|FG000|Part 2|Other|1
6011090|NCT00111761|9603922|FG001|Part 2|Other|0
6011091|NCT00111800|9603934|FG000|Period 1: Main Phase (12 Weeks)|Adverse Event|5
6011092|NCT00111800|9603935|FG001|Period 1: Main Phase (12 Weeks)|Adverse Event|4
6011093|NCT00111800|9603936|FG002|Period 1: Main Phase (12 Weeks)|Adverse Event|0
6011094|NCT00111800|9603937|FG003|Period 1: Main Phase (12 Weeks)|Adverse Event|0
6011095|NCT00111800|9603938|FG004|Period 1: Main Phase (12 Weeks)|Adverse Event|1
6011096|NCT00111800|9603939|FG005|Period 1: Main Phase (12 Weeks)|Adverse Event|0
6011097|NCT00111800|9603934|FG000|Period 1: Main Phase (12 Weeks)|Lost to Follow-up|1
6011098|NCT00111800|9603935|FG001|Period 1: Main Phase (12 Weeks)|Lost to Follow-up|0
6011099|NCT00111800|9603936|FG002|Period 1: Main Phase (12 Weeks)|Lost to Follow-up|2
6011100|NCT00111800|9603937|FG003|Period 1: Main Phase (12 Weeks)|Lost to Follow-up|0
6011101|NCT00111800|9603938|FG004|Period 1: Main Phase (12 Weeks)|Lost to Follow-up|0
6011102|NCT00111800|9603939|FG005|Period 1: Main Phase (12 Weeks)|Lost to Follow-up|2
6011103|NCT00111800|9603934|FG000|Period 1: Main Phase (12 Weeks)|Protocol Violation|0
6011104|NCT00111800|9603935|FG001|Period 1: Main Phase (12 Weeks)|Protocol Violation|2
6011105|NCT00111800|9603936|FG002|Period 1: Main Phase (12 Weeks)|Protocol Violation|4
6011106|NCT00111800|9603937|FG003|Period 1: Main Phase (12 Weeks)|Protocol Violation|2
6011107|NCT00111800|9603938|FG004|Period 1: Main Phase (12 Weeks)|Protocol Violation|1
6011108|NCT00111800|9603939|FG005|Period 1: Main Phase (12 Weeks)|Protocol Violation|1
6011109|NCT00111800|9603934|FG000|Period 1: Main Phase (12 Weeks)|Withdrawal by Subject|2
6011110|NCT00111800|9603935|FG001|Period 1: Main Phase (12 Weeks)|Withdrawal by Subject|2
6011111|NCT00111800|9603936|FG002|Period 1: Main Phase (12 Weeks)|Withdrawal by Subject|3
6011112|NCT00111800|9603937|FG003|Period 1: Main Phase (12 Weeks)|Withdrawal by Subject|0
6011113|NCT00111800|9603938|FG004|Period 1: Main Phase (12 Weeks)|Withdrawal by Subject|0
6011114|NCT00111800|9603939|FG005|Period 1: Main Phase (12 Weeks)|Withdrawal by Subject|1
6011115|NCT00111800|9603934|FG000|Period 1: Main Phase (12 Weeks)|Lack of Efficacy|3
6011116|NCT00111800|9603935|FG001|Period 1: Main Phase (12 Weeks)|Lack of Efficacy|0
6011117|NCT00111800|9603936|FG002|Period 1: Main Phase (12 Weeks)|Lack of Efficacy|0
6011118|NCT00111800|9603937|FG003|Period 1: Main Phase (12 Weeks)|Lack of Efficacy|1
6011119|NCT00111800|9603938|FG004|Period 1: Main Phase (12 Weeks)|Lack of Efficacy|0
6011120|NCT00111800|9603939|FG005|Period 1: Main Phase (12 Weeks)|Lack of Efficacy|0
6011121|NCT00111800|9603934|FG000|Period 1: Main Phase (12 Weeks)|Insufficient therapeutic effect|1
6011122|NCT00111800|9603935|FG001|Period 1: Main Phase (12 Weeks)|Insufficient therapeutic effect|0
6011123|NCT00111800|9603936|FG002|Period 1: Main Phase (12 Weeks)|Insufficient therapeutic effect|0
6011124|NCT00111800|9603937|FG003|Period 1: Main Phase (12 Weeks)|Insufficient therapeutic effect|0
6011125|NCT00111800|9603938|FG004|Period 1: Main Phase (12 Weeks)|Insufficient therapeutic effect|1
6011126|NCT00111800|9603939|FG005|Period 1: Main Phase (12 Weeks)|Insufficient therapeutic effect|0
6011127|NCT00111800|9603934|FG000|Period 1: Main Phase (12 Weeks)|Not meet treatment eligibility criteria|1
6011128|NCT00111800|9603935|FG001|Period 1: Main Phase (12 Weeks)|Not meet treatment eligibility criteria|1
6011129|NCT00111800|9603936|FG002|Period 1: Main Phase (12 Weeks)|Not meet treatment eligibility criteria|0
6011130|NCT00111800|9603937|FG003|Period 1: Main Phase (12 Weeks)|Not meet treatment eligibility criteria|1
6011131|NCT00111800|9603938|FG004|Period 1: Main Phase (12 Weeks)|Not meet treatment eligibility criteria|0
6011132|NCT00111800|9603939|FG005|Period 1: Main Phase (12 Weeks)|Not meet treatment eligibility criteria|0
6011133|NCT00111800|9603934|FG000|Period 1: Main Phase (12 Weeks)|Lack of glycaemic control|1
6011134|NCT00111800|9603935|FG001|Period 1: Main Phase (12 Weeks)|Lack of glycaemic control|1
6011135|NCT00111800|9603936|FG002|Period 1: Main Phase (12 Weeks)|Lack of glycaemic control|0
6011136|NCT00111800|9603937|FG003|Period 1: Main Phase (12 Weeks)|Lack of glycaemic control|0
6011137|NCT00111800|9603938|FG004|Period 1: Main Phase (12 Weeks)|Lack of glycaemic control|0
6011138|NCT00111800|9603939|FG005|Period 1: Main Phase (12 Weeks)|Lack of glycaemic control|0
6011139|NCT00111800|9603934|FG000|Period 1: Main Phase (12 Weeks)|Discontinued for not receiving incentive|1
6011140|NCT00111800|9603935|FG001|Period 1: Main Phase (12 Weeks)|Discontinued for not receiving incentive|0
6011141|NCT00111800|9603936|FG002|Period 1: Main Phase (12 Weeks)|Discontinued for not receiving incentive|0
6011142|NCT00111800|9603937|FG003|Period 1: Main Phase (12 Weeks)|Discontinued for not receiving incentive|0
6011143|NCT00111800|9603938|FG004|Period 1: Main Phase (12 Weeks)|Discontinued for not receiving incentive|0
6011144|NCT00111800|9603939|FG005|Period 1: Main Phase (12 Weeks)|Discontinued for not receiving incentive|0
6011145|NCT00111800|9603934|FG000|Period 1: Main Phase (12 Weeks)|Would have been a drop out at Visit 4|0
6011146|NCT00111800|9603935|FG001|Period 1: Main Phase (12 Weeks)|Would have been a drop out at Visit 4|1
6011147|NCT00111800|9603936|FG002|Period 1: Main Phase (12 Weeks)|Would have been a drop out at Visit 4|0
6011148|NCT00111800|9603937|FG003|Period 1: Main Phase (12 Weeks)|Would have been a drop out at Visit 4|0
6011149|NCT00111800|9603938|FG004|Period 1: Main Phase (12 Weeks)|Would have been a drop out at Visit 4|0
6011150|NCT00111800|9603939|FG005|Period 1: Main Phase (12 Weeks)|Would have been a drop out at Visit 4|0
6011151|NCT00111800|9603934|FG000|Period 1: Main Phase (12 Weeks)|Fasting plasma glucose (FPG) below 140|0
6011152|NCT00111800|9603935|FG001|Period 1: Main Phase (12 Weeks)|Fasting plasma glucose (FPG) below 140|1
6011153|NCT00111800|9603936|FG002|Period 1: Main Phase (12 Weeks)|Fasting plasma glucose (FPG) below 140|0
6011154|NCT00111800|9603937|FG003|Period 1: Main Phase (12 Weeks)|Fasting plasma glucose (FPG) below 140|0
6011155|NCT00111800|9603938|FG004|Period 1: Main Phase (12 Weeks)|Fasting plasma glucose (FPG) below 140|0
6011156|NCT00111800|9603939|FG005|Period 1: Main Phase (12 Weeks)|Fasting plasma glucose (FPG) below 140|0
6011157|NCT00111800|9603934|FG000|Period 1: Main Phase (12 Weeks)|Elevated triglycerides|0
6011158|NCT00111800|9603935|FG001|Period 1: Main Phase (12 Weeks)|Elevated triglycerides|1
6011159|NCT00111800|9603936|FG002|Period 1: Main Phase (12 Weeks)|Elevated triglycerides|0
6011160|NCT00111800|9603937|FG003|Period 1: Main Phase (12 Weeks)|Elevated triglycerides|0
6011161|NCT00111800|9603938|FG004|Period 1: Main Phase (12 Weeks)|Elevated triglycerides|0
6011162|NCT00111800|9603939|FG005|Period 1: Main Phase (12 Weeks)|Elevated triglycerides|0
6011163|NCT00111800|9603934|FG000|Period 1: Main Phase (12 Weeks)|Decrease in hemoglobin and hematocrit|0
6011164|NCT00111800|9603935|FG001|Period 1: Main Phase (12 Weeks)|Decrease in hemoglobin and hematocrit|1
6011165|NCT00111800|9603936|FG002|Period 1: Main Phase (12 Weeks)|Decrease in hemoglobin and hematocrit|0
6011166|NCT00111800|9603937|FG003|Period 1: Main Phase (12 Weeks)|Decrease in hemoglobin and hematocrit|0
6011167|NCT00111800|9603938|FG004|Period 1: Main Phase (12 Weeks)|Decrease in hemoglobin and hematocrit|0
6011168|NCT00111800|9603939|FG005|Period 1: Main Phase (12 Weeks)|Decrease in hemoglobin and hematocrit|0
6011169|NCT00111800|9603934|FG000|Period 1: Main Phase (12 Weeks)|Other-Protocol violator|0
6011170|NCT00111800|9603935|FG001|Period 1: Main Phase (12 Weeks)|Other-Protocol violator|0
6011171|NCT00111800|9603936|FG002|Period 1: Main Phase (12 Weeks)|Other-Protocol violator|0
6011172|NCT00111800|9603937|FG003|Period 1: Main Phase (12 Weeks)|Other-Protocol violator|1
6011173|NCT00111800|9603938|FG004|Period 1: Main Phase (12 Weeks)|Other-Protocol violator|0
6011174|NCT00111800|9603939|FG005|Period 1: Main Phase (12 Weeks)|Other-Protocol violator|0
6011175|NCT00111800|9603934|FG000|Period 1: Main Phase (12 Weeks)|Participant went on extended holiday|0
6011176|NCT00111800|9603935|FG001|Period 1: Main Phase (12 Weeks)|Participant went on extended holiday|0
6011177|NCT00111800|9603936|FG002|Period 1: Main Phase (12 Weeks)|Participant went on extended holiday|0
6011178|NCT00111800|9603937|FG003|Period 1: Main Phase (12 Weeks)|Participant went on extended holiday|1
6011179|NCT00111800|9603938|FG004|Period 1: Main Phase (12 Weeks)|Participant went on extended holiday|0
6011180|NCT00111800|9603939|FG005|Period 1: Main Phase (12 Weeks)|Participant went on extended holiday|0
6011181|NCT00111800|9603934|FG000|Period 1: Main Phase (12 Weeks)|Participant's study medication stolen|0
6011182|NCT00111800|9603935|FG001|Period 1: Main Phase (12 Weeks)|Participant's study medication stolen|0
6011183|NCT00111800|9603936|FG002|Period 1: Main Phase (12 Weeks)|Participant's study medication stolen|0
6011184|NCT00111800|9603937|FG003|Period 1: Main Phase (12 Weeks)|Participant's study medication stolen|0
6011185|NCT00111800|9603938|FG004|Period 1: Main Phase (12 Weeks)|Participant's study medication stolen|1
6011186|NCT00111800|9603939|FG005|Period 1: Main Phase (12 Weeks)|Participant's study medication stolen|0
6011187|NCT00111800|9603934|FG000|Period 1: Main Phase (12 Weeks)|Participant moved out of area|0
6011188|NCT00111800|9603935|FG001|Period 1: Main Phase (12 Weeks)|Participant moved out of area|0
6011189|NCT00111800|9603936|FG002|Period 1: Main Phase (12 Weeks)|Participant moved out of area|0
6011190|NCT00111800|9603937|FG003|Period 1: Main Phase (12 Weeks)|Participant moved out of area|0
6011191|NCT00111800|9603938|FG004|Period 1: Main Phase (12 Weeks)|Participant moved out of area|1
6011192|NCT00111800|9603939|FG005|Period 1: Main Phase (12 Weeks)|Participant moved out of area|0
6011193|NCT00111800|9603934|FG000|Period 1: Main Phase (12 Weeks)|Sponsor requested withdrawal|0
6011194|NCT00111800|9603935|FG001|Period 1: Main Phase (12 Weeks)|Sponsor requested withdrawal|0
6011195|NCT00111800|9603936|FG002|Period 1: Main Phase (12 Weeks)|Sponsor requested withdrawal|0
6011196|NCT00111800|9603937|FG003|Period 1: Main Phase (12 Weeks)|Sponsor requested withdrawal|0
6011197|NCT00111800|9603938|FG004|Period 1: Main Phase (12 Weeks)|Sponsor requested withdrawal|0
6011198|NCT00111800|9603939|FG005|Period 1: Main Phase (12 Weeks)|Sponsor requested withdrawal|1
6011199|NCT00111800|9603934|FG000|Period 2: Extension Phase (12 Weeks)|Adverse Event|0
6011200|NCT00111800|9603935|FG001|Period 2: Extension Phase (12 Weeks)|Adverse Event|2
6011201|NCT00111800|9603936|FG002|Period 2: Extension Phase (12 Weeks)|Adverse Event|1
6011202|NCT00111800|9603937|FG003|Period 2: Extension Phase (12 Weeks)|Adverse Event|3
6011203|NCT00111800|9603938|FG004|Period 2: Extension Phase (12 Weeks)|Adverse Event|0
6011204|NCT00111800|9603939|FG005|Period 2: Extension Phase (12 Weeks)|Adverse Event|0
6011205|NCT00111800|9603934|FG000|Period 2: Extension Phase (12 Weeks)|Protocol Violation|0
6011206|NCT00111800|9603935|FG001|Period 2: Extension Phase (12 Weeks)|Protocol Violation|1
6011207|NCT00111800|9603936|FG002|Period 2: Extension Phase (12 Weeks)|Protocol Violation|1
6011208|NCT00111800|9603937|FG003|Period 2: Extension Phase (12 Weeks)|Protocol Violation|0
6011209|NCT00111800|9603938|FG004|Period 2: Extension Phase (12 Weeks)|Protocol Violation|0
6011210|NCT00111800|9603939|FG005|Period 2: Extension Phase (12 Weeks)|Protocol Violation|0
6011211|NCT00111800|9603934|FG000|Period 2: Extension Phase (12 Weeks)|Withdrawal by Subject|0
6011212|NCT00111800|9603935|FG001|Period 2: Extension Phase (12 Weeks)|Withdrawal by Subject|2
6011213|NCT00111800|9603936|FG002|Period 2: Extension Phase (12 Weeks)|Withdrawal by Subject|2
6011214|NCT00111800|9603937|FG003|Period 2: Extension Phase (12 Weeks)|Withdrawal by Subject|0
6011215|NCT00111800|9603938|FG004|Period 2: Extension Phase (12 Weeks)|Withdrawal by Subject|3
6011216|NCT00111800|9603939|FG005|Period 2: Extension Phase (12 Weeks)|Withdrawal by Subject|0
6011217|NCT00111800|9603934|FG000|Period 2: Extension Phase (12 Weeks)|Lack of Efficacy|1
6011218|NCT00111800|9603935|FG001|Period 2: Extension Phase (12 Weeks)|Lack of Efficacy|0
6011219|NCT00111800|9603936|FG002|Period 2: Extension Phase (12 Weeks)|Lack of Efficacy|1
6011220|NCT00111800|9603937|FG003|Period 2: Extension Phase (12 Weeks)|Lack of Efficacy|1
6011221|NCT00111800|9603938|FG004|Period 2: Extension Phase (12 Weeks)|Lack of Efficacy|0
6011222|NCT00111800|9603939|FG005|Period 2: Extension Phase (12 Weeks)|Lack of Efficacy|1
6011223|NCT00111800|9603934|FG000|Period 2: Extension Phase (12 Weeks)|Insufficient therapeutic effect|1
6011224|NCT00111800|9603935|FG001|Period 2: Extension Phase (12 Weeks)|Insufficient therapeutic effect|1
6011225|NCT00111800|9603936|FG002|Period 2: Extension Phase (12 Weeks)|Insufficient therapeutic effect|0
6011226|NCT00111800|9603937|FG003|Period 2: Extension Phase (12 Weeks)|Insufficient therapeutic effect|1
6011227|NCT00111800|9603938|FG004|Period 2: Extension Phase (12 Weeks)|Insufficient therapeutic effect|1
6011228|NCT00111800|9603939|FG005|Period 2: Extension Phase (12 Weeks)|Insufficient therapeutic effect|1
6011229|NCT00111800|9603934|FG000|Period 2: Extension Phase (12 Weeks)|Lack of Glycaemic Control|0
6011230|NCT00111800|9603935|FG001|Period 2: Extension Phase (12 Weeks)|Lack of Glycaemic Control|1
6011231|NCT00111800|9603936|FG002|Period 2: Extension Phase (12 Weeks)|Lack of Glycaemic Control|0
6011232|NCT00111800|9603937|FG003|Period 2: Extension Phase (12 Weeks)|Lack of Glycaemic Control|0
6011233|NCT00111800|9603938|FG004|Period 2: Extension Phase (12 Weeks)|Lack of Glycaemic Control|0
6011234|NCT00111800|9603939|FG005|Period 2: Extension Phase (12 Weeks)|Lack of Glycaemic Control|0
6011235|NCT00111800|9603934|FG000|Period 2: Extension Phase (12 Weeks)|Electrocardiogram (ECG) results|0
6011236|NCT00111800|9603935|FG001|Period 2: Extension Phase (12 Weeks)|Electrocardiogram (ECG) results|0
6011237|NCT00111800|9603936|FG002|Period 2: Extension Phase (12 Weeks)|Electrocardiogram (ECG) results|1
6011238|NCT00111800|9603937|FG003|Period 2: Extension Phase (12 Weeks)|Electrocardiogram (ECG) results|0
6011239|NCT00111800|9603938|FG004|Period 2: Extension Phase (12 Weeks)|Electrocardiogram (ECG) results|0
6011240|NCT00111800|9603939|FG005|Period 2: Extension Phase (12 Weeks)|Electrocardiogram (ECG) results|0
6011241|NCT00111800|9603934|FG000|Period 2: Extension Phase (12 Weeks)|Participant received metformin|0
6011242|NCT00111800|9603935|FG001|Period 2: Extension Phase (12 Weeks)|Participant received metformin|0
6011243|NCT00111800|9603936|FG002|Period 2: Extension Phase (12 Weeks)|Participant received metformin|1
6011244|NCT00111800|9603937|FG003|Period 2: Extension Phase (12 Weeks)|Participant received metformin|0
6011245|NCT00111800|9603938|FG004|Period 2: Extension Phase (12 Weeks)|Participant received metformin|0
6011246|NCT00111800|9603939|FG005|Period 2: Extension Phase (12 Weeks)|Participant received metformin|0
6011247|NCT00111813|9603962|FG000|Overall Study|Adverse Event|1
6011248|NCT00111813|9603963|FG001|Overall Study|Adverse Event|2
6011249|NCT00111813|9603964|FG002|Overall Study|Adverse Event|4
6011250|NCT00111813|9603965|FG003|Overall Study|Adverse Event|2
6011251|NCT00111813|9603966|FG004|Overall Study|Adverse Event|2
6011252|NCT00111813|9603967|FG005|Overall Study|Adverse Event|2
6011253|NCT00111813|9603962|FG000|Overall Study|Progressive disease|2
6011254|NCT00111813|9603963|FG001|Overall Study|Progressive disease|1
6011255|NCT00111813|9603964|FG002|Overall Study|Progressive disease|5
6011256|NCT00111813|9603965|FG003|Overall Study|Progressive disease|3
6011257|NCT00111813|9603966|FG004|Overall Study|Progressive disease|4
6011258|NCT00111813|9603967|FG005|Overall Study|Progressive disease|3
6011259|NCT00111813|9603962|FG000|Overall Study|Lack of Efficacy|0
6011260|NCT00111813|9603963|FG001|Overall Study|Lack of Efficacy|0
6011261|NCT00111813|9603964|FG002|Overall Study|Lack of Efficacy|0
6011262|NCT00111813|9603965|FG003|Overall Study|Lack of Efficacy|0
6011263|NCT00111813|9603966|FG004|Overall Study|Lack of Efficacy|0
6011264|NCT00111813|9603967|FG005|Overall Study|Lack of Efficacy|1
6011265|NCT00111813|9603962|FG000|Overall Study|Other|0
6011266|NCT00111813|9603963|FG001|Overall Study|Other|0
6011267|NCT00111813|9603964|FG002|Overall Study|Other|1
6011268|NCT00111813|9603965|FG003|Overall Study|Other|0
6011269|NCT00111813|9603966|FG004|Overall Study|Other|0
6011270|NCT00111813|9603967|FG005|Overall Study|Other|0
6011271|NCT00111839|9603985|FG000|Overall Study|Disease Progression|30
6011272|NCT00111839|9603986|FG001|Overall Study|Disease Progression|33
6011273|NCT00111839|9603987|FG002|Overall Study|Disease Progression|33
6011274|NCT00111839|9603985|FG000|Overall Study|Adverse Event|5
6011275|NCT00111839|9603986|FG001|Overall Study|Adverse Event|3
6011276|NCT00111839|9603987|FG002|Overall Study|Adverse Event|1
6011277|NCT00111839|9603985|FG000|Overall Study|Protocol Violation|2
6011278|NCT00111839|9603986|FG001|Overall Study|Protocol Violation|4
6011279|NCT00111839|9603987|FG002|Overall Study|Protocol Violation|2
6011280|NCT00111839|9603985|FG000|Overall Study|Death|1
6011281|NCT00111839|9603986|FG001|Overall Study|Death|1
6011282|NCT00111839|9603987|FG002|Overall Study|Death|6
6011283|NCT00111839|9603985|FG000|Overall Study|Withdrawal by Subject|2
6011284|NCT00111839|9603986|FG001|Overall Study|Withdrawal by Subject|2
6011285|NCT00111839|9603987|FG002|Overall Study|Withdrawal by Subject|2
6011286|NCT00111839|9603985|FG000|Overall Study|Lost to Follow-up|1
6011287|NCT00111839|9603986|FG001|Overall Study|Lost to Follow-up|0
6011288|NCT00111839|9603987|FG002|Overall Study|Lost to Follow-up|0
6011289|NCT00111839|9603985|FG000|Overall Study|Logistical Constraint|1
6011290|NCT00111839|9603986|FG001|Overall Study|Logistical Constraint|0
6011291|NCT00111839|9603987|FG002|Overall Study|Logistical Constraint|0
6011292|NCT00111839|9603985|FG000|Overall Study|Other|6
6011293|NCT00111839|9603986|FG001|Overall Study|Other|3
6011294|NCT00111839|9603987|FG002|Overall Study|Other|3
6011295|NCT00111839|9603985|FG000|Overall Study|Randomized but Not Treated|0
6011296|NCT00111839|9603986|FG001|Overall Study|Randomized but Not Treated|0
6011297|NCT00111839|9603987|FG002|Overall Study|Randomized but Not Treated|2
6011298|NCT00111917|9603997|FG000|Overall Study|Withdrawal by Subject|1
6011299|NCT00111917|9603998|FG001|Overall Study|Withdrawal by Subject|1
6011300|NCT00112047|9604010|FG000|Randomized Phase|Lost to Follow-up|26
6011301|NCT00112047|9604011|FG001|Randomized Phase|Lost to Follow-up|33
6011302|NCT00112047|9604010|FG000|Randomized Phase|Adverse Event|10
6011303|NCT00112047|9604011|FG001|Randomized Phase|Adverse Event|10
6011304|NCT00112047|9604010|FG000|Randomized Phase|Withrawal of consent|10
6011305|NCT00112047|9604011|FG001|Randomized Phase|Withrawal of consent|18
6011306|NCT00112047|9604010|FG000|Randomized Phase|Sub-optimal virological response|3
6011307|NCT00112047|9604011|FG001|Randomized Phase|Sub-optimal virological response|13
6011308|NCT00112047|9604010|FG000|Randomized Phase|Noncompliance|8
6011309|NCT00112047|9604011|FG001|Randomized Phase|Noncompliance|4
6011310|NCT00112047|9604010|FG000|Randomized Phase|Protocol Violation|2
6011311|NCT00112047|9604011|FG001|Randomized Phase|Protocol Violation|0
6011312|NCT00112047|9604010|FG000|Randomized Phase|Pregnancy|3
6011313|NCT00112047|9604011|FG001|Randomized Phase|Pregnancy|1
6011314|NCT00112047|9604010|FG000|Randomized Phase|Death|1
6011315|NCT00112047|9604011|FG001|Randomized Phase|Death|3
6011316|NCT00112047|9604010|FG000|Randomized Phase|Hepatitis C treatment contraindicated|0
6011317|NCT00112047|9604011|FG001|Randomized Phase|Hepatitis C treatment contraindicated|1
6011318|NCT00112047|9604010|FG000|Randomized Phase|Inability to swallow pills|0
6011319|NCT00112047|9604011|FG001|Randomized Phase|Inability to swallow pills|1
6011320|NCT00112047|9604010|FG000|Randomized Phase|Incarceration|3
6011321|NCT00112047|9604011|FG001|Randomized Phase|Incarceration|2
6011322|NCT00112047|9604010|FG000|Randomized Phase|Moved out of State|0
6011323|NCT00112047|9604011|FG001|Randomized Phase|Moved out of State|1
6011324|NCT00112047|9604010|FG000|Randomized Phase|Baseline NNRTI resistance mutations|4
6011325|NCT00112047|9604011|FG001|Randomized Phase|Baseline NNRTI resistance mutations|0
6011326|NCT00112047|9604010|FG000|Randomized Phase|High Hepatitis B DNA|0
6011327|NCT00112047|9604011|FG001|Randomized Phase|High Hepatitis B DNA|1
6011328|NCT00112047|9604010|FG000|Atripla Phase|Adverse Event|2
6011329|NCT00112047|9604011|FG001|Atripla Phase|Adverse Event|1
6011330|NCT00112047|9604010|FG000|Atripla Phase|Lost to Follow-up|5
6011331|NCT00112047|9604011|FG001|Atripla Phase|Lost to Follow-up|7
6011332|NCT00112047|9604010|FG000|Atripla Phase|Pregnancy|0
6011333|NCT00112047|9604011|FG001|Atripla Phase|Pregnancy|1
6011334|NCT00112047|9604010|FG000|Atripla Phase|Death|0
6011335|NCT00112047|9604011|FG001|Atripla Phase|Death|2
6011336|NCT00112047|9604010|FG000|Atripla Phase|Withdrew consent|7
6011337|NCT00112047|9604011|FG001|Atripla Phase|Withdrew consent|7
6011338|NCT00112047|9604010|FG000|Atripla Phase|Sub-optimal virological response|0
6011339|NCT00112047|9604011|FG001|Atripla Phase|Sub-optimal virological response|1
6011340|NCT00112047|9604010|FG000|Atripla Phase|Non-compliance|1
6011341|NCT00112047|9604011|FG001|Atripla Phase|Non-compliance|0
6011342|NCT00112047|9604010|FG000|Atripla Phase|Other|3
6011343|NCT00112047|9604011|FG001|Atripla Phase|Other|1
6011344|NCT00112294|9604093|FG000|Overall Study|Still on study|5
6011345|NCT00112294|9604094|FG001|Overall Study|Still on study|0
6011346|NCT00112359|9604102|FG000|Overall Study|Unrelated adverse event|16
6011347|NCT00112359|9604103|FG001|Overall Study|Unrelated adverse event|8
6011348|NCT00112359|9604102|FG000|Overall Study|Trial drug intolerance (adverse event)|2
6011349|NCT00112359|9604103|FG001|Overall Study|Trial drug intolerance (adverse event)|0
6011350|NCT00112359|9604102|FG000|Overall Study|Related adverse event|5
6011351|NCT00112359|9604103|FG001|Overall Study|Related adverse event|3
6011352|NCT00112359|9604102|FG000|Overall Study|Lost to Follow-up|0
6011353|NCT00112359|9604103|FG001|Overall Study|Lost to Follow-up|1
6011354|NCT00112359|9604102|FG000|Overall Study|Personal/administrative|1
6011355|NCT00112359|9604103|FG001|Overall Study|Personal/administrative|1
6011356|NCT00112359|9604102|FG000|Overall Study|Other|3
6011357|NCT00112359|9604103|FG001|Overall Study|Other|0
6011358|NCT00112385|9604111|FG000|Overall Study|Lost to Follow-up|1
6011359|NCT00112385|9604112|FG001|Overall Study|Lost to Follow-up|0
6011360|NCT00112385|9604111|FG000|Overall Study|Withdrawal by Subject|0
6011361|NCT00112385|9604112|FG001|Overall Study|Withdrawal by Subject|1
6011362|NCT00112437|9604123|FG000|Year 1 (12-Month Base Study)|Adverse Event|9
6011363|NCT00112437|9604124|FG001|Year 1 (12-Month Base Study)|Adverse Event|10
6011364|NCT00112437|9604125|FG002|Year 1 (12-Month Base Study)|Adverse Event|6
6011365|NCT00112437|9604126|FG003|Year 1 (12-Month Base Study)|Adverse Event|4
6011366|NCT00112437|9604127|FG004|Year 1 (12-Month Base Study)|Adverse Event|3
6011367|NCT00112437|9604128|FG005|Year 1 (12-Month Base Study)|Adverse Event|0
6011368|NCT00112437|9604129|FG006|Year 1 (12-Month Base Study)|Adverse Event|0
6011369|NCT00112437|9604130|FG007|Year 1 (12-Month Base Study)|Adverse Event|0
6011370|NCT00112437|9604131|FG008|Year 1 (12-Month Base Study)|Adverse Event|0
6011371|NCT00112437|9604132|FG009|Year 1 (12-Month Base Study)|Adverse Event|0
6011372|NCT00112437|9604133|FG010|Year 1 (12-Month Base Study)|Adverse Event|0
6011373|NCT00112437|9604134|FG011|Year 1 (12-Month Base Study)|Adverse Event|0
6011374|NCT00112437|9604135|FG012|Year 1 (12-Month Base Study)|Adverse Event|0
6011375|NCT00112437|9604136|FG013|Year 1 (12-Month Base Study)|Adverse Event|0
6011376|NCT00112437|9604137|FG014|Year 1 (12-Month Base Study)|Adverse Event|0
6011377|NCT00112437|9604138|FG015|Year 1 (12-Month Base Study)|Adverse Event|0
6011378|NCT00112437|9604139|FG016|Year 1 (12-Month Base Study)|Adverse Event|0
6011379|NCT00112437|9604140|FG017|Year 1 (12-Month Base Study)|Adverse Event|0
6011380|NCT00112437|9604141|FG018|Year 1 (12-Month Base Study)|Adverse Event|0
6011381|NCT00112437|9604142|FG019|Year 1 (12-Month Base Study)|Adverse Event|0
6011382|NCT00112437|9604143|FG020|Year 1 (12-Month Base Study)|Adverse Event|0
6011383|NCT00112437|9604144|FG021|Year 1 (12-Month Base Study)|Adverse Event|0
6011384|NCT00112437|9604145|FG022|Year 1 (12-Month Base Study)|Adverse Event|0
6011385|NCT00112437|9604146|FG023|Year 1 (12-Month Base Study)|Adverse Event|0
6011386|NCT00112437|9604147|FG024|Year 1 (12-Month Base Study)|Adverse Event|0
6011387|NCT00112437|9604148|FG025|Year 1 (12-Month Base Study)|Adverse Event|0
6011388|NCT00112437|9604123|FG000|Year 1 (12-Month Base Study)|Lack of Efficacy|0
6011389|NCT00112437|9604124|FG001|Year 1 (12-Month Base Study)|Lack of Efficacy|1
6011390|NCT00112437|9604125|FG002|Year 1 (12-Month Base Study)|Lack of Efficacy|0
6011391|NCT00112437|9604126|FG003|Year 1 (12-Month Base Study)|Lack of Efficacy|0
6011392|NCT00112437|9604127|FG004|Year 1 (12-Month Base Study)|Lack of Efficacy|0
6011393|NCT00112437|9604128|FG005|Year 1 (12-Month Base Study)|Lack of Efficacy|0
6011394|NCT00112437|9604129|FG006|Year 1 (12-Month Base Study)|Lack of Efficacy|0
6011395|NCT00112437|9604130|FG007|Year 1 (12-Month Base Study)|Lack of Efficacy|0
6011396|NCT00112437|9604131|FG008|Year 1 (12-Month Base Study)|Lack of Efficacy|0
6011397|NCT00112437|9604132|FG009|Year 1 (12-Month Base Study)|Lack of Efficacy|0
6011398|NCT00112437|9604133|FG010|Year 1 (12-Month Base Study)|Lack of Efficacy|0
6011399|NCT00112437|9604134|FG011|Year 1 (12-Month Base Study)|Lack of Efficacy|0
6011400|NCT00112437|9604135|FG012|Year 1 (12-Month Base Study)|Lack of Efficacy|0
6011401|NCT00112437|9604136|FG013|Year 1 (12-Month Base Study)|Lack of Efficacy|0
6011402|NCT00112437|9604137|FG014|Year 1 (12-Month Base Study)|Lack of Efficacy|0
6011403|NCT00112437|9604138|FG015|Year 1 (12-Month Base Study)|Lack of Efficacy|0
6011404|NCT00112437|9604139|FG016|Year 1 (12-Month Base Study)|Lack of Efficacy|0
6011405|NCT00112437|9604140|FG017|Year 1 (12-Month Base Study)|Lack of Efficacy|0
6011406|NCT00112437|9604141|FG018|Year 1 (12-Month Base Study)|Lack of Efficacy|0
6011407|NCT00112437|9604142|FG019|Year 1 (12-Month Base Study)|Lack of Efficacy|0
6011408|NCT00112437|9604143|FG020|Year 1 (12-Month Base Study)|Lack of Efficacy|0
6011409|NCT00112437|9604144|FG021|Year 1 (12-Month Base Study)|Lack of Efficacy|0
6011410|NCT00112437|9604145|FG022|Year 1 (12-Month Base Study)|Lack of Efficacy|0
6011411|NCT00112437|9604146|FG023|Year 1 (12-Month Base Study)|Lack of Efficacy|0
6011412|NCT00112437|9604147|FG024|Year 1 (12-Month Base Study)|Lack of Efficacy|0
6011413|NCT00112437|9604148|FG025|Year 1 (12-Month Base Study)|Lack of Efficacy|0
6011414|NCT00112437|9604123|FG000|Year 1 (12-Month Base Study)|Lost to Follow-up|0
6011415|NCT00112437|9604124|FG001|Year 1 (12-Month Base Study)|Lost to Follow-up|1
6011416|NCT00112437|9604125|FG002|Year 1 (12-Month Base Study)|Lost to Follow-up|0
6011417|NCT00112437|9604126|FG003|Year 1 (12-Month Base Study)|Lost to Follow-up|0
6011418|NCT00112437|9604127|FG004|Year 1 (12-Month Base Study)|Lost to Follow-up|0
6011419|NCT00112437|9604128|FG005|Year 1 (12-Month Base Study)|Lost to Follow-up|0
6011420|NCT00112437|9604129|FG006|Year 1 (12-Month Base Study)|Lost to Follow-up|0
6011421|NCT00112437|9604130|FG007|Year 1 (12-Month Base Study)|Lost to Follow-up|0
6011422|NCT00112437|9604131|FG008|Year 1 (12-Month Base Study)|Lost to Follow-up|0
6011423|NCT00112437|9604132|FG009|Year 1 (12-Month Base Study)|Lost to Follow-up|0
6011424|NCT00112437|9604133|FG010|Year 1 (12-Month Base Study)|Lost to Follow-up|0
6011425|NCT00112437|9604134|FG011|Year 1 (12-Month Base Study)|Lost to Follow-up|0
6011426|NCT00112437|9604135|FG012|Year 1 (12-Month Base Study)|Lost to Follow-up|0
6011427|NCT00112437|9604136|FG013|Year 1 (12-Month Base Study)|Lost to Follow-up|0
6011428|NCT00112437|9604137|FG014|Year 1 (12-Month Base Study)|Lost to Follow-up|0
6011429|NCT00112437|9604138|FG015|Year 1 (12-Month Base Study)|Lost to Follow-up|0
6011430|NCT00112437|9604139|FG016|Year 1 (12-Month Base Study)|Lost to Follow-up|0
6011431|NCT00112437|9604140|FG017|Year 1 (12-Month Base Study)|Lost to Follow-up|0
6011432|NCT00112437|9604141|FG018|Year 1 (12-Month Base Study)|Lost to Follow-up|0
6011433|NCT00112437|9604142|FG019|Year 1 (12-Month Base Study)|Lost to Follow-up|0
6011434|NCT00112437|9604143|FG020|Year 1 (12-Month Base Study)|Lost to Follow-up|0
6011435|NCT00112437|9604144|FG021|Year 1 (12-Month Base Study)|Lost to Follow-up|0
6011436|NCT00112437|9604145|FG022|Year 1 (12-Month Base Study)|Lost to Follow-up|0
6011437|NCT00112437|9604146|FG023|Year 1 (12-Month Base Study)|Lost to Follow-up|0
6011438|NCT00112437|9604147|FG024|Year 1 (12-Month Base Study)|Lost to Follow-up|0
6011439|NCT00112437|9604148|FG025|Year 1 (12-Month Base Study)|Lost to Follow-up|0
6011440|NCT00112437|9604123|FG000|Year 1 (12-Month Base Study)|Protocol Violation|1
6011441|NCT00112437|9604124|FG001|Year 1 (12-Month Base Study)|Protocol Violation|0
6011442|NCT00112437|9604125|FG002|Year 1 (12-Month Base Study)|Protocol Violation|3
6011443|NCT00112437|9604126|FG003|Year 1 (12-Month Base Study)|Protocol Violation|1
6011444|NCT00112437|9604127|FG004|Year 1 (12-Month Base Study)|Protocol Violation|1
6011445|NCT00112437|9604128|FG005|Year 1 (12-Month Base Study)|Protocol Violation|0
6011446|NCT00112437|9604129|FG006|Year 1 (12-Month Base Study)|Protocol Violation|0
6011447|NCT00112437|9604130|FG007|Year 1 (12-Month Base Study)|Protocol Violation|0
6011448|NCT00112437|9604131|FG008|Year 1 (12-Month Base Study)|Protocol Violation|0
6011449|NCT00112437|9604132|FG009|Year 1 (12-Month Base Study)|Protocol Violation|0
6011450|NCT00112437|9604133|FG010|Year 1 (12-Month Base Study)|Protocol Violation|0
6011451|NCT00112437|9604134|FG011|Year 1 (12-Month Base Study)|Protocol Violation|0
6011452|NCT00112437|9604135|FG012|Year 1 (12-Month Base Study)|Protocol Violation|0
6011453|NCT00112437|9604136|FG013|Year 1 (12-Month Base Study)|Protocol Violation|0
6011454|NCT00112437|9604137|FG014|Year 1 (12-Month Base Study)|Protocol Violation|0
6011455|NCT00112437|9604138|FG015|Year 1 (12-Month Base Study)|Protocol Violation|0
6011456|NCT00112437|9604139|FG016|Year 1 (12-Month Base Study)|Protocol Violation|0
6011457|NCT00112437|9604140|FG017|Year 1 (12-Month Base Study)|Protocol Violation|0
6011458|NCT00112437|9604141|FG018|Year 1 (12-Month Base Study)|Protocol Violation|0
6011459|NCT00112437|9604142|FG019|Year 1 (12-Month Base Study)|Protocol Violation|0
6011460|NCT00112437|9604143|FG020|Year 1 (12-Month Base Study)|Protocol Violation|0
6011461|NCT00112437|9604144|FG021|Year 1 (12-Month Base Study)|Protocol Violation|0
6011462|NCT00112437|9604145|FG022|Year 1 (12-Month Base Study)|Protocol Violation|0
6011463|NCT00112437|9604146|FG023|Year 1 (12-Month Base Study)|Protocol Violation|0
6011464|NCT00112437|9604147|FG024|Year 1 (12-Month Base Study)|Protocol Violation|0
6011465|NCT00112437|9604148|FG025|Year 1 (12-Month Base Study)|Protocol Violation|0
6011466|NCT00112437|9604123|FG000|Year 1 (12-Month Base Study)|Withdrawal by Subject|5
6011467|NCT00112437|9604124|FG001|Year 1 (12-Month Base Study)|Withdrawal by Subject|5
6011468|NCT00112437|9604125|FG002|Year 1 (12-Month Base Study)|Withdrawal by Subject|2
6011469|NCT00112437|9604126|FG003|Year 1 (12-Month Base Study)|Withdrawal by Subject|1
6011470|NCT00112437|9604127|FG004|Year 1 (12-Month Base Study)|Withdrawal by Subject|7
6011471|NCT00112437|9604128|FG005|Year 1 (12-Month Base Study)|Withdrawal by Subject|0
6011472|NCT00112437|9604129|FG006|Year 1 (12-Month Base Study)|Withdrawal by Subject|0
6011473|NCT00112437|9604130|FG007|Year 1 (12-Month Base Study)|Withdrawal by Subject|0
6011474|NCT00112437|9604131|FG008|Year 1 (12-Month Base Study)|Withdrawal by Subject|0
6011475|NCT00112437|9604132|FG009|Year 1 (12-Month Base Study)|Withdrawal by Subject|0
6011476|NCT00112437|9604133|FG010|Year 1 (12-Month Base Study)|Withdrawal by Subject|0
6011477|NCT00112437|9604134|FG011|Year 1 (12-Month Base Study)|Withdrawal by Subject|0
6011478|NCT00112437|9604135|FG012|Year 1 (12-Month Base Study)|Withdrawal by Subject|0
6011479|NCT00112437|9604136|FG013|Year 1 (12-Month Base Study)|Withdrawal by Subject|0
6011480|NCT00112437|9604137|FG014|Year 1 (12-Month Base Study)|Withdrawal by Subject|0
6011481|NCT00112437|9604138|FG015|Year 1 (12-Month Base Study)|Withdrawal by Subject|0
6011482|NCT00112437|9604139|FG016|Year 1 (12-Month Base Study)|Withdrawal by Subject|0
6011483|NCT00112437|9604140|FG017|Year 1 (12-Month Base Study)|Withdrawal by Subject|0
6011484|NCT00112437|9604141|FG018|Year 1 (12-Month Base Study)|Withdrawal by Subject|0
6011485|NCT00112437|9604142|FG019|Year 1 (12-Month Base Study)|Withdrawal by Subject|0
6011486|NCT00112437|9604143|FG020|Year 1 (12-Month Base Study)|Withdrawal by Subject|0
6011487|NCT00112437|9604144|FG021|Year 1 (12-Month Base Study)|Withdrawal by Subject|0
6011488|NCT00112437|9604145|FG022|Year 1 (12-Month Base Study)|Withdrawal by Subject|0
6011489|NCT00112437|9604146|FG023|Year 1 (12-Month Base Study)|Withdrawal by Subject|0
6011490|NCT00112437|9604147|FG024|Year 1 (12-Month Base Study)|Withdrawal by Subject|0
6011491|NCT00112437|9604148|FG025|Year 1 (12-Month Base Study)|Withdrawal by Subject|0
6011492|NCT00112437|9604123|FG000|Year 1 (12-Month Base Study)|moved|0
6011493|NCT00112437|9604124|FG001|Year 1 (12-Month Base Study)|moved|1
6011494|NCT00112437|9604125|FG002|Year 1 (12-Month Base Study)|moved|1
6011495|NCT00112437|9604126|FG003|Year 1 (12-Month Base Study)|moved|0
6011496|NCT00112437|9604127|FG004|Year 1 (12-Month Base Study)|moved|0
6011497|NCT00112437|9604128|FG005|Year 1 (12-Month Base Study)|moved|0
6011498|NCT00112437|9604129|FG006|Year 1 (12-Month Base Study)|moved|0
6011499|NCT00112437|9604130|FG007|Year 1 (12-Month Base Study)|moved|0
6011500|NCT00112437|9604131|FG008|Year 1 (12-Month Base Study)|moved|0
6011501|NCT00112437|9604132|FG009|Year 1 (12-Month Base Study)|moved|0
6011502|NCT00112437|9604133|FG010|Year 1 (12-Month Base Study)|moved|0
6011503|NCT00112437|9604134|FG011|Year 1 (12-Month Base Study)|moved|0
6011504|NCT00112437|9604135|FG012|Year 1 (12-Month Base Study)|moved|0
6011505|NCT00112437|9604136|FG013|Year 1 (12-Month Base Study)|moved|0
6011506|NCT00112437|9604137|FG014|Year 1 (12-Month Base Study)|moved|0
6011507|NCT00112437|9604138|FG015|Year 1 (12-Month Base Study)|moved|0
6011508|NCT00112437|9604139|FG016|Year 1 (12-Month Base Study)|moved|0
6011509|NCT00112437|9604140|FG017|Year 1 (12-Month Base Study)|moved|0
6011510|NCT00112437|9604141|FG018|Year 1 (12-Month Base Study)|moved|0
6011511|NCT00112437|9604142|FG019|Year 1 (12-Month Base Study)|moved|0
6011512|NCT00112437|9604143|FG020|Year 1 (12-Month Base Study)|moved|0
6011513|NCT00112437|9604144|FG021|Year 1 (12-Month Base Study)|moved|0
6011514|NCT00112437|9604145|FG022|Year 1 (12-Month Base Study)|moved|0
6011515|NCT00112437|9604146|FG023|Year 1 (12-Month Base Study)|moved|0
6011516|NCT00112437|9604147|FG024|Year 1 (12-Month Base Study)|moved|0
6011517|NCT00112437|9604148|FG025|Year 1 (12-Month Base Study)|moved|0
6011518|NCT00112437|9604123|FG000|Year 1 (12-Month Base Study)|patient was unsure that they needed drug|0
6011519|NCT00112437|9604124|FG001|Year 1 (12-Month Base Study)|patient was unsure that they needed drug|0
6011520|NCT00112437|9604125|FG002|Year 1 (12-Month Base Study)|patient was unsure that they needed drug|0
6011521|NCT00112437|9604126|FG003|Year 1 (12-Month Base Study)|patient was unsure that they needed drug|2
6011522|NCT00112437|9604127|FG004|Year 1 (12-Month Base Study)|patient was unsure that they needed drug|0
6011523|NCT00112437|9604128|FG005|Year 1 (12-Month Base Study)|patient was unsure that they needed drug|0
6011524|NCT00112437|9604129|FG006|Year 1 (12-Month Base Study)|patient was unsure that they needed drug|0
6011525|NCT00112437|9604130|FG007|Year 1 (12-Month Base Study)|patient was unsure that they needed drug|0
6011526|NCT00112437|9604131|FG008|Year 1 (12-Month Base Study)|patient was unsure that they needed drug|0
6011527|NCT00112437|9604132|FG009|Year 1 (12-Month Base Study)|patient was unsure that they needed drug|0
6011528|NCT00112437|9604133|FG010|Year 1 (12-Month Base Study)|patient was unsure that they needed drug|0
6011529|NCT00112437|9604134|FG011|Year 1 (12-Month Base Study)|patient was unsure that they needed drug|0
6011530|NCT00112437|9604135|FG012|Year 1 (12-Month Base Study)|patient was unsure that they needed drug|0
6011531|NCT00112437|9604136|FG013|Year 1 (12-Month Base Study)|patient was unsure that they needed drug|0
6011532|NCT00112437|9604137|FG014|Year 1 (12-Month Base Study)|patient was unsure that they needed drug|0
6011533|NCT00112437|9604138|FG015|Year 1 (12-Month Base Study)|patient was unsure that they needed drug|0
6011534|NCT00112437|9604139|FG016|Year 1 (12-Month Base Study)|patient was unsure that they needed drug|0
6011535|NCT00112437|9604140|FG017|Year 1 (12-Month Base Study)|patient was unsure that they needed drug|0
6011536|NCT00112437|9604141|FG018|Year 1 (12-Month Base Study)|patient was unsure that they needed drug|0
6011537|NCT00112437|9604142|FG019|Year 1 (12-Month Base Study)|patient was unsure that they needed drug|0
6011538|NCT00112437|9604143|FG020|Year 1 (12-Month Base Study)|patient was unsure that they needed drug|0
6011539|NCT00112437|9604144|FG021|Year 1 (12-Month Base Study)|patient was unsure that they needed drug|0
6011540|NCT00112437|9604145|FG022|Year 1 (12-Month Base Study)|patient was unsure that they needed drug|0
6011541|NCT00112437|9604146|FG023|Year 1 (12-Month Base Study)|patient was unsure that they needed drug|0
6011542|NCT00112437|9604147|FG024|Year 1 (12-Month Base Study)|patient was unsure that they needed drug|0
6011543|NCT00112437|9604148|FG025|Year 1 (12-Month Base Study)|patient was unsure that they needed drug|0
6011544|NCT00112437|9604123|FG000|Year 1 (12-Month Base Study)|DXA was lower by more than 8%|0
6011545|NCT00112437|9604124|FG001|Year 1 (12-Month Base Study)|DXA was lower by more than 8%|0
6011546|NCT00112437|9604125|FG002|Year 1 (12-Month Base Study)|DXA was lower by more than 8%|0
6011547|NCT00112437|9604126|FG003|Year 1 (12-Month Base Study)|DXA was lower by more than 8%|0
6011548|NCT00112437|9604127|FG004|Year 1 (12-Month Base Study)|DXA was lower by more than 8%|1
6011549|NCT00112437|9604128|FG005|Year 1 (12-Month Base Study)|DXA was lower by more than 8%|0
6011550|NCT00112437|9604129|FG006|Year 1 (12-Month Base Study)|DXA was lower by more than 8%|0
6011551|NCT00112437|9604130|FG007|Year 1 (12-Month Base Study)|DXA was lower by more than 8%|0
6011552|NCT00112437|9604131|FG008|Year 1 (12-Month Base Study)|DXA was lower by more than 8%|0
6011553|NCT00112437|9604132|FG009|Year 1 (12-Month Base Study)|DXA was lower by more than 8%|0
6011554|NCT00112437|9604133|FG010|Year 1 (12-Month Base Study)|DXA was lower by more than 8%|0
6011555|NCT00112437|9604134|FG011|Year 1 (12-Month Base Study)|DXA was lower by more than 8%|0
6011556|NCT00112437|9604135|FG012|Year 1 (12-Month Base Study)|DXA was lower by more than 8%|0
6011557|NCT00112437|9604136|FG013|Year 1 (12-Month Base Study)|DXA was lower by more than 8%|0
6011558|NCT00112437|9604137|FG014|Year 1 (12-Month Base Study)|DXA was lower by more than 8%|0
6011559|NCT00112437|9604138|FG015|Year 1 (12-Month Base Study)|DXA was lower by more than 8%|0
6011560|NCT00112437|9604139|FG016|Year 1 (12-Month Base Study)|DXA was lower by more than 8%|0
6011561|NCT00112437|9604140|FG017|Year 1 (12-Month Base Study)|DXA was lower by more than 8%|0
6011562|NCT00112437|9604141|FG018|Year 1 (12-Month Base Study)|DXA was lower by more than 8%|0
6011563|NCT00112437|9604142|FG019|Year 1 (12-Month Base Study)|DXA was lower by more than 8%|0
6011564|NCT00112437|9604143|FG020|Year 1 (12-Month Base Study)|DXA was lower by more than 8%|0
6011565|NCT00112437|9604144|FG021|Year 1 (12-Month Base Study)|DXA was lower by more than 8%|0
6011566|NCT00112437|9604145|FG022|Year 1 (12-Month Base Study)|DXA was lower by more than 8%|0
6011567|NCT00112437|9604146|FG023|Year 1 (12-Month Base Study)|DXA was lower by more than 8%|0
6011568|NCT00112437|9604147|FG024|Year 1 (12-Month Base Study)|DXA was lower by more than 8%|0
6011569|NCT00112437|9604148|FG025|Year 1 (12-Month Base Study)|DXA was lower by more than 8%|0
6011570|NCT00112437|9604123|FG000|Year 2 (12-Month Extension)|Adverse Event|0
6011571|NCT00112437|9604124|FG001|Year 2 (12-Month Extension)|Adverse Event|0
6011572|NCT00112437|9604125|FG002|Year 2 (12-Month Extension)|Adverse Event|0
6011573|NCT00112437|9604126|FG003|Year 2 (12-Month Extension)|Adverse Event|0
6011574|NCT00112437|9604127|FG004|Year 2 (12-Month Extension)|Adverse Event|0
6011575|NCT00112437|9604128|FG005|Year 2 (12-Month Extension)|Adverse Event|1
6011576|NCT00112437|9604129|FG006|Year 2 (12-Month Extension)|Adverse Event|2
6011577|NCT00112437|9604130|FG007|Year 2 (12-Month Extension)|Adverse Event|6
6011578|NCT00112437|9604131|FG008|Year 2 (12-Month Extension)|Adverse Event|1
6011579|NCT00112437|9604132|FG009|Year 2 (12-Month Extension)|Adverse Event|7
6011580|NCT00112437|9604133|FG010|Year 2 (12-Month Extension)|Adverse Event|0
6011581|NCT00112437|9604134|FG011|Year 2 (12-Month Extension)|Adverse Event|0
6011582|NCT00112437|9604135|FG012|Year 2 (12-Month Extension)|Adverse Event|0
6011583|NCT00112437|9604136|FG013|Year 2 (12-Month Extension)|Adverse Event|0
6011584|NCT00112437|9604137|FG014|Year 2 (12-Month Extension)|Adverse Event|0
6011585|NCT00112437|9604138|FG015|Year 2 (12-Month Extension)|Adverse Event|0
6011586|NCT00112437|9604139|FG016|Year 2 (12-Month Extension)|Adverse Event|0
6011587|NCT00112437|9604140|FG017|Year 2 (12-Month Extension)|Adverse Event|0
6011588|NCT00112437|9604141|FG018|Year 2 (12-Month Extension)|Adverse Event|0
6011589|NCT00112437|9604142|FG019|Year 2 (12-Month Extension)|Adverse Event|0
6011590|NCT00112437|9604143|FG020|Year 2 (12-Month Extension)|Adverse Event|0
6011591|NCT00112437|9604144|FG021|Year 2 (12-Month Extension)|Adverse Event|0
6011592|NCT00112437|9604145|FG022|Year 2 (12-Month Extension)|Adverse Event|0
6011593|NCT00112437|9604146|FG023|Year 2 (12-Month Extension)|Adverse Event|0
6011594|NCT00112437|9604147|FG024|Year 2 (12-Month Extension)|Adverse Event|0
6011595|NCT00112437|9604148|FG025|Year 2 (12-Month Extension)|Adverse Event|0
6011596|NCT00112437|9604123|FG000|Year 2 (12-Month Extension)|Lack of Efficacy|0
6011597|NCT00112437|9604124|FG001|Year 2 (12-Month Extension)|Lack of Efficacy|0
6011598|NCT00112437|9604125|FG002|Year 2 (12-Month Extension)|Lack of Efficacy|0
6011599|NCT00112437|9604126|FG003|Year 2 (12-Month Extension)|Lack of Efficacy|0
6011600|NCT00112437|9604127|FG004|Year 2 (12-Month Extension)|Lack of Efficacy|0
6075650|NCT00582426|9680183|FG000|Overall Study|Withdrawal by Subject|3
6075651|NCT00582426|9680184|FG001|Overall Study|Withdrawal by Subject|2
6075652|NCT00582426|9680183|FG000|Overall Study|Disease Progression|2
6075653|NCT00582426|9680184|FG001|Overall Study|Disease Progression|2
6075654|NCT00582426|9680183|FG000|Overall Study|Use of illicit drugs|1
6075655|NCT00582426|9680184|FG001|Overall Study|Use of illicit drugs|0
6075656|NCT00582491|9680192|FG000|Overall Study|Withdrawal by Subject|1
6075657|NCT00582491|9680193|FG001|Overall Study|Withdrawal by Subject|0
6075658|NCT00582556|9680211|FG000|Overall Study|Withdrawal by Subject|0
6011601|NCT00112437|9604128|FG005|Year 2 (12-Month Extension)|Lack of Efficacy|1
6011602|NCT00112437|9604129|FG006|Year 2 (12-Month Extension)|Lack of Efficacy|6
6011603|NCT00112437|9604130|FG007|Year 2 (12-Month Extension)|Lack of Efficacy|0
6011604|NCT00112437|9604131|FG008|Year 2 (12-Month Extension)|Lack of Efficacy|0
6011605|NCT00112437|9604132|FG009|Year 2 (12-Month Extension)|Lack of Efficacy|2
6011606|NCT00112437|9604133|FG010|Year 2 (12-Month Extension)|Lack of Efficacy|0
6011607|NCT00112437|9604134|FG011|Year 2 (12-Month Extension)|Lack of Efficacy|0
6011608|NCT00112437|9604135|FG012|Year 2 (12-Month Extension)|Lack of Efficacy|0
6011609|NCT00112437|9604136|FG013|Year 2 (12-Month Extension)|Lack of Efficacy|0
6011610|NCT00112437|9604137|FG014|Year 2 (12-Month Extension)|Lack of Efficacy|0
6011611|NCT00112437|9604138|FG015|Year 2 (12-Month Extension)|Lack of Efficacy|0
6011612|NCT00112437|9604139|FG016|Year 2 (12-Month Extension)|Lack of Efficacy|0
6011613|NCT00112437|9604140|FG017|Year 2 (12-Month Extension)|Lack of Efficacy|0
6011614|NCT00112437|9604141|FG018|Year 2 (12-Month Extension)|Lack of Efficacy|0
6011615|NCT00112437|9604142|FG019|Year 2 (12-Month Extension)|Lack of Efficacy|0
6011616|NCT00112437|9604143|FG020|Year 2 (12-Month Extension)|Lack of Efficacy|0
6011617|NCT00112437|9604144|FG021|Year 2 (12-Month Extension)|Lack of Efficacy|0
6011618|NCT00112437|9604145|FG022|Year 2 (12-Month Extension)|Lack of Efficacy|0
6011619|NCT00112437|9604146|FG023|Year 2 (12-Month Extension)|Lack of Efficacy|0
6011620|NCT00112437|9604147|FG024|Year 2 (12-Month Extension)|Lack of Efficacy|0
6011621|NCT00112437|9604148|FG025|Year 2 (12-Month Extension)|Lack of Efficacy|0
6011622|NCT00112437|9604123|FG000|Year 2 (12-Month Extension)|Lost to Follow-up|0
6011623|NCT00112437|9604124|FG001|Year 2 (12-Month Extension)|Lost to Follow-up|0
6011624|NCT00112437|9604125|FG002|Year 2 (12-Month Extension)|Lost to Follow-up|0
6011625|NCT00112437|9604126|FG003|Year 2 (12-Month Extension)|Lost to Follow-up|0
6011626|NCT00112437|9604127|FG004|Year 2 (12-Month Extension)|Lost to Follow-up|0
6011627|NCT00112437|9604128|FG005|Year 2 (12-Month Extension)|Lost to Follow-up|0
6011628|NCT00112437|9604129|FG006|Year 2 (12-Month Extension)|Lost to Follow-up|0
6011629|NCT00112437|9604130|FG007|Year 2 (12-Month Extension)|Lost to Follow-up|0
6011630|NCT00112437|9604131|FG008|Year 2 (12-Month Extension)|Lost to Follow-up|1
6011631|NCT00112437|9604132|FG009|Year 2 (12-Month Extension)|Lost to Follow-up|0
6011632|NCT00112437|9604133|FG010|Year 2 (12-Month Extension)|Lost to Follow-up|0
6011633|NCT00112437|9604134|FG011|Year 2 (12-Month Extension)|Lost to Follow-up|0
6011634|NCT00112437|9604135|FG012|Year 2 (12-Month Extension)|Lost to Follow-up|0
6011635|NCT00112437|9604136|FG013|Year 2 (12-Month Extension)|Lost to Follow-up|0
6011636|NCT00112437|9604137|FG014|Year 2 (12-Month Extension)|Lost to Follow-up|0
6011637|NCT00112437|9604138|FG015|Year 2 (12-Month Extension)|Lost to Follow-up|0
6011638|NCT00112437|9604139|FG016|Year 2 (12-Month Extension)|Lost to Follow-up|0
6011639|NCT00112437|9604140|FG017|Year 2 (12-Month Extension)|Lost to Follow-up|0
6011640|NCT00112437|9604141|FG018|Year 2 (12-Month Extension)|Lost to Follow-up|0
6011641|NCT00112437|9604142|FG019|Year 2 (12-Month Extension)|Lost to Follow-up|0
6011642|NCT00112437|9604143|FG020|Year 2 (12-Month Extension)|Lost to Follow-up|0
6011643|NCT00112437|9604144|FG021|Year 2 (12-Month Extension)|Lost to Follow-up|0
6011644|NCT00112437|9604145|FG022|Year 2 (12-Month Extension)|Lost to Follow-up|0
6011645|NCT00112437|9604146|FG023|Year 2 (12-Month Extension)|Lost to Follow-up|0
6011646|NCT00112437|9604147|FG024|Year 2 (12-Month Extension)|Lost to Follow-up|0
6011647|NCT00112437|9604148|FG025|Year 2 (12-Month Extension)|Lost to Follow-up|0
6011648|NCT00112437|9604123|FG000|Year 2 (12-Month Extension)|Protocol Violation|0
6011649|NCT00112437|9604124|FG001|Year 2 (12-Month Extension)|Protocol Violation|0
6011650|NCT00112437|9604125|FG002|Year 2 (12-Month Extension)|Protocol Violation|0
6011651|NCT00112437|9604126|FG003|Year 2 (12-Month Extension)|Protocol Violation|0
6011652|NCT00112437|9604127|FG004|Year 2 (12-Month Extension)|Protocol Violation|0
6011653|NCT00112437|9604128|FG005|Year 2 (12-Month Extension)|Protocol Violation|0
6011654|NCT00112437|9604129|FG006|Year 2 (12-Month Extension)|Protocol Violation|0
6011655|NCT00112437|9604130|FG007|Year 2 (12-Month Extension)|Protocol Violation|0
6011656|NCT00112437|9604131|FG008|Year 2 (12-Month Extension)|Protocol Violation|1
6011657|NCT00112437|9604132|FG009|Year 2 (12-Month Extension)|Protocol Violation|0
6011658|NCT00112437|9604133|FG010|Year 2 (12-Month Extension)|Protocol Violation|0
6011659|NCT00112437|9604134|FG011|Year 2 (12-Month Extension)|Protocol Violation|0
6011660|NCT00112437|9604135|FG012|Year 2 (12-Month Extension)|Protocol Violation|0
6011661|NCT00112437|9604136|FG013|Year 2 (12-Month Extension)|Protocol Violation|0
6011662|NCT00112437|9604137|FG014|Year 2 (12-Month Extension)|Protocol Violation|0
6011663|NCT00112437|9604138|FG015|Year 2 (12-Month Extension)|Protocol Violation|0
6011664|NCT00112437|9604139|FG016|Year 2 (12-Month Extension)|Protocol Violation|0
6011665|NCT00112437|9604140|FG017|Year 2 (12-Month Extension)|Protocol Violation|0
6011666|NCT00112437|9604141|FG018|Year 2 (12-Month Extension)|Protocol Violation|0
6011667|NCT00112437|9604142|FG019|Year 2 (12-Month Extension)|Protocol Violation|0
6011668|NCT00112437|9604143|FG020|Year 2 (12-Month Extension)|Protocol Violation|0
6011669|NCT00112437|9604144|FG021|Year 2 (12-Month Extension)|Protocol Violation|0
6011670|NCT00112437|9604145|FG022|Year 2 (12-Month Extension)|Protocol Violation|0
6011671|NCT00112437|9604146|FG023|Year 2 (12-Month Extension)|Protocol Violation|0
6011672|NCT00112437|9604147|FG024|Year 2 (12-Month Extension)|Protocol Violation|0
6011673|NCT00112437|9604148|FG025|Year 2 (12-Month Extension)|Protocol Violation|0
6011674|NCT00112437|9604123|FG000|Year 2 (12-Month Extension)|Withdrawal by Subject|0
6011675|NCT00112437|9604124|FG001|Year 2 (12-Month Extension)|Withdrawal by Subject|0
6011676|NCT00112437|9604125|FG002|Year 2 (12-Month Extension)|Withdrawal by Subject|0
6011677|NCT00112437|9604126|FG003|Year 2 (12-Month Extension)|Withdrawal by Subject|0
6011678|NCT00112437|9604127|FG004|Year 2 (12-Month Extension)|Withdrawal by Subject|0
6011679|NCT00112437|9604128|FG005|Year 2 (12-Month Extension)|Withdrawal by Subject|1
6011680|NCT00112437|9604129|FG006|Year 2 (12-Month Extension)|Withdrawal by Subject|1
6011681|NCT00112437|9604130|FG007|Year 2 (12-Month Extension)|Withdrawal by Subject|2
6011682|NCT00112437|9604131|FG008|Year 2 (12-Month Extension)|Withdrawal by Subject|4
6011683|NCT00112437|9604132|FG009|Year 2 (12-Month Extension)|Withdrawal by Subject|1
6011684|NCT00112437|9604133|FG010|Year 2 (12-Month Extension)|Withdrawal by Subject|0
6011685|NCT00112437|9604134|FG011|Year 2 (12-Month Extension)|Withdrawal by Subject|0
6011686|NCT00112437|9604135|FG012|Year 2 (12-Month Extension)|Withdrawal by Subject|0
6011687|NCT00112437|9604136|FG013|Year 2 (12-Month Extension)|Withdrawal by Subject|0
6011688|NCT00112437|9604137|FG014|Year 2 (12-Month Extension)|Withdrawal by Subject|0
6011689|NCT00112437|9604138|FG015|Year 2 (12-Month Extension)|Withdrawal by Subject|0
6011690|NCT00112437|9604139|FG016|Year 2 (12-Month Extension)|Withdrawal by Subject|0
6011691|NCT00112437|9604140|FG017|Year 2 (12-Month Extension)|Withdrawal by Subject|0
6011692|NCT00112437|9604141|FG018|Year 2 (12-Month Extension)|Withdrawal by Subject|0
6011693|NCT00112437|9604142|FG019|Year 2 (12-Month Extension)|Withdrawal by Subject|0
6011694|NCT00112437|9604143|FG020|Year 2 (12-Month Extension)|Withdrawal by Subject|0
6011695|NCT00112437|9604144|FG021|Year 2 (12-Month Extension)|Withdrawal by Subject|0
6011696|NCT00112437|9604145|FG022|Year 2 (12-Month Extension)|Withdrawal by Subject|0
6011697|NCT00112437|9604146|FG023|Year 2 (12-Month Extension)|Withdrawal by Subject|0
6011698|NCT00112437|9604147|FG024|Year 2 (12-Month Extension)|Withdrawal by Subject|0
6011699|NCT00112437|9604148|FG025|Year 2 (12-Month Extension)|Withdrawal by Subject|0
6011700|NCT00112437|9604123|FG000|Year 2 (12-Month Extension)|Patient stopped taking medication|0
6011701|NCT00112437|9604124|FG001|Year 2 (12-Month Extension)|Patient stopped taking medication|0
6011702|NCT00112437|9604125|FG002|Year 2 (12-Month Extension)|Patient stopped taking medication|0
6011703|NCT00112437|9604126|FG003|Year 2 (12-Month Extension)|Patient stopped taking medication|0
6011704|NCT00112437|9604127|FG004|Year 2 (12-Month Extension)|Patient stopped taking medication|0
6011705|NCT00112437|9604128|FG005|Year 2 (12-Month Extension)|Patient stopped taking medication|0
6011706|NCT00112437|9604129|FG006|Year 2 (12-Month Extension)|Patient stopped taking medication|0
6011707|NCT00112437|9604130|FG007|Year 2 (12-Month Extension)|Patient stopped taking medication|0
6011708|NCT00112437|9604131|FG008|Year 2 (12-Month Extension)|Patient stopped taking medication|0
6011709|NCT00112437|9604132|FG009|Year 2 (12-Month Extension)|Patient stopped taking medication|1
6011710|NCT00112437|9604133|FG010|Year 2 (12-Month Extension)|Patient stopped taking medication|0
6011711|NCT00112437|9604134|FG011|Year 2 (12-Month Extension)|Patient stopped taking medication|0
6011712|NCT00112437|9604135|FG012|Year 2 (12-Month Extension)|Patient stopped taking medication|0
6011713|NCT00112437|9604136|FG013|Year 2 (12-Month Extension)|Patient stopped taking medication|0
6011714|NCT00112437|9604137|FG014|Year 2 (12-Month Extension)|Patient stopped taking medication|0
6011715|NCT00112437|9604138|FG015|Year 2 (12-Month Extension)|Patient stopped taking medication|0
6011716|NCT00112437|9604139|FG016|Year 2 (12-Month Extension)|Patient stopped taking medication|0
6011717|NCT00112437|9604140|FG017|Year 2 (12-Month Extension)|Patient stopped taking medication|0
6011718|NCT00112437|9604141|FG018|Year 2 (12-Month Extension)|Patient stopped taking medication|0
6011719|NCT00112437|9604142|FG019|Year 2 (12-Month Extension)|Patient stopped taking medication|0
6011720|NCT00112437|9604143|FG020|Year 2 (12-Month Extension)|Patient stopped taking medication|0
6011721|NCT00112437|9604144|FG021|Year 2 (12-Month Extension)|Patient stopped taking medication|0
6011722|NCT00112437|9604145|FG022|Year 2 (12-Month Extension)|Patient stopped taking medication|0
6011723|NCT00112437|9604146|FG023|Year 2 (12-Month Extension)|Patient stopped taking medication|0
6011724|NCT00112437|9604147|FG024|Year 2 (12-Month Extension)|Patient stopped taking medication|0
6011725|NCT00112437|9604148|FG025|Year 2 (12-Month Extension)|Patient stopped taking medication|0
6011726|NCT00112437|9604123|FG000|Year 2 (12-Month Extension)|patient was out of windows|0
6011727|NCT00112437|9604124|FG001|Year 2 (12-Month Extension)|patient was out of windows|0
6011728|NCT00112437|9604125|FG002|Year 2 (12-Month Extension)|patient was out of windows|0
6011729|NCT00112437|9604126|FG003|Year 2 (12-Month Extension)|patient was out of windows|0
6011730|NCT00112437|9604127|FG004|Year 2 (12-Month Extension)|patient was out of windows|0
6011731|NCT00112437|9604128|FG005|Year 2 (12-Month Extension)|patient was out of windows|0
6011732|NCT00112437|9604129|FG006|Year 2 (12-Month Extension)|patient was out of windows|0
6011733|NCT00112437|9604130|FG007|Year 2 (12-Month Extension)|patient was out of windows|0
6011734|NCT00112437|9604131|FG008|Year 2 (12-Month Extension)|patient was out of windows|0
6011735|NCT00112437|9604132|FG009|Year 2 (12-Month Extension)|patient was out of windows|1
6011736|NCT00112437|9604133|FG010|Year 2 (12-Month Extension)|patient was out of windows|0
6011737|NCT00112437|9604134|FG011|Year 2 (12-Month Extension)|patient was out of windows|0
6011738|NCT00112437|9604135|FG012|Year 2 (12-Month Extension)|patient was out of windows|0
6011739|NCT00112437|9604136|FG013|Year 2 (12-Month Extension)|patient was out of windows|0
6011740|NCT00112437|9604137|FG014|Year 2 (12-Month Extension)|patient was out of windows|0
6011741|NCT00112437|9604138|FG015|Year 2 (12-Month Extension)|patient was out of windows|0
6011742|NCT00112437|9604139|FG016|Year 2 (12-Month Extension)|patient was out of windows|0
6011743|NCT00112437|9604140|FG017|Year 2 (12-Month Extension)|patient was out of windows|0
6011744|NCT00112437|9604141|FG018|Year 2 (12-Month Extension)|patient was out of windows|0
6011745|NCT00112437|9604142|FG019|Year 2 (12-Month Extension)|patient was out of windows|0
6011746|NCT00112437|9604143|FG020|Year 2 (12-Month Extension)|patient was out of windows|0
6011747|NCT00112437|9604144|FG021|Year 2 (12-Month Extension)|patient was out of windows|0
6011748|NCT00112437|9604145|FG022|Year 2 (12-Month Extension)|patient was out of windows|0
6011749|NCT00112437|9604146|FG023|Year 2 (12-Month Extension)|patient was out of windows|0
6011750|NCT00112437|9604147|FG024|Year 2 (12-Month Extension)|patient was out of windows|0
6011751|NCT00112437|9604148|FG025|Year 2 (12-Month Extension)|patient was out of windows|0
6011752|NCT00112437|9604123|FG000|Year 2 (12-Month Extension)|Moved|0
6011753|NCT00112437|9604124|FG001|Year 2 (12-Month Extension)|Moved|0
6011754|NCT00112437|9604125|FG002|Year 2 (12-Month Extension)|Moved|0
6011755|NCT00112437|9604126|FG003|Year 2 (12-Month Extension)|Moved|0
6011756|NCT00112437|9604127|FG004|Year 2 (12-Month Extension)|Moved|0
6011757|NCT00112437|9604128|FG005|Year 2 (12-Month Extension)|Moved|0
6011758|NCT00112437|9604129|FG006|Year 2 (12-Month Extension)|Moved|0
6011759|NCT00112437|9604130|FG007|Year 2 (12-Month Extension)|Moved|0
6011760|NCT00112437|9604131|FG008|Year 2 (12-Month Extension)|Moved|0
6011761|NCT00112437|9604132|FG009|Year 2 (12-Month Extension)|Moved|1
6011762|NCT00112437|9604133|FG010|Year 2 (12-Month Extension)|Moved|0
6011763|NCT00112437|9604134|FG011|Year 2 (12-Month Extension)|Moved|0
6011764|NCT00112437|9604135|FG012|Year 2 (12-Month Extension)|Moved|0
6011765|NCT00112437|9604136|FG013|Year 2 (12-Month Extension)|Moved|0
6011766|NCT00112437|9604137|FG014|Year 2 (12-Month Extension)|Moved|0
6011767|NCT00112437|9604138|FG015|Year 2 (12-Month Extension)|Moved|0
6011768|NCT00112437|9604139|FG016|Year 2 (12-Month Extension)|Moved|0
6011769|NCT00112437|9604140|FG017|Year 2 (12-Month Extension)|Moved|0
6011770|NCT00112437|9604141|FG018|Year 2 (12-Month Extension)|Moved|0
6011771|NCT00112437|9604142|FG019|Year 2 (12-Month Extension)|Moved|0
6011772|NCT00112437|9604143|FG020|Year 2 (12-Month Extension)|Moved|0
6011773|NCT00112437|9604144|FG021|Year 2 (12-Month Extension)|Moved|0
6011774|NCT00112437|9604145|FG022|Year 2 (12-Month Extension)|Moved|0
6011775|NCT00112437|9604146|FG023|Year 2 (12-Month Extension)|Moved|0
6011776|NCT00112437|9604147|FG024|Year 2 (12-Month Extension)|Moved|0
6011777|NCT00112437|9604148|FG025|Year 2 (12-Month Extension)|Moved|0
6011778|NCT00112437|9604123|FG000|Year 3 (12-Month Extension)|Adverse Event|0
6011779|NCT00112437|9604124|FG001|Year 3 (12-Month Extension)|Adverse Event|0
6011780|NCT00112437|9604125|FG002|Year 3 (12-Month Extension)|Adverse Event|0
6011781|NCT00112437|9604126|FG003|Year 3 (12-Month Extension)|Adverse Event|0
6011782|NCT00112437|9604127|FG004|Year 3 (12-Month Extension)|Adverse Event|0
6011783|NCT00112437|9604128|FG005|Year 3 (12-Month Extension)|Adverse Event|0
6011784|NCT00112437|9604129|FG006|Year 3 (12-Month Extension)|Adverse Event|0
6011785|NCT00112437|9604130|FG007|Year 3 (12-Month Extension)|Adverse Event|0
6011786|NCT00112437|9604131|FG008|Year 3 (12-Month Extension)|Adverse Event|0
6011787|NCT00112437|9604132|FG009|Year 3 (12-Month Extension)|Adverse Event|0
6011788|NCT00112437|9604133|FG010|Year 3 (12-Month Extension)|Adverse Event|1
6011789|NCT00112437|9604134|FG011|Year 3 (12-Month Extension)|Adverse Event|0
6011790|NCT00112437|9604135|FG012|Year 3 (12-Month Extension)|Adverse Event|0
6011791|NCT00112437|9604136|FG013|Year 3 (12-Month Extension)|Adverse Event|0
6011792|NCT00112437|9604137|FG014|Year 3 (12-Month Extension)|Adverse Event|0
6011793|NCT00112437|9604138|FG015|Year 3 (12-Month Extension)|Adverse Event|1
6011794|NCT00112437|9604139|FG016|Year 3 (12-Month Extension)|Adverse Event|3
6011795|NCT00112437|9604140|FG017|Year 3 (12-Month Extension)|Adverse Event|1
6011796|NCT00112437|9604141|FG018|Year 3 (12-Month Extension)|Adverse Event|0
6011797|NCT00112437|9604142|FG019|Year 3 (12-Month Extension)|Adverse Event|1
6011798|NCT00112437|9604143|FG020|Year 3 (12-Month Extension)|Adverse Event|0
6011799|NCT00112437|9604144|FG021|Year 3 (12-Month Extension)|Adverse Event|0
6011800|NCT00112437|9604145|FG022|Year 3 (12-Month Extension)|Adverse Event|0
6011801|NCT00112437|9604146|FG023|Year 3 (12-Month Extension)|Adverse Event|0
6011802|NCT00112437|9604147|FG024|Year 3 (12-Month Extension)|Adverse Event|0
6011803|NCT00112437|9604148|FG025|Year 3 (12-Month Extension)|Adverse Event|0
6011804|NCT00112437|9604123|FG000|Year 3 (12-Month Extension)|Lack of Efficacy|0
6011805|NCT00112437|9604124|FG001|Year 3 (12-Month Extension)|Lack of Efficacy|0
6011806|NCT00112437|9604125|FG002|Year 3 (12-Month Extension)|Lack of Efficacy|0
6011807|NCT00112437|9604126|FG003|Year 3 (12-Month Extension)|Lack of Efficacy|0
6011808|NCT00112437|9604127|FG004|Year 3 (12-Month Extension)|Lack of Efficacy|0
6011809|NCT00112437|9604128|FG005|Year 3 (12-Month Extension)|Lack of Efficacy|0
6075659|NCT00582556|9680212|FG001|Overall Study|Withdrawal by Subject|1
6075660|NCT00582556|9680213|FG002|Overall Study|Withdrawal by Subject|1
6075661|NCT00582556|9680211|FG000|Overall Study|Physician Decision|0
6075662|NCT00582556|9680212|FG001|Overall Study|Physician Decision|0
6075663|NCT00582556|9680213|FG002|Overall Study|Physician Decision|1
6011810|NCT00112437|9604129|FG006|Year 3 (12-Month Extension)|Lack of Efficacy|0
6011811|NCT00112437|9604130|FG007|Year 3 (12-Month Extension)|Lack of Efficacy|0
6011812|NCT00112437|9604131|FG008|Year 3 (12-Month Extension)|Lack of Efficacy|0
6011813|NCT00112437|9604132|FG009|Year 3 (12-Month Extension)|Lack of Efficacy|0
6011814|NCT00112437|9604133|FG010|Year 3 (12-Month Extension)|Lack of Efficacy|0
6011815|NCT00112437|9604134|FG011|Year 3 (12-Month Extension)|Lack of Efficacy|1
6011816|NCT00112437|9604135|FG012|Year 3 (12-Month Extension)|Lack of Efficacy|0
6011817|NCT00112437|9604136|FG013|Year 3 (12-Month Extension)|Lack of Efficacy|1
6011818|NCT00112437|9604137|FG014|Year 3 (12-Month Extension)|Lack of Efficacy|0
6075664|NCT00582608|9680222|FG000|Overall Study|Not Treated|7
6075665|NCT00582608|9680222|FG000|Overall Study|Patient Ineligible|1
6011819|NCT00112437|9604138|FG015|Year 3 (12-Month Extension)|Lack of Efficacy|1
6011820|NCT00112437|9604139|FG016|Year 3 (12-Month Extension)|Lack of Efficacy|0
6011821|NCT00112437|9604140|FG017|Year 3 (12-Month Extension)|Lack of Efficacy|0
6011822|NCT00112437|9604141|FG018|Year 3 (12-Month Extension)|Lack of Efficacy|2
6011823|NCT00112437|9604142|FG019|Year 3 (12-Month Extension)|Lack of Efficacy|0
6011824|NCT00112437|9604143|FG020|Year 3 (12-Month Extension)|Lack of Efficacy|0
6011825|NCT00112437|9604144|FG021|Year 3 (12-Month Extension)|Lack of Efficacy|0
6011826|NCT00112437|9604145|FG022|Year 3 (12-Month Extension)|Lack of Efficacy|0
6011827|NCT00112437|9604146|FG023|Year 3 (12-Month Extension)|Lack of Efficacy|0
6011828|NCT00112437|9604147|FG024|Year 3 (12-Month Extension)|Lack of Efficacy|0
6011829|NCT00112437|9604148|FG025|Year 3 (12-Month Extension)|Lack of Efficacy|0
6011830|NCT00112437|9604123|FG000|Year 3 (12-Month Extension)|Lost to Follow-up|0
6011831|NCT00112437|9604124|FG001|Year 3 (12-Month Extension)|Lost to Follow-up|0
6011832|NCT00112437|9604125|FG002|Year 3 (12-Month Extension)|Lost to Follow-up|0
6011833|NCT00112437|9604126|FG003|Year 3 (12-Month Extension)|Lost to Follow-up|0
6011834|NCT00112437|9604127|FG004|Year 3 (12-Month Extension)|Lost to Follow-up|0
6011835|NCT00112437|9604128|FG005|Year 3 (12-Month Extension)|Lost to Follow-up|0
6011836|NCT00112437|9604129|FG006|Year 3 (12-Month Extension)|Lost to Follow-up|0
6011837|NCT00112437|9604130|FG007|Year 3 (12-Month Extension)|Lost to Follow-up|0
6011838|NCT00112437|9604131|FG008|Year 3 (12-Month Extension)|Lost to Follow-up|0
6011839|NCT00112437|9604132|FG009|Year 3 (12-Month Extension)|Lost to Follow-up|0
6011840|NCT00112437|9604133|FG010|Year 3 (12-Month Extension)|Lost to Follow-up|0
6011841|NCT00112437|9604134|FG011|Year 3 (12-Month Extension)|Lost to Follow-up|0
6011842|NCT00112437|9604135|FG012|Year 3 (12-Month Extension)|Lost to Follow-up|0
6011843|NCT00112437|9604136|FG013|Year 3 (12-Month Extension)|Lost to Follow-up|0
6011844|NCT00112437|9604137|FG014|Year 3 (12-Month Extension)|Lost to Follow-up|0
6011845|NCT00112437|9604138|FG015|Year 3 (12-Month Extension)|Lost to Follow-up|1
6011846|NCT00112437|9604139|FG016|Year 3 (12-Month Extension)|Lost to Follow-up|0
6011847|NCT00112437|9604140|FG017|Year 3 (12-Month Extension)|Lost to Follow-up|0
6011848|NCT00112437|9604141|FG018|Year 3 (12-Month Extension)|Lost to Follow-up|0
6011849|NCT00112437|9604142|FG019|Year 3 (12-Month Extension)|Lost to Follow-up|0
6011850|NCT00112437|9604143|FG020|Year 3 (12-Month Extension)|Lost to Follow-up|0
6011851|NCT00112437|9604144|FG021|Year 3 (12-Month Extension)|Lost to Follow-up|0
6011852|NCT00112437|9604145|FG022|Year 3 (12-Month Extension)|Lost to Follow-up|0
6011853|NCT00112437|9604146|FG023|Year 3 (12-Month Extension)|Lost to Follow-up|0
6011854|NCT00112437|9604147|FG024|Year 3 (12-Month Extension)|Lost to Follow-up|0
6011855|NCT00112437|9604148|FG025|Year 3 (12-Month Extension)|Lost to Follow-up|0
6011856|NCT00112437|9604123|FG000|Year 3 (12-Month Extension)|Protocol Violation|0
6011857|NCT00112437|9604124|FG001|Year 3 (12-Month Extension)|Protocol Violation|0
6011858|NCT00112437|9604125|FG002|Year 3 (12-Month Extension)|Protocol Violation|0
6011859|NCT00112437|9604126|FG003|Year 3 (12-Month Extension)|Protocol Violation|0
6011860|NCT00112437|9604127|FG004|Year 3 (12-Month Extension)|Protocol Violation|0
6011861|NCT00112437|9604128|FG005|Year 3 (12-Month Extension)|Protocol Violation|0
6011862|NCT00112437|9604129|FG006|Year 3 (12-Month Extension)|Protocol Violation|0
6011863|NCT00112437|9604130|FG007|Year 3 (12-Month Extension)|Protocol Violation|0
6011864|NCT00112437|9604131|FG008|Year 3 (12-Month Extension)|Protocol Violation|0
6011865|NCT00112437|9604132|FG009|Year 3 (12-Month Extension)|Protocol Violation|0
6011866|NCT00112437|9604133|FG010|Year 3 (12-Month Extension)|Protocol Violation|0
6011867|NCT00112437|9604134|FG011|Year 3 (12-Month Extension)|Protocol Violation|0
6011868|NCT00112437|9604135|FG012|Year 3 (12-Month Extension)|Protocol Violation|0
6011869|NCT00112437|9604136|FG013|Year 3 (12-Month Extension)|Protocol Violation|0
6011870|NCT00112437|9604137|FG014|Year 3 (12-Month Extension)|Protocol Violation|0
6011871|NCT00112437|9604138|FG015|Year 3 (12-Month Extension)|Protocol Violation|1
6011872|NCT00112437|9604139|FG016|Year 3 (12-Month Extension)|Protocol Violation|0
6011873|NCT00112437|9604140|FG017|Year 3 (12-Month Extension)|Protocol Violation|0
6011874|NCT00112437|9604141|FG018|Year 3 (12-Month Extension)|Protocol Violation|0
6011875|NCT00112437|9604142|FG019|Year 3 (12-Month Extension)|Protocol Violation|0
6011876|NCT00112437|9604143|FG020|Year 3 (12-Month Extension)|Protocol Violation|0
6011877|NCT00112437|9604144|FG021|Year 3 (12-Month Extension)|Protocol Violation|0
6011878|NCT00112437|9604145|FG022|Year 3 (12-Month Extension)|Protocol Violation|0
6011879|NCT00112437|9604146|FG023|Year 3 (12-Month Extension)|Protocol Violation|0
6011880|NCT00112437|9604147|FG024|Year 3 (12-Month Extension)|Protocol Violation|0
6011881|NCT00112437|9604148|FG025|Year 3 (12-Month Extension)|Protocol Violation|0
6011882|NCT00112437|9604123|FG000|Year 3 (12-Month Extension)|Withdrawal by Subject|0
6011883|NCT00112437|9604124|FG001|Year 3 (12-Month Extension)|Withdrawal by Subject|0
6011884|NCT00112437|9604125|FG002|Year 3 (12-Month Extension)|Withdrawal by Subject|0
6011885|NCT00112437|9604126|FG003|Year 3 (12-Month Extension)|Withdrawal by Subject|0
6011886|NCT00112437|9604127|FG004|Year 3 (12-Month Extension)|Withdrawal by Subject|0
6011887|NCT00112437|9604128|FG005|Year 3 (12-Month Extension)|Withdrawal by Subject|0
6011888|NCT00112437|9604129|FG006|Year 3 (12-Month Extension)|Withdrawal by Subject|0
6011889|NCT00112437|9604130|FG007|Year 3 (12-Month Extension)|Withdrawal by Subject|0
6011890|NCT00112437|9604131|FG008|Year 3 (12-Month Extension)|Withdrawal by Subject|0
6011891|NCT00112437|9604132|FG009|Year 3 (12-Month Extension)|Withdrawal by Subject|0
6011892|NCT00112437|9604133|FG010|Year 3 (12-Month Extension)|Withdrawal by Subject|0
6011893|NCT00112437|9604134|FG011|Year 3 (12-Month Extension)|Withdrawal by Subject|3
6011894|NCT00112437|9604135|FG012|Year 3 (12-Month Extension)|Withdrawal by Subject|0
6011895|NCT00112437|9604136|FG013|Year 3 (12-Month Extension)|Withdrawal by Subject|0
6011896|NCT00112437|9604137|FG014|Year 3 (12-Month Extension)|Withdrawal by Subject|1
6011897|NCT00112437|9604138|FG015|Year 3 (12-Month Extension)|Withdrawal by Subject|0
6011898|NCT00112437|9604139|FG016|Year 3 (12-Month Extension)|Withdrawal by Subject|0
6011899|NCT00112437|9604140|FG017|Year 3 (12-Month Extension)|Withdrawal by Subject|0
6011900|NCT00112437|9604141|FG018|Year 3 (12-Month Extension)|Withdrawal by Subject|0
6011901|NCT00112437|9604142|FG019|Year 3 (12-Month Extension)|Withdrawal by Subject|0
6011902|NCT00112437|9604143|FG020|Year 3 (12-Month Extension)|Withdrawal by Subject|0
6011903|NCT00112437|9604144|FG021|Year 3 (12-Month Extension)|Withdrawal by Subject|0
6011904|NCT00112437|9604145|FG022|Year 3 (12-Month Extension)|Withdrawal by Subject|0
6011905|NCT00112437|9604146|FG023|Year 3 (12-Month Extension)|Withdrawal by Subject|0
6011906|NCT00112437|9604147|FG024|Year 3 (12-Month Extension)|Withdrawal by Subject|0
6011907|NCT00112437|9604148|FG025|Year 3 (12-Month Extension)|Withdrawal by Subject|0
6011908|NCT00112437|9604123|FG000|Year 3 (12-Month Extension)|cortisone therapy, upcoming surgery|0
6011909|NCT00112437|9604124|FG001|Year 3 (12-Month Extension)|cortisone therapy, upcoming surgery|0
6011910|NCT00112437|9604125|FG002|Year 3 (12-Month Extension)|cortisone therapy, upcoming surgery|0
6011911|NCT00112437|9604126|FG003|Year 3 (12-Month Extension)|cortisone therapy, upcoming surgery|0
6011912|NCT00112437|9604127|FG004|Year 3 (12-Month Extension)|cortisone therapy, upcoming surgery|0
6011913|NCT00112437|9604128|FG005|Year 3 (12-Month Extension)|cortisone therapy, upcoming surgery|0
6011914|NCT00112437|9604129|FG006|Year 3 (12-Month Extension)|cortisone therapy, upcoming surgery|0
6011915|NCT00112437|9604130|FG007|Year 3 (12-Month Extension)|cortisone therapy, upcoming surgery|0
6011916|NCT00112437|9604131|FG008|Year 3 (12-Month Extension)|cortisone therapy, upcoming surgery|0
6011917|NCT00112437|9604132|FG009|Year 3 (12-Month Extension)|cortisone therapy, upcoming surgery|0
6011918|NCT00112437|9604133|FG010|Year 3 (12-Month Extension)|cortisone therapy, upcoming surgery|1
6011919|NCT00112437|9604134|FG011|Year 3 (12-Month Extension)|cortisone therapy, upcoming surgery|1
6011920|NCT00112437|9604135|FG012|Year 3 (12-Month Extension)|cortisone therapy, upcoming surgery|0
6011921|NCT00112437|9604136|FG013|Year 3 (12-Month Extension)|cortisone therapy, upcoming surgery|0
6011922|NCT00112437|9604137|FG014|Year 3 (12-Month Extension)|cortisone therapy, upcoming surgery|0
6011923|NCT00112437|9604138|FG015|Year 3 (12-Month Extension)|cortisone therapy, upcoming surgery|0
6011924|NCT00112437|9604139|FG016|Year 3 (12-Month Extension)|cortisone therapy, upcoming surgery|0
6011925|NCT00112437|9604140|FG017|Year 3 (12-Month Extension)|cortisone therapy, upcoming surgery|0
6011926|NCT00112437|9604141|FG018|Year 3 (12-Month Extension)|cortisone therapy, upcoming surgery|0
6011927|NCT00112437|9604142|FG019|Year 3 (12-Month Extension)|cortisone therapy, upcoming surgery|0
6011928|NCT00112437|9604143|FG020|Year 3 (12-Month Extension)|cortisone therapy, upcoming surgery|0
6011929|NCT00112437|9604144|FG021|Year 3 (12-Month Extension)|cortisone therapy, upcoming surgery|0
6011930|NCT00112437|9604145|FG022|Year 3 (12-Month Extension)|cortisone therapy, upcoming surgery|0
6011931|NCT00112437|9604146|FG023|Year 3 (12-Month Extension)|cortisone therapy, upcoming surgery|0
6011932|NCT00112437|9604147|FG024|Year 3 (12-Month Extension)|cortisone therapy, upcoming surgery|0
6011933|NCT00112437|9604148|FG025|Year 3 (12-Month Extension)|cortisone therapy, upcoming surgery|0
6011934|NCT00112437|9604123|FG000|Years 4-5 (24-Month Extension)|Lack of Efficacy|0
6011935|NCT00112437|9604124|FG001|Years 4-5 (24-Month Extension)|Lack of Efficacy|0
6011936|NCT00112437|9604125|FG002|Years 4-5 (24-Month Extension)|Lack of Efficacy|0
6011937|NCT00112437|9604126|FG003|Years 4-5 (24-Month Extension)|Lack of Efficacy|0
6011938|NCT00112437|9604127|FG004|Years 4-5 (24-Month Extension)|Lack of Efficacy|0
6011939|NCT00112437|9604128|FG005|Years 4-5 (24-Month Extension)|Lack of Efficacy|0
6011940|NCT00112437|9604129|FG006|Years 4-5 (24-Month Extension)|Lack of Efficacy|0
6011941|NCT00112437|9604130|FG007|Years 4-5 (24-Month Extension)|Lack of Efficacy|0
6011942|NCT00112437|9604131|FG008|Years 4-5 (24-Month Extension)|Lack of Efficacy|0
6011943|NCT00112437|9604132|FG009|Years 4-5 (24-Month Extension)|Lack of Efficacy|0
6011944|NCT00112437|9604133|FG010|Years 4-5 (24-Month Extension)|Lack of Efficacy|0
6011945|NCT00112437|9604134|FG011|Years 4-5 (24-Month Extension)|Lack of Efficacy|0
6011946|NCT00112437|9604135|FG012|Years 4-5 (24-Month Extension)|Lack of Efficacy|0
6011947|NCT00112437|9604136|FG013|Years 4-5 (24-Month Extension)|Lack of Efficacy|0
6011948|NCT00112437|9604137|FG014|Years 4-5 (24-Month Extension)|Lack of Efficacy|0
6011949|NCT00112437|9604138|FG015|Years 4-5 (24-Month Extension)|Lack of Efficacy|0
6011950|NCT00112437|9604139|FG016|Years 4-5 (24-Month Extension)|Lack of Efficacy|0
6011951|NCT00112437|9604140|FG017|Years 4-5 (24-Month Extension)|Lack of Efficacy|0
6011952|NCT00112437|9604141|FG018|Years 4-5 (24-Month Extension)|Lack of Efficacy|0
6011953|NCT00112437|9604142|FG019|Years 4-5 (24-Month Extension)|Lack of Efficacy|0
6011954|NCT00112437|9604143|FG020|Years 4-5 (24-Month Extension)|Lack of Efficacy|2
6011955|NCT00112437|9604144|FG021|Years 4-5 (24-Month Extension)|Lack of Efficacy|1
6011956|NCT00112437|9604145|FG022|Years 4-5 (24-Month Extension)|Lack of Efficacy|0
6011957|NCT00112437|9604146|FG023|Years 4-5 (24-Month Extension)|Lack of Efficacy|0
6011958|NCT00112437|9604147|FG024|Years 4-5 (24-Month Extension)|Lack of Efficacy|0
6011959|NCT00112437|9604148|FG025|Years 4-5 (24-Month Extension)|Lack of Efficacy|0
6011960|NCT00112437|9604123|FG000|Years 4-5 (24-Month Extension)|Discontinued for other reasons|0
6011961|NCT00112437|9604124|FG001|Years 4-5 (24-Month Extension)|Discontinued for other reasons|0
6011962|NCT00112437|9604125|FG002|Years 4-5 (24-Month Extension)|Discontinued for other reasons|0
6011963|NCT00112437|9604126|FG003|Years 4-5 (24-Month Extension)|Discontinued for other reasons|0
6011964|NCT00112437|9604127|FG004|Years 4-5 (24-Month Extension)|Discontinued for other reasons|0
6011965|NCT00112437|9604128|FG005|Years 4-5 (24-Month Extension)|Discontinued for other reasons|0
6011966|NCT00112437|9604129|FG006|Years 4-5 (24-Month Extension)|Discontinued for other reasons|0
6011967|NCT00112437|9604130|FG007|Years 4-5 (24-Month Extension)|Discontinued for other reasons|0
6011968|NCT00112437|9604131|FG008|Years 4-5 (24-Month Extension)|Discontinued for other reasons|0
6011969|NCT00112437|9604132|FG009|Years 4-5 (24-Month Extension)|Discontinued for other reasons|0
6075666|NCT00582608|9680222|FG000|Overall Study|Lack of accrual|4
6011970|NCT00112437|9604133|FG010|Years 4-5 (24-Month Extension)|Discontinued for other reasons|0
6011971|NCT00112437|9604134|FG011|Years 4-5 (24-Month Extension)|Discontinued for other reasons|0
6011972|NCT00112437|9604135|FG012|Years 4-5 (24-Month Extension)|Discontinued for other reasons|0
6011973|NCT00112437|9604136|FG013|Years 4-5 (24-Month Extension)|Discontinued for other reasons|0
6011974|NCT00112437|9604137|FG014|Years 4-5 (24-Month Extension)|Discontinued for other reasons|0
6011975|NCT00112437|9604138|FG015|Years 4-5 (24-Month Extension)|Discontinued for other reasons|0
6011976|NCT00112437|9604139|FG016|Years 4-5 (24-Month Extension)|Discontinued for other reasons|0
6011977|NCT00112437|9604140|FG017|Years 4-5 (24-Month Extension)|Discontinued for other reasons|0
6011978|NCT00112437|9604141|FG018|Years 4-5 (24-Month Extension)|Discontinued for other reasons|0
6011979|NCT00112437|9604142|FG019|Years 4-5 (24-Month Extension)|Discontinued for other reasons|0
6011980|NCT00112437|9604143|FG020|Years 4-5 (24-Month Extension)|Discontinued for other reasons|1
6011981|NCT00112437|9604144|FG021|Years 4-5 (24-Month Extension)|Discontinued for other reasons|0
6011982|NCT00112437|9604145|FG022|Years 4-5 (24-Month Extension)|Discontinued for other reasons|0
6011983|NCT00112437|9604146|FG023|Years 4-5 (24-Month Extension)|Discontinued for other reasons|0
6011984|NCT00112437|9604147|FG024|Years 4-5 (24-Month Extension)|Discontinued for other reasons|0
6011985|NCT00112437|9604148|FG025|Years 4-5 (24-Month Extension)|Discontinued for other reasons|0
6011986|NCT00112437|9604123|FG000|Years 4-5 (24-Month Extension)|Adverse Event|0
6011987|NCT00112437|9604124|FG001|Years 4-5 (24-Month Extension)|Adverse Event|0
6011988|NCT00112437|9604125|FG002|Years 4-5 (24-Month Extension)|Adverse Event|0
6011989|NCT00112437|9604126|FG003|Years 4-5 (24-Month Extension)|Adverse Event|0
6011990|NCT00112437|9604127|FG004|Years 4-5 (24-Month Extension)|Adverse Event|0
6011991|NCT00112437|9604128|FG005|Years 4-5 (24-Month Extension)|Adverse Event|0
6011992|NCT00112437|9604129|FG006|Years 4-5 (24-Month Extension)|Adverse Event|0
6011993|NCT00112437|9604130|FG007|Years 4-5 (24-Month Extension)|Adverse Event|0
6011994|NCT00112437|9604131|FG008|Years 4-5 (24-Month Extension)|Adverse Event|0
6011995|NCT00112437|9604132|FG009|Years 4-5 (24-Month Extension)|Adverse Event|0
6011996|NCT00112437|9604133|FG010|Years 4-5 (24-Month Extension)|Adverse Event|0
6011997|NCT00112437|9604134|FG011|Years 4-5 (24-Month Extension)|Adverse Event|0
6011998|NCT00112437|9604135|FG012|Years 4-5 (24-Month Extension)|Adverse Event|0
6011999|NCT00112437|9604136|FG013|Years 4-5 (24-Month Extension)|Adverse Event|0
6012000|NCT00112437|9604137|FG014|Years 4-5 (24-Month Extension)|Adverse Event|0
6012001|NCT00112437|9604138|FG015|Years 4-5 (24-Month Extension)|Adverse Event|0
6012002|NCT00112437|9604139|FG016|Years 4-5 (24-Month Extension)|Adverse Event|0
6012003|NCT00112437|9604140|FG017|Years 4-5 (24-Month Extension)|Adverse Event|0
6012004|NCT00112437|9604141|FG018|Years 4-5 (24-Month Extension)|Adverse Event|0
6012005|NCT00112437|9604142|FG019|Years 4-5 (24-Month Extension)|Adverse Event|0
6012006|NCT00112437|9604143|FG020|Years 4-5 (24-Month Extension)|Adverse Event|0
6012007|NCT00112437|9604144|FG021|Years 4-5 (24-Month Extension)|Adverse Event|4
6012008|NCT00112437|9604145|FG022|Years 4-5 (24-Month Extension)|Adverse Event|0
6012009|NCT00112437|9604146|FG023|Years 4-5 (24-Month Extension)|Adverse Event|0
6012010|NCT00112437|9604147|FG024|Years 4-5 (24-Month Extension)|Adverse Event|0
6012011|NCT00112437|9604148|FG025|Years 4-5 (24-Month Extension)|Adverse Event|0
6012012|NCT00112437|9604123|FG000|Years 4-5 (24-Month Extension)|Participant moved|0
6012013|NCT00112437|9604124|FG001|Years 4-5 (24-Month Extension)|Participant moved|0
6012014|NCT00112437|9604125|FG002|Years 4-5 (24-Month Extension)|Participant moved|0
6012015|NCT00112437|9604126|FG003|Years 4-5 (24-Month Extension)|Participant moved|0
6012016|NCT00112437|9604127|FG004|Years 4-5 (24-Month Extension)|Participant moved|0
6012017|NCT00112437|9604128|FG005|Years 4-5 (24-Month Extension)|Participant moved|0
6012018|NCT00112437|9604129|FG006|Years 4-5 (24-Month Extension)|Participant moved|0
6012019|NCT00112437|9604130|FG007|Years 4-5 (24-Month Extension)|Participant moved|0
6075667|NCT00582738|9680237|FG000|Overall Study|Administrative Problems|7
6075668|NCT00582738|9680238|FG001|Overall Study|Administrative Problems|8
6075669|NCT00582738|9680237|FG000|Overall Study|Adverse Event|0
6075670|NCT00582738|9680238|FG001|Overall Study|Adverse Event|5
6075671|NCT00582738|9680237|FG000|Overall Study|Graft Lost|0
6075672|NCT00582738|9680238|FG001|Overall Study|Graft Lost|1
6075673|NCT00582738|9680237|FG000|Overall Study|Other|1
6075674|NCT00582738|9680238|FG001|Overall Study|Other|0
6075675|NCT00582738|9680237|FG000|Overall Study|Protocol Violation|1
6075676|NCT00582738|9680238|FG001|Overall Study|Protocol Violation|1
6075677|NCT00582738|9680237|FG000|Overall Study|Withdrawal by Subject|0
6075678|NCT00582738|9680238|FG001|Overall Study|Withdrawal by Subject|3
6075679|NCT00582790|9680250|FG000|Overall Study|Rapid progression of disease|1
6012020|NCT00112437|9604131|FG008|Years 4-5 (24-Month Extension)|Participant moved|0
6012021|NCT00112437|9604132|FG009|Years 4-5 (24-Month Extension)|Participant moved|0
6075680|NCT00582816|9680255|FG000|Overall Study|Engraftment Failure|3
6075681|NCT00582907|9680263|FG000|1st Course|Withdrawal by Subject|1
6012022|NCT00112437|9604133|FG010|Years 4-5 (24-Month Extension)|Participant moved|0
6012023|NCT00112437|9604134|FG011|Years 4-5 (24-Month Extension)|Participant moved|0
6012024|NCT00112437|9604135|FG012|Years 4-5 (24-Month Extension)|Participant moved|0
6012025|NCT00112437|9604136|FG013|Years 4-5 (24-Month Extension)|Participant moved|0
6012026|NCT00112437|9604137|FG014|Years 4-5 (24-Month Extension)|Participant moved|0
6012027|NCT00112437|9604138|FG015|Years 4-5 (24-Month Extension)|Participant moved|0
6012028|NCT00112437|9604139|FG016|Years 4-5 (24-Month Extension)|Participant moved|0
6012029|NCT00112437|9604140|FG017|Years 4-5 (24-Month Extension)|Participant moved|0
6012030|NCT00112437|9604141|FG018|Years 4-5 (24-Month Extension)|Participant moved|0
6012031|NCT00112437|9604142|FG019|Years 4-5 (24-Month Extension)|Participant moved|0
6012032|NCT00112437|9604143|FG020|Years 4-5 (24-Month Extension)|Participant moved|0
6012033|NCT00112437|9604144|FG021|Years 4-5 (24-Month Extension)|Participant moved|1
6012034|NCT00112437|9604145|FG022|Years 4-5 (24-Month Extension)|Participant moved|0
6012035|NCT00112437|9604146|FG023|Years 4-5 (24-Month Extension)|Participant moved|0
6012036|NCT00112437|9604147|FG024|Years 4-5 (24-Month Extension)|Participant moved|0
6012037|NCT00112437|9604148|FG025|Years 4-5 (24-Month Extension)|Participant moved|0
6012038|NCT00112437|9604123|FG000|Years 4-5 (24-Month Extension)|Withdrawal by Subject|0
6012039|NCT00112437|9604124|FG001|Years 4-5 (24-Month Extension)|Withdrawal by Subject|0
6012040|NCT00112437|9604125|FG002|Years 4-5 (24-Month Extension)|Withdrawal by Subject|0
6012041|NCT00112437|9604126|FG003|Years 4-5 (24-Month Extension)|Withdrawal by Subject|0
6012042|NCT00112437|9604127|FG004|Years 4-5 (24-Month Extension)|Withdrawal by Subject|0
6012043|NCT00112437|9604128|FG005|Years 4-5 (24-Month Extension)|Withdrawal by Subject|0
6012044|NCT00112437|9604129|FG006|Years 4-5 (24-Month Extension)|Withdrawal by Subject|0
6012045|NCT00112437|9604130|FG007|Years 4-5 (24-Month Extension)|Withdrawal by Subject|0
6012046|NCT00112437|9604131|FG008|Years 4-5 (24-Month Extension)|Withdrawal by Subject|0
6012047|NCT00112437|9604132|FG009|Years 4-5 (24-Month Extension)|Withdrawal by Subject|0
6012048|NCT00112437|9604133|FG010|Years 4-5 (24-Month Extension)|Withdrawal by Subject|0
6012049|NCT00112437|9604134|FG011|Years 4-5 (24-Month Extension)|Withdrawal by Subject|0
6012050|NCT00112437|9604135|FG012|Years 4-5 (24-Month Extension)|Withdrawal by Subject|0
6012051|NCT00112437|9604136|FG013|Years 4-5 (24-Month Extension)|Withdrawal by Subject|0
6012052|NCT00112437|9604137|FG014|Years 4-5 (24-Month Extension)|Withdrawal by Subject|0
6012053|NCT00112437|9604138|FG015|Years 4-5 (24-Month Extension)|Withdrawal by Subject|0
6012054|NCT00112437|9604139|FG016|Years 4-5 (24-Month Extension)|Withdrawal by Subject|0
6012055|NCT00112437|9604140|FG017|Years 4-5 (24-Month Extension)|Withdrawal by Subject|0
6012056|NCT00112437|9604141|FG018|Years 4-5 (24-Month Extension)|Withdrawal by Subject|0
6012057|NCT00112437|9604142|FG019|Years 4-5 (24-Month Extension)|Withdrawal by Subject|0
6012058|NCT00112437|9604143|FG020|Years 4-5 (24-Month Extension)|Withdrawal by Subject|1
6012059|NCT00112437|9604144|FG021|Years 4-5 (24-Month Extension)|Withdrawal by Subject|2
6012060|NCT00112437|9604145|FG022|Years 4-5 (24-Month Extension)|Withdrawal by Subject|0
6012061|NCT00112437|9604146|FG023|Years 4-5 (24-Month Extension)|Withdrawal by Subject|0
6012062|NCT00112437|9604147|FG024|Years 4-5 (24-Month Extension)|Withdrawal by Subject|0
6012063|NCT00112437|9604148|FG025|Years 4-5 (24-Month Extension)|Withdrawal by Subject|0
6012064|NCT00112437|9604123|FG000|Years 6-10 (60-Month Extension)|Adverse Event|0
6012065|NCT00112437|9604124|FG001|Years 6-10 (60-Month Extension)|Adverse Event|0
6012066|NCT00112437|9604125|FG002|Years 6-10 (60-Month Extension)|Adverse Event|0
6012067|NCT00112437|9604126|FG003|Years 6-10 (60-Month Extension)|Adverse Event|0
6012068|NCT00112437|9604127|FG004|Years 6-10 (60-Month Extension)|Adverse Event|0
6012069|NCT00112437|9604128|FG005|Years 6-10 (60-Month Extension)|Adverse Event|0
6012070|NCT00112437|9604129|FG006|Years 6-10 (60-Month Extension)|Adverse Event|0
6012071|NCT00112437|9604130|FG007|Years 6-10 (60-Month Extension)|Adverse Event|0
6012072|NCT00112437|9604131|FG008|Years 6-10 (60-Month Extension)|Adverse Event|0
6012073|NCT00112437|9604132|FG009|Years 6-10 (60-Month Extension)|Adverse Event|0
6012074|NCT00112437|9604133|FG010|Years 6-10 (60-Month Extension)|Adverse Event|0
6012075|NCT00112437|9604134|FG011|Years 6-10 (60-Month Extension)|Adverse Event|0
6012076|NCT00112437|9604135|FG012|Years 6-10 (60-Month Extension)|Adverse Event|0
6012077|NCT00112437|9604136|FG013|Years 6-10 (60-Month Extension)|Adverse Event|0
6012078|NCT00112437|9604137|FG014|Years 6-10 (60-Month Extension)|Adverse Event|0
6012079|NCT00112437|9604138|FG015|Years 6-10 (60-Month Extension)|Adverse Event|0
6012080|NCT00112437|9604139|FG016|Years 6-10 (60-Month Extension)|Adverse Event|0
6012081|NCT00112437|9604140|FG017|Years 6-10 (60-Month Extension)|Adverse Event|0
6012082|NCT00112437|9604141|FG018|Years 6-10 (60-Month Extension)|Adverse Event|0
6012083|NCT00112437|9604142|FG019|Years 6-10 (60-Month Extension)|Adverse Event|0
6012084|NCT00112437|9604143|FG020|Years 6-10 (60-Month Extension)|Adverse Event|0
6012085|NCT00112437|9604144|FG021|Years 6-10 (60-Month Extension)|Adverse Event|0
6012086|NCT00112437|9604145|FG022|Years 6-10 (60-Month Extension)|Adverse Event|1
6012087|NCT00112437|9604146|FG023|Years 6-10 (60-Month Extension)|Adverse Event|2
6012088|NCT00112437|9604147|FG024|Years 6-10 (60-Month Extension)|Adverse Event|0
6012089|NCT00112437|9604148|FG025|Years 6-10 (60-Month Extension)|Adverse Event|1
6012090|NCT00112437|9604123|FG000|Years 6-10 (60-Month Extension)|Death|0
6012091|NCT00112437|9604124|FG001|Years 6-10 (60-Month Extension)|Death|0
6012092|NCT00112437|9604125|FG002|Years 6-10 (60-Month Extension)|Death|0
6012093|NCT00112437|9604126|FG003|Years 6-10 (60-Month Extension)|Death|0
6012094|NCT00112437|9604127|FG004|Years 6-10 (60-Month Extension)|Death|0
6012095|NCT00112437|9604128|FG005|Years 6-10 (60-Month Extension)|Death|0
6012096|NCT00112437|9604129|FG006|Years 6-10 (60-Month Extension)|Death|0
6012097|NCT00112437|9604130|FG007|Years 6-10 (60-Month Extension)|Death|0
6012098|NCT00112437|9604131|FG008|Years 6-10 (60-Month Extension)|Death|0
6012099|NCT00112437|9604132|FG009|Years 6-10 (60-Month Extension)|Death|0
6012100|NCT00112437|9604133|FG010|Years 6-10 (60-Month Extension)|Death|0
6012101|NCT00112437|9604134|FG011|Years 6-10 (60-Month Extension)|Death|0
6012102|NCT00112437|9604135|FG012|Years 6-10 (60-Month Extension)|Death|0
6012103|NCT00112437|9604136|FG013|Years 6-10 (60-Month Extension)|Death|0
6012104|NCT00112437|9604137|FG014|Years 6-10 (60-Month Extension)|Death|0
6012105|NCT00112437|9604138|FG015|Years 6-10 (60-Month Extension)|Death|0
6012106|NCT00112437|9604139|FG016|Years 6-10 (60-Month Extension)|Death|0
6012107|NCT00112437|9604140|FG017|Years 6-10 (60-Month Extension)|Death|0
6012108|NCT00112437|9604141|FG018|Years 6-10 (60-Month Extension)|Death|0
6012109|NCT00112437|9604142|FG019|Years 6-10 (60-Month Extension)|Death|0
6012110|NCT00112437|9604143|FG020|Years 6-10 (60-Month Extension)|Death|0
6012111|NCT00112437|9604144|FG021|Years 6-10 (60-Month Extension)|Death|0
6012112|NCT00112437|9604145|FG022|Years 6-10 (60-Month Extension)|Death|0
6012113|NCT00112437|9604146|FG023|Years 6-10 (60-Month Extension)|Death|2
6012114|NCT00112437|9604147|FG024|Years 6-10 (60-Month Extension)|Death|0
6012115|NCT00112437|9604148|FG025|Years 6-10 (60-Month Extension)|Death|0
6012116|NCT00112437|9604123|FG000|Years 6-10 (60-Month Extension)|Lost to Follow-up|0
6012117|NCT00112437|9604124|FG001|Years 6-10 (60-Month Extension)|Lost to Follow-up|0
6012118|NCT00112437|9604125|FG002|Years 6-10 (60-Month Extension)|Lost to Follow-up|0
6012119|NCT00112437|9604126|FG003|Years 6-10 (60-Month Extension)|Lost to Follow-up|0
6012120|NCT00112437|9604127|FG004|Years 6-10 (60-Month Extension)|Lost to Follow-up|0
6012121|NCT00112437|9604128|FG005|Years 6-10 (60-Month Extension)|Lost to Follow-up|0
6012122|NCT00112437|9604129|FG006|Years 6-10 (60-Month Extension)|Lost to Follow-up|0
6012123|NCT00112437|9604130|FG007|Years 6-10 (60-Month Extension)|Lost to Follow-up|0
6012124|NCT00112437|9604131|FG008|Years 6-10 (60-Month Extension)|Lost to Follow-up|0
6012125|NCT00112437|9604132|FG009|Years 6-10 (60-Month Extension)|Lost to Follow-up|0
6075682|NCT00582907|9680264|FG001|1st Course|Withdrawal by Subject|0
6075683|NCT00582907|9680265|FG002|1st Course|Withdrawal by Subject|0
6012126|NCT00112437|9604133|FG010|Years 6-10 (60-Month Extension)|Lost to Follow-up|0
6012127|NCT00112437|9604134|FG011|Years 6-10 (60-Month Extension)|Lost to Follow-up|0
6012128|NCT00112437|9604135|FG012|Years 6-10 (60-Month Extension)|Lost to Follow-up|0
6012129|NCT00112437|9604136|FG013|Years 6-10 (60-Month Extension)|Lost to Follow-up|0
6012130|NCT00112437|9604137|FG014|Years 6-10 (60-Month Extension)|Lost to Follow-up|0
6012131|NCT00112437|9604138|FG015|Years 6-10 (60-Month Extension)|Lost to Follow-up|0
6012132|NCT00112437|9604139|FG016|Years 6-10 (60-Month Extension)|Lost to Follow-up|0
6012133|NCT00112437|9604140|FG017|Years 6-10 (60-Month Extension)|Lost to Follow-up|0
6012134|NCT00112437|9604141|FG018|Years 6-10 (60-Month Extension)|Lost to Follow-up|0
6012135|NCT00112437|9604142|FG019|Years 6-10 (60-Month Extension)|Lost to Follow-up|0
6012136|NCT00112437|9604143|FG020|Years 6-10 (60-Month Extension)|Lost to Follow-up|0
6012137|NCT00112437|9604144|FG021|Years 6-10 (60-Month Extension)|Lost to Follow-up|0
6012138|NCT00112437|9604145|FG022|Years 6-10 (60-Month Extension)|Lost to Follow-up|0
6075684|NCT00582907|9680266|FG003|1st Course|Withdrawal by Subject|0
6075685|NCT00582907|9680263|FG000|1st Course|Lost to Follow-up|0
6075686|NCT00582907|9680264|FG001|1st Course|Lost to Follow-up|0
6075687|NCT00582907|9680265|FG002|1st Course|Lost to Follow-up|0
6075688|NCT00582907|9680266|FG003|1st Course|Lost to Follow-up|1
6075689|NCT00582907|9680263|FG000|2nd Course|Lack of Efficacy|1
6075690|NCT00582907|9680264|FG001|2nd Course|Lack of Efficacy|0
6075691|NCT00582907|9680265|FG002|2nd Course|Lack of Efficacy|0
6075692|NCT00582907|9680266|FG003|2nd Course|Lack of Efficacy|0
6075693|NCT00582933|9680272|FG000|Overall Study|Physician Decision|3
6075694|NCT00582972|9680280|FG000|Overall Study|Protocol Violation|2
6075695|NCT00583102|9680308|FG000|Overall Study|Adverse Event|3
6075696|NCT00583219|9680312|FG000|Phase 2|Withdrawal by Subject|1
6075697|NCT00583362|9680316|FG000|Overall Study|Adverse Event|44
6075698|NCT00583362|9680316|FG000|Overall Study|Lack of Efficacy|22
6075699|NCT00583362|9680316|FG000|Overall Study|Lost to Follow-up|4
6075700|NCT00583362|9680316|FG000|Overall Study|Non-compliance with study drug|28
6075701|NCT00583362|9680316|FG000|Overall Study|Pregnancy|7
6075702|NCT00583362|9680316|FG000|Overall Study|Miscommunication of visit window|5
6075703|NCT00583362|9680316|FG000|Overall Study|Current site closed|7
6075704|NCT00583362|9680316|FG000|Overall Study|Subject not dosed in LBSL99|1
6075705|NCT00583362|9680316|FG000|Overall Study|Subject moved out of the country/state|2
6075706|NCT00583362|9680316|FG000|Overall Study|Missed visits due to staff changes|1
6075707|NCT00583362|9680316|FG000|Overall Study|Misunderstanding of protocol|1
6075708|NCT00583362|9680316|FG000|Overall Study|Behavioral problems and non-compliance|1
6075709|NCT00583362|9680316|FG000|Overall Study|Sponsor request due to missed doses|1
6012139|NCT00112437|9604146|FG023|Years 6-10 (60-Month Extension)|Lost to Follow-up|0
6012140|NCT00112437|9604147|FG024|Years 6-10 (60-Month Extension)|Lost to Follow-up|0
6012141|NCT00112437|9604148|FG025|Years 6-10 (60-Month Extension)|Lost to Follow-up|1
6075710|NCT00583362|9680316|FG000|Overall Study|Physician Decision|19
6075711|NCT00583362|9680316|FG000|Overall Study|Protocol Violation|2
6012142|NCT00112437|9604123|FG000|Years 6-10 (60-Month Extension)|Other|0
6012143|NCT00112437|9604124|FG001|Years 6-10 (60-Month Extension)|Other|0
6075712|NCT00583362|9680316|FG000|Overall Study|Withdrawal by Subject|57
6012144|NCT00112437|9604125|FG002|Years 6-10 (60-Month Extension)|Other|0
6012145|NCT00112437|9604126|FG003|Years 6-10 (60-Month Extension)|Other|0
6012146|NCT00112437|9604127|FG004|Years 6-10 (60-Month Extension)|Other|0
6012147|NCT00112437|9604128|FG005|Years 6-10 (60-Month Extension)|Other|0
6012148|NCT00112437|9604129|FG006|Years 6-10 (60-Month Extension)|Other|0
6012149|NCT00112437|9604130|FG007|Years 6-10 (60-Month Extension)|Other|0
6012150|NCT00112437|9604131|FG008|Years 6-10 (60-Month Extension)|Other|0
6075713|NCT00583453|9680335|FG000|Overall Study|discontinued intervention|0
6075714|NCT00583453|9680336|FG001|Overall Study|discontinued intervention|2
6075715|NCT00583557|9680353|FG000|Overall Study|Withdrawal by Subject|18
6012151|NCT00112437|9604132|FG009|Years 6-10 (60-Month Extension)|Other|0
6012152|NCT00112437|9604133|FG010|Years 6-10 (60-Month Extension)|Other|0
6012153|NCT00112437|9604134|FG011|Years 6-10 (60-Month Extension)|Other|0
6012154|NCT00112437|9604135|FG012|Years 6-10 (60-Month Extension)|Other|0
6012155|NCT00112437|9604136|FG013|Years 6-10 (60-Month Extension)|Other|0
6012156|NCT00112437|9604137|FG014|Years 6-10 (60-Month Extension)|Other|0
6012157|NCT00112437|9604138|FG015|Years 6-10 (60-Month Extension)|Other|0
6012158|NCT00112437|9604139|FG016|Years 6-10 (60-Month Extension)|Other|0
6012159|NCT00112437|9604140|FG017|Years 6-10 (60-Month Extension)|Other|0
6012160|NCT00112437|9604141|FG018|Years 6-10 (60-Month Extension)|Other|0
6012161|NCT00112437|9604142|FG019|Years 6-10 (60-Month Extension)|Other|0
6012162|NCT00112437|9604143|FG020|Years 6-10 (60-Month Extension)|Other|0
6012163|NCT00112437|9604144|FG021|Years 6-10 (60-Month Extension)|Other|0
6012164|NCT00112437|9604145|FG022|Years 6-10 (60-Month Extension)|Other|0
6012165|NCT00112437|9604146|FG023|Years 6-10 (60-Month Extension)|Other|0
6012166|NCT00112437|9604147|FG024|Years 6-10 (60-Month Extension)|Other|1
6012167|NCT00112437|9604148|FG025|Years 6-10 (60-Month Extension)|Other|0
6012168|NCT00112437|9604123|FG000|Years 6-10 (60-Month Extension)|Physician Decision|0
6012169|NCT00112437|9604124|FG001|Years 6-10 (60-Month Extension)|Physician Decision|0
6012170|NCT00112437|9604125|FG002|Years 6-10 (60-Month Extension)|Physician Decision|0
6012171|NCT00112437|9604126|FG003|Years 6-10 (60-Month Extension)|Physician Decision|0
6012172|NCT00112437|9604127|FG004|Years 6-10 (60-Month Extension)|Physician Decision|0
6012173|NCT00112437|9604128|FG005|Years 6-10 (60-Month Extension)|Physician Decision|0
6012174|NCT00112437|9604129|FG006|Years 6-10 (60-Month Extension)|Physician Decision|0
6012175|NCT00112437|9604130|FG007|Years 6-10 (60-Month Extension)|Physician Decision|0
6012176|NCT00112437|9604131|FG008|Years 6-10 (60-Month Extension)|Physician Decision|0
6012177|NCT00112437|9604132|FG009|Years 6-10 (60-Month Extension)|Physician Decision|0
6012178|NCT00112437|9604133|FG010|Years 6-10 (60-Month Extension)|Physician Decision|0
6012179|NCT00112437|9604134|FG011|Years 6-10 (60-Month Extension)|Physician Decision|0
6012180|NCT00112437|9604135|FG012|Years 6-10 (60-Month Extension)|Physician Decision|0
6012181|NCT00112437|9604136|FG013|Years 6-10 (60-Month Extension)|Physician Decision|0
6012182|NCT00112437|9604137|FG014|Years 6-10 (60-Month Extension)|Physician Decision|0
6012183|NCT00112437|9604138|FG015|Years 6-10 (60-Month Extension)|Physician Decision|0
6012184|NCT00112437|9604139|FG016|Years 6-10 (60-Month Extension)|Physician Decision|0
6012185|NCT00112437|9604140|FG017|Years 6-10 (60-Month Extension)|Physician Decision|0
6012186|NCT00112437|9604141|FG018|Years 6-10 (60-Month Extension)|Physician Decision|0
6012187|NCT00112437|9604142|FG019|Years 6-10 (60-Month Extension)|Physician Decision|0
6012188|NCT00112437|9604143|FG020|Years 6-10 (60-Month Extension)|Physician Decision|0
6012189|NCT00112437|9604144|FG021|Years 6-10 (60-Month Extension)|Physician Decision|0
6012190|NCT00112437|9604145|FG022|Years 6-10 (60-Month Extension)|Physician Decision|0
6012191|NCT00112437|9604146|FG023|Years 6-10 (60-Month Extension)|Physician Decision|2
6012192|NCT00112437|9604147|FG024|Years 6-10 (60-Month Extension)|Physician Decision|0
6012193|NCT00112437|9604148|FG025|Years 6-10 (60-Month Extension)|Physician Decision|0
6012194|NCT00112437|9604123|FG000|Years 6-10 (60-Month Extension)|Withdrawal by Subject|0
6012195|NCT00112437|9604124|FG001|Years 6-10 (60-Month Extension)|Withdrawal by Subject|0
6012196|NCT00112437|9604125|FG002|Years 6-10 (60-Month Extension)|Withdrawal by Subject|0
6012197|NCT00112437|9604126|FG003|Years 6-10 (60-Month Extension)|Withdrawal by Subject|0
6012198|NCT00112437|9604127|FG004|Years 6-10 (60-Month Extension)|Withdrawal by Subject|0
6012199|NCT00112437|9604128|FG005|Years 6-10 (60-Month Extension)|Withdrawal by Subject|0
6012200|NCT00112437|9604129|FG006|Years 6-10 (60-Month Extension)|Withdrawal by Subject|0
6012201|NCT00112437|9604130|FG007|Years 6-10 (60-Month Extension)|Withdrawal by Subject|0
6012202|NCT00112437|9604131|FG008|Years 6-10 (60-Month Extension)|Withdrawal by Subject|0
6012203|NCT00112437|9604132|FG009|Years 6-10 (60-Month Extension)|Withdrawal by Subject|0
6012204|NCT00112437|9604133|FG010|Years 6-10 (60-Month Extension)|Withdrawal by Subject|0
6012205|NCT00112437|9604134|FG011|Years 6-10 (60-Month Extension)|Withdrawal by Subject|0
6012206|NCT00112437|9604135|FG012|Years 6-10 (60-Month Extension)|Withdrawal by Subject|0
6012207|NCT00112437|9604136|FG013|Years 6-10 (60-Month Extension)|Withdrawal by Subject|0
6012208|NCT00112437|9604137|FG014|Years 6-10 (60-Month Extension)|Withdrawal by Subject|0
6012209|NCT00112437|9604138|FG015|Years 6-10 (60-Month Extension)|Withdrawal by Subject|0
6012210|NCT00112437|9604139|FG016|Years 6-10 (60-Month Extension)|Withdrawal by Subject|0
6012211|NCT00112437|9604140|FG017|Years 6-10 (60-Month Extension)|Withdrawal by Subject|0
6047459|NCT00411632|9646454|FG000|Overall Study|Death|1
6075716|NCT00583557|9680353|FG000|Overall Study|Adverse Event|9
6075717|NCT00583557|9680353|FG000|Overall Study|Lack of Efficacy|31
6012212|NCT00112437|9604141|FG018|Years 6-10 (60-Month Extension)|Withdrawal by Subject|0
6012213|NCT00112437|9604142|FG019|Years 6-10 (60-Month Extension)|Withdrawal by Subject|0
6012214|NCT00112437|9604143|FG020|Years 6-10 (60-Month Extension)|Withdrawal by Subject|0
6012215|NCT00112437|9604144|FG021|Years 6-10 (60-Month Extension)|Withdrawal by Subject|0
6012216|NCT00112437|9604145|FG022|Years 6-10 (60-Month Extension)|Withdrawal by Subject|4
6012217|NCT00112437|9604146|FG023|Years 6-10 (60-Month Extension)|Withdrawal by Subject|6
6012218|NCT00112437|9604147|FG024|Years 6-10 (60-Month Extension)|Withdrawal by Subject|0
6012219|NCT00112437|9604148|FG025|Years 6-10 (60-Month Extension)|Withdrawal by Subject|3
6012220|NCT00112463|9604202|FG000|Overall Study|Physician Decision|1
6012221|NCT00112463|9604202|FG000|Overall Study|Progression|30
6075718|NCT00583557|9680353|FG000|Overall Study|Lack of Compliance|5
6012222|NCT00112463|9604202|FG000|Overall Study|Second Primary|1
6012223|NCT00112463|9604202|FG000|Overall Study|Toxicity|3
6012224|NCT00112463|9604202|FG000|Overall Study|Withdrawal by Subject|2
6012225|NCT00112463|9604202|FG000|Overall Study|Never started treatment|2
6012226|NCT00112489|9604207|FG000|Overall Study|Refused further treatment|8
6012227|NCT00112489|9604207|FG000|Overall Study|Adverse Event|12
6012228|NCT00112489|9604207|FG000|Overall Study|Death|2
6012229|NCT00112489|9604207|FG000|Overall Study|Other, Not Specified|9
6012230|NCT00112489|9604207|FG000|Overall Study|Patient never treated|2
6012231|NCT00112489|9604207|FG000|Overall Study|Ineligible|7
6012232|NCT00112502|9604225|FG000|Overall Study|Withdrawal by Subject|0
6012233|NCT00112502|9604226|FG001|Overall Study|Withdrawal by Subject|1
6012234|NCT00112502|9604227|FG002|Overall Study|Withdrawal by Subject|1
6012235|NCT00112502|9604228|FG003|Overall Study|Withdrawal by Subject|4
6012236|NCT00112502|9604229|FG004|Overall Study|Withdrawal by Subject|2
6012237|NCT00112502|9604230|FG005|Overall Study|Withdrawal by Subject|5
6012238|NCT00112502|9604231|FG006|Overall Study|Withdrawal by Subject|3
6012239|NCT00112502|9604232|FG007|Overall Study|Withdrawal by Subject|7
6012240|NCT00112580|9604262|FG000|Overall Study|Adverse Event|1
6012241|NCT00112580|9604263|FG001|Overall Study|Adverse Event|2
6012242|NCT00112580|9604262|FG000|Overall Study|Disease progression|5
6012243|NCT00112580|9604263|FG001|Overall Study|Disease progression|16
6012244|NCT00112580|9604262|FG000|Overall Study|Participant withdrew consent|2
6012245|NCT00112580|9604263|FG001|Overall Study|Participant withdrew consent|1
6012246|NCT00112736|9604302|FG000|Overall Study|1 pt never had had RX due rapid decline|1
6012247|NCT00112736|9604303|FG001|Overall Study|1 pt never had had RX due rapid decline|0
6012248|NCT00112866|9604339|FG000|Overall Study|Protocol Violation|1
6012249|NCT00112866|9604340|FG001|Overall Study|Protocol Violation|0
6012250|NCT00112866|9604339|FG000|Overall Study|did not start treatment post-op|1
6075719|NCT00583557|9680353|FG000|Overall Study|Other|5
6075720|NCT00583557|9680353|FG000|Overall Study|Did not receive belimumab in LBRA99|2
6075721|NCT00583596|9680357|FG000|Overall Study|Lost to Follow-up|110
6075722|NCT00583596|9680357|FG000|Overall Study|Excluded due to Hurricane Katrina|30
6075723|NCT00583596|9680357|FG000|Overall Study|Death|2
6075724|NCT00583596|9680357|FG000|Overall Study|Withdrawal by Subject|6
6075725|NCT00583596|9680357|FG000|Overall Study|Lost to Follow-up|94
6075726|NCT00583596|9680357|FG000|Overall Study|Data not complete|1
6075727|NCT00583596|9680357|FG000|Overall Study|Not consented|15
6075728|NCT00583596|9680357|FG000|Overall Study|Outside f-up window|26
6075729|NCT00583791|9680393|FG000|Overall Study|Other|67
6075730|NCT00583791|9680393|FG000|Overall Study|Death|6
6075731|NCT00583947|9680428|FG000|Cross-over Period|Adverse Event|2
6075732|NCT00583947|9680429|FG001|Cross-over Period|Adverse Event|0
6075733|NCT00583947|9680428|FG000|Cross-over Period|Withdrawal by Subject|2
6075734|NCT00583947|9680429|FG001|Cross-over Period|Withdrawal by Subject|0
6075735|NCT00583947|9680428|FG000|Cross-over Period|Did not meet-no longer met entry criteri|0
6075736|NCT00583947|9680429|FG001|Cross-over Period|Did not meet-no longer met entry criteri|1
6075737|NCT00583947|9680428|FG000|Cross-over Period|Other|1
6075738|NCT00583947|9680429|FG001|Cross-over Period|Other|1
6075739|NCT00584194|9680442|FG000|Overall Study|Other|135
6075740|NCT00584415|9680461|FG000|Overall Study|Adverse Event|7
6075741|NCT00584454|9680466|FG000|Overall Study|Adverse Event|1
6075742|NCT00584454|9680466|FG000|Overall Study|Relocation|1
6075743|NCT00584454|9680466|FG000|Overall Study|Clinical Hold|2
6075744|NCT00584727|9680484|FG000|First Intervention|Discontinuation|0
6012251|NCT00112866|9604340|FG001|Overall Study|did not start treatment post-op|2
6012252|NCT00112905|9604354|FG000|Overall Study|Adverse Event|4
6075745|NCT00584727|9680485|FG001|First Intervention|Discontinuation|0
6075746|NCT00584727|9680486|FG002|First Intervention|Discontinuation|1
6075747|NCT00584727|9680487|FG003|First Intervention|Discontinuation|0
6075748|NCT00584727|9680488|FG004|First Intervention|Discontinuation|0
6075749|NCT00584727|9680489|FG005|First Intervention|Discontinuation|0
6075750|NCT00584727|9680484|FG000|Third Intervention|Protocol Violation|0
6075751|NCT00584727|9680485|FG001|Third Intervention|Protocol Violation|0
6075752|NCT00584727|9680486|FG002|Third Intervention|Protocol Violation|1
6075753|NCT00584727|9680487|FG003|Third Intervention|Protocol Violation|0
6075754|NCT00584727|9680488|FG004|Third Intervention|Protocol Violation|4
6075755|NCT00584727|9680489|FG005|Third Intervention|Protocol Violation|2
6012253|NCT00112905|9604354|FG000|Overall Study|Death|1
6012254|NCT00112905|9604354|FG000|Overall Study|Ineligibility|5
6012255|NCT00112905|9604354|FG000|Overall Study|Alternative treatment|1
6012256|NCT00112905|9604354|FG000|Overall Study|performance status was deteiorating|1
6012257|NCT00112957|9604371|FG000|Overall Study|Progressive disease|18
6012258|NCT00112957|9604371|FG000|Overall Study|Physician Decision|1
6047460|NCT00411645|9646460|FG000|Overall Study|Consent Withdrawn|13
6047461|NCT00411645|9646461|FG001|Overall Study|Consent Withdrawn|22
6047462|NCT00411645|9646460|FG000|Overall Study|Death|56
6047463|NCT00411645|9646461|FG001|Overall Study|Death|135
6047464|NCT00411645|9646460|FG000|Overall Study|Investigator/Sponsor Decision|10
6047465|NCT00411645|9646461|FG001|Overall Study|Investigator/Sponsor Decision|7
6047466|NCT00411645|9646460|FG000|Overall Study|Lost to Follow-up|2
6047467|NCT00411645|9646461|FG001|Overall Study|Lost to Follow-up|0
6047468|NCT00411671|9646468|FG000|Overall Study|Adverse Event|15
6047469|NCT00411671|9646468|FG000|Overall Study|Death|2
6047470|NCT00411671|9646468|FG000|Overall Study|Lost to Follow-up|3
6047471|NCT00411762|9646489|FG000|Overall Study|Withdrawal by Subject|5
6047472|NCT00411788|9646493|FG000|Overall Study|Protocol Violation|1
6047473|NCT00411788|9646493|FG000|Overall Study|Adverse Event|1
6047474|NCT00412061|9646499|FG000|Double Blind Phase|Disease Progression|101
6047475|NCT00412061|9646500|FG001|Double Blind Phase|Disease Progression|154
6047476|NCT00412061|9646499|FG000|Double Blind Phase|Adverse Event|61
6047477|NCT00412061|9646500|FG001|Double Blind Phase|Adverse Event|16
6047478|NCT00412061|9646499|FG000|Double Blind Phase|Final Primary Analysis|26
6047479|NCT00412061|9646500|FG001|Double Blind Phase|Final Primary Analysis|14
6047480|NCT00412061|9646499|FG000|Double Blind Phase|Withdrawal by Subject|18
6047481|NCT00412061|9646500|FG001|Double Blind Phase|Withdrawal by Subject|20
6047482|NCT00412061|9646499|FG000|Double Blind Phase|Death|6
6047483|NCT00412061|9646500|FG001|Double Blind Phase|Death|3
6047484|NCT00412061|9646499|FG000|Double Blind Phase|Protocol Violation|3
6047485|NCT00412061|9646500|FG001|Double Blind Phase|Protocol Violation|4
6047486|NCT00412061|9646499|FG000|Double Blind Phase|New Cander Therapy|1
6047487|NCT00412061|9646500|FG001|Double Blind Phase|New Cander Therapy|1
6047488|NCT00412061|9646499|FG000|Double Blind Phase|Lost to Follow-up|0
6047489|NCT00412061|9646500|FG001|Double Blind Phase|Lost to Follow-up|1
6047490|NCT00412061|9646499|FG000|Open Label Phase|Disease Progression|0
6047491|NCT00412061|9646500|FG001|Open Label Phase|Disease Progression|86
6047492|NCT00412061|9646499|FG000|Open Label Phase|Adverse Event|0
6047493|NCT00412061|9646500|FG001|Open Label Phase|Adverse Event|46
6047494|NCT00412061|9646499|FG000|Open Label Phase|Withdrawal by Subject|0
6047495|NCT00412061|9646500|FG001|Open Label Phase|Withdrawal by Subject|15
6047496|NCT00412061|9646499|FG000|Open Label Phase|Administrative Problems|0
6047497|NCT00412061|9646500|FG001|Open Label Phase|Administrative Problems|13
6047498|NCT00412061|9646499|FG000|Open Label Phase|Death|0
6047499|NCT00412061|9646500|FG001|Open Label Phase|Death|7
6047500|NCT00412061|9646499|FG000|Open Label Phase|Lost to Follow-up|0
6047501|NCT00412061|9646500|FG001|Open Label Phase|Lost to Follow-up|2
6047502|NCT00412061|9646499|FG000|Open Label Phase|New Cancer Therapy|0
6047503|NCT00412061|9646500|FG001|Open Label Phase|New Cancer Therapy|1
6047504|NCT00412113|9646536|FG000|Overall Study|Adverse Event|11
6047505|NCT00412113|9646537|FG001|Overall Study|Adverse Event|15
6047506|NCT00412113|9646536|FG000|Overall Study|did not receive treatment|1
6047507|NCT00412113|9646537|FG001|Overall Study|did not receive treatment|0
6047508|NCT00412217|9646545|FG000|Overall Study|Insufficient Data Available|8
6047509|NCT00412217|9646546|FG001|Overall Study|Insufficient Data Available|3
6047510|NCT00412217|9646545|FG000|Overall Study|Death|5
6047511|NCT00412217|9646546|FG001|Overall Study|Death|4
6047512|NCT00412217|9646545|FG000|Overall Study|Disease Progression|2
6047513|NCT00412217|9646546|FG001|Overall Study|Disease Progression|3
6047514|NCT00412217|9646545|FG000|Overall Study|Investigator Decision|1
6047515|NCT00412217|9646546|FG001|Overall Study|Investigator Decision|0
6047516|NCT00412217|9646545|FG000|Overall Study|Withdrawal by Subject|2
6047517|NCT00412217|9646546|FG001|Overall Study|Withdrawal by Subject|0
6047518|NCT00412217|9646545|FG000|Overall Study|Lost to Follow-up|1
6047519|NCT00412217|9646546|FG001|Overall Study|Lost to Follow-up|4
6047520|NCT00412217|9646545|FG000|Overall Study|Study Terminated by Sponsor|26
6047521|NCT00412217|9646546|FG001|Overall Study|Study Terminated by Sponsor|33
6047522|NCT00412217|9646545|FG000|Overall Study|Other|1
6047523|NCT00412217|9646546|FG001|Overall Study|Other|1
6047524|NCT00412360|9646558|FG000|Overall Study|Lost to Follow-up|0
6047525|NCT00412360|9646559|FG001|Overall Study|Lost to Follow-up|1
6047526|NCT00412360|9646558|FG000|Overall Study|Not Transplanted|1
6047527|NCT00412360|9646559|FG001|Overall Study|Not Transplanted|2
6047528|NCT00412373|9646567|FG000|Overall Study|Adverse Event|8
6047529|NCT00412373|9646568|FG001|Overall Study|Adverse Event|13
6047530|NCT00412373|9646567|FG000|Overall Study|Lack of Efficacy|16
6047531|NCT00412373|9646568|FG001|Overall Study|Lack of Efficacy|22
6047532|NCT00412373|9646567|FG000|Overall Study|Lost to Follow-up|7
6047533|NCT00412373|9646568|FG001|Overall Study|Lost to Follow-up|13
6047534|NCT00412373|9646567|FG000|Overall Study|Withdrawal by Subject|8
6047535|NCT00412373|9646568|FG001|Overall Study|Withdrawal by Subject|27
6047536|NCT00412373|9646567|FG000|Overall Study|Other|2
6047537|NCT00412373|9646568|FG001|Overall Study|Other|2
6047538|NCT00412542|9646628|FG000|Overall Study|Withdrawal by Subject|0
6047539|NCT00412542|9646629|FG001|Overall Study|Withdrawal by Subject|2
6047540|NCT00412542|9646628|FG000|Overall Study|Not Eligible|0
6047541|NCT00412542|9646629|FG001|Overall Study|Not Eligible|1
6012259|NCT00113087|9604386|FG000|Overall Study|Death or Transplant|14
6012260|NCT00113087|9604387|FG001|Overall Study|Death or Transplant|16
6012261|NCT00113087|9604386|FG000|Overall Study|Family or MD withdrew subject|10
6012262|NCT00113087|9604387|FG001|Overall Study|Family or MD withdrew subject|5
6012263|NCT00113269|9604405|FG000|Overall Study|Not transplanted, donor issues|4
6012264|NCT00113269|9604406|FG001|Overall Study|Not transplanted, donor issues|0
6012265|NCT00113269|9604407|FG002|Overall Study|Not transplanted, donor issues|2
6012266|NCT00113269|9604408|FG003|Overall Study|Not transplanted, donor issues|2
6012267|NCT00113269|9604405|FG000|Overall Study|Not transplanted, recipient issues|2
6012268|NCT00113269|9604406|FG001|Overall Study|Not transplanted, recipient issues|1
6012269|NCT00113269|9604407|FG002|Overall Study|Not transplanted, recipient issues|7
6012270|NCT00113269|9604408|FG003|Overall Study|Not transplanted, recipient issues|4
6012271|NCT00113269|9604405|FG000|Overall Study|Early graft loss, technical|0
6012272|NCT00113269|9604406|FG001|Overall Study|Early graft loss, technical|0
6012273|NCT00113269|9604407|FG002|Overall Study|Early graft loss, technical|2
6012274|NCT00113269|9604408|FG003|Overall Study|Early graft loss, technical|0
6012275|NCT00113269|9604405|FG000|Overall Study|Death in operating room|0
6012276|NCT00113269|9604406|FG001|Overall Study|Death in operating room|0
6012277|NCT00113269|9604407|FG002|Overall Study|Death in operating room|0
6012278|NCT00113269|9604408|FG003|Overall Study|Death in operating room|1
6012279|NCT00113269|9604405|FG000|Overall Study|Did not meet eligibility - pre-treatment|0
6012280|NCT00113269|9604406|FG001|Overall Study|Did not meet eligibility - pre-treatment|0
6012281|NCT00113269|9604407|FG002|Overall Study|Did not meet eligibility - pre-treatment|0
6012282|NCT00113269|9604408|FG003|Overall Study|Did not meet eligibility - pre-treatment|2
6012283|NCT00113269|9604405|FG000|Overall Study|Adverse Event|2
6012284|NCT00113269|9604406|FG001|Overall Study|Adverse Event|7
6012285|NCT00113269|9604407|FG002|Overall Study|Adverse Event|11
6012286|NCT00113269|9604408|FG003|Overall Study|Adverse Event|7
6012287|NCT00113269|9604405|FG000|Overall Study|Withdrawal by Subject|4
6012288|NCT00113269|9604406|FG001|Overall Study|Withdrawal by Subject|3
6012289|NCT00113269|9604407|FG002|Overall Study|Withdrawal by Subject|4
6012290|NCT00113269|9604408|FG003|Overall Study|Withdrawal by Subject|2
6012291|NCT00113269|9604405|FG000|Overall Study|Graft loss|6
6012292|NCT00113269|9604406|FG001|Overall Study|Graft loss|6
6012293|NCT00113269|9604407|FG002|Overall Study|Graft loss|4
6012294|NCT00113269|9604408|FG003|Overall Study|Graft loss|9
6012295|NCT00113269|9604405|FG000|Overall Study|Protocol Violation|1
6012296|NCT00113269|9604406|FG001|Overall Study|Protocol Violation|0
6012297|NCT00113269|9604407|FG002|Overall Study|Protocol Violation|4
6012298|NCT00113269|9604408|FG003|Overall Study|Protocol Violation|2
6012299|NCT00113269|9604405|FG000|Overall Study|Lost to Follow-up|2
6012300|NCT00113269|9604406|FG001|Overall Study|Lost to Follow-up|3
6012301|NCT00113269|9604407|FG002|Overall Study|Lost to Follow-up|6
6012302|NCT00113269|9604408|FG003|Overall Study|Lost to Follow-up|3
6012303|NCT00113269|9604405|FG000|Overall Study|Sponsor elected to discontinue patient|1
6012304|NCT00113269|9604406|FG001|Overall Study|Sponsor elected to discontinue patient|0
6012305|NCT00113269|9604407|FG002|Overall Study|Sponsor elected to discontinue patient|0
6012306|NCT00113269|9604408|FG003|Overall Study|Sponsor elected to discontinue patient|1
6012307|NCT00113269|9604405|FG000|Overall Study|Discontinued due to rejection|0
6012308|NCT00113269|9604406|FG001|Overall Study|Discontinued due to rejection|0
6012309|NCT00113269|9604407|FG002|Overall Study|Discontinued due to rejection|1
6012310|NCT00113269|9604408|FG003|Overall Study|Discontinued due to rejection|0
6012311|NCT00113269|9604405|FG000|Overall Study|Moved|0
6012312|NCT00113269|9604406|FG001|Overall Study|Moved|1
6012313|NCT00113269|9604407|FG002|Overall Study|Moved|0
6012314|NCT00113269|9604408|FG003|Overall Study|Moved|3
6012315|NCT00113269|9604405|FG000|Overall Study|Received pancreas transplant|0
6012316|NCT00113269|9604406|FG001|Overall Study|Received pancreas transplant|0
6012317|NCT00113269|9604407|FG002|Overall Study|Received pancreas transplant|0
6012318|NCT00113269|9604408|FG003|Overall Study|Received pancreas transplant|2
6012319|NCT00113269|9604405|FG000|Overall Study|Withdrew consent, Prednisone initiated|0
6012320|NCT00113269|9604406|FG001|Overall Study|Withdrew consent, Prednisone initiated|0
6012321|NCT00113269|9604407|FG002|Overall Study|Withdrew consent, Prednisone initiated|0
6012322|NCT00113269|9604408|FG003|Overall Study|Withdrew consent, Prednisone initiated|1
6012323|NCT00113269|9604405|FG000|Overall Study|Did not meet eligibility criteria|1
6012324|NCT00113269|9604406|FG001|Overall Study|Did not meet eligibility criteria|0
6012325|NCT00113269|9604407|FG002|Overall Study|Did not meet eligibility criteria|0
6012326|NCT00113269|9604408|FG003|Overall Study|Did not meet eligibility criteria|1
6012327|NCT00113269|9604405|FG000|Overall Study|Unable to return for follow up|2
6012328|NCT00113269|9604406|FG001|Overall Study|Unable to return for follow up|1
6012329|NCT00113269|9604407|FG002|Overall Study|Unable to return for follow up|0
6012330|NCT00113269|9604408|FG003|Overall Study|Unable to return for follow up|0
6012331|NCT00113295|9604420|FG000|Overall Study|Adverse Event|4
6012332|NCT00113295|9604421|FG001|Overall Study|Adverse Event|1
6012333|NCT00113295|9604420|FG000|Overall Study|Unrelated Medical Illness|1
6012334|NCT00113295|9604421|FG001|Overall Study|Unrelated Medical Illness|0
6012335|NCT00113360|9604437|FG000|Overall Study|Adverse Event|3
6012336|NCT00113360|9604437|FG000|Overall Study|Subject required surgery|1
6012337|NCT00113360|9604437|FG000|Overall Study|Did not meet eligibility criteria|3
6075756|NCT00584740|9680502|FG000|Overall Study|Adverse Event|1
6075757|NCT00584740|9680503|FG001|Overall Study|Adverse Event|1
6075758|NCT00584740|9680502|FG000|Overall Study|Lack of Efficacy|8
6075759|NCT00584740|9680503|FG001|Overall Study|Lack of Efficacy|2
6075760|NCT00584740|9680502|FG000|Overall Study|Withdrawal by Subject|3
6075761|NCT00584740|9680503|FG001|Overall Study|Withdrawal by Subject|2
6075762|NCT00584740|9680502|FG000|Overall Study|Lost to Follow-up|0
6075763|NCT00584740|9680503|FG001|Overall Study|Lost to Follow-up|1
6012338|NCT00113373|9604441|FG000|Overall Study|Ineligible: wrong primary|1
6012339|NCT00113373|9604441|FG000|Overall Study|Ineligible: second primary|1
6012340|NCT00113373|9604441|FG000|Overall Study|Never Treated|1
6012341|NCT00113490|9604457|FG000|Overall Study|Withdrawal by Subject|1
6012342|NCT00113490|9604458|FG001|Overall Study|Withdrawal by Subject|3
6012343|NCT00113490|9604457|FG000|Overall Study|Lost to Follow-up|1
6012344|NCT00113490|9604458|FG001|Overall Study|Lost to Follow-up|0
6012345|NCT00113516|9604464|FG000|Part 1|Adverse Event|6
6012346|NCT00113516|9604465|FG001|Part 1|Adverse Event|0
6012347|NCT00113516|9604464|FG000|Part 1|Death|3
6012348|NCT00113516|9604465|FG001|Part 1|Death|0
6012349|NCT00113516|9604464|FG000|Part 1|Other|3
6012350|NCT00113516|9604465|FG001|Part 1|Other|0
6012351|NCT00113516|9604464|FG000|Part 1|Withdrawal by Subject|2
6012352|NCT00113516|9604465|FG001|Part 1|Withdrawal by Subject|0
6012353|NCT00113516|9604464|FG000|Part 1|Lack of Efficacy|2
6012354|NCT00113516|9604465|FG001|Part 1|Lack of Efficacy|0
6012355|NCT00113516|9604464|FG000|Part 1|Did Not Meet Entrance Criteria|1
6012356|NCT00113516|9604465|FG001|Part 1|Did Not Meet Entrance Criteria|0
6012357|NCT00113516|9604464|FG000|Part 1|Laboratory Abnormality|1
6012358|NCT00113516|9604465|FG001|Part 1|Laboratory Abnormality|0
6012359|NCT00113516|9604464|FG000|Part 1|Ongoing|1
6012360|NCT00113516|9604465|FG001|Part 1|Ongoing|0
6012361|NCT00113516|9604464|FG000|Part 1|Missing|65
6012362|NCT00113516|9604465|FG001|Part 1|Missing|0
6012363|NCT00113516|9604464|FG000|Part 2|Adverse Event|0
6012364|NCT00113516|9604465|FG001|Part 2|Adverse Event|16
6012365|NCT00113516|9604464|FG000|Part 2|Death|0
6012366|NCT00113516|9604465|FG001|Part 2|Death|5
6012367|NCT00113516|9604464|FG000|Part 2|Lack of Efficacy|0
6012368|NCT00113516|9604465|FG001|Part 2|Lack of Efficacy|37
6012369|NCT00113516|9604464|FG000|Part 2|Withdrawal by Subject|0
6012370|NCT00113516|9604465|FG001|Part 2|Withdrawal by Subject|3
6012371|NCT00113516|9604464|FG000|Part 2|Other|0
6012372|NCT00113516|9604465|FG001|Part 2|Other|3
6012373|NCT00113516|9604464|FG000|Part 2|Laboratory Abnormality|0
6012374|NCT00113516|9604465|FG001|Part 2|Laboratory Abnormality|1
6012375|NCT00113516|9604464|FG000|Part 2|Ongoing|0
6012376|NCT00113516|9604465|FG001|Part 2|Ongoing|1
6012377|NCT00113529|9604471|FG000|Overall Study|Adverse Event|4
6012378|NCT00113529|9604471|FG000|Overall Study|Lack of Efficacy|20
6012379|NCT00113529|9604471|FG000|Overall Study|Decision of sponsor|6
6012380|NCT00113529|9604471|FG000|Overall Study|Withdrawal by Subject|4
6012381|NCT00113555|9604475|FG000|Overall Study|Baseline Failure|59
6012382|NCT00113555|9604475|FG000|Overall Study|Permanently Explanted|7
6012383|NCT00113555|9604475|FG000|Overall Study|Death|1
6012384|NCT00113555|9604475|FG000|Overall Study|Missed Followup|4
6012385|NCT00113555|9604475|FG000|Overall Study|Lost to Follow-up|8
6012386|NCT00113568|9604480|FG000|Overall Study|Adverse Event|97
6012387|NCT00113568|9604480|FG000|Overall Study|Death|1
6012388|NCT00113568|9604480|FG000|Overall Study|Lack of Efficacy|30
6012389|NCT00113568|9604480|FG000|Overall Study|Lost to Follow-up|156
6012390|NCT00113568|9604480|FG000|Overall Study|Protocol Violation|32
6012391|NCT00113568|9604480|FG000|Overall Study|Withdrawal by Subject|117
6012392|NCT00113568|9604480|FG000|Overall Study|Other|112
6012393|NCT00113607|9604486|FG000|Overall Study|Adverse Event|40
6012394|NCT00113607|9604487|FG001|Overall Study|Adverse Event|71
6012395|NCT00113607|9604486|FG000|Overall Study|Death|8
6012396|NCT00113607|9604487|FG001|Overall Study|Death|8
6012397|NCT00113607|9604486|FG000|Overall Study|Withdrawal by Subject|50
6012398|NCT00113607|9604487|FG001|Overall Study|Withdrawal by Subject|58
6012399|NCT00113607|9604486|FG000|Overall Study|Lost to Follow-up|0
6012400|NCT00113607|9604487|FG001|Overall Study|Lost to Follow-up|2
6012401|NCT00113607|9604486|FG000|Overall Study|Disease Progression|180
6012402|NCT00113607|9604487|FG001|Overall Study|Disease Progression|142
6012403|NCT00113607|9604486|FG000|Overall Study|Complete Response (Confirmed)|14
6012404|NCT00113607|9604487|FG001|Overall Study|Complete Response (Confirmed)|24
6012405|NCT00113607|9604486|FG000|Overall Study|Other|43
6012406|NCT00113607|9604487|FG001|Overall Study|Other|32
6012407|NCT00113763|9604496|FG000|Overall Study|Adverse Event|5
6012408|NCT00113763|9604497|FG001|Overall Study|Adverse Event|2
6075764|NCT00584805|9680509|FG000|Overall Study|No longer at risk of exposure|39
6075765|NCT00584805|9680509|FG000|Overall Study|Relocation|36
6075766|NCT00584805|9680509|FG000|Overall Study|Withdrawal by Subject|18
6075767|NCT00584805|9680509|FG000|Overall Study|Non-compliance|1
6012409|NCT00113763|9604496|FG000|Overall Study|Disease Progression|28
6012410|NCT00113763|9604497|FG001|Overall Study|Disease Progression|14
6012411|NCT00113763|9604496|FG000|Overall Study|Lost to Follow-up|10
6012412|NCT00113763|9604497|FG001|Overall Study|Lost to Follow-up|0
6012413|NCT00113763|9604496|FG000|Overall Study|Withdrawal by Subject|1
6012414|NCT00113763|9604497|FG001|Overall Study|Withdrawal by Subject|4
6012415|NCT00113763|9604496|FG000|Overall Study|Other|27
6075768|NCT00584805|9680509|FG000|Overall Study|Lost to follow up|3
6012416|NCT00113763|9604497|FG001|Overall Study|Other|6
6012417|NCT00113763|9604496|FG000|Overall Study|Non-compliance|1
6012418|NCT00113763|9604497|FG001|Overall Study|Non-compliance|0
6012419|NCT00113763|9604496|FG000|Overall Study|Ongoing|1
6012420|NCT00113763|9604497|FG001|Overall Study|Ongoing|0
6012421|NCT00113841|9604506|FG000|Overall Study|Disease progression|0
6012422|NCT00113841|9604507|FG001|Overall Study|Disease progression|2
6012423|NCT00113841|9604506|FG000|Overall Study|Non-compliant|1
6012424|NCT00113841|9604507|FG001|Overall Study|Non-compliant|0
6012425|NCT00114127|9604562|FG000|Overall Study|Adverse Event|2
6012426|NCT00114127|9604563|FG001|Overall Study|Adverse Event|1
6012427|NCT00114127|9604562|FG000|Overall Study|Lost to Follow-up|1
6012428|NCT00114127|9604563|FG001|Overall Study|Lost to Follow-up|0
6012429|NCT00114127|9604562|FG000|Overall Study|Withdrawal by Subject|1
6012430|NCT00114127|9604563|FG001|Overall Study|Withdrawal by Subject|3
6012431|NCT00114140|9604569|FG000|Overall Study|Protocol Violation|7
6012432|NCT00114166|9604582|FG000|Overall Study|Wrong primary|0
6012433|NCT00114166|9604583|FG001|Overall Study|Wrong primary|1
6012434|NCT00114218|9604591|FG000|Overall Study|Wrong Cell Type|2
6012435|NCT00114218|9604591|FG000|Overall Study|Wrong Primary|1
6012436|NCT00114218|9604591|FG000|Overall Study|Never Treated|1
6012437|NCT00114231|9604597|FG000|Overall Study|No consent|2
6012438|NCT00114231|9604598|FG001|Overall Study|No consent|0
6012439|NCT00114231|9604597|FG000|Overall Study|QARC requirement not met|1
6012440|NCT00114231|9604598|FG001|Overall Study|QARC requirement not met|0
6012441|NCT00114231|9604597|FG000|Overall Study|Suspected metastatic disease|1
6012442|NCT00114231|9604598|FG001|Overall Study|Suspected metastatic disease|0
6012443|NCT00114231|9604597|FG000|Overall Study|No adenocarcinoma|1
6012444|NCT00114231|9604598|FG001|Overall Study|No adenocarcinoma|0
6012445|NCT00114231|9604597|FG000|Overall Study|Low creatinine clearance|0
6012446|NCT00114231|9604598|FG001|Overall Study|Low creatinine clearance|1
6012447|NCT00114231|9604597|FG000|Overall Study|Tumor size > 4cm|1
6012448|NCT00114231|9604598|FG001|Overall Study|Tumor size > 4cm|0
6012449|NCT00114231|9604597|FG000|Overall Study|Tumor fixed on digital exam|0
6012450|NCT00114231|9604598|FG001|Overall Study|Tumor fixed on digital exam|1
6012451|NCT00114231|9604597|FG000|Overall Study|No Absolute Neutrophil Count|2
6012452|NCT00114231|9604598|FG001|Overall Study|No Absolute Neutrophil Count|0
6012453|NCT00114231|9604597|FG000|Overall Study|Biopsy done after registration|1
6012454|NCT00114231|9604598|FG001|Overall Study|Biopsy done after registration|0
6012455|NCT00114244|9604605|FG000|Overall Study|Adverse Event|2
6012456|NCT00114244|9604606|FG001|Overall Study|Adverse Event|5
6012457|NCT00114244|9604605|FG000|Overall Study|Withdrawal by Subject|0
6012458|NCT00114244|9604606|FG001|Overall Study|Withdrawal by Subject|2
6012459|NCT00114530|9604640|FG000|Overall Study|Death|3
6012460|NCT00114530|9604641|FG001|Overall Study|Death|11
6012461|NCT00114530|9604640|FG000|Overall Study|Lost to Follow-up|1
6012462|NCT00114530|9604641|FG001|Overall Study|Lost to Follow-up|1
6012463|NCT00114530|9604640|FG000|Overall Study|Physician Decision|1
6012464|NCT00114530|9604641|FG001|Overall Study|Physician Decision|1
6012465|NCT00114530|9604640|FG000|Overall Study|Withdrawal by Subject|2
6012466|NCT00114530|9604641|FG001|Overall Study|Withdrawal by Subject|6
6012467|NCT00114530|9604640|FG000|Overall Study|Breast Cancer|1
6012468|NCT00114530|9604641|FG001|Overall Study|Breast Cancer|0
6012469|NCT00114530|9604640|FG000|Overall Study|Subject decision after endpoint failure|0
6012470|NCT00114530|9604641|FG001|Overall Study|Subject decision after endpoint failure|1
6012471|NCT00114530|9604640|FG000|Overall Study|Ineligible|1
6012472|NCT00114530|9604641|FG001|Overall Study|Ineligible|0
6012473|NCT00114634|9604651|FG000|Overall Study|failure to return forms|3
6012474|NCT00114738|9604657|FG000|Bortezomib Then Bortezomib + Induction|Withdrawal by Subject|1
6012475|NCT00114738|9604658|FG001|Bortezomib Then Bortezomib + Induction|Withdrawal by Subject|0
6012476|NCT00114738|9604659|FG002|Bortezomib Then Bortezomib + Induction|Withdrawal by Subject|0
6012477|NCT00114738|9604657|FG000|Bortezomib Then Bortezomib + Induction|Progressive Disease|1
6012478|NCT00114738|9604658|FG001|Bortezomib Then Bortezomib + Induction|Progressive Disease|0
6012479|NCT00114738|9604659|FG002|Bortezomib Then Bortezomib + Induction|Progressive Disease|0
6012480|NCT00114738|9604657|FG000|Screening for Randomization|Neuropathy|17
6012481|NCT00114738|9604658|FG001|Screening for Randomization|Neuropathy|0
6012482|NCT00114738|9604659|FG002|Screening for Randomization|Neuropathy|0
6012483|NCT00114738|9604657|FG000|Screening for Randomization|Progressive disease|2
6012484|NCT00114738|9604658|FG001|Screening for Randomization|Progressive disease|0
6012485|NCT00114738|9604659|FG002|Screening for Randomization|Progressive disease|0
6012486|NCT00114738|9604657|FG000|Screening for Randomization|CNS Hemorrhage|1
6012487|NCT00114738|9604658|FG001|Screening for Randomization|CNS Hemorrhage|0
6012488|NCT00114738|9604659|FG002|Screening for Randomization|CNS Hemorrhage|0
6012489|NCT00114738|9604657|FG000|Screening for Randomization|Other|1
6012490|NCT00114738|9604658|FG001|Screening for Randomization|Other|0
6012491|NCT00114738|9604659|FG002|Screening for Randomization|Other|0
6012492|NCT00114777|9604669|FG000|Randomization to Month 36|Death|10
6012493|NCT00114777|9604670|FG001|Randomization to Month 36|Death|4
6012494|NCT00114777|9604671|FG002|Randomization to Month 36|Death|3
6012495|NCT00114777|9604669|FG000|Randomization to Month 36|No Longer Met Study Criteria|0
6047542|NCT00412607|9646633|FG000|Overall Study|Withdrawal by Subject|9
6012496|NCT00114777|9604670|FG001|Randomization to Month 36|No Longer Met Study Criteria|0
6012497|NCT00114777|9604671|FG002|Randomization to Month 36|No Longer Met Study Criteria|2
6012498|NCT00114777|9604669|FG000|Randomization to Month 36|Lack of Efficacy|19
6012499|NCT00114777|9604670|FG001|Randomization to Month 36|Lack of Efficacy|15
6012500|NCT00114777|9604671|FG002|Randomization to Month 36|Lack of Efficacy|17
6012501|NCT00114777|9604669|FG000|Randomization to Month 36|Poor or Non-Compliance|0
6012502|NCT00114777|9604670|FG001|Randomization to Month 36|Poor or Non-Compliance|0
6012503|NCT00114777|9604671|FG002|Randomization to Month 36|Poor or Non-Compliance|1
6012504|NCT00114777|9604669|FG000|Randomization to Month 36|Adverse Event|34
6012505|NCT00114777|9604670|FG001|Randomization to Month 36|Adverse Event|35
6012506|NCT00114777|9604671|FG002|Randomization to Month 36|Adverse Event|44
6012507|NCT00114777|9604669|FG000|Randomization to Month 36|Withdrawal by Subject|3
6012508|NCT00114777|9604670|FG001|Randomization to Month 36|Withdrawal by Subject|4
6012509|NCT00114777|9604671|FG002|Randomization to Month 36|Withdrawal by Subject|5
6012510|NCT00114777|9604669|FG000|Randomization to Month 36|Other|9
6012511|NCT00114777|9604670|FG001|Randomization to Month 36|Other|3
6012512|NCT00114777|9604671|FG002|Randomization to Month 36|Other|12
6012513|NCT00114777|9604669|FG000|Long-Term Extension to Month 84|Death|8
6012514|NCT00114777|9604670|FG001|Long-Term Extension to Month 84|Death|13
6012515|NCT00114777|9604671|FG002|Long-Term Extension to Month 84|Death|7
6012516|NCT00114777|9604669|FG000|Long-Term Extension to Month 84|No Longer Met Study Criteria|1
6012517|NCT00114777|9604670|FG001|Long-Term Extension to Month 84|No Longer Met Study Criteria|0
6012518|NCT00114777|9604671|FG002|Long-Term Extension to Month 84|No Longer Met Study Criteria|1
6012519|NCT00114777|9604669|FG000|Long-Term Extension to Month 84|Lack of Efficacy|1
6012520|NCT00114777|9604670|FG001|Long-Term Extension to Month 84|Lack of Efficacy|0
6012521|NCT00114777|9604671|FG002|Long-Term Extension to Month 84|Lack of Efficacy|1
6012522|NCT00114777|9604669|FG000|Long-Term Extension to Month 84|Poor or Non-Compliance|1
6012523|NCT00114777|9604670|FG001|Long-Term Extension to Month 84|Poor or Non-Compliance|1
6012524|NCT00114777|9604671|FG002|Long-Term Extension to Month 84|Poor or Non-Compliance|3
6012525|NCT00114777|9604669|FG000|Long-Term Extension to Month 84|Adverse Event|15
6012526|NCT00114777|9604670|FG001|Long-Term Extension to Month 84|Adverse Event|14
6012527|NCT00114777|9604671|FG002|Long-Term Extension to Month 84|Adverse Event|7
6012528|NCT00114777|9604669|FG000|Long-Term Extension to Month 84|Withdrawal by Subject|2
6012529|NCT00114777|9604670|FG001|Long-Term Extension to Month 84|Withdrawal by Subject|1
6012530|NCT00114777|9604671|FG002|Long-Term Extension to Month 84|Withdrawal by Subject|6
6012531|NCT00114777|9604669|FG000|Long-Term Extension to Month 84|Lost to Follow-up|0
6012532|NCT00114777|9604670|FG001|Long-Term Extension to Month 84|Lost to Follow-up|0
6012533|NCT00114777|9604671|FG002|Long-Term Extension to Month 84|Lost to Follow-up|2
6012534|NCT00114777|9604669|FG000|Long-Term Extension to Month 84|Administrative Reason by Sponsor|0
6012535|NCT00114777|9604670|FG001|Long-Term Extension to Month 84|Administrative Reason by Sponsor|0
6012536|NCT00114777|9604671|FG002|Long-Term Extension to Month 84|Administrative Reason by Sponsor|1
6012537|NCT00114777|9604669|FG000|Long-Term Extension to Month 84|Other|2
6012538|NCT00114777|9604670|FG001|Long-Term Extension to Month 84|Other|0
6012539|NCT00114777|9604671|FG002|Long-Term Extension to Month 84|Other|2
6012540|NCT00114959|9604680|FG000|Overall Study|Lack of Efficacy|6
6012541|NCT00114959|9604680|FG000|Overall Study|Physician Decision|1
6012542|NCT00114959|9604680|FG000|Overall Study|Death|1
6012543|NCT00114972|9604686|FG000|Overall Study|Withdrawal by Subject|40
6012544|NCT00114972|9604687|FG001|Overall Study|Withdrawal by Subject|7
6012545|NCT00114972|9604686|FG000|Overall Study|Lost to Follow-up|8
6012546|NCT00114972|9604687|FG001|Overall Study|Lost to Follow-up|5
6012547|NCT00115037|9604695|FG000|Phase1|Lost to Follow-up|16
6012548|NCT00115037|9604696|FG001|Phase1|Lost to Follow-up|23
6012549|NCT00115037|9604697|FG002|Phase1|Lost to Follow-up|0
6012550|NCT00115037|9604698|FG003|Phase1|Lost to Follow-up|0
6012551|NCT00115037|9604699|FG004|Phase1|Lost to Follow-up|0
6012552|NCT00115037|9604700|FG005|Phase1|Lost to Follow-up|0
6012553|NCT00115037|9604695|FG000|Phase1|Withdrawal by Subject|9
6012554|NCT00115037|9604696|FG001|Phase1|Withdrawal by Subject|4
6012555|NCT00115037|9604697|FG002|Phase1|Withdrawal by Subject|0
6012556|NCT00115037|9604698|FG003|Phase1|Withdrawal by Subject|0
6012557|NCT00115037|9604699|FG004|Phase1|Withdrawal by Subject|0
6012558|NCT00115037|9604700|FG005|Phase1|Withdrawal by Subject|0
6012559|NCT00115037|9604695|FG000|Phase2|Death|0
6012560|NCT00115037|9604696|FG001|Phase2|Death|0
6012561|NCT00115037|9604697|FG002|Phase2|Death|1
6012562|NCT00115037|9604698|FG003|Phase2|Death|0
6012563|NCT00115037|9604699|FG004|Phase2|Death|0
6012564|NCT00115037|9604700|FG005|Phase2|Death|1
6012565|NCT00115037|9604695|FG000|Phase2|Withdrawal by Subject|0
6012566|NCT00115037|9604696|FG001|Phase2|Withdrawal by Subject|0
6012567|NCT00115037|9604697|FG002|Phase2|Withdrawal by Subject|2
6012568|NCT00115037|9604698|FG003|Phase2|Withdrawal by Subject|1
6012569|NCT00115037|9604699|FG004|Phase2|Withdrawal by Subject|2
6012570|NCT00115037|9604700|FG005|Phase2|Withdrawal by Subject|1
6012571|NCT00115037|9604695|FG000|Phase2|Lost to Follow-up|0
6012572|NCT00115037|9604696|FG001|Phase2|Lost to Follow-up|0
6012573|NCT00115037|9604697|FG002|Phase2|Lost to Follow-up|12
6012574|NCT00115037|9604698|FG003|Phase2|Lost to Follow-up|14
6012575|NCT00115037|9604699|FG004|Phase2|Lost to Follow-up|4
6012576|NCT00115037|9604700|FG005|Phase2|Lost to Follow-up|10
6012577|NCT00115063|9604716|FG000|Overall Study|Lost to Follow-up|98
6012578|NCT00115063|9604717|FG001|Overall Study|Lost to Follow-up|104
6012579|NCT00115063|9604716|FG000|Overall Study|Death|1
6012580|NCT00115063|9604717|FG001|Overall Study|Death|0
6012581|NCT00115336|9604741|FG000|Overall Study|Hospital discharge before study drug|0
6012582|NCT00115336|9604742|FG001|Overall Study|Hospital discharge before study drug|1
6012583|NCT00115349|9604752|FG000|Overall Study|Study closed due to low enrollment.|11
6012584|NCT00115349|9604753|FG001|Overall Study|Study closed due to low enrollment.|9
6012585|NCT00115739|9604759|FG000|Overall Study|Lost to Follow-up|3
6012586|NCT00115765|9604769|FG000|Overall Study|Withdrawal by Subject|22
6012587|NCT00115765|9604770|FG001|Overall Study|Withdrawal by Subject|53
6012588|NCT00115765|9604771|FG002|Overall Study|Withdrawal by Subject|76
6012589|NCT00115765|9604772|FG003|Overall Study|Withdrawal by Subject|15
6012590|NCT00115765|9604769|FG000|Overall Study|Physician Decision|4
6012591|NCT00115765|9604770|FG001|Overall Study|Physician Decision|15
6012592|NCT00115765|9604771|FG002|Overall Study|Physician Decision|18
6012593|NCT00115765|9604772|FG003|Overall Study|Physician Decision|13
6012594|NCT00115765|9604769|FG000|Overall Study|Lost to Follow-up|3
6012595|NCT00115765|9604770|FG001|Overall Study|Lost to Follow-up|20
6012596|NCT00115765|9604771|FG002|Overall Study|Lost to Follow-up|18
6012597|NCT00115765|9604772|FG003|Overall Study|Lost to Follow-up|1
6012598|NCT00115765|9604769|FG000|Overall Study|Other|6
6012599|NCT00115765|9604770|FG001|Overall Study|Other|12
6012600|NCT00115765|9604771|FG002|Overall Study|Other|9
6012601|NCT00115765|9604772|FG003|Overall Study|Other|2
6012602|NCT00115778|9604780|FG000|Overall Study|Withdrawal by Subject|0
6012603|NCT00115778|9604781|FG001|Overall Study|Withdrawal by Subject|1
6012604|NCT00115804|9604787|FG000|Overall Study|Adverse Event|2
6012605|NCT00115934|9604806|FG000|Overall Study|Lost to Follow-up|1
6012606|NCT00115934|9604807|FG001|Overall Study|Lost to Follow-up|0
6012607|NCT00115934|9604806|FG000|Overall Study|Did not receive intervention|3
6012608|NCT00115934|9604807|FG001|Overall Study|Did not receive intervention|2
6012609|NCT00116168|9604817|FG000|Overall Study|Lost to Follow-up|6
6012610|NCT00116168|9604818|FG001|Overall Study|Lost to Follow-up|5
6012611|NCT00116168|9604819|FG002|Overall Study|Lost to Follow-up|0
6012612|NCT00116168|9604820|FG003|Overall Study|Lost to Follow-up|0
6012613|NCT00116272|9604841|FG000|Overall Study|Lost to Follow-up|11
6012614|NCT00116272|9604842|FG001|Overall Study|Lost to Follow-up|6
6012615|NCT00116428|9604863|FG000|Overall Study|Withdrawal by Subject|2
6012616|NCT00116428|9604864|FG001|Overall Study|Withdrawal by Subject|5
6012617|NCT00116428|9604863|FG000|Overall Study|Did not meet inclusion criteria|1
6012618|NCT00116428|9604864|FG001|Overall Study|Did not meet inclusion criteria|0
6012619|NCT00116558|9604876|FG000|Overall Study|Death|11
6012620|NCT00116558|9604877|FG001|Overall Study|Death|5
6012621|NCT00116558|9604878|FG002|Overall Study|Death|3
6012622|NCT00116558|9604876|FG000|Overall Study|Withdrawal by Subject|17
6012623|NCT00116558|9604877|FG001|Overall Study|Withdrawal by Subject|3
6012624|NCT00116558|9604878|FG002|Overall Study|Withdrawal by Subject|12
6012625|NCT00116558|9604876|FG000|Overall Study|disease progression|3
6012626|NCT00116558|9604877|FG001|Overall Study|disease progression|7
6012627|NCT00116558|9604878|FG002|Overall Study|disease progression|18
6012628|NCT00116584|9604887|FG000|Overall Study|Withdrawal by Subject|1
6012629|NCT00116584|9604888|FG001|Overall Study|Withdrawal by Subject|0
6012630|NCT00116584|9604887|FG000|Overall Study|Protocol Violation|1
6012631|NCT00116584|9604888|FG001|Overall Study|Protocol Violation|1
6012632|NCT00116649|9604894|FG000|Overall Study|Adverse Event|20
6012633|NCT00116649|9604894|FG000|Overall Study|Lack of Efficacy|1
6012634|NCT00116649|9604894|FG000|Overall Study|Lost to Follow-up|32
6012635|NCT00116649|9604894|FG000|Overall Study|Withdrawal by Subject|68
6012636|NCT00116649|9604894|FG000|Overall Study|Local Skin Reaction|9
6012637|NCT00116649|9604894|FG000|Overall Study|Various Reasons|18
6012638|NCT00116649|9604894|FG000|Overall Study|Protocol Specified|7
6012639|NCT00116688|9604900|FG000|Overall Study|Protocol deviation|1
6012640|NCT00116688|9604901|FG001|Overall Study|Protocol deviation|0
6012641|NCT00116688|9604900|FG000|Overall Study|Noncompliance|3
6012642|NCT00116688|9604901|FG001|Overall Study|Noncompliance|1
6012643|NCT00116688|9604900|FG000|Overall Study|Adverse Event|11
6012644|NCT00116688|9604901|FG001|Overall Study|Adverse Event|0
6012645|NCT00116688|9604900|FG000|Overall Study|Withdrawal by Subject|26
6012646|NCT00116688|9604901|FG001|Overall Study|Withdrawal by Subject|2
6012647|NCT00116688|9604900|FG000|Overall Study|Requirement for alternative therapy|11
6012648|NCT00116688|9604901|FG001|Overall Study|Requirement for alternative therapy|1
6012649|NCT00116688|9604900|FG000|Overall Study|Physician Decision|7
6012650|NCT00116688|9604901|FG001|Overall Study|Physician Decision|0
6012651|NCT00116688|9604900|FG000|Overall Study|Lost to Follow-up|3
6012652|NCT00116688|9604901|FG001|Overall Study|Lost to Follow-up|0
6012653|NCT00116688|9604900|FG000|Overall Study|Death|15
6012654|NCT00116688|9604901|FG001|Overall Study|Death|0
6012655|NCT00116688|9604900|FG000|Overall Study|Protocol-specified criteria|3
6012656|NCT00116688|9604901|FG001|Overall Study|Protocol-specified criteria|0
6012657|NCT00116688|9604900|FG000|Overall Study|Pregnancy|1
6012658|NCT00116688|9604901|FG001|Overall Study|Pregnancy|0
6012659|NCT00116688|9604900|FG000|Overall Study|Other|11
6012660|NCT00116688|9604901|FG001|Overall Study|Other|0
6012661|NCT00116753|9604910|FG000|Overall Study|Adverse Event|16
6012662|NCT00116753|9604911|FG001|Overall Study|Adverse Event|10
6012663|NCT00116753|9604912|FG002|Overall Study|Adverse Event|7
6012664|NCT00116753|9604910|FG000|Overall Study|Withdrawal by Subject|11
6012665|NCT00116753|9604911|FG001|Overall Study|Withdrawal by Subject|12
6012666|NCT00116753|9604912|FG002|Overall Study|Withdrawal by Subject|8
6012667|NCT00116753|9604910|FG000|Overall Study|Lost to Follow-up|0
6012668|NCT00116753|9604911|FG001|Overall Study|Lost to Follow-up|2
6012669|NCT00116753|9604912|FG002|Overall Study|Lost to Follow-up|1
6012670|NCT00116753|9604910|FG000|Overall Study|Protocol Violation|0
6012671|NCT00116753|9604911|FG001|Overall Study|Protocol Violation|0
6012672|NCT00116753|9604912|FG002|Overall Study|Protocol Violation|1
6012673|NCT00116753|9604910|FG000|Overall Study|Did not Fulfil Eligibility Criteria|1
6012674|NCT00116753|9604911|FG001|Overall Study|Did not Fulfil Eligibility Criteria|1
6012675|NCT00116753|9604912|FG002|Overall Study|Did not Fulfil Eligibility Criteria|3
6012676|NCT00116753|9604910|FG000|Overall Study|Disease Progression|3
6012677|NCT00116753|9604911|FG001|Overall Study|Disease Progression|4
6012678|NCT00116753|9604912|FG002|Overall Study|Disease Progression|3
6012679|NCT00116753|9604910|FG000|Overall Study|Abnormal Echocardiogram|0
6012680|NCT00116753|9604911|FG001|Overall Study|Abnormal Echocardiogram|0
6012681|NCT00116753|9604912|FG002|Overall Study|Abnormal Echocardiogram|1
6012682|NCT00116753|9604910|FG000|Overall Study|Progressive Parkinson's Disease|1
6012683|NCT00116753|9604911|FG001|Overall Study|Progressive Parkinson's Disease|0
6012684|NCT00116753|9604912|FG002|Overall Study|Progressive Parkinson's Disease|0
6012685|NCT00116753|9604910|FG000|Overall Study|Dosing Error|0
6012686|NCT00116753|9604911|FG001|Overall Study|Dosing Error|1
6012687|NCT00116753|9604912|FG002|Overall Study|Dosing Error|0
6012688|NCT00116779|9604922|FG000|Overall Study|Adverse Event|4
6012689|NCT00116779|9604923|FG001|Overall Study|Adverse Event|2
6012690|NCT00116779|9604922|FG000|Overall Study|Protocol Violation|1
6012691|NCT00116779|9604923|FG001|Overall Study|Protocol Violation|4
6012692|NCT00116779|9604922|FG000|Overall Study|Withdrawal by Subject|4
6012693|NCT00116779|9604923|FG001|Overall Study|Withdrawal by Subject|1
6012694|NCT00116779|9604922|FG000|Overall Study|Inadequate testosterone suppression|7
6012695|NCT00116779|9604923|FG001|Overall Study|Inadequate testosterone suppression|9
6012696|NCT00116779|9604922|FG000|Overall Study|Physician Decision|3
6012697|NCT00116779|9604923|FG001|Overall Study|Physician Decision|1
6012698|NCT00116779|9604922|FG000|Overall Study|Elevated PSA levels|2
6012699|NCT00116779|9604923|FG001|Overall Study|Elevated PSA levels|2
6012700|NCT00116805|9604931|FG000|Double-blind Period Through Week 48|Lost to Follow-up|6
6012701|NCT00116805|9604932|FG001|Double-blind Period Through Week 48|Lost to Follow-up|2
6012702|NCT00116805|9604931|FG000|Double-blind Period Through Week 48|Protocol Violation|1
6012703|NCT00116805|9604932|FG001|Double-blind Period Through Week 48|Protocol Violation|1
6012704|NCT00116805|9604931|FG000|Double-blind Period Through Week 48|Withdrew Consent|4
6012705|NCT00116805|9604932|FG001|Double-blind Period Through Week 48|Withdrew Consent|2
6012706|NCT00116805|9604931|FG000|Open-label Period Weeks 49 - 96|Investigator's Discretion|1
6012707|NCT00116805|9604932|FG001|Open-label Period Weeks 49 - 96|Investigator's Discretion|0
6012708|NCT00116805|9604931|FG000|Open-label Period Weeks 49 - 96|Lost to Follow-up|2
6012709|NCT00116805|9604932|FG001|Open-label Period Weeks 49 - 96|Lost to Follow-up|0
6075769|NCT00584805|9680509|FG000|Overall Study|Screen failures|2
6075770|NCT00584844|9680543|FG000|Overall Study|Withdrawal by Subject|59
6075771|NCT00584844|9680543|FG000|Overall Study|Screen Failure|20
6075772|NCT00584870|9680558|FG000|Overall Study|Adverse Event|4
6075773|NCT00584870|9680559|FG001|Overall Study|Adverse Event|3
6075774|NCT00584870|9680560|FG002|Overall Study|Adverse Event|2
6075775|NCT00584870|9680558|FG000|Overall Study|Lost to Follow-up|4
6075776|NCT00584870|9680559|FG001|Overall Study|Lost to Follow-up|1
6075777|NCT00584870|9680560|FG002|Overall Study|Lost to Follow-up|1
6075778|NCT00584870|9680558|FG000|Overall Study|Lack of Efficacy|7
6075779|NCT00584870|9680559|FG001|Overall Study|Lack of Efficacy|14
6075780|NCT00584870|9680560|FG002|Overall Study|Lack of Efficacy|8
6075781|NCT00584870|9680558|FG000|Overall Study|Withdrawal by Subject|10
6075782|NCT00584870|9680559|FG001|Overall Study|Withdrawal by Subject|5
6075783|NCT00584870|9680560|FG002|Overall Study|Withdrawal by Subject|3
6227285|NCT01716520|9900043|FG002|Washout Period 1 (10 to 14 Days)|Lack of Efficacy|0
6012710|NCT00116805|9604931|FG000|Open-label Period Weeks 49 - 96|Protocol Violation|2
6012711|NCT00116805|9604932|FG001|Open-label Period Weeks 49 - 96|Protocol Violation|0
6012712|NCT00116805|9604931|FG000|Open-label Period Weeks 49 - 96|Safety, Tolerability, or Efficacy Reason|1
6012713|NCT00116805|9604932|FG001|Open-label Period Weeks 49 - 96|Safety, Tolerability, or Efficacy Reason|0
6012714|NCT00116805|9604931|FG000|Open-label Period Weeks 49 - 96|Seroconversion|2
6012715|NCT00116805|9604932|FG001|Open-label Period Weeks 49 - 96|Seroconversion|0
6012716|NCT00116805|9604931|FG000|Open-label Period Weeks 49 - 96|Withdrew Consent|2
6012717|NCT00116805|9604932|FG001|Open-label Period Weeks 49 - 96|Withdrew Consent|1
6012718|NCT00116805|9604931|FG000|Open-label Period Weeks 97 - 144|Completed Study|1
6012719|NCT00116805|9604932|FG001|Open-label Period Weeks 97 - 144|Completed Study|0
6012720|NCT00116805|9604931|FG000|Open-label Period Weeks 97 - 144|Investigator's Discretion|2
6012721|NCT00116805|9604932|FG001|Open-label Period Weeks 97 - 144|Investigator's Discretion|0
6075784|NCT00584870|9680558|FG000|Overall Study|Protocol Violation|1
6075785|NCT00584870|9680559|FG001|Overall Study|Protocol Violation|1
6075786|NCT00584870|9680560|FG002|Overall Study|Protocol Violation|2
6075787|NCT00584870|9680558|FG000|Overall Study|Did not met entrance criteria|1
6075788|NCT00584870|9680559|FG001|Overall Study|Did not met entrance criteria|0
6012722|NCT00116805|9604931|FG000|Open-label Period Weeks 97 - 144|Lost to Follow-up|5
6012723|NCT00116805|9604932|FG001|Open-label Period Weeks 97 - 144|Lost to Follow-up|2
6012724|NCT00116805|9604931|FG000|Open-label Period Weeks 97 - 144|Protocol Violation|0
6012725|NCT00116805|9604932|FG001|Open-label Period Weeks 97 - 144|Protocol Violation|1
6012726|NCT00116805|9604931|FG000|Open-label Period Weeks 97 - 144|Seroconversion|2
6012727|NCT00116805|9604932|FG001|Open-label Period Weeks 97 - 144|Seroconversion|3
6012728|NCT00116805|9604931|FG000|Open-label Period Weeks 97 - 144|Withdrew Consent|1
6012729|NCT00116805|9604932|FG001|Open-label Period Weeks 97 - 144|Withdrew Consent|3
6012730|NCT00116805|9604931|FG000|Open-label Period Weeks 145 - 192|Completed Study|1
6012731|NCT00116805|9604932|FG001|Open-label Period Weeks 145 - 192|Completed Study|1
6012732|NCT00116805|9604931|FG000|Open-label Period Weeks 145 - 192|Investigator's Discretion|2
6012733|NCT00116805|9604932|FG001|Open-label Period Weeks 145 - 192|Investigator's Discretion|0
6012734|NCT00116805|9604931|FG000|Open-label Period Weeks 145 - 192|Lost to Follow-up|3
6012735|NCT00116805|9604932|FG001|Open-label Period Weeks 145 - 192|Lost to Follow-up|1
6012736|NCT00116805|9604931|FG000|Open-label Period Weeks 145 - 192|Protocol Violation|1
6012737|NCT00116805|9604932|FG001|Open-label Period Weeks 145 - 192|Protocol Violation|0
6012738|NCT00116805|9604931|FG000|Open-label Period Weeks 145 - 192|Safety, Tolerability, or Efficacy Reason|0
6012739|NCT00116805|9604932|FG001|Open-label Period Weeks 145 - 192|Safety, Tolerability, or Efficacy Reason|1
6012740|NCT00116805|9604931|FG000|Open-label Period Weeks 145 - 192|Seroconversion|0
6012741|NCT00116805|9604932|FG001|Open-label Period Weeks 145 - 192|Seroconversion|1
6012742|NCT00116805|9604931|FG000|Open-label Period Weeks 145 - 192|Withdrew Consent|3
6012743|NCT00116805|9604932|FG001|Open-label Period Weeks 145 - 192|Withdrew Consent|2
6012744|NCT00116805|9604931|FG000|Open-label Period Weeks 193 - 240|Completed Study|0
6012745|NCT00116805|9604932|FG001|Open-label Period Weeks 193 - 240|Completed Study|1
6012746|NCT00116805|9604931|FG000|Open-label Period Weeks 193 - 240|Investigator's Discretion|1
6012747|NCT00116805|9604932|FG001|Open-label Period Weeks 193 - 240|Investigator's Discretion|0
6012748|NCT00116805|9604931|FG000|Open-label Period Weeks 193 - 240|Lost to Follow-up|3
6012749|NCT00116805|9604932|FG001|Open-label Period Weeks 193 - 240|Lost to Follow-up|0
6012750|NCT00116805|9604931|FG000|Open-label Period Weeks 193 - 240|Safety, Tolerability, or Efficacy Reason|2
6012751|NCT00116805|9604932|FG001|Open-label Period Weeks 193 - 240|Safety, Tolerability, or Efficacy Reason|2
6012752|NCT00116805|9604931|FG000|Open-label Period Weeks 193 - 240|Withdrew Consent|7
6012753|NCT00116805|9604932|FG001|Open-label Period Weeks 193 - 240|Withdrew Consent|1
6012754|NCT00116805|9604931|FG000|Open-label Period Weeks 241 - 288|Safety, Tolerability, or Efficacy Reason|2
6012755|NCT00116805|9604932|FG001|Open-label Period Weeks 241 - 288|Safety, Tolerability, or Efficacy Reason|0
6012756|NCT00116805|9604931|FG000|Open-label Period Weeks 241 - 288|Withdrew Consent|4
6012757|NCT00116805|9604932|FG001|Open-label Period Weeks 241 - 288|Withdrew Consent|0
6012758|NCT00116805|9604931|FG000|Open-label Period Weeks 289 - 336|Completed Study|0
6012759|NCT00116805|9604932|FG001|Open-label Period Weeks 289 - 336|Completed Study|1
6012760|NCT00116805|9604931|FG000|Open-label Period Weeks 289 - 336|Investigator's Discretion|3
6012761|NCT00116805|9604932|FG001|Open-label Period Weeks 289 - 336|Investigator's Discretion|2
6012762|NCT00116805|9604931|FG000|Open-label Period Weeks 289 - 336|Lost to Follow-up|1
6012763|NCT00116805|9604932|FG001|Open-label Period Weeks 289 - 336|Lost to Follow-up|1
6012764|NCT00116805|9604931|FG000|Open-label Period Weeks 289 - 336|Protocol Violation|0
6012765|NCT00116805|9604932|FG001|Open-label Period Weeks 289 - 336|Protocol Violation|1
6012766|NCT00116805|9604931|FG000|Open-label Period Weeks 289 - 336|Safety, Tolerability, or Efficacy Reason|0
6012767|NCT00116805|9604932|FG001|Open-label Period Weeks 289 - 336|Safety, Tolerability, or Efficacy Reason|1
6012768|NCT00116805|9604931|FG000|Open-label Period Weeks 289 - 336|Study Site Discontinued|0
6012769|NCT00116805|9604932|FG001|Open-label Period Weeks 289 - 336|Study Site Discontinued|1
6012770|NCT00116805|9604931|FG000|Open-label Period Weeks 289 - 336|Withdrew Consent|2
6012771|NCT00116805|9604932|FG001|Open-label Period Weeks 289 - 336|Withdrew Consent|0
6012772|NCT00116805|9604931|FG000|Open-label Period Weeks 337 - 384|Completed Study|1
6012773|NCT00116805|9604932|FG001|Open-label Period Weeks 337 - 384|Completed Study|0
6012774|NCT00116805|9604931|FG000|Open-label Period Weeks 337 - 384|Investigator's Discretion|1
6012775|NCT00116805|9604932|FG001|Open-label Period Weeks 337 - 384|Investigator's Discretion|0
6012776|NCT00116805|9604931|FG000|Open-label Period Weeks 337 - 384|Lost to Follow-up|2
6012777|NCT00116805|9604932|FG001|Open-label Period Weeks 337 - 384|Lost to Follow-up|0
6012778|NCT00116805|9604931|FG000|Open-label Period Weeks 337 - 384|Protocol Violation|1
6012779|NCT00116805|9604932|FG001|Open-label Period Weeks 337 - 384|Protocol Violation|0
6012780|NCT00116805|9604931|FG000|Open-label Period Weeks 337 - 384|Withdrew Consent|3
6012781|NCT00116805|9604932|FG001|Open-label Period Weeks 337 - 384|Withdrew Consent|1
6012782|NCT00116805|9604931|FG000|Open-label Period Weeks 385 - 432|Investigator's Discretion|1
6012783|NCT00116805|9604932|FG001|Open-label Period Weeks 385 - 432|Investigator's Discretion|0
6012784|NCT00116805|9604931|FG000|Open-label Period Weeks 385 - 432|Withdrew Consent|1
6012785|NCT00116805|9604932|FG001|Open-label Period Weeks 385 - 432|Withdrew Consent|0
6012786|NCT00116805|9604931|FG000|Open-label Period Weeks 433 - 480|Investigator's Discretion|1
6012787|NCT00116805|9604932|FG001|Open-label Period Weeks 433 - 480|Investigator's Discretion|0
6012788|NCT00116805|9604931|FG000|Open-label Period Weeks 433 - 480|Withdrew Consent|3
6012789|NCT00116805|9604932|FG001|Open-label Period Weeks 433 - 480|Withdrew Consent|0
6012790|NCT00116831|9604949|FG000|Overall Study|Adverse Event|14
6012791|NCT00116831|9604950|FG001|Overall Study|Adverse Event|16
6012792|NCT00116831|9604949|FG000|Overall Study|Baseline IVUS determined unevaluable|12
6012793|NCT00116831|9604950|FG001|Overall Study|Baseline IVUS determined unevaluable|11
6012794|NCT00116831|9604949|FG000|Overall Study|Lost to Follow-up|8
6012795|NCT00116831|9604950|FG001|Overall Study|Lost to Follow-up|6
6012796|NCT00116831|9604949|FG000|Overall Study|Protocol Violation|3
6012797|NCT00116831|9604950|FG001|Overall Study|Protocol Violation|6
6012798|NCT00116831|9604949|FG000|Overall Study|Hypoglycaemic events|1
6012799|NCT00116831|9604950|FG001|Overall Study|Hypoglycaemic events|0
6012800|NCT00116831|9604949|FG000|Overall Study|Low haemoglobin on screening|1
6012801|NCT00116831|9604950|FG001|Overall Study|Low haemoglobin on screening|0
6012802|NCT00116831|9604949|FG000|Overall Study|Withdrawn investigational product|1
6012803|NCT00116831|9604950|FG001|Overall Study|Withdrawn investigational product|0
6012804|NCT00116831|9604949|FG000|Overall Study|Withdrawal by Subject|32
6012805|NCT00116831|9604950|FG001|Overall Study|Withdrawal by Subject|32
6012806|NCT00116831|9604949|FG000|Overall Study|Insufficient therapeutic effect|0
6012807|NCT00116831|9604950|FG001|Overall Study|Insufficient therapeutic effect|1
6012808|NCT00116831|9604949|FG000|Overall Study|Missing data for participant|1
6012809|NCT00116831|9604950|FG001|Overall Study|Missing data for participant|0
6012810|NCT00116844|9604958|FG000|Period 1: Treatment Period 1 (60 Days)|Lost to Follow-up|1
6012811|NCT00116844|9604959|FG001|Period 1: Treatment Period 1 (60 Days)|Lost to Follow-up|1
6012812|NCT00116844|9604958|FG000|Period 1: Treatment Period 1 (60 Days)|Protocol Violation|0
6012813|NCT00116844|9604959|FG001|Period 1: Treatment Period 1 (60 Days)|Protocol Violation|1
6012814|NCT00116844|9604958|FG000|Period 1: Treatment Period 1 (60 Days)|Withdrawal by Subject|5
6012815|NCT00116844|9604959|FG001|Period 1: Treatment Period 1 (60 Days)|Withdrawal by Subject|0
6012816|NCT00116844|9604958|FG000|Period 1: Treatment Period 1 (60 Days)|Other|1
6012817|NCT00116844|9604959|FG001|Period 1: Treatment Period 1 (60 Days)|Other|1
6012818|NCT00116844|9604958|FG000|Period 1: Treatment Period 2 (60 Days)|Adverse Event|1
6012819|NCT00116844|9604959|FG001|Period 1: Treatment Period 2 (60 Days)|Adverse Event|0
6012820|NCT00116844|9604958|FG000|Period 1: Treatment Period 2 (60 Days)|Lost to Follow-up|2
6012821|NCT00116844|9604959|FG001|Period 1: Treatment Period 2 (60 Days)|Lost to Follow-up|1
6012822|NCT00116844|9604958|FG000|Period 1: Treatment Period 2 (60 Days)|Other|0
6012823|NCT00116844|9604959|FG001|Period 1: Treatment Period 2 (60 Days)|Other|2
6012824|NCT00116844|9604958|FG000|Period 1: Treatment Period 2 (60 Days)|Protocol Violation|0
6012825|NCT00116844|9604959|FG001|Period 1: Treatment Period 2 (60 Days)|Protocol Violation|1
6012826|NCT00116844|9604958|FG000|Period 1: Treatment Period 2 (60 Days)|Withdrawal by Subject|1
6012827|NCT00116844|9604959|FG001|Period 1: Treatment Period 2 (60 Days)|Withdrawal by Subject|1
6012828|NCT00117156|9604991|FG000|Overall Study|Adverse Event|9
6012829|NCT00117156|9604991|FG000|Overall Study|Physician Decision|1
6012830|NCT00117156|9604991|FG000|Overall Study|Trt for Pre-Exist Second Primary|1
6012831|NCT00117286|9604997|FG000|Overall Study|Adverse Event|12
6012832|NCT00117286|9604998|FG001|Overall Study|Adverse Event|6
6012833|NCT00117286|9604997|FG000|Overall Study|Lost to Follow-up|2
6012834|NCT00117286|9604998|FG001|Overall Study|Lost to Follow-up|0
6012835|NCT00117286|9604997|FG000|Overall Study|Protocol Violation|3
6012836|NCT00117286|9604998|FG001|Overall Study|Protocol Violation|3
6012837|NCT00117286|9604997|FG000|Overall Study|Withdrawal by Subject|6
6012838|NCT00117286|9604998|FG001|Overall Study|Withdrawal by Subject|2
6012839|NCT00117286|9604997|FG000|Overall Study|Physician Decision|3
6012840|NCT00117286|9604998|FG001|Overall Study|Physician Decision|7
6012841|NCT00117286|9604997|FG000|Overall Study|Lack of Efficacy|2
6012842|NCT00117286|9604998|FG001|Overall Study|Lack of Efficacy|1
6012843|NCT00117286|9604997|FG000|Overall Study|Research site closing|0
6012844|NCT00117286|9604998|FG001|Overall Study|Research site closing|2
6012845|NCT00117312|9605008|FG000|Overall Study|Testosterone >1.0 ng/mL|9
6012846|NCT00117312|9605009|FG001|Overall Study|Testosterone >1.0 ng/mL|9
6012847|NCT00117312|9605010|FG002|Overall Study|Testosterone >1.0 ng/mL|5
6012848|NCT00117312|9605011|FG003|Overall Study|Testosterone >1.0 ng/mL|9
6075789|NCT00584870|9680560|FG002|Overall Study|Did not met entrance criteria|0
6075790|NCT00584870|9680558|FG000|Overall Study|Other|2
6075791|NCT00584870|9680559|FG001|Overall Study|Other|0
6075792|NCT00584870|9680560|FG002|Overall Study|Other|0
6075793|NCT00584870|9680558|FG000|Overall Study|Randomized but not treated|0
6075794|NCT00584870|9680559|FG001|Overall Study|Randomized but not treated|1
6075795|NCT00584870|9680560|FG002|Overall Study|Randomized but not treated|2
6075796|NCT00584909|9680568|FG000|Overall Study|Adverse Event|4
6075797|NCT00584987|9680589|FG000|Overall Study|Protocol Violation|1
6075798|NCT00584987|9680590|FG001|Overall Study|Protocol Violation|1
6075799|NCT00584987|9680591|FG002|Overall Study|Protocol Violation|1
6012849|NCT00117312|9605008|FG000|Overall Study|Testosterone 0.5 - 1.0 ng/mL|1
6012850|NCT00117312|9605009|FG001|Overall Study|Testosterone 0.5 - 1.0 ng/mL|0
6012851|NCT00117312|9605010|FG002|Overall Study|Testosterone 0.5 - 1.0 ng/mL|3
6012852|NCT00117312|9605011|FG003|Overall Study|Testosterone 0.5 - 1.0 ng/mL|2
6012853|NCT00117312|9605008|FG000|Overall Study|Prostate-specific antigen increase >=25%|0
6012854|NCT00117312|9605009|FG001|Overall Study|Prostate-specific antigen increase >=25%|1
6075800|NCT00584987|9680592|FG003|Overall Study|Protocol Violation|0
6075801|NCT00584987|9680589|FG000|Overall Study|Adverse Event|0
6075802|NCT00584987|9680590|FG001|Overall Study|Adverse Event|0
6012855|NCT00117312|9605010|FG002|Overall Study|Prostate-specific antigen increase >=25%|5
6012856|NCT00117312|9605011|FG003|Overall Study|Prostate-specific antigen increase >=25%|3
6012857|NCT00117312|9605008|FG000|Overall Study|Other|0
6012858|NCT00117312|9605009|FG001|Overall Study|Other|1
6012859|NCT00117312|9605010|FG002|Overall Study|Other|3
6012860|NCT00117312|9605011|FG003|Overall Study|Other|1
6012861|NCT00117312|9605008|FG000|Overall Study|Patient choice|0
6012862|NCT00117312|9605009|FG001|Overall Study|Patient choice|0
6012863|NCT00117312|9605010|FG002|Overall Study|Patient choice|2
6012864|NCT00117312|9605011|FG003|Overall Study|Patient choice|1
6012865|NCT00117312|9605008|FG000|Overall Study|Adverse Event|0
6012866|NCT00117312|9605009|FG001|Overall Study|Adverse Event|2
6012867|NCT00117312|9605010|FG002|Overall Study|Adverse Event|0
6012868|NCT00117312|9605011|FG003|Overall Study|Adverse Event|0
6012869|NCT00117312|9605008|FG000|Overall Study|Protocol Violation|0
6012870|NCT00117312|9605009|FG001|Overall Study|Protocol Violation|1
6012871|NCT00117312|9605010|FG002|Overall Study|Protocol Violation|3
6012872|NCT00117312|9605011|FG003|Overall Study|Protocol Violation|0
6012873|NCT00117312|9605008|FG000|Overall Study|PSA decrease <=50%|0
6012874|NCT00117312|9605009|FG001|Overall Study|PSA decrease <=50%|2
6012875|NCT00117312|9605010|FG002|Overall Study|PSA decrease <=50%|2
6012876|NCT00117312|9605011|FG003|Overall Study|PSA decrease <=50%|4
6012877|NCT00117312|9605008|FG000|Overall Study|PSA increase >= 10ng/mL|0
6012878|NCT00117312|9605009|FG001|Overall Study|PSA increase >= 10ng/mL|1
6012879|NCT00117312|9605010|FG002|Overall Study|PSA increase >= 10ng/mL|1
6012880|NCT00117312|9605011|FG003|Overall Study|PSA increase >= 10ng/mL|0
6012881|NCT00117312|9605008|FG000|Overall Study|Hepatic abnormality|0
6012882|NCT00117312|9605009|FG001|Overall Study|Hepatic abnormality|1
6012883|NCT00117312|9605010|FG002|Overall Study|Hepatic abnormality|0
6012884|NCT00117312|9605011|FG003|Overall Study|Hepatic abnormality|1
6012885|NCT00117312|9605008|FG000|Overall Study|Withdrawal by Subject|0
6012886|NCT00117312|9605009|FG001|Overall Study|Withdrawal by Subject|2
6012887|NCT00117312|9605010|FG002|Overall Study|Withdrawal by Subject|0
6012888|NCT00117312|9605011|FG003|Overall Study|Withdrawal by Subject|0
6012889|NCT00117325|9605023|FG000|Overall Study|Adverse Event|3
6012890|NCT00117325|9605024|FG001|Overall Study|Adverse Event|3
6012891|NCT00117325|9605023|FG000|Overall Study|Lost to Follow-up|1
6012892|NCT00117325|9605024|FG001|Overall Study|Lost to Follow-up|1
6012893|NCT00117325|9605023|FG000|Overall Study|Protocol Violation|2
6012894|NCT00117325|9605024|FG001|Overall Study|Protocol Violation|3
6012895|NCT00117325|9605023|FG000|Overall Study|Withdrawal by Subject|3
6012896|NCT00117325|9605024|FG001|Overall Study|Withdrawal by Subject|2
6012897|NCT00117325|9605023|FG000|Overall Study|Lack of Efficacy|1
6012898|NCT00117325|9605024|FG001|Overall Study|Lack of Efficacy|0
6012899|NCT00117325|9605023|FG000|Overall Study|Use of prohibited medicine|1
6012900|NCT00117325|9605024|FG001|Overall Study|Use of prohibited medicine|2
6012901|NCT00117325|9605023|FG000|Overall Study|Early termination|1
6012902|NCT00117325|9605024|FG001|Overall Study|Early termination|1
6012903|NCT00117325|9605023|FG000|Overall Study|Admisnitrative|1
6012904|NCT00117325|9605024|FG001|Overall Study|Admisnitrative|0
6012905|NCT00117507|9605031|FG000|Overall Study|Adverse Event|4
6012906|NCT00117507|9605031|FG000|Overall Study|Abnormal laboratory values|3
6012907|NCT00117507|9605031|FG000|Overall Study|Unsatisfactory therapeutic effect|1
6012908|NCT00117507|9605031|FG000|Overall Study|Patient withdrew consent|4
6012909|NCT00117507|9605031|FG000|Overall Study|Death|3
6012910|NCT00117572|9605047|FG000|Overall Study|Site withdrew before starting treatment|2
6012911|NCT00117572|9605048|FG001|Overall Study|Site withdrew before starting treatment|3
6012912|NCT00117572|9605047|FG000|Overall Study|Withdrawal by Subject|3
6012913|NCT00117572|9605048|FG001|Overall Study|Withdrawal by Subject|3
6012914|NCT00117572|9605047|FG000|Overall Study|Protocol Violation|1
6012915|NCT00117572|9605048|FG001|Overall Study|Protocol Violation|0
6012916|NCT00117598|9605061|FG000|Prior to Treatment Cross Over|Death|40
6012917|NCT00117598|9605062|FG001|Prior to Treatment Cross Over|Death|41
6012918|NCT00117598|9605063|FG002|Prior to Treatment Cross Over|Death|37
6012919|NCT00117598|9605064|FG003|Prior to Treatment Cross Over|Death|0
6012920|NCT00117598|9605065|FG004|Prior to Treatment Cross Over|Death|0
6012921|NCT00117598|9605061|FG000|Prior to Treatment Cross Over|Lost to Follow-up|0
6012922|NCT00117598|9605062|FG001|Prior to Treatment Cross Over|Lost to Follow-up|2
6012923|NCT00117598|9605063|FG002|Prior to Treatment Cross Over|Lost to Follow-up|2
6012924|NCT00117598|9605064|FG003|Prior to Treatment Cross Over|Lost to Follow-up|0
6309510|NCT02640053|10038185|FG001|Overall Study|Adverse Event|1
6309511|NCT02640053|10038184|FG000|Overall Study|Alternative Therapy|1
6012925|NCT00117598|9605065|FG004|Prior to Treatment Cross Over|Lost to Follow-up|0
6012926|NCT00117598|9605061|FG000|Prior to Treatment Cross Over|Withdrawal by Subject|2
6012927|NCT00117598|9605062|FG001|Prior to Treatment Cross Over|Withdrawal by Subject|1
6012928|NCT00117598|9605063|FG002|Prior to Treatment Cross Over|Withdrawal by Subject|4
6012929|NCT00117598|9605064|FG003|Prior to Treatment Cross Over|Withdrawal by Subject|0
6012930|NCT00117598|9605065|FG004|Prior to Treatment Cross Over|Withdrawal by Subject|0
6012931|NCT00117598|9605061|FG000|Prior to Treatment Cross Over|Other|15
6012932|NCT00117598|9605062|FG001|Prior to Treatment Cross Over|Other|9
6012933|NCT00117598|9605063|FG002|Prior to Treatment Cross Over|Other|9
6012934|NCT00117598|9605064|FG003|Prior to Treatment Cross Over|Other|0
6012935|NCT00117598|9605065|FG004|Prior to Treatment Cross Over|Other|0
6012936|NCT00117598|9605061|FG000|After Treament Cross Over|Death|0
6012937|NCT00117598|9605062|FG001|After Treament Cross Over|Death|0
6012938|NCT00117598|9605063|FG002|After Treament Cross Over|Death|0
6012939|NCT00117598|9605064|FG003|After Treament Cross Over|Death|1
6012940|NCT00117598|9605065|FG004|After Treament Cross Over|Death|2
6012941|NCT00117598|9605061|FG000|After Treament Cross Over|Withdrawal by Subject|0
6012942|NCT00117598|9605062|FG001|After Treament Cross Over|Withdrawal by Subject|0
6012943|NCT00117598|9605063|FG002|After Treament Cross Over|Withdrawal by Subject|0
6012944|NCT00117598|9605064|FG003|After Treament Cross Over|Withdrawal by Subject|1
6012945|NCT00117598|9605065|FG004|After Treament Cross Over|Withdrawal by Subject|0
6012946|NCT00117598|9605061|FG000|After Treament Cross Over|Other|0
6012947|NCT00117598|9605062|FG001|After Treament Cross Over|Other|0
6012948|NCT00117598|9605063|FG002|After Treament Cross Over|Other|0
6012949|NCT00117598|9605064|FG003|After Treament Cross Over|Other|1
6012950|NCT00117598|9605065|FG004|After Treament Cross Over|Other|2
6012951|NCT00117637|9605077|FG000|First Intervention (Period 1)|Adverse Event|11
6012952|NCT00117637|9605078|FG001|First Intervention (Period 1)|Adverse Event|16
6012953|NCT00117637|9605077|FG000|First Intervention (Period 1)|Lost to Follow-up|0
6012954|NCT00117637|9605078|FG001|First Intervention (Period 1)|Lost to Follow-up|2
6012955|NCT00117637|9605077|FG000|First Intervention (Period 1)|Protocol Violation|1
6012956|NCT00117637|9605078|FG001|First Intervention (Period 1)|Protocol Violation|0
6012957|NCT00117637|9605077|FG000|First Intervention (Period 1)|Withdrawal by Subject|2
6012958|NCT00117637|9605078|FG001|First Intervention (Period 1)|Withdrawal by Subject|4
6012959|NCT00117637|9605077|FG000|First Intervention (Period 1)|study terminated by the sponsor|3
6012960|NCT00117637|9605078|FG001|First Intervention (Period 1)|study terminated by the sponsor|1
6012961|NCT00117637|9605077|FG000|First Intervention (Period 1)|protocol driven decision point|1
6012962|NCT00117637|9605078|FG001|First Intervention (Period 1)|protocol driven decision point|0
6012963|NCT00117637|9605077|FG000|First Intervention (Period 1)|investig. decision, not protocol driven|0
6012964|NCT00117637|9605078|FG001|First Intervention (Period 1)|investig. decision, not protocol driven|1
6012965|NCT00117637|9605077|FG000|First Intervention (Period 1)|reason not reported|0
6012966|NCT00117637|9605078|FG001|First Intervention (Period 1)|reason not reported|1
6012967|NCT00117637|9605077|FG000|Second Intervention (Period 2)|Adverse Event|0
6012968|NCT00117637|9605078|FG001|Second Intervention (Period 2)|Adverse Event|9
6012969|NCT00117637|9605077|FG000|Second Intervention (Period 2)|Lost to Follow-up|1
6012970|NCT00117637|9605078|FG001|Second Intervention (Period 2)|Lost to Follow-up|0
6012971|NCT00117637|9605077|FG000|Second Intervention (Period 2)|Protocol Violation|1
6012972|NCT00117637|9605078|FG001|Second Intervention (Period 2)|Protocol Violation|0
6012973|NCT00117637|9605077|FG000|Second Intervention (Period 2)|Withdrawal by Subject|4
6012974|NCT00117637|9605078|FG001|Second Intervention (Period 2)|Withdrawal by Subject|3
6012975|NCT00117637|9605077|FG000|Second Intervention (Period 2)|study terminated by the sponsor|2
6012976|NCT00117637|9605078|FG001|Second Intervention (Period 2)|study terminated by the sponsor|9
6012977|NCT00117637|9605077|FG000|Second Intervention (Period 2)|non compliant with study medication|1
6012978|NCT00117637|9605078|FG001|Second Intervention (Period 2)|non compliant with study medication|1
6012979|NCT00117637|9605077|FG000|Second Intervention (Period 2)|reason not reported|1
6012980|NCT00117637|9605078|FG001|Second Intervention (Period 2)|reason not reported|0
6012981|NCT00117676|9605093|FG000|Double-blind Period Through Week 48|Randomized but Not Treated|4
6012982|NCT00117676|9605094|FG001|Double-blind Period Through Week 48|Randomized but Not Treated|3
6012983|NCT00117676|9605093|FG000|Double-blind Period Through Week 48|Lost to Follow-up|1
6012984|NCT00117676|9605094|FG001|Double-blind Period Through Week 48|Lost to Follow-up|0
6012985|NCT00117676|9605093|FG000|Double-blind Period Through Week 48|Protocol Violation|0
6012986|NCT00117676|9605094|FG001|Double-blind Period Through Week 48|Protocol Violation|1
6012987|NCT00117676|9605093|FG000|Double-blind Period Through Week 48|Safety, Tolerability, or Efficacy Reason|5
6012988|NCT00117676|9605094|FG001|Double-blind Period Through Week 48|Safety, Tolerability, or Efficacy Reason|2
6012989|NCT00117676|9605093|FG000|Double-blind Period Through Week 48|Withdrew Consent|0
6012990|NCT00117676|9605094|FG001|Double-blind Period Through Week 48|Withdrew Consent|1
6012991|NCT00117676|9605093|FG000|Open-label Period: Weeks 49 - 96|Lost to Follow-up|2
6012992|NCT00117676|9605094|FG001|Open-label Period: Weeks 49 - 96|Lost to Follow-up|0
6012993|NCT00117676|9605093|FG000|Open-label Period: Weeks 49 - 96|Safety, Tolerability, or Efficacy Reason|3
6012994|NCT00117676|9605094|FG001|Open-label Period: Weeks 49 - 96|Safety, Tolerability, or Efficacy Reason|1
6012995|NCT00117676|9605093|FG000|Open-label Period: Weeks 49 - 96|Withdrew Consent|5
6012996|NCT00117676|9605094|FG001|Open-label Period: Weeks 49 - 96|Withdrew Consent|1
6012997|NCT00117676|9605093|FG000|Open-label Period: Weeks 97 - 144|Lost to Follow-up|4
6012998|NCT00117676|9605094|FG001|Open-label Period: Weeks 97 - 144|Lost to Follow-up|1
6012999|NCT00117676|9605093|FG000|Open-label Period: Weeks 97 - 144|Safety, Tolerability, or Efficacy Reason|1
6013000|NCT00117676|9605094|FG001|Open-label Period: Weeks 97 - 144|Safety, Tolerability, or Efficacy Reason|0
6013001|NCT00117676|9605093|FG000|Open-label Period: Weeks 97 - 144|Withdrew Consent|1
6013002|NCT00117676|9605094|FG001|Open-label Period: Weeks 97 - 144|Withdrew Consent|0
6013003|NCT00117676|9605093|FG000|Open-label Period: Weeks 145 - 192|Investigator's Discretion|2
6013004|NCT00117676|9605094|FG001|Open-label Period: Weeks 145 - 192|Investigator's Discretion|0
6013005|NCT00117676|9605093|FG000|Open-label Period: Weeks 145 - 192|Lost to Follow-up|3
6013006|NCT00117676|9605094|FG001|Open-label Period: Weeks 145 - 192|Lost to Follow-up|1
6013007|NCT00117676|9605093|FG000|Open-label Period: Weeks 145 - 192|Withdrew Consent|5
6013008|NCT00117676|9605094|FG001|Open-label Period: Weeks 145 - 192|Withdrew Consent|2
6013009|NCT00117676|9605093|FG000|Open-label Period: Weeks 193 - 240|Investigator's Discretion|1
6013010|NCT00117676|9605094|FG001|Open-label Period: Weeks 193 - 240|Investigator's Discretion|1
6013011|NCT00117676|9605093|FG000|Open-label Period: Weeks 193 - 240|Lost to Follow-up|0
6013012|NCT00117676|9605094|FG001|Open-label Period: Weeks 193 - 240|Lost to Follow-up|1
6013013|NCT00117676|9605093|FG000|Open-label Period: Weeks 193 - 240|Safety, Tolerability, or Efficacy Reason|2
6013014|NCT00117676|9605094|FG001|Open-label Period: Weeks 193 - 240|Safety, Tolerability, or Efficacy Reason|0
6013015|NCT00117676|9605093|FG000|Open-label Period: Weeks 193 - 240|Withdrew Consent|4
6013016|NCT00117676|9605094|FG001|Open-label Period: Weeks 193 - 240|Withdrew Consent|1
6013017|NCT00117676|9605093|FG000|Open-label Period: Weeks 241 - 288|Investigator's Discretion|0
6013018|NCT00117676|9605094|FG001|Open-label Period: Weeks 241 - 288|Investigator's Discretion|1
6013019|NCT00117676|9605093|FG000|Open-label Period: Weeks 241 - 288|Lost to Follow-up|2
6013020|NCT00117676|9605094|FG001|Open-label Period: Weeks 241 - 288|Lost to Follow-up|1
6013021|NCT00117676|9605093|FG000|Open-label Period: Weeks 241 - 288|Protocol Violation|2
6013022|NCT00117676|9605094|FG001|Open-label Period: Weeks 241 - 288|Protocol Violation|0
6013023|NCT00117676|9605093|FG000|Open-label Period: Weeks 241 - 288|Safety, Tolerability, or Efficacy Reason|1
6013024|NCT00117676|9605094|FG001|Open-label Period: Weeks 241 - 288|Safety, Tolerability, or Efficacy Reason|0
6013025|NCT00117676|9605093|FG000|Open-label Period: Weeks 241 - 288|Withdrew Consent|5
6013026|NCT00117676|9605094|FG001|Open-label Period: Weeks 241 - 288|Withdrew Consent|1
6013027|NCT00117676|9605093|FG000|Open-label Period: Weeks 289 - 336|Investigator's Discretion|7
6013028|NCT00117676|9605094|FG001|Open-label Period: Weeks 289 - 336|Investigator's Discretion|4
6013029|NCT00117676|9605093|FG000|Open-label Period: Weeks 289 - 336|Lost to Follow-up|2
6013030|NCT00117676|9605094|FG001|Open-label Period: Weeks 289 - 336|Lost to Follow-up|2
6013031|NCT00117676|9605093|FG000|Open-label Period: Weeks 289 - 336|Withdrew Consent|0
6013032|NCT00117676|9605094|FG001|Open-label Period: Weeks 289 - 336|Withdrew Consent|1
6013033|NCT00117676|9605093|FG000|Open-label Period: Weeks 337 - 384|Investigator's Discretion|1
6013034|NCT00117676|9605094|FG001|Open-label Period: Weeks 337 - 384|Investigator's Discretion|1
6013035|NCT00117676|9605093|FG000|Open-label Period: Weeks 337 - 384|Lost to Follow-up|3
6013036|NCT00117676|9605094|FG001|Open-label Period: Weeks 337 - 384|Lost to Follow-up|1
6013037|NCT00117676|9605093|FG000|Open-label Period: Weeks 337 - 384|Study Site Discontinued|1
6013038|NCT00117676|9605094|FG001|Open-label Period: Weeks 337 - 384|Study Site Discontinued|0
6013039|NCT00117676|9605093|FG000|Open-label Period: Weeks 337 - 384|Withdrew Consent|2
6013040|NCT00117676|9605094|FG001|Open-label Period: Weeks 337 - 384|Withdrew Consent|1
6013041|NCT00117676|9605093|FG000|Open-label Period: Weeks 385 - 432|Investigator's Discretion|0
6013042|NCT00117676|9605094|FG001|Open-label Period: Weeks 385 - 432|Investigator's Discretion|1
6013043|NCT00117676|9605093|FG000|Open-label Period: Weeks 385 - 432|Safety, Tolerability, or Efficacy Reason|0
6013044|NCT00117676|9605094|FG001|Open-label Period: Weeks 385 - 432|Safety, Tolerability, or Efficacy Reason|1
6013045|NCT00117676|9605093|FG000|Open-label Period: Weeks 433 - 480|Lost to Follow-up|1
6013046|NCT00117676|9605094|FG001|Open-label Period: Weeks 433 - 480|Lost to Follow-up|0
6013047|NCT00117676|9605093|FG000|Open-label Period: Weeks 433 - 480|Safety, Tolerability, or Efficacy Reason|1
6013048|NCT00117676|9605094|FG001|Open-label Period: Weeks 433 - 480|Safety, Tolerability, or Efficacy Reason|1
6013049|NCT00117676|9605093|FG000|Open-label Period: Weeks 433 - 480|Withdrew Consent|0
6013050|NCT00117676|9605094|FG001|Open-label Period: Weeks 433 - 480|Withdrew Consent|1
6013051|NCT00117793|9605109|FG000|Overall Study|Withdrawal by Subject|12
6013052|NCT00117845|9605126|FG000|Overall Study|stopped treatment/drug supplyinterrupted|1
6013053|NCT00117949|9605134|FG000|Overall Study|Testosterone >1.0 ng/mL|10
6013054|NCT00117949|9605135|FG001|Overall Study|Testosterone >1.0 ng/mL|18
6013055|NCT00117949|9605136|FG002|Overall Study|Testosterone >1.0 ng/mL|17
6013056|NCT00117949|9605137|FG003|Overall Study|Testosterone >1.0 ng/mL|15
6013057|NCT00117949|9605134|FG000|Overall Study|Testosterone 0.5 - 1.0 ng/mL|0
6013058|NCT00117949|9605135|FG001|Overall Study|Testosterone 0.5 - 1.0 ng/mL|1
6013059|NCT00117949|9605136|FG002|Overall Study|Testosterone 0.5 - 1.0 ng/mL|3
6013060|NCT00117949|9605137|FG003|Overall Study|Testosterone 0.5 - 1.0 ng/mL|2
6013061|NCT00117949|9605134|FG000|Overall Study|Prostate-specific antigen increase >=25%|0
6013062|NCT00117949|9605135|FG001|Overall Study|Prostate-specific antigen increase >=25%|1
6013063|NCT00117949|9605136|FG002|Overall Study|Prostate-specific antigen increase >=25%|1
6013064|NCT00117949|9605137|FG003|Overall Study|Prostate-specific antigen increase >=25%|2
6013065|NCT00117949|9605134|FG000|Overall Study|PSA increase >=10ng/mL|0
6013066|NCT00117949|9605135|FG001|Overall Study|PSA increase >=10ng/mL|1
6013067|NCT00117949|9605136|FG002|Overall Study|PSA increase >=10ng/mL|1
6013068|NCT00117949|9605137|FG003|Overall Study|PSA increase >=10ng/mL|0
6013069|NCT00117949|9605134|FG000|Overall Study|PSA reduction <=50%|0
6013070|NCT00117949|9605135|FG001|Overall Study|PSA reduction <=50%|2
6013071|NCT00117949|9605136|FG002|Overall Study|PSA reduction <=50%|2
6013072|NCT00117949|9605137|FG003|Overall Study|PSA reduction <=50%|4
6013073|NCT00117949|9605134|FG000|Overall Study|Hepatic abnormalities|0
6013074|NCT00117949|9605135|FG001|Overall Study|Hepatic abnormalities|1
6013075|NCT00117949|9605136|FG002|Overall Study|Hepatic abnormalities|0
6013076|NCT00117949|9605137|FG003|Overall Study|Hepatic abnormalities|1
6075803|NCT00584987|9680591|FG002|Overall Study|Adverse Event|0
6075804|NCT00584987|9680592|FG003|Overall Study|Adverse Event|1
6075805|NCT00585039|9680615|FG000|Overall Study|medication spilled|2
6075806|NCT00585039|9680616|FG001|Overall Study|medication spilled|0
6075807|NCT00585052|9680624|FG000|Overall Study|Withdrawal by Subject|1
6075808|NCT00585078|9680628|FG000|Overall Study|Withdrawal by Subject|4
6075809|NCT00585078|9680628|FG000|Overall Study|Poor performance status|1
6075810|NCT00585078|9680628|FG000|Overall Study|Disease Progression|24
6075811|NCT00585078|9680628|FG000|Overall Study|Adverse Event|10
6075812|NCT00585078|9680628|FG000|Overall Study|Death|1
6075813|NCT00585169|9680636|FG000|Overall Study|Withdrawal by Subject|1
6087384|NCT00667576|9697584|FG003|Overall Study|Protocol Violation|1
6087385|NCT00667576|9697585|FG004|Overall Study|Protocol Violation|0
6087386|NCT00667576|9697581|FG000|Overall Study|Physician Decision|0
6087387|NCT00667576|9697582|FG001|Overall Study|Physician Decision|0
6087388|NCT00667576|9697583|FG002|Overall Study|Physician Decision|0
6087389|NCT00667576|9697584|FG003|Overall Study|Physician Decision|1
6087390|NCT00667576|9697585|FG004|Overall Study|Physician Decision|0
6087391|NCT00667576|9697581|FG000|Overall Study|Missed Visit|0
6087392|NCT00667576|9697582|FG001|Overall Study|Missed Visit|0
6087393|NCT00667576|9697583|FG002|Overall Study|Missed Visit|0
6087394|NCT00667576|9697584|FG003|Overall Study|Missed Visit|1
6087395|NCT00667576|9697585|FG004|Overall Study|Missed Visit|0
6087396|NCT00667602|9697617|FG000|Overall Study|Withdrawal by Subject|4
6087397|NCT00667602|9697618|FG001|Overall Study|Withdrawal by Subject|9
6087398|NCT00667602|9697619|FG002|Overall Study|Withdrawal by Subject|10
6087399|NCT00667602|9697617|FG000|Overall Study|Lost to Follow-up|4
6013077|NCT00117988|9605156|FG000|Overall Study|Death|3
6013078|NCT00117988|9605156|FG000|Overall Study|Adverse Event|1
6013079|NCT00118040|9605163|FG000|Overall Study|Adverse Event|0
6013080|NCT00118040|9605164|FG001|Overall Study|Adverse Event|1
6013081|NCT00118040|9605165|FG002|Overall Study|Adverse Event|0
6013082|NCT00118040|9605163|FG000|Overall Study|Withdrawal by Subject|0
6013083|NCT00118040|9605164|FG001|Overall Study|Withdrawal by Subject|0
6013084|NCT00118040|9605165|FG002|Overall Study|Withdrawal by Subject|2
6013085|NCT00118040|9605163|FG000|Overall Study|Medical Contraindication|0
6013086|NCT00118040|9605164|FG001|Overall Study|Medical Contraindication|0
6013087|NCT00118040|9605165|FG002|Overall Study|Medical Contraindication|1
6013088|NCT00118040|9605163|FG000|Overall Study|Non-Compliant Participant|1
6013089|NCT00118040|9605164|FG001|Overall Study|Non-Compliant Participant|1
6013090|NCT00118040|9605165|FG002|Overall Study|Non-Compliant Participant|2
6013091|NCT00118040|9605163|FG000|Overall Study|Other|0
6013092|NCT00118040|9605164|FG001|Overall Study|Other|0
6013093|NCT00118040|9605165|FG002|Overall Study|Other|1
6013094|NCT00118092|9605178|FG000|Overall Study|Withdrawal by Subject|1
6013095|NCT00118092|9605178|FG000|Overall Study|Protocol Violation|1
6013096|NCT00118157|9605192|FG000|Overall Study|Adverse Event|2
6013097|NCT00118157|9605192|FG000|Overall Study|Death|8
6013098|NCT00118157|9605192|FG000|Overall Study|Withdrawal by Subject|2
6013099|NCT00118287|9605231|FG000|Overall Study|Intracranial haemorrhage|1
6013100|NCT00118287|9605231|FG000|Overall Study|Muscle pain|1
6013101|NCT00118417|9605311|FG000|Phase I (Weeks 0 to 6)|Remission|8
6013102|NCT00118417|9605312|FG001|Phase I (Weeks 0 to 6)|Remission|0
6013103|NCT00118417|9605311|FG000|Phase I (Weeks 0 to 6)|Lost to Follow-up|6
6013104|NCT00118417|9605312|FG001|Phase I (Weeks 0 to 6)|Lost to Follow-up|0
6013105|NCT00118417|9605311|FG000|Phase I (Weeks 0 to 6)|Loss of Eligibility for Phase 2|4
6013106|NCT00118417|9605312|FG001|Phase I (Weeks 0 to 6)|Loss of Eligibility for Phase 2|0
6013107|NCT00118417|9605311|FG000|Phase II (Weeks 6 to 12)|Withdrawal by Subject|1
6013108|NCT00118417|9605312|FG001|Phase II (Weeks 6 to 12)|Withdrawal by Subject|1
6013109|NCT00118417|9605311|FG000|Phase II (Weeks 6 to 12)|Remission|1
6013110|NCT00118417|9605312|FG001|Phase II (Weeks 6 to 12)|Remission|2
6087400|NCT00667602|9697618|FG001|Overall Study|Lost to Follow-up|5
6087401|NCT00667602|9697619|FG002|Overall Study|Lost to Follow-up|6
6087402|NCT00667602|9697617|FG000|Overall Study|Administrative reason|0
6087403|NCT00667602|9697618|FG001|Overall Study|Administrative reason|0
6087404|NCT00667602|9697619|FG002|Overall Study|Administrative reason|2
6087405|NCT00667602|9697617|FG000|Overall Study|Protocol Violation|0
6087406|NCT00667602|9697618|FG001|Overall Study|Protocol Violation|1
6013111|NCT00118430|9605325|FG000|Overall Study|Withdrawal by Subject|6
6013112|NCT00118430|9605326|FG001|Overall Study|Withdrawal by Subject|2
6013113|NCT00118430|9605327|FG002|Overall Study|Withdrawal by Subject|0
6013114|NCT00118430|9605325|FG000|Overall Study|Lost to Follow-up|15
6087407|NCT00667602|9697619|FG002|Overall Study|Protocol Violation|0
6087408|NCT00667719|9697645|FG000|Overall Study|Adverse Event|39
6013115|NCT00118430|9605326|FG001|Overall Study|Lost to Follow-up|22
6013116|NCT00118430|9605327|FG002|Overall Study|Lost to Follow-up|28
6087409|NCT00667719|9697645|FG000|Overall Study|Abnormal Test Procedure|1
6087410|NCT00667719|9697645|FG000|Overall Study|Unsatisfactory Therapeutic Effect|3
6087411|NCT00667719|9697645|FG000|Overall Study|Protocol Violation|3
6087412|NCT00667719|9697645|FG000|Overall Study|Withdrawal by Subject|17
6087413|NCT00667719|9697645|FG000|Overall Study|Lost to Follow-up|8
6087414|NCT00667732|9697656|FG000|Run -In (8 Weeks)|Adverse Event|4
6087415|NCT00667732|9697657|FG001|Run -In (8 Weeks)|Adverse Event|0
6087416|NCT00667732|9697658|FG002|Run -In (8 Weeks)|Adverse Event|0
6087417|NCT00667732|9697656|FG000|Run -In (8 Weeks)|Withdrawal by Subject|3
6013117|NCT00118482|9605336|FG000|Overall Study|Lost to Follow-up|7
6013118|NCT00118482|9605337|FG001|Overall Study|Lost to Follow-up|7
6013119|NCT00118482|9605336|FG000|Overall Study|Withdrawal by Subject|23
6013120|NCT00118482|9605337|FG001|Overall Study|Withdrawal by Subject|22
6013121|NCT00118703|9605355|FG000|Overall Study|Protocol Violation|1
6013122|NCT00118703|9605356|FG001|Overall Study|Protocol Violation|0
6013123|NCT00118703|9605355|FG000|Overall Study|Adverse Event|1
6013124|NCT00118703|9605356|FG001|Overall Study|Adverse Event|1
6013125|NCT00118703|9605355|FG000|Overall Study|Participant took two different treatment|0
6013126|NCT00118703|9605356|FG001|Overall Study|Participant took two different treatment|1
6013127|NCT00118703|9605355|FG000|Overall Study|Withdrawal by Subject|2
6013128|NCT00118703|9605356|FG001|Overall Study|Withdrawal by Subject|5
6013129|NCT00118703|9605355|FG000|Overall Study|Lost to Follow-up|1
6013130|NCT00118703|9605356|FG001|Overall Study|Lost to Follow-up|2
6013131|NCT00118716|9605364|FG000|Overall Study|Adverse Event|2
6013132|NCT00118716|9605365|FG001|Overall Study|Adverse Event|7
6013133|NCT00118716|9605364|FG000|Overall Study|Protocol Violation|5
6013134|NCT00118716|9605365|FG001|Overall Study|Protocol Violation|4
6013135|NCT00118716|9605364|FG000|Overall Study|Withdrawal by Subject|0
6013136|NCT00118716|9605365|FG001|Overall Study|Withdrawal by Subject|1
6075814|NCT00585286|9680655|FG000|Overall Study|Lost to Follow-up|1
6075815|NCT00585312|9680661|FG000|Overall Study|Adverse Event|3
6075816|NCT00585312|9680662|FG001|Overall Study|Adverse Event|0
6075817|NCT00585312|9680661|FG000|Overall Study|Lack of Efficacy|6
6075818|NCT00585312|9680662|FG001|Overall Study|Lack of Efficacy|11
6075819|NCT00585312|9680661|FG000|Overall Study|Lost to Follow-up|1
6075820|NCT00585312|9680662|FG001|Overall Study|Lost to Follow-up|1
6075821|NCT00585312|9680661|FG000|Overall Study|Reason not specified|2
6075822|NCT00585312|9680662|FG001|Overall Study|Reason not specified|0
6075823|NCT00585312|9680661|FG000|Overall Study|Withdrawal by Subject|5
6075824|NCT00585312|9680662|FG001|Overall Study|Withdrawal by Subject|1
6013137|NCT00118716|9605364|FG000|Overall Study|Exacerbation|2
6013138|NCT00118716|9605365|FG001|Overall Study|Exacerbation|2
6013139|NCT00118716|9605364|FG000|Overall Study|Discontinued by sponsor|1
6013140|NCT00118716|9605365|FG001|Overall Study|Discontinued by sponsor|1
6013141|NCT00118716|9605364|FG000|Overall Study|Non-compliance|1
6013142|NCT00118716|9605365|FG001|Overall Study|Non-compliance|3
6075825|NCT00585312|9680661|FG000|Overall Study|Study terminated by the sponsor|34
6075826|NCT00585312|9680662|FG001|Overall Study|Study terminated by the sponsor|31
6075827|NCT00585325|9680670|FG000|Overall Study|Withdrawal by Subject|1
6075828|NCT00585325|9680671|FG001|Overall Study|Withdrawal by Subject|1
6075829|NCT00585351|9680683|FG000|Notification Period (Informed Consent)|Physician Decision|0
6075830|NCT00585351|9680684|FG001|Notification Period (Informed Consent)|Physician Decision|2
6075831|NCT00585351|9680685|FG002|Notification Period (Informed Consent)|Physician Decision|0
6075832|NCT00585351|9680686|FG003|Notification Period (Informed Consent)|Physician Decision|0
6075833|NCT00585351|9680687|FG004|Notification Period (Informed Consent)|Physician Decision|0
6075834|NCT00585351|9680688|FG005|Notification Period (Informed Consent)|Physician Decision|0
6075835|NCT00585351|9680689|FG006|Notification Period (Informed Consent)|Physician Decision|0
6075836|NCT00585351|9680690|FG007|Notification Period (Informed Consent)|Physician Decision|0
6075837|NCT00585351|9680683|FG000|Notification Period (Informed Consent)|Flight aborted|2
6075838|NCT00585351|9680684|FG001|Notification Period (Informed Consent)|Flight aborted|1
6075839|NCT00585351|9680685|FG002|Notification Period (Informed Consent)|Flight aborted|0
6075840|NCT00585351|9680686|FG003|Notification Period (Informed Consent)|Flight aborted|0
6075841|NCT00585351|9680687|FG004|Notification Period (Informed Consent)|Flight aborted|0
6075842|NCT00585351|9680688|FG005|Notification Period (Informed Consent)|Flight aborted|0
6075843|NCT00585351|9680689|FG006|Notification Period (Informed Consent)|Flight aborted|0
6075844|NCT00585351|9680690|FG007|Notification Period (Informed Consent)|Flight aborted|0
6075845|NCT00585351|9680683|FG000|Notification Period (Informed Consent)|No study medication on flight|0
6075846|NCT00585351|9680684|FG001|Notification Period (Informed Consent)|No study medication on flight|1
6075847|NCT00585351|9680685|FG002|Notification Period (Informed Consent)|No study medication on flight|0
6075848|NCT00585351|9680686|FG003|Notification Period (Informed Consent)|No study medication on flight|0
6075849|NCT00585351|9680687|FG004|Notification Period (Informed Consent)|No study medication on flight|0
6075850|NCT00585351|9680688|FG005|Notification Period (Informed Consent)|No study medication on flight|0
6075851|NCT00585351|9680689|FG006|Notification Period (Informed Consent)|No study medication on flight|0
6075852|NCT00585351|9680690|FG007|Notification Period (Informed Consent)|No study medication on flight|0
6075853|NCT00585351|9680683|FG000|Notification Period (Informed Consent)|Subject refused consent for AIRDOC|21
6075854|NCT00585351|9680684|FG001|Notification Period (Informed Consent)|Subject refused consent for AIRDOC|21
6075855|NCT00585351|9680685|FG002|Notification Period (Informed Consent)|Subject refused consent for AIRDOC|0
6075856|NCT00585351|9680686|FG003|Notification Period (Informed Consent)|Subject refused consent for AIRDOC|0
6075857|NCT00585351|9680687|FG004|Notification Period (Informed Consent)|Subject refused consent for AIRDOC|0
6075858|NCT00585351|9680688|FG005|Notification Period (Informed Consent)|Subject refused consent for AIRDOC|0
6075859|NCT00585351|9680689|FG006|Notification Period (Informed Consent)|Subject refused consent for AIRDOC|0
6013143|NCT00118716|9605364|FG000|Overall Study|misrandomized|1
6013144|NCT00118716|9605365|FG001|Overall Study|misrandomized|1
6013145|NCT00118716|9605364|FG000|Overall Study|Expired drug use|1
6013146|NCT00118716|9605365|FG001|Overall Study|Expired drug use|2
6013147|NCT00118716|9605364|FG000|Overall Study|Investigator discretion|0
6013148|NCT00118716|9605365|FG001|Overall Study|Investigator discretion|1
6047543|NCT00412607|9646633|FG000|Overall Study|Lost to Follow-up|19
6047544|NCT00412607|9646633|FG000|Overall Study|Death|61
6047545|NCT00412607|9646633|FG000|Overall Study|Not meet inclusion/exclusion Criteria|15
6047546|NCT00412737|9646642|FG000|Overall Study|Death|1
6047547|NCT00412737|9646643|FG001|Overall Study|Death|0
6047548|NCT00412737|9646642|FG000|Overall Study|Adverse Event|3
6047549|NCT00412737|9646643|FG001|Overall Study|Adverse Event|2
6047550|NCT00412737|9646642|FG000|Overall Study|Refused Treatment|6
6047551|NCT00412737|9646643|FG001|Overall Study|Refused Treatment|2
6047552|NCT00412737|9646642|FG000|Overall Study|Failure to Return|6
6047553|NCT00412737|9646643|FG001|Overall Study|Failure to Return|2
6047554|NCT00412750|9646652|FG000|Overall Study|Abnormal laboratory value(s)|1
6047555|NCT00412750|9646653|FG001|Overall Study|Abnormal laboratory value(s)|0
6047556|NCT00412750|9646654|FG002|Overall Study|Abnormal laboratory value(s)|0
6047557|NCT00412750|9646652|FG000|Overall Study|Administrative problems|21
6047558|NCT00412750|9646653|FG001|Overall Study|Administrative problems|17
6047559|NCT00412750|9646654|FG002|Overall Study|Administrative problems|14
6047560|NCT00412750|9646652|FG000|Overall Study|Adverse Event|8
6047561|NCT00412750|9646653|FG001|Overall Study|Adverse Event|3
6047562|NCT00412750|9646654|FG002|Overall Study|Adverse Event|3
6047563|NCT00412750|9646652|FG000|Overall Study|Lost to Follow-up|1
6047564|NCT00412750|9646653|FG001|Overall Study|Lost to Follow-up|0
6047565|NCT00412750|9646654|FG002|Overall Study|Lost to Follow-up|1
6047566|NCT00412750|9646652|FG000|Overall Study|Withdrawal by Subject|0
6047567|NCT00412750|9646653|FG001|Overall Study|Withdrawal by Subject|1
6047568|NCT00412750|9646654|FG002|Overall Study|Withdrawal by Subject|2
6047569|NCT00412750|9646652|FG000|Overall Study|Lack of Efficacy|0
6047570|NCT00412750|9646653|FG001|Overall Study|Lack of Efficacy|0
6047571|NCT00412750|9646654|FG002|Overall Study|Lack of Efficacy|3
6047572|NCT00412854|9646676|FG000|Overall Study|Withdrawn due to adverse events|1
6047573|NCT00412854|9646677|FG001|Overall Study|Withdrawn due to adverse events|5
6047574|NCT00412854|9646676|FG000|Overall Study|Withdrawn for other reasons|13
6047575|NCT00412854|9646677|FG001|Overall Study|Withdrawn for other reasons|11
6047576|NCT00412893|9646690|FG000|Overall Study|Adverse Event|31
6047577|NCT00412893|9646691|FG001|Overall Study|Adverse Event|53
6047578|NCT00412893|9646690|FG000|Overall Study|Death|17
6047579|NCT00412893|9646691|FG001|Overall Study|Death|21
6047580|NCT00412893|9646690|FG000|Overall Study|Insufficient Therapeutic Response|39
6047581|NCT00412893|9646691|FG001|Overall Study|Insufficient Therapeutic Response|23
6047582|NCT00412893|9646690|FG000|Overall Study|Lost to Follow-up|2
6047583|NCT00412893|9646691|FG001|Overall Study|Lost to Follow-up|1
6047584|NCT00412893|9646690|FG000|Overall Study|Violation of Selection at Entry|17
6047585|NCT00412893|9646691|FG001|Overall Study|Violation of Selection at Entry|10
6047586|NCT00412893|9646690|FG000|Overall Study|Other Protocol Violation|10
6047587|NCT00412893|9646691|FG001|Overall Study|Other Protocol Violation|6
6047588|NCT00412893|9646690|FG000|Overall Study|Did Not Cooperate|12
6047589|NCT00412893|9646691|FG001|Overall Study|Did Not Cooperate|9
6047590|NCT00412893|9646690|FG000|Overall Study|Administrative Reason|12
6047591|NCT00412893|9646691|FG001|Overall Study|Administrative Reason|15
6047592|NCT00412893|9646690|FG000|Overall Study|Randomized but Never Received Study Drug|5
6047593|NCT00412893|9646691|FG001|Overall Study|Randomized but Never Received Study Drug|6
6047594|NCT00412958|9646701|FG000|Overall Study|Withdrawal by Subject|3
6047595|NCT00412958|9646702|FG001|Overall Study|Withdrawal by Subject|0
6047596|NCT00412958|9646703|FG002|Overall Study|Withdrawal by Subject|0
6047597|NCT00412958|9646704|FG003|Overall Study|Withdrawal by Subject|1
6047598|NCT00412958|9646701|FG000|Overall Study|Adverse Event|0
6047599|NCT00412958|9646702|FG001|Overall Study|Adverse Event|1
6047600|NCT00412958|9646703|FG002|Overall Study|Adverse Event|0
6047601|NCT00412958|9646704|FG003|Overall Study|Adverse Event|0
6047602|NCT00412958|9646701|FG000|Overall Study|Lost to Follow-up|0
6047603|NCT00412958|9646702|FG001|Overall Study|Lost to Follow-up|1
6047604|NCT00412958|9646703|FG002|Overall Study|Lost to Follow-up|0
6047605|NCT00412958|9646704|FG003|Overall Study|Lost to Follow-up|0
6047606|NCT00412958|9646701|FG000|Overall Study|Death|0
6047607|NCT00412958|9646702|FG001|Overall Study|Death|1
6047608|NCT00412958|9646703|FG002|Overall Study|Death|0
6047609|NCT00412958|9646704|FG003|Overall Study|Death|0
6047610|NCT00412958|9646701|FG000|Overall Study|Transport issue|0
6047611|NCT00412958|9646702|FG001|Overall Study|Transport issue|1
6047612|NCT00412958|9646703|FG002|Overall Study|Transport issue|0
6047613|NCT00412958|9646704|FG003|Overall Study|Transport issue|0
6047614|NCT00412971|9646716|FG000|Overall Study|Lost to Follow-up|17
6047615|NCT00412971|9646717|FG001|Overall Study|Lost to Follow-up|9
6047616|NCT00412971|9646716|FG000|Overall Study|Protocol Violation|13
6047617|NCT00412971|9646717|FG001|Overall Study|Protocol Violation|1
6047618|NCT00412984|9646725|FG000|Overall Study|Death|331
6047619|NCT00412984|9646726|FG001|Overall Study|Death|349
6047620|NCT00412984|9646725|FG000|Overall Study|Adverse Event|679
6047621|NCT00412984|9646726|FG001|Overall Study|Adverse Event|738
6047622|NCT00412984|9646725|FG000|Overall Study|Withdrawal by Subject|921
6047623|NCT00412984|9646726|FG001|Overall Study|Withdrawal by Subject|989
6047624|NCT00412984|9646725|FG000|Overall Study|Lost to Follow-up|51
6013149|NCT00118898|9605393|FG000|Overall Study|Death|6
6013150|NCT00118898|9605394|FG001|Overall Study|Death|11
6013151|NCT00118898|9605395|FG002|Overall Study|Death|6
6013152|NCT00118898|9605396|FG003|Overall Study|Death|8
6013153|NCT00118898|9605393|FG000|Overall Study|Lost to Follow-up|26
6013154|NCT00118898|9605394|FG001|Overall Study|Lost to Follow-up|34
6013155|NCT00118898|9605395|FG002|Overall Study|Lost to Follow-up|33
6013156|NCT00118898|9605396|FG003|Overall Study|Lost to Follow-up|33
6013157|NCT00118898|9605393|FG000|Overall Study|Withdrawal by Subject|10
6013158|NCT00118898|9605394|FG001|Overall Study|Withdrawal by Subject|5
6013159|NCT00118898|9605395|FG002|Overall Study|Withdrawal by Subject|8
6013160|NCT00118898|9605396|FG003|Overall Study|Withdrawal by Subject|8
6013161|NCT00118898|9605393|FG000|Overall Study|Site Closure|33
6013162|NCT00118898|9605394|FG001|Overall Study|Site Closure|31
6013163|NCT00118898|9605395|FG002|Overall Study|Site Closure|28
6013164|NCT00118898|9605396|FG003|Overall Study|Site Closure|37
6013165|NCT00118898|9605393|FG000|Overall Study|Severe debilitation|1
6013166|NCT00118898|9605394|FG001|Overall Study|Severe debilitation|4
6013167|NCT00118898|9605395|FG002|Overall Study|Severe debilitation|6
6013168|NCT00118898|9605396|FG003|Overall Study|Severe debilitation|4
6013169|NCT00118898|9605393|FG000|Overall Study|Not compliant with requirements|11
6013170|NCT00118898|9605394|FG001|Overall Study|Not compliant with requirements|13
6013171|NCT00118898|9605395|FG002|Overall Study|Not compliant with requirements|11
6013172|NCT00118898|9605396|FG003|Overall Study|Not compliant with requirements|11
6013173|NCT00118898|9605393|FG000|Overall Study|Not able to get to clinic|34
6013174|NCT00118898|9605394|FG001|Overall Study|Not able to get to clinic|43
6013175|NCT00118898|9605395|FG002|Overall Study|Not able to get to clinic|31
6013176|NCT00118898|9605396|FG003|Overall Study|Not able to get to clinic|40
6013177|NCT00118911|9605408|FG000|Overall Study|Withdrawal by Subject|2
6013178|NCT00118911|9605409|FG001|Overall Study|Withdrawal by Subject|5
6013179|NCT00119015|9605417|FG000|Open-Label Phase (2 Weeks)|Did not have residual symptoms|48
6013180|NCT00119015|9605418|FG001|Open-Label Phase (2 Weeks)|Did not have residual symptoms|0
6013181|NCT00119015|9605419|FG002|Open-Label Phase (2 Weeks)|Did not have residual symptoms|0
6013182|NCT00119106|9605441|FG000|Overall Study|HIV infected at baseline|179
6013183|NCT00119106|9605442|FG001|Overall Study|HIV infected at baseline|178
6013184|NCT00119262|9605467|FG000|Overall Study|Lack of Efficacy|0
6013185|NCT00119262|9605468|FG001|Overall Study|Lack of Efficacy|3
6013186|NCT00119262|9605467|FG000|Overall Study|Withdrawal by Subject|12
6013187|NCT00119262|9605468|FG001|Overall Study|Withdrawal by Subject|11
6013188|NCT00119262|9605467|FG000|Overall Study|Adverse Event|33
6013189|NCT00119262|9605468|FG001|Overall Study|Adverse Event|35
6013190|NCT00119262|9605467|FG000|Overall Study|other disease|0
6013191|NCT00119262|9605468|FG001|Overall Study|other disease|2
6013192|NCT00119262|9605467|FG000|Overall Study|ineligble|1
6013193|NCT00119262|9605468|FG001|Overall Study|ineligble|2
6013194|NCT00119262|9605467|FG000|Overall Study|others|0
6013195|NCT00119262|9605468|FG001|Overall Study|others|5
6013196|NCT00119379|9605476|FG000|Overall Study|Adverse Event|4
6013197|NCT00119379|9605477|FG001|Overall Study|Adverse Event|1
6013198|NCT00119405|9605487|FG000|Overall Study|Withdrawal by Subject|1
6013199|NCT00119678|9605493|FG000|Double-blind Treatment Period|Death|1
6013200|NCT00119678|9605494|FG001|Double-blind Treatment Period|Death|0
6013201|NCT00119678|9605493|FG000|Double-blind Treatment Period|Adverse Event|7
6013202|NCT00119678|9605494|FG001|Double-blind Treatment Period|Adverse Event|1
6013203|NCT00119678|9605493|FG000|Double-blind Treatment Period|Lack of Efficacy|21
6013204|NCT00119678|9605494|FG001|Double-blind Treatment Period|Lack of Efficacy|12
6013205|NCT00119678|9605493|FG000|Double-blind Treatment Period|Lost to Follow-up|1
6013206|NCT00119678|9605494|FG001|Double-blind Treatment Period|Lost to Follow-up|2
6013207|NCT00119678|9605493|FG000|Double-blind Treatment Period|Participant withdrew consent|4
6013208|NCT00119678|9605494|FG001|Double-blind Treatment Period|Participant withdrew consent|4
6013209|NCT00119678|9605493|FG000|Double-blind Treatment Period|Participants not meeting study criteria|0
6013210|NCT00119678|9605494|FG001|Double-blind Treatment Period|Participants not meeting study criteria|1
6013211|NCT00119678|9605493|FG000|Double-blind Treatment Period|Poor/Non-compliance|3
6013212|NCT00119678|9605494|FG001|Double-blind Treatment Period|Poor/Non-compliance|0
6013213|NCT00119678|9605493|FG000|Double-blind Treatment Period|Pregnancy|0
6013214|NCT00119678|9605494|FG001|Double-blind Treatment Period|Pregnancy|2
6013215|NCT00119678|9605493|FG000|Double-blind Treatment Period|Not treated|1
6013216|NCT00119678|9605494|FG001|Double-blind Treatment Period|Not treated|2
6075860|NCT00585351|9680690|FG007|Notification Period (Informed Consent)|Subject refused consent for AIRDOC|0
6075861|NCT00585351|9680683|FG000|Enrollment Period (Intervention)|Lost to Follow-up|0
6013217|NCT00119678|9605493|FG000|Double-blind Treatment Period|Site closed due to non-compliance|3
6013218|NCT00119678|9605494|FG001|Double-blind Treatment Period|Site closed due to non-compliance|2
6013219|NCT00119678|9605493|FG000|Open-label Treatment Period|Death|1
6013220|NCT00119678|9605494|FG001|Open-label Treatment Period|Death|0
6013221|NCT00119678|9605493|FG000|Open-label Treatment Period|Adverse Event|3
6013222|NCT00119678|9605494|FG001|Open-label Treatment Period|Adverse Event|0
6013223|NCT00119678|9605493|FG000|Open-label Treatment Period|Lack of Efficacy|9
6013224|NCT00119678|9605494|FG001|Open-label Treatment Period|Lack of Efficacy|0
6013225|NCT00119678|9605493|FG000|Open-label Treatment Period|Lost to Follow-up|3
6013226|NCT00119678|9605494|FG001|Open-label Treatment Period|Lost to Follow-up|0
6013227|NCT00119678|9605493|FG000|Open-label Treatment Period|Participant withdrew consent|4
6013228|NCT00119678|9605494|FG001|Open-label Treatment Period|Participant withdrew consent|0
6013229|NCT00119678|9605493|FG000|Open-label Treatment Period|Participants not meeting study criteria|2
6013230|NCT00119678|9605494|FG001|Open-label Treatment Period|Participants not meeting study criteria|0
6013231|NCT00119678|9605493|FG000|Open-label Treatment Period|Pregnancy|1
6013232|NCT00119678|9605494|FG001|Open-label Treatment Period|Pregnancy|0
6013233|NCT00119678|9605493|FG000|Open-label Treatment Period|Administrative reasons by sponsor|87
6013234|NCT00119678|9605494|FG001|Open-label Treatment Period|Administrative reasons by sponsor|0
6013235|NCT00120250|9605502|FG000|Overall Study|Lost to Follow-up|1
6013236|NCT00120250|9605503|FG001|Overall Study|Lost to Follow-up|1
6013237|NCT00120250|9605502|FG000|Overall Study|Protocol Violation|0
6013238|NCT00120250|9605503|FG001|Overall Study|Protocol Violation|1
6013239|NCT00120289|9605512|FG000|Overall Study|Death|96
6013240|NCT00120289|9605513|FG001|Overall Study|Death|82
6013241|NCT00120289|9605512|FG000|Overall Study|Lost to Follow-up|11
6013242|NCT00120289|9605513|FG001|Overall Study|Lost to Follow-up|14
6013243|NCT00120289|9605512|FG000|Overall Study|Withdrawal by Subject|14
6013244|NCT00120289|9605513|FG001|Overall Study|Withdrawal by Subject|13
6013245|NCT00120406|9605521|FG000|Overall Study|Death|9
6013246|NCT00120406|9605522|FG001|Overall Study|Death|4
6013247|NCT00120406|9605521|FG000|Overall Study|Withdrawal by Subject|5
6013248|NCT00120406|9605522|FG001|Overall Study|Withdrawal by Subject|7
6013249|NCT00120406|9605521|FG000|Overall Study|Lost to Follow-up|5
6013250|NCT00120406|9605522|FG001|Overall Study|Lost to Follow-up|2
6013251|NCT00120406|9605521|FG000|Overall Study|received non-study stent|0
6013252|NCT00120406|9605522|FG001|Overall Study|received non-study stent|2
6013253|NCT00120406|9605521|FG000|Overall Study|patient moved but has not withdrawn|0
6013254|NCT00120406|9605522|FG001|Overall Study|patient moved but has not withdrawn|1
6013255|NCT00120627|9605540|FG000|Overall Study|Withdrawal by Subject|5
6013256|NCT00120627|9605541|FG001|Overall Study|Withdrawal by Subject|5
6013257|NCT00120874|9605558|FG000|Overall Study|Death|0
6013258|NCT00120874|9605559|FG001|Overall Study|Death|1
6013259|NCT00121134|9605569|FG000|Overall Study|Progression of Disease|5
6013260|NCT00121134|9605570|FG001|Overall Study|Progression of Disease|3
6013261|NCT00121134|9605571|FG002|Overall Study|Progression of Disease|4
6013262|NCT00121134|9605572|FG003|Overall Study|Progression of Disease|2
6013263|NCT00121134|9605569|FG000|Overall Study|Toxicity|4
6013264|NCT00121134|9605570|FG001|Overall Study|Toxicity|7
6013265|NCT00121134|9605571|FG002|Overall Study|Toxicity|13
6013266|NCT00121134|9605572|FG003|Overall Study|Toxicity|5
6013267|NCT00121134|9605569|FG000|Overall Study|Physician Decision|6
6013268|NCT00121134|9605570|FG001|Overall Study|Physician Decision|4
6013269|NCT00121134|9605571|FG002|Overall Study|Physician Decision|4
6013270|NCT00121134|9605572|FG003|Overall Study|Physician Decision|1
6013271|NCT00121134|9605569|FG000|Overall Study|Treatment Delay|1
6013272|NCT00121134|9605570|FG001|Overall Study|Treatment Delay|0
6013273|NCT00121134|9605571|FG002|Overall Study|Treatment Delay|0
6013274|NCT00121134|9605572|FG003|Overall Study|Treatment Delay|0
6013275|NCT00121134|9605569|FG000|Overall Study|Intercurrent Illness|0
6013276|NCT00121134|9605570|FG001|Overall Study|Intercurrent Illness|0
6013277|NCT00121134|9605571|FG002|Overall Study|Intercurrent Illness|0
6013278|NCT00121134|9605572|FG003|Overall Study|Intercurrent Illness|1
6013279|NCT00121134|9605569|FG000|Overall Study|Patient Personal Reasons|0
6013280|NCT00121134|9605570|FG001|Overall Study|Patient Personal Reasons|1
6013281|NCT00121134|9605571|FG002|Overall Study|Patient Personal Reasons|0
6013282|NCT00121134|9605572|FG003|Overall Study|Patient Personal Reasons|0
6013283|NCT00121199|9605602|FG000|Overall Study|Adverse Event|11
6013284|NCT00121199|9605602|FG000|Overall Study|Refusal Unrelated to Adverse Event|1
6013285|NCT00121199|9605602|FG000|Overall Study|Progression/Relapse|1
6013286|NCT00121199|9605602|FG000|Overall Study|Death|3
6013287|NCT00121199|9605602|FG000|Overall Study|Other - Not Protocol Specified|3
6013288|NCT00121199|9605602|FG000|Overall Study|Ineligible|9
6013289|NCT00121238|9605611|FG000|Overall Study|disease progression before intervention|1
6013290|NCT00121238|9605611|FG000|Overall Study|Protocol Violation|2
6013291|NCT00121485|9605629|FG000|Overall Study|Not implanted|1
6013292|NCT00121485|9605630|FG001|Overall Study|Not implanted|5
6013293|NCT00121485|9605629|FG000|Overall Study|Crossover|0
6013294|NCT00121485|9605630|FG001|Overall Study|Crossover|2
6013295|NCT00121641|9605641|FG000|24-week Short-term Treatment Period|Lack of Efficacy|15
6013296|NCT00121641|9605642|FG001|24-week Short-term Treatment Period|Lack of Efficacy|21
6013297|NCT00121641|9605643|FG002|24-week Short-term Treatment Period|Lack of Efficacy|14
6013298|NCT00121641|9605644|FG003|24-week Short-term Treatment Period|Lack of Efficacy|25
6013299|NCT00121641|9605645|FG004|24-week Short-term Treatment Period|Lack of Efficacy|30
6013300|NCT00121641|9605641|FG000|24-week Short-term Treatment Period|Subject Withdrew Consent|9
6013301|NCT00121641|9605642|FG001|24-week Short-term Treatment Period|Subject Withdrew Consent|11
6013302|NCT00121641|9605643|FG002|24-week Short-term Treatment Period|Subject Withdrew Consent|5
6013303|NCT00121641|9605644|FG003|24-week Short-term Treatment Period|Subject Withdrew Consent|10
6013304|NCT00121641|9605645|FG004|24-week Short-term Treatment Period|Subject Withdrew Consent|3
6013305|NCT00121641|9605641|FG000|24-week Short-term Treatment Period|Adverse Event|3
6013306|NCT00121641|9605642|FG001|24-week Short-term Treatment Period|Adverse Event|3
6013307|NCT00121641|9605643|FG002|24-week Short-term Treatment Period|Adverse Event|4
6013308|NCT00121641|9605644|FG003|24-week Short-term Treatment Period|Adverse Event|0
6013309|NCT00121641|9605645|FG004|24-week Short-term Treatment Period|Adverse Event|2
6013310|NCT00121641|9605641|FG000|24-week Short-term Treatment Period|Lost to Follow-up|0
6013311|NCT00121641|9605642|FG001|24-week Short-term Treatment Period|Lost to Follow-up|2
6013312|NCT00121641|9605643|FG002|24-week Short-term Treatment Period|Lost to Follow-up|3
6013313|NCT00121641|9605644|FG003|24-week Short-term Treatment Period|Lost to Follow-up|4
6013314|NCT00121641|9605645|FG004|24-week Short-term Treatment Period|Lost to Follow-up|4
6013315|NCT00121641|9605641|FG000|24-week Short-term Treatment Period|Poor / Non-compliance|0
6013316|NCT00121641|9605642|FG001|24-week Short-term Treatment Period|Poor / Non-compliance|0
6013317|NCT00121641|9605643|FG002|24-week Short-term Treatment Period|Poor / Non-compliance|3
6013318|NCT00121641|9605644|FG003|24-week Short-term Treatment Period|Poor / Non-compliance|1
6013319|NCT00121641|9605645|FG004|24-week Short-term Treatment Period|Poor / Non-compliance|1
6013320|NCT00121641|9605641|FG000|24-week Short-term Treatment Period|Subject No Longer Meets Study Criteria|1
6013321|NCT00121641|9605642|FG001|24-week Short-term Treatment Period|Subject No Longer Meets Study Criteria|1
6013322|NCT00121641|9605643|FG002|24-week Short-term Treatment Period|Subject No Longer Meets Study Criteria|0
6013323|NCT00121641|9605644|FG003|24-week Short-term Treatment Period|Subject No Longer Meets Study Criteria|0
6013324|NCT00121641|9605645|FG004|24-week Short-term Treatment Period|Subject No Longer Meets Study Criteria|1
6013325|NCT00121641|9605641|FG000|24-week Short-term Treatment Period|Other Reason|1
6013326|NCT00121641|9605642|FG001|24-week Short-term Treatment Period|Other Reason|0
6013327|NCT00121641|9605643|FG002|24-week Short-term Treatment Period|Other Reason|0
6013328|NCT00121641|9605644|FG003|24-week Short-term Treatment Period|Other Reason|0
6013329|NCT00121641|9605645|FG004|24-week Short-term Treatment Period|Other Reason|0
6013330|NCT00121641|9605641|FG000|48-month Short Term + Long Term Period|Lack of Efficacy|26
6013331|NCT00121641|9605642|FG001|48-month Short Term + Long Term Period|Lack of Efficacy|27
6013332|NCT00121641|9605643|FG002|48-month Short Term + Long Term Period|Lack of Efficacy|21
6013333|NCT00121641|9605644|FG003|48-month Short Term + Long Term Period|Lack of Efficacy|26
6013334|NCT00121641|9605645|FG004|48-month Short Term + Long Term Period|Lack of Efficacy|25
6013335|NCT00121641|9605641|FG000|48-month Short Term + Long Term Period|Subject Withdrew Consent|25
6013336|NCT00121641|9605642|FG001|48-month Short Term + Long Term Period|Subject Withdrew Consent|28
6013337|NCT00121641|9605643|FG002|48-month Short Term + Long Term Period|Subject Withdrew Consent|17
6013338|NCT00121641|9605644|FG003|48-month Short Term + Long Term Period|Subject Withdrew Consent|24
6013339|NCT00121641|9605645|FG004|48-month Short Term + Long Term Period|Subject Withdrew Consent|10
6013340|NCT00121641|9605641|FG000|48-month Short Term + Long Term Period|Adverse Event|9
6013341|NCT00121641|9605642|FG001|48-month Short Term + Long Term Period|Adverse Event|10
6013342|NCT00121641|9605643|FG002|48-month Short Term + Long Term Period|Adverse Event|10
6013343|NCT00121641|9605644|FG003|48-month Short Term + Long Term Period|Adverse Event|5
6013344|NCT00121641|9605645|FG004|48-month Short Term + Long Term Period|Adverse Event|5
6013345|NCT00121641|9605641|FG000|48-month Short Term + Long Term Period|Lost to Follow-up|9
6013346|NCT00121641|9605642|FG001|48-month Short Term + Long Term Period|Lost to Follow-up|7
6013347|NCT00121641|9605643|FG002|48-month Short Term + Long Term Period|Lost to Follow-up|12
6013348|NCT00121641|9605644|FG003|48-month Short Term + Long Term Period|Lost to Follow-up|11
6013349|NCT00121641|9605645|FG004|48-month Short Term + Long Term Period|Lost to Follow-up|12
6013350|NCT00121641|9605641|FG000|48-month Short Term + Long Term Period|Poor / Non-compliance|4
6075862|NCT00585351|9680684|FG001|Enrollment Period (Intervention)|Lost to Follow-up|0
6075863|NCT00585351|9680685|FG002|Enrollment Period (Intervention)|Lost to Follow-up|0
6075864|NCT00585351|9680686|FG003|Enrollment Period (Intervention)|Lost to Follow-up|0
6075865|NCT00585351|9680687|FG004|Enrollment Period (Intervention)|Lost to Follow-up|0
6075866|NCT00585351|9680688|FG005|Enrollment Period (Intervention)|Lost to Follow-up|0
6075867|NCT00585351|9680689|FG006|Enrollment Period (Intervention)|Lost to Follow-up|1
6075868|NCT00585351|9680690|FG007|Enrollment Period (Intervention)|Lost to Follow-up|1
6075869|NCT00585351|9680683|FG000|Enrollment Period (Intervention)|Death|0
6075870|NCT00585351|9680684|FG001|Enrollment Period (Intervention)|Death|0
6075871|NCT00585351|9680685|FG002|Enrollment Period (Intervention)|Death|0
6075872|NCT00585351|9680686|FG003|Enrollment Period (Intervention)|Death|0
6075873|NCT00585351|9680687|FG004|Enrollment Period (Intervention)|Death|1
6075874|NCT00585351|9680688|FG005|Enrollment Period (Intervention)|Death|0
6075875|NCT00585351|9680689|FG006|Enrollment Period (Intervention)|Death|1
6075876|NCT00585351|9680690|FG007|Enrollment Period (Intervention)|Death|0
6075877|NCT00585351|9680683|FG000|Enrollment Period (Intervention)|Unknown if alive or deceased|0
6075878|NCT00585351|9680684|FG001|Enrollment Period (Intervention)|Unknown if alive or deceased|0
6075879|NCT00585351|9680685|FG002|Enrollment Period (Intervention)|Unknown if alive or deceased|0
6075880|NCT00585351|9680686|FG003|Enrollment Period (Intervention)|Unknown if alive or deceased|0
6075881|NCT00585351|9680687|FG004|Enrollment Period (Intervention)|Unknown if alive or deceased|1
6075882|NCT00585351|9680688|FG005|Enrollment Period (Intervention)|Unknown if alive or deceased|2
6075883|NCT00585351|9680689|FG006|Enrollment Period (Intervention)|Unknown if alive or deceased|0
6075884|NCT00585351|9680690|FG007|Enrollment Period (Intervention)|Unknown if alive or deceased|0
6075885|NCT00585468|9680708|FG000|First Intervention|Withdrawal by Subject|1
6075886|NCT00585468|9680709|FG001|First Intervention|Withdrawal by Subject|1
6013351|NCT00121641|9605642|FG001|48-month Short Term + Long Term Period|Poor / Non-compliance|1
6013352|NCT00121641|9605643|FG002|48-month Short Term + Long Term Period|Poor / Non-compliance|4
6075887|NCT00585533|9680721|FG000|Overall Study|objective or symptomatic progression|9
6075888|NCT00585546|9680725|FG000|Clenbuterol Treatment - up to 12 Months|Death|1
6013353|NCT00121641|9605644|FG003|48-month Short Term + Long Term Period|Poor / Non-compliance|2
6013354|NCT00121641|9605645|FG004|48-month Short Term + Long Term Period|Poor / Non-compliance|2
6013355|NCT00121641|9605641|FG000|48-month Short Term + Long Term Period|Subject No Longer Meets Study Criteria|1
6013356|NCT00121641|9605642|FG001|48-month Short Term + Long Term Period|Subject No Longer Meets Study Criteria|3
6013357|NCT00121641|9605643|FG002|48-month Short Term + Long Term Period|Subject No Longer Meets Study Criteria|2
6013358|NCT00121641|9605644|FG003|48-month Short Term + Long Term Period|Subject No Longer Meets Study Criteria|1
6013359|NCT00121641|9605645|FG004|48-month Short Term + Long Term Period|Subject No Longer Meets Study Criteria|2
6013360|NCT00121641|9605641|FG000|48-month Short Term + Long Term Period|Pregnancy|0
6013361|NCT00121641|9605642|FG001|48-month Short Term + Long Term Period|Pregnancy|1
6013362|NCT00121641|9605643|FG002|48-month Short Term + Long Term Period|Pregnancy|0
6013363|NCT00121641|9605644|FG003|48-month Short Term + Long Term Period|Pregnancy|1
6013364|NCT00121641|9605645|FG004|48-month Short Term + Long Term Period|Pregnancy|0
6013365|NCT00121641|9605641|FG000|48-month Short Term + Long Term Period|Administrative Reason by Sponsor|0
6013366|NCT00121641|9605642|FG001|48-month Short Term + Long Term Period|Administrative Reason by Sponsor|2
6013367|NCT00121641|9605643|FG002|48-month Short Term + Long Term Period|Administrative Reason by Sponsor|1
6013368|NCT00121641|9605644|FG003|48-month Short Term + Long Term Period|Administrative Reason by Sponsor|0
6013369|NCT00121641|9605645|FG004|48-month Short Term + Long Term Period|Administrative Reason by Sponsor|1
6013370|NCT00121641|9605641|FG000|48-month Short Term + Long Term Period|Death|0
6013371|NCT00121641|9605642|FG001|48-month Short Term + Long Term Period|Death|0
6013372|NCT00121641|9605643|FG002|48-month Short Term + Long Term Period|Death|0
6013373|NCT00121641|9605644|FG003|48-month Short Term + Long Term Period|Death|1
6013374|NCT00121641|9605645|FG004|48-month Short Term + Long Term Period|Death|0
6013375|NCT00121641|9605641|FG000|48-month Short Term + Long Term Period|Missing|0
6013376|NCT00121641|9605642|FG001|48-month Short Term + Long Term Period|Missing|0
6013377|NCT00121641|9605643|FG002|48-month Short Term + Long Term Period|Missing|1
6013378|NCT00121641|9605644|FG003|48-month Short Term + Long Term Period|Missing|0
6013379|NCT00121641|9605645|FG004|48-month Short Term + Long Term Period|Missing|0
6013380|NCT00121641|9605641|FG000|48-month Short Term + Long Term Period|Other Reason|5
6013381|NCT00121641|9605642|FG001|48-month Short Term + Long Term Period|Other Reason|3
6013382|NCT00121641|9605643|FG002|48-month Short Term + Long Term Period|Other Reason|2
6013383|NCT00121641|9605644|FG003|48-month Short Term + Long Term Period|Other Reason|0
6013384|NCT00121641|9605645|FG004|48-month Short Term + Long Term Period|Other Reason|1
6013385|NCT00121667|9605663|FG000|Short Term (ST) Period|Lack of Efficacy|25
6013386|NCT00121667|9605664|FG001|Short Term (ST) Period|Lack of Efficacy|22
6013387|NCT00121667|9605665|FG002|Short Term (ST) Period|Lack of Efficacy|27
6013388|NCT00121667|9605666|FG003|Short Term (ST) Period|Lack of Efficacy|44
6013389|NCT00121667|9605663|FG000|Short Term (ST) Period|Subject Withdrew Consent|8
6013390|NCT00121667|9605664|FG001|Short Term (ST) Period|Subject Withdrew Consent|13
6013391|NCT00121667|9605665|FG002|Short Term (ST) Period|Subject Withdrew Consent|4
6013392|NCT00121667|9605666|FG003|Short Term (ST) Period|Subject Withdrew Consent|11
6013393|NCT00121667|9605663|FG000|Short Term (ST) Period|Adverse Event|5
6013394|NCT00121667|9605664|FG001|Short Term (ST) Period|Adverse Event|6
6013395|NCT00121667|9605665|FG002|Short Term (ST) Period|Adverse Event|5
6013396|NCT00121667|9605666|FG003|Short Term (ST) Period|Adverse Event|3
6013397|NCT00121667|9605663|FG000|Short Term (ST) Period|Lost to Follow-up|3
6013398|NCT00121667|9605664|FG001|Short Term (ST) Period|Lost to Follow-up|4
6013399|NCT00121667|9605665|FG002|Short Term (ST) Period|Lost to Follow-up|4
6013400|NCT00121667|9605666|FG003|Short Term (ST) Period|Lost to Follow-up|3
6013401|NCT00121667|9605663|FG000|Short Term (ST) Period|Poor / Non-compliance|0
6013402|NCT00121667|9605664|FG001|Short Term (ST) Period|Poor / Non-compliance|1
6013403|NCT00121667|9605665|FG002|Short Term (ST) Period|Poor / Non-compliance|1
6013404|NCT00121667|9605666|FG003|Short Term (ST) Period|Poor / Non-compliance|2
6013405|NCT00121667|9605663|FG000|Short Term (ST) Period|Subject No Longer Meets Study Criteria|0
6013406|NCT00121667|9605664|FG001|Short Term (ST) Period|Subject No Longer Meets Study Criteria|2
6013407|NCT00121667|9605665|FG002|Short Term (ST) Period|Subject No Longer Meets Study Criteria|0
6013408|NCT00121667|9605666|FG003|Short Term (ST) Period|Subject No Longer Meets Study Criteria|2
6013409|NCT00121667|9605663|FG000|Short Term (ST) Period|Other Reason|3
6013410|NCT00121667|9605664|FG001|Short Term (ST) Period|Other Reason|0
6013411|NCT00121667|9605665|FG002|Short Term (ST) Period|Other Reason|0
6013412|NCT00121667|9605666|FG003|Short Term (ST) Period|Other Reason|0
6013413|NCT00121667|9605663|FG000|Short Term (ST) Period|Death|0
6013414|NCT00121667|9605664|FG001|Short Term (ST) Period|Death|0
6013415|NCT00121667|9605665|FG002|Short Term (ST) Period|Death|0
6013416|NCT00121667|9605666|FG003|Short Term (ST) Period|Death|1
6013417|NCT00121667|9605663|FG000|Short Term (ST) Period|Pregnancy|0
6013418|NCT00121667|9605664|FG001|Short Term (ST) Period|Pregnancy|0
6013419|NCT00121667|9605665|FG002|Short Term (ST) Period|Pregnancy|0
6013420|NCT00121667|9605666|FG003|Short Term (ST) Period|Pregnancy|1
6075889|NCT00585546|9680725|FG000|Clenbuterol Treatment - up to 12 Months|Adverse Event|3
6013421|NCT00121667|9605663|FG000|Short Term (ST) + Long Term (LT) Period|Lack of Efficacy|54
6013422|NCT00121667|9605664|FG001|Short Term (ST) + Long Term (LT) Period|Lack of Efficacy|51
6013423|NCT00121667|9605665|FG002|Short Term (ST) + Long Term (LT) Period|Lack of Efficacy|42
6013424|NCT00121667|9605666|FG003|Short Term (ST) + Long Term (LT) Period|Lack of Efficacy|65
6013425|NCT00121667|9605663|FG000|Short Term (ST) + Long Term (LT) Period|Subject Withdrew Consent|38
6013426|NCT00121667|9605664|FG001|Short Term (ST) + Long Term (LT) Period|Subject Withdrew Consent|34
6013427|NCT00121667|9605665|FG002|Short Term (ST) + Long Term (LT) Period|Subject Withdrew Consent|26
6013428|NCT00121667|9605666|FG003|Short Term (ST) + Long Term (LT) Period|Subject Withdrew Consent|30
6013429|NCT00121667|9605663|FG000|Short Term (ST) + Long Term (LT) Period|Adverse Event|12
6013430|NCT00121667|9605664|FG001|Short Term (ST) + Long Term (LT) Period|Adverse Event|18
6013431|NCT00121667|9605665|FG002|Short Term (ST) + Long Term (LT) Period|Adverse Event|13
6013432|NCT00121667|9605666|FG003|Short Term (ST) + Long Term (LT) Period|Adverse Event|10
6013433|NCT00121667|9605663|FG000|Short Term (ST) + Long Term (LT) Period|Lost to Follow-up|11
6013434|NCT00121667|9605664|FG001|Short Term (ST) + Long Term (LT) Period|Lost to Follow-up|11
6013435|NCT00121667|9605665|FG002|Short Term (ST) + Long Term (LT) Period|Lost to Follow-up|13
6013436|NCT00121667|9605666|FG003|Short Term (ST) + Long Term (LT) Period|Lost to Follow-up|16
6013437|NCT00121667|9605663|FG000|Short Term (ST) + Long Term (LT) Period|Other Reason|5
6013438|NCT00121667|9605664|FG001|Short Term (ST) + Long Term (LT) Period|Other Reason|7
6013439|NCT00121667|9605665|FG002|Short Term (ST) + Long Term (LT) Period|Other Reason|6
6013440|NCT00121667|9605666|FG003|Short Term (ST) + Long Term (LT) Period|Other Reason|3
6013441|NCT00121667|9605663|FG000|Short Term (ST) + Long Term (LT) Period|Subject No Longer Meets Study Criteria|3
6013442|NCT00121667|9605664|FG001|Short Term (ST) + Long Term (LT) Period|Subject No Longer Meets Study Criteria|6
6013443|NCT00121667|9605665|FG002|Short Term (ST) + Long Term (LT) Period|Subject No Longer Meets Study Criteria|5
6013444|NCT00121667|9605666|FG003|Short Term (ST) + Long Term (LT) Period|Subject No Longer Meets Study Criteria|9
6013445|NCT00121667|9605663|FG000|Short Term (ST) + Long Term (LT) Period|Poor / Non-compliance|3
6013446|NCT00121667|9605664|FG001|Short Term (ST) + Long Term (LT) Period|Poor / Non-compliance|5
6013447|NCT00121667|9605665|FG002|Short Term (ST) + Long Term (LT) Period|Poor / Non-compliance|8
6013448|NCT00121667|9605666|FG003|Short Term (ST) + Long Term (LT) Period|Poor / Non-compliance|4
6013449|NCT00121667|9605663|FG000|Short Term (ST) + Long Term (LT) Period|Pregnancy|1
6013450|NCT00121667|9605664|FG001|Short Term (ST) + Long Term (LT) Period|Pregnancy|1
6013451|NCT00121667|9605665|FG002|Short Term (ST) + Long Term (LT) Period|Pregnancy|0
6013452|NCT00121667|9605666|FG003|Short Term (ST) + Long Term (LT) Period|Pregnancy|1
6013453|NCT00121667|9605663|FG000|Short Term (ST) + Long Term (LT) Period|Death|1
6013454|NCT00121667|9605664|FG001|Short Term (ST) + Long Term (LT) Period|Death|0
6013455|NCT00121667|9605665|FG002|Short Term (ST) + Long Term (LT) Period|Death|0
6013456|NCT00121667|9605666|FG003|Short Term (ST) + Long Term (LT) Period|Death|2
6013457|NCT00121992|9605759|FG000|Overall Study|Treatment not received|2
6013458|NCT00121992|9605760|FG001|Overall Study|Treatment not received|11
6013459|NCT00122109|9605768|FG000|Overall Study|Did not meet criteria|6
6013460|NCT00122109|9605769|FG001|Overall Study|Did not meet criteria|7
6013461|NCT00122135|9605780|FG000|Overall Study|Withdrawal by Subject|3
6013462|NCT00122135|9605781|FG001|Overall Study|Withdrawal by Subject|0
6013463|NCT00122187|9605789|FG000|Overall Study|Withdrew because of resource limitations|2
6075890|NCT00585689|9680755|FG000|Overall Study|Received different ABI-007 schedule|3
6075891|NCT00585689|9680755|FG000|Overall Study|Adverse Event|1
6075892|NCT00585689|9680755|FG000|Overall Study|Patient Declined Surgery|1
6075893|NCT00585689|9680755|FG000|Overall Study|Patient had unresectable disease|1
6075894|NCT00585689|9680755|FG000|Overall Study|Death|1
6075895|NCT00585923|9680796|FG000|Overall Study|Physician decided not to continue|31
6075896|NCT00585923|9680797|FG001|Overall Study|Physician decided not to continue|33
6075897|NCT00585975|9680805|FG000|Overall Study|Withdrawal by Subject|3
6075898|NCT00585975|9680806|FG001|Overall Study|Withdrawal by Subject|3
6075899|NCT00585975|9680805|FG000|Overall Study|Lost to Follow-up|2
6075900|NCT00585975|9680806|FG001|Overall Study|Lost to Follow-up|1
6075901|NCT00585975|9680805|FG000|Overall Study|Enrollment met/over-enrolled|10
6075902|NCT00585975|9680806|FG001|Overall Study|Enrollment met/over-enrolled|9
6075903|NCT00586066|9680824|FG000|Overall Study|Lost to Follow-up|6
6075904|NCT00586066|9680825|FG001|Overall Study|Lost to Follow-up|3
6075905|NCT00586066|9680824|FG000|Overall Study|Lack of Efficacy|5
6075906|NCT00586066|9680825|FG001|Overall Study|Lack of Efficacy|3
6075907|NCT00586066|9680824|FG000|Overall Study|Adverse Event|2
6075908|NCT00586066|9680825|FG001|Overall Study|Adverse Event|2
6075909|NCT00586066|9680824|FG000|Overall Study|Physician Decision|1
6075910|NCT00586066|9680825|FG001|Overall Study|Physician Decision|0
6075911|NCT00586066|9680824|FG000|Overall Study|Withdrawal of consent|4
6075912|NCT00586066|9680825|FG001|Overall Study|Withdrawal of consent|2
6075913|NCT00586105|9680831|FG000|Overall Study|Adverse Event|4
6075914|NCT00586105|9680831|FG000|Overall Study|Death|2
6075915|NCT00586105|9680831|FG000|Overall Study|Protocol Violation|1
6075916|NCT00586105|9680831|FG000|Overall Study|Withdrawal by Subject|3
6075917|NCT00586105|9680831|FG000|Overall Study|Disease progression|19
6075918|NCT00586105|9680831|FG000|Overall Study|Switched to commercial drug|9
6075919|NCT00586105|9680831|FG000|Overall Study|Reason not reported|1
6075920|NCT00586157|9680835|FG000|First Intervention|Worsening behavior|1
6075921|NCT00586157|9680836|FG001|First Intervention|Worsening behavior|0
6013464|NCT00122187|9605790|FG001|Overall Study|Withdrew because of resource limitations|2
6013465|NCT00122278|9605800|FG000|Overall Study|Lost to Follow-up|2
6013466|NCT00122278|9605801|FG001|Overall Study|Lost to Follow-up|0
6013467|NCT00122317|9605807|FG000|Overall Study|Death|3
6013468|NCT00122317|9605807|FG000|Overall Study|Adverse Event|4
6013469|NCT00122317|9605807|FG000|Overall Study|Physician Decision|2
6013470|NCT00122317|9605807|FG000|Overall Study|patient non-compliance|1
6013471|NCT00122317|9605807|FG000|Overall Study|Withdrawal by Subject|1
6013472|NCT00122382|9605829|FG000|Double-Blind Study|Adverse Event|9
6013473|NCT00122382|9605830|FG001|Double-Blind Study|Adverse Event|11
6013474|NCT00122382|9605831|FG002|Double-Blind Study|Adverse Event|0
6013475|NCT00122382|9605829|FG000|Double-Blind Study|Death|2
6013476|NCT00122382|9605830|FG001|Double-Blind Study|Death|2
6013477|NCT00122382|9605831|FG002|Double-Blind Study|Death|0
6013478|NCT00122382|9605829|FG000|Double-Blind Study|Lack of Efficacy|0
6013479|NCT00122382|9605830|FG001|Double-Blind Study|Lack of Efficacy|8
6013480|NCT00122382|9605831|FG002|Double-Blind Study|Lack of Efficacy|0
6013481|NCT00122382|9605829|FG000|Double-Blind Study|Lost to Follow-up|2
6013482|NCT00122382|9605830|FG001|Double-Blind Study|Lost to Follow-up|1
6013483|NCT00122382|9605831|FG002|Double-Blind Study|Lost to Follow-up|0
6013484|NCT00122382|9605829|FG000|Double-Blind Study|Pregnancy|2
6013485|NCT00122382|9605830|FG001|Double-Blind Study|Pregnancy|0
6013486|NCT00122382|9605831|FG002|Double-Blind Study|Pregnancy|0
6013487|NCT00122382|9605829|FG000|Double-Blind Study|Subject No Longer Meets Study Criteria|1
6013488|NCT00122382|9605830|FG001|Double-Blind Study|Subject No Longer Meets Study Criteria|0
6013489|NCT00122382|9605831|FG002|Double-Blind Study|Subject No Longer Meets Study Criteria|0
6013490|NCT00122382|9605829|FG000|Double-Blind Study|Withdrawal of Consent|7
6013491|NCT00122382|9605830|FG001|Double-Blind Study|Withdrawal of Consent|3
6013492|NCT00122382|9605831|FG002|Double-Blind Study|Withdrawal of Consent|0
6013493|NCT00122382|9605829|FG000|Double-Blind Study|Protocol Violation|1
6013494|NCT00122382|9605830|FG001|Double-Blind Study|Protocol Violation|0
6013495|NCT00122382|9605831|FG002|Double-Blind Study|Protocol Violation|0
6013496|NCT00122382|9605829|FG000|Double-Blind Study|Methotrexate Discontinued|0
6013497|NCT00122382|9605830|FG001|Double-Blind Study|Methotrexate Discontinued|1
6013498|NCT00122382|9605831|FG002|Double-Blind Study|Methotrexate Discontinued|0
6013499|NCT00122382|9605829|FG000|Double-Blind Study|Randomized but not treated|0
6013500|NCT00122382|9605830|FG001|Double-Blind Study|Randomized but not treated|2
6013501|NCT00122382|9605831|FG002|Double-Blind Study|Randomized but not treated|0
6013502|NCT00122382|9605829|FG000|Open-Label Study|Adverse Event|0
6013503|NCT00122382|9605830|FG001|Open-Label Study|Adverse Event|0
6013504|NCT00122382|9605831|FG002|Open-Label Study|Adverse Event|11
6013505|NCT00122382|9605829|FG000|Open-Label Study|Death|0
6013506|NCT00122382|9605830|FG001|Open-Label Study|Death|0
6013507|NCT00122382|9605831|FG002|Open-Label Study|Death|2
6075922|NCT00586157|9680835|FG000|Second Intervention|Withdrawal by Subject|1
6013508|NCT00122382|9605829|FG000|Open-Label Study|Lack of Efficacy|0
6013509|NCT00122382|9605830|FG001|Open-Label Study|Lack of Efficacy|0
6013510|NCT00122382|9605831|FG002|Open-Label Study|Lack of Efficacy|3
6013511|NCT00122382|9605829|FG000|Open-Label Study|Lost to Follow-up|0
6013512|NCT00122382|9605830|FG001|Open-Label Study|Lost to Follow-up|0
6013513|NCT00122382|9605831|FG002|Open-Label Study|Lost to Follow-up|3
6013514|NCT00122382|9605829|FG000|Open-Label Study|Pregnancy|0
6013515|NCT00122382|9605830|FG001|Open-Label Study|Pregnancy|0
6013516|NCT00122382|9605831|FG002|Open-Label Study|Pregnancy|2
6075923|NCT00586157|9680836|FG001|Second Intervention|Withdrawal by Subject|0
6075924|NCT00586157|9680835|FG000|Second Intervention|Worsening behavior|1
6075925|NCT00586157|9680836|FG001|Second Intervention|Worsening behavior|0
6075926|NCT00586157|9680835|FG000|Second Intervention|Adverse Event|0
6075927|NCT00586157|9680836|FG001|Second Intervention|Adverse Event|1
6075928|NCT00586313|9680869|FG000|Overall Study|Lack of Efficacy|2
6075929|NCT00586326|9680873|FG000|Enrollment to Device Placement-Enrolled|Skin Distance|6
6075930|NCT00586326|9680873|FG000|Enrollment to Device Placement-Enrolled|Cavity Conformance|4
6075931|NCT00586326|9680873|FG000|Enrollment to Device Placement-Enrolled|Microinvasion|2
6075932|NCT00586326|9680873|FG000|Enrollment to Device Placement-Enrolled|Physician Decision|1
6075933|NCT00586326|9680873|FG000|Enrollment to Device Placement-Enrolled|Withdrawal by Subject|1
6075934|NCT00586326|9680873|FG000|Enrollment to Device Placement-Enrolled|Other|1
6075935|NCT00586326|9680873|FG000|Device Placed toTreatment-ITT|Skin Distance|7
6075936|NCT00586326|9680873|FG000|Device Placed toTreatment-ITT|Cavity Conformance|6
6075937|NCT00586326|9680873|FG000|Device Placed toTreatment-ITT|Microinvasion|1
6075938|NCT00586326|9680873|FG000|Device Placed toTreatment-ITT|Positive Margins|3
6075939|NCT00586326|9680873|FG000|Device Placed toTreatment-ITT|Physician Decision|1
6075940|NCT00586326|9680873|FG000|Treated Through 5-yr Follow Up-Treated|Clinical Reason|1
6013517|NCT00122382|9605829|FG000|Open-Label Study|Poor/Non-Compliance|0
6013518|NCT00122382|9605830|FG001|Open-Label Study|Poor/Non-Compliance|0
6013519|NCT00122382|9605831|FG002|Open-Label Study|Poor/Non-Compliance|1
6013520|NCT00122382|9605829|FG000|Open-Label Study|Withdrawal of Consent|0
6013521|NCT00122382|9605830|FG001|Open-Label Study|Withdrawal of Consent|0
6013522|NCT00122382|9605831|FG002|Open-Label Study|Withdrawal of Consent|4
6013523|NCT00122460|9605872|FG000|Overall Study|investigational study phase ongoing|7
6075941|NCT00586326|9680873|FG000|Treated Through 5-yr Follow Up-Treated|Death|2
6075942|NCT00586326|9680873|FG000|Treated Through 5-yr Follow Up-Treated|Medical Reason|2
6013524|NCT00122460|9605873|FG001|Overall Study|investigational study phase ongoing|1
6013525|NCT00122681|9605881|FG000|Overall Study|Adverse Event|20
6013526|NCT00122681|9605882|FG001|Overall Study|Adverse Event|16
6013527|NCT00122681|9605881|FG000|Overall Study|Lost to Follow-up|1080
6013528|NCT00122681|9605882|FG001|Overall Study|Lost to Follow-up|1097
6013529|NCT00122681|9605881|FG000|Overall Study|Protocol Violation|7
6013530|NCT00122681|9605882|FG001|Overall Study|Protocol Violation|10
6013531|NCT00122681|9605881|FG000|Overall Study|Withdrawal by Subject|257
6013532|NCT00122681|9605882|FG001|Overall Study|Withdrawal by Subject|251
6013533|NCT00122681|9605881|FG000|Overall Study|Personal reasons|150
6013534|NCT00122681|9605882|FG001|Overall Study|Personal reasons|147
6013535|NCT00122954|9605898|FG000|Overall Study|Withdrawal by Subject|2
6013536|NCT00122954|9605899|FG001|Overall Study|Withdrawal by Subject|2
6013537|NCT00122954|9605898|FG000|Overall Study|Protocol Violation|0
6013538|NCT00122954|9605899|FG001|Overall Study|Protocol Violation|1
6013539|NCT00122980|9605907|FG000|Overall Study|Death|0
6013540|NCT00122980|9605908|FG001|Overall Study|Death|1
6075943|NCT00586326|9680873|FG000|Treated Through 5-yr Follow Up-Treated|Withdrawal by Subject|5
6075944|NCT00586326|9680873|FG000|Treated Through 5-yr Follow Up-Treated|Lost to Follow-up|14
6075945|NCT00586326|9680873|FG000|Treated Through 5-yr Follow Up-Treated|Other|2
6075946|NCT00586339|9680884|FG000|Overall Study|Withdrawal by Subject|1
6075947|NCT00586339|9680885|FG001|Overall Study|Withdrawal by Subject|3
6075948|NCT00586339|9680886|FG002|Overall Study|Withdrawal by Subject|1
6075949|NCT00586339|9680884|FG000|Overall Study|Migrated/moved from study area|3
6075950|NCT00586339|9680885|FG001|Overall Study|Migrated/moved from study area|2
6075951|NCT00586339|9680886|FG002|Overall Study|Migrated/moved from study area|4
6075952|NCT00586339|9680884|FG000|Overall Study|Lost to Follow-up|3
6075953|NCT00586339|9680885|FG001|Overall Study|Lost to Follow-up|2
6075954|NCT00586339|9680886|FG002|Overall Study|Lost to Follow-up|1
6075955|NCT00586469|9680896|FG000|Overall Study|Adverse Event|0
6075956|NCT00586469|9680897|FG001|Overall Study|Adverse Event|1
6075957|NCT00586495|9680912|FG000|Treatment Period|Adverse Event|11
6075958|NCT00586495|9680912|FG000|Treatment Period|Death|1
6075959|NCT00586495|9680912|FG000|Treatment Period|Protocol Violation|1
6075960|NCT00586495|9680912|FG000|Treatment Period|Withdrawal by Subject|1
6075961|NCT00586495|9680912|FG000|Treatment Period|Disease progression, recurrence/relapse|71
6075962|NCT00586495|9680912|FG000|Treatment Period|Switch to commercial drug|10
6075963|NCT00586495|9680912|FG000|Follow-up|Death|40
6075964|NCT00586495|9680912|FG000|Follow-up|Lost to Follow-up|1
6075965|NCT00586495|9680912|FG000|Follow-up|Withdrawal by Subject|4
6075966|NCT00586495|9680912|FG000|Follow-up|Protocol driven decision point|37
6075967|NCT00586495|9680912|FG000|Follow-up|Switch to commercial drug|10
6075968|NCT00586508|9680918|FG000|Overall Study|Progressive disease|52
6075969|NCT00586508|9680919|FG001|Overall Study|Progressive disease|8
6075970|NCT00586508|9680918|FG000|Overall Study|Death|0
6075971|NCT00586508|9680919|FG001|Overall Study|Death|1
6075972|NCT00586508|9680918|FG000|Overall Study|Adverse Event|12
6075973|NCT00586508|9680919|FG001|Overall Study|Adverse Event|4
6075974|NCT00586508|9680918|FG000|Overall Study|Withdrawal by Subject|4
6075975|NCT00586508|9680919|FG001|Overall Study|Withdrawal by Subject|0
6075976|NCT00586521|9680925|FG000|On Demand Treatment (Months 1-6)|Withdrawal by Subject|1
6075977|NCT00586612|9680935|FG000|Primary Phase|Protocol Violation|1
6075978|NCT00586612|9680936|FG001|Primary Phase|Protocol Violation|0
6075979|NCT00586612|9680935|FG000|Primary Phase|Lost to Follow-up|0
6075980|NCT00586612|9680936|FG001|Primary Phase|Lost to Follow-up|1
6075981|NCT00586612|9680935|FG000|Primary Phase|Withdrawal by Subject|0
6075982|NCT00586612|9680936|FG001|Primary Phase|Withdrawal by Subject|2
6075983|NCT00586612|9680935|FG000|Booster Phase|Lost to Follow-up|3
6075984|NCT00586612|9680936|FG001|Booster Phase|Lost to Follow-up|1
6075985|NCT00586625|9680944|FG000|Overall Study|Adverse Event|6
6075986|NCT00586625|9680945|FG001|Overall Study|Adverse Event|6
6075987|NCT00586625|9680944|FG000|Overall Study|Protocol Violation|3
6075988|NCT00586625|9680945|FG001|Overall Study|Protocol Violation|0
6075989|NCT00586625|9680944|FG000|Overall Study|Withdrawal by Subject|32
6075990|NCT00586625|9680945|FG001|Overall Study|Withdrawal by Subject|10
6075991|NCT00586625|9680944|FG000|Overall Study|Subject non-compliance|0
6075992|NCT00586625|9680945|FG001|Overall Study|Subject non-compliance|1
6075993|NCT00586625|9680944|FG000|Overall Study|Subject unable to return for visit|2
6075994|NCT00586625|9680945|FG001|Overall Study|Subject unable to return for visit|0
6075995|NCT00586664|9680954|FG000|Overall Study|Withdrawal by Subject|3
6075996|NCT00586664|9680955|FG001|Overall Study|Withdrawal by Subject|7
6075997|NCT00586664|9680956|FG002|Overall Study|Withdrawal by Subject|1
6075998|NCT00586664|9680954|FG000|Overall Study|Exclusion criteria met|2
6075999|NCT00586664|9680955|FG001|Overall Study|Exclusion criteria met|0
6076000|NCT00586664|9680956|FG002|Overall Study|Exclusion criteria met|0
6013541|NCT00122980|9605907|FG000|Overall Study|Physician Decision|2
6013542|NCT00122980|9605908|FG001|Overall Study|Physician Decision|0
6013543|NCT00122980|9605907|FG000|Overall Study|Protocol Violation|5
6013544|NCT00122980|9605908|FG001|Overall Study|Protocol Violation|1
6013545|NCT00122980|9605907|FG000|Overall Study|Withdrawal by Subject|2
6013546|NCT00122980|9605908|FG001|Overall Study|Withdrawal by Subject|3
6076001|NCT00586690|9680966|FG000|Overall Study|Death|2
6076002|NCT00586690|9680967|FG001|Overall Study|Death|0
6076003|NCT00586690|9680966|FG000|Overall Study|Disease Progression|10
6013547|NCT00122980|9605907|FG000|Overall Study|Adjudicated stroke (study endpoint)|7
6013548|NCT00122980|9605908|FG001|Overall Study|Adjudicated stroke (study endpoint)|0
6013549|NCT00122980|9605907|FG000|Overall Study|Study termination|27
6013550|NCT00122980|9605908|FG001|Overall Study|Study termination|35
6013551|NCT00123422|9605963|FG000|Overall Study|Physician Decision|2
6013552|NCT00123422|9605964|FG001|Overall Study|Physician Decision|2
6013553|NCT00123422|9605965|FG002|Overall Study|Physician Decision|6
6013554|NCT00123422|9605963|FG000|Overall Study|Withdrawal by Subject|1
6013555|NCT00123422|9605964|FG001|Overall Study|Withdrawal by Subject|2
6013556|NCT00123422|9605965|FG002|Overall Study|Withdrawal by Subject|2
6013557|NCT00123422|9605963|FG000|Overall Study|Lost to Follow-up|1
6013558|NCT00123422|9605964|FG001|Overall Study|Lost to Follow-up|2
6013559|NCT00123422|9605965|FG002|Overall Study|Lost to Follow-up|2
6013560|NCT00123474|9605977|FG000|Randomized to Treatment|Randomized, never treated|1
6013561|NCT00123474|9605978|FG001|Randomized to Treatment|Randomized, never treated|4
6013562|NCT00123474|9605979|FG002|Randomized to Treatment|Randomized, never treated|2
6013563|NCT00123474|9605980|FG003|Randomized to Treatment|Randomized, never treated|1
6013564|NCT00123474|9605977|FG000|As Treated at Study Closure|not reported when site closed|1
6013565|NCT00123474|9605978|FG001|As Treated at Study Closure|not reported when site closed|0
6013566|NCT00123474|9605979|FG002|As Treated at Study Closure|not reported when site closed|1
6013567|NCT00123474|9605980|FG003|As Treated at Study Closure|not reported when site closed|0
6013568|NCT00123474|9605977|FG000|As Treated at Study Closure|Adverse Event|10
6013569|NCT00123474|9605978|FG001|As Treated at Study Closure|Adverse Event|4
6013570|NCT00123474|9605979|FG002|As Treated at Study Closure|Adverse Event|10
6013571|NCT00123474|9605980|FG003|As Treated at Study Closure|Adverse Event|8
6013572|NCT00123474|9605977|FG000|As Treated at Study Closure|Disease Progression|35
6013573|NCT00123474|9605978|FG001|As Treated at Study Closure|Disease Progression|42
6013574|NCT00123474|9605979|FG002|As Treated at Study Closure|Disease Progression|29
6013575|NCT00123474|9605980|FG003|As Treated at Study Closure|Disease Progression|27
6013576|NCT00123474|9605977|FG000|As Treated at Study Closure|Investigator Request|12
6013577|NCT00123474|9605978|FG001|As Treated at Study Closure|Investigator Request|6
6013578|NCT00123474|9605979|FG002|As Treated at Study Closure|Investigator Request|7
6013579|NCT00123474|9605980|FG003|As Treated at Study Closure|Investigator Request|5
6013580|NCT00123474|9605977|FG000|As Treated at Study Closure|non-specified|54
6013581|NCT00123474|9605978|FG001|As Treated at Study Closure|non-specified|47
6013582|NCT00123474|9605979|FG002|As Treated at Study Closure|non-specified|57
6013583|NCT00123474|9605980|FG003|As Treated at Study Closure|non-specified|60
6013584|NCT00123474|9605977|FG000|As Treated at Study Closure|Study Drug Toxicity|39
6013585|NCT00123474|9605978|FG001|As Treated at Study Closure|Study Drug Toxicity|45
6013586|NCT00123474|9605979|FG002|As Treated at Study Closure|Study Drug Toxicity|45
6013587|NCT00123474|9605980|FG003|As Treated at Study Closure|Study Drug Toxicity|51
6013588|NCT00123474|9605977|FG000|As Treated at Study Closure|Withdrawal by Subject|14
6013589|NCT00123474|9605978|FG001|As Treated at Study Closure|Withdrawal by Subject|19
6013590|NCT00123474|9605979|FG002|As Treated at Study Closure|Withdrawal by Subject|18
6013591|NCT00123474|9605980|FG003|As Treated at Study Closure|Withdrawal by Subject|16
6013592|NCT00123487|9606013|FG000|Randomized|Death prior to starting treatment|0
6013593|NCT00123487|9606014|FG001|Randomized|Death prior to starting treatment|1
6013594|NCT00123487|9606013|FG000|Randomized|SAE prior to starting treatment|1
6013595|NCT00123487|9606014|FG001|Randomized|SAE prior to starting treatment|0
6013596|NCT00123487|9606013|FG000|Treated With Study Drug|Adverse Event|23
6013597|NCT00123487|9606014|FG001|Treated With Study Drug|Adverse Event|22
6013598|NCT00123487|9606013|FG000|Treated With Study Drug|Disease Progression|141
6013599|NCT00123487|9606014|FG001|Treated With Study Drug|Disease Progression|122
6013600|NCT00123487|9606013|FG000|Treated With Study Drug|Physician Decision|8
6013601|NCT00123487|9606014|FG001|Treated With Study Drug|Physician Decision|9
6013602|NCT00123487|9606013|FG000|Treated With Study Drug|Other|59
6013603|NCT00123487|9606014|FG001|Treated With Study Drug|Other|58
6013604|NCT00123487|9606013|FG000|Treated With Study Drug|Study Drug Toxicity|62
6013605|NCT00123487|9606014|FG001|Treated With Study Drug|Study Drug Toxicity|80
6013606|NCT00123487|9606013|FG000|Treated With Study Drug|Withdrawal by Subject|11
6013607|NCT00123487|9606014|FG001|Treated With Study Drug|Withdrawal by Subject|13
6013608|NCT00123487|9606013|FG000|Treated With Study Drug|Unknown (case report form lost)|0
6013609|NCT00123487|9606014|FG001|Treated With Study Drug|Unknown (case report form lost)|1
6013610|NCT00123734|9606069|FG000|Overall Study|Death|3
6013611|NCT00123734|9606069|FG000|Overall Study|Lost to Follow-up|3
6013612|NCT00123734|9606069|FG000|Overall Study|Dropout|1
6013613|NCT00123734|9606069|FG000|Overall Study|Withdrawal by Subject|1
6013614|NCT00123955|9606078|FG000|Overall Study|Adverse Event|1
6013615|NCT00123955|9606079|FG001|Overall Study|Adverse Event|0
6013616|NCT00123955|9606078|FG000|Overall Study|Withdrawal by Subject|4
6013617|NCT00123955|9606079|FG001|Overall Study|Withdrawal by Subject|3
6013618|NCT00123955|9606078|FG000|Overall Study|Death|0
6013619|NCT00123955|9606079|FG001|Overall Study|Death|1
6013620|NCT00124020|9606087|FG000|Overall Study|Death|67
6013621|NCT00124020|9606088|FG001|Overall Study|Death|71
6013622|NCT00124020|9606087|FG000|Overall Study|Withdrawal by Subject|13
6013623|NCT00124020|9606088|FG001|Overall Study|Withdrawal by Subject|11
6013624|NCT00124020|9606087|FG000|Overall Study|Lost to Follow-up|5
6013625|NCT00124020|9606088|FG001|Overall Study|Lost to Follow-up|8
6013626|NCT00124020|9606087|FG000|Overall Study|Other|1
6013627|NCT00124020|9606088|FG001|Overall Study|Other|1
6013628|NCT00124020|9606087|FG000|Overall Study|Transfer to another hospital|2
6013629|NCT00124020|9606088|FG001|Overall Study|Transfer to another hospital|0
6013630|NCT00124072|9606098|FG000|Overall Study|Lost to Follow-up for Mortality|0
6013631|NCT00124072|9606099|FG001|Overall Study|Lost to Follow-up for Mortality|3
6013632|NCT00124072|9606100|FG002|Overall Study|Lost to Follow-up for Mortality|2
6013633|NCT00124072|9606101|FG003|Overall Study|Lost to Follow-up for Mortality|2
6013634|NCT00124072|9606098|FG000|Overall Study|Lost to Follow-up for Morbidity|15
6013635|NCT00124072|9606099|FG001|Overall Study|Lost to Follow-up for Morbidity|25
6013636|NCT00124072|9606100|FG002|Overall Study|Lost to Follow-up for Morbidity|19
6013637|NCT00124072|9606101|FG003|Overall Study|Lost to Follow-up for Morbidity|18
6013638|NCT00124072|9606098|FG000|Overall Study|Death|499
6013639|NCT00124072|9606099|FG001|Overall Study|Death|484
6013640|NCT00124072|9606100|FG002|Overall Study|Death|471
6013641|NCT00124072|9606101|FG003|Overall Study|Death|480
6013642|NCT00124449|9606122|FG000|6-month Double-Blind Treatment Period|Adverse Event|1
6013643|NCT00124449|9606123|FG001|6-month Double-Blind Treatment Period|Adverse Event|0
6013644|NCT00124449|9606122|FG000|6-month Double-Blind Treatment Period|Lack of Efficacy|3
6013645|NCT00124449|9606123|FG001|6-month Double-Blind Treatment Period|Lack of Efficacy|8
6013646|NCT00124449|9606122|FG000|6-month Double-Blind Treatment Period|Withdrawal by Subject|1
6013647|NCT00124449|9606123|FG001|6-month Double-Blind Treatment Period|Withdrawal by Subject|1
6013648|NCT00124449|9606122|FG000|6-month Double-Blind Treatment Period|Poor/Noncompliance|1
6013649|NCT00124449|9606123|FG001|6-month Double-Blind Treatment Period|Poor/Noncompliance|0
6013650|NCT00124449|9606122|FG000|6-month Double-Blind Treatment Period|Sponsor request|0
6013651|NCT00124449|9606123|FG001|6-month Double-Blind Treatment Period|Sponsor request|1
6013652|NCT00124449|9606122|FG000|6-month Double-Blind Treatment Period|Exposure to mycobacterium tuberculosis|0
6013653|NCT00124449|9606123|FG001|6-month Double-Blind Treatment Period|Exposure to mycobacterium tuberculosis|1
6013654|NCT00124449|9606122|FG000|18-Month Untreated Observation Period|Adverse Event|0
6013655|NCT00124449|9606123|FG001|18-Month Untreated Observation Period|Adverse Event|1
6013656|NCT00124449|9606122|FG000|18-Month Untreated Observation Period|Lack of Efficacy|11
6013657|NCT00124449|9606123|FG001|18-Month Untreated Observation Period|Lack of Efficacy|12
6013658|NCT00124449|9606122|FG000|18-Month Untreated Observation Period|Lost to Follow-up|1
6013659|NCT00124449|9606123|FG001|18-Month Untreated Observation Period|Lost to Follow-up|0
6013660|NCT00124449|9606122|FG000|18-Month Untreated Observation Period|Pregnancy|1
6013661|NCT00124449|9606123|FG001|18-Month Untreated Observation Period|Pregnancy|0
6013662|NCT00124449|9606122|FG000|18-Month Untreated Observation Period|Poor/Noncompliance|1
6013663|NCT00124449|9606123|FG001|18-Month Untreated Observation Period|Poor/Noncompliance|0
6013664|NCT00124449|9606122|FG000|18-Month Untreated Observation Period|Relocated|1
6013665|NCT00124449|9606123|FG001|18-Month Untreated Observation Period|Relocated|0
6013666|NCT00124462|9606132|FG000|Overall Study|Lost to Follow-up|3
6013667|NCT00124462|9606133|FG001|Overall Study|Lost to Follow-up|3
6013668|NCT00124462|9606132|FG000|Overall Study|Physician Decision|3
6013669|NCT00124462|9606133|FG001|Overall Study|Physician Decision|4
6013670|NCT00124462|9606132|FG000|Overall Study|Withdrawal by Subject|4
6013671|NCT00124462|9606133|FG001|Overall Study|Withdrawal by Subject|5
6013672|NCT00124462|9606132|FG000|Overall Study|Device fitting, n=2, other hlth issues|1
6013673|NCT00124462|9606133|FG001|Overall Study|Device fitting, n=2, other hlth issues|1
6013674|NCT00124618|9606160|FG000|Overall Study|Ineligible|1
6013675|NCT00124657|9606167|FG000|Overall Study|Toxicity|0
6013676|NCT00124657|9606168|FG001|Overall Study|Toxicity|0
6013677|NCT00124657|9606169|FG002|Overall Study|Toxicity|1
6013678|NCT00124657|9606167|FG000|Overall Study|Non-compliance|1
6013679|NCT00124657|9606168|FG001|Overall Study|Non-compliance|0
6013680|NCT00124657|9606169|FG002|Overall Study|Non-compliance|4
6013681|NCT00124657|9606167|FG000|Overall Study|Progressive disease|14
6013682|NCT00124657|9606168|FG001|Overall Study|Progressive disease|5
6013683|NCT00124657|9606169|FG002|Overall Study|Progressive disease|27
6013684|NCT00124657|9606167|FG000|Overall Study|Intercurrent illness|1
6013685|NCT00124657|9606168|FG001|Overall Study|Intercurrent illness|0
6013686|NCT00124657|9606169|FG002|Overall Study|Intercurrent illness|0
6013687|NCT00124709|9606192|FG000|Overall Study|Randomized but did not take medication|3
6013688|NCT00124709|9606193|FG001|Overall Study|Randomized but did not take medication|1
6013689|NCT00124709|9606192|FG000|Overall Study|Adverse Event|3
6013690|NCT00124709|9606193|FG001|Overall Study|Adverse Event|0
6013691|NCT00124709|9606192|FG000|Overall Study|Lack of Efficacy|5
6013692|NCT00124709|9606193|FG001|Overall Study|Lack of Efficacy|10
6013693|NCT00124709|9606192|FG000|Overall Study|Protocol Violation|3
6013694|NCT00124709|9606193|FG001|Overall Study|Protocol Violation|5
6013695|NCT00124709|9606192|FG000|Overall Study|Withdrawal by Subject|127
6013696|NCT00124709|9606193|FG001|Overall Study|Withdrawal by Subject|136
6013697|NCT00124709|9606192|FG000|Overall Study|Lost to Follow-up|114
6013698|NCT00124709|9606193|FG001|Overall Study|Lost to Follow-up|120
6013699|NCT00124748|9606234|FG000|Overall Study|Adverse Event|8
6013700|NCT00124748|9606235|FG001|Overall Study|Adverse Event|39
6013701|NCT00124748|9606234|FG000|Overall Study|Abnormal laboratory Value|2
6013702|NCT00124748|9606235|FG001|Overall Study|Abnormal laboratory Value|2
6013703|NCT00124748|9606234|FG000|Overall Study|Abnormal Procedure|0
6013704|NCT00124748|9606235|FG001|Overall Study|Abnormal Procedure|1
6013705|NCT00124748|9606234|FG000|Overall Study|Lack of Efficacy|20
6013706|NCT00124748|9606235|FG001|Overall Study|Lack of Efficacy|41
6013707|NCT00124748|9606234|FG000|Overall Study|No longer requires study drug|1
6013708|NCT00124748|9606235|FG001|Overall Study|No longer requires study drug|1
6013709|NCT00124748|9606234|FG000|Overall Study|Protocol Violation|3
6013710|NCT00124748|9606235|FG001|Overall Study|Protocol Violation|1
6013711|NCT00124748|9606234|FG000|Overall Study|Withdrawal by Subject|5
6013712|NCT00124748|9606235|FG001|Overall Study|Withdrawal by Subject|15
6013713|NCT00124748|9606234|FG000|Overall Study|Lost to Follow-up|2
6013714|NCT00124748|9606235|FG001|Overall Study|Lost to Follow-up|7
6013715|NCT00124748|9606234|FG000|Overall Study|Administrative Problem(Study Terminated)|101
6013716|NCT00124748|9606235|FG001|Overall Study|Administrative Problem(Study Terminated)|174
6013717|NCT00124748|9606234|FG000|Overall Study|Death|1
6013718|NCT00124748|9606235|FG001|Overall Study|Death|3
6013719|NCT00124917|9606241|FG000|Overall Study|Physician Decision|3
6013720|NCT00124943|9606250|FG000|Phase II|Adverse Event|0
6013721|NCT00124943|9606251|FG001|Phase II|Adverse Event|2
6013722|NCT00124943|9606252|FG002|Phase II|Adverse Event|0
6013723|NCT00124943|9606253|FG003|Phase II|Adverse Event|1
6013724|NCT00124943|9606250|FG000|Phase II|Protocol Violation|0
6013725|NCT00124943|9606251|FG001|Phase II|Protocol Violation|0
6013726|NCT00124943|9606252|FG002|Phase II|Protocol Violation|0
6013727|NCT00124943|9606253|FG003|Phase II|Protocol Violation|1
6013728|NCT00124943|9606250|FG000|Phase II|Lost to Follow-up|0
6013729|NCT00124943|9606251|FG001|Phase II|Lost to Follow-up|0
6013730|NCT00124943|9606252|FG002|Phase II|Lost to Follow-up|0
6013731|NCT00124943|9606253|FG003|Phase II|Lost to Follow-up|1
6013732|NCT00124943|9606250|FG000|Phase II|Withdrawal by Subject|0
6013733|NCT00124943|9606251|FG001|Phase II|Withdrawal by Subject|0
6013734|NCT00124943|9606252|FG002|Phase II|Withdrawal by Subject|0
6013735|NCT00124943|9606253|FG003|Phase II|Withdrawal by Subject|2
6013736|NCT00124982|9606265|FG000|Short-term Period|Death|1
6013737|NCT00124982|9606266|FG001|Short-term Period|Death|1
6013738|NCT00124982|9606267|FG002|Short-term Period|Death|0
6013739|NCT00124982|9606265|FG000|Short-term Period|Adverse Event|17
6013740|NCT00124982|9606266|FG001|Short-term Period|Adverse Event|22
6013741|NCT00124982|9606267|FG002|Short-term Period|Adverse Event|0
6013742|NCT00124982|9606265|FG000|Short-term Period|Lack of Efficacy|32
6013743|NCT00124982|9606266|FG001|Short-term Period|Lack of Efficacy|73
6076004|NCT00586690|9680967|FG001|Overall Study|Disease Progression|0
6076005|NCT00586690|9680966|FG000|Overall Study|Adverse Event|1
6076006|NCT00586690|9680967|FG001|Overall Study|Adverse Event|0
6076007|NCT00586690|9680966|FG000|Overall Study|Lack of Efficacy|2
6076008|NCT00586690|9680967|FG001|Overall Study|Lack of Efficacy|0
6076009|NCT00586690|9680966|FG000|Overall Study|Lab can't accommodate|1
6076010|NCT00586690|9680967|FG001|Overall Study|Lab can't accommodate|0
6076011|NCT00586703|9680972|FG000|Overall Study|Death|12
6076012|NCT00586820|9680987|FG000|Overall Study|Unsuccessful PCI|1
6076013|NCT00586820|9680988|FG001|Overall Study|Unsuccessful PCI|0
6076014|NCT00586846|9680994|FG000|Overall Study|Physician Decision|1
6076015|NCT00586846|9680994|FG000|Overall Study|Death|1
6076016|NCT00586846|9680994|FG000|Overall Study|Evaluable for Toxicity Only|4
6076017|NCT00586898|9680998|FG000|Overall Study|Adverse Event|1
6076018|NCT00586898|9680998|FG000|Overall Study|Patiemt Non-compliance|1
6076019|NCT00586898|9680998|FG000|Overall Study|Evaluable for Toxicity Only|5
6076020|NCT00587054|9681015|FG000|Overall Study|Patient not treated|9
6076021|NCT00587158|9681042|FG000|Overall Study|Did not want to do 24 hr urine collect.|4
6076022|NCT00587158|9681043|FG001|Overall Study|Did not want to do 24 hr urine collect.|3
6076023|NCT00587158|9681042|FG000|Overall Study|Physician Decision|0
6076024|NCT00587158|9681043|FG001|Overall Study|Physician Decision|1
6076025|NCT00587158|9681042|FG000|Overall Study|Lost to Follow-up|1
6076026|NCT00587158|9681043|FG001|Overall Study|Lost to Follow-up|2
6076027|NCT00587158|9681042|FG000|Overall Study|Death|0
6076028|NCT00587158|9681043|FG001|Overall Study|Death|1
6076029|NCT00587158|9681042|FG000|Overall Study|Subject did not want to take study med|0
6076030|NCT00587158|9681043|FG001|Overall Study|Subject did not want to take study med|1
6076031|NCT00587171|9681051|FG000|Overall Study|Lost to Follow-up|1
6076032|NCT00587171|9681052|FG001|Overall Study|Lost to Follow-up|1
6076033|NCT00587288|9681060|FG000|Overall Study|Adverse Event|0
6076034|NCT00587288|9681061|FG001|Overall Study|Adverse Event|1
6076035|NCT00587288|9681060|FG000|Overall Study|Lack of Efficacy|2
6076036|NCT00587288|9681061|FG001|Overall Study|Lack of Efficacy|8
6076037|NCT00587288|9681060|FG000|Overall Study|Protocol Violation|1
6076038|NCT00587288|9681061|FG001|Overall Study|Protocol Violation|0
6076039|NCT00587431|9681071|FG000|Overall Study|Adverse Event|1
6076040|NCT00587431|9681072|FG001|Overall Study|Adverse Event|0
6076041|NCT00587431|9681071|FG000|Overall Study|Withdrawal by Subject|0
6076042|NCT00587431|9681072|FG001|Overall Study|Withdrawal by Subject|1
6013744|NCT00124982|9606267|FG002|Short-term Period|Lack of Efficacy|0
6013745|NCT00124982|9606265|FG000|Short-term Period|Lost to Follow-up|8
6013746|NCT00124982|9606266|FG001|Short-term Period|Lost to Follow-up|5
6013747|NCT00124982|9606267|FG002|Short-term Period|Lost to Follow-up|0
6076043|NCT00587457|9681084|FG000|Overall Study|Adverse Event|1
6076044|NCT00587457|9681085|FG001|Overall Study|Adverse Event|2
6076045|NCT00587457|9681086|FG002|Overall Study|Adverse Event|1
6076046|NCT00587457|9681084|FG000|Overall Study|Disease progression|2
6013748|NCT00124982|9606265|FG000|Short-term Period|Withdrawal of Consent|7
6013749|NCT00124982|9606266|FG001|Short-term Period|Withdrawal of Consent|9
6013750|NCT00124982|9606267|FG002|Short-term Period|Withdrawal of Consent|0
6013751|NCT00124982|9606265|FG000|Short-term Period|Poor/Non-compliance|3
6013752|NCT00124982|9606266|FG001|Short-term Period|Poor/Non-compliance|1
6013753|NCT00124982|9606267|FG002|Short-term Period|Poor/Non-compliance|0
6013754|NCT00124982|9606265|FG000|Short-term Period|No Longer Meets Study Criteria|1
6013755|NCT00124982|9606266|FG001|Short-term Period|No Longer Meets Study Criteria|2
6013756|NCT00124982|9606267|FG002|Short-term Period|No Longer Meets Study Criteria|0
6013757|NCT00124982|9606265|FG000|Short-term Period|Participant Decision|1
6013758|NCT00124982|9606266|FG001|Short-term Period|Participant Decision|0
6013759|NCT00124982|9606267|FG002|Short-term Period|Participant Decision|0
6013760|NCT00124982|9606265|FG000|Short-term Period|Participant Chose Own Doctor|0
6013761|NCT00124982|9606266|FG001|Short-term Period|Participant Chose Own Doctor|1
6013762|NCT00124982|9606267|FG002|Short-term Period|Participant Chose Own Doctor|0
6013763|NCT00124982|9606265|FG000|Short-term Period|Investigator Decision-No Specific AE|1
6013764|NCT00124982|9606266|FG001|Short-term Period|Investigator Decision-No Specific AE|0
6013765|NCT00124982|9606267|FG002|Short-term Period|Investigator Decision-No Specific AE|0
6013766|NCT00124982|9606265|FG000|Short-term Period|Participant Had Lymphopenia|1
6013767|NCT00124982|9606266|FG001|Short-term Period|Participant Had Lymphopenia|0
6013768|NCT00124982|9606267|FG002|Short-term Period|Participant Had Lymphopenia|0
6013769|NCT00124982|9606265|FG000|Long-term Period|Death|0
6013770|NCT00124982|9606266|FG001|Long-term Period|Death|0
6013771|NCT00124982|9606267|FG002|Long-term Period|Death|1
6013772|NCT00124982|9606265|FG000|Long-term Period|Adverse Event|0
6013773|NCT00124982|9606266|FG001|Long-term Period|Adverse Event|0
6076047|NCT00587457|9681085|FG001|Overall Study|Disease progression|0
6076048|NCT00587457|9681086|FG002|Overall Study|Disease progression|2
6076049|NCT00587457|9681084|FG000|Overall Study|Initiation of alternative therapy|0
6076050|NCT00587457|9681085|FG001|Overall Study|Initiation of alternative therapy|1
6076051|NCT00587457|9681086|FG002|Overall Study|Initiation of alternative therapy|0
6076052|NCT00587457|9681084|FG000|Overall Study|Undefined|0
6076053|NCT00587457|9681085|FG001|Overall Study|Undefined|0
6076054|NCT00587457|9681086|FG002|Overall Study|Undefined|1
6076055|NCT00587457|9681084|FG000|Overall Study|Development of neutralizing Abs|0
6076056|NCT00587457|9681085|FG001|Overall Study|Development of neutralizing Abs|0
6076057|NCT00587457|9681086|FG002|Overall Study|Development of neutralizing Abs|1
6076058|NCT00587587|9681109|FG000|Overall Study|Lost to Follow-up|6
6076059|NCT00587587|9681110|FG001|Overall Study|Lost to Follow-up|1
6076060|NCT00587639|9681118|FG000|Overall Study|Withdrawal by Subject|1
6076061|NCT00587847|9681154|FG000|Overall Study|Lack of Efficacy|5
6076062|NCT00587847|9681154|FG000|Overall Study|Adverse Event|2
6087418|NCT00667732|9697657|FG001|Run -In (8 Weeks)|Withdrawal by Subject|0
6087419|NCT00667732|9697658|FG002|Run -In (8 Weeks)|Withdrawal by Subject|0
6087420|NCT00667732|9697656|FG000|Randomization (24 Weeks)|Withdrawal by Subject|0
6087421|NCT00667732|9697657|FG001|Randomization (24 Weeks)|Withdrawal by Subject|1
6087422|NCT00667732|9697658|FG002|Randomization (24 Weeks)|Withdrawal by Subject|0
6087423|NCT00667810|9697682|FG000|Overall Study|Adverse Event|13
6087424|NCT00667810|9697683|FG001|Overall Study|Adverse Event|14
6087425|NCT00667810|9697684|FG002|Overall Study|Adverse Event|19
6087426|NCT00667810|9697685|FG003|Overall Study|Adverse Event|1
6087427|NCT00667810|9697682|FG000|Overall Study|Death|1
6087428|NCT00667810|9697683|FG001|Overall Study|Death|1
6087429|NCT00667810|9697684|FG002|Overall Study|Death|3
6087430|NCT00667810|9697685|FG003|Overall Study|Death|0
6087431|NCT00667810|9697682|FG000|Overall Study|Lack of Efficacy|1
6087432|NCT00667810|9697683|FG001|Overall Study|Lack of Efficacy|0
6087433|NCT00667810|9697684|FG002|Overall Study|Lack of Efficacy|2
6087434|NCT00667810|9697685|FG003|Overall Study|Lack of Efficacy|0
6087435|NCT00667810|9697682|FG000|Overall Study|Lost to Follow-up|1
6087436|NCT00667810|9697683|FG001|Overall Study|Lost to Follow-up|4
6087437|NCT00667810|9697684|FG002|Overall Study|Lost to Follow-up|2
6087438|NCT00667810|9697685|FG003|Overall Study|Lost to Follow-up|0
6087439|NCT00667810|9697682|FG000|Overall Study|Physician Decision|1
6087440|NCT00667810|9697683|FG001|Overall Study|Physician Decision|1
6087441|NCT00667810|9697684|FG002|Overall Study|Physician Decision|2
6087442|NCT00667810|9697685|FG003|Overall Study|Physician Decision|0
6087443|NCT00667810|9697682|FG000|Overall Study|Protocol Violation|0
6087444|NCT00667810|9697683|FG001|Overall Study|Protocol Violation|2
6087445|NCT00667810|9697684|FG002|Overall Study|Protocol Violation|0
6087446|NCT00667810|9697685|FG003|Overall Study|Protocol Violation|0
6087447|NCT00667810|9697682|FG000|Overall Study|Withdrawal by Subject|14
6087448|NCT00667810|9697683|FG001|Overall Study|Withdrawal by Subject|20
6087449|NCT00667810|9697684|FG002|Overall Study|Withdrawal by Subject|29
6013774|NCT00124982|9606267|FG002|Long-term Period|Adverse Event|17
6013775|NCT00124982|9606265|FG000|Long-term Period|Lack of Efficacy|0
6013776|NCT00124982|9606266|FG001|Long-term Period|Lack of Efficacy|0
6013777|NCT00124982|9606267|FG002|Long-term Period|Lack of Efficacy|46
6087450|NCT00667810|9697685|FG003|Overall Study|Withdrawal by Subject|1
6087451|NCT00667810|9697682|FG000|Overall Study|Discontinuation of Study by Sponsor|130
6087452|NCT00667810|9697683|FG001|Overall Study|Discontinuation of Study by Sponsor|118
6087453|NCT00667810|9697684|FG002|Overall Study|Discontinuation of Study by Sponsor|155
6087454|NCT00667810|9697685|FG003|Overall Study|Discontinuation of Study by Sponsor|0
6013778|NCT00124982|9606265|FG000|Long-term Period|Lost to Follow-up|0
6013779|NCT00124982|9606266|FG001|Long-term Period|Lost to Follow-up|0
6013780|NCT00124982|9606267|FG002|Long-term Period|Lost to Follow-up|4
6013781|NCT00124982|9606265|FG000|Long-term Period|Withdrawal by Subject|0
6013782|NCT00124982|9606266|FG001|Long-term Period|Withdrawal by Subject|0
6013783|NCT00124982|9606267|FG002|Long-term Period|Withdrawal by Subject|16
6013784|NCT00124982|9606265|FG000|Long-term Period|Pregnancy|0
6013785|NCT00124982|9606266|FG001|Long-term Period|Pregnancy|0
6013786|NCT00124982|9606267|FG002|Long-term Period|Pregnancy|1
6013787|NCT00124982|9606265|FG000|Long-term Period|Poor/Non-compliance|0
6013788|NCT00124982|9606266|FG001|Long-term Period|Poor/Non-compliance|0
6013789|NCT00124982|9606267|FG002|Long-term Period|Poor/Non-compliance|2
6013790|NCT00124982|9606265|FG000|Long-term Period|Administrative Reason by Sponsor|0
6013791|NCT00124982|9606266|FG001|Long-term Period|Administrative Reason by Sponsor|0
6013792|NCT00124982|9606267|FG002|Long-term Period|Administrative Reason by Sponsor|1
6013793|NCT00124982|9606265|FG000|Long-term Period|Neurologist Recommendation|0
6013794|NCT00124982|9606266|FG001|Long-term Period|Neurologist Recommendation|0
6013795|NCT00124982|9606267|FG002|Long-term Period|Neurologist Recommendation|1
6013796|NCT00125138|9606289|FG000|Overall Study|Adverse Event|1
6013797|NCT00125138|9606290|FG001|Overall Study|Adverse Event|0
6013798|NCT00125138|9606291|FG002|Overall Study|Adverse Event|3
6013799|NCT00125138|9606292|FG003|Overall Study|Adverse Event|2
6013800|NCT00125138|9606289|FG000|Overall Study|Withdrawal by Subject|2
6013801|NCT00125138|9606290|FG001|Overall Study|Withdrawal by Subject|3
6013802|NCT00125138|9606291|FG002|Overall Study|Withdrawal by Subject|1
6013803|NCT00125138|9606292|FG003|Overall Study|Withdrawal by Subject|1
6013804|NCT00125138|9606289|FG000|Overall Study|Lack of Efficacy|0
6076063|NCT04411680|9681165|FG000|Treatment Period|Adverse Event|3
6076064|NCT04411680|9681166|FG001|Treatment Period|Adverse Event|0
6076065|NCT04411680|9681165|FG000|Treatment Period|Discharged from hospital|18
6076066|NCT04411680|9681166|FG001|Treatment Period|Discharged from hospital|7
6076067|NCT04411680|9681165|FG000|Treatment Period|Missed 1 or more doses|8
6076068|NCT04411680|9681166|FG001|Treatment Period|Missed 1 or more doses|0
6076069|NCT04411680|9681165|FG000|Treatment Period|Transferred to another hospital|0
6076070|NCT04411680|9681166|FG001|Treatment Period|Transferred to another hospital|1
6076071|NCT04411680|9681165|FG000|Follow up Period|Withdrawal by Subject|2
6076072|NCT04411680|9681166|FG001|Follow up Period|Withdrawal by Subject|0
6076073|NCT04411680|9681165|FG000|Follow up Period|Lost to Follow-up|5
6076074|NCT04411680|9681166|FG001|Follow up Period|Lost to Follow-up|6
6076075|NCT04411680|9681165|FG000|Follow up Period|Death|11
6076076|NCT04411680|9681166|FG001|Follow up Period|Death|8
6076077|NCT04364984|9681175|FG000|Overall Study|Death|2
6076078|NCT04364984|9681176|FG001|Overall Study|Death|2
6076079|NCT04364984|9681177|FG002|Overall Study|Death|0
6076080|NCT03711266|9681221|FG000|Overall Study|Lost to Follow-up|10
6076081|NCT03630393|9681227|FG000|Overall Study|Death|1
6076082|NCT03630393|9681228|FG001|Overall Study|Death|0
6076083|NCT03359811|9681245|FG000|Overall Study|Protocol Violation|2
6076084|NCT03359811|9681246|FG001|Overall Study|Protocol Violation|0
6076085|NCT02954406|9681288|FG000|Overall Study|Adverse Event|0
6076086|NCT02954406|9681289|FG001|Overall Study|Adverse Event|1
6076087|NCT02954406|9681290|FG002|Overall Study|Adverse Event|0
6076088|NCT02954406|9681291|FG003|Overall Study|Adverse Event|0
6076089|NCT02954406|9681292|FG004|Overall Study|Adverse Event|1
6076090|NCT02954406|9681293|FG005|Overall Study|Adverse Event|0
6076091|NCT02954406|9681294|FG006|Overall Study|Adverse Event|0
6076092|NCT02954406|9681295|FG007|Overall Study|Adverse Event|0
6076093|NCT02954406|9681296|FG008|Overall Study|Adverse Event|1
6076094|NCT02954406|9681297|FG009|Overall Study|Adverse Event|1
6076095|NCT02954406|9681298|FG010|Overall Study|Adverse Event|0
6076096|NCT02954406|9681288|FG000|Overall Study|Progressive Disease|3
6076097|NCT02954406|9681289|FG001|Overall Study|Progressive Disease|4
6076098|NCT02954406|9681290|FG002|Overall Study|Progressive Disease|3
6076099|NCT02954406|9681291|FG003|Overall Study|Progressive Disease|4
6076100|NCT02954406|9681292|FG004|Overall Study|Progressive Disease|3
6076101|NCT02954406|9681293|FG005|Overall Study|Progressive Disease|3
6076102|NCT02954406|9681294|FG006|Overall Study|Progressive Disease|2
6076103|NCT02954406|9681295|FG007|Overall Study|Progressive Disease|2
6076104|NCT02954406|9681296|FG008|Overall Study|Progressive Disease|1
6076105|NCT02954406|9681297|FG009|Overall Study|Progressive Disease|1
6013805|NCT00125138|9606290|FG001|Overall Study|Lack of Efficacy|0
6013806|NCT00125138|9606291|FG002|Overall Study|Lack of Efficacy|0
6076106|NCT02954406|9681298|FG010|Overall Study|Progressive Disease|0
6076107|NCT02954406|9681288|FG000|Overall Study|Symptomatic Deterioration|0
6076108|NCT02954406|9681289|FG001|Overall Study|Symptomatic Deterioration|1
6013807|NCT00125138|9606292|FG003|Overall Study|Lack of Efficacy|1
6013808|NCT00125138|9606289|FG000|Overall Study|Sponsor decision-pt moved to assist care|0
6013809|NCT00125138|9606290|FG001|Overall Study|Sponsor decision-pt moved to assist care|0
6076109|NCT02954406|9681290|FG002|Overall Study|Symptomatic Deterioration|0
6076110|NCT02954406|9681291|FG003|Overall Study|Symptomatic Deterioration|0
6076111|NCT02954406|9681292|FG004|Overall Study|Symptomatic Deterioration|0
6076112|NCT02954406|9681293|FG005|Overall Study|Symptomatic Deterioration|0
6076113|NCT02954406|9681294|FG006|Overall Study|Symptomatic Deterioration|0
6076114|NCT02954406|9681295|FG007|Overall Study|Symptomatic Deterioration|0
6013810|NCT00125138|9606291|FG002|Overall Study|Sponsor decision-pt moved to assist care|0
6013811|NCT00125138|9606292|FG003|Overall Study|Sponsor decision-pt moved to assist care|1
6013812|NCT00125164|9606306|FG000|Overall Study|Adverse Event|0
6013813|NCT00125164|9606307|FG001|Overall Study|Adverse Event|0
6013814|NCT00125164|9606308|FG002|Overall Study|Adverse Event|2
6013815|NCT00125164|9606309|FG003|Overall Study|Adverse Event|4
6013816|NCT00125164|9606306|FG000|Overall Study|Lost to Follow-up|0
6013817|NCT00125164|9606307|FG001|Overall Study|Lost to Follow-up|0
6013818|NCT00125164|9606308|FG002|Overall Study|Lost to Follow-up|1
6013819|NCT00125164|9606309|FG003|Overall Study|Lost to Follow-up|1
6013820|NCT00125164|9606306|FG000|Overall Study|Withdrawal by Subject|2
6013821|NCT00125164|9606307|FG001|Overall Study|Withdrawal by Subject|0
6013822|NCT00125164|9606308|FG002|Overall Study|Withdrawal by Subject|1
6013823|NCT00125164|9606309|FG003|Overall Study|Withdrawal by Subject|1
6013824|NCT00125190|9606319|FG000|Overall Study|Subject/Parent Decision|7
6013825|NCT00125190|9606319|FG000|Overall Study|Non-compliance|2
6013826|NCT00125190|9606319|FG000|Overall Study|Adverse Event|1
6013827|NCT00125190|9606319|FG000|Overall Study|Other|1
6013828|NCT00125190|9606319|FG000|Overall Study|Lost to Follow-up|4
6013829|NCT00125242|9606326|FG000|Overall Study|did not qualify|7
6013830|NCT00125242|9606327|FG001|Overall Study|did not qualify|2
6013831|NCT00125359|9606332|FG000|Overall Study|Death|4
6013832|NCT00125359|9606332|FG000|Overall Study|Adverse Event|5
6013833|NCT00125359|9606332|FG000|Overall Study|Physician Decision|14
6013834|NCT00125853|9606405|FG000|Wash-out (4 Weeks)|Lost to Follow-up|3
6013835|NCT00125853|9606406|FG001|Wash-out (4 Weeks)|Lost to Follow-up|7
6013836|NCT00126126|9606436|FG000|Overall Study|Lost to Follow-up|0
6013837|NCT00126126|9606437|FG001|Overall Study|Lost to Follow-up|2
6013838|NCT00126191|9606445|FG000|Overall Study|Physician Decision|0
6013839|NCT00126191|9606446|FG001|Overall Study|Physician Decision|1
6013840|NCT00126191|9606445|FG000|Overall Study|Death|0
6013841|NCT00126191|9606446|FG001|Overall Study|Death|1
6013842|NCT00126425|9606454|FG000|Overall Study|Withdrawal by Subject|17
6013843|NCT00126425|9606455|FG001|Overall Study|Withdrawal by Subject|1
6013844|NCT00126425|9606454|FG000|Overall Study|Lost to Follow-up|8
6013845|NCT00126425|9606455|FG001|Overall Study|Lost to Follow-up|4
6013846|NCT00126425|9606454|FG000|Overall Study|Protocol Violation|9
6013847|NCT00126425|9606455|FG001|Overall Study|Protocol Violation|6
6013848|NCT00126425|9606454|FG000|Overall Study|Adverse Event|1
6013849|NCT00126425|9606455|FG001|Overall Study|Adverse Event|0
6013850|NCT00126425|9606454|FG000|Overall Study|Failed Inclusion Exclusion Criteria|1
6013851|NCT00126425|9606455|FG001|Overall Study|Failed Inclusion Exclusion Criteria|0
6013852|NCT00126425|9606454|FG000|Overall Study|Other|5
6013853|NCT00126425|9606455|FG001|Overall Study|Other|0
6013854|NCT00126438|9606463|FG000|Overall Study|Withdrawal due to adverse event|1
6013855|NCT00126438|9606464|FG001|Overall Study|Withdrawal due to adverse event|0
6013856|NCT00126438|9606463|FG000|Overall Study|Lost to Follow-up|22
6013857|NCT00126438|9606464|FG001|Overall Study|Lost to Follow-up|0
6013858|NCT00126438|9606463|FG000|Overall Study|Protocol Violation|8
6013859|NCT00126438|9606464|FG001|Overall Study|Protocol Violation|8
6013860|NCT00126438|9606463|FG000|Overall Study|Withdrawal by Subject|3
6013861|NCT00126438|9606464|FG001|Overall Study|Withdrawal by Subject|2
6013862|NCT00126490|9606470|FG000|Overall Study|Stopped after 1 infusion (fall/injury)|1
6013863|NCT00126503|9606476|FG000|Overall Study|disease progression|23
6013864|NCT00126503|9606477|FG001|Overall Study|disease progression|14
6013865|NCT00126503|9606476|FG000|Overall Study|Withdrawal by Subject|0
6013866|NCT00126503|9606477|FG001|Overall Study|Withdrawal by Subject|1
6013867|NCT00126503|9606476|FG000|Overall Study|alternative therapy|1
6013868|NCT00126503|9606477|FG001|Overall Study|alternative therapy|1
6013869|NCT00126503|9606476|FG000|Overall Study|other complicating disease|4
6013870|NCT00126503|9606477|FG001|Overall Study|other complicating disease|1
6013871|NCT00126503|9606476|FG000|Overall Study|Death|3
6013872|NCT00126503|9606477|FG001|Overall Study|Death|0
6013873|NCT00126503|9606476|FG000|Overall Study|Adverse Event|13
6013874|NCT00126503|9606477|FG001|Overall Study|Adverse Event|3
6013875|NCT00126503|9606476|FG000|Overall Study|non-compliant|1
6013876|NCT00126503|9606477|FG001|Overall Study|non-compliant|0
6013877|NCT00126503|9606476|FG000|Overall Study|Physician Decision|2
6013878|NCT00126503|9606477|FG001|Overall Study|Physician Decision|1
6013879|NCT00126555|9606487|FG000|Overall Study|Withdrawal by Subject|1
6013880|NCT00126555|9606487|FG000|Overall Study|Adverse Event|2
6013881|NCT00126555|9606487|FG000|Overall Study|Progressive Disease|3
6013882|NCT00126568|9606503|FG000|Overall Study|Death|2
6013883|NCT00126581|9606510|FG000|Overall Study|Adverse Event|3
6013884|NCT00126581|9606511|FG001|Overall Study|Adverse Event|7
6013885|NCT00126581|9606510|FG000|Overall Study|Death|3
6013886|NCT00126581|9606511|FG001|Overall Study|Death|2
6013887|NCT00126581|9606510|FG000|Overall Study|Withdrawal by Subject|1
6013888|NCT00126581|9606511|FG001|Overall Study|Withdrawal by Subject|4
6013889|NCT00126581|9606510|FG000|Overall Study|Alternative therapy|3
6013890|NCT00126581|9606511|FG001|Overall Study|Alternative therapy|3
6013891|NCT00126581|9606510|FG000|Overall Study|Other illness/MD discretion|3
6013892|NCT00126581|9606511|FG001|Overall Study|Other illness/MD discretion|4
6013893|NCT00126594|9606521|FG000|Overall Study|Ineligible|2
6013894|NCT00126594|9606522|FG001|Overall Study|Ineligible|0
6013895|NCT00126594|9606521|FG000|Overall Study|Withdrawal by Subject|0
6013896|NCT00126594|9606522|FG001|Overall Study|Withdrawal by Subject|4
6013897|NCT00126594|9606521|FG000|Overall Study|Physician Decision|1
6013898|NCT00126594|9606522|FG001|Overall Study|Physician Decision|3
6013899|NCT00126594|9606521|FG000|Overall Study|Adverse Event|7
6013900|NCT00126594|9606522|FG001|Overall Study|Adverse Event|5
6013901|NCT00126594|9606521|FG000|Overall Study|Non-compliance|0
6013902|NCT00126594|9606522|FG001|Overall Study|Non-compliance|1
6013903|NCT00126594|9606521|FG000|Overall Study|Disease Progression|29
6013904|NCT00126594|9606522|FG001|Overall Study|Disease Progression|24
6013905|NCT00127036|9606560|FG000|Overall Study|Insufficient Data for Analysis|6
6013906|NCT00127036|9606561|FG001|Overall Study|Insufficient Data for Analysis|11
6013907|NCT00127036|9606560|FG000|Overall Study|Screen Failure|2
6013908|NCT00127036|9606561|FG001|Overall Study|Screen Failure|0
6013909|NCT00127101|9606586|FG000|Base Protocol|Adverse Event|0
6013910|NCT00127101|9606587|FG001|Base Protocol|Adverse Event|2
6013911|NCT00127101|9606588|FG002|Base Protocol|Adverse Event|1
6013912|NCT00127101|9606589|FG003|Base Protocol|Adverse Event|0
6013913|NCT00127101|9606590|FG004|Base Protocol|Adverse Event|0
6013914|NCT00127101|9606591|FG005|Base Protocol|Adverse Event|0
6013915|NCT00127101|9606586|FG000|Base Protocol|Lack of Efficacy|1
6013916|NCT00127101|9606587|FG001|Base Protocol|Lack of Efficacy|0
6013917|NCT00127101|9606588|FG002|Base Protocol|Lack of Efficacy|0
6013918|NCT00127101|9606589|FG003|Base Protocol|Lack of Efficacy|0
6013919|NCT00127101|9606590|FG004|Base Protocol|Lack of Efficacy|2
6013920|NCT00127101|9606591|FG005|Base Protocol|Lack of Efficacy|0
6013921|NCT00127101|9606586|FG000|Base Protocol|Withdrawal by Subject|1
6076115|NCT02954406|9681296|FG008|Overall Study|Symptomatic Deterioration|0
6076116|NCT02954406|9681297|FG009|Overall Study|Symptomatic Deterioration|0
6076117|NCT02954406|9681298|FG010|Overall Study|Symptomatic Deterioration|0
6076118|NCT02954406|9681288|FG000|Overall Study|Death|0
6076119|NCT02954406|9681289|FG001|Overall Study|Death|0
6076120|NCT02954406|9681290|FG002|Overall Study|Death|0
6076121|NCT02954406|9681291|FG003|Overall Study|Death|0
6076122|NCT02954406|9681292|FG004|Overall Study|Death|1
6076123|NCT02954406|9681293|FG005|Overall Study|Death|0
6076124|NCT02954406|9681294|FG006|Overall Study|Death|0
6076125|NCT02954406|9681295|FG007|Overall Study|Death|0
6076126|NCT02954406|9681296|FG008|Overall Study|Death|1
6076127|NCT02954406|9681297|FG009|Overall Study|Death|1
6076128|NCT02954406|9681298|FG010|Overall Study|Death|0
6076129|NCT02954406|9681288|FG000|Overall Study|Reason Not Specified|0
6076130|NCT02954406|9681289|FG001|Overall Study|Reason Not Specified|0
6076131|NCT02954406|9681290|FG002|Overall Study|Reason Not Specified|3
6076132|NCT02954406|9681291|FG003|Overall Study|Reason Not Specified|2
6076133|NCT02954406|9681292|FG004|Overall Study|Reason Not Specified|2
6076134|NCT02954406|9681293|FG005|Overall Study|Reason Not Specified|0
6076135|NCT02954406|9681294|FG006|Overall Study|Reason Not Specified|1
6076136|NCT02954406|9681295|FG007|Overall Study|Reason Not Specified|0
6076137|NCT02954406|9681296|FG008|Overall Study|Reason Not Specified|1
6076138|NCT02954406|9681297|FG009|Overall Study|Reason Not Specified|0
6076139|NCT02954406|9681298|FG010|Overall Study|Reason Not Specified|0
6076140|NCT02927145|9681333|FG000|Initial Recruitment|Withdrawal by Subject|0
6076141|NCT02927145|9681334|FG001|Initial Recruitment|Withdrawal by Subject|1
6076142|NCT02927145|9681335|FG002|Initial Recruitment|Withdrawal by Subject|1
6076143|NCT02927145|9681336|FG003|Initial Recruitment|Withdrawal by Subject|4
6076144|NCT02927145|9681337|FG004|Initial Recruitment|Withdrawal by Subject|1
6076145|NCT02927145|9681338|FG005|Initial Recruitment|Withdrawal by Subject|1
6076146|NCT02927145|9681339|FG006|Initial Recruitment|Withdrawal by Subject|0
6076147|NCT02927145|9681340|FG007|Initial Recruitment|Withdrawal by Subject|0
6076148|NCT02927145|9681341|FG008|Initial Recruitment|Withdrawal by Subject|2
6076149|NCT02927145|9681333|FG000|Initial Recruitment|Adverse Event|0
6076150|NCT02927145|9681334|FG001|Initial Recruitment|Adverse Event|0
6076151|NCT02927145|9681335|FG002|Initial Recruitment|Adverse Event|0
6076152|NCT02927145|9681336|FG003|Initial Recruitment|Adverse Event|0
6076153|NCT02927145|9681337|FG004|Initial Recruitment|Adverse Event|2
6076154|NCT02927145|9681338|FG005|Initial Recruitment|Adverse Event|0
6076155|NCT02927145|9681339|FG006|Initial Recruitment|Adverse Event|0
6076156|NCT02927145|9681340|FG007|Initial Recruitment|Adverse Event|0
6076157|NCT02927145|9681341|FG008|Initial Recruitment|Adverse Event|0
6076158|NCT02927145|9681333|FG000|Invitation for Additional Challenge|Pregnancy|0
6076159|NCT02927145|9681334|FG001|Invitation for Additional Challenge|Pregnancy|0
6076160|NCT02927145|9681335|FG002|Invitation for Additional Challenge|Pregnancy|0
6013922|NCT00127101|9606587|FG001|Base Protocol|Withdrawal by Subject|2
6013923|NCT00127101|9606588|FG002|Base Protocol|Withdrawal by Subject|1
6013924|NCT00127101|9606589|FG003|Base Protocol|Withdrawal by Subject|0
6013925|NCT00127101|9606590|FG004|Base Protocol|Withdrawal by Subject|0
6076161|NCT02927145|9681336|FG003|Invitation for Additional Challenge|Pregnancy|0
6076162|NCT02927145|9681337|FG004|Invitation for Additional Challenge|Pregnancy|0
6076163|NCT02927145|9681338|FG005|Invitation for Additional Challenge|Pregnancy|0
6076164|NCT02927145|9681339|FG006|Invitation for Additional Challenge|Pregnancy|1
6076165|NCT02927145|9681340|FG007|Invitation for Additional Challenge|Pregnancy|0
6076166|NCT02927145|9681341|FG008|Invitation for Additional Challenge|Pregnancy|0
6013926|NCT00127101|9606591|FG005|Base Protocol|Withdrawal by Subject|1
6013927|NCT00127101|9606586|FG000|Continuation Phase|Adverse Event|0
6013928|NCT00127101|9606587|FG001|Continuation Phase|Adverse Event|0
6013929|NCT00127101|9606588|FG002|Continuation Phase|Adverse Event|0
6013930|NCT00127101|9606589|FG003|Continuation Phase|Adverse Event|0
6013931|NCT00127101|9606590|FG004|Continuation Phase|Adverse Event|1
6013932|NCT00127101|9606591|FG005|Continuation Phase|Adverse Event|1
6013933|NCT00127101|9606586|FG000|Continuation Phase|Lack of Efficacy|0
6013934|NCT00127101|9606587|FG001|Continuation Phase|Lack of Efficacy|0
6013935|NCT00127101|9606588|FG002|Continuation Phase|Lack of Efficacy|0
6013936|NCT00127101|9606589|FG003|Continuation Phase|Lack of Efficacy|0
6013937|NCT00127101|9606590|FG004|Continuation Phase|Lack of Efficacy|0
6013938|NCT00127101|9606591|FG005|Continuation Phase|Lack of Efficacy|1
6013939|NCT00127101|9606586|FG000|Continuation Phase|Withdrawal by Subject|0
6013940|NCT00127101|9606587|FG001|Continuation Phase|Withdrawal by Subject|0
6013941|NCT00127101|9606588|FG002|Continuation Phase|Withdrawal by Subject|1
6013942|NCT00127101|9606589|FG003|Continuation Phase|Withdrawal by Subject|0
6013943|NCT00127101|9606590|FG004|Continuation Phase|Withdrawal by Subject|2
6013944|NCT00127101|9606591|FG005|Continuation Phase|Withdrawal by Subject|1
6013945|NCT00127166|9606607|FG000|Period I|Protocol Violation|0
6013946|NCT00127166|9606608|FG001|Period I|Protocol Violation|2
6013947|NCT00127166|9606607|FG000|Period I|Withdrawal by Subject|2
6013948|NCT00127166|9606608|FG001|Period I|Withdrawal by Subject|0
6013949|NCT00127166|9606607|FG000|Period I|Patient did not meet inclusion criteria|1
6013950|NCT00127166|9606608|FG001|Period I|Patient did not meet inclusion criteria|0
6013951|NCT00127166|9606607|FG000|Washout Period|Patient did not meet inclusion criteria|0
6013952|NCT00127166|9606608|FG001|Washout Period|Patient did not meet inclusion criteria|1
6013953|NCT00127166|9606607|FG000|Period II|Withdrawal by Subject|2
6013954|NCT00127166|9606608|FG001|Period II|Withdrawal by Subject|0
6013955|NCT00127166|9606607|FG000|Period II|Patient did not perform Visit 6 exercise|1
6013956|NCT00127166|9606608|FG001|Period II|Patient did not perform Visit 6 exercise|0
6013957|NCT00127192|9606619|FG000|Overall Study|Adverse Event|0
6013958|NCT00127192|9606620|FG001|Overall Study|Adverse Event|1
6013959|NCT00127192|9606621|FG002|Overall Study|Adverse Event|1
6013960|NCT00127192|9606622|FG003|Overall Study|Adverse Event|1
6013961|NCT00127192|9606623|FG004|Overall Study|Adverse Event|0
6013962|NCT00127192|9606619|FG000|Overall Study|Lack of Efficacy|2
6013963|NCT00127192|9606620|FG001|Overall Study|Lack of Efficacy|0
6013964|NCT00127192|9606621|FG002|Overall Study|Lack of Efficacy|0
6013965|NCT00127192|9606622|FG003|Overall Study|Lack of Efficacy|0
6013966|NCT00127192|9606623|FG004|Overall Study|Lack of Efficacy|2
6013967|NCT00127192|9606619|FG000|Overall Study|Withdrawal by Subject|0
6013968|NCT00127192|9606620|FG001|Overall Study|Withdrawal by Subject|0
6013969|NCT00127192|9606621|FG002|Overall Study|Withdrawal by Subject|1
6013970|NCT00127192|9606622|FG003|Overall Study|Withdrawal by Subject|0
6013971|NCT00127192|9606623|FG004|Overall Study|Withdrawal by Subject|3
6013972|NCT00127192|9606619|FG000|Overall Study|Adverse event in pre-treatment period|1
6013973|NCT00127192|9606620|FG001|Overall Study|Adverse event in pre-treatment period|0
6013974|NCT00127192|9606621|FG002|Overall Study|Adverse event in pre-treatment period|0
6013975|NCT00127192|9606622|FG003|Overall Study|Adverse event in pre-treatment period|0
6076167|NCT02910583|9681364|FG000|Overall Study|Withdrawal by Subject|6
6076168|NCT02910583|9681365|FG001|Overall Study|Withdrawal by Subject|7
6076169|NCT02910583|9681364|FG000|Overall Study|Other, Not Specified|1
6076170|NCT02910583|9681365|FG001|Overall Study|Other, Not Specified|0
6076171|NCT02598388|9681422|FG000|Overall Study|Lost to Follow-up|1
6076172|NCT02598388|9681423|FG001|Overall Study|Lost to Follow-up|0
6076173|NCT02598388|9681424|FG002|Overall Study|Lost to Follow-up|1
6076174|NCT02598388|9681425|FG003|Overall Study|Lost to Follow-up|0
6076175|NCT02598388|9681426|FG004|Overall Study|Lost to Follow-up|5
6076176|NCT02598388|9681427|FG005|Overall Study|Lost to Follow-up|1
6076177|NCT02598388|9681428|FG006|Overall Study|Lost to Follow-up|2
6076178|NCT02598388|9681429|FG007|Overall Study|Lost to Follow-up|1
6076179|NCT02598388|9681430|FG008|Overall Study|Lost to Follow-up|0
6076180|NCT02598388|9681431|FG009|Overall Study|Lost to Follow-up|0
6076181|NCT02598388|9681432|FG010|Overall Study|Lost to Follow-up|1
6076182|NCT02598388|9681433|FG011|Overall Study|Lost to Follow-up|0
6076183|NCT02598388|9681422|FG000|Overall Study|Withdrawal by Subject|0
6076184|NCT02598388|9681423|FG001|Overall Study|Withdrawal by Subject|0
6076185|NCT02598388|9681424|FG002|Overall Study|Withdrawal by Subject|0
6076186|NCT02598388|9681425|FG003|Overall Study|Withdrawal by Subject|0
6076187|NCT02598388|9681426|FG004|Overall Study|Withdrawal by Subject|2
6076188|NCT02598388|9681427|FG005|Overall Study|Withdrawal by Subject|0
6013976|NCT00127192|9606623|FG004|Overall Study|Adverse event in pre-treatment period|0
6076189|NCT02598388|9681428|FG006|Overall Study|Withdrawal by Subject|2
6076190|NCT02598388|9681429|FG007|Overall Study|Withdrawal by Subject|0
6076191|NCT02598388|9681430|FG008|Overall Study|Withdrawal by Subject|0
6076192|NCT02598388|9681431|FG009|Overall Study|Withdrawal by Subject|1
6076193|NCT02598388|9681432|FG010|Overall Study|Withdrawal by Subject|0
6076194|NCT02598388|9681433|FG011|Overall Study|Withdrawal by Subject|0
6013977|NCT00127205|9606638|FG000|Overall Study|Adverse Event|228
6013978|NCT00127205|9606639|FG001|Overall Study|Adverse Event|387
6076195|NCT02598388|9681422|FG000|Overall Study|Other|0
6076196|NCT02598388|9681423|FG001|Overall Study|Other|0
6013979|NCT00127205|9606640|FG002|Overall Study|Adverse Event|273
6013980|NCT00127205|9606638|FG000|Overall Study|Death|8
6013981|NCT00127205|9606639|FG001|Overall Study|Death|6
6013982|NCT00127205|9606640|FG002|Overall Study|Death|5
6013983|NCT00127205|9606638|FG000|Overall Study|Withdrawal by Subject|318
6013984|NCT00127205|9606639|FG001|Overall Study|Withdrawal by Subject|310
6013985|NCT00127205|9606640|FG002|Overall Study|Withdrawal by Subject|172
6013986|NCT00127205|9606638|FG000|Overall Study|Other-non protocol specified|142
6013987|NCT00127205|9606639|FG001|Overall Study|Other-non protocol specified|129
6013988|NCT00127205|9606640|FG002|Overall Study|Other-non protocol specified|77
6013989|NCT00127205|9606638|FG000|Overall Study|Data not reported|6
6013990|NCT00127205|9606639|FG001|Overall Study|Data not reported|10
6013991|NCT00127205|9606640|FG002|Overall Study|Data not reported|1
6013992|NCT00127205|9606638|FG000|Overall Study|Progression|127
6013993|NCT00127205|9606639|FG001|Overall Study|Progression|131
6013994|NCT00127205|9606640|FG002|Overall Study|Progression|84
6013995|NCT00127413|9606674|FG000|Overall Study|Lost to Follow-up|6
6013996|NCT00127413|9606675|FG001|Overall Study|Lost to Follow-up|4
6013997|NCT00127413|9606676|FG002|Overall Study|Lost to Follow-up|8
6013998|NCT00127413|9606677|FG003|Overall Study|Lost to Follow-up|2
6013999|NCT00127608|9606708|FG000|Overall Study|VZV DNA negative|1
6014000|NCT00127660|9606716|FG000|Overall Study|Protocol Violation|3
6014001|NCT00127660|9606717|FG001|Overall Study|Protocol Violation|3
6014002|NCT00127660|9606718|FG002|Overall Study|Protocol Violation|5
6014003|NCT00127660|9606719|FG003|Overall Study|Protocol Violation|0
6014004|NCT00127712|9606731|FG000|Overall Study|Adverse Event|3
6014005|NCT00127712|9606732|FG001|Overall Study|Adverse Event|0
6014006|NCT00127712|9606731|FG000|Overall Study|Lack of GI access to continue|2
6014007|NCT00127712|9606732|FG001|Overall Study|Lack of GI access to continue|0
6014008|NCT00127803|9606759|FG000|Overall Study|Adverse Event|2
6014009|NCT00127803|9606760|FG001|Overall Study|Adverse Event|0
6014010|NCT00127803|9606761|FG002|Overall Study|Adverse Event|0
6014011|NCT00127803|9606762|FG003|Overall Study|Adverse Event|0
6014012|NCT00127803|9606759|FG000|Overall Study|Withdrawal by Subject|1
6014013|NCT00127803|9606760|FG001|Overall Study|Withdrawal by Subject|0
6014014|NCT00127803|9606761|FG002|Overall Study|Withdrawal by Subject|0
6014015|NCT00127803|9606762|FG003|Overall Study|Withdrawal by Subject|0
6014016|NCT00127803|9606759|FG000|Overall Study|Lost to Follow-up|0
6014017|NCT00127803|9606760|FG001|Overall Study|Lost to Follow-up|0
6014018|NCT00127803|9606761|FG002|Overall Study|Lost to Follow-up|0
6014019|NCT00127803|9606762|FG003|Overall Study|Lost to Follow-up|1
6014020|NCT00127842|9606772|FG000|Overall Study|Adverse Event|15
6014021|NCT00127842|9606772|FG000|Overall Study|Withdrawal by Subject|3
6014022|NCT00127842|9606772|FG000|Overall Study|Lost to Follow-up|1
6014023|NCT00127842|9606772|FG000|Overall Study|Lack of Efficacy|12
6014024|NCT00127842|9606772|FG000|Overall Study|Noncompliance|2
6014025|NCT00127842|9606772|FG000|Overall Study|Protocol Violation|1
6014026|NCT00127842|9606772|FG000|Overall Study|Other|5
6014027|NCT00127855|9606781|FG000|Primary Vaccination Course|Adverse Event|0
6014028|NCT00127855|9606782|FG001|Primary Vaccination Course|Adverse Event|0
6309512|NCT02640053|10038185|FG001|Overall Study|Alternative Therapy|1
6309513|NCT02640053|10038184|FG000|Overall Study|Chemo regimen changed after 1st Rx|0
6309514|NCT02640053|10038185|FG001|Overall Study|Chemo regimen changed after 1st Rx|1
6014029|NCT00127855|9606783|FG002|Primary Vaccination Course|Adverse Event|1
6014030|NCT00127855|9606784|FG003|Primary Vaccination Course|Adverse Event|0
6014031|NCT00127855|9606785|FG004|Primary Vaccination Course|Adverse Event|0
6014032|NCT00127855|9606781|FG000|Primary Vaccination Course|Withdrawal by Subject|1
6014033|NCT00127855|9606782|FG001|Primary Vaccination Course|Withdrawal by Subject|0
6014034|NCT00127855|9606783|FG002|Primary Vaccination Course|Withdrawal by Subject|0
6014035|NCT00127855|9606784|FG003|Primary Vaccination Course|Withdrawal by Subject|0
6014036|NCT00127855|9606785|FG004|Primary Vaccination Course|Withdrawal by Subject|1
6014037|NCT00127855|9606781|FG000|Primary Vaccination Course|Lost to Follow-up|1
6014038|NCT00127855|9606782|FG001|Primary Vaccination Course|Lost to Follow-up|1
6014039|NCT00127855|9606783|FG002|Primary Vaccination Course|Lost to Follow-up|1
6014040|NCT00127855|9606784|FG003|Primary Vaccination Course|Lost to Follow-up|0
6014041|NCT00127855|9606785|FG004|Primary Vaccination Course|Lost to Follow-up|2
6014042|NCT00127855|9606781|FG000|Primary Vaccination Course|Other|0
6014043|NCT00127855|9606782|FG001|Primary Vaccination Course|Other|0
6014044|NCT00127855|9606783|FG002|Primary Vaccination Course|Other|0
6014045|NCT00127855|9606784|FG003|Primary Vaccination Course|Other|0
6014046|NCT00127855|9606785|FG004|Primary Vaccination Course|Other|1
6014047|NCT00127933|9606799|FG000|Overall Study|Randomized but not dosed|1
6014048|NCT00127933|9606800|FG001|Overall Study|Randomized but not dosed|0
6014049|NCT00128102|9606808|FG000|Overall Study|Site Discontinued|3
6014050|NCT00128102|9606809|FG001|Overall Study|Site Discontinued|6
6014051|NCT00128102|9606808|FG000|Overall Study|Other|0
6014052|NCT00128102|9606809|FG001|Overall Study|Other|1
6014053|NCT00128102|9606808|FG000|Overall Study|Progressive Disease|255
6014054|NCT00128102|9606809|FG001|Overall Study|Progressive Disease|285
6309515|NCT02640157|10038194|FG000|Overall Study|Adverse Event|2
6014055|NCT00128102|9606808|FG000|Overall Study|Adverse Event|34
6014056|NCT00128102|9606809|FG001|Overall Study|Adverse Event|11
6014057|NCT00128102|9606808|FG000|Overall Study|Death|12
6014058|NCT00128102|9606809|FG001|Overall Study|Death|13
6014059|NCT00128102|9606808|FG000|Overall Study|Physician Decision|3
6014060|NCT00128102|9606809|FG001|Overall Study|Physician Decision|3
6014061|NCT00128102|9606808|FG000|Overall Study|Withdrawal by Subject|19
6014062|NCT00128102|9606809|FG001|Overall Study|Withdrawal by Subject|11
6014063|NCT00128102|9606808|FG000|Overall Study|Protocol Violation|2
6014064|NCT00128102|9606809|FG001|Overall Study|Protocol Violation|2
6014065|NCT00128206|9606929|FG000|Overall Study|Lost to Follow-up|137
6014066|NCT00128206|9606930|FG001|Overall Study|Lost to Follow-up|118
6014067|NCT00128206|9606929|FG000|Overall Study|Adverse Event|0
6014068|NCT00128206|9606930|FG001|Overall Study|Adverse Event|2
6014069|NCT00128492|9606957|FG000|Overall Study|AE unrelated to study|2
6014070|NCT00128492|9606958|FG001|Overall Study|AE unrelated to study|9
6014071|NCT00128492|9606957|FG000|Overall Study|Study drug intolerance (AE)|2
6014072|NCT00128492|9606958|FG001|Overall Study|Study drug intolerance (AE)|8
6014073|NCT00128492|9606957|FG000|Overall Study|AE related to study|1
6014074|NCT00128492|9606958|FG001|Overall Study|AE related to study|4
6014075|NCT00128492|9606957|FG000|Overall Study|Death|1
6014076|NCT00128492|9606958|FG001|Overall Study|Death|0
6014077|NCT00128492|9606957|FG000|Overall Study|Lost to Follow-up|1
6014078|NCT00128492|9606958|FG001|Overall Study|Lost to Follow-up|5
6014079|NCT00128492|9606957|FG000|Overall Study|Noncompliance|0
6014080|NCT00128492|9606958|FG001|Overall Study|Noncompliance|5
6014081|NCT00128492|9606957|FG000|Overall Study|Personal or administrative|10
6014082|NCT00128492|9606958|FG001|Overall Study|Personal or administrative|22
6014083|NCT00128492|9606957|FG000|Overall Study|Withdrawal by Subject|3
6014084|NCT00128492|9606958|FG001|Overall Study|Withdrawal by Subject|5
6014085|NCT00128492|9606957|FG000|Overall Study|Pregnancy|0
6014086|NCT00128492|9606958|FG001|Overall Study|Pregnancy|1
6014087|NCT00128661|9606966|FG000|Overall Study|Adverse Event|14
6014088|NCT00128661|9606967|FG001|Overall Study|Adverse Event|11
6014089|NCT00128661|9606966|FG000|Overall Study|Lost to Follow-up|10
6014090|NCT00128661|9606967|FG001|Overall Study|Lost to Follow-up|7
6014091|NCT00128661|9606966|FG000|Overall Study|Withdrawal by Subject|243
6014092|NCT00128661|9606967|FG001|Overall Study|Withdrawal by Subject|232
6014093|NCT00128661|9606966|FG000|Overall Study|Other|7
6014094|NCT00128661|9606967|FG001|Overall Study|Other|8
6014095|NCT00128830|9606986|FG000|Overall Study|Adverse Event|10
6014096|NCT00128830|9606986|FG000|Overall Study|Withdrawal by Subject|14
6014097|NCT00128830|9606986|FG000|Overall Study|Lost to Follow-up|4
6014098|NCT00128830|9606986|FG000|Overall Study|Reached a virologic endpoint|29
6014099|NCT00128830|9606986|FG000|Overall Study|Non-compliant|4
6014100|NCT00128830|9606986|FG000|Overall Study|Discontinued or ineligible for study|2
6014101|NCT00128830|9606986|FG000|Overall Study|Other|9
6014102|NCT00129116|9607012|FG000|Primary Phase|Lost to Follow-up|1
6014103|NCT00129116|9607013|FG001|Primary Phase|Lost to Follow-up|1
6014104|NCT00129116|9607014|FG002|Primary Phase|Lost to Follow-up|0
6014105|NCT00129116|9607015|FG003|Primary Phase|Lost to Follow-up|1
6014106|NCT00129116|9607016|FG004|Primary Phase|Lost to Follow-up|1
6014107|NCT00129116|9607012|FG000|Primary Phase|Protocol Violation|0
6014108|NCT00129116|9607013|FG001|Primary Phase|Protocol Violation|1
6014109|NCT00129116|9607014|FG002|Primary Phase|Protocol Violation|0
6014110|NCT00129116|9607015|FG003|Primary Phase|Protocol Violation|0
6014111|NCT00129116|9607016|FG004|Primary Phase|Protocol Violation|0
6014112|NCT00129116|9607012|FG000|Primary Phase|Adverse Event|1
6014113|NCT00129116|9607013|FG001|Primary Phase|Adverse Event|1
6014114|NCT00129116|9607014|FG002|Primary Phase|Adverse Event|0
6014115|NCT00129116|9607015|FG003|Primary Phase|Adverse Event|0
6014116|NCT00129116|9607016|FG004|Primary Phase|Adverse Event|0
6014117|NCT00129116|9607012|FG000|Primary Phase|Withdrawal by Subject|0
6014118|NCT00129116|9607013|FG001|Primary Phase|Withdrawal by Subject|1
6014119|NCT00129116|9607014|FG002|Primary Phase|Withdrawal by Subject|0
6014120|NCT00129116|9607015|FG003|Primary Phase|Withdrawal by Subject|0
6014121|NCT00129116|9607016|FG004|Primary Phase|Withdrawal by Subject|0
6014122|NCT00129116|9607012|FG000|Primary Phase|Other|0
6014123|NCT00129116|9607013|FG001|Primary Phase|Other|0
6014124|NCT00129116|9607014|FG002|Primary Phase|Other|1
6014125|NCT00129116|9607015|FG003|Primary Phase|Other|0
6014126|NCT00129116|9607016|FG004|Primary Phase|Other|0
6014127|NCT00129116|9607012|FG000|Booster Phase|Lost to Follow-up|2
6014128|NCT00129116|9607013|FG001|Booster Phase|Lost to Follow-up|0
6014129|NCT00129116|9607014|FG002|Booster Phase|Lost to Follow-up|0
6014130|NCT00129116|9607015|FG003|Booster Phase|Lost to Follow-up|0
6076197|NCT02598388|9681424|FG002|Overall Study|Other|1
6014131|NCT00129116|9607016|FG004|Booster Phase|Lost to Follow-up|1
6014132|NCT00129129|9607031|FG000|Primary Phase|Adverse Event|2
6014133|NCT00129129|9607032|FG001|Primary Phase|Adverse Event|1
6014134|NCT00129129|9607033|FG002|Primary Phase|Adverse Event|0
6014135|NCT00129129|9607034|FG003|Primary Phase|Adverse Event|0
6014136|NCT00129129|9607035|FG004|Primary Phase|Adverse Event|0
6014137|NCT00129129|9607031|FG000|Primary Phase|Withdrawal by Subject|12
6014138|NCT00129129|9607032|FG001|Primary Phase|Withdrawal by Subject|10
6014139|NCT00129129|9607033|FG002|Primary Phase|Withdrawal by Subject|0
6014140|NCT00129129|9607034|FG003|Primary Phase|Withdrawal by Subject|0
6014141|NCT00129129|9607035|FG004|Primary Phase|Withdrawal by Subject|0
6014142|NCT00129129|9607031|FG000|Primary Phase|Migration from study area|1
6014143|NCT00129129|9607032|FG001|Primary Phase|Migration from study area|3
6014144|NCT00129129|9607033|FG002|Primary Phase|Migration from study area|0
6076198|NCT02598388|9681425|FG003|Overall Study|Other|0
6014145|NCT00129129|9607034|FG003|Primary Phase|Migration from study area|0
6014146|NCT00129129|9607035|FG004|Primary Phase|Migration from study area|0
6014147|NCT00129129|9607031|FG000|Primary Phase|Lost to Follow-up|8
6014148|NCT00129129|9607032|FG001|Primary Phase|Lost to Follow-up|6
6014149|NCT00129129|9607033|FG002|Primary Phase|Lost to Follow-up|0
6014150|NCT00129129|9607034|FG003|Primary Phase|Lost to Follow-up|0
6014151|NCT00129129|9607035|FG004|Primary Phase|Lost to Follow-up|0
6014152|NCT00129129|9607031|FG000|Primary Phase|Other|2
6014153|NCT00129129|9607032|FG001|Primary Phase|Other|5
6014154|NCT00129129|9607033|FG002|Primary Phase|Other|0
6014155|NCT00129129|9607034|FG003|Primary Phase|Other|0
6014156|NCT00129129|9607035|FG004|Primary Phase|Other|0
6014157|NCT00129129|9607031|FG000|Fourth Dose Phase|Lost to Follow-up|4
6014158|NCT00129129|9607032|FG001|Fourth Dose Phase|Lost to Follow-up|0
6014159|NCT00129129|9607033|FG002|Fourth Dose Phase|Lost to Follow-up|0
6014160|NCT00129129|9607034|FG003|Fourth Dose Phase|Lost to Follow-up|2
6014161|NCT00129129|9607035|FG004|Fourth Dose Phase|Lost to Follow-up|2
6014162|NCT00129129|9607031|FG000|Fourth Dose Phase|Withdrawal by Subject|0
6014163|NCT00129129|9607032|FG001|Fourth Dose Phase|Withdrawal by Subject|0
6014164|NCT00129129|9607033|FG002|Fourth Dose Phase|Withdrawal by Subject|0
6014165|NCT00129129|9607034|FG003|Fourth Dose Phase|Withdrawal by Subject|0
6014166|NCT00129129|9607035|FG004|Fourth Dose Phase|Withdrawal by Subject|1
6014167|NCT00129129|9607031|FG000|Fourth Dose Phase|Migration from study area|0
6076199|NCT02598388|9681426|FG004|Overall Study|Other|3
6076200|NCT02598388|9681427|FG005|Overall Study|Other|0
6076201|NCT02598388|9681428|FG006|Overall Study|Other|1
6076202|NCT02598388|9681429|FG007|Overall Study|Other|0
6076203|NCT02598388|9681430|FG008|Overall Study|Other|0
6076204|NCT02598388|9681431|FG009|Overall Study|Other|0
6076205|NCT02598388|9681432|FG010|Overall Study|Other|0
6076206|NCT02598388|9681433|FG011|Overall Study|Other|0
6076207|NCT02493751|9681466|FG000|Overall Study|Withdrawal by Subject|2
6076208|NCT02493751|9681467|FG001|Overall Study|Withdrawal by Subject|8
6076209|NCT02493751|9681466|FG000|Overall Study|Death|6
6076210|NCT02493751|9681467|FG001|Overall Study|Death|13
6076211|NCT02493751|9681466|FG000|Overall Study|Lost to Follow-up|2
6076212|NCT02493751|9681467|FG001|Overall Study|Lost to Follow-up|3
6076213|NCT02493751|9681466|FG000|Overall Study|Study closed by Sponsor due to an internal decision with no safety concerns related.|6
6076214|NCT02493751|9681467|FG001|Overall Study|Study closed by Sponsor due to an internal decision with no safety concerns related.|15
6076215|NCT02285166|9681474|FG000|Overall Study|Case Report Forms Uncollected|564
6076216|NCT02285166|9681474|FG000|Overall Study|Protocol Deviation|402
6076217|NCT02075593|9681480|FG000|Overall Study|Withdrawal by Subject|1
6076218|NCT02075593|9681480|FG000|Overall Study|Treatment ongoing at the time of analysis|2
6087455|NCT00667810|9697682|FG000|Overall Study|Failed to Return|0
6087456|NCT00667810|9697683|FG001|Overall Study|Failed to Return|0
6087457|NCT00667810|9697684|FG002|Overall Study|Failed to Return|2
6087458|NCT00667810|9697685|FG003|Overall Study|Failed to Return|0
6087459|NCT00667810|9697682|FG000|Overall Study|Loss of Caregiver|0
6087460|NCT00667810|9697683|FG001|Overall Study|Loss of Caregiver|1
6087461|NCT00667810|9697684|FG002|Overall Study|Loss of Caregiver|3
6087462|NCT00667810|9697685|FG003|Overall Study|Loss of Caregiver|0
6087463|NCT00667810|9697682|FG000|Overall Study|Vasogenic Edema Recurrence|0
6087464|NCT00667810|9697683|FG001|Overall Study|Vasogenic Edema Recurrence|3
6087465|NCT00667810|9697684|FG002|Overall Study|Vasogenic Edema Recurrence|0
6087466|NCT00667810|9697685|FG003|Overall Study|Vasogenic Edema Recurrence|0
6087467|NCT00667810|9697682|FG000|Overall Study|Other|6
6087468|NCT00667810|9697683|FG001|Overall Study|Other|6
6087469|NCT00667810|9697684|FG002|Overall Study|Other|5
6087470|NCT00667810|9697685|FG003|Overall Study|Other|0
6087471|NCT00667862|9697712|FG000|Overall Study|Adverse Event|9
6087472|NCT00667862|9697712|FG000|Overall Study|Death|1
6087473|NCT00667862|9697712|FG000|Overall Study|Disease Progression|22
6087474|NCT00667862|9697712|FG000|Overall Study|Withdrawal by Subject|3
6087475|NCT00667875|9697719|FG000|Overall Study|Adverse Event|0
6087476|NCT00667875|9697720|FG001|Overall Study|Adverse Event|2
6087477|NCT00667875|9697721|FG002|Overall Study|Adverse Event|6
6087478|NCT00667875|9697719|FG000|Overall Study|Withdrawal by Subject|10
6087479|NCT00667875|9697720|FG001|Overall Study|Withdrawal by Subject|9
6087480|NCT00667875|9697721|FG002|Overall Study|Withdrawal by Subject|7
6087481|NCT00667888|9697737|FG000|Overall Study|Death|1
6087482|NCT00667888|9697738|FG001|Overall Study|Death|1
6087483|NCT00667888|9697737|FG000|Overall Study|Withdrawal by Subject|6
6087484|NCT00667888|9697738|FG001|Overall Study|Withdrawal by Subject|3
6087485|NCT00667888|9697737|FG000|Overall Study|Proceed with other treatment|3
6014168|NCT00129129|9607032|FG001|Fourth Dose Phase|Migration from study area|0
6087486|NCT00667888|9697738|FG001|Overall Study|Proceed with other treatment|3
6087487|NCT00667888|9697737|FG000|Overall Study|Ineligible after SIM|0
6087488|NCT00667888|9697738|FG001|Overall Study|Ineligible after SIM|2
6087489|NCT00667992|9697746|FG000|First Intervention 100 Mcg Twice Daily|Condition Under Investigation Worsened|2
6087490|NCT00667992|9697747|FG001|First Intervention 100 Mcg Twice Daily|Condition Under Investigation Worsened|3
6087491|NCT00667992|9697746|FG000|First Intervention 100 Mcg Twice Daily|Withdrawal by Subject|2
6014169|NCT00129129|9607033|FG002|Fourth Dose Phase|Migration from study area|0
6047625|NCT00412984|9646726|FG001|Overall Study|Lost to Follow-up|39
6014170|NCT00129129|9607034|FG003|Fourth Dose Phase|Migration from study area|0
6014171|NCT00129129|9607035|FG004|Fourth Dose Phase|Migration from study area|2
6014172|NCT00129129|9607031|FG000|Fourth Dose Phase|Other|0
6014173|NCT00129129|9607032|FG001|Fourth Dose Phase|Other|0
6014174|NCT00129129|9607033|FG002|Fourth Dose Phase|Other|0
6014175|NCT00129129|9607034|FG003|Fourth Dose Phase|Other|1
6014176|NCT00129129|9607035|FG004|Fourth Dose Phase|Other|1
6014177|NCT00129129|9607031|FG000|Fourth Dose Phase|Protocol Violation|0
6014178|NCT00129129|9607032|FG001|Fourth Dose Phase|Protocol Violation|0
6014179|NCT00129129|9607033|FG002|Fourth Dose Phase|Protocol Violation|0
6014180|NCT00129129|9607034|FG003|Fourth Dose Phase|Protocol Violation|1
6014181|NCT00129129|9607035|FG004|Fourth Dose Phase|Protocol Violation|0
6014182|NCT00129220|9607058|FG000|Study Period II|Adverse Event|9
6014183|NCT00129220|9607059|FG001|Study Period II|Adverse Event|5
6014184|NCT00129220|9607060|FG002|Study Period II|Adverse Event|7
6014185|NCT00129220|9607058|FG000|Study Period II|Lack of Efficacy|15
6014186|NCT00129220|9607059|FG001|Study Period II|Lack of Efficacy|1
6014187|NCT00129220|9607060|FG002|Study Period II|Lack of Efficacy|28
6014188|NCT00129220|9607058|FG000|Study Period II|Entry Criteria Not Met|2
6014189|NCT00129220|9607059|FG001|Study Period II|Entry Criteria Not Met|0
6014190|NCT00129220|9607060|FG002|Study Period II|Entry Criteria Not Met|2
6014191|NCT00129220|9607058|FG000|Study Period II|Protocol Violation|4
6014192|NCT00129220|9607059|FG001|Study Period II|Protocol Violation|2
6014193|NCT00129220|9607060|FG002|Study Period II|Protocol Violation|1
6014194|NCT00129220|9607058|FG000|Study Period II|Physician Decision|0
6014195|NCT00129220|9607059|FG001|Study Period II|Physician Decision|1
6014196|NCT00129220|9607060|FG002|Study Period II|Physician Decision|0
6014197|NCT00129220|9607058|FG000|Study Period II|Withdrawal by Subject|1
6076219|NCT00587860|9681488|FG000|Overall Study|Lost to Follow-up|2
6076220|NCT00587860|9681489|FG001|Overall Study|Lost to Follow-up|2
6076221|NCT00587860|9681488|FG000|Overall Study|Withdrawal by Subject|3
6076222|NCT00587860|9681489|FG001|Overall Study|Withdrawal by Subject|3
6076223|NCT00587964|9681495|FG000|Overall Study|Withdrawal by Subject|1
6076224|NCT00587964|9681495|FG000|Overall Study|Lost to Follow-up|1
6076225|NCT00587964|9681495|FG000|Overall Study|Patient found to be ineligible|1
6076226|NCT00587964|9681495|FG000|Overall Study|Patient did not receive intervention|5
6076227|NCT00587964|9681495|FG000|Overall Study|Progression of Disease|4
6076228|NCT00587990|9681502|FG000|Overall Study|Death|0
6076229|NCT00587990|9681503|FG001|Overall Study|Death|0
6076230|NCT00587990|9681504|FG002|Overall Study|Death|1
6076231|NCT00588094|9681512|FG000|Overall Study|Adverse Event|3
6076232|NCT00588094|9681512|FG000|Overall Study|Progression of Disease|2
6076233|NCT00588237|9681525|FG000|Overall Study|Evaluable for toxicity only|3
6076234|NCT00588237|9681525|FG000|Overall Study|Patien not treated|1
6076235|NCT00588341|9681529|FG000|Overall Study|Withdrawal by Subject|3
6076236|NCT00588341|9681529|FG000|Overall Study|Not treated due to metastatic disease|1
6076237|NCT00588341|9681529|FG000|Overall Study|Patient ineligible|1
6076238|NCT00588354|9681535|FG000|Baseline to 2 Weeks|Adverse Event|1
6076239|NCT00588354|9681536|FG001|Baseline to 2 Weeks|Adverse Event|0
6076240|NCT00588354|9681535|FG000|Baseline to 2 Weeks|Lack of Efficacy|1
6076241|NCT00588354|9681536|FG001|Baseline to 2 Weeks|Lack of Efficacy|0
6076242|NCT00588354|9681535|FG000|Baseline to 4 Weeks|Lost to Follow-up|0
6076243|NCT00588354|9681536|FG001|Baseline to 4 Weeks|Lost to Follow-up|1
6076244|NCT00588445|9681557|FG000|Overall Study|Protocol Violation|1
6076245|NCT00588445|9681557|FG000|Overall Study|Withdrawal by Subject|3
6076246|NCT00588445|9681557|FG000|Overall Study|Disease Progression|1
6076247|NCT00588445|9681557|FG000|Overall Study|Not Treated|10
6076248|NCT00588640|9681567|FG000|Overall Study|Physician Decision|1
6076249|NCT00588640|9681567|FG000|Overall Study|Ineligible Patient|1
6076250|NCT00588666|9681571|FG000|Overall Study|Adverse Event|4
6076251|NCT00588692|9681577|FG000|Overall Study|Withdrawal by Subject|4
6076252|NCT00588692|9681578|FG001|Overall Study|Withdrawal by Subject|2
6076253|NCT00588692|9681577|FG000|Overall Study|Hip Surgery|0
6076254|NCT00588692|9681578|FG001|Overall Study|Hip Surgery|1
6076255|NCT00588692|9681577|FG000|Overall Study|Severe Peptic Ulcer Disease|1
6076256|NCT00588692|9681578|FG001|Overall Study|Severe Peptic Ulcer Disease|0
6076257|NCT00588692|9681577|FG000|Overall Study|Cancer|1
6076258|NCT00588692|9681578|FG001|Overall Study|Cancer|0
6076259|NCT00588692|9681577|FG000|Overall Study|Death|1
6076260|NCT00588692|9681578|FG001|Overall Study|Death|0
6076261|NCT00588731|9681588|FG000|Overall Study|Withdrawal by Subject|3
6076262|NCT00588731|9681589|FG001|Overall Study|Withdrawal by Subject|2
6076263|NCT00588822|9681599|FG000|Overall Study|progression of disease|8
6076264|NCT00588848|9681605|FG000|Overall Study|Physician Decision|0
6076265|NCT00588848|9681606|FG001|Overall Study|Physician Decision|3
6076266|NCT00588952|9681620|FG000|Overall Study|Adverse Event|0
6076267|NCT00588952|9681621|FG001|Overall Study|Adverse Event|2
6076268|NCT00588952|9681620|FG000|Overall Study|Withdrawal by Subject|3
6076269|NCT00588952|9681621|FG001|Overall Study|Withdrawal by Subject|5
6076270|NCT00589108|9681640|FG000|Overall Study|Lost to Follow-up|1
6076271|NCT00589108|9681641|FG001|Overall Study|Lost to Follow-up|1
6014198|NCT00129220|9607059|FG001|Study Period II|Withdrawal by Subject|3
6014199|NCT00129220|9607060|FG002|Study Period II|Withdrawal by Subject|4
6014200|NCT00129220|9607058|FG000|Study Period II|Reason Not Specified|2
6076272|NCT00589108|9681642|FG002|Overall Study|Lost to Follow-up|1
6014201|NCT00129220|9607059|FG001|Study Period II|Reason Not Specified|0
6014202|NCT00129220|9607060|FG002|Study Period II|Reason Not Specified|5
6014203|NCT00129220|9607058|FG000|Study Period III|Adverse Event|1
6014204|NCT00129220|9607059|FG001|Study Period III|Adverse Event|0
6014205|NCT00129220|9607060|FG002|Study Period III|Adverse Event|3
6014206|NCT00129220|9607058|FG000|Study Period III|Protocol Violation|1
6014207|NCT00129220|9607059|FG001|Study Period III|Protocol Violation|1
6014208|NCT00129220|9607060|FG002|Study Period III|Protocol Violation|2
6014209|NCT00129220|9607058|FG000|Study Period III|Withdrawal by Subject|1
6076273|NCT00589108|9681640|FG000|Overall Study|Death|3
6076274|NCT00589108|9681641|FG001|Overall Study|Death|3
6076275|NCT00589108|9681642|FG002|Overall Study|Death|4
6076276|NCT00589121|9681652|FG000|Overall Study|Protocol Violation|2
6076277|NCT00589121|9681653|FG001|Overall Study|Protocol Violation|6
6076278|NCT00589121|9681652|FG000|Overall Study|No protocol treatment received|0
6076279|NCT00589121|9681653|FG001|Overall Study|No protocol treatment received|1
6076280|NCT00589290|9681671|FG000|Overall Study|Withdrawal by Subject|1
6076281|NCT00589303|9681679|FG000|Overall Study|Withdrawal by Subject|2
6076282|NCT00589303|9681680|FG001|Overall Study|Withdrawal by Subject|1
6076283|NCT00589472|9681696|FG000|Overall Study|Adverse Event|1
6076284|NCT00589602|9681704|FG000|Overall Study|Did not collect enough CD34+ cells|1
6076285|NCT00589628|9681712|FG000|Overall Study|Lost to Follow-up|0
6076286|NCT00589628|9681713|FG001|Overall Study|Lost to Follow-up|1
6076287|NCT00589667|9681719|FG000|Overall Study|Adverse Event|2
6076288|NCT00589667|9681719|FG000|Overall Study|Withdrawal by Subject|1
6076289|NCT00589693|9681725|FG000|Overall Study|randomized in error|12
6076290|NCT00589693|9681726|FG001|Overall Study|randomized in error|6
6076291|NCT00589693|9681725|FG000|Overall Study|Adverse Event|4
6076292|NCT00589693|9681726|FG001|Overall Study|Adverse Event|4
6076293|NCT00589693|9681725|FG000|Overall Study|Death|26
6076294|NCT00589693|9681726|FG001|Overall Study|Death|16
6076295|NCT00589693|9681725|FG000|Overall Study|Lack of Efficacy|0
6076296|NCT00589693|9681726|FG001|Overall Study|Lack of Efficacy|1
6076297|NCT00589693|9681725|FG000|Overall Study|Lost to Follow-up|1
6076298|NCT00589693|9681726|FG001|Overall Study|Lost to Follow-up|0
6076299|NCT00589693|9681725|FG000|Overall Study|Physician Decision|0
6076300|NCT00589693|9681726|FG001|Overall Study|Physician Decision|1
6076301|NCT00589693|9681725|FG000|Overall Study|Protocol Violation|1
6076302|NCT00589693|9681726|FG001|Overall Study|Protocol Violation|1
6076303|NCT00589784|9681734|FG000|Overall Study|Withdrawal by Subject|0
6076304|NCT00589784|9681735|FG001|Overall Study|Withdrawal by Subject|6
6076305|NCT00589784|9681734|FG000|Overall Study|Patient inevaluable|1
6076306|NCT00589784|9681735|FG001|Overall Study|Patient inevaluable|0
6076307|NCT00589784|9681734|FG000|Overall Study|Adverse Event|0
6076308|NCT00589784|9681735|FG001|Overall Study|Adverse Event|4
6076309|NCT00589797|9681742|FG000|Overall Study|Death|1
6076310|NCT00589797|9681743|FG001|Overall Study|Death|0
6076311|NCT00589797|9681742|FG000|Overall Study|Lost to Follow-up|12
6076312|NCT00589797|9681743|FG001|Overall Study|Lost to Follow-up|9
6076313|NCT00589797|9681742|FG000|Overall Study|Physician Decision|8
6076314|NCT00589797|9681743|FG001|Overall Study|Physician Decision|3
6076315|NCT00589797|9681742|FG000|Overall Study|Withdrawal by Subject|6
6076316|NCT00589797|9681743|FG001|Overall Study|Withdrawal by Subject|5
6076317|NCT00589797|9681742|FG000|Overall Study|Non-Randomized Training Subjects|46
6076318|NCT00589797|9681743|FG001|Overall Study|Non-Randomized Training Subjects|6
6076319|NCT00589914|9681780|FG000|Overall Study|Adverse Event|19
6076320|NCT00589914|9681781|FG001|Overall Study|Adverse Event|10
6076321|NCT00589914|9681780|FG000|Overall Study|Death|2
6076322|NCT00589914|9681781|FG001|Overall Study|Death|0
6076323|NCT00589914|9681780|FG000|Overall Study|Lack of Efficacy|40
6076324|NCT00589914|9681781|FG001|Overall Study|Lack of Efficacy|43
6076325|NCT00589914|9681780|FG000|Overall Study|Lost to Follow-up|11
6076326|NCT00589914|9681781|FG001|Overall Study|Lost to Follow-up|18
6076327|NCT00589914|9681780|FG000|Overall Study|Pregnancy|1
6076328|NCT00589914|9681781|FG001|Overall Study|Pregnancy|0
6076329|NCT00589914|9681780|FG000|Overall Study|Withdrawal by Subject|55
6076330|NCT00589914|9681781|FG001|Overall Study|Withdrawal by Subject|49
6076331|NCT00589914|9681780|FG000|Overall Study|Other|22
6076332|NCT00589914|9681781|FG001|Overall Study|Other|17
6076333|NCT00589979|9681789|FG000|Run-In Period|Adverse Event|5
6076334|NCT00589979|9681790|FG001|Run-In Period|Adverse Event|0
6076335|NCT00589979|9681791|FG002|Run-In Period|Adverse Event|0
6076336|NCT00589979|9681789|FG000|Run-In Period|Protocol Violation|3
6076337|NCT00589979|9681790|FG001|Run-In Period|Protocol Violation|0
6076338|NCT00589979|9681791|FG002|Run-In Period|Protocol Violation|0
6076339|NCT00589979|9681789|FG000|Run-In Period|Did not qualify for randomization|54
6076340|NCT00589979|9681790|FG001|Run-In Period|Did not qualify for randomization|0
6076341|NCT00589979|9681791|FG002|Run-In Period|Did not qualify for randomization|0
6076342|NCT00589979|9681789|FG000|Run-In Period|Withdrawal by Subject|10
6076343|NCT00589979|9681790|FG001|Run-In Period|Withdrawal by Subject|0
6076344|NCT00589979|9681791|FG002|Run-In Period|Withdrawal by Subject|0
6014210|NCT00129220|9607059|FG001|Study Period III|Withdrawal by Subject|0
6014211|NCT00129220|9607060|FG002|Study Period III|Withdrawal by Subject|3
6076345|NCT00589979|9681789|FG000|Run-In Period|Informed Consent Withdrawn|4
6076346|NCT00589979|9681790|FG001|Run-In Period|Informed Consent Withdrawn|0
6076347|NCT00589979|9681791|FG002|Run-In Period|Informed Consent Withdrawn|0
6014212|NCT00129220|9607058|FG000|Study Period III|Sponsor Decision|1
6014213|NCT00129220|9607059|FG001|Study Period III|Sponsor Decision|0
6014214|NCT00129220|9607060|FG002|Study Period III|Sponsor Decision|0
6146255|NCT01076010|9780833|FG001|Overall Study|Significant Surgical Procedure|1
6146256|NCT01076010|9780834|FG002|Overall Study|Significant Surgical Procedure|0
6146257|NCT01076010|9780832|FG000|Overall Study|Protocol Violation|0
6146258|NCT01076010|9780833|FG001|Overall Study|Protocol Violation|1
6146259|NCT01076010|9780834|FG002|Overall Study|Protocol Violation|0
6014215|NCT00129220|9607058|FG000|Study Period III|Reason Not Specified|9
6014216|NCT00129220|9607059|FG001|Study Period III|Reason Not Specified|0
6014217|NCT00129220|9607060|FG002|Study Period III|Reason Not Specified|2
6014218|NCT00129259|9607081|FG000|Overall Study|Lost to Follow-up|1
6014219|NCT00129259|9607082|FG001|Overall Study|Lost to Follow-up|1
6014220|NCT00129259|9607081|FG000|Overall Study|Withdrawal by Subject|2
6014221|NCT00129259|9607082|FG001|Overall Study|Withdrawal by Subject|1
6014222|NCT00129259|9607081|FG000|Overall Study|Only available minimal phone assessments|0
6014223|NCT00129259|9607082|FG001|Overall Study|Only available minimal phone assessments|1
6014224|NCT00129272|9607090|FG000|Overall Study|Lost to Follow-up|12
6014225|NCT00129272|9607091|FG001|Overall Study|Lost to Follow-up|11
6014226|NCT00129272|9607090|FG000|Overall Study|Withdrawal by Subject|5
6014227|NCT00129272|9607091|FG001|Overall Study|Withdrawal by Subject|11
6014228|NCT00129311|9607116|FG000|Overall Study|Withdrawal by Subject|12
6014229|NCT00129311|9607117|FG001|Overall Study|Withdrawal by Subject|19
6014230|NCT00129376|9607123|FG000|Overall Study|Adverse Event|1
6014231|NCT00129376|9607123|FG000|Overall Study|Lack of Efficacy|1
6014232|NCT00129389|9607129|FG000|Overall Study|Adverse Event|19
6014233|NCT00129389|9607130|FG001|Overall Study|Adverse Event|87
6014234|NCT00129389|9607129|FG000|Overall Study|Death|0
6014235|NCT00129389|9607130|FG001|Overall Study|Death|1
6014236|NCT00129389|9607129|FG000|Overall Study|Lost to Follow-up|2
6014237|NCT00129389|9607130|FG001|Overall Study|Lost to Follow-up|1
6014238|NCT00129389|9607129|FG000|Overall Study|Physician Decision|0
6014239|NCT00129389|9607130|FG001|Overall Study|Physician Decision|4
6014240|NCT00129389|9607129|FG000|Overall Study|Protocol Violation|0
6014241|NCT00129389|9607130|FG001|Overall Study|Protocol Violation|6
6014242|NCT00129389|9607129|FG000|Overall Study|Withdrawal by Subject|9
6014243|NCT00129389|9607130|FG001|Overall Study|Withdrawal by Subject|23
6014244|NCT00129389|9607129|FG000|Overall Study|Relapse|1
6014245|NCT00129389|9607130|FG001|Overall Study|Relapse|0
6014246|NCT00129389|9607129|FG000|Overall Study|Not eligible|1
6014247|NCT00129389|9607130|FG001|Overall Study|Not eligible|2
6014248|NCT00129389|9607129|FG000|Overall Study|Crossed to the other arm|1
6014249|NCT00129389|9607130|FG001|Overall Study|Crossed to the other arm|16
6014250|NCT00129467|9607147|FG000|Received Intervention|Death|1
6014251|NCT00129467|9607148|FG001|Received Intervention|Death|1
6014252|NCT00129467|9607147|FG000|Received Intervention|Cardiac SAE (hypertension)|1
6014253|NCT00129467|9607148|FG001|Received Intervention|Cardiac SAE (hypertension)|1
6014254|NCT00129467|9607147|FG000|Received Intervention|Delirium|2
6014255|NCT00129467|9607148|FG001|Received Intervention|Delirium|0
6014256|NCT00129467|9607147|FG000|Received Intervention|Withdrawal by Subject|1
6014257|NCT00129467|9607148|FG001|Received Intervention|Withdrawal by Subject|0
6014258|NCT00129467|9607147|FG000|Received Intervention|Nausea|1
6014259|NCT00129467|9607148|FG001|Received Intervention|Nausea|0
6014260|NCT00129467|9607147|FG000|Received Intervention|Intolerance to citalopram|0
6014261|NCT00129467|9607148|FG001|Received Intervention|Intolerance to citalopram|1
6014262|NCT00129467|9607147|FG000|Received Intervention|Dizzyness, fatigue|0
6014263|NCT00129467|9607148|FG001|Received Intervention|Dizzyness, fatigue|1
6014264|NCT00129467|9607147|FG000|Open Label for SSRI+Methylphenidate Arm|Death|1
6014265|NCT00129467|9607148|FG001|Open Label for SSRI+Methylphenidate Arm|Death|0
6014266|NCT00129467|9607147|FG000|Open Label for SSRI+Methylphenidate Arm|Delirium|1
6014267|NCT00129467|9607148|FG001|Open Label for SSRI+Methylphenidate Arm|Delirium|0
6014268|NCT00129545|9607166|FG000|Overall Study|Death|5
6014269|NCT00129545|9607167|FG001|Overall Study|Death|60
6014270|NCT00129545|9607168|FG002|Overall Study|Death|44
6014271|NCT00129545|9607166|FG000|Overall Study|Withdrawal by Subject|3
6014272|NCT00129545|9607167|FG001|Overall Study|Withdrawal by Subject|18
6014273|NCT00129545|9607168|FG002|Overall Study|Withdrawal by Subject|44
6014274|NCT00129545|9607166|FG000|Overall Study|Lost to Follow-up|2
6014275|NCT00129545|9607167|FG001|Overall Study|Lost to Follow-up|22
6014276|NCT00129545|9607168|FG002|Overall Study|Lost to Follow-up|13
6014277|NCT00129545|9607166|FG000|Overall Study|Physician Decision|0
6014278|NCT00129545|9607167|FG001|Overall Study|Physician Decision|3
6014279|NCT00129545|9607168|FG002|Overall Study|Physician Decision|10
6014280|NCT00129545|9607166|FG000|Overall Study|Device not implanted|16
6014281|NCT00129545|9607167|FG001|Overall Study|Device not implanted|61
6014282|NCT00129545|9607168|FG002|Overall Study|Device not implanted|0
6014283|NCT00129623|9607178|FG000|Overall Study|Adverse Event|3
6014284|NCT00129623|9607179|FG001|Overall Study|Adverse Event|7
6014285|NCT00129623|9607178|FG000|Overall Study|Refused Treatment|5
6014286|NCT00129623|9607179|FG001|Overall Study|Refused Treatment|3
6014287|NCT00129623|9607178|FG000|Overall Study|Failure to Return|1
6014288|NCT00129623|9607179|FG001|Overall Study|Failure to Return|1
6014289|NCT00129623|9607178|FG000|Overall Study|Relocated job out of state|1
6014290|NCT00129623|9607179|FG001|Overall Study|Relocated job out of state|0
6014291|NCT00129623|9607178|FG000|Overall Study|Uncertainty to return|0
6014292|NCT00129623|9607179|FG001|Overall Study|Uncertainty to return|1
6014293|NCT00129649|9607189|FG000|Overall Study|Withdrawal by Subject|76
6014294|NCT00129649|9607190|FG001|Overall Study|Withdrawal by Subject|65
6014295|NCT00129701|9607196|FG000|Overall Study|Withdrawal by Subject|33
6014296|NCT00129766|9607213|FG000|Overall Study|Death|3
6014297|NCT00129766|9607214|FG001|Overall Study|Death|8
6014298|NCT00129766|9607213|FG000|Overall Study|Withdrawal of consent|31
6014299|NCT00129766|9607214|FG001|Overall Study|Withdrawal of consent|30
6014300|NCT00129766|9607213|FG000|Overall Study|Lost to Follow-up|26
6014301|NCT00129766|9607214|FG001|Overall Study|Lost to Follow-up|21
6014302|NCT00129935|9607223|FG000|Overall Study|Adverse Event|18
6014303|NCT00129935|9607224|FG001|Overall Study|Adverse Event|56
6014304|NCT00129935|9607223|FG000|Overall Study|Death|1
6014305|NCT00129935|9607224|FG001|Overall Study|Death|1
6014306|NCT00129935|9607223|FG000|Overall Study|Withdrawal by Subject|7
6014307|NCT00129935|9607224|FG001|Overall Study|Withdrawal by Subject|20
6014308|NCT00129935|9607223|FG000|Overall Study|Protocol Violation|0
6014309|NCT00129935|9607224|FG001|Overall Study|Protocol Violation|4
6014310|NCT00129935|9607223|FG000|Overall Study|Physician Decision|3
6014311|NCT00129935|9607224|FG001|Overall Study|Physician Decision|4
6014312|NCT00129935|9607223|FG000|Overall Study|Recurrence|1
6014313|NCT00129935|9607224|FG001|Overall Study|Recurrence|3
6014314|NCT00129935|9607223|FG000|Overall Study|Second primary|0
6014315|NCT00129935|9607224|FG001|Overall Study|Second primary|1
6014316|NCT00129935|9607223|FG000|Overall Study|Other|3
6014317|NCT00129935|9607224|FG001|Overall Study|Other|2
6014318|NCT00129935|9607223|FG000|Overall Study|Crossed to the other arm|2
6014319|NCT00129935|9607224|FG001|Overall Study|Crossed to the other arm|1
6014320|NCT00129935|9607223|FG000|Overall Study|Incorrect study treatment|1
6014321|NCT00129935|9607224|FG001|Overall Study|Incorrect study treatment|0
6014322|NCT00129961|9607232|FG000|Overall Study|Adverse Event|1
6014323|NCT00129961|9607233|FG001|Overall Study|Adverse Event|0
6014324|NCT00129961|9607232|FG000|Overall Study|Death|1
6014325|NCT00129961|9607233|FG001|Overall Study|Death|1
6014326|NCT00129961|9607232|FG000|Overall Study|Withdrawal by Sponsor|14
6014327|NCT00129961|9607233|FG001|Overall Study|Withdrawal by Sponsor|20
6014328|NCT00129961|9607232|FG000|Overall Study|Physician Decision|1
6014329|NCT00129961|9607233|FG001|Overall Study|Physician Decision|0
6014330|NCT00129961|9607232|FG000|Overall Study|Withdrawal by Subject|2
6014331|NCT00129961|9607233|FG001|Overall Study|Withdrawal by Subject|1
6014332|NCT00129961|9607232|FG000|Overall Study|Missing Record|0
6014333|NCT00129961|9607233|FG001|Overall Study|Missing Record|1
6014334|NCT00129987|9607241|FG000|1st Educational Session|Withdrawal by Subject|141
6014335|NCT00129987|9607242|FG001|1st Educational Session|Withdrawal by Subject|109
6014336|NCT00129987|9607241|FG000|1 Year|Withdrawal by Subject|32
6014337|NCT00129987|9607242|FG001|1 Year|Withdrawal by Subject|21
6014338|NCT00130039|9607250|FG000|Overall Study|Withdrawal by Subject|15
6014339|NCT00130039|9607251|FG001|Overall Study|Withdrawal by Subject|11
6014340|NCT00130039|9607250|FG000|Overall Study|Lost to Follow-up|3
6014341|NCT00130039|9607251|FG001|Overall Study|Lost to Follow-up|1
6014342|NCT00130039|9607250|FG000|Overall Study|Adverse Event|4
6014343|NCT00130039|9607251|FG001|Overall Study|Adverse Event|2
6014344|NCT00130039|9607250|FG000|Overall Study|Physician Decision|3
6014345|NCT00130039|9607251|FG001|Overall Study|Physician Decision|0
6014346|NCT00130039|9607250|FG000|Overall Study|clinical events without follow up MRI|5
6014347|NCT00130039|9607251|FG001|Overall Study|clinical events without follow up MRI|4
6014348|NCT00130208|9607269|FG000|Maintenance Period (26 Weeks)|Adverse Event|10
6014349|NCT00130208|9607270|FG001|Maintenance Period (26 Weeks)|Adverse Event|12
6014350|NCT00130208|9607269|FG000|Maintenance Period (26 Weeks)|Physician Decision|0
6014351|NCT00130208|9607270|FG001|Maintenance Period (26 Weeks)|Physician Decision|2
6014352|NCT00130208|9607269|FG000|Maintenance Period (26 Weeks)|Withdrawal by Subject|8
6014353|NCT00130208|9607270|FG001|Maintenance Period (26 Weeks)|Withdrawal by Subject|11
6014354|NCT00130208|9607269|FG000|Maintenance Period (26 Weeks)|Lost to Follow-up|5
6014355|NCT00130208|9607270|FG001|Maintenance Period (26 Weeks)|Lost to Follow-up|4
6014356|NCT00130208|9607269|FG000|Maintenance Period (26 Weeks)|Other|1
6014357|NCT00130208|9607270|FG001|Maintenance Period (26 Weeks)|Other|1
6014358|NCT00130208|9607269|FG000|Washout Period (8 Weeks)|Adverse Event|3
6014359|NCT00130208|9607270|FG001|Washout Period (8 Weeks)|Adverse Event|6
6014360|NCT00130208|9607269|FG000|Washout Period (8 Weeks)|Withdrawal by Subject|2
6014361|NCT00130208|9607270|FG001|Washout Period (8 Weeks)|Withdrawal by Subject|4
6014362|NCT00130208|9607269|FG000|Washout Period (8 Weeks)|Lost to Follow-up|0
6014363|NCT00130208|9607270|FG001|Washout Period (8 Weeks)|Lost to Follow-up|1
6014364|NCT00130208|9607269|FG000|Washout Period (8 Weeks)|Other|1
6014365|NCT00130208|9607270|FG001|Washout Period (8 Weeks)|Other|1
6014366|NCT00130247|9607278|FG000|Overall Study|Pregnancy|1
6014367|NCT00130247|9607279|FG001|Overall Study|Pregnancy|0
6014368|NCT00130247|9607278|FG000|Overall Study|Post-randomization exclusion|1
6014369|NCT00130247|9607279|FG001|Overall Study|Post-randomization exclusion|2
6014370|NCT00130247|9607278|FG000|Overall Study|Not compliant with DOT|0
6014371|NCT00130247|9607279|FG001|Overall Study|Not compliant with DOT|2
6076348|NCT00589979|9681789|FG000|Double-Blind Treatment Period 1|Adverse Event|0
6014372|NCT00130286|9607289|FG000|Overall Study|Withdrawal by Subject|0
6014373|NCT00130286|9607290|FG001|Overall Study|Withdrawal by Subject|1
6014374|NCT00130286|9607291|FG002|Overall Study|Withdrawal by Subject|2
6014375|NCT00130286|9607292|FG003|Overall Study|Withdrawal by Subject|2
6014376|NCT00130286|9607289|FG000|Overall Study|Adverse Event|0
6014377|NCT00130286|9607290|FG001|Overall Study|Adverse Event|0
6014378|NCT00130286|9607291|FG002|Overall Study|Adverse Event|2
6014379|NCT00130286|9607292|FG003|Overall Study|Adverse Event|0
6014380|NCT00130286|9607289|FG000|Overall Study|Missing lab specimens|0
6014381|NCT00130286|9607290|FG001|Overall Study|Missing lab specimens|2
6014382|NCT00130286|9607291|FG002|Overall Study|Missing lab specimens|0
6014383|NCT00130286|9607292|FG003|Overall Study|Missing lab specimens|0
6014384|NCT00130442|9607304|FG000|Overall Study|Withdrawal by Subject|0
6014385|NCT00130442|9607305|FG001|Overall Study|Withdrawal by Subject|1
6014386|NCT00130442|9607304|FG000|Overall Study|did not meet criteria|1
6014387|NCT00130442|9607305|FG001|Overall Study|did not meet criteria|1
6014388|NCT00130520|9607313|FG000|Overall Study|Adverse Event|11
6014389|NCT00130520|9607313|FG000|Overall Study|Death|1
6014390|NCT00130520|9607313|FG000|Overall Study|Physician Decision|1
6014391|NCT00130520|9607313|FG000|Overall Study|Withdrawal by Subject|1
6014392|NCT00130520|9607313|FG000|Overall Study|Disease Progression|23
6014393|NCT00130520|9607313|FG000|Overall Study|Protocol non-compliance|1
6014394|NCT00130520|9607313|FG000|Overall Study|Did not meet re-treatment criteria|1
6014395|NCT00130533|9607319|FG000|Overall Study|Withdrawal by Subject|33
6014396|NCT00130533|9607320|FG001|Overall Study|Withdrawal by Subject|6
6014397|NCT00130533|9607319|FG000|Overall Study|Adverse Event|34
6014398|NCT00130533|9607320|FG001|Overall Study|Adverse Event|1
6014399|NCT00130533|9607319|FG000|Overall Study|Disease relapse|9
6014400|NCT00130533|9607320|FG001|Overall Study|Disease relapse|13
6014401|NCT00130533|9607319|FG000|Overall Study|Interruption of treatment > 3 weeks|11
6014402|NCT00130533|9607320|FG001|Overall Study|Interruption of treatment > 3 weeks|0
6014403|NCT00130533|9607319|FG000|Overall Study|Death|4
6014404|NCT00130533|9607320|FG001|Overall Study|Death|2
6014405|NCT00130533|9607319|FG000|Overall Study|Protocol Violation|5
6014406|NCT00130533|9607320|FG001|Overall Study|Protocol Violation|1
6014407|NCT00130533|9607319|FG000|Overall Study|Lost to Follow-up|1
6014408|NCT00130533|9607320|FG001|Overall Study|Lost to Follow-up|1
6014409|NCT00130533|9607319|FG000|Overall Study|Sponsor´s decision|2
6014410|NCT00130533|9607320|FG001|Overall Study|Sponsor´s decision|0
6014411|NCT00130533|9607319|FG000|Overall Study|Second Primary Malignancy|0
6014412|NCT00130533|9607320|FG001|Overall Study|Second Primary Malignancy|1
6014413|NCT00130533|9607319|FG000|Overall Study|Other|12
6014414|NCT00130533|9607320|FG001|Overall Study|Other|5
6014415|NCT00130637|9607326|FG000|Overall Study|Adverse Event|2
6014416|NCT00130637|9607326|FG000|Overall Study|Withdrawal by Subject|1
6014417|NCT00130689|9607330|FG000|Overall Study|Progressive Disease|29
6014418|NCT00130689|9607330|FG000|Overall Study|Death|1
6014419|NCT00130689|9607330|FG000|Overall Study|Clinical Deterioration|4
6014420|NCT00130689|9607330|FG000|Overall Study|Withdrawal by Subject|3
6014421|NCT00130689|9607330|FG000|Overall Study|Ineligible|6
6014422|NCT00130728|9607336|FG000|Overall Study|Death|258
6014423|NCT00130728|9607337|FG001|Overall Study|Death|258
6014424|NCT00130728|9607336|FG000|Overall Study|Lost to Follow-up|4
6014425|NCT00130728|9607337|FG001|Overall Study|Lost to Follow-up|0
6014426|NCT00130728|9607336|FG000|Overall Study|Withdrawal by Subject|0
6014427|NCT00130728|9607337|FG001|Overall Study|Withdrawal by Subject|2
6014428|NCT00130793|9607354|FG000|Overall Study|Lost to Follow-up|1
6076349|NCT00589979|9681790|FG001|Double-Blind Treatment Period 1|Adverse Event|1
6076350|NCT00589979|9681791|FG002|Double-Blind Treatment Period 1|Adverse Event|0
6076351|NCT00589979|9681789|FG000|Double-Blind Treatment Period 1|Protocol Violation|0
6076352|NCT00589979|9681790|FG001|Double-Blind Treatment Period 1|Protocol Violation|1
6076353|NCT00589979|9681791|FG002|Double-Blind Treatment Period 1|Protocol Violation|1
6076354|NCT00589979|9681789|FG000|Double-Blind Treatment Period 1|Withdrawal by Subject|0
6076355|NCT00589979|9681790|FG001|Double-Blind Treatment Period 1|Withdrawal by Subject|0
6076356|NCT00589979|9681791|FG002|Double-Blind Treatment Period 1|Withdrawal by Subject|1
6076357|NCT00589979|9681789|FG000|Double-Blind Treatment Period 2|Adverse Event|0
6076358|NCT00589979|9681790|FG001|Double-Blind Treatment Period 2|Adverse Event|1
6076359|NCT00589979|9681791|FG002|Double-Blind Treatment Period 2|Adverse Event|0
6076360|NCT00589979|9681789|FG000|Double-Blind Treatment Period 2|Withdrawal by Subject|0
6076361|NCT00589979|9681790|FG001|Double-Blind Treatment Period 2|Withdrawal by Subject|0
6076362|NCT00589979|9681791|FG002|Double-Blind Treatment Period 2|Withdrawal by Subject|1
6076363|NCT00589979|9681789|FG000|Double-Blind Treatment Period 2|Other|0
6014429|NCT00130793|9607355|FG001|Overall Study|Lost to Follow-up|4
6014430|NCT00130793|9607354|FG000|Overall Study|Withdrew consent|2
6014431|NCT00130793|9607355|FG001|Overall Study|Withdrew consent|0
6076364|NCT00589979|9681790|FG001|Double-Blind Treatment Period 2|Other|0
6076365|NCT00589979|9681791|FG002|Double-Blind Treatment Period 2|Other|1
6014432|NCT00130832|9607364|FG000|Overall Study|Adverse Event|1
6014433|NCT00130832|9607365|FG001|Overall Study|Adverse Event|1
6014434|NCT00130832|9607364|FG000|Overall Study|Lost to Follow-up|1
6014435|NCT00130832|9607365|FG001|Overall Study|Lost to Follow-up|2
6014436|NCT00130832|9607364|FG000|Overall Study|Protocol Violation|6
6014437|NCT00130832|9607365|FG001|Overall Study|Protocol Violation|8
6014438|NCT00130832|9607364|FG000|Overall Study|Withdrawal by Subject|6
6014439|NCT00130832|9607365|FG001|Overall Study|Withdrawal by Subject|1
6014440|NCT00130832|9607364|FG000|Overall Study|Moved|2
6014441|NCT00130832|9607365|FG001|Overall Study|Moved|2
6014442|NCT00130832|9607364|FG000|Overall Study|Other|0
6014443|NCT00130832|9607365|FG001|Overall Study|Other|3
6014444|NCT00131248|9607381|FG000|Intervention 1 (3-day Course)|Withdrawal by Subject|1
6014445|NCT00131248|9607382|FG001|Intervention 1 (3-day Course)|Withdrawal by Subject|0
6014446|NCT00131352|9607390|FG000|Initial Treatment Period|Adverse Event|1
6014447|NCT00131352|9607391|FG001|Initial Treatment Period|Adverse Event|3
6014448|NCT00131352|9607390|FG000|Initial Treatment Period|Non-compliant|1
6014449|NCT00131352|9607391|FG001|Initial Treatment Period|Non-compliant|2
6014450|NCT00131352|9607390|FG000|Initial Treatment Period|Withdrawal by Subject|1
6014451|NCT00131352|9607391|FG001|Initial Treatment Period|Withdrawal by Subject|1
6014452|NCT00131352|9607390|FG000|Initial Treatment Period|Lack of Efficacy|6
6014453|NCT00131352|9607391|FG001|Initial Treatment Period|Lack of Efficacy|4
6014454|NCT00131352|9607390|FG000|Initial Treatment Period|Other|0
6014455|NCT00131352|9607391|FG001|Initial Treatment Period|Other|2
6014456|NCT00131352|9607390|FG000|Repeat Treatment Period|Adverse Event|1
6014457|NCT00131352|9607391|FG001|Repeat Treatment Period|Adverse Event|0
6014458|NCT00131352|9607390|FG000|Repeat Treatment Period|Other|1
6014459|NCT00131352|9607391|FG001|Repeat Treatment Period|Other|0
6014460|NCT00131365|9607399|FG000|Overall Study|Withdrawal by Subject|1
6014461|NCT00131365|9607399|FG000|Overall Study|Alternative treatment|3
6014462|NCT00131469|9607434|FG000|Overall Study|Withdrawal by Subject|3
6014463|NCT00131469|9607435|FG001|Overall Study|Withdrawal by Subject|4
6014464|NCT00131469|9607434|FG000|Overall Study|Protocol Violation|3
6014465|NCT00131469|9607435|FG001|Overall Study|Protocol Violation|1
6014466|NCT00131469|9607434|FG000|Overall Study|Death|0
6014467|NCT00131469|9607435|FG001|Overall Study|Death|1
6014468|NCT00131469|9607434|FG000|Overall Study|Lost to Follow-up|0
6014469|NCT00131469|9607435|FG001|Overall Study|Lost to Follow-up|1
6014470|NCT00131469|9607434|FG000|Overall Study|scan not analyzable|3
6014471|NCT00131469|9607435|FG001|Overall Study|scan not analyzable|6
6014472|NCT00131508|9607443|FG000|Overall Study|Disease progression|0
6014473|NCT00131508|9607444|FG001|Overall Study|Disease progression|2
6014474|NCT00131508|9607443|FG000|Overall Study|Non-Compliance|2
6014475|NCT00131508|9607444|FG001|Overall Study|Non-Compliance|4
6014476|NCT00131508|9607443|FG000|Overall Study|Withdrawal by Subject|1
6014477|NCT00131508|9607444|FG001|Overall Study|Withdrawal by Subject|2
6014478|NCT00131664|9607463|FG000|First Period (First 6 Months)|Lost to Follow-up|7
6014479|NCT00131664|9607464|FG001|First Period (First 6 Months)|Lost to Follow-up|3
6014480|NCT00131664|9607465|FG002|First Period (First 6 Months)|Lost to Follow-up|3
6014481|NCT00131664|9607466|FG003|First Period (First 6 Months)|Lost to Follow-up|0
6014482|NCT00131664|9607467|FG004|First Period (First 6 Months)|Lost to Follow-up|0
6014483|NCT00131664|9607468|FG005|First Period (First 6 Months)|Lost to Follow-up|0
6014484|NCT00131664|9607463|FG000|First Period (First 6 Months)|Death|0
6014485|NCT00131664|9607464|FG001|First Period (First 6 Months)|Death|1
6014486|NCT00131664|9607465|FG002|First Period (First 6 Months)|Death|0
6014487|NCT00131664|9607466|FG003|First Period (First 6 Months)|Death|0
6014488|NCT00131664|9607467|FG004|First Period (First 6 Months)|Death|0
6014489|NCT00131664|9607468|FG005|First Period (First 6 Months)|Death|0
6014490|NCT00131664|9607463|FG000|First Period (First 6 Months)|Protocol Violation|2
6014491|NCT00131664|9607464|FG001|First Period (First 6 Months)|Protocol Violation|2
6014492|NCT00131664|9607465|FG002|First Period (First 6 Months)|Protocol Violation|1
6014493|NCT00131664|9607466|FG003|First Period (First 6 Months)|Protocol Violation|0
6014494|NCT00131664|9607467|FG004|First Period (First 6 Months)|Protocol Violation|0
6014495|NCT00131664|9607468|FG005|First Period (First 6 Months)|Protocol Violation|0
6014496|NCT00131664|9607463|FG000|First Period (First 6 Months)|Withdrawal by Subject|4
6014497|NCT00131664|9607464|FG001|First Period (First 6 Months)|Withdrawal by Subject|6
6014498|NCT00131664|9607465|FG002|First Period (First 6 Months)|Withdrawal by Subject|2
6014499|NCT00131664|9607466|FG003|First Period (First 6 Months)|Withdrawal by Subject|0
6014500|NCT00131664|9607467|FG004|First Period (First 6 Months)|Withdrawal by Subject|0
6014501|NCT00131664|9607468|FG005|First Period (First 6 Months)|Withdrawal by Subject|0
6014502|NCT00131664|9607463|FG000|First Period (First 6 Months)|Adverse Event|9
6014503|NCT00131664|9607464|FG001|First Period (First 6 Months)|Adverse Event|4
6014504|NCT00131664|9607465|FG002|First Period (First 6 Months)|Adverse Event|5
6014505|NCT00131664|9607466|FG003|First Period (First 6 Months)|Adverse Event|0
6014506|NCT00131664|9607467|FG004|First Period (First 6 Months)|Adverse Event|0
6014507|NCT00131664|9607468|FG005|First Period (First 6 Months)|Adverse Event|0
6014508|NCT00131664|9607463|FG000|First Period (First 6 Months)|Clinically significant lab abnormalities|1
6014509|NCT00131664|9607464|FG001|First Period (First 6 Months)|Clinically significant lab abnormalities|2
6014510|NCT00131664|9607465|FG002|First Period (First 6 Months)|Clinically significant lab abnormalities|0
6014511|NCT00131664|9607466|FG003|First Period (First 6 Months)|Clinically significant lab abnormalities|0
6014512|NCT00131664|9607467|FG004|First Period (First 6 Months)|Clinically significant lab abnormalities|0
6014513|NCT00131664|9607468|FG005|First Period (First 6 Months)|Clinically significant lab abnormalities|0
6014514|NCT00131664|9607463|FG000|First Period (First 6 Months)|Administrative reasons|2
6014515|NCT00131664|9607464|FG001|First Period (First 6 Months)|Administrative reasons|0
6014516|NCT00131664|9607465|FG002|First Period (First 6 Months)|Administrative reasons|5
6014517|NCT00131664|9607466|FG003|First Period (First 6 Months)|Administrative reasons|0
6014518|NCT00131664|9607467|FG004|First Period (First 6 Months)|Administrative reasons|0
6014519|NCT00131664|9607468|FG005|First Period (First 6 Months)|Administrative reasons|0
6014520|NCT00131664|9607463|FG000|Second Period (Additional Drug Added)|Lost to Follow-up|3
6014521|NCT00131664|9607464|FG001|Second Period (Additional Drug Added)|Lost to Follow-up|0
6014522|NCT00131664|9607465|FG002|Second Period (Additional Drug Added)|Lost to Follow-up|2
6014523|NCT00131664|9607466|FG003|Second Period (Additional Drug Added)|Lost to Follow-up|1
6014524|NCT00131664|9607467|FG004|Second Period (Additional Drug Added)|Lost to Follow-up|0
6014525|NCT00131664|9607468|FG005|Second Period (Additional Drug Added)|Lost to Follow-up|2
6014526|NCT00131664|9607463|FG000|Second Period (Additional Drug Added)|Protocol Violation|0
6014527|NCT00131664|9607464|FG001|Second Period (Additional Drug Added)|Protocol Violation|1
6014528|NCT00131664|9607465|FG002|Second Period (Additional Drug Added)|Protocol Violation|1
6014529|NCT00131664|9607466|FG003|Second Period (Additional Drug Added)|Protocol Violation|0
6014530|NCT00131664|9607467|FG004|Second Period (Additional Drug Added)|Protocol Violation|0
6014531|NCT00131664|9607468|FG005|Second Period (Additional Drug Added)|Protocol Violation|0
6014532|NCT00131664|9607463|FG000|Second Period (Additional Drug Added)|Withdrawal by Subject|2
6014533|NCT00131664|9607464|FG001|Second Period (Additional Drug Added)|Withdrawal by Subject|0
6014534|NCT00131664|9607465|FG002|Second Period (Additional Drug Added)|Withdrawal by Subject|0
6014535|NCT00131664|9607466|FG003|Second Period (Additional Drug Added)|Withdrawal by Subject|0
6014536|NCT00131664|9607467|FG004|Second Period (Additional Drug Added)|Withdrawal by Subject|0
6014537|NCT00131664|9607468|FG005|Second Period (Additional Drug Added)|Withdrawal by Subject|0
6014538|NCT00131664|9607463|FG000|Second Period (Additional Drug Added)|Adverse Event|0
6014539|NCT00131664|9607464|FG001|Second Period (Additional Drug Added)|Adverse Event|1
6014540|NCT00131664|9607465|FG002|Second Period (Additional Drug Added)|Adverse Event|0
6014541|NCT00131664|9607466|FG003|Second Period (Additional Drug Added)|Adverse Event|0
6014542|NCT00131664|9607467|FG004|Second Period (Additional Drug Added)|Adverse Event|0
6014543|NCT00131664|9607468|FG005|Second Period (Additional Drug Added)|Adverse Event|1
6014544|NCT00131664|9607463|FG000|Second Period (Additional Drug Added)|Clinically significant lab abnormalities|0
6014545|NCT00131664|9607464|FG001|Second Period (Additional Drug Added)|Clinically significant lab abnormalities|0
6014546|NCT00131664|9607465|FG002|Second Period (Additional Drug Added)|Clinically significant lab abnormalities|0
6014547|NCT00131664|9607466|FG003|Second Period (Additional Drug Added)|Clinically significant lab abnormalities|1
6014548|NCT00131664|9607467|FG004|Second Period (Additional Drug Added)|Clinically significant lab abnormalities|0
6014549|NCT00131664|9607468|FG005|Second Period (Additional Drug Added)|Clinically significant lab abnormalities|0
6014550|NCT00131664|9607463|FG000|Second Period (Additional Drug Added)|Administrative reasons|4
6014551|NCT00131664|9607464|FG001|Second Period (Additional Drug Added)|Administrative reasons|2
6014552|NCT00131664|9607465|FG002|Second Period (Additional Drug Added)|Administrative reasons|0
6014553|NCT00131664|9607466|FG003|Second Period (Additional Drug Added)|Administrative reasons|0
6014554|NCT00131664|9607467|FG004|Second Period (Additional Drug Added)|Administrative reasons|1
6014555|NCT00131664|9607468|FG005|Second Period (Additional Drug Added)|Administrative reasons|0
6014556|NCT00131911|9607512|FG000|Overall Study|Withdrawal by Subject|1
6014557|NCT00131911|9607513|FG001|Overall Study|Withdrawal by Subject|0
6014558|NCT00131937|9607518|FG000|Overall Study|Adverse Event|3
6014559|NCT00131937|9607518|FG000|Overall Study|Withdrawal by Subject|2
6014560|NCT00131937|9607518|FG000|Overall Study|Physician Decision|1
6014561|NCT00131937|9607518|FG000|Overall Study|Disease Progression|7
6014562|NCT00131937|9607518|FG000|Overall Study|Alternative therapy|1
6014563|NCT00132028|9607526|FG000|Overall Study|Adverse Event|7
6014564|NCT00132028|9607526|FG000|Overall Study|Death|2
6014565|NCT00132028|9607526|FG000|Overall Study|Lack of Efficacy|11
6014566|NCT00132028|9607526|FG000|Overall Study|Withdrawal by Subject|2
6014567|NCT00132028|9607526|FG000|Overall Study|not eligible|2
6014568|NCT00132028|9607526|FG000|Overall Study|Physician Decision|3
6014569|NCT00132041|9607530|FG000|Baseline|Ineligible|6
6014570|NCT00132041|9607530|FG000|3 Months Post Ablation|Transplant|1
6014571|NCT00132041|9607530|FG000|3 Months Post Ablation|Non-Protocol Treatment|2
6014572|NCT00132041|9607530|FG000|6 Months Post Ablation|Withdrawal by Subject|2
6014573|NCT00132041|9607530|FG000|6 Months Post Ablation|Death|2
6014574|NCT00132041|9607530|FG000|6 Months Post Ablation|Transplant|6
6014575|NCT00132041|9607530|FG000|9 Months Post Ablation|Death|1
6014576|NCT00132041|9607530|FG000|9 Months Post Ablation|Transplant|1
6014577|NCT00132041|9607530|FG000|12 Months Post Ablation|Withdrawal by Subject|1
6014578|NCT00132041|9607530|FG000|12 Months Post Ablation|Death|1
6014579|NCT00132041|9607530|FG000|12 Months Post Ablation|Transplant|1
6014580|NCT00132041|9607530|FG000|12 Months Post Ablation|non-protocol Treatment|1
6014581|NCT00132041|9607530|FG000|15 Months Post Ablation|Withdrawal by Subject|1
6014582|NCT00132041|9607530|FG000|15 Months Post Ablation|Death|1
6014583|NCT00132041|9607530|FG000|15 Months Post Ablation|Transplant|5
6014584|NCT00132041|9607530|FG000|15 Months Post Ablation|Non-Protocol Treatment|1
6014585|NCT00132041|9607530|FG000|18 Months Post Ablation|Withdrawal by Subject|1
6014586|NCT00132041|9607530|FG000|18 Months Post Ablation|Transplant|1
6014587|NCT00132041|9607530|FG000|18 Months Post Ablation|Non-Protocol Treatment|3
6076366|NCT00589979|9681789|FG000|Double-Blind Treatment Period 3|Protocol Violation|0
6014588|NCT00132041|9607530|FG000|18 Months Post Ablation|ExtraHepatic tumor|1
6014589|NCT00132132|9607542|FG000|Overall Study|Lost to Follow-up|7
6014590|NCT00132132|9607543|FG001|Overall Study|Lost to Follow-up|2
6014591|NCT00132301|9607551|FG000|Overall Study|Death|7
6014592|NCT00132301|9607552|FG001|Overall Study|Death|6
6014593|NCT00132301|9607551|FG000|Overall Study|Withdrawal by Subject|5
6014594|NCT00132301|9607552|FG001|Overall Study|Withdrawal by Subject|2
6014595|NCT00132301|9607551|FG000|Overall Study|Physician Decision|1
6014596|NCT00132301|9607552|FG001|Overall Study|Physician Decision|1
6014597|NCT00132301|9607551|FG000|Overall Study|Lost to Follow-up|5
6014598|NCT00132301|9607552|FG001|Overall Study|Lost to Follow-up|3
6014599|NCT00132301|9607551|FG000|Overall Study|Other|1
6014600|NCT00132301|9607552|FG001|Overall Study|Other|1
6014601|NCT00132301|9607551|FG000|Overall Study|Excluded by Data Monitoring Committee|1
6014602|NCT00132301|9607552|FG001|Overall Study|Excluded by Data Monitoring Committee|0
6014603|NCT00132314|9607560|FG000|Overall Study|Lost to Follow-up|70
6014604|NCT00132314|9607561|FG001|Overall Study|Lost to Follow-up|62
6076367|NCT00589979|9681790|FG001|Double-Blind Treatment Period 3|Protocol Violation|1
6076368|NCT00589979|9681791|FG002|Double-Blind Treatment Period 3|Protocol Violation|0
6076369|NCT00589979|9681789|FG000|Double-Blind Treatment Period 3|Withdrawal by Subject|0
6076370|NCT00589979|9681790|FG001|Double-Blind Treatment Period 3|Withdrawal by Subject|0
6076371|NCT00589979|9681791|FG002|Double-Blind Treatment Period 3|Withdrawal by Subject|1
6076372|NCT00590031|9681819|FG000|Overall Study|Adverse Event|3
6076373|NCT00590031|9681819|FG000|Overall Study|Withdrawal by Subject|1
6076374|NCT00590031|9681819|FG000|Overall Study|Metastatic Disease|1
6076375|NCT00590031|9681819|FG000|Overall Study|Admin Hold|1
6076376|NCT00590044|9681825|FG000|Overall Study|Withdrawal by Subject|2
6076377|NCT00590044|9681826|FG001|Overall Study|Withdrawal by Subject|2
6076378|NCT00590044|9681825|FG000|Overall Study|wrong insulin arm assigned|1
6076379|NCT00590044|9681826|FG001|Overall Study|wrong insulin arm assigned|0
6076380|NCT00590044|9681825|FG000|Overall Study|Protocol Violation|1
6076381|NCT00590044|9681826|FG001|Overall Study|Protocol Violation|0
6087492|NCT00667992|9697747|FG001|First Intervention 100 Mcg Twice Daily|Withdrawal by Subject|0
6087493|NCT00667992|9697746|FG000|First Intervention 100 Mcg Twice Daily|Adverse Event|0
6087494|NCT00667992|9697747|FG001|First Intervention 100 Mcg Twice Daily|Adverse Event|1
6087495|NCT00667992|9697746|FG000|First Intervention 100 Mcg Twice Daily|Pregnancy|1
6087496|NCT00667992|9697747|FG001|First Intervention 100 Mcg Twice Daily|Pregnancy|0
6087497|NCT00667992|9697746|FG000|First Intervention 100 Mcg Twice Daily|Adverse Event|0
6087498|NCT00667992|9697747|FG001|First Intervention 100 Mcg Twice Daily|Adverse Event|1
6087499|NCT00667992|9697746|FG000|Second Intervention 400 Mcg Twice Daily|Withdrawal by Subject|1
6087500|NCT00667992|9697747|FG001|Second Intervention 400 Mcg Twice Daily|Withdrawal by Subject|0
6087501|NCT00667992|9697746|FG000|Second Intervention 400 Mcg Twice Daily|Condition Under Investigation Worsened|2
6087502|NCT00667992|9697747|FG001|Second Intervention 400 Mcg Twice Daily|Condition Under Investigation Worsened|3
6087503|NCT00667992|9697746|FG000|Second Intervention 400 Mcg Twice Daily|Medication not allowed taken|0
6087504|NCT00667992|9697747|FG001|Second Intervention 400 Mcg Twice Daily|Medication not allowed taken|1
6087505|NCT00667992|9697746|FG000|Wash-out|Not within one doubling dilution|4
6087506|NCT00667992|9697747|FG001|Wash-out|Not within one doubling dilution|3
6087507|NCT00667992|9697746|FG000|Wash-out|Failure to wash-out|2
6087508|NCT00667992|9697747|FG001|Wash-out|Failure to wash-out|2
6087509|NCT00667992|9697746|FG000|Wash-out|Withdrawal by Subject|1
6087510|NCT00667992|9697747|FG001|Wash-out|Withdrawal by Subject|0
6087511|NCT00667992|9697746|FG000|Third Intervention 100 Mcg Twice Daily|Withdrawal by Subject|1
6087512|NCT00667992|9697747|FG001|Third Intervention 100 Mcg Twice Daily|Withdrawal by Subject|0
6087513|NCT00667992|9697746|FG000|Third Intervention 100 Mcg Twice Daily|Adverse Event|0
6087514|NCT00667992|9697747|FG001|Third Intervention 100 Mcg Twice Daily|Adverse Event|1
6087515|NCT00668148|9697763|FG000|Overall Study|Adverse Event|5
6087516|NCT00668148|9697763|FG000|Overall Study|Subject Non-compliance|1
6087517|NCT00668148|9697763|FG000|Overall Study|Progressive Disease Before Treatment|2
6087518|NCT00668148|9697763|FG000|Overall Study|Withdrawal of Consent|2
6087519|NCT00668200|9697778|FG000|Overall Study|Withdrawal by Subject|2
6087520|NCT00668200|9697778|FG000|Overall Study|Lost to Follow-up|1
6087521|NCT00668317|9697782|FG000|Overall Study|Adverse Event|2
6087522|NCT00668395|9697793|FG000|Overall Study|Withdrawal by Subject|4
6087523|NCT00668395|9697794|FG001|Overall Study|Withdrawal by Subject|4
6087524|NCT00668395|9697795|FG002|Overall Study|Withdrawal by Subject|1
6087525|NCT00668395|9697793|FG000|Overall Study|Adverse Event|1
6087526|NCT00668395|9697794|FG001|Overall Study|Adverse Event|1
6087527|NCT00668395|9697795|FG002|Overall Study|Adverse Event|0
6087528|NCT00668395|9697793|FG000|Overall Study|Physician Decision|1
6087529|NCT00668395|9697794|FG001|Overall Study|Physician Decision|1
6087530|NCT00668395|9697795|FG002|Overall Study|Physician Decision|0
6087531|NCT00668707|9697831|FG000|Overall Study|Cancer Recurrence|58
6087532|NCT00668707|9697832|FG001|Overall Study|Cancer Recurrence|58
6087533|NCT00668707|9697831|FG000|Overall Study|Withdrawal by Subject|117
6014605|NCT00132314|9607560|FG000|Overall Study|Lacked SSN|1
6087534|NCT00668707|9697832|FG001|Overall Study|Withdrawal by Subject|100
6087535|NCT00668707|9697831|FG000|Overall Study|Lost to Follow-up|3
6014606|NCT00132314|9607561|FG001|Overall Study|Lacked SSN|3
6014607|NCT00132314|9607560|FG000|Overall Study|Refused intervention at baseline|2
6014608|NCT00132314|9607561|FG001|Overall Study|Refused intervention at baseline|7
6014609|NCT00132496|9607569|FG000|Overall Study|Withdrawal by Subject|1
6014610|NCT00132496|9607570|FG001|Overall Study|Withdrawal by Subject|2
6014611|NCT00132496|9607569|FG000|Overall Study|Physician Decision|1
6014612|NCT00132496|9607570|FG001|Overall Study|Physician Decision|0
6014613|NCT00132678|9607578|FG000|Period II (Open-Label Oral Risperidone)|Death|0
6014614|NCT00132678|9607579|FG001|Period II (Open-Label Oral Risperidone)|Death|0
6014615|NCT00132678|9607580|FG002|Period II (Open-Label Oral Risperidone)|Death|1
6014616|NCT00132678|9607578|FG000|Period II (Open-Label Oral Risperidone)|Adverse Event|0
6014617|NCT00132678|9607579|FG001|Period II (Open-Label Oral Risperidone)|Adverse Event|0
6014618|NCT00132678|9607580|FG002|Period II (Open-Label Oral Risperidone)|Adverse Event|13
6014619|NCT00132678|9607578|FG000|Period II (Open-Label Oral Risperidone)|Non responder|0
6014620|NCT00132678|9607579|FG001|Period II (Open-Label Oral Risperidone)|Non responder|0
6014621|NCT00132678|9607580|FG002|Period II (Open-Label Oral Risperidone)|Non responder|6
6014622|NCT00132678|9607578|FG000|Period II (Open-Label Oral Risperidone)|Ineligible to continue trial|0
6014623|NCT00132678|9607579|FG001|Period II (Open-Label Oral Risperidone)|Ineligible to continue trial|0
6014624|NCT00132678|9607580|FG002|Period II (Open-Label Oral Risperidone)|Ineligible to continue trial|7
6014625|NCT00132678|9607578|FG000|Period II (Open-Label Oral Risperidone)|Lost to Follow-up|0
6014626|NCT00132678|9607579|FG001|Period II (Open-Label Oral Risperidone)|Lost to Follow-up|0
6014627|NCT00132678|9607580|FG002|Period II (Open-Label Oral Risperidone)|Lost to Follow-up|14
6014628|NCT00132678|9607578|FG000|Period II (Open-Label Oral Risperidone)|Withdrawal by Subject|0
6014629|NCT00132678|9607579|FG001|Period II (Open-Label Oral Risperidone)|Withdrawal by Subject|0
6014630|NCT00132678|9607580|FG002|Period II (Open-Label Oral Risperidone)|Withdrawal by Subject|16
6014631|NCT00132678|9607578|FG000|Period II (Open-Label Oral Risperidone)|Physician Decision|0
6014632|NCT00132678|9607579|FG001|Period II (Open-Label Oral Risperidone)|Physician Decision|0
6014633|NCT00132678|9607580|FG002|Period II (Open-Label Oral Risperidone)|Physician Decision|1
6014634|NCT00132678|9607578|FG000|Period III (Open-Label Stabilization)|Death|2
6014635|NCT00132678|9607579|FG001|Period III (Open-Label Stabilization)|Death|0
6014636|NCT00132678|9607580|FG002|Period III (Open-Label Stabilization)|Death|0
6014637|NCT00132678|9607578|FG000|Period III (Open-Label Stabilization)|Adverse Event|12
6014638|NCT00132678|9607579|FG001|Period III (Open-Label Stabilization)|Adverse Event|0
6014639|NCT00132678|9607580|FG002|Period III (Open-Label Stabilization)|Adverse Event|0
6014640|NCT00132678|9607578|FG000|Period III (Open-Label Stabilization)|Non responder|107
6014641|NCT00132678|9607579|FG001|Period III (Open-Label Stabilization)|Non responder|0
6014642|NCT00132678|9607580|FG002|Period III (Open-Label Stabilization)|Non responder|0
6014643|NCT00132678|9607578|FG000|Period III (Open-Label Stabilization)|Ineligible to continue trial|5
6014644|NCT00132678|9607579|FG001|Period III (Open-Label Stabilization)|Ineligible to continue trial|0
6014645|NCT00132678|9607580|FG002|Period III (Open-Label Stabilization)|Ineligible to continue trial|0
6014646|NCT00132678|9607578|FG000|Period III (Open-Label Stabilization)|Lost to Follow-up|19
6014647|NCT00132678|9607579|FG001|Period III (Open-Label Stabilization)|Lost to Follow-up|0
6014648|NCT00132678|9607580|FG002|Period III (Open-Label Stabilization)|Lost to Follow-up|0
6014649|NCT00132678|9607578|FG000|Period III (Open-Label Stabilization)|Withdrawal by Subject|49
6014650|NCT00132678|9607579|FG001|Period III (Open-Label Stabilization)|Withdrawal by Subject|0
6014651|NCT00132678|9607580|FG002|Period III (Open-Label Stabilization)|Withdrawal by Subject|0
6014652|NCT00132678|9607578|FG000|Period III (Open-Label Stabilization)|Subject non-compliant|1
6014653|NCT00132678|9607579|FG001|Period III (Open-Label Stabilization)|Subject non-compliant|0
6014654|NCT00132678|9607580|FG002|Period III (Open-Label Stabilization)|Subject non-compliant|0
6014655|NCT00132678|9607578|FG000|Period III (Open-Label Stabilization)|Physician Decision|1
6014656|NCT00132678|9607579|FG001|Period III (Open-Label Stabilization)|Physician Decision|0
6014657|NCT00132678|9607580|FG002|Period III (Open-Label Stabilization)|Physician Decision|0
6014658|NCT00132678|9607578|FG000|Period III (Open-Label Stabilization)|Pregnancy|2
6014659|NCT00132678|9607579|FG001|Period III (Open-Label Stabilization)|Pregnancy|0
6014660|NCT00132678|9607580|FG002|Period III (Open-Label Stabilization)|Pregnancy|0
6014661|NCT00132678|9607578|FG000|Period IV (Double-Blind Treatment)|Adverse Event|1
6014662|NCT00132678|9607579|FG001|Period IV (Double-Blind Treatment)|Adverse Event|1
6014663|NCT00132678|9607580|FG002|Period IV (Double-Blind Treatment)|Adverse Event|0
6014664|NCT00132678|9607578|FG000|Period IV (Double-Blind Treatment)|Ineligible to continue the trial|4
6014665|NCT00132678|9607579|FG001|Period IV (Double-Blind Treatment)|Ineligible to continue the trial|4
6014666|NCT00132678|9607580|FG002|Period IV (Double-Blind Treatment)|Ineligible to continue the trial|0
6014667|NCT00132678|9607578|FG000|Period IV (Double-Blind Treatment)|Lost to Follow-up|6
6014668|NCT00132678|9607579|FG001|Period IV (Double-Blind Treatment)|Lost to Follow-up|3
6014669|NCT00132678|9607580|FG002|Period IV (Double-Blind Treatment)|Lost to Follow-up|0
6014670|NCT00132678|9607578|FG000|Period IV (Double-Blind Treatment)|Withdrawal by Subject|14
6014671|NCT00132678|9607579|FG001|Period IV (Double-Blind Treatment)|Withdrawal by Subject|15
6014672|NCT00132678|9607580|FG002|Period IV (Double-Blind Treatment)|Withdrawal by Subject|0
6014673|NCT00132678|9607578|FG000|Period IV (Double-Blind Treatment)|Physician Decision|10
6014674|NCT00132678|9607579|FG001|Period IV (Double-Blind Treatment)|Physician Decision|14
6014675|NCT00132678|9607580|FG002|Period IV (Double-Blind Treatment)|Physician Decision|0
6014676|NCT00132678|9607578|FG000|Period IV (Double-Blind Treatment)|Subject Non-compliant|2
6014677|NCT00132678|9607579|FG001|Period IV (Double-Blind Treatment)|Subject Non-compliant|1
6014678|NCT00132678|9607580|FG002|Period IV (Double-Blind Treatment)|Subject Non-compliant|0
6014679|NCT00132678|9607578|FG000|Period IV (Double-Blind Treatment)|Pregnancy|0
6014680|NCT00132678|9607579|FG001|Period IV (Double-Blind Treatment)|Pregnancy|2
6014681|NCT00132678|9607580|FG002|Period IV (Double-Blind Treatment)|Pregnancy|0
6014682|NCT00132691|9607590|FG000|Overall Study|Lost to Follow-up|5
6014683|NCT00132691|9607591|FG001|Overall Study|Lost to Follow-up|8
6014684|NCT00132691|9607590|FG000|Overall Study|Missed 2-year visit|4
6014685|NCT00132691|9607591|FG001|Overall Study|Missed 2-year visit|4
6014686|NCT00132691|9607590|FG000|Overall Study|Death|2
6014687|NCT00132691|9607591|FG001|Overall Study|Death|0
6014688|NCT00132730|9607606|FG000|Period II - 12-week Treatment (Base)|Clinical adverse experience|11
6014689|NCT00132730|9607607|FG001|Period II - 12-week Treatment (Base)|Clinical adverse experience|4
6014690|NCT00132730|9607608|FG002|Period II - 12-week Treatment (Base)|Clinical adverse experience|9
6014691|NCT00132730|9607609|FG003|Period II - 12-week Treatment (Base)|Clinical adverse experience|9
6014692|NCT00132730|9607610|FG004|Period II - 12-week Treatment (Base)|Clinical adverse experience|0
6014693|NCT00132730|9607611|FG005|Period II - 12-week Treatment (Base)|Clinical adverse experience|0
6014694|NCT00132730|9607606|FG000|Period II - 12-week Treatment (Base)|Laboratory adverse experience|1
6014695|NCT00132730|9607607|FG001|Period II - 12-week Treatment (Base)|Laboratory adverse experience|1
6014696|NCT00132730|9607608|FG002|Period II - 12-week Treatment (Base)|Laboratory adverse experience|0
6014697|NCT00132730|9607609|FG003|Period II - 12-week Treatment (Base)|Laboratory adverse experience|0
6014698|NCT00132730|9607610|FG004|Period II - 12-week Treatment (Base)|Laboratory adverse experience|0
6014699|NCT00132730|9607611|FG005|Period II - 12-week Treatment (Base)|Laboratory adverse experience|0
6014700|NCT00132730|9607606|FG000|Period II - 12-week Treatment (Base)|Other reasons|11
6014701|NCT00132730|9607607|FG001|Period II - 12-week Treatment (Base)|Other reasons|10
6014702|NCT00132730|9607608|FG002|Period II - 12-week Treatment (Base)|Other reasons|9
6014703|NCT00132730|9607609|FG003|Period II - 12-week Treatment (Base)|Other reasons|13
6014704|NCT00132730|9607610|FG004|Period II - 12-week Treatment (Base)|Other reasons|0
6014705|NCT00132730|9607611|FG005|Period II - 12-week Treatment (Base)|Other reasons|0
6014706|NCT00132730|9607606|FG000|Period III - Blinded Extension (EXT1)|Site terminated|0
6014707|NCT00132730|9607607|FG001|Period III - Blinded Extension (EXT1)|Site terminated|0
6014708|NCT00132730|9607608|FG002|Period III - Blinded Extension (EXT1)|Site terminated|57
6014709|NCT00132730|9607609|FG003|Period III - Blinded Extension (EXT1)|Site terminated|20
6014710|NCT00132730|9607610|FG004|Period III - Blinded Extension (EXT1)|Site terminated|0
6014711|NCT00132730|9607611|FG005|Period III - Blinded Extension (EXT1)|Site terminated|0
6014712|NCT00132730|9607606|FG000|Period III - Blinded Extension (EXT1)|Clinical adverse experience|0
6014713|NCT00132730|9607607|FG001|Period III - Blinded Extension (EXT1)|Clinical adverse experience|0
6014714|NCT00132730|9607608|FG002|Period III - Blinded Extension (EXT1)|Clinical adverse experience|11
6014715|NCT00132730|9607609|FG003|Period III - Blinded Extension (EXT1)|Clinical adverse experience|1
6014716|NCT00132730|9607610|FG004|Period III - Blinded Extension (EXT1)|Clinical adverse experience|0
6014717|NCT00132730|9607611|FG005|Period III - Blinded Extension (EXT1)|Clinical adverse experience|0
6014718|NCT00132730|9607606|FG000|Period III - Blinded Extension (EXT1)|Laboratory adverse experience|0
6014719|NCT00132730|9607607|FG001|Period III - Blinded Extension (EXT1)|Laboratory adverse experience|0
6014720|NCT00132730|9607608|FG002|Period III - Blinded Extension (EXT1)|Laboratory adverse experience|0
6014721|NCT00132730|9607609|FG003|Period III - Blinded Extension (EXT1)|Laboratory adverse experience|1
6014722|NCT00132730|9607610|FG004|Period III - Blinded Extension (EXT1)|Laboratory adverse experience|0
6014723|NCT00132730|9607611|FG005|Period III - Blinded Extension (EXT1)|Laboratory adverse experience|0
6014724|NCT00132730|9607606|FG000|Period III - Blinded Extension (EXT1)|Other reasons|0
6014725|NCT00132730|9607607|FG001|Period III - Blinded Extension (EXT1)|Other reasons|0
6014726|NCT00132730|9607608|FG002|Period III - Blinded Extension (EXT1)|Other reasons|14
6014727|NCT00132730|9607609|FG003|Period III - Blinded Extension (EXT1)|Other reasons|3
6014728|NCT00132730|9607610|FG004|Period III - Blinded Extension (EXT1)|Other reasons|0
6014729|NCT00132730|9607611|FG005|Period III - Blinded Extension (EXT1)|Other reasons|0
6014730|NCT00132730|9607606|FG000|Period IV - Open-label Extension (EXT2)|Site terminated|0
6014731|NCT00132730|9607607|FG001|Period IV - Open-label Extension (EXT2)|Site terminated|0
6014732|NCT00132730|9607608|FG002|Period IV - Open-label Extension (EXT2)|Site terminated|0
6014733|NCT00132730|9607609|FG003|Period IV - Open-label Extension (EXT2)|Site terminated|0
6014734|NCT00132730|9607610|FG004|Period IV - Open-label Extension (EXT2)|Site terminated|169
6014735|NCT00132730|9607611|FG005|Period IV - Open-label Extension (EXT2)|Site terminated|68
6076382|NCT00590317|9681855|FG000|Overall Study|Lack of Efficacy|1
6076383|NCT00590317|9681856|FG001|Overall Study|Lack of Efficacy|5
6076384|NCT00590564|9681884|FG000|Overall Study|Withdrawal by Subject|4
6076385|NCT00590564|9681884|FG000|Overall Study|Lost to Follow-up|6
6076386|NCT00590564|9681884|FG000|Overall Study|Protocol Violation|1
6076387|NCT00590564|9681884|FG000|Overall Study|Patient Found to be Ineligible|1
6076388|NCT00590564|9681884|FG000|Overall Study|Patient Non-compliance|6
6076389|NCT00590577|9681892|FG000|Overall Study|Lack of Efficacy|31
6076390|NCT00590577|9681893|FG001|Overall Study|Lack of Efficacy|28
6014736|NCT00132730|9607606|FG000|Period IV - Open-label Extension (EXT2)|Clinical adverse experience|0
6014737|NCT00132730|9607607|FG001|Period IV - Open-label Extension (EXT2)|Clinical adverse experience|0
6014738|NCT00132730|9607608|FG002|Period IV - Open-label Extension (EXT2)|Clinical adverse experience|0
6076391|NCT00590577|9681894|FG002|Overall Study|Lack of Efficacy|23
6076392|NCT00590577|9681895|FG003|Overall Study|Lack of Efficacy|45
6076393|NCT00590577|9681892|FG000|Overall Study|Withdrawal by Subject|23
6076394|NCT00590577|9681893|FG001|Overall Study|Withdrawal by Subject|28
6076395|NCT00590577|9681894|FG002|Overall Study|Withdrawal by Subject|30
6076396|NCT00590577|9681895|FG003|Overall Study|Withdrawal by Subject|26
6076397|NCT00590577|9681892|FG000|Overall Study|Adverse Event|10
6076398|NCT00590577|9681893|FG001|Overall Study|Adverse Event|10
6076399|NCT00590577|9681894|FG002|Overall Study|Adverse Event|13
6076400|NCT00590577|9681895|FG003|Overall Study|Adverse Event|11
6076401|NCT00590577|9681892|FG000|Overall Study|Lost to Follow-up|12
6076402|NCT00590577|9681893|FG001|Overall Study|Lost to Follow-up|6
6076403|NCT00590577|9681894|FG002|Overall Study|Lost to Follow-up|6
6076404|NCT00590577|9681895|FG003|Overall Study|Lost to Follow-up|9
6076405|NCT00590577|9681892|FG000|Overall Study|Pregnancy|0
6076406|NCT00590577|9681893|FG001|Overall Study|Pregnancy|1
6076407|NCT00590577|9681894|FG002|Overall Study|Pregnancy|0
6076408|NCT00590577|9681895|FG003|Overall Study|Pregnancy|0
6076409|NCT00590577|9681892|FG000|Overall Study|Various reasons|1
6076410|NCT00590577|9681893|FG001|Overall Study|Various reasons|3
6076411|NCT00590577|9681894|FG002|Overall Study|Various reasons|1
6076412|NCT00590577|9681895|FG003|Overall Study|Various reasons|2
6076413|NCT00590590|9681908|FG000|Overall Study|Lack of Efficacy|1
6076414|NCT00590590|9681909|FG001|Overall Study|Lack of Efficacy|2
6076415|NCT00590590|9681910|FG002|Overall Study|Lack of Efficacy|0
6076416|NCT00590590|9681908|FG000|Overall Study|Adverse Event|1
6076417|NCT00590590|9681909|FG001|Overall Study|Adverse Event|0
6076418|NCT00590590|9681910|FG002|Overall Study|Adverse Event|0
6076419|NCT00590590|9681908|FG000|Overall Study|Protocol Violation|0
6076420|NCT00590590|9681909|FG001|Overall Study|Protocol Violation|0
6076421|NCT00590590|9681910|FG002|Overall Study|Protocol Violation|2
6076422|NCT00590590|9681908|FG000|Overall Study|Lost to Follow-up|4
6076423|NCT00590590|9681909|FG001|Overall Study|Lost to Follow-up|1
6076424|NCT00590590|9681910|FG002|Overall Study|Lost to Follow-up|2
6076425|NCT00590590|9681908|FG000|Overall Study|Withdrawal by Subject|0
6076426|NCT00590590|9681909|FG001|Overall Study|Withdrawal by Subject|1
6076427|NCT00590590|9681910|FG002|Overall Study|Withdrawal by Subject|1
6076428|NCT00590590|9681908|FG000|Overall Study|Did not complete due to study closure|1
6076429|NCT00590590|9681909|FG001|Overall Study|Did not complete due to study closure|1
6076430|NCT00590590|9681910|FG002|Overall Study|Did not complete due to study closure|1
6076431|NCT00590590|9681908|FG000|Overall Study|Did not complete study|0
6076432|NCT00590590|9681909|FG001|Overall Study|Did not complete study|1
6076433|NCT00590590|9681910|FG002|Overall Study|Did not complete study|0
6076434|NCT00590681|9681918|FG000|Overall Study|Withdrawal by Subject|7
6076435|NCT00590681|9681918|FG000|Overall Study|Adverse Event|8
6076436|NCT00590681|9681918|FG000|Overall Study|Death|3
6076437|NCT00590681|9681918|FG000|Overall Study|Lost to Follow-up|1
6076438|NCT00590681|9681918|FG000|Overall Study|disease progression|1
6076439|NCT00590720|9681933|FG000|Overall Study|Lost to Follow-up|1
6076440|NCT00590720|9681934|FG001|Overall Study|Lost to Follow-up|0
6076441|NCT00590720|9681933|FG000|Overall Study|Withdrawal by Subject|0
6076442|NCT00590720|9681934|FG001|Overall Study|Withdrawal by Subject|1
6076443|NCT00590759|9681940|FG000|Overall Study|Death|52
6076444|NCT00590759|9681940|FG000|Overall Study|Lost to Follow-up|28
6076445|NCT00590824|9681954|FG000|Overall Study|Disease could not be resected|0
6076446|NCT00590824|9681955|FG001|Overall Study|Disease could not be resected|2
6076447|NCT00590824|9681956|FG002|Overall Study|Disease could not be resected|1
6076448|NCT00590824|9681957|FG003|Overall Study|Disease could not be resected|0
6076449|NCT00590824|9681954|FG000|Overall Study|Adverse Event|0
6076450|NCT00590824|9681955|FG001|Overall Study|Adverse Event|0
6076451|NCT00590824|9681956|FG002|Overall Study|Adverse Event|0
6076452|NCT00590824|9681957|FG003|Overall Study|Adverse Event|1
6076453|NCT00590902|9681990|FG000|Overall Study|Death|1
6014739|NCT00132730|9607609|FG003|Period IV - Open-label Extension (EXT2)|Clinical adverse experience|0
6014740|NCT00132730|9607610|FG004|Period IV - Open-label Extension (EXT2)|Clinical adverse experience|3
6014741|NCT00132730|9607611|FG005|Period IV - Open-label Extension (EXT2)|Clinical adverse experience|0
6076454|NCT00590954|9681994|FG000|Overall Study|Inevaluable|2
6076455|NCT00590967|9682002|FG000|Overall Study|Withdrawal by Subject|1
6076456|NCT00590967|9682003|FG001|Overall Study|Withdrawal by Subject|1
6076457|NCT00590967|9682002|FG000|Overall Study|Ineligible|1
6076458|NCT00590967|9682003|FG001|Overall Study|Ineligible|0
6014742|NCT00132730|9607606|FG000|Period IV - Open-label Extension (EXT2)|Laboratory adverse experience|0
6014743|NCT00132730|9607607|FG001|Period IV - Open-label Extension (EXT2)|Laboratory adverse experience|0
6014744|NCT00132730|9607608|FG002|Period IV - Open-label Extension (EXT2)|Laboratory adverse experience|0
6014745|NCT00132730|9607609|FG003|Period IV - Open-label Extension (EXT2)|Laboratory adverse experience|0
6014746|NCT00132730|9607610|FG004|Period IV - Open-label Extension (EXT2)|Laboratory adverse experience|1
6014747|NCT00132730|9607611|FG005|Period IV - Open-label Extension (EXT2)|Laboratory adverse experience|0
6014748|NCT00132730|9607606|FG000|Period IV - Open-label Extension (EXT2)|Other reasons|0
6076459|NCT00590967|9682002|FG000|Overall Study|Poor performance status|0
6076460|NCT00590967|9682003|FG001|Overall Study|Poor performance status|1
6076461|NCT00590967|9682002|FG000|Overall Study|Non-compliant|0
6076462|NCT00590967|9682003|FG001|Overall Study|Non-compliant|2
6076463|NCT00590967|9682002|FG000|Overall Study|Did not sign consent form|0
6076464|NCT00590967|9682003|FG001|Overall Study|Did not sign consent form|1
6076465|NCT00590967|9682002|FG000|Overall Study|Did not receive chemo per protocol|1
6076466|NCT00590967|9682003|FG001|Overall Study|Did not receive chemo per protocol|0
6076467|NCT00590980|9682009|FG000|Overall Study|Did not meet all inclusion criteria|10
6076468|NCT00591006|9682013|FG000|Overall Study|Withdrawal by Subject|0
6076469|NCT00591006|9682014|FG001|Overall Study|Withdrawal by Subject|0
6076470|NCT00591006|9682015|FG002|Overall Study|Withdrawal by Subject|0
6076471|NCT00591006|9682016|FG003|Overall Study|Withdrawal by Subject|0
6076472|NCT00591006|9682017|FG004|Overall Study|Withdrawal by Subject|0
6076473|NCT00591006|9682018|FG005|Overall Study|Withdrawal by Subject|0
6076474|NCT00591006|9682019|FG006|Overall Study|Withdrawal by Subject|0
6076475|NCT00591006|9682020|FG007|Overall Study|Withdrawal by Subject|0
6076476|NCT00591006|9682021|FG008|Overall Study|Withdrawal by Subject|0
6076477|NCT00591006|9682022|FG009|Overall Study|Withdrawal by Subject|0
6076478|NCT00591006|9682023|FG010|Overall Study|Withdrawal by Subject|0
6076479|NCT00591006|9682024|FG011|Overall Study|Withdrawal by Subject|0
6076480|NCT00591006|9682025|FG012|Overall Study|Withdrawal by Subject|0
6076481|NCT00591006|9682026|FG013|Overall Study|Withdrawal by Subject|0
6076482|NCT00591006|9682027|FG014|Overall Study|Withdrawal by Subject|0
6076483|NCT00591006|9682028|FG015|Overall Study|Withdrawal by Subject|1
6076484|NCT00591006|9682029|FG016|Overall Study|Withdrawal by Subject|0
6076485|NCT00591006|9682030|FG017|Overall Study|Withdrawal by Subject|0
6076486|NCT00591006|9682031|FG018|Overall Study|Withdrawal by Subject|0
6076487|NCT00591006|9682032|FG019|Overall Study|Withdrawal by Subject|0
6076488|NCT00591006|9682033|FG020|Overall Study|Withdrawal by Subject|0
6076489|NCT00591006|9682034|FG021|Overall Study|Withdrawal by Subject|0
6076490|NCT00591006|9682035|FG022|Overall Study|Withdrawal by Subject|0
6076491|NCT00591006|9682036|FG023|Overall Study|Withdrawal by Subject|1
6076492|NCT00591006|9682013|FG000|Overall Study|Adverse Event|0
6076493|NCT00591006|9682014|FG001|Overall Study|Adverse Event|0
6076494|NCT00591006|9682015|FG002|Overall Study|Adverse Event|0
6076495|NCT00591006|9682016|FG003|Overall Study|Adverse Event|0
6076496|NCT00591006|9682017|FG004|Overall Study|Adverse Event|0
6076497|NCT00591006|9682018|FG005|Overall Study|Adverse Event|0
6076498|NCT00591006|9682019|FG006|Overall Study|Adverse Event|0
6076499|NCT00591006|9682020|FG007|Overall Study|Adverse Event|0
6076500|NCT00591006|9682021|FG008|Overall Study|Adverse Event|0
6076501|NCT00591006|9682022|FG009|Overall Study|Adverse Event|0
6076502|NCT00591006|9682023|FG010|Overall Study|Adverse Event|0
6076503|NCT00591006|9682024|FG011|Overall Study|Adverse Event|0
6076504|NCT00591006|9682025|FG012|Overall Study|Adverse Event|0
6076505|NCT00591006|9682026|FG013|Overall Study|Adverse Event|0
6076506|NCT00591006|9682027|FG014|Overall Study|Adverse Event|0
6076507|NCT00591006|9682028|FG015|Overall Study|Adverse Event|0
6076508|NCT00591006|9682029|FG016|Overall Study|Adverse Event|0
6076509|NCT00591006|9682030|FG017|Overall Study|Adverse Event|0
6076510|NCT00591006|9682031|FG018|Overall Study|Adverse Event|0
6076511|NCT00591006|9682032|FG019|Overall Study|Adverse Event|0
6076512|NCT00591006|9682033|FG020|Overall Study|Adverse Event|0
6076513|NCT00591006|9682034|FG021|Overall Study|Adverse Event|0
6076514|NCT00591006|9682035|FG022|Overall Study|Adverse Event|1
6076515|NCT00591006|9682036|FG023|Overall Study|Adverse Event|0
6076516|NCT00591149|9682066|FG000|Overall Study|Adverse Event|4
6076517|NCT00591149|9682066|FG000|Overall Study|Withdrawal by Subject|1
6076518|NCT00591214|9682070|FG000|Overall Study|Physician Decision|7
6076519|NCT00591214|9682070|FG000|Overall Study|Withdrawal by Subject|1
6076520|NCT00591253|9682086|FG000|Overall Study|Adverse Event|3
6076521|NCT00591253|9682087|FG001|Overall Study|Adverse Event|3
6076522|NCT00591253|9682088|FG002|Overall Study|Adverse Event|1
6076523|NCT00591253|9682086|FG000|Overall Study|Protocol Violation|2
6076524|NCT00591253|9682087|FG001|Overall Study|Protocol Violation|2
6076525|NCT00591253|9682088|FG002|Overall Study|Protocol Violation|2
6076526|NCT00591253|9682086|FG000|Overall Study|Lost to Follow-up|2
6076527|NCT00591253|9682087|FG001|Overall Study|Lost to Follow-up|4
6076528|NCT00591253|9682088|FG002|Overall Study|Lost to Follow-up|0
6076529|NCT00591253|9682086|FG000|Overall Study|Withdrawal by Subject|1
6076530|NCT00591253|9682087|FG001|Overall Study|Withdrawal by Subject|7
6076531|NCT00591253|9682088|FG002|Overall Study|Withdrawal by Subject|6
6076532|NCT00591253|9682086|FG000|Overall Study|Lack of Efficacy|1
6076533|NCT00591253|9682087|FG001|Overall Study|Lack of Efficacy|0
6076534|NCT00591253|9682088|FG002|Overall Study|Lack of Efficacy|3
6076535|NCT00591253|9682086|FG000|Overall Study|Other|5
6076536|NCT00591253|9682087|FG001|Overall Study|Other|5
6076537|NCT00591253|9682088|FG002|Overall Study|Other|3
6076538|NCT00591266|9682099|FG000|Overall Study|Adverse Event|2
6076539|NCT00591266|9682100|FG001|Overall Study|Adverse Event|2
6076540|NCT00591266|9682101|FG002|Overall Study|Adverse Event|3
6076541|NCT00591266|9682099|FG000|Overall Study|Lost to Follow-up|0
6076542|NCT00591266|9682100|FG001|Overall Study|Lost to Follow-up|1
6076543|NCT00591266|9682101|FG002|Overall Study|Lost to Follow-up|0
6076544|NCT00591266|9682099|FG000|Overall Study|Protocol Violation|0
6014749|NCT00132730|9607607|FG001|Period IV - Open-label Extension (EXT2)|Other reasons|0
6014750|NCT00132730|9607608|FG002|Period IV - Open-label Extension (EXT2)|Other reasons|0
6014751|NCT00132730|9607609|FG003|Period IV - Open-label Extension (EXT2)|Other reasons|0
6014752|NCT00132730|9607610|FG004|Period IV - Open-label Extension (EXT2)|Other reasons|6
6014753|NCT00132730|9607611|FG005|Period IV - Open-label Extension (EXT2)|Other reasons|0
6014754|NCT00132730|9607606|FG000|Period V - Open-label Extension (EXT2)|Site terminated|0
6014755|NCT00132730|9607607|FG001|Period V - Open-label Extension (EXT2)|Site terminated|0
6014756|NCT00132730|9607608|FG002|Period V - Open-label Extension (EXT2)|Site terminated|0
6014757|NCT00132730|9607609|FG003|Period V - Open-label Extension (EXT2)|Site terminated|0
6014758|NCT00132730|9607610|FG004|Period V - Open-label Extension (EXT2)|Site terminated|7
6014759|NCT00132730|9607611|FG005|Period V - Open-label Extension (EXT2)|Site terminated|2
6014760|NCT00132769|9607627|FG000|Overall Study|Withdrawal by Subject|1
6014761|NCT00132769|9607628|FG001|Overall Study|Withdrawal by Subject|3
6014762|NCT00132769|9607627|FG000|Overall Study|Lack of Efficacy|7
6014763|NCT00132769|9607628|FG001|Overall Study|Lack of Efficacy|6
6014764|NCT00132769|9607627|FG000|Overall Study|Adverse Event|2
6014765|NCT00132769|9607628|FG001|Overall Study|Adverse Event|1
6014766|NCT00132769|9607627|FG000|Overall Study|Protocol Violation|1
6014767|NCT00132769|9607628|FG001|Overall Study|Protocol Violation|1
6014768|NCT00132808|9607637|FG000|Stratum I|Adverse Event|2
6014769|NCT00132808|9607638|FG001|Stratum I|Adverse Event|1
6014770|NCT00132808|9607639|FG002|Stratum I|Adverse Event|0
6014771|NCT00132808|9607637|FG000|Stratum I|Lost to Follow-up|3
6014772|NCT00132808|9607638|FG001|Stratum I|Lost to Follow-up|4
6014773|NCT00132808|9607639|FG002|Stratum I|Lost to Follow-up|1
6014774|NCT00132808|9607637|FG000|Stratum I|Withdrawal by Subject|4
6014775|NCT00132808|9607638|FG001|Stratum I|Withdrawal by Subject|7
6014776|NCT00132808|9607639|FG002|Stratum I|Withdrawal by Subject|3
6014777|NCT00132808|9607637|FG000|Stratum I|Abnormal test procedure result (s)|0
6014778|NCT00132808|9607638|FG001|Stratum I|Abnormal test procedure result (s)|0
6014779|NCT00132808|9607639|FG002|Stratum I|Abnormal test procedure result (s)|1
6014780|NCT00132808|9607637|FG000|Stratum II|Adverse Event|1
6014781|NCT00132808|9607638|FG001|Stratum II|Adverse Event|2
6014782|NCT00132808|9607639|FG002|Stratum II|Adverse Event|1
6014783|NCT00132808|9607637|FG000|Stratum II|Death|1
6014784|NCT00132808|9607638|FG001|Stratum II|Death|0
6014785|NCT00132808|9607639|FG002|Stratum II|Death|0
6014786|NCT00132808|9607637|FG000|Stratum II|Lost to Follow-up|2
6014787|NCT00132808|9607638|FG001|Stratum II|Lost to Follow-up|2
6014788|NCT00132808|9607639|FG002|Stratum II|Lost to Follow-up|1
6014789|NCT00132808|9607637|FG000|Stratum II|Protocol Violation|0
6014790|NCT00132808|9607638|FG001|Stratum II|Protocol Violation|2
6014791|NCT00132808|9607639|FG002|Stratum II|Protocol Violation|1
6014792|NCT00132808|9607637|FG000|Stratum II|Withdrawal by Subject|4
6014793|NCT00132808|9607638|FG001|Stratum II|Withdrawal by Subject|9
6014794|NCT00132808|9607639|FG002|Stratum II|Withdrawal by Subject|6
6014795|NCT00132873|9607647|FG000|Overall Study|Adverse Event|3
6014796|NCT00132873|9607647|FG000|Overall Study|Lost to Follow-up|1
6014797|NCT00132873|9607647|FG000|Overall Study|Lack of Efficacy|1
6014798|NCT00132873|9607647|FG000|Overall Study|Withdrawal by Subject|3
6014799|NCT00132873|9607647|FG000|Overall Study|Planned Pregnancy|1
6014800|NCT00133705|9607691|FG000|Overall Study|Withdrawal by Subject|2
6014801|NCT00133705|9607692|FG001|Overall Study|Withdrawal by Subject|3
6047626|NCT00412984|9646725|FG000|Overall Study|Poor/Noncompliance|57
6047627|NCT00412984|9646726|FG001|Overall Study|Poor/Noncompliance|77
6047628|NCT00412984|9646725|FG000|Overall Study|Pregnancy|1
6047629|NCT00412984|9646726|FG001|Overall Study|Pregnancy|0
6047630|NCT00412984|9646725|FG000|Overall Study|Subject No Longer Meets Study Criteria|87
6047631|NCT00412984|9646726|FG001|Overall Study|Subject No Longer Meets Study Criteria|100
6047632|NCT00412984|9646725|FG000|Overall Study|Administrative Reason by Sponsor|11
6047633|NCT00412984|9646726|FG001|Overall Study|Administrative Reason by Sponsor|8
6047634|NCT00412984|9646725|FG000|Overall Study|Physician Refused to Continue Treatment|81
6047635|NCT00412984|9646726|FG001|Overall Study|Physician Refused to Continue Treatment|89
6047636|NCT00412984|9646725|FG000|Overall Study|Other Reason|80
6047637|NCT00412984|9646726|FG001|Overall Study|Other Reason|92
6047638|NCT00412984|9646725|FG000|Overall Study|Not Reported|11
6047639|NCT00412984|9646726|FG001|Overall Study|Not Reported|12
6047640|NCT00413010|9646734|FG000|Overall Study|Adverse Event|8
6047641|NCT00413010|9646735|FG001|Overall Study|Adverse Event|4
6047642|NCT00413010|9646734|FG000|Overall Study|Laboratory abnormality|0
6047643|NCT00413010|9646735|FG001|Overall Study|Laboratory abnormality|2
6047644|NCT00413010|9646734|FG000|Overall Study|Lack of Efficacy|0
6047645|NCT00413010|9646735|FG001|Overall Study|Lack of Efficacy|3
6047646|NCT00413010|9646734|FG000|Overall Study|Lost to Follow-up|3
6047647|NCT00413010|9646735|FG001|Overall Study|Lost to Follow-up|0
6047648|NCT00413010|9646734|FG000|Overall Study|Withdrawal by Subject|7
6047649|NCT00413010|9646735|FG001|Overall Study|Withdrawal by Subject|2
6047650|NCT00413010|9646734|FG000|Overall Study|Due to termination of the study|54
6047651|NCT00413010|9646735|FG001|Overall Study|Due to termination of the study|52
6047652|NCT00413036|9646741|FG000|Overall Study|Adverse Event|44
6047653|NCT00413036|9646741|FG000|Overall Study|Lack of Efficacy|129
6047654|NCT00413036|9646741|FG000|Overall Study|Withdrawal by Subject|7
6014802|NCT00133952|9607704|FG000|Overall Study|Adverse Event|1
6014803|NCT00133952|9607705|FG001|Overall Study|Adverse Event|2
6014804|NCT00133952|9607704|FG000|Overall Study|Death|3
6014805|NCT00133952|9607705|FG001|Overall Study|Death|2
6014806|NCT00133952|9607704|FG000|Overall Study|Lost to Follow-up|9
6014807|NCT00133952|9607705|FG001|Overall Study|Lost to Follow-up|14
6014808|NCT00133952|9607704|FG000|Overall Study|Protocol Entry Criteria Exclusion|4
6014809|NCT00133952|9607705|FG001|Overall Study|Protocol Entry Criteria Exclusion|1
6014810|NCT00133952|9607704|FG000|Overall Study|Protocol Violation|1
6014811|NCT00133952|9607705|FG001|Overall Study|Protocol Violation|1
6014812|NCT00133952|9607704|FG000|Overall Study|Withdrawal by Subject|20
6014813|NCT00133952|9607705|FG001|Overall Study|Withdrawal by Subject|4
6014814|NCT00133952|9607704|FG000|Overall Study|Physician Decision|4
6014815|NCT00133952|9607705|FG001|Overall Study|Physician Decision|3
6014816|NCT00133952|9607704|FG000|Overall Study|Sponsor Decision|0
6014817|NCT00133952|9607705|FG001|Overall Study|Sponsor Decision|1
6014818|NCT00133991|9607732|FG000|Overall Study|Death|4
6014819|NCT00134056|9607754|FG000|Randomization|Not eligible for assigned treatment|22
6014820|NCT00134056|9607755|FG001|Randomization|Not eligible for assigned treatment|20
6014821|NCT00134056|9607754|FG000|Eligible for Protocol Assigned Treatment|Lack of Efficacy|171
6014822|NCT00134056|9607755|FG001|Eligible for Protocol Assigned Treatment|Lack of Efficacy|171
6014823|NCT00134056|9607754|FG000|Eligible for Protocol Assigned Treatment|Adverse Event|81
6076545|NCT00591266|9682100|FG001|Overall Study|Protocol Violation|0
6076546|NCT00591266|9682101|FG002|Overall Study|Protocol Violation|1
6076547|NCT00591266|9682099|FG000|Overall Study|Withdrawal by Subject|6
6076548|NCT00591266|9682100|FG001|Overall Study|Withdrawal by Subject|2
6076549|NCT00591266|9682101|FG002|Overall Study|Withdrawal by Subject|5
6076550|NCT00591266|9682099|FG000|Overall Study|Lack of Efficacy|0
6014824|NCT00134056|9607755|FG001|Eligible for Protocol Assigned Treatment|Adverse Event|67
6014825|NCT00134056|9607754|FG000|Eligible for Protocol Assigned Treatment|Withdrawal by Subject|20
6014826|NCT00134056|9607755|FG001|Eligible for Protocol Assigned Treatment|Withdrawal by Subject|21
6014827|NCT00134056|9607754|FG000|Eligible for Protocol Assigned Treatment|Other|55
6014828|NCT00134056|9607755|FG001|Eligible for Protocol Assigned Treatment|Other|56
6014829|NCT00134082|9607764|FG000|Overall Study|Adverse Event|2
6014830|NCT00134082|9607764|FG000|Overall Study|Death|1
6014831|NCT00134563|9607793|FG000|Overall Study|Not treated due to protocol violation|0
6014832|NCT00134563|9607794|FG001|Overall Study|Not treated due to protocol violation|1
6014833|NCT00134563|9607795|FG002|Overall Study|Not treated due to protocol violation|1
6014834|NCT00134563|9607793|FG000|Overall Study|Adverse Event|29
6014835|NCT00134563|9607794|FG001|Overall Study|Adverse Event|37
6014836|NCT00134563|9607795|FG002|Overall Study|Adverse Event|38
6014837|NCT00134563|9607793|FG000|Overall Study|Lack of Efficacy|24
6014838|NCT00134563|9607794|FG001|Overall Study|Lack of Efficacy|14
6014839|NCT00134563|9607795|FG002|Overall Study|Lack of Efficacy|17
6014840|NCT00134563|9607793|FG000|Overall Study|Protocol Violation|3
6014841|NCT00134563|9607794|FG001|Overall Study|Protocol Violation|2
6014842|NCT00134563|9607795|FG002|Overall Study|Protocol Violation|5
6014843|NCT00134563|9607793|FG000|Overall Study|Lost to Follow-up|4
6014844|NCT00134563|9607794|FG001|Overall Study|Lost to Follow-up|0
6014845|NCT00134563|9607795|FG002|Overall Study|Lost to Follow-up|2
6014846|NCT00134563|9607793|FG000|Overall Study|progressive disease|11
6014847|NCT00134563|9607794|FG001|Overall Study|progressive disease|4
6014848|NCT00134563|9607795|FG002|Overall Study|progressive disease|2
6014849|NCT00134563|9607793|FG000|Overall Study|did not wish to continue|33
6014850|NCT00134563|9607794|FG001|Overall Study|did not wish to continue|32
6014851|NCT00134563|9607795|FG002|Overall Study|did not wish to continue|26
6014852|NCT00134563|9607793|FG000|Overall Study|Reason other than above|0
6014853|NCT00134563|9607794|FG001|Overall Study|Reason other than above|2
6014854|NCT00134563|9607795|FG002|Overall Study|Reason other than above|5
6014855|NCT00134719|9607806|FG000|Primary Vaccination Phase|Adverse Event|4
6014856|NCT00134719|9607807|FG001|Primary Vaccination Phase|Adverse Event|0
6014857|NCT00134719|9607808|FG002|Primary Vaccination Phase|Adverse Event|0
6014858|NCT00134719|9607806|FG000|Primary Vaccination Phase|Protocol Violation|1
6014859|NCT00134719|9607807|FG001|Primary Vaccination Phase|Protocol Violation|0
6014860|NCT00134719|9607808|FG002|Primary Vaccination Phase|Protocol Violation|0
6014861|NCT00134719|9607806|FG000|Primary Vaccination Phase|Withdrawal by Subject|2
6014862|NCT00134719|9607807|FG001|Primary Vaccination Phase|Withdrawal by Subject|3
6014863|NCT00134719|9607808|FG002|Primary Vaccination Phase|Withdrawal by Subject|2
6014864|NCT00134719|9607806|FG000|Primary Vaccination Phase|Lost to Follow-up|7
6014865|NCT00134719|9607807|FG001|Primary Vaccination Phase|Lost to Follow-up|3
6014866|NCT00134719|9607808|FG002|Primary Vaccination Phase|Lost to Follow-up|3
6014867|NCT00134719|9607806|FG000|Fourth Dose Vaccination Phase|Lost to Follow-up|1
6076551|NCT00591266|9682100|FG001|Overall Study|Lack of Efficacy|2
6076552|NCT00591266|9682101|FG002|Overall Study|Lack of Efficacy|0
6076553|NCT00591266|9682099|FG000|Overall Study|Other|1
6076554|NCT00591266|9682100|FG001|Overall Study|Other|4
6014868|NCT00134719|9607807|FG001|Fourth Dose Vaccination Phase|Lost to Follow-up|3
6014869|NCT00134719|9607808|FG002|Fourth Dose Vaccination Phase|Lost to Follow-up|1
6076555|NCT00591266|9682101|FG002|Overall Study|Other|5
6076556|NCT00591344|9682121|FG000|Overall Study|Transportation issues|1
6076557|NCT00591344|9682122|FG001|Overall Study|Transportation issues|0
6076558|NCT00591344|9682121|FG000|Overall Study|Moved out of state|1
6014870|NCT00134719|9607806|FG000|Fourth Dose Vaccination Phase|Mother just delivered a new baby|1
6014871|NCT00134719|9607807|FG001|Fourth Dose Vaccination Phase|Mother just delivered a new baby|0
6014872|NCT00134719|9607808|FG002|Fourth Dose Vaccination Phase|Mother just delivered a new baby|0
6014873|NCT00134784|9607820|FG000|Overall Study|Withdrawal by Subject|2
6014874|NCT00134784|9607821|FG001|Overall Study|Withdrawal by Subject|2
6014875|NCT00134784|9607822|FG002|Overall Study|Withdrawal by Subject|2
6014876|NCT00134784|9607823|FG003|Overall Study|Withdrawal by Subject|1
6014877|NCT00134901|9607832|FG000|Overall Study|Lost to Follow-up|5
6014878|NCT00134901|9607833|FG001|Overall Study|Lost to Follow-up|5
6014879|NCT00134901|9607832|FG000|Overall Study|discontinued intervention|12
6014880|NCT00134901|9607833|FG001|Overall Study|discontinued intervention|10
6014881|NCT00135330|9607863|FG000|Overall Study|Adverse Event|2
6014882|NCT00135330|9607864|FG001|Overall Study|Adverse Event|5
6014883|NCT00135330|9607865|FG002|Overall Study|Adverse Event|1
6014884|NCT00135330|9607863|FG000|Overall Study|Lost to Follow-up|0
6014885|NCT00135330|9607864|FG001|Overall Study|Lost to Follow-up|2
6014886|NCT00135330|9607865|FG002|Overall Study|Lost to Follow-up|3
6014887|NCT00135330|9607863|FG000|Overall Study|Physician Decision|1
6014888|NCT00135330|9607864|FG001|Overall Study|Physician Decision|1
6014889|NCT00135330|9607865|FG002|Overall Study|Physician Decision|0
6014890|NCT00135330|9607863|FG000|Overall Study|Protocol Violation|4
6014891|NCT00135330|9607864|FG001|Overall Study|Protocol Violation|3
6014892|NCT00135330|9607865|FG002|Overall Study|Protocol Violation|3
6014893|NCT00135330|9607863|FG000|Overall Study|Patient Decision|5
6014894|NCT00135330|9607864|FG001|Overall Study|Patient Decision|1
6014895|NCT00135330|9607865|FG002|Overall Study|Patient Decision|4
6014896|NCT00135330|9607863|FG000|Overall Study|Sponsor Decision|0
6014897|NCT00135330|9607864|FG001|Overall Study|Sponsor Decision|1
6014898|NCT00135330|9607865|FG002|Overall Study|Sponsor Decision|0
6014899|NCT00135356|9607875|FG000|Overall Study|Adverse Event|6
6014900|NCT00135356|9607876|FG001|Overall Study|Adverse Event|2
6014901|NCT00135356|9607875|FG000|Overall Study|Lack of Efficacy|2
6014902|NCT00135356|9607876|FG001|Overall Study|Lack of Efficacy|0
6014903|NCT00135356|9607875|FG000|Overall Study|Lost to Follow-up|3
6014904|NCT00135356|9607876|FG001|Overall Study|Lost to Follow-up|1
6014905|NCT00135356|9607875|FG000|Overall Study|Surgery for abdominal fat|1
6014906|NCT00135356|9607876|FG001|Overall Study|Surgery for abdominal fat|0
6014907|NCT00135356|9607875|FG000|Overall Study|Change in antiviral regimen|0
6076559|NCT00591344|9682122|FG001|Overall Study|Moved out of state|0
6076560|NCT00591344|9682121|FG000|Overall Study|Medical complications|1
6076561|NCT00591344|9682122|FG001|Overall Study|Medical complications|3
6076562|NCT00591344|9682121|FG000|Overall Study|Underwent DBS|2
6076563|NCT00591344|9682122|FG001|Overall Study|Underwent DBS|2
6076564|NCT00591344|9682121|FG000|Overall Study|Death|0
6076565|NCT00591344|9682122|FG001|Overall Study|Death|1
6076566|NCT00591344|9682121|FG000|Overall Study|Lost to Follow-up|0
6076567|NCT00591344|9682122|FG001|Overall Study|Lost to Follow-up|1
6227286|NCT01716520|9900044|FG003|Washout Period 1 (10 to 14 Days)|Lack of Efficacy|0
6076568|NCT00591344|9682121|FG000|Overall Study|Did not want to come off medication|0
6076569|NCT00591344|9682122|FG001|Overall Study|Did not want to come off medication|1
6076570|NCT00591370|9682132|FG000|Overall Study|Not Treated|2
6076571|NCT00591409|9682146|FG000|Overall Study|Not Treated|0
6076572|NCT00591409|9682147|FG001|Overall Study|Not Treated|0
6076573|NCT00591409|9682148|FG002|Overall Study|Not Treated|0
6076574|NCT00591409|9682149|FG003|Overall Study|Not Treated|0
6076575|NCT00591409|9682150|FG004|Overall Study|Not Treated|1
6076576|NCT00591409|9682151|FG005|Overall Study|Not Treated|0
6076577|NCT00591409|9682152|FG006|Overall Study|Not Treated|0
6076578|NCT00591409|9682153|FG007|Overall Study|Not Treated|0
6076579|NCT00591409|9682154|FG008|Overall Study|Not Treated|0
6076580|NCT00591409|9682155|FG009|Overall Study|Not Treated|1
6076581|NCT00591565|9682177|FG000|Overall Study|lost follow up, withdrawn|5
6076582|NCT00591578|9682184|FG000|Double-Blind Treatment Phase|Adverse Event|20
6076583|NCT00591578|9682185|FG001|Double-Blind Treatment Phase|Adverse Event|26
6076584|NCT00591578|9682186|FG002|Double-Blind Treatment Phase|Adverse Event|19
6076585|NCT00591578|9682184|FG000|Double-Blind Treatment Phase|Protocol Violation|3
6076586|NCT00591578|9682185|FG001|Double-Blind Treatment Phase|Protocol Violation|2
6076587|NCT00591578|9682186|FG002|Double-Blind Treatment Phase|Protocol Violation|3
6076588|NCT00591578|9682184|FG000|Double-Blind Treatment Phase|Lost to Follow-up|12
6076589|NCT00591578|9682185|FG001|Double-Blind Treatment Phase|Lost to Follow-up|12
6076590|NCT00591578|9682186|FG002|Double-Blind Treatment Phase|Lost to Follow-up|11
6076591|NCT00591578|9682184|FG000|Double-Blind Treatment Phase|Withdrawal by Subject|22
6076592|NCT00591578|9682185|FG001|Double-Blind Treatment Phase|Withdrawal by Subject|22
6076593|NCT00591578|9682186|FG002|Double-Blind Treatment Phase|Withdrawal by Subject|22
6076594|NCT00591578|9682184|FG000|Double-Blind Treatment Phase|Pregnancy|1
6076595|NCT00591578|9682185|FG001|Double-Blind Treatment Phase|Pregnancy|0
6076596|NCT00591578|9682186|FG002|Double-Blind Treatment Phase|Pregnancy|0
6076597|NCT00591578|9682184|FG000|Double-Blind Treatment Phase|Lack of Efficacy|16
6014908|NCT00135356|9607876|FG001|Overall Study|Change in antiviral regimen|1
6014909|NCT00135356|9607875|FG000|Overall Study|Poor/noncompliance|1
6014910|NCT00135356|9607876|FG001|Overall Study|Poor/noncompliance|1
6076598|NCT00591578|9682185|FG001|Double-Blind Treatment Phase|Lack of Efficacy|9
6076599|NCT00591578|9682186|FG002|Double-Blind Treatment Phase|Lack of Efficacy|25
6014911|NCT00135356|9607875|FG000|Overall Study|No longer meets study criteria|2
6014912|NCT00135356|9607876|FG001|Overall Study|No longer meets study criteria|0
6014913|NCT00135356|9607875|FG000|Overall Study|Withdrawal by Subject|2
6014914|NCT00135356|9607876|FG001|Overall Study|Withdrawal by Subject|4
6014915|NCT00135512|9607882|FG000|Overall Study|Adverse Event|56
6014916|NCT00135512|9607882|FG000|Overall Study|Lack of Efficacy|25
6014917|NCT00135512|9607882|FG000|Overall Study|Other|42
6014918|NCT00135694|9607889|FG000|Overall Study|Adverse Event|17
6014919|NCT00135694|9607890|FG001|Overall Study|Adverse Event|4
6014920|NCT00135694|9607891|FG002|Overall Study|Adverse Event|0
6014921|NCT00135694|9607889|FG000|Overall Study|Death|14
6014922|NCT00135694|9607890|FG001|Overall Study|Death|1
6014923|NCT00135694|9607891|FG002|Overall Study|Death|2
6014924|NCT00135694|9607889|FG000|Overall Study|Lost to Follow-up|8
6014925|NCT00135694|9607890|FG001|Overall Study|Lost to Follow-up|7
6014926|NCT00135694|9607891|FG002|Overall Study|Lost to Follow-up|1
6014927|NCT00135694|9607889|FG000|Overall Study|Withdrawal by Subject|41
6014928|NCT00135694|9607890|FG001|Overall Study|Withdrawal by Subject|7
6014929|NCT00135694|9607891|FG002|Overall Study|Withdrawal by Subject|4
6014930|NCT00135694|9607889|FG000|Overall Study|Protocol Violation|19
6014931|NCT00135694|9607890|FG001|Overall Study|Protocol Violation|1
6014932|NCT00135694|9607891|FG002|Overall Study|Protocol Violation|0
6014933|NCT00135694|9607889|FG000|Overall Study|Hepatitis C related reasons|39
6014934|NCT00135694|9607890|FG001|Overall Study|Hepatitis C related reasons|1
6014935|NCT00135694|9607891|FG002|Overall Study|Hepatitis C related reasons|0
6014936|NCT00135694|9607889|FG000|Overall Study|Ineligible for Random assignment|42
6014937|NCT00135694|9607890|FG001|Overall Study|Ineligible for Random assignment|0
6014938|NCT00135694|9607891|FG002|Overall Study|Ineligible for Random assignment|0
6014939|NCT00135707|9607901|FG000|Overall Study|Lost to Follow-up|94
6014940|NCT00135707|9607902|FG001|Overall Study|Lost to Follow-up|89
6014941|NCT00135707|9607901|FG000|Overall Study|Withdrawal by Subject|0
6014942|NCT00135707|9607902|FG001|Overall Study|Withdrawal by Subject|1
6014943|NCT00135707|9607901|FG000|Overall Study|Institutional review board request|1
6014944|NCT00135707|9607902|FG001|Overall Study|Institutional review board request|0
6014945|NCT00136084|9607926|FG000|Overall Study|Death|12
6014946|NCT00136084|9607927|FG001|Overall Study|Death|5
6014947|NCT00136084|9607926|FG000|Overall Study|Unacceptable toxicity|8
6014948|NCT00136084|9607927|FG001|Overall Study|Unacceptable toxicity|11
6014949|NCT00136084|9607926|FG000|Overall Study|Relapse|20
6014950|NCT00136084|9607927|FG001|Overall Study|Relapse|23
6014951|NCT00136084|9607926|FG000|Overall Study|Lost to Follow-up|2
6014952|NCT00136084|9607927|FG001|Overall Study|Lost to Follow-up|0
6014953|NCT00136084|9607926|FG000|Overall Study|No Response|1
6014954|NCT00136084|9607927|FG001|Overall Study|No Response|2
6014955|NCT00136084|9607926|FG000|Overall Study|Withdrawal by Subject|5
6014956|NCT00136084|9607927|FG001|Overall Study|Withdrawal by Subject|1
6014957|NCT00136318|9607952|FG000|Overall Study|Adverse Event|5
6014958|NCT00136318|9607953|FG001|Overall Study|Adverse Event|5
6014959|NCT00136318|9607952|FG000|Overall Study|Withdrawal by Subject|2
6014960|NCT00136318|9607953|FG001|Overall Study|Withdrawal by Subject|2
6014961|NCT00136357|9607962|FG000|Overall Study|Withdrawal by Subject|3
6014962|NCT00136357|9607963|FG001|Overall Study|Withdrawal by Subject|2
6014963|NCT00136604|9607974|FG000|Overall Study|Lost to Follow-up|1
6014964|NCT00136604|9607975|FG001|Overall Study|Lost to Follow-up|0
6014965|NCT00136604|9607976|FG002|Overall Study|Lost to Follow-up|0
6014966|NCT00136604|9607977|FG003|Overall Study|Lost to Follow-up|0
6014967|NCT00136604|9607978|FG004|Overall Study|Lost to Follow-up|1
6014968|NCT00136604|9607974|FG000|Overall Study|Migrated/moved from study area|0
6014969|NCT00136604|9607975|FG001|Overall Study|Migrated/moved from study area|1
6014970|NCT00136604|9607976|FG002|Overall Study|Migrated/moved from study area|0
6014971|NCT00136604|9607977|FG003|Overall Study|Migrated/moved from study area|0
6014972|NCT00136604|9607978|FG004|Overall Study|Migrated/moved from study area|0
6014973|NCT00136916|9608040|FG000|Overall Study|Never received study treatment|3
6014974|NCT00136916|9608041|FG001|Overall Study|Never received study treatment|5
6014975|NCT00136916|9608040|FG000|Overall Study|Death|1
6014976|NCT00136916|9608041|FG001|Overall Study|Death|3
6014977|NCT00136916|9608040|FG000|Overall Study|Adverse Event|27
6014978|NCT00136916|9608041|FG001|Overall Study|Adverse Event|8
6014979|NCT00136916|9608040|FG000|Overall Study|Laboratory abnormality|0
6014980|NCT00136916|9608041|FG001|Overall Study|Laboratory abnormality|1
6014981|NCT00136916|9608040|FG000|Overall Study|Lack of Efficacy|13
6014982|NCT00136916|9608041|FG001|Overall Study|Lack of Efficacy|3
6014983|NCT00136916|9608040|FG000|Overall Study|Lost to Follow-up|12
6014984|NCT00136916|9608041|FG001|Overall Study|Lost to Follow-up|14
6014985|NCT00136916|9608040|FG000|Overall Study|Withdrawal by Subject|44
6014986|NCT00136916|9608041|FG001|Overall Study|Withdrawal by Subject|46
6014987|NCT00136916|9608040|FG000|Overall Study|Other|22
6014988|NCT00136916|9608041|FG001|Overall Study|Other|24
6014989|NCT00136916|9608040|FG000|Overall Study|Discontinued in follow up period|3
6014990|NCT00136916|9608041|FG001|Overall Study|Discontinued in follow up period|0
6014991|NCT00136955|9608049|FG000|Overall Study|Adverse Event|8
6014992|NCT00136955|9608049|FG000|Overall Study|Lost to Follow-up|1
6014993|NCT00136955|9608049|FG000|Overall Study|Withdrawal by Subject|2
6014994|NCT00136955|9608049|FG000|Overall Study|Incl. prog. disease, protocol violation|12
6014995|NCT00137046|9608055|FG000|Overall Study|Death|2
6014996|NCT00137046|9608056|FG001|Overall Study|Death|1
6014997|NCT00137046|9608055|FG000|Overall Study|Adverse Event|16
6014998|NCT00137046|9608056|FG001|Overall Study|Adverse Event|5
6014999|NCT00137046|9608055|FG000|Overall Study|Laboratory Abnormality|2
6015000|NCT00137046|9608056|FG001|Overall Study|Laboratory Abnormality|0
6015001|NCT00137046|9608055|FG000|Overall Study|Lack of Efficacy|13
6015002|NCT00137046|9608056|FG001|Overall Study|Lack of Efficacy|1
6015003|NCT00137046|9608055|FG000|Overall Study|Lost to Follow-up|8
6015004|NCT00137046|9608056|FG001|Overall Study|Lost to Follow-up|24
6015005|NCT00137046|9608055|FG000|Overall Study|Other|23
6015006|NCT00137046|9608056|FG001|Overall Study|Other|19
6015007|NCT00137046|9608055|FG000|Overall Study|Withdrawal by Subject|33
6015008|NCT00137046|9608056|FG001|Overall Study|Withdrawal by Subject|42
6015009|NCT00137046|9608055|FG000|Overall Study|Adverse Event 4 Days after Last Dose|1
6015010|NCT00137046|9608056|FG001|Overall Study|Adverse Event 4 Days after Last Dose|0
6015011|NCT00137046|9608055|FG000|Overall Study|Withdrew prior to study treatment|1
6015012|NCT00137046|9608056|FG001|Overall Study|Withdrew prior to study treatment|1
6015013|NCT00137111|9608070|FG000|Total Therapy|Death|35
6015014|NCT00137111|9608071|FG001|Total Therapy|Death|0
6015015|NCT00137111|9608072|FG002|Total Therapy|Death|0
6015016|NCT00137111|9608073|FG003|Total Therapy|Death|0
6015017|NCT00137111|9608070|FG000|Total Therapy|Non Compliance|5
6015018|NCT00137111|9608071|FG001|Total Therapy|Non Compliance|0
6015019|NCT00137111|9608072|FG002|Total Therapy|Non Compliance|0
6015020|NCT00137111|9608073|FG003|Total Therapy|Non Compliance|0
6015021|NCT00137267|9608082|FG000|Overall Study|Lost to Follow-up|15
6015022|NCT00137267|9608083|FG001|Overall Study|Lost to Follow-up|21
6015023|NCT00137423|9608100|FG000|Overall Study|Adverse Event|7
6015024|NCT00137423|9608101|FG001|Overall Study|Adverse Event|9
6015025|NCT00137423|9608100|FG000|Overall Study|consent withdrawn|1
6015026|NCT00137423|9608101|FG001|Overall Study|consent withdrawn|1
6015027|NCT00137423|9608100|FG000|Overall Study|Lack of Efficacy|31
6015028|NCT00137423|9608101|FG001|Overall Study|Lack of Efficacy|33
6015029|NCT00137423|9608100|FG000|Overall Study|Death|0
6015030|NCT00137423|9608101|FG001|Overall Study|Death|1
6015031|NCT00137436|9608111|FG000|Overall Study|Adverse Event|13
6015032|NCT00137436|9608111|FG000|Overall Study|Death|2
6015033|NCT00137436|9608111|FG000|Overall Study|Lack of Efficacy|17
6015034|NCT00137436|9608111|FG000|Overall Study|Withdrawal by Subject|6
6015035|NCT00137436|9608111|FG000|Overall Study|Other|5
6015036|NCT00137449|9608117|FG000|Overall Study|Disease Progression|8
6015037|NCT00137449|9608118|FG001|Overall Study|Disease Progression|13
6015038|NCT00137449|9608117|FG000|Overall Study|Death|4
6015039|NCT00137449|9608118|FG001|Overall Study|Death|3
6015040|NCT00137449|9608117|FG000|Overall Study|Adverse Event|3
6015041|NCT00137449|9608118|FG001|Overall Study|Adverse Event|1
6015042|NCT00137449|9608117|FG000|Overall Study|Withdrawal by Subject|1
6015043|NCT00137449|9608118|FG001|Overall Study|Withdrawal by Subject|1
6015044|NCT00137631|9608127|FG000|Overall Study|Lost to Follow-up|37
6015045|NCT00137631|9608128|FG001|Overall Study|Lost to Follow-up|41
6015046|NCT00137839|9608134|FG000|Overall Study|Adverse Event|7
6015047|NCT00137839|9608134|FG000|Overall Study|Physician Decision|7
6015048|NCT00137839|9608134|FG000|Overall Study|Death|8
6015049|NCT00137839|9608134|FG000|Overall Study|Disease Progression|60
6015050|NCT00137839|9608134|FG000|Overall Study|Not Start Treatment|1
6015051|NCT00137839|9608134|FG000|Overall Study|Prolonged Treatment Delay|1
6015052|NCT00138424|9608179|FG000|Overall Study|Physician Decision|0
6015053|NCT00138424|9608180|FG001|Overall Study|Physician Decision|1
6015054|NCT00138424|9608181|FG002|Overall Study|Physician Decision|0
6015055|NCT00138424|9608182|FG003|Overall Study|Physician Decision|0
6015056|NCT00138658|9608203|FG000|Overall Study|Adverse Event|23
6015057|NCT00138658|9608203|FG000|Overall Study|Death|1
6076600|NCT00591578|9682184|FG000|Double-Blind Treatment Phase|Other|4
6076601|NCT00591578|9682185|FG001|Double-Blind Treatment Phase|Other|9
6076602|NCT00591578|9682186|FG002|Double-Blind Treatment Phase|Other|4
6076603|NCT00591578|9682184|FG000|Open-Label Extension Phase|Adverse Event|3
6076604|NCT00591578|9682185|FG001|Open-Label Extension Phase|Adverse Event|5
6076605|NCT00591578|9682186|FG002|Open-Label Extension Phase|Adverse Event|0
6076606|NCT00591578|9682184|FG000|Open-Label Extension Phase|Lost to Follow-up|1
6076607|NCT00591578|9682185|FG001|Open-Label Extension Phase|Lost to Follow-up|4
6076608|NCT00591578|9682186|FG002|Open-Label Extension Phase|Lost to Follow-up|0
6076609|NCT00591578|9682184|FG000|Open-Label Extension Phase|Withdrawal by Subject|1
6076610|NCT00591578|9682185|FG001|Open-Label Extension Phase|Withdrawal by Subject|1
6076611|NCT00591578|9682186|FG002|Open-Label Extension Phase|Withdrawal by Subject|0
6076612|NCT00591578|9682184|FG000|Open-Label Extension Phase|Other|1
6076613|NCT00591578|9682185|FG001|Open-Label Extension Phase|Other|0
6076614|NCT00591578|9682186|FG002|Open-Label Extension Phase|Other|0
6076615|NCT00591591|9682197|FG000|Overall Study|Withdrawal by Subject|1
6015058|NCT00138658|9608203|FG000|Overall Study|Disease Progression|21
6015059|NCT00138658|9608203|FG000|Overall Study|Physician Decision|11
6015060|NCT00138658|9608203|FG000|Overall Study|Withdrawal by Subject|5
6015061|NCT00138671|9608211|FG000|Overall Study|Death|0
6015062|NCT00138671|9608212|FG001|Overall Study|Death|3
6015063|NCT00138671|9608211|FG000|Overall Study|Adverse Event|6
6015064|NCT00138671|9608212|FG001|Overall Study|Adverse Event|3
6015065|NCT00138671|9608211|FG000|Overall Study|Lost to Follow-up|1
6015066|NCT00138671|9608212|FG001|Overall Study|Lost to Follow-up|2
6015067|NCT00138671|9608211|FG000|Overall Study|Withdrawal by Subject|3
6015068|NCT00138671|9608212|FG001|Overall Study|Withdrawal by Subject|5
6015069|NCT00138671|9608211|FG000|Overall Study|Other|3
6015070|NCT00138671|9608212|FG001|Overall Study|Other|3
6015071|NCT00139477|9608231|FG000|First Intervention -Baseline to 6Months|No Longer Interested|6
6015072|NCT00139477|9608232|FG001|First Intervention -Baseline to 6Months|No Longer Interested|7
6015073|NCT00139477|9608231|FG000|First Intervention -Baseline to 6Months|Relocation|1
6015074|NCT00139477|9608232|FG001|First Intervention -Baseline to 6Months|Relocation|2
6015075|NCT00139477|9608231|FG000|First Intervention -Baseline to 6Months|Lost to Follow-up|3
6015076|NCT00139477|9608232|FG001|First Intervention -Baseline to 6Months|Lost to Follow-up|3
6015077|NCT00139477|9608231|FG000|First Intervention -Baseline to 6Months|Impaired Glucose Tolerance at Screening|2
6015078|NCT00139477|9608232|FG001|First Intervention -Baseline to 6Months|Impaired Glucose Tolerance at Screening|0
6015079|NCT00139477|9608231|FG000|Second Intervention -6Months to 12Months|No Longer Interested|0
6015080|NCT00139477|9608232|FG001|Second Intervention -6Months to 12Months|No Longer Interested|2
6015081|NCT00139477|9608231|FG000|Second Intervention -6Months to 12Months|Relocation|1
6015082|NCT00139477|9608232|FG001|Second Intervention -6Months to 12Months|Relocation|0
6015083|NCT00139477|9608231|FG000|Second Intervention -6Months to 12Months|Lost to Follow-up|4
6015084|NCT00139477|9608232|FG001|Second Intervention -6Months to 12Months|Lost to Follow-up|3
6015085|NCT00139659|9608242|FG000|Overall Study|Adverse Event|12
6015086|NCT00139659|9608243|FG001|Overall Study|Adverse Event|1
6015087|NCT00139659|9608242|FG000|Overall Study|Lack of Efficacy|1
6015088|NCT00139659|9608243|FG001|Overall Study|Lack of Efficacy|1
6015089|NCT00139659|9608242|FG000|Overall Study|Lost to Follow-up|7
6015090|NCT00139659|9608243|FG001|Overall Study|Lost to Follow-up|3
6015091|NCT00139659|9608242|FG000|Overall Study|Reason not Specified|6
6015092|NCT00139659|9608243|FG001|Overall Study|Reason not Specified|3
6015093|NCT00139659|9608242|FG000|Overall Study|Withdrawal by Subject|14
6015094|NCT00139659|9608243|FG001|Overall Study|Withdrawal by Subject|10
6015095|NCT00139737|9608253|FG000|Overall Study|Withdrawal by Subject|190
6015096|NCT00139737|9608253|FG000|Overall Study|Adverse Event|58
6015097|NCT00139737|9608253|FG000|Overall Study|Lack of Efficacy|40
6015098|NCT00139737|9608253|FG000|Overall Study|Lost to Follow-up|8
6015099|NCT00139737|9608253|FG000|Overall Study|Death|3
6015100|NCT00139737|9608253|FG000|Overall Study|Laboratory Abnormality|2
6015101|NCT00139737|9608253|FG000|Overall Study|Protocol Violation|18
6015102|NCT00139737|9608253|FG000|Overall Study|Withdrew During Screening Phase|8
6015103|NCT00139737|9608253|FG000|Overall Study|Did Not Meet Entrance Criteria|1
6015104|NCT00139737|9608253|FG000|Overall Study|Screened, Not Treated|13
6015105|NCT00139776|9608259|FG000|Period I|Did not enter Period II|575
6015106|NCT00139776|9608260|FG001|Period I|Did not enter Period II|0
6015107|NCT00139776|9608261|FG002|Period I|Did not enter Period II|0
6015108|NCT00139776|9608262|FG003|Period I|Did not enter Period II|0
6015109|NCT00139776|9608259|FG000|Period II|Not Randomized into Period III|0
6015110|NCT00139776|9608260|FG001|Period II|Not Randomized into Period III|322
6015111|NCT00139776|9608261|FG002|Period II|Not Randomized into Period III|0
6015112|NCT00139776|9608262|FG003|Period II|Not Randomized into Period III|0
6015113|NCT00139776|9608259|FG000|Period III|Adverse Event|0
6015114|NCT00139776|9608260|FG001|Period III|Adverse Event|0
6015115|NCT00139776|9608261|FG002|Period III|Adverse Event|22
6015116|NCT00139776|9608262|FG003|Period III|Adverse Event|23
6015117|NCT00139776|9608259|FG000|Period III|Other|0
6015118|NCT00139776|9608260|FG001|Period III|Other|0
6015119|NCT00139776|9608261|FG002|Period III|Other|23
6015120|NCT00139776|9608262|FG003|Period III|Other|34
6015121|NCT00139776|9608259|FG000|Period III|Lack of Efficacy|0
6015122|NCT00139776|9608260|FG001|Period III|Lack of Efficacy|0
6015123|NCT00139776|9608261|FG002|Period III|Lack of Efficacy|10
6015124|NCT00139776|9608262|FG003|Period III|Lack of Efficacy|24
6015125|NCT00139776|9608259|FG000|Period III|Lost to Follow-up|0
6015126|NCT00139776|9608260|FG001|Period III|Lost to Follow-up|0
6015127|NCT00139776|9608261|FG002|Period III|Lost to Follow-up|5
6015128|NCT00139776|9608262|FG003|Period III|Lost to Follow-up|4
6015129|NCT00139776|9608259|FG000|Period III|Withdrawal by Subject|0
6015130|NCT00139776|9608260|FG001|Period III|Withdrawal by Subject|0
6015131|NCT00139776|9608261|FG002|Period III|Withdrawal by Subject|16
6015132|NCT00139776|9608262|FG003|Period III|Withdrawal by Subject|21
6015133|NCT00140140|9608281|FG000|Overall Study|Unacceptable toxicity|1
6015134|NCT00140140|9608282|FG001|Overall Study|Unacceptable toxicity|1
6015135|NCT00140140|9608283|FG002|Overall Study|Unacceptable toxicity|2
6015136|NCT00140140|9608281|FG000|Overall Study|Physician Decision|1
6015137|NCT00140140|9608282|FG001|Overall Study|Physician Decision|1
6015138|NCT00140140|9608283|FG002|Overall Study|Physician Decision|0
6015139|NCT00140413|9608344|FG000|Overall Study|Lost to Follow-up|1
6015140|NCT00140413|9608345|FG001|Overall Study|Lost to Follow-up|0
6015141|NCT00140413|9608344|FG000|Overall Study|Withdrawal by Subject|2
6015142|NCT00140413|9608345|FG001|Overall Study|Withdrawal by Subject|0
6015143|NCT00140426|9608354|FG000|Overall Study|Withdrawal by Subject|0
6015144|NCT00140426|9608355|FG001|Overall Study|Withdrawal by Subject|3
6015145|NCT00140855|9608383|FG000|Overall Study|Progressive disease|2
6015146|NCT00141037|9608389|FG000|Overall Study|Physician Decision|1
6015147|NCT00141037|9608390|FG001|Overall Study|Physician Decision|2
6015148|NCT00141037|9608389|FG000|Overall Study|Lost to Follow-up|3
6015149|NCT00141037|9608390|FG001|Overall Study|Lost to Follow-up|1
6015150|NCT00141037|9608389|FG000|Overall Study|Protocol Violation|0
6015151|NCT00141037|9608390|FG001|Overall Study|Protocol Violation|2
6015152|NCT00141037|9608389|FG000|Overall Study|Withdrawal by Subject|2
6015153|NCT00141037|9608390|FG001|Overall Study|Withdrawal by Subject|1
6015154|NCT00141037|9608389|FG000|Overall Study|Other|0
6015155|NCT00141037|9608390|FG001|Overall Study|Other|1
6015156|NCT00141037|9608389|FG000|Overall Study|Moved from area|1
6015157|NCT00141037|9608390|FG001|Overall Study|Moved from area|7
6015158|NCT00141037|9608389|FG000|Overall Study|Graft Failure|3
6015159|NCT00141037|9608390|FG001|Overall Study|Graft Failure|4
6015160|NCT00141102|9608398|FG000|Overall Study|Adverse Event|233
6015161|NCT00141102|9608399|FG001|Overall Study|Adverse Event|305
6015162|NCT00141102|9608398|FG000|Overall Study|Laboratory Abnormality|9
6015163|NCT00141102|9608399|FG001|Overall Study|Laboratory Abnormality|33
6015164|NCT00141102|9608398|FG000|Overall Study|Lack of Efficacy|21
6015165|NCT00141102|9608399|FG001|Overall Study|Lack of Efficacy|26
6015166|NCT00141102|9608398|FG000|Overall Study|Lost to Follow-up|29
6015167|NCT00141102|9608399|FG001|Overall Study|Lost to Follow-up|32
6015168|NCT00141102|9608398|FG000|Overall Study|Other|87
6015169|NCT00141102|9608399|FG001|Overall Study|Other|76
6015170|NCT00141102|9608398|FG000|Overall Study|Withdrawal by Subject|112
6015171|NCT00141102|9608399|FG001|Overall Study|Withdrawal by Subject|142
6015172|NCT00141102|9608398|FG000|Overall Study|Randomized But Did Not Receive Treatment|15
6015173|NCT00141102|9608399|FG001|Overall Study|Randomized But Did Not Receive Treatment|9
6015174|NCT00141102|9608398|FG000|Overall Study|Death|2
6015175|NCT00141102|9608399|FG001|Overall Study|Death|2
6015176|NCT00141219|9608413|FG000|Overall Study|Protocol violations|5
6015177|NCT00141219|9608414|FG001|Overall Study|Protocol violations|4
6015178|NCT00141219|9608413|FG000|Overall Study|Adverse Event|8
6015179|NCT00141219|9608414|FG001|Overall Study|Adverse Event|6
6015180|NCT00141219|9608413|FG000|Overall Study|Lack of Efficacy|5
6015181|NCT00141219|9608414|FG001|Overall Study|Lack of Efficacy|4
6015182|NCT00141219|9608413|FG000|Overall Study|Withdrawal by Subject|6
6015183|NCT00141219|9608414|FG001|Overall Study|Withdrawal by Subject|2
6015184|NCT00141271|9608423|FG000|Overall Study|Adverse Event|31
6015185|NCT00141271|9608424|FG001|Overall Study|Adverse Event|19
6015186|NCT00141271|9608425|FG002|Overall Study|Adverse Event|17
6015187|NCT00141271|9608423|FG000|Overall Study|Laboratory Abnormality|2
6015188|NCT00141271|9608424|FG001|Overall Study|Laboratory Abnormality|1
6015189|NCT00141271|9608425|FG002|Overall Study|Laboratory Abnormality|1
6015190|NCT00141271|9608423|FG000|Overall Study|Lack of Efficacy|7
6015191|NCT00141271|9608424|FG001|Overall Study|Lack of Efficacy|7
6015192|NCT00141271|9608425|FG002|Overall Study|Lack of Efficacy|3
6015193|NCT00141271|9608423|FG000|Overall Study|Lost to Follow-up|15
6015194|NCT00141271|9608424|FG001|Overall Study|Lost to Follow-up|15
6015195|NCT00141271|9608425|FG002|Overall Study|Lost to Follow-up|21
6015196|NCT00141271|9608423|FG000|Overall Study|Withdrawal by Subject|14
6015197|NCT00141271|9608424|FG001|Overall Study|Withdrawal by Subject|9
6015198|NCT00141271|9608425|FG002|Overall Study|Withdrawal by Subject|10
6015199|NCT00141271|9608423|FG000|Overall Study|Other|11
6015200|NCT00141271|9608424|FG001|Overall Study|Other|12
6015201|NCT00141271|9608425|FG002|Overall Study|Other|5
6015202|NCT00141297|9608435|FG000|Overall Study|Adverse Event|0
6015203|NCT00141297|9608436|FG001|Overall Study|Adverse Event|0
6015204|NCT00141297|9608437|FG002|Overall Study|Adverse Event|1
6015205|NCT00141297|9608438|FG003|Overall Study|Adverse Event|0
6015206|NCT00141297|9608439|FG004|Overall Study|Adverse Event|1
6015207|NCT00141297|9608440|FG005|Overall Study|Adverse Event|1
6015208|NCT00141297|9608441|FG006|Overall Study|Adverse Event|0
6015209|NCT00141297|9608442|FG007|Overall Study|Adverse Event|1
6015210|NCT00141297|9608443|FG008|Overall Study|Adverse Event|1
6015211|NCT00141297|9608444|FG009|Overall Study|Adverse Event|0
6015212|NCT00141297|9608435|FG000|Overall Study|Death|1
6015213|NCT00141297|9608436|FG001|Overall Study|Death|0
6015214|NCT00141297|9608437|FG002|Overall Study|Death|0
6015215|NCT00141297|9608438|FG003|Overall Study|Death|0
6015216|NCT00141297|9608439|FG004|Overall Study|Death|0
6015217|NCT00141297|9608440|FG005|Overall Study|Death|0
6015218|NCT00141297|9608441|FG006|Overall Study|Death|0
6015219|NCT00141297|9608442|FG007|Overall Study|Death|0
6015220|NCT00141297|9608443|FG008|Overall Study|Death|1
6015221|NCT00141297|9608444|FG009|Overall Study|Death|0
6015222|NCT00141297|9608435|FG000|Overall Study|Withdrawal by Subject|0
6015223|NCT00141297|9608436|FG001|Overall Study|Withdrawal by Subject|0
6015224|NCT00141297|9608437|FG002|Overall Study|Withdrawal by Subject|0
6015225|NCT00141297|9608438|FG003|Overall Study|Withdrawal by Subject|0
6015226|NCT00141297|9608439|FG004|Overall Study|Withdrawal by Subject|0
6015227|NCT00141297|9608440|FG005|Overall Study|Withdrawal by Subject|0
6015228|NCT00141297|9608441|FG006|Overall Study|Withdrawal by Subject|0
6015229|NCT00141297|9608442|FG007|Overall Study|Withdrawal by Subject|0
6015230|NCT00141297|9608443|FG008|Overall Study|Withdrawal by Subject|1
6015231|NCT00141297|9608444|FG009|Overall Study|Withdrawal by Subject|0
6015232|NCT00141297|9608435|FG000|Overall Study|Other|0
6015233|NCT00141297|9608436|FG001|Overall Study|Other|0
6015234|NCT00141297|9608437|FG002|Overall Study|Other|0
6015235|NCT00141297|9608438|FG003|Overall Study|Other|1
6015236|NCT00141297|9608439|FG004|Overall Study|Other|5
6015237|NCT00141297|9608440|FG005|Overall Study|Other|0
6015238|NCT00141297|9608441|FG006|Overall Study|Other|0
6015239|NCT00141297|9608442|FG007|Overall Study|Other|0
6015240|NCT00141297|9608443|FG008|Overall Study|Other|2
6015241|NCT00141297|9608444|FG009|Overall Study|Other|0
6015242|NCT00141297|9608435|FG000|Overall Study|Progressive Disease|2
6015243|NCT00141297|9608436|FG001|Overall Study|Progressive Disease|3
6015244|NCT00141297|9608437|FG002|Overall Study|Progressive Disease|6
6015245|NCT00141297|9608438|FG003|Overall Study|Progressive Disease|2
6015246|NCT00141297|9608439|FG004|Overall Study|Progressive Disease|15
6015247|NCT00141297|9608440|FG005|Overall Study|Progressive Disease|2
6015248|NCT00141297|9608441|FG006|Overall Study|Progressive Disease|3
6015249|NCT00141297|9608442|FG007|Overall Study|Progressive Disease|3
6015250|NCT00141297|9608443|FG008|Overall Study|Progressive Disease|15
6015251|NCT00141297|9608444|FG009|Overall Study|Progressive Disease|6
6015252|NCT00141297|9608435|FG000|Overall Study|Transitioned|0
6015253|NCT00141297|9608436|FG001|Overall Study|Transitioned|0
6015254|NCT00141297|9608437|FG002|Overall Study|Transitioned|0
6015255|NCT00141297|9608438|FG003|Overall Study|Transitioned|0
6015256|NCT00141297|9608439|FG004|Overall Study|Transitioned|1
6015257|NCT00141297|9608440|FG005|Overall Study|Transitioned|0
6015258|NCT00141297|9608441|FG006|Overall Study|Transitioned|0
6015259|NCT00141297|9608442|FG007|Overall Study|Transitioned|0
6015260|NCT00141297|9608443|FG008|Overall Study|Transitioned|0
6015261|NCT00141297|9608444|FG009|Overall Study|Transitioned|0
6015262|NCT00141453|9608479|FG000|Overall Study|Protocol Violation|6
6015263|NCT00141453|9608480|FG001|Overall Study|Protocol Violation|5
6015264|NCT00141518|9608489|FG000|Overall Study|Withdrew Consent Prior to Treatment|1
6015265|NCT00141518|9608490|FG001|Overall Study|Withdrew Consent Prior to Treatment|0
6015266|NCT00141518|9608491|FG002|Overall Study|Withdrew Consent Prior to Treatment|0
6015267|NCT00141518|9608489|FG000|Overall Study|Adverse Event|7
6015268|NCT00141518|9608490|FG001|Overall Study|Adverse Event|5
6015269|NCT00141518|9608491|FG002|Overall Study|Adverse Event|2
6015270|NCT00141518|9608489|FG000|Overall Study|Withdrawal by Subject|2
6015271|NCT00141518|9608490|FG001|Overall Study|Withdrawal by Subject|0
6015272|NCT00141518|9608491|FG002|Overall Study|Withdrawal by Subject|2
6015273|NCT00141518|9608489|FG000|Overall Study|Protocol Violation|1
6015274|NCT00141518|9608490|FG001|Overall Study|Protocol Violation|1
6015275|NCT00141518|9608491|FG002|Overall Study|Protocol Violation|2
6015276|NCT00141518|9608489|FG000|Overall Study|Lack of Efficacy|5
6015277|NCT00141518|9608490|FG001|Overall Study|Lack of Efficacy|0
6015278|NCT00141518|9608491|FG002|Overall Study|Lack of Efficacy|0
6015279|NCT00141726|9608501|FG000|Overall Study|Completed <50% Scheduled Dosing|3
6015280|NCT00141778|9608518|FG000|Randomization Prior to Study Med|Withdrawal by Subject|5
6015281|NCT00141778|9608519|FG001|Randomization Prior to Study Med|Withdrawal by Subject|2
6015282|NCT00141778|9608520|FG002|Randomization Prior to Study Med|Withdrawal by Subject|6
6015283|NCT00141778|9608518|FG000|Started Study Medication|Met safety criteria for discontinuation|2
6015284|NCT00141778|9608519|FG001|Started Study Medication|Met safety criteria for discontinuation|4
6015285|NCT00141778|9608520|FG002|Started Study Medication|Met safety criteria for discontinuation|3
6015286|NCT00141778|9608518|FG000|Started Study Medication|Withdrawal by Subject|0
6015287|NCT00141778|9608519|FG001|Started Study Medication|Withdrawal by Subject|2
6015288|NCT00141778|9608520|FG002|Started Study Medication|Withdrawal by Subject|0
6015289|NCT00141778|9608518|FG000|Started Study Medication|Difficulty Swallowing|0
6015290|NCT00141778|9608519|FG001|Started Study Medication|Difficulty Swallowing|1
6015291|NCT00141778|9608520|FG002|Started Study Medication|Difficulty Swallowing|0
6076616|NCT00591591|9682198|FG001|Overall Study|Withdrawal by Subject|37
6076617|NCT00591591|9682197|FG000|Overall Study|Lack of Efficacy|10
6076618|NCT00591591|9682198|FG001|Overall Study|Lack of Efficacy|2
6076619|NCT00591630|9682208|FG000|Overall Study|Death|0
6076620|NCT00591630|9682209|FG001|Overall Study|Death|0
6076621|NCT00591630|9682210|FG002|Overall Study|Death|1
6076622|NCT00591630|9682211|FG003|Overall Study|Death|0
6076623|NCT00591721|9682223|FG000|Overall Study|Withdrawal by Subject|10
6076624|NCT00591721|9682224|FG001|Overall Study|Withdrawal by Subject|10
6076625|NCT00591721|9682223|FG000|Overall Study|Lost to Follow-up|1
6076626|NCT00591721|9682224|FG001|Overall Study|Lost to Follow-up|4
6076627|NCT00591721|9682223|FG000|Overall Study|Intervention not received|10
6076628|NCT00591721|9682224|FG001|Overall Study|Intervention not received|8
6015292|NCT00141778|9608518|FG000|Started Study Medication|Chest Discomfort|0
6015293|NCT00141778|9608519|FG001|Started Study Medication|Chest Discomfort|0
6015294|NCT00141778|9608520|FG002|Started Study Medication|Chest Discomfort|1
6015295|NCT00141817|9608532|FG000|Overall Study|Protocol Violation|0
6015296|NCT00141817|9608533|FG001|Overall Study|Protocol Violation|0
6015297|NCT00141817|9608534|FG002|Overall Study|Protocol Violation|1
6015298|NCT00141817|9608535|FG003|Overall Study|Protocol Violation|0
6015299|NCT00141817|9608532|FG000|Overall Study|Parent request|1
6015300|NCT00141817|9608533|FG001|Overall Study|Parent request|0
6015301|NCT00141817|9608534|FG002|Overall Study|Parent request|0
6015302|NCT00141817|9608535|FG003|Overall Study|Parent request|0
6015303|NCT00141921|9608545|FG000|Overall Study|Remain on Study|28
6015304|NCT00141921|9608545|FG000|Overall Study|Withdrawal by Subject|42
6076629|NCT00591734|9682230|FG000|Overall Study|Lack of Efficacy|35
6076630|NCT00591734|9682230|FG000|Overall Study|Adverse Event|5
6015305|NCT00141921|9608545|FG000|Overall Study|Lost to Follow-up|19
6015306|NCT00141921|9608545|FG000|Overall Study|Noncompliance|17
6015307|NCT00141921|9608545|FG000|Overall Study|Disease Progression|7
6015308|NCT00141921|9608545|FG000|Overall Study|Protocol Deviation|7
6015309|NCT00141921|9608545|FG000|Overall Study|Adverse Event|5
6015310|NCT00141921|9608545|FG000|Overall Study|Administrative Decision|2
6015311|NCT00141921|9608545|FG000|Overall Study|Pregnancy|4
6015312|NCT00141921|9608545|FG000|Overall Study|Ineligibility Determined|2
6015313|NCT00141921|9608545|FG000|Overall Study|Other|8
6015314|NCT00142298|9608568|FG000|Overall Study|Adverse Event|10
6015315|NCT00142298|9608569|FG001|Overall Study|Adverse Event|10
6015316|NCT00142298|9608570|FG002|Overall Study|Adverse Event|1
6015317|NCT00142298|9608571|FG003|Overall Study|Adverse Event|5
6015318|NCT00142298|9608572|FG004|Overall Study|Adverse Event|2
6015319|NCT00142298|9608573|FG005|Overall Study|Adverse Event|2
6015320|NCT00142298|9608574|FG006|Overall Study|Adverse Event|0
6015321|NCT00142298|9608575|FG007|Overall Study|Adverse Event|0
6015322|NCT00142298|9608576|FG008|Overall Study|Adverse Event|0
6015323|NCT00142298|9608577|FG009|Overall Study|Adverse Event|0
6015324|NCT00142298|9608568|FG000|Overall Study|Clinical disease progression|1
6015325|NCT00142298|9608569|FG001|Overall Study|Clinical disease progression|0
6015326|NCT00142298|9608570|FG002|Overall Study|Clinical disease progression|0
6015327|NCT00142298|9608571|FG003|Overall Study|Clinical disease progression|0
6015328|NCT00142298|9608572|FG004|Overall Study|Clinical disease progression|0
6015329|NCT00142298|9608573|FG005|Overall Study|Clinical disease progression|0
6015330|NCT00142298|9608574|FG006|Overall Study|Clinical disease progression|0
6015331|NCT00142298|9608575|FG007|Overall Study|Clinical disease progression|0
6015332|NCT00142298|9608576|FG008|Overall Study|Clinical disease progression|0
6015333|NCT00142298|9608577|FG009|Overall Study|Clinical disease progression|0
6015334|NCT00142298|9608568|FG000|Overall Study|Death|1
6015335|NCT00142298|9608569|FG001|Overall Study|Death|1
6015336|NCT00142298|9608570|FG002|Overall Study|Death|1
6015337|NCT00142298|9608571|FG003|Overall Study|Death|0
6015338|NCT00142298|9608572|FG004|Overall Study|Death|0
6015339|NCT00142298|9608573|FG005|Overall Study|Death|6
6015340|NCT00142298|9608574|FG006|Overall Study|Death|0
6015341|NCT00142298|9608575|FG007|Overall Study|Death|0
6015342|NCT00142298|9608576|FG008|Overall Study|Death|0
6015343|NCT00142298|9608577|FG009|Overall Study|Death|0
6015344|NCT00142298|9608568|FG000|Overall Study|Lack of Efficacy|44
6015345|NCT00142298|9608569|FG001|Overall Study|Lack of Efficacy|62
6015346|NCT00142298|9608570|FG002|Overall Study|Lack of Efficacy|9
6015347|NCT00142298|9608571|FG003|Overall Study|Lack of Efficacy|12
6015348|NCT00142298|9608572|FG004|Overall Study|Lack of Efficacy|1
6015349|NCT00142298|9608573|FG005|Overall Study|Lack of Efficacy|0
6015350|NCT00142298|9608574|FG006|Overall Study|Lack of Efficacy|0
6015351|NCT00142298|9608575|FG007|Overall Study|Lack of Efficacy|1
6015352|NCT00142298|9608576|FG008|Overall Study|Lack of Efficacy|0
6015353|NCT00142298|9608577|FG009|Overall Study|Lack of Efficacy|0
6015354|NCT00142298|9608568|FG000|Overall Study|Non-compliance|15
6015355|NCT00142298|9608569|FG001|Overall Study|Non-compliance|13
6015356|NCT00142298|9608570|FG002|Overall Study|Non-compliance|0
6015357|NCT00142298|9608571|FG003|Overall Study|Non-compliance|6
6015358|NCT00142298|9608572|FG004|Overall Study|Non-compliance|1
6015359|NCT00142298|9608573|FG005|Overall Study|Non-compliance|0
6015360|NCT00142298|9608574|FG006|Overall Study|Non-compliance|0
6015361|NCT00142298|9608575|FG007|Overall Study|Non-compliance|3
6015362|NCT00142298|9608576|FG008|Overall Study|Non-compliance|3
6015363|NCT00142298|9608577|FG009|Overall Study|Non-compliance|0
6015364|NCT00142298|9608568|FG000|Overall Study|Patient, Investigator,or Sponsor request|66
6015365|NCT00142298|9608569|FG001|Overall Study|Patient, Investigator,or Sponsor request|60
6015366|NCT00142298|9608570|FG002|Overall Study|Patient, Investigator,or Sponsor request|11
6015367|NCT00142298|9608571|FG003|Overall Study|Patient, Investigator,or Sponsor request|51
6015368|NCT00142298|9608572|FG004|Overall Study|Patient, Investigator,or Sponsor request|4
6015369|NCT00142298|9608573|FG005|Overall Study|Patient, Investigator,or Sponsor request|3
6015370|NCT00142298|9608574|FG006|Overall Study|Patient, Investigator,or Sponsor request|1
6015371|NCT00142298|9608575|FG007|Overall Study|Patient, Investigator,or Sponsor request|4
6015372|NCT00142298|9608576|FG008|Overall Study|Patient, Investigator,or Sponsor request|1
6015373|NCT00142298|9608577|FG009|Overall Study|Patient, Investigator,or Sponsor request|0
6015374|NCT00142298|9608568|FG000|Overall Study|Pregnancy|4
6015375|NCT00142298|9608569|FG001|Overall Study|Pregnancy|4
6015376|NCT00142298|9608570|FG002|Overall Study|Pregnancy|2
6015377|NCT00142298|9608571|FG003|Overall Study|Pregnancy|3
6015378|NCT00142298|9608572|FG004|Overall Study|Pregnancy|0
6015379|NCT00142298|9608573|FG005|Overall Study|Pregnancy|0
6076631|NCT00591734|9682230|FG000|Overall Study|Physician Decision|5
6015380|NCT00142298|9608574|FG006|Overall Study|Pregnancy|0
6015381|NCT00142298|9608575|FG007|Overall Study|Pregnancy|0
6015382|NCT00142298|9608576|FG008|Overall Study|Pregnancy|1
6015383|NCT00142298|9608577|FG009|Overall Study|Pregnancy|0
6015384|NCT00142298|9608568|FG000|Overall Study|Virologic breakthrough|19
6015385|NCT00142298|9608569|FG001|Overall Study|Virologic breakthrough|23
6015386|NCT00142298|9608570|FG002|Overall Study|Virologic breakthrough|9
6015387|NCT00142298|9608571|FG003|Overall Study|Virologic breakthrough|7
6015388|NCT00142298|9608572|FG004|Overall Study|Virologic breakthrough|2
6076632|NCT00591734|9682230|FG000|Overall Study|Intercurrent Illness|8
6076633|NCT00591773|9682246|FG000|Overall Study|Adverse Event|9
6076634|NCT00591773|9682247|FG001|Overall Study|Adverse Event|9
6076635|NCT00591773|9682248|FG002|Overall Study|Adverse Event|6
6076636|NCT00591773|9682246|FG000|Overall Study|Protocol Violation|2
6076637|NCT00591773|9682247|FG001|Overall Study|Protocol Violation|3
6076638|NCT00591773|9682248|FG002|Overall Study|Protocol Violation|0
6015389|NCT00142298|9608573|FG005|Overall Study|Virologic breakthrough|3
6015390|NCT00142298|9608574|FG006|Overall Study|Virologic breakthrough|3
6015391|NCT00142298|9608575|FG007|Overall Study|Virologic breakthrough|0
6015392|NCT00142298|9608576|FG008|Overall Study|Virologic breakthrough|0
6015393|NCT00142298|9608577|FG009|Overall Study|Virologic breakthrough|0
6015394|NCT00142298|9608568|FG000|Overall Study|Other- not specified|0
6015395|NCT00142298|9608569|FG001|Overall Study|Other- not specified|3
6015396|NCT00142298|9608570|FG002|Overall Study|Other- not specified|0
6015397|NCT00142298|9608571|FG003|Overall Study|Other- not specified|1
6015398|NCT00142298|9608572|FG004|Overall Study|Other- not specified|0
6015399|NCT00142298|9608573|FG005|Overall Study|Other- not specified|0
6015400|NCT00142298|9608574|FG006|Overall Study|Other- not specified|0
6015401|NCT00142298|9608575|FG007|Overall Study|Other- not specified|0
6015402|NCT00142298|9608576|FG008|Overall Study|Other- not specified|0
6015403|NCT00142298|9608577|FG009|Overall Study|Other- not specified|0
6015404|NCT00142298|9608568|FG000|Overall Study|Lost to Follow-up|0
6015405|NCT00142298|9608569|FG001|Overall Study|Lost to Follow-up|0
6015406|NCT00142298|9608570|FG002|Overall Study|Lost to Follow-up|0
6015407|NCT00142298|9608571|FG003|Overall Study|Lost to Follow-up|0
6015408|NCT00142298|9608572|FG004|Overall Study|Lost to Follow-up|0
6015409|NCT00142298|9608573|FG005|Overall Study|Lost to Follow-up|0
6015410|NCT00142298|9608574|FG006|Overall Study|Lost to Follow-up|2
6015411|NCT00142298|9608575|FG007|Overall Study|Lost to Follow-up|0
6015412|NCT00142298|9608576|FG008|Overall Study|Lost to Follow-up|0
6015413|NCT00142298|9608577|FG009|Overall Study|Lost to Follow-up|0
6015414|NCT00142298|9608568|FG000|Overall Study|Treatment Failure|0
6015415|NCT00142298|9608569|FG001|Overall Study|Treatment Failure|0
6015416|NCT00142298|9608570|FG002|Overall Study|Treatment Failure|0
6015417|NCT00142298|9608571|FG003|Overall Study|Treatment Failure|0
6015418|NCT00142298|9608572|FG004|Overall Study|Treatment Failure|0
6015419|NCT00142298|9608573|FG005|Overall Study|Treatment Failure|2
6015420|NCT00142298|9608574|FG006|Overall Study|Treatment Failure|2
6015421|NCT00142298|9608575|FG007|Overall Study|Treatment Failure|0
6015422|NCT00142298|9608576|FG008|Overall Study|Treatment Failure|0
6015423|NCT00142298|9608577|FG009|Overall Study|Treatment Failure|0
6015424|NCT00142415|9608605|FG000|Overall Study|Physician Decision|0
6015425|NCT00142415|9608606|FG001|Overall Study|Physician Decision|0
6015426|NCT00142415|9608607|FG002|Overall Study|Physician Decision|0
6015427|NCT00142415|9608608|FG003|Overall Study|Physician Decision|0
6015428|NCT00142415|9608609|FG004|Overall Study|Physician Decision|1
6015429|NCT00142415|9608610|FG005|Overall Study|Physician Decision|2
6015430|NCT00142792|9608651|FG000|Overall Study|Death|0
6015431|NCT00142792|9608652|FG001|Overall Study|Death|0
6015432|NCT00142792|9608653|FG002|Overall Study|Death|1
6015433|NCT00142792|9608651|FG000|Overall Study|Withdrawal by Subject|3
6015434|NCT00142792|9608652|FG001|Overall Study|Withdrawal by Subject|2
6015435|NCT00142792|9608653|FG002|Overall Study|Withdrawal by Subject|3
6015436|NCT00142792|9608651|FG000|Overall Study|Lost to Follow-up|8
6015437|NCT00142792|9608652|FG001|Overall Study|Lost to Follow-up|11
6015438|NCT00142792|9608653|FG002|Overall Study|Lost to Follow-up|7
6015439|NCT00142792|9608651|FG000|Overall Study|No category|1
6015440|NCT00142792|9608652|FG001|Overall Study|No category|2
6015441|NCT00142792|9608653|FG002|Overall Study|No category|1
6015442|NCT00142909|9608684|FG000|Randomization|Various Reasons|7
6015443|NCT00142909|9608685|FG001|Randomization|Various Reasons|10
6015444|NCT00142909|9608684|FG000|Medications Begin|Protocol Violation|2
6015445|NCT00142909|9608685|FG001|Medications Begin|Protocol Violation|0
6015446|NCT00142909|9608684|FG000|Medications Begin|Withdrawal by Subject|5
6015447|NCT00142909|9608685|FG001|Medications Begin|Withdrawal by Subject|3
6015448|NCT00142909|9608684|FG000|Medications Begin|Withdrawal by Subject|2
6015449|NCT00142909|9608685|FG001|Medications Begin|Withdrawal by Subject|0
6015450|NCT00142935|9608694|FG000|Overall Study|Other reason|1
6015451|NCT00142935|9608695|FG001|Overall Study|Other reason|1
6015452|NCT00142935|9608696|FG002|Overall Study|Other reason|1
6015453|NCT00142935|9608694|FG000|Overall Study|Lost to Follow-up|2
6015454|NCT00142935|9608695|FG001|Overall Study|Lost to Follow-up|5
6015455|NCT00142935|9608696|FG002|Overall Study|Lost to Follow-up|5
6015456|NCT00142935|9608694|FG000|Overall Study|Death|0
6015457|NCT00142935|9608695|FG001|Overall Study|Death|2
6015458|NCT00142935|9608696|FG002|Overall Study|Death|1
6015459|NCT00143247|9608708|FG000|Overall Study|Death|8
6015460|NCT00143247|9608708|FG000|Overall Study|Adverse Event|19
6015461|NCT00143247|9608708|FG000|Overall Study|Lack of Efficacy|3
6015462|NCT00143247|9608708|FG000|Overall Study|Withdrawal by Subject|55
6015463|NCT00143247|9608708|FG000|Overall Study|Study terminated by sponsor|31
6015464|NCT00143247|9608708|FG000|Overall Study|Protocol Violation|15
6015465|NCT00143247|9608708|FG000|Overall Study|Lost to Follow-up|12
6015466|NCT00143247|9608708|FG000|Overall Study|following inaccurate lab adverse event|1
6076639|NCT00591773|9682246|FG000|Overall Study|Lost to Follow-up|1
6015467|NCT00143247|9608708|FG000|Overall Study|Other|12
6015468|NCT00143312|9608712|FG000|Overall Study|Death|11
6015469|NCT00143312|9608712|FG000|Overall Study|Adverse Event|2
6015470|NCT00143312|9608712|FG000|Overall Study|Lost to Follow-up|1
6015471|NCT00143312|9608712|FG000|Overall Study|Other|1
6015472|NCT00143312|9608712|FG000|Overall Study|Withdrawal by Subject|1
6015473|NCT00143390|9608718|FG000|Overall Study|Death|2
6015474|NCT00143390|9608719|FG001|Overall Study|Death|0
6015475|NCT00143390|9608718|FG000|Overall Study|Not meeting entry criteria|2
6015476|NCT00143390|9608719|FG001|Overall Study|Not meeting entry criteria|5
6015477|NCT00143390|9608718|FG000|Overall Study|Withdrawal by Subject|4
6015478|NCT00143390|9608719|FG001|Overall Study|Withdrawal by Subject|4
6015479|NCT00143390|9608718|FG000|Overall Study|Progressive disease|119
6015480|NCT00143390|9608719|FG001|Overall Study|Progressive disease|115
6015481|NCT00143390|9608718|FG000|Overall Study|Protocol Violation|2
6015482|NCT00143390|9608719|FG001|Overall Study|Protocol Violation|0
6015483|NCT00143390|9608718|FG000|Overall Study|Study termination|10
6015484|NCT00143390|9608719|FG001|Overall Study|Study termination|15
6015485|NCT00143390|9608718|FG000|Overall Study|Adverse Event|9
6015486|NCT00143390|9608719|FG001|Overall Study|Adverse Event|8
6015487|NCT00143390|9608718|FG000|Overall Study|Other|1
6015488|NCT00143390|9608719|FG001|Overall Study|Other|2
6015489|NCT00143403|9608727|FG000|Overall Study|Adverse Event|3
6015490|NCT00143403|9608728|FG001|Overall Study|Adverse Event|8
6015491|NCT00143403|9608727|FG000|Overall Study|Death|1
6015492|NCT00143403|9608728|FG001|Overall Study|Death|0
6015493|NCT00143403|9608727|FG000|Overall Study|Withdrawal by Subject|3
6015494|NCT00143403|9608728|FG001|Overall Study|Withdrawal by Subject|12
6015495|NCT00143403|9608727|FG000|Overall Study|Relapse|15
6015496|NCT00143403|9608728|FG001|Overall Study|Relapse|7
6015497|NCT00143403|9608727|FG000|Overall Study|Protocol Violation|2
6015498|NCT00143403|9608728|FG001|Overall Study|Protocol Violation|2
6015499|NCT00143403|9608727|FG000|Overall Study|specified by site|4
6015500|NCT00143403|9608728|FG001|Overall Study|specified by site|9
6015501|NCT00143403|9608727|FG000|Overall Study|Randomized Not Treated|7
6015502|NCT00143403|9608728|FG001|Overall Study|Randomized Not Treated|8
6015503|NCT00143455|9608738|FG000|Cohort 1|Adverse Event|8
6015504|NCT00143455|9608739|FG001|Cohort 1|Adverse Event|4
6015505|NCT00143455|9608740|FG002|Cohort 1|Adverse Event|0
6015506|NCT00143455|9608741|FG003|Cohort 1|Adverse Event|0
6015507|NCT00143455|9608738|FG000|Cohort 1|Death|5
6015508|NCT00143455|9608739|FG001|Cohort 1|Death|2
6015509|NCT00143455|9608740|FG002|Cohort 1|Death|0
6015510|NCT00143455|9608741|FG003|Cohort 1|Death|0
6015511|NCT00143455|9608738|FG000|Cohort 1|Progressive Disease|0
6015512|NCT00143455|9608739|FG001|Cohort 1|Progressive Disease|6
6015513|NCT00143455|9608740|FG002|Cohort 1|Progressive Disease|0
6015514|NCT00143455|9608741|FG003|Cohort 1|Progressive Disease|0
6015515|NCT00143455|9608738|FG000|Cohort 1|Withdrawal by Subject|1
6015516|NCT00143455|9608739|FG001|Cohort 1|Withdrawal by Subject|4
6015517|NCT00143455|9608740|FG002|Cohort 1|Withdrawal by Subject|0
6015518|NCT00143455|9608741|FG003|Cohort 1|Withdrawal by Subject|0
6015519|NCT00143455|9608738|FG000|Cohort 1|Randomized But Not Treated|0
6015520|NCT00143455|9608739|FG001|Cohort 1|Randomized But Not Treated|1
6015521|NCT00143455|9608740|FG002|Cohort 1|Randomized But Not Treated|0
6015522|NCT00143455|9608741|FG003|Cohort 1|Randomized But Not Treated|0
6015523|NCT00143455|9608738|FG000|Cohort 2|Adverse Event|0
6015524|NCT00143455|9608739|FG001|Cohort 2|Adverse Event|0
6015525|NCT00143455|9608740|FG002|Cohort 2|Adverse Event|42
6015526|NCT00143455|9608741|FG003|Cohort 2|Adverse Event|30
6015527|NCT00143455|9608738|FG000|Cohort 2|No Longer Required Study Treatment|0
6015528|NCT00143455|9608739|FG001|Cohort 2|No Longer Required Study Treatment|0
6015529|NCT00143455|9608740|FG002|Cohort 2|No Longer Required Study Treatment|1
6015530|NCT00143455|9608741|FG003|Cohort 2|No Longer Required Study Treatment|0
6015531|NCT00143455|9608738|FG000|Cohort 2|Protocol Violation|0
6015532|NCT00143455|9608739|FG001|Cohort 2|Protocol Violation|0
6015533|NCT00143455|9608740|FG002|Cohort 2|Protocol Violation|1
6015534|NCT00143455|9608741|FG003|Cohort 2|Protocol Violation|1
6015535|NCT00143455|9608738|FG000|Cohort 2|Lost to Follow-up|0
6015536|NCT00143455|9608739|FG001|Cohort 2|Lost to Follow-up|0
6015537|NCT00143455|9608740|FG002|Cohort 2|Lost to Follow-up|1
6015538|NCT00143455|9608741|FG003|Cohort 2|Lost to Follow-up|4
6015539|NCT00143455|9608738|FG000|Cohort 2|Death|0
6015540|NCT00143455|9608739|FG001|Cohort 2|Death|0
6015541|NCT00143455|9608740|FG002|Cohort 2|Death|20
6015542|NCT00143455|9608741|FG003|Cohort 2|Death|12
6015543|NCT00143455|9608738|FG000|Cohort 2|Progressive Disease|0
6015544|NCT00143455|9608739|FG001|Cohort 2|Progressive Disease|0
6015545|NCT00143455|9608740|FG002|Cohort 2|Progressive Disease|20
6015546|NCT00143455|9608741|FG003|Cohort 2|Progressive Disease|27
6015547|NCT00143455|9608738|FG000|Cohort 2|Withdrawal by Subject|0
6015548|NCT00143455|9608739|FG001|Cohort 2|Withdrawal by Subject|0
6015549|NCT00143455|9608740|FG002|Cohort 2|Withdrawal by Subject|13
6015550|NCT00143455|9608741|FG003|Cohort 2|Withdrawal by Subject|12
6015551|NCT00143455|9608738|FG000|Cohort 2|Other|0
6015552|NCT00143455|9608739|FG001|Cohort 2|Other|0
6015553|NCT00143455|9608740|FG002|Cohort 2|Other|7
6015554|NCT00143455|9608741|FG003|Cohort 2|Other|6
6015555|NCT00143455|9608738|FG000|Cohort 2|Randomized But Not Treated|0
6015556|NCT00143455|9608739|FG001|Cohort 2|Randomized But Not Treated|0
6015557|NCT00143455|9608740|FG002|Cohort 2|Randomized But Not Treated|1
6015558|NCT00143455|9608741|FG003|Cohort 2|Randomized But Not Treated|1
6015559|NCT00143507|9608755|FG000|Overall Study|Death|572
6015560|NCT00143507|9608756|FG001|Overall Study|Death|547
6015561|NCT00143507|9608755|FG000|Overall Study|Withdrawal by Subject|114
6015562|NCT00143507|9608756|FG001|Overall Study|Withdrawal by Subject|102
6015563|NCT00143507|9608755|FG000|Overall Study|Lost to Follow-up|1
6015564|NCT00143507|9608756|FG001|Overall Study|Lost to Follow-up|0
6015565|NCT00143507|9608755|FG000|Overall Study|Withdrawn by sponsor's decision|0
6015566|NCT00143507|9608756|FG001|Overall Study|Withdrawn by sponsor's decision|3
6015567|NCT00143598|9608764|FG000|Overall Study|Lost to Follow-up|23
6015568|NCT00143598|9608765|FG001|Overall Study|Lost to Follow-up|21
6015569|NCT00143598|9608764|FG000|Overall Study|Withdrawal by Subject|33
6015570|NCT00143598|9608765|FG001|Overall Study|Withdrawal by Subject|37
6015571|NCT00143598|9608764|FG000|Overall Study|Death|36
6015572|NCT00143598|9608765|FG001|Overall Study|Death|36
6047655|NCT00413036|9646741|FG000|Overall Study|Death|9
6047656|NCT00413036|9646741|FG000|Overall Study|Other|26
6047657|NCT00413036|9646741|FG000|Overall Study|Missing|2
6047658|NCT00413049|9646747|FG000|Overall Study|Adverse Event|10
6047659|NCT00413049|9646748|FG001|Overall Study|Adverse Event|8
6047660|NCT00413049|9646747|FG000|Overall Study|Withdrawal by Subject|7
6047661|NCT00413049|9646748|FG001|Overall Study|Withdrawal by Subject|5
6047662|NCT00413049|9646747|FG000|Overall Study|Lost to Follow-up|2
6047663|NCT00413049|9646748|FG001|Overall Study|Lost to Follow-up|3
6047664|NCT00413049|9646747|FG000|Overall Study|Protocol Violation|3
6047665|NCT00413049|9646748|FG001|Overall Study|Protocol Violation|1
6047666|NCT00413049|9646747|FG000|Overall Study|Subject no longer requires study drug|0
6047667|NCT00413049|9646748|FG001|Overall Study|Subject no longer requires study drug|1
6047668|NCT00413049|9646747|FG000|Overall Study|Abnormal laboratory value(s)|1
6047669|NCT00413049|9646748|FG001|Overall Study|Abnormal laboratory value(s)|0
6047670|NCT00413049|9646747|FG000|Overall Study|Lack of Efficacy|1
6047671|NCT00413049|9646748|FG001|Overall Study|Lack of Efficacy|0
6047672|NCT00413153|9646756|FG000|Overall Study|Withdrawal by Subject|1
6047673|NCT00413153|9646757|FG001|Overall Study|Withdrawal by Subject|1
6047674|NCT00413153|9646756|FG000|Overall Study|Adverse Event|1
6047675|NCT00413153|9646757|FG001|Overall Study|Adverse Event|0
6047676|NCT00413192|9646780|FG000|Overall Study|Disease progression|26
6047677|NCT00413192|9646781|FG001|Overall Study|Disease progression|31
6047678|NCT00413192|9646782|FG002|Overall Study|Disease progression|16
6047679|NCT00413192|9646783|FG003|Overall Study|Disease progression|25
6047680|NCT00413192|9646780|FG000|Overall Study|Toxicity|3
6047681|NCT00413192|9646781|FG001|Overall Study|Toxicity|2
6047682|NCT00413192|9646782|FG002|Overall Study|Toxicity|2
6047683|NCT00413192|9646783|FG003|Overall Study|Toxicity|2
6047684|NCT00413192|9646780|FG000|Overall Study|Withdrawal by Subject|3
6047685|NCT00413192|9646781|FG001|Overall Study|Withdrawal by Subject|5
6047686|NCT00413192|9646782|FG002|Overall Study|Withdrawal by Subject|0
6047687|NCT00413192|9646783|FG003|Overall Study|Withdrawal by Subject|1
6047688|NCT00413192|9646780|FG000|Overall Study|Intercurrent illness|0
6047689|NCT00413192|9646781|FG001|Overall Study|Intercurrent illness|0
6047690|NCT00413192|9646782|FG002|Overall Study|Intercurrent illness|0
6047691|NCT00413192|9646783|FG003|Overall Study|Intercurrent illness|1
6047692|NCT00413192|9646780|FG000|Overall Study|Intercurrent death|0
6047693|NCT00413192|9646781|FG001|Overall Study|Intercurrent death|1
6047694|NCT00413192|9646782|FG002|Overall Study|Intercurrent death|0
6047695|NCT00413192|9646783|FG003|Overall Study|Intercurrent death|0
6047696|NCT00413192|9646780|FG000|Overall Study|Other|5
6047697|NCT00413192|9646781|FG001|Overall Study|Other|1
6047698|NCT00413192|9646782|FG002|Overall Study|Other|1
6047699|NCT00413192|9646783|FG003|Overall Study|Other|2
6047700|NCT00413192|9646780|FG000|Overall Study|Not treated|0
6047701|NCT00413192|9646781|FG001|Overall Study|Not treated|0
6047702|NCT00413192|9646782|FG002|Overall Study|Not treated|0
6047703|NCT00413192|9646783|FG003|Overall Study|Not treated|1
6047704|NCT00413218|9646795|FG000|Overall Study|Randomized but didn't receive study drug|2
6047705|NCT00413218|9646796|FG001|Overall Study|Randomized but didn't receive study drug|8
6047706|NCT00413218|9646795|FG000|Overall Study|Death|57
6047707|NCT00413218|9646796|FG001|Overall Study|Death|56
6076640|NCT00591773|9682247|FG001|Overall Study|Lost to Follow-up|4
6047708|NCT00413218|9646795|FG000|Overall Study|Lost to Follow-up|14
6047709|NCT00413218|9646796|FG001|Overall Study|Lost to Follow-up|17
6047710|NCT00413218|9646795|FG000|Overall Study|Admin|20
6047711|NCT00413218|9646796|FG001|Overall Study|Admin|14
6047712|NCT00413218|9646795|FG000|Overall Study|Missing|1
6047713|NCT00413218|9646796|FG001|Overall Study|Missing|0
6047714|NCT00413218|9646795|FG000|Overall Study|Withdrawal by Subject|9
6047715|NCT00413218|9646796|FG001|Overall Study|Withdrawal by Subject|1
6047716|NCT00413231|9646803|FG000|0 to 30-day Post Treatment|Death|5
6047717|NCT00413231|9646803|FG000|0 to 30-day Post Treatment|Intend to treat, but not implanted|3
6047718|NCT00413231|9646803|FG000|30-day to 365-day Post Treatment|Death|13
6047719|NCT00413231|9646803|FG000|365-day to 60-month Post Treatment|Death|36
6047720|NCT00413231|9646803|FG000|365-day to 60-month Post Treatment|Withdrawal by Subject|5
6047721|NCT00413231|9646803|FG000|365-day to 60-month Post Treatment|Lost to Follow-up|4
6047722|NCT00413231|9646803|FG000|365-day to 60-month Post Treatment|Exited after surgical conversion|1
6076641|NCT00591773|9682248|FG002|Overall Study|Lost to Follow-up|1
6076642|NCT00591773|9682246|FG000|Overall Study|Withdrawal by Subject|2
6076643|NCT00591773|9682247|FG001|Overall Study|Withdrawal by Subject|5
6076644|NCT00591773|9682248|FG002|Overall Study|Withdrawal by Subject|3
6076645|NCT00591773|9682246|FG000|Overall Study|Lack of Efficacy|1
6076646|NCT00591773|9682247|FG001|Overall Study|Lack of Efficacy|2
6076647|NCT00591773|9682248|FG002|Overall Study|Lack of Efficacy|2
6076648|NCT00591773|9682246|FG000|Overall Study|Other|1
6076649|NCT00591773|9682247|FG001|Overall Study|Other|1
6076650|NCT00591773|9682248|FG002|Overall Study|Other|4
6076651|NCT00591786|9682266|FG000|Overall Study|Withdrawal of Informed Consent|0
6076652|NCT00591786|9682267|FG001|Overall Study|Withdrawal of Informed Consent|0
6076653|NCT00591786|9682268|FG002|Overall Study|Withdrawal of Informed Consent|1
6076654|NCT00591786|9682269|FG003|Overall Study|Withdrawal of Informed Consent|0
6076655|NCT00591786|9682270|FG004|Overall Study|Withdrawal of Informed Consent|0
6015573|NCT00144027|9608790|FG000|Overall Study|Lost to Follow-up|1
6015574|NCT00144027|9608791|FG001|Overall Study|Lost to Follow-up|3
6015575|NCT00144027|9608790|FG000|Overall Study|Withdrawal by Subject|2
6015576|NCT00144027|9608791|FG001|Overall Study|Withdrawal by Subject|2
6015577|NCT00144027|9608790|FG000|Overall Study|did not complete baseline assessment|0
6015578|NCT00144027|9608791|FG001|Overall Study|did not complete baseline assessment|6
6015579|NCT00144170|9608799|FG000|Overall Study|Adverse Event|84
6015580|NCT00144170|9608800|FG001|Overall Study|Adverse Event|41
6015581|NCT00144170|9608799|FG000|Overall Study|Protocol Violation|23
6015582|NCT00144170|9608800|FG001|Overall Study|Protocol Violation|16
6015583|NCT00144170|9608799|FG000|Overall Study|Lost to Follow-up|5
6015584|NCT00144170|9608800|FG001|Overall Study|Lost to Follow-up|10
6015585|NCT00144170|9608799|FG000|Overall Study|Withdrawal by Subject|29
6015586|NCT00144170|9608800|FG001|Overall Study|Withdrawal by Subject|13
6015587|NCT00144170|9608799|FG000|Overall Study|Other reason not defined above|211
6015588|NCT00144170|9608800|FG001|Overall Study|Other reason not defined above|316
6015589|NCT00144300|9608808|FG000|Overall Study|Adverse Event|18
6015590|NCT00144300|9608809|FG001|Overall Study|Adverse Event|16
6015591|NCT00144300|9608808|FG000|Overall Study|Protocol Violation|1
6015592|NCT00144300|9608809|FG001|Overall Study|Protocol Violation|3
6015593|NCT00144300|9608808|FG000|Overall Study|Lost to Follow-up|3
6015594|NCT00144300|9608809|FG001|Overall Study|Lost to Follow-up|0
6015595|NCT00144300|9608808|FG000|Overall Study|Withdrawal by Subject|6
6015596|NCT00144300|9608809|FG001|Overall Study|Withdrawal by Subject|6
6015597|NCT00144300|9608808|FG000|Overall Study|Other reason (not specified)|1
6015598|NCT00144300|9608809|FG001|Overall Study|Other reason (not specified)|3
6015599|NCT00144339|9608817|FG000|Overall Study|Adverse Event|746
6015600|NCT00144339|9608818|FG001|Overall Study|Adverse Event|627
6015601|NCT00144339|9608817|FG000|Overall Study|Protocol Violation|75
6015602|NCT00144339|9608818|FG001|Overall Study|Protocol Violation|48
6015603|NCT00144339|9608817|FG000|Overall Study|Withdrawal by Subject|403
6015604|NCT00144339|9608818|FG001|Overall Study|Withdrawal by Subject|300
6015605|NCT00144339|9608817|FG000|Overall Study|Lost to Follow-up|76
6015606|NCT00144339|9608818|FG001|Overall Study|Lost to Follow-up|64
6015607|NCT00144339|9608817|FG000|Overall Study|Other|58
6015608|NCT00144339|9608818|FG001|Overall Study|Other|60
6015609|NCT00144781|9608837|FG000|Overall Study|Adverse Event|0
6015610|NCT00144781|9608838|FG001|Overall Study|Adverse Event|1
6015611|NCT00144781|9608839|FG002|Overall Study|Adverse Event|0
6015612|NCT00144781|9608840|FG003|Overall Study|Adverse Event|0
6015613|NCT00144781|9608837|FG000|Overall Study|Non-compliant|0
6015614|NCT00144781|9608838|FG001|Overall Study|Non-compliant|1
6015615|NCT00144781|9608839|FG002|Overall Study|Non-compliant|0
6015616|NCT00144781|9608840|FG003|Overall Study|Non-compliant|0
6015617|NCT00145119|9608858|FG000|Overall Study|Death|45
6015618|NCT00145327|9608882|FG000|Overall Study|Withdrawal by Subject|77
6015619|NCT00145327|9608883|FG001|Overall Study|Withdrawal by Subject|72
6015620|NCT00145327|9608884|FG002|Overall Study|Withdrawal by Subject|164
6015621|NCT00145327|9608882|FG000|Overall Study|Death|26
6015622|NCT00145327|9608883|FG001|Overall Study|Death|18
6015623|NCT00145327|9608884|FG002|Overall Study|Death|30
6015624|NCT00145327|9608882|FG000|Overall Study|Adverse Event|14
6015625|NCT00145327|9608883|FG001|Overall Study|Adverse Event|11
6015626|NCT00145327|9608884|FG002|Overall Study|Adverse Event|22
6015627|NCT00145327|9608882|FG000|Overall Study|Lost to Follow-up|9
6015628|NCT00145327|9608883|FG001|Overall Study|Lost to Follow-up|14
6015629|NCT00145327|9608884|FG002|Overall Study|Lost to Follow-up|14
6015630|NCT00145327|9608882|FG000|Overall Study|Administrative problems|12
6076656|NCT00591786|9682271|FG005|Overall Study|Withdrawal of Informed Consent|0
6076657|NCT00591786|9682272|FG006|Overall Study|Withdrawal of Informed Consent|0
6015631|NCT00145327|9608883|FG001|Overall Study|Administrative problems|9
6015632|NCT00145327|9608884|FG002|Overall Study|Administrative problems|13
6015633|NCT00145327|9608882|FG000|Overall Study|Protocol Violation|2
6015634|NCT00145327|9608883|FG001|Overall Study|Protocol Violation|0
6015635|NCT00145327|9608884|FG002|Overall Study|Protocol Violation|2
6015636|NCT00145327|9608882|FG000|Overall Study|Abnormal laboratory value(s)|1
6015637|NCT00145327|9608883|FG001|Overall Study|Abnormal laboratory value(s)|0
6015638|NCT00145327|9608884|FG002|Overall Study|Abnormal laboratory value(s)|2
6076658|NCT00591786|9682273|FG007|Overall Study|Withdrawal of Informed Consent|0
6015639|NCT00145327|9608882|FG000|Overall Study|Missing - not stated|1
6015640|NCT00145327|9608883|FG001|Overall Study|Missing - not stated|0
6015641|NCT00145327|9608884|FG002|Overall Study|Missing - not stated|1
6015642|NCT00145574|9608899|FG000|Double Blind|Adverse Event|0
6015643|NCT00145574|9608900|FG001|Double Blind|Adverse Event|3
6015644|NCT00145574|9608901|FG002|Double Blind|Adverse Event|1
6015645|NCT00145574|9608899|FG000|Double Blind|Withdrawal by Subject|1
6015646|NCT00145574|9608900|FG001|Double Blind|Withdrawal by Subject|1
6015647|NCT00145574|9608901|FG002|Double Blind|Withdrawal by Subject|1
6015648|NCT00145574|9608899|FG000|Double Blind|required restricted medicine|0
6015649|NCT00145574|9608900|FG001|Double Blind|required restricted medicine|1
6015650|NCT00145574|9608901|FG002|Double Blind|required restricted medicine|0
6015651|NCT00145574|9608899|FG000|Open Label Long-term Extension|Adverse Event|0
6015652|NCT00145574|9608900|FG001|Open Label Long-term Extension|Adverse Event|0
6015653|NCT00145574|9608901|FG002|Open Label Long-term Extension|Adverse Event|5
6015654|NCT00145574|9608899|FG000|Open Label Long-term Extension|Lost to Follow-up|0
6015655|NCT00145574|9608900|FG001|Open Label Long-term Extension|Lost to Follow-up|0
6015656|NCT00145574|9608901|FG002|Open Label Long-term Extension|Lost to Follow-up|1
6015657|NCT00145574|9608899|FG000|Open Label Long-term Extension|Withdrawal by Subject|0
6015658|NCT00145574|9608900|FG001|Open Label Long-term Extension|Withdrawal by Subject|0
6015659|NCT00145574|9608901|FG002|Open Label Long-term Extension|Withdrawal by Subject|4
6015660|NCT00145574|9608899|FG000|Open Label Long-term Extension|required restricted medicine|0
6015661|NCT00145574|9608900|FG001|Open Label Long-term Extension|required restricted medicine|0
6076659|NCT00591786|9682274|FG008|Overall Study|Withdrawal of Informed Consent|0
6015662|NCT00145574|9608901|FG002|Open Label Long-term Extension|required restricted medicine|1
6015663|NCT00145626|9608925|FG000|Overall Study|Did not have NK infusions|2
6015664|NCT00145626|9608925|FG000|Overall Study|Turned 2 years old before treatment|1
6015665|NCT00145626|9608925|FG000|Overall Study|Death|1
6015666|NCT00145626|9608925|FG000|Overall Study|Withdrawal by Subject|1
6015667|NCT00145795|9608947|FG000|Overall Study|Adverse Event|1
6015668|NCT00145795|9608948|FG001|Overall Study|Adverse Event|0
6015669|NCT00145977|9608956|FG000|Overall Study|Lack of Efficacy|0
6015670|NCT00145977|9608957|FG001|Overall Study|Lack of Efficacy|4
6015671|NCT00145977|9608956|FG000|Overall Study|Lost to Follow-up|1
6015672|NCT00145977|9608957|FG001|Overall Study|Lost to Follow-up|0
6015673|NCT00145977|9608956|FG000|Overall Study|Withdrawal by Subject|1
6015674|NCT00145977|9608957|FG001|Overall Study|Withdrawal by Subject|0
6015675|NCT00146172|9608971|FG000|Overall Study|Adverse Event|0
6015676|NCT00146172|9608972|FG001|Overall Study|Adverse Event|0
6015677|NCT00146172|9608973|FG002|Overall Study|Adverse Event|1
6015678|NCT00146172|9608974|FG003|Overall Study|Adverse Event|1
6015679|NCT00146172|9608975|FG004|Overall Study|Adverse Event|0
6015680|NCT00146172|9608976|FG005|Overall Study|Adverse Event|2
6015681|NCT00146172|9608977|FG006|Overall Study|Adverse Event|3
6015682|NCT00146172|9608978|FG007|Overall Study|Adverse Event|10
6015683|NCT00146172|9608971|FG000|Overall Study|Lost to Follow-up|0
6015684|NCT00146172|9608972|FG001|Overall Study|Lost to Follow-up|0
6015685|NCT00146172|9608973|FG002|Overall Study|Lost to Follow-up|0
6015686|NCT00146172|9608974|FG003|Overall Study|Lost to Follow-up|0
6015687|NCT00146172|9608975|FG004|Overall Study|Lost to Follow-up|0
6015688|NCT00146172|9608976|FG005|Overall Study|Lost to Follow-up|0
6076660|NCT00591786|9682275|FG009|Overall Study|Withdrawal of Informed Consent|0
6076661|NCT00591838|9682329|FG000|Overall Study|Withdrawal by Subject|0
6076662|NCT00591838|9682330|FG001|Overall Study|Withdrawal by Subject|0
6076663|NCT00591838|9682331|FG002|Overall Study|Withdrawal by Subject|0
6076664|NCT00591838|9682332|FG003|Overall Study|Withdrawal by Subject|1
6076665|NCT00591838|9682333|FG004|Overall Study|Withdrawal by Subject|0
6076666|NCT00591851|9682346|FG000|Overall Study|Withdrawal by Subject|3
6076667|NCT00591851|9682346|FG000|Overall Study|Adverse Event|2
6076668|NCT00591851|9682346|FG000|Overall Study|Progressive Disease|1
6076669|NCT00591864|9682350|FG000|Overall Study|Incomplete Imaging|5
6015689|NCT00146172|9608977|FG006|Overall Study|Lost to Follow-up|0
6015690|NCT00146172|9608978|FG007|Overall Study|Lost to Follow-up|1
6015691|NCT00146172|9608971|FG000|Overall Study|Disease Progression|2
6015692|NCT00146172|9608972|FG001|Overall Study|Disease Progression|4
6015693|NCT00146172|9608973|FG002|Overall Study|Disease Progression|2
6015694|NCT00146172|9608974|FG003|Overall Study|Disease Progression|5
6015695|NCT00146172|9608975|FG004|Overall Study|Disease Progression|2
6015696|NCT00146172|9608976|FG005|Overall Study|Disease Progression|2
6015697|NCT00146172|9608977|FG006|Overall Study|Disease Progression|1
6015698|NCT00146172|9608978|FG007|Overall Study|Disease Progression|22
6015699|NCT00146172|9608971|FG000|Overall Study|Death|0
6076670|NCT00592072|9682362|FG000|Wash Out Period|Lost to Follow-up|1
6076671|NCT00592072|9682363|FG001|Wash Out Period|Lost to Follow-up|1
6076672|NCT00592319|9682396|FG000|Overall Study|Lost to Follow-up|0
6076673|NCT00592319|9682397|FG001|Overall Study|Lost to Follow-up|3
6015700|NCT00146172|9608972|FG001|Overall Study|Death|0
6015701|NCT00146172|9608973|FG002|Overall Study|Death|0
6015702|NCT00146172|9608974|FG003|Overall Study|Death|0
6015703|NCT00146172|9608975|FG004|Overall Study|Death|0
6015704|NCT00146172|9608976|FG005|Overall Study|Death|0
6015705|NCT00146172|9608977|FG006|Overall Study|Death|1
6015706|NCT00146172|9608978|FG007|Overall Study|Death|0
6076674|NCT00592358|9682405|FG000|Overall Study|Withdrawal by Subject|2
6015707|NCT00146172|9608971|FG000|Overall Study|Physician Decision|0
6015708|NCT00146172|9608972|FG001|Overall Study|Physician Decision|0
6015709|NCT00146172|9608973|FG002|Overall Study|Physician Decision|0
6015710|NCT00146172|9608974|FG003|Overall Study|Physician Decision|0
6015711|NCT00146172|9608975|FG004|Overall Study|Physician Decision|0
6015712|NCT00146172|9608976|FG005|Overall Study|Physician Decision|0
6015713|NCT00146172|9608977|FG006|Overall Study|Physician Decision|0
6015714|NCT00146172|9608978|FG007|Overall Study|Physician Decision|1
6015715|NCT00146172|9608971|FG000|Overall Study|Withdrawal by Subject|0
6015716|NCT00146172|9608972|FG001|Overall Study|Withdrawal by Subject|0
6015717|NCT00146172|9608973|FG002|Overall Study|Withdrawal by Subject|0
6015718|NCT00146172|9608974|FG003|Overall Study|Withdrawal by Subject|0
6015719|NCT00146172|9608975|FG004|Overall Study|Withdrawal by Subject|0
6015720|NCT00146172|9608976|FG005|Overall Study|Withdrawal by Subject|1
6015721|NCT00146172|9608977|FG006|Overall Study|Withdrawal by Subject|1
6015722|NCT00146172|9608978|FG007|Overall Study|Withdrawal by Subject|4
6015723|NCT00146172|9608971|FG000|Overall Study|Symptomatic Deterioration|1
6015724|NCT00146172|9608972|FG001|Overall Study|Symptomatic Deterioration|0
6015725|NCT00146172|9608973|FG002|Overall Study|Symptomatic Deterioration|1
6015726|NCT00146172|9608974|FG003|Overall Study|Symptomatic Deterioration|0
6015727|NCT00146172|9608975|FG004|Overall Study|Symptomatic Deterioration|1
6015728|NCT00146172|9608976|FG005|Overall Study|Symptomatic Deterioration|2
6015729|NCT00146172|9608977|FG006|Overall Study|Symptomatic Deterioration|0
6015730|NCT00146172|9608978|FG007|Overall Study|Symptomatic Deterioration|2
6015731|NCT00146328|9609007|FG000|Overall Study|Adverse Event|39
6015732|NCT00146328|9609008|FG001|Overall Study|Adverse Event|48
6015733|NCT00146328|9609009|FG002|Overall Study|Adverse Event|79
6015734|NCT00146328|9609007|FG000|Overall Study|Protocol Violation|11
6015735|NCT00146328|9609008|FG001|Overall Study|Protocol Violation|6
6015736|NCT00146328|9609009|FG002|Overall Study|Protocol Violation|12
6015737|NCT00146328|9609007|FG000|Overall Study|Lost to Follow-up|7
6015738|NCT00146328|9609008|FG001|Overall Study|Lost to Follow-up|4
6015739|NCT00146328|9609009|FG002|Overall Study|Lost to Follow-up|7
6015740|NCT00146328|9609007|FG000|Overall Study|Withdrawal by Subject|16
6015741|NCT00146328|9609008|FG001|Overall Study|Withdrawal by Subject|16
6015742|NCT00146328|9609009|FG002|Overall Study|Withdrawal by Subject|22
6015743|NCT00146328|9609007|FG000|Overall Study|Virologic Failure/lack of efficacy|54
6015744|NCT00146328|9609008|FG001|Overall Study|Virologic Failure/lack of efficacy|72
6015745|NCT00146328|9609009|FG002|Overall Study|Virologic Failure/lack of efficacy|142
6015746|NCT00146328|9609007|FG000|Overall Study|Trial ended/site closed|8
6015747|NCT00146328|9609008|FG001|Overall Study|Trial ended/site closed|2
6015748|NCT00146328|9609009|FG002|Overall Study|Trial ended/site closed|19
6015749|NCT00146328|9609007|FG000|Overall Study|Patient decision to end|0
6015750|NCT00146328|9609008|FG001|Overall Study|Patient decision to end|1
6015751|NCT00146328|9609009|FG002|Overall Study|Patient decision to end|6
6015752|NCT00146328|9609007|FG000|Overall Study|Enroll into other trial|2
6015753|NCT00146328|9609008|FG001|Overall Study|Enroll into other trial|4
6015754|NCT00146328|9609009|FG002|Overall Study|Enroll into other trial|2
6015755|NCT00146328|9609007|FG000|Overall Study|Death|0
6015756|NCT00146328|9609008|FG001|Overall Study|Death|1
6015757|NCT00146328|9609009|FG002|Overall Study|Death|1
6015758|NCT00146328|9609007|FG000|Overall Study|Moved|2
6015759|NCT00146328|9609008|FG001|Overall Study|Moved|0
6015760|NCT00146328|9609009|FG002|Overall Study|Moved|0
6015761|NCT00146328|9609007|FG000|Overall Study|Interaction with other medication|2
6015762|NCT00146328|9609008|FG001|Overall Study|Interaction with other medication|0
6015763|NCT00146328|9609009|FG002|Overall Study|Interaction with other medication|1
6015764|NCT00146640|9609019|FG000|Overall Study|Adverse Event|12
6015765|NCT00146640|9609020|FG001|Overall Study|Adverse Event|10
6015766|NCT00146640|9609019|FG000|Overall Study|Medical Reasons|3
6015767|NCT00146640|9609020|FG001|Overall Study|Medical Reasons|0
6015768|NCT00146640|9609019|FG000|Overall Study|Non-Medical Reasons|8
6015769|NCT00146640|9609020|FG001|Overall Study|Non-Medical Reasons|4
6015770|NCT00146757|9609026|FG000|Overall Study|Death|1
6015771|NCT00146757|9609027|FG001|Overall Study|Death|0
6015772|NCT00146757|9609026|FG000|Overall Study|Adverse Event|1
6015773|NCT00146757|9609027|FG001|Overall Study|Adverse Event|0
6015774|NCT00146770|9609035|FG000|Overall Study|Adverse Event|2
6015775|NCT00146770|9609036|FG001|Overall Study|Adverse Event|0
6015776|NCT00146770|9609035|FG000|Overall Study|Pregnancy|1
6015777|NCT00146770|9609036|FG001|Overall Study|Pregnancy|0
6015778|NCT00146770|9609035|FG000|Overall Study|Withdrawal by Subject|2
6015779|NCT00146770|9609036|FG001|Overall Study|Withdrawal by Subject|0
6015780|NCT00146848|9609045|FG000|Pre-randomization|Death|19
6015781|NCT00146848|9609046|FG001|Pre-randomization|Death|0
6015782|NCT00146848|9609047|FG002|Pre-randomization|Death|0
6015783|NCT00146848|9609045|FG000|Pre-randomization|Lost to Follow-up|70
6015784|NCT00146848|9609046|FG001|Pre-randomization|Lost to Follow-up|0
6015785|NCT00146848|9609047|FG002|Pre-randomization|Lost to Follow-up|0
6015786|NCT00146848|9609045|FG000|Pre-randomization|Physician Decision|8
6015787|NCT00146848|9609046|FG001|Pre-randomization|Physician Decision|0
6015788|NCT00146848|9609047|FG002|Pre-randomization|Physician Decision|0
6015789|NCT00146848|9609045|FG000|Pre-randomization|Protocol Violation|172
6015790|NCT00146848|9609046|FG001|Pre-randomization|Protocol Violation|0
6015791|NCT00146848|9609047|FG002|Pre-randomization|Protocol Violation|0
6015792|NCT00146848|9609045|FG000|Pre-randomization|Withdrawal by Subject|40
6015793|NCT00146848|9609046|FG001|Pre-randomization|Withdrawal by Subject|0
6015794|NCT00146848|9609047|FG002|Pre-randomization|Withdrawal by Subject|0
6076675|NCT00592358|9682405|FG000|Overall Study|Adverse Event|1
6076676|NCT00592358|9682405|FG000|Overall Study|Lack of Efficacy|2
6076677|NCT00592358|9682405|FG000|Overall Study|Inability to swallow pills|1
6076678|NCT00592384|9682411|FG000|Overall Study|Withdrawal by Subject|5
6076679|NCT00592384|9682412|FG001|Overall Study|Withdrawal by Subject|6
6076680|NCT00592501|9682442|FG000|Overall Study|Withdrawal by Subject|1
6076681|NCT00592501|9682442|FG000|Overall Study|Participant found to have metastatic disease after enrollment thus deemed ineligible|1
6076682|NCT00592553|9682449|FG000|Overall Study|Protocol Noncompliance|1
6076683|NCT00592553|9682450|FG001|Overall Study|Protocol Noncompliance|0
6076684|NCT00592553|9682451|FG002|Overall Study|Protocol Noncompliance|0
6076685|NCT00592631|9682461|FG000|Overall Study|Lost to Follow-up|0
6076686|NCT00592631|9682462|FG001|Overall Study|Lost to Follow-up|2
6076687|NCT00592683|9682470|FG000|Overall Study|Found ineligible|0
6076688|NCT00592683|9682471|FG001|Overall Study|Found ineligible|1
6015795|NCT00146848|9609045|FG000|Post-randomization|Lost to Follow-up|12
6015796|NCT00146848|9609046|FG001|Post-randomization|Lost to Follow-up|15
6015797|NCT00146848|9609047|FG002|Post-randomization|Lost to Follow-up|12
6015798|NCT00146848|9609045|FG000|Post-randomization|Withdrawn|26
6015799|NCT00146848|9609046|FG001|Post-randomization|Withdrawn|32
6015800|NCT00146848|9609047|FG002|Post-randomization|Withdrawn|27
6015801|NCT00147225|9609133|FG000|Overall Study|Withdrawal by Subject|1
6015802|NCT00147225|9609134|FG001|Overall Study|Withdrawal by Subject|0
6015803|NCT00147225|9609135|FG002|Overall Study|Withdrawal by Subject|1
6015804|NCT00147225|9609136|FG003|Overall Study|Withdrawal by Subject|0
6015805|NCT00147225|9609137|FG004|Overall Study|Withdrawal by Subject|0
6015806|NCT00147225|9609138|FG005|Overall Study|Withdrawal by Subject|1
6015807|NCT00147225|9609133|FG000|Overall Study|Adverse Event|0
6015808|NCT00147225|9609134|FG001|Overall Study|Adverse Event|0
6015809|NCT00147225|9609135|FG002|Overall Study|Adverse Event|1
6015810|NCT00147225|9609136|FG003|Overall Study|Adverse Event|1
6015811|NCT00147225|9609137|FG004|Overall Study|Adverse Event|0
6015812|NCT00147225|9609138|FG005|Overall Study|Adverse Event|0
6015813|NCT00147225|9609133|FG000|Overall Study|Screen Failure|0
6015814|NCT00147225|9609134|FG001|Overall Study|Screen Failure|0
6015815|NCT00147225|9609135|FG002|Overall Study|Screen Failure|0
6015816|NCT00147225|9609136|FG003|Overall Study|Screen Failure|0
6015817|NCT00147225|9609137|FG004|Overall Study|Screen Failure|1
6015818|NCT00147225|9609138|FG005|Overall Study|Screen Failure|0
6015819|NCT00147225|9609133|FG000|Overall Study|Chemotherapy Changed|0
6015820|NCT00147225|9609134|FG001|Overall Study|Chemotherapy Changed|0
6015821|NCT00147225|9609135|FG002|Overall Study|Chemotherapy Changed|0
6015822|NCT00147225|9609136|FG003|Overall Study|Chemotherapy Changed|0
6015823|NCT00147225|9609137|FG004|Overall Study|Chemotherapy Changed|0
6015824|NCT00147225|9609138|FG005|Overall Study|Chemotherapy Changed|1
6015825|NCT00147251|9609154|FG000|Recruitment and Enrollment|change in treatment guidelines|24
6015826|NCT00147251|9609155|FG001|Recruitment and Enrollment|change in treatment guidelines|25
6015827|NCT00147498|9609182|FG000|Overall Study|Adverse Event|1
6015828|NCT00147498|9609183|FG001|Overall Study|Adverse Event|6
6015829|NCT00147498|9609184|FG002|Overall Study|Adverse Event|7
6015830|NCT00147498|9609185|FG003|Overall Study|Adverse Event|3
6015831|NCT00147498|9609182|FG000|Overall Study|Lack of Efficacy|1
6015832|NCT00147498|9609183|FG001|Overall Study|Lack of Efficacy|1
6015833|NCT00147498|9609184|FG002|Overall Study|Lack of Efficacy|1
6015834|NCT00147498|9609185|FG003|Overall Study|Lack of Efficacy|8
6015835|NCT00147498|9609182|FG000|Overall Study|Laboratory abnormality|0
6015836|NCT00147498|9609183|FG001|Overall Study|Laboratory abnormality|0
6015837|NCT00147498|9609184|FG002|Overall Study|Laboratory abnormality|2
6015838|NCT00147498|9609185|FG003|Overall Study|Laboratory abnormality|0
6015839|NCT00147498|9609182|FG000|Overall Study|Participant defaulted|0
6015840|NCT00147498|9609183|FG001|Overall Study|Participant defaulted|1
6015841|NCT00147498|9609184|FG002|Overall Study|Participant defaulted|4
6015842|NCT00147498|9609185|FG003|Overall Study|Participant defaulted|3
6015843|NCT00147498|9609182|FG000|Overall Study|Other|1
6015844|NCT00147498|9609183|FG001|Overall Study|Other|1
6015845|NCT00147498|9609184|FG002|Overall Study|Other|3
6015846|NCT00147498|9609185|FG003|Overall Study|Other|3
6015847|NCT00147537|9609199|FG000|Phase 1b|Death|0
6015848|NCT00147537|9609200|FG001|Phase 1b|Death|1
6015849|NCT00147537|9609201|FG002|Phase 1b|Death|2
6076689|NCT00592683|9682470|FG000|Overall Study|Withdrawal by Subject|1
6076690|NCT00592683|9682471|FG001|Overall Study|Withdrawal by Subject|0
6076691|NCT00592683|9682470|FG000|Overall Study|Adverse Event|0
6015850|NCT00147537|9609202|FG003|Phase 1b|Death|1
6015851|NCT00147537|9609203|FG004|Phase 1b|Death|2
6015852|NCT00147537|9609204|FG005|Phase 1b|Death|2
6015853|NCT00147537|9609205|FG006|Phase 1b|Death|1
6015854|NCT00147537|9609206|FG007|Phase 1b|Death|3
6015855|NCT00147537|9609207|FG008|Phase 1b|Death|9
6015856|NCT00147537|9609208|FG009|Phase 1b|Death|0
6015857|NCT00147537|9609209|FG010|Phase 1b|Death|0
6015858|NCT00147537|9609199|FG000|Phase 1b|Lost to Follow-up|2
6015859|NCT00147537|9609200|FG001|Phase 1b|Lost to Follow-up|1
6015860|NCT00147537|9609201|FG002|Phase 1b|Lost to Follow-up|0
6015861|NCT00147537|9609202|FG003|Phase 1b|Lost to Follow-up|0
6015862|NCT00147537|9609203|FG004|Phase 1b|Lost to Follow-up|0
6015863|NCT00147537|9609204|FG005|Phase 1b|Lost to Follow-up|0
6015864|NCT00147537|9609205|FG006|Phase 1b|Lost to Follow-up|2
6015865|NCT00147537|9609206|FG007|Phase 1b|Lost to Follow-up|0
6015866|NCT00147537|9609207|FG008|Phase 1b|Lost to Follow-up|1
6015867|NCT00147537|9609208|FG009|Phase 1b|Lost to Follow-up|0
6015868|NCT00147537|9609209|FG010|Phase 1b|Lost to Follow-up|0
6015869|NCT00147537|9609199|FG000|Phase 1b|Other|0
6015870|NCT00147537|9609200|FG001|Phase 1b|Other|0
6015871|NCT00147537|9609201|FG002|Phase 1b|Other|2
6015872|NCT00147537|9609202|FG003|Phase 1b|Other|1
6015873|NCT00147537|9609203|FG004|Phase 1b|Other|1
6015874|NCT00147537|9609204|FG005|Phase 1b|Other|1
6015875|NCT00147537|9609205|FG006|Phase 1b|Other|14
6015876|NCT00147537|9609206|FG007|Phase 1b|Other|4
6015877|NCT00147537|9609207|FG008|Phase 1b|Other|4
6015878|NCT00147537|9609208|FG009|Phase 1b|Other|0
6015879|NCT00147537|9609209|FG010|Phase 1b|Other|0
6015880|NCT00147537|9609199|FG000|Phase 1b|Withdrawal by Subject|0
6015881|NCT00147537|9609200|FG001|Phase 1b|Withdrawal by Subject|0
6015882|NCT00147537|9609201|FG002|Phase 1b|Withdrawal by Subject|0
6015883|NCT00147537|9609202|FG003|Phase 1b|Withdrawal by Subject|0
6015884|NCT00147537|9609203|FG004|Phase 1b|Withdrawal by Subject|0
6015885|NCT00147537|9609204|FG005|Phase 1b|Withdrawal by Subject|0
6015886|NCT00147537|9609205|FG006|Phase 1b|Withdrawal by Subject|0
6015887|NCT00147537|9609206|FG007|Phase 1b|Withdrawal by Subject|0
6015888|NCT00147537|9609207|FG008|Phase 1b|Withdrawal by Subject|2
6015889|NCT00147537|9609208|FG009|Phase 1b|Withdrawal by Subject|0
6015890|NCT00147537|9609209|FG010|Phase 1b|Withdrawal by Subject|0
6015891|NCT00147537|9609199|FG000|Phase 1b|Randomized but not treated|0
6015892|NCT00147537|9609200|FG001|Phase 1b|Randomized but not treated|0
6015893|NCT00147537|9609201|FG002|Phase 1b|Randomized but not treated|0
6015894|NCT00147537|9609202|FG003|Phase 1b|Randomized but not treated|0
6015895|NCT00147537|9609203|FG004|Phase 1b|Randomized but not treated|0
6015896|NCT00147537|9609204|FG005|Phase 1b|Randomized but not treated|0
6015897|NCT00147537|9609205|FG006|Phase 1b|Randomized but not treated|1
6015898|NCT00147537|9609206|FG007|Phase 1b|Randomized but not treated|0
6015899|NCT00147537|9609207|FG008|Phase 1b|Randomized but not treated|1
6015900|NCT00147537|9609208|FG009|Phase 1b|Randomized but not treated|0
6015901|NCT00147537|9609209|FG010|Phase 1b|Randomized but not treated|0
6015902|NCT00147537|9609199|FG000|Phase 2|Death|0
6015903|NCT00147537|9609200|FG001|Phase 2|Death|0
6015904|NCT00147537|9609201|FG002|Phase 2|Death|0
6015905|NCT00147537|9609202|FG003|Phase 2|Death|0
6015906|NCT00147537|9609203|FG004|Phase 2|Death|0
6015907|NCT00147537|9609204|FG005|Phase 2|Death|0
6015908|NCT00147537|9609205|FG006|Phase 2|Death|0
6015909|NCT00147537|9609206|FG007|Phase 2|Death|0
6015910|NCT00147537|9609207|FG008|Phase 2|Death|0
6015911|NCT00147537|9609208|FG009|Phase 2|Death|85
6015912|NCT00147537|9609209|FG010|Phase 2|Death|31
6015913|NCT00147537|9609199|FG000|Phase 2|Lost to Follow-up|0
6015914|NCT00147537|9609200|FG001|Phase 2|Lost to Follow-up|0
6015915|NCT00147537|9609201|FG002|Phase 2|Lost to Follow-up|0
6015916|NCT00147537|9609202|FG003|Phase 2|Lost to Follow-up|0
6015917|NCT00147537|9609203|FG004|Phase 2|Lost to Follow-up|0
6015918|NCT00147537|9609204|FG005|Phase 2|Lost to Follow-up|0
6015919|NCT00147537|9609205|FG006|Phase 2|Lost to Follow-up|0
6015920|NCT00147537|9609206|FG007|Phase 2|Lost to Follow-up|0
6015921|NCT00147537|9609207|FG008|Phase 2|Lost to Follow-up|0
6015922|NCT00147537|9609208|FG009|Phase 2|Lost to Follow-up|12
6015923|NCT00147537|9609209|FG010|Phase 2|Lost to Follow-up|4
6015924|NCT00147537|9609199|FG000|Phase 2|Other|0
6015925|NCT00147537|9609200|FG001|Phase 2|Other|0
6015926|NCT00147537|9609201|FG002|Phase 2|Other|0
6015927|NCT00147537|9609202|FG003|Phase 2|Other|0
6015928|NCT00147537|9609203|FG004|Phase 2|Other|0
6015929|NCT00147537|9609204|FG005|Phase 2|Other|0
6015930|NCT00147537|9609205|FG006|Phase 2|Other|0
6015931|NCT00147537|9609206|FG007|Phase 2|Other|0
6015932|NCT00147537|9609207|FG008|Phase 2|Other|0
6015933|NCT00147537|9609208|FG009|Phase 2|Other|47
6015934|NCT00147537|9609209|FG010|Phase 2|Other|12
6015935|NCT00147537|9609199|FG000|Phase 2|Withdrawal by Subject|0
6015936|NCT00147537|9609200|FG001|Phase 2|Withdrawal by Subject|0
6015937|NCT00147537|9609201|FG002|Phase 2|Withdrawal by Subject|0
6015938|NCT00147537|9609202|FG003|Phase 2|Withdrawal by Subject|0
6015939|NCT00147537|9609203|FG004|Phase 2|Withdrawal by Subject|0
6015940|NCT00147537|9609204|FG005|Phase 2|Withdrawal by Subject|0
6015941|NCT00147537|9609205|FG006|Phase 2|Withdrawal by Subject|0
6015942|NCT00147537|9609206|FG007|Phase 2|Withdrawal by Subject|0
6015943|NCT00147537|9609207|FG008|Phase 2|Withdrawal by Subject|0
6015944|NCT00147537|9609208|FG009|Phase 2|Withdrawal by Subject|16
6015945|NCT00147537|9609209|FG010|Phase 2|Withdrawal by Subject|4
6015946|NCT00147537|9609199|FG000|Phase 2|Randomized but not treated|0
6015947|NCT00147537|9609200|FG001|Phase 2|Randomized but not treated|0
6015948|NCT00147537|9609201|FG002|Phase 2|Randomized but not treated|0
6015949|NCT00147537|9609202|FG003|Phase 2|Randomized but not treated|0
6015950|NCT00147537|9609203|FG004|Phase 2|Randomized but not treated|0
6015951|NCT00147537|9609204|FG005|Phase 2|Randomized but not treated|0
6015952|NCT00147537|9609205|FG006|Phase 2|Randomized but not treated|0
6015953|NCT00147537|9609206|FG007|Phase 2|Randomized but not treated|0
6015954|NCT00147537|9609207|FG008|Phase 2|Randomized but not treated|0
6015955|NCT00147537|9609208|FG009|Phase 2|Randomized but not treated|1
6015956|NCT00147537|9609209|FG010|Phase 2|Randomized but not treated|1
6015957|NCT00147745|9609257|FG000|Overall Study|Withdrawal by Subject|1
6015958|NCT00147745|9609258|FG001|Overall Study|Withdrawal by Subject|0
6015959|NCT00147745|9609259|FG002|Overall Study|Withdrawal by Subject|0
6015960|NCT00147823|9609269|FG000|Overall Study|Lost to Follow-up|6
6015961|NCT00147823|9609270|FG001|Overall Study|Lost to Follow-up|12
6015962|NCT00147823|9609269|FG000|Overall Study|Physician Decision|1
6015963|NCT00147823|9609270|FG001|Overall Study|Physician Decision|0
6015964|NCT00147823|9609269|FG000|Overall Study|Withdrawal by Subject|0
6015965|NCT00147823|9609270|FG001|Overall Study|Withdrawal by Subject|1
6015966|NCT00147823|9609269|FG000|Overall Study|Did not receive vitoss due to infection|6
6015967|NCT00147823|9609270|FG001|Overall Study|Did not receive vitoss due to infection|2
6015968|NCT00148109|9609282|FG000|Overall Study|Lack of Efficacy|10
6015969|NCT00148109|9609283|FG001|Overall Study|Lack of Efficacy|18
6015970|NCT00148109|9609282|FG000|Overall Study|Adverse Event|0
6015971|NCT00148109|9609283|FG001|Overall Study|Adverse Event|2
6015972|NCT00148109|9609282|FG000|Overall Study|Withdrawal by Subject|2
6015973|NCT00148109|9609283|FG001|Overall Study|Withdrawal by Subject|0
6015974|NCT00148122|9609289|FG000|Overall Study|Withdrawal by Subject|2
6015975|NCT00148317|9609293|FG000|Mobilization (VEL+CYTOXAN+FILGRASTIM)|Adverse Event|8
6015976|NCT00148317|9609293|FG000|Mobilization (VEL+CYTOXAN+FILGRASTIM)|Lack of Efficacy|2
6015977|NCT00148317|9609293|FG000|Mobilization (VEL+CYTOXAN+FILGRASTIM)|unable to tolerate|1
6015978|NCT00148343|9609302|FG000|Overall Study|Withdrawal by Subject|12
6015979|NCT00148343|9609303|FG001|Overall Study|Withdrawal by Subject|7
6015980|NCT00148343|9609302|FG000|Overall Study|Physician Decision|3
6015981|NCT00148343|9609303|FG001|Overall Study|Physician Decision|4
6015982|NCT00148759|9609320|FG000|Overall Study|Withdrawal by Subject|1
6015983|NCT00148759|9609321|FG001|Overall Study|Withdrawal by Subject|1
6015984|NCT00148759|9609320|FG000|Overall Study|Lost to Follow-up|1
6015985|NCT00148759|9609321|FG001|Overall Study|Lost to Follow-up|0
6015986|NCT00148941|9609342|FG000|Overall Study|Lost to Follow-up|17
6015987|NCT00148941|9609343|FG001|Overall Study|Lost to Follow-up|24
6015988|NCT00148941|9609344|FG002|Overall Study|Lost to Follow-up|18
6015989|NCT00148941|9609345|FG003|Overall Study|Lost to Follow-up|22
6015990|NCT00148941|9609342|FG000|Overall Study|Withdrawal by Subject|1
6015991|NCT00148941|9609343|FG001|Overall Study|Withdrawal by Subject|0
6015992|NCT00148941|9609344|FG002|Overall Study|Withdrawal by Subject|1
6015993|NCT00148941|9609345|FG003|Overall Study|Withdrawal by Subject|0
6015994|NCT00148941|9609342|FG000|Overall Study|Other|0
6015995|NCT00148941|9609343|FG001|Overall Study|Other|0
6015996|NCT00148941|9609344|FG002|Overall Study|Other|1
6015997|NCT00148941|9609345|FG003|Overall Study|Other|2
6015998|NCT00149214|9609366|FG000|Overall Study|Adverse Event|12
6015999|NCT00149214|9609367|FG001|Overall Study|Adverse Event|9
6016000|NCT00149214|9609366|FG000|Overall Study|Withdrawal by Subject|4
6016001|NCT00149214|9609367|FG001|Overall Study|Withdrawal by Subject|1
6016002|NCT00149214|9609366|FG000|Overall Study|Physician Decision|3
6016003|NCT00149214|9609367|FG001|Overall Study|Physician Decision|3
6016004|NCT00149214|9609366|FG000|Overall Study|Sponsor Decision|0
6016005|NCT00149214|9609367|FG001|Overall Study|Sponsor Decision|1
6016006|NCT00149214|9609366|FG000|Overall Study|Progressive Disease|7
6016007|NCT00149214|9609367|FG001|Overall Study|Progressive Disease|3
6016008|NCT00149396|9609382|FG000|Overall Study|Death|15
6016009|NCT00149396|9609382|FG000|Overall Study|Withdrawal by Subject|1
6016010|NCT00149396|9609382|FG000|Overall Study|Subject noncompliance|2
6016011|NCT00149396|9609382|FG000|Overall Study|other treatment|5
6016012|NCT00149630|9609395|FG000|Overall Study|Incarceration|2
6016013|NCT00149630|9609396|FG001|Overall Study|Incarceration|0
6016014|NCT00149630|9609395|FG000|Overall Study|Treatment Programs|4
6016015|NCT00149630|9609396|FG001|Overall Study|Treatment Programs|5
6016016|NCT00149630|9609395|FG000|Overall Study|Adverse Event|2
6016017|NCT00149630|9609396|FG001|Overall Study|Adverse Event|0
6016018|NCT00149747|9609435|FG000|Overall Study|Death|1
6016019|NCT00149747|9609436|FG001|Overall Study|Death|0
6016020|NCT00149747|9609435|FG000|Overall Study|Withdrawal by Subject|3
6016021|NCT00149747|9609436|FG001|Overall Study|Withdrawal by Subject|3
6016022|NCT00149825|9609456|FG000|Overall Study|Intolerance to medication side effects|1
6016023|NCT00149825|9609457|FG001|Overall Study|Intolerance to medication side effects|2
6016024|NCT00149825|9609456|FG000|Overall Study|Time commitments|2
6016025|NCT00149825|9609457|FG001|Overall Study|Time commitments|1
6016026|NCT00149825|9609456|FG000|Overall Study|Not liking insomnia therapy|1
6016027|NCT00149825|9609457|FG001|Overall Study|Not liking insomnia therapy|0
6016028|NCT00149825|9609456|FG000|Overall Study|Other|1
6016029|NCT00149825|9609457|FG001|Overall Study|Other|0
6016030|NCT00149890|9609480|FG000|Overall Study|Adverse Event|1
6016031|NCT00149890|9609481|FG001|Overall Study|Adverse Event|8
6016032|NCT00149890|9609480|FG000|Overall Study|Lack of Efficacy|8
6016033|NCT00149890|9609481|FG001|Overall Study|Lack of Efficacy|9
6016034|NCT00149890|9609480|FG000|Overall Study|Protocol Violation|1
6016035|NCT00149890|9609481|FG001|Overall Study|Protocol Violation|0
6016036|NCT00149890|9609480|FG000|Overall Study|Lost to Follow-up|1
6016037|NCT00149890|9609481|FG001|Overall Study|Lost to Follow-up|0
6016038|NCT00149890|9609480|FG000|Overall Study|Graft Loss|2
6016039|NCT00149890|9609481|FG001|Overall Study|Graft Loss|1
6016040|NCT00149994|9609489|FG000|Overall Study|Administrative problems:|1
6016041|NCT00149994|9609490|FG001|Overall Study|Administrative problems:|0
6016042|NCT00149994|9609489|FG000|Overall Study|Protocol Violation|0
6016043|NCT00149994|9609490|FG001|Overall Study|Protocol Violation|1
6016044|NCT00150345|9609498|FG000|Overall Study|Death|5
6016045|NCT00150345|9609499|FG001|Overall Study|Death|2
6016046|NCT00150345|9609498|FG000|Overall Study|Adverse Event|8
6016047|NCT00150345|9609499|FG001|Overall Study|Adverse Event|6
6016048|NCT00150345|9609498|FG000|Overall Study|Lack of Efficacy|5
6016049|NCT00150345|9609499|FG001|Overall Study|Lack of Efficacy|4
6016050|NCT00150345|9609498|FG000|Overall Study|Withdrawal by Subject|3
6016051|NCT00150345|9609499|FG001|Overall Study|Withdrawal by Subject|4
6016052|NCT00150345|9609498|FG000|Overall Study|Laboratory abnormality|1
6016053|NCT00150345|9609499|FG001|Overall Study|Laboratory abnormality|2
6016054|NCT00150345|9609498|FG000|Overall Study|Other|12
6016055|NCT00150345|9609499|FG001|Overall Study|Other|14
6016056|NCT00150462|9609517|FG000|Overall Study|Disease Progression or Relapse|3
6016057|NCT00150462|9609518|FG001|Overall Study|Disease Progression or Relapse|1
6016058|NCT00150462|9609519|FG002|Overall Study|Disease Progression or Relapse|2
6016059|NCT00150462|9609520|FG003|Overall Study|Disease Progression or Relapse|1
6016060|NCT00150462|9609521|FG004|Overall Study|Disease Progression or Relapse|2
6016061|NCT00150462|9609522|FG005|Overall Study|Disease Progression or Relapse|2
6016062|NCT00150462|9609523|FG006|Overall Study|Disease Progression or Relapse|3
6016063|NCT00150462|9609524|FG007|Overall Study|Disease Progression or Relapse|5
6016064|NCT00150462|9609525|FG008|Overall Study|Disease Progression or Relapse|5
6016065|NCT00150462|9609526|FG009|Overall Study|Disease Progression or Relapse|3
6016066|NCT00150462|9609527|FG010|Overall Study|Disease Progression or Relapse|2
6016067|NCT00150462|9609517|FG000|Overall Study|Withdrawal by Subject|0
6016068|NCT00150462|9609518|FG001|Overall Study|Withdrawal by Subject|1
6016069|NCT00150462|9609519|FG002|Overall Study|Withdrawal by Subject|1
6016070|NCT00150462|9609520|FG003|Overall Study|Withdrawal by Subject|0
6016071|NCT00150462|9609521|FG004|Overall Study|Withdrawal by Subject|1
6016072|NCT00150462|9609522|FG005|Overall Study|Withdrawal by Subject|2
6016073|NCT00150462|9609523|FG006|Overall Study|Withdrawal by Subject|0
6016074|NCT00150462|9609524|FG007|Overall Study|Withdrawal by Subject|1
6016075|NCT00150462|9609525|FG008|Overall Study|Withdrawal by Subject|0
6016076|NCT00150462|9609526|FG009|Overall Study|Withdrawal by Subject|1
6016077|NCT00150462|9609527|FG010|Overall Study|Withdrawal by Subject|0
6016078|NCT00150462|9609517|FG000|Overall Study|Death|0
6016079|NCT00150462|9609518|FG001|Overall Study|Death|1
6016080|NCT00150462|9609519|FG002|Overall Study|Death|0
6016081|NCT00150462|9609520|FG003|Overall Study|Death|0
6016082|NCT00150462|9609521|FG004|Overall Study|Death|0
6016083|NCT00150462|9609522|FG005|Overall Study|Death|0
6016084|NCT00150462|9609523|FG006|Overall Study|Death|0
6016085|NCT00150462|9609524|FG007|Overall Study|Death|0
6016086|NCT00150462|9609525|FG008|Overall Study|Death|1
6016087|NCT00150462|9609526|FG009|Overall Study|Death|0
6016088|NCT00150462|9609527|FG010|Overall Study|Death|0
6016089|NCT00150462|9609517|FG000|Overall Study|Adverse Event|0
6016090|NCT00150462|9609518|FG001|Overall Study|Adverse Event|0
6016091|NCT00150462|9609519|FG002|Overall Study|Adverse Event|0
6016092|NCT00150462|9609520|FG003|Overall Study|Adverse Event|1
6016093|NCT00150462|9609521|FG004|Overall Study|Adverse Event|0
6016094|NCT00150462|9609522|FG005|Overall Study|Adverse Event|0
6016095|NCT00150462|9609523|FG006|Overall Study|Adverse Event|0
6076692|NCT00592683|9682471|FG001|Overall Study|Adverse Event|2
6076693|NCT00592683|9682470|FG000|Overall Study|Protocol Violation|1
6076694|NCT00592683|9682471|FG001|Overall Study|Protocol Violation|0
6076695|NCT00592683|9682470|FG000|Overall Study|Study drug expired|1
6076696|NCT00592683|9682471|FG001|Overall Study|Study drug expired|0
6076697|NCT00592683|9682470|FG000|Overall Study|Other|1
6076698|NCT00592683|9682471|FG001|Overall Study|Other|0
6076699|NCT00592683|9682470|FG000|Overall Study|Lost to Follow-up|0
6076700|NCT00592683|9682471|FG001|Overall Study|Lost to Follow-up|1
6076701|NCT00592774|9682489|FG000|Overall Study|Adverse Event|5
6076702|NCT00592774|9682490|FG001|Overall Study|Adverse Event|19
6076703|NCT00592774|9682491|FG002|Overall Study|Adverse Event|2
6076704|NCT00592774|9682492|FG003|Overall Study|Adverse Event|14
6076705|NCT00592774|9682493|FG004|Overall Study|Adverse Event|8
6076706|NCT00592774|9682489|FG000|Overall Study|Protocol Violation|0
6016096|NCT00150462|9609524|FG007|Overall Study|Adverse Event|2
6016097|NCT00150462|9609525|FG008|Overall Study|Adverse Event|0
6016098|NCT00150462|9609526|FG009|Overall Study|Adverse Event|1
6016099|NCT00150462|9609527|FG010|Overall Study|Adverse Event|0
6016100|NCT00150462|9609517|FG000|Overall Study|Physician Decision|0
6016101|NCT00150462|9609518|FG001|Overall Study|Physician Decision|0
6016102|NCT00150462|9609519|FG002|Overall Study|Physician Decision|1
6016103|NCT00150462|9609520|FG003|Overall Study|Physician Decision|1
6016104|NCT00150462|9609521|FG004|Overall Study|Physician Decision|0
6016105|NCT00150462|9609522|FG005|Overall Study|Physician Decision|0
6076707|NCT00592774|9682490|FG001|Overall Study|Protocol Violation|1
6076708|NCT00592774|9682491|FG002|Overall Study|Protocol Violation|0
6076709|NCT00592774|9682492|FG003|Overall Study|Protocol Violation|0
6016106|NCT00150462|9609523|FG006|Overall Study|Physician Decision|0
6016107|NCT00150462|9609524|FG007|Overall Study|Physician Decision|0
6016108|NCT00150462|9609525|FG008|Overall Study|Physician Decision|0
6016109|NCT00150462|9609526|FG009|Overall Study|Physician Decision|0
6016110|NCT00150462|9609527|FG010|Overall Study|Physician Decision|0
6016111|NCT00150462|9609517|FG000|Overall Study|Other|0
6016112|NCT00150462|9609518|FG001|Overall Study|Other|0
6016113|NCT00150462|9609519|FG002|Overall Study|Other|0
6016114|NCT00150462|9609520|FG003|Overall Study|Other|0
6016115|NCT00150462|9609521|FG004|Overall Study|Other|0
6016116|NCT00150462|9609522|FG005|Overall Study|Other|0
6016117|NCT00150462|9609523|FG006|Overall Study|Other|0
6016118|NCT00150462|9609524|FG007|Overall Study|Other|0
6016119|NCT00150462|9609525|FG008|Overall Study|Other|0
6016120|NCT00150462|9609526|FG009|Overall Study|Other|1
6016121|NCT00150462|9609527|FG010|Overall Study|Other|1
6016122|NCT00150592|9609556|FG000|Overall Study|Adverse Event|4
6016123|NCT00150592|9609557|FG001|Overall Study|Adverse Event|1
6016124|NCT00150592|9609556|FG000|Overall Study|Protocol Violation|1
6016125|NCT00150592|9609557|FG001|Overall Study|Protocol Violation|0
6016126|NCT00150592|9609556|FG000|Overall Study|Withdrawal by Subject|1
6016127|NCT00150592|9609557|FG001|Overall Study|Withdrawal by Subject|2
6016128|NCT00150592|9609556|FG000|Overall Study|Non-compliance|1
6016129|NCT00150592|9609557|FG001|Overall Study|Non-compliance|0
6016130|NCT00150618|9609568|FG000|Overall Study|Adverse Event|2
6016131|NCT00150618|9609569|FG001|Overall Study|Adverse Event|2
6016132|NCT00150618|9609570|FG002|Overall Study|Adverse Event|6
6016133|NCT00150618|9609571|FG003|Overall Study|Adverse Event|9
6016134|NCT00150618|9609572|FG004|Overall Study|Adverse Event|5
6016135|NCT00150618|9609568|FG000|Overall Study|Withdrawal by Subject|6
6016136|NCT00150618|9609569|FG001|Overall Study|Withdrawal by Subject|8
6016137|NCT00150618|9609570|FG002|Overall Study|Withdrawal by Subject|8
6016138|NCT00150618|9609571|FG003|Overall Study|Withdrawal by Subject|4
6016139|NCT00150618|9609572|FG004|Overall Study|Withdrawal by Subject|5
6016140|NCT00150618|9609568|FG000|Overall Study|Lost to Follow-up|4
6016141|NCT00150618|9609569|FG001|Overall Study|Lost to Follow-up|1
6016142|NCT00150618|9609570|FG002|Overall Study|Lost to Follow-up|5
6016143|NCT00150618|9609571|FG003|Overall Study|Lost to Follow-up|8
6016144|NCT00150618|9609572|FG004|Overall Study|Lost to Follow-up|4
6016145|NCT00150618|9609568|FG000|Overall Study|Protocol Violation|1
6016146|NCT00150618|9609569|FG001|Overall Study|Protocol Violation|0
6016147|NCT00150618|9609570|FG002|Overall Study|Protocol Violation|0
6016148|NCT00150618|9609571|FG003|Overall Study|Protocol Violation|0
6016149|NCT00150618|9609572|FG004|Overall Study|Protocol Violation|1
6016150|NCT00150618|9609568|FG000|Overall Study|Lack of Efficacy|1
6016151|NCT00150618|9609569|FG001|Overall Study|Lack of Efficacy|4
6016152|NCT00150618|9609570|FG002|Overall Study|Lack of Efficacy|7
6016153|NCT00150618|9609571|FG003|Overall Study|Lack of Efficacy|4
6016154|NCT00150618|9609572|FG004|Overall Study|Lack of Efficacy|6
6016155|NCT00150618|9609568|FG000|Overall Study|No study meds|0
6016156|NCT00150618|9609569|FG001|Overall Study|No study meds|0
6016157|NCT00150618|9609570|FG002|Overall Study|No study meds|0
6016158|NCT00150618|9609571|FG003|Overall Study|No study meds|0
6016159|NCT00150618|9609572|FG004|Overall Study|No study meds|2
6016160|NCT00150618|9609568|FG000|Overall Study|Physician Decision|0
6016161|NCT00150618|9609569|FG001|Overall Study|Physician Decision|2
6016162|NCT00150618|9609570|FG002|Overall Study|Physician Decision|0
6016163|NCT00150618|9609571|FG003|Overall Study|Physician Decision|0
6016164|NCT00150618|9609572|FG004|Overall Study|Physician Decision|1
6016165|NCT00150618|9609568|FG000|Overall Study|Lack of compliance|2
6016166|NCT00150618|9609569|FG001|Overall Study|Lack of compliance|1
6016167|NCT00150618|9609570|FG002|Overall Study|Lack of compliance|1
6016168|NCT00150618|9609571|FG003|Overall Study|Lack of compliance|0
6016169|NCT00150618|9609572|FG004|Overall Study|Lack of compliance|1
6016170|NCT00150618|9609568|FG000|Overall Study|Abnormal ECG|1
6016171|NCT00150618|9609569|FG001|Overall Study|Abnormal ECG|0
6016172|NCT00150618|9609570|FG002|Overall Study|Abnormal ECG|0
6016173|NCT00150618|9609571|FG003|Overall Study|Abnormal ECG|0
6016174|NCT00150618|9609572|FG004|Overall Study|Abnormal ECG|0
6016175|NCT00150618|9609568|FG000|Overall Study|Sponsor's decision|0
6016176|NCT00150618|9609569|FG001|Overall Study|Sponsor's decision|0
6016177|NCT00150618|9609570|FG002|Overall Study|Sponsor's decision|0
6016178|NCT00150618|9609571|FG003|Overall Study|Sponsor's decision|1
6016179|NCT00150618|9609572|FG004|Overall Study|Sponsor's decision|0
6016180|NCT00150800|9609584|FG000|Overall Study|Adverse Event|89
6016181|NCT00150800|9609584|FG000|Overall Study|Death|18
6016182|NCT00150800|9609584|FG000|Overall Study|Lack of Efficacy|166
6016183|NCT00150800|9609584|FG000|Overall Study|Lost to Follow-up|58
6016184|NCT00150800|9609584|FG000|Overall Study|Subject's choice|90
6016185|NCT00150800|9609584|FG000|Overall Study|No compliance|18
6016186|NCT00150800|9609584|FG000|Overall Study|IP misshandling|1
6016187|NCT00150800|9609584|FG000|Overall Study|Site closure|24
6016188|NCT00150800|9609584|FG000|Overall Study|Protocol non-adherence|2
6016189|NCT00150800|9609584|FG000|Overall Study|Nobody to accompany patient|1
6016190|NCT00150800|9609584|FG000|Overall Study|Distance too long for patient|1
6016191|NCT00150800|9609584|FG000|Overall Study|Neurosurgery|2
6016192|NCT00150800|9609584|FG000|Overall Study|BRV monotherapy|1
6016193|NCT00150800|9609584|FG000|Overall Study|Visit refusal|3
6016194|NCT00150800|9609584|FG000|Overall Study|Sponsor's request|2
6016195|NCT00150800|9609584|FG000|Overall Study|Generalized Epilepsy|1
6016196|NCT00150800|9609584|FG000|Overall Study|Moved from area/country|8
6016197|NCT00150800|9609584|FG000|Overall Study|PI retiring|2
6016198|NCT00150800|9609584|FG000|Overall Study|PI leaving site|2
6016199|NCT00150800|9609584|FG000|Overall Study|Patient insurance|1
6016200|NCT00150800|9609584|FG000|Overall Study|Surgical intervention|4
6016201|NCT00150800|9609584|FG000|Overall Study|Pregnancy planned|1
6016202|NCT00150800|9609584|FG000|Overall Study|PI discontinuation request|1
6016203|NCT00150813|9609589|FG000|Overall Study|Adverse Event|1
6016204|NCT00150813|9609589|FG000|Overall Study|Lack of Efficacy|1
6016205|NCT00150813|9609589|FG000|Overall Study|Lost to Follow-up|5
6016206|NCT00150813|9609589|FG000|Overall Study|Withdrawal by Subject|5
6016207|NCT00150813|9609589|FG000|Overall Study|Remission|3
6016208|NCT00150813|9609589|FG000|Overall Study|Planned pregancy|1
6016209|NCT00150813|9609589|FG000|Overall Study|Switch to commercially available LEV|2
6016210|NCT00150969|9609595|FG000|24 Month Main Study|Adverse Event|3
6016211|NCT00150969|9609596|FG001|24 Month Main Study|Adverse Event|4
6016212|NCT00150969|9609595|FG000|24 Month Main Study|Death|1
6016213|NCT00150969|9609596|FG001|24 Month Main Study|Death|1
6016214|NCT00150969|9609595|FG000|24 Month Main Study|Lack of Efficacy|1
6016215|NCT00150969|9609596|FG001|24 Month Main Study|Lack of Efficacy|8
6016216|NCT00150969|9609595|FG000|24 Month Main Study|Lost to Follow-up|3
6016217|NCT00150969|9609596|FG001|24 Month Main Study|Lost to Follow-up|2
6016218|NCT00150969|9609595|FG000|24 Month Main Study|Protocol Violation|4
6016219|NCT00150969|9609596|FG001|24 Month Main Study|Protocol Violation|2
6016220|NCT00150969|9609595|FG000|24 Month Main Study|Withdrawal by Subject|7
6016221|NCT00150969|9609596|FG001|24 Month Main Study|Withdrawal by Subject|4
6016222|NCT00150969|9609595|FG000|24-48 Month Extension|Withdrawal by Subject|6
6016223|NCT00150969|9609596|FG001|24-48 Month Extension|Withdrawal by Subject|5
6016224|NCT00150969|9609595|FG000|24-48 Month Extension|Lack of Efficacy|0
6016225|NCT00150969|9609596|FG001|24-48 Month Extension|Lack of Efficacy|1
6016226|NCT00150969|9609595|FG000|24-48 Month Extension|Adverse Event|1
6016227|NCT00150969|9609596|FG001|24-48 Month Extension|Adverse Event|3
6016228|NCT00150969|9609595|FG000|24-48 Month Extension|Other Reason|81
6016229|NCT00150969|9609596|FG001|24-48 Month Extension|Other Reason|91
6016230|NCT00151281|9609603|FG000|Overall Study|Not evaluable|3
6016231|NCT00151372|9609617|FG000|Overall Study|Death|12
6016232|NCT00151372|9609618|FG001|Overall Study|Death|11
6016233|NCT00151372|9609617|FG000|Overall Study|Lost to Follow-up|5
6016234|NCT00151372|9609618|FG001|Overall Study|Lost to Follow-up|5
6016235|NCT00151372|9609617|FG000|Overall Study|Too sick medically to continue|5
6016236|NCT00151372|9609618|FG001|Overall Study|Too sick medically to continue|6
6016237|NCT00151372|9609617|FG000|Overall Study|Withdrawal by Subject|7
6016238|NCT00151372|9609618|FG001|Overall Study|Withdrawal by Subject|7
6016239|NCT00151411|9609626|FG000|Overall Study|Lost to Follow-up|15
6016240|NCT00151411|9609627|FG001|Overall Study|Lost to Follow-up|19
6016241|NCT00151411|9609626|FG000|Overall Study|Withdrawal by Subject|12
6016242|NCT00151411|9609627|FG001|Overall Study|Withdrawal by Subject|20
6016243|NCT00151411|9609626|FG000|Overall Study|Adverse Event|6
6016244|NCT00151411|9609627|FG001|Overall Study|Adverse Event|0
6016245|NCT00151411|9609626|FG000|Overall Study|Pregnancy|0
6016246|NCT00151411|9609627|FG001|Overall Study|Pregnancy|4
6016247|NCT00151476|9609636|FG000|FAP Identified Subjects|Protocol Violation|0
6016248|NCT00151476|9609637|FG001|FAP Identified Subjects|Protocol Violation|1
6016249|NCT00151476|9609636|FG000|FAP Analyzed Subjects|Lost to Follow-up|0
6016250|NCT00151476|9609637|FG001|FAP Analyzed Subjects|Lost to Follow-up|2
6016251|NCT00151476|9609636|FG000|FAP Analyzed Subjects|Other study participation|0
6016252|NCT00151476|9609637|FG001|FAP Analyzed Subjects|Other study participation|1
6016253|NCT00151775|9609649|FG000|Period 2 - Double-Blind Dose Response|Adverse Event|1
6016254|NCT00151775|9609650|FG001|Period 2 - Double-Blind Dose Response|Adverse Event|2
6016255|NCT00151775|9609651|FG002|Period 2 - Double-Blind Dose Response|Adverse Event|0
6016256|NCT00151775|9609652|FG003|Period 2 - Double-Blind Dose Response|Adverse Event|0
6016257|NCT00151775|9609653|FG004|Period 2 - Double-Blind Dose Response|Adverse Event|0
6016258|NCT00151775|9609654|FG005|Period 2 - Double-Blind Dose Response|Adverse Event|0
6016259|NCT00151775|9609655|FG006|Period 2 - Double-Blind Dose Response|Adverse Event|0
6016260|NCT00151775|9609656|FG007|Period 2 - Double-Blind Dose Response|Adverse Event|0
6016261|NCT00151775|9609657|FG008|Period 2 - Double-Blind Dose Response|Adverse Event|0
6016262|NCT00151775|9609658|FG009|Period 2 - Double-Blind Dose Response|Adverse Event|0
6016263|NCT00151775|9609659|FG010|Period 2 - Double-Blind Dose Response|Adverse Event|0
6016264|NCT00151775|9609660|FG011|Period 2 - Double-Blind Dose Response|Adverse Event|0
6016265|NCT00151775|9609649|FG000|Period 2 - Double-Blind Dose Response|Lost to Follow-up|1
6016266|NCT00151775|9609650|FG001|Period 2 - Double-Blind Dose Response|Lost to Follow-up|0
6016267|NCT00151775|9609651|FG002|Period 2 - Double-Blind Dose Response|Lost to Follow-up|0
6016268|NCT00151775|9609652|FG003|Period 2 - Double-Blind Dose Response|Lost to Follow-up|0
6016269|NCT00151775|9609653|FG004|Period 2 - Double-Blind Dose Response|Lost to Follow-up|0
6016270|NCT00151775|9609654|FG005|Period 2 - Double-Blind Dose Response|Lost to Follow-up|0
6016271|NCT00151775|9609655|FG006|Period 2 - Double-Blind Dose Response|Lost to Follow-up|1
6016272|NCT00151775|9609656|FG007|Period 2 - Double-Blind Dose Response|Lost to Follow-up|0
6016273|NCT00151775|9609657|FG008|Period 2 - Double-Blind Dose Response|Lost to Follow-up|0
6016274|NCT00151775|9609658|FG009|Period 2 - Double-Blind Dose Response|Lost to Follow-up|0
6016275|NCT00151775|9609659|FG010|Period 2 - Double-Blind Dose Response|Lost to Follow-up|1
6016276|NCT00151775|9609660|FG011|Period 2 - Double-Blind Dose Response|Lost to Follow-up|0
6016277|NCT00151775|9609649|FG000|Period 2 - Double-Blind Dose Response|Protocol Violation|0
6016278|NCT00151775|9609650|FG001|Period 2 - Double-Blind Dose Response|Protocol Violation|4
6016279|NCT00151775|9609651|FG002|Period 2 - Double-Blind Dose Response|Protocol Violation|0
6016280|NCT00151775|9609652|FG003|Period 2 - Double-Blind Dose Response|Protocol Violation|0
6016281|NCT00151775|9609653|FG004|Period 2 - Double-Blind Dose Response|Protocol Violation|0
6016282|NCT00151775|9609654|FG005|Period 2 - Double-Blind Dose Response|Protocol Violation|0
6016283|NCT00151775|9609655|FG006|Period 2 - Double-Blind Dose Response|Protocol Violation|0
6016284|NCT00151775|9609656|FG007|Period 2 - Double-Blind Dose Response|Protocol Violation|0
6016285|NCT00151775|9609657|FG008|Period 2 - Double-Blind Dose Response|Protocol Violation|0
6016286|NCT00151775|9609658|FG009|Period 2 - Double-Blind Dose Response|Protocol Violation|0
6016287|NCT00151775|9609659|FG010|Period 2 - Double-Blind Dose Response|Protocol Violation|0
6016288|NCT00151775|9609660|FG011|Period 2 - Double-Blind Dose Response|Protocol Violation|0
6016289|NCT00151775|9609649|FG000|Period 2 - Double-Blind Dose Response|Other|0
6016290|NCT00151775|9609650|FG001|Period 2 - Double-Blind Dose Response|Other|0
6016291|NCT00151775|9609651|FG002|Period 2 - Double-Blind Dose Response|Other|0
6016292|NCT00151775|9609652|FG003|Period 2 - Double-Blind Dose Response|Other|0
6016293|NCT00151775|9609653|FG004|Period 2 - Double-Blind Dose Response|Other|0
6016294|NCT00151775|9609654|FG005|Period 2 - Double-Blind Dose Response|Other|0
6016295|NCT00151775|9609655|FG006|Period 2 - Double-Blind Dose Response|Other|1
6016296|NCT00151775|9609656|FG007|Period 2 - Double-Blind Dose Response|Other|0
6016297|NCT00151775|9609657|FG008|Period 2 - Double-Blind Dose Response|Other|0
6016298|NCT00151775|9609658|FG009|Period 2 - Double-Blind Dose Response|Other|0
6016299|NCT00151775|9609659|FG010|Period 2 - Double-Blind Dose Response|Other|0
6016300|NCT00151775|9609660|FG011|Period 2 - Double-Blind Dose Response|Other|0
6016301|NCT00151775|9609649|FG000|Period 2 - Double-Blind Dose Response|non-compliance|0
6016302|NCT00151775|9609650|FG001|Period 2 - Double-Blind Dose Response|non-compliance|0
6016303|NCT00151775|9609651|FG002|Period 2 - Double-Blind Dose Response|non-compliance|0
6016304|NCT00151775|9609652|FG003|Period 2 - Double-Blind Dose Response|non-compliance|0
6016305|NCT00151775|9609653|FG004|Period 2 - Double-Blind Dose Response|non-compliance|0
6016306|NCT00151775|9609654|FG005|Period 2 - Double-Blind Dose Response|non-compliance|1
6016307|NCT00151775|9609655|FG006|Period 2 - Double-Blind Dose Response|non-compliance|0
6016308|NCT00151775|9609656|FG007|Period 2 - Double-Blind Dose Response|non-compliance|0
6016309|NCT00151775|9609657|FG008|Period 2 - Double-Blind Dose Response|non-compliance|0
6016310|NCT00151775|9609658|FG009|Period 2 - Double-Blind Dose Response|non-compliance|0
6016311|NCT00151775|9609659|FG010|Period 2 - Double-Blind Dose Response|non-compliance|0
6016312|NCT00151775|9609660|FG011|Period 2 - Double-Blind Dose Response|non-compliance|0
6016313|NCT00151775|9609649|FG000|Period 2 - Double-Blind Dose Response|Physician Decision|0
6016314|NCT00151775|9609650|FG001|Period 2 - Double-Blind Dose Response|Physician Decision|0
6016315|NCT00151775|9609651|FG002|Period 2 - Double-Blind Dose Response|Physician Decision|0
6016316|NCT00151775|9609652|FG003|Period 2 - Double-Blind Dose Response|Physician Decision|0
6016317|NCT00151775|9609653|FG004|Period 2 - Double-Blind Dose Response|Physician Decision|0
6016318|NCT00151775|9609654|FG005|Period 2 - Double-Blind Dose Response|Physician Decision|1
6016319|NCT00151775|9609655|FG006|Period 2 - Double-Blind Dose Response|Physician Decision|0
6016320|NCT00151775|9609656|FG007|Period 2 - Double-Blind Dose Response|Physician Decision|0
6016321|NCT00151775|9609657|FG008|Period 2 - Double-Blind Dose Response|Physician Decision|0
6016322|NCT00151775|9609658|FG009|Period 2 - Double-Blind Dose Response|Physician Decision|0
6016323|NCT00151775|9609659|FG010|Period 2 - Double-Blind Dose Response|Physician Decision|0
6016324|NCT00151775|9609660|FG011|Period 2 - Double-Blind Dose Response|Physician Decision|0
6016325|NCT00151775|9609649|FG000|Period 2 - Double-Blind Dose Response|The blood pressure goal was met|0
6016326|NCT00151775|9609650|FG001|Period 2 - Double-Blind Dose Response|The blood pressure goal was met|0
6016327|NCT00151775|9609651|FG002|Period 2 - Double-Blind Dose Response|The blood pressure goal was met|0
6016328|NCT00151775|9609652|FG003|Period 2 - Double-Blind Dose Response|The blood pressure goal was met|0
6016329|NCT00151775|9609653|FG004|Period 2 - Double-Blind Dose Response|The blood pressure goal was met|0
6016330|NCT00151775|9609654|FG005|Period 2 - Double-Blind Dose Response|The blood pressure goal was met|0
6016331|NCT00151775|9609655|FG006|Period 2 - Double-Blind Dose Response|The blood pressure goal was met|1
6016332|NCT00151775|9609656|FG007|Period 2 - Double-Blind Dose Response|The blood pressure goal was met|0
6016333|NCT00151775|9609657|FG008|Period 2 - Double-Blind Dose Response|The blood pressure goal was met|0
6016334|NCT00151775|9609658|FG009|Period 2 - Double-Blind Dose Response|The blood pressure goal was met|0
6016335|NCT00151775|9609659|FG010|Period 2 - Double-Blind Dose Response|The blood pressure goal was met|0
6016336|NCT00151775|9609660|FG011|Period 2 - Double-Blind Dose Response|The blood pressure goal was met|0
6016337|NCT00151775|9609649|FG000|Period 3: Double-blind, Withdrawal|Withdrawal by Subject|0
6016338|NCT00151775|9609650|FG001|Period 3: Double-blind, Withdrawal|Withdrawal by Subject|0
6016339|NCT00151775|9609651|FG002|Period 3: Double-blind, Withdrawal|Withdrawal by Subject|0
6016340|NCT00151775|9609652|FG003|Period 3: Double-blind, Withdrawal|Withdrawal by Subject|0
6016341|NCT00151775|9609653|FG004|Period 3: Double-blind, Withdrawal|Withdrawal by Subject|0
6047723|NCT00413244|9646810|FG000|Overall Study|Withdrawal by Subject|10
6016342|NCT00151775|9609654|FG005|Period 3: Double-blind, Withdrawal|Withdrawal by Subject|1
6016343|NCT00151775|9609655|FG006|Period 3: Double-blind, Withdrawal|Withdrawal by Subject|0
6016344|NCT00151775|9609656|FG007|Period 3: Double-blind, Withdrawal|Withdrawal by Subject|0
6016345|NCT00151775|9609657|FG008|Period 3: Double-blind, Withdrawal|Withdrawal by Subject|0
6016346|NCT00151775|9609658|FG009|Period 3: Double-blind, Withdrawal|Withdrawal by Subject|0
6016347|NCT00151775|9609659|FG010|Period 3: Double-blind, Withdrawal|Withdrawal by Subject|0
6016348|NCT00151775|9609660|FG011|Period 3: Double-blind, Withdrawal|Withdrawal by Subject|0
6016349|NCT00151775|9609649|FG000|Period 3: Double-blind, Withdrawal|Other|0
6016350|NCT00151775|9609650|FG001|Period 3: Double-blind, Withdrawal|Other|0
6016351|NCT00151775|9609651|FG002|Period 3: Double-blind, Withdrawal|Other|1
6016352|NCT00151775|9609652|FG003|Period 3: Double-blind, Withdrawal|Other|0
6016353|NCT00151775|9609653|FG004|Period 3: Double-blind, Withdrawal|Other|0
6016354|NCT00151775|9609654|FG005|Period 3: Double-blind, Withdrawal|Other|0
6016355|NCT00151775|9609655|FG006|Period 3: Double-blind, Withdrawal|Other|0
6016356|NCT00151775|9609656|FG007|Period 3: Double-blind, Withdrawal|Other|1
6016357|NCT00151775|9609657|FG008|Period 3: Double-blind, Withdrawal|Other|0
6016358|NCT00151775|9609658|FG009|Period 3: Double-blind, Withdrawal|Other|0
6016359|NCT00151775|9609659|FG010|Period 3: Double-blind, Withdrawal|Other|0
6016360|NCT00151775|9609660|FG011|Period 3: Double-blind, Withdrawal|Other|0
6016361|NCT00151775|9609649|FG000|Period 3: Double-blind, Withdrawal|Met blood pressure goal|0
6016362|NCT00151775|9609650|FG001|Period 3: Double-blind, Withdrawal|Met blood pressure goal|0
6016363|NCT00151775|9609651|FG002|Period 3: Double-blind, Withdrawal|Met blood pressure goal|0
6016364|NCT00151775|9609652|FG003|Period 3: Double-blind, Withdrawal|Met blood pressure goal|0
6016365|NCT00151775|9609653|FG004|Period 3: Double-blind, Withdrawal|Met blood pressure goal|0
6016366|NCT00151775|9609654|FG005|Period 3: Double-blind, Withdrawal|Met blood pressure goal|0
6016367|NCT00151775|9609655|FG006|Period 3: Double-blind, Withdrawal|Met blood pressure goal|1
6016368|NCT00151775|9609656|FG007|Period 3: Double-blind, Withdrawal|Met blood pressure goal|0
6016369|NCT00151775|9609657|FG008|Period 3: Double-blind, Withdrawal|Met blood pressure goal|0
6016370|NCT00151775|9609658|FG009|Period 3: Double-blind, Withdrawal|Met blood pressure goal|0
6016371|NCT00151775|9609659|FG010|Period 3: Double-blind, Withdrawal|Met blood pressure goal|0
6016372|NCT00151775|9609660|FG011|Period 3: Double-blind, Withdrawal|Met blood pressure goal|0
6016373|NCT00151775|9609649|FG000|Period 3: Double-blind, Withdrawal|Adverse Event|0
6016374|NCT00151775|9609650|FG001|Period 3: Double-blind, Withdrawal|Adverse Event|0
6016375|NCT00151775|9609651|FG002|Period 3: Double-blind, Withdrawal|Adverse Event|1
6016376|NCT00151775|9609652|FG003|Period 3: Double-blind, Withdrawal|Adverse Event|0
6016377|NCT00151775|9609653|FG004|Period 3: Double-blind, Withdrawal|Adverse Event|0
6016378|NCT00151775|9609654|FG005|Period 3: Double-blind, Withdrawal|Adverse Event|0
6016379|NCT00151775|9609655|FG006|Period 3: Double-blind, Withdrawal|Adverse Event|0
6016380|NCT00151775|9609656|FG007|Period 3: Double-blind, Withdrawal|Adverse Event|0
6016381|NCT00151775|9609657|FG008|Period 3: Double-blind, Withdrawal|Adverse Event|0
6016382|NCT00151775|9609658|FG009|Period 3: Double-blind, Withdrawal|Adverse Event|0
6016383|NCT00151775|9609659|FG010|Period 3: Double-blind, Withdrawal|Adverse Event|0
6016384|NCT00151775|9609660|FG011|Period 3: Double-blind, Withdrawal|Adverse Event|0
6016385|NCT00151775|9609649|FG000|Period 3: Double-blind, Withdrawal|Protocol Violation|0
6016386|NCT00151775|9609650|FG001|Period 3: Double-blind, Withdrawal|Protocol Violation|0
6016387|NCT00151775|9609651|FG002|Period 3: Double-blind, Withdrawal|Protocol Violation|1
6016388|NCT00151775|9609652|FG003|Period 3: Double-blind, Withdrawal|Protocol Violation|0
6016389|NCT00151775|9609653|FG004|Period 3: Double-blind, Withdrawal|Protocol Violation|0
6016390|NCT00151775|9609654|FG005|Period 3: Double-blind, Withdrawal|Protocol Violation|0
6016391|NCT00151775|9609655|FG006|Period 3: Double-blind, Withdrawal|Protocol Violation|0
6016392|NCT00151775|9609656|FG007|Period 3: Double-blind, Withdrawal|Protocol Violation|0
6016393|NCT00151775|9609657|FG008|Period 3: Double-blind, Withdrawal|Protocol Violation|0
6016394|NCT00151775|9609658|FG009|Period 3: Double-blind, Withdrawal|Protocol Violation|0
6016395|NCT00151775|9609659|FG010|Period 3: Double-blind, Withdrawal|Protocol Violation|0
6016396|NCT00151775|9609660|FG011|Period 3: Double-blind, Withdrawal|Protocol Violation|0
6016397|NCT00151775|9609649|FG000|Period 3: Double-blind, Withdrawal|Lost to Follow-up|0
6016398|NCT00151775|9609650|FG001|Period 3: Double-blind, Withdrawal|Lost to Follow-up|0
6016399|NCT00151775|9609651|FG002|Period 3: Double-blind, Withdrawal|Lost to Follow-up|0
6016400|NCT00151775|9609652|FG003|Period 3: Double-blind, Withdrawal|Lost to Follow-up|0
6016401|NCT00151775|9609653|FG004|Period 3: Double-blind, Withdrawal|Lost to Follow-up|0
6076710|NCT00592774|9682493|FG004|Overall Study|Protocol Violation|1
6076711|NCT00592774|9682489|FG000|Overall Study|Withdrawal by Subject|3
6076712|NCT00592774|9682490|FG001|Overall Study|Withdrawal by Subject|7
6076713|NCT00592774|9682491|FG002|Overall Study|Withdrawal by Subject|0
6076714|NCT00592774|9682492|FG003|Overall Study|Withdrawal by Subject|0
6076715|NCT00592774|9682493|FG004|Overall Study|Withdrawal by Subject|0
6076716|NCT00592774|9682489|FG000|Overall Study|Lack of Efficacy|3
6076717|NCT00592774|9682490|FG001|Overall Study|Lack of Efficacy|3
6076718|NCT00592774|9682491|FG002|Overall Study|Lack of Efficacy|0
6076719|NCT00592774|9682492|FG003|Overall Study|Lack of Efficacy|0
6076720|NCT00592774|9682493|FG004|Overall Study|Lack of Efficacy|2
6016402|NCT00151775|9609654|FG005|Period 3: Double-blind, Withdrawal|Lost to Follow-up|0
6076721|NCT00592774|9682489|FG000|Overall Study|Physician Decision|0
6076722|NCT00592774|9682490|FG001|Overall Study|Physician Decision|1
6076723|NCT00592774|9682491|FG002|Overall Study|Physician Decision|1
6076724|NCT00592774|9682492|FG003|Overall Study|Physician Decision|0
6076725|NCT00592774|9682493|FG004|Overall Study|Physician Decision|1
6076726|NCT00592774|9682489|FG000|Overall Study|Other|0
6076727|NCT00592774|9682490|FG001|Overall Study|Other|1
6076728|NCT00592774|9682491|FG002|Overall Study|Other|1
6016403|NCT00151775|9609655|FG006|Period 3: Double-blind, Withdrawal|Lost to Follow-up|0
6016404|NCT00151775|9609656|FG007|Period 3: Double-blind, Withdrawal|Lost to Follow-up|0
6016405|NCT00151775|9609657|FG008|Period 3: Double-blind, Withdrawal|Lost to Follow-up|0
6016406|NCT00151775|9609658|FG009|Period 3: Double-blind, Withdrawal|Lost to Follow-up|0
6016407|NCT00151775|9609659|FG010|Period 3: Double-blind, Withdrawal|Lost to Follow-up|0
6016408|NCT00151775|9609660|FG011|Period 3: Double-blind, Withdrawal|Lost to Follow-up|1
6016409|NCT00151775|9609649|FG000|Period 4: Open Label|Increased blood pressure|0
6016410|NCT00151775|9609650|FG001|Period 4: Open Label|Increased blood pressure|0
6016411|NCT00151775|9609651|FG002|Period 4: Open Label|Increased blood pressure|0
6016412|NCT00151775|9609652|FG003|Period 4: Open Label|Increased blood pressure|0
6016413|NCT00151775|9609653|FG004|Period 4: Open Label|Increased blood pressure|1
6016414|NCT00151775|9609654|FG005|Period 4: Open Label|Increased blood pressure|0
6016415|NCT00151775|9609655|FG006|Period 4: Open Label|Increased blood pressure|0
6016416|NCT00151775|9609656|FG007|Period 4: Open Label|Increased blood pressure|0
6016417|NCT00151775|9609657|FG008|Period 4: Open Label|Increased blood pressure|0
6016418|NCT00151775|9609658|FG009|Period 4: Open Label|Increased blood pressure|1
6016419|NCT00151775|9609659|FG010|Period 4: Open Label|Increased blood pressure|0
6016420|NCT00151775|9609660|FG011|Period 4: Open Label|Increased blood pressure|0
6016421|NCT00151775|9609649|FG000|Period 4: Open Label|Withdrawal by Subject|0
6016422|NCT00151775|9609650|FG001|Period 4: Open Label|Withdrawal by Subject|0
6016423|NCT00151775|9609651|FG002|Period 4: Open Label|Withdrawal by Subject|0
6016424|NCT00151775|9609652|FG003|Period 4: Open Label|Withdrawal by Subject|0
6016425|NCT00151775|9609653|FG004|Period 4: Open Label|Withdrawal by Subject|5
6016426|NCT00151775|9609654|FG005|Period 4: Open Label|Withdrawal by Subject|0
6016427|NCT00151775|9609655|FG006|Period 4: Open Label|Withdrawal by Subject|0
6016428|NCT00151775|9609656|FG007|Period 4: Open Label|Withdrawal by Subject|0
6016429|NCT00151775|9609657|FG008|Period 4: Open Label|Withdrawal by Subject|0
6016430|NCT00151775|9609658|FG009|Period 4: Open Label|Withdrawal by Subject|2
6016431|NCT00151775|9609659|FG010|Period 4: Open Label|Withdrawal by Subject|0
6016432|NCT00151775|9609660|FG011|Period 4: Open Label|Withdrawal by Subject|0
6016433|NCT00151775|9609649|FG000|Period 4: Open Label|Adverse Event|0
6016434|NCT00151775|9609650|FG001|Period 4: Open Label|Adverse Event|0
6016435|NCT00151775|9609651|FG002|Period 4: Open Label|Adverse Event|0
6016436|NCT00151775|9609652|FG003|Period 4: Open Label|Adverse Event|0
6016437|NCT00151775|9609653|FG004|Period 4: Open Label|Adverse Event|1
6016438|NCT00151775|9609654|FG005|Period 4: Open Label|Adverse Event|0
6016439|NCT00151775|9609655|FG006|Period 4: Open Label|Adverse Event|0
6016440|NCT00151775|9609656|FG007|Period 4: Open Label|Adverse Event|0
6016441|NCT00151775|9609657|FG008|Period 4: Open Label|Adverse Event|0
6016442|NCT00151775|9609658|FG009|Period 4: Open Label|Adverse Event|2
6016443|NCT00151775|9609659|FG010|Period 4: Open Label|Adverse Event|0
6016444|NCT00151775|9609660|FG011|Period 4: Open Label|Adverse Event|0
6016445|NCT00151775|9609649|FG000|Period 4: Open Label|Lost to Follow-up|0
6016446|NCT00151775|9609650|FG001|Period 4: Open Label|Lost to Follow-up|0
6016447|NCT00151775|9609651|FG002|Period 4: Open Label|Lost to Follow-up|0
6016448|NCT00151775|9609652|FG003|Period 4: Open Label|Lost to Follow-up|0
6016449|NCT00151775|9609653|FG004|Period 4: Open Label|Lost to Follow-up|17
6016450|NCT00151775|9609654|FG005|Period 4: Open Label|Lost to Follow-up|0
6016451|NCT00151775|9609655|FG006|Period 4: Open Label|Lost to Follow-up|0
6016452|NCT00151775|9609656|FG007|Period 4: Open Label|Lost to Follow-up|0
6016453|NCT00151775|9609657|FG008|Period 4: Open Label|Lost to Follow-up|0
6016454|NCT00151775|9609658|FG009|Period 4: Open Label|Lost to Follow-up|7
6016455|NCT00151775|9609659|FG010|Period 4: Open Label|Lost to Follow-up|0
6016456|NCT00151775|9609660|FG011|Period 4: Open Label|Lost to Follow-up|0
6016457|NCT00151775|9609649|FG000|Period 4: Open Label|Non-compliance with protocol|0
6016458|NCT00151775|9609650|FG001|Period 4: Open Label|Non-compliance with protocol|0
6016459|NCT00151775|9609651|FG002|Period 4: Open Label|Non-compliance with protocol|0
6016460|NCT00151775|9609652|FG003|Period 4: Open Label|Non-compliance with protocol|0
6016461|NCT00151775|9609653|FG004|Period 4: Open Label|Non-compliance with protocol|4
6016462|NCT00151775|9609654|FG005|Period 4: Open Label|Non-compliance with protocol|0
6016463|NCT00151775|9609655|FG006|Period 4: Open Label|Non-compliance with protocol|0
6016464|NCT00151775|9609656|FG007|Period 4: Open Label|Non-compliance with protocol|0
6016465|NCT00151775|9609657|FG008|Period 4: Open Label|Non-compliance with protocol|0
6076729|NCT00592774|9682492|FG003|Overall Study|Other|0
6016466|NCT00151775|9609658|FG009|Period 4: Open Label|Non-compliance with protocol|4
6016467|NCT00151775|9609659|FG010|Period 4: Open Label|Non-compliance with protocol|0
6016468|NCT00151775|9609660|FG011|Period 4: Open Label|Non-compliance with protocol|0
6016469|NCT00151775|9609649|FG000|Period 4: Open Label|Other|0
6076730|NCT00592774|9682493|FG004|Overall Study|Other|2
6076731|NCT00592839|9682508|FG000|Overall Study|Withdrawal by Subject|1
6076732|NCT00592839|9682509|FG001|Overall Study|Withdrawal by Subject|1
6016470|NCT00151775|9609650|FG001|Period 4: Open Label|Other|0
6016471|NCT00151775|9609651|FG002|Period 4: Open Label|Other|0
6016472|NCT00151775|9609652|FG003|Period 4: Open Label|Other|0
6016473|NCT00151775|9609653|FG004|Period 4: Open Label|Other|1
6016474|NCT00151775|9609654|FG005|Period 4: Open Label|Other|0
6016475|NCT00151775|9609655|FG006|Period 4: Open Label|Other|0
6016476|NCT00151775|9609656|FG007|Period 4: Open Label|Other|0
6076733|NCT00592839|9682510|FG002|Overall Study|Withdrawal by Subject|3
6076734|NCT00592839|9682508|FG000|Overall Study|Protocol Violation|1
6076735|NCT00592839|9682509|FG001|Overall Study|Protocol Violation|1
6076736|NCT00592839|9682510|FG002|Overall Study|Protocol Violation|2
6076737|NCT00592839|9682508|FG000|Overall Study|Adverse Event|0
6076738|NCT00592839|9682509|FG001|Overall Study|Adverse Event|1
6076739|NCT00592839|9682510|FG002|Overall Study|Adverse Event|0
6076740|NCT00592839|9682508|FG000|Overall Study|Lost to Follow-up|0
6076741|NCT00592839|9682509|FG001|Overall Study|Lost to Follow-up|1
6076742|NCT00592839|9682510|FG002|Overall Study|Lost to Follow-up|1
6076743|NCT00592852|9682518|FG000|Overall Study|Non-compliance|1
6076744|NCT00592852|9682518|FG000|Overall Study|Adverse Event|3
6076745|NCT00592852|9682518|FG000|Overall Study|Found ineligible|1
6076746|NCT00592852|9682518|FG000|Overall Study|Withdrawal by Subject|1
6076747|NCT00592904|9682526|FG000|Overall Study|Adverse Event|15
6076748|NCT00592904|9682527|FG001|Overall Study|Adverse Event|25
6076749|NCT00592904|9682528|FG002|Overall Study|Adverse Event|13
6076750|NCT00592904|9682529|FG003|Overall Study|Adverse Event|5
6076751|NCT00592904|9682526|FG000|Overall Study|Protocol Violation|1
6076752|NCT00592904|9682527|FG001|Overall Study|Protocol Violation|1
6076753|NCT00592904|9682528|FG002|Overall Study|Protocol Violation|0
6076754|NCT00592904|9682529|FG003|Overall Study|Protocol Violation|1
6076755|NCT00592904|9682526|FG000|Overall Study|Withdrawal by Subject|4
6076756|NCT00592904|9682527|FG001|Overall Study|Withdrawal by Subject|16
6076757|NCT00592904|9682528|FG002|Overall Study|Withdrawal by Subject|1
6076758|NCT00592904|9682529|FG003|Overall Study|Withdrawal by Subject|2
6076759|NCT00592904|9682526|FG000|Overall Study|Lack of Efficacy|2
6076760|NCT00592904|9682527|FG001|Overall Study|Lack of Efficacy|7
6076761|NCT00592904|9682528|FG002|Overall Study|Lack of Efficacy|2
6076762|NCT00592904|9682529|FG003|Overall Study|Lack of Efficacy|3
6076763|NCT00592904|9682526|FG000|Overall Study|Physician Decision|0
6076764|NCT00592904|9682527|FG001|Overall Study|Physician Decision|3
6076765|NCT00592904|9682528|FG002|Overall Study|Physician Decision|1
6076766|NCT00592904|9682529|FG003|Overall Study|Physician Decision|0
6076767|NCT00592904|9682526|FG000|Overall Study|Other|3
6076768|NCT00592904|9682527|FG001|Overall Study|Other|3
6076769|NCT00592904|9682528|FG002|Overall Study|Other|0
6076770|NCT00592904|9682529|FG003|Overall Study|Other|0
6076771|NCT00593112|9682550|FG000|Overall Study|Scan Anxiety|3
6076772|NCT00593112|9682551|FG001|Overall Study|Scan Anxiety|0
6076773|NCT00593112|9682550|FG000|Overall Study|Abnormal Scan|1
6076774|NCT00593112|9682551|FG001|Overall Study|Abnormal Scan|0
6076775|NCT00593112|9682550|FG000|Overall Study|Unreadable Scan|1
6076776|NCT00593112|9682551|FG001|Overall Study|Unreadable Scan|0
6076777|NCT00593112|9682550|FG000|Overall Study|Withdrawal by Subject|5
6076778|NCT00593112|9682551|FG001|Overall Study|Withdrawal by Subject|0
6016477|NCT00151775|9609657|FG008|Period 4: Open Label|Other|0
6016478|NCT00151775|9609658|FG009|Period 4: Open Label|Other|3
6016479|NCT00151775|9609659|FG010|Period 4: Open Label|Other|0
6016480|NCT00151775|9609660|FG011|Period 4: Open Label|Other|0
6016481|NCT00151775|9609649|FG000|Period 4: Open Label|Physician Decision|0
6016482|NCT00151775|9609650|FG001|Period 4: Open Label|Physician Decision|0
6016483|NCT00151775|9609651|FG002|Period 4: Open Label|Physician Decision|0
6016484|NCT00151775|9609652|FG003|Period 4: Open Label|Physician Decision|0
6016485|NCT00151775|9609653|FG004|Period 4: Open Label|Physician Decision|0
6016486|NCT00151775|9609654|FG005|Period 4: Open Label|Physician Decision|0
6016487|NCT00151775|9609655|FG006|Period 4: Open Label|Physician Decision|0
6016488|NCT00151775|9609656|FG007|Period 4: Open Label|Physician Decision|0
6016489|NCT00151775|9609657|FG008|Period 4: Open Label|Physician Decision|0
6016490|NCT00151775|9609658|FG009|Period 4: Open Label|Physician Decision|2
6016491|NCT00151775|9609659|FG010|Period 4: Open Label|Physician Decision|0
6016492|NCT00151775|9609660|FG011|Period 4: Open Label|Physician Decision|0
6016493|NCT00151775|9609649|FG000|Period 4: Open Label|Protocol Violation|0
6016494|NCT00151775|9609650|FG001|Period 4: Open Label|Protocol Violation|0
6016495|NCT00151775|9609651|FG002|Period 4: Open Label|Protocol Violation|0
6016496|NCT00151775|9609652|FG003|Period 4: Open Label|Protocol Violation|0
6016497|NCT00151775|9609653|FG004|Period 4: Open Label|Protocol Violation|1
6016498|NCT00151775|9609654|FG005|Period 4: Open Label|Protocol Violation|0
6016499|NCT00151775|9609655|FG006|Period 4: Open Label|Protocol Violation|0
6016500|NCT00151775|9609656|FG007|Period 4: Open Label|Protocol Violation|0
6016501|NCT00151775|9609657|FG008|Period 4: Open Label|Protocol Violation|0
6016502|NCT00151775|9609658|FG009|Period 4: Open Label|Protocol Violation|0
6016503|NCT00151775|9609659|FG010|Period 4: Open Label|Protocol Violation|0
6016504|NCT00151775|9609660|FG011|Period 4: Open Label|Protocol Violation|0
6016505|NCT00151892|9609715|FG000|Overall Study|Lack of Efficacy|50
6016506|NCT00151892|9609716|FG001|Overall Study|Lack of Efficacy|57
6016507|NCT00151892|9609715|FG000|Overall Study|Patient request|10
6016508|NCT00151892|9609716|FG001|Overall Study|Patient request|7
6016509|NCT00151892|9609715|FG000|Overall Study|Lost to Follow-up|5
6016510|NCT00151892|9609716|FG001|Overall Study|Lost to Follow-up|10
6016511|NCT00151892|9609715|FG000|Overall Study|Adverse Event|6
6016512|NCT00151892|9609716|FG001|Overall Study|Adverse Event|3
6016513|NCT00151892|9609715|FG000|Overall Study|Protocol Violation|3
6016514|NCT00151892|9609716|FG001|Overall Study|Protocol Violation|3
6016515|NCT00151892|9609715|FG000|Overall Study|Non-compliance|0
6016516|NCT00151892|9609716|FG001|Overall Study|Non-compliance|1
6016517|NCT00151892|9609715|FG000|Overall Study|Pregnancy|0
6016518|NCT00151892|9609716|FG001|Overall Study|Pregnancy|1
6016519|NCT00151892|9609715|FG000|Overall Study|Did not return for a visit|1
6016520|NCT00151892|9609716|FG001|Overall Study|Did not return for a visit|0
6016521|NCT00151892|9609715|FG000|Overall Study|Used prohibited corticosteroids|1
6016522|NCT00151892|9609716|FG001|Overall Study|Used prohibited corticosteroids|0
6016523|NCT00151892|9609715|FG000|Overall Study|Lack of study medication at center|0
6016524|NCT00151892|9609716|FG001|Overall Study|Lack of study medication at center|1
6016525|NCT00151996|9609724|FG000|Overall Study|Adverse Event|3
6016526|NCT00151996|9609725|FG001|Overall Study|Adverse Event|2
6016527|NCT00151996|9609724|FG000|Overall Study|Withdrawal by Subject|1
6016528|NCT00151996|9609725|FG001|Overall Study|Withdrawal by Subject|1
6016529|NCT00151996|9609724|FG000|Overall Study|Protocol Violation|1
6016530|NCT00151996|9609725|FG001|Overall Study|Protocol Violation|2
6016531|NCT00151996|9609724|FG000|Overall Study|Sponsor's decision|0
6016532|NCT00151996|9609725|FG001|Overall Study|Sponsor's decision|2
6016533|NCT00152009|9609735|FG000|Overall Study|Adverse Event|9
6016534|NCT00152009|9609736|FG001|Overall Study|Adverse Event|13
6016535|NCT00152009|9609737|FG002|Overall Study|Adverse Event|20
6016536|NCT00152009|9609738|FG003|Overall Study|Adverse Event|1
6016537|NCT00152009|9609735|FG000|Overall Study|Protocol Violation|3
6016538|NCT00152009|9609736|FG001|Overall Study|Protocol Violation|0
6016539|NCT00152009|9609737|FG002|Overall Study|Protocol Violation|0
6016540|NCT00152009|9609738|FG003|Overall Study|Protocol Violation|1
6016541|NCT00152009|9609735|FG000|Overall Study|Withdrawal by Subject|2
6016542|NCT00152009|9609736|FG001|Overall Study|Withdrawal by Subject|3
6016543|NCT00152009|9609737|FG002|Overall Study|Withdrawal by Subject|4
6016544|NCT00152009|9609738|FG003|Overall Study|Withdrawal by Subject|9
6016545|NCT00152009|9609735|FG000|Overall Study|Lost to Follow-up|2
6016546|NCT00152009|9609736|FG001|Overall Study|Lost to Follow-up|4
6016547|NCT00152009|9609737|FG002|Overall Study|Lost to Follow-up|3
6016548|NCT00152009|9609738|FG003|Overall Study|Lost to Follow-up|3
6016549|NCT00152009|9609735|FG000|Overall Study|Lack of Efficacy|8
6016550|NCT00152009|9609736|FG001|Overall Study|Lack of Efficacy|6
6016551|NCT00152009|9609737|FG002|Overall Study|Lack of Efficacy|7
6016552|NCT00152009|9609738|FG003|Overall Study|Lack of Efficacy|15
6016553|NCT00152009|9609735|FG000|Overall Study|ECG abnormalities|2
6016554|NCT00152009|9609736|FG001|Overall Study|ECG abnormalities|2
6016555|NCT00152009|9609737|FG002|Overall Study|ECG abnormalities|2
6016556|NCT00152009|9609738|FG003|Overall Study|ECG abnormalities|1
6016557|NCT00152009|9609735|FG000|Overall Study|Sponsor's decision|3
6016558|NCT00152009|9609736|FG001|Overall Study|Sponsor's decision|3
6016559|NCT00152009|9609737|FG002|Overall Study|Sponsor's decision|1
6016560|NCT00152009|9609738|FG003|Overall Study|Sponsor's decision|3
6016561|NCT00152464|9609750|FG000|Overall Study|Adverse Event|3
6016562|NCT00152464|9609751|FG001|Overall Study|Adverse Event|6
6016563|NCT00152464|9609750|FG000|Overall Study|Lost to Follow-up|8
6016564|NCT00152464|9609751|FG001|Overall Study|Lost to Follow-up|4
6016565|NCT00152464|9609750|FG000|Overall Study|Protocol Violation|3
6016566|NCT00152464|9609751|FG001|Overall Study|Protocol Violation|1
6016567|NCT00152464|9609750|FG000|Overall Study|Withdrawal by Subject|21
6016568|NCT00152464|9609751|FG001|Overall Study|Withdrawal by Subject|22
6016569|NCT00152464|9609750|FG000|Overall Study|Atopic dermatitis poorly controlled|0
6016570|NCT00152464|9609751|FG001|Overall Study|Atopic dermatitis poorly controlled|1
6016571|NCT00152464|9609750|FG000|Overall Study|Eczema deterioration|0
6016572|NCT00152464|9609751|FG001|Overall Study|Eczema deterioration|1
6016573|NCT00152464|9609750|FG000|Overall Study|Parent decision|1
6016574|NCT00152464|9609751|FG001|Overall Study|Parent decision|1
6016575|NCT00152464|9609750|FG000|Overall Study|Investigator decision|1
6016576|NCT00152464|9609751|FG001|Overall Study|Investigator decision|0
6016577|NCT00152464|9609750|FG000|Overall Study|Lack of Efficacy|1
6016578|NCT00152464|9609751|FG001|Overall Study|Lack of Efficacy|0
6016579|NCT00152464|9609750|FG000|Overall Study|Eczema poorly controlled|1
6016580|NCT00152464|9609751|FG001|Overall Study|Eczema poorly controlled|0
6016581|NCT00152464|9609750|FG000|Overall Study|Patient relocated|1
6016582|NCT00152464|9609751|FG001|Overall Study|Patient relocated|0
6016583|NCT00152516|9609757|FG000|Overall Study|Adverse Event|18
6016584|NCT00152516|9609757|FG000|Overall Study|Lack and Loss of Efficacy|30
6016585|NCT00152516|9609757|FG000|Overall Study|Lost to Follow-up|5
6016586|NCT00152516|9609757|FG000|Overall Study|Withdrawal by Subject|8
6016587|NCT00152516|9609757|FG000|Overall Study|Protocol Violation|3
6016588|NCT00152516|9609757|FG000|Overall Study|Other: Mother Refused To Cooperate|1
6016589|NCT00152516|9609757|FG000|Overall Study|Other: Given Commercial Drug in Error|2
6016590|NCT00152516|9609757|FG000|Overall Study|Other: Parents Withdrew Consent|2
6016591|NCT00152516|9609757|FG000|Overall Study|Other: Non-Compliance|2
6016592|NCT00152516|9609757|FG000|Overall Study|Other: Primary Care Physician's Decision|1
6016593|NCT00152516|9609757|FG000|Overall Study|Other: Moved Out Of State|1
6016594|NCT00152516|9609757|FG000|Overall Study|Other: Underwent Surgery for Epilepsy|1
6016595|NCT00152516|9609757|FG000|Overall Study|Other: Sz Worsening, Seeking 2nd Opinion|1
6016596|NCT00152763|9609765|FG000|Overall Study|Death|4
6016597|NCT00152763|9609766|FG001|Overall Study|Death|1
6016598|NCT00152763|9609767|FG002|Overall Study|Death|2
6016599|NCT00152763|9609768|FG003|Overall Study|Death|1
6016600|NCT00152763|9609765|FG000|Overall Study|Lost to Follow-up|6
6016601|NCT00152763|9609766|FG001|Overall Study|Lost to Follow-up|4
6016602|NCT00152763|9609767|FG002|Overall Study|Lost to Follow-up|2
6016603|NCT00152763|9609768|FG003|Overall Study|Lost to Follow-up|13
6016604|NCT00152971|9609783|FG000|Overall Study|Adverse Event|12
6016605|NCT00152971|9609784|FG001|Overall Study|Adverse Event|10
6016606|NCT00152971|9609785|FG002|Overall Study|Adverse Event|9
6016607|NCT00152971|9609783|FG000|Overall Study|Protocol Violation|10
6016608|NCT00152971|9609784|FG001|Overall Study|Protocol Violation|11
6016609|NCT00152971|9609785|FG002|Overall Study|Protocol Violation|8
6016610|NCT00152971|9609783|FG000|Overall Study|Lost to Follow-up|17
6016611|NCT00152971|9609784|FG001|Overall Study|Lost to Follow-up|14
6016612|NCT00152971|9609785|FG002|Overall Study|Lost to Follow-up|13
6016613|NCT00152971|9609783|FG000|Overall Study|Withdrawal by Subject|9
6016614|NCT00152971|9609784|FG001|Overall Study|Withdrawal by Subject|8
6016615|NCT00152971|9609785|FG002|Overall Study|Withdrawal by Subject|14
6016616|NCT00152971|9609783|FG000|Overall Study|Other|3
6016617|NCT00152971|9609784|FG001|Overall Study|Other|5
6016618|NCT00152971|9609785|FG002|Overall Study|Other|5
6016619|NCT00152971|9609783|FG000|Treatment|Adverse Event|49
6016620|NCT00152971|9609784|FG001|Treatment|Adverse Event|40
6016621|NCT00152971|9609785|FG002|Treatment|Adverse Event|54
6016622|NCT00152971|9609783|FG000|Treatment|Protocol Violation|8
6016623|NCT00152971|9609784|FG001|Treatment|Protocol Violation|6
6016624|NCT00152971|9609785|FG002|Treatment|Protocol Violation|10
6016625|NCT00152971|9609783|FG000|Treatment|Lost to Follow-up|1
6016626|NCT00152971|9609784|FG001|Treatment|Lost to Follow-up|2
6016627|NCT00152971|9609785|FG002|Treatment|Lost to Follow-up|1
6016628|NCT00152971|9609783|FG000|Treatment|Withdrawal by Subject|4
6016629|NCT00152971|9609784|FG001|Treatment|Withdrawal by Subject|4
6016630|NCT00152971|9609785|FG002|Treatment|Withdrawal by Subject|5
6016631|NCT00152971|9609783|FG000|Treatment|Other|9
6016632|NCT00152971|9609784|FG001|Treatment|Other|11
6016633|NCT00152971|9609785|FG002|Treatment|Other|10
6016634|NCT00153062|9609797|FG000|Overall Study|Death|360
6016635|NCT00153062|9609798|FG001|Overall Study|Death|352
6016636|NCT00153062|9609799|FG002|Overall Study|Death|369
6016637|NCT00153062|9609800|FG003|Overall Study|Death|365
6016638|NCT00153062|9609797|FG000|Overall Study|Withdrawal by Subject|14
6016639|NCT00153062|9609798|FG001|Overall Study|Withdrawal by Subject|30
6016640|NCT00153062|9609799|FG002|Overall Study|Withdrawal by Subject|27
6016641|NCT00153062|9609800|FG003|Overall Study|Withdrawal by Subject|28
6016642|NCT00153062|9609797|FG000|Overall Study|Lost to Follow-up|12
6016643|NCT00153062|9609798|FG001|Overall Study|Lost to Follow-up|20
6016644|NCT00153062|9609799|FG002|Overall Study|Lost to Follow-up|15
6016645|NCT00153062|9609800|FG003|Overall Study|Lost to Follow-up|16
6016646|NCT00153062|9609797|FG000|Overall Study|Adverse Event|0
6016647|NCT00153062|9609798|FG001|Overall Study|Adverse Event|1
6016648|NCT00153062|9609799|FG002|Overall Study|Adverse Event|1
6016649|NCT00153062|9609800|FG003|Overall Study|Adverse Event|0
6016650|NCT00153062|9609797|FG000|Overall Study|Protocol Violation|0
6016651|NCT00153062|9609798|FG001|Overall Study|Protocol Violation|2
6016652|NCT00153062|9609799|FG002|Overall Study|Protocol Violation|1
6016653|NCT00153062|9609800|FG003|Overall Study|Protocol Violation|1
6016654|NCT00153062|9609797|FG000|Overall Study|No disposition data available|1
6016655|NCT00153062|9609798|FG001|Overall Study|No disposition data available|1
6016656|NCT00153062|9609799|FG002|Overall Study|No disposition data available|1
6016657|NCT00153062|9609800|FG003|Overall Study|No disposition data available|1
6016658|NCT00153062|9609797|FG000|Overall Study|Other|0
6016659|NCT00153062|9609798|FG001|Overall Study|Other|0
6016660|NCT00153062|9609799|FG002|Overall Study|Other|1
6016661|NCT00153062|9609800|FG003|Overall Study|Other|0
6016662|NCT00153101|9609815|FG000|Overall Study|Lost to Follow-up|14
6016663|NCT00153101|9609816|FG001|Overall Study|Lost to Follow-up|14
6016664|NCT00153101|9609817|FG002|Overall Study|Lost to Follow-up|12
6016665|NCT00153101|9609818|FG003|Overall Study|Lost to Follow-up|5
6016666|NCT00153101|9609819|FG004|Overall Study|Lost to Follow-up|5
6016667|NCT00153101|9609815|FG000|Overall Study|Withdrawal by Subject|3
6016668|NCT00153101|9609816|FG001|Overall Study|Withdrawal by Subject|4
6016669|NCT00153101|9609817|FG002|Overall Study|Withdrawal by Subject|3
6016670|NCT00153101|9609818|FG003|Overall Study|Withdrawal by Subject|3
6016671|NCT00153101|9609819|FG004|Overall Study|Withdrawal by Subject|5
6016672|NCT00153179|9609849|FG000|Study Visit Day 2|Withdrawal by Subject|1
6016673|NCT00153179|9609850|FG001|Study Visit Day 2|Withdrawal by Subject|0
6016674|NCT00153179|9609851|FG002|Study Visit Day 2|Withdrawal by Subject|2
6016675|NCT00153179|9609852|FG003|Study Visit Day 2|Withdrawal by Subject|2
6016676|NCT00153816|9609878|FG000|Overall Study|Death|6
6016677|NCT00153816|9609879|FG001|Overall Study|Death|5
6016678|NCT00153816|9609880|FG002|Overall Study|Death|4
6016679|NCT00153816|9609881|FG003|Overall Study|Death|6
6016680|NCT00153816|9609882|FG004|Overall Study|Death|0
6016681|NCT00153816|9609883|FG005|Overall Study|Death|2
6016682|NCT00153816|9609878|FG000|Overall Study|Lost to Follow-up|7
6016683|NCT00153816|9609879|FG001|Overall Study|Lost to Follow-up|8
6016684|NCT00153816|9609880|FG002|Overall Study|Lost to Follow-up|5
6016685|NCT00153816|9609881|FG003|Overall Study|Lost to Follow-up|8
6016686|NCT00153816|9609882|FG004|Overall Study|Lost to Follow-up|7
6016687|NCT00153816|9609883|FG005|Overall Study|Lost to Follow-up|9
6016688|NCT00153816|9609878|FG000|Overall Study|Withdrawal by Subject|9
6016689|NCT00153816|9609879|FG001|Overall Study|Withdrawal by Subject|9
6016690|NCT00153816|9609880|FG002|Overall Study|Withdrawal by Subject|9
6016691|NCT00153816|9609881|FG003|Overall Study|Withdrawal by Subject|4
6016692|NCT00153816|9609882|FG004|Overall Study|Withdrawal by Subject|1
6016693|NCT00153816|9609883|FG005|Overall Study|Withdrawal by Subject|5
6016694|NCT00153816|9609878|FG000|Overall Study|Follow-up exam not done|8
6016695|NCT00153816|9609879|FG001|Overall Study|Follow-up exam not done|7
6016696|NCT00153816|9609880|FG002|Overall Study|Follow-up exam not done|11
6016697|NCT00153816|9609881|FG003|Overall Study|Follow-up exam not done|10
6016698|NCT00153816|9609882|FG004|Overall Study|Follow-up exam not done|8
6016699|NCT00153816|9609883|FG005|Overall Study|Follow-up exam not done|9
6016700|NCT00153816|9609878|FG000|Overall Study|Follow-up exam done, histology missing|2
6016701|NCT00153816|9609879|FG001|Overall Study|Follow-up exam done, histology missing|3
6016702|NCT00153816|9609880|FG002|Overall Study|Follow-up exam done, histology missing|3
6016703|NCT00153816|9609881|FG003|Overall Study|Follow-up exam done, histology missing|3
6016704|NCT00153816|9609882|FG004|Overall Study|Follow-up exam done, histology missing|1
6016705|NCT00153816|9609883|FG005|Overall Study|Follow-up exam done, histology missing|2
6016706|NCT00153920|9609908|FG000|Overall Study|Adverse Event|9
6016707|NCT00153920|9609908|FG000|Overall Study|Progressive Disease|9
6016708|NCT00153920|9609908|FG000|Overall Study|Physician Decision|3
6016709|NCT00153920|9609908|FG000|Overall Study|Lack of Response|3
6016710|NCT00153920|9609908|FG000|Overall Study|Death|2
6016711|NCT00153920|9609908|FG000|Overall Study|Withdrawal by Subject|1
6016712|NCT00153920|9609908|FG000|Overall Study|Non-Protocol Therapy|1
6016713|NCT00153920|9609908|FG000|Overall Study|Withdrawal of Consent before Trt|1
6016714|NCT00153920|9609908|FG000|Overall Study|Progressive Disease before Trt|1
6016715|NCT00154063|9609918|FG000|Overall Study|Adverse Event|4
6016716|NCT00154063|9609919|FG001|Overall Study|Adverse Event|8
6016717|NCT00154063|9609918|FG000|Overall Study|Protocol Violation|1
6016718|NCT00154063|9609919|FG001|Overall Study|Protocol Violation|1
6016719|NCT00154063|9609918|FG000|Overall Study|Investigator or Sponsor Request|0
6016720|NCT00154063|9609919|FG001|Overall Study|Investigator or Sponsor Request|1
6016721|NCT00154063|9609918|FG000|Overall Study|Withdrawal by Subject|4
6016722|NCT00154063|9609919|FG001|Overall Study|Withdrawal by Subject|9
6016723|NCT00154063|9609918|FG000|Overall Study|Other|3
6016724|NCT00154063|9609919|FG001|Overall Study|Other|3
6016725|NCT00154102|9609931|FG000|Overall Study|investigational study phase ongoing|7
6016726|NCT00154102|9609932|FG001|Overall Study|investigational study phase ongoing|2
6016727|NCT00154284|9609940|FG000|Overall Study|Adverse Event|6
6016728|NCT00154284|9609941|FG001|Overall Study|Adverse Event|9
6016729|NCT00154284|9609940|FG000|Overall Study|Abnormal laboratory value(s)|0
6016730|NCT00154284|9609941|FG001|Overall Study|Abnormal laboratory value(s)|1
6016731|NCT00154284|9609940|FG000|Overall Study|Lack of Efficacy|1
6016732|NCT00154284|9609941|FG001|Overall Study|Lack of Efficacy|2
6016733|NCT00154284|9609940|FG000|Overall Study|Protocol Violation|0
6016734|NCT00154284|9609941|FG001|Overall Study|Protocol Violation|1
6016735|NCT00154297|9609951|FG000|Overall Study|Death|5
6016736|NCT00154297|9609952|FG001|Overall Study|Death|2
6016737|NCT00154297|9609951|FG000|Overall Study|Withdrawal by Subject|0
6016738|NCT00154297|9609952|FG001|Overall Study|Withdrawal by Subject|5
6016739|NCT00154297|9609951|FG000|Overall Study|Lost to Follow-up|3
6016740|NCT00154297|9609952|FG001|Overall Study|Lost to Follow-up|0
6016741|NCT00154310|9609960|FG000|Overall Study|Adverse Event|19
6016742|NCT00154310|9609961|FG001|Overall Study|Adverse Event|9
6016743|NCT00154310|9609960|FG000|Overall Study|Lack of Efficacy|5
6016744|NCT00154310|9609961|FG001|Overall Study|Lack of Efficacy|4
6016745|NCT00154310|9609960|FG000|Overall Study|Protocol Violation|4
6016746|NCT00154310|9609961|FG001|Overall Study|Protocol Violation|2
6016747|NCT00154310|9609960|FG000|Overall Study|Withdrawal by Subject|9
6016748|NCT00154310|9609961|FG001|Overall Study|Withdrawal by Subject|3
6016749|NCT00154310|9609960|FG000|Overall Study|Lost to Follow-up|0
6016750|NCT00154310|9609961|FG001|Overall Study|Lost to Follow-up|8
6016751|NCT00154310|9609960|FG000|Overall Study|Administrative problems|0
6016752|NCT00154310|9609961|FG001|Overall Study|Administrative problems|1
6016753|NCT00154310|9609960|FG000|Overall Study|Death|0
6016754|NCT00154310|9609961|FG001|Overall Study|Death|1
6016755|NCT00154375|9609969|FG000|Overall Study|Unsatisfactory therapeutic effect|25
6016756|NCT00154375|9609970|FG001|Overall Study|Unsatisfactory therapeutic effect|26
6016757|NCT00154375|9609969|FG000|Overall Study|Adverse Event|18
6016758|NCT00154375|9609970|FG001|Overall Study|Adverse Event|20
6016759|NCT00154375|9609969|FG000|Overall Study|Withdrawal by Subject|14
6016760|NCT00154375|9609970|FG001|Overall Study|Withdrawal by Subject|10
6016761|NCT00154375|9609969|FG000|Overall Study|Death|5
6016762|NCT00154375|9609970|FG001|Overall Study|Death|13
6016763|NCT00154375|9609969|FG000|Overall Study|Study drug no longer required|5
6016764|NCT00154375|9609970|FG001|Overall Study|Study drug no longer required|3
6016765|NCT00154375|9609969|FG000|Overall Study|Lost to Follow-up|2
6016766|NCT00154375|9609970|FG001|Overall Study|Lost to Follow-up|1
6016767|NCT00154375|9609969|FG000|Overall Study|Abnormal laboratory value(s)|0
6016768|NCT00154375|9609970|FG001|Overall Study|Abnormal laboratory value(s)|2
6016769|NCT00154375|9609969|FG000|Overall Study|Protocol Violation|0
6016770|NCT00154375|9609970|FG001|Overall Study|Protocol Violation|1
6016771|NCT00154375|9609969|FG000|Overall Study|Suspected progression of disease|44
6016772|NCT00154375|9609970|FG001|Overall Study|Suspected progression of disease|30
6047724|NCT00413244|9646811|FG001|Overall Study|Withdrawal by Subject|1
6047725|NCT00413283|9646821|FG000|Overall Study|Withdrawal by Subject|1
6309516|NCT02640157|10038195|FG001|Overall Study|Adverse Event|2
6309517|NCT02640157|10038196|FG002|Overall Study|Adverse Event|1
6309518|NCT02640157|10038194|FG000|Overall Study|Withdrew consent|2
6309519|NCT02640157|10038195|FG001|Overall Study|Withdrew consent|0
6309520|NCT02640157|10038196|FG002|Overall Study|Withdrew consent|2
6047726|NCT00413283|9646822|FG001|Overall Study|Withdrawal by Subject|0
6047727|NCT00413283|9646823|FG002|Overall Study|Withdrawal by Subject|0
6047728|NCT00413283|9646824|FG003|Overall Study|Withdrawal by Subject|1
6047729|NCT00413283|9646821|FG000|Overall Study|Death|0
6047730|NCT00413283|9646822|FG001|Overall Study|Death|0
6047731|NCT00413283|9646823|FG002|Overall Study|Death|1
6047732|NCT00413283|9646824|FG003|Overall Study|Death|1
6047733|NCT00413283|9646821|FG000|Overall Study|Adverse Event|0
6047734|NCT00413283|9646822|FG001|Overall Study|Adverse Event|0
6047735|NCT00413283|9646823|FG002|Overall Study|Adverse Event|0
6047736|NCT00413283|9646824|FG003|Overall Study|Adverse Event|1
6047737|NCT00413283|9646821|FG000|Overall Study|Ineligibility determined|0
6047738|NCT00413283|9646822|FG001|Overall Study|Ineligibility determined|0
6047739|NCT00413283|9646823|FG002|Overall Study|Ineligibility determined|0
6047740|NCT00413283|9646824|FG003|Overall Study|Ineligibility determined|1
6047741|NCT00413283|9646821|FG000|Overall Study|Protocol deviation|0
6047742|NCT00413283|9646822|FG001|Overall Study|Protocol deviation|1
6047743|NCT00413283|9646823|FG002|Overall Study|Protocol deviation|0
6047744|NCT00413283|9646824|FG003|Overall Study|Protocol deviation|0
6047745|NCT00413283|9646821|FG000|Overall Study|Requirement for alternative therapy|0
6047746|NCT00413283|9646822|FG001|Overall Study|Requirement for alternative therapy|2
6047747|NCT00413283|9646823|FG002|Overall Study|Requirement for alternative therapy|0
6047748|NCT00413283|9646824|FG003|Overall Study|Requirement for alternative therapy|0
6047749|NCT00413283|9646821|FG000|Overall Study|Other|0
6047750|NCT00413283|9646822|FG001|Overall Study|Other|0
6047751|NCT00413283|9646823|FG002|Overall Study|Other|1
6047752|NCT00413283|9646824|FG003|Overall Study|Other|0
6047753|NCT00413374|9646845|FG000|Overall Study|Ineligible due to screening criteria.|3
6047754|NCT00413374|9646846|FG001|Overall Study|Ineligible due to screening criteria.|0
6047755|NCT00413374|9646845|FG000|Overall Study|Adverse Event|1
6047756|NCT00413374|9646846|FG001|Overall Study|Adverse Event|0
6047757|NCT00413374|9646845|FG000|Overall Study|Lost to Follow-up|1
6047758|NCT00413374|9646846|FG001|Overall Study|Lost to Follow-up|0
6047759|NCT00413374|9646845|FG000|Overall Study|Surgery|1
6047760|NCT00413374|9646846|FG001|Overall Study|Surgery|0
6047761|NCT00413413|9646867|FG000|Single-Blind|Adverse Event|0
6047762|NCT00413413|9646868|FG001|Single-Blind|Adverse Event|9
6047763|NCT00413413|9646869|FG002|Single-Blind|Adverse Event|0
6047764|NCT00413413|9646867|FG000|Single-Blind|Lack of Efficacy|0
6047765|NCT00413413|9646868|FG001|Single-Blind|Lack of Efficacy|5
6047766|NCT00413413|9646869|FG002|Single-Blind|Lack of Efficacy|0
6047767|NCT00413413|9646867|FG000|Single-Blind|Subject no longer requires study drug|0
6047768|NCT00413413|9646868|FG001|Single-Blind|Subject no longer requires study drug|151
6047769|NCT00413413|9646869|FG002|Single-Blind|Subject no longer requires study drug|0
6047770|NCT00413413|9646867|FG000|Single-Blind|Protocol Violation|0
6047771|NCT00413413|9646868|FG001|Single-Blind|Protocol Violation|16
6047772|NCT00413413|9646869|FG002|Single-Blind|Protocol Violation|0
6047773|NCT00413413|9646867|FG000|Single-Blind|Withdrawal by Subject|0
6047774|NCT00413413|9646868|FG001|Single-Blind|Withdrawal by Subject|27
6047775|NCT00413413|9646869|FG002|Single-Blind|Withdrawal by Subject|0
6047776|NCT00413413|9646867|FG000|Single-Blind|Lost to Follow-up|0
6047777|NCT00413413|9646868|FG001|Single-Blind|Lost to Follow-up|8
6047778|NCT00413413|9646869|FG002|Single-Blind|Lost to Follow-up|0
6047779|NCT00413413|9646867|FG000|Double-Blind|Adverse Event|6
6047780|NCT00413413|9646868|FG001|Double-Blind|Adverse Event|0
6047781|NCT00413413|9646869|FG002|Double-Blind|Adverse Event|5
6047782|NCT00413413|9646867|FG000|Double-Blind|Unsatisfactory therapeutic effect|1
6047783|NCT00413413|9646868|FG001|Double-Blind|Unsatisfactory therapeutic effect|2
6047784|NCT00413413|9646869|FG002|Double-Blind|Unsatisfactory therapeutic effect|1
6047785|NCT00413413|9646867|FG000|Double-Blind|Protocol deviation|1
6309521|NCT02640157|10038194|FG000|Overall Study|Lost to Follow-up|9
6047786|NCT00413413|9646868|FG001|Double-Blind|Protocol deviation|2
6047787|NCT00413413|9646869|FG002|Double-Blind|Protocol deviation|1
6047788|NCT00413413|9646867|FG000|Double-Blind|Subject withdrew consent|4
6047789|NCT00413413|9646868|FG001|Double-Blind|Subject withdrew consent|6
6047790|NCT00413413|9646869|FG002|Double-Blind|Subject withdrew consent|9
6047791|NCT00413413|9646867|FG000|Double-Blind|Lost to Follow-up|3
6309522|NCT02640157|10038195|FG001|Overall Study|Lost to Follow-up|2
6047792|NCT00413413|9646868|FG001|Double-Blind|Lost to Follow-up|4
6016773|NCT00156533|9610016|FG000|Overall Study|Withdrawn - Medication Expiration|0
6016774|NCT00156533|9610017|FG001|Overall Study|Withdrawn - Medication Expiration|2
6016775|NCT00156533|9610018|FG002|Overall Study|Withdrawn - Medication Expiration|1
6016776|NCT00156533|9610019|FG003|Overall Study|Withdrawn - Medication Expiration|0
6016777|NCT00156533|9610016|FG000|Overall Study|Withdrawal by Subject|1
6016778|NCT00156533|9610017|FG001|Overall Study|Withdrawal by Subject|0
6016779|NCT00156533|9610018|FG002|Overall Study|Withdrawal by Subject|0
6016780|NCT00156533|9610019|FG003|Overall Study|Withdrawal by Subject|1
6076779|NCT00593333|9682559|FG000|Overall Study|Lost to Follow-up|10
6076780|NCT00593333|9682560|FG001|Overall Study|Lost to Follow-up|11
6076781|NCT00593385|9682580|FG000|Overall Study|Death|14
6016781|NCT00156533|9610016|FG000|Overall Study|Failed Screening|1
6016782|NCT00156533|9610017|FG001|Overall Study|Failed Screening|0
6076782|NCT00593385|9682580|FG000|Overall Study|Lost to Follow-up|17
6076783|NCT00593385|9682580|FG000|Overall Study|Withdrawal by Subject|9
6076784|NCT00593489|9682605|FG000|Allocation|did not attend workshop; allocation not|2
6076785|NCT00593489|9682606|FG001|Allocation|did not attend workshop; allocation not|1
6076786|NCT00593554|9682616|FG000|Overall Study|Death|1
6076787|NCT00593554|9682617|FG001|Overall Study|Death|2
6016783|NCT00156533|9610018|FG002|Overall Study|Failed Screening|1
6016784|NCT00156533|9610019|FG003|Overall Study|Failed Screening|1
6016785|NCT00156819|9610038|FG000|Overall Study|Lost to Follow-up|1
6016786|NCT00156819|9610039|FG001|Overall Study|Lost to Follow-up|1
6016787|NCT00156819|9610040|FG002|Overall Study|Lost to Follow-up|3
6016788|NCT00157014|9610079|FG000|Overall Study|Death|4
6016789|NCT00157014|9610080|FG001|Overall Study|Death|2
6016790|NCT00157014|9610081|FG002|Overall Study|Death|1
6016791|NCT00157014|9610082|FG003|Overall Study|Death|1
6016792|NCT00157014|9610079|FG000|Overall Study|Physician Decision|0
6016793|NCT00157014|9610080|FG001|Overall Study|Physician Decision|1
6076788|NCT00593554|9682616|FG000|Overall Study|Physician Decision|0
6076789|NCT00593554|9682617|FG001|Overall Study|Physician Decision|1
6076790|NCT00593554|9682616|FG000|Overall Study|Withdrawal by Subject|1
6076791|NCT00593554|9682617|FG001|Overall Study|Withdrawal by Subject|0
6076792|NCT00593554|9682616|FG000|Overall Study|Disease Progression|1
6076793|NCT00593554|9682617|FG001|Overall Study|Disease Progression|2
6076794|NCT00593606|9682623|FG000|Overall Study|Adverse Event|13
6076795|NCT00593606|9682623|FG000|Overall Study|Withdrawal by Subject|1
6076796|NCT00593606|9682623|FG000|Overall Study|Protocol Violation|3
6076797|NCT00593606|9682623|FG000|Overall Study|Lost to Follow-up|2
6076798|NCT00593606|9682623|FG000|Overall Study|Run-In Failure|5
6076799|NCT00593606|9682623|FG000|Overall Study|Screen Failure|3
6076800|NCT00593684|9682633|FG000|Overall Study|Death|2
6076801|NCT00593684|9682634|FG001|Overall Study|Death|1
6076802|NCT00593736|9682644|FG000|Screening Period and Placebo Run-in|Adverse Event|0
6076803|NCT00593736|9682645|FG001|Screening Period and Placebo Run-in|Adverse Event|0
6076804|NCT00593736|9682646|FG002|Screening Period and Placebo Run-in|Adverse Event|0
6076805|NCT00593736|9682647|FG003|Screening Period and Placebo Run-in|Adverse Event|3
6076806|NCT00593736|9682644|FG000|Screening Period and Placebo Run-in|Lost to Follow-up|0
6076807|NCT00593736|9682645|FG001|Screening Period and Placebo Run-in|Lost to Follow-up|0
6076808|NCT00593736|9682646|FG002|Screening Period and Placebo Run-in|Lost to Follow-up|0
6076809|NCT00593736|9682647|FG003|Screening Period and Placebo Run-in|Lost to Follow-up|9
6076810|NCT00593736|9682644|FG000|Screening Period and Placebo Run-in|Withdrawal by Subject|0
6076811|NCT00593736|9682645|FG001|Screening Period and Placebo Run-in|Withdrawal by Subject|0
6076812|NCT00593736|9682646|FG002|Screening Period and Placebo Run-in|Withdrawal by Subject|0
6076813|NCT00593736|9682647|FG003|Screening Period and Placebo Run-in|Withdrawal by Subject|43
6076814|NCT00593736|9682644|FG000|Screening Period and Placebo Run-in|Study Termination|0
6076815|NCT00593736|9682645|FG001|Screening Period and Placebo Run-in|Study Termination|0
6076816|NCT00593736|9682646|FG002|Screening Period and Placebo Run-in|Study Termination|0
6076817|NCT00593736|9682647|FG003|Screening Period and Placebo Run-in|Study Termination|15
6076818|NCT00593736|9682644|FG000|Screening Period and Placebo Run-in|Did Not Meet Criteria|0
6076819|NCT00593736|9682645|FG001|Screening Period and Placebo Run-in|Did Not Meet Criteria|0
6076820|NCT00593736|9682646|FG002|Screening Period and Placebo Run-in|Did Not Meet Criteria|0
6076821|NCT00593736|9682647|FG003|Screening Period and Placebo Run-in|Did Not Meet Criteria|322
6076822|NCT00593736|9682644|FG000|Screening Period and Placebo Run-in|Various|0
6076823|NCT00593736|9682645|FG001|Screening Period and Placebo Run-in|Various|0
6076824|NCT00593736|9682646|FG002|Screening Period and Placebo Run-in|Various|0
6076825|NCT00593736|9682647|FG003|Screening Period and Placebo Run-in|Various|25
6076826|NCT00593736|9682644|FG000|Treatment Period and Placebo Run-out|Lost to Follow-up|2
6076827|NCT00593736|9682645|FG001|Treatment Period and Placebo Run-out|Lost to Follow-up|1
6076828|NCT00593736|9682646|FG002|Treatment Period and Placebo Run-out|Lost to Follow-up|2
6076829|NCT00593736|9682647|FG003|Treatment Period and Placebo Run-out|Lost to Follow-up|0
6076830|NCT00593736|9682644|FG000|Treatment Period and Placebo Run-out|Protocol Violation|0
6076831|NCT00593736|9682645|FG001|Treatment Period and Placebo Run-out|Protocol Violation|0
6076832|NCT00593736|9682646|FG002|Treatment Period and Placebo Run-out|Protocol Violation|1
6076833|NCT00593736|9682647|FG003|Treatment Period and Placebo Run-out|Protocol Violation|1
6076834|NCT00593736|9682644|FG000|Treatment Period and Placebo Run-out|Withdrawal by Subject|0
6016794|NCT00157014|9610081|FG002|Overall Study|Physician Decision|0
6016795|NCT00157014|9610082|FG003|Overall Study|Physician Decision|0
6016796|NCT00157014|9610079|FG000|Overall Study|Medications withdrawn on family request|0
6016797|NCT00157014|9610080|FG001|Overall Study|Medications withdrawn on family request|1
6016798|NCT00157014|9610081|FG002|Overall Study|Medications withdrawn on family request|0
6016799|NCT00157014|9610082|FG003|Overall Study|Medications withdrawn on family request|0
6016800|NCT00157014|9610079|FG000|Overall Study|Patient withdrawn by investigator|1
6016801|NCT00157014|9610080|FG001|Overall Study|Patient withdrawn by investigator|0
6016802|NCT00157014|9610081|FG002|Overall Study|Patient withdrawn by investigator|0
6016803|NCT00157014|9610082|FG003|Overall Study|Patient withdrawn by investigator|0
6016804|NCT00157014|9610079|FG000|Overall Study|Patient unable to return in nursing home|1
6016805|NCT00157014|9610080|FG001|Overall Study|Patient unable to return in nursing home|0
6016806|NCT00157014|9610081|FG002|Overall Study|Patient unable to return in nursing home|0
6016807|NCT00157014|9610082|FG003|Overall Study|Patient unable to return in nursing home|0
6016808|NCT00157014|9610079|FG000|Overall Study|Patient would not receive transplant|0
6016809|NCT00157014|9610080|FG001|Overall Study|Patient would not receive transplant|1
6016810|NCT00157014|9610081|FG002|Overall Study|Patient would not receive transplant|0
6016811|NCT00157014|9610082|FG003|Overall Study|Patient would not receive transplant|0
6016812|NCT00157014|9610079|FG000|Overall Study|Withdrawal by Subject|1
6016813|NCT00157014|9610080|FG001|Overall Study|Withdrawal by Subject|0
6016814|NCT00157014|9610081|FG002|Overall Study|Withdrawal by Subject|0
6016815|NCT00157014|9610082|FG003|Overall Study|Withdrawal by Subject|0
6016816|NCT00157157|9610092|FG000|Overall Study|Withdrawal by Subject|6
6016817|NCT00157157|9610092|FG000|Overall Study|Physician Decision|1
6016818|NCT00157157|9610092|FG000|Overall Study|Lost to Follow-up|1
6016819|NCT00157157|9610092|FG000|Overall Study|Enrolled in another study|1
6016820|NCT00157157|9610092|FG000|Overall Study|Met exclusion criteria|1
6016821|NCT00157157|9610092|FG000|Overall Study|Inclusion not met- baseline FVIII value|1
6016822|NCT00157196|9610103|FG000|Overall Study|Ongoing at data cut-off|9
6016823|NCT00157209|9610109|FG000|Overall Study|Ongoing at data cut-off|10
6016824|NCT00157209|9610110|FG001|Overall Study|Ongoing at data cut-off|0
6016825|NCT00157248|9610120|FG000|Overall Study|Adverse Event|36
6016826|NCT00157248|9610121|FG001|Overall Study|Adverse Event|25
6016827|NCT00157248|9610122|FG002|Overall Study|Adverse Event|13
6016828|NCT00157248|9610123|FG003|Overall Study|Adverse Event|33
6016829|NCT00157248|9610120|FG000|Overall Study|Protocol Violation|4
6016830|NCT00157248|9610121|FG001|Overall Study|Protocol Violation|0
6016831|NCT00157248|9610122|FG002|Overall Study|Protocol Violation|2
6016832|NCT00157248|9610123|FG003|Overall Study|Protocol Violation|2
6016833|NCT00157248|9610120|FG000|Overall Study|Lost to Follow-up|0
6016834|NCT00157248|9610121|FG001|Overall Study|Lost to Follow-up|1
6016835|NCT00157248|9610122|FG002|Overall Study|Lost to Follow-up|0
6016836|NCT00157248|9610123|FG003|Overall Study|Lost to Follow-up|0
6016837|NCT00157248|9610120|FG000|Overall Study|Withdrawal by Subject|1
6016838|NCT00157248|9610121|FG001|Overall Study|Withdrawal by Subject|4
6016839|NCT00157248|9610122|FG002|Overall Study|Withdrawal by Subject|3
6016840|NCT00157248|9610123|FG003|Overall Study|Withdrawal by Subject|3
6016841|NCT00157248|9610120|FG000|Overall Study|site closures, subject moving|7
6016842|NCT00157248|9610121|FG001|Overall Study|site closures, subject moving|7
6016843|NCT00157248|9610122|FG002|Overall Study|site closures, subject moving|3
6076835|NCT00593736|9682645|FG001|Treatment Period and Placebo Run-out|Withdrawal by Subject|0
6146260|NCT01076010|9780832|FG000|Overall Study|Noncompliance|1
6146261|NCT01076010|9780833|FG001|Overall Study|Noncompliance|1
6146262|NCT01076010|9780834|FG002|Overall Study|Noncompliance|0
6146263|NCT01076010|9780832|FG000|Overall Study|Withdrawal by Subject|3
6146264|NCT01076010|9780833|FG001|Overall Study|Withdrawal by Subject|0
6146265|NCT01076010|9780834|FG002|Overall Study|Withdrawal by Subject|1
6146266|NCT01076010|9780832|FG000|Overall Study|Other|5
6016844|NCT00157248|9610123|FG003|Overall Study|site closures, subject moving|9
6016845|NCT00157755|9610145|FG000|Overall Study|Death|2
6016846|NCT00157755|9610146|FG001|Overall Study|Death|3
6016847|NCT00157755|9610147|FG002|Overall Study|Death|3
6016848|NCT00157755|9610148|FG003|Overall Study|Death|2
6016849|NCT00157755|9610149|FG004|Overall Study|Death|0
6016850|NCT00157755|9610150|FG005|Overall Study|Death|0
6016851|NCT00157755|9610145|FG000|Overall Study|Lost to Follow-up|0
6016852|NCT00157755|9610146|FG001|Overall Study|Lost to Follow-up|0
6016853|NCT00157755|9610147|FG002|Overall Study|Lost to Follow-up|1
6016854|NCT00157755|9610148|FG003|Overall Study|Lost to Follow-up|0
6016855|NCT00157755|9610149|FG004|Overall Study|Lost to Follow-up|0
6016856|NCT00157755|9610150|FG005|Overall Study|Lost to Follow-up|0
6016857|NCT00157755|9610145|FG000|Overall Study|Withdrawal by Subject|0
6016858|NCT00157755|9610146|FG001|Overall Study|Withdrawal by Subject|0
6016859|NCT00157755|9610147|FG002|Overall Study|Withdrawal by Subject|1
6016860|NCT00157755|9610148|FG003|Overall Study|Withdrawal by Subject|1
6016861|NCT00157755|9610149|FG004|Overall Study|Withdrawal by Subject|1
6146267|NCT01076010|9780833|FG001|Overall Study|Other|2
6146268|NCT01076010|9780834|FG002|Overall Study|Other|0
6016862|NCT00157755|9610150|FG005|Overall Study|Withdrawal by Subject|2
6016863|NCT00157755|9610145|FG000|Overall Study|Explant due to infection|0
6016864|NCT00157755|9610146|FG001|Overall Study|Explant due to infection|0
6016865|NCT00157755|9610147|FG002|Overall Study|Explant due to infection|1
6016866|NCT00157755|9610148|FG003|Overall Study|Explant due to infection|0
6076836|NCT00593736|9682646|FG002|Treatment Period and Placebo Run-out|Withdrawal by Subject|1
6076837|NCT00593736|9682647|FG003|Treatment Period and Placebo Run-out|Withdrawal by Subject|3
6076838|NCT00593736|9682644|FG000|Treatment Period and Placebo Run-out|Various|1
6076839|NCT00593736|9682645|FG001|Treatment Period and Placebo Run-out|Various|1
6076840|NCT00593736|9682646|FG002|Treatment Period and Placebo Run-out|Various|1
6076841|NCT00593736|9682647|FG003|Treatment Period and Placebo Run-out|Various|0
6076842|NCT00593814|9682659|FG000|Overall Study|Death|7
6076843|NCT00593814|9682660|FG001|Overall Study|Death|0
6076844|NCT00593814|9682659|FG000|Overall Study|Withdrawal by Subject|7
6076845|NCT00593814|9682660|FG001|Overall Study|Withdrawal by Subject|0
6076846|NCT00593814|9682659|FG000|Overall Study|Lost to Follow-up|7
6076847|NCT00593814|9682660|FG001|Overall Study|Lost to Follow-up|0
6076848|NCT00593814|9682659|FG000|Overall Study|Physician Decision|3
6076849|NCT00593814|9682660|FG001|Overall Study|Physician Decision|0
6076850|NCT00593827|9682668|FG000|Overall Study|On Active Treatment/Pending|0
6076851|NCT00593827|9682669|FG001|Overall Study|On Active Treatment/Pending|2
6076852|NCT00593840|9682675|FG000|Overall Study|Withdrawal by Subject|1
6076853|NCT00593918|9682685|FG000|Overall Study|Withdrawal by Subject|5
6076854|NCT00593918|9682686|FG001|Overall Study|Withdrawal by Subject|24
6076855|NCT00593957|9682695|FG000|Overall Study|Physician Decision|0
6076856|NCT00593957|9682696|FG001|Overall Study|Physician Decision|1
6076857|NCT00593957|9682697|FG002|Overall Study|Physician Decision|2
6076858|NCT00594035|9682734|FG000|Overall Study|Lost to Follow-up|1
6076859|NCT00594035|9682735|FG001|Overall Study|Lost to Follow-up|1
6076860|NCT00594035|9682734|FG000|Overall Study|Withdrawal by Subject|1
6016867|NCT00157755|9610149|FG004|Overall Study|Explant due to infection|0
6016868|NCT00157755|9610150|FG005|Overall Study|Explant due to infection|0
6016869|NCT00157755|9610145|FG000|Overall Study|Medical reason|0
6016870|NCT00157755|9610146|FG001|Overall Study|Medical reason|0
6016871|NCT00157755|9610147|FG002|Overall Study|Medical reason|1
6016872|NCT00157755|9610148|FG003|Overall Study|Medical reason|1
6016873|NCT00157755|9610149|FG004|Overall Study|Medical reason|0
6016874|NCT00157755|9610150|FG005|Overall Study|Medical reason|0
6016875|NCT00157755|9610145|FG000|Overall Study|Study site closure|0
6016876|NCT00157755|9610146|FG001|Overall Study|Study site closure|1
6016877|NCT00157755|9610147|FG002|Overall Study|Study site closure|0
6016878|NCT00157755|9610148|FG003|Overall Study|Study site closure|0
6016879|NCT00157755|9610149|FG004|Overall Study|Study site closure|0
6016880|NCT00157755|9610150|FG005|Overall Study|Study site closure|0
6016881|NCT00157755|9610145|FG000|Overall Study|Subject non-compliance|0
6016882|NCT00157755|9610146|FG001|Overall Study|Subject non-compliance|0
6016883|NCT00157755|9610147|FG002|Overall Study|Subject non-compliance|0
6016884|NCT00157755|9610148|FG003|Overall Study|Subject non-compliance|0
6016885|NCT00157755|9610149|FG004|Overall Study|Subject non-compliance|0
6016886|NCT00157755|9610150|FG005|Overall Study|Subject non-compliance|1
6016887|NCT00157755|9610145|FG000|Overall Study|Study completion|0
6016888|NCT00157755|9610146|FG001|Overall Study|Study completion|0
6016889|NCT00157755|9610147|FG002|Overall Study|Study completion|0
6016890|NCT00157755|9610148|FG003|Overall Study|Study completion|0
6016891|NCT00157755|9610149|FG004|Overall Study|Study completion|1
6016892|NCT00157755|9610150|FG005|Overall Study|Study completion|2
6016893|NCT00157820|9610159|FG000|Randomized|Physician Decision|4
6016894|NCT00157820|9610160|FG001|Randomized|Physician Decision|2
6016895|NCT00157820|9610161|FG002|Randomized|Physician Decision|3
6016896|NCT00157820|9610159|FG000|Randomized|Withdrawal by Subject|1
6016897|NCT00157820|9610160|FG001|Randomized|Withdrawal by Subject|2
6016898|NCT00157820|9610161|FG002|Randomized|Withdrawal by Subject|3
6016899|NCT00157820|9610159|FG000|Randomized|Protocol Violation|2
6016900|NCT00157820|9610160|FG001|Randomized|Protocol Violation|1
6016901|NCT00157820|9610161|FG002|Randomized|Protocol Violation|2
6016902|NCT00157820|9610159|FG000|1st 8 Month|Death|7
6016903|NCT00157820|9610160|FG001|1st 8 Month|Death|8
6016904|NCT00157820|9610161|FG002|1st 8 Month|Death|3
6016905|NCT00157820|9610159|FG000|1st 8 Month|Lost to Follow-up|1
6016906|NCT00157820|9610160|FG001|1st 8 Month|Lost to Follow-up|2
6016907|NCT00157820|9610161|FG002|1st 8 Month|Lost to Follow-up|1
6016908|NCT00157820|9610159|FG000|1st 8 Month|Premature cross-over|0
6016909|NCT00157820|9610160|FG001|1st 8 Month|Premature cross-over|2
6016910|NCT00157820|9610161|FG002|1st 8 Month|Premature cross-over|2
6016911|NCT00157820|9610159|FG000|2nd 8 Months|Death|3
6016912|NCT00157820|9610160|FG001|2nd 8 Months|Death|1
6016913|NCT00157820|9610161|FG002|2nd 8 Months|Death|3
6016914|NCT00157820|9610159|FG000|2nd 8 Months|Lost to Follow-up|1
6016915|NCT00157820|9610160|FG001|2nd 8 Months|Lost to Follow-up|5
6016916|NCT00157820|9610161|FG002|2nd 8 Months|Lost to Follow-up|2
6016917|NCT00157820|9610159|FG000|2nd 8 Months|Premature cross-over|1
6016918|NCT00157820|9610160|FG001|2nd 8 Months|Premature cross-over|7
6016919|NCT00157820|9610161|FG002|2nd 8 Months|Premature cross-over|9
6076861|NCT00594035|9682735|FG001|Overall Study|Withdrawal by Subject|0
6076862|NCT00594035|9682734|FG000|Overall Study|Subject transferred to nursing home|0
6076863|NCT00594035|9682735|FG001|Overall Study|Subject transferred to nursing home|1
6076864|NCT00594035|9682734|FG000|Overall Study|Subject couldn't return due to job|0
6076865|NCT00594035|9682735|FG001|Overall Study|Subject couldn't return due to job|1
6016920|NCT00157950|9610172|FG000|Overall Study|Death|1
6016921|NCT00157950|9610173|FG001|Overall Study|Death|0
6016922|NCT00158054|9610181|FG000|Overall Study|Refused to continue|3
6016923|NCT00158054|9610182|FG001|Overall Study|Refused to continue|0
6016924|NCT00158054|9610181|FG000|Overall Study|Unavailable for follow up|7
6016925|NCT00158054|9610182|FG001|Overall Study|Unavailable for follow up|3
6016926|NCT00158184|9610190|FG000|Overall Study|personal issues|3
6016927|NCT00158184|9610191|FG001|Overall Study|personal issues|1
6016928|NCT00158184|9610190|FG000|Overall Study|failed for follow unit/study rules|2
6016929|NCT00158184|9610191|FG001|Overall Study|failed for follow unit/study rules|0
6016930|NCT00158184|9610190|FG000|Overall Study|Adverse Event|1
6016931|NCT00158184|9610191|FG001|Overall Study|Adverse Event|1
6016932|NCT00158262|9610236|FG000|Overall Study|Lost to Follow-up|1
6016933|NCT00158262|9610237|FG001|Overall Study|Lost to Follow-up|1
6016934|NCT00158600|9610249|FG000|Overall Study|unable to commit time to study|0
6016935|NCT00158600|9610250|FG001|Overall Study|unable to commit time to study|1
6016936|NCT00158600|9610249|FG000|Overall Study|Adverse Event|2
6016937|NCT00158600|9610250|FG001|Overall Study|Adverse Event|1
6016938|NCT00158600|9610249|FG000|Overall Study|Death|1
6016939|NCT00158600|9610250|FG001|Overall Study|Death|0
6016940|NCT00158600|9610249|FG000|Overall Study|Withdrawal by Subject|2
6016941|NCT00158600|9610250|FG001|Overall Study|Withdrawal by Subject|2
6016942|NCT00158756|9610271|FG000|Overall Study|Withdrawal by Subject|5
6016943|NCT00158756|9610272|FG001|Overall Study|Withdrawal by Subject|0
6016944|NCT00158756|9610273|FG002|Overall Study|Withdrawal by Subject|6
6016945|NCT00158756|9610274|FG003|Overall Study|Withdrawal by Subject|1
6016946|NCT00158756|9610275|FG004|Overall Study|Withdrawal by Subject|3
6016947|NCT00158756|9610271|FG000|Overall Study|Adverse Event|0
6076866|NCT00594100|9682745|FG000|Procedure|Technical Failure|9
6076867|NCT00594100|9682745|FG000|Follow-up Through 30 Days Post Procedure|Death / Reintervention / Medical Reasons|2
6076868|NCT00594100|9682745|FG000|Follow-up Through 30 Days Post Procedure|Discontinued Prior to Visit|6
6076869|NCT00594100|9682745|FG000|Follow-up Through 30 Days Post Procedure|Missed Visit - Phone Contact Follow-up|4
6076870|NCT00594165|9682749|FG000|Overall Study|Major protocol violation|1
6076871|NCT00594165|9682749|FG000|Overall Study|Lack of Efficacy|12
6076872|NCT00594165|9682749|FG000|Overall Study|Adverse Event|52
6076873|NCT00594165|9682749|FG000|Overall Study|Unsatisfactory compliance of subject|6
6076874|NCT00594165|9682749|FG000|Overall Study|Subject withdrew consent|27
6076875|NCT00594165|9682749|FG000|Overall Study|Study ended per sponsor|102
6076876|NCT00594165|9682749|FG000|Overall Study|Lost to Follow-up|4
6076877|NCT00594165|9682749|FG000|Overall Study|Other: PI discretion|5
6076878|NCT00594165|9682749|FG000|Overall Study|Other: Subject moving|3
6076879|NCT00594165|9682749|FG000|Overall Study|Other: Brain surgery controlled symptoms|1
6076880|NCT00594165|9682749|FG000|Overall Study|Other: House bound; can't get to clinic|1
6076881|NCT00594165|9682749|FG000|Overall Study|Other: Subject enrolled in other trial|1
6076882|NCT00594165|9682749|FG000|Overall Study|Other: Site terminated participation|2
6076883|NCT00594178|9682753|FG000|Overall Study|Physician Decision|5
6076884|NCT00594204|9682759|FG000|Overall Study|Adverse Event|15
6076885|NCT00594204|9682760|FG001|Overall Study|Adverse Event|3
6076886|NCT00594204|9682759|FG000|Overall Study|Lost to Follow-up|9
6076887|NCT00594204|9682760|FG001|Overall Study|Lost to Follow-up|5
6076888|NCT00594204|9682759|FG000|Overall Study|Withdrawal by Subject|23
6076889|NCT00594204|9682760|FG001|Overall Study|Withdrawal by Subject|29
6076890|NCT00594204|9682759|FG000|Overall Study|Other|4
6076891|NCT00594204|9682760|FG001|Overall Study|Other|3
6076892|NCT00594204|9682759|FG000|Overall Study|Lack of Efficacy|3
6076893|NCT00594204|9682760|FG001|Overall Study|Lack of Efficacy|4
6076894|NCT00594204|9682759|FG000|Overall Study|Randomized but not treated|4
6076895|NCT00594204|9682760|FG001|Overall Study|Randomized but not treated|1
6076896|NCT00594386|9682784|FG000|Overall Study|Major protocol violation|2
6076897|NCT00594386|9682784|FG000|Overall Study|Lack of Efficacy|12
6076898|NCT00594386|9682784|FG000|Overall Study|Adverse Event|68
6076899|NCT00594386|9682784|FG000|Overall Study|Unsatisfactory compliance of subject|11
6076900|NCT00594386|9682784|FG000|Overall Study|Subject withdrew consent|35
6076901|NCT00594386|9682784|FG000|Overall Study|Study ended per sponsor|115
6076902|NCT00594386|9682784|FG000|Overall Study|Lost to Follow-up|6
6076903|NCT00594386|9682784|FG000|Overall Study|Other: Patient went off patch (hospital)|1
6076904|NCT00594386|9682784|FG000|Overall Study|Other: Subject moved to Seattle|1
6076905|NCT00594386|9682784|FG000|Overall Study|Other: Subject admitted to nursing home|1
6076906|NCT00594386|9682784|FG000|Overall Study|Other: Study terminated per investigator|2
6076907|NCT00594386|9682784|FG000|Overall Study|Other: Sponsor closure of study|1
6076908|NCT00594386|9682784|FG000|Overall Study|Other: Site terminated participation|1
6076909|NCT00594386|9682784|FG000|Overall Study|Other: Patient wants prescription Neupro|1
6076910|NCT00594386|9682784|FG000|Overall Study|Other: Loss of drivers license|1
6076911|NCT00594399|9682790|FG000|Initial 3 Month Counseling|Not ready to exercise|1
6076912|NCT00594399|9682791|FG001|Initial 3 Month Counseling|Not ready to exercise|0
6076913|NCT00594399|9682792|FG002|Initial 3 Month Counseling|Not ready to exercise|0
6076914|NCT00594399|9682790|FG000|Initial 3 Month Counseling|Lack of Interest|3
6076915|NCT00594399|9682791|FG001|Initial 3 Month Counseling|Lack of Interest|3
6016948|NCT00158756|9610272|FG001|Overall Study|Adverse Event|0
6076916|NCT00594399|9682792|FG002|Initial 3 Month Counseling|Lack of Interest|0
6076917|NCT00594399|9682790|FG000|Initial 3 Month Counseling|Personal issues|2
6076918|NCT00594399|9682791|FG001|Initial 3 Month Counseling|Personal issues|0
6016949|NCT00158756|9610273|FG002|Overall Study|Adverse Event|1
6016950|NCT00158756|9610274|FG003|Overall Study|Adverse Event|0
6016951|NCT00158756|9610275|FG004|Overall Study|Adverse Event|0
6016952|NCT00158756|9610271|FG000|Overall Study|Serious adverse event|0
6016953|NCT00158756|9610272|FG001|Overall Study|Serious adverse event|0
6016954|NCT00158756|9610273|FG002|Overall Study|Serious adverse event|1
6016955|NCT00158756|9610274|FG003|Overall Study|Serious adverse event|0
6016956|NCT00158756|9610275|FG004|Overall Study|Serious adverse event|0
6016957|NCT00158860|9610289|FG000|Overall Study|Adverse Event|3
6016958|NCT00158860|9610290|FG001|Overall Study|Adverse Event|6
6016959|NCT00158860|9610289|FG000|Overall Study|Lost to Follow-up|11
6016960|NCT00158860|9610290|FG001|Overall Study|Lost to Follow-up|17
6016961|NCT00158860|9610289|FG000|Overall Study|Protocol Violation|8
6016962|NCT00158860|9610290|FG001|Overall Study|Protocol Violation|23
6016963|NCT00158860|9610289|FG000|Overall Study|Withdrawal by Subject|7
6016964|NCT00158860|9610290|FG001|Overall Study|Withdrawal by Subject|17
6016965|NCT00158860|9610289|FG000|Overall Study|MOVING OUT OF STATE|1
6016966|NCT00158860|9610290|FG001|Overall Study|MOVING OUT OF STATE|0
6016967|NCT00158860|9610289|FG000|Overall Study|Pregnancy|3
6016968|NCT00158860|9610290|FG001|Overall Study|Pregnancy|3
6016969|NCT00158860|9610289|FG000|Overall Study|SPONSOR STOPPED STUDY|2
6016970|NCT00158860|9610290|FG001|Overall Study|SPONSOR STOPPED STUDY|2
6016971|NCT00158860|9610289|FG000|Overall Study|SPONSOR REQUEST|0
6016972|NCT00158860|9610290|FG001|Overall Study|SPONSOR REQUEST|1
6016973|NCT00158860|9610289|FG000|Overall Study|Lost to Follow up but returned per GSK|0
6016974|NCT00158860|9610290|FG001|Overall Study|Lost to Follow up but returned per GSK|1
6016975|NCT00158860|9610289|FG000|Overall Study|Closed per sponsor|0
6016976|NCT00158860|9610290|FG001|Overall Study|Closed per sponsor|1
6016977|NCT00159432|9610338|FG000|Overall Study|Adverse Event|1
6016978|NCT00159432|9610338|FG000|Overall Study|Death|1
6016979|NCT00159432|9610338|FG000|Overall Study|Lack of Efficacy|8
6016980|NCT00159822|9610342|FG000|Voriconazole Treatment Period|Lack of Efficacy|3
6016981|NCT00159822|9610342|FG000|Voriconazole Treatment Period|Adverse Event|9
6016982|NCT00159822|9610342|FG000|Voriconazole Treatment Period|Death|4
6016983|NCT00159822|9610342|FG000|Voriconazole Treatment Period|Protocol Violation|2
6016984|NCT00159822|9610342|FG000|Voriconazole Treatment Period|Lost to Follow-up|2
6016985|NCT00159822|9610342|FG000|Voriconazole Treatment Period|Withdrawal by Subject|2
6016986|NCT00159822|9610342|FG000|Post-treatment Follow-up Period|Death|1
6016987|NCT00159822|9610342|FG000|Post-treatment Follow-up Period|Withdrawal by Subject|1
6016988|NCT00159822|9610342|FG000|Post-treatment Follow-up Period|Reason unspecified|1
6016989|NCT00159861|9610348|FG000|Core Study - 16 Weeks|Death|3
6016990|NCT00159861|9610349|FG001|Core Study - 16 Weeks|Death|0
6016991|NCT00159861|9610348|FG000|Core Study - 16 Weeks|Adverse Event|12
6016992|NCT00159861|9610349|FG001|Core Study - 16 Weeks|Adverse Event|6
6016993|NCT00159861|9610348|FG000|Core Study - 16 Weeks|Lack of Efficacy|2
6016994|NCT00159861|9610349|FG001|Core Study - 16 Weeks|Lack of Efficacy|3
6016995|NCT00159861|9610348|FG000|Core Study - 16 Weeks|Reason Unspecified|5
6016996|NCT00159861|9610349|FG001|Core Study - 16 Weeks|Reason Unspecified|3
6016997|NCT00159861|9610348|FG000|Core Study - 16 Weeks|Subject Defaulted|1
6016998|NCT00159861|9610349|FG001|Core Study - 16 Weeks|Subject Defaulted|0
6016999|NCT00159861|9610348|FG000|Core Study - 16 Weeks|Randomized but not Treated|2
6017000|NCT00159861|9610349|FG001|Core Study - 16 Weeks|Randomized but not Treated|0
6017001|NCT00159861|9610348|FG000|Extension Study - up to 3 Years|Death|24
6017002|NCT00159861|9610349|FG001|Extension Study - up to 3 Years|Death|28
6017003|NCT00159861|9610348|FG000|Extension Study - up to 3 Years|Adverse Event|14
6017004|NCT00159861|9610349|FG001|Extension Study - up to 3 Years|Adverse Event|14
6017005|NCT00159861|9610348|FG000|Extension Study - up to 3 Years|Lack of Efficacy|5
6017006|NCT00159861|9610349|FG001|Extension Study - up to 3 Years|Lack of Efficacy|1
6017007|NCT00159861|9610348|FG000|Extension Study - up to 3 Years|Reason Unspecified|12
6017008|NCT00159861|9610349|FG001|Extension Study - up to 3 Years|Reason Unspecified|19
6017009|NCT00159861|9610348|FG000|Extension Study - up to 3 Years|Withdrawal by Subject|7
6017010|NCT00159861|9610349|FG001|Extension Study - up to 3 Years|Withdrawal by Subject|9
6017011|NCT00159874|9610367|FG000|Overall Study|Adverse Event|2
6017012|NCT00159874|9610368|FG001|Overall Study|Adverse Event|2
6017013|NCT00159874|9610369|FG002|Overall Study|Adverse Event|5
6017014|NCT00159874|9610370|FG003|Overall Study|Adverse Event|1
6017015|NCT00159874|9610371|FG004|Overall Study|Adverse Event|1
6017016|NCT00159874|9610372|FG005|Overall Study|Adverse Event|2
6017017|NCT00159874|9610373|FG006|Overall Study|Adverse Event|0
6017018|NCT00159874|9610367|FG000|Overall Study|Does Not Meet Entrance Criteria|1
6017019|NCT00159874|9610368|FG001|Overall Study|Does Not Meet Entrance Criteria|0
6017020|NCT00159874|9610369|FG002|Overall Study|Does Not Meet Entrance Criteria|1
6017021|NCT00159874|9610370|FG003|Overall Study|Does Not Meet Entrance Criteria|0
6017022|NCT00159874|9610371|FG004|Overall Study|Does Not Meet Entrance Criteria|0
6017023|NCT00159874|9610372|FG005|Overall Study|Does Not Meet Entrance Criteria|0
6017024|NCT00159874|9610373|FG006|Overall Study|Does Not Meet Entrance Criteria|0
6017025|NCT00159874|9610367|FG000|Overall Study|Lack of Efficacy|2
6017026|NCT00159874|9610368|FG001|Overall Study|Lack of Efficacy|0
6017027|NCT00159874|9610369|FG002|Overall Study|Lack of Efficacy|1
6017028|NCT00159874|9610370|FG003|Overall Study|Lack of Efficacy|1
6017029|NCT00159874|9610371|FG004|Overall Study|Lack of Efficacy|0
6017030|NCT00159874|9610372|FG005|Overall Study|Lack of Efficacy|3
6017031|NCT00159874|9610373|FG006|Overall Study|Lack of Efficacy|0
6017032|NCT00159874|9610367|FG000|Overall Study|Lost to Follow-up|1
6017033|NCT00159874|9610368|FG001|Overall Study|Lost to Follow-up|0
6017034|NCT00159874|9610369|FG002|Overall Study|Lost to Follow-up|3
6017035|NCT00159874|9610370|FG003|Overall Study|Lost to Follow-up|0
6017036|NCT00159874|9610371|FG004|Overall Study|Lost to Follow-up|1
6017037|NCT00159874|9610372|FG005|Overall Study|Lost to Follow-up|2
6017038|NCT00159874|9610373|FG006|Overall Study|Lost to Follow-up|1
6017039|NCT00159874|9610367|FG000|Overall Study|Other|8
6017040|NCT00159874|9610368|FG001|Overall Study|Other|8
6017041|NCT00159874|9610369|FG002|Overall Study|Other|8
6017042|NCT00159874|9610370|FG003|Overall Study|Other|0
6017043|NCT00159874|9610371|FG004|Overall Study|Other|2
6017044|NCT00159874|9610372|FG005|Overall Study|Other|1
6017045|NCT00159874|9610373|FG006|Overall Study|Other|3
6017046|NCT00159874|9610367|FG000|Overall Study|Protocol Violation|0
6017047|NCT00159874|9610368|FG001|Overall Study|Protocol Violation|5
6017048|NCT00159874|9610369|FG002|Overall Study|Protocol Violation|2
6017049|NCT00159874|9610370|FG003|Overall Study|Protocol Violation|0
6017050|NCT00159874|9610371|FG004|Overall Study|Protocol Violation|0
6017051|NCT00159874|9610372|FG005|Overall Study|Protocol Violation|0
6017052|NCT00159874|9610373|FG006|Overall Study|Protocol Violation|0
6017053|NCT00159874|9610367|FG000|Overall Study|Death|3
6017054|NCT00159874|9610368|FG001|Overall Study|Death|8
6017055|NCT00159874|9610369|FG002|Overall Study|Death|15
6017056|NCT00159874|9610370|FG003|Overall Study|Death|0
6017057|NCT00159874|9610371|FG004|Overall Study|Death|1
6017058|NCT00159874|9610372|FG005|Overall Study|Death|2
6017059|NCT00159874|9610373|FG006|Overall Study|Death|0
6017060|NCT00159874|9610367|FG000|Overall Study|Withdrawal by Subject|2
6017061|NCT00159874|9610368|FG001|Overall Study|Withdrawal by Subject|6
6017062|NCT00159874|9610369|FG002|Overall Study|Withdrawal by Subject|8
6017063|NCT00159874|9610370|FG003|Overall Study|Withdrawal by Subject|4
6017064|NCT00159874|9610371|FG004|Overall Study|Withdrawal by Subject|3
6017065|NCT00159874|9610372|FG005|Overall Study|Withdrawal by Subject|2
6076919|NCT00594399|9682792|FG002|Initial 3 Month Counseling|Personal issues|0
6076920|NCT00594399|9682790|FG000|Initial 3 Month Counseling|Too busy|7
6076921|NCT00594399|9682791|FG001|Initial 3 Month Counseling|Too busy|1
6076922|NCT00594399|9682792|FG002|Initial 3 Month Counseling|Too busy|0
6076923|NCT00594399|9682790|FG000|Initial 3 Month Counseling|Pain|2
6076924|NCT00594399|9682791|FG001|Initial 3 Month Counseling|Pain|0
6076925|NCT00594399|9682792|FG002|Initial 3 Month Counseling|Pain|0
6076926|NCT00594399|9682790|FG000|Initial 3 Month Counseling|Moved|1
6076927|NCT00594399|9682791|FG001|Initial 3 Month Counseling|Moved|0
6076928|NCT00594399|9682792|FG002|Initial 3 Month Counseling|Moved|0
6076929|NCT00594399|9682790|FG000|Initial 3 Month Counseling|Family illness|1
6076930|NCT00594399|9682791|FG001|Initial 3 Month Counseling|Family illness|0
6076931|NCT00594399|9682792|FG002|Initial 3 Month Counseling|Family illness|0
6076932|NCT00594399|9682790|FG000|Rerandomization Arm 1 Only|Death|2
6076933|NCT00594399|9682791|FG001|Rerandomization Arm 1 Only|Death|1
6076934|NCT00594399|9682792|FG002|Rerandomization Arm 1 Only|Death|0
6076935|NCT00594399|9682790|FG000|Rerandomization Arm 1 Only|Withdrawal by Subject|0
6076936|NCT00594399|9682791|FG001|Rerandomization Arm 1 Only|Withdrawal by Subject|3
6017066|NCT00159874|9610373|FG006|Overall Study|Withdrawal by Subject|1
6017067|NCT00159874|9610367|FG000|Overall Study|Pregnancy|1
6017068|NCT00159874|9610368|FG001|Overall Study|Pregnancy|1
6017069|NCT00159874|9610369|FG002|Overall Study|Pregnancy|0
6017070|NCT00159874|9610370|FG003|Overall Study|Pregnancy|0
6017071|NCT00159874|9610371|FG004|Overall Study|Pregnancy|0
6017072|NCT00159874|9610372|FG005|Overall Study|Pregnancy|0
6017073|NCT00159874|9610373|FG006|Overall Study|Pregnancy|0
6017074|NCT00159913|9610393|FG000|Overall Study|Adverse Event|1
6017075|NCT00159913|9610394|FG001|Overall Study|Adverse Event|0
6017076|NCT00159913|9610395|FG002|Overall Study|Adverse Event|1
6017077|NCT00159913|9610396|FG003|Overall Study|Adverse Event|0
6017078|NCT00159913|9610393|FG000|Overall Study|Withdrawal by Subject|0
6017079|NCT00159913|9610394|FG001|Overall Study|Withdrawal by Subject|0
6017080|NCT00159913|9610395|FG002|Overall Study|Withdrawal by Subject|0
6017081|NCT00159913|9610396|FG003|Overall Study|Withdrawal by Subject|1
6017082|NCT00159913|9610393|FG000|Overall Study|Lost to Follow-up|0
6017083|NCT00159913|9610394|FG001|Overall Study|Lost to Follow-up|0
6017084|NCT00159913|9610395|FG002|Overall Study|Lost to Follow-up|0
6017085|NCT00159913|9610396|FG003|Overall Study|Lost to Follow-up|1
6017086|NCT00159913|9610393|FG000|Overall Study|Protocol Violation|1
6017087|NCT00159913|9610394|FG001|Overall Study|Protocol Violation|0
6017088|NCT00159913|9610395|FG002|Overall Study|Protocol Violation|1
6017089|NCT00159913|9610396|FG003|Overall Study|Protocol Violation|0
6017090|NCT00160199|9610419|FG000|Overall Study|Adverse Event|5
6017091|NCT00160199|9610420|FG001|Overall Study|Adverse Event|14
6017092|NCT00160199|9610419|FG000|Overall Study|Lack of Efficacy|0
6017093|NCT00160199|9610420|FG001|Overall Study|Lack of Efficacy|1
6017094|NCT00160199|9610419|FG000|Overall Study|Lost to Follow-up|7
6017095|NCT00160199|9610420|FG001|Overall Study|Lost to Follow-up|7
6017096|NCT00160199|9610419|FG000|Overall Study|Withdrawal by Subject|4
6017097|NCT00160199|9610420|FG001|Overall Study|Withdrawal by Subject|6
6076937|NCT00594399|9682792|FG002|Rerandomization Arm 1 Only|Withdrawal by Subject|0
6076938|NCT00594464|9682811|FG000|Overall Study|Withdrawal by Subject|1
6076939|NCT00594464|9682811|FG000|Overall Study|Delay in operation|2
6017098|NCT00160199|9610419|FG000|Overall Study|Administrative|0
6017099|NCT00160199|9610420|FG001|Overall Study|Administrative|1
6017100|NCT00160199|9610419|FG000|Overall Study|Protocol Violation|8
6017101|NCT00160199|9610420|FG001|Overall Study|Protocol Violation|8
6017102|NCT00160251|9610432|FG000|Prior to Amendment 2|Adverse Event|2
6017103|NCT00160251|9610433|FG001|Prior to Amendment 2|Adverse Event|1
6017104|NCT00160251|9610434|FG002|Prior to Amendment 2|Adverse Event|3
6017105|NCT00160251|9610435|FG003|Prior to Amendment 2|Adverse Event|1
6017106|NCT00160251|9610436|FG004|Prior to Amendment 2|Adverse Event|1
6017107|NCT00160251|9610437|FG005|Prior to Amendment 2|Adverse Event|1
6017108|NCT00160251|9610438|FG006|Prior to Amendment 2|Adverse Event|1
6017109|NCT00160251|9610439|FG007|Prior to Amendment 2|Adverse Event|0
6017110|NCT00160251|9610432|FG000|Prior to Amendment 2|Lack of Efficacy|0
6017111|NCT00160251|9610433|FG001|Prior to Amendment 2|Lack of Efficacy|4
6017112|NCT00160251|9610434|FG002|Prior to Amendment 2|Lack of Efficacy|37
6017113|NCT00160251|9610435|FG003|Prior to Amendment 2|Lack of Efficacy|35
6017114|NCT00160251|9610436|FG004|Prior to Amendment 2|Lack of Efficacy|24
6017115|NCT00160251|9610437|FG005|Prior to Amendment 2|Lack of Efficacy|55
6017116|NCT00160251|9610438|FG006|Prior to Amendment 2|Lack of Efficacy|0
6017117|NCT00160251|9610439|FG007|Prior to Amendment 2|Lack of Efficacy|0
6017118|NCT00160251|9610432|FG000|Prior to Amendment 2|Lost to Follow-up|0
6017119|NCT00160251|9610433|FG001|Prior to Amendment 2|Lost to Follow-up|0
6017120|NCT00160251|9610434|FG002|Prior to Amendment 2|Lost to Follow-up|1
6017121|NCT00160251|9610435|FG003|Prior to Amendment 2|Lost to Follow-up|0
6017122|NCT00160251|9610436|FG004|Prior to Amendment 2|Lost to Follow-up|1
6017123|NCT00160251|9610437|FG005|Prior to Amendment 2|Lost to Follow-up|1
6017124|NCT00160251|9610438|FG006|Prior to Amendment 2|Lost to Follow-up|0
6017125|NCT00160251|9610439|FG007|Prior to Amendment 2|Lost to Follow-up|0
6017126|NCT00160251|9610432|FG000|Prior to Amendment 2|Withdrawal by Subject|3
6017127|NCT00160251|9610433|FG001|Prior to Amendment 2|Withdrawal by Subject|1
6017128|NCT00160251|9610434|FG002|Prior to Amendment 2|Withdrawal by Subject|3
6017129|NCT00160251|9610435|FG003|Prior to Amendment 2|Withdrawal by Subject|4
6017130|NCT00160251|9610436|FG004|Prior to Amendment 2|Withdrawal by Subject|2
6017131|NCT00160251|9610437|FG005|Prior to Amendment 2|Withdrawal by Subject|3
6017132|NCT00160251|9610438|FG006|Prior to Amendment 2|Withdrawal by Subject|3
6017133|NCT00160251|9610439|FG007|Prior to Amendment 2|Withdrawal by Subject|0
6017134|NCT00160251|9610432|FG000|Prior to Amendment 2|Noncompliance with protocol|1
6017135|NCT00160251|9610433|FG001|Prior to Amendment 2|Noncompliance with protocol|0
6017136|NCT00160251|9610434|FG002|Prior to Amendment 2|Noncompliance with protocol|0
6017137|NCT00160251|9610435|FG003|Prior to Amendment 2|Noncompliance with protocol|0
6017138|NCT00160251|9610436|FG004|Prior to Amendment 2|Noncompliance with protocol|0
6017139|NCT00160251|9610437|FG005|Prior to Amendment 2|Noncompliance with protocol|0
6017140|NCT00160251|9610438|FG006|Prior to Amendment 2|Noncompliance with protocol|0
6017141|NCT00160251|9610439|FG007|Prior to Amendment 2|Noncompliance with protocol|0
6017142|NCT00160251|9610432|FG000|Prior to Amendment 2|Completed Treatment Phase|3
6017143|NCT00160251|9610433|FG001|Prior to Amendment 2|Completed Treatment Phase|0
6017144|NCT00160251|9610434|FG002|Prior to Amendment 2|Completed Treatment Phase|0
6017145|NCT00160251|9610435|FG003|Prior to Amendment 2|Completed Treatment Phase|0
6017146|NCT00160251|9610436|FG004|Prior to Amendment 2|Completed Treatment Phase|0
6017147|NCT00160251|9610437|FG005|Prior to Amendment 2|Completed Treatment Phase|23
6017148|NCT00160251|9610438|FG006|Prior to Amendment 2|Completed Treatment Phase|0
6017149|NCT00160251|9610439|FG007|Prior to Amendment 2|Completed Treatment Phase|0
6017150|NCT00160251|9610432|FG000|Post-amendment 2|Adverse Event|0
6017151|NCT00160251|9610433|FG001|Post-amendment 2|Adverse Event|0
6017152|NCT00160251|9610434|FG002|Post-amendment 2|Adverse Event|0
6017153|NCT00160251|9610435|FG003|Post-amendment 2|Adverse Event|0
6017154|NCT00160251|9610436|FG004|Post-amendment 2|Adverse Event|0
6017155|NCT00160251|9610437|FG005|Post-amendment 2|Adverse Event|0
6017156|NCT00160251|9610438|FG006|Post-amendment 2|Adverse Event|0
6017157|NCT00160251|9610439|FG007|Post-amendment 2|Adverse Event|20
6017158|NCT00160251|9610432|FG000|Post-amendment 2|Lack of Efficacy|0
6017159|NCT00160251|9610433|FG001|Post-amendment 2|Lack of Efficacy|0
6017160|NCT00160251|9610434|FG002|Post-amendment 2|Lack of Efficacy|0
6017161|NCT00160251|9610435|FG003|Post-amendment 2|Lack of Efficacy|0
6017162|NCT00160251|9610436|FG004|Post-amendment 2|Lack of Efficacy|0
6017163|NCT00160251|9610437|FG005|Post-amendment 2|Lack of Efficacy|0
6017164|NCT00160251|9610438|FG006|Post-amendment 2|Lack of Efficacy|0
6017165|NCT00160251|9610439|FG007|Post-amendment 2|Lack of Efficacy|24
6017166|NCT00160251|9610432|FG000|Post-amendment 2|Lost to follow-up/withdrawal by subject|0
6017167|NCT00160251|9610433|FG001|Post-amendment 2|Lost to follow-up/withdrawal by subject|0
6017168|NCT00160251|9610434|FG002|Post-amendment 2|Lost to follow-up/withdrawal by subject|0
6017169|NCT00160251|9610435|FG003|Post-amendment 2|Lost to follow-up/withdrawal by subject|0
6017170|NCT00160251|9610436|FG004|Post-amendment 2|Lost to follow-up/withdrawal by subject|0
6017171|NCT00160251|9610437|FG005|Post-amendment 2|Lost to follow-up/withdrawal by subject|0
6017172|NCT00160251|9610438|FG006|Post-amendment 2|Lost to follow-up/withdrawal by subject|0
6017173|NCT00160251|9610439|FG007|Post-amendment 2|Lost to follow-up/withdrawal by subject|11
6017174|NCT00160524|9610496|FG000|Overall Study|Adverse Event|119
6017175|NCT00160524|9610496|FG000|Overall Study|Adverse Event and Other|94
6017176|NCT00160524|9610496|FG000|Overall Study|Protocol Violation|16
6017177|NCT00160524|9610496|FG000|Overall Study|Protocol Violation and Other|2
6017178|NCT00160524|9610496|FG000|Overall Study|Withdrawal by Subject|141
6017179|NCT00160524|9610496|FG000|Overall Study|Withdrawal by Subject and Other|17
6017180|NCT00160524|9610496|FG000|Overall Study|Physician Decision|27
6017181|NCT00160524|9610496|FG000|Overall Study|Physician Decision and Other|6
6017182|NCT00160524|9610496|FG000|Overall Study|Lost to Follow-up|13
6017183|NCT00160524|9610496|FG000|Overall Study|Lost to Follow-up and Other|1
6017184|NCT00160524|9610496|FG000|Overall Study|Lack of Efficacy|21
6017185|NCT00160524|9610496|FG000|Overall Study|Lack of Efficacy and Other|1
6017186|NCT00160524|9610496|FG000|Overall Study|Other|20
6017187|NCT00160615|9610502|FG000|Overall Study|Adverse Event|5
6017188|NCT00160615|9610503|FG001|Overall Study|Adverse Event|12
6017189|NCT00160615|9610502|FG000|Overall Study|Withdrawal by Subject|0
6017190|NCT00160615|9610503|FG001|Overall Study|Withdrawal by Subject|2
6017191|NCT00160615|9610502|FG000|Overall Study|Lack of Efficacy|11
6017192|NCT00160615|9610503|FG001|Overall Study|Lack of Efficacy|23
6017193|NCT00160615|9610502|FG000|Overall Study|Patient decision|1
6017194|NCT00160615|9610503|FG001|Overall Study|Patient decision|2
6017195|NCT00160615|9610502|FG000|Overall Study|Investigator decision|1
6017196|NCT00160615|9610503|FG001|Overall Study|Investigator decision|1
6017197|NCT00160615|9610502|FG000|Overall Study|AE agents had to be discontinued (exam.)|0
6017198|NCT00160615|9610503|FG001|Overall Study|AE agents had to be discontinued (exam.)|1
6076940|NCT00594516|9682821|FG000|Open Label (OL): Tapentadol IR|Withdrawal by Subject|4
6076941|NCT00594516|9682822|FG001|Open Label (OL): Tapentadol IR|Withdrawal by Subject|0
6076942|NCT00594516|9682823|FG002|Open Label (OL): Tapentadol IR|Withdrawal by Subject|0
6076943|NCT00594516|9682821|FG000|Open Label (OL): Tapentadol IR|Lost to Follow-up|2
6076944|NCT00594516|9682822|FG001|Open Label (OL): Tapentadol IR|Lost to Follow-up|0
6076945|NCT00594516|9682823|FG002|Open Label (OL): Tapentadol IR|Lost to Follow-up|0
6076946|NCT00594516|9682821|FG000|Open Label (OL): Tapentadol IR|Adverse Event|16
6017199|NCT00160615|9610502|FG000|Overall Study|Switch to surgical treatment|0
6017200|NCT00160615|9610503|FG001|Overall Study|Switch to surgical treatment|2
6017201|NCT00160615|9610502|FG000|Overall Study|Non-compliance was suspected|0
6017202|NCT00160615|9610503|FG001|Overall Study|Non-compliance was suspected|1
6017203|NCT00160615|9610502|FG000|Overall Study|Poor compliance|0
6017204|NCT00160615|9610503|FG001|Overall Study|Poor compliance|1
6017205|NCT00160641|9610511|FG000|Overall Study|Adverse Event|102
6017206|NCT00160641|9610511|FG000|Overall Study|Withdrawal by Subject|87
6017207|NCT00160641|9610511|FG000|Overall Study|Lost to Follow-up|8
6017208|NCT00160641|9610511|FG000|Overall Study|Lack of Efficacy|12
6017209|NCT00160641|9610511|FG000|Overall Study|Protocol Violation|3
6017210|NCT00160641|9610511|FG000|Overall Study|Other|9
6017211|NCT00160654|9610515|FG000|Overall Study|Adverse Event|14
6017212|NCT00160654|9610515|FG000|Overall Study|Lack of Efficacy|4
6017213|NCT00160654|9610515|FG000|Overall Study|Lost to Follow-up|2
6017214|NCT00160654|9610515|FG000|Overall Study|Intake of expired drug|7
6017215|NCT00160654|9610515|FG000|Overall Study|Psychological trauma|1
6017216|NCT00160654|9610515|FG000|Overall Study|Sponsor decision|1
6017217|NCT00160654|9610515|FG000|Overall Study|Patient met exclusion criteria|1
6017218|NCT00160654|9610515|FG000|Overall Study|Patient decision|1
6017219|NCT00160654|9610515|FG000|Overall Study|Poor compliance, dilantin toxicity|1
6017220|NCT00160654|9610515|FG000|Overall Study|Met exclusion criteria|1
6017221|NCT00160667|9610522|FG000|Overall Study|Adverse Event|3
6017222|NCT00160667|9610523|FG001|Overall Study|Adverse Event|1
6017223|NCT00160667|9610524|FG002|Overall Study|Adverse Event|4
6017224|NCT00160667|9610522|FG000|Overall Study|Withdrawal by Subject|2
6017225|NCT00160667|9610523|FG001|Overall Study|Withdrawal by Subject|0
6017226|NCT00160667|9610524|FG002|Overall Study|Withdrawal by Subject|1
6017227|NCT00160667|9610522|FG000|Overall Study|Lack of Efficacy|0
6017228|NCT00160667|9610523|FG001|Overall Study|Lack of Efficacy|1
6017229|NCT00160667|9610524|FG002|Overall Study|Lack of Efficacy|0
6017230|NCT00160667|9610522|FG000|Overall Study|Protocol Violation|0
6017231|NCT00160667|9610523|FG001|Overall Study|Protocol Violation|1
6017232|NCT00160667|9610524|FG002|Overall Study|Protocol Violation|0
6017233|NCT00160667|9610522|FG000|Overall Study|Patient decision|0
6017234|NCT00160667|9610523|FG001|Overall Study|Patient decision|0
6017235|NCT00160667|9610524|FG002|Overall Study|Patient decision|1
6017236|NCT00160680|9610535|FG000|Overall Study|Adverse Event|0
6017237|NCT00160680|9610536|FG001|Overall Study|Adverse Event|1
6017238|NCT00160680|9610535|FG000|Overall Study|Lack of Efficacy|2
6017239|NCT00160680|9610536|FG001|Overall Study|Lack of Efficacy|1
6017240|NCT00160680|9610535|FG000|Overall Study|Lost to Follow-up|3
6017241|NCT00160680|9610536|FG001|Overall Study|Lost to Follow-up|2
6017242|NCT00160680|9610535|FG000|Overall Study|Withdrawal by Subject|4
6017243|NCT00160680|9610536|FG001|Overall Study|Withdrawal by Subject|9
6017244|NCT00160693|9610542|FG000|Overall Study|Adverse Event|97
6017245|NCT00160693|9610542|FG000|Overall Study|Lack of Efficacy|30
6017246|NCT00160693|9610542|FG000|Overall Study|Protocol Violation|24
6017247|NCT00160693|9610542|FG000|Overall Study|Lost to Follow-up|15
6017248|NCT00160693|9610542|FG000|Overall Study|Withdrawal by Subject|54
6017249|NCT00160693|9610542|FG000|Overall Study|Study terminated by sponsor|15
6017250|NCT00160706|9610546|FG000|Overall Study|Adverse Event|53
6017251|NCT00160706|9610546|FG000|Overall Study|Adverse Event and Other Reason|105
6076947|NCT00594516|9682822|FG001|Open Label (OL): Tapentadol IR|Adverse Event|0
6017252|NCT00160706|9610546|FG000|Overall Study|Protocol Violation|3
6017253|NCT00160706|9610546|FG000|Overall Study|Withdrawal by Subject|41
6017254|NCT00160706|9610546|FG000|Overall Study|Withdrawal by Subject and Other|12
6017255|NCT00160706|9610546|FG000|Overall Study|Physician Decision|10
6017256|NCT00160706|9610546|FG000|Overall Study|Physician Decision and Other|3
6017257|NCT00160706|9610546|FG000|Overall Study|Lost to Follow-up|4
6017258|NCT00160706|9610546|FG000|Overall Study|Lost to Follow-up and Other|1
6017259|NCT00160706|9610546|FG000|Overall Study|Lack of Efficacy|42
6017260|NCT00160706|9610546|FG000|Overall Study|Lack of Efficacy and Other|1
6017261|NCT00160706|9610546|FG000|Overall Study|Other Reason|11
6017262|NCT00161213|9610550|FG000|Overall Study|Withdrawal by Subject|1
6017263|NCT00161213|9610550|FG000|Overall Study|Evaluable for toxicity but not response|1
6017264|NCT00161616|9610574|FG000|Overall Study|Withdrawal by Subject|6
6017265|NCT00161616|9610575|FG001|Overall Study|Withdrawal by Subject|5
6017266|NCT00161616|9610574|FG000|Overall Study|Physician Decision|1
6017267|NCT00161616|9610575|FG001|Overall Study|Physician Decision|0
6017268|NCT00161616|9610574|FG000|Overall Study|Death|1
6017269|NCT00161616|9610575|FG001|Overall Study|Death|1
6017270|NCT00161616|9610574|FG000|Overall Study|Lost to Follow-up|17
6017271|NCT00161616|9610575|FG001|Overall Study|Lost to Follow-up|13
6017272|NCT00161616|9610574|FG000|Overall Study|Protocol deviation|1
6017273|NCT00161616|9610575|FG001|Overall Study|Protocol deviation|0
6017274|NCT00162032|9610583|FG000|Overall Study|Lost to Follow-up|4
6017275|NCT00162032|9610584|FG001|Overall Study|Lost to Follow-up|2
6017276|NCT00162032|9610583|FG000|Overall Study|Reason not specified|1
6017277|NCT00162032|9610584|FG001|Overall Study|Reason not specified|0
6017278|NCT00162097|9610599|FG000|Overall Study|Participant no longer met study criteria|0
6017279|NCT00162097|9610600|FG001|Overall Study|Participant no longer met study criteria|0
6017280|NCT00162097|9610601|FG002|Overall Study|Participant no longer met study criteria|0
6017281|NCT00162097|9610602|FG003|Overall Study|Participant no longer met study criteria|1
6017282|NCT00162123|9610626|FG000|Overall Study|Disease progression|27
6017283|NCT00162123|9610627|FG001|Overall Study|Disease progression|19
6017284|NCT00162123|9610628|FG002|Overall Study|Disease progression|10
6017285|NCT00162123|9610629|FG003|Overall Study|Disease progression|4
6017286|NCT00162123|9610630|FG004|Overall Study|Disease progression|8
6017287|NCT00162123|9610631|FG005|Overall Study|Disease progression|3
6017288|NCT00162123|9610632|FG006|Overall Study|Disease progression|1
6017289|NCT00162123|9610633|FG007|Overall Study|Disease progression|0
6017290|NCT00162123|9610626|FG000|Overall Study|Study drug toxicity|6
6017291|NCT00162123|9610627|FG001|Overall Study|Study drug toxicity|1
6017292|NCT00162123|9610628|FG002|Overall Study|Study drug toxicity|5
6076948|NCT00594516|9682823|FG002|Open Label (OL): Tapentadol IR|Adverse Event|0
6076949|NCT00594516|9682821|FG000|Open Label (OL): Tapentadol IR|Lack of Efficacy|1
6076950|NCT00594516|9682822|FG001|Open Label (OL): Tapentadol IR|Lack of Efficacy|0
6076951|NCT00594516|9682823|FG002|Open Label (OL): Tapentadol IR|Lack of Efficacy|0
6076952|NCT00594516|9682821|FG000|Open Label (OL): Tapentadol IR|Study Medication Non Compliant|6
6076953|NCT00594516|9682822|FG001|Open Label (OL): Tapentadol IR|Study Medication Non Compliant|0
6076954|NCT00594516|9682823|FG002|Open Label (OL): Tapentadol IR|Study Medication Non Compliant|0
6076955|NCT00594516|9682821|FG000|DB: Tapentadol IR to ER & ER to IR|Withdrawal by Subject|0
6076956|NCT00594516|9682822|FG001|DB: Tapentadol IR to ER & ER to IR|Withdrawal by Subject|3
6076957|NCT00594516|9682823|FG002|DB: Tapentadol IR to ER & ER to IR|Withdrawal by Subject|3
6076958|NCT00594516|9682821|FG000|DB: Tapentadol IR to ER & ER to IR|Study Medication Non compliant|0
6076959|NCT00594516|9682822|FG001|DB: Tapentadol IR to ER & ER to IR|Study Medication Non compliant|3
6076960|NCT00594516|9682823|FG002|DB: Tapentadol IR to ER & ER to IR|Study Medication Non compliant|2
6076961|NCT00594516|9682821|FG000|DB: Tapentadol IR to ER & ER to IR|Lack of Efficacy|0
6076962|NCT00594516|9682822|FG001|DB: Tapentadol IR to ER & ER to IR|Lack of Efficacy|1
6076963|NCT00594516|9682823|FG002|DB: Tapentadol IR to ER & ER to IR|Lack of Efficacy|1
6076964|NCT00594516|9682821|FG000|DB: Tapentadol IR to ER & ER to IR|Adverse Event|0
6076965|NCT00594516|9682822|FG001|DB: Tapentadol IR to ER & ER to IR|Adverse Event|0
6076966|NCT00594516|9682823|FG002|DB: Tapentadol IR to ER & ER to IR|Adverse Event|2
6076967|NCT00594568|9682830|FG000|Initial Treatment|Adverse Event|51
6076968|NCT00594568|9682831|FG001|Initial Treatment|Adverse Event|121
6076969|NCT00594568|9682832|FG002|Initial Treatment|Adverse Event|144
6076970|NCT00594568|9682830|FG000|Initial Treatment|Death|6
6076971|NCT00594568|9682831|FG001|Initial Treatment|Death|11
6076972|NCT00594568|9682832|FG002|Initial Treatment|Death|15
6076973|NCT00594568|9682830|FG000|Initial Treatment|Lost to Follow-up|4
6076974|NCT00594568|9682831|FG001|Initial Treatment|Lost to Follow-up|1
6076975|NCT00594568|9682832|FG002|Initial Treatment|Lost to Follow-up|4
6076976|NCT00594568|9682830|FG000|Initial Treatment|Physician Decision|3
6076977|NCT00594568|9682831|FG001|Initial Treatment|Physician Decision|2
6076978|NCT00594568|9682832|FG002|Initial Treatment|Physician Decision|4
6076979|NCT00594568|9682830|FG000|Initial Treatment|Protocol Violation|2
6076980|NCT00594568|9682831|FG001|Initial Treatment|Protocol Violation|2
6076981|NCT00594568|9682832|FG002|Initial Treatment|Protocol Violation|5
6076982|NCT00594568|9682830|FG000|Initial Treatment|Withdrawal by Subject|25
6076983|NCT00594568|9682831|FG001|Initial Treatment|Withdrawal by Subject|31
6076984|NCT00594568|9682832|FG002|Initial Treatment|Withdrawal by Subject|46
6076985|NCT00594568|9682830|FG000|Initial Treatment|Sponsor decision|193
6076986|NCT00594568|9682831|FG001|Initial Treatment|Sponsor decision|142
6017293|NCT00162123|9610629|FG003|Overall Study|Study drug toxicity|0
6017294|NCT00162123|9610630|FG004|Overall Study|Study drug toxicity|4
6017295|NCT00162123|9610631|FG005|Overall Study|Study drug toxicity|1
6017296|NCT00162123|9610632|FG006|Overall Study|Study drug toxicity|1
6017297|NCT00162123|9610633|FG007|Overall Study|Study drug toxicity|0
6017298|NCT00162123|9610626|FG000|Overall Study|Death|3
6017299|NCT00162123|9610627|FG001|Overall Study|Death|3
6017300|NCT00162123|9610628|FG002|Overall Study|Death|1
6017301|NCT00162123|9610629|FG003|Overall Study|Death|1
6017302|NCT00162123|9610630|FG004|Overall Study|Death|1
6017303|NCT00162123|9610631|FG005|Overall Study|Death|1
6017304|NCT00162123|9610632|FG006|Overall Study|Death|0
6017305|NCT00162123|9610633|FG007|Overall Study|Death|0
6017306|NCT00162123|9610626|FG000|Overall Study|Withdrawal by Subject|2
6017307|NCT00162123|9610627|FG001|Overall Study|Withdrawal by Subject|0
6017308|NCT00162123|9610628|FG002|Overall Study|Withdrawal by Subject|2
6017309|NCT00162123|9610629|FG003|Overall Study|Withdrawal by Subject|1
6017310|NCT00162123|9610630|FG004|Overall Study|Withdrawal by Subject|1
6017311|NCT00162123|9610631|FG005|Overall Study|Withdrawal by Subject|2
6017312|NCT00162123|9610632|FG006|Overall Study|Withdrawal by Subject|1
6017313|NCT00162123|9610633|FG007|Overall Study|Withdrawal by Subject|0
6017314|NCT00162123|9610626|FG000|Overall Study|Deterioration without progression|2
6017315|NCT00162123|9610627|FG001|Overall Study|Deterioration without progression|2
6017316|NCT00162123|9610628|FG002|Overall Study|Deterioration without progression|3
6017317|NCT00162123|9610629|FG003|Overall Study|Deterioration without progression|0
6017318|NCT00162123|9610630|FG004|Overall Study|Deterioration without progression|1
6017319|NCT00162123|9610631|FG005|Overall Study|Deterioration without progression|0
6017320|NCT00162123|9610632|FG006|Overall Study|Deterioration without progression|0
6017321|NCT00162123|9610633|FG007|Overall Study|Deterioration without progression|0
6017322|NCT00162123|9610626|FG000|Overall Study|Adverse Event|1
6017323|NCT00162123|9610627|FG001|Overall Study|Adverse Event|2
6017324|NCT00162123|9610628|FG002|Overall Study|Adverse Event|0
6017325|NCT00162123|9610629|FG003|Overall Study|Adverse Event|2
6017326|NCT00162123|9610630|FG004|Overall Study|Adverse Event|1
6017327|NCT00162123|9610631|FG005|Overall Study|Adverse Event|0
6017328|NCT00162123|9610632|FG006|Overall Study|Adverse Event|0
6017329|NCT00162123|9610633|FG007|Overall Study|Adverse Event|0
6017330|NCT00162123|9610626|FG000|Overall Study|Not specified (before treatment)|2
6017331|NCT00162123|9610627|FG001|Overall Study|Not specified (before treatment)|0
6017332|NCT00162123|9610628|FG002|Overall Study|Not specified (before treatment)|0
6017333|NCT00162123|9610629|FG003|Overall Study|Not specified (before treatment)|0
6017334|NCT00162123|9610630|FG004|Overall Study|Not specified (before treatment)|12
6017335|NCT00162123|9610631|FG005|Overall Study|Not specified (before treatment)|1
6017336|NCT00162123|9610632|FG006|Overall Study|Not specified (before treatment)|0
6017337|NCT00162123|9610633|FG007|Overall Study|Not specified (before treatment)|0
6017338|NCT00162123|9610626|FG000|Overall Study|Not specified (after start of treatment)|0
6017339|NCT00162123|9610627|FG001|Overall Study|Not specified (after start of treatment)|0
6017340|NCT00162123|9610628|FG002|Overall Study|Not specified (after start of treatment)|0
6017341|NCT00162123|9610629|FG003|Overall Study|Not specified (after start of treatment)|0
6017342|NCT00162123|9610630|FG004|Overall Study|Not specified (after start of treatment)|3
6017343|NCT00162123|9610631|FG005|Overall Study|Not specified (after start of treatment)|0
6017344|NCT00162123|9610632|FG006|Overall Study|Not specified (after start of treatment)|0
6017345|NCT00162123|9610633|FG007|Overall Study|Not specified (after start of treatment)|0
6017346|NCT00162123|9610626|FG000|Overall Study|Physician Decision|1
6017347|NCT00162123|9610627|FG001|Overall Study|Physician Decision|2
6076987|NCT00594568|9682832|FG002|Initial Treatment|Sponsor decision|147
6076988|NCT00594568|9682830|FG000|Initial Treatment|Caregiver decision|21
6076989|NCT00594568|9682831|FG001|Initial Treatment|Caregiver decision|36
6076990|NCT00594568|9682832|FG002|Initial Treatment|Caregiver decision|36
6076991|NCT00594568|9682830|FG000|Initial Treatment|Abnormal lab/electrocardiogram (ECG)|7
6076992|NCT00594568|9682831|FG001|Initial Treatment|Abnormal lab/electrocardiogram (ECG)|7
6076993|NCT00594568|9682832|FG002|Initial Treatment|Abnormal lab/electrocardiogram (ECG)|6
6076994|NCT00594568|9682830|FG000|Initial Treatment|Entry criteria exclusion|0
6076995|NCT00594568|9682831|FG001|Initial Treatment|Entry criteria exclusion|1
6076996|NCT00594568|9682832|FG002|Initial Treatment|Entry criteria exclusion|1
6076997|NCT00594568|9682830|FG000|Delayed Start|Death|0
6076998|NCT00594568|9682831|FG001|Delayed Start|Death|0
6076999|NCT00594568|9682832|FG002|Delayed Start|Death|1
6077000|NCT00594568|9682830|FG000|Delayed Start|Adverse Event|12
6077001|NCT00594568|9682831|FG001|Delayed Start|Adverse Event|2
6077002|NCT00594568|9682832|FG002|Delayed Start|Adverse Event|2
6077003|NCT00594568|9682830|FG000|Delayed Start|Withdrawal by Subject|4
6017348|NCT00162123|9610628|FG002|Overall Study|Physician Decision|0
6017349|NCT00162123|9610629|FG003|Overall Study|Physician Decision|0
6017350|NCT00162123|9610630|FG004|Overall Study|Physician Decision|0
6017351|NCT00162123|9610631|FG005|Overall Study|Physician Decision|1
6017352|NCT00162123|9610632|FG006|Overall Study|Physician Decision|1
6017353|NCT00162123|9610633|FG007|Overall Study|Physician Decision|0
6077004|NCT00594568|9682831|FG001|Delayed Start|Withdrawal by Subject|3
6077005|NCT00594568|9682832|FG002|Delayed Start|Withdrawal by Subject|0
6077006|NCT00594568|9682830|FG000|Delayed Start|Physician Decision|0
6077007|NCT00594568|9682831|FG001|Delayed Start|Physician Decision|0
6077008|NCT00594568|9682832|FG002|Delayed Start|Physician Decision|1
6077009|NCT00594568|9682830|FG000|Delayed Start|Lost to Follow-up|0
6077010|NCT00594568|9682831|FG001|Delayed Start|Lost to Follow-up|0
6077011|NCT00594568|9682832|FG002|Delayed Start|Lost to Follow-up|1
6077012|NCT00594568|9682830|FG000|Delayed Start|Caregiver Decision|5
6077013|NCT00594568|9682831|FG001|Delayed Start|Caregiver Decision|6
6077014|NCT00594568|9682832|FG002|Delayed Start|Caregiver Decision|2
6077015|NCT00594568|9682830|FG000|Delayed Start|Sponsor Decision|77
6077016|NCT00594568|9682831|FG001|Delayed Start|Sponsor Decision|66
6077017|NCT00594568|9682832|FG002|Delayed Start|Sponsor Decision|59
6077018|NCT00594568|9682830|FG000|Safety Follow Up (SFU)-Optional|Death|0
6077019|NCT00594568|9682831|FG001|Safety Follow Up (SFU)-Optional|Death|1
6077020|NCT00594568|9682832|FG002|Safety Follow Up (SFU)-Optional|Death|0
6077021|NCT00594568|9682830|FG000|Safety Follow Up (SFU)-Optional|Adverse Event|5
6077022|NCT00594568|9682831|FG001|Safety Follow Up (SFU)-Optional|Adverse Event|0
6077023|NCT00594568|9682832|FG002|Safety Follow Up (SFU)-Optional|Adverse Event|0
6077024|NCT00594568|9682830|FG000|Safety Follow Up (SFU)-Optional|Withdrawal by Subject|12
6077025|NCT00594568|9682831|FG001|Safety Follow Up (SFU)-Optional|Withdrawal by Subject|15
6077026|NCT00594568|9682832|FG002|Safety Follow Up (SFU)-Optional|Withdrawal by Subject|13
6077027|NCT00594568|9682830|FG000|Safety Follow Up (SFU)-Optional|Lost to Follow-up|2
6077028|NCT00594568|9682831|FG001|Safety Follow Up (SFU)-Optional|Lost to Follow-up|1
6077029|NCT00594568|9682832|FG002|Safety Follow Up (SFU)-Optional|Lost to Follow-up|2
6077030|NCT00594568|9682830|FG000|Safety Follow Up (SFU)-Optional|Caregiver Decision|17
6077031|NCT00594568|9682831|FG001|Safety Follow Up (SFU)-Optional|Caregiver Decision|16
6077032|NCT00594568|9682832|FG002|Safety Follow Up (SFU)-Optional|Caregiver Decision|9
6077033|NCT00594568|9682830|FG000|Safety Follow Up (SFU)-Optional|No safety visit or follow up|25
6077034|NCT00594568|9682831|FG001|Safety Follow Up (SFU)-Optional|No safety visit or follow up|22
6077035|NCT00594568|9682832|FG002|Safety Follow Up (SFU)-Optional|No safety visit or follow up|18
6077036|NCT00594646|9682848|FG000|Overall Study|Withdrawal by Subject|1
6077037|NCT00594646|9682848|FG000|Overall Study|Lost to Follow-up|15
6077038|NCT00594659|9682856|FG000|Overall Study|Lost to Follow-up|13
6077039|NCT00594659|9682857|FG001|Overall Study|Lost to Follow-up|9
6077040|NCT00594659|9682858|FG002|Overall Study|Lost to Follow-up|7
6087536|NCT00668707|9697832|FG001|Overall Study|Lost to Follow-up|6
6087537|NCT00668707|9697831|FG000|Overall Study|Protocol Violation|10
6087538|NCT00668707|9697832|FG001|Overall Study|Protocol Violation|12
6087539|NCT00668707|9697831|FG000|Overall Study|Death|11
6087540|NCT00668707|9697832|FG001|Overall Study|Death|4
6087541|NCT00668733|9697845|FG000|Overall Study|Lost to Follow-up|2
6087542|NCT00668733|9697846|FG001|Overall Study|Lost to Follow-up|3
6087543|NCT00668733|9697845|FG000|Overall Study|Withdrawal by Subject|0
6087544|NCT00668733|9697846|FG001|Overall Study|Withdrawal by Subject|4
6087545|NCT00668746|9697854|FG000|Overall Study|Lost to Follow-up|2
6087546|NCT00668746|9697855|FG001|Overall Study|Lost to Follow-up|1
6087547|NCT00668863|9697875|FG000|Overall Study|Objective Progression or Relapse|42
6087548|NCT00668863|9697875|FG000|Overall Study|Adverse Event|13
6087549|NCT00668863|9697875|FG000|Overall Study|Study Terminated by Sponsor|8
6087550|NCT00668863|9697875|FG000|Overall Study|Global Deterioration of Health Status|4
6087551|NCT00668863|9697875|FG000|Overall Study|Withdrawal by Subject|1
6087552|NCT00668863|9697875|FG000|Overall Study|Surgery|1
6087553|NCT00668863|9697875|FG000|Overall Study|Subject's work scheduling problem|1
6087554|NCT00668863|9697875|FG000|Overall Study|Physician Decision|1
6087555|NCT00669032|9697898|FG000|Overall Study|Lost to Follow-up|6
6087556|NCT00669032|9697899|FG001|Overall Study|Lost to Follow-up|5
6087557|NCT00669032|9697898|FG000|Overall Study|Lack of Efficacy|8
6087558|NCT00669032|9697899|FG001|Overall Study|Lack of Efficacy|19
6087559|NCT00669032|9697898|FG000|Overall Study|Withdrawal by Subject|12
6087560|NCT00669032|9697899|FG001|Overall Study|Withdrawal by Subject|13
6017354|NCT00162123|9610626|FG000|Overall Study|Tumor assessment only (not treated)|0
6017355|NCT00162123|9610627|FG001|Overall Study|Tumor assessment only (not treated)|0
6017356|NCT00162123|9610628|FG002|Overall Study|Tumor assessment only (not treated)|0
6017357|NCT00162123|9610629|FG003|Overall Study|Tumor assessment only (not treated)|0
6017358|NCT00162123|9610630|FG004|Overall Study|Tumor assessment only (not treated)|0
6017359|NCT00162123|9610631|FG005|Overall Study|Tumor assessment only (not treated)|0
6017360|NCT00162123|9610632|FG006|Overall Study|Tumor assessment only (not treated)|0
6017361|NCT00162123|9610633|FG007|Overall Study|Tumor assessment only (not treated)|1
6087561|NCT00669032|9697898|FG000|Overall Study|Adverse Event|12
6087562|NCT00669032|9697899|FG001|Overall Study|Adverse Event|16
6087563|NCT00669032|9697898|FG000|Overall Study|Physician Decision|1
6087564|NCT00669032|9697899|FG001|Overall Study|Physician Decision|1
6017362|NCT00162123|9610626|FG000|Overall Study|Follow-up only (not treated or assessed)|0
6087565|NCT00669032|9697898|FG000|Overall Study|No fulfilment of the selection criteria|5
6087566|NCT00669032|9697899|FG001|Overall Study|No fulfilment of the selection criteria|5
6087567|NCT00669071|9697905|FG000|Overall Study|Lost to Follow-up|3
6087568|NCT00669071|9697905|FG000|Overall Study|Final visit 40 days out of window|1
6087569|NCT00669110|9697913|FG000|Overall Study|Adverse Event|4
6087570|NCT00669110|9697914|FG001|Overall Study|Adverse Event|3
6087571|NCT00669110|9697913|FG000|Overall Study|Caregiver request|3
6087572|NCT00669110|9697914|FG001|Overall Study|Caregiver request|2
6087573|NCT00669110|9697913|FG000|Overall Study|Physician Decision|0
6017363|NCT00162123|9610627|FG001|Overall Study|Follow-up only (not treated or assessed)|0
6017364|NCT00162123|9610628|FG002|Overall Study|Follow-up only (not treated or assessed)|0
6017365|NCT00162123|9610629|FG003|Overall Study|Follow-up only (not treated or assessed)|0
6017366|NCT00162123|9610630|FG004|Overall Study|Follow-up only (not treated or assessed)|0
6017367|NCT00162123|9610631|FG005|Overall Study|Follow-up only (not treated or assessed)|0
6017368|NCT00162123|9610632|FG006|Overall Study|Follow-up only (not treated or assessed)|0
6017369|NCT00162123|9610633|FG007|Overall Study|Follow-up only (not treated or assessed)|57
6017370|NCT00162136|9610658|FG000|Overall Study|Adverse Event|1
6017371|NCT00162136|9610658|FG000|Overall Study|Death|1
6017372|NCT00162136|9610658|FG000|Overall Study|Disease Progression/Relapse|23
6017373|NCT00162136|9610658|FG000|Overall Study|Investigator Request|5
6017374|NCT00162136|9610658|FG000|Overall Study|Study Drug Toxicity|4
6017375|NCT00162136|9610658|FG000|Overall Study|Withdrawal by Subject|1
6017376|NCT00162266|9610685|FG000|Double-Blind Period|Adverse Event|5
6017377|NCT00162266|9610686|FG001|Double-Blind Period|Adverse Event|9
6017378|NCT00162266|9610687|FG002|Double-Blind Period|Adverse Event|11
6017379|NCT00162266|9610688|FG003|Double-Blind Period|Adverse Event|0
6017380|NCT00162266|9610685|FG000|Double-Blind Period|Death|0
6017381|NCT00162266|9610686|FG001|Double-Blind Period|Death|1
6017382|NCT00162266|9610687|FG002|Double-Blind Period|Death|0
6017383|NCT00162266|9610688|FG003|Double-Blind Period|Death|0
6017384|NCT00162266|9610685|FG000|Double-Blind Period|Lost to Follow-up|1
6017385|NCT00162266|9610686|FG001|Double-Blind Period|Lost to Follow-up|2
6017386|NCT00162266|9610687|FG002|Double-Blind Period|Lost to Follow-up|0
6017387|NCT00162266|9610688|FG003|Double-Blind Period|Lost to Follow-up|0
6017388|NCT00162266|9610685|FG000|Double-Blind Period|Other Reason|1
6017389|NCT00162266|9610686|FG001|Double-Blind Period|Other Reason|0
6017390|NCT00162266|9610687|FG002|Double-Blind Period|Other Reason|1
6017391|NCT00162266|9610688|FG003|Double-Blind Period|Other Reason|0
6017392|NCT00162266|9610685|FG000|Double-Blind Period|Lack of Efficacy|13
6017393|NCT00162266|9610686|FG001|Double-Blind Period|Lack of Efficacy|17
6017394|NCT00162266|9610687|FG002|Double-Blind Period|Lack of Efficacy|30
6017395|NCT00162266|9610688|FG003|Double-Blind Period|Lack of Efficacy|0
6017396|NCT00162266|9610685|FG000|Double-Blind Period|Withdrawal by Subject|5
6017397|NCT00162266|9610686|FG001|Double-Blind Period|Withdrawal by Subject|2
6017398|NCT00162266|9610687|FG002|Double-Blind Period|Withdrawal by Subject|6
6017399|NCT00162266|9610688|FG003|Double-Blind Period|Withdrawal by Subject|0
6017400|NCT00162266|9610685|FG000|Open-Label Period|Death|0
6017401|NCT00162266|9610686|FG001|Open-Label Period|Death|0
6017402|NCT00162266|9610687|FG002|Open-Label Period|Death|0
6017403|NCT00162266|9610688|FG003|Open-Label Period|Death|7
6017404|NCT00162266|9610685|FG000|Open-Label Period|Adverse Event|0
6017405|NCT00162266|9610686|FG001|Open-Label Period|Adverse Event|0
6017406|NCT00162266|9610687|FG002|Open-Label Period|Adverse Event|0
6017407|NCT00162266|9610688|FG003|Open-Label Period|Adverse Event|46
6017408|NCT00162266|9610685|FG000|Open-Label Period|Lack of Efficacy|0
6017409|NCT00162266|9610686|FG001|Open-Label Period|Lack of Efficacy|0
6017410|NCT00162266|9610687|FG002|Open-Label Period|Lack of Efficacy|0
6017411|NCT00162266|9610688|FG003|Open-Label Period|Lack of Efficacy|26
6017412|NCT00162266|9610685|FG000|Open-Label Period|Lost to Follow-up|0
6017413|NCT00162266|9610686|FG001|Open-Label Period|Lost to Follow-up|0
6017414|NCT00162266|9610687|FG002|Open-Label Period|Lost to Follow-up|0
6017415|NCT00162266|9610688|FG003|Open-Label Period|Lost to Follow-up|3
6017416|NCT00162266|9610685|FG000|Open-Label Period|Withdrawal by Subject|0
6017417|NCT00162266|9610686|FG001|Open-Label Period|Withdrawal by Subject|0
6017418|NCT00162266|9610687|FG002|Open-Label Period|Withdrawal by Subject|0
6017419|NCT00162266|9610688|FG003|Open-Label Period|Withdrawal by Subject|31
6017420|NCT00162266|9610685|FG000|Open-Label Period|Administrative Reason By Sponsor|0
6017421|NCT00162266|9610686|FG001|Open-Label Period|Administrative Reason By Sponsor|0
6017422|NCT00162266|9610687|FG002|Open-Label Period|Administrative Reason By Sponsor|0
6017423|NCT00162266|9610688|FG003|Open-Label Period|Administrative Reason By Sponsor|9
6017424|NCT00162266|9610685|FG000|Open-Label Period|Other Reasons|0
6017425|NCT00162266|9610686|FG001|Open-Label Period|Other Reasons|0
6017426|NCT00162266|9610687|FG002|Open-Label Period|Other Reasons|0
6017427|NCT00162266|9610688|FG003|Open-Label Period|Other Reasons|15
6017428|NCT00162981|9610742|FG000|Overall Study|Adverse Event|2
6017429|NCT00162981|9610743|FG001|Overall Study|Adverse Event|5
6017430|NCT00162981|9610742|FG000|Overall Study|Withdrawal by Subject|1
6017431|NCT00162981|9610743|FG001|Overall Study|Withdrawal by Subject|1
6017432|NCT00162981|9610742|FG000|Overall Study|Physician Decision|1
6017433|NCT00162981|9610743|FG001|Overall Study|Physician Decision|0
6017434|NCT00163020|9610751|FG000|Overall Study|Lost to Follow-up|0
6017435|NCT00163020|9610752|FG001|Overall Study|Lost to Follow-up|2
6017436|NCT00163189|9610760|FG000|Overall Study|Other|6
6017437|NCT00163189|9610760|FG000|Overall Study|Lost to Follow-up|1
6017438|NCT00163189|9610760|FG000|Overall Study|Protocol Violation|2
6017439|NCT00163189|9610760|FG000|Overall Study|Death|3
6017440|NCT00163189|9610760|FG000|Overall Study|Adverse Event|6
6017441|NCT00163189|9610760|FG000|Overall Study|Lack of Efficacy|7
6017442|NCT00163189|9610760|FG000|Overall Study|Study terminated by sponsor|11
6017443|NCT00163189|9610760|FG000|Overall Study|Withdrawal by Subject|11
6017444|NCT00163189|9610760|FG000|Overall Study|Did not meet continuation criterion|16
6017445|NCT00163215|9610764|FG000|Overall Study|Lack of Efficacy|3
6017446|NCT00163215|9610764|FG000|Overall Study|Withdrawal by Subject|5
6017447|NCT00163215|9610764|FG000|Overall Study|Other|7
6017448|NCT00163657|9610784|FG000|Overall Study|Death|12
6017449|NCT00163657|9610785|FG001|Overall Study|Death|14
6017450|NCT00163657|9610786|FG002|Overall Study|Death|19
6017451|NCT00163657|9610784|FG000|Overall Study|graft loss|4
6017452|NCT00163657|9610785|FG001|Overall Study|graft loss|1
6017453|NCT00163657|9610786|FG002|Overall Study|graft loss|2
6017454|NCT00163657|9610784|FG000|Overall Study|Withdrawal by Subject|2
6017455|NCT00163657|9610785|FG001|Overall Study|Withdrawal by Subject|3
6017456|NCT00163657|9610786|FG002|Overall Study|Withdrawal by Subject|2
6017457|NCT00163657|9610784|FG000|Overall Study|Physician Decision|0
6017458|NCT00163657|9610785|FG001|Overall Study|Physician Decision|1
6017459|NCT00163657|9610786|FG002|Overall Study|Physician Decision|1
6017460|NCT00163657|9610784|FG000|Overall Study|Non Compliance|1
6017461|NCT00163657|9610785|FG001|Overall Study|Non Compliance|0
6017462|NCT00163657|9610786|FG002|Overall Study|Non Compliance|0
6017463|NCT00163657|9610784|FG000|Overall Study|Lost to Follow-up|1
6017464|NCT00163657|9610785|FG001|Overall Study|Lost to Follow-up|3
6017465|NCT00163657|9610786|FG002|Overall Study|Lost to Follow-up|10
6017466|NCT00163657|9610784|FG000|Overall Study|Other reason|0
6017467|NCT00163657|9610785|FG001|Overall Study|Other reason|1
6017468|NCT00163657|9610786|FG002|Overall Study|Other reason|3
6017469|NCT00165646|9610797|FG000|Overall Study|Adverse Event|1
6017470|NCT00165646|9610798|FG001|Overall Study|Adverse Event|1
6017471|NCT00165646|9610799|FG002|Overall Study|Adverse Event|1
6017472|NCT00165646|9610797|FG000|Overall Study|Lack of Efficacy|1
6017473|NCT00165646|9610798|FG001|Overall Study|Lack of Efficacy|2
6017474|NCT00165646|9610799|FG002|Overall Study|Lack of Efficacy|0
6017475|NCT00165646|9610797|FG000|Overall Study|Withdrawal by Subject|0
6017476|NCT00165646|9610798|FG001|Overall Study|Withdrawal by Subject|2
6017477|NCT00165646|9610799|FG002|Overall Study|Withdrawal by Subject|1
6017478|NCT00165646|9610797|FG000|Overall Study|Physician Decision|2
6017479|NCT00165646|9610798|FG001|Overall Study|Physician Decision|0
6017480|NCT00165646|9610799|FG002|Overall Study|Physician Decision|2
6017481|NCT00165646|9610797|FG000|Overall Study|Protocol Violation|1
6017482|NCT00165646|9610798|FG001|Overall Study|Protocol Violation|0
6017483|NCT00165646|9610799|FG002|Overall Study|Protocol Violation|0
6017484|NCT00165672|9610809|FG000|Overall Study|Adverse Event|0
6017485|NCT00165672|9610810|FG001|Overall Study|Adverse Event|1
6017486|NCT00165698|9610818|FG000|Overall Study|Adverse Event|2
6017487|NCT00165698|9610819|FG001|Overall Study|Adverse Event|10
6017488|NCT00165698|9610818|FG000|Overall Study|Lost to Follow-up|2
6017489|NCT00165698|9610819|FG001|Overall Study|Lost to Follow-up|2
6017490|NCT00165698|9610818|FG000|Overall Study|Withdrawal by Subject|2
6017491|NCT00165698|9610819|FG001|Overall Study|Withdrawal by Subject|1
6017492|NCT00165698|9610818|FG000|Overall Study|Protocol Violation|1
6017493|NCT00165698|9610819|FG001|Overall Study|Protocol Violation|0
6017494|NCT00165698|9610818|FG000|Overall Study|Not Taken/Lost the medicine|1
6017495|NCT00165698|9610819|FG001|Overall Study|Not Taken/Lost the medicine|2
6017496|NCT00165776|9610829|FG000|Overall Study|Lack of Efficacy|0
6017497|NCT00165776|9610830|FG001|Overall Study|Lack of Efficacy|0
6017498|NCT00165776|9610831|FG002|Overall Study|Lack of Efficacy|0
6017499|NCT00165776|9610832|FG003|Overall Study|Lack of Efficacy|1
6017500|NCT00165776|9610829|FG000|Overall Study|Withdrawal by Subject|4
6017501|NCT00165776|9610830|FG001|Overall Study|Withdrawal by Subject|1
6017502|NCT00165776|9610831|FG002|Overall Study|Withdrawal by Subject|2
6017503|NCT00165776|9610832|FG003|Overall Study|Withdrawal by Subject|0
6017504|NCT00165776|9610829|FG000|Overall Study|Worsening of Cervical Dystonia|0
6017505|NCT00165776|9610830|FG001|Overall Study|Worsening of Cervical Dystonia|0
6017506|NCT00165776|9610831|FG002|Overall Study|Worsening of Cervical Dystonia|0
6017507|NCT00165776|9610832|FG003|Overall Study|Worsening of Cervical Dystonia|1
6017508|NCT00165789|9610846|FG000|Overall Study|Adverse Event|0
6017509|NCT00165789|9610847|FG001|Overall Study|Adverse Event|3
6017510|NCT00165789|9610848|FG002|Overall Study|Adverse Event|0
6017511|NCT00165789|9610849|FG003|Overall Study|Adverse Event|12
6017512|NCT00165789|9610846|FG000|Overall Study|Withdrawal by Subject|0
6017513|NCT00165789|9610847|FG001|Overall Study|Withdrawal by Subject|1
6017514|NCT00165789|9610848|FG002|Overall Study|Withdrawal by Subject|1
6017515|NCT00165789|9610849|FG003|Overall Study|Withdrawal by Subject|2
6017516|NCT00165841|9610861|FG000|Overall Study|Adverse Event|2
6017517|NCT00165841|9610862|FG001|Overall Study|Adverse Event|3
6017518|NCT00165841|9610861|FG000|Overall Study|Lack of Efficacy|6
6017519|NCT00165841|9610862|FG001|Overall Study|Lack of Efficacy|33
6017520|NCT00165841|9610861|FG000|Overall Study|Lost to Follow-up|4
6017521|NCT00165841|9610862|FG001|Overall Study|Lost to Follow-up|4
6017522|NCT00165841|9610861|FG000|Overall Study|Withdrawal by Subject|7
6017523|NCT00165841|9610862|FG001|Overall Study|Withdrawal by Subject|8
6017524|NCT00165841|9610861|FG000|Overall Study|Physician Decision|1
6017525|NCT00165841|9610862|FG001|Overall Study|Physician Decision|0
6017526|NCT00165841|9610861|FG000|Overall Study|Protocol Violation|6
6017527|NCT00165841|9610862|FG001|Overall Study|Protocol Violation|8
6017528|NCT00165841|9610861|FG000|Overall Study|Other|3
6017529|NCT00165841|9610862|FG001|Overall Study|Other|5
6017530|NCT00165841|9610861|FG000|Overall Study|Medication Noncompliance|1
6017531|NCT00165841|9610862|FG001|Overall Study|Medication Noncompliance|1
6017532|NCT00165984|9610877|FG000|Overall Study|Death|15
6017533|NCT00166114|9610896|FG000|Overall Study|Protocol Violation|2
6017534|NCT00166114|9610897|FG001|Overall Study|Protocol Violation|1
6017535|NCT00166114|9610896|FG000|Overall Study|Withdrawal by Subject|10
6017536|NCT00166114|9610897|FG001|Overall Study|Withdrawal by Subject|4
6017537|NCT00166114|9610896|FG000|Overall Study|Adverse Event|2
6017538|NCT00166114|9610897|FG001|Overall Study|Adverse Event|1
6017539|NCT00166296|9610931|FG000|Overall Study|Withdrawal by Subject|1
6017540|NCT00166296|9610932|FG001|Overall Study|Withdrawal by Subject|3
6017541|NCT00166296|9610931|FG000|Overall Study|Adverse Event|2
6017542|NCT00166296|9610932|FG001|Overall Study|Adverse Event|4
6017543|NCT00166296|9610931|FG000|Overall Study|Lost to Follow-up|4
6017544|NCT00166296|9610932|FG001|Overall Study|Lost to Follow-up|2
6017545|NCT00166439|9610947|FG000|Overall Study|Ineligible|5
6017546|NCT00166517|9610953|FG000|Overall Study|Lost to Follow-up|1
6017547|NCT00166517|9610954|FG001|Overall Study|Lost to Follow-up|0
6017548|NCT00166517|9610953|FG000|Overall Study|Protocol Violation|4
6017549|NCT00166517|9610954|FG001|Overall Study|Protocol Violation|1
6017550|NCT00166517|9610953|FG000|Overall Study|Withdrawal by Subject|0
6017551|NCT00166517|9610954|FG001|Overall Study|Withdrawal by Subject|1
6017552|NCT00166712|9610962|FG000|Overall Study|Death|0
6017553|NCT00166712|9610963|FG001|Overall Study|Death|1
6017554|NCT00166712|9610962|FG000|Overall Study|Adverse Event|1
6017555|NCT00166712|9610963|FG001|Overall Study|Adverse Event|0
6017556|NCT00166712|9610962|FG000|Overall Study|Withdrawal by Subject|1
6017557|NCT00166712|9610963|FG001|Overall Study|Withdrawal by Subject|2
6017558|NCT00166712|9610962|FG000|Overall Study|Physician Decision|0
6017559|NCT00166712|9610963|FG001|Overall Study|Physician Decision|2
6017560|NCT00167245|9610999|FG000|Overall Study|Lost to Follow-up|20
6017561|NCT00167245|9611000|FG001|Overall Study|Lost to Follow-up|31
6017562|NCT00167245|9610999|FG000|Overall Study|Withdrawal by Subject|5
6017563|NCT00167245|9611000|FG001|Overall Study|Withdrawal by Subject|8
6017564|NCT00167245|9610999|FG000|Overall Study|Incarcerated|3
6017565|NCT00167245|9611000|FG001|Overall Study|Incarcerated|2
6017566|NCT00167245|9610999|FG000|Overall Study|Drowsy|1
6017567|NCT00167245|9611000|FG001|Overall Study|Drowsy|0
6017568|NCT00167310|9611011|FG000|Overall Study|Protocol Violation|5
6017569|NCT00167310|9611012|FG001|Overall Study|Protocol Violation|3
6017570|NCT00167310|9611011|FG000|Overall Study|Withdrawal by Subject|3
6017571|NCT00167310|9611012|FG001|Overall Study|Withdrawal by Subject|7
6017572|NCT00167414|9611033|FG000|Overall Study|Death|10
6017573|NCT00167778|9611050|FG000|Overall Study|Withdrawal by Subject|1
6017574|NCT00168038|9611064|FG000|Overall Study|Adverse Event|1
6017575|NCT00168038|9611064|FG000|Overall Study|Therapy failure|1
6017576|NCT00168064|9611070|FG000|Overall Study|Adverse Event|26
6017577|NCT00168064|9611071|FG001|Overall Study|Adverse Event|22
6017578|NCT00168064|9611070|FG000|Overall Study|Withdrawal by Subject|3
6017579|NCT00168064|9611071|FG001|Overall Study|Withdrawal by Subject|4
6017580|NCT00168064|9611070|FG000|Overall Study|Lack of Efficacy|4
6017581|NCT00168064|9611071|FG001|Overall Study|Lack of Efficacy|4
6017582|NCT00168064|9611070|FG000|Overall Study|Lost to Follow-up|4
6017583|NCT00168064|9611071|FG001|Overall Study|Lost to Follow-up|3
6017584|NCT00168064|9611070|FG000|Overall Study|Non-compliance|2
6017585|NCT00168064|9611071|FG001|Overall Study|Non-compliance|3
6017586|NCT00168064|9611070|FG000|Overall Study|Concurrent Illness|4
6017587|NCT00168064|9611071|FG001|Overall Study|Concurrent Illness|3
6017588|NCT00168064|9611070|FG000|Overall Study|Subject's Best interest|2
6017589|NCT00168064|9611071|FG001|Overall Study|Subject's Best interest|2
6017590|NCT00168064|9611070|FG000|Overall Study|Various|4
6017591|NCT00168064|9611071|FG001|Overall Study|Various|3
6017592|NCT00168103|9611082|FG000|Overall Study|Withdrawal by Subject|1
6017593|NCT00168103|9611083|FG001|Overall Study|Withdrawal by Subject|2
6017594|NCT00168103|9611084|FG002|Overall Study|Withdrawal by Subject|1
6017595|NCT00168103|9611085|FG003|Overall Study|Withdrawal by Subject|0
6017596|NCT00168103|9611082|FG000|Overall Study|Lost to Follow-up|1
6017597|NCT00168103|9611083|FG001|Overall Study|Lost to Follow-up|3
6017598|NCT00168103|9611084|FG002|Overall Study|Lost to Follow-up|0
6017599|NCT00168103|9611085|FG003|Overall Study|Lost to Follow-up|0
6047793|NCT00413413|9646869|FG002|Double-Blind|Lost to Follow-up|2
6047794|NCT00413660|9646908|FG000|Up To Week 12|Adverse Event|1
6047795|NCT00413660|9646909|FG001|Up To Week 12|Adverse Event|3
6047796|NCT00413660|9646910|FG002|Up To Week 12|Adverse Event|1
6047797|NCT00413660|9646911|FG003|Up To Week 12|Adverse Event|4
6047798|NCT00413660|9646912|FG004|Up To Week 12|Adverse Event|6
6047799|NCT00413660|9646913|FG005|Up To Week 12|Adverse Event|4
6047800|NCT00413660|9646914|FG006|Up To Week 12|Adverse Event|1
6047801|NCT00413660|9646915|FG007|Up To Week 12|Adverse Event|0
6047802|NCT00413660|9646916|FG008|Up To Week 12|Adverse Event|0
6047803|NCT00413660|9646917|FG009|Up To Week 12|Adverse Event|0
6047804|NCT00413660|9646918|FG010|Up To Week 12|Adverse Event|0
6047805|NCT00413660|9646908|FG000|Up To Week 12|Lack of Efficacy|2
6047806|NCT00413660|9646909|FG001|Up To Week 12|Lack of Efficacy|0
6047807|NCT00413660|9646910|FG002|Up To Week 12|Lack of Efficacy|0
6047808|NCT00413660|9646911|FG003|Up To Week 12|Lack of Efficacy|0
6047809|NCT00413660|9646912|FG004|Up To Week 12|Lack of Efficacy|0
6047810|NCT00413660|9646913|FG005|Up To Week 12|Lack of Efficacy|0
6047811|NCT00413660|9646914|FG006|Up To Week 12|Lack of Efficacy|5
6017600|NCT00168805|9611191|FG000|Overall Study|Adverse Event|7
6017601|NCT00168805|9611192|FG001|Overall Study|Adverse Event|11
6017602|NCT00168805|9611193|FG002|Overall Study|Adverse Event|16
6017603|NCT00168805|9611191|FG000|Overall Study|Protocol Violation|12
6017604|NCT00168805|9611192|FG001|Overall Study|Protocol Violation|11
6017605|NCT00168805|9611193|FG002|Overall Study|Protocol Violation|8
6017606|NCT00168805|9611191|FG000|Overall Study|Lost to Follow-up|12
6017607|NCT00168805|9611192|FG001|Overall Study|Lost to Follow-up|17
6017608|NCT00168805|9611193|FG002|Overall Study|Lost to Follow-up|11
6017609|NCT00168805|9611191|FG000|Overall Study|Withdrawal by Subject|16
6017610|NCT00168805|9611192|FG001|Overall Study|Withdrawal by Subject|18
6017611|NCT00168805|9611193|FG002|Overall Study|Withdrawal by Subject|21
6017612|NCT00168805|9611191|FG000|Overall Study|Other|24
6017613|NCT00168805|9611192|FG001|Overall Study|Other|21
6017614|NCT00168805|9611193|FG002|Overall Study|Other|22
6017615|NCT00168805|9611191|FG000|Treatment|Adverse Event|25
6017616|NCT00168805|9611192|FG001|Treatment|Adverse Event|26
6017617|NCT00168805|9611193|FG002|Treatment|Adverse Event|32
6017618|NCT00168805|9611191|FG000|Treatment|Protocol Violation|3
6017619|NCT00168805|9611192|FG001|Treatment|Protocol Violation|5
6017620|NCT00168805|9611193|FG002|Treatment|Protocol Violation|5
6017621|NCT00168805|9611191|FG000|Treatment|Withdrawal by Subject|3
6017622|NCT00168805|9611192|FG001|Treatment|Withdrawal by Subject|7
6017623|NCT00168805|9611193|FG002|Treatment|Withdrawal by Subject|8
6017624|NCT00168805|9611191|FG000|Treatment|Other|18
6017625|NCT00168805|9611192|FG001|Treatment|Other|18
6017626|NCT00168805|9611193|FG002|Treatment|Other|17
6017627|NCT00168818|9611204|FG000|Overall Study|Adverse Event|23
6017628|NCT00168818|9611205|FG001|Overall Study|Adverse Event|29
6017629|NCT00168818|9611206|FG002|Overall Study|Adverse Event|31
6017630|NCT00168818|9611204|FG000|Overall Study|Protocol Violation|16
6017631|NCT00168818|9611205|FG001|Overall Study|Protocol Violation|11
6017632|NCT00168818|9611206|FG002|Overall Study|Protocol Violation|11
6017633|NCT00168818|9611204|FG000|Overall Study|Lost to Follow-up|13
6017634|NCT00168818|9611205|FG001|Overall Study|Lost to Follow-up|4
6017635|NCT00168818|9611206|FG002|Overall Study|Lost to Follow-up|15
6017636|NCT00168818|9611204|FG000|Overall Study|Withdrawal by Subject|43
6017637|NCT00168818|9611205|FG001|Overall Study|Withdrawal by Subject|41
6017638|NCT00168818|9611206|FG002|Overall Study|Withdrawal by Subject|37
6017639|NCT00168818|9611204|FG000|Overall Study|Other|22
6017640|NCT00168818|9611205|FG001|Overall Study|Other|24
6017641|NCT00168818|9611206|FG002|Overall Study|Other|30
6017642|NCT00168818|9611204|FG000|Treatment|Adverse Event|77
6017643|NCT00168818|9611205|FG001|Treatment|Adverse Event|89
6017644|NCT00168818|9611206|FG002|Treatment|Adverse Event|68
6017645|NCT00168818|9611204|FG000|Treatment|Protocol Violation|8
6017646|NCT00168818|9611205|FG001|Treatment|Protocol Violation|11
6017647|NCT00168818|9611206|FG002|Treatment|Protocol Violation|11
6017648|NCT00168818|9611204|FG000|Treatment|Lost to Follow-up|0
6017649|NCT00168818|9611205|FG001|Treatment|Lost to Follow-up|2
6017650|NCT00168818|9611206|FG002|Treatment|Lost to Follow-up|1
6017651|NCT00168818|9611204|FG000|Treatment|Withdrawal by Subject|25
6017652|NCT00168818|9611205|FG001|Treatment|Withdrawal by Subject|20
6017653|NCT00168818|9611206|FG002|Treatment|Withdrawal by Subject|22
6017654|NCT00168818|9611204|FG000|Treatment|Other|23
6017655|NCT00168818|9611205|FG001|Treatment|Other|29
6017656|NCT00168818|9611206|FG002|Treatment|Other|31
6017657|NCT00168831|9611217|FG000|Overall Study|Adverse Event|36
6017658|NCT00168831|9611218|FG001|Overall Study|Adverse Event|47
6017659|NCT00168831|9611219|FG002|Overall Study|Adverse Event|74
6017660|NCT00168831|9611217|FG000|Overall Study|Lost to Follow-up|5
6017661|NCT00168831|9611218|FG001|Overall Study|Lost to Follow-up|6
6017662|NCT00168831|9611219|FG002|Overall Study|Lost to Follow-up|4
6017663|NCT00168831|9611217|FG000|Overall Study|Withdrawal by Subject|7
6017664|NCT00168831|9611218|FG001|Overall Study|Withdrawal by Subject|14
6017665|NCT00168831|9611219|FG002|Overall Study|Withdrawal by Subject|19
6017666|NCT00168831|9611217|FG000|Overall Study|Protocol Violation|6
6017667|NCT00168831|9611218|FG001|Overall Study|Protocol Violation|11
6017668|NCT00168831|9611219|FG002|Overall Study|Protocol Violation|11
6017669|NCT00168831|9611217|FG000|Overall Study|Other|6
6017670|NCT00168831|9611218|FG001|Overall Study|Other|3
6017671|NCT00168831|9611219|FG002|Overall Study|Other|6
6017672|NCT00168844|9611230|FG000|Overall Study|Adverse Event|31
6017673|NCT00168844|9611231|FG001|Overall Study|Adverse Event|32
6017674|NCT00168844|9611232|FG002|Overall Study|Adverse Event|48
6017675|NCT00168844|9611230|FG000|Overall Study|Lost to Follow-up|4
6017676|NCT00168844|9611231|FG001|Overall Study|Lost to Follow-up|5
6017677|NCT00168844|9611232|FG002|Overall Study|Lost to Follow-up|11
6017678|NCT00168844|9611230|FG000|Overall Study|Withdrawal by Subject|12
6017679|NCT00168844|9611231|FG001|Overall Study|Withdrawal by Subject|9
6017680|NCT00168844|9611232|FG002|Overall Study|Withdrawal by Subject|19
6017681|NCT00168844|9611230|FG000|Overall Study|Protocol Violation|2
6017682|NCT00168844|9611231|FG001|Overall Study|Protocol Violation|2
6017683|NCT00168844|9611232|FG002|Overall Study|Protocol Violation|4
6017684|NCT00168844|9611230|FG000|Overall Study|Other|6
6017685|NCT00168844|9611231|FG001|Overall Study|Other|7
6017686|NCT00168844|9611232|FG002|Overall Study|Other|9
6017687|NCT00169104|9611242|FG000|Overall Study|Withdrawal by Subject|2
6017688|NCT00169104|9611243|FG001|Overall Study|Withdrawal by Subject|0
6017689|NCT00169104|9611242|FG000|Overall Study|Protocol Violation|0
6017690|NCT00169104|9611243|FG001|Overall Study|Protocol Violation|1
6017691|NCT00169104|9611242|FG000|Overall Study|Physician Decision|0
6017692|NCT00169104|9611243|FG001|Overall Study|Physician Decision|1
6017693|NCT00169442|9611256|FG000|Overall Study|Withdrawal by Subject|0
6017694|NCT00169442|9611257|FG001|Overall Study|Withdrawal by Subject|0
6017695|NCT00169442|9611258|FG002|Overall Study|Withdrawal by Subject|1
6017696|NCT00169442|9611259|FG003|Overall Study|Withdrawal by Subject|0
6017697|NCT00169442|9611260|FG004|Overall Study|Withdrawal by Subject|0
6017698|NCT00169442|9611261|FG005|Overall Study|Withdrawal by Subject|0
6017699|NCT00169442|9611256|FG000|Overall Study|Migrated/moved from study area|0
6017700|NCT00169442|9611257|FG001|Overall Study|Migrated/moved from study area|0
6017701|NCT00169442|9611258|FG002|Overall Study|Migrated/moved from study area|0
6017702|NCT00169442|9611259|FG003|Overall Study|Migrated/moved from study area|0
6017703|NCT00169442|9611260|FG004|Overall Study|Migrated/moved from study area|0
6017704|NCT00169442|9611261|FG005|Overall Study|Migrated/moved from study area|2
6017705|NCT00169442|9611256|FG000|Overall Study|Lost to follow-up (incompl. vaccination)|0
6017706|NCT00169442|9611257|FG001|Overall Study|Lost to follow-up (incompl. vaccination)|0
6017707|NCT00169442|9611258|FG002|Overall Study|Lost to follow-up (incompl. vaccination)|0
6017708|NCT00169442|9611259|FG003|Overall Study|Lost to follow-up (incompl. vaccination)|0
6017709|NCT00169442|9611260|FG004|Overall Study|Lost to follow-up (incompl. vaccination)|1
6017710|NCT00169442|9611261|FG005|Overall Study|Lost to follow-up (incompl. vaccination)|0
6017711|NCT00169442|9611256|FG000|Overall Study|Lost to follow-up (compl. vaccination)|0
6017712|NCT00169442|9611257|FG001|Overall Study|Lost to follow-up (compl. vaccination)|1
6017713|NCT00169442|9611258|FG002|Overall Study|Lost to follow-up (compl. vaccination)|0
6017714|NCT00169442|9611259|FG003|Overall Study|Lost to follow-up (compl. vaccination)|0
6017715|NCT00169442|9611260|FG004|Overall Study|Lost to follow-up (compl. vaccination)|0
6017716|NCT00169442|9611261|FG005|Overall Study|Lost to follow-up (compl. vaccination)|0
6017717|NCT00170846|9611291|FG000|Overall Study|Subject withdrew Informed Consent|5
6017718|NCT00170846|9611292|FG001|Overall Study|Subject withdrew Informed Consent|12
6017719|NCT00170846|9611293|FG002|Overall Study|Subject withdrew Informed Consent|8
6017720|NCT00170846|9611291|FG000|Overall Study|Lost to Follow-up|6
6017721|NCT00170846|9611292|FG001|Overall Study|Lost to Follow-up|3
6017722|NCT00170846|9611293|FG002|Overall Study|Lost to Follow-up|2
6017723|NCT00170846|9611291|FG000|Overall Study|Death|0
6017724|NCT00170846|9611292|FG001|Overall Study|Death|3
6017725|NCT00170846|9611293|FG002|Overall Study|Death|3
6017726|NCT00170846|9611291|FG000|Overall Study|Reason Missing|0
6017727|NCT00170846|9611292|FG001|Overall Study|Reason Missing|1
6309523|NCT02640157|10038196|FG002|Overall Study|Lost to Follow-up|7
6309524|NCT02640157|10038194|FG000|Overall Study|Randomized in error; did not receive Tx|0
6309525|NCT02640157|10038195|FG001|Overall Study|Randomized in error; did not receive Tx|1
6309526|NCT02640157|10038196|FG002|Overall Study|Randomized in error; did not receive Tx|0
6309527|NCT02640235|10038207|FG000|Overall Study|Withdrawal by Subject|7
6017728|NCT00170846|9611293|FG002|Overall Study|Reason Missing|0
6017729|NCT00170950|9611303|FG000|Overall Study|Death|236
6017730|NCT00170950|9611304|FG001|Overall Study|Death|274
6017731|NCT00170950|9611303|FG000|Overall Study|Withdrawal by Subject|496
6017732|NCT00170950|9611304|FG001|Overall Study|Withdrawal by Subject|498
6017733|NCT00170950|9611303|FG000|Overall Study|Lost to Follow-up|134
6017734|NCT00170950|9611304|FG001|Overall Study|Lost to Follow-up|115
6017735|NCT00170950|9611303|FG000|Overall Study|Missing|2
6017736|NCT00170950|9611304|FG001|Overall Study|Missing|1
6017737|NCT00170950|9611303|FG000|Overall Study|Termination Data Not Recorded|17
6017738|NCT00170950|9611304|FG001|Overall Study|Termination Data Not Recorded|22
6017739|NCT00171054|9611312|FG000|Overall Study|Protocol Violation|1
6017740|NCT00171054|9611313|FG001|Overall Study|Protocol Violation|2
6017741|NCT00171054|9611312|FG000|Overall Study|Patient withdrew consent|1
6017742|NCT00171054|9611313|FG001|Overall Study|Patient withdrew consent|0
6017743|NCT00171054|9611312|FG000|Overall Study|Lost to Follow-up|0
6017744|NCT00171054|9611313|FG001|Overall Study|Lost to Follow-up|1
6017745|NCT00171054|9611312|FG000|Overall Study|Adverse Event|8
6017746|NCT00171054|9611313|FG001|Overall Study|Adverse Event|8
6017747|NCT00171054|9611312|FG000|Overall Study|Condition no longer required study drug|0
6017748|NCT00171054|9611313|FG001|Overall Study|Condition no longer required study drug|1
6017749|NCT00171158|9611319|FG000|Core Study|Death|27
6017750|NCT00171158|9611319|FG000|Core Study|Unsatisfactory therapeutic effect|163
6017751|NCT00171158|9611319|FG000|Core Study|Protocol Violation|4
6017752|NCT00171158|9611319|FG000|Core Study|Administrative problems|1
6017753|NCT00171158|9611319|FG000|Core Study|Adverse event, non-fatal|21
6017754|NCT00171158|9611319|FG000|Core Study|Consent withdrawn by subject|6
6017755|NCT00171158|9611319|FG000|Core Study|No longer required drug (BMT)|14
6017756|NCT00171158|9611319|FG000|Core Study|Abnormal Laboratory Values|2
6017757|NCT00171158|9611319|FG000|Core Study|Lost to Follow-up|1
6017758|NCT00171158|9611319|FG000|E2 Extension|Other|7
6017759|NCT00171210|9611325|FG000|Overall Study|Adverse Event|16
6017760|NCT00171210|9611326|FG001|Overall Study|Adverse Event|27
6017761|NCT00171210|9611325|FG000|Overall Study|Abnormal laboratory value(s)|6
6017762|NCT00171210|9611326|FG001|Overall Study|Abnormal laboratory value(s)|3
6017763|NCT00171210|9611325|FG000|Overall Study|Abnormal test procedure result(s)|0
6017764|NCT00171210|9611326|FG001|Overall Study|Abnormal test procedure result(s)|1
6017765|NCT00171210|9611325|FG000|Overall Study|Unsatisfactory therapeutic effect|11
6017766|NCT00171210|9611326|FG001|Overall Study|Unsatisfactory therapeutic effect|15
6017767|NCT00171210|9611325|FG000|Overall Study|Protocol Violation|0
6017768|NCT00171210|9611326|FG001|Overall Study|Protocol Violation|2
6017769|NCT00171210|9611325|FG000|Overall Study|Withdrawal by Subject|32
6017770|NCT00171210|9611326|FG001|Overall Study|Withdrawal by Subject|30
6017771|NCT00171210|9611325|FG000|Overall Study|Lost to Follow-up|1
6017772|NCT00171210|9611326|FG001|Overall Study|Lost to Follow-up|0
6017773|NCT00171210|9611325|FG000|Overall Study|Administrative problems|1
6017774|NCT00171210|9611326|FG001|Overall Study|Administrative problems|1
6017775|NCT00171210|9611325|FG000|Overall Study|Death|2
6017776|NCT00171210|9611326|FG001|Overall Study|Death|3
6017777|NCT00171210|9611325|FG000|Overall Study|Stopped at end of core|0
6017778|NCT00171210|9611326|FG001|Overall Study|Stopped at end of core|32
6017779|NCT00171210|9611325|FG000|Overall Study|Stopped at end of extension 1|0
6017780|NCT00171210|9611326|FG001|Overall Study|Stopped at end of extension 1|1
6017781|NCT00171223|9611335|FG000|Overall Study|Adverse Event (Non-fatal)|6
6017782|NCT00171223|9611336|FG001|Overall Study|Adverse Event (Non-fatal)|5
6017783|NCT00171223|9611337|FG002|Overall Study|Adverse Event (Non-fatal)|19
6017784|NCT00171223|9611335|FG000|Overall Study|Abnormal Laboratory Value (s)|4
6017785|NCT00171223|9611336|FG001|Overall Study|Abnormal Laboratory Value (s)|2
6017786|NCT00171223|9611337|FG002|Overall Study|Abnormal Laboratory Value (s)|3
6017787|NCT00171223|9611335|FG000|Overall Study|Abnormal Procedure|1
6017788|NCT00171223|9611336|FG001|Overall Study|Abnormal Procedure|0
6017789|NCT00171223|9611337|FG002|Overall Study|Abnormal Procedure|0
6017790|NCT00171223|9611335|FG000|Overall Study|Unsatisfactory Therapeutic Effect|57
6017791|NCT00171223|9611336|FG001|Overall Study|Unsatisfactory Therapeutic Effect|43
6017792|NCT00171223|9611337|FG002|Overall Study|Unsatisfactory Therapeutic Effect|52
6017793|NCT00171223|9611335|FG000|Overall Study|No Longer Requires Study Drug (Bone Marrow Transplant)|2
6017794|NCT00171223|9611336|FG001|Overall Study|No Longer Requires Study Drug (Bone Marrow Transplant)|4
6017795|NCT00171223|9611337|FG002|Overall Study|No Longer Requires Study Drug (Bone Marrow Transplant)|2
6017796|NCT00171223|9611335|FG000|Overall Study|Protocol Violation|2
6017797|NCT00171223|9611336|FG001|Overall Study|Protocol Violation|2
6017798|NCT00171223|9611337|FG002|Overall Study|Protocol Violation|3
6017799|NCT00171223|9611335|FG000|Overall Study|Participant Withdrew Consent|12
6017800|NCT00171223|9611336|FG001|Overall Study|Participant Withdrew Consent|21
6017801|NCT00171223|9611337|FG002|Overall Study|Participant Withdrew Consent|15
6017802|NCT00171223|9611335|FG000|Overall Study|Lost to Follow-up|5
6017803|NCT00171223|9611336|FG001|Overall Study|Lost to Follow-up|2
6017804|NCT00171223|9611337|FG002|Overall Study|Lost to Follow-up|3
6017805|NCT00171223|9611335|FG000|Overall Study|Administrative Problems|4
6017806|NCT00171223|9611336|FG001|Overall Study|Administrative Problems|7
6017807|NCT00171223|9611337|FG002|Overall Study|Administrative Problems|6
6017808|NCT00171223|9611335|FG000|Overall Study|Adverse Event (Serious Fatal)|6
6017809|NCT00171223|9611336|FG001|Overall Study|Adverse Event (Serious Fatal)|8
6017810|NCT00171223|9611337|FG002|Overall Study|Adverse Event (Serious Fatal)|9
6017811|NCT00171223|9611335|FG000|Overall Study|Not Specified (No Data Collected After Cut-off)|41
6017812|NCT00171223|9611336|FG001|Overall Study|Not Specified (No Data Collected After Cut-off)|47
6017813|NCT00171223|9611337|FG002|Overall Study|Not Specified (No Data Collected After Cut-off)|58
6017814|NCT00171249|9611343|FG000|Overall Study|Withdrawal by Subject|2
6017815|NCT00171249|9611344|FG001|Overall Study|Withdrawal by Subject|0
6017816|NCT00171249|9611345|FG002|Overall Study|Withdrawal by Subject|0
6017817|NCT00171249|9611346|FG003|Overall Study|Withdrawal by Subject|6
6017818|NCT00171249|9611347|FG004|Overall Study|Withdrawal by Subject|0
6017819|NCT00171249|9611348|FG005|Overall Study|Withdrawal by Subject|0
6017820|NCT00171249|9611349|FG006|Overall Study|Withdrawal by Subject|0
6017821|NCT00171249|9611343|FG000|Overall Study|Unsatisfactory Therapeutic Effect|44
6017822|NCT00171249|9611344|FG001|Overall Study|Unsatisfactory Therapeutic Effect|3
6017823|NCT00171249|9611345|FG002|Overall Study|Unsatisfactory Therapeutic Effect|5
6017824|NCT00171249|9611346|FG003|Overall Study|Unsatisfactory Therapeutic Effect|70
6017825|NCT00171249|9611347|FG004|Overall Study|Unsatisfactory Therapeutic Effect|3
6017826|NCT00171249|9611348|FG005|Overall Study|Unsatisfactory Therapeutic Effect|31
6017827|NCT00171249|9611349|FG006|Overall Study|Unsatisfactory Therapeutic Effect|1
6017828|NCT00171249|9611343|FG000|Overall Study|Death|7
6017829|NCT00171249|9611344|FG001|Overall Study|Death|1
6017830|NCT00171249|9611345|FG002|Overall Study|Death|0
6017831|NCT00171249|9611346|FG003|Overall Study|Death|4
6017832|NCT00171249|9611347|FG004|Overall Study|Death|0
6017833|NCT00171249|9611348|FG005|Overall Study|Death|3
6017834|NCT00171249|9611349|FG006|Overall Study|Death|1
6017835|NCT00171249|9611343|FG000|Overall Study|Other|10
6017836|NCT00171249|9611344|FG001|Overall Study|Other|0
6017837|NCT00171249|9611345|FG002|Overall Study|Other|0
6017838|NCT00171249|9611346|FG003|Overall Study|Other|43
6017839|NCT00171249|9611347|FG004|Overall Study|Other|0
6017840|NCT00171249|9611348|FG005|Overall Study|Other|2
6017841|NCT00171249|9611349|FG006|Overall Study|Other|0
6017842|NCT00171249|9611343|FG000|Overall Study|No Longer Requires Study Drug|4
6017843|NCT00171249|9611344|FG001|Overall Study|No Longer Requires Study Drug|0
6017844|NCT00171249|9611345|FG002|Overall Study|No Longer Requires Study Drug|0
6017845|NCT00171249|9611346|FG003|Overall Study|No Longer Requires Study Drug|3
6017846|NCT00171249|9611347|FG004|Overall Study|No Longer Requires Study Drug|0
6017847|NCT00171249|9611348|FG005|Overall Study|No Longer Requires Study Drug|5
6017848|NCT00171249|9611349|FG006|Overall Study|No Longer Requires Study Drug|0
6017849|NCT00171249|9611343|FG000|Overall Study|Administrative Problems|1
6017850|NCT00171249|9611344|FG001|Overall Study|Administrative Problems|0
6017851|NCT00171249|9611345|FG002|Overall Study|Administrative Problems|0
6017852|NCT00171249|9611346|FG003|Overall Study|Administrative Problems|2
6017853|NCT00171249|9611347|FG004|Overall Study|Administrative Problems|0
6017854|NCT00171249|9611348|FG005|Overall Study|Administrative Problems|0
6017855|NCT00171249|9611349|FG006|Overall Study|Administrative Problems|0
6017856|NCT00171249|9611343|FG000|Overall Study|Adverse Event|3
6017857|NCT00171249|9611344|FG001|Overall Study|Adverse Event|1
6017858|NCT00171249|9611345|FG002|Overall Study|Adverse Event|0
6017859|NCT00171249|9611346|FG003|Overall Study|Adverse Event|15
6017860|NCT00171249|9611347|FG004|Overall Study|Adverse Event|0
6017861|NCT00171249|9611348|FG005|Overall Study|Adverse Event|2
6017862|NCT00171249|9611349|FG006|Overall Study|Adverse Event|0
6017863|NCT00171249|9611343|FG000|Overall Study|Lost to Follow-up|5
6017864|NCT00171249|9611344|FG001|Overall Study|Lost to Follow-up|0
6017865|NCT00171249|9611345|FG002|Overall Study|Lost to Follow-up|0
6017866|NCT00171249|9611346|FG003|Overall Study|Lost to Follow-up|9
6017867|NCT00171249|9611347|FG004|Overall Study|Lost to Follow-up|0
6017868|NCT00171249|9611348|FG005|Overall Study|Lost to Follow-up|0
6017869|NCT00171249|9611349|FG006|Overall Study|Lost to Follow-up|0
6017870|NCT00171301|9611360|FG000|Overall Study|Death|1
6017871|NCT00171301|9611361|FG001|Overall Study|Death|2
6017872|NCT00171301|9611360|FG000|Overall Study|Adverse Event|1
6017873|NCT00171301|9611361|FG001|Overall Study|Adverse Event|2
6017874|NCT00171301|9611360|FG000|Overall Study|Lost to Follow-up|6
6017875|NCT00171301|9611361|FG001|Overall Study|Lost to Follow-up|2
6017876|NCT00171301|9611360|FG000|Overall Study|Protocol Violation|0
6017877|NCT00171301|9611361|FG001|Overall Study|Protocol Violation|2
6017878|NCT00171301|9611360|FG000|Overall Study|Withdrawal by Subject|0
6017879|NCT00171301|9611361|FG001|Overall Study|Withdrawal by Subject|1
6017880|NCT00171314|9611370|FG000|Overall Study|Adverse Event|44
6017881|NCT00171314|9611371|FG001|Overall Study|Adverse Event|41
6017882|NCT00171314|9611370|FG000|Overall Study|Lack of Efficacy|19
6017883|NCT00171314|9611371|FG001|Overall Study|Lack of Efficacy|14
6017884|NCT00171314|9611370|FG000|Overall Study|Withdrawal by Subject|9
6017885|NCT00171314|9611371|FG001|Overall Study|Withdrawal by Subject|6
6017886|NCT00171314|9611370|FG000|Overall Study|Abnormal Test Procedure Results|9
6017887|NCT00171314|9611371|FG001|Overall Study|Abnormal Test Procedure Results|3
6017888|NCT00171314|9611370|FG000|Overall Study|Protocol Violation|3
6017889|NCT00171314|9611371|FG001|Overall Study|Protocol Violation|7
6017890|NCT00171314|9611370|FG000|Overall Study|Administrative Problems|4
6017891|NCT00171314|9611371|FG001|Overall Study|Administrative Problems|3
6017892|NCT00171314|9611370|FG000|Overall Study|Lost to Follow-up|1
6017893|NCT00171314|9611371|FG001|Overall Study|Lost to Follow-up|3
6017894|NCT00171314|9611370|FG000|Overall Study|Death|2
6017895|NCT00171314|9611371|FG001|Overall Study|Death|1
6017896|NCT00171340|9611379|FG000|Overall Study|Adverse Event|46
6017897|NCT00171340|9611380|FG001|Overall Study|Adverse Event|42
6017898|NCT00171340|9611379|FG000|Overall Study|Lack of Efficacy|29
6017899|NCT00171340|9611380|FG001|Overall Study|Lack of Efficacy|41
6017900|NCT00171340|9611379|FG000|Overall Study|Protocol Violation|7
6017901|NCT00171340|9611380|FG001|Overall Study|Protocol Violation|8
6017902|NCT00171340|9611379|FG000|Overall Study|Withdrawal by Subject|22
6017903|NCT00171340|9611380|FG001|Overall Study|Withdrawal by Subject|19
6017904|NCT00171340|9611379|FG000|Overall Study|Lost to Follow-up|0
6017905|NCT00171340|9611380|FG001|Overall Study|Lost to Follow-up|5
6017906|NCT00171340|9611379|FG000|Overall Study|Abnormal Laboratory Results|2
6017907|NCT00171340|9611380|FG001|Overall Study|Abnormal Laboratory Results|0
6017908|NCT00171340|9611379|FG000|Overall Study|Abnormal Test Procedure Results|6
6017909|NCT00171340|9611380|FG001|Overall Study|Abnormal Test Procedure Results|11
6017910|NCT00171340|9611379|FG000|Overall Study|No Longer Required Study Drug|1
6017911|NCT00171340|9611380|FG001|Overall Study|No Longer Required Study Drug|1
6017912|NCT00171340|9611379|FG000|Overall Study|Administrative Problems|5
6017913|NCT00171340|9611380|FG001|Overall Study|Administrative Problems|2
6017914|NCT00171340|9611379|FG000|Overall Study|Death|6
6017915|NCT00171340|9611380|FG001|Overall Study|Death|6
6017916|NCT00171704|9611390|FG000|Overall Study|Adverse Event|24
6017917|NCT00171704|9611391|FG001|Overall Study|Adverse Event|33
6017918|NCT00171704|9611390|FG000|Overall Study|Disease Progression|14
6017919|NCT00171704|9611391|FG001|Overall Study|Disease Progression|9
6017920|NCT00171704|9611390|FG000|Overall Study|New therapy for 2nd non-breast prim canc|1
6017921|NCT00171704|9611391|FG001|Overall Study|New therapy for 2nd non-breast prim canc|0
6017922|NCT00171704|9611390|FG000|Overall Study|Administrative Problems|2
6017923|NCT00171704|9611391|FG001|Overall Study|Administrative Problems|1
6017924|NCT00171704|9611390|FG000|Overall Study|Death|2
6017925|NCT00171704|9611391|FG001|Overall Study|Death|2
6017926|NCT00171704|9611390|FG000|Overall Study|Withdrawal by Subject|1
6017927|NCT00171704|9611391|FG001|Overall Study|Withdrawal by Subject|3
6017928|NCT00171704|9611390|FG000|Overall Study|Protocol Violation|0
6017929|NCT00171704|9611391|FG001|Overall Study|Protocol Violation|1
6017930|NCT00171730|9611397|FG000|Overall Study|Adverse Event|3
6017931|NCT00171730|9611397|FG000|Overall Study|Abnormal Laboratory Value(s)|1
6017932|NCT00171730|9611397|FG000|Overall Study|Unsatisfactory Therapeutic Effect|8
6017933|NCT00171730|9611397|FG000|Overall Study|Withdrawal by Subject|3
6017934|NCT00171834|9611414|FG000|Overall Study|Adverse Event|2
6017935|NCT00171834|9611415|FG001|Overall Study|Adverse Event|1
6017936|NCT00171834|9611416|FG002|Overall Study|Adverse Event|3
6017937|NCT00171834|9611417|FG003|Overall Study|Adverse Event|2
6017938|NCT00171834|9611418|FG004|Overall Study|Adverse Event|2
6017939|NCT00171834|9611419|FG005|Overall Study|Adverse Event|15
6017940|NCT00171834|9611420|FG006|Overall Study|Adverse Event|1
6017941|NCT00171834|9611414|FG000|Overall Study|Withdrawal by Subject|0
6017942|NCT00171834|9611415|FG001|Overall Study|Withdrawal by Subject|2
6017943|NCT00171834|9611416|FG002|Overall Study|Withdrawal by Subject|0
6017944|NCT00171834|9611417|FG003|Overall Study|Withdrawal by Subject|1
6017945|NCT00171834|9611418|FG004|Overall Study|Withdrawal by Subject|1
6017946|NCT00171834|9611419|FG005|Overall Study|Withdrawal by Subject|1
6017947|NCT00171834|9611420|FG006|Overall Study|Withdrawal by Subject|0
6017948|NCT00171834|9611414|FG000|Overall Study|Death from study indication|0
6017949|NCT00171834|9611415|FG001|Overall Study|Death from study indication|1
6017950|NCT00171834|9611416|FG002|Overall Study|Death from study indication|0
6017951|NCT00171834|9611417|FG003|Overall Study|Death from study indication|0
6017952|NCT00171834|9611418|FG004|Overall Study|Death from study indication|1
6017953|NCT00171834|9611419|FG005|Overall Study|Death from study indication|0
6017954|NCT00171834|9611420|FG006|Overall Study|Death from study indication|0
6017955|NCT00171834|9611414|FG000|Overall Study|Disease Progression|4
6017956|NCT00171834|9611415|FG001|Overall Study|Disease Progression|8
6017957|NCT00171834|9611416|FG002|Overall Study|Disease Progression|8
6017958|NCT00171834|9611417|FG003|Overall Study|Disease Progression|9
6017959|NCT00171834|9611418|FG004|Overall Study|Disease Progression|2
6017960|NCT00171834|9611419|FG005|Overall Study|Disease Progression|18
6017961|NCT00171834|9611420|FG006|Overall Study|Disease Progression|3
6017962|NCT00171834|9611414|FG000|Overall Study|Treatment Duration Completed|0
6017963|NCT00171834|9611415|FG001|Overall Study|Treatment Duration Completed|0
6017964|NCT00171834|9611416|FG002|Overall Study|Treatment Duration Completed|1
6017965|NCT00171834|9611417|FG003|Overall Study|Treatment Duration Completed|0
6017966|NCT00171834|9611418|FG004|Overall Study|Treatment Duration Completed|2
6017967|NCT00171834|9611419|FG005|Overall Study|Treatment Duration Completed|1
6017968|NCT00171834|9611420|FG006|Overall Study|Treatment Duration Completed|0
6017969|NCT00171873|9611452|FG000|Overall Study|Withdrawal by Subject|4
6017970|NCT00171873|9611453|FG001|Overall Study|Withdrawal by Subject|2
6017971|NCT00171873|9611452|FG000|Overall Study|Adverse Event|5
6017972|NCT00171873|9611453|FG001|Overall Study|Adverse Event|0
6017973|NCT00171873|9611452|FG000|Overall Study|Switched to Octreotide|0
6017974|NCT00171873|9611453|FG001|Overall Study|Switched to Octreotide|1
6017975|NCT00171925|9611461|FG000|Overall Study|Adverse Event|10
6017976|NCT00171925|9611462|FG001|Overall Study|Adverse Event|6
6017977|NCT00171925|9611461|FG000|Overall Study|Protocol Violation|1
6017978|NCT00171925|9611462|FG001|Overall Study|Protocol Violation|1
6017979|NCT00171925|9611461|FG000|Overall Study|Withdrawal by Subject|6
6017980|NCT00171925|9611462|FG001|Overall Study|Withdrawal by Subject|9
6017981|NCT00171925|9611461|FG000|Overall Study|Lost to Follow-up|2
6017982|NCT00171925|9611462|FG001|Overall Study|Lost to Follow-up|2
6017983|NCT00171925|9611461|FG000|Overall Study|Administrative problems|10
6017984|NCT00171925|9611462|FG001|Overall Study|Administrative problems|11
6017985|NCT00171925|9611461|FG000|Overall Study|Death|1
6017986|NCT00171925|9611462|FG001|Overall Study|Death|2
6017987|NCT00171951|9611468|FG000|Overall Study|Adverse Event|1
6017988|NCT00171951|9611468|FG000|Overall Study|Abnormal Laboratory Values|2
6017989|NCT00171951|9611468|FG000|Overall Study|Unsatisfactory Therapeutic Effect|3
6017990|NCT00171951|9611468|FG000|Overall Study|Participants Withdrew Consent|3
6017991|NCT00171951|9611468|FG000|Overall Study|New Cancer Therapy|5
6017992|NCT00171951|9611468|FG000|Overall Study|Reason not Specified|2
6017993|NCT00172042|9611477|FG000|Overall Study|Adverse Event|27
6017994|NCT00172042|9611478|FG001|Overall Study|Adverse Event|13
6017995|NCT00172042|9611477|FG000|Overall Study|Abnormal laboratory value(s)|5
6017996|NCT00172042|9611478|FG001|Overall Study|Abnormal laboratory value(s)|1
6017997|NCT00172042|9611477|FG000|Overall Study|Abnormal test procedure(s)|0
6017998|NCT00172042|9611478|FG001|Overall Study|Abnormal test procedure(s)|3
6017999|NCT00172042|9611477|FG000|Overall Study|Unsatisfactory therapeutic effect|13
6018000|NCT00172042|9611478|FG001|Overall Study|Unsatisfactory therapeutic effect|11
6018001|NCT00172042|9611477|FG000|Overall Study|Patient no longer requires study drug|10
6018002|NCT00172042|9611478|FG001|Overall Study|Patient no longer requires study drug|8
6018003|NCT00172042|9611477|FG000|Overall Study|Protocol Violation|8
6018004|NCT00172042|9611478|FG001|Overall Study|Protocol Violation|7
6018005|NCT00172042|9611477|FG000|Overall Study|Withdrawal by Subject|37
6018006|NCT00172042|9611478|FG001|Overall Study|Withdrawal by Subject|25
6018007|NCT00172042|9611477|FG000|Overall Study|Lost to Follow-up|3
6018008|NCT00172042|9611478|FG001|Overall Study|Lost to Follow-up|5
6018009|NCT00172042|9611477|FG000|Overall Study|Administrative problems|13
6018010|NCT00172042|9611478|FG001|Overall Study|Administrative problems|10
6018011|NCT00172042|9611477|FG000|Overall Study|Death|42
6018012|NCT00172042|9611478|FG001|Overall Study|Death|42
6018013|NCT00172185|9611488|FG000|Overall Study|Adverse Event|0
6018014|NCT00172185|9611489|FG001|Overall Study|Adverse Event|1
6018015|NCT00172185|9611490|FG002|Overall Study|Adverse Event|3
6018016|NCT00172185|9611491|FG003|Overall Study|Adverse Event|4
6018017|NCT00172185|9611488|FG000|Overall Study|Physician Decision|0
6018018|NCT00172185|9611489|FG001|Overall Study|Physician Decision|0
6018019|NCT00172185|9611490|FG002|Overall Study|Physician Decision|1
6018020|NCT00172185|9611491|FG003|Overall Study|Physician Decision|0
6018021|NCT00172185|9611488|FG000|Overall Study|SPONSOR Decision|0
6018022|NCT00172185|9611489|FG001|Overall Study|SPONSOR Decision|1
6018023|NCT00172185|9611490|FG002|Overall Study|SPONSOR Decision|0
6018024|NCT00172185|9611491|FG003|Overall Study|SPONSOR Decision|0
6018025|NCT00172185|9611488|FG000|Overall Study|Withdrawal by Subject|0
6018026|NCT00172185|9611489|FG001|Overall Study|Withdrawal by Subject|0
6018027|NCT00172185|9611490|FG002|Overall Study|Withdrawal by Subject|1
6018028|NCT00172185|9611491|FG003|Overall Study|Withdrawal by Subject|0
6018029|NCT00174187|9611507|FG000|Period 1 (up to 3 Years)|Serious adverse event|0
6018030|NCT00174187|9611508|FG001|Period 1 (up to 3 Years)|Serious adverse event|1
6018031|NCT00174187|9611509|FG002|Period 1 (up to 3 Years)|Serious adverse event|0
6018032|NCT00174187|9611507|FG000|Period 1 (up to 3 Years)|Non compliance|0
6018033|NCT00174187|9611508|FG001|Period 1 (up to 3 Years)|Non compliance|1
6018034|NCT00174187|9611509|FG002|Period 1 (up to 3 Years)|Non compliance|0
6018035|NCT00174187|9611507|FG000|Period 1 (up to 3 Years)|Withdrawal by Subject|0
6018036|NCT00174187|9611508|FG001|Period 1 (up to 3 Years)|Withdrawal by Subject|1
6018037|NCT00174187|9611509|FG002|Period 1 (up to 3 Years)|Withdrawal by Subject|0
6018038|NCT00174187|9611507|FG000|Period 1 (up to 3 Years)|Other|0
6018039|NCT00174187|9611508|FG001|Period 1 (up to 3 Years)|Other|1
6018040|NCT00174187|9611509|FG002|Period 1 (up to 3 Years)|Other|0
6018041|NCT00174187|9611507|FG000|Between Period 1 and Period 2|Did not consent to continue treatment|0
6018042|NCT00174187|9611508|FG001|Between Period 1 and Period 2|Did not consent to continue treatment|0
6018043|NCT00174187|9611509|FG002|Between Period 1 and Period 2|Did not consent to continue treatment|2
6018044|NCT00174187|9611507|FG000|Between Period 1 and Period 2|Consented, not assigned to treatment|0
6018045|NCT00174187|9611508|FG001|Between Period 1 and Period 2|Consented, not assigned to treatment|0
6018046|NCT00174187|9611509|FG002|Between Period 1 and Period 2|Consented, not assigned to treatment|3
6018047|NCT00174187|9611507|FG000|Period 2 (After 3 Years)|Lost to Follow-up|0
6018048|NCT00174187|9611508|FG001|Period 2 (After 3 Years)|Lost to Follow-up|0
6018049|NCT00174187|9611509|FG002|Period 2 (After 3 Years)|Lost to Follow-up|2
6018050|NCT00174187|9611507|FG000|Period 2 (After 3 Years)|Withdrawal by Subject|0
6018051|NCT00174187|9611508|FG001|Period 2 (After 3 Years)|Withdrawal by Subject|0
6018052|NCT00174187|9611509|FG002|Period 2 (After 3 Years)|Withdrawal by Subject|1
6018053|NCT00174187|9611507|FG000|Period 2 (After 3 Years)|Other|0
6018054|NCT00174187|9611508|FG001|Period 2 (After 3 Years)|Other|0
6018055|NCT00174187|9611509|FG002|Period 2 (After 3 Years)|Other|5
6018056|NCT00174252|9611517|FG000|Overall Study|Protocol Violation|2
6018057|NCT00174291|9611525|FG000|Overall Study|Lost to Follow-up|1
6018058|NCT00174291|9611526|FG001|Overall Study|Lost to Follow-up|1
6018059|NCT00174291|9611525|FG000|Overall Study|Protocol Violation|0
6018060|NCT00174291|9611526|FG001|Overall Study|Protocol Violation|2
6018061|NCT00174291|9611525|FG000|Overall Study|Study terminated by sponsor|1
6018062|NCT00174291|9611526|FG001|Overall Study|Study terminated by sponsor|0
6018063|NCT00174291|9611525|FG000|Overall Study|Withdrawal by Subject|3
6018064|NCT00174291|9611526|FG001|Overall Study|Withdrawal by Subject|3
6018065|NCT00174382|9611532|FG000|Overall Study|Death|2
6018066|NCT00174382|9611532|FG000|Overall Study|Adverse Event|19
6018067|NCT00174382|9611532|FG000|Overall Study|Withdrawal by Subject|6
6018068|NCT00174382|9611532|FG000|Overall Study|Protocol Violation|3
6018069|NCT00174382|9611532|FG000|Overall Study|Arrived early for last visit in error|1
6018070|NCT00174382|9611532|FG000|Overall Study|Subject felt pill not effective enough|1
6018071|NCT00174382|9611532|FG000|Overall Study|Lost to Follow-up|1
6018072|NCT00174447|9611536|FG000|Overall Study|Adverse Event|19
6018073|NCT00174447|9611536|FG000|Overall Study|Withdrawal by Subject|15
6018074|NCT00174447|9611536|FG000|Overall Study|Protocol Violation|1
6018075|NCT00174447|9611536|FG000|Overall Study|Lack of Efficacy|1
6018076|NCT00174447|9611536|FG000|Overall Study|Administrative reason/Other|2
6018077|NCT00174460|9611542|FG000|Overall Study|Withdrawal by Subject|0
6018078|NCT00174460|9611543|FG001|Overall Study|Withdrawal by Subject|1
6018079|NCT00174785|9611552|FG000|Overall Study|Adverse Event|293
6018080|NCT00174785|9611553|FG001|Overall Study|Adverse Event|191
6018081|NCT00174785|9611552|FG000|Overall Study|Protocol Violation|14
6018082|NCT00174785|9611553|FG001|Overall Study|Protocol Violation|14
6018083|NCT00174785|9611552|FG000|Overall Study|Withdrawal by Subject|173
6018084|NCT00174785|9611553|FG001|Overall Study|Withdrawal by Subject|175
6018085|NCT00174785|9611552|FG000|Overall Study|Atrial Fibrillation/Flutter recurrence|110
6018086|NCT00174785|9611553|FG001|Overall Study|Atrial Fibrillation/Flutter recurrence|167
6018087|NCT00174785|9611552|FG000|Overall Study|Prohibited antiarrhythmic medication|39
6018088|NCT00174785|9611553|FG001|Overall Study|Prohibited antiarrhythmic medication|88
6018089|NCT00174785|9611552|FG000|Overall Study|Other prohibited medication|5
6018090|NCT00174785|9611553|FG001|Overall Study|Other prohibited medication|3
6018091|NCT00174785|9611552|FG000|Overall Study|Family request|6
6018092|NCT00174785|9611553|FG001|Overall Study|Family request|8
6018093|NCT00174785|9611552|FG000|Overall Study|Not pre-specified/Not coded|56
6077041|NCT00594815|9682870|FG000|Overall Study|Never Treated|3
6077042|NCT00594815|9682870|FG000|Overall Study|Withdrawal by Subject|2
6077043|NCT00594815|9682870|FG000|Overall Study|Toxicity|4
6077044|NCT00594854|9682876|FG000|Overall Study|Study terminated|7
6077045|NCT00594854|9682877|FG001|Overall Study|Study terminated|10
6077046|NCT00594880|9682885|FG000|Overall Study|Withdrawal by Subject|1
6077047|NCT00594880|9682886|FG001|Overall Study|Withdrawal by Subject|1
6018094|NCT00174785|9611553|FG001|Overall Study|Not pre-specified/Not coded|70
6018095|NCT00174915|9611564|FG000|Overall Study|Lost to Follow-up|19
6018096|NCT00174915|9611565|FG001|Overall Study|Lost to Follow-up|17
6018097|NCT00174915|9611566|FG002|Overall Study|Lost to Follow-up|9
6018098|NCT00174915|9611567|FG003|Overall Study|Lost to Follow-up|17
6018099|NCT00174915|9611568|FG004|Overall Study|Lost to Follow-up|10
6018100|NCT00174915|9611564|FG000|Overall Study|Adverse Event|18
6018101|NCT00174915|9611565|FG001|Overall Study|Adverse Event|16
6018102|NCT00174915|9611566|FG002|Overall Study|Adverse Event|11
6018103|NCT00174915|9611567|FG003|Overall Study|Adverse Event|18
6018104|NCT00174915|9611568|FG004|Overall Study|Adverse Event|5
6018105|NCT00174915|9611564|FG000|Overall Study|Personal Reason(s)|16
6018106|NCT00174915|9611565|FG001|Overall Study|Personal Reason(s)|16
6018107|NCT00174915|9611566|FG002|Overall Study|Personal Reason(s)|9
6018108|NCT00174915|9611567|FG003|Overall Study|Personal Reason(s)|9
6018109|NCT00174915|9611568|FG004|Overall Study|Personal Reason(s)|9
6018110|NCT00174915|9611564|FG000|Overall Study|Other|15
6018111|NCT00174915|9611565|FG001|Overall Study|Other|8
6018112|NCT00174915|9611566|FG002|Overall Study|Other|6
6018113|NCT00174915|9611567|FG003|Overall Study|Other|5
6018114|NCT00174915|9611568|FG004|Overall Study|Other|3
6018115|NCT00174915|9611564|FG000|Overall Study|Gout Flare|13
6018116|NCT00174915|9611565|FG001|Overall Study|Gout Flare|6
6018117|NCT00174915|9611566|FG002|Overall Study|Gout Flare|8
6018118|NCT00174915|9611567|FG003|Overall Study|Gout Flare|1
6018119|NCT00174915|9611568|FG004|Overall Study|Gout Flare|0
6018120|NCT00174915|9611564|FG000|Overall Study|Protocol Violation|6
6018121|NCT00174915|9611565|FG001|Overall Study|Protocol Violation|3
6018122|NCT00174915|9611566|FG002|Overall Study|Protocol Violation|3
6018123|NCT00174915|9611567|FG003|Overall Study|Protocol Violation|6
6018124|NCT00174915|9611568|FG004|Overall Study|Protocol Violation|3
6018125|NCT00174915|9611564|FG000|Overall Study|Therapeutic Failure|6
6018126|NCT00174915|9611565|FG001|Overall Study|Therapeutic Failure|3
6018127|NCT00174915|9611566|FG002|Overall Study|Therapeutic Failure|2
6018128|NCT00174915|9611567|FG003|Overall Study|Therapeutic Failure|1
6018129|NCT00174915|9611568|FG004|Overall Study|Therapeutic Failure|3
6018130|NCT00174941|9611583|FG000|Overall Study|Adverse Event|1
6018131|NCT00174941|9611584|FG001|Overall Study|Adverse Event|10
6018132|NCT00174941|9611585|FG002|Overall Study|Adverse Event|2
6018133|NCT00174941|9611586|FG003|Overall Study|Adverse Event|13
6018134|NCT00174941|9611583|FG000|Overall Study|Protocol Violation|0
6018135|NCT00174941|9611584|FG001|Overall Study|Protocol Violation|1
6018136|NCT00174941|9611585|FG002|Overall Study|Protocol Violation|0
6018137|NCT00174941|9611586|FG003|Overall Study|Protocol Violation|1
6018138|NCT00174941|9611583|FG000|Overall Study|Lost to Follow-up|0
6018139|NCT00174941|9611584|FG001|Overall Study|Lost to Follow-up|3
6018140|NCT00174941|9611585|FG002|Overall Study|Lost to Follow-up|2
6018141|NCT00174941|9611586|FG003|Overall Study|Lost to Follow-up|5
6018142|NCT00174941|9611583|FG000|Overall Study|Personal Reason(s)|0
6018143|NCT00174941|9611584|FG001|Overall Study|Personal Reason(s)|14
6018144|NCT00174941|9611585|FG002|Overall Study|Personal Reason(s)|8
6018145|NCT00174941|9611586|FG003|Overall Study|Personal Reason(s)|22
6018146|NCT00174941|9611583|FG000|Overall Study|Gout Flare|0
6018147|NCT00174941|9611584|FG001|Overall Study|Gout Flare|4
6018148|NCT00174941|9611585|FG002|Overall Study|Gout Flare|4
6018149|NCT00174941|9611586|FG003|Overall Study|Gout Flare|8
6018150|NCT00174941|9611583|FG000|Overall Study|Reason Not Specified|1
6018151|NCT00174941|9611584|FG001|Overall Study|Reason Not Specified|6
6018152|NCT00174941|9611585|FG002|Overall Study|Reason Not Specified|2
6018153|NCT00174941|9611586|FG003|Overall Study|Reason Not Specified|9
6018154|NCT00174954|9611596|FG000|Overall Study|Adverse Event|2
6018155|NCT00174954|9611596|FG000|Overall Study|No tophi found in MRI|1
6018156|NCT00174954|9611596|FG000|Overall Study|Physician Decision|1
6018157|NCT00174967|9611604|FG000|Overall Study|Adverse Event|1
6018158|NCT00174967|9611605|FG001|Overall Study|Adverse Event|2
6018159|NCT00174967|9611606|FG002|Overall Study|Adverse Event|2
6018160|NCT00174967|9611607|FG003|Overall Study|Adverse Event|1
6018161|NCT00174967|9611604|FG000|Overall Study|Gout Flare|0
6018162|NCT00174967|9611605|FG001|Overall Study|Gout Flare|0
6018163|NCT00174967|9611606|FG002|Overall Study|Gout Flare|0
6018164|NCT00174967|9611607|FG003|Overall Study|Gout Flare|1
6018165|NCT00174967|9611604|FG000|Overall Study|Other|0
6018166|NCT00174967|9611605|FG001|Overall Study|Other|1
6018167|NCT00174967|9611606|FG002|Overall Study|Other|0
6018168|NCT00174967|9611607|FG003|Overall Study|Other|0
6018169|NCT00175019|9611624|FG000|Overall Study|Adverse Event|54
6018170|NCT00175019|9611625|FG001|Overall Study|Adverse Event|22
6018171|NCT00175019|9611626|FG002|Overall Study|Adverse Event|2
6018172|NCT00175019|9611624|FG000|Overall Study|Protocol Violation|6
6018173|NCT00175019|9611625|FG001|Overall Study|Protocol Violation|3
6077048|NCT00594880|9682885|FG000|Overall Study|Lost to Follow-up|1
6077049|NCT00594880|9682886|FG001|Overall Study|Lost to Follow-up|0
6077050|NCT00594906|9682898|FG000|Overall Study|Physician Decision|1
6018174|NCT00175019|9611626|FG002|Overall Study|Protocol Violation|3
6018175|NCT00175019|9611624|FG000|Overall Study|Lost to Follow-up|42
6018176|NCT00175019|9611625|FG001|Overall Study|Lost to Follow-up|39
6018177|NCT00175019|9611626|FG002|Overall Study|Lost to Follow-up|9
6018178|NCT00175019|9611624|FG000|Overall Study|Did not continue under Amendment 4|1
6018179|NCT00175019|9611625|FG001|Overall Study|Did not continue under Amendment 4|1
6018180|NCT00175019|9611626|FG002|Overall Study|Did not continue under Amendment 4|2
6018181|NCT00175019|9611624|FG000|Overall Study|Personal Reason(s)|39
6018182|NCT00175019|9611625|FG001|Overall Study|Personal Reason(s)|31
6018183|NCT00175019|9611626|FG002|Overall Study|Personal Reason(s)|8
6018184|NCT00175019|9611624|FG000|Overall Study|Therapeutic Failure|10
6018185|NCT00175019|9611625|FG001|Overall Study|Therapeutic Failure|38
6018186|NCT00175019|9611626|FG002|Overall Study|Therapeutic Failure|22
6018187|NCT00175019|9611624|FG000|Overall Study|Gout Flare|2
6018188|NCT00175019|9611625|FG001|Overall Study|Gout Flare|3
6018189|NCT00175019|9611626|FG002|Overall Study|Gout Flare|0
6018190|NCT00175019|9611624|FG000|Overall Study|Reason Not Specified|40
6018191|NCT00175019|9611625|FG001|Overall Study|Reason Not Specified|34
6018192|NCT00175019|9611626|FG002|Overall Study|Reason Not Specified|11
6018193|NCT00175825|9611638|FG000|Overall Study|Adverse Event|3
6018194|NCT00175825|9611639|FG001|Overall Study|Adverse Event|2
6018195|NCT00175825|9611640|FG002|Overall Study|Adverse Event|1
6018196|NCT00175825|9611641|FG003|Overall Study|Adverse Event|1
6018197|NCT00175825|9611638|FG000|Overall Study|Lost to Follow-up|1
6018198|NCT00175825|9611639|FG001|Overall Study|Lost to Follow-up|2
6018199|NCT00175825|9611640|FG002|Overall Study|Lost to Follow-up|0
6018200|NCT00175825|9611641|FG003|Overall Study|Lost to Follow-up|0
6018201|NCT00175825|9611638|FG000|Overall Study|Withdrawal by Subject|1
6018202|NCT00175825|9611639|FG001|Overall Study|Withdrawal by Subject|0
6018203|NCT00175825|9611640|FG002|Overall Study|Withdrawal by Subject|0
6018204|NCT00175825|9611641|FG003|Overall Study|Withdrawal by Subject|0
6018205|NCT00175877|9611651|FG000|Overall Study|Adverse Event|136
6018206|NCT00175877|9611651|FG000|Overall Study|Withdrawal by Subject|141
6018207|NCT00175877|9611651|FG000|Overall Study|Lost to Follow-up|9
6018208|NCT00175877|9611651|FG000|Overall Study|Lack of Efficacy|26
6018209|NCT00175877|9611651|FG000|Overall Study|Protocol Violation|15
6018210|NCT00175877|9611651|FG000|Overall Study|Other Reason|20
6018211|NCT00175877|9611651|FG000|Overall Study|AE & Other|1
6018212|NCT00175877|9611651|FG000|Overall Study|Withdrawal by subject & Other|1
6018213|NCT00175916|9611655|FG000|Overall Study|Death|19
6018214|NCT00175916|9611655|FG000|Overall Study|Adverse Event|81
6018215|NCT00175916|9611655|FG000|Overall Study|Lack of Efficacy|354
6018216|NCT00175916|9611655|FG000|Overall Study|Lost to Follow-up|17
6018217|NCT00175916|9611655|FG000|Overall Study|Subject Choice|98
6018218|NCT00175916|9611655|FG000|Overall Study|Lack of compliance|8
6018219|NCT00175916|9611655|FG000|Overall Study|Patient cannot record seizures|1
6018220|NCT00175916|9611655|FG000|Overall Study|Sponsor decision|17
6018221|NCT00175916|9611655|FG000|Overall Study|Vigabatrin intake|1
6018222|NCT00175916|9611655|FG000|Overall Study|Suicidal behaviour|1
6018223|NCT00175916|9611655|FG000|Overall Study|Withdrawal by Subject|1
6018224|NCT00175916|9611655|FG000|Overall Study|Seizure - free|4
6018225|NCT00175916|9611655|FG000|Overall Study|Administrative reason|1
6018226|NCT00175916|9611655|FG000|Overall Study|Pregnancy|1
6018227|NCT00175916|9611655|FG000|Overall Study|Patient's request|2
6018228|NCT00175916|9611655|FG000|Overall Study|Treating physiciant's choice|1
6018229|NCT00175916|9611655|FG000|Overall Study|Moved overseas|1
6018230|NCT00175916|9611655|FG000|Overall Study|Loss of job and economic burden|1
6018231|NCT00175916|9611655|FG000|Overall Study|Site was closed|9
6018232|NCT00175916|9611655|FG000|Overall Study|Patient went to prison|1
6018233|NCT00176254|9611676|FG000|Overall Study|Lost to Follow-up|1
6018234|NCT00176462|9611695|FG000|Induction (4 Weeks)|Withdrawal by Subject|0
6018235|NCT00176462|9611696|FG001|Induction (4 Weeks)|Withdrawal by Subject|2
6018236|NCT00176462|9611695|FG000|Induction (4 Weeks)|Death|1
6018237|NCT00176462|9611696|FG001|Induction (4 Weeks)|Death|2
6018238|NCT00176462|9611695|FG000|Induction (4 Weeks)|Lack of Efficacy|0
6018239|NCT00176462|9611696|FG001|Induction (4 Weeks)|Lack of Efficacy|1
6018240|NCT00176462|9611695|FG000|Consolidation (12 Weeks)|Patient moved to another state|0
6018241|NCT00176462|9611696|FG001|Consolidation (12 Weeks)|Patient moved to another state|1
6018242|NCT00176462|9611695|FG000|Consolidation (12 Weeks)|Adverse Event|0
6018243|NCT00176462|9611696|FG001|Consolidation (12 Weeks)|Adverse Event|1
6018244|NCT00176462|9611695|FG000|Consolidation (12 Weeks)|Lack of Efficacy|0
6018245|NCT00176462|9611696|FG001|Consolidation (12 Weeks)|Lack of Efficacy|2
6018246|NCT00176462|9611695|FG000|Consolidation (12 Weeks)|Not documented|0
6018247|NCT00176462|9611696|FG001|Consolidation (12 Weeks)|Not documented|1
6018248|NCT00176462|9611695|FG000|Intensive Continuation (8X8-week Cycles)|Death|1
6018249|NCT00176462|9611696|FG001|Intensive Continuation (8X8-week Cycles)|Death|0
6018250|NCT00176462|9611695|FG000|Intensive Continuation (8X8-week Cycles)|Lack of Efficacy|0
6018251|NCT00176462|9611696|FG001|Intensive Continuation (8X8-week Cycles)|Lack of Efficacy|3
6018252|NCT00176605|9611712|FG000|Overall Study|Withdrawal by Subject|2
6018253|NCT00176644|9611716|FG000|Overall Study|Withdrawal by Subject|1
6018254|NCT00177164|9611813|FG000|Overall Study|Protocol Violation|0
6018255|NCT00177164|9611814|FG001|Overall Study|Protocol Violation|7
6018256|NCT00177164|9611813|FG000|Overall Study|Lost to Follow-up|4
6018257|NCT00177164|9611814|FG001|Overall Study|Lost to Follow-up|5
6018258|NCT00177164|9611813|FG000|Overall Study|increase in alcohol and drug use|1
6018259|NCT00177164|9611814|FG001|Overall Study|increase in alcohol and drug use|2
6018260|NCT00177164|9611813|FG000|Overall Study|Adverse Event|1
6077051|NCT00594906|9682899|FG001|Overall Study|Physician Decision|0
6077052|NCT00594906|9682898|FG000|Overall Study|Physician Decision|0
6077053|NCT00594906|9682899|FG001|Overall Study|Physician Decision|1
6077054|NCT00594906|9682898|FG000|Overall Study|Death|0
6018261|NCT00177164|9611814|FG001|Overall Study|Adverse Event|0
6018262|NCT00177164|9611813|FG000|Overall Study|discharge from hospital|1
6018263|NCT00177164|9611814|FG001|Overall Study|discharge from hospital|0
6018264|NCT00177164|9611813|FG000|Overall Study|Lack of Efficacy|2
6018265|NCT00177164|9611814|FG001|Overall Study|Lack of Efficacy|1
6018266|NCT00177164|9611813|FG000|Overall Study|Pregnancy|0
6018267|NCT00177164|9611814|FG001|Overall Study|Pregnancy|1
6018268|NCT00177216|9611823|FG000|Overall Study|Withdrawal by Subject|6
6018269|NCT00177216|9611824|FG001|Overall Study|Withdrawal by Subject|3
6018270|NCT00177216|9611825|FG002|Overall Study|Withdrawal by Subject|1
6018271|NCT00177294|9611843|FG000|Overall Study|Withdrawal by Subject|7
6018272|NCT00177294|9611844|FG001|Overall Study|Withdrawal by Subject|5
6018273|NCT00177307|9611850|FG000|Overall Study|Withdrawal by Subject|1
6018274|NCT00177671|9611856|FG000|Overall Study|Withdrawal by Subject|5
6018275|NCT00177671|9611857|FG001|Overall Study|Withdrawal by Subject|6
6018276|NCT00177671|9611856|FG000|Overall Study|medical complications|2
6018277|NCT00177671|9611857|FG001|Overall Study|medical complications|0
6018278|NCT00177671|9611856|FG000|Overall Study|Adverse Event|6
6018279|NCT00177671|9611857|FG001|Overall Study|Adverse Event|0
6018280|NCT00177671|9611856|FG000|Overall Study|Physician Decision|12
6018281|NCT00177671|9611857|FG001|Overall Study|Physician Decision|8
6018282|NCT00178126|9611865|FG000|Overall Study|Lost to Follow-up|21
6018283|NCT00178126|9611866|FG001|Overall Study|Lost to Follow-up|21
6018284|NCT00178126|9611865|FG000|Overall Study|did not receive intervention|4
6018285|NCT00178126|9611866|FG001|Overall Study|did not receive intervention|6
6018286|NCT00178256|9611902|FG000|Overall Study|Adverse Event|2
6018287|NCT00178256|9611903|FG001|Overall Study|Adverse Event|0
6018288|NCT00178256|9611904|FG002|Overall Study|Adverse Event|0
6018289|NCT00178256|9611905|FG003|Overall Study|Adverse Event|0
6018290|NCT00178256|9611902|FG000|Overall Study|Death|0
6018291|NCT00178256|9611903|FG001|Overall Study|Death|1
6018292|NCT00178256|9611904|FG002|Overall Study|Death|0
6018293|NCT00178256|9611905|FG003|Overall Study|Death|1
6018294|NCT00178256|9611902|FG000|Overall Study|Cancer progression|2
6018295|NCT00178256|9611903|FG001|Overall Study|Cancer progression|0
6018296|NCT00178256|9611904|FG002|Overall Study|Cancer progression|0
6018297|NCT00178256|9611905|FG003|Overall Study|Cancer progression|1
6018298|NCT00178399|9611912|FG000|Overall Study|Physician Decision|4
6018299|NCT00178399|9611912|FG000|Overall Study|Withdrawal by Subject|8
6018300|NCT00178399|9611912|FG000|Overall Study|Lost to Follow-up|1
6018301|NCT00178464|9611917|FG000|Overall Study|Withdrawal by Subject|1
6018302|NCT00178464|9611917|FG000|Overall Study|Physician Decision|1
6018303|NCT00178633|9611936|FG000|Overall Study|Lost to Follow-up|6
6018304|NCT00178685|9611960|FG000|Overall Study|Death|3
6018305|NCT00178685|9611961|FG001|Overall Study|Death|3
6018306|NCT00178685|9611962|FG002|Overall Study|Death|6
6018307|NCT00178685|9611960|FG000|Overall Study|Lost to Follow-up|100
6077055|NCT00594906|9682899|FG001|Overall Study|Death|1
6077056|NCT00594932|9682907|FG000|First 3 Months|Withdrawal by Subject|1
6077057|NCT00594932|9682908|FG001|First 3 Months|Withdrawal by Subject|3
6018308|NCT00178685|9611961|FG001|Overall Study|Lost to Follow-up|187
6018309|NCT00178685|9611962|FG002|Overall Study|Lost to Follow-up|183
6018310|NCT00178685|9611960|FG000|Overall Study|Withdrawal by Subject|8
6018311|NCT00178685|9611961|FG001|Overall Study|Withdrawal by Subject|14
6018312|NCT00178685|9611962|FG002|Overall Study|Withdrawal by Subject|7
6018313|NCT00179010|9611997|FG000|Overall Study|Muscle probe defective|1
6018314|NCT00179010|9611998|FG001|Overall Study|Muscle probe defective|1
6018315|NCT00179010|9611997|FG000|Overall Study|Failure to place arterial line|0
6018316|NCT00179010|9611998|FG001|Overall Study|Failure to place arterial line|1
6018317|NCT00179309|9612007|FG000|Treatment|Toxicity|2
6018318|NCT00179309|9612008|FG001|Treatment|Toxicity|3
6018319|NCT00179309|9612007|FG000|Treatment|Withdrawal by Subject|1
6018320|NCT00179309|9612008|FG001|Treatment|Withdrawal by Subject|2
6018321|NCT00179309|9612007|FG000|Treatment|Allergy|1
6018322|NCT00179309|9612008|FG001|Treatment|Allergy|0
6018323|NCT00179413|9612016|FG000|Overall Study|Adverse Event|38
6018324|NCT00179413|9612017|FG001|Overall Study|Adverse Event|20
6018325|NCT00179413|9612016|FG000|Overall Study|Withdrawal by Subject|87
6018326|NCT00179413|9612017|FG001|Overall Study|Withdrawal by Subject|95
6018327|NCT00179517|9612033|FG000|Overall Study|Withdrawal by Subject|2
6018328|NCT00179517|9612034|FG001|Overall Study|Withdrawal by Subject|1
6018329|NCT00179621|9612043|FG000|Double-Blind Period|Lack of Therapeutic Effect|59
6018330|NCT00179621|9612044|FG001|Double-Blind Period|Lack of Therapeutic Effect|35
6018331|NCT00179621|9612045|FG002|Double-Blind Period|Lack of Therapeutic Effect|19
6018332|NCT00179621|9612046|FG003|Double-Blind Period|Lack of Therapeutic Effect|0
6018333|NCT00179621|9612043|FG000|Double-Blind Period|Adverse Event|2
6018334|NCT00179621|9612044|FG001|Double-Blind Period|Adverse Event|7
6077058|NCT00594932|9682907|FG000|Final 3 Months|Withdrawal by Subject|4
6018335|NCT00179621|9612045|FG002|Double-Blind Period|Adverse Event|4
6018336|NCT00179621|9612046|FG003|Double-Blind Period|Adverse Event|0
6018337|NCT00179621|9612043|FG000|Double-Blind Period|Withdrawal by Subject|2
6018338|NCT00179621|9612044|FG001|Double-Blind Period|Withdrawal by Subject|1
6018339|NCT00179621|9612045|FG002|Double-Blind Period|Withdrawal by Subject|3
6018340|NCT00179621|9612046|FG003|Double-Blind Period|Withdrawal by Subject|0
6018341|NCT00179621|9612043|FG000|Double-Blind Period|Death|0
6018342|NCT00179621|9612044|FG001|Double-Blind Period|Death|1
6018343|NCT00179621|9612045|FG002|Double-Blind Period|Death|2
6018344|NCT00179621|9612046|FG003|Double-Blind Period|Death|0
6018345|NCT00179621|9612043|FG000|Double-Blind Period|Protocol Violation|1
6018346|NCT00179621|9612044|FG001|Double-Blind Period|Protocol Violation|0
6018347|NCT00179621|9612045|FG002|Double-Blind Period|Protocol Violation|0
6018348|NCT00179621|9612046|FG003|Double-Blind Period|Protocol Violation|0
6018349|NCT00179621|9612043|FG000|Double-Blind Period|Other|0
6018350|NCT00179621|9612044|FG001|Double-Blind Period|Other|2
6018351|NCT00179621|9612045|FG002|Double-Blind Period|Other|2
6018352|NCT00179621|9612046|FG003|Double-Blind Period|Other|0
6018353|NCT00179621|9612043|FG000|Open-Label Period|Lack of Therapeutic Effect|0
6018354|NCT00179621|9612044|FG001|Open-Label Period|Lack of Therapeutic Effect|19
6018355|NCT00179621|9612045|FG002|Open-Label Period|Lack of Therapeutic Effect|19
6018356|NCT00179621|9612046|FG003|Open-Label Period|Lack of Therapeutic Effect|31
6018357|NCT00179621|9612043|FG000|Open-Label Period|Adverse Event|0
6018358|NCT00179621|9612044|FG001|Open-Label Period|Adverse Event|6
6018359|NCT00179621|9612045|FG002|Open-Label Period|Adverse Event|5
6018360|NCT00179621|9612046|FG003|Open-Label Period|Adverse Event|6
6018361|NCT00179621|9612043|FG000|Open-Label Period|Withdrawal by Subject|0
6018362|NCT00179621|9612044|FG001|Open-Label Period|Withdrawal by Subject|2
6018363|NCT00179621|9612045|FG002|Open-Label Period|Withdrawal by Subject|2
6018364|NCT00179621|9612046|FG003|Open-Label Period|Withdrawal by Subject|2
6018365|NCT00179621|9612043|FG000|Open-Label Period|Death|0
6018366|NCT00179621|9612044|FG001|Open-Label Period|Death|0
6018367|NCT00179621|9612045|FG002|Open-Label Period|Death|1
6018368|NCT00179621|9612046|FG003|Open-Label Period|Death|2
6018369|NCT00179621|9612043|FG000|Open-Label Period|Other|0
6018370|NCT00179621|9612044|FG001|Open-Label Period|Other|1
6018371|NCT00179621|9612045|FG002|Open-Label Period|Other|1
6018372|NCT00179621|9612046|FG003|Open-Label Period|Other|2
6018373|NCT00179647|9612055|FG000|Overall Study|Adverse Event|294
6018374|NCT00179647|9612055|FG000|Overall Study|Lack of Efficacy|478
6018375|NCT00179647|9612055|FG000|Overall Study|Withdrawal by Subject|83
6018376|NCT00179647|9612055|FG000|Overall Study|Lost to Follow-up|4
6018377|NCT00179647|9612055|FG000|Overall Study|Death|94
6018378|NCT00179647|9612055|FG000|Overall Study|Other|960
6018379|NCT00179660|9612059|FG000|Overall Study|Adverse Event|7
6018380|NCT00179660|9612059|FG000|Overall Study|Lack of therapeutic effect|28
6018381|NCT00179660|9612059|FG000|Overall Study|Withdrawal by Subject|2
6018382|NCT00179660|9612059|FG000|Overall Study|Lost to Follow-up|1
6018383|NCT00179660|9612059|FG000|Overall Study|Death|3
6018384|NCT00179660|9612059|FG000|Overall Study|Other - Unspecified|9
6018385|NCT00179673|9612063|FG000|Overall Study|Adverse Event|7
6018386|NCT00179673|9612063|FG000|Overall Study|Lack of Efficacy|15
6018387|NCT00179673|9612063|FG000|Overall Study|Withdrawal by Subject|3
6077059|NCT00594932|9682908|FG001|Final 3 Months|Withdrawal by Subject|3
6077060|NCT00594958|9682928|FG000|Overall Study|Withdrawal by Subject|1
6077061|NCT00594958|9682929|FG001|Overall Study|Withdrawal by Subject|0
6077062|NCT00594958|9682930|FG002|Overall Study|Withdrawal by Subject|1
6077063|NCT00594958|9682928|FG000|Overall Study|Adverse Event|4
6077064|NCT00594958|9682929|FG001|Overall Study|Adverse Event|1
6077065|NCT00594958|9682930|FG002|Overall Study|Adverse Event|2
6077066|NCT00594958|9682928|FG000|Overall Study|Pregnancy|0
6077067|NCT00594958|9682929|FG001|Overall Study|Pregnancy|2
6077068|NCT00594958|9682930|FG002|Overall Study|Pregnancy|0
6077069|NCT00594958|9682928|FG000|Overall Study|Protocol Violation|1
6077070|NCT00594958|9682929|FG001|Overall Study|Protocol Violation|0
6077071|NCT00594958|9682930|FG002|Overall Study|Protocol Violation|2
6077072|NCT00594958|9682928|FG000|Overall Study|Lost to Follow-up|5
6077073|NCT00594958|9682929|FG001|Overall Study|Lost to Follow-up|0
6077074|NCT00594958|9682930|FG002|Overall Study|Lost to Follow-up|3
6077075|NCT00594958|9682928|FG000|Overall Study|administrative|3
6077076|NCT00594958|9682929|FG001|Overall Study|administrative|0
6077077|NCT00594958|9682930|FG002|Overall Study|administrative|2
6077078|NCT00595075|9682951|FG000|Overall Study|Withdrawal by Subject|1
6018388|NCT00179673|9612063|FG000|Overall Study|Death|4
6018389|NCT00179673|9612063|FG000|Overall Study|Other Observations and options|14
6018390|NCT00179959|9612080|FG000|Overall Study|Lost to Follow-up|3
6018391|NCT00179959|9612081|FG001|Overall Study|Lost to Follow-up|1
6018392|NCT00179959|9612080|FG000|Overall Study|Withdrawal by Subject|3
6018393|NCT00179959|9612081|FG001|Overall Study|Withdrawal by Subject|2
6018394|NCT00180479|9612128|FG000|Overall Study|Death|4
6018395|NCT00180479|9612129|FG001|Overall Study|Death|2
6018396|NCT00180479|9612128|FG000|Overall Study|Lost to Follow-up|9
6018397|NCT00180479|9612129|FG001|Overall Study|Lost to Follow-up|7
6018398|NCT00180479|9612128|FG000|Overall Study|Withdrawal by Subject|3
6077079|NCT00595075|9682952|FG001|Overall Study|Withdrawal by Subject|0
6077080|NCT00595127|9682988|FG000|Overall Study|Death|6
6077081|NCT00595127|9682988|FG000|Overall Study|Relapsed|3
6018399|NCT00180479|9612129|FG001|Overall Study|Withdrawal by Subject|3
6018400|NCT00180479|9612128|FG000|Overall Study|Informed consent not signed|0
6018401|NCT00180479|9612129|FG001|Overall Study|Informed consent not signed|1
6018402|NCT00180674|9612144|FG000|Phase 1, Observation Period|Withdrawal by Subject|4
6018403|NCT00180674|9612144|FG000|Phase 2, Warfarin Treatment Period|Adverse Event|1
6047812|NCT00413660|9646915|FG007|Up To Week 12|Lack of Efficacy|0
6047813|NCT00413660|9646916|FG008|Up To Week 12|Lack of Efficacy|0
6047814|NCT00413660|9646917|FG009|Up To Week 12|Lack of Efficacy|0
6047815|NCT00413660|9646918|FG010|Up To Week 12|Lack of Efficacy|0
6047816|NCT00413660|9646908|FG000|Up To Week 12|Lost to Follow-up|0
6047817|NCT00413660|9646909|FG001|Up To Week 12|Lost to Follow-up|1
6047818|NCT00413660|9646910|FG002|Up To Week 12|Lost to Follow-up|0
6047819|NCT00413660|9646911|FG003|Up To Week 12|Lost to Follow-up|0
6047820|NCT00413660|9646912|FG004|Up To Week 12|Lost to Follow-up|1
6047821|NCT00413660|9646913|FG005|Up To Week 12|Lost to Follow-up|0
6047822|NCT00413660|9646914|FG006|Up To Week 12|Lost to Follow-up|0
6047823|NCT00413660|9646915|FG007|Up To Week 12|Lost to Follow-up|0
6047824|NCT00413660|9646916|FG008|Up To Week 12|Lost to Follow-up|0
6047825|NCT00413660|9646917|FG009|Up To Week 12|Lost to Follow-up|0
6047826|NCT00413660|9646918|FG010|Up To Week 12|Lost to Follow-up|0
6047827|NCT00413660|9646908|FG000|Up To Week 12|Withdrawal by Subject|0
6047828|NCT00413660|9646909|FG001|Up To Week 12|Withdrawal by Subject|2
6047829|NCT00413660|9646910|FG002|Up To Week 12|Withdrawal by Subject|0
6047830|NCT00413660|9646911|FG003|Up To Week 12|Withdrawal by Subject|2
6047831|NCT00413660|9646912|FG004|Up To Week 12|Withdrawal by Subject|0
6047832|NCT00413660|9646913|FG005|Up To Week 12|Withdrawal by Subject|2
6047833|NCT00413660|9646914|FG006|Up To Week 12|Withdrawal by Subject|2
6047834|NCT00413660|9646915|FG007|Up To Week 12|Withdrawal by Subject|0
6047835|NCT00413660|9646916|FG008|Up To Week 12|Withdrawal by Subject|0
6047836|NCT00413660|9646917|FG009|Up To Week 12|Withdrawal by Subject|0
6047837|NCT00413660|9646918|FG010|Up To Week 12|Withdrawal by Subject|0
6047838|NCT00413660|9646908|FG000|Up To Week 12|Randomized, Not Treated|1
6047839|NCT00413660|9646909|FG001|Up To Week 12|Randomized, Not Treated|0
6047840|NCT00413660|9646910|FG002|Up To Week 12|Randomized, Not Treated|0
6047841|NCT00413660|9646911|FG003|Up To Week 12|Randomized, Not Treated|1
6047842|NCT00413660|9646912|FG004|Up To Week 12|Randomized, Not Treated|0
6047843|NCT00413660|9646913|FG005|Up To Week 12|Randomized, Not Treated|0
6047844|NCT00413660|9646914|FG006|Up To Week 12|Randomized, Not Treated|0
6047845|NCT00413660|9646915|FG007|Up To Week 12|Randomized, Not Treated|0
6047846|NCT00413660|9646916|FG008|Up To Week 12|Randomized, Not Treated|0
6047847|NCT00413660|9646917|FG009|Up To Week 12|Randomized, Not Treated|0
6047848|NCT00413660|9646918|FG010|Up To Week 12|Randomized, Not Treated|0
6047849|NCT00413660|9646908|FG000|Up To Week 12|Other|3
6047850|NCT00413660|9646909|FG001|Up To Week 12|Other|1
6047851|NCT00413660|9646910|FG002|Up To Week 12|Other|6
6047852|NCT00413660|9646911|FG003|Up To Week 12|Other|1
6047853|NCT00413660|9646912|FG004|Up To Week 12|Other|2
6047854|NCT00413660|9646913|FG005|Up To Week 12|Other|4
6047855|NCT00413660|9646914|FG006|Up To Week 12|Other|3
6047856|NCT00413660|9646915|FG007|Up To Week 12|Other|0
6047857|NCT00413660|9646916|FG008|Up To Week 12|Other|0
6047858|NCT00413660|9646917|FG009|Up To Week 12|Other|0
6047859|NCT00413660|9646918|FG010|Up To Week 12|Other|0
6047860|NCT00413660|9646908|FG000|Post Week 12|Adverse Event|2
6047861|NCT00413660|9646909|FG001|Post Week 12|Adverse Event|0
6047862|NCT00413660|9646910|FG002|Post Week 12|Adverse Event|2
6047863|NCT00413660|9646911|FG003|Post Week 12|Adverse Event|1
6047864|NCT00413660|9646912|FG004|Post Week 12|Adverse Event|4
6047865|NCT00413660|9646913|FG005|Post Week 12|Adverse Event|2
6047866|NCT00413660|9646914|FG006|Post Week 12|Adverse Event|2
6047867|NCT00413660|9646915|FG007|Post Week 12|Adverse Event|0
6047868|NCT00413660|9646916|FG008|Post Week 12|Adverse Event|0
6047869|NCT00413660|9646917|FG009|Post Week 12|Adverse Event|0
6047870|NCT00413660|9646918|FG010|Post Week 12|Adverse Event|0
6047871|NCT00413660|9646908|FG000|Post Week 12|Lack of Efficacy|0
6047872|NCT00413660|9646909|FG001|Post Week 12|Lack of Efficacy|0
6047873|NCT00413660|9646910|FG002|Post Week 12|Lack of Efficacy|1
6047874|NCT00413660|9646911|FG003|Post Week 12|Lack of Efficacy|0
6047875|NCT00413660|9646912|FG004|Post Week 12|Lack of Efficacy|0
6047876|NCT00413660|9646913|FG005|Post Week 12|Lack of Efficacy|0
6047877|NCT00413660|9646914|FG006|Post Week 12|Lack of Efficacy|0
6047878|NCT00413660|9646915|FG007|Post Week 12|Lack of Efficacy|0
6047879|NCT00413660|9646916|FG008|Post Week 12|Lack of Efficacy|0
6047880|NCT00413660|9646917|FG009|Post Week 12|Lack of Efficacy|1
6047881|NCT00413660|9646918|FG010|Post Week 12|Lack of Efficacy|0
6047882|NCT00413660|9646908|FG000|Post Week 12|Lost to Follow-up|0
6047883|NCT00413660|9646909|FG001|Post Week 12|Lost to Follow-up|1
6047884|NCT00413660|9646910|FG002|Post Week 12|Lost to Follow-up|1
6047885|NCT00413660|9646911|FG003|Post Week 12|Lost to Follow-up|0
6047886|NCT00413660|9646912|FG004|Post Week 12|Lost to Follow-up|0
6047887|NCT00413660|9646913|FG005|Post Week 12|Lost to Follow-up|0
6047888|NCT00413660|9646914|FG006|Post Week 12|Lost to Follow-up|0
6047889|NCT00413660|9646915|FG007|Post Week 12|Lost to Follow-up|0
6047890|NCT00413660|9646916|FG008|Post Week 12|Lost to Follow-up|0
6047891|NCT00413660|9646917|FG009|Post Week 12|Lost to Follow-up|0
6047892|NCT00413660|9646918|FG010|Post Week 12|Lost to Follow-up|0
6047893|NCT00413660|9646908|FG000|Post Week 12|Withdrawal by Subject|0
6018404|NCT00180713|9612171|FG000|Overall Study|Withdrawal by Subject|2
6018405|NCT00180713|9612172|FG001|Overall Study|Withdrawal by Subject|0
6018406|NCT00180713|9612171|FG000|Overall Study|Adverse Event|3
6018407|NCT00180713|9612172|FG001|Overall Study|Adverse Event|3
6018408|NCT00181155|9612178|FG000|Overall Study|Physician Decision|1
6018409|NCT00181155|9612179|FG001|Overall Study|Physician Decision|0
6018410|NCT00181155|9612178|FG000|Overall Study|Withdrawal by Subject|1
6018411|NCT00181155|9612179|FG001|Overall Study|Withdrawal by Subject|0
6018412|NCT00181766|9612243|FG000|Overall Study|Lost to Follow-up|6
6018413|NCT00181766|9612243|FG000|Overall Study|Adverse Event|4
6018414|NCT00181766|9612243|FG000|Overall Study|non-compliance|2
6018415|NCT00181844|9612247|FG000|Signed Consent|Withdrawal by Subject|5
6018416|NCT00181844|9612247|FG000|Signed Consent|Did not meet entrance criteria|7
6018417|NCT00181844|9612247|FG000|Exposed to Study Medication|Adverse Event|10
6018418|NCT00181844|9612247|FG000|Exposed to Study Medication|Lack of Efficacy|2
6018419|NCT00181844|9612247|FG000|Exposed to Study Medication|Non-compliance|2
6018420|NCT00181844|9612247|FG000|Exposed to Study Medication|Withdrawal by Subject|1
6018421|NCT00181844|9612247|FG000|Exposed to Study Medication|Difficulty meeting study schedule|2
6018422|NCT00181883|9612251|FG000|Overall Study|Lack of Efficacy|2
6018423|NCT00181883|9612251|FG000|Overall Study|Treatment Limiting AEs|3
6018424|NCT00181883|9612251|FG000|Overall Study|Withdrawal by Subject|4
6018425|NCT00181883|9612251|FG000|Overall Study|Lost to Follow-up|1
6018426|NCT00182078|9612275|FG000|Overall Study|Withdrawal by Subject|1
6018427|NCT00182078|9612276|FG001|Overall Study|Withdrawal by Subject|0
6018428|NCT00182091|9612286|FG000|Overall Study|Withdrawal by Subject|1
6018429|NCT00182091|9612287|FG001|Overall Study|Withdrawal by Subject|0
6018430|NCT00182091|9612288|FG002|Overall Study|Withdrawal by Subject|0
6018431|NCT00182091|9612289|FG003|Overall Study|Withdrawal by Subject|0
6018432|NCT00182325|9612299|FG000|Overall Study|Lost to Follow-up|7
6018433|NCT00182325|9612300|FG001|Overall Study|Lost to Follow-up|7
6018434|NCT00182325|9612299|FG000|Overall Study|Miscarriage|5
6018435|NCT00182325|9612300|FG001|Overall Study|Miscarriage|3
6018436|NCT00182325|9612299|FG000|Overall Study|Did not complete survey|22
6018437|NCT00182325|9612300|FG001|Overall Study|Did not complete survey|43
6018438|NCT00182689|9612308|FG000|Overall Study|Adverse Event|8
6018439|NCT00182689|9612309|FG001|Overall Study|Adverse Event|11
6018440|NCT00182689|9612308|FG000|Overall Study|Withdrawal by Subject|2
6018441|NCT00182689|9612309|FG001|Overall Study|Withdrawal by Subject|2
6018442|NCT00182689|9612308|FG000|Overall Study|Progression|27
6018443|NCT00182689|9612309|FG001|Overall Study|Progression|29
6018444|NCT00182689|9612308|FG000|Overall Study|Death|1
6018445|NCT00182689|9612309|FG001|Overall Study|Death|0
6018446|NCT00182689|9612308|FG000|Overall Study|not protocol specified|0
6018447|NCT00182689|9612309|FG001|Overall Study|not protocol specified|3
6018448|NCT00182689|9612308|FG000|Overall Study|Ineligible|1
6018449|NCT00182689|9612309|FG001|Overall Study|Ineligible|4
6018450|NCT00182689|9612308|FG000|Overall Study|Never received treatment|1
6018451|NCT00182689|9612309|FG001|Overall Study|Never received treatment|0
6018452|NCT00183170|9612364|FG000|First Intervention|Did not complete study|1
6018453|NCT00183170|9612365|FG001|First Intervention|Did not complete study|0
6018454|NCT00183170|9612364|FG000|First Intervention|Did not meet targeted BrAC|1
6018455|NCT00183170|9612365|FG001|First Intervention|Did not meet targeted BrAC|0
6018456|NCT00183170|9612364|FG000|Washout 1 Week|Did not complete study|6
6018457|NCT00183170|9612365|FG001|Washout 1 Week|Did not complete study|8
6018458|NCT00183170|9612364|FG000|Second Intervention|Did not complete study|1
6018459|NCT00183170|9612365|FG001|Second Intervention|Did not complete study|0
6018460|NCT00183170|9612364|FG000|Second Intervention|Did not meet targeted BrAC|0
6018461|NCT00183170|9612365|FG001|Second Intervention|Did not meet targeted BrAC|2
6018462|NCT00183196|9612374|FG000|Overall Study|Withdrawal by Subject|18
6018463|NCT00183196|9612375|FG001|Overall Study|Withdrawal by Subject|11
6018464|NCT00183196|9612376|FG002|Overall Study|Withdrawal by Subject|13
6018465|NCT00183196|9612374|FG000|Overall Study|Adverse Event|1
6018466|NCT00183196|9612375|FG001|Overall Study|Adverse Event|2
6018467|NCT00183196|9612376|FG002|Overall Study|Adverse Event|2
6018468|NCT00183196|9612374|FG000|Overall Study|Legal event|1
6018469|NCT00183196|9612375|FG001|Overall Study|Legal event|1
6018470|NCT00183196|9612376|FG002|Overall Study|Legal event|1
6018471|NCT00183196|9612374|FG000|Overall Study|Required more intensive care|0
6018472|NCT00183196|9612375|FG001|Overall Study|Required more intensive care|1
6018473|NCT00183196|9612376|FG002|Overall Study|Required more intensive care|2
6018474|NCT00183248|9612386|FG000|Overall Study|Lost to Follow-up|0
6018475|NCT00183248|9612387|FG001|Overall Study|Lost to Follow-up|1
6018476|NCT00183248|9612386|FG000|Overall Study|Focal glomerulosclerosis proteinuria|1
6018477|NCT00183248|9612387|FG001|Overall Study|Focal glomerulosclerosis proteinuria|0
6018478|NCT00183274|9612393|FG000|Phase 1: Open-Label|Adverse Event|31
6018479|NCT00183274|9612394|FG001|Phase 1: Open-Label|Adverse Event|0
6018480|NCT00183274|9612395|FG002|Phase 1: Open-Label|Adverse Event|0
6018481|NCT00183274|9612396|FG003|Phase 1: Open-Label|Adverse Event|0
6018482|NCT00183274|9612397|FG004|Phase 1: Open-Label|Adverse Event|0
6018483|NCT00183274|9612398|FG005|Phase 1: Open-Label|Adverse Event|0
6018484|NCT00183274|9612393|FG000|Phase 1: Open-Label|Lack of Efficacy|13
6018485|NCT00183274|9612394|FG001|Phase 1: Open-Label|Lack of Efficacy|0
6018486|NCT00183274|9612395|FG002|Phase 1: Open-Label|Lack of Efficacy|0
6018487|NCT00183274|9612396|FG003|Phase 1: Open-Label|Lack of Efficacy|0
6018488|NCT00183274|9612397|FG004|Phase 1: Open-Label|Lack of Efficacy|0
6018489|NCT00183274|9612398|FG005|Phase 1: Open-Label|Lack of Efficacy|0
6018490|NCT00183274|9612393|FG000|Phase 1: Open-Label|Protocol Violation|11
6018491|NCT00183274|9612394|FG001|Phase 1: Open-Label|Protocol Violation|0
6018492|NCT00183274|9612395|FG002|Phase 1: Open-Label|Protocol Violation|0
6018493|NCT00183274|9612396|FG003|Phase 1: Open-Label|Protocol Violation|0
6018494|NCT00183274|9612397|FG004|Phase 1: Open-Label|Protocol Violation|0
6018495|NCT00183274|9612398|FG005|Phase 1: Open-Label|Protocol Violation|0
6018496|NCT00183274|9612393|FG000|Phase 1: Open-Label|Withdrawal by Subject|13
6018497|NCT00183274|9612394|FG001|Phase 1: Open-Label|Withdrawal by Subject|0
6018498|NCT00183274|9612395|FG002|Phase 1: Open-Label|Withdrawal by Subject|0
6018499|NCT00183274|9612396|FG003|Phase 1: Open-Label|Withdrawal by Subject|0
6018500|NCT00183274|9612397|FG004|Phase 1: Open-Label|Withdrawal by Subject|0
6018501|NCT00183274|9612398|FG005|Phase 1: Open-Label|Withdrawal by Subject|0
6018502|NCT00183274|9612393|FG000|Phase 1: Open-Label|Lost to Follow-up|33
6018503|NCT00183274|9612394|FG001|Phase 1: Open-Label|Lost to Follow-up|0
6018504|NCT00183274|9612395|FG002|Phase 1: Open-Label|Lost to Follow-up|0
6018505|NCT00183274|9612396|FG003|Phase 1: Open-Label|Lost to Follow-up|0
6018506|NCT00183274|9612397|FG004|Phase 1: Open-Label|Lost to Follow-up|0
6018507|NCT00183274|9612398|FG005|Phase 1: Open-Label|Lost to Follow-up|0
6018508|NCT00183274|9612393|FG000|Phase 1: Open-Label|Other|9
6018509|NCT00183274|9612394|FG001|Phase 1: Open-Label|Other|0
6018510|NCT00183274|9612395|FG002|Phase 1: Open-Label|Other|0
6018511|NCT00183274|9612396|FG003|Phase 1: Open-Label|Other|0
6018512|NCT00183274|9612397|FG004|Phase 1: Open-Label|Other|0
6018513|NCT00183274|9612398|FG005|Phase 1: Open-Label|Other|0
6018514|NCT00183274|9612393|FG000|Phase 2: Double-Blind|Relapsed|0
6018515|NCT00183274|9612394|FG001|Phase 2: Double-Blind|Relapsed|8
6018516|NCT00183274|9612395|FG002|Phase 2: Double-Blind|Relapsed|29
6018517|NCT00183274|9612396|FG003|Phase 2: Double-Blind|Relapsed|0
6018518|NCT00183274|9612397|FG004|Phase 2: Double-Blind|Relapsed|0
6018519|NCT00183274|9612398|FG005|Phase 2: Double-Blind|Relapsed|0
6018520|NCT00183274|9612393|FG000|Phase 2: Double-Blind|Withdrawal by Subject|0
6018521|NCT00183274|9612394|FG001|Phase 2: Double-Blind|Withdrawal by Subject|18
6018522|NCT00183274|9612395|FG002|Phase 2: Double-Blind|Withdrawal by Subject|14
6018523|NCT00183274|9612396|FG003|Phase 2: Double-Blind|Withdrawal by Subject|0
6018524|NCT00183274|9612397|FG004|Phase 2: Double-Blind|Withdrawal by Subject|0
6018525|NCT00183274|9612398|FG005|Phase 2: Double-Blind|Withdrawal by Subject|0
6018526|NCT00183274|9612393|FG000|Phase 3: Double-Blind|Withdrawal by Subject|0
6018527|NCT00183274|9612394|FG001|Phase 3: Double-Blind|Withdrawal by Subject|0
6018528|NCT00183274|9612395|FG002|Phase 3: Double-Blind|Withdrawal by Subject|0
6018529|NCT00183274|9612396|FG003|Phase 3: Double-Blind|Withdrawal by Subject|1
6018530|NCT00183274|9612397|FG004|Phase 3: Double-Blind|Withdrawal by Subject|9
6018531|NCT00183274|9612398|FG005|Phase 3: Double-Blind|Withdrawal by Subject|2
6018532|NCT00183274|9612393|FG000|Phase 3: Double-Blind|Relapsed|0
6018533|NCT00183274|9612394|FG001|Phase 3: Double-Blind|Relapsed|0
6018534|NCT00183274|9612395|FG002|Phase 3: Double-Blind|Relapsed|0
6018535|NCT00183274|9612396|FG003|Phase 3: Double-Blind|Relapsed|1
6018536|NCT00183274|9612397|FG004|Phase 3: Double-Blind|Relapsed|11
6018537|NCT00183274|9612398|FG005|Phase 3: Double-Blind|Relapsed|2
6018538|NCT00183391|9612427|FG000|Block 1 - 5 Weeks|Withdrawal by Subject|13
6018539|NCT00183391|9612428|FG001|Block 1 - 5 Weeks|Withdrawal by Subject|14
6018540|NCT00183391|9612427|FG000|Block 2 - 5 Weeks|Withdrawal by Subject|4
6018541|NCT00183391|9612428|FG001|Block 2 - 5 Weeks|Withdrawal by Subject|2
6018542|NCT00183430|9612438|FG000|Overall Study|Adverse Event|1
6018543|NCT00183430|9612439|FG001|Overall Study|Adverse Event|0
6018544|NCT00183430|9612438|FG000|Overall Study|Lost to Follow-up|3
6018545|NCT00183430|9612439|FG001|Overall Study|Lost to Follow-up|0
6018546|NCT00183430|9612438|FG000|Overall Study|did not meet inclusion criteria|1
6018547|NCT00183430|9612439|FG001|Overall Study|did not meet inclusion criteria|0
6018548|NCT00183430|9612438|FG000|Overall Study|Withdrawal by Subject|1
6018549|NCT00183430|9612439|FG001|Overall Study|Withdrawal by Subject|0
6018550|NCT00183625|9612486|FG000|Overall Study|Withdrawal by Subject|18
6018551|NCT00183625|9612487|FG001|Overall Study|Withdrawal by Subject|18
6018552|NCT00183625|9612488|FG002|Overall Study|Withdrawal by Subject|19
6018553|NCT00183625|9612489|FG003|Overall Study|Withdrawal by Subject|14
6018554|NCT00183872|9612514|FG000|Overall Study|Death|3
6018555|NCT00183872|9612514|FG000|Overall Study|Adverse Event|9
6018556|NCT00183872|9612514|FG000|Overall Study|Withdrawal by Subject|2
6018557|NCT00183872|9612514|FG000|Overall Study|Drug delayed more than 28 days|2
6018558|NCT00184002|9612518|FG000|Overall Study|Adverse Event|9
6018559|NCT00184002|9612518|FG000|Overall Study|Death|3
6018560|NCT00184002|9612518|FG000|Overall Study|Physician Decision|1
6018561|NCT00184002|9612518|FG000|Overall Study|Withdrawal by Subject|4
6018562|NCT00184028|9612522|FG000|Overall Study|Death|1
6018563|NCT00184028|9612522|FG000|Overall Study|Lack of Efficacy|4
6018564|NCT00184028|9612522|FG000|Overall Study|Adverse Event|2
6018565|NCT00184028|9612522|FG000|Overall Study|Withdrawal by Subject|1
6018566|NCT00184028|9612522|FG000|Overall Study|Non-compliance|2
6018567|NCT00184054|9612527|FG000|Overall Study|Adverse Event|1
6018568|NCT00184093|9612531|FG000|Overall Study|Adverse Event|3
6018569|NCT00184093|9612531|FG000|Overall Study|Lost to Follow-up|3
6018570|NCT00184093|9612531|FG000|Overall Study|Physician Decision|1
6018571|NCT00184093|9612531|FG000|Overall Study|Withdrawal by Subject|2
6018572|NCT00184600|9612555|FG000|Overall Study|Adverse Event|9
6018573|NCT00184600|9612556|FG001|Overall Study|Adverse Event|0
6018574|NCT00184600|9612557|FG002|Overall Study|Adverse Event|5
6018575|NCT00184600|9612555|FG000|Overall Study|Death|3
6018576|NCT00184600|9612556|FG001|Overall Study|Death|9
6018577|NCT00184600|9612557|FG002|Overall Study|Death|7
6018578|NCT00184600|9612555|FG000|Overall Study|Lack of Efficacy|3
6018579|NCT00184600|9612556|FG001|Overall Study|Lack of Efficacy|1
6018580|NCT00184600|9612557|FG002|Overall Study|Lack of Efficacy|3
6018581|NCT00184600|9612555|FG000|Overall Study|Lost to Follow-up|4
6018582|NCT00184600|9612556|FG001|Overall Study|Lost to Follow-up|6
6018583|NCT00184600|9612557|FG002|Overall Study|Lost to Follow-up|1
6018584|NCT00184600|9612555|FG000|Overall Study|Protocol Violation|2
6018585|NCT00184600|9612556|FG001|Overall Study|Protocol Violation|2
6018586|NCT00184600|9612557|FG002|Overall Study|Protocol Violation|3
6018587|NCT00184600|9612555|FG000|Overall Study|Withdrawal by Subject|20
6018588|NCT00184600|9612556|FG001|Overall Study|Withdrawal by Subject|28
6018589|NCT00184600|9612557|FG002|Overall Study|Withdrawal by Subject|12
6018590|NCT00184600|9612555|FG000|Overall Study|Unclassified|4
6018591|NCT00184600|9612556|FG001|Overall Study|Unclassified|5
6018592|NCT00184600|9612557|FG002|Overall Study|Unclassified|3
6018593|NCT00185211|9612584|FG000|Placebo-controlled Study (92012)|Adverse Event|8
6018594|NCT00185211|9612585|FG001|Placebo-controlled Study (92012)|Adverse Event|0
6018595|NCT00185211|9612584|FG000|Placebo-controlled Study (92012)|Lost to Follow-up|3
6018596|NCT00185211|9612585|FG001|Placebo-controlled Study (92012)|Lost to Follow-up|2
6018597|NCT00185211|9612584|FG000|Placebo-controlled Study (92012)|Withdrawal by Subject|9
6018598|NCT00185211|9612585|FG001|Placebo-controlled Study (92012)|Withdrawal by Subject|7
6018599|NCT00185211|9612584|FG000|Placebo-controlled Study (92012)|fulfilled local def. and McDonald crit.|0
6018600|NCT00185211|9612585|FG001|Placebo-controlled Study (92012)|fulfilled local def. and McDonald crit.|1
6018601|NCT00185211|9612584|FG000|Placebo-controlled Study (92012)|Adverse event, then subject's withdrawal|1
6018602|NCT00185211|9612585|FG001|Placebo-controlled Study (92012)|Adverse event, then subject's withdrawal|0
6018603|NCT00185211|9612584|FG000|Follow-up Study (91031 - This Study)|Adverse Event|5
6018604|NCT00185211|9612585|FG001|Follow-up Study (91031 - This Study)|Adverse Event|6
6018605|NCT00185211|9612584|FG000|Follow-up Study (91031 - This Study)|Lack of Efficacy|1
6018606|NCT00185211|9612585|FG001|Follow-up Study (91031 - This Study)|Lack of Efficacy|0
6018607|NCT00185211|9612584|FG000|Follow-up Study (91031 - This Study)|Lost to Follow-up|6
6018608|NCT00185211|9612585|FG001|Follow-up Study (91031 - This Study)|Lost to Follow-up|4
6018609|NCT00185211|9612584|FG000|Follow-up Study (91031 - This Study)|Physician Decision|1
6018610|NCT00185211|9612585|FG001|Follow-up Study (91031 - This Study)|Physician Decision|0
6018611|NCT00185211|9612584|FG000|Follow-up Study (91031 - This Study)|Pregnancy|0
6018612|NCT00185211|9612585|FG001|Follow-up Study (91031 - This Study)|Pregnancy|1
6018613|NCT00185211|9612584|FG000|Follow-up Study (91031 - This Study)|Withdrawal by Subject|13
6018614|NCT00185211|9612585|FG001|Follow-up Study (91031 - This Study)|Withdrawal by Subject|21
6018615|NCT00185211|9612584|FG000|Follow-up Study (91031 - This Study)|other disease modif. treatment|0
6018616|NCT00185211|9612585|FG001|Follow-up Study (91031 - This Study)|other disease modif. treatment|2
6018617|NCT00185380|9612595|FG000|Overall Study|Adverse Event|41
6018618|NCT00185380|9612596|FG001|Overall Study|Adverse Event|43
6018619|NCT00185380|9612597|FG002|Overall Study|Adverse Event|48
6077082|NCT00595127|9682988|FG000|Overall Study|joined another trial|1
6077083|NCT00595309|9683027|FG000|Overall Study|Lost to Follow-up|1
6077084|NCT00595309|9683027|FG000|Overall Study|planned vaccination against yellow fever|1
6077085|NCT00595309|9683027|FG000|Overall Study|acute infection after V0|1
6077086|NCT00595309|9683027|FG000|Overall Study|personal reason|1
6018620|NCT00185380|9612595|FG000|Overall Study|Lost to Follow-up|0
6018621|NCT00185380|9612596|FG001|Overall Study|Lost to Follow-up|4
6018622|NCT00185380|9612597|FG002|Overall Study|Lost to Follow-up|3
6018623|NCT00185380|9612595|FG000|Overall Study|Pregnancy|1
6018624|NCT00185380|9612596|FG001|Overall Study|Pregnancy|4
6018625|NCT00185380|9612597|FG002|Overall Study|Pregnancy|0
6018626|NCT00185380|9612595|FG000|Overall Study|Protocol Violation|2
6018627|NCT00185380|9612596|FG001|Overall Study|Protocol Violation|2
6018628|NCT00185380|9612597|FG002|Overall Study|Protocol Violation|1
6018629|NCT00185380|9612595|FG000|Overall Study|Withdrawal by Subject|1
6018630|NCT00185380|9612596|FG001|Overall Study|Withdrawal by Subject|2
6018631|NCT00185380|9612597|FG002|Overall Study|Withdrawal by Subject|0
6018632|NCT00185380|9612595|FG000|Overall Study|Failed insertion|1
6018633|NCT00185380|9612596|FG001|Overall Study|Failed insertion|1
6018634|NCT00185380|9612597|FG002|Overall Study|Failed insertion|2
6018635|NCT00185380|9612595|FG000|Overall Study|Planned pregnancy|9
6018636|NCT00185380|9612596|FG001|Overall Study|Planned pregnancy|12
6018637|NCT00185380|9612597|FG002|Overall Study|Planned pregnancy|12
6018638|NCT00185380|9612595|FG000|Overall Study|No need for contraception|3
6018639|NCT00185380|9612596|FG001|Overall Study|No need for contraception|3
6018640|NCT00185380|9612597|FG002|Overall Study|No need for contraception|3
6018641|NCT00185380|9612595|FG000|Overall Study|Could not attend visits|2
6018642|NCT00185380|9612596|FG001|Overall Study|Could not attend visits|0
6018643|NCT00185380|9612597|FG002|Overall Study|Could not attend visits|4
6077087|NCT00595335|9683033|FG000|Baseline to Six Months|Withdrawal by Subject|0
6018644|NCT00185380|9612595|FG000|Overall Study|personal reason|6
6018645|NCT00185380|9612596|FG001|Overall Study|personal reason|1
6018646|NCT00185380|9612597|FG002|Overall Study|personal reason|1
6018647|NCT00185458|9612605|FG000|Contraception Phase|Adverse Event|37
6018648|NCT00185458|9612605|FG000|Contraception Phase|Lost to Follow-up|10
6018649|NCT00185458|9612605|FG000|Contraception Phase|Protocol Violation|2
6018650|NCT00185458|9612605|FG000|Contraception Phase|Physician Decision|2
6018651|NCT00185458|9612605|FG000|Contraception Phase|Withdrawal by Subject|7
6018652|NCT00185458|9612605|FG000|HRT Phase|Adverse Event|18
6018653|NCT00185458|9612605|FG000|HRT Phase|Lost to Follow-up|4
6018654|NCT00185458|9612605|FG000|HRT Phase|Protocol Violation|2
6018655|NCT00185458|9612605|FG000|HRT Phase|Withdrawal by Subject|3
6018656|NCT00185588|9612621|FG000|Overall Study|Adverse Event|3
6018657|NCT00185588|9612622|FG001|Overall Study|Adverse Event|1
6018658|NCT00185588|9612623|FG002|Overall Study|Adverse Event|4
6018659|NCT00185588|9612624|FG003|Overall Study|Adverse Event|2
6018660|NCT00185588|9612621|FG000|Overall Study|Lost to Follow-up|0
6018661|NCT00185588|9612622|FG001|Overall Study|Lost to Follow-up|0
6018662|NCT00185588|9612623|FG002|Overall Study|Lost to Follow-up|1
6018663|NCT00185588|9612624|FG003|Overall Study|Lost to Follow-up|2
6018664|NCT00185588|9612621|FG000|Overall Study|Withdrawal by Subject|0
6018665|NCT00185588|9612622|FG001|Overall Study|Withdrawal by Subject|1
6018666|NCT00185588|9612623|FG002|Overall Study|Withdrawal by Subject|0
6018667|NCT00185588|9612624|FG003|Overall Study|Withdrawal by Subject|0
6018668|NCT00185588|9612621|FG000|Overall Study|Physician Decision|0
6018669|NCT00185588|9612622|FG001|Overall Study|Physician Decision|0
6018670|NCT00185588|9612623|FG002|Overall Study|Physician Decision|1
6018671|NCT00185588|9612624|FG003|Overall Study|Physician Decision|0
6018672|NCT00185614|9612634|FG000|Inter-treatment Period|Physician Decision|1
6018673|NCT00185614|9612634|FG000|Inter-treatment Period|Relapse|2
6018674|NCT00185614|9612634|FG000|Inter-treatment Period|Lack of allogenic donor|1
6018675|NCT00185640|9612638|FG000|Overall Study|Not Eligible|4
6018676|NCT00185640|9612638|FG000|Overall Study|Withdrawal by Subject|3
6018677|NCT00185640|9612638|FG000|Overall Study|Death|138
6077088|NCT00595335|9683034|FG001|Baseline to Six Months|Withdrawal by Subject|1
6077089|NCT00595335|9683033|FG000|Baseline to Six Months|Disease Progression|1
6077090|NCT00595335|9683034|FG001|Baseline to Six Months|Disease Progression|1
6077091|NCT00595335|9683033|FG000|Baseline to Six Months|Adverse Event|1
6077092|NCT00595335|9683034|FG001|Baseline to Six Months|Adverse Event|0
6077093|NCT00595335|9683033|FG000|Six Months to Twelve Months|Withdrawal by Subject|0
6077094|NCT00595335|9683034|FG001|Six Months to Twelve Months|Withdrawal by Subject|1
6077095|NCT00595335|9683033|FG000|Six Months to Twelve Months|Disease Progression|1
6077096|NCT00595335|9683034|FG001|Six Months to Twelve Months|Disease Progression|0
6077097|NCT00595413|9683057|FG000|Overall Study|Adverse Event|0
6077098|NCT00595413|9683058|FG001|Overall Study|Adverse Event|2
6077099|NCT00595413|9683059|FG002|Overall Study|Adverse Event|1
6077100|NCT00595413|9683060|FG003|Overall Study|Adverse Event|1
6077101|NCT00595413|9683057|FG000|Overall Study|Lost to Follow-up|2
6077102|NCT00595413|9683058|FG001|Overall Study|Lost to Follow-up|2
6077103|NCT00595413|9683059|FG002|Overall Study|Lost to Follow-up|1
6077104|NCT00595413|9683060|FG003|Overall Study|Lost to Follow-up|3
6077105|NCT00595413|9683057|FG000|Overall Study|Death|0
6077106|NCT00595413|9683058|FG001|Overall Study|Death|0
6077107|NCT00595413|9683059|FG002|Overall Study|Death|1
6077108|NCT00595413|9683060|FG003|Overall Study|Death|0
6077109|NCT00595413|9683057|FG000|Overall Study|Other|5
6077110|NCT00595413|9683058|FG001|Overall Study|Other|1
6077111|NCT00595413|9683059|FG002|Overall Study|Other|5
6077112|NCT00595413|9683060|FG003|Overall Study|Other|0
6077113|NCT00595465|9683073|FG000|Overall Study|Adverse Event|4
6077114|NCT00595465|9683074|FG001|Overall Study|Adverse Event|3
6077115|NCT00595465|9683075|FG002|Overall Study|Adverse Event|3
6077116|NCT00595465|9683073|FG000|Overall Study|Pregnancy|0
6077117|NCT00595465|9683074|FG001|Overall Study|Pregnancy|0
6077118|NCT00595465|9683075|FG002|Overall Study|Pregnancy|1
6077119|NCT00595465|9683073|FG000|Overall Study|Protocol Violation|2
6077120|NCT00595465|9683074|FG001|Overall Study|Protocol Violation|1
6018678|NCT00185731|9612650|FG000|Overall Study|Withdrawal by Subject|1
6018679|NCT00185731|9612650|FG000|Overall Study|Not Eligible|1
6018680|NCT00185965|9612667|FG000|Overall Study|Adverse Event|0
6018681|NCT00185965|9612668|FG001|Overall Study|Adverse Event|1
6018682|NCT00186043|9612686|FG000|Overall Study|Lack of Efficacy|1
6077121|NCT00595465|9683075|FG002|Overall Study|Protocol Violation|0
6018683|NCT00186043|9612687|FG001|Overall Study|Lack of Efficacy|3
6018684|NCT00186043|9612686|FG000|Overall Study|Lost to Follow-up|4
6018685|NCT00186043|9612687|FG001|Overall Study|Lost to Follow-up|6
6018686|NCT00186043|9612686|FG000|Overall Study|Withdrawal by Subject|1
6018687|NCT00186043|9612687|FG001|Overall Study|Withdrawal by Subject|0
6018688|NCT00186043|9612686|FG000|Overall Study|Adverse Event|7
6018689|NCT00186043|9612687|FG001|Overall Study|Adverse Event|3
6077122|NCT00595465|9683073|FG000|Overall Study|Lost to Follow-up|0
6077123|NCT00595465|9683074|FG001|Overall Study|Lost to Follow-up|0
6077124|NCT00595465|9683075|FG002|Overall Study|Lost to Follow-up|2
6077125|NCT00595465|9683073|FG000|Overall Study|administrative reason|0
6077126|NCT00595465|9683074|FG001|Overall Study|administrative reason|0
6077127|NCT00595465|9683075|FG002|Overall Study|administrative reason|1
6018690|NCT00186043|9612686|FG000|Overall Study|Protocol Violation|2
6018691|NCT00186043|9612687|FG001|Overall Study|Protocol Violation|1
6018692|NCT00186121|9612711|FG000|Overall Study|Subject withdrawal (no treatment)|1
6018693|NCT00186121|9612711|FG000|Overall Study|Underwent oophorectomy (no treatment)|1
6018694|NCT00186121|9612711|FG000|Overall Study|Not eligible (no treatment)|1
6018695|NCT00186186|9612715|FG000|Overall Study|Lack of Efficacy|3
6018696|NCT00186186|9612715|FG000|Overall Study|Withdrawal by Subject|3
6018697|NCT00186186|9612715|FG000|Overall Study|Not reported as to reason|2
6018698|NCT00186485|9612726|FG000|Overall Study|Lost to Follow-up|3
6018699|NCT00186537|9612742|FG000|Overall Study|Withdrawal by Subject|4
6018700|NCT00186537|9612743|FG001|Overall Study|Withdrawal by Subject|0
6018701|NCT00186537|9612744|FG002|Overall Study|Withdrawal by Subject|3
6018702|NCT00186537|9612742|FG000|Overall Study|ALT > 1.5 x ULN|3
6018703|NCT00186537|9612743|FG001|Overall Study|ALT > 1.5 x ULN|0
6018704|NCT00186537|9612744|FG002|Overall Study|ALT > 1.5 x ULN|0
6018705|NCT00186628|9612752|FG000|Overall Study|Death|2
6018706|NCT00186628|9612752|FG000|Overall Study|Withdrawal by subject (before treatment)|1
6018707|NCT00186901|9612771|FG000|Overall Study|Pregnancy|6
6018708|NCT00186901|9612772|FG001|Overall Study|Pregnancy|3
6018709|NCT00186901|9612773|FG002|Overall Study|Pregnancy|0
6018710|NCT00186901|9612771|FG000|Overall Study|Lost to Follow-up|6
6018711|NCT00186901|9612772|FG001|Overall Study|Lost to Follow-up|3
6018712|NCT00186901|9612773|FG002|Overall Study|Lost to Follow-up|0
6018713|NCT00186901|9612771|FG000|Overall Study|Bone Mineral Density dropped > 5%|9
6018714|NCT00186901|9612772|FG001|Overall Study|Bone Mineral Density dropped > 5%|7
6018715|NCT00186901|9612773|FG002|Overall Study|Bone Mineral Density dropped > 5%|0
6018716|NCT00186901|9612771|FG000|Overall Study|ALL relapse or second malignancy|1
6077128|NCT00595478|9683085|FG000|36-week Follow-up Period|Lost to Follow-up|5
6077129|NCT00595478|9683086|FG001|36-week Follow-up Period|Lost to Follow-up|4
6077130|NCT00595478|9683085|FG000|36-week Follow-up Period|Withdrawal by Subject|4
6077131|NCT00595478|9683086|FG001|36-week Follow-up Period|Withdrawal by Subject|4
6077132|NCT00595504|9683094|FG000|Overall Study|Withdrawal by Subject|1
6077133|NCT00595504|9683095|FG001|Overall Study|Withdrawal by Subject|3
6077134|NCT00595504|9683094|FG000|Overall Study|Physician Decision|1
6077135|NCT00595504|9683095|FG001|Overall Study|Physician Decision|0
6077136|NCT00595517|9683101|FG000|Overall Study|Adverse Event|6
6077137|NCT00595517|9683101|FG000|Overall Study|Withdrawal by Subject|4
6077138|NCT00595517|9683101|FG000|Overall Study|Protocol Violation|2
6077139|NCT00595517|9683101|FG000|Overall Study|Recurrence of ulcer|5
6077140|NCT00595517|9683101|FG000|Overall Study|usage of prohibited treatment|1
6077141|NCT00595517|9683101|FG000|Overall Study|No intention to attend regularly|1
6077142|NCT00595621|9683121|FG000|Open Label Run in|Adverse Event|1
6077143|NCT00595621|9683122|FG001|Open Label Run in|Adverse Event|0
6077144|NCT00595621|9683121|FG000|Open Label Run in|Physician Decision|1
6077145|NCT00595621|9683122|FG001|Open Label Run in|Physician Decision|0
6077146|NCT00595621|9683121|FG000|Open Label Run in|Withdrawal by Subject|1
6077147|NCT00595621|9683122|FG001|Open Label Run in|Withdrawal by Subject|0
6077148|NCT00595621|9683121|FG000|Randomization and Study|Adverse Event|2
6077149|NCT00595621|9683122|FG001|Randomization and Study|Adverse Event|0
6077150|NCT00595621|9683121|FG000|Randomization and Study|Withdrawal by Subject|0
6077151|NCT00595621|9683122|FG001|Randomization and Study|Withdrawal by Subject|1
6077152|NCT00595764|9683131|FG000|Overall Study|Protocol Violation|24
6077153|NCT00595764|9683132|FG001|Overall Study|Protocol Violation|19
6077154|NCT00595764|9683131|FG000|Overall Study|Missed Medication >1 week|10
6077155|NCT00595764|9683132|FG001|Overall Study|Missed Medication >1 week|17
6077156|NCT00595764|9683131|FG000|Overall Study|Missed 3 PM visits|1
6077157|NCT00595764|9683132|FG001|Overall Study|Missed 3 PM visits|7
6077158|NCT00595764|9683131|FG000|Overall Study|Withdrawal by Subject|4
6077159|NCT00595764|9683132|FG001|Overall Study|Withdrawal by Subject|0
6077160|NCT00595868|9683153|FG000|Overall Study|Lost to Follow-up|45
6077161|NCT00595868|9683154|FG001|Overall Study|Lost to Follow-up|50
6077162|NCT00595959|9683174|FG000|Overall Study|Withdrawal by Subject|1
6077163|NCT00595959|9683174|FG000|Overall Study|Lost to Follow-up|1
6077164|NCT00596011|9683180|FG000|Overall Study|Withdrawal by Subject|2
6077165|NCT00596011|9683181|FG001|Overall Study|Withdrawal by Subject|3
6077166|NCT00596011|9683180|FG000|Overall Study|Adverse Event|11
6077167|NCT00596011|9683181|FG001|Overall Study|Adverse Event|7
6018717|NCT00186901|9612772|FG001|Overall Study|ALL relapse or second malignancy|2
6018718|NCT00186901|9612773|FG002|Overall Study|ALL relapse or second malignancy|0
6077168|NCT00596362|9683217|FG000|Overall Study|Progressive Disease|1
6077169|NCT00596427|9683223|FG000|Overall Study|Withdrawal by Subject|2
6077170|NCT00596427|9683224|FG001|Overall Study|Withdrawal by Subject|2
6018719|NCT00186901|9612771|FG000|Overall Study|Withdrawal by Subject|4
6077171|NCT00596427|9683223|FG000|Overall Study|Increased Fasting Triacylglycerol level|1
6077172|NCT00596427|9683224|FG001|Overall Study|Increased Fasting Triacylglycerol level|0
6077173|NCT00596427|9683223|FG000|Overall Study|Protocol Violation|1
6077174|NCT00596427|9683224|FG001|Overall Study|Protocol Violation|0
6077175|NCT00596466|9683249|FG000|Overall Study|Lack of Efficacy|5
6077176|NCT00596466|9683249|FG000|Overall Study|Adverse Event|4
6077177|NCT00596466|9683249|FG000|Overall Study|Withdrawal by Subject|2
6077178|NCT00596466|9683249|FG000|Overall Study|Protocol Violation|2
6077179|NCT00596466|9683249|FG000|Overall Study|Unpecified|2
6018720|NCT00186901|9612772|FG001|Overall Study|Withdrawal by Subject|5
6018721|NCT00186901|9612773|FG002|Overall Study|Withdrawal by Subject|0
6018722|NCT00186901|9612771|FG000|Overall Study|Open label|3
6018723|NCT00186901|9612772|FG001|Overall Study|Open label|2
6018724|NCT00186901|9612773|FG002|Overall Study|Open label|0
6018725|NCT00186901|9612771|FG000|Overall Study|Limited adherence to study requirements|20
6018726|NCT00186901|9612772|FG001|Overall Study|Limited adherence to study requirements|23
6018727|NCT00186901|9612773|FG002|Overall Study|Limited adherence to study requirements|0
6018728|NCT00186901|9612771|FG000|Overall Study|Bone Mineral Density > 0|0
6018729|NCT00186901|9612772|FG001|Overall Study|Bone Mineral Density > 0|0
6018730|NCT00186901|9612773|FG002|Overall Study|Bone Mineral Density > 0|149
6018731|NCT00187096|9612813|FG000|Overall Study|unacceptable toxicity|0
6018732|NCT00187096|9612814|FG001|Overall Study|unacceptable toxicity|0
6018733|NCT00187096|9612815|FG002|Overall Study|unacceptable toxicity|1
6018734|NCT00187135|9612829|FG000|Visit One|Withdrawal by Subject|1
6018735|NCT00187135|9612830|FG001|Visit One|Withdrawal by Subject|0
6018736|NCT00187135|9612831|FG002|Visit One|Withdrawal by Subject|0
6018737|NCT00187135|9612832|FG003|Visit One|Withdrawal by Subject|0
6018738|NCT00187135|9612833|FG004|Visit One|Withdrawal by Subject|0
6018739|NCT00187135|9612834|FG005|Visit One|Withdrawal by Subject|1
6018740|NCT00187135|9612829|FG000|Visit One|Physician Decision|3
6018741|NCT00187135|9612830|FG001|Visit One|Physician Decision|1
6018742|NCT00187135|9612831|FG002|Visit One|Physician Decision|0
6018743|NCT00187135|9612832|FG003|Visit One|Physician Decision|0
6018744|NCT00187135|9612833|FG004|Visit One|Physician Decision|0
6018745|NCT00187135|9612834|FG005|Visit One|Physician Decision|1
6018746|NCT00187135|9612829|FG000|Visit Two|Death|0
6077180|NCT00596466|9683249|FG000|Overall Study|Enrolled, not treated|2
6077181|NCT00596635|9683268|FG000|Overall Study|Lost to Follow-up|0
6077182|NCT00596635|9683269|FG001|Overall Study|Lost to Follow-up|2
6077183|NCT00596635|9683270|FG002|Overall Study|Lost to Follow-up|0
6077184|NCT00596635|9683268|FG000|Overall Study|Treatment for symptomatic UTI|4
6077185|NCT00596635|9683269|FG001|Overall Study|Treatment for symptomatic UTI|6
6077186|NCT00596635|9683270|FG002|Overall Study|Treatment for symptomatic UTI|3
6077187|NCT00596635|9683268|FG000|Overall Study|Hip fracture|2
6077188|NCT00596635|9683269|FG001|Overall Study|Hip fracture|3
6077189|NCT00596635|9683270|FG002|Overall Study|Hip fracture|3
6077190|NCT00596635|9683268|FG000|Overall Study|Could not provide urine specimen|1
6077191|NCT00596635|9683269|FG001|Overall Study|Could not provide urine specimen|2
6077192|NCT00596635|9683270|FG002|Overall Study|Could not provide urine specimen|2
6077193|NCT00596687|9683280|FG000|Overall Study|< 24 hours of insulin treatment|8
6077194|NCT00596687|9683281|FG001|Overall Study|< 24 hours of insulin treatment|6
6077195|NCT00596687|9683280|FG000|Overall Study|continuous insulin infusion during TPN|2
6077196|NCT00596687|9683281|FG001|Overall Study|continuous insulin infusion during TPN|1
6077197|NCT00596687|9683280|FG000|Overall Study|Withdrawal by Subject|3
6077198|NCT00596687|9683281|FG001|Overall Study|Withdrawal by Subject|1
6077199|NCT00596687|9683280|FG000|Overall Study|cancelled surgery|1
6077200|NCT00596687|9683281|FG001|Overall Study|cancelled surgery|1
6077201|NCT00596752|9683289|FG000|Overall Study|Other Reason|44
6077202|NCT00596752|9683290|FG001|Overall Study|Other Reason|49
6077203|NCT00596752|9683289|FG000|Overall Study|Adverse Event|34
6077204|NCT00596752|9683290|FG001|Overall Study|Adverse Event|34
6077205|NCT00596752|9683289|FG000|Overall Study|Lost to Follow-up|22
6077206|NCT00596752|9683290|FG001|Overall Study|Lost to Follow-up|38
6077207|NCT00596752|9683289|FG000|Overall Study|Withdrawal by Subject|12
6077208|NCT00596752|9683290|FG001|Overall Study|Withdrawal by Subject|9
6077209|NCT00596752|9683289|FG000|Overall Study|Unsatisfactory Compliance|9
6077210|NCT00596752|9683290|FG001|Overall Study|Unsatisfactory Compliance|6
6077211|NCT00596752|9683289|FG000|Overall Study|Lack of Efficacy|4
6077212|NCT00596752|9683290|FG001|Overall Study|Lack of Efficacy|7
6077213|NCT00596752|9683289|FG000|Overall Study|Protocol Violation|1
6077214|NCT00596752|9683290|FG001|Overall Study|Protocol Violation|0
6077215|NCT00596817|9683299|FG000|Open-label Period|Adverse Event|0
6077216|NCT00596817|9683300|FG001|Open-label Period|Adverse Event|49
6077217|NCT00596817|9683299|FG000|Open-label Period|Lack of Efficacy|0
6018747|NCT00187135|9612830|FG001|Visit Two|Death|0
6018748|NCT00187135|9612831|FG002|Visit Two|Death|0
6018749|NCT00187135|9612832|FG003|Visit Two|Death|1
6018750|NCT00187135|9612833|FG004|Visit Two|Death|0
6018751|NCT00187135|9612834|FG005|Visit Two|Death|1
6077218|NCT00596817|9683300|FG001|Open-label Period|Lack of Efficacy|33
6077219|NCT00596817|9683299|FG000|Open-label Period|Other Reasons|0
6077220|NCT00596817|9683300|FG001|Open-label Period|Other Reasons|65
6077221|NCT00596817|9683299|FG000|Open-label Period to Double-blind Period|Adverse Event|0
6077222|NCT00596817|9683300|FG001|Open-label Period to Double-blind Period|Adverse Event|5
6018752|NCT00187135|9612829|FG000|Visit Two|Physician Decision|1
6018753|NCT00187135|9612830|FG001|Visit Two|Physician Decision|0
6018754|NCT00187135|9612831|FG002|Visit Two|Physician Decision|0
6077223|NCT00596817|9683299|FG000|Open-label Period to Double-blind Period|Lack of Efficacy|0
6077224|NCT00596817|9683300|FG001|Open-label Period to Double-blind Period|Lack of Efficacy|24
6077225|NCT00596817|9683299|FG000|Open-label Period to Double-blind Period|Not Eligible|0
6077226|NCT00596817|9683300|FG001|Open-label Period to Double-blind Period|Not Eligible|49
6077227|NCT00596817|9683299|FG000|Open-label Period to Double-blind Period|Other Reasons|0
6018755|NCT00187135|9612832|FG003|Visit Two|Physician Decision|0
6018756|NCT00187135|9612833|FG004|Visit Two|Physician Decision|0
6018757|NCT00187135|9612834|FG005|Visit Two|Physician Decision|0
6018758|NCT00187135|9612829|FG000|Visit Two|Withdrawal by Subject|1
6018759|NCT00187135|9612830|FG001|Visit Two|Withdrawal by Subject|1
6018760|NCT00187135|9612831|FG002|Visit Two|Withdrawal by Subject|1
6018761|NCT00187135|9612832|FG003|Visit Two|Withdrawal by Subject|0
6018762|NCT00187135|9612833|FG004|Visit Two|Withdrawal by Subject|1
6018763|NCT00187135|9612834|FG005|Visit Two|Withdrawal by Subject|1
6018764|NCT00187135|9612829|FG000|Visit Two|Study Discontinued|3
6018765|NCT00187135|9612830|FG001|Visit Two|Study Discontinued|2
6018766|NCT00187135|9612831|FG002|Visit Two|Study Discontinued|1
6018767|NCT00187135|9612832|FG003|Visit Two|Study Discontinued|7
6018768|NCT00187135|9612833|FG004|Visit Two|Study Discontinued|5
6018769|NCT00187135|9612834|FG005|Visit Two|Study Discontinued|6
6018770|NCT00187135|9612829|FG000|Visit Three|Death|0
6018771|NCT00187135|9612830|FG001|Visit Three|Death|0
6018772|NCT00187135|9612831|FG002|Visit Three|Death|1
6018773|NCT00187135|9612832|FG003|Visit Three|Death|0
6018774|NCT00187135|9612833|FG004|Visit Three|Death|1
6018775|NCT00187135|9612834|FG005|Visit Three|Death|0
6018776|NCT00187135|9612829|FG000|Visit Three|Withdrawal by Subject|0
6018777|NCT00187135|9612830|FG001|Visit Three|Withdrawal by Subject|1
6018778|NCT00187135|9612831|FG002|Visit Three|Withdrawal by Subject|1
6018779|NCT00187135|9612832|FG003|Visit Three|Withdrawal by Subject|2
6018780|NCT00187135|9612833|FG004|Visit Three|Withdrawal by Subject|0
6018781|NCT00187135|9612834|FG005|Visit Three|Withdrawal by Subject|0
6018782|NCT00187135|9612829|FG000|Visit Three|Study Discontinued|7
6018783|NCT00187135|9612830|FG001|Visit Three|Study Discontinued|6
6018784|NCT00187135|9612831|FG002|Visit Three|Study Discontinued|7
6018785|NCT00187135|9612832|FG003|Visit Three|Study Discontinued|7
6018786|NCT00187135|9612833|FG004|Visit Three|Study Discontinued|7
6018787|NCT00187135|9612834|FG005|Visit Three|Study Discontinued|6
6018788|NCT00187278|9612859|FG000|Overall Study|Protocol Violation|10
6018789|NCT00187278|9612860|FG001|Overall Study|Protocol Violation|13
6018790|NCT00187486|9612883|FG000|Overall Study|Protocol Violation|1
6077228|NCT00596817|9683300|FG001|Open-label Period to Double-blind Period|Other Reasons|14
6077229|NCT00596817|9683299|FG000|Double-blind Period|Adverse Event|5
6077230|NCT00596817|9683300|FG001|Double-blind Period|Adverse Event|16
6077231|NCT00596817|9683299|FG000|Double-blind Period|Lack of Efficacy|52
6077232|NCT00596817|9683300|FG001|Double-blind Period|Lack of Efficacy|28
6077233|NCT00596817|9683299|FG000|Double-blind Period|Non-compliance With Study Product|3
6077234|NCT00596817|9683300|FG001|Double-blind Period|Non-compliance With Study Product|4
6077235|NCT00596817|9683299|FG000|Double-blind Period|Protocol Violation|11
6077236|NCT00596817|9683300|FG001|Double-blind Period|Protocol Violation|8
6077237|NCT00596817|9683299|FG000|Double-blind Period|Withdrawal of Consent|7
6077238|NCT00596817|9683300|FG001|Double-blind Period|Withdrawal of Consent|3
6077239|NCT00596817|9683299|FG000|Double-blind Period|Lost to Follow-up|0
6077240|NCT00596817|9683300|FG001|Double-blind Period|Lost to Follow-up|2
6077241|NCT00596817|9683299|FG000|Double-blind Period|Other Reasons|10
6077242|NCT00596817|9683300|FG001|Double-blind Period|Other Reasons|18
6077243|NCT00596830|9683309|FG000|Overall Study|Death|258
6077244|NCT00596830|9683310|FG001|Overall Study|Death|247
6077245|NCT00596830|9683309|FG000|Overall Study|Lost to Follow-up|7
6077246|NCT00596830|9683310|FG001|Overall Study|Lost to Follow-up|11
6077247|NCT00596830|9683309|FG000|Overall Study|Withdrawal by Subject|22
6077248|NCT00596830|9683310|FG001|Overall Study|Withdrawal by Subject|12
6077249|NCT00596830|9683309|FG000|Overall Study|Study terminated by sponsor|51
6077250|NCT00596830|9683310|FG001|Overall Study|Study terminated by sponsor|62
6077251|NCT00596830|9683309|FG000|Overall Study|Follow-up was discontinued|1
6077252|NCT00596830|9683310|FG001|Overall Study|Follow-up was discontinued|0
6077253|NCT00596830|9683309|FG000|Overall Study|Randomized but not treated|3
6077254|NCT00596830|9683310|FG001|Overall Study|Randomized but not treated|7
6077255|NCT00596934|9683316|FG000|Overall Study|Protocol Violation|1
6077256|NCT00596934|9683316|FG000|Overall Study|Withdrawal by Subject|1
6077257|NCT00596960|9683324|FG000|Overall Study|Death|1
6077258|NCT00596960|9683325|FG001|Overall Study|Death|2
6077259|NCT00596960|9683324|FG000|Overall Study|Lost to Follow-up|6
6077260|NCT00596960|9683325|FG001|Overall Study|Lost to Follow-up|5
6077261|NCT00596960|9683324|FG000|Overall Study|Withdrawal by Subject|1
6018791|NCT00187889|9612923|FG000|Overall Study|Withdrawal by Subject|6
6018792|NCT00187889|9612924|FG001|Overall Study|Withdrawal by Subject|4
6018793|NCT00189202|9612951|FG000|Overall Study|Physician Decision|5
6018794|NCT00189306|9612959|FG000|Treatment Period|Withdrawal by Subject|2
6018795|NCT00189306|9612959|FG000|Treatment Period|Adverse Event|2
6018796|NCT00189306|9612959|FG000|Treatment Period|Protocol Violation|1
6018797|NCT00189306|9612959|FG000|Posttreatment Period|Death|1
6018798|NCT00189306|9612959|FG000|Posttreatment Period|Withdrawal by Subject|2
6018799|NCT00189306|9612959|FG000|Posttreatment Period|Noncompliance|1
6018800|NCT00189306|9612959|FG000|Posttreatment Period|Target lesion excised|1
6077262|NCT00596960|9683325|FG001|Overall Study|Withdrawal by Subject|0
6077263|NCT00596960|9683324|FG000|Overall Study|Incarcerated|2
6077264|NCT00596960|9683325|FG001|Overall Study|Incarcerated|0
6077265|NCT00596960|9683324|FG000|Overall Study|Physician Decision|1
6077266|NCT00596960|9683325|FG001|Overall Study|Physician Decision|0
6077267|NCT00596960|9683324|FG000|Overall Study|Protocol Violation|0
6018801|NCT00189306|9612959|FG000|Posttreatment Period|Protocol Violation|1
6018802|NCT00189306|9612959|FG000|Posttreatment Period|Evidence of Superficial Basal Cell Ca|5
6018803|NCT00189306|9612959|FG000|Posttreatment Period|Local skin reaction/sign|1
6018804|NCT00189306|9612959|FG000|Long-Term Follow-up|Adverse Event|2
6018805|NCT00189306|9612959|FG000|Long-Term Follow-up|Death|4
6018806|NCT00189306|9612959|FG000|Long-Term Follow-up|Withdrawal by Subject|1
6018807|NCT00189306|9612959|FG000|Long-Term Follow-up|Intercurrent disease|2
6018808|NCT00189306|9612959|FG000|Long-Term Follow-up|Lost to Follow-up|9
6018809|NCT00189306|9612959|FG000|Long-Term Follow-up|Evidence of Superficial Basal Cell Ca|20
6018810|NCT00189423|9612965|FG000|Overall Study|Death|746
6018811|NCT00189423|9612966|FG001|Overall Study|Death|747
6018812|NCT00189423|9612965|FG000|Overall Study|Withdrawal by Subject|9
6018813|NCT00189423|9612966|FG001|Overall Study|Withdrawal by Subject|9
6018814|NCT00189423|9612965|FG000|Overall Study|Lost to Follow-up|10
6018815|NCT00189423|9612966|FG001|Overall Study|Lost to Follow-up|10
6018816|NCT00189462|9612983|FG000|Overall Study|Lack of Efficacy|5
6018817|NCT00189462|9612984|FG001|Overall Study|Lack of Efficacy|1
6018818|NCT00189462|9612983|FG000|Overall Study|Lost to Follow-up|18
6018819|NCT00189462|9612984|FG001|Overall Study|Lost to Follow-up|20
6018820|NCT00189488|9613001|FG000|Overall Study|Ineligibility determined|1
6018821|NCT00189488|9613002|FG001|Overall Study|Ineligibility determined|0
6018822|NCT00189488|9613001|FG000|Overall Study|Protocol deviation|2
6018823|NCT00189488|9613002|FG001|Overall Study|Protocol deviation|1
6018824|NCT00189488|9613001|FG000|Overall Study|Adverse Event|2
6018825|NCT00189488|9613002|FG001|Overall Study|Adverse Event|1
6018826|NCT00189488|9613001|FG000|Overall Study|Withdrawal by Subject|2
6018827|NCT00189488|9613002|FG001|Overall Study|Withdrawal by Subject|6
6018828|NCT00189488|9613001|FG000|Overall Study|Disease progression|2
6018829|NCT00189488|9613002|FG001|Overall Study|Disease progression|4
6018830|NCT00189488|9613001|FG000|Overall Study|Administrative Decision|0
6018831|NCT00189488|9613002|FG001|Overall Study|Administrative Decision|2
6018832|NCT00189488|9613001|FG000|Overall Study|Death|5
6018833|NCT00189488|9613002|FG001|Overall Study|Death|8
6018834|NCT00189488|9613001|FG000|Overall Study|Other|1
6018835|NCT00189488|9613002|FG001|Overall Study|Other|0
6018836|NCT00189540|9613011|FG000|Overall Study|Withdrawal by Subject|3
6018837|NCT00189540|9613012|FG001|Overall Study|Withdrawal by Subject|0
6018838|NCT00189540|9613011|FG000|Overall Study|Death|4
6077268|NCT00596960|9683325|FG001|Overall Study|Protocol Violation|1
6077269|NCT00596960|9683324|FG000|Overall Study|No alcohol use data|0
6077270|NCT00596960|9683325|FG001|Overall Study|No alcohol use data|1
6077271|NCT00597012|9683333|FG000|Overall Study|Death|1
6077272|NCT00597012|9683334|FG001|Overall Study|Death|1
6077273|NCT00597012|9683333|FG000|Overall Study|Underwent Total Knee Replacement (TKR)|3
6077274|NCT00597012|9683334|FG001|Overall Study|Underwent Total Knee Replacement (TKR)|1
6077275|NCT00597012|9683333|FG000|Overall Study|Withdrawal by Subject|7
6077276|NCT00597012|9683334|FG001|Overall Study|Withdrawal by Subject|4
6077277|NCT00597012|9683333|FG000|Overall Study|Ineligible|2
6077278|NCT00597012|9683334|FG001|Overall Study|Ineligible|0
6077279|NCT00597012|9683333|FG000|Overall Study|Lost to Follow-up|0
6077280|NCT00597012|9683334|FG001|Overall Study|Lost to Follow-up|2
6077281|NCT00597116|9683355|FG000|Overall Study|Adverse Event|2
6077282|NCT00597116|9683356|FG001|Overall Study|Adverse Event|1
6077283|NCT00597116|9683355|FG000|Overall Study|Withdrawal by Subject|0
6077284|NCT00597116|9683356|FG001|Overall Study|Withdrawal by Subject|2
6077285|NCT00597116|9683355|FG000|Overall Study|Physician Decision|0
6077286|NCT00597116|9683356|FG001|Overall Study|Physician Decision|1
6077287|NCT00597116|9683355|FG000|Overall Study|Death|0
6077288|NCT00597116|9683356|FG001|Overall Study|Death|1
6077289|NCT00597116|9683355|FG000|Overall Study|Lost to Follow-up|1
6077290|NCT00597116|9683356|FG001|Overall Study|Lost to Follow-up|0
6077291|NCT00597116|9683355|FG000|Overall Study|Progressive disease|11
6077292|NCT00597116|9683356|FG001|Overall Study|Progressive disease|6
6077293|NCT00597207|9683364|FG000|Overall Study|Lost to Follow-up|5
6077294|NCT00597207|9683365|FG001|Overall Study|Lost to Follow-up|7
6077295|NCT00597376|9683406|FG000|Overall Study|Withdrawal by Subject|4
6077296|NCT00597376|9683407|FG001|Overall Study|Withdrawal by Subject|3
6077297|NCT00597376|9683406|FG000|Overall Study|Adverse Event|4
6077298|NCT00597376|9683407|FG001|Overall Study|Adverse Event|1
6077299|NCT00597506|9683434|FG000|Overall Study|Subject is being followed for survival|1
6077300|NCT00597519|9683438|FG000|Overall Study|Death|1
6077301|NCT00597584|9683457|FG000|Overall Study|Adverse Event|4
6018839|NCT00189540|9613012|FG001|Overall Study|Death|1
6018840|NCT00190671|9613020|FG000|Overall Study|Satisfactory Response|4
6018841|NCT00190671|9613021|FG001|Overall Study|Satisfactory Response|7
6018842|NCT00190671|9613020|FG000|Overall Study|Lack of Efficacy|19
6018843|NCT00190671|9613021|FG001|Overall Study|Lack of Efficacy|24
6018844|NCT00190671|9613020|FG000|Overall Study|Death from Study Disease|1
6018845|NCT00190671|9613021|FG001|Overall Study|Death from Study Disease|1
6018846|NCT00190671|9613020|FG000|Overall Study|Adverse Event|3
6077302|NCT00597584|9683458|FG001|Overall Study|Adverse Event|2
6077303|NCT00597584|9683457|FG000|Overall Study|Death|53
6077304|NCT00597584|9683458|FG001|Overall Study|Death|30
6077305|NCT00597584|9683457|FG000|Overall Study|Lack of Efficacy|1
6077306|NCT00597584|9683458|FG001|Overall Study|Lack of Efficacy|0
6077307|NCT00597584|9683457|FG000|Overall Study|Lost to Follow-up|2
6018847|NCT00190671|9613021|FG001|Overall Study|Adverse Event|2
6018848|NCT00190671|9613020|FG000|Overall Study|Clinical Relapse|0
6018849|NCT00190671|9613021|FG001|Overall Study|Clinical Relapse|1
6018850|NCT00190671|9613020|FG000|Overall Study|Death from Study-Drug Toxicity|0
6018851|NCT00190671|9613021|FG001|Overall Study|Death from Study-Drug Toxicity|2
6018852|NCT00190671|9613020|FG000|Overall Study|Death from Other Causes|0
6018853|NCT00190671|9613021|FG001|Overall Study|Death from Other Causes|2
6018854|NCT00190671|9613020|FG000|Overall Study|Protocol Violation|0
6018855|NCT00190671|9613021|FG001|Overall Study|Protocol Violation|1
6018856|NCT00190671|9613020|FG000|Overall Study|Withdrawal by Subject|0
6018857|NCT00190671|9613021|FG001|Overall Study|Withdrawal by Subject|2
6018858|NCT00190684|9613028|FG000|Overall Study|Adverse Event|86
6018859|NCT00190684|9613028|FG000|Overall Study|Satisfactory response|80
6018860|NCT00190684|9613028|FG000|Overall Study|Lack of efficacy|204
6018861|NCT00190684|9613028|FG000|Overall Study|Lost to Follow-up|232
6018862|NCT00190684|9613028|FG000|Overall Study|Patient moved|60
6018863|NCT00190684|9613028|FG000|Overall Study|Patient Decision|432
6077308|NCT00597584|9683458|FG001|Overall Study|Lost to Follow-up|4
6077309|NCT00597584|9683457|FG000|Overall Study|Physician Decision|3
6077310|NCT00597584|9683458|FG001|Overall Study|Physician Decision|0
6077311|NCT00597584|9683457|FG000|Overall Study|Pregnancy|2
6077312|NCT00597584|9683458|FG001|Overall Study|Pregnancy|0
6077313|NCT00597584|9683457|FG000|Overall Study|Withdrawal by Subject|44
6077314|NCT00597584|9683458|FG001|Overall Study|Withdrawal by Subject|12
6077315|NCT00597584|9683457|FG000|Overall Study|Discontinued Dialysis|0
6077316|NCT00597584|9683458|FG001|Overall Study|Discontinued Dialysis|1
6077317|NCT00597584|9683457|FG000|Overall Study|Lost ability to consent|1
6077318|NCT00597584|9683458|FG001|Overall Study|Lost ability to consent|1
6077319|NCT00597584|9683457|FG000|Overall Study|Never dosed|1
6077320|NCT00597584|9683458|FG001|Overall Study|Never dosed|0
6077321|NCT00597584|9683457|FG000|Overall Study|Relocation|8
6077322|NCT00597584|9683458|FG001|Overall Study|Relocation|6
6077323|NCT00597584|9683457|FG000|Overall Study|Renal transplant|9
6077324|NCT00597584|9683458|FG001|Overall Study|Renal transplant|7
6077325|NCT00597701|9683477|FG000|Overall Study|Withdrawal by Subject|5
6077326|NCT00597701|9683478|FG001|Overall Study|Withdrawal by Subject|5
6077327|NCT00597701|9683477|FG000|Overall Study|Death|0
6077328|NCT00597701|9683478|FG001|Overall Study|Death|1
6077329|NCT00597701|9683477|FG000|Overall Study|Physician Decision|2
6077330|NCT00597701|9683478|FG001|Overall Study|Physician Decision|0
6077331|NCT00597701|9683477|FG000|Overall Study|Did not start intervention (pharmacy er)|0
6077332|NCT00597701|9683478|FG001|Overall Study|Did not start intervention (pharmacy er)|2
6077333|NCT00597714|9683486|FG000|Overall Study|Death|56
6077334|NCT00597714|9683487|FG001|Overall Study|Death|46
6077335|NCT00597714|9683488|FG002|Overall Study|Death|0
6077336|NCT00597714|9683486|FG000|Overall Study|Recipient death|0
6077337|NCT00597714|9683487|FG001|Overall Study|Recipient death|0
6077338|NCT00597714|9683488|FG002|Overall Study|Recipient death|10
6077339|NCT00597753|9683521|FG000|Overall Study|Adverse Event|6
6077340|NCT00597753|9683522|FG001|Overall Study|Adverse Event|2
6077341|NCT00597753|9683521|FG000|Overall Study|Death|55
6077342|NCT00597753|9683522|FG001|Overall Study|Death|29
6077343|NCT00597753|9683521|FG000|Overall Study|Lack of Efficacy|2
6077344|NCT00597753|9683522|FG001|Overall Study|Lack of Efficacy|0
6077345|NCT00597753|9683521|FG000|Overall Study|Lost to Follow-up|10
6077346|NCT00597753|9683522|FG001|Overall Study|Lost to Follow-up|3
6077347|NCT00597753|9683521|FG000|Overall Study|Physician Decision|5
6077348|NCT00597753|9683522|FG001|Overall Study|Physician Decision|1
6077349|NCT00597753|9683521|FG000|Overall Study|Pregnancy|1
6077350|NCT00597753|9683522|FG001|Overall Study|Pregnancy|0
6077351|NCT00597753|9683521|FG000|Overall Study|Withdrawal by Subject|35
6077352|NCT00597753|9683522|FG001|Overall Study|Withdrawal by Subject|12
6077353|NCT00597753|9683521|FG000|Overall Study|Discontinued Dialysis|0
6077354|NCT00597753|9683522|FG001|Overall Study|Discontinued Dialysis|1
6077355|NCT00597753|9683521|FG000|Overall Study|Never dosed|2
6077356|NCT00597753|9683522|FG001|Overall Study|Never dosed|0
6077357|NCT00597753|9683521|FG000|Overall Study|Noncompliance|2
6077358|NCT00597753|9683522|FG001|Overall Study|Noncompliance|1
6018864|NCT00190684|9613028|FG000|Overall Study|Clinical relapse|67
6018865|NCT00190684|9613028|FG000|Overall Study|Sponsor's decision|17
6018866|NCT00190684|9613028|FG000|Overall Study|Physician Decision|84
6018867|NCT00190684|9613028|FG000|Overall Study|Protocol Violation|123
6018868|NCT00190684|9613028|FG000|Overall Study|Study Period III Completed|103
6077359|NCT00597753|9683521|FG000|Overall Study|Relocation|17
6077360|NCT00597753|9683522|FG001|Overall Study|Relocation|6
6077361|NCT00597753|9683521|FG000|Overall Study|Renal transplant|10
6077362|NCT00597753|9683522|FG001|Overall Study|Renal transplant|3
6077363|NCT00597753|9683521|FG000|Overall Study|Site closed by sponsor|19
6077364|NCT00597753|9683522|FG001|Overall Study|Site closed by sponsor|7
6077365|NCT00597753|9683521|FG000|Overall Study|Site elected to close|2
6077366|NCT00597753|9683522|FG001|Overall Study|Site elected to close|4
6077367|NCT00597766|9683531|FG000|Follow-up 1, Week 4|Withdrawal by Subject|1
6077368|NCT00597766|9683532|FG001|Follow-up 1, Week 4|Withdrawal by Subject|0
6077369|NCT00597766|9683533|FG002|Follow-up 1, Week 4|Withdrawal by Subject|0
6077370|NCT00597766|9683531|FG000|Follow-up 2, Week 8|Lost to Follow-up|0
6077371|NCT00597766|9683532|FG001|Follow-up 2, Week 8|Lost to Follow-up|0
6077372|NCT00597766|9683533|FG002|Follow-up 2, Week 8|Lost to Follow-up|1
6018869|NCT00190684|9613028|FG000|Overall Study|Study Period V Completed|1
6018870|NCT00190749|9613034|FG000|Overall Study|Lost to Follow-up|8
6018871|NCT00190749|9613035|FG001|Overall Study|Lost to Follow-up|11
6018872|NCT00190749|9613034|FG000|Overall Study|Withdrawal by Subject|10
6018873|NCT00190749|9613035|FG001|Overall Study|Withdrawal by Subject|6
6018874|NCT00190749|9613034|FG000|Overall Study|Protocol Violation|5
6018875|NCT00190749|9613035|FG001|Overall Study|Protocol Violation|4
6018876|NCT00190749|9613034|FG000|Overall Study|Adverse Event|0
6018877|NCT00190749|9613035|FG001|Overall Study|Adverse Event|5
6018878|NCT00190749|9613034|FG000|Overall Study|Lack of Efficacy|2
6018879|NCT00190749|9613035|FG001|Overall Study|Lack of Efficacy|3
6018880|NCT00190749|9613034|FG000|Overall Study|Reason Not Specified|0
6018881|NCT00190749|9613035|FG001|Overall Study|Reason Not Specified|2
6018882|NCT00190749|9613034|FG000|Overall Study|Sponsor Decision|1
6018883|NCT00190749|9613035|FG001|Overall Study|Sponsor Decision|0
6018884|NCT00190775|9613043|FG000|Overall Study|Adverse Event|57
6018885|NCT00190775|9613044|FG001|Overall Study|Adverse Event|22
6018886|NCT00190775|9613043|FG000|Overall Study|Satisfactory Response|1
6018887|NCT00190775|9613044|FG001|Overall Study|Satisfactory Response|0
6018888|NCT00190775|9613043|FG000|Overall Study|Lack of Efficacy|28
6018889|NCT00190775|9613044|FG001|Overall Study|Lack of Efficacy|32
6018890|NCT00190775|9613043|FG000|Overall Study|Lost to Follow-up|31
6018891|NCT00190775|9613044|FG001|Overall Study|Lost to Follow-up|23
6018892|NCT00190775|9613043|FG000|Overall Study|Participant Moved|0
6018893|NCT00190775|9613044|FG001|Overall Study|Participant Moved|1
6018894|NCT00190775|9613043|FG000|Overall Study|Withdrawal by Subject|24
6018895|NCT00190775|9613044|FG001|Overall Study|Withdrawal by Subject|13
6018896|NCT00190775|9613043|FG000|Overall Study|Sponsor Decision|1
6018897|NCT00190775|9613044|FG001|Overall Study|Sponsor Decision|0
6018898|NCT00190775|9613043|FG000|Overall Study|Physician Decision|3
6018899|NCT00190775|9613044|FG001|Overall Study|Physician Decision|0
6018900|NCT00190775|9613043|FG000|Overall Study|Noncompliance|3
6018901|NCT00190775|9613044|FG001|Overall Study|Noncompliance|5
6018902|NCT00190775|9613043|FG000|Overall Study|Protocol Violation|0
6018903|NCT00190775|9613044|FG001|Overall Study|Protocol Violation|1
6018904|NCT00190775|9613043|FG000|Overall Study|Exclusion Criteria Met|1
6018905|NCT00190775|9613044|FG001|Overall Study|Exclusion Criteria Met|3
6018906|NCT00190983|9613057|FG000|Overall Study|Inevaluable (never treated)|2
6018907|NCT00191100|9613063|FG000|Overall Study|Adverse Event|18
6018908|NCT00191100|9613064|FG001|Overall Study|Adverse Event|1
6018909|NCT00191100|9613063|FG000|Overall Study|Lost to Follow-up|2
6018910|NCT00191100|9613064|FG001|Overall Study|Lost to Follow-up|0
6018911|NCT00191100|9613063|FG000|Overall Study|Patient Moved|0
6018912|NCT00191100|9613064|FG001|Overall Study|Patient Moved|1
6018913|NCT00191100|9613063|FG000|Overall Study|Withdrawal by Subject|9
6018914|NCT00191100|9613064|FG001|Overall Study|Withdrawal by Subject|3
6018915|NCT00191100|9613063|FG000|Overall Study|Protocol Entry Criteria Not Met|2
6018916|NCT00191100|9613064|FG001|Overall Study|Protocol Entry Criteria Not Met|1
6018917|NCT00191100|9613063|FG000|Overall Study|Clinical Relapse|2
6018918|NCT00191100|9613064|FG001|Overall Study|Clinical Relapse|1
6018919|NCT00191100|9613063|FG000|Overall Study|Lack of Efficacy, Progressive Disease|1
6018920|NCT00191100|9613064|FG001|Overall Study|Lack of Efficacy, Progressive Disease|2
6018921|NCT00191100|9613063|FG000|Overall Study|Lack of Efficacy, Stable Disease|1
6018922|NCT00191100|9613064|FG001|Overall Study|Lack of Efficacy, Stable Disease|0
6018923|NCT00191100|9613063|FG000|Overall Study|Physician Decision|3
6018924|NCT00191100|9613064|FG001|Overall Study|Physician Decision|1
6018925|NCT00191100|9613063|FG000|Overall Study|Death from Study Drug Toxicity|2
6018926|NCT00191100|9613064|FG001|Overall Study|Death from Study Drug Toxicity|0
6018927|NCT00191100|9613063|FG000|Overall Study|Protocol Violation|1
6018928|NCT00191100|9613064|FG001|Overall Study|Protocol Violation|1
6018929|NCT00191100|9613063|FG000|Overall Study|Death from Other Cause|1
6018930|NCT00191100|9613064|FG001|Overall Study|Death from Other Cause|0
6018931|NCT00191100|9613063|FG000|Overall Study|Reason Not Specified|0
6018932|NCT00191100|9613064|FG001|Overall Study|Reason Not Specified|1
6018933|NCT00191113|9613072|FG000|Core Study|Withdrawal by Subject|25
6018934|NCT00191113|9613073|FG001|Core Study|Withdrawal by Subject|9
6018935|NCT00191113|9613072|FG000|Core Study|Protocol Violation|6
6018936|NCT00191113|9613073|FG001|Core Study|Protocol Violation|2
6018937|NCT00191113|9613072|FG000|Core Study|Lost to Follow-up|3
6018938|NCT00191113|9613073|FG001|Core Study|Lost to Follow-up|0
6018939|NCT00191113|9613072|FG000|Core Study|Adverse Event|0
6018940|NCT00191113|9613073|FG001|Core Study|Adverse Event|2
6018941|NCT00191113|9613072|FG000|Core Study|Lack of Efficacy|0
6018942|NCT00191113|9613073|FG001|Core Study|Lack of Efficacy|2
6018943|NCT00191113|9613072|FG000|Core Study|Death|1
6018944|NCT00191113|9613073|FG001|Core Study|Death|0
6018945|NCT00191139|9613087|FG000|Overall Study|Adverse Event|2
6018946|NCT00191139|9613088|FG001|Overall Study|Adverse Event|6
6018947|NCT00191139|9613087|FG000|Overall Study|Death|2
6018948|NCT00191139|9613088|FG001|Overall Study|Death|0
6018949|NCT00191139|9613087|FG000|Overall Study|Withdrawal by Subject|0
6018950|NCT00191139|9613088|FG001|Overall Study|Withdrawal by Subject|3
6018951|NCT00191139|9613087|FG000|Overall Study|Disease Progression|0
6018952|NCT00191139|9613088|FG001|Overall Study|Disease Progression|1
6018953|NCT00191139|9613087|FG000|Overall Study|Other|1
6018954|NCT00191139|9613088|FG001|Overall Study|Other|2
6018955|NCT00191152|9613096|FG000|Initial Treatment|Adverse Event|43
6018956|NCT00191152|9613097|FG001|Initial Treatment|Adverse Event|67
6018957|NCT00191152|9613096|FG000|Initial Treatment|Physician Decision|40
6018958|NCT00191152|9613097|FG001|Initial Treatment|Physician Decision|31
6018959|NCT00191152|9613096|FG000|Initial Treatment|Withdrawal by Subject|40
6018960|NCT00191152|9613097|FG001|Initial Treatment|Withdrawal by Subject|28
6018961|NCT00191152|9613096|FG000|Initial Treatment|Lost to Follow-up|0
6018962|NCT00191152|9613097|FG001|Initial Treatment|Lost to Follow-up|6
6018963|NCT00191152|9613096|FG000|Initial Treatment|Other|18
6018964|NCT00191152|9613097|FG001|Initial Treatment|Other|21
6018965|NCT00191152|9613096|FG000|Crossover Treatment|Adverse Event|8
6018966|NCT00191152|9613097|FG001|Crossover Treatment|Adverse Event|8
6018967|NCT00191152|9613096|FG000|Crossover Treatment|Physician Decision|7
6018968|NCT00191152|9613097|FG001|Crossover Treatment|Physician Decision|7
6018969|NCT00191152|9613096|FG000|Crossover Treatment|Withdrawal by Subject|6
6018970|NCT00191152|9613097|FG001|Crossover Treatment|Withdrawal by Subject|9
6018971|NCT00191152|9613096|FG000|Crossover Treatment|Lost to Follow-up|2
6018972|NCT00191152|9613097|FG001|Crossover Treatment|Lost to Follow-up|1
6018973|NCT00191152|9613096|FG000|Crossover Treatment|Other|4
6018974|NCT00191152|9613097|FG001|Crossover Treatment|Other|3
6047894|NCT00413660|9646909|FG001|Post Week 12|Withdrawal by Subject|1
6047895|NCT00413660|9646910|FG002|Post Week 12|Withdrawal by Subject|1
6047896|NCT00413660|9646911|FG003|Post Week 12|Withdrawal by Subject|0
6047897|NCT00413660|9646912|FG004|Post Week 12|Withdrawal by Subject|1
6047898|NCT00413660|9646913|FG005|Post Week 12|Withdrawal by Subject|0
6047899|NCT00413660|9646914|FG006|Post Week 12|Withdrawal by Subject|0
6047900|NCT00413660|9646915|FG007|Post Week 12|Withdrawal by Subject|0
6047901|NCT00413660|9646916|FG008|Post Week 12|Withdrawal by Subject|0
6047902|NCT00413660|9646917|FG009|Post Week 12|Withdrawal by Subject|0
6047903|NCT00413660|9646918|FG010|Post Week 12|Withdrawal by Subject|1
6047904|NCT00413660|9646908|FG000|Post Week 12|Other|1
6047905|NCT00413660|9646909|FG001|Post Week 12|Other|2
6047906|NCT00413660|9646910|FG002|Post Week 12|Other|3
6047907|NCT00413660|9646911|FG003|Post Week 12|Other|0
6047908|NCT00413660|9646912|FG004|Post Week 12|Other|1
6047909|NCT00413660|9646913|FG005|Post Week 12|Other|1
6047910|NCT00413660|9646914|FG006|Post Week 12|Other|1
6047911|NCT00413660|9646915|FG007|Post Week 12|Other|0
6047912|NCT00413660|9646916|FG008|Post Week 12|Other|0
6047913|NCT00413660|9646917|FG009|Post Week 12|Other|0
6047914|NCT00413660|9646918|FG010|Post Week 12|Other|0
6047915|NCT00413777|9646950|FG000|Fixed-dose Period|Lost to Follow-up|1
6047916|NCT00413777|9646951|FG001|Fixed-dose Period|Lost to Follow-up|1
6047917|NCT00413777|9646950|FG000|Fixed-dose Period|Adverse Event|2
6047918|NCT00413777|9646951|FG001|Fixed-dose Period|Adverse Event|1
6047919|NCT00413777|9646950|FG000|Fixed-dose Period|Met Withdrawal Criteria|1
6047920|NCT00413777|9646951|FG001|Fixed-dose Period|Met Withdrawal Criteria|0
6047921|NCT00413777|9646950|FG000|Fixed-dose Period|Withdrew Consent|0
6077373|NCT00598078|9683585|FG000|Period 2 (Day 2)|Adverse Event|1
6077374|NCT00598078|9683586|FG001|Period 2 (Day 2)|Adverse Event|0
6077375|NCT00598273|9683597|FG000|Overall Study|Adverse Event|4
6077376|NCT00598273|9683598|FG001|Overall Study|Adverse Event|5
6077377|NCT00598273|9683599|FG002|Overall Study|Adverse Event|2
6077378|NCT00598273|9683597|FG000|Overall Study|Death|6
6077379|NCT00598273|9683598|FG001|Overall Study|Death|12
6077380|NCT00598273|9683599|FG002|Overall Study|Death|8
6077381|NCT00598273|9683597|FG000|Overall Study|Lost to Follow-up|8
6077382|NCT00598273|9683598|FG001|Overall Study|Lost to Follow-up|3
6077383|NCT00598273|9683599|FG002|Overall Study|Lost to Follow-up|5
6077384|NCT00598273|9683597|FG000|Overall Study|Physician Decision|0
6077385|NCT00598273|9683598|FG001|Overall Study|Physician Decision|0
6077386|NCT00598273|9683599|FG002|Overall Study|Physician Decision|1
6077387|NCT00598273|9683597|FG000|Overall Study|Withdrawal by Subject|12
6077388|NCT00598273|9683598|FG001|Overall Study|Withdrawal by Subject|10
6077389|NCT00598273|9683599|FG002|Overall Study|Withdrawal by Subject|10
6077390|NCT00598273|9683597|FG000|Overall Study|Noncompliance|3
6077391|NCT00598273|9683598|FG001|Overall Study|Noncompliance|2
6077392|NCT00598273|9683599|FG002|Overall Study|Noncompliance|3
6047922|NCT00413777|9646951|FG001|Fixed-dose Period|Withdrew Consent|1
6047923|NCT00413894|9646957|FG000|Overall Study|Withdrawal by Subject|10
6047924|NCT00413894|9646957|FG000|Overall Study|Administrative Reasons|1
6047925|NCT00413894|9646957|FG000|Overall Study|Hb <10 grams/deciliter|12
6047926|NCT00413894|9646957|FG000|Overall Study|Adverse Event|28
6047927|NCT00413894|9646957|FG000|Overall Study|Protocol Violation|11
6047928|NCT00413894|9646957|FG000|Overall Study|Other|18
6047929|NCT00413920|9646966|FG000|Overall Study|Adverse Event|9
6047930|NCT00413920|9646967|FG001|Overall Study|Adverse Event|11
6047931|NCT00413920|9646966|FG000|Overall Study|Lack of Efficacy|11
6047932|NCT00413920|9646967|FG001|Overall Study|Lack of Efficacy|9
6047933|NCT00413920|9646966|FG000|Overall Study|Death|3
6077393|NCT00598273|9683597|FG000|Overall Study|Relocation|0
6077394|NCT00598273|9683598|FG001|Overall Study|Relocation|2
6077395|NCT00598273|9683599|FG002|Overall Study|Relocation|4
6077396|NCT00598273|9683597|FG000|Overall Study|Renal transplant|1
6077397|NCT00598273|9683598|FG001|Overall Study|Renal transplant|0
6077398|NCT00598273|9683599|FG002|Overall Study|Renal transplant|1
6018975|NCT00191165|9613117|FG000|Overall Study|Adverse Event|2
6018976|NCT00191165|9613118|FG001|Overall Study|Adverse Event|0
6018977|NCT00191165|9613117|FG000|Overall Study|Protocol Violation|0
6018978|NCT00191165|9613118|FG001|Overall Study|Protocol Violation|1
6018979|NCT00191165|9613117|FG000|Overall Study|Participant Moved Away|0
6018980|NCT00191165|9613118|FG001|Overall Study|Participant Moved Away|1
6018981|NCT00191191|9613126|FG000|Overall Study|Entry Criteria Exclusion|2
6018982|NCT00191191|9613127|FG001|Overall Study|Entry Criteria Exclusion|0
6018983|NCT00191191|9613126|FG000|Overall Study|Treated with Another Systemic Agent|1
6018984|NCT00191191|9613127|FG001|Overall Study|Treated with Another Systemic Agent|1
6018985|NCT00191191|9613126|FG000|Overall Study|Adverse Event|11
6018986|NCT00191191|9613127|FG001|Overall Study|Adverse Event|21
6018987|NCT00191191|9613126|FG000|Overall Study|Progressive Disease|84
6018988|NCT00191191|9613127|FG001|Overall Study|Progressive Disease|72
6018989|NCT00191191|9613126|FG000|Overall Study|Toxicity After Dose Reduction|7
6018990|NCT00191191|9613127|FG001|Overall Study|Toxicity After Dose Reduction|8
6018991|NCT00191191|9613126|FG000|Overall Study|Family/Caregiver Decision|5
6018992|NCT00191191|9613127|FG001|Overall Study|Family/Caregiver Decision|7
6018993|NCT00191191|9613126|FG000|Overall Study|Lost to Follow-up|1
6018994|NCT00191191|9613127|FG001|Overall Study|Lost to Follow-up|0
6018995|NCT00191191|9613126|FG000|Overall Study|Physician Decision|3
6018996|NCT00191191|9613127|FG001|Overall Study|Physician Decision|2
6018997|NCT00191191|9613126|FG000|Overall Study|Good Clinical Practice Violation|0
6018998|NCT00191191|9613127|FG001|Overall Study|Good Clinical Practice Violation|1
6018999|NCT00191269|9613135|FG000|Overall Study|Protocol Violation|0
6019000|NCT00191269|9613136|FG001|Overall Study|Protocol Violation|2
6019001|NCT00191269|9613135|FG000|Overall Study|Adverse Event|1
6019002|NCT00191269|9613136|FG001|Overall Study|Adverse Event|4
6019003|NCT00191269|9613135|FG000|Overall Study|Progression of Disease|4
6019004|NCT00191269|9613136|FG001|Overall Study|Progression of Disease|42
6019005|NCT00191269|9613135|FG000|Overall Study|Lack of Efficacy|1
6019006|NCT00191269|9613136|FG001|Overall Study|Lack of Efficacy|5
6019007|NCT00191269|9613135|FG000|Overall Study|Withdrawal by Subject|0
6019008|NCT00191269|9613136|FG001|Overall Study|Withdrawal by Subject|1
6019009|NCT00191269|9613135|FG000|Overall Study|Pathologic Aggrevation|0
6019010|NCT00191269|9613136|FG001|Overall Study|Pathologic Aggrevation|1
6019011|NCT00191269|9613135|FG000|Overall Study|Physician Decision|0
6019012|NCT00191269|9613136|FG001|Overall Study|Physician Decision|3
6019013|NCT00191282|9613145|FG000|Overall Study|Adverse Event|5
6019014|NCT00191282|9613146|FG001|Overall Study|Adverse Event|6
6019015|NCT00191282|9613145|FG000|Overall Study|Death|51
6019016|NCT00191282|9613146|FG001|Overall Study|Death|51
6019017|NCT00191282|9613145|FG000|Overall Study|Lack of Efficacy|11
6019018|NCT00191282|9613146|FG001|Overall Study|Lack of Efficacy|6
6019019|NCT00191282|9613145|FG000|Overall Study|Noncompliance|14
6019020|NCT00191282|9613146|FG001|Overall Study|Noncompliance|17
6019021|NCT00191282|9613145|FG000|Overall Study|Patient moved|11
6019022|NCT00191282|9613146|FG001|Overall Study|Patient moved|14
6019023|NCT00191282|9613145|FG000|Overall Study|Withdrawal by Subject|59
6019024|NCT00191282|9613146|FG001|Overall Study|Withdrawal by Subject|44
6019025|NCT00191282|9613145|FG000|Overall Study|Physician Decision|18
6019026|NCT00191282|9613146|FG001|Overall Study|Physician Decision|15
6019027|NCT00191282|9613145|FG000|Overall Study|Protocol entry criteria not met|14
6077399|NCT00598273|9683597|FG000|Overall Study|Site elected to close|1
6077400|NCT00598273|9683598|FG001|Overall Study|Site elected to close|0
6077401|NCT00598273|9683599|FG002|Overall Study|Site elected to close|0
6077402|NCT00598273|9683597|FG000|Overall Study|Started dialysis|6
6077403|NCT00598273|9683598|FG001|Overall Study|Started dialysis|4
6077404|NCT00598273|9683599|FG002|Overall Study|Started dialysis|5
6077405|NCT00598442|9683610|FG000|Overall Study|Adverse Event|3
6077406|NCT00598442|9683611|FG001|Overall Study|Adverse Event|0
6077407|NCT00598442|9683612|FG002|Overall Study|Adverse Event|0
6077408|NCT00598442|9683610|FG000|Overall Study|Death|19
6077409|NCT00598442|9683611|FG001|Overall Study|Death|11
6077410|NCT00598442|9683612|FG002|Overall Study|Death|11
6077411|NCT00598442|9683610|FG000|Overall Study|Lost to Follow-up|4
6077412|NCT00598442|9683611|FG001|Overall Study|Lost to Follow-up|3
6077413|NCT00598442|9683612|FG002|Overall Study|Lost to Follow-up|3
6077414|NCT00598442|9683610|FG000|Overall Study|Physician Decision|2
6077415|NCT00598442|9683611|FG001|Overall Study|Physician Decision|1
6077416|NCT00598442|9683612|FG002|Overall Study|Physician Decision|1
6077417|NCT00598442|9683610|FG000|Overall Study|Withdrawal by Subject|8
6019028|NCT00191282|9613146|FG001|Overall Study|Protocol entry criteria not met|9
6019029|NCT00191282|9613145|FG000|Overall Study|Protocol Violation|9
6019030|NCT00191282|9613146|FG001|Overall Study|Protocol Violation|12
6019031|NCT00191282|9613145|FG000|Overall Study|Severity of outcome|2
6019032|NCT00191282|9613146|FG001|Overall Study|Severity of outcome|5
6019033|NCT00191282|9613145|FG000|Overall Study|Sponsor's decision|2
6019034|NCT00191282|9613146|FG001|Overall Study|Sponsor's decision|2
6019035|NCT00191282|9613145|FG000|Overall Study|Lost to Follow-up|24
6077418|NCT00598442|9683611|FG001|Overall Study|Withdrawal by Subject|16
6077419|NCT00598442|9683612|FG002|Overall Study|Withdrawal by Subject|6
6077420|NCT00598442|9683610|FG000|Overall Study|Noncompliance|0
6077421|NCT00598442|9683611|FG001|Overall Study|Noncompliance|2
6077422|NCT00598442|9683612|FG002|Overall Study|Noncompliance|1
6077423|NCT00598442|9683610|FG000|Overall Study|Relocation|1
6019036|NCT00191282|9613146|FG001|Overall Study|Lost to Follow-up|31
6019037|NCT00191308|9613152|FG000|Overall Study|Adverse Event|1
6019038|NCT00191334|9613156|FG000|Overall Study|Adverse Event|4
6019039|NCT00191334|9613156|FG000|Overall Study|Disease Progression or Relapse|8
6019040|NCT00191334|9613156|FG000|Overall Study|Physician Decision|1
6019041|NCT00191334|9613156|FG000|Overall Study|Withdrawal by Subject|4
6019042|NCT00191386|9613160|FG000|Overall Study|Adverse Event|16
6019043|NCT00191386|9613160|FG000|Overall Study|Lost to Follow-up|1
6019044|NCT00191386|9613160|FG000|Overall Study|Entry Criteria Exclusion|3
6019045|NCT00191386|9613160|FG000|Overall Study|Protocol Violation|18
6019046|NCT00191386|9613160|FG000|Overall Study|Withdrawal by Subject|96
6019047|NCT00191386|9613160|FG000|Overall Study|Physician Decision|11
6019048|NCT00191386|9613160|FG000|Overall Study|Lack of Efficacy|15
6019049|NCT00191451|9613167|FG000|Overall Study|Withdrawal by Subject|2
6019050|NCT00191451|9613168|FG001|Overall Study|Withdrawal by Subject|3
6019051|NCT00191451|9613169|FG002|Overall Study|Withdrawal by Subject|5
6019052|NCT00191451|9613167|FG000|Overall Study|Physician Decision|2
6019053|NCT00191451|9613168|FG001|Overall Study|Physician Decision|9
6019054|NCT00191451|9613169|FG002|Overall Study|Physician Decision|6
6019055|NCT00191451|9613167|FG000|Overall Study|Sponsor Decision|1
6019056|NCT00191451|9613168|FG001|Overall Study|Sponsor Decision|0
6019057|NCT00191451|9613169|FG002|Overall Study|Sponsor Decision|0
6019058|NCT00191451|9613167|FG000|Overall Study|Ineligible|0
6019059|NCT00191451|9613168|FG001|Overall Study|Ineligible|1
6019060|NCT00191451|9613169|FG002|Overall Study|Ineligible|0
6019061|NCT00191451|9613167|FG000|Overall Study|Reason Not Specified|2
6019062|NCT00191451|9613168|FG001|Overall Study|Reason Not Specified|1
6019063|NCT00191451|9613169|FG002|Overall Study|Reason Not Specified|3
6019064|NCT00191477|9613179|FG000|Overall Study|Tumor Recurrence|49
6019065|NCT00191477|9613180|FG001|Overall Study|Tumor Recurrence|48
6019066|NCT00191477|9613179|FG000|Overall Study|Death, Study Disease|1
6019067|NCT00191477|9613180|FG001|Overall Study|Death, Study Disease|1
6019068|NCT00191477|9613179|FG000|Overall Study|Death, Other Cause|3
6019069|NCT00191477|9613180|FG001|Overall Study|Death, Other Cause|6
6019070|NCT00191477|9613179|FG000|Overall Study|Lost to Follow-up|23
6019071|NCT00191477|9613180|FG001|Overall Study|Lost to Follow-up|21
6019072|NCT00191477|9613179|FG000|Overall Study|Protocol Violation|1
6019073|NCT00191477|9613180|FG001|Overall Study|Protocol Violation|1
6019074|NCT00191477|9613179|FG000|Overall Study|Treatment Change|2
6019075|NCT00191477|9613180|FG001|Overall Study|Treatment Change|0
6077424|NCT00598442|9683611|FG001|Overall Study|Relocation|4
6077425|NCT00598442|9683612|FG002|Overall Study|Relocation|0
6077426|NCT00598442|9683610|FG000|Overall Study|Renal transplant|0
6077427|NCT00598442|9683611|FG001|Overall Study|Renal transplant|0
6077428|NCT00598442|9683612|FG002|Overall Study|Renal transplant|1
6077429|NCT00598442|9683610|FG000|Overall Study|Site closed by sponsor|5
6077430|NCT00598442|9683611|FG001|Overall Study|Site closed by sponsor|2
6077431|NCT00598442|9683612|FG002|Overall Study|Site closed by sponsor|1
6077432|NCT00598442|9683610|FG000|Overall Study|Started dialysis|1
6077433|NCT00598442|9683611|FG001|Overall Study|Started dialysis|0
6077434|NCT00598442|9683612|FG002|Overall Study|Started dialysis|0
6077435|NCT00598481|9683620|FG000|Treatment|Physician Decision|1
6077436|NCT00598559|9683634|FG000|Overall Study|Adverse Event|11
6077437|NCT00598559|9683635|FG001|Overall Study|Adverse Event|7
6077438|NCT00598559|9683636|FG002|Overall Study|Adverse Event|0
6077439|NCT00598559|9683634|FG000|Overall Study|Withdrawal by Subject|2
6077440|NCT00598559|9683635|FG001|Overall Study|Withdrawal by Subject|2
6077441|NCT00598559|9683636|FG002|Overall Study|Withdrawal by Subject|0
6077442|NCT00598559|9683634|FG000|Overall Study|Protocol Non-compliance|1
6077443|NCT00598559|9683635|FG001|Overall Study|Protocol Non-compliance|0
6077444|NCT00598559|9683636|FG002|Overall Study|Protocol Non-compliance|0
6077445|NCT00598559|9683634|FG000|Overall Study|Early discharge from hospital|9
6077446|NCT00598559|9683635|FG001|Overall Study|Early discharge from hospital|12
6077447|NCT00598559|9683636|FG002|Overall Study|Early discharge from hospital|3
6077448|NCT00598559|9683634|FG000|Overall Study|Subject unable/unwilling to attend visit|4
6077449|NCT00598559|9683635|FG001|Overall Study|Subject unable/unwilling to attend visit|7
6077450|NCT00598559|9683636|FG002|Overall Study|Subject unable/unwilling to attend visit|0
6077451|NCT00598585|9683646|FG000|Overall Study|Lost to Follow-up|1
6077452|NCT00598585|9683647|FG001|Overall Study|Lost to Follow-up|0
6077453|NCT00598650|9683653|FG000|Overall Study|Withdrawal by Subject|3
6019076|NCT00191477|9613179|FG000|Overall Study|Withdrawal by Subject|2
6019077|NCT00191477|9613180|FG001|Overall Study|Withdrawal by Subject|0
6019078|NCT00191477|9613179|FG000|Overall Study|Other|2
6019079|NCT00191477|9613180|FG001|Overall Study|Other|0
6019080|NCT00191477|9613179|FG000|Overall Study|Not Eligible|41
6019081|NCT00191477|9613180|FG001|Overall Study|Not Eligible|38
6019082|NCT00191477|9613179|FG000|Overall Study|Pathological Specimen Lost|1
6019083|NCT00191477|9613180|FG001|Overall Study|Pathological Specimen Lost|0
6077454|NCT00598650|9683653|FG000|Overall Study|Adverse Event|18
6077455|NCT00598650|9683653|FG000|Overall Study|No treatment for 3 weeks|1
6077456|NCT00598650|9683653|FG000|Overall Study|Not eligible|1
6077457|NCT00598650|9683653|FG000|Overall Study|Prohibited Concomitant Medication|2
6077458|NCT00598650|9683653|FG000|Overall Study|Physician Decision|2
6077459|NCT00598702|9683687|FG000|Overall Study|Other|0
6077460|NCT00598702|9683688|FG001|Overall Study|Other|2
6019084|NCT00191477|9613179|FG000|Overall Study|Discontinued Prior to Instillation|13
6019085|NCT00191477|9613180|FG001|Overall Study|Discontinued Prior to Instillation|14
6019086|NCT00191646|9613188|FG000|Overall Study|Toxicity|26
6019087|NCT00191646|9613189|FG001|Overall Study|Toxicity|37
6019088|NCT00191646|9613188|FG000|Overall Study|Disease Progression|5
6019089|NCT00191646|9613189|FG001|Overall Study|Disease Progression|6
6019090|NCT00191646|9613188|FG000|Overall Study|Physician Decision|20
6019091|NCT00191646|9613189|FG001|Overall Study|Physician Decision|11
6019092|NCT00191646|9613188|FG000|Overall Study|Withdrawal by Subject|58
6019093|NCT00191646|9613189|FG001|Overall Study|Withdrawal by Subject|39
6019094|NCT00191646|9613188|FG000|Overall Study|Protocol Violation|5
6019095|NCT00191646|9613189|FG001|Overall Study|Protocol Violation|7
6019096|NCT00191646|9613188|FG000|Overall Study|Death|6
6019097|NCT00191646|9613189|FG001|Overall Study|Death|8
6019098|NCT00191646|9613188|FG000|Overall Study|Other|33
6019099|NCT00191646|9613189|FG001|Overall Study|Other|34
6019100|NCT00191646|9613188|FG000|Overall Study|Missing Data|18
6019101|NCT00191646|9613189|FG001|Overall Study|Missing Data|11
6019102|NCT00191724|9613208|FG000|Overall Study|Adverse Event|0
6019103|NCT00191724|9613209|FG001|Overall Study|Adverse Event|0
6019104|NCT00191724|9613210|FG002|Overall Study|Adverse Event|1
6019105|NCT00191724|9613211|FG003|Overall Study|Adverse Event|0
6019106|NCT00191724|9613212|FG004|Overall Study|Adverse Event|0
6019107|NCT00191724|9613208|FG000|Overall Study|Lost to Follow-up|1
6019108|NCT00191724|9613209|FG001|Overall Study|Lost to Follow-up|1
6019109|NCT00191724|9613210|FG002|Overall Study|Lost to Follow-up|0
6019110|NCT00191724|9613211|FG003|Overall Study|Lost to Follow-up|2
6019111|NCT00191724|9613212|FG004|Overall Study|Lost to Follow-up|3
6019112|NCT00191724|9613208|FG000|Overall Study|Withdrawal by Subject|0
6019113|NCT00191724|9613209|FG001|Overall Study|Withdrawal by Subject|0
6019114|NCT00191724|9613210|FG002|Overall Study|Withdrawal by Subject|0
6019115|NCT00191724|9613211|FG003|Overall Study|Withdrawal by Subject|1
6019116|NCT00191724|9613212|FG004|Overall Study|Withdrawal by Subject|0
6077461|NCT00598702|9683689|FG002|Overall Study|Other|0
6077462|NCT00598702|9683690|FG003|Overall Study|Other|0
6077463|NCT00598702|9683691|FG004|Overall Study|Other|0
6077464|NCT00598702|9683692|FG005|Overall Study|Other|1
6077465|NCT00598702|9683693|FG006|Overall Study|Other|0
6077466|NCT00598702|9683694|FG007|Overall Study|Other|0
6077467|NCT00598702|9683687|FG000|Overall Study|Early discharge from hospital|0
6077468|NCT00598702|9683688|FG001|Overall Study|Early discharge from hospital|0
6077469|NCT00598702|9683689|FG002|Overall Study|Early discharge from hospital|2
6077470|NCT00598702|9683690|FG003|Overall Study|Early discharge from hospital|5
6077471|NCT00598702|9683691|FG004|Overall Study|Early discharge from hospital|0
6077472|NCT00598702|9683692|FG005|Overall Study|Early discharge from hospital|10
6077473|NCT00598702|9683693|FG006|Overall Study|Early discharge from hospital|1
6077474|NCT00598702|9683694|FG007|Overall Study|Early discharge from hospital|0
6077475|NCT00598702|9683687|FG000|Overall Study|Adverse Event|0
6077476|NCT00598702|9683688|FG001|Overall Study|Adverse Event|0
6077477|NCT00598702|9683689|FG002|Overall Study|Adverse Event|0
6077478|NCT00598702|9683690|FG003|Overall Study|Adverse Event|1
6077479|NCT00598702|9683691|FG004|Overall Study|Adverse Event|0
6077480|NCT00598702|9683692|FG005|Overall Study|Adverse Event|0
6077481|NCT00598702|9683693|FG006|Overall Study|Adverse Event|0
6077482|NCT00598702|9683694|FG007|Overall Study|Adverse Event|0
6077483|NCT00598702|9683687|FG000|Overall Study|Withdrawal by Subject|0
6077484|NCT00598702|9683688|FG001|Overall Study|Withdrawal by Subject|0
6077485|NCT00598702|9683689|FG002|Overall Study|Withdrawal by Subject|0
6077486|NCT00598702|9683690|FG003|Overall Study|Withdrawal by Subject|1
6077487|NCT00598702|9683691|FG004|Overall Study|Withdrawal by Subject|1
6077488|NCT00598702|9683692|FG005|Overall Study|Withdrawal by Subject|0
6077489|NCT00598702|9683693|FG006|Overall Study|Withdrawal by Subject|0
6077490|NCT00598702|9683694|FG007|Overall Study|Withdrawal by Subject|0
6077491|NCT00598702|9683687|FG000|Overall Study|Physician Decision|0
6077492|NCT00598702|9683688|FG001|Overall Study|Physician Decision|0
6077493|NCT00598702|9683689|FG002|Overall Study|Physician Decision|0
6077494|NCT00598702|9683690|FG003|Overall Study|Physician Decision|0
6077495|NCT00598702|9683691|FG004|Overall Study|Physician Decision|1
6019117|NCT00191789|9613224|FG000|Overall Study|Adverse Event|5
6019118|NCT00191789|9613224|FG000|Overall Study|Patient: Satisfactory Response|5
6019119|NCT00191789|9613224|FG000|Overall Study|Patient/Physician: Satisfactory Response|4
6019120|NCT00191789|9613224|FG000|Overall Study|Withdrawal by Subject|4
6019121|NCT00191789|9613224|FG000|Overall Study|Death - Possibly Study Drug Related|4
6019122|NCT00191789|9613224|FG000|Overall Study|Progressive Disease/Lack of Efficacy|2
6019123|NCT00191789|9613224|FG000|Overall Study|Death - Not Study-Drug Related|1
6077496|NCT00598702|9683692|FG005|Overall Study|Physician Decision|0
6077497|NCT00598702|9683693|FG006|Overall Study|Physician Decision|0
6077498|NCT00598702|9683694|FG007|Overall Study|Physician Decision|0
6077499|NCT00598702|9683687|FG000|Overall Study|Dose limiting toxicity|0
6077500|NCT00598702|9683688|FG001|Overall Study|Dose limiting toxicity|0
6077501|NCT00598702|9683689|FG002|Overall Study|Dose limiting toxicity|0
6077502|NCT00598702|9683690|FG003|Overall Study|Dose limiting toxicity|1
6077503|NCT00598702|9683691|FG004|Overall Study|Dose limiting toxicity|1
6077504|NCT00598702|9683692|FG005|Overall Study|Dose limiting toxicity|1
6019124|NCT00191815|9613228|FG000|Overall Study|Adverse Event|2
6019125|NCT00191815|9613228|FG000|Overall Study|Disease progression or relapse|24
6019126|NCT00191815|9613228|FG000|Overall Study|Death|2
6019127|NCT00191815|9613228|FG000|Overall Study|Protocol Violation|3
6019128|NCT00191815|9613228|FG000|Overall Study|Physician Decision|2
6019129|NCT00191815|9613228|FG000|Overall Study|Withdrawal by Subject|7
6019130|NCT00191854|9613235|FG000|Overall Study|Death|26
6019131|NCT00191854|9613236|FG001|Overall Study|Death|23
6019132|NCT00191854|9613237|FG002|Overall Study|Death|29
6019133|NCT00191854|9613235|FG000|Overall Study|Lost to Follow-up|7
6019134|NCT00191854|9613236|FG001|Overall Study|Lost to Follow-up|5
6019135|NCT00191854|9613237|FG002|Overall Study|Lost to Follow-up|5
6019136|NCT00191854|9613235|FG000|Overall Study|Withdrawal by Subject|4
6019137|NCT00191854|9613236|FG001|Overall Study|Withdrawal by Subject|2
6019138|NCT00191854|9613237|FG002|Overall Study|Withdrawal by Subject|3
6019139|NCT00191854|9613235|FG000|Overall Study|Sponsor Decision|0
6019140|NCT00191854|9613236|FG001|Overall Study|Sponsor Decision|0
6019141|NCT00191854|9613237|FG002|Overall Study|Sponsor Decision|1
6019142|NCT00191854|9613235|FG000|Overall Study|Screen Failure|0
6019143|NCT00191854|9613236|FG001|Overall Study|Screen Failure|0
6019144|NCT00191854|9613237|FG002|Overall Study|Screen Failure|1
6019145|NCT00191906|9613249|FG000|Study Period II|Adverse Event|0
6019146|NCT00191906|9613250|FG001|Study Period II|Adverse Event|1
6019147|NCT00191906|9613251|FG002|Study Period II|Adverse Event|0
6019148|NCT00191906|9613252|FG003|Study Period II|Adverse Event|0
6019149|NCT00191906|9613249|FG000|Study Period II|Withdrawal by Subject|0
6019150|NCT00191906|9613250|FG001|Study Period II|Withdrawal by Subject|3
6019151|NCT00191906|9613251|FG002|Study Period II|Withdrawal by Subject|0
6019152|NCT00191906|9613252|FG003|Study Period II|Withdrawal by Subject|0
6019153|NCT00191906|9613249|FG000|Study Period II|Parent/Caregiver Decision|0
6019154|NCT00191906|9613250|FG001|Study Period II|Parent/Caregiver Decision|1
6019155|NCT00191906|9613251|FG002|Study Period II|Parent/Caregiver Decision|0
6019156|NCT00191906|9613252|FG003|Study Period II|Parent/Caregiver Decision|0
6019157|NCT00191906|9613249|FG000|Study Period II|Entry Criteria Exclusion|0
6019158|NCT00191906|9613250|FG001|Study Period II|Entry Criteria Exclusion|0
6019159|NCT00191906|9613251|FG002|Study Period II|Entry Criteria Exclusion|1
6019160|NCT00191906|9613252|FG003|Study Period II|Entry Criteria Exclusion|0
6019161|NCT00191906|9613249|FG000|Study Period III|Adverse Event|1
6019162|NCT00191906|9613250|FG001|Study Period III|Adverse Event|0
6019163|NCT00191906|9613251|FG002|Study Period III|Adverse Event|0
6019164|NCT00191906|9613252|FG003|Study Period III|Adverse Event|0
6019165|NCT00191906|9613249|FG000|Study Period III|Lost to Follow-up|0
6019166|NCT00191906|9613250|FG001|Study Period III|Lost to Follow-up|1
6019167|NCT00191906|9613251|FG002|Study Period III|Lost to Follow-up|0
6019168|NCT00191906|9613252|FG003|Study Period III|Lost to Follow-up|0
6019169|NCT00191906|9613249|FG000|Study Period III|Parent/Caregiver Decision|1
6019170|NCT00191906|9613250|FG001|Study Period III|Parent/Caregiver Decision|0
6019171|NCT00191906|9613251|FG002|Study Period III|Parent/Caregiver Decision|0
6019172|NCT00191906|9613252|FG003|Study Period III|Parent/Caregiver Decision|0
6019173|NCT00191906|9613249|FG000|Study Period III|Lack of Efficacy|3
6077505|NCT00598702|9683693|FG006|Overall Study|Dose limiting toxicity|0
6077506|NCT00598702|9683694|FG007|Overall Study|Dose limiting toxicity|0
6077507|NCT00598832|9683727|FG000|Overall Study|Lack of Efficacy|3
6077508|NCT00598832|9683728|FG001|Overall Study|Lack of Efficacy|7
6077509|NCT00598832|9683727|FG000|Overall Study|Adverse Event|6
6077510|NCT00598832|9683728|FG001|Overall Study|Adverse Event|2
6019174|NCT00191906|9613250|FG001|Study Period III|Lack of Efficacy|3
6019175|NCT00191906|9613251|FG002|Study Period III|Lack of Efficacy|0
6019176|NCT00191906|9613252|FG003|Study Period III|Lack of Efficacy|0
6019177|NCT00191945|9613270|FG000|Double-Blind Acute Treatment|Parent's Decision|3
6019178|NCT00191945|9613271|FG001|Double-Blind Acute Treatment|Parent's Decision|0
6019179|NCT00191945|9613270|FG000|Double-Blind Acute Treatment|Lost to Follow-up|0
6019180|NCT00191945|9613271|FG001|Double-Blind Acute Treatment|Lost to Follow-up|1
6019181|NCT00191945|9613270|FG000|Double-Blind Acute Treatment|Non Protocol Compliance|3
6019182|NCT00191945|9613271|FG001|Double-Blind Acute Treatment|Non Protocol Compliance|0
6019183|NCT00191945|9613270|FG000|Double-Blind Acute Treatment|Physician Decision|0
6019184|NCT00191945|9613271|FG001|Double-Blind Acute Treatment|Physician Decision|2
6019185|NCT00191984|9613278|FG000|Overall Study|Disease Progression|21
6077511|NCT00598832|9683727|FG000|Overall Study|Withdrawal by Subject|25
6077512|NCT00598832|9683728|FG001|Overall Study|Withdrawal by Subject|36
6077513|NCT00598832|9683727|FG000|Overall Study|Protocol Violation|0
6077514|NCT00598832|9683728|FG001|Overall Study|Protocol Violation|2
6077515|NCT00598832|9683727|FG000|Overall Study|Lost to Follow-up|24
6077516|NCT00598832|9683728|FG001|Overall Study|Lost to Follow-up|29
6019186|NCT00191984|9613278|FG000|Overall Study|Adverse Event|4
6019187|NCT00191984|9613278|FG000|Overall Study|Death|2
6019188|NCT00191984|9613278|FG000|Overall Study|Entry Criteria Exclusion|1
6019189|NCT00191984|9613278|FG000|Overall Study|Withdrawal by Subject|7
6019190|NCT00191984|9613278|FG000|Overall Study|Physician Decision|4
6019191|NCT00192023|9613284|FG000|Period III - Double-Blind|Adverse Event|3
6077517|NCT00598832|9683727|FG000|Overall Study|Pregnancy|2
6077518|NCT00598832|9683728|FG001|Overall Study|Pregnancy|2
6077519|NCT00598832|9683727|FG000|Overall Study|Physician Decision|1
6077520|NCT00598832|9683728|FG001|Overall Study|Physician Decision|4
6019192|NCT00192023|9613285|FG001|Period III - Double-Blind|Adverse Event|0
6019193|NCT00192023|9613284|FG000|Period III - Double-Blind|Physician Decision|2
6019194|NCT00192023|9613285|FG001|Period III - Double-Blind|Physician Decision|0
6019195|NCT00192023|9613284|FG000|Period III - Double-Blind|Parent/Caregiver Decision|2
6019196|NCT00192023|9613285|FG001|Period III - Double-Blind|Parent/Caregiver Decision|0
6019197|NCT00192023|9613284|FG000|Period IV - Optional Open-Label|Adverse Event|6
6019198|NCT00192023|9613285|FG001|Period IV - Optional Open-Label|Adverse Event|0
6019199|NCT00192023|9613284|FG000|Period IV - Optional Open-Label|Lack of Efficacy|7
6019200|NCT00192023|9613285|FG001|Period IV - Optional Open-Label|Lack of Efficacy|0
6019201|NCT00192023|9613284|FG000|Period IV - Optional Open-Label|Patient/Caregiver Decision|46
6019202|NCT00192023|9613285|FG001|Period IV - Optional Open-Label|Patient/Caregiver Decision|0
6019203|NCT00192023|9613284|FG000|Period IV - Optional Open-Label|Lost to Follow-up|2
6019204|NCT00192023|9613285|FG001|Period IV - Optional Open-Label|Lost to Follow-up|0
6019205|NCT00192023|9613284|FG000|Period IV - Optional Open-Label|Protocol Violation|1
6019206|NCT00192023|9613285|FG001|Period IV - Optional Open-Label|Protocol Violation|0
6019207|NCT00192023|9613284|FG000|Period IV - Optional Open-Label|Withdrawal by Subject|4
6019208|NCT00192023|9613285|FG001|Period IV - Optional Open-Label|Withdrawal by Subject|0
6019209|NCT00192023|9613284|FG000|Period IV - Optional Open-Label|Physician Decision|9
6019210|NCT00192023|9613285|FG001|Period IV - Optional Open-Label|Physician Decision|0
6019211|NCT00192036|9613291|FG000|Overall Study|Protocol Violation|3
6019212|NCT00192036|9613291|FG000|Overall Study|Adverse Event|6
6019213|NCT00192036|9613291|FG000|Overall Study|Patient/Physician Perception|1
6019214|NCT00192036|9613291|FG000|Overall Study|Objective Tumor Progression|4
6019215|NCT00192036|9613291|FG000|Overall Study|Clinical Disease Progression|1
6019216|NCT00192036|9613291|FG000|Overall Study|Death|1
6019217|NCT00192036|9613291|FG000|Overall Study|Unknown or Not Specified|5
6019218|NCT00192075|9613297|FG000|Overall Study|Disease Progression|23
6019219|NCT00192075|9613298|FG001|Overall Study|Disease Progression|6
6019220|NCT00192075|9613297|FG000|Overall Study|Adverse Event|1
6019221|NCT00192075|9613298|FG001|Overall Study|Adverse Event|3
6019222|NCT00192075|9613297|FG000|Overall Study|Death|0
6019223|NCT00192075|9613298|FG001|Overall Study|Death|1
6019224|NCT00192075|9613297|FG000|Overall Study|Lack of Efficacy|0
6019225|NCT00192075|9613298|FG001|Overall Study|Lack of Efficacy|0
6019226|NCT00192075|9613297|FG000|Overall Study|Physician Decision|3
6019227|NCT00192075|9613298|FG001|Overall Study|Physician Decision|0
6019228|NCT00192075|9613297|FG000|Overall Study|Withdrawal by Subject|5
6019229|NCT00192075|9613298|FG001|Overall Study|Withdrawal by Subject|5
6019230|NCT00192075|9613297|FG000|Overall Study|Patient Non-Compliance|0
6019231|NCT00192075|9613298|FG001|Overall Study|Patient Non-Compliance|1
6019232|NCT00192075|9613297|FG000|Overall Study|Unacceptable Toxicity Exhibited by Drug|2
6077521|NCT00598832|9683727|FG000|Overall Study|Non compliance|1
6077522|NCT00598832|9683728|FG001|Overall Study|Non compliance|0
6077523|NCT00598871|9683736|FG000|Overall Study|Adverse Event|0
6077524|NCT00598871|9683737|FG001|Overall Study|Adverse Event|1
6077525|NCT00598975|9683745|FG000|Overall Study|Adverse Event|1
6077526|NCT00598975|9683746|FG001|Overall Study|Adverse Event|1
6077527|NCT00598975|9683745|FG000|Overall Study|Brain metastases|1
6077528|NCT00598975|9683746|FG001|Overall Study|Brain metastases|0
6077529|NCT00598975|9683745|FG000|Overall Study|Withdrawal by Subject|1
6077530|NCT00598975|9683746|FG001|Overall Study|Withdrawal by Subject|1
6077531|NCT00598975|9683745|FG000|Overall Study|Withdrawal of consent|0
6077532|NCT00598975|9683746|FG001|Overall Study|Withdrawal of consent|1
6077533|NCT00598975|9683745|FG000|Overall Study|Disease progression|8
6077534|NCT00598975|9683746|FG001|Overall Study|Disease progression|3
6077535|NCT00598975|9683745|FG000|Overall Study|Tx delayed >2 wks, hospitalized for AE|1
6077536|NCT00598975|9683746|FG001|Overall Study|Tx delayed >2 wks, hospitalized for AE|0
6077537|NCT00599196|9683767|FG000|Overall Study|Lack of Efficacy|22
6077538|NCT00599196|9683767|FG000|Overall Study|Adverse Event|93
6077539|NCT00599196|9683767|FG000|Overall Study|Unsatisfactory compliance of subject|3
6077540|NCT00599196|9683767|FG000|Overall Study|Subject withdrew consent|43
6077541|NCT00599196|9683767|FG000|Overall Study|Study ended per sponsor|197
6077542|NCT00599196|9683767|FG000|Overall Study|Lost to Follow-up|17
6077543|NCT00599196|9683767|FG000|Overall Study|Other: Patient Leaving For Israel|1
6077544|NCT00599196|9683767|FG000|Overall Study|Other: Spouse Withdrew Consent|1
6077545|NCT00599196|9683767|FG000|Overall Study|Other: Diagnosis No Longer Idiopathic Pd|1
6077546|NCT00599196|9683767|FG000|Overall Study|Other: Pt Moved To Australia|1
6077547|NCT00599196|9683767|FG000|Overall Study|Other: Patient Stopped Due To Moving|1
6077548|NCT00599196|9683767|FG000|Overall Study|Other: Inv Switched Dopamine Agonist|1
6146269|NCT01076036|9780842|FG000|Overall Study|Didn't meet inclusion/exclusion criteria|2
6019233|NCT00192075|9613298|FG001|Overall Study|Unacceptable Toxicity Exhibited by Drug|1
6019234|NCT00192075|9613297|FG000|Overall Study|Other|5
6019235|NCT00192075|9613298|FG001|Overall Study|Other|2
6019236|NCT00192114|9613309|FG000|Overall Study|Objective Tumor Progression|19
6077549|NCT00599313|9683785|FG000|Overall Study|Adverse Event|19
6077550|NCT00599313|9683785|FG000|Overall Study|Disease Progression|12
6077551|NCT00599313|9683785|FG000|Overall Study|Patient Request|4
6077552|NCT00599313|9683785|FG000|Overall Study|Ineligible|1
6077553|NCT00599326|9683789|FG000|Overall Study|Lost to Follow-up|1
6077554|NCT00599326|9683789|FG000|Overall Study|Noncompliant|1
6019237|NCT00192114|9613309|FG000|Overall Study|Adverse Event|2
6019238|NCT00192114|9613309|FG000|Overall Study|Clinical Progression|2
6019239|NCT00192114|9613309|FG000|Overall Study|Death|1
6019240|NCT00192296|9613317|FG000|Overall Study|Withdrawal by Subject|0
6019241|NCT00192296|9613318|FG001|Overall Study|Withdrawal by Subject|1
6019242|NCT00192296|9613319|FG002|Overall Study|Withdrawal by Subject|0
6019243|NCT00192296|9613320|FG003|Overall Study|Withdrawal by Subject|0
6019244|NCT00192504|9613334|FG000|Overall Study|Lost to Follow-up|1
6019245|NCT00192504|9613335|FG001|Overall Study|Lost to Follow-up|0
6019246|NCT00192504|9613336|FG002|Overall Study|Lost to Follow-up|0
6019247|NCT00192504|9613337|FG003|Overall Study|Lost to Follow-up|0
6019248|NCT00192504|9613334|FG000|Overall Study|Dosing window missed|0
6019249|NCT00192504|9613335|FG001|Overall Study|Dosing window missed|0
6019250|NCT00192504|9613336|FG002|Overall Study|Dosing window missed|1
6019251|NCT00192504|9613337|FG003|Overall Study|Dosing window missed|0
6019252|NCT00192647|9613349|FG000|Overall Study|Death|1
6019253|NCT00192647|9613350|FG001|Overall Study|Death|1
6019254|NCT00192647|9613349|FG000|Overall Study|Adverse Event|35
6019255|NCT00192647|9613350|FG001|Overall Study|Adverse Event|29
6019256|NCT00192647|9613349|FG000|Overall Study|Laboratory Test Abnormality|4
6019257|NCT00192647|9613350|FG001|Overall Study|Laboratory Test Abnormality|2
6019258|NCT00192647|9613349|FG000|Overall Study|Insufficient Therapeutic Response|53
6019259|NCT00192647|9613350|FG001|Overall Study|Insufficient Therapeutic Response|83
6019260|NCT00192647|9613349|FG000|Overall Study|Entry Criteria Violation|6
6019261|NCT00192647|9613350|FG001|Overall Study|Entry Criteria Violation|6
6019262|NCT00192647|9613349|FG000|Overall Study|Protocol Violation|3
6019263|NCT00192647|9613350|FG001|Overall Study|Protocol Violation|1
6019264|NCT00192647|9613349|FG000|Overall Study|Refused Treatment/Did not Cooperate|10
6019265|NCT00192647|9613350|FG001|Overall Study|Refused Treatment/Did not Cooperate|8
6019266|NCT00192647|9613349|FG000|Overall Study|Failure to Return|11
6019267|NCT00192647|9613350|FG001|Overall Study|Failure to Return|13
6019268|NCT00192647|9613349|FG000|Overall Study|Other/Administrative|5
6019269|NCT00192647|9613350|FG001|Overall Study|Other/Administrative|3
6019270|NCT00193050|9613365|FG000|Neoadjuvant Treatment|Lack of Efficacy|2
6019271|NCT00193050|9613365|FG000|Neoadjuvant Treatment|Intercurrent Illness|3
6019272|NCT00193050|9613365|FG000|Neoadjuvant Treatment|Physician Decision|2
6019273|NCT00193050|9613365|FG000|Neoadjuvant Treatment|Adverse Event|2
6019274|NCT00193050|9613365|FG000|Adjuvant|Physician Decision|5
6019275|NCT00193050|9613365|FG000|Adjuvant|Intercurrent Hospitalization|3
6019276|NCT00193050|9613365|FG000|Adjuvant|Lack of Efficacy|2
6019277|NCT00193063|9613370|FG000|Overall Study|Lack of Efficacy|3
6019278|NCT00193063|9613370|FG000|Overall Study|Adverse Event|1
6019279|NCT00193180|9613385|FG000|Overall Study|Lack of Efficacy|1
6019280|NCT00193180|9613385|FG000|Overall Study|Adverse Event|8
6019281|NCT00193180|9613385|FG000|Overall Study|Protocol Violation|1
6019282|NCT00193206|9613390|FG000|Preoperative Therapy|Lack of Efficacy|2
6019283|NCT00193206|9613390|FG000|Preoperative Therapy|Adverse Event|2
6077555|NCT00599339|9683793|FG000|Overall Study|Adverse Event|79
6077556|NCT00599339|9683793|FG000|Overall Study|Withdrawal by Subject|137
6077557|NCT00599339|9683793|FG000|Overall Study|Other Reason|179
6077558|NCT00599339|9683793|FG000|Overall Study|Lost to Follow-up|221
6077559|NCT00599339|9683793|FG000|Overall Study|No valid data consent|36
6077560|NCT00599339|9683793|FG000|Overall Study|Study Termination Status Unknown|12
6077561|NCT00599521|9683817|FG000|Overall Study|Lack of Efficacy|4
6077562|NCT00599521|9683818|FG001|Overall Study|Lack of Efficacy|8
6077563|NCT00599521|9683817|FG000|Overall Study|Adverse Event|4
6077564|NCT00599521|9683818|FG001|Overall Study|Adverse Event|1
6077565|NCT00599521|9683817|FG000|Overall Study|Withdrawal by Subject|28
6077566|NCT00599521|9683818|FG001|Overall Study|Withdrawal by Subject|34
6077567|NCT00599521|9683817|FG000|Overall Study|Protocol Violation|1
6077568|NCT00599521|9683818|FG001|Overall Study|Protocol Violation|1
6077569|NCT00599521|9683817|FG000|Overall Study|Lost to Follow-up|23
6077570|NCT00599521|9683818|FG001|Overall Study|Lost to Follow-up|23
6077571|NCT00599521|9683817|FG000|Overall Study|Pregnancy|0
6077572|NCT00599521|9683818|FG001|Overall Study|Pregnancy|2
6077573|NCT00599638|9683828|FG000|First Intervention Period (2 Weeks)|Adverse Event|1
6077574|NCT00599638|9683829|FG001|First Intervention Period (2 Weeks)|Adverse Event|0
6077575|NCT00599638|9683830|FG002|First Intervention Period (2 Weeks)|Adverse Event|3
6077576|NCT00599638|9683831|FG003|First Intervention Period (2 Weeks)|Adverse Event|2
6077577|NCT00599638|9683828|FG000|First Intervention Period (2 Weeks)|Withdrawal by Subject|1
6077578|NCT00599638|9683829|FG001|First Intervention Period (2 Weeks)|Withdrawal by Subject|0
6077579|NCT00599638|9683830|FG002|First Intervention Period (2 Weeks)|Withdrawal by Subject|0
6077580|NCT00599638|9683831|FG003|First Intervention Period (2 Weeks)|Withdrawal by Subject|1
6019284|NCT00193206|9613390|FG000|Preoperative Therapy|Withdrawal by Subject|2
6019285|NCT00193206|9613390|FG000|Preoperative Therapy|False Positive Pregnancy Test|1
6019286|NCT00193206|9613390|FG000|Postoperative Therapy|Withdrawal by Subject|7
6019287|NCT00193206|9613390|FG000|Postoperative Therapy|Physician Decision|3
6019288|NCT00193206|9613390|FG000|Postoperative Therapy|Intercurrent Illness|2
6019289|NCT00193206|9613390|FG000|Postoperative Therapy|Lack of Efficacy|1
6077581|NCT00599638|9683828|FG000|First Intervention Period (2 Weeks)|Protocol Violation|0
6077582|NCT00599638|9683829|FG001|First Intervention Period (2 Weeks)|Protocol Violation|1
6077583|NCT00599638|9683830|FG002|First Intervention Period (2 Weeks)|Protocol Violation|0
6019290|NCT00193206|9613390|FG000|Postoperative Therapy|Protocol Violation|1
6019291|NCT00193609|9613424|FG000|Overall Study|Lack of Efficacy|2
6019292|NCT00193609|9613424|FG000|Overall Study|Adverse Event|2
6019293|NCT00194012|9613430|FG000|Randomized Phase|Lack of Efficacy|8
6019294|NCT00194012|9613431|FG001|Randomized Phase|Lack of Efficacy|18
6019295|NCT00194012|9613430|FG000|Randomized Phase|Study nonadherence|2
6019296|NCT00194012|9613431|FG001|Randomized Phase|Study nonadherence|1
6019297|NCT00194012|9613430|FG000|Randomized Phase|Withdrawal by Subject|3
6019298|NCT00194012|9613431|FG001|Randomized Phase|Withdrawal by Subject|3
6019299|NCT00194012|9613430|FG000|Randomized Phase|Adverse Event|2
6019300|NCT00194012|9613431|FG001|Randomized Phase|Adverse Event|1
6019301|NCT00194012|9613430|FG000|Randomized Phase|Participant reported having a rash|1
6019302|NCT00194012|9613431|FG001|Randomized Phase|Participant reported having a rash|0
6019303|NCT00194012|9613430|FG000|Randomized Phase|Emesis and enuresis|0
6019304|NCT00194012|9613431|FG001|Randomized Phase|Emesis and enuresis|1
6019305|NCT00194012|9613430|FG000|Randomized Phase|Oral/nasal twitching|0
6019306|NCT00194012|9613431|FG001|Randomized Phase|Oral/nasal twitching|1
6019307|NCT00194012|9613430|FG000|Open Label Extension (OLE)|Weight Gain|1
6019308|NCT00194012|9613431|FG001|Open Label Extension (OLE)|Weight Gain|0
6019309|NCT00194012|9613430|FG000|Open Label Extension (OLE)|Drowsiness; Jittery|0
6019310|NCT00194012|9613431|FG001|Open Label Extension (OLE)|Drowsiness; Jittery|1
6019311|NCT00194012|9613430|FG000|Open Label Extension (OLE)|Lost to Follow-up|3
6019312|NCT00194012|9613431|FG001|Open Label Extension (OLE)|Lost to Follow-up|5
6019313|NCT00194012|9613430|FG000|Open Label Extension (OLE)|Lack of Efficacy|1
6019314|NCT00194012|9613431|FG001|Open Label Extension (OLE)|Lack of Efficacy|0
6019315|NCT00194025|9613443|FG000|Overall Study|Adverse Event|1
6077584|NCT00599638|9683831|FG003|First Intervention Period (2 Weeks)|Protocol Violation|1
6077585|NCT00599638|9683828|FG000|First Intervention Period (2 Weeks)|Randomized but not Treated|0
6077586|NCT00599638|9683829|FG001|First Intervention Period (2 Weeks)|Randomized but not Treated|1
6077587|NCT00599638|9683830|FG002|First Intervention Period (2 Weeks)|Randomized but not Treated|0
6077588|NCT00599638|9683831|FG003|First Intervention Period (2 Weeks)|Randomized but not Treated|1
6077589|NCT00599638|9683828|FG000|Washout Period (2 Weeks)|Withdrawal by Subject|1
6077590|NCT00599638|9683829|FG001|Washout Period (2 Weeks)|Withdrawal by Subject|0
6077591|NCT00599638|9683830|FG002|Washout Period (2 Weeks)|Withdrawal by Subject|0
6077592|NCT00599638|9683831|FG003|Washout Period (2 Weeks)|Withdrawal by Subject|1
6077593|NCT00599638|9683828|FG000|Washout Period (2 Weeks)|Adverse Event|0
6077594|NCT00599638|9683829|FG001|Washout Period (2 Weeks)|Adverse Event|0
6077595|NCT00599638|9683830|FG002|Washout Period (2 Weeks)|Adverse Event|0
6077596|NCT00599638|9683831|FG003|Washout Period (2 Weeks)|Adverse Event|1
6077597|NCT00599638|9683828|FG000|Washout Period (2 Weeks)|Lost to Follow-up|0
6077598|NCT00599638|9683829|FG001|Washout Period (2 Weeks)|Lost to Follow-up|0
6077599|NCT00599638|9683830|FG002|Washout Period (2 Weeks)|Lost to Follow-up|0
6077600|NCT00599638|9683831|FG003|Washout Period (2 Weeks)|Lost to Follow-up|1
6077601|NCT00599638|9683828|FG000|Washout Period (2 Weeks)|Protocol Violation|0
6077602|NCT00599638|9683829|FG001|Washout Period (2 Weeks)|Protocol Violation|1
6077603|NCT00599638|9683830|FG002|Washout Period (2 Weeks)|Protocol Violation|0
6077604|NCT00599638|9683831|FG003|Washout Period (2 Weeks)|Protocol Violation|0
6077605|NCT00599638|9683828|FG000|Second Intervention Period (2 Weeks)|Protocol Violation|1
6077606|NCT00599638|9683829|FG001|Second Intervention Period (2 Weeks)|Protocol Violation|0
6077607|NCT00599638|9683830|FG002|Second Intervention Period (2 Weeks)|Protocol Violation|0
6077608|NCT00599638|9683831|FG003|Second Intervention Period (2 Weeks)|Protocol Violation|0
6087574|NCT00669110|9697914|FG001|Overall Study|Physician Decision|1
6087575|NCT00669110|9697913|FG000|Overall Study|Lost to Follow-up|1
6087576|NCT00669110|9697914|FG001|Overall Study|Lost to Follow-up|0
6087577|NCT00669110|9697913|FG000|Overall Study|Protocol Violation|0
6087578|NCT00669110|9697914|FG001|Overall Study|Protocol Violation|5
6087579|NCT00669110|9697913|FG000|Overall Study|Withdrawal by Subject|0
6087580|NCT00669110|9697914|FG001|Overall Study|Withdrawal by Subject|2
6087581|NCT00669162|9697920|FG000|Overall Study|Withdrawal by Subject|1
6087582|NCT00669240|9697937|FG000|Overall Study|Lack of Efficacy|33
6087583|NCT00669240|9697937|FG000|Overall Study|Withdrawal by Subject|42
6087584|NCT00669240|9697937|FG000|Overall Study|Lost to Follow-up|34
6087585|NCT00669240|9697937|FG000|Overall Study|Adverse Event|21
6087586|NCT00669240|9697937|FG000|Overall Study|Other|19
6087587|NCT00669240|9697937|FG000|Overall Study|Enrolled but not treated|15
6087588|NCT00669240|9697937|FG000|Overall Study|Enrolled but no dosing record|1
6087589|NCT00669318|9697950|FG000|Overall Study|Withdrawal by Subject|2
6087590|NCT00669331|9697956|FG000|Randomisation to First Dose|Adverse Event|1
6087591|NCT00669331|9697957|FG001|Randomisation to First Dose|Adverse Event|0
6087592|NCT00669331|9697956|FG000|Randomisation to First Dose|Protocol Violation|1
6087593|NCT00669331|9697957|FG001|Randomisation to First Dose|Protocol Violation|0
6087594|NCT00669331|9697956|FG000|Randomisation to First Dose|Withdrawal by Subject|3
6087595|NCT00669331|9697957|FG001|Randomisation to First Dose|Withdrawal by Subject|2
6087596|NCT00669331|9697956|FG000|Randomisation to First Dose|Lost to Follow-up|2
6019316|NCT00194025|9613443|FG000|Overall Study|non-adherence with study medication|4
6087597|NCT00669331|9697957|FG001|Randomisation to First Dose|Lost to Follow-up|0
6087598|NCT00669331|9697956|FG000|Randomisation to First Dose|Death|1
6087599|NCT00669331|9697957|FG001|Randomisation to First Dose|Death|0
6019317|NCT00194077|9613449|FG000|Overall Study|Lack of Efficacy|22
6019318|NCT00194077|9613450|FG001|Overall Study|Lack of Efficacy|29
6019319|NCT00194077|9613449|FG000|Overall Study|Study nonadherence|1
6019320|NCT00194077|9613450|FG001|Overall Study|Study nonadherence|0
6019321|NCT00194077|9613449|FG000|Overall Study|Withdrawal by Subject|1
6019322|NCT00194077|9613450|FG001|Overall Study|Withdrawal by Subject|1
6019323|NCT00194675|9613501|FG000|Overall Study|Lost to Follow-up|1
6019324|NCT00194675|9613502|FG001|Overall Study|Lost to Follow-up|1
6019325|NCT00194675|9613501|FG000|Overall Study|lack of interest|1
6019326|NCT00194675|9613502|FG001|Overall Study|lack of interest|1
6019327|NCT00194675|9613501|FG000|Overall Study|"withdrew due to edgy feeling"|1
6019328|NCT00194675|9613502|FG001|Overall Study|"withdrew due to edgy feeling"|0
6019329|NCT00194675|9613501|FG000|Overall Study|Protocol Violation|1
6019330|NCT00194675|9613502|FG001|Overall Study|Protocol Violation|0
6019331|NCT00194675|9613501|FG000|Overall Study|Death|1
6019332|NCT00194675|9613502|FG001|Overall Study|Death|0
6019333|NCT00194792|9613514|FG000|Overall Study|Withdrawal by Subject|1
6019334|NCT00194987|9613537|FG000|Overall Study|Withdrawal by Subject|0
6019335|NCT00194987|9613538|FG001|Overall Study|Withdrawal by Subject|3
6019336|NCT00195260|9613561|FG000|Part 1: Dose Escalation|Adverse Event|0
6019337|NCT00195260|9613562|FG001|Part 1: Dose Escalation|Adverse Event|1
6019338|NCT00195260|9613563|FG002|Part 1: Dose Escalation|Adverse Event|0
6019339|NCT00195260|9613564|FG003|Part 1: Dose Escalation|Adverse Event|1
6019340|NCT00195260|9613565|FG004|Part 1: Dose Escalation|Adverse Event|1
6019341|NCT00195260|9613566|FG005|Part 1: Dose Escalation|Adverse Event|0
6019342|NCT00195260|9613567|FG006|Part 1: Dose Escalation|Adverse Event|3
6019343|NCT00195260|9613568|FG007|Part 1: Dose Escalation|Adverse Event|0
6019344|NCT00195260|9613569|FG008|Part 1: Dose Escalation|Adverse Event|0
6019345|NCT00195260|9613570|FG009|Part 1: Dose Escalation|Adverse Event|0
6019346|NCT00195260|9613571|FG010|Part 1: Dose Escalation|Adverse Event|0
6019347|NCT00195260|9613561|FG000|Part 1: Dose Escalation|Withdrawal by Subject|0
6019348|NCT00195260|9613562|FG001|Part 1: Dose Escalation|Withdrawal by Subject|0
6019349|NCT00195260|9613563|FG002|Part 1: Dose Escalation|Withdrawal by Subject|0
6019350|NCT00195260|9613564|FG003|Part 1: Dose Escalation|Withdrawal by Subject|0
6019351|NCT00195260|9613565|FG004|Part 1: Dose Escalation|Withdrawal by Subject|2
6019352|NCT00195260|9613566|FG005|Part 1: Dose Escalation|Withdrawal by Subject|0
6019353|NCT00195260|9613567|FG006|Part 1: Dose Escalation|Withdrawal by Subject|0
6019354|NCT00195260|9613568|FG007|Part 1: Dose Escalation|Withdrawal by Subject|1
6019355|NCT00195260|9613569|FG008|Part 1: Dose Escalation|Withdrawal by Subject|0
6019356|NCT00195260|9613570|FG009|Part 1: Dose Escalation|Withdrawal by Subject|0
6019357|NCT00195260|9613571|FG010|Part 1: Dose Escalation|Withdrawal by Subject|0
6019358|NCT00195260|9613561|FG000|Part 1: Dose Escalation|Death|0
6019359|NCT00195260|9613562|FG001|Part 1: Dose Escalation|Death|0
6019360|NCT00195260|9613563|FG002|Part 1: Dose Escalation|Death|0
6019361|NCT00195260|9613564|FG003|Part 1: Dose Escalation|Death|0
6019362|NCT00195260|9613565|FG004|Part 1: Dose Escalation|Death|0
6019363|NCT00195260|9613566|FG005|Part 1: Dose Escalation|Death|0
6019364|NCT00195260|9613567|FG006|Part 1: Dose Escalation|Death|0
6019365|NCT00195260|9613568|FG007|Part 1: Dose Escalation|Death|1
6019366|NCT00195260|9613569|FG008|Part 1: Dose Escalation|Death|0
6019367|NCT00195260|9613570|FG009|Part 1: Dose Escalation|Death|0
6019368|NCT00195260|9613571|FG010|Part 1: Dose Escalation|Death|0
6019369|NCT00195260|9613561|FG000|Part 1: Dose Escalation|Disease Progression|3
6019370|NCT00195260|9613562|FG001|Part 1: Dose Escalation|Disease Progression|2
6019371|NCT00195260|9613563|FG002|Part 1: Dose Escalation|Disease Progression|5
6019372|NCT00195260|9613564|FG003|Part 1: Dose Escalation|Disease Progression|6
6019373|NCT00195260|9613565|FG004|Part 1: Dose Escalation|Disease Progression|4
6019374|NCT00195260|9613566|FG005|Part 1: Dose Escalation|Disease Progression|6
6019375|NCT00195260|9613567|FG006|Part 1: Dose Escalation|Disease Progression|7
6019376|NCT00195260|9613568|FG007|Part 1: Dose Escalation|Disease Progression|4
6019377|NCT00195260|9613569|FG008|Part 1: Dose Escalation|Disease Progression|0
6019378|NCT00195260|9613570|FG009|Part 1: Dose Escalation|Disease Progression|0
6019379|NCT00195260|9613571|FG010|Part 1: Dose Escalation|Disease Progression|0
6019380|NCT00195260|9613561|FG000|Part 1: Dose Escalation|Symptomatic Deterioration|1
6019381|NCT00195260|9613562|FG001|Part 1: Dose Escalation|Symptomatic Deterioration|1
6019382|NCT00195260|9613563|FG002|Part 1: Dose Escalation|Symptomatic Deterioration|1
6019383|NCT00195260|9613564|FG003|Part 1: Dose Escalation|Symptomatic Deterioration|0
6019384|NCT00195260|9613565|FG004|Part 1: Dose Escalation|Symptomatic Deterioration|0
6019385|NCT00195260|9613566|FG005|Part 1: Dose Escalation|Symptomatic Deterioration|1
6019386|NCT00195260|9613567|FG006|Part 1: Dose Escalation|Symptomatic Deterioration|0
6019387|NCT00195260|9613568|FG007|Part 1: Dose Escalation|Symptomatic Deterioration|0
6019388|NCT00195260|9613569|FG008|Part 1: Dose Escalation|Symptomatic Deterioration|0
6019389|NCT00195260|9613570|FG009|Part 1: Dose Escalation|Symptomatic Deterioration|0
6019390|NCT00195260|9613571|FG010|Part 1: Dose Escalation|Symptomatic Deterioration|0
6019391|NCT00195260|9613561|FG000|Part 2: Recommended Phase 2 Dose (RP2D)|Death|0
6019392|NCT00195260|9613562|FG001|Part 2: Recommended Phase 2 Dose (RP2D)|Death|0
6019393|NCT00195260|9613563|FG002|Part 2: Recommended Phase 2 Dose (RP2D)|Death|0
6019394|NCT00195260|9613564|FG003|Part 2: Recommended Phase 2 Dose (RP2D)|Death|0
6019395|NCT00195260|9613565|FG004|Part 2: Recommended Phase 2 Dose (RP2D)|Death|0
6077609|NCT00599755|9683839|FG000|Overall Study|Adverse Event|11
6077610|NCT00599755|9683839|FG000|Overall Study|Withdrawal by Subject|2
6077611|NCT00599755|9683839|FG000|Overall Study|Progression of Disease|3
6077612|NCT00599755|9683839|FG000|Overall Study|Other Reason|2
6077613|NCT00599755|9683839|FG000|Overall Study|No data available|1
6077614|NCT00599924|9683863|FG000|Overall Study|Lack of Efficacy|3
6077615|NCT00599924|9683864|FG001|Overall Study|Lack of Efficacy|5
6077616|NCT00599924|9683865|FG002|Overall Study|Lack of Efficacy|1
6077617|NCT00599924|9683866|FG003|Overall Study|Lack of Efficacy|2
6077618|NCT00599924|9683867|FG004|Overall Study|Lack of Efficacy|3
6077619|NCT00599924|9683868|FG005|Overall Study|Lack of Efficacy|2
6077620|NCT00599924|9683869|FG006|Overall Study|Lack of Efficacy|0
6077621|NCT00599924|9683863|FG000|Overall Study|Adverse Event|0
6077622|NCT00599924|9683864|FG001|Overall Study|Adverse Event|0
6077623|NCT00599924|9683865|FG002|Overall Study|Adverse Event|0
6077624|NCT00599924|9683866|FG003|Overall Study|Adverse Event|2
6077625|NCT00599924|9683867|FG004|Overall Study|Adverse Event|0
6019396|NCT00195260|9613566|FG005|Part 2: Recommended Phase 2 Dose (RP2D)|Death|0
6019397|NCT00195260|9613567|FG006|Part 2: Recommended Phase 2 Dose (RP2D)|Death|0
6019398|NCT00195260|9613568|FG007|Part 2: Recommended Phase 2 Dose (RP2D)|Death|0
6019399|NCT00195260|9613569|FG008|Part 2: Recommended Phase 2 Dose (RP2D)|Death|21
6019400|NCT00195260|9613570|FG009|Part 2: Recommended Phase 2 Dose (RP2D)|Death|29
6019401|NCT00195260|9613571|FG010|Part 2: Recommended Phase 2 Dose (RP2D)|Death|15
6019402|NCT00195260|9613561|FG000|Part 2: Recommended Phase 2 Dose (RP2D)|Withdrawal by Subject|0
6019403|NCT00195260|9613562|FG001|Part 2: Recommended Phase 2 Dose (RP2D)|Withdrawal by Subject|0
6019404|NCT00195260|9613563|FG002|Part 2: Recommended Phase 2 Dose (RP2D)|Withdrawal by Subject|0
6019405|NCT00195260|9613564|FG003|Part 2: Recommended Phase 2 Dose (RP2D)|Withdrawal by Subject|0
6019406|NCT00195260|9613565|FG004|Part 2: Recommended Phase 2 Dose (RP2D)|Withdrawal by Subject|0
6019407|NCT00195260|9613566|FG005|Part 2: Recommended Phase 2 Dose (RP2D)|Withdrawal by Subject|0
6019408|NCT00195260|9613567|FG006|Part 2: Recommended Phase 2 Dose (RP2D)|Withdrawal by Subject|0
6019409|NCT00195260|9613568|FG007|Part 2: Recommended Phase 2 Dose (RP2D)|Withdrawal by Subject|0
6019410|NCT00195260|9613569|FG008|Part 2: Recommended Phase 2 Dose (RP2D)|Withdrawal by Subject|5
6019411|NCT00195260|9613570|FG009|Part 2: Recommended Phase 2 Dose (RP2D)|Withdrawal by Subject|3
6019412|NCT00195260|9613571|FG010|Part 2: Recommended Phase 2 Dose (RP2D)|Withdrawal by Subject|2
6019413|NCT00195260|9613561|FG000|Part 2: Recommended Phase 2 Dose (RP2D)|Lost to Follow-up|0
6019414|NCT00195260|9613562|FG001|Part 2: Recommended Phase 2 Dose (RP2D)|Lost to Follow-up|0
6019415|NCT00195260|9613563|FG002|Part 2: Recommended Phase 2 Dose (RP2D)|Lost to Follow-up|0
6019416|NCT00195260|9613564|FG003|Part 2: Recommended Phase 2 Dose (RP2D)|Lost to Follow-up|0
6019417|NCT00195260|9613565|FG004|Part 2: Recommended Phase 2 Dose (RP2D)|Lost to Follow-up|0
6019418|NCT00195260|9613566|FG005|Part 2: Recommended Phase 2 Dose (RP2D)|Lost to Follow-up|0
6019419|NCT00195260|9613567|FG006|Part 2: Recommended Phase 2 Dose (RP2D)|Lost to Follow-up|0
6019420|NCT00195260|9613568|FG007|Part 2: Recommended Phase 2 Dose (RP2D)|Lost to Follow-up|0
6019421|NCT00195260|9613569|FG008|Part 2: Recommended Phase 2 Dose (RP2D)|Lost to Follow-up|1
6019422|NCT00195260|9613570|FG009|Part 2: Recommended Phase 2 Dose (RP2D)|Lost to Follow-up|2
6019423|NCT00195260|9613571|FG010|Part 2: Recommended Phase 2 Dose (RP2D)|Lost to Follow-up|3
6019424|NCT00195260|9613561|FG000|Part 2: Recommended Phase 2 Dose (RP2D)|Other|0
6019425|NCT00195260|9613562|FG001|Part 2: Recommended Phase 2 Dose (RP2D)|Other|0
6019426|NCT00195260|9613563|FG002|Part 2: Recommended Phase 2 Dose (RP2D)|Other|0
6019427|NCT00195260|9613564|FG003|Part 2: Recommended Phase 2 Dose (RP2D)|Other|0
6019428|NCT00195260|9613565|FG004|Part 2: Recommended Phase 2 Dose (RP2D)|Other|0
6019429|NCT00195260|9613566|FG005|Part 2: Recommended Phase 2 Dose (RP2D)|Other|0
6019430|NCT00195260|9613567|FG006|Part 2: Recommended Phase 2 Dose (RP2D)|Other|0
6019431|NCT00195260|9613568|FG007|Part 2: Recommended Phase 2 Dose (RP2D)|Other|0
6019432|NCT00195260|9613569|FG008|Part 2: Recommended Phase 2 Dose (RP2D)|Other|6
6019433|NCT00195260|9613570|FG009|Part 2: Recommended Phase 2 Dose (RP2D)|Other|4
6019434|NCT00195260|9613571|FG010|Part 2: Recommended Phase 2 Dose (RP2D)|Other|3
6019435|NCT00195273|9613601|FG000|Overall Study|Adverse Event|9
6019436|NCT00195273|9613602|FG001|Overall Study|Adverse Event|9
6019437|NCT00195273|9613601|FG000|Overall Study|Protocol deviation|0
6019438|NCT00195273|9613602|FG001|Overall Study|Protocol deviation|1
6019439|NCT00195273|9613601|FG000|Overall Study|Lack of Efficacy|3
6019440|NCT00195273|9613602|FG001|Overall Study|Lack of Efficacy|1
6019441|NCT00195273|9613601|FG000|Overall Study|Procedural complications|9
6019442|NCT00195273|9613602|FG001|Overall Study|Procedural complications|3
6019443|NCT00195338|9613608|FG000|Overall Study|Lost to Follow-up|2
6019444|NCT00195338|9613608|FG000|Overall Study|Adverse Event|5
6019445|NCT00195338|9613608|FG000|Overall Study|Lack of Efficacy|1
6019446|NCT00195338|9613608|FG000|Overall Study|Early closure of the site|4
6019447|NCT00195351|9613614|FG000|Overall Study|Lost to Follow-up|9
6019448|NCT00195351|9613615|FG001|Overall Study|Lost to Follow-up|9
6019449|NCT00195351|9613614|FG000|Overall Study|Withdrawal by Subject|6
6019450|NCT00195351|9613615|FG001|Overall Study|Withdrawal by Subject|3
6019451|NCT00195351|9613614|FG000|Overall Study|Protocol Deviation|3
6077626|NCT00599924|9683868|FG005|Overall Study|Adverse Event|0
6077627|NCT00599924|9683869|FG006|Overall Study|Adverse Event|2
6077628|NCT00599924|9683863|FG000|Overall Study|Death|0
6077629|NCT00599924|9683864|FG001|Overall Study|Death|0
6077630|NCT00599924|9683865|FG002|Overall Study|Death|0
6019452|NCT00195351|9613615|FG001|Overall Study|Protocol Deviation|2
6019453|NCT00195351|9613614|FG000|Overall Study|Death|3
6019454|NCT00195351|9613615|FG001|Overall Study|Death|1
6019455|NCT00195351|9613614|FG000|Overall Study|Lack of Efficacy|0
6019456|NCT00195351|9613615|FG001|Overall Study|Lack of Efficacy|1
6019457|NCT00195429|9613627|FG000|Overall Study|Adverse Event|2
6019458|NCT00195429|9613628|FG001|Overall Study|Adverse Event|4
6019459|NCT00195429|9613627|FG000|Overall Study|Lack of Efficacy|2
6019460|NCT00195429|9613628|FG001|Overall Study|Lack of Efficacy|1
6019461|NCT00195429|9613627|FG000|Overall Study|Lost to Follow-up|1
6019462|NCT00195429|9613628|FG001|Overall Study|Lost to Follow-up|0
6019463|NCT00195442|9613634|FG000|Overall Study|Less than expected therapeutic effect|38
6019464|NCT00195442|9613634|FG000|Overall Study|Lost to Follow-up|27
6019465|NCT00195442|9613634|FG000|Overall Study|Switch to other Factor VIII preparation|23
6019466|NCT00195442|9613634|FG000|Overall Study|Intermittent product shortage|21
6019467|NCT00195442|9613634|FG000|Overall Study|Death|7
6019468|NCT00195442|9613634|FG000|Overall Study|No reason specified|4
6019469|NCT00195442|9613634|FG000|Overall Study|Poor cooperation|2
6019470|NCT00195442|9613634|FG000|Overall Study|Other|14
6019471|NCT00195494|9613640|FG000|Year 1|Adverse Event|0
6019472|NCT00195494|9613641|FG001|Year 1|Adverse Event|0
6019473|NCT00195494|9613642|FG002|Year 1|Adverse Event|0
6019474|NCT00195494|9613643|FG003|Year 1|Adverse Event|0
6019475|NCT00195494|9613644|FG004|Year 1|Adverse Event|34
6019476|NCT00195494|9613645|FG005|Year 1|Adverse Event|27
6019477|NCT00195494|9613640|FG000|Year 1|System Toxicity|0
6019478|NCT00195494|9613641|FG001|Year 1|System Toxicity|0
6019479|NCT00195494|9613642|FG002|Year 1|System Toxicity|0
6019480|NCT00195494|9613643|FG003|Year 1|System Toxicity|0
6019481|NCT00195494|9613644|FG004|Year 1|System Toxicity|0
6019482|NCT00195494|9613645|FG005|Year 1|System Toxicity|1
6019483|NCT00195494|9613640|FG000|Year 1|Lack of Efficacy|0
6019484|NCT00195494|9613641|FG001|Year 1|Lack of Efficacy|0
6019485|NCT00195494|9613642|FG002|Year 1|Lack of Efficacy|0
6019486|NCT00195494|9613643|FG003|Year 1|Lack of Efficacy|0
6019487|NCT00195494|9613644|FG004|Year 1|Lack of Efficacy|24
6019488|NCT00195494|9613645|FG005|Year 1|Lack of Efficacy|9
6019489|NCT00195494|9613640|FG000|Year 1|Compliance|0
6019490|NCT00195494|9613641|FG001|Year 1|Compliance|0
6019491|NCT00195494|9613642|FG002|Year 1|Compliance|0
6019492|NCT00195494|9613643|FG003|Year 1|Compliance|0
6019493|NCT00195494|9613644|FG004|Year 1|Compliance|5
6019494|NCT00195494|9613645|FG005|Year 1|Compliance|1
6019495|NCT00195494|9613640|FG000|Year 1|Lost to Follow-up|0
6019496|NCT00195494|9613641|FG001|Year 1|Lost to Follow-up|0
6019497|NCT00195494|9613642|FG002|Year 1|Lost to Follow-up|0
6019498|NCT00195494|9613643|FG003|Year 1|Lost to Follow-up|0
6019499|NCT00195494|9613644|FG004|Year 1|Lost to Follow-up|1
6077631|NCT00599924|9683866|FG003|Overall Study|Death|2
6077632|NCT00599924|9683867|FG004|Overall Study|Death|0
6077633|NCT00599924|9683868|FG005|Overall Study|Death|2
6077634|NCT00599924|9683869|FG006|Overall Study|Death|1
6077635|NCT00599924|9683863|FG000|Overall Study|Protocol Violation|0
6077636|NCT00599924|9683864|FG001|Overall Study|Protocol Violation|0
6077637|NCT00599924|9683865|FG002|Overall Study|Protocol Violation|0
6077638|NCT00599924|9683866|FG003|Overall Study|Protocol Violation|1
6077639|NCT00599924|9683867|FG004|Overall Study|Protocol Violation|0
6077640|NCT00599924|9683868|FG005|Overall Study|Protocol Violation|0
6077641|NCT00599924|9683869|FG006|Overall Study|Protocol Violation|0
6077642|NCT00599924|9683863|FG000|Overall Study|Withdrawal by Subject|0
6077643|NCT00599924|9683864|FG001|Overall Study|Withdrawal by Subject|0
6077644|NCT00599924|9683865|FG002|Overall Study|Withdrawal by Subject|1
6077645|NCT00599924|9683866|FG003|Overall Study|Withdrawal by Subject|0
6077646|NCT00599924|9683867|FG004|Overall Study|Withdrawal by Subject|1
6077647|NCT00599924|9683868|FG005|Overall Study|Withdrawal by Subject|0
6077648|NCT00599924|9683869|FG006|Overall Study|Withdrawal by Subject|0
6077649|NCT00599924|9683863|FG000|Overall Study|Other|0
6077650|NCT00599924|9683864|FG001|Overall Study|Other|0
6077651|NCT00599924|9683865|FG002|Overall Study|Other|0
6077652|NCT00599924|9683866|FG003|Overall Study|Other|1
6077653|NCT00599924|9683867|FG004|Overall Study|Other|2
6077654|NCT00599924|9683868|FG005|Overall Study|Other|0
6077655|NCT00599924|9683869|FG006|Overall Study|Other|2
6077656|NCT00600028|9683892|FG000|First Intervention (12 Weeks)|Withdrawal by Subject|1
6019500|NCT00195494|9613645|FG005|Year 1|Lost to Follow-up|0
6019501|NCT00195494|9613640|FG000|Year 1|Missed >4 consecutive doses|0
6019502|NCT00195494|9613641|FG001|Year 1|Missed >4 consecutive doses|0
6019503|NCT00195494|9613642|FG002|Year 1|Missed >4 consecutive doses|0
6019504|NCT00195494|9613643|FG003|Year 1|Missed >4 consecutive doses|0
6019505|NCT00195494|9613644|FG004|Year 1|Missed >4 consecutive doses|3
6019506|NCT00195494|9613645|FG005|Year 1|Missed >4 consecutive doses|2
6019507|NCT00195494|9613640|FG000|Year 1|Protocol deviation|0
6019508|NCT00195494|9613641|FG001|Year 1|Protocol deviation|0
6019509|NCT00195494|9613642|FG002|Year 1|Protocol deviation|0
6019510|NCT00195494|9613643|FG003|Year 1|Protocol deviation|0
6019511|NCT00195494|9613644|FG004|Year 1|Protocol deviation|2
6019512|NCT00195494|9613645|FG005|Year 1|Protocol deviation|3
6077657|NCT00600028|9683893|FG001|First Intervention (12 Weeks)|Withdrawal by Subject|0
6077658|NCT00600028|9683892|FG000|First Intervention (12 Weeks)|Adverse Event|0
6077659|NCT00600028|9683893|FG001|First Intervention (12 Weeks)|Adverse Event|1
6019513|NCT00195494|9613640|FG000|Year 1|Physician Decision|0
6019514|NCT00195494|9613641|FG001|Year 1|Physician Decision|0
6077660|NCT00600028|9683892|FG000|Second Intervention (12 Weeks)|Adverse Event|0
6077661|NCT00600028|9683893|FG001|Second Intervention (12 Weeks)|Adverse Event|2
6077662|NCT00600067|9683904|FG000|Overall Study|Adverse Event|0
6077663|NCT00600067|9683905|FG001|Overall Study|Adverse Event|1
6077664|NCT00600067|9683904|FG000|Overall Study|Lost to Follow-up|2
6077665|NCT00600067|9683905|FG001|Overall Study|Lost to Follow-up|3
6077666|NCT00600067|9683904|FG000|Overall Study|protocol non-compliance|0
6077667|NCT00600067|9683905|FG001|Overall Study|protocol non-compliance|3
6077668|NCT00600067|9683904|FG000|Overall Study|Lack of Efficacy|1
6077669|NCT00600067|9683905|FG001|Overall Study|Lack of Efficacy|0
6077670|NCT00600106|9683921|FG000|Overall Study|Withdrawal by Subject|1
6077671|NCT00600106|9683922|FG001|Overall Study|Withdrawal by Subject|1
6077672|NCT00600119|9683934|FG000|Single-blind Placebo run-in Period|Other - Not specified|1
6077673|NCT00600119|9683935|FG001|Single-blind Placebo run-in Period|Other - Not specified|0
6077674|NCT00600119|9683936|FG002|Single-blind Placebo run-in Period|Other - Not specified|0
6077675|NCT00600119|9683937|FG003|Single-blind Placebo run-in Period|Other - Not specified|0
6077676|NCT00600119|9683938|FG004|Single-blind Placebo run-in Period|Other - Not specified|1
6077677|NCT00600119|9683939|FG005|Single-blind Placebo run-in Period|Other - Not specified|1
6077678|NCT00600119|9683934|FG000|Single-blind Placebo run-in Period|Inclusion/Exclusion Criteria Not Met|0
6077679|NCT00600119|9683935|FG001|Single-blind Placebo run-in Period|Inclusion/Exclusion Criteria Not Met|1
6077680|NCT00600119|9683936|FG002|Single-blind Placebo run-in Period|Inclusion/Exclusion Criteria Not Met|1
6077681|NCT00600119|9683937|FG003|Single-blind Placebo run-in Period|Inclusion/Exclusion Criteria Not Met|0
6077682|NCT00600119|9683938|FG004|Single-blind Placebo run-in Period|Inclusion/Exclusion Criteria Not Met|0
6077683|NCT00600119|9683939|FG005|Single-blind Placebo run-in Period|Inclusion/Exclusion Criteria Not Met|0
6077684|NCT00600119|9683934|FG000|Single-blind Placebo run-in Period|Sponsor Decision|0
6077685|NCT00600119|9683935|FG001|Single-blind Placebo run-in Period|Sponsor Decision|0
6077686|NCT00600119|9683936|FG002|Single-blind Placebo run-in Period|Sponsor Decision|1
6077687|NCT00600119|9683937|FG003|Single-blind Placebo run-in Period|Sponsor Decision|0
6077688|NCT00600119|9683938|FG004|Single-blind Placebo run-in Period|Sponsor Decision|1
6077689|NCT00600119|9683939|FG005|Single-blind Placebo run-in Period|Sponsor Decision|0
6077690|NCT00600119|9683934|FG000|Single-blind Placebo run-in Period|Lost to Follow-up|1
6077691|NCT00600119|9683935|FG001|Single-blind Placebo run-in Period|Lost to Follow-up|0
6077692|NCT00600119|9683936|FG002|Single-blind Placebo run-in Period|Lost to Follow-up|0
6077693|NCT00600119|9683937|FG003|Single-blind Placebo run-in Period|Lost to Follow-up|0
6077694|NCT00600119|9683938|FG004|Single-blind Placebo run-in Period|Lost to Follow-up|0
6077695|NCT00600119|9683939|FG005|Single-blind Placebo run-in Period|Lost to Follow-up|0
6077696|NCT00600119|9683934|FG000|Single-blind Placebo run-in Period|Adverse Event|0
6077697|NCT00600119|9683935|FG001|Single-blind Placebo run-in Period|Adverse Event|0
6077698|NCT00600119|9683936|FG002|Single-blind Placebo run-in Period|Adverse Event|0
6077699|NCT00600119|9683937|FG003|Single-blind Placebo run-in Period|Adverse Event|1
6077700|NCT00600119|9683938|FG004|Single-blind Placebo run-in Period|Adverse Event|0
6077701|NCT00600119|9683939|FG005|Single-blind Placebo run-in Period|Adverse Event|1
6077702|NCT00600119|9683934|FG000|Single-blind Placebo run-in Period|Withdrawal by Subject|2
6077703|NCT00600119|9683935|FG001|Single-blind Placebo run-in Period|Withdrawal by Subject|1
6077704|NCT00600119|9683936|FG002|Single-blind Placebo run-in Period|Withdrawal by Subject|0
6077705|NCT00600119|9683937|FG003|Single-blind Placebo run-in Period|Withdrawal by Subject|0
6077706|NCT00600119|9683938|FG004|Single-blind Placebo run-in Period|Withdrawal by Subject|0
6077707|NCT00600119|9683939|FG005|Single-blind Placebo run-in Period|Withdrawal by Subject|0
6077708|NCT00600119|9683934|FG000|Double-blind Treatment Period|Withdrawal by Subject|2
6077709|NCT00600119|9683935|FG001|Double-blind Treatment Period|Withdrawal by Subject|0
6077710|NCT00600119|9683936|FG002|Double-blind Treatment Period|Withdrawal by Subject|0
6077711|NCT00600119|9683937|FG003|Double-blind Treatment Period|Withdrawal by Subject|1
6077712|NCT00600119|9683938|FG004|Double-blind Treatment Period|Withdrawal by Subject|0
6077713|NCT00600119|9683939|FG005|Double-blind Treatment Period|Withdrawal by Subject|3
6077714|NCT00600119|9683934|FG000|Double-blind Treatment Period|Other|0
6077715|NCT00600119|9683935|FG001|Double-blind Treatment Period|Other|0
6077716|NCT00600119|9683936|FG002|Double-blind Treatment Period|Other|0
6077717|NCT00600119|9683937|FG003|Double-blind Treatment Period|Other|0
6019515|NCT00195494|9613642|FG002|Year 1|Physician Decision|0
6019516|NCT00195494|9613643|FG003|Year 1|Physician Decision|0
6019517|NCT00195494|9613644|FG004|Year 1|Physician Decision|1
6019518|NCT00195494|9613645|FG005|Year 1|Physician Decision|0
6019519|NCT00195494|9613640|FG000|Year 1|Withdrawal by Subject|0
6019520|NCT00195494|9613641|FG001|Year 1|Withdrawal by Subject|0
6019521|NCT00195494|9613642|FG002|Year 1|Withdrawal by Subject|0
6019522|NCT00195494|9613643|FG003|Year 1|Withdrawal by Subject|0
6019523|NCT00195494|9613644|FG004|Year 1|Withdrawal by Subject|8
6019524|NCT00195494|9613645|FG005|Year 1|Withdrawal by Subject|9
6077718|NCT00600119|9683938|FG004|Double-blind Treatment Period|Other|2
6077719|NCT00600119|9683939|FG005|Double-blind Treatment Period|Other|1
6077720|NCT00600119|9683934|FG000|Double-blind Treatment Period|Inclusion/Exclusion Criteria Not Met|0
6077721|NCT00600119|9683935|FG001|Double-blind Treatment Period|Inclusion/Exclusion Criteria Not Met|1
6019525|NCT00195494|9613640|FG000|Year 1|Protocol Violation|0
6019526|NCT00195494|9613641|FG001|Year 1|Protocol Violation|0
6019527|NCT00195494|9613642|FG002|Year 1|Protocol Violation|0
6019528|NCT00195494|9613643|FG003|Year 1|Protocol Violation|0
6019529|NCT00195494|9613644|FG004|Year 1|Protocol Violation|1
6019530|NCT00195494|9613645|FG005|Year 1|Protocol Violation|1
6019531|NCT00195494|9613640|FG000|Year 2|Adverse Event|3
6019532|NCT00195494|9613641|FG001|Year 2|Adverse Event|7
6019533|NCT00195494|9613642|FG002|Year 2|Adverse Event|5
6019534|NCT00195494|9613643|FG003|Year 2|Adverse Event|9
6019535|NCT00195494|9613644|FG004|Year 2|Adverse Event|0
6019536|NCT00195494|9613645|FG005|Year 2|Adverse Event|0
6019537|NCT00195494|9613640|FG000|Year 2|Lack of Efficacy|0
6019538|NCT00195494|9613641|FG001|Year 2|Lack of Efficacy|1
6019539|NCT00195494|9613642|FG002|Year 2|Lack of Efficacy|7
6019540|NCT00195494|9613643|FG003|Year 2|Lack of Efficacy|7
6019541|NCT00195494|9613644|FG004|Year 2|Lack of Efficacy|0
6019542|NCT00195494|9613645|FG005|Year 2|Lack of Efficacy|0
6019543|NCT00195494|9613640|FG000|Year 2|Compliance|1
6019544|NCT00195494|9613641|FG001|Year 2|Compliance|0
6019545|NCT00195494|9613642|FG002|Year 2|Compliance|0
6019546|NCT00195494|9613643|FG003|Year 2|Compliance|2
6019547|NCT00195494|9613644|FG004|Year 2|Compliance|0
6019548|NCT00195494|9613645|FG005|Year 2|Compliance|0
6019549|NCT00195494|9613640|FG000|Year 2|Lost to Follow-up|0
6019550|NCT00195494|9613641|FG001|Year 2|Lost to Follow-up|0
6019551|NCT00195494|9613642|FG002|Year 2|Lost to Follow-up|1
6019552|NCT00195494|9613643|FG003|Year 2|Lost to Follow-up|1
6019553|NCT00195494|9613644|FG004|Year 2|Lost to Follow-up|0
6019554|NCT00195494|9613645|FG005|Year 2|Lost to Follow-up|0
6019555|NCT00195494|9613640|FG000|Year 2|Missed >4 consecutive doses|1
6019556|NCT00195494|9613641|FG001|Year 2|Missed >4 consecutive doses|1
6019557|NCT00195494|9613642|FG002|Year 2|Missed >4 consecutive doses|1
6019558|NCT00195494|9613643|FG003|Year 2|Missed >4 consecutive doses|0
6019559|NCT00195494|9613644|FG004|Year 2|Missed >4 consecutive doses|0
6019560|NCT00195494|9613645|FG005|Year 2|Missed >4 consecutive doses|0
6019561|NCT00195494|9613640|FG000|Year 2|Protocol deviation|0
6019562|NCT00195494|9613641|FG001|Year 2|Protocol deviation|1
6019563|NCT00195494|9613642|FG002|Year 2|Protocol deviation|0
6019564|NCT00195494|9613643|FG003|Year 2|Protocol deviation|0
6019565|NCT00195494|9613644|FG004|Year 2|Protocol deviation|0
6077722|NCT00600119|9683936|FG002|Double-blind Treatment Period|Inclusion/Exclusion Criteria Not Met|0
6077723|NCT00600119|9683937|FG003|Double-blind Treatment Period|Inclusion/Exclusion Criteria Not Met|0
6077724|NCT00600119|9683938|FG004|Double-blind Treatment Period|Inclusion/Exclusion Criteria Not Met|1
6077725|NCT00600119|9683939|FG005|Double-blind Treatment Period|Inclusion/Exclusion Criteria Not Met|0
6077726|NCT00600119|9683934|FG000|Double-blind Treatment Period|Moderate to Severe Opioid Withdrawal|0
6077727|NCT00600119|9683935|FG001|Double-blind Treatment Period|Moderate to Severe Opioid Withdrawal|1
6077728|NCT00600119|9683936|FG002|Double-blind Treatment Period|Moderate to Severe Opioid Withdrawal|0
6077729|NCT00600119|9683937|FG003|Double-blind Treatment Period|Moderate to Severe Opioid Withdrawal|0
6077730|NCT00600119|9683938|FG004|Double-blind Treatment Period|Moderate to Severe Opioid Withdrawal|0
6077731|NCT00600119|9683939|FG005|Double-blind Treatment Period|Moderate to Severe Opioid Withdrawal|0
6077732|NCT00600119|9683934|FG000|Double-blind Treatment Period|Sponsor Decision|0
6077733|NCT00600119|9683935|FG001|Double-blind Treatment Period|Sponsor Decision|1
6077734|NCT00600119|9683936|FG002|Double-blind Treatment Period|Sponsor Decision|0
6077735|NCT00600119|9683937|FG003|Double-blind Treatment Period|Sponsor Decision|0
6077736|NCT00600119|9683938|FG004|Double-blind Treatment Period|Sponsor Decision|1
6077737|NCT00600119|9683939|FG005|Double-blind Treatment Period|Sponsor Decision|0
6077738|NCT00600119|9683934|FG000|Double-blind Treatment Period|Physician Decision|2
6077739|NCT00600119|9683935|FG001|Double-blind Treatment Period|Physician Decision|0
6077740|NCT00600119|9683936|FG002|Double-blind Treatment Period|Physician Decision|0
6077741|NCT00600119|9683937|FG003|Double-blind Treatment Period|Physician Decision|0
6077742|NCT00600119|9683938|FG004|Double-blind Treatment Period|Physician Decision|0
6077743|NCT00600119|9683939|FG005|Double-blind Treatment Period|Physician Decision|0
6077744|NCT00600119|9683934|FG000|Double-blind Treatment Period|Lost to Follow-up|0
6077745|NCT00600119|9683935|FG001|Double-blind Treatment Period|Lost to Follow-up|1
6077746|NCT00600119|9683936|FG002|Double-blind Treatment Period|Lost to Follow-up|0
6077747|NCT00600119|9683937|FG003|Double-blind Treatment Period|Lost to Follow-up|0
6077748|NCT00600119|9683938|FG004|Double-blind Treatment Period|Lost to Follow-up|0
6077749|NCT00600119|9683939|FG005|Double-blind Treatment Period|Lost to Follow-up|0
6077750|NCT00600119|9683934|FG000|Double-blind Treatment Period|Adverse Event|1
6077751|NCT00600119|9683935|FG001|Double-blind Treatment Period|Adverse Event|1
6077752|NCT00600119|9683936|FG002|Double-blind Treatment Period|Adverse Event|0
6019566|NCT00195494|9613645|FG005|Year 2|Protocol deviation|0
6019567|NCT00195494|9613640|FG000|Year 2|Physician Decision|1
6019568|NCT00195494|9613641|FG001|Year 2|Physician Decision|1
6019569|NCT00195494|9613642|FG002|Year 2|Physician Decision|0
6019570|NCT00195494|9613643|FG003|Year 2|Physician Decision|0
6019571|NCT00195494|9613644|FG004|Year 2|Physician Decision|0
6019572|NCT00195494|9613645|FG005|Year 2|Physician Decision|0
6019573|NCT00195494|9613640|FG000|Year 2|Withdrawal by Subject|1
6019574|NCT00195494|9613641|FG001|Year 2|Withdrawal by Subject|5
6019575|NCT00195494|9613642|FG002|Year 2|Withdrawal by Subject|4
6019576|NCT00195494|9613643|FG003|Year 2|Withdrawal by Subject|3
6019577|NCT00195494|9613644|FG004|Year 2|Withdrawal by Subject|0
6019578|NCT00195494|9613645|FG005|Year 2|Withdrawal by Subject|0
6019579|NCT00195494|9613640|FG000|Year 2|System toxicity|0
6019580|NCT00195494|9613641|FG001|Year 2|System toxicity|0
6019581|NCT00195494|9613642|FG002|Year 2|System toxicity|0
6019582|NCT00195494|9613643|FG003|Year 2|System toxicity|1
6019583|NCT00195494|9613644|FG004|Year 2|System toxicity|0
6019584|NCT00195494|9613645|FG005|Year 2|System toxicity|0
6019585|NCT00195507|9613663|FG000|Overall Study|Adverse Event|24
6019586|NCT00195507|9613664|FG001|Overall Study|Adverse Event|13
6019587|NCT00195507|9613663|FG000|Overall Study|Death|0
6019588|NCT00195507|9613664|FG001|Overall Study|Death|1
6019589|NCT00195507|9613663|FG000|Overall Study|Failed to Return|4
6019590|NCT00195507|9613664|FG001|Overall Study|Failed to Return|3
6019591|NCT00195507|9613663|FG000|Overall Study|Physician Decision|1
6019592|NCT00195507|9613664|FG001|Overall Study|Physician Decision|2
6019593|NCT00195507|9613663|FG000|Overall Study|Lost to Follow-up|3
6019594|NCT00195507|9613664|FG001|Overall Study|Lost to Follow-up|2
6019595|NCT00195507|9613663|FG000|Overall Study|Protocol Violation|5
6019596|NCT00195507|9613664|FG001|Overall Study|Protocol Violation|4
6019597|NCT00195507|9613663|FG000|Overall Study|Lack of Efficacy|40
6019598|NCT00195507|9613664|FG001|Overall Study|Lack of Efficacy|67
6019599|NCT00195507|9613663|FG000|Overall Study|Withdrawal by Subject|16
6019600|NCT00195507|9613664|FG001|Overall Study|Withdrawal by Subject|23
6019601|NCT00195507|9613663|FG000|Overall Study|Protocol Deviation|6
6019602|NCT00195507|9613664|FG001|Overall Study|Protocol Deviation|3
6019603|NCT00195650|9613679|FG000|Overall Study|Adverse Event|194
6019604|NCT00195650|9613679|FG000|Overall Study|Lack of Efficacy|99
6077753|NCT00600119|9683937|FG003|Double-blind Treatment Period|Adverse Event|1
6077754|NCT00600119|9683938|FG004|Double-blind Treatment Period|Adverse Event|2
6077755|NCT00600119|9683939|FG005|Double-blind Treatment Period|Adverse Event|10
6077756|NCT00600119|9683934|FG000|Follow-up Period|Adverse Event|0
6077757|NCT00600119|9683935|FG001|Follow-up Period|Adverse Event|0
6077758|NCT00600119|9683936|FG002|Follow-up Period|Adverse Event|0
6077759|NCT00600119|9683937|FG003|Follow-up Period|Adverse Event|0
6077760|NCT00600119|9683938|FG004|Follow-up Period|Adverse Event|0
6077761|NCT00600119|9683939|FG005|Follow-up Period|Adverse Event|1
6077762|NCT00600119|9683934|FG000|Follow-up Period|Other|1
6077763|NCT00600119|9683935|FG001|Follow-up Period|Other|0
6077764|NCT00600119|9683936|FG002|Follow-up Period|Other|0
6077765|NCT00600119|9683937|FG003|Follow-up Period|Other|0
6077766|NCT00600119|9683938|FG004|Follow-up Period|Other|0
6077767|NCT00600119|9683939|FG005|Follow-up Period|Other|0
6077768|NCT00600171|9683959|FG000|Overall Study|Adverse Event|0
6077769|NCT00600171|9683960|FG001|Overall Study|Adverse Event|1
6077770|NCT00600171|9683961|FG002|Overall Study|Adverse Event|0
6077771|NCT00600171|9683962|FG003|Overall Study|Adverse Event|0
6077772|NCT00600171|9683963|FG004|Overall Study|Adverse Event|1
6077773|NCT00600171|9683964|FG005|Overall Study|Adverse Event|0
6077774|NCT00600171|9683959|FG000|Overall Study|Lack of Efficacy|9
6077775|NCT00600171|9683960|FG001|Overall Study|Lack of Efficacy|12
6077776|NCT00600171|9683961|FG002|Overall Study|Lack of Efficacy|3
6077777|NCT00600171|9683962|FG003|Overall Study|Lack of Efficacy|5
6077778|NCT00600171|9683963|FG004|Overall Study|Lack of Efficacy|4
6077779|NCT00600171|9683964|FG005|Overall Study|Lack of Efficacy|0
6077780|NCT00600171|9683959|FG000|Overall Study|Protocol Violation|1
6077781|NCT00600171|9683960|FG001|Overall Study|Protocol Violation|2
6077782|NCT00600171|9683961|FG002|Overall Study|Protocol Violation|0
6077783|NCT00600171|9683962|FG003|Overall Study|Protocol Violation|1
6077784|NCT00600171|9683963|FG004|Overall Study|Protocol Violation|0
6077785|NCT00600171|9683964|FG005|Overall Study|Protocol Violation|0
6077786|NCT00600171|9683959|FG000|Overall Study|Met Protocol-defined Stopping Criteria|3
6077787|NCT00600171|9683960|FG001|Overall Study|Met Protocol-defined Stopping Criteria|1
6077788|NCT00600171|9683961|FG002|Overall Study|Met Protocol-defined Stopping Criteria|7
6077789|NCT00600171|9683962|FG003|Overall Study|Met Protocol-defined Stopping Criteria|3
6077790|NCT00600171|9683963|FG004|Overall Study|Met Protocol-defined Stopping Criteria|2
6077791|NCT00600171|9683964|FG005|Overall Study|Met Protocol-defined Stopping Criteria|2
6077792|NCT00600171|9683959|FG000|Overall Study|Withdrawal by Subject|3
6077793|NCT00600171|9683960|FG001|Overall Study|Withdrawal by Subject|0
6077794|NCT00600171|9683961|FG002|Overall Study|Withdrawal by Subject|0
6077795|NCT00600171|9683962|FG003|Overall Study|Withdrawal by Subject|1
6019605|NCT00195650|9613679|FG000|Overall Study|Withdrawal by Subject|67
6019606|NCT00195650|9613679|FG000|Overall Study|Lost to Follow-up|44
6019607|NCT00195650|9613679|FG000|Overall Study|Death|23
6019608|NCT00195650|9613679|FG000|Overall Study|Protocol Violation|15
6019609|NCT00195650|9613679|FG000|Overall Study|Administrative reasons|83
6019610|NCT00195663|9613686|FG000|2-year Double-blind Treatment Period|Adverse Event|21
6019611|NCT00195663|9613687|FG001|2-year Double-blind Treatment Period|Adverse Event|27
6019612|NCT00195663|9613688|FG002|2-year Double-blind Treatment Period|Adverse Event|32
6077796|NCT00600171|9683963|FG004|Overall Study|Withdrawal by Subject|1
6077797|NCT00600171|9683964|FG005|Overall Study|Withdrawal by Subject|1
6077798|NCT00600171|9683959|FG000|Overall Study|Physician Decision|0
6077799|NCT00600171|9683960|FG001|Overall Study|Physician Decision|1
6077800|NCT00600171|9683961|FG002|Overall Study|Physician Decision|0
6077801|NCT00600171|9683962|FG003|Overall Study|Physician Decision|1
6077802|NCT00600171|9683963|FG004|Overall Study|Physician Decision|0
6077803|NCT00600171|9683964|FG005|Overall Study|Physician Decision|2
6019613|NCT00195663|9613686|FG000|2-year Double-blind Treatment Period|Death|0
6019614|NCT00195663|9613687|FG001|2-year Double-blind Treatment Period|Death|2
6019615|NCT00195663|9613688|FG002|2-year Double-blind Treatment Period|Death|0
6019616|NCT00195663|9613686|FG000|2-year Double-blind Treatment Period|Lost to Follow-up|0
6019617|NCT00195663|9613687|FG001|2-year Double-blind Treatment Period|Lost to Follow-up|0
6019618|NCT00195663|9613688|FG002|2-year Double-blind Treatment Period|Lost to Follow-up|1
6019619|NCT00195663|9613686|FG000|2-year Double-blind Treatment Period|Withdrawal by Subject|15
6019620|NCT00195663|9613687|FG001|2-year Double-blind Treatment Period|Withdrawal by Subject|18
6019621|NCT00195663|9613688|FG002|2-year Double-blind Treatment Period|Withdrawal by Subject|12
6019622|NCT00195663|9613686|FG000|2-year Double-blind Treatment Period|Lack of Efficacy|47
6019623|NCT00195663|9613687|FG001|2-year Double-blind Treatment Period|Lack of Efficacy|52
6019624|NCT00195663|9613688|FG002|2-year Double-blind Treatment Period|Lack of Efficacy|13
6019625|NCT00195663|9613686|FG000|2-year Double-blind Treatment Period|Protocol Violation|6
6019626|NCT00195663|9613687|FG001|2-year Double-blind Treatment Period|Protocol Violation|6
6019627|NCT00195663|9613688|FG002|2-year Double-blind Treatment Period|Protocol Violation|4
6019628|NCT00195663|9613686|FG000|2-year Double-blind Treatment Period|Planned selection criteria|0
6019629|NCT00195663|9613687|FG001|2-year Double-blind Treatment Period|Planned selection criteria|1
6019630|NCT00195663|9613688|FG002|2-year Double-blind Treatment Period|Planned selection criteria|0
6019631|NCT00195663|9613686|FG000|2-year Double-blind Treatment Period|Recovery|1
6019632|NCT00195663|9613687|FG001|2-year Double-blind Treatment Period|Recovery|0
6019633|NCT00195663|9613688|FG002|2-year Double-blind Treatment Period|Recovery|1
6019634|NCT00195663|9613686|FG000|2-year Double-blind Treatment Period|Administrative reasons|3
6019635|NCT00195663|9613687|FG001|2-year Double-blind Treatment Period|Administrative reasons|2
6019636|NCT00195663|9613688|FG002|2-year Double-blind Treatment Period|Administrative reasons|9
6019637|NCT00195663|9613686|FG000|Open-Label Extension Period|Adverse Event|21
6019638|NCT00195663|9613687|FG001|Open-Label Extension Period|Adverse Event|32
6019639|NCT00195663|9613688|FG002|Open-Label Extension Period|Adverse Event|36
6019640|NCT00195663|9613686|FG000|Open-Label Extension Period|Lost to Follow-up|9
6019641|NCT00195663|9613687|FG001|Open-Label Extension Period|Lost to Follow-up|2
6019642|NCT00195663|9613688|FG002|Open-Label Extension Period|Lost to Follow-up|6
6019643|NCT00195663|9613686|FG000|Open-Label Extension Period|Recovery|0
6019644|NCT00195663|9613687|FG001|Open-Label Extension Period|Recovery|2
6019645|NCT00195663|9613688|FG002|Open-Label Extension Period|Recovery|2
6019646|NCT00195663|9613686|FG000|Open-Label Extension Period|Protocol Violation|3
6019647|NCT00195663|9613687|FG001|Open-Label Extension Period|Protocol Violation|4
6019648|NCT00195663|9613688|FG002|Open-Label Extension Period|Protocol Violation|4
6019649|NCT00195663|9613686|FG000|Open-Label Extension Period|Death|2
6019650|NCT00195663|9613687|FG001|Open-Label Extension Period|Death|2
6019651|NCT00195663|9613688|FG002|Open-Label Extension Period|Death|2
6019652|NCT00195663|9613686|FG000|Open-Label Extension Period|Withdrawal by Subject|16
6019653|NCT00195663|9613687|FG001|Open-Label Extension Period|Withdrawal by Subject|15
6019654|NCT00195663|9613688|FG002|Open-Label Extension Period|Withdrawal by Subject|22
6019655|NCT00195663|9613686|FG000|Open-Label Extension Period|Lack of Efficacy|14
6019656|NCT00195663|9613687|FG001|Open-Label Extension Period|Lack of Efficacy|6
6019657|NCT00195663|9613688|FG002|Open-Label Extension Period|Lack of Efficacy|12
6019658|NCT00195663|9613686|FG000|Open-Label Extension Period|Administrative reasons|11
6019659|NCT00195663|9613687|FG001|Open-Label Extension Period|Administrative reasons|11
6019660|NCT00195663|9613688|FG002|Open-Label Extension Period|Administrative reasons|13
6077804|NCT00600171|9683959|FG000|Overall Study|Lost to Follow-up|0
6077805|NCT00600171|9683960|FG001|Overall Study|Lost to Follow-up|0
6077806|NCT00600171|9683961|FG002|Overall Study|Lost to Follow-up|0
6077807|NCT00600171|9683962|FG003|Overall Study|Lost to Follow-up|1
6077808|NCT00600171|9683963|FG004|Overall Study|Lost to Follow-up|0
6077809|NCT00600171|9683964|FG005|Overall Study|Lost to Follow-up|0
6077810|NCT00600353|9683991|FG000|Overall Study|history of malignancy within 5 years|1
6077811|NCT00600353|9683992|FG001|Overall Study|history of malignancy within 5 years|0
6077812|NCT00600353|9683991|FG000|Overall Study|History of prepartive regimen|0
6077813|NCT00600353|9683992|FG001|Overall Study|History of prepartive regimen|1
6077814|NCT00600613|9683998|FG000|Overall Study|Protocol Deviation|1
6077815|NCT00600756|9684039|FG000|Analysis After 6 Months|Adverse Event|43
6077816|NCT00600756|9684040|FG001|Analysis After 6 Months|Adverse Event|33
6077817|NCT00600756|9684039|FG000|Analysis After 6 Months|Withdrawal by Subject|38
6077818|NCT00600756|9684040|FG001|Analysis After 6 Months|Withdrawal by Subject|30
6077819|NCT00600756|9684039|FG000|Analysis After 6 Months|Incorrect Enrollment|12
6077820|NCT00600756|9684040|FG001|Analysis After 6 Months|Incorrect Enrollment|21
6077821|NCT00600756|9684039|FG000|Analysis After 6 Months|worsening symptom, lack of efficacy|11
6077822|NCT00600756|9684040|FG001|Analysis After 6 Months|worsening symptom, lack of efficacy|14
6077823|NCT00600756|9684039|FG000|Analysis After 6 Months|Severe non-compliance to protocol|11
6077824|NCT00600756|9684040|FG001|Analysis After 6 Months|Severe non-compliance to protocol|11
6077825|NCT00600756|9684039|FG000|Analysis After 6 Months|Lost to Follow-up|10
6077826|NCT00600756|9684040|FG001|Analysis After 6 Months|Lost to Follow-up|8
6077827|NCT00600756|9684039|FG000|Analysis After 6 Months|Study-specific discontinuation criteria|6
6077828|NCT00600756|9684040|FG001|Analysis After 6 Months|Study-specific discontinuation criteria|3
6077829|NCT00600756|9684039|FG000|Overall Study Analysis After 12 Months|Adverse Event|53
6019661|NCT00195676|9613706|FG000|Period O - Open-label Treatment|Adverse Event|82
6019662|NCT00195676|9613706|FG000|Period O - Open-label Treatment|Death|6
6019663|NCT00195676|9613706|FG000|Period O - Open-label Treatment|Lack of Efficacy|198
6019664|NCT00195676|9613706|FG000|Period O - Open-label Treatment|Lost to Follow-up|91
6077830|NCT00600756|9684040|FG001|Overall Study Analysis After 12 Months|Adverse Event|44
6077831|NCT00600756|9684039|FG000|Overall Study Analysis After 12 Months|Withdrawal by Subject|51
6077832|NCT00600756|9684040|FG001|Overall Study Analysis After 12 Months|Withdrawal by Subject|41
6077833|NCT00600756|9684039|FG000|Overall Study Analysis After 12 Months|Incorrect enrollment|21
6077834|NCT00600756|9684040|FG001|Overall Study Analysis After 12 Months|Incorrect enrollment|29
6077835|NCT00600756|9684039|FG000|Overall Study Analysis After 12 Months|worsening symptom, lack of efficacy|17
6077836|NCT00600756|9684040|FG001|Overall Study Analysis After 12 Months|worsening symptom, lack of efficacy|20
6077837|NCT00600756|9684039|FG000|Overall Study Analysis After 12 Months|Severe non-compliance to protocol|16
6077838|NCT00600756|9684040|FG001|Overall Study Analysis After 12 Months|Severe non-compliance to protocol|20
6077839|NCT00600756|9684039|FG000|Overall Study Analysis After 12 Months|Lost to Follow-up|16
6077840|NCT00600756|9684040|FG001|Overall Study Analysis After 12 Months|Lost to Follow-up|13
6077841|NCT00600756|9684039|FG000|Overall Study Analysis After 12 Months|Study-specific discontinuation criteria|9
6077842|NCT00600756|9684040|FG001|Overall Study Analysis After 12 Months|Study-specific discontinuation criteria|9
6077843|NCT00600821|9684048|FG000|Overall Study|Death|45
6077844|NCT00600821|9684049|FG001|Overall Study|Death|46
6077845|NCT00600821|9684048|FG000|Overall Study|Lost to Follow-up|2
6077846|NCT00600821|9684049|FG001|Overall Study|Lost to Follow-up|2
6077847|NCT00600821|9684048|FG000|Overall Study|Withdrawal by Subject|1
6077848|NCT00600821|9684049|FG001|Overall Study|Withdrawal by Subject|1
6077849|NCT00600821|9684048|FG000|Overall Study|Terminated by sponsor|8
6077850|NCT00600821|9684049|FG001|Overall Study|Terminated by sponsor|6
6077851|NCT00600821|9684048|FG000|Overall Study|Objective progression or relapse|0
6077852|NCT00600821|9684049|FG001|Overall Study|Objective progression or relapse|1
6077853|NCT00600821|9684048|FG000|Overall Study|Randomized but not treated|0
6077854|NCT00600821|9684049|FG001|Overall Study|Randomized but not treated|1
6077855|NCT00600821|9684048|FG000|Overall Study|Other|2
6077856|NCT00600821|9684049|FG001|Overall Study|Other|3
6077857|NCT00600886|9684059|FG000|Core Phase - Full Analysis Set (FAS)|Adverse Event|14
6077858|NCT00600886|9684060|FG001|Core Phase - Full Analysis Set (FAS)|Adverse Event|6
6077859|NCT00600886|9684059|FG000|Core Phase - Full Analysis Set (FAS)|Protocol Violation|7
6077860|NCT00600886|9684060|FG001|Core Phase - Full Analysis Set (FAS)|Protocol Violation|8
6077861|NCT00600886|9684059|FG000|Core Phase - Full Analysis Set (FAS)|Lack of Efficacy|5
6077862|NCT00600886|9684060|FG001|Core Phase - Full Analysis Set (FAS)|Lack of Efficacy|8
6077863|NCT00600886|9684059|FG000|Core Phase - Full Analysis Set (FAS)|Withdrawal by Subject|5
6077864|NCT00600886|9684060|FG001|Core Phase - Full Analysis Set (FAS)|Withdrawal by Subject|3
6077865|NCT00600886|9684059|FG000|Core Phase - Full Analysis Set (FAS)|Administrative Problems|2
6077866|NCT00600886|9684060|FG001|Core Phase - Full Analysis Set (FAS)|Administrative Problems|0
6077867|NCT00600886|9684059|FG000|Core Phase - Full Analysis Set (FAS)|Abnormal laboratory value(s)|1
6077868|NCT00600886|9684060|FG001|Core Phase - Full Analysis Set (FAS)|Abnormal laboratory value(s)|0
6077869|NCT00600886|9684059|FG000|Core Phase - Full Analysis Set (FAS)|Lost to Follow-up|1
6077870|NCT00600886|9684060|FG001|Core Phase - Full Analysis Set (FAS)|Lost to Follow-up|0
6077871|NCT00600886|9684059|FG000|Core Phase - Full Analysis Set (FAS)|Death|0
6077872|NCT00600886|9684060|FG001|Core Phase - Full Analysis Set (FAS)|Death|1
6077873|NCT00600886|9684059|FG000|Extension - Same Treatment (FAS)|Withdrawal by Subject|16
6077874|NCT00600886|9684060|FG001|Extension - Same Treatment (FAS)|Withdrawal by Subject|2
6077875|NCT00600886|9684059|FG000|Extension - Same Treatment (FAS)|Lack of Efficacy|3
6077876|NCT00600886|9684060|FG001|Extension - Same Treatment (FAS)|Lack of Efficacy|3
6077877|NCT00600886|9684059|FG000|Extension - Same Treatment (FAS)|Administrative Problems|9
6077878|NCT00600886|9684060|FG001|Extension - Same Treatment (FAS)|Administrative Problems|3
6077879|NCT00600886|9684059|FG000|Extension - Same Treatment (FAS)|Lost to Follow-up|3
6077880|NCT00600886|9684060|FG001|Extension - Same Treatment (FAS)|Lost to Follow-up|1
6077881|NCT00600886|9684059|FG000|Extension - Same Treatment (FAS)|Adverse Event|4
6077882|NCT00600886|9684060|FG001|Extension - Same Treatment (FAS)|Adverse Event|1
6077883|NCT00600886|9684059|FG000|Extension - Same Treatment (FAS)|Abnormal Lab Value (s)|4
6077884|NCT00600886|9684060|FG001|Extension - Same Treatment (FAS)|Abnormal Lab Value (s)|0
6077885|NCT00600886|9684059|FG000|Extension - Same Treatment (FAS)|Death|1
6077886|NCT00600886|9684060|FG001|Extension - Same Treatment (FAS)|Death|1
6077887|NCT00600886|9684059|FG000|Extension - Same Treatment (FAS)|Condition no longer requires study drug|6
6077888|NCT00600886|9684060|FG001|Extension - Same Treatment (FAS)|Condition no longer requires study drug|0
6077889|NCT00600886|9684059|FG000|Extension - After Crossover (CAS)|Adverse Event|19
6019665|NCT00195676|9613706|FG000|Period O - Open-label Treatment|Protocol Violation|12
6019666|NCT00195676|9613706|FG000|Period O - Open-label Treatment|Withdrawal by Subject|147
6019667|NCT00195676|9613706|FG000|Period O - Open-label Treatment|Administrative reasons|2
6019668|NCT00195676|9613706|FG000|Period O - Open-label Treatment|Other reasons|68
6019669|NCT00195676|9613706|FG000|Period W (Withdrawal) - No Treatment|Adverse Event|4
6019670|NCT00195676|9613706|FG000|Period W (Withdrawal) - No Treatment|Death|2
6019671|NCT00195676|9613706|FG000|Period W (Withdrawal) - No Treatment|Lost to Follow-up|11
6019672|NCT00195676|9613706|FG000|Period W (Withdrawal) - No Treatment|Withdrawal by Subject|46
6019673|NCT00195676|9613706|FG000|Period W (Withdrawal) - No Treatment|Relapse (PGA >= 3)|397
6019674|NCT00195676|9613706|FG000|Period W (Withdrawal) - No Treatment|Period W Close-out|129
6019675|NCT00195676|9613706|FG000|Period W (Withdrawal) - No Treatment|Administrative reasons|1
6019676|NCT00195676|9613706|FG000|Period W (Withdrawal) - No Treatment|Other reasons|18
6019677|NCT00195676|9613706|FG000|Period R - Retreatment 16 Weeks|Adverse Event|4
6019678|NCT00195676|9613706|FG000|Period R - Retreatment 16 Weeks|Lack of Efficacy|5
6019679|NCT00195676|9613706|FG000|Period R - Retreatment 16 Weeks|Lost to Follow-up|11
6019680|NCT00195676|9613706|FG000|Period R - Retreatment 16 Weeks|Withdrawal by Subject|9
6019681|NCT00195676|9613706|FG000|Period R - Retreatment 16 Weeks|Other reasons|6
6019682|NCT00195715|9613735|FG000|Overall Study|Adverse Event|122
6019683|NCT00195715|9613735|FG000|Overall Study|Withdrawal by Subject|58
6019684|NCT00195715|9613735|FG000|Overall Study|Lost to Follow-up|27
6019685|NCT00195715|9613735|FG000|Overall Study|Protocol Violation|13
6019686|NCT00195715|9613735|FG000|Overall Study|Lack of Efficacy|93
6019687|NCT00195715|9613735|FG000|Overall Study|Pregnancy|14
6019688|NCT00195715|9613735|FG000|Overall Study|Investigative site closure|8
6019689|NCT00195715|9613735|FG000|Overall Study|Subject moved/relocated|7
6019690|NCT00195715|9613735|FG000|Overall Study|Subject non-compliance|6
6019691|NCT00195715|9613735|FG000|Overall Study|Subject started commercial Humira|5
6019692|NCT00195715|9613735|FG000|Overall Study|Subject choice|3
6019693|NCT00195715|9613735|FG000|Overall Study|Loss of response/no improvement|3
6019694|NCT00195715|9613735|FG000|Overall Study|Sponsor stopped study|1
6019695|NCT00195715|9613735|FG000|Overall Study|Administrative reasons|2
6019696|NCT00195715|9613735|FG000|Overall Study|Investigator's decision|2
6019697|NCT00195715|9613735|FG000|Overall Study|Subject wants to get pregnant|4
6019698|NCT00195715|9613735|FG000|Overall Study|Use of prohibited medication|2
6019699|NCT00195715|9613735|FG000|Overall Study|Planned surgery|2
6019700|NCT00195715|9613735|FG000|Overall Study|Increased infection rate|1
6019701|NCT00195715|9613735|FG000|Overall Study|Ineligible|1
6019702|NCT00195715|9613735|FG000|Overall Study|Colonic stricture|1
6019703|NCT00195715|9613735|FG000|Overall Study|Sponsor discontinued trial|1
6019704|NCT00195715|9613735|FG000|Overall Study|Sponsor discretion - trial ended early|1
6019705|NCT00195819|9613739|FG000|Double-Blind|Withdrawal by Subject|1
6019706|NCT00195819|9613740|FG001|Double-Blind|Withdrawal by Subject|0
6019707|NCT00195819|9613739|FG000|Double-Blind|Moved|1
6019708|NCT00195819|9613740|FG001|Double-Blind|Moved|0
6019709|NCT00195819|9613739|FG000|Open-label|Adverse Event|0
6019710|NCT00195819|9613740|FG001|Open-label|Adverse Event|9
6019711|NCT00195819|9613739|FG000|Open-label|Lack of Efficacy|0
6019712|NCT00195819|9613740|FG001|Open-label|Lack of Efficacy|2
6019713|NCT00195819|9613739|FG000|Open-label|Pregnancy|0
6019714|NCT00195819|9613740|FG001|Open-label|Pregnancy|1
6019715|NCT00195819|9613739|FG000|Open-label|Protocol Violation|0
6019716|NCT00195819|9613740|FG001|Open-label|Protocol Violation|2
6019717|NCT00195819|9613739|FG000|Open-label|Moved|0
6019718|NCT00195819|9613740|FG001|Open-label|Moved|1
6019719|NCT00195819|9613739|FG000|Open-label|Withdrawal by Subject|0
6019720|NCT00195819|9613740|FG001|Open-label|Withdrawal by Subject|5
6019721|NCT00196105|9613755|FG000|Overall Study|Lost to Follow-up|4
6019722|NCT00196105|9613756|FG001|Overall Study|Lost to Follow-up|5
6019723|NCT00196105|9613757|FG002|Overall Study|Lost to Follow-up|7
6019724|NCT00196196|9613765|FG000|Overall Study|Withdrawal by Subject|2
6019725|NCT00196196|9613765|FG000|Overall Study|Did not have required condition (hydroce|5
6019726|NCT00196313|9613771|FG000|Overall Study|Protocol Violation|2
6019727|NCT00196313|9613772|FG001|Overall Study|Protocol Violation|3
6019728|NCT00196313|9613771|FG000|Overall Study|Withdrawal by Subject|3
6019729|NCT00196313|9613772|FG001|Overall Study|Withdrawal by Subject|1
6019730|NCT00196313|9613771|FG000|Overall Study|Adverse Event|3
6019731|NCT00196313|9613772|FG001|Overall Study|Adverse Event|1
6019732|NCT00196313|9613771|FG000|Overall Study|Subject Pregnant|1
6019733|NCT00196313|9613772|FG001|Overall Study|Subject Pregnant|1
6019734|NCT00196313|9613771|FG000|Overall Study|Lost to Follow-up|2
6019735|NCT00196313|9613772|FG001|Overall Study|Lost to Follow-up|2
6019736|NCT00196326|9613779|FG000|Overall Study|Did not meet protocol requirements|64
6019737|NCT00196326|9613779|FG000|Overall Study|Non-compliance with the protocol|81
6019738|NCT00196326|9613779|FG000|Overall Study|Physician Decision|3
6019739|NCT00196326|9613779|FG000|Overall Study|Withdrawal by Subject|225
6019740|NCT00196326|9613779|FG000|Overall Study|Adverse Event|253
6019741|NCT00196326|9613779|FG000|Overall Study|Pregnancy|34
6019742|NCT00196326|9613779|FG000|Overall Study|Lost to Follow-up|304
6019743|NCT00196326|9613779|FG000|Overall Study|Other|22
6019744|NCT00196937|9613792|FG000|Overall Study|Serious Adverse Event|1
6019745|NCT00196937|9613793|FG001|Overall Study|Serious Adverse Event|0
6019746|NCT00196937|9613794|FG002|Overall Study|Serious Adverse Event|0
6019747|NCT00196937|9613792|FG000|Overall Study|Non-serious adverse event|1
6019748|NCT00196937|9613793|FG001|Overall Study|Non-serious adverse event|1
6019749|NCT00196937|9613794|FG002|Overall Study|Non-serious adverse event|1
6019750|NCT00196937|9613792|FG000|Overall Study|Withdrawal by Subject|0
6019751|NCT00196937|9613793|FG001|Overall Study|Withdrawal by Subject|0
6019752|NCT00196937|9613794|FG002|Overall Study|Withdrawal by Subject|2
6019753|NCT00196937|9613792|FG000|Overall Study|Lost to Follow-up|4
6019754|NCT00196937|9613793|FG001|Overall Study|Lost to Follow-up|3
6019755|NCT00196937|9613794|FG002|Overall Study|Lost to Follow-up|3
6019756|NCT00196937|9613792|FG000|Overall Study|Other|3
6019757|NCT00196937|9613793|FG001|Overall Study|Other|1
6019758|NCT00196937|9613794|FG002|Overall Study|Other|1
6019759|NCT00196976|9613817|FG000|Primary Study|Migrated from study area|0
6019760|NCT00196976|9613818|FG001|Primary Study|Migrated from study area|0
6019761|NCT00196976|9613819|FG002|Primary Study|Migrated from study area|0
6019762|NCT00196976|9613820|FG003|Primary Study|Migrated from study area|0
6019763|NCT00196976|9613821|FG004|Primary Study|Migrated from study area|0
6019764|NCT00196976|9613822|FG005|Primary Study|Migrated from study area|0
6019765|NCT00196976|9613823|FG006|Primary Study|Migrated from study area|0
6019766|NCT00196976|9613824|FG007|Primary Study|Migrated from study area|1
6019767|NCT00196976|9613825|FG008|Primary Study|Migrated from study area|0
6019768|NCT00196976|9613826|FG009|Primary Study|Migrated from study area|0
6019769|NCT00196976|9613827|FG010|Primary Study|Migrated from study area|0
6019770|NCT00196976|9613828|FG011|Primary Study|Migrated from study area|0
6019771|NCT00196976|9613829|FG012|Primary Study|Migrated from study area|0
6019772|NCT00196976|9613830|FG013|Primary Study|Migrated from study area|0
6019773|NCT00196976|9613817|FG000|Primary Study|Protocol Violation|0
6019774|NCT00196976|9613818|FG001|Primary Study|Protocol Violation|1
6019775|NCT00196976|9613819|FG002|Primary Study|Protocol Violation|1
6019776|NCT00196976|9613820|FG003|Primary Study|Protocol Violation|0
6019777|NCT00196976|9613821|FG004|Primary Study|Protocol Violation|0
6019778|NCT00196976|9613822|FG005|Primary Study|Protocol Violation|0
6019779|NCT00196976|9613823|FG006|Primary Study|Protocol Violation|0
6019780|NCT00196976|9613824|FG007|Primary Study|Protocol Violation|0
6019781|NCT00196976|9613825|FG008|Primary Study|Protocol Violation|0
6019782|NCT00196976|9613826|FG009|Primary Study|Protocol Violation|0
6019783|NCT00196976|9613827|FG010|Primary Study|Protocol Violation|0
6019784|NCT00196976|9613828|FG011|Primary Study|Protocol Violation|0
6019785|NCT00196976|9613829|FG012|Primary Study|Protocol Violation|0
6019786|NCT00196976|9613830|FG013|Primary Study|Protocol Violation|0
6019787|NCT00196976|9613817|FG000|Primary Study|Withdrawal by Subject|1
6019788|NCT00196976|9613818|FG001|Primary Study|Withdrawal by Subject|0
6019789|NCT00196976|9613819|FG002|Primary Study|Withdrawal by Subject|1
6019790|NCT00196976|9613820|FG003|Primary Study|Withdrawal by Subject|1
6019791|NCT00196976|9613821|FG004|Primary Study|Withdrawal by Subject|2
6019792|NCT00196976|9613822|FG005|Primary Study|Withdrawal by Subject|1
6019793|NCT00196976|9613823|FG006|Primary Study|Withdrawal by Subject|0
6019794|NCT00196976|9613824|FG007|Primary Study|Withdrawal by Subject|0
6019795|NCT00196976|9613825|FG008|Primary Study|Withdrawal by Subject|0
6019796|NCT00196976|9613826|FG009|Primary Study|Withdrawal by Subject|1
6019797|NCT00196976|9613827|FG010|Primary Study|Withdrawal by Subject|0
6019798|NCT00196976|9613828|FG011|Primary Study|Withdrawal by Subject|0
6019799|NCT00196976|9613829|FG012|Primary Study|Withdrawal by Subject|0
6019800|NCT00196976|9613830|FG013|Primary Study|Withdrawal by Subject|0
6019801|NCT00196976|9613817|FG000|Primary Study|Lost to Follow-up|0
6019802|NCT00196976|9613818|FG001|Primary Study|Lost to Follow-up|0
6019803|NCT00196976|9613819|FG002|Primary Study|Lost to Follow-up|0
6019804|NCT00196976|9613820|FG003|Primary Study|Lost to Follow-up|0
6019805|NCT00196976|9613821|FG004|Primary Study|Lost to Follow-up|1
6019806|NCT00196976|9613822|FG005|Primary Study|Lost to Follow-up|1
6019807|NCT00196976|9613823|FG006|Primary Study|Lost to Follow-up|0
6019808|NCT00196976|9613824|FG007|Primary Study|Lost to Follow-up|2
6019809|NCT00196976|9613825|FG008|Primary Study|Lost to Follow-up|0
6019810|NCT00196976|9613826|FG009|Primary Study|Lost to Follow-up|0
6019811|NCT00196976|9613827|FG010|Primary Study|Lost to Follow-up|0
6019812|NCT00196976|9613828|FG011|Primary Study|Lost to Follow-up|0
6019813|NCT00196976|9613829|FG012|Primary Study|Lost to Follow-up|0
6019814|NCT00196976|9613830|FG013|Primary Study|Lost to Follow-up|0
6019815|NCT00196976|9613817|FG000|Primary Study|Other|0
6019816|NCT00196976|9613818|FG001|Primary Study|Other|0
6019817|NCT00196976|9613819|FG002|Primary Study|Other|2
6019818|NCT00196976|9613820|FG003|Primary Study|Other|0
6019819|NCT00196976|9613821|FG004|Primary Study|Other|0
6019820|NCT00196976|9613822|FG005|Primary Study|Other|0
6019821|NCT00196976|9613823|FG006|Primary Study|Other|0
6019822|NCT00196976|9613824|FG007|Primary Study|Other|0
6019823|NCT00196976|9613825|FG008|Primary Study|Other|0
6019824|NCT00196976|9613826|FG009|Primary Study|Other|0
6019825|NCT00196976|9613827|FG010|Primary Study|Other|0
6019826|NCT00196976|9613828|FG011|Primary Study|Other|0
6019827|NCT00196976|9613829|FG012|Primary Study|Other|0
6019828|NCT00196976|9613830|FG013|Primary Study|Other|0
6019829|NCT00196976|9613817|FG000|Booster Study|Withdrawal by Subject|0
6019830|NCT00196976|9613818|FG001|Booster Study|Withdrawal by Subject|0
6019831|NCT00196976|9613819|FG002|Booster Study|Withdrawal by Subject|0
6019832|NCT00196976|9613820|FG003|Booster Study|Withdrawal by Subject|0
6019833|NCT00196976|9613821|FG004|Booster Study|Withdrawal by Subject|0
6019834|NCT00196976|9613822|FG005|Booster Study|Withdrawal by Subject|0
6019835|NCT00196976|9613823|FG006|Booster Study|Withdrawal by Subject|0
6019836|NCT00196976|9613824|FG007|Booster Study|Withdrawal by Subject|0
6019837|NCT00196976|9613825|FG008|Booster Study|Withdrawal by Subject|0
6019838|NCT00196976|9613826|FG009|Booster Study|Withdrawal by Subject|0
6019839|NCT00196976|9613827|FG010|Booster Study|Withdrawal by Subject|1
6019840|NCT00196976|9613828|FG011|Booster Study|Withdrawal by Subject|0
6019841|NCT00196976|9613829|FG012|Booster Study|Withdrawal by Subject|0
6019842|NCT00196976|9613830|FG013|Booster Study|Withdrawal by Subject|0
6019843|NCT00196976|9613817|FG000|Booster Study|Lost to Follow-up|0
6019844|NCT00196976|9613818|FG001|Booster Study|Lost to Follow-up|0
6019845|NCT00196976|9613819|FG002|Booster Study|Lost to Follow-up|0
6019846|NCT00196976|9613820|FG003|Booster Study|Lost to Follow-up|0
6019847|NCT00196976|9613821|FG004|Booster Study|Lost to Follow-up|0
6019848|NCT00196976|9613822|FG005|Booster Study|Lost to Follow-up|0
6019849|NCT00196976|9613823|FG006|Booster Study|Lost to Follow-up|0
6019850|NCT00196976|9613824|FG007|Booster Study|Lost to Follow-up|0
6019851|NCT00196976|9613825|FG008|Booster Study|Lost to Follow-up|0
6019852|NCT00196976|9613826|FG009|Booster Study|Lost to Follow-up|0
6019853|NCT00196976|9613827|FG010|Booster Study|Lost to Follow-up|1
6019854|NCT00196976|9613828|FG011|Booster Study|Lost to Follow-up|2
6019855|NCT00196976|9613829|FG012|Booster Study|Lost to Follow-up|0
6019856|NCT00196976|9613830|FG013|Booster Study|Lost to Follow-up|0
6019857|NCT00197002|9613873|FG000|Overall Study|Adverse Event|0
6019858|NCT00197002|9613874|FG001|Overall Study|Adverse Event|1
6019859|NCT00197002|9613875|FG002|Overall Study|Adverse Event|0
6019860|NCT00197002|9613873|FG000|Overall Study|Protocol Violation|1
6019861|NCT00197002|9613874|FG001|Overall Study|Protocol Violation|0
6019862|NCT00197002|9613875|FG002|Overall Study|Protocol Violation|2
6019863|NCT00197002|9613873|FG000|Overall Study|Withdrawal by Subject|9
6019864|NCT00197002|9613874|FG001|Overall Study|Withdrawal by Subject|5
6019865|NCT00197002|9613875|FG002|Overall Study|Withdrawal by Subject|7
6019866|NCT00197002|9613873|FG000|Overall Study|Migrated/moved from study area|3
6019867|NCT00197002|9613874|FG001|Overall Study|Migrated/moved from study area|5
6019868|NCT00197002|9613875|FG002|Overall Study|Migrated/moved from study area|1
6019869|NCT00197002|9613873|FG000|Overall Study|Lost to follow-up (incompl. vaccination)|4
6019870|NCT00197002|9613874|FG001|Overall Study|Lost to follow-up (incompl. vaccination)|4
6019871|NCT00197002|9613875|FG002|Overall Study|Lost to follow-up (incompl. vaccination)|5
6019872|NCT00197002|9613873|FG000|Overall Study|Lost to follow-up (compl. vaccination)|2
6019873|NCT00197002|9613874|FG001|Overall Study|Lost to follow-up (compl. vaccination)|2
6019874|NCT00197002|9613875|FG002|Overall Study|Lost to follow-up (compl. vaccination)|1
6019875|NCT00197002|9613873|FG000|Overall Study|Others|3
6019876|NCT00197002|9613874|FG001|Overall Study|Others|1
6019877|NCT00197002|9613875|FG002|Overall Study|Others|1
6019878|NCT00197015|9613889|FG000|Overall Study|Adverse Event|3
6019879|NCT00197015|9613890|FG001|Overall Study|Adverse Event|0
6077890|NCT00600886|9684060|FG001|Extension - After Crossover (CAS)|Adverse Event|1
6077891|NCT00600886|9684059|FG000|Extension - After Crossover (CAS)|Withdrawal by Subject|19
6077892|NCT00600886|9684060|FG001|Extension - After Crossover (CAS)|Withdrawal by Subject|4
6077893|NCT00600886|9684059|FG000|Extension - After Crossover (CAS)|Lack of Efficacy|13
6077894|NCT00600886|9684060|FG001|Extension - After Crossover (CAS)|Lack of Efficacy|4
6077895|NCT00600886|9684059|FG000|Extension - After Crossover (CAS)|Administrative Problems|4
6077896|NCT00600886|9684060|FG001|Extension - After Crossover (CAS)|Administrative Problems|4
6077897|NCT00600886|9684059|FG000|Extension - After Crossover (CAS)|Subject no longer requires study drug|3
6077898|NCT00600886|9684060|FG001|Extension - After Crossover (CAS)|Subject no longer requires study drug|0
6077899|NCT00600886|9684059|FG000|Extension - After Crossover (CAS)|Abnormal Lab Value (s)|3
6077900|NCT00600886|9684060|FG001|Extension - After Crossover (CAS)|Abnormal Lab Value (s)|0
6077901|NCT00600886|9684059|FG000|Extension - After Crossover (CAS)|Death|1
6077902|NCT00600886|9684060|FG001|Extension - After Crossover (CAS)|Death|0
6077903|NCT00600938|9684091|FG000|Core Study|Abnormal test procedure result(s)|3
6077904|NCT00600938|9684092|FG001|Core Study|Abnormal test procedure result(s)|2
6077905|NCT00600938|9684093|FG002|Core Study|Abnormal test procedure result(s)|0
6077906|NCT00600938|9684094|FG003|Core Study|Abnormal test procedure result(s)|0
6077907|NCT00600938|9684091|FG000|Core Study|Unsatisfactory therapeutic effect|1
6077908|NCT00600938|9684092|FG001|Core Study|Unsatisfactory therapeutic effect|2
6077909|NCT00600938|9684093|FG002|Core Study|Unsatisfactory therapeutic effect|0
6077910|NCT00600938|9684094|FG003|Core Study|Unsatisfactory therapeutic effect|0
6077911|NCT00600938|9684091|FG000|Core Study|Patient withdrew consent|7
6019880|NCT00197015|9613891|FG002|Overall Study|Adverse Event|1
6019881|NCT00197015|9613889|FG000|Overall Study|Protocol Violation|0
6019882|NCT00197015|9613890|FG001|Overall Study|Protocol Violation|3
6019883|NCT00197015|9613891|FG002|Overall Study|Protocol Violation|3
6019884|NCT00197015|9613889|FG000|Overall Study|Withdrawal by Subject|17
6019885|NCT00197015|9613890|FG001|Overall Study|Withdrawal by Subject|37
6019886|NCT00197015|9613891|FG002|Overall Study|Withdrawal by Subject|34
6019887|NCT00197015|9613889|FG000|Overall Study|Lost to Follow-up|28
6019888|NCT00197015|9613890|FG001|Overall Study|Lost to Follow-up|46
6077912|NCT00600938|9684092|FG001|Core Study|Patient withdrew consent|12
6077913|NCT00600938|9684093|FG002|Core Study|Patient withdrew consent|0
6019889|NCT00197015|9613891|FG002|Overall Study|Lost to Follow-up|37
6019890|NCT00197015|9613889|FG000|Overall Study|Other|2
6019891|NCT00197015|9613890|FG001|Overall Study|Other|3
6019892|NCT00197015|9613891|FG002|Overall Study|Other|2
6019893|NCT00197028|9613901|FG000|Overall Study|Adverse Event|2
6019894|NCT00197028|9613902|FG001|Overall Study|Adverse Event|2
6019895|NCT00197028|9613901|FG000|Overall Study|Protocol Violation|2
6019896|NCT00197028|9613902|FG001|Overall Study|Protocol Violation|1
6019897|NCT00197028|9613901|FG000|Overall Study|Withdrawal by Subject|8
6019898|NCT00197028|9613902|FG001|Overall Study|Withdrawal by Subject|12
6019899|NCT00197028|9613901|FG000|Overall Study|Lost to Follow-up|1
6077914|NCT00600938|9684094|FG003|Core Study|Patient withdrew consent|0
6077915|NCT00600938|9684091|FG000|Core Study|Lost to Follow-up|3
6077916|NCT00600938|9684092|FG001|Core Study|Lost to Follow-up|2
6077917|NCT00600938|9684093|FG002|Core Study|Lost to Follow-up|0
6077918|NCT00600938|9684094|FG003|Core Study|Lost to Follow-up|0
6077919|NCT00600938|9684091|FG000|Core Study|Death|1
6077920|NCT00600938|9684092|FG001|Core Study|Death|1
6077921|NCT00600938|9684093|FG002|Core Study|Death|0
6077922|NCT00600938|9684094|FG003|Core Study|Death|0
6077923|NCT00600938|9684091|FG000|Core Study|Protocol Violation|1
6077924|NCT00600938|9684092|FG001|Core Study|Protocol Violation|2
6077925|NCT00600938|9684093|FG002|Core Study|Protocol Violation|0
6077926|NCT00600938|9684094|FG003|Core Study|Protocol Violation|0
6077927|NCT00600938|9684091|FG000|Extension Study|Adverse Event|1
6077928|NCT00600938|9684092|FG001|Extension Study|Adverse Event|0
6077929|NCT00600938|9684093|FG002|Extension Study|Adverse Event|2
6077930|NCT00600938|9684094|FG003|Extension Study|Adverse Event|0
6077931|NCT00600938|9684091|FG000|Extension Study|Abnormal test procedure results|0
6077932|NCT00600938|9684092|FG001|Extension Study|Abnormal test procedure results|1
6077933|NCT00600938|9684093|FG002|Extension Study|Abnormal test procedure results|1
6077934|NCT00600938|9684094|FG003|Extension Study|Abnormal test procedure results|1
6077935|NCT00600938|9684091|FG000|Extension Study|Unsatisfactory therapeutic effect|4
6077936|NCT00600938|9684092|FG001|Extension Study|Unsatisfactory therapeutic effect|1
6077937|NCT00600938|9684093|FG002|Extension Study|Unsatisfactory therapeutic effect|1
6077938|NCT00600938|9684094|FG003|Extension Study|Unsatisfactory therapeutic effect|0
6077939|NCT00600938|9684091|FG000|Extension Study|Withdrawal by Subject|2
6077940|NCT00600938|9684092|FG001|Extension Study|Withdrawal by Subject|2
6077941|NCT00600938|9684093|FG002|Extension Study|Withdrawal by Subject|3
6077942|NCT00600938|9684094|FG003|Extension Study|Withdrawal by Subject|0
6077943|NCT00600938|9684091|FG000|Extension Study|Lost to Follow-up|1
6077944|NCT00600938|9684092|FG001|Extension Study|Lost to Follow-up|1
6077945|NCT00600938|9684093|FG002|Extension Study|Lost to Follow-up|2
6077946|NCT00600938|9684094|FG003|Extension Study|Lost to Follow-up|0
6077947|NCT00600938|9684091|FG000|Extension Study|Death|1
6077948|NCT00600938|9684092|FG001|Extension Study|Death|0
6077949|NCT00600938|9684093|FG002|Extension Study|Death|0
6077950|NCT00600938|9684094|FG003|Extension Study|Death|0
6077951|NCT00601107|9684123|FG000|Overall Study|Adverse Event|0
6077952|NCT00601107|9684124|FG001|Overall Study|Adverse Event|1
6077953|NCT00601107|9684125|FG002|Overall Study|Adverse Event|3
6077954|NCT00601107|9684126|FG003|Overall Study|Adverse Event|0
6077955|NCT00601107|9684123|FG000|Overall Study|Withdrawal by Subject|5
6077956|NCT00601107|9684124|FG001|Overall Study|Withdrawal by Subject|4
6077957|NCT00601107|9684125|FG002|Overall Study|Withdrawal by Subject|7
6077958|NCT00601107|9684126|FG003|Overall Study|Withdrawal by Subject|4
6077959|NCT00601107|9684123|FG000|Overall Study|Lost to Follow-up|3
6077960|NCT00601107|9684124|FG001|Overall Study|Lost to Follow-up|3
6077961|NCT00601107|9684125|FG002|Overall Study|Lost to Follow-up|0
6077962|NCT00601107|9684126|FG003|Overall Study|Lost to Follow-up|3
6077963|NCT00601107|9684123|FG000|Overall Study|Serum Calcium >11.5 milligram/deciliter|0
6077964|NCT00601107|9684124|FG001|Overall Study|Serum Calcium >11.5 milligram/deciliter|0
6077965|NCT00601107|9684125|FG002|Overall Study|Serum Calcium >11.5 milligram/deciliter|0
6019900|NCT00197028|9613902|FG001|Overall Study|Lost to Follow-up|0
6019901|NCT00197028|9613901|FG000|Overall Study|Other|3
6019902|NCT00197028|9613902|FG001|Overall Study|Other|6
6019903|NCT00197054|9613911|FG000|Overall Study|Withdrawal by Subject|9
6019904|NCT00197054|9613912|FG001|Overall Study|Withdrawal by Subject|3
6019905|NCT00197054|9613913|FG002|Overall Study|Withdrawal by Subject|3
6019906|NCT00197054|9613911|FG000|Overall Study|Moved from area|7
6019907|NCT00197054|9613912|FG001|Overall Study|Moved from area|14
6019908|NCT00197054|9613913|FG002|Overall Study|Moved from area|9
6019909|NCT00197054|9613911|FG000|Overall Study|Lost to Follow-up|1
6019910|NCT00197054|9613912|FG001|Overall Study|Lost to Follow-up|4
6019911|NCT00197054|9613913|FG002|Overall Study|Lost to Follow-up|0
6019912|NCT00197106|9613933|FG000|4-Week Run-In Period|Did not meet entry criteria|99
6019913|NCT00197106|9613934|FG001|4-Week Run-In Period|Did not meet entry criteria|0
6019914|NCT00197106|9613935|FG002|4-Week Run-In Period|Did not meet entry criteria|0
6019915|NCT00197106|9613933|FG000|Overall Treatment Period|Lack of Efficacy|0
6019916|NCT00197106|9613934|FG001|Overall Treatment Period|Lack of Efficacy|1
6019917|NCT00197106|9613935|FG002|Overall Treatment Period|Lack of Efficacy|0
6019918|NCT00197106|9613933|FG000|Overall Treatment Period|Lost to Follow-up|0
6019919|NCT00197106|9613934|FG001|Overall Treatment Period|Lost to Follow-up|0
6019920|NCT00197106|9613935|FG002|Overall Treatment Period|Lost to Follow-up|2
6019921|NCT00197106|9613933|FG000|Overall Treatment Period|Protocol Violation|0
6019922|NCT00197106|9613934|FG001|Overall Treatment Period|Protocol Violation|0
6019923|NCT00197106|9613935|FG002|Overall Treatment Period|Protocol Violation|2
6077966|NCT00601107|9684126|FG003|Overall Study|Serum Calcium >11.5 milligram/deciliter|1
6077967|NCT00601107|9684123|FG000|Overall Study|Worsening of Psoriasis|4
6077968|NCT00601107|9684124|FG001|Overall Study|Worsening of Psoriasis|1
6077969|NCT00601107|9684125|FG002|Overall Study|Worsening of Psoriasis|1
6077970|NCT00601107|9684126|FG003|Overall Study|Worsening of Psoriasis|4
6019924|NCT00197106|9613933|FG000|Overall Treatment Period|Withdrawal by Subject|0
6019925|NCT00197106|9613934|FG001|Overall Treatment Period|Withdrawal by Subject|0
6019926|NCT00197106|9613935|FG002|Overall Treatment Period|Withdrawal by Subject|2
6019927|NCT00197145|9613952|FG000|Period 1: Randomized Treatment Phase|Withdrawal by Subject|1
6019928|NCT00197145|9613953|FG001|Period 1: Randomized Treatment Phase|Withdrawal by Subject|1
6019929|NCT00197145|9613952|FG000|Period 1: Randomized Treatment Phase|Sponsor terminated study|10
6019930|NCT00197145|9613953|FG001|Period 1: Randomized Treatment Phase|Sponsor terminated study|8
6019931|NCT00197145|9613952|FG000|Period 1: Randomized Treatment Phase|Other|2
6019932|NCT00197145|9613953|FG001|Period 1: Randomized Treatment Phase|Other|2
6019933|NCT00197145|9613952|FG000|Period 2 : Open Label Phase|Insufficient viral load response|1
6019934|NCT00197145|9613953|FG001|Period 2 : Open Label Phase|Insufficient viral load response|0
6019935|NCT00197145|9613952|FG000|Period 2 : Open Label Phase|Protocol defined virological failure|3
6019936|NCT00197145|9613953|FG001|Period 2 : Open Label Phase|Protocol defined virological failure|0
6019937|NCT00197145|9613952|FG000|Period 2 : Open Label Phase|Availability of alternative ART|2
6019938|NCT00197145|9613953|FG001|Period 2 : Open Label Phase|Availability of alternative ART|0
6019939|NCT00197145|9613952|FG000|Period 2 : Open Label Phase|Were ongoing till data freeze|3
6019940|NCT00197145|9613953|FG001|Period 2 : Open Label Phase|Were ongoing till data freeze|0
6019941|NCT00197145|9613952|FG000|Period 2 : Open Label Phase|Other|1
6019942|NCT00197145|9613953|FG001|Period 2 : Open Label Phase|Other|0
6019943|NCT00197236|9613972|FG000|Overall Study|Adverse Event|1
6019944|NCT00197236|9613973|FG001|Overall Study|Adverse Event|0
6019945|NCT00197236|9613974|FG002|Overall Study|Adverse Event|1
6019946|NCT00197236|9613972|FG000|Overall Study|Lost to Follow-up|5
6019947|NCT00197236|9613973|FG001|Overall Study|Lost to Follow-up|14
6019948|NCT00197236|9613974|FG002|Overall Study|Lost to Follow-up|6
6019949|NCT00197236|9613972|FG000|Overall Study|Protocol Violation|0
6019950|NCT00197236|9613973|FG001|Overall Study|Protocol Violation|0
6019951|NCT00197236|9613974|FG002|Overall Study|Protocol Violation|1
6019952|NCT00197236|9613972|FG000|Overall Study|Withdrawal by Subject|7
6019953|NCT00197236|9613973|FG001|Overall Study|Withdrawal by Subject|3
6019954|NCT00197236|9613974|FG002|Overall Study|Withdrawal by Subject|11
6019955|NCT00197236|9613972|FG000|Overall Study|Study drug/medication expiration|1
6019956|NCT00197236|9613973|FG001|Overall Study|Study drug/medication expiration|0
6019957|NCT00197236|9613974|FG002|Overall Study|Study drug/medication expiration|3
6019958|NCT00197236|9613972|FG000|Overall Study|Returned out of specified time window|0
6019959|NCT00197236|9613973|FG001|Overall Study|Returned out of specified time window|0
6019960|NCT00197236|9613974|FG002|Overall Study|Returned out of specified time window|1
6019961|NCT00197496|9614012|FG000|Baseline to Discharge|not interested|1
6019962|NCT00197496|9614013|FG001|Baseline to Discharge|not interested|0
6019963|NCT00197496|9614012|FG000|Baseline to Discharge|MRSA|1
6019964|NCT00197496|9614013|FG001|Baseline to Discharge|MRSA|0
6019965|NCT00197496|9614012|FG000|Baseline to Discharge|Physician Decision|0
6019966|NCT00197496|9614013|FG001|Baseline to Discharge|Physician Decision|1
6019967|NCT00197496|9614012|FG000|Baseline to Discharge|Protocol Violation|0
6019968|NCT00197496|9614013|FG001|Baseline to Discharge|Protocol Violation|1
6019969|NCT00197496|9614012|FG000|Follow-up|Lost to Follow-up|2
6019970|NCT00197496|9614013|FG001|Follow-up|Lost to Follow-up|1
6019971|NCT00198029|9614019|FG000|Overall Study|Withdrawal by Subject|4
6019972|NCT00198107|9614043|FG000|Double-Blind Period|Adverse Event|1
6019973|NCT00198107|9614044|FG001|Double-Blind Period|Adverse Event|1
6019974|NCT00198107|9614045|FG002|Double-Blind Period|Adverse Event|0
6019975|NCT00198107|9614043|FG000|Double-Blind Period|Lack of Efficacy|2
6019976|NCT00198107|9614044|FG001|Double-Blind Period|Lack of Efficacy|0
6019977|NCT00198107|9614045|FG002|Double-Blind Period|Lack of Efficacy|0
6019978|NCT00198107|9614043|FG000|Double-Blind Period|Lost to Follow-up|2
6019979|NCT00198107|9614044|FG001|Double-Blind Period|Lost to Follow-up|1
6019980|NCT00198107|9614045|FG002|Double-Blind Period|Lost to Follow-up|0
6019981|NCT00198107|9614043|FG000|Double-Blind Period|Physician Decision|1
6019982|NCT00198107|9614044|FG001|Double-Blind Period|Physician Decision|0
6019983|NCT00198107|9614045|FG002|Double-Blind Period|Physician Decision|0
6019984|NCT00198107|9614043|FG000|Double-Blind Period|Withdrawal by Subject|0
6019985|NCT00198107|9614044|FG001|Double-Blind Period|Withdrawal by Subject|1
6019986|NCT00198107|9614045|FG002|Double-Blind Period|Withdrawal by Subject|0
6019987|NCT00198107|9614043|FG000|Pilot Add-On Aripiprazole +D-cycloserine|Withdrawal by Subject|0
6019988|NCT00198107|9614044|FG001|Pilot Add-On Aripiprazole +D-cycloserine|Withdrawal by Subject|0
6019989|NCT00198107|9614045|FG002|Pilot Add-On Aripiprazole +D-cycloserine|Withdrawal by Subject|2
6019990|NCT00198133|9614055|FG000|Overall Study|Disease progression|2
6019991|NCT00198133|9614056|FG001|Overall Study|Disease progression|5
6019992|NCT00198133|9614055|FG000|Overall Study|Adverse Event|1
6019993|NCT00198133|9614056|FG001|Overall Study|Adverse Event|3
6019994|NCT00198133|9614055|FG000|Overall Study|Withdrawal by Subject|1
6019995|NCT00198133|9614056|FG001|Overall Study|Withdrawal by Subject|0
6019996|NCT00198133|9614055|FG000|Overall Study|Physician Decision|1
6019997|NCT00198133|9614056|FG001|Overall Study|Physician Decision|0
6019998|NCT00198822|9614065|FG000|Overall Study|Lost to Follow-up|14
6019999|NCT00198822|9614066|FG001|Overall Study|Lost to Follow-up|20
6020000|NCT00198822|9614067|FG002|Overall Study|Lost to Follow-up|21
6020001|NCT00199381|9614075|FG000|Overall Study|Withdrawal by Subject|38
6020002|NCT00199381|9614075|FG000|Overall Study|Adverse Event|73
6020003|NCT00199381|9614075|FG000|Overall Study|Protocol Violation|6
6020004|NCT00199381|9614075|FG000|Overall Study|Lack of Efficacy|27
6020005|NCT00199381|9614075|FG000|Overall Study|Not including due to early termination|37
6020006|NCT00199381|9614075|FG000|Overall Study|Study termination by Sponsor|323
6020007|NCT00199797|9614079|FG000|Overall Study|Progressive Disease|1
6020008|NCT00199797|9614079|FG000|Overall Study|Adverse Event|1
6020009|NCT00199797|9614079|FG000|Overall Study|Physician Decision|1
6020010|NCT00199836|9614084|FG000|Overall Study|Progressive Disease|5
6020011|NCT00199836|9614084|FG000|Overall Study|Death|1
6020012|NCT00199849|9614092|FG000|Overall Study|Unrelated illness or complication|0
6020013|NCT00199849|9614093|FG001|Overall Study|Unrelated illness or complication|1
6020014|NCT00199849|9614094|FG002|Overall Study|Unrelated illness or complication|0
6020015|NCT00199849|9614092|FG000|Overall Study|Progressive disease requiring intervention|0
6020016|NCT00199849|9614093|FG001|Overall Study|Progressive disease requiring intervention|0
6020017|NCT00199849|9614094|FG002|Overall Study|Progressive disease requiring intervention|1
6020018|NCT00199849|9614092|FG000|Overall Study|Did not meet eligibility criteria - not dosed|0
6020019|NCT00199849|9614093|FG001|Overall Study|Did not meet eligibility criteria - not dosed|0
6020020|NCT00199849|9614094|FG002|Overall Study|Did not meet eligibility criteria - not dosed|1
6020021|NCT00199875|9614107|FG000|Overall Study|Withdrawal by Subject|0
6020022|NCT00199875|9614108|FG001|Overall Study|Withdrawal by Subject|0
6020023|NCT00199875|9614109|FG002|Overall Study|Withdrawal by Subject|0
6020024|NCT00199875|9614110|FG003|Overall Study|Withdrawal by Subject|0
6020025|NCT00199875|9614111|FG004|Overall Study|Withdrawal by Subject|1
6020026|NCT00199888|9614123|FG000|Overall Study|Lost to Follow-up|1
6020027|NCT00199901|9614129|FG000|Overall Study|Protocol Violation|2
6020028|NCT00199901|9614130|FG001|Overall Study|Protocol Violation|0
6020029|NCT00199901|9614129|FG000|Overall Study|Withdrawal by Subject|1
6020030|NCT00199901|9614130|FG001|Overall Study|Withdrawal by Subject|0
6020031|NCT00199901|9614129|FG000|Overall Study|Progressive Disease|24
6020032|NCT00199901|9614130|FG001|Overall Study|Progressive Disease|24
6020033|NCT00200057|9614147|FG000|Overall Study|Lack of Efficacy|3
6020034|NCT00200057|9614147|FG000|Overall Study|Exited due to terminal illness of PI|2
6020035|NCT00200057|9614147|FG000|Overall Study|Withdrawal by Subject|1
6020036|NCT00200057|9614147|FG000|Overall Study|Change in medical condition|1
6020037|NCT00200057|9614147|FG000|Overall Study|Infection|1
6020038|NCT00200057|9614147|FG000|Overall Study|Death|1
6047934|NCT00413920|9646967|FG001|Overall Study|Death|5
6047935|NCT00413920|9646966|FG000|Overall Study|Graft Loss|5
6047936|NCT00413920|9646967|FG001|Overall Study|Graft Loss|3
6047937|NCT00413959|9646973|FG000|Overall Study|Pt had only one cycle.|1
6047938|NCT00414011|9646977|FG000|Overall Study|Physician Decision|3
6047939|NCT00414011|9646977|FG000|Overall Study|Withdrawal by Subject|2
6047940|NCT00414050|9646986|FG000|Overall Study|Adverse Event|1
6047941|NCT00414050|9646987|FG001|Overall Study|Adverse Event|1
6047942|NCT00414050|9646988|FG002|Overall Study|Adverse Event|1
6047943|NCT00414050|9646989|FG003|Overall Study|Adverse Event|1
6047944|NCT00414050|9646986|FG000|Overall Study|Lost to Follow-up|2
6047945|NCT00414050|9646987|FG001|Overall Study|Lost to Follow-up|2
6047946|NCT00414050|9646988|FG002|Overall Study|Lost to Follow-up|1
6047947|NCT00414050|9646989|FG003|Overall Study|Lost to Follow-up|1
6047948|NCT00414050|9646986|FG000|Overall Study|Withdrawal by Subject|5
6047949|NCT00414050|9646987|FG001|Overall Study|Withdrawal by Subject|3
6047950|NCT00414050|9646988|FG002|Overall Study|Withdrawal by Subject|2
6047951|NCT00414050|9646989|FG003|Overall Study|Withdrawal by Subject|4
6047952|NCT00414050|9646986|FG000|Overall Study|Subject discontinued for other reason|1
6047953|NCT00414050|9646987|FG001|Overall Study|Subject discontinued for other reason|2
6047954|NCT00414050|9646988|FG002|Overall Study|Subject discontinued for other reason|2
6047955|NCT00414050|9646989|FG003|Overall Study|Subject discontinued for other reason|1
6047956|NCT00414050|9646986|FG000|Overall Study|Subject Moved|0
6047957|NCT00414050|9646987|FG001|Overall Study|Subject Moved|0
6047958|NCT00414050|9646988|FG002|Overall Study|Subject Moved|0
6047959|NCT00414050|9646989|FG003|Overall Study|Subject Moved|1
6047960|NCT00414076|9647001|FG000|Overall Study|Progression|1
6047961|NCT00414076|9647002|FG001|Overall Study|Progression|2
6047962|NCT00414076|9647001|FG000|Overall Study|Withdrawal by Subject|1
6047963|NCT00414076|9647002|FG001|Overall Study|Withdrawal by Subject|3
6047964|NCT00414076|9647001|FG000|Overall Study|Adverse Event|1
6047965|NCT00414076|9647002|FG001|Overall Study|Adverse Event|0
6047966|NCT00414310|9647038|FG000|Overall Study|Not treated|1
6047967|NCT00414310|9647039|FG001|Overall Study|Not treated|0
6047968|NCT00414388|9647047|FG000|Overall Study|Adverse Event|1
6047969|NCT00414440|9647054|FG000|Core Period|Withdrawal by Subject|70
6047970|NCT00414440|9647055|FG001|Core Period|Withdrawal by Subject|32
6047971|NCT00414440|9647054|FG000|Extension Period|Lost to Follow-up|44
6047972|NCT00414440|9647055|FG001|Extension Period|Lost to Follow-up|52
6047973|NCT00414440|9647054|FG000|Extension Period|Did not consent to continue follow up|61
6047974|NCT00414440|9647055|FG001|Extension Period|Did not consent to continue follow up|54
6047975|NCT00414440|9647054|FG000|Extension Period|Other|1
6047976|NCT00414440|9647055|FG001|Extension Period|Other|1
6047977|NCT00414440|9647054|FG000|Extension Period|Administrative|16
6047978|NCT00414440|9647055|FG001|Extension Period|Administrative|16
6047979|NCT00414440|9647054|FG000|Extension Period|Death|1
6020039|NCT00200356|9614175|FG000|Overall Study|Lack of Efficacy|3
6020040|NCT00200356|9614176|FG001|Overall Study|Lack of Efficacy|3
6020041|NCT00200356|9614175|FG000|Overall Study|Protocol Violation|4
6020042|NCT00200356|9614176|FG001|Overall Study|Protocol Violation|4
6020043|NCT00200356|9614175|FG000|Overall Study|Nontreatment|1
6020044|NCT00200356|9614176|FG001|Overall Study|Nontreatment|0
6020045|NCT00200850|9614194|FG000|Overall Study|relocation|1
6020046|NCT00200850|9614195|FG001|Overall Study|relocation|0
6020047|NCT00200850|9614196|FG002|Overall Study|relocation|1
6020048|NCT00200850|9614194|FG000|Overall Study|too busy|1
6020049|NCT00200850|9614195|FG001|Overall Study|too busy|0
6020050|NCT00200850|9614196|FG002|Overall Study|too busy|0
6020051|NCT00200850|9614194|FG000|Overall Study|Pregnancy|0
6020052|NCT00200850|9614195|FG001|Overall Study|Pregnancy|0
6020053|NCT00200850|9614196|FG002|Overall Study|Pregnancy|1
6020054|NCT00200850|9614194|FG000|Overall Study|Poor adherence|0
6020055|NCT00200850|9614195|FG001|Overall Study|Poor adherence|0
6020056|NCT00200850|9614196|FG002|Overall Study|Poor adherence|1
6020057|NCT00200850|9614194|FG000|Overall Study|optic neuritis|0
6020058|NCT00200850|9614195|FG001|Overall Study|optic neuritis|0
6020059|NCT00200850|9614196|FG002|Overall Study|optic neuritis|1
6020060|NCT00200850|9614194|FG000|Overall Study|Adverse Event|1
6020061|NCT00200850|9614195|FG001|Overall Study|Adverse Event|1
6020062|NCT00200850|9614196|FG002|Overall Study|Adverse Event|2
6020063|NCT00200967|9614225|FG000|First Treatment Period|Withdrawal by Subject|5
6020064|NCT00200967|9614226|FG001|First Treatment Period|Withdrawal by Subject|1
6020065|NCT00200967|9614225|FG000|First Treatment Period|Pregnancy|1
6020066|NCT00200967|9614226|FG001|First Treatment Period|Pregnancy|0
6020067|NCT00200967|9614225|FG000|Wash-out Period|Lost to Follow-up|0
6020068|NCT00200967|9614226|FG001|Wash-out Period|Lost to Follow-up|1
6020069|NCT00200967|9614225|FG000|Second Treatment Period|Withdrawal by Subject|1
6020070|NCT00200967|9614226|FG001|Second Treatment Period|Withdrawal by Subject|2
6020071|NCT00200967|9614225|FG000|Run-out Period|Lost to Follow-up|1
6020072|NCT00200967|9614226|FG001|Run-out Period|Lost to Follow-up|0
6020073|NCT00201006|9614235|FG000|Overall Study|Withdrawal by Subject|7
6020074|NCT00201006|9614236|FG001|Overall Study|Withdrawal by Subject|2
6020075|NCT00201006|9614237|FG002|Overall Study|Withdrawal by Subject|3
6020076|NCT00201006|9614235|FG000|Overall Study|Adverse Event|1
6020077|NCT00201006|9614236|FG001|Overall Study|Adverse Event|0
6020078|NCT00201006|9614237|FG002|Overall Study|Adverse Event|1
6020079|NCT00201201|9614264|FG000|Overall Study|Death|0
6020080|NCT00201201|9614265|FG001|Overall Study|Death|2
6020081|NCT00201201|9614264|FG000|Overall Study|Withdrawal by Subject|5
6020082|NCT00201201|9614265|FG001|Overall Study|Withdrawal by Subject|5
6020083|NCT00201643|9614298|FG000|Overall Study|Withdrawal by Subject|5
6020084|NCT00201643|9614299|FG001|Overall Study|Withdrawal by Subject|4
6020085|NCT00201851|9614353|FG000|Overall Study|Lost to Follow-up|2
6020086|NCT00201851|9614354|FG001|Overall Study|Lost to Follow-up|1
6020087|NCT00201851|9614355|FG002|Overall Study|Lost to Follow-up|0
6020088|NCT00201851|9614353|FG000|Overall Study|Ineligible post enrollment|6
6020089|NCT00201851|9614354|FG001|Overall Study|Ineligible post enrollment|1
6020090|NCT00201851|9614355|FG002|Overall Study|Ineligible post enrollment|1
6020091|NCT00202644|9614389|FG000|Overall Study|Adverse Event|12
6020092|NCT00202644|9614390|FG001|Overall Study|Adverse Event|13
6020093|NCT00202644|9614389|FG000|Overall Study|Withdrawal by Subject|8
6020094|NCT00202644|9614390|FG001|Overall Study|Withdrawal by Subject|6
6020095|NCT00202644|9614389|FG000|Overall Study|Lack of Efficacy|6
6020096|NCT00202644|9614390|FG001|Overall Study|Lack of Efficacy|6
6020097|NCT00202644|9614389|FG000|Overall Study|Lost to Follow-up|0
6020098|NCT00202644|9614390|FG001|Overall Study|Lost to Follow-up|1
6020099|NCT00202644|9614389|FG000|Overall Study|Other|9
6020100|NCT00202644|9614390|FG001|Overall Study|Other|1
6020101|NCT00202839|9614403|FG000|Overall Study|Adverse Event|1
6020102|NCT00202839|9614404|FG001|Overall Study|Adverse Event|5
6020103|NCT00202839|9614403|FG000|Overall Study|Physician Decision|12
6020104|NCT00202839|9614404|FG001|Overall Study|Physician Decision|0
6020105|NCT00202839|9614403|FG000|Overall Study|Withdrawal by Subject|6
6020106|NCT00202839|9614404|FG001|Overall Study|Withdrawal by Subject|2
6020107|NCT00202839|9614403|FG000|Overall Study|Protocol Violation|2
6020108|NCT00202839|9614404|FG001|Overall Study|Protocol Violation|1
6020109|NCT00202839|9614403|FG000|Overall Study|Lost to Follow-up|3
6020110|NCT00202839|9614404|FG001|Overall Study|Lost to Follow-up|2
6020111|NCT00203021|9614416|FG000|Overall Study|Death|4
6020112|NCT00203021|9614417|FG001|Overall Study|Death|1
6020113|NCT00203021|9614416|FG000|Overall Study|Adverse Event|10
6020114|NCT00203021|9614417|FG001|Overall Study|Adverse Event|5
6020115|NCT00203021|9614416|FG000|Overall Study|Withdrawal by Subject|45
6020116|NCT00203021|9614417|FG001|Overall Study|Withdrawal by Subject|48
6020117|NCT00203021|9614416|FG000|Overall Study|Lost to Follow-up|9
6020118|NCT00203021|9614417|FG001|Overall Study|Lost to Follow-up|7
6020119|NCT00203021|9614416|FG000|Overall Study|Other than specified|11
6020120|NCT00203021|9614417|FG001|Overall Study|Other than specified|16
6020121|NCT00203047|9614425|FG000|Overall Study|Ongoing: in database - January 29, 2009|131
6020122|NCT00203047|9614426|FG001|Overall Study|Ongoing: in database - January 29, 2009|109
6020123|NCT00203047|9614425|FG000|Overall Study|Ongoing: not in database - Jan 29, 2009|5
6020124|NCT00203047|9614426|FG001|Overall Study|Ongoing: not in database - Jan 29, 2009|1
6020125|NCT00203047|9614425|FG000|Overall Study|Withdrawal by Subject|13
6020126|NCT00203047|9614426|FG001|Overall Study|Withdrawal by Subject|47
6020127|NCT00203047|9614425|FG000|Overall Study|Teva requested participant withdrawal|1
6020128|NCT00203047|9614426|FG001|Overall Study|Teva requested participant withdrawal|1
6020129|NCT00203047|9614425|FG000|Overall Study|Physician Decision|8
6020130|NCT00203047|9614426|FG001|Overall Study|Physician Decision|7
6020131|NCT00203047|9614425|FG000|Overall Study|Non-compliance|4
6020132|NCT00203047|9614426|FG001|Overall Study|Non-compliance|8
6020133|NCT00203047|9614425|FG000|Overall Study|Protocol Violation|1
6020134|NCT00203047|9614426|FG001|Overall Study|Protocol Violation|0
6020135|NCT00203047|9614425|FG000|Overall Study|Lost to Follow-up|11
6020136|NCT00203047|9614426|FG001|Overall Study|Lost to Follow-up|5
6020137|NCT00203047|9614425|FG000|Overall Study|Adverse Event|8
6020138|NCT00203047|9614426|FG001|Overall Study|Adverse Event|18
6020139|NCT00203047|9614425|FG000|Overall Study|Death|1
6020140|NCT00203047|9614426|FG001|Overall Study|Death|2
6020141|NCT00203047|9614425|FG000|Overall Study|Pregnancy|3
6020142|NCT00203047|9614426|FG001|Overall Study|Pregnancy|0
6020143|NCT00203047|9614425|FG000|Overall Study|Other|5
6020144|NCT00203047|9614426|FG001|Overall Study|Other|5
6020145|NCT00203242|9614454|FG000|Overall Study|Lost to Follow-up|1
6020146|NCT00203268|9614458|FG000|Early Treatment|only treated one headache|2
6020147|NCT00203268|9614458|FG000|Early Treatment|Lost to Follow-up|1
6020148|NCT00203268|9614458|FG000|Early Treatment|Withdrawal by Subject|1
6020149|NCT00203294|9614466|FG000|Overall Study|Withdrawal by Subject|8
6020150|NCT00203294|9614467|FG001|Overall Study|Withdrawal by Subject|13
6020151|NCT00203307|9614475|FG000|First Intervention|Adverse Event|2
6020152|NCT00203307|9614476|FG001|First Intervention|Adverse Event|0
6020153|NCT00203411|9614482|FG000|Follow-up|Progressive Disease|4
6020154|NCT00203424|9614487|FG000|Treatment Period|Withdrawal by Subject|4
6020155|NCT00203424|9614487|FG000|Treatment Period|Adverse Event|5
6020156|NCT00203424|9614487|FG000|Treatment Period|progressive disease|2
6020157|NCT00203424|9614487|FG000|Follow-up Period|Withdrawal by Subject|1
6020158|NCT00203424|9614487|FG000|Follow-up Period|progressive disease|4
6020159|NCT00203424|9614487|FG000|Follow-up Period|Lost to Follow-up|1
6020160|NCT00203476|9614494|FG000|Overall Study|Lost to Follow-up|1
6020161|NCT00203476|9614495|FG001|Overall Study|Lost to Follow-up|0
6020162|NCT00203476|9614496|FG002|Overall Study|Lost to Follow-up|0
6020163|NCT00203476|9614494|FG000|Overall Study|Withdrawal by Subject|0
6020164|NCT00203476|9614495|FG001|Overall Study|Withdrawal by Subject|1
6020165|NCT00203476|9614496|FG002|Overall Study|Withdrawal by Subject|0
6020166|NCT00203502|9614504|FG000|Overall Study|Death|1
6020167|NCT00203892|9614511|FG000|Overall Study|Physician Decision|1
6020168|NCT00203892|9614512|FG001|Overall Study|Physician Decision|2
6020169|NCT00203892|9614513|FG002|Overall Study|Physician Decision|0
6020170|NCT00203892|9614511|FG000|Overall Study|Death|1
6020171|NCT00203892|9614512|FG001|Overall Study|Death|0
6020172|NCT00203892|9614513|FG002|Overall Study|Death|0
6020173|NCT00203996|9614540|FG000|Overall Study|Lost to Follow-up|0
6020174|NCT00203996|9614541|FG001|Overall Study|Lost to Follow-up|0
6020175|NCT00203996|9614542|FG002|Overall Study|Lost to Follow-up|0
6020176|NCT00203996|9614543|FG003|Overall Study|Lost to Follow-up|1
6020177|NCT00203996|9614544|FG004|Overall Study|Lost to Follow-up|0
6020178|NCT00203996|9614545|FG005|Overall Study|Lost to Follow-up|0
6020179|NCT00203996|9614546|FG006|Overall Study|Lost to Follow-up|0
6020180|NCT00203996|9614547|FG007|Overall Study|Lost to Follow-up|0
6020181|NCT00203996|9614548|FG008|Overall Study|Lost to Follow-up|0
6020182|NCT00203996|9614549|FG009|Overall Study|Lost to Follow-up|0
6020183|NCT00203996|9614540|FG000|Overall Study|Protocol Violation|0
6020184|NCT00203996|9614541|FG001|Overall Study|Protocol Violation|0
6020185|NCT00203996|9614542|FG002|Overall Study|Protocol Violation|0
6020186|NCT00203996|9614543|FG003|Overall Study|Protocol Violation|6
6020187|NCT00203996|9614544|FG004|Overall Study|Protocol Violation|1
6020188|NCT00203996|9614545|FG005|Overall Study|Protocol Violation|0
6020189|NCT00203996|9614546|FG006|Overall Study|Protocol Violation|0
6020190|NCT00203996|9614547|FG007|Overall Study|Protocol Violation|0
6020191|NCT00203996|9614548|FG008|Overall Study|Protocol Violation|0
6020192|NCT00203996|9614549|FG009|Overall Study|Protocol Violation|0
6020193|NCT00203996|9614540|FG000|Overall Study|Physician Decision|0
6020194|NCT00203996|9614541|FG001|Overall Study|Physician Decision|0
6020195|NCT00203996|9614542|FG002|Overall Study|Physician Decision|0
6020196|NCT00203996|9614543|FG003|Overall Study|Physician Decision|2
6020197|NCT00203996|9614544|FG004|Overall Study|Physician Decision|0
6020198|NCT00203996|9614545|FG005|Overall Study|Physician Decision|0
6020199|NCT00203996|9614546|FG006|Overall Study|Physician Decision|0
6020200|NCT00203996|9614547|FG007|Overall Study|Physician Decision|0
6020201|NCT00203996|9614548|FG008|Overall Study|Physician Decision|0
6020202|NCT00203996|9614549|FG009|Overall Study|Physician Decision|1
6020203|NCT00203996|9614540|FG000|Overall Study|CPAP machine malfunction|0
6020204|NCT00203996|9614541|FG001|Overall Study|CPAP machine malfunction|0
6020205|NCT00203996|9614542|FG002|Overall Study|CPAP machine malfunction|0
6020206|NCT00203996|9614543|FG003|Overall Study|CPAP machine malfunction|1
6020207|NCT00203996|9614544|FG004|Overall Study|CPAP machine malfunction|0
6020208|NCT00203996|9614545|FG005|Overall Study|CPAP machine malfunction|0
6020209|NCT00203996|9614546|FG006|Overall Study|CPAP machine malfunction|0
6020210|NCT00203996|9614547|FG007|Overall Study|CPAP machine malfunction|0
6020211|NCT00203996|9614548|FG008|Overall Study|CPAP machine malfunction|0
6020212|NCT00203996|9614549|FG009|Overall Study|CPAP machine malfunction|0
6020213|NCT00203996|9614540|FG000|Overall Study|Scheduling issue|0
6020214|NCT00203996|9614541|FG001|Overall Study|Scheduling issue|0
6020215|NCT00203996|9614542|FG002|Overall Study|Scheduling issue|0
6020216|NCT00203996|9614543|FG003|Overall Study|Scheduling issue|0
6020217|NCT00203996|9614544|FG004|Overall Study|Scheduling issue|0
6020218|NCT00203996|9614545|FG005|Overall Study|Scheduling issue|0
6020219|NCT00203996|9614546|FG006|Overall Study|Scheduling issue|0
6020220|NCT00203996|9614547|FG007|Overall Study|Scheduling issue|2
6020221|NCT00203996|9614548|FG008|Overall Study|Scheduling issue|0
6020222|NCT00203996|9614549|FG009|Overall Study|Scheduling issue|0
6020223|NCT00205179|9614580|FG000|Overall Study|Death|0
6020224|NCT00205179|9614581|FG001|Overall Study|Death|2
6020225|NCT00205179|9614580|FG000|Overall Study|Physician Decision|1
6020226|NCT00205179|9614581|FG001|Overall Study|Physician Decision|1
6020227|NCT00205179|9614580|FG000|Overall Study|Adverse Event|1
6020228|NCT00205179|9614581|FG001|Overall Study|Adverse Event|1
6020229|NCT00205699|9614627|FG000|Overall Study|Lost to Follow-up|1
6020230|NCT00205699|9614628|FG001|Overall Study|Lost to Follow-up|3
6020231|NCT00205699|9614629|FG002|Overall Study|Lost to Follow-up|5
6020232|NCT00205699|9614627|FG000|Overall Study|Adverse Event|1
6020233|NCT00205699|9614628|FG001|Overall Study|Adverse Event|0
6020234|NCT00205699|9614629|FG002|Overall Study|Adverse Event|0
6020235|NCT00205699|9614627|FG000|Overall Study|Withdrawal by Subject|1
6020236|NCT00205699|9614628|FG001|Overall Study|Withdrawal by Subject|2
6020237|NCT00205699|9614629|FG002|Overall Study|Withdrawal by Subject|1
6020238|NCT00205699|9614627|FG000|Overall Study|Lack of Efficacy|0
6020239|NCT00205699|9614628|FG001|Overall Study|Lack of Efficacy|1
6020240|NCT00205699|9614629|FG002|Overall Study|Lack of Efficacy|0
6020241|NCT00205712|9614642|FG000|Overall Study|Lost to Follow-up|0
6020242|NCT00205712|9614643|FG001|Overall Study|Lost to Follow-up|1
6020243|NCT00205777|9614655|FG000|Core Study (Up to 3 Years)|Adverse Event|260
6020244|NCT00205777|9614656|FG001|Core Study (Up to 3 Years)|Adverse Event|267
6020245|NCT00205777|9614657|FG002|Core Study (Up to 3 Years)|Adverse Event|252
6020246|NCT00205777|9614658|FG003|Core Study (Up to 3 Years)|Adverse Event|232
6020247|NCT00205777|9614659|FG004|Core Study (Up to 3 Years)|Adverse Event|0
6020248|NCT00205777|9614660|FG005|Core Study (Up to 3 Years)|Adverse Event|0
6020249|NCT00205777|9614655|FG000|Core Study (Up to 3 Years)|Death|9
6020250|NCT00205777|9614656|FG001|Core Study (Up to 3 Years)|Death|7
6020251|NCT00205777|9614657|FG002|Core Study (Up to 3 Years)|Death|14
6020252|NCT00205777|9614658|FG003|Core Study (Up to 3 Years)|Death|7
6020253|NCT00205777|9614659|FG004|Core Study (Up to 3 Years)|Death|0
6020254|NCT00205777|9614660|FG005|Core Study (Up to 3 Years)|Death|0
6020255|NCT00205777|9614655|FG000|Core Study (Up to 3 Years)|Failed to return|40
6020256|NCT00205777|9614656|FG001|Core Study (Up to 3 Years)|Failed to return|25
6020257|NCT00205777|9614657|FG002|Core Study (Up to 3 Years)|Failed to return|27
6020258|NCT00205777|9614658|FG003|Core Study (Up to 3 Years)|Failed to return|27
6020259|NCT00205777|9614659|FG004|Core Study (Up to 3 Years)|Failed to return|0
6020260|NCT00205777|9614660|FG005|Core Study (Up to 3 Years)|Failed to return|0
6020261|NCT00205777|9614655|FG000|Core Study (Up to 3 Years)|Other Event|49
6020262|NCT00205777|9614656|FG001|Core Study (Up to 3 Years)|Other Event|52
6020263|NCT00205777|9614657|FG002|Core Study (Up to 3 Years)|Other Event|41
6020264|NCT00205777|9614658|FG003|Core Study (Up to 3 Years)|Other Event|58
6020265|NCT00205777|9614659|FG004|Core Study (Up to 3 Years)|Other Event|0
6020266|NCT00205777|9614660|FG005|Core Study (Up to 3 Years)|Other Event|0
6020267|NCT00205777|9614655|FG000|Core Study (Up to 3 Years)|Withdrawal by Subject|144
6020268|NCT00205777|9614656|FG001|Core Study (Up to 3 Years)|Withdrawal by Subject|169
6020269|NCT00205777|9614657|FG002|Core Study (Up to 3 Years)|Withdrawal by Subject|149
6020270|NCT00205777|9614658|FG003|Core Study (Up to 3 Years)|Withdrawal by Subject|162
6020271|NCT00205777|9614659|FG004|Core Study (Up to 3 Years)|Withdrawal by Subject|0
6020272|NCT00205777|9614660|FG005|Core Study (Up to 3 Years)|Withdrawal by Subject|0
6020273|NCT00205777|9614655|FG000|Core Study (Up to 3 Years)|Protocol Violation|53
6020274|NCT00205777|9614656|FG001|Core Study (Up to 3 Years)|Protocol Violation|55
6020275|NCT00205777|9614657|FG002|Core Study (Up to 3 Years)|Protocol Violation|50
6020276|NCT00205777|9614658|FG003|Core Study (Up to 3 Years)|Protocol Violation|42
6020277|NCT00205777|9614659|FG004|Core Study (Up to 3 Years)|Protocol Violation|0
6020278|NCT00205777|9614660|FG005|Core Study (Up to 3 Years)|Protocol Violation|0
6020279|NCT00205777|9614655|FG000|Core Study (Up to 3 Years)|Lack of Efficacy|52
6020280|NCT00205777|9614656|FG001|Core Study (Up to 3 Years)|Lack of Efficacy|52
6020281|NCT00205777|9614657|FG002|Core Study (Up to 3 Years)|Lack of Efficacy|39
6020282|NCT00205777|9614658|FG003|Core Study (Up to 3 Years)|Lack of Efficacy|75
6020283|NCT00205777|9614659|FG004|Core Study (Up to 3 Years)|Lack of Efficacy|0
6020284|NCT00205777|9614660|FG005|Core Study (Up to 3 Years)|Lack of Efficacy|0
6020285|NCT00205777|9614655|FG000|Core Study (Up to 3 Years)|Randomized but not treated|21
6020286|NCT00205777|9614656|FG001|Core Study (Up to 3 Years)|Randomized but not treated|32
6020287|NCT00205777|9614657|FG002|Core Study (Up to 3 Years)|Randomized but not treated|35
6020288|NCT00205777|9614658|FG003|Core Study (Up to 3 Years)|Randomized but not treated|29
6020289|NCT00205777|9614659|FG004|Core Study (Up to 3 Years)|Randomized but not treated|0
6020290|NCT00205777|9614660|FG005|Core Study (Up to 3 Years)|Randomized but not treated|0
6020291|NCT00205777|9614655|FG000|Completed Core Study, Entered SE I|Withdrawal by Subject|180
6020292|NCT00205777|9614656|FG001|Completed Core Study, Entered SE I|Withdrawal by Subject|158
6020293|NCT00205777|9614657|FG002|Completed Core Study, Entered SE I|Withdrawal by Subject|160
6020294|NCT00205777|9614658|FG003|Completed Core Study, Entered SE I|Withdrawal by Subject|174
6020295|NCT00205777|9614659|FG004|Completed Core Study, Entered SE I|Withdrawal by Subject|0
6020296|NCT00205777|9614660|FG005|Completed Core Study, Entered SE I|Withdrawal by Subject|0
6020297|NCT00205777|9614655|FG000|Completed Core Study, Entered SE I|Other Event|52
6020298|NCT00205777|9614656|FG001|Completed Core Study, Entered SE I|Other Event|46
6020299|NCT00205777|9614657|FG002|Completed Core Study, Entered SE I|Other Event|47
6020300|NCT00205777|9614658|FG003|Completed Core Study, Entered SE I|Other Event|50
6020301|NCT00205777|9614659|FG004|Completed Core Study, Entered SE I|Other Event|0
6020302|NCT00205777|9614660|FG005|Completed Core Study, Entered SE I|Other Event|0
6020303|NCT00205777|9614655|FG000|Study Extension I|Adverse Event|57
6020304|NCT00205777|9614656|FG001|Study Extension I|Adverse Event|0
6020305|NCT00205777|9614657|FG002|Study Extension I|Adverse Event|0
6020306|NCT00205777|9614658|FG003|Study Extension I|Adverse Event|61
6020307|NCT00205777|9614659|FG004|Study Extension I|Adverse Event|58
6020308|NCT00205777|9614660|FG005|Study Extension I|Adverse Event|0
6020309|NCT00205777|9614655|FG000|Study Extension I|Death|5
6020310|NCT00205777|9614656|FG001|Study Extension I|Death|0
6020311|NCT00205777|9614657|FG002|Study Extension I|Death|0
6020312|NCT00205777|9614658|FG003|Study Extension I|Death|1
6020313|NCT00205777|9614659|FG004|Study Extension I|Death|2
6020314|NCT00205777|9614660|FG005|Study Extension I|Death|0
6020315|NCT00205777|9614655|FG000|Study Extension I|Withdrawal by Subject|99
6020316|NCT00205777|9614656|FG001|Study Extension I|Withdrawal by Subject|0
6020317|NCT00205777|9614657|FG002|Study Extension I|Withdrawal by Subject|0
6020318|NCT00205777|9614658|FG003|Study Extension I|Withdrawal by Subject|106
6020319|NCT00205777|9614659|FG004|Study Extension I|Withdrawal by Subject|89
6020320|NCT00205777|9614660|FG005|Study Extension I|Withdrawal by Subject|0
6020321|NCT00205777|9614655|FG000|Study Extension I|Protocol Violation|4
6020322|NCT00205777|9614656|FG001|Study Extension I|Protocol Violation|0
6020323|NCT00205777|9614657|FG002|Study Extension I|Protocol Violation|0
6020324|NCT00205777|9614658|FG003|Study Extension I|Protocol Violation|8
6020325|NCT00205777|9614659|FG004|Study Extension I|Protocol Violation|8
6020326|NCT00205777|9614660|FG005|Study Extension I|Protocol Violation|0
6020327|NCT00205777|9614655|FG000|Study Extension I|Lack of Efficacy|0
6020328|NCT00205777|9614656|FG001|Study Extension I|Lack of Efficacy|0
6020329|NCT00205777|9614657|FG002|Study Extension I|Lack of Efficacy|0
6020330|NCT00205777|9614658|FG003|Study Extension I|Lack of Efficacy|1
6020331|NCT00205777|9614659|FG004|Study Extension I|Lack of Efficacy|2
6020332|NCT00205777|9614660|FG005|Study Extension I|Lack of Efficacy|0
6020333|NCT00205777|9614655|FG000|Study Extension I|Failed to return|15
6020334|NCT00205777|9614656|FG001|Study Extension I|Failed to return|0
6020335|NCT00205777|9614657|FG002|Study Extension I|Failed to return|0
6020336|NCT00205777|9614658|FG003|Study Extension I|Failed to return|17
6020337|NCT00205777|9614659|FG004|Study Extension I|Failed to return|13
6020338|NCT00205777|9614660|FG005|Study Extension I|Failed to return|0
6020339|NCT00205777|9614655|FG000|Study Extension I|Other Event|34
6020340|NCT00205777|9614656|FG001|Study Extension I|Other Event|0
6020341|NCT00205777|9614657|FG002|Study Extension I|Other Event|0
6020342|NCT00205777|9614658|FG003|Study Extension I|Other Event|34
6020343|NCT00205777|9614659|FG004|Study Extension I|Other Event|29
6020344|NCT00205777|9614660|FG005|Study Extension I|Other Event|0
6020345|NCT00205777|9614655|FG000|Study Extension I|Withdrawn as per protocol|0
6020346|NCT00205777|9614656|FG001|Study Extension I|Withdrawn as per protocol|0
6020347|NCT00205777|9614657|FG002|Study Extension I|Withdrawn as per protocol|1070
6020348|NCT00205777|9614658|FG003|Study Extension I|Withdrawn as per protocol|0
6020349|NCT00205777|9614659|FG004|Study Extension I|Withdrawn as per protocol|0
6020350|NCT00205777|9614660|FG005|Study Extension I|Withdrawn as per protocol|0
6020351|NCT00205777|9614655|FG000|Completed SE I, Entered Extension SE II|No-consent/eligible/SEII continuing site|273
6020352|NCT00205777|9614656|FG001|Completed SE I, Entered Extension SE II|No-consent/eligible/SEII continuing site|0
6020353|NCT00205777|9614657|FG002|Completed SE I, Entered Extension SE II|No-consent/eligible/SEII continuing site|0
6020354|NCT00205777|9614658|FG003|Completed SE I, Entered Extension SE II|No-consent/eligible/SEII continuing site|240
6020355|NCT00205777|9614659|FG004|Completed SE I, Entered Extension SE II|No-consent/eligible/SEII continuing site|258
6020356|NCT00205777|9614660|FG005|Completed SE I, Entered Extension SE II|No-consent/eligible/SEII continuing site|0
6020357|NCT00205777|9614655|FG000|Study Extension II|Adverse Event|0
6020358|NCT00205777|9614656|FG001|Study Extension II|Adverse Event|0
6020359|NCT00205777|9614657|FG002|Study Extension II|Adverse Event|0
6020360|NCT00205777|9614658|FG003|Study Extension II|Adverse Event|14
6020361|NCT00205777|9614659|FG004|Study Extension II|Adverse Event|0
6020362|NCT00205777|9614660|FG005|Study Extension II|Adverse Event|30
6020363|NCT00205777|9614655|FG000|Study Extension II|Death|0
6020364|NCT00205777|9614656|FG001|Study Extension II|Death|0
6020365|NCT00205777|9614657|FG002|Study Extension II|Death|0
6020366|NCT00205777|9614658|FG003|Study Extension II|Death|2
6020367|NCT00205777|9614659|FG004|Study Extension II|Death|0
6020368|NCT00205777|9614660|FG005|Study Extension II|Death|5
6020369|NCT00205777|9614655|FG000|Study Extension II|Withdrawal by Subject|0
6020370|NCT00205777|9614656|FG001|Study Extension II|Withdrawal by Subject|0
6020371|NCT00205777|9614657|FG002|Study Extension II|Withdrawal by Subject|0
6020372|NCT00205777|9614658|FG003|Study Extension II|Withdrawal by Subject|35
6020373|NCT00205777|9614659|FG004|Study Extension II|Withdrawal by Subject|0
6020374|NCT00205777|9614660|FG005|Study Extension II|Withdrawal by Subject|59
6020375|NCT00205777|9614655|FG000|Study Extension II|Protocol Violation|0
6020376|NCT00205777|9614656|FG001|Study Extension II|Protocol Violation|0
6020377|NCT00205777|9614657|FG002|Study Extension II|Protocol Violation|0
6020378|NCT00205777|9614658|FG003|Study Extension II|Protocol Violation|1
6020379|NCT00205777|9614659|FG004|Study Extension II|Protocol Violation|0
6020380|NCT00205777|9614660|FG005|Study Extension II|Protocol Violation|10
6020381|NCT00205777|9614655|FG000|Study Extension II|Lack of Efficacy|0
6020382|NCT00205777|9614656|FG001|Study Extension II|Lack of Efficacy|0
6020383|NCT00205777|9614657|FG002|Study Extension II|Lack of Efficacy|0
6020384|NCT00205777|9614658|FG003|Study Extension II|Lack of Efficacy|0
6020385|NCT00205777|9614659|FG004|Study Extension II|Lack of Efficacy|0
6020386|NCT00205777|9614660|FG005|Study Extension II|Lack of Efficacy|1
6020387|NCT00205777|9614655|FG000|Study Extension II|Failed to return|0
6020388|NCT00205777|9614656|FG001|Study Extension II|Failed to return|0
6020389|NCT00205777|9614657|FG002|Study Extension II|Failed to return|0
6020390|NCT00205777|9614658|FG003|Study Extension II|Failed to return|14
6020391|NCT00205777|9614659|FG004|Study Extension II|Failed to return|0
6020392|NCT00205777|9614660|FG005|Study Extension II|Failed to return|26
6020393|NCT00205777|9614655|FG000|Study Extension II|Other Event|0
6020394|NCT00205777|9614656|FG001|Study Extension II|Other Event|0
6020395|NCT00205777|9614657|FG002|Study Extension II|Other Event|0
6020396|NCT00205777|9614658|FG003|Study Extension II|Other Event|12
6020397|NCT00205777|9614659|FG004|Study Extension II|Other Event|0
6020398|NCT00205777|9614660|FG005|Study Extension II|Other Event|20
6020399|NCT00205777|9614655|FG000|Study Extension II|Enrolled but not treated|0
6020400|NCT00205777|9614656|FG001|Study Extension II|Enrolled but not treated|0
6020401|NCT00205777|9614657|FG002|Study Extension II|Enrolled but not treated|0
6020402|NCT00205777|9614658|FG003|Study Extension II|Enrolled but not treated|71
6020403|NCT00205777|9614659|FG004|Study Extension II|Enrolled but not treated|0
6020404|NCT00205777|9614660|FG005|Study Extension II|Enrolled but not treated|131
6020405|NCT00205803|9614677|FG000|Infant Series|Lost to Follow-up|10
6020406|NCT00205803|9614678|FG001|Infant Series|Lost to Follow-up|4
6020407|NCT00205803|9614677|FG000|Infant Series|Withdrawal by Subject|2
6020408|NCT00205803|9614678|FG001|Infant Series|Withdrawal by Subject|5
6020409|NCT00205803|9614677|FG000|Infant Series|Physician Decision|3
6020410|NCT00205803|9614678|FG001|Infant Series|Physician Decision|1
6020411|NCT00205803|9614677|FG000|Infant Series|Protocol Violation|1
6020412|NCT00205803|9614678|FG001|Infant Series|Protocol Violation|0
6020413|NCT00205803|9614677|FG000|Infant Series|Lost Kaiser coverage|0
6020414|NCT00205803|9614678|FG001|Infant Series|Lost Kaiser coverage|1
6020415|NCT00205803|9614677|FG000|Infant Series|Non-compliant|1
6020416|NCT00205803|9614678|FG001|Infant Series|Non-compliant|0
6020417|NCT00205803|9614677|FG000|Infant Series|Sponsor request|1
6020418|NCT00205803|9614678|FG001|Infant Series|Sponsor request|0
6020419|NCT00205803|9614677|FG000|After Infant Series|Adverse Event|1
6020420|NCT00205803|9614678|FG001|After Infant Series|Adverse Event|1
6020421|NCT00205803|9614677|FG000|After Infant Series|Protocol Violation|1
6020422|NCT00205803|9614678|FG001|After Infant Series|Protocol Violation|1
6020423|NCT00205803|9614677|FG000|After Infant Series|Lost to Follow-up|2
6020424|NCT00205803|9614678|FG001|After Infant Series|Lost to Follow-up|1
6020425|NCT00205803|9614677|FG000|After Infant Series|Physician Decision|3
6020426|NCT00205803|9614678|FG001|After Infant Series|Physician Decision|2
6020427|NCT00205803|9614677|FG000|After Infant Series|Withdrawal by Subject|1
6020428|NCT00205803|9614678|FG001|After Infant Series|Withdrawal by Subject|4
6020429|NCT00205803|9614677|FG000|After Infant Series|Other|10
6020430|NCT00205803|9614678|FG001|After Infant Series|Other|4
6020431|NCT00205803|9614677|FG000|Toddler Dose|Lost to Follow-up|2
6020432|NCT00205803|9614678|FG001|Toddler Dose|Lost to Follow-up|3
6020433|NCT00205855|9614702|FG000|Overall Study|Only received temporary implants|16
6020434|NCT00205855|9614702|FG000|Overall Study|Withdrawal by Subject|5
6020435|NCT00205881|9614706|FG000|Overall Study|Withdrawal by Subject|16
6020436|NCT00206076|9614713|FG000|Overall Study|Physician Decision|2
6020437|NCT00206076|9614714|FG001|Overall Study|Physician Decision|0
6020438|NCT00206076|9614713|FG000|Overall Study|Withdrawal by Subject|1
6020439|NCT00206076|9614714|FG001|Overall Study|Withdrawal by Subject|1
6020440|NCT00206102|9614724|FG000|Overall Study|Adverse Event|119
6020441|NCT00206102|9614725|FG001|Overall Study|Adverse Event|82
6020442|NCT00206102|9614724|FG000|Overall Study|Protocol Violation|0
6020443|NCT00206102|9614725|FG001|Overall Study|Protocol Violation|2
6020444|NCT00206102|9614724|FG000|Overall Study|Lack of therapeutic response|16
6020445|NCT00206102|9614725|FG001|Overall Study|Lack of therapeutic response|11
6020446|NCT00206102|9614724|FG000|Overall Study|Lost to Follow-up|95
6020447|NCT00206102|9614725|FG001|Overall Study|Lost to Follow-up|66
6020448|NCT00206102|9614724|FG000|Overall Study|Withdrawal by Subject|118
6020449|NCT00206102|9614725|FG001|Overall Study|Withdrawal by Subject|101
6020450|NCT00206102|9614724|FG000|Overall Study|Study-specific discontinuation criteria|18
6020451|NCT00206102|9614725|FG001|Overall Study|Study-specific discontinuation criteria|17
6020452|NCT00206102|9614724|FG000|Overall Study|None of those categories|42
6020453|NCT00206102|9614725|FG001|Overall Study|None of those categories|36
6020454|NCT00206323|9614733|FG000|Overall Study|Lack of Efficacy|4
6020455|NCT00206323|9614734|FG001|Overall Study|Lack of Efficacy|1
6020456|NCT00206323|9614733|FG000|Overall Study|Adverse Event|1
6020457|NCT00206323|9614734|FG001|Overall Study|Adverse Event|1
6020458|NCT00206323|9614733|FG000|Overall Study|Lost to Follow-up|1
6020459|NCT00206323|9614734|FG001|Overall Study|Lost to Follow-up|1
6020460|NCT00206427|9614744|FG000|Overall Study|Adverse Event|2
6020461|NCT00206440|9614750|FG000|Overall Study|Protocol Violation|1
6020462|NCT00206440|9614751|FG001|Overall Study|Protocol Violation|2
6020463|NCT00206440|9614750|FG000|Overall Study|Adverse Event|4
6020464|NCT00206440|9614751|FG001|Overall Study|Adverse Event|2
6020465|NCT00206518|9614759|FG000|Overall Study|Lack of Efficacy|6
6020466|NCT00206518|9614760|FG001|Overall Study|Lack of Efficacy|4
6020467|NCT00206518|9614759|FG000|Overall Study|Adverse Event|2
6020468|NCT00206518|9614760|FG001|Overall Study|Adverse Event|1
6020469|NCT00206518|9614759|FG000|Overall Study|Physician Decision|1
6020470|NCT00206518|9614760|FG001|Overall Study|Physician Decision|0
6020471|NCT00206518|9614759|FG000|Overall Study|Protocol Violation|1
6020472|NCT00206518|9614760|FG001|Overall Study|Protocol Violation|1
6020473|NCT00206726|9614766|FG000|Overall Study|Delayed recovery of blood counts|1
6020474|NCT00206726|9614766|FG000|Overall Study|Progressive disease or relapsed disease|18
6020475|NCT00206726|9614766|FG000|Overall Study|Placed on new protocol|1
6020476|NCT00206726|9614766|FG000|Overall Study|Bone marrow transplant|1
6020477|NCT00206726|9614766|FG000|Overall Study|Adverse Event|17
6020478|NCT00206726|9614766|FG000|Overall Study|Death|4
6020479|NCT00206726|9614766|FG000|Overall Study|Protocol Violation|1
6020480|NCT00206726|9614766|FG000|Overall Study|Withdrawal by Subject|8
6020481|NCT00207090|9614770|FG000|Overall Study|Study drug toxicity|3
6020482|NCT00207090|9614770|FG000|Overall Study|Chest wall mass larger|1
6020483|NCT00207090|9614770|FG000|Overall Study|Disease progression/relapse|2
6020484|NCT00207090|9614770|FG000|Overall Study|Physician Decision|1
6020485|NCT00207142|9614782|FG000|Induction Phase|Adverse Event|9
6020486|NCT00207142|9614783|FG001|Induction Phase|Adverse Event|0
6020487|NCT00207142|9614784|FG002|Induction Phase|Adverse Event|0
6020488|NCT00207142|9614785|FG003|Induction Phase|Adverse Event|0
6020489|NCT00207142|9614782|FG000|Induction Phase|Death|1
6020490|NCT00207142|9614783|FG001|Induction Phase|Death|0
6020491|NCT00207142|9614784|FG002|Induction Phase|Death|0
6020492|NCT00207142|9614785|FG003|Induction Phase|Death|0
6020493|NCT00207142|9614782|FG000|Induction Phase|Lack of Efficacy|1
6020494|NCT00207142|9614783|FG001|Induction Phase|Lack of Efficacy|0
6020495|NCT00207142|9614784|FG002|Induction Phase|Lack of Efficacy|0
6020496|NCT00207142|9614785|FG003|Induction Phase|Lack of Efficacy|0
6020497|NCT00207142|9614782|FG000|Induction Phase|Lost to Follow-up|5
6020498|NCT00207142|9614783|FG001|Induction Phase|Lost to Follow-up|0
6020499|NCT00207142|9614784|FG002|Induction Phase|Lost to Follow-up|0
6020500|NCT00207142|9614785|FG003|Induction Phase|Lost to Follow-up|0
6020501|NCT00207142|9614782|FG000|Induction Phase|Physician Decision|2
6020502|NCT00207142|9614783|FG001|Induction Phase|Physician Decision|0
6020503|NCT00207142|9614784|FG002|Induction Phase|Physician Decision|0
6020504|NCT00207142|9614785|FG003|Induction Phase|Physician Decision|0
6020505|NCT00207142|9614782|FG000|Induction Phase|Poor/noncompliance|2
6020506|NCT00207142|9614783|FG001|Induction Phase|Poor/noncompliance|0
6020507|NCT00207142|9614784|FG002|Induction Phase|Poor/noncompliance|0
6020508|NCT00207142|9614785|FG003|Induction Phase|Poor/noncompliance|0
6020509|NCT00207142|9614782|FG000|Induction Phase|Pregnancy|1
6020510|NCT00207142|9614783|FG001|Induction Phase|Pregnancy|0
6020511|NCT00207142|9614784|FG002|Induction Phase|Pregnancy|0
6020512|NCT00207142|9614785|FG003|Induction Phase|Pregnancy|0
6020513|NCT00207142|9614782|FG000|Induction Phase|Subject no longer meets study criteria|3
6020514|NCT00207142|9614783|FG001|Induction Phase|Subject no longer meets study criteria|0
6020515|NCT00207142|9614784|FG002|Induction Phase|Subject no longer meets study criteria|0
6020516|NCT00207142|9614785|FG003|Induction Phase|Subject no longer meets study criteria|0
6020517|NCT00207142|9614782|FG000|Induction Phase|Withdrawal by Subject|4
6020518|NCT00207142|9614783|FG001|Induction Phase|Withdrawal by Subject|0
6020519|NCT00207142|9614784|FG002|Induction Phase|Withdrawal by Subject|0
6020520|NCT00207142|9614785|FG003|Induction Phase|Withdrawal by Subject|0
6020521|NCT00207142|9614782|FG000|Induction Phase|Incarceration|1
6020522|NCT00207142|9614783|FG001|Induction Phase|Incarceration|0
6020523|NCT00207142|9614784|FG002|Induction Phase|Incarceration|0
6020524|NCT00207142|9614785|FG003|Induction Phase|Incarceration|0
6020525|NCT00207142|9614782|FG000|Induction Phase|Missing lab data|1
6020526|NCT00207142|9614783|FG001|Induction Phase|Missing lab data|0
6020527|NCT00207142|9614784|FG002|Induction Phase|Missing lab data|0
6020528|NCT00207142|9614785|FG003|Induction Phase|Missing lab data|0
6020529|NCT00207142|9614782|FG000|Maintenance Phase/Rescue Phase|Adverse Event|0
6020530|NCT00207142|9614783|FG001|Maintenance Phase/Rescue Phase|Adverse Event|1
6020531|NCT00207142|9614784|FG002|Maintenance Phase/Rescue Phase|Adverse Event|4
6020532|NCT00207142|9614785|FG003|Maintenance Phase/Rescue Phase|Adverse Event|1
6020533|NCT00207142|9614782|FG000|Maintenance Phase/Rescue Phase|Lost to Follow-up|0
6020534|NCT00207142|9614783|FG001|Maintenance Phase/Rescue Phase|Lost to Follow-up|1
6020535|NCT00207142|9614784|FG002|Maintenance Phase/Rescue Phase|Lost to Follow-up|1
6020536|NCT00207142|9614785|FG003|Maintenance Phase/Rescue Phase|Lost to Follow-up|2
6020537|NCT00207142|9614782|FG000|Maintenance Phase/Rescue Phase|RTV intake impossible|0
6020538|NCT00207142|9614783|FG001|Maintenance Phase/Rescue Phase|RTV intake impossible|0
6020539|NCT00207142|9614784|FG002|Maintenance Phase/Rescue Phase|RTV intake impossible|1
6020540|NCT00207142|9614785|FG003|Maintenance Phase/Rescue Phase|RTV intake impossible|0
6020541|NCT00207142|9614782|FG000|Maintenance Phase/Rescue Phase|Poor/noncompliance|0
6020542|NCT00207142|9614783|FG001|Maintenance Phase/Rescue Phase|Poor/noncompliance|3
6020543|NCT00207142|9614784|FG002|Maintenance Phase/Rescue Phase|Poor/noncompliance|2
6020544|NCT00207142|9614785|FG003|Maintenance Phase/Rescue Phase|Poor/noncompliance|3
6020545|NCT00207142|9614782|FG000|Maintenance Phase/Rescue Phase|Pregnancy|0
6020546|NCT00207142|9614783|FG001|Maintenance Phase/Rescue Phase|Pregnancy|2
6020547|NCT00207142|9614784|FG002|Maintenance Phase/Rescue Phase|Pregnancy|2
6020548|NCT00207142|9614785|FG003|Maintenance Phase/Rescue Phase|Pregnancy|0
6020549|NCT00207142|9614782|FG000|Maintenance Phase/Rescue Phase|Subject no longer meets study criteria|0
6020550|NCT00207142|9614783|FG001|Maintenance Phase/Rescue Phase|Subject no longer meets study criteria|0
6020551|NCT00207142|9614784|FG002|Maintenance Phase/Rescue Phase|Subject no longer meets study criteria|1
6020552|NCT00207142|9614785|FG003|Maintenance Phase/Rescue Phase|Subject no longer meets study criteria|0
6020553|NCT00207142|9614782|FG000|Maintenance Phase/Rescue Phase|Withdrawal by Subject|0
6020554|NCT00207142|9614783|FG001|Maintenance Phase/Rescue Phase|Withdrawal by Subject|2
6020555|NCT00207142|9614784|FG002|Maintenance Phase/Rescue Phase|Withdrawal by Subject|2
6020556|NCT00207142|9614785|FG003|Maintenance Phase/Rescue Phase|Withdrawal by Subject|1
6020557|NCT00207142|9614782|FG000|Maintenance Phase/Rescue Phase|Death|0
6020558|NCT00207142|9614783|FG001|Maintenance Phase/Rescue Phase|Death|0
6020559|NCT00207142|9614784|FG002|Maintenance Phase/Rescue Phase|Death|0
6020560|NCT00207142|9614785|FG003|Maintenance Phase/Rescue Phase|Death|1
6020561|NCT00207142|9614782|FG000|Maintenance Phase/Rescue Phase|Lack of Efficacy|0
6020562|NCT00207142|9614783|FG001|Maintenance Phase/Rescue Phase|Lack of Efficacy|0
6020563|NCT00207142|9614784|FG002|Maintenance Phase/Rescue Phase|Lack of Efficacy|0
6020564|NCT00207142|9614785|FG003|Maintenance Phase/Rescue Phase|Lack of Efficacy|1
6020565|NCT00207714|9614805|FG000|Overall Study|Adverse Event|6
6020566|NCT00207714|9614806|FG001|Overall Study|Adverse Event|2
6020567|NCT00207714|9614807|FG002|Overall Study|Adverse Event|4
6020568|NCT00207714|9614808|FG003|Overall Study|Adverse Event|3
6020569|NCT00207714|9614809|FG004|Overall Study|Adverse Event|1
6020570|NCT00207714|9614805|FG000|Overall Study|Unsatisfactory therapeutic effect|5
6020571|NCT00207714|9614806|FG001|Overall Study|Unsatisfactory therapeutic effect|3
6020572|NCT00207714|9614807|FG002|Overall Study|Unsatisfactory therapeutic effect|1
6020573|NCT00207714|9614808|FG003|Overall Study|Unsatisfactory therapeutic effect|4
6020574|NCT00207714|9614809|FG004|Overall Study|Unsatisfactory therapeutic effect|4
6020575|NCT00207714|9614805|FG000|Overall Study|Other|3
6020576|NCT00207714|9614806|FG001|Overall Study|Other|2
6020577|NCT00207714|9614807|FG002|Overall Study|Other|5
6020578|NCT00207714|9614808|FG003|Overall Study|Other|1
6020579|NCT00207714|9614809|FG004|Overall Study|Other|0
6020580|NCT00207727|9614833|FG000|Overall Study|Withdrawal by Subject|0
6020581|NCT00207727|9614834|FG001|Overall Study|Withdrawal by Subject|0
6020582|NCT00207727|9614835|FG002|Overall Study|Withdrawal by Subject|0
6020583|NCT00207727|9614836|FG003|Overall Study|Withdrawal by Subject|0
6020584|NCT00207727|9614837|FG004|Overall Study|Withdrawal by Subject|1
6020585|NCT00207727|9614833|FG000|Overall Study|Lost to Follow-up|0
6020586|NCT00207727|9614834|FG001|Overall Study|Lost to Follow-up|1
6020587|NCT00207727|9614835|FG002|Overall Study|Lost to Follow-up|0
6020588|NCT00207727|9614836|FG003|Overall Study|Lost to Follow-up|0
6020589|NCT00207727|9614837|FG004|Overall Study|Lost to Follow-up|0
6020590|NCT00207727|9614833|FG000|Overall Study|Other|38
6020591|NCT00207727|9614834|FG001|Overall Study|Other|41
6020592|NCT00207727|9614835|FG002|Overall Study|Other|41
6020593|NCT00207727|9614836|FG003|Overall Study|Other|37
6020594|NCT00207727|9614837|FG004|Overall Study|Other|33
6020595|NCT00207740|9614853|FG000|Overall Study|Adverse Event|4
6020596|NCT00207740|9614854|FG001|Overall Study|Adverse Event|14
6020597|NCT00207740|9614855|FG002|Overall Study|Adverse Event|14
6020598|NCT00207740|9614856|FG003|Overall Study|Adverse Event|11
6020599|NCT00207740|9614853|FG000|Overall Study|Unsatisfactory therapeutic effect|1
6020600|NCT00207740|9614854|FG001|Overall Study|Unsatisfactory therapeutic effect|0
6020601|NCT00207740|9614855|FG002|Overall Study|Unsatisfactory therapeutic effect|2
6020602|NCT00207740|9614856|FG003|Overall Study|Unsatisfactory therapeutic effect|4
6020603|NCT00207740|9614853|FG000|Overall Study|Lost to Follow-up|0
6020604|NCT00207740|9614854|FG001|Overall Study|Lost to Follow-up|2
6020605|NCT00207740|9614855|FG002|Overall Study|Lost to Follow-up|1
6020606|NCT00207740|9614856|FG003|Overall Study|Lost to Follow-up|1
6020607|NCT00207740|9614853|FG000|Overall Study|Death|0
6020608|NCT00207740|9614854|FG001|Overall Study|Death|0
6020609|NCT00207740|9614855|FG002|Overall Study|Death|0
6020610|NCT00207740|9614856|FG003|Overall Study|Death|1
6020611|NCT00207740|9614853|FG000|Overall Study|Sponsor Directive|22
6020612|NCT00207740|9614854|FG001|Overall Study|Sponsor Directive|15
6020613|NCT00207740|9614855|FG002|Overall Study|Sponsor Directive|16
6020614|NCT00207740|9614856|FG003|Overall Study|Sponsor Directive|21
6020615|NCT00207740|9614853|FG000|Overall Study|Other|2
6020616|NCT00207740|9614854|FG001|Overall Study|Other|10
6020617|NCT00207740|9614855|FG002|Overall Study|Other|7
6020618|NCT00207740|9614856|FG003|Overall Study|Other|5
6020619|NCT00208325|9614897|FG000|Overall Study|Death|18
6020620|NCT00208325|9614898|FG001|Overall Study|Death|19
6020621|NCT00208325|9614899|FG002|Overall Study|Death|7
6020622|NCT00208325|9614900|FG003|Overall Study|Death|5
6020623|NCT00208325|9614897|FG000|Overall Study|Withdrawal by Subject|0
6020624|NCT00208325|9614898|FG001|Overall Study|Withdrawal by Subject|1
6020625|NCT00208325|9614899|FG002|Overall Study|Withdrawal by Subject|0
6020626|NCT00208325|9614900|FG003|Overall Study|Withdrawal by Subject|0
6020627|NCT00208325|9614897|FG000|Overall Study|Revision|4
6020628|NCT00208325|9614898|FG001|Overall Study|Revision|1
6020629|NCT00208325|9614899|FG002|Overall Study|Revision|0
6020630|NCT00208325|9614900|FG003|Overall Study|Revision|4
6020631|NCT00208325|9614897|FG000|Overall Study|Lost to Follow-up|1
6020632|NCT00208325|9614898|FG001|Overall Study|Lost to Follow-up|0
6020633|NCT00208325|9614899|FG002|Overall Study|Lost to Follow-up|2
6020634|NCT00208325|9614900|FG003|Overall Study|Lost to Follow-up|0
6020635|NCT00208325|9614897|FG000|Overall Study|Unsurfaced to Resurfaced Patella|4
6020636|NCT00208325|9614898|FG001|Overall Study|Unsurfaced to Resurfaced Patella|4
6020637|NCT00208325|9614899|FG002|Overall Study|Unsurfaced to Resurfaced Patella|1
6020638|NCT00208325|9614900|FG003|Overall Study|Unsurfaced to Resurfaced Patella|3
6020639|NCT00208325|9614897|FG000|Overall Study|Does not wish to Continue in Study|5
6020640|NCT00208325|9614898|FG001|Overall Study|Does not wish to Continue in Study|8
6020641|NCT00208325|9614899|FG002|Overall Study|Does not wish to Continue in Study|3
6020642|NCT00208325|9614900|FG003|Overall Study|Does not wish to Continue in Study|2
6020643|NCT00208325|9614897|FG000|Overall Study|Other|2
6020644|NCT00208325|9614898|FG001|Overall Study|Other|1
6020645|NCT00208325|9614899|FG002|Overall Study|Other|1
6020646|NCT00208325|9614900|FG003|Overall Study|Other|0
6020647|NCT00208325|9614897|FG000|Overall Study|Mis-Randomized|17
6020648|NCT00208325|9614898|FG001|Overall Study|Mis-Randomized|20
6020649|NCT00208325|9614899|FG002|Overall Study|Mis-Randomized|0
6020650|NCT00208325|9614900|FG003|Overall Study|Mis-Randomized|0
6020651|NCT00208767|9614930|FG000|Overall Study|Adverse Event|9
6020652|NCT00208767|9614931|FG001|Overall Study|Adverse Event|1
6020653|NCT00208767|9614930|FG000|Overall Study|Withdrawal by Subject|14
6020654|NCT00208767|9614931|FG001|Overall Study|Withdrawal by Subject|3
6020655|NCT00208767|9614930|FG000|Overall Study|Death|1
6020656|NCT00208767|9614931|FG001|Overall Study|Death|0
6020657|NCT00208767|9614930|FG000|Overall Study|Lost to Follow-up|3
6020658|NCT00208767|9614931|FG001|Overall Study|Lost to Follow-up|3
6020659|NCT00209092|9614953|FG000|Overall Study|Progression of disease|7
6020660|NCT00209092|9614954|FG001|Overall Study|Progression of disease|1
6077971|NCT00601107|9684123|FG000|Overall Study|Undefined|1
6077972|NCT00601107|9684124|FG001|Overall Study|Undefined|0
6077973|NCT00601107|9684125|FG002|Overall Study|Undefined|1
6077974|NCT00601107|9684126|FG003|Overall Study|Undefined|0
6020661|NCT00209092|9614953|FG000|Overall Study|Adverse Event|0
6020662|NCT00209092|9614954|FG001|Overall Study|Adverse Event|1
6020663|NCT00209092|9614953|FG000|Overall Study|Withdrawal by Subject|1
6020664|NCT00209092|9614954|FG001|Overall Study|Withdrawal by Subject|0
6020665|NCT00209170|9614962|FG000|Overall Study|Adverse Event|0
6020666|NCT00209170|9614963|FG001|Overall Study|Adverse Event|1
6020667|NCT00209170|9614962|FG000|Overall Study|Withdrawal by Subject|2
6020668|NCT00209170|9614963|FG001|Overall Study|Withdrawal by Subject|1
6020669|NCT00209170|9614962|FG000|Overall Study|Lack of Efficacy|0
6020670|NCT00209170|9614963|FG001|Overall Study|Lack of Efficacy|1
6020671|NCT00209274|9614971|FG000|Overall Study|Missed visit|3
6020672|NCT00209274|9614972|FG001|Overall Study|Missed visit|2
6020673|NCT00209274|9614971|FG000|Overall Study|Death|32
6020674|NCT00209274|9614972|FG001|Overall Study|Death|15
6020675|NCT00209274|9614971|FG000|Overall Study|Withdrawal by Subject|30
6020676|NCT00209274|9614972|FG001|Overall Study|Withdrawal by Subject|15
6020677|NCT00209274|9614971|FG000|Overall Study|Randomized not treated (RNT)|6
6020678|NCT00209274|9614972|FG001|Overall Study|Randomized not treated (RNT)|15
6020679|NCT00209339|9614978|FG000|At 12 Months Follow-up|Withdrawal by Subject|8
6020680|NCT00209339|9614978|FG000|At 12 Months Follow-up|Death|1
6020681|NCT00209339|9614978|FG000|At 12 Months Follow-up|No MitraClip Device Implanted|6
6020682|NCT00209339|9614978|FG000|At 24 Months Follow-up|Withdrawal by Subject|4
6020683|NCT00209339|9614978|FG000|At 24 Months Follow-up|Withdrawal because of other reasons|6
6020684|NCT00209339|9614978|FG000|At 24 Months Follow-up|Death|1
6020685|NCT00209339|9614978|FG000|At 3 Years Follow-up|Withdrawal by Subject|1
6020686|NCT00209339|9614978|FG000|At 4 Years Follow-up|Withdrawal by Subject|4
6020687|NCT00209339|9614978|FG000|At 4 Years Follow-up|Death|1
6020688|NCT00209339|9614978|FG000|At 5 Years Follow-up|Withdrawal by Subject|2
6020689|NCT00209339|9614978|FG000|At 5 Years Follow-up|Withdrawal because of other reasons|5
6020690|NCT00209339|9614978|FG000|At 5 Years Follow-up|Death|1
6020691|NCT00209560|9614993|FG000|Overall Study|Lack of Efficacy|1
6020692|NCT00209560|9614994|FG001|Overall Study|Lack of Efficacy|0
6020693|NCT00210106|9615000|FG000|Overall Study|Death|1
6020694|NCT00210106|9615000|FG000|Overall Study|Protocol Violation|13
6020695|NCT00210119|9615005|FG000|Overall Study|Protocol Violation|1
6020696|NCT00210119|9615005|FG000|Overall Study|Withdrawal by Subject|1
6077975|NCT00601172|9684142|FG000|Overall Study|Adverse Event|43
6020697|NCT00210184|9615009|FG000|Overall Study|The medical record was lost for these patients: no clinical data is available|2
6020698|NCT00210626|9615040|FG000|Overall Study|Adverse Event|1
6020699|NCT00210626|9615041|FG001|Overall Study|Adverse Event|2
6020700|NCT00210626|9615040|FG000|Overall Study|Protocol Violation|1
6077976|NCT00601172|9684143|FG001|Overall Study|Adverse Event|32
6020701|NCT00210626|9615041|FG001|Overall Study|Protocol Violation|5
6020702|NCT00210626|9615040|FG000|Overall Study|Lost to Follow-up|11
6020703|NCT00210626|9615041|FG001|Overall Study|Lost to Follow-up|11
6020704|NCT00210626|9615040|FG000|Overall Study|Death|1
6020705|NCT00210626|9615041|FG001|Overall Study|Death|0
6020706|NCT00210626|9615040|FG000|Overall Study|Withdrawal by Subject|29
6020707|NCT00210626|9615041|FG001|Overall Study|Withdrawal by Subject|20
6020708|NCT00210626|9615040|FG000|Overall Study|Physician Decision|0
6020709|NCT00210626|9615041|FG001|Overall Study|Physician Decision|2
6020710|NCT00210626|9615040|FG000|Overall Study|Sponser Request|1
6020711|NCT00210626|9615041|FG001|Overall Study|Sponser Request|0
6020712|NCT00210626|9615040|FG000|Overall Study|Other|4
6020713|NCT00210626|9615041|FG001|Overall Study|Other|5
6020714|NCT00210639|9615049|FG000|Overall Study|Lost to Follow-up|37
6020715|NCT00210639|9615050|FG001|Overall Study|Lost to Follow-up|29
6020716|NCT00210639|9615049|FG000|Overall Study|Withdrawal by Subject|8
6020717|NCT00210639|9615050|FG001|Overall Study|Withdrawal by Subject|1
6020718|NCT00210639|9615049|FG000|Overall Study|Other|18
6020719|NCT00210639|9615050|FG001|Overall Study|Other|12
6020720|NCT00211081|9615056|FG000|Overall Study|Withdrawal by Subject|2
6020721|NCT00211172|9615062|FG000|Overall Study|Died or lost health plan eligibility|39
6020722|NCT00211172|9615063|FG001|Overall Study|Died or lost health plan eligibility|32
6020723|NCT00211185|9615069|FG000|Overall Study|Death|2
6020724|NCT00211185|9615069|FG000|Overall Study|Disease progression|7
6020725|NCT00211185|9615069|FG000|Overall Study|Withdrawal by Subject|6
6020726|NCT00211185|9615069|FG000|Overall Study|Physician Decision|5
6020727|NCT00211237|9615075|FG000|Baseline|Withdrew|1
6020728|NCT00211237|9615076|FG001|Baseline|Withdrew|3
6020729|NCT00211237|9615077|FG002|Baseline|Withdrew|0
6020730|NCT00211237|9615075|FG000|Baseline|Refused random assignment|1
6020731|NCT00211237|9615076|FG001|Baseline|Refused random assignment|0
6020732|NCT00211237|9615077|FG002|Baseline|Refused random assignment|0
6020733|NCT00211237|9615075|FG000|1 Month|Death|2
6020734|NCT00211237|9615076|FG001|1 Month|Death|1
6020735|NCT00211237|9615077|FG002|1 Month|Death|0
6020736|NCT00211237|9615075|FG000|1 Month|Lost to Follow-up|0
6020737|NCT00211237|9615076|FG001|1 Month|Lost to Follow-up|2
6020738|NCT00211237|9615077|FG002|1 Month|Lost to Follow-up|0
6020739|NCT00211237|9615075|FG000|1 Month|Withdrew|0
6020740|NCT00211237|9615076|FG001|1 Month|Withdrew|4
6020741|NCT00211237|9615077|FG002|1 Month|Withdrew|0
6020742|NCT00211237|9615075|FG000|1 Month|Additional surgery needed|1
6020743|NCT00211237|9615076|FG001|1 Month|Additional surgery needed|0
6020744|NCT00211237|9615077|FG002|1 Month|Additional surgery needed|0
6020745|NCT00211237|9615075|FG000|1 Month|Non-medical problem|0
6020746|NCT00211237|9615076|FG001|1 Month|Non-medical problem|2
6020747|NCT00211237|9615077|FG002|1 Month|Non-medical problem|0
6020748|NCT00211237|9615075|FG000|3 Months|Death|7
6020749|NCT00211237|9615076|FG001|3 Months|Death|3
6020750|NCT00211237|9615077|FG002|3 Months|Death|0
6020751|NCT00211237|9615075|FG000|3 Months|Could not comply with protocol|1
6020752|NCT00211237|9615076|FG001|3 Months|Could not comply with protocol|0
6020753|NCT00211237|9615077|FG002|3 Months|Could not comply with protocol|0
6020754|NCT00211237|9615075|FG000|3 Months|Withdrew|0
6020755|NCT00211237|9615076|FG001|3 Months|Withdrew|1
6020756|NCT00211237|9615077|FG002|3 Months|Withdrew|0
6020757|NCT00211237|9615075|FG000|3 Months|Non-medical problem|0
6020758|NCT00211237|9615076|FG001|3 Months|Non-medical problem|0
6020759|NCT00211237|9615077|FG002|3 Months|Non-medical problem|1
6020760|NCT00211237|9615075|FG000|6 Months|Death|6
6020761|NCT00211237|9615076|FG001|6 Months|Death|0
6020762|NCT00211237|9615077|FG002|6 Months|Death|3
6020763|NCT00211237|9615075|FG000|6 Months|Lost to Follow-up|2
6020764|NCT00211237|9615076|FG001|6 Months|Lost to Follow-up|0
6020765|NCT00211237|9615077|FG002|6 Months|Lost to Follow-up|0
6020766|NCT00211237|9615075|FG000|6 Months|Could not comply with protocol|0
6020767|NCT00211237|9615076|FG001|6 Months|Could not comply with protocol|2
6020768|NCT00211237|9615077|FG002|6 Months|Could not comply with protocol|0
6020769|NCT00211237|9615075|FG000|12 Months|Death|8
6020770|NCT00211237|9615076|FG001|12 Months|Death|2
6020771|NCT00211237|9615077|FG002|12 Months|Death|3
6020772|NCT00211237|9615075|FG000|12 Months|Lost to Follow-up|1
6020773|NCT00211237|9615076|FG001|12 Months|Lost to Follow-up|0
6020774|NCT00211237|9615077|FG002|12 Months|Lost to Follow-up|1
6020775|NCT00211237|9615075|FG000|12 Months|Withdrew|0
6020776|NCT00211237|9615076|FG001|12 Months|Withdrew|0
6020777|NCT00211237|9615077|FG002|12 Months|Withdrew|1
6020778|NCT00211237|9615075|FG000|12 Months|unrelated medical problem|0
6020779|NCT00211237|9615076|FG001|12 Months|unrelated medical problem|0
6020780|NCT00211237|9615077|FG002|12 Months|unrelated medical problem|1
6020781|NCT00211510|9615096|FG000|Overall Study|Physician Decision|3
6020782|NCT00211510|9615097|FG001|Overall Study|Physician Decision|1
6020783|NCT00211510|9615096|FG000|Overall Study|Withdrawal by Subject|3
6020784|NCT00211510|9615097|FG001|Overall Study|Withdrawal by Subject|1
6020785|NCT00211536|9615108|FG000|Overall Study|Withdrawal by Subject|2
6020786|NCT00211536|9615109|FG001|Overall Study|Withdrawal by Subject|2
6020787|NCT00211536|9615108|FG000|Overall Study|Physician Decision|0
6020788|NCT00211536|9615109|FG001|Overall Study|Physician Decision|5
6020789|NCT00211536|9615108|FG000|Overall Study|Adverse Event|2
6020790|NCT00211536|9615109|FG001|Overall Study|Adverse Event|0
6020791|NCT00211757|9615126|FG000|Overall Study|Withdrawal by Subject|1
6020792|NCT00211757|9615127|FG001|Overall Study|Withdrawal by Subject|1
6020793|NCT00211757|9615126|FG000|Overall Study|Lack of Efficacy|0
6020794|NCT00211757|9615127|FG001|Overall Study|Lack of Efficacy|1
6020795|NCT00211809|9615135|FG000|Overall Study|Lack of Efficacy|1
6020796|NCT00211809|9615135|FG000|Overall Study|Lost to Follow-up|2
6020797|NCT00211809|9615135|FG000|Overall Study|Pregnancy|1
6020798|NCT00211809|9615135|FG000|Overall Study|side effects|2
6020799|NCT00211887|9615144|FG000|Overall Study|Adverse Event|8
6020800|NCT00211887|9615145|FG001|Overall Study|Adverse Event|4
6020801|NCT00211887|9615146|FG002|Overall Study|Adverse Event|6
6020802|NCT00211887|9615144|FG000|Overall Study|Death|1
6020803|NCT00211887|9615145|FG001|Overall Study|Death|1
6020804|NCT00211887|9615146|FG002|Overall Study|Death|1
6020805|NCT00211887|9615144|FG000|Overall Study|Lost to Follow-up|28
6020806|NCT00211887|9615145|FG001|Overall Study|Lost to Follow-up|13
6020807|NCT00211887|9615146|FG002|Overall Study|Lost to Follow-up|9
6020808|NCT00211887|9615144|FG000|Overall Study|Non-medical reason|31
6020809|NCT00211887|9615145|FG001|Overall Study|Non-medical reason|14
6020810|NCT00211887|9615146|FG002|Overall Study|Non-medical reason|8
6020811|NCT00211887|9615144|FG000|Overall Study|Other medical reason|15
6020812|NCT00211887|9615145|FG001|Overall Study|Other medical reason|11
6020813|NCT00211887|9615146|FG002|Overall Study|Other medical reason|7
6020814|NCT00211887|9615144|FG000|Overall Study|Side effects|19
6020815|NCT00211887|9615145|FG001|Overall Study|Side effects|13
6020816|NCT00211887|9615146|FG002|Overall Study|Side effects|5
6047980|NCT00414440|9647055|FG001|Extension Period|Death|2
6047981|NCT00414440|9647054|FG000|Extension Period|Withdrawal by Subject|9
6047982|NCT00414440|9647055|FG001|Extension Period|Withdrawal by Subject|7
6047983|NCT00414440|9647054|FG000|Extension Period|Not included in follow up period|18
6047984|NCT00414440|9647055|FG001|Extension Period|Not included in follow up period|8
6047985|NCT00414466|9647065|FG000|Overall Study|Adverse Event|0
6047986|NCT00414466|9647066|FG001|Overall Study|Adverse Event|0
6047987|NCT00414466|9647067|FG002|Overall Study|Adverse Event|1
6047988|NCT00414466|9647068|FG003|Overall Study|Adverse Event|1
6047989|NCT00414466|9647065|FG000|Overall Study|Lack of Efficacy|1
6047990|NCT00414466|9647066|FG001|Overall Study|Lack of Efficacy|0
6047991|NCT00414466|9647067|FG002|Overall Study|Lack of Efficacy|0
6047992|NCT00414466|9647068|FG003|Overall Study|Lack of Efficacy|0
6047993|NCT00414466|9647065|FG000|Overall Study|Withdrawn by Sponsor|1
6047994|NCT00414466|9647066|FG001|Overall Study|Withdrawn by Sponsor|0
6047995|NCT00414466|9647067|FG002|Overall Study|Withdrawn by Sponsor|0
6047996|NCT00414466|9647068|FG003|Overall Study|Withdrawn by Sponsor|0
6047997|NCT00414544|9647094|FG000|Overall Study|Lost to Follow-up|14
6047998|NCT00414596|9647100|FG000|Overall Study|Protocol Violation|2
6047999|NCT00414609|9647106|FG000|Core Study|Adverse Event|9
6048000|NCT00414609|9647107|FG001|Core Study|Adverse Event|11
6048001|NCT00414609|9647108|FG002|Core Study|Adverse Event|0
6048002|NCT00414609|9647106|FG000|Core Study|Abnormal laboratory values|0
6048003|NCT00414609|9647107|FG001|Core Study|Abnormal laboratory values|1
6048004|NCT00414609|9647108|FG002|Core Study|Abnormal laboratory values|0
6048005|NCT00414609|9647106|FG000|Core Study|Abnormal test procedure results|1
6048006|NCT00414609|9647107|FG001|Core Study|Abnormal test procedure results|1
6048007|NCT00414609|9647108|FG002|Core Study|Abnormal test procedure results|0
6048008|NCT00414609|9647106|FG000|Core Study|Protocol deviation|0
6048009|NCT00414609|9647107|FG001|Core Study|Protocol deviation|1
6048010|NCT00414609|9647108|FG002|Core Study|Protocol deviation|0
6048011|NCT00414609|9647106|FG000|Core Study|Patient withdrew consent|10
6048012|NCT00414609|9647107|FG001|Core Study|Patient withdrew consent|11
6048013|NCT00414609|9647108|FG002|Core Study|Patient withdrew consent|0
6048014|NCT00414609|9647106|FG000|Core Study|Lost to Follow-up|7
6048015|NCT00414609|9647107|FG001|Core Study|Lost to Follow-up|4
6048016|NCT00414609|9647108|FG002|Core Study|Lost to Follow-up|0
6048017|NCT00414609|9647106|FG000|Core Study|Administrative problems|0
6048018|NCT00414609|9647107|FG001|Core Study|Administrative problems|2
6048019|NCT00414609|9647108|FG002|Core Study|Administrative problems|0
6048020|NCT00414609|9647106|FG000|Core Study|Death|7
6048021|NCT00414609|9647107|FG001|Core Study|Death|14
6048022|NCT00414609|9647108|FG002|Core Study|Death|0
6048023|NCT00414609|9647106|FG000|Extension Study|Adverse Event|0
6048024|NCT00414609|9647107|FG001|Extension Study|Adverse Event|0
6048025|NCT00414609|9647108|FG002|Extension Study|Adverse Event|14
6048026|NCT00414609|9647106|FG000|Extension Study|Unsatisfactory therapeutic effect|0
6048027|NCT00414609|9647107|FG001|Extension Study|Unsatisfactory therapeutic effect|0
6048028|NCT00414609|9647108|FG002|Extension Study|Unsatisfactory therapeutic effect|2
6048029|NCT00414609|9647106|FG000|Extension Study|Withdrawal by Subject|0
6048030|NCT00414609|9647107|FG001|Extension Study|Withdrawal by Subject|0
6048031|NCT00414609|9647108|FG002|Extension Study|Withdrawal by Subject|13
6048032|NCT00414609|9647106|FG000|Extension Study|Lost to Follow-up|0
6048033|NCT00414609|9647107|FG001|Extension Study|Lost to Follow-up|0
6048034|NCT00414609|9647108|FG002|Extension Study|Lost to Follow-up|10
6048035|NCT00414609|9647106|FG000|Extension Study|Administrative problems|0
6048036|NCT00414609|9647107|FG001|Extension Study|Administrative problems|0
6048037|NCT00414609|9647108|FG002|Extension Study|Administrative problems|1
6048038|NCT00414609|9647106|FG000|Extension Study|Death|0
6048039|NCT00414609|9647107|FG001|Extension Study|Death|0
6048040|NCT00414609|9647108|FG002|Extension Study|Death|17
6020817|NCT00212355|9615180|FG000|Overall Study|Adverse Event|1
6020818|NCT00212355|9615180|FG000|Overall Study|Withdrawal by Subject|1
6020819|NCT00212355|9615180|FG000|Overall Study|A change of address|1
6020820|NCT00212758|9615188|FG000|Standard Therapy of GH (12 Months)|Adverse Event|1
6020821|NCT00212758|9615189|FG001|Standard Therapy of GH (12 Months)|Adverse Event|0
6020822|NCT00212758|9615188|FG000|Standard Therapy of GH (12 Months)|Lost to Follow-up|1
6020823|NCT00212758|9615189|FG001|Standard Therapy of GH (12 Months)|Lost to Follow-up|1
6020824|NCT00213135|9615213|FG000|Overall Study|Adverse Event|9
6020825|NCT00213135|9615214|FG001|Overall Study|Adverse Event|5
6020826|NCT00213135|9615215|FG002|Overall Study|Adverse Event|5
6020827|NCT00213135|9615213|FG000|Overall Study|Lost to Follow-up|11
6020828|NCT00213135|9615214|FG001|Overall Study|Lost to Follow-up|8
6020829|NCT00213135|9615215|FG002|Overall Study|Lost to Follow-up|4
6020830|NCT00213135|9615213|FG000|Overall Study|Protocol Violation|4
6077977|NCT00601172|9684142|FG000|Overall Study|Lack of Efficacy|11
6077978|NCT00601172|9684143|FG001|Overall Study|Lack of Efficacy|12
6077979|NCT00601172|9684142|FG000|Overall Study|Protocol Violation|2
6077980|NCT00601172|9684143|FG001|Overall Study|Protocol Violation|5
6077981|NCT00601172|9684142|FG000|Overall Study|Lost to Follow-up|4
6077982|NCT00601172|9684143|FG001|Overall Study|Lost to Follow-up|3
6077983|NCT00601172|9684142|FG000|Overall Study|Physician Decision|27
6077984|NCT00601172|9684143|FG001|Overall Study|Physician Decision|28
6020831|NCT00213135|9615214|FG001|Overall Study|Protocol Violation|4
6020832|NCT00213135|9615215|FG002|Overall Study|Protocol Violation|10
6020833|NCT00213135|9615213|FG000|Overall Study|Death|1
6020834|NCT00213135|9615214|FG001|Overall Study|Death|1
6020835|NCT00213135|9615215|FG002|Overall Study|Death|2
6020836|NCT00213135|9615213|FG000|Overall Study|Disease progression|4
6020837|NCT00213135|9615214|FG001|Overall Study|Disease progression|5
6020838|NCT00213135|9615215|FG002|Overall Study|Disease progression|21
6020839|NCT00213135|9615213|FG000|Overall Study|Other|21
6020840|NCT00213135|9615214|FG001|Overall Study|Other|12
6020841|NCT00213135|9615215|FG002|Overall Study|Other|15
6020842|NCT00213148|9615227|FG000|Cycle 1 (1 Month)|Lost to Follow-up|1
6020843|NCT00213148|9615228|FG001|Cycle 1 (1 Month)|Lost to Follow-up|0
6020844|NCT00213148|9615229|FG002|Cycle 1 (1 Month)|Lost to Follow-up|2
6020845|NCT00213148|9615230|FG003|Cycle 1 (1 Month)|Lost to Follow-up|2
6020846|NCT00213148|9615231|FG004|Cycle 1 (1 Month)|Lost to Follow-up|1
6020847|NCT00213148|9615227|FG000|Cycle 1 (1 Month)|Adverse Event|0
6020848|NCT00213148|9615228|FG001|Cycle 1 (1 Month)|Adverse Event|0
6020849|NCT00213148|9615229|FG002|Cycle 1 (1 Month)|Adverse Event|1
6020850|NCT00213148|9615230|FG003|Cycle 1 (1 Month)|Adverse Event|0
6020851|NCT00213148|9615231|FG004|Cycle 1 (1 Month)|Adverse Event|0
6020852|NCT00213148|9615227|FG000|Cycle 1 (1 Month)|Lack of Efficacy|4
6020853|NCT00213148|9615228|FG001|Cycle 1 (1 Month)|Lack of Efficacy|0
6020854|NCT00213148|9615229|FG002|Cycle 1 (1 Month)|Lack of Efficacy|8
6020855|NCT00213148|9615230|FG003|Cycle 1 (1 Month)|Lack of Efficacy|5
6020856|NCT00213148|9615231|FG004|Cycle 1 (1 Month)|Lack of Efficacy|8
6020857|NCT00213148|9615227|FG000|Cycle 1 (1 Month)|Protocol Violation|1
6020858|NCT00213148|9615228|FG001|Cycle 1 (1 Month)|Protocol Violation|0
6020859|NCT00213148|9615229|FG002|Cycle 1 (1 Month)|Protocol Violation|1
6020860|NCT00213148|9615230|FG003|Cycle 1 (1 Month)|Protocol Violation|0
6020861|NCT00213148|9615231|FG004|Cycle 1 (1 Month)|Protocol Violation|0
6020862|NCT00213148|9615227|FG000|Cycle 1 (1 Month)|Other|3
6020863|NCT00213148|9615228|FG001|Cycle 1 (1 Month)|Other|0
6020864|NCT00213148|9615229|FG002|Cycle 1 (1 Month)|Other|2
6020865|NCT00213148|9615230|FG003|Cycle 1 (1 Month)|Other|2
6020866|NCT00213148|9615231|FG004|Cycle 1 (1 Month)|Other|7
6020867|NCT00213148|9615227|FG000|Cycle 1 (1 Month)|Pregnancy Unrelated to Therapy|0
6020868|NCT00213148|9615228|FG001|Cycle 1 (1 Month)|Pregnancy Unrelated to Therapy|0
6020869|NCT00213148|9615229|FG002|Cycle 1 (1 Month)|Pregnancy Unrelated to Therapy|0
6020870|NCT00213148|9615230|FG003|Cycle 1 (1 Month)|Pregnancy Unrelated to Therapy|1
6020871|NCT00213148|9615231|FG004|Cycle 1 (1 Month)|Pregnancy Unrelated to Therapy|0
6020872|NCT00213148|9615227|FG000|Cycle 1 (1 Month)|Non Resolving Cyst > 25mm|0
6020873|NCT00213148|9615228|FG001|Cycle 1 (1 Month)|Non Resolving Cyst > 25mm|0
6020874|NCT00213148|9615229|FG002|Cycle 1 (1 Month)|Non Resolving Cyst > 25mm|0
6020875|NCT00213148|9615230|FG003|Cycle 1 (1 Month)|Non Resolving Cyst > 25mm|0
6020876|NCT00213148|9615231|FG004|Cycle 1 (1 Month)|Non Resolving Cyst > 25mm|1
6020877|NCT00213148|9615227|FG000|Cycle 1 (1 Month)|Discontinued Before Start of Cycle 2|15
6020878|NCT00213148|9615228|FG001|Cycle 1 (1 Month)|Discontinued Before Start of Cycle 2|0
6020879|NCT00213148|9615229|FG002|Cycle 1 (1 Month)|Discontinued Before Start of Cycle 2|5
6077985|NCT00601172|9684142|FG000|Overall Study|Withdrawal by Subject|35
6020880|NCT00213148|9615230|FG003|Cycle 1 (1 Month)|Discontinued Before Start of Cycle 2|8
6020881|NCT00213148|9615231|FG004|Cycle 1 (1 Month)|Discontinued Before Start of Cycle 2|5
6020882|NCT00213148|9615227|FG000|Cycle 2 (1 Month)|Lost to Follow-up|0
6020883|NCT00213148|9615228|FG001|Cycle 2 (1 Month)|Lost to Follow-up|0
6020884|NCT00213148|9615229|FG002|Cycle 2 (1 Month)|Lost to Follow-up|2
6020885|NCT00213148|9615230|FG003|Cycle 2 (1 Month)|Lost to Follow-up|2
6020886|NCT00213148|9615231|FG004|Cycle 2 (1 Month)|Lost to Follow-up|1
6020887|NCT00213148|9615227|FG000|Cycle 2 (1 Month)|Lack of Efficacy|1
6020888|NCT00213148|9615228|FG001|Cycle 2 (1 Month)|Lack of Efficacy|3
6077986|NCT00601172|9684143|FG001|Overall Study|Withdrawal by Subject|27
6077987|NCT00601172|9684142|FG000|Overall Study|Did not meet continuation criteria|19
6020889|NCT00213148|9615229|FG002|Cycle 2 (1 Month)|Lack of Efficacy|7
6020890|NCT00213148|9615230|FG003|Cycle 2 (1 Month)|Lack of Efficacy|6
6020891|NCT00213148|9615231|FG004|Cycle 2 (1 Month)|Lack of Efficacy|16
6020892|NCT00213148|9615227|FG000|Cycle 2 (1 Month)|Other|2
6020893|NCT00213148|9615228|FG001|Cycle 2 (1 Month)|Other|1
6020894|NCT00213148|9615229|FG002|Cycle 2 (1 Month)|Other|2
6020895|NCT00213148|9615230|FG003|Cycle 2 (1 Month)|Other|8
6020896|NCT00213148|9615231|FG004|Cycle 2 (1 Month)|Other|7
6020897|NCT00213148|9615227|FG000|Cycle 2 (1 Month)|Pregnancy Unrelated to Therapy|0
6020898|NCT00213148|9615228|FG001|Cycle 2 (1 Month)|Pregnancy Unrelated to Therapy|1
6020899|NCT00213148|9615229|FG002|Cycle 2 (1 Month)|Pregnancy Unrelated to Therapy|0
6020900|NCT00213148|9615230|FG003|Cycle 2 (1 Month)|Pregnancy Unrelated to Therapy|0
6020901|NCT00213148|9615231|FG004|Cycle 2 (1 Month)|Pregnancy Unrelated to Therapy|0
6020902|NCT00213148|9615227|FG000|Cycle 2 (1 Month)|Non Resolving Cyst > 25mm|1
6020903|NCT00213148|9615228|FG001|Cycle 2 (1 Month)|Non Resolving Cyst > 25mm|0
6020904|NCT00213148|9615229|FG002|Cycle 2 (1 Month)|Non Resolving Cyst > 25mm|0
6020905|NCT00213148|9615230|FG003|Cycle 2 (1 Month)|Non Resolving Cyst > 25mm|0
6020906|NCT00213148|9615231|FG004|Cycle 2 (1 Month)|Non Resolving Cyst > 25mm|0
6020907|NCT00213148|9615227|FG000|Cycle 2 (1 Month)|Discontinued Before Start of Cycle 3|10
6020908|NCT00213148|9615228|FG001|Cycle 2 (1 Month)|Discontinued Before Start of Cycle 3|1
6020909|NCT00213148|9615229|FG002|Cycle 2 (1 Month)|Discontinued Before Start of Cycle 3|3
6020910|NCT00213148|9615230|FG003|Cycle 2 (1 Month)|Discontinued Before Start of Cycle 3|3
6020911|NCT00213148|9615231|FG004|Cycle 2 (1 Month)|Discontinued Before Start of Cycle 3|6
6020912|NCT00213148|9615227|FG000|Cycle 3 (1 Month)|Lost to Follow-up|0
6020913|NCT00213148|9615228|FG001|Cycle 3 (1 Month)|Lost to Follow-up|2
6020914|NCT00213148|9615229|FG002|Cycle 3 (1 Month)|Lost to Follow-up|0
6020915|NCT00213148|9615230|FG003|Cycle 3 (1 Month)|Lost to Follow-up|0
6020916|NCT00213148|9615231|FG004|Cycle 3 (1 Month)|Lost to Follow-up|1
6020917|NCT00213148|9615227|FG000|Cycle 3 (1 Month)|Other|0
6020918|NCT00213148|9615228|FG001|Cycle 3 (1 Month)|Other|0
6020919|NCT00213148|9615229|FG002|Cycle 3 (1 Month)|Other|1
6020920|NCT00213148|9615230|FG003|Cycle 3 (1 Month)|Other|1
6020921|NCT00213148|9615231|FG004|Cycle 3 (1 Month)|Other|0
6020922|NCT00213980|9615262|FG000|Overall Study|Withdrawal by Subject|3
6020923|NCT00213980|9615263|FG001|Overall Study|Withdrawal by Subject|1
6020924|NCT00213980|9615262|FG000|Overall Study|Adverse Event|1
6020925|NCT00213980|9615263|FG001|Overall Study|Adverse Event|1
6020926|NCT00213980|9615262|FG000|Overall Study|Disease progression|0
6020927|NCT00213980|9615263|FG001|Overall Study|Disease progression|2
6020928|NCT00213980|9615262|FG000|Overall Study|Developed ovarian cancer|1
6020929|NCT00213980|9615263|FG001|Overall Study|Developed ovarian cancer|0
6020930|NCT00213980|9615262|FG000|Overall Study|Failed to obtain all 3 DXAs|1
6020931|NCT00213980|9615263|FG001|Overall Study|Failed to obtain all 3 DXAs|3
6020932|NCT00214019|9615269|FG000|Overall Study|Lost to Follow-up|11
6020933|NCT00214019|9615269|FG000|Overall Study|Withdrawal by Subject|2
6020934|NCT00214019|9615269|FG000|Overall Study|Screen Failed prior to randomization|17
6020935|NCT00214136|9615304|FG000|Overall Study|Death|5
6020936|NCT00214201|9615310|FG000|Overall Study|Withdrawal by Subject|2
6020937|NCT00214201|9615311|FG001|Overall Study|Withdrawal by Subject|0
6020938|NCT00214201|9615310|FG000|Overall Study|Death|0
6020939|NCT00214201|9615311|FG001|Overall Study|Death|2
6020940|NCT00214383|9615320|FG000|Overall Study|Lost to Follow-up|16
6020941|NCT00214383|9615321|FG001|Overall Study|Lost to Follow-up|26
6020942|NCT00214422|9615330|FG000|Overall Study|Physician Decision|2
6020943|NCT00214422|9615331|FG001|Overall Study|Physician Decision|0
6020944|NCT00214422|9615332|FG002|Overall Study|Physician Decision|0
6020945|NCT00214422|9615330|FG000|Overall Study|Developed esophageal ca|1
6020946|NCT00214422|9615331|FG001|Overall Study|Developed esophageal ca|0
6020947|NCT00214422|9615332|FG002|Overall Study|Developed esophageal ca|0
6020948|NCT00214422|9615330|FG000|Overall Study|Pt taken off study|1
6020949|NCT00214422|9615331|FG001|Overall Study|Pt taken off study|1
6020950|NCT00214422|9615332|FG002|Overall Study|Pt taken off study|0
6020951|NCT00214422|9615330|FG000|Overall Study|Disease progression on study|1
6020952|NCT00214422|9615331|FG001|Overall Study|Disease progression on study|0
6020953|NCT00214422|9615332|FG002|Overall Study|Disease progression on study|0
6309528|NCT02640235|10038208|FG001|Overall Study|Withdrawal by Subject|6
6309529|NCT02640235|10038207|FG000|Overall Study|Lost to Follow-up|4
6309530|NCT02640235|10038208|FG001|Overall Study|Lost to Follow-up|3
6020954|NCT00214422|9615330|FG000|Overall Study|Unable to make a radiation treatment|0
6020955|NCT00214422|9615331|FG001|Overall Study|Unable to make a radiation treatment|0
6020956|NCT00214422|9615332|FG002|Overall Study|Unable to make a radiation treatment|1
6020957|NCT00214461|9615348|FG000|Overall Study|Adverse Event|0
6020958|NCT00214461|9615349|FG001|Overall Study|Adverse Event|0
6020959|NCT00214461|9615350|FG002|Overall Study|Adverse Event|1
6020960|NCT00214461|9615351|FG003|Overall Study|Adverse Event|1
6020961|NCT00214461|9615348|FG000|Overall Study|Withdrawal by Subject|0
6020962|NCT00214461|9615349|FG001|Overall Study|Withdrawal by Subject|0
6020963|NCT00214461|9615350|FG002|Overall Study|Withdrawal by Subject|1
6020964|NCT00214461|9615351|FG003|Overall Study|Withdrawal by Subject|0
6020965|NCT00215137|9615424|FG000|Open Label Escitalopram|Lack of Efficacy|1
6020966|NCT00215137|9615425|FG001|Open Label Escitalopram|Lack of Efficacy|0
6020967|NCT00215137|9615426|FG002|Open Label Escitalopram|Lack of Efficacy|0
6020968|NCT00215137|9615424|FG000|Randomization Period|Lost to Follow-up|0
6020969|NCT00215137|9615425|FG001|Randomization Period|Lost to Follow-up|1
6020970|NCT00215137|9615426|FG002|Randomization Period|Lost to Follow-up|0
6020971|NCT00215137|9615424|FG000|Randomization Period|Withdrawal by Subject|0
6020972|NCT00215137|9615425|FG001|Randomization Period|Withdrawal by Subject|1
6020973|NCT00215137|9615426|FG002|Randomization Period|Withdrawal by Subject|0
6020974|NCT00215150|9615434|FG000|Open Label Phase|Lost to Follow-up|7
6020975|NCT00215150|9615434|FG000|Open Label Phase|Withdrawal by Subject|1
6020976|NCT00215150|9615434|FG000|Open Label Phase|Did not complete a post base visit|13
6020977|NCT00215150|9615434|FG000|Open Label Phase|Did not meet randomization criteria|9
6020978|NCT00215150|9615434|FG000|Randomization Phase Ziprasidone|Lost to Follow-up|2
6020979|NCT00215150|9615434|FG000|Randomization Phase Ziprasidone|Withdrawal by Subject|1
6020980|NCT00215150|9615434|FG000|Randomization Phase Placebo|Withdrawal by Subject|1
6020981|NCT00215540|9615445|FG000|Overall Study|Withdrew from study medication|1
6020982|NCT00215540|9615446|FG001|Overall Study|Withdrew from study medication|0
6020983|NCT00215540|9615447|FG002|Overall Study|Withdrew from study medication|0
6020984|NCT00215553|9615462|FG000|Overall Study|Adverse Event|0
6020985|NCT00215553|9615463|FG001|Overall Study|Adverse Event|1
6020986|NCT00215553|9615464|FG002|Overall Study|Adverse Event|2
6020987|NCT00215553|9615465|FG003|Overall Study|Adverse Event|1
6020988|NCT00215553|9615466|FG004|Overall Study|Adverse Event|2
6020989|NCT00215553|9615467|FG005|Overall Study|Adverse Event|6
6020990|NCT00215553|9615468|FG006|Overall Study|Adverse Event|0
6020991|NCT00215644|9615486|FG000|Overall Study|Disease Progression|28
6020992|NCT00215644|9615487|FG001|Overall Study|Disease Progression|10
6020993|NCT00215644|9615486|FG000|Overall Study|Adverse Event|2
6020994|NCT00215644|9615487|FG001|Overall Study|Adverse Event|9
6020995|NCT00215644|9615486|FG000|Overall Study|Death|1
6020996|NCT00215644|9615487|FG001|Overall Study|Death|2
6020997|NCT00215644|9615486|FG000|Overall Study|Withdrawal by Subject|1
6020998|NCT00215644|9615487|FG001|Overall Study|Withdrawal by Subject|0
6020999|NCT00215644|9615486|FG000|Overall Study|Other|3
6021000|NCT00215644|9615487|FG001|Overall Study|Other|15
6021001|NCT00215644|9615486|FG000|Overall Study|Randomized but Not Treated|1
6021002|NCT00215644|9615487|FG001|Overall Study|Randomized but Not Treated|0
6021003|NCT00215657|9615501|FG000|Overall Study|Adverse Event|5
6021004|NCT00215657|9615502|FG001|Overall Study|Adverse Event|1
6021005|NCT00215657|9615503|FG002|Overall Study|Adverse Event|3
6021006|NCT00215657|9615504|FG003|Overall Study|Adverse Event|0
6021007|NCT00215657|9615505|FG004|Overall Study|Adverse Event|3
6021008|NCT00215657|9615506|FG005|Overall Study|Adverse Event|1
6021009|NCT00215657|9615507|FG006|Overall Study|Adverse Event|0
6021010|NCT00215657|9615508|FG007|Overall Study|Adverse Event|3
6021011|NCT00215657|9615501|FG000|Overall Study|Withdrawal by Subject|6
6021012|NCT00215657|9615502|FG001|Overall Study|Withdrawal by Subject|3
6021013|NCT00215657|9615503|FG002|Overall Study|Withdrawal by Subject|3
6021014|NCT00215657|9615504|FG003|Overall Study|Withdrawal by Subject|1
6021015|NCT00215657|9615505|FG004|Overall Study|Withdrawal by Subject|6
6021016|NCT00215657|9615506|FG005|Overall Study|Withdrawal by Subject|1
6021017|NCT00215657|9615507|FG006|Overall Study|Withdrawal by Subject|10
6021018|NCT00215657|9615508|FG007|Overall Study|Withdrawal by Subject|3
6021019|NCT00215657|9615501|FG000|Overall Study|Insuff prostate specific antigen resp|3
6021020|NCT00215657|9615502|FG001|Overall Study|Insuff prostate specific antigen resp|2
6021021|NCT00215657|9615503|FG002|Overall Study|Insuff prostate specific antigen resp|2
6021022|NCT00215657|9615504|FG003|Overall Study|Insuff prostate specific antigen resp|2
6021023|NCT00215657|9615505|FG004|Overall Study|Insuff prostate specific antigen resp|1
6021024|NCT00215657|9615506|FG005|Overall Study|Insuff prostate specific antigen resp|2
6021025|NCT00215657|9615507|FG006|Overall Study|Insuff prostate specific antigen resp|3
6021026|NCT00215657|9615508|FG007|Overall Study|Insuff prostate specific antigen resp|2
6021027|NCT00215657|9615501|FG000|Overall Study|Insufficient testosterone response|5
6021028|NCT00215657|9615502|FG001|Overall Study|Insufficient testosterone response|4
6021029|NCT00215657|9615503|FG002|Overall Study|Insufficient testosterone response|1
6021030|NCT00215657|9615504|FG003|Overall Study|Insufficient testosterone response|12
6021031|NCT00215657|9615505|FG004|Overall Study|Insufficient testosterone response|8
6021032|NCT00215657|9615506|FG005|Overall Study|Insufficient testosterone response|12
6021033|NCT00215657|9615507|FG006|Overall Study|Insufficient testosterone response|4
6021034|NCT00215657|9615508|FG007|Overall Study|Insufficient testosterone response|7
6021035|NCT00215657|9615501|FG000|Overall Study|Other|3
6021036|NCT00215657|9615502|FG001|Overall Study|Other|1
6077988|NCT00601172|9684143|FG001|Overall Study|Did not meet continuation criteria|20
6077989|NCT00601250|9684152|FG000|Overall Study|Adverse Event|3
6021037|NCT00215657|9615503|FG002|Overall Study|Other|2
6021038|NCT00215657|9615504|FG003|Overall Study|Other|3
6021039|NCT00215657|9615505|FG004|Overall Study|Other|5
6021040|NCT00215657|9615506|FG005|Overall Study|Other|4
6021041|NCT00215657|9615507|FG006|Overall Study|Other|6
6021042|NCT00215657|9615508|FG007|Overall Study|Other|1
6021043|NCT00215683|9615529|FG000|Overall Study|Adverse Event|15
6021044|NCT00215683|9615530|FG001|Overall Study|Adverse Event|16
6021045|NCT00215683|9615531|FG002|Overall Study|Adverse Event|15
6021046|NCT00215683|9615529|FG000|Overall Study|Lack of Efficacy|5
6021047|NCT00215683|9615530|FG001|Overall Study|Lack of Efficacy|1
6021048|NCT00215683|9615531|FG002|Overall Study|Lack of Efficacy|2
6021049|NCT00215683|9615529|FG000|Overall Study|Lost to Follow-up|0
6021050|NCT00215683|9615530|FG001|Overall Study|Lost to Follow-up|2
6021051|NCT00215683|9615531|FG002|Overall Study|Lost to Follow-up|1
6021052|NCT00215683|9615529|FG000|Overall Study|Withdrawal by Subject|9
6021053|NCT00215683|9615530|FG001|Overall Study|Withdrawal by Subject|4
6021054|NCT00215683|9615531|FG002|Overall Study|Withdrawal by Subject|13
6021055|NCT00215683|9615529|FG000|Overall Study|Physician Decision|0
6021056|NCT00215683|9615530|FG001|Overall Study|Physician Decision|0
6021057|NCT00215683|9615531|FG002|Overall Study|Physician Decision|1
6021058|NCT00215683|9615529|FG000|Overall Study|Difficult to attend visits|0
6021059|NCT00215683|9615530|FG001|Overall Study|Difficult to attend visits|1
6021060|NCT00215683|9615531|FG002|Overall Study|Difficult to attend visits|0
6021061|NCT00215683|9615529|FG000|Overall Study|No study drug available|0
6021062|NCT00215683|9615530|FG001|Overall Study|No study drug available|1
6021063|NCT00215683|9615531|FG002|Overall Study|No study drug available|0
6021064|NCT00215683|9615529|FG000|Overall Study|Intermittent therapy required|0
6021065|NCT00215683|9615530|FG001|Overall Study|Intermittent therapy required|1
6021066|NCT00215683|9615531|FG002|Overall Study|Intermittent therapy required|0
6021067|NCT00215943|9615550|FG000|Overall Study|Disease Progression|3
6021068|NCT00215943|9615551|FG001|Overall Study|Disease Progression|5
6021069|NCT00215943|9615550|FG000|Overall Study|Alternate therapy|0
6021070|NCT00215943|9615551|FG001|Overall Study|Alternate therapy|1
6021071|NCT00215943|9615550|FG000|Overall Study|Adverse Event|3
6021072|NCT00215943|9615551|FG001|Overall Study|Adverse Event|6
6021073|NCT00215943|9615550|FG000|Overall Study|Other disease|0
6021074|NCT00215943|9615551|FG001|Overall Study|Other disease|1
6021075|NCT00215943|9615550|FG000|Overall Study|Other complications|3
6021076|NCT00215943|9615551|FG001|Overall Study|Other complications|1
6021077|NCT00216086|9615568|FG000|Overall Study|Protocol Violation|1
6021078|NCT00216086|9615568|FG000|Overall Study|Diagnosis of Metastatic Disease|1
6021079|NCT00216086|9615568|FG000|Overall Study|Social Reasons|2
6021080|NCT00216203|9615585|FG000|Overall Study|Withdrawal by Subject|2
6021081|NCT00216476|9615606|FG000|Overall Study|Withdrawal by Subject|59
6021082|NCT00216476|9615607|FG001|Overall Study|Withdrawal by Subject|72
6021083|NCT00216476|9615608|FG002|Overall Study|Withdrawal by Subject|9
6021084|NCT00216476|9615606|FG000|Overall Study|Lost to Follow-up|10
6021085|NCT00216476|9615607|FG001|Overall Study|Lost to Follow-up|9
6021086|NCT00216476|9615608|FG002|Overall Study|Lost to Follow-up|1
6021087|NCT00216476|9615606|FG000|Overall Study|Adverse Event|6
6021088|NCT00216476|9615607|FG001|Overall Study|Adverse Event|10
6021089|NCT00216476|9615608|FG002|Overall Study|Adverse Event|1
6021090|NCT00216476|9615606|FG000|Overall Study|Lack of Efficacy|4
6021091|NCT00216476|9615607|FG001|Overall Study|Lack of Efficacy|3
6021092|NCT00216476|9615608|FG002|Overall Study|Lack of Efficacy|0
6021093|NCT00216476|9615606|FG000|Overall Study|Death|2
6021094|NCT00216476|9615607|FG001|Overall Study|Death|0
6021095|NCT00216476|9615608|FG002|Overall Study|Death|0
6021096|NCT00216476|9615606|FG000|Overall Study|Pregnancy|0
6021097|NCT00216476|9615607|FG001|Overall Study|Pregnancy|1
6021098|NCT00216476|9615608|FG002|Overall Study|Pregnancy|1
6021099|NCT00216476|9615606|FG000|Overall Study|Other|0
6021100|NCT00216476|9615607|FG001|Overall Study|Other|0
6021101|NCT00216476|9615608|FG002|Overall Study|Other|1
6021102|NCT00216476|9615606|FG000|Overall Study|Refuses Injection|11
6021103|NCT00216476|9615607|FG001|Overall Study|Refuses Injection|0
6021104|NCT00216476|9615608|FG002|Overall Study|Refuses Injection|0
6021105|NCT00216476|9615606|FG000|Overall Study|No Further Need for Treatment|3
6021106|NCT00216476|9615607|FG001|Overall Study|No Further Need for Treatment|4
6021107|NCT00216476|9615608|FG002|Overall Study|No Further Need for Treatment|1
6021108|NCT00216476|9615606|FG000|Overall Study|Non-compliance|0
6021109|NCT00216476|9615607|FG001|Overall Study|Non-compliance|4
6021110|NCT00216476|9615608|FG002|Overall Study|Non-compliance|1
6021111|NCT00216476|9615606|FG000|Overall Study|Higher dose/Extra Medication Required|2
6021112|NCT00216476|9615607|FG001|Overall Study|Higher dose/Extra Medication Required|0
6021113|NCT00216476|9615608|FG002|Overall Study|Higher dose/Extra Medication Required|2
6021114|NCT00216476|9615606|FG000|Overall Study|Administrative Reasons|1
6021115|NCT00216476|9615607|FG001|Overall Study|Administrative Reasons|1
6021116|NCT00216476|9615608|FG002|Overall Study|Administrative Reasons|0
6021117|NCT00216476|9615606|FG000|Overall Study|Protocol Deviation|5
6021118|NCT00216476|9615607|FG001|Overall Study|Protocol Deviation|1
6021119|NCT00216476|9615608|FG002|Overall Study|Protocol Deviation|0
6021120|NCT00216476|9615606|FG000|Overall Study|Patient Moved|2
6021121|NCT00216476|9615607|FG001|Overall Study|Patient Moved|2
6021122|NCT00216476|9615608|FG002|Overall Study|Patient Moved|0
6021123|NCT00216671|9615621|FG000|Overall Study|Adverse Event|4
6021124|NCT00216671|9615622|FG001|Overall Study|Adverse Event|9
6021125|NCT00216671|9615621|FG000|Overall Study|Pregnancy|0
6021126|NCT00216671|9615622|FG001|Overall Study|Pregnancy|1
6021127|NCT00216671|9615621|FG000|Overall Study|Withdrawal by Subject|4
6021128|NCT00216671|9615622|FG001|Overall Study|Withdrawal by Subject|2
6021129|NCT00216671|9615621|FG000|Overall Study|Refused Injections|3
6021130|NCT00216671|9615622|FG001|Overall Study|Refused Injections|13
6021131|NCT00216671|9615621|FG000|Overall Study|No Need to Continue Medication|1
6021132|NCT00216671|9615622|FG001|Overall Study|No Need to Continue Medication|1
6021133|NCT00216671|9615621|FG000|Overall Study|Insufficient Response|9
6021134|NCT00216671|9615622|FG001|Overall Study|Insufficient Response|4
6021135|NCT00216671|9615621|FG000|Overall Study|Lost to Follow-up|3
6021136|NCT00216671|9615622|FG001|Overall Study|Lost to Follow-up|5
6021137|NCT00216671|9615621|FG000|Overall Study|Non compliant|2
6021138|NCT00216671|9615622|FG001|Overall Study|Non compliant|2
6021139|NCT00216671|9615621|FG000|Overall Study|Ineligible|0
6021140|NCT00216671|9615622|FG001|Overall Study|Ineligible|2
6021141|NCT00216671|9615621|FG000|Overall Study|Physician Decision|1
6021142|NCT00216671|9615622|FG001|Overall Study|Physician Decision|1
6021143|NCT00216671|9615621|FG000|Overall Study|Protocol Violation|3
6021144|NCT00216671|9615622|FG001|Overall Study|Protocol Violation|5
6021145|NCT00216671|9615621|FG000|Overall Study|Relapse|1
6021146|NCT00216671|9615622|FG001|Overall Study|Relapse|0
6021147|NCT00216671|9615621|FG000|Overall Study|Investigator Illness|0
6021148|NCT00216671|9615622|FG001|Overall Study|Investigator Illness|1
6021149|NCT00216671|9615621|FG000|Overall Study|Patient Moved|0
6021150|NCT00216671|9615622|FG001|Overall Study|Patient Moved|1
6021151|NCT00216671|9615621|FG000|Overall Study|Ineligible, no efficacy data|2
6021152|NCT00216671|9615622|FG001|Overall Study|Ineligible, no efficacy data|2
6021153|NCT00216671|9615621|FG000|Overall Study|Insufficient Response Adverse Event|2
6021154|NCT00216671|9615622|FG001|Overall Study|Insufficient Response Adverse Event|1
6021155|NCT00216736|9615630|FG000|Overall Study|Lost to Follow-up|1
6021156|NCT00216736|9615631|FG001|Overall Study|Lost to Follow-up|1
6021157|NCT00217022|9615639|FG000|Overall Study|Withdrawal by Subject|1
6021158|NCT00217022|9615640|FG001|Overall Study|Withdrawal by Subject|1
6021159|NCT00217087|9615648|FG000|Overall Study|decided to have esophagectomy|1
6021160|NCT00217087|9615649|FG001|Overall Study|decided to have esophagectomy|2
6021161|NCT00217087|9615648|FG000|Overall Study|completed less than 12 months return|10
6021162|NCT00217087|9615649|FG001|Overall Study|completed less than 12 months return|18
6021163|NCT00217425|9615667|FG000|Overall Study|Never started treatment|2
6021164|NCT00217425|9615667|FG000|Overall Study|Patient ineligible|5
6021165|NCT00217425|9615667|FG000|Overall Study|Lack of Efficacy|13
6021166|NCT00217425|9615667|FG000|Overall Study|Adverse Event|8
6021167|NCT00217425|9615667|FG000|Overall Study|Withdrawal by Subject|4
6021168|NCT00217425|9615667|FG000|Overall Study|Other complicating disease|1
6021169|NCT00217425|9615667|FG000|Overall Study|Other|4
6021170|NCT00217464|9615680|FG000|Overall Study|Progression|15
6021171|NCT00217464|9615680|FG000|Overall Study|Other|2
6021172|NCT00217581|9615705|FG000|Overall Study|Withdrawal by Subject|1
6021173|NCT00217620|9615714|FG000|Overall Study|Adverse Event|2
6021174|NCT00217620|9615714|FG000|Overall Study|Progression|31
6021175|NCT00217620|9615714|FG000|Overall Study|Not Protocol Specified|4
6021176|NCT00217620|9615714|FG000|Overall Study|Ineligible|13
6021177|NCT00217620|9615714|FG000|Overall Study|Never received treatment|1
6021178|NCT00217672|9615722|FG000|Allocation|Ineligible|2
6021179|NCT00217672|9615723|FG001|Allocation|Ineligible|0
6021180|NCT00217672|9615722|FG000|Treatment|disease progression|33
6021181|NCT00217672|9615723|FG001|Treatment|disease progression|4
6021182|NCT00217672|9615722|FG000|Treatment|Adverse Event|18
6021183|NCT00217672|9615723|FG001|Treatment|Adverse Event|2
6021184|NCT00217672|9615722|FG000|Treatment|reqd treatment not permitted by protocol|6
6021185|NCT00217672|9615723|FG001|Treatment|reqd treatment not permitted by protocol|0
6021186|NCT00217672|9615722|FG000|Treatment|Physician Decision|6
6021187|NCT00217672|9615723|FG001|Treatment|Physician Decision|0
6021188|NCT00217672|9615722|FG000|Treatment|insurance issues|1
6021189|NCT00217672|9615723|FG001|Treatment|insurance issues|1
6021190|NCT00217672|9615722|FG000|Treatment|Death|2
6021191|NCT00217672|9615723|FG001|Treatment|Death|0
6021192|NCT00217672|9615722|FG000|Treatment|secondary malignancy|1
6021193|NCT00217672|9615723|FG001|Treatment|secondary malignancy|0
6021194|NCT00217672|9615722|FG000|Follow-up|Withdrawal by Subject|4
6021195|NCT00217672|9615723|FG001|Follow-up|Withdrawal by Subject|0
6021196|NCT00217672|9615722|FG000|Follow-up|Lost to Follow-up|1
6021197|NCT00217672|9615723|FG001|Follow-up|Lost to Follow-up|0
6021198|NCT00217971|9615736|FG000|Overall Study|Adverse Event|1
6021199|NCT00217971|9615737|FG001|Overall Study|Adverse Event|1
6021200|NCT00217971|9615736|FG000|Overall Study|Lost to Follow-up|15
6021201|NCT00217971|9615737|FG001|Overall Study|Lost to Follow-up|19
6021202|NCT00217971|9615736|FG000|Overall Study|Physician Decision|0
6021203|NCT00217971|9615737|FG001|Overall Study|Physician Decision|1
6021204|NCT00217971|9615736|FG000|Overall Study|Withdrawal by Subject|7
6021205|NCT00217971|9615737|FG001|Overall Study|Withdrawal by Subject|12
6021206|NCT00217971|9615736|FG000|Overall Study|non compliant|1
6021207|NCT00217971|9615737|FG001|Overall Study|non compliant|0
6021208|NCT00218257|9615777|FG000|Period Between Visit 1 and 2|Lost to Follow-up|4
6021209|NCT00218257|9615778|FG001|Period Between Visit 1 and 2|Lost to Follow-up|3
6021210|NCT00218296|9615789|FG000|Overall Study|Lost to Follow-up|9
6021211|NCT00218296|9615790|FG001|Overall Study|Lost to Follow-up|7
6021212|NCT00218296|9615789|FG000|Overall Study|Withdrawal by Subject|36
6021213|NCT00218296|9615790|FG001|Overall Study|Withdrawal by Subject|47
6021214|NCT00218296|9615789|FG000|Overall Study|Randomized but did not enter treatment|66
6021215|NCT00218296|9615790|FG001|Overall Study|Randomized but did not enter treatment|67
6021216|NCT00218543|9615885|FG000|Overall Study|Lost to Follow-up|8
6021217|NCT00218543|9615885|FG000|Overall Study|relocated|1
6021218|NCT00218543|9615885|FG000|Overall Study|Withdrawal by Subject|1
6021219|NCT00218543|9615885|FG000|Overall Study|Physician Decision|3
6021220|NCT00218543|9615885|FG000|Overall Study|Adverse Event|2
6021221|NCT00218634|9615891|FG000|Overall Study|Lost to Follow-up|8
6021222|NCT00218634|9615892|FG001|Overall Study|Lost to Follow-up|15
6021223|NCT00219141|9615904|FG000|Overall Study|Adverse Event|4
6021224|NCT00219141|9615905|FG001|Overall Study|Adverse Event|10
6021225|NCT00219141|9615906|FG002|Overall Study|Adverse Event|5
6021226|NCT00219141|9615904|FG000|Overall Study|Lack of Efficacy|3
6021227|NCT00219141|9615905|FG001|Overall Study|Lack of Efficacy|2
6021228|NCT00219141|9615906|FG002|Overall Study|Lack of Efficacy|0
6021229|NCT00219141|9615904|FG000|Overall Study|Administrative problems|0
6021230|NCT00219141|9615905|FG001|Overall Study|Administrative problems|1
6021231|NCT00219141|9615906|FG002|Overall Study|Administrative problems|0
6021232|NCT00219141|9615904|FG000|Overall Study|Lost to Follow-up|2
6021233|NCT00219141|9615905|FG001|Overall Study|Lost to Follow-up|4
6021234|NCT00219141|9615906|FG002|Overall Study|Lost to Follow-up|1
6021235|NCT00219141|9615904|FG000|Overall Study|Protocol Violation|3
6021236|NCT00219141|9615905|FG001|Overall Study|Protocol Violation|1
6021237|NCT00219141|9615906|FG002|Overall Study|Protocol Violation|1
6021238|NCT00219141|9615904|FG000|Overall Study|Withdrawal by Subject|1
6021239|NCT00219141|9615905|FG001|Overall Study|Withdrawal by Subject|3
6021240|NCT00219141|9615906|FG002|Overall Study|Withdrawal by Subject|5
6021241|NCT00219141|9615904|FG000|Overall Study|Condition no longer requires study drug|1
6021242|NCT00219141|9615905|FG001|Overall Study|Condition no longer requires study drug|0
6021243|NCT00219141|9615906|FG002|Overall Study|Condition no longer requires study drug|0
6021244|NCT00219284|9615916|FG000|Treatment Phase - 16 Weeks|Adverse Event|26
6021245|NCT00219284|9615917|FG001|Treatment Phase - 16 Weeks|Adverse Event|24
6021246|NCT00219284|9615916|FG000|Treatment Phase - 16 Weeks|Abnormal laboratory value(s)|0
6021247|NCT00219284|9615917|FG001|Treatment Phase - 16 Weeks|Abnormal laboratory value(s)|1
6021248|NCT00219284|9615916|FG000|Treatment Phase - 16 Weeks|Lack of Efficacy|3
6021249|NCT00219284|9615917|FG001|Treatment Phase - 16 Weeks|Lack of Efficacy|10
6021250|NCT00219284|9615916|FG000|Treatment Phase - 16 Weeks|Protocol Violation|9
6021251|NCT00219284|9615917|FG001|Treatment Phase - 16 Weeks|Protocol Violation|5
6021252|NCT00219284|9615916|FG000|Treatment Phase - 16 Weeks|Withdrawal by Subject|5
6021253|NCT00219284|9615917|FG001|Treatment Phase - 16 Weeks|Withdrawal by Subject|9
6021254|NCT00219284|9615916|FG000|Treatment Phase - 16 Weeks|Lost to Follow-up|1
6021255|NCT00219284|9615917|FG001|Treatment Phase - 16 Weeks|Lost to Follow-up|2
6021256|NCT00219284|9615916|FG000|Extension Phase - 8 Weeks|Adverse Event|2
6021257|NCT00219284|9615917|FG001|Extension Phase - 8 Weeks|Adverse Event|3
6021258|NCT00219284|9615916|FG000|Extension Phase - 8 Weeks|Withdrawal by Subject|0
6021259|NCT00219284|9615917|FG001|Extension Phase - 8 Weeks|Withdrawal by Subject|2
6021260|NCT00219284|9615916|FG000|Extension Phase - 8 Weeks|Lost to Follow-up|0
6021261|NCT00219284|9615917|FG001|Extension Phase - 8 Weeks|Lost to Follow-up|2
6021262|NCT00219349|9615923|FG000|Cognitive Behavioral Therapy Phase|Lost to Follow-up|6
6021263|NCT00219349|9615923|FG000|Cognitive Behavioral Therapy Phase|Withdrawal by Subject|2
6021264|NCT00219349|9615923|FG000|Cognitive Behavioral Therapy Phase|Protocol Violation|2
6021265|NCT00219349|9615923|FG000|Escitalopram Phase|Withdrawal by Subject|3
6021266|NCT00219544|9615927|FG000|Single Blind Treatment Period|Lack of Efficacy|5
6021267|NCT00219544|9615928|FG001|Single Blind Treatment Period|Lack of Efficacy|0
6021268|NCT00219544|9615927|FG000|Single Blind Treatment Period|Adverse Event|9
6021269|NCT00219544|9615928|FG001|Single Blind Treatment Period|Adverse Event|0
6021270|NCT00219544|9615927|FG000|Single Blind Treatment Period|Protocol Violation|4
6021271|NCT00219544|9615928|FG001|Single Blind Treatment Period|Protocol Violation|0
6021272|NCT00219544|9615927|FG000|Single Blind Treatment Period|Lost to Follow-up|2
6021273|NCT00219544|9615928|FG001|Single Blind Treatment Period|Lost to Follow-up|0
6021274|NCT00219544|9615927|FG000|Single Blind Treatment Period|Investigator decision to withdraw|1
6021275|NCT00219544|9615928|FG001|Single Blind Treatment Period|Investigator decision to withdraw|0
6021276|NCT00219544|9615927|FG000|Single Blind Treatment Period|Withdrawal by Subject|1
6021277|NCT00219544|9615928|FG001|Single Blind Treatment Period|Withdrawal by Subject|0
6021278|NCT00219557|9615939|FG000|Phase 1|Lack of Efficacy|3
6021279|NCT00219557|9615940|FG001|Phase 1|Lack of Efficacy|0
6021280|NCT00219557|9615941|FG002|Phase 1|Lack of Efficacy|0
6021281|NCT00219557|9615939|FG000|Phase 1|Adverse Event|2
6021282|NCT00219557|9615940|FG001|Phase 1|Adverse Event|0
6021283|NCT00219557|9615941|FG002|Phase 1|Adverse Event|0
6021284|NCT00219557|9615939|FG000|Phase 1|Withdrawal by Subject|1
6021285|NCT00219557|9615940|FG001|Phase 1|Withdrawal by Subject|0
6021286|NCT00219557|9615941|FG002|Phase 1|Withdrawal by Subject|0
6021287|NCT00219557|9615939|FG000|Phase 1|Started chemotherapy at other institute|1
6021288|NCT00219557|9615940|FG001|Phase 1|Started chemotherapy at other institute|0
6021289|NCT00219557|9615941|FG002|Phase 1|Started chemotherapy at other institute|0
6021290|NCT00219557|9615939|FG000|Phase 2|Lack of Efficacy|0
6021291|NCT00219557|9615940|FG001|Phase 2|Lack of Efficacy|21
6021292|NCT00219557|9615941|FG002|Phase 2|Lack of Efficacy|15
6021293|NCT00219557|9615939|FG000|Phase 2|Adverse Event|0
6021294|NCT00219557|9615940|FG001|Phase 2|Adverse Event|22
6021295|NCT00219557|9615941|FG002|Phase 2|Adverse Event|2
6021296|NCT00219557|9615939|FG000|Phase 2|Death|0
6021297|NCT00219557|9615940|FG001|Phase 2|Death|8
6021298|NCT00219557|9615941|FG002|Phase 2|Death|2
6021299|NCT00219557|9615939|FG000|Phase 2|Other|0
6021300|NCT00219557|9615940|FG001|Phase 2|Other|8
6021301|NCT00219557|9615941|FG002|Phase 2|Other|6
6021302|NCT00219557|9615939|FG000|Phase 2|Withdrawal by Subject|0
6021303|NCT00219557|9615940|FG001|Phase 2|Withdrawal by Subject|9
6021304|NCT00219557|9615941|FG002|Phase 2|Withdrawal by Subject|5
6021305|NCT00219557|9615939|FG000|Phase 2|Treatment not received|0
6021306|NCT00219557|9615940|FG001|Phase 2|Treatment not received|1
6021307|NCT00219557|9615941|FG002|Phase 2|Treatment not received|3
6021308|NCT00220636|9615950|FG000|Overall Study|Withdrawal by Subject|4
6021309|NCT00220701|9615957|FG000|Overall Study|Lost to Follow-up|5
6021310|NCT00220701|9615958|FG001|Overall Study|Lost to Follow-up|4
6021311|NCT00220727|9615966|FG000|Second Infusion (Week <6)|Pt did not meet study requirement|1
6021312|NCT00220727|9615967|FG001|Second Infusion (Week <6)|Pt did not meet study requirement|0
6021313|NCT00220740|9615977|FG000|Efficacy Period|Entered rescue treatment with placebo|23
6021314|NCT00220740|9615978|FG001|Efficacy Period|Entered rescue treatment with placebo|0
6021315|NCT00220740|9615977|FG000|Efficacy Period|Adverse Event|1
6021316|NCT00220740|9615978|FG001|Efficacy Period|Adverse Event|1
6021317|NCT00220740|9615977|FG000|Efficacy Period|Withdrawal by Subject|1
6021318|NCT00220740|9615978|FG001|Efficacy Period|Withdrawal by Subject|0
6021319|NCT00220740|9615977|FG000|Efficacy Period|Protocol Violation|1
6021320|NCT00220740|9615978|FG001|Efficacy Period|Protocol Violation|0
6021321|NCT00220740|9615977|FG000|Efficacy Period|Entered Rescue Treatment with IGIV-C|0
6021322|NCT00220740|9615978|FG001|Efficacy Period|Entered Rescue Treatment with IGIV-C|45
6021323|NCT00220779|9615989|FG000|Overall Study|Adverse Event|1
6021324|NCT00220779|9615990|FG001|Overall Study|Adverse Event|0
6021325|NCT00220779|9615991|FG002|Overall Study|Adverse Event|0
6021326|NCT00220779|9615989|FG000|Overall Study|Withdrawal by Subject|1
6021327|NCT00220779|9615990|FG001|Overall Study|Withdrawal by Subject|4
6021328|NCT00220779|9615991|FG002|Overall Study|Withdrawal by Subject|1
6021329|NCT00220779|9615989|FG000|Overall Study|Non-compliance|1
6021330|NCT00220779|9615990|FG001|Overall Study|Non-compliance|0
6021331|NCT00220779|9615991|FG002|Overall Study|Non-compliance|0
6021332|NCT00220779|9615989|FG000|Overall Study|Too time consuming|1
6021333|NCT00220779|9615990|FG001|Overall Study|Too time consuming|0
6021334|NCT00220779|9615991|FG002|Overall Study|Too time consuming|0
6021335|NCT00220779|9615989|FG000|Overall Study|Pregnancy|0
6021336|NCT00220779|9615990|FG001|Overall Study|Pregnancy|0
6021337|NCT00220779|9615991|FG002|Overall Study|Pregnancy|2
6021338|NCT00220779|9615989|FG000|Overall Study|Lack of Efficacy|3
6021339|NCT00220779|9615990|FG001|Overall Study|Lack of Efficacy|0
6021340|NCT00220779|9615991|FG002|Overall Study|Lack of Efficacy|1
6021341|NCT00220805|9616001|FG000|Overall Study|Adverse Event|1
6021342|NCT00220805|9616002|FG001|Overall Study|Adverse Event|3
6021343|NCT00220805|9616001|FG000|Overall Study|Withdrawal by Subject|3
6021344|NCT00220805|9616002|FG001|Overall Study|Withdrawal by Subject|0
6021345|NCT00220805|9616001|FG000|Overall Study|Lack of Efficacy|1
6021346|NCT00220805|9616002|FG001|Overall Study|Lack of Efficacy|0
6021347|NCT00220805|9616001|FG000|Overall Study|Develop. of choroidal neovascularization|3
6021348|NCT00220805|9616002|FG001|Overall Study|Develop. of choroidal neovascularization|8
6021349|NCT00221104|9616019|FG000|Overall Study|Adverse Event|1
6021350|NCT00221104|9616020|FG001|Overall Study|Adverse Event|0
6021351|NCT00221104|9616019|FG000|Overall Study|Physician Decision|1
6021352|NCT00221104|9616020|FG001|Overall Study|Physician Decision|0
6021353|NCT00221104|9616019|FG000|Overall Study|Protocol Violation|2
6021354|NCT00221104|9616020|FG001|Overall Study|Protocol Violation|0
6021355|NCT00221104|9616019|FG000|Overall Study|Withdrawal by Subject|42
6021356|NCT00221104|9616020|FG001|Overall Study|Withdrawal by Subject|29
6021357|NCT00221104|9616019|FG000|Overall Study|Others|37
6021358|NCT00221104|9616020|FG001|Overall Study|Others|47
6021359|NCT00221195|9616041|FG000|Therapy 1 (Months 1-6)|Withdrawal by Subject|3
6021360|NCT00221195|9616042|FG001|Therapy 1 (Months 1-6)|Withdrawal by Subject|1
6021361|NCT00221195|9616041|FG000|Therapy 1 (Months 1-6)|Lost to Follow-up|0
6021362|NCT00221195|9616042|FG001|Therapy 1 (Months 1-6)|Lost to Follow-up|1
6021363|NCT00221195|9616041|FG000|Washout Period (Months 7-9)|Death|0
6021364|NCT00221195|9616042|FG001|Washout Period (Months 7-9)|Death|1
6021365|NCT00221195|9616041|FG000|Therapy 2 (Months 10-15)|Death|1
6021366|NCT00221195|9616042|FG001|Therapy 2 (Months 10-15)|Death|0
6021367|NCT00221195|9616041|FG000|Therapy 2 (Months 10-15)|Adverse Event|1
6021368|NCT00221195|9616042|FG001|Therapy 2 (Months 10-15)|Adverse Event|0
6021369|NCT00221403|9616075|FG000|Overall Study|Protocol Violation|1
6021370|NCT00221403|9616076|FG001|Overall Study|Protocol Violation|0
6021371|NCT00221403|9616077|FG002|Overall Study|Protocol Violation|0
6021372|NCT00221403|9616075|FG000|Overall Study|Physician Decision|1
6021373|NCT00221403|9616076|FG001|Overall Study|Physician Decision|0
6021374|NCT00221403|9616077|FG002|Overall Study|Physician Decision|0
6021375|NCT00221403|9616075|FG000|Overall Study|Withdrawal by Subject|0
6021376|NCT00221403|9616076|FG001|Overall Study|Withdrawal by Subject|3
6021377|NCT00221403|9616077|FG002|Overall Study|Withdrawal by Subject|0
6021378|NCT00221403|9616075|FG000|Overall Study|Lack of Efficacy|0
6021379|NCT00221403|9616076|FG001|Overall Study|Lack of Efficacy|1
6021380|NCT00221403|9616077|FG002|Overall Study|Lack of Efficacy|0
6021381|NCT00221403|9616075|FG000|Overall Study|Adverse Event|0
6021382|NCT00221403|9616076|FG001|Overall Study|Adverse Event|1
6021383|NCT00221403|9616077|FG002|Overall Study|Adverse Event|0
6021384|NCT00222105|9616085|FG000|Overall Study|Removed due to wrong diagnosis|1
6021385|NCT00222105|9616085|FG000|Overall Study|Withdrawal by Subject|1
6021386|NCT00222105|9616085|FG000|Overall Study|Adverse Event|8
6021387|NCT00222105|9616085|FG000|Overall Study|Treatment delays|2
6021388|NCT00222105|9616085|FG000|Overall Study|Death|2
6021389|NCT00222729|9616098|FG000|Overall Study|Adverse Event|3
6021390|NCT00223080|9616104|FG000|Overall Study|Withdrawal by Subject|253
6021391|NCT00223080|9616105|FG001|Overall Study|Withdrawal by Subject|232
6021392|NCT00223080|9616104|FG000|Overall Study|Required contraindicated med|0
6021393|NCT00223080|9616105|FG001|Overall Study|Required contraindicated med|1
6021394|NCT00223080|9616104|FG000|Overall Study|Non-compliant|7
6021395|NCT00223080|9616105|FG001|Overall Study|Non-compliant|7
6021396|NCT00223080|9616104|FG000|Overall Study|Moved from study area|37
6021397|NCT00223080|9616105|FG001|Overall Study|Moved from study area|47
6021398|NCT00223080|9616104|FG000|Overall Study|Lost to Follow-up|259
6021399|NCT00223080|9616105|FG001|Overall Study|Lost to Follow-up|284
6021400|NCT00223080|9616104|FG000|Overall Study|Death|85
6021401|NCT00223080|9616105|FG001|Overall Study|Death|74
6021402|NCT00223080|9616104|FG000|Overall Study|Other|14
6021403|NCT00223080|9616105|FG001|Overall Study|Other|11
6021404|NCT00223080|9616104|FG000|Overall Study|Reason not provided|141
6021405|NCT00223080|9616105|FG001|Overall Study|Reason not provided|140
6021406|NCT00223080|9616104|FG000|Overall Study|Adverse Event|0
6021407|NCT00223080|9616105|FG001|Overall Study|Adverse Event|1
6021408|NCT00223496|9616129|FG000|Overall Study|screen failure|9
6021409|NCT00223496|9616129|FG000|Overall Study|Lost to Follow-up|4
6021410|NCT00223496|9616129|FG000|Overall Study|Lack of Efficacy|6
6021411|NCT00223496|9616129|FG000|Overall Study|Withdrawal by Subject|1
6021412|NCT00223496|9616129|FG000|Overall Study|Physician Decision|2
6021413|NCT00223795|9616170|FG000|First Intervention - Eight Weeks|Lost to Follow-up|7
6021414|NCT00223795|9616171|FG001|First Intervention - Eight Weeks|Lost to Follow-up|9
6021415|NCT00223795|9616170|FG000|Second Intervention - All Use Canes 4 mo|Lost to Follow-up|1
6021416|NCT00223795|9616171|FG001|Second Intervention - All Use Canes 4 mo|Lost to Follow-up|1
6021417|NCT00223808|9616181|FG000|Overall Study|<5 hrs therapy before discharge|3
6021418|NCT00223808|9616182|FG001|Overall Study|<5 hrs therapy before discharge|5
6021419|NCT00223808|9616183|FG002|Overall Study|<5 hrs therapy before discharge|5
6048041|NCT00414661|9647130|FG000|Overall Study|Death|2
6048042|NCT00414661|9647131|FG001|Overall Study|Death|5
6048043|NCT00414661|9647132|FG002|Overall Study|Death|0
6048044|NCT00414661|9647133|FG003|Overall Study|Death|0
6048045|NCT00414661|9647130|FG000|Overall Study|Lost to Follow-up|1
6048046|NCT00414661|9647131|FG001|Overall Study|Lost to Follow-up|4
6048047|NCT00414661|9647132|FG002|Overall Study|Lost to Follow-up|0
6048048|NCT00414661|9647133|FG003|Overall Study|Lost to Follow-up|1
6048049|NCT00414661|9647130|FG000|Overall Study|Withdrawal by Subject|5
6048050|NCT00414661|9647131|FG001|Overall Study|Withdrawal by Subject|2
6048051|NCT00414661|9647132|FG002|Overall Study|Withdrawal by Subject|2
6048052|NCT00414661|9647133|FG003|Overall Study|Withdrawal by Subject|2
6048053|NCT00414661|9647130|FG000|Overall Study|Other|6
6048054|NCT00414661|9647131|FG001|Overall Study|Other|3
6048055|NCT00414661|9647132|FG002|Overall Study|Other|0
6048056|NCT00414661|9647133|FG003|Overall Study|Other|0
6048057|NCT00414726|9647154|FG000|Overall Study|Withdrawal by Subject|0
6048058|NCT00414726|9647155|FG001|Overall Study|Withdrawal by Subject|1
6048059|NCT00414765|9647163|FG000|Overall Study|Adverse Event|5
6048060|NCT00414765|9647164|FG001|Overall Study|Adverse Event|9
6048061|NCT00414765|9647163|FG000|Overall Study|Withdrawal by Subject|1
6048062|NCT00414765|9647164|FG001|Overall Study|Withdrawal by Subject|1
6048063|NCT00414765|9647163|FG000|Overall Study|Disease Progression|0
6048064|NCT00414765|9647164|FG001|Overall Study|Disease Progression|1
6048065|NCT00414908|9647181|FG000|Overall Study|Protocol Violation|1
6048066|NCT00414908|9647182|FG001|Overall Study|Protocol Violation|1
6048067|NCT00414960|9647192|FG000|Overall Study|Adverse Event|4
6048068|NCT00414960|9647193|FG001|Overall Study|Adverse Event|0
6048069|NCT00414960|9647192|FG000|Overall Study|Withdrawal by Subject|3
6048070|NCT00414960|9647193|FG001|Overall Study|Withdrawal by Subject|0
6048071|NCT00414960|9647192|FG000|Overall Study|Physician Decision|0
6048072|NCT00414960|9647193|FG001|Overall Study|Physician Decision|1
6048073|NCT00414973|9647203|FG000|Overall Study|Withdrawal by Subject|14
6048074|NCT00414973|9647204|FG001|Overall Study|Withdrawal by Subject|4
6048075|NCT00414973|9647205|FG002|Overall Study|Withdrawal by Subject|1
6048076|NCT00414973|9647206|FG003|Overall Study|Withdrawal by Subject|0
6048077|NCT00414973|9647203|FG000|Overall Study|Adverse Event|10
6048078|NCT00414973|9647204|FG001|Overall Study|Adverse Event|0
6048079|NCT00414973|9647205|FG002|Overall Study|Adverse Event|1
6048080|NCT00414973|9647206|FG003|Overall Study|Adverse Event|0
6048081|NCT00414973|9647203|FG000|Overall Study|Protocol Violation|3
6048082|NCT00414973|9647204|FG001|Overall Study|Protocol Violation|4
6048083|NCT00414973|9647205|FG002|Overall Study|Protocol Violation|0
6048084|NCT00414973|9647206|FG003|Overall Study|Protocol Violation|0
6048085|NCT00414973|9647203|FG000|Overall Study|Lost to Follow-up|0
6048086|NCT00414973|9647204|FG001|Overall Study|Lost to Follow-up|2
6048087|NCT00414973|9647205|FG002|Overall Study|Lost to Follow-up|0
6048088|NCT00414973|9647206|FG003|Overall Study|Lost to Follow-up|0
6048089|NCT00414973|9647203|FG000|Overall Study|Sponsor Decision|1
6021420|NCT00223977|9616203|FG000|Overall Study|Adverse Event|7
6021421|NCT00223977|9616204|FG001|Overall Study|Adverse Event|10
6021422|NCT00223977|9616205|FG002|Overall Study|Adverse Event|0
6021423|NCT00223977|9616203|FG000|Overall Study|Protocol Violation|0
6021424|NCT00223977|9616204|FG001|Overall Study|Protocol Violation|0
6021425|NCT00223977|9616205|FG002|Overall Study|Protocol Violation|1
6021426|NCT00223977|9616203|FG000|Overall Study|Withdrawal by Subject|1
6021427|NCT00223977|9616204|FG001|Overall Study|Withdrawal by Subject|1
6021428|NCT00223977|9616205|FG002|Overall Study|Withdrawal by Subject|2
6021429|NCT00223977|9616203|FG000|Overall Study|Other|1
6021430|NCT00223977|9616204|FG001|Overall Study|Other|0
6021431|NCT00223977|9616205|FG002|Overall Study|Other|0
6021432|NCT00223990|9616215|FG000|Overall Study|Moved from area|2
6021433|NCT00223990|9616216|FG001|Overall Study|Moved from area|1
6021434|NCT00223990|9616215|FG000|Overall Study|Withdrawal by Subject|4
6021435|NCT00223990|9616216|FG001|Overall Study|Withdrawal by Subject|8
6021436|NCT00223990|9616215|FG000|Overall Study|Lost to Follow-up|1
6021437|NCT00223990|9616216|FG001|Overall Study|Lost to Follow-up|0
6021438|NCT00224016|9616224|FG000|Titration Period|Withdrawal by Subject|0
6021439|NCT00224016|9616225|FG001|Titration Period|Withdrawal by Subject|1
6021440|NCT00224016|9616224|FG000|Titration Period|Lost to Follow-up|1
6021441|NCT00224016|9616225|FG001|Titration Period|Lost to Follow-up|0
6021442|NCT00224016|9616224|FG000|Maintenance Period|Withdrawal by Subject|2
6021443|NCT00224016|9616225|FG001|Maintenance Period|Withdrawal by Subject|0
6021444|NCT00224016|9616224|FG000|Maintenance Period|Lost to Follow-up|0
6021445|NCT00224016|9616225|FG001|Maintenance Period|Lost to Follow-up|1
6021446|NCT00224029|9616231|FG000|Overall Study|Lost to Follow-up|1
6021447|NCT00224029|9616231|FG000|Overall Study|Withdrawal by Subject|4
6021448|NCT00224029|9616231|FG000|Overall Study|Other|1
6021449|NCT00224042|9616237|FG000|Overall Study|Adverse Event|2
6021450|NCT00224042|9616238|FG001|Overall Study|Adverse Event|1
6021451|NCT00224042|9616237|FG000|Overall Study|Protocol Violation|0
6021452|NCT00224042|9616238|FG001|Overall Study|Protocol Violation|1
6021453|NCT00224042|9616237|FG000|Overall Study|Physician Decision|0
6021454|NCT00224042|9616238|FG001|Overall Study|Physician Decision|1
6021455|NCT00224042|9616237|FG000|Overall Study|Did not meet lab incusion criteria|2
6021456|NCT00224042|9616238|FG001|Overall Study|Did not meet lab incusion criteria|3
6021457|NCT00224042|9616237|FG000|Overall Study|Other|2
6021458|NCT00224042|9616238|FG001|Overall Study|Other|0
6021459|NCT00224055|9616246|FG000|Overall Study|Adverse Event|9
6021460|NCT00224055|9616247|FG001|Overall Study|Adverse Event|3
6021461|NCT00224055|9616246|FG000|Overall Study|Lost to Follow-up|1
6021462|NCT00224055|9616247|FG001|Overall Study|Lost to Follow-up|2
6021463|NCT00224055|9616246|FG000|Overall Study|Protocol Violation|1
6021464|NCT00224055|9616247|FG001|Overall Study|Protocol Violation|1
6021465|NCT00224055|9616246|FG000|Overall Study|Inclusion Violation|3
6021466|NCT00224055|9616247|FG001|Overall Study|Inclusion Violation|6
6021467|NCT00224055|9616246|FG000|Overall Study|Withdrawal by Subject|0
6021468|NCT00224055|9616247|FG001|Overall Study|Withdrawal by Subject|2
6021469|NCT00224055|9616246|FG000|Overall Study|Other|1
6021470|NCT00224055|9616247|FG001|Overall Study|Other|0
6021471|NCT00224107|9616255|FG000|Overall Study|Adverse Event|20
6021472|NCT00224107|9616256|FG001|Overall Study|Adverse Event|6
6021473|NCT00224107|9616255|FG000|Overall Study|Protocol Violation|2
6021474|NCT00224107|9616256|FG001|Overall Study|Protocol Violation|3
6021475|NCT00224107|9616255|FG000|Overall Study|Withdrawal by Subject|1
6021476|NCT00224107|9616256|FG001|Overall Study|Withdrawal by Subject|4
6021477|NCT00224107|9616255|FG000|Overall Study|Lack of Efficacy|2
6021478|NCT00224107|9616256|FG001|Overall Study|Lack of Efficacy|0
6021479|NCT00224107|9616255|FG000|Overall Study|Lost to Follow-up|4
6021480|NCT00224107|9616256|FG001|Overall Study|Lost to Follow-up|0
6021481|NCT00224107|9616255|FG000|Overall Study|Physician Decision|1
6021482|NCT00224107|9616256|FG001|Overall Study|Physician Decision|0
6021483|NCT00224107|9616255|FG000|Overall Study|Other|1
6021484|NCT00224107|9616256|FG001|Overall Study|Other|1
6021485|NCT00224120|9616264|FG000|Overall Study|Adverse Event|10
6021486|NCT00224120|9616265|FG001|Overall Study|Adverse Event|4
6021487|NCT00224120|9616264|FG000|Overall Study|Protocol Violation|1
6021488|NCT00224120|9616265|FG001|Overall Study|Protocol Violation|0
6021489|NCT00224120|9616264|FG000|Overall Study|Withdrawal by Subject|5
6021490|NCT00224120|9616265|FG001|Overall Study|Withdrawal by Subject|10
6021491|NCT00224120|9616264|FG000|Overall Study|Lack of Efficacy|0
6021492|NCT00224120|9616265|FG001|Overall Study|Lack of Efficacy|2
6021493|NCT00224120|9616264|FG000|Overall Study|Lost to Follow-up|2
6021494|NCT00224120|9616265|FG001|Overall Study|Lost to Follow-up|3
6021495|NCT00224120|9616264|FG000|Overall Study|Other|4
6021496|NCT00224120|9616265|FG001|Overall Study|Other|5
6021497|NCT00224133|9616271|FG000|Overall Study|Adverse Event|93
6021498|NCT00224133|9616271|FG000|Overall Study|Protocol Violation|6
6021499|NCT00224133|9616271|FG000|Overall Study|Withdrawal by Subject|33
6021500|NCT00224133|9616271|FG000|Overall Study|Lack of Efficacy|58
6021501|NCT00224133|9616271|FG000|Overall Study|Lost to Follow-up|21
6021502|NCT00224133|9616271|FG000|Overall Study|Physician Decision|1
6021503|NCT00224133|9616271|FG000|Overall Study|Other|14
6021504|NCT00224484|9616282|FG000|Overall Study|Serious Adverse Event|1
6021505|NCT00224484|9616283|FG001|Overall Study|Serious Adverse Event|1
6021506|NCT00224484|9616284|FG002|Overall Study|Serious Adverse Event|0
6021507|NCT00224484|9616282|FG000|Overall Study|Non-Serious Adverse Event|5
6021508|NCT00224484|9616283|FG001|Overall Study|Non-Serious Adverse Event|7
6021509|NCT00224484|9616284|FG002|Overall Study|Non-Serious Adverse Event|3
6021510|NCT00224484|9616282|FG000|Overall Study|Protocol Violation|2
6021511|NCT00224484|9616283|FG001|Overall Study|Protocol Violation|2
6021512|NCT00224484|9616284|FG002|Overall Study|Protocol Violation|0
6077990|NCT00601250|9684153|FG001|Overall Study|Adverse Event|9
6077991|NCT00601250|9684152|FG000|Overall Study|Protocol Violation|3
6077992|NCT00601250|9684153|FG001|Overall Study|Protocol Violation|2
6077993|NCT00601250|9684152|FG000|Overall Study|Lost to Follow-up|2
6077994|NCT00601250|9684153|FG001|Overall Study|Lost to Follow-up|6
6077995|NCT00601250|9684152|FG000|Overall Study|Withdrawal by Subject|4
6077996|NCT00601250|9684153|FG001|Overall Study|Withdrawal by Subject|13
6077997|NCT00601250|9684152|FG000|Overall Study|Other incl. lack of efficacy|2
6077998|NCT00601250|9684153|FG001|Overall Study|Other incl. lack of efficacy|9
6077999|NCT00601354|9684161|FG000|Overall Study|Lost to Follow-up|4
6078000|NCT00601354|9684162|FG001|Overall Study|Lost to Follow-up|5
6078001|NCT00601419|9684172|FG000|Overall Study|Lost to Follow-up|3
6078002|NCT00601419|9684172|FG000|Overall Study|Missed Visits|1
6078003|NCT00601458|9684195|FG000|Overall Study|Dosing Error|1
6078004|NCT00601458|9684196|FG001|Overall Study|Dosing Error|0
6078005|NCT00601458|9684197|FG002|Overall Study|Dosing Error|0
6078006|NCT00601458|9684195|FG000|Overall Study|Incomplete Data|0
6078007|NCT00601458|9684196|FG001|Overall Study|Incomplete Data|2
6078008|NCT00601458|9684197|FG002|Overall Study|Incomplete Data|0
6078009|NCT00601458|9684195|FG000|Overall Study|Protocol Violation|3
6078010|NCT00601458|9684196|FG001|Overall Study|Protocol Violation|2
6078011|NCT00601458|9684197|FG002|Overall Study|Protocol Violation|1
6078012|NCT00601458|9684195|FG000|Overall Study|Early Termination|0
6078013|NCT00601458|9684196|FG001|Overall Study|Early Termination|1
6078014|NCT00601458|9684197|FG002|Overall Study|Early Termination|1
6078015|NCT00601484|9684207|FG000|Overall Study|Adverse Event|0
6078016|NCT00601484|9684208|FG001|Overall Study|Adverse Event|1
6078017|NCT00601484|9684207|FG000|Overall Study|Lost to Follow-up|4
6078018|NCT00601484|9684208|FG001|Overall Study|Lost to Follow-up|3
6078019|NCT00601484|9684207|FG000|Overall Study|Lack of Efficacy|0
6078020|NCT00601484|9684208|FG001|Overall Study|Lack of Efficacy|2
6078021|NCT00601484|9684207|FG000|Overall Study|Withdrawal by Subject|1
6078022|NCT00601484|9684208|FG001|Overall Study|Withdrawal by Subject|1
6078023|NCT00601484|9684207|FG000|Overall Study|Randomized, but not treated|0
6078024|NCT00601484|9684208|FG001|Overall Study|Randomized, but not treated|1
6078025|NCT00601523|9684216|FG000|Overall Study|Adverse Event|42
6078026|NCT00601523|9684217|FG001|Overall Study|Adverse Event|14
6078027|NCT00601523|9684216|FG000|Overall Study|Lack of Efficacy|3
6078028|NCT00601523|9684217|FG001|Overall Study|Lack of Efficacy|0
6021513|NCT00224484|9616282|FG000|Overall Study|Withdrawal by Subject|49
6021514|NCT00224484|9616283|FG001|Overall Study|Withdrawal by Subject|18
6021515|NCT00224484|9616284|FG002|Overall Study|Withdrawal by Subject|16
6021516|NCT00224484|9616282|FG000|Overall Study|Migrated/moved from study area|18
6021517|NCT00224484|9616283|FG001|Overall Study|Migrated/moved from study area|5
6021518|NCT00224484|9616284|FG002|Overall Study|Migrated/moved from study area|5
6021519|NCT00224484|9616282|FG000|Overall Study|Lost to Follow-up|66
6021520|NCT00224484|9616283|FG001|Overall Study|Lost to Follow-up|28
6021521|NCT00224484|9616284|FG002|Overall Study|Lost to Follow-up|36
6021522|NCT00224484|9616282|FG000|Overall Study|Reason not specified|5
6021523|NCT00224484|9616283|FG001|Overall Study|Reason not specified|4
6021524|NCT00224484|9616284|FG002|Overall Study|Reason not specified|2
6021525|NCT00224770|9616298|FG000|Overall Study|Lost to Follow-up|4
6021526|NCT00224770|9616299|FG001|Overall Study|Lost to Follow-up|2
6021527|NCT00224770|9616300|FG002|Overall Study|Lost to Follow-up|0
6021528|NCT00224874|9616313|FG000|Overall Study|Withdrawal by Subject|0
6021529|NCT00224874|9616314|FG001|Overall Study|Withdrawal by Subject|0
6021530|NCT00224874|9616315|FG002|Overall Study|Withdrawal by Subject|1
6021531|NCT00224874|9616316|FG003|Overall Study|Withdrawal by Subject|0
6021532|NCT00224887|9616328|FG000|Overall Study|Pregnancy|6
6078029|NCT00601523|9684216|FG000|Overall Study|Protocol Violation|5
6078030|NCT00601523|9684217|FG001|Overall Study|Protocol Violation|1
6078031|NCT00601523|9684216|FG000|Overall Study|Lost to Follow-up|0
6078032|NCT00601523|9684217|FG001|Overall Study|Lost to Follow-up|1
6078033|NCT00601523|9684216|FG000|Overall Study|Withdrawal by Subject|18
6078034|NCT00601523|9684217|FG001|Overall Study|Withdrawal by Subject|9
6078035|NCT00601523|9684216|FG000|Overall Study|Other|9
6078036|NCT00601523|9684217|FG001|Overall Study|Other|1
6078037|NCT00601640|9684230|FG000|Overall Study|Withdrawal by Subject|3
6078038|NCT00601640|9684231|FG001|Overall Study|Withdrawal by Subject|0
6078039|NCT00601640|9684232|FG002|Overall Study|Withdrawal by Subject|7
6078040|NCT00601640|9684230|FG000|Overall Study|Death|1
6078041|NCT00601640|9684231|FG001|Overall Study|Death|0
6078042|NCT00601640|9684232|FG002|Overall Study|Death|0
6078043|NCT00601640|9684230|FG000|Overall Study|Adverse Event|0
6021533|NCT00224887|9616329|FG001|Overall Study|Pregnancy|6
6078044|NCT00601640|9684231|FG001|Overall Study|Adverse Event|4
6078045|NCT00601640|9684232|FG002|Overall Study|Adverse Event|2
6078046|NCT00601640|9684230|FG000|Overall Study|intercurrent illness|1
6078047|NCT00601640|9684231|FG001|Overall Study|intercurrent illness|0
6078048|NCT00601640|9684232|FG002|Overall Study|intercurrent illness|0
6021534|NCT00225147|9616362|FG000|Open-label Phase|Lost to Follow-up|0
6021535|NCT00225147|9616363|FG001|Open-label Phase|Lost to Follow-up|0
6021536|NCT00225147|9616364|FG002|Open-label Phase|Lost to Follow-up|0
6021537|NCT00225147|9616365|FG003|Open-label Phase|Lost to Follow-up|4
6021538|NCT00225147|9616362|FG000|Open-label Phase|Withdrawal by Subject|0
6021539|NCT00225147|9616363|FG001|Open-label Phase|Withdrawal by Subject|0
6021540|NCT00225147|9616364|FG002|Open-label Phase|Withdrawal by Subject|0
6021541|NCT00225147|9616365|FG003|Open-label Phase|Withdrawal by Subject|6
6021542|NCT00225212|9616377|FG000|Overall Study|Disease progression|2
6021543|NCT00225212|9616377|FG000|Overall Study|Death|1
6021544|NCT00225212|9616377|FG000|Overall Study|Adverse Event|2
6021545|NCT00225212|9616377|FG000|Overall Study|Intercurrent illness|1
6021546|NCT00225251|9616383|FG000|Overall Study|Withdrawal by Subject|1
6021547|NCT00225251|9616384|FG001|Overall Study|Withdrawal by Subject|1
6021548|NCT00225277|9616392|FG000|Overall Study|Adverse Event|30
6021549|NCT00225277|9616393|FG001|Overall Study|Adverse Event|34
6021550|NCT00225277|9616392|FG000|Overall Study|Lack of Efficacy|4
6021551|NCT00225277|9616393|FG001|Overall Study|Lack of Efficacy|1
6021552|NCT00225277|9616392|FG000|Overall Study|Lost to Follow-up|4
6021553|NCT00225277|9616393|FG001|Overall Study|Lost to Follow-up|6
6021554|NCT00225277|9616392|FG000|Overall Study|Physician Decision|6
6021555|NCT00225277|9616393|FG001|Overall Study|Physician Decision|8
6021556|NCT00225277|9616392|FG000|Overall Study|Protocol Violation|6
6021557|NCT00225277|9616393|FG001|Overall Study|Protocol Violation|3
6021558|NCT00225277|9616392|FG000|Overall Study|Withdrawal by Subject|40
6021559|NCT00225277|9616393|FG001|Overall Study|Withdrawal by Subject|34
6021560|NCT00225277|9616392|FG000|Overall Study|Other|7
6021561|NCT00225277|9616393|FG001|Overall Study|Other|9
6021562|NCT00225758|9616421|FG000|Overall Study|Adverse Event|4
6021563|NCT00226499|9616442|FG000|Overall Study|Adverse Event|10
6021564|NCT00226499|9616443|FG001|Overall Study|Adverse Event|6
6021565|NCT00226499|9616444|FG002|Overall Study|Adverse Event|3
6021566|NCT00226499|9616442|FG000|Overall Study|Others|1064
6021567|NCT00226499|9616443|FG001|Overall Study|Others|1066
6021568|NCT00226499|9616444|FG002|Overall Study|Others|356
6021569|NCT00226655|9616463|FG000|Overall Study|Death|13
6021570|NCT00226655|9616463|FG000|Overall Study|Withdrawal by Subject|15
6021571|NCT00226655|9616463|FG000|Overall Study|Adverse Event|35
6021572|NCT00226655|9616463|FG000|Overall Study|Physician Decision|6
6021573|NCT00226655|9616463|FG000|Overall Study|Clinical deterioration|10
6021574|NCT00226811|9616467|FG000|Overall Study|Death|8
6021575|NCT00226811|9616467|FG000|Overall Study|Adverse Event|11
6021576|NCT00226811|9616467|FG000|Overall Study|Lack of Efficacy|55
6021577|NCT00226811|9616467|FG000|Overall Study|Withdrawal by Subject|2
6021578|NCT00226941|9616475|FG000|Overall Study|Withdrawal by subject - toxicity|0
6021579|NCT00226941|9616476|FG001|Overall Study|Withdrawal by subject - toxicity|0
6021580|NCT00226941|9616477|FG002|Overall Study|Withdrawal by subject - toxicity|0
6021581|NCT00226941|9616478|FG003|Overall Study|Withdrawal by subject - toxicity|1
6021582|NCT00226941|9616475|FG000|Overall Study|Withdrawn by investigator - unrelated AE|0
6021583|NCT00226941|9616476|FG001|Overall Study|Withdrawn by investigator - unrelated AE|0
6021584|NCT00226941|9616477|FG002|Overall Study|Withdrawn by investigator - unrelated AE|0
6021585|NCT00226941|9616478|FG003|Overall Study|Withdrawn by investigator - unrelated AE|1
6021586|NCT00227266|9616502|FG000|Overall Study|Withdrawal by Subject|0
6021587|NCT00227266|9616503|FG001|Overall Study|Withdrawal by Subject|0
6021588|NCT00227266|9616504|FG002|Overall Study|Withdrawal by Subject|1
6021589|NCT00227266|9616502|FG000|Overall Study|Protocol Violation|1
6021590|NCT00227266|9616503|FG001|Overall Study|Protocol Violation|0
6021591|NCT00227266|9616504|FG002|Overall Study|Protocol Violation|1
6021592|NCT00227266|9616502|FG000|Overall Study|Excessive weight gain|0
6021593|NCT00227266|9616503|FG001|Overall Study|Excessive weight gain|0
6021594|NCT00227266|9616504|FG002|Overall Study|Excessive weight gain|2
6021595|NCT00227305|9616515|FG000|Overall Study|Adverse Event|40
6021596|NCT00227305|9616515|FG000|Overall Study|Withdrawal by Subject|42
6021597|NCT00227305|9616515|FG000|Overall Study|Lost to Follow-up|33
6021598|NCT00227305|9616515|FG000|Overall Study|Study specific discontinuation|13
6021599|NCT00227305|9616515|FG000|Overall Study|MOVED OUT OF AREA|3
6021600|NCT00227305|9616515|FG000|Overall Study|Lack of Efficacy|7
6021601|NCT00227305|9616515|FG000|Overall Study|Physician Decision|3
6021602|NCT00227305|9616515|FG000|Overall Study|PERIOD SHORTENED FROM 6 wks to 4 wks|1
6021603|NCT00227305|9616515|FG000|Overall Study|LEAVING TOWN FOR 6 WEEKS|1
6021604|NCT00227305|9616515|FG000|Overall Study|NECESSITY OF USING ANTI DEPRESSANT|1
6021605|NCT00227344|9616521|FG000|Overall Study|study terminated early|12
6021606|NCT00227344|9616522|FG001|Overall Study|study terminated early|5
6021607|NCT00227370|9616530|FG000|Overall Study|Withdrawal by Subject|1
6021608|NCT00227370|9616531|FG001|Overall Study|Withdrawal by Subject|2
6021609|NCT00227370|9616530|FG000|Overall Study|Death|3
6021610|NCT00227370|9616531|FG001|Overall Study|Death|4
6021611|NCT00227370|9616530|FG000|Overall Study|Adverse Event|6
6021612|NCT00227370|9616531|FG001|Overall Study|Adverse Event|11
6021613|NCT00227370|9616530|FG000|Overall Study|Physician Decision|9
6021614|NCT00227370|9616531|FG001|Overall Study|Physician Decision|6
6021615|NCT00227370|9616530|FG000|Overall Study|Other reasons|2
6021616|NCT00227370|9616531|FG001|Overall Study|Other reasons|1
6021617|NCT00227539|9616537|FG000|Overall Study|Protocol Violation|1
6021618|NCT00227591|9616541|FG000|Overall Study|Withdrawal by Subject|1
6021619|NCT00227721|9616559|FG000|Overall Study|On study, but never treated.|1
6021620|NCT00227877|9616571|FG000|Pre-visit Assessment|Technical difficulties|7
6021621|NCT00227877|9616572|FG001|Pre-visit Assessment|Technical difficulties|3
6021622|NCT00227877|9616573|FG002|Pre-visit Assessment|Technical difficulties|0
6021623|NCT00227877|9616574|FG003|Pre-visit Assessment|Technical difficulties|0
6021624|NCT00227877|9616571|FG000|Post-visit Checklist|Lost to Follow-up|24
6021625|NCT00227877|9616572|FG001|Post-visit Checklist|Lost to Follow-up|13
6021626|NCT00227877|9616573|FG002|Post-visit Checklist|Lost to Follow-up|1
6021627|NCT00227877|9616574|FG003|Post-visit Checklist|Lost to Follow-up|0
6021628|NCT00227877|9616571|FG000|3-months Follow-up|Completed late|135
6021629|NCT00227877|9616572|FG001|3-months Follow-up|Completed late|128
6021630|NCT00227877|9616573|FG002|3-months Follow-up|Completed late|34
6021631|NCT00227877|9616574|FG003|3-months Follow-up|Completed late|8
6021632|NCT00227877|9616571|FG000|3-months Follow-up|Lost to Follow-up|178
6021633|NCT00227877|9616572|FG001|3-months Follow-up|Lost to Follow-up|139
6021634|NCT00227877|9616573|FG002|3-months Follow-up|Lost to Follow-up|18
6021635|NCT00227877|9616574|FG003|3-months Follow-up|Lost to Follow-up|13
6021636|NCT00227877|9616571|FG000|12-months Follow-up|Completed late|78
6021637|NCT00227877|9616572|FG001|12-months Follow-up|Completed late|74
6021638|NCT00227877|9616573|FG002|12-months Follow-up|Completed late|1
6021639|NCT00227877|9616574|FG003|12-months Follow-up|Completed late|0
6021640|NCT00227877|9616571|FG000|12-months Follow-up|Lost to Follow-up|232
6021641|NCT00227877|9616572|FG001|12-months Follow-up|Lost to Follow-up|189
6021642|NCT00227877|9616573|FG002|12-months Follow-up|Lost to Follow-up|30
6021643|NCT00227877|9616574|FG003|12-months Follow-up|Lost to Follow-up|26
6021644|NCT00227903|9616588|FG000|Overall Study|Withdrawal by Subject|2
6021645|NCT00227903|9616589|FG001|Overall Study|Withdrawal by Subject|5
6021646|NCT00227903|9616588|FG000|Overall Study|Subject moved out of area|1
6021647|NCT00227903|9616589|FG001|Overall Study|Subject moved out of area|2
6021648|NCT00227903|9616588|FG000|Overall Study|Lost to Follow-up|1
6021649|NCT00227903|9616589|FG001|Overall Study|Lost to Follow-up|3
6021650|NCT00227903|9616588|FG000|Overall Study|Miscarriage|1
6021651|NCT00227903|9616589|FG001|Overall Study|Miscarriage|0
6021652|NCT00228384|9616606|FG000|Overall Study|Death|9
6021653|NCT00228384|9616607|FG001|Overall Study|Death|3
6021654|NCT00228384|9616606|FG000|Overall Study|Lost to Follow-up|6
6021655|NCT00228384|9616607|FG001|Overall Study|Lost to Follow-up|10
6021656|NCT00228384|9616606|FG000|Overall Study|Surgical Intervention (bypass)|5
6021657|NCT00228384|9616607|FG001|Overall Study|Surgical Intervention (bypass)|5
6021658|NCT00228384|9616606|FG000|Overall Study|Withdrawal by Subject|9
6021659|NCT00228384|9616607|FG001|Overall Study|Withdrawal by Subject|10
6021660|NCT00228384|9616606|FG000|Overall Study|Physician Decision|0
6021661|NCT00228384|9616607|FG001|Overall Study|Physician Decision|1
6021662|NCT00228423|9616615|FG000|Overall Study|Adverse Event|2
6021663|NCT00228423|9616616|FG001|Overall Study|Adverse Event|5
6021664|NCT00228423|9616615|FG000|Overall Study|Withdrawal by Subject|7
6021665|NCT00228423|9616616|FG001|Overall Study|Withdrawal by Subject|3
6021666|NCT00228423|9616615|FG000|Overall Study|Protocol Violation|1
6021667|NCT00228423|9616616|FG001|Overall Study|Protocol Violation|3
6021668|NCT00228423|9616615|FG000|Overall Study|Physician Decision|0
6021669|NCT00228423|9616616|FG001|Overall Study|Physician Decision|1
6021670|NCT00228553|9616622|FG000|Overall Study|Adverse Event|112
6021671|NCT00228553|9616622|FG000|Overall Study|Lack of Efficacy|34
6021672|NCT00228553|9616622|FG000|Overall Study|Lost to Follow-up|67
6021673|NCT00228553|9616622|FG000|Overall Study|Physician Decision|48
6021674|NCT00228553|9616622|FG000|Overall Study|Protocol Violation|6
6021675|NCT00228553|9616622|FG000|Overall Study|Withdrawal by Subject|115
6021676|NCT00228553|9616622|FG000|Overall Study|Pregnancy|2
6021677|NCT00228553|9616622|FG000|Overall Study|Miscellaneous|46
6021678|NCT00228566|9616626|FG000|Overall Study|Adverse Event|31
6021679|NCT00228566|9616626|FG000|Overall Study|Lack of Efficacy|14
6021680|NCT00228566|9616626|FG000|Overall Study|Lost to Follow-up|16
6021681|NCT00228566|9616626|FG000|Overall Study|Physician Decision|5
6021682|NCT00228566|9616626|FG000|Overall Study|Withdrawal by Subject|4
6021683|NCT00228566|9616626|FG000|Overall Study|Miscellaneous|1
6021684|NCT00228813|9616630|FG000|Overall Study|Death|4
6021685|NCT00228917|9616642|FG000|Overall Study|Migrated/moved from study area|0
6021686|NCT00228917|9616643|FG001|Overall Study|Migrated/moved from study area|0
6021687|NCT00228917|9616644|FG002|Overall Study|Migrated/moved from study area|0
6021688|NCT00228917|9616645|FG003|Overall Study|Migrated/moved from study area|0
6021689|NCT00228917|9616646|FG004|Overall Study|Migrated/moved from study area|0
6021690|NCT00228917|9616647|FG005|Overall Study|Migrated/moved from study area|2
6021691|NCT00228917|9616648|FG006|Overall Study|Migrated/moved from study area|0
6021692|NCT00228917|9616649|FG007|Overall Study|Migrated/moved from study area|0
6021693|NCT00229203|9616671|FG000|Overall Study|Progressive disease|18
6021694|NCT00229203|9616672|FG001|Overall Study|Progressive disease|9
6021695|NCT00229203|9616671|FG000|Overall Study|Toxicity|6
6021696|NCT00229203|9616672|FG001|Overall Study|Toxicity|1
6021697|NCT00229203|9616671|FG000|Overall Study|Death|4
6021698|NCT00229203|9616672|FG001|Overall Study|Death|2
6021699|NCT00229203|9616671|FG000|Overall Study|Other|3
6021700|NCT00229203|9616672|FG001|Overall Study|Other|3
6021701|NCT00229203|9616671|FG000|Overall Study|Withdrawal by Subject|1
6021702|NCT00229203|9616672|FG001|Overall Study|Withdrawal by Subject|4
6021703|NCT00229658|9616686|FG000|Overall Study|Administrative|2
6021704|NCT00229658|9616687|FG001|Overall Study|Administrative|1
6021705|NCT00229658|9616686|FG000|Overall Study|Investigator decision|13
6021706|NCT00229658|9616687|FG001|Overall Study|Investigator decision|10
6021707|NCT00229658|9616686|FG000|Overall Study|Other|80
6021708|NCT00229658|9616687|FG001|Overall Study|Other|60
6021709|NCT00229658|9616686|FG000|Overall Study|Lost to Follow-up|82
6021710|NCT00229658|9616687|FG001|Overall Study|Lost to Follow-up|55
6021711|NCT00229658|9616686|FG000|Overall Study|Serious Adverse Event|2
6021712|NCT00229658|9616687|FG001|Overall Study|Serious Adverse Event|2
6021713|NCT00229658|9616686|FG000|Overall Study|Withdrawal of consent|46
6021714|NCT00229658|9616687|FG001|Overall Study|Withdrawal of consent|39
6021715|NCT00229723|9616700|FG000|Concomitant Phase|Adverse Event|4
6021716|NCT00229723|9616701|FG001|Concomitant Phase|Adverse Event|2
6021717|NCT00229723|9616702|FG002|Concomitant Phase|Adverse Event|5
6021718|NCT00229723|9616703|FG003|Concomitant Phase|Adverse Event|2
6021719|NCT00229723|9616704|FG004|Concomitant Phase|Adverse Event|0
6021720|NCT00229723|9616705|FG005|Concomitant Phase|Adverse Event|1
6021721|NCT00229723|9616706|FG006|Concomitant Phase|Adverse Event|2
6021722|NCT00229723|9616700|FG000|Concomitant Phase|Objective disease progression|0
6021723|NCT00229723|9616701|FG001|Concomitant Phase|Objective disease progression|0
6021724|NCT00229723|9616702|FG002|Concomitant Phase|Objective disease progression|0
6021725|NCT00229723|9616703|FG003|Concomitant Phase|Objective disease progression|0
6021726|NCT00229723|9616704|FG004|Concomitant Phase|Objective disease progression|0
6021727|NCT00229723|9616705|FG005|Concomitant Phase|Objective disease progression|0
6021728|NCT00229723|9616706|FG006|Concomitant Phase|Objective disease progression|0
6021729|NCT00229723|9616700|FG000|Concomitant Phase|Clinical progression|0
6021730|NCT00229723|9616701|FG001|Concomitant Phase|Clinical progression|0
6021731|NCT00229723|9616702|FG002|Concomitant Phase|Clinical progression|0
6021732|NCT00229723|9616703|FG003|Concomitant Phase|Clinical progression|0
6021733|NCT00229723|9616704|FG004|Concomitant Phase|Clinical progression|0
6021734|NCT00229723|9616705|FG005|Concomitant Phase|Clinical progression|0
6021735|NCT00229723|9616706|FG006|Concomitant Phase|Clinical progression|1
6021736|NCT00229723|9616700|FG000|Concomitant Phase|Lost to Follow-up|0
6021737|NCT00229723|9616701|FG001|Concomitant Phase|Lost to Follow-up|0
6021738|NCT00229723|9616702|FG002|Concomitant Phase|Lost to Follow-up|0
6021739|NCT00229723|9616703|FG003|Concomitant Phase|Lost to Follow-up|0
6021740|NCT00229723|9616704|FG004|Concomitant Phase|Lost to Follow-up|1
6021741|NCT00229723|9616705|FG005|Concomitant Phase|Lost to Follow-up|0
6021742|NCT00229723|9616706|FG006|Concomitant Phase|Lost to Follow-up|0
6021743|NCT00229723|9616700|FG000|Concomitant Phase|Informed consent withdrawn|3
6021744|NCT00229723|9616701|FG001|Concomitant Phase|Informed consent withdrawn|2
6021745|NCT00229723|9616702|FG002|Concomitant Phase|Informed consent withdrawn|0
6021746|NCT00229723|9616703|FG003|Concomitant Phase|Informed consent withdrawn|2
6021747|NCT00229723|9616704|FG004|Concomitant Phase|Informed consent withdrawn|0
6021748|NCT00229723|9616705|FG005|Concomitant Phase|Informed consent withdrawn|0
6021749|NCT00229723|9616706|FG006|Concomitant Phase|Informed consent withdrawn|0
6021750|NCT00229723|9616700|FG000|Concomitant Phase|Severe non-compliance|0
6021751|NCT00229723|9616701|FG001|Concomitant Phase|Severe non-compliance|1
6021752|NCT00229723|9616702|FG002|Concomitant Phase|Severe non-compliance|0
6021753|NCT00229723|9616703|FG003|Concomitant Phase|Severe non-compliance|0
6021754|NCT00229723|9616704|FG004|Concomitant Phase|Severe non-compliance|1
6021755|NCT00229723|9616705|FG005|Concomitant Phase|Severe non-compliance|0
6021756|NCT00229723|9616706|FG006|Concomitant Phase|Severe non-compliance|0
6021757|NCT00229723|9616700|FG000|Concomitant Phase|Other|3
6021758|NCT00229723|9616701|FG001|Concomitant Phase|Other|0
6021759|NCT00229723|9616702|FG002|Concomitant Phase|Other|1
6021760|NCT00229723|9616703|FG003|Concomitant Phase|Other|1
6021761|NCT00229723|9616704|FG004|Concomitant Phase|Other|0
6021762|NCT00229723|9616705|FG005|Concomitant Phase|Other|2
6021763|NCT00229723|9616706|FG006|Concomitant Phase|Other|0
6021764|NCT00229723|9616700|FG000|Maintenance Phase|Adverse Event|7
6021765|NCT00229723|9616701|FG001|Maintenance Phase|Adverse Event|2
6021766|NCT00229723|9616702|FG002|Maintenance Phase|Adverse Event|1
6021767|NCT00229723|9616703|FG003|Maintenance Phase|Adverse Event|4
6021768|NCT00229723|9616704|FG004|Maintenance Phase|Adverse Event|7
6021769|NCT00229723|9616705|FG005|Maintenance Phase|Adverse Event|5
6021770|NCT00229723|9616706|FG006|Maintenance Phase|Adverse Event|2
6021771|NCT00229723|9616700|FG000|Maintenance Phase|Objective disease progression|5
6021772|NCT00229723|9616701|FG001|Maintenance Phase|Objective disease progression|5
6021773|NCT00229723|9616702|FG002|Maintenance Phase|Objective disease progression|3
6021774|NCT00229723|9616703|FG003|Maintenance Phase|Objective disease progression|6
6021775|NCT00229723|9616704|FG004|Maintenance Phase|Objective disease progression|2
6021776|NCT00229723|9616705|FG005|Maintenance Phase|Objective disease progression|9
6021777|NCT00229723|9616706|FG006|Maintenance Phase|Objective disease progression|5
6021778|NCT00229723|9616700|FG000|Maintenance Phase|Clinical progression|4
6021779|NCT00229723|9616701|FG001|Maintenance Phase|Clinical progression|1
6021780|NCT00229723|9616702|FG002|Maintenance Phase|Clinical progression|2
6021781|NCT00229723|9616703|FG003|Maintenance Phase|Clinical progression|2
6021782|NCT00229723|9616704|FG004|Maintenance Phase|Clinical progression|1
6021783|NCT00229723|9616705|FG005|Maintenance Phase|Clinical progression|1
6021784|NCT00229723|9616706|FG006|Maintenance Phase|Clinical progression|1
6021785|NCT00229723|9616700|FG000|Maintenance Phase|Lost to Follow-up|0
6021786|NCT00229723|9616701|FG001|Maintenance Phase|Lost to Follow-up|1
6021787|NCT00229723|9616702|FG002|Maintenance Phase|Lost to Follow-up|2
6021788|NCT00229723|9616703|FG003|Maintenance Phase|Lost to Follow-up|2
6021789|NCT00229723|9616704|FG004|Maintenance Phase|Lost to Follow-up|0
6021790|NCT00229723|9616705|FG005|Maintenance Phase|Lost to Follow-up|0
6021791|NCT00229723|9616706|FG006|Maintenance Phase|Lost to Follow-up|1
6021792|NCT00229723|9616700|FG000|Maintenance Phase|Informed consent withdrawn|1
6021793|NCT00229723|9616701|FG001|Maintenance Phase|Informed consent withdrawn|0
6021794|NCT00229723|9616702|FG002|Maintenance Phase|Informed consent withdrawn|0
6021795|NCT00229723|9616703|FG003|Maintenance Phase|Informed consent withdrawn|1
6021796|NCT00229723|9616704|FG004|Maintenance Phase|Informed consent withdrawn|1
6021797|NCT00229723|9616705|FG005|Maintenance Phase|Informed consent withdrawn|1
6021798|NCT00229723|9616706|FG006|Maintenance Phase|Informed consent withdrawn|0
6021799|NCT00229723|9616700|FG000|Maintenance Phase|Severe non-compliance|3
6021800|NCT00229723|9616701|FG001|Maintenance Phase|Severe non-compliance|1
6021801|NCT00229723|9616702|FG002|Maintenance Phase|Severe non-compliance|0
6021802|NCT00229723|9616703|FG003|Maintenance Phase|Severe non-compliance|0
6021803|NCT00229723|9616704|FG004|Maintenance Phase|Severe non-compliance|1
6021804|NCT00229723|9616705|FG005|Maintenance Phase|Severe non-compliance|0
6021805|NCT00229723|9616706|FG006|Maintenance Phase|Severe non-compliance|0
6021806|NCT00229723|9616700|FG000|Maintenance Phase|Other|5
6021807|NCT00229723|9616701|FG001|Maintenance Phase|Other|4
6021808|NCT00229723|9616702|FG002|Maintenance Phase|Other|1
6021809|NCT00229723|9616703|FG003|Maintenance Phase|Other|2
6021810|NCT00229723|9616704|FG004|Maintenance Phase|Other|3
6021811|NCT00229723|9616705|FG005|Maintenance Phase|Other|3
6021812|NCT00229723|9616706|FG006|Maintenance Phase|Other|1
6021813|NCT00230048|9616751|FG000|Overall Study|Lost to Follow-up|13
6021814|NCT00230048|9616752|FG001|Overall Study|Lost to Follow-up|18
6021815|NCT00230178|9616783|FG000|Overall Study|Adverse Event|1
6021816|NCT00230178|9616784|FG001|Overall Study|Adverse Event|5
6021817|NCT00230178|9616785|FG002|Overall Study|Adverse Event|2
6021818|NCT00230178|9616783|FG000|Overall Study|Withdrawal by Subject|0
6021819|NCT00230178|9616784|FG001|Overall Study|Withdrawal by Subject|0
6021820|NCT00230178|9616785|FG002|Overall Study|Withdrawal by Subject|1
6021821|NCT00230178|9616783|FG000|Overall Study|Various other reasons|3
6021822|NCT00230178|9616784|FG001|Overall Study|Various other reasons|2
6021823|NCT00230178|9616785|FG002|Overall Study|Various other reasons|4
6021824|NCT00230282|9616793|FG000|Fludarabine + Cyclophosphamide|Lost to Follow-up|4
6021825|NCT00230282|9616793|FG000|Fludarabine + Cyclophosphamide|Withdrawal by Subject|1
6021826|NCT00230282|9616793|FG000|Fludarabine + Cyclophosphamide|Change in diagnosis|1
6021827|NCT00230282|9616793|FG000|Fludarabine + Cyclophosphamide|Richters transformation (progression)|2
6021828|NCT00230971|9616823|FG000|Randomization|No study drug administered|3
6021829|NCT00230971|9616824|FG001|Randomization|No study drug administered|3
6021830|NCT00230971|9616823|FG000|Baseline Participants|Lost to Follow-up|5
6021831|NCT00230971|9616824|FG001|Baseline Participants|Lost to Follow-up|12
6021832|NCT00230971|9616823|FG000|Baseline Participants|Death|6
6021833|NCT00230971|9616824|FG001|Baseline Participants|Death|5
6021834|NCT00230971|9616823|FG000|Baseline Participants|Withdrawal by Subject|7
6021835|NCT00230971|9616824|FG001|Baseline Participants|Withdrawal by Subject|1
6021836|NCT00230971|9616823|FG000|Baseline Participants|Adverse Event|1
6021837|NCT00230971|9616824|FG001|Baseline Participants|Adverse Event|0
6021838|NCT00230971|9616823|FG000|Baseline Participants|No bacteria observed|1
6021839|NCT00230971|9616824|FG001|Baseline Participants|No bacteria observed|0
6021840|NCT00230971|9616823|FG000|Baseline Participants|Failure to return|1
6021841|NCT00230971|9616824|FG001|Baseline Participants|Failure to return|1
6021842|NCT00230971|9616823|FG000|Baseline Participants|Reintervention|1
6021843|NCT00230971|9616824|FG001|Baseline Participants|Reintervention|0
6021844|NCT00231062|9616830|FG000|Overall Study|Physician Decision|6
6021845|NCT00231114|9616836|FG000|Randomized|Withdrawal by Subject|6
6021846|NCT00231114|9616837|FG001|Randomized|Withdrawal by Subject|3
6021847|NCT00231114|9616836|FG000|Treatment Period|Death: Motor Vehicle Accident|1
6021848|NCT00231114|9616837|FG001|Treatment Period|Death: Motor Vehicle Accident|0
6021849|NCT00231114|9616836|FG000|Post-Treatment Period|Lost to Follow-up|6
6021850|NCT00231114|9616837|FG001|Post-Treatment Period|Lost to Follow-up|1
6021851|NCT00231114|9616836|FG000|Post-Treatment Period|Physician Decision|1
6021852|NCT00231114|9616837|FG001|Post-Treatment Period|Physician Decision|0
6021853|NCT00231114|9616836|FG000|Post-Treatment Period|Withdrawal by Subject|1
6021854|NCT00231114|9616837|FG001|Post-Treatment Period|Withdrawal by Subject|0
6021855|NCT00231179|9616847|FG000|Overall Study|Lost to Follow-up|21
6021856|NCT00231179|9616848|FG001|Overall Study|Lost to Follow-up|21
6021857|NCT00231179|9616847|FG000|Overall Study|Withdrawal by Subject|3
6021858|NCT00231179|9616848|FG001|Overall Study|Withdrawal by Subject|3
6021859|NCT00231413|9616870|FG000|Overall Study|Non-serious AE|0
6021860|NCT00231413|9616871|FG001|Overall Study|Non-serious AE|0
6021861|NCT00231413|9616872|FG002|Overall Study|Non-serious AE|1
6021862|NCT00231413|9616873|FG003|Overall Study|Non-serious AE|0
6021863|NCT00231413|9616874|FG004|Overall Study|Non-serious AE|0
6021864|NCT00231413|9616875|FG005|Overall Study|Non-serious AE|0
6021865|NCT00231413|9616876|FG006|Overall Study|Non-serious AE|1
6021866|NCT00231413|9616870|FG000|Overall Study|Withdrawal by Subject|3
6021867|NCT00231413|9616871|FG001|Overall Study|Withdrawal by Subject|1
6021868|NCT00231413|9616872|FG002|Overall Study|Withdrawal by Subject|4
6021869|NCT00231413|9616873|FG003|Overall Study|Withdrawal by Subject|2
6021870|NCT00231413|9616874|FG004|Overall Study|Withdrawal by Subject|2
6021871|NCT00231413|9616875|FG005|Overall Study|Withdrawal by Subject|0
6021872|NCT00231413|9616876|FG006|Overall Study|Withdrawal by Subject|3
6021873|NCT00231413|9616870|FG000|Overall Study|Migrated/moved from study area|0
6021874|NCT00231413|9616871|FG001|Overall Study|Migrated/moved from study area|0
6021875|NCT00231413|9616872|FG002|Overall Study|Migrated/moved from study area|1
6021876|NCT00231413|9616873|FG003|Overall Study|Migrated/moved from study area|0
6021877|NCT00231413|9616874|FG004|Overall Study|Migrated/moved from study area|0
6021878|NCT00231413|9616875|FG005|Overall Study|Migrated/moved from study area|1
6021879|NCT00231413|9616876|FG006|Overall Study|Migrated/moved from study area|0
6021880|NCT00231413|9616870|FG000|Overall Study|Lost to Follow-up|4
6021881|NCT00231413|9616871|FG001|Overall Study|Lost to Follow-up|4
6021882|NCT00231413|9616872|FG002|Overall Study|Lost to Follow-up|1
6021883|NCT00231413|9616873|FG003|Overall Study|Lost to Follow-up|1
6021884|NCT00231413|9616874|FG004|Overall Study|Lost to Follow-up|1
6021885|NCT00231413|9616875|FG005|Overall Study|Lost to Follow-up|4
6021886|NCT00231413|9616876|FG006|Overall Study|Lost to Follow-up|0
6021887|NCT00231413|9616870|FG000|Overall Study|Pregnancy|1
6021888|NCT00231413|9616871|FG001|Overall Study|Pregnancy|0
6021889|NCT00231413|9616872|FG002|Overall Study|Pregnancy|0
6021890|NCT00231413|9616873|FG003|Overall Study|Pregnancy|0
6021891|NCT00231413|9616874|FG004|Overall Study|Pregnancy|0
6021892|NCT00231413|9616875|FG005|Overall Study|Pregnancy|0
6021893|NCT00231413|9616876|FG006|Overall Study|Pregnancy|0
6021894|NCT00231465|9616892|FG000|Overall Study|Completed only one cycle|1
6021895|NCT00231465|9616892|FG000|Overall Study|Did not have follow up CT scans|1
6021896|NCT00231478|9616898|FG000|Overall Study|Protocol Violation|3
6021897|NCT00231478|9616899|FG001|Overall Study|Protocol Violation|2
6021898|NCT00231478|9616898|FG000|Overall Study|Refused Treatment|1
6021899|NCT00231478|9616899|FG001|Overall Study|Refused Treatment|1
6021900|NCT00231478|9616898|FG000|Overall Study|Withdrawal by Subject|1
6021901|NCT00231478|9616899|FG001|Overall Study|Withdrawal by Subject|0
6021902|NCT00231478|9616898|FG000|Overall Study|Adverse Event|0
6021903|NCT00231478|9616899|FG001|Overall Study|Adverse Event|1
6021904|NCT00231478|9616898|FG000|Overall Study|Administrative|3
6021905|NCT00231478|9616899|FG001|Overall Study|Administrative|2
6021906|NCT00231777|9616907|FG000|Overall Study|Lost to Follow-up|3
6021907|NCT00231777|9616908|FG001|Overall Study|Lost to Follow-up|0
6021908|NCT00231777|9616907|FG000|Overall Study|Other|3
6021909|NCT00231777|9616908|FG001|Overall Study|Other|2
6021910|NCT00231816|9616916|FG000|Overall Study|Adverse Event|1
6021911|NCT00231816|9616917|FG001|Overall Study|Adverse Event|0
6021912|NCT00231816|9616916|FG000|Overall Study|Lost to Follow-up|8
6021913|NCT00231816|9616917|FG001|Overall Study|Lost to Follow-up|5
6021914|NCT00231816|9616916|FG000|Overall Study|Protocol Violation|2
6021915|NCT00231816|9616917|FG001|Overall Study|Protocol Violation|3
6021916|NCT00231816|9616916|FG000|Overall Study|Withdrawal by Subject|3
6021917|NCT00231816|9616917|FG001|Overall Study|Withdrawal by Subject|3
6021918|NCT00231816|9616916|FG000|Overall Study|Other|2
6021919|NCT00231816|9616917|FG001|Overall Study|Other|1
6021920|NCT00231842|9616924|FG000|Overall Study|Withdrawal by Subject|3
6021921|NCT00231842|9616924|FG000|Overall Study|Did not complete the last 3 cycle|8
6021922|NCT00231894|9616935|FG000|Overall Study|Withdrawal by Subject|1
6021923|NCT00231894|9616936|FG001|Overall Study|Withdrawal by Subject|1
6021924|NCT00232180|9616950|FG000|Double-blind (DB) Phase|Death|186
6021925|NCT00232180|9616951|FG001|Double-blind (DB) Phase|Death|222
6021926|NCT00232180|9616952|FG002|Double-blind (DB) Phase|Death|0
6021927|NCT00232180|9616950|FG000|Double-blind (DB) Phase|Lost to Follow-up|34
6021928|NCT00232180|9616951|FG001|Double-blind (DB) Phase|Lost to Follow-up|28
6021929|NCT00232180|9616952|FG002|Double-blind (DB) Phase|Lost to Follow-up|0
6021930|NCT00232180|9616950|FG000|Double-blind (DB) Phase|Withdrawal by Subject|131
6021931|NCT00232180|9616951|FG001|Double-blind (DB) Phase|Withdrawal by Subject|148
6021932|NCT00232180|9616952|FG002|Double-blind (DB) Phase|Withdrawal by Subject|0
6021933|NCT00232180|9616950|FG000|Double-blind (DB) Phase|Protocol Violation|28
6021934|NCT00232180|9616951|FG001|Double-blind (DB) Phase|Protocol Violation|21
6021935|NCT00232180|9616952|FG002|Double-blind (DB) Phase|Protocol Violation|0
6021936|NCT00232180|9616950|FG000|Double-blind (DB) Phase|Adverse Event|83
6021937|NCT00232180|9616951|FG001|Double-blind (DB) Phase|Adverse Event|100
6021938|NCT00232180|9616952|FG002|Double-blind (DB) Phase|Adverse Event|0
6021939|NCT00232180|9616950|FG000|Double-blind (DB) Phase|Other|70
6021940|NCT00232180|9616951|FG001|Double-blind (DB) Phase|Other|75
6021941|NCT00232180|9616952|FG002|Double-blind (DB) Phase|Other|0
6021942|NCT00232180|9616950|FG000|Double-blind (DB) Phase|Randomized but not treated|3
6021943|NCT00232180|9616951|FG001|Double-blind (DB) Phase|Randomized but not treated|4
6021944|NCT00232180|9616952|FG002|Double-blind (DB) Phase|Randomized but not treated|0
6021945|NCT00232180|9616950|FG000|Double-blind (DB) Phase|Laboratory abnormality|6
6021946|NCT00232180|9616951|FG001|Double-blind (DB) Phase|Laboratory abnormality|7
6021947|NCT00232180|9616952|FG002|Double-blind (DB) Phase|Laboratory abnormality|0
6021948|NCT00232180|9616950|FG000|Open Label Phase|Death|0
6021949|NCT00232180|9616951|FG001|Open Label Phase|Death|0
6021950|NCT00232180|9616952|FG002|Open Label Phase|Death|48
6021951|NCT00232180|9616950|FG000|Open Label Phase|Lost to Follow-up|0
6021952|NCT00232180|9616951|FG001|Open Label Phase|Lost to Follow-up|0
6021953|NCT00232180|9616952|FG002|Open Label Phase|Lost to Follow-up|5
6021954|NCT00232180|9616950|FG000|Open Label Phase|Protocol Violation|0
6021955|NCT00232180|9616951|FG001|Open Label Phase|Protocol Violation|0
6021956|NCT00232180|9616952|FG002|Open Label Phase|Protocol Violation|3
6021957|NCT00232180|9616950|FG000|Open Label Phase|Study terminated by sponsor|0
6021958|NCT00232180|9616951|FG001|Open Label Phase|Study terminated by sponsor|0
6021959|NCT00232180|9616952|FG002|Open Label Phase|Study terminated by sponsor|3
6021960|NCT00232180|9616950|FG000|Open Label Phase|Withdrawal by Subject|0
6021961|NCT00232180|9616951|FG001|Open Label Phase|Withdrawal by Subject|0
6021962|NCT00232180|9616952|FG002|Open Label Phase|Withdrawal by Subject|37
6021963|NCT00232180|9616950|FG000|Open Label Phase|Other|0
6021964|NCT00232180|9616951|FG001|Open Label Phase|Other|0
6021965|NCT00232180|9616952|FG002|Open Label Phase|Other|16
6021966|NCT00232180|9616950|FG000|Open Label Phase|Adverse Event|0
6021967|NCT00232180|9616951|FG001|Open Label Phase|Adverse Event|0
6021968|NCT00232180|9616952|FG002|Open Label Phase|Adverse Event|25
6021969|NCT00232180|9616950|FG000|Open Label Phase|Laboratory abnormality|0
6021970|NCT00232180|9616951|FG001|Open Label Phase|Laboratory abnormality|0
6021971|NCT00232180|9616952|FG002|Open Label Phase|Laboratory abnormality|10
6021972|NCT00232180|9616950|FG000|Open Label Phase|Randomized but not treated|0
6021973|NCT00232180|9616951|FG001|Open Label Phase|Randomized but not treated|0
6021974|NCT00232180|9616952|FG002|Open Label Phase|Randomized but not treated|1
6021975|NCT00232544|9616981|FG000|Overall Study|Lost to Follow-up|20
6021976|NCT00232544|9616982|FG001|Overall Study|Lost to Follow-up|15
6021977|NCT00232557|9616990|FG000|Overall Study|Lost to Follow-up|3
6021978|NCT00232557|9616991|FG001|Overall Study|Lost to Follow-up|5
6021979|NCT00232596|9617012|FG000|6-Week Titration Phase|Adverse Event|6
6021980|NCT00232596|9617013|FG001|6-Week Titration Phase|Adverse Event|19
6021981|NCT00232596|9617012|FG000|6-Week Titration Phase|Failed to Return|2
6021982|NCT00232596|9617013|FG001|6-Week Titration Phase|Failed to Return|1
6021983|NCT00232596|9617012|FG000|6-Week Titration Phase|Unsatisfactory Response - Efficacy|1
6021984|NCT00232596|9617013|FG001|6-Week Titration Phase|Unsatisfactory Response - Efficacy|2
6021985|NCT00232596|9617012|FG000|6-Week Titration Phase|Protocol Violation|1
6021986|NCT00232596|9617013|FG001|6-Week Titration Phase|Protocol Violation|3
6021987|NCT00232596|9617012|FG000|6-Week Titration Phase|Participant Request Unrelated to Study|1
6021988|NCT00232596|9617013|FG001|6-Week Titration Phase|Participant Request Unrelated to Study|0
6021989|NCT00232596|9617012|FG000|6-Week Titration Phase|Other|3
6021990|NCT00232596|9617013|FG001|6-Week Titration Phase|Other|3
6021991|NCT00232596|9617012|FG000|6-Week Titration Phase|Participant Did Not Receive Study Drug|0
6021992|NCT00232596|9617013|FG001|6-Week Titration Phase|Participant Did Not Receive Study Drug|1
6021993|NCT00232596|9617012|FG000|12-Week Maintenance Phase|Adverse Event|7
6021994|NCT00232596|9617013|FG001|12-Week Maintenance Phase|Adverse Event|22
6021995|NCT00232596|9617012|FG000|12-Week Maintenance Phase|Unsatisfactory Response -Efficacy|1
6021996|NCT00232596|9617013|FG001|12-Week Maintenance Phase|Unsatisfactory Response -Efficacy|2
6021997|NCT00232596|9617012|FG000|12-Week Maintenance Phase|Protocol Violation|3
6021998|NCT00232596|9617013|FG001|12-Week Maintenance Phase|Protocol Violation|1
6021999|NCT00232596|9617012|FG000|12-Week Maintenance Phase|Other|1
6022000|NCT00232596|9617013|FG001|12-Week Maintenance Phase|Other|3
6022001|NCT00233064|9617037|FG000|Overall Study|Lost to Follow-up|7
6022002|NCT00233064|9617038|FG001|Overall Study|Lost to Follow-up|7
6022003|NCT00233064|9617037|FG000|Overall Study|Withdrawal by Subject|5
6022004|NCT00233064|9617038|FG001|Overall Study|Withdrawal by Subject|3
6022005|NCT00233064|9617037|FG000|Overall Study|Death|0
6022006|NCT00233064|9617038|FG001|Overall Study|Death|1
6022007|NCT00233064|9617037|FG000|Overall Study|Relocation|0
6022008|NCT00233064|9617038|FG001|Overall Study|Relocation|1
6022009|NCT00233064|9617037|FG000|Overall Study|Protocol Violation|1
6022010|NCT00233064|9617038|FG001|Overall Study|Protocol Violation|0
6022011|NCT00233064|9617037|FG000|Overall Study|Moved to Dom. Republic|1
6022012|NCT00233064|9617038|FG001|Overall Study|Moved to Dom. Republic|0
6022013|NCT00233324|9617058|FG000|Main Study|Death|68
6022014|NCT00233324|9617059|FG001|Main Study|Death|60
6022015|NCT00233324|9617060|FG002|Main Study|Death|62
6022016|NCT00233324|9617061|FG003|Main Study|Death|47
6022017|NCT00233324|9617058|FG000|Follow up at 18-22 Months Corrected Age|Death|5
6022018|NCT00233324|9617059|FG001|Follow up at 18-22 Months Corrected Age|Death|7
6022019|NCT00233324|9617060|FG002|Follow up at 18-22 Months Corrected Age|Death|5
6022020|NCT00233324|9617061|FG003|Follow up at 18-22 Months Corrected Age|Death|4
6022021|NCT00233324|9617058|FG000|Follow up at 18-22 Months Corrected Age|Undetermined retinopathy status|8
6022022|NCT00233324|9617059|FG001|Follow up at 18-22 Months Corrected Age|Undetermined retinopathy status|7
6022023|NCT00233324|9617060|FG002|Follow up at 18-22 Months Corrected Age|Undetermined retinopathy status|13
6022024|NCT00233324|9617061|FG003|Follow up at 18-22 Months Corrected Age|Undetermined retinopathy status|7
6022025|NCT00233363|9617080|FG000|Overall Study|Adverse Event|1
6022026|NCT00233363|9617081|FG001|Overall Study|Adverse Event|2
6022027|NCT00233363|9617080|FG000|Overall Study|Lack of Efficacy|0
6022028|NCT00233363|9617081|FG001|Overall Study|Lack of Efficacy|2
6022029|NCT00233363|9617080|FG000|Overall Study|Withdrawal by Subject|1
6022030|NCT00233363|9617081|FG001|Overall Study|Withdrawal by Subject|1
6022031|NCT00233363|9617080|FG000|Overall Study|Aggravation of complication|1
6022032|NCT00233363|9617081|FG001|Overall Study|Aggravation of complication|0
6022033|NCT00233389|9617089|FG000|Overall Study|Adverse Event|5
6022034|NCT00233389|9617090|FG001|Overall Study|Adverse Event|5
6022035|NCT00233389|9617089|FG000|Overall Study|Lack of Efficacy|11
6022036|NCT00233389|9617090|FG001|Overall Study|Lack of Efficacy|8
6022037|NCT00233389|9617089|FG000|Overall Study|Lost to Follow-up|1
6022038|NCT00233389|9617090|FG001|Overall Study|Lost to Follow-up|1
6022039|NCT00233389|9617089|FG000|Overall Study|Physician Decision|1
6022040|NCT00233389|9617090|FG001|Overall Study|Physician Decision|0
6022041|NCT00233389|9617089|FG000|Overall Study|Protocol Violation|0
6022042|NCT00233389|9617090|FG001|Overall Study|Protocol Violation|1
6022043|NCT00233389|9617089|FG000|Overall Study|Withdrawal by Subject|0
6022044|NCT00233389|9617090|FG001|Overall Study|Withdrawal by Subject|1
6022045|NCT00233402|9617098|FG000|Overall Study|No pathology data|12
6022046|NCT00233402|9617099|FG001|Overall Study|No pathology data|9
6022047|NCT00233402|9617098|FG000|Overall Study|No Ta/T1|89
6022048|NCT00233402|9617099|FG001|Overall Study|No Ta/T1|94
6022049|NCT00233402|9617098|FG000|Overall Study|Lost to follow up etc|3
6022050|NCT00233402|9617099|FG001|Overall Study|Lost to follow up etc|21
6022051|NCT00233454|9617107|FG000|Overall Study|Death|6
6022052|NCT00233480|9617113|FG000|Overall Study|Underwent status II heart transplant|0
6022053|NCT00233480|9617114|FG001|Overall Study|Underwent status II heart transplant|1
6022054|NCT00233948|9617133|FG000|Overall Study|Adverse Event|1
6022055|NCT00233948|9617134|FG001|Overall Study|Adverse Event|0
6022056|NCT00233948|9617135|FG002|Overall Study|Adverse Event|0
6022057|NCT00233948|9617136|FG003|Overall Study|Adverse Event|0
6022058|NCT00233948|9617137|FG004|Overall Study|Adverse Event|0
6022059|NCT00233948|9617138|FG005|Overall Study|Adverse Event|0
6022060|NCT00233987|9617153|FG000|Overall Study|Withdrawal by Subject|1
6022061|NCT00233987|9617153|FG000|Overall Study|Lack of Efficacy|2
6022062|NCT00233987|9617153|FG000|Overall Study|Reason Under Review|1
6022063|NCT00233987|9617153|FG000|Overall Study|Other - Not Protocol Specified|5
6022064|NCT00233987|9617153|FG000|Overall Study|Eligible but No Treatment Received|2
6022065|NCT00233987|9617153|FG000|Overall Study|Ineligible|4
6022066|NCT00234039|9617157|FG000|Overall Study|Adverse Event|2
6022067|NCT00234039|9617157|FG000|Overall Study|Progression/relapse|34
6022068|NCT00234039|9617157|FG000|Overall Study|Other - Not Protocol Specified|3
6022069|NCT00234039|9617157|FG000|Overall Study|Ineligible|9
6022070|NCT00234039|9617157|FG000|Overall Study|No Protocol Treatment Received|2
6048090|NCT00414973|9647204|FG001|Overall Study|Sponsor Decision|0
6048091|NCT00414973|9647205|FG002|Overall Study|Sponsor Decision|0
6048092|NCT00414973|9647206|FG003|Overall Study|Sponsor Decision|0
6048093|NCT00414973|9647203|FG000|Overall Study|Death|0
6048094|NCT00414973|9647204|FG001|Overall Study|Death|0
6048095|NCT00414973|9647205|FG002|Overall Study|Death|1
6048096|NCT00414973|9647206|FG003|Overall Study|Death|0
6048097|NCT00415051|9647216|FG000|Overall Study|Protocol Violation|1
6048098|NCT00415168|9647220|FG000|Overall Study|Death|26
6048099|NCT00415168|9647220|FG000|Overall Study|Lost to Follow-up|3
6048100|NCT00415168|9647220|FG000|Overall Study|Physician Decision|13
6048101|NCT00415168|9647220|FG000|Overall Study|Sponsor Decision|4
6048102|NCT00415168|9647220|FG000|Overall Study|Withdrawal by Subject|6
6048103|NCT00415194|9647226|FG000|Overall Study|Adverse Event|37
6048104|NCT00415194|9647227|FG001|Overall Study|Adverse Event|32
6048105|NCT00415194|9647226|FG000|Overall Study|Entry Criteria Not Met|4
6048106|NCT00415194|9647227|FG001|Overall Study|Entry Criteria Not Met|8
6048107|NCT00415194|9647226|FG000|Overall Study|Lost to Follow-up|1
6048108|NCT00415194|9647227|FG001|Overall Study|Lost to Follow-up|0
6048109|NCT00415194|9647226|FG000|Overall Study|Physician Decision|10
6048110|NCT00415194|9647227|FG001|Overall Study|Physician Decision|16
6048111|NCT00415194|9647226|FG000|Overall Study|Progressive Disease|180
6048112|NCT00415194|9647227|FG001|Overall Study|Progressive Disease|217
6048113|NCT00415194|9647226|FG000|Overall Study|Protocol Violation|4
6048114|NCT00415194|9647227|FG001|Overall Study|Protocol Violation|2
6048115|NCT00415194|9647226|FG000|Overall Study|Withdrawal by Subject|28
6048116|NCT00415194|9647227|FG001|Overall Study|Withdrawal by Subject|21
6048117|NCT00415194|9647226|FG000|Overall Study|Death Due to Study Disease|26
6048118|NCT00415194|9647227|FG001|Overall Study|Death Due to Study Disease|29
6048119|NCT00415194|9647226|FG000|Overall Study|Death Due to Study Drug Related AE|11
6048120|NCT00415194|9647227|FG001|Overall Study|Death Due to Study Drug Related AE|1
6048121|NCT00415194|9647226|FG000|Overall Study|Death Due to Procedural Related AE|0
6048122|NCT00415194|9647227|FG001|Overall Study|Death Due to Procedural Related AE|1
6048123|NCT00415194|9647226|FG000|Overall Study|Death Due to AE (Other Causes)|27
6048124|NCT00415194|9647227|FG001|Overall Study|Death Due to AE (Other Causes)|15
6048125|NCT00415363|9647235|FG000|Overall Study|Withdrawal by Subject|4
6048126|NCT00415363|9647236|FG001|Overall Study|Withdrawal by Subject|4
6048127|NCT00415363|9647235|FG000|Overall Study|Adverse Event|4
6048128|NCT00415363|9647236|FG001|Overall Study|Adverse Event|4
6048129|NCT00415363|9647235|FG000|Overall Study|Lost to Follow-up|2
6048130|NCT00415363|9647236|FG001|Overall Study|Lost to Follow-up|1
6048131|NCT00415363|9647235|FG000|Overall Study|Physician Decision|3
6048132|NCT00415363|9647236|FG001|Overall Study|Physician Decision|1
6048133|NCT00415363|9647235|FG000|Overall Study|Death|16
6048134|NCT00415363|9647236|FG001|Overall Study|Death|12
6022071|NCT00234052|9617161|FG000|Treatment|Withdrawal by Subject|3
6022072|NCT00234052|9617161|FG000|Treatment|Adverse Event|5
6022073|NCT00234052|9617161|FG000|Treatment|Death|2
6022074|NCT00234052|9617161|FG000|Treatment|Progressive Disease|11
6022075|NCT00234052|9617161|FG000|Follow-up for 5 Years|Death|41
6022076|NCT00234052|9617161|FG000|Follow-up for 5 Years|Lost to Follow-up|1
6022077|NCT00234052|9617161|FG000|Follow-up for 5 Years|Other|7
6022078|NCT00234065|9617167|FG000|Overall Study|Adverse Event|268
6022079|NCT00234065|9617168|FG001|Overall Study|Adverse Event|166
6022080|NCT00234065|9617167|FG000|Overall Study|Withdrawal by Subject|73
6022081|NCT00234065|9617168|FG001|Overall Study|Withdrawal by Subject|56
6022082|NCT00234065|9617167|FG000|Overall Study|Physician Decision|23
6022083|NCT00234065|9617168|FG001|Overall Study|Physician Decision|22
6022084|NCT00234065|9617167|FG000|Overall Study|Not Classified|111
6022085|NCT00234065|9617168|FG001|Overall Study|Not Classified|112
6022086|NCT00234104|9617195|FG000|Overall Study|Adverse Event|4
6022087|NCT00234104|9617196|FG001|Overall Study|Adverse Event|0
6022088|NCT00234104|9617197|FG002|Overall Study|Adverse Event|3
6022089|NCT00234104|9617198|FG003|Overall Study|Adverse Event|5
6022090|NCT00234104|9617195|FG000|Overall Study|Protocol Violation|0
6022091|NCT00234104|9617196|FG001|Overall Study|Protocol Violation|0
6022092|NCT00234104|9617197|FG002|Overall Study|Protocol Violation|0
6022093|NCT00234104|9617198|FG003|Overall Study|Protocol Violation|1
6022094|NCT00234104|9617195|FG000|Overall Study|Physician Decision|0
6022095|NCT00234104|9617196|FG001|Overall Study|Physician Decision|1
6022096|NCT00234104|9617197|FG002|Overall Study|Physician Decision|2
6022097|NCT00234104|9617198|FG003|Overall Study|Physician Decision|2
6022098|NCT00234494|9617241|FG000|Overall Study|Protocol Violation|2
6022099|NCT00234533|9617245|FG000|Overall Study|Withdrawal by Subject|6
6022100|NCT00234533|9617245|FG000|Overall Study|Adverse Event|2
6022101|NCT00234533|9617245|FG000|Overall Study|Enrolled but not treated|3
6022102|NCT00235391|9617276|FG000|Overall Study|Adverse Event|4
6022103|NCT00235391|9617277|FG001|Overall Study|Adverse Event|5
6022104|NCT00235391|9617278|FG002|Overall Study|Adverse Event|10
6022105|NCT00235391|9617279|FG003|Overall Study|Adverse Event|72
6022106|NCT00235391|9617280|FG004|Overall Study|Adverse Event|5
6022107|NCT00235391|9617281|FG005|Overall Study|Adverse Event|2
6022108|NCT00235391|9617276|FG000|Overall Study|Abnormal laboratory value(s)|3
6022109|NCT00235391|9617277|FG001|Overall Study|Abnormal laboratory value(s)|5
6022110|NCT00235391|9617278|FG002|Overall Study|Abnormal laboratory value(s)|4
6022111|NCT00235391|9617279|FG003|Overall Study|Abnormal laboratory value(s)|27
6022112|NCT00235391|9617280|FG004|Overall Study|Abnormal laboratory value(s)|1
6022113|NCT00235391|9617281|FG005|Overall Study|Abnormal laboratory value(s)|2
6022114|NCT00235391|9617276|FG000|Overall Study|Unsatisfactory therapeutic effect|0
6022115|NCT00235391|9617277|FG001|Overall Study|Unsatisfactory therapeutic effect|2
6022116|NCT00235391|9617278|FG002|Overall Study|Unsatisfactory therapeutic effect|2
6022117|NCT00235391|9617279|FG003|Overall Study|Unsatisfactory therapeutic effect|17
6022118|NCT00235391|9617280|FG004|Overall Study|Unsatisfactory therapeutic effect|0
6022119|NCT00235391|9617281|FG005|Overall Study|Unsatisfactory therapeutic effect|0
6022120|NCT00235391|9617276|FG000|Overall Study|Condition no longer requires treatment|3
6022121|NCT00235391|9617277|FG001|Overall Study|Condition no longer requires treatment|0
6022122|NCT00235391|9617278|FG002|Overall Study|Condition no longer requires treatment|0
6022123|NCT00235391|9617279|FG003|Overall Study|Condition no longer requires treatment|11
6022124|NCT00235391|9617280|FG004|Overall Study|Condition no longer requires treatment|1
6022125|NCT00235391|9617281|FG005|Overall Study|Condition no longer requires treatment|0
6022126|NCT00235391|9617276|FG000|Overall Study|Protocol deviation|0
6022127|NCT00235391|9617277|FG001|Overall Study|Protocol deviation|0
6022128|NCT00235391|9617278|FG002|Overall Study|Protocol deviation|1
6022129|NCT00235391|9617279|FG003|Overall Study|Protocol deviation|11
6022130|NCT00235391|9617280|FG004|Overall Study|Protocol deviation|0
6022131|NCT00235391|9617281|FG005|Overall Study|Protocol deviation|0
6022132|NCT00235391|9617276|FG000|Overall Study|Withdrawal by Subject|2
6022133|NCT00235391|9617277|FG001|Overall Study|Withdrawal by Subject|3
6022134|NCT00235391|9617278|FG002|Overall Study|Withdrawal by Subject|3
6022135|NCT00235391|9617279|FG003|Overall Study|Withdrawal by Subject|61
6022136|NCT00235391|9617280|FG004|Overall Study|Withdrawal by Subject|5
6022137|NCT00235391|9617281|FG005|Overall Study|Withdrawal by Subject|0
6022138|NCT00235391|9617276|FG000|Overall Study|Lost to Follow-up|0
6022139|NCT00235391|9617277|FG001|Overall Study|Lost to Follow-up|3
6022140|NCT00235391|9617278|FG002|Overall Study|Lost to Follow-up|3
6022141|NCT00235391|9617279|FG003|Overall Study|Lost to Follow-up|16
6022142|NCT00235391|9617280|FG004|Overall Study|Lost to Follow-up|0
6022143|NCT00235391|9617281|FG005|Overall Study|Lost to Follow-up|0
6022144|NCT00235391|9617276|FG000|Overall Study|Administrative problems|0
6022145|NCT00235391|9617277|FG001|Overall Study|Administrative problems|0
6022146|NCT00235391|9617278|FG002|Overall Study|Administrative problems|0
6022147|NCT00235391|9617279|FG003|Overall Study|Administrative problems|1
6022148|NCT00235391|9617280|FG004|Overall Study|Administrative problems|0
6022149|NCT00235391|9617281|FG005|Overall Study|Administrative problems|0
6022150|NCT00235391|9617276|FG000|Overall Study|Death|0
6022151|NCT00235391|9617277|FG001|Overall Study|Death|0
6022152|NCT00235391|9617278|FG002|Overall Study|Death|1
6022153|NCT00235391|9617279|FG003|Overall Study|Death|4
6022154|NCT00235391|9617280|FG004|Overall Study|Death|0
6022155|NCT00235391|9617281|FG005|Overall Study|Death|0
6022156|NCT00235443|9617296|FG000|Overall Study|Adverse Event|4
6022157|NCT00235443|9617297|FG001|Overall Study|Adverse Event|12
6022158|NCT00235443|9617298|FG002|Overall Study|Adverse Event|17
6022159|NCT00235443|9617299|FG003|Overall Study|Adverse Event|44
6022160|NCT00235443|9617300|FG004|Overall Study|Adverse Event|10
6022161|NCT00235443|9617301|FG005|Overall Study|Adverse Event|15
6022162|NCT00235443|9617296|FG000|Overall Study|Lack of Efficacy|0
6022163|NCT00235443|9617297|FG001|Overall Study|Lack of Efficacy|1
6022164|NCT00235443|9617298|FG002|Overall Study|Lack of Efficacy|5
6022165|NCT00235443|9617299|FG003|Overall Study|Lack of Efficacy|12
6022166|NCT00235443|9617300|FG004|Overall Study|Lack of Efficacy|2
6022167|NCT00235443|9617301|FG005|Overall Study|Lack of Efficacy|9
6022168|NCT00235443|9617296|FG000|Overall Study|Withdrawal by Subject|3
6022169|NCT00235443|9617297|FG001|Overall Study|Withdrawal by Subject|9
6022170|NCT00235443|9617298|FG002|Overall Study|Withdrawal by Subject|25
6022171|NCT00235443|9617299|FG003|Overall Study|Withdrawal by Subject|24
6022172|NCT00235443|9617300|FG004|Overall Study|Withdrawal by Subject|10
6022173|NCT00235443|9617301|FG005|Overall Study|Withdrawal by Subject|12
6022174|NCT00235443|9617296|FG000|Overall Study|Lost to Follow-up|0
6022175|NCT00235443|9617297|FG001|Overall Study|Lost to Follow-up|8
6022176|NCT00235443|9617298|FG002|Overall Study|Lost to Follow-up|6
6022177|NCT00235443|9617299|FG003|Overall Study|Lost to Follow-up|6
6022178|NCT00235443|9617300|FG004|Overall Study|Lost to Follow-up|4
6022179|NCT00235443|9617301|FG005|Overall Study|Lost to Follow-up|3
6022180|NCT00235443|9617296|FG000|Overall Study|Unsatisfactory compliance|0
6022181|NCT00235443|9617297|FG001|Overall Study|Unsatisfactory compliance|2
6022182|NCT00235443|9617298|FG002|Overall Study|Unsatisfactory compliance|3
6022183|NCT00235443|9617299|FG003|Overall Study|Unsatisfactory compliance|4
6022184|NCT00235443|9617300|FG004|Overall Study|Unsatisfactory compliance|1
6022185|NCT00235443|9617301|FG005|Overall Study|Unsatisfactory compliance|0
6022186|NCT00235443|9617296|FG000|Overall Study|Other reasons for premature termination|1
6022187|NCT00235443|9617297|FG001|Overall Study|Other reasons for premature termination|6
6022188|NCT00235443|9617298|FG002|Overall Study|Other reasons for premature termination|6
6022189|NCT00235443|9617299|FG003|Overall Study|Other reasons for premature termination|7
6022190|NCT00235443|9617300|FG004|Overall Study|Other reasons for premature termination|3
6022191|NCT00235443|9617301|FG005|Overall Study|Other reasons for premature termination|6
6022192|NCT00235495|9617328|FG000|Overall Study|Death|52
6022193|NCT00235495|9617329|FG001|Overall Study|Death|42
6022194|NCT00235495|9617328|FG000|Overall Study|Withdrawal by Subject|5
6022195|NCT00235495|9617329|FG001|Overall Study|Withdrawal by Subject|3
6022196|NCT00235495|9617328|FG000|Overall Study|Lost to Follow-up|11
6022197|NCT00235495|9617329|FG001|Overall Study|Lost to Follow-up|13
6022198|NCT00235495|9617328|FG000|Overall Study|Visit/assessmen outside window/missing|0
6022199|NCT00235495|9617329|FG001|Overall Study|Visit/assessmen outside window/missing|10
6022200|NCT00235716|9617352|FG000|Overall Study|Death|26
6022201|NCT00235716|9617353|FG001|Overall Study|Death|39
6022202|NCT00235716|9617354|FG002|Overall Study|Death|32
6022203|NCT00235716|9617355|FG003|Overall Study|Death|31
6022204|NCT00235716|9617352|FG000|Overall Study|Withdrawal by Subject|23
6022205|NCT00235716|9617353|FG001|Overall Study|Withdrawal by Subject|19
6022206|NCT00235716|9617354|FG002|Overall Study|Withdrawal by Subject|17
6022207|NCT00235716|9617355|FG003|Overall Study|Withdrawal by Subject|18
6022208|NCT00235716|9617352|FG000|Overall Study|Lost to Follow-up|12
6022209|NCT00235716|9617353|FG001|Overall Study|Lost to Follow-up|7
6022210|NCT00235716|9617354|FG002|Overall Study|Lost to Follow-up|14
6022211|NCT00235716|9617355|FG003|Overall Study|Lost to Follow-up|10
6022212|NCT00235716|9617352|FG000|Overall Study|Adverse Event|1
6022213|NCT00235716|9617353|FG001|Overall Study|Adverse Event|1
6022214|NCT00235716|9617354|FG002|Overall Study|Adverse Event|1
6022215|NCT00235716|9617355|FG003|Overall Study|Adverse Event|0
6022216|NCT00235716|9617352|FG000|Overall Study|Physician Decision|0
6022217|NCT00235716|9617353|FG001|Overall Study|Physician Decision|1
6022218|NCT00235716|9617354|FG002|Overall Study|Physician Decision|1
6022219|NCT00235716|9617355|FG003|Overall Study|Physician Decision|3
6022220|NCT00235755|9617368|FG000|4-Week Titration Phase|Adverse Event|6
6022221|NCT00235755|9617369|FG001|4-Week Titration Phase|Adverse Event|14
6022222|NCT00235755|9617370|FG002|4-Week Titration Phase|Adverse Event|20
6022223|NCT00235755|9617368|FG000|4-Week Titration Phase|Lost to Follow-up|0
6022224|NCT00235755|9617369|FG001|4-Week Titration Phase|Lost to Follow-up|1
6022225|NCT00235755|9617370|FG002|4-Week Titration Phase|Lost to Follow-up|1
6022226|NCT00235755|9617368|FG000|4-Week Titration Phase|Protocol Violation|2
6022227|NCT00235755|9617369|FG001|4-Week Titration Phase|Protocol Violation|2
6022228|NCT00235755|9617370|FG002|4-Week Titration Phase|Protocol Violation|1
6022229|NCT00235755|9617368|FG000|4-Week Titration Phase|Withdrawal by Subject|1
6022230|NCT00235755|9617369|FG001|4-Week Titration Phase|Withdrawal by Subject|2
6022231|NCT00235755|9617370|FG002|4-Week Titration Phase|Withdrawal by Subject|3
6022232|NCT00235755|9617368|FG000|4-Week Titration Phase|Participant Did Not Receive Study Drug|0
6022233|NCT00235755|9617369|FG001|4-Week Titration Phase|Participant Did Not Receive Study Drug|0
6022234|NCT00235755|9617370|FG002|4-Week Titration Phase|Participant Did Not Receive Study Drug|1
6022235|NCT00235755|9617368|FG000|4-Week Titration Phase|Randomization Occurred in Error|1
6022236|NCT00235755|9617369|FG001|4-Week Titration Phase|Randomization Occurred in Error|0
6022237|NCT00235755|9617370|FG002|4-Week Titration Phase|Randomization Occurred in Error|0
6022238|NCT00235755|9617368|FG000|4-Week Titration Phase|Prolonged QT Interval at Visit 3|1
6078049|NCT00601640|9684230|FG000|Overall Study|change in eligibility status|0
6078050|NCT00601640|9684231|FG001|Overall Study|change in eligibility status|1
6078051|NCT00601640|9684232|FG002|Overall Study|change in eligibility status|1
6078052|NCT00601705|9684242|FG000|Overall Study|Withdrawal by Subject|1
6078053|NCT00601835|9684298|FG000|Overall Study|Withdrawal by Subject|9
6078054|NCT00601835|9684299|FG001|Overall Study|Withdrawal by Subject|6
6078055|NCT00601835|9684298|FG000|Overall Study|Physician Decision|1
6078056|NCT00601835|9684299|FG001|Overall Study|Physician Decision|0
6022239|NCT00235755|9617369|FG001|4-Week Titration Phase|Prolonged QT Interval at Visit 3|0
6022240|NCT00235755|9617370|FG002|4-Week Titration Phase|Prolonged QT Interval at Visit 3|0
6022241|NCT00235755|9617368|FG000|12-Week Maintenance Phase|Adverse Event|8
6022242|NCT00235755|9617369|FG001|12-Week Maintenance Phase|Adverse Event|12
6022243|NCT00235755|9617370|FG002|12-Week Maintenance Phase|Adverse Event|26
6022244|NCT00235755|9617368|FG000|12-Week Maintenance Phase|Lost to Follow-up|2
6022245|NCT00235755|9617369|FG001|12-Week Maintenance Phase|Lost to Follow-up|3
6022246|NCT00235755|9617370|FG002|12-Week Maintenance Phase|Lost to Follow-up|0
6022247|NCT00235755|9617368|FG000|12-Week Maintenance Phase|Lack of Efficacy|5
6022248|NCT00235755|9617369|FG001|12-Week Maintenance Phase|Lack of Efficacy|0
6022249|NCT00235755|9617370|FG002|12-Week Maintenance Phase|Lack of Efficacy|0
6022250|NCT00235755|9617368|FG000|12-Week Maintenance Phase|Protocol Violation|0
6022251|NCT00235755|9617369|FG001|12-Week Maintenance Phase|Protocol Violation|4
6022252|NCT00235755|9617370|FG002|12-Week Maintenance Phase|Protocol Violation|2
6022253|NCT00235755|9617368|FG000|12-Week Maintenance Phase|Withdrawal by Subject|0
6022254|NCT00235755|9617369|FG001|12-Week Maintenance Phase|Withdrawal by Subject|8
6022255|NCT00235755|9617370|FG002|12-Week Maintenance Phase|Withdrawal by Subject|3
6022256|NCT00235755|9617368|FG000|12-Week Maintenance Phase|Abnormal Electrocardiogram Test Result|1
6022257|NCT00235755|9617369|FG001|12-Week Maintenance Phase|Abnormal Electrocardiogram Test Result|0
6022258|NCT00235755|9617370|FG002|12-Week Maintenance Phase|Abnormal Electrocardiogram Test Result|0
6022259|NCT00235872|9617397|FG000|Overall Study|Adverse Event|34
6022260|NCT00235872|9617397|FG000|Overall Study|Death|1
6022261|NCT00235872|9617397|FG000|Overall Study|Lost to Follow-up|1
6022262|NCT00235872|9617397|FG000|Overall Study|Withdrawal by Subject|50
6022263|NCT00235872|9617397|FG000|Overall Study|Administrative reason|61
6022264|NCT00235989|9617405|FG000|Core Treatment Period (CT)|Lost to Follow-up|0
6022265|NCT00235989|9617406|FG001|Core Treatment Period (CT)|Lost to Follow-up|0
6022266|NCT00235989|9617407|FG002|Core Treatment Period (CT)|Lost to Follow-up|0
6022267|NCT00235989|9617408|FG003|Core Treatment Period (CT)|Lost to Follow-up|0
6022268|NCT00235989|9617409|FG004|Core Treatment Period (CT)|Lost to Follow-up|0
6022269|NCT00235989|9617410|FG005|Core Treatment Period (CT)|Lost to Follow-up|2
6022270|NCT00235989|9617405|FG000|Extension Treatment Period (ET)|Adverse Event|3
6022271|NCT00235989|9617406|FG001|Extension Treatment Period (ET)|Adverse Event|0
6022272|NCT00235989|9617407|FG002|Extension Treatment Period (ET)|Adverse Event|2
6022273|NCT00235989|9617408|FG003|Extension Treatment Period (ET)|Adverse Event|0
6022274|NCT00235989|9617409|FG004|Extension Treatment Period (ET)|Adverse Event|0
6022275|NCT00235989|9617410|FG005|Extension Treatment Period (ET)|Adverse Event|0
6022276|NCT00235989|9617405|FG000|Extension Treatment Period (ET)|Lost to Follow-up|2
6022277|NCT00235989|9617406|FG001|Extension Treatment Period (ET)|Lost to Follow-up|0
6022278|NCT00235989|9617407|FG002|Extension Treatment Period (ET)|Lost to Follow-up|1
6022279|NCT00235989|9617408|FG003|Extension Treatment Period (ET)|Lost to Follow-up|0
6022280|NCT00235989|9617409|FG004|Extension Treatment Period (ET)|Lost to Follow-up|0
6022281|NCT00235989|9617410|FG005|Extension Treatment Period (ET)|Lost to Follow-up|0
6022282|NCT00235989|9617405|FG000|Extension Treatment Period (ET)|Withdrawal by Subject|1
6022283|NCT00235989|9617406|FG001|Extension Treatment Period (ET)|Withdrawal by Subject|1
6022284|NCT00235989|9617407|FG002|Extension Treatment Period (ET)|Withdrawal by Subject|1
6022285|NCT00235989|9617408|FG003|Extension Treatment Period (ET)|Withdrawal by Subject|4
6022286|NCT00235989|9617409|FG004|Extension Treatment Period (ET)|Withdrawal by Subject|0
6022287|NCT00235989|9617410|FG005|Extension Treatment Period (ET)|Withdrawal by Subject|0
6022288|NCT00235989|9617405|FG000|Extension Treatment Period (ET)|´Other´ not further itemized|2
6022289|NCT00235989|9617406|FG001|Extension Treatment Period (ET)|´Other´ not further itemized|3
6022290|NCT00235989|9617407|FG002|Extension Treatment Period (ET)|´Other´ not further itemized|1
6022291|NCT00235989|9617408|FG003|Extension Treatment Period (ET)|´Other´ not further itemized|2
6022292|NCT00235989|9617409|FG004|Extension Treatment Period (ET)|´Other´ not further itemized|0
6022293|NCT00235989|9617410|FG005|Extension Treatment Period (ET)|´Other´ not further itemized|0
6022294|NCT00236080|9617425|FG000|Overall Study|Adverse Event|0
6022295|NCT00236080|9617426|FG001|Overall Study|Adverse Event|0
6022296|NCT00236080|9617427|FG002|Overall Study|Adverse Event|3
6022297|NCT00236080|9617428|FG003|Overall Study|Adverse Event|1
6022298|NCT00236080|9617429|FG004|Overall Study|Adverse Event|0
6022299|NCT00236080|9617425|FG000|Overall Study|Lost to Follow-up|0
6022300|NCT00236080|9617426|FG001|Overall Study|Lost to Follow-up|1
6022301|NCT00236080|9617427|FG002|Overall Study|Lost to Follow-up|0
6022302|NCT00236080|9617428|FG003|Overall Study|Lost to Follow-up|0
6078057|NCT00601835|9684298|FG000|Overall Study|Lost to Follow-up|37
6078058|NCT00601835|9684299|FG001|Overall Study|Lost to Follow-up|5
6022303|NCT00236080|9617429|FG004|Overall Study|Lost to Follow-up|0
6022304|NCT00236080|9617425|FG000|Overall Study|Physician Decision|1
6022305|NCT00236080|9617426|FG001|Overall Study|Physician Decision|0
6022306|NCT00236080|9617427|FG002|Overall Study|Physician Decision|1
6022307|NCT00236080|9617428|FG003|Overall Study|Physician Decision|1
6022308|NCT00236080|9617429|FG004|Overall Study|Physician Decision|1
6022309|NCT00236080|9617425|FG000|Overall Study|Withdrawal by Subject|1
6022310|NCT00236080|9617426|FG001|Overall Study|Withdrawal by Subject|0
6022311|NCT00236080|9617427|FG002|Overall Study|Withdrawal by Subject|0
6022312|NCT00236080|9617428|FG003|Overall Study|Withdrawal by Subject|0
6022313|NCT00236080|9617429|FG004|Overall Study|Withdrawal by Subject|0
6022314|NCT00236080|9617425|FG000|Overall Study|Miscellaneous|0
6022315|NCT00236080|9617426|FG001|Overall Study|Miscellaneous|0
6022316|NCT00236080|9617427|FG002|Overall Study|Miscellaneous|1
6022317|NCT00236080|9617428|FG003|Overall Study|Miscellaneous|0
6022318|NCT00236080|9617429|FG004|Overall Study|Miscellaneous|0
6022319|NCT00236184|9617443|FG000|Overall Study|Adverse Event|5
6022320|NCT00236184|9617444|FG001|Overall Study|Adverse Event|2
6022321|NCT00236184|9617443|FG000|Overall Study|Lack of Efficacy|0
6022322|NCT00236184|9617444|FG001|Overall Study|Lack of Efficacy|1
6022323|NCT00236184|9617443|FG000|Overall Study|Lost to Follow-up|3
6022324|NCT00236184|9617444|FG001|Overall Study|Lost to Follow-up|4
6022325|NCT00236184|9617443|FG000|Overall Study|Physician Decision|1
6022326|NCT00236184|9617444|FG001|Overall Study|Physician Decision|1
6022327|NCT00236184|9617443|FG000|Overall Study|Withdrawal by Subject|3
6022328|NCT00236184|9617444|FG001|Overall Study|Withdrawal by Subject|0
6022329|NCT00236184|9617443|FG000|Overall Study|Protocol Violation|3
6022330|NCT00236184|9617444|FG001|Overall Study|Protocol Violation|0
6022331|NCT00236184|9617443|FG000|Overall Study|non-compliance with study drug|2
6022332|NCT00236184|9617444|FG001|Overall Study|non-compliance with study drug|1
6022333|NCT00236184|9617443|FG000|Overall Study|other|1
6022334|NCT00236184|9617444|FG001|Overall Study|other|2
6022335|NCT00236197|9617452|FG000|Overall Study|Withdrawal by Subject|3
6022336|NCT00236197|9617453|FG001|Overall Study|Withdrawal by Subject|2
6022337|NCT00236197|9617452|FG000|Overall Study|Lost to Follow-up|1
6022338|NCT00236197|9617453|FG001|Overall Study|Lost to Follow-up|5
6022339|NCT00236197|9617452|FG000|Overall Study|Protocol Violation|0
6022340|NCT00236197|9617453|FG001|Overall Study|Protocol Violation|3
6022341|NCT00236197|9617452|FG000|Overall Study|Medication non-compliance|1
6022342|NCT00236197|9617453|FG001|Overall Study|Medication non-compliance|2
6022343|NCT00236197|9617452|FG000|Overall Study|Other|0
6022344|NCT00236197|9617453|FG001|Overall Study|Other|2
6022345|NCT00236899|9617463|FG000|Overall Study|Adverse Event (Study Related)|1
6022346|NCT00236899|9617464|FG001|Overall Study|Adverse Event (Study Related)|1
6022347|NCT00236899|9617465|FG002|Overall Study|Adverse Event (Study Related)|2
6022348|NCT00236899|9617466|FG003|Overall Study|Adverse Event (Study Related)|1
6022349|NCT00236899|9617463|FG000|Overall Study|Adverse Event (Not Study Related)|3
6022350|NCT00236899|9617464|FG001|Overall Study|Adverse Event (Not Study Related)|3
6022351|NCT00236899|9617465|FG002|Overall Study|Adverse Event (Not Study Related)|4
6022352|NCT00236899|9617466|FG003|Overall Study|Adverse Event (Not Study Related)|7
6022353|NCT00236899|9617463|FG000|Overall Study|Death (Study Disease)|1
6022354|NCT00236899|9617464|FG001|Overall Study|Death (Study Disease)|4
6022355|NCT00236899|9617465|FG002|Overall Study|Death (Study Disease)|0
6022356|NCT00236899|9617466|FG003|Overall Study|Death (Study Disease)|0
6022357|NCT00236899|9617463|FG000|Overall Study|Death (Not Study Related)|2
6022358|NCT00236899|9617464|FG001|Overall Study|Death (Not Study Related)|0
6022359|NCT00236899|9617465|FG002|Overall Study|Death (Not Study Related)|0
6022360|NCT00236899|9617466|FG003|Overall Study|Death (Not Study Related)|0
6022361|NCT00236899|9617463|FG000|Overall Study|Death (Study Drug Toxicity)|1
6022362|NCT00236899|9617464|FG001|Overall Study|Death (Study Drug Toxicity)|0
6022363|NCT00236899|9617465|FG002|Overall Study|Death (Study Drug Toxicity)|0
6022364|NCT00236899|9617466|FG003|Overall Study|Death (Study Drug Toxicity)|0
6022365|NCT00236899|9617463|FG000|Overall Study|Lost to Follow-up|0
6022366|NCT00236899|9617464|FG001|Overall Study|Lost to Follow-up|1
6022367|NCT00236899|9617465|FG002|Overall Study|Lost to Follow-up|0
6022368|NCT00236899|9617466|FG003|Overall Study|Lost to Follow-up|0
6022369|NCT00236899|9617463|FG000|Overall Study|Entry Criteria Exclusion|0
6022370|NCT00236899|9617464|FG001|Overall Study|Entry Criteria Exclusion|1
6022371|NCT00236899|9617465|FG002|Overall Study|Entry Criteria Exclusion|1
6022372|NCT00236899|9617466|FG003|Overall Study|Entry Criteria Exclusion|0
6022373|NCT00236899|9617463|FG000|Overall Study|Protocol Violation|1
6022374|NCT00236899|9617464|FG001|Overall Study|Protocol Violation|0
6022375|NCT00236899|9617465|FG002|Overall Study|Protocol Violation|0
6022376|NCT00236899|9617466|FG003|Overall Study|Protocol Violation|0
6022377|NCT00236899|9617463|FG000|Overall Study|Withdrawal by Subject|6
6022378|NCT00236899|9617464|FG001|Overall Study|Withdrawal by Subject|4
6022379|NCT00236899|9617465|FG002|Overall Study|Withdrawal by Subject|5
6022380|NCT00236899|9617466|FG003|Overall Study|Withdrawal by Subject|2
6022381|NCT00236899|9617463|FG000|Overall Study|Physician Decision|7
6022382|NCT00236899|9617464|FG001|Overall Study|Physician Decision|8
6022383|NCT00236899|9617465|FG002|Overall Study|Physician Decision|7
6022384|NCT00236899|9617466|FG003|Overall Study|Physician Decision|6
6022385|NCT00236899|9617463|FG000|Overall Study|Satisfactory Response|2
6022386|NCT00236899|9617464|FG001|Overall Study|Satisfactory Response|0
6022387|NCT00236899|9617465|FG002|Overall Study|Satisfactory Response|0
6022388|NCT00236899|9617466|FG003|Overall Study|Satisfactory Response|1
6022389|NCT00236899|9617463|FG000|Overall Study|Lack of Efficacy|18
6022390|NCT00236899|9617464|FG001|Overall Study|Lack of Efficacy|18
6022391|NCT00236899|9617465|FG002|Overall Study|Lack of Efficacy|25
6022392|NCT00236899|9617466|FG003|Overall Study|Lack of Efficacy|23
6022393|NCT00237042|9617521|FG000|Treatment|Became ineligible post-randomization|0
6022394|NCT00237042|9617522|FG001|Treatment|Became ineligible post-randomization|1
6022395|NCT00237042|9617523|FG002|Treatment|Became ineligible post-randomization|16
6022396|NCT00237042|9617521|FG000|Treatment|Moved out of state|1
6022397|NCT00237042|9617522|FG001|Treatment|Moved out of state|1
6022398|NCT00237042|9617523|FG002|Treatment|Moved out of state|1
6022399|NCT00237042|9617521|FG000|Treatment|Completed no treatment|5
6022400|NCT00237042|9617522|FG001|Treatment|Completed no treatment|5
6022401|NCT00237042|9617523|FG002|Treatment|Completed no treatment|21
6022402|NCT00237042|9617521|FG000|Short Term (6 Month) Follow up|Lost to Follow-up|9
6022403|NCT00237042|9617522|FG001|Short Term (6 Month) Follow up|Lost to Follow-up|8
6022404|NCT00237042|9617523|FG002|Short Term (6 Month) Follow up|Lost to Follow-up|11
6022405|NCT00237042|9617521|FG000|Long Term (12 Month) Follow up|Lost to Follow-up|11
6022406|NCT00237042|9617522|FG001|Long Term (12 Month) Follow up|Lost to Follow-up|9
6022407|NCT00237042|9617523|FG002|Long Term (12 Month) Follow up|Lost to Follow-up|9
6022408|NCT00237185|9617533|FG000|Core|Adverse Event|3
6022409|NCT00237185|9617534|FG001|Core|Adverse Event|4
6022410|NCT00237185|9617533|FG000|Core|Abnormal laboratory value|0
6022411|NCT00237185|9617534|FG001|Core|Abnormal laboratory value|4
6022412|NCT00237185|9617533|FG000|Core|Abnormal test procedure results|1
6022413|NCT00237185|9617534|FG001|Core|Abnormal test procedure results|0
6022414|NCT00237185|9617533|FG000|Core|Lack of Efficacy|30
6022415|NCT00237185|9617534|FG001|Core|Lack of Efficacy|23
6022416|NCT00237185|9617533|FG000|Core|Protocol Violation|1
6022417|NCT00237185|9617534|FG001|Core|Protocol Violation|1
6022418|NCT00237185|9617533|FG000|Core|Withdrawal by Subject|4
6022419|NCT00237185|9617534|FG001|Core|Withdrawal by Subject|4
6022420|NCT00237185|9617533|FG000|Core|Administrative problems|0
6022421|NCT00237185|9617534|FG001|Core|Administrative problems|1
6022422|NCT00237185|9617533|FG000|Core|Death|4
6022423|NCT00237185|9617534|FG001|Core|Death|0
6022424|NCT00237185|9617533|FG000|Core|Determined ineligible post randomization|1
6022425|NCT00237185|9617534|FG001|Core|Determined ineligible post randomization|0
6022426|NCT00237185|9617533|FG000|Extension|Adverse Event|1
6022427|NCT00237185|9617534|FG001|Extension|Adverse Event|0
6022428|NCT00237185|9617533|FG000|Extension|Abnormal laboratory value|0
6022429|NCT00237185|9617534|FG001|Extension|Abnormal laboratory value|1
6022430|NCT00237185|9617533|FG000|Extension|Lack of Efficacy|9
6022431|NCT00237185|9617534|FG001|Extension|Lack of Efficacy|14
6022432|NCT00237185|9617533|FG000|Extension|Condition no longer required study drug|0
6022433|NCT00237185|9617534|FG001|Extension|Condition no longer required study drug|1
6022434|NCT00237185|9617533|FG000|Extension|Withdrawal by Subject|3
6022435|NCT00237185|9617534|FG001|Extension|Withdrawal by Subject|2
6022436|NCT00237185|9617533|FG000|Extension|Lost to Follow-up|1
6022437|NCT00237185|9617534|FG001|Extension|Lost to Follow-up|0
6022438|NCT00237185|9617533|FG000|Extension|Administrative problems|1
6022439|NCT00237185|9617534|FG001|Extension|Administrative problems|0
6022440|NCT00237185|9617533|FG000|Extension|Death|1
6022441|NCT00237185|9617534|FG001|Extension|Death|1
6022442|NCT00237458|9617540|FG000|Overall Study|Lack of Efficacy|1
6022443|NCT00237458|9617540|FG000|Overall Study|Adverse Event|1
6022444|NCT00237458|9617540|FG000|Overall Study|Withdrawal by Subject|1
6022445|NCT00237692|9617552|FG000|Overall Study|Lost to Follow-up|9
6022446|NCT00237692|9617553|FG001|Overall Study|Lost to Follow-up|3
6022447|NCT00237692|9617554|FG002|Overall Study|Lost to Follow-up|5
6022448|NCT00237692|9617555|FG003|Overall Study|Lost to Follow-up|3
6022449|NCT00237692|9617552|FG000|Overall Study|Death|1
6022450|NCT00237692|9617553|FG001|Overall Study|Death|2
6022451|NCT00237692|9617554|FG002|Overall Study|Death|2
6022452|NCT00237692|9617555|FG003|Overall Study|Death|3
6022453|NCT00237692|9617552|FG000|Overall Study|Excluded - did not meet criteria|4
6022454|NCT00237692|9617553|FG001|Overall Study|Excluded - did not meet criteria|3
6022455|NCT00237692|9617554|FG002|Overall Study|Excluded - did not meet criteria|5
6022456|NCT00237692|9617555|FG003|Overall Study|Excluded - did not meet criteria|9
6022457|NCT00237692|9617552|FG000|Overall Study|Withdrawal by Subject|4
6022458|NCT00237692|9617553|FG001|Overall Study|Withdrawal by Subject|6
6022459|NCT00237692|9617554|FG002|Overall Study|Withdrawal by Subject|10
6022460|NCT00237692|9617555|FG003|Overall Study|Withdrawal by Subject|4
6022461|NCT00237744|9617577|FG000|Overall Study|Withdrawal by Subject|3
6022462|NCT00237744|9617578|FG001|Overall Study|Withdrawal by Subject|1
6022463|NCT00237744|9617579|FG002|Overall Study|Withdrawal by Subject|0
6022464|NCT00237796|9617605|FG000|Overall Study|Baseline and one other ILSS required|10
6022465|NCT00237796|9617606|FG001|Overall Study|Baseline and one other ILSS required|5
6022466|NCT00237809|9617617|FG000|Overall Study|Lost to Follow-up|11
6022467|NCT00237809|9617618|FG001|Overall Study|Lost to Follow-up|10
6022468|NCT00237809|9617619|FG002|Overall Study|Lost to Follow-up|9
6022469|NCT00237809|9617620|FG003|Overall Study|Lost to Follow-up|9
6022470|NCT00238121|9617641|FG000|Overall Study|Withdrawal by Subject|1
6022471|NCT00238121|9617642|FG001|Overall Study|Withdrawal by Subject|1
6022472|NCT00238121|9617641|FG000|Overall Study|Adverse Event|2
6022473|NCT00238121|9617642|FG001|Overall Study|Adverse Event|1
6022474|NCT00238238|9617650|FG000|Overall Study|Withdrawal by Subject|0
6022475|NCT00238238|9617651|FG001|Overall Study|Withdrawal by Subject|3
6022476|NCT00238238|9617652|FG002|Overall Study|Withdrawal by Subject|0
6022477|NCT00238264|9617660|FG000|Overall Study|Death|7
6022478|NCT00238264|9617660|FG000|Overall Study|Lost to Follow-up|18
6022479|NCT00238264|9617660|FG000|Overall Study|Withdrawal by Subject|4
6022480|NCT00238264|9617660|FG000|Overall Study|Ineligible|7
6022481|NCT00238303|9617667|FG000|Overall Study|Withdrawal by Subject|11
6022482|NCT00238303|9617668|FG001|Overall Study|Withdrawal by Subject|1
6022483|NCT00238303|9617669|FG002|Overall Study|Withdrawal by Subject|2
6022484|NCT00238303|9617667|FG000|Overall Study|Death|1
6022485|NCT00238303|9617668|FG001|Overall Study|Death|0
6022486|NCT00238303|9617669|FG002|Overall Study|Death|1
6022487|NCT00238303|9617667|FG000|Overall Study|Other Medical Problems|2
6022488|NCT00238303|9617668|FG001|Overall Study|Other Medical Problems|0
6022489|NCT00238303|9617669|FG002|Overall Study|Other Medical Problems|2
6022490|NCT00238303|9617667|FG000|Overall Study|Poor tolerance of study treatment|1
6022491|NCT00238303|9617668|FG001|Overall Study|Poor tolerance of study treatment|0
6022492|NCT00238303|9617669|FG002|Overall Study|Poor tolerance of study treatment|1
6022493|NCT00238303|9617667|FG000|Overall Study|Adverse Event|0
6022494|NCT00238303|9617668|FG001|Overall Study|Adverse Event|1
6078059|NCT00601835|9684298|FG000|Overall Study|Adverse Event|1
6078060|NCT00601835|9684299|FG001|Overall Study|Adverse Event|1
6078061|NCT00601835|9684298|FG000|Overall Study|Relocate|12
6078062|NCT00601835|9684299|FG001|Overall Study|Relocate|2
6078063|NCT00602420|9684375|FG000|Overall Study|Death|1
6078064|NCT00602420|9684376|FG001|Overall Study|Death|4
6078065|NCT00602420|9684375|FG000|Overall Study|Chemotoxicity, Inc. Data,Ineligible|5
6078066|NCT00602420|9684376|FG001|Overall Study|Chemotoxicity, Inc. Data,Ineligible|3
6078067|NCT00602420|9684375|FG000|Overall Study|Withdrawal by Subject|18
6078068|NCT00602420|9684376|FG001|Overall Study|Withdrawal by Subject|17
6078069|NCT00602420|9684375|FG000|Overall Study|Adverse Event|1
6078070|NCT00602420|9684376|FG001|Overall Study|Adverse Event|0
6078071|NCT00602472|9684388|FG000|Overall Study|Adverse Event|5
6078072|NCT00602472|9684389|FG001|Overall Study|Adverse Event|23
6078073|NCT00602472|9684388|FG000|Overall Study|Protocol Violation|4
6078074|NCT00602472|9684389|FG001|Overall Study|Protocol Violation|19
6078075|NCT00602472|9684388|FG000|Overall Study|Withdrawal by Subject|8
6078076|NCT00602472|9684389|FG001|Overall Study|Withdrawal by Subject|14
6078077|NCT00602472|9684388|FG000|Overall Study|Other incl. lack of efficacy|4
6078078|NCT00602472|9684389|FG001|Overall Study|Other incl. lack of efficacy|2
6078079|NCT00602537|9684397|FG000|12 Week Double Blind Comparison|Adverse Event|2
6078080|NCT00602537|9684398|FG001|12 Week Double Blind Comparison|Adverse Event|5
6078081|NCT00602537|9684397|FG000|12 Week Double Blind Comparison|Lack of Efficacy|13
6078082|NCT00602537|9684398|FG001|12 Week Double Blind Comparison|Lack of Efficacy|23
6078083|NCT00602537|9684397|FG000|12 Week Double Blind Comparison|Lost to Follow-up|5
6078084|NCT00602537|9684398|FG001|12 Week Double Blind Comparison|Lost to Follow-up|6
6078085|NCT00602537|9684397|FG000|12 Week Double Blind Comparison|Withdrawal by Subject|3
6078086|NCT00602537|9684398|FG001|12 Week Double Blind Comparison|Withdrawal by Subject|13
6022495|NCT00238303|9617669|FG002|Overall Study|Adverse Event|3
6022496|NCT00238433|9617682|FG000|Overall Study|Screen failure|1
6022497|NCT00238433|9617682|FG000|Overall Study|Lost to Follow-up|1
6022498|NCT00238433|9617682|FG000|Overall Study|Death|1
6022499|NCT00239005|9617695|FG000|Overall Study|Adverse Event|6
6022500|NCT00239005|9617696|FG001|Overall Study|Adverse Event|6
6022501|NCT00239005|9617695|FG000|Overall Study|Withdrawal by Subject|3
6022502|NCT00239005|9617696|FG001|Overall Study|Withdrawal by Subject|4
6022503|NCT00239005|9617695|FG000|Overall Study|Unsatisfactory Therapeutic effect|2
6022504|NCT00239005|9617696|FG001|Overall Study|Unsatisfactory Therapeutic effect|0
6022505|NCT00239005|9617695|FG000|Overall Study|Protocol Violation|1
6022506|NCT00239005|9617696|FG001|Overall Study|Protocol Violation|0
6022507|NCT00239005|9617695|FG000|Overall Study|Subj. cond. no longer needs study drug|0
6022508|NCT00239005|9617696|FG001|Overall Study|Subj. cond. no longer needs study drug|1
6022509|NCT00239005|9617695|FG000|Overall Study|Lost to Follow-up|0
6022510|NCT00239005|9617696|FG001|Overall Study|Lost to Follow-up|1
6022511|NCT00239226|9617706|FG000|Overall Study|permAF during stabilization period|0
6022512|NCT00239226|9617707|FG001|Overall Study|permAF during stabilization period|0
6022513|NCT00239226|9617708|FG002|Overall Study|permAF during stabilization period|0
6022514|NCT00239226|9617709|FG003|Overall Study|permAF during stabilization period|3
6022515|NCT00239226|9617706|FG000|Overall Study|Lost to Follow-up|1
6022516|NCT00239226|9617707|FG001|Overall Study|Lost to Follow-up|0
6022517|NCT00239226|9617708|FG002|Overall Study|Lost to Follow-up|1
6022518|NCT00239226|9617709|FG003|Overall Study|Lost to Follow-up|0
6022519|NCT00239356|9617721|FG000|Overall Study|Lack of Efficacy|1
6078087|NCT00602537|9684397|FG000|Follow Up Study Comparison|Adverse Event|1
6078088|NCT00602537|9684398|FG001|Follow Up Study Comparison|Adverse Event|0
6078089|NCT00602537|9684397|FG000|Follow Up Study Comparison|Lost to Follow-up|8
6146270|NCT01076075|9780863|FG000|Overall Study|Adverse Event|3
6022520|NCT00239356|9617722|FG001|Overall Study|Lack of Efficacy|0
6022521|NCT00239356|9617721|FG000|Overall Study|Adverse Event|6
6022522|NCT00239356|9617722|FG001|Overall Study|Adverse Event|0
6022523|NCT00239356|9617721|FG000|Overall Study|Withdrawal by Subject|15
6022524|NCT00239356|9617722|FG001|Overall Study|Withdrawal by Subject|6
6022525|NCT00239356|9617721|FG000|Overall Study|Lost to Follow-up|3
6022526|NCT00239356|9617722|FG001|Overall Study|Lost to Follow-up|0
6022527|NCT00239356|9617721|FG000|Overall Study|poor/non-compliance|2
6022528|NCT00239356|9617722|FG001|Overall Study|poor/non-compliance|0
6022529|NCT00239356|9617721|FG000|Overall Study|Pregnancy|1
6022530|NCT00239356|9617722|FG001|Overall Study|Pregnancy|0
6022531|NCT00239356|9617721|FG000|Overall Study|Administrative reason|0
6022532|NCT00239356|9617722|FG001|Overall Study|Administrative reason|1
6022533|NCT00239356|9617721|FG000|Overall Study|Drug available on market|11
6022534|NCT00239356|9617722|FG001|Overall Study|Drug available on market|2
6022535|NCT00239577|9617732|FG000|Primary Phase|Adverse Event|0
6022536|NCT00239577|9617733|FG001|Primary Phase|Adverse Event|0
6022537|NCT00239577|9617734|FG002|Primary Phase|Adverse Event|1
6022538|NCT00239577|9617735|FG003|Primary Phase|Adverse Event|0
6022539|NCT00239577|9617732|FG000|Primary Phase|Other|5
6022540|NCT00239577|9617733|FG001|Primary Phase|Other|3
6022541|NCT00239577|9617734|FG002|Primary Phase|Other|2
6022542|NCT00239577|9617735|FG003|Primary Phase|Other|0
6022543|NCT00239590|9617747|FG000|Randomized|Lost to Follow-up|0
6022544|NCT00239590|9617748|FG001|Randomized|Lost to Follow-up|1
6022545|NCT00239590|9617747|FG000|Randomized|Withdrawal by Subject|0
6022546|NCT00239590|9617748|FG001|Randomized|Withdrawal by Subject|1
6022547|NCT00239590|9617747|FG000|Completed Study Protocol|Adverse Event|1
6022548|NCT00239590|9617748|FG001|Completed Study Protocol|Adverse Event|1
6022549|NCT00239590|9617747|FG000|Completed Study Protocol|Withdrawal by Subject|0
6022550|NCT00239590|9617748|FG001|Completed Study Protocol|Withdrawal by Subject|1
6022551|NCT00239681|9617771|FG000|Overall Study|Adverse Event|100
6022552|NCT00239681|9617772|FG001|Overall Study|Adverse Event|99
6022553|NCT00239681|9617771|FG000|Overall Study|Withdrawal by Subject|458
6022554|NCT00239681|9617772|FG001|Overall Study|Withdrawal by Subject|489
6022555|NCT00239681|9617771|FG000|Overall Study|Lost to Follow-up|28
6022556|NCT00239681|9617772|FG001|Overall Study|Lost to Follow-up|22
6022557|NCT00239681|9617771|FG000|Overall Study|Protocol Violation|4
6022558|NCT00239681|9617772|FG001|Overall Study|Protocol Violation|4
6022559|NCT00239681|9617771|FG000|Overall Study|Physician Decision|13
6022560|NCT00239681|9617772|FG001|Overall Study|Physician Decision|17
6022561|NCT00239681|9617771|FG000|Overall Study|No information chacked on CaseReportForm|90
6022562|NCT00239681|9617772|FG001|Overall Study|No information chacked on CaseReportForm|84
6022563|NCT00239837|9617784|FG000|Overall Study|Lost to Follow-up|3
6022564|NCT00239837|9617785|FG001|Overall Study|Lost to Follow-up|7
6022565|NCT00239928|9617793|FG000|Overall Study|Lack of Efficacy|1
6022566|NCT00239928|9617793|FG000|Overall Study|Adverse Event|4
6022567|NCT00239928|9617793|FG000|Overall Study|Not need to continue study|3
6022568|NCT00239928|9617793|FG000|Overall Study|Withdrawal by Subject|2
6022569|NCT00240071|9617797|FG000|Overall Study|Withdrawal by Subject|3
6022570|NCT00240097|9617802|FG000|Part I|Adverse Event|1
6022571|NCT00240097|9617802|FG000|Part I|Death|1
6022572|NCT00240097|9617802|FG000|Part I|histology|1
6022573|NCT00240097|9617802|FG000|Part I|unevaluable|1
6022574|NCT00240097|9617802|FG000|Part II|did not continue from Part I|23
6022575|NCT00240110|9617812|FG000|Overall Study|Lost to Follow-up|6
6022576|NCT00240110|9617813|FG001|Overall Study|Lost to Follow-up|7
6022577|NCT00240331|9617827|FG000|Overall Study|Withdrawal by Subject|125
6022578|NCT00240331|9617828|FG001|Overall Study|Withdrawal by Subject|132
6022579|NCT00240331|9617827|FG000|Overall Study|Option selected by investigator|1
6022580|NCT00240331|9617828|FG001|Overall Study|Option selected by investigator|2
6022581|NCT00240994|9617891|FG000|Overall Study|Lost to Follow-up|1
6022582|NCT00240994|9617891|FG000|Overall Study|Protocol Violation|1
6022583|NCT00240994|9617891|FG000|Overall Study|Graft failure|1
6022584|NCT00241280|9617902|FG000|Overall Study|Adverse Event|2
6022585|NCT00241280|9617903|FG001|Overall Study|Adverse Event|6
6022586|NCT00241280|9617902|FG000|Overall Study|Discomfort|11
6022587|NCT00241280|9617903|FG001|Overall Study|Discomfort|16
6022588|NCT00241280|9617902|FG000|Overall Study|Pregnancy|1
6022589|NCT00241280|9617903|FG001|Overall Study|Pregnancy|5
6022590|NCT00241280|9617902|FG000|Overall Study|Lost to Follow-up|5
6022591|NCT00241280|9617903|FG001|Overall Study|Lost to Follow-up|8
6022592|NCT00241280|9617902|FG000|Overall Study|Withdrawal by Subject|7
6022593|NCT00241280|9617903|FG001|Overall Study|Withdrawal by Subject|4
6022594|NCT00241280|9617902|FG000|Overall Study|Protocol Violation|4
6022595|NCT00241280|9617903|FG001|Overall Study|Protocol Violation|10
6022596|NCT00241280|9617902|FG000|Overall Study|Relocation|4
6022597|NCT00241280|9617903|FG001|Overall Study|Relocation|4
6022598|NCT00241280|9617902|FG000|Overall Study|Unsatisfactory Physiological Response|1
6022599|NCT00241280|9617903|FG001|Overall Study|Unsatisfactory Physiological Response|1
6022600|NCT00241280|9617902|FG000|Overall Study|Unsatisfactory Visual Response|1
6022601|NCT00241280|9617903|FG001|Overall Study|Unsatisfactory Visual Response|1
6022602|NCT00241280|9617902|FG000|Overall Study|Diabetic|1
6022603|NCT00241280|9617903|FG001|Overall Study|Diabetic|0
6022604|NCT00241280|9617902|FG000|Overall Study|Subject Ineligible/Dispensed|9
6022605|NCT00241280|9617903|FG001|Overall Study|Subject Ineligible/Dispensed|6
6022606|NCT00241280|9617902|FG000|Overall Study|Dispensed incorrect test article|1
6022607|NCT00241280|9617903|FG001|Overall Study|Dispensed incorrect test article|2
6022608|NCT00241280|9617902|FG000|Overall Study|Unacceptable Fit|0
6022609|NCT00241280|9617903|FG001|Overall Study|Unacceptable Fit|1
6022610|NCT00241280|9617902|FG000|Overall Study|Scheduling Conflict|0
6022611|NCT00241280|9617903|FG001|Overall Study|Scheduling Conflict|2
6022612|NCT00241280|9617902|FG000|Overall Study|History of Ocular Surgery|0
6022613|NCT00241280|9617903|FG001|Overall Study|History of Ocular Surgery|1
6022614|NCT00241280|9617902|FG000|Overall Study|Coating on Lens|1
6022615|NCT00241280|9617903|FG001|Overall Study|Coating on Lens|0
6022616|NCT00241280|9617902|FG000|Overall Study|Excessive Dryness|0
6022617|NCT00241280|9617903|FG001|Overall Study|Excessive Dryness|1
6022618|NCT00241358|9617913|FG000|Overall Study|Determined to be not ineligible|0
6022619|NCT00241358|9617914|FG001|Overall Study|Determined to be not ineligible|1
6022620|NCT00241358|9617915|FG002|Overall Study|Determined to be not ineligible|1
6022621|NCT00241631|9617924|FG000|Run in (2 Weeks)|Physician Decision|3
6022622|NCT00241631|9617925|FG001|Run in (2 Weeks)|Physician Decision|3
6022623|NCT00241631|9617924|FG000|Phase 1 (4 Weeks)|sore throat|1
6022624|NCT00241631|9617925|FG001|Phase 1 (4 Weeks)|sore throat|0
6022625|NCT00241631|9617924|FG000|Phase 1 (4 Weeks)|Withdrawal by Subject|4
6022626|NCT00241631|9617925|FG001|Phase 1 (4 Weeks)|Withdrawal by Subject|4
6022627|NCT00241631|9617924|FG000|Phase 1 (4 Weeks)|Lost to Follow-up|3
6022628|NCT00241631|9617925|FG001|Phase 1 (4 Weeks)|Lost to Follow-up|0
6022629|NCT00241631|9617924|FG000|Phase 1 (4 Weeks)|Lack of Efficacy|0
6022630|NCT00241631|9617925|FG001|Phase 1 (4 Weeks)|Lack of Efficacy|1
6022631|NCT00241644|9617935|FG000|First Efficacy Period (Year 1)|Adverse Event|46
6022632|NCT00241644|9617936|FG001|First Efficacy Period (Year 1)|Adverse Event|45
6022633|NCT00241644|9617937|FG002|First Efficacy Period (Year 1)|Adverse Event|45
6022634|NCT00241644|9617938|FG003|First Efficacy Period (Year 1)|Adverse Event|91
6022635|NCT00241644|9617935|FG000|First Efficacy Period (Year 1)|Protocol Violation|3
6022636|NCT00241644|9617936|FG001|First Efficacy Period (Year 1)|Protocol Violation|5
6022637|NCT00241644|9617937|FG002|First Efficacy Period (Year 1)|Protocol Violation|4
6022638|NCT00241644|9617938|FG003|First Efficacy Period (Year 1)|Protocol Violation|8
6022639|NCT00241644|9617935|FG000|First Efficacy Period (Year 1)|Withdrawal by Subject|59
6022640|NCT00241644|9617936|FG001|First Efficacy Period (Year 1)|Withdrawal by Subject|74
6022641|NCT00241644|9617937|FG002|First Efficacy Period (Year 1)|Withdrawal by Subject|81
6022642|NCT00241644|9617938|FG003|First Efficacy Period (Year 1)|Withdrawal by Subject|133
6022643|NCT00241644|9617935|FG000|First Efficacy Period (Year 1)|Lost to Follow-up|116
6022644|NCT00241644|9617936|FG001|First Efficacy Period (Year 1)|Lost to Follow-up|142
6022645|NCT00241644|9617937|FG002|First Efficacy Period (Year 1)|Lost to Follow-up|116
6022646|NCT00241644|9617938|FG003|First Efficacy Period (Year 1)|Lost to Follow-up|258
6022647|NCT00241644|9617935|FG000|First Efficacy Period (Year 1)|Non-compliance|2
6022648|NCT00241644|9617936|FG001|First Efficacy Period (Year 1)|Non-compliance|1
6022649|NCT00241644|9617937|FG002|First Efficacy Period (Year 1)|Non-compliance|2
6022650|NCT00241644|9617938|FG003|First Efficacy Period (Year 1)|Non-compliance|3
6022651|NCT00241644|9617935|FG000|First Efficacy Period (Year 1)|Return dates not reliable|1
6022652|NCT00241644|9617936|FG001|First Efficacy Period (Year 1)|Return dates not reliable|0
6022653|NCT00241644|9617937|FG002|First Efficacy Period (Year 1)|Return dates not reliable|0
6022654|NCT00241644|9617938|FG003|First Efficacy Period (Year 1)|Return dates not reliable|1
6022655|NCT00241644|9617935|FG000|First Efficacy Period (Year 1)|Vaccinated at regular clinic|0
6022656|NCT00241644|9617936|FG001|First Efficacy Period (Year 1)|Vaccinated at regular clinic|0
6022657|NCT00241644|9617937|FG002|First Efficacy Period (Year 1)|Vaccinated at regular clinic|1
6022658|NCT00241644|9617938|FG003|First Efficacy Period (Year 1)|Vaccinated at regular clinic|0
6022659|NCT00241644|9617935|FG000|First Efficacy Period (Year 1)|Subject's parent passed away|0
6022660|NCT00241644|9617936|FG001|First Efficacy Period (Year 1)|Subject's parent passed away|1
6022661|NCT00241644|9617937|FG002|First Efficacy Period (Year 1)|Subject's parent passed away|0
6022662|NCT00241644|9617938|FG003|First Efficacy Period (Year 1)|Subject's parent passed away|1
6022663|NCT00241644|9617935|FG000|Second Efficacy Period (Year 2)|Adverse Event|11
6022664|NCT00241644|9617936|FG001|Second Efficacy Period (Year 2)|Adverse Event|9
6022665|NCT00241644|9617937|FG002|Second Efficacy Period (Year 2)|Adverse Event|12
6022666|NCT00241644|9617938|FG003|Second Efficacy Period (Year 2)|Adverse Event|20
6022667|NCT00241644|9617935|FG000|Second Efficacy Period (Year 2)|Protocol Violation|2
6022668|NCT00241644|9617936|FG001|Second Efficacy Period (Year 2)|Protocol Violation|1
6022669|NCT00241644|9617937|FG002|Second Efficacy Period (Year 2)|Protocol Violation|2
6022670|NCT00241644|9617938|FG003|Second Efficacy Period (Year 2)|Protocol Violation|3
6022671|NCT00241644|9617935|FG000|Second Efficacy Period (Year 2)|Withdrawal by Subject|4
6022672|NCT00241644|9617936|FG001|Second Efficacy Period (Year 2)|Withdrawal by Subject|3
6022673|NCT00241644|9617937|FG002|Second Efficacy Period (Year 2)|Withdrawal by Subject|2
6022674|NCT00241644|9617938|FG003|Second Efficacy Period (Year 2)|Withdrawal by Subject|7
6022675|NCT00241644|9617935|FG000|Second Efficacy Period (Year 2)|Lost to Follow-up|43
6022676|NCT00241644|9617936|FG001|Second Efficacy Period (Year 2)|Lost to Follow-up|43
6022677|NCT00241644|9617937|FG002|Second Efficacy Period (Year 2)|Lost to Follow-up|46
6022678|NCT00241644|9617938|FG003|Second Efficacy Period (Year 2)|Lost to Follow-up|86
6022679|NCT00241644|9617935|FG000|Second Efficacy Period (Year 2)|Consenting parent passed away|1
6022680|NCT00241644|9617936|FG001|Second Efficacy Period (Year 2)|Consenting parent passed away|1
6022681|NCT00241644|9617937|FG002|Second Efficacy Period (Year 2)|Consenting parent passed away|2
6022682|NCT00241644|9617938|FG003|Second Efficacy Period (Year 2)|Consenting parent passed away|2
6022683|NCT00241839|9617950|FG000|Overall Study|Withdrawal by Subject|18
6022684|NCT00241839|9617951|FG001|Overall Study|Withdrawal by Subject|17
6022685|NCT00241839|9617950|FG000|Overall Study|Adverse Event|1
6022686|NCT00241839|9617951|FG001|Overall Study|Adverse Event|1
6022687|NCT00242216|9617978|FG000|Overall Study|Lost to Follow-up|12
6022688|NCT00242216|9617979|FG001|Overall Study|Lost to Follow-up|17
6022689|NCT00242216|9617978|FG000|Overall Study|Death|4
6022690|NCT00242216|9617979|FG001|Overall Study|Death|2
6022691|NCT00242216|9617978|FG000|Overall Study|Lack of Efficacy|1
6022692|NCT00242216|9617979|FG001|Overall Study|Lack of Efficacy|2
6022693|NCT00242216|9617978|FG000|Overall Study|no medicaiton dispensed|1
6022694|NCT00242216|9617979|FG001|Overall Study|no medicaiton dispensed|1
6022695|NCT00242567|9617998|FG000|Overall Study|Adverse Event|70
6022696|NCT00242567|9617999|FG001|Overall Study|Adverse Event|43
6022697|NCT00242567|9617998|FG000|Overall Study|Disease Progression|17
6022698|NCT00242567|9617999|FG001|Overall Study|Disease Progression|22
6022699|NCT00242567|9617998|FG000|Overall Study|Symptomatic deterioration|9
6022700|NCT00242567|9617999|FG001|Overall Study|Symptomatic deterioration|3
6022701|NCT00242567|9617998|FG000|Overall Study|Lack of Efficacy|2
6022702|NCT00242567|9617999|FG001|Overall Study|Lack of Efficacy|2
6022703|NCT00242567|9617998|FG000|Overall Study|Lost to Follow-up|9
6022704|NCT00242567|9617999|FG001|Overall Study|Lost to Follow-up|19
6022705|NCT00242567|9617998|FG000|Overall Study|Withdrawal by Subject|33
6022706|NCT00242567|9617999|FG001|Overall Study|Withdrawal by Subject|28
6022707|NCT00242567|9617998|FG000|Overall Study|Protocol Violation|12
6022708|NCT00242567|9617999|FG001|Overall Study|Protocol Violation|12
6022709|NCT00242567|9617998|FG000|Overall Study|Use of an inhibitor of bone resorption|0
6022710|NCT00242567|9617999|FG001|Overall Study|Use of an inhibitor of bone resorption|2
6022711|NCT00242567|9617998|FG000|Overall Study|Other|14
6022712|NCT00242567|9617999|FG001|Overall Study|Other|9
6022713|NCT00242580|9618010|FG000|Overall Study|Adverse Event|3
6022714|NCT00242580|9618011|FG001|Overall Study|Adverse Event|0
6022715|NCT00242580|9618012|FG002|Overall Study|Adverse Event|2
6022716|NCT00242580|9618010|FG000|Overall Study|Unsatisfactory therapeutic effect|4
6022717|NCT00242580|9618011|FG001|Overall Study|Unsatisfactory therapeutic effect|5
6022718|NCT00242580|9618012|FG002|Overall Study|Unsatisfactory therapeutic effect|5
6022719|NCT00242580|9618010|FG000|Overall Study|Protocol Violation|0
6022720|NCT00242580|9618011|FG001|Overall Study|Protocol Violation|0
6022721|NCT00242580|9618012|FG002|Overall Study|Protocol Violation|1
6022722|NCT00242580|9618010|FG000|Overall Study|Subject withdrew consent|2
6022723|NCT00242580|9618011|FG001|Overall Study|Subject withdrew consent|2
6022724|NCT00242580|9618012|FG002|Overall Study|Subject withdrew consent|5
6022725|NCT00242580|9618010|FG000|Overall Study|Lost to Follow-up|0
6022726|NCT00242580|9618011|FG001|Overall Study|Lost to Follow-up|3
6022727|NCT00242580|9618012|FG002|Overall Study|Lost to Follow-up|0
6022728|NCT00242580|9618010|FG000|Overall Study|Death|1
6022729|NCT00242580|9618011|FG001|Overall Study|Death|2
6022730|NCT00242580|9618012|FG002|Overall Study|Death|1
6022731|NCT00242658|9618041|FG000|Overall Study|Lost to Follow-up|22
6022732|NCT00242658|9618042|FG001|Overall Study|Lost to Follow-up|19
6022733|NCT00242710|9618056|FG000|Core Study (up to Year 1)|Adverse Event|30
6022734|NCT00242710|9618057|FG001|Core Study (up to Year 1)|Adverse Event|25
6022735|NCT00242710|9618058|FG002|Core Study (up to Year 1)|Adverse Event|23
6022736|NCT00242710|9618059|FG003|Core Study (up to Year 1)|Adverse Event|14
6022737|NCT00242710|9618056|FG000|Core Study (up to Year 1)|Death|0
6022738|NCT00242710|9618057|FG001|Core Study (up to Year 1)|Death|0
6022739|NCT00242710|9618058|FG002|Core Study (up to Year 1)|Death|1
6022740|NCT00242710|9618059|FG003|Core Study (up to Year 1)|Death|0
6022741|NCT00242710|9618056|FG000|Core Study (up to Year 1)|Physician Decision|0
6022742|NCT00242710|9618057|FG001|Core Study (up to Year 1)|Physician Decision|1
6022743|NCT00242710|9618058|FG002|Core Study (up to Year 1)|Physician Decision|0
6022744|NCT00242710|9618059|FG003|Core Study (up to Year 1)|Physician Decision|1
6022745|NCT00242710|9618056|FG000|Core Study (up to Year 1)|Lost to Follow-up|8
6022746|NCT00242710|9618057|FG001|Core Study (up to Year 1)|Lost to Follow-up|8
6022747|NCT00242710|9618058|FG002|Core Study (up to Year 1)|Lost to Follow-up|7
6022748|NCT00242710|9618059|FG003|Core Study (up to Year 1)|Lost to Follow-up|3
6022749|NCT00242710|9618056|FG000|Core Study (up to Year 1)|Other|6
6022750|NCT00242710|9618057|FG001|Core Study (up to Year 1)|Other|1
6022751|NCT00242710|9618058|FG002|Core Study (up to Year 1)|Other|0
6022752|NCT00242710|9618059|FG003|Core Study (up to Year 1)|Other|2
6022753|NCT00242710|9618056|FG000|Core Study (up to Year 1)|Protocol Violation|2
6022754|NCT00242710|9618057|FG001|Core Study (up to Year 1)|Protocol Violation|9
6022755|NCT00242710|9618058|FG002|Core Study (up to Year 1)|Protocol Violation|1
6022756|NCT00242710|9618059|FG003|Core Study (up to Year 1)|Protocol Violation|3
6022757|NCT00242710|9618056|FG000|Core Study (up to Year 1)|Withdrawal by Subject|27
6022758|NCT00242710|9618057|FG001|Core Study (up to Year 1)|Withdrawal by Subject|16
6022759|NCT00242710|9618058|FG002|Core Study (up to Year 1)|Withdrawal by Subject|15
6022760|NCT00242710|9618059|FG003|Core Study (up to Year 1)|Withdrawal by Subject|6
6022761|NCT00242710|9618056|FG000|Core Study (up to Year 1)|Lack of Efficacy|1
6022762|NCT00242710|9618057|FG001|Core Study (up to Year 1)|Lack of Efficacy|0
6022763|NCT00242710|9618058|FG002|Core Study (up to Year 1)|Lack of Efficacy|0
6022764|NCT00242710|9618059|FG003|Core Study (up to Year 1)|Lack of Efficacy|0
6022765|NCT00242710|9618056|FG000|Core Study (up to Year 1)|Randomized but not Treated|12
6022766|NCT00242710|9618057|FG001|Core Study (up to Year 1)|Randomized but not Treated|4
6022767|NCT00242710|9618058|FG002|Core Study (up to Year 1)|Randomized but not Treated|4
6022768|NCT00242710|9618059|FG003|Core Study (up to Year 1)|Randomized but not Treated|2
6022769|NCT00242710|9618056|FG000|Period Between Core Study and Extension|Adverse Event|2
6022770|NCT00242710|9618057|FG001|Period Between Core Study and Extension|Adverse Event|3
6022771|NCT00242710|9618058|FG002|Period Between Core Study and Extension|Adverse Event|5
6022772|NCT00242710|9618059|FG003|Period Between Core Study and Extension|Adverse Event|2
6022773|NCT00242710|9618056|FG000|Period Between Core Study and Extension|Physician Decision|1
6022774|NCT00242710|9618057|FG001|Period Between Core Study and Extension|Physician Decision|1
6022775|NCT00242710|9618058|FG002|Period Between Core Study and Extension|Physician Decision|0
6022776|NCT00242710|9618059|FG003|Period Between Core Study and Extension|Physician Decision|0
6022777|NCT00242710|9618056|FG000|Period Between Core Study and Extension|Other|24
6022778|NCT00242710|9618057|FG001|Period Between Core Study and Extension|Other|24
6022779|NCT00242710|9618058|FG002|Period Between Core Study and Extension|Other|9
6022780|NCT00242710|9618059|FG003|Period Between Core Study and Extension|Other|11
6022781|NCT00242710|9618056|FG000|Period Between Core Study and Extension|Extension not Available|17
6022782|NCT00242710|9618057|FG001|Period Between Core Study and Extension|Extension not Available|21
6022783|NCT00242710|9618058|FG002|Period Between Core Study and Extension|Extension not Available|8
6022784|NCT00242710|9618059|FG003|Period Between Core Study and Extension|Extension not Available|7
6022785|NCT00242710|9618056|FG000|Period Between Core Study and Extension|Protocol Violation|0
6022786|NCT00242710|9618057|FG001|Period Between Core Study and Extension|Protocol Violation|0
6022787|NCT00242710|9618058|FG002|Period Between Core Study and Extension|Protocol Violation|2
6022788|NCT00242710|9618059|FG003|Period Between Core Study and Extension|Protocol Violation|1
6022789|NCT00242710|9618056|FG000|Period Between Core Study and Extension|Withdrawal by Subject|75
6022790|NCT00242710|9618057|FG001|Period Between Core Study and Extension|Withdrawal by Subject|63
6022791|NCT00242710|9618058|FG002|Period Between Core Study and Extension|Withdrawal by Subject|24
6022792|NCT00242710|9618059|FG003|Period Between Core Study and Extension|Withdrawal by Subject|28
6022793|NCT00242710|9618056|FG000|Study Extension (up to Year 2)|Adverse Event|7
6022794|NCT00242710|9618057|FG001|Study Extension (up to Year 2)|Adverse Event|9
6022795|NCT00242710|9618058|FG002|Study Extension (up to Year 2)|Adverse Event|2
6022796|NCT00242710|9618059|FG003|Study Extension (up to Year 2)|Adverse Event|4
6022797|NCT00242710|9618056|FG000|Study Extension (up to Year 2)|Death|0
6022798|NCT00242710|9618057|FG001|Study Extension (up to Year 2)|Death|0
6022799|NCT00242710|9618058|FG002|Study Extension (up to Year 2)|Death|0
6022800|NCT00242710|9618059|FG003|Study Extension (up to Year 2)|Death|1
6022801|NCT00242710|9618056|FG000|Study Extension (up to Year 2)|Lost to Follow-up|7
6022802|NCT00242710|9618057|FG001|Study Extension (up to Year 2)|Lost to Follow-up|7
6022803|NCT00242710|9618058|FG002|Study Extension (up to Year 2)|Lost to Follow-up|5
6022804|NCT00242710|9618059|FG003|Study Extension (up to Year 2)|Lost to Follow-up|0
6022805|NCT00242710|9618056|FG000|Study Extension (up to Year 2)|Other|3
6022806|NCT00242710|9618057|FG001|Study Extension (up to Year 2)|Other|5
6022807|NCT00242710|9618058|FG002|Study Extension (up to Year 2)|Other|4
6022808|NCT00242710|9618059|FG003|Study Extension (up to Year 2)|Other|3
6022809|NCT00242710|9618056|FG000|Study Extension (up to Year 2)|Protocol Violation|0
6022810|NCT00242710|9618057|FG001|Study Extension (up to Year 2)|Protocol Violation|2
6022811|NCT00242710|9618058|FG002|Study Extension (up to Year 2)|Protocol Violation|0
6022812|NCT00242710|9618059|FG003|Study Extension (up to Year 2)|Protocol Violation|1
6022813|NCT00242710|9618056|FG000|Study Extension (up to Year 2)|Withdrawal by Subject|10
6022814|NCT00242710|9618057|FG001|Study Extension (up to Year 2)|Withdrawal by Subject|6
6022815|NCT00242710|9618058|FG002|Study Extension (up to Year 2)|Withdrawal by Subject|4
6022816|NCT00242710|9618059|FG003|Study Extension (up to Year 2)|Withdrawal by Subject|1
6022817|NCT00243022|9618071|FG000|Overall Study|Withdrawal by Subject|1
6022818|NCT00243022|9618072|FG001|Overall Study|Withdrawal by Subject|0
6022819|NCT00243022|9618071|FG000|Overall Study|Death|1
6022820|NCT00243022|9618072|FG001|Overall Study|Death|0
6022821|NCT00243022|9618071|FG000|Overall Study|Difficult Travel Distance|0
6022822|NCT00243022|9618072|FG001|Overall Study|Difficult Travel Distance|1
6022823|NCT00243074|9618084|FG000|Overall Study|Ineligible|6
6022824|NCT00243074|9618084|FG000|Overall Study|Adverse Event|6
6022825|NCT00243074|9618084|FG000|Overall Study|Withdrawal by Subject|2
6022826|NCT00243074|9618084|FG000|Overall Study|Lack of Efficacy|36
6022827|NCT00243074|9618084|FG000|Overall Study|Death|2
6022828|NCT00243074|9618084|FG000|Overall Study|not protocol specified|1
6022829|NCT00243074|9618084|FG000|Overall Study|Did not receive any treatment|1
6022830|NCT00243230|9618104|FG000|Double-Blind Period|Adverse Event|0
6022831|NCT00243230|9618105|FG001|Double-Blind Period|Adverse Event|2
6022832|NCT00243230|9618106|FG002|Double-Blind Period|Adverse Event|2
6022833|NCT00243230|9618107|FG003|Double-Blind Period|Adverse Event|0
6022834|NCT00243230|9618104|FG000|Double-Blind Period|Withdrawal by Subject|1
6022835|NCT00243230|9618105|FG001|Double-Blind Period|Withdrawal by Subject|0
6022836|NCT00243230|9618106|FG002|Double-Blind Period|Withdrawal by Subject|0
6022837|NCT00243230|9618107|FG003|Double-Blind Period|Withdrawal by Subject|0
6022838|NCT00243230|9618104|FG000|Double-Blind Period|Protocol Violation|0
6022839|NCT00243230|9618105|FG001|Double-Blind Period|Protocol Violation|0
6022840|NCT00243230|9618106|FG002|Double-Blind Period|Protocol Violation|1
6022841|NCT00243230|9618107|FG003|Double-Blind Period|Protocol Violation|0
6022842|NCT00243230|9618104|FG000|Double-Blind Period|Randomized but Not Treated|0
6022843|NCT00243230|9618105|FG001|Double-Blind Period|Randomized but Not Treated|0
6022844|NCT00243230|9618106|FG002|Double-Blind Period|Randomized but Not Treated|2
6022845|NCT00243230|9618107|FG003|Double-Blind Period|Randomized but Not Treated|0
6022846|NCT00243230|9618104|FG000|Double-Blind Period|Treatment Failure - Virologic Failure defined by investigator|5
6022847|NCT00243230|9618105|FG001|Double-Blind Period|Treatment Failure - Virologic Failure defined by investigator|3
6022848|NCT00243230|9618106|FG002|Double-Blind Period|Treatment Failure - Virologic Failure defined by investigator|14
6022849|NCT00243230|9618107|FG003|Double-Blind Period|Treatment Failure - Virologic Failure defined by investigator|0
6022850|NCT00243230|9618104|FG000|Open Label Period|Adverse Event|0
6022851|NCT00243230|9618105|FG001|Open Label Period|Adverse Event|0
6022852|NCT00243230|9618106|FG002|Open Label Period|Adverse Event|0
6022853|NCT00243230|9618107|FG003|Open Label Period|Adverse Event|2
6022854|NCT00243230|9618104|FG000|Open Label Period|Treatment Failure - Virologic Failure|0
6022855|NCT00243230|9618105|FG001|Open Label Period|Treatment Failure - Virologic Failure|0
6022856|NCT00243230|9618106|FG002|Open Label Period|Treatment Failure - Virologic Failure|0
6022857|NCT00243230|9618107|FG003|Open Label Period|Treatment Failure - Virologic Failure|13
6022858|NCT00243230|9618104|FG000|Open Label Period|Progressive Disease (AIDS-Event)|0
6022859|NCT00243230|9618105|FG001|Open Label Period|Progressive Disease (AIDS-Event)|0
6022860|NCT00243230|9618106|FG002|Open Label Period|Progressive Disease (AIDS-Event)|0
6022861|NCT00243230|9618107|FG003|Open Label Period|Progressive Disease (AIDS-Event)|1
6022862|NCT00243230|9618104|FG000|Open Label Period|Lost to Follow-up|0
6022863|NCT00243230|9618105|FG001|Open Label Period|Lost to Follow-up|0
6022864|NCT00243230|9618106|FG002|Open Label Period|Lost to Follow-up|0
6022865|NCT00243230|9618107|FG003|Open Label Period|Lost to Follow-up|2
6022866|NCT00243230|9618104|FG000|Open Label Period|Withdrawal by Subject|0
6022867|NCT00243230|9618105|FG001|Open Label Period|Withdrawal by Subject|0
6022868|NCT00243230|9618106|FG002|Open Label Period|Withdrawal by Subject|0
6022869|NCT00243230|9618107|FG003|Open Label Period|Withdrawal by Subject|2
6022870|NCT00243230|9618104|FG000|Open Label Period|Protocol Violation|0
6022871|NCT00243230|9618105|FG001|Open Label Period|Protocol Violation|0
6022872|NCT00243230|9618106|FG002|Open Label Period|Protocol Violation|0
6022873|NCT00243230|9618107|FG003|Open Label Period|Protocol Violation|2
6022874|NCT00243230|9618104|FG000|Open Label Period|Administrative Reason|0
6022875|NCT00243230|9618105|FG001|Open Label Period|Administrative Reason|0
6078090|NCT00602537|9684398|FG001|Follow Up Study Comparison|Lost to Follow-up|1
6078091|NCT00602537|9684397|FG000|Follow Up Study Comparison|Withdrawal by Subject|2
6078092|NCT00602537|9684398|FG001|Follow Up Study Comparison|Withdrawal by Subject|2
6078093|NCT00602797|9684413|FG000|Overall Study|Adverse Event|1
6078094|NCT00602927|9684424|FG000|Period 1: 13 Days|Protocol Violation|2
6078095|NCT00602927|9684425|FG001|Period 1: 13 Days|Protocol Violation|4
6078096|NCT00602927|9684424|FG000|Period 1: 13 Days|MRI scanner technical issue|1
6078097|NCT00602927|9684425|FG001|Period 1: 13 Days|MRI scanner technical issue|0
6078098|NCT00602927|9684424|FG000|Period 1: 13 Days|Time|1
6078099|NCT00602927|9684425|FG001|Period 1: 13 Days|Time|0
6078100|NCT00602927|9684424|FG000|Period 1: 13 Days|Claustrophobia|0
6078101|NCT00602927|9684425|FG001|Period 1: 13 Days|Claustrophobia|1
6078102|NCT00602927|9684424|FG000|Period 2: 14 Days|Protocol Violation|0
6078103|NCT00602927|9684425|FG001|Period 2: 14 Days|Protocol Violation|2
6078104|NCT00602927|9684424|FG000|Period 3: 13 Days|Protocol Violation|0
6078105|NCT00602927|9684425|FG001|Period 3: 13 Days|Protocol Violation|1
6078106|NCT00602927|9684424|FG000|Period 3: 13 Days|MRI data quality|2
6078107|NCT00602927|9684425|FG001|Period 3: 13 Days|MRI data quality|2
6078108|NCT00602979|9684457|FG000|Overall Study|Lost to Follow-up|3
6078109|NCT00602979|9684458|FG001|Overall Study|Lost to Follow-up|2
6078110|NCT00602979|9684459|FG002|Overall Study|Lost to Follow-up|3
6078111|NCT00602979|9684460|FG003|Overall Study|Lost to Follow-up|2
6078112|NCT00602979|9684461|FG004|Overall Study|Lost to Follow-up|3
6078113|NCT00602979|9684457|FG000|Overall Study|Failed Intubation|0
6078114|NCT00602979|9684458|FG001|Overall Study|Failed Intubation|1
6078115|NCT00602979|9684459|FG002|Overall Study|Failed Intubation|0
6078116|NCT00602979|9684460|FG003|Overall Study|Failed Intubation|1
6078117|NCT00602979|9684461|FG004|Overall Study|Failed Intubation|0
6078118|NCT00603239|9684493|FG000|Overall Study|Adverse Event|4
6078119|NCT00603239|9684494|FG001|Overall Study|Adverse Event|1
6022876|NCT00243230|9618106|FG002|Open Label Period|Administrative Reason|0
6022877|NCT00243230|9618107|FG003|Open Label Period|Administrative Reason|63
6022878|NCT00243269|9618130|FG000|Overall Study|Protocol Violation|2
6022879|NCT00243269|9618131|FG001|Overall Study|Protocol Violation|1
6022880|NCT00243269|9618132|FG002|Overall Study|Protocol Violation|0
6022881|NCT00243269|9618133|FG003|Overall Study|Protocol Violation|1
6022882|NCT00243269|9618130|FG000|Overall Study|Lost to Follow-up|1
6022883|NCT00243269|9618131|FG001|Overall Study|Lost to Follow-up|0
6022884|NCT00243269|9618132|FG002|Overall Study|Lost to Follow-up|1
6022885|NCT00243269|9618133|FG003|Overall Study|Lost to Follow-up|3
6022886|NCT00243347|9618143|FG000|Overall Study|Lack of Efficacy|4
6022887|NCT00243347|9618143|FG000|Overall Study|Adverse Event|2
6078120|NCT00603239|9684493|FG000|Overall Study|Entry criteria not met|0
6078121|NCT00603239|9684494|FG001|Overall Study|Entry criteria not met|1
6022888|NCT00243347|9618143|FG000|Overall Study|Death|1
6022889|NCT00243347|9618143|FG000|Overall Study|Withdrawal by Subject|5
6022890|NCT00243347|9618143|FG000|Overall Study|Condition worsened|7
6022891|NCT00243386|9618147|FG000|On-Demand Regimen (Study Part 1)|Withdrawal by Subject|1
6022892|NCT00243386|9618148|FG001|On-Demand Regimen (Study Part 1)|Withdrawal by Subject|0
6022893|NCT00243386|9618149|FG002|On-Demand Regimen (Study Part 1)|Withdrawal by Subject|0
6022894|NCT00243386|9618147|FG000|On-Demand Regimen (Study Part 1)|Lost to Follow-up|1
6022895|NCT00243386|9618148|FG001|On-Demand Regimen (Study Part 1)|Lost to Follow-up|0
6022896|NCT00243386|9618149|FG002|On-Demand Regimen (Study Part 1)|Lost to Follow-up|0
6022897|NCT00243386|9618147|FG000|On-Demand Regimen (Study Part 1)|Screen Failures|2
6022898|NCT00243386|9618148|FG001|On-Demand Regimen (Study Part 1)|Screen Failures|0
6022899|NCT00243386|9618149|FG002|On-Demand Regimen (Study Part 1)|Screen Failures|0
6022900|NCT00243386|9618147|FG000|End of Part 1, But Prior to Prophylaxis|Withdrawal by Subject|1
6022901|NCT00243386|9618148|FG001|End of Part 1, But Prior to Prophylaxis|Withdrawal by Subject|0
6022902|NCT00243386|9618149|FG002|End of Part 1, But Prior to Prophylaxis|Withdrawal by Subject|0
6022903|NCT00243386|9618147|FG000|End of Part 1, But Prior to Prophylaxis|Lost to Follow-up|1
6022904|NCT00243386|9618148|FG001|End of Part 1, But Prior to Prophylaxis|Lost to Follow-up|0
6022905|NCT00243386|9618149|FG002|End of Part 1, But Prior to Prophylaxis|Lost to Follow-up|0
6022906|NCT00243386|9618147|FG000|End of Part 1, But Prior to Prophylaxis|Withdrawn for Non-Compliance|1
6022907|NCT00243386|9618148|FG001|End of Part 1, But Prior to Prophylaxis|Withdrawn for Non-Compliance|0
6022908|NCT00243386|9618149|FG002|End of Part 1, But Prior to Prophylaxis|Withdrawn for Non-Compliance|0
6022909|NCT00243386|9618147|FG000|PK-Driven or Standard Prophylaxis|Withdrawn for Non-Compliance|0
6022910|NCT00243386|9618148|FG001|PK-Driven or Standard Prophylaxis|Withdrawn for Non-Compliance|2
6022911|NCT00243386|9618149|FG002|PK-Driven or Standard Prophylaxis|Withdrawn for Non-Compliance|0
6022912|NCT00243386|9618147|FG000|PK-Driven or Standard Prophylaxis|Lack of Efficacy|0
6022913|NCT00243386|9618148|FG001|PK-Driven or Standard Prophylaxis|Lack of Efficacy|1
6022914|NCT00243386|9618149|FG002|PK-Driven or Standard Prophylaxis|Lack of Efficacy|0
6022915|NCT00243412|9618187|FG000|Overall Study|Death|0
6022916|NCT00243412|9618188|FG001|Overall Study|Death|1
6022917|NCT00243412|9618187|FG000|Overall Study|Adverse Event|4
6022918|NCT00243412|9618188|FG001|Overall Study|Adverse Event|2
6022919|NCT00243412|9618187|FG000|Overall Study|Lost to Follow-up|0
6022920|NCT00243412|9618188|FG001|Overall Study|Lost to Follow-up|1
6022921|NCT00243412|9618187|FG000|Overall Study|Physician Decision|1
6022922|NCT00243412|9618188|FG001|Overall Study|Physician Decision|1
6022923|NCT00243412|9618187|FG000|Overall Study|Withdrawal by Subject|4
6022924|NCT00243412|9618188|FG001|Overall Study|Withdrawal by Subject|5
6022925|NCT00243412|9618187|FG000|Overall Study|Other|1
6022926|NCT00243412|9618188|FG001|Overall Study|Other|1
6022927|NCT00243503|9618194|FG000|Overall Study|Adverse Event|11
6022928|NCT00243503|9618194|FG000|Overall Study|Withdrawal by Subject|1
6022929|NCT00243503|9618194|FG000|Overall Study|Lack of Efficacy|44
6022930|NCT00243503|9618194|FG000|Overall Study|Death|1
6022931|NCT00243503|9618194|FG000|Overall Study|Other|1
6022932|NCT00243659|9618201|FG000|Overall Study|Withdrawal by Subject|1
6022933|NCT00243659|9618202|FG001|Overall Study|Withdrawal by Subject|1
6022934|NCT00243659|9618201|FG000|Overall Study|Protocol Violation|1
6022935|NCT00243659|9618202|FG001|Overall Study|Protocol Violation|2
6022936|NCT00243841|9618211|FG000|Overall Study|Physician Decision|0
6022937|NCT00243841|9618212|FG001|Overall Study|Physician Decision|0
6022938|NCT00243841|9618213|FG002|Overall Study|Physician Decision|1
6022939|NCT00243841|9618214|FG003|Overall Study|Physician Decision|0
6022940|NCT00243841|9618215|FG004|Overall Study|Physician Decision|0
6022941|NCT00243841|9618216|FG005|Overall Study|Physician Decision|2
6022942|NCT00243919|9618235|FG000|Overall Study|Death|3
6022943|NCT00243919|9618236|FG001|Overall Study|Death|4
6022944|NCT00243919|9618237|FG002|Overall Study|Death|6
6022945|NCT00243919|9618235|FG000|Overall Study|Withdrawal by Subject|6
6022946|NCT00243919|9618236|FG001|Overall Study|Withdrawal by Subject|6
6022947|NCT00243919|9618237|FG002|Overall Study|Withdrawal by Subject|2
6022948|NCT00243919|9618235|FG000|Overall Study|Lost to Follow-up|6
6022949|NCT00243919|9618236|FG001|Overall Study|Lost to Follow-up|7
6022950|NCT00243919|9618237|FG002|Overall Study|Lost to Follow-up|3
6022951|NCT00243919|9618235|FG000|Overall Study|Administrative Error|1
6022952|NCT00243919|9618236|FG001|Overall Study|Administrative Error|0
6022953|NCT00243919|9618237|FG002|Overall Study|Administrative Error|0
6022954|NCT00243919|9618235|FG000|Overall Study|Physician Decision|1
6022955|NCT00243919|9618236|FG001|Overall Study|Physician Decision|1
6022956|NCT00243919|9618237|FG002|Overall Study|Physician Decision|0
6022957|NCT00243932|9618248|FG000|Stage 1: Dose Selection|Lost to Follow-up|2
6022958|NCT00243932|9618249|FG001|Stage 1: Dose Selection|Lost to Follow-up|0
6022959|NCT00243932|9618250|FG002|Stage 1: Dose Selection|Lost to Follow-up|0
6048135|NCT00415363|9647235|FG000|Overall Study|Progressive disease|26
6048136|NCT00415363|9647236|FG001|Overall Study|Progressive disease|32
6049107|NCT00421304|9648323|FG001|Overall Study|Mistakenly randomized, chose not to participate in study|0
6078122|NCT00603239|9684493|FG000|Overall Study|Loss of glucose control|3
6049108|NCT00421304|9648324|FG002|Overall Study|Mistakenly randomized, chose not to participate in study|0
6049109|NCT00421304|9648322|FG000|Overall Study|Did not attend Day 360 visit|0
6049110|NCT00421304|9648323|FG001|Overall Study|Did not attend Day 360 visit|0
6022960|NCT00244374|9618280|FG000|Pre-Randomization Cross-sectional Study|Did not complete baseline procedures|105
6022961|NCT00244374|9618281|FG001|Pre-Randomization Cross-sectional Study|Did not complete baseline procedures|0
6022962|NCT00244374|9618282|FG002|Pre-Randomization Cross-sectional Study|Did not complete baseline procedures|0
6022963|NCT00244374|9618283|FG003|Pre-Randomization Cross-sectional Study|Did not complete baseline procedures|0
6022964|NCT00244374|9618284|FG004|Pre-Randomization Cross-sectional Study|Did not complete baseline procedures|0
6022965|NCT00244374|9618280|FG000|Pre-Randomization Cross-sectional Study|Technical difficulty loss of data|17
6022966|NCT00244374|9618281|FG001|Pre-Randomization Cross-sectional Study|Technical difficulty loss of data|0
6022967|NCT00244374|9618282|FG002|Pre-Randomization Cross-sectional Study|Technical difficulty loss of data|0
6022968|NCT00244374|9618283|FG003|Pre-Randomization Cross-sectional Study|Technical difficulty loss of data|0
6022969|NCT00244374|9618284|FG004|Pre-Randomization Cross-sectional Study|Technical difficulty loss of data|0
6022970|NCT00244374|9618280|FG000|Pre-Randomization Cross-sectional Study|Did not respond to willingness questions|14
6022971|NCT00244374|9618281|FG001|Pre-Randomization Cross-sectional Study|Did not respond to willingness questions|0
6022972|NCT00244374|9618282|FG002|Pre-Randomization Cross-sectional Study|Did not respond to willingness questions|0
6022973|NCT00244374|9618283|FG003|Pre-Randomization Cross-sectional Study|Did not respond to willingness questions|0
6022974|NCT00244374|9618284|FG004|Pre-Randomization Cross-sectional Study|Did not respond to willingness questions|0
6022975|NCT00244374|9618280|FG000|Pre-Randomization Cross-sectional Study|Interviewer lack confidence in responses|1
6022976|NCT00244374|9618281|FG001|Pre-Randomization Cross-sectional Study|Interviewer lack confidence in responses|0
6022977|NCT00244374|9618282|FG002|Pre-Randomization Cross-sectional Study|Interviewer lack confidence in responses|0
6022978|NCT00244374|9618283|FG003|Pre-Randomization Cross-sectional Study|Interviewer lack confidence in responses|0
6022979|NCT00244374|9618284|FG004|Pre-Randomization Cross-sectional Study|Interviewer lack confidence in responses|0
6022980|NCT00244374|9618280|FG000|Evaluation for Vaccine Adherence Cohort|Evidence of hepatitis B immunization|172
6022981|NCT00244374|9618281|FG001|Evaluation for Vaccine Adherence Cohort|Evidence of hepatitis B immunization|0
6022982|NCT00244374|9618282|FG002|Evaluation for Vaccine Adherence Cohort|Evidence of hepatitis B immunization|0
6022983|NCT00244374|9618283|FG003|Evaluation for Vaccine Adherence Cohort|Evidence of hepatitis B immunization|0
6022984|NCT00244374|9618284|FG004|Evaluation for Vaccine Adherence Cohort|Evidence of hepatitis B immunization|0
6022985|NCT00244374|9618280|FG000|Evaluation for Vaccine Adherence Cohort|Unable/unwilling to complete enrollment|51
6022986|NCT00244374|9618281|FG001|Evaluation for Vaccine Adherence Cohort|Unable/unwilling to complete enrollment|0
6022987|NCT00244374|9618282|FG002|Evaluation for Vaccine Adherence Cohort|Unable/unwilling to complete enrollment|0
6022988|NCT00244374|9618283|FG003|Evaluation for Vaccine Adherence Cohort|Unable/unwilling to complete enrollment|0
6022989|NCT00244374|9618284|FG004|Evaluation for Vaccine Adherence Cohort|Unable/unwilling to complete enrollment|0
6022990|NCT00244374|9618280|FG000|Evaluation for Vaccine Adherence Cohort|Did not return for screening test result|34
6022991|NCT00244374|9618281|FG001|Evaluation for Vaccine Adherence Cohort|Did not return for screening test result|0
6022992|NCT00244374|9618282|FG002|Evaluation for Vaccine Adherence Cohort|Did not return for screening test result|0
6022993|NCT00244374|9618283|FG003|Evaluation for Vaccine Adherence Cohort|Did not return for screening test result|0
6022994|NCT00244374|9618284|FG004|Evaluation for Vaccine Adherence Cohort|Did not return for screening test result|0
6022995|NCT00244374|9618280|FG000|Evaluation for Vaccine Adherence Cohort|Returned for results after enroll window|4
6022996|NCT00244374|9618281|FG001|Evaluation for Vaccine Adherence Cohort|Returned for results after enroll window|0
6022997|NCT00244374|9618282|FG002|Evaluation for Vaccine Adherence Cohort|Returned for results after enroll window|0
6022998|NCT00244374|9618283|FG003|Evaluation for Vaccine Adherence Cohort|Returned for results after enroll window|0
6022999|NCT00244374|9618284|FG004|Evaluation for Vaccine Adherence Cohort|Returned for results after enroll window|0
6023000|NCT00244374|9618280|FG000|Evaluation for Vaccine Adherence Cohort|Declined to participate in cohort|12
6023001|NCT00244374|9618281|FG001|Evaluation for Vaccine Adherence Cohort|Declined to participate in cohort|0
6023002|NCT00244374|9618282|FG002|Evaluation for Vaccine Adherence Cohort|Declined to participate in cohort|0
6023003|NCT00244374|9618283|FG003|Evaluation for Vaccine Adherence Cohort|Declined to participate in cohort|0
6023004|NCT00244374|9618284|FG004|Evaluation for Vaccine Adherence Cohort|Declined to participate in cohort|0
6023005|NCT00244621|9618303|FG000|Double-blind Treatment Period|Lost to Follow-up|0
6023006|NCT00244621|9618304|FG001|Double-blind Treatment Period|Lost to Follow-up|0
6023007|NCT00244621|9618305|FG002|Double-blind Treatment Period|Lost to Follow-up|1
6023008|NCT00244621|9618303|FG000|Double-blind Treatment Period|Withdrawal by Subject|0
6023009|NCT00244621|9618304|FG001|Double-blind Treatment Period|Withdrawal by Subject|1
6023010|NCT00244621|9618305|FG002|Double-blind Treatment Period|Withdrawal by Subject|0
6023011|NCT00244621|9618303|FG000|Double-blind Treatment Period|Lack of Efficacy|0
6023012|NCT00244621|9618304|FG001|Double-blind Treatment Period|Lack of Efficacy|1
6023013|NCT00244621|9618305|FG002|Double-blind Treatment Period|Lack of Efficacy|0
6023014|NCT00244621|9618303|FG000|Double-blind Treatment Period|Multiple Reasons|2
6023015|NCT00244621|9618304|FG001|Double-blind Treatment Period|Multiple Reasons|1
6023016|NCT00244621|9618305|FG002|Double-blind Treatment Period|Multiple Reasons|1
6023017|NCT00244621|9618303|FG000|Open-label Treatment Period|Lost to Follow-up|0
6023018|NCT00244621|9618304|FG001|Open-label Treatment Period|Lost to Follow-up|1
6023019|NCT00244621|9618305|FG002|Open-label Treatment Period|Lost to Follow-up|0
6023020|NCT00244621|9618303|FG000|Open-label Treatment Period|Withdrawal by Subject|1
6023021|NCT00244621|9618304|FG001|Open-label Treatment Period|Withdrawal by Subject|0
6023022|NCT00244621|9618305|FG002|Open-label Treatment Period|Withdrawal by Subject|0
6023023|NCT00244621|9618303|FG000|Open-label Treatment Period|Adverse Event|0
6023024|NCT00244621|9618304|FG001|Open-label Treatment Period|Adverse Event|0
6023025|NCT00244621|9618305|FG002|Open-label Treatment Period|Adverse Event|1
6023026|NCT00244621|9618303|FG000|Open-label Treatment Period|Moved abroad|0
6023027|NCT00244621|9618304|FG001|Open-label Treatment Period|Moved abroad|0
6023028|NCT00244621|9618305|FG002|Open-label Treatment Period|Moved abroad|1
6023029|NCT00244712|9618315|FG000|Overall Study|Adverse Event|20
6023030|NCT00244712|9618316|FG001|Overall Study|Adverse Event|21
6023031|NCT00244712|9618315|FG000|Overall Study|Protocol-Defined Virologic Failure|8
6023032|NCT00244712|9618316|FG001|Overall Study|Protocol-Defined Virologic Failure|6
6023033|NCT00244712|9618315|FG000|Overall Study|Lack of Compliance|10
6023034|NCT00244712|9618316|FG001|Overall Study|Lack of Compliance|11
6023035|NCT00244712|9618315|FG000|Overall Study|Lost to Follow-up|45
6023036|NCT00244712|9618316|FG001|Overall Study|Lost to Follow-up|52
6023037|NCT00244712|9618315|FG000|Overall Study|Withdrawal by Subject|13
6023038|NCT00244712|9618316|FG001|Overall Study|Withdrawal by Subject|23
6023039|NCT00244712|9618315|FG000|Overall Study|Protocol Violation, disease progression|13
6023040|NCT00244712|9618316|FG001|Overall Study|Protocol Violation, disease progression|11
6023041|NCT00244725|9618326|FG000|Overall Study|Lost to Follow-up|3
6023042|NCT00244725|9618327|FG001|Overall Study|Lost to Follow-up|4
6023043|NCT00244725|9618328|FG002|Overall Study|Lost to Follow-up|9
6023044|NCT00244725|9618329|FG003|Overall Study|Lost to Follow-up|2
6023045|NCT00244725|9618326|FG000|Overall Study|Withdrawal by Subject|9
6023046|NCT00244725|9618327|FG001|Overall Study|Withdrawal by Subject|7
6023047|NCT00244725|9618328|FG002|Overall Study|Withdrawal by Subject|7
6023048|NCT00244725|9618329|FG003|Overall Study|Withdrawal by Subject|8
6023049|NCT00244725|9618326|FG000|Overall Study|Not meet treatment eligibility criteria|1
6023050|NCT00244725|9618327|FG001|Overall Study|Not meet treatment eligibility criteria|2
6023051|NCT00244725|9618328|FG002|Overall Study|Not meet treatment eligibility criteria|0
6023052|NCT00244725|9618329|FG003|Overall Study|Not meet treatment eligibility criteria|0
6023053|NCT00244725|9618326|FG000|Overall Study|Physician Decision|3
6023054|NCT00244725|9618327|FG001|Overall Study|Physician Decision|0
6023055|NCT00244725|9618328|FG002|Overall Study|Physician Decision|1
6023056|NCT00244725|9618329|FG003|Overall Study|Physician Decision|2
6023057|NCT00244725|9618326|FG000|Overall Study|Adverse Events|3
6023058|NCT00244725|9618327|FG001|Overall Study|Adverse Events|1
6023059|NCT00244725|9618328|FG002|Overall Study|Adverse Events|4
6023060|NCT00244725|9618329|FG003|Overall Study|Adverse Events|4
6023061|NCT00244725|9618326|FG000|Overall Study|Withdrwal by participant|1
6023062|NCT00244725|9618327|FG001|Overall Study|Withdrwal by participant|0
6023063|NCT00244725|9618328|FG002|Overall Study|Withdrwal by participant|0
6023064|NCT00244725|9618329|FG003|Overall Study|Withdrwal by participant|1
6023065|NCT00244725|9618326|FG000|Overall Study|Liver function test abnormality|2
6023066|NCT00244725|9618327|FG001|Overall Study|Liver function test abnormality|0
6023067|NCT00244725|9618328|FG002|Overall Study|Liver function test abnormality|0
6023068|NCT00244725|9618329|FG003|Overall Study|Liver function test abnormality|1
6023069|NCT00244725|9618326|FG000|Overall Study|Sponsor withdrew the participant|1
6023070|NCT00244725|9618327|FG001|Overall Study|Sponsor withdrew the participant|0
6023071|NCT00244725|9618328|FG002|Overall Study|Sponsor withdrew the participant|0
6023072|NCT00244725|9618329|FG003|Overall Study|Sponsor withdrew the participant|1
6023073|NCT00244725|9618326|FG000|Overall Study|Mediciation Error|0
6023074|NCT00244725|9618327|FG001|Overall Study|Mediciation Error|1
6023075|NCT00244725|9618328|FG002|Overall Study|Mediciation Error|0
6023076|NCT00244725|9618329|FG003|Overall Study|Mediciation Error|0
6023077|NCT00244725|9618326|FG000|Overall Study|Rehab Refused to allow participantion|0
6023078|NCT00244725|9618327|FG001|Overall Study|Rehab Refused to allow participantion|1
6023079|NCT00244725|9618328|FG002|Overall Study|Rehab Refused to allow participantion|0
6023080|NCT00244725|9618329|FG003|Overall Study|Rehab Refused to allow participantion|0
6023081|NCT00244725|9618326|FG000|Overall Study|Headache|0
6023082|NCT00244725|9618327|FG001|Overall Study|Headache|1
6023083|NCT00244725|9618328|FG002|Overall Study|Headache|0
6023084|NCT00244725|9618329|FG003|Overall Study|Headache|0
6023085|NCT00244725|9618326|FG000|Overall Study|Received prohibited medication|0
6023086|NCT00244725|9618327|FG001|Overall Study|Received prohibited medication|1
6023087|NCT00244725|9618328|FG002|Overall Study|Received prohibited medication|0
6023088|NCT00244725|9618329|FG003|Overall Study|Received prohibited medication|1
6023089|NCT00244725|9618326|FG000|Overall Study|Confirmed venous thromboembolism (VTE)|0
6023090|NCT00244725|9618327|FG001|Overall Study|Confirmed venous thromboembolism (VTE)|1
6023091|NCT00244725|9618328|FG002|Overall Study|Confirmed venous thromboembolism (VTE)|0
6023092|NCT00244725|9618329|FG003|Overall Study|Confirmed venous thromboembolism (VTE)|0
6023093|NCT00244725|9618326|FG000|Overall Study|Administrative reason|0
6023094|NCT00244725|9618327|FG001|Overall Study|Administrative reason|0
6023095|NCT00244725|9618328|FG002|Overall Study|Administrative reason|1
6023096|NCT00244725|9618329|FG003|Overall Study|Administrative reason|0
6023097|NCT00244725|9618326|FG000|Overall Study|Vomit|0
6023098|NCT00244725|9618327|FG001|Overall Study|Vomit|0
6023099|NCT00244725|9618328|FG002|Overall Study|Vomit|1
6023100|NCT00244725|9618329|FG003|Overall Study|Vomit|0
6023101|NCT00244725|9618326|FG000|Overall Study|Failed to follow-up|0
6023102|NCT00244725|9618327|FG001|Overall Study|Failed to follow-up|0
6023103|NCT00244725|9618328|FG002|Overall Study|Failed to follow-up|1
6023104|NCT00244725|9618329|FG003|Overall Study|Failed to follow-up|1
6023105|NCT00244751|9618342|FG000|Overall Study|Adverse Event|7
6023106|NCT00244751|9618343|FG001|Overall Study|Adverse Event|7
6023107|NCT00244751|9618344|FG002|Overall Study|Adverse Event|5
6023108|NCT00244751|9618342|FG000|Overall Study|Lost to Follow-up|0
6023109|NCT00244751|9618343|FG001|Overall Study|Lost to Follow-up|1
6023110|NCT00244751|9618344|FG002|Overall Study|Lost to Follow-up|0
6023111|NCT00244751|9618342|FG000|Overall Study|Protocol Violation|1
6023112|NCT00244751|9618343|FG001|Overall Study|Protocol Violation|0
6023113|NCT00244751|9618344|FG002|Overall Study|Protocol Violation|1
6023114|NCT00244751|9618342|FG000|Overall Study|Withdrawal by Subject|7
6023115|NCT00244751|9618343|FG001|Overall Study|Withdrawal by Subject|5
6023116|NCT00244751|9618344|FG002|Overall Study|Withdrawal by Subject|3
6023117|NCT00244751|9618342|FG000|Overall Study|Elevated liver enzymes|1
6023118|NCT00244751|9618343|FG001|Overall Study|Elevated liver enzymes|0
6023119|NCT00244751|9618344|FG002|Overall Study|Elevated liver enzymes|0
6023120|NCT00244751|9618342|FG000|Overall Study|Lack of compliance with protocol|0
6023121|NCT00244751|9618343|FG001|Overall Study|Lack of compliance with protocol|1
6023122|NCT00244751|9618344|FG002|Overall Study|Lack of compliance with protocol|0
6023123|NCT00244751|9618342|FG000|Overall Study|Safety reasons|0
6023124|NCT00244751|9618343|FG001|Overall Study|Safety reasons|1
6023125|NCT00244751|9618344|FG002|Overall Study|Safety reasons|0
6023126|NCT00244751|9618342|FG000|Overall Study|Participant randomized by mistake|0
6023127|NCT00244751|9618343|FG001|Overall Study|Participant randomized by mistake|0
6023128|NCT00244751|9618344|FG002|Overall Study|Participant randomized by mistake|1
6023129|NCT00244764|9618361|FG000|Overall Study|Adverse Event|37
6023130|NCT00244764|9618361|FG000|Overall Study|Lost to Follow-up|23
6023131|NCT00244764|9618361|FG000|Overall Study|Withdrawal by Subject|12
6023132|NCT00244764|9618361|FG000|Overall Study|Disease Progression|13
6023133|NCT00244764|9618361|FG000|Overall Study|Protocol Violation|2
6023134|NCT00244764|9618361|FG000|Overall Study|Death|1
6023135|NCT00244764|9618361|FG000|Overall Study|Off Study Medication for >21 Days|1
6023136|NCT00244764|9618361|FG000|Overall Study|Declining Performance Status|1
6023137|NCT00244764|9618361|FG000|Overall Study|Participant was Hospitalized until Death|1
6023138|NCT00244764|9618361|FG000|Overall Study|Primary Investigator Discretion|2
6023139|NCT00244764|9618361|FG000|Overall Study|Sponsor Terminated Study|2
6023140|NCT00244764|9618361|FG000|Overall Study|Developed Secondary Malignancy|1
6023141|NCT00244855|9618368|FG000|Overall Study|Withdrawal by Subject|0
6023142|NCT00244855|9618369|FG001|Overall Study|Withdrawal by Subject|1
6023143|NCT00244881|9618377|FG000|Overall Study|Withdrawal by Subject|3
6023144|NCT00244933|9618381|FG000|Overall Study|Not response evaluable|2
6023145|NCT00245011|9618389|FG000|Overall Study|Lack of Efficacy|1
6023146|NCT00245037|9618393|FG000|Overall Study|Death|17
6023147|NCT00245050|9618399|FG000|Overall Study|Adverse Event|3
6023148|NCT00245050|9618400|FG001|Overall Study|Adverse Event|2
6023149|NCT00245063|9618408|FG000|Overall Study|Adverse Event|6
6023150|NCT00245063|9618409|FG001|Overall Study|Adverse Event|5
6023151|NCT00245063|9618408|FG000|Overall Study|Death|1
6023152|NCT00245063|9618409|FG001|Overall Study|Death|0
6023153|NCT00245102|9618421|FG000|Overall Study|Not Treated|1
6023154|NCT00245102|9618422|FG001|Overall Study|Not Treated|0
6023155|NCT00245102|9618423|FG002|Overall Study|Not Treated|1
6023156|NCT00245102|9618424|FG003|Overall Study|Not Treated|0
6023157|NCT00245102|9618425|FG004|Overall Study|Not Treated|0
6023158|NCT00245102|9618426|FG005|Overall Study|Not Treated|0
6023159|NCT00245102|9618421|FG000|Overall Study|Protocol Violation|1
6023160|NCT00245102|9618422|FG001|Overall Study|Protocol Violation|0
6023161|NCT00245102|9618423|FG002|Overall Study|Protocol Violation|0
6023162|NCT00245102|9618424|FG003|Overall Study|Protocol Violation|0
6023163|NCT00245102|9618425|FG004|Overall Study|Protocol Violation|0
6023164|NCT00245102|9618426|FG005|Overall Study|Protocol Violation|0
6023165|NCT00245102|9618421|FG000|Overall Study|Death|0
6023166|NCT00245102|9618422|FG001|Overall Study|Death|0
6023167|NCT00245102|9618423|FG002|Overall Study|Death|0
6023168|NCT00245102|9618424|FG003|Overall Study|Death|1
6023169|NCT00245102|9618425|FG004|Overall Study|Death|0
6023170|NCT00245102|9618426|FG005|Overall Study|Death|0
6023171|NCT00245102|9618421|FG000|Overall Study|Adverse Event|4
6023172|NCT00245102|9618422|FG001|Overall Study|Adverse Event|2
6023173|NCT00245102|9618423|FG002|Overall Study|Adverse Event|5
6023174|NCT00245102|9618424|FG003|Overall Study|Adverse Event|1
6023175|NCT00245102|9618425|FG004|Overall Study|Adverse Event|0
6023176|NCT00245102|9618426|FG005|Overall Study|Adverse Event|2
6023177|NCT00245102|9618421|FG000|Overall Study|Decline in performance|0
6023178|NCT00245102|9618422|FG001|Overall Study|Decline in performance|2
6023179|NCT00245102|9618423|FG002|Overall Study|Decline in performance|0
6023180|NCT00245102|9618424|FG003|Overall Study|Decline in performance|1
6023181|NCT00245102|9618425|FG004|Overall Study|Decline in performance|0
6023182|NCT00245102|9618426|FG005|Overall Study|Decline in performance|2
6023183|NCT00245102|9618421|FG000|Overall Study|Participant needed surgery|0
6023184|NCT00245102|9618422|FG001|Overall Study|Participant needed surgery|0
6023185|NCT00245102|9618423|FG002|Overall Study|Participant needed surgery|1
6023186|NCT00245102|9618424|FG003|Overall Study|Participant needed surgery|0
6023187|NCT00245102|9618425|FG004|Overall Study|Participant needed surgery|0
6023188|NCT00245102|9618426|FG005|Overall Study|Participant needed surgery|0
6023189|NCT00245102|9618421|FG000|Overall Study|Clinical progression|1
6023190|NCT00245102|9618422|FG001|Overall Study|Clinical progression|0
6023191|NCT00245102|9618423|FG002|Overall Study|Clinical progression|0
6023192|NCT00245102|9618424|FG003|Overall Study|Clinical progression|0
6023193|NCT00245102|9618425|FG004|Overall Study|Clinical progression|0
6023194|NCT00245102|9618426|FG005|Overall Study|Clinical progression|0
6023195|NCT00245466|9618456|FG000|Overall Study|Adverse Event|2
6023196|NCT00245466|9618457|FG001|Overall Study|Adverse Event|8
6023197|NCT00245466|9618458|FG002|Overall Study|Adverse Event|4
6023198|NCT00245466|9618456|FG000|Overall Study|Low prostate specific antigen suppr|16
6023199|NCT00245466|9618457|FG001|Overall Study|Low prostate specific antigen suppr|14
6023200|NCT00245466|9618458|FG002|Overall Study|Low prostate specific antigen suppr|5
6023201|NCT00245466|9618456|FG000|Overall Study|Insufficient testosterone suppr|12
6023202|NCT00245466|9618457|FG001|Overall Study|Insufficient testosterone suppr|12
6023203|NCT00245466|9618458|FG002|Overall Study|Insufficient testosterone suppr|21
6023204|NCT00245466|9618456|FG000|Overall Study|Insufficient PSA and testosterone suppr|0
6023205|NCT00245466|9618457|FG001|Overall Study|Insufficient PSA and testosterone suppr|0
6023206|NCT00245466|9618458|FG002|Overall Study|Insufficient PSA and testosterone suppr|3
6023207|NCT00245466|9618456|FG000|Overall Study|Withdrawal by Subject|2
6023208|NCT00245466|9618457|FG001|Overall Study|Withdrawal by Subject|2
6023209|NCT00245466|9618458|FG002|Overall Study|Withdrawal by Subject|1
6023210|NCT00245466|9618456|FG000|Overall Study|Lost to Follow-up|3
6023211|NCT00245466|9618457|FG001|Overall Study|Lost to Follow-up|0
6023212|NCT00245466|9618458|FG002|Overall Study|Lost to Follow-up|0
6023213|NCT00245466|9618456|FG000|Overall Study|Disease progression|0
6023214|NCT00245466|9618457|FG001|Overall Study|Disease progression|3
6023215|NCT00245466|9618458|FG002|Overall Study|Disease progression|1
6023216|NCT00245466|9618456|FG000|Overall Study|Protocol Violation|1
6023217|NCT00245466|9618457|FG001|Overall Study|Protocol Violation|2
6023218|NCT00245466|9618458|FG002|Overall Study|Protocol Violation|2
6023219|NCT00245466|9618456|FG000|Overall Study|Death|0
6023220|NCT00245466|9618457|FG001|Overall Study|Death|2
6023221|NCT00245466|9618458|FG002|Overall Study|Death|0
6023222|NCT00245466|9618456|FG000|Overall Study|Administrative reasons|0
6023223|NCT00245466|9618457|FG001|Overall Study|Administrative reasons|1
6023224|NCT00245466|9618458|FG002|Overall Study|Administrative reasons|0
6023225|NCT00245583|9618487|FG000|Overall Study|Lost to Follow-up|1
6023226|NCT00245583|9618488|FG001|Overall Study|Lost to Follow-up|5
6023227|NCT00245583|9618487|FG000|Overall Study|Adverse Event|2
6023228|NCT00245583|9618488|FG001|Overall Study|Adverse Event|1
6023229|NCT00245583|9618487|FG000|Overall Study|Lack of Efficacy|1
6023230|NCT00245583|9618488|FG001|Overall Study|Lack of Efficacy|0
6023231|NCT00245583|9618487|FG000|Overall Study|Withdrawal by Subject|2
6023232|NCT00245583|9618488|FG001|Overall Study|Withdrawal by Subject|3
6023233|NCT00245765|9618506|FG000|Overall Study|Adverse Event|1
6023234|NCT00245765|9618507|FG001|Overall Study|Adverse Event|1
6023235|NCT00245765|9618508|FG002|Overall Study|Adverse Event|0
6023236|NCT00245765|9618506|FG000|Overall Study|Lack of Efficacy|14
6023237|NCT00245765|9618507|FG001|Overall Study|Lack of Efficacy|7
6023238|NCT00245765|9618508|FG002|Overall Study|Lack of Efficacy|0
6023239|NCT00245765|9618506|FG000|Overall Study|Lost to Follow-up|1
6023240|NCT00245765|9618507|FG001|Overall Study|Lost to Follow-up|2
6023241|NCT00245765|9618508|FG002|Overall Study|Lost to Follow-up|0
6023242|NCT00245765|9618506|FG000|Overall Study|Withdrawal by Subject|1
6023243|NCT00245765|9618507|FG001|Overall Study|Withdrawal by Subject|0
6023244|NCT00245765|9618508|FG002|Overall Study|Withdrawal by Subject|3
6023245|NCT00245765|9618506|FG000|Overall Study|Other reason|2
6023246|NCT00245765|9618507|FG001|Overall Study|Other reason|0
6023247|NCT00245765|9618508|FG002|Overall Study|Other reason|1
6023248|NCT00245765|9618506|FG000|Overall Study|Other|13
6023249|NCT00245765|9618507|FG001|Overall Study|Other|4
6023250|NCT00245765|9618508|FG002|Overall Study|Other|4
6023251|NCT00245856|9618516|FG000|Period Two|Withdrawal by Subject|0
6023252|NCT00245856|9618517|FG001|Period Two|Withdrawal by Subject|1
6023253|NCT00246012|9618533|FG000|Overall Study|Adverse Event|0
6023254|NCT00246012|9618534|FG001|Overall Study|Adverse Event|0
6023255|NCT00246012|9618535|FG002|Overall Study|Adverse Event|0
6023256|NCT00246012|9618536|FG003|Overall Study|Adverse Event|0
6023257|NCT00246012|9618537|FG004|Overall Study|Adverse Event|0
6023258|NCT00246012|9618538|FG005|Overall Study|Adverse Event|1
6023259|NCT00246012|9618539|FG006|Overall Study|Adverse Event|0
6023260|NCT00246012|9618540|FG007|Overall Study|Adverse Event|0
6023261|NCT00246012|9618541|FG008|Overall Study|Adverse Event|2
6023262|NCT00246012|9618533|FG000|Overall Study|Withdrawal by Subject|0
6023263|NCT00246012|9618534|FG001|Overall Study|Withdrawal by Subject|0
6023264|NCT00246012|9618535|FG002|Overall Study|Withdrawal by Subject|0
6023265|NCT00246012|9618536|FG003|Overall Study|Withdrawal by Subject|0
6023266|NCT00246012|9618537|FG004|Overall Study|Withdrawal by Subject|0
6023267|NCT00246012|9618538|FG005|Overall Study|Withdrawal by Subject|1
6023268|NCT00246012|9618539|FG006|Overall Study|Withdrawal by Subject|0
6023269|NCT00246012|9618540|FG007|Overall Study|Withdrawal by Subject|0
6023270|NCT00246012|9618541|FG008|Overall Study|Withdrawal by Subject|0
6023271|NCT00246012|9618533|FG000|Overall Study|Disease progression|3
6023272|NCT00246012|9618534|FG001|Overall Study|Disease progression|1
6023273|NCT00246012|9618535|FG002|Overall Study|Disease progression|2
6023274|NCT00246012|9618536|FG003|Overall Study|Disease progression|3
6023275|NCT00246012|9618537|FG004|Overall Study|Disease progression|3
6023276|NCT00246012|9618538|FG005|Overall Study|Disease progression|25
6023277|NCT00246012|9618539|FG006|Overall Study|Disease progression|30
6023278|NCT00246012|9618540|FG007|Overall Study|Disease progression|27
6023279|NCT00246012|9618541|FG008|Overall Study|Disease progression|26
6023280|NCT00246012|9618533|FG000|Overall Study|Other|0
6023281|NCT00246012|9618534|FG001|Overall Study|Other|0
6023282|NCT00246012|9618535|FG002|Overall Study|Other|0
6023283|NCT00246012|9618536|FG003|Overall Study|Other|0
6023284|NCT00246012|9618537|FG004|Overall Study|Other|0
6023285|NCT00246012|9618538|FG005|Overall Study|Other|0
6023286|NCT00246012|9618539|FG006|Overall Study|Other|0
6023287|NCT00246012|9618540|FG007|Overall Study|Other|1
6023288|NCT00246012|9618541|FG008|Overall Study|Other|0
6023289|NCT00246012|9618533|FG000|Overall Study|Randomly assigned but not treated|0
6023290|NCT00246012|9618534|FG001|Overall Study|Randomly assigned but not treated|0
6023291|NCT00246012|9618535|FG002|Overall Study|Randomly assigned but not treated|0
6023292|NCT00246012|9618536|FG003|Overall Study|Randomly assigned but not treated|0
6023293|NCT00246012|9618537|FG004|Overall Study|Randomly assigned but not treated|0
6023294|NCT00246012|9618538|FG005|Overall Study|Randomly assigned but not treated|1
6023295|NCT00246012|9618539|FG006|Overall Study|Randomly assigned but not treated|1
6023296|NCT00246012|9618540|FG007|Overall Study|Randomly assigned but not treated|0
6023297|NCT00246012|9618541|FG008|Overall Study|Randomly assigned but not treated|0
6023298|NCT00246025|9618567|FG000|Overall Study|Adverse Event|7
6023299|NCT00246025|9618568|FG001|Overall Study|Adverse Event|9
6023300|NCT00246025|9618569|FG002|Overall Study|Adverse Event|9
6023301|NCT00246025|9618570|FG003|Overall Study|Adverse Event|10
6023302|NCT00246025|9618567|FG000|Overall Study|Withdrawal by Subject|3
6023303|NCT00246025|9618568|FG001|Overall Study|Withdrawal by Subject|0
6023304|NCT00246025|9618569|FG002|Overall Study|Withdrawal by Subject|1
6023305|NCT00246025|9618570|FG003|Overall Study|Withdrawal by Subject|2
6023306|NCT00246025|9618567|FG000|Overall Study|unsuitable medical history was found|0
6023307|NCT00246025|9618568|FG001|Overall Study|unsuitable medical history was found|0
6023308|NCT00246025|9618569|FG002|Overall Study|unsuitable medical history was found|0
6023309|NCT00246025|9618570|FG003|Overall Study|unsuitable medical history was found|1
6023310|NCT00246090|9618580|FG000|Overall Study|Adverse Event|25
6023311|NCT00246090|9618580|FG000|Overall Study|Withdrawal by Subject|7
6023312|NCT00246090|9618580|FG000|Overall Study|Progressive Disease|212
6023313|NCT00246090|9618580|FG000|Overall Study|Clinical Progression|30
6023314|NCT00246090|9618580|FG000|Overall Study|Physician Decision|11
6023315|NCT00246090|9618580|FG000|Overall Study|Not Otherwise Specified|10
6023316|NCT00246129|9618586|FG000|Overall Study|Lost to Follow-up|1
6023317|NCT00246129|9618587|FG001|Overall Study|Lost to Follow-up|0
6023318|NCT00246129|9618586|FG000|Overall Study|Death|2
6023319|NCT00246129|9618587|FG001|Overall Study|Death|1
6023320|NCT00246129|9618586|FG000|Overall Study|suffered primary non-function|1
6023321|NCT00246129|9618587|FG001|Overall Study|suffered primary non-function|0
6023322|NCT00246129|9618586|FG000|Overall Study|grafts failed|3
6023323|NCT00246129|9618587|FG001|Overall Study|grafts failed|1
6023324|NCT00246259|9618598|FG000|Overall Study|Other|3
6023325|NCT00246259|9618599|FG001|Overall Study|Other|3
6023326|NCT00246259|9618598|FG000|Overall Study|Not stable by Week 18|2
6023327|NCT00246259|9618599|FG001|Overall Study|Not stable by Week 18|1
6023328|NCT00246259|9618598|FG000|Overall Study|Participant non-compliant|4
6023329|NCT00246259|9618599|FG001|Overall Study|Participant non-compliant|9
6023330|NCT00246259|9618598|FG000|Overall Study|Lack of Efficacy|2
6023331|NCT00246259|9618599|FG001|Overall Study|Lack of Efficacy|2
6023332|NCT00246259|9618598|FG000|Overall Study|Investigator withdrew participant|2
6023333|NCT00246259|9618599|FG001|Overall Study|Investigator withdrew participant|0
6023334|NCT00246259|9618598|FG000|Overall Study|Adverse Event|5
6023335|NCT00246259|9618599|FG001|Overall Study|Adverse Event|0
6023336|NCT00246259|9618598|FG000|Overall Study|Lost to Follow-up|3
6023337|NCT00246259|9618599|FG001|Overall Study|Lost to Follow-up|4
6023338|NCT00246259|9618598|FG000|Overall Study|Withdrawal by Subject|5
6023339|NCT00246259|9618599|FG001|Overall Study|Withdrawal by Subject|1
6023340|NCT00246259|9618598|FG000|Overall Study|randomly assigned, not eligible for ITT|2
6023341|NCT00246259|9618599|FG001|Overall Study|randomly assigned, not eligible for ITT|6
6023342|NCT00246324|9618605|FG000|Overall Study|Withdrawal by Subject|1
6023343|NCT00246337|9618618|FG000|Overall Study|Lost to Follow-up|3
6023344|NCT00246337|9618619|FG001|Overall Study|Lost to Follow-up|0
6023345|NCT00246337|9618620|FG002|Overall Study|Lost to Follow-up|0
6023346|NCT00246337|9618621|FG003|Overall Study|Lost to Follow-up|0
6023347|NCT00246337|9618622|FG004|Overall Study|Lost to Follow-up|2
6023348|NCT00246337|9618623|FG005|Overall Study|Lost to Follow-up|2
6023349|NCT00246337|9618624|FG006|Overall Study|Lost to Follow-up|1
6023350|NCT00246337|9618625|FG007|Overall Study|Lost to Follow-up|2
6023351|NCT00246337|9618626|FG008|Overall Study|Lost to Follow-up|0
6023352|NCT00246337|9618618|FG000|Overall Study|Protocol Violation|1
6023353|NCT00246337|9618619|FG001|Overall Study|Protocol Violation|0
6023354|NCT00246337|9618620|FG002|Overall Study|Protocol Violation|0
6023355|NCT00246337|9618621|FG003|Overall Study|Protocol Violation|0
6023356|NCT00246337|9618622|FG004|Overall Study|Protocol Violation|1
6078123|NCT00603239|9684494|FG001|Overall Study|Loss of glucose control|0
6078124|NCT00603239|9684493|FG000|Overall Study|Lost to Follow-up|2
6078125|NCT00603239|9684494|FG001|Overall Study|Lost to Follow-up|1
6078126|NCT00603239|9684493|FG000|Overall Study|Physician Decision|2
6078127|NCT00603239|9684494|FG001|Overall Study|Physician Decision|0
6078128|NCT00603239|9684493|FG000|Overall Study|Protocol Violation|2
6078129|NCT00603239|9684494|FG001|Overall Study|Protocol Violation|0
6078130|NCT00603239|9684493|FG000|Overall Study|Subject decision|2
6078131|NCT00603239|9684494|FG001|Overall Study|Subject decision|1
6078132|NCT00603265|9684503|FG000|Overall Study|Adverse Event|2
6078133|NCT00603265|9684504|FG001|Overall Study|Adverse Event|11
6023357|NCT00246337|9618623|FG005|Overall Study|Protocol Violation|0
6023358|NCT00246337|9618624|FG006|Overall Study|Protocol Violation|1
6023359|NCT00246337|9618625|FG007|Overall Study|Protocol Violation|1
6023360|NCT00246337|9618626|FG008|Overall Study|Protocol Violation|0
6078134|NCT00603265|9684505|FG002|Overall Study|Adverse Event|1
6078135|NCT00603265|9684503|FG000|Overall Study|Withdrawal by Subject|1
6023361|NCT00246337|9618618|FG000|Overall Study|Withdrawal by Subject|2
6023362|NCT00246337|9618619|FG001|Overall Study|Withdrawal by Subject|0
6023363|NCT00246337|9618620|FG002|Overall Study|Withdrawal by Subject|0
6023364|NCT00246337|9618621|FG003|Overall Study|Withdrawal by Subject|0
6023365|NCT00246337|9618622|FG004|Overall Study|Withdrawal by Subject|0
6023366|NCT00246337|9618623|FG005|Overall Study|Withdrawal by Subject|0
6023367|NCT00246337|9618624|FG006|Overall Study|Withdrawal by Subject|1
6023368|NCT00246337|9618625|FG007|Overall Study|Withdrawal by Subject|1
6023369|NCT00246337|9618626|FG008|Overall Study|Withdrawal by Subject|0
6023370|NCT00246337|9618618|FG000|Overall Study|Lack of Qualifying Event|8
6023371|NCT00246337|9618619|FG001|Overall Study|Lack of Qualifying Event|2
6023372|NCT00246337|9618620|FG002|Overall Study|Lack of Qualifying Event|1
6023373|NCT00246337|9618621|FG003|Overall Study|Lack of Qualifying Event|1
6023374|NCT00246337|9618622|FG004|Overall Study|Lack of Qualifying Event|1
6023375|NCT00246337|9618623|FG005|Overall Study|Lack of Qualifying Event|3
6023376|NCT00246337|9618624|FG006|Overall Study|Lack of Qualifying Event|3
6023377|NCT00246337|9618625|FG007|Overall Study|Lack of Qualifying Event|2
6023378|NCT00246337|9618626|FG008|Overall Study|Lack of Qualifying Event|5
6023379|NCT00246337|9618618|FG000|Overall Study|Site Terminated|10
6023380|NCT00246337|9618619|FG001|Overall Study|Site Terminated|0
6023381|NCT00246337|9618620|FG002|Overall Study|Site Terminated|0
6023382|NCT00246337|9618621|FG003|Overall Study|Site Terminated|0
6023383|NCT00246337|9618622|FG004|Overall Study|Site Terminated|0
6023384|NCT00246337|9618623|FG005|Overall Study|Site Terminated|7
6023385|NCT00246337|9618624|FG006|Overall Study|Site Terminated|1
6023386|NCT00246337|9618625|FG007|Overall Study|Site Terminated|6
6023387|NCT00246337|9618626|FG008|Overall Study|Site Terminated|2
6023388|NCT00246337|9618618|FG000|Overall Study|Abnormal baseline lab values|7
6023389|NCT00246337|9618619|FG001|Overall Study|Abnormal baseline lab values|0
6023390|NCT00246337|9618620|FG002|Overall Study|Abnormal baseline lab values|2
6023391|NCT00246337|9618621|FG003|Overall Study|Abnormal baseline lab values|0
6023392|NCT00246337|9618622|FG004|Overall Study|Abnormal baseline lab values|0
6023393|NCT00246337|9618623|FG005|Overall Study|Abnormal baseline lab values|2
6023394|NCT00246337|9618624|FG006|Overall Study|Abnormal baseline lab values|2
6023395|NCT00246337|9618625|FG007|Overall Study|Abnormal baseline lab values|0
6023396|NCT00246337|9618626|FG008|Overall Study|Abnormal baseline lab values|4
6023397|NCT00246337|9618618|FG000|Overall Study|Overwhelmed|0
6023398|NCT00246337|9618619|FG001|Overall Study|Overwhelmed|0
6023399|NCT00246337|9618620|FG002|Overall Study|Overwhelmed|0
6023400|NCT00246337|9618621|FG003|Overall Study|Overwhelmed|0
6023401|NCT00246337|9618622|FG004|Overall Study|Overwhelmed|0
6023402|NCT00246337|9618623|FG005|Overall Study|Overwhelmed|1
6023403|NCT00246337|9618624|FG006|Overall Study|Overwhelmed|0
6023404|NCT00246337|9618625|FG007|Overall Study|Overwhelmed|0
6023405|NCT00246337|9618626|FG008|Overall Study|Overwhelmed|0
6023406|NCT00246337|9618618|FG000|Overall Study|Protocol Violator|1
6023407|NCT00246337|9618619|FG001|Overall Study|Protocol Violator|0
6023408|NCT00246337|9618620|FG002|Overall Study|Protocol Violator|0
6023409|NCT00246337|9618621|FG003|Overall Study|Protocol Violator|0
6023410|NCT00246337|9618622|FG004|Overall Study|Protocol Violator|0
6023411|NCT00246337|9618623|FG005|Overall Study|Protocol Violator|0
6023412|NCT00246337|9618624|FG006|Overall Study|Protocol Violator|0
6023413|NCT00246337|9618625|FG007|Overall Study|Protocol Violator|0
6023414|NCT00246337|9618626|FG008|Overall Study|Protocol Violator|0
6023415|NCT00246337|9618618|FG000|Overall Study|Reported as completing trial in error|0
6023416|NCT00246337|9618619|FG001|Overall Study|Reported as completing trial in error|0
6078136|NCT00603265|9684504|FG001|Overall Study|Withdrawal by Subject|2
6023417|NCT00246337|9618620|FG002|Overall Study|Reported as completing trial in error|0
6023418|NCT00246337|9618621|FG003|Overall Study|Reported as completing trial in error|0
6023419|NCT00246337|9618622|FG004|Overall Study|Reported as completing trial in error|0
6023420|NCT00246337|9618623|FG005|Overall Study|Reported as completing trial in error|0
6023421|NCT00246337|9618624|FG006|Overall Study|Reported as completing trial in error|0
6023422|NCT00246337|9618625|FG007|Overall Study|Reported as completing trial in error|1
6023423|NCT00246337|9618626|FG008|Overall Study|Reported as completing trial in error|0
6078137|NCT00603265|9684505|FG002|Overall Study|Withdrawal by Subject|1
6078138|NCT00603265|9684503|FG000|Overall Study|Lack of Efficacy|3
6023424|NCT00246376|9618651|FG000|Overall Study|Dropped/withdrew during dietary run-in|11
6023425|NCT00246376|9618652|FG001|Overall Study|Dropped/withdrew during dietary run-in|5
6023426|NCT00246376|9618653|FG002|Overall Study|Dropped/withdrew during dietary run-in|4
6023427|NCT00246376|9618654|FG003|Overall Study|Dropped/withdrew during dietary run-in|7
6023428|NCT00246376|9618655|FG004|Overall Study|Dropped/withdrew during dietary run-in|3
6023429|NCT00246376|9618651|FG000|Overall Study|Adverse Event|2
6023430|NCT00246376|9618652|FG001|Overall Study|Adverse Event|3
6023431|NCT00246376|9618653|FG002|Overall Study|Adverse Event|1
6023432|NCT00246376|9618654|FG003|Overall Study|Adverse Event|3
6023433|NCT00246376|9618655|FG004|Overall Study|Adverse Event|1
6023434|NCT00246376|9618651|FG000|Overall Study|Lost to Follow-up|2
6023435|NCT00246376|9618652|FG001|Overall Study|Lost to Follow-up|11
6023436|NCT00246376|9618653|FG002|Overall Study|Lost to Follow-up|11
6023437|NCT00246376|9618654|FG003|Overall Study|Lost to Follow-up|16
6023438|NCT00246376|9618655|FG004|Overall Study|Lost to Follow-up|13
6023439|NCT00246571|9618693|FG000|Overall Study|Adverse Event|7
6023440|NCT00246571|9618694|FG001|Overall Study|Adverse Event|0
6023441|NCT00246571|9618693|FG000|Overall Study|Protocol Violation|0
6023442|NCT00246571|9618694|FG001|Overall Study|Protocol Violation|1
6023443|NCT00246571|9618693|FG000|Overall Study|Withdrawal by Subject|2
6023444|NCT00246571|9618694|FG001|Overall Study|Withdrawal by Subject|3
6023445|NCT00246571|9618693|FG000|Overall Study|Lack of Efficacy|84
6023446|NCT00246571|9618694|FG001|Overall Study|Lack of Efficacy|21
6023447|NCT00246571|9618693|FG000|Overall Study|Death|17
6023448|NCT00246571|9618694|FG001|Overall Study|Death|3
6023449|NCT00246571|9618693|FG000|Overall Study|Sponsor|0
6023450|NCT00246571|9618694|FG001|Overall Study|Sponsor|1
6023451|NCT00246571|9618693|FG000|Overall Study|Did not meet entrance criteria|2
6023452|NCT00246571|9618694|FG001|Overall Study|Did not meet entrance criteria|1
6023453|NCT00246571|9618693|FG000|Overall Study|Laboratory abnormalities|1
6023454|NCT00246571|9618694|FG001|Overall Study|Laboratory abnormalities|0
6023455|NCT00246571|9618693|FG000|Overall Study|Crossover participants|0
6023456|NCT00246571|9618694|FG001|Overall Study|Crossover participants|74
6023457|NCT00246740|9618702|FG000|Initial Enrollment|Death|1
6023458|NCT00246740|9618703|FG001|Initial Enrollment|Death|0
6023459|NCT00246740|9618702|FG000|Initial Enrollment|Additional surgery scheduled|0
6023460|NCT00246740|9618703|FG001|Initial Enrollment|Additional surgery scheduled|2
6023461|NCT00246740|9618702|FG000|Initial Enrollment|Surgery schedule change|4
6023462|NCT00246740|9618703|FG001|Initial Enrollment|Surgery schedule change|4
6023463|NCT00246740|9618702|FG000|Initial Enrollment|Other|1
6023464|NCT00246740|9618703|FG001|Initial Enrollment|Other|2
6023465|NCT00246753|9618709|FG000|Overall Study|Withdrawal by Subject|2
6023466|NCT00246753|9618709|FG000|Overall Study|Physician Decision|2
6023467|NCT00246753|9618709|FG000|Overall Study|Adverse Event|2
6023468|NCT00246753|9618709|FG000|Overall Study|Unacceptable toxicity|2
6023469|NCT00246805|9618715|FG000|Phase 1|Lost to Follow-up|1
6023470|NCT00246805|9618716|FG001|Phase 1|Lost to Follow-up|0
6023471|NCT00247273|9618724|FG000|Overall Study|Adverse Event|85
6023472|NCT00247273|9618725|FG001|Overall Study|Adverse Event|80
6023473|NCT00247273|9618724|FG000|Overall Study|Physician Decision|6
6023474|NCT00247273|9618725|FG001|Overall Study|Physician Decision|3
6023475|NCT00247273|9618724|FG000|Overall Study|Lost to Follow-up|7
6023476|NCT00247273|9618725|FG001|Overall Study|Lost to Follow-up|7
6023477|NCT00247273|9618724|FG000|Overall Study|Withdrawal by Subject|46
6023478|NCT00247273|9618725|FG001|Overall Study|Withdrawal by Subject|47
6023479|NCT00247273|9618724|FG000|Overall Study|Did not take any study drug|2
6023480|NCT00247273|9618725|FG001|Overall Study|Did not take any study drug|0
6023481|NCT00247416|9618742|FG000|Overall Study|3 patients were found to be ineligible|1
6023482|NCT00247416|9618743|FG001|Overall Study|3 patients were found to be ineligible|2
6023483|NCT00247611|9618753|FG000|Baselined|Completed baseline, never placed on ARVs|8
6023484|NCT00247611|9618754|FG001|Baselined|Completed baseline, never placed on ARVs|5
6023485|NCT00247611|9618753|FG000|Baselined|Completed baseline only|9
6023486|NCT00247611|9618754|FG001|Baselined|Completed baseline only|8
6023487|NCT00247676|9618775|FG000|Overall Study|Death|5
6023488|NCT00247676|9618775|FG000|Overall Study|Adverse Event|11
6023489|NCT00247676|9618775|FG000|Overall Study|Lack of Efficacy|15
6023490|NCT00247676|9618775|FG000|Overall Study|Other|3
6023491|NCT00247676|9618775|FG000|Overall Study|Withdrawal by Subject|2
6023492|NCT00247962|9618796|FG000|Overall Study|Adverse Event|15
6023493|NCT00247962|9618797|FG001|Overall Study|Adverse Event|12
6023494|NCT00247962|9618796|FG000|Overall Study|Lost to Follow-up|3
6023495|NCT00247962|9618797|FG001|Overall Study|Lost to Follow-up|1
6023496|NCT00247962|9618796|FG000|Overall Study|Physician Decision|0
6023497|NCT00247962|9618797|FG001|Overall Study|Physician Decision|1
6023498|NCT00247962|9618796|FG000|Overall Study|Protocol Violation|1
6023499|NCT00247962|9618797|FG001|Overall Study|Protocol Violation|1
6023500|NCT00247962|9618796|FG000|Overall Study|Withdrawal by Subject|3
6023501|NCT00247962|9618797|FG001|Overall Study|Withdrawal by Subject|2
6023502|NCT00247962|9618796|FG000|Overall Study|Lack of Efficacy|4
6023503|NCT00247962|9618797|FG001|Overall Study|Lack of Efficacy|2
6023504|NCT00248040|9618806|FG000|Overall Study|transplantectomy|2
6023505|NCT00248040|9618807|FG001|Overall Study|transplantectomy|1
6023506|NCT00248040|9618808|FG002|Overall Study|transplantectomy|3
6023507|NCT00248040|9618806|FG000|Overall Study|transplant cancelled post treat start|1
6023508|NCT00248040|9618807|FG001|Overall Study|transplant cancelled post treat start|0
6023509|NCT00248040|9618808|FG002|Overall Study|transplant cancelled post treat start|0
6023510|NCT00248040|9618806|FG000|Overall Study|Death|0
6023511|NCT00248040|9618807|FG001|Overall Study|Death|0
6023512|NCT00248040|9618808|FG002|Overall Study|Death|1
6023513|NCT00248170|9618819|FG000|Overall Study|Withdrawal by Subject|71
6023514|NCT00248170|9618820|FG001|Overall Study|Withdrawal by Subject|79
6023515|NCT00248170|9618819|FG000|Overall Study|Protocol Violation|35
6023516|NCT00248170|9618820|FG001|Overall Study|Protocol Violation|30
6023517|NCT00248170|9618819|FG000|Overall Study|Lost to Follow-up|28
6023518|NCT00248170|9618820|FG001|Overall Study|Lost to Follow-up|35
6023519|NCT00248170|9618819|FG000|Overall Study|Disease progression|196
6023520|NCT00248170|9618820|FG001|Overall Study|Disease progression|216
6023521|NCT00248170|9618819|FG000|Overall Study|Death|28
6023522|NCT00248170|9618820|FG001|Overall Study|Death|47
6023523|NCT00248170|9618819|FG000|Overall Study|Adverse Event|311
6023524|NCT00248170|9618820|FG001|Overall Study|Adverse Event|296
6023525|NCT00248170|9618819|FG000|Overall Study|Administrative problems|22
6023526|NCT00248170|9618820|FG001|Overall Study|Administrative problems|25
6023527|NCT00248170|9618819|FG000|Overall Study|Abnormal test procedure(s) result|49
6023528|NCT00248170|9618820|FG001|Overall Study|Abnormal test procedure(s) result|61
6023529|NCT00248170|9618819|FG000|Overall Study|Abnormal laboratory values|4
6023530|NCT00248170|9618820|FG001|Overall Study|Abnormal laboratory values|0
6023531|NCT00248170|9618819|FG000|Overall Study|Protocol deviation|17
6023532|NCT00248170|9618820|FG001|Overall Study|Protocol deviation|19
6023533|NCT00248495|9618826|FG000|Overall Study|Withdrawal by Subject|1
6023534|NCT00248625|9618869|FG000|Overall Study|Withdrawal by Subject|0
6023535|NCT00248625|9618870|FG001|Overall Study|Withdrawal by Subject|2
6023536|NCT00248651|9618890|FG000|Overall Study|Withdrawal by Subject|28
6023537|NCT00248651|9618891|FG001|Overall Study|Withdrawal by Subject|40
6023538|NCT00248651|9618892|FG002|Overall Study|Withdrawal by Subject|32
6023539|NCT00248794|9618912|FG000|Overall Study|Lost to Follow-up|6
6023540|NCT00248794|9618913|FG001|Overall Study|Lost to Follow-up|8
6023541|NCT00248794|9618914|FG002|Overall Study|Lost to Follow-up|3
6023542|NCT00248833|9618946|FG000|Overall Study|Adverse Event|2
6023543|NCT00248833|9618947|FG001|Overall Study|Adverse Event|0
6023544|NCT00248833|9618948|FG002|Overall Study|Adverse Event|0
6023545|NCT00248833|9618946|FG000|Overall Study|Withdrawal by Subject|0
6023546|NCT00248833|9618947|FG001|Overall Study|Withdrawal by Subject|1
6023547|NCT00248833|9618948|FG002|Overall Study|Withdrawal by Subject|1
6023548|NCT00248833|9618946|FG000|Overall Study|Lost to Follow-up|1
6023549|NCT00248833|9618947|FG001|Overall Study|Lost to Follow-up|1
6023550|NCT00248833|9618948|FG002|Overall Study|Lost to Follow-up|1
6023551|NCT00248833|9618946|FG000|Overall Study|Other|0
6023552|NCT00248833|9618947|FG001|Overall Study|Other|1
6023553|NCT00248833|9618948|FG002|Overall Study|Other|0
6023554|NCT00249002|9618958|FG000|Overall Study|Adverse Event|2
6023555|NCT00249002|9618958|FG000|Overall Study|Study cancellation|3
6023556|NCT00249002|9618958|FG000|Overall Study|Other|2
6023557|NCT00249288|9618981|FG000|Overall Study|Lost to Follow-up|3
6023558|NCT00249288|9618982|FG001|Overall Study|Lost to Follow-up|3
6023559|NCT00249288|9618981|FG000|Overall Study|Withdrawal by Subject|2
6023560|NCT00249288|9618982|FG001|Overall Study|Withdrawal by Subject|2
6023561|NCT00249444|9619007|FG000|Overall Study|Lost to Follow-up|2
6023562|NCT00249444|9619008|FG001|Overall Study|Lost to Follow-up|2
6023563|NCT00249444|9619007|FG000|Overall Study|non-compliant|9
6023564|NCT00249444|9619008|FG001|Overall Study|non-compliant|11
6023565|NCT00249444|9619007|FG000|Overall Study|Adverse Event|1
6023566|NCT00249444|9619008|FG001|Overall Study|Adverse Event|1
6023567|NCT00249444|9619007|FG000|Overall Study|life event|0
6023568|NCT00249444|9619008|FG001|Overall Study|life event|1
6023569|NCT00249613|9619036|FG000|12 Month Follow-up|Death|1
6023570|NCT00249613|9619037|FG001|12 Month Follow-up|Death|1
6023571|NCT00249613|9619036|FG000|12 Month Follow-up|Withdrawal by Subject|6
6023572|NCT00249613|9619037|FG001|12 Month Follow-up|Withdrawal by Subject|6
6023573|NCT00249613|9619036|FG000|12 Month Follow-up|Lost to Follow-up|10
6023574|NCT00249613|9619037|FG001|12 Month Follow-up|Lost to Follow-up|8
6023575|NCT00249769|9619049|FG000|Overall Study|Withdrawal by Subject|1
6023576|NCT00249769|9619050|FG001|Overall Study|Withdrawal by Subject|10
6023577|NCT00249769|9619051|FG002|Overall Study|Withdrawal by Subject|6
6023578|NCT00249769|9619049|FG000|Overall Study|Migration from Study Area|1
6023579|NCT00249769|9619050|FG001|Overall Study|Migration from Study Area|3
6023580|NCT00249769|9619051|FG002|Overall Study|Migration from Study Area|14
6023581|NCT00249769|9619049|FG000|Overall Study|Miscellaneous|0
6023582|NCT00249769|9619050|FG001|Overall Study|Miscellaneous|2
6023583|NCT00249769|9619051|FG002|Overall Study|Miscellaneous|2
6023584|NCT00249769|9619049|FG000|Overall Study|Adverse Event|0
6023585|NCT00249769|9619050|FG001|Overall Study|Adverse Event|0
6023586|NCT00249769|9619051|FG002|Overall Study|Adverse Event|1
6023587|NCT00249769|9619049|FG000|Overall Study|Physician Decision|0
6023588|NCT00249769|9619050|FG001|Overall Study|Physician Decision|0
6023589|NCT00249769|9619051|FG002|Overall Study|Physician Decision|2
6023590|NCT00249769|9619049|FG000|Overall Study|Lost to Follow-up|0
6023591|NCT00249769|9619050|FG001|Overall Study|Lost to Follow-up|0
6023592|NCT00249769|9619051|FG002|Overall Study|Lost to Follow-up|3
6023593|NCT00249795|9619061|FG000|Overall Study|Not treated|16
6023594|NCT00249795|9619062|FG001|Overall Study|Not treated|14
6023595|NCT00249795|9619061|FG000|Overall Study|Symptomatic hypotension|127
6023596|NCT00249795|9619062|FG001|Overall Study|Symptomatic hypotension|64
6023597|NCT00249795|9619061|FG000|Overall Study|Other Serious Adverse Event|84
6023598|NCT00249795|9619062|FG001|Overall Study|Other Serious Adverse Event|93
6023599|NCT00249795|9619061|FG000|Overall Study|Qualifying condition not present|26
6023600|NCT00249795|9619062|FG001|Overall Study|Qualifying condition not present|29
6023601|NCT00249795|9619061|FG000|Overall Study|Withdrawal by Subject|678
6023602|NCT00249795|9619062|FG001|Overall Study|Withdrawal by Subject|742
6023603|NCT00249795|9619061|FG000|Overall Study|Thromboembolic / outcome event|39
6023604|NCT00249795|9619062|FG001|Overall Study|Thromboembolic / outcome event|45
6023605|NCT00249795|9619061|FG000|Overall Study|Oral anticoagulant required|2
6023606|NCT00249795|9619062|FG001|Overall Study|Oral anticoagulant required|0
6023607|NCT00249795|9619061|FG000|Overall Study|Minor bleeding (e.g.,bruising,epistaxis)|7
6023608|NCT00249795|9619062|FG001|Overall Study|Minor bleeding (e.g.,bruising,epistaxis)|3
6023609|NCT00249795|9619061|FG000|Overall Study|Non-compliance|71
6023610|NCT00249795|9619062|FG001|Overall Study|Non-compliance|69
6023611|NCT00249795|9619061|FG000|Overall Study|Study drug intolerance|3
6023612|NCT00249795|9619062|FG001|Overall Study|Study drug intolerance|3
6023613|NCT00249795|9619061|FG000|Overall Study|Other adverse events (non-serious)|188
6023614|NCT00249795|9619062|FG001|Overall Study|Other adverse events (non-serious)|159
6023615|NCT00249795|9619061|FG000|Overall Study|Physician withdrew consent|71
6023616|NCT00249795|9619062|FG001|Overall Study|Physician withdrew consent|63
6023617|NCT00249795|9619061|FG000|Overall Study|Surgery / procedure|4
6023618|NCT00249795|9619062|FG001|Overall Study|Surgery / procedure|5
6023619|NCT00249795|9619061|FG000|Overall Study|Angiotensin II receptor blocker required|35
6023620|NCT00249795|9619062|FG001|Overall Study|Angiotensin II receptor blocker required|58
6023621|NCT00249795|9619061|FG000|Overall Study|Lightheadedness / dizziness|15
6023622|NCT00249795|9619062|FG001|Overall Study|Lightheadedness / dizziness|11
6023623|NCT00249795|9619061|FG000|Overall Study|Hypotension (non-symptomatic)|5
6023624|NCT00249795|9619062|FG001|Overall Study|Hypotension (non-symptomatic)|5
6023625|NCT00249795|9619061|FG000|Overall Study|Other contraindicated medication|1
6023626|NCT00249795|9619062|FG001|Overall Study|Other contraindicated medication|1
6023627|NCT00249795|9619061|FG000|Overall Study|Event related to cardiac condition|17
6023628|NCT00249795|9619062|FG001|Overall Study|Event related to cardiac condition|16
6023629|NCT00249795|9619061|FG000|Overall Study|Patient not wish to continue after May08|4
6023630|NCT00249795|9619062|FG001|Overall Study|Patient not wish to continue after May08|6
6023631|NCT00249795|9619061|FG000|Overall Study|Site not agree to continue after May08|1
6023632|NCT00249795|9619062|FG001|Overall Study|Site not agree to continue after May08|1
6023633|NCT00249795|9619061|FG000|Overall Study|Lost to Follow-up|0
6023634|NCT00249795|9619062|FG001|Overall Study|Lost to Follow-up|2
6023635|NCT00249795|9619061|FG000|Overall Study|Missing|0
6023636|NCT00249795|9619062|FG001|Overall Study|Missing|1
6023637|NCT00249808|9619068|FG000|Overall Study|Other|27
6023638|NCT00249808|9619068|FG000|Overall Study|Protocol Violation|3
6023639|NCT00249808|9619068|FG000|Overall Study|Lost to Follow-up|8
6023640|NCT00249808|9619068|FG000|Overall Study|Adverse Event|81
6023641|NCT00249808|9619068|FG000|Overall Study|Lack of Efficacy|52
6023642|NCT00249808|9619068|FG000|Overall Study|Did Not Provide Post-Baseline Data|11
6023643|NCT00249821|9619074|FG000|Overall Study|Technical problem|0
6023644|NCT00249821|9619075|FG001|Overall Study|Technical problem|1
6023645|NCT00249834|9619089|FG000|Overall Study|Ovarian stimulation failed|1
6023646|NCT00249834|9619090|FG001|Overall Study|Ovarian stimulation failed|0
6023647|NCT00249834|9619091|FG002|Overall Study|Ovarian stimulation failed|0
6023648|NCT00249834|9619092|FG003|Overall Study|Ovarian stimulation failed|0
6023649|NCT00249834|9619093|FG004|Overall Study|Ovarian stimulation failed|0
6023650|NCT00249834|9619094|FG005|Overall Study|Ovarian stimulation failed|0
6023651|NCT00249834|9619095|FG006|Overall Study|Ovarian stimulation failed|0
6023652|NCT00249834|9619096|FG007|Overall Study|Ovarian stimulation failed|0
6023653|NCT00249834|9619089|FG000|Overall Study|Failure of down-regulation|0
6023654|NCT00249834|9619090|FG001|Overall Study|Failure of down-regulation|0
6023655|NCT00249834|9619091|FG002|Overall Study|Failure of down-regulation|0
6023656|NCT00249834|9619092|FG003|Overall Study|Failure of down-regulation|0
6023657|NCT00249834|9619093|FG004|Overall Study|Failure of down-regulation|0
6023658|NCT00249834|9619094|FG005|Overall Study|Failure of down-regulation|0
6023659|NCT00249834|9619095|FG006|Overall Study|Failure of down-regulation|1
6023660|NCT00249834|9619096|FG007|Overall Study|Failure of down-regulation|0
6023661|NCT00249834|9619089|FG000|Overall Study|Protocol Violation|0
6023662|NCT00249834|9619090|FG001|Overall Study|Protocol Violation|19
6023663|NCT00249834|9619091|FG002|Overall Study|Protocol Violation|14
6023664|NCT00249834|9619092|FG003|Overall Study|Protocol Violation|8
6023665|NCT00249834|9619093|FG004|Overall Study|Protocol Violation|5
6023666|NCT00249834|9619094|FG005|Overall Study|Protocol Violation|2
6023667|NCT00249834|9619095|FG006|Overall Study|Protocol Violation|0
6023668|NCT00249834|9619096|FG007|Overall Study|Protocol Violation|0
6023669|NCT00249873|9619110|FG000|Overall Study|Not treated|7
6023670|NCT00249873|9619111|FG001|Overall Study|Not treated|8
6023671|NCT00249873|9619110|FG000|Overall Study|Significant thrombocytopenia|9
6023672|NCT00249873|9619111|FG001|Overall Study|Significant thrombocytopenia|8
6023673|NCT00249873|9619110|FG000|Overall Study|Severe allergic reaction|8
6023674|NCT00249873|9619111|FG001|Overall Study|Severe allergic reaction|1
6023675|NCT00249873|9619110|FG000|Overall Study|Serious haemorrhagic Adverse Event|74
6023676|NCT00249873|9619111|FG001|Overall Study|Serious haemorrhagic Adverse Event|30
6023677|NCT00249873|9619110|FG000|Overall Study|Other Serious Adverse Event|86
6023678|NCT00249873|9619111|FG001|Overall Study|Other Serious Adverse Event|97
6023679|NCT00249873|9619110|FG000|Overall Study|Qualifying condition not present|20
6023680|NCT00249873|9619111|FG001|Overall Study|Qualifying condition not present|23
6023681|NCT00249873|9619110|FG000|Overall Study|Contraindication to oral anticoagulant|4
6023682|NCT00249873|9619111|FG001|Overall Study|Contraindication to oral anticoagulant|8
6023683|NCT00249873|9619110|FG000|Overall Study|Withdrawal by Subject|504
6023684|NCT00249873|9619111|FG001|Overall Study|Withdrawal by Subject|466
6023685|NCT00249873|9619110|FG000|Overall Study|Lost to Follow-up|4
6023686|NCT00249873|9619111|FG001|Overall Study|Lost to Follow-up|7
6023687|NCT00249873|9619110|FG000|Overall Study|Minor bleeding|99
6023688|NCT00249873|9619111|FG001|Overall Study|Minor bleeding|37
6023689|NCT00249873|9619110|FG000|Overall Study|Non-compliance|41
6023690|NCT00249873|9619111|FG001|Overall Study|Non-compliance|46
6023691|NCT00249873|9619110|FG000|Overall Study|Other non serious Adverse Event|112
6023692|NCT00249873|9619111|FG001|Overall Study|Other non serious Adverse Event|108
6023693|NCT00249873|9619110|FG000|Overall Study|Other contraindicated medication|1
6023694|NCT00249873|9619111|FG001|Overall Study|Other contraindicated medication|0
6023695|NCT00249873|9619110|FG000|Overall Study|Patient not wish to continue after May08|3
6023696|NCT00249873|9619111|FG001|Overall Study|Patient not wish to continue after May08|4
6023697|NCT00249873|9619110|FG000|Overall Study|Physician withdrew consent|59
6023698|NCT00249873|9619111|FG001|Overall Study|Physician withdrew consent|60
6023699|NCT00249873|9619110|FG000|Overall Study|Open label clopidogrel required|31
6023700|NCT00249873|9619111|FG001|Overall Study|Open label clopidogrel required|42
6023701|NCT00249873|9619110|FG000|Overall Study|Angiotensin II receptor blocker required|1
6023702|NCT00249873|9619111|FG001|Overall Study|Angiotensin II receptor blocker required|0
6023703|NCT00249873|9619110|FG000|Overall Study|Oral anticoagulant required|159
6023704|NCT00249873|9619111|FG001|Overall Study|Oral anticoagulant required|157
6023705|NCT00249873|9619110|FG000|Overall Study|Study drug intolerance|5
6023706|NCT00249873|9619111|FG001|Overall Study|Study drug intolerance|0
6023707|NCT00249873|9619110|FG000|Overall Study|Surgery/ procedure|9
6023708|NCT00249873|9619111|FG001|Overall Study|Surgery/ procedure|9
6023709|NCT00249873|9619110|FG000|Overall Study|Event related to cardiac condition|12
6023710|NCT00249873|9619111|FG001|Overall Study|Event related to cardiac condition|21
6023711|NCT00249873|9619110|FG000|Overall Study|Thromboembolic/outcome event|82
6023712|NCT00249873|9619111|FG001|Overall Study|Thromboembolic/outcome event|122
6023713|NCT00250276|9619121|FG000|Overall Study|Serious Adverse Event|0
6023714|NCT00250276|9619122|FG001|Overall Study|Serious Adverse Event|0
6023715|NCT00250276|9619123|FG002|Overall Study|Serious Adverse Event|1
6023716|NCT00250276|9619124|FG003|Overall Study|Serious Adverse Event|0
6023717|NCT00250276|9619121|FG000|Overall Study|Non-serious Adverse Event|2
6023718|NCT00250276|9619122|FG001|Overall Study|Non-serious Adverse Event|0
6023719|NCT00250276|9619123|FG002|Overall Study|Non-serious Adverse Event|0
6023720|NCT00250276|9619124|FG003|Overall Study|Non-serious Adverse Event|2
6023721|NCT00250276|9619121|FG000|Overall Study|Protocol Violation|0
6023722|NCT00250276|9619122|FG001|Overall Study|Protocol Violation|1
6023723|NCT00250276|9619123|FG002|Overall Study|Protocol Violation|0
6023724|NCT00250276|9619124|FG003|Overall Study|Protocol Violation|0
6023725|NCT00250276|9619121|FG000|Overall Study|Withdrawal by Subject|1
6023726|NCT00250276|9619122|FG001|Overall Study|Withdrawal by Subject|2
6023727|NCT00250276|9619123|FG002|Overall Study|Withdrawal by Subject|3
6023728|NCT00250276|9619124|FG003|Overall Study|Withdrawal by Subject|2
6023729|NCT00250276|9619121|FG000|Overall Study|Migrated/moved from study area|3
6023730|NCT00250276|9619122|FG001|Overall Study|Migrated/moved from study area|0
6023731|NCT00250276|9619123|FG002|Overall Study|Migrated/moved from study area|2
6023732|NCT00250276|9619124|FG003|Overall Study|Migrated/moved from study area|7
6023733|NCT00250276|9619121|FG000|Overall Study|Lost to Follow-up|11
6023734|NCT00250276|9619122|FG001|Overall Study|Lost to Follow-up|18
6023735|NCT00250276|9619123|FG002|Overall Study|Lost to Follow-up|13
6023736|NCT00250276|9619124|FG003|Overall Study|Lost to Follow-up|8
6023737|NCT00250432|9619141|FG000|Overall Study|Adverse Event|25
6078139|NCT00603265|9684504|FG001|Overall Study|Lack of Efficacy|0
6078140|NCT00603265|9684505|FG002|Overall Study|Lack of Efficacy|3
6078141|NCT00603265|9684503|FG000|Overall Study|Lost to Follow-up|0
6078142|NCT00603265|9684504|FG001|Overall Study|Lost to Follow-up|1
6078143|NCT00603265|9684505|FG002|Overall Study|Lost to Follow-up|0
6078144|NCT00603265|9684503|FG000|Overall Study|Out of Town, Ran Out of Study Drug|0
6078145|NCT00603265|9684504|FG001|Overall Study|Out of Town, Ran Out of Study Drug|1
6078146|NCT00603265|9684505|FG002|Overall Study|Out of Town, Ran Out of Study Drug|0
6023738|NCT00250432|9619142|FG001|Overall Study|Adverse Event|29
6023739|NCT00250432|9619141|FG000|Overall Study|Lack of Efficacy|2
6023740|NCT00250432|9619142|FG001|Overall Study|Lack of Efficacy|1
6023741|NCT00250432|9619141|FG000|Overall Study|Lost to Follow-up|6
6023742|NCT00250432|9619142|FG001|Overall Study|Lost to Follow-up|5
6023743|NCT00250432|9619141|FG000|Overall Study|Patient Moved|0
6078147|NCT00603265|9684503|FG000|Overall Study|Participant Left Country, No Responses|0
6023744|NCT00250432|9619142|FG001|Overall Study|Patient Moved|1
6023745|NCT00250432|9619141|FG000|Overall Study|Protocol Violation|0
6023746|NCT00250432|9619142|FG001|Overall Study|Protocol Violation|3
6023747|NCT00250432|9619141|FG000|Overall Study|Withdrawal by Subject|6
6023748|NCT00250432|9619142|FG001|Overall Study|Withdrawal by Subject|2
6023749|NCT00250432|9619141|FG000|Overall Study|Pt died out of posttherapy report period|6
6023750|NCT00250432|9619142|FG001|Overall Study|Pt died out of posttherapy report period|5
6023751|NCT00250432|9619141|FG000|Overall Study|Pt was considered untreatable|0
6023752|NCT00250432|9619142|FG001|Overall Study|Pt was considered untreatable|1
6023753|NCT00250588|9619169|FG000|Overall Study|Withdrawal by Subject|3
6023754|NCT00250588|9619170|FG001|Overall Study|Withdrawal by Subject|6
6023755|NCT00250588|9619171|FG002|Overall Study|Withdrawal by Subject|0
6023756|NCT00250588|9619169|FG000|Overall Study|Lost to Follow-up|6
6023757|NCT00250588|9619170|FG001|Overall Study|Lost to Follow-up|13
6023758|NCT00250588|9619171|FG002|Overall Study|Lost to Follow-up|13
6023759|NCT00250679|9619182|FG000|Overall Study|Adverse Event|12
6023760|NCT00250679|9619183|FG001|Overall Study|Adverse Event|15
6023761|NCT00250679|9619184|FG002|Overall Study|Adverse Event|16
6023762|NCT00250679|9619182|FG000|Overall Study|Protocol Violation|2
6023763|NCT00250679|9619183|FG001|Overall Study|Protocol Violation|4
6023764|NCT00250679|9619184|FG002|Overall Study|Protocol Violation|3
6023765|NCT00250679|9619182|FG000|Overall Study|Withdrawal by Subject|15
6023766|NCT00250679|9619183|FG001|Overall Study|Withdrawal by Subject|18
6023767|NCT00250679|9619184|FG002|Overall Study|Withdrawal by Subject|15
6023768|NCT00250679|9619182|FG000|Overall Study|Lost to Follow-up|3
6023769|NCT00250679|9619183|FG001|Overall Study|Lost to Follow-up|4
6023770|NCT00250679|9619184|FG002|Overall Study|Lost to Follow-up|2
6023771|NCT00250679|9619182|FG000|Overall Study|Does Not Meet Entry Criteria|1
6023772|NCT00250679|9619183|FG001|Overall Study|Does Not Meet Entry Criteria|4
6023773|NCT00250679|9619184|FG002|Overall Study|Does Not Meet Entry Criteria|2
6023774|NCT00250679|9619182|FG000|Overall Study|Lack of Efficacy|0
6023775|NCT00250679|9619183|FG001|Overall Study|Lack of Efficacy|1
6023776|NCT00250679|9619184|FG002|Overall Study|Lack of Efficacy|3
6023777|NCT00250679|9619182|FG000|Overall Study|Technical Holter issues|1
6023778|NCT00250679|9619183|FG001|Overall Study|Technical Holter issues|0
6023779|NCT00250679|9619184|FG002|Overall Study|Technical Holter issues|2
6023780|NCT00250679|9619182|FG000|Overall Study|Moved|1
6023781|NCT00250679|9619183|FG001|Overall Study|Moved|1
6023782|NCT00250679|9619184|FG002|Overall Study|Moved|0
6023783|NCT00250679|9619182|FG000|Overall Study|Non-compliance|1
6023784|NCT00250679|9619183|FG001|Overall Study|Non-compliance|1
6023785|NCT00250679|9619184|FG002|Overall Study|Non-compliance|0
6023786|NCT00250679|9619182|FG000|Overall Study|various single events: hip surgery,diary|3
6023787|NCT00250679|9619183|FG001|Overall Study|various single events: hip surgery,diary|1
6023788|NCT00250679|9619184|FG002|Overall Study|various single events: hip surgery,diary|1
6023789|NCT00250705|9619192|FG000|Overall Study|Lack of Efficacy|2
6023790|NCT00250835|9619198|FG000|Overall Study|Withdrawal by Subject|1
6023791|NCT00251004|9619210|FG000|Overall Study|Withdrawal by Subject|23
6023792|NCT00251004|9619211|FG001|Overall Study|Withdrawal by Subject|16
6023793|NCT00251004|9619212|FG002|Overall Study|Withdrawal by Subject|14
6023794|NCT00251004|9619210|FG000|Overall Study|Death|9
6023795|NCT00251004|9619211|FG001|Overall Study|Death|10
6023796|NCT00251004|9619212|FG002|Overall Study|Death|8
6023797|NCT00251004|9619210|FG000|Overall Study|Lost to Follow-up|1
6023798|NCT00251004|9619211|FG001|Overall Study|Lost to Follow-up|2
6023799|NCT00251004|9619212|FG002|Overall Study|Lost to Follow-up|1
6023800|NCT00251004|9619210|FG000|Overall Study|Graft Loss|12
6023801|NCT00251004|9619211|FG001|Overall Study|Graft Loss|13
6023802|NCT00251004|9619212|FG002|Overall Study|Graft Loss|8
6078148|NCT00603265|9684504|FG001|Overall Study|Participant Left Country, No Responses|1
6078149|NCT00603265|9684505|FG002|Overall Study|Participant Left Country, No Responses|0
6078150|NCT00603265|9684503|FG000|Overall Study|Protocol Violation|1
6078151|NCT00603265|9684504|FG001|Overall Study|Protocol Violation|0
6078152|NCT00603265|9684505|FG002|Overall Study|Protocol Violation|0
6078153|NCT00603278|9684519|FG000|Overall Study|Lack of Efficacy|35
6078154|NCT00603278|9684520|FG001|Overall Study|Lack of Efficacy|10
6078155|NCT00603278|9684521|FG002|Overall Study|Lack of Efficacy|11
6078156|NCT00603278|9684522|FG003|Overall Study|Lack of Efficacy|8
6078157|NCT00603278|9684523|FG004|Overall Study|Lack of Efficacy|7
6078158|NCT00603278|9684524|FG005|Overall Study|Lack of Efficacy|14
6078159|NCT00603278|9684519|FG000|Overall Study|Adverse Event|0
6078160|NCT00603278|9684520|FG001|Overall Study|Adverse Event|3
6078161|NCT00603278|9684521|FG002|Overall Study|Adverse Event|1
6023803|NCT00251316|9619246|FG000|Overall Study|Physician Decision|2
6023804|NCT00251316|9619247|FG001|Overall Study|Physician Decision|3
6023805|NCT00251589|9619257|FG000|Overall Study|Adverse Event|5
6023806|NCT00251589|9619258|FG001|Overall Study|Adverse Event|1
6023807|NCT00251589|9619259|FG002|Overall Study|Adverse Event|2
6023808|NCT00251589|9619260|FG003|Overall Study|Adverse Event|1
6078162|NCT00603278|9684522|FG003|Overall Study|Adverse Event|0
6023809|NCT00251589|9619257|FG000|Overall Study|Withdrawal by Subject|1
6023810|NCT00251589|9619258|FG001|Overall Study|Withdrawal by Subject|1
6023811|NCT00251589|9619259|FG002|Overall Study|Withdrawal by Subject|0
6023812|NCT00251589|9619260|FG003|Overall Study|Withdrawal by Subject|0
6023813|NCT00251589|9619257|FG000|Overall Study|Discontinued due to progressive disease|9
6023814|NCT00251589|9619258|FG001|Overall Study|Discontinued due to progressive disease|1
6078163|NCT00603278|9684523|FG004|Overall Study|Adverse Event|2
6023815|NCT00251589|9619259|FG002|Overall Study|Discontinued due to progressive disease|0
6023816|NCT00251589|9619260|FG003|Overall Study|Discontinued due to progressive disease|1
6023817|NCT00251641|9619272|FG000|Overall Study|Adverse Event|80
6023818|NCT00251641|9619273|FG001|Overall Study|Adverse Event|8
6023819|NCT00251641|9619272|FG000|Overall Study|Lack of Efficacy|2
6023820|NCT00251641|9619273|FG001|Overall Study|Lack of Efficacy|1
6023821|NCT00251641|9619272|FG000|Overall Study|Progression of Disease|0
6023822|NCT00251641|9619273|FG001|Overall Study|Progression of Disease|2
6023823|NCT00251641|9619272|FG000|Overall Study|Lost to Follow-up|3
6023824|NCT00251641|9619273|FG001|Overall Study|Lost to Follow-up|3
6023825|NCT00251641|9619272|FG000|Overall Study|Withdrawal by Subject|6
6023826|NCT00251641|9619273|FG001|Overall Study|Withdrawal by Subject|8
6023827|NCT00251641|9619272|FG000|Overall Study|Protocol Violation|10
6023828|NCT00251641|9619273|FG001|Overall Study|Protocol Violation|2
6023829|NCT00251641|9619272|FG000|Overall Study|Did not Meet protocol Eligibility|2
6023830|NCT00251641|9619273|FG001|Overall Study|Did not Meet protocol Eligibility|1
6023831|NCT00251641|9619272|FG000|Overall Study|Switched Treatment|9
6023832|NCT00251641|9619273|FG001|Overall Study|Switched Treatment|63
6023833|NCT00251693|9619284|FG000|Overall Study|Adverse Event|17
6023834|NCT00251693|9619285|FG001|Overall Study|Adverse Event|9
6023835|NCT00251693|9619286|FG002|Overall Study|Adverse Event|9
6023836|NCT00251693|9619284|FG000|Overall Study|Protocol Violation|2
6023837|NCT00251693|9619285|FG001|Overall Study|Protocol Violation|0
6078164|NCT00603278|9684524|FG005|Overall Study|Adverse Event|1
6078165|NCT00603278|9684519|FG000|Overall Study|Withdrawal by Subject|2
6078166|NCT00603278|9684520|FG001|Overall Study|Withdrawal by Subject|3
6078167|NCT00603278|9684521|FG002|Overall Study|Withdrawal by Subject|1
6078168|NCT00603278|9684522|FG003|Overall Study|Withdrawal by Subject|2
6078169|NCT00603278|9684523|FG004|Overall Study|Withdrawal by Subject|1
6078170|NCT00603278|9684524|FG005|Overall Study|Withdrawal by Subject|2
6078171|NCT00603278|9684519|FG000|Overall Study|Protocol Violation|3
6078172|NCT00603278|9684520|FG001|Overall Study|Protocol Violation|0
6078173|NCT00603278|9684521|FG002|Overall Study|Protocol Violation|1
6078174|NCT00603278|9684522|FG003|Overall Study|Protocol Violation|1
6078175|NCT00603278|9684523|FG004|Overall Study|Protocol Violation|0
6078176|NCT00603278|9684524|FG005|Overall Study|Protocol Violation|1
6078177|NCT00603278|9684519|FG000|Overall Study|Physician Decision|0
6078178|NCT00603278|9684520|FG001|Overall Study|Physician Decision|1
6078179|NCT00603278|9684521|FG002|Overall Study|Physician Decision|0
6078180|NCT00603278|9684522|FG003|Overall Study|Physician Decision|0
6078181|NCT00603278|9684523|FG004|Overall Study|Physician Decision|2
6078182|NCT00603278|9684524|FG005|Overall Study|Physician Decision|1
6078183|NCT00603278|9684519|FG000|Overall Study|Lost to Follow-up|1
6078184|NCT00603278|9684520|FG001|Overall Study|Lost to Follow-up|0
6078185|NCT00603278|9684521|FG002|Overall Study|Lost to Follow-up|0
6078186|NCT00603278|9684522|FG003|Overall Study|Lost to Follow-up|0
6078187|NCT00603278|9684523|FG004|Overall Study|Lost to Follow-up|1
6078188|NCT00603278|9684524|FG005|Overall Study|Lost to Follow-up|0
6078189|NCT00603304|9684553|FG000|Overall Study|Lost to Follow-up|5
6078190|NCT00603304|9684554|FG001|Overall Study|Lost to Follow-up|7
6078191|NCT00603304|9684553|FG000|Overall Study|Withdrawal by Subject|8
6078192|NCT00603304|9684554|FG001|Overall Study|Withdrawal by Subject|5
6078193|NCT00603304|9684553|FG000|Overall Study|Protocol Violation|1
6078194|NCT00603304|9684554|FG001|Overall Study|Protocol Violation|0
6078195|NCT00603304|9684553|FG000|Overall Study|Adverse Event|4
6078196|NCT00603304|9684554|FG001|Overall Study|Adverse Event|2
6078197|NCT00603304|9684553|FG000|Overall Study|Unacceptable Treatment Toxicity|5
6078198|NCT00603304|9684554|FG001|Overall Study|Unacceptable Treatment Toxicity|8
6078199|NCT00603304|9684553|FG000|Overall Study|Crossed Over to Open Label Therapy|3
6078200|NCT00603304|9684554|FG001|Overall Study|Crossed Over to Open Label Therapy|3
6078201|NCT00603304|9684553|FG000|Overall Study|Exclusionary Medication|2
6078202|NCT00603304|9684554|FG001|Overall Study|Exclusionary Medication|3
6078203|NCT00603304|9684553|FG000|Overall Study|Non-Compliant|0
6078204|NCT00603304|9684554|FG001|Overall Study|Non-Compliant|1
6078205|NCT00603304|9684553|FG000|Overall Study|Moved Away|0
6078206|NCT00603304|9684554|FG001|Overall Study|Moved Away|2
6078207|NCT00603304|9684553|FG000|Overall Study|Other|2
6078208|NCT00603304|9684554|FG001|Overall Study|Other|0
6078209|NCT00603304|9684553|FG000|Overall Study|Patient Decision|2
6078210|NCT00603304|9684554|FG001|Overall Study|Patient Decision|0
6078211|NCT00603382|9684568|FG000|Overall Study|Adverse Event|0
6078212|NCT00603382|9684569|FG001|Overall Study|Adverse Event|1
6078213|NCT00603382|9684570|FG002|Overall Study|Adverse Event|1
6023838|NCT00251693|9619286|FG002|Overall Study|Protocol Violation|2
6023839|NCT00251693|9619284|FG000|Overall Study|Lost to Follow-up|12
6078214|NCT00603382|9684571|FG003|Overall Study|Adverse Event|2
6023840|NCT00251693|9619285|FG001|Overall Study|Lost to Follow-up|7
6023841|NCT00251693|9619286|FG002|Overall Study|Lost to Follow-up|8
6023842|NCT00251693|9619284|FG000|Overall Study|Withdrawal by Subject|11
6023843|NCT00251693|9619285|FG001|Overall Study|Withdrawal by Subject|17
6078215|NCT00603382|9684572|FG004|Overall Study|Adverse Event|1
6078216|NCT00603382|9684573|FG005|Overall Study|Adverse Event|2
6078217|NCT00603382|9684568|FG000|Overall Study|Lack of Efficacy|14
6078218|NCT00603382|9684569|FG001|Overall Study|Lack of Efficacy|9
6078219|NCT00603382|9684570|FG002|Overall Study|Lack of Efficacy|3
6078220|NCT00603382|9684571|FG003|Overall Study|Lack of Efficacy|6
6023844|NCT00251693|9619286|FG002|Overall Study|Withdrawal by Subject|14
6023845|NCT00251693|9619284|FG000|Overall Study|Lack of Efficacy|0
6023846|NCT00251693|9619285|FG001|Overall Study|Lack of Efficacy|1
6023847|NCT00251693|9619286|FG002|Overall Study|Lack of Efficacy|0
6023848|NCT00251693|9619284|FG000|Overall Study|Inclusion/exclusion criteria not met|5
6023849|NCT00251693|9619285|FG001|Overall Study|Inclusion/exclusion criteria not met|3
6023850|NCT00251693|9619286|FG002|Overall Study|Inclusion/exclusion criteria not met|8
6023851|NCT00251693|9619284|FG000|Overall Study|Noncompliant|0
6023852|NCT00251693|9619285|FG001|Overall Study|Noncompliant|0
6023853|NCT00251693|9619286|FG002|Overall Study|Noncompliant|2
6023854|NCT00251693|9619284|FG000|Overall Study|Possible Barrett's esophagus|3
6023855|NCT00251693|9619285|FG001|Overall Study|Possible Barrett's esophagus|5
6023856|NCT00251693|9619286|FG002|Overall Study|Possible Barrett's esophagus|2
6023857|NCT00251693|9619284|FG000|Overall Study|Subject request/subject unavailable|1
6023858|NCT00251693|9619285|FG001|Overall Study|Subject request/subject unavailable|2
6023859|NCT00251693|9619286|FG002|Overall Study|Subject request/subject unavailable|0
6023860|NCT00251693|9619284|FG000|Overall Study|Abnormal laboratory findings|0
6023861|NCT00251693|9619285|FG001|Overall Study|Abnormal laboratory findings|0
6023862|NCT00251693|9619286|FG002|Overall Study|Abnormal laboratory findings|1
6023863|NCT00251719|9619297|FG000|Overall Study|Adverse Event|14
6023864|NCT00251719|9619298|FG001|Overall Study|Adverse Event|8
6023865|NCT00251719|9619299|FG002|Overall Study|Adverse Event|7
6023866|NCT00251719|9619297|FG000|Overall Study|Protocol Violation|1
6023867|NCT00251719|9619298|FG001|Overall Study|Protocol Violation|1
6023868|NCT00251719|9619299|FG002|Overall Study|Protocol Violation|1
6023869|NCT00251719|9619297|FG000|Overall Study|Lost to Follow-up|5
6023870|NCT00251719|9619298|FG001|Overall Study|Lost to Follow-up|11
6023871|NCT00251719|9619299|FG002|Overall Study|Lost to Follow-up|8
6023872|NCT00251719|9619297|FG000|Overall Study|Withdrawal by Subject|14
6023873|NCT00251719|9619298|FG001|Overall Study|Withdrawal by Subject|12
6078221|NCT00603382|9684572|FG004|Overall Study|Lack of Efficacy|6
6078222|NCT00603382|9684573|FG005|Overall Study|Lack of Efficacy|11
6078223|NCT00603382|9684568|FG000|Overall Study|Protocol Violation|1
6078224|NCT00603382|9684569|FG001|Overall Study|Protocol Violation|0
6078225|NCT00603382|9684570|FG002|Overall Study|Protocol Violation|1
6078226|NCT00603382|9684571|FG003|Overall Study|Protocol Violation|2
6078227|NCT00603382|9684572|FG004|Overall Study|Protocol Violation|1
6078228|NCT00603382|9684573|FG005|Overall Study|Protocol Violation|0
6078229|NCT00603382|9684568|FG000|Overall Study|Lost to Follow-up|0
6078230|NCT00603382|9684569|FG001|Overall Study|Lost to Follow-up|1
6078231|NCT00603382|9684570|FG002|Overall Study|Lost to Follow-up|1
6078232|NCT00603382|9684571|FG003|Overall Study|Lost to Follow-up|1
6078233|NCT00603382|9684572|FG004|Overall Study|Lost to Follow-up|0
6078234|NCT00603382|9684573|FG005|Overall Study|Lost to Follow-up|1
6078235|NCT00603382|9684568|FG000|Overall Study|Physician Decision|0
6078236|NCT00603382|9684569|FG001|Overall Study|Physician Decision|0
6078237|NCT00603382|9684570|FG002|Overall Study|Physician Decision|2
6078238|NCT00603382|9684571|FG003|Overall Study|Physician Decision|0
6078239|NCT00603382|9684572|FG004|Overall Study|Physician Decision|1
6078240|NCT00603382|9684573|FG005|Overall Study|Physician Decision|3
6078241|NCT00603382|9684568|FG000|Overall Study|Withdrawal by Subject|3
6078242|NCT00603382|9684569|FG001|Overall Study|Withdrawal by Subject|3
6078243|NCT00603382|9684570|FG002|Overall Study|Withdrawal by Subject|1
6078244|NCT00603382|9684571|FG003|Overall Study|Withdrawal by Subject|1
6078245|NCT00603382|9684572|FG004|Overall Study|Withdrawal by Subject|0
6078246|NCT00603382|9684573|FG005|Overall Study|Withdrawal by Subject|1
6078247|NCT00603447|9684599|FG000|Overall Study|Adverse Event|0
6078248|NCT00603447|9684600|FG001|Overall Study|Adverse Event|1
6078249|NCT00603447|9684601|FG002|Overall Study|Adverse Event|1
6078250|NCT00603447|9684602|FG003|Overall Study|Adverse Event|2
6078251|NCT00603447|9684603|FG004|Overall Study|Adverse Event|1
6078252|NCT00603447|9684604|FG005|Overall Study|Adverse Event|2
6078253|NCT00603447|9684605|FG006|Overall Study|Adverse Event|10
6078254|NCT00603447|9684599|FG000|Overall Study|Other|0
6078255|NCT00603447|9684600|FG001|Overall Study|Other|0
6078256|NCT00603447|9684601|FG002|Overall Study|Other|1
6078257|NCT00603447|9684602|FG003|Overall Study|Other|0
6078258|NCT00603447|9684603|FG004|Overall Study|Other|3
6078259|NCT00603447|9684604|FG005|Overall Study|Other|0
6078260|NCT00603447|9684605|FG006|Overall Study|Other|13
6078261|NCT00603447|9684599|FG000|Overall Study|Withdrew Consent|0
6078262|NCT00603447|9684600|FG001|Overall Study|Withdrew Consent|2
6078263|NCT00603447|9684601|FG002|Overall Study|Withdrew Consent|0
6023874|NCT00251719|9619299|FG002|Overall Study|Withdrawal by Subject|11
6023875|NCT00251719|9619297|FG000|Overall Study|Lack of Efficacy|2
6023876|NCT00251719|9619298|FG001|Overall Study|Lack of Efficacy|1
6023877|NCT00251719|9619299|FG002|Overall Study|Lack of Efficacy|0
6023878|NCT00251719|9619297|FG000|Overall Study|Inclusion/exclusion criteria not met|12
6023879|NCT00251719|9619298|FG001|Overall Study|Inclusion/exclusion criteria not met|6
6078264|NCT00603447|9684602|FG003|Overall Study|Withdrew Consent|0
6023880|NCT00251719|9619299|FG002|Overall Study|Inclusion/exclusion criteria not met|2
6078265|NCT00603447|9684603|FG004|Overall Study|Withdrew Consent|1
6078266|NCT00603447|9684604|FG005|Overall Study|Withdrew Consent|0
6078267|NCT00603447|9684605|FG006|Overall Study|Withdrew Consent|1
6078268|NCT00603473|9684621|FG000|Overall Study|Adverse Event|4
6023881|NCT00251719|9619297|FG000|Overall Study|Investigator decision|1
6023882|NCT00251719|9619298|FG001|Overall Study|Investigator decision|1
6023883|NCT00251719|9619299|FG002|Overall Study|Investigator decision|0
6023884|NCT00251719|9619297|FG000|Overall Study|Noncompliance|2
6023885|NCT00251719|9619298|FG001|Overall Study|Noncompliance|3
6023886|NCT00251719|9619299|FG002|Overall Study|Noncompliance|1
6023887|NCT00251719|9619297|FG000|Overall Study|Barrett's esophagus|2
6023888|NCT00251719|9619298|FG001|Overall Study|Barrett's esophagus|2
6023889|NCT00251719|9619299|FG002|Overall Study|Barrett's esophagus|0
6023890|NCT00251745|9619310|FG000|Overall Study|Adverse Event|7
6023891|NCT00251745|9619311|FG001|Overall Study|Adverse Event|9
6023892|NCT00251745|9619312|FG002|Overall Study|Adverse Event|11
6023893|NCT00251745|9619310|FG000|Overall Study|Lost to Follow-up|4
6023894|NCT00251745|9619311|FG001|Overall Study|Lost to Follow-up|2
6023895|NCT00251745|9619312|FG002|Overall Study|Lost to Follow-up|5
6023896|NCT00251745|9619310|FG000|Overall Study|Withdrawal by Subject|13
6023897|NCT00251745|9619311|FG001|Overall Study|Withdrawal by Subject|7
6023898|NCT00251745|9619312|FG002|Overall Study|Withdrawal by Subject|3
6023899|NCT00251745|9619310|FG000|Overall Study|Unmet Inclusion/Exclusion Criteria|0
6023900|NCT00251745|9619311|FG001|Overall Study|Unmet Inclusion/Exclusion Criteria|6
6023901|NCT00251745|9619312|FG002|Overall Study|Unmet Inclusion/Exclusion Criteria|5
6023902|NCT00251745|9619310|FG000|Overall Study|Lack of Efficacy|3
6023903|NCT00251745|9619311|FG001|Overall Study|Lack of Efficacy|0
6023904|NCT00251745|9619312|FG002|Overall Study|Lack of Efficacy|0
6023905|NCT00251745|9619310|FG000|Overall Study|Noncompliant|0
6023906|NCT00251745|9619311|FG001|Overall Study|Noncompliant|2
6023907|NCT00251745|9619312|FG002|Overall Study|Noncompliant|2
6023908|NCT00251745|9619310|FG000|Overall Study|Pregnancy|0
6023909|NCT00251745|9619311|FG001|Overall Study|Pregnancy|1
6023910|NCT00251745|9619312|FG002|Overall Study|Pregnancy|0
6023911|NCT00251745|9619310|FG000|Overall Study|Per Subject Request|0
6023912|NCT00251745|9619311|FG001|Overall Study|Per Subject Request|0
6023913|NCT00251745|9619312|FG002|Overall Study|Per Subject Request|1
6023914|NCT00251745|9619310|FG000|Overall Study|Per Investigator Request|1
6023915|NCT00251745|9619311|FG001|Overall Study|Per Investigator Request|0
6023916|NCT00251745|9619312|FG002|Overall Study|Per Investigator Request|0
6023917|NCT00251758|9619323|FG000|Overall Study|Adverse Event|7
6023918|NCT00251758|9619324|FG001|Overall Study|Adverse Event|9
6023919|NCT00251758|9619325|FG002|Overall Study|Adverse Event|11
6023920|NCT00251758|9619323|FG000|Overall Study|Lost to Follow-up|4
6023921|NCT00251758|9619324|FG001|Overall Study|Lost to Follow-up|2
6023922|NCT00251758|9619325|FG002|Overall Study|Lost to Follow-up|5
6023923|NCT00251758|9619323|FG000|Overall Study|Withdrawal by Subject|13
6023924|NCT00251758|9619324|FG001|Overall Study|Withdrawal by Subject|7
6023925|NCT00251758|9619325|FG002|Overall Study|Withdrawal by Subject|3
6023926|NCT00251758|9619323|FG000|Overall Study|Unmet Inclusion/Exclusion Criteria|0
6023927|NCT00251758|9619324|FG001|Overall Study|Unmet Inclusion/Exclusion Criteria|6
6023928|NCT00251758|9619325|FG002|Overall Study|Unmet Inclusion/Exclusion Criteria|5
6023929|NCT00251758|9619323|FG000|Overall Study|Lack of Efficacy|3
6023930|NCT00251758|9619324|FG001|Overall Study|Lack of Efficacy|0
6023931|NCT00251758|9619325|FG002|Overall Study|Lack of Efficacy|0
6023932|NCT00251758|9619323|FG000|Overall Study|Noncompliant|0
6023933|NCT00251758|9619324|FG001|Overall Study|Noncompliant|2
6023934|NCT00251758|9619325|FG002|Overall Study|Noncompliant|2
6023935|NCT00251758|9619323|FG000|Overall Study|Pregnancy|0
6023936|NCT00251758|9619324|FG001|Overall Study|Pregnancy|1
6023937|NCT00251758|9619325|FG002|Overall Study|Pregnancy|0
6023938|NCT00251758|9619323|FG000|Overall Study|Per Subject Request|0
6023939|NCT00251758|9619324|FG001|Overall Study|Per Subject Request|0
6023940|NCT00251758|9619325|FG002|Overall Study|Per Subject Request|1
6023941|NCT00251758|9619323|FG000|Overall Study|Per Investigator Request|1
6023942|NCT00251758|9619324|FG001|Overall Study|Per Investigator Request|0
6023943|NCT00251758|9619325|FG002|Overall Study|Per Investigator Request|0
6023944|NCT00251927|9619348|FG000|Overall Study|Adverse Event|3
6023945|NCT00251927|9619349|FG001|Overall Study|Adverse Event|15
6023946|NCT00251927|9619348|FG000|Overall Study|Lack of Efficacy|22
6023947|NCT00251927|9619349|FG001|Overall Study|Lack of Efficacy|16
6023948|NCT00251927|9619348|FG000|Overall Study|Lost to Follow-up|22
6023949|NCT00251927|9619349|FG001|Overall Study|Lost to Follow-up|8
6023950|NCT00251927|9619348|FG000|Overall Study|Protocol Violation|1
6023951|NCT00251927|9619349|FG001|Overall Study|Protocol Violation|2
6023952|NCT00251927|9619348|FG000|Overall Study|Pregnancy|2
6023953|NCT00251927|9619349|FG001|Overall Study|Pregnancy|0
6023954|NCT00251927|9619348|FG000|Overall Study|Withdrawal by Subject|40
6023955|NCT00251927|9619349|FG001|Overall Study|Withdrawal by Subject|25
6023956|NCT00251927|9619348|FG000|Overall Study|Study-specific discont. achieved|13
6023957|NCT00251927|9619349|FG001|Overall Study|Study-specific discont. achieved|2
6023958|NCT00251927|9619348|FG000|Overall Study|Study procedure non-compliance|5
6023959|NCT00251927|9619349|FG001|Overall Study|Study procedure non-compliance|6
6023960|NCT00251979|9619358|FG000|Overall Study|Protocol Violation|3
6023961|NCT00251979|9619359|FG001|Overall Study|Protocol Violation|5
6023962|NCT00251979|9619358|FG000|Overall Study|Adverse Event|11
6023963|NCT00251979|9619359|FG001|Overall Study|Adverse Event|17
6023964|NCT00251979|9619358|FG000|Overall Study|Withdrawal by Subject|13
6023965|NCT00251979|9619359|FG001|Overall Study|Withdrawal by Subject|7
6023966|NCT00251979|9619358|FG000|Overall Study|Lost to Follow-up|8
6023967|NCT00251979|9619359|FG001|Overall Study|Lost to Follow-up|6
6023968|NCT00251979|9619358|FG000|Overall Study|Death|3
6023969|NCT00251979|9619359|FG001|Overall Study|Death|5
6023970|NCT00252057|9619367|FG000|Overall Study|Withdrawal by Subject|2
6023971|NCT00252057|9619368|FG001|Overall Study|Withdrawal by Subject|5
6023972|NCT00252057|9619367|FG000|Overall Study|Death|1
6023973|NCT00252057|9619368|FG001|Overall Study|Death|2
6023974|NCT00252057|9619367|FG000|Overall Study|Participant previously enrolled|0
6023975|NCT00252057|9619368|FG001|Overall Study|Participant previously enrolled|1
6023976|NCT00252187|9619376|FG000|Overall Study|Adverse Event|3
6023977|NCT00252187|9619377|FG001|Overall Study|Adverse Event|1
6023978|NCT00252187|9619376|FG000|Overall Study|Withdrawal by Subject|1
6023979|NCT00252187|9619377|FG001|Overall Study|Withdrawal by Subject|0
6023980|NCT00252239|9619387|FG000|Overall Study|Withdrawal by Subject|1
6023981|NCT00252239|9619388|FG001|Overall Study|Withdrawal by Subject|0
6023982|NCT00252239|9619389|FG002|Overall Study|Withdrawal by Subject|0
6023983|NCT00252239|9619390|FG003|Overall Study|Withdrawal by Subject|1
6023984|NCT00252239|9619387|FG000|Overall Study|Lost to Follow-up|0
6023985|NCT00252239|9619388|FG001|Overall Study|Lost to Follow-up|0
6023986|NCT00252239|9619389|FG002|Overall Study|Lost to Follow-up|2
6023987|NCT00252239|9619390|FG003|Overall Study|Lost to Follow-up|0
6048137|NCT00415519|9647263|FG000|Overall Study|Adverse Event|1
6048138|NCT00415519|9647264|FG001|Overall Study|Adverse Event|0
6048139|NCT00415519|9647263|FG000|Overall Study|Withdrawal by Subject|2
6048140|NCT00415519|9647264|FG001|Overall Study|Withdrawal by Subject|0
6048141|NCT00415519|9647263|FG000|Overall Study|Patient's convenience|1
6048142|NCT00415519|9647264|FG001|Overall Study|Patient's convenience|0
6048143|NCT00415532|9647272|FG000|Treatment Period|Adverse Event|2
6048144|NCT00415532|9647273|FG001|Treatment Period|Adverse Event|3
6048145|NCT00415532|9647272|FG000|Treatment Period|Death|2
6048146|NCT00415532|9647273|FG001|Treatment Period|Death|1
6048147|NCT00415532|9647272|FG000|Treatment Period|Lost to Follow-up|1
6048148|NCT00415532|9647273|FG001|Treatment Period|Lost to Follow-up|1
6048149|NCT00415532|9647272|FG000|Treatment Period|Protocol Violation|1
6048150|NCT00415532|9647273|FG001|Treatment Period|Protocol Violation|0
6048151|NCT00415532|9647272|FG000|Treatment Period|Withdrawal by Subject|6
6048152|NCT00415532|9647273|FG001|Treatment Period|Withdrawal by Subject|6
6048153|NCT00415532|9647272|FG000|Treatment Period|Other|2
6048154|NCT00415532|9647273|FG001|Treatment Period|Other|2
6048155|NCT00415532|9647272|FG000|Treatment Period|Ineligibility determined|1
6048156|NCT00415532|9647273|FG001|Treatment Period|Ineligibility determined|1
6048157|NCT00415532|9647272|FG000|Treatment Period|Noncompliance|1
6048158|NCT00415532|9647273|FG001|Treatment Period|Noncompliance|1
6048159|NCT00415532|9647272|FG000|Treatment Period|Requirement for alternative therapy|1
6048160|NCT00415532|9647273|FG001|Treatment Period|Requirement for alternative therapy|0
6048161|NCT00415532|9647272|FG000|Safety Follow Up Period|Adverse Event|1
6048162|NCT00415532|9647273|FG001|Safety Follow Up Period|Adverse Event|3
6048163|NCT00415532|9647272|FG000|Safety Follow Up Period|Death|3
6048164|NCT00415532|9647273|FG001|Safety Follow Up Period|Death|0
6048165|NCT00415532|9647272|FG000|Safety Follow Up Period|Withdrawal by Subject|2
6048166|NCT00415532|9647273|FG001|Safety Follow Up Period|Withdrawal by Subject|3
6048167|NCT00415532|9647272|FG000|Safety Follow Up Period|Other|1
6048168|NCT00415532|9647273|FG001|Safety Follow Up Period|Other|4
6048169|NCT00415532|9647272|FG000|Safety Follow Up Period|Ineligibility determined|1
6048170|NCT00415532|9647273|FG001|Safety Follow Up Period|Ineligibility determined|1
6078269|NCT00603473|9684621|FG000|Overall Study|Lack of Efficacy|4
6078270|NCT00603473|9684621|FG000|Overall Study|Protocol Violation|1
6078271|NCT00603512|9684630|FG000|Overall Study|Adverse Event|0
6078272|NCT00603512|9684631|FG001|Overall Study|Adverse Event|2
6078273|NCT00603512|9684632|FG002|Overall Study|Adverse Event|4
6078274|NCT00603512|9684633|FG003|Overall Study|Adverse Event|4
6078275|NCT00603512|9684634|FG004|Overall Study|Adverse Event|2
6078276|NCT00603512|9684630|FG000|Overall Study|Lack of Efficacy|0
6078277|NCT00603512|9684631|FG001|Overall Study|Lack of Efficacy|1
6078278|NCT00603512|9684632|FG002|Overall Study|Lack of Efficacy|0
6078279|NCT00603512|9684633|FG003|Overall Study|Lack of Efficacy|0
6078280|NCT00603512|9684634|FG004|Overall Study|Lack of Efficacy|1
6078281|NCT00603512|9684630|FG000|Overall Study|Other|2
6078282|NCT00603512|9684631|FG001|Overall Study|Other|1
6078283|NCT00603512|9684632|FG002|Overall Study|Other|0
6078284|NCT00603512|9684633|FG003|Overall Study|Other|1
6048171|NCT00415532|9647272|FG000|Safety Follow Up Period|Noncompliance|1
6048172|NCT00415532|9647273|FG001|Safety Follow Up Period|Noncompliance|0
6048173|NCT00415532|9647272|FG000|Safety Follow Up Period|Requirement for alternative therapy|0
6048174|NCT00415532|9647273|FG001|Safety Follow Up Period|Requirement for alternative therapy|1
6048175|NCT00415597|9647279|FG000|Enrollment|Withdrawal by Subject|1
6048176|NCT00415597|9647279|FG000|Enrollment|Protocol Violation|1
6048177|NCT00415597|9647279|FG000|Treatment|Adverse Event|110
6048178|NCT00415597|9647279|FG000|Treatment|Lack of Efficacy|39
6048179|NCT00415597|9647279|FG000|Treatment|Protocol Violation|67
6048180|NCT00415597|9647279|FG000|Treatment|Physician Decision|3
6048181|NCT00415597|9647279|FG000|Treatment|Withdrawal by Subject|51
6048182|NCT00415597|9647279|FG000|Treatment|Lost to Follow-up|28
6078285|NCT00603512|9684634|FG004|Overall Study|Other|1
6023988|NCT00252499|9619407|FG000|Overall Study|Lost to Follow-up|1
6023989|NCT00252499|9619408|FG001|Overall Study|Lost to Follow-up|0
6023990|NCT00252499|9619409|FG002|Overall Study|Lost to Follow-up|0
6023991|NCT00252564|9619434|FG000|Overall Study|Adverse Event|17
6023992|NCT00252564|9619435|FG001|Overall Study|Adverse Event|13
6023993|NCT00252564|9619434|FG000|Overall Study|Unrelated Complication|2
6023994|NCT00252564|9619435|FG001|Overall Study|Unrelated Complication|1
6023995|NCT00252564|9619434|FG000|Overall Study|Disease Progression|14
6023996|NCT00252564|9619435|FG001|Overall Study|Disease Progression|20
6023997|NCT00252564|9619434|FG000|Overall Study|Death|0
6023998|NCT00252564|9619435|FG001|Overall Study|Death|3
6023999|NCT00252564|9619434|FG000|Overall Study|Physician Decision|1
6024000|NCT00252564|9619435|FG001|Overall Study|Physician Decision|0
6024001|NCT00252564|9619434|FG000|Overall Study|Lost to Follow-up|1
6024002|NCT00252564|9619435|FG001|Overall Study|Lost to Follow-up|0
6024003|NCT00252564|9619434|FG000|Overall Study|Patient Request|4
6024004|NCT00252564|9619435|FG001|Overall Study|Patient Request|5
6024005|NCT00252564|9619434|FG000|Overall Study|Withdrawal by Subject|0
6024006|NCT00252564|9619435|FG001|Overall Study|Withdrawal by Subject|2
6024007|NCT00252577|9619441|FG000|Overall Study|Lost to Follow-up|20
6024008|NCT00252694|9619478|FG000|Overall Study|Withdrawal by Subject|83
6024009|NCT00252694|9619479|FG001|Overall Study|Withdrawal by Subject|91
6024010|NCT00252694|9619478|FG000|Overall Study|Death|36
6024011|NCT00252694|9619479|FG001|Overall Study|Death|34
6024012|NCT00252694|9619478|FG000|Overall Study|Mostly Lost to Follow Up|8
6024013|NCT00252694|9619479|FG001|Overall Study|Mostly Lost to Follow Up|13
6024014|NCT00252694|9619478|FG000|Overall Study|Patient Moving|17
6024015|NCT00252694|9619479|FG001|Overall Study|Patient Moving|16
6024016|NCT00252720|9619487|FG000|Overall Study|Withdrawal by Subject|95
6024017|NCT00252720|9619488|FG001|Overall Study|Withdrawal by Subject|97
6024018|NCT00252720|9619487|FG000|Overall Study|Death|7
6024019|NCT00252720|9619488|FG001|Overall Study|Death|8
6024020|NCT00252720|9619487|FG000|Overall Study|Moving|23
6024021|NCT00252720|9619488|FG001|Overall Study|Moving|42
6024022|NCT00252720|9619487|FG000|Overall Study|Mainly patients lost to follow-up|7
6024023|NCT00252720|9619488|FG001|Overall Study|Mainly patients lost to follow-up|18
6024024|NCT00252733|9619496|FG000|Overall Study|Withdrawal by Subject|73
6024025|NCT00252733|9619497|FG001|Overall Study|Withdrawal by Subject|67
6024026|NCT00252733|9619496|FG000|Overall Study|Death|7
6024027|NCT00252733|9619497|FG001|Overall Study|Death|5
6024028|NCT00252733|9619496|FG000|Overall Study|Lost to Follow-up|12
6024029|NCT00252733|9619497|FG001|Overall Study|Lost to Follow-up|6
6024030|NCT00252733|9619496|FG000|Overall Study|Multiple Reasons|14
6024031|NCT00252733|9619497|FG001|Overall Study|Multiple Reasons|14
6024032|NCT00253370|9619525|FG000|Overall Study|Adverse Event|18
6024033|NCT00253370|9619525|FG000|Overall Study|Disease progression|13
6024034|NCT00253370|9619525|FG000|Overall Study|Death|2
6024035|NCT00253370|9619525|FG000|Overall Study|Withdrawal by Subject|6
6024036|NCT00253370|9619525|FG000|Overall Study|Non-protocol therapy|1
6024037|NCT00253370|9619525|FG000|Overall Study|Physician Decision|1
6024038|NCT00253370|9619525|FG000|Overall Study|Protocol Violation|1
6024039|NCT00253370|9619525|FG000|Overall Study|Abdominal pain due to disease|1
6024040|NCT00253448|9619539|FG000|Overall Study|Withdrawal by Subject|1
6024041|NCT00253630|9619547|FG000|Overall Study|ineligible|2
6024042|NCT00253643|9619555|FG000|Overall Study|Withdrawal by Subject|0
6024043|NCT00253643|9619556|FG001|Overall Study|Withdrawal by Subject|0
6024044|NCT00253643|9619557|FG002|Overall Study|Withdrawal by Subject|1
6024045|NCT00253643|9619558|FG003|Overall Study|Withdrawal by Subject|1
6024046|NCT00253643|9619555|FG000|Overall Study|Non-Compliance|0
6024047|NCT00253643|9619556|FG001|Overall Study|Non-Compliance|0
6024048|NCT00253643|9619557|FG002|Overall Study|Non-Compliance|0
6024049|NCT00253643|9619558|FG003|Overall Study|Non-Compliance|2
6024050|NCT00253747|9619583|FG000|Overall Study|Lost to Follow-up|13
6024051|NCT00253747|9619584|FG001|Overall Study|Lost to Follow-up|14
6024052|NCT00253747|9619583|FG000|Overall Study|Withdrawal by Subject|10
6024053|NCT00253747|9619584|FG001|Overall Study|Withdrawal by Subject|11
6024054|NCT00253747|9619583|FG000|Overall Study|Administrative Discharge (1), Other (2)|1
6024055|NCT00253747|9619584|FG001|Overall Study|Administrative Discharge (1), Other (2)|2
6024056|NCT00254163|9619620|FG000|Overall Study|Adverse Event|29
6024057|NCT00254163|9619621|FG001|Overall Study|Adverse Event|26
6024058|NCT00254163|9619620|FG000|Overall Study|Patient request/withdrew consent|6
6024059|NCT00254163|9619621|FG001|Overall Study|Patient request/withdrew consent|4
6024060|NCT00254163|9619620|FG000|Overall Study|Investigator request|1
6024061|NCT00254163|9619621|FG001|Overall Study|Investigator request|3
6024062|NCT00254163|9619620|FG000|Overall Study|Failed entry|1
6024063|NCT00254163|9619621|FG001|Overall Study|Failed entry|3
6024064|NCT00254163|9619620|FG000|Overall Study|Progressive disease|0
6024065|NCT00254163|9619621|FG001|Overall Study|Progressive disease|1
6024066|NCT00254163|9619620|FG000|Overall Study|Death|0
6024067|NCT00254163|9619621|FG001|Overall Study|Death|1
6024068|NCT00254163|9619620|FG000|Overall Study|Other|8
6024069|NCT00254163|9619621|FG001|Overall Study|Other|8
6024070|NCT00254293|9619633|FG000|Short Term (12 Week) Randomized Dosing|Adverse Event|0
6024071|NCT00254293|9619634|FG001|Short Term (12 Week) Randomized Dosing|Adverse Event|1
6024072|NCT00254293|9619635|FG002|Short Term (12 Week) Randomized Dosing|Adverse Event|0
6024073|NCT00254293|9619636|FG003|Short Term (12 Week) Randomized Dosing|Adverse Event|1
6024074|NCT00254293|9619637|FG004|Short Term (12 Week) Randomized Dosing|Adverse Event|0
6024075|NCT00254293|9619638|FG005|Short Term (12 Week) Randomized Dosing|Adverse Event|0
6024076|NCT00254293|9619639|FG006|Short Term (12 Week) Randomized Dosing|Adverse Event|0
6024077|NCT00254293|9619633|FG000|Short Term (12 Week) Randomized Dosing|Lost to Follow-up|0
6024078|NCT00254293|9619634|FG001|Short Term (12 Week) Randomized Dosing|Lost to Follow-up|0
6024079|NCT00254293|9619635|FG002|Short Term (12 Week) Randomized Dosing|Lost to Follow-up|1
6024080|NCT00254293|9619636|FG003|Short Term (12 Week) Randomized Dosing|Lost to Follow-up|0
6024081|NCT00254293|9619637|FG004|Short Term (12 Week) Randomized Dosing|Lost to Follow-up|0
6024082|NCT00254293|9619638|FG005|Short Term (12 Week) Randomized Dosing|Lost to Follow-up|0
6024083|NCT00254293|9619639|FG006|Short Term (12 Week) Randomized Dosing|Lost to Follow-up|0
6024084|NCT00254293|9619633|FG000|Short Term (12 Week) Randomized Dosing|poor/non-compliance by participant|0
6024085|NCT00254293|9619634|FG001|Short Term (12 Week) Randomized Dosing|poor/non-compliance by participant|0
6024086|NCT00254293|9619635|FG002|Short Term (12 Week) Randomized Dosing|poor/non-compliance by participant|2
6024087|NCT00254293|9619636|FG003|Short Term (12 Week) Randomized Dosing|poor/non-compliance by participant|0
6024088|NCT00254293|9619637|FG004|Short Term (12 Week) Randomized Dosing|poor/non-compliance by participant|0
6024089|NCT00254293|9619638|FG005|Short Term (12 Week) Randomized Dosing|poor/non-compliance by participant|0
6024090|NCT00254293|9619639|FG006|Short Term (12 Week) Randomized Dosing|poor/non-compliance by participant|0
6024091|NCT00254293|9619633|FG000|LTE Open Label Variable SC Dosing|Death|0
6024092|NCT00254293|9619634|FG001|LTE Open Label Variable SC Dosing|Death|0
6024093|NCT00254293|9619635|FG002|LTE Open Label Variable SC Dosing|Death|1
6024094|NCT00254293|9619636|FG003|LTE Open Label Variable SC Dosing|Death|0
6024095|NCT00254293|9619637|FG004|LTE Open Label Variable SC Dosing|Death|0
6024096|NCT00254293|9619638|FG005|LTE Open Label Variable SC Dosing|Death|0
6024097|NCT00254293|9619639|FG006|LTE Open Label Variable SC Dosing|Death|0
6024098|NCT00254293|9619633|FG000|LTE Open Label Variable SC Dosing|Adverse Event|1
6024099|NCT00254293|9619634|FG001|LTE Open Label Variable SC Dosing|Adverse Event|0
6024100|NCT00254293|9619635|FG002|LTE Open Label Variable SC Dosing|Adverse Event|2
6024101|NCT00254293|9619636|FG003|LTE Open Label Variable SC Dosing|Adverse Event|0
6024102|NCT00254293|9619637|FG004|LTE Open Label Variable SC Dosing|Adverse Event|1
6024103|NCT00254293|9619638|FG005|LTE Open Label Variable SC Dosing|Adverse Event|0
6024104|NCT00254293|9619639|FG006|LTE Open Label Variable SC Dosing|Adverse Event|0
6024105|NCT00254293|9619633|FG000|LTE Open Label Variable SC Dosing|Lack of Efficacy|2
6024106|NCT00254293|9619634|FG001|LTE Open Label Variable SC Dosing|Lack of Efficacy|0
6024107|NCT00254293|9619635|FG002|LTE Open Label Variable SC Dosing|Lack of Efficacy|2
6024108|NCT00254293|9619636|FG003|LTE Open Label Variable SC Dosing|Lack of Efficacy|0
6024109|NCT00254293|9619637|FG004|LTE Open Label Variable SC Dosing|Lack of Efficacy|1
6024110|NCT00254293|9619638|FG005|LTE Open Label Variable SC Dosing|Lack of Efficacy|0
6024111|NCT00254293|9619639|FG006|LTE Open Label Variable SC Dosing|Lack of Efficacy|0
6024112|NCT00254293|9619633|FG000|LTE Open Label Variable SC Dosing|Lost to Follow-up|0
6024113|NCT00254293|9619634|FG001|LTE Open Label Variable SC Dosing|Lost to Follow-up|0
6024114|NCT00254293|9619635|FG002|LTE Open Label Variable SC Dosing|Lost to Follow-up|1
6024115|NCT00254293|9619636|FG003|LTE Open Label Variable SC Dosing|Lost to Follow-up|0
6024116|NCT00254293|9619637|FG004|LTE Open Label Variable SC Dosing|Lost to Follow-up|0
6024117|NCT00254293|9619638|FG005|LTE Open Label Variable SC Dosing|Lost to Follow-up|0
6024118|NCT00254293|9619639|FG006|LTE Open Label Variable SC Dosing|Lost to Follow-up|0
6024119|NCT00254293|9619633|FG000|LTE Open Label Variable SC Dosing|Withdrawal by Subject|0
6024120|NCT00254293|9619634|FG001|LTE Open Label Variable SC Dosing|Withdrawal by Subject|0
6024121|NCT00254293|9619635|FG002|LTE Open Label Variable SC Dosing|Withdrawal by Subject|1
6024122|NCT00254293|9619636|FG003|LTE Open Label Variable SC Dosing|Withdrawal by Subject|0
6024123|NCT00254293|9619637|FG004|LTE Open Label Variable SC Dosing|Withdrawal by Subject|0
6024124|NCT00254293|9619638|FG005|LTE Open Label Variable SC Dosing|Withdrawal by Subject|0
6078286|NCT00603512|9684630|FG000|Overall Study|Withdrawal by Subject|0
6078287|NCT00603512|9684631|FG001|Overall Study|Withdrawal by Subject|0
6078288|NCT00603512|9684632|FG002|Overall Study|Withdrawal by Subject|0
6078289|NCT00603512|9684633|FG003|Overall Study|Withdrawal by Subject|0
6078290|NCT00603512|9684634|FG004|Overall Study|Withdrawal by Subject|1
6078291|NCT00603512|9684630|FG000|Overall Study|Randomized but not treated|0
6078292|NCT00603512|9684631|FG001|Overall Study|Randomized but not treated|1
6024125|NCT00254293|9619639|FG006|LTE Open Label Variable SC Dosing|Withdrawal by Subject|0
6024126|NCT00254293|9619633|FG000|LTE Open Label Variable SC Dosing|Poor or non-compliance|0
6024127|NCT00254293|9619634|FG001|LTE Open Label Variable SC Dosing|Poor or non-compliance|0
6024128|NCT00254293|9619635|FG002|LTE Open Label Variable SC Dosing|Poor or non-compliance|1
6024129|NCT00254293|9619636|FG003|LTE Open Label Variable SC Dosing|Poor or non-compliance|0
6024130|NCT00254293|9619637|FG004|LTE Open Label Variable SC Dosing|Poor or non-compliance|0
6024131|NCT00254293|9619638|FG005|LTE Open Label Variable SC Dosing|Poor or non-compliance|0
6024132|NCT00254293|9619639|FG006|LTE Open Label Variable SC Dosing|Poor or non-compliance|0
6024133|NCT00254293|9619633|FG000|LTE Open Label Variable SC Dosing|Other|0
6024134|NCT00254293|9619634|FG001|LTE Open Label Variable SC Dosing|Other|0
6024135|NCT00254293|9619635|FG002|LTE Open Label Variable SC Dosing|Other|2
6024136|NCT00254293|9619636|FG003|LTE Open Label Variable SC Dosing|Other|0
6024137|NCT00254293|9619637|FG004|LTE Open Label Variable SC Dosing|Other|0
6024138|NCT00254293|9619638|FG005|LTE Open Label Variable SC Dosing|Other|0
6024139|NCT00254293|9619639|FG006|LTE Open Label Variable SC Dosing|Other|0
6024140|NCT00254293|9619633|FG000|LTE Open Label Fixed Dosing|Death|0
6024141|NCT00254293|9619634|FG001|LTE Open Label Fixed Dosing|Death|0
6024142|NCT00254293|9619635|FG002|LTE Open Label Fixed Dosing|Death|0
6024143|NCT00254293|9619636|FG003|LTE Open Label Fixed Dosing|Death|0
6024144|NCT00254293|9619637|FG004|LTE Open Label Fixed Dosing|Death|0
6024145|NCT00254293|9619638|FG005|LTE Open Label Fixed Dosing|Death|0
6024146|NCT00254293|9619639|FG006|LTE Open Label Fixed Dosing|Death|3
6024147|NCT00254293|9619633|FG000|LTE Open Label Fixed Dosing|Adverse Event|0
6024148|NCT00254293|9619634|FG001|LTE Open Label Fixed Dosing|Adverse Event|0
6024149|NCT00254293|9619635|FG002|LTE Open Label Fixed Dosing|Adverse Event|0
6024150|NCT00254293|9619636|FG003|LTE Open Label Fixed Dosing|Adverse Event|0
6024151|NCT00254293|9619637|FG004|LTE Open Label Fixed Dosing|Adverse Event|0
6024152|NCT00254293|9619638|FG005|LTE Open Label Fixed Dosing|Adverse Event|0
6024153|NCT00254293|9619639|FG006|LTE Open Label Fixed Dosing|Adverse Event|1
6024154|NCT00254293|9619633|FG000|LTE Open Label Fixed Dosing|Lack of Efficacy|0
6024155|NCT00254293|9619634|FG001|LTE Open Label Fixed Dosing|Lack of Efficacy|0
6024156|NCT00254293|9619635|FG002|LTE Open Label Fixed Dosing|Lack of Efficacy|0
6024157|NCT00254293|9619636|FG003|LTE Open Label Fixed Dosing|Lack of Efficacy|0
6024158|NCT00254293|9619637|FG004|LTE Open Label Fixed Dosing|Lack of Efficacy|0
6024159|NCT00254293|9619638|FG005|LTE Open Label Fixed Dosing|Lack of Efficacy|0
6024160|NCT00254293|9619639|FG006|LTE Open Label Fixed Dosing|Lack of Efficacy|3
6024161|NCT00254293|9619633|FG000|LTE Open Label Fixed Dosing|Lost to Follow-up|0
6078293|NCT00603512|9684632|FG002|Overall Study|Randomized but not treated|1
6078294|NCT00603512|9684633|FG003|Overall Study|Randomized but not treated|2
6078295|NCT00603512|9684634|FG004|Overall Study|Randomized but not treated|0
6078296|NCT00603525|9684648|FG000|DB Treatment Period (24 Weeks)|Adverse Event|3
6078297|NCT00603525|9684649|FG001|DB Treatment Period (24 Weeks)|Adverse Event|9
6078298|NCT00603525|9684650|FG002|DB Treatment Period (24 Weeks)|Adverse Event|0
6078299|NCT00603525|9684648|FG000|DB Treatment Period (24 Weeks)|Lack of Efficacy|7
6078300|NCT00603525|9684649|FG001|DB Treatment Period (24 Weeks)|Lack of Efficacy|0
6078301|NCT00603525|9684650|FG002|DB Treatment Period (24 Weeks)|Lack of Efficacy|0
6078302|NCT00603525|9684648|FG000|DB Treatment Period (24 Weeks)|Protocol Violation|1
6078303|NCT00603525|9684649|FG001|DB Treatment Period (24 Weeks)|Protocol Violation|2
6078304|NCT00603525|9684650|FG002|DB Treatment Period (24 Weeks)|Protocol Violation|0
6078305|NCT00603525|9684648|FG000|DB Treatment Period (24 Weeks)|Lost to Follow-up|1
6078306|NCT00603525|9684649|FG001|DB Treatment Period (24 Weeks)|Lost to Follow-up|3
6078307|NCT00603525|9684650|FG002|DB Treatment Period (24 Weeks)|Lost to Follow-up|0
6078308|NCT00603525|9684648|FG000|DB Treatment Period (24 Weeks)|Withdrawal by Subject|5
6078309|NCT00603525|9684649|FG001|DB Treatment Period (24 Weeks)|Withdrawal by Subject|6
6078310|NCT00603525|9684650|FG002|DB Treatment Period (24 Weeks)|Withdrawal by Subject|0
6078311|NCT00603525|9684648|FG000|DB Treatment Period (24 Weeks)|Physician Decision|0
6078312|NCT00603525|9684649|FG001|DB Treatment Period (24 Weeks)|Physician Decision|1
6078313|NCT00603525|9684650|FG002|DB Treatment Period (24 Weeks)|Physician Decision|0
6078314|NCT00603525|9684648|FG000|DB Treatment Period (24 Weeks)|Participant Met Stopping Criteria|0
6078315|NCT00603525|9684649|FG001|DB Treatment Period (24 Weeks)|Participant Met Stopping Criteria|1
6078316|NCT00603525|9684650|FG002|DB Treatment Period (24 Weeks)|Participant Met Stopping Criteria|0
6078317|NCT00603525|9684648|FG000|OL Treatment Period (120 Weeks)|Adverse Event|0
6078318|NCT00603525|9684649|FG001|OL Treatment Period (120 Weeks)|Adverse Event|12
6078319|NCT00603525|9684650|FG002|OL Treatment Period (120 Weeks)|Adverse Event|0
6078320|NCT00603525|9684648|FG000|OL Treatment Period (120 Weeks)|Lack of Efficacy|0
6078321|NCT00603525|9684649|FG001|OL Treatment Period (120 Weeks)|Lack of Efficacy|13
6078322|NCT00603525|9684650|FG002|OL Treatment Period (120 Weeks)|Lack of Efficacy|0
6078323|NCT00603525|9684648|FG000|OL Treatment Period (120 Weeks)|Protocol Violation|0
6078324|NCT00603525|9684649|FG001|OL Treatment Period (120 Weeks)|Protocol Violation|1
6078325|NCT00603525|9684650|FG002|OL Treatment Period (120 Weeks)|Protocol Violation|0
6078326|NCT00603525|9684648|FG000|OL Treatment Period (120 Weeks)|Protocol-defined Stopping Criteria Met|0
6078327|NCT00603525|9684649|FG001|OL Treatment Period (120 Weeks)|Protocol-defined Stopping Criteria Met|5
6078328|NCT00603525|9684650|FG002|OL Treatment Period (120 Weeks)|Protocol-defined Stopping Criteria Met|0
6078329|NCT00603525|9684648|FG000|OL Treatment Period (120 Weeks)|Study Closed/Terminated|0
6078330|NCT00603525|9684649|FG001|OL Treatment Period (120 Weeks)|Study Closed/Terminated|71
6078331|NCT00603525|9684650|FG002|OL Treatment Period (120 Weeks)|Study Closed/Terminated|0
6078332|NCT00603525|9684648|FG000|OL Treatment Period (120 Weeks)|Physician Decision|0
6078333|NCT00603525|9684649|FG001|OL Treatment Period (120 Weeks)|Physician Decision|2
6078334|NCT00603525|9684650|FG002|OL Treatment Period (120 Weeks)|Physician Decision|0
6078335|NCT00603525|9684648|FG000|OL Treatment Period (120 Weeks)|Withdrawal by Subject|0
6078336|NCT00603525|9684649|FG001|OL Treatment Period (120 Weeks)|Withdrawal by Subject|8
6078337|NCT00603525|9684650|FG002|OL Treatment Period (120 Weeks)|Withdrawal by Subject|0
6078338|NCT00603525|9684648|FG000|Follow-up Period (Approximately 2 Years)|Unknown Reason for Withdrawal|0
6078339|NCT00603525|9684649|FG001|Follow-up Period (Approximately 2 Years)|Unknown Reason for Withdrawal|0
6024162|NCT00254293|9619634|FG001|LTE Open Label Fixed Dosing|Lost to Follow-up|0
6024163|NCT00254293|9619635|FG002|LTE Open Label Fixed Dosing|Lost to Follow-up|0
6024164|NCT00254293|9619636|FG003|LTE Open Label Fixed Dosing|Lost to Follow-up|0
6024165|NCT00254293|9619637|FG004|LTE Open Label Fixed Dosing|Lost to Follow-up|0
6024166|NCT00254293|9619638|FG005|LTE Open Label Fixed Dosing|Lost to Follow-up|0
6024167|NCT00254293|9619639|FG006|LTE Open Label Fixed Dosing|Lost to Follow-up|1
6024168|NCT00254293|9619633|FG000|LTE Open Label Fixed Dosing|Withdrawal by Subject|0
6024169|NCT00254293|9619634|FG001|LTE Open Label Fixed Dosing|Withdrawal by Subject|0
6024170|NCT00254293|9619635|FG002|LTE Open Label Fixed Dosing|Withdrawal by Subject|0
6024171|NCT00254293|9619636|FG003|LTE Open Label Fixed Dosing|Withdrawal by Subject|0
6024172|NCT00254293|9619637|FG004|LTE Open Label Fixed Dosing|Withdrawal by Subject|0
6024173|NCT00254293|9619638|FG005|LTE Open Label Fixed Dosing|Withdrawal by Subject|0
6024174|NCT00254293|9619639|FG006|LTE Open Label Fixed Dosing|Withdrawal by Subject|3
6024175|NCT00254293|9619633|FG000|LTE Open Label Fixed Dosing|Poor or non-compliance|0
6024176|NCT00254293|9619634|FG001|LTE Open Label Fixed Dosing|Poor or non-compliance|0
6024177|NCT00254293|9619635|FG002|LTE Open Label Fixed Dosing|Poor or non-compliance|0
6024178|NCT00254293|9619636|FG003|LTE Open Label Fixed Dosing|Poor or non-compliance|0
6024179|NCT00254293|9619637|FG004|LTE Open Label Fixed Dosing|Poor or non-compliance|0
6024180|NCT00254293|9619638|FG005|LTE Open Label Fixed Dosing|Poor or non-compliance|0
6024181|NCT00254293|9619639|FG006|LTE Open Label Fixed Dosing|Poor or non-compliance|1
6024182|NCT00254293|9619633|FG000|LTE Open Label Fixed Dosing|Other|0
6024183|NCT00254293|9619634|FG001|LTE Open Label Fixed Dosing|Other|0
6024184|NCT00254293|9619635|FG002|LTE Open Label Fixed Dosing|Other|0
6024185|NCT00254293|9619636|FG003|LTE Open Label Fixed Dosing|Other|0
6024186|NCT00254293|9619637|FG004|LTE Open Label Fixed Dosing|Other|0
6024187|NCT00254293|9619638|FG005|LTE Open Label Fixed Dosing|Other|0
6024188|NCT00254293|9619639|FG006|LTE Open Label Fixed Dosing|Other|1
6024189|NCT00254397|9619686|FG000|Overall Study|Disease Progression|4
6024190|NCT00254397|9619687|FG001|Overall Study|Disease Progression|1
6024191|NCT00254397|9619688|FG002|Overall Study|Disease Progression|16
6024192|NCT00254397|9619689|FG003|Overall Study|Disease Progression|23
6024193|NCT00254397|9619686|FG000|Overall Study|Non-Compliant|0
6024194|NCT00254397|9619687|FG001|Overall Study|Non-Compliant|0
6024195|NCT00254397|9619688|FG002|Overall Study|Non-Compliant|0
6024196|NCT00254397|9619689|FG003|Overall Study|Non-Compliant|1
6024197|NCT00254397|9619686|FG000|Overall Study|Adverse Event|2
6024198|NCT00254397|9619687|FG001|Overall Study|Adverse Event|0
6024199|NCT00254397|9619688|FG002|Overall Study|Adverse Event|3
6024200|NCT00254397|9619689|FG003|Overall Study|Adverse Event|1
6024201|NCT00254501|9619724|FG000|Overall Study|Lost to Follow-up|1
6024202|NCT00254501|9619725|FG001|Overall Study|Lost to Follow-up|1
6024203|NCT00254540|9619735|FG000|Overall Study|Adverse Event|6
6024204|NCT00254540|9619736|FG001|Overall Study|Adverse Event|7
6024205|NCT00254540|9619735|FG000|Overall Study|Lack of Efficacy|13
6024206|NCT00254540|9619736|FG001|Overall Study|Lack of Efficacy|13
6024207|NCT00254540|9619735|FG000|Overall Study|Death|0
6024208|NCT00254540|9619736|FG001|Overall Study|Death|1
6024209|NCT00254540|9619735|FG000|Overall Study|Laboratory Test Abnormality|0
6024210|NCT00254540|9619736|FG001|Overall Study|Laboratory Test Abnormality|1
6024211|NCT00254566|9619745|FG000|Overall Study|Death|1
6024212|NCT00254566|9619746|FG001|Overall Study|Death|0
6024213|NCT00254566|9619745|FG000|Overall Study|Adverse Event|5
6024214|NCT00254566|9619746|FG001|Overall Study|Adverse Event|4
6024215|NCT00254566|9619745|FG000|Overall Study|Lack of Efficacy|12
6024216|NCT00254566|9619746|FG001|Overall Study|Lack of Efficacy|9
6024217|NCT00254566|9619745|FG000|Overall Study|Other|1
6024218|NCT00254566|9619746|FG001|Overall Study|Other|5
6024219|NCT00254566|9619745|FG000|Overall Study|Withdrawal by Subject|5
6024220|NCT00254566|9619746|FG001|Overall Study|Withdrawal by Subject|6
6024221|NCT00254566|9619745|FG000|Overall Study|Lost to Follow-up|7
6024222|NCT00254566|9619746|FG001|Overall Study|Lost to Follow-up|2
6024223|NCT00254982|9619758|FG000|Overall Study|Other|2
6024224|NCT00254982|9619759|FG001|Overall Study|Other|1
6024225|NCT00254982|9619758|FG000|Overall Study|Lack of Efficacy|5
6024226|NCT00254982|9619759|FG001|Overall Study|Lack of Efficacy|3
6024227|NCT00254982|9619758|FG000|Overall Study|Lost to Follow-up|5
6024228|NCT00254982|9619759|FG001|Overall Study|Lost to Follow-up|3
6024229|NCT00254982|9619758|FG000|Overall Study|Adverse Event|18
6024230|NCT00254982|9619759|FG001|Overall Study|Adverse Event|16
6024231|NCT00254982|9619758|FG000|Overall Study|Withdrawal by Subject|1
6024232|NCT00254982|9619759|FG001|Overall Study|Withdrawal by Subject|1
6024233|NCT00254982|9619758|FG000|Overall Study|Inclusion/exclusion criteria violation|0
6024234|NCT00254982|9619759|FG001|Overall Study|Inclusion/exclusion criteria violation|2
6078340|NCT00603525|9684650|FG002|Follow-up Period (Approximately 2 Years)|Unknown Reason for Withdrawal|111
6078341|NCT00603538|9684664|FG000|Overall Study|Adverse Event|0
6078342|NCT00603538|9684665|FG001|Overall Study|Adverse Event|4
6078343|NCT00603538|9684666|FG002|Overall Study|Adverse Event|2
6024235|NCT00254982|9619758|FG000|Overall Study|Protocol deviation|1
6024236|NCT00254982|9619759|FG001|Overall Study|Protocol deviation|1
6024237|NCT00254982|9619758|FG000|Overall Study|Diagnosis of Tuberculosis|1
6024238|NCT00254982|9619759|FG001|Overall Study|Diagnosis of Tuberculosis|1
6024239|NCT00254982|9619758|FG000|Overall Study|Malignancy|0
6024240|NCT00254982|9619759|FG001|Overall Study|Malignancy|2
6024241|NCT00254982|9619758|FG000|Overall Study|Opportunistic infection|1
6024242|NCT00254982|9619759|FG001|Overall Study|Opportunistic infection|0
6024243|NCT00254982|9619758|FG000|Overall Study|Abnormal liver function tests|2
6024244|NCT00254982|9619759|FG001|Overall Study|Abnormal liver function tests|1
6024245|NCT00255008|9619780|FG000|Overall Study|Adverse Event|1
6024246|NCT00255008|9619781|FG001|Overall Study|Adverse Event|1
6024247|NCT00255008|9619782|FG002|Overall Study|Adverse Event|2
6024248|NCT00255008|9619783|FG003|Overall Study|Adverse Event|0
6024249|NCT00255008|9619780|FG000|Overall Study|Lost to Follow-up|1
6024250|NCT00255008|9619781|FG001|Overall Study|Lost to Follow-up|0
6024251|NCT00255008|9619782|FG002|Overall Study|Lost to Follow-up|1
6024252|NCT00255008|9619783|FG003|Overall Study|Lost to Follow-up|2
6024253|NCT00255008|9619780|FG000|Overall Study|Did not meet viral reduction criteria|4
6024254|NCT00255008|9619781|FG001|Overall Study|Did not meet viral reduction criteria|5
6024255|NCT00255008|9619782|FG002|Overall Study|Did not meet viral reduction criteria|0
6024256|NCT00255008|9619783|FG003|Overall Study|Did not meet viral reduction criteria|1
6024257|NCT00255008|9619780|FG000|Overall Study|Withdrew consent|0
6078344|NCT00603538|9684664|FG000|Overall Study|Objective progression or relapse|3
6078345|NCT00603538|9684665|FG001|Overall Study|Objective progression or relapse|0
6078346|NCT00603538|9684666|FG002|Overall Study|Objective progression or relapse|0
6078347|NCT00603590|9684688|FG000|Overall Study|Did not attend study clinic|39
6078348|NCT00603590|9684689|FG001|Overall Study|Did not attend study clinic|30
6078349|NCT00603590|9684688|FG000|Overall Study|Refused blood test|5
6078350|NCT00603590|9684689|FG001|Overall Study|Refused blood test|1
6078351|NCT00603590|9684688|FG000|Overall Study|Patient discontinued study drug|22
6078352|NCT00603590|9684689|FG001|Overall Study|Patient discontinued study drug|15
6078353|NCT00603590|9684688|FG000|Overall Study|Adverse Event|2
6078354|NCT00603590|9684689|FG001|Overall Study|Adverse Event|0
6078355|NCT00603590|9684688|FG000|Overall Study|Lost to Follow-up|8
6078356|NCT00603590|9684689|FG001|Overall Study|Lost to Follow-up|4
6078357|NCT00603590|9684688|FG000|Overall Study|Cardiovascular event|0
6078358|NCT00603590|9684689|FG001|Overall Study|Cardiovascular event|1
6078359|NCT00603733|9684727|FG000|Active Phase ITT|Adverse Event|8
6078360|NCT00603733|9684728|FG001|Active Phase ITT|Adverse Event|7
6078361|NCT00603733|9684727|FG000|Active Phase ITT|Withdrawal by Subject|0
6078362|NCT00603733|9684728|FG001|Active Phase ITT|Withdrawal by Subject|3
6078363|NCT00603733|9684727|FG000|Active Phase ITT|Lost to Follow-up|0
6078364|NCT00603733|9684728|FG001|Active Phase ITT|Lost to Follow-up|1
6078365|NCT00603733|9684727|FG000|Active Phase ITT|Did not meet inclusion/exclusion|1
6078366|NCT00603733|9684728|FG001|Active Phase ITT|Did not meet inclusion/exclusion|3
6078367|NCT00603733|9684727|FG000|Active Phase ITT|Lack of Efficacy|1
6078368|NCT00603733|9684728|FG001|Active Phase ITT|Lack of Efficacy|2
6078369|NCT00603733|9684727|FG000|Active Phase ITT|Subject moved, site closed|1
6078370|NCT00603733|9684728|FG001|Active Phase ITT|Subject moved, site closed|1
6078371|NCT00603733|9684727|FG000|Run-In Phase - 4 Weeks|Adverse Event|2
6078372|NCT00603733|9684728|FG001|Run-In Phase - 4 Weeks|Adverse Event|1
6078373|NCT00603733|9684727|FG000|Run-In Phase - 4 Weeks|Withdrawal by Subject|4
6078374|NCT00603733|9684728|FG001|Run-In Phase - 4 Weeks|Withdrawal by Subject|1
6078375|NCT00603733|9684727|FG000|Run-In Phase - 4 Weeks|Lost to Follow-up|1
6078376|NCT00603733|9684728|FG001|Run-In Phase - 4 Weeks|Lost to Follow-up|0
6078377|NCT00603733|9684727|FG000|Run-In Phase - 4 Weeks|Did not meet incl/excl criteria|5
6078378|NCT00603733|9684728|FG001|Run-In Phase - 4 Weeks|Did not meet incl/excl criteria|10
6078379|NCT00603733|9684727|FG000|Run-In Phase - 4 Weeks|Lack of Efficacy|2
6078380|NCT00603733|9684728|FG001|Run-In Phase - 4 Weeks|Lack of Efficacy|1
6078381|NCT00603733|9684727|FG000|Maintenance Phase ITT|Adverse Event|3
6078382|NCT00603733|9684728|FG001|Maintenance Phase ITT|Adverse Event|6
6078383|NCT00603733|9684727|FG000|Maintenance Phase ITT|Withdrawal by Subject|1
6078384|NCT00603733|9684728|FG001|Maintenance Phase ITT|Withdrawal by Subject|0
6078385|NCT00603733|9684727|FG000|Maintenance Phase ITT|Protocol Violation|1
6078386|NCT00603733|9684728|FG001|Maintenance Phase ITT|Protocol Violation|1
6078387|NCT00603733|9684727|FG000|Maintenance Phase ITT|Lost to Follow-up|0
6078388|NCT00603733|9684728|FG001|Maintenance Phase ITT|Lost to Follow-up|1
6078389|NCT00603733|9684727|FG000|Maintenance Phase ITT|Lack of Efficacy|2
6078390|NCT00603733|9684728|FG001|Maintenance Phase ITT|Lack of Efficacy|2
6078391|NCT00603733|9684727|FG000|Maintenance Phase ITT|Physician Decision|0
6078392|NCT00603733|9684728|FG001|Maintenance Phase ITT|Physician Decision|1
6078393|NCT00603733|9684727|FG000|Maintenance Phase ITT|Site withdrew, subject away, lost IMP|3
6078394|NCT00603733|9684728|FG001|Maintenance Phase ITT|Site withdrew, subject away, lost IMP|5
6078395|NCT00603746|9684740|FG000|Overall Study|Adverse Event|2
6078396|NCT00603746|9684741|FG001|Overall Study|Adverse Event|3
6078397|NCT00603746|9684742|FG002|Overall Study|Adverse Event|0
6078398|NCT00603746|9684743|FG003|Overall Study|Adverse Event|1
6078399|NCT00603746|9684744|FG004|Overall Study|Adverse Event|0
6078400|NCT00603746|9684745|FG005|Overall Study|Adverse Event|4
6078401|NCT00603746|9684740|FG000|Overall Study|Lack of Efficacy|34
6078402|NCT00603746|9684741|FG001|Overall Study|Lack of Efficacy|11
6078403|NCT00603746|9684742|FG002|Overall Study|Lack of Efficacy|6
6078404|NCT00603746|9684743|FG003|Overall Study|Lack of Efficacy|11
6078405|NCT00603746|9684744|FG004|Overall Study|Lack of Efficacy|12
6078406|NCT00603746|9684745|FG005|Overall Study|Lack of Efficacy|8
6078407|NCT00603746|9684740|FG000|Overall Study|Protocol Violation|0
6078408|NCT00603746|9684741|FG001|Overall Study|Protocol Violation|3
6024258|NCT00255008|9619781|FG001|Overall Study|Withdrew consent|0
6024259|NCT00255008|9619782|FG002|Overall Study|Withdrew consent|2
6024260|NCT00255008|9619783|FG003|Overall Study|Withdrew consent|0
6024261|NCT00255008|9619780|FG000|Overall Study|Sponsor request|18
6024262|NCT00255008|9619781|FG001|Overall Study|Sponsor request|3
6024263|NCT00255008|9619782|FG002|Overall Study|Sponsor request|8
6024264|NCT00255008|9619783|FG003|Overall Study|Sponsor request|17
6024265|NCT00255008|9619780|FG000|Overall Study|Adverse lab experience|1
6024266|NCT00255008|9619781|FG001|Overall Study|Adverse lab experience|0
6024267|NCT00255008|9619782|FG002|Overall Study|Adverse lab experience|0
6024268|NCT00255008|9619783|FG003|Overall Study|Adverse lab experience|0
6024269|NCT00255008|9619780|FG000|Overall Study|Other|7
6024270|NCT00255008|9619781|FG001|Overall Study|Other|0
6024271|NCT00255008|9619782|FG002|Overall Study|Other|3
6024272|NCT00255008|9619783|FG003|Overall Study|Other|2
6024273|NCT00255034|9619795|FG000|Overall Study|Withdrawal by Subject|15
6024274|NCT00255034|9619796|FG001|Overall Study|Withdrawal by Subject|38
6024275|NCT00255047|9619806|FG000|Overall Study|Serious Adverse Events|2
6024276|NCT00255047|9619807|FG001|Overall Study|Serious Adverse Events|1
6024277|NCT00255047|9619808|FG002|Overall Study|Serious Adverse Events|2
6024278|NCT00255047|9619809|FG003|Overall Study|Serious Adverse Events|1
6024279|NCT00255047|9619806|FG000|Overall Study|Adverse Event|0
6024280|NCT00255047|9619807|FG001|Overall Study|Adverse Event|3
6024281|NCT00255047|9619808|FG002|Overall Study|Adverse Event|2
6024282|NCT00255047|9619809|FG003|Overall Study|Adverse Event|1
6024283|NCT00255047|9619806|FG000|Overall Study|Protocol Violation|13
6024284|NCT00255047|9619807|FG001|Overall Study|Protocol Violation|13
6024285|NCT00255047|9619808|FG002|Overall Study|Protocol Violation|16
6024286|NCT00255047|9619809|FG003|Overall Study|Protocol Violation|20
6024287|NCT00255047|9619806|FG000|Overall Study|Lost to Follow-up|9
6024288|NCT00255047|9619807|FG001|Overall Study|Lost to Follow-up|8
6024289|NCT00255047|9619808|FG002|Overall Study|Lost to Follow-up|5
6024290|NCT00255047|9619809|FG003|Overall Study|Lost to Follow-up|6
6024291|NCT00255047|9619806|FG000|Overall Study|Withdrawal by Subject|24
6024292|NCT00255047|9619807|FG001|Overall Study|Withdrawal by Subject|23
6024293|NCT00255047|9619808|FG002|Overall Study|Withdrawal by Subject|25
6024294|NCT00255047|9619809|FG003|Overall Study|Withdrawal by Subject|18
6024295|NCT00255086|9619821|FG000|Overall Study|Adverse Event|1
6024296|NCT00255086|9619822|FG001|Overall Study|Adverse Event|1
6024297|NCT00255086|9619821|FG000|Overall Study|Protocol Violation|1
6024298|NCT00255086|9619822|FG001|Overall Study|Protocol Violation|1
6024299|NCT00255151|9619843|FG000|Overall Study|Adverse Event|10
6024300|NCT00255151|9619844|FG001|Overall Study|Adverse Event|6
6024301|NCT00255151|9619845|FG002|Overall Study|Adverse Event|9
6024302|NCT00255151|9619843|FG000|Overall Study|Lost to Follow-up|4
6024303|NCT00255151|9619844|FG001|Overall Study|Lost to Follow-up|3
6024304|NCT00255151|9619845|FG002|Overall Study|Lost to Follow-up|4
6024305|NCT00255151|9619843|FG000|Overall Study|Withdrawal by Subject|18
6024306|NCT00255151|9619844|FG001|Overall Study|Withdrawal by Subject|17
6024307|NCT00255151|9619845|FG002|Overall Study|Withdrawal by Subject|8
6024308|NCT00255151|9619843|FG000|Overall Study|Noncompliance|0
6024309|NCT00255151|9619844|FG001|Overall Study|Noncompliance|1
6024310|NCT00255151|9619845|FG002|Overall Study|Noncompliance|2
6024311|NCT00255151|9619843|FG000|Overall Study|Subject Request/Subject Unavailable|1
6024312|NCT00255151|9619844|FG001|Overall Study|Subject Request/Subject Unavailable|1
6024313|NCT00255151|9619845|FG002|Overall Study|Subject Request/Subject Unavailable|2
6024314|NCT00255151|9619843|FG000|Overall Study|Relapse of Erosive Esophagitis|78
6024315|NCT00255151|9619844|FG001|Overall Study|Relapse of Erosive Esophagitis|16
6024316|NCT00255151|9619845|FG002|Overall Study|Relapse of Erosive Esophagitis|12
6024317|NCT00255151|9619843|FG000|Overall Study|Possible Barrett's Esophagus|1
6024318|NCT00255151|9619844|FG001|Overall Study|Possible Barrett's Esophagus|3
6024319|NCT00255151|9619845|FG002|Overall Study|Possible Barrett's Esophagus|8
6024320|NCT00255151|9619843|FG000|Overall Study|Esophageal Stricture|0
6024321|NCT00255151|9619844|FG001|Overall Study|Esophageal Stricture|0
6024322|NCT00255151|9619845|FG002|Overall Study|Esophageal Stricture|1
6024323|NCT00255151|9619843|FG000|Overall Study|Therapeutic Failure|11
6024324|NCT00255151|9619844|FG001|Overall Study|Therapeutic Failure|2
6024325|NCT00255151|9619845|FG002|Overall Study|Therapeutic Failure|3
6024326|NCT00255164|9619856|FG000|Overall Study|Adverse Event|10
6024327|NCT00255164|9619857|FG001|Overall Study|Adverse Event|6
6024328|NCT00255164|9619858|FG002|Overall Study|Adverse Event|9
6024329|NCT00255164|9619856|FG000|Overall Study|Lost to Follow-up|4
6024330|NCT00255164|9619857|FG001|Overall Study|Lost to Follow-up|3
6024331|NCT00255164|9619858|FG002|Overall Study|Lost to Follow-up|4
6024332|NCT00255164|9619856|FG000|Overall Study|Withdrawal by Subject|18
6024333|NCT00255164|9619857|FG001|Overall Study|Withdrawal by Subject|17
6024334|NCT00255164|9619858|FG002|Overall Study|Withdrawal by Subject|8
6024335|NCT00255164|9619856|FG000|Overall Study|Noncompliance|0
6024336|NCT00255164|9619857|FG001|Overall Study|Noncompliance|1
6024337|NCT00255164|9619858|FG002|Overall Study|Noncompliance|2
6024338|NCT00255164|9619856|FG000|Overall Study|Subject Request/Subject Unavailable|1
6024339|NCT00255164|9619857|FG001|Overall Study|Subject Request/Subject Unavailable|1
6024340|NCT00255164|9619858|FG002|Overall Study|Subject Request/Subject Unavailable|2
6024341|NCT00255164|9619856|FG000|Overall Study|Relapse of Erosive Esophagitis|78
6024342|NCT00255164|9619857|FG001|Overall Study|Relapse of Erosive Esophagitis|16
6024343|NCT00255164|9619858|FG002|Overall Study|Relapse of Erosive Esophagitis|12
6024344|NCT00255164|9619856|FG000|Overall Study|Possible Barrett's Esophagus|1
6024345|NCT00255164|9619857|FG001|Overall Study|Possible Barrett's Esophagus|3
6024346|NCT00255164|9619858|FG002|Overall Study|Possible Barrett's Esophagus|8
6024347|NCT00255164|9619856|FG000|Overall Study|Esophageal Stricture|0
6024348|NCT00255164|9619857|FG001|Overall Study|Esophageal Stricture|0
6024349|NCT00255164|9619858|FG002|Overall Study|Esophageal Stricture|1
6024350|NCT00255164|9619856|FG000|Overall Study|Therapeutic Failure|11
6024351|NCT00255164|9619857|FG001|Overall Study|Therapeutic Failure|2
6024352|NCT00255164|9619858|FG002|Overall Study|Therapeutic Failure|3
6024353|NCT00255190|9619885|FG000|Overall Study|Adverse Event|17
6024354|NCT00255190|9619886|FG001|Overall Study|Adverse Event|36
6024355|NCT00255190|9619885|FG000|Overall Study|Protocol Violation|2
6024356|NCT00255190|9619886|FG001|Overall Study|Protocol Violation|2
6024357|NCT00255190|9619885|FG000|Overall Study|Lost to Follow-up|10
6024358|NCT00255190|9619886|FG001|Overall Study|Lost to Follow-up|27
6024359|NCT00255190|9619885|FG000|Overall Study|Withdrew Consent|17
6024360|NCT00255190|9619886|FG001|Overall Study|Withdrew Consent|48
6024361|NCT00255190|9619885|FG000|Overall Study|Inclusion/Exclusion criteria not met|0
6024362|NCT00255190|9619886|FG001|Overall Study|Inclusion/Exclusion criteria not met|1
6024363|NCT00255190|9619885|FG000|Overall Study|Erosive esophagitis not healed|0
6024364|NCT00255190|9619886|FG001|Overall Study|Erosive esophagitis not healed|20
6024365|NCT00255190|9619885|FG000|Overall Study|Various|4
6024366|NCT00255190|9619886|FG001|Overall Study|Various|23
6024367|NCT00255346|9619897|FG000|Overall Study|Adverse Event|1
6024368|NCT00255346|9619898|FG001|Overall Study|Adverse Event|0
6024369|NCT00255346|9619899|FG002|Overall Study|Adverse Event|0
6024370|NCT00255346|9619900|FG003|Overall Study|Adverse Event|0
6024371|NCT00255346|9619901|FG004|Overall Study|Adverse Event|0
6024372|NCT00255723|9619915|FG000|Overall Study|Adverse Event|1
6024373|NCT00255723|9619916|FG001|Overall Study|Adverse Event|1
6024374|NCT00255723|9619915|FG000|Overall Study|Death|0
6024375|NCT00255723|9619916|FG001|Overall Study|Death|1
6024376|NCT00255723|9619915|FG000|Overall Study|Response Data Not Available|1
6024377|NCT00255723|9619916|FG001|Overall Study|Response Data Not Available|0
6024378|NCT00255840|9619928|FG000|Overall Study|Lost to Follow-up|10
6024379|NCT00255840|9619929|FG001|Overall Study|Lost to Follow-up|14
6024380|NCT00255840|9619928|FG000|Overall Study|Discontinued intervention|53
6024381|NCT00255840|9619929|FG001|Overall Study|Discontinued intervention|56
6024382|NCT00255944|9619937|FG000|Overall Study|Lost to Follow-up|797
6024383|NCT00255944|9619938|FG001|Overall Study|Lost to Follow-up|834
6024384|NCT00256126|9619955|FG000|Overall Study|Adverse Event|1
6024385|NCT00256126|9619956|FG001|Overall Study|Adverse Event|0
6024386|NCT00256126|9619955|FG000|Overall Study|Other|1
6024387|NCT00256126|9619956|FG001|Overall Study|Other|2
6024388|NCT00256204|9619966|FG000|Overall Study|Adverse Event|10
6024389|NCT00256204|9619967|FG001|Overall Study|Adverse Event|14
6024390|NCT00256204|9619968|FG002|Overall Study|Adverse Event|16
6024391|NCT00256204|9619969|FG003|Overall Study|Adverse Event|14
6024392|NCT00256204|9619966|FG000|Overall Study|Death|0
6024393|NCT00256204|9619967|FG001|Overall Study|Death|1
6024394|NCT00256204|9619968|FG002|Overall Study|Death|0
6024395|NCT00256204|9619969|FG003|Overall Study|Death|0
6024396|NCT00256204|9619966|FG000|Overall Study|Lost to Follow-up|1
6024397|NCT00256204|9619967|FG001|Overall Study|Lost to Follow-up|1
6024398|NCT00256204|9619968|FG002|Overall Study|Lost to Follow-up|1
6024399|NCT00256204|9619969|FG003|Overall Study|Lost to Follow-up|2
6024400|NCT00256204|9619966|FG000|Overall Study|Protocol Violation|1
6024401|NCT00256204|9619967|FG001|Overall Study|Protocol Violation|0
6024402|NCT00256204|9619968|FG002|Overall Study|Protocol Violation|2
6024403|NCT00256204|9619969|FG003|Overall Study|Protocol Violation|1
6024404|NCT00256204|9619966|FG000|Overall Study|Physician Decision|0
6024405|NCT00256204|9619967|FG001|Overall Study|Physician Decision|0
6024406|NCT00256204|9619968|FG002|Overall Study|Physician Decision|1
6024407|NCT00256204|9619969|FG003|Overall Study|Physician Decision|2
6024408|NCT00256204|9619966|FG000|Overall Study|Withdrawal by Subject|17
6024409|NCT00256204|9619967|FG001|Overall Study|Withdrawal by Subject|6
6024410|NCT00256204|9619968|FG002|Overall Study|Withdrawal by Subject|7
6024411|NCT00256204|9619969|FG003|Overall Study|Withdrawal by Subject|5
6024412|NCT00256204|9619966|FG000|Overall Study|Need for additional prohibited treatment|38
6024413|NCT00256204|9619967|FG001|Overall Study|Need for additional prohibited treatment|28
6024414|NCT00256204|9619968|FG002|Overall Study|Need for additional prohibited treatment|27
6024415|NCT00256204|9619969|FG003|Overall Study|Need for additional prohibited treatment|25
6024416|NCT00256243|9619986|FG000|Overall Study|Lost to Follow-up|2
6024417|NCT00256243|9619986|FG000|Overall Study|Death|7
6024418|NCT00256243|9619986|FG000|Overall Study|Not treated|1
6024419|NCT00256282|9619991|FG000|Overall Study|Disease progression, relapse during acti|12
6024420|NCT00256282|9619991|FG000|Overall Study|Adverse Event|3
6024421|NCT00256282|9619991|FG000|Overall Study|Physician Decision|1
6024422|NCT00256308|9619995|FG000|Overall Study|Death|2
6024423|NCT00256698|9620014|FG000|Overall Study|Withdrawal by Subject|7
6024424|NCT00256698|9620015|FG001|Overall Study|Withdrawal by Subject|7
6024425|NCT00256698|9620014|FG000|Overall Study|Adverse Event|13
6024426|NCT00256698|9620015|FG001|Overall Study|Adverse Event|6
6024427|NCT00256698|9620014|FG000|Overall Study|Protocol Violation|6
6024428|NCT00256698|9620015|FG001|Overall Study|Protocol Violation|5
6024429|NCT00256698|9620014|FG000|Overall Study|Lost to Follow-up|1
6024430|NCT00256698|9620015|FG001|Overall Study|Lost to Follow-up|3
6024431|NCT00256698|9620014|FG000|Overall Study|disease progression|97
6024432|NCT00256698|9620015|FG001|Overall Study|disease progression|105
6024433|NCT00256698|9620014|FG000|Overall Study|still ongoing at data cut-off|41
6024434|NCT00256698|9620015|FG001|Overall Study|still ongoing at data cut-off|46
6024435|NCT00256698|9620014|FG000|Overall Study|withdrawn due to osteoporosis|1
6024436|NCT00256698|9620015|FG001|Overall Study|withdrawn due to osteoporosis|0
6024437|NCT00256698|9620014|FG000|Overall Study|Prematurely Discontinued|1
6024438|NCT00256698|9620015|FG001|Overall Study|Prematurely Discontinued|0
6024439|NCT00256724|9620023|FG000|Overall Study|Physician Decision|2
6024440|NCT00256724|9620024|FG001|Overall Study|Physician Decision|5
6024441|NCT00256724|9620023|FG000|Overall Study|Protocol Violation|3
6024442|NCT00256724|9620024|FG001|Overall Study|Protocol Violation|3
6024443|NCT00256750|9620033|FG000|Transplanted Pre-Treatment|Withdrawal by Subject|3
6024444|NCT00256750|9620034|FG001|Transplanted Pre-Treatment|Withdrawal by Subject|0
6024445|NCT00256750|9620035|FG002|Transplanted Pre-Treatment|Withdrawal by Subject|0
6024446|NCT00256750|9620033|FG000|Transplanted Pre-Treatment|Other|2
6024447|NCT00256750|9620034|FG001|Transplanted Pre-Treatment|Other|0
6024448|NCT00256750|9620035|FG002|Transplanted Pre-Treatment|Other|0
6024449|NCT00256750|9620033|FG000|Transplanted Pre-Treatment|Death|1
6024450|NCT00256750|9620034|FG001|Transplanted Pre-Treatment|Death|0
6024451|NCT00256750|9620035|FG002|Transplanted Pre-Treatment|Death|0
6024452|NCT00256750|9620033|FG000|Post-Transplant Treated (12 Months)|Adverse Event|20
6024453|NCT00256750|9620034|FG001|Post-Transplant Treated (12 Months)|Adverse Event|12
6024454|NCT00256750|9620035|FG002|Post-Transplant Treated (12 Months)|Adverse Event|8
6024455|NCT00256750|9620033|FG000|Post-Transplant Treated (12 Months)|Death|3
6024456|NCT00256750|9620034|FG001|Post-Transplant Treated (12 Months)|Death|2
6024457|NCT00256750|9620035|FG002|Post-Transplant Treated (12 Months)|Death|4
6024458|NCT00256750|9620033|FG000|Post-Transplant Treated (12 Months)|Lack of Efficacy|10
6024459|NCT00256750|9620034|FG001|Post-Transplant Treated (12 Months)|Lack of Efficacy|22
6024460|NCT00256750|9620035|FG002|Post-Transplant Treated (12 Months)|Lack of Efficacy|27
6024461|NCT00256750|9620033|FG000|Post-Transplant Treated (12 Months)|Lost to Follow-up|1
6024462|NCT00256750|9620034|FG001|Post-Transplant Treated (12 Months)|Lost to Follow-up|0
6024463|NCT00256750|9620035|FG002|Post-Transplant Treated (12 Months)|Lost to Follow-up|0
6024464|NCT00256750|9620033|FG000|Post-Transplant Treated (12 Months)|Other|5
6024465|NCT00256750|9620034|FG001|Post-Transplant Treated (12 Months)|Other|4
6024466|NCT00256750|9620035|FG002|Post-Transplant Treated (12 Months)|Other|2
6024467|NCT00256750|9620033|FG000|Post-Transplant Treated (12 Months)|Withdrawal by Subject|0
6024468|NCT00256750|9620034|FG001|Post-Transplant Treated (12 Months)|Withdrawal by Subject|3
6024469|NCT00256750|9620035|FG002|Post-Transplant Treated (12 Months)|Withdrawal by Subject|5
6024470|NCT00256750|9620033|FG000|Post-Transplant Treated (12 Months)|Protocol Violation|2
6024471|NCT00256750|9620034|FG001|Post-Transplant Treated (12 Months)|Protocol Violation|0
6024472|NCT00256750|9620035|FG002|Post-Transplant Treated (12 Months)|Protocol Violation|0
6024473|NCT00256750|9620033|FG000|Post-Transplant Treated (24 Months)|Adverse Event|7
6024474|NCT00256750|9620034|FG001|Post-Transplant Treated (24 Months)|Adverse Event|3
6024475|NCT00256750|9620035|FG002|Post-Transplant Treated (24 Months)|Adverse Event|6
6024476|NCT00256750|9620033|FG000|Post-Transplant Treated (24 Months)|Withdrawal by Subject|5
6024477|NCT00256750|9620034|FG001|Post-Transplant Treated (24 Months)|Withdrawal by Subject|1
6024478|NCT00256750|9620035|FG002|Post-Transplant Treated (24 Months)|Withdrawal by Subject|0
6024479|NCT00256750|9620033|FG000|Post-Transplant Treated (24 Months)|Death|3
6024480|NCT00256750|9620034|FG001|Post-Transplant Treated (24 Months)|Death|0
6024481|NCT00256750|9620035|FG002|Post-Transplant Treated (24 Months)|Death|0
6024482|NCT00256750|9620033|FG000|Post-Transplant Treated (24 Months)|Lack of Efficacy|4
6024483|NCT00256750|9620034|FG001|Post-Transplant Treated (24 Months)|Lack of Efficacy|3
6024484|NCT00256750|9620035|FG002|Post-Transplant Treated (24 Months)|Lack of Efficacy|2
6024485|NCT00256750|9620033|FG000|Post-Transplant Treated (24 Months)|Other|2
6024486|NCT00256750|9620034|FG001|Post-Transplant Treated (24 Months)|Other|0
6024487|NCT00256750|9620035|FG002|Post-Transplant Treated (24 Months)|Other|1
6024488|NCT00256750|9620033|FG000|Post-Transplant Treated (36 Months)|Adverse Event|5
6024489|NCT00256750|9620034|FG001|Post-Transplant Treated (36 Months)|Adverse Event|1
6024490|NCT00256750|9620035|FG002|Post-Transplant Treated (36 Months)|Adverse Event|2
6024491|NCT00256750|9620033|FG000|Post-Transplant Treated (36 Months)|Withdrawal by Subject|1
6024492|NCT00256750|9620034|FG001|Post-Transplant Treated (36 Months)|Withdrawal by Subject|0
6024493|NCT00256750|9620035|FG002|Post-Transplant Treated (36 Months)|Withdrawal by Subject|1
6024494|NCT00256750|9620033|FG000|Post-Transplant Treated (36 Months)|Death|0
6024495|NCT00256750|9620034|FG001|Post-Transplant Treated (36 Months)|Death|2
6024496|NCT00256750|9620035|FG002|Post-Transplant Treated (36 Months)|Death|1
6024497|NCT00256750|9620033|FG000|Post-Transplant Treated (36 Months)|Subject no longer meets study criteria|0
6024498|NCT00256750|9620034|FG001|Post-Transplant Treated (36 Months)|Subject no longer meets study criteria|0
6024499|NCT00256750|9620035|FG002|Post-Transplant Treated (36 Months)|Subject no longer meets study criteria|1
6024500|NCT00256750|9620033|FG000|Post-Transplant Treated (36 Months)|Lack of Efficacy|4
6024501|NCT00256750|9620034|FG001|Post-Transplant Treated (36 Months)|Lack of Efficacy|1
6024502|NCT00256750|9620035|FG002|Post-Transplant Treated (36 Months)|Lack of Efficacy|0
6048183|NCT00415597|9647279|FG000|Treatment|Drug Screen|2
6024503|NCT00256750|9620033|FG000|Post-Transplant Treated (36 Months)|Protocol Violation|0
6024504|NCT00256750|9620034|FG001|Post-Transplant Treated (36 Months)|Protocol Violation|1
6024505|NCT00256750|9620035|FG002|Post-Transplant Treated (36 Months)|Protocol Violation|0
6024506|NCT00256750|9620033|FG000|Post-Transplant Treated (36 Months)|Other|0
6024507|NCT00256750|9620034|FG001|Post-Transplant Treated (36 Months)|Other|1
6024508|NCT00256750|9620035|FG002|Post-Transplant Treated (36 Months)|Other|1
6024509|NCT00256750|9620033|FG000|Long Term Extension (LTE; 84 Months)|Adverse Event|13
6024510|NCT00256750|9620034|FG001|Long Term Extension (LTE; 84 Months)|Adverse Event|11
6024511|NCT00256750|9620035|FG002|Long Term Extension (LTE; 84 Months)|Adverse Event|14
6024512|NCT00256750|9620033|FG000|Long Term Extension (LTE; 84 Months)|Withdrawal by Subject|5
6024513|NCT00256750|9620034|FG001|Long Term Extension (LTE; 84 Months)|Withdrawal by Subject|4
6024514|NCT00256750|9620035|FG002|Long Term Extension (LTE; 84 Months)|Withdrawal by Subject|1
6024515|NCT00256750|9620033|FG000|Long Term Extension (LTE; 84 Months)|Lost to Follow-up|4
6024516|NCT00256750|9620034|FG001|Long Term Extension (LTE; 84 Months)|Lost to Follow-up|1
6024517|NCT00256750|9620035|FG002|Long Term Extension (LTE; 84 Months)|Lost to Follow-up|1
6024518|NCT00256750|9620033|FG000|Long Term Extension (LTE; 84 Months)|Death|9
6024519|NCT00256750|9620034|FG001|Long Term Extension (LTE; 84 Months)|Death|4
6024520|NCT00256750|9620035|FG002|Long Term Extension (LTE; 84 Months)|Death|4
6024521|NCT00256750|9620033|FG000|Long Term Extension (LTE; 84 Months)|Lack of Efficacy|6
6024522|NCT00256750|9620034|FG001|Long Term Extension (LTE; 84 Months)|Lack of Efficacy|3
6024523|NCT00256750|9620035|FG002|Long Term Extension (LTE; 84 Months)|Lack of Efficacy|0
6024524|NCT00256750|9620033|FG000|Long Term Extension (LTE; 84 Months)|Poor/Non-compliance|4
6024525|NCT00256750|9620034|FG001|Long Term Extension (LTE; 84 Months)|Poor/Non-compliance|1
6024526|NCT00256750|9620035|FG002|Long Term Extension (LTE; 84 Months)|Poor/Non-compliance|1
6024527|NCT00256750|9620033|FG000|Long Term Extension (LTE; 84 Months)|Pregnancy|0
6024528|NCT00256750|9620034|FG001|Long Term Extension (LTE; 84 Months)|Pregnancy|1
6024529|NCT00256750|9620035|FG002|Long Term Extension (LTE; 84 Months)|Pregnancy|2
6024530|NCT00256750|9620033|FG000|Long Term Extension (LTE; 84 Months)|Administrative Reason By Sponsor|1
6024531|NCT00256750|9620034|FG001|Long Term Extension (LTE; 84 Months)|Administrative Reason By Sponsor|1
6024532|NCT00256750|9620035|FG002|Long Term Extension (LTE; 84 Months)|Administrative Reason By Sponsor|0
6024533|NCT00256750|9620033|FG000|Long Term Extension (LTE; 84 Months)|Other|5
6024534|NCT00256750|9620034|FG001|Long Term Extension (LTE; 84 Months)|Other|4
6024535|NCT00256750|9620035|FG002|Long Term Extension (LTE; 84 Months)|Other|5
6024536|NCT00256854|9620061|FG000|Overall Study|Withdrawal by Subject|2
6024537|NCT00256854|9620062|FG001|Overall Study|Withdrawal by Subject|3
6024538|NCT00256854|9620063|FG002|Overall Study|Withdrawal by Subject|0
6024539|NCT00256854|9620064|FG003|Overall Study|Withdrawal by Subject|0
6024540|NCT00256854|9620065|FG004|Overall Study|Withdrawal by Subject|0
6024541|NCT00256854|9620066|FG005|Overall Study|Withdrawal by Subject|0
6024542|NCT00256854|9620061|FG000|Overall Study|Lack of Efficacy|1
6024543|NCT00256854|9620062|FG001|Overall Study|Lack of Efficacy|0
6024544|NCT00256854|9620063|FG002|Overall Study|Lack of Efficacy|0
6024545|NCT00256854|9620064|FG003|Overall Study|Lack of Efficacy|0
6024546|NCT00256854|9620065|FG004|Overall Study|Lack of Efficacy|0
6078409|NCT00603746|9684742|FG002|Overall Study|Protocol Violation|1
6078410|NCT00603746|9684743|FG003|Overall Study|Protocol Violation|0
6078411|NCT00603746|9684744|FG004|Overall Study|Protocol Violation|1
6078412|NCT00603746|9684745|FG005|Overall Study|Protocol Violation|0
6078413|NCT00603746|9684740|FG000|Overall Study|Lost to Follow-up|0
6078414|NCT00603746|9684741|FG001|Overall Study|Lost to Follow-up|1
6078415|NCT00603746|9684742|FG002|Overall Study|Lost to Follow-up|1
6078416|NCT00603746|9684743|FG003|Overall Study|Lost to Follow-up|0
6078417|NCT00603746|9684744|FG004|Overall Study|Lost to Follow-up|0
6078418|NCT00603746|9684745|FG005|Overall Study|Lost to Follow-up|0
6078419|NCT00603746|9684740|FG000|Overall Study|Physician Decision|1
6078420|NCT00603746|9684741|FG001|Overall Study|Physician Decision|0
6078421|NCT00603746|9684742|FG002|Overall Study|Physician Decision|0
6078422|NCT00603746|9684743|FG003|Overall Study|Physician Decision|0
6078423|NCT00603746|9684744|FG004|Overall Study|Physician Decision|1
6078424|NCT00603746|9684745|FG005|Overall Study|Physician Decision|0
6078425|NCT00603746|9684740|FG000|Overall Study|Withdrawal by Subject|1
6078426|NCT00603746|9684741|FG001|Overall Study|Withdrawal by Subject|0
6078427|NCT00603746|9684742|FG002|Overall Study|Withdrawal by Subject|0
6078428|NCT00603746|9684743|FG003|Overall Study|Withdrawal by Subject|1
6078429|NCT00603746|9684744|FG004|Overall Study|Withdrawal by Subject|3
6078430|NCT00603746|9684745|FG005|Overall Study|Withdrawal by Subject|1
6024547|NCT00256854|9620066|FG005|Overall Study|Lack of Efficacy|0
6024548|NCT00256854|9620061|FG000|Overall Study|Protocol Violation|0
6024549|NCT00256854|9620062|FG001|Overall Study|Protocol Violation|1
6024550|NCT00256854|9620063|FG002|Overall Study|Protocol Violation|1
6024551|NCT00256854|9620064|FG003|Overall Study|Protocol Violation|1
6024552|NCT00256854|9620065|FG004|Overall Study|Protocol Violation|0
6024553|NCT00256854|9620066|FG005|Overall Study|Protocol Violation|0
6078431|NCT00603798|9684762|FG000|Overall Study|Adverse Event|4
6078432|NCT00603798|9684763|FG001|Overall Study|Adverse Event|2
6078433|NCT00603798|9684764|FG002|Overall Study|Adverse Event|1
6078434|NCT00603798|9684762|FG000|Overall Study|Withdrawal by Subject|4
6024554|NCT00256854|9620061|FG000|Overall Study|Adverse Event|0
6078435|NCT00603798|9684763|FG001|Overall Study|Withdrawal by Subject|3
6024555|NCT00256854|9620062|FG001|Overall Study|Adverse Event|0
6024556|NCT00256854|9620063|FG002|Overall Study|Adverse Event|2
6024557|NCT00256854|9620064|FG003|Overall Study|Adverse Event|2
6024558|NCT00256854|9620065|FG004|Overall Study|Adverse Event|0
6024559|NCT00256854|9620066|FG005|Overall Study|Adverse Event|1
6024560|NCT00256854|9620061|FG000|Overall Study|Not compliant with the study drug|0
6024561|NCT00256854|9620062|FG001|Overall Study|Not compliant with the study drug|0
6024562|NCT00256854|9620063|FG002|Overall Study|Not compliant with the study drug|0
6024563|NCT00256854|9620064|FG003|Overall Study|Not compliant with the study drug|0
6024564|NCT00256854|9620065|FG004|Overall Study|Not compliant with the study drug|1
6024565|NCT00256854|9620066|FG005|Overall Study|Not compliant with the study drug|0
6024566|NCT00256867|9620089|FG000|Overall Study|Adverse Event|0
6024567|NCT00256867|9620090|FG001|Overall Study|Adverse Event|1
6024568|NCT00256867|9620091|FG002|Overall Study|Adverse Event|1
6024569|NCT00256867|9620092|FG003|Overall Study|Adverse Event|1
6024570|NCT00256867|9620093|FG004|Overall Study|Adverse Event|2
6024571|NCT00256867|9620094|FG005|Overall Study|Adverse Event|2
6024572|NCT00256867|9620095|FG006|Overall Study|Adverse Event|1
6024573|NCT00256867|9620096|FG007|Overall Study|Adverse Event|4
6024574|NCT00256867|9620089|FG000|Overall Study|Lost to Follow-up|2
6024575|NCT00256867|9620090|FG001|Overall Study|Lost to Follow-up|2
6024576|NCT00256867|9620091|FG002|Overall Study|Lost to Follow-up|2
6024577|NCT00256867|9620092|FG003|Overall Study|Lost to Follow-up|3
6024578|NCT00256867|9620093|FG004|Overall Study|Lost to Follow-up|2
6024579|NCT00256867|9620094|FG005|Overall Study|Lost to Follow-up|0
6024580|NCT00256867|9620095|FG006|Overall Study|Lost to Follow-up|1
6024581|NCT00256867|9620096|FG007|Overall Study|Lost to Follow-up|2
6024582|NCT00256867|9620089|FG000|Overall Study|Protocol Violation|0
6024583|NCT00256867|9620090|FG001|Overall Study|Protocol Violation|0
6024584|NCT00256867|9620091|FG002|Overall Study|Protocol Violation|0
6024585|NCT00256867|9620092|FG003|Overall Study|Protocol Violation|1
6024586|NCT00256867|9620093|FG004|Overall Study|Protocol Violation|0
6024587|NCT00256867|9620094|FG005|Overall Study|Protocol Violation|1
6024588|NCT00256867|9620095|FG006|Overall Study|Protocol Violation|0
6024589|NCT00256867|9620096|FG007|Overall Study|Protocol Violation|1
6024590|NCT00256867|9620089|FG000|Overall Study|Withdrawal by Subject|0
6024591|NCT00256867|9620090|FG001|Overall Study|Withdrawal by Subject|0
6024592|NCT00256867|9620091|FG002|Overall Study|Withdrawal by Subject|1
6024593|NCT00256867|9620092|FG003|Overall Study|Withdrawal by Subject|1
6024594|NCT00256867|9620093|FG004|Overall Study|Withdrawal by Subject|2
6024595|NCT00256867|9620094|FG005|Overall Study|Withdrawal by Subject|2
6024596|NCT00256867|9620095|FG006|Overall Study|Withdrawal by Subject|3
6024597|NCT00256867|9620096|FG007|Overall Study|Withdrawal by Subject|2
6024598|NCT00256867|9620089|FG000|Overall Study|Fasting plasma glucose >240 mg/dL|0
6024599|NCT00256867|9620090|FG001|Overall Study|Fasting plasma glucose >240 mg/dL|1
6024600|NCT00256867|9620091|FG002|Overall Study|Fasting plasma glucose >240 mg/dL|0
6024601|NCT00256867|9620092|FG003|Overall Study|Fasting plasma glucose >240 mg/dL|0
6024602|NCT00256867|9620093|FG004|Overall Study|Fasting plasma glucose >240 mg/dL|0
6024603|NCT00256867|9620094|FG005|Overall Study|Fasting plasma glucose >240 mg/dL|0
6024604|NCT00256867|9620095|FG006|Overall Study|Fasting plasma glucose >240 mg/dL|0
6024605|NCT00256867|9620096|FG007|Overall Study|Fasting plasma glucose >240 mg/dL|0
6024606|NCT00256867|9620089|FG000|Overall Study|Glycemia over 13.3 millimole per litre|0
6024607|NCT00256867|9620090|FG001|Overall Study|Glycemia over 13.3 millimole per litre|0
6024608|NCT00256867|9620091|FG002|Overall Study|Glycemia over 13.3 millimole per litre|0
6024609|NCT00256867|9620092|FG003|Overall Study|Glycemia over 13.3 millimole per litre|0
6024610|NCT00256867|9620093|FG004|Overall Study|Glycemia over 13.3 millimole per litre|0
6024611|NCT00256867|9620094|FG005|Overall Study|Glycemia over 13.3 millimole per litre|0
6024612|NCT00256867|9620095|FG006|Overall Study|Glycemia over 13.3 millimole per litre|0
6024613|NCT00256867|9620096|FG007|Overall Study|Glycemia over 13.3 millimole per litre|1
6024614|NCT00256867|9620089|FG000|Overall Study|Investigator's Decision|0
6024615|NCT00256867|9620090|FG001|Overall Study|Investigator's Decision|0
6024616|NCT00256867|9620091|FG002|Overall Study|Investigator's Decision|0
6024617|NCT00256867|9620092|FG003|Overall Study|Investigator's Decision|0
6024618|NCT00256867|9620093|FG004|Overall Study|Investigator's Decision|1
6024619|NCT00256867|9620094|FG005|Overall Study|Investigator's Decision|0
6024620|NCT00256867|9620095|FG006|Overall Study|Investigator's Decision|0
6024621|NCT00256867|9620096|FG007|Overall Study|Investigator's Decision|0
6024622|NCT00256867|9620089|FG000|Overall Study|Non-compliance with study medication|0
6024623|NCT00256867|9620090|FG001|Overall Study|Non-compliance with study medication|0
6024624|NCT00256867|9620091|FG002|Overall Study|Non-compliance with study medication|0
6024625|NCT00256867|9620092|FG003|Overall Study|Non-compliance with study medication|0
6024626|NCT00256867|9620093|FG004|Overall Study|Non-compliance with study medication|0
6024627|NCT00256867|9620094|FG005|Overall Study|Non-compliance with study medication|0
6024628|NCT00256867|9620095|FG006|Overall Study|Non-compliance with study medication|0
6024629|NCT00256867|9620096|FG007|Overall Study|Non-compliance with study medication|1
6024630|NCT00256867|9620089|FG000|Overall Study|Participant travelled Overseas|0
6024631|NCT00256867|9620090|FG001|Overall Study|Participant travelled Overseas|1
6024632|NCT00256867|9620091|FG002|Overall Study|Participant travelled Overseas|0
6024633|NCT00256867|9620092|FG003|Overall Study|Participant travelled Overseas|0
6024634|NCT00256867|9620093|FG004|Overall Study|Participant travelled Overseas|0
6024635|NCT00256867|9620094|FG005|Overall Study|Participant travelled Overseas|0
6024636|NCT00256867|9620095|FG006|Overall Study|Participant travelled Overseas|0
6024637|NCT00256867|9620096|FG007|Overall Study|Participant travelled Overseas|0
6024638|NCT00256867|9620089|FG000|Overall Study|Participant out of assessment window|0
6024639|NCT00256867|9620090|FG001|Overall Study|Participant out of assessment window|0
6024640|NCT00256867|9620091|FG002|Overall Study|Participant out of assessment window|1
6024641|NCT00256867|9620092|FG003|Overall Study|Participant out of assessment window|0
6024642|NCT00256867|9620093|FG004|Overall Study|Participant out of assessment window|0
6024643|NCT00256867|9620094|FG005|Overall Study|Participant out of assessment window|0
6024644|NCT00256867|9620095|FG006|Overall Study|Participant out of assessment window|0
6024645|NCT00256867|9620096|FG007|Overall Study|Participant out of assessment window|0
6024646|NCT00256867|9620089|FG000|Overall Study|Withdrawal by participant|0
6024647|NCT00256867|9620090|FG001|Overall Study|Withdrawal by participant|0
6024648|NCT00256867|9620091|FG002|Overall Study|Withdrawal by participant|0
6024649|NCT00256867|9620092|FG003|Overall Study|Withdrawal by participant|0
6024650|NCT00256867|9620093|FG004|Overall Study|Withdrawal by participant|0
6024651|NCT00256867|9620094|FG005|Overall Study|Withdrawal by participant|1
6024652|NCT00256867|9620095|FG006|Overall Study|Withdrawal by participant|0
6024653|NCT00256867|9620096|FG007|Overall Study|Withdrawal by participant|0
6024654|NCT00256997|9620125|FG000|Overall Study|Protocol Violation|1
6024655|NCT00256997|9620126|FG001|Overall Study|Protocol Violation|4
6024656|NCT00256997|9620125|FG000|Overall Study|Lack of Efficacy|1
6024657|NCT00256997|9620126|FG001|Overall Study|Lack of Efficacy|4
6024658|NCT00256997|9620125|FG000|Overall Study|Death|2
6024659|NCT00256997|9620126|FG001|Overall Study|Death|0
6024660|NCT00256997|9620125|FG000|Overall Study|Adverse Event|4
6024661|NCT00256997|9620126|FG001|Overall Study|Adverse Event|0
6024662|NCT00256997|9620125|FG000|Overall Study|Lost to Follow-up|3
6024663|NCT00256997|9620126|FG001|Overall Study|Lost to Follow-up|5
6024664|NCT00256997|9620125|FG000|Overall Study|Withdrawal by Subject|13
6024665|NCT00256997|9620126|FG001|Overall Study|Withdrawal by Subject|3
6024666|NCT00256997|9620125|FG000|Overall Study|Started but not treated|2
6024667|NCT00256997|9620126|FG001|Overall Study|Started but not treated|0
6024668|NCT00256997|9620125|FG000|Overall Study|Other|5
6024669|NCT00256997|9620126|FG001|Overall Study|Other|8
6024670|NCT00256997|9620125|FG000|Overall Study|End of Study (As Per Sponsor)|12
6024671|NCT00256997|9620126|FG001|Overall Study|End of Study (As Per Sponsor)|24
6024672|NCT00256997|9620125|FG000|Overall Study|Participant Non-compliant|3
6024673|NCT00256997|9620126|FG001|Overall Study|Participant Non-compliant|6
6024674|NCT00256997|9620125|FG000|Overall Study|Investigator Withdrew Participant|2
6024675|NCT00256997|9620126|FG001|Overall Study|Investigator Withdrew Participant|1
6024676|NCT00257010|9620133|FG000|Overall Study|Lack of Efficacy|11
6024677|NCT00257010|9620133|FG000|Overall Study|Lost to Follow-up|53
6024678|NCT00257010|9620133|FG000|Overall Study|Withdrawal by Subject|34
6024679|NCT00257010|9620133|FG000|Overall Study|Adverse Event|10
6024680|NCT00257010|9620133|FG000|Overall Study|various|11
6024681|NCT00257010|9620133|FG000|Overall Study|no headache reported|9
6024682|NCT00257166|9620139|FG000|Overall Study|Adverse Event|18
6024683|NCT00257166|9620140|FG001|Overall Study|Adverse Event|13
6024684|NCT00257166|9620139|FG000|Overall Study|Laboratory abnormality|1
6024685|NCT00257166|9620140|FG001|Overall Study|Laboratory abnormality|0
6024686|NCT00257166|9620139|FG000|Overall Study|Lost to Follow-up|8
6024687|NCT00257166|9620140|FG001|Overall Study|Lost to Follow-up|1
6024688|NCT00257166|9620139|FG000|Overall Study|Withdrawal by Subject|9
6024689|NCT00257166|9620140|FG001|Overall Study|Withdrawal by Subject|2
6024690|NCT00257166|9620139|FG000|Overall Study|Other|16
6024691|NCT00257166|9620140|FG001|Overall Study|Other|21
6024692|NCT00257166|9620139|FG000|Overall Study|Randomized, but not treated|1
6024693|NCT00257166|9620140|FG001|Overall Study|Randomized, but not treated|0
6024694|NCT00257192|9620148|FG000|Overall Study|Adverse Event|21
6024695|NCT00257192|9620149|FG001|Overall Study|Adverse Event|10
6024696|NCT00257192|9620148|FG000|Overall Study|Laboratory abnormality|1
6024697|NCT00257192|9620149|FG001|Overall Study|Laboratory abnormality|1
6024698|NCT00257192|9620148|FG000|Overall Study|Lost to Follow-up|3
6024699|NCT00257192|9620149|FG001|Overall Study|Lost to Follow-up|3
6024700|NCT00257192|9620148|FG000|Overall Study|Insufficient clinical response|18
6024701|NCT00257192|9620149|FG001|Overall Study|Insufficient clinical response|18
6024702|NCT00257192|9620148|FG000|Overall Study|Withdrawal by Subject|14
6024703|NCT00257192|9620149|FG001|Overall Study|Withdrawal by Subject|2
6024704|NCT00257192|9620148|FG000|Overall Study|Randomized but not treated|0
6024705|NCT00257192|9620149|FG001|Overall Study|Randomized but not treated|1
6024706|NCT00257192|9620148|FG000|Overall Study|Study terminated by sponsor|1
6024707|NCT00257192|9620149|FG001|Overall Study|Study terminated by sponsor|0
6024708|NCT00257192|9620148|FG000|Overall Study|Miscellaneous|0
6024709|NCT00257192|9620149|FG001|Overall Study|Miscellaneous|4
6024710|NCT00257556|9620170|FG000|Overall Study|Adverse Event|1
6024711|NCT00257556|9620171|FG001|Overall Study|Adverse Event|4
6024712|NCT00257556|9620170|FG000|Overall Study|Physician Decision|6
6024713|NCT00257556|9620171|FG001|Overall Study|Physician Decision|0
6024714|NCT00257556|9620170|FG000|Overall Study|Did not meet hCG criterion|3
6024715|NCT00257556|9620171|FG001|Overall Study|Did not meet hCG criterion|0
6078436|NCT00603798|9684764|FG002|Overall Study|Withdrawal by Subject|4
6078437|NCT00603798|9684762|FG000|Overall Study|Lost to Follow-up|1
6024716|NCT00257556|9620170|FG000|Overall Study|other reason|4
6024717|NCT00257556|9620171|FG001|Overall Study|other reason|6
6024718|NCT00257608|9620179|FG000|Chemotherapy Phase|Adverse Event|138
6024719|NCT00257608|9620180|FG001|Chemotherapy Phase|Adverse Event|0
6024720|NCT00257608|9620181|FG002|Chemotherapy Phase|Adverse Event|0
6024721|NCT00257608|9620179|FG000|Chemotherapy Phase|Disease progression|139
6024722|NCT00257608|9620180|FG001|Chemotherapy Phase|Disease progression|0
6024723|NCT00257608|9620181|FG002|Chemotherapy Phase|Disease progression|0
6024724|NCT00257608|9620179|FG000|Chemotherapy Phase|Unwillingness or inability to comply|6
6024725|NCT00257608|9620180|FG001|Chemotherapy Phase|Unwillingness or inability to comply|0
6024726|NCT00257608|9620181|FG002|Chemotherapy Phase|Unwillingness or inability to comply|0
6024727|NCT00257608|9620179|FG000|Chemotherapy Phase|Need for concomitant/ancillary therapy|27
6024728|NCT00257608|9620180|FG001|Chemotherapy Phase|Need for concomitant/ancillary therapy|0
6024729|NCT00257608|9620181|FG002|Chemotherapy Phase|Need for concomitant/ancillary therapy|0
6024730|NCT00257608|9620179|FG000|Chemotherapy Phase|Patient's decision to discontinue|35
6024731|NCT00257608|9620180|FG001|Chemotherapy Phase|Patient's decision to discontinue|0
6024732|NCT00257608|9620181|FG002|Chemotherapy Phase|Patient's decision to discontinue|0
6024733|NCT00257608|9620179|FG000|Chemotherapy Phase|Unrelated intercurrent illness|3
6024734|NCT00257608|9620180|FG001|Chemotherapy Phase|Unrelated intercurrent illness|0
6024735|NCT00257608|9620181|FG002|Chemotherapy Phase|Unrelated intercurrent illness|0
6024736|NCT00257608|9620179|FG000|Chemotherapy Phase|Physician Decision|28
6024737|NCT00257608|9620180|FG001|Chemotherapy Phase|Physician Decision|0
6024738|NCT00257608|9620181|FG002|Chemotherapy Phase|Physician Decision|0
6024739|NCT00257608|9620179|FG000|Post Chemotherapy Phase|Adverse Event|0
6024740|NCT00257608|9620180|FG001|Post Chemotherapy Phase|Adverse Event|34
6024741|NCT00257608|9620181|FG002|Post Chemotherapy Phase|Adverse Event|38
6024742|NCT00257608|9620179|FG000|Post Chemotherapy Phase|Disease progression|0
6024743|NCT00257608|9620180|FG001|Post Chemotherapy Phase|Disease progression|204
6024744|NCT00257608|9620181|FG002|Post Chemotherapy Phase|Disease progression|168
6024745|NCT00257608|9620179|FG000|Post Chemotherapy Phase|Unwillingness or inability to comply|0
6024746|NCT00257608|9620180|FG001|Post Chemotherapy Phase|Unwillingness or inability to comply|4
6024747|NCT00257608|9620181|FG002|Post Chemotherapy Phase|Unwillingness or inability to comply|5
6024748|NCT00257608|9620179|FG000|Post Chemotherapy Phase|Need for concomitant/ancillary therapy|0
6024749|NCT00257608|9620180|FG001|Post Chemotherapy Phase|Need for concomitant/ancillary therapy|5
6024750|NCT00257608|9620181|FG002|Post Chemotherapy Phase|Need for concomitant/ancillary therapy|5
6024751|NCT00257608|9620179|FG000|Post Chemotherapy Phase|Patient's decision to discontinue|0
6024752|NCT00257608|9620180|FG001|Post Chemotherapy Phase|Patient's decision to discontinue|4
6024753|NCT00257608|9620181|FG002|Post Chemotherapy Phase|Patient's decision to discontinue|8
6024754|NCT00257608|9620179|FG000|Post Chemotherapy Phase|Unrelated intercurrent illness|0
6024755|NCT00257608|9620180|FG001|Post Chemotherapy Phase|Unrelated intercurrent illness|0
6024756|NCT00257608|9620181|FG002|Post Chemotherapy Phase|Unrelated intercurrent illness|1
6024757|NCT00257608|9620179|FG000|Post Chemotherapy Phase|Lost to Follow-up|0
6024758|NCT00257608|9620180|FG001|Post Chemotherapy Phase|Lost to Follow-up|0
6024759|NCT00257608|9620181|FG002|Post Chemotherapy Phase|Lost to Follow-up|1
6024760|NCT00257608|9620179|FG000|Post Chemotherapy Phase|Physician Decision|0
6024761|NCT00257608|9620180|FG001|Post Chemotherapy Phase|Physician Decision|8
6024762|NCT00257608|9620181|FG002|Post Chemotherapy Phase|Physician Decision|11
6024763|NCT00257608|9620179|FG000|Post Chemotherapy Phase|Sponsor's decision to terminate study|0
6024764|NCT00257608|9620180|FG001|Post Chemotherapy Phase|Sponsor's decision to terminate study|1
6024765|NCT00257608|9620181|FG002|Post Chemotherapy Phase|Sponsor's decision to terminate study|0
6024766|NCT00257608|9620179|FG000|Post Chemotherapy Phase|Not treated|0
6024767|NCT00257608|9620180|FG001|Post Chemotherapy Phase|Not treated|4
6024768|NCT00257608|9620181|FG002|Post Chemotherapy Phase|Not treated|7
6024769|NCT00257660|9620196|FG000|Overall Study|Lack of Efficacy|5
6024770|NCT00257660|9620197|FG001|Overall Study|Lack of Efficacy|23
6024771|NCT00257660|9620196|FG000|Overall Study|Withdrawal by Subject|2
6024772|NCT00257660|9620197|FG001|Overall Study|Withdrawal by Subject|0
6024773|NCT00257660|9620196|FG000|Overall Study|Lost to Follow-up|1
6024774|NCT00257660|9620197|FG001|Overall Study|Lost to Follow-up|0
6024775|NCT00257660|9620196|FG000|Overall Study|PI & Subject Schedule Conflicts|1
6024776|NCT00257660|9620197|FG001|Overall Study|PI & Subject Schedule Conflicts|0
6024777|NCT00257660|9620196|FG000|Overall Study|No longer wanted to do blood draws|1
6024778|NCT00257660|9620197|FG001|Overall Study|No longer wanted to do blood draws|0
6024779|NCT00257725|9620228|FG000|Overall Study|Adverse Event|3
6024780|NCT00257920|9620244|FG000|Period: Washout Period of Two Weeks|Lost to Follow-up|0
6024781|NCT00257920|9620245|FG001|Period: Washout Period of Two Weeks|Lost to Follow-up|1
6024782|NCT00257920|9620244|FG000|Period: Second Intervention|Other|2
6024783|NCT00257920|9620245|FG001|Period: Second Intervention|Other|1
6024784|NCT00258154|9620278|FG000|Overall Study|Adverse Event|1
6024785|NCT00258154|9620279|FG001|Overall Study|Adverse Event|0
6078438|NCT00603798|9684763|FG001|Overall Study|Lost to Follow-up|0
6078439|NCT00603798|9684764|FG002|Overall Study|Lost to Follow-up|1
6078440|NCT00603798|9684762|FG000|Overall Study|Non-compliance with study procedures|0
6078441|NCT00603798|9684763|FG001|Overall Study|Non-compliance with study procedures|1
6024786|NCT00258154|9620278|FG000|Overall Study|Lost to Follow-up|0
6024787|NCT00258154|9620279|FG001|Overall Study|Lost to Follow-up|1
6024788|NCT00258154|9620278|FG000|Overall Study|Protocol Violation|2
6024789|NCT00258154|9620279|FG001|Overall Study|Protocol Violation|1
6024790|NCT00258154|9620278|FG000|Overall Study|Withdrawal by Subject|3
6024791|NCT00258154|9620279|FG001|Overall Study|Withdrawal by Subject|4
6024792|NCT00258154|9620278|FG000|Overall Study|Patient Moved|3
6024793|NCT00258154|9620279|FG001|Overall Study|Patient Moved|1
6024794|NCT00258440|9620312|FG000|Overall Study|Withdrawal by Subject|0
6024795|NCT00258440|9620313|FG001|Overall Study|Withdrawal by Subject|0
6024796|NCT00258440|9620314|FG002|Overall Study|Withdrawal by Subject|1
6024797|NCT00258674|9620325|FG000|Overall Study|Death|32
6024798|NCT00258674|9620326|FG001|Overall Study|Death|53
6024799|NCT00258674|9620327|FG002|Overall Study|Death|34
6024800|NCT00258856|9620357|FG000|Overall Study|Lost to Follow-up|1
6024801|NCT00258856|9620358|FG001|Overall Study|Lost to Follow-up|0
6024802|NCT00258856|9620359|FG002|Overall Study|Lost to Follow-up|2
6024803|NCT00258856|9620360|FG003|Overall Study|Lost to Follow-up|0
6024804|NCT00258856|9620357|FG000|Overall Study|Non-compliance|2
6024805|NCT00258856|9620358|FG001|Overall Study|Non-compliance|0
6024806|NCT00258856|9620359|FG002|Overall Study|Non-compliance|0
6024807|NCT00258856|9620360|FG003|Overall Study|Non-compliance|1
6024808|NCT00258895|9620383|FG000|Overall Study|Lost to Follow-up|3
6024809|NCT00258895|9620384|FG001|Overall Study|Lost to Follow-up|1
6024810|NCT00258895|9620383|FG000|Overall Study|Protocol Violation|6
6024811|NCT00258895|9620384|FG001|Overall Study|Protocol Violation|2
6024812|NCT00258895|9620383|FG000|Overall Study|Withdrawal by Subject|1
6024813|NCT00258895|9620384|FG001|Overall Study|Withdrawal by Subject|0
6024814|NCT00258960|9620394|FG000|Overall Study|Death|2
6024815|NCT00258960|9620394|FG000|Overall Study|Disease Progression|7
6024816|NCT00258960|9620394|FG000|Overall Study|Adverse Event|4
6024817|NCT00258960|9620394|FG000|Overall Study|Physician Decision|1
6024818|NCT00258960|9620394|FG000|Overall Study|Withdrawal by Subject|1
6024819|NCT00258960|9620394|FG000|Overall Study|Mistake|2
6024820|NCT00259012|9620400|FG000|Overall Study|Adverse Event|0
6024821|NCT00259012|9620401|FG001|Overall Study|Adverse Event|1
6024822|NCT00259012|9620400|FG000|Overall Study|Withdrawal by Subject|1
6024823|NCT00259012|9620401|FG001|Overall Study|Withdrawal by Subject|0
6024824|NCT00259012|9620400|FG000|Overall Study|Physician Decision|0
6024825|NCT00259012|9620401|FG001|Overall Study|Physician Decision|1
6024826|NCT00259012|9620400|FG000|Overall Study|Lost to Follow-up|0
6024827|NCT00259012|9620401|FG001|Overall Study|Lost to Follow-up|1
6024828|NCT00259012|9620400|FG000|Overall Study|Protocol Violation|1
6024829|NCT00259012|9620401|FG001|Overall Study|Protocol Violation|1
6024830|NCT00259272|9620424|FG000|Overall Study|Adverse Event|2
6024831|NCT00259272|9620425|FG001|Overall Study|Adverse Event|1
6024832|NCT00259272|9620426|FG002|Overall Study|Adverse Event|0
6024833|NCT00259272|9620427|FG003|Overall Study|Adverse Event|3
6024834|NCT00259272|9620424|FG000|Overall Study|Lack of Efficacy|5
6024835|NCT00259272|9620425|FG001|Overall Study|Lack of Efficacy|1
6024836|NCT00259272|9620426|FG002|Overall Study|Lack of Efficacy|2
6024837|NCT00259272|9620427|FG003|Overall Study|Lack of Efficacy|6
6024838|NCT00259272|9620424|FG000|Overall Study|Physician Decision|1
6024839|NCT00259272|9620425|FG001|Overall Study|Physician Decision|2
6024840|NCT00259272|9620426|FG002|Overall Study|Physician Decision|1
6024841|NCT00259272|9620427|FG003|Overall Study|Physician Decision|3
6024842|NCT00259272|9620424|FG000|Overall Study|Protocol Violation|2
6024843|NCT00259272|9620425|FG001|Overall Study|Protocol Violation|0
6024844|NCT00259272|9620426|FG002|Overall Study|Protocol Violation|0
6024845|NCT00259272|9620427|FG003|Overall Study|Protocol Violation|1
6024846|NCT00259272|9620424|FG000|Overall Study|Sponsor Decision|0
6024847|NCT00259272|9620425|FG001|Overall Study|Sponsor Decision|1
6024848|NCT00259272|9620426|FG002|Overall Study|Sponsor Decision|0
6024849|NCT00259272|9620427|FG003|Overall Study|Sponsor Decision|0
6024850|NCT00259272|9620424|FG000|Overall Study|Withdrawal by Subject|4
6024851|NCT00259272|9620425|FG001|Overall Study|Withdrawal by Subject|2
6024852|NCT00259272|9620426|FG002|Overall Study|Withdrawal by Subject|2
6024853|NCT00259272|9620427|FG003|Overall Study|Withdrawal by Subject|7
6024854|NCT00259272|9620424|FG000|Overall Study|Lost to Follow-up|1
6024855|NCT00259272|9620425|FG001|Overall Study|Lost to Follow-up|0
6024856|NCT00259272|9620426|FG002|Overall Study|Lost to Follow-up|0
6024857|NCT00259272|9620427|FG003|Overall Study|Lost to Follow-up|1
6048184|NCT00415597|9647279|FG000|Treatment|Administrative|3
6048185|NCT00415597|9647279|FG000|Treatment|Sponsor Decision|1
6048186|NCT00415597|9647279|FG000|Treatment|Multiple Reasons|1
6048187|NCT00415610|9647286|FG000|Overall Study|Death|3
6048188|NCT00415610|9647287|FG001|Overall Study|Death|2
6048189|NCT00415610|9647288|FG002|Overall Study|Death|5
6048190|NCT00415636|9647302|FG000|Overall Study|Symptomatic deterioration|1
6048191|NCT00415636|9647303|FG001|Overall Study|Symptomatic deterioration|0
6048192|NCT00415636|9647304|FG002|Overall Study|Symptomatic deterioration|1
6048193|NCT00415636|9647305|FG003|Overall Study|Symptomatic deterioration|2
6048194|NCT00415636|9647306|FG004|Overall Study|Symptomatic deterioration|0
6048195|NCT00415636|9647307|FG005|Overall Study|Symptomatic deterioration|1
6048196|NCT00415636|9647302|FG000|Overall Study|Adverse Event|0
6048197|NCT00415636|9647303|FG001|Overall Study|Adverse Event|0
6048198|NCT00415636|9647304|FG002|Overall Study|Adverse Event|0
6024858|NCT00259298|9620446|FG000|Overall Study|Withdrawal by Subject|1
6024859|NCT00259298|9620446|FG000|Overall Study|Physician Decision|2
6024860|NCT00259610|9620454|FG000|Overall Study|Withdrawal by Subject|33
6024861|NCT00259610|9620455|FG001|Overall Study|Withdrawal by Subject|25
6024862|NCT00259610|9620456|FG002|Overall Study|Withdrawal by Subject|29
6024863|NCT00259610|9620457|FG003|Overall Study|Withdrawal by Subject|19
6024864|NCT00259610|9620454|FG000|Overall Study|Lost to Follow-up|19
6024865|NCT00259610|9620455|FG001|Overall Study|Lost to Follow-up|8
6024866|NCT00259610|9620456|FG002|Overall Study|Lost to Follow-up|18
6024867|NCT00259610|9620457|FG003|Overall Study|Lost to Follow-up|15
6024868|NCT00259610|9620454|FG000|Overall Study|Physician Decision|6
6024869|NCT00259610|9620455|FG001|Overall Study|Physician Decision|4
6024870|NCT00259610|9620456|FG002|Overall Study|Physician Decision|7
6024871|NCT00259610|9620457|FG003|Overall Study|Physician Decision|2
6024872|NCT00259610|9620454|FG000|Overall Study|Death|1
6024873|NCT00259610|9620455|FG001|Overall Study|Death|1
6024874|NCT00259610|9620456|FG002|Overall Study|Death|2
6024875|NCT00259610|9620457|FG003|Overall Study|Death|0
6024876|NCT00259610|9620454|FG000|Overall Study|non medical reason|6
6024877|NCT00259610|9620455|FG001|Overall Study|non medical reason|2
6024878|NCT00259610|9620456|FG002|Overall Study|non medical reason|10
6024879|NCT00259610|9620457|FG003|Overall Study|non medical reason|3
6024880|NCT00259610|9620454|FG000|Overall Study|Adverse Event|3
6024881|NCT00259610|9620455|FG001|Overall Study|Adverse Event|4
6024882|NCT00259610|9620456|FG002|Overall Study|Adverse Event|5
6024883|NCT00259610|9620457|FG003|Overall Study|Adverse Event|2
6024884|NCT00259610|9620454|FG000|Overall Study|Serious Adverse Event|8
6024885|NCT00259610|9620455|FG001|Overall Study|Serious Adverse Event|2
6024886|NCT00259610|9620456|FG002|Overall Study|Serious Adverse Event|2
6024887|NCT00259610|9620457|FG003|Overall Study|Serious Adverse Event|2
6024888|NCT00259649|9620467|FG000|Overall Study|Lost to Follow-up|7
6024889|NCT00259649|9620467|FG000|Overall Study|irregular menses|3
6024890|NCT00259740|9620473|FG000|Overall Study|Physician Decision|1
6024891|NCT00259740|9620474|FG001|Overall Study|Physician Decision|1
6024892|NCT00259740|9620473|FG000|Overall Study|Adverse Event|0
6024893|NCT00259740|9620474|FG001|Overall Study|Adverse Event|2
6024894|NCT00259740|9620473|FG000|Overall Study|Withdrawal by Subject|2
6024895|NCT00259740|9620474|FG001|Overall Study|Withdrawal by Subject|6
6024896|NCT00259740|9620473|FG000|Overall Study|Death|1
6024897|NCT00259740|9620474|FG001|Overall Study|Death|1
6024898|NCT00259740|9620473|FG000|Overall Study|Disease progression|19
6024899|NCT00259740|9620474|FG001|Overall Study|Disease progression|36
6024900|NCT00259740|9620473|FG000|Overall Study|Ongoing|17
6024901|NCT00259740|9620474|FG001|Overall Study|Ongoing|3
6024902|NCT00259740|9620473|FG000|Overall Study|Other|3
6024903|NCT00259740|9620474|FG001|Overall Study|Other|0
6024904|NCT00259740|9620473|FG000|Overall Study|Requirement for alternative therapy|0
6024905|NCT00259740|9620474|FG001|Overall Study|Requirement for alternative therapy|4
6024906|NCT00259857|9620482|FG000|12 Months Treatment|Gr-1, lost followup; Gr-2, not compliant|1
6024907|NCT00259857|9620483|FG001|12 Months Treatment|Gr-1, lost followup; Gr-2, not compliant|2
6024908|NCT00259857|9620482|FG000|24 Months Treatment|Lost to Follow-up|0
6024909|NCT00259857|9620483|FG001|24 Months Treatment|Lost to Follow-up|3
6024910|NCT00260065|9620489|FG000|Overall Study|Progressive Disease|22
6024911|NCT00260065|9620489|FG000|Overall Study|Adverse Event|17
6024912|NCT00260065|9620489|FG000|Overall Study|Death|13
6024913|NCT00260065|9620489|FG000|Overall Study|Withdrawal by Subject|13
6024914|NCT00260065|9620489|FG000|Overall Study|Physician Decision|19
6024915|NCT00260065|9620489|FG000|Overall Study|Not otherwise specified|8
6024916|NCT00260065|9620489|FG000|Overall Study|Medication Noncompliance|1
6024917|NCT00260208|9620505|FG000|Overall Study|Subject withdrew consent|11
6024918|NCT00260208|9620506|FG001|Overall Study|Subject withdrew consent|7
6024919|NCT00260208|9620505|FG000|Overall Study|Lost to Follow-up|6
6024920|NCT00260208|9620506|FG001|Overall Study|Lost to Follow-up|1
6024921|NCT00260208|9620505|FG000|Overall Study|Death|12
6024922|NCT00260208|9620506|FG001|Overall Study|Death|10
6024923|NCT00260208|9620505|FG000|Overall Study|Missing|18
6024924|NCT00260208|9620506|FG001|Overall Study|Missing|16
6024925|NCT00260429|9620514|FG000|Overall Study|failure to follow appointments|1
6024926|NCT00260429|9620515|FG001|Overall Study|failure to follow appointments|0
6024927|NCT00260429|9620514|FG000|Overall Study|scheduled hand surgery|1
6024928|NCT00260429|9620515|FG001|Overall Study|scheduled hand surgery|0
6024929|NCT00260533|9620523|FG000|Overall Study|Other|3
6024930|NCT00260533|9620524|FG001|Overall Study|Other|3
6024931|NCT00260832|9620545|FG000|Overall Study|Adverse Event|26
6024932|NCT00260832|9620546|FG001|Overall Study|Adverse Event|19
6024933|NCT00260832|9620545|FG000|Overall Study|Progression|116
6024934|NCT00260832|9620546|FG001|Overall Study|Progression|96
6024935|NCT00260832|9620545|FG000|Overall Study|Withdrawal by Subject|15
6024936|NCT00260832|9620546|FG001|Overall Study|Withdrawal by Subject|17
6024937|NCT00260832|9620545|FG000|Overall Study|Physician Decision|15
6024938|NCT00260832|9620546|FG001|Overall Study|Physician Decision|9
6024939|NCT00260832|9620545|FG000|Overall Study|Death|43
6024940|NCT00260832|9620546|FG001|Overall Study|Death|62
6024941|NCT00260832|9620545|FG000|Overall Study|Other|10
6024942|NCT00260832|9620546|FG001|Overall Study|Other|7
6024943|NCT00260832|9620545|FG000|Overall Study|Protocol Violation|3
6024944|NCT00260832|9620546|FG001|Overall Study|Protocol Violation|1
6024945|NCT00261443|9620572|FG000|1: Confirmation of Partial Nonresponse|Adverse Event|33
6024946|NCT00261443|9620573|FG001|1: Confirmation of Partial Nonresponse|Adverse Event|0
6024947|NCT00261443|9620574|FG002|1: Confirmation of Partial Nonresponse|Adverse Event|0
6024948|NCT00261443|9620572|FG000|1: Confirmation of Partial Nonresponse|Withdrawal by Subject|93
6024949|NCT00261443|9620573|FG001|1: Confirmation of Partial Nonresponse|Withdrawal by Subject|0
6024950|NCT00261443|9620574|FG002|1: Confirmation of Partial Nonresponse|Withdrawal by Subject|0
6024951|NCT00261443|9620572|FG000|1: Confirmation of Partial Nonresponse|Lost to Follow-up|111
6024952|NCT00261443|9620573|FG001|1: Confirmation of Partial Nonresponse|Lost to Follow-up|0
6024953|NCT00261443|9620574|FG002|1: Confirmation of Partial Nonresponse|Lost to Follow-up|0
6024954|NCT00261443|9620572|FG000|1: Confirmation of Partial Nonresponse|Poor/Noncompliance|23
6024955|NCT00261443|9620573|FG001|1: Confirmation of Partial Nonresponse|Poor/Noncompliance|0
6024956|NCT00261443|9620574|FG002|1: Confirmation of Partial Nonresponse|Poor/Noncompliance|0
6024957|NCT00261443|9620572|FG000|1: Confirmation of Partial Nonresponse|Pregnancy|1
6024958|NCT00261443|9620573|FG001|1: Confirmation of Partial Nonresponse|Pregnancy|0
6024959|NCT00261443|9620574|FG002|1: Confirmation of Partial Nonresponse|Pregnancy|0
6024960|NCT00261443|9620572|FG000|1: Confirmation of Partial Nonresponse|Subject No Longer Met Study Criteria|307
6024961|NCT00261443|9620573|FG001|1: Confirmation of Partial Nonresponse|Subject No Longer Met Study Criteria|0
6024962|NCT00261443|9620574|FG002|1: Confirmation of Partial Nonresponse|Subject No Longer Met Study Criteria|0
6024963|NCT00261443|9620572|FG000|1: Confirmation of Partial Nonresponse|Other Reasons|16
6024964|NCT00261443|9620573|FG001|1: Confirmation of Partial Nonresponse|Other Reasons|0
6024965|NCT00261443|9620574|FG002|1: Confirmation of Partial Nonresponse|Other Reasons|0
6024966|NCT00261443|9620572|FG000|2: Stability & Maintenance of Stability|Lack of Efficacy|43
6024967|NCT00261443|9620573|FG001|2: Stability & Maintenance of Stability|Lack of Efficacy|0
6024968|NCT00261443|9620574|FG002|2: Stability & Maintenance of Stability|Lack of Efficacy|0
6024969|NCT00261443|9620572|FG000|2: Stability & Maintenance of Stability|Adverse Event|93
6024970|NCT00261443|9620573|FG001|2: Stability & Maintenance of Stability|Adverse Event|0
6024971|NCT00261443|9620574|FG002|2: Stability & Maintenance of Stability|Adverse Event|0
6024972|NCT00261443|9620572|FG000|2: Stability & Maintenance of Stability|Withdrawal by Subject|65
6078442|NCT00603798|9684764|FG002|Overall Study|Non-compliance with study procedures|0
6078443|NCT00603798|9684762|FG000|Overall Study|Not due to AE|1
6078444|NCT00603798|9684763|FG001|Overall Study|Not due to AE|1
6078445|NCT00603798|9684764|FG002|Overall Study|Not due to AE|4
6078446|NCT00603837|9684774|FG000|Overall Study|Physician Decision|3
6078447|NCT00603837|9684775|FG001|Overall Study|Physician Decision|0
6078448|NCT00603915|9684798|FG000|Overall Study|Physician Decision|1
6078449|NCT00603941|9684805|FG000|Overall Study|Disease progression|6
6078450|NCT00603941|9684806|FG001|Overall Study|Disease progression|7
6078451|NCT00603941|9684807|FG002|Overall Study|Disease progression|1
6078452|NCT00603941|9684805|FG000|Overall Study|Adverse Event|1
6078453|NCT00603941|9684806|FG001|Overall Study|Adverse Event|0
6078454|NCT00603941|9684807|FG002|Overall Study|Adverse Event|1
6078455|NCT00603941|9684805|FG000|Overall Study|Physician Decision|0
6078456|NCT00603941|9684806|FG001|Overall Study|Physician Decision|1
6078457|NCT00603941|9684807|FG002|Overall Study|Physician Decision|0
6078458|NCT00603941|9684805|FG000|Overall Study|Withdrawal by Subject|0
6078459|NCT00603941|9684806|FG001|Overall Study|Withdrawal by Subject|2
6078460|NCT00603941|9684807|FG002|Overall Study|Withdrawal by Subject|0
6078461|NCT00603980|9684816|FG000|Study Qualification|Protocol Violation|3
6078462|NCT00603980|9684816|FG000|Study Qualification|Inconsistent data reporting|13
6078463|NCT00603980|9684816|FG000|Main Study|14th subject completed trial|1
6078464|NCT00604162|9684858|FG000|Overall Study|Physician Decision|3
6078465|NCT00604162|9684858|FG000|Overall Study|Withdrawal by Subject|1
6078466|NCT00604175|9684868|FG000|Entry Through Week 28|Death|2
6078467|NCT00604175|9684869|FG001|Entry Through Week 28|Death|0
6078468|NCT00604175|9684870|FG002|Entry Through Week 28|Death|0
6078469|NCT00604175|9684868|FG000|Entry Through Week 28|Withdrawal by Subject|1
6078470|NCT00604175|9684869|FG001|Entry Through Week 28|Withdrawal by Subject|0
6078471|NCT00604175|9684870|FG002|Entry Through Week 28|Withdrawal by Subject|0
6078472|NCT00604175|9684868|FG000|Entry Through Week 28|Lost to Follow-up|4
6078473|NCT00604175|9684869|FG001|Entry Through Week 28|Lost to Follow-up|3
6078474|NCT00604175|9684870|FG002|Entry Through Week 28|Lost to Follow-up|0
6078475|NCT00604175|9684868|FG000|Entry Through Week 28|Ineligible|1
6078476|NCT00604175|9684869|FG001|Entry Through Week 28|Ineligible|0
6078477|NCT00604175|9684870|FG002|Entry Through Week 28|Ineligible|0
6078478|NCT00604175|9684868|FG000|Entry Through Week 28|Did not start intervention|2
6078479|NCT00604175|9684869|FG001|Entry Through Week 28|Did not start intervention|0
6078480|NCT00604175|9684870|FG002|Entry Through Week 28|Did not start intervention|1
6078481|NCT00604175|9684868|FG000|Week 29 Through Week 72|Death|0
6078482|NCT00604175|9684869|FG001|Week 29 Through Week 72|Death|0
6078483|NCT00604175|9684870|FG002|Week 29 Through Week 72|Death|1
6078484|NCT00604175|9684868|FG000|Week 29 Through Week 72|Lost to Follow-up|12
6078485|NCT00604175|9684869|FG001|Week 29 Through Week 72|Lost to Follow-up|6
6078486|NCT00604175|9684870|FG002|Week 29 Through Week 72|Lost to Follow-up|2
6078487|NCT00604175|9684868|FG000|Week 29 Through Week 72|Site closure|0
6078488|NCT00604175|9684869|FG001|Week 29 Through Week 72|Site closure|1
6078489|NCT00604175|9684870|FG002|Week 29 Through Week 72|Site closure|0
6146271|NCT01076075|9780864|FG001|Overall Study|Adverse Event|9
6024973|NCT00261443|9620573|FG001|2: Stability & Maintenance of Stability|Withdrawal by Subject|0
6024974|NCT00261443|9620574|FG002|2: Stability & Maintenance of Stability|Withdrawal by Subject|0
6024975|NCT00261443|9620572|FG000|2: Stability & Maintenance of Stability|Lost to Follow-up|59
6024976|NCT00261443|9620573|FG001|2: Stability & Maintenance of Stability|Lost to Follow-up|0
6024977|NCT00261443|9620574|FG002|2: Stability & Maintenance of Stability|Lost to Follow-up|0
6024978|NCT00261443|9620572|FG000|2: Stability & Maintenance of Stability|Poor/Noncompliance|33
6024979|NCT00261443|9620573|FG001|2: Stability & Maintenance of Stability|Poor/Noncompliance|0
6024980|NCT00261443|9620574|FG002|2: Stability & Maintenance of Stability|Poor/Noncompliance|0
6024981|NCT00261443|9620572|FG000|2: Stability & Maintenance of Stability|Pregnancy|1
6024982|NCT00261443|9620573|FG001|2: Stability & Maintenance of Stability|Pregnancy|0
6024983|NCT00261443|9620574|FG002|2: Stability & Maintenance of Stability|Pregnancy|0
6024984|NCT00261443|9620572|FG000|2: Stability & Maintenance of Stability|subject No Longer Met Study Criteria|32
6024985|NCT00261443|9620573|FG001|2: Stability & Maintenance of Stability|subject No Longer Met Study Criteria|0
6024986|NCT00261443|9620574|FG002|2: Stability & Maintenance of Stability|subject No Longer Met Study Criteria|0
6024987|NCT00261443|9620572|FG000|2: Stability & Maintenance of Stability|Administrative Reason by Sponsor|1
6024988|NCT00261443|9620573|FG001|2: Stability & Maintenance of Stability|Administrative Reason by Sponsor|0
6024989|NCT00261443|9620574|FG002|2: Stability & Maintenance of Stability|Administrative Reason by Sponsor|0
6024990|NCT00261443|9620572|FG000|2: Stability & Maintenance of Stability|Other Reasons|13
6024991|NCT00261443|9620573|FG001|2: Stability & Maintenance of Stability|Other Reasons|0
6024992|NCT00261443|9620574|FG002|2: Stability & Maintenance of Stability|Other Reasons|0
6024993|NCT00261443|9620572|FG000|3: Assessment of Relapse|Lack of Efficacy|0
6024994|NCT00261443|9620573|FG001|3: Assessment of Relapse|Lack of Efficacy|31
6024995|NCT00261443|9620574|FG002|3: Assessment of Relapse|Lack of Efficacy|14
6024996|NCT00261443|9620572|FG000|3: Assessment of Relapse|Adverse Event|0
6024997|NCT00261443|9620573|FG001|3: Assessment of Relapse|Adverse Event|15
6024998|NCT00261443|9620574|FG002|3: Assessment of Relapse|Adverse Event|19
6024999|NCT00261443|9620572|FG000|3: Assessment of Relapse|Withdrawal by Subject|0
6025000|NCT00261443|9620573|FG001|3: Assessment of Relapse|Withdrawal by Subject|14
6025001|NCT00261443|9620574|FG002|3: Assessment of Relapse|Withdrawal by Subject|15
6025002|NCT00261443|9620572|FG000|3: Assessment of Relapse|Death|0
6025003|NCT00261443|9620573|FG001|3: Assessment of Relapse|Death|0
6025004|NCT00261443|9620574|FG002|3: Assessment of Relapse|Death|1
6025005|NCT00261443|9620572|FG000|3: Assessment of Relapse|Lost to Follow-up|0
6025006|NCT00261443|9620573|FG001|3: Assessment of Relapse|Lost to Follow-up|7
6025007|NCT00261443|9620574|FG002|3: Assessment of Relapse|Lost to Follow-up|6
6025008|NCT00261443|9620572|FG000|3: Assessment of Relapse|Poor/Noncompliance|0
6025009|NCT00261443|9620573|FG001|3: Assessment of Relapse|Poor/Noncompliance|5
6025010|NCT00261443|9620574|FG002|3: Assessment of Relapse|Poor/Noncompliance|3
6025011|NCT00261443|9620572|FG000|3: Assessment of Relapse|Pregnancy|0
6025012|NCT00261443|9620573|FG001|3: Assessment of Relapse|Pregnancy|2
6025013|NCT00261443|9620574|FG002|3: Assessment of Relapse|Pregnancy|1
6025014|NCT00261443|9620572|FG000|3: Assessment of Relapse|Subject No Longer Meets Study Criteria|0
6025015|NCT00261443|9620573|FG001|3: Assessment of Relapse|Subject No Longer Meets Study Criteria|2
6025016|NCT00261443|9620574|FG002|3: Assessment of Relapse|Subject No Longer Meets Study Criteria|1
6025017|NCT00261443|9620572|FG000|3: Assessment of Relapse|Administrative Reason By Sponsor|0
6025018|NCT00261443|9620573|FG001|3: Assessment of Relapse|Administrative Reason By Sponsor|0
6025019|NCT00261443|9620574|FG002|3: Assessment of Relapse|Administrative Reason By Sponsor|2
6025020|NCT00261443|9620572|FG000|3: Assessment of Relapse|Other Reasons|0
6025021|NCT00261443|9620573|FG001|3: Assessment of Relapse|Other Reasons|4
6025022|NCT00261443|9620574|FG002|3: Assessment of Relapse|Other Reasons|3
6025023|NCT00261443|9620572|FG000|4: Extension Phase|Adverse Event|0
6025024|NCT00261443|9620573|FG001|4: Extension Phase|Adverse Event|1
6025025|NCT00261443|9620574|FG002|4: Extension Phase|Adverse Event|0
6025026|NCT00261443|9620572|FG000|4: Extension Phase|Withdrawal by Subject|0
6025027|NCT00261443|9620573|FG001|4: Extension Phase|Withdrawal by Subject|1
6025028|NCT00261443|9620574|FG002|4: Extension Phase|Withdrawal by Subject|2
6025029|NCT00261443|9620572|FG000|4: Extension Phase|Lost to Follow-up|0
6078490|NCT00604175|9684868|FG000|Week 29 Through Week 72|Non-adherence to study requirements|0
6078491|NCT00604175|9684869|FG001|Week 29 Through Week 72|Non-adherence to study requirements|0
6078492|NCT00604175|9684870|FG002|Week 29 Through Week 72|Non-adherence to study requirements|1
6078493|NCT00604188|9684904|FG000|Overall Study|Adverse Event|1
6078494|NCT00604188|9684905|FG001|Overall Study|Adverse Event|4
6078495|NCT00604188|9684904|FG000|Overall Study|Lost to Follow-up|17
6078496|NCT00604188|9684905|FG001|Overall Study|Lost to Follow-up|15
6078497|NCT00604188|9684904|FG000|Overall Study|Withdrawal by Subject|5
6078498|NCT00604188|9684905|FG001|Overall Study|Withdrawal by Subject|1
6078499|NCT00604188|9684904|FG000|Overall Study|Non-compliance with protocol|4
6078500|NCT00604188|9684905|FG001|Overall Study|Non-compliance with protocol|4
6078501|NCT00604188|9684904|FG000|Overall Study|Did not receive study drug|0
6078502|NCT00604188|9684905|FG001|Overall Study|Did not receive study drug|1
6025030|NCT00261443|9620573|FG001|4: Extension Phase|Lost to Follow-up|1
6025031|NCT00261443|9620574|FG002|4: Extension Phase|Lost to Follow-up|0
6078503|NCT00604214|9684913|FG000|Baseline to Day 28|Death|223
6078504|NCT00604214|9684914|FG001|Baseline to Day 28|Death|202
6025032|NCT00261495|9620587|FG000|Titration Phase (Weeks 0 to 4)|Adverse Event|28
6025033|NCT00261495|9620588|FG001|Titration Phase (Weeks 0 to 4)|Adverse Event|36
6025034|NCT00261495|9620587|FG000|Titration Phase (Weeks 0 to 4)|Withdrawal by Subject|6
6025035|NCT00261495|9620588|FG001|Titration Phase (Weeks 0 to 4)|Withdrawal by Subject|11
6025036|NCT00261495|9620587|FG000|Titration Phase (Weeks 0 to 4)|Lack of Efficacy|8
6025037|NCT00261495|9620588|FG001|Titration Phase (Weeks 0 to 4)|Lack of Efficacy|8
6025038|NCT00261495|9620587|FG000|Titration Phase (Weeks 0 to 4)|Physician Decision|3
6025039|NCT00261495|9620588|FG001|Titration Phase (Weeks 0 to 4)|Physician Decision|1
6025040|NCT00261495|9620587|FG000|Titration Phase (Weeks 0 to 4)|Non-compliance|2
6025041|NCT00261495|9620588|FG001|Titration Phase (Weeks 0 to 4)|Non-compliance|5
6025042|NCT00261495|9620587|FG000|Titration Phase (Weeks 0 to 4)|Protocol Violation|1
6025043|NCT00261495|9620588|FG001|Titration Phase (Weeks 0 to 4)|Protocol Violation|4
6025044|NCT00261495|9620587|FG000|Maintenance Phase (Weeks 4 to 24)|Adverse Event|29
6025045|NCT00261495|9620588|FG001|Maintenance Phase (Weeks 4 to 24)|Adverse Event|20
6025046|NCT00261495|9620587|FG000|Maintenance Phase (Weeks 4 to 24)|Lack of Efficacy|14
6025047|NCT00261495|9620588|FG001|Maintenance Phase (Weeks 4 to 24)|Lack of Efficacy|10
6025048|NCT00261495|9620587|FG000|Maintenance Phase (Weeks 4 to 24)|Withdrawal by Subject|6
6025049|NCT00261495|9620588|FG001|Maintenance Phase (Weeks 4 to 24)|Withdrawal by Subject|5
6025050|NCT00261495|9620587|FG000|Maintenance Phase (Weeks 4 to 24)|Non-compliance|1
6025051|NCT00261495|9620588|FG001|Maintenance Phase (Weeks 4 to 24)|Non-compliance|5
6025052|NCT00261495|9620587|FG000|Maintenance Phase (Weeks 4 to 24)|Protocol Violation|5
6025053|NCT00261495|9620588|FG001|Maintenance Phase (Weeks 4 to 24)|Protocol Violation|2
6025054|NCT00261495|9620587|FG000|Maintenance Phase (Weeks 4 to 24)|Other|6
6025055|NCT00261495|9620588|FG001|Maintenance Phase (Weeks 4 to 24)|Other|5
6025056|NCT00261495|9620587|FG000|Maintenance Phase (Weeks 4 to 24)|Physician Decision|1
6025057|NCT00261495|9620588|FG001|Maintenance Phase (Weeks 4 to 24)|Physician Decision|1
6025058|NCT00261495|9620587|FG000|Maintenance Phase (Weeks 4 to 24)|Treatment completed, no follow-up|2
6025059|NCT00261495|9620588|FG001|Maintenance Phase (Weeks 4 to 24)|Treatment completed, no follow-up|0
6025060|NCT00261495|9620587|FG000|Maintenance Phase (Weeks 4 to 24)|Lost to Follow-up|2
6025061|NCT00261495|9620588|FG001|Maintenance Phase (Weeks 4 to 24)|Lost to Follow-up|0
6025062|NCT00261495|9620587|FG000|Extension Phase (Weeks 24 to 52)|Other|4
6025063|NCT00261495|9620588|FG001|Extension Phase (Weeks 24 to 52)|Other|2
6025064|NCT00261495|9620587|FG000|Extension Phase (Weeks 24 to 52)|Adverse Event|4
6025065|NCT00261495|9620588|FG001|Extension Phase (Weeks 24 to 52)|Adverse Event|1
6025066|NCT00261495|9620587|FG000|Extension Phase (Weeks 24 to 52)|Lack of Efficacy|0
6025067|NCT00261495|9620588|FG001|Extension Phase (Weeks 24 to 52)|Lack of Efficacy|1
6025068|NCT00261495|9620587|FG000|Extension Phase (Weeks 24 to 52)|Withdrawal by Subject|0
6025069|NCT00261495|9620588|FG001|Extension Phase (Weeks 24 to 52)|Withdrawal by Subject|1
6025070|NCT00261495|9620587|FG000|Extension Phase (Weeks 24 to 52)|Non-compliance|1
6025071|NCT00261495|9620588|FG001|Extension Phase (Weeks 24 to 52)|Non-compliance|0
6025072|NCT00261495|9620587|FG000|Extension Phase (Weeks 24 to 52)|Lost to Follow-up|1
6025073|NCT00261495|9620588|FG001|Extension Phase (Weeks 24 to 52)|Lost to Follow-up|0
6025074|NCT00261716|9620596|FG000|Overall Study|Withdrawal by Subject|6
6025075|NCT00261716|9620597|FG001|Overall Study|Withdrawal by Subject|8
6025076|NCT00261716|9620596|FG000|Overall Study|Lost to Follow-up|0
6025077|NCT00261716|9620597|FG001|Overall Study|Lost to Follow-up|2
6025078|NCT00261833|9620609|FG000|Overall Study|Death|1
6025079|NCT00261833|9620610|FG001|Overall Study|Death|3
6078505|NCT00604214|9684913|FG000|Baseline to Day 28|Lost to Follow-up|2
6078506|NCT00604214|9684914|FG001|Baseline to Day 28|Lost to Follow-up|4
6078507|NCT00604214|9684913|FG000|Baseline to Day 28|Withdrawal by Subject|3
6078508|NCT00604214|9684914|FG001|Baseline to Day 28|Withdrawal by Subject|7
6078509|NCT00604214|9684913|FG000|Day 29 to Day 90|Death|64
6078510|NCT00604214|9684914|FG001|Day 29 to Day 90|Death|67
6078511|NCT00604214|9684913|FG000|Day 29 to Day 90|Lost to Follow-up|4
6078512|NCT00604214|9684914|FG001|Day 29 to Day 90|Lost to Follow-up|6
6078513|NCT00604214|9684913|FG000|Day 29 to Day 90|Withdrawal by Subject|0
6078514|NCT00604214|9684914|FG001|Day 29 to Day 90|Withdrawal by Subject|6
6078515|NCT00604214|9684913|FG000|Day 91 to Day 180|Death|19
6078516|NCT00604214|9684914|FG001|Day 91 to Day 180|Death|23
6078517|NCT00604214|9684913|FG000|Day 91 to Day 180|Lost to Follow-up|6
6078518|NCT00604214|9684914|FG001|Day 91 to Day 180|Lost to Follow-up|8
6078519|NCT00604214|9684913|FG000|Day 91 to Day 180|Withdrawal by Subject|1
6078520|NCT00604214|9684914|FG001|Day 91 to Day 180|Withdrawal by Subject|1
6078521|NCT00604279|9684922|FG000|Overall Study|Lack of Efficacy|22
6078522|NCT00604279|9684923|FG001|Overall Study|Lack of Efficacy|9
6078523|NCT00604279|9684922|FG000|Overall Study|Lost to Follow-up|9
6078524|NCT00604279|9684923|FG001|Overall Study|Lost to Follow-up|14
6078525|NCT00604279|9684922|FG000|Overall Study|Pregnancy|2
6078526|NCT00604279|9684923|FG001|Overall Study|Pregnancy|0
6078527|NCT00604279|9684922|FG000|Overall Study|Protocol Violation|3
6078528|NCT00604279|9684923|FG001|Overall Study|Protocol Violation|1
6078529|NCT00604279|9684922|FG000|Overall Study|Withdrawal by Subject|16
6078530|NCT00604279|9684923|FG001|Overall Study|Withdrawal by Subject|5
6078531|NCT00604279|9684922|FG000|Overall Study|Adverse Event|4
6078532|NCT00604279|9684923|FG001|Overall Study|Adverse Event|5
6078533|NCT00604279|9684922|FG000|Overall Study|Other|8
6078534|NCT00604279|9684923|FG001|Overall Study|Other|4
6025080|NCT00261833|9620609|FG000|Overall Study|Adverse Event|1
6025081|NCT00261833|9620610|FG001|Overall Study|Adverse Event|4
6025082|NCT00261833|9620609|FG000|Overall Study|Withdrawal by Subject|5
6025083|NCT00261833|9620610|FG001|Overall Study|Withdrawal by Subject|7
6025084|NCT00261833|9620609|FG000|Overall Study|Protocol Violation|0
6025085|NCT00261833|9620610|FG001|Overall Study|Protocol Violation|1
6025086|NCT00261833|9620609|FG000|Overall Study|Suspicion of pulmonary cancer|0
6025087|NCT00261833|9620610|FG001|Overall Study|Suspicion of pulmonary cancer|1
6025088|NCT00261833|9620609|FG000|Overall Study|Lung transplantation|1
6025089|NCT00261833|9620610|FG001|Overall Study|Lung transplantation|1
6025090|NCT00261833|9620609|FG000|Overall Study|Missing reason|1
6025091|NCT00261833|9620610|FG001|Overall Study|Missing reason|0
6025092|NCT00261833|9620609|FG000|Overall Study|Not interested in being participant|0
6025093|NCT00261833|9620610|FG001|Overall Study|Not interested in being participant|1
6025094|NCT00261846|9620626|FG000|Period 1: Part 1 (Dose Escalation)|Continued in to Part 2|3
6025095|NCT00261846|9620627|FG001|Period 1: Part 1 (Dose Escalation)|Continued in to Part 2|3
6025096|NCT00261846|9620628|FG002|Period 1: Part 1 (Dose Escalation)|Continued in to Part 2|12
6025097|NCT00261846|9620629|FG003|Period 1: Part 1 (Dose Escalation)|Continued in to Part 2|0
6025098|NCT00261846|9620630|FG004|Period 1: Part 1 (Dose Escalation)|Continued in to Part 2|0
6025099|NCT00261846|9620631|FG005|Period 1: Part 1 (Dose Escalation)|Continued in to Part 2|0
6025100|NCT00261846|9620632|FG006|Period 1: Part 1 (Dose Escalation)|Continued in to Part 2|0
6025101|NCT00261846|9620633|FG007|Period 1: Part 1 (Dose Escalation)|Continued in to Part 2|0
6025102|NCT00261846|9620634|FG008|Period 1: Part 1 (Dose Escalation)|Continued in to Part 2|0
6025103|NCT00261846|9620635|FG009|Period 1: Part 1 (Dose Escalation)|Continued in to Part 2|0
6025104|NCT00261846|9620636|FG010|Period 1: Part 1 (Dose Escalation)|Continued in to Part 2|0
6025105|NCT00261846|9620637|FG011|Period 1: Part 1 (Dose Escalation)|Continued in to Part 2|0
6025106|NCT00261846|9620626|FG000|Period 2: Part 2 (Efficacy)|Discontinuation of study by sponsor|0
6025107|NCT00261846|9620627|FG001|Period 2: Part 2 (Efficacy)|Discontinuation of study by sponsor|0
6025108|NCT00261846|9620628|FG002|Period 2: Part 2 (Efficacy)|Discontinuation of study by sponsor|0
6025109|NCT00261846|9620629|FG003|Period 2: Part 2 (Efficacy)|Discontinuation of study by sponsor|1
6025110|NCT00261846|9620630|FG004|Period 2: Part 2 (Efficacy)|Discontinuation of study by sponsor|0
6025111|NCT00261846|9620631|FG005|Period 2: Part 2 (Efficacy)|Discontinuation of study by sponsor|0
6025112|NCT00261846|9620632|FG006|Period 2: Part 2 (Efficacy)|Discontinuation of study by sponsor|0
6025113|NCT00261846|9620633|FG007|Period 2: Part 2 (Efficacy)|Discontinuation of study by sponsor|0
6025114|NCT00261846|9620634|FG008|Period 2: Part 2 (Efficacy)|Discontinuation of study by sponsor|1
6025115|NCT00261846|9620635|FG009|Period 2: Part 2 (Efficacy)|Discontinuation of study by sponsor|0
6025116|NCT00261846|9620636|FG010|Period 2: Part 2 (Efficacy)|Discontinuation of study by sponsor|0
6025117|NCT00261846|9620637|FG011|Period 2: Part 2 (Efficacy)|Discontinuation of study by sponsor|0
6025118|NCT00261846|9620626|FG000|Period 2: Part 2 (Efficacy)|Withdrawal by Subject|0
6025119|NCT00261846|9620627|FG001|Period 2: Part 2 (Efficacy)|Withdrawal by Subject|0
6025120|NCT00261846|9620628|FG002|Period 2: Part 2 (Efficacy)|Withdrawal by Subject|0
6025121|NCT00261846|9620629|FG003|Period 2: Part 2 (Efficacy)|Withdrawal by Subject|9
6025122|NCT00261846|9620630|FG004|Period 2: Part 2 (Efficacy)|Withdrawal by Subject|8
6025123|NCT00261846|9620631|FG005|Period 2: Part 2 (Efficacy)|Withdrawal by Subject|1
6025124|NCT00261846|9620632|FG006|Period 2: Part 2 (Efficacy)|Withdrawal by Subject|3
6025125|NCT00261846|9620633|FG007|Period 2: Part 2 (Efficacy)|Withdrawal by Subject|3
6025126|NCT00261846|9620634|FG008|Period 2: Part 2 (Efficacy)|Withdrawal by Subject|0
6025127|NCT00261846|9620635|FG009|Period 2: Part 2 (Efficacy)|Withdrawal by Subject|2
6025128|NCT00261846|9620636|FG010|Period 2: Part 2 (Efficacy)|Withdrawal by Subject|0
6025129|NCT00261846|9620637|FG011|Period 2: Part 2 (Efficacy)|Withdrawal by Subject|0
6025130|NCT00261846|9620626|FG000|Period 2: Part 2 (Efficacy)|Lost to Follow-up|0
6025131|NCT00261846|9620627|FG001|Period 2: Part 2 (Efficacy)|Lost to Follow-up|0
6025132|NCT00261846|9620628|FG002|Period 2: Part 2 (Efficacy)|Lost to Follow-up|0
6025133|NCT00261846|9620629|FG003|Period 2: Part 2 (Efficacy)|Lost to Follow-up|12
6025134|NCT00261846|9620630|FG004|Period 2: Part 2 (Efficacy)|Lost to Follow-up|4
6025135|NCT00261846|9620631|FG005|Period 2: Part 2 (Efficacy)|Lost to Follow-up|0
6025136|NCT00261846|9620632|FG006|Period 2: Part 2 (Efficacy)|Lost to Follow-up|4
6025137|NCT00261846|9620633|FG007|Period 2: Part 2 (Efficacy)|Lost to Follow-up|0
6025138|NCT00261846|9620634|FG008|Period 2: Part 2 (Efficacy)|Lost to Follow-up|1
6025139|NCT00261846|9620635|FG009|Period 2: Part 2 (Efficacy)|Lost to Follow-up|4
6025140|NCT00261846|9620636|FG010|Period 2: Part 2 (Efficacy)|Lost to Follow-up|4
6025141|NCT00261846|9620637|FG011|Period 2: Part 2 (Efficacy)|Lost to Follow-up|0
6025142|NCT00261846|9620626|FG000|Period 2: Part 2 (Efficacy)|Other|0
6025143|NCT00261846|9620627|FG001|Period 2: Part 2 (Efficacy)|Other|0
6025144|NCT00261846|9620628|FG002|Period 2: Part 2 (Efficacy)|Other|0
6025145|NCT00261846|9620629|FG003|Period 2: Part 2 (Efficacy)|Other|15
6025146|NCT00261846|9620630|FG004|Period 2: Part 2 (Efficacy)|Other|4
6025147|NCT00261846|9620631|FG005|Period 2: Part 2 (Efficacy)|Other|0
6025148|NCT00261846|9620632|FG006|Period 2: Part 2 (Efficacy)|Other|1
6025149|NCT00261846|9620633|FG007|Period 2: Part 2 (Efficacy)|Other|5
6025150|NCT00261846|9620634|FG008|Period 2: Part 2 (Efficacy)|Other|4
6025151|NCT00261846|9620635|FG009|Period 2: Part 2 (Efficacy)|Other|4
6025152|NCT00261846|9620636|FG010|Period 2: Part 2 (Efficacy)|Other|0
6025153|NCT00261846|9620637|FG011|Period 2: Part 2 (Efficacy)|Other|0
6025154|NCT00261846|9620626|FG000|Period 2: Part 2 (Efficacy)|Death|0
6025155|NCT00261846|9620627|FG001|Period 2: Part 2 (Efficacy)|Death|0
6025156|NCT00261846|9620628|FG002|Period 2: Part 2 (Efficacy)|Death|0
6025157|NCT00261846|9620629|FG003|Period 2: Part 2 (Efficacy)|Death|37
6025158|NCT00261846|9620630|FG004|Period 2: Part 2 (Efficacy)|Death|7
6025159|NCT00261846|9620631|FG005|Period 2: Part 2 (Efficacy)|Death|1
6025160|NCT00261846|9620632|FG006|Period 2: Part 2 (Efficacy)|Death|10
6025161|NCT00261846|9620633|FG007|Period 2: Part 2 (Efficacy)|Death|12
6025162|NCT00261846|9620634|FG008|Period 2: Part 2 (Efficacy)|Death|3
6025163|NCT00261846|9620635|FG009|Period 2: Part 2 (Efficacy)|Death|30
6025164|NCT00261846|9620636|FG010|Period 2: Part 2 (Efficacy)|Death|44
6025165|NCT00261846|9620637|FG011|Period 2: Part 2 (Efficacy)|Death|22
6025166|NCT00261846|9620626|FG000|Period 2: Part 2 (Efficacy)|Extension study|0
6025167|NCT00261846|9620627|FG001|Period 2: Part 2 (Efficacy)|Extension study|0
6025168|NCT00261846|9620628|FG002|Period 2: Part 2 (Efficacy)|Extension study|0
6025169|NCT00261846|9620629|FG003|Period 2: Part 2 (Efficacy)|Extension study|61
6025170|NCT00261846|9620630|FG004|Period 2: Part 2 (Efficacy)|Extension study|27
6025171|NCT00261846|9620631|FG005|Period 2: Part 2 (Efficacy)|Extension study|0
6025172|NCT00261846|9620632|FG006|Period 2: Part 2 (Efficacy)|Extension study|4
6025173|NCT00261846|9620633|FG007|Period 2: Part 2 (Efficacy)|Extension study|9
6025174|NCT00261846|9620634|FG008|Period 2: Part 2 (Efficacy)|Extension study|5
6025175|NCT00261846|9620635|FG009|Period 2: Part 2 (Efficacy)|Extension study|9
6025176|NCT00261846|9620636|FG010|Period 2: Part 2 (Efficacy)|Extension study|1
6025177|NCT00261846|9620637|FG011|Period 2: Part 2 (Efficacy)|Extension study|1
6025178|NCT00261950|9620676|FG000|Overall Study|Lost to Follow-up|2
6025179|NCT00261950|9620676|FG000|Overall Study|Death|6
6025180|NCT00261950|9620676|FG000|Overall Study|Withdrawal by Subject|5
6025181|NCT00261950|9620676|FG000|Overall Study|Other|1
6025182|NCT00261950|9620676|FG000|Overall Study|Physician Decision|1
6025183|NCT00261950|9620676|FG000|Overall Study|Protocol specified Criteria|11
6025184|NCT00262002|9620687|FG000|Overall Study|Adverse Event|2
6025185|NCT00262002|9620688|FG001|Overall Study|Adverse Event|1
6025186|NCT00262002|9620689|FG002|Overall Study|Adverse Event|0
6025187|NCT00262002|9620690|FG003|Overall Study|Adverse Event|0
6025188|NCT00262002|9620691|FG004|Overall Study|Adverse Event|0
6025189|NCT00262002|9620692|FG005|Overall Study|Adverse Event|1
6025190|NCT00262002|9620693|FG006|Overall Study|Adverse Event|0
6025191|NCT00262002|9620687|FG000|Overall Study|Withdrawal by Subject|4
6025192|NCT00262002|9620688|FG001|Overall Study|Withdrawal by Subject|2
6025193|NCT00262002|9620689|FG002|Overall Study|Withdrawal by Subject|0
6025194|NCT00262002|9620690|FG003|Overall Study|Withdrawal by Subject|1
6025195|NCT00262002|9620691|FG004|Overall Study|Withdrawal by Subject|2
6025196|NCT00262002|9620692|FG005|Overall Study|Withdrawal by Subject|2
6025197|NCT00262002|9620693|FG006|Overall Study|Withdrawal by Subject|2
6025198|NCT00262002|9620687|FG000|Overall Study|Lost to Follow-up|2
6025199|NCT00262002|9620688|FG001|Overall Study|Lost to Follow-up|0
6025200|NCT00262002|9620689|FG002|Overall Study|Lost to Follow-up|0
6025201|NCT00262002|9620690|FG003|Overall Study|Lost to Follow-up|2
6025202|NCT00262002|9620691|FG004|Overall Study|Lost to Follow-up|0
6025203|NCT00262002|9620692|FG005|Overall Study|Lost to Follow-up|1
6025204|NCT00262002|9620693|FG006|Overall Study|Lost to Follow-up|0
6025205|NCT00262002|9620687|FG000|Overall Study|Inapropriate enrollment|0
6025206|NCT00262002|9620688|FG001|Overall Study|Inapropriate enrollment|1
6025207|NCT00262002|9620689|FG002|Overall Study|Inapropriate enrollment|0
6025208|NCT00262002|9620690|FG003|Overall Study|Inapropriate enrollment|0
6025209|NCT00262002|9620691|FG004|Overall Study|Inapropriate enrollment|0
6025210|NCT00262002|9620692|FG005|Overall Study|Inapropriate enrollment|0
6025211|NCT00262002|9620693|FG006|Overall Study|Inapropriate enrollment|0
6025212|NCT00262002|9620687|FG000|Overall Study|Protocol Violation|3
6025213|NCT00262002|9620688|FG001|Overall Study|Protocol Violation|2
6025214|NCT00262002|9620689|FG002|Overall Study|Protocol Violation|0
6025215|NCT00262002|9620690|FG003|Overall Study|Protocol Violation|2
6025216|NCT00262002|9620691|FG004|Overall Study|Protocol Violation|5
6025217|NCT00262002|9620692|FG005|Overall Study|Protocol Violation|3
6025218|NCT00262002|9620693|FG006|Overall Study|Protocol Violation|2
6025219|NCT00262002|9620687|FG000|Overall Study|Unable to classify|0
6025220|NCT00262002|9620688|FG001|Overall Study|Unable to classify|0
6025221|NCT00262002|9620689|FG002|Overall Study|Unable to classify|0
6025222|NCT00262002|9620690|FG003|Overall Study|Unable to classify|0
6025223|NCT00262002|9620691|FG004|Overall Study|Unable to classify|0
6025224|NCT00262002|9620692|FG005|Overall Study|Unable to classify|0
6025225|NCT00262002|9620693|FG006|Overall Study|Unable to classify|2
6025226|NCT00262028|9620767|FG000|Overall Study|Withdrawal by Subject|6
6025227|NCT00262028|9620768|FG001|Overall Study|Withdrawal by Subject|3
6025228|NCT00262028|9620769|FG002|Overall Study|Withdrawal by Subject|6
6025229|NCT00262028|9620770|FG003|Overall Study|Withdrawal by Subject|5
6025230|NCT00262028|9620771|FG004|Overall Study|Withdrawal by Subject|2
6025231|NCT00262028|9620772|FG005|Overall Study|Withdrawal by Subject|3
6025232|NCT00262028|9620773|FG006|Overall Study|Withdrawal by Subject|5
6025233|NCT00262028|9620774|FG007|Overall Study|Withdrawal by Subject|7
6025234|NCT00262028|9620775|FG008|Overall Study|Withdrawal by Subject|2
6025235|NCT00262028|9620767|FG000|Overall Study|Lost to Follow-up|7
6025236|NCT00262028|9620768|FG001|Overall Study|Lost to Follow-up|7
6025237|NCT00262028|9620769|FG002|Overall Study|Lost to Follow-up|5
6025238|NCT00262028|9620770|FG003|Overall Study|Lost to Follow-up|5
6025239|NCT00262028|9620771|FG004|Overall Study|Lost to Follow-up|4
6025240|NCT00262028|9620772|FG005|Overall Study|Lost to Follow-up|3
6025241|NCT00262028|9620773|FG006|Overall Study|Lost to Follow-up|3
6025242|NCT00262028|9620774|FG007|Overall Study|Lost to Follow-up|5
6078535|NCT00604383|9684931|FG000|Overall Study|Withdrawal by Subject|33
6078536|NCT00604383|9684932|FG001|Overall Study|Withdrawal by Subject|31
6078537|NCT00604383|9684931|FG000|Overall Study|Lost to Follow-up|24
6078538|NCT00604383|9684932|FG001|Overall Study|Lost to Follow-up|19
6078539|NCT00604383|9684931|FG000|Overall Study|Death|14
6078540|NCT00604383|9684932|FG001|Overall Study|Death|22
6025243|NCT00262028|9620775|FG008|Overall Study|Lost to Follow-up|6
6025244|NCT00262028|9620767|FG000|Overall Study|Administrative Reason|11
6078541|NCT00604383|9684931|FG000|Overall Study|Adverse Event|16
6078542|NCT00604383|9684932|FG001|Overall Study|Adverse Event|9
6078543|NCT00604383|9684931|FG000|Overall Study|Physician Decision|0
6078544|NCT00604383|9684932|FG001|Overall Study|Physician Decision|3
6078545|NCT00604565|9684955|FG000|Overall Study|Study terminated|0
6078546|NCT00604565|9684956|FG001|Overall Study|Study terminated|3
6078547|NCT00604669|9684962|FG000|Overall Study|lack of information in chart|7
6078548|NCT00604695|9684968|FG000|Overall Study|Did not receive first bolus.|0
6078549|NCT00604695|9684969|FG001|Overall Study|Did not receive first bolus.|4
6078550|NCT00604708|9684977|FG000|Overall Study|Withdrawal by Subject|9
6078551|NCT00604708|9684978|FG001|Overall Study|Withdrawal by Subject|10
6078552|NCT00604708|9684977|FG000|Overall Study|Protocol Violation|2
6078553|NCT00604708|9684978|FG001|Overall Study|Protocol Violation|8
6078554|NCT00604708|9684977|FG000|Overall Study|Lost to Follow-up|5
6078555|NCT00604708|9684978|FG001|Overall Study|Lost to Follow-up|5
6078556|NCT00604708|9684977|FG000|Overall Study|administrative reasons|9
6078557|NCT00604708|9684978|FG001|Overall Study|administrative reasons|11
6078558|NCT00604708|9684977|FG000|Overall Study|Adverse Event|6
6078559|NCT00604708|9684978|FG001|Overall Study|Adverse Event|6
6078560|NCT00604721|9684984|FG000|Overall Study|Physician Decision|1
6078561|NCT00604721|9684984|FG000|Overall Study|Withdrawal by Subject|1
6078562|NCT00604786|9684991|FG000|Overall Study|Lost to Follow-up|2
6078563|NCT00604786|9684992|FG001|Overall Study|Lost to Follow-up|0
6078564|NCT00604825|9685002|FG000|Overall Study|Adverse Event|2
6078565|NCT00604825|9685003|FG001|Overall Study|Adverse Event|6
6078566|NCT00604825|9685004|FG002|Overall Study|Adverse Event|7
6078567|NCT00604825|9685005|FG003|Overall Study|Adverse Event|4
6078568|NCT00604825|9685002|FG000|Overall Study|Lost to Follow-up|0
6078569|NCT00604825|9685003|FG001|Overall Study|Lost to Follow-up|3
6078570|NCT00604825|9685004|FG002|Overall Study|Lost to Follow-up|1
6078571|NCT00604825|9685005|FG003|Overall Study|Lost to Follow-up|0
6078572|NCT00604825|9685002|FG000|Overall Study|Protocol Violation|0
6078573|NCT00604825|9685003|FG001|Overall Study|Protocol Violation|1
6025245|NCT00262028|9620768|FG001|Overall Study|Administrative Reason|14
6025246|NCT00262028|9620769|FG002|Overall Study|Administrative Reason|9
6025247|NCT00262028|9620770|FG003|Overall Study|Administrative Reason|12
6025248|NCT00262028|9620771|FG004|Overall Study|Administrative Reason|6
6025249|NCT00262028|9620772|FG005|Overall Study|Administrative Reason|7
6025250|NCT00262028|9620773|FG006|Overall Study|Administrative Reason|4
6025251|NCT00262028|9620774|FG007|Overall Study|Administrative Reason|6
6025252|NCT00262028|9620775|FG008|Overall Study|Administrative Reason|10
6025253|NCT00262028|9620767|FG000|Overall Study|Protocol Violation|0
6025254|NCT00262028|9620768|FG001|Overall Study|Protocol Violation|0
6025255|NCT00262028|9620769|FG002|Overall Study|Protocol Violation|0
6025256|NCT00262028|9620770|FG003|Overall Study|Protocol Violation|1
6025257|NCT00262028|9620771|FG004|Overall Study|Protocol Violation|0
6025258|NCT00262028|9620772|FG005|Overall Study|Protocol Violation|0
6025259|NCT00262028|9620773|FG006|Overall Study|Protocol Violation|0
6025260|NCT00262028|9620774|FG007|Overall Study|Protocol Violation|0
6025261|NCT00262028|9620775|FG008|Overall Study|Protocol Violation|0
6025262|NCT00262028|9620767|FG000|Overall Study|Unable to classify|0
6025263|NCT00262028|9620768|FG001|Overall Study|Unable to classify|3
6025264|NCT00262028|9620769|FG002|Overall Study|Unable to classify|0
6025265|NCT00262028|9620770|FG003|Overall Study|Unable to classify|0
6025266|NCT00262028|9620771|FG004|Overall Study|Unable to classify|0
6025267|NCT00262028|9620772|FG005|Overall Study|Unable to classify|0
6025268|NCT00262028|9620773|FG006|Overall Study|Unable to classify|0
6025269|NCT00262028|9620774|FG007|Overall Study|Unable to classify|0
6025270|NCT00262028|9620775|FG008|Overall Study|Unable to classify|1
6025271|NCT00262041|9620821|FG000|Overall Study|Withdrawal by Subject|0
6025272|NCT00262041|9620822|FG001|Overall Study|Withdrawal by Subject|3
6025273|NCT00262041|9620823|FG002|Overall Study|Withdrawal by Subject|1
6025274|NCT00262041|9620821|FG000|Overall Study|Lost to Follow-up|1
6078574|NCT00604825|9685004|FG002|Overall Study|Protocol Violation|0
6078575|NCT00604825|9685005|FG003|Overall Study|Protocol Violation|0
6078576|NCT00604825|9685002|FG000|Overall Study|Withdrawal by Subject|4
6025275|NCT00262041|9620822|FG001|Overall Study|Lost to Follow-up|1
6025276|NCT00262041|9620823|FG002|Overall Study|Lost to Follow-up|5
6025277|NCT00262041|9620821|FG000|Overall Study|Unable to classify|1
6078577|NCT00604825|9685003|FG001|Overall Study|Withdrawal by Subject|3
6078578|NCT00604825|9685004|FG002|Overall Study|Withdrawal by Subject|5
6078579|NCT00604825|9685005|FG003|Overall Study|Withdrawal by Subject|5
6078580|NCT00604825|9685002|FG000|Overall Study|Lack of Efficacy|3
6025278|NCT00262041|9620822|FG001|Overall Study|Unable to classify|0
6025279|NCT00262041|9620823|FG002|Overall Study|Unable to classify|0
6025280|NCT00262067|9620841|FG000|Overall Study|Death|190
6025281|NCT00262067|9620842|FG001|Overall Study|Death|89
6025282|NCT00262067|9620843|FG002|Overall Study|Death|186
6025283|NCT00262067|9620844|FG003|Overall Study|Death|99
6025284|NCT00262067|9620841|FG000|Overall Study|Lost to Follow-up|5
6025285|NCT00262067|9620842|FG001|Overall Study|Lost to Follow-up|4
6025286|NCT00262067|9620843|FG002|Overall Study|Lost to Follow-up|7
6025287|NCT00262067|9620844|FG003|Overall Study|Lost to Follow-up|5
6025288|NCT00262067|9620841|FG000|Overall Study|Sponsor's Decision to Terminate Study|1
6025289|NCT00262067|9620842|FG001|Overall Study|Sponsor's Decision to Terminate Study|0
6025290|NCT00262067|9620843|FG002|Overall Study|Sponsor's Decision to Terminate Study|0
6025291|NCT00262067|9620844|FG003|Overall Study|Sponsor's Decision to Terminate Study|0
6025292|NCT00262067|9620841|FG000|Overall Study|Patient Withdrew for Survival Follow-up|23
6025293|NCT00262067|9620842|FG001|Overall Study|Patient Withdrew for Survival Follow-up|7
6025294|NCT00262067|9620843|FG002|Overall Study|Patient Withdrew for Survival Follow-up|23
6025295|NCT00262067|9620844|FG003|Overall Study|Patient Withdrew for Survival Follow-up|9
6025296|NCT00262080|9620857|FG000|Double Blind Treatment Period|Lost to Follow-up|1
6025297|NCT00262080|9620858|FG001|Double Blind Treatment Period|Lost to Follow-up|0
6025298|NCT00262080|9620859|FG002|Double Blind Treatment Period|Lost to Follow-up|0
6025299|NCT00262080|9620857|FG000|Repeat Dose Treatment Period|Adverse Event|1
6025300|NCT00262080|9620858|FG001|Repeat Dose Treatment Period|Adverse Event|0
6025301|NCT00262080|9620859|FG002|Repeat Dose Treatment Period|Adverse Event|0
6025302|NCT00262080|9620857|FG000|Repeat Dose Treatment Period|Withdrawal by Subject|0
6025303|NCT00262080|9620858|FG001|Repeat Dose Treatment Period|Withdrawal by Subject|1
6025304|NCT00262080|9620859|FG002|Repeat Dose Treatment Period|Withdrawal by Subject|1
6025305|NCT00262080|9620857|FG000|Repeat Dose Treatment Period|Lost to Follow-up|2
6025306|NCT00262080|9620858|FG001|Repeat Dose Treatment Period|Lost to Follow-up|0
6025307|NCT00262080|9620859|FG002|Repeat Dose Treatment Period|Lost to Follow-up|2
6025308|NCT00262080|9620857|FG000|Repeat Dose Treatment Period|Decision to discontinue the study|0
6025309|NCT00262080|9620858|FG001|Repeat Dose Treatment Period|Decision to discontinue the study|0
6025310|NCT00262080|9620859|FG002|Repeat Dose Treatment Period|Decision to discontinue the study|2
6025311|NCT00262080|9620857|FG000|Repeat Dose Treatment Period|enrolled in EDEMA4|1
6025312|NCT00262080|9620858|FG001|Repeat Dose Treatment Period|enrolled in EDEMA4|0
6025313|NCT00262080|9620859|FG002|Repeat Dose Treatment Period|enrolled in EDEMA4|0
6025314|NCT00262119|9620870|FG000|Overall Study|Lost to Follow-up|38
6025315|NCT00262119|9620871|FG001|Overall Study|Lost to Follow-up|51
6025316|NCT00262119|9620872|FG002|Overall Study|Lost to Follow-up|42
6025317|NCT00262119|9620870|FG000|Overall Study|Death|20
6025318|NCT00262119|9620871|FG001|Overall Study|Death|19
6025319|NCT00262119|9620872|FG002|Overall Study|Death|16
6025320|NCT00262223|9620882|FG000|Treatment Phase|Withdrawal by Subject|3
6025321|NCT00262223|9620883|FG001|Treatment Phase|Withdrawal by Subject|6
6025322|NCT00262223|9620882|FG000|Treatment Phase|Adverse Event|1
6025323|NCT00262223|9620883|FG001|Treatment Phase|Adverse Event|2
6025324|NCT00262223|9620882|FG000|1-week Post-treatment Follow-up|Lost to Follow-up|4
6025325|NCT00262223|9620883|FG001|1-week Post-treatment Follow-up|Lost to Follow-up|4
6025326|NCT00262223|9620882|FG000|6-month Post-treatment Follow-up|Lost to Follow-up|6
6025327|NCT00262223|9620883|FG001|6-month Post-treatment Follow-up|Lost to Follow-up|1
6025328|NCT00262223|9620882|FG000|12-month Post-treatment Follow-up|Lost to Follow-up|7
6025329|NCT00262223|9620883|FG001|12-month Post-treatment Follow-up|Lost to Follow-up|7
6025330|NCT00262301|9620893|FG000|Double-blind Phase|Lost to Follow-up|1
6025331|NCT00262301|9620894|FG001|Double-blind Phase|Lost to Follow-up|0
6025332|NCT00262301|9620895|FG002|Double-blind Phase|Lost to Follow-up|0
6025333|NCT00262301|9620893|FG000|Double-blind Phase|"worsening of HAE symptoms"|0
6025334|NCT00262301|9620894|FG001|Double-blind Phase|"worsening of HAE symptoms"|1
6025335|NCT00262301|9620895|FG002|Double-blind Phase|"worsening of HAE symptoms"|0
6025336|NCT00262314|9620903|FG000|Overall Study|Changing physicians|38
6025337|NCT00262314|9620903|FG000|Overall Study|Death|12
6025338|NCT00262314|9620903|FG000|Overall Study|Patient's decision|92
6025339|NCT00262314|9620903|FG000|Overall Study|Other|95
6025340|NCT00262314|9620903|FG000|Overall Study|Lost to Follow-up|70
6025341|NCT00262314|9620903|FG000|Overall Study|Administrative withdrawal|30
6025342|NCT00262522|9620920|FG000|Study Start Through 8 Weeks|Adverse Event|1
6025343|NCT00262522|9620921|FG001|Study Start Through 8 Weeks|Adverse Event|2
6025344|NCT00262522|9620922|FG002|Study Start Through 8 Weeks|Adverse Event|3
6025345|NCT00262522|9620923|FG003|Study Start Through 8 Weeks|Adverse Event|1
6025346|NCT00262522|9620920|FG000|Study Start Through 8 Weeks|Withdrawal by Subject|1
6025347|NCT00262522|9620921|FG001|Study Start Through 8 Weeks|Withdrawal by Subject|1
6025348|NCT00262522|9620922|FG002|Study Start Through 8 Weeks|Withdrawal by Subject|3
6025349|NCT00262522|9620923|FG003|Study Start Through 8 Weeks|Withdrawal by Subject|0
6025350|NCT00262522|9620920|FG000|Study Start Through 8 Weeks|Lost to Follow-up|1
6025351|NCT00262522|9620921|FG001|Study Start Through 8 Weeks|Lost to Follow-up|2
6025352|NCT00262522|9620922|FG002|Study Start Through 8 Weeks|Lost to Follow-up|3
6025353|NCT00262522|9620923|FG003|Study Start Through 8 Weeks|Lost to Follow-up|2
6025354|NCT00262522|9620920|FG000|Study Start Through 8 Weeks|Noncompliance|0
6025355|NCT00262522|9620921|FG001|Study Start Through 8 Weeks|Noncompliance|0
6025356|NCT00262522|9620922|FG002|Study Start Through 8 Weeks|Noncompliance|2
6025357|NCT00262522|9620923|FG003|Study Start Through 8 Weeks|Noncompliance|2
6025358|NCT00262522|9620920|FG000|Study Start Through 8 Weeks|Death|1
6025359|NCT00262522|9620921|FG001|Study Start Through 8 Weeks|Death|0
6025360|NCT00262522|9620922|FG002|Study Start Through 8 Weeks|Death|0
6025361|NCT00262522|9620923|FG003|Study Start Through 8 Weeks|Death|0
6025362|NCT00262522|9620920|FG000|Study Start Through 48 Weeks|Adverse Event|16
6025363|NCT00262522|9620921|FG001|Study Start Through 48 Weeks|Adverse Event|0
6025364|NCT00262522|9620922|FG002|Study Start Through 48 Weeks|Adverse Event|10
6025365|NCT00262522|9620923|FG003|Study Start Through 48 Weeks|Adverse Event|0
6025366|NCT00262522|9620920|FG000|Study Start Through 48 Weeks|Withdrawal by Subject|10
6025367|NCT00262522|9620921|FG001|Study Start Through 48 Weeks|Withdrawal by Subject|0
6025368|NCT00262522|9620922|FG002|Study Start Through 48 Weeks|Withdrawal by Subject|11
6025369|NCT00262522|9620923|FG003|Study Start Through 48 Weeks|Withdrawal by Subject|0
6025370|NCT00262522|9620920|FG000|Study Start Through 48 Weeks|Lost to Follow-up|8
6025371|NCT00262522|9620921|FG001|Study Start Through 48 Weeks|Lost to Follow-up|0
6025372|NCT00262522|9620922|FG002|Study Start Through 48 Weeks|Lost to Follow-up|14
6025373|NCT00262522|9620923|FG003|Study Start Through 48 Weeks|Lost to Follow-up|0
6025374|NCT00262522|9620920|FG000|Study Start Through 48 Weeks|Noncompliance|3
6025375|NCT00262522|9620921|FG001|Study Start Through 48 Weeks|Noncompliance|0
6078581|NCT00604825|9685003|FG001|Overall Study|Lack of Efficacy|2
6078582|NCT00604825|9685004|FG002|Overall Study|Lack of Efficacy|1
6078583|NCT00604825|9685005|FG003|Overall Study|Lack of Efficacy|0
6078584|NCT00604825|9685002|FG000|Overall Study|Did not meet eligibility criteria|0
6078585|NCT00604825|9685003|FG001|Overall Study|Did not meet eligibility criteria|0
6078586|NCT00604825|9685004|FG002|Overall Study|Did not meet eligibility criteria|2
6078587|NCT00604825|9685005|FG003|Overall Study|Did not meet eligibility criteria|0
6078588|NCT00604825|9685002|FG000|Overall Study|Physician Decision|0
6078589|NCT00604825|9685003|FG001|Overall Study|Physician Decision|0
6078590|NCT00604825|9685004|FG002|Overall Study|Physician Decision|0
6078591|NCT00604825|9685005|FG003|Overall Study|Physician Decision|1
6078592|NCT00604825|9685002|FG000|Overall Study|Exclusion criterion met|0
6078593|NCT00604825|9685003|FG001|Overall Study|Exclusion criterion met|0
6078594|NCT00604825|9685004|FG002|Overall Study|Exclusion criterion met|0
6078595|NCT00604825|9685005|FG003|Overall Study|Exclusion criterion met|1
6087600|NCT00669331|9697956|FG000|Randomisation to First Dose|Sponsor decision|0
6087601|NCT00669331|9697957|FG001|Randomisation to First Dose|Sponsor decision|1
6087602|NCT00669331|9697956|FG000|Randomisation to First Dose|Randomised in error|3
6087603|NCT00669331|9697957|FG001|Randomisation to First Dose|Randomised in error|10
6087604|NCT00669331|9697956|FG000|Blinded Treatment Period|Adverse Event|16
6087605|NCT00669331|9697957|FG001|Blinded Treatment Period|Adverse Event|10
6087606|NCT00669331|9697956|FG000|Blinded Treatment Period|Protocol Violation|1
6087607|NCT00669331|9697957|FG001|Blinded Treatment Period|Protocol Violation|1
6087608|NCT00669331|9697956|FG000|Blinded Treatment Period|Withdrawal by Subject|17
6087609|NCT00669331|9697957|FG001|Blinded Treatment Period|Withdrawal by Subject|19
6087610|NCT00669331|9697956|FG000|Blinded Treatment Period|Lost to Follow-up|3
6087611|NCT00669331|9697957|FG001|Blinded Treatment Period|Lost to Follow-up|2
6087612|NCT00669331|9697956|FG000|Blinded Treatment Period|Death|0
6087613|NCT00669331|9697957|FG001|Blinded Treatment Period|Death|2
6087614|NCT00669331|9697956|FG000|Blinded Treatment Period|Physician Decision|3
6087615|NCT00669331|9697957|FG001|Blinded Treatment Period|Physician Decision|3
6087616|NCT00669331|9697956|FG000|Blinded Treatment Period|Unable/unwilling to comply w trial reqs|2
6087617|NCT00669331|9697957|FG001|Blinded Treatment Period|Unable/unwilling to comply w trial reqs|2
6087618|NCT00669396|9697976|FG000|Overall Study|Lost to Follow-up|10
6087619|NCT00669396|9697977|FG001|Overall Study|Lost to Follow-up|12
6087620|NCT00669409|9697989|FG000|Part 2|Withdrawal by Subject|0
6087621|NCT00669409|9697990|FG001|Part 2|Withdrawal by Subject|0
6087622|NCT00669409|9697991|FG002|Part 2|Withdrawal by Subject|0
6087623|NCT00669409|9697992|FG003|Part 2|Withdrawal by Subject|0
6087624|NCT00669409|9697993|FG004|Part 2|Withdrawal by Subject|0
6087625|NCT00669409|9697994|FG005|Part 2|Withdrawal by Subject|0
6087626|NCT00669409|9697995|FG006|Part 2|Withdrawal by Subject|0
6087627|NCT00669409|9697996|FG007|Part 2|Withdrawal by Subject|0
6087628|NCT00669409|9697997|FG008|Part 2|Withdrawal by Subject|0
6087629|NCT00669409|9697998|FG009|Part 2|Withdrawal by Subject|1
6087630|NCT00669409|9697999|FG010|Part 2|Withdrawal by Subject|0
6087631|NCT00669617|9698049|FG000|Period 1|Withdrawal by Subject|0
6087632|NCT00669617|9698050|FG001|Period 1|Withdrawal by Subject|0
6087633|NCT00669617|9698051|FG002|Period 1|Withdrawal by Subject|1
6087634|NCT00669617|9698052|FG003|Period 1|Withdrawal by Subject|0
6087635|NCT00669617|9698053|FG004|Period 1|Withdrawal by Subject|0
6087636|NCT00669617|9698049|FG000|Period 1|Protocol Deviation|0
6087637|NCT00669617|9698050|FG001|Period 1|Protocol Deviation|0
6087638|NCT00669617|9698051|FG002|Period 1|Protocol Deviation|0
6025376|NCT00262522|9620922|FG002|Study Start Through 48 Weeks|Noncompliance|8
6025377|NCT00262522|9620923|FG003|Study Start Through 48 Weeks|Noncompliance|0
6025378|NCT00262522|9620920|FG000|Study Start Through 48 Weeks|Death|2
6025379|NCT00262522|9620921|FG001|Study Start Through 48 Weeks|Death|0
6025380|NCT00262522|9620922|FG002|Study Start Through 48 Weeks|Death|1
6025381|NCT00262522|9620923|FG003|Study Start Through 48 Weeks|Death|0
6025382|NCT00262522|9620920|FG000|Study Start Through 48 Weeks|Virologic failure|2
6025383|NCT00262522|9620921|FG001|Study Start Through 48 Weeks|Virologic failure|0
6025384|NCT00262522|9620922|FG002|Study Start Through 48 Weeks|Virologic failure|4
6025385|NCT00262522|9620923|FG003|Study Start Through 48 Weeks|Virologic failure|0
6025386|NCT00262522|9620920|FG000|Study Start Through 48 Weeks|Relocated, Needed to take twice daily|8
6025387|NCT00262522|9620921|FG001|Study Start Through 48 Weeks|Relocated, Needed to take twice daily|0
6025388|NCT00262522|9620922|FG002|Study Start Through 48 Weeks|Relocated, Needed to take twice daily|7
6025389|NCT00262522|9620923|FG003|Study Start Through 48 Weeks|Relocated, Needed to take twice daily|0
6025390|NCT00262522|9620920|FG000|Study Start Through 96 Weeks|Adverse Event|20
6025391|NCT00262522|9620921|FG001|Study Start Through 96 Weeks|Adverse Event|0
6025392|NCT00262522|9620922|FG002|Study Start Through 96 Weeks|Adverse Event|16
6025393|NCT00262522|9620923|FG003|Study Start Through 96 Weeks|Adverse Event|0
6025394|NCT00262522|9620920|FG000|Study Start Through 96 Weeks|Withdrawal by Subject|15
6025395|NCT00262522|9620921|FG001|Study Start Through 96 Weeks|Withdrawal by Subject|0
6025396|NCT00262522|9620922|FG002|Study Start Through 96 Weeks|Withdrawal by Subject|13
6025397|NCT00262522|9620923|FG003|Study Start Through 96 Weeks|Withdrawal by Subject|0
6078596|NCT00605033|9685039|FG000|Overall Study|Adverse Event|2
6078597|NCT00605033|9685040|FG001|Overall Study|Adverse Event|2
6078598|NCT00605033|9685039|FG000|Overall Study|Lost to Follow-up|1
6078599|NCT00605033|9685040|FG001|Overall Study|Lost to Follow-up|1
6078600|NCT00605033|9685039|FG000|Overall Study|Withdrawal by Subject|3
6078601|NCT00605033|9685040|FG001|Overall Study|Withdrawal by Subject|4
6078602|NCT00605033|9685039|FG000|Overall Study|Protocol Violation|1
6078603|NCT00605033|9685040|FG001|Overall Study|Protocol Violation|1
6078604|NCT00605085|9685061|FG000|Overall Study|Withdrawal by Subject|8
6078605|NCT00605085|9685062|FG001|Overall Study|Withdrawal by Subject|5
6078606|NCT00605085|9685061|FG000|Overall Study|Adverse Event|9
6078607|NCT00605085|9685062|FG001|Overall Study|Adverse Event|5
6078608|NCT00605085|9685061|FG000|Overall Study|Pregnancy|2
6078609|NCT00605085|9685062|FG001|Overall Study|Pregnancy|0
6078610|NCT00605085|9685061|FG000|Overall Study|Protocol Violation|3
6078611|NCT00605085|9685062|FG001|Overall Study|Protocol Violation|2
6078612|NCT00605085|9685061|FG000|Overall Study|Lost to Follow-up|10
6078613|NCT00605085|9685062|FG001|Overall Study|Lost to Follow-up|5
6078614|NCT00605085|9685061|FG000|Overall Study|administrative reasons|18
6078615|NCT00605085|9685062|FG001|Overall Study|administrative reasons|8
6078616|NCT00605176|9685071|FG000|Overall Study|Adverse Event|2
6078617|NCT00605176|9685072|FG001|Overall Study|Adverse Event|1
6078618|NCT00605176|9685073|FG002|Overall Study|Adverse Event|3
6078619|NCT00605176|9685071|FG000|Overall Study|Withdrawal by Subject|4
6078620|NCT00605176|9685072|FG001|Overall Study|Withdrawal by Subject|2
6078621|NCT00605176|9685073|FG002|Overall Study|Withdrawal by Subject|4
6078622|NCT00605176|9685071|FG000|Overall Study|Lost to Follow-up|2
6078623|NCT00605176|9685072|FG001|Overall Study|Lost to Follow-up|2
6078624|NCT00605176|9685073|FG002|Overall Study|Lost to Follow-up|1
6078625|NCT00605176|9685071|FG000|Overall Study|Non-complicance with study procedures|1
6078626|NCT00605176|9685072|FG001|Overall Study|Non-complicance with study procedures|0
6078627|NCT00605176|9685073|FG002|Overall Study|Non-complicance with study procedures|0
6078628|NCT00605176|9685071|FG000|Overall Study|Use of concomitant therapy|1
6078629|NCT00605176|9685072|FG001|Overall Study|Use of concomitant therapy|0
6078630|NCT00605176|9685073|FG002|Overall Study|Use of concomitant therapy|1
6078631|NCT00605176|9685071|FG000|Overall Study|Other (not due to AE)|1
6078632|NCT00605176|9685072|FG001|Overall Study|Other (not due to AE)|1
6078633|NCT00605176|9685073|FG002|Overall Study|Other (not due to AE)|0
6078634|NCT00605189|9685084|FG000|Overall Study|Adverse Event|1
6078635|NCT00605189|9685085|FG001|Overall Study|Adverse Event|0
6078636|NCT00605189|9685086|FG002|Overall Study|Adverse Event|0
6078637|NCT00605189|9685084|FG000|Overall Study|Other|2
6078638|NCT00605189|9685085|FG001|Overall Study|Other|2
6078639|NCT00605189|9685086|FG002|Overall Study|Other|0
6078640|NCT00605267|9685103|FG000|Overall Study|Adverse Event|0
6078641|NCT00605267|9685104|FG001|Overall Study|Adverse Event|1
6078642|NCT00605267|9685103|FG000|Overall Study|Lack of Efficacy|1
6078643|NCT00605267|9685104|FG001|Overall Study|Lack of Efficacy|5
6078644|NCT00605267|9685103|FG000|Overall Study|Withdrawal by Subject|2
6078645|NCT00605267|9685104|FG001|Overall Study|Withdrawal by Subject|3
6078646|NCT00605280|9685114|FG000|Year 1|Protocol Violation|0
6078647|NCT00605280|9685115|FG001|Year 1|Protocol Violation|0
6078648|NCT00605280|9685116|FG002|Year 1|Protocol Violation|0
6078649|NCT00605280|9685117|FG003|Year 1|Protocol Violation|1
6078650|NCT00605280|9685114|FG000|Year 1|Adverse Event|3
6078651|NCT00605280|9685115|FG001|Year 1|Adverse Event|1
6078652|NCT00605280|9685116|FG002|Year 1|Adverse Event|1
6025398|NCT00262522|9620920|FG000|Study Start Through 96 Weeks|Lost to Follow-up|19
6025399|NCT00262522|9620921|FG001|Study Start Through 96 Weeks|Lost to Follow-up|0
6025400|NCT00262522|9620922|FG002|Study Start Through 96 Weeks|Lost to Follow-up|18
6025401|NCT00262522|9620923|FG003|Study Start Through 96 Weeks|Lost to Follow-up|0
6025402|NCT00262522|9620920|FG000|Study Start Through 96 Weeks|Noncompliance|6
6025403|NCT00262522|9620921|FG001|Study Start Through 96 Weeks|Noncompliance|0
6078653|NCT00605280|9685117|FG003|Year 1|Adverse Event|5
6078654|NCT00605280|9685114|FG000|Year 1|Physician Decision|7
6078655|NCT00605280|9685115|FG001|Year 1|Physician Decision|4
6025404|NCT00262522|9620922|FG002|Study Start Through 96 Weeks|Noncompliance|11
6025405|NCT00262522|9620923|FG003|Study Start Through 96 Weeks|Noncompliance|0
6025406|NCT00262522|9620920|FG000|Study Start Through 96 Weeks|Death|2
6025407|NCT00262522|9620921|FG001|Study Start Through 96 Weeks|Death|0
6025408|NCT00262522|9620922|FG002|Study Start Through 96 Weeks|Death|2
6025409|NCT00262522|9620923|FG003|Study Start Through 96 Weeks|Death|0
6025410|NCT00262522|9620920|FG000|Study Start Through 96 Weeks|Virologic failure|5
6078656|NCT00605280|9685116|FG002|Year 1|Physician Decision|0
6078657|NCT00605280|9685117|FG003|Year 1|Physician Decision|6
6078658|NCT00605280|9685114|FG000|Year 1|Withdrawal by Subject|2
6078659|NCT00605280|9685115|FG001|Year 1|Withdrawal by Subject|4
6078660|NCT00605280|9685116|FG002|Year 1|Withdrawal by Subject|0
6078661|NCT00605280|9685117|FG003|Year 1|Withdrawal by Subject|4
6078662|NCT00605280|9685114|FG000|Year 1|Other|2
6078663|NCT00605280|9685115|FG001|Year 1|Other|1
6078664|NCT00605280|9685116|FG002|Year 1|Other|0
6078665|NCT00605280|9685117|FG003|Year 1|Other|1
6078666|NCT00605280|9685114|FG000|Year 1|Lost to Follow-up or Patient non-comply|5
6078667|NCT00605280|9685115|FG001|Year 1|Lost to Follow-up or Patient non-comply|1
6078668|NCT00605280|9685116|FG002|Year 1|Lost to Follow-up or Patient non-comply|0
6078669|NCT00605280|9685117|FG003|Year 1|Lost to Follow-up or Patient non-comply|2
6078670|NCT00605280|9685114|FG000|Year 2|Adverse Event|4
6078671|NCT00605280|9685115|FG001|Year 2|Adverse Event|0
6078672|NCT00605280|9685116|FG002|Year 2|Adverse Event|2
6078673|NCT00605280|9685117|FG003|Year 2|Adverse Event|4
6078674|NCT00605280|9685114|FG000|Year 2|Physician Decision|11
6078675|NCT00605280|9685115|FG001|Year 2|Physician Decision|6
6078676|NCT00605280|9685116|FG002|Year 2|Physician Decision|4
6078677|NCT00605280|9685117|FG003|Year 2|Physician Decision|11
6078678|NCT00605280|9685114|FG000|Year 2|Withdrawal by Subject|4
6078679|NCT00605280|9685115|FG001|Year 2|Withdrawal by Subject|0
6078680|NCT00605280|9685116|FG002|Year 2|Withdrawal by Subject|0
6078681|NCT00605280|9685117|FG003|Year 2|Withdrawal by Subject|4
6078682|NCT00605280|9685114|FG000|Year 2|Other|1
6078683|NCT00605280|9685115|FG001|Year 2|Other|0
6078684|NCT00605280|9685116|FG002|Year 2|Other|0
6078685|NCT00605280|9685117|FG003|Year 2|Other|1
6078686|NCT00605280|9685114|FG000|Year 2|Lost to Follow-up or Patient non-comply|4
6078687|NCT00605280|9685115|FG001|Year 2|Lost to Follow-up or Patient non-comply|0
6078688|NCT00605280|9685116|FG002|Year 2|Lost to Follow-up or Patient non-comply|0
6078689|NCT00605280|9685117|FG003|Year 2|Lost to Follow-up or Patient non-comply|2
6078690|NCT00605280|9685114|FG000|Year 3 Extension|Adverse Event|2
6078691|NCT00605280|9685115|FG001|Year 3 Extension|Adverse Event|0
6078692|NCT00605280|9685116|FG002|Year 3 Extension|Adverse Event|0
6078693|NCT00605280|9685117|FG003|Year 3 Extension|Adverse Event|2
6078694|NCT00605280|9685114|FG000|Year 3 Extension|Physician Decision|0
6078695|NCT00605280|9685115|FG001|Year 3 Extension|Physician Decision|0
6078696|NCT00605280|9685116|FG002|Year 3 Extension|Physician Decision|0
6078697|NCT00605280|9685117|FG003|Year 3 Extension|Physician Decision|2
6078698|NCT00605280|9685114|FG000|Year 3 Extension|Withdrawal by Subject|2
6078699|NCT00605280|9685115|FG001|Year 3 Extension|Withdrawal by Subject|0
6078700|NCT00605280|9685116|FG002|Year 3 Extension|Withdrawal by Subject|0
6078701|NCT00605280|9685117|FG003|Year 3 Extension|Withdrawal by Subject|5
6078702|NCT00605280|9685114|FG000|Year 3 Extension|Other|2
6078703|NCT00605280|9685115|FG001|Year 3 Extension|Other|0
6078704|NCT00605280|9685116|FG002|Year 3 Extension|Other|0
6078705|NCT00605280|9685117|FG003|Year 3 Extension|Other|0
6078706|NCT00605280|9685114|FG000|Year 3 Extension|Lost to Follow-up or Patient non-comply|2
6078707|NCT00605280|9685115|FG001|Year 3 Extension|Lost to Follow-up or Patient non-comply|0
6078708|NCT00605280|9685116|FG002|Year 3 Extension|Lost to Follow-up or Patient non-comply|0
6078709|NCT00605280|9685117|FG003|Year 3 Extension|Lost to Follow-up or Patient non-comply|0
6078710|NCT00605293|9685129|FG000|Overall Study|Death|2
6078711|NCT00605293|9685130|FG001|Overall Study|Death|1
6078712|NCT00605293|9685129|FG000|Overall Study|Insufficient Therapeutic Response|2
6078713|NCT00605293|9685130|FG001|Overall Study|Insufficient Therapeutic Response|0
6078714|NCT00605293|9685129|FG000|Overall Study|Adverse Event|1
6078715|NCT00605293|9685130|FG001|Overall Study|Adverse Event|0
6078716|NCT00605293|9685129|FG000|Overall Study|Holidays Dialysis Out|1
6078717|NCT00605293|9685130|FG001|Overall Study|Holidays Dialysis Out|0
6078718|NCT00605293|9685129|FG000|Overall Study|Blood Transfusion|7
6078719|NCT00605293|9685130|FG001|Overall Study|Blood Transfusion|1
6078720|NCT00605293|9685129|FG000|Overall Study|Renal Transplantation|3
6078721|NCT00605293|9685130|FG001|Overall Study|Renal Transplantation|1
6078722|NCT00605293|9685129|FG000|Overall Study|Incorrect Epoetin Beta Administration|1
6078723|NCT00605293|9685130|FG001|Overall Study|Incorrect Epoetin Beta Administration|0
6078724|NCT00605293|9685129|FG000|Overall Study|Dialysis Out of Centre for 3 Months|0
6078725|NCT00605293|9685130|FG001|Overall Study|Dialysis Out of Centre for 3 Months|1
6078726|NCT00605293|9685129|FG000|Overall Study|Principal Investigator Decision|0
6025411|NCT00262522|9620921|FG001|Study Start Through 96 Weeks|Virologic failure|0
6025412|NCT00262522|9620922|FG002|Study Start Through 96 Weeks|Virologic failure|8
6025413|NCT00262522|9620923|FG003|Study Start Through 96 Weeks|Virologic failure|0
6048199|NCT00415636|9647305|FG003|Overall Study|Adverse Event|1
6078727|NCT00605293|9685130|FG001|Overall Study|Principal Investigator Decision|1
6078728|NCT00605306|9685138|FG000|Overall Study|Adverse Event|0
6078729|NCT00605306|9685139|FG001|Overall Study|Adverse Event|1
6025414|NCT00262522|9620920|FG000|Study Start Through 96 Weeks|Relocated, Needed to take twice daily|10
6025415|NCT00262522|9620921|FG001|Study Start Through 96 Weeks|Relocated, Needed to take twice daily|0
6025416|NCT00262522|9620922|FG002|Study Start Through 96 Weeks|Relocated, Needed to take twice daily|9
6025417|NCT00262522|9620923|FG003|Study Start Through 96 Weeks|Relocated, Needed to take twice daily|0
6025418|NCT00262600|9620934|FG000|Overall Study|Lost to Follow-up|17
6025419|NCT00262600|9620935|FG001|Overall Study|Lost to Follow-up|31
6025420|NCT00262600|9620936|FG002|Overall Study|Lost to Follow-up|41
6025421|NCT00262600|9620934|FG000|Overall Study|Withdrawal by Subject|128
6025422|NCT00262600|9620935|FG001|Overall Study|Withdrawal by Subject|145
6025423|NCT00262600|9620936|FG002|Overall Study|Withdrawal by Subject|139
6025424|NCT00262600|9620934|FG000|Overall Study|Not Treated|32
6025425|NCT00262600|9620935|FG001|Overall Study|Not Treated|17
6025426|NCT00262600|9620936|FG002|Overall Study|Not Treated|24
6025427|NCT00262600|9620934|FG000|Overall Study|Other|58
6025428|NCT00262600|9620935|FG001|Overall Study|Other|59
6025429|NCT00262600|9620936|FG002|Overall Study|Other|62
6025430|NCT00262743|9620967|FG000|Overall Study|Adverse Event|0
6025431|NCT00262743|9620968|FG001|Overall Study|Adverse Event|9
6025432|NCT00262743|9620967|FG000|Overall Study|Disease progression|0
6078730|NCT00605319|9685145|FG000|Overall Study|Adverse Event|6
6078731|NCT00605345|9685157|FG000|Overall Study|Withdrawal by Subject|1
6078732|NCT00605345|9685158|FG001|Overall Study|Withdrawal by Subject|0
6078733|NCT00605345|9685157|FG000|Overall Study|Adverse Event|0
6078734|NCT00605345|9685158|FG001|Overall Study|Adverse Event|1
6078735|NCT00605345|9685157|FG000|Overall Study|Protocol Violation|0
6078736|NCT00605345|9685158|FG001|Overall Study|Protocol Violation|2
6078737|NCT00605475|9685201|FG000|Overall Study|Abnormal Laboratory Values|0
6078738|NCT00605475|9685202|FG001|Overall Study|Abnormal Laboratory Values|0
6078739|NCT00605475|9685203|FG002|Overall Study|Abnormal Laboratory Values|0
6078740|NCT00605475|9685204|FG003|Overall Study|Abnormal Laboratory Values|0
6078741|NCT00605475|9685205|FG004|Overall Study|Abnormal Laboratory Values|0
6078742|NCT00605475|9685206|FG005|Overall Study|Abnormal Laboratory Values|0
6078743|NCT00605475|9685207|FG006|Overall Study|Abnormal Laboratory Values|0
6078744|NCT00605475|9685208|FG007|Overall Study|Abnormal Laboratory Values|0
6078745|NCT00605475|9685209|FG008|Overall Study|Abnormal Laboratory Values|1
6078746|NCT00605475|9685210|FG009|Overall Study|Abnormal Laboratory Values|0
6078747|NCT00605475|9685201|FG000|Overall Study|Administrative problems|0
6078748|NCT00605475|9685202|FG001|Overall Study|Administrative problems|0
6078749|NCT00605475|9685203|FG002|Overall Study|Administrative problems|0
6078750|NCT00605475|9685204|FG003|Overall Study|Administrative problems|0
6078751|NCT00605475|9685205|FG004|Overall Study|Administrative problems|0
6078752|NCT00605475|9685206|FG005|Overall Study|Administrative problems|0
6078753|NCT00605475|9685207|FG006|Overall Study|Administrative problems|1
6078754|NCT00605475|9685208|FG007|Overall Study|Administrative problems|0
6078755|NCT00605475|9685209|FG008|Overall Study|Administrative problems|0
6078756|NCT00605475|9685210|FG009|Overall Study|Administrative problems|0
6078757|NCT00605475|9685201|FG000|Overall Study|Lost to Follow-up|0
6078758|NCT00605475|9685202|FG001|Overall Study|Lost to Follow-up|0
6078759|NCT00605475|9685203|FG002|Overall Study|Lost to Follow-up|0
6078760|NCT00605475|9685204|FG003|Overall Study|Lost to Follow-up|0
6078761|NCT00605475|9685205|FG004|Overall Study|Lost to Follow-up|0
6078762|NCT00605475|9685206|FG005|Overall Study|Lost to Follow-up|0
6078763|NCT00605475|9685207|FG006|Overall Study|Lost to Follow-up|0
6078764|NCT00605475|9685208|FG007|Overall Study|Lost to Follow-up|0
6078765|NCT00605475|9685209|FG008|Overall Study|Lost to Follow-up|1
6078766|NCT00605475|9685210|FG009|Overall Study|Lost to Follow-up|1
6078767|NCT00605475|9685201|FG000|Overall Study|Protocol Violation|0
6078768|NCT00605475|9685202|FG001|Overall Study|Protocol Violation|0
6078769|NCT00605475|9685203|FG002|Overall Study|Protocol Violation|0
6078770|NCT00605475|9685204|FG003|Overall Study|Protocol Violation|0
6078771|NCT00605475|9685205|FG004|Overall Study|Protocol Violation|1
6078772|NCT00605475|9685206|FG005|Overall Study|Protocol Violation|0
6078773|NCT00605475|9685207|FG006|Overall Study|Protocol Violation|0
6078774|NCT00605475|9685208|FG007|Overall Study|Protocol Violation|0
6078775|NCT00605475|9685209|FG008|Overall Study|Protocol Violation|0
6078776|NCT00605475|9685210|FG009|Overall Study|Protocol Violation|0
6078777|NCT00605475|9685201|FG000|Overall Study|Withdrawal by Subject|0
6078778|NCT00605475|9685202|FG001|Overall Study|Withdrawal by Subject|0
6025433|NCT00262743|9620968|FG001|Overall Study|Disease progression|3
6025434|NCT00262821|9620974|FG000|Overall Study|Ineligible - wrong stage|0
6025435|NCT00262821|9620975|FG001|Overall Study|Ineligible - wrong stage|3
6025436|NCT00262821|9620974|FG000|Overall Study|Ineligible - wrong cell type|2
6025437|NCT00262821|9620975|FG001|Overall Study|Ineligible - wrong cell type|2
6025438|NCT00262821|9620974|FG000|Overall Study|Ineligible - wrong primary|0
6025439|NCT00262821|9620975|FG001|Overall Study|Ineligible - wrong primary|1
6025440|NCT00262821|9620974|FG000|Overall Study|Ineligible - inadequate pathology|1
6025441|NCT00262821|9620975|FG001|Overall Study|Ineligible - inadequate pathology|3
6025442|NCT00262821|9620974|FG000|Overall Study|Ineligible - elevated creatinine|0
6025443|NCT00262821|9620975|FG001|Overall Study|Ineligible - elevated creatinine|2
6025444|NCT00262821|9620974|FG000|Overall Study|Ineligible - required test not done|1
6025445|NCT00262821|9620975|FG001|Overall Study|Ineligible - required test not done|4
6078779|NCT00605475|9685203|FG002|Overall Study|Withdrawal by Subject|0
6078780|NCT00605475|9685204|FG003|Overall Study|Withdrawal by Subject|0
6025446|NCT00262821|9620974|FG000|Overall Study|Inevaluable - inadequate data|0
6025447|NCT00262821|9620975|FG001|Overall Study|Inevaluable - inadequate data|4
6025448|NCT00262834|9620983|FG000|Overall Study|Surgery delayed/tissue not collected|1
6025449|NCT00262834|9620984|FG001|Overall Study|Surgery delayed/tissue not collected|4
6025450|NCT00262847|9620993|FG000|Overall Study|Disease Progression|309
6025451|NCT00262847|9620994|FG001|Overall Study|Disease Progression|274
6025452|NCT00262847|9620995|FG002|Overall Study|Disease Progression|195
6025453|NCT00262847|9620993|FG000|Overall Study|Patient Refusal|41
6025454|NCT00262847|9620994|FG001|Overall Study|Patient Refusal|52
6025455|NCT00262847|9620995|FG002|Overall Study|Patient Refusal|47
6025456|NCT00262847|9620993|FG000|Overall Study|Adverse Event|74
6025457|NCT00262847|9620994|FG001|Overall Study|Adverse Event|88
6025458|NCT00262847|9620995|FG002|Overall Study|Adverse Event|108
6025459|NCT00262847|9620993|FG000|Overall Study|Death|8
6025460|NCT00262847|9620994|FG001|Overall Study|Death|8
6025461|NCT00262847|9620995|FG002|Overall Study|Death|11
6025462|NCT00262847|9620993|FG000|Overall Study|Concomitant disease|3
6025463|NCT00262847|9620994|FG001|Overall Study|Concomitant disease|2
6025464|NCT00262847|9620995|FG002|Overall Study|Concomitant disease|4
6025465|NCT00262847|9620993|FG000|Overall Study|Other Reasons|79
6025466|NCT00262847|9620994|FG001|Overall Study|Other Reasons|88
6025467|NCT00262847|9620995|FG002|Overall Study|Other Reasons|27
6025468|NCT00262847|9620993|FG000|Overall Study|Did not receive study treatment|4
6025469|NCT00262847|9620994|FG001|Overall Study|Did not receive study treatment|1
6025470|NCT00262847|9620995|FG002|Overall Study|Did not receive study treatment|4
6025471|NCT00262860|9621006|FG000|Overall Study|Adverse Event|2
6025472|NCT00262873|9621010|FG000|Overall Study|Adverse Event|3
6025473|NCT00262873|9621010|FG000|Overall Study|Withdrawal by Subject|5
6025474|NCT00262925|9621014|FG000|Overall Study|Lack of Efficacy|3
6025475|NCT00262925|9621014|FG000|Overall Study|Adverse Event|4
6078781|NCT00605475|9685205|FG004|Overall Study|Withdrawal by Subject|0
6078782|NCT00605475|9685206|FG005|Overall Study|Withdrawal by Subject|2
6078783|NCT00605475|9685207|FG006|Overall Study|Withdrawal by Subject|0
6078784|NCT00605475|9685208|FG007|Overall Study|Withdrawal by Subject|0
6078785|NCT00605475|9685209|FG008|Overall Study|Withdrawal by Subject|0
6078786|NCT00605475|9685210|FG009|Overall Study|Withdrawal by Subject|1
6078787|NCT00605540|9685253|FG000|Overall Study|Death|15
6078788|NCT00605540|9685253|FG000|Overall Study|Lost to Follow-up|23
6078789|NCT00605566|9685257|FG000|Overall Study|Adverse Event|1
6078790|NCT00605566|9685257|FG000|Overall Study|Clinical deterioration|1
6078791|NCT00605566|9685257|FG000|Overall Study|Poor compliance in run-in period|1
6078792|NCT00605657|9685282|FG000|Overall Study|Adverse Event|1
6078793|NCT00605657|9685282|FG000|Overall Study|Protocol Violation|1
6078794|NCT00605722|9685295|FG000|Overall Study|Adverse Event|6
6078795|NCT00605722|9685295|FG000|Overall Study|Insufficient therapeutic response|44
6078796|NCT00605722|9685295|FG000|Overall Study|Failure to return|1
6078797|NCT00605813|9685299|FG000|Overall Study|Protocol Violation|25
6078798|NCT00605839|9685324|FG000|Overall Study|Protocol Violation|1
6078799|NCT00605839|9685325|FG001|Overall Study|Protocol Violation|0
6078800|NCT00605839|9685326|FG002|Overall Study|Protocol Violation|0
6078801|NCT00605865|9685334|FG000|Overall Study|Protocol Violation|115
6078802|NCT00605917|9685375|FG000|Overall Study|Protocol Violation|79
6078803|NCT00606008|9685410|FG000|Overall Study|Adverse Event|1
6078804|NCT00606008|9685410|FG000|Overall Study|Withdrawal by Subject|4
6078805|NCT00606021|9685420|FG000|Induction Phase|Death|73
6078806|NCT00606021|9685421|FG001|Induction Phase|Death|0
6078807|NCT00606021|9685422|FG002|Induction Phase|Death|0
6078808|NCT00606021|9685420|FG000|Induction Phase|Physician Decision|2
6078809|NCT00606021|9685421|FG001|Induction Phase|Physician Decision|0
6078810|NCT00606021|9685422|FG002|Induction Phase|Physician Decision|0
6078811|NCT00606021|9685420|FG000|Induction Phase|Withdrawal by Subject|2
6078812|NCT00606021|9685421|FG001|Induction Phase|Withdrawal by Subject|0
6078813|NCT00606021|9685422|FG002|Induction Phase|Withdrawal by Subject|0
6078814|NCT00606021|9685420|FG000|Induction Phase|Lost to Follow-up|10
6078815|NCT00606021|9685421|FG001|Induction Phase|Lost to Follow-up|0
6078816|NCT00606021|9685422|FG002|Induction Phase|Lost to Follow-up|0
6078817|NCT00606021|9685420|FG000|Maintenance Phase|Death|0
6078818|NCT00606021|9685421|FG001|Maintenance Phase|Death|17
6078819|NCT00606021|9685422|FG002|Maintenance Phase|Death|15
6078820|NCT00606021|9685420|FG000|Maintenance Phase|Physician Decision|0
6078821|NCT00606021|9685421|FG001|Maintenance Phase|Physician Decision|1
6078822|NCT00606021|9685422|FG002|Maintenance Phase|Physician Decision|0
6078823|NCT00606021|9685420|FG000|Maintenance Phase|Lost to Follow-up|0
6078824|NCT00606021|9685421|FG001|Maintenance Phase|Lost to Follow-up|5
6078825|NCT00606021|9685422|FG002|Maintenance Phase|Lost to Follow-up|2
6078826|NCT00606034|9685430|FG000|Overall Study|incarceration|1
6078827|NCT00606086|9685442|FG000|Overall Study|Adverse Event|1
6146272|NCT01076075|9780863|FG000|Overall Study|Lack of Efficacy|5
6025476|NCT00262925|9621014|FG000|Overall Study|Death|2
6025477|NCT00262925|9621014|FG000|Overall Study|alternative therapy|1
6025478|NCT00262925|9621014|FG000|Overall Study|Other|1
6025479|NCT00262951|9621020|FG000|Overall Study|Progressive disease/relapse|3
6025480|NCT00262951|9621020|FG000|Overall Study|Adverse Event|7
6025481|NCT00262951|9621020|FG000|Overall Study|Death|1
6025482|NCT00262951|9621020|FG000|Overall Study|Withdrawal by Subject|1
6025483|NCT00262951|9621020|FG000|Overall Study|Alternative treatment|3
6025484|NCT00262951|9621020|FG000|Overall Study|Off treatment for other disease|1
6025485|NCT00263211|9621053|FG000|Overall Study|Death|1
6025486|NCT00263211|9621054|FG001|Overall Study|Death|0
6025487|NCT00263211|9621053|FG000|Overall Study|Withdrawal by Subject|3
6025488|NCT00263211|9621054|FG001|Overall Study|Withdrawal by Subject|0
6025489|NCT00263211|9621053|FG000|Overall Study|Protocol Violation|1
6025490|NCT00263211|9621054|FG001|Overall Study|Protocol Violation|0
6025491|NCT00263211|9621053|FG000|Overall Study|Disease Progression|0
6078828|NCT00606086|9685443|FG001|Overall Study|Adverse Event|1
6078829|NCT00606086|9685442|FG000|Overall Study|Lost to Follow-up|4
6078830|NCT00606086|9685443|FG001|Overall Study|Lost to Follow-up|8
6078831|NCT00606086|9685442|FG000|Overall Study|Protocol Violation|1
6078832|NCT00606086|9685443|FG001|Overall Study|Protocol Violation|0
6078833|NCT00606086|9685442|FG000|Overall Study|Withdrawal by Subject|5
6078834|NCT00606086|9685443|FG001|Overall Study|Withdrawal by Subject|3
6078835|NCT00606086|9685442|FG000|Overall Study|Non-compliance|0
6078836|NCT00606086|9685443|FG001|Overall Study|Non-compliance|1
6078837|NCT00606086|9685442|FG000|Overall Study|Randomized, not treated|1
6078838|NCT00606086|9685443|FG001|Overall Study|Randomized, not treated|2
6078839|NCT00606177|9685460|FG000|Overall Study|Adverse Event|9
6078840|NCT00606177|9685461|FG001|Overall Study|Adverse Event|5
6078841|NCT00606177|9685460|FG000|Overall Study|Lack of Efficacy|3
6078842|NCT00606177|9685461|FG001|Overall Study|Lack of Efficacy|7
6078843|NCT00606177|9685460|FG000|Overall Study|Physician Decision|1
6078844|NCT00606177|9685461|FG001|Overall Study|Physician Decision|0
6078845|NCT00606177|9685460|FG000|Overall Study|Protocol Violation|1
6078846|NCT00606177|9685461|FG001|Overall Study|Protocol Violation|4
6078847|NCT00606177|9685460|FG000|Overall Study|Withdrawal by Subject|5
6078848|NCT00606177|9685461|FG001|Overall Study|Withdrawal by Subject|6
6078849|NCT00606177|9685460|FG000|Overall Study|Progression to depressive phase|6
6078850|NCT00606177|9685461|FG001|Overall Study|Progression to depressive phase|1
6078851|NCT00606177|9685460|FG000|Overall Study|Diabetic blood glucose level/ High HbA1c|1
6078852|NCT00606177|9685461|FG001|Overall Study|Diabetic blood glucose level/ High HbA1c|1
6078853|NCT00606177|9685460|FG000|Overall Study|Change of residence or other commitments|1
6078854|NCT00606177|9685461|FG001|Overall Study|Change of residence or other commitments|1
6078855|NCT00606229|9685467|FG000|Overall Study|Adverse Event|11
6078856|NCT00606229|9685467|FG000|Overall Study|Lack of Efficacy|1
6078857|NCT00606229|9685467|FG000|Overall Study|Withdrawal by Subject|4
6078858|NCT00606229|9685467|FG000|Overall Study|does not meet inclusion criterion 1-3|4
6078859|NCT00606229|9685467|FG000|Overall Study|change of residence or other commitments|2
6078860|NCT00606281|9685473|FG000|Overall Study|Adverse Event|11
6078861|NCT00606281|9685474|FG001|Overall Study|Adverse Event|12
6078862|NCT00606281|9685473|FG000|Overall Study|Death|1
6078863|NCT00606281|9685474|FG001|Overall Study|Death|0
6078864|NCT00606281|9685473|FG000|Overall Study|Lack of Efficacy|28
6078865|NCT00606281|9685474|FG001|Overall Study|Lack of Efficacy|35
6078866|NCT00606281|9685473|FG000|Overall Study|Physician Decision|0
6078867|NCT00606281|9685474|FG001|Overall Study|Physician Decision|1
6078868|NCT00606281|9685473|FG000|Overall Study|Protocol Violation|3
6078869|NCT00606281|9685474|FG001|Overall Study|Protocol Violation|3
6078870|NCT00606281|9685473|FG000|Overall Study|Withdrawal by Subject|11
6078871|NCT00606281|9685474|FG001|Overall Study|Withdrawal by Subject|13
6078872|NCT00606281|9685473|FG000|Overall Study|Progression to depressive phase|1
6078873|NCT00606281|9685474|FG001|Overall Study|Progression to depressive phase|1
6078874|NCT00606281|9685473|FG000|Overall Study|Change of residence or other commitments|1
6078875|NCT00606281|9685474|FG001|Overall Study|Change of residence or other commitments|1
6078876|NCT00606294|9685482|FG000|Overall Study|Withdrawal by Subject|36
6078877|NCT00606294|9685483|FG001|Overall Study|Withdrawal by Subject|0
6078878|NCT00606307|9685489|FG000|Overall Study|Adverse Event|2
6078879|NCT00606307|9685489|FG000|Overall Study|Withdrawal by Subject|2
6078880|NCT00606307|9685489|FG000|Overall Study|Disease progression|6
6078881|NCT00606307|9685489|FG000|Overall Study|QTc prolongation|1
6078882|NCT00606320|9685493|FG000|Overall Study|Adverse Event|3
6078883|NCT00606320|9685493|FG000|Overall Study|Lack of Efficacy|5
6078884|NCT00606320|9685493|FG000|Overall Study|Physician Decision|7
6078885|NCT00606320|9685493|FG000|Overall Study|Protocol Violation|8
6078886|NCT00606320|9685493|FG000|Overall Study|Withdrawal by Subject|10
6146273|NCT01076075|9780864|FG001|Overall Study|Lack of Efficacy|4
6025492|NCT00263211|9621054|FG001|Overall Study|Disease Progression|1
6025493|NCT00263328|9621066|FG000|Overall Study|Death|0
6025494|NCT00263328|9621067|FG001|Overall Study|Death|0
6025495|NCT00263328|9621068|FG002|Overall Study|Death|1
6025496|NCT00263328|9621066|FG000|Overall Study|Lost to Follow-up|1
6078887|NCT00606320|9685493|FG000|Overall Study|Progression to depressive phase|4
6078888|NCT00606502|9685508|FG000|Randomization|Randomized but not treated|3
6078889|NCT00606502|9685509|FG001|Randomization|Randomized but not treated|0
6078890|NCT00606502|9685508|FG000|Treatment|Treatment ongoing at time of data cutoff|0
6078891|NCT00606502|9685509|FG001|Treatment|Treatment ongoing at time of data cutoff|3
6078892|NCT00606580|9685531|FG000|Overall Study|Lost to Follow-up|1
6078893|NCT00606580|9685532|FG001|Overall Study|Lost to Follow-up|1
6078894|NCT00606580|9685533|FG002|Overall Study|Lost to Follow-up|4
6078895|NCT00606580|9685531|FG000|Overall Study|Clinical failures|1
6025497|NCT00263328|9621067|FG001|Overall Study|Lost to Follow-up|1
6025498|NCT00263328|9621068|FG002|Overall Study|Lost to Follow-up|0
6025499|NCT00263328|9621066|FG000|Overall Study|Withdrawal by Subject|3
6025500|NCT00263328|9621067|FG001|Overall Study|Withdrawal by Subject|0
6025501|NCT00263328|9621068|FG002|Overall Study|Withdrawal by Subject|1
6025502|NCT00263328|9621066|FG000|Overall Study|Other|3
6025503|NCT00263328|9621067|FG001|Overall Study|Other|0
6025504|NCT00263328|9621068|FG002|Overall Study|Other|1
6025505|NCT00263328|9621066|FG000|Overall Study|Adverse Event|1
6025506|NCT00263328|9621067|FG001|Overall Study|Adverse Event|1
6025507|NCT00263328|9621068|FG002|Overall Study|Adverse Event|4
6025508|NCT00263562|9621080|FG000|Overall Study|Protocol Violation|3
6025509|NCT00263562|9621081|FG001|Overall Study|Protocol Violation|0
6025510|NCT00263575|9621089|FG000|Titration Period|Adverse Event|14
6025511|NCT00263575|9621089|FG000|Titration Period|Withdrawal by Subject|10
6025512|NCT00263575|9621089|FG000|Titration Period|Protocol Violation|9
6025513|NCT00263575|9621089|FG000|Titration Period|Sponsor Decision|2
6025514|NCT00263575|9621089|FG000|Titration Period|Other|2
6025515|NCT00263575|9621089|FG000|Titration Period|Lack of Efficacy|6
6025516|NCT00263575|9621089|FG000|Maintence Period|Adverse Event|23
6025517|NCT00263575|9621089|FG000|Maintence Period|Withdrawal by Subject|8
6025518|NCT00263575|9621089|FG000|Maintence Period|Protocol Violation|4
6025519|NCT00263575|9621089|FG000|Maintence Period|Lack of Efficacy|4
6025520|NCT00263575|9621089|FG000|Maintence Period|Physician Decision|6
6025521|NCT00263575|9621089|FG000|Maintence Period|Lost to Follow-up|1
6025522|NCT00263575|9621089|FG000|Maintence Period|Sponsor Decision|24
6025523|NCT00263575|9621089|FG000|Maintence Period|Other|7
6078896|NCT00606580|9685532|FG001|Overall Study|Clinical failures|0
6078897|NCT00606580|9685533|FG002|Overall Study|Clinical failures|12
6078898|NCT00606580|9685531|FG000|Overall Study|Withdrawal by investigator|0
6078899|NCT00606580|9685532|FG001|Overall Study|Withdrawal by investigator|1
6078900|NCT00606580|9685533|FG002|Overall Study|Withdrawal by investigator|6
6078901|NCT00606580|9685531|FG000|Overall Study|Withdrawal by Subject|0
6078902|NCT00606580|9685532|FG001|Overall Study|Withdrawal by Subject|1
6078903|NCT00606580|9685533|FG002|Overall Study|Withdrawal by Subject|0
6078904|NCT00606593|9685541|FG000|Overall Study|Adverse Event|0
6078905|NCT00606593|9685542|FG001|Overall Study|Adverse Event|0
6078906|NCT00606593|9685543|FG002|Overall Study|Adverse Event|0
6078907|NCT00606593|9685544|FG003|Overall Study|Adverse Event|1
6078908|NCT00606593|9685545|FG004|Overall Study|Adverse Event|1
6078909|NCT00606593|9685546|FG005|Overall Study|Adverse Event|0
6078910|NCT00606593|9685547|FG006|Overall Study|Adverse Event|1
6078911|NCT00606593|9685548|FG007|Overall Study|Adverse Event|2
6078912|NCT00606593|9685549|FG008|Overall Study|Adverse Event|1
6078913|NCT00606593|9685550|FG009|Overall Study|Adverse Event|0
6078914|NCT00606593|9685541|FG000|Overall Study|Withdrawal of consent|1
6078915|NCT00606593|9685542|FG001|Overall Study|Withdrawal of consent|0
6078916|NCT00606593|9685543|FG002|Overall Study|Withdrawal of consent|1
6078917|NCT00606593|9685544|FG003|Overall Study|Withdrawal of consent|0
6078918|NCT00606593|9685545|FG004|Overall Study|Withdrawal of consent|0
6078919|NCT00606593|9685546|FG005|Overall Study|Withdrawal of consent|0
6078920|NCT00606593|9685547|FG006|Overall Study|Withdrawal of consent|0
6078921|NCT00606593|9685548|FG007|Overall Study|Withdrawal of consent|0
6078922|NCT00606593|9685549|FG008|Overall Study|Withdrawal of consent|0
6078923|NCT00606593|9685550|FG009|Overall Study|Withdrawal of consent|0
6078924|NCT00606593|9685541|FG000|Overall Study|Administrative/Other|0
6078925|NCT00606593|9685542|FG001|Overall Study|Administrative/Other|0
6078926|NCT00606593|9685543|FG002|Overall Study|Administrative/Other|1
6078927|NCT00606593|9685544|FG003|Overall Study|Administrative/Other|0
6078928|NCT00606593|9685545|FG004|Overall Study|Administrative/Other|0
6078929|NCT00606593|9685546|FG005|Overall Study|Administrative/Other|0
6078930|NCT00606593|9685547|FG006|Overall Study|Administrative/Other|0
6078931|NCT00606593|9685548|FG007|Overall Study|Administrative/Other|0
6078932|NCT00606593|9685549|FG008|Overall Study|Administrative/Other|0
6078933|NCT00606593|9685550|FG009|Overall Study|Administrative/Other|0
6078934|NCT00606632|9685563|FG000|Overall Study|Withdrawal by Subject|13
6078935|NCT00606632|9685563|FG000|Overall Study|Miscellaneous reasons|9
6078936|NCT00606684|9685578|FG000|2-week Single-Blind Run-in Period|Did Not Meet Continuation Criteria|173
6078937|NCT00606684|9685579|FG001|2-week Single-Blind Run-in Period|Did Not Meet Continuation Criteria|0
6078938|NCT00606684|9685580|FG002|2-week Single-Blind Run-in Period|Did Not Meet Continuation Criteria|0
6078939|NCT00606684|9685581|FG003|2-week Single-Blind Run-in Period|Did Not Meet Continuation Criteria|0
6025524|NCT00263588|9621097|FG000|Overall Study|Death|54
6025525|NCT00263588|9621098|FG001|Overall Study|Death|90
6025526|NCT00263588|9621097|FG000|Overall Study|disease progression, coma, 1 unknown|10
6025527|NCT00263588|9621098|FG001|Overall Study|disease progression, coma, 1 unknown|11
6078940|NCT00606684|9685582|FG004|2-week Single-Blind Run-in Period|Did Not Meet Continuation Criteria|0
6078941|NCT00606684|9685583|FG005|2-week Single-Blind Run-in Period|Did Not Meet Continuation Criteria|0
6078942|NCT00606684|9685584|FG006|2-week Single-Blind Run-in Period|Did Not Meet Continuation Criteria|0
6078943|NCT00606684|9685578|FG000|2-week Single-Blind Run-in Period|Study Closed/Terminated|32
6078944|NCT00606684|9685579|FG001|2-week Single-Blind Run-in Period|Study Closed/Terminated|0
6025528|NCT00263588|9621097|FG000|Overall Study|Lost to Follow-up|7
6025529|NCT00263588|9621098|FG001|Overall Study|Lost to Follow-up|10
6025530|NCT00263588|9621097|FG000|Overall Study|Withdrawal by Subject|3
6025531|NCT00263588|9621098|FG001|Overall Study|Withdrawal by Subject|4
6025532|NCT00263588|9621097|FG000|Overall Study|Protocol Violation|0
6025533|NCT00263588|9621098|FG001|Overall Study|Protocol Violation|1
6025534|NCT00263588|9621097|FG000|Overall Study|Investigator decision|7
6025535|NCT00263588|9621098|FG001|Overall Study|Investigator decision|15
6025536|NCT00263588|9621097|FG000|Overall Study|Sponsor terminated study|0
6025537|NCT00263588|9621098|FG001|Overall Study|Sponsor terminated study|1
6025538|NCT00263666|9621107|FG000|Overall Study|Adverse Event|6
6025539|NCT00263666|9621108|FG001|Overall Study|Adverse Event|8
6146274|NCT01076075|9780863|FG000|Overall Study|Lost to Follow-up|6
6146275|NCT01076075|9780864|FG001|Overall Study|Lost to Follow-up|5
6146276|NCT01076075|9780863|FG000|Overall Study|other|19
6146277|NCT01076075|9780864|FG001|Overall Study|other|9
6146278|NCT01076075|9780863|FG000|Overall Study|Protocol Violation|0
6146279|NCT01076075|9780864|FG001|Overall Study|Protocol Violation|1
6146280|NCT01076075|9780863|FG000|Overall Study|Withdrawal by Subject|8
6146281|NCT01076075|9780864|FG001|Overall Study|Withdrawal by Subject|19
6146282|NCT01076088|9780879|FG000|Overall Study|Adverse Event|1
6146283|NCT01076088|9780880|FG001|Overall Study|Adverse Event|6
6146284|NCT01076088|9780881|FG002|Overall Study|Adverse Event|3
6146285|NCT01076088|9780882|FG003|Overall Study|Adverse Event|2
6146286|NCT01076088|9780883|FG004|Overall Study|Adverse Event|3
6146287|NCT01076088|9780884|FG005|Overall Study|Adverse Event|3
6146288|NCT01076088|9780879|FG000|Overall Study|Lost to Follow-up|1
6146289|NCT01076088|9780880|FG001|Overall Study|Lost to Follow-up|1
6146290|NCT01076088|9780881|FG002|Overall Study|Lost to Follow-up|0
6146291|NCT01076088|9780882|FG003|Overall Study|Lost to Follow-up|1
6146292|NCT01076088|9780883|FG004|Overall Study|Lost to Follow-up|1
6146293|NCT01076088|9780884|FG005|Overall Study|Lost to Follow-up|2
6146294|NCT01076088|9780879|FG000|Overall Study|Non-compliance with study drug|0
6025540|NCT00263666|9621107|FG000|Overall Study|Lost to Follow-up|1
6025541|NCT00263666|9621108|FG001|Overall Study|Lost to Follow-up|2
6025542|NCT00263666|9621107|FG000|Overall Study|Withdrawal by Subject|0
6025543|NCT00263666|9621108|FG001|Overall Study|Withdrawal by Subject|1
6025544|NCT00263757|9621116|FG000|Overall Study|Withdrawal by Subject|5
6025545|NCT00263757|9621117|FG001|Overall Study|Withdrawal by Subject|4
6025546|NCT00263757|9621116|FG000|Overall Study|Screen failure|0
6025547|NCT00263757|9621117|FG001|Overall Study|Screen failure|1
6025548|NCT00263757|9621116|FG000|Overall Study|Adverse Event|3
6025549|NCT00263757|9621117|FG001|Overall Study|Adverse Event|3
6025550|NCT00263887|9621125|FG000|Overall Study|Withdrawal by Subject|1
6025551|NCT00263887|9621126|FG001|Overall Study|Withdrawal by Subject|1
6025552|NCT00263887|9621125|FG000|Overall Study|Lung transplantation|1
6025553|NCT00263887|9621126|FG001|Overall Study|Lung transplantation|2
6025554|NCT00263887|9621125|FG000|Overall Study|Too ill to attend visit|1
6025555|NCT00263887|9621126|FG001|Overall Study|Too ill to attend visit|0
6025556|NCT00263887|9621125|FG000|Overall Study|Adverse Event|0
6025557|NCT00263887|9621126|FG001|Overall Study|Adverse Event|2
6025558|NCT00263887|9621125|FG000|Overall Study|Disease progression|0
6025559|NCT00263887|9621126|FG001|Overall Study|Disease progression|1
6025560|NCT00263887|9621125|FG000|Overall Study|Lack of Efficacy|0
6025561|NCT00263887|9621126|FG001|Overall Study|Lack of Efficacy|1
6025562|NCT00264004|9621136|FG000|Overall Study|Adverse Event|2
6025563|NCT00264004|9621137|FG001|Overall Study|Adverse Event|3
6025564|NCT00264004|9621138|FG002|Overall Study|Adverse Event|6
6025565|NCT00264004|9621139|FG003|Overall Study|Adverse Event|4
6025566|NCT00264004|9621136|FG000|Overall Study|Withdrawal by Subject|0
6025567|NCT00264004|9621137|FG001|Overall Study|Withdrawal by Subject|1
6025568|NCT00264004|9621138|FG002|Overall Study|Withdrawal by Subject|2
6025569|NCT00264004|9621139|FG003|Overall Study|Withdrawal by Subject|2
6025570|NCT00264004|9621136|FG000|Overall Study|Other|2
6025571|NCT00264004|9621137|FG001|Overall Study|Other|2
6025572|NCT00264004|9621138|FG002|Overall Study|Other|0
6025573|NCT00264004|9621139|FG003|Overall Study|Other|3
6025574|NCT00264004|9621136|FG000|Overall Study|Development study specific disc. crit.|1
6025575|NCT00264004|9621137|FG001|Overall Study|Development study specific disc. crit.|0
6025576|NCT00264004|9621138|FG002|Overall Study|Development study specific disc. crit.|1
6146295|NCT01076088|9780880|FG001|Overall Study|Non-compliance with study drug|0
6025577|NCT00264004|9621139|FG003|Overall Study|Development study specific disc. crit.|0
6025578|NCT00264004|9621136|FG000|Overall Study|Cond. under inv. worsened|9
6025579|NCT00264004|9621137|FG001|Overall Study|Cond. under inv. worsened|5
6025580|NCT00264004|9621138|FG002|Overall Study|Cond. under inv. worsened|3
6025581|NCT00264004|9621139|FG003|Overall Study|Cond. under inv. worsened|4
6025582|NCT00264004|9621136|FG000|Overall Study|Not treated|3
6025583|NCT00264004|9621137|FG001|Overall Study|Not treated|0
6025584|NCT00264004|9621138|FG002|Overall Study|Not treated|2
6025585|NCT00264004|9621139|FG003|Overall Study|Not treated|2
6025586|NCT00264238|9621149|FG000|Overall Study|Protocol Violation|1
6146296|NCT01076088|9780881|FG002|Overall Study|Non-compliance with study drug|0
6146297|NCT01076088|9780882|FG003|Overall Study|Non-compliance with study drug|1
6025587|NCT00264290|9621157|FG000|Intervention (8 Weeks)|Adverse Event|1
6025588|NCT00264290|9621158|FG001|Intervention (8 Weeks)|Adverse Event|0
6025589|NCT00264303|9621170|FG000|Overall Study|Adverse Event|4
6025590|NCT00264303|9621171|FG001|Overall Study|Adverse Event|3
6025591|NCT00264303|9621170|FG000|Overall Study|Lack of Efficacy|10
6025592|NCT00264303|9621171|FG001|Overall Study|Lack of Efficacy|13
6025593|NCT00264303|9621170|FG000|Overall Study|Lost to Follow-up|3
6025594|NCT00264303|9621171|FG001|Overall Study|Lost to Follow-up|3
6025595|NCT00264303|9621170|FG000|Overall Study|Withdrawal by Subject|2
6025596|NCT00264303|9621171|FG001|Overall Study|Withdrawal by Subject|3
6025597|NCT00264303|9621170|FG000|Overall Study|Various reasons listed in study report|6
6025598|NCT00264303|9621171|FG001|Overall Study|Various reasons listed in study report|7
6025599|NCT00264498|9621188|FG000|Randomized Treatment|Death|0
6025600|NCT00264498|9621189|FG001|Randomized Treatment|Death|3
6025601|NCT00264498|9621188|FG000|Randomized Treatment|Withdrawal by Subject|0
6025602|NCT00264498|9621189|FG001|Randomized Treatment|Withdrawal by Subject|1
6025603|NCT00264498|9621188|FG000|Randomized Treatment|Objective disease Progression|13
6025604|NCT00264498|9621189|FG001|Randomized Treatment|Objective disease Progression|14
6025605|NCT00264498|9621188|FG000|Randomized Treatment|Physician Decision|1
6025606|NCT00264498|9621189|FG001|Randomized Treatment|Physician Decision|0
6025607|NCT00264498|9621188|FG000|Randomized Treatment|Incorrectly randomized|1
6025608|NCT00264498|9621189|FG001|Randomized Treatment|Incorrectly randomized|0
6025609|NCT00264498|9621188|FG000|Randomized Treatment|Study Closure|1
6078945|NCT00606684|9685580|FG002|2-week Single-Blind Run-in Period|Study Closed/Terminated|0
6078946|NCT00606684|9685581|FG003|2-week Single-Blind Run-in Period|Study Closed/Terminated|0
6078947|NCT00606684|9685582|FG004|2-week Single-Blind Run-in Period|Study Closed/Terminated|0
6078948|NCT00606684|9685583|FG005|2-week Single-Blind Run-in Period|Study Closed/Terminated|0
6078949|NCT00606684|9685584|FG006|2-week Single-Blind Run-in Period|Study Closed/Terminated|0
6078950|NCT00606684|9685578|FG000|2-week Single-Blind Run-in Period|Physician Decision|18
6078951|NCT00606684|9685579|FG001|2-week Single-Blind Run-in Period|Physician Decision|0
6078952|NCT00606684|9685580|FG002|2-week Single-Blind Run-in Period|Physician Decision|0
6078953|NCT00606684|9685581|FG003|2-week Single-Blind Run-in Period|Physician Decision|0
6078954|NCT00606684|9685582|FG004|2-week Single-Blind Run-in Period|Physician Decision|0
6078955|NCT00606684|9685583|FG005|2-week Single-Blind Run-in Period|Physician Decision|0
6078956|NCT00606684|9685584|FG006|2-week Single-Blind Run-in Period|Physician Decision|0
6078957|NCT00606684|9685578|FG000|2-week Single-Blind Run-in Period|Withdrawal by Subject|15
6078958|NCT00606684|9685579|FG001|2-week Single-Blind Run-in Period|Withdrawal by Subject|0
6078959|NCT00606684|9685580|FG002|2-week Single-Blind Run-in Period|Withdrawal by Subject|0
6078960|NCT00606684|9685581|FG003|2-week Single-Blind Run-in Period|Withdrawal by Subject|0
6078961|NCT00606684|9685582|FG004|2-week Single-Blind Run-in Period|Withdrawal by Subject|0
6078962|NCT00606684|9685583|FG005|2-week Single-Blind Run-in Period|Withdrawal by Subject|0
6078963|NCT00606684|9685584|FG006|2-week Single-Blind Run-in Period|Withdrawal by Subject|0
6078964|NCT00606684|9685578|FG000|2-week Single-Blind Run-in Period|Lost to Follow-up|5
6025610|NCT00264498|9621189|FG001|Randomized Treatment|Study Closure|0
6025611|NCT00264498|9621188|FG000|Randomized Treatment|Protocol Violation|1
6025612|NCT00264498|9621189|FG001|Randomized Treatment|Protocol Violation|0
6025613|NCT00264498|9621188|FG000|Crossover Treatment|Death|1
6025614|NCT00264498|9621189|FG001|Crossover Treatment|Death|3
6025615|NCT00264498|9621188|FG000|Crossover Treatment|Objective disease progression|4
6025616|NCT00264498|9621189|FG001|Crossover Treatment|Objective disease progression|5
6025617|NCT00264498|9621188|FG000|Crossover Treatment|Study closure|0
6025618|NCT00264498|9621189|FG001|Crossover Treatment|Study closure|1
6025619|NCT00264498|9621188|FG000|Crossover Treatment|Withdrawal by Subject|1
6025620|NCT00264498|9621189|FG001|Crossover Treatment|Withdrawal by Subject|0
6025621|NCT00264537|9621199|FG000|Overall Study|Death|0
6025622|NCT00264537|9621200|FG001|Overall Study|Death|3
6078965|NCT00606684|9685579|FG001|2-week Single-Blind Run-in Period|Lost to Follow-up|0
6078966|NCT00606684|9685580|FG002|2-week Single-Blind Run-in Period|Lost to Follow-up|0
6078967|NCT00606684|9685581|FG003|2-week Single-Blind Run-in Period|Lost to Follow-up|0
6078968|NCT00606684|9685582|FG004|2-week Single-Blind Run-in Period|Lost to Follow-up|0
6078969|NCT00606684|9685583|FG005|2-week Single-Blind Run-in Period|Lost to Follow-up|0
6078970|NCT00606684|9685584|FG006|2-week Single-Blind Run-in Period|Lost to Follow-up|0
6078971|NCT00606684|9685578|FG000|2-week Single-Blind Run-in Period|Adverse Event|2
6078972|NCT00606684|9685579|FG001|2-week Single-Blind Run-in Period|Adverse Event|0
6078973|NCT00606684|9685580|FG002|2-week Single-Blind Run-in Period|Adverse Event|0
6078974|NCT00606684|9685581|FG003|2-week Single-Blind Run-in Period|Adverse Event|0
6078975|NCT00606684|9685582|FG004|2-week Single-Blind Run-in Period|Adverse Event|0
6078976|NCT00606684|9685583|FG005|2-week Single-Blind Run-in Period|Adverse Event|0
6078977|NCT00606684|9685584|FG006|2-week Single-Blind Run-in Period|Adverse Event|0
6078978|NCT00606684|9685578|FG000|2-week Single-Blind Run-in Period|Received Study Medication in Error|1
6078979|NCT00606684|9685579|FG001|2-week Single-Blind Run-in Period|Received Study Medication in Error|0
6078980|NCT00606684|9685580|FG002|2-week Single-Blind Run-in Period|Received Study Medication in Error|0
6078981|NCT00606684|9685581|FG003|2-week Single-Blind Run-in Period|Received Study Medication in Error|0
6025623|NCT00264537|9621201|FG002|Overall Study|Death|3
6025624|NCT00264537|9621202|FG003|Overall Study|Death|2
6025625|NCT00264537|9621199|FG000|Overall Study|Lost to Follow-up|3
6025626|NCT00264537|9621200|FG001|Overall Study|Lost to Follow-up|4
6025627|NCT00264537|9621201|FG002|Overall Study|Lost to Follow-up|7
6025628|NCT00264537|9621202|FG003|Overall Study|Lost to Follow-up|6
6025629|NCT00264537|9621199|FG000|Overall Study|Adverse Event|21
6025630|NCT00264537|9621200|FG001|Overall Study|Adverse Event|32
6025631|NCT00264537|9621201|FG002|Overall Study|Adverse Event|24
6025632|NCT00264537|9621202|FG003|Overall Study|Adverse Event|34
6025633|NCT00264537|9621199|FG000|Overall Study|Unsatisfactory therapeutic effect|5
6025634|NCT00264537|9621200|FG001|Overall Study|Unsatisfactory therapeutic effect|6
6025635|NCT00264537|9621201|FG002|Overall Study|Unsatisfactory therapeutic effect|5
6025636|NCT00264537|9621202|FG003|Overall Study|Unsatisfactory therapeutic effect|7
6025637|NCT00264537|9621199|FG000|Overall Study|Other|21
6025638|NCT00264537|9621200|FG001|Overall Study|Other|11
6025639|NCT00264537|9621201|FG002|Overall Study|Other|10
6025640|NCT00264537|9621202|FG003|Overall Study|Other|11
6025641|NCT00264537|9621199|FG000|Overall Study|Not treated|0
6025642|NCT00264537|9621200|FG001|Overall Study|Not treated|2
6025643|NCT00264537|9621201|FG002|Overall Study|Not treated|1
6025644|NCT00264537|9621202|FG003|Overall Study|Not treated|0
6025645|NCT00264550|9621218|FG000|Overall Study|Death|0
6025646|NCT00264550|9621219|FG001|Overall Study|Death|3
6025647|NCT00264550|9621220|FG002|Overall Study|Death|0
6025648|NCT00264550|9621221|FG003|Overall Study|Death|0
6025649|NCT00264550|9621218|FG000|Overall Study|Lost to Follow-up|3
6025650|NCT00264550|9621219|FG001|Overall Study|Lost to Follow-up|1
6025651|NCT00264550|9621220|FG002|Overall Study|Lost to Follow-up|1
6025652|NCT00264550|9621221|FG003|Overall Study|Lost to Follow-up|1
6025653|NCT00264550|9621218|FG000|Overall Study|Adverse Event|23
6025654|NCT00264550|9621219|FG001|Overall Study|Adverse Event|18
6025655|NCT00264550|9621220|FG002|Overall Study|Adverse Event|9
6025656|NCT00264550|9621221|FG003|Overall Study|Adverse Event|14
6025657|NCT00264550|9621218|FG000|Overall Study|Unsatisfactory therapeutic effect|4
6025658|NCT00264550|9621219|FG001|Overall Study|Unsatisfactory therapeutic effect|11
6025659|NCT00264550|9621220|FG002|Overall Study|Unsatisfactory therapeutic effect|4
6025660|NCT00264550|9621221|FG003|Overall Study|Unsatisfactory therapeutic effect|6
6025661|NCT00264550|9621218|FG000|Overall Study|Discontinued oral study agent|0
6025662|NCT00264550|9621219|FG001|Overall Study|Discontinued oral study agent|1
6025663|NCT00264550|9621220|FG002|Overall Study|Discontinued oral study agent|0
6025664|NCT00264550|9621221|FG003|Overall Study|Discontinued oral study agent|0
6025665|NCT00264550|9621218|FG000|Overall Study|Other|13
6025666|NCT00264550|9621219|FG001|Overall Study|Other|7
6025667|NCT00264550|9621220|FG002|Overall Study|Other|3
6078982|NCT00606684|9685582|FG004|2-week Single-Blind Run-in Period|Received Study Medication in Error|0
6078983|NCT00606684|9685583|FG005|2-week Single-Blind Run-in Period|Received Study Medication in Error|0
6078984|NCT00606684|9685584|FG006|2-week Single-Blind Run-in Period|Received Study Medication in Error|0
6078985|NCT00606684|9685578|FG000|Double-Blind Treatment Period|Adverse Event|0
6078986|NCT00606684|9685579|FG001|Double-Blind Treatment Period|Adverse Event|3
6078987|NCT00606684|9685580|FG002|Double-Blind Treatment Period|Adverse Event|2
6078988|NCT00606684|9685581|FG003|Double-Blind Treatment Period|Adverse Event|4
6078989|NCT00606684|9685582|FG004|Double-Blind Treatment Period|Adverse Event|2
6078990|NCT00606684|9685583|FG005|Double-Blind Treatment Period|Adverse Event|0
6078991|NCT00606684|9685584|FG006|Double-Blind Treatment Period|Adverse Event|1
6078992|NCT00606684|9685578|FG000|Double-Blind Treatment Period|Lack of Efficacy|0
6078993|NCT00606684|9685579|FG001|Double-Blind Treatment Period|Lack of Efficacy|1
6078994|NCT00606684|9685580|FG002|Double-Blind Treatment Period|Lack of Efficacy|0
6078995|NCT00606684|9685581|FG003|Double-Blind Treatment Period|Lack of Efficacy|0
6078996|NCT00606684|9685582|FG004|Double-Blind Treatment Period|Lack of Efficacy|1
6078997|NCT00606684|9685583|FG005|Double-Blind Treatment Period|Lack of Efficacy|0
6078998|NCT00606684|9685584|FG006|Double-Blind Treatment Period|Lack of Efficacy|0
6078999|NCT00606684|9685578|FG000|Double-Blind Treatment Period|Protocol Violation|0
6079000|NCT00606684|9685579|FG001|Double-Blind Treatment Period|Protocol Violation|5
6079001|NCT00606684|9685580|FG002|Double-Blind Treatment Period|Protocol Violation|5
6079002|NCT00606684|9685581|FG003|Double-Blind Treatment Period|Protocol Violation|3
6079003|NCT00606684|9685582|FG004|Double-Blind Treatment Period|Protocol Violation|0
6079004|NCT00606684|9685583|FG005|Double-Blind Treatment Period|Protocol Violation|3
6025668|NCT00264550|9621221|FG003|Overall Study|Other|9
6025669|NCT00264576|9621233|FG000|Overall Study|Lost to Follow-up|1
6025670|NCT00264576|9621234|FG001|Overall Study|Lost to Follow-up|1
6025671|NCT00264797|9621251|FG000|Overall Study|Withdrawal by Subject|11
6025672|NCT00264797|9621252|FG001|Overall Study|Withdrawal by Subject|11
6025673|NCT00264797|9621251|FG000|Overall Study|Lost to Follow-up|9
6025674|NCT00264797|9621252|FG001|Overall Study|Lost to Follow-up|17
6025675|NCT00264797|9621251|FG000|Overall Study|Moved from area|3
6025676|NCT00264797|9621252|FG001|Overall Study|Moved from area|1
6079005|NCT00606684|9685584|FG006|Double-Blind Treatment Period|Protocol Violation|4
6079006|NCT00606684|9685578|FG000|Double-Blind Treatment Period|Met Protocol Defined Stopping Criteria|0
6079007|NCT00606684|9685579|FG001|Double-Blind Treatment Period|Met Protocol Defined Stopping Criteria|1
6079008|NCT00606684|9685580|FG002|Double-Blind Treatment Period|Met Protocol Defined Stopping Criteria|2
6079009|NCT00606684|9685581|FG003|Double-Blind Treatment Period|Met Protocol Defined Stopping Criteria|1
6079010|NCT00606684|9685582|FG004|Double-Blind Treatment Period|Met Protocol Defined Stopping Criteria|2
6025677|NCT00264797|9621251|FG000|Overall Study|Practical Problems|2
6025678|NCT00264797|9621252|FG001|Overall Study|Practical Problems|3
6025679|NCT00264797|9621251|FG000|Overall Study|Incarceration|4
6025680|NCT00264797|9621252|FG001|Overall Study|Incarceration|5
6025681|NCT00264797|9621251|FG000|Overall Study|Pressure/advice from Outsiders|1
6025682|NCT00264797|9621252|FG001|Overall Study|Pressure/advice from Outsiders|1
6025683|NCT00264797|9621251|FG000|Overall Study|Feels treatment not necessary, not worki|0
6025684|NCT00264797|9621252|FG001|Overall Study|Feels treatment not necessary, not worki|1
6025685|NCT00264797|9621251|FG000|Overall Study|Other|3
6025686|NCT00264797|9621252|FG001|Overall Study|Other|4
6025687|NCT00264810|9621260|FG000|Baseline|Withdrawal by Subject|10
6025688|NCT00264810|9621261|FG001|Baseline|Withdrawal by Subject|10
6025689|NCT00264810|9621260|FG000|Baseline|Physician Decision|7
6025690|NCT00264810|9621261|FG001|Baseline|Physician Decision|8
6025691|NCT00264810|9621260|FG000|Baseline|Subject Compliance Failure|3
6079011|NCT00606684|9685583|FG005|Double-Blind Treatment Period|Met Protocol Defined Stopping Criteria|3
6079012|NCT00606684|9685584|FG006|Double-Blind Treatment Period|Met Protocol Defined Stopping Criteria|1
6079013|NCT00606684|9685578|FG000|Double-Blind Treatment Period|Physician Decision|0
6079014|NCT00606684|9685579|FG001|Double-Blind Treatment Period|Physician Decision|5
6079015|NCT00606684|9685580|FG002|Double-Blind Treatment Period|Physician Decision|1
6079016|NCT00606684|9685581|FG003|Double-Blind Treatment Period|Physician Decision|0
6079017|NCT00606684|9685582|FG004|Double-Blind Treatment Period|Physician Decision|3
6079018|NCT00606684|9685583|FG005|Double-Blind Treatment Period|Physician Decision|1
6079019|NCT00606684|9685584|FG006|Double-Blind Treatment Period|Physician Decision|2
6079020|NCT00606684|9685578|FG000|Double-Blind Treatment Period|Withdrawal by Subject|0
6079021|NCT00606684|9685579|FG001|Double-Blind Treatment Period|Withdrawal by Subject|1
6079022|NCT00606684|9685580|FG002|Double-Blind Treatment Period|Withdrawal by Subject|1
6079023|NCT00606684|9685581|FG003|Double-Blind Treatment Period|Withdrawal by Subject|2
6079024|NCT00606684|9685582|FG004|Double-Blind Treatment Period|Withdrawal by Subject|1
6079025|NCT00606684|9685583|FG005|Double-Blind Treatment Period|Withdrawal by Subject|2
6079026|NCT00606684|9685584|FG006|Double-Blind Treatment Period|Withdrawal by Subject|0
6079027|NCT00606801|9685600|FG000|Intervention|Protocol Violation|3
6079028|NCT00606801|9685601|FG001|Intervention|Protocol Violation|3
6079029|NCT00606892|9685611|FG000|First Intervention|Protocol Violation|1
6079030|NCT00606892|9685612|FG001|First Intervention|Protocol Violation|4
6079031|NCT00606905|9685646|FG000|Overall Study|No Pregnancy|9
6079032|NCT00606905|9685647|FG001|Overall Study|No Pregnancy|6
6079033|NCT00606905|9685646|FG000|Overall Study|Non-Index Pregnancy|1
6079034|NCT00606905|9685647|FG001|Overall Study|Non-Index Pregnancy|4
6079035|NCT00606905|9685646|FG000|Overall Study|Withdrew|5
6079036|NCT00606905|9685647|FG001|Overall Study|Withdrew|5
6079037|NCT00606931|9685653|FG000|Overall Study|Withdrawal by Subject|3
6079038|NCT00607022|9685669|FG000|Overall Study|Withdrawal by Subject|1
6079039|NCT00607022|9685670|FG001|Overall Study|Withdrawal by Subject|0
6079040|NCT00607022|9685671|FG002|Overall Study|Withdrawal by Subject|0
6079041|NCT00607048|9685681|FG000|Overall Study|Adverse Event|0
6079042|NCT00607048|9685682|FG001|Overall Study|Adverse Event|1
6079043|NCT00607048|9685683|FG002|Overall Study|Adverse Event|0
6079044|NCT00607048|9685684|FG003|Overall Study|Adverse Event|0
6079045|NCT00607048|9685685|FG004|Overall Study|Adverse Event|4
6079046|NCT00607048|9685686|FG005|Overall Study|Adverse Event|0
6079047|NCT00607048|9685681|FG000|Overall Study|Global deterioration of health|1
6079048|NCT00607048|9685682|FG001|Overall Study|Global deterioration of health|0
6079049|NCT00607048|9685683|FG002|Overall Study|Global deterioration of health|0
6079050|NCT00607048|9685684|FG003|Overall Study|Global deterioration of health|0
6079051|NCT00607048|9685685|FG004|Overall Study|Global deterioration of health|0
6079052|NCT00607048|9685686|FG005|Overall Study|Global deterioration of health|0
6079053|NCT00607048|9685681|FG000|Overall Study|Objective disease progression - relapse|1
6079054|NCT00607048|9685682|FG001|Overall Study|Objective disease progression - relapse|2
6079055|NCT00607048|9685683|FG002|Overall Study|Objective disease progression - relapse|4
6079056|NCT00607048|9685684|FG003|Overall Study|Objective disease progression - relapse|2
6079057|NCT00607048|9685685|FG004|Overall Study|Objective disease progression - relapse|2
6079058|NCT00607048|9685686|FG005|Overall Study|Objective disease progression - relapse|2
6079059|NCT00607048|9685681|FG000|Overall Study|Withdrawal by Subject|0
6079060|NCT00607048|9685682|FG001|Overall Study|Withdrawal by Subject|0
6079061|NCT00607048|9685683|FG002|Overall Study|Withdrawal by Subject|0
6079062|NCT00607048|9685684|FG003|Overall Study|Withdrawal by Subject|1
6079063|NCT00607048|9685685|FG004|Overall Study|Withdrawal by Subject|0
6079064|NCT00607048|9685686|FG005|Overall Study|Withdrawal by Subject|2
6079065|NCT00607048|9685681|FG000|Overall Study|Other|1
6079066|NCT00607048|9685682|FG001|Overall Study|Other|1
6079067|NCT00607048|9685683|FG002|Overall Study|Other|0
6079068|NCT00607048|9685684|FG003|Overall Study|Other|0
6079069|NCT00607048|9685685|FG004|Overall Study|Other|0
6025692|NCT00264810|9621261|FG001|Baseline|Subject Compliance Failure|3
6025693|NCT00264810|9621260|FG000|Baseline|Insufficient Seizure Frequency|2
6025694|NCT00264810|9621261|FG001|Baseline|Insufficient Seizure Frequency|2
6079070|NCT00607048|9685686|FG005|Overall Study|Other|1
6079071|NCT00607087|9685705|FG000|Overall Study|Withdrawal by Subject|9
6079072|NCT00607087|9685706|FG001|Overall Study|Withdrawal by Subject|4
6079073|NCT00607087|9685707|FG002|Overall Study|Withdrawal by Subject|4
6079074|NCT00607087|9685705|FG000|Overall Study|Adverse Event|3
6079075|NCT00607087|9685706|FG001|Overall Study|Adverse Event|2
6025695|NCT00264810|9621260|FG000|Baseline|Did not Meet/Maintain Study I/E Criteria|1
6025696|NCT00264810|9621261|FG001|Baseline|Did not Meet/Maintain Study I/E Criteria|2
6025697|NCT00264810|9621260|FG000|Baseline|Other|0
6025698|NCT00264810|9621261|FG001|Baseline|Other|1
6025699|NCT00264810|9621260|FG000|Stimulation Optimization Period|Withdrawal by Subject|1
6025700|NCT00264810|9621261|FG001|Stimulation Optimization Period|Withdrawal by Subject|0
6025701|NCT00264810|9621260|FG000|Stimulation Optimization Period|Death|0
6025702|NCT00264810|9621261|FG001|Stimulation Optimization Period|Death|1
6025703|NCT00264810|9621260|FG000|Blinded Evaluation Period|Explant due to infection|1
6025704|NCT00264810|9621261|FG001|Blinded Evaluation Period|Explant due to infection|1
6025705|NCT00264810|9621260|FG000|Open Label Evaluation Period|Explant due to infection|1
6025706|NCT00264810|9621261|FG001|Open Label Evaluation Period|Explant due to infection|1
6025707|NCT00264810|9621260|FG000|Open Label Evaluation Period|Death|3
6025708|NCT00264810|9621261|FG001|Open Label Evaluation Period|Death|2
6025709|NCT00264810|9621260|FG000|Open Label Evaluation Period|Pursue Other Treatment Options|2
6025710|NCT00264810|9621261|FG001|Open Label Evaluation Period|Pursue Other Treatment Options|3
6025711|NCT00264849|9621271|FG000|Overall Study|Adverse Event|7
6025712|NCT00264849|9621272|FG001|Overall Study|Adverse Event|2
6025713|NCT00264849|9621271|FG000|Overall Study|Withdrawal by Subject|7
6025714|NCT00264849|9621272|FG001|Overall Study|Withdrawal by Subject|11
6025715|NCT00264849|9621271|FG000|Overall Study|Protocol Violation|5
6025716|NCT00264849|9621272|FG001|Overall Study|Protocol Violation|3
6025717|NCT00264849|9621271|FG000|Overall Study|Lack of Efficacy|1
6025718|NCT00264849|9621272|FG001|Overall Study|Lack of Efficacy|6
6025719|NCT00264849|9621271|FG000|Overall Study|Lost to Follow-up|0
6025720|NCT00264849|9621272|FG001|Overall Study|Lost to Follow-up|2
6025721|NCT00264849|9621271|FG000|Overall Study|Death|0
6025722|NCT00264849|9621272|FG001|Overall Study|Death|1
6025723|NCT00264849|9621271|FG000|Overall Study|Administrative Problems|2
6025724|NCT00264849|9621272|FG001|Overall Study|Administrative Problems|0
6025725|NCT00264875|9621278|FG000|Overall Study|Adverse Event|6
6025726|NCT00264875|9621278|FG000|Overall Study|Lost to Follow-up|6
6079076|NCT00607087|9685707|FG002|Overall Study|Adverse Event|3
6079077|NCT00607087|9685705|FG000|Overall Study|Other reason|1
6079078|NCT00607087|9685706|FG001|Overall Study|Other reason|5
6079079|NCT00607087|9685707|FG002|Overall Study|Other reason|2
6079080|NCT00607087|9685705|FG000|Overall Study|Poor compliance to protocol|1
6079081|NCT00607087|9685706|FG001|Overall Study|Poor compliance to protocol|0
6025727|NCT00264875|9621278|FG000|Overall Study|Protocol Violation|11
6025728|NCT00264875|9621278|FG000|Overall Study|Withdrawal by Subject|7
6025729|NCT00265083|9621285|FG000|Overall Study|Adverse Event|5
6025730|NCT00265083|9621286|FG001|Overall Study|Adverse Event|13
6025731|NCT00265083|9621287|FG002|Overall Study|Adverse Event|15
6025732|NCT00265083|9621285|FG000|Overall Study|Lost to Follow-up|3
6025733|NCT00265083|9621286|FG001|Overall Study|Lost to Follow-up|4
6025734|NCT00265083|9621287|FG002|Overall Study|Lost to Follow-up|4
6025735|NCT00265083|9621285|FG000|Overall Study|Unsatisfactory therapeutic effect|8
6025736|NCT00265083|9621286|FG001|Overall Study|Unsatisfactory therapeutic effect|13
6025737|NCT00265083|9621287|FG002|Overall Study|Unsatisfactory therapeutic effect|14
6025738|NCT00265083|9621285|FG000|Overall Study|Other|1
6025739|NCT00265083|9621286|FG001|Overall Study|Other|12
6079082|NCT00607087|9685707|FG002|Overall Study|Poor compliance to protocol|1
6079083|NCT00607087|9685705|FG000|Overall Study|Lost to Follow-up|1
6079084|NCT00607087|9685706|FG001|Overall Study|Lost to Follow-up|0
6146298|NCT01076088|9780883|FG004|Overall Study|Non-compliance with study drug|0
6146299|NCT01076088|9780884|FG005|Overall Study|Non-compliance with study drug|0
6146300|NCT01076088|9780879|FG000|Overall Study|Physician Decision|1
6146301|NCT01076088|9780880|FG001|Overall Study|Physician Decision|3
6146302|NCT01076088|9780881|FG002|Overall Study|Physician Decision|0
6146303|NCT01076088|9780882|FG003|Overall Study|Physician Decision|1
6146304|NCT01076088|9780883|FG004|Overall Study|Physician Decision|1
6146305|NCT01076088|9780884|FG005|Overall Study|Physician Decision|0
6146306|NCT01076088|9780879|FG000|Overall Study|Withdrawal by Subject|8
6146307|NCT01076088|9780880|FG001|Overall Study|Withdrawal by Subject|8
6146308|NCT01076088|9780881|FG002|Overall Study|Withdrawal by Subject|14
6146309|NCT01076088|9780882|FG003|Overall Study|Withdrawal by Subject|10
6146310|NCT01076088|9780883|FG004|Overall Study|Withdrawal by Subject|11
6146311|NCT01076088|9780884|FG005|Overall Study|Withdrawal by Subject|17
6146312|NCT01076088|9780879|FG000|Overall Study|Other protocol specified criteria|0
6146313|NCT01076088|9780880|FG001|Overall Study|Other protocol specified criteria|0
6146314|NCT01076088|9780881|FG002|Overall Study|Other protocol specified criteria|0
6025740|NCT00265083|9621287|FG002|Overall Study|Other|9
6025741|NCT00265096|9621299|FG000|Overall Study|Adverse Event|14
6025742|NCT00265096|9621300|FG001|Overall Study|Adverse Event|18
6025743|NCT00265096|9621301|FG002|Overall Study|Adverse Event|18
6025744|NCT00265096|9621299|FG000|Overall Study|Lost to Follow-up|2
6025745|NCT00265096|9621300|FG001|Overall Study|Lost to Follow-up|5
6025746|NCT00265096|9621301|FG002|Overall Study|Lost to Follow-up|3
6271852|NCT02168478|9973880|FG000|Overall Study|Withdrawal by Subject|1
6025747|NCT00265096|9621299|FG000|Overall Study|Death|0
6025748|NCT00265096|9621300|FG001|Overall Study|Death|1
6025749|NCT00265096|9621301|FG002|Overall Study|Death|2
6079085|NCT00607087|9685707|FG002|Overall Study|Lost to Follow-up|0
6079086|NCT00607087|9685705|FG000|Period 1|Withdrawal by Subject|7
6025750|NCT00265096|9621299|FG000|Overall Study|Unsatisfactory therapeutic effect|9
6079087|NCT00607087|9685706|FG001|Period 1|Withdrawal by Subject|2
6079088|NCT00607087|9685707|FG002|Period 1|Withdrawal by Subject|3
6079089|NCT00607087|9685705|FG000|Period 1|Adverse Event|3
6079090|NCT00607087|9685706|FG001|Period 1|Adverse Event|0
6079091|NCT00607087|9685707|FG002|Period 1|Adverse Event|0
6079092|NCT00607087|9685705|FG000|Period 1|Poor compliance to protocol|1
6025751|NCT00265096|9621300|FG001|Overall Study|Unsatisfactory therapeutic effect|8
6025752|NCT00265096|9621301|FG002|Overall Study|Unsatisfactory therapeutic effect|6
6025753|NCT00265096|9621299|FG000|Overall Study|Other|11
6025754|NCT00265096|9621300|FG001|Overall Study|Other|19
6025755|NCT00265096|9621301|FG002|Overall Study|Other|10
6025756|NCT00265109|9621311|FG000|Overall Study|Withdrawal by Subject|5
6025757|NCT00265109|9621311|FG000|Overall Study|Adverse Event|1
6025758|NCT00265122|9621322|FG000|Intervention Period 1 (Weeks 0 to 8):|Withdrawal by Subject|1
6025759|NCT00265122|9621323|FG001|Intervention Period 1 (Weeks 0 to 8):|Withdrawal by Subject|1
6025760|NCT00265122|9621324|FG002|Intervention Period 1 (Weeks 0 to 8):|Withdrawal by Subject|3
6025761|NCT00265122|9621325|FG003|Intervention Period 1 (Weeks 0 to 8):|Withdrawal by Subject|0
6025762|NCT00265122|9621326|FG004|Intervention Period 1 (Weeks 0 to 8):|Withdrawal by Subject|1
6025763|NCT00265122|9621327|FG005|Intervention Period 1 (Weeks 0 to 8):|Withdrawal by Subject|0
6025764|NCT00265122|9621322|FG000|Intervention Period 1 (Weeks 0 to 8):|Lost to Follow-up|1
6025765|NCT00265122|9621323|FG001|Intervention Period 1 (Weeks 0 to 8):|Lost to Follow-up|0
6025766|NCT00265122|9621324|FG002|Intervention Period 1 (Weeks 0 to 8):|Lost to Follow-up|0
6025767|NCT00265122|9621325|FG003|Intervention Period 1 (Weeks 0 to 8):|Lost to Follow-up|1
6025768|NCT00265122|9621326|FG004|Intervention Period 1 (Weeks 0 to 8):|Lost to Follow-up|0
6025769|NCT00265122|9621327|FG005|Intervention Period 1 (Weeks 0 to 8):|Lost to Follow-up|0
6025770|NCT00265122|9621322|FG000|Intervention Period 1 (Weeks 0 to 8):|Other|0
6025771|NCT00265122|9621323|FG001|Intervention Period 1 (Weeks 0 to 8):|Other|1
6025772|NCT00265122|9621324|FG002|Intervention Period 1 (Weeks 0 to 8):|Other|2
6025773|NCT00265122|9621325|FG003|Intervention Period 1 (Weeks 0 to 8):|Other|1
6025774|NCT00265122|9621326|FG004|Intervention Period 1 (Weeks 0 to 8):|Other|0
6025775|NCT00265122|9621327|FG005|Intervention Period 1 (Weeks 0 to 8):|Other|0
6025776|NCT00265122|9621322|FG000|Intervention Period 2 (Weeks 8 to 28):|Withdrawal by Subject|2
6025777|NCT00265122|9621323|FG001|Intervention Period 2 (Weeks 8 to 28):|Withdrawal by Subject|1
6025778|NCT00265122|9621324|FG002|Intervention Period 2 (Weeks 8 to 28):|Withdrawal by Subject|3
6025779|NCT00265122|9621325|FG003|Intervention Period 2 (Weeks 8 to 28):|Withdrawal by Subject|1
6025780|NCT00265122|9621326|FG004|Intervention Period 2 (Weeks 8 to 28):|Withdrawal by Subject|3
6025781|NCT00265122|9621327|FG005|Intervention Period 2 (Weeks 8 to 28):|Withdrawal by Subject|0
6025782|NCT00265122|9621322|FG000|Intervention Period 2 (Weeks 8 to 28):|Lost to Follow-up|1
6025783|NCT00265122|9621323|FG001|Intervention Period 2 (Weeks 8 to 28):|Lost to Follow-up|0
6025784|NCT00265122|9621324|FG002|Intervention Period 2 (Weeks 8 to 28):|Lost to Follow-up|0
6025785|NCT00265122|9621325|FG003|Intervention Period 2 (Weeks 8 to 28):|Lost to Follow-up|2
6025786|NCT00265122|9621326|FG004|Intervention Period 2 (Weeks 8 to 28):|Lost to Follow-up|2
6025787|NCT00265122|9621327|FG005|Intervention Period 2 (Weeks 8 to 28):|Lost to Follow-up|1
6025788|NCT00265122|9621322|FG000|Intervention Period 2 (Weeks 8 to 28):|Other|4
6025789|NCT00265122|9621323|FG001|Intervention Period 2 (Weeks 8 to 28):|Other|0
6025790|NCT00265122|9621324|FG002|Intervention Period 2 (Weeks 8 to 28):|Other|1
6025791|NCT00265122|9621325|FG003|Intervention Period 2 (Weeks 8 to 28):|Other|1
6025792|NCT00265122|9621326|FG004|Intervention Period 2 (Weeks 8 to 28):|Other|0
6079093|NCT00607087|9685706|FG001|Period 1|Poor compliance to protocol|0
6079094|NCT00607087|9685707|FG002|Period 1|Poor compliance to protocol|0
6079095|NCT00607087|9685705|FG000|Period 1|Lost to Follow-up|1
6079096|NCT00607087|9685706|FG001|Period 1|Lost to Follow-up|0
6079097|NCT00607087|9685707|FG002|Period 1|Lost to Follow-up|0
6079098|NCT00607087|9685705|FG000|Period 1|Other reason|0
6079099|NCT00607087|9685706|FG001|Period 1|Other reason|4
6079100|NCT00607087|9685707|FG002|Period 1|Other reason|2
6079101|NCT00607087|9685705|FG000|Period 2|Withdrawal by Subject|0
6079102|NCT00607087|9685706|FG001|Period 2|Withdrawal by Subject|1
6079103|NCT00607087|9685707|FG002|Period 2|Withdrawal by Subject|1
6079104|NCT00607087|9685705|FG000|Period 2|Other reason|1
6079105|NCT00607087|9685706|FG001|Period 2|Other reason|1
6079106|NCT00607087|9685707|FG002|Period 2|Other reason|0
6079107|NCT00607087|9685705|FG000|Period 2|Adverse Event|0
6079108|NCT00607087|9685706|FG001|Period 2|Adverse Event|1
6079109|NCT00607087|9685707|FG002|Period 2|Adverse Event|3
6079110|NCT00607087|9685705|FG000|Period 2|Poor compliance to protocol|0
6079111|NCT00607087|9685706|FG001|Period 2|Poor compliance to protocol|0
6079112|NCT00607087|9685707|FG002|Period 2|Poor compliance to protocol|1
6079113|NCT00607087|9685705|FG000|Period 3|Withdrawal by Subject|2
6079114|NCT00607087|9685706|FG001|Period 3|Withdrawal by Subject|1
6079115|NCT00607087|9685707|FG002|Period 3|Withdrawal by Subject|0
6079116|NCT00607087|9685705|FG000|Period 3|Adverse Event|0
6079117|NCT00607087|9685706|FG001|Period 3|Adverse Event|1
6079118|NCT00607087|9685707|FG002|Period 3|Adverse Event|0
6079119|NCT00607373|9685758|FG000|Treatment Period|Adverse Event|0
6079120|NCT00607373|9685759|FG001|Treatment Period|Adverse Event|4
6079121|NCT00607373|9685758|FG000|Treatment Period|Physician Decision|0
6079122|NCT00607373|9685759|FG001|Treatment Period|Physician Decision|1
6025793|NCT00265122|9621327|FG005|Intervention Period 2 (Weeks 8 to 28):|Other|0
6025794|NCT00265148|9621348|FG000|Overall Study|Adverse Event|2
6025795|NCT00265148|9621349|FG001|Overall Study|Adverse Event|2
6025796|NCT00265148|9621348|FG000|Overall Study|Lack of Efficacy|0
6025797|NCT00265148|9621349|FG001|Overall Study|Lack of Efficacy|2
6025798|NCT00265148|9621348|FG000|Overall Study|Protocol Violation|3
6025799|NCT00265148|9621349|FG001|Overall Study|Protocol Violation|2
6025800|NCT00265148|9621348|FG000|Overall Study|Lost to Follow-up|0
6025801|NCT00265148|9621349|FG001|Overall Study|Lost to Follow-up|1
6025802|NCT00265148|9621348|FG000|Overall Study|Withdrawal by Subject|2
6025803|NCT00265148|9621349|FG001|Overall Study|Withdrawal by Subject|1
6025804|NCT00265148|9621348|FG000|Overall Study|Physician Decision|1
6025805|NCT00265148|9621349|FG001|Overall Study|Physician Decision|0
6079123|NCT00607373|9685758|FG000|Treatment Period|Withdrawal by Subject|0
6079124|NCT00607373|9685759|FG001|Treatment Period|Withdrawal by Subject|1
6079125|NCT00607373|9685758|FG000|Follow-up Period|Other|0
6079126|NCT00607373|9685759|FG001|Follow-up Period|Other|1
6079127|NCT00607373|9685758|FG000|Follow-up Period|Protocol Violation|0
6079128|NCT00607373|9685759|FG001|Follow-up Period|Protocol Violation|1
6079129|NCT00607373|9685758|FG000|Follow-up Period|Withdrawal by Subject|1
6079130|NCT00607373|9685759|FG001|Follow-up Period|Withdrawal by Subject|3
6079131|NCT00607386|9685765|FG000|Overall Study|Physician Decision|1
6079132|NCT00607724|9685807|FG000|Stage 1: Dose Escalation|Tumour Progression-Clinical/Radiographic|7
6079133|NCT00607724|9685808|FG001|Stage 1: Dose Escalation|Tumour Progression-Clinical/Radiographic|8
6079134|NCT00607724|9685809|FG002|Stage 1: Dose Escalation|Tumour Progression-Clinical/Radiographic|4
6079135|NCT00607724|9685810|FG003|Stage 1: Dose Escalation|Tumour Progression-Clinical/Radiographic|0
6079136|NCT00607724|9685811|FG004|Stage 1: Dose Escalation|Tumour Progression-Clinical/Radiographic|0
6079137|NCT00607724|9685812|FG005|Stage 1: Dose Escalation|Tumour Progression-Clinical/Radiographic|0
6079138|NCT00607724|9685813|FG006|Stage 1: Dose Escalation|Tumour Progression-Clinical/Radiographic|0
6079139|NCT00607724|9685807|FG000|Stage 2: Expanded Cohort|Adverse Event|0
6079140|NCT00607724|9685808|FG001|Stage 2: Expanded Cohort|Adverse Event|0
6146315|NCT01076088|9780882|FG003|Overall Study|Other protocol specified criteria|0
6146316|NCT01076088|9780883|FG004|Overall Study|Other protocol specified criteria|0
6146317|NCT01076088|9780884|FG005|Overall Study|Other protocol specified criteria|1
6146318|NCT01076153|9780899|FG000|Overall Study|Symptoms improved/resolved|10
6146319|NCT01076153|9780899|FG000|Overall Study|Adverse Event|1
6146320|NCT01076166|9780907|FG000|Overall Study|Adverse Event|3
6146321|NCT01076166|9780907|FG000|Overall Study|Symptoms improved/resolved|6
6146322|NCT01076179|9780914|FG000|Overall Study|Withdrawal by Subject|1
6146323|NCT01076192|9780919|FG000|Overall Study|Other|197
6146324|NCT01076205|9780924|FG000|Overall Study|Adverse Drug Reaction|299
6146325|NCT01076205|9780924|FG000|Overall Study|Lack of Effectiveness|1423
6146326|NCT01076205|9780924|FG000|Overall Study|Other Reason|1075
6146327|NCT01076205|9780924|FG000|Overall Study|Unknown Reason|71
6146328|NCT01076205|9780924|FG000|Overall Study|Lost to Follow-up|3151
6146329|NCT01076335|9780990|FG000|Overall Study|Withdrawal by Subject|3
6146330|NCT01076335|9780990|FG000|Overall Study|Withdrawal without treatment|1
6146331|NCT01076361|9780998|FG000|Overall Study|22 leads were excluded from analysis|21
6146332|NCT01076400|9781002|FG000|Overall Study|Adverse Event|2
6146333|NCT01076400|9781003|FG001|Overall Study|Adverse Event|0
6146334|NCT01076400|9781004|FG002|Overall Study|Adverse Event|0
6146335|NCT01076400|9781002|FG000|Overall Study|Progressive Disease|5
6146336|NCT01076400|9781003|FG001|Overall Study|Progressive Disease|0
6146337|NCT01076400|9781004|FG002|Overall Study|Progressive Disease|0
6146338|NCT01076543|9781027|FG000|Overall Study|Withdrawal by Subject|2
6146339|NCT01076543|9781028|FG001|Overall Study|Withdrawal by Subject|0
6146340|NCT01076543|9781029|FG002|Overall Study|Withdrawal by Subject|0
6146341|NCT01076543|9781030|FG003|Overall Study|Withdrawal by Subject|0
6146342|NCT01076543|9781031|FG004|Overall Study|Withdrawal by Subject|0
6146343|NCT01076543|9781032|FG005|Overall Study|Withdrawal by Subject|0
6146344|NCT01076647|9781049|FG000|Overall Study|Adverse Event|4
6146345|NCT01076647|9781050|FG001|Overall Study|Adverse Event|1
6146346|NCT01076647|9781049|FG000|Overall Study|Lack of Efficacy|0
6146347|NCT01076647|9781050|FG001|Overall Study|Lack of Efficacy|1
6146348|NCT01076647|9781049|FG000|Overall Study|Protocol Violation|7
6146349|NCT01076647|9781050|FG001|Overall Study|Protocol Violation|9
6146350|NCT01076647|9781049|FG000|Overall Study|Withdrawal criteria|2
6146351|NCT01076647|9781050|FG001|Overall Study|Withdrawal criteria|2
6146352|NCT01076647|9781049|FG000|Overall Study|Unclassified|12
6146353|NCT01076647|9781050|FG001|Overall Study|Unclassified|12
6146354|NCT01076959|9781073|FG000|Overall Study|Adverse Event|767
6146355|NCT01076959|9781073|FG000|Overall Study|Lack of Efficacy|849
6146356|NCT01076959|9781073|FG000|Overall Study|Non-compliance|274
6146357|NCT01076959|9781073|FG000|Overall Study|Lost to Follow-up|241
6146358|NCT01076959|9781073|FG000|Overall Study|Other|119
6146359|NCT01077024|9781112|FG000|Overall Study|Lost to Follow-up|20
6146360|NCT01077024|9781113|FG001|Overall Study|Lost to Follow-up|14
6146361|NCT01077024|9781112|FG000|Overall Study|Withdrawal by Subject|0
6146362|NCT01077024|9781113|FG001|Overall Study|Withdrawal by Subject|2
6146363|NCT01077024|9781112|FG000|Overall Study|Incarcerated|7
6146364|NCT01077024|9781113|FG001|Overall Study|Incarcerated|8
6146365|NCT01077024|9781112|FG000|Overall Study|Other|4
6025806|NCT00265148|9621348|FG000|Overall Study|Increasing frailty|0
6025807|NCT00265148|9621349|FG001|Overall Study|Increasing frailty|1
6025808|NCT00265148|9621348|FG000|Overall Study|Subject chose to change of the dose|1
6025809|NCT00265148|9621349|FG001|Overall Study|Subject chose to change of the dose|0
6025810|NCT00265239|9621362|FG000|Overall Study|Adverse Event|2
6025811|NCT00265239|9621363|FG001|Overall Study|Adverse Event|1
6025812|NCT00265317|9621373|FG000|Lead-In|Objective progression or relapse|6
6025813|NCT00265317|9621374|FG001|Lead-In|Objective progression or relapse|11
6025814|NCT00265317|9621375|FG002|Lead-In|Objective progression or relapse|0
6025815|NCT00265317|9621376|FG003|Lead-In|Objective progression or relapse|0
6025816|NCT00265317|9621373|FG000|Lead-In|Adverse Event|2
6025817|NCT00265317|9621374|FG001|Lead-In|Adverse Event|1
6025818|NCT00265317|9621375|FG002|Lead-In|Adverse Event|0
6025819|NCT00265317|9621376|FG003|Lead-In|Adverse Event|0
6025820|NCT00265317|9621373|FG000|Lead-In|Death|3
6025821|NCT00265317|9621374|FG001|Lead-In|Death|5
6025822|NCT00265317|9621375|FG002|Lead-In|Death|0
6025823|NCT00265317|9621376|FG003|Lead-In|Death|0
6025824|NCT00265317|9621373|FG000|Lead-In|Withdrawal/other than adverse event|1
6025825|NCT00265317|9621374|FG001|Lead-In|Withdrawal/other than adverse event|0
6025826|NCT00265317|9621375|FG002|Lead-In|Withdrawal/other than adverse event|0
6025827|NCT00265317|9621376|FG003|Lead-In|Withdrawal/other than adverse event|0
6025828|NCT00265317|9621373|FG000|Phase 2|Objective progression or relapse|0
6025829|NCT00265317|9621374|FG001|Phase 2|Objective progression or relapse|0
6025830|NCT00265317|9621375|FG002|Phase 2|Objective progression or relapse|37
6025831|NCT00265317|9621376|FG003|Phase 2|Objective progression or relapse|38
6025832|NCT00265317|9621373|FG000|Phase 2|Global deterioration of health status|0
6025833|NCT00265317|9621374|FG001|Phase 2|Global deterioration of health status|0
6025834|NCT00265317|9621375|FG002|Phase 2|Global deterioration of health status|3
6025835|NCT00265317|9621376|FG003|Phase 2|Global deterioration of health status|0
6025836|NCT00265317|9621373|FG000|Phase 2|Adverse Event|0
6025837|NCT00265317|9621374|FG001|Phase 2|Adverse Event|0
6025838|NCT00265317|9621375|FG002|Phase 2|Adverse Event|7
6025839|NCT00265317|9621376|FG003|Phase 2|Adverse Event|5
6025840|NCT00265317|9621373|FG000|Phase 2|Death|0
6025841|NCT00265317|9621374|FG001|Phase 2|Death|0
6025842|NCT00265317|9621375|FG002|Phase 2|Death|12
6025843|NCT00265317|9621376|FG003|Phase 2|Death|15
6025844|NCT00265317|9621373|FG000|Phase 2|Protocol Violation|0
6025845|NCT00265317|9621374|FG001|Phase 2|Protocol Violation|0
6025846|NCT00265317|9621375|FG002|Phase 2|Protocol Violation|1
6025847|NCT00265317|9621376|FG003|Phase 2|Protocol Violation|4
6025848|NCT00265317|9621373|FG000|Phase 2|Lost to Follow-up|0
6025849|NCT00265317|9621374|FG001|Phase 2|Lost to Follow-up|0
6025850|NCT00265317|9621375|FG002|Phase 2|Lost to Follow-up|0
6025851|NCT00265317|9621376|FG003|Phase 2|Lost to Follow-up|1
6025852|NCT00265317|9621373|FG000|Phase 2|Withdrawal/other than adverse event|0
6025853|NCT00265317|9621374|FG001|Phase 2|Withdrawal/other than adverse event|0
6025854|NCT00265317|9621375|FG002|Phase 2|Withdrawal/other than adverse event|2
6025855|NCT00265317|9621376|FG003|Phase 2|Withdrawal/other than adverse event|1
6025856|NCT00265317|9621373|FG000|Phase 2|Study terminated by sponsor|0
6025857|NCT00265317|9621374|FG001|Phase 2|Study terminated by sponsor|0
6025858|NCT00265317|9621375|FG002|Phase 2|Study terminated by sponsor|1
6025859|NCT00265317|9621376|FG003|Phase 2|Study terminated by sponsor|0
6025860|NCT00265317|9621373|FG000|Phase 2|Other|0
6025861|NCT00265317|9621374|FG001|Phase 2|Other|0
6025862|NCT00265317|9621375|FG002|Phase 2|Other|1
6025863|NCT00265317|9621376|FG003|Phase 2|Other|1
6025864|NCT00265330|9621395|FG000|Overall Study|Adverse Event|41
6025865|NCT00265330|9621395|FG000|Overall Study|Lost to Follow-up|8
6025866|NCT00265330|9621395|FG000|Overall Study|Withdrawal by Subject|34
6025867|NCT00265330|9621395|FG000|Overall Study|Patient Wanted to Start Psychotherapy|1
6025868|NCT00265330|9621395|FG000|Overall Study|Lack of Efficacy|4
6146366|NCT01077024|9781113|FG001|Overall Study|Other|4
6146367|NCT01077050|9781119|FG000|Overall Study|Subjects signed ICF could not be located|1
6146368|NCT01077050|9781119|FG000|Overall Study|Screen failure|8
6025869|NCT00265330|9621395|FG000|Overall Study|Family Scheduling Conflicts|1
6025870|NCT00265330|9621395|FG000|Overall Study|Began Taking Formulary Geodon|1
6025871|NCT00265330|9621395|FG000|Overall Study|Discharged from Unit for Long Term Care|1
6025872|NCT00265330|9621395|FG000|Overall Study|Site Closed by Sponsor|1
6025873|NCT00265330|9621395|FG000|Overall Study|Principal Investigators Request|1
6025874|NCT00265330|9621395|FG000|Overall Study|Withdrew Consent|1
6025875|NCT00265330|9621395|FG000|Overall Study|Protocol Violation|1
6025876|NCT00265382|9621399|FG000|Overall Study|Adverse Event|21
6025877|NCT00265382|9621399|FG000|Overall Study|Laboratory Abnormality|1
6025878|NCT00265382|9621399|FG000|Overall Study|Lost to Follow-up|3
6025879|NCT00265382|9621399|FG000|Overall Study|Lack of Efficacy|6
6025880|NCT00265382|9621399|FG000|Overall Study|Miscellaneous|6
6025881|NCT00265382|9621399|FG000|Overall Study|Withdrawal by Subject|13
6025882|NCT00265382|9621399|FG000|Overall Study|Study terminated by sponsor|94
6025883|NCT00265382|9621399|FG000|Overall Study|Death|1
6025884|NCT00265395|9621405|FG000|Overall Study|Adverse Event|3
6025885|NCT00265395|9621406|FG001|Overall Study|Adverse Event|6
6025886|NCT00265395|9621405|FG000|Overall Study|Lost to Follow-up|2
6025887|NCT00265395|9621406|FG001|Overall Study|Lost to Follow-up|1
6025888|NCT00265395|9621405|FG000|Overall Study|Withdrawal by Subject|1
6025889|NCT00265395|9621406|FG001|Overall Study|Withdrawal by Subject|6
6025890|NCT00265395|9621405|FG000|Overall Study|Protocol Violation|2
6025891|NCT00265395|9621406|FG001|Overall Study|Protocol Violation|2
6025892|NCT00265395|9621405|FG000|Overall Study|Lack of Efficacy|0
6025893|NCT00265395|9621406|FG001|Overall Study|Lack of Efficacy|1
6025894|NCT00265395|9621405|FG000|Overall Study|Administrative|0
6025895|NCT00265395|9621406|FG001|Overall Study|Administrative|1
6025896|NCT00265564|9621444|FG000|Overall Study|Lost to Follow-up|5
6025897|NCT00265564|9621445|FG001|Overall Study|Lost to Follow-up|7
6025898|NCT00265564|9621444|FG000|Overall Study|met exclusion criteria|5
6025899|NCT00265564|9621445|FG001|Overall Study|met exclusion criteria|2
6025900|NCT00265759|9621466|FG000|Overall Study|Withdrawal by Subject|0
6025901|NCT00265759|9621467|FG001|Overall Study|Withdrawal by Subject|1
6025902|NCT00265759|9621468|FG002|Overall Study|Withdrawal by Subject|2
6025903|NCT00265759|9621469|FG003|Overall Study|Withdrawal by Subject|2
6025904|NCT00265759|9621466|FG000|Overall Study|Cancel|0
6025905|NCT00265759|9621467|FG001|Overall Study|Cancel|0
6025906|NCT00265759|9621468|FG002|Overall Study|Cancel|0
6025907|NCT00265759|9621469|FG003|Overall Study|Cancel|3
6025908|NCT00265759|9621466|FG000|Overall Study|Ineligible|0
6025909|NCT00265759|9621467|FG001|Overall Study|Ineligible|0
6025910|NCT00265759|9621468|FG002|Overall Study|Ineligible|0
6025911|NCT00265759|9621469|FG003|Overall Study|Ineligible|1
6025912|NCT00265759|9621466|FG000|Overall Study|Bilateral disease|0
6025913|NCT00265759|9621467|FG001|Overall Study|Bilateral disease|0
6025914|NCT00265759|9621468|FG002|Overall Study|Bilateral disease|0
6025915|NCT00265759|9621469|FG003|Overall Study|Bilateral disease|2
6025916|NCT00265759|9621466|FG000|Overall Study|Discontinued due to intolerability|0
6025917|NCT00265759|9621467|FG001|Overall Study|Discontinued due to intolerability|0
6025918|NCT00265759|9621468|FG002|Overall Study|Discontinued due to intolerability|0
6025919|NCT00265759|9621469|FG003|Overall Study|Discontinued due to intolerability|1
6025920|NCT00265785|9621480|FG000|Overall Study|Adverse Event|4
6025921|NCT00265785|9621480|FG000|Overall Study|Withdrawal by Subject|3
6025922|NCT00265785|9621480|FG000|Overall Study|Progression/Relapse|15
6025923|NCT00265785|9621480|FG000|Overall Study|Not protocol specified|2
6025924|NCT00265785|9621480|FG000|Overall Study|Ineligible|1
6025925|NCT00265785|9621480|FG000|Overall Study|Did not receive protocol treatment|2
6025926|NCT00265889|9621496|FG000|Overall Study|Physician Decision|1
6025927|NCT00265889|9621496|FG000|Overall Study|Protocol Violation|1
6025928|NCT00265889|9621496|FG000|Overall Study|Insurance denied the request|3
6025929|NCT00265941|9621502|FG000|Overall Study|Protocol Violation|22
6025930|NCT00265941|9621503|FG001|Overall Study|Protocol Violation|25
6025931|NCT00265941|9621502|FG000|Overall Study|Lost to Follow-up|1
6025932|NCT00265941|9621503|FG001|Overall Study|Lost to Follow-up|1
6025933|NCT00266032|9621524|FG000|Treatment|Adverse Event|42
6025934|NCT00266032|9621525|FG001|Treatment|Adverse Event|26
6025935|NCT00266032|9621526|FG002|Treatment|Adverse Event|10
6025936|NCT00266032|9621524|FG000|Treatment|Lost to Follow-up|19
6025937|NCT00266032|9621525|FG001|Treatment|Lost to Follow-up|4
6025938|NCT00266032|9621526|FG002|Treatment|Lost to Follow-up|2
6025939|NCT00266032|9621524|FG000|Treatment|Pregnancy|3
6025940|NCT00266032|9621525|FG001|Treatment|Pregnancy|2
6025941|NCT00266032|9621526|FG002|Treatment|Pregnancy|2
6025942|NCT00266032|9621524|FG000|Treatment|Protocol Violation|6
6025943|NCT00266032|9621525|FG001|Treatment|Protocol Violation|14
6025944|NCT00266032|9621526|FG002|Treatment|Protocol Violation|13
6025945|NCT00266032|9621524|FG000|Treatment|Withdrawal by Subject|28
6025946|NCT00266032|9621525|FG001|Treatment|Withdrawal by Subject|13
6025947|NCT00266032|9621526|FG002|Treatment|Withdrawal by Subject|12
6025948|NCT00266032|9621524|FG000|Treatment|patient moved/wish for pregnancy/no need|13
6025949|NCT00266032|9621525|FG001|Treatment|patient moved/wish for pregnancy/no need|5
6025950|NCT00266032|9621526|FG002|Treatment|patient moved/wish for pregnancy/no need|8
6025951|NCT00266032|9621524|FG000|Open-label Safety Extension|Adverse Event|5
6025952|NCT00266032|9621525|FG001|Open-label Safety Extension|Adverse Event|0
6025953|NCT00266032|9621526|FG002|Open-label Safety Extension|Adverse Event|4
6025954|NCT00266032|9621524|FG000|Open-label Safety Extension|Lost to Follow-up|2
6025955|NCT00266032|9621525|FG001|Open-label Safety Extension|Lost to Follow-up|5
6025956|NCT00266032|9621526|FG002|Open-label Safety Extension|Lost to Follow-up|4
6025957|NCT00266032|9621524|FG000|Open-label Safety Extension|Pregnancy|4
6025958|NCT00266032|9621525|FG001|Open-label Safety Extension|Pregnancy|1
6025959|NCT00266032|9621526|FG002|Open-label Safety Extension|Pregnancy|2
6025960|NCT00266032|9621524|FG000|Open-label Safety Extension|Protocol Violation|1
6025961|NCT00266032|9621525|FG001|Open-label Safety Extension|Protocol Violation|3
6025962|NCT00266032|9621526|FG002|Open-label Safety Extension|Protocol Violation|2
6025963|NCT00266032|9621524|FG000|Open-label Safety Extension|Withdrawal by Subject|19
6025964|NCT00266032|9621525|FG001|Open-label Safety Extension|Withdrawal by Subject|3
6025965|NCT00266032|9621526|FG002|Open-label Safety Extension|Withdrawal by Subject|12
6025966|NCT00266032|9621524|FG000|Open-label Safety Extension|patient moved/wish for pregnancy/no need|10
6025967|NCT00266032|9621525|FG001|Open-label Safety Extension|patient moved/wish for pregnancy/no need|2
6025968|NCT00266032|9621526|FG002|Open-label Safety Extension|patient moved/wish for pregnancy/no need|1
6025969|NCT00266227|9621541|FG000|Initial Treatment|Adverse Event|0
6025970|NCT00266227|9621542|FG001|Initial Treatment|Adverse Event|0
6025971|NCT00266227|9621543|FG002|Initial Treatment|Adverse Event|13
6025972|NCT00266227|9621541|FG000|Initial Treatment|Lost to Follow-up|0
6025973|NCT00266227|9621542|FG001|Initial Treatment|Lost to Follow-up|0
6025974|NCT00266227|9621543|FG002|Initial Treatment|Lost to Follow-up|6
6025975|NCT00266227|9621541|FG000|Initial Treatment|Subject/Guardian decision to withdraw|0
6025976|NCT00266227|9621542|FG001|Initial Treatment|Subject/Guardian decision to withdraw|0
6025977|NCT00266227|9621543|FG002|Initial Treatment|Subject/Guardian decision to withdraw|45
6025978|NCT00266227|9621541|FG000|Initial Treatment|Physician decision to withdraw|0
6079141|NCT00607724|9685809|FG002|Stage 2: Expanded Cohort|Adverse Event|0
6079142|NCT00607724|9685810|FG003|Stage 2: Expanded Cohort|Adverse Event|0
6025979|NCT00266227|9621542|FG001|Initial Treatment|Physician decision to withdraw|0
6025980|NCT00266227|9621543|FG002|Initial Treatment|Physician decision to withdraw|12
6025981|NCT00266227|9621541|FG000|Initial Treatment|Pregnancy|0
6025982|NCT00266227|9621542|FG001|Initial Treatment|Pregnancy|0
6025983|NCT00266227|9621543|FG002|Initial Treatment|Pregnancy|1
6025984|NCT00266227|9621541|FG000|Retreatment: Up to Week 48|Death|1
6025985|NCT00266227|9621542|FG001|Retreatment: Up to Week 48|Death|0
6025986|NCT00266227|9621543|FG002|Retreatment: Up to Week 48|Death|0
6025987|NCT00266227|9621541|FG000|Retreatment: Up to Week 48|Adverse Event|7
6025988|NCT00266227|9621542|FG001|Retreatment: Up to Week 48|Adverse Event|7
6025989|NCT00266227|9621543|FG002|Retreatment: Up to Week 48|Adverse Event|0
6025990|NCT00266227|9621541|FG000|Retreatment: Up to Week 48|Lost to Follow-up|3
6025991|NCT00266227|9621542|FG001|Retreatment: Up to Week 48|Lost to Follow-up|0
6025992|NCT00266227|9621543|FG002|Retreatment: Up to Week 48|Lost to Follow-up|0
6025993|NCT00266227|9621541|FG000|Retreatment: Up to Week 48|Subject/Guardian Decision to Withdraw|11
6025994|NCT00266227|9621542|FG001|Retreatment: Up to Week 48|Subject/Guardian Decision to Withdraw|14
6025995|NCT00266227|9621543|FG002|Retreatment: Up to Week 48|Subject/Guardian Decision to Withdraw|0
6025996|NCT00266227|9621541|FG000|Retreatment: Up to Week 48|Physician's Decision to Withdraw|4
6025997|NCT00266227|9621542|FG001|Retreatment: Up to Week 48|Physician's Decision to Withdraw|2
6025998|NCT00266227|9621543|FG002|Retreatment: Up to Week 48|Physician's Decision to Withdraw|0
6025999|NCT00266227|9621541|FG000|Retreatment: Up to Week 48|Pregnancy|1
6026000|NCT00266227|9621542|FG001|Retreatment: Up to Week 48|Pregnancy|0
6026001|NCT00266227|9621543|FG002|Retreatment: Up to Week 48|Pregnancy|0
6026002|NCT00266227|9621541|FG000|Retreatment: Week 48 to Week 72|Death|1
6026003|NCT00266227|9621542|FG001|Retreatment: Week 48 to Week 72|Death|1
6026004|NCT00266227|9621543|FG002|Retreatment: Week 48 to Week 72|Death|0
6026005|NCT00266227|9621541|FG000|Retreatment: Week 48 to Week 72|Adverse Event|6
6026006|NCT00266227|9621542|FG001|Retreatment: Week 48 to Week 72|Adverse Event|2
6026007|NCT00266227|9621543|FG002|Retreatment: Week 48 to Week 72|Adverse Event|0
6026008|NCT00266227|9621541|FG000|Retreatment: Week 48 to Week 72|Lost to Follow-up|1
6026009|NCT00266227|9621542|FG001|Retreatment: Week 48 to Week 72|Lost to Follow-up|0
6026010|NCT00266227|9621543|FG002|Retreatment: Week 48 to Week 72|Lost to Follow-up|0
6026011|NCT00266227|9621541|FG000|Retreatment: Week 48 to Week 72|Subject/Guardian Decision to Withdraw|41
6026012|NCT00266227|9621542|FG001|Retreatment: Week 48 to Week 72|Subject/Guardian Decision to Withdraw|29
6026013|NCT00266227|9621543|FG002|Retreatment: Week 48 to Week 72|Subject/Guardian Decision to Withdraw|0
6026014|NCT00266227|9621541|FG000|Retreatment: Week 48 to Week 72|Physician's Decision to Withdraw|15
6026015|NCT00266227|9621542|FG001|Retreatment: Week 48 to Week 72|Physician's Decision to Withdraw|10
6026016|NCT00266227|9621543|FG002|Retreatment: Week 48 to Week 72|Physician's Decision to Withdraw|0
6026017|NCT00266409|9621561|FG000|Overall Study|Lack of Efficacy|2
6026018|NCT00266409|9621562|FG001|Overall Study|Lack of Efficacy|6
6026019|NCT00266409|9621563|FG002|Overall Study|Lack of Efficacy|1
6026020|NCT00266409|9621564|FG003|Overall Study|Lack of Efficacy|2
6026021|NCT00266409|9621561|FG000|Overall Study|Adverse Event|7
6026022|NCT00266409|9621562|FG001|Overall Study|Adverse Event|2
6026023|NCT00266409|9621563|FG002|Overall Study|Adverse Event|1
6026024|NCT00266409|9621564|FG003|Overall Study|Adverse Event|1
6026025|NCT00266409|9621561|FG000|Overall Study|Lost to Follow-up|18
6026026|NCT00266409|9621562|FG001|Overall Study|Lost to Follow-up|21
6026027|NCT00266409|9621563|FG002|Overall Study|Lost to Follow-up|6
6026028|NCT00266409|9621564|FG003|Overall Study|Lost to Follow-up|8
6026029|NCT00266409|9621561|FG000|Overall Study|Withdrawal by Subject|6
6026030|NCT00266409|9621562|FG001|Overall Study|Withdrawal by Subject|10
6026031|NCT00266409|9621563|FG002|Overall Study|Withdrawal by Subject|3
6026032|NCT00266409|9621564|FG003|Overall Study|Withdrawal by Subject|9
6026033|NCT00266409|9621561|FG000|Overall Study|Protocol Violation|5
6026034|NCT00266409|9621562|FG001|Overall Study|Protocol Violation|3
6026035|NCT00266409|9621563|FG002|Overall Study|Protocol Violation|4
6026036|NCT00266409|9621564|FG003|Overall Study|Protocol Violation|2
6026037|NCT00266409|9621561|FG000|Overall Study|Other|7
6026038|NCT00266409|9621562|FG001|Overall Study|Other|4
6026039|NCT00266409|9621563|FG002|Overall Study|Other|2
6026040|NCT00266409|9621564|FG003|Overall Study|Other|0
6026041|NCT00266630|9621576|FG000|Overall Study|Adverse Event|8
6026042|NCT00266630|9621577|FG001|Overall Study|Adverse Event|6
6026043|NCT00266630|9621576|FG000|Overall Study|Lack of Efficacy|1
6026044|NCT00266630|9621577|FG001|Overall Study|Lack of Efficacy|4
6026045|NCT00266630|9621576|FG000|Overall Study|Entry Criteria not met|1
6026046|NCT00266630|9621577|FG001|Overall Study|Entry Criteria not met|0
6026047|NCT00266630|9621576|FG000|Overall Study|Protocol Violation|1
6026048|NCT00266630|9621577|FG001|Overall Study|Protocol Violation|3
6026049|NCT00266630|9621576|FG000|Overall Study|Physician Decision|1
6026050|NCT00266630|9621577|FG001|Overall Study|Physician Decision|2
6026051|NCT00266630|9621576|FG000|Overall Study|Withdrawal by Subject|10
6026052|NCT00266630|9621577|FG001|Overall Study|Withdrawal by Subject|2
6026053|NCT00266630|9621576|FG000|Overall Study|Lost to Follow-up|1
6026054|NCT00266630|9621577|FG001|Overall Study|Lost to Follow-up|0
6026055|NCT00266630|9621576|FG000|Overall Study|Other|19
6026056|NCT00266630|9621577|FG001|Overall Study|Other|11
6026057|NCT00266656|9621587|FG000|Overall Study|Death|1
6026058|NCT00266656|9621588|FG001|Overall Study|Death|0
6026059|NCT00266656|9621587|FG000|Overall Study|Lost to Follow-up|4
6026060|NCT00266656|9621588|FG001|Overall Study|Lost to Follow-up|1
6026061|NCT00266656|9621587|FG000|Overall Study|Withdrawal by Subject|4
6079143|NCT00607724|9685811|FG004|Stage 2: Expanded Cohort|Adverse Event|0
6079144|NCT00607724|9685812|FG005|Stage 2: Expanded Cohort|Adverse Event|0
6079145|NCT00607724|9685813|FG006|Stage 2: Expanded Cohort|Adverse Event|1
6079146|NCT00607724|9685807|FG000|Stage 2: Expanded Cohort|Tumour Progression-Clinical/Radiographic|0
6079147|NCT00607724|9685808|FG001|Stage 2: Expanded Cohort|Tumour Progression-Clinical/Radiographic|0
6026062|NCT00266656|9621588|FG001|Overall Study|Withdrawal by Subject|2
6026063|NCT00266656|9621587|FG000|Overall Study|Did Not Reach Final Height|4
6026064|NCT00266656|9621588|FG001|Overall Study|Did Not Reach Final Height|8
6026065|NCT00266656|9621587|FG000|Overall Study|Parent/Caregiver Decision|1
6026066|NCT00266656|9621588|FG001|Overall Study|Parent/Caregiver Decision|2
6026067|NCT00266695|9621594|FG000|Overall Study|Adverse Event|1
6026068|NCT00266695|9621594|FG000|Overall Study|Death|9
6026069|NCT00266695|9621594|FG000|Overall Study|Physician Decision|1
6026070|NCT00266695|9621594|FG000|Overall Study|Lost to Follow-up|3
6026071|NCT00266695|9621594|FG000|Overall Study|Withdrawal by Subject|15
6026072|NCT00266708|9621600|FG000|Overall Study|No renal function|1
6026073|NCT00266708|9621601|FG001|Overall Study|No renal function|1
6026074|NCT00266708|9621600|FG000|Overall Study|Refused biopsy|3
6026075|NCT00266708|9621601|FG001|Overall Study|Refused biopsy|6
6026076|NCT00266708|9621600|FG000|Overall Study|Asthma|0
6026077|NCT00266708|9621601|FG001|Overall Study|Asthma|2
6026078|NCT00266812|9621618|FG000|Overall Study|Disease Progression|9
6026079|NCT00266812|9621619|FG001|Overall Study|Disease Progression|3
6026080|NCT00266812|9621618|FG000|Overall Study|Death|5
6026081|NCT00266812|9621619|FG001|Overall Study|Death|4
6026082|NCT00266812|9621618|FG000|Overall Study|Adverse Event|3
6026083|NCT00266812|9621619|FG001|Overall Study|Adverse Event|1
6026084|NCT00266812|9621618|FG000|Overall Study|Protocol Violation|0
6026085|NCT00266812|9621619|FG001|Overall Study|Protocol Violation|1
6026086|NCT00266812|9621618|FG000|Overall Study|Withdrawal by Subject|0
6026087|NCT00266812|9621619|FG001|Overall Study|Withdrawal by Subject|2
6026088|NCT00266812|9621618|FG000|Overall Study|Discontinued before starting study drug|4
6026089|NCT00266812|9621619|FG001|Overall Study|Discontinued before starting study drug|0
6026090|NCT00266825|9621627|FG000|Completed Follow-Up|Lost to Follow-up|14
6026091|NCT00266825|9621628|FG001|Completed Follow-Up|Lost to Follow-up|19
6026092|NCT00266825|9621627|FG000|Completed Follow-Up|Withdrawal by Subject|11
6026093|NCT00266825|9621628|FG001|Completed Follow-Up|Withdrawal by Subject|5
6048200|NCT00415636|9647306|FG004|Overall Study|Adverse Event|1
6048201|NCT00415636|9647307|FG005|Overall Study|Adverse Event|0
6048202|NCT00415636|9647302|FG000|Overall Study|Withdrawal by Subject|0
6048203|NCT00415636|9647303|FG001|Overall Study|Withdrawal by Subject|0
6048204|NCT00415636|9647304|FG002|Overall Study|Withdrawal by Subject|0
6048205|NCT00415636|9647305|FG003|Overall Study|Withdrawal by Subject|0
6048206|NCT00415636|9647306|FG004|Overall Study|Withdrawal by Subject|1
6048207|NCT00415636|9647307|FG005|Overall Study|Withdrawal by Subject|0
6048208|NCT00415636|9647302|FG000|Overall Study|Disease progression|0
6048209|NCT00415636|9647303|FG001|Overall Study|Disease progression|0
6048210|NCT00415636|9647304|FG002|Overall Study|Disease progression|0
6048211|NCT00415636|9647305|FG003|Overall Study|Disease progression|3
6048212|NCT00415636|9647306|FG004|Overall Study|Disease progression|0
6048213|NCT00415636|9647307|FG005|Overall Study|Disease progression|1
6048214|NCT00415909|9647347|FG000|Overall Study|Withdrawal by Subject|2
6048215|NCT00415909|9647347|FG000|Overall Study|Death|1
6048216|NCT00416078|9647353|FG000|Overall Study|Death|3
6048217|NCT00416078|9647354|FG001|Overall Study|Death|4
6048218|NCT00416078|9647353|FG000|Overall Study|Withdrawal by Subject|3
6048219|NCT00416078|9647354|FG001|Overall Study|Withdrawal by Subject|2
6048220|NCT00416078|9647353|FG000|Overall Study|Physician Decision|1
6048221|NCT00416078|9647354|FG001|Overall Study|Physician Decision|0
6048222|NCT00416078|9647353|FG000|Overall Study|Lost to Follow-up|4
6048223|NCT00416078|9647354|FG001|Overall Study|Lost to Follow-up|2
6048224|NCT00416195|9647377|FG000|Overall Study|Adverse Event|1
6048225|NCT00416195|9647378|FG001|Overall Study|Adverse Event|2
6048226|NCT00416195|9647377|FG000|Overall Study|Protocol Violation|1
6048227|NCT00416195|9647378|FG001|Overall Study|Protocol Violation|1
6048228|NCT00416195|9647377|FG000|Overall Study|Other|0
6048229|NCT00416195|9647378|FG001|Overall Study|Other|1
6048230|NCT00416312|9647384|FG000|Overall Study|tumors not visible on imaging|2
6048231|NCT00416455|9647390|FG000|Overall Study|PET / CT not done|3
6048232|NCT00416455|9647391|FG001|Overall Study|PET / CT not done|5
6048233|NCT00416455|9647390|FG000|Overall Study|PET / CT poor quality|2
6048234|NCT00416455|9647391|FG001|Overall Study|PET / CT poor quality|1
6048235|NCT00416455|9647390|FG000|Overall Study|Inadequate pathology|11
6026094|NCT00266864|9621655|FG000|Overall Study|Lost to Follow-up|4
6026095|NCT00266864|9621656|FG001|Overall Study|Lost to Follow-up|1
6026096|NCT00266864|9621655|FG000|Overall Study|Withdrawal by Subject|1
6026097|NCT00266864|9621656|FG001|Overall Study|Withdrawal by Subject|1
6026098|NCT00266877|9621665|FG000|Overall Study|Death|1
6026099|NCT00266877|9621666|FG001|Overall Study|Death|1
6026100|NCT00266877|9621667|FG002|Overall Study|Death|1
6026101|NCT00266877|9621665|FG000|Overall Study|Adverse Event|6
6026102|NCT00266877|9621666|FG001|Overall Study|Adverse Event|4
6026103|NCT00266877|9621667|FG002|Overall Study|Adverse Event|1
6026104|NCT00266877|9621665|FG000|Overall Study|Physician Decision|2
6026105|NCT00266877|9621666|FG001|Overall Study|Physician Decision|1
6026106|NCT00266877|9621667|FG002|Overall Study|Physician Decision|1
6026107|NCT00266877|9621665|FG000|Overall Study|Withdrawal by Subject|3
6026108|NCT00266877|9621666|FG001|Overall Study|Withdrawal by Subject|1
6026109|NCT00266877|9621667|FG002|Overall Study|Withdrawal by Subject|1
6026110|NCT00266877|9621665|FG000|Overall Study|Disease Progression|72
6026111|NCT00266877|9621666|FG001|Overall Study|Disease Progression|37
6026112|NCT00266877|9621667|FG002|Overall Study|Disease Progression|23
6026113|NCT00266877|9621665|FG000|Overall Study|Symptomatic Deterioration|6
6026114|NCT00266877|9621666|FG001|Overall Study|Symptomatic Deterioration|3
6026115|NCT00266877|9621667|FG002|Overall Study|Symptomatic Deterioration|1
6079148|NCT00607724|9685809|FG002|Stage 2: Expanded Cohort|Tumour Progression-Clinical/Radiographic|0
6079149|NCT00607724|9685810|FG003|Stage 2: Expanded Cohort|Tumour Progression-Clinical/Radiographic|4
6079150|NCT00607724|9685811|FG004|Stage 2: Expanded Cohort|Tumour Progression-Clinical/Radiographic|8
6079151|NCT00607724|9685812|FG005|Stage 2: Expanded Cohort|Tumour Progression-Clinical/Radiographic|11
6079152|NCT00607724|9685813|FG006|Stage 2: Expanded Cohort|Tumour Progression-Clinical/Radiographic|10
6079153|NCT00607724|9685807|FG000|Stage 2: Expanded Cohort|Physician Decision|0
6079154|NCT00607724|9685808|FG001|Stage 2: Expanded Cohort|Physician Decision|0
6079155|NCT00607724|9685809|FG002|Stage 2: Expanded Cohort|Physician Decision|0
6079156|NCT00607724|9685810|FG003|Stage 2: Expanded Cohort|Physician Decision|0
6079157|NCT00607724|9685811|FG004|Stage 2: Expanded Cohort|Physician Decision|1
6079158|NCT00607724|9685812|FG005|Stage 2: Expanded Cohort|Physician Decision|1
6079159|NCT00607724|9685813|FG006|Stage 2: Expanded Cohort|Physician Decision|0
6026116|NCT00266877|9621665|FG000|Overall Study|Hospitalization|1
6026117|NCT00266877|9621666|FG001|Overall Study|Hospitalization|0
6026118|NCT00266877|9621667|FG002|Overall Study|Hospitalization|0
6026119|NCT00266877|9621665|FG000|Overall Study|Concomitant Radiotherapy|0
6026120|NCT00266877|9621666|FG001|Overall Study|Concomitant Radiotherapy|1
6026121|NCT00266877|9621667|FG002|Overall Study|Concomitant Radiotherapy|0
6026122|NCT00267007|9621677|FG000|Overall Study|Withdrawal by Subject|6
6026123|NCT00267007|9621678|FG001|Overall Study|Withdrawal by Subject|0
6026124|NCT00267007|9621677|FG000|Overall Study|Lost to Follow-up|1
6026125|NCT00267007|9621678|FG001|Overall Study|Lost to Follow-up|0
6026126|NCT00267007|9621677|FG000|Overall Study|Non-compliance|0
6026127|NCT00267007|9621678|FG001|Overall Study|Non-compliance|1
6026128|NCT00267007|9621677|FG000|Overall Study|Adverse Event|1
6026129|NCT00267007|9621678|FG001|Overall Study|Adverse Event|0
6026130|NCT00267020|9621686|FG000|Overall Study|Adverse Event|22
6026131|NCT00267020|9621687|FG001|Overall Study|Adverse Event|5
6026132|NCT00267020|9621686|FG000|Overall Study|Death|2
6026133|NCT00267020|9621687|FG001|Overall Study|Death|1
6026134|NCT00267020|9621686|FG000|Overall Study|Withdrawal by Subject|17
6026135|NCT00267020|9621687|FG001|Overall Study|Withdrawal by Subject|7
6026136|NCT00267020|9621686|FG000|Overall Study|Physician Decision|3
6026137|NCT00267020|9621687|FG001|Overall Study|Physician Decision|2
6026138|NCT00267020|9621686|FG000|Overall Study|Disease Progression|39
6026139|NCT00267020|9621687|FG001|Overall Study|Disease Progression|25
6026140|NCT00267020|9621686|FG000|Overall Study|Unrelated Complication|1
6026141|NCT00267020|9621687|FG001|Overall Study|Unrelated Complication|1
6026142|NCT00267020|9621686|FG000|Overall Study|Sponsor Request|1
6026143|NCT00267020|9621687|FG001|Overall Study|Sponsor Request|0
6026144|NCT00267020|9621686|FG000|Overall Study|Other|1
6026145|NCT00267020|9621687|FG001|Overall Study|Other|2
6026146|NCT00267046|9621695|FG000|Overall Study|Disease progression|4
6026147|NCT00267046|9621696|FG001|Overall Study|Disease progression|2
6026148|NCT00267046|9621695|FG000|Overall Study|Chemotoxicity|2
6026149|NCT00267046|9621696|FG001|Overall Study|Chemotoxicity|0
6026150|NCT00267046|9621695|FG000|Overall Study|Open-label palifermin|2
6026151|NCT00267046|9621696|FG001|Overall Study|Open-label palifermin|7
6026152|NCT00267046|9621695|FG000|Overall Study|Surgery|3
6026153|NCT00267046|9621696|FG001|Overall Study|Surgery|1
6079160|NCT00607724|9685807|FG000|Stage 2: Expanded Cohort|Withdrawal by Subject|0
6026154|NCT00267046|9621695|FG000|Overall Study|Withdrawal by Subject|1
6026155|NCT00267046|9621696|FG001|Overall Study|Withdrawal by Subject|0
6026156|NCT00267046|9621695|FG000|Overall Study|Radiation|0
6026157|NCT00267046|9621696|FG001|Overall Study|Radiation|1
6026158|NCT00267098|9621718|FG000|Overall Study|Death|0
6026159|NCT00267098|9621719|FG001|Overall Study|Death|0
6026160|NCT00267098|9621720|FG002|Overall Study|Death|57
6026161|NCT00267098|9621721|FG003|Overall Study|Death|66
6026162|NCT00267098|9621722|FG004|Overall Study|Death|14
6026163|NCT00267098|9621723|FG005|Overall Study|Death|23
6026164|NCT00267098|9621724|FG006|Overall Study|Death|28
6026165|NCT00267098|9621725|FG007|Overall Study|Death|9
6026166|NCT00267098|9621718|FG000|Overall Study|Lost to Follow-up|0
6026167|NCT00267098|9621719|FG001|Overall Study|Lost to Follow-up|0
6026168|NCT00267098|9621720|FG002|Overall Study|Lost to Follow-up|6
6026169|NCT00267098|9621721|FG003|Overall Study|Lost to Follow-up|5
6026170|NCT00267098|9621722|FG004|Overall Study|Lost to Follow-up|2
6026171|NCT00267098|9621723|FG005|Overall Study|Lost to Follow-up|3
6026172|NCT00267098|9621724|FG006|Overall Study|Lost to Follow-up|1
6026173|NCT00267098|9621725|FG007|Overall Study|Lost to Follow-up|1
6026174|NCT00267098|9621718|FG000|Overall Study|Withdrawal by Subject|8
6026175|NCT00267098|9621719|FG001|Overall Study|Withdrawal by Subject|0
6026176|NCT00267098|9621720|FG002|Overall Study|Withdrawal by Subject|24
6026177|NCT00267098|9621721|FG003|Overall Study|Withdrawal by Subject|21
6026178|NCT00267098|9621722|FG004|Overall Study|Withdrawal by Subject|12
6026179|NCT00267098|9621723|FG005|Overall Study|Withdrawal by Subject|9
6026180|NCT00267098|9621724|FG006|Overall Study|Withdrawal by Subject|12
6026181|NCT00267098|9621725|FG007|Overall Study|Withdrawal by Subject|5
6026182|NCT00267098|9621718|FG000|Overall Study|Physician Decision|5
6026183|NCT00267098|9621719|FG001|Overall Study|Physician Decision|0
6026184|NCT00267098|9621720|FG002|Overall Study|Physician Decision|7
6026185|NCT00267098|9621721|FG003|Overall Study|Physician Decision|11
6026186|NCT00267098|9621722|FG004|Overall Study|Physician Decision|5
6026187|NCT00267098|9621723|FG005|Overall Study|Physician Decision|4
6026188|NCT00267098|9621724|FG006|Overall Study|Physician Decision|3
6026189|NCT00267098|9621725|FG007|Overall Study|Physician Decision|0
6026190|NCT00267098|9621718|FG000|Overall Study|Inclusion/Exclusion Criteria Not Met|96
6026191|NCT00267098|9621719|FG001|Overall Study|Inclusion/Exclusion Criteria Not Met|0
6026192|NCT00267098|9621720|FG002|Overall Study|Inclusion/Exclusion Criteria Not Met|0
6026193|NCT00267098|9621721|FG003|Overall Study|Inclusion/Exclusion Criteria Not Met|0
6026194|NCT00267098|9621722|FG004|Overall Study|Inclusion/Exclusion Criteria Not Met|2
6026195|NCT00267098|9621723|FG005|Overall Study|Inclusion/Exclusion Criteria Not Met|0
6026196|NCT00267098|9621724|FG006|Overall Study|Inclusion/Exclusion Criteria Not Met|0
6026197|NCT00267098|9621725|FG007|Overall Study|Inclusion/Exclusion Criteria Not Met|0
6026198|NCT00267098|9621718|FG000|Overall Study|Unsuccessful Implant Exit Per Protocol|0
6079161|NCT00607724|9685808|FG001|Stage 2: Expanded Cohort|Withdrawal by Subject|0
6079162|NCT00607724|9685809|FG002|Stage 2: Expanded Cohort|Withdrawal by Subject|0
6079163|NCT00607724|9685810|FG003|Stage 2: Expanded Cohort|Withdrawal by Subject|1
6079164|NCT00607724|9685811|FG004|Stage 2: Expanded Cohort|Withdrawal by Subject|0
6079165|NCT00607724|9685812|FG005|Stage 2: Expanded Cohort|Withdrawal by Subject|0
6079166|NCT00607724|9685813|FG006|Stage 2: Expanded Cohort|Withdrawal by Subject|0
6079167|NCT00607789|9685839|FG000|Overall Study|Adverse Event|3
6079168|NCT00607789|9685840|FG001|Overall Study|Adverse Event|0
6079169|NCT00607789|9685839|FG000|Overall Study|Lack of Efficacy|0
6079170|NCT00607789|9685840|FG001|Overall Study|Lack of Efficacy|1
6079171|NCT00607789|9685839|FG000|Overall Study|Inadequate adherence|3
6079172|NCT00607789|9685840|FG001|Overall Study|Inadequate adherence|0
6079173|NCT00607789|9685839|FG000|Overall Study|Lost to Follow-up|0
6079174|NCT00607789|9685840|FG001|Overall Study|Lost to Follow-up|5
6079175|NCT00607789|9685839|FG000|Overall Study|Withdrawal by Subject|1
6079176|NCT00607789|9685840|FG001|Overall Study|Withdrawal by Subject|0
6079177|NCT00607880|9685868|FG000|Overall Study|Unable to place port due to occlusion|1
6087639|NCT00669617|9698052|FG003|Period 1|Protocol Deviation|0
6146369|NCT01077063|9781125|FG000|Overall Study|Adverse Event|3
6146370|NCT01077063|9781126|FG001|Overall Study|Adverse Event|0
6026199|NCT00267098|9621719|FG001|Overall Study|Unsuccessful Implant Exit Per Protocol|51
6026200|NCT00267098|9621720|FG002|Overall Study|Unsuccessful Implant Exit Per Protocol|0
6026201|NCT00267098|9621721|FG003|Overall Study|Unsuccessful Implant Exit Per Protocol|0
6026202|NCT00267098|9621722|FG004|Overall Study|Unsuccessful Implant Exit Per Protocol|0
6026203|NCT00267098|9621723|FG005|Overall Study|Unsuccessful Implant Exit Per Protocol|0
6026204|NCT00267098|9621724|FG006|Overall Study|Unsuccessful Implant Exit Per Protocol|0
6026205|NCT00267098|9621725|FG007|Overall Study|Unsuccessful Implant Exit Per Protocol|0
6026206|NCT00267098|9621718|FG000|Overall Study|Site closure|0
6026207|NCT00267098|9621719|FG001|Overall Study|Site closure|0
6026208|NCT00267098|9621720|FG002|Overall Study|Site closure|0
6026209|NCT00267098|9621721|FG003|Overall Study|Site closure|1
6026210|NCT00267098|9621722|FG004|Overall Study|Site closure|0
6026211|NCT00267098|9621723|FG005|Overall Study|Site closure|1
6026212|NCT00267098|9621724|FG006|Overall Study|Site closure|1
6026213|NCT00267098|9621725|FG007|Overall Study|Site closure|0
6026214|NCT00267098|9621718|FG000|Overall Study|Explanted Medtronic device|0
6026215|NCT00267098|9621719|FG001|Overall Study|Explanted Medtronic device|0
6026216|NCT00267098|9621720|FG002|Overall Study|Explanted Medtronic device|0
6026217|NCT00267098|9621721|FG003|Overall Study|Explanted Medtronic device|1
6026218|NCT00267098|9621722|FG004|Overall Study|Explanted Medtronic device|0
6026219|NCT00267098|9621723|FG005|Overall Study|Explanted Medtronic device|0
6026220|NCT00267098|9621724|FG006|Overall Study|Explanted Medtronic device|0
6026221|NCT00267098|9621725|FG007|Overall Study|Explanted Medtronic device|0
6146371|NCT01077063|9781125|FG000|Overall Study|Death|1
6146372|NCT01077063|9781126|FG001|Overall Study|Death|1
6146373|NCT01077063|9781125|FG000|Overall Study|Withdrawal by Subject|0
6146374|NCT01077063|9781126|FG001|Overall Study|Withdrawal by Subject|2
6146375|NCT01077076|9781132|FG000|First Intervention|Withdrawal by Subject|1
6026222|NCT00267098|9621718|FG000|Overall Study|Non-Medtronic LV Lead Implanted|0
6026223|NCT00267098|9621719|FG001|Overall Study|Non-Medtronic LV Lead Implanted|0
6026224|NCT00267098|9621720|FG002|Overall Study|Non-Medtronic LV Lead Implanted|0
6026225|NCT00267098|9621721|FG003|Overall Study|Non-Medtronic LV Lead Implanted|0
6026226|NCT00267098|9621722|FG004|Overall Study|Non-Medtronic LV Lead Implanted|2
6026227|NCT00267098|9621723|FG005|Overall Study|Non-Medtronic LV Lead Implanted|0
6026228|NCT00267098|9621724|FG006|Overall Study|Non-Medtronic LV Lead Implanted|0
6026229|NCT00267098|9621725|FG007|Overall Study|Non-Medtronic LV Lead Implanted|0
6026230|NCT00267098|9621718|FG000|Overall Study|Subject listed for heart transplant|0
6026231|NCT00267098|9621719|FG001|Overall Study|Subject listed for heart transplant|0
6026232|NCT00267098|9621720|FG002|Overall Study|Subject listed for heart transplant|0
6026233|NCT00267098|9621721|FG003|Overall Study|Subject listed for heart transplant|0
6026234|NCT00267098|9621722|FG004|Overall Study|Subject listed for heart transplant|0
6026235|NCT00267098|9621723|FG005|Overall Study|Subject listed for heart transplant|0
6026236|NCT00267098|9621724|FG006|Overall Study|Subject listed for heart transplant|1
6026237|NCT00267098|9621725|FG007|Overall Study|Subject listed for heart transplant|0
6026238|NCT00267098|9621718|FG000|Overall Study|Sponsor withdrew subject|0
6026239|NCT00267098|9621719|FG001|Overall Study|Sponsor withdrew subject|0
6026240|NCT00267098|9621720|FG002|Overall Study|Sponsor withdrew subject|0
6026241|NCT00267098|9621721|FG003|Overall Study|Sponsor withdrew subject|1
6026242|NCT00267098|9621722|FG004|Overall Study|Sponsor withdrew subject|0
6026243|NCT00267098|9621723|FG005|Overall Study|Sponsor withdrew subject|0
6026244|NCT00267098|9621724|FG006|Overall Study|Sponsor withdrew subject|0
6026245|NCT00267098|9621725|FG007|Overall Study|Sponsor withdrew subject|0
6026246|NCT00267150|9621758|FG000|Overall Study|Adverse Event|1
6026247|NCT00267189|9621764|FG000|Overall Study|Patient withdrew consent|1
6026248|NCT00267189|9621765|FG001|Overall Study|Patient withdrew consent|1
6026249|NCT00267189|9621764|FG000|Overall Study|Death|1
6026250|NCT00267189|9621765|FG001|Overall Study|Death|0
6026251|NCT00267189|9621764|FG000|Overall Study|Missing|3
6026252|NCT00267189|9621765|FG001|Overall Study|Missing|0
6026253|NCT00267202|9621773|FG000|Overall Study|Unsatisfactory therapeutic effect|21
6026254|NCT00267202|9621774|FG001|Overall Study|Unsatisfactory therapeutic effect|8
6026255|NCT00267202|9621773|FG000|Overall Study|Withdrawal by Subject|12
6026256|NCT00267202|9621774|FG001|Overall Study|Withdrawal by Subject|15
6026257|NCT00267202|9621773|FG000|Overall Study|Adverse Event|13
6026258|NCT00267202|9621774|FG001|Overall Study|Adverse Event|7
6026259|NCT00267202|9621773|FG000|Overall Study|Protocol Violation|2
6026260|NCT00267202|9621774|FG001|Overall Study|Protocol Violation|3
6026261|NCT00267202|9621773|FG000|Overall Study|Administrative problems|2
6026262|NCT00267202|9621774|FG001|Overall Study|Administrative problems|1
6026263|NCT00267202|9621773|FG000|Overall Study|Lost to Follow-up|3
6026264|NCT00267202|9621774|FG001|Overall Study|Lost to Follow-up|0
6026265|NCT00267488|9621794|FG000|Overall Study|Sponsor Terminated Study|9
6026266|NCT00267488|9621794|FG000|Overall Study|Protocol Violation|1
6026267|NCT00267488|9621794|FG000|Overall Study|Other (Disease Progression)|1
6026268|NCT00267748|9621835|FG000|Non-randomized Period|Progressive disease|10
6026269|NCT00267748|9621836|FG001|Non-randomized Period|Progressive disease|0
6026270|NCT00267748|9621837|FG002|Non-randomized Period|Progressive disease|0
6026271|NCT00267748|9621835|FG000|Non-randomized Period|Adverse Event|8
6026272|NCT00267748|9621836|FG001|Non-randomized Period|Adverse Event|0
6026273|NCT00267748|9621837|FG002|Non-randomized Period|Adverse Event|0
6026274|NCT00267748|9621835|FG000|Non-randomized Period|Death|1
6026275|NCT00267748|9621836|FG001|Non-randomized Period|Death|0
6026276|NCT00267748|9621837|FG002|Non-randomized Period|Death|0
6026277|NCT00267748|9621835|FG000|Non-randomized Period|Participant not willing to participate|1
6026278|NCT00267748|9621836|FG001|Non-randomized Period|Participant not willing to participate|0
6026279|NCT00267748|9621837|FG002|Non-randomized Period|Participant not willing to participate|0
6026280|NCT00267748|9621835|FG000|Non-randomized Period|Other|3
6026281|NCT00267748|9621836|FG001|Non-randomized Period|Other|0
6026282|NCT00267748|9621837|FG002|Non-randomized Period|Other|0
6026283|NCT00267748|9621835|FG000|Randomized Period|Death|0
6026284|NCT00267748|9621836|FG001|Randomized Period|Death|2
6026285|NCT00267748|9621837|FG002|Randomized Period|Death|3
6026286|NCT00267748|9621835|FG000|Randomized Period|Adverse Event|0
6026287|NCT00267748|9621836|FG001|Randomized Period|Adverse Event|23
6026288|NCT00267748|9621837|FG002|Randomized Period|Adverse Event|25
6026289|NCT00267748|9621835|FG000|Randomized Period|Global deterioration of health status|0
6026290|NCT00267748|9621836|FG001|Randomized Period|Global deterioration of health status|6
6026291|NCT00267748|9621837|FG002|Randomized Period|Global deterioration of health status|7
6026292|NCT00267748|9621835|FG000|Randomized Period|Lost to Follow-up|0
6026293|NCT00267748|9621836|FG001|Randomized Period|Lost to Follow-up|1
6026294|NCT00267748|9621837|FG002|Randomized Period|Lost to Follow-up|0
6026295|NCT00267748|9621835|FG000|Randomized Period|Objective progression or relapse|0
6026296|NCT00267748|9621836|FG001|Randomized Period|Objective progression or relapse|77
6026297|NCT00267748|9621837|FG002|Randomized Period|Objective progression or relapse|86
6026298|NCT00267748|9621835|FG000|Randomized Period|Withdrawal by Subject|0
6026299|NCT00267748|9621836|FG001|Randomized Period|Withdrawal by Subject|9
6026300|NCT00267748|9621837|FG002|Randomized Period|Withdrawal by Subject|2
6026301|NCT00267748|9621835|FG000|Randomized Period|Other|0
6026302|NCT00267748|9621836|FG001|Randomized Period|Other|9
6026303|NCT00267748|9621837|FG002|Randomized Period|Other|6
6026304|NCT00267748|9621835|FG000|Randomized Period|randomized but not treated|0
6026305|NCT00267748|9621836|FG001|Randomized Period|randomized but not treated|0
6026306|NCT00267748|9621837|FG002|Randomized Period|randomized but not treated|3
6026307|NCT00267865|9621853|FG000|Induction Treatment|Died before completing.|2
6026308|NCT00267865|9621853|FG000|Induction Treatment|Started induction w/MTX, RIX, & Temozol|1
6026309|NCT00267956|9621859|FG000|Controlled Period|Adverse Event|4
6026310|NCT00267956|9621860|FG001|Controlled Period|Adverse Event|1
6026311|NCT00267956|9621861|FG002|Controlled Period|Adverse Event|0
6026312|NCT00267956|9621862|FG003|Controlled Period|Adverse Event|0
6026313|NCT00267956|9621859|FG000|Controlled Period|Lack of Efficacy|4
6026314|NCT00267956|9621860|FG001|Controlled Period|Lack of Efficacy|2
6026315|NCT00267956|9621861|FG002|Controlled Period|Lack of Efficacy|0
6026316|NCT00267956|9621862|FG003|Controlled Period|Lack of Efficacy|0
6026317|NCT00267956|9621859|FG000|Controlled Period|Lost to Follow-up|2
6026318|NCT00267956|9621860|FG001|Controlled Period|Lost to Follow-up|0
6026319|NCT00267956|9621861|FG002|Controlled Period|Lost to Follow-up|0
6026320|NCT00267956|9621862|FG003|Controlled Period|Lost to Follow-up|0
6026321|NCT00267956|9621859|FG000|Controlled Period|Withdrew consent|3
6026322|NCT00267956|9621860|FG001|Controlled Period|Withdrew consent|1
6026323|NCT00267956|9621861|FG002|Controlled Period|Withdrew consent|0
6026324|NCT00267956|9621862|FG003|Controlled Period|Withdrew consent|0
6026325|NCT00267956|9621859|FG000|After Controlled Period|Adverse Event|0
6026326|NCT00267956|9621860|FG001|After Controlled Period|Adverse Event|0
6026327|NCT00267956|9621861|FG002|After Controlled Period|Adverse Event|2
6026328|NCT00267956|9621862|FG003|After Controlled Period|Adverse Event|1
6026329|NCT00267956|9621859|FG000|After Controlled Period|Lack of Efficacy|0
6026330|NCT00267956|9621860|FG001|After Controlled Period|Lack of Efficacy|0
6026331|NCT00267956|9621861|FG002|After Controlled Period|Lack of Efficacy|1
6026332|NCT00267956|9621862|FG003|After Controlled Period|Lack of Efficacy|1
6026333|NCT00267956|9621859|FG000|After Controlled Period|Lost to Follow-up|0
6026334|NCT00267956|9621860|FG001|After Controlled Period|Lost to Follow-up|0
6026335|NCT00267956|9621861|FG002|After Controlled Period|Lost to Follow-up|1
6026336|NCT00267956|9621862|FG003|After Controlled Period|Lost to Follow-up|0
6026337|NCT00267956|9621859|FG000|After Controlled Period|Withdrew consent|0
6026338|NCT00267956|9621860|FG001|After Controlled Period|Withdrew consent|0
6026339|NCT00267956|9621861|FG002|After Controlled Period|Withdrew consent|1
6026340|NCT00267956|9621862|FG003|After Controlled Period|Withdrew consent|0
6026341|NCT00267969|9621873|FG000|Controlled Period|Adverse Event|6
6026342|NCT00267969|9621874|FG001|Controlled Period|Adverse Event|0
6026343|NCT00267969|9621875|FG002|Controlled Period|Adverse Event|2
6026344|NCT00267969|9621876|FG003|Controlled Period|Adverse Event|0
6026345|NCT00267969|9621877|FG004|Controlled Period|Adverse Event|0
6026346|NCT00267969|9621878|FG005|Controlled Period|Adverse Event|0
6026347|NCT00267969|9621879|FG006|Controlled Period|Adverse Event|0
6026348|NCT00267969|9621873|FG000|Controlled Period|Lack of Efficacy|3
6026349|NCT00267969|9621874|FG001|Controlled Period|Lack of Efficacy|0
6026350|NCT00267969|9621875|FG002|Controlled Period|Lack of Efficacy|1
6026351|NCT00267969|9621876|FG003|Controlled Period|Lack of Efficacy|0
6026352|NCT00267969|9621877|FG004|Controlled Period|Lack of Efficacy|0
6026353|NCT00267969|9621878|FG005|Controlled Period|Lack of Efficacy|0
6026354|NCT00267969|9621879|FG006|Controlled Period|Lack of Efficacy|0
6026355|NCT00267969|9621873|FG000|Controlled Period|Lost to Follow-up|1
6026356|NCT00267969|9621874|FG001|Controlled Period|Lost to Follow-up|0
6026357|NCT00267969|9621875|FG002|Controlled Period|Lost to Follow-up|1
6026358|NCT00267969|9621876|FG003|Controlled Period|Lost to Follow-up|0
6026359|NCT00267969|9621877|FG004|Controlled Period|Lost to Follow-up|0
6026360|NCT00267969|9621878|FG005|Controlled Period|Lost to Follow-up|0
6026361|NCT00267969|9621879|FG006|Controlled Period|Lost to Follow-up|0
6026362|NCT00267969|9621873|FG000|Controlled Period|Randomized but not treated|0
6026363|NCT00267969|9621874|FG001|Controlled Period|Randomized but not treated|0
6026364|NCT00267969|9621875|FG002|Controlled Period|Randomized but not treated|1
6026365|NCT00267969|9621876|FG003|Controlled Period|Randomized but not treated|0
6026366|NCT00267969|9621877|FG004|Controlled Period|Randomized but not treated|0
6026367|NCT00267969|9621878|FG005|Controlled Period|Randomized but not treated|0
6026368|NCT00267969|9621879|FG006|Controlled Period|Randomized but not treated|0
6026369|NCT00267969|9621873|FG000|Controlled Period|Other|2
6026370|NCT00267969|9621874|FG001|Controlled Period|Other|1
6026371|NCT00267969|9621875|FG002|Controlled Period|Other|6
6026372|NCT00267969|9621876|FG003|Controlled Period|Other|0
6026373|NCT00267969|9621877|FG004|Controlled Period|Other|0
6026374|NCT00267969|9621878|FG005|Controlled Period|Other|0
6026375|NCT00267969|9621879|FG006|Controlled Period|Other|0
6026376|NCT00267969|9621873|FG000|After Controlled Period|Adverse Event|0
6026377|NCT00267969|9621874|FG001|After Controlled Period|Adverse Event|0
6026378|NCT00267969|9621875|FG002|After Controlled Period|Adverse Event|0
6026379|NCT00267969|9621876|FG003|After Controlled Period|Adverse Event|7
6026380|NCT00267969|9621877|FG004|After Controlled Period|Adverse Event|8
6026381|NCT00267969|9621878|FG005|After Controlled Period|Adverse Event|23
6026382|NCT00267969|9621879|FG006|After Controlled Period|Adverse Event|21
6026383|NCT00267969|9621873|FG000|After Controlled Period|Death|0
6026384|NCT00267969|9621874|FG001|After Controlled Period|Death|0
6026385|NCT00267969|9621875|FG002|After Controlled Period|Death|0
6026386|NCT00267969|9621876|FG003|After Controlled Period|Death|1
6026387|NCT00267969|9621877|FG004|After Controlled Period|Death|2
6026388|NCT00267969|9621878|FG005|After Controlled Period|Death|0
6026389|NCT00267969|9621879|FG006|After Controlled Period|Death|1
6026390|NCT00267969|9621873|FG000|After Controlled Period|Lack of Efficacy|0
6026391|NCT00267969|9621874|FG001|After Controlled Period|Lack of Efficacy|0
6026392|NCT00267969|9621875|FG002|After Controlled Period|Lack of Efficacy|0
6026393|NCT00267969|9621876|FG003|After Controlled Period|Lack of Efficacy|10
6026394|NCT00267969|9621877|FG004|After Controlled Period|Lack of Efficacy|6
6026395|NCT00267969|9621878|FG005|After Controlled Period|Lack of Efficacy|28
6026396|NCT00267969|9621879|FG006|After Controlled Period|Lack of Efficacy|15
6026397|NCT00267969|9621873|FG000|After Controlled Period|Lost to Follow-up|0
6026398|NCT00267969|9621874|FG001|After Controlled Period|Lost to Follow-up|0
6026399|NCT00267969|9621875|FG002|After Controlled Period|Lost to Follow-up|0
6079178|NCT00607880|9685869|FG001|Overall Study|Unable to place port due to occlusion|0
6079179|NCT00607893|9685877|FG000|Overall Study|Lost to Follow-up|4
6079180|NCT00607893|9685878|FG001|Overall Study|Lost to Follow-up|0
6079181|NCT00607893|9685877|FG000|Overall Study|withdrew due to loss of interest|0
6079182|NCT00607893|9685878|FG001|Overall Study|withdrew due to loss of interest|1
6079183|NCT00607893|9685877|FG000|Overall Study|Withdrew due to osteomyelitis surgery|0
6079184|NCT00607893|9685878|FG001|Overall Study|Withdrew due to osteomyelitis surgery|1
6079185|NCT00607893|9685877|FG000|Overall Study|withdrew could not tolerate CPAP|0
6079186|NCT00607893|9685878|FG001|Overall Study|withdrew could not tolerate CPAP|1
6079187|NCT00607893|9685877|FG000|Overall Study|Declined to be treated|1
6079188|NCT00607893|9685878|FG001|Overall Study|Declined to be treated|0
6079189|NCT00607893|9685877|FG000|Overall Study|Withdrew due to hypertensive urgency|1
6079190|NCT00607893|9685878|FG001|Overall Study|Withdrew due to hypertensive urgency|1
6079191|NCT00607919|9685888|FG000|Acute Phase|Adverse Event|9
6026400|NCT00267969|9621876|FG003|After Controlled Period|Lost to Follow-up|5
6026401|NCT00267969|9621877|FG004|After Controlled Period|Lost to Follow-up|8
6026402|NCT00267969|9621878|FG005|After Controlled Period|Lost to Follow-up|9
6026403|NCT00267969|9621879|FG006|After Controlled Period|Lost to Follow-up|10
6026404|NCT00267969|9621873|FG000|After Controlled Period|Other|0
6026405|NCT00267969|9621874|FG001|After Controlled Period|Other|0
6026406|NCT00267969|9621875|FG002|After Controlled Period|Other|0
6026407|NCT00267969|9621876|FG003|After Controlled Period|Other|13
6026408|NCT00267969|9621877|FG004|After Controlled Period|Other|11
6026409|NCT00267969|9621878|FG005|After Controlled Period|Other|22
6026410|NCT00267969|9621879|FG006|After Controlled Period|Other|25
6026411|NCT00268203|9621897|FG000|Overall Study|Lost to Follow-up|92
6026412|NCT00268203|9621897|FG000|Overall Study|Withdrawal by Subject|9
6026413|NCT00268203|9621897|FG000|Overall Study|Received Other NHL Therapy|7
6026414|NCT00268203|9621897|FG000|Overall Study|Progressive Disease|359
6026415|NCT00268203|9621897|FG000|Overall Study|Death|84
6026416|NCT00268203|9621897|FG000|Overall Study|Reason Not Specified|34
6026417|NCT00268203|9621897|FG000|Overall Study|Completed 2 Years of Follow-up|62
6026418|NCT00268242|9621901|FG000|Overall Study|Death|1
6026419|NCT00268346|9621907|FG000|Overall Study|Adverse Event|0
6026420|NCT00268346|9621908|FG001|Overall Study|Adverse Event|1
6026421|NCT00268346|9621907|FG000|Overall Study|Death|0
6026422|NCT00268346|9621908|FG001|Overall Study|Death|1
6026423|NCT00268346|9621907|FG000|Overall Study|Withdrawal by Subject|0
6026424|NCT00268346|9621908|FG001|Overall Study|Withdrawal by Subject|1
6026425|NCT00268437|9621914|FG000|Overall Study|Ineligible|1
6026426|NCT00268892|9621926|FG000|Overall Study|Adverse Event|14
6026427|NCT00268892|9621927|FG001|Overall Study|Adverse Event|17
6026428|NCT00268892|9621928|FG002|Overall Study|Adverse Event|20
6026429|NCT00268892|9621926|FG000|Overall Study|Lack of Efficacy|1
6026430|NCT00268892|9621927|FG001|Overall Study|Lack of Efficacy|3
6026431|NCT00268892|9621928|FG002|Overall Study|Lack of Efficacy|0
6026432|NCT00268892|9621926|FG000|Overall Study|Withdrawal by Subject|14
6026433|NCT00268892|9621927|FG001|Overall Study|Withdrawal by Subject|15
6026434|NCT00268892|9621928|FG002|Overall Study|Withdrawal by Subject|13
6026435|NCT00268892|9621926|FG000|Overall Study|Physician Decision|0
6026436|NCT00268892|9621927|FG001|Overall Study|Physician Decision|1
6026437|NCT00268892|9621928|FG002|Overall Study|Physician Decision|0
6026438|NCT00268892|9621926|FG000|Overall Study|Lost to Follow-up|5
6026439|NCT00268892|9621927|FG001|Overall Study|Lost to Follow-up|2
6026440|NCT00268892|9621928|FG002|Overall Study|Lost to Follow-up|4
6026441|NCT00268892|9621926|FG000|Overall Study|Protocol Violation|0
6026442|NCT00268892|9621927|FG001|Overall Study|Protocol Violation|1
6026443|NCT00268892|9621928|FG002|Overall Study|Protocol Violation|0
6026444|NCT00268892|9621926|FG000|Overall Study|Disease Progression|1
6026445|NCT00268892|9621927|FG001|Overall Study|Disease Progression|1
6026446|NCT00268892|9621928|FG002|Overall Study|Disease Progression|0
6026447|NCT00268892|9621926|FG000|Overall Study|Trial Site Closed|4
6026448|NCT00268892|9621927|FG001|Overall Study|Trial Site Closed|2
6026449|NCT00268892|9621928|FG002|Overall Study|Trial Site Closed|2
6026450|NCT00268905|9621939|FG000|Overall Study|Adverse Event|3
6026451|NCT00268905|9621940|FG001|Overall Study|Adverse Event|0
6026452|NCT00268905|9621941|FG002|Overall Study|Adverse Event|4
6026453|NCT00268905|9621939|FG000|Overall Study|Lost to Follow-up|0
6026454|NCT00268905|9621940|FG001|Overall Study|Lost to Follow-up|1
6026455|NCT00268905|9621941|FG002|Overall Study|Lost to Follow-up|0
6026456|NCT00268905|9621939|FG000|Overall Study|Withdrawal by Subject|0
6026457|NCT00268905|9621940|FG001|Overall Study|Withdrawal by Subject|0
6026458|NCT00268905|9621941|FG002|Overall Study|Withdrawal by Subject|3
6026459|NCT00268905|9621939|FG000|Overall Study|Progressive Disease|28
6026460|NCT00268905|9621940|FG001|Overall Study|Progressive Disease|4
6026461|NCT00268905|9621941|FG002|Overall Study|Progressive Disease|3
6026462|NCT00268905|9621939|FG000|Overall Study|Physician Decision|3
6026463|NCT00268905|9621940|FG001|Overall Study|Physician Decision|0
6026464|NCT00268905|9621941|FG002|Overall Study|Physician Decision|1
6079192|NCT00607919|9685889|FG001|Acute Phase|Adverse Event|2
6079193|NCT00607919|9685888|FG000|Acute Phase|Entry Criteria Not Met|1
6079194|NCT00607919|9685889|FG001|Acute Phase|Entry Criteria Not Met|1
6026465|NCT00268905|9621939|FG000|Overall Study|Clinical Progression|9
6026466|NCT00268905|9621940|FG001|Overall Study|Clinical Progression|4
6026467|NCT00268905|9621941|FG002|Overall Study|Clinical Progression|1
6026468|NCT00268983|9621951|FG000|Overall Study|Death|3
6026469|NCT00268983|9621952|FG001|Overall Study|Death|0
6026470|NCT00268996|9621960|FG000|Overall Study|Adverse Event|11
6026471|NCT00268996|9621961|FG001|Overall Study|Adverse Event|7
6026472|NCT00268996|9621960|FG000|Overall Study|Lost to Follow-up|3
6026473|NCT00268996|9621961|FG001|Overall Study|Lost to Follow-up|1
6026474|NCT00268996|9621960|FG000|Overall Study|Withdrawal by Subject|5
6026475|NCT00268996|9621961|FG001|Overall Study|Withdrawal by Subject|11
6026476|NCT00268996|9621960|FG000|Overall Study|Non-compliance|1
6026477|NCT00268996|9621961|FG001|Overall Study|Non-compliance|0
6026478|NCT00268996|9621960|FG000|Overall Study|Other|1
6026479|NCT00268996|9621961|FG001|Overall Study|Other|1
6026480|NCT00269087|9621969|FG000|Overall Study|Adverse Event|20
6026481|NCT00269087|9621969|FG000|Overall Study|Withdrawal by Subject|1
6026482|NCT00269087|9621969|FG000|Overall Study|Exacerbation of COPD|13
6026483|NCT00269113|9621975|FG000|Overall Study|Adverse Event|14
6026484|NCT00269113|9621976|FG001|Overall Study|Adverse Event|7
6026485|NCT00269113|9621975|FG000|Overall Study|Lack of Efficacy|35
6026486|NCT00269113|9621976|FG001|Overall Study|Lack of Efficacy|18
6026487|NCT00269113|9621975|FG000|Overall Study|Early Improvement|2
6026488|NCT00269113|9621976|FG001|Overall Study|Early Improvement|0
6026489|NCT00269113|9621975|FG000|Overall Study|Withdrawal by Subject|0
6026490|NCT00269113|9621976|FG001|Overall Study|Withdrawal by Subject|2
6026491|NCT00269113|9621975|FG000|Overall Study|Death|6
6026492|NCT00269113|9621976|FG001|Overall Study|Death|2
6026493|NCT00269113|9621975|FG000|Overall Study|Lost to Follow-up|2
6026494|NCT00269113|9621976|FG001|Overall Study|Lost to Follow-up|1
6026495|NCT00269113|9621975|FG000|Overall Study|Protocol Violation|15
6026496|NCT00269113|9621976|FG001|Overall Study|Protocol Violation|5
6026497|NCT00269113|9621975|FG000|Overall Study|Other|0
6026498|NCT00269113|9621976|FG001|Overall Study|Other|2
6026499|NCT00269152|9621984|FG000|Overall Study|Adverse Event|9
6026500|NCT00269152|9621985|FG001|Overall Study|Adverse Event|3
6026501|NCT00269152|9621984|FG000|Overall Study|Withdrawal by Subject|7
6026502|NCT00269152|9621985|FG001|Overall Study|Withdrawal by Subject|3
6026503|NCT00269152|9621984|FG000|Overall Study|Physician Decision|2
6026504|NCT00269152|9621985|FG001|Overall Study|Physician Decision|3
6026505|NCT00269152|9621984|FG000|Overall Study|Protocol Violation|0
6026506|NCT00269152|9621985|FG001|Overall Study|Protocol Violation|1
6026507|NCT00269399|9621993|FG000|Overall Study|Lack of Efficacy|27
6026508|NCT00269399|9621994|FG001|Overall Study|Lack of Efficacy|10
6026509|NCT00269399|9621993|FG000|Overall Study|Adverse Event|10
6026510|NCT00269399|9621994|FG001|Overall Study|Adverse Event|4
6026511|NCT00269399|9621993|FG000|Overall Study|Withdrawal by Subject|2
6026512|NCT00269399|9621994|FG001|Overall Study|Withdrawal by Subject|5
6026513|NCT00269399|9621993|FG000|Overall Study|Negative Lab Result for C. difficile|2
6026514|NCT00269399|9621994|FG001|Overall Study|Negative Lab Result for C. difficile|3
6026515|NCT00269399|9621993|FG000|Overall Study|Other|0
6026516|NCT00269399|9621994|FG001|Overall Study|Other|4
6026517|NCT00269399|9621993|FG000|Overall Study|Development of exclusion criteria|0
6026518|NCT00269399|9621994|FG001|Overall Study|Development of exclusion criteria|1
6026519|NCT00269477|9622004|FG000|Overall Study|Protocol Violation|5
6026520|NCT00269477|9622005|FG001|Overall Study|Protocol Violation|5
6026521|NCT00269477|9622006|FG002|Overall Study|Protocol Violation|1
6026522|NCT00269477|9622007|FG003|Overall Study|Protocol Violation|0
6026523|NCT00269477|9622004|FG000|Overall Study|Missed post-vaccination blood draw|0
6026524|NCT00269477|9622005|FG001|Overall Study|Missed post-vaccination blood draw|1
6026525|NCT00269477|9622006|FG002|Overall Study|Missed post-vaccination blood draw|0
6026526|NCT00269477|9622007|FG003|Overall Study|Missed post-vaccination blood draw|0
6026527|NCT00269633|9622019|FG000|Overall Study|Withdrawal by Subject|1
6026528|NCT00269633|9622020|FG001|Overall Study|Withdrawal by Subject|0
6026529|NCT00269919|9622026|FG000|Overall Study|Other|26
6026530|NCT00269919|9622026|FG000|Overall Study|Started but not treated|1
6026531|NCT00270205|9622035|FG000|Overall Study|Lost to Follow-up|1
6026532|NCT00270205|9622036|FG001|Overall Study|Lost to Follow-up|0
6026533|NCT00270205|9622037|FG002|Overall Study|Lost to Follow-up|0
6026534|NCT00270205|9622038|FG003|Overall Study|Lost to Follow-up|1
6026535|NCT00270231|9622048|FG000|First Intervention|Lost to Follow-up|1
6079195|NCT00607919|9685888|FG000|Acute Phase|Lack of Efficacy|1
6079196|NCT00607919|9685889|FG001|Acute Phase|Lack of Efficacy|2
6079197|NCT00607919|9685888|FG000|Acute Phase|Lost to Follow-up|9
6079198|NCT00607919|9685889|FG001|Acute Phase|Lost to Follow-up|3
6026536|NCT00270231|9622049|FG001|First Intervention|Lost to Follow-up|1
6026537|NCT00270231|9622048|FG000|Washout Period|Lost to Follow-up|1
6026538|NCT00270231|9622049|FG001|Washout Period|Lost to Follow-up|0
6026539|NCT00270231|9622048|FG000|Second Intervention|Lost to Follow-up|0
6026540|NCT00270231|9622049|FG001|Second Intervention|Lost to Follow-up|1
6026541|NCT00270257|9622057|FG000|Overall Study|Data Safety Monitoring Board (DSMB) halt|412
6026542|NCT00270257|9622058|FG001|Overall Study|Data Safety Monitoring Board (DSMB) halt|424
6026543|NCT00270855|9622119|FG000|Overall Study|Withdrawal by Subject|8
6026544|NCT00270855|9622120|FG001|Overall Study|Withdrawal by Subject|8
6026545|NCT00270894|9622128|FG000|Overall Study|Adverse Event|1
6026546|NCT00270894|9622128|FG000|Overall Study|Withdrawal by Subject|1
6026547|NCT00270998|9622135|FG000|3 Month Follow-up|Adverse Event|1
6026548|NCT00270998|9622136|FG001|3 Month Follow-up|Adverse Event|0
6026549|NCT00270998|9622137|FG002|3 Month Follow-up|Adverse Event|0
6026550|NCT00270998|9622135|FG000|3 Month Follow-up|Lack of Efficacy|1
6026551|NCT00270998|9622136|FG001|3 Month Follow-up|Lack of Efficacy|2
6026552|NCT00270998|9622137|FG002|3 Month Follow-up|Lack of Efficacy|1
6026553|NCT00270998|9622135|FG000|3 Month Follow-up|Withdrawal by Subject|11
6026554|NCT00270998|9622136|FG001|3 Month Follow-up|Withdrawal by Subject|14
6026555|NCT00270998|9622137|FG002|3 Month Follow-up|Withdrawal by Subject|15
6026556|NCT00270998|9622135|FG000|3 Month Follow-up|Pessary did not fit|12
6026557|NCT00270998|9622136|FG001|3 Month Follow-up|Pessary did not fit|0
6026558|NCT00270998|9622137|FG002|3 Month Follow-up|Pessary did not fit|0
6026559|NCT00270998|9622135|FG000|3 Month Follow-up|Personal/family health|1
6026560|NCT00270998|9622136|FG001|3 Month Follow-up|Personal/family health|1
6026561|NCT00270998|9622137|FG002|3 Month Follow-up|Personal/family health|0
6026562|NCT00270998|9622135|FG000|3 Month Follow-up|Received/desired alternate treatment|13
6026563|NCT00270998|9622136|FG001|3 Month Follow-up|Received/desired alternate treatment|5
6026564|NCT00270998|9622137|FG002|3 Month Follow-up|Received/desired alternate treatment|2
6026565|NCT00270998|9622135|FG000|12 Month Follow-up|Lack of Efficacy|5
6026566|NCT00270998|9622136|FG001|12 Month Follow-up|Lack of Efficacy|4
6026567|NCT00270998|9622137|FG002|12 Month Follow-up|Lack of Efficacy|3
6026568|NCT00270998|9622135|FG000|12 Month Follow-up|Withdrawal by Subject|7
6026569|NCT00270998|9622136|FG001|12 Month Follow-up|Withdrawal by Subject|12
6026570|NCT00270998|9622137|FG002|12 Month Follow-up|Withdrawal by Subject|16
6026571|NCT00270998|9622135|FG000|12 Month Follow-up|Pessary did not fit|1
6026572|NCT00270998|9622136|FG001|12 Month Follow-up|Pessary did not fit|0
6026573|NCT00270998|9622137|FG002|12 Month Follow-up|Pessary did not fit|0
6026574|NCT00270998|9622135|FG000|12 Month Follow-up|Personal/family health|0
6026575|NCT00270998|9622136|FG001|12 Month Follow-up|Personal/family health|5
6026576|NCT00270998|9622137|FG002|12 Month Follow-up|Personal/family health|1
6026577|NCT00270998|9622135|FG000|12 Month Follow-up|Received/desired alternate treatment|1
6026578|NCT00270998|9622136|FG001|12 Month Follow-up|Received/desired alternate treatment|4
6026579|NCT00270998|9622137|FG002|12 Month Follow-up|Received/desired alternate treatment|1
6026580|NCT00271024|9622151|FG000|Overall Study|Lost Interest|3
6026581|NCT00271024|9622152|FG001|Overall Study|Lost Interest|4
6026582|NCT00271024|9622153|FG002|Overall Study|Lost Interest|2
6026583|NCT00271024|9622154|FG003|Overall Study|Lost Interest|3
6026584|NCT00271024|9622151|FG000|Overall Study|Unknown/Unspecified|11
6026585|NCT00271024|9622152|FG001|Overall Study|Unknown/Unspecified|11
6026586|NCT00271024|9622153|FG002|Overall Study|Unknown/Unspecified|8
6026587|NCT00271024|9622154|FG003|Overall Study|Unknown/Unspecified|4
6026588|NCT00271024|9622151|FG000|Overall Study|Protocol Violation|1
6026589|NCT00271024|9622152|FG001|Overall Study|Protocol Violation|6
6026590|NCT00271024|9622153|FG002|Overall Study|Protocol Violation|5
6026591|NCT00271024|9622154|FG003|Overall Study|Protocol Violation|11
6026592|NCT00271024|9622151|FG000|Overall Study|Unpleasant Reaction To Tablet|1
6026593|NCT00271024|9622152|FG001|Overall Study|Unpleasant Reaction To Tablet|3
6026594|NCT00271024|9622153|FG002|Overall Study|Unpleasant Reaction To Tablet|4
6026595|NCT00271024|9622154|FG003|Overall Study|Unpleasant Reaction To Tablet|2
6026596|NCT00271024|9622151|FG000|Overall Study|Time Commitment, Scheduling, or Travel|6
6026597|NCT00271024|9622152|FG001|Overall Study|Time Commitment, Scheduling, or Travel|2
6026598|NCT00271024|9622153|FG002|Overall Study|Time Commitment, Scheduling, or Travel|4
6026599|NCT00271024|9622154|FG003|Overall Study|Time Commitment, Scheduling, or Travel|4
6026600|NCT00271505|9622201|FG000|Overall Study|Screen Failure|3
6026601|NCT00271505|9622201|FG000|Overall Study|Adverse Event|1
6026602|NCT00271505|9622201|FG000|Overall Study|Death|1
6026603|NCT00271596|9622217|FG000|Overall Study|Protocol Violation|1
6026604|NCT00271596|9622218|FG001|Overall Study|Protocol Violation|0
6026605|NCT00271596|9622217|FG000|Overall Study|Withdrawal by Subject|0
6026606|NCT00271596|9622218|FG001|Overall Study|Withdrawal by Subject|1
6026607|NCT00271609|9622226|FG000|Overall Study|Adverse Event|11
6026608|NCT00271609|9622227|FG001|Overall Study|Adverse Event|3
6026609|NCT00271609|9622226|FG000|Overall Study|Withdrawal by Subject|2
6026610|NCT00271609|9622227|FG001|Overall Study|Withdrawal by Subject|0
6026611|NCT00271856|9622244|FG000|Overall Study|Withdrawal by Subject|1
6079199|NCT00607919|9685888|FG000|Acute Phase|Parent/Caregiver Decision|6
6026612|NCT00271856|9622245|FG001|Overall Study|Withdrawal by Subject|7
6026613|NCT00271856|9622244|FG000|Overall Study|Lost to Follow-up|10
6026614|NCT00271856|9622245|FG001|Overall Study|Lost to Follow-up|11
6026615|NCT00272038|9622251|FG000|Overall Study|withdrew before they received 2 cycles|7
6026616|NCT00272779|9622309|FG000|Baseline Through Week 48|Adverse event before Week 48|10
6026617|NCT00272779|9622310|FG001|Baseline Through Week 48|Adverse event before Week 48|14
6026618|NCT00272779|9622309|FG000|Baseline Through Week 48|Death before Week 48|4
6026619|NCT00272779|9622310|FG001|Baseline Through Week 48|Death before Week 48|4
6026620|NCT00272779|9622309|FG000|Baseline Through Week 48|Lack of efficacy before Week 48|5
6026621|NCT00272779|9622310|FG001|Baseline Through Week 48|Lack of efficacy before Week 48|8
6026622|NCT00272779|9622309|FG000|Baseline Through Week 48|Lost to follow-up before Week 48|6
6026623|NCT00272779|9622310|FG001|Baseline Through Week 48|Lost to follow-up before Week 48|6
6026624|NCT00272779|9622309|FG000|Baseline Through Week 48|Viral load rebound before Week 48|1
6026625|NCT00272779|9622310|FG001|Baseline Through Week 48|Viral load rebound before Week 48|0
6026626|NCT00272779|9622309|FG000|Baseline Through Week 48|Poor/non compliance before Week 48|6
6026627|NCT00272779|9622310|FG001|Baseline Through Week 48|Poor/non compliance before Week 48|9
6026628|NCT00272779|9622309|FG000|Baseline Through Week 48|Pregnancy before Week 48|2
6026629|NCT00272779|9622310|FG001|Baseline Through Week 48|Pregnancy before Week 48|2
6026630|NCT00272779|9622309|FG000|Baseline Through Week 48|No longer meets criteria before Week 48|1
6026631|NCT00272779|9622310|FG001|Baseline Through Week 48|No longer meets criteria before Week 48|0
6026632|NCT00272779|9622309|FG000|Baseline Through Week 48|Withdrew consent before Week 48|4
6026633|NCT00272779|9622310|FG001|Baseline Through Week 48|Withdrew consent before Week 48|13
6026634|NCT00272779|9622309|FG000|Baseline Through Week 48|Participant's decision before wk 48|0
6026635|NCT00272779|9622310|FG001|Baseline Through Week 48|Participant's decision before wk 48|1
6026636|NCT00272779|9622309|FG000|Baseline Through Week 48|Chose different site before wk 48|0
6026637|NCT00272779|9622310|FG001|Baseline Through Week 48|Chose different site before wk 48|1
6026638|NCT00272779|9622309|FG000|Baseline Through Week 48|Adverse event on/after Week 48|1
6026639|NCT00272779|9622310|FG001|Baseline Through Week 48|Adverse event on/after Week 48|1
6026640|NCT00272779|9622309|FG000|Baseline Through Week 48|Death on/after Week 48|1
6026641|NCT00272779|9622310|FG001|Baseline Through Week 48|Death on/after Week 48|1
6026642|NCT00272779|9622309|FG000|Baseline Through Week 48|Lack of efficacy on/after Week 48|7
6026643|NCT00272779|9622310|FG001|Baseline Through Week 48|Lack of efficacy on/after Week 48|1
6026644|NCT00272779|9622309|FG000|Baseline Through Week 48|Poor/non compliance on/after Week|2
6026645|NCT00272779|9622310|FG001|Baseline Through Week 48|Poor/non compliance on/after Week|2
6026646|NCT00272779|9622309|FG000|Baseline Through Week 48|No longer meets criteria on/after Wk 48|2
6026647|NCT00272779|9622310|FG001|Baseline Through Week 48|No longer meets criteria on/after Wk 48|2
6026648|NCT00272779|9622309|FG000|Baseline Through Week 48|Pregnancy on/after Week 48|1
6026649|NCT00272779|9622310|FG001|Baseline Through Week 48|Pregnancy on/after Week 48|2
6026650|NCT00272779|9622309|FG000|Baseline Through Week 48|Withdrew consent on/after Week 48|0
6026651|NCT00272779|9622310|FG001|Baseline Through Week 48|Withdrew consent on/after Week 48|2
6026652|NCT00272779|9622309|FG000|Baseline Through Week 48|Continuing treatment|385
6026653|NCT00272779|9622310|FG001|Baseline Through Week 48|Continuing treatment|368
6026654|NCT00272779|9622309|FG000|Baseline Through Week 48|Lost to follow-up on/after Week 48|0
6026655|NCT00272779|9622310|FG001|Baseline Through Week 48|Lost to follow-up on/after Week 48|3
6026656|NCT00272779|9622309|FG000|Baseline Through Week 48|Never treated|2
6026657|NCT00272779|9622310|FG001|Baseline Through Week 48|Never treated|3
6026658|NCT00272779|9622309|FG000|Baseline Through Week 96|Adverse event before Week 96|13
6026659|NCT00272779|9622310|FG001|Baseline Through Week 96|Adverse event before Week 96|22
6026660|NCT00272779|9622309|FG000|Baseline Through Week 96|Death before Week 96|6
6026661|NCT00272779|9622310|FG001|Baseline Through Week 96|Death before Week 96|5
6026662|NCT00272779|9622309|FG000|Baseline Through Week 96|Lack of efficacy before Week 96|16
6026663|NCT00272779|9622310|FG001|Baseline Through Week 96|Lack of efficacy before Week 96|10
6026664|NCT00272779|9622309|FG000|Baseline Through Week 96|Lost to follow up before Week 96|10
6026665|NCT00272779|9622310|FG001|Baseline Through Week 96|Lost to follow up before Week 96|13
6026666|NCT00272779|9622309|FG000|Baseline Through Week 96|Participant Imprisoned before Week 96|1
6026667|NCT00272779|9622310|FG001|Baseline Through Week 96|Participant Imprisoned before Week 96|0
6026668|NCT00272779|9622309|FG000|Baseline Through Week 96|Poor/non compliance before Week 96|12
6026669|NCT00272779|9622310|FG001|Baseline Through Week 96|Poor/non compliance before Week 96|16
6026670|NCT00272779|9622309|FG000|Baseline Through Week 96|Pregnancy before Week 96|5
6026671|NCT00272779|9622310|FG001|Baseline Through Week 96|Pregnancy before Week 96|7
6026672|NCT00272779|9622309|FG000|Baseline Through Week 96|No longer meets criteria before Week 96|4
6026673|NCT00272779|9622310|FG001|Baseline Through Week 96|No longer meets criteria before Week 96|3
6026674|NCT00272779|9622309|FG000|Baseline Through Week 96|Withdrew consent before Week 96|5
6026675|NCT00272779|9622310|FG001|Baseline Through Week 96|Withdrew consent before Week 96|18
6026676|NCT00272779|9622309|FG000|Baseline Through Week 96|Changed address before Week 96|0
6026677|NCT00272779|9622310|FG001|Baseline Through Week 96|Changed address before Week 96|1
6026678|NCT00272779|9622309|FG000|Baseline Through Week 96|Lost to follow-up at Week 96|1
6026679|NCT00272779|9622310|FG001|Baseline Through Week 96|Lost to follow-up at Week 96|0
6026680|NCT00272779|9622309|FG000|Baseline Through Week 96|Poor/non compliance at Week 96]|2
6026681|NCT00272779|9622310|FG001|Baseline Through Week 96|Poor/non compliance at Week 96]|0
6026682|NCT00272779|9622309|FG000|Baseline Through Week 96|Pregnancy at Week 96|1
6026683|NCT00272779|9622310|FG001|Baseline Through Week 96|Pregnancy at Week 96|0
6026684|NCT00272779|9622309|FG000|Baseline Through Week 96|Never treated|2
6026685|NCT00272779|9622310|FG001|Baseline Through Week 96|Never treated|3
6026686|NCT00272779|9622309|FG000|Baseline Through Week 96|Continuing on treatment|61
6026687|NCT00272779|9622310|FG001|Baseline Through Week 96|Continuing on treatment|38
6026688|NCT00272792|9622319|FG000|Part 1: Responsiveness|Lost to Follow-up|1
6026689|NCT00272792|9622320|FG001|Part 1: Responsiveness|Lost to Follow-up|0
6026690|NCT00272792|9622319|FG000|Part 2: Blinded, Placebo Control Period|Withdrawal by Subject|0
6026691|NCT00272792|9622320|FG001|Part 2: Blinded, Placebo Control Period|Withdrawal by Subject|2
6026692|NCT00272792|9622319|FG000|Part 2: Blinded, Placebo Control Period|Lack of Efficacy|1
6026693|NCT00272792|9622320|FG001|Part 2: Blinded, Placebo Control Period|Lack of Efficacy|0
6026694|NCT00272792|9622319|FG000|Part 2: Blinded, Placebo Control Period|Patient Uncooperative|0
6026695|NCT00272792|9622320|FG001|Part 2: Blinded, Placebo Control Period|Patient Uncooperative|1
6026696|NCT00272844|9622326|FG000|Overall Study|Withdrawal by Subject|5
6026697|NCT00272961|9622335|FG000|Placebo Run-in Phase: Up to Week 2|Physician Decision|1
6026698|NCT00272961|9622336|FG001|Placebo Run-in Phase: Up to Week 2|Physician Decision|0
6026699|NCT00272961|9622337|FG002|Placebo Run-in Phase: Up to Week 2|Physician Decision|0
6026700|NCT00272961|9622338|FG003|Placebo Run-in Phase: Up to Week 2|Physician Decision|0
6026701|NCT00272961|9622339|FG004|Placebo Run-in Phase: Up to Week 2|Physician Decision|0
6026702|NCT00272961|9622335|FG000|Placebo Run-in Phase: Up to Week 2|Sponsor Decision|1
6026703|NCT00272961|9622336|FG001|Placebo Run-in Phase: Up to Week 2|Sponsor Decision|0
6026704|NCT00272961|9622337|FG002|Placebo Run-in Phase: Up to Week 2|Sponsor Decision|0
6026705|NCT00272961|9622338|FG003|Placebo Run-in Phase: Up to Week 2|Sponsor Decision|0
6026706|NCT00272961|9622339|FG004|Placebo Run-in Phase: Up to Week 2|Sponsor Decision|0
6026707|NCT00272961|9622335|FG000|Placebo Run-in Phase: Up to Week 2|Subject Defaulted|5
6026708|NCT00272961|9622336|FG001|Placebo Run-in Phase: Up to Week 2|Subject Defaulted|0
6026709|NCT00272961|9622337|FG002|Placebo Run-in Phase: Up to Week 2|Subject Defaulted|0
6026710|NCT00272961|9622338|FG003|Placebo Run-in Phase: Up to Week 2|Subject Defaulted|0
6026711|NCT00272961|9622339|FG004|Placebo Run-in Phase: Up to Week 2|Subject Defaulted|0
6026712|NCT00272961|9622335|FG000|Placebo Run-in Phase: Up to Week 2|Participant Needed Prohibited Medication|2
6026713|NCT00272961|9622336|FG001|Placebo Run-in Phase: Up to Week 2|Participant Needed Prohibited Medication|0
6026714|NCT00272961|9622337|FG002|Placebo Run-in Phase: Up to Week 2|Participant Needed Prohibited Medication|0
6026715|NCT00272961|9622338|FG003|Placebo Run-in Phase: Up to Week 2|Participant Needed Prohibited Medication|0
6026716|NCT00272961|9622339|FG004|Placebo Run-in Phase: Up to Week 2|Participant Needed Prohibited Medication|0
6026717|NCT00272961|9622335|FG000|Placebo Run-in Phase: Up to Week 2|Other|2
6026718|NCT00272961|9622336|FG001|Placebo Run-in Phase: Up to Week 2|Other|0
6026719|NCT00272961|9622337|FG002|Placebo Run-in Phase: Up to Week 2|Other|0
6026720|NCT00272961|9622338|FG003|Placebo Run-in Phase: Up to Week 2|Other|0
6026721|NCT00272961|9622339|FG004|Placebo Run-in Phase: Up to Week 2|Other|0
6026722|NCT00272961|9622335|FG000|Treatment Phase: Week 3 Up to Week 12|Adverse Event|0
6026723|NCT00272961|9622336|FG001|Treatment Phase: Week 3 Up to Week 12|Adverse Event|1
6026724|NCT00272961|9622337|FG002|Treatment Phase: Week 3 Up to Week 12|Adverse Event|0
6026725|NCT00272961|9622338|FG003|Treatment Phase: Week 3 Up to Week 12|Adverse Event|1
6026726|NCT00272961|9622339|FG004|Treatment Phase: Week 3 Up to Week 12|Adverse Event|2
6026727|NCT00272961|9622335|FG000|Treatment Phase: Week 3 Up to Week 12|Participant Defaulted|1
6026728|NCT00272961|9622336|FG001|Treatment Phase: Week 3 Up to Week 12|Participant Defaulted|0
6026729|NCT00272961|9622337|FG002|Treatment Phase: Week 3 Up to Week 12|Participant Defaulted|1
6026730|NCT00272961|9622338|FG003|Treatment Phase: Week 3 Up to Week 12|Participant Defaulted|0
6026731|NCT00272961|9622339|FG004|Treatment Phase: Week 3 Up to Week 12|Participant Defaulted|0
6026732|NCT00272961|9622335|FG000|Treatment Phase: Week 3 Up to Week 12|Other|1
6026733|NCT00272961|9622336|FG001|Treatment Phase: Week 3 Up to Week 12|Other|3
6026734|NCT00272961|9622337|FG002|Treatment Phase: Week 3 Up to Week 12|Other|3
6026735|NCT00272961|9622338|FG003|Treatment Phase: Week 3 Up to Week 12|Other|2
6026736|NCT00272961|9622339|FG004|Treatment Phase: Week 3 Up to Week 12|Other|2
6026737|NCT00272987|9622354|FG000|Overall Study|Adverse Event|1
6026738|NCT00272987|9622355|FG001|Overall Study|Adverse Event|0
6026739|NCT00272987|9622356|FG002|Overall Study|Adverse Event|0
6026740|NCT00272987|9622354|FG000|Overall Study|Lost to Follow-up|3
6026741|NCT00272987|9622355|FG001|Overall Study|Lost to Follow-up|1
6026742|NCT00272987|9622356|FG002|Overall Study|Lost to Follow-up|1
6026743|NCT00272987|9622354|FG000|Overall Study|Withdrawal by Subject|1
6026744|NCT00272987|9622355|FG001|Overall Study|Withdrawal by Subject|0
6026745|NCT00272987|9622356|FG002|Overall Study|Withdrawal by Subject|3
6026746|NCT00272987|9622354|FG000|Overall Study|Sponsor Terminated study|0
6026747|NCT00272987|9622355|FG001|Overall Study|Sponsor Terminated study|1
6026748|NCT00272987|9622356|FG002|Overall Study|Sponsor Terminated study|1
6026749|NCT00272987|9622354|FG000|Overall Study|Disease progression|1
6026750|NCT00272987|9622355|FG001|Overall Study|Disease progression|1
6026751|NCT00272987|9622356|FG002|Overall Study|Disease progression|2
6026752|NCT00272987|9622354|FG000|Overall Study|Non-compliant- study visits, trtmnts, req. surgery|2
6026753|NCT00272987|9622355|FG001|Overall Study|Non-compliant- study visits, trtmnts, req. surgery|1
6026754|NCT00272987|9622356|FG002|Overall Study|Non-compliant- study visits, trtmnts, req. surgery|4
6026755|NCT00272987|9622354|FG000|Overall Study|Death|1
6026756|NCT00272987|9622355|FG001|Overall Study|Death|0
6026757|NCT00272987|9622356|FG002|Overall Study|Death|0
6026758|NCT00273052|9622366|FG000|Overall Study|Withdrawal by Subject|16
6026759|NCT00273052|9622367|FG001|Overall Study|Withdrawal by Subject|19
6026760|NCT00273052|9622366|FG000|Overall Study|Adverse Event|21
6026761|NCT00273052|9622367|FG001|Overall Study|Adverse Event|19
6026762|NCT00273052|9622366|FG000|Overall Study|Protocol Violation|14
6026763|NCT00273052|9622367|FG001|Overall Study|Protocol Violation|18
6026764|NCT00273052|9622366|FG000|Overall Study|Lost to Follow-up|7
6026765|NCT00273052|9622367|FG001|Overall Study|Lost to Follow-up|25
6026766|NCT00273052|9622366|FG000|Overall Study|Lack of Efficacy|6
6026767|NCT00273052|9622367|FG001|Overall Study|Lack of Efficacy|4
6026768|NCT00273052|9622366|FG000|Overall Study|Non-Compliance|3
6026769|NCT00273052|9622367|FG001|Overall Study|Non-Compliance|1
6026770|NCT00273052|9622366|FG000|Overall Study|Other|2
6026771|NCT00273052|9622367|FG001|Overall Study|Other|0
6026772|NCT00273052|9622366|FG000|Overall Study|Worsening serum lipid levels|0
6026773|NCT00273052|9622367|FG001|Overall Study|Worsening serum lipid levels|2
6026774|NCT00273182|9622373|FG000|Overall Study|Death|450
6026775|NCT00273182|9622373|FG000|Overall Study|Lost to Follow-up|88
6026776|NCT00273182|9622373|FG000|Overall Study|Withdrawal by Subject|257
6026777|NCT00273182|9622373|FG000|Overall Study|Device/System Explant|154
6026778|NCT00273182|9622373|FG000|Overall Study|Site exit, system change, 36 m FU missed|36
6026779|NCT00273858|9622421|FG000|Overall Study|Not completed 24 month observation time|334
6026780|NCT00273858|9622421|FG000|Overall Study|Lost to Follow-up|101
6026781|NCT00273858|9622421|FG000|Overall Study|Withdrawal by Subject|21
6026782|NCT00273858|9622421|FG000|Overall Study|Adverse Event|81
6026783|NCT00274261|9622452|FG000|Overall Study|Adverse Event|19
6026784|NCT00274261|9622453|FG001|Overall Study|Adverse Event|11
6026785|NCT00274261|9622452|FG000|Overall Study|Pregnancy|114
6026786|NCT00274261|9622453|FG001|Overall Study|Pregnancy|83
6026787|NCT00274261|9622452|FG000|Overall Study|Withdrawal by Subject|179
6026788|NCT00274261|9622453|FG001|Overall Study|Withdrawal by Subject|126
6026789|NCT00274261|9622452|FG000|Overall Study|Protocol Violation|71
6026790|NCT00274261|9622453|FG001|Overall Study|Protocol Violation|42
6026791|NCT00274261|9622452|FG000|Overall Study|Lost to Follow-up|106
6026792|NCT00274261|9622453|FG001|Overall Study|Lost to Follow-up|75
6026793|NCT00274287|9622461|FG000|Overall Study|Withdrawal by Subject|1
6026794|NCT00274287|9622461|FG000|Overall Study|subject non-compliance|1
6026795|NCT00274456|9622470|FG000|Overall Study|Still on treatment|2
6026796|NCT00274456|9622471|FG001|Overall Study|Still on treatment|3
6026797|NCT00274456|9622472|FG002|Overall Study|Still on treatment|5
6026798|NCT00274456|9622473|FG003|Overall Study|Still on treatment|1
6026799|NCT00274456|9622470|FG000|Overall Study|Unacceptable toxicity|10
6026800|NCT00274456|9622471|FG001|Overall Study|Unacceptable toxicity|5
6026801|NCT00274456|9622472|FG002|Overall Study|Unacceptable toxicity|12
6026802|NCT00274456|9622473|FG003|Overall Study|Unacceptable toxicity|16
6026803|NCT00274456|9622470|FG000|Overall Study|Adverse Event|0
6026804|NCT00274456|9622471|FG001|Overall Study|Adverse Event|1
6026805|NCT00274456|9622472|FG002|Overall Study|Adverse Event|2
6026806|NCT00274456|9622473|FG003|Overall Study|Adverse Event|2
6026807|NCT00274456|9622470|FG000|Overall Study|Physician Decision|7
6026808|NCT00274456|9622471|FG001|Overall Study|Physician Decision|5
6026809|NCT00274456|9622472|FG002|Overall Study|Physician Decision|6
6026810|NCT00274456|9622473|FG003|Overall Study|Physician Decision|13
6026811|NCT00274456|9622470|FG000|Overall Study|Lost to Follow-up|0
6026812|NCT00274456|9622471|FG001|Overall Study|Lost to Follow-up|0
6026813|NCT00274456|9622472|FG002|Overall Study|Lost to Follow-up|1
6026814|NCT00274456|9622473|FG003|Overall Study|Lost to Follow-up|0
6026815|NCT00274456|9622470|FG000|Overall Study|Withdrawal by Subject|18
6026816|NCT00274456|9622471|FG001|Overall Study|Withdrawal by Subject|13
6026817|NCT00274456|9622472|FG002|Overall Study|Withdrawal by Subject|9
6026818|NCT00274456|9622473|FG003|Overall Study|Withdrawal by Subject|13
6026819|NCT00274469|9622485|FG000|Overall Study|Death|63
6026820|NCT00274469|9622486|FG001|Overall Study|Death|74
6026821|NCT00274469|9622485|FG000|Overall Study|Did not consent to OS follow-up|16
6026822|NCT00274469|9622486|FG001|Overall Study|Did not consent to OS follow-up|19
6026823|NCT00274625|9622494|FG000|Overall Study|Lost to Follow-up|46
6026824|NCT00274625|9622495|FG001|Overall Study|Lost to Follow-up|54
6026825|NCT00274625|9622494|FG000|Overall Study|Excluded from analysis|14
6026826|NCT00274625|9622495|FG001|Overall Study|Excluded from analysis|8
6026827|NCT00274651|9622503|FG000|Overall Study|Adverse Event|6
6026828|NCT00274651|9622504|FG001|Overall Study|Adverse Event|3
6026829|NCT00274651|9622503|FG000|Overall Study|Lack of Efficacy|13
6026830|NCT00274651|9622504|FG001|Overall Study|Lack of Efficacy|6
6026831|NCT00274651|9622503|FG000|Overall Study|Death|1
6026832|NCT00274651|9622504|FG001|Overall Study|Death|3
6026833|NCT00274651|9622503|FG000|Overall Study|Withdrawal by Subject|0
6026834|NCT00274651|9622504|FG001|Overall Study|Withdrawal by Subject|1
6026835|NCT00274651|9622503|FG000|Overall Study|Physician Decision|8
6026836|NCT00274651|9622504|FG001|Overall Study|Physician Decision|7
6026837|NCT00274716|9622517|FG000|Phase A|Other non-reported reason|4
6026838|NCT00274716|9622518|FG001|Phase A|Other non-reported reason|2
6026839|NCT00274716|9622519|FG002|Phase A|Other non-reported reason|1
6026840|NCT00274716|9622520|FG003|Phase A|Other non-reported reason|2
6026841|NCT00274716|9622521|FG004|Phase A|Other non-reported reason|0
6026842|NCT00274716|9622522|FG005|Phase A|Other non-reported reason|1
6026843|NCT00274716|9622517|FG000|Phase A|Participant moved|0
6026844|NCT00274716|9622518|FG001|Phase A|Participant moved|0
6026845|NCT00274716|9622519|FG002|Phase A|Participant moved|1
6026846|NCT00274716|9622520|FG003|Phase A|Participant moved|0
6026847|NCT00274716|9622521|FG004|Phase A|Participant moved|0
6026848|NCT00274716|9622522|FG005|Phase A|Participant moved|1
6026849|NCT00274716|9622517|FG000|Phase A|Site Terminated|0
6026850|NCT00274716|9622518|FG001|Phase A|Site Terminated|0
6026851|NCT00274716|9622519|FG002|Phase A|Site Terminated|0
6026852|NCT00274716|9622520|FG003|Phase A|Site Terminated|1
6026853|NCT00274716|9622521|FG004|Phase A|Site Terminated|0
6026854|NCT00274716|9622522|FG005|Phase A|Site Terminated|0
6026855|NCT00274716|9622517|FG000|Phase A|Protocol Violation|1
6026856|NCT00274716|9622518|FG001|Phase A|Protocol Violation|0
6026857|NCT00274716|9622519|FG002|Phase A|Protocol Violation|0
6026858|NCT00274716|9622520|FG003|Phase A|Protocol Violation|1
6026859|NCT00274716|9622521|FG004|Phase A|Protocol Violation|0
6026860|NCT00274716|9622522|FG005|Phase A|Protocol Violation|0
6026861|NCT00274716|9622517|FG000|Phase A|Met criteria for discontinuation|1
6026862|NCT00274716|9622518|FG001|Phase A|Met criteria for discontinuation|1
6026863|NCT00274716|9622519|FG002|Phase A|Met criteria for discontinuation|0
6026864|NCT00274716|9622520|FG003|Phase A|Met criteria for discontinuation|0
6026865|NCT00274716|9622521|FG004|Phase A|Met criteria for discontinuation|0
6026866|NCT00274716|9622522|FG005|Phase A|Met criteria for discontinuation|0
6026867|NCT00274716|9622517|FG000|Phase A|Withdrawal by Subject|2
6026868|NCT00274716|9622518|FG001|Phase A|Withdrawal by Subject|2
6026869|NCT00274716|9622519|FG002|Phase A|Withdrawal by Subject|1
6026870|NCT00274716|9622520|FG003|Phase A|Withdrawal by Subject|3
6026871|NCT00274716|9622521|FG004|Phase A|Withdrawal by Subject|0
6026872|NCT00274716|9622522|FG005|Phase A|Withdrawal by Subject|1
6026873|NCT00274716|9622517|FG000|Phase A|Adverse Event|2
6026874|NCT00274716|9622518|FG001|Phase A|Adverse Event|3
6026875|NCT00274716|9622519|FG002|Phase A|Adverse Event|3
6026876|NCT00274716|9622520|FG003|Phase A|Adverse Event|0
6026877|NCT00274716|9622521|FG004|Phase A|Adverse Event|2
6026878|NCT00274716|9622522|FG005|Phase A|Adverse Event|0
6026879|NCT00274716|9622517|FG000|Phase A|Completed but did not enter Phase B|1
6026880|NCT00274716|9622518|FG001|Phase A|Completed but did not enter Phase B|2
6026881|NCT00274716|9622519|FG002|Phase A|Completed but did not enter Phase B|2
6026882|NCT00274716|9622520|FG003|Phase A|Completed but did not enter Phase B|2
6026883|NCT00274716|9622521|FG004|Phase A|Completed but did not enter Phase B|1
6026884|NCT00274716|9622522|FG005|Phase A|Completed but did not enter Phase B|1
6026885|NCT00274716|9622517|FG000|Phase B|Adverse Event|0
6026886|NCT00274716|9622518|FG001|Phase B|Adverse Event|0
6026887|NCT00274716|9622519|FG002|Phase B|Adverse Event|2
6026888|NCT00274716|9622520|FG003|Phase B|Adverse Event|0
6026889|NCT00274716|9622521|FG004|Phase B|Adverse Event|0
6026890|NCT00274716|9622522|FG005|Phase B|Adverse Event|1
6026891|NCT00274716|9622517|FG000|Phase B|Protocol Violation|0
6026892|NCT00274716|9622518|FG001|Phase B|Protocol Violation|2
6026893|NCT00274716|9622519|FG002|Phase B|Protocol Violation|0
6026894|NCT00274716|9622520|FG003|Phase B|Protocol Violation|0
6026895|NCT00274716|9622521|FG004|Phase B|Protocol Violation|0
6026896|NCT00274716|9622522|FG005|Phase B|Protocol Violation|0
6026897|NCT00274716|9622517|FG000|Phase B|Withdrawal by Subject|0
6026898|NCT00274716|9622518|FG001|Phase B|Withdrawal by Subject|1
6026899|NCT00274716|9622519|FG002|Phase B|Withdrawal by Subject|0
6026900|NCT00274716|9622520|FG003|Phase B|Withdrawal by Subject|0
6026901|NCT00274716|9622521|FG004|Phase B|Withdrawal by Subject|0
6026902|NCT00274716|9622522|FG005|Phase B|Withdrawal by Subject|0
6026903|NCT00274716|9622517|FG000|Phase B|Participant moved|1
6026904|NCT00274716|9622518|FG001|Phase B|Participant moved|0
6026905|NCT00274716|9622519|FG002|Phase B|Participant moved|0
6026906|NCT00274716|9622520|FG003|Phase B|Participant moved|0
6026907|NCT00274716|9622521|FG004|Phase B|Participant moved|0
6026908|NCT00274716|9622522|FG005|Phase B|Participant moved|0
6026909|NCT00274716|9622517|FG000|Phase B|Other non-reported reason|0
6026910|NCT00274716|9622518|FG001|Phase B|Other non-reported reason|0
6026911|NCT00274716|9622519|FG002|Phase B|Other non-reported reason|1
6026912|NCT00274716|9622520|FG003|Phase B|Other non-reported reason|1
6026913|NCT00274716|9622521|FG004|Phase B|Other non-reported reason|0
6026914|NCT00274716|9622522|FG005|Phase B|Other non-reported reason|0
6026915|NCT00274716|9622517|FG000|Phase B|Lost to Follow-up|0
6026916|NCT00274716|9622518|FG001|Phase B|Lost to Follow-up|1
6026917|NCT00274716|9622519|FG002|Phase B|Lost to Follow-up|0
6026918|NCT00274716|9622520|FG003|Phase B|Lost to Follow-up|0
6146376|NCT01077076|9781133|FG001|First Intervention|Withdrawal by Subject|0
6146377|NCT01077076|9781134|FG002|First Intervention|Withdrawal by Subject|0
6026919|NCT00274716|9622521|FG004|Phase B|Lost to Follow-up|0
6026920|NCT00274716|9622522|FG005|Phase B|Lost to Follow-up|0
6026921|NCT00274742|9622546|FG000|Overall Study|Adverse Event|0
6026922|NCT00274742|9622547|FG001|Overall Study|Adverse Event|4
6026923|NCT00274742|9622548|FG002|Overall Study|Adverse Event|1
6026924|NCT00274742|9622549|FG003|Overall Study|Adverse Event|4
6026925|NCT00274742|9622550|FG004|Overall Study|Adverse Event|12
6026926|NCT00274742|9622551|FG005|Overall Study|Adverse Event|3
6026927|NCT00274742|9622546|FG000|Overall Study|Lost to Follow-up|0
6026928|NCT00274742|9622547|FG001|Overall Study|Lost to Follow-up|0
6026929|NCT00274742|9622548|FG002|Overall Study|Lost to Follow-up|0
6026930|NCT00274742|9622549|FG003|Overall Study|Lost to Follow-up|0
6026931|NCT00274742|9622550|FG004|Overall Study|Lost to Follow-up|1
6026932|NCT00274742|9622551|FG005|Overall Study|Lost to Follow-up|0
6026933|NCT00274742|9622546|FG000|Overall Study|End of Study|0
6026934|NCT00274742|9622547|FG001|Overall Study|End of Study|0
6026935|NCT00274742|9622548|FG002|Overall Study|End of Study|0
6026936|NCT00274742|9622549|FG003|Overall Study|End of Study|1
6026937|NCT00274742|9622550|FG004|Overall Study|End of Study|0
6079200|NCT00607919|9685889|FG001|Acute Phase|Parent/Caregiver Decision|4
6079201|NCT00607919|9685888|FG000|Acute Phase|Protocol Violation|5
6079202|NCT00607919|9685889|FG001|Acute Phase|Protocol Violation|1
6079203|NCT00607919|9685888|FG000|Acute Phase|Withdrawal by Subject|3
6079204|NCT00607919|9685889|FG001|Acute Phase|Withdrawal by Subject|3
6079205|NCT00607919|9685888|FG000|Open-Label Phase|Adverse Event|1
6079206|NCT00607919|9685889|FG001|Open-Label Phase|Adverse Event|5
6079207|NCT00607919|9685888|FG000|Open-Label Phase|Lost to Follow-up|4
6079208|NCT00607919|9685889|FG001|Open-Label Phase|Lost to Follow-up|1
6079209|NCT00607919|9685888|FG000|Open-Label Phase|Protocol Violation|2
6079210|NCT00607919|9685889|FG001|Open-Label Phase|Protocol Violation|2
6079211|NCT00607919|9685888|FG000|Open-Label Phase|Withdrawal by Subject|2
6079212|NCT00607919|9685889|FG001|Open-Label Phase|Withdrawal by Subject|2
6079213|NCT00607919|9685888|FG000|Open-Label Phase|Parent/Caregiver Decision|1
6079214|NCT00607919|9685889|FG001|Open-Label Phase|Parent/Caregiver Decision|2
6079215|NCT00607997|9685901|FG000|Overall Study|Lack of Efficacy|6
6079216|NCT00607997|9685902|FG001|Overall Study|Lack of Efficacy|20
6079217|NCT00607997|9685903|FG002|Overall Study|Lack of Efficacy|14
6079218|NCT00607997|9685904|FG003|Overall Study|Lack of Efficacy|10
6079219|NCT00607997|9685901|FG000|Overall Study|Death|8
6026938|NCT00274742|9622551|FG005|Overall Study|End of Study|0
6026939|NCT00274742|9622546|FG000|Overall Study|Disease Progression|0
6026940|NCT00274742|9622547|FG001|Overall Study|Disease Progression|1
6026941|NCT00274742|9622548|FG002|Overall Study|Disease Progression|1
6026942|NCT00274742|9622549|FG003|Overall Study|Disease Progression|0
6026943|NCT00274742|9622550|FG004|Overall Study|Disease Progression|1
6026944|NCT00274742|9622551|FG005|Overall Study|Disease Progression|0
6026945|NCT00274742|9622546|FG000|Overall Study|Other|0
6079220|NCT00607997|9685902|FG001|Overall Study|Death|5
6079221|NCT00607997|9685903|FG002|Overall Study|Death|2
6079222|NCT00607997|9685904|FG003|Overall Study|Death|5
6026946|NCT00274742|9622547|FG001|Overall Study|Other|3
6026947|NCT00274742|9622548|FG002|Overall Study|Other|0
6026948|NCT00274742|9622549|FG003|Overall Study|Other|0
6026949|NCT00274742|9622550|FG004|Overall Study|Other|2
6026950|NCT00274742|9622551|FG005|Overall Study|Other|0
6026951|NCT00274846|9622580|FG000|Overall Study|Did not receive adequate NK cells|1
6026952|NCT00274924|9622588|FG000|Step 1 (R-CHOP X 3 Cycles)|Patient ineligible|4
6026953|NCT00274924|9622589|FG001|Step 1 (R-CHOP X 3 Cycles)|Patient ineligible|14
6026954|NCT00274924|9622590|FG002|Step 1 (R-CHOP X 3 Cycles)|Patient ineligible|1
6026955|NCT00274924|9622588|FG000|Step 1 (R-CHOP X 3 Cycles)|Did not start treatment|0
6026956|NCT00274924|9622589|FG001|Step 1 (R-CHOP X 3 Cycles)|Did not start treatment|0
6026957|NCT00274924|9622590|FG002|Step 1 (R-CHOP X 3 Cycles)|Did not start treatment|1
6026958|NCT00274924|9622588|FG000|Step 1 (R-CHOP X 3 Cycles)|Adverse Event|0
6026959|NCT00274924|9622589|FG001|Step 1 (R-CHOP X 3 Cycles)|Adverse Event|0
6026960|NCT00274924|9622590|FG002|Step 1 (R-CHOP X 3 Cycles)|Adverse Event|1
6026961|NCT00274924|9622588|FG000|Step 1 (R-CHOP X 3 Cycles)|Withdrawal by Subject|0
6026962|NCT00274924|9622589|FG001|Step 1 (R-CHOP X 3 Cycles)|Withdrawal by Subject|0
6026963|NCT00274924|9622590|FG002|Step 1 (R-CHOP X 3 Cycles)|Withdrawal by Subject|1
6026964|NCT00274924|9622588|FG000|Step 1 (R-CHOP X 3 Cycles)|Lost to Follow-up|0
6026965|NCT00274924|9622589|FG001|Step 1 (R-CHOP X 3 Cycles)|Lost to Follow-up|0
6026966|NCT00274924|9622590|FG002|Step 1 (R-CHOP X 3 Cycles)|Lost to Follow-up|1
6026967|NCT00274924|9622588|FG000|Step 1 (R-CHOP X 3 Cycles)|Other complicating disease|0
6026968|NCT00274924|9622589|FG001|Step 1 (R-CHOP X 3 Cycles)|Other complicating disease|0
6026969|NCT00274924|9622590|FG002|Step 1 (R-CHOP X 3 Cycles)|Other complicating disease|1
6026970|NCT00274924|9622588|FG000|Step 2 (Tx Based on Mid-treatment PET)|Patient ineligible|4
6026971|NCT00274924|9622589|FG001|Step 2 (Tx Based on Mid-treatment PET)|Patient ineligible|15
6026972|NCT00274924|9622590|FG002|Step 2 (Tx Based on Mid-treatment PET)|Patient ineligible|0
6026973|NCT00274924|9622588|FG000|Step 2 (Tx Based on Mid-treatment PET)|Adverse Event|1
6026974|NCT00274924|9622589|FG001|Step 2 (Tx Based on Mid-treatment PET)|Adverse Event|0
6026975|NCT00274924|9622590|FG002|Step 2 (Tx Based on Mid-treatment PET)|Adverse Event|0
6026976|NCT00274924|9622588|FG000|Step 2 (Tx Based on Mid-treatment PET)|Withdrawal by Subject|1
6026977|NCT00274924|9622589|FG001|Step 2 (Tx Based on Mid-treatment PET)|Withdrawal by Subject|0
6026978|NCT00274924|9622590|FG002|Step 2 (Tx Based on Mid-treatment PET)|Withdrawal by Subject|0
6026979|NCT00274924|9622588|FG000|Step 2 (Tx Based on Mid-treatment PET)|Other complicating disease|1
6026980|NCT00274924|9622589|FG001|Step 2 (Tx Based on Mid-treatment PET)|Other complicating disease|0
6026981|NCT00274924|9622590|FG002|Step 2 (Tx Based on Mid-treatment PET)|Other complicating disease|0
6079223|NCT00607997|9685901|FG000|Overall Study|Adverse Event|3
6079224|NCT00607997|9685902|FG001|Overall Study|Adverse Event|1
6079225|NCT00607997|9685903|FG002|Overall Study|Adverse Event|2
6079226|NCT00607997|9685904|FG003|Overall Study|Adverse Event|0
6079227|NCT00607997|9685901|FG000|Overall Study|Physician Decision|4
6026982|NCT00274924|9622588|FG000|Step 2 (Tx Based on Mid-treatment PET)|Death|0
6026983|NCT00274924|9622589|FG001|Step 2 (Tx Based on Mid-treatment PET)|Death|1
6026984|NCT00274924|9622590|FG002|Step 2 (Tx Based on Mid-treatment PET)|Death|0
6026985|NCT00274924|9622588|FG000|Step 2 (Tx Based on Mid-treatment PET)|Lack of Efficacy|0
6026986|NCT00274924|9622589|FG001|Step 2 (Tx Based on Mid-treatment PET)|Lack of Efficacy|1
6026987|NCT00274924|9622590|FG002|Step 2 (Tx Based on Mid-treatment PET)|Lack of Efficacy|0
6026988|NCT00274924|9622588|FG000|Step 2 (Tx Based on Mid-treatment PET)|Alternative therapy|0
6026989|NCT00274924|9622589|FG001|Step 2 (Tx Based on Mid-treatment PET)|Alternative therapy|1
6026990|NCT00274924|9622590|FG002|Step 2 (Tx Based on Mid-treatment PET)|Alternative therapy|0
6026991|NCT00274937|9622597|FG000|Overall Study|Physician Decision|10
6026992|NCT00274937|9622597|FG000|Overall Study|Withdrawal by Subject|6
6026993|NCT00274937|9622597|FG000|Overall Study|Progressive Disease|4
6026994|NCT00275002|9622603|FG000|Overall Study|Death|1
6026995|NCT00275002|9622604|FG001|Overall Study|Death|0
6026996|NCT00275002|9622603|FG000|Overall Study|Disease progression|21
6026997|NCT00275002|9622604|FG001|Overall Study|Disease progression|15
6026998|NCT00275002|9622603|FG000|Overall Study|Adverse Event|0
6026999|NCT00275002|9622604|FG001|Overall Study|Adverse Event|1
6027000|NCT00275028|9622610|FG000|Overall Study|Withdrew consent before treatment began|1
6027001|NCT00275028|9622610|FG000|Overall Study|Withdrawal by Subject|5
6027002|NCT00275028|9622610|FG000|Overall Study|Adverse Event|9
6027003|NCT00275028|9622610|FG000|Overall Study|Progressive Disease|30
6027004|NCT00275028|9622610|FG000|Overall Study|Physician Decision|2
6027005|NCT00275262|9622616|FG000|Overall Study|Adverse Event|2
6027006|NCT00275262|9622617|FG001|Overall Study|Adverse Event|0
6027007|NCT00275262|9622616|FG000|Overall Study|Disease progression|2
6027008|NCT00275262|9622617|FG001|Overall Study|Disease progression|5
6027009|NCT00275262|9622616|FG000|Overall Study|Lost to Follow-up|0
6027010|NCT00275262|9622617|FG001|Overall Study|Lost to Follow-up|2
6027011|NCT00275262|9622616|FG000|Overall Study|Protocol Violation|0
6027012|NCT00275262|9622617|FG001|Overall Study|Protocol Violation|2
6027013|NCT00275262|9622616|FG000|Overall Study|Death|1
6027014|NCT00275262|9622617|FG001|Overall Study|Death|0
6027015|NCT00275262|9622616|FG000|Overall Study|Started Chemotherapy|1
6027016|NCT00275262|9622617|FG001|Overall Study|Started Chemotherapy|0
6027017|NCT00275301|9622636|FG000|Overall Study|Adverse Event|5
6027018|NCT00275509|9622651|FG000|Overall Study|graft thrombosis, post-operative day #8|0
6027019|NCT00275509|9622652|FG001|Overall Study|graft thrombosis, post-operative day #8|1
6027020|NCT00275561|9622660|FG000|Overall Study|Withdrawal by Subject|0
6027021|NCT00275561|9622661|FG001|Overall Study|Withdrawal by Subject|1
6027022|NCT00275561|9622660|FG000|Overall Study|Travel|1
6027023|NCT00275561|9622661|FG001|Overall Study|Travel|1
6027024|NCT00275561|9622660|FG000|Overall Study|Scheduling|1
6027025|NCT00275561|9622661|FG001|Overall Study|Scheduling|2
6027026|NCT00275561|9622660|FG000|Overall Study|Family Issues|0
6027027|NCT00275561|9622661|FG001|Overall Study|Family Issues|2
6027028|NCT00275821|9622670|FG000|Overall Study|Adverse Event|4
6027029|NCT00275821|9622671|FG001|Overall Study|Adverse Event|12
6027030|NCT00275821|9622672|FG002|Overall Study|Adverse Event|5
6027031|NCT00275821|9622670|FG000|Overall Study|Administrative problems|3
6027032|NCT00275821|9622671|FG001|Overall Study|Administrative problems|4
6027033|NCT00275821|9622672|FG002|Overall Study|Administrative problems|4
6027034|NCT00275821|9622670|FG000|Overall Study|Withdrawal by Subject|0
6027035|NCT00275821|9622671|FG001|Overall Study|Withdrawal by Subject|2
6027036|NCT00275821|9622672|FG002|Overall Study|Withdrawal by Subject|1
6027037|NCT00275821|9622670|FG000|Overall Study|Lost to Follow-up|0
6027038|NCT00275821|9622671|FG001|Overall Study|Lost to Follow-up|1
6027039|NCT00275821|9622672|FG002|Overall Study|Lost to Follow-up|1
6027040|NCT00275821|9622670|FG000|Overall Study|Death|0
6027041|NCT00275821|9622671|FG001|Overall Study|Death|2
6027042|NCT00275821|9622672|FG002|Overall Study|Death|1
6027043|NCT00275821|9622670|FG000|Overall Study|Lack of Efficacy|2
6027044|NCT00275821|9622671|FG001|Overall Study|Lack of Efficacy|1
6027045|NCT00275821|9622672|FG002|Overall Study|Lack of Efficacy|0
6027046|NCT00275821|9622670|FG000|Overall Study|Protocol Violation|5
6027047|NCT00275821|9622671|FG001|Overall Study|Protocol Violation|1
6027048|NCT00275821|9622672|FG002|Overall Study|Protocol Violation|0
6027049|NCT00276094|9622698|FG000|Overall Study|Adverse Event|15
6027050|NCT00276094|9622699|FG001|Overall Study|Adverse Event|13
6027051|NCT00276094|9622700|FG002|Overall Study|Adverse Event|11
6027052|NCT00276094|9622698|FG000|Overall Study|Withdrawal by Subject|14
6027053|NCT00276094|9622699|FG001|Overall Study|Withdrawal by Subject|14
6027054|NCT00276094|9622700|FG002|Overall Study|Withdrawal by Subject|12
6027055|NCT00276094|9622698|FG000|Overall Study|Protocol Violation|16
6027056|NCT00276094|9622699|FG001|Overall Study|Protocol Violation|7
6027057|NCT00276094|9622700|FG002|Overall Study|Protocol Violation|10
6027058|NCT00276094|9622698|FG000|Overall Study|Lost to Follow-up|8
6027059|NCT00276094|9622699|FG001|Overall Study|Lost to Follow-up|6
6027060|NCT00276094|9622700|FG002|Overall Study|Lost to Follow-up|4
6027061|NCT00276094|9622698|FG000|Overall Study|Other-Subject moved out of country|1
6027062|NCT00276094|9622699|FG001|Overall Study|Other-Subject moved out of country|0
6027063|NCT00276094|9622700|FG002|Overall Study|Other-Subject moved out of country|0
6027064|NCT00276094|9622698|FG000|Overall Study|Other-Scheduled gastroplasty|1
6027065|NCT00276094|9622699|FG001|Overall Study|Other-Scheduled gastroplasty|0
6027066|NCT00276094|9622700|FG002|Overall Study|Other-Scheduled gastroplasty|0
6027067|NCT00276094|9622698|FG000|Overall Study|Other-Lack of efficacy|1
6027068|NCT00276094|9622699|FG001|Overall Study|Other-Lack of efficacy|0
6027069|NCT00276094|9622700|FG002|Overall Study|Other-Lack of efficacy|0
6027070|NCT00276094|9622698|FG000|Overall Study|Other-Refused follow-up visit|1
6027071|NCT00276094|9622699|FG001|Overall Study|Other-Refused follow-up visit|0
6027072|NCT00276094|9622700|FG002|Overall Study|Other-Refused follow-up visit|0
6027073|NCT00276094|9622698|FG000|Overall Study|Other-Repeat safety labs-exclusionary|0
6027074|NCT00276094|9622699|FG001|Overall Study|Other-Repeat safety labs-exclusionary|1
6027075|NCT00276094|9622700|FG002|Overall Study|Other-Repeat safety labs-exclusionary|0
6027076|NCT00276094|9622698|FG000|Overall Study|Other-Relocation|0
6027077|NCT00276094|9622699|FG001|Overall Study|Other-Relocation|1
6027078|NCT00276094|9622700|FG002|Overall Study|Other-Relocation|0
6027079|NCT00276094|9622698|FG000|Overall Study|Other-Study medication lost|0
6027080|NCT00276094|9622699|FG001|Overall Study|Other-Study medication lost|0
6027081|NCT00276094|9622700|FG002|Overall Study|Other-Study medication lost|1
6027082|NCT00276159|9622708|FG000|Overall Study|Did not receive all 24 doses of 852A|6
6048236|NCT00416455|9647391|FG001|Overall Study|Inadequate pathology|2
6048237|NCT00416520|9647419|FG000|Open-label Period|Adverse Event|28
6048238|NCT00416520|9647420|FG001|Open-label Period|Adverse Event|10
6048239|NCT00416520|9647421|FG002|Open-label Period|Adverse Event|0
6048240|NCT00416520|9647422|FG003|Open-label Period|Adverse Event|0
6048241|NCT00416520|9647419|FG000|Open-label Period|Death|2
6048242|NCT00416520|9647420|FG001|Open-label Period|Death|1
6048243|NCT00416520|9647421|FG002|Open-label Period|Death|0
6048244|NCT00416520|9647422|FG003|Open-label Period|Death|0
6048245|NCT00416520|9647419|FG000|Open-label Period|Lack of Efficacy|8
6048246|NCT00416520|9647420|FG001|Open-label Period|Lack of Efficacy|1
6048247|NCT00416520|9647421|FG002|Open-label Period|Lack of Efficacy|0
6048248|NCT00416520|9647422|FG003|Open-label Period|Lack of Efficacy|0
6048249|NCT00416520|9647419|FG000|Open-label Period|Protocol Violation|3
6048250|NCT00416520|9647420|FG001|Open-label Period|Protocol Violation|3
6048251|NCT00416520|9647421|FG002|Open-label Period|Protocol Violation|0
6048252|NCT00416520|9647422|FG003|Open-label Period|Protocol Violation|0
6048253|NCT00416520|9647419|FG000|Open-label Period|Withdrawal by Subject|16
6048254|NCT00416520|9647420|FG001|Open-label Period|Withdrawal by Subject|5
6048255|NCT00416520|9647421|FG002|Open-label Period|Withdrawal by Subject|0
6048256|NCT00416520|9647422|FG003|Open-label Period|Withdrawal by Subject|0
6048257|NCT00416520|9647419|FG000|Open-label Period|Other Reasons|3
6048258|NCT00416520|9647420|FG001|Open-label Period|Other Reasons|12
6048259|NCT00416520|9647421|FG002|Open-label Period|Other Reasons|0
6048260|NCT00416520|9647422|FG003|Open-label Period|Other Reasons|0
6048261|NCT00416520|9647419|FG000|Placebo-controlled Withdrawal Period|Adverse Event|0
6048262|NCT00416520|9647420|FG001|Placebo-controlled Withdrawal Period|Adverse Event|0
6048263|NCT00416520|9647421|FG002|Placebo-controlled Withdrawal Period|Adverse Event|0
6048264|NCT00416520|9647422|FG003|Placebo-controlled Withdrawal Period|Adverse Event|1
6048265|NCT00416520|9647419|FG000|Placebo-controlled Withdrawal Period|Lack of Efficacy|0
6048266|NCT00416520|9647420|FG001|Placebo-controlled Withdrawal Period|Lack of Efficacy|0
6048267|NCT00416520|9647421|FG002|Placebo-controlled Withdrawal Period|Lack of Efficacy|0
6048268|NCT00416520|9647422|FG003|Placebo-controlled Withdrawal Period|Lack of Efficacy|3
6048269|NCT00416520|9647419|FG000|Placebo-controlled Withdrawal Period|Protocol Violation|0
6048270|NCT00416520|9647420|FG001|Placebo-controlled Withdrawal Period|Protocol Violation|0
6048271|NCT00416520|9647421|FG002|Placebo-controlled Withdrawal Period|Protocol Violation|1
6048272|NCT00416520|9647422|FG003|Placebo-controlled Withdrawal Period|Protocol Violation|1
6048273|NCT00416598|9647445|FG000|Induction & Intensification|Adverse Event|38
6048274|NCT00416598|9647445|FG000|Induction & Intensification|Death|32
6048275|NCT00416598|9647445|FG000|Induction & Intensification|Withdrawal by Subject|46
6048276|NCT00416598|9647445|FG000|Induction & Intensification|Alternative Treatment|135
6048277|NCT00416598|9647445|FG000|Induction & Intensification|Physician discretion/other medical issue|45
6048278|NCT00416598|9647445|FG000|Induction & Intensification|Relapse/progression|29
6048279|NCT00416598|9647445|FG000|Induction & Intensification|Failed induction|87
6048280|NCT00416598|9647445|FG000|Decitabine Maintenance|Adverse Event|5
6048281|NCT00416598|9647445|FG000|Decitabine Maintenance|Withdrawal by Subject|18
6048282|NCT00416598|9647445|FG000|Decitabine Maintenance|Progression/relapse|38
6048283|NCT00416598|9647445|FG000|Decitabine Maintenance|Alternative treatment|2
6048284|NCT00416598|9647445|FG000|Decitabine Maintenance|Physician discretion/other medical issue|9
6048285|NCT00416624|9647453|FG000|Overall Study|Withdrawal by Subject|1
6048286|NCT00416624|9647454|FG001|Overall Study|Withdrawal by Subject|6
6048287|NCT00416624|9647455|FG002|Overall Study|Withdrawal by Subject|4
6048288|NCT00416624|9647456|FG003|Overall Study|Withdrawal by Subject|9
6048289|NCT00416624|9647453|FG000|Overall Study|Death|4
6048290|NCT00416624|9647454|FG001|Overall Study|Death|7
6048291|NCT00416624|9647455|FG002|Overall Study|Death|7
6048292|NCT00416624|9647456|FG003|Overall Study|Death|1
6048293|NCT00416624|9647453|FG000|Overall Study|Adverse Event|8
6048294|NCT00416624|9647454|FG001|Overall Study|Adverse Event|3
6048295|NCT00416624|9647455|FG002|Overall Study|Adverse Event|2
6048296|NCT00416624|9647456|FG003|Overall Study|Adverse Event|2
6048297|NCT00416624|9647453|FG000|Overall Study|Other|8
6048298|NCT00416624|9647454|FG001|Overall Study|Other|11
6027083|NCT00276380|9622727|FG000|Overall Study|Adverse Event|5
6027084|NCT00276380|9622728|FG001|Overall Study|Adverse Event|3
6027085|NCT00276380|9622727|FG000|Overall Study|Lost to Follow-up|1
6027086|NCT00276380|9622728|FG001|Overall Study|Lost to Follow-up|1
6027087|NCT00276380|9622727|FG000|Overall Study|Withdrawal by Subject|3
6027088|NCT00276380|9622728|FG001|Overall Study|Withdrawal by Subject|6
6027089|NCT00276380|9622727|FG000|Overall Study|Death|5
6027090|NCT00276380|9622728|FG001|Overall Study|Death|3
6027091|NCT00276380|9622727|FG000|Overall Study|Abnormal aPPT Levels|0
6027092|NCT00276380|9622728|FG001|Overall Study|Abnormal aPPT Levels|1
6027093|NCT00276614|9622748|FG000|Overall Study|Progression of disease under study|3
6027094|NCT00276744|9622752|FG000|PART A|Reason unknown|98
6027095|NCT00277095|9622761|FG000|Overall Study|Death|2
6027096|NCT00277095|9622761|FG000|Overall Study|Explanted|7
6027097|NCT00277095|9622761|FG000|Overall Study|Lost to Follow-up|2
6027098|NCT00277095|9622761|FG000|Overall Study|Missed Follow-up|9
6027099|NCT00277095|9622761|FG000|Overall Study|Physician Decision|1
6027100|NCT00277212|9622765|FG000|Phase 1 - Single-Blind Treatment|Lack of Efficacy|61
6027101|NCT00277212|9622766|FG001|Phase 1 - Single-Blind Treatment|Lack of Efficacy|0
6027102|NCT00277212|9622767|FG002|Phase 1 - Single-Blind Treatment|Lack of Efficacy|0
6027103|NCT00277212|9622765|FG000|Phase 1 - Single-Blind Treatment|Adverse Event|93
6027104|NCT00277212|9622766|FG001|Phase 1 - Single-Blind Treatment|Adverse Event|0
6027105|NCT00277212|9622767|FG002|Phase 1 - Single-Blind Treatment|Adverse Event|0
6027106|NCT00277212|9622765|FG000|Phase 1 - Single-Blind Treatment|Withdrawal by Subject|96
6027107|NCT00277212|9622766|FG001|Phase 1 - Single-Blind Treatment|Withdrawal by Subject|0
6027108|NCT00277212|9622767|FG002|Phase 1 - Single-Blind Treatment|Withdrawal by Subject|0
6027109|NCT00277212|9622765|FG000|Phase 1 - Single-Blind Treatment|Lost to Follow-up|87
6027110|NCT00277212|9622766|FG001|Phase 1 - Single-Blind Treatment|Lost to Follow-up|0
6027111|NCT00277212|9622767|FG002|Phase 1 - Single-Blind Treatment|Lost to Follow-up|0
6027112|NCT00277212|9622765|FG000|Phase 1 - Single-Blind Treatment|Poor/Noncompliance|35
6027113|NCT00277212|9622766|FG001|Phase 1 - Single-Blind Treatment|Poor/Noncompliance|0
6027114|NCT00277212|9622767|FG002|Phase 1 - Single-Blind Treatment|Poor/Noncompliance|0
6027115|NCT00277212|9622765|FG000|Phase 1 - Single-Blind Treatment|Pregnancy|6
6027116|NCT00277212|9622766|FG001|Phase 1 - Single-Blind Treatment|Pregnancy|0
6027117|NCT00277212|9622767|FG002|Phase 1 - Single-Blind Treatment|Pregnancy|0
6027118|NCT00277212|9622765|FG000|Phase 1 - Single-Blind Treatment|Subject No Longer Met Study Criteria|44
6027119|NCT00277212|9622766|FG001|Phase 1 - Single-Blind Treatment|Subject No Longer Met Study Criteria|0
6027120|NCT00277212|9622767|FG002|Phase 1 - Single-Blind Treatment|Subject No Longer Met Study Criteria|0
6027121|NCT00277212|9622765|FG000|Phase 1 - Single-Blind Treatment|Administrative Reason by Sponsor|1
6027122|NCT00277212|9622766|FG001|Phase 1 - Single-Blind Treatment|Administrative Reason by Sponsor|0
6027123|NCT00277212|9622767|FG002|Phase 1 - Single-Blind Treatment|Administrative Reason by Sponsor|0
6027124|NCT00277212|9622765|FG000|Phase 1 - Single-Blind Treatment|Other Reasons|12
6027125|NCT00277212|9622766|FG001|Phase 1 - Single-Blind Treatment|Other Reasons|0
6027126|NCT00277212|9622767|FG002|Phase 1 - Single-Blind Treatment|Other Reasons|0
6027127|NCT00277212|9622765|FG000|Phase 2 - Double-Blind Treatment|Lack of Efficacy|0
6027128|NCT00277212|9622766|FG001|Phase 2 - Double-Blind Treatment|Lack of Efficacy|54
6027129|NCT00277212|9622767|FG002|Phase 2 - Double-Blind Treatment|Lack of Efficacy|39
6027130|NCT00277212|9622765|FG000|Phase 2 - Double-Blind Treatment|Adverse Event|0
6027131|NCT00277212|9622766|FG001|Phase 2 - Double-Blind Treatment|Adverse Event|10
6027132|NCT00277212|9622767|FG002|Phase 2 - Double-Blind Treatment|Adverse Event|16
6027133|NCT00277212|9622765|FG000|Phase 2 - Double-Blind Treatment|Withdrawal by Subject|0
6027134|NCT00277212|9622766|FG001|Phase 2 - Double-Blind Treatment|Withdrawal by Subject|17
6027135|NCT00277212|9622767|FG002|Phase 2 - Double-Blind Treatment|Withdrawal by Subject|16
6027136|NCT00277212|9622765|FG000|Phase 2 - Double-Blind Treatment|Lost to Follow-up|0
6027137|NCT00277212|9622766|FG001|Phase 2 - Double-Blind Treatment|Lost to Follow-up|18
6027138|NCT00277212|9622767|FG002|Phase 2 - Double-Blind Treatment|Lost to Follow-up|18
6027139|NCT00277212|9622765|FG000|Phase 2 - Double-Blind Treatment|Poor/Noncompliance|0
6027140|NCT00277212|9622766|FG001|Phase 2 - Double-Blind Treatment|Poor/Noncompliance|7
6027141|NCT00277212|9622767|FG002|Phase 2 - Double-Blind Treatment|Poor/Noncompliance|8
6027142|NCT00277212|9622765|FG000|Phase 2 - Double-Blind Treatment|Pregnancy|0
6027143|NCT00277212|9622766|FG001|Phase 2 - Double-Blind Treatment|Pregnancy|2
6027144|NCT00277212|9622767|FG002|Phase 2 - Double-Blind Treatment|Pregnancy|2
6027145|NCT00277212|9622765|FG000|Phase 2 - Double-Blind Treatment|Subject No Longer Meets Study Criteria|0
6027146|NCT00277212|9622766|FG001|Phase 2 - Double-Blind Treatment|Subject No Longer Meets Study Criteria|4
6027147|NCT00277212|9622767|FG002|Phase 2 - Double-Blind Treatment|Subject No Longer Meets Study Criteria|6
6027148|NCT00277212|9622765|FG000|Phase 2 - Double-Blind Treatment|Administrative Reasons By Sponsor|0
6027149|NCT00277212|9622766|FG001|Phase 2 - Double-Blind Treatment|Administrative Reasons By Sponsor|1
6027150|NCT00277212|9622767|FG002|Phase 2 - Double-Blind Treatment|Administrative Reasons By Sponsor|3
6027151|NCT00277212|9622765|FG000|Phase 2 - Double-Blind Treatment|Other reasons|0
6027152|NCT00277212|9622766|FG001|Phase 2 - Double-Blind Treatment|Other reasons|7
6027153|NCT00277212|9622767|FG002|Phase 2 - Double-Blind Treatment|Other reasons|5
6027154|NCT00277355|9622777|FG000|Overall Study|Withdrawal by Subject|3
6027155|NCT00277355|9622778|FG001|Overall Study|Withdrawal by Subject|3
6027156|NCT00277355|9622777|FG000|Overall Study|Lost to Follow-up|2
6027157|NCT00277355|9622778|FG001|Overall Study|Lost to Follow-up|2
6027158|NCT00277355|9622777|FG000|Overall Study|Adverse Event|5
6027159|NCT00277355|9622778|FG001|Overall Study|Adverse Event|0
6027160|NCT00277355|9622777|FG000|Overall Study|Death|3
6027161|NCT00277355|9622778|FG001|Overall Study|Death|0
6027162|NCT00277355|9622777|FG000|Overall Study|Physician Decision|1
6027163|NCT00277355|9622778|FG001|Overall Study|Physician Decision|0
6027164|NCT00278109|9622819|FG000|Overall Study|Adverse Event|3
6027165|NCT00278109|9622819|FG000|Overall Study|social circumstances|1
6027166|NCT00278148|9622823|FG000|Phase II - Expansion Phase|Disease progression|0
6027167|NCT00278148|9622824|FG001|Phase II - Expansion Phase|Disease progression|0
6027168|NCT00278148|9622825|FG002|Phase II - Expansion Phase|Disease progression|4
6027169|NCT00278148|9622823|FG000|Phase II - Expansion Phase|Adverse Event|0
6027170|NCT00278148|9622824|FG001|Phase II - Expansion Phase|Adverse Event|0
6027171|NCT00278148|9622825|FG002|Phase II - Expansion Phase|Adverse Event|2
6027172|NCT00278161|9622832|FG000|Overall Study|Death|11
6027173|NCT00278200|9622838|FG000|Overall Study|Death|1
6027174|NCT00278200|9622839|FG001|Overall Study|Death|3
6027175|NCT00278200|9622838|FG000|Overall Study|Physician Decision|0
6027176|NCT00278200|9622839|FG001|Overall Study|Physician Decision|1
6027177|NCT00278395|9622845|FG000|Overall Study|Adverse Event|2
6027178|NCT00278395|9622845|FG000|Overall Study|Nonevaluable|1
6027179|NCT00278473|9622854|FG000|Overall Study|drop out|4
6027180|NCT00278473|9622855|FG001|Overall Study|drop out|3
6027181|NCT00278512|9622863|FG000|Overall Study|Death|1
6027182|NCT00278512|9622864|FG001|Overall Study|Death|0
6027183|NCT00278564|9622883|FG000|Overall Study|Lack of Efficacy|4
6027184|NCT00278629|9622887|FG000|Overall Study|Non-CIDP Immune-Mediated Peripheral Neur|14
6027185|NCT00278889|9622913|FG000|Overall Study|Withdrawal by Subject|0
6027186|NCT00278889|9622914|FG001|Overall Study|Withdrawal by Subject|5
6027187|NCT00278889|9622915|FG002|Overall Study|Withdrawal by Subject|3
6027188|NCT00278889|9622913|FG000|Overall Study|Lost to Follow-up|1
6027189|NCT00278889|9622914|FG001|Overall Study|Lost to Follow-up|1
6027190|NCT00278889|9622915|FG002|Overall Study|Lost to Follow-up|0
6027191|NCT00278889|9622913|FG000|Overall Study|Death|24
6027192|NCT00278889|9622914|FG001|Overall Study|Death|21
6027193|NCT00278889|9622915|FG002|Overall Study|Death|17
6027194|NCT00278954|9622923|FG000|Overall Study|Adverse Event|3
6027195|NCT00278954|9622923|FG000|Overall Study|Lost to Follow-up|1
6027196|NCT00278954|9622923|FG000|Overall Study|Withdrawal by Subject|1
6027197|NCT00278993|9622927|FG000|Overall Study|Adverse Event|24
6027198|NCT00278993|9622927|FG000|Overall Study|Withdrawal by Subject|5
6027199|NCT00278993|9622927|FG000|Overall Study|Progressive Disease|65
6027200|NCT00278993|9622927|FG000|Overall Study|Physician Decision|9
6027201|NCT00278993|9622927|FG000|Overall Study|Not Otherwise Specified|4
6027202|NCT00279201|9622933|FG000|Initiation|Death|1
6027203|NCT00279201|9622934|FG001|Initiation|Death|5
6027204|NCT00279201|9622935|FG002|Initiation|Death|0
6027205|NCT00279201|9622936|FG003|Initiation|Death|0
6027206|NCT00279201|9622937|FG004|Initiation|Death|0
6027207|NCT00279201|9622938|FG005|Initiation|Death|0
6027208|NCT00279201|9622933|FG000|Initiation|Adverse Event|6
6027209|NCT00279201|9622934|FG001|Initiation|Adverse Event|15
6027210|NCT00279201|9622935|FG002|Initiation|Adverse Event|0
6027211|NCT00279201|9622936|FG003|Initiation|Adverse Event|0
6027212|NCT00279201|9622937|FG004|Initiation|Adverse Event|0
6027213|NCT00279201|9622938|FG005|Initiation|Adverse Event|0
6027214|NCT00279201|9622933|FG000|Initiation|Lost to Follow-up|42
6027215|NCT00279201|9622934|FG001|Initiation|Lost to Follow-up|41
6027216|NCT00279201|9622935|FG002|Initiation|Lost to Follow-up|0
6027217|NCT00279201|9622936|FG003|Initiation|Lost to Follow-up|0
6027218|NCT00279201|9622937|FG004|Initiation|Lost to Follow-up|0
6027219|NCT00279201|9622938|FG005|Initiation|Lost to Follow-up|0
6027220|NCT00279201|9622933|FG000|Initiation|Entry Criteria Exclusion|7
6027221|NCT00279201|9622934|FG001|Initiation|Entry Criteria Exclusion|9
6027222|NCT00279201|9622935|FG002|Initiation|Entry Criteria Exclusion|0
6027223|NCT00279201|9622936|FG003|Initiation|Entry Criteria Exclusion|0
6027224|NCT00279201|9622937|FG004|Initiation|Entry Criteria Exclusion|0
6027225|NCT00279201|9622938|FG005|Initiation|Entry Criteria Exclusion|0
6027226|NCT00279201|9622933|FG000|Initiation|Protocol Violation|9
6027227|NCT00279201|9622934|FG001|Initiation|Protocol Violation|10
6027228|NCT00279201|9622935|FG002|Initiation|Protocol Violation|0
6027229|NCT00279201|9622936|FG003|Initiation|Protocol Violation|0
6027230|NCT00279201|9622937|FG004|Initiation|Protocol Violation|0
6027231|NCT00279201|9622938|FG005|Initiation|Protocol Violation|0
6027232|NCT00279201|9622933|FG000|Initiation|Withdrawal by Subject|35
6027233|NCT00279201|9622934|FG001|Initiation|Withdrawal by Subject|41
6027234|NCT00279201|9622935|FG002|Initiation|Withdrawal by Subject|0
6027235|NCT00279201|9622936|FG003|Initiation|Withdrawal by Subject|0
6027236|NCT00279201|9622937|FG004|Initiation|Withdrawal by Subject|0
6027237|NCT00279201|9622938|FG005|Initiation|Withdrawal by Subject|0
6027238|NCT00279201|9622933|FG000|Initiation|Physician Decision|15
6027239|NCT00279201|9622934|FG001|Initiation|Physician Decision|18
6027240|NCT00279201|9622935|FG002|Initiation|Physician Decision|0
6027241|NCT00279201|9622936|FG003|Initiation|Physician Decision|0
6027242|NCT00279201|9622937|FG004|Initiation|Physician Decision|0
6027243|NCT00279201|9622938|FG005|Initiation|Physician Decision|0
6027244|NCT00279201|9622933|FG000|Initiation|Sponsor Decision|13
6027245|NCT00279201|9622934|FG001|Initiation|Sponsor Decision|5
6027246|NCT00279201|9622935|FG002|Initiation|Sponsor Decision|0
6027247|NCT00279201|9622936|FG003|Initiation|Sponsor Decision|0
6027248|NCT00279201|9622937|FG004|Initiation|Sponsor Decision|0
6027249|NCT00279201|9622938|FG005|Initiation|Sponsor Decision|0
6027250|NCT00279201|9622933|FG000|Initiation|Discontinuation Oral Antihyperglycemics|0
6027251|NCT00279201|9622934|FG001|Initiation|Discontinuation Oral Antihyperglycemics|1
6027252|NCT00279201|9622935|FG002|Initiation|Discontinuation Oral Antihyperglycemics|0
6027253|NCT00279201|9622936|FG003|Initiation|Discontinuation Oral Antihyperglycemics|0
6027254|NCT00279201|9622937|FG004|Initiation|Discontinuation Oral Antihyperglycemics|0
6027255|NCT00279201|9622938|FG005|Initiation|Discontinuation Oral Antihyperglycemics|0
6027256|NCT00279201|9622933|FG000|Maintenance|Lack of Efficacy|32
6027257|NCT00279201|9622934|FG001|Maintenance|Lack of Efficacy|30
6027258|NCT00279201|9622935|FG002|Maintenance|Lack of Efficacy|0
6027259|NCT00279201|9622936|FG003|Maintenance|Lack of Efficacy|0
6027260|NCT00279201|9622937|FG004|Maintenance|Lack of Efficacy|0
6027261|NCT00279201|9622938|FG005|Maintenance|Lack of Efficacy|0
6027262|NCT00279201|9622933|FG000|Maintenance|Discontinuation Antihyperglycemic Drugs|3
6027263|NCT00279201|9622934|FG001|Maintenance|Discontinuation Antihyperglycemic Drugs|2
6027264|NCT00279201|9622935|FG002|Maintenance|Discontinuation Antihyperglycemic Drugs|0
6027265|NCT00279201|9622936|FG003|Maintenance|Discontinuation Antihyperglycemic Drugs|0
6027266|NCT00279201|9622937|FG004|Maintenance|Discontinuation Antihyperglycemic Drugs|0
6027267|NCT00279201|9622938|FG005|Maintenance|Discontinuation Antihyperglycemic Drugs|0
6027268|NCT00279201|9622933|FG000|Maintenance|Adverse Event|4
6027269|NCT00279201|9622934|FG001|Maintenance|Adverse Event|4
6027270|NCT00279201|9622935|FG002|Maintenance|Adverse Event|0
6027271|NCT00279201|9622936|FG003|Maintenance|Adverse Event|0
6027272|NCT00279201|9622937|FG004|Maintenance|Adverse Event|0
6027273|NCT00279201|9622938|FG005|Maintenance|Adverse Event|0
6027274|NCT00279201|9622933|FG000|Maintenance|Death|4
6027275|NCT00279201|9622934|FG001|Maintenance|Death|4
6027276|NCT00279201|9622935|FG002|Maintenance|Death|0
6027277|NCT00279201|9622936|FG003|Maintenance|Death|0
6027278|NCT00279201|9622937|FG004|Maintenance|Death|0
6027279|NCT00279201|9622938|FG005|Maintenance|Death|0
6027280|NCT00279201|9622933|FG000|Maintenance|Lost to Follow-up|17
6027281|NCT00279201|9622934|FG001|Maintenance|Lost to Follow-up|13
6027282|NCT00279201|9622935|FG002|Maintenance|Lost to Follow-up|0
6027283|NCT00279201|9622936|FG003|Maintenance|Lost to Follow-up|0
6027284|NCT00279201|9622937|FG004|Maintenance|Lost to Follow-up|0
6027285|NCT00279201|9622938|FG005|Maintenance|Lost to Follow-up|0
6027286|NCT00279201|9622933|FG000|Maintenance|Entry Criteria Exclusion|1
6027287|NCT00279201|9622934|FG001|Maintenance|Entry Criteria Exclusion|4
6027288|NCT00279201|9622935|FG002|Maintenance|Entry Criteria Exclusion|0
6027289|NCT00279201|9622936|FG003|Maintenance|Entry Criteria Exclusion|0
6027290|NCT00279201|9622937|FG004|Maintenance|Entry Criteria Exclusion|0
6027291|NCT00279201|9622938|FG005|Maintenance|Entry Criteria Exclusion|0
6027292|NCT00279201|9622933|FG000|Maintenance|Protocol Violation|16
6027293|NCT00279201|9622934|FG001|Maintenance|Protocol Violation|24
6027294|NCT00279201|9622935|FG002|Maintenance|Protocol Violation|0
6027295|NCT00279201|9622936|FG003|Maintenance|Protocol Violation|0
6027296|NCT00279201|9622937|FG004|Maintenance|Protocol Violation|0
6027297|NCT00279201|9622938|FG005|Maintenance|Protocol Violation|0
6027298|NCT00279201|9622933|FG000|Maintenance|Withdrawal by Subject|18
6027299|NCT00279201|9622934|FG001|Maintenance|Withdrawal by Subject|18
6027300|NCT00279201|9622935|FG002|Maintenance|Withdrawal by Subject|0
6027301|NCT00279201|9622936|FG003|Maintenance|Withdrawal by Subject|0
6027302|NCT00279201|9622937|FG004|Maintenance|Withdrawal by Subject|0
6027303|NCT00279201|9622938|FG005|Maintenance|Withdrawal by Subject|0
6027304|NCT00279201|9622933|FG000|Maintenance|Physician Decision|9
6027305|NCT00279201|9622934|FG001|Maintenance|Physician Decision|9
6027306|NCT00279201|9622935|FG002|Maintenance|Physician Decision|0
6027307|NCT00279201|9622936|FG003|Maintenance|Physician Decision|0
6027308|NCT00279201|9622937|FG004|Maintenance|Physician Decision|0
6027309|NCT00279201|9622938|FG005|Maintenance|Physician Decision|0
6027310|NCT00279201|9622933|FG000|Maintenance|Sponsor Decision|4
6027311|NCT00279201|9622934|FG001|Maintenance|Sponsor Decision|0
6027312|NCT00279201|9622935|FG002|Maintenance|Sponsor Decision|0
6027313|NCT00279201|9622936|FG003|Maintenance|Sponsor Decision|0
6027314|NCT00279201|9622937|FG004|Maintenance|Sponsor Decision|0
6027315|NCT00279201|9622938|FG005|Maintenance|Sponsor Decision|0
6027316|NCT00279201|9622933|FG000|Maintenance|HbA1c>7.5%|123
6027317|NCT00279201|9622934|FG001|Maintenance|HbA1c>7.5%|126
6027318|NCT00279201|9622935|FG002|Maintenance|HbA1c>7.5%|0
6027319|NCT00279201|9622936|FG003|Maintenance|HbA1c>7.5%|0
6027320|NCT00279201|9622937|FG004|Maintenance|HbA1c>7.5%|0
6027321|NCT00279201|9622938|FG005|Maintenance|HbA1c>7.5%|0
6027322|NCT00279201|9622933|FG000|Intensification Addendum|Withdrawal by Subject|0
6027323|NCT00279201|9622934|FG001|Intensification Addendum|Withdrawal by Subject|0
6027324|NCT00279201|9622935|FG002|Intensification Addendum|Withdrawal by Subject|12
6027325|NCT00279201|9622936|FG003|Intensification Addendum|Withdrawal by Subject|14
6027326|NCT00279201|9622937|FG004|Intensification Addendum|Withdrawal by Subject|9
6027327|NCT00279201|9622938|FG005|Intensification Addendum|Withdrawal by Subject|18
6027328|NCT00279201|9622933|FG000|Intensification Addendum|Lost to Follow-up|0
6027329|NCT00279201|9622934|FG001|Intensification Addendum|Lost to Follow-up|0
6027330|NCT00279201|9622935|FG002|Intensification Addendum|Lost to Follow-up|4
6027331|NCT00279201|9622936|FG003|Intensification Addendum|Lost to Follow-up|6
6027332|NCT00279201|9622937|FG004|Intensification Addendum|Lost to Follow-up|7
6027333|NCT00279201|9622938|FG005|Intensification Addendum|Lost to Follow-up|7
6027334|NCT00279201|9622933|FG000|Intensification Addendum|Protocol Violation|0
6027335|NCT00279201|9622934|FG001|Intensification Addendum|Protocol Violation|0
6027336|NCT00279201|9622935|FG002|Intensification Addendum|Protocol Violation|2
6027337|NCT00279201|9622936|FG003|Intensification Addendum|Protocol Violation|2
6027338|NCT00279201|9622937|FG004|Intensification Addendum|Protocol Violation|6
6027339|NCT00279201|9622938|FG005|Intensification Addendum|Protocol Violation|6
6027340|NCT00279201|9622933|FG000|Intensification Addendum|Adverse Event|0
6027341|NCT00279201|9622934|FG001|Intensification Addendum|Adverse Event|0
6027342|NCT00279201|9622935|FG002|Intensification Addendum|Adverse Event|0
6027343|NCT00279201|9622936|FG003|Intensification Addendum|Adverse Event|4
6027344|NCT00279201|9622937|FG004|Intensification Addendum|Adverse Event|1
6027345|NCT00279201|9622938|FG005|Intensification Addendum|Adverse Event|3
6027346|NCT00279201|9622933|FG000|Intensification Addendum|Physician Decision|0
6027347|NCT00279201|9622934|FG001|Intensification Addendum|Physician Decision|0
6027348|NCT00279201|9622935|FG002|Intensification Addendum|Physician Decision|4
6027349|NCT00279201|9622936|FG003|Intensification Addendum|Physician Decision|1
6027350|NCT00279201|9622937|FG004|Intensification Addendum|Physician Decision|3
6027351|NCT00279201|9622938|FG005|Intensification Addendum|Physician Decision|2
6027352|NCT00279201|9622933|FG000|Intensification Addendum|Sponsor Decision|0
6027353|NCT00279201|9622934|FG001|Intensification Addendum|Sponsor Decision|0
6027354|NCT00279201|9622935|FG002|Intensification Addendum|Sponsor Decision|0
6027355|NCT00279201|9622936|FG003|Intensification Addendum|Sponsor Decision|0
6027356|NCT00279201|9622937|FG004|Intensification Addendum|Sponsor Decision|1
6027357|NCT00279201|9622938|FG005|Intensification Addendum|Sponsor Decision|1
6027358|NCT00279201|9622933|FG000|Intensification Addendum|Entry Criteria Exclusion|0
6027359|NCT00279201|9622934|FG001|Intensification Addendum|Entry Criteria Exclusion|0
6027360|NCT00279201|9622935|FG002|Intensification Addendum|Entry Criteria Exclusion|1
6027361|NCT00279201|9622936|FG003|Intensification Addendum|Entry Criteria Exclusion|0
6027362|NCT00279201|9622937|FG004|Intensification Addendum|Entry Criteria Exclusion|0
6027363|NCT00279201|9622938|FG005|Intensification Addendum|Entry Criteria Exclusion|0
6027364|NCT00279201|9622933|FG000|Intensification Addendum|Lack of Efficacy|0
6027365|NCT00279201|9622934|FG001|Intensification Addendum|Lack of Efficacy|0
6027366|NCT00279201|9622935|FG002|Intensification Addendum|Lack of Efficacy|0
6027367|NCT00279201|9622936|FG003|Intensification Addendum|Lack of Efficacy|1
6027368|NCT00279201|9622937|FG004|Intensification Addendum|Lack of Efficacy|1
6027369|NCT00279201|9622938|FG005|Intensification Addendum|Lack of Efficacy|0
6027370|NCT00279201|9622933|FG000|Intensification Addendum|Death|0
6027371|NCT00279201|9622934|FG001|Intensification Addendum|Death|0
6027372|NCT00279201|9622935|FG002|Intensification Addendum|Death|0
6027373|NCT00279201|9622936|FG003|Intensification Addendum|Death|0
6027374|NCT00279201|9622937|FG004|Intensification Addendum|Death|1
6027375|NCT00279201|9622938|FG005|Intensification Addendum|Death|0
6027376|NCT00279214|9622973|FG000|Overall Study|Physician Decision|3
6027377|NCT00279214|9622974|FG001|Overall Study|Physician Decision|2
6027378|NCT00279305|9622982|FG000|Overall Study|Pregnancy|1
6027379|NCT00279305|9622983|FG001|Overall Study|Pregnancy|0
6027380|NCT00279305|9622982|FG000|Overall Study|Withdrawal by Subject|2
6027381|NCT00279305|9622983|FG001|Overall Study|Withdrawal by Subject|0
6027382|NCT00279305|9622982|FG000|Overall Study|Dificulting establishing IV|1
6027383|NCT00279305|9622983|FG001|Overall Study|Dificulting establishing IV|0
6027384|NCT00279305|9622982|FG000|Overall Study|FDA Safety Alert|4
6027385|NCT00279305|9622983|FG001|Overall Study|FDA Safety Alert|1
6027386|NCT00279708|9623006|FG000|Overall Study|Withdrawal by Subject|2
6027387|NCT00279708|9623007|FG001|Overall Study|Withdrawal by Subject|3
6027388|NCT00279708|9623006|FG000|Overall Study|Adverse Event|1
6027389|NCT00279708|9623007|FG001|Overall Study|Adverse Event|1
6027390|NCT00279812|9623019|FG000|Overall Study|Protocol Violation|1
6027391|NCT00279812|9623020|FG001|Overall Study|Protocol Violation|1
6027392|NCT00279812|9623021|FG002|Overall Study|Protocol Violation|0
6027393|NCT00279812|9623022|FG003|Overall Study|Protocol Violation|0
6027394|NCT00279812|9623023|FG004|Overall Study|Protocol Violation|1
6027395|NCT00279812|9623024|FG005|Overall Study|Protocol Violation|0
6027396|NCT00279812|9623019|FG000|Overall Study|Withdrawal by Subject|0
6027397|NCT00279812|9623020|FG001|Overall Study|Withdrawal by Subject|4
6027398|NCT00279812|9623021|FG002|Overall Study|Withdrawal by Subject|2
6027399|NCT00279812|9623022|FG003|Overall Study|Withdrawal by Subject|0
6027400|NCT00279812|9623023|FG004|Overall Study|Withdrawal by Subject|0
6027401|NCT00279812|9623024|FG005|Overall Study|Withdrawal by Subject|0
6027402|NCT00279812|9623019|FG000|Overall Study|Adverse Event|0
6027403|NCT00279812|9623020|FG001|Overall Study|Adverse Event|1
6027404|NCT00279812|9623021|FG002|Overall Study|Adverse Event|1
6027405|NCT00279812|9623022|FG003|Overall Study|Adverse Event|0
6027406|NCT00279812|9623023|FG004|Overall Study|Adverse Event|2
6027407|NCT00279812|9623024|FG005|Overall Study|Adverse Event|1
6027408|NCT00279916|9623040|FG000|Overall Study|Withdrawal by Subject|4
6027409|NCT00279916|9623041|FG001|Overall Study|Withdrawal by Subject|3
6027410|NCT00279916|9623040|FG000|Overall Study|Lost to Follow-up|3
6027411|NCT00279916|9623041|FG001|Overall Study|Lost to Follow-up|2
6027412|NCT00280059|9623061|FG000|Efficacy Assessment Phase|Death|2
6027413|NCT00280059|9623062|FG001|Efficacy Assessment Phase|Death|0
6027414|NCT00280059|9623061|FG000|Efficacy Assessment Phase|Adverse Event|33
6027415|NCT00280059|9623062|FG001|Efficacy Assessment Phase|Adverse Event|31
6027416|NCT00280059|9623061|FG000|Efficacy Assessment Phase|Laboratory abnormaility|1
6027417|NCT00280059|9623062|FG001|Efficacy Assessment Phase|Laboratory abnormaility|0
6027418|NCT00280059|9623061|FG000|Efficacy Assessment Phase|Lack of Efficacy|19
6027419|NCT00280059|9623062|FG001|Efficacy Assessment Phase|Lack of Efficacy|3
6027420|NCT00280059|9623061|FG000|Efficacy Assessment Phase|Lost to Follow-up|6
6027421|NCT00280059|9623062|FG001|Efficacy Assessment Phase|Lost to Follow-up|13
6027422|NCT00280059|9623061|FG000|Efficacy Assessment Phase|Other|7
6027423|NCT00280059|9623062|FG001|Efficacy Assessment Phase|Other|8
6027424|NCT00280059|9623061|FG000|Efficacy Assessment Phase|Withdrawal by Subject|26
6027425|NCT00280059|9623062|FG001|Efficacy Assessment Phase|Withdrawal by Subject|25
6027426|NCT00280150|9623080|FG000|Overall Study|Adverse Event|0
6027427|NCT00280150|9623081|FG001|Overall Study|Adverse Event|1
6027428|NCT00280150|9623082|FG002|Overall Study|Adverse Event|2
6027429|NCT00280150|9623083|FG003|Overall Study|Adverse Event|3
6027430|NCT00280150|9623080|FG000|Overall Study|Lack of Efficacy|0
6027431|NCT00280150|9623081|FG001|Overall Study|Lack of Efficacy|0
6027432|NCT00280150|9623082|FG002|Overall Study|Lack of Efficacy|0
6027433|NCT00280150|9623083|FG003|Overall Study|Lack of Efficacy|3
6027434|NCT00280150|9623080|FG000|Overall Study|Physician Decision|0
6027435|NCT00280150|9623081|FG001|Overall Study|Physician Decision|0
6027436|NCT00280150|9623082|FG002|Overall Study|Physician Decision|0
6027437|NCT00280150|9623083|FG003|Overall Study|Physician Decision|1
6027438|NCT00280150|9623080|FG000|Overall Study|Protocol Violation|0
6027439|NCT00280150|9623081|FG001|Overall Study|Protocol Violation|0
6027440|NCT00280150|9623082|FG002|Overall Study|Protocol Violation|0
6027441|NCT00280150|9623083|FG003|Overall Study|Protocol Violation|1
6027442|NCT00280150|9623080|FG000|Overall Study|Withdrawal by Subject|0
6027443|NCT00280150|9623081|FG001|Overall Study|Withdrawal by Subject|0
6027444|NCT00280150|9623082|FG002|Overall Study|Withdrawal by Subject|0
6027445|NCT00280150|9623083|FG003|Overall Study|Withdrawal by Subject|1
6027446|NCT00280150|9623080|FG000|Overall Study|Did not get consolidation therapy|3
6027447|NCT00280150|9623081|FG001|Overall Study|Did not get consolidation therapy|0
6027448|NCT00280150|9623082|FG002|Overall Study|Did not get consolidation therapy|3
6027449|NCT00280150|9623083|FG003|Overall Study|Did not get consolidation therapy|0
6027450|NCT00280150|9623080|FG000|Overall Study|Declining Performance Status|0
6027451|NCT00280150|9623081|FG001|Overall Study|Declining Performance Status|0
6027452|NCT00280150|9623082|FG002|Overall Study|Declining Performance Status|0
6027453|NCT00280150|9623083|FG003|Overall Study|Declining Performance Status|1
6027454|NCT00280293|9623100|FG000|Overall Study|Protocol Violation|3
6027455|NCT00280293|9623101|FG001|Overall Study|Protocol Violation|0
6027456|NCT00280293|9623100|FG000|Overall Study|Physician Decision|5
6027457|NCT00280293|9623101|FG001|Overall Study|Physician Decision|4
6027458|NCT00280293|9623100|FG000|Overall Study|Lost to Follow-up|14
6027459|NCT00280293|9623101|FG001|Overall Study|Lost to Follow-up|12
6027460|NCT00280293|9623100|FG000|Overall Study|Withdrawal by Subject|3
6027461|NCT00280293|9623101|FG001|Overall Study|Withdrawal by Subject|5
6027462|NCT00280293|9623100|FG000|Overall Study|Incarceration/Legal Reasons|1
6027463|NCT00280293|9623101|FG001|Overall Study|Incarceration/Legal Reasons|1
6027464|NCT00280293|9623100|FG000|Overall Study|Adverse Event|0
6027465|NCT00280293|9623101|FG001|Overall Study|Adverse Event|1
6027466|NCT00280397|9623140|FG000|Overall Study|Adverse Event|1
6027467|NCT00280566|9623148|FG000|Period 1 Open Label Ziprasidone|Lack of Efficacy|31
6027468|NCT00280566|9623149|FG001|Period 1 Open Label Ziprasidone|Lack of Efficacy|0
6027469|NCT00280566|9623150|FG002|Period 1 Open Label Ziprasidone|Lack of Efficacy|0
6027470|NCT00280566|9623148|FG000|Period 1 Open Label Ziprasidone|Laboratory Abnormality|3
6027471|NCT00280566|9623149|FG001|Period 1 Open Label Ziprasidone|Laboratory Abnormality|0
6027472|NCT00280566|9623150|FG002|Period 1 Open Label Ziprasidone|Laboratory Abnormality|0
6027473|NCT00280566|9623148|FG000|Period 1 Open Label Ziprasidone|Adverse Event|148
6027474|NCT00280566|9623149|FG001|Period 1 Open Label Ziprasidone|Adverse Event|0
6027475|NCT00280566|9623150|FG002|Period 1 Open Label Ziprasidone|Adverse Event|0
6027476|NCT00280566|9623148|FG000|Period 1 Open Label Ziprasidone|Lost to Follow-up|35
6027477|NCT00280566|9623149|FG001|Period 1 Open Label Ziprasidone|Lost to Follow-up|0
6027478|NCT00280566|9623150|FG002|Period 1 Open Label Ziprasidone|Lost to Follow-up|0
6027479|NCT00280566|9623148|FG000|Period 1 Open Label Ziprasidone|Withdrawal by Subject|76
6027480|NCT00280566|9623149|FG001|Period 1 Open Label Ziprasidone|Withdrawal by Subject|0
6027481|NCT00280566|9623150|FG002|Period 1 Open Label Ziprasidone|Withdrawal by Subject|0
6027482|NCT00280566|9623148|FG000|Period 1 Open Label Ziprasidone|Miscellaneous|50
6027483|NCT00280566|9623149|FG001|Period 1 Open Label Ziprasidone|Miscellaneous|0
6027484|NCT00280566|9623150|FG002|Period 1 Open Label Ziprasidone|Miscellaneous|0
6027485|NCT00280566|9623148|FG000|Period 2 Double Blind|Lack of Efficacy|0
6027486|NCT00280566|9623149|FG001|Period 2 Double Blind|Lack of Efficacy|9
6027487|NCT00280566|9623150|FG002|Period 2 Double Blind|Lack of Efficacy|22
6027488|NCT00280566|9623148|FG000|Period 2 Double Blind|Laboratory Abnormality|0
6027489|NCT00280566|9623149|FG001|Period 2 Double Blind|Laboratory Abnormality|1
6027490|NCT00280566|9623150|FG002|Period 2 Double Blind|Laboratory Abnormality|0
6027491|NCT00280566|9623148|FG000|Period 2 Double Blind|Adverse Event|0
6027492|NCT00280566|9623149|FG001|Period 2 Double Blind|Adverse Event|11
6027493|NCT00280566|9623150|FG002|Period 2 Double Blind|Adverse Event|15
6027494|NCT00280566|9623148|FG000|Period 2 Double Blind|Lost to Follow-up|0
6027495|NCT00280566|9623149|FG001|Period 2 Double Blind|Lost to Follow-up|3
6027496|NCT00280566|9623150|FG002|Period 2 Double Blind|Lost to Follow-up|6
6027497|NCT00280566|9623148|FG000|Period 2 Double Blind|Withdrawal by Subject|0
6027498|NCT00280566|9623149|FG001|Period 2 Double Blind|Withdrawal by Subject|9
6027499|NCT00280566|9623150|FG002|Period 2 Double Blind|Withdrawal by Subject|9
6027500|NCT00280566|9623148|FG000|Period 2 Double Blind|miscellaneous|0
6027501|NCT00280566|9623149|FG001|Period 2 Double Blind|miscellaneous|10
6027502|NCT00280566|9623150|FG002|Period 2 Double Blind|miscellaneous|5
6027503|NCT00280683|9623159|FG000|Overall Study|Withdrawal by Subject|1
6027504|NCT00280683|9623160|FG001|Overall Study|Withdrawal by Subject|2
6027505|NCT00280683|9623159|FG000|Overall Study|Adverse Event|1
6027506|NCT00280683|9623160|FG001|Overall Study|Adverse Event|1
6027507|NCT00280735|9623168|FG000|Overall Study|Adverse Event|5
6027508|NCT00280735|9623168|FG000|Overall Study|Lack of Efficacy|3
6027509|NCT00280735|9623168|FG000|Overall Study|Withdrawal by Subject|8
6027510|NCT00280735|9623168|FG000|Overall Study|Intercurrent Illness|2
6027511|NCT00280748|9623176|FG000|Overall Study|Decline in performance|3
6027512|NCT00280748|9623176|FG000|Overall Study|Extra-cranial disease progression|1
6027513|NCT00280917|9623193|FG000|Overall Study|Adverse Event|1
6027514|NCT00280917|9623194|FG001|Overall Study|Adverse Event|1
6027515|NCT00280917|9623195|FG002|Overall Study|Adverse Event|4
6027516|NCT00280917|9623196|FG003|Overall Study|Adverse Event|1
6027517|NCT00280917|9623193|FG000|Overall Study|Change Therapy|1
6027518|NCT00280917|9623194|FG001|Overall Study|Change Therapy|2
6027519|NCT00280917|9623195|FG002|Overall Study|Change Therapy|0
6027520|NCT00280917|9623196|FG003|Overall Study|Change Therapy|0
6027521|NCT00280917|9623193|FG000|Overall Study|Withdrawal by Subject|0
6027522|NCT00280917|9623194|FG001|Overall Study|Withdrawal by Subject|2
6027523|NCT00280917|9623195|FG002|Overall Study|Withdrawal by Subject|0
6027524|NCT00280917|9623196|FG003|Overall Study|Withdrawal by Subject|1
6027525|NCT00280917|9623193|FG000|Overall Study|Noncompliance|0
6027526|NCT00280917|9623194|FG001|Overall Study|Noncompliance|1
6027527|NCT00280917|9623195|FG002|Overall Study|Noncompliance|2
6027528|NCT00280917|9623196|FG003|Overall Study|Noncompliance|0
6027529|NCT00281099|9623212|FG000|Overall Study|Death|46
6027530|NCT00281099|9623213|FG001|Overall Study|Death|57
6027531|NCT00281099|9623212|FG000|Overall Study|Lost to Follow-up|10
6027532|NCT00281099|9623213|FG001|Overall Study|Lost to Follow-up|19
6027533|NCT00281099|9623212|FG000|Overall Study|Withdrawal by Subject|65
6027534|NCT00281099|9623213|FG001|Overall Study|Withdrawal by Subject|70
6027535|NCT00281099|9623212|FG000|Overall Study|Physician Decision|79
6027536|NCT00281099|9623213|FG001|Overall Study|Physician Decision|72
6027537|NCT00281099|9623212|FG000|Overall Study|Heart Transplant/Device Exit/Changeout|5
6027538|NCT00281099|9623213|FG001|Overall Study|Heart Transplant/Device Exit/Changeout|4
6027539|NCT00281528|9623227|FG000|Overall Study|Progressive Disease|28
6027540|NCT00281528|9623228|FG001|Overall Study|Progressive Disease|18
6027541|NCT00281528|9623229|FG002|Overall Study|Progressive Disease|27
6027542|NCT00281528|9623227|FG000|Overall Study|Unacceptable Toxicity-related to trt|21
6027543|NCT00281528|9623228|FG001|Overall Study|Unacceptable Toxicity-related to trt|24
6027544|NCT00281528|9623229|FG002|Overall Study|Unacceptable Toxicity-related to trt|32
6027545|NCT00281528|9623227|FG000|Overall Study|Adverse Event-unrelated to treatment|3
6027546|NCT00281528|9623228|FG001|Overall Study|Adverse Event-unrelated to treatment|0
6027547|NCT00281528|9623229|FG002|Overall Study|Adverse Event-unrelated to treatment|2
6027548|NCT00281528|9623227|FG000|Overall Study|Physician Decision|11
6027549|NCT00281528|9623228|FG001|Overall Study|Physician Decision|4
6027550|NCT00281528|9623229|FG002|Overall Study|Physician Decision|5
6027551|NCT00281528|9623227|FG000|Overall Study|Protocol Violation|1
6027552|NCT00281528|9623228|FG001|Overall Study|Protocol Violation|0
6027553|NCT00281528|9623229|FG002|Overall Study|Protocol Violation|1
6027554|NCT00281528|9623227|FG000|Overall Study|Withdrawal by Subject|5
6027555|NCT00281528|9623228|FG001|Overall Study|Withdrawal by Subject|5
6027556|NCT00281528|9623229|FG002|Overall Study|Withdrawal by Subject|7
6027557|NCT00281528|9623227|FG000|Overall Study|Other|6
6027558|NCT00281528|9623228|FG001|Overall Study|Other|3
6027559|NCT00281528|9623229|FG002|Overall Study|Other|5
6079228|NCT00607997|9685902|FG001|Overall Study|Physician Decision|1
6027560|NCT00281580|9623253|FG000|Overall Study|Adverse Event|2
6027561|NCT00281580|9623254|FG001|Overall Study|Adverse Event|0
6027562|NCT00281580|9623255|FG002|Overall Study|Adverse Event|2
6027563|NCT00281580|9623256|FG003|Overall Study|Adverse Event|4
6027564|NCT00281580|9623257|FG004|Overall Study|Adverse Event|1
6027565|NCT00281580|9623258|FG005|Overall Study|Adverse Event|0
6027566|NCT00281580|9623259|FG006|Overall Study|Adverse Event|1
6027567|NCT00281580|9623260|FG007|Overall Study|Adverse Event|0
6027568|NCT00281580|9623261|FG008|Overall Study|Adverse Event|1
6027569|NCT00281580|9623262|FG009|Overall Study|Adverse Event|6
6027570|NCT00281580|9623263|FG010|Overall Study|Adverse Event|0
6027571|NCT00281580|9623264|FG011|Overall Study|Adverse Event|5
6027572|NCT00281580|9623265|FG012|Overall Study|Adverse Event|8
6027573|NCT00281580|9623266|FG013|Overall Study|Adverse Event|2
6027574|NCT00281580|9623267|FG014|Overall Study|Adverse Event|3
6027575|NCT00281580|9623268|FG015|Overall Study|Adverse Event|3
6027576|NCT00281580|9623253|FG000|Overall Study|Protocol Violation|0
6027577|NCT00281580|9623254|FG001|Overall Study|Protocol Violation|0
6027578|NCT00281580|9623255|FG002|Overall Study|Protocol Violation|1
6027579|NCT00281580|9623256|FG003|Overall Study|Protocol Violation|1
6027580|NCT00281580|9623257|FG004|Overall Study|Protocol Violation|0
6027581|NCT00281580|9623258|FG005|Overall Study|Protocol Violation|0
6027582|NCT00281580|9623259|FG006|Overall Study|Protocol Violation|1
6027583|NCT00281580|9623260|FG007|Overall Study|Protocol Violation|0
6027584|NCT00281580|9623261|FG008|Overall Study|Protocol Violation|2
6027585|NCT00281580|9623262|FG009|Overall Study|Protocol Violation|0
6027586|NCT00281580|9623263|FG010|Overall Study|Protocol Violation|1
6027587|NCT00281580|9623264|FG011|Overall Study|Protocol Violation|2
6027588|NCT00281580|9623265|FG012|Overall Study|Protocol Violation|0
6027589|NCT00281580|9623266|FG013|Overall Study|Protocol Violation|1
6027590|NCT00281580|9623267|FG014|Overall Study|Protocol Violation|1
6027591|NCT00281580|9623268|FG015|Overall Study|Protocol Violation|3
6027592|NCT00281580|9623253|FG000|Overall Study|Withdrawal by Subject|3
6027593|NCT00281580|9623254|FG001|Overall Study|Withdrawal by Subject|0
6027594|NCT00281580|9623255|FG002|Overall Study|Withdrawal by Subject|1
6027595|NCT00281580|9623256|FG003|Overall Study|Withdrawal by Subject|1
6027596|NCT00281580|9623257|FG004|Overall Study|Withdrawal by Subject|1
6027597|NCT00281580|9623258|FG005|Overall Study|Withdrawal by Subject|2
6027598|NCT00281580|9623259|FG006|Overall Study|Withdrawal by Subject|2
6027599|NCT00281580|9623260|FG007|Overall Study|Withdrawal by Subject|0
6027600|NCT00281580|9623261|FG008|Overall Study|Withdrawal by Subject|1
6027601|NCT00281580|9623262|FG009|Overall Study|Withdrawal by Subject|4
6027602|NCT00281580|9623263|FG010|Overall Study|Withdrawal by Subject|1
6027603|NCT00281580|9623264|FG011|Overall Study|Withdrawal by Subject|1
6027604|NCT00281580|9623265|FG012|Overall Study|Withdrawal by Subject|2
6027605|NCT00281580|9623266|FG013|Overall Study|Withdrawal by Subject|2
6027606|NCT00281580|9623267|FG014|Overall Study|Withdrawal by Subject|1
6027607|NCT00281580|9623268|FG015|Overall Study|Withdrawal by Subject|5
6027608|NCT00281580|9623253|FG000|Overall Study|Lack of Efficacy|2
6027609|NCT00281580|9623254|FG001|Overall Study|Lack of Efficacy|1
6027610|NCT00281580|9623255|FG002|Overall Study|Lack of Efficacy|1
6027611|NCT00281580|9623256|FG003|Overall Study|Lack of Efficacy|6
6027612|NCT00281580|9623257|FG004|Overall Study|Lack of Efficacy|2
6027613|NCT00281580|9623258|FG005|Overall Study|Lack of Efficacy|0
6027614|NCT00281580|9623259|FG006|Overall Study|Lack of Efficacy|0
6027615|NCT00281580|9623260|FG007|Overall Study|Lack of Efficacy|0
6027616|NCT00281580|9623261|FG008|Overall Study|Lack of Efficacy|0
6027617|NCT00281580|9623262|FG009|Overall Study|Lack of Efficacy|0
6027618|NCT00281580|9623263|FG010|Overall Study|Lack of Efficacy|0
6027619|NCT00281580|9623264|FG011|Overall Study|Lack of Efficacy|1
6027620|NCT00281580|9623265|FG012|Overall Study|Lack of Efficacy|0
6027621|NCT00281580|9623266|FG013|Overall Study|Lack of Efficacy|2
6027622|NCT00281580|9623267|FG014|Overall Study|Lack of Efficacy|1
6027623|NCT00281580|9623268|FG015|Overall Study|Lack of Efficacy|0
6027624|NCT00281580|9623253|FG000|Overall Study|Lost to Follow-up|0
6027625|NCT00281580|9623254|FG001|Overall Study|Lost to Follow-up|0
6027626|NCT00281580|9623255|FG002|Overall Study|Lost to Follow-up|0
6027627|NCT00281580|9623256|FG003|Overall Study|Lost to Follow-up|3
6027628|NCT00281580|9623257|FG004|Overall Study|Lost to Follow-up|0
6027629|NCT00281580|9623258|FG005|Overall Study|Lost to Follow-up|1
6027630|NCT00281580|9623259|FG006|Overall Study|Lost to Follow-up|0
6027631|NCT00281580|9623260|FG007|Overall Study|Lost to Follow-up|1
6027632|NCT00281580|9623261|FG008|Overall Study|Lost to Follow-up|2
6027633|NCT00281580|9623262|FG009|Overall Study|Lost to Follow-up|1
6027634|NCT00281580|9623263|FG010|Overall Study|Lost to Follow-up|1
6027635|NCT00281580|9623264|FG011|Overall Study|Lost to Follow-up|0
6027636|NCT00281580|9623265|FG012|Overall Study|Lost to Follow-up|1
6027637|NCT00281580|9623266|FG013|Overall Study|Lost to Follow-up|0
6027638|NCT00281580|9623267|FG014|Overall Study|Lost to Follow-up|0
6027639|NCT00281580|9623268|FG015|Overall Study|Lost to Follow-up|0
6309531|NCT02640235|10038207|FG000|Overall Study|Death|2
6309532|NCT02640235|10038208|FG001|Overall Study|Death|3
6309533|NCT02640235|10038207|FG000|Overall Study|Other|1
6309534|NCT02640235|10038208|FG001|Overall Study|Other|2
6309535|NCT02640404|10038216|FG000|Overall Study|Protocol Violation|1
6309536|NCT02640404|10038217|FG001|Overall Study|Protocol Violation|0
6027640|NCT00281580|9623253|FG000|Overall Study|Randomised in error; pregnancy; moving|0
6027641|NCT00281580|9623254|FG001|Overall Study|Randomised in error; pregnancy; moving|0
6027642|NCT00281580|9623255|FG002|Overall Study|Randomised in error; pregnancy; moving|0
6027643|NCT00281580|9623256|FG003|Overall Study|Randomised in error; pregnancy; moving|2
6027644|NCT00281580|9623257|FG004|Overall Study|Randomised in error; pregnancy; moving|0
6027645|NCT00281580|9623258|FG005|Overall Study|Randomised in error; pregnancy; moving|0
6027646|NCT00281580|9623259|FG006|Overall Study|Randomised in error; pregnancy; moving|1
6027647|NCT00281580|9623260|FG007|Overall Study|Randomised in error; pregnancy; moving|0
6027648|NCT00281580|9623261|FG008|Overall Study|Randomised in error; pregnancy; moving|2
6027649|NCT00281580|9623262|FG009|Overall Study|Randomised in error; pregnancy; moving|1
6027650|NCT00281580|9623263|FG010|Overall Study|Randomised in error; pregnancy; moving|1
6309537|NCT02640404|10038216|FG000|Overall Study|Withdrawal by Subject|1
6027651|NCT00281580|9623264|FG011|Overall Study|Randomised in error; pregnancy; moving|1
6309538|NCT02640404|10038217|FG001|Overall Study|Withdrawal by Subject|0
6027652|NCT00281580|9623265|FG012|Overall Study|Randomised in error; pregnancy; moving|2
6027653|NCT00281580|9623266|FG013|Overall Study|Randomised in error; pregnancy; moving|0
6027654|NCT00281580|9623267|FG014|Overall Study|Randomised in error; pregnancy; moving|1
6027655|NCT00281580|9623268|FG015|Overall Study|Randomised in error; pregnancy; moving|2
6027656|NCT00281632|9623337|FG000|Overall Study|Adverse Event|7
6027657|NCT00281632|9623337|FG000|Overall Study|Withdrawal by Subject|2
6027658|NCT00281632|9623337|FG000|Overall Study|Disease Progression|22
6027659|NCT00281632|9623337|FG000|Overall Study|Death|1
6027660|NCT00281632|9623337|FG000|Overall Study|Physician Decision|1
6027661|NCT00281632|9623337|FG000|Overall Study|Ongoing|3
6027662|NCT00281684|9623363|FG000|Overall Study|Lost to Follow-up|0
6027663|NCT00281684|9623364|FG001|Overall Study|Lost to Follow-up|0
6027664|NCT00281684|9623365|FG002|Overall Study|Lost to Follow-up|1
6027665|NCT00281684|9623366|FG003|Overall Study|Lost to Follow-up|0
6027666|NCT00281684|9623363|FG000|Overall Study|Withdrawal by Subject|1
6027667|NCT00281684|9623364|FG001|Overall Study|Withdrawal by Subject|0
6027668|NCT00281684|9623365|FG002|Overall Study|Withdrawal by Subject|0
6027669|NCT00281684|9623366|FG003|Overall Study|Withdrawal by Subject|0
6027670|NCT00281697|9623380|FG000|Overall Study|> 60 days since last dose of study drug|4
6027671|NCT00281697|9623381|FG001|Overall Study|> 60 days since last dose of study drug|4
6027672|NCT00281697|9623380|FG000|Overall Study|Adverse Event|54
6027673|NCT00281697|9623381|FG001|Overall Study|Adverse Event|15
6027674|NCT00281697|9623380|FG000|Overall Study|Death|8
6027675|NCT00281697|9623381|FG001|Overall Study|Death|3
6027676|NCT00281697|9623380|FG000|Overall Study|Disease progression|279
6027677|NCT00281697|9623381|FG001|Overall Study|Disease progression|149
6027678|NCT00281697|9623380|FG000|Overall Study|Other|5
6027679|NCT00281697|9623381|FG001|Overall Study|Other|6
6027680|NCT00281697|9623380|FG000|Overall Study|Physician's decision to withdraw|15
6027681|NCT00281697|9623381|FG001|Overall Study|Physician's decision to withdraw|12
6027682|NCT00281697|9623380|FG000|Overall Study|Subject/guardian's decision to withdraw|33
6027683|NCT00281697|9623381|FG001|Overall Study|Subject/guardian's decision to withdraw|6
6027684|NCT00281697|9623380|FG000|Overall Study|Did not receive study drug|3
6027685|NCT00281697|9623381|FG001|Overall Study|Did not receive study drug|2
6027686|NCT00281840|9623393|FG000|Overall Study|Adverse Event|12
6027687|NCT00281840|9623393|FG000|Overall Study|Physician Decision|6
6027688|NCT00281840|9623393|FG000|Overall Study|Withdrawal by Subject|3
6027689|NCT00281840|9623393|FG000|Overall Study|Disease Progression|2
6027690|NCT00281840|9623393|FG000|Overall Study|exceed maximum delay in treatment|1
6027691|NCT00281840|9623393|FG000|Overall Study|Complicating Disease|1
6027692|NCT00281957|9623409|FG000|Overall Study|Adverse Event|7
6027693|NCT00281957|9623410|FG001|Overall Study|Adverse Event|2
6027694|NCT00281957|9623409|FG000|Overall Study|Death|1
6027695|NCT00281957|9623410|FG001|Overall Study|Death|0
6027696|NCT00281957|9623409|FG000|Overall Study|Progression/relapse|47
6027697|NCT00281957|9623410|FG001|Overall Study|Progression/relapse|35
6027698|NCT00281957|9623409|FG000|Overall Study|Not protocol specified|8
6027699|NCT00281957|9623410|FG001|Overall Study|Not protocol specified|1
6027700|NCT00281957|9623409|FG000|Overall Study|Not eligible|1
6027701|NCT00281957|9623410|FG001|Overall Study|Not eligible|2
6027702|NCT00281957|9623409|FG000|Overall Study|Did not start treatment|3
6027703|NCT00281957|9623410|FG001|Overall Study|Did not start treatment|1
6027704|NCT00281957|9623409|FG000|Overall Study|Refusal unrelated to adverse events|0
6027705|NCT00281957|9623410|FG001|Overall Study|Refusal unrelated to adverse events|1
6027706|NCT00282048|9623418|FG000|Overall Study|Lack of Efficacy|30
6027707|NCT00282048|9623418|FG000|Overall Study|Adverse Event|22
6027708|NCT00282048|9623418|FG000|Overall Study|Withdrawal by Subject|1
6027709|NCT00282048|9623418|FG000|Overall Study|Other|8
6027710|NCT00282048|9623418|FG000|Overall Study|Ongoing|1
6027711|NCT00282087|9623422|FG000|Overall Study|Death|1
6027712|NCT00282113|9623430|FG000|Overall Study|Removed at parents request|1
6027713|NCT00282113|9623431|FG001|Overall Study|Removed at parents request|0
6027714|NCT00282113|9623432|FG002|Overall Study|Removed at parents request|0
6027715|NCT00282152|9623442|FG000|Overall Study|Withdrawal by Subject|1
6027716|NCT00282152|9623443|FG001|Overall Study|Withdrawal by Subject|0
6027717|NCT00282243|9623450|FG000|Pharmacokinetic Treatment Period|Adverse Event|3
6027718|NCT00282243|9623450|FG000|Pharmacokinetic Treatment Period|Withdrawal by Subject|2
6027719|NCT00282243|9623450|FG000|Extension Treatment Period|Adverse Event|15
6027720|NCT00282243|9623450|FG000|Extension Treatment Period|Withdrawal by Subject|4
6027721|NCT00282243|9623450|FG000|Extension Treatment Period|Non-compliance|2
6027722|NCT00282243|9623450|FG000|Extension Treatment Period|Physician Decision|1
6027723|NCT00282256|9623454|FG000|Pharmacokinetic Treatment Period|Poor venous access|1
6027724|NCT00282256|9623454|FG000|Extension Treatment Period|Adverse Event|2
6027725|NCT00282295|9623466|FG000|Overall Study|Adverse Event|0
6027726|NCT00282295|9623467|FG001|Overall Study|Adverse Event|1
6027727|NCT00282295|9623468|FG002|Overall Study|Adverse Event|0
6027728|NCT00282295|9623466|FG000|Overall Study|Serious Adverse Events|0
6027729|NCT00282295|9623467|FG001|Overall Study|Serious Adverse Events|0
6027730|NCT00282295|9623468|FG002|Overall Study|Serious Adverse Events|1
6027731|NCT00282295|9623466|FG000|Overall Study|Protocol Violation|0
6027732|NCT00282295|9623467|FG001|Overall Study|Protocol Violation|2
6027733|NCT00282295|9623468|FG002|Overall Study|Protocol Violation|1
6027734|NCT00282295|9623466|FG000|Overall Study|Withdrawal by Subject|2
6027735|NCT00282295|9623467|FG001|Overall Study|Withdrawal by Subject|6
6027736|NCT00282295|9623468|FG002|Overall Study|Withdrawal by Subject|4
6027737|NCT00282295|9623466|FG000|Overall Study|Lost to Follow-up|1
6027738|NCT00282295|9623467|FG001|Overall Study|Lost to Follow-up|7
6027739|NCT00282295|9623468|FG002|Overall Study|Lost to Follow-up|2
6027740|NCT00282295|9623466|FG000|Overall Study|Other|0
6027741|NCT00282295|9623467|FG001|Overall Study|Other|1
6027742|NCT00282295|9623468|FG002|Overall Study|Other|0
6027743|NCT00282308|9623483|FG000|Treatment Period|Lost to Follow-up|1
6027744|NCT00282308|9623484|FG001|Treatment Period|Lost to Follow-up|0
6027745|NCT00282308|9623485|FG002|Treatment Period|Lost to Follow-up|0
6027746|NCT00282308|9623483|FG000|Treatment Period|Subject/Guardian Decision to Withdraw|2
6027747|NCT00282308|9623484|FG001|Treatment Period|Subject/Guardian Decision to Withdraw|4
6027748|NCT00282308|9623485|FG002|Treatment Period|Subject/Guardian Decision to Withdraw|0
6027749|NCT00282308|9623483|FG000|Treatment Period|Adverse Event|0
6027750|NCT00282308|9623484|FG001|Treatment Period|Adverse Event|2
6027751|NCT00282308|9623485|FG002|Treatment Period|Adverse Event|0
6027752|NCT00282308|9623483|FG000|Treatment Period|Not Treated with Study Drug|1
6027753|NCT00282308|9623484|FG001|Treatment Period|Not Treated with Study Drug|0
6027754|NCT00282308|9623485|FG002|Treatment Period|Not Treated with Study Drug|0
6027755|NCT00282308|9623483|FG000|Optional Extension Re-treatment Period|Adverse Event|0
6027756|NCT00282308|9623484|FG001|Optional Extension Re-treatment Period|Adverse Event|0
6027757|NCT00282308|9623485|FG002|Optional Extension Re-treatment Period|Adverse Event|4
6027758|NCT00282308|9623483|FG000|Optional Extension Re-treatment Period|Physician's Decision to Withdraw|0
6027759|NCT00282308|9623484|FG001|Optional Extension Re-treatment Period|Physician's Decision to Withdraw|0
6027760|NCT00282308|9623485|FG002|Optional Extension Re-treatment Period|Physician's Decision to Withdraw|1
6027761|NCT00282308|9623483|FG000|Optional Extension Re-treatment Period|Subject/Guardian Decision to Withdraw|0
6027762|NCT00282308|9623484|FG001|Optional Extension Re-treatment Period|Subject/Guardian Decision to Withdraw|0
6027763|NCT00282308|9623485|FG002|Optional Extension Re-treatment Period|Subject/Guardian Decision to Withdraw|1
6027764|NCT00282308|9623483|FG000|Safety Follow-up Period|Adverse Event|0
6027765|NCT00282308|9623484|FG001|Safety Follow-up Period|Adverse Event|0
6027766|NCT00282308|9623485|FG002|Safety Follow-up Period|Adverse Event|1
6079229|NCT00607997|9685903|FG002|Overall Study|Physician Decision|0
6079230|NCT00607997|9685904|FG003|Overall Study|Physician Decision|0
6079231|NCT00607997|9685901|FG000|Overall Study|Relapse, recurrent illness|4
6079232|NCT00607997|9685902|FG001|Overall Study|Relapse, recurrent illness|0
6079233|NCT00607997|9685903|FG002|Overall Study|Relapse, recurrent illness|2
6079234|NCT00607997|9685904|FG003|Overall Study|Relapse, recurrent illness|0
6079235|NCT00607997|9685901|FG000|Overall Study|Other without explanation|2
6027767|NCT00282308|9623483|FG000|Safety Follow-up Period|Lost to Follow-up|0
6027768|NCT00282308|9623484|FG001|Safety Follow-up Period|Lost to Follow-up|0
6027769|NCT00282308|9623485|FG002|Safety Follow-up Period|Lost to Follow-up|5
6027770|NCT00282308|9623483|FG000|Safety Follow-up Period|Physician Decision to Withdraw|0
6027771|NCT00282308|9623484|FG001|Safety Follow-up Period|Physician Decision to Withdraw|0
6027772|NCT00282308|9623485|FG002|Safety Follow-up Period|Physician Decision to Withdraw|1
6027773|NCT00282308|9623483|FG000|Safety Follow-up Period|Subject/Guardian Decision to Withdraw|0
6027774|NCT00282308|9623484|FG001|Safety Follow-up Period|Subject/Guardian Decision to Withdraw|0
6027775|NCT00282308|9623485|FG002|Safety Follow-up Period|Subject/Guardian Decision to Withdraw|12
6027776|NCT00282334|9623497|FG000|Overall Study|Withdrawal by Subject|8
6027777|NCT00282334|9623498|FG001|Overall Study|Withdrawal by Subject|5
6027778|NCT00282347|9623506|FG000|Treatment Period|Death|2
6027779|NCT00282347|9623507|FG001|Treatment Period|Death|0
6027780|NCT00282347|9623506|FG000|Treatment Period|Lost to Follow-up|2
6027781|NCT00282347|9623507|FG001|Treatment Period|Lost to Follow-up|5
6027782|NCT00282347|9623506|FG000|Treatment Period|Withdrawal by Subject|1
6027783|NCT00282347|9623507|FG001|Treatment Period|Withdrawal by Subject|3
6027784|NCT00282347|9623506|FG000|Treatment Period|Physician Decision|0
6027785|NCT00282347|9623507|FG001|Treatment Period|Physician Decision|1
6027786|NCT00282347|9623506|FG000|Safety Follow-up Period|Lost to Follow-up|0
6027787|NCT00282347|9623507|FG001|Safety Follow-up Period|Lost to Follow-up|2
6027788|NCT00282347|9623506|FG000|Safety Follow-up Period|Withdrawal by Subject|2
6027789|NCT00282347|9623507|FG001|Safety Follow-up Period|Withdrawal by Subject|1
6027790|NCT00282347|9623506|FG000|Safety Follow-up Period|Physician Decision|1
6027791|NCT00282347|9623507|FG001|Safety Follow-up Period|Physician Decision|1
6027792|NCT00282347|9623506|FG000|Safety Follow-up Period|Protocol Deviation|0
6027793|NCT00282347|9623507|FG001|Safety Follow-up Period|Protocol Deviation|2
6027794|NCT00282347|9623506|FG000|B Cell Follow-up Period|Withdrawal by Subject|2
6027795|NCT00282347|9623507|FG001|B Cell Follow-up Period|Withdrawal by Subject|0
6027796|NCT00282347|9623506|FG000|B Cell Follow-up Period|Physician Decision|1
6027797|NCT00282347|9623507|FG001|B Cell Follow-up Period|Physician Decision|0
6027798|NCT00282347|9623506|FG000|B Cell Follow-up Period|Reason Not Specified|2
6079236|NCT00607997|9685902|FG001|Overall Study|Other without explanation|0
6027799|NCT00282347|9623507|FG001|B Cell Follow-up Period|Reason Not Specified|0
6027800|NCT00282412|9623515|FG000|Overall Study|Death|2
6027801|NCT00282438|9623521|FG000|Overall Study|Lack of Efficacy|1
6079237|NCT00607997|9685903|FG002|Overall Study|Other without explanation|4
6027802|NCT00282438|9623522|FG001|Overall Study|Lack of Efficacy|0
6027803|NCT00282438|9623521|FG000|Overall Study|Death|0
6027804|NCT00282438|9623522|FG001|Overall Study|Death|1
6027805|NCT00282464|9623530|FG000|Overall Study|Adverse Event|26
6027806|NCT00282464|9623531|FG001|Overall Study|Adverse Event|20
6027807|NCT00282464|9623530|FG000|Overall Study|Lack of Efficacy|8
6027808|NCT00282464|9623531|FG001|Overall Study|Lack of Efficacy|8
6027809|NCT00282464|9623530|FG000|Overall Study|Lost to Follow-up|10
6027810|NCT00282464|9623531|FG001|Overall Study|Lost to Follow-up|10
6027811|NCT00282464|9623530|FG000|Overall Study|Withdrawal by Subject|24
6027812|NCT00282464|9623531|FG001|Overall Study|Withdrawal by Subject|10
6027813|NCT00282464|9623530|FG000|Overall Study|laboratory abnormality|1
6027814|NCT00282464|9623531|FG001|Overall Study|laboratory abnormality|2
6027815|NCT00282464|9623530|FG000|Overall Study|Protocol Violation|0
6027816|NCT00282464|9623531|FG001|Overall Study|Protocol Violation|7
6027817|NCT00282464|9623530|FG000|Overall Study|Patient moved|1
6027818|NCT00282464|9623531|FG001|Overall Study|Patient moved|0
6027819|NCT00282464|9623530|FG000|Overall Study|patient non-compliant|3
6027820|NCT00282464|9623531|FG001|Overall Study|patient non-compliant|0
6027821|NCT00282464|9623530|FG000|Overall Study|patient no show|0
6027822|NCT00282464|9623531|FG001|Overall Study|patient no show|1
6027823|NCT00282464|9623530|FG000|Overall Study|patient incarcerated|0
6079238|NCT00607997|9685904|FG003|Overall Study|Other without explanation|1
6079239|NCT00608205|9685966|FG000|Overall Study|Adverse Event|3
6079240|NCT00608205|9685967|FG001|Overall Study|Adverse Event|2
6079241|NCT00608205|9685966|FG000|Overall Study|Patient non-compliant|0
6079242|NCT00608205|9685967|FG001|Overall Study|Patient non-compliant|1
6079243|NCT00608244|9685975|FG000|Overall Study|Adverse Event|1
6079244|NCT00608244|9685975|FG000|Overall Study|Low trough levels|1
6079245|NCT00608322|9685983|FG000|Overall Study|Death|2
6079246|NCT00608322|9685984|FG001|Overall Study|Death|1
6079247|NCT00608426|9685992|FG000|Overall Study|Death|32
6079248|NCT00608426|9685993|FG001|Overall Study|Death|36
6079249|NCT00608426|9685992|FG000|Overall Study|Lost to Follow-up|485
6079250|NCT00608426|9685993|FG001|Overall Study|Lost to Follow-up|521
6079251|NCT00608426|9685992|FG000|Overall Study|refused, health issues, wrong address|319
6079252|NCT00608426|9685993|FG001|Overall Study|refused, health issues, wrong address|348
6079253|NCT00608517|9686011|FG000|Overall Study|Death|1
6079254|NCT00608517|9686012|FG001|Overall Study|Death|0
6079255|NCT00608517|9686013|FG002|Overall Study|Death|0
6079256|NCT00608530|9686026|FG000|Study 1 Psychologist-delivered Treatment|Withdrawal by Subject|11
6079257|NCT00608530|9686027|FG001|Study 1 Psychologist-delivered Treatment|Withdrawal by Subject|5
6079258|NCT00608530|9686028|FG002|Study 1 Psychologist-delivered Treatment|Withdrawal by Subject|0
6079259|NCT00608530|9686029|FG003|Study 1 Psychologist-delivered Treatment|Withdrawal by Subject|0
6079260|NCT00608530|9686026|FG000|Study 2 Nurse-delivered Treatments|Withdrawal by Subject|0
6079261|NCT00608530|9686027|FG001|Study 2 Nurse-delivered Treatments|Withdrawal by Subject|0
6079262|NCT00608530|9686028|FG002|Study 2 Nurse-delivered Treatments|Withdrawal by Subject|3
6079263|NCT00608530|9686029|FG003|Study 2 Nurse-delivered Treatments|Withdrawal by Subject|3
6079264|NCT00608530|9686026|FG000|Study 2 Nurse-delivered Treatments|Lack of Efficacy|0
6027824|NCT00282464|9623531|FG001|Overall Study|patient incarcerated|1
6027825|NCT00282464|9623530|FG000|Overall Study|family crisis|0
6027826|NCT00282464|9623531|FG001|Overall Study|family crisis|1
6027827|NCT00282464|9623530|FG000|Overall Study|dispensed wrong kit|0
6027828|NCT00282464|9623531|FG001|Overall Study|dispensed wrong kit|1
6027829|NCT00282464|9623530|FG000|Overall Study|dropped due to missed visits|0
6027830|NCT00282464|9623531|FG001|Overall Study|dropped due to missed visits|1
6027831|NCT00282568|9623537|FG000|Pharmacokinetic Treatment Period|Discontinued prior to Day 1|2
6027832|NCT00282568|9623537|FG000|Pharmacokinetic Treatment Period|Enrolled erroneously|1
6027833|NCT00282568|9623537|FG000|Extended Treatment Period|Adverse Event|17
6027834|NCT00282568|9623537|FG000|Extended Treatment Period|Non-compliance|4
6027835|NCT00282568|9623537|FG000|Extended Treatment Period|Physician Decision|1
6027836|NCT00282568|9623537|FG000|Extended Treatment Period|Lost to Follow-up|2
6027837|NCT00282919|9623612|FG000|Overall Study|Lack of Efficacy|4
6027838|NCT00282919|9623612|FG000|Overall Study|Withdrawal by Subject|1
6027839|NCT00282919|9623612|FG000|Overall Study|Asymptomatic Parasitemia|2
6027840|NCT00282984|9623627|FG000|Overall Study|Death|2
6027841|NCT00282984|9623628|FG001|Overall Study|Death|5
6027842|NCT00282984|9623627|FG000|Overall Study|Adverse Event|8
6027843|NCT00282984|9623628|FG001|Overall Study|Adverse Event|5
6027844|NCT00282984|9623627|FG000|Overall Study|Lack of Efficacy|0
6027845|NCT00282984|9623628|FG001|Overall Study|Lack of Efficacy|2
6027846|NCT00282984|9623627|FG000|Overall Study|Lost to Follow-up|14
6027847|NCT00282984|9623628|FG001|Overall Study|Lost to Follow-up|10
6027848|NCT00282984|9623627|FG000|Overall Study|Withdrawal by Participant|22
6027849|NCT00282984|9623628|FG001|Overall Study|Withdrawal by Participant|34
6027850|NCT00282984|9623627|FG000|Overall Study|Participant stopped study medication|2
6027851|NCT00282984|9623628|FG001|Overall Study|Participant stopped study medication|2
6027852|NCT00282984|9623627|FG000|Overall Study|Participant only allowed phone follow-up|0
6027853|NCT00282984|9623628|FG001|Overall Study|Participant only allowed phone follow-up|1
6027854|NCT00282984|9623627|FG000|Overall Study|Participant used antipsychosis meds|0
6048299|NCT00416624|9647455|FG002|Overall Study|Other|5
6079265|NCT00608530|9686027|FG001|Study 2 Nurse-delivered Treatments|Lack of Efficacy|0
6027855|NCT00282984|9623628|FG001|Overall Study|Participant used antipsychosis meds|1
6027856|NCT00282984|9623627|FG000|Overall Study|lack of motivation|1
6027857|NCT00282984|9623628|FG001|Overall Study|lack of motivation|0
6027858|NCT00282984|9623627|FG000|Overall Study|in prison|0
6027859|NCT00282984|9623628|FG001|Overall Study|in prison|1
6027860|NCT00282984|9623627|FG000|Overall Study|Protocol Violation|2
6027861|NCT00282984|9623628|FG001|Overall Study|Protocol Violation|0
6027862|NCT00283049|9623637|FG000|Overall Study|Adverse Event|6
6027863|NCT00283049|9623638|FG001|Overall Study|Adverse Event|1
6027864|NCT00283049|9623639|FG002|Overall Study|Adverse Event|4
6027865|NCT00283049|9623637|FG000|Overall Study|Protocol Violation|3
6027866|NCT00283049|9623638|FG001|Overall Study|Protocol Violation|0
6027867|NCT00283049|9623639|FG002|Overall Study|Protocol Violation|3
6027868|NCT00283049|9623637|FG000|Overall Study|Death|1
6027869|NCT00283049|9623638|FG001|Overall Study|Death|1
6027870|NCT00283049|9623639|FG002|Overall Study|Death|1
6027871|NCT00283049|9623637|FG000|Overall Study|Lack of Efficacy|0
6027872|NCT00283049|9623638|FG001|Overall Study|Lack of Efficacy|1
6027873|NCT00283049|9623639|FG002|Overall Study|Lack of Efficacy|1
6027874|NCT00283049|9623637|FG000|Overall Study|Lost to Follow-up|4
6027875|NCT00283049|9623638|FG001|Overall Study|Lost to Follow-up|2
6027876|NCT00283049|9623639|FG002|Overall Study|Lost to Follow-up|5
6027877|NCT00283049|9623637|FG000|Overall Study|Withdrawal by Subject|26
6027878|NCT00283049|9623638|FG001|Overall Study|Withdrawal by Subject|24
6027879|NCT00283049|9623639|FG002|Overall Study|Withdrawal by Subject|19
6027880|NCT00283049|9623637|FG000|Overall Study|Discontinuation of Study|18
6027881|NCT00283049|9623638|FG001|Overall Study|Discontinuation of Study|16
6027882|NCT00283049|9623639|FG002|Overall Study|Discontinuation of Study|20
6027883|NCT00283049|9623637|FG000|Overall Study|No longer requires study treatment|0
6027884|NCT00283049|9623638|FG001|Overall Study|No longer requires study treatment|0
6027885|NCT00283049|9623639|FG002|Overall Study|No longer requires study treatment|1
6027886|NCT00283062|9623651|FG000|Overall Study|Did not receive any study medication|5
6027887|NCT00283062|9623652|FG001|Overall Study|Did not receive any study medication|4
6027888|NCT00283062|9623653|FG002|Overall Study|Did not receive any study medication|36
6027889|NCT00283062|9623654|FG003|Overall Study|Did not receive any study medication|45
6027890|NCT00283062|9623651|FG000|Overall Study|Adverse Event|2
6027891|NCT00283062|9623652|FG001|Overall Study|Adverse Event|0
6027892|NCT00283062|9623653|FG002|Overall Study|Adverse Event|1
6027893|NCT00283062|9623654|FG003|Overall Study|Adverse Event|0
6027894|NCT00283062|9623651|FG000|Overall Study|Lost to Follow-up|1
6027895|NCT00283062|9623652|FG001|Overall Study|Lost to Follow-up|0
6027896|NCT00283062|9623653|FG002|Overall Study|Lost to Follow-up|1
6027897|NCT00283062|9623654|FG003|Overall Study|Lost to Follow-up|0
6027898|NCT00283062|9623651|FG000|Overall Study|Progressive disease|0
6027899|NCT00283062|9623652|FG001|Overall Study|Progressive disease|0
6027900|NCT00283062|9623653|FG002|Overall Study|Progressive disease|1
6027901|NCT00283062|9623654|FG003|Overall Study|Progressive disease|0
6027902|NCT00283062|9623651|FG000|Overall Study|Participant did not wish to continue|3
6027903|NCT00283062|9623652|FG001|Overall Study|Participant did not wish to continue|2
6027904|NCT00283062|9623653|FG002|Overall Study|Participant did not wish to continue|1
6027905|NCT00283062|9623654|FG003|Overall Study|Participant did not wish to continue|0
6027906|NCT00283062|9623651|FG000|Overall Study|Undefined|0
6027907|NCT00283062|9623652|FG001|Overall Study|Undefined|1
6027908|NCT00283062|9623653|FG002|Overall Study|Undefined|1
6027909|NCT00283062|9623654|FG003|Overall Study|Undefined|4
6027910|NCT00283062|9623651|FG000|Overall Study|chemotherapy not completed (cycle 6)|1
6027911|NCT00283062|9623652|FG001|Overall Study|chemotherapy not completed (cycle 6)|0
6027912|NCT00283062|9623653|FG002|Overall Study|chemotherapy not completed (cycle 6)|0
6027913|NCT00283062|9623654|FG003|Overall Study|chemotherapy not completed (cycle 6)|0
6027914|NCT00283244|9623679|FG000|Overall Study|Adverse Event|0
6027915|NCT00283244|9623680|FG001|Overall Study|Adverse Event|8
6027916|NCT00283244|9623681|FG002|Overall Study|Adverse Event|11
6027917|NCT00283244|9623679|FG000|Overall Study|Death|4
6027918|NCT00283244|9623680|FG001|Overall Study|Death|3
6027919|NCT00283244|9623681|FG002|Overall Study|Death|2
6079266|NCT00608530|9686028|FG002|Study 2 Nurse-delivered Treatments|Lack of Efficacy|2
6079267|NCT00608530|9686029|FG003|Study 2 Nurse-delivered Treatments|Lack of Efficacy|3
6079268|NCT00608530|9686026|FG000|Study 2 Nurse-delivered Treatments|Protocol Violation|0
6079269|NCT00608530|9686027|FG001|Study 2 Nurse-delivered Treatments|Protocol Violation|0
6079270|NCT00608530|9686028|FG002|Study 2 Nurse-delivered Treatments|Protocol Violation|2
6079271|NCT00608530|9686029|FG003|Study 2 Nurse-delivered Treatments|Protocol Violation|0
6027920|NCT00283244|9623679|FG000|Overall Study|Lack of Efficacy|8
6027921|NCT00283244|9623680|FG001|Overall Study|Lack of Efficacy|32
6027922|NCT00283244|9623681|FG002|Overall Study|Lack of Efficacy|26
6027923|NCT00283244|9623679|FG000|Overall Study|Withdrawal by Subject|1
6027924|NCT00283244|9623680|FG001|Overall Study|Withdrawal by Subject|2
6027925|NCT00283244|9623681|FG002|Overall Study|Withdrawal by Subject|2
6027926|NCT00283244|9623679|FG000|Overall Study|Physician Decision|0
6027927|NCT00283244|9623680|FG001|Overall Study|Physician Decision|0
6027928|NCT00283244|9623681|FG002|Overall Study|Physician Decision|1
6027929|NCT00283244|9623679|FG000|Overall Study|Medical illness (other complicating dz)|4
6027930|NCT00283244|9623680|FG001|Overall Study|Medical illness (other complicating dz)|3
6027931|NCT00283244|9623681|FG002|Overall Study|Medical illness (other complicating dz)|6
6027932|NCT00283244|9623679|FG000|Overall Study|Clinical deterioration|1
6027933|NCT00283244|9623680|FG001|Overall Study|Clinical deterioration|3
6027934|NCT00283244|9623681|FG002|Overall Study|Clinical deterioration|3
6027935|NCT00283296|9623712|FG000|Overall Study|in-home trial not completed|5
6027936|NCT00283387|9623717|FG000|First Intervention|Subject non-compliant|1
6027937|NCT00283387|9623718|FG001|First Intervention|Subject non-compliant|1
6027938|NCT00283387|9623717|FG000|First Intervention|Withdrawal by Subject|0
6027939|NCT00283387|9623718|FG001|First Intervention|Withdrawal by Subject|1
6027940|NCT00283400|9623728|FG000|Overall Study|Withdrawal by Subject|1
6027941|NCT00283400|9623729|FG001|Overall Study|Withdrawal by Subject|1
6027942|NCT00283400|9623730|FG002|Overall Study|Withdrawal by Subject|0
6027943|NCT00283400|9623731|FG003|Overall Study|Withdrawal by Subject|0
6027944|NCT00283400|9623728|FG000|Overall Study|Death|1
6027945|NCT00283400|9623729|FG001|Overall Study|Death|0
6027946|NCT00283400|9623730|FG002|Overall Study|Death|1
6027947|NCT00283400|9623731|FG003|Overall Study|Death|0
6027948|NCT00283439|9623745|FG000|Overall Study|Adverse Event|0
6027949|NCT00283439|9623746|FG001|Overall Study|Adverse Event|0
6027950|NCT00283439|9623747|FG002|Overall Study|Adverse Event|0
6079272|NCT00608530|9686026|FG000|Study 2 Nurse-delivered Treatments|Time demands of study|0
6079273|NCT00608530|9686027|FG001|Study 2 Nurse-delivered Treatments|Time demands of study|0
6079274|NCT00608530|9686028|FG002|Study 2 Nurse-delivered Treatments|Time demands of study|4
6079275|NCT00608530|9686029|FG003|Study 2 Nurse-delivered Treatments|Time demands of study|1
6079276|NCT00608530|9686026|FG000|Study 2 Nurse-delivered Treatments|Lost to Follow-up|0
6079277|NCT00608530|9686027|FG001|Study 2 Nurse-delivered Treatments|Lost to Follow-up|0
6079278|NCT00608530|9686028|FG002|Study 2 Nurse-delivered Treatments|Lost to Follow-up|1
6079279|NCT00608530|9686029|FG003|Study 2 Nurse-delivered Treatments|Lost to Follow-up|0
6079280|NCT00608543|9686044|FG000|Overall Study|Adverse Event|4
6079281|NCT00608569|9686051|FG000|Overall Study|Death|4
6079282|NCT00608569|9686052|FG001|Overall Study|Death|3
6079283|NCT00608569|9686051|FG000|Overall Study|Lost to Follow-up|4
6079284|NCT00608569|9686052|FG001|Overall Study|Lost to Follow-up|5
6079285|NCT00608569|9686051|FG000|Overall Study|Withdrawal by Subject|1
6079286|NCT00608569|9686052|FG001|Overall Study|Withdrawal by Subject|0
6027951|NCT00283439|9623748|FG003|Overall Study|Adverse Event|1
6027952|NCT00283439|9623745|FG000|Overall Study|Death|0
6027953|NCT00283439|9623746|FG001|Overall Study|Death|0
6027954|NCT00283439|9623747|FG002|Overall Study|Death|1
6027955|NCT00283439|9623748|FG003|Overall Study|Death|0
6027956|NCT00283439|9623745|FG000|Overall Study|Disease progression|0
6027957|NCT00283439|9623746|FG001|Overall Study|Disease progression|1
6027958|NCT00283439|9623747|FG002|Overall Study|Disease progression|0
6027959|NCT00283439|9623748|FG003|Overall Study|Disease progression|0
6027960|NCT00283439|9623745|FG000|Overall Study|Requirement for alternative therapy|1
6027961|NCT00283439|9623746|FG001|Overall Study|Requirement for alternative therapy|2
6027962|NCT00283439|9623747|FG002|Overall Study|Requirement for alternative therapy|5
6027963|NCT00283439|9623748|FG003|Overall Study|Requirement for alternative therapy|2
6027964|NCT00283439|9623745|FG000|Overall Study|Stem cell transplant|6
6027965|NCT00283439|9623746|FG001|Overall Study|Stem cell transplant|6
6027966|NCT00283439|9623747|FG002|Overall Study|Stem cell transplant|4
6027967|NCT00283439|9623748|FG003|Overall Study|Stem cell transplant|3
6027968|NCT00283439|9623745|FG000|Overall Study|Treatment discontinued|0
6027969|NCT00283439|9623746|FG001|Overall Study|Treatment discontinued|2
6027970|NCT00283439|9623747|FG002|Overall Study|Treatment discontinued|1
6027971|NCT00283439|9623748|FG003|Overall Study|Treatment discontinued|3
6027972|NCT00283439|9623745|FG000|Overall Study|Other|1
6027973|NCT00283439|9623746|FG001|Overall Study|Other|0
6027974|NCT00283439|9623747|FG002|Overall Study|Other|0
6027975|NCT00283439|9623748|FG003|Overall Study|Other|0
6027976|NCT00283595|9623771|FG000|Overall Study|Withdrawal by Subject|1
6027977|NCT00283595|9623772|FG001|Overall Study|Withdrawal by Subject|2
6027978|NCT00283686|9623782|FG000|Overall Study|Death|1
6027979|NCT00283686|9623783|FG001|Overall Study|Death|1
6027980|NCT00283686|9623784|FG002|Overall Study|Death|1
6027981|NCT00283686|9623785|FG003|Overall Study|Death|0
6027982|NCT00283686|9623782|FG000|Overall Study|Lost to Follow-up|21
6027983|NCT00283686|9623783|FG001|Overall Study|Lost to Follow-up|31
6027984|NCT00283686|9623784|FG002|Overall Study|Lost to Follow-up|26
6027985|NCT00283686|9623785|FG003|Overall Study|Lost to Follow-up|20
6027986|NCT00283686|9623782|FG000|Overall Study|Less than full participation|7
6027987|NCT00283686|9623783|FG001|Overall Study|Less than full participation|9
6027988|NCT00283686|9623784|FG002|Overall Study|Less than full participation|6
6027989|NCT00283686|9623785|FG003|Overall Study|Less than full participation|12
6027990|NCT00283712|9623797|FG000|Overall Study|Death|0
6027991|NCT00283712|9623798|FG001|Overall Study|Death|1
6048300|NCT00416624|9647456|FG003|Overall Study|Other|5
6048301|NCT00416624|9647453|FG000|Overall Study|Cancel|1
6048302|NCT00416624|9647454|FG001|Overall Study|Cancel|0
6048303|NCT00416624|9647455|FG002|Overall Study|Cancel|0
6079287|NCT00608569|9686051|FG000|Overall Study|Adverse Event|1
6048304|NCT00416624|9647456|FG003|Overall Study|Cancel|0
6048305|NCT00416715|9647466|FG000|Overall Study|Not evaluable for joint aches|7
6079288|NCT00608569|9686052|FG001|Overall Study|Adverse Event|0
6027992|NCT00283803|9623804|FG000|Overall Study|Physician Decision|9
6027993|NCT00283803|9623804|FG000|Overall Study|Withdrawal by Subject|4
6027994|NCT00283842|9623824|FG000|Overall Study|Adverse Event|8
6027995|NCT00283842|9623825|FG001|Overall Study|Adverse Event|7
6027996|NCT00283842|9623826|FG002|Overall Study|Adverse Event|21
6027997|NCT00283842|9623827|FG003|Overall Study|Adverse Event|21
6027998|NCT00283842|9623828|FG004|Overall Study|Adverse Event|5
6027999|NCT00283842|9623824|FG000|Overall Study|Protocol Violation|1
6028000|NCT00283842|9623825|FG001|Overall Study|Protocol Violation|5
6028001|NCT00283842|9623826|FG002|Overall Study|Protocol Violation|4
6028002|NCT00283842|9623827|FG003|Overall Study|Protocol Violation|0
6028003|NCT00283842|9623828|FG004|Overall Study|Protocol Violation|0
6028004|NCT00283842|9623824|FG000|Overall Study|Protocol deviation|0
6028005|NCT00283842|9623825|FG001|Overall Study|Protocol deviation|0
6028006|NCT00283842|9623826|FG002|Overall Study|Protocol deviation|0
6028007|NCT00283842|9623827|FG003|Overall Study|Protocol deviation|0
6028008|NCT00283842|9623828|FG004|Overall Study|Protocol deviation|2
6028009|NCT00283842|9623824|FG000|Overall Study|Withdrawal by Subject|2
6028010|NCT00283842|9623825|FG001|Overall Study|Withdrawal by Subject|1
6028011|NCT00283842|9623826|FG002|Overall Study|Withdrawal by Subject|1
6028012|NCT00283842|9623827|FG003|Overall Study|Withdrawal by Subject|5
6028013|NCT00283842|9623828|FG004|Overall Study|Withdrawal by Subject|4
6028014|NCT00283842|9623824|FG000|Overall Study|Lack of Efficacy|1
6028015|NCT00283842|9623825|FG001|Overall Study|Lack of Efficacy|3
6028016|NCT00283842|9623826|FG002|Overall Study|Lack of Efficacy|1
6028017|NCT00283842|9623827|FG003|Overall Study|Lack of Efficacy|0
6028018|NCT00283842|9623828|FG004|Overall Study|Lack of Efficacy|3
6028019|NCT00283842|9623824|FG000|Overall Study|Lost to Follow-up|0
6028020|NCT00283842|9623825|FG001|Overall Study|Lost to Follow-up|2
6028021|NCT00283842|9623826|FG002|Overall Study|Lost to Follow-up|4
6028022|NCT00283842|9623827|FG003|Overall Study|Lost to Follow-up|1
6028023|NCT00283842|9623828|FG004|Overall Study|Lost to Follow-up|1
6028024|NCT00284050|9623847|FG000|Overall Study|Adverse Event|1
6028025|NCT00284050|9623848|FG001|Overall Study|Adverse Event|1
6028026|NCT00284050|9623849|FG002|Overall Study|Adverse Event|1
6028027|NCT00284050|9623847|FG000|Overall Study|Lack of Efficacy|0
6028028|NCT00284050|9623848|FG001|Overall Study|Lack of Efficacy|1
6028029|NCT00284050|9623849|FG002|Overall Study|Lack of Efficacy|3
6028030|NCT00284050|9623847|FG000|Overall Study|Protocol Violation|0
6028031|NCT00284050|9623848|FG001|Overall Study|Protocol Violation|1
6028032|NCT00284050|9623849|FG002|Overall Study|Protocol Violation|2
6028033|NCT00284050|9623847|FG000|Overall Study|Withdrawal by Subject|2
6028034|NCT00284050|9623848|FG001|Overall Study|Withdrawal by Subject|2
6028035|NCT00284050|9623849|FG002|Overall Study|Withdrawal by Subject|2
6028036|NCT00284050|9623847|FG000|Overall Study|Lost to Follow-up|1
6028037|NCT00284050|9623848|FG001|Overall Study|Lost to Follow-up|0
6028038|NCT00284050|9623849|FG002|Overall Study|Lost to Follow-up|1
6028039|NCT00284050|9623847|FG000|Overall Study|Death|1
6028040|NCT00284050|9623848|FG001|Overall Study|Death|0
6028041|NCT00284050|9623849|FG002|Overall Study|Death|0
6028042|NCT00284089|9623861|FG000|Multiple Dose Phase|Adverse Event|1
6028043|NCT00284089|9623862|FG001|Multiple Dose Phase|Adverse Event|0
6028044|NCT00284089|9623863|FG002|Multiple Dose Phase|Adverse Event|1
6028045|NCT00284089|9623864|FG003|Multiple Dose Phase|Adverse Event|1
6028046|NCT00284089|9623861|FG000|Multiple Dose Phase|Protocol Violation|0
6028047|NCT00284089|9623862|FG001|Multiple Dose Phase|Protocol Violation|0
6028048|NCT00284089|9623863|FG002|Multiple Dose Phase|Protocol Violation|1
6028049|NCT00284089|9623864|FG003|Multiple Dose Phase|Protocol Violation|0
6028050|NCT00284089|9623861|FG000|Multiple Dose Phase|Withdrawal by Subject|0
6028051|NCT00284089|9623862|FG001|Multiple Dose Phase|Withdrawal by Subject|0
6028052|NCT00284089|9623863|FG002|Multiple Dose Phase|Withdrawal by Subject|1
6028053|NCT00284089|9623864|FG003|Multiple Dose Phase|Withdrawal by Subject|2
6028054|NCT00284089|9623861|FG000|Multiple Dose Phase|Death|0
6028055|NCT00284089|9623862|FG001|Multiple Dose Phase|Death|0
6028056|NCT00284089|9623863|FG002|Multiple Dose Phase|Death|1
6028057|NCT00284089|9623864|FG003|Multiple Dose Phase|Death|1
6028058|NCT00284089|9623861|FG000|Extension Phase|Adverse Event|0
6028059|NCT00284089|9623862|FG001|Extension Phase|Adverse Event|0
6028060|NCT00284089|9623863|FG002|Extension Phase|Adverse Event|2
6028061|NCT00284089|9623864|FG003|Extension Phase|Adverse Event|2
6028062|NCT00284089|9623861|FG000|Extension Phase|condition no longer requires study drug|2
6028063|NCT00284089|9623862|FG001|Extension Phase|condition no longer requires study drug|0
6028064|NCT00284089|9623863|FG002|Extension Phase|condition no longer requires study drug|2
6028065|NCT00284089|9623864|FG003|Extension Phase|condition no longer requires study drug|7
6028066|NCT00284089|9623861|FG000|Extension Phase|Protocol Violation|0
6028067|NCT00284089|9623862|FG001|Extension Phase|Protocol Violation|0
6028068|NCT00284089|9623863|FG002|Extension Phase|Protocol Violation|1
6028069|NCT00284089|9623864|FG003|Extension Phase|Protocol Violation|0
6028070|NCT00284089|9623861|FG000|Extension Phase|Withdrawal by Subject|0
6028071|NCT00284089|9623862|FG001|Extension Phase|Withdrawal by Subject|0
6028072|NCT00284089|9623863|FG002|Extension Phase|Withdrawal by Subject|1
6028073|NCT00284089|9623864|FG003|Extension Phase|Withdrawal by Subject|3
6028074|NCT00284141|9623874|FG000|Overall Study|Disease Progression / Lack of efficacy|51
6028075|NCT00284141|9623874|FG000|Overall Study|Adverse Event|19
6028076|NCT00284141|9623874|FG000|Overall Study|Participant's request|9
6028077|NCT00284141|9623874|FG000|Overall Study|Symptomatic / Clinical Progression|11
6028078|NCT00284141|9623874|FG000|Overall Study|Clinical deterioration / death|2
6028079|NCT00284141|9623874|FG000|Overall Study|General decline|1
6028080|NCT00284141|9623874|FG000|Overall Study|Pneumonia|1
6028081|NCT00284141|9623874|FG000|Overall Study|Did not take study medication|2
6028082|NCT00284141|9623874|FG000|Overall Study|Ongoing treatment|2
6028083|NCT00284934|9623930|FG000|Overall Study|Adverse Event|1
6028084|NCT00284934|9623931|FG001|Overall Study|Adverse Event|2
6028085|NCT00284934|9623930|FG000|Overall Study|Other reasons|3
6028086|NCT00284934|9623931|FG001|Overall Study|Other reasons|1
6028087|NCT00285012|9623939|FG000|Assigned to Study Treatment (Tx)|Other|2
6028088|NCT00285012|9623940|FG001|Assigned to Study Treatment (Tx)|Other|3
6028089|NCT00285012|9623939|FG000|Received Study Tx|Death|2
6028090|NCT00285012|9623940|FG001|Received Study Tx|Death|1
6028091|NCT00285012|9623939|FG000|Received Study Tx|Adverse Event|5
6028092|NCT00285012|9623940|FG001|Received Study Tx|Adverse Event|11
6028093|NCT00285012|9623939|FG000|Received Study Tx|Lack of Efficacy|0
6028094|NCT00285012|9623940|FG001|Received Study Tx|Lack of Efficacy|3
6028095|NCT00285012|9623939|FG000|Received Study Tx|Lost to Follow-up|29
6028096|NCT00285012|9623940|FG001|Received Study Tx|Lost to Follow-up|31
6028097|NCT00285012|9623939|FG000|Received Study Tx|Withdrawal by Subject|31
6028098|NCT00285012|9623940|FG001|Received Study Tx|Withdrawal by Subject|43
6028099|NCT00285012|9623939|FG000|Received Study Tx|Other|5
6028100|NCT00285012|9623940|FG001|Received Study Tx|Other|5
6028101|NCT00285207|9623948|FG000|Overall Study|Lost to Follow-up|3
6028102|NCT00285207|9623949|FG001|Overall Study|Lost to Follow-up|2
6028103|NCT00285207|9623948|FG000|Overall Study|Withdrawal by Subject|5
6028104|NCT00285207|9623949|FG001|Overall Study|Withdrawal by Subject|2
6028105|NCT00285207|9623948|FG000|Overall Study|Pregnancy|1
6028106|NCT00285207|9623949|FG001|Overall Study|Pregnancy|1
6028107|NCT00285207|9623948|FG000|Overall Study|non-compliance|0
6028108|NCT00285207|9623949|FG001|Overall Study|non-compliance|1
6028109|NCT00285584|9623970|FG000|Month 3|Lost to Follow-up|3
6028110|NCT00285584|9623971|FG001|Month 3|Lost to Follow-up|3
6028111|NCT00285584|9623970|FG000|Month 3|Withdrawal by Subject|1
6028112|NCT00285584|9623971|FG001|Month 3|Withdrawal by Subject|0
6028113|NCT00285584|9623970|FG000|Month 6|Lost to Follow-up|0
6028114|NCT00285584|9623971|FG001|Month 6|Lost to Follow-up|1
6028115|NCT00285649|9623984|FG000|Overall Study|Lost to Follow-up|6
6028116|NCT00285649|9623985|FG001|Overall Study|Lost to Follow-up|4
6028117|NCT00285649|9623986|FG002|Overall Study|Lost to Follow-up|4
6028118|NCT00285649|9623984|FG000|Overall Study|Withdrawal by Subject|3
6028119|NCT00285649|9623985|FG001|Overall Study|Withdrawal by Subject|2
6028120|NCT00285649|9623986|FG002|Overall Study|Withdrawal by Subject|2
6028121|NCT00285818|9624005|FG000|Overall Study|Withdrawal by Subject|3
6028122|NCT00285818|9624006|FG001|Overall Study|Withdrawal by Subject|2
6028123|NCT00285818|9624005|FG000|Overall Study|Lost to Follow-up|1
6028124|NCT00285818|9624006|FG001|Overall Study|Lost to Follow-up|0
6028125|NCT00285857|9624012|FG000|Overall Study|Withdrawal by Subject|2
6028126|NCT00285857|9624012|FG000|Overall Study|Inadequate initial breast cytology|1
6028127|NCT00285857|9624012|FG000|Overall Study|Adverse Event|1
6079289|NCT00608569|9686051|FG000|Overall Study|Unable to adhere with study requirements|0
6079290|NCT00608569|9686052|FG001|Overall Study|Unable to adhere with study requirements|1
6079291|NCT00608582|9686060|FG000|Overall Study|Lost to Follow-up|2
6079292|NCT00608582|9686061|FG001|Overall Study|Lost to Follow-up|0
6079293|NCT00608582|9686060|FG000|Overall Study|No Best Response in Phase 1 located|1
6079294|NCT00608582|9686061|FG001|Overall Study|No Best Response in Phase 1 located|1
6079295|NCT00608582|9686060|FG000|Overall Study|Illicit Drug Use|1
6079296|NCT00608582|9686061|FG001|Overall Study|Illicit Drug Use|0
6079297|NCT00608582|9686060|FG000|Overall Study|Early stage Design Change|0
6079298|NCT00608582|9686061|FG001|Overall Study|Early stage Design Change|3
6079299|NCT00608829|9686084|FG000|Overall Study|Death|6
6079300|NCT00608829|9686084|FG000|Overall Study|Withdrawal by Subject|4
6079301|NCT00608829|9686084|FG000|Overall Study|Subject refuses to follow up or return.|5
6028128|NCT00286091|9624032|FG000|Double-blind Treatment Phase|Withdrawal by Subject|103
6028129|NCT00286091|9624033|FG001|Double-blind Treatment Phase|Withdrawal by Subject|113
6028130|NCT00286091|9624032|FG000|Double-blind Treatment Phase|Protocol-Specified Criteria|307
6028131|NCT00286091|9624033|FG001|Double-blind Treatment Phase|Protocol-Specified Criteria|269
6028132|NCT00286091|9624032|FG000|Double-blind Treatment Phase|Death|58
6028133|NCT00286091|9624033|FG001|Double-blind Treatment Phase|Death|65
6028134|NCT00286091|9624032|FG000|Double-blind Treatment Phase|Adverse Event|28
6028135|NCT00286091|9624033|FG001|Double-blind Treatment Phase|Adverse Event|40
6028136|NCT00286091|9624032|FG000|Double-blind Treatment Phase|Disease Progression|22
6028137|NCT00286091|9624033|FG001|Double-blind Treatment Phase|Disease Progression|35
6028138|NCT00286091|9624032|FG000|Double-blind Treatment Phase|Other|25
6028139|NCT00286091|9624033|FG001|Double-blind Treatment Phase|Other|33
6028140|NCT00286091|9624032|FG000|Double-blind Treatment Phase|Administrative Decision|20
6028141|NCT00286091|9624033|FG001|Double-blind Treatment Phase|Administrative Decision|21
6028142|NCT00286091|9624032|FG000|Double-blind Treatment Phase|Noncompliance|8
6028143|NCT00286091|9624033|FG001|Double-blind Treatment Phase|Noncompliance|8
6079302|NCT00608842|9686092|FG000|Overall Study|Participant's Request|0
6079303|NCT00608842|9686093|FG001|Overall Study|Participant's Request|1
6028144|NCT00286091|9624032|FG000|Double-blind Treatment Phase|Lost to Follow-up|11
6028145|NCT00286091|9624033|FG001|Double-blind Treatment Phase|Lost to Follow-up|4
6028146|NCT00286091|9624032|FG000|Double-blind Treatment Phase|Protocol Deviation|1
6028147|NCT00286091|9624033|FG001|Double-blind Treatment Phase|Protocol Deviation|3
6028148|NCT00286091|9624032|FG000|Double-blind Treatment Phase|Ineligibility Determined|1
6028149|NCT00286091|9624033|FG001|Double-blind Treatment Phase|Ineligibility Determined|2
6028150|NCT00286091|9624032|FG000|Open-label Treatment Phase|Physician Decision|24
6028151|NCT00286091|9624033|FG001|Open-label Treatment Phase|Physician Decision|21
6028152|NCT00286091|9624032|FG000|Open-label Treatment Phase|Adverse Event|5
6028153|NCT00286091|9624033|FG001|Open-label Treatment Phase|Adverse Event|16
6028154|NCT00286091|9624032|FG000|Open-label Treatment Phase|Other|11
6028155|NCT00286091|9624033|FG001|Open-label Treatment Phase|Other|11
6028156|NCT00286091|9624032|FG000|Open-label Treatment Phase|Withdrawal by Subject|14
6028157|NCT00286091|9624033|FG001|Open-label Treatment Phase|Withdrawal by Subject|10
6227287|NCT01716520|9900045|FG004|Washout Period 1 (10 to 14 Days)|Lack of Efficacy|0
6227288|NCT01716520|9900046|FG005|Washout Period 1 (10 to 14 Days)|Lack of Efficacy|1
6227289|NCT01716520|9900041|FG000|Washout Period 1 (10 to 14 Days)|Withdrawal by Subject|0
6227290|NCT01716520|9900042|FG001|Washout Period 1 (10 to 14 Days)|Withdrawal by Subject|0
6028158|NCT00286091|9624032|FG000|Open-label Treatment Phase|Death|10
6028159|NCT00286091|9624033|FG001|Open-label Treatment Phase|Death|7
6028160|NCT00286091|9624032|FG000|Open-label Treatment Phase|Disease Progression|9
6028161|NCT00286091|9624033|FG001|Open-label Treatment Phase|Disease Progression|3
6028162|NCT00286091|9624032|FG000|Open-label Treatment Phase|Noncompliance|3
6028163|NCT00286091|9624033|FG001|Open-label Treatment Phase|Noncompliance|1
6028164|NCT00286091|9624032|FG000|Open-label Treatment Phase|Lost to Follow-up|0
6028165|NCT00286091|9624033|FG001|Open-label Treatment Phase|Lost to Follow-up|1
6028166|NCT00286091|9624032|FG000|Open-label Treatment Phase|Protocol-specified Criteria|1
6028167|NCT00286091|9624033|FG001|Open-label Treatment Phase|Protocol-specified Criteria|0
6028168|NCT00286091|9624032|FG000|Open-label Treatment Phase|Missing End of Study Information|0
6028169|NCT00286091|9624033|FG001|Open-label Treatment Phase|Missing End of Study Information|1
6028170|NCT00286156|9624044|FG000|Overall Study|Missed 12 month visit|0
6028171|NCT00286156|9624045|FG001|Overall Study|Missed 12 month visit|0
6028172|NCT00286156|9624046|FG002|Overall Study|Missed 12 month visit|1
6028173|NCT00286156|9624044|FG000|Overall Study|AE: pulmonary embolus|0
6028174|NCT00286156|9624045|FG001|Overall Study|AE: pulmonary embolus|1
6028175|NCT00286156|9624046|FG002|Overall Study|AE: pulmonary embolus|0
6028176|NCT00286156|9624044|FG000|Overall Study|AE: nephrotic-range proteinuruia|1
6028177|NCT00286156|9624045|FG001|Overall Study|AE: nephrotic-range proteinuruia|0
6028178|NCT00286156|9624046|FG002|Overall Study|AE: nephrotic-range proteinuruia|0
6028179|NCT00286156|9624044|FG000|Overall Study|AE: pneumonia|1
6028180|NCT00286156|9624045|FG001|Overall Study|AE: pneumonia|0
6028181|NCT00286156|9624046|FG002|Overall Study|AE: pneumonia|0
6028182|NCT00286221|9624067|FG000|Overall Study|Protocol Violation|2
6028183|NCT00286221|9624068|FG001|Overall Study|Protocol Violation|1
6028184|NCT00286221|9624069|FG002|Overall Study|Protocol Violation|6
6028185|NCT00286221|9624070|FG003|Overall Study|Protocol Violation|4
6028186|NCT00286221|9624067|FG000|Overall Study|Unanticipated Neurosurgical Complication|6
6028187|NCT00286221|9624068|FG001|Overall Study|Unanticipated Neurosurgical Complication|3
6028188|NCT00286221|9624069|FG002|Overall Study|Unanticipated Neurosurgical Complication|3
6028189|NCT00286221|9624070|FG003|Overall Study|Unanticipated Neurosurgical Complication|2
6028190|NCT00286221|9624067|FG000|Overall Study|Inability to trigger PCA|2
6028191|NCT00286221|9624068|FG001|Overall Study|Inability to trigger PCA|0
6028192|NCT00286221|9624069|FG002|Overall Study|Inability to trigger PCA|0
6028193|NCT00286221|9624070|FG003|Overall Study|Inability to trigger PCA|0
6028194|NCT00286221|9624067|FG000|Overall Study|Unrecognized exclusion criteria met|0
6028195|NCT00286221|9624068|FG001|Overall Study|Unrecognized exclusion criteria met|1
6028196|NCT00286221|9624069|FG002|Overall Study|Unrecognized exclusion criteria met|0
6028197|NCT00286221|9624070|FG003|Overall Study|Unrecognized exclusion criteria met|0
6028198|NCT00286234|9624084|FG000|Overall Study|Protocol Violation|1
6028199|NCT00286234|9624085|FG001|Overall Study|Protocol Violation|2
6028200|NCT00286234|9624086|FG002|Overall Study|Protocol Violation|0
6028201|NCT00286234|9624087|FG003|Overall Study|Protocol Violation|1
6028202|NCT00286234|9624084|FG000|Overall Study|Physician Decision|1
6028203|NCT00286234|9624085|FG001|Overall Study|Physician Decision|0
6028204|NCT00286234|9624086|FG002|Overall Study|Physician Decision|0
6028205|NCT00286234|9624087|FG003|Overall Study|Physician Decision|1
6028206|NCT00286234|9624084|FG000|Overall Study|Adverse Event|0
6028207|NCT00286234|9624085|FG001|Overall Study|Adverse Event|0
6028208|NCT00286234|9624086|FG002|Overall Study|Adverse Event|0
6028209|NCT00286234|9624087|FG003|Overall Study|Adverse Event|1
6028210|NCT00286234|9624084|FG000|Overall Study|Adverse Event|0
6028211|NCT00286234|9624085|FG001|Overall Study|Adverse Event|0
6028212|NCT00286234|9624086|FG002|Overall Study|Adverse Event|0
6028213|NCT00286234|9624087|FG003|Overall Study|Adverse Event|1
6028214|NCT00286429|9624104|FG000|Overall Study|Adverse Event|4
6028215|NCT00286429|9624105|FG001|Overall Study|Adverse Event|1
6028216|NCT00286429|9624106|FG002|Overall Study|Adverse Event|6
6028217|NCT00286429|9624104|FG000|Overall Study|Lack of Efficacy|52
6028218|NCT00286429|9624105|FG001|Overall Study|Lack of Efficacy|27
6028219|NCT00286429|9624106|FG002|Overall Study|Lack of Efficacy|25
6079304|NCT00608842|9686094|FG002|Overall Study|Participant's Request|2
6079305|NCT00608842|9686095|FG003|Overall Study|Participant's Request|1
6079306|NCT00608842|9686092|FG000|Overall Study|Lost to Follow-up|1
6079307|NCT00608842|9686093|FG001|Overall Study|Lost to Follow-up|0
6079308|NCT00608842|9686094|FG002|Overall Study|Lost to Follow-up|0
6079309|NCT00608842|9686095|FG003|Overall Study|Lost to Follow-up|0
6028220|NCT00286429|9624104|FG000|Overall Study|Lost to Follow-up|2
6028221|NCT00286429|9624105|FG001|Overall Study|Lost to Follow-up|4
6028222|NCT00286429|9624106|FG002|Overall Study|Lost to Follow-up|3
6028223|NCT00286429|9624104|FG000|Overall Study|Physician Decision|10
6028224|NCT00286429|9624105|FG001|Overall Study|Physician Decision|7
6028225|NCT00286429|9624106|FG002|Overall Study|Physician Decision|7
6028226|NCT00286429|9624104|FG000|Overall Study|Protocol Violation|3
6028227|NCT00286429|9624105|FG001|Overall Study|Protocol Violation|5
6028228|NCT00286429|9624106|FG002|Overall Study|Protocol Violation|4
6028229|NCT00286429|9624104|FG000|Overall Study|Withdrawal by Subject|3
6028230|NCT00286429|9624105|FG001|Overall Study|Withdrawal by Subject|2
6028231|NCT00286429|9624106|FG002|Overall Study|Withdrawal by Subject|6
6028232|NCT00286429|9624104|FG000|Overall Study|Administrative Error|1
6028233|NCT00286429|9624105|FG001|Overall Study|Administrative Error|1
6028234|NCT00286429|9624106|FG002|Overall Study|Administrative Error|1
6028235|NCT00286429|9624104|FG000|Overall Study|Administrative Decision|0
6028236|NCT00286429|9624105|FG001|Overall Study|Administrative Decision|1
6028237|NCT00286429|9624106|FG002|Overall Study|Administrative Decision|0
6028238|NCT00286442|9624117|FG000|Overall Study|Hyperglycemic Rescue|19
6028239|NCT00286442|9624118|FG001|Overall Study|Hyperglycemic Rescue|17
6028240|NCT00286442|9624119|FG002|Overall Study|Hyperglycemic Rescue|25
6028241|NCT00286442|9624117|FG000|Overall Study|Adverse Event|7
6028242|NCT00286442|9624118|FG001|Overall Study|Adverse Event|6
6028243|NCT00286442|9624119|FG002|Overall Study|Adverse Event|1
6028244|NCT00286442|9624117|FG000|Overall Study|Protocol Violation|2
6079310|NCT00608868|9686105|FG000|Overall Study|Withdrawal by Subject|7
6079311|NCT00608868|9686105|FG000|Overall Study|Protocol Violation|3
6079312|NCT00608868|9686105|FG000|Overall Study|Lost to Follow-up|2
6079313|NCT00608868|9686105|FG000|Overall Study|Adverse Event|1
6079314|NCT00608868|9686105|FG000|Overall Study|Physician Decision|2
6079315|NCT00608881|9686111|FG000|Overall Study|Death|22
6079316|NCT00608881|9686112|FG001|Overall Study|Death|13
6079317|NCT00608881|9686111|FG000|Overall Study|Adverse Event|5
6079318|NCT00608881|9686112|FG001|Overall Study|Adverse Event|3
6079319|NCT00608881|9686111|FG000|Overall Study|Lost to Follow-up|28
6079320|NCT00608881|9686112|FG001|Overall Study|Lost to Follow-up|14
6079321|NCT00608881|9686111|FG000|Overall Study|Withdrawal by Subject|18
6079322|NCT00608881|9686112|FG001|Overall Study|Withdrawal by Subject|29
6079323|NCT00608881|9686111|FG000|Overall Study|Physician Decision|5
6079324|NCT00608881|9686112|FG001|Overall Study|Physician Decision|5
6079325|NCT00608881|9686111|FG000|Overall Study|Institutionalized|1
6079326|NCT00608881|9686112|FG001|Overall Study|Institutionalized|2
6079327|NCT00608894|9686120|FG000|Overall Study|Withdrawal by Subject|0
6079328|NCT00608894|9686121|FG001|Overall Study|Withdrawal by Subject|2
6079329|NCT00608907|9686132|FG000|Overall Study|Adverse Event|6
6079330|NCT00608907|9686133|FG001|Overall Study|Adverse Event|0
6079331|NCT00608907|9686134|FG002|Overall Study|Adverse Event|1
6079332|NCT00608907|9686132|FG000|Overall Study|Death|1
6079333|NCT00608907|9686133|FG001|Overall Study|Death|0
6079334|NCT00608907|9686134|FG002|Overall Study|Death|0
6079335|NCT00608907|9686132|FG000|Overall Study|Withdrawal by Subject|4
6079336|NCT00608907|9686133|FG001|Overall Study|Withdrawal by Subject|0
6079337|NCT00608907|9686134|FG002|Overall Study|Withdrawal by Subject|0
6079338|NCT00608907|9686132|FG000|Overall Study|Progressive Disease|1
6079339|NCT00608907|9686133|FG001|Overall Study|Progressive Disease|0
6079340|NCT00608907|9686134|FG002|Overall Study|Progressive Disease|0
6079341|NCT00608959|9686144|FG000|Part 1|Did not meet eligibility criteria|1
6079342|NCT00608985|9686158|FG000|Overall Study|Adverse Event|2
6079343|NCT00608985|9686159|FG001|Overall Study|Adverse Event|7
6079344|NCT00608985|9686160|FG002|Overall Study|Adverse Event|4
6079345|NCT00608985|9686161|FG003|Overall Study|Adverse Event|6
6079346|NCT00608985|9686158|FG000|Overall Study|Administrative/Other|7
6079347|NCT00608985|9686159|FG001|Overall Study|Administrative/Other|4
6079348|NCT00608985|9686160|FG002|Overall Study|Administrative/Other|1
6079349|NCT00608985|9686161|FG003|Overall Study|Administrative/Other|2
6079350|NCT00608985|9686158|FG000|Overall Study|Withdrawal of Consent|5
6079351|NCT00608985|9686159|FG001|Overall Study|Withdrawal of Consent|1
6079352|NCT00608985|9686160|FG002|Overall Study|Withdrawal of Consent|1
6079353|NCT00608985|9686161|FG003|Overall Study|Withdrawal of Consent|1
6146378|NCT01077076|9781135|FG003|First Intervention|Withdrawal by Subject|0
6146379|NCT01077076|9781136|FG004|First Intervention|Withdrawal by Subject|0
6028245|NCT00286442|9624118|FG001|Overall Study|Protocol Violation|4
6028246|NCT00286442|9624119|FG002|Overall Study|Protocol Violation|2
6028247|NCT00286442|9624117|FG000|Overall Study|Lost to Follow-up|5
6028248|NCT00286442|9624118|FG001|Overall Study|Lost to Follow-up|2
6028249|NCT00286442|9624119|FG002|Overall Study|Lost to Follow-up|1
6028250|NCT00286442|9624117|FG000|Overall Study|Physician Decision|1
6079354|NCT00608985|9686158|FG000|Overall Study|Lost to Follow-up|2
6079355|NCT00608985|9686159|FG001|Overall Study|Lost to Follow-up|1
6079356|NCT00608985|9686160|FG002|Overall Study|Lost to Follow-up|0
6028251|NCT00286442|9624118|FG001|Overall Study|Physician Decision|1
6028252|NCT00286442|9624119|FG002|Overall Study|Physician Decision|1
6028253|NCT00286442|9624117|FG000|Overall Study|Administrative Error|1
6028254|NCT00286442|9624118|FG001|Overall Study|Administrative Error|1
6028255|NCT00286442|9624119|FG002|Overall Study|Administrative Error|0
6028256|NCT00286442|9624117|FG000|Overall Study|Withdrawal by Subject|2
6028257|NCT00286442|9624118|FG001|Overall Study|Withdrawal by Subject|14
6028258|NCT00286442|9624119|FG002|Overall Study|Withdrawal by Subject|2
6028259|NCT00286455|9624130|FG000|Overall Study|Hyperglycemia rescue|19
6028260|NCT00286455|9624131|FG001|Overall Study|Hyperglycemia rescue|13
6028261|NCT00286455|9624132|FG002|Overall Study|Hyperglycemia rescue|10
6028262|NCT00286455|9624130|FG000|Overall Study|Adverse Event|1
6028263|NCT00286455|9624131|FG001|Overall Study|Adverse Event|3
6028264|NCT00286455|9624132|FG002|Overall Study|Adverse Event|2
6028265|NCT00286455|9624130|FG000|Overall Study|Lost to Follow-up|0
6028266|NCT00286455|9624131|FG001|Overall Study|Lost to Follow-up|3
6028267|NCT00286455|9624132|FG002|Overall Study|Lost to Follow-up|3
6028268|NCT00286455|9624130|FG000|Overall Study|Physician Decision|3
6028269|NCT00286455|9624131|FG001|Overall Study|Physician Decision|0
6028270|NCT00286455|9624132|FG002|Overall Study|Physician Decision|2
6028271|NCT00286455|9624130|FG000|Overall Study|Protocol Violation|1
6028272|NCT00286455|9624131|FG001|Overall Study|Protocol Violation|1
6028273|NCT00286455|9624132|FG002|Overall Study|Protocol Violation|0
6028274|NCT00286455|9624130|FG000|Overall Study|Participant Non-compliance|1
6028275|NCT00286455|9624131|FG001|Overall Study|Participant Non-compliance|0
6028276|NCT00286455|9624132|FG002|Overall Study|Participant Non-compliance|0
6028277|NCT00286455|9624130|FG000|Overall Study|Withdrawal by Subject|0
6028278|NCT00286455|9624131|FG001|Overall Study|Withdrawal by Subject|8
6028279|NCT00286455|9624132|FG002|Overall Study|Withdrawal by Subject|7
6028280|NCT00286468|9624143|FG000|Overall Study|Hyperglycemic Rescue|28
6028281|NCT00286468|9624144|FG001|Overall Study|Hyperglycemic Rescue|30
6028282|NCT00286468|9624145|FG002|Overall Study|Hyperglycemic Rescue|31
6028283|NCT00286468|9624143|FG000|Overall Study|Adverse Event|2
6028284|NCT00286468|9624144|FG001|Overall Study|Adverse Event|6
6028285|NCT00286468|9624145|FG002|Overall Study|Adverse Event|4
6028286|NCT00286468|9624143|FG000|Overall Study|Protocol Violation|0
6028287|NCT00286468|9624144|FG001|Overall Study|Protocol Violation|3
6028288|NCT00286468|9624145|FG002|Overall Study|Protocol Violation|1
6028289|NCT00286468|9624143|FG000|Overall Study|Lost to Follow-up|1
6028290|NCT00286468|9624144|FG001|Overall Study|Lost to Follow-up|1
6028291|NCT00286468|9624145|FG002|Overall Study|Lost to Follow-up|2
6028292|NCT00286468|9624143|FG000|Overall Study|Withdrawal by Subject|3
6028293|NCT00286468|9624144|FG001|Overall Study|Withdrawal by Subject|8
6028294|NCT00286468|9624145|FG002|Overall Study|Withdrawal by Subject|11
6028295|NCT00286468|9624143|FG000|Overall Study|Physician Decision|3
6028296|NCT00286468|9624144|FG001|Overall Study|Physician Decision|2
6028297|NCT00286468|9624145|FG002|Overall Study|Physician Decision|1
6028298|NCT00286494|9624156|FG000|Overall Study|Hyperglycemic rescue|12
6028299|NCT00286494|9624157|FG001|Overall Study|Hyperglycemic rescue|19
6028300|NCT00286494|9624158|FG002|Overall Study|Hyperglycemic rescue|18
6028301|NCT00286494|9624156|FG000|Overall Study|Withdrawal by Subject|2
6028302|NCT00286494|9624157|FG001|Overall Study|Withdrawal by Subject|10
6028303|NCT00286494|9624158|FG002|Overall Study|Withdrawal by Subject|9
6028304|NCT00286494|9624156|FG000|Overall Study|Adverse Event|3
6028305|NCT00286494|9624157|FG001|Overall Study|Adverse Event|8
6028306|NCT00286494|9624158|FG002|Overall Study|Adverse Event|6
6028307|NCT00286494|9624156|FG000|Overall Study|Physician Decision|5
6028308|NCT00286494|9624157|FG001|Overall Study|Physician Decision|5
6028309|NCT00286494|9624158|FG002|Overall Study|Physician Decision|1
6028310|NCT00286494|9624156|FG000|Overall Study|Lost to Follow-up|3
6028311|NCT00286494|9624157|FG001|Overall Study|Lost to Follow-up|1
6028312|NCT00286494|9624158|FG002|Overall Study|Lost to Follow-up|3
6028313|NCT00286494|9624156|FG000|Overall Study|Protocol Violation|1
6028314|NCT00286494|9624157|FG001|Overall Study|Protocol Violation|1
6028315|NCT00286494|9624158|FG002|Overall Study|Protocol Violation|2
6028316|NCT00286754|9624190|FG000|Overall Study|Adverse Event|2
6028317|NCT00286754|9624191|FG001|Overall Study|Adverse Event|2
6028318|NCT00286754|9624192|FG002|Overall Study|Adverse Event|3
6028319|NCT00286754|9624190|FG000|Overall Study|Withdrawal by Subject|6
6028320|NCT00286754|9624191|FG001|Overall Study|Withdrawal by Subject|2
6028321|NCT00286754|9624192|FG002|Overall Study|Withdrawal by Subject|0
6028322|NCT00286754|9624190|FG000|Overall Study|Lost to Follow-up|12
6028323|NCT00286754|9624191|FG001|Overall Study|Lost to Follow-up|14
6028324|NCT00286754|9624192|FG002|Overall Study|Lost to Follow-up|6
6028325|NCT00286754|9624190|FG000|Overall Study|Moved out of state|0
6028326|NCT00286754|9624191|FG001|Overall Study|Moved out of state|0
6028327|NCT00286754|9624192|FG002|Overall Study|Moved out of state|1
6028328|NCT00287079|9624223|FG000|Overall Study|Qualifying relapse|12
6028329|NCT00287079|9624224|FG001|Overall Study|Qualifying relapse|1
6028330|NCT00287079|9624223|FG000|Overall Study|Non-qualifying relapse|1
6028331|NCT00287079|9624224|FG001|Overall Study|Non-qualifying relapse|0
6028332|NCT00287079|9624223|FG000|Overall Study|Adverse Event|5
6028333|NCT00287079|9624224|FG001|Overall Study|Adverse Event|0
6028334|NCT00287079|9624223|FG000|Overall Study|Protocol Violation|1
6028335|NCT00287079|9624224|FG001|Overall Study|Protocol Violation|0
6028336|NCT00287079|9624223|FG000|Overall Study|Other|3
6028337|NCT00287079|9624224|FG001|Overall Study|Other|0
6028338|NCT00287118|9624230|FG000|Overall Study|Adverse Event|30
6028339|NCT00287118|9624230|FG000|Overall Study|Death|1
6028340|NCT00287118|9624230|FG000|Overall Study|Lack of Efficacy|11
6028341|NCT00287118|9624230|FG000|Overall Study|Lost to Follow-up|1
6028342|NCT00287118|9624230|FG000|Overall Study|Protocol Violation|2
6028343|NCT00287118|9624230|FG000|Overall Study|Other|7
6028344|NCT00287365|9624251|FG000|Overall Study|sample not acquired|13
6028345|NCT00287469|9624258|FG000|Overall Study|serious adverse event|1
6028346|NCT00287469|9624259|FG001|Overall Study|serious adverse event|6
6028347|NCT00287469|9624258|FG000|Overall Study|Adverse Event|1
6028348|NCT00287469|9624259|FG001|Overall Study|Adverse Event|1
6028349|NCT00287469|9624258|FG000|Overall Study|moved from area|144
6028350|NCT00287469|9624259|FG001|Overall Study|moved from area|138
6028351|NCT00287469|9624258|FG000|Overall Study|Lost to Follow-up|74
6028352|NCT00287469|9624259|FG001|Overall Study|Lost to Follow-up|69
6028353|NCT00287586|9624269|FG000|Overall Study|Withdrew Consent|19
6028354|NCT00287586|9624270|FG001|Overall Study|Withdrew Consent|30
6028355|NCT00287586|9624269|FG000|Overall Study|Lost to Follow-up|5
6028356|NCT00287586|9624270|FG001|Overall Study|Lost to Follow-up|4
6028357|NCT00287586|9624269|FG000|Overall Study|Death|2
6028358|NCT00287586|9624270|FG001|Overall Study|Death|3
6028359|NCT00287586|9624269|FG000|Overall Study|Elevated Hematocrit|3
6028360|NCT00287586|9624270|FG001|Overall Study|Elevated Hematocrit|0
6028361|NCT00287586|9624269|FG000|Overall Study|Rash|3
6028362|NCT00287586|9624270|FG001|Overall Study|Rash|0
6028363|NCT00287586|9624269|FG000|Overall Study|Elevated Prostate Specific Antigen|2
6028364|NCT00287586|9624270|FG001|Overall Study|Elevated Prostate Specific Antigen|0
6028365|NCT00287586|9624269|FG000|Overall Study|Stroke|2
6028366|NCT00287586|9624270|FG001|Overall Study|Stroke|0
6028367|NCT00287586|9624269|FG000|Overall Study|Myocardial Infarction|1
6028368|NCT00287586|9624270|FG001|Overall Study|Myocardial Infarction|0
6028369|NCT00287586|9624269|FG000|Overall Study|Lower Urinary Tract Symptoms|1
6028370|NCT00287586|9624270|FG001|Overall Study|Lower Urinary Tract Symptoms|0
6028371|NCT00287586|9624269|FG000|Overall Study|Cognitive Impairment|1
6028372|NCT00287586|9624270|FG001|Overall Study|Cognitive Impairment|0
6028373|NCT00287586|9624269|FG000|Overall Study|Pancreatic Cancer|1
6028374|NCT00287586|9624270|FG001|Overall Study|Pancreatic Cancer|3
6028375|NCT00287586|9624269|FG000|Overall Study|Sleep Apnea|1
6028376|NCT00287586|9624270|FG001|Overall Study|Sleep Apnea|0
6028377|NCT00287586|9624269|FG000|Overall Study|Shoulder Pain|1
6028378|NCT00287586|9624270|FG001|Overall Study|Shoulder Pain|0
6028379|NCT00287586|9624269|FG000|Overall Study|Inappropriate Behaviour with Staff|1
6309539|NCT02640482|10038225|FG000|Overall Study|Lost to Follow-up|3
6309540|NCT02640482|10038226|FG001|Overall Study|Lost to Follow-up|0
6309541|NCT02640547|10038232|FG000|Overall Study|Failure to Return|1
6079357|NCT00608985|9686161|FG003|Overall Study|Lost to Follow-up|0
6079358|NCT00609167|9686178|FG000|Overall Study|Withdrawal by Subject|1
6079359|NCT00609167|9686179|FG001|Overall Study|Withdrawal by Subject|0
6079360|NCT00609167|9686178|FG000|Overall Study|Lack of Efficacy|1
6079361|NCT00609167|9686179|FG001|Overall Study|Lack of Efficacy|0
6079362|NCT00609167|9686178|FG000|Overall Study|Adverse Event|5
6079363|NCT00609167|9686179|FG001|Overall Study|Adverse Event|1
6079364|NCT00609167|9686178|FG000|Overall Study|Disease Progression|1
6028380|NCT00287586|9624270|FG001|Overall Study|Inappropriate Behaviour with Staff|0
6028381|NCT00287586|9624269|FG000|Overall Study|Nonadherence|1
6028382|NCT00287586|9624270|FG001|Overall Study|Nonadherence|1
6028383|NCT00287586|9624269|FG000|Overall Study|Enrolled in Another Study|1
6028384|NCT00287586|9624270|FG001|Overall Study|Enrolled in Another Study|0
6028385|NCT00287586|9624269|FG000|Overall Study|Major Depression|0
6309542|NCT02640547|10038232|FG000|Overall Study|Withdrawal by Subject|1
6309543|NCT02640547|10038232|FG000|Overall Study|Death|6
6309544|NCT02640547|10038232|FG000|Overall Study|Miscellaneous|3
6028386|NCT00287586|9624270|FG001|Overall Study|Major Depression|2
6028387|NCT00287586|9624269|FG000|Overall Study|Lung Cancer|0
6028388|NCT00287586|9624270|FG001|Overall Study|Lung Cancer|2
6028389|NCT00287586|9624269|FG000|Overall Study|Elevated IPSS Score|0
6028390|NCT00287586|9624270|FG001|Overall Study|Elevated IPSS Score|1
6028391|NCT00287586|9624269|FG000|Overall Study|Retroperitoneal Cancer|0
6028392|NCT00287586|9624270|FG001|Overall Study|Retroperitoneal Cancer|1
6028393|NCT00287586|9624269|FG000|Overall Study|Mastodynia and Gynecomastia|0
6028394|NCT00287586|9624270|FG001|Overall Study|Mastodynia and Gynecomastia|1
6028395|NCT00287586|9624269|FG000|Overall Study|Mood Swings and Irritability|0
6028396|NCT00287586|9624270|FG001|Overall Study|Mood Swings and Irritability|1
6028397|NCT00287586|9624269|FG000|Overall Study|Bradycardia|0
6079365|NCT00609167|9686179|FG001|Overall Study|Disease Progression|0
6028398|NCT00287586|9624270|FG001|Overall Study|Bradycardia|1
6309545|NCT02640612|10038247|FG000|Overall Study|Adverse Event|6
6309546|NCT02640612|10038248|FG001|Overall Study|Adverse Event|7
6309547|NCT02640612|10038249|FG002|Overall Study|Adverse Event|2
6028399|NCT00287586|9624269|FG000|Overall Study|Itchy Swollen Eyes|0
6028400|NCT00287586|9624270|FG001|Overall Study|Itchy Swollen Eyes|1
6028401|NCT00287586|9624269|FG000|Overall Study|Recurrent Melanoma|0
6028402|NCT00287586|9624270|FG001|Overall Study|Recurrent Melanoma|1
6028403|NCT00287690|9624278|FG000|Overall Study|Protocol Violation|20
6028404|NCT00287690|9624279|FG001|Overall Study|Protocol Violation|26
6309548|NCT02640612|10038247|FG000|Overall Study|Death|1
6309549|NCT02640612|10038248|FG001|Overall Study|Death|0
6309550|NCT02640612|10038249|FG002|Overall Study|Death|0
6309551|NCT02640612|10038247|FG000|Overall Study|Withdrawal by Subject|10
6028405|NCT00288015|9624325|FG000|Bevacizumab Treatment Cycles 1-2|Withdrawal by Subject|1
6028406|NCT00288015|9624325|FG000|Bevacizumab Treatment Cycles 1-2|Physician Decision|1
6028407|NCT00288015|9624325|FG000|First Response Assessment|Withdrawal by Subject|1
6028408|NCT00288015|9624325|FG000|First Response Assessment|Death|1
6028409|NCT00288015|9624325|FG000|First Response Assessment|Physician Decision|2
6028410|NCT00288015|9624325|FG000|Continued Bevacizumab Cycle 3+|Disease progressed|7
6028411|NCT00288015|9624325|FG000|Follow up for Survival x 2 Years|Death|13
6028412|NCT00288015|9624325|FG000|Follow up for Survival x 2 Years|Lost to Follow-up|4
6028413|NCT00288015|9624325|FG000|Follow up for Survival x 2 Years|Other|9
6028414|NCT00288054|9624329|FG000|Overall Study|Protocol Violation|2
6028415|NCT00288054|9624329|FG000|Overall Study|Lack of Efficacy|16
6028416|NCT00288054|9624329|FG000|Overall Study|Adverse Event|3
6028417|NCT00288054|9624329|FG000|Overall Study|Withdrawal by Subject|1
6028418|NCT00288054|9624329|FG000|Overall Study|Not protocol specified|2
6028419|NCT00288509|9624350|FG000|Treatment Cycle 1|Adverse Event|1
6028420|NCT00288509|9624350|FG000|Treatment Cycle 1|Lack of Efficacy|1
6028421|NCT00288509|9624350|FG000|Treatment Cycle 1|Withdrawal by Subject|1
6028422|NCT00288509|9624350|FG000|Treatment Cycle 1|Lost to Follow-up|2
6028423|NCT00288509|9624350|FG000|Treatment Cycle 1|Treatment stopped according to protocol|1
6028424|NCT00288509|9624350|FG000|Treatment Cycle 2|Lack of Efficacy|1
6028425|NCT00288509|9624350|FG000|Treatment Cycle 2|Withdrawal by Subject|2
6028426|NCT00288509|9624350|FG000|Treatment Cycle 3|Lack of Efficacy|1
6028427|NCT00288509|9624350|FG000|Treatment Cycle 3|Withdrawal by Subject|1
6028428|NCT00288509|9624350|FG000|Treatment Cycle 3|Lost to Follow-up|2
6028429|NCT00288509|9624350|FG000|Treatment Cycle 3|Treatment stopped according to protocol|1
6028430|NCT00288509|9624350|FG000|Treatment Cycle 4|Withdrawal by Subject|3
6028431|NCT00288509|9624350|FG000|Treatment Cycle 4|Physician Decision|4
6028432|NCT00288509|9624350|FG000|Treatment Cycle 4|Treatment stopped according to protocol|1
6028433|NCT00288587|9624368|FG000|Overall Study|Death|4
6028434|NCT00288587|9624369|FG001|Overall Study|Death|4
6028435|NCT00288587|9624368|FG000|Overall Study|Transplant|0
6028436|NCT00288587|9624369|FG001|Overall Study|Transplant|3
6028437|NCT00288587|9624368|FG000|Overall Study|Adverse Event|0
6028438|NCT00288587|9624369|FG001|Overall Study|Adverse Event|1
6028439|NCT00288587|9624368|FG000|Overall Study|Physician Decision|0
6028440|NCT00288587|9624369|FG001|Overall Study|Physician Decision|2
6028441|NCT00288587|9624368|FG000|Overall Study|Severe Aortic Stenosis|1
6079366|NCT00609167|9686178|FG000|Overall Study|Stem Cell Transplant|0
6028442|NCT00288587|9624369|FG001|Overall Study|Severe Aortic Stenosis|0
6028443|NCT00288626|9624384|FG000|Overall Study|Death|3
6028444|NCT00288626|9624384|FG000|Overall Study|Withdrawal by Subject|4
6028445|NCT00288639|9624390|FG000|Overall Study|Adverse Event|5
6028446|NCT00288639|9624390|FG000|Overall Study|Lack of Efficacy|4
6028447|NCT00288639|9624390|FG000|Overall Study|Withdrawal by Subject|2
6028448|NCT00288639|9624390|FG000|Overall Study|Other|1
6028449|NCT00288704|9624397|FG000|Part A, Double Blind, Weeks 1-6|Pre-dose Condition|0
6028450|NCT00288704|9624398|FG001|Part A, Double Blind, Weeks 1-6|Pre-dose Condition|1
6028451|NCT00288704|9624399|FG002|Part A, Double Blind, Weeks 1-6|Pre-dose Condition|0
6028452|NCT00288704|9624397|FG000|Part B, Randomized Withdrawal, Wks 15-24|Adverse Event|0
6028453|NCT00288704|9624398|FG001|Part B, Randomized Withdrawal, Wks 15-24|Adverse Event|1
6028454|NCT00288704|9624399|FG002|Part B, Randomized Withdrawal, Wks 15-24|Adverse Event|0
6028455|NCT00288704|9624397|FG000|Open-Label Extension (OLE) Weeks 24-117|Adverse Event|0
6028456|NCT00288704|9624398|FG001|Open-Label Extension (OLE) Weeks 24-117|Adverse Event|0
6028457|NCT00288704|9624399|FG002|Open-Label Extension (OLE) Weeks 24-117|Adverse Event|1
6028458|NCT00288704|9624397|FG000|Open-Label Extension (OLE) Weeks 24-117|Withdrawal by Subject|0
6028459|NCT00288704|9624398|FG001|Open-Label Extension (OLE) Weeks 24-117|Withdrawal by Subject|0
6028460|NCT00288704|9624399|FG002|Open-Label Extension (OLE) Weeks 24-117|Withdrawal by Subject|1
6028461|NCT00288704|9624397|FG000|Open-Label Extension (OLE) Weeks 24-117|Death|0
6028462|NCT00288704|9624398|FG001|Open-Label Extension (OLE) Weeks 24-117|Death|0
6028463|NCT00288704|9624399|FG002|Open-Label Extension (OLE) Weeks 24-117|Death|2
6028464|NCT00288704|9624397|FG000|Open-Label Extension (OLE) Weeks 24-117|Sponsor Decision|0
6028465|NCT00288704|9624398|FG001|Open-Label Extension (OLE) Weeks 24-117|Sponsor Decision|0
6028466|NCT00288704|9624399|FG002|Open-Label Extension (OLE) Weeks 24-117|Sponsor Decision|15
6028467|NCT00288704|9624397|FG000|Open-Label Extension (OLE) Weeks 24-117|Pregnancy|0
6028468|NCT00288704|9624398|FG001|Open-Label Extension (OLE) Weeks 24-117|Pregnancy|0
6028469|NCT00288704|9624399|FG002|Open-Label Extension (OLE) Weeks 24-117|Pregnancy|1
6028470|NCT00288860|9624408|FG000|Overall Study|Did not complete intake|4
6028471|NCT00288860|9624409|FG001|Overall Study|Did not complete intake|8
6028472|NCT00288860|9624408|FG000|Overall Study|Death|4
6028473|NCT00288860|9624409|FG001|Overall Study|Death|3
6028474|NCT00288860|9624408|FG000|Overall Study|Withdrawal by Subject|20
6028475|NCT00288860|9624409|FG001|Overall Study|Withdrawal by Subject|15
6028476|NCT00288860|9624408|FG000|Overall Study|Lost to Follow-up|74
6028477|NCT00288860|9624409|FG001|Overall Study|Lost to Follow-up|71
6079367|NCT00609167|9686179|FG001|Overall Study|Stem Cell Transplant|6
6079368|NCT00609245|9686185|FG000|Overall Study|Adverse Event|1
6028478|NCT00288912|9624430|FG000|Overall Study|Developed exclusion criterion|4
6028479|NCT00288912|9624431|FG001|Overall Study|Developed exclusion criterion|6
6028480|NCT00288912|9624432|FG002|Overall Study|Developed exclusion criterion|7
6028481|NCT00288912|9624430|FG000|Overall Study|Lost to Follow-up|9
6028482|NCT00288912|9624431|FG001|Overall Study|Lost to Follow-up|6
6028483|NCT00288912|9624432|FG002|Overall Study|Lost to Follow-up|9
6028484|NCT00288912|9624430|FG000|Overall Study|Withdrawal by Subject|4
6028485|NCT00288912|9624431|FG001|Overall Study|Withdrawal by Subject|5
6028486|NCT00288912|9624432|FG002|Overall Study|Withdrawal by Subject|12
6028487|NCT00289016|9624440|FG000|Overall Study|Disease Progression|29
6028488|NCT00289016|9624440|FG000|Overall Study|Death|2
6028489|NCT00289016|9624440|FG000|Overall Study|Unrelated Medical Condition or Accident|2
6028490|NCT00289016|9624440|FG000|Overall Study|Withdrawal by Subject|2
6028491|NCT00289016|9624440|FG000|Overall Study|Adverse Event|1
6028492|NCT00289016|9624440|FG000|Overall Study|Other|1
6028493|NCT00289133|9624472|FG000|Overall Study|Non-study device implanted|12
6028494|NCT00289133|9624473|FG001|Overall Study|Non-study device implanted|0
6028495|NCT00289133|9624472|FG000|Overall Study|Protocol Violation|32
6028496|NCT00289133|9624473|FG001|Overall Study|Protocol Violation|38
6028497|NCT00289133|9624472|FG000|Overall Study|Withdrawal by Subject|9
6028498|NCT00289133|9624473|FG001|Overall Study|Withdrawal by Subject|10
6028499|NCT00289133|9624472|FG000|Overall Study|Death|5
6028500|NCT00289133|9624473|FG001|Overall Study|Death|10
6028501|NCT00289133|9624472|FG000|Overall Study|Lost to Follow-up - Hurricane Katri|73
6028502|NCT00289133|9624473|FG001|Overall Study|Lost to Follow-up - Hurricane Katri|74
6028503|NCT00289133|9624472|FG000|Overall Study|Physician Decision|41
6028504|NCT00289133|9624473|FG001|Overall Study|Physician Decision|45
6028505|NCT00289133|9624472|FG000|Overall Study|Revision|8
6028506|NCT00289133|9624473|FG001|Overall Study|Revision|6
6028507|NCT00289133|9624472|FG000|Overall Study|Lost to Follow-up|92
6028508|NCT00289133|9624473|FG001|Overall Study|Lost to Follow-up|115
6028509|NCT00289185|9624485|FG000|Overall Study|Withdrawal by Subject|4
6028510|NCT00289185|9624486|FG001|Overall Study|Withdrawal by Subject|8
6079369|NCT00609336|9686200|FG000|Overall Study|Protocol Violation|3
6079370|NCT00609336|9686200|FG000|Overall Study|Death|1
6079371|NCT00609336|9686200|FG000|Overall Study|LA or Met at Surgery|9
6087640|NCT00669617|9698053|FG004|Period 1|Protocol Deviation|1
6087641|NCT00669617|9698049|FG000|Period 3|Lost to Follow-up|1
6087642|NCT00669617|9698050|FG001|Period 3|Lost to Follow-up|0
6028511|NCT00289185|9624485|FG000|Overall Study|Lost to Follow-up|23
6028512|NCT00289185|9624486|FG001|Overall Study|Lost to Follow-up|17
6028513|NCT00289185|9624485|FG000|Overall Study|Death|1
6028514|NCT00289185|9624486|FG001|Overall Study|Death|1
6028515|NCT00289198|9624495|FG000|Overall Study|Adverse Event|0
6028516|NCT00289198|9624496|FG001|Overall Study|Adverse Event|2
6028517|NCT00289198|9624495|FG000|Overall Study|Protocol Violation|2
6028518|NCT00289198|9624496|FG001|Overall Study|Protocol Violation|1
6028519|NCT00289198|9624495|FG000|Overall Study|Withdrawal by Subject|4
6028520|NCT00289198|9624496|FG001|Overall Study|Withdrawal by Subject|1
6028521|NCT00289198|9624495|FG000|Overall Study|Lack of Efficacy|2
6028522|NCT00289198|9624496|FG001|Overall Study|Lack of Efficacy|0
6028523|NCT00289198|9624495|FG000|Overall Study|Other: Low compliance|0
6028524|NCT00289198|9624496|FG001|Overall Study|Other: Low compliance|1
6028525|NCT00289198|9624495|FG000|Overall Study|Other: Physician's decision|0
6028526|NCT00289198|9624496|FG001|Overall Study|Other: Physician's decision|1
6028527|NCT00289198|9624495|FG000|Overall Study|Other: Unable to attend on schedule|2
6028528|NCT00289198|9624496|FG001|Overall Study|Other: Unable to attend on schedule|1
6028529|NCT00289198|9624495|FG000|Overall Study|Other: Miscalculation of the visit date|21
6028530|NCT00289198|9624496|FG001|Overall Study|Other: Miscalculation of the visit date|22
6028531|NCT00289198|9624495|FG000|Overall Study|Other: Impossible to come on visit|0
6028532|NCT00289198|9624496|FG001|Overall Study|Other: Impossible to come on visit|1
6028533|NCT00289276|9624516|FG000|Second Part of FAST Study (Expansion)|Death|0
6028534|NCT00289276|9624517|FG001|Second Part of FAST Study (Expansion)|Death|2
6028535|NCT00289276|9624516|FG000|Second Part of FAST Study (Expansion)|Lost to Follow-up|0
6028536|NCT00289276|9624517|FG001|Second Part of FAST Study (Expansion)|Lost to Follow-up|1
6028537|NCT00289289|9624526|FG000|Overall Study|Withdrawal by Subject|5
6028538|NCT00289289|9624527|FG001|Overall Study|Withdrawal by Subject|3
6028539|NCT00289289|9624528|FG002|Overall Study|Withdrawal by Subject|15
6028540|NCT00289289|9624526|FG000|Overall Study|Lost to Follow-up|1
6028541|NCT00289289|9624527|FG001|Overall Study|Lost to Follow-up|0
6028542|NCT00289289|9624528|FG002|Overall Study|Lost to Follow-up|1
6028543|NCT00289289|9624526|FG000|Overall Study|Death|4
6028544|NCT00289289|9624527|FG001|Overall Study|Death|2
6087643|NCT00669617|9698051|FG002|Period 3|Lost to Follow-up|0
6028545|NCT00289289|9624528|FG002|Overall Study|Death|5
6028546|NCT00289289|9624526|FG000|Overall Study|No implant attempted|0
6028547|NCT00289289|9624527|FG001|Overall Study|No implant attempted|0
6028548|NCT00289289|9624528|FG002|Overall Study|No implant attempted|1
6028549|NCT00289289|9624526|FG000|Overall Study|Physician Decision|1
6028550|NCT00289289|9624527|FG001|Overall Study|Physician Decision|0
6087644|NCT00669617|9698052|FG003|Period 3|Lost to Follow-up|0
6028551|NCT00289289|9624528|FG002|Overall Study|Physician Decision|6
6087645|NCT00669617|9698053|FG004|Period 3|Lost to Follow-up|0
6028552|NCT00289289|9624526|FG000|Overall Study|Non-study device implanted|2
6028553|NCT00289289|9624527|FG001|Overall Study|Non-study device implanted|1
6028554|NCT00289289|9624528|FG002|Overall Study|Non-study device implanted|3
6028555|NCT00289289|9624526|FG000|Overall Study|Did not meet inclusion/exclusion|0
6028556|NCT00289289|9624527|FG001|Overall Study|Did not meet inclusion/exclusion|0
6028557|NCT00289289|9624528|FG002|Overall Study|Did not meet inclusion/exclusion|6
6028558|NCT00289289|9624526|FG000|Overall Study|Other Exit Reason|6
6028559|NCT00289289|9624527|FG001|Overall Study|Other Exit Reason|4
6028560|NCT00289289|9624528|FG002|Overall Study|Other Exit Reason|12
6028561|NCT00289458|9624564|FG000|Overall Study|Death|1
6028562|NCT00289458|9624565|FG001|Overall Study|Death|0
6028563|NCT00289458|9624566|FG002|Overall Study|Death|0
6028564|NCT00289458|9624564|FG000|Overall Study|Physician Decision|3
6028565|NCT00289458|9624565|FG001|Overall Study|Physician Decision|4
6028566|NCT00289458|9624566|FG002|Overall Study|Physician Decision|2
6028567|NCT00289458|9624564|FG000|Overall Study|Withdrawal by Subject|2
6028568|NCT00289458|9624565|FG001|Overall Study|Withdrawal by Subject|2
6028569|NCT00289458|9624566|FG002|Overall Study|Withdrawal by Subject|4
6028570|NCT00289536|9624578|FG000|Period 3|Lost to Follow-up|0
6028571|NCT00289536|9624579|FG001|Period 3|Lost to Follow-up|0
6028572|NCT00289536|9624580|FG002|Period 3|Lost to Follow-up|1
6028573|NCT00289731|9624603|FG000|Overall Study|Adverse Event|1
6028574|NCT00289731|9624604|FG001|Overall Study|Adverse Event|2
6028575|NCT00289731|9624605|FG002|Overall Study|Adverse Event|2
6028576|NCT00289731|9624603|FG000|Overall Study|Other|1
6028577|NCT00289731|9624604|FG001|Overall Study|Other|0
6028578|NCT00289731|9624605|FG002|Overall Study|Other|0
6028579|NCT00289770|9624629|FG000|Year 15|Withdrawal by Subject|1
6028580|NCT00289783|9624635|FG000|Primary Phase|Adverse Event|10
6028581|NCT00289783|9624636|FG001|Primary Phase|Adverse Event|1
6028582|NCT00289783|9624635|FG000|Primary Phase|Protocol Violation|27
6028583|NCT00289783|9624636|FG001|Primary Phase|Protocol Violation|6
6028584|NCT00289783|9624635|FG000|Primary Phase|Withdrawal by Subject|93
6028585|NCT00289783|9624636|FG001|Primary Phase|Withdrawal by Subject|40
6028586|NCT00289783|9624635|FG000|Primary Phase|Lost to Follow-up|60
6028587|NCT00289783|9624636|FG001|Primary Phase|Lost to Follow-up|14
6028588|NCT00289783|9624635|FG000|Primary Phase|Migration from the study area|26
6028589|NCT00289783|9624636|FG001|Primary Phase|Migration from the study area|10
6028590|NCT00289783|9624635|FG000|Primary Phase|Other|32
6028591|NCT00289783|9624636|FG001|Primary Phase|Other|12
6028592|NCT00289783|9624635|FG000|Fourth Dose Phase|Adverse Event|1
6028593|NCT00289783|9624636|FG001|Fourth Dose Phase|Adverse Event|0
6028594|NCT00289783|9624635|FG000|Fourth Dose Phase|Withdrawal by Subject|10
6028595|NCT00289783|9624636|FG001|Fourth Dose Phase|Withdrawal by Subject|1
6028596|NCT00289783|9624635|FG000|Fourth Dose Phase|Lost to Follow-up|53
6028597|NCT00289783|9624636|FG001|Fourth Dose Phase|Lost to Follow-up|12
6028598|NCT00289783|9624635|FG000|Fourth Dose Phase|Migration from the study area|1
6028599|NCT00289783|9624636|FG001|Fourth Dose Phase|Migration from the study area|1
6028600|NCT00289783|9624635|FG000|Fourth Dose Phase|Other|22
6028601|NCT00289783|9624636|FG001|Fourth Dose Phase|Other|10
6028602|NCT00289848|9624652|FG000|Overall Study|Adverse Event|6
6028603|NCT00289848|9624653|FG001|Overall Study|Adverse Event|4
6028604|NCT00289848|9624652|FG000|Overall Study|Death|1
6028605|NCT00289848|9624653|FG001|Overall Study|Death|0
6028606|NCT00289848|9624652|FG000|Overall Study|Lack of Efficacy|20
6028607|NCT00289848|9624653|FG001|Overall Study|Lack of Efficacy|24
6028608|NCT00289848|9624652|FG000|Overall Study|Lost to Follow-up|3
6028609|NCT00289848|9624653|FG001|Overall Study|Lost to Follow-up|1
6028610|NCT00289848|9624652|FG000|Overall Study|Protocol Violation|5
6028611|NCT00289848|9624653|FG001|Overall Study|Protocol Violation|2
6028612|NCT00289848|9624652|FG000|Overall Study|Withdrawal by Subject|5
6028613|NCT00289848|9624653|FG001|Overall Study|Withdrawal by Subject|11
6028614|NCT00289848|9624652|FG000|Overall Study|Patient Moved|6
6028615|NCT00289848|9624653|FG001|Overall Study|Patient Moved|2
6028616|NCT00289848|9624652|FG000|Overall Study|Open-Label AHA Treatment Requested|0
6028617|NCT00289848|9624653|FG001|Overall Study|Open-Label AHA Treatment Requested|1
6028618|NCT00289900|9624665|FG000|Overall Study|Adverse Event|28
6028619|NCT00289900|9624666|FG001|Overall Study|Adverse Event|40
6028620|NCT00289900|9624667|FG002|Overall Study|Adverse Event|13
6028621|NCT00289900|9624668|FG003|Overall Study|Adverse Event|19
6028622|NCT00289900|9624669|FG004|Overall Study|Adverse Event|20
6028623|NCT00289900|9624670|FG005|Overall Study|Adverse Event|33
6028624|NCT00289900|9624665|FG000|Overall Study|Lost to Follow-up|7
6028625|NCT00289900|9624666|FG001|Overall Study|Lost to Follow-up|7
6028626|NCT00289900|9624667|FG002|Overall Study|Lost to Follow-up|8
6028627|NCT00289900|9624668|FG003|Overall Study|Lost to Follow-up|8
6028628|NCT00289900|9624669|FG004|Overall Study|Lost to Follow-up|4
6028629|NCT00289900|9624670|FG005|Overall Study|Lost to Follow-up|8
6028630|NCT00289900|9624665|FG000|Overall Study|Participant had flushing|18
6028631|NCT00289900|9624666|FG001|Overall Study|Participant had flushing|42
6028632|NCT00289900|9624667|FG002|Overall Study|Participant had flushing|1
6028633|NCT00289900|9624668|FG003|Overall Study|Participant had flushing|2
6146380|NCT01077076|9781137|FG005|First Intervention|Withdrawal by Subject|0
6028634|NCT00289900|9624669|FG004|Overall Study|Participant had flushing|0
6028635|NCT00289900|9624670|FG005|Overall Study|Participant had flushing|4
6028636|NCT00289900|9624665|FG000|Overall Study|Other|0
6028637|NCT00289900|9624666|FG001|Overall Study|Other|0
6028638|NCT00289900|9624667|FG002|Overall Study|Other|0
6028639|NCT00289900|9624668|FG003|Overall Study|Other|5
6028640|NCT00289900|9624669|FG004|Overall Study|Other|1
6028641|NCT00289900|9624670|FG005|Overall Study|Other|0
6028642|NCT00289900|9624665|FG000|Overall Study|Participant moved|1
6028643|NCT00289900|9624666|FG001|Overall Study|Participant moved|0
6028644|NCT00289900|9624667|FG002|Overall Study|Participant moved|0
6028645|NCT00289900|9624668|FG003|Overall Study|Participant moved|1
6028646|NCT00289900|9624669|FG004|Overall Study|Participant moved|1
6028647|NCT00289900|9624670|FG005|Overall Study|Participant moved|1
6028648|NCT00289900|9624665|FG000|Overall Study|Withdrawal by Subject|10
6028649|NCT00289900|9624666|FG001|Overall Study|Withdrawal by Subject|21
6028650|NCT00289900|9624667|FG002|Overall Study|Withdrawal by Subject|8
6028651|NCT00289900|9624668|FG003|Overall Study|Withdrawal by Subject|18
6028652|NCT00289900|9624669|FG004|Overall Study|Withdrawal by Subject|12
6028653|NCT00289900|9624670|FG005|Overall Study|Withdrawal by Subject|11
6028654|NCT00289900|9624665|FG000|Overall Study|Protocol Violation|3
6028655|NCT00289900|9624666|FG001|Overall Study|Protocol Violation|9
6028656|NCT00289900|9624667|FG002|Overall Study|Protocol Violation|2
6028657|NCT00289900|9624668|FG003|Overall Study|Protocol Violation|6
6028658|NCT00289900|9624669|FG004|Overall Study|Protocol Violation|7
6028659|NCT00289900|9624670|FG005|Overall Study|Protocol Violation|4
6028660|NCT00289900|9624665|FG000|Overall Study|site terminated|1
6028661|NCT00289900|9624666|FG001|Overall Study|site terminated|0
6028662|NCT00289900|9624667|FG002|Overall Study|site terminated|1
6028663|NCT00289900|9624668|FG003|Overall Study|site terminated|0
6028664|NCT00289900|9624669|FG004|Overall Study|site terminated|0
6028665|NCT00289900|9624670|FG005|Overall Study|site terminated|0
6028666|NCT00289900|9624665|FG000|Overall Study|Not treated|0
6028667|NCT00289900|9624666|FG001|Overall Study|Not treated|1
6028668|NCT00289900|9624667|FG002|Overall Study|Not treated|0
6028669|NCT00289900|9624668|FG003|Overall Study|Not treated|0
6028670|NCT00289900|9624669|FG004|Overall Study|Not treated|0
6028671|NCT00289900|9624670|FG005|Overall Study|Not treated|0
6028672|NCT00289913|9624692|FG000|Visit 1 (Stage I and Stage II)|Protocol deviation during safety F/U|0
6028673|NCT00289913|9624693|FG001|Visit 1 (Stage I and Stage II)|Protocol deviation during safety F/U|1
6028674|NCT00289913|9624694|FG002|Visit 1 (Stage I and Stage II)|Protocol deviation during safety F/U|0
6028675|NCT00289913|9624695|FG003|Visit 1 (Stage I and Stage II)|Protocol deviation during safety F/U|0
6028676|NCT00289913|9624696|FG004|Visit 1 (Stage I and Stage II)|Protocol deviation during safety F/U|0
6028677|NCT00289913|9624692|FG000|Visit 1 (Stage I and Stage II)|Lost during safety F/U|3
6028678|NCT00289913|9624693|FG001|Visit 1 (Stage I and Stage II)|Lost during safety F/U|2
6028679|NCT00289913|9624694|FG002|Visit 1 (Stage I and Stage II)|Lost during safety F/U|2
6028680|NCT00289913|9624695|FG003|Visit 1 (Stage I and Stage II)|Lost during safety F/U|2
6028681|NCT00289913|9624696|FG004|Visit 1 (Stage I and Stage II)|Lost during safety F/U|1
6028682|NCT00289913|9624692|FG000|Visit 1 (Stage I and Stage II)|Withdrew consent during safety F/U|2
6028683|NCT00289913|9624693|FG001|Visit 1 (Stage I and Stage II)|Withdrew consent during safety F/U|2
6028684|NCT00289913|9624694|FG002|Visit 1 (Stage I and Stage II)|Withdrew consent during safety F/U|0
6028685|NCT00289913|9624695|FG003|Visit 1 (Stage I and Stage II)|Withdrew consent during safety F/U|2
6028686|NCT00289913|9624696|FG004|Visit 1 (Stage I and Stage II)|Withdrew consent during safety F/U|2
6028687|NCT00289913|9624692|FG000|Visit 1 (Stage I and Stage II)|Moved during safety F/U|0
6028688|NCT00289913|9624693|FG001|Visit 1 (Stage I and Stage II)|Moved during safety F/U|0
6028689|NCT00289913|9624694|FG002|Visit 1 (Stage I and Stage II)|Moved during safety F/U|0
6028690|NCT00289913|9624695|FG003|Visit 1 (Stage I and Stage II)|Moved during safety F/U|0
6028691|NCT00289913|9624696|FG004|Visit 1 (Stage I and Stage II)|Moved during safety F/U|1
6028692|NCT00289913|9624692|FG000|Visit 1 (Stage I and Stage II)|Other reasons during safety F/U|0
6028693|NCT00289913|9624693|FG001|Visit 1 (Stage I and Stage II)|Other reasons during safety F/U|0
6028694|NCT00289913|9624694|FG002|Visit 1 (Stage I and Stage II)|Other reasons during safety F/U|0
6028695|NCT00289913|9624695|FG003|Visit 1 (Stage I and Stage II)|Other reasons during safety F/U|1
6028696|NCT00289913|9624696|FG004|Visit 1 (Stage I and Stage II)|Other reasons during safety F/U|0
6028697|NCT00289913|9624692|FG000|Visit 1 (Stage I and Stage II)|Protocol deviation after safety F/U|1
6028698|NCT00289913|9624693|FG001|Visit 1 (Stage I and Stage II)|Protocol deviation after safety F/U|2
6028699|NCT00289913|9624694|FG002|Visit 1 (Stage I and Stage II)|Protocol deviation after safety F/U|0
6028700|NCT00289913|9624695|FG003|Visit 1 (Stage I and Stage II)|Protocol deviation after safety F/U|0
6028701|NCT00289913|9624696|FG004|Visit 1 (Stage I and Stage II)|Protocol deviation after safety F/U|0
6028702|NCT00289913|9624692|FG000|Visit 1 (Stage I and Stage II)|Lost after safety F/U|2
6028703|NCT00289913|9624693|FG001|Visit 1 (Stage I and Stage II)|Lost after safety F/U|1
6028704|NCT00289913|9624694|FG002|Visit 1 (Stage I and Stage II)|Lost after safety F/U|0
6028705|NCT00289913|9624695|FG003|Visit 1 (Stage I and Stage II)|Lost after safety F/U|0
6028706|NCT00289913|9624696|FG004|Visit 1 (Stage I and Stage II)|Lost after safety F/U|5
6028707|NCT00289913|9624692|FG000|Visit 1 (Stage I and Stage II)|Withdrew consent after safety F/U]|0
6028708|NCT00289913|9624693|FG001|Visit 1 (Stage I and Stage II)|Withdrew consent after safety F/U]|8
6028709|NCT00289913|9624694|FG002|Visit 1 (Stage I and Stage II)|Withdrew consent after safety F/U]|5
6028710|NCT00289913|9624695|FG003|Visit 1 (Stage I and Stage II)|Withdrew consent after safety F/U]|6
6028711|NCT00289913|9624696|FG004|Visit 1 (Stage I and Stage II)|Withdrew consent after safety F/U]|0
6028712|NCT00289913|9624692|FG000|Visit 1 (Stage I and Stage II)|Other reasons after safety F/U|1
6028713|NCT00289913|9624693|FG001|Visit 1 (Stage I and Stage II)|Other reasons after safety F/U|0
6028714|NCT00289913|9624694|FG002|Visit 1 (Stage I and Stage II)|Other reasons after safety F/U|2
6028715|NCT00289913|9624695|FG003|Visit 1 (Stage I and Stage II)|Other reasons after safety F/U|0
6028716|NCT00289913|9624696|FG004|Visit 1 (Stage I and Stage II)|Other reasons after safety F/U|0
6028717|NCT00289913|9624692|FG000|Visit 2 (Stage I and Stage II)|Protocol deviation during safety F/U|0
6028718|NCT00289913|9624693|FG001|Visit 2 (Stage I and Stage II)|Protocol deviation during safety F/U|0
6028719|NCT00289913|9624694|FG002|Visit 2 (Stage I and Stage II)|Protocol deviation during safety F/U|1
6079372|NCT00609362|9686207|FG000|Overall Study|Withdrawal by Subject|2
6079373|NCT00609362|9686208|FG001|Overall Study|Withdrawal by Subject|1
6079374|NCT00609362|9686207|FG000|Overall Study|Adverse Event|1
6079375|NCT00609362|9686208|FG001|Overall Study|Adverse Event|0
6079376|NCT00609466|9686217|FG000|Overall Study|Withdrawal by Subject|0
6079377|NCT00609466|9686218|FG001|Overall Study|Withdrawal by Subject|1
6079378|NCT00609466|9686219|FG002|Overall Study|Withdrawal by Subject|1
6079379|NCT00609466|9686217|FG000|Overall Study|Adverse Event|2
6028720|NCT00289913|9624695|FG003|Visit 2 (Stage I and Stage II)|Protocol deviation during safety F/U|0
6028721|NCT00289913|9624696|FG004|Visit 2 (Stage I and Stage II)|Protocol deviation during safety F/U|0
6028722|NCT00289913|9624692|FG000|Visit 2 (Stage I and Stage II)|Lost during safety F/U|8
6028723|NCT00289913|9624693|FG001|Visit 2 (Stage I and Stage II)|Lost during safety F/U|11
6028724|NCT00289913|9624694|FG002|Visit 2 (Stage I and Stage II)|Lost during safety F/U|2
6028725|NCT00289913|9624695|FG003|Visit 2 (Stage I and Stage II)|Lost during safety F/U|2
6028726|NCT00289913|9624696|FG004|Visit 2 (Stage I and Stage II)|Lost during safety F/U|0
6028727|NCT00289913|9624692|FG000|Visit 2 (Stage I and Stage II)|Subject moved during safety F/U|0
6028728|NCT00289913|9624693|FG001|Visit 2 (Stage I and Stage II)|Subject moved during safety F/U|1
6028729|NCT00289913|9624694|FG002|Visit 2 (Stage I and Stage II)|Subject moved during safety F/U|0
6028730|NCT00289913|9624695|FG003|Visit 2 (Stage I and Stage II)|Subject moved during safety F/U|0
6028731|NCT00289913|9624696|FG004|Visit 2 (Stage I and Stage II)|Subject moved during safety F/U|0
6028732|NCT00289913|9624692|FG000|Visit 2 (Stage I and Stage II)|Withdrew consent during safety F/U|3
6028733|NCT00289913|9624693|FG001|Visit 2 (Stage I and Stage II)|Withdrew consent during safety F/U|2
6028734|NCT00289913|9624694|FG002|Visit 2 (Stage I and Stage II)|Withdrew consent during safety F/U|1
6028735|NCT00289913|9624695|FG003|Visit 2 (Stage I and Stage II)|Withdrew consent during safety F/U|0
6028736|NCT00289913|9624696|FG004|Visit 2 (Stage I and Stage II)|Withdrew consent during safety F/U|0
6028737|NCT00289913|9624692|FG000|Visit 2 (Stage I and Stage II)|Other reasons during safety F/U|1
6028738|NCT00289913|9624693|FG001|Visit 2 (Stage I and Stage II)|Other reasons during safety F/U|0
6028739|NCT00289913|9624694|FG002|Visit 2 (Stage I and Stage II)|Other reasons during safety F/U|1
6028740|NCT00289913|9624695|FG003|Visit 2 (Stage I and Stage II)|Other reasons during safety F/U|0
6028741|NCT00289913|9624696|FG004|Visit 2 (Stage I and Stage II)|Other reasons during safety F/U|0
6028742|NCT00289913|9624692|FG000|Visit 2 (Stage I and Stage II)|Protocol deviation after safety F/U|0
6028743|NCT00289913|9624693|FG001|Visit 2 (Stage I and Stage II)|Protocol deviation after safety F/U|1
6028744|NCT00289913|9624694|FG002|Visit 2 (Stage I and Stage II)|Protocol deviation after safety F/U|3
6028745|NCT00289913|9624695|FG003|Visit 2 (Stage I and Stage II)|Protocol deviation after safety F/U|1
6028746|NCT00289913|9624696|FG004|Visit 2 (Stage I and Stage II)|Protocol deviation after safety F/U|0
6028747|NCT00289913|9624692|FG000|Visit 2 (Stage I and Stage II)|Lost after safety F/U|2
6028748|NCT00289913|9624693|FG001|Visit 2 (Stage I and Stage II)|Lost after safety F/U|5
6028749|NCT00289913|9624694|FG002|Visit 2 (Stage I and Stage II)|Lost after safety F/U|0
6028750|NCT00289913|9624695|FG003|Visit 2 (Stage I and Stage II)|Lost after safety F/U|3
6028751|NCT00289913|9624696|FG004|Visit 2 (Stage I and Stage II)|Lost after safety F/U|0
6028752|NCT00289913|9624692|FG000|Visit 2 (Stage I and Stage II)|Withdrew consent after safety F/U|0
6028753|NCT00289913|9624693|FG001|Visit 2 (Stage I and Stage II)|Withdrew consent after safety F/U|1
6028754|NCT00289913|9624694|FG002|Visit 2 (Stage I and Stage II)|Withdrew consent after safety F/U|2
6028755|NCT00289913|9624695|FG003|Visit 2 (Stage I and Stage II)|Withdrew consent after safety F/U|0
6028756|NCT00289913|9624696|FG004|Visit 2 (Stage I and Stage II)|Withdrew consent after safety F/U|0
6028757|NCT00289913|9624692|FG000|Visit 2 (Stage I and Stage II)|Other reasons after safety F/U]|1
6028758|NCT00289913|9624693|FG001|Visit 2 (Stage I and Stage II)|Other reasons after safety F/U]|0
6028759|NCT00289913|9624694|FG002|Visit 2 (Stage I and Stage II)|Other reasons after safety F/U]|0
6028760|NCT00289913|9624695|FG003|Visit 2 (Stage I and Stage II)|Other reasons after safety F/U]|0
6028761|NCT00289913|9624696|FG004|Visit 2 (Stage I and Stage II)|Other reasons after safety F/U]|0
6028762|NCT00289913|9624692|FG000|Visit 2 (Stage I and Stage II)|Protocol deviation (Stage II)|0
6028763|NCT00289913|9624693|FG001|Visit 2 (Stage I and Stage II)|Protocol deviation (Stage II)|0
6028764|NCT00289913|9624694|FG002|Visit 2 (Stage I and Stage II)|Protocol deviation (Stage II)|0
6028765|NCT00289913|9624695|FG003|Visit 2 (Stage I and Stage II)|Protocol deviation (Stage II)|0
6028766|NCT00289913|9624696|FG004|Visit 2 (Stage I and Stage II)|Protocol deviation (Stage II)|7
6028767|NCT00289913|9624692|FG000|Visit 2 (Stage I and Stage II)|Lost (Stage II)|0
6079380|NCT00609466|9686218|FG001|Overall Study|Adverse Event|3
6079381|NCT00609466|9686219|FG002|Overall Study|Adverse Event|1
6079382|NCT00609466|9686217|FG000|Overall Study|Lack of Efficacy|0
6079383|NCT00609466|9686218|FG001|Overall Study|Lack of Efficacy|2
6028768|NCT00289913|9624693|FG001|Visit 2 (Stage I and Stage II)|Lost (Stage II)|0
6028769|NCT00289913|9624694|FG002|Visit 2 (Stage I and Stage II)|Lost (Stage II)|0
6028770|NCT00289913|9624695|FG003|Visit 2 (Stage I and Stage II)|Lost (Stage II)|0
6028771|NCT00289913|9624696|FG004|Visit 2 (Stage I and Stage II)|Lost (Stage II)|11
6028772|NCT00289913|9624692|FG000|Visit 2 (Stage I and Stage II)|Moved (Stage II)|0
6028773|NCT00289913|9624693|FG001|Visit 2 (Stage I and Stage II)|Moved (Stage II)|0
6028774|NCT00289913|9624694|FG002|Visit 2 (Stage I and Stage II)|Moved (Stage II)|0
6028775|NCT00289913|9624695|FG003|Visit 2 (Stage I and Stage II)|Moved (Stage II)|0
6028776|NCT00289913|9624696|FG004|Visit 2 (Stage I and Stage II)|Moved (Stage II)|6
6028777|NCT00289913|9624692|FG000|Visit 2 (Stage I and Stage II)|Withdrew consent (Stage II)|0
6028778|NCT00289913|9624693|FG001|Visit 2 (Stage I and Stage II)|Withdrew consent (Stage II)|0
6028779|NCT00289913|9624694|FG002|Visit 2 (Stage I and Stage II)|Withdrew consent (Stage II)|0
6028780|NCT00289913|9624695|FG003|Visit 2 (Stage I and Stage II)|Withdrew consent (Stage II)|0
6028781|NCT00289913|9624696|FG004|Visit 2 (Stage I and Stage II)|Withdrew consent (Stage II)|7
6028782|NCT00289913|9624692|FG000|Visit 2 (Stage I and Stage II)|Other reasons (Stage II)|0
6028783|NCT00289913|9624693|FG001|Visit 2 (Stage I and Stage II)|Other reasons (Stage II)|0
6028784|NCT00289913|9624694|FG002|Visit 2 (Stage I and Stage II)|Other reasons (Stage II)|0
6028785|NCT00289913|9624695|FG003|Visit 2 (Stage I and Stage II)|Other reasons (Stage II)|0
6028786|NCT00289913|9624696|FG004|Visit 2 (Stage I and Stage II)|Other reasons (Stage II)|9
6028787|NCT00289913|9624692|FG000|Visit 3 (Stage I and Stage II)|Protocol deviation during safety F/U|0
6028788|NCT00289913|9624693|FG001|Visit 3 (Stage I and Stage II)|Protocol deviation during safety F/U|1
6028789|NCT00289913|9624694|FG002|Visit 3 (Stage I and Stage II)|Protocol deviation during safety F/U|0
6028790|NCT00289913|9624695|FG003|Visit 3 (Stage I and Stage II)|Protocol deviation during safety F/U|0
6028791|NCT00289913|9624696|FG004|Visit 3 (Stage I and Stage II)|Protocol deviation during safety F/U|0
6028792|NCT00289913|9624692|FG000|Visit 3 (Stage I and Stage II)|Lost during safety F/U|8
6028793|NCT00289913|9624693|FG001|Visit 3 (Stage I and Stage II)|Lost during safety F/U|3
6028794|NCT00289913|9624694|FG002|Visit 3 (Stage I and Stage II)|Lost during safety F/U|1
6028795|NCT00289913|9624695|FG003|Visit 3 (Stage I and Stage II)|Lost during safety F/U|2
6028796|NCT00289913|9624696|FG004|Visit 3 (Stage I and Stage II)|Lost during safety F/U|2
6028797|NCT00289913|9624692|FG000|Visit 3 (Stage I and Stage II)|Withdrew consent during safety F/U|0
6028798|NCT00289913|9624693|FG001|Visit 3 (Stage I and Stage II)|Withdrew consent during safety F/U|0
6028799|NCT00289913|9624694|FG002|Visit 3 (Stage I and Stage II)|Withdrew consent during safety F/U|0
6028800|NCT00289913|9624695|FG003|Visit 3 (Stage I and Stage II)|Withdrew consent during safety F/U|1
6028801|NCT00289913|9624696|FG004|Visit 3 (Stage I and Stage II)|Withdrew consent during safety F/U|0
6028802|NCT00289913|9624692|FG000|Visit 3 (Stage I and Stage II)|Other reasons during safety F/U|0
6028803|NCT00289913|9624693|FG001|Visit 3 (Stage I and Stage II)|Other reasons during safety F/U|0
6028804|NCT00289913|9624694|FG002|Visit 3 (Stage I and Stage II)|Other reasons during safety F/U|0
6028805|NCT00289913|9624695|FG003|Visit 3 (Stage I and Stage II)|Other reasons during safety F/U|0
6028806|NCT00289913|9624696|FG004|Visit 3 (Stage I and Stage II)|Other reasons during safety F/U|1
6028807|NCT00289913|9624692|FG000|Visit 3 (Stage I and Stage II)|Lost after safety F/U|1
6028808|NCT00289913|9624693|FG001|Visit 3 (Stage I and Stage II)|Lost after safety F/U|2
6028809|NCT00289913|9624694|FG002|Visit 3 (Stage I and Stage II)|Lost after safety F/U|0
6028810|NCT00289913|9624695|FG003|Visit 3 (Stage I and Stage II)|Lost after safety F/U|1
6028811|NCT00289913|9624696|FG004|Visit 3 (Stage I and Stage II)|Lost after safety F/U|4
6028812|NCT00289913|9624692|FG000|Visit 3 (Stage I and Stage II)|Withdrew consent after safety F/U]|0
6028813|NCT00289913|9624693|FG001|Visit 3 (Stage I and Stage II)|Withdrew consent after safety F/U]|1
6028814|NCT00289913|9624694|FG002|Visit 3 (Stage I and Stage II)|Withdrew consent after safety F/U]|1
6028815|NCT00289913|9624695|FG003|Visit 3 (Stage I and Stage II)|Withdrew consent after safety F/U]|0
6028816|NCT00289913|9624696|FG004|Visit 3 (Stage I and Stage II)|Withdrew consent after safety F/U]|0
6028817|NCT00289913|9624692|FG000|Visit 3 (Stage I and Stage II)|Moved after safety F/U|0
6028818|NCT00289913|9624693|FG001|Visit 3 (Stage I and Stage II)|Moved after safety F/U|0
6028819|NCT00289913|9624694|FG002|Visit 3 (Stage I and Stage II)|Moved after safety F/U|0
6028820|NCT00289913|9624695|FG003|Visit 3 (Stage I and Stage II)|Moved after safety F/U|0
6028821|NCT00289913|9624696|FG004|Visit 3 (Stage I and Stage II)|Moved after safety F/U|1
6028822|NCT00289913|9624692|FG000|Visit 3 (Stage I and Stage II)|Other reasons after safety F/U|0
6028823|NCT00289913|9624693|FG001|Visit 3 (Stage I and Stage II)|Other reasons after safety F/U|1
6028824|NCT00289913|9624694|FG002|Visit 3 (Stage I and Stage II)|Other reasons after safety F/U|0
6028825|NCT00289913|9624695|FG003|Visit 3 (Stage I and Stage II)|Other reasons after safety F/U|0
6028826|NCT00289913|9624696|FG004|Visit 3 (Stage I and Stage II)|Other reasons after safety F/U|0
6028827|NCT00289978|9624714|FG000|Overall Study|Withdrawal by Subject|31
6028828|NCT00289978|9624715|FG001|Overall Study|Withdrawal by Subject|17
6028829|NCT00289978|9624716|FG002|Overall Study|Withdrawal by Subject|28
6028830|NCT00289978|9624714|FG000|Overall Study|Adverse Event|22
6028831|NCT00289978|9624715|FG001|Overall Study|Adverse Event|13
6028832|NCT00289978|9624716|FG002|Overall Study|Adverse Event|18
6028833|NCT00289978|9624714|FG000|Overall Study|Lack of Efficacy|13
6028834|NCT00289978|9624715|FG001|Overall Study|Lack of Efficacy|6
6028835|NCT00289978|9624716|FG002|Overall Study|Lack of Efficacy|25
6028836|NCT00289978|9624714|FG000|Overall Study|Abnormal laboratory value(s)|20
6028837|NCT00289978|9624715|FG001|Overall Study|Abnormal laboratory value(s)|9
6028838|NCT00289978|9624716|FG002|Overall Study|Abnormal laboratory value(s)|1
6028839|NCT00289978|9624714|FG000|Overall Study|Lost to Follow-up|3
6028840|NCT00289978|9624715|FG001|Overall Study|Lost to Follow-up|5
6028841|NCT00289978|9624716|FG002|Overall Study|Lost to Follow-up|7
6028842|NCT00289978|9624714|FG000|Overall Study|Protocol Violation|5
6028843|NCT00289978|9624715|FG001|Overall Study|Protocol Violation|5
6028844|NCT00289978|9624716|FG002|Overall Study|Protocol Violation|4
6028845|NCT00289978|9624714|FG000|Overall Study|Abnormal test procedure result(s)|2
6028846|NCT00289978|9624715|FG001|Overall Study|Abnormal test procedure result(s)|1
6028847|NCT00289978|9624716|FG002|Overall Study|Abnormal test procedure result(s)|1
6028848|NCT00289978|9624714|FG000|Overall Study|Death|1
6028849|NCT00289978|9624715|FG001|Overall Study|Death|0
6028850|NCT00289978|9624716|FG002|Overall Study|Death|2
6028851|NCT00289991|9624726|FG000|Overall Study|Death|35
6028852|NCT00289991|9624727|FG001|Overall Study|Death|38
6028853|NCT00289991|9624726|FG000|Overall Study|Adverse Event|15
6028854|NCT00289991|9624727|FG001|Overall Study|Adverse Event|13
6028855|NCT00289991|9624726|FG000|Overall Study|Failure of prophylaxis|1
6028856|NCT00289991|9624727|FG001|Overall Study|Failure of prophylaxis|1
6028857|NCT00289991|9624726|FG000|Overall Study|Fungal breakthrough infection|0
6028858|NCT00289991|9624727|FG001|Overall Study|Fungal breakthrough infection|1
6028859|NCT00289991|9624726|FG000|Overall Study|Lost to Follow-up|0
6028860|NCT00289991|9624727|FG001|Overall Study|Lost to Follow-up|1
6028861|NCT00289991|9624726|FG000|Overall Study|Withdrawal by Subject|2
6028862|NCT00289991|9624727|FG001|Overall Study|Withdrawal by Subject|12
6028863|NCT00289991|9624726|FG000|Overall Study|Other|5
6028864|NCT00289991|9624727|FG001|Overall Study|Other|14
6028865|NCT00290186|9624744|FG000|Overall Study|Adverse Event|1
6028866|NCT00290186|9624745|FG001|Overall Study|Adverse Event|1
6028867|NCT00290186|9624744|FG000|Overall Study|Lost to Follow-up|3
6028868|NCT00290186|9624745|FG001|Overall Study|Lost to Follow-up|2
6028869|NCT00290186|9624744|FG000|Overall Study|Study was terminated prior to 3-month te|1
6028870|NCT00290186|9624745|FG001|Overall Study|Study was terminated prior to 3-month te|1
6028871|NCT00290186|9624744|FG000|Overall Study|Withdrawal by Subject|0
6028872|NCT00290186|9624745|FG001|Overall Study|Withdrawal by Subject|1
6028873|NCT00290238|9624766|FG000|Overall Study|Study terminated|27
6028874|NCT00290238|9624767|FG001|Overall Study|Study terminated|27
6028875|NCT00290238|9624766|FG000|Overall Study|Lost to Follow-up|0
6028876|NCT00290238|9624767|FG001|Overall Study|Lost to Follow-up|1
6028877|NCT00290238|9624766|FG000|Overall Study|Withdrawal by Subject|15
6028878|NCT00290238|9624767|FG001|Overall Study|Withdrawal by Subject|13
6028879|NCT00290290|9624775|FG000|Overall Study|Death|3
6028880|NCT00290290|9624776|FG001|Overall Study|Death|4
6028881|NCT00290290|9624775|FG000|Overall Study|Withdrawal by Subject|2
6028882|NCT00290290|9624776|FG001|Overall Study|Withdrawal by Subject|2
6028883|NCT00290290|9624775|FG000|Overall Study|Underwent clean surgical procedure|13
6028884|NCT00290290|9624776|FG001|Overall Study|Underwent clean surgical procedure|12
6028885|NCT00290342|9624799|FG000|Overall Study|Other|0
6028886|NCT00290342|9624800|FG001|Overall Study|Other|1
6028887|NCT00290342|9624799|FG000|Overall Study|Withdrawal by Subject|6
6028888|NCT00290342|9624800|FG001|Overall Study|Withdrawal by Subject|4
6028889|NCT00290342|9624799|FG000|Overall Study|Lost to Follow-up|1
6028890|NCT00290342|9624800|FG001|Overall Study|Lost to Follow-up|0
6048306|NCT00416715|9647466|FG000|Overall Study|Vitamin D levels not evaluable|8
6048307|NCT00416884|9647477|FG000|Overall Study|Study terminated due to low accrual|1
6048308|NCT00416949|9647481|FG000|Overall Study|Patients refused to participate|5
6048309|NCT00417027|9647488|FG000|Overall Study|Protocol Violation|0
6048310|NCT00417027|9647489|FG001|Overall Study|Protocol Violation|5
6048311|NCT00417027|9647490|FG002|Overall Study|Protocol Violation|5
6048312|NCT00417079|9647500|FG000|Overall Study|Disease progression|267
6048313|NCT00417079|9647501|FG001|Overall Study|Disease progression|180
6048314|NCT00417079|9647500|FG000|Overall Study|Adverse Event|32
6048315|NCT00417079|9647501|FG001|Overall Study|Adverse Event|67
6048316|NCT00417079|9647500|FG000|Overall Study|Non-compliance to protocol|0
6048317|NCT00417079|9647501|FG001|Overall Study|Non-compliance to protocol|1
6048318|NCT00417079|9647500|FG000|Overall Study|Lost to Follow-up|2
6048319|NCT00417079|9647501|FG001|Overall Study|Lost to Follow-up|0
6048320|NCT00417079|9647500|FG000|Overall Study|Withdrawal by Subject|17
6048321|NCT00417079|9647501|FG001|Overall Study|Withdrawal by Subject|8
6048322|NCT00417079|9647500|FG000|Overall Study|Not treated|6
6048323|NCT00417079|9647501|FG001|Overall Study|Not treated|7
6048324|NCT00417079|9647500|FG000|Overall Study|Screened failure|2
6048325|NCT00417079|9647501|FG001|Overall Study|Screened failure|1
6048326|NCT00417079|9647500|FG000|Overall Study|Investigator's decision|1
6048327|NCT00417079|9647501|FG001|Overall Study|Investigator's decision|4
6048328|NCT00417079|9647500|FG000|Overall Study|Non-confirmed Disease progression|1
6048329|NCT00417079|9647501|FG001|Overall Study|Non-confirmed Disease progression|1
6048330|NCT00417079|9647500|FG000|Overall Study|Clinical deterioration|1
6048331|NCT00417079|9647501|FG001|Overall Study|Clinical deterioration|0
6048332|NCT00417079|9647500|FG000|Overall Study|Screening error|2
6048333|NCT00417079|9647501|FG001|Overall Study|Screening error|1
6048334|NCT00417079|9647500|FG000|Overall Study|Withdrawal by subject's family|0
6048335|NCT00417079|9647501|FG001|Overall Study|Withdrawal by subject's family|1
6028891|NCT00290355|9624808|FG000|Overall Study|Serious adverse event|7
6028892|NCT00290355|9624809|FG001|Overall Study|Serious adverse event|4
6028893|NCT00290355|9624808|FG000|Overall Study|Study product reactogenicity|1
6028894|NCT00290355|9624809|FG001|Overall Study|Study product reactogenicity|0
6028895|NCT00290355|9624808|FG000|Overall Study|Protocol Violation|1
6028896|NCT00290355|9624809|FG001|Overall Study|Protocol Violation|0
6028897|NCT00290355|9624808|FG000|Overall Study|Withdrawal by Subject|2
6028898|NCT00290355|9624809|FG001|Overall Study|Withdrawal by Subject|0
6028899|NCT00290355|9624808|FG000|Overall Study|Migrated / moved from the study area|1
6028900|NCT00290355|9624809|FG001|Overall Study|Migrated / moved from the study area|0
6028901|NCT00290355|9624808|FG000|Overall Study|Lost to Follow-up|3
6028902|NCT00290355|9624809|FG001|Overall Study|Lost to Follow-up|1
6028903|NCT00290355|9624808|FG000|Overall Study|Other|2
6028904|NCT00290355|9624809|FG001|Overall Study|Other|0
6028905|NCT00290433|9624815|FG000|Overall Study|Disease Progression|13
6028906|NCT00290433|9624815|FG000|Overall Study|Adverse Event|14
6028907|NCT00290433|9624815|FG000|Overall Study|Withdrawal by Subject|1
6028908|NCT00290433|9624815|FG000|Overall Study|Non-Compliance|1
6028909|NCT00290433|9624815|FG000|Overall Study|Congestive Heart Failure|1
6028910|NCT00290433|9624815|FG000|Overall Study|Transplant in CR|5
6028911|NCT00290433|9624815|FG000|Overall Study|Unrelated Infection/Death|1
6028912|NCT00290498|9624832|FG000|Overall Study|Death|2
6028913|NCT00290498|9624833|FG001|Overall Study|Death|0
6028914|NCT00290498|9624832|FG000|Overall Study|Physician Decision|1
6028915|NCT00290498|9624833|FG001|Overall Study|Physician Decision|0
6028916|NCT00290498|9624832|FG000|Overall Study|Withdrawal by Subject|1
6028917|NCT00290498|9624833|FG001|Overall Study|Withdrawal by Subject|0
6028918|NCT00290498|9624832|FG000|Overall Study|Ineligible|3
6028919|NCT00290498|9624833|FG001|Overall Study|Ineligible|0
6028920|NCT00290498|9624832|FG000|Overall Study|Non-Compliance|1
6028921|NCT00290498|9624833|FG001|Overall Study|Non-Compliance|0
6028922|NCT00290589|9624848|FG000|Overall Study|Lost to Follow-up|2
6028923|NCT00290589|9624849|FG001|Overall Study|Lost to Follow-up|2
6028924|NCT00290693|9624863|FG000|Overall Study|Withdrawal by Subject|2
6028925|NCT00290706|9624872|FG000|Overall Study|Withdrawal by Subject|2
6028926|NCT00290706|9624873|FG001|Overall Study|Withdrawal by Subject|0
6028927|NCT00290706|9624874|FG002|Overall Study|Withdrawal by Subject|0
6028928|NCT00290706|9624875|FG003|Overall Study|Withdrawal by Subject|0
6028929|NCT00290706|9624872|FG000|Overall Study|Progressive Disease|3
6028930|NCT00290706|9624873|FG001|Overall Study|Progressive Disease|5
6028931|NCT00290706|9624874|FG002|Overall Study|Progressive Disease|4
6028932|NCT00290706|9624875|FG003|Overall Study|Progressive Disease|10
6028933|NCT00290706|9624872|FG000|Overall Study|Adverse Event|0
6028934|NCT00290706|9624873|FG001|Overall Study|Adverse Event|1
6028935|NCT00290706|9624874|FG002|Overall Study|Adverse Event|2
6028936|NCT00290706|9624875|FG003|Overall Study|Adverse Event|0
6028937|NCT00290706|9624872|FG000|Overall Study|Receive auto transplant or radiation|0
6028938|NCT00290706|9624873|FG001|Overall Study|Receive auto transplant or radiation|0
6028939|NCT00290706|9624874|FG002|Overall Study|Receive auto transplant or radiation|0
6028940|NCT00290706|9624875|FG003|Overall Study|Receive auto transplant or radiation|1
6028941|NCT00290706|9624872|FG000|Overall Study|Physician Decision|0
6028942|NCT00290706|9624873|FG001|Overall Study|Physician Decision|0
6028943|NCT00290706|9624874|FG002|Overall Study|Physician Decision|0
6028944|NCT00290706|9624875|FG003|Overall Study|Physician Decision|1
6028945|NCT00290732|9624888|FG000|Overall Study|Inability to instill drug intraductally.|0
6028946|NCT00290732|9624889|FG001|Overall Study|Inability to instill drug intraductally.|1
6028947|NCT00290732|9624890|FG002|Overall Study|Inability to instill drug intraductally.|1
6028948|NCT00290732|9624891|FG003|Overall Study|Inability to instill drug intraductally.|0
6028949|NCT00290732|9624892|FG004|Overall Study|Inability to instill drug intraductally.|0
6028950|NCT00290745|9624905|FG000|Overall Study|Withdrawal by Subject|4
6028951|NCT00290745|9624905|FG000|Overall Study|Physician Decision|2
6028952|NCT00290745|9624905|FG000|Overall Study|Surgery after 3 months for progression|3
6028953|NCT00290745|9624905|FG000|Overall Study|Baseline MRI not available|3
6028954|NCT00290771|9624911|FG000|Overall Study|Disease progression|95
6028955|NCT00290771|9624912|FG001|Overall Study|Disease progression|73
6028956|NCT00290771|9624911|FG000|Overall Study|Death|11
6028957|NCT00290771|9624912|FG001|Overall Study|Death|10
6028958|NCT00290771|9624911|FG000|Overall Study|Adverse Event|12
6028959|NCT00290771|9624912|FG001|Overall Study|Adverse Event|6
6028960|NCT00290771|9624911|FG000|Overall Study|Withdrawal by Subject|5
6028961|NCT00290771|9624912|FG001|Overall Study|Withdrawal by Subject|6
6028962|NCT00290771|9624911|FG000|Overall Study|Administrative problems|2
6028963|NCT00290771|9624912|FG001|Overall Study|Administrative problems|1
6028964|NCT00290771|9624911|FG000|Overall Study|Protocol Violation|2
6028965|NCT00290771|9624912|FG001|Overall Study|Protocol Violation|0
6028966|NCT00290771|9624911|FG000|Overall Study|Lost to Follow-up|0
6028967|NCT00290771|9624912|FG001|Overall Study|Lost to Follow-up|1
6028968|NCT00290888|9624925|FG000|Overall Study|Physician Decision|3
6028969|NCT00290888|9624926|FG001|Overall Study|Physician Decision|1
6028970|NCT00291018|9624936|FG000|Overall Study|Not Consented or Declined PAS|12
6028971|NCT00291018|9624937|FG001|Overall Study|Not Consented or Declined PAS|15
6028972|NCT00291018|9624938|FG002|Overall Study|Not Consented or Declined PAS|15
6028973|NCT00291018|9624936|FG000|Overall Study|Death|3
6028974|NCT00291018|9624937|FG001|Overall Study|Death|3
6028975|NCT00291018|9624938|FG002|Overall Study|Death|4
6028976|NCT00291018|9624936|FG000|Overall Study|Withdrawal by Subject|2
6028977|NCT00291018|9624937|FG001|Overall Study|Withdrawal by Subject|8
6028978|NCT00291018|9624938|FG002|Overall Study|Withdrawal by Subject|1
6028979|NCT00291018|9624936|FG000|Overall Study|Failures|5
6028980|NCT00291018|9624937|FG001|Overall Study|Failures|12
6028981|NCT00291018|9624938|FG002|Overall Study|Failures|5
6028982|NCT00291018|9624936|FG000|Overall Study|Lost to Follow-up|3
6028983|NCT00291018|9624937|FG001|Overall Study|Lost to Follow-up|4
6028984|NCT00291018|9624938|FG002|Overall Study|Lost to Follow-up|18
6028985|NCT00291187|9624972|FG000|Overall Study|Protocol Violation- No Drug Administered|0
6028986|NCT00291187|9624973|FG001|Overall Study|Protocol Violation- No Drug Administered|0
6028987|NCT00291187|9624974|FG002|Overall Study|Protocol Violation- No Drug Administered|1
6028988|NCT00291187|9624975|FG003|Overall Study|Protocol Violation- No Drug Administered|0
6028989|NCT00291330|9625005|FG000|Overall Study|Adverse Event|47
6028990|NCT00291330|9625006|FG001|Overall Study|Adverse Event|40
6028991|NCT00291330|9625005|FG000|Overall Study|Protocol Violation|13
6028992|NCT00291330|9625006|FG001|Overall Study|Protocol Violation|20
6028993|NCT00291330|9625005|FG000|Overall Study|Lost to Follow-up|16
6028994|NCT00291330|9625006|FG001|Overall Study|Lost to Follow-up|11
6028995|NCT00291330|9625005|FG000|Overall Study|Withdrawal by Subject|22
6028996|NCT00291330|9625006|FG001|Overall Study|Withdrawal by Subject|25
6028997|NCT00291330|9625005|FG000|Overall Study|Other|3
6028998|NCT00291330|9625006|FG001|Overall Study|Other|1
6028999|NCT00291499|9625041|FG000|Overall Study|Adverse Event|3
6029000|NCT00291499|9625042|FG001|Overall Study|Adverse Event|8
6029001|NCT00291499|9625041|FG000|Overall Study|Change to other therapy|2
6029002|NCT00291499|9625042|FG001|Overall Study|Change to other therapy|1
6029003|NCT00291499|9625041|FG000|Overall Study|Intercurrent illness|1
6029004|NCT00291499|9625042|FG001|Overall Study|Intercurrent illness|0
6029005|NCT00291499|9625041|FG000|Overall Study|Protocol Violation|2
6029006|NCT00291499|9625042|FG001|Overall Study|Protocol Violation|2
6029007|NCT00291499|9625041|FG000|Overall Study|Other reasons|1
6029008|NCT00291499|9625042|FG001|Overall Study|Other reasons|4
6029009|NCT00291551|9625048|FG000|Overall Study|Death|7
6029010|NCT00291551|9625048|FG000|Overall Study|Withdrawal by Subject|6
6029011|NCT00291577|9625053|FG000|Overall Study|Adverse Event|1
6029012|NCT00291577|9625053|FG000|Overall Study|Other|4
6029013|NCT00291577|9625053|FG000|Overall Study|Withdrawal by Subject|2
6029014|NCT00291577|9625053|FG000|Overall Study|Lack of Efficacy|14
6029015|NCT00291642|9625062|FG000|Overall Study|Adverse Event|1
6029016|NCT00291642|9625063|FG001|Overall Study|Adverse Event|0
6029017|NCT00291642|9625064|FG002|Overall Study|Adverse Event|1
6029018|NCT00291642|9625065|FG003|Overall Study|Adverse Event|0
6029019|NCT00291642|9625066|FG004|Overall Study|Adverse Event|1
6029020|NCT00291642|9625062|FG000|Overall Study|Patient missed visit|0
6029021|NCT00291642|9625063|FG001|Overall Study|Patient missed visit|0
6029022|NCT00291642|9625064|FG002|Overall Study|Patient missed visit|1
6029023|NCT00291642|9625065|FG003|Overall Study|Patient missed visit|0
6029024|NCT00291642|9625066|FG004|Overall Study|Patient missed visit|0
6029025|NCT00291642|9625062|FG000|Overall Study|Intake of prohibited medication|1
6029026|NCT00291642|9625063|FG001|Overall Study|Intake of prohibited medication|0
6029027|NCT00291642|9625064|FG002|Overall Study|Intake of prohibited medication|0
6029028|NCT00291642|9625065|FG003|Overall Study|Intake of prohibited medication|0
6029029|NCT00291642|9625066|FG004|Overall Study|Intake of prohibited medication|0
6029030|NCT00291668|9625085|FG000|Overall Study|Lack of Efficacy|1
6029031|NCT00291668|9625086|FG001|Overall Study|Lack of Efficacy|0
6029032|NCT00291668|9625087|FG002|Overall Study|Lack of Efficacy|0
6029033|NCT00291668|9625085|FG000|Overall Study|SAE, non-fatal|1
6029034|NCT00291668|9625086|FG001|Overall Study|SAE, non-fatal|1
6029035|NCT00291668|9625087|FG002|Overall Study|SAE, non-fatal|1
6029036|NCT00291668|9625085|FG000|Overall Study|AE, non-serious non-fatal|1
6029037|NCT00291668|9625086|FG001|Overall Study|AE, non-serious non-fatal|0
6029038|NCT00291668|9625087|FG002|Overall Study|AE, non-serious non-fatal|0
6029039|NCT00291668|9625085|FG000|Overall Study|SAE, non-fatal+AE, non-serious non-fatal|1
6029040|NCT00291668|9625086|FG001|Overall Study|SAE, non-fatal+AE, non-serious non-fatal|0
6029041|NCT00291668|9625087|FG002|Overall Study|SAE, non-fatal+AE, non-serious non-fatal|0
6029042|NCT00292045|9625110|FG000|Core Study (Through Week 13)|Adverse Event|1
6029043|NCT00292045|9625110|FG000|Core Study (Through Week 13)|Withdrawal by Subject|1
6029044|NCT00292188|9625125|FG000|Single-Blind|Adverse Event|14
6029045|NCT00292188|9625126|FG001|Single-Blind|Adverse Event|0
6029046|NCT00292188|9625127|FG002|Single-Blind|Adverse Event|0
6029047|NCT00292188|9625125|FG000|Single-Blind|Lack of Efficacy|2
6029048|NCT00292188|9625126|FG001|Single-Blind|Lack of Efficacy|0
6029049|NCT00292188|9625127|FG002|Single-Blind|Lack of Efficacy|0
6029050|NCT00292188|9625125|FG000|Single-Blind|Laboratory Abnormality|5
6029051|NCT00292188|9625126|FG001|Single-Blind|Laboratory Abnormality|0
6029052|NCT00292188|9625127|FG002|Single-Blind|Laboratory Abnormality|0
6029053|NCT00292188|9625125|FG000|Single-Blind|Lost to Follow-up|3
6029054|NCT00292188|9625126|FG001|Single-Blind|Lost to Follow-up|0
6029055|NCT00292188|9625127|FG002|Single-Blind|Lost to Follow-up|0
6029056|NCT00292188|9625125|FG000|Single-Blind|Other|77
6029057|NCT00292188|9625126|FG001|Single-Blind|Other|0
6029058|NCT00292188|9625127|FG002|Single-Blind|Other|0
6029059|NCT00292188|9625125|FG000|Single-Blind|Withdrawal by Subject|12
6029060|NCT00292188|9625126|FG001|Single-Blind|Withdrawal by Subject|0
6029061|NCT00292188|9625127|FG002|Single-Blind|Withdrawal by Subject|0
6029062|NCT00292188|9625125|FG000|Single-Blind|Did not receive treatment|1
6029063|NCT00292188|9625126|FG001|Single-Blind|Did not receive treatment|0
6029064|NCT00292188|9625127|FG002|Single-Blind|Did not receive treatment|0
6029065|NCT00292188|9625125|FG000|Double-Blind|Adverse Event|0
6029066|NCT00292188|9625126|FG001|Double-Blind|Adverse Event|25
6029067|NCT00292188|9625127|FG002|Double-Blind|Adverse Event|9
6029068|NCT00292188|9625125|FG000|Double-Blind|Lack of Efficacy|0
6029069|NCT00292188|9625126|FG001|Double-Blind|Lack of Efficacy|2
6029070|NCT00292188|9625127|FG002|Double-Blind|Lack of Efficacy|12
6029071|NCT00292188|9625125|FG000|Double-Blind|Lost to Follow-up|0
6029072|NCT00292188|9625126|FG001|Double-Blind|Lost to Follow-up|1
6029073|NCT00292188|9625127|FG002|Double-Blind|Lost to Follow-up|0
6029074|NCT00292188|9625125|FG000|Double-Blind|Other|0
6029075|NCT00292188|9625126|FG001|Double-Blind|Other|3
6029076|NCT00292188|9625127|FG002|Double-Blind|Other|4
6029077|NCT00292188|9625125|FG000|Double-Blind|Withdrawal by Subject|0
6029078|NCT00292188|9625126|FG001|Double-Blind|Withdrawal by Subject|0
6029079|NCT00292188|9625127|FG002|Double-Blind|Withdrawal by Subject|3
6029080|NCT00292188|9625125|FG000|Double-Blind|Laboratory Abnormality|0
6029081|NCT00292188|9625126|FG001|Double-Blind|Laboratory Abnormality|0
6029082|NCT00292188|9625127|FG002|Double-Blind|Laboratory Abnormality|1
6029083|NCT00292227|9625136|FG000|Patch Period|Adverse Event|1
6029084|NCT00292227|9625137|FG001|Patch Period|Adverse Event|0
6029085|NCT00292227|9625138|FG002|Patch Period|Adverse Event|2
6029086|NCT00292227|9625136|FG000|Patch Period|Withdrawal by Subject|0
6029087|NCT00292227|9625137|FG001|Patch Period|Withdrawal by Subject|0
6029088|NCT00292227|9625138|FG002|Patch Period|Withdrawal by Subject|1
6029089|NCT00292318|9625148|FG000|Overall Study|Study terminated by officials|2
6029090|NCT00292318|9625149|FG001|Overall Study|Study terminated by officials|1
6029091|NCT00292370|9625158|FG000|Phase I - Open-Label Paroxetine (OLP)|Adverse Event|12
6029092|NCT00292370|9625159|FG001|Phase I - Open-Label Paroxetine (OLP)|Adverse Event|0
6029093|NCT00292370|9625160|FG002|Phase I - Open-Label Paroxetine (OLP)|Adverse Event|0
6029094|NCT00292370|9625158|FG000|Phase I - Open-Label Paroxetine (OLP)|Lost to Follow-up|22
6029095|NCT00292370|9625159|FG001|Phase I - Open-Label Paroxetine (OLP)|Lost to Follow-up|0
6029096|NCT00292370|9625160|FG002|Phase I - Open-Label Paroxetine (OLP)|Lost to Follow-up|0
6029097|NCT00292370|9625158|FG000|Phase I - Open-Label Paroxetine (OLP)|Physician Decision|8
6029098|NCT00292370|9625159|FG001|Phase I - Open-Label Paroxetine (OLP)|Physician Decision|0
6029099|NCT00292370|9625160|FG002|Phase I - Open-Label Paroxetine (OLP)|Physician Decision|0
6029100|NCT00292370|9625158|FG000|Phase I - Open-Label Paroxetine (OLP)|Withdrawal by Subject|4
6029101|NCT00292370|9625159|FG001|Phase I - Open-Label Paroxetine (OLP)|Withdrawal by Subject|0
6029102|NCT00292370|9625160|FG002|Phase I - Open-Label Paroxetine (OLP)|Withdrawal by Subject|0
6029103|NCT00292370|9625158|FG000|Phase II: OLP + DB Quetiapine or Placebo|Lost to Follow-up|0
6029104|NCT00292370|9625159|FG001|Phase II: OLP + DB Quetiapine or Placebo|Lost to Follow-up|3
6029105|NCT00292370|9625160|FG002|Phase II: OLP + DB Quetiapine or Placebo|Lost to Follow-up|2
6029106|NCT00292370|9625158|FG000|Phase II: OLP + DB Quetiapine or Placebo|Withdrawal by Subject|0
6029107|NCT00292370|9625159|FG001|Phase II: OLP + DB Quetiapine or Placebo|Withdrawal by Subject|1
6029108|NCT00292370|9625160|FG002|Phase II: OLP + DB Quetiapine or Placebo|Withdrawal by Subject|5
6029109|NCT00292461|9625169|FG000|Overall Study|Adverse Event|4
6029110|NCT00292461|9625170|FG001|Overall Study|Adverse Event|2
6029111|NCT00292461|9625169|FG000|Overall Study|Lack of Efficacy|1
6029112|NCT00292461|9625170|FG001|Overall Study|Lack of Efficacy|0
6029113|NCT00292461|9625169|FG000|Overall Study|Withdrawal by Subject|0
6029114|NCT00292461|9625170|FG001|Overall Study|Withdrawal by Subject|1
6029115|NCT00292461|9625169|FG000|Overall Study|Protocol Violation|4
6029116|NCT00292461|9625170|FG001|Overall Study|Protocol Violation|3
6029117|NCT00292461|9625169|FG000|Overall Study|Lost to Follow-up|1
6029118|NCT00292461|9625170|FG001|Overall Study|Lost to Follow-up|0
6029119|NCT00292942|9625193|FG000|Overall Study|Withdrawal by Subject|0
6029120|NCT00292942|9625194|FG001|Overall Study|Withdrawal by Subject|0
6029121|NCT00292942|9625195|FG002|Overall Study|Withdrawal by Subject|1
6029122|NCT00292942|9625196|FG003|Overall Study|Withdrawal by Subject|0
6029123|NCT00292942|9625193|FG000|Overall Study|Adverse Event|0
6029124|NCT00292942|9625194|FG001|Overall Study|Adverse Event|0
6029125|NCT00292942|9625195|FG002|Overall Study|Adverse Event|0
6029126|NCT00292942|9625196|FG003|Overall Study|Adverse Event|1
6029127|NCT00292981|9625209|FG000|Overall Study|Adverse Event|1
6029128|NCT00292981|9625209|FG000|Overall Study|Lost to Follow-up|13
6029129|NCT00292981|9625209|FG000|Overall Study|Withdrawal by Subject|22
6029130|NCT00292981|9625209|FG000|Overall Study|Other|3
6029131|NCT00293020|9625213|FG000|Overall Study|Withdrawal by Subject|34
6029132|NCT00293020|9625213|FG000|Overall Study|Adverse Event|30
6029133|NCT00293020|9625213|FG000|Overall Study|Death|32
6029134|NCT00293020|9625213|FG000|Overall Study|Lack of Efficacy|12
6029135|NCT00293020|9625213|FG000|Overall Study|Lost to Follow-up|4
6029136|NCT00293020|9625213|FG000|Overall Study|Protocol Violation|6
6029137|NCT00293020|9625213|FG000|Overall Study|Physician Decision|21
6029138|NCT00293020|9625213|FG000|Overall Study|Other Reason|22
6029139|NCT00293020|9625213|FG000|Overall Study|No dose taken|1
6029140|NCT00293033|9625217|FG000|Open-label Titration Period|Adverse Event|10
6029141|NCT00293033|9625217|FG000|Open-label Titration Period|Death|3
6029142|NCT00293033|9625217|FG000|Open-label Titration Period|Lack of Efficacy|5
6029143|NCT00293033|9625217|FG000|Open-label Titration Period|Protocol Violation|2
6029144|NCT00293033|9625217|FG000|Open-label Titration Period|Withdrawal by Subject|22
6029145|NCT00293033|9625217|FG000|Open-label Titration Period|Noncompliance and other|27
6029146|NCT00293033|9625217|FG000|Double-blind Treatment Period|Adverse Event|3
6029147|NCT00293033|9625217|FG000|Double-blind Treatment Period|Lack of Efficacy|1
6029148|NCT00293033|9625217|FG000|Double-blind Treatment Period|Withdrawal by Subject|4
6029149|NCT00293033|9625217|FG000|Double-blind Treatment Period|Noncompliance|4
6029150|NCT00293059|9625227|FG000|Overall Study|Adverse Event|12
6029151|NCT00293059|9625228|FG001|Overall Study|Adverse Event|4
6029152|NCT00293059|9625227|FG000|Overall Study|Lack of Efficacy|2
6029153|NCT00293059|9625228|FG001|Overall Study|Lack of Efficacy|0
6029154|NCT00293059|9625227|FG000|Overall Study|Lost to Follow-up|2
6029155|NCT00293059|9625228|FG001|Overall Study|Lost to Follow-up|3
6029156|NCT00293059|9625227|FG000|Overall Study|Pregnancy|1
6029157|NCT00293059|9625228|FG001|Overall Study|Pregnancy|1
6029158|NCT00293059|9625227|FG000|Overall Study|Protocol Violation|2
6029159|NCT00293059|9625228|FG001|Overall Study|Protocol Violation|0
6029160|NCT00293059|9625227|FG000|Overall Study|Withdrawal by Subject|11
6029161|NCT00293059|9625228|FG001|Overall Study|Withdrawal by Subject|5
6029162|NCT00293059|9625227|FG000|Overall Study|Participant moved out of state|1
6029163|NCT00293059|9625228|FG001|Overall Study|Participant moved out of state|0
6029164|NCT00293059|9625227|FG000|Overall Study|Participant stopped study drug|1
6029165|NCT00293059|9625228|FG001|Overall Study|Participant stopped study drug|0
6029166|NCT00293059|9625227|FG000|Overall Study|Noncompliant - sanitary pads collection|0
6029167|NCT00293059|9625228|FG001|Overall Study|Noncompliant - sanitary pads collection|1
6029168|NCT00293059|9625227|FG000|Overall Study|missing|3
6029169|NCT00293059|9625228|FG001|Overall Study|missing|5
6029170|NCT00293202|9625236|FG000|Overall Study|Withdrawal by Subject|1
6029171|NCT00293202|9625237|FG001|Overall Study|Withdrawal by Subject|2
6029172|NCT00293202|9625236|FG000|Overall Study|positive ANA (antinuclear antibody)|1
6029173|NCT00293202|9625237|FG001|Overall Study|positive ANA (antinuclear antibody)|0
6029174|NCT00293202|9625236|FG000|Overall Study|on-hold due to fistula maturation time|1
6029175|NCT00293202|9625237|FG001|Overall Study|on-hold due to fistula maturation time|0
6029176|NCT00293215|9625249|FG000|Overall Study|Progressive disease|3
6029177|NCT00293215|9625250|FG001|Overall Study|Progressive disease|1
6029178|NCT00293215|9625249|FG000|Overall Study|Adverse Event|2
6029179|NCT00293215|9625250|FG001|Overall Study|Adverse Event|2
6029180|NCT00293241|9625258|FG000|Overall Study|Lost to Follow-up|9
6029181|NCT00293241|9625259|FG001|Overall Study|Lost to Follow-up|16
6029182|NCT00293241|9625258|FG000|Overall Study|Physician Decision|23
6029183|NCT00293241|9625259|FG001|Overall Study|Physician Decision|17
6029184|NCT00293241|9625258|FG000|Overall Study|Withdrawal by Subject|4
6029185|NCT00293241|9625259|FG001|Overall Study|Withdrawal by Subject|8
6029186|NCT00293254|9625270|FG000|Primary Study - Double-Blind Week 0-48|Never Treated|2
6029187|NCT00293254|9625271|FG001|Primary Study - Double-Blind Week 0-48|Never Treated|0
6029188|NCT00293254|9625270|FG000|Primary Study - Double-Blind Week 0-48|Adverse Event|2
6029189|NCT00293254|9625271|FG001|Primary Study - Double-Blind Week 0-48|Adverse Event|1
6029190|NCT00293254|9625270|FG000|Primary Study - Double-Blind Week 0-48|Death|5
6029191|NCT00293254|9625271|FG001|Primary Study - Double-Blind Week 0-48|Death|2
6029192|NCT00293254|9625270|FG000|Primary Study - Double-Blind Week 0-48|Lack of Efficacy|2
6029193|NCT00293254|9625271|FG001|Primary Study - Double-Blind Week 0-48|Lack of Efficacy|2
6029194|NCT00293254|9625270|FG000|Primary Study - Double-Blind Week 0-48|Lost to Follow-up|3
6029195|NCT00293254|9625271|FG001|Primary Study - Double-Blind Week 0-48|Lost to Follow-up|1
6029196|NCT00293254|9625270|FG000|Primary Study - Double-Blind Week 0-48|Withdrawal by Subject|5
6029197|NCT00293254|9625271|FG001|Primary Study - Double-Blind Week 0-48|Withdrawal by Subject|1
6029198|NCT00293254|9625270|FG000|Primary Study - Double-Blind Week 0-48|Moved or trial terminated at site|1
6029199|NCT00293254|9625271|FG001|Primary Study - Double-Blind Week 0-48|Moved or trial terminated at site|0
6029200|NCT00293254|9625270|FG000|Primary Study - Double-Blind Week 0-48|Entered OLPVF Phase|35
6029201|NCT00293254|9625271|FG001|Primary Study - Double-Blind Week 0-48|Entered OLPVF Phase|57
6029202|NCT00293254|9625270|FG000|Extension - Double-Blind Week 49-156|Adverse Event|4
6029203|NCT00293254|9625271|FG001|Extension - Double-Blind Week 49-156|Adverse Event|1
6029204|NCT00293254|9625270|FG000|Extension - Double-Blind Week 49-156|Death|4
6029205|NCT00293254|9625271|FG001|Extension - Double-Blind Week 49-156|Death|1
6029206|NCT00293254|9625270|FG000|Extension - Double-Blind Week 49-156|Lack of Efficacy|3
6029207|NCT00293254|9625271|FG001|Extension - Double-Blind Week 49-156|Lack of Efficacy|4
6029208|NCT00293254|9625270|FG000|Extension - Double-Blind Week 49-156|Lost to Follow-up|3
6029209|NCT00293254|9625271|FG001|Extension - Double-Blind Week 49-156|Lost to Follow-up|3
6029210|NCT00293254|9625270|FG000|Extension - Double-Blind Week 49-156|Withdrawal by Subject|12
6029211|NCT00293254|9625271|FG001|Extension - Double-Blind Week 49-156|Withdrawal by Subject|8
6029212|NCT00293254|9625270|FG000|Extension - Double-Blind Week 49-156|Participant Moved/Site Stopped Trial|6
6029213|NCT00293254|9625271|FG001|Extension - Double-Blind Week 49-156|Participant Moved/Site Stopped Trial|3
6029214|NCT00293254|9625270|FG000|Extension - Double-Blind Week 49-156|Other Reason|10
6029215|NCT00293254|9625271|FG001|Extension - Double-Blind Week 49-156|Other Reason|2
6029216|NCT00293254|9625270|FG000|Extension - Double-Blind Week 49-156|Entered OLPVF Phase|15
6029217|NCT00293254|9625271|FG001|Extension - Double-Blind Week 49-156|Entered OLPVF Phase|7
6029218|NCT00293254|9625270|FG000|Extension - Open-Label Week 157-240|Adverse Event|2
6029219|NCT00293254|9625271|FG001|Extension - Open-Label Week 157-240|Adverse Event|1
6029220|NCT00293254|9625270|FG000|Extension - Open-Label Week 157-240|Lack of Efficacy|1
6029221|NCT00293254|9625271|FG001|Extension - Open-Label Week 157-240|Lack of Efficacy|0
6029222|NCT00293254|9625270|FG000|Extension - Open-Label Week 157-240|Withdrawal by Subject|1
6029223|NCT00293254|9625271|FG001|Extension - Open-Label Week 157-240|Withdrawal by Subject|0
6029224|NCT00293254|9625270|FG000|Extension - Open-Label Week 157-240|Lost to Follow-up|2
6029225|NCT00293254|9625271|FG001|Extension - Open-Label Week 157-240|Lost to Follow-up|0
6029226|NCT00293254|9625270|FG000|Extension - Open-Label Week 157-240|Other Reason|4
6029227|NCT00293254|9625271|FG001|Extension - Open-Label Week 157-240|Other Reason|0
6029228|NCT00293254|9625270|FG000|Open-Label Post Virologic Failure Phase|Adverse Event|4
6029229|NCT00293254|9625271|FG001|Open-Label Post Virologic Failure Phase|Adverse Event|7
6029230|NCT00293254|9625270|FG000|Open-Label Post Virologic Failure Phase|Lack of Efficacy|16
6029231|NCT00293254|9625271|FG001|Open-Label Post Virologic Failure Phase|Lack of Efficacy|14
6029232|NCT00293254|9625270|FG000|Open-Label Post Virologic Failure Phase|Withdrawal by Subject|6
6029233|NCT00293254|9625271|FG001|Open-Label Post Virologic Failure Phase|Withdrawal by Subject|3
6029234|NCT00293254|9625270|FG000|Open-Label Post Virologic Failure Phase|Lost to Follow-up|3
6029235|NCT00293254|9625271|FG001|Open-Label Post Virologic Failure Phase|Lost to Follow-up|0
6029236|NCT00293254|9625270|FG000|Open-Label Post Virologic Failure Phase|Participant Moved/Site Stopped Trial|1
6029237|NCT00293254|9625271|FG001|Open-Label Post Virologic Failure Phase|Participant Moved/Site Stopped Trial|1
6029238|NCT00293254|9625270|FG000|Open-Label Post Virologic Failure Phase|Other Reason|1
6029239|NCT00293254|9625271|FG001|Open-Label Post Virologic Failure Phase|Other Reason|2
6029240|NCT00293267|9625281|FG000|Primary Study - Double-Blind Week 0-48|Never Treated|2
6029241|NCT00293267|9625282|FG001|Primary Study - Double-Blind Week 0-48|Never Treated|0
6029242|NCT00293267|9625281|FG000|Primary Study - Double-Blind Week 0-48|Adverse Event|1
6029243|NCT00293267|9625282|FG001|Primary Study - Double-Blind Week 0-48|Adverse Event|1
6029244|NCT00293267|9625281|FG000|Primary Study - Double-Blind Week 0-48|Death|3
6029245|NCT00293267|9625282|FG001|Primary Study - Double-Blind Week 0-48|Death|3
6029246|NCT00293267|9625281|FG000|Primary Study - Double-Blind Week 0-48|Lack of Efficacy|0
6029247|NCT00293267|9625282|FG001|Primary Study - Double-Blind Week 0-48|Lack of Efficacy|2
6029248|NCT00293267|9625281|FG000|Primary Study - Double-Blind Week 0-48|Lost to Follow-up|1
6029249|NCT00293267|9625282|FG001|Primary Study - Double-Blind Week 0-48|Lost to Follow-up|1
6029250|NCT00293267|9625281|FG000|Primary Study - Double-Blind Week 0-48|Withdrawal by Subject|1
6029251|NCT00293267|9625282|FG001|Primary Study - Double-Blind Week 0-48|Withdrawal by Subject|1
6029252|NCT00293267|9625281|FG000|Primary Study - Double-Blind Week 0-48|Entered OLPVF Phase|33
6029253|NCT00293267|9625282|FG001|Primary Study - Double-Blind Week 0-48|Entered OLPVF Phase|60
6029254|NCT00293267|9625281|FG000|Extension - Double-Blind Week 49-156|Adverse Event|1
6029255|NCT00293267|9625282|FG001|Extension - Double-Blind Week 49-156|Adverse Event|4
6029256|NCT00293267|9625281|FG000|Extension - Double-Blind Week 49-156|Lack of Efficacy|7
6029257|NCT00293267|9625282|FG001|Extension - Double-Blind Week 49-156|Lack of Efficacy|1
6029258|NCT00293267|9625281|FG000|Extension - Double-Blind Week 49-156|Lost to Follow-up|4
6029259|NCT00293267|9625282|FG001|Extension - Double-Blind Week 49-156|Lost to Follow-up|0
6029260|NCT00293267|9625281|FG000|Extension - Double-Blind Week 49-156|Withdrawal by Subject|13
6029261|NCT00293267|9625282|FG001|Extension - Double-Blind Week 49-156|Withdrawal by Subject|4
6029262|NCT00293267|9625281|FG000|Extension - Double-Blind Week 49-156|Death|3
6029263|NCT00293267|9625282|FG001|Extension - Double-Blind Week 49-156|Death|0
6029264|NCT00293267|9625281|FG000|Extension - Double-Blind Week 49-156|Participant relocated or site terminated|2
6029265|NCT00293267|9625282|FG001|Extension - Double-Blind Week 49-156|Participant relocated or site terminated|0
6029266|NCT00293267|9625281|FG000|Extension - Double-Blind Week 49-156|Other Reason|7
6029267|NCT00293267|9625282|FG001|Extension - Double-Blind Week 49-156|Other Reason|0
6029268|NCT00293267|9625281|FG000|Extension - Double-Blind Week 49-156|Entered OLPVF Phase|15
6029269|NCT00293267|9625282|FG001|Extension - Double-Blind Week 49-156|Entered OLPVF Phase|6
6029270|NCT00293267|9625281|FG000|Extension - Open-Label Week 157-240|Adverse Event|5
6029271|NCT00293267|9625282|FG001|Extension - Open-Label Week 157-240|Adverse Event|0
6029272|NCT00293267|9625281|FG000|Extension - Open-Label Week 157-240|Lack of Efficacy|7
6029273|NCT00293267|9625282|FG001|Extension - Open-Label Week 157-240|Lack of Efficacy|0
6029274|NCT00293267|9625281|FG000|Extension - Open-Label Week 157-240|Lost to Follow-up|1
6029275|NCT00293267|9625282|FG001|Extension - Open-Label Week 157-240|Lost to Follow-up|0
6029276|NCT00293267|9625281|FG000|Extension - Open-Label Week 157-240|Withdrawal by Subject|2
6029277|NCT00293267|9625282|FG001|Extension - Open-Label Week 157-240|Withdrawal by Subject|1
6029278|NCT00293267|9625281|FG000|Extension - Open-Label Week 157-240|Participant relocated or site terminated|2
6029279|NCT00293267|9625282|FG001|Extension - Open-Label Week 157-240|Participant relocated or site terminated|0
6029280|NCT00293267|9625281|FG000|Extension - Open-Label Week 157-240|Other Reason|3
6029281|NCT00293267|9625282|FG001|Extension - Open-Label Week 157-240|Other Reason|1
6079384|NCT00609466|9686219|FG002|Overall Study|Lack of Efficacy|2
6029282|NCT00293267|9625281|FG000|Open-Label Post Virologic Failure Phase|Adverse Event|2
6029283|NCT00293267|9625282|FG001|Open-Label Post Virologic Failure Phase|Adverse Event|3
6029284|NCT00293267|9625281|FG000|Open-Label Post Virologic Failure Phase|Lack of Efficacy|23
6029285|NCT00293267|9625282|FG001|Open-Label Post Virologic Failure Phase|Lack of Efficacy|19
6029286|NCT00293267|9625281|FG000|Open-Label Post Virologic Failure Phase|Withdrawal by Subject|2
6029287|NCT00293267|9625282|FG001|Open-Label Post Virologic Failure Phase|Withdrawal by Subject|4
6029288|NCT00293267|9625281|FG000|Open-Label Post Virologic Failure Phase|Lost to Follow-up|2
6029289|NCT00293267|9625282|FG001|Open-Label Post Virologic Failure Phase|Lost to Follow-up|2
6029290|NCT00293267|9625281|FG000|Open-Label Post Virologic Failure Phase|Laboratory Adverse Event|0
6029291|NCT00293267|9625282|FG001|Open-Label Post Virologic Failure Phase|Laboratory Adverse Event|2
6029292|NCT00293267|9625281|FG000|Open-Label Post Virologic Failure Phase|Participant Moved or Site Terminated|0
6029293|NCT00293267|9625282|FG001|Open-Label Post Virologic Failure Phase|Participant Moved or Site Terminated|2
6029294|NCT00293267|9625281|FG000|Open-Label Post Virologic Failure Phase|Other Reason|4
6029295|NCT00293267|9625282|FG001|Open-Label Post Virologic Failure Phase|Other Reason|5
6029296|NCT00293293|9625292|FG000|Overall Study|Withdrawal by Subject|1
6029297|NCT00293293|9625293|FG001|Overall Study|Withdrawal by Subject|1
6029298|NCT00293293|9625292|FG000|Overall Study|"Patient too anxious to complete trial"|1
6029299|NCT00293293|9625293|FG001|Overall Study|"Patient too anxious to complete trial"|0
6029300|NCT00293293|9625292|FG000|Overall Study|Patient discontinued chemotherapy|0
6029301|NCT00293293|9625293|FG001|Overall Study|Patient discontinued chemotherapy|1
6029302|NCT00293384|9625300|FG000|Overall Study|Non-compliance|2
6029303|NCT00293384|9625300|FG000|Overall Study|Missed dosage/study drug|1
6029304|NCT00293384|9625300|FG000|Overall Study|Ineligible|2
6029305|NCT00293397|9625304|FG000|Overall Study|Death|2
6029306|NCT00293423|9625311|FG000|Surgical Resection|Less than a 90% extent of resection|0
6029307|NCT00293423|9625312|FG001|Surgical Resection|Less than a 90% extent of resection|1
6029308|NCT00293423|9625311|FG000|Surgical Resection|Postoperative Karnofsky Performance Score <70%|0
6029309|NCT00293423|9625312|FG001|Surgical Resection|Postoperative Karnofsky Performance Score <70%|4
6029310|NCT00293423|9625311|FG000|Surgical Resection|Insufficient tumor obtained to generate vaccine|9
6029311|NCT00293423|9625312|FG001|Surgical Resection|Insufficient tumor obtained to generate vaccine|13
6029312|NCT00293423|9625311|FG000|Surgical Resection|disease progression prior to initial vaccination|2
6029313|NCT00293423|9625312|FG001|Surgical Resection|disease progression prior to initial vaccination|9
6029314|NCT00293423|9625311|FG000|Surgical Resection|processing error during surgical resection|1
6029315|NCT00293423|9625312|FG001|Surgical Resection|processing error during surgical resection|0
6029316|NCT00293423|9625311|FG000|Surgical Resection|Withdrawal by Subject|4
6029317|NCT00293423|9625312|FG001|Surgical Resection|Withdrawal by Subject|0
6029318|NCT00293423|9625311|FG000|Vaccination Treatment Period|Received < 4 required vaccinations|0
6029319|NCT00293423|9625312|FG001|Vaccination Treatment Period|Received < 4 required vaccinations|3
6029320|NCT00293462|9625321|FG000|Overall Study|Withdrawal by Subject|4
6029321|NCT00293462|9625322|FG001|Overall Study|Withdrawal by Subject|3
6029322|NCT00293462|9625323|FG002|Overall Study|Withdrawal by Subject|8
6029323|NCT00293462|9625321|FG000|Overall Study|Death|1
6029324|NCT00293462|9625322|FG001|Overall Study|Death|0
6029325|NCT00293462|9625323|FG002|Overall Study|Death|0
6029326|NCT00293462|9625321|FG000|Overall Study|Lost to Follow-up|0
6029327|NCT00293462|9625322|FG001|Overall Study|Lost to Follow-up|1
6029328|NCT00293462|9625323|FG002|Overall Study|Lost to Follow-up|0
6029329|NCT00293462|9625321|FG000|Overall Study|Change Treatment Regimen (ineligible)|1
6029330|NCT00293462|9625322|FG001|Overall Study|Change Treatment Regimen (ineligible)|0
6029331|NCT00293462|9625323|FG002|Overall Study|Change Treatment Regimen (ineligible)|0
6029332|NCT00293462|9625321|FG000|Overall Study|Hypersensitive Reaction (to Salt & Soda)|0
6029333|NCT00293462|9625322|FG001|Overall Study|Hypersensitive Reaction (to Salt & Soda)|1
6029334|NCT00293462|9625323|FG002|Overall Study|Hypersensitive Reaction (to Salt & Soda)|0
6029335|NCT00293462|9625321|FG000|Overall Study|Refuse Radiation Treatment|1
6029336|NCT00293462|9625322|FG001|Overall Study|Refuse Radiation Treatment|0
6029337|NCT00293462|9625323|FG002|Overall Study|Refuse Radiation Treatment|0
6029338|NCT00293462|9625321|FG000|Overall Study|No Show|0
6029339|NCT00293462|9625322|FG001|Overall Study|No Show|0
6029340|NCT00293462|9625323|FG002|Overall Study|No Show|1
6029341|NCT00293462|9625321|FG000|Overall Study|Went back to his home country|0
6029342|NCT00293462|9625322|FG001|Overall Study|Went back to his home country|0
6029343|NCT00293462|9625323|FG002|Overall Study|Went back to his home country|1
6029344|NCT00293462|9625321|FG000|Overall Study|Blood clot after chemotherapy|0
6029345|NCT00293462|9625322|FG001|Overall Study|Blood clot after chemotherapy|0
6029346|NCT00293462|9625323|FG002|Overall Study|Blood clot after chemotherapy|1
6029347|NCT00293462|9625321|FG000|Overall Study|Ischemic stroke after chemotherapy|0
6029348|NCT00293462|9625322|FG001|Overall Study|Ischemic stroke after chemotherapy|0
6029349|NCT00293462|9625323|FG002|Overall Study|Ischemic stroke after chemotherapy|1
6029350|NCT00293462|9625321|FG000|Overall Study|Possible Tracheostomy leakage|0
6029351|NCT00293462|9625322|FG001|Overall Study|Possible Tracheostomy leakage|1
6029352|NCT00293462|9625323|FG002|Overall Study|Possible Tracheostomy leakage|0
6029353|NCT00293462|9625321|FG000|Overall Study|Low radiation dose in oral cavity|0
6029354|NCT00293462|9625322|FG001|Overall Study|Low radiation dose in oral cavity|1
6029355|NCT00293462|9625323|FG002|Overall Study|Low radiation dose in oral cavity|0
6029356|NCT00293462|9625321|FG000|Overall Study|Physician Decision|0
6029357|NCT00293462|9625322|FG001|Overall Study|Physician Decision|1
6029358|NCT00293462|9625323|FG002|Overall Study|Physician Decision|0
6029359|NCT00293579|9625340|FG000|Overall Study|Withdrawal by Subject|1
6029360|NCT00293709|9625345|FG000|Overall Study|Other|47
6029361|NCT00293722|9625349|FG000|Overall Study|Other|427
6029362|NCT00293813|9625356|FG000|Overall Study|Physician Decision|0
6029363|NCT00293813|9625357|FG001|Overall Study|Physician Decision|1
6029364|NCT00293813|9625358|FG002|Overall Study|Physician Decision|0
6029365|NCT00293813|9625356|FG000|Overall Study|Adverse Event|3
6029366|NCT00293813|9625357|FG001|Overall Study|Adverse Event|1
6029367|NCT00293813|9625358|FG002|Overall Study|Adverse Event|1
6029368|NCT00293813|9625356|FG000|Overall Study|Withdrawal by Subject|7
6029369|NCT00293813|9625357|FG001|Overall Study|Withdrawal by Subject|4
6029370|NCT00293813|9625358|FG002|Overall Study|Withdrawal by Subject|4
6029371|NCT00293813|9625356|FG000|Overall Study|Lost to Follow-up|3
6029372|NCT00293813|9625357|FG001|Overall Study|Lost to Follow-up|2
6029373|NCT00293813|9625358|FG002|Overall Study|Lost to Follow-up|3
6029374|NCT00293813|9625356|FG000|Overall Study|Noncompliance|0
6029375|NCT00293813|9625357|FG001|Overall Study|Noncompliance|1
6029376|NCT00293813|9625358|FG002|Overall Study|Noncompliance|0
6029377|NCT00294047|9625368|FG000|Month 48|Adverse Event|28
6029378|NCT00294047|9625369|FG001|Month 48|Adverse Event|13
6029379|NCT00294047|9625368|FG000|Month 48|Protocol Violation|4
6029380|NCT00294047|9625369|FG001|Month 48|Protocol Violation|4
6029381|NCT00294047|9625368|FG000|Month 48|Withdrawal by Subject|111
6029382|NCT00294047|9625369|FG001|Month 48|Withdrawal by Subject|115
6029383|NCT00294047|9625368|FG000|Month 48|Lost to Follow-up|272
6029384|NCT00294047|9625369|FG001|Month 48|Lost to Follow-up|287
6029385|NCT00294047|9625368|FG000|Month 48|Other|10
6029386|NCT00294047|9625369|FG001|Month 48|Other|14
6029387|NCT00294047|9625368|FG000|Month 84|Adverse Event|4
6029388|NCT00294047|9625369|FG001|Month 84|Adverse Event|2
6029389|NCT00294047|9625368|FG000|Month 84|Protocol Violation|1
6029390|NCT00294047|9625369|FG001|Month 84|Protocol Violation|1
6029391|NCT00294047|9625368|FG000|Month 84|Withdrawal by Subject|33
6029392|NCT00294047|9625369|FG001|Month 84|Withdrawal by Subject|31
6029393|NCT00294047|9625368|FG000|Month 84|Lost to Follow-up|187
6029394|NCT00294047|9625369|FG001|Month 84|Lost to Follow-up|190
6029395|NCT00294047|9625368|FG000|Month 84|Absent Cervix|2
6029396|NCT00294047|9625369|FG001|Month 84|Absent Cervix|0
6029397|NCT00294047|9625368|FG000|Month 84|Work related reasons|4
6029398|NCT00294047|9625369|FG001|Month 84|Work related reasons|2
6029399|NCT00294047|9625368|FG000|Month 84|Center closed, subject did not transfer|1
6029400|NCT00294047|9625369|FG001|Month 84|Center closed, subject did not transfer|0
6029401|NCT00294047|9625368|FG000|Month 84|Family problems|2
6029402|NCT00294047|9625369|FG001|Month 84|Family problems|2
6029403|NCT00294047|9625368|FG000|Month 84|Lack of time|3
6029404|NCT00294047|9625369|FG001|Month 84|Lack of time|1
6029405|NCT00294047|9625368|FG000|Month 84|Personal reason|2
6029406|NCT00294047|9625369|FG001|Month 84|Personal reason|4
6029407|NCT00294047|9625368|FG000|Month 84|Subject does not want male physician|1
6029408|NCT00294047|9625369|FG001|Month 84|Subject does not want male physician|0
6029409|NCT00294047|9625368|FG000|Month 84|Transport reimbursement delayed|0
6029410|NCT00294047|9625369|FG001|Month 84|Transport reimbursement delayed|1
6029411|NCT00294047|9625368|FG000|Month 84|Unable to reach study site|1
6029412|NCT00294047|9625369|FG001|Month 84|Unable to reach study site|0
6029413|NCT00294047|9625368|FG000|Month 84|Under investigation locally|1
6029414|NCT00294047|9625369|FG001|Month 84|Under investigation locally|0
6029415|NCT00294047|9625368|FG000|Month 84|Visit missed|0
6029416|NCT00294047|9625369|FG001|Month 84|Visit missed|1
6029417|NCT00294047|9625368|FG000|Month 84|No consent for Month 84 Follow-up|731
6029418|NCT00294047|9625369|FG001|Month 84|No consent for Month 84 Follow-up|754
6029419|NCT00294060|9625376|FG000|Overall Study|Death|225
6029420|NCT00294060|9625376|FG000|Overall Study|Other|59
6029421|NCT00294060|9625376|FG000|Overall Study|Lost to Follow-up|55
6029422|NCT00294060|9625376|FG000|Overall Study|Withdrawal by Subject|11
6029423|NCT00294060|9625376|FG000|Overall Study|Physician Decision|797
6029424|NCT00294060|9625376|FG000|Overall Study|Medical condition|3
6029425|NCT00294060|9625376|FG000|Overall Study|Device explanted/not replaced|23
6029426|NCT00294398|9625382|FG000|Overall Study|Lost to Follow-up|21
6029427|NCT00294398|9625383|FG001|Overall Study|Lost to Follow-up|26
6029428|NCT00294554|9625400|FG000|Overall Study|Lack of Efficacy|0
6029429|NCT00294554|9625401|FG001|Overall Study|Lack of Efficacy|1
6029430|NCT00294554|9625400|FG000|Overall Study|Physician Decision|0
6029431|NCT00294554|9625401|FG001|Overall Study|Physician Decision|1
6029432|NCT00294645|9625419|FG000|Overall Study|Death|10
6029433|NCT00294645|9625420|FG001|Overall Study|Death|18
6029434|NCT00294645|9625419|FG000|Overall Study|Lost to Follow-up|1
6029435|NCT00294645|9625420|FG001|Overall Study|Lost to Follow-up|10
6029436|NCT00294645|9625419|FG000|Overall Study|Withdrawal by Subject|18
6029437|NCT00294645|9625420|FG001|Overall Study|Withdrawal by Subject|34
6029438|NCT00294645|9625419|FG000|Overall Study|Physician Decision|15
6029439|NCT00294645|9625420|FG001|Overall Study|Physician Decision|20
6029440|NCT00294645|9625419|FG000|Overall Study|Other|4
6029441|NCT00294645|9625420|FG001|Overall Study|Other|10
6029442|NCT00294658|9625428|FG000|Overall Study|Death|0
6029443|NCT00294658|9625429|FG001|Overall Study|Death|1
6029444|NCT00294658|9625428|FG000|Overall Study|Lost to Follow-up|4
6029445|NCT00294658|9625429|FG001|Overall Study|Lost to Follow-up|0
6029446|NCT00294658|9625428|FG000|Overall Study|Physician Decision|1
6029447|NCT00294658|9625429|FG001|Overall Study|Physician Decision|2
6029448|NCT00294658|9625428|FG000|Overall Study|Pregnancy|0
6029449|NCT00294658|9625429|FG001|Overall Study|Pregnancy|1
6029450|NCT00294658|9625428|FG000|Overall Study|Withdrawal by Subject|0
6029451|NCT00294658|9625429|FG001|Overall Study|Withdrawal by Subject|4
6029452|NCT00294658|9625428|FG000|Overall Study|Found to have invasive thymoma|1
6079385|NCT00609492|9686230|FG000|Overall Study|Withdrawal by Subject|0
6079386|NCT00609492|9686231|FG001|Overall Study|Withdrawal by Subject|2
6029453|NCT00294658|9625429|FG001|Overall Study|Found to have invasive thymoma|0
6029454|NCT00294658|9625428|FG000|Overall Study|Patient and family were not satisfied|0
6029455|NCT00294658|9625429|FG001|Overall Study|Patient and family were not satisfied|1
6029456|NCT00294671|9625437|FG000|Overall Study|Lack of Efficacy|11
6029457|NCT00294671|9625438|FG001|Overall Study|Lack of Efficacy|23
6029458|NCT00294671|9625437|FG000|Overall Study|Liver transplant|7
6029459|NCT00294671|9625438|FG001|Overall Study|Liver transplant|9
6029460|NCT00294671|9625437|FG000|Overall Study|Drug related adverse event (AE)|4
6029461|NCT00294671|9625438|FG001|Overall Study|Drug related adverse event (AE)|2
6029462|NCT00294671|9625437|FG000|Overall Study|Non-drug related AE|3
6029463|NCT00294671|9625438|FG001|Overall Study|Non-drug related AE|2
6029464|NCT00294671|9625437|FG000|Overall Study|Lost to Follow-up|1
6029465|NCT00294671|9625438|FG001|Overall Study|Lost to Follow-up|3
6029466|NCT00294671|9625437|FG000|Overall Study|Non-compliance|1
6029467|NCT00294671|9625438|FG001|Overall Study|Non-compliance|0
6029468|NCT00294671|9625437|FG000|Overall Study|Death|0
6029469|NCT00294671|9625438|FG001|Overall Study|Death|1
6029470|NCT00294684|9625446|FG000|Overall Study|Lost to Follow-up|5
6029471|NCT00294684|9625447|FG001|Overall Study|Lost to Follow-up|8
6029472|NCT00294723|9625456|FG000|Double-Blind Period 52 Weeks|Adverse Event|18
6029473|NCT00294723|9625457|FG001|Double-Blind Period 52 Weeks|Adverse Event|25
6029474|NCT00294723|9625458|FG002|Double-Blind Period 52 Weeks|Adverse Event|15
6029475|NCT00294723|9625456|FG000|Double-Blind Period 52 Weeks|Lack of Efficacy|9
6029476|NCT00294723|9625457|FG001|Double-Blind Period 52 Weeks|Lack of Efficacy|15
6079387|NCT00609492|9686232|FG002|Overall Study|Withdrawal by Subject|3
6079388|NCT00609492|9686230|FG000|Overall Study|Lost to Follow-up|1
6079389|NCT00609492|9686231|FG001|Overall Study|Lost to Follow-up|1
6079390|NCT00609492|9686232|FG002|Overall Study|Lost to Follow-up|4
6079391|NCT00609518|9686244|FG000|Overall Study|Death from Study Disease|32
6079392|NCT00609518|9686245|FG001|Overall Study|Death from Study Disease|32
6029477|NCT00294723|9625458|FG002|Double-Blind Period 52 Weeks|Lack of Efficacy|25
6029478|NCT00294723|9625456|FG000|Double-Blind Period 52 Weeks|Protocol Violation|11
6029479|NCT00294723|9625457|FG001|Double-Blind Period 52 Weeks|Protocol Violation|11
6029480|NCT00294723|9625458|FG002|Double-Blind Period 52 Weeks|Protocol Violation|5
6029481|NCT00294723|9625456|FG000|Double-Blind Period 52 Weeks|Not specified in study report|36
6029482|NCT00294723|9625457|FG001|Double-Blind Period 52 Weeks|Not specified in study report|38
6029483|NCT00294723|9625458|FG002|Double-Blind Period 52 Weeks|Not specified in study report|51
6029484|NCT00294723|9625456|FG000|Open-Label Extension 52 Weeks|Adverse Event|5
6029485|NCT00294723|9625457|FG001|Open-Label Extension 52 Weeks|Adverse Event|5
6029486|NCT00294723|9625458|FG002|Open-Label Extension 52 Weeks|Adverse Event|2
6029487|NCT00294723|9625456|FG000|Open-Label Extension 52 Weeks|Lack of Efficacy|12
6029488|NCT00294723|9625457|FG001|Open-Label Extension 52 Weeks|Lack of Efficacy|15
6029489|NCT00294723|9625458|FG002|Open-Label Extension 52 Weeks|Lack of Efficacy|21
6029490|NCT00294723|9625456|FG000|Open-Label Extension 52 Weeks|Protocol Violation|4
6029491|NCT00294723|9625457|FG001|Open-Label Extension 52 Weeks|Protocol Violation|3
6029492|NCT00294723|9625458|FG002|Open-Label Extension 52 Weeks|Protocol Violation|3
6029493|NCT00294723|9625456|FG000|Open-Label Extension 52 Weeks|Not specified in study report|19
6029494|NCT00294723|9625457|FG001|Open-Label Extension 52 Weeks|Not specified in study report|16
6029495|NCT00294723|9625458|FG002|Open-Label Extension 52 Weeks|Not specified in study report|14
6029496|NCT00294723|9625456|FG000|Additional Open-Label Extension 91 Weeks|Adverse Event|1
6029497|NCT00294723|9625457|FG001|Additional Open-Label Extension 91 Weeks|Adverse Event|1
6029498|NCT00294723|9625458|FG002|Additional Open-Label Extension 91 Weeks|Adverse Event|0
6029499|NCT00294723|9625456|FG000|Additional Open-Label Extension 91 Weeks|Lack of Efficacy|24
6029500|NCT00294723|9625457|FG001|Additional Open-Label Extension 91 Weeks|Lack of Efficacy|14
6029501|NCT00294723|9625458|FG002|Additional Open-Label Extension 91 Weeks|Lack of Efficacy|16
6029502|NCT00294723|9625456|FG000|Additional Open-Label Extension 91 Weeks|Protocol Violation|1
6029503|NCT00294723|9625457|FG001|Additional Open-Label Extension 91 Weeks|Protocol Violation|1
6029504|NCT00294723|9625458|FG002|Additional Open-Label Extension 91 Weeks|Protocol Violation|1
6029505|NCT00294723|9625456|FG000|Additional Open-Label Extension 91 Weeks|Not specified in study report|2
6029506|NCT00294723|9625457|FG001|Additional Open-Label Extension 91 Weeks|Not specified in study report|5
6029507|NCT00294723|9625458|FG002|Additional Open-Label Extension 91 Weeks|Not specified in study report|3
6029508|NCT00294762|9625471|FG000|Overall Study|Did not receive study treatment|3
6029509|NCT00294762|9625472|FG001|Overall Study|Did not receive study treatment|3
6029510|NCT00295022|9625506|FG000|Overall Study|Adverse Event|1
6029511|NCT00295022|9625507|FG001|Overall Study|Adverse Event|1
6029512|NCT00295022|9625508|FG002|Overall Study|Adverse Event|2
6029513|NCT00295022|9625506|FG000|Overall Study|Lost to Follow-up|0
6029514|NCT00295022|9625507|FG001|Overall Study|Lost to Follow-up|0
6029515|NCT00295022|9625508|FG002|Overall Study|Lost to Follow-up|1
6029516|NCT00295022|9625506|FG000|Overall Study|Withdrawal by Subject|0
6029517|NCT00295022|9625507|FG001|Overall Study|Withdrawal by Subject|0
6029518|NCT00295022|9625508|FG002|Overall Study|Withdrawal by Subject|2
6029519|NCT00295620|9625534|FG000|Overall Study|Lost to Follow-up|9
6029520|NCT00295620|9625535|FG001|Overall Study|Lost to Follow-up|5
6029521|NCT00295620|9625534|FG000|Overall Study|Withdrawal by Subject|37
6029522|NCT00295620|9625535|FG001|Overall Study|Withdrawal by Subject|50
6029523|NCT00295620|9625534|FG000|Overall Study|Death|206
6029524|NCT00295620|9625535|FG001|Overall Study|Death|207
6029525|NCT00295620|9625534|FG000|Overall Study|Other reasons|10
6029526|NCT00295620|9625535|FG001|Overall Study|Other reasons|9
6029527|NCT00295620|9625534|FG000|Overall Study|Discontinuation by sponsor|580
6029528|NCT00295620|9625535|FG001|Overall Study|Discontinuation by sponsor|593
6029529|NCT00295620|9625534|FG000|Overall Study|Protocol Violation|30
6029530|NCT00295620|9625535|FG001|Overall Study|Protocol Violation|32
6029531|NCT00295633|9625544|FG000|Overall Study|Lack of Efficacy|19
6029532|NCT00295633|9625545|FG001|Overall Study|Lack of Efficacy|7
6029533|NCT00295633|9625546|FG002|Overall Study|Lack of Efficacy|16
6029534|NCT00295633|9625544|FG000|Overall Study|Withdrawal of consent by subject|16
6029535|NCT00295633|9625545|FG001|Overall Study|Withdrawal of consent by subject|16
6029536|NCT00295633|9625546|FG002|Overall Study|Withdrawal of consent by subject|26
6029537|NCT00295633|9625544|FG000|Overall Study|Adverse Event|9
6029538|NCT00295633|9625545|FG001|Overall Study|Adverse Event|17
6029539|NCT00295633|9625546|FG002|Overall Study|Adverse Event|9
6029540|NCT00295633|9625544|FG000|Overall Study|Lost to Follow-up|6
6029541|NCT00295633|9625545|FG001|Overall Study|Lost to Follow-up|11
6029542|NCT00295633|9625546|FG002|Overall Study|Lost to Follow-up|7
6029543|NCT00295633|9625544|FG000|Overall Study|Physician Decision|9
6029544|NCT00295633|9625545|FG001|Overall Study|Physician Decision|10
6029545|NCT00295633|9625546|FG002|Overall Study|Physician Decision|8
6029546|NCT00295633|9625544|FG000|Overall Study|Poor/Noncompliance|2
6029547|NCT00295633|9625545|FG001|Overall Study|Poor/Noncompliance|2
6029548|NCT00295633|9625546|FG002|Overall Study|Poor/Noncompliance|6
6029549|NCT00295633|9625544|FG000|Overall Study|Subject No Longer Meets Study Criteria|0
6029550|NCT00295633|9625545|FG001|Overall Study|Subject No Longer Meets Study Criteria|3
6029551|NCT00295633|9625546|FG002|Overall Study|Subject No Longer Meets Study Criteria|3
6029552|NCT00295633|9625544|FG000|Overall Study|Death|1
6029553|NCT00295633|9625545|FG001|Overall Study|Death|1
6029554|NCT00295633|9625546|FG002|Overall Study|Death|0
6029555|NCT00295633|9625544|FG000|Overall Study|Administrative reason by sponsor|0
6029556|NCT00295633|9625545|FG001|Overall Study|Administrative reason by sponsor|0
6029557|NCT00295633|9625546|FG002|Overall Study|Administrative reason by sponsor|1
6029558|NCT00295750|9625557|FG000|Overall Study|Adverse Event|19
6029559|NCT00295750|9625558|FG001|Overall Study|Adverse Event|15
6029560|NCT00295750|9625559|FG002|Overall Study|Adverse Event|12
6029561|NCT00295750|9625557|FG000|Overall Study|Lack of Efficacy|1
6079393|NCT00609518|9686244|FG000|Overall Study|Withdrawal by Subject|5
6079394|NCT00609518|9686245|FG001|Overall Study|Withdrawal by Subject|3
6079395|NCT00609518|9686244|FG000|Overall Study|Lost to Follow-up|3
6079396|NCT00609518|9686245|FG001|Overall Study|Lost to Follow-up|0
6079397|NCT00609518|9686244|FG000|Overall Study|Physician Decision|1
6079398|NCT00609518|9686245|FG001|Overall Study|Physician Decision|3
6079399|NCT00609518|9686244|FG000|Overall Study|Death from Adverse Event|2
6079400|NCT00609518|9686245|FG001|Overall Study|Death from Adverse Event|2
6079401|NCT00609609|9686253|FG000|Overall Study|Withdrawal by Subject|2
6079402|NCT00609609|9686254|FG001|Overall Study|Withdrawal by Subject|0
6079403|NCT00609609|9686253|FG000|Overall Study|Progression|4
6079404|NCT00609609|9686254|FG001|Overall Study|Progression|2
6079405|NCT00609622|9686262|FG000|Overall Study|Adverse Event|14
6079406|NCT00609622|9686263|FG001|Overall Study|Adverse Event|10
6029562|NCT00295750|9625558|FG001|Overall Study|Lack of Efficacy|1
6029563|NCT00295750|9625559|FG002|Overall Study|Lack of Efficacy|0
6029564|NCT00295750|9625557|FG000|Overall Study|Lost to Follow-up|1
6029565|NCT00295750|9625558|FG001|Overall Study|Lost to Follow-up|4
6029566|NCT00295750|9625559|FG002|Overall Study|Lost to Follow-up|1
6029567|NCT00295750|9625557|FG000|Overall Study|Taking prohibited therapy|2
6029568|NCT00295750|9625558|FG001|Overall Study|Taking prohibited therapy|3
6029569|NCT00295750|9625559|FG002|Overall Study|Taking prohibited therapy|2
6029570|NCT00295750|9625557|FG000|Overall Study|Administrative errors|2
6029571|NCT00295750|9625558|FG001|Overall Study|Administrative errors|4
6079407|NCT00609622|9686262|FG000|Overall Study|Withdrawal by Subject|4
6079408|NCT00609622|9686263|FG001|Overall Study|Withdrawal by Subject|20
6029572|NCT00295750|9625559|FG002|Overall Study|Administrative errors|5
6029573|NCT00295750|9625557|FG000|Overall Study|Trial drug errors|1
6029574|NCT00295750|9625558|FG001|Overall Study|Trial drug errors|1
6079409|NCT00609622|9686262|FG000|Overall Study|Death|1
6079410|NCT00609622|9686263|FG001|Overall Study|Death|4
6079411|NCT00609622|9686262|FG000|Overall Study|Protocol Violation|1
6029575|NCT00295750|9625559|FG002|Overall Study|Trial drug errors|0
6029576|NCT00295750|9625557|FG000|Overall Study|Disease progression|2
6029577|NCT00295750|9625558|FG001|Overall Study|Disease progression|1
6029578|NCT00295750|9625559|FG002|Overall Study|Disease progression|0
6029579|NCT00295750|9625557|FG000|Overall Study|Personal reasons|0
6029580|NCT00295750|9625558|FG001|Overall Study|Personal reasons|1
6029581|NCT00295750|9625559|FG002|Overall Study|Personal reasons|0
6029582|NCT00295750|9625557|FG000|Overall Study|Randomized but never received trial drug|4
6029583|NCT00295750|9625558|FG001|Overall Study|Randomized but never received trial drug|3
6029584|NCT00295750|9625559|FG002|Overall Study|Randomized but never received trial drug|3
6029585|NCT00295750|9625557|FG000|Overall Study|Withdrawal by Subject|9
6029586|NCT00295750|9625558|FG001|Overall Study|Withdrawal by Subject|4
6029587|NCT00295750|9625559|FG002|Overall Study|Withdrawal by Subject|7
6029588|NCT00295750|9625557|FG000|Overall Study|Protocol Violation|2
6029589|NCT00295750|9625558|FG001|Overall Study|Protocol Violation|4
6029590|NCT00295750|9625559|FG002|Overall Study|Protocol Violation|2
6029591|NCT00295854|9625570|FG000|Overall Study|Adverse Event|7
6029592|NCT00295854|9625571|FG001|Overall Study|Adverse Event|7
6029593|NCT00295854|9625572|FG002|Overall Study|Adverse Event|6
6029594|NCT00295854|9625570|FG000|Overall Study|Protocol Violation|1
6029595|NCT00295854|9625571|FG001|Overall Study|Protocol Violation|1
6029596|NCT00295854|9625572|FG002|Overall Study|Protocol Violation|1
6029597|NCT00295854|9625570|FG000|Overall Study|Lost to Follow-up|2
6029598|NCT00295854|9625571|FG001|Overall Study|Lost to Follow-up|0
6029599|NCT00295854|9625572|FG002|Overall Study|Lost to Follow-up|1
6029600|NCT00295854|9625570|FG000|Overall Study|Withdrawal by Subject|3
6029601|NCT00295854|9625571|FG001|Overall Study|Withdrawal by Subject|7
6029602|NCT00295854|9625572|FG002|Overall Study|Withdrawal by Subject|4
6029603|NCT00295854|9625570|FG000|Overall Study|did not continue to meet criteria|1
6029604|NCT00295854|9625571|FG001|Overall Study|did not continue to meet criteria|1
6029605|NCT00295854|9625572|FG002|Overall Study|did not continue to meet criteria|2
6029606|NCT00295854|9625570|FG000|Overall Study|required a prohibited medication|1
6029607|NCT00295854|9625571|FG001|Overall Study|required a prohibited medication|0
6029608|NCT00295854|9625572|FG002|Overall Study|required a prohibited medication|0
6029609|NCT00295854|9625570|FG000|Overall Study|Other|3
6029610|NCT00295854|9625571|FG001|Overall Study|Other|5
6029611|NCT00295854|9625572|FG002|Overall Study|Other|1
6029612|NCT00295880|9625584|FG000|Overall Study|IBMI unit could not be volume reduced|1
6029613|NCT00295880|9625584|FG000|Overall Study|Unit randomization did not occur|1
6029614|NCT00295932|9625599|FG000|Overall Study|Not Treated|0
6029615|NCT00295932|9625600|FG001|Overall Study|Not Treated|0
6029616|NCT00295932|9625601|FG002|Overall Study|Not Treated|0
6029617|NCT00295932|9625602|FG003|Overall Study|Not Treated|0
6029618|NCT00295932|9625603|FG004|Overall Study|Not Treated|0
6029619|NCT00295932|9625604|FG005|Overall Study|Not Treated|0
6029620|NCT00295932|9625605|FG006|Overall Study|Not Treated|0
6029621|NCT00295932|9625606|FG007|Overall Study|Not Treated|0
6029622|NCT00295932|9625607|FG008|Overall Study|Not Treated|0
6029623|NCT00295932|9625608|FG009|Overall Study|Not Treated|0
6029624|NCT00295932|9625609|FG010|Overall Study|Not Treated|1
6029625|NCT00296036|9625637|FG000|Overall Study|Withdrawal by Subject|1
6029626|NCT00296036|9625638|FG001|Overall Study|Withdrawal by Subject|0
6029627|NCT00296036|9625639|FG002|Overall Study|Withdrawal by Subject|2
6029628|NCT00296036|9625640|FG003|Overall Study|Withdrawal by Subject|1
6029629|NCT00296036|9625641|FG004|Overall Study|Withdrawal by Subject|2
6029630|NCT00296036|9625642|FG005|Overall Study|Withdrawal by Subject|1
6029631|NCT00296036|9625637|FG000|Overall Study|Protocol Violation|0
6029632|NCT00296036|9625638|FG001|Overall Study|Protocol Violation|0
6029633|NCT00296036|9625639|FG002|Overall Study|Protocol Violation|0
6029634|NCT00296036|9625640|FG003|Overall Study|Protocol Violation|0
6029635|NCT00296036|9625641|FG004|Overall Study|Protocol Violation|0
6029636|NCT00296036|9625642|FG005|Overall Study|Protocol Violation|3
6029637|NCT00296140|9625661|FG000|Overall Study|Lost to Follow-up|1
6029638|NCT00296140|9625662|FG001|Overall Study|Lost to Follow-up|0
6029639|NCT00296140|9625661|FG000|Overall Study|Withdrawal by Subject|1
6029640|NCT00296140|9625662|FG001|Overall Study|Withdrawal by Subject|0
6029641|NCT00296140|9625661|FG000|Overall Study|Discharge to Nursing Home|1
6029642|NCT00296140|9625662|FG001|Overall Study|Discharge to Nursing Home|0
6029643|NCT00296244|9625695|FG000|Overall Study|Underwent retransplant|0
6029644|NCT00296244|9625696|FG001|Overall Study|Underwent retransplant|1
6029645|NCT00296335|9625727|FG000|Overall Study|Recurrence|3
6029646|NCT00296335|9625728|FG001|Overall Study|Recurrence|51
6029647|NCT00296335|9625727|FG000|Overall Study|Adverse Event|17
6029648|NCT00296335|9625728|FG001|Overall Study|Adverse Event|27
6029649|NCT00296335|9625727|FG000|Overall Study|Lost to Follow-up|7
6029650|NCT00296335|9625728|FG001|Overall Study|Lost to Follow-up|33
6029651|NCT00296335|9625727|FG000|Overall Study|Physician Decision|3
6029652|NCT00296335|9625728|FG001|Overall Study|Physician Decision|11
6029653|NCT00296374|9625739|FG000|Overall Study|Adverse Event|14
6029654|NCT00296374|9625740|FG001|Overall Study|Adverse Event|10
6029655|NCT00296374|9625741|FG002|Overall Study|Adverse Event|7
6029656|NCT00296374|9625739|FG000|Overall Study|Withdrawal by Subject|3
6029657|NCT00296374|9625740|FG001|Overall Study|Withdrawal by Subject|5
6029658|NCT00296374|9625741|FG002|Overall Study|Withdrawal by Subject|11
6029659|NCT00296374|9625739|FG000|Overall Study|Incorrect enrollment|3
6029660|NCT00296374|9625740|FG001|Overall Study|Incorrect enrollment|3
6029661|NCT00296374|9625741|FG002|Overall Study|Incorrect enrollment|4
6029662|NCT00296374|9625739|FG000|Overall Study|Protocol Violation|1
6029663|NCT00296374|9625740|FG001|Overall Study|Protocol Violation|2
6029664|NCT00296374|9625741|FG002|Overall Study|Protocol Violation|3
6029665|NCT00296374|9625739|FG000|Overall Study|Lost to Follow-up|3
6029666|NCT00296374|9625740|FG001|Overall Study|Lost to Follow-up|1
6029667|NCT00296374|9625741|FG002|Overall Study|Lost to Follow-up|1
6029668|NCT00296374|9625739|FG000|Overall Study|Relocated to another state|1
6029669|NCT00296374|9625740|FG001|Overall Study|Relocated to another state|0
6029670|NCT00296374|9625741|FG002|Overall Study|Relocated to another state|0
6029671|NCT00296374|9625739|FG000|Overall Study|Stopped drug before end of study visit|0
6029672|NCT00296374|9625740|FG001|Overall Study|Stopped drug before end of study visit|1
6029673|NCT00296374|9625741|FG002|Overall Study|Stopped drug before end of study visit|0
6029674|NCT00296374|9625739|FG000|Overall Study|Nephrologist introduced ACE|0
6029675|NCT00296374|9625740|FG001|Overall Study|Nephrologist introduced ACE|1
6029676|NCT00296374|9625741|FG002|Overall Study|Nephrologist introduced ACE|0
6029677|NCT00296374|9625739|FG000|Overall Study|Pregnancy|0
6029678|NCT00296374|9625740|FG001|Overall Study|Pregnancy|0
6029679|NCT00296374|9625741|FG002|Overall Study|Pregnancy|2
6029680|NCT00296374|9625739|FG000|Overall Study|Other|0
6029681|NCT00296374|9625740|FG001|Overall Study|Other|0
6029682|NCT00296374|9625741|FG002|Overall Study|Other|1
6029683|NCT00296400|9625758|FG000|Overall Study|Adverse Event|7
6029684|NCT00296400|9625759|FG001|Overall Study|Adverse Event|7
6029685|NCT00296400|9625760|FG002|Overall Study|Adverse Event|7
6029686|NCT00296400|9625758|FG000|Overall Study|Withdrawal by Subject|5
6029687|NCT00296400|9625759|FG001|Overall Study|Withdrawal by Subject|6
6029688|NCT00296400|9625760|FG002|Overall Study|Withdrawal by Subject|2
6029689|NCT00296400|9625758|FG000|Overall Study|Incorrect enrollment|2
6029690|NCT00296400|9625759|FG001|Overall Study|Incorrect enrollment|0
6029691|NCT00296400|9625760|FG002|Overall Study|Incorrect enrollment|0
6029692|NCT00296400|9625758|FG000|Overall Study|Protocol Violation|1
6029693|NCT00296400|9625759|FG001|Overall Study|Protocol Violation|1
6029694|NCT00296400|9625760|FG002|Overall Study|Protocol Violation|1
6029695|NCT00296400|9625758|FG000|Overall Study|Lost to Follow-up|1
6029696|NCT00296400|9625759|FG001|Overall Study|Lost to Follow-up|1
6029697|NCT00296400|9625760|FG002|Overall Study|Lost to Follow-up|2
6029698|NCT00296400|9625758|FG000|Overall Study|Study specific discontinuation criteria|0
6029699|NCT00296400|9625759|FG001|Overall Study|Study specific discontinuation criteria|0
6029700|NCT00296400|9625760|FG002|Overall Study|Study specific discontinuation criteria|1
6029701|NCT00296400|9625758|FG000|Overall Study|Visit 10 was performed earlier|0
6029702|NCT00296400|9625759|FG001|Overall Study|Visit 10 was performed earlier|1
6029703|NCT00296400|9625760|FG002|Overall Study|Visit 10 was performed earlier|0
6029704|NCT00296400|9625758|FG000|Overall Study|Pregnancy|1
6029705|NCT00296400|9625759|FG001|Overall Study|Pregnancy|2
6029706|NCT00296400|9625760|FG002|Overall Study|Pregnancy|0
6048336|NCT00417079|9647500|FG000|Overall Study|Patient unable to come to the clinic|0
6048337|NCT00417079|9647501|FG001|Overall Study|Patient unable to come to the clinic|1
6048338|NCT00417079|9647500|FG000|Overall Study|abnormal liver function tests|0
6048339|NCT00417079|9647501|FG001|Overall Study|abnormal liver function tests|1
6048340|NCT00417170|9647509|FG000|Overall Study|Adverse Event|1
6048341|NCT00417170|9647510|FG001|Overall Study|Adverse Event|1
6048342|NCT00417170|9647509|FG000|Overall Study|Withdrawal by Subject|1
6048343|NCT00417170|9647510|FG001|Overall Study|Withdrawal by Subject|1
6048344|NCT00417170|9647509|FG000|Overall Study|Lost to Follow-up|0
6048345|NCT00417170|9647510|FG001|Overall Study|Lost to Follow-up|1
6048346|NCT00417482|9647534|FG000|Phase B 1st 16 Weeks|Lack of Efficacy|14
6048347|NCT00417482|9647535|FG001|Phase B 1st 16 Weeks|Lack of Efficacy|8
6048348|NCT00417482|9647536|FG002|Phase B 1st 16 Weeks|Lack of Efficacy|24
6048349|NCT00417482|9647534|FG000|Phase B 1st 16 Weeks|Adverse Event|2
6048350|NCT00417482|9647535|FG001|Phase B 1st 16 Weeks|Adverse Event|0
6048351|NCT00417482|9647536|FG002|Phase B 1st 16 Weeks|Adverse Event|1
6048352|NCT00417482|9647534|FG000|Phase B 1st 16 Weeks|Moved, Unclear reasons|2
6048353|NCT00417482|9647535|FG001|Phase B 1st 16 Weeks|Moved, Unclear reasons|3
6048354|NCT00417482|9647536|FG002|Phase B 1st 16 Weeks|Moved, Unclear reasons|2
6048355|NCT00417482|9647534|FG000|Phase B 1st 16 Weeks|Death|1
6048356|NCT00417482|9647535|FG001|Phase B 1st 16 Weeks|Death|0
6048357|NCT00417482|9647536|FG002|Phase B 1st 16 Weeks|Death|0
6048358|NCT00417482|9647534|FG000|Phase B 2nd 16 Weeks|Lack of Efficacy|1
6048359|NCT00417482|9647535|FG001|Phase B 2nd 16 Weeks|Lack of Efficacy|12
6048360|NCT00417482|9647536|FG002|Phase B 2nd 16 Weeks|Lack of Efficacy|2
6048361|NCT00417482|9647534|FG000|Phase B 2nd 16 Weeks|Adverse Event|0
6048362|NCT00417482|9647535|FG001|Phase B 2nd 16 Weeks|Adverse Event|0
6048363|NCT00417482|9647536|FG002|Phase B 2nd 16 Weeks|Adverse Event|1
6048364|NCT00417482|9647534|FG000|Phase B 2nd 16 Weeks|Moved; unclear reason|1
6048365|NCT00417482|9647535|FG001|Phase B 2nd 16 Weeks|Moved; unclear reason|0
6048366|NCT00417482|9647536|FG002|Phase B 2nd 16 Weeks|Moved; unclear reason|0
6048367|NCT00417482|9647534|FG000|Phase B 2nd 16 Weeks|Death|1
6048368|NCT00417482|9647535|FG001|Phase B 2nd 16 Weeks|Death|1
6048369|NCT00417482|9647536|FG002|Phase B 2nd 16 Weeks|Death|0
6048370|NCT00417612|9647552|FG000|Overall Study|Errant diagnosis|0
6048371|NCT00417612|9647553|FG001|Overall Study|Errant diagnosis|1
6048372|NCT00417612|9647552|FG000|Overall Study|Adverse Event|2
6048373|NCT00417612|9647553|FG001|Overall Study|Adverse Event|0
6029707|NCT00296491|9625775|FG000|Overall Study|Low Pollen Counts|18
6029708|NCT00296491|9625776|FG001|Overall Study|Low Pollen Counts|26
6029709|NCT00296491|9625777|FG002|Overall Study|Low Pollen Counts|25
6029710|NCT00296491|9625778|FG003|Overall Study|Low Pollen Counts|16
6029711|NCT00296491|9625775|FG000|Overall Study|Protocol Violation|4
6029712|NCT00296491|9625776|FG001|Overall Study|Protocol Violation|6
6029713|NCT00296491|9625777|FG002|Overall Study|Protocol Violation|2
6029714|NCT00296491|9625778|FG003|Overall Study|Protocol Violation|3
6029715|NCT00296491|9625775|FG000|Overall Study|Adverse Event|1
6029716|NCT00296491|9625776|FG001|Overall Study|Adverse Event|3
6029717|NCT00296491|9625777|FG002|Overall Study|Adverse Event|1
6029718|NCT00296491|9625778|FG003|Overall Study|Adverse Event|4
6029719|NCT00296491|9625775|FG000|Overall Study|Withdrawn due to Asthma|0
6029720|NCT00296491|9625776|FG001|Overall Study|Withdrawn due to Asthma|0
6029721|NCT00296491|9625777|FG002|Overall Study|Withdrawn due to Asthma|0
6029722|NCT00296491|9625778|FG003|Overall Study|Withdrawn due to Asthma|4
6029723|NCT00296491|9625775|FG000|Overall Study|Withdrawal by Subject|7
6029724|NCT00296491|9625776|FG001|Overall Study|Withdrawal by Subject|3
6029725|NCT00296491|9625777|FG002|Overall Study|Withdrawal by Subject|3
6029726|NCT00296491|9625778|FG003|Overall Study|Withdrawal by Subject|2
6029727|NCT00296491|9625775|FG000|Overall Study|Non-Compliance|12
6029728|NCT00296491|9625776|FG001|Overall Study|Non-Compliance|13
6029729|NCT00296491|9625777|FG002|Overall Study|Non-Compliance|10
6029730|NCT00296491|9625778|FG003|Overall Study|Non-Compliance|14
6029731|NCT00296491|9625775|FG000|Overall Study|Lost to Follow-up|0
6029732|NCT00296491|9625776|FG001|Overall Study|Lost to Follow-up|2
6029733|NCT00296491|9625777|FG002|Overall Study|Lost to Follow-up|2
6029734|NCT00296491|9625778|FG003|Overall Study|Lost to Follow-up|0
6029735|NCT00296504|9625803|FG000|Interim Analysis|Withdrawal by Subject|8
6029736|NCT00296504|9625804|FG001|Interim Analysis|Withdrawal by Subject|0
6029737|NCT00296504|9625805|FG002|Interim Analysis|Withdrawal by Subject|12
6029738|NCT00296504|9625806|FG003|Interim Analysis|Withdrawal by Subject|0
6029739|NCT00296504|9625807|FG004|Interim Analysis|Withdrawal by Subject|5
6029740|NCT00296504|9625808|FG005|Interim Analysis|Withdrawal by Subject|5
6029741|NCT00296504|9625809|FG006|Interim Analysis|Withdrawal by Subject|9
6029742|NCT00296504|9625810|FG007|Interim Analysis|Withdrawal by Subject|3
6029743|NCT00296504|9625811|FG008|Interim Analysis|Withdrawal by Subject|0
6029744|NCT00296504|9625803|FG000|Interim Analysis|Lost to Follow-up|13
6029745|NCT00296504|9625804|FG001|Interim Analysis|Lost to Follow-up|3
6029746|NCT00296504|9625805|FG002|Interim Analysis|Lost to Follow-up|26
6029747|NCT00296504|9625806|FG003|Interim Analysis|Lost to Follow-up|8
6029748|NCT00296504|9625807|FG004|Interim Analysis|Lost to Follow-up|14
6029749|NCT00296504|9625808|FG005|Interim Analysis|Lost to Follow-up|4
6029750|NCT00296504|9625809|FG006|Interim Analysis|Lost to Follow-up|11
6029751|NCT00296504|9625810|FG007|Interim Analysis|Lost to Follow-up|4
6029752|NCT00296504|9625811|FG008|Interim Analysis|Lost to Follow-up|0
6029753|NCT00296504|9625803|FG000|Interim Analysis|Clinical Progression|1
6029754|NCT00296504|9625804|FG001|Interim Analysis|Clinical Progression|0
6029755|NCT00296504|9625805|FG002|Interim Analysis|Clinical Progression|1
6029756|NCT00296504|9625806|FG003|Interim Analysis|Clinical Progression|1
6029757|NCT00296504|9625807|FG004|Interim Analysis|Clinical Progression|0
6029758|NCT00296504|9625808|FG005|Interim Analysis|Clinical Progression|2
6029759|NCT00296504|9625809|FG006|Interim Analysis|Clinical Progression|1
6029760|NCT00296504|9625810|FG007|Interim Analysis|Clinical Progression|2
6029761|NCT00296504|9625811|FG008|Interim Analysis|Clinical Progression|0
6029762|NCT00296504|9625803|FG000|Interim Analysis|Insufficient Viral Load Response|5
6029763|NCT00296504|9625804|FG001|Interim Analysis|Insufficient Viral Load Response|1
6029764|NCT00296504|9625805|FG002|Interim Analysis|Insufficient Viral Load Response|12
6029765|NCT00296504|9625806|FG003|Interim Analysis|Insufficient Viral Load Response|2
6029766|NCT00296504|9625807|FG004|Interim Analysis|Insufficient Viral Load Response|7
6029767|NCT00296504|9625808|FG005|Interim Analysis|Insufficient Viral Load Response|9
6029768|NCT00296504|9625809|FG006|Interim Analysis|Insufficient Viral Load Response|2
6029769|NCT00296504|9625810|FG007|Interim Analysis|Insufficient Viral Load Response|24
6029770|NCT00296504|9625811|FG008|Interim Analysis|Insufficient Viral Load Response|0
6029771|NCT00296504|9625803|FG000|Interim Analysis|Adverse Event|0
6029772|NCT00296504|9625804|FG001|Interim Analysis|Adverse Event|0
6029773|NCT00296504|9625805|FG002|Interim Analysis|Adverse Event|13
6029774|NCT00296504|9625806|FG003|Interim Analysis|Adverse Event|4
6029775|NCT00296504|9625807|FG004|Interim Analysis|Adverse Event|6
6029776|NCT00296504|9625808|FG005|Interim Analysis|Adverse Event|3
6029777|NCT00296504|9625809|FG006|Interim Analysis|Adverse Event|4
6029778|NCT00296504|9625810|FG007|Interim Analysis|Adverse Event|5
6029779|NCT00296504|9625811|FG008|Interim Analysis|Adverse Event|0
6029780|NCT00296504|9625803|FG000|Interim Analysis|Protocol Violation|0
6029781|NCT00296504|9625804|FG001|Interim Analysis|Protocol Violation|0
6029782|NCT00296504|9625805|FG002|Interim Analysis|Protocol Violation|2
6029783|NCT00296504|9625806|FG003|Interim Analysis|Protocol Violation|0
6029784|NCT00296504|9625807|FG004|Interim Analysis|Protocol Violation|1
6029785|NCT00296504|9625808|FG005|Interim Analysis|Protocol Violation|0
6029786|NCT00296504|9625809|FG006|Interim Analysis|Protocol Violation|0
6029787|NCT00296504|9625810|FG007|Interim Analysis|Protocol Violation|1
6029788|NCT00296504|9625811|FG008|Interim Analysis|Protocol Violation|0
6048374|NCT00417612|9647552|FG000|Overall Study|Protocol Violation|0
6029789|NCT00296504|9625803|FG000|Interim Analysis|Insufficient CD4 Response|0
6029790|NCT00296504|9625804|FG001|Interim Analysis|Insufficient CD4 Response|0
6029791|NCT00296504|9625805|FG002|Interim Analysis|Insufficient CD4 Response|0
6029792|NCT00296504|9625806|FG003|Interim Analysis|Insufficient CD4 Response|0
6029793|NCT00296504|9625807|FG004|Interim Analysis|Insufficient CD4 Response|1
6029794|NCT00296504|9625808|FG005|Interim Analysis|Insufficient CD4 Response|1
6029795|NCT00296504|9625809|FG006|Interim Analysis|Insufficient CD4 Response|0
6029796|NCT00296504|9625810|FG007|Interim Analysis|Insufficient CD4 Response|0
6029797|NCT00296504|9625811|FG008|Interim Analysis|Insufficient CD4 Response|0
6029798|NCT00296504|9625803|FG000|Interim Analysis|Switched to Commercially Available Drug|2
6029799|NCT00296504|9625804|FG001|Interim Analysis|Switched to Commercially Available Drug|0
6029800|NCT00296504|9625805|FG002|Interim Analysis|Switched to Commercially Available Drug|4
6029801|NCT00296504|9625806|FG003|Interim Analysis|Switched to Commercially Available Drug|1
6029802|NCT00296504|9625807|FG004|Interim Analysis|Switched to Commercially Available Drug|0
6029803|NCT00296504|9625808|FG005|Interim Analysis|Switched to Commercially Available Drug|5
6029804|NCT00296504|9625809|FG006|Interim Analysis|Switched to Commercially Available Drug|3
6029805|NCT00296504|9625810|FG007|Interim Analysis|Switched to Commercially Available Drug|4
6079412|NCT00609622|9686263|FG001|Overall Study|Protocol Violation|1
6029806|NCT00296504|9625811|FG008|Interim Analysis|Switched to Commercially Available Drug|0
6029807|NCT00296504|9625803|FG000|Interim Analysis|Pregnancy|4
6029808|NCT00296504|9625804|FG001|Interim Analysis|Pregnancy|1
6029809|NCT00296504|9625805|FG002|Interim Analysis|Pregnancy|4
6029810|NCT00296504|9625806|FG003|Interim Analysis|Pregnancy|2
6029811|NCT00296504|9625807|FG004|Interim Analysis|Pregnancy|0
6029812|NCT00296504|9625808|FG005|Interim Analysis|Pregnancy|1
6029813|NCT00296504|9625809|FG006|Interim Analysis|Pregnancy|1
6029814|NCT00296504|9625810|FG007|Interim Analysis|Pregnancy|1
6029815|NCT00296504|9625811|FG008|Interim Analysis|Pregnancy|0
6029816|NCT00296504|9625803|FG000|Interim Analysis|Death|1
6029817|NCT00296504|9625804|FG001|Interim Analysis|Death|0
6029818|NCT00296504|9625805|FG002|Interim Analysis|Death|3
6029819|NCT00296504|9625806|FG003|Interim Analysis|Death|0
6029820|NCT00296504|9625807|FG004|Interim Analysis|Death|0
6029821|NCT00296504|9625808|FG005|Interim Analysis|Death|0
6029822|NCT00296504|9625809|FG006|Interim Analysis|Death|0
6029823|NCT00296504|9625810|FG007|Interim Analysis|Death|0
6309552|NCT02640612|10038248|FG001|Overall Study|Withdrawal by Subject|3
6309553|NCT02640612|10038249|FG002|Overall Study|Withdrawal by Subject|3
6309554|NCT02640612|10038247|FG000|Overall Study|Lost to Follow-up|4
6309555|NCT02640612|10038248|FG001|Overall Study|Lost to Follow-up|1
6029824|NCT00296504|9625811|FG008|Interim Analysis|Death|0
6029825|NCT00296504|9625803|FG000|Interim Analysis|Participant Non-compliant|0
6029826|NCT00296504|9625804|FG001|Interim Analysis|Participant Non-compliant|1
6079413|NCT00609622|9686262|FG000|Overall Study|Objective progression or relapse|47
6079414|NCT00609622|9686263|FG001|Overall Study|Objective progression or relapse|41
6079415|NCT00609622|9686262|FG000|Overall Study|Study terminated by sponsor|16
6079416|NCT00609622|9686263|FG001|Overall Study|Study terminated by sponsor|3
6079417|NCT00609622|9686262|FG000|Overall Study|Other|7
6079418|NCT00609622|9686263|FG001|Overall Study|Other|14
6079419|NCT00609622|9686262|FG000|Overall Study|Global deterioration of health status|6
6079420|NCT00609622|9686263|FG001|Overall Study|Global deterioration of health status|2
6079421|NCT00609674|9686271|FG000|Overall Study|Adverse Event|1
6029827|NCT00296504|9625805|FG002|Interim Analysis|Participant Non-compliant|2
6029828|NCT00296504|9625806|FG003|Interim Analysis|Participant Non-compliant|1
6029829|NCT00296504|9625807|FG004|Interim Analysis|Participant Non-compliant|1
6029830|NCT00296504|9625808|FG005|Interim Analysis|Participant Non-compliant|3
6029831|NCT00296504|9625809|FG006|Interim Analysis|Participant Non-compliant|6
6029832|NCT00296504|9625810|FG007|Interim Analysis|Participant Non-compliant|2
6029833|NCT00296504|9625811|FG008|Interim Analysis|Participant Non-compliant|0
6029834|NCT00296504|9625803|FG000|Interim Analysis|Participant Wanted to Become Pregnant|0
6029835|NCT00296504|9625804|FG001|Interim Analysis|Participant Wanted to Become Pregnant|0
6029836|NCT00296504|9625805|FG002|Interim Analysis|Participant Wanted to Become Pregnant|2
6029837|NCT00296504|9625806|FG003|Interim Analysis|Participant Wanted to Become Pregnant|0
6029838|NCT00296504|9625807|FG004|Interim Analysis|Participant Wanted to Become Pregnant|0
6029839|NCT00296504|9625808|FG005|Interim Analysis|Participant Wanted to Become Pregnant|1
6029840|NCT00296504|9625809|FG006|Interim Analysis|Participant Wanted to Become Pregnant|0
6029841|NCT00296504|9625810|FG007|Interim Analysis|Participant Wanted to Become Pregnant|0
6029842|NCT00296504|9625811|FG008|Interim Analysis|Participant Wanted to Become Pregnant|0
6029843|NCT00296504|9625803|FG000|Interim Analysis|To Simplify Treatment|0
6029844|NCT00296504|9625804|FG001|Interim Analysis|To Simplify Treatment|0
6029845|NCT00296504|9625805|FG002|Interim Analysis|To Simplify Treatment|1
6029846|NCT00296504|9625806|FG003|Interim Analysis|To Simplify Treatment|0
6029847|NCT00296504|9625807|FG004|Interim Analysis|To Simplify Treatment|0
6029848|NCT00296504|9625808|FG005|Interim Analysis|To Simplify Treatment|0
6029849|NCT00296504|9625809|FG006|Interim Analysis|To Simplify Treatment|2
6029850|NCT00296504|9625810|FG007|Interim Analysis|To Simplify Treatment|0
6029851|NCT00296504|9625811|FG008|Interim Analysis|To Simplify Treatment|0
6029852|NCT00296504|9625803|FG000|Interim Analysis|Participant Had Problems with Alcohol|0
6079422|NCT00609674|9686272|FG001|Overall Study|Adverse Event|1
6029853|NCT00296504|9625804|FG001|Interim Analysis|Participant Had Problems with Alcohol|0
6029854|NCT00296504|9625805|FG002|Interim Analysis|Participant Had Problems with Alcohol|1
6029855|NCT00296504|9625806|FG003|Interim Analysis|Participant Had Problems with Alcohol|0
6029856|NCT00296504|9625807|FG004|Interim Analysis|Participant Had Problems with Alcohol|0
6029857|NCT00296504|9625808|FG005|Interim Analysis|Participant Had Problems with Alcohol|0
6029858|NCT00296504|9625809|FG006|Interim Analysis|Participant Had Problems with Alcohol|0
6029859|NCT00296504|9625810|FG007|Interim Analysis|Participant Had Problems with Alcohol|0
6029860|NCT00296504|9625811|FG008|Interim Analysis|Participant Had Problems with Alcohol|0
6029861|NCT00296504|9625803|FG000|Interim Analysis|Participant Moved|1
6029862|NCT00296504|9625804|FG001|Interim Analysis|Participant Moved|0
6029863|NCT00296504|9625805|FG002|Interim Analysis|Participant Moved|1
6029864|NCT00296504|9625806|FG003|Interim Analysis|Participant Moved|0
6029865|NCT00296504|9625807|FG004|Interim Analysis|Participant Moved|0
6029866|NCT00296504|9625808|FG005|Interim Analysis|Participant Moved|1
6029867|NCT00296504|9625809|FG006|Interim Analysis|Participant Moved|1
6029868|NCT00296504|9625810|FG007|Interim Analysis|Participant Moved|0
6029869|NCT00296504|9625811|FG008|Interim Analysis|Participant Moved|0
6029870|NCT00296504|9625803|FG000|Interim Analysis|Participant Was Incarcerated|2
6029871|NCT00296504|9625804|FG001|Interim Analysis|Participant Was Incarcerated|0
6029872|NCT00296504|9625805|FG002|Interim Analysis|Participant Was Incarcerated|1
6029873|NCT00296504|9625806|FG003|Interim Analysis|Participant Was Incarcerated|0
6029874|NCT00296504|9625807|FG004|Interim Analysis|Participant Was Incarcerated|0
6029875|NCT00296504|9625808|FG005|Interim Analysis|Participant Was Incarcerated|0
6029876|NCT00296504|9625809|FG006|Interim Analysis|Participant Was Incarcerated|0
6029877|NCT00296504|9625810|FG007|Interim Analysis|Participant Was Incarcerated|0
6029878|NCT00296504|9625811|FG008|Interim Analysis|Participant Was Incarcerated|0
6029879|NCT00296504|9625803|FG000|Interim Analysis|Resistance to FPV|0
6029880|NCT00296504|9625804|FG001|Interim Analysis|Resistance to FPV|0
6029881|NCT00296504|9625805|FG002|Interim Analysis|Resistance to FPV|1
6029882|NCT00296504|9625806|FG003|Interim Analysis|Resistance to FPV|0
6029883|NCT00296504|9625807|FG004|Interim Analysis|Resistance to FPV|0
6029884|NCT00296504|9625808|FG005|Interim Analysis|Resistance to FPV|0
6029885|NCT00296504|9625809|FG006|Interim Analysis|Resistance to FPV|0
6029886|NCT00296504|9625810|FG007|Interim Analysis|Resistance to FPV|0
6029887|NCT00296504|9625811|FG008|Interim Analysis|Resistance to FPV|0
6029888|NCT00296504|9625803|FG000|Interim Analysis|Physician Decision|0
6029889|NCT00296504|9625804|FG001|Interim Analysis|Physician Decision|0
6029890|NCT00296504|9625805|FG002|Interim Analysis|Physician Decision|1
6029891|NCT00296504|9625806|FG003|Interim Analysis|Physician Decision|0
6029892|NCT00296504|9625807|FG004|Interim Analysis|Physician Decision|0
6029893|NCT00296504|9625808|FG005|Interim Analysis|Physician Decision|0
6029894|NCT00296504|9625809|FG006|Interim Analysis|Physician Decision|0
6029895|NCT00296504|9625810|FG007|Interim Analysis|Physician Decision|0
6029896|NCT00296504|9625811|FG008|Interim Analysis|Physician Decision|0
6029897|NCT00296504|9625803|FG000|Interim Analysis|Principle Investigator Discretion|2
6079423|NCT00609674|9686271|FG000|Overall Study|Protocol Violation|3
6079424|NCT00609674|9686272|FG001|Overall Study|Protocol Violation|5
6079425|NCT00609674|9686271|FG000|Overall Study|Lost to Follow-up|1
6079426|NCT00609674|9686272|FG001|Overall Study|Lost to Follow-up|0
6079427|NCT00609674|9686271|FG000|Overall Study|Withdrew consent|2
6079428|NCT00609674|9686272|FG001|Overall Study|Withdrew consent|1
6079429|NCT00609869|9686294|FG000|Overall Study|Withdrawn, ischemic stroke|1
6079430|NCT00609869|9686294|FG000|Overall Study|Severe hematologic toxicity|1
6079431|NCT00609869|9686294|FG000|Overall Study|Withdrawal by Subject|1
6079432|NCT00609869|9686294|FG000|Overall Study|Seizures|1
6079433|NCT00609869|9686294|FG000|Overall Study|Severe tumor flare reaction|1
6079434|NCT00609869|9686294|FG000|Overall Study|Hepatitis B infection|1
6079435|NCT00609869|9686294|FG000|Overall Study|Rituximab reaction prior to lenalidomide|1
6079436|NCT00609869|9686294|FG000|Overall Study|Mantle cell: not evaluable|4
6079437|NCT00609947|9686298|FG000|Overall Study|Death|1
6079438|NCT00609973|9686305|FG000|Overall Study|Adverse Event|2
6079439|NCT00609973|9686306|FG001|Overall Study|Adverse Event|1
6079440|NCT00609973|9686305|FG000|Overall Study|Protocol Violation|4
6079441|NCT00609973|9686306|FG001|Overall Study|Protocol Violation|3
6079442|NCT00609973|9686305|FG000|Overall Study|Lost to Follow-up|2
6079443|NCT00609973|9686306|FG001|Overall Study|Lost to Follow-up|1
6079444|NCT00609973|9686305|FG000|Overall Study|Withdrawal by Subject|0
6079445|NCT00609973|9686306|FG001|Overall Study|Withdrawal by Subject|1
6079446|NCT00609986|9686314|FG000|Overall Study|Did not receive transplant or treatment|8
6079447|NCT00609986|9686315|FG001|Overall Study|Did not receive transplant or treatment|3
6029898|NCT00296504|9625804|FG001|Interim Analysis|Principle Investigator Discretion|0
6029899|NCT00296504|9625805|FG002|Interim Analysis|Principle Investigator Discretion|1
6029900|NCT00296504|9625806|FG003|Interim Analysis|Principle Investigator Discretion|1
6029901|NCT00296504|9625807|FG004|Interim Analysis|Principle Investigator Discretion|0
6029902|NCT00296504|9625808|FG005|Interim Analysis|Principle Investigator Discretion|0
6079448|NCT00610129|9686325|FG000|Overall Study|Not treated since patients ineligible|3
6079449|NCT00610155|9686329|FG000|Period 1|Withdrawal by Subject|0
6079450|NCT00610155|9686330|FG001|Period 1|Withdrawal by Subject|0
6079451|NCT00610155|9686331|FG002|Period 1|Withdrawal by Subject|1
6029903|NCT00296504|9625809|FG006|Interim Analysis|Principle Investigator Discretion|0
6029904|NCT00296504|9625810|FG007|Interim Analysis|Principle Investigator Discretion|0
6029905|NCT00296504|9625811|FG008|Interim Analysis|Principle Investigator Discretion|0
6029906|NCT00296504|9625803|FG000|Interim Analysis|Principle Investigator Terminated Study|0
6029907|NCT00296504|9625804|FG001|Interim Analysis|Principle Investigator Terminated Study|0
6029908|NCT00296504|9625805|FG002|Interim Analysis|Principle Investigator Terminated Study|1
6029909|NCT00296504|9625806|FG003|Interim Analysis|Principle Investigator Terminated Study|0
6029910|NCT00296504|9625807|FG004|Interim Analysis|Principle Investigator Terminated Study|0
6029911|NCT00296504|9625808|FG005|Interim Analysis|Principle Investigator Terminated Study|0
6029912|NCT00296504|9625809|FG006|Interim Analysis|Principle Investigator Terminated Study|0
6029913|NCT00296504|9625810|FG007|Interim Analysis|Principle Investigator Terminated Study|0
6029914|NCT00296504|9625811|FG008|Interim Analysis|Principle Investigator Terminated Study|0
6029915|NCT00296504|9625803|FG000|Interim Analysis|Non-adherence|2
6029916|NCT00296504|9625804|FG001|Interim Analysis|Non-adherence|0
6029917|NCT00296504|9625805|FG002|Interim Analysis|Non-adherence|0
6029918|NCT00296504|9625806|FG003|Interim Analysis|Non-adherence|0
6029919|NCT00296504|9625807|FG004|Interim Analysis|Non-adherence|1
6029920|NCT00296504|9625808|FG005|Interim Analysis|Non-adherence|0
6029921|NCT00296504|9625809|FG006|Interim Analysis|Non-adherence|0
6029922|NCT00296504|9625810|FG007|Interim Analysis|Non-adherence|1
6029923|NCT00296504|9625811|FG008|Interim Analysis|Non-adherence|0
6029924|NCT00296504|9625803|FG000|Interim Analysis|Site Closing|1
6029925|NCT00296504|9625804|FG001|Interim Analysis|Site Closing|0
6029926|NCT00296504|9625805|FG002|Interim Analysis|Site Closing|0
6029927|NCT00296504|9625806|FG003|Interim Analysis|Site Closing|0
6029928|NCT00296504|9625807|FG004|Interim Analysis|Site Closing|0
6029929|NCT00296504|9625808|FG005|Interim Analysis|Site Closing|1
6029930|NCT00296504|9625809|FG006|Interim Analysis|Site Closing|2
6029931|NCT00296504|9625810|FG007|Interim Analysis|Site Closing|0
6029932|NCT00296504|9625811|FG008|Interim Analysis|Site Closing|0
6029933|NCT00296504|9625803|FG000|Interim Analysis|Lack of Personnel at Site|1
6029934|NCT00296504|9625804|FG001|Interim Analysis|Lack of Personnel at Site|0
6029935|NCT00296504|9625805|FG002|Interim Analysis|Lack of Personnel at Site|0
6029936|NCT00296504|9625806|FG003|Interim Analysis|Lack of Personnel at Site|0
6029937|NCT00296504|9625807|FG004|Interim Analysis|Lack of Personnel at Site|0
6029938|NCT00296504|9625808|FG005|Interim Analysis|Lack of Personnel at Site|0
6029939|NCT00296504|9625809|FG006|Interim Analysis|Lack of Personnel at Site|0
6029940|NCT00296504|9625810|FG007|Interim Analysis|Lack of Personnel at Site|0
6029941|NCT00296504|9625811|FG008|Interim Analysis|Lack of Personnel at Site|0
6029942|NCT00296504|9625803|FG000|Interim Analysis|Missed Schedule Date|1
6029943|NCT00296504|9625804|FG001|Interim Analysis|Missed Schedule Date|0
6029944|NCT00296504|9625805|FG002|Interim Analysis|Missed Schedule Date|0
6029945|NCT00296504|9625806|FG003|Interim Analysis|Missed Schedule Date|0
6029946|NCT00296504|9625807|FG004|Interim Analysis|Missed Schedule Date|0
6029947|NCT00296504|9625808|FG005|Interim Analysis|Missed Schedule Date|0
6029948|NCT00296504|9625809|FG006|Interim Analysis|Missed Schedule Date|0
6029949|NCT00296504|9625810|FG007|Interim Analysis|Missed Schedule Date|0
6029950|NCT00296504|9625811|FG008|Interim Analysis|Missed Schedule Date|0
6029951|NCT00296504|9625803|FG000|Interim Analysis|Inclusion in Other Protocol|0
6029952|NCT00296504|9625804|FG001|Interim Analysis|Inclusion in Other Protocol|0
6029953|NCT00296504|9625805|FG002|Interim Analysis|Inclusion in Other Protocol|0
6029954|NCT00296504|9625806|FG003|Interim Analysis|Inclusion in Other Protocol|1
6029955|NCT00296504|9625807|FG004|Interim Analysis|Inclusion in Other Protocol|0
6029956|NCT00296504|9625808|FG005|Interim Analysis|Inclusion in Other Protocol|0
6029957|NCT00296504|9625809|FG006|Interim Analysis|Inclusion in Other Protocol|0
6029958|NCT00296504|9625810|FG007|Interim Analysis|Inclusion in Other Protocol|0
6029959|NCT00296504|9625811|FG008|Interim Analysis|Inclusion in Other Protocol|0
6029960|NCT00296504|9625803|FG000|Interim Analysis|Participant Stopped|0
6029961|NCT00296504|9625804|FG001|Interim Analysis|Participant Stopped|0
6029962|NCT00296504|9625805|FG002|Interim Analysis|Participant Stopped|0
6029963|NCT00296504|9625806|FG003|Interim Analysis|Participant Stopped|0
6029964|NCT00296504|9625807|FG004|Interim Analysis|Participant Stopped|1
6029965|NCT00296504|9625808|FG005|Interim Analysis|Participant Stopped|0
6029966|NCT00296504|9625809|FG006|Interim Analysis|Participant Stopped|0
6029967|NCT00296504|9625810|FG007|Interim Analysis|Participant Stopped|0
6029968|NCT00296504|9625811|FG008|Interim Analysis|Participant Stopped|0
6029969|NCT00296504|9625803|FG000|Interim Analysis|Physician and Participant Decision|0
6029970|NCT00296504|9625804|FG001|Interim Analysis|Physician and Participant Decision|0
6029971|NCT00296504|9625805|FG002|Interim Analysis|Physician and Participant Decision|0
6029972|NCT00296504|9625806|FG003|Interim Analysis|Physician and Participant Decision|0
6029973|NCT00296504|9625807|FG004|Interim Analysis|Physician and Participant Decision|0
6029974|NCT00296504|9625808|FG005|Interim Analysis|Physician and Participant Decision|1
6029975|NCT00296504|9625809|FG006|Interim Analysis|Physician and Participant Decision|0
6029976|NCT00296504|9625810|FG007|Interim Analysis|Physician and Participant Decision|0
6029977|NCT00296504|9625811|FG008|Interim Analysis|Physician and Participant Decision|0
6029978|NCT00296504|9625803|FG000|Interim Analysis|Participant Stopped HIV Medications|0
6029979|NCT00296504|9625804|FG001|Interim Analysis|Participant Stopped HIV Medications|0
6029980|NCT00296504|9625805|FG002|Interim Analysis|Participant Stopped HIV Medications|0
6029981|NCT00296504|9625806|FG003|Interim Analysis|Participant Stopped HIV Medications|0
6029982|NCT00296504|9625807|FG004|Interim Analysis|Participant Stopped HIV Medications|0
6029983|NCT00296504|9625808|FG005|Interim Analysis|Participant Stopped HIV Medications|0
6029984|NCT00296504|9625809|FG006|Interim Analysis|Participant Stopped HIV Medications|1
6029985|NCT00296504|9625810|FG007|Interim Analysis|Participant Stopped HIV Medications|0
6029986|NCT00296504|9625811|FG008|Interim Analysis|Participant Stopped HIV Medications|0
6029987|NCT00296504|9625803|FG000|Interim Analysis|Study Ended|0
6029988|NCT00296504|9625804|FG001|Interim Analysis|Study Ended|0
6029989|NCT00296504|9625805|FG002|Interim Analysis|Study Ended|0
6029990|NCT00296504|9625806|FG003|Interim Analysis|Study Ended|0
6029991|NCT00296504|9625807|FG004|Interim Analysis|Study Ended|0
6029992|NCT00296504|9625808|FG005|Interim Analysis|Study Ended|0
6029993|NCT00296504|9625809|FG006|Interim Analysis|Study Ended|1
6029994|NCT00296504|9625810|FG007|Interim Analysis|Study Ended|0
6029995|NCT00296504|9625811|FG008|Interim Analysis|Study Ended|0
6029996|NCT00296504|9625803|FG000|Interim Analysis|Participant Needed Interferon|0
6029997|NCT00296504|9625804|FG001|Interim Analysis|Participant Needed Interferon|0
6029998|NCT00296504|9625805|FG002|Interim Analysis|Participant Needed Interferon|0
6029999|NCT00296504|9625806|FG003|Interim Analysis|Participant Needed Interferon|0
6030000|NCT00296504|9625807|FG004|Interim Analysis|Participant Needed Interferon|0
6030001|NCT00296504|9625808|FG005|Interim Analysis|Participant Needed Interferon|0
6030002|NCT00296504|9625809|FG006|Interim Analysis|Participant Needed Interferon|0
6030003|NCT00296504|9625810|FG007|Interim Analysis|Participant Needed Interferon|1
6030004|NCT00296504|9625811|FG008|Interim Analysis|Participant Needed Interferon|0
6030005|NCT00296504|9625803|FG000|Interim Analysis|Ongoing|32
6030006|NCT00296504|9625804|FG001|Interim Analysis|Ongoing|12
6030007|NCT00296504|9625805|FG002|Interim Analysis|Ongoing|16
6030008|NCT00296504|9625806|FG003|Interim Analysis|Ongoing|22
6030009|NCT00296504|9625807|FG004|Interim Analysis|Ongoing|0
6030010|NCT00296504|9625808|FG005|Interim Analysis|Ongoing|0
6030011|NCT00296504|9625809|FG006|Interim Analysis|Ongoing|30
6030012|NCT00296504|9625810|FG007|Interim Analysis|Ongoing|1
6030013|NCT00296504|9625811|FG008|Interim Analysis|Ongoing|0
6030014|NCT00296504|9625803|FG000|Final Analysis|Withdrawal by Subject|0
6030015|NCT00296504|9625804|FG001|Final Analysis|Withdrawal by Subject|0
6030016|NCT00296504|9625805|FG002|Final Analysis|Withdrawal by Subject|0
6030017|NCT00296504|9625806|FG003|Final Analysis|Withdrawal by Subject|0
6030018|NCT00296504|9625807|FG004|Final Analysis|Withdrawal by Subject|0
6030019|NCT00296504|9625808|FG005|Final Analysis|Withdrawal by Subject|0
6030020|NCT00296504|9625809|FG006|Final Analysis|Withdrawal by Subject|0
6030021|NCT00296504|9625810|FG007|Final Analysis|Withdrawal by Subject|0
6030022|NCT00296504|9625811|FG008|Final Analysis|Withdrawal by Subject|1
6030023|NCT00296504|9625803|FG000|Final Analysis|Lost to Follow-up|0
6030024|NCT00296504|9625804|FG001|Final Analysis|Lost to Follow-up|0
6030025|NCT00296504|9625805|FG002|Final Analysis|Lost to Follow-up|0
6030026|NCT00296504|9625806|FG003|Final Analysis|Lost to Follow-up|0
6030027|NCT00296504|9625807|FG004|Final Analysis|Lost to Follow-up|0
6030028|NCT00296504|9625808|FG005|Final Analysis|Lost to Follow-up|0
6030029|NCT00296504|9625809|FG006|Final Analysis|Lost to Follow-up|0
6030030|NCT00296504|9625810|FG007|Final Analysis|Lost to Follow-up|0
6030031|NCT00296504|9625811|FG008|Final Analysis|Lost to Follow-up|5
6030032|NCT00296504|9625803|FG000|Final Analysis|Insufficient Viral Load Response|0
6030033|NCT00296504|9625804|FG001|Final Analysis|Insufficient Viral Load Response|0
6030034|NCT00296504|9625805|FG002|Final Analysis|Insufficient Viral Load Response|0
6030035|NCT00296504|9625806|FG003|Final Analysis|Insufficient Viral Load Response|0
6030036|NCT00296504|9625807|FG004|Final Analysis|Insufficient Viral Load Response|0
6030037|NCT00296504|9625808|FG005|Final Analysis|Insufficient Viral Load Response|0
6030038|NCT00296504|9625809|FG006|Final Analysis|Insufficient Viral Load Response|0
6030039|NCT00296504|9625810|FG007|Final Analysis|Insufficient Viral Load Response|0
6030040|NCT00296504|9625811|FG008|Final Analysis|Insufficient Viral Load Response|6
6030041|NCT00296504|9625803|FG000|Final Analysis|Adverse Event|0
6030042|NCT00296504|9625804|FG001|Final Analysis|Adverse Event|0
6030043|NCT00296504|9625805|FG002|Final Analysis|Adverse Event|0
6030044|NCT00296504|9625806|FG003|Final Analysis|Adverse Event|0
6030045|NCT00296504|9625807|FG004|Final Analysis|Adverse Event|0
6030046|NCT00296504|9625808|FG005|Final Analysis|Adverse Event|0
6030047|NCT00296504|9625809|FG006|Final Analysis|Adverse Event|0
6030048|NCT00296504|9625810|FG007|Final Analysis|Adverse Event|0
6030049|NCT00296504|9625811|FG008|Final Analysis|Adverse Event|2
6030050|NCT00296504|9625803|FG000|Final Analysis|Pregnancy|0
6030051|NCT00296504|9625804|FG001|Final Analysis|Pregnancy|0
6030052|NCT00296504|9625805|FG002|Final Analysis|Pregnancy|0
6030053|NCT00296504|9625806|FG003|Final Analysis|Pregnancy|0
6030054|NCT00296504|9625807|FG004|Final Analysis|Pregnancy|0
6030055|NCT00296504|9625808|FG005|Final Analysis|Pregnancy|0
6030056|NCT00296504|9625809|FG006|Final Analysis|Pregnancy|0
6030057|NCT00296504|9625810|FG007|Final Analysis|Pregnancy|0
6030058|NCT00296504|9625811|FG008|Final Analysis|Pregnancy|4
6030059|NCT00296504|9625803|FG000|Final Analysis|Tuberculosis|0
6030060|NCT00296504|9625804|FG001|Final Analysis|Tuberculosis|0
6030061|NCT00296504|9625805|FG002|Final Analysis|Tuberculosis|0
6030062|NCT00296504|9625806|FG003|Final Analysis|Tuberculosis|0
6030063|NCT00296504|9625807|FG004|Final Analysis|Tuberculosis|0
6079452|NCT00610155|9686332|FG003|Period 1|Withdrawal by Subject|0
6079453|NCT00610155|9686333|FG004|Period 1|Withdrawal by Subject|0
6079454|NCT00610155|9686334|FG005|Period 1|Withdrawal by Subject|0
6079455|NCT00610155|9686329|FG000|Period 3|Adverse Event|1
6079456|NCT00610155|9686330|FG001|Period 3|Adverse Event|0
6079457|NCT00610155|9686331|FG002|Period 3|Adverse Event|0
6079458|NCT00610155|9686332|FG003|Period 3|Adverse Event|0
6079459|NCT00610155|9686333|FG004|Period 3|Adverse Event|0
6079460|NCT00610155|9686334|FG005|Period 3|Adverse Event|0
6079461|NCT00610168|9686344|FG000|Overall Study|Withdrawal by Subject|2
6079462|NCT00610168|9686345|FG001|Overall Study|Withdrawal by Subject|0
6079463|NCT00610207|9686351|FG000|Overall Study|Lost to Follow-up|3
6079464|NCT00610363|9686361|FG000|Overall Study|Non-compliance with protocol|0
6079465|NCT00610363|9686362|FG001|Overall Study|Non-compliance with protocol|1
6079466|NCT00610363|9686361|FG000|Overall Study|Adverse Event|3
6079467|NCT00610363|9686362|FG001|Overall Study|Adverse Event|1
6079468|NCT00610363|9686361|FG000|Overall Study|Lack of Efficacy|2
6079469|NCT00610363|9686362|FG001|Overall Study|Lack of Efficacy|0
6079470|NCT00610363|9686361|FG000|Overall Study|Lost to Follow-up|4
6079471|NCT00610363|9686362|FG001|Overall Study|Lost to Follow-up|0
6079472|NCT00610363|9686361|FG000|Overall Study|Withdrawal by Subject|1
6079473|NCT00610363|9686362|FG001|Overall Study|Withdrawal by Subject|0
6079474|NCT00610363|9686361|FG000|Overall Study|Other than specified above|1
6079475|NCT00610363|9686362|FG001|Overall Study|Other than specified above|1
6079476|NCT00610441|9686386|FG000|Treatment Period 1 - 3 Weeks|Adverse Event|1
6079477|NCT00610441|9686387|FG001|Treatment Period 1 - 3 Weeks|Adverse Event|1
6079478|NCT00610441|9686388|FG002|Treatment Period 1 - 3 Weeks|Adverse Event|4
6079479|NCT00610441|9686389|FG003|Treatment Period 1 - 3 Weeks|Adverse Event|1
6079480|NCT00610441|9686386|FG000|Treatment Period 1 - 3 Weeks|Lack of Efficacy|0
6079481|NCT00610441|9686387|FG001|Treatment Period 1 - 3 Weeks|Lack of Efficacy|0
6079482|NCT00610441|9686388|FG002|Treatment Period 1 - 3 Weeks|Lack of Efficacy|1
6079483|NCT00610441|9686389|FG003|Treatment Period 1 - 3 Weeks|Lack of Efficacy|0
6079484|NCT00610441|9686386|FG000|Treatment Period 1 - 3 Weeks|Lost to Follow-up|1
6030064|NCT00296504|9625808|FG005|Final Analysis|Tuberculosis|0
6030065|NCT00296504|9625809|FG006|Final Analysis|Tuberculosis|0
6030066|NCT00296504|9625810|FG007|Final Analysis|Tuberculosis|0
6030067|NCT00296504|9625811|FG008|Final Analysis|Tuberculosis|1
6030068|NCT00296504|9625803|FG000|Final Analysis|Participant Moved to Another Country|0
6030069|NCT00296504|9625804|FG001|Final Analysis|Participant Moved to Another Country|0
6030070|NCT00296504|9625805|FG002|Final Analysis|Participant Moved to Another Country|0
6030071|NCT00296504|9625806|FG003|Final Analysis|Participant Moved to Another Country|0
6030072|NCT00296504|9625807|FG004|Final Analysis|Participant Moved to Another Country|0
6030073|NCT00296504|9625808|FG005|Final Analysis|Participant Moved to Another Country|0
6030074|NCT00296504|9625809|FG006|Final Analysis|Participant Moved to Another Country|0
6030075|NCT00296504|9625810|FG007|Final Analysis|Participant Moved to Another Country|0
6030076|NCT00296504|9625811|FG008|Final Analysis|Participant Moved to Another Country|1
6030077|NCT00296504|9625803|FG000|Final Analysis|Poor Adherence|0
6030078|NCT00296504|9625804|FG001|Final Analysis|Poor Adherence|0
6030079|NCT00296504|9625805|FG002|Final Analysis|Poor Adherence|0
6030080|NCT00296504|9625806|FG003|Final Analysis|Poor Adherence|0
6030081|NCT00296504|9625807|FG004|Final Analysis|Poor Adherence|0
6030082|NCT00296504|9625808|FG005|Final Analysis|Poor Adherence|0
6030083|NCT00296504|9625809|FG006|Final Analysis|Poor Adherence|0
6030084|NCT00296504|9625810|FG007|Final Analysis|Poor Adherence|0
6030085|NCT00296504|9625811|FG008|Final Analysis|Poor Adherence|1
6030086|NCT00296517|9625838|FG000|Dose Level 2 - Week 2|Adverse Event|1
6079485|NCT00610441|9686387|FG001|Treatment Period 1 - 3 Weeks|Lost to Follow-up|1
6079486|NCT00610441|9686388|FG002|Treatment Period 1 - 3 Weeks|Lost to Follow-up|1
6079487|NCT00610441|9686389|FG003|Treatment Period 1 - 3 Weeks|Lost to Follow-up|0
6079488|NCT00610441|9686386|FG000|Treatment Period 1 - 3 Weeks|Withdrawal by Subject|1
6079489|NCT00610441|9686387|FG001|Treatment Period 1 - 3 Weeks|Withdrawal by Subject|0
6079490|NCT00610441|9686388|FG002|Treatment Period 1 - 3 Weeks|Withdrawal by Subject|1
6030087|NCT00296517|9625839|FG001|Dose Level 2 - Week 2|Adverse Event|5
6030088|NCT00296517|9625838|FG000|Dose Level 2 - Week 2|Withdrawal by Subject|1
6030089|NCT00296517|9625839|FG001|Dose Level 2 - Week 2|Withdrawal by Subject|0
6030090|NCT00296517|9625838|FG000|Dose Level 3 - Weeks 3-12|Adverse Event|30
6030091|NCT00296517|9625839|FG001|Dose Level 3 - Weeks 3-12|Adverse Event|34
6030092|NCT00296517|9625838|FG000|Dose Level 3 - Weeks 3-12|Lack of Efficacy|3
6030093|NCT00296517|9625839|FG001|Dose Level 3 - Weeks 3-12|Lack of Efficacy|6
6030094|NCT00296517|9625838|FG000|Dose Level 3 - Weeks 3-12|Lost to Follow-up|3
6079491|NCT00610441|9686389|FG003|Treatment Period 1 - 3 Weeks|Withdrawal by Subject|1
6087646|NCT00669864|9698070|FG000|Overall Study|Lost to Follow-up|2
6030095|NCT00296517|9625839|FG001|Dose Level 3 - Weeks 3-12|Lost to Follow-up|2
6030096|NCT00296517|9625838|FG000|Dose Level 3 - Weeks 3-12|Protocol Violation|1
6030097|NCT00296517|9625839|FG001|Dose Level 3 - Weeks 3-12|Protocol Violation|0
6030098|NCT00296517|9625838|FG000|Dose Level 3 - Weeks 3-12|Withdrawal by Subject|7
6030099|NCT00296517|9625839|FG001|Dose Level 3 - Weeks 3-12|Withdrawal by Subject|18
6030100|NCT00296517|9625838|FG000|Dose Level 3 - Weeks 3-12|Non - Compliance|1
6030101|NCT00296517|9625839|FG001|Dose Level 3 - Weeks 3-12|Non - Compliance|0
6030102|NCT00296517|9625838|FG000|Dose Level 3 - Weeks 3-12|Other|0
6030103|NCT00296517|9625839|FG001|Dose Level 3 - Weeks 3-12|Other|2
6030104|NCT00296647|9625850|FG000|Overall Study|Death|4
6030105|NCT00296647|9625851|FG001|Overall Study|Death|1
6030106|NCT00296647|9625852|FG002|Overall Study|Death|2
6030107|NCT00296647|9625853|FG003|Overall Study|Death|1
6030108|NCT00296647|9625854|FG004|Overall Study|Death|1
6030109|NCT00296647|9625850|FG000|Overall Study|Withdrawal by Subject|28
6030110|NCT00296647|9625851|FG001|Overall Study|Withdrawal by Subject|27
6030111|NCT00296647|9625852|FG002|Overall Study|Withdrawal by Subject|32
6030112|NCT00296647|9625853|FG003|Overall Study|Withdrawal by Subject|16
6030113|NCT00296647|9625854|FG004|Overall Study|Withdrawal by Subject|19
6030114|NCT00296725|9625866|FG000|Phase 1: Fluoxetine (1-12 Weeks)|Lost to Follow-up|1
6030115|NCT00296725|9625866|FG000|Phase 1: Fluoxetine (1-12 Weeks)|Adverse Event|4
6030116|NCT00296725|9625866|FG000|Phase 2: Imipramine (1-6 Weeks)|Lost to Follow-up|1
6030117|NCT00296816|9625874|FG000|Overall Study|Disease Progression|37
6030118|NCT00296816|9625874|FG000|Overall Study|Adverse Event|18
6030119|NCT00296816|9625874|FG000|Overall Study|Investigator/Participant request|5
6030120|NCT00296816|9625874|FG000|Overall Study|Non-compliance|1
6030121|NCT00296816|9625874|FG000|Overall Study|Missing for end of treatment|4
6030122|NCT00296816|9625874|FG000|Overall Study|Progression based on CA-125 (biomarker)|2
6030123|NCT00296816|9625874|FG000|Overall Study|Poor performance status|1
6030124|NCT00296816|9625874|FG000|Overall Study|Relocation to Florida|1
6030125|NCT00296816|9625874|FG000|Overall Study|Noncompliance/decision to discontinue|1
6030126|NCT00296816|9625874|FG000|Overall Study|Urine protein/creatinine ratio delay|1
6030127|NCT00296816|9625874|FG000|Overall Study|Neuropathy/patient preference|1
6030128|NCT00296816|9625874|FG000|Overall Study|Proteinuria|1
6030129|NCT00296816|9625874|FG000|Overall Study|ineligibility due to radiation treatment|1
6030130|NCT00297037|9625880|FG000|Overall Study|Withdrawal by Subject|2
6030131|NCT00297037|9625881|FG001|Overall Study|Withdrawal by Subject|0
6048375|NCT00417612|9647553|FG001|Overall Study|Protocol Violation|2
6048376|NCT00417612|9647552|FG000|Overall Study|Lost to Follow-up|1
6048377|NCT00417612|9647553|FG001|Overall Study|Lost to Follow-up|0
6048378|NCT00417885|9647572|FG000|Overall Study|Adverse Event|1
6048379|NCT00417885|9647572|FG000|Overall Study|Objective Progression or Relapse|3
6048380|NCT00417885|9647572|FG000|Overall Study|Transferred to Another Sunitinib Study|2
6048381|NCT00417963|9647576|FG000|Overall Study|Lost to Follow-up|3
6048382|NCT00417963|9647576|FG000|Overall Study|Withdrawal by Subject|18
6048383|NCT00417963|9647576|FG000|Overall Study|Death|17
6048384|NCT00417963|9647576|FG000|Overall Study|Study device could not be deployed|3
6048385|NCT00417976|9647585|FG000|Overall Study|Non compliance unrelated to toxicity|1
6048386|NCT00417976|9647585|FG000|Overall Study|Treatment -related toxicity|2
6048387|NCT00417989|9647592|FG000|Overall Study|Withdrawal by Subject|13
6048388|NCT00417989|9647593|FG001|Overall Study|Withdrawal by Subject|13
6048389|NCT00417989|9647592|FG000|Overall Study|Lost to Follow-up|1
6048390|NCT00417989|9647593|FG001|Overall Study|Lost to Follow-up|6
6048391|NCT00417989|9647592|FG000|Overall Study|Protocol Violation|1
6048392|NCT00417989|9647593|FG001|Overall Study|Protocol Violation|0
6048393|NCT00417989|9647592|FG000|Overall Study|Death|0
6048394|NCT00417989|9647593|FG001|Overall Study|Death|1
6048395|NCT00417989|9647592|FG000|Overall Study|Physician Decision|5
6048396|NCT00417989|9647593|FG001|Overall Study|Physician Decision|2
6048397|NCT00418184|9647633|FG000|Double-blind Phase|Withdrawal by Subject|22
6048398|NCT00418184|9647634|FG001|Double-blind Phase|Withdrawal by Subject|9
6048399|NCT00418184|9647633|FG000|Double-blind Phase|Adverse Event|2
6048400|NCT00418184|9647634|FG001|Double-blind Phase|Adverse Event|1
6048401|NCT00418184|9647633|FG000|Double-blind Phase|Poor compliance|3
6048402|NCT00418184|9647634|FG001|Double-blind Phase|Poor compliance|1
6048403|NCT00418314|9647650|FG000|Overall Study|Withdrawal by Subject|1
6048404|NCT00418314|9647651|FG001|Overall Study|Withdrawal by Subject|2
6048405|NCT00418379|9647660|FG000|Year 1|Adverse Event|9
6048406|NCT00418379|9647661|FG001|Year 1|Adverse Event|15
6048407|NCT00418379|9647662|FG002|Year 1|Adverse Event|3
6048408|NCT00418379|9647660|FG000|Year 1|Withdrawal by Subject|7
6048409|NCT00418379|9647661|FG001|Year 1|Withdrawal by Subject|8
6048410|NCT00418379|9647662|FG002|Year 1|Withdrawal by Subject|5
6048411|NCT00418379|9647660|FG000|Year 1|Any other reason not above-mentioned|2
6048412|NCT00418379|9647661|FG001|Year 1|Any other reason not above-mentioned|5
6048413|NCT00418379|9647662|FG002|Year 1|Any other reason not above-mentioned|7
6048414|NCT00418379|9647660|FG000|Year 2|Adverse Event|5
6048415|NCT00418379|9647661|FG001|Year 2|Adverse Event|2
6048416|NCT00418379|9647662|FG002|Year 2|Adverse Event|1
6048417|NCT00418379|9647660|FG000|Year 2|Withdrawal by Subject|1
6048418|NCT00418379|9647661|FG001|Year 2|Withdrawal by Subject|1
6048419|NCT00418379|9647662|FG002|Year 2|Withdrawal by Subject|3
6048420|NCT00418379|9647660|FG000|Year 2|Any other reason not above-mentioned|2
6048421|NCT00418379|9647661|FG001|Year 2|Any other reason not above-mentioned|1
6048422|NCT00418379|9647662|FG002|Year 2|Any other reason not above-mentioned|6
6048423|NCT00418379|9647660|FG000|Year 3|Withdrawal by Subject|1
6048424|NCT00418379|9647661|FG001|Year 3|Withdrawal by Subject|1
6048425|NCT00418379|9647662|FG002|Year 3|Withdrawal by Subject|2
6048426|NCT00418379|9647660|FG000|Year 3|Any other reason not above-mentioned|2
6048427|NCT00418379|9647661|FG001|Year 3|Any other reason not above-mentioned|1
6048428|NCT00418379|9647662|FG002|Year 3|Any other reason not above-mentioned|1
6030132|NCT00297167|9625907|FG000|Open-label Dose Normalization Period 1|Withdrawal by Subject|0
6030133|NCT00297167|9625908|FG001|Open-label Dose Normalization Period 1|Withdrawal by Subject|0
6030134|NCT00297167|9625909|FG002|Open-label Dose Normalization Period 1|Withdrawal by Subject|1
6030135|NCT00297167|9625907|FG000|Second Double-blind Intervention Period|Protocol Violation|1
6030136|NCT00297167|9625908|FG001|Second Double-blind Intervention Period|Protocol Violation|0
6030137|NCT00297167|9625909|FG002|Second Double-blind Intervention Period|Protocol Violation|0
6030138|NCT00297232|9625916|FG000|Overall Study|Lack of Efficacy|7
6030139|NCT00297232|9625916|FG000|Overall Study|Lost to Follow-up|10
6030140|NCT00297232|9625916|FG000|Overall Study|Adverse Event|63
6030141|NCT00297232|9625916|FG000|Overall Study|Voluntary Withdrawal|120
6030142|NCT00297232|9625916|FG000|Overall Study|Subject was Noncompliant|9
6030143|NCT00297232|9625916|FG000|Overall Study|Death|9
6030144|NCT00297232|9625916|FG000|Overall Study|Anti-natalizumab Positive|8
6030145|NCT00297232|9625916|FG000|Overall Study|Switched to Commercial Tysabri|22
6030146|NCT00297232|9625916|FG000|Overall Study|Disease Progression|8
6030147|NCT00297232|9625916|FG000|Overall Study|Fear of PML|10
6030148|NCT00297232|9625916|FG000|Overall Study|Anti-JCV Antibody Positive|13
6030149|NCT00297232|9625916|FG000|Overall Study|Miscellaneous|5
6030150|NCT00297232|9625916|FG000|Overall Study|Sponsor Decision|34
6030151|NCT00297232|9625916|FG000|Overall Study|Subject Relocated|7
6030152|NCT00297232|9625916|FG000|Overall Study|Subject Withdrew Consent|37
6030153|NCT00297232|9625916|FG000|Overall Study|Persistently Positive Antibodies|11
6030154|NCT00297232|9625916|FG000|Overall Study|Investigator Withdrew From Program|19
6030155|NCT00297232|9625916|FG000|Overall Study|Did Not Enroll to Week 264|34
6030156|NCT00297232|9625916|FG000|Overall Study|Did Not Enroll to Week 480|17
6030157|NCT00297232|9625916|FG000|Overall Study|No data available after Week 264|161
6030158|NCT00297232|9625916|FG000|Overall Study|Other|1
6030159|NCT00297258|9625920|FG000|Overall Study|Disease Progression, Relapse, Death|120
6030160|NCT00297258|9625920|FG000|Overall Study|Toxicity (or Toxic Death)|10
6030161|NCT00297258|9625920|FG000|Overall Study|Patient Refusal: Not Related to Toxicity|2
6030162|NCT00297258|9625920|FG000|Overall Study|Intercurrent Illness|3
6030163|NCT00297258|9625920|FG000|Overall Study|Intercurrent Death|2
6030164|NCT00297258|9625920|FG000|Overall Study|Deteriorization of General Condition|1
6030165|NCT00297258|9625920|FG000|Overall Study|Radiotherapy to Destroy Last Lesion|1
6030166|NCT00297258|9625920|FG000|Overall Study|Surgery Performed on Target Lesion|1
6030167|NCT00297258|9625920|FG000|Overall Study|Switch to Commercial Treatment|1
6030168|NCT00297258|9625920|FG000|Overall Study|Interruption: Cold/Flu-like Symptoms|1
6030169|NCT00297427|9625929|FG000|Phase 1: Initial Intervention|Withdrawal by Subject|8
6030170|NCT00297427|9625930|FG001|Phase 1: Initial Intervention|Withdrawal by Subject|5
6030171|NCT00297427|9625929|FG000|Phase 1: Initial Intervention|Lost to Follow-up|0
6030172|NCT00297427|9625930|FG001|Phase 1: Initial Intervention|Lost to Follow-up|3
6030173|NCT00297427|9625929|FG000|Phase 1: Initial Intervention|Death|0
6030174|NCT00297427|9625930|FG001|Phase 1: Initial Intervention|Death|1
6030175|NCT00297427|9625929|FG000|Phase 2: Optional Crossover for Sham|Withdrawal by Subject|15
6030176|NCT00297427|9625930|FG001|Phase 2: Optional Crossover for Sham|Withdrawal by Subject|0
6030177|NCT00297427|9625929|FG000|Phase 2: Optional Crossover for Sham|Lost to Follow-up|1
6030178|NCT00297427|9625930|FG001|Phase 2: Optional Crossover for Sham|Lost to Follow-up|0
6030179|NCT00297427|9625929|FG000|Phase 3: Follow-up Post-True Acupuncture|Withdrawal by Subject|29
6030180|NCT00297427|9625930|FG001|Phase 3: Follow-up Post-True Acupuncture|Withdrawal by Subject|0
6030181|NCT00297427|9625929|FG000|Phase 3: Follow-up Post-True Acupuncture|Lost to Follow-up|3
6030182|NCT00297427|9625930|FG001|Phase 3: Follow-up Post-True Acupuncture|Lost to Follow-up|0
6030183|NCT00297427|9625929|FG000|Phase 3: Follow-up Post-True Acupuncture|Could not complete outcome diary|2
6030184|NCT00297427|9625930|FG001|Phase 3: Follow-up Post-True Acupuncture|Could not complete outcome diary|0
6030185|NCT00297479|9625947|FG000|Overall Study|Lost to Follow-up|37
6030186|NCT00297479|9625948|FG001|Overall Study|Lost to Follow-up|54
6030187|NCT00297479|9625949|FG002|Overall Study|Lost to Follow-up|51
6030188|NCT00297492|9625960|FG000|Set Quit Date|Lost to Follow-up|7
6030189|NCT00297492|9625961|FG001|Set Quit Date|Lost to Follow-up|13
6030190|NCT00297492|9625962|FG002|Set Quit Date|Lost to Follow-up|5
6030191|NCT00297492|9625960|FG000|6 Month Follow-up|Lost to Follow-up|63
6030192|NCT00297492|9625961|FG001|6 Month Follow-up|Lost to Follow-up|49
6030193|NCT00297492|9625962|FG002|6 Month Follow-up|Lost to Follow-up|27
6030194|NCT00297648|9625974|FG000|Overall Study|Adverse Event|13
6030195|NCT00297648|9625974|FG000|Overall Study|Lack of Efficacy|18
6030196|NCT00297648|9625974|FG000|Overall Study|Lost to Follow-up|1
6030197|NCT00297648|9625974|FG000|Overall Study|Withdrawal by Subject|3
6030198|NCT00297648|9625974|FG000|Overall Study|Other: Incompliance|1
6030199|NCT00297778|9625980|FG000|Overall Study|Adverse Event|16
6030200|NCT00297778|9625981|FG001|Overall Study|Adverse Event|10
6030201|NCT00297778|9625980|FG000|Overall Study|Withdrawal by Subject|1
6030202|NCT00297778|9625981|FG001|Overall Study|Withdrawal by Subject|5
6030203|NCT00297778|9625980|FG000|Overall Study|Lack of Efficacy|2
6030204|NCT00297778|9625981|FG001|Overall Study|Lack of Efficacy|1
6030205|NCT00297778|9625980|FG000|Overall Study|Non-compliant with trial protocol|0
6030206|NCT00297778|9625981|FG001|Overall Study|Non-compliant with trial protocol|3
6030207|NCT00297778|9625980|FG000|Overall Study|Other|0
6030208|NCT00297778|9625981|FG001|Overall Study|Other|1
6030209|NCT00297830|9625990|FG000|6 Month Visit|Death|1
6030210|NCT00297830|9625991|FG001|6 Month Visit|Death|0
6030211|NCT00297830|9625992|FG002|6 Month Visit|Death|2
6030212|NCT00297830|9625990|FG000|6 Month Visit|Withdrawal by Subject|2
6030213|NCT00297830|9625991|FG001|6 Month Visit|Withdrawal by Subject|1
6030214|NCT00297830|9625992|FG002|6 Month Visit|Withdrawal by Subject|1
6030215|NCT00297830|9625990|FG000|6 Month Visit|Adverse Event|0
6030216|NCT00297830|9625991|FG001|6 Month Visit|Adverse Event|1
6030217|NCT00297830|9625992|FG002|6 Month Visit|Adverse Event|0
6030218|NCT00297830|9625990|FG000|12 Month Visit|Lost to Follow-up|1
6030219|NCT00297830|9625991|FG001|12 Month Visit|Lost to Follow-up|0
6030220|NCT00297830|9625992|FG002|12 Month Visit|Lost to Follow-up|0
6030221|NCT00297830|9625990|FG000|12 Month Visit|Adverse Event|0
6030222|NCT00297830|9625991|FG001|12 Month Visit|Adverse Event|3
6030223|NCT00297830|9625992|FG002|12 Month Visit|Adverse Event|0
6030224|NCT00297830|9625990|FG000|12 Month Visit|Withdrawal by Subject|0
6030225|NCT00297830|9625991|FG001|12 Month Visit|Withdrawal by Subject|3
6030226|NCT00297830|9625992|FG002|12 Month Visit|Withdrawal by Subject|0
6030227|NCT00297882|9626002|FG000|Day 14|Lack of Efficacy|12
6030228|NCT00297882|9626003|FG001|Day 14|Lack of Efficacy|49
6030229|NCT00297882|9626002|FG000|Day 28|Lost to Follow-up|13
6030230|NCT00297882|9626003|FG001|Day 28|Lost to Follow-up|23
6030231|NCT00297882|9626002|FG000|Day 28|Lack of Efficacy|3
6030232|NCT00297882|9626003|FG001|Day 28|Lack of Efficacy|0
6030233|NCT00298038|9626013|FG000|Overall Study|Lost to Follow-up|0
6030234|NCT00298038|9626014|FG001|Overall Study|Lost to Follow-up|1
6030235|NCT00298038|9626013|FG000|Overall Study|Liver Transplant|0
6030236|NCT00298038|9626014|FG001|Overall Study|Liver Transplant|1
6030237|NCT00298038|9626013|FG000|Overall Study|Protocol Violation|1
6030238|NCT00298038|9626014|FG001|Overall Study|Protocol Violation|3
6030239|NCT00298038|9626013|FG000|Overall Study|Death|6
6030240|NCT00298038|9626014|FG001|Overall Study|Death|3
6030241|NCT00298038|9626013|FG000|Overall Study|Withdrawal by Subject|6
6030242|NCT00298038|9626014|FG001|Overall Study|Withdrawal by Subject|9
6030243|NCT00298038|9626013|FG000|Overall Study|Adverse Event|8
6030244|NCT00298038|9626014|FG001|Overall Study|Adverse Event|7
6030245|NCT00298038|9626013|FG000|Overall Study|Breakthrough overt HE episode|28
6030246|NCT00298038|9626014|FG001|Overall Study|Breakthrough overt HE episode|69
6030247|NCT00298038|9626013|FG000|Overall Study|Noncompliance|1
6030248|NCT00298038|9626014|FG001|Overall Study|Noncompliance|0
6030249|NCT00298038|9626013|FG000|Overall Study|Cocaine Abuse|1
6030250|NCT00298038|9626014|FG001|Overall Study|Cocaine Abuse|0
6030251|NCT00298038|9626013|FG000|Overall Study|Severe Gastrointestinal Bleed|1
6030252|NCT00298038|9626014|FG001|Overall Study|Severe Gastrointestinal Bleed|0
6030253|NCT00298272|9626050|FG000|Double-blind Phase|Adverse Event|2
6030254|NCT00298272|9626051|FG001|Double-blind Phase|Adverse Event|0
6030255|NCT00298272|9626050|FG000|Double-blind Phase|Failure to Return|2
6030256|NCT00298272|9626051|FG001|Double-blind Phase|Failure to Return|0
6030257|NCT00298272|9626050|FG000|Double-blind Phase|Protocol Violation|2
6030258|NCT00298272|9626051|FG001|Double-blind Phase|Protocol Violation|0
6030259|NCT00298272|9626050|FG000|Double-blind Phase|Withdrawal by Subject|2
6030260|NCT00298272|9626051|FG001|Double-blind Phase|Withdrawal by Subject|0
6030261|NCT00298272|9626050|FG000|Open Label Retreatment Phase|Adverse Event|1
6030262|NCT00298272|9626051|FG001|Open Label Retreatment Phase|Adverse Event|2
6030263|NCT00298272|9626050|FG000|Open Label Retreatment Phase|Insufficient Therapeutic Response|2
6030264|NCT00298272|9626051|FG001|Open Label Retreatment Phase|Insufficient Therapeutic Response|1
6030265|NCT00298272|9626050|FG000|Open Label Retreatment Phase|Failure to Return|1
6030266|NCT00298272|9626051|FG001|Open Label Retreatment Phase|Failure to Return|0
6030267|NCT00298272|9626050|FG000|Open Label Retreatment Phase|Protocol Violation|2
6030268|NCT00298272|9626051|FG001|Open Label Retreatment Phase|Protocol Violation|1
6030269|NCT00298272|9626050|FG000|Open Label Retreatment Phase|Withdrawal by Subject|1
6030270|NCT00298272|9626051|FG001|Open Label Retreatment Phase|Withdrawal by Subject|0
6030271|NCT00298272|9626050|FG000|Open Label Retreatment Phase|Administrative/Other Reason|2
6030272|NCT00298272|9626051|FG001|Open Label Retreatment Phase|Administrative/Other Reason|0
6030273|NCT00298272|9626050|FG000|Safety Follow-up Phase|Failure to Return|1
6030274|NCT00298272|9626051|FG001|Safety Follow-up Phase|Failure to Return|1
6030275|NCT00298272|9626050|FG000|Safety Follow-up Phase|Withdrawal by Subject|2
6030276|NCT00298272|9626051|FG001|Safety Follow-up Phase|Withdrawal by Subject|2
6030277|NCT00298272|9626050|FG000|Safety Follow-up Phase|Administrative/Other Reason|1
6030278|NCT00298272|9626051|FG001|Safety Follow-up Phase|Administrative/Other Reason|1
6030279|NCT00298363|9626063|FG000|Overall Study|Lost to Follow-up|0
6030280|NCT00298363|9626064|FG001|Overall Study|Lost to Follow-up|0
6030281|NCT00298363|9626065|FG002|Overall Study|Lost to Follow-up|1
6030282|NCT00298363|9626063|FG000|Overall Study|Physician Decision|4
6030283|NCT00298363|9626064|FG001|Overall Study|Physician Decision|1
6030284|NCT00298363|9626065|FG002|Overall Study|Physician Decision|0
6030285|NCT00298363|9626063|FG000|Overall Study|Protocol Violation|1
6030286|NCT00298363|9626064|FG001|Overall Study|Protocol Violation|1
6030287|NCT00298363|9626065|FG002|Overall Study|Protocol Violation|0
6030288|NCT00298363|9626063|FG000|Overall Study|Withdrawal by Subject|5
6030289|NCT00298363|9626064|FG001|Overall Study|Withdrawal by Subject|1
6030290|NCT00298363|9626065|FG002|Overall Study|Withdrawal by Subject|3
6030291|NCT00298363|9626063|FG000|Overall Study|Adverse Event|5
6030292|NCT00298363|9626064|FG001|Overall Study|Adverse Event|2
6030293|NCT00298363|9626065|FG002|Overall Study|Adverse Event|2
6030294|NCT00298363|9626063|FG000|Overall Study|Lack of Efficacy|2
6030295|NCT00298363|9626064|FG001|Overall Study|Lack of Efficacy|3
6030296|NCT00298363|9626065|FG002|Overall Study|Lack of Efficacy|0
6030297|NCT00298766|9626113|FG000|Overall Study|Adverse Event|18
6030298|NCT00298766|9626113|FG000|Overall Study|Death|2
6030299|NCT00298766|9626113|FG000|Overall Study|Withdrawal by Subject|9
6030300|NCT00298766|9626113|FG000|Overall Study|Treatment ongoing|4
6030301|NCT00298766|9626113|FG000|Overall Study|Progression of amyloid markers|4
6030302|NCT00298766|9626113|FG000|Overall Study|Deterioration in KPS and organ function|1
6030303|NCT00298766|9626113|FG000|Overall Study|Subjects overall condition deterioration|4
6030304|NCT00298766|9626113|FG000|Overall Study|Other|4
6030305|NCT00298831|9626117|FG000|Overall Study|Adverse Event|1
6030306|NCT00298831|9626117|FG000|Overall Study|Lost to Follow-up|3
6030307|NCT00298831|9626117|FG000|Overall Study|Withdrawal by Subject|1
6030308|NCT00298831|9626117|FG000|Overall Study|Participants did not receive treatment|27
6030309|NCT00298896|9626121|FG000|Overall Study|Death|3
6030310|NCT00298896|9626121|FG000|Overall Study|Physician Decision|2
6030311|NCT00298896|9626121|FG000|Overall Study|Intercurrent Illness|1
6030312|NCT00298896|9626121|FG000|Overall Study|Disease Progression|41
6030313|NCT00298896|9626121|FG000|Overall Study|Withdrawal by Subject|2
6030314|NCT00298896|9626121|FG000|Overall Study|Assigned to treatment in error|1
6030315|NCT00299104|9626137|FG000|Treatment Period|Adverse Event|14
6030316|NCT00299104|9626138|FG001|Treatment Period|Adverse Event|9
6030317|NCT00299104|9626139|FG002|Treatment Period|Adverse Event|7
6030318|NCT00299104|9626137|FG000|Treatment Period|Death|1
6030319|NCT00299104|9626138|FG001|Treatment Period|Death|1
6030320|NCT00299104|9626139|FG002|Treatment Period|Death|1
6030321|NCT00299104|9626137|FG000|Treatment Period|Insufficient therapeutic response|34
6030322|NCT00299104|9626138|FG001|Treatment Period|Insufficient therapeutic response|13
6030323|NCT00299104|9626139|FG002|Treatment Period|Insufficient therapeutic response|8
6030324|NCT00299104|9626137|FG000|Treatment Period|Failure to return|9
6030325|NCT00299104|9626138|FG001|Treatment Period|Failure to return|8
6030326|NCT00299104|9626139|FG002|Treatment Period|Failure to return|8
6030327|NCT00299104|9626137|FG000|Treatment Period|Violation of selection criteria|1
6030328|NCT00299104|9626138|FG001|Treatment Period|Violation of selection criteria|2
6030329|NCT00299104|9626139|FG002|Treatment Period|Violation of selection criteria|0
6030330|NCT00299104|9626137|FG000|Treatment Period|Protocol Violation|1
6030331|NCT00299104|9626138|FG001|Treatment Period|Protocol Violation|1
6030332|NCT00299104|9626139|FG002|Treatment Period|Protocol Violation|0
6030333|NCT00299104|9626137|FG000|Treatment Period|Refused treatment|9
6030334|NCT00299104|9626138|FG001|Treatment Period|Refused treatment|2
6030335|NCT00299104|9626139|FG002|Treatment Period|Refused treatment|2
6030336|NCT00299104|9626137|FG000|Treatment Period|Withdrew consent|14
6030337|NCT00299104|9626138|FG001|Treatment Period|Withdrew consent|19
6030338|NCT00299104|9626139|FG002|Treatment Period|Withdrew consent|9
6030339|NCT00299104|9626137|FG000|Treatment Period|Administrative reasons|106
6030340|NCT00299104|9626138|FG001|Treatment Period|Administrative reasons|120
6030341|NCT00299104|9626139|FG002|Treatment Period|Administrative reasons|137
6030342|NCT00299104|9626137|FG000|Safety Follow-Up (SFU) Period|Death|3
6030343|NCT00299104|9626138|FG001|Safety Follow-Up (SFU) Period|Death|2
6030344|NCT00299104|9626139|FG002|Safety Follow-Up (SFU) Period|Death|1
6030345|NCT00299104|9626137|FG000|Safety Follow-Up (SFU) Period|Lost to Follow-up|9
6030346|NCT00299104|9626138|FG001|Safety Follow-Up (SFU) Period|Lost to Follow-up|11
6030347|NCT00299104|9626139|FG002|Safety Follow-Up (SFU) Period|Lost to Follow-up|20
6030348|NCT00299104|9626137|FG000|Safety Follow-Up (SFU) Period|Withdrawal by Subject|16
6030349|NCT00299104|9626138|FG001|Safety Follow-Up (SFU) Period|Withdrawal by Subject|21
6030350|NCT00299104|9626139|FG002|Safety Follow-Up (SFU) Period|Withdrawal by Subject|11
6030351|NCT00299104|9626137|FG000|Safety Follow-Up (SFU) Period|Administrative reasons|27
6030352|NCT00299104|9626138|FG001|Safety Follow-Up (SFU) Period|Administrative reasons|7
6030353|NCT00299104|9626139|FG002|Safety Follow-Up (SFU) Period|Administrative reasons|5
6030354|NCT00299104|9626137|FG000|Extended Safety Follow-Up (ESFU) Period|Death|0
6030355|NCT00299104|9626138|FG001|Extended Safety Follow-Up (ESFU) Period|Death|1
6030356|NCT00299104|9626139|FG002|Extended Safety Follow-Up (ESFU) Period|Death|0
6030357|NCT00299104|9626137|FG000|Extended Safety Follow-Up (ESFU) Period|Lost to Follow-up|2
6030358|NCT00299104|9626138|FG001|Extended Safety Follow-Up (ESFU) Period|Lost to Follow-up|2
6030359|NCT00299104|9626139|FG002|Extended Safety Follow-Up (ESFU) Period|Lost to Follow-up|2
6030360|NCT00299104|9626137|FG000|Extended Safety Follow-Up (ESFU) Period|Withdrawal by Subject|2
6030361|NCT00299104|9626138|FG001|Extended Safety Follow-Up (ESFU) Period|Withdrawal by Subject|4
6030362|NCT00299104|9626139|FG002|Extended Safety Follow-Up (ESFU) Period|Withdrawal by Subject|8
6030363|NCT00299104|9626137|FG000|Extended Safety Follow-Up (ESFU) Period|Administrative reasons|1
6030364|NCT00299104|9626138|FG001|Extended Safety Follow-Up (ESFU) Period|Administrative reasons|2
6030365|NCT00299104|9626139|FG002|Extended Safety Follow-Up (ESFU) Period|Administrative reasons|2
6030366|NCT00299130|9626150|FG000|Treatment Period (up to 5 Years)|Adverse Event|13
6030367|NCT00299130|9626151|FG001|Treatment Period (up to 5 Years)|Adverse Event|8
6030368|NCT00299130|9626152|FG002|Treatment Period (up to 5 Years)|Adverse Event|13
6030369|NCT00299130|9626150|FG000|Treatment Period (up to 5 Years)|Death|1
6030370|NCT00299130|9626151|FG001|Treatment Period (up to 5 Years)|Death|3
6030371|NCT00299130|9626152|FG002|Treatment Period (up to 5 Years)|Death|1
6030372|NCT00299130|9626150|FG000|Treatment Period (up to 5 Years)|Insufficient Therapeutic Response|19
6030373|NCT00299130|9626151|FG001|Treatment Period (up to 5 Years)|Insufficient Therapeutic Response|6
6030374|NCT00299130|9626152|FG002|Treatment Period (up to 5 Years)|Insufficient Therapeutic Response|6
6030375|NCT00299130|9626150|FG000|Treatment Period (up to 5 Years)|Protocol Violation|0
6030376|NCT00299130|9626151|FG001|Treatment Period (up to 5 Years)|Protocol Violation|1
6030377|NCT00299130|9626152|FG002|Treatment Period (up to 5 Years)|Protocol Violation|0
6030378|NCT00299130|9626150|FG000|Treatment Period (up to 5 Years)|Refused Treatment|12
6030379|NCT00299130|9626151|FG001|Treatment Period (up to 5 Years)|Refused Treatment|12
6030380|NCT00299130|9626152|FG002|Treatment Period (up to 5 Years)|Refused Treatment|19
6030381|NCT00299130|9626150|FG000|Treatment Period (up to 5 Years)|Failure to Return|4
6030382|NCT00299130|9626151|FG001|Treatment Period (up to 5 Years)|Failure to Return|6
6030383|NCT00299130|9626152|FG002|Treatment Period (up to 5 Years)|Failure to Return|6
6079492|NCT00610441|9686386|FG000|Placebo Washout Period - 2 Weeks|Adverse Event|0
6079493|NCT00610441|9686387|FG001|Placebo Washout Period - 2 Weeks|Adverse Event|0
6079494|NCT00610441|9686388|FG002|Placebo Washout Period - 2 Weeks|Adverse Event|2
6079495|NCT00610441|9686389|FG003|Placebo Washout Period - 2 Weeks|Adverse Event|0
6079496|NCT00610441|9686386|FG000|Placebo Washout Period - 2 Weeks|Withdrawal by Subject|0
6079497|NCT00610441|9686387|FG001|Placebo Washout Period - 2 Weeks|Withdrawal by Subject|1
6079498|NCT00610441|9686388|FG002|Placebo Washout Period - 2 Weeks|Withdrawal by Subject|0
6079499|NCT00610441|9686389|FG003|Placebo Washout Period - 2 Weeks|Withdrawal by Subject|0
6079500|NCT00610441|9686386|FG000|Treatment Period 2 - 3 Weeks|Other|1
6079501|NCT00610441|9686387|FG001|Treatment Period 2 - 3 Weeks|Other|1
6079502|NCT00610441|9686388|FG002|Treatment Period 2 - 3 Weeks|Other|0
6079503|NCT00610441|9686389|FG003|Treatment Period 2 - 3 Weeks|Other|1
6079504|NCT00610441|9686386|FG000|Treatment Period 2 - 3 Weeks|Adverse Event|0
6079505|NCT00610441|9686387|FG001|Treatment Period 2 - 3 Weeks|Adverse Event|0
6079506|NCT00610441|9686388|FG002|Treatment Period 2 - 3 Weeks|Adverse Event|0
6079507|NCT00610441|9686389|FG003|Treatment Period 2 - 3 Weeks|Adverse Event|1
6079508|NCT00610441|9686386|FG000|Treatment Period 2 - 3 Weeks|Lack of Efficacy|1
6079509|NCT00610441|9686387|FG001|Treatment Period 2 - 3 Weeks|Lack of Efficacy|0
6079510|NCT00610441|9686388|FG002|Treatment Period 2 - 3 Weeks|Lack of Efficacy|0
6079511|NCT00610441|9686389|FG003|Treatment Period 2 - 3 Weeks|Lack of Efficacy|0
6079512|NCT00610649|9686421|FG000|Overall Study|Adverse Event|1
6079513|NCT00610649|9686422|FG001|Overall Study|Adverse Event|0
6079514|NCT00610649|9686423|FG002|Overall Study|Adverse Event|0
6079515|NCT00610649|9686424|FG003|Overall Study|Adverse Event|0
6079516|NCT00610649|9686425|FG004|Overall Study|Adverse Event|0
6079517|NCT00610649|9686426|FG005|Overall Study|Adverse Event|0
6079518|NCT00610649|9686427|FG006|Overall Study|Adverse Event|0
6079519|NCT00610649|9686428|FG007|Overall Study|Adverse Event|0
6079520|NCT00610649|9686429|FG008|Overall Study|Adverse Event|0
6079521|NCT00610649|9686430|FG009|Overall Study|Adverse Event|0
6079522|NCT00610649|9686431|FG010|Overall Study|Adverse Event|1
6079523|NCT00610649|9686421|FG000|Overall Study|Family Emergency|0
6079524|NCT00610649|9686422|FG001|Overall Study|Family Emergency|1
6079525|NCT00610649|9686423|FG002|Overall Study|Family Emergency|0
6079526|NCT00610649|9686424|FG003|Overall Study|Family Emergency|0
6079527|NCT00610649|9686425|FG004|Overall Study|Family Emergency|0
6079528|NCT00610649|9686426|FG005|Overall Study|Family Emergency|0
6079529|NCT00610649|9686427|FG006|Overall Study|Family Emergency|0
6079530|NCT00610649|9686428|FG007|Overall Study|Family Emergency|0
6079531|NCT00610649|9686429|FG008|Overall Study|Family Emergency|0
6079532|NCT00610649|9686430|FG009|Overall Study|Family Emergency|0
6079533|NCT00610649|9686431|FG010|Overall Study|Family Emergency|0
6079534|NCT00610649|9686421|FG000|Overall Study|Withdrawal by Subject|0
6079535|NCT00610649|9686422|FG001|Overall Study|Withdrawal by Subject|0
6079536|NCT00610649|9686423|FG002|Overall Study|Withdrawal by Subject|0
6079537|NCT00610649|9686424|FG003|Overall Study|Withdrawal by Subject|0
6079538|NCT00610649|9686425|FG004|Overall Study|Withdrawal by Subject|0
6079539|NCT00610649|9686426|FG005|Overall Study|Withdrawal by Subject|0
6079540|NCT00610649|9686427|FG006|Overall Study|Withdrawal by Subject|0
6079541|NCT00610649|9686428|FG007|Overall Study|Withdrawal by Subject|0
6079542|NCT00610649|9686429|FG008|Overall Study|Withdrawal by Subject|0
6079543|NCT00610649|9686430|FG009|Overall Study|Withdrawal by Subject|1
6079544|NCT00610649|9686431|FG010|Overall Study|Withdrawal by Subject|0
6079545|NCT00610675|9686455|FG000|Overall Study|Untreated|4
6079546|NCT00610675|9686455|FG000|Overall Study|Adverse Event|67
6079547|NCT00610675|9686455|FG000|Overall Study|Insufficient Effect|31
6079548|NCT00610675|9686455|FG000|Overall Study|Withdrawal by Subject|28
6079549|NCT00610675|9686455|FG000|Overall Study|Reasons unrelated to trial|27
6079550|NCT00610675|9686455|FG000|Overall Study|Lack of Compliance|7
6079551|NCT00610675|9686455|FG000|Overall Study|Lost to Follow-up|31
6079552|NCT00610675|9686455|FG000|Overall Study|Other reason (not specified)|25
6079553|NCT00610714|9686483|FG000|Overall Study|Adverse Event|3
6079554|NCT00610714|9686484|FG001|Overall Study|Adverse Event|1
6079555|NCT00610714|9686483|FG000|Overall Study|Death|12
6079556|NCT00610714|9686484|FG001|Overall Study|Death|18
6079557|NCT00610714|9686483|FG000|Overall Study|Withdrawal by Subject|9
6030384|NCT00299130|9626150|FG000|Treatment Period (up to 5 Years)|Reason not Specified|4
6030385|NCT00299130|9626151|FG001|Treatment Period (up to 5 Years)|Reason not Specified|6
6030386|NCT00299130|9626152|FG002|Treatment Period (up to 5 Years)|Reason not Specified|4
6030387|NCT00299130|9626150|FG000|Treatment Period (up to 5 Years)|Withdrawal by Subject|0
6030388|NCT00299130|9626151|FG001|Treatment Period (up to 5 Years)|Withdrawal by Subject|1
6030389|NCT00299130|9626152|FG002|Treatment Period (up to 5 Years)|Withdrawal by Subject|1
6030390|NCT00299130|9626150|FG000|Safety Follow-up (SFU) (48 Weeks)|Administrative/Other|4
6030391|NCT00299130|9626151|FG001|Safety Follow-up (SFU) (48 Weeks)|Administrative/Other|9
6030392|NCT00299130|9626152|FG002|Safety Follow-up (SFU) (48 Weeks)|Administrative/Other|4
6030393|NCT00299130|9626150|FG000|Safety Follow-up (SFU) (48 Weeks)|Death|4
6030394|NCT00299130|9626151|FG001|Safety Follow-up (SFU) (48 Weeks)|Death|5
6030395|NCT00299130|9626152|FG002|Safety Follow-up (SFU) (48 Weeks)|Death|3
6030396|NCT00299130|9626150|FG000|Safety Follow-up (SFU) (48 Weeks)|Did not Co-operate|1
6030397|NCT00299130|9626151|FG001|Safety Follow-up (SFU) (48 Weeks)|Did not Co-operate|1
6030398|NCT00299130|9626152|FG002|Safety Follow-up (SFU) (48 Weeks)|Did not Co-operate|2
6030399|NCT00299130|9626150|FG000|Safety Follow-up (SFU) (48 Weeks)|Failure to Return|14
6030400|NCT00299130|9626151|FG001|Safety Follow-up (SFU) (48 Weeks)|Failure to Return|7
6030401|NCT00299130|9626152|FG002|Safety Follow-up (SFU) (48 Weeks)|Failure to Return|15
6030402|NCT00299130|9626150|FG000|Safety Follow-up (SFU) (48 Weeks)|No SFU Week 48 Date Recorded|0
6030403|NCT00299130|9626151|FG001|Safety Follow-up (SFU) (48 Weeks)|No SFU Week 48 Date Recorded|1
6030404|NCT00299130|9626152|FG002|Safety Follow-up (SFU) (48 Weeks)|No SFU Week 48 Date Recorded|0
6030405|NCT00299130|9626150|FG000|Safety Follow-up (SFU) (48 Weeks)|Withdrawal by Subject|22
6030406|NCT00299130|9626151|FG001|Safety Follow-up (SFU) (48 Weeks)|Withdrawal by Subject|22
6030407|NCT00299130|9626152|FG002|Safety Follow-up (SFU) (48 Weeks)|Withdrawal by Subject|21
6079558|NCT00610714|9686484|FG001|Overall Study|Withdrawal by Subject|3
6079559|NCT00610714|9686483|FG000|Overall Study|Study completion at 120 PFS events|2
6030408|NCT00299130|9626150|FG000|Extended SFU (ESFU) (up to 5.1 Years)|Death|0
6030409|NCT00299130|9626151|FG001|Extended SFU (ESFU) (up to 5.1 Years)|Death|3
6030410|NCT00299130|9626152|FG002|Extended SFU (ESFU) (up to 5.1 Years)|Death|0
6030411|NCT00299130|9626150|FG000|Extended SFU (ESFU) (up to 5.1 Years)|Failure to Return|0
6030412|NCT00299130|9626151|FG001|Extended SFU (ESFU) (up to 5.1 Years)|Failure to Return|2
6030413|NCT00299130|9626152|FG002|Extended SFU (ESFU) (up to 5.1 Years)|Failure to Return|2
6030414|NCT00299130|9626150|FG000|Extended SFU (ESFU) (up to 5.1 Years)|Did not Cooperate/Withdrew Consent|0
6030415|NCT00299130|9626151|FG001|Extended SFU (ESFU) (up to 5.1 Years)|Did not Cooperate/Withdrew Consent|3
6079560|NCT00610714|9686484|FG001|Overall Study|Study completion at 120 PFS events|2
6030416|NCT00299130|9626152|FG002|Extended SFU (ESFU) (up to 5.1 Years)|Did not Cooperate/Withdrew Consent|4
6030417|NCT00299156|9626170|FG000|Period 2 (Randomized)|Screen Failure|0
6030418|NCT00299156|9626171|FG001|Period 2 (Randomized)|Screen Failure|1
6030419|NCT00299156|9626172|FG002|Period 2 (Randomized)|Screen Failure|0
6030420|NCT00299182|9626187|FG000|Overall Study|Withdrawal by Subject|0
6030421|NCT00299182|9626188|FG001|Overall Study|Withdrawal by Subject|0
6030422|NCT00299182|9626189|FG002|Overall Study|Withdrawal by Subject|1
6030423|NCT00299182|9626190|FG003|Overall Study|Withdrawal by Subject|0
6030424|NCT00299182|9626191|FG004|Overall Study|Withdrawal by Subject|1
6030425|NCT00299182|9626192|FG005|Overall Study|Withdrawal by Subject|2
6030426|NCT00299182|9626193|FG006|Overall Study|Withdrawal by Subject|0
6030427|NCT00299182|9626187|FG000|Overall Study|Chemotherapy Changed|0
6030428|NCT00299182|9626188|FG001|Overall Study|Chemotherapy Changed|0
6030429|NCT00299182|9626189|FG002|Overall Study|Chemotherapy Changed|1
6030430|NCT00299182|9626190|FG003|Overall Study|Chemotherapy Changed|0
6030431|NCT00299182|9626191|FG004|Overall Study|Chemotherapy Changed|1
6030432|NCT00299182|9626192|FG005|Overall Study|Chemotherapy Changed|0
6030433|NCT00299182|9626193|FG006|Overall Study|Chemotherapy Changed|1
6030434|NCT00299182|9626187|FG000|Overall Study|Adverse Event|0
6030435|NCT00299182|9626188|FG001|Overall Study|Adverse Event|0
6030436|NCT00299182|9626189|FG002|Overall Study|Adverse Event|0
6030437|NCT00299182|9626190|FG003|Overall Study|Adverse Event|0
6030438|NCT00299182|9626191|FG004|Overall Study|Adverse Event|0
6030439|NCT00299182|9626192|FG005|Overall Study|Adverse Event|1
6030440|NCT00299182|9626193|FG006|Overall Study|Adverse Event|0
6030441|NCT00299182|9626187|FG000|Overall Study|Not Eligible|0
6030442|NCT00299182|9626188|FG001|Overall Study|Not Eligible|0
6030443|NCT00299182|9626189|FG002|Overall Study|Not Eligible|0
6030444|NCT00299182|9626190|FG003|Overall Study|Not Eligible|0
6030445|NCT00299182|9626191|FG004|Overall Study|Not Eligible|1
6030446|NCT00299182|9626192|FG005|Overall Study|Not Eligible|0
6030447|NCT00299182|9626193|FG006|Overall Study|Not Eligible|0
6030448|NCT00299494|9626230|FG000|Overall Study|Withdrawal by Subject|0
6030449|NCT00299494|9626231|FG001|Overall Study|Withdrawal by Subject|0
6030450|NCT00299494|9626232|FG002|Overall Study|Withdrawal by Subject|0
6030451|NCT00299494|9626233|FG003|Overall Study|Withdrawal by Subject|3
6030452|NCT00299494|9626234|FG004|Overall Study|Withdrawal by Subject|1
6030453|NCT00299494|9626235|FG005|Overall Study|Withdrawal by Subject|4
6030454|NCT00299494|9626230|FG000|Overall Study|Physician Decision|0
6030455|NCT00299494|9626231|FG001|Overall Study|Physician Decision|0
6079561|NCT00610857|9686523|FG000|Overall Study|Not evaluable for response|2
6079562|NCT00610935|9686533|FG000|Overall Study|Lost to Follow-up|0
6030456|NCT00299494|9626232|FG002|Overall Study|Physician Decision|0
6030457|NCT00299494|9626233|FG003|Overall Study|Physician Decision|0
6030458|NCT00299494|9626234|FG004|Overall Study|Physician Decision|1
6030459|NCT00299494|9626235|FG005|Overall Study|Physician Decision|0
6030460|NCT00299494|9626230|FG000|Overall Study|Death|3
6030461|NCT00299494|9626231|FG001|Overall Study|Death|1
6030462|NCT00299494|9626232|FG002|Overall Study|Death|4
6030463|NCT00299494|9626233|FG003|Overall Study|Death|6
6030464|NCT00299494|9626234|FG004|Overall Study|Death|18
6030465|NCT00299494|9626235|FG005|Overall Study|Death|19
6030466|NCT00299494|9626230|FG000|Overall Study|Lost to Follow-up|0
6030467|NCT00299494|9626231|FG001|Overall Study|Lost to Follow-up|0
6030468|NCT00299494|9626232|FG002|Overall Study|Lost to Follow-up|0
6030469|NCT00299494|9626233|FG003|Overall Study|Lost to Follow-up|0
6030470|NCT00299494|9626234|FG004|Overall Study|Lost to Follow-up|3
6030471|NCT00299494|9626235|FG005|Overall Study|Lost to Follow-up|1
6030472|NCT00299494|9626230|FG000|Overall Study|Other - Unspecified|0
6030473|NCT00299494|9626231|FG001|Overall Study|Other - Unspecified|0
6030474|NCT00299494|9626232|FG002|Overall Study|Other - Unspecified|0
6030475|NCT00299494|9626233|FG003|Overall Study|Other - Unspecified|0
6030476|NCT00299494|9626234|FG004|Overall Study|Other - Unspecified|3
6030477|NCT00299494|9626235|FG005|Overall Study|Other - Unspecified|1
6030478|NCT00299494|9626230|FG000|Overall Study|Other - site closure|0
6030479|NCT00299494|9626231|FG001|Overall Study|Other - site closure|0
6030480|NCT00299494|9626232|FG002|Overall Study|Other - site closure|0
6030481|NCT00299494|9626233|FG003|Overall Study|Other - site closure|1
6030482|NCT00299494|9626234|FG004|Overall Study|Other - site closure|1
6030483|NCT00299494|9626235|FG005|Overall Study|Other - site closure|1
6030484|NCT00299546|9626263|FG000|Overall Study|Death|3
6030485|NCT00299546|9626264|FG001|Overall Study|Death|2
6030486|NCT00299546|9626265|FG002|Overall Study|Death|0
6030487|NCT00299546|9626263|FG000|Overall Study|Lost to Follow-up|2
6030488|NCT00299546|9626264|FG001|Overall Study|Lost to Follow-up|2
6030489|NCT00299546|9626265|FG002|Overall Study|Lost to Follow-up|5
6030490|NCT00299546|9626263|FG000|Overall Study|Adverse Event|37
6030491|NCT00299546|9626264|FG001|Overall Study|Adverse Event|22
6030492|NCT00299546|9626265|FG002|Overall Study|Adverse Event|27
6030493|NCT00299546|9626263|FG000|Overall Study|Unsatisfactory therapeutic effect|34
6030494|NCT00299546|9626264|FG001|Overall Study|Unsatisfactory therapeutic effect|39
6030495|NCT00299546|9626265|FG002|Overall Study|Unsatisfactory therapeutic effect|34
6030496|NCT00299546|9626263|FG000|Overall Study|Other|24
6030497|NCT00299546|9626264|FG001|Overall Study|Other|26
6030498|NCT00299546|9626265|FG002|Overall Study|Other|19
6030499|NCT00299546|9626263|FG000|Overall Study|Not treated|0
6030500|NCT00299546|9626264|FG001|Overall Study|Not treated|1
6030501|NCT00299546|9626265|FG002|Overall Study|Not treated|1
6030502|NCT00299702|9626280|FG000|Overall Study|Death|1
6030503|NCT00299702|9626281|FG001|Overall Study|Death|0
6030504|NCT00299702|9626280|FG000|Overall Study|Adverse Event|0
6030505|NCT00299702|9626281|FG001|Overall Study|Adverse Event|4
6030506|NCT00299702|9626280|FG000|Overall Study|Lost to Follow-up|18
6030507|NCT00299702|9626281|FG001|Overall Study|Lost to Follow-up|10
6030508|NCT00299702|9626280|FG000|Overall Study|Withdrawal by Subject|25
6030509|NCT00299702|9626281|FG001|Overall Study|Withdrawal by Subject|23
6030510|NCT00299702|9626280|FG000|Overall Study|Pregnancy|0
6030511|NCT00299702|9626281|FG001|Overall Study|Pregnancy|1
6030512|NCT00299702|9626280|FG000|Overall Study|Insufficient Response|4
6030513|NCT00299702|9626281|FG001|Overall Study|Insufficient Response|3
6030514|NCT00299702|9626280|FG000|Overall Study|Admin issues, sponsor decision, etc.|5
6030515|NCT00299702|9626281|FG001|Overall Study|Admin issues, sponsor decision, etc.|9
6030516|NCT00299975|9626294|FG000|Overall Study|Adverse Event|1
6030517|NCT00299975|9626295|FG001|Overall Study|Adverse Event|0
6030518|NCT00299975|9626296|FG002|Overall Study|Adverse Event|2
6030519|NCT00299975|9626294|FG000|Overall Study|Pregnancy|0
6030520|NCT00299975|9626295|FG001|Overall Study|Pregnancy|0
6030521|NCT00299975|9626296|FG002|Overall Study|Pregnancy|1
6030522|NCT00299975|9626294|FG000|Overall Study|Lack of Efficacy|1
6030523|NCT00299975|9626295|FG001|Overall Study|Lack of Efficacy|0
6030524|NCT00299975|9626296|FG002|Overall Study|Lack of Efficacy|1
6030525|NCT00299975|9626294|FG000|Overall Study|Lost to Follow-up|1
6030526|NCT00299975|9626295|FG001|Overall Study|Lost to Follow-up|0
6030527|NCT00299975|9626296|FG002|Overall Study|Lost to Follow-up|0
6030528|NCT00299975|9626294|FG000|Overall Study|Withdrawal by Subject|0
6030529|NCT00299975|9626295|FG001|Overall Study|Withdrawal by Subject|1
6030530|NCT00299975|9626296|FG002|Overall Study|Withdrawal by Subject|3
6030531|NCT00299975|9626294|FG000|Overall Study|Physician Decision|0
6030532|NCT00299975|9626295|FG001|Overall Study|Physician Decision|0
6030533|NCT00299975|9626296|FG002|Overall Study|Physician Decision|1
6030534|NCT00300053|9626317|FG000|Overall Study|Patient/Caregiver Preference|2
6030535|NCT00300053|9626318|FG001|Overall Study|Patient/Caregiver Preference|2
6030536|NCT00300053|9626319|FG002|Overall Study|Patient/Caregiver Preference|3
6030537|NCT00300053|9626317|FG000|Overall Study|Death|0
6030538|NCT00300053|9626318|FG001|Overall Study|Death|0
6030539|NCT00300053|9626319|FG002|Overall Study|Death|3
6030540|NCT00300053|9626317|FG000|Overall Study|Lost to Follow-up|0
6030541|NCT00300053|9626318|FG001|Overall Study|Lost to Follow-up|1
6030542|NCT00300053|9626319|FG002|Overall Study|Lost to Follow-up|0
6030543|NCT00300274|9626352|FG000|Overall Study|Withdrawal by Subject|12
6030544|NCT00300274|9626353|FG001|Overall Study|Withdrawal by Subject|3
6030545|NCT00300274|9626354|FG002|Overall Study|Withdrawal by Subject|14
6030546|NCT00300274|9626352|FG000|Overall Study|Lost to Follow-up|3
6030547|NCT00300274|9626353|FG001|Overall Study|Lost to Follow-up|4
6030548|NCT00300274|9626354|FG002|Overall Study|Lost to Follow-up|5
6030549|NCT00300274|9626352|FG000|Overall Study|Death|31
6030550|NCT00300274|9626353|FG001|Overall Study|Death|20
6030551|NCT00300274|9626354|FG002|Overall Study|Death|25
6030552|NCT00300274|9626352|FG000|Overall Study|Re-transplant|0
6030553|NCT00300274|9626353|FG001|Overall Study|Re-transplant|0
6030554|NCT00300274|9626354|FG002|Overall Study|Re-transplant|1
6030555|NCT00300365|9626364|FG000|Overall Study|Lost to Follow-up|1
6030556|NCT00300365|9626365|FG001|Overall Study|Lost to Follow-up|0
6030557|NCT00300365|9626364|FG000|Overall Study|Physician Decision|2
6030558|NCT00300365|9626365|FG001|Overall Study|Physician Decision|0
6030559|NCT00300365|9626364|FG000|Overall Study|Withdrawal by Subject|1
6030560|NCT00300365|9626365|FG001|Overall Study|Withdrawal by Subject|0
6030561|NCT00300365|9626364|FG000|Overall Study|Adverse Event|0
6030562|NCT00300365|9626365|FG001|Overall Study|Adverse Event|2
6030563|NCT00300495|9626471|FG000|Overall Study|Protocol Violation|4
6030564|NCT00300495|9626472|FG001|Overall Study|Protocol Violation|1
6030565|NCT00300755|9626490|FG000|Overall Study|Adverse Event|1
6030566|NCT00300755|9626491|FG001|Overall Study|Adverse Event|2
6030567|NCT00300755|9626492|FG002|Overall Study|Adverse Event|1
6030568|NCT00300755|9626490|FG000|Overall Study|Withdrawal by Subject|0
6030569|NCT00300755|9626491|FG001|Overall Study|Withdrawal by Subject|2
6030570|NCT00300755|9626492|FG002|Overall Study|Withdrawal by Subject|0
6030571|NCT00300755|9626490|FG000|Overall Study|Protocol Violation|0
6030572|NCT00300755|9626491|FG001|Overall Study|Protocol Violation|0
6030573|NCT00300755|9626492|FG002|Overall Study|Protocol Violation|1
6030574|NCT00300781|9626502|FG000|Overall Study|Disease Progression|55
6030575|NCT00300781|9626503|FG001|Overall Study|Disease Progression|52
6030576|NCT00300781|9626502|FG000|Overall Study|Adverse Event|5
6030577|NCT00300781|9626503|FG001|Overall Study|Adverse Event|6
6030578|NCT00300781|9626502|FG000|Overall Study|Withdrawal by Subject|1
6030579|NCT00300781|9626503|FG001|Overall Study|Withdrawal by Subject|2
6030580|NCT00300781|9626502|FG000|Overall Study|Physician Decision|1
6030581|NCT00300781|9626503|FG001|Overall Study|Physician Decision|0
6030582|NCT00300781|9626502|FG000|Overall Study|Not Recorded|0
6030583|NCT00300781|9626503|FG001|Overall Study|Not Recorded|1
6030584|NCT00300781|9626502|FG000|Overall Study|Symptomatic Deterioration|1
6030585|NCT00300781|9626503|FG001|Overall Study|Symptomatic Deterioration|0
6030586|NCT00300781|9626502|FG000|Overall Study|Lost to Follow-up|0
6030587|NCT00300781|9626503|FG001|Overall Study|Lost to Follow-up|1
6030588|NCT00300885|9626511|FG000|Treatment|Adverse Event|134
6030589|NCT00300885|9626512|FG001|Treatment|Adverse Event|82
6030590|NCT00300885|9626511|FG000|Treatment|Death|20
6030591|NCT00300885|9626512|FG001|Treatment|Death|7
6030592|NCT00300885|9626511|FG000|Treatment|Lack of Efficacy|1
6030593|NCT00300885|9626512|FG001|Treatment|Lack of Efficacy|1
6030594|NCT00300885|9626511|FG000|Treatment|Lost to Follow-up|3
6030595|NCT00300885|9626512|FG001|Treatment|Lost to Follow-up|2
6030596|NCT00300885|9626511|FG000|Treatment|Physician Decision|4
6030597|NCT00300885|9626512|FG001|Treatment|Physician Decision|5
6030598|NCT00300885|9626511|FG000|Treatment|Protocol Violation|11
6030599|NCT00300885|9626512|FG001|Treatment|Protocol Violation|11
6030600|NCT00300885|9626511|FG000|Treatment|Withdrawal by Subject|26
6030601|NCT00300885|9626512|FG001|Treatment|Withdrawal by Subject|23
6030602|NCT00300885|9626511|FG000|Treatment|Disease progression|171
6030603|NCT00300885|9626512|FG001|Treatment|Disease progression|238
6030604|NCT00300885|9626511|FG000|Treatment|Random code broken (subject died)|0
6030605|NCT00300885|9626512|FG001|Treatment|Random code broken (subject died)|1
6030606|NCT00300885|9626511|FG000|Treatment|Non-compliant with study medication|3
6079563|NCT00610935|9686534|FG001|Overall Study|Lost to Follow-up|1
6079564|NCT00610935|9686533|FG000|Overall Study|Withdrawal by Subject|0
6079565|NCT00610935|9686534|FG001|Overall Study|Withdrawal by Subject|2
6079566|NCT00610935|9686533|FG000|Overall Study|Sponsor Discontinuation|1
6079567|NCT00610935|9686534|FG001|Overall Study|Sponsor Discontinuation|0
6079568|NCT00611026|9686552|FG000|Randomized to Double-blind Treatment|Not treated|2
6079569|NCT00611026|9686553|FG001|Randomized to Double-blind Treatment|Not treated|1
6030607|NCT00300885|9626512|FG001|Treatment|Non-compliant with study medication|4
6030608|NCT00300885|9626511|FG000|Follow-up|Death|141
6030609|NCT00300885|9626512|FG001|Follow-up|Death|163
6030610|NCT00300885|9626511|FG000|Follow-up|Lost to Follow-up|11
6030611|NCT00300885|9626512|FG001|Follow-up|Lost to Follow-up|7
6030612|NCT00300885|9626511|FG000|Follow-up|Withdrawal by Subject|26
6030613|NCT00300885|9626512|FG001|Follow-up|Withdrawal by Subject|25
6030614|NCT00301067|9626522|FG000|Completed DLT Period/1st Cycle|Progressive Disease|1
6030615|NCT00301067|9626523|FG001|Completed DLT Period/1st Cycle|Progressive Disease|0
6030616|NCT00301067|9626524|FG002|Completed DLT Period/1st Cycle|Progressive Disease|0
6030617|NCT00301067|9626525|FG003|Completed DLT Period/1st Cycle|Progressive Disease|1
6030618|NCT00301067|9626522|FG000|Reached 1st Response/2 Cycles|Progressive Disease|2
6030619|NCT00301067|9626523|FG001|Reached 1st Response/2 Cycles|Progressive Disease|1
6030620|NCT00301067|9626524|FG002|Reached 1st Response/2 Cycles|Progressive Disease|1
6048429|NCT00418379|9647660|FG000|Year 4|Adverse Event|0
6030621|NCT00301067|9626525|FG003|Reached 1st Response/2 Cycles|Progressive Disease|2
6030622|NCT00301067|9626522|FG000|Completed 4 Cycles of Treatment|Progressive disease|1
6030623|NCT00301067|9626523|FG001|Completed 4 Cycles of Treatment|Progressive disease|1
6030624|NCT00301067|9626524|FG002|Completed 4 Cycles of Treatment|Progressive disease|2
6030625|NCT00301067|9626525|FG003|Completed 4 Cycles of Treatment|Progressive disease|5
6030626|NCT00301067|9626522|FG000|Completed 12 Cycles of Treatment|Progressive Disease|0
6030627|NCT00301067|9626523|FG001|Completed 12 Cycles of Treatment|Progressive Disease|1
6030628|NCT00301067|9626524|FG002|Completed 12 Cycles of Treatment|Progressive Disease|0
6030629|NCT00301067|9626525|FG003|Completed 12 Cycles of Treatment|Progressive Disease|1
6030630|NCT00301067|9626522|FG000|Completed 12 Cycles of Treatment|Adverse Event|0
6030631|NCT00301067|9626523|FG001|Completed 12 Cycles of Treatment|Adverse Event|0
6030632|NCT00301067|9626524|FG002|Completed 12 Cycles of Treatment|Adverse Event|0
6030633|NCT00301067|9626525|FG003|Completed 12 Cycles of Treatment|Adverse Event|1
6030634|NCT00301067|9626522|FG000|Follow up Until Death|Alive at last data cut point|1
6030635|NCT00301067|9626523|FG001|Follow up Until Death|Alive at last data cut point|0
6030636|NCT00301067|9626524|FG002|Follow up Until Death|Alive at last data cut point|0
6030637|NCT00301067|9626525|FG003|Follow up Until Death|Alive at last data cut point|1
6030638|NCT00301366|9626536|FG000|Overall Study|Adverse Event|1
6030639|NCT00301808|9626550|FG000|Overall Study|Adverse Event|5
6030640|NCT00301808|9626550|FG000|Overall Study|Death|3
6030641|NCT00301808|9626550|FG000|Overall Study|Lack of Efficacy|4
6030642|NCT00301821|9626554|FG000|Overall Study|Ineligible|25
6030643|NCT00301821|9626554|FG000|Overall Study|Cancel|1
6030644|NCT00301834|9626558|FG000|Overall Study|Death|1
6030645|NCT00301964|9626569|FG000|Overall Study|Second primary|2
6030646|NCT00301964|9626569|FG000|Overall Study|Wrong primary|1
6030647|NCT00301964|9626569|FG000|Overall Study|Inadequate pathology|1
6030648|NCT00302003|9626579|FG000|Overall Study|Lack of Efficacy|62
6030649|NCT00302003|9626579|FG000|Overall Study|Lost to Follow-up|1
6030650|NCT00302003|9626579|FG000|Overall Study|Physician Decision|2
6030651|NCT00302003|9626579|FG000|Overall Study|Withdrawal by Subject|5
6030652|NCT00302003|9626579|FG000|Overall Study|Ineligible|9
6030653|NCT00302003|9626579|FG000|Overall Study|Protocol Violation|1
6030654|NCT00302081|9626618|FG000|Overall Study|Adverse Event|6
6030655|NCT00302081|9626619|FG001|Overall Study|Adverse Event|5
6030656|NCT00302081|9626620|FG002|Overall Study|Adverse Event|4
6030657|NCT00302081|9626618|FG000|Overall Study|Lost to Follow-up|21
6030658|NCT00302081|9626619|FG001|Overall Study|Lost to Follow-up|18
6030659|NCT00302081|9626620|FG002|Overall Study|Lost to Follow-up|28
6030660|NCT00302081|9626618|FG000|Overall Study|Withdrawal by Subject|8
6030661|NCT00302081|9626619|FG001|Overall Study|Withdrawal by Subject|12
6030662|NCT00302081|9626620|FG002|Overall Study|Withdrawal by Subject|8
6030663|NCT00302081|9626618|FG000|Overall Study|Protocol Violation|5
6030664|NCT00302081|9626619|FG001|Overall Study|Protocol Violation|1
6030665|NCT00302081|9626620|FG002|Overall Study|Protocol Violation|2
6030666|NCT00302081|9626618|FG000|Overall Study|Lack of Efficacy|1
6030667|NCT00302081|9626619|FG001|Overall Study|Lack of Efficacy|0
6030668|NCT00302081|9626620|FG002|Overall Study|Lack of Efficacy|5
6030669|NCT00302081|9626618|FG000|Overall Study|Death|2
6030670|NCT00302081|9626619|FG001|Overall Study|Death|1
6030671|NCT00302081|9626620|FG002|Overall Study|Death|0
6030672|NCT00302081|9626618|FG000|Overall Study|Other|13
6030673|NCT00302081|9626619|FG001|Overall Study|Other|6
6030674|NCT00302081|9626620|FG002|Overall Study|Other|5
6030675|NCT00302107|9626630|FG000|Overall Study|Lost to Follow-up|6
6030676|NCT00302107|9626631|FG001|Overall Study|Lost to Follow-up|5
6030677|NCT00302107|9626630|FG000|Overall Study|Protocol Violation|1
6030678|NCT00302107|9626631|FG001|Overall Study|Protocol Violation|0
6030679|NCT00302107|9626630|FG000|Overall Study|Relocation|0
6030680|NCT00302107|9626631|FG001|Overall Study|Relocation|1
6030681|NCT00302107|9626630|FG000|Overall Study|Withdrawal by Subject|0
6030682|NCT00302107|9626631|FG001|Overall Study|Withdrawal by Subject|3
6030683|NCT00302107|9626630|FG000|Overall Study|Adverse Event|1
6030684|NCT00302107|9626631|FG001|Overall Study|Adverse Event|0
6030685|NCT00302159|9626646|FG000|Overall Study|pt declined before treatment started|1
6030686|NCT00302159|9626646|FG000|Overall Study|pt started Avastin|1
6030687|NCT00302211|9626654|FG000|Double Blind Period (New Patients)|Withdrawal by Subject|2
6030688|NCT00302211|9626655|FG001|Double Blind Period (New Patients)|Withdrawal by Subject|1
6030689|NCT00302211|9626656|FG002|Double Blind Period (New Patients)|Withdrawal by Subject|0
6030690|NCT00302211|9626657|FG003|Double Blind Period (New Patients)|Withdrawal by Subject|0
6030691|NCT00302211|9626658|FG004|Double Blind Period (New Patients)|Withdrawal by Subject|0
6030692|NCT00302211|9626654|FG000|Double Blind Period (New Patients)|Adverse Event|0
6030693|NCT00302211|9626655|FG001|Double Blind Period (New Patients)|Adverse Event|0
6030694|NCT00302211|9626656|FG002|Double Blind Period (New Patients)|Adverse Event|3
6030695|NCT00302211|9626657|FG003|Double Blind Period (New Patients)|Adverse Event|0
6030696|NCT00302211|9626658|FG004|Double Blind Period (New Patients)|Adverse Event|0
6030697|NCT00302211|9626654|FG000|Double Blind Period (New Patients)|Investigator's judgement|1
6030698|NCT00302211|9626655|FG001|Double Blind Period (New Patients)|Investigator's judgement|0
6030699|NCT00302211|9626656|FG002|Double Blind Period (New Patients)|Investigator's judgement|0
6030700|NCT00302211|9626657|FG003|Double Blind Period (New Patients)|Investigator's judgement|0
6048430|NCT00418379|9647661|FG001|Year 4|Adverse Event|1
6030701|NCT00302211|9626658|FG004|Double Blind Period (New Patients)|Investigator's judgement|0
6030702|NCT00302211|9626654|FG000|Double Blind Period (New Patients)|Disease progression|0
6030703|NCT00302211|9626655|FG001|Double Blind Period (New Patients)|Disease progression|1
6030704|NCT00302211|9626656|FG002|Double Blind Period (New Patients)|Disease progression|1
6030705|NCT00302211|9626657|FG003|Double Blind Period (New Patients)|Disease progression|0
6030706|NCT00302211|9626658|FG004|Double Blind Period (New Patients)|Disease progression|0
6030707|NCT00302211|9626654|FG000|Open Label-Patients From Double-Blind|Withdrawal by Subject|0
6030708|NCT00302211|9626655|FG001|Open Label-Patients From Double-Blind|Withdrawal by Subject|0
6030709|NCT00302211|9626656|FG002|Open Label-Patients From Double-Blind|Withdrawal by Subject|0
6030710|NCT00302211|9626657|FG003|Open Label-Patients From Double-Blind|Withdrawal by Subject|3
6030711|NCT00302211|9626658|FG004|Open Label-Patients From Double-Blind|Withdrawal by Subject|3
6030712|NCT00302211|9626654|FG000|Open Label-Patients From Double-Blind|Adverse Event|0
6030713|NCT00302211|9626655|FG001|Open Label-Patients From Double-Blind|Adverse Event|0
6079570|NCT00611026|9686554|FG002|Randomized to Double-blind Treatment|Not treated|3
6079571|NCT00611026|9686552|FG000|Double-blind Treatment Period|Death|1
6079572|NCT00611026|9686553|FG001|Double-blind Treatment Period|Death|0
6079573|NCT00611026|9686554|FG002|Double-blind Treatment Period|Death|0
6079574|NCT00611026|9686552|FG000|Double-blind Treatment Period|Adverse Event|9
6079575|NCT00611026|9686553|FG001|Double-blind Treatment Period|Adverse Event|28
6079576|NCT00611026|9686554|FG002|Double-blind Treatment Period|Adverse Event|46
6079577|NCT00611026|9686552|FG000|Double-blind Treatment Period|Lack of Efficacy|11
6030714|NCT00302211|9626656|FG002|Open Label-Patients From Double-Blind|Adverse Event|0
6030715|NCT00302211|9626657|FG003|Open Label-Patients From Double-Blind|Adverse Event|1
6030716|NCT00302211|9626658|FG004|Open Label-Patients From Double-Blind|Adverse Event|0
6030717|NCT00302211|9626654|FG000|Open Label-Patients From Double-Blind|Investigator's judgement|0
6030718|NCT00302211|9626655|FG001|Open Label-Patients From Double-Blind|Investigator's judgement|0
6030719|NCT00302211|9626656|FG002|Open Label-Patients From Double-Blind|Investigator's judgement|0
6030720|NCT00302211|9626657|FG003|Open Label-Patients From Double-Blind|Investigator's judgement|1
6030721|NCT00302211|9626658|FG004|Open Label-Patients From Double-Blind|Investigator's judgement|0
6030722|NCT00302211|9626654|FG000|Open Label-Patients From Double-Blind|Disease progression|0
6030723|NCT00302211|9626655|FG001|Open Label-Patients From Double-Blind|Disease progression|0
6030724|NCT00302211|9626656|FG002|Open Label-Patients From Double-Blind|Disease progression|0
6030725|NCT00302211|9626657|FG003|Open Label-Patients From Double-Blind|Disease progression|1
6030726|NCT00302211|9626658|FG004|Open Label-Patients From Double-Blind|Disease progression|2
6030727|NCT00302211|9626654|FG000|Open Label-Patients From Double-Blind|Death|0
6030728|NCT00302211|9626655|FG001|Open Label-Patients From Double-Blind|Death|0
6030729|NCT00302211|9626656|FG002|Open Label-Patients From Double-Blind|Death|0
6030730|NCT00302211|9626657|FG003|Open Label-Patients From Double-Blind|Death|1
6030731|NCT00302211|9626658|FG004|Open Label-Patients From Double-Blind|Death|1
6030732|NCT00302211|9626654|FG000|Open Label-Patients From Double-Blind|Lost to Follow-up|0
6030733|NCT00302211|9626655|FG001|Open Label-Patients From Double-Blind|Lost to Follow-up|0
6030734|NCT00302211|9626656|FG002|Open Label-Patients From Double-Blind|Lost to Follow-up|0
6030735|NCT00302211|9626657|FG003|Open Label-Patients From Double-Blind|Lost to Follow-up|0
6030736|NCT00302211|9626658|FG004|Open Label-Patients From Double-Blind|Lost to Follow-up|1
6030737|NCT00302211|9626654|FG000|Open Label-Patients From Double-Blind|PH requiring lung transplant|0
6030738|NCT00302211|9626655|FG001|Open Label-Patients From Double-Blind|PH requiring lung transplant|0
6030739|NCT00302211|9626656|FG002|Open Label-Patients From Double-Blind|PH requiring lung transplant|0
6030740|NCT00302211|9626657|FG003|Open Label-Patients From Double-Blind|PH requiring lung transplant|0
6030741|NCT00302211|9626658|FG004|Open Label-Patients From Double-Blind|PH requiring lung transplant|1
6030742|NCT00302211|9626654|FG000|Open Label-Patients From Double-Blind|Termination of the study by the sponsor|0
6030743|NCT00302211|9626655|FG001|Open Label-Patients From Double-Blind|Termination of the study by the sponsor|0
6030744|NCT00302211|9626656|FG002|Open Label-Patients From Double-Blind|Termination of the study by the sponsor|0
6030745|NCT00302211|9626657|FG003|Open Label-Patients From Double-Blind|Termination of the study by the sponsor|1
6030746|NCT00302211|9626658|FG004|Open Label-Patients From Double-Blind|Termination of the study by the sponsor|0
6030747|NCT00302328|9626673|FG000|Overall Study|Physician Decision|0
6030748|NCT00302328|9626674|FG001|Overall Study|Physician Decision|1
6030749|NCT00302328|9626675|FG002|Overall Study|Physician Decision|0
6030750|NCT00302458|9626686|FG000|Overall Study|Lost to Follow-up|1
6030751|NCT00302458|9626686|FG000|Overall Study|Ineligible after screening|1
6030752|NCT00302458|9626686|FG000|Overall Study|Withdrawal by Subject|1
6030753|NCT00302718|9626698|FG000|Overall Study|Participant left the hospital|1
6030754|NCT00302718|9626699|FG001|Overall Study|Participant left the hospital|0
6030755|NCT00302718|9626700|FG002|Overall Study|Participant left the hospital|0
6030756|NCT00302718|9626701|FG003|Overall Study|Participant left the hospital|1
6030757|NCT00302718|9626698|FG000|Overall Study|Withdrawal by Subject|0
6030758|NCT00302718|9626699|FG001|Overall Study|Withdrawal by Subject|1
6030759|NCT00302718|9626700|FG002|Overall Study|Withdrawal by Subject|0
6030760|NCT00302718|9626701|FG003|Overall Study|Withdrawal by Subject|0
6079578|NCT00611026|9686553|FG001|Double-blind Treatment Period|Lack of Efficacy|10
6079579|NCT00611026|9686554|FG002|Double-blind Treatment Period|Lack of Efficacy|4
6030761|NCT00302718|9626698|FG000|Overall Study|Participant left primary care setting|0
6030762|NCT00302718|9626699|FG001|Overall Study|Participant left primary care setting|0
6030763|NCT00302718|9626700|FG002|Overall Study|Participant left primary care setting|2
6030764|NCT00302718|9626701|FG003|Overall Study|Participant left primary care setting|1
6030765|NCT00302731|9626720|FG000|Overall Study|Lost to Follow-up|1
6030766|NCT00302731|9626721|FG001|Overall Study|Lost to Follow-up|2
6030767|NCT00302731|9626722|FG002|Overall Study|Lost to Follow-up|0
6030768|NCT00302731|9626723|FG003|Overall Study|Lost to Follow-up|0
6030769|NCT00302731|9626720|FG000|Overall Study|Adverse Event|0
6030770|NCT00302731|9626721|FG001|Overall Study|Adverse Event|2
6030771|NCT00302731|9626722|FG002|Overall Study|Adverse Event|2
6030772|NCT00302731|9626723|FG003|Overall Study|Adverse Event|0
6030773|NCT00302731|9626720|FG000|Overall Study|Withdrawal by Subject|1
6030774|NCT00302731|9626721|FG001|Overall Study|Withdrawal by Subject|1
6030775|NCT00302731|9626722|FG002|Overall Study|Withdrawal by Subject|0
6030776|NCT00302731|9626723|FG003|Overall Study|Withdrawal by Subject|0
6030777|NCT00302731|9626720|FG000|Overall Study|Protocol Violation|1
6030778|NCT00302731|9626721|FG001|Overall Study|Protocol Violation|0
6030779|NCT00302731|9626722|FG002|Overall Study|Protocol Violation|0
6030780|NCT00302731|9626723|FG003|Overall Study|Protocol Violation|0
6030781|NCT00302731|9626720|FG000|Overall Study|cancer unrelated to study discovered|1
6030782|NCT00302731|9626721|FG001|Overall Study|cancer unrelated to study discovered|0
6030783|NCT00302731|9626722|FG002|Overall Study|cancer unrelated to study discovered|1
6030784|NCT00302731|9626723|FG003|Overall Study|cancer unrelated to study discovered|0
6030785|NCT00302952|9626747|FG000|Overall Study|Physician Decision|1
6030786|NCT00302952|9626748|FG001|Overall Study|Physician Decision|1
6030787|NCT00302952|9626747|FG000|Overall Study|Withdrawal by Subject|2
6030788|NCT00302952|9626748|FG001|Overall Study|Withdrawal by Subject|3
6030789|NCT00302952|9626747|FG000|Overall Study|Elevated SGOT (AST) lab value|0
6030790|NCT00302952|9626748|FG001|Overall Study|Elevated SGOT (AST) lab value|1
6030791|NCT00303069|9626758|FG000|Overall Study|Lost to Follow-up|1
6030792|NCT00303069|9626759|FG001|Overall Study|Lost to Follow-up|0
6030793|NCT00303069|9626760|FG002|Overall Study|Lost to Follow-up|0
6030794|NCT00303069|9626761|FG003|Overall Study|Lost to Follow-up|2
6030795|NCT00303069|9626758|FG000|Overall Study|subject moved|1
6030796|NCT00303069|9626759|FG001|Overall Study|subject moved|0
6030797|NCT00303069|9626760|FG002|Overall Study|subject moved|0
6030798|NCT00303069|9626761|FG003|Overall Study|subject moved|0
6030799|NCT00303069|9626758|FG000|Overall Study|Recruitment into Army Reserves|0
6030800|NCT00303069|9626759|FG001|Overall Study|Recruitment into Army Reserves|0
6030801|NCT00303069|9626760|FG002|Overall Study|Recruitment into Army Reserves|1
6030802|NCT00303069|9626761|FG003|Overall Study|Recruitment into Army Reserves|0
6030803|NCT00303108|9626774|FG000|Overall Study|Adverse Event|5
6030804|NCT00303108|9626775|FG001|Overall Study|Adverse Event|6
6030805|NCT00303108|9626776|FG002|Overall Study|Adverse Event|7
6030806|NCT00303108|9626774|FG000|Overall Study|Patient Request|4
6030807|NCT00303108|9626775|FG001|Overall Study|Patient Request|2
6030808|NCT00303108|9626776|FG002|Overall Study|Patient Request|8
6030809|NCT00303108|9626774|FG000|Overall Study|Failed Entry|1
6030810|NCT00303108|9626775|FG001|Overall Study|Failed Entry|0
6030811|NCT00303108|9626776|FG002|Overall Study|Failed Entry|1
6030812|NCT00303108|9626774|FG000|Overall Study|ineligible|2
6030813|NCT00303108|9626775|FG001|Overall Study|ineligible|1
6030814|NCT00303108|9626776|FG002|Overall Study|ineligible|0
6030815|NCT00303186|9626783|FG000|Overall Study|Other|52
6030816|NCT00303316|9626789|FG000|Overall Study|Protocol Violation|1
6030817|NCT00303316|9626790|FG001|Overall Study|Protocol Violation|0
6030818|NCT00303316|9626789|FG000|Overall Study|Lost to Follow-up|0
6030819|NCT00303316|9626790|FG001|Overall Study|Lost to Follow-up|1
6030820|NCT00303316|9626789|FG000|Overall Study|Withdrawal by Subject|1
6030821|NCT00303316|9626790|FG001|Overall Study|Withdrawal by Subject|2
6030822|NCT00303329|9626798|FG000|Overall Study|Adverse Event|7
6030823|NCT00303329|9626799|FG001|Overall Study|Adverse Event|14
6030824|NCT00303329|9626798|FG000|Overall Study|Abnormal Laboratory Values|0
6030825|NCT00303329|9626799|FG001|Overall Study|Abnormal Laboratory Values|1
6030826|NCT00303329|9626798|FG000|Overall Study|Unsatisfactory therapeutic effect|9
6030827|NCT00303329|9626799|FG001|Overall Study|Unsatisfactory therapeutic effect|2
6030828|NCT00303329|9626798|FG000|Overall Study|Condition no longer requires study drug|0
6030829|NCT00303329|9626799|FG001|Overall Study|Condition no longer requires study drug|8
6030830|NCT00303329|9626798|FG000|Overall Study|Protocol Violation|3
6030831|NCT00303329|9626799|FG001|Overall Study|Protocol Violation|0
6030832|NCT00303329|9626798|FG000|Overall Study|Withdrawal by Subject|9
6030833|NCT00303329|9626799|FG001|Overall Study|Withdrawal by Subject|15
6030834|NCT00303329|9626798|FG000|Overall Study|Lost to Follow-up|0
6030835|NCT00303329|9626799|FG001|Overall Study|Lost to Follow-up|1
6030836|NCT00303329|9626798|FG000|Overall Study|Administrative problems|1
6030837|NCT00303329|9626799|FG001|Overall Study|Administrative problems|0
6030838|NCT00303329|9626798|FG000|Overall Study|Death|2
6030839|NCT00303329|9626799|FG001|Overall Study|Death|12
6030840|NCT00303329|9626798|FG000|Overall Study|Stopped at end of core|3
6030841|NCT00303329|9626799|FG001|Overall Study|Stopped at end of core|9
6030842|NCT00303329|9626798|FG000|Overall Study|Stopped at end of extension 1|1
6030843|NCT00303329|9626799|FG001|Overall Study|Stopped at end of extension 1|0
6030844|NCT00303446|9626807|FG000|Overall Study|Withdrawal by Subject|2
6030845|NCT00303446|9626808|FG001|Overall Study|Withdrawal by Subject|2
6030846|NCT00303446|9626807|FG000|Overall Study|Death|0
6030847|NCT00303446|9626808|FG001|Overall Study|Death|1
6030848|NCT00303446|9626807|FG000|Overall Study|Physician Decision|0
6030849|NCT00303446|9626808|FG001|Overall Study|Physician Decision|1
6030850|NCT00303459|9626816|FG000|Overall Study|Death|33
6030851|NCT00303459|9626817|FG001|Overall Study|Death|44
6030852|NCT00303459|9626816|FG000|Overall Study|Withdrawal of consent|32
6030853|NCT00303459|9626817|FG001|Overall Study|Withdrawal of consent|26
6030854|NCT00303459|9626816|FG000|Overall Study|Lost to Follow-up|5
6030855|NCT00303459|9626817|FG001|Overall Study|Lost to Follow-up|4
6030856|NCT00303459|9626816|FG000|Overall Study|Administrative reason|7
6030857|NCT00303459|9626817|FG001|Overall Study|Administrative reason|7
6030858|NCT00303459|9626816|FG000|Overall Study|Decision by the investigator|5
6030859|NCT00303459|9626817|FG001|Overall Study|Decision by the investigator|7
6030860|NCT00303459|9626816|FG000|Overall Study|Lung transplantation|1
6030861|NCT00303459|9626817|FG001|Overall Study|Lung transplantation|1
6030862|NCT00303472|9626831|FG000|Treatment Period|Adverse Event|0
6030863|NCT00303472|9626832|FG001|Treatment Period|Adverse Event|0
6030864|NCT00303472|9626833|FG002|Treatment Period|Adverse Event|0
6030865|NCT00303472|9626834|FG003|Treatment Period|Adverse Event|0
6030866|NCT00303472|9626835|FG004|Treatment Period|Adverse Event|1
6030867|NCT00303472|9626836|FG005|Treatment Period|Adverse Event|0
6030868|NCT00303472|9626837|FG006|Treatment Period|Adverse Event|0
6030869|NCT00303472|9626831|FG000|Treatment Period|Death|0
6030870|NCT00303472|9626832|FG001|Treatment Period|Death|0
6030871|NCT00303472|9626833|FG002|Treatment Period|Death|0
6030872|NCT00303472|9626834|FG003|Treatment Period|Death|1
6030873|NCT00303472|9626835|FG004|Treatment Period|Death|0
6030874|NCT00303472|9626836|FG005|Treatment Period|Death|0
6030875|NCT00303472|9626837|FG006|Treatment Period|Death|1
6030876|NCT00303472|9626831|FG000|Treatment Period|Withdrawal by Subject|0
6030877|NCT00303472|9626832|FG001|Treatment Period|Withdrawal by Subject|0
6030878|NCT00303472|9626833|FG002|Treatment Period|Withdrawal by Subject|0
6030879|NCT00303472|9626834|FG003|Treatment Period|Withdrawal by Subject|1
6030880|NCT00303472|9626835|FG004|Treatment Period|Withdrawal by Subject|0
6030881|NCT00303472|9626836|FG005|Treatment Period|Withdrawal by Subject|1
6030882|NCT00303472|9626837|FG006|Treatment Period|Withdrawal by Subject|0
6030883|NCT00303472|9626831|FG000|Treatment Period|Other|0
6030884|NCT00303472|9626832|FG001|Treatment Period|Other|0
6079580|NCT00611026|9686552|FG000|Double-blind Treatment Period|Lost to Follow-up|6
6030885|NCT00303472|9626833|FG002|Treatment Period|Other|0
6030886|NCT00303472|9626834|FG003|Treatment Period|Other|0
6030887|NCT00303472|9626835|FG004|Treatment Period|Other|1
6030888|NCT00303472|9626836|FG005|Treatment Period|Other|0
6030889|NCT00303472|9626837|FG006|Treatment Period|Other|1
6030890|NCT00303472|9626831|FG000|Treatment Period|Disease Progression (to AML)|0
6030891|NCT00303472|9626832|FG001|Treatment Period|Disease Progression (to AML)|0
6030892|NCT00303472|9626833|FG002|Treatment Period|Disease Progression (to AML)|0
6030893|NCT00303472|9626834|FG003|Treatment Period|Disease Progression (to AML)|0
6030894|NCT00303472|9626835|FG004|Treatment Period|Disease Progression (to AML)|1
6079581|NCT00611026|9686553|FG001|Double-blind Treatment Period|Lost to Follow-up|11
6079582|NCT00611026|9686554|FG002|Double-blind Treatment Period|Lost to Follow-up|14
6079583|NCT00611026|9686552|FG000|Double-blind Treatment Period|Withdrawal by Subject|7
6079584|NCT00611026|9686553|FG001|Double-blind Treatment Period|Withdrawal by Subject|19
6079585|NCT00611026|9686554|FG002|Double-blind Treatment Period|Withdrawal by Subject|16
6079586|NCT00611026|9686552|FG000|Double-blind Treatment Period|Other|13
6079587|NCT00611026|9686553|FG001|Double-blind Treatment Period|Other|20
6079588|NCT00611026|9686554|FG002|Double-blind Treatment Period|Other|18
6079589|NCT00611130|9686566|FG000|Overall Study|Lost to Follow-up|25
6079590|NCT00611130|9686567|FG001|Overall Study|Lost to Follow-up|29
6079591|NCT00611130|9686566|FG000|Overall Study|Protocol noncompliance|7
6079592|NCT00611130|9686567|FG001|Overall Study|Protocol noncompliance|6
6079593|NCT00611130|9686566|FG000|Overall Study|Withdrawal by Subject|6
6079594|NCT00611130|9686567|FG001|Overall Study|Withdrawal by Subject|5
6079595|NCT00611130|9686566|FG000|Overall Study|Other|5
6079596|NCT00611130|9686567|FG001|Overall Study|Other|4
6030895|NCT00303472|9626836|FG005|Treatment Period|Disease Progression (to AML)|0
6030896|NCT00303472|9626837|FG006|Treatment Period|Disease Progression (to AML)|0
6030897|NCT00303472|9626831|FG000|Treatment Extension (Optional)|Adverse Event|1
6030898|NCT00303472|9626832|FG001|Treatment Extension (Optional)|Adverse Event|0
6030899|NCT00303472|9626833|FG002|Treatment Extension (Optional)|Adverse Event|1
6030900|NCT00303472|9626834|FG003|Treatment Extension (Optional)|Adverse Event|0
6030901|NCT00303472|9626835|FG004|Treatment Extension (Optional)|Adverse Event|0
6030902|NCT00303472|9626836|FG005|Treatment Extension (Optional)|Adverse Event|0
6030903|NCT00303472|9626837|FG006|Treatment Extension (Optional)|Adverse Event|0
6030904|NCT00303472|9626831|FG000|Treatment Extension (Optional)|Death|2
6030905|NCT00303472|9626832|FG001|Treatment Extension (Optional)|Death|0
6030906|NCT00303472|9626833|FG002|Treatment Extension (Optional)|Death|1
6030907|NCT00303472|9626834|FG003|Treatment Extension (Optional)|Death|0
6030908|NCT00303472|9626835|FG004|Treatment Extension (Optional)|Death|0
6079597|NCT00611130|9686566|FG000|Overall Study|Incarceration|3
6030909|NCT00303472|9626836|FG005|Treatment Extension (Optional)|Death|0
6030910|NCT00303472|9626837|FG006|Treatment Extension (Optional)|Death|0
6030911|NCT00303472|9626831|FG000|Treatment Extension (Optional)|Lost to Follow-up|0
6030912|NCT00303472|9626832|FG001|Treatment Extension (Optional)|Lost to Follow-up|0
6030913|NCT00303472|9626833|FG002|Treatment Extension (Optional)|Lost to Follow-up|0
6030914|NCT00303472|9626834|FG003|Treatment Extension (Optional)|Lost to Follow-up|1
6030915|NCT00303472|9626835|FG004|Treatment Extension (Optional)|Lost to Follow-up|0
6030916|NCT00303472|9626836|FG005|Treatment Extension (Optional)|Lost to Follow-up|0
6030917|NCT00303472|9626837|FG006|Treatment Extension (Optional)|Lost to Follow-up|0
6030918|NCT00303472|9626831|FG000|Treatment Extension (Optional)|Physician Decision|0
6030919|NCT00303472|9626832|FG001|Treatment Extension (Optional)|Physician Decision|4
6030920|NCT00303472|9626833|FG002|Treatment Extension (Optional)|Physician Decision|2
6030921|NCT00303472|9626834|FG003|Treatment Extension (Optional)|Physician Decision|3
6030922|NCT00303472|9626835|FG004|Treatment Extension (Optional)|Physician Decision|2
6030923|NCT00303472|9626836|FG005|Treatment Extension (Optional)|Physician Decision|0
6030924|NCT00303472|9626837|FG006|Treatment Extension (Optional)|Physician Decision|0
6030925|NCT00303472|9626831|FG000|Treatment Extension (Optional)|Withdrawal by Subject|1
6030926|NCT00303472|9626832|FG001|Treatment Extension (Optional)|Withdrawal by Subject|0
6030927|NCT00303472|9626833|FG002|Treatment Extension (Optional)|Withdrawal by Subject|1
6030928|NCT00303472|9626834|FG003|Treatment Extension (Optional)|Withdrawal by Subject|2
6030929|NCT00303472|9626835|FG004|Treatment Extension (Optional)|Withdrawal by Subject|1
6030930|NCT00303472|9626836|FG005|Treatment Extension (Optional)|Withdrawal by Subject|0
6030931|NCT00303472|9626837|FG006|Treatment Extension (Optional)|Withdrawal by Subject|0
6030932|NCT00303472|9626831|FG000|Treatment Extension (Optional)|Other|0
6030933|NCT00303472|9626832|FG001|Treatment Extension (Optional)|Other|2
6030934|NCT00303472|9626833|FG002|Treatment Extension (Optional)|Other|4
6030935|NCT00303472|9626834|FG003|Treatment Extension (Optional)|Other|2
6030936|NCT00303472|9626835|FG004|Treatment Extension (Optional)|Other|1
6030937|NCT00303472|9626836|FG005|Treatment Extension (Optional)|Other|0
6030938|NCT00303472|9626837|FG006|Treatment Extension (Optional)|Other|0
6030939|NCT00303472|9626831|FG000|Treatment Extension (Optional)|Disease Progression (to AML)|1
6079598|NCT00611130|9686567|FG001|Overall Study|Incarceration|2
6079599|NCT00611130|9686566|FG000|Overall Study|Administrative|1
6079600|NCT00611130|9686567|FG001|Overall Study|Administrative|1
6079601|NCT00611130|9686566|FG000|Overall Study|Adverse Event|1
6079602|NCT00611130|9686567|FG001|Overall Study|Adverse Event|0
6079603|NCT00611130|9686566|FG000|Overall Study|Death|1
6079604|NCT00611130|9686567|FG001|Overall Study|Death|0
6079605|NCT00611247|9686576|FG000|Overall Study|Death|1
6079606|NCT00611247|9686577|FG001|Overall Study|Death|5
6079607|NCT00611247|9686576|FG000|Overall Study|Lack of Efficacy|1
6079608|NCT00611247|9686577|FG001|Overall Study|Lack of Efficacy|16
6079609|NCT00611455|9686617|FG000|DB Treatment Period (24 Weeks)|Adverse Event|2
6079610|NCT00611455|9686618|FG001|DB Treatment Period (24 Weeks)|Adverse Event|8
6079611|NCT00611455|9686619|FG002|DB Treatment Period (24 Weeks)|Adverse Event|0
6079612|NCT00611455|9686617|FG000|DB Treatment Period (24 Weeks)|Lack of Efficacy|2
6079613|NCT00611455|9686618|FG001|DB Treatment Period (24 Weeks)|Lack of Efficacy|0
6079614|NCT00611455|9686619|FG002|DB Treatment Period (24 Weeks)|Lack of Efficacy|0
6079615|NCT00611455|9686617|FG000|DB Treatment Period (24 Weeks)|Protocol Violation|4
6079616|NCT00611455|9686618|FG001|DB Treatment Period (24 Weeks)|Protocol Violation|1
6079617|NCT00611455|9686619|FG002|DB Treatment Period (24 Weeks)|Protocol Violation|0
6079618|NCT00611455|9686617|FG000|DB Treatment Period (24 Weeks)|Withdrawal by Subject|2
6079619|NCT00611455|9686618|FG001|DB Treatment Period (24 Weeks)|Withdrawal by Subject|3
6079620|NCT00611455|9686619|FG002|DB Treatment Period (24 Weeks)|Withdrawal by Subject|0
6079621|NCT00611455|9686617|FG000|DB Treatment Period (24 Weeks)|Randomized in Error; Not Treated|2
6079622|NCT00611455|9686618|FG001|DB Treatment Period (24 Weeks)|Randomized in Error; Not Treated|2
6079623|NCT00611455|9686619|FG002|DB Treatment Period (24 Weeks)|Randomized in Error; Not Treated|0
6079624|NCT00611455|9686617|FG000|DB Treatment Period (24 Weeks)|Randomized, but Not Treated|1
6079625|NCT00611455|9686618|FG001|DB Treatment Period (24 Weeks)|Randomized, but Not Treated|0
6079626|NCT00611455|9686619|FG002|DB Treatment Period (24 Weeks)|Randomized, but Not Treated|0
6079627|NCT00611455|9686617|FG000|OL Treatment Period (120 Weeks)|Adverse Event|0
6079628|NCT00611455|9686618|FG001|OL Treatment Period (120 Weeks)|Adverse Event|17
6079629|NCT00611455|9686619|FG002|OL Treatment Period (120 Weeks)|Adverse Event|0
6079630|NCT00611455|9686617|FG000|OL Treatment Period (120 Weeks)|Lack of Efficacy|0
6079631|NCT00611455|9686618|FG001|OL Treatment Period (120 Weeks)|Lack of Efficacy|9
6079632|NCT00611455|9686619|FG002|OL Treatment Period (120 Weeks)|Lack of Efficacy|0
6079633|NCT00611455|9686617|FG000|OL Treatment Period (120 Weeks)|Protocol Violation|0
6079634|NCT00611455|9686618|FG001|OL Treatment Period (120 Weeks)|Protocol Violation|3
6079635|NCT00611455|9686619|FG002|OL Treatment Period (120 Weeks)|Protocol Violation|0
6079636|NCT00611455|9686617|FG000|OL Treatment Period (120 Weeks)|Protocol-defined Stopping Criteria Met|0
6079637|NCT00611455|9686618|FG001|OL Treatment Period (120 Weeks)|Protocol-defined Stopping Criteria Met|12
6079638|NCT00611455|9686619|FG002|OL Treatment Period (120 Weeks)|Protocol-defined Stopping Criteria Met|0
6079639|NCT00611455|9686617|FG000|OL Treatment Period (120 Weeks)|Study Closed/Terminated|0
6079640|NCT00611455|9686618|FG001|OL Treatment Period (120 Weeks)|Study Closed/Terminated|110
6087647|NCT00669864|9698070|FG000|Overall Study|Protocol Violation|2
6030940|NCT00303472|9626832|FG001|Treatment Extension (Optional)|Disease Progression (to AML)|0
6030941|NCT00303472|9626833|FG002|Treatment Extension (Optional)|Disease Progression (to AML)|0
6030942|NCT00303472|9626834|FG003|Treatment Extension (Optional)|Disease Progression (to AML)|0
6030943|NCT00303472|9626835|FG004|Treatment Extension (Optional)|Disease Progression (to AML)|0
6030944|NCT00303472|9626836|FG005|Treatment Extension (Optional)|Disease Progression (to AML)|1
6030945|NCT00303472|9626837|FG006|Treatment Extension (Optional)|Disease Progression (to AML)|0
6030946|NCT00303485|9626855|FG000|Overall Study|Adverse Event/Intercurrent Illness|0
6030947|NCT00303485|9626856|FG001|Overall Study|Adverse Event/Intercurrent Illness|1
6030948|NCT00303485|9626855|FG000|Overall Study|Failure to return|0
6030949|NCT00303485|9626856|FG001|Overall Study|Failure to return|1
6030950|NCT00303485|9626855|FG000|Overall Study|Withdrawal by Subject|1
6030951|NCT00303485|9626856|FG001|Overall Study|Withdrawal by Subject|0
6030952|NCT00303602|9626868|FG000|Overall Study|Adverse Event|2
6030953|NCT00303602|9626869|FG001|Overall Study|Adverse Event|2
6030954|NCT00303602|9626868|FG000|Overall Study|Withdrawal by Subject|5
6030955|NCT00303602|9626869|FG001|Overall Study|Withdrawal by Subject|6
6030956|NCT00303602|9626868|FG000|Overall Study|Lost to Follow-up|5
6030957|NCT00303602|9626869|FG001|Overall Study|Lost to Follow-up|2
6030958|NCT00303602|9626868|FG000|Overall Study|Protocol entry criteria not met|2
6030959|NCT00303602|9626869|FG001|Overall Study|Protocol entry criteria not met|2
6030960|NCT00303602|9626868|FG000|Overall Study|Physician Decision|2
6030961|NCT00303602|9626869|FG001|Overall Study|Physician Decision|1
6030962|NCT00303602|9626868|FG000|Overall Study|Noncompliance|2
6030963|NCT00303602|9626869|FG001|Overall Study|Noncompliance|2
6030964|NCT00303602|9626868|FG000|Overall Study|Protocol Violation|1
6030965|NCT00303602|9626869|FG001|Overall Study|Protocol Violation|0
6030966|NCT00303628|9626877|FG000|Overall Study|Disease progression|0
6030967|NCT00303628|9626878|FG001|Overall Study|Disease progression|1
6030968|NCT00303628|9626877|FG000|Overall Study|Adverse Event|26
6030969|NCT00303628|9626878|FG001|Overall Study|Adverse Event|36
6030970|NCT00303628|9626877|FG000|Overall Study|Death|0
6030971|NCT00303628|9626878|FG001|Overall Study|Death|1
6030972|NCT00303628|9626877|FG000|Overall Study|Withdrawal by Subject|11
6030973|NCT00303628|9626878|FG001|Overall Study|Withdrawal by Subject|20
6030974|NCT00303628|9626877|FG000|Overall Study|Alternative therapy|2
6030975|NCT00303628|9626878|FG001|Overall Study|Alternative therapy|0
6030976|NCT00303628|9626877|FG000|Overall Study|Other complicating disease|0
6030977|NCT00303628|9626878|FG001|Overall Study|Other complicating disease|1
6030978|NCT00303628|9626877|FG000|Overall Study|Not start protocol therapy|3
6030979|NCT00303628|9626878|FG001|Overall Study|Not start protocol therapy|5
6030980|NCT00303628|9626877|FG000|Overall Study|Other|8
6030981|NCT00303628|9626878|FG001|Overall Study|Other|9
6030982|NCT00303667|9626886|FG000|Overall Study|Death|0
6030983|NCT00303667|9626887|FG001|Overall Study|Death|4
6030984|NCT00303719|9626895|FG000|Overall Study|Not evaluable, prior therapies|0
6030985|NCT00303719|9626896|FG001|Overall Study|Not evaluable, prior therapies|30
6030986|NCT00303719|9626895|FG000|Overall Study|Lost to Follow-up|0
6030987|NCT00303719|9626896|FG001|Overall Study|Lost to Follow-up|7
6030988|NCT00303953|9626920|FG000|Overall Study|Ineligible|1
6030989|NCT00303953|9626920|FG000|Overall Study|Death|1
6030990|NCT00303953|9626920|FG000|Overall Study|Adverse Event|4
6030991|NCT00303953|9626920|FG000|Overall Study|Lack of Efficacy|12
6030992|NCT00303953|9626920|FG000|Overall Study|Physician Decision|1
6030993|NCT00304031|9626953|FG000|Concomitant RT+TMZ (Pre-randomization)|Ineligible due to insufficient tissue|144
6030994|NCT00304031|9626954|FG001|Concomitant RT+TMZ (Pre-randomization)|Ineligible due to insufficient tissue|0
6030995|NCT00304031|9626955|FG002|Concomitant RT+TMZ (Pre-randomization)|Ineligible due to insufficient tissue|0
6030996|NCT00304031|9626953|FG000|Concomitant RT+TMZ (Pre-randomization)|Disease progression|48
6030997|NCT00304031|9626954|FG001|Concomitant RT+TMZ (Pre-randomization)|Disease progression|0
6030998|NCT00304031|9626955|FG002|Concomitant RT+TMZ (Pre-randomization)|Disease progression|0
6030999|NCT00304031|9626953|FG000|Concomitant RT+TMZ (Pre-randomization)|Patient refusal|19
6031000|NCT00304031|9626954|FG001|Concomitant RT+TMZ (Pre-randomization)|Patient refusal|0
6031001|NCT00304031|9626955|FG002|Concomitant RT+TMZ (Pre-randomization)|Patient refusal|0
6031002|NCT00304031|9626953|FG000|Concomitant RT+TMZ (Pre-randomization)|Death|18
6031003|NCT00304031|9626954|FG001|Concomitant RT+TMZ (Pre-randomization)|Death|0
6031004|NCT00304031|9626955|FG002|Concomitant RT+TMZ (Pre-randomization)|Death|0
6031005|NCT00304031|9626953|FG000|Concomitant RT+TMZ (Pre-randomization)|Physician preference|15
6031006|NCT00304031|9626954|FG001|Concomitant RT+TMZ (Pre-randomization)|Physician preference|0
6031007|NCT00304031|9626955|FG002|Concomitant RT+TMZ (Pre-randomization)|Physician preference|0
6031008|NCT00304031|9626953|FG000|Concomitant RT+TMZ (Pre-randomization)|Toxicity|10
6031009|NCT00304031|9626954|FG001|Concomitant RT+TMZ (Pre-randomization)|Toxicity|0
6031010|NCT00304031|9626955|FG002|Concomitant RT+TMZ (Pre-randomization)|Toxicity|0
6031011|NCT00304031|9626953|FG000|Concomitant RT+TMZ (Pre-randomization)|Other complicating disease|1
6031012|NCT00304031|9626954|FG001|Concomitant RT+TMZ (Pre-randomization)|Other complicating disease|0
6031013|NCT00304031|9626955|FG002|Concomitant RT+TMZ (Pre-randomization)|Other complicating disease|0
6031014|NCT00304031|9626953|FG000|Concomitant RT+TMZ (Pre-randomization)|Other, not otherwise specified|37
6031015|NCT00304031|9626954|FG001|Concomitant RT+TMZ (Pre-randomization)|Other, not otherwise specified|0
6031016|NCT00304031|9626955|FG002|Concomitant RT+TMZ (Pre-randomization)|Other, not otherwise specified|0
6031017|NCT00304031|9626953|FG000|Randomization to Adjuvant TMZ Arm|No follow-up collected|0
6031018|NCT00304031|9626954|FG001|Randomization to Adjuvant TMZ Arm|No follow-up collected|0
6031019|NCT00304031|9626955|FG002|Randomization to Adjuvant TMZ Arm|No follow-up collected|2
6048431|NCT00418379|9647662|FG002|Year 4|Adverse Event|0
6048432|NCT00418379|9647660|FG000|Year 4|Withdrawal by Subject|2
6048433|NCT00418379|9647661|FG001|Year 4|Withdrawal by Subject|3
6048434|NCT00418379|9647662|FG002|Year 4|Withdrawal by Subject|2
6048435|NCT00418379|9647660|FG000|Year 4|Any other reason not above-mentioned|1
6048436|NCT00418379|9647661|FG001|Year 4|Any other reason not above-mentioned|1
6048437|NCT00418379|9647662|FG002|Year 4|Any other reason not above-mentioned|0
6048438|NCT00418379|9647660|FG000|Year 5|Adverse Event|0
6048439|NCT00418379|9647661|FG001|Year 5|Adverse Event|1
6048440|NCT00418379|9647662|FG002|Year 5|Adverse Event|0
6048441|NCT00418379|9647660|FG000|Year 5|Any other reason not above-mentioned|2
6048442|NCT00418379|9647661|FG001|Year 5|Any other reason not above-mentioned|4
6048443|NCT00418379|9647662|FG002|Year 5|Any other reason not above-mentioned|3
6048444|NCT00418522|9647681|FG000|Overall Study|Adverse Event|7
6048445|NCT00418522|9647682|FG001|Overall Study|Adverse Event|1
6048446|NCT00418522|9647681|FG000|Overall Study|Lack of Efficacy|1
6048447|NCT00418522|9647682|FG001|Overall Study|Lack of Efficacy|3
6048448|NCT00418522|9647681|FG000|Overall Study|Lost to Follow-up|10
6048449|NCT00418522|9647682|FG001|Overall Study|Lost to Follow-up|4
6048450|NCT00418522|9647681|FG000|Overall Study|Withdrawal by Subject|31
6048451|NCT00418522|9647682|FG001|Overall Study|Withdrawal by Subject|7
6048452|NCT00418522|9647681|FG000|Overall Study|Other|27
6048453|NCT00418522|9647682|FG001|Overall Study|Other|23
6048454|NCT00418522|9647681|FG000|Overall Study|Randomized but did not receive treatment|7
6048455|NCT00418522|9647682|FG001|Overall Study|Randomized but did not receive treatment|4
6048456|NCT00418561|9647691|FG000|Overall Study|Participant's (guardian's) decision|0
6079641|NCT00611455|9686619|FG002|OL Treatment Period (120 Weeks)|Study Closed/Terminated|0
6079642|NCT00611455|9686617|FG000|OL Treatment Period (120 Weeks)|Lost to Follow-up|0
6079643|NCT00611455|9686618|FG001|OL Treatment Period (120 Weeks)|Lost to Follow-up|5
6079644|NCT00611455|9686619|FG002|OL Treatment Period (120 Weeks)|Lost to Follow-up|0
6079645|NCT00611455|9686617|FG000|OL Treatment Period (120 Weeks)|Physician Decision|0
6079646|NCT00611455|9686618|FG001|OL Treatment Period (120 Weeks)|Physician Decision|5
6079647|NCT00611455|9686619|FG002|OL Treatment Period (120 Weeks)|Physician Decision|0
6079648|NCT00611455|9686617|FG000|OL Treatment Period (120 Weeks)|Withdrawal by Subject|0
6079649|NCT00611455|9686618|FG001|OL Treatment Period (120 Weeks)|Withdrawal by Subject|18
6079650|NCT00611455|9686619|FG002|OL Treatment Period (120 Weeks)|Withdrawal by Subject|0
6079651|NCT00611455|9686617|FG000|Follow-up Period (Approximately 2 Years)|Adverse Event|0
6079652|NCT00611455|9686618|FG001|Follow-up Period (Approximately 2 Years)|Adverse Event|0
6079653|NCT00611455|9686619|FG002|Follow-up Period (Approximately 2 Years)|Adverse Event|30
6079654|NCT00611455|9686617|FG000|Follow-up Period (Approximately 2 Years)|Lack of Efficacy|0
6079655|NCT00611455|9686618|FG001|Follow-up Period (Approximately 2 Years)|Lack of Efficacy|0
6079656|NCT00611455|9686619|FG002|Follow-up Period (Approximately 2 Years)|Lack of Efficacy|12
6079657|NCT00611455|9686617|FG000|Follow-up Period (Approximately 2 Years)|Protocol Violation|0
6079658|NCT00611455|9686618|FG001|Follow-up Period (Approximately 2 Years)|Protocol Violation|0
6079659|NCT00611455|9686619|FG002|Follow-up Period (Approximately 2 Years)|Protocol Violation|4
6079660|NCT00611455|9686617|FG000|Follow-up Period (Approximately 2 Years)|Protocol-defined Stopping Criteria Met|0
6079661|NCT00611455|9686618|FG001|Follow-up Period (Approximately 2 Years)|Protocol-defined Stopping Criteria Met|0
6079662|NCT00611455|9686619|FG002|Follow-up Period (Approximately 2 Years)|Protocol-defined Stopping Criteria Met|23
6079663|NCT00611455|9686617|FG000|Follow-up Period (Approximately 2 Years)|Study Closed/Terminated|0
6079664|NCT00611455|9686618|FG001|Follow-up Period (Approximately 2 Years)|Study Closed/Terminated|0
6079665|NCT00611455|9686619|FG002|Follow-up Period (Approximately 2 Years)|Study Closed/Terminated|80
6079666|NCT00611455|9686617|FG000|Follow-up Period (Approximately 2 Years)|Lost to Follow-up|0
6079667|NCT00611455|9686618|FG001|Follow-up Period (Approximately 2 Years)|Lost to Follow-up|0
6079668|NCT00611455|9686619|FG002|Follow-up Period (Approximately 2 Years)|Lost to Follow-up|13
6079669|NCT00611455|9686617|FG000|Follow-up Period (Approximately 2 Years)|Withdrawal by Subject|0
6079670|NCT00611455|9686618|FG001|Follow-up Period (Approximately 2 Years)|Withdrawal by Subject|0
6079671|NCT00611455|9686619|FG002|Follow-up Period (Approximately 2 Years)|Withdrawal by Subject|49
6079672|NCT00611533|9686636|FG000|First Intervention (6 Weeks)|Never started study|0
6079673|NCT00611533|9686637|FG001|First Intervention (6 Weeks)|Never started study|1
6079674|NCT00611533|9686636|FG000|First Intervention (6 Weeks)|Adverse Event|0
6079675|NCT00611533|9686637|FG001|First Intervention (6 Weeks)|Adverse Event|1
6079676|NCT00611533|9686636|FG000|Second Intervention (6 Weeks)|Adverse Event|0
6048457|NCT00418561|9647692|FG001|Overall Study|Participant's (guardian's) decision|1
6048458|NCT00418561|9647693|FG002|Overall Study|Participant's (guardian's) decision|0
6048459|NCT00418665|9647713|FG000|Treatment Period|Ineligibility determined|1
6048460|NCT00418665|9647714|FG001|Treatment Period|Ineligibility determined|1
6048461|NCT00418665|9647715|FG002|Treatment Period|Ineligibility determined|0
6048462|NCT00418665|9647713|FG000|Treatment Period|Adverse Event|2
6048463|NCT00418665|9647714|FG001|Treatment Period|Adverse Event|2
6079677|NCT00611533|9686637|FG001|Second Intervention (6 Weeks)|Adverse Event|2
6079678|NCT00611559|9686647|FG000|Overall Study|Lost to Follow-up|0
6031020|NCT00304083|9626972|FG000|Overall Study|Withdrawal by Subject|4
6031021|NCT00304083|9626973|FG001|Overall Study|Withdrawal by Subject|2
6031022|NCT00304083|9626972|FG000|Overall Study|Physician Decision|8
6031023|NCT00304083|9626973|FG001|Overall Study|Physician Decision|3
6031024|NCT00304083|9626972|FG000|Overall Study|Disease Progression|5
6031025|NCT00304083|9626973|FG001|Overall Study|Disease Progression|1
6031026|NCT00304083|9626972|FG000|Overall Study|Other|5
6031027|NCT00304083|9626973|FG001|Overall Study|Other|2
6031028|NCT00304278|9627017|FG000|Overall Study|lack of insurance coverage for chemoRT|1
6031029|NCT00304278|9627017|FG000|Overall Study|PT had medical condition preventing TX|1
6031030|NCT00304356|9627021|FG000|Nitazoxanide|Physician Decision|5
6031031|NCT00304356|9627021|FG000|Nitazoxanide|Physician Decision|1
6031032|NCT00304356|9627021|FG000|Nitazoxanide|number is 0|1
6031033|NCT00304356|9627021|FG000|Nitazoxanide|Physician Decision|1
6031034|NCT00304356|9627021|FG000|Nitazoxanide|Physician Decision|1
6031035|NCT00304356|9627021|FG000|Nitazoxanide|Physician Decision|1
6048464|NCT00418665|9647715|FG002|Treatment Period|Adverse Event|0
6048465|NCT00418665|9647713|FG000|Treatment Period|Withdrawal by Subject|0
6048466|NCT00418665|9647714|FG001|Treatment Period|Withdrawal by Subject|3
6048467|NCT00418665|9647715|FG002|Treatment Period|Withdrawal by Subject|1
6048468|NCT00418665|9647713|FG000|Treatment Period|Requirement for alternative therapy|1
6048469|NCT00418665|9647714|FG001|Treatment Period|Requirement for alternative therapy|0
6048470|NCT00418665|9647715|FG002|Treatment Period|Requirement for alternative therapy|0
6048471|NCT00418665|9647713|FG000|Treatment Period|Physician Decision|1
6048472|NCT00418665|9647714|FG001|Treatment Period|Physician Decision|0
6048473|NCT00418665|9647715|FG002|Treatment Period|Physician Decision|3
6048474|NCT00418665|9647713|FG000|Treatment Extension|Adverse Event|1
6048475|NCT00418665|9647714|FG001|Treatment Extension|Adverse Event|0
6048476|NCT00418665|9647715|FG002|Treatment Extension|Adverse Event|0
6048477|NCT00418665|9647713|FG000|Treatment Extension|Withdrawal by Subject|1
6048478|NCT00418665|9647714|FG001|Treatment Extension|Withdrawal by Subject|0
6048479|NCT00418665|9647715|FG002|Treatment Extension|Withdrawal by Subject|0
6048480|NCT00418665|9647713|FG000|Treatment Extension|Requirement for alternative therapy|2
6048481|NCT00418665|9647714|FG001|Treatment Extension|Requirement for alternative therapy|2
6048482|NCT00418665|9647715|FG002|Treatment Extension|Requirement for alternative therapy|0
6048483|NCT00418665|9647713|FG000|Treatment Extension|Physician Decision|2
6048484|NCT00418665|9647714|FG001|Treatment Extension|Physician Decision|2
6048485|NCT00418665|9647715|FG002|Treatment Extension|Physician Decision|1
6048486|NCT00418665|9647713|FG000|Treatment Extension|Death|0
6048487|NCT00418665|9647714|FG001|Treatment Extension|Death|0
6048488|NCT00418665|9647715|FG002|Treatment Extension|Death|1
6048489|NCT00418691|9647726|FG000|Overall Study|Lost to Follow-up|1
6048490|NCT00418691|9647727|FG001|Overall Study|Lost to Follow-up|2
6048491|NCT00418691|9647728|FG002|Overall Study|Lost to Follow-up|3
6048492|NCT00418691|9647726|FG000|Overall Study|Started new medication voiding entry|0
6048493|NCT00418691|9647727|FG001|Overall Study|Started new medication voiding entry|0
6048494|NCT00418691|9647728|FG002|Overall Study|Started new medication voiding entry|1
6048495|NCT00418691|9647726|FG000|Overall Study|Progressive Disease|1
6048496|NCT00418691|9647727|FG001|Overall Study|Progressive Disease|0
6048497|NCT00418691|9647728|FG002|Overall Study|Progressive Disease|1
6048498|NCT00418717|9647736|FG000|Treatment Period A - Weeks 1-4|Protocol Violation|1
6048499|NCT00418717|9647736|FG000|Treatment Period B - Weeks 5-12|Adverse Event|2
6048500|NCT00418886|9647742|FG000|Overall Study|discontinue treatment survival follow up|90
6048501|NCT00418886|9647743|FG001|Overall Study|discontinue treatment survival follow up|91
6079679|NCT00611559|9686648|FG001|Overall Study|Lost to Follow-up|1
6079680|NCT00611559|9686649|FG002|Overall Study|Lost to Follow-up|0
6079681|NCT00611559|9686647|FG000|Overall Study|Protocol Violation|1
6079682|NCT00611559|9686648|FG001|Overall Study|Protocol Violation|0
6079683|NCT00611559|9686649|FG002|Overall Study|Protocol Violation|1
6079684|NCT00611715|9686664|FG000|Overall Study|Disease Progression|24
6079685|NCT00611715|9686665|FG001|Overall Study|Disease Progression|4
6079686|NCT00611715|9686664|FG000|Overall Study|Withdrawal by Subject|5
6079687|NCT00611715|9686665|FG001|Overall Study|Withdrawal by Subject|1
6079688|NCT00611715|9686664|FG000|Overall Study|Adverse Event|9
6079689|NCT00611715|9686665|FG001|Overall Study|Adverse Event|1
6079690|NCT00611715|9686664|FG000|Overall Study|Death|1
6079691|NCT00611715|9686665|FG001|Overall Study|Death|0
6079692|NCT00611715|9686664|FG000|Overall Study|two patients are still on treatment|2
6079693|NCT00611715|9686665|FG001|Overall Study|two patients are still on treatment|0
6079694|NCT00611767|9686679|FG000|Overall Study|Withdrawal by Subject|4
6079695|NCT00611767|9686680|FG001|Overall Study|Withdrawal by Subject|1
6048502|NCT00418886|9647742|FG000|Overall Study|Death|122
6048503|NCT00418886|9647743|FG001|Overall Study|Death|147
6079696|NCT00611767|9686679|FG000|Overall Study|Thiopental not available|3
6079697|NCT00611767|9686680|FG001|Overall Study|Thiopental not available|0
6048504|NCT00418886|9647742|FG000|Overall Study|Withdrawal by Subject|9
6048505|NCT00418886|9647743|FG001|Overall Study|Withdrawal by Subject|10
6048506|NCT00418886|9647742|FG000|Overall Study|Lost to Follow-up|4
6048507|NCT00418886|9647743|FG001|Overall Study|Lost to Follow-up|6
6048508|NCT00418886|9647742|FG000|Overall Study|withdrawn due to other reason|1
6048509|NCT00418886|9647743|FG001|Overall Study|withdrawn due to other reason|0
6048510|NCT00418886|9647742|FG000|Overall Study|randomised but no treatment received|0
6031036|NCT04493931|9627096|FG000|Cohort1:Treatment Period 1(Up to 3 Days)|Adverse Event|1
6031037|NCT04493931|9627097|FG001|Cohort1:Treatment Period 1(Up to 3 Days)|Adverse Event|0
6031038|NCT04493931|9627098|FG002|Cohort1:Treatment Period 1(Up to 3 Days)|Adverse Event|0
6031039|NCT04493931|9627099|FG003|Cohort1:Treatment Period 1(Up to 3 Days)|Adverse Event|0
6031040|NCT04493931|9627100|FG004|Cohort1:Treatment Period 1(Up to 3 Days)|Adverse Event|0
6031041|NCT04493931|9627101|FG005|Cohort1:Treatment Period 1(Up to 3 Days)|Adverse Event|0
6031042|NCT04493931|9627102|FG006|Cohort1:Treatment Period 1(Up to 3 Days)|Adverse Event|0
6031043|NCT04493931|9627096|FG000|Cohort2:Treatment Period2(Up to 10 Days)|Physician Decision|0
6031044|NCT04493931|9627097|FG001|Cohort2:Treatment Period2(Up to 10 Days)|Physician Decision|2
6031045|NCT04493931|9627098|FG002|Cohort2:Treatment Period2(Up to 10 Days)|Physician Decision|0
6031046|NCT04493931|9627099|FG003|Cohort2:Treatment Period2(Up to 10 Days)|Physician Decision|0
6031047|NCT04493931|9627100|FG004|Cohort2:Treatment Period2(Up to 10 Days)|Physician Decision|0
6031048|NCT04493931|9627101|FG005|Cohort2:Treatment Period2(Up to 10 Days)|Physician Decision|0
6031049|NCT04493931|9627102|FG006|Cohort2:Treatment Period2(Up to 10 Days)|Physician Decision|0
6031050|NCT04493931|9627096|FG000|Cohort2:Treatment Period2(Up to 10 Days)|Withdrawal by Subject|0
6031051|NCT04493931|9627097|FG001|Cohort2:Treatment Period2(Up to 10 Days)|Withdrawal by Subject|1
6031052|NCT04493931|9627098|FG002|Cohort2:Treatment Period2(Up to 10 Days)|Withdrawal by Subject|0
6031053|NCT04493931|9627099|FG003|Cohort2:Treatment Period2(Up to 10 Days)|Withdrawal by Subject|0
6031054|NCT04493931|9627100|FG004|Cohort2:Treatment Period2(Up to 10 Days)|Withdrawal by Subject|0
6031055|NCT04493931|9627101|FG005|Cohort2:Treatment Period2(Up to 10 Days)|Withdrawal by Subject|0
6031056|NCT04493931|9627102|FG006|Cohort2:Treatment Period2(Up to 10 Days)|Withdrawal by Subject|0
6031057|NCT04493931|9627096|FG000|Cohort3:Treatment Period 1(Up to 5 Days)|Protocol Violation|0
6031058|NCT04493931|9627097|FG001|Cohort3:Treatment Period 1(Up to 5 Days)|Protocol Violation|0
6079698|NCT00611767|9686679|FG000|Overall Study|didn't like the medication|1
6079699|NCT00611767|9686680|FG001|Overall Study|didn't like the medication|1
6079700|NCT00611767|9686679|FG000|Overall Study|Physician Decision|1
6079701|NCT00611767|9686680|FG001|Overall Study|Physician Decision|0
6079702|NCT00611806|9686688|FG000|Overall Study|Withdrawal by Subject|8
6079703|NCT00611806|9686689|FG001|Overall Study|Withdrawal by Subject|2
6079704|NCT00611806|9686688|FG000|Overall Study|Adverse Event|2
6079705|NCT00611806|9686689|FG001|Overall Study|Adverse Event|1
6079706|NCT00611806|9686688|FG000|Overall Study|Lost to Follow-up|6
6079707|NCT00611806|9686689|FG001|Overall Study|Lost to Follow-up|0
6079708|NCT00611858|9686695|FG000|Overall Study|Adverse Event|2
6079709|NCT00611858|9686695|FG000|Overall Study|Withdrawal by Subject|2
6079710|NCT00611884|9686705|FG000|Overall Study|Adverse Event|1
6079711|NCT00611884|9686706|FG001|Overall Study|Adverse Event|0
6079712|NCT00611884|9686707|FG002|Overall Study|Adverse Event|0
6079713|NCT00611884|9686708|FG003|Overall Study|Adverse Event|1
6079714|NCT00611884|9686705|FG000|Overall Study|Non-Compliance|1
6079715|NCT00611884|9686706|FG001|Overall Study|Non-Compliance|4
6079716|NCT00611884|9686707|FG002|Overall Study|Non-Compliance|2
6079717|NCT00611884|9686708|FG003|Overall Study|Non-Compliance|2
6079718|NCT00611884|9686705|FG000|Overall Study|Lack of Efficacy|0
6079719|NCT00611884|9686706|FG001|Overall Study|Lack of Efficacy|1
6079720|NCT00611884|9686707|FG002|Overall Study|Lack of Efficacy|0
6079721|NCT00611884|9686708|FG003|Overall Study|Lack of Efficacy|0
6079722|NCT00611884|9686705|FG000|Overall Study|Unclassified|7
6079723|NCT00611884|9686706|FG001|Overall Study|Unclassified|4
6079724|NCT00611884|9686707|FG002|Overall Study|Unclassified|2
6079725|NCT00611884|9686708|FG003|Overall Study|Unclassified|3
6079726|NCT00611923|9686729|FG000|Overall Study|Withdrawal by Subject|2
6079727|NCT00611923|9686730|FG001|Overall Study|Withdrawal by Subject|2
6079728|NCT00611975|9686740|FG000|Overall Study|Withdrawal by Subject|3
6079729|NCT00611975|9686741|FG001|Overall Study|Withdrawal by Subject|7
6079730|NCT00611975|9686740|FG000|Overall Study|Pregnancy|2
6079731|NCT00611975|9686741|FG001|Overall Study|Pregnancy|1
6079732|NCT00612040|9686750|FG000|Overall Study|Adverse Event|0
6079733|NCT00612040|9686751|FG001|Overall Study|Adverse Event|2
6079734|NCT00612040|9686752|FG002|Overall Study|Adverse Event|1
6079735|NCT00612040|9686750|FG000|Overall Study|Protocol Violation|1
6079736|NCT00612040|9686751|FG001|Overall Study|Protocol Violation|2
6079737|NCT00612040|9686752|FG002|Overall Study|Protocol Violation|1
6079738|NCT00612040|9686750|FG000|Overall Study|Lack of Efficacy|2
6079739|NCT00612040|9686751|FG001|Overall Study|Lack of Efficacy|1
6079740|NCT00612040|9686752|FG002|Overall Study|Lack of Efficacy|0
6079741|NCT00612040|9686750|FG000|Overall Study|Unclassified|2
6079742|NCT00612040|9686751|FG001|Overall Study|Unclassified|2
6079743|NCT00612040|9686752|FG002|Overall Study|Unclassified|5
6079744|NCT00612066|9686760|FG000|Overall Study|Adverse Event|1
6079745|NCT00612105|9686766|FG000|Period Title 1: 6-Week Titration Phase|Adverse Event|18
6079746|NCT00612105|9686767|FG001|Period Title 1: 6-Week Titration Phase|Adverse Event|1
6079747|NCT00612105|9686766|FG000|Period Title 1: 6-Week Titration Phase|Withdrawal by Subject|6
6079748|NCT00612105|9686767|FG001|Period Title 1: 6-Week Titration Phase|Withdrawal by Subject|1
6079749|NCT00612105|9686766|FG000|Period Title 1: 6-Week Titration Phase|Lost to Follow-up|2
6079750|NCT00612105|9686767|FG001|Period Title 1: 6-Week Titration Phase|Lost to Follow-up|0
6079751|NCT00612105|9686766|FG000|Period Title 1: 6-Week Titration Phase|Physician Decision|1
6087648|NCT00669864|9698070|FG000|Overall Study|Withdrawal by Subject|3
6031059|NCT04493931|9627098|FG002|Cohort3:Treatment Period 1(Up to 5 Days)|Protocol Violation|1
6031060|NCT04493931|9627099|FG003|Cohort3:Treatment Period 1(Up to 5 Days)|Protocol Violation|0
6031061|NCT04493931|9627100|FG004|Cohort3:Treatment Period 1(Up to 5 Days)|Protocol Violation|0
6031062|NCT04493931|9627101|FG005|Cohort3:Treatment Period 1(Up to 5 Days)|Protocol Violation|0
6031063|NCT04493931|9627102|FG006|Cohort3:Treatment Period 1(Up to 5 Days)|Protocol Violation|0
6048511|NCT00418886|9647743|FG001|Overall Study|randomised but no treatment received|1
6048512|NCT00418938|9647751|FG000|Overall Study|Reimbursement|1
6048513|NCT00418938|9647752|FG001|Overall Study|Reimbursement|0
6048514|NCT00418938|9647751|FG000|Overall Study|Administrative decision|3
6048515|NCT00418938|9647752|FG001|Overall Study|Administrative decision|3
6048516|NCT00418938|9647751|FG000|Overall Study|Withdrawal by Subject|16
6048517|NCT00418938|9647752|FG001|Overall Study|Withdrawal by Subject|15
6048518|NCT00418938|9647751|FG000|Overall Study|Lost to Follow-up|1
6048519|NCT00418938|9647752|FG001|Overall Study|Lost to Follow-up|3
6048520|NCT00418938|9647751|FG000|Overall Study|Adverse Event|1
6048521|NCT00418938|9647752|FG001|Overall Study|Adverse Event|1
6048522|NCT00418938|9647751|FG000|Overall Study|On-going|1
6048523|NCT00418938|9647752|FG001|Overall Study|On-going|1
6048524|NCT00418938|9647751|FG000|Overall Study|Ineligibility Determined|1
6048525|NCT00418938|9647752|FG001|Overall Study|Ineligibility Determined|0
6048526|NCT00419003|9647795|FG000|Phase I, Ketamine Infusion|Lack of Efficacy|6
6048527|NCT00419003|9647796|FG001|Phase I, Ketamine Infusion|Lack of Efficacy|6
6048528|NCT00419003|9647795|FG000|Phase 2, Riluzole/Placebo Follow-Up|Withdrawal by Subject|1
6048529|NCT00419003|9647796|FG001|Phase 2, Riluzole/Placebo Follow-Up|Withdrawal by Subject|0
6048530|NCT00419094|9647807|FG000|Overall Study|Adverse Event|3
6048531|NCT00419094|9647808|FG001|Overall Study|Adverse Event|7
6048532|NCT00419094|9647807|FG000|Overall Study|Lack of Efficacy|1
6048533|NCT00419094|9647808|FG001|Overall Study|Lack of Efficacy|0
6048534|NCT00419094|9647807|FG000|Overall Study|Lost to Follow-up|0
6048535|NCT00419094|9647808|FG001|Overall Study|Lost to Follow-up|2
6048536|NCT00419094|9647807|FG000|Overall Study|Protocol Violation|1
6048537|NCT00419094|9647808|FG001|Overall Study|Protocol Violation|14
6048538|NCT00419094|9647807|FG000|Overall Study|Withdrawal of consent|1
6048539|NCT00419094|9647808|FG001|Overall Study|Withdrawal of consent|5
6048540|NCT00419094|9647807|FG000|Overall Study|Other: Error determining exit criteria|1
6048541|NCT00419094|9647808|FG001|Overall Study|Other: Error determining exit criteria|0
6048542|NCT00419094|9647807|FG000|Overall Study|Other: Patient non-compliant|0
6048543|NCT00419094|9647808|FG001|Overall Study|Other: Patient non-compliant|1
6048544|NCT00419094|9647807|FG000|Overall Study|Other: No contact for extended period|0
6048545|NCT00419094|9647808|FG001|Overall Study|Other: No contact for extended period|1
6048546|NCT00419120|9647814|FG000|Long Term Follow up Period|study ongoing|10
6048547|NCT00419159|9647820|FG000|Overall Study|Adverse Event|7
6048548|NCT00419159|9647821|FG001|Overall Study|Adverse Event|15
6048549|NCT00419159|9647820|FG000|Overall Study|Abnormal laboratory value(s)|0
6048550|NCT00419159|9647821|FG001|Overall Study|Abnormal laboratory value(s)|2
6048551|NCT00419159|9647820|FG000|Overall Study|Subject's no longer requires study drug|0
6079752|NCT00612105|9686767|FG001|Period Title 1: 6-Week Titration Phase|Physician Decision|1
6079753|NCT00612105|9686766|FG000|Period Title 1: 6-Week Titration Phase|Protocol Violation|1
6079754|NCT00612105|9686767|FG001|Period Title 1: 6-Week Titration Phase|Protocol Violation|0
6079755|NCT00612105|9686766|FG000|Period Title 1: 6-Week Titration Phase|Missed study drug for more than two days|3
6079756|NCT00612105|9686767|FG001|Period Title 1: 6-Week Titration Phase|Missed study drug for more than two days|1
6079757|NCT00612105|9686766|FG000|Period Title 1: 6-Week Titration Phase|Lack of Efficacy|5
6079758|NCT00612105|9686767|FG001|Period Title 1: 6-Week Titration Phase|Lack of Efficacy|0
6079759|NCT00612105|9686766|FG000|Period Title 1: 6-Week Titration Phase|Other|0
6079760|NCT00612105|9686767|FG001|Period Title 1: 6-Week Titration Phase|Other|1
6079761|NCT00612105|9686766|FG000|Period Title 2: 4-Week Maintenance Phase|Adverse Event|9
6079762|NCT00612105|9686767|FG001|Period Title 2: 4-Week Maintenance Phase|Adverse Event|1
6079763|NCT00612105|9686766|FG000|Period Title 2: 4-Week Maintenance Phase|Missed study drug for more than two days|1
6079764|NCT00612105|9686767|FG001|Period Title 2: 4-Week Maintenance Phase|Missed study drug for more than two days|1
6079765|NCT00612105|9686766|FG000|Period Title 2: 4-Week Maintenance Phase|Lost to Follow-up|1
6079766|NCT00612105|9686767|FG001|Period Title 2: 4-Week Maintenance Phase|Lost to Follow-up|0
6079767|NCT00612105|9686766|FG000|Period Title 3: 3-Week Taper Phase|Other|1
6079768|NCT00612105|9686767|FG001|Period Title 3: 3-Week Taper Phase|Other|0
6079769|NCT00612313|9686797|FG000|Overall Study|Withdrawal by Subject|6
6079770|NCT00612313|9686798|FG001|Overall Study|Withdrawal by Subject|9
6079771|NCT00612313|9686797|FG000|Overall Study|Lost to Follow-up|11
6079772|NCT00612313|9686798|FG001|Overall Study|Lost to Follow-up|4
6079773|NCT00612352|9686816|FG000|Overall Study|Adverse Event|1
6079774|NCT00612352|9686817|FG001|Overall Study|Adverse Event|0
6079775|NCT00612352|9686816|FG000|Overall Study|Withdrawal by Subject|3
6079776|NCT00612352|9686817|FG001|Overall Study|Withdrawal by Subject|5
6079777|NCT00612352|9686816|FG000|Overall Study|moved out of state|1
6079778|NCT00612352|9686817|FG001|Overall Study|moved out of state|0
6048552|NCT00419159|9647821|FG001|Overall Study|Subject's no longer requires study drug|1
6048553|NCT00419159|9647820|FG000|Overall Study|Protocol Violation|1
6079779|NCT00612352|9686816|FG000|Overall Study|didn't return calls/show up on test date|4
6031064|NCT04428034|9627132|FG000|Enrollment to Intervention Completion|Protocol Violation|9
6031065|NCT04428034|9627132|FG000|Enrollment to Intervention Completion|Suspected Fraudulent Case|1
6031066|NCT03999554|9627161|FG000|Overall Study|Lost to Follow-up|4
6031067|NCT03999554|9627162|FG001|Overall Study|Lost to Follow-up|5
6031068|NCT03999554|9627163|FG002|Overall Study|Lost to Follow-up|4
6031069|NCT03999554|9627164|FG003|Overall Study|Lost to Follow-up|5
6031070|NCT03999554|9627165|FG004|Overall Study|Lost to Follow-up|8
6031071|NCT03999554|9627161|FG000|Overall Study|Protocol Violation|0
6031072|NCT03999554|9627162|FG001|Overall Study|Protocol Violation|0
6031073|NCT03999554|9627163|FG002|Overall Study|Protocol Violation|5
6031074|NCT03999554|9627164|FG003|Overall Study|Protocol Violation|0
6079780|NCT00612352|9686817|FG001|Overall Study|didn't return calls/show up on test date|1
6079781|NCT00612456|9686837|FG000|Overall Study|Adverse Event|1
6079782|NCT00612456|9686838|FG001|Overall Study|Adverse Event|0
6079783|NCT00612456|9686839|FG002|Overall Study|Adverse Event|0
6079784|NCT00612456|9686837|FG000|Overall Study|Lack of Efficacy|1
6079785|NCT00612456|9686838|FG001|Overall Study|Lack of Efficacy|1
6079786|NCT00612456|9686839|FG002|Overall Study|Lack of Efficacy|0
6079787|NCT00612456|9686837|FG000|Overall Study|Withdrawal by Subject|0
6079788|NCT00612456|9686838|FG001|Overall Study|Withdrawal by Subject|1
6079789|NCT00612456|9686839|FG002|Overall Study|Withdrawal by Subject|0
6079790|NCT00612508|9686851|FG000|Overall Study|Withdrawal by Subject|3
6079791|NCT00612508|9686852|FG001|Overall Study|Withdrawal by Subject|4
6079792|NCT00612534|9686864|FG000|Overall Study|Adverse Event|0
6079793|NCT00612534|9686865|FG001|Overall Study|Adverse Event|4
6079794|NCT00612534|9686866|FG002|Overall Study|Adverse Event|2
6079795|NCT00612534|9686867|FG003|Overall Study|Adverse Event|1
6079796|NCT00612534|9686864|FG000|Overall Study|Lack of Efficacy|13
6079797|NCT00612534|9686865|FG001|Overall Study|Lack of Efficacy|12
6079798|NCT00612534|9686866|FG002|Overall Study|Lack of Efficacy|5
6079799|NCT00612534|9686867|FG003|Overall Study|Lack of Efficacy|16
6079800|NCT00612534|9686864|FG000|Overall Study|Other Reason|0
6079801|NCT00612534|9686865|FG001|Overall Study|Other Reason|1
6079802|NCT00612534|9686866|FG002|Overall Study|Other Reason|0
6079803|NCT00612534|9686867|FG003|Overall Study|Other Reason|0
6079804|NCT00612586|9686913|FG000|Overall Study|Adverse Event|6
6079805|NCT00612586|9686914|FG001|Overall Study|Adverse Event|2
6079806|NCT00612586|9686913|FG000|Overall Study|Death|1
6079807|NCT00612586|9686914|FG001|Overall Study|Death|0
6079808|NCT00612586|9686913|FG000|Overall Study|Entry Criteria Not Met|0
6079809|NCT00612586|9686914|FG001|Overall Study|Entry Criteria Not Met|2
6079810|NCT00612586|9686913|FG000|Overall Study|Withdrawal by Subject|7
6079811|NCT00612586|9686914|FG001|Overall Study|Withdrawal by Subject|9
6079812|NCT00612586|9686913|FG000|Overall Study|Physician Decision|1
6079813|NCT00612586|9686914|FG001|Overall Study|Physician Decision|2
6079814|NCT00612586|9686913|FG000|Overall Study|Sponsor Decision|1
6079815|NCT00612586|9686914|FG001|Overall Study|Sponsor Decision|1
6079816|NCT00612586|9686913|FG000|Overall Study|Progressive Disease|26
6079817|NCT00612586|9686914|FG001|Overall Study|Progressive Disease|24
6079818|NCT00612586|9686913|FG000|Overall Study|Randomized and Not Treated|1
6079819|NCT00612586|9686914|FG001|Overall Study|Randomized and Not Treated|1
6079820|NCT00612690|9686923|FG000|Overall Study|Lost to Follow-up|72
6079821|NCT00612690|9686924|FG001|Overall Study|Lost to Follow-up|98
6079822|NCT00612690|9686923|FG000|Overall Study|Withdrawal by Subject|32
6079823|NCT00612690|9686924|FG001|Overall Study|Withdrawal by Subject|20
6079824|NCT00612690|9686923|FG000|Overall Study|Withdrawal by Site|11
6079825|NCT00612690|9686924|FG001|Overall Study|Withdrawal by Site|0
6079826|NCT00612807|9686963|FG000|Overall Study|Withdrawal by Subject|2
6079827|NCT00612807|9686964|FG001|Overall Study|Withdrawal by Subject|0
6079828|NCT00613015|9686986|FG000|Overall Study|Lost to Follow-up|0
6079829|NCT00613015|9686987|FG001|Overall Study|Lost to Follow-up|1
6079830|NCT00613015|9686988|FG002|Overall Study|Lost to Follow-up|3
6079831|NCT00613015|9686989|FG003|Overall Study|Lost to Follow-up|3
6079832|NCT00613015|9686990|FG004|Overall Study|Lost to Follow-up|2
6079833|NCT00613015|9686991|FG005|Overall Study|Lost to Follow-up|3
6079834|NCT00613080|9687014|FG000|Overall Study|Ineligible / no protocol treatment|11
6079835|NCT00613106|9687020|FG000|Overall Study|Adverse Event|3
6079836|NCT00613106|9687021|FG001|Overall Study|Adverse Event|1
6079837|NCT00613106|9687020|FG000|Overall Study|Withdrawal by Subject|6
6079838|NCT00613106|9687021|FG001|Overall Study|Withdrawal by Subject|3
6079839|NCT00613106|9687020|FG000|Overall Study|Lost to Follow-up|7
6079840|NCT00613106|9687021|FG001|Overall Study|Lost to Follow-up|2
6079841|NCT00613106|9687020|FG000|Overall Study|misc|4
6079842|NCT00613106|9687021|FG001|Overall Study|misc|3
6079843|NCT00613171|9687027|FG000|Overall Study|Adverse Event|7
6079844|NCT00613171|9687027|FG000|Overall Study|Withdrawal by Subject|3
6079845|NCT00613171|9687027|FG000|Overall Study|Reason not Specified|4
6079846|NCT00613301|9687032|FG000|Overall Study|Adverse Event|49
6079847|NCT00613301|9687032|FG000|Overall Study|Lost to Follow-up|88
6079848|NCT00613301|9687032|FG000|Overall Study|Withdrawal by Subject|5
6079849|NCT00613301|9687032|FG000|Overall Study|Death|6
6079850|NCT00613301|9687032|FG000|Overall Study|Lack of Efficacy|13
6031075|NCT03999554|9627165|FG004|Overall Study|Protocol Violation|0
6031076|NCT03999554|9627161|FG000|Overall Study|Pregnancy|0
6031077|NCT03999554|9627162|FG001|Overall Study|Pregnancy|0
6079851|NCT00613301|9687032|FG000|Overall Study|Physician Decision|2
6031078|NCT03999554|9627163|FG002|Overall Study|Pregnancy|1
6031079|NCT03999554|9627164|FG003|Overall Study|Pregnancy|0
6031080|NCT03999554|9627165|FG004|Overall Study|Pregnancy|0
6031081|NCT03999554|9627161|FG000|Overall Study|Withdrawal by Subject|2
6031082|NCT03999554|9627162|FG001|Overall Study|Withdrawal by Subject|2
6031083|NCT03999554|9627163|FG002|Overall Study|Withdrawal by Subject|2
6031084|NCT03999554|9627164|FG003|Overall Study|Withdrawal by Subject|1
6031085|NCT03999554|9627165|FG004|Overall Study|Withdrawal by Subject|1
6031086|NCT03999554|9627161|FG000|Overall Study|failure to comply with protocol requirements|0
6031087|NCT03999554|9627162|FG001|Overall Study|failure to comply with protocol requirements|0
6031088|NCT03999554|9627163|FG002|Overall Study|failure to comply with protocol requirements|0
6031089|NCT03999554|9627164|FG003|Overall Study|failure to comply with protocol requirements|1
6031090|NCT03999554|9627165|FG004|Overall Study|failure to comply with protocol requirements|0
6048554|NCT00419159|9647821|FG001|Overall Study|Protocol Violation|0
6048555|NCT00419159|9647820|FG000|Overall Study|Withdrawal by Subject|10
6048556|NCT00419159|9647821|FG001|Overall Study|Withdrawal by Subject|3
6048557|NCT00419159|9647820|FG000|Overall Study|Lost to Follow-up|0
6048558|NCT00419159|9647821|FG001|Overall Study|Lost to Follow-up|1
6048559|NCT00419159|9647820|FG000|Overall Study|Death|2
6048560|NCT00419159|9647821|FG001|Overall Study|Death|2
6048561|NCT00419159|9647820|FG000|Overall Study|Disease progression|79
6048562|NCT00419159|9647821|FG001|Overall Study|Disease progression|76
6048563|NCT00419263|9647838|FG000|Overall Study|Lost to Follow-up|2
6048564|NCT00419263|9647839|FG001|Overall Study|Lost to Follow-up|1
6048565|NCT00419263|9647840|FG002|Overall Study|Lost to Follow-up|1
6048566|NCT00419263|9647838|FG000|Overall Study|Randomized in Error, Not Treated|1
6048567|NCT00419263|9647839|FG001|Overall Study|Randomized in Error, Not Treated|1
6048568|NCT00419263|9647840|FG002|Overall Study|Randomized in Error, Not Treated|0
6048569|NCT00419263|9647838|FG000|Overall Study|Adverse Event|0
6048570|NCT00419263|9647839|FG001|Overall Study|Adverse Event|0
6048571|NCT00419263|9647840|FG002|Overall Study|Adverse Event|1
6048572|NCT00419263|9647838|FG000|Overall Study|Withdrawal by Subject|0
6048573|NCT00419263|9647839|FG001|Overall Study|Withdrawal by Subject|0
6048574|NCT00419263|9647840|FG002|Overall Study|Withdrawal by Subject|1
6079852|NCT00613301|9687032|FG000|Overall Study|No data was collected|53
6079853|NCT00613301|9687032|FG000|Overall Study|Irregularly enrolled patients|12
6079854|NCT00613314|9687037|FG000|Overall Study|Adverse Event|5
6079855|NCT00613314|9687037|FG000|Overall Study|Protocol Violation|14
6079856|NCT00613314|9687037|FG000|Overall Study|Lost to Follow-up|46
6079857|NCT00613314|9687037|FG000|Overall Study|Other reason not defined above|90
6079858|NCT00613327|9687041|FG000|Overall Study|Adverse Event|38
6079859|NCT00613327|9687041|FG000|Overall Study|Lost to Follow-up|8
6079860|NCT00613327|9687041|FG000|Overall Study|Withdrawal by Subject|6
6079861|NCT00613327|9687041|FG000|Overall Study|Protocol Violation|2
6079862|NCT00613327|9687041|FG000|Overall Study|Other|47
6079863|NCT00613366|9687047|FG000|Overall Study|Withdrawal by Subject|3
6079864|NCT00613366|9687048|FG001|Overall Study|Withdrawal by Subject|2
6079865|NCT00613509|9687078|FG000|Cycle 1|Adverse Event|2
6079866|NCT00613509|9687079|FG001|Cycle 1|Adverse Event|1
6079867|NCT00613509|9687078|FG000|Cycle 1|Disease Progression|2
6079868|NCT00613509|9687079|FG001|Cycle 1|Disease Progression|6
6079869|NCT00613509|9687078|FG000|Cycle 1|Unacceptable Toxicity|1
6079870|NCT00613509|9687079|FG001|Cycle 1|Unacceptable Toxicity|0
6079871|NCT00613509|9687078|FG000|Cycle 1|Other administrative reason|0
6079872|NCT00613509|9687079|FG001|Cycle 1|Other administrative reason|1
6079873|NCT00613574|9687085|FG000|Overall Study|Adverse Event|3
6079874|NCT00613574|9687085|FG000|Overall Study|Lost to Follow-up|2
6079875|NCT00613574|9687085|FG000|Overall Study|Other|1
6079876|NCT00613626|9687092|FG000|Overall Study|Ineligible|0
6079877|NCT00613626|9687093|FG001|Overall Study|Ineligible|1
6079878|NCT00613626|9687094|FG002|Overall Study|Ineligible|0
6079879|NCT00613821|9687103|FG000|Overall Study|Withdrawal by Subject|1
6079880|NCT00613821|9687104|FG001|Overall Study|Withdrawal by Subject|0
6079881|NCT00613821|9687103|FG000|Overall Study|Physician Decision|1
6079882|NCT00613821|9687104|FG001|Overall Study|Physician Decision|1
6079883|NCT00613834|9687112|FG000|Overall Study|Withdrawal by Subject|0
6079884|NCT00613834|9687113|FG001|Overall Study|Withdrawal by Subject|3
6079885|NCT00613925|9687123|FG000|Overall Study|1 did not tolerate outpatient biopsy|0
6079886|NCT00613925|9687124|FG001|Overall Study|1 did not tolerate outpatient biopsy|1
6079887|NCT00613938|9687134|FG000|Overall Study|Withdrawal by Subject|2
6079888|NCT00613938|9687135|FG001|Overall Study|Withdrawal by Subject|4
6048575|NCT00419341|9647858|FG000|Wash in/Wash Out Period|Withdrawal by Subject|8
6048576|NCT00419341|9647858|FG000|Wash in/Wash Out Period|Adverse Event|2
6048577|NCT00419341|9647858|FG000|Wash in/Wash Out Period|Disqualifying laboratory results|1
6079889|NCT00613938|9687136|FG002|Overall Study|Withdrawal by Subject|9
6079890|NCT00613938|9687137|FG003|Overall Study|Withdrawal by Subject|9
6079891|NCT00613938|9687134|FG000|Overall Study|Adverse Event|1
6079892|NCT00613938|9687135|FG001|Overall Study|Adverse Event|4
6048578|NCT00419341|9647858|FG000|Efficacy Period|Withdrawal by Subject|6
6048579|NCT00419341|9647858|FG000|Efficacy Period|Protocol Violation|1
6079893|NCT00613938|9687136|FG002|Overall Study|Adverse Event|8
6079894|NCT00613938|9687137|FG003|Overall Study|Adverse Event|5
6079895|NCT00613938|9687134|FG000|Overall Study|Lack of Efficacy|16
6031091|NCT03651622|9627181|FG000|Diet Period 1 (Randomization 1)|Lost to Follow-up|0
6031092|NCT03651622|9627182|FG001|Diet Period 1 (Randomization 1)|Lost to Follow-up|6
6031093|NCT03651622|9627183|FG002|Diet Period 1 (Randomization 1)|Lost to Follow-up|2
6031094|NCT03651622|9627181|FG000|Diet Period 1 (Randomization 1)|Withdrawal by Subject|4
6031095|NCT03651622|9627182|FG001|Diet Period 1 (Randomization 1)|Withdrawal by Subject|1
6031096|NCT03651622|9627183|FG002|Diet Period 1 (Randomization 1)|Withdrawal by Subject|7
6031097|NCT03651622|9627181|FG000|Diet Period 2 (Randomization 2)|Lost to Follow-up|0
6031098|NCT03651622|9627182|FG001|Diet Period 2 (Randomization 2)|Lost to Follow-up|2
6031099|NCT03651622|9627183|FG002|Diet Period 2 (Randomization 2)|Lost to Follow-up|3
6031100|NCT03651622|9627181|FG000|Diet Period 2 (Randomization 2)|Withdrawal by Subject|2
6031101|NCT03651622|9627182|FG001|Diet Period 2 (Randomization 2)|Withdrawal by Subject|0
6031102|NCT03651622|9627183|FG002|Diet Period 2 (Randomization 2)|Withdrawal by Subject|0
6031103|NCT03651622|9627181|FG000|Diet Period 3 (Randomization 3)|Withdrawal by Subject|0
6031104|NCT03651622|9627182|FG001|Diet Period 3 (Randomization 3)|Withdrawal by Subject|0
6031105|NCT03651622|9627183|FG002|Diet Period 3 (Randomization 3)|Withdrawal by Subject|1
6031106|NCT03563716|9627193|FG000|Overall Study|Death|20
6031107|NCT03563716|9627194|FG001|Overall Study|Death|14
6031108|NCT03563716|9627193|FG000|Overall Study|Withdrawal by Subject|3
6031109|NCT03563716|9627194|FG001|Overall Study|Withdrawal by Subject|3
6079896|NCT00613938|9687135|FG001|Overall Study|Lack of Efficacy|18
6079897|NCT00613938|9687136|FG002|Overall Study|Lack of Efficacy|5
6079898|NCT00613938|9687137|FG003|Overall Study|Lack of Efficacy|9
6079899|NCT00613938|9687134|FG000|Overall Study|Other|1
6031110|NCT03563716|9627193|FG000|Overall Study|Still on Study|45
6031111|NCT03563716|9627194|FG001|Overall Study|Still on Study|50
6031112|NCT03410992|9627202|FG000|Initial Treatment Period: up to Wk16|Adverse Event|0
6031113|NCT03410992|9627203|FG001|Initial Treatment Period: up to Wk16|Adverse Event|5
6031114|NCT03410992|9627204|FG002|Initial Treatment Period: up to Wk16|Adverse Event|0
6031115|NCT03410992|9627205|FG003|Initial Treatment Period: up to Wk16|Adverse Event|0
6031116|NCT03410992|9627206|FG004|Initial Treatment Period: up to Wk16|Adverse Event|0
6031117|NCT03410992|9627207|FG005|Initial Treatment Period: up to Wk16|Adverse Event|0
6079900|NCT00613938|9687135|FG001|Overall Study|Other|2
6079901|NCT00613938|9687136|FG002|Overall Study|Other|1
6079902|NCT00613938|9687137|FG003|Overall Study|Other|3
6079903|NCT00613951|9687150|FG000|Overall Study|Adverse Event|1
6079904|NCT00613951|9687151|FG001|Overall Study|Adverse Event|0
6079905|NCT00613951|9687152|FG002|Overall Study|Adverse Event|1
6079906|NCT00613951|9687150|FG000|Overall Study|Lack of Efficacy|0
6079907|NCT00613951|9687151|FG001|Overall Study|Lack of Efficacy|1
6079908|NCT00613951|9687152|FG002|Overall Study|Lack of Efficacy|1
6079909|NCT00613951|9687150|FG000|Overall Study|Protocol Violation|1
6079910|NCT00613951|9687151|FG001|Overall Study|Protocol Violation|1
6079911|NCT00613951|9687152|FG002|Overall Study|Protocol Violation|1
6079912|NCT00613951|9687150|FG000|Overall Study|Unclassified|5
6079913|NCT00613951|9687151|FG001|Overall Study|Unclassified|3
6079914|NCT00613951|9687152|FG002|Overall Study|Unclassified|2
6079915|NCT00614055|9687166|FG000|Overall Study|Adverse Event|1
6079916|NCT00614055|9687167|FG001|Overall Study|Adverse Event|0
6079917|NCT00614055|9687168|FG002|Overall Study|Adverse Event|0
6079918|NCT00614055|9687166|FG000|Overall Study|Protocol Violation|2
6079919|NCT00614055|9687167|FG001|Overall Study|Protocol Violation|2
6079920|NCT00614055|9687168|FG002|Overall Study|Protocol Violation|1
6079921|NCT00614055|9687166|FG000|Overall Study|Lack of Efficacy|0
6079922|NCT00614055|9687167|FG001|Overall Study|Lack of Efficacy|0
6079923|NCT00614055|9687168|FG002|Overall Study|Lack of Efficacy|2
6079924|NCT00614055|9687166|FG000|Overall Study|Unclassified|1
6079925|NCT00614055|9687167|FG001|Overall Study|Unclassified|4
6079926|NCT00614055|9687168|FG002|Overall Study|Unclassified|2
6079927|NCT00614120|9687183|FG000|Overall Study|Adverse Event|9
6079928|NCT00614120|9687184|FG001|Overall Study|Adverse Event|22
6079929|NCT00614120|9687185|FG002|Overall Study|Adverse Event|30
6079930|NCT00614120|9687186|FG003|Overall Study|Adverse Event|3
6079931|NCT00614120|9687183|FG000|Overall Study|Lack of Efficacy|3
6079932|NCT00614120|9687184|FG001|Overall Study|Lack of Efficacy|3
6079933|NCT00614120|9687185|FG002|Overall Study|Lack of Efficacy|2
6079934|NCT00614120|9687186|FG003|Overall Study|Lack of Efficacy|2
6079935|NCT00614120|9687183|FG000|Overall Study|Protocol Violation|2
6079936|NCT00614120|9687184|FG001|Overall Study|Protocol Violation|5
6079937|NCT00614120|9687185|FG002|Overall Study|Protocol Violation|3
6079938|NCT00614120|9687186|FG003|Overall Study|Protocol Violation|1
6031118|NCT03410992|9627208|FG006|Initial Treatment Period: up to Wk16|Adverse Event|0
6031119|NCT03410992|9627209|FG007|Initial Treatment Period: up to Wk16|Adverse Event|0
6079939|NCT00614120|9687183|FG000|Overall Study|Withdrawal criteria|1
6079940|NCT00614120|9687184|FG001|Overall Study|Withdrawal criteria|0
6079941|NCT00614120|9687185|FG002|Overall Study|Withdrawal criteria|0
6309556|NCT02640612|10038249|FG002|Overall Study|Lost to Follow-up|1
6079942|NCT00614120|9687186|FG003|Overall Study|Withdrawal criteria|0
6079943|NCT00614120|9687183|FG000|Overall Study|Withdrawal by Subject|9
6079944|NCT00614120|9687184|FG001|Overall Study|Withdrawal by Subject|10
6079945|NCT00614120|9687185|FG002|Overall Study|Withdrawal by Subject|16
6079946|NCT00614120|9687186|FG003|Overall Study|Withdrawal by Subject|3
6079947|NCT00614120|9687183|FG000|Overall Study|Did not meet trial criteria|0
6031120|NCT03410992|9627210|FG008|Initial Treatment Period: up to Wk16|Adverse Event|0
6031121|NCT03410992|9627211|FG009|Initial Treatment Period: up to Wk16|Adverse Event|0
6031122|NCT03410992|9627212|FG010|Initial Treatment Period: up to Wk16|Adverse Event|0
6031123|NCT03410992|9627202|FG000|Initial Treatment Period: up to Wk16|Lack of Efficacy|2
6031124|NCT03410992|9627203|FG001|Initial Treatment Period: up to Wk16|Lack of Efficacy|1
6031125|NCT03410992|9627204|FG002|Initial Treatment Period: up to Wk16|Lack of Efficacy|0
6031126|NCT03410992|9627205|FG003|Initial Treatment Period: up to Wk16|Lack of Efficacy|0
6031127|NCT03410992|9627206|FG004|Initial Treatment Period: up to Wk16|Lack of Efficacy|0
6031128|NCT03410992|9627207|FG005|Initial Treatment Period: up to Wk16|Lack of Efficacy|0
6031129|NCT03410992|9627208|FG006|Initial Treatment Period: up to Wk16|Lack of Efficacy|0
6031130|NCT03410992|9627209|FG007|Initial Treatment Period: up to Wk16|Lack of Efficacy|0
6031131|NCT03410992|9627210|FG008|Initial Treatment Period: up to Wk16|Lack of Efficacy|0
6079948|NCT00614120|9687184|FG001|Overall Study|Did not meet trial criteria|1
6079949|NCT00614120|9687185|FG002|Overall Study|Did not meet trial criteria|1
6079950|NCT00614120|9687186|FG003|Overall Study|Did not meet trial criteria|1
6079951|NCT00614120|9687183|FG000|Overall Study|hCG positive (not pregnant)|0
6079952|NCT00614120|9687184|FG001|Overall Study|hCG positive (not pregnant)|0
6079953|NCT00614120|9687185|FG002|Overall Study|hCG positive (not pregnant)|1
6079954|NCT00614120|9687186|FG003|Overall Study|hCG positive (not pregnant)|0
6079955|NCT00614120|9687183|FG000|Overall Study|Hypoglycaemia|0
6079956|NCT00614120|9687184|FG001|Overall Study|Hypoglycaemia|0
6079957|NCT00614120|9687185|FG002|Overall Study|Hypoglycaemia|0
6079958|NCT00614120|9687186|FG003|Overall Study|Hypoglycaemia|1
6079959|NCT00614120|9687183|FG000|Overall Study|Lack of trial product|3
6079960|NCT00614120|9687184|FG001|Overall Study|Lack of trial product|3
6079961|NCT00614120|9687185|FG002|Overall Study|Lack of trial product|2
6079962|NCT00614120|9687186|FG003|Overall Study|Lack of trial product|0
6079963|NCT00614120|9687183|FG000|Overall Study|Late syphilis, latent|1
6079964|NCT00614120|9687184|FG001|Overall Study|Late syphilis, latent|0
6079965|NCT00614120|9687185|FG002|Overall Study|Late syphilis, latent|0
6079966|NCT00614120|9687186|FG003|Overall Study|Late syphilis, latent|0
6079967|NCT00614120|9687183|FG000|Overall Study|Taken inhibition medication eg Prandin|0
6079968|NCT00614120|9687184|FG001|Overall Study|Taken inhibition medication eg Prandin|0
6079969|NCT00614120|9687185|FG002|Overall Study|Taken inhibition medication eg Prandin|1
6079970|NCT00614120|9687186|FG003|Overall Study|Taken inhibition medication eg Prandin|1
6079971|NCT00614120|9687183|FG000|Overall Study|Lost to Follow-up|1
6079972|NCT00614120|9687184|FG001|Overall Study|Lost to Follow-up|2
6079973|NCT00614120|9687185|FG002|Overall Study|Lost to Follow-up|3
6079974|NCT00614120|9687186|FG003|Overall Study|Lost to Follow-up|4
6079975|NCT00614380|9687213|FG000|Overall Study|Adverse Event|14
6079976|NCT00614380|9687214|FG001|Overall Study|Adverse Event|4
6079977|NCT00614380|9687215|FG002|Overall Study|Adverse Event|0
6079978|NCT00614380|9687216|FG003|Overall Study|Adverse Event|0
6079979|NCT00614380|9687213|FG000|Overall Study|Lost to Follow-up|6
6079980|NCT00614380|9687214|FG001|Overall Study|Lost to Follow-up|1
6079981|NCT00614380|9687215|FG002|Overall Study|Lost to Follow-up|0
6079982|NCT00614380|9687216|FG003|Overall Study|Lost to Follow-up|0
6079983|NCT00614380|9687213|FG000|Overall Study|Non compliant with the protocol|12
6079984|NCT00614380|9687214|FG001|Overall Study|Non compliant with the protocol|2
6079985|NCT00614380|9687215|FG002|Overall Study|Non compliant with the protocol|1
6079986|NCT00614380|9687216|FG003|Overall Study|Non compliant with the protocol|2
6079987|NCT00614380|9687213|FG000|Overall Study|Consent withdrawn|3
6079988|NCT00614380|9687214|FG001|Overall Study|Consent withdrawn|1
6079989|NCT00614380|9687215|FG002|Overall Study|Consent withdrawn|0
6079990|NCT00614380|9687216|FG003|Overall Study|Consent withdrawn|0
6079991|NCT00614393|9687236|FG000|Overall Study|Adverse Event|20
6079992|NCT00614393|9687237|FG001|Overall Study|Adverse Event|2
6079993|NCT00614393|9687238|FG002|Overall Study|Adverse Event|3
6079994|NCT00614393|9687239|FG003|Overall Study|Adverse Event|13
6079995|NCT00614393|9687240|FG004|Overall Study|Adverse Event|21
6146381|NCT01077076|9781132|FG000|Third Intervention|Death in the participant's family|0
6146382|NCT01077076|9781133|FG001|Third Intervention|Death in the participant's family|0
6146383|NCT01077076|9781134|FG002|Third Intervention|Death in the participant's family|0
6146384|NCT01077076|9781135|FG003|Third Intervention|Death in the participant's family|0
6146385|NCT01077076|9781136|FG004|Third Intervention|Death in the participant's family|0
6146386|NCT01077076|9781137|FG005|Third Intervention|Death in the participant's family|1
6146387|NCT01077128|9781145|FG000|Overall Study|Adverse Event|8
6146388|NCT01077128|9781145|FG000|Overall Study|Lack of Efficacy|1
6031132|NCT03410992|9627211|FG009|Initial Treatment Period: up to Wk16|Lack of Efficacy|0
6031133|NCT03410992|9627212|FG010|Initial Treatment Period: up to Wk16|Lack of Efficacy|0
6079996|NCT00614393|9687236|FG000|Overall Study|Lost to Follow-up|0
6079997|NCT00614393|9687237|FG001|Overall Study|Lost to Follow-up|0
6079998|NCT00614393|9687238|FG002|Overall Study|Lost to Follow-up|0
6079999|NCT00614393|9687239|FG003|Overall Study|Lost to Follow-up|1
6080000|NCT00614393|9687240|FG004|Overall Study|Lost to Follow-up|2
6080001|NCT00614393|9687236|FG000|Overall Study|Physician Decision|17
6080002|NCT00614393|9687237|FG001|Overall Study|Physician Decision|0
6080003|NCT00614393|9687238|FG002|Overall Study|Physician Decision|1
6080004|NCT00614393|9687239|FG003|Overall Study|Physician Decision|8
6146389|NCT01077128|9781145|FG000|Overall Study|Disease exacerbation|1
6031134|NCT03410992|9627202|FG000|Initial Treatment Period: up to Wk16|Lost to Follow-up|1
6031135|NCT03410992|9627203|FG001|Initial Treatment Period: up to Wk16|Lost to Follow-up|3
6031136|NCT03410992|9627204|FG002|Initial Treatment Period: up to Wk16|Lost to Follow-up|0
6031137|NCT03410992|9627205|FG003|Initial Treatment Period: up to Wk16|Lost to Follow-up|0
6031138|NCT03410992|9627206|FG004|Initial Treatment Period: up to Wk16|Lost to Follow-up|0
6031139|NCT03410992|9627207|FG005|Initial Treatment Period: up to Wk16|Lost to Follow-up|0
6031140|NCT03410992|9627208|FG006|Initial Treatment Period: up to Wk16|Lost to Follow-up|0
6031141|NCT03410992|9627209|FG007|Initial Treatment Period: up to Wk16|Lost to Follow-up|0
6031142|NCT03410992|9627210|FG008|Initial Treatment Period: up to Wk16|Lost to Follow-up|0
6031143|NCT03410992|9627211|FG009|Initial Treatment Period: up to Wk16|Lost to Follow-up|0
6031144|NCT03410992|9627212|FG010|Initial Treatment Period: up to Wk16|Lost to Follow-up|0
6031145|NCT03410992|9627202|FG000|Initial Treatment Period: up to Wk16|Withdrawal by Subject|1
6031146|NCT03410992|9627203|FG001|Initial Treatment Period: up to Wk16|Withdrawal by Subject|0
6031147|NCT03410992|9627204|FG002|Initial Treatment Period: up to Wk16|Withdrawal by Subject|0
6031148|NCT03410992|9627205|FG003|Initial Treatment Period: up to Wk16|Withdrawal by Subject|0
6031149|NCT03410992|9627206|FG004|Initial Treatment Period: up to Wk16|Withdrawal by Subject|0
6031150|NCT03410992|9627207|FG005|Initial Treatment Period: up to Wk16|Withdrawal by Subject|0
6031151|NCT03410992|9627208|FG006|Initial Treatment Period: up to Wk16|Withdrawal by Subject|0
6031152|NCT03410992|9627209|FG007|Initial Treatment Period: up to Wk16|Withdrawal by Subject|0
6031153|NCT03410992|9627210|FG008|Initial Treatment Period: up to Wk16|Withdrawal by Subject|0
6031154|NCT03410992|9627211|FG009|Initial Treatment Period: up to Wk16|Withdrawal by Subject|0
6031155|NCT03410992|9627212|FG010|Initial Treatment Period: up to Wk16|Withdrawal by Subject|0
6031156|NCT03410992|9627202|FG000|Week 16 Assessment|PASI90 Non-Response at Week 16|81
6031157|NCT03410992|9627203|FG001|Week 16 Assessment|PASI90 Non-Response at Week 16|23
6031158|NCT03410992|9627204|FG002|Week 16 Assessment|PASI90 Non-Response at Week 16|0
6031159|NCT03410992|9627205|FG003|Week 16 Assessment|PASI90 Non-Response at Week 16|0
6031160|NCT03410992|9627206|FG004|Week 16 Assessment|PASI90 Non-Response at Week 16|0
6031161|NCT03410992|9627207|FG005|Week 16 Assessment|PASI90 Non-Response at Week 16|0
6031162|NCT03410992|9627208|FG006|Week 16 Assessment|PASI90 Non-Response at Week 16|0
6031163|NCT03410992|9627209|FG007|Week 16 Assessment|PASI90 Non-Response at Week 16|0
6080005|NCT00614393|9687240|FG004|Overall Study|Physician Decision|9
6080006|NCT00614393|9687236|FG000|Overall Study|Progressive Disease|118
6080007|NCT00614393|9687237|FG001|Overall Study|Progressive Disease|5
6080008|NCT00614393|9687238|FG002|Overall Study|Progressive Disease|5
6080009|NCT00614393|9687239|FG003|Overall Study|Progressive Disease|138
6080010|NCT00614393|9687240|FG004|Overall Study|Progressive Disease|130
6080011|NCT00614393|9687236|FG000|Overall Study|Protocol Violation|1
6080012|NCT00614393|9687237|FG001|Overall Study|Protocol Violation|0
6080013|NCT00614393|9687238|FG002|Overall Study|Protocol Violation|0
6080014|NCT00614393|9687239|FG003|Overall Study|Protocol Violation|0
6080015|NCT00614393|9687240|FG004|Overall Study|Protocol Violation|0
6080016|NCT00614393|9687236|FG000|Overall Study|Terminated by Sponsor|0
6080017|NCT00614393|9687237|FG001|Overall Study|Terminated by Sponsor|0
6080018|NCT00614393|9687238|FG002|Overall Study|Terminated by Sponsor|0
6080019|NCT00614393|9687239|FG003|Overall Study|Terminated by Sponsor|0
6080020|NCT00614393|9687240|FG004|Overall Study|Terminated by Sponsor|1
6080021|NCT00614393|9687236|FG000|Overall Study|Withdrawal by Subject|20
6080022|NCT00614393|9687237|FG001|Overall Study|Withdrawal by Subject|1
6080023|NCT00614393|9687238|FG002|Overall Study|Withdrawal by Subject|1
6080024|NCT00614393|9687239|FG003|Overall Study|Withdrawal by Subject|16
6080025|NCT00614393|9687240|FG004|Overall Study|Withdrawal by Subject|13
6080026|NCT00614393|9687236|FG000|Overall Study|Other|4
6080027|NCT00614393|9687237|FG001|Overall Study|Other|0
6080028|NCT00614393|9687238|FG002|Overall Study|Other|0
6080029|NCT00614393|9687239|FG003|Overall Study|Other|4
6080030|NCT00614393|9687240|FG004|Overall Study|Other|2
6080031|NCT00614393|9687236|FG000|Overall Study|Not Treated|0
6080032|NCT00614393|9687237|FG001|Overall Study|Not Treated|0
6080033|NCT00614393|9687238|FG002|Overall Study|Not Treated|0
6080034|NCT00614393|9687239|FG003|Overall Study|Not Treated|0
6080035|NCT00614393|9687240|FG004|Overall Study|Not Treated|2
6087649|NCT00669864|9698070|FG000|Overall Study|Other|2
6087650|NCT00669877|9698074|FG000|Overall Study|Disease Progression/Death|4
6087651|NCT00669903|9698082|FG000|Overall Study|Adverse Event|0
6087652|NCT00669903|9698083|FG001|Overall Study|Adverse Event|1
6087653|NCT00669903|9698084|FG002|Overall Study|Adverse Event|3
6087654|NCT00669903|9698085|FG003|Overall Study|Adverse Event|1
6087655|NCT00669903|9698082|FG000|Overall Study|Withdrawal by Subject|0
6087656|NCT00669903|9698083|FG001|Overall Study|Withdrawal by Subject|2
6087657|NCT00669903|9698084|FG002|Overall Study|Withdrawal by Subject|2
6087658|NCT00669903|9698085|FG003|Overall Study|Withdrawal by Subject|2
6087659|NCT00669903|9698082|FG000|Overall Study|Lost to Follow-up|1
6087660|NCT00669903|9698083|FG001|Overall Study|Lost to Follow-up|1
6087661|NCT00669903|9698084|FG002|Overall Study|Lost to Follow-up|0
6087662|NCT00669903|9698085|FG003|Overall Study|Lost to Follow-up|1
6087663|NCT00669903|9698082|FG000|Overall Study|Protocol Violation|0
6087664|NCT00669903|9698083|FG001|Overall Study|Protocol Violation|1
6087665|NCT00669903|9698084|FG002|Overall Study|Protocol Violation|0
6087666|NCT00669903|9698085|FG003|Overall Study|Protocol Violation|0
6031164|NCT03410992|9627210|FG008|Week 16 Assessment|PASI90 Non-Response at Week 16|0
6031165|NCT03410992|9627211|FG009|Week 16 Assessment|PASI90 Non-Response at Week 16|0
6031166|NCT03410992|9627212|FG010|Week 16 Assessment|PASI90 Non-Response at Week 16|0
6031167|NCT03410992|9627202|FG000|Week 16 Assessment|Incorrect escapers|0
6031168|NCT03410992|9627203|FG001|Week 16 Assessment|Incorrect escapers|6
6031169|NCT03410992|9627204|FG002|Week 16 Assessment|Incorrect escapers|0
6031170|NCT03410992|9627205|FG003|Week 16 Assessment|Incorrect escapers|0
6031171|NCT03410992|9627206|FG004|Week 16 Assessment|Incorrect escapers|0
6031172|NCT03410992|9627207|FG005|Week 16 Assessment|Incorrect escapers|0
6031173|NCT03410992|9627208|FG006|Week 16 Assessment|Incorrect escapers|0
6031174|NCT03410992|9627209|FG007|Week 16 Assessment|Incorrect escapers|0
6031175|NCT03410992|9627210|FG008|Week 16 Assessment|Incorrect escapers|0
6031176|NCT03410992|9627211|FG009|Week 16 Assessment|Incorrect escapers|0
6031177|NCT03410992|9627212|FG010|Week 16 Assessment|Incorrect escapers|0
6031178|NCT03410992|9627202|FG000|Randomized-Withdrawal Period: up to Wk56|Adverse Event|0
6031179|NCT03410992|9627203|FG001|Randomized-Withdrawal Period: up to Wk56|Adverse Event|0
6031180|NCT03410992|9627204|FG002|Randomized-Withdrawal Period: up to Wk56|Adverse Event|0
6080036|NCT00614523|9687290|FG000|Overall Study|Adverse Event|4
6080037|NCT00614523|9687291|FG001|Overall Study|Adverse Event|20
6080038|NCT00614523|9687290|FG000|Overall Study|Death|5
6080039|NCT00614523|9687291|FG001|Overall Study|Death|8
6080040|NCT00614523|9687290|FG000|Overall Study|Lack of Efficacy|9
6080041|NCT00614523|9687291|FG001|Overall Study|Lack of Efficacy|11
6080042|NCT00614523|9687290|FG000|Overall Study|Lost to Follow-up|0
6080043|NCT00614523|9687291|FG001|Overall Study|Lost to Follow-up|1
6080044|NCT00614523|9687290|FG000|Overall Study|Protocol Violation|3
6080045|NCT00614523|9687291|FG001|Overall Study|Protocol Violation|2
6080046|NCT00614523|9687290|FG000|Overall Study|Withdrawal by Subject|12
6031181|NCT03410992|9627205|FG003|Randomized-Withdrawal Period: up to Wk56|Adverse Event|3
6031182|NCT03410992|9627206|FG004|Randomized-Withdrawal Period: up to Wk56|Adverse Event|2
6031183|NCT03410992|9627207|FG005|Randomized-Withdrawal Period: up to Wk56|Adverse Event|0
6031184|NCT03410992|9627208|FG006|Randomized-Withdrawal Period: up to Wk56|Adverse Event|0
6031185|NCT03410992|9627209|FG007|Randomized-Withdrawal Period: up to Wk56|Adverse Event|0
6031186|NCT03410992|9627210|FG008|Randomized-Withdrawal Period: up to Wk56|Adverse Event|0
6031187|NCT03410992|9627211|FG009|Randomized-Withdrawal Period: up to Wk56|Adverse Event|0
6031188|NCT03410992|9627212|FG010|Randomized-Withdrawal Period: up to Wk56|Adverse Event|0
6031189|NCT03410992|9627202|FG000|Randomized-Withdrawal Period: up to Wk56|Lost to Follow-up|0
6031190|NCT03410992|9627203|FG001|Randomized-Withdrawal Period: up to Wk56|Lost to Follow-up|0
6031191|NCT03410992|9627204|FG002|Randomized-Withdrawal Period: up to Wk56|Lost to Follow-up|0
6031192|NCT03410992|9627205|FG003|Randomized-Withdrawal Period: up to Wk56|Lost to Follow-up|2
6031193|NCT03410992|9627206|FG004|Randomized-Withdrawal Period: up to Wk56|Lost to Follow-up|1
6031194|NCT03410992|9627207|FG005|Randomized-Withdrawal Period: up to Wk56|Lost to Follow-up|2
6031195|NCT03410992|9627208|FG006|Randomized-Withdrawal Period: up to Wk56|Lost to Follow-up|0
6031196|NCT03410992|9627209|FG007|Randomized-Withdrawal Period: up to Wk56|Lost to Follow-up|0
6031197|NCT03410992|9627210|FG008|Randomized-Withdrawal Period: up to Wk56|Lost to Follow-up|0
6031198|NCT03410992|9627211|FG009|Randomized-Withdrawal Period: up to Wk56|Lost to Follow-up|0
6048580|NCT00419341|9647858|FG000|Efficacy Period|Lost to Follow-up|1
6080047|NCT00614523|9687291|FG001|Overall Study|Withdrawal by Subject|22
6080048|NCT00614523|9687290|FG000|Overall Study|Other|6
6080049|NCT00614523|9687291|FG001|Overall Study|Other|11
6080050|NCT00614523|9687290|FG000|Overall Study|Ineligibility Determined|1
6080051|NCT00614523|9687291|FG001|Overall Study|Ineligibility Determined|2
6080052|NCT00614523|9687290|FG000|Overall Study|Disease Progression|0
6080053|NCT00614523|9687291|FG001|Overall Study|Disease Progression|8
6080054|NCT00614523|9687290|FG000|Overall Study|Administrative Decision|23
6080055|NCT00614523|9687291|FG001|Overall Study|Administrative Decision|46
6080056|NCT00614575|9687297|FG000|Overall Study|Adverse Event|106
6080057|NCT00614575|9687297|FG000|Overall Study|Lost to Follow-up|55
6080058|NCT00614575|9687297|FG000|Overall Study|Lack of Efficacy|14
6080059|NCT00614575|9687297|FG000|Overall Study|Withdrawal by Subject|6
6080060|NCT00614575|9687297|FG000|Overall Study|Death|3
6080061|NCT00614575|9687297|FG000|Overall Study|Physician Decision|2
6080062|NCT00614575|9687297|FG000|Overall Study|No data were collected.|18
6080063|NCT00614575|9687297|FG000|Overall Study|Irregularly enrolled patients|23
6080064|NCT00614575|9687297|FG000|Overall Study|No treatment|1
6080065|NCT00614614|9687303|FG000|Primary Vaccination Phase|Adverse Event|6
6080066|NCT00614614|9687304|FG001|Primary Vaccination Phase|Adverse Event|0
6080067|NCT00614614|9687305|FG002|Primary Vaccination Phase|Adverse Event|0
6080068|NCT00614614|9687306|FG003|Primary Vaccination Phase|Adverse Event|0
6080069|NCT00614614|9687307|FG004|Primary Vaccination Phase|Adverse Event|0
6080070|NCT00614614|9687303|FG000|Primary Vaccination Phase|Withdrawal by Subject|45
6080071|NCT00614614|9687304|FG001|Primary Vaccination Phase|Withdrawal by Subject|6
6080072|NCT00614614|9687305|FG002|Primary Vaccination Phase|Withdrawal by Subject|0
6080073|NCT00614614|9687306|FG003|Primary Vaccination Phase|Withdrawal by Subject|0
6080074|NCT00614614|9687307|FG004|Primary Vaccination Phase|Withdrawal by Subject|0
6080075|NCT00614614|9687303|FG000|Primary Vaccination Phase|Lost to Follow-up|26
6146390|NCT01077128|9781145|FG000|Overall Study|Adverse event and consent withdrawal|1
6146391|NCT01077128|9781145|FG000|Overall Study|Adverse event and disease exacerbation|1
6031199|NCT03410992|9627212|FG010|Randomized-Withdrawal Period: up to Wk56|Lost to Follow-up|0
6031200|NCT03410992|9627202|FG000|Randomized-Withdrawal Period: up to Wk56|Withdrawal by Subject|0
6031201|NCT03410992|9627203|FG001|Randomized-Withdrawal Period: up to Wk56|Withdrawal by Subject|0
6031202|NCT03410992|9627204|FG002|Randomized-Withdrawal Period: up to Wk56|Withdrawal by Subject|0
6031203|NCT03410992|9627205|FG003|Randomized-Withdrawal Period: up to Wk56|Withdrawal by Subject|0
6031204|NCT03410992|9627206|FG004|Randomized-Withdrawal Period: up to Wk56|Withdrawal by Subject|0
6031205|NCT03410992|9627207|FG005|Randomized-Withdrawal Period: up to Wk56|Withdrawal by Subject|3
6031206|NCT03410992|9627208|FG006|Randomized-Withdrawal Period: up to Wk56|Withdrawal by Subject|0
6031207|NCT03410992|9627209|FG007|Randomized-Withdrawal Period: up to Wk56|Withdrawal by Subject|0
6031208|NCT03410992|9627210|FG008|Randomized-Withdrawal Period: up to Wk56|Withdrawal by Subject|0
6031209|NCT03410992|9627211|FG009|Randomized-Withdrawal Period: up to Wk56|Withdrawal by Subject|0
6080076|NCT00614614|9687304|FG001|Primary Vaccination Phase|Lost to Follow-up|8
6080077|NCT00614614|9687305|FG002|Primary Vaccination Phase|Lost to Follow-up|0
6080078|NCT00614614|9687306|FG003|Primary Vaccination Phase|Lost to Follow-up|0
6080079|NCT00614614|9687307|FG004|Primary Vaccination Phase|Lost to Follow-up|0
6080080|NCT00614614|9687303|FG000|Primary Vaccination Phase|Protocol Violation|9
6080081|NCT00614614|9687304|FG001|Primary Vaccination Phase|Protocol Violation|3
6080082|NCT00614614|9687305|FG002|Primary Vaccination Phase|Protocol Violation|0
6080083|NCT00614614|9687306|FG003|Primary Vaccination Phase|Protocol Violation|0
6080084|NCT00614614|9687307|FG004|Primary Vaccination Phase|Protocol Violation|0
6080085|NCT00614614|9687303|FG000|Primary Vaccination Phase|Other|4
6080086|NCT00614614|9687304|FG001|Primary Vaccination Phase|Other|0
6080087|NCT00614614|9687305|FG002|Primary Vaccination Phase|Other|0
6080088|NCT00614614|9687306|FG003|Primary Vaccination Phase|Other|0
6080089|NCT00614614|9687307|FG004|Primary Vaccination Phase|Other|0
6080090|NCT00614614|9687303|FG000|Booster Vaccination Phase|Adverse Event|0
6080091|NCT00614614|9687304|FG001|Booster Vaccination Phase|Adverse Event|0
6080092|NCT00614614|9687305|FG002|Booster Vaccination Phase|Adverse Event|1
6080093|NCT00614614|9687306|FG003|Booster Vaccination Phase|Adverse Event|1
6080094|NCT00614614|9687307|FG004|Booster Vaccination Phase|Adverse Event|0
6080095|NCT00614614|9687303|FG000|Booster Vaccination Phase|Withdrawal by Subject|0
6080096|NCT00614614|9687304|FG001|Booster Vaccination Phase|Withdrawal by Subject|0
6146392|NCT01077128|9781145|FG000|Overall Study|Lack of efficacy/disease exacerbation|1
6146393|NCT01077128|9781145|FG000|Overall Study|Other|54
6146394|NCT01077154|9781201|FG000|Overall Study|Protocol-specified Criteria: Study Ended|1524
6146395|NCT01077154|9781202|FG001|Overall Study|Protocol-specified Criteria: Study Ended|1514
6146396|NCT01077154|9781201|FG000|Overall Study|Withdrawal by Subject|369
6146397|NCT01077154|9781202|FG001|Overall Study|Withdrawal by Subject|385
6146398|NCT01077154|9781201|FG000|Overall Study|Death|215
6146399|NCT01077154|9781202|FG001|Overall Study|Death|214
6146400|NCT01077154|9781201|FG000|Overall Study|Lost to Follow-up|43
6031210|NCT03410992|9627212|FG010|Randomized-Withdrawal Period: up to Wk56|Withdrawal by Subject|0
6031211|NCT03410992|9627202|FG000|Randomized-Withdrawal Period: up to Wk56|Relapse at Week 20 or later|0
6031212|NCT03410992|9627203|FG001|Randomized-Withdrawal Period: up to Wk56|Relapse at Week 20 or later|0
6031213|NCT03410992|9627204|FG002|Randomized-Withdrawal Period: up to Wk56|Relapse at Week 20 or later|0
6031214|NCT03410992|9627205|FG003|Randomized-Withdrawal Period: up to Wk56|Relapse at Week 20 or later|67
6031215|NCT03410992|9627206|FG004|Randomized-Withdrawal Period: up to Wk56|Relapse at Week 20 or later|4
6031216|NCT03410992|9627207|FG005|Randomized-Withdrawal Period: up to Wk56|Relapse at Week 20 or later|7
6031217|NCT03410992|9627208|FG006|Randomized-Withdrawal Period: up to Wk56|Relapse at Week 20 or later|0
6031218|NCT03410992|9627209|FG007|Randomized-Withdrawal Period: up to Wk56|Relapse at Week 20 or later|0
6031219|NCT03410992|9627210|FG008|Randomized-Withdrawal Period: up to Wk56|Relapse at Week 20 or later|0
6031220|NCT03410992|9627211|FG009|Randomized-Withdrawal Period: up to Wk56|Relapse at Week 20 or later|0
6031221|NCT03410992|9627212|FG010|Randomized-Withdrawal Period: up to Wk56|Relapse at Week 20 or later|0
6031222|NCT03410992|9627202|FG000|Escape Treatment: 12 Weeks|Adverse Event|0
6031223|NCT03410992|9627203|FG001|Escape Treatment: 12 Weeks|Adverse Event|0
6031224|NCT03410992|9627204|FG002|Escape Treatment: 12 Weeks|Adverse Event|0
6031225|NCT03410992|9627205|FG003|Escape Treatment: 12 Weeks|Adverse Event|0
6031226|NCT03410992|9627206|FG004|Escape Treatment: 12 Weeks|Adverse Event|0
6031227|NCT03410992|9627207|FG005|Escape Treatment: 12 Weeks|Adverse Event|0
6031228|NCT03410992|9627208|FG006|Escape Treatment: 12 Weeks|Adverse Event|0
6031229|NCT03410992|9627209|FG007|Escape Treatment: 12 Weeks|Adverse Event|1
6031230|NCT03410992|9627210|FG008|Escape Treatment: 12 Weeks|Adverse Event|0
6031231|NCT03410992|9627211|FG009|Escape Treatment: 12 Weeks|Adverse Event|0
6031232|NCT03410992|9627212|FG010|Escape Treatment: 12 Weeks|Adverse Event|0
6031233|NCT03410992|9627202|FG000|Escape Treatment: 12 Weeks|Withdrawal by Subject|0
6031234|NCT03410992|9627203|FG001|Escape Treatment: 12 Weeks|Withdrawal by Subject|0
6080097|NCT00614614|9687305|FG002|Booster Vaccination Phase|Withdrawal by Subject|4
6146401|NCT01077154|9781202|FG001|Overall Study|Lost to Follow-up|35
6146402|NCT01077154|9781201|FG000|Overall Study|Noncompliance|22
6146403|NCT01077154|9781202|FG001|Overall Study|Noncompliance|20
6146404|NCT01077154|9781201|FG000|Overall Study|Disease Progression|18
6146405|NCT01077154|9781202|FG001|Overall Study|Disease Progression|20
6146406|NCT01077154|9781201|FG000|Overall Study|Ineligibility Determined|10
6031235|NCT03410992|9627204|FG002|Escape Treatment: 12 Weeks|Withdrawal by Subject|0
6031236|NCT03410992|9627205|FG003|Escape Treatment: 12 Weeks|Withdrawal by Subject|0
6031237|NCT03410992|9627206|FG004|Escape Treatment: 12 Weeks|Withdrawal by Subject|0
6031238|NCT03410992|9627207|FG005|Escape Treatment: 12 Weeks|Withdrawal by Subject|0
6031239|NCT03410992|9627208|FG006|Escape Treatment: 12 Weeks|Withdrawal by Subject|0
6031240|NCT03410992|9627209|FG007|Escape Treatment: 12 Weeks|Withdrawal by Subject|0
6031241|NCT03410992|9627210|FG008|Escape Treatment: 12 Weeks|Withdrawal by Subject|1
6031242|NCT03410992|9627211|FG009|Escape Treatment: 12 Weeks|Withdrawal by Subject|0
6031243|NCT03410992|9627212|FG010|Escape Treatment: 12 Weeks|Withdrawal by Subject|0
6031244|NCT03197935|9627244|FG000|Overall Study|Death due to any cause|9
6031245|NCT03197935|9627245|FG001|Overall Study|Death due to any cause|7
6031246|NCT03197935|9627244|FG000|Overall Study|Lost to Follow-up|0
6031247|NCT03197935|9627245|FG001|Overall Study|Lost to Follow-up|3
6031248|NCT03197935|9627244|FG000|Overall Study|Physician Decision|0
6031249|NCT03197935|9627245|FG001|Overall Study|Physician Decision|1
6031250|NCT03197935|9627244|FG000|Overall Study|Withdrawal by Subject|11
6031251|NCT03197935|9627245|FG001|Overall Study|Withdrawal by Subject|7
6031252|NCT03197935|9627244|FG000|Overall Study|On-Going in Study|147
6031253|NCT03197935|9627245|FG001|Overall Study|On-Going in Study|146
6031254|NCT03197935|9627244|FG000|Overall Study|Did not receive any study treatment|1
6031255|NCT03197935|9627245|FG001|Overall Study|Did not receive any study treatment|1
6031256|NCT02678351|9627284|FG000|Overall Study|Withdrawal by Subject|1
6031257|NCT02272790|9627298|FG000|Overall Study|Physician Decision|0
6031258|NCT02272790|9627299|FG001|Overall Study|Physician Decision|1
6031259|NCT02272790|9627300|FG002|Overall Study|Physician Decision|0
6031260|NCT02272790|9627301|FG003|Overall Study|Physician Decision|0
6031261|NCT02272790|9627302|FG004|Overall Study|Physician Decision|0
6031262|NCT02272790|9627303|FG005|Overall Study|Physician Decision|0
6048581|NCT00419341|9647858|FG000|Efficacy Period|Non-compliance|1
6048582|NCT00419341|9647858|FG000|Efficacy Period|Termination of study site|1
6048583|NCT00419380|9647866|FG000|Overall Study|Lack of Efficacy|1
6048584|NCT00419380|9647867|FG001|Overall Study|Lack of Efficacy|7
6048585|NCT00419380|9647866|FG000|Overall Study|Physician Decision|0
6048586|NCT00419380|9647867|FG001|Overall Study|Physician Decision|1
6048587|NCT00419380|9647866|FG000|Overall Study|Lost to Follow-up|0
6048588|NCT00419380|9647867|FG001|Overall Study|Lost to Follow-up|1
6048589|NCT00419380|9647866|FG000|Overall Study|Withdrawal by Subject|0
6048590|NCT00419380|9647867|FG001|Overall Study|Withdrawal by Subject|1
6048591|NCT00419393|9647873|FG000|Overall Study|Adverse Event|5
6048592|NCT00419393|9647873|FG000|Overall Study|Protocol Violation|5
6048593|NCT00419393|9647873|FG000|Overall Study|Withdrawal by Subject|7
6048594|NCT00419393|9647873|FG000|Overall Study|Other: Sponsor request|3
6048595|NCT00419393|9647873|FG000|Overall Study|Other: Subject had temporal lobectomy|1
6048596|NCT00419393|9647873|FG000|Overall Study|Other: Site closure|1
6048597|NCT00419393|9647873|FG000|Overall Study|Other: Other health problems|1
6048598|NCT00419393|9647873|FG000|Overall Study|Other: Investigator decision|1
6048599|NCT00419562|9647892|FG000|Overall Study|Lost to Follow-up|12
6048600|NCT00419562|9647893|FG001|Overall Study|Lost to Follow-up|13
6048601|NCT00419562|9647892|FG000|Overall Study|Withdrawal by Subject|20
6048602|NCT00419562|9647893|FG001|Overall Study|Withdrawal by Subject|18
6048603|NCT00419562|9647892|FG000|Overall Study|Participant Institutionalized|1
6048604|NCT00419562|9647893|FG001|Overall Study|Participant Institutionalized|0
6048605|NCT00419744|9647906|FG000|Overall Study|Adverse Event|39
6048606|NCT00419744|9647907|FG001|Overall Study|Adverse Event|40
6048607|NCT00419744|9647908|FG002|Overall Study|Adverse Event|50
6048608|NCT00419744|9647906|FG000|Overall Study|Withdrawal by Subject|45
6048609|NCT00419744|9647907|FG001|Overall Study|Withdrawal by Subject|49
6048610|NCT00419744|9647908|FG002|Overall Study|Withdrawal by Subject|52
6048611|NCT00419744|9647906|FG000|Overall Study|Lost to Follow-up|8
6048612|NCT00419744|9647907|FG001|Overall Study|Lost to Follow-up|10
6048613|NCT00419744|9647908|FG002|Overall Study|Lost to Follow-up|6
6048614|NCT00419744|9647906|FG000|Overall Study|Protocol Violation|4
6048615|NCT00419744|9647907|FG001|Overall Study|Protocol Violation|7
6048616|NCT00419744|9647908|FG002|Overall Study|Protocol Violation|8
6048617|NCT00419744|9647906|FG000|Overall Study|Randomized in error|9
6080098|NCT00614614|9687306|FG003|Booster Vaccination Phase|Withdrawal by Subject|3
6080099|NCT00614614|9687307|FG004|Booster Vaccination Phase|Withdrawal by Subject|4
6080100|NCT00614614|9687303|FG000|Booster Vaccination Phase|Lost to Follow-up|0
6080101|NCT00614614|9687304|FG001|Booster Vaccination Phase|Lost to Follow-up|5
6080102|NCT00614614|9687305|FG002|Booster Vaccination Phase|Lost to Follow-up|17
6080103|NCT00614614|9687306|FG003|Booster Vaccination Phase|Lost to Follow-up|10
6080104|NCT00614614|9687307|FG004|Booster Vaccination Phase|Lost to Follow-up|8
6048618|NCT00419744|9647907|FG001|Overall Study|Randomized in error|6
6048619|NCT00419744|9647908|FG002|Overall Study|Randomized in error|7
6048620|NCT00419744|9647906|FG000|Overall Study|Moving out of state|2
6080105|NCT00614614|9687303|FG000|Booster Vaccination Phase|Protocol Violation|0
6048621|NCT00419744|9647907|FG001|Overall Study|Moving out of state|0
6048622|NCT00419744|9647908|FG002|Overall Study|Moving out of state|1
6048623|NCT00419744|9647906|FG000|Overall Study|Physician Decision|10
6048624|NCT00419744|9647907|FG001|Overall Study|Physician Decision|5
6048625|NCT00419744|9647908|FG002|Overall Study|Physician Decision|6
6048626|NCT00419744|9647906|FG000|Overall Study|Spirometry mouthpiece issues|0
6031263|NCT01693692|9627339|FG000|Overall Study|Withdrawal by Subject|12
6031264|NCT01693692|9627340|FG001|Overall Study|Withdrawal by Subject|10
6031265|NCT01693692|9627341|FG002|Overall Study|Withdrawal by Subject|11
6031266|NCT01693692|9627339|FG000|Overall Study|Adverse Event|7
6031267|NCT01693692|9627340|FG001|Overall Study|Adverse Event|14
6031268|NCT01693692|9627341|FG002|Overall Study|Adverse Event|9
6031269|NCT01693692|9627339|FG000|Overall Study|Physician Decision|0
6031270|NCT01693692|9627340|FG001|Overall Study|Physician Decision|0
6031271|NCT01693692|9627341|FG002|Overall Study|Physician Decision|1
6031272|NCT01693692|9627339|FG000|Overall Study|Protocol Violation|5
6031273|NCT01693692|9627340|FG001|Overall Study|Protocol Violation|4
6031274|NCT01693692|9627341|FG002|Overall Study|Protocol Violation|6
6031275|NCT01693692|9627339|FG000|Overall Study|Lost to Follow-up|2
6031276|NCT01693692|9627340|FG001|Overall Study|Lost to Follow-up|2
6031277|NCT01693692|9627341|FG002|Overall Study|Lost to Follow-up|3
6031278|NCT01693692|9627339|FG000|Overall Study|Other|4
6031279|NCT01693692|9627340|FG001|Overall Study|Other|4
6031280|NCT01693692|9627341|FG002|Overall Study|Other|6
6031281|NCT01685606|9627349|FG000|Overall Study|Withdrawal by Subject|1
6031282|NCT01650285|9627359|FG000|Overall Study|Adverse Event|1
6031283|NCT01083771|9627363|FG000|Overall Study|non-compliant|2
6031284|NCT01083771|9627363|FG000|Overall Study|Withdrawal by Subject|3
6031285|NCT00743197|9627369|FG000|Overall Study|Study terminated due to departure of PI.|1
6031286|NCT00743197|9627370|FG001|Overall Study|Study terminated due to departure of PI.|2
6031287|NCT00304915|9627378|FG000|Overall Study|Lost to Follow-up|11
6031288|NCT00304915|9627379|FG001|Overall Study|Lost to Follow-up|11
6031289|NCT00304915|9627378|FG000|Overall Study|Death|4
6031290|NCT00304915|9627379|FG001|Overall Study|Death|5
6031291|NCT00304915|9627378|FG000|Overall Study|Withdrawal by Subject|3
6031292|NCT00304915|9627379|FG001|Overall Study|Withdrawal by Subject|0
6031293|NCT00304954|9627389|FG000|Overall Study|Withdrawal by Subject|0
6031294|NCT00304954|9627390|FG001|Overall Study|Withdrawal by Subject|0
6031295|NCT00304954|9627391|FG002|Overall Study|Withdrawal by Subject|1
6031296|NCT00304954|9627392|FG003|Overall Study|Withdrawal by Subject|0
6031297|NCT00304954|9627389|FG000|Overall Study|Adverse Event|1
6031298|NCT00304954|9627390|FG001|Overall Study|Adverse Event|0
6031299|NCT00304954|9627391|FG002|Overall Study|Adverse Event|0
6031300|NCT00304954|9627392|FG003|Overall Study|Adverse Event|0
6031301|NCT00305006|9627412|FG000|Overall Study|Withdrawal by Subject|1
6031302|NCT00305006|9627413|FG001|Overall Study|Withdrawal by Subject|0
6031303|NCT00305006|9627412|FG000|Overall Study|Failure to complete pretest|0
6031304|NCT00305006|9627413|FG001|Overall Study|Failure to complete pretest|1
6031305|NCT00305058|9627421|FG000|Overall Study|Participant too young|1
6031306|NCT00305058|9627422|FG001|Overall Study|Participant too young|0
6031307|NCT00305058|9627421|FG000|Overall Study|Missing data collection instrument|3
6031308|NCT00305058|9627422|FG001|Overall Study|Missing data collection instrument|2
6031309|NCT00305058|9627421|FG000|Overall Study|Missing outcome data|3
6031310|NCT00305058|9627422|FG001|Overall Study|Missing outcome data|2
6031311|NCT00305110|9627477|FG000|Overall Study|Missing data|29
6031312|NCT00305227|9627493|FG000|Overall Study|Lost to Follow-up|7
6031313|NCT00305227|9627494|FG001|Overall Study|Lost to Follow-up|6
6031314|NCT00305253|9627502|FG000|Overall Study|Withdrawal by Subject|0
6031315|NCT00305253|9627503|FG001|Overall Study|Withdrawal by Subject|1
6031316|NCT00305448|9627512|FG000|Overall Study|Protocol Violation|0
6031317|NCT00305448|9627513|FG001|Overall Study|Protocol Violation|1
6031318|NCT00305448|9627514|FG002|Overall Study|Protocol Violation|0
6031319|NCT00305448|9627512|FG000|Overall Study|Withdrawal by Subject|2
6031320|NCT00305448|9627513|FG001|Overall Study|Withdrawal by Subject|0
6031321|NCT00305448|9627514|FG002|Overall Study|Withdrawal by Subject|1
6031322|NCT00305448|9627512|FG000|Overall Study|Adverse Event|1
6031323|NCT00305448|9627513|FG001|Overall Study|Adverse Event|0
6031324|NCT00305448|9627514|FG002|Overall Study|Adverse Event|1
6031325|NCT00305448|9627512|FG000|Overall Study|Disease Progression|27
6031326|NCT00305448|9627513|FG001|Overall Study|Disease Progression|31
6031327|NCT00305448|9627514|FG002|Overall Study|Disease Progression|28
6031328|NCT00305448|9627512|FG000|Overall Study|Subjective Disease Progression|1
6031329|NCT00305448|9627513|FG001|Overall Study|Subjective Disease Progression|2
6031330|NCT00305448|9627514|FG002|Overall Study|Subjective Disease Progression|2
6031331|NCT00305448|9627512|FG000|Overall Study|Tumor Marker Elevation|0
6031332|NCT00305448|9627513|FG001|Overall Study|Tumor Marker Elevation|0
6031333|NCT00305448|9627514|FG002|Overall Study|Tumor Marker Elevation|1
6031334|NCT00305604|9627548|FG000|Overall Study|Adverse Event|6
6031335|NCT00305604|9627549|FG001|Overall Study|Adverse Event|3
6031336|NCT00305604|9627548|FG000|Overall Study|Lack of Efficacy|11
6031337|NCT00305604|9627549|FG001|Overall Study|Lack of Efficacy|18
6031338|NCT00305604|9627548|FG000|Overall Study|Lost to Follow-up|0
6031339|NCT00305604|9627549|FG001|Overall Study|Lost to Follow-up|4
6031340|NCT00305604|9627548|FG000|Overall Study|Protocol Violation|2
6031341|NCT00305604|9627549|FG001|Overall Study|Protocol Violation|1
6031342|NCT00305604|9627548|FG000|Overall Study|Withdrawal by Subject|12
6031343|NCT00305604|9627549|FG001|Overall Study|Withdrawal by Subject|21
6031344|NCT00305604|9627548|FG000|Overall Study|Patient moved|1
6031345|NCT00305604|9627549|FG001|Overall Study|Patient moved|0
6031346|NCT00305695|9627582|FG000|Overall Study|Withdrawal by subject prior to 18 month|40
6031347|NCT00305695|9627583|FG001|Overall Study|Withdrawal by subject prior to 18 month|26
6031348|NCT00305695|9627582|FG000|Overall Study|Did not have baseline scan|1
6031349|NCT00305695|9627583|FG001|Overall Study|Did not have baseline scan|1
6080106|NCT00614614|9687304|FG001|Booster Vaccination Phase|Protocol Violation|0
6080107|NCT00614614|9687305|FG002|Booster Vaccination Phase|Protocol Violation|2
6080108|NCT00614614|9687306|FG003|Booster Vaccination Phase|Protocol Violation|3
6080109|NCT00614614|9687307|FG004|Booster Vaccination Phase|Protocol Violation|0
6080110|NCT00614614|9687303|FG000|Booster Vaccination Phase|Other|0
6080111|NCT00614614|9687304|FG001|Booster Vaccination Phase|Other|1
6080112|NCT00614614|9687305|FG002|Booster Vaccination Phase|Other|3
6080113|NCT00614614|9687306|FG003|Booster Vaccination Phase|Other|2
6080114|NCT00614614|9687307|FG004|Booster Vaccination Phase|Other|1
6080115|NCT00614744|9687324|FG000|Overall Study|Lost to Follow-up|5
6080116|NCT00614744|9687325|FG001|Overall Study|Lost to Follow-up|4
6080117|NCT00614744|9687324|FG000|Overall Study|Incomplete for Behavior Issues|0
6080118|NCT00614744|9687325|FG001|Overall Study|Incomplete for Behavior Issues|2
6080119|NCT00614822|9687331|FG000|Overall Study|Adverse Event|3
6080120|NCT00614874|9687336|FG000|Overall Study|Protocol Violation|1
6080121|NCT00614874|9687336|FG000|Overall Study|Withdrawal by Subject|1
6080122|NCT00614926|9687346|FG000|Overall Study|Burden of travel|1
6080123|NCT00614926|9687347|FG001|Overall Study|Burden of travel|0
6080124|NCT00614926|9687346|FG000|Overall Study|Adverse Event|3
6080125|NCT00614926|9687347|FG001|Overall Study|Adverse Event|0
6080126|NCT00614939|9687355|FG000|Overall Study|Withdrawal by Subject|10
6080127|NCT00614939|9687356|FG001|Overall Study|Withdrawal by Subject|17
6080128|NCT00614939|9687355|FG000|Overall Study|Study specific discontinuation criteris|13
6080129|NCT00614939|9687356|FG001|Overall Study|Study specific discontinuation criteris|16
6080130|NCT00614939|9687355|FG000|Overall Study|Adverse Event|2
6080131|NCT00614939|9687356|FG001|Overall Study|Adverse Event|5
6080132|NCT00614939|9687355|FG000|Overall Study|Incorrect enrollment|1
6080133|NCT00614939|9687356|FG001|Overall Study|Incorrect enrollment|2
6080134|NCT00614939|9687355|FG000|Overall Study|Death|4
6080135|NCT00614939|9687356|FG001|Overall Study|Death|3
6080136|NCT00614939|9687355|FG000|Overall Study|Poor/non-compliance|4
6080137|NCT00614939|9687356|FG001|Overall Study|Poor/non-compliance|0
6080138|NCT00614939|9687355|FG000|Overall Study|Hospitalized due to kidney transplant|1
6080139|NCT00614939|9687356|FG001|Overall Study|Hospitalized due to kidney transplant|0
6080140|NCT00614991|9687368|FG000|Overall Study|Adverse Event|3
6080141|NCT00614991|9687369|FG001|Overall Study|Adverse Event|3
6080142|NCT00614991|9687370|FG002|Overall Study|Adverse Event|0
6080143|NCT00614991|9687371|FG003|Overall Study|Adverse Event|0
6080144|NCT00614991|9687372|FG004|Overall Study|Adverse Event|1
6080145|NCT00614991|9687373|FG005|Overall Study|Adverse Event|0
6080146|NCT00615017|9687398|FG000|Overall Study|Adverse Event|0
6080147|NCT00615017|9687399|FG001|Overall Study|Adverse Event|1
6080148|NCT00615017|9687400|FG002|Overall Study|Adverse Event|2
6080149|NCT00615017|9687401|FG003|Overall Study|Adverse Event|0
6080150|NCT00615017|9687402|FG004|Overall Study|Adverse Event|0
6080151|NCT00615017|9687403|FG005|Overall Study|Adverse Event|1
6080152|NCT00615017|9687398|FG000|Overall Study|Death|0
6080153|NCT00615017|9687399|FG001|Overall Study|Death|0
6080154|NCT00615017|9687400|FG002|Overall Study|Death|2
6080155|NCT00615017|9687401|FG003|Overall Study|Death|0
6080156|NCT00615017|9687402|FG004|Overall Study|Death|1
6080157|NCT00615017|9687403|FG005|Overall Study|Death|1
6080158|NCT00615017|9687398|FG000|Overall Study|Sepsis resolved|0
6080159|NCT00615017|9687399|FG001|Overall Study|Sepsis resolved|0
6080160|NCT00615017|9687400|FG002|Overall Study|Sepsis resolved|1
6080161|NCT00615017|9687401|FG003|Overall Study|Sepsis resolved|0
6080162|NCT00615017|9687402|FG004|Overall Study|Sepsis resolved|0
6080163|NCT00615017|9687403|FG005|Overall Study|Sepsis resolved|0
6080164|NCT00615017|9687398|FG000|Overall Study|Transferred out of Intensive Care Unit|0
6080165|NCT00615017|9687399|FG001|Overall Study|Transferred out of Intensive Care Unit|0
6080166|NCT00615017|9687400|FG002|Overall Study|Transferred out of Intensive Care Unit|0
6080167|NCT00615017|9687401|FG003|Overall Study|Transferred out of Intensive Care Unit|1
6080168|NCT00615017|9687402|FG004|Overall Study|Transferred out of Intensive Care Unit|0
6080169|NCT00615017|9687403|FG005|Overall Study|Transferred out of Intensive Care Unit|0
6080170|NCT00615017|9687398|FG000|Overall Study|Physician discontinued drug|0
6080171|NCT00615017|9687399|FG001|Overall Study|Physician discontinued drug|0
6031350|NCT00305773|9627595|FG000|Overall Study|Death|3
6031351|NCT00305773|9627596|FG001|Overall Study|Death|2
6031352|NCT00305773|9627595|FG000|Overall Study|Adverse Event|1
6031353|NCT00305773|9627596|FG001|Overall Study|Adverse Event|2
6031354|NCT00305773|9627595|FG000|Overall Study|Alternative Treatment|4
6031355|NCT00305773|9627596|FG001|Overall Study|Alternative Treatment|4
6031356|NCT00305773|9627595|FG000|Overall Study|Physician Decision|1
6031357|NCT00305773|9627596|FG001|Overall Study|Physician Decision|1
6031358|NCT00305773|9627595|FG000|Overall Study|Withdrawal by Subject|1
6031359|NCT00305773|9627596|FG001|Overall Study|Withdrawal by Subject|4
6031360|NCT00305773|9627595|FG000|Overall Study|Disease Progression|1
6031361|NCT00305773|9627596|FG001|Overall Study|Disease Progression|3
6031362|NCT00305773|9627595|FG000|Overall Study|All other reasons|3
6031363|NCT00305773|9627596|FG001|Overall Study|All other reasons|2
6031364|NCT00305864|9627606|FG000|Overall Study|Ineligible / No protocol treatment|0
6031365|NCT00305864|9627607|FG001|Overall Study|Ineligible / No protocol treatment|1
6031366|NCT00305864|9627608|FG002|Overall Study|Ineligible / No protocol treatment|1
6031367|NCT00305864|9627609|FG003|Overall Study|Ineligible / No protocol treatment|13
6031368|NCT00305877|9627621|FG000|Overall Study|Lack of Efficacy|6
6031369|NCT00305877|9627622|FG001|Overall Study|Lack of Efficacy|9
6031370|NCT00305877|9627621|FG000|Overall Study|Adverse Event|9
6031371|NCT00305877|9627622|FG001|Overall Study|Adverse Event|14
6031372|NCT00305877|9627621|FG000|Overall Study|Death|0
6031373|NCT00305877|9627622|FG001|Overall Study|Death|1
6031374|NCT00305877|9627621|FG000|Overall Study|Withdrawal by Subject|4
6031375|NCT00305877|9627622|FG001|Overall Study|Withdrawal by Subject|2
6031376|NCT00305877|9627621|FG000|Overall Study|Physician Decision|1
6031377|NCT00305877|9627622|FG001|Overall Study|Physician Decision|1
6031378|NCT00305877|9627621|FG000|Overall Study|Never start treatment|2
6031379|NCT00305877|9627622|FG001|Overall Study|Never start treatment|5
6031380|NCT00305877|9627621|FG000|Overall Study|Ineligible|2
6031381|NCT00305877|9627622|FG001|Overall Study|Ineligible|1
6031382|NCT00305877|9627621|FG000|Overall Study|Transportation issue with daily RT|0
6031383|NCT00305877|9627622|FG001|Overall Study|Transportation issue with daily RT|1
6031384|NCT00306189|9627645|FG000|Overall Study|Physician Decision|0
6031385|NCT00306189|9627646|FG001|Overall Study|Physician Decision|0
6031386|NCT00306189|9627647|FG002|Overall Study|Physician Decision|0
6031387|NCT00306189|9627648|FG003|Overall Study|Physician Decision|1
6080172|NCT00615017|9687400|FG002|Overall Study|Physician discontinued drug|0
6080173|NCT00615017|9687401|FG003|Overall Study|Physician discontinued drug|0
6080174|NCT00615017|9687402|FG004|Overall Study|Physician discontinued drug|0
6080175|NCT00615017|9687403|FG005|Overall Study|Physician discontinued drug|1
6080176|NCT00615030|9687417|FG000|Period I|Administrative problem|0
6080177|NCT00615030|9687418|FG001|Period I|Administrative problem|0
6080178|NCT00615030|9687419|FG002|Period I|Administrative problem|0
6080179|NCT00615030|9687420|FG003|Period I|Administrative problem|0
6080180|NCT00615030|9687421|FG004|Period I|Administrative problem|1
6080181|NCT00615030|9687422|FG005|Period I|Administrative problem|0
6080182|NCT00615030|9687423|FG006|Period I|Administrative problem|0
6080183|NCT00615030|9687424|FG007|Period I|Administrative problem|0
6080184|NCT00615030|9687425|FG008|Period I|Administrative problem|0
6080185|NCT00615030|9687426|FG009|Period I|Administrative problem|0
6080186|NCT00615030|9687427|FG010|Period I|Administrative problem|0
6080187|NCT00615030|9687428|FG011|Period I|Administrative problem|0
6080188|NCT00615030|9687417|FG000|Period I|Protocol deviation|1
6080189|NCT00615030|9687418|FG001|Period I|Protocol deviation|0
6080190|NCT00615030|9687419|FG002|Period I|Protocol deviation|0
6080191|NCT00615030|9687420|FG003|Period I|Protocol deviation|0
6080192|NCT00615030|9687421|FG004|Period I|Protocol deviation|0
6080193|NCT00615030|9687422|FG005|Period I|Protocol deviation|0
6080194|NCT00615030|9687423|FG006|Period I|Protocol deviation|0
6080195|NCT00615030|9687424|FG007|Period I|Protocol deviation|0
6080196|NCT00615030|9687425|FG008|Period I|Protocol deviation|0
6080197|NCT00615030|9687426|FG009|Period I|Protocol deviation|0
6080198|NCT00615030|9687427|FG010|Period I|Protocol deviation|0
6080199|NCT00615030|9687428|FG011|Period I|Protocol deviation|0
6080200|NCT00615030|9687417|FG000|Period I|Subject withdrew consent|0
6080201|NCT00615030|9687418|FG001|Period I|Subject withdrew consent|0
6080202|NCT00615030|9687419|FG002|Period I|Subject withdrew consent|0
6080203|NCT00615030|9687420|FG003|Period I|Subject withdrew consent|0
6080204|NCT00615030|9687421|FG004|Period I|Subject withdrew consent|0
6080205|NCT00615030|9687422|FG005|Period I|Subject withdrew consent|0
6080206|NCT00615030|9687423|FG006|Period I|Subject withdrew consent|0
6080207|NCT00615030|9687424|FG007|Period I|Subject withdrew consent|0
6080208|NCT00615030|9687425|FG008|Period I|Subject withdrew consent|1
6080209|NCT00615030|9687426|FG009|Period I|Subject withdrew consent|0
6031388|NCT00306189|9627645|FG000|Overall Study|Adverse Event|3
6031389|NCT00306189|9627646|FG001|Overall Study|Adverse Event|3
6031390|NCT00306189|9627647|FG002|Overall Study|Adverse Event|2
6031391|NCT00306189|9627648|FG003|Overall Study|Adverse Event|2
6031392|NCT00306189|9627645|FG000|Overall Study|Withdrawal by Subject|4
6080210|NCT00615030|9687427|FG010|Period I|Subject withdrew consent|1
6080211|NCT00615030|9687428|FG011|Period I|Subject withdrew consent|1
6080212|NCT00615030|9687417|FG000|Period I|Abnormal laboratory value(s)|0
6031393|NCT00306189|9627646|FG001|Overall Study|Withdrawal by Subject|2
6146407|NCT01077154|9781202|FG001|Overall Study|Ineligibility Determined|14
6146408|NCT01077154|9781201|FG000|Overall Study|Other|14
6146409|NCT01077154|9781202|FG001|Overall Study|Other|11
6031394|NCT00306189|9627647|FG002|Overall Study|Withdrawal by Subject|8
6080213|NCT00615030|9687418|FG001|Period I|Abnormal laboratory value(s)|0
6080214|NCT00615030|9687419|FG002|Period I|Abnormal laboratory value(s)|0
6146410|NCT01077154|9781201|FG000|Overall Study|Adverse Event|9
6031395|NCT00306189|9627648|FG003|Overall Study|Withdrawal by Subject|1
6031396|NCT00306189|9627645|FG000|Overall Study|Ineligibility determined|1
6031397|NCT00306189|9627646|FG001|Overall Study|Ineligibility determined|1
6031398|NCT00306189|9627647|FG002|Overall Study|Ineligibility determined|1
6031399|NCT00306189|9627648|FG003|Overall Study|Ineligibility determined|1
6031400|NCT00306189|9627645|FG000|Overall Study|Other|1
6031401|NCT00306189|9627646|FG001|Overall Study|Other|0
6031402|NCT00306189|9627647|FG002|Overall Study|Other|0
6031403|NCT00306189|9627648|FG003|Overall Study|Other|0
6031404|NCT00306293|9627709|FG000|Period 1 (Day 1 to Day 60)|Adverse Event|1
6146411|NCT01077154|9781202|FG001|Overall Study|Adverse Event|9
6031405|NCT00306293|9627710|FG001|Period 1 (Day 1 to Day 60)|Adverse Event|0
6031406|NCT00306293|9627709|FG000|Period 1 (Day 1 to Day 60)|Lost to Follow-up|3
6031407|NCT00306293|9627710|FG001|Period 1 (Day 1 to Day 60)|Lost to Follow-up|4
6031408|NCT00306293|9627709|FG000|Period 1 (Day 1 to Day 60)|Withdrawal by Subject|2
6031409|NCT00306293|9627710|FG001|Period 1 (Day 1 to Day 60)|Withdrawal by Subject|2
6031410|NCT00306293|9627709|FG000|Period 1 (Day 1 to Day 60)|Positive pregnancy Test|2
6031411|NCT00306293|9627710|FG001|Period 1 (Day 1 to Day 60)|Positive pregnancy Test|2
6031412|NCT00306293|9627709|FG000|Period 2 (Day 67 to Day 126 )|Adverse Event|1
6031413|NCT00306293|9627710|FG001|Period 2 (Day 67 to Day 126 )|Adverse Event|0
6031414|NCT00306293|9627709|FG000|Period 2 (Day 67 to Day 126 )|Lost to Follow-up|1
6031415|NCT00306293|9627710|FG001|Period 2 (Day 67 to Day 126 )|Lost to Follow-up|0
6031416|NCT00306293|9627709|FG000|Period 2 (Day 67 to Day 126 )|Participant determined HSV-2 negative|0
6031417|NCT00306293|9627710|FG001|Period 2 (Day 67 to Day 126 )|Participant determined HSV-2 negative|1
6031418|NCT00306293|9627709|FG000|Period 2 (Day 67 to Day 126 )|Pregnancy|1
6031419|NCT00306293|9627710|FG001|Period 2 (Day 67 to Day 126 )|Pregnancy|0
6031420|NCT00306384|9627721|FG000|Overall Study|Adverse Event|103
6031421|NCT00306384|9627722|FG001|Overall Study|Adverse Event|87
6031422|NCT00306384|9627723|FG002|Overall Study|Adverse Event|40
6031423|NCT00306384|9627721|FG000|Overall Study|Major protocol deviation|43
6031424|NCT00306384|9627722|FG001|Overall Study|Major protocol deviation|51
6031425|NCT00306384|9627723|FG002|Overall Study|Major protocol deviation|18
6031426|NCT00306384|9627721|FG000|Overall Study|Lost to Follow-up|57
6146412|NCT01077154|9781201|FG000|Overall Study|Administrative Decision|1
6146413|NCT01077154|9781202|FG001|Overall Study|Administrative Decision|6
6146414|NCT01077154|9781201|FG000|Overall Study|Protocol Deviation|1
6146415|NCT01077154|9781202|FG001|Overall Study|Protocol Deviation|0
6146416|NCT01077193|9781208|FG000|Overall Study|Lost to Follow-up|1
6146417|NCT01077193|9781208|FG000|Overall Study|Withdrawal by Subject|2
6146418|NCT01077193|9781208|FG000|Overall Study|Lack of Efficacy|1
6146419|NCT01077193|9781208|FG000|Overall Study|Study Terminated by Sponsor|40
6146420|NCT01077258|9781212|FG000|Overall Study|Lost to Follow-up|1390
6146421|NCT01077258|9781212|FG000|Overall Study|Adverse drug reaction|218
6146422|NCT01077258|9781212|FG000|Overall Study|Lack of Efficacy|663
6146423|NCT01077258|9781212|FG000|Overall Study|Clinical remission|37
6146424|NCT01077258|9781212|FG000|Overall Study|Other reasons|260
6146425|NCT01077271|9781229|FG000|Overall Study|Parental desire|8
6146426|NCT01077271|9781229|FG000|Overall Study|Screen failure, did not take palivizumab|4
6146427|NCT01077271|9781229|FG000|Overall Study|Noncompliance|2
6146428|NCT01077271|9781229|FG000|Overall Study|Quota used up (insurance reimb issue)|2
6146429|NCT01077271|9781229|FG000|Overall Study|Changed doctors|2
6146430|NCT01077271|9781229|FG000|Overall Study|Parents thought too many injections|2
6146431|NCT01077271|9781229|FG000|Overall Study|End of RSV season nearly reached|1
6146432|NCT01077271|9781229|FG000|Overall Study|Mother unconvinced of the necessity|1
6146433|NCT01077284|9781244|FG000|Overall Study|Adverse Event|2
6146434|NCT01077284|9781245|FG001|Overall Study|Adverse Event|0
6146435|NCT01077284|9781246|FG002|Overall Study|Adverse Event|1
6146436|NCT01077284|9781244|FG000|Overall Study|Lost to Follow-up|1
6146437|NCT01077284|9781245|FG001|Overall Study|Lost to Follow-up|2
6146438|NCT01077284|9781246|FG002|Overall Study|Lost to Follow-up|0
6031427|NCT00306384|9627722|FG001|Overall Study|Lost to Follow-up|41
6031428|NCT00306384|9627723|FG002|Overall Study|Lost to Follow-up|35
6031429|NCT00306384|9627721|FG000|Overall Study|Voluntary withdrawal|199
6031430|NCT00306384|9627722|FG001|Overall Study|Voluntary withdrawal|187
6031431|NCT00306384|9627723|FG002|Overall Study|Voluntary withdrawal|91
6031432|NCT00306384|9627721|FG000|Overall Study|Study termination|1
6031433|NCT00306384|9627722|FG001|Overall Study|Study termination|0
6031434|NCT00306384|9627723|FG002|Overall Study|Study termination|1
6031435|NCT00306384|9627721|FG000|Overall Study|Pregnancy|3
6031436|NCT00306384|9627722|FG001|Overall Study|Pregnancy|1
6031437|NCT00306384|9627723|FG002|Overall Study|Pregnancy|1
6031438|NCT00306384|9627721|FG000|Overall Study|Lack of Efficacy|26
6031439|NCT00306384|9627722|FG001|Overall Study|Lack of Efficacy|40
6031440|NCT00306384|9627723|FG002|Overall Study|Lack of Efficacy|38
6146439|NCT01077284|9781244|FG000|Overall Study|Withdrawal by Subject|2
6146440|NCT01077284|9781245|FG001|Overall Study|Withdrawal by Subject|3
6031441|NCT00306384|9627721|FG000|Overall Study|Investigator discretion|28
6031442|NCT00306384|9627722|FG001|Overall Study|Investigator discretion|31
6031443|NCT00306384|9627723|FG002|Overall Study|Investigator discretion|21
6031444|NCT00306384|9627721|FG000|Overall Study|Other|80
6031445|NCT00306384|9627722|FG001|Overall Study|Other|70
6031446|NCT00306384|9627723|FG002|Overall Study|Other|32
6031447|NCT00306384|9627721|FG000|Overall Study|Site closure|2
6031448|NCT00306384|9627722|FG001|Overall Study|Site closure|0
6031449|NCT00306384|9627723|FG002|Overall Study|Site closure|0
6031450|NCT00306527|9627740|FG000|Overall Study|Lost to Follow-up|3
6031451|NCT00306527|9627741|FG001|Overall Study|Lost to Follow-up|4
6031452|NCT00306527|9627742|FG002|Overall Study|Lost to Follow-up|3
6031453|NCT00306527|9627743|FG003|Overall Study|Lost to Follow-up|0
6031454|NCT00306527|9627740|FG000|Overall Study|Withdrawal by Subject|2
6031455|NCT00306527|9627741|FG001|Overall Study|Withdrawal by Subject|3
6031456|NCT00306527|9627742|FG002|Overall Study|Withdrawal by Subject|0
6031457|NCT00306527|9627743|FG003|Overall Study|Withdrawal by Subject|3
6031458|NCT00306527|9627740|FG000|Overall Study|Adverse Event|0
6031459|NCT00306527|9627741|FG001|Overall Study|Adverse Event|0
6031460|NCT00306527|9627742|FG002|Overall Study|Adverse Event|1
6031461|NCT00306527|9627743|FG003|Overall Study|Adverse Event|1
6031462|NCT00306527|9627740|FG000|Overall Study|Death|1
6031463|NCT00306527|9627741|FG001|Overall Study|Death|0
6031464|NCT00306527|9627742|FG002|Overall Study|Death|1
6031465|NCT00306527|9627743|FG003|Overall Study|Death|2
6031466|NCT00306592|9627757|FG000|Overall Study|Adverse Event|8
6031467|NCT00306592|9627758|FG001|Overall Study|Adverse Event|15
6031468|NCT00306592|9627757|FG000|Overall Study|Lost to Follow-up|1
6146441|NCT01077284|9781246|FG002|Overall Study|Withdrawal by Subject|1
6146442|NCT01077284|9781244|FG000|Overall Study|Other|0
6146443|NCT01077284|9781245|FG001|Overall Study|Other|0
6146444|NCT01077284|9781246|FG002|Overall Study|Other|1
6146445|NCT01077323|9781271|FG000|Overall Study|<9 months enroll before drug dispensed|11226
6146446|NCT01077323|9781272|FG001|Overall Study|<9 months enroll before drug dispensed|263954
6146447|NCT01077323|9781273|FG002|Overall Study|<9 months enroll before drug dispensed|11655523
6146448|NCT01077323|9781271|FG000|Overall Study|Dispensing of drug in baseline period|0
6146449|NCT01077323|9781272|FG001|Overall Study|Dispensing of drug in baseline period|120229
6146450|NCT01077323|9781273|FG002|Overall Study|Dispensing of drug in baseline period|256446
6146451|NCT01077323|9781271|FG000|Overall Study|Baseline diagnosis of pancreatic disease|152
6146452|NCT01077323|9781272|FG001|Overall Study|Baseline diagnosis of pancreatic disease|2080
6146453|NCT01077323|9781273|FG002|Overall Study|Baseline diagnosis of pancreatic disease|120
6146454|NCT01077362|9781284|FG000|Overall Study|Lack of Efficacy|13
6146455|NCT01077362|9781285|FG001|Overall Study|Lack of Efficacy|8
6146456|NCT01077362|9781286|FG002|Overall Study|Lack of Efficacy|10
6146457|NCT01077362|9781284|FG000|Overall Study|Lost to Follow-up|1
6146458|NCT01077362|9781285|FG001|Overall Study|Lost to Follow-up|0
6146459|NCT01077362|9781286|FG002|Overall Study|Lost to Follow-up|3
6146460|NCT01077362|9781284|FG000|Overall Study|Adverse Event|12
6146461|NCT01077362|9781285|FG001|Overall Study|Adverse Event|7
6146462|NCT01077362|9781286|FG002|Overall Study|Adverse Event|4
6146463|NCT01077362|9781284|FG000|Overall Study|Withdrawal by Subject|5
6146464|NCT01077362|9781285|FG001|Overall Study|Withdrawal by Subject|3
6146465|NCT01077362|9781286|FG002|Overall Study|Withdrawal by Subject|5
6146466|NCT01077362|9781284|FG000|Overall Study|Other|0
6146467|NCT01077362|9781285|FG001|Overall Study|Other|1
6146468|NCT01077362|9781286|FG002|Overall Study|Other|2
6146469|NCT01077375|9781301|FG000|Overall Study|Adverse Event|2
6146470|NCT01077375|9781302|FG001|Overall Study|Adverse Event|15
6146471|NCT01077375|9781301|FG000|Overall Study|Lack of Efficacy|6
6146472|NCT01077375|9781302|FG001|Overall Study|Lack of Efficacy|8
6146473|NCT01077375|9781301|FG000|Overall Study|Withdrawal by Subject|0
6146474|NCT01077375|9781302|FG001|Overall Study|Withdrawal by Subject|6
6146475|NCT01077375|9781301|FG000|Overall Study|Lost to Follow-up|2
6146476|NCT01077375|9781302|FG001|Overall Study|Lost to Follow-up|5
6146477|NCT01077375|9781301|FG000|Overall Study|Other Reason|0
6146478|NCT01077375|9781302|FG001|Overall Study|Other Reason|1
6146479|NCT01077518|9781321|FG000|Treatment Phase - no Optional Ofa|Lost to Follow-up|8
6146480|NCT01077518|9781322|FG001|Treatment Phase - no Optional Ofa|Lost to Follow-up|4
6146481|NCT01077518|9781323|FG002|Treatment Phase - no Optional Ofa|Lost to Follow-up|0
6146482|NCT01077518|9781321|FG000|Treatment Phase - no Optional Ofa|Physician Decision|10
6146483|NCT01077518|9781322|FG001|Treatment Phase - no Optional Ofa|Physician Decision|11
6146484|NCT01077518|9781323|FG002|Treatment Phase - no Optional Ofa|Physician Decision|0
6146485|NCT01077518|9781321|FG000|Treatment Phase - no Optional Ofa|Study Terminated by Sponsor|28
6146486|NCT01077518|9781322|FG001|Treatment Phase - no Optional Ofa|Study Terminated by Sponsor|22
6146487|NCT01077518|9781323|FG002|Treatment Phase - no Optional Ofa|Study Terminated by Sponsor|0
6146488|NCT01077518|9781321|FG000|Treatment Phase - no Optional Ofa|Withdrawal by Subject|32
6146489|NCT01077518|9781322|FG001|Treatment Phase - no Optional Ofa|Withdrawal by Subject|28
6146490|NCT01077518|9781323|FG002|Treatment Phase - no Optional Ofa|Withdrawal by Subject|0
6146491|NCT01077518|9781321|FG000|Optional Ofa Phase|Physician Decision|0
6031469|NCT00306592|9627758|FG001|Overall Study|Lost to Follow-up|0
6031470|NCT00306592|9627757|FG000|Overall Study|Noncompliance|0
6031471|NCT00306592|9627758|FG001|Overall Study|Noncompliance|2
6031472|NCT00306592|9627757|FG000|Overall Study|Persistent Antibodies|6
6146492|NCT01077518|9781322|FG001|Optional Ofa Phase|Physician Decision|0
6146493|NCT01077518|9781323|FG002|Optional Ofa Phase|Physician Decision|1
6146494|NCT01077518|9781321|FG000|Optional Ofa Phase|Study Terminated by Sponsor|0
6146495|NCT01077518|9781322|FG001|Optional Ofa Phase|Study Terminated by Sponsor|0
6031473|NCT00306592|9627758|FG001|Overall Study|Persistent Antibodies|3
6031474|NCT00306592|9627757|FG000|Overall Study|Voluntary|10
6031475|NCT00306592|9627758|FG001|Overall Study|Voluntary|6
6031476|NCT00306592|9627757|FG000|Overall Study|Other|5
6031477|NCT00306592|9627758|FG001|Overall Study|Other|10
6031478|NCT00306592|9627757|FG000|Overall Study|Other|1
6031479|NCT00306592|9627758|FG001|Overall Study|Other|2
6031480|NCT00306592|9627757|FG000|Overall Study|48-week Treatment Period Ongoing|0
6031481|NCT00306592|9627758|FG001|Overall Study|48-week Treatment Period Ongoing|20
6031482|NCT00306670|9627764|FG000|Overall Study|patients recruited; Genentech, the st|0
6031483|NCT00306670|9627765|FG001|Overall Study|patients recruited; Genentech, the st|2
6031484|NCT00306787|9627773|FG000|Overall Study|Discontinued without taking study drug|208
6031485|NCT00306787|9627774|FG001|Overall Study|Discontinued without taking study drug|215
6031486|NCT00306787|9627773|FG000|Overall Study|Adverse Event|1
6031487|NCT00306787|9627774|FG001|Overall Study|Adverse Event|1
6031488|NCT00306787|9627773|FG000|Overall Study|Lack of Efficacy|1
6031489|NCT00306787|9627774|FG001|Overall Study|Lack of Efficacy|0
6031490|NCT00306787|9627773|FG000|Overall Study|Protocol Violation|8
6031491|NCT00306787|9627774|FG001|Overall Study|Protocol Violation|10
6031492|NCT00306787|9627773|FG000|Overall Study|Withdrawal by Subject|2
6031493|NCT00306787|9627774|FG001|Overall Study|Withdrawal by Subject|9
6031494|NCT00306787|9627773|FG000|Overall Study|Lost to Follow-up|9
6031495|NCT00306787|9627774|FG001|Overall Study|Lost to Follow-up|6
6031496|NCT00306787|9627773|FG000|Overall Study|Administrative problems|4
6031497|NCT00306787|9627774|FG001|Overall Study|Administrative problems|0
6031498|NCT00306787|9627773|FG000|Overall Study|Abnormal laboratory value(s)|1
6031499|NCT00306787|9627774|FG001|Overall Study|Abnormal laboratory value(s)|0
6146496|NCT01077518|9781323|FG002|Optional Ofa Phase|Study Terminated by Sponsor|12
6146497|NCT01077518|9781321|FG000|Optional Ofa Phase|Withdrawal by Subject|0
6146498|NCT01077518|9781322|FG001|Optional Ofa Phase|Withdrawal by Subject|0
6146499|NCT01077518|9781323|FG002|Optional Ofa Phase|Withdrawal by Subject|3
6146500|NCT01077544|9781334|FG000|Overall Study|New Cancer Therapy|3
6146501|NCT01077544|9781335|FG001|Overall Study|New Cancer Therapy|3
6146502|NCT01077544|9781334|FG000|Overall Study|Adverse Event|0
6146503|NCT01077544|9781335|FG001|Overall Study|Adverse Event|1
6146504|NCT01077544|9781334|FG000|Overall Study|Disease Progression|0
6146505|NCT01077544|9781335|FG001|Overall Study|Disease Progression|1
6146506|NCT01077622|9781385|FG000|Overall Study|Physician Decision|2
6146507|NCT01077622|9781385|FG000|Overall Study|Withdrawal by Subject|1
6146508|NCT01077713|9781391|FG000|Overall Study|Withdrawal by Subject|1
6146509|NCT01077713|9781392|FG001|Overall Study|Withdrawal by Subject|2
6146510|NCT01077713|9781391|FG000|Overall Study|Progressive Disease (PD)|0
6146511|NCT01077713|9781392|FG001|Overall Study|Progressive Disease (PD)|1
6146512|NCT01077713|9781391|FG000|Overall Study|Death|28
6146513|NCT01077713|9781392|FG001|Overall Study|Death|29
6146514|NCT01077713|9781391|FG000|Overall Study|Lost to Follow-up|1
6146515|NCT01077713|9781392|FG001|Overall Study|Lost to Follow-up|1
6146516|NCT01077713|9781391|FG000|Overall Study|Adverse Event|2
6146517|NCT01077713|9781392|FG001|Overall Study|Adverse Event|1
6146518|NCT01077713|9781391|FG000|Overall Study|Other|4
6146519|NCT01077713|9781392|FG001|Overall Study|Other|2
6146520|NCT01077739|9781400|FG000|Overall Study|Premature withdrawal|1
6146521|NCT01077739|9781401|FG001|Overall Study|Premature withdrawal|3
6146522|NCT01077739|9781400|FG000|Overall Study|Withdrawal by Subject|1
6146523|NCT01077739|9781401|FG001|Overall Study|Withdrawal by Subject|0
6146524|NCT01077739|9781400|FG000|Overall Study|Death|0
6146525|NCT01077739|9781401|FG001|Overall Study|Death|3
6146526|NCT01077739|9781400|FG000|Overall Study|Unacceptable toxicity|1
6146527|NCT01077739|9781401|FG001|Overall Study|Unacceptable toxicity|2
6146528|NCT01077739|9781400|FG000|Overall Study|Other|2
6146529|NCT01077739|9781401|FG001|Overall Study|Other|2
6146530|NCT01077804|9781407|FG000|Overall Study|Unreachable|102
6146531|NCT01077804|9781407|FG000|Overall Study|Refused to continue|79
6146532|NCT01077804|9781407|FG000|Overall Study|Other|18
6146533|NCT01077960|9781466|FG000|Overall Study|Adverse Event|6
6146534|NCT01077960|9781466|FG000|Overall Study|Protocol Violation|3
6146535|NCT01077960|9781466|FG000|Overall Study|Lost to Follow-up|5
6146536|NCT01077960|9781466|FG000|Overall Study|Subject decision|1
6146537|NCT01077960|9781466|FG000|Overall Study|Reason unspecified|1
6146538|NCT01078090|9781485|FG000|Overall Study|Lost to Follow-up|2363
6146539|NCT01078090|9781485|FG000|Overall Study|Adverse drug reaction (ADR)|453
6146540|NCT01078090|9781485|FG000|Overall Study|Lack of Efficacy|1193
6146541|NCT01078090|9781485|FG000|Overall Study|ADR and lack of efficacy|61
6146542|NCT01078090|9781485|FG000|Overall Study|Other|523
6146543|NCT01078116|9781503|FG000|Overall Study|Lost to Follow-up|17
6146544|NCT01078116|9781503|FG000|Overall Study|Adverse Event|5
6146545|NCT01078116|9781503|FG000|Overall Study|Withdrawal by Subject|8
6146546|NCT01078116|9781503|FG000|Overall Study|Lack of effectiveness|15
6146547|NCT01078116|9781503|FG000|Overall Study|Case report form not completed|3
6146548|NCT01078155|9781507|FG000|Overall Study|Adverse Event|7
6146549|NCT01078155|9781507|FG000|Overall Study|Lack of Efficacy|16
6146550|NCT01078155|9781507|FG000|Overall Study|Participant's Decision|6
6031500|NCT00306852|9627782|FG000|Overall Study|Death|14
6031501|NCT00306852|9627783|FG001|Overall Study|Death|14
6031502|NCT00306852|9627782|FG000|Overall Study|Lost to Follow-up|15
6031503|NCT00306852|9627783|FG001|Overall Study|Lost to Follow-up|24
6031504|NCT00306891|9627793|FG000|Part A|Withdrawal by Subject|1
6031505|NCT00306891|9627794|FG001|Part A|Withdrawal by Subject|1
6031506|NCT00306891|9627795|FG002|Part A|Withdrawal by Subject|0
6031507|NCT00306891|9627796|FG003|Part A|Withdrawal by Subject|0
6031508|NCT00306891|9627793|FG000|Part A|Condition under investigation worsened|2
6031509|NCT00306891|9627794|FG001|Part A|Condition under investigation worsened|2
6031510|NCT00306891|9627795|FG002|Part A|Condition under investigation worsened|0
6031511|NCT00306891|9627796|FG003|Part A|Condition under investigation worsened|0
6031512|NCT00306891|9627793|FG000|Part A|Incorrect enrol/entry crit not fulfilled|0
6031513|NCT00306891|9627794|FG001|Part A|Incorrect enrol/entry crit not fulfilled|1
6031514|NCT00306891|9627795|FG002|Part A|Incorrect enrol/entry crit not fulfilled|0
6031515|NCT00306891|9627796|FG003|Part A|Incorrect enrol/entry crit not fulfilled|0
6031516|NCT00306891|9627793|FG000|Part A|Partial bowel obstruction|1
6031517|NCT00306891|9627794|FG001|Part A|Partial bowel obstruction|0
6031518|NCT00306891|9627795|FG002|Part A|Partial bowel obstruction|0
6031519|NCT00306891|9627796|FG003|Part A|Partial bowel obstruction|0
6031520|NCT00306891|9627793|FG000|Part A|Reaccumul. of ascites following drainage|0
6031521|NCT00306891|9627794|FG001|Part A|Reaccumul. of ascites following drainage|1
6031522|NCT00306891|9627795|FG002|Part A|Reaccumul. of ascites following drainage|0
6031523|NCT00306891|9627796|FG003|Part A|Reaccumul. of ascites following drainage|0
6031524|NCT00306891|9627793|FG000|Part A|Suspicion of second malignancy|0
6031525|NCT00306891|9627794|FG001|Part A|Suspicion of second malignancy|1
6031526|NCT00306891|9627795|FG002|Part A|Suspicion of second malignancy|0
6031527|NCT00306891|9627796|FG003|Part A|Suspicion of second malignancy|0
6031528|NCT00306891|9627793|FG000|Part A|QTC interval outwith elig. criteria|1
6031529|NCT00306891|9627794|FG001|Part A|QTC interval outwith elig. criteria|0
6031530|NCT00306891|9627795|FG002|Part A|QTC interval outwith elig. criteria|0
6031531|NCT00306891|9627796|FG003|Part A|QTC interval outwith elig. criteria|0
6031532|NCT00306891|9627793|FG000|Part B|Death|0
6031533|NCT00306891|9627794|FG001|Part B|Death|0
6031534|NCT00306891|9627795|FG002|Part B|Death|1
6031535|NCT00306891|9627796|FG003|Part B|Death|2
6031536|NCT00306891|9627793|FG000|Part B|Adverse Event|0
6031537|NCT00306891|9627794|FG001|Part B|Adverse Event|0
6031538|NCT00306891|9627795|FG002|Part B|Adverse Event|5
6031539|NCT00306891|9627796|FG003|Part B|Adverse Event|5
6031540|NCT00306891|9627793|FG000|Part B|Withdrawal by Subject|0
6031541|NCT00306891|9627794|FG001|Part B|Withdrawal by Subject|0
6031542|NCT00306891|9627795|FG002|Part B|Withdrawal by Subject|3
6031543|NCT00306891|9627796|FG003|Part B|Withdrawal by Subject|1
6031544|NCT00306891|9627793|FG000|Part B|Condition under investigation worsened|0
6031545|NCT00306891|9627794|FG001|Part B|Condition under investigation worsened|0
6031546|NCT00306891|9627795|FG002|Part B|Condition under investigation worsened|2
6031547|NCT00306891|9627796|FG003|Part B|Condition under investigation worsened|8
6031548|NCT00306891|9627793|FG000|Part B|Development of study specific disc crit.|0
6031549|NCT00306891|9627794|FG001|Part B|Development of study specific disc crit.|0
6031550|NCT00306891|9627795|FG002|Part B|Development of study specific disc crit.|0
6031551|NCT00306891|9627796|FG003|Part B|Development of study specific disc crit.|1
6031552|NCT00306995|9627823|FG000|Study Part I|Withdrawal by Subject|0
6031553|NCT00306995|9627824|FG001|Study Part I|Withdrawal by Subject|0
6031554|NCT00306995|9627825|FG002|Study Part I|Withdrawal by Subject|0
6031555|NCT00306995|9627826|FG003|Study Part I|Withdrawal by Subject|0
6031556|NCT00306995|9627827|FG004|Study Part I|Withdrawal by Subject|0
6031557|NCT00306995|9627828|FG005|Study Part I|Withdrawal by Subject|0
6031558|NCT00306995|9627829|FG006|Study Part I|Withdrawal by Subject|1
6031559|NCT00306995|9627823|FG000|Study Part II for Subset 2|Serious Adverse Event|0
6031560|NCT00306995|9627824|FG001|Study Part II for Subset 2|Serious Adverse Event|1
6031561|NCT00306995|9627825|FG002|Study Part II for Subset 2|Serious Adverse Event|0
6031562|NCT00306995|9627826|FG003|Study Part II for Subset 2|Serious Adverse Event|0
6031563|NCT00306995|9627827|FG004|Study Part II for Subset 2|Serious Adverse Event|0
6031564|NCT00306995|9627828|FG005|Study Part II for Subset 2|Serious Adverse Event|0
6031565|NCT00306995|9627829|FG006|Study Part II for Subset 2|Serious Adverse Event|0
6031566|NCT00307034|9627876|FG000|Overall Study|Adverse Event|1
6031567|NCT00307034|9627877|FG001|Overall Study|Adverse Event|2
6031568|NCT00307034|9627876|FG000|Overall Study|Withdrawal by Subject|1
6031569|NCT00307034|9627877|FG001|Overall Study|Withdrawal by Subject|2
6031570|NCT00307034|9627876|FG000|Overall Study|Lost to Follow-up|0
6031571|NCT00307034|9627877|FG001|Overall Study|Lost to Follow-up|3
6031572|NCT00307047|9627885|FG000|Overall Study|Lost to Follow-up|35
6146551|NCT01078155|9781507|FG000|Overall Study|Lost to Follow-up|15
6031573|NCT00307047|9627886|FG001|Overall Study|Lost to Follow-up|24
6031574|NCT00307047|9627885|FG000|Overall Study|Withdrawal by Subject|6
6031575|NCT00307047|9627886|FG001|Overall Study|Withdrawal by Subject|6
6031576|NCT00307047|9627885|FG000|Overall Study|Physician Decision|1
6031577|NCT00307047|9627886|FG001|Overall Study|Physician Decision|2
6031578|NCT00307047|9627885|FG000|Overall Study|Lost to follow-up for other reasons|0
6031579|NCT00307047|9627886|FG001|Overall Study|Lost to follow-up for other reasons|1
6031580|NCT00307047|9627885|FG000|Overall Study|All death, all MI, all Revascularization|27
6031581|NCT00307047|9627886|FG001|Overall Study|All death, all MI, all Revascularization|16
6031582|NCT00307086|9627892|FG000|Overall Study|ineligible|5
6031583|NCT00307125|9627898|FG000|Screening Phase|Adverse Event|1
6031584|NCT00307125|9627899|FG001|Screening Phase|Adverse Event|0
6031585|NCT00307125|9627900|FG002|Screening Phase|Adverse Event|0
6031586|NCT00307125|9627898|FG000|Screening Phase|Protocol Violation|27
6031587|NCT00307125|9627899|FG001|Screening Phase|Protocol Violation|0
6031588|NCT00307125|9627900|FG002|Screening Phase|Protocol Violation|0
6031589|NCT00307125|9627898|FG000|Screening Phase|Lost to Follow-up|87
6031590|NCT00307125|9627899|FG001|Screening Phase|Lost to Follow-up|0
6031591|NCT00307125|9627900|FG002|Screening Phase|Lost to Follow-up|0
6031592|NCT00307125|9627898|FG000|Screening Phase|Death|10
6031593|NCT00307125|9627899|FG001|Screening Phase|Death|0
6031594|NCT00307125|9627900|FG002|Screening Phase|Death|0
6031595|NCT00307125|9627898|FG000|Screening Phase|Withdrawal by Subject|77
6031596|NCT00307125|9627899|FG001|Screening Phase|Withdrawal by Subject|0
6031597|NCT00307125|9627900|FG002|Screening Phase|Withdrawal by Subject|0
6031598|NCT00307125|9627898|FG000|Screening Phase|Physician Decision|26
6031599|NCT00307125|9627899|FG001|Screening Phase|Physician Decision|0
6031600|NCT00307125|9627900|FG002|Screening Phase|Physician Decision|0
6031601|NCT00307125|9627898|FG000|Screening Phase|Sponsor Decision|4
6031602|NCT00307125|9627899|FG001|Screening Phase|Sponsor Decision|0
6031603|NCT00307125|9627900|FG002|Screening Phase|Sponsor Decision|0
6031604|NCT00307125|9627898|FG000|Screening Phase|Study Terminated|17
6031605|NCT00307125|9627899|FG001|Screening Phase|Study Terminated|0
6031606|NCT00307125|9627900|FG002|Screening Phase|Study Terminated|0
6031607|NCT00307125|9627898|FG000|Screening Phase|Graft Loss|3
6031608|NCT00307125|9627899|FG001|Screening Phase|Graft Loss|0
6031609|NCT00307125|9627900|FG002|Screening Phase|Graft Loss|0
6031610|NCT00307125|9627898|FG000|Screening Phase|Graft Failure|8
6031611|NCT00307125|9627899|FG001|Screening Phase|Graft Failure|0
6031612|NCT00307125|9627900|FG002|Screening Phase|Graft Failure|0
6031613|NCT00307125|9627898|FG000|Screening Phase|Follow-up period ended on Dec 31, 2011|83
6031614|NCT00307125|9627899|FG001|Screening Phase|Follow-up period ended on Dec 31, 2011|0
6031615|NCT00307125|9627900|FG002|Screening Phase|Follow-up period ended on Dec 31, 2011|0
6031616|NCT00307125|9627898|FG000|Screening Phase|Scheduling issues/Non-compliance|55
6031617|NCT00307125|9627899|FG001|Screening Phase|Scheduling issues/Non-compliance|0
6031618|NCT00307125|9627900|FG002|Screening Phase|Scheduling issues/Non-compliance|0
6031619|NCT00307125|9627898|FG000|Screening Phase|Moved or transferred facilities|34
6031620|NCT00307125|9627899|FG001|Screening Phase|Moved or transferred facilities|0
6031621|NCT00307125|9627900|FG002|Screening Phase|Moved or transferred facilities|0
6031622|NCT00307125|9627898|FG000|Screening Phase|Received Pancreas Transplant|8
6031623|NCT00307125|9627899|FG001|Screening Phase|Received Pancreas Transplant|0
6031624|NCT00307125|9627900|FG002|Screening Phase|Received Pancreas Transplant|0
6031625|NCT00307125|9627898|FG000|Screening Phase|Ineligible for pilot|4
6031626|NCT00307125|9627899|FG001|Screening Phase|Ineligible for pilot|0
6031627|NCT00307125|9627900|FG002|Screening Phase|Ineligible for pilot|0
6031628|NCT00307125|9627898|FG000|Screening Phase|Try to get pregnant|1
6031629|NCT00307125|9627899|FG001|Screening Phase|Try to get pregnant|0
6031630|NCT00307125|9627900|FG002|Screening Phase|Try to get pregnant|0
6031631|NCT00307125|9627898|FG000|Screening Phase|Developed acute leukemia|1
6031632|NCT00307125|9627899|FG001|Screening Phase|Developed acute leukemia|0
6031633|NCT00307125|9627900|FG002|Screening Phase|Developed acute leukemia|0
6031634|NCT00307125|9627898|FG000|Screening Phase|Metastatic colon cancer|1
6031635|NCT00307125|9627899|FG001|Screening Phase|Metastatic colon cancer|0
6031636|NCT00307125|9627900|FG002|Screening Phase|Metastatic colon cancer|0
6031637|NCT00307125|9627898|FG000|Screening Phase|Malignancy|1
6031638|NCT00307125|9627899|FG001|Screening Phase|Malignancy|0
6031639|NCT00307125|9627900|FG002|Screening Phase|Malignancy|0
6031640|NCT00307125|9627898|FG000|Screening Phase|PAK|1
6031641|NCT00307125|9627899|FG001|Screening Phase|PAK|0
6031642|NCT00307125|9627900|FG002|Screening Phase|PAK|0
6031643|NCT00307125|9627898|FG000|Screening Phase|Ineligible|1
6031644|NCT00307125|9627899|FG001|Screening Phase|Ineligible|0
6146552|NCT01078168|9781513|FG000|Overall Study|Physician Decision|0
6146553|NCT01078168|9781514|FG001|Overall Study|Physician Decision|1
6146554|NCT01078298|9781573|FG000|Overall Study|Lost to Follow-up|12
6146555|NCT01078298|9781574|FG001|Overall Study|Lost to Follow-up|13
6146556|NCT01078298|9781573|FG000|Overall Study|Withdrawal by Subject|31
6146557|NCT01078298|9781574|FG001|Overall Study|Withdrawal by Subject|33
6146558|NCT01078298|9781573|FG000|Overall Study|Protocol Violation|6
6146559|NCT01078298|9781574|FG001|Overall Study|Protocol Violation|6
6146560|NCT01078298|9781573|FG000|Overall Study|Adverse Event|6
6146561|NCT01078298|9781574|FG001|Overall Study|Adverse Event|5
6146562|NCT01078298|9781573|FG000|Overall Study|Death|2
6146563|NCT01078298|9781574|FG001|Overall Study|Death|0
6031645|NCT00307125|9627900|FG002|Screening Phase|Ineligible|0
6031646|NCT00307125|9627898|FG000|Screening Phase|Screen Error|1
6031647|NCT00307125|9627899|FG001|Screening Phase|Screen Error|0
6031648|NCT00307125|9627900|FG002|Screening Phase|Screen Error|0
6031649|NCT00307125|9627898|FG000|Screening Phase|Sample of Anti-HLA Ab was not obtained|1
6031650|NCT00307125|9627899|FG001|Screening Phase|Sample of Anti-HLA Ab was not obtained|0
6031651|NCT00307125|9627900|FG002|Screening Phase|Sample of Anti-HLA Ab was not obtained|0
6031652|NCT00307125|9627898|FG000|Screening Phase|AMR and treated with rituximab|1
6031653|NCT00307125|9627899|FG001|Screening Phase|AMR and treated with rituximab|0
6146564|NCT01078298|9781573|FG000|Overall Study|Did not meet entrance criteria|0
6146565|NCT01078298|9781574|FG001|Overall Study|Did not meet entrance criteria|1
6031654|NCT00307125|9627900|FG002|Screening Phase|AMR and treated with rituximab|0
6031655|NCT00307125|9627898|FG000|Screening Phase|Coronary artery bypass|1
6031656|NCT00307125|9627899|FG001|Screening Phase|Coronary artery bypass|0
6031657|NCT00307125|9627900|FG002|Screening Phase|Coronary artery bypass|0
6031658|NCT00307125|9627898|FG000|Pilot Phase|Lost to Follow-up|0
6031659|NCT00307125|9627899|FG001|Pilot Phase|Lost to Follow-up|1
6031660|NCT00307125|9627900|FG002|Pilot Phase|Lost to Follow-up|0
6031661|NCT00307125|9627898|FG000|Pilot Phase|Withdrawal by Subject|0
6031662|NCT00307125|9627899|FG001|Pilot Phase|Withdrawal by Subject|1
6031663|NCT00307125|9627900|FG002|Pilot Phase|Withdrawal by Subject|1
6031664|NCT00307151|9627914|FG000|Overall Study|Death|4
6031665|NCT00307151|9627915|FG001|Overall Study|Death|3
6031666|NCT00307151|9627916|FG002|Overall Study|Death|10
6031667|NCT00307151|9627917|FG003|Overall Study|Death|3
6031668|NCT00307151|9627914|FG000|Overall Study|Severe debilitation, unable to continue|1
6031669|NCT00307151|9627915|FG001|Overall Study|Severe debilitation, unable to continue|0
6031670|NCT00307151|9627916|FG002|Overall Study|Severe debilitation, unable to continue|0
6031671|NCT00307151|9627917|FG003|Overall Study|Severe debilitation, unable to continue|0
6031672|NCT00307151|9627914|FG000|Overall Study|Subject unable to get to clinic|1
6031673|NCT00307151|9627915|FG001|Overall Study|Subject unable to get to clinic|0
6031674|NCT00307151|9627916|FG002|Overall Study|Subject unable to get to clinic|6
6031675|NCT00307151|9627917|FG003|Overall Study|Subject unable to get to clinic|2
6031676|NCT00307151|9627914|FG000|Overall Study|Withdrew consent|0
6031677|NCT00307151|9627915|FG001|Overall Study|Withdrew consent|1
6031678|NCT00307151|9627916|FG002|Overall Study|Withdrew consent|1
6031679|NCT00307151|9627917|FG003|Overall Study|Withdrew consent|3
6031680|NCT00307151|9627914|FG000|Overall Study|Not willing to adhere to study reqs|2
6031681|NCT00307151|9627915|FG001|Overall Study|Not willing to adhere to study reqs|0
6031682|NCT00307151|9627916|FG002|Overall Study|Not willing to adhere to study reqs|2
6031683|NCT00307151|9627917|FG003|Overall Study|Not willing to adhere to study reqs|2
6031684|NCT00307151|9627914|FG000|Overall Study|Clinic unable to contact subject|3
6031685|NCT00307151|9627915|FG001|Overall Study|Clinic unable to contact subject|3
6031686|NCT00307151|9627916|FG002|Overall Study|Clinic unable to contact subject|1
6031687|NCT00307151|9627917|FG003|Overall Study|Clinic unable to contact subject|1
6031688|NCT00307164|9627929|FG000|Overall Study|Death|1
6031689|NCT00307164|9627930|FG001|Overall Study|Death|0
6031690|NCT00307164|9627929|FG000|Overall Study|Severe debilitation, unable to continue|1
6031691|NCT00307164|9627930|FG001|Overall Study|Severe debilitation, unable to continue|0
6031692|NCT00307164|9627929|FG000|Overall Study|Subject/parent not able to get to clinic|2
6031693|NCT00307164|9627930|FG001|Overall Study|Subject/parent not able to get to clinic|1
6031694|NCT00307164|9627929|FG000|Overall Study|Withdrawal by Subject|1
6031695|NCT00307164|9627930|FG001|Overall Study|Withdrawal by Subject|8
6031696|NCT00307164|9627929|FG000|Overall Study|Not compliant with requirements|4
6031697|NCT00307164|9627930|FG001|Overall Study|Not compliant with requirements|4
6031698|NCT00307164|9627929|FG000|Overall Study|Lost to Follow-up|6
6031699|NCT00307164|9627930|FG001|Overall Study|Lost to Follow-up|1
6031700|NCT00307294|9627936|FG000|Overall Study|Withdrawal by Subject|1
6031701|NCT00307333|9627943|FG000|Overall Study|Lost to Follow-up|11
6031702|NCT00307333|9627944|FG001|Overall Study|Lost to Follow-up|3
6031703|NCT00307437|9627953|FG000|Controlled Period|Adverse Event|7
6031704|NCT00307437|9627954|FG001|Controlled Period|Adverse Event|2
6031705|NCT00307437|9627955|FG002|Controlled Period|Adverse Event|5
6031706|NCT00307437|9627956|FG003|Controlled Period|Adverse Event|0
6031707|NCT00307437|9627957|FG004|Controlled Period|Adverse Event|0
6031708|NCT00307437|9627958|FG005|Controlled Period|Adverse Event|0
6031709|NCT00307437|9627959|FG006|Controlled Period|Adverse Event|0
6031710|NCT00307437|9627953|FG000|Controlled Period|Death|0
6031711|NCT00307437|9627954|FG001|Controlled Period|Death|0
6031712|NCT00307437|9627955|FG002|Controlled Period|Death|1
6031713|NCT00307437|9627956|FG003|Controlled Period|Death|0
6031714|NCT00307437|9627957|FG004|Controlled Period|Death|0
6031715|NCT00307437|9627958|FG005|Controlled Period|Death|0
6031716|NCT00307437|9627959|FG006|Controlled Period|Death|0
6146566|NCT01078298|9781573|FG000|Overall Study|Other|24
6146567|NCT01078298|9781574|FG001|Overall Study|Other|32
6146568|NCT01078389|9781613|FG000|Overall Study|Adverse Event|10
6146569|NCT01078389|9781614|FG001|Overall Study|Adverse Event|6
6146570|NCT01078389|9781613|FG000|Overall Study|Major Protocol Deviation|2
6146571|NCT01078389|9781614|FG001|Overall Study|Major Protocol Deviation|0
6146572|NCT01078389|9781613|FG000|Overall Study|Lost to Follow-up|23
6146573|NCT01078389|9781614|FG001|Overall Study|Lost to Follow-up|23
6146574|NCT01078389|9781613|FG000|Overall Study|Voluntary Withdrawal|20
6146575|NCT01078389|9781614|FG001|Overall Study|Voluntary Withdrawal|36
6146576|NCT01078389|9781613|FG000|Overall Study|Other|9
6146577|NCT01078389|9781614|FG001|Overall Study|Other|2
6031717|NCT00307437|9627953|FG000|Controlled Period|Lack of Efficacy|2
6031718|NCT00307437|9627954|FG001|Controlled Period|Lack of Efficacy|0
6031719|NCT00307437|9627955|FG002|Controlled Period|Lack of Efficacy|0
6031720|NCT00307437|9627956|FG003|Controlled Period|Lack of Efficacy|0
6031721|NCT00307437|9627957|FG004|Controlled Period|Lack of Efficacy|0
6031722|NCT00307437|9627958|FG005|Controlled Period|Lack of Efficacy|0
6031723|NCT00307437|9627959|FG006|Controlled Period|Lack of Efficacy|0
6031724|NCT00307437|9627953|FG000|Controlled Period|Lost to Follow-up|2
6031725|NCT00307437|9627954|FG001|Controlled Period|Lost to Follow-up|3
6031726|NCT00307437|9627955|FG002|Controlled Period|Lost to Follow-up|0
6031727|NCT00307437|9627956|FG003|Controlled Period|Lost to Follow-up|0
6031728|NCT00307437|9627957|FG004|Controlled Period|Lost to Follow-up|0
6031729|NCT00307437|9627958|FG005|Controlled Period|Lost to Follow-up|0
6031730|NCT00307437|9627959|FG006|Controlled Period|Lost to Follow-up|0
6031731|NCT00307437|9627953|FG000|Controlled Period|Other|5
6031732|NCT00307437|9627954|FG001|Controlled Period|Other|1
6031733|NCT00307437|9627955|FG002|Controlled Period|Other|3
6031734|NCT00307437|9627956|FG003|Controlled Period|Other|0
6031735|NCT00307437|9627957|FG004|Controlled Period|Other|0
6031736|NCT00307437|9627958|FG005|Controlled Period|Other|0
6031737|NCT00307437|9627959|FG006|Controlled Period|Other|0
6031738|NCT00307437|9627953|FG000|After Controlled Period|Adverse Event|0
6031739|NCT00307437|9627954|FG001|After Controlled Period|Adverse Event|0
6146578|NCT01078441|9781637|FG000|Overall Study|Withdrawal by Subject|1
6146579|NCT01078545|9781641|FG000|Overall Study|Lost to Follow-up|13
6146580|NCT01078545|9781641|FG000|Overall Study|Physician Decision|6
6146581|NCT01078545|9781641|FG000|Overall Study|Withdrawal by Subject|3
6146582|NCT01078545|9781641|FG000|Overall Study|Death|3
6146583|NCT01078545|9781641|FG000|Overall Study|Participant moved to another physician|1
6146584|NCT01078571|9781658|FG000|Overall Study|Adverse Event|36
6146585|NCT01078571|9781658|FG000|Overall Study|Lack of effectiveness|36
6146586|NCT01078571|9781658|FG000|Overall Study|Reason not reported|21
6146587|NCT01078571|9781658|FG000|Overall Study|Withdrawal by Subject|12
6146588|NCT01078571|9781658|FG000|Overall Study|Lost to Follow-up|8
6146589|NCT01078571|9781658|FG000|Overall Study|Protocol Violation|2
6146590|NCT01078584|9781667|FG000|Overall Study|Final Status Unknown|1073
6146591|NCT01078584|9781667|FG000|Overall Study|Lost to Follow-up|670
6146592|NCT01078584|9781667|FG000|Overall Study|Non-serious Adverse Event|577
6146593|NCT01078584|9781667|FG000|Overall Study|Withdrawal of Consent|244
6146594|NCT01078584|9781667|FG000|Overall Study|Physician Withdrew from Study|90
6146595|NCT01078584|9781667|FG000|Overall Study|Non-compliance|67
6146596|NCT01078584|9781667|FG000|Overall Study|Blood Pressure Controlled|49
6146597|NCT01078584|9781667|FG000|Overall Study|Physician Switched Medication|26
6146598|NCT01078584|9781667|FG000|Overall Study|Physician Discontinued Patient|12
6146599|NCT01078584|9781667|FG000|Overall Study|Lack of Efficacy|98
6146600|NCT01078584|9781667|FG000|Overall Study|Protocol Violation|75
6146601|NCT01078584|9781667|FG000|Overall Study|Serious Adverse Event|27
6146602|NCT01078584|9781667|FG000|Overall Study|Multiple Reasons|2
6146603|NCT01078623|9781684|FG000|Treatment Period 1|Adverse Event|1
6146604|NCT01078623|9781685|FG001|Treatment Period 1|Adverse Event|1
6146605|NCT01078623|9781686|FG002|Treatment Period 1|Adverse Event|1
6146606|NCT01078623|9781687|FG003|Treatment Period 1|Adverse Event|0
6146607|NCT01078623|9781688|FG004|Treatment Period 1|Adverse Event|0
6146608|NCT01078623|9781689|FG005|Treatment Period 1|Adverse Event|0
6146609|NCT01078623|9781690|FG006|Treatment Period 1|Adverse Event|1
6146610|NCT01078623|9781691|FG007|Treatment Period 1|Adverse Event|0
6146611|NCT01078623|9781692|FG008|Treatment Period 1|Adverse Event|1
6146612|NCT01078623|9781693|FG009|Treatment Period 1|Adverse Event|1
6146613|NCT01078623|9781694|FG010|Treatment Period 1|Adverse Event|0
6146614|NCT01078623|9781695|FG011|Treatment Period 1|Adverse Event|0
6146615|NCT01078623|9781696|FG012|Treatment Period 1|Adverse Event|0
6146616|NCT01078623|9781697|FG013|Treatment Period 1|Adverse Event|0
6146617|NCT01078623|9781698|FG014|Treatment Period 1|Adverse Event|0
6146618|NCT01078623|9781699|FG015|Treatment Period 1|Adverse Event|0
6146619|NCT01078623|9781700|FG016|Treatment Period 1|Adverse Event|0
6146620|NCT01078623|9781701|FG017|Treatment Period 1|Adverse Event|0
6146621|NCT01078623|9781702|FG018|Treatment Period 1|Adverse Event|0
6146622|NCT01078623|9781703|FG019|Treatment Period 1|Adverse Event|0
6146623|NCT01078623|9781684|FG000|Treatment Period 1|Withdrawal by Subject|0
6146624|NCT01078623|9781685|FG001|Treatment Period 1|Withdrawal by Subject|0
6146625|NCT01078623|9781686|FG002|Treatment Period 1|Withdrawal by Subject|0
6146626|NCT01078623|9781687|FG003|Treatment Period 1|Withdrawal by Subject|0
6146627|NCT01078623|9781688|FG004|Treatment Period 1|Withdrawal by Subject|0
6146628|NCT01078623|9781689|FG005|Treatment Period 1|Withdrawal by Subject|0
6146629|NCT01078623|9781690|FG006|Treatment Period 1|Withdrawal by Subject|0
6146630|NCT01078623|9781691|FG007|Treatment Period 1|Withdrawal by Subject|1
6146631|NCT01078623|9781692|FG008|Treatment Period 1|Withdrawal by Subject|0
6146632|NCT01078623|9781693|FG009|Treatment Period 1|Withdrawal by Subject|0
6146633|NCT01078623|9781694|FG010|Treatment Period 1|Withdrawal by Subject|1
6146634|NCT01078623|9781695|FG011|Treatment Period 1|Withdrawal by Subject|0
6146635|NCT01078623|9781696|FG012|Treatment Period 1|Withdrawal by Subject|0
6146636|NCT01078623|9781697|FG013|Treatment Period 1|Withdrawal by Subject|0
6146637|NCT01078623|9781698|FG014|Treatment Period 1|Withdrawal by Subject|0
6146638|NCT01078623|9781699|FG015|Treatment Period 1|Withdrawal by Subject|0
6146639|NCT01078623|9781700|FG016|Treatment Period 1|Withdrawal by Subject|0
6146640|NCT01078623|9781701|FG017|Treatment Period 1|Withdrawal by Subject|0
6146641|NCT01078623|9781702|FG018|Treatment Period 1|Withdrawal by Subject|0
6031740|NCT00307437|9627955|FG002|After Controlled Period|Adverse Event|0
6146642|NCT01078623|9781703|FG019|Treatment Period 1|Withdrawal by Subject|0
6146643|NCT01078623|9781684|FG000|Treatment Period 1|Protocol Violation|0
6146644|NCT01078623|9781685|FG001|Treatment Period 1|Protocol Violation|0
6146645|NCT01078623|9781686|FG002|Treatment Period 1|Protocol Violation|0
6031741|NCT00307437|9627956|FG003|After Controlled Period|Adverse Event|18
6031742|NCT00307437|9627957|FG004|After Controlled Period|Adverse Event|16
6031743|NCT00307437|9627958|FG005|After Controlled Period|Adverse Event|31
6031744|NCT00307437|9627959|FG006|After Controlled Period|Adverse Event|40
6031745|NCT00307437|9627953|FG000|After Controlled Period|Death|0
6031746|NCT00307437|9627954|FG001|After Controlled Period|Death|0
6031747|NCT00307437|9627955|FG002|After Controlled Period|Death|0
6031748|NCT00307437|9627956|FG003|After Controlled Period|Death|3
6031749|NCT00307437|9627957|FG004|After Controlled Period|Death|1
6031750|NCT00307437|9627958|FG005|After Controlled Period|Death|1
6031751|NCT00307437|9627959|FG006|After Controlled Period|Death|3
6031752|NCT00307437|9627953|FG000|After Controlled Period|Lack of Efficacy|0
6031753|NCT00307437|9627954|FG001|After Controlled Period|Lack of Efficacy|0
6031754|NCT00307437|9627955|FG002|After Controlled Period|Lack of Efficacy|0
6031755|NCT00307437|9627956|FG003|After Controlled Period|Lack of Efficacy|15
6031756|NCT00307437|9627957|FG004|After Controlled Period|Lack of Efficacy|17
6031757|NCT00307437|9627958|FG005|After Controlled Period|Lack of Efficacy|37
6031758|NCT00307437|9627959|FG006|After Controlled Period|Lack of Efficacy|24
6031759|NCT00307437|9627953|FG000|After Controlled Period|Lost to Follow-up|0
6031760|NCT00307437|9627954|FG001|After Controlled Period|Lost to Follow-up|0
6031761|NCT00307437|9627955|FG002|After Controlled Period|Lost to Follow-up|0
6031762|NCT00307437|9627956|FG003|After Controlled Period|Lost to Follow-up|7
6031763|NCT00307437|9627957|FG004|After Controlled Period|Lost to Follow-up|12
6031764|NCT00307437|9627958|FG005|After Controlled Period|Lost to Follow-up|13
6031765|NCT00307437|9627959|FG006|After Controlled Period|Lost to Follow-up|18
6146646|NCT01078623|9781687|FG003|Treatment Period 1|Protocol Violation|0
6146647|NCT01078623|9781688|FG004|Treatment Period 1|Protocol Violation|0
6146648|NCT01078623|9781689|FG005|Treatment Period 1|Protocol Violation|1
6146649|NCT01078623|9781690|FG006|Treatment Period 1|Protocol Violation|0
6146650|NCT01078623|9781691|FG007|Treatment Period 1|Protocol Violation|0
6146651|NCT01078623|9781692|FG008|Treatment Period 1|Protocol Violation|0
6146652|NCT01078623|9781693|FG009|Treatment Period 1|Protocol Violation|0
6146653|NCT01078623|9781694|FG010|Treatment Period 1|Protocol Violation|0
6146654|NCT01078623|9781695|FG011|Treatment Period 1|Protocol Violation|0
6146655|NCT01078623|9781696|FG012|Treatment Period 1|Protocol Violation|0
6146656|NCT01078623|9781697|FG013|Treatment Period 1|Protocol Violation|0
6146657|NCT01078623|9781698|FG014|Treatment Period 1|Protocol Violation|0
6146658|NCT01078623|9781699|FG015|Treatment Period 1|Protocol Violation|0
6146659|NCT01078623|9781700|FG016|Treatment Period 1|Protocol Violation|0
6146660|NCT01078623|9781701|FG017|Treatment Period 1|Protocol Violation|0
6146661|NCT01078623|9781702|FG018|Treatment Period 1|Protocol Violation|0
6146662|NCT01078623|9781703|FG019|Treatment Period 1|Protocol Violation|0
6146663|NCT01078623|9781684|FG000|Treatment Period 2|Adverse Event|0
6146664|NCT01078623|9781685|FG001|Treatment Period 2|Adverse Event|0
6146665|NCT01078623|9781686|FG002|Treatment Period 2|Adverse Event|0
6146666|NCT01078623|9781687|FG003|Treatment Period 2|Adverse Event|0
6146667|NCT01078623|9781688|FG004|Treatment Period 2|Adverse Event|0
6146668|NCT01078623|9781689|FG005|Treatment Period 2|Adverse Event|0
6146669|NCT01078623|9781690|FG006|Treatment Period 2|Adverse Event|1
6146670|NCT01078623|9781691|FG007|Treatment Period 2|Adverse Event|0
6146671|NCT01078623|9781692|FG008|Treatment Period 2|Adverse Event|0
6146672|NCT01078623|9781693|FG009|Treatment Period 2|Adverse Event|0
6146673|NCT01078623|9781694|FG010|Treatment Period 2|Adverse Event|0
6146674|NCT01078623|9781695|FG011|Treatment Period 2|Adverse Event|0
6146675|NCT01078623|9781696|FG012|Treatment Period 2|Adverse Event|0
6146676|NCT01078623|9781697|FG013|Treatment Period 2|Adverse Event|0
6146677|NCT01078623|9781698|FG014|Treatment Period 2|Adverse Event|0
6146678|NCT01078623|9781699|FG015|Treatment Period 2|Adverse Event|0
6146679|NCT01078623|9781700|FG016|Treatment Period 2|Adverse Event|0
6146680|NCT01078623|9781701|FG017|Treatment Period 2|Adverse Event|0
6146681|NCT01078623|9781702|FG018|Treatment Period 2|Adverse Event|1
6146682|NCT01078623|9781703|FG019|Treatment Period 2|Adverse Event|0
6146683|NCT01078623|9781684|FG000|Treatment Period 2|Withdrawal by Subject|0
6146684|NCT01078623|9781685|FG001|Treatment Period 2|Withdrawal by Subject|0
6146685|NCT01078623|9781686|FG002|Treatment Period 2|Withdrawal by Subject|0
6146686|NCT01078623|9781687|FG003|Treatment Period 2|Withdrawal by Subject|0
6146687|NCT01078623|9781688|FG004|Treatment Period 2|Withdrawal by Subject|0
6146688|NCT01078623|9781689|FG005|Treatment Period 2|Withdrawal by Subject|1
6146689|NCT01078623|9781690|FG006|Treatment Period 2|Withdrawal by Subject|0
6146690|NCT01078623|9781691|FG007|Treatment Period 2|Withdrawal by Subject|0
6146691|NCT01078623|9781692|FG008|Treatment Period 2|Withdrawal by Subject|0
6146692|NCT01078623|9781693|FG009|Treatment Period 2|Withdrawal by Subject|0
6146693|NCT01078623|9781694|FG010|Treatment Period 2|Withdrawal by Subject|0
6146694|NCT01078623|9781695|FG011|Treatment Period 2|Withdrawal by Subject|0
6146695|NCT01078623|9781696|FG012|Treatment Period 2|Withdrawal by Subject|0
6146696|NCT01078623|9781697|FG013|Treatment Period 2|Withdrawal by Subject|0
6031766|NCT00307437|9627953|FG000|After Controlled Period|Other|0
6031767|NCT00307437|9627954|FG001|After Controlled Period|Other|0
6031768|NCT00307437|9627955|FG002|After Controlled Period|Other|0
6031769|NCT00307437|9627956|FG003|After Controlled Period|Other|15
6146697|NCT01078623|9781698|FG014|Treatment Period 2|Withdrawal by Subject|0
6146698|NCT01078623|9781699|FG015|Treatment Period 2|Withdrawal by Subject|0
6146699|NCT01078623|9781700|FG016|Treatment Period 2|Withdrawal by Subject|0
6031770|NCT00307437|9627957|FG004|After Controlled Period|Other|9
6031771|NCT00307437|9627958|FG005|After Controlled Period|Other|40
6031772|NCT00307437|9627959|FG006|After Controlled Period|Other|28
6031773|NCT00307489|9627983|FG000|Baseline Through Week 48|Lost to Follow-up|0
6031774|NCT00307489|9627984|FG001|Baseline Through Week 48|Lost to Follow-up|1
6031775|NCT00307489|9627983|FG000|Baseline Through Week 48|Physician Decision|1
6031776|NCT00307489|9627984|FG001|Baseline Through Week 48|Physician Decision|0
6031777|NCT00307489|9627983|FG000|Baseline Through Week 48|Withdrawal by Subject|0
6031778|NCT00307489|9627984|FG001|Baseline Through Week 48|Withdrawal by Subject|1
6031779|NCT00307489|9627983|FG000|Week 48 Through Week 168|Adverse Event|1
6031780|NCT00307489|9627984|FG001|Week 48 Through Week 168|Adverse Event|0
6031781|NCT00307489|9627983|FG000|Week 48 Through Week 168|Physician Decision|1
6031782|NCT00307489|9627984|FG001|Week 48 Through Week 168|Physician Decision|0
6031783|NCT00307489|9627983|FG000|Week 48 Through Week 168|Withdrawal by Subject|1
6031784|NCT00307489|9627984|FG001|Week 48 Through Week 168|Withdrawal by Subject|2
6031785|NCT00307489|9627983|FG000|Week 48 Through Week 168|Lack of Efficacy|2
6031786|NCT00307489|9627984|FG001|Week 48 Through Week 168|Lack of Efficacy|2
6031787|NCT00307489|9627983|FG000|Week 48 Through Week 168|Death|0
6031788|NCT00307489|9627984|FG001|Week 48 Through Week 168|Death|1
6031789|NCT00307489|9627983|FG000|Week 48 Through Week 168|Lost to Follow-up|0
6031790|NCT00307489|9627984|FG001|Week 48 Through Week 168|Lost to Follow-up|1
6031791|NCT00307489|9627983|FG000|Week 48 Through Week 168|Seroconversion|1
6031792|NCT00307489|9627984|FG001|Week 48 Through Week 168|Seroconversion|0
6031793|NCT00307684|9627990|FG000|Open Label Phase|Lack of Efficacy|0
6146700|NCT01078623|9781701|FG017|Treatment Period 2|Withdrawal by Subject|0
6146701|NCT01078623|9781702|FG018|Treatment Period 2|Withdrawal by Subject|0
6146702|NCT01078623|9781703|FG019|Treatment Period 2|Withdrawal by Subject|0
6146703|NCT01078623|9781684|FG000|Treatment Period 3|Adverse Event|0
6146704|NCT01078623|9781685|FG001|Treatment Period 3|Adverse Event|0
6146705|NCT01078623|9781686|FG002|Treatment Period 3|Adverse Event|0
6146706|NCT01078623|9781687|FG003|Treatment Period 3|Adverse Event|0
6146707|NCT01078623|9781688|FG004|Treatment Period 3|Adverse Event|1
6146708|NCT01078623|9781689|FG005|Treatment Period 3|Adverse Event|0
6146709|NCT01078623|9781690|FG006|Treatment Period 3|Adverse Event|0
6146710|NCT01078623|9781691|FG007|Treatment Period 3|Adverse Event|0
6146711|NCT01078623|9781692|FG008|Treatment Period 3|Adverse Event|0
6146712|NCT01078623|9781693|FG009|Treatment Period 3|Adverse Event|0
6146713|NCT01078623|9781694|FG010|Treatment Period 3|Adverse Event|0
6146714|NCT01078623|9781695|FG011|Treatment Period 3|Adverse Event|0
6146715|NCT01078623|9781696|FG012|Treatment Period 3|Adverse Event|0
6146716|NCT01078623|9781697|FG013|Treatment Period 3|Adverse Event|1
6146717|NCT01078623|9781698|FG014|Treatment Period 3|Adverse Event|0
6146718|NCT01078623|9781699|FG015|Treatment Period 3|Adverse Event|0
6146719|NCT01078623|9781700|FG016|Treatment Period 3|Adverse Event|0
6146720|NCT01078623|9781701|FG017|Treatment Period 3|Adverse Event|0
6146721|NCT01078623|9781702|FG018|Treatment Period 3|Adverse Event|0
6146722|NCT01078623|9781703|FG019|Treatment Period 3|Adverse Event|0
6146723|NCT01078623|9781684|FG000|Treatment Period 4|Adverse Event|0
6146724|NCT01078623|9781685|FG001|Treatment Period 4|Adverse Event|0
6146725|NCT01078623|9781686|FG002|Treatment Period 4|Adverse Event|1
6146726|NCT01078623|9781687|FG003|Treatment Period 4|Adverse Event|0
6146727|NCT01078623|9781688|FG004|Treatment Period 4|Adverse Event|0
6146728|NCT01078623|9781689|FG005|Treatment Period 4|Adverse Event|0
6146729|NCT01078623|9781690|FG006|Treatment Period 4|Adverse Event|0
6146730|NCT01078623|9781691|FG007|Treatment Period 4|Adverse Event|0
6146731|NCT01078623|9781692|FG008|Treatment Period 4|Adverse Event|0
6146732|NCT01078623|9781693|FG009|Treatment Period 4|Adverse Event|0
6146733|NCT01078623|9781694|FG010|Treatment Period 4|Adverse Event|0
6146734|NCT01078623|9781695|FG011|Treatment Period 4|Adverse Event|0
6146735|NCT01078623|9781696|FG012|Treatment Period 4|Adverse Event|0
6146736|NCT01078623|9781697|FG013|Treatment Period 4|Adverse Event|0
6146737|NCT01078623|9781698|FG014|Treatment Period 4|Adverse Event|0
6146738|NCT01078623|9781699|FG015|Treatment Period 4|Adverse Event|0
6146739|NCT01078623|9781700|FG016|Treatment Period 4|Adverse Event|0
6146740|NCT01078623|9781701|FG017|Treatment Period 4|Adverse Event|0
6146741|NCT01078623|9781702|FG018|Treatment Period 4|Adverse Event|0
6146742|NCT01078623|9781703|FG019|Treatment Period 4|Adverse Event|0
6146743|NCT01078623|9781684|FG000|Treatment Period 4|Withdrawal by Subject|0
6146744|NCT01078623|9781685|FG001|Treatment Period 4|Withdrawal by Subject|0
6146745|NCT01078623|9781686|FG002|Treatment Period 4|Withdrawal by Subject|0
6146746|NCT01078623|9781687|FG003|Treatment Period 4|Withdrawal by Subject|0
6146747|NCT01078623|9781688|FG004|Treatment Period 4|Withdrawal by Subject|0
6146748|NCT01078623|9781689|FG005|Treatment Period 4|Withdrawal by Subject|0
6146749|NCT01078623|9781690|FG006|Treatment Period 4|Withdrawal by Subject|0
6146750|NCT01078623|9781691|FG007|Treatment Period 4|Withdrawal by Subject|0
6146751|NCT01078623|9781692|FG008|Treatment Period 4|Withdrawal by Subject|0
6146752|NCT01078623|9781693|FG009|Treatment Period 4|Withdrawal by Subject|0
6146753|NCT01078623|9781694|FG010|Treatment Period 4|Withdrawal by Subject|0
6146754|NCT01078623|9781695|FG011|Treatment Period 4|Withdrawal by Subject|0
6146755|NCT01078623|9781696|FG012|Treatment Period 4|Withdrawal by Subject|0
6146756|NCT01078623|9781697|FG013|Treatment Period 4|Withdrawal by Subject|0
6146757|NCT01078623|9781698|FG014|Treatment Period 4|Withdrawal by Subject|0
6146758|NCT01078623|9781699|FG015|Treatment Period 4|Withdrawal by Subject|1
6146759|NCT01078623|9781700|FG016|Treatment Period 4|Withdrawal by Subject|0
6031794|NCT00307684|9627991|FG001|Open Label Phase|Lack of Efficacy|0
6031795|NCT00307684|9627992|FG002|Open Label Phase|Lack of Efficacy|3
6031796|NCT00307684|9627990|FG000|Open Label Phase|Adverse Event|0
6031797|NCT00307684|9627991|FG001|Open Label Phase|Adverse Event|0
6031798|NCT00307684|9627992|FG002|Open Label Phase|Adverse Event|16
6031799|NCT00307684|9627990|FG000|Open Label Phase|Withdrawal by Subject|0
6031800|NCT00307684|9627991|FG001|Open Label Phase|Withdrawal by Subject|0
6031801|NCT00307684|9627992|FG002|Open Label Phase|Withdrawal by Subject|15
6031802|NCT00307684|9627990|FG000|Open Label Phase|Lost to Follow-up|0
6031803|NCT00307684|9627991|FG001|Open Label Phase|Lost to Follow-up|0
6031804|NCT00307684|9627992|FG002|Open Label Phase|Lost to Follow-up|11
6031805|NCT00307684|9627990|FG000|Open Label Phase|non compliance|0
6031806|NCT00307684|9627991|FG001|Open Label Phase|non compliance|0
6031807|NCT00307684|9627992|FG002|Open Label Phase|non compliance|5
6031808|NCT00307684|9627990|FG000|Open Label Phase|other|0
6146760|NCT01078623|9781701|FG017|Treatment Period 4|Withdrawal by Subject|0
6146761|NCT01078623|9781702|FG018|Treatment Period 4|Withdrawal by Subject|0
6146762|NCT01078623|9781703|FG019|Treatment Period 4|Withdrawal by Subject|0
6146763|NCT01078675|9781717|FG000|Overall Study|Withdrawal by Subject|7
6146764|NCT01078675|9781718|FG001|Overall Study|Withdrawal by Subject|3
6146765|NCT01078675|9781717|FG000|Overall Study|Protocol Violation|56
6146766|NCT01078675|9781718|FG001|Overall Study|Protocol Violation|0
6146767|NCT01078675|9781717|FG000|Overall Study|Provided in CRF for specific reasons|2
6146768|NCT01078675|9781718|FG001|Overall Study|Provided in CRF for specific reasons|3
6146769|NCT01078675|9781717|FG000|Overall Study|Adverse Event|3
6146770|NCT01078675|9781718|FG001|Overall Study|Adverse Event|0
6146771|NCT01078805|9781733|FG000|Overall Study|Clinically significant abnormal lab|5
6146772|NCT01078805|9781733|FG000|Overall Study|Death|134
6146773|NCT01078805|9781733|FG000|Overall Study|Lost to Follow-up|676
6146774|NCT01078805|9781733|FG000|Overall Study|Physician Decision|169
6146775|NCT01078805|9781733|FG000|Overall Study|Serious adverse event|26
6146776|NCT01078805|9781733|FG000|Overall Study|Sponsor decision|46
6146777|NCT01078805|9781733|FG000|Overall Study|Withdrawal by Subject|739
6146778|NCT01078805|9781733|FG000|Overall Study|Other|173
6146779|NCT01078805|9781733|FG000|Overall Study|Didn't take study drug|82
6146780|NCT01078922|9781758|FG000|Overall Study|Adverse Event|1
6146781|NCT01078974|9781763|FG000|Overall Study|Adverse Event|3
6146782|NCT01079130|9781773|FG000|Overall Study|Adverse Event|1
6146783|NCT01079130|9781774|FG001|Overall Study|Adverse Event|1
6146784|NCT01079130|9781775|FG002|Overall Study|Adverse Event|0
6146785|NCT01079130|9781776|FG003|Overall Study|Adverse Event|1
6146786|NCT01079130|9781777|FG004|Overall Study|Adverse Event|5
6146787|NCT01079130|9781778|FG005|Overall Study|Adverse Event|1
6146788|NCT01079130|9781773|FG000|Overall Study|Administrative problems|1
6146789|NCT01079130|9781774|FG001|Overall Study|Administrative problems|3
6146790|NCT01079130|9781775|FG002|Overall Study|Administrative problems|0
6146791|NCT01079130|9781776|FG003|Overall Study|Administrative problems|0
6146792|NCT01079130|9781777|FG004|Overall Study|Administrative problems|0
6146793|NCT01079130|9781778|FG005|Overall Study|Administrative problems|1
6146794|NCT01079130|9781773|FG000|Overall Study|Withdrawal by Subject|0
6146795|NCT01079130|9781774|FG001|Overall Study|Withdrawal by Subject|1
6146796|NCT01079130|9781775|FG002|Overall Study|Withdrawal by Subject|0
6146797|NCT01079130|9781776|FG003|Overall Study|Withdrawal by Subject|0
6146798|NCT01079130|9781777|FG004|Overall Study|Withdrawal by Subject|1
6146799|NCT01079130|9781778|FG005|Overall Study|Withdrawal by Subject|3
6146800|NCT01079130|9781773|FG000|Overall Study|Protocol deviation|0
6146801|NCT01079130|9781774|FG001|Overall Study|Protocol deviation|2
6146802|NCT01079130|9781775|FG002|Overall Study|Protocol deviation|1
6146803|NCT01079130|9781776|FG003|Overall Study|Protocol deviation|2
6146804|NCT01079130|9781777|FG004|Overall Study|Protocol deviation|0
6146805|NCT01079130|9781778|FG005|Overall Study|Protocol deviation|0
6146806|NCT01079130|9781773|FG000|Overall Study|Abnormal test procedure result(s)|0
6146807|NCT01079130|9781774|FG001|Overall Study|Abnormal test procedure result(s)|0
6146808|NCT01079130|9781775|FG002|Overall Study|Abnormal test procedure result(s)|0
6146809|NCT01079130|9781776|FG003|Overall Study|Abnormal test procedure result(s)|0
6146810|NCT01079130|9781777|FG004|Overall Study|Abnormal test procedure result(s)|1
6146811|NCT01079130|9781778|FG005|Overall Study|Abnormal test procedure result(s)|0
6146812|NCT01079130|9781773|FG000|Overall Study|Unsatisfactory therapeutic effect|0
6146813|NCT01079130|9781774|FG001|Overall Study|Unsatisfactory therapeutic effect|0
6146814|NCT01079130|9781775|FG002|Overall Study|Unsatisfactory therapeutic effect|0
6146815|NCT01079130|9781776|FG003|Overall Study|Unsatisfactory therapeutic effect|2
6146816|NCT01079130|9781777|FG004|Overall Study|Unsatisfactory therapeutic effect|0
6146817|NCT01079130|9781778|FG005|Overall Study|Unsatisfactory therapeutic effect|0
6146818|NCT01079130|9781773|FG000|Overall Study|Lost to Follow-up|0
6146819|NCT01079130|9781774|FG001|Overall Study|Lost to Follow-up|0
6146820|NCT01079130|9781775|FG002|Overall Study|Lost to Follow-up|0
6146821|NCT01079130|9781776|FG003|Overall Study|Lost to Follow-up|0
6146822|NCT01079130|9781777|FG004|Overall Study|Lost to Follow-up|1
6146823|NCT01079130|9781778|FG005|Overall Study|Lost to Follow-up|0
6031809|NCT00307684|9627991|FG001|Open Label Phase|other|0
6031810|NCT00307684|9627992|FG002|Open Label Phase|other|6
6031811|NCT00307684|9627990|FG000|Double Blind Phase|Lack of Efficacy|2
6031812|NCT00307684|9627991|FG001|Double Blind Phase|Lack of Efficacy|5
6031813|NCT00307684|9627992|FG002|Double Blind Phase|Lack of Efficacy|0
6031814|NCT00307736|9628000|FG000|Overall Study|Adverse Event|0
6031815|NCT00307736|9628001|FG001|Overall Study|Adverse Event|0
6031816|NCT00307736|9628002|FG002|Overall Study|Adverse Event|1
6031817|NCT00307736|9628003|FG003|Overall Study|Adverse Event|3
6031818|NCT00307736|9628000|FG000|Overall Study|Withdrawal by Subject|0
6031819|NCT00307736|9628001|FG001|Overall Study|Withdrawal by Subject|0
6031820|NCT00307736|9628002|FG002|Overall Study|Withdrawal by Subject|2
6031821|NCT00307736|9628003|FG003|Overall Study|Withdrawal by Subject|0
6031822|NCT00307801|9628016|FG000|Overall Study|Adverse Event|12
6031823|NCT00307801|9628017|FG001|Overall Study|Adverse Event|4
6031824|NCT00307801|9628016|FG000|Overall Study|Withdrawal by Subject|9
6031825|NCT00307801|9628017|FG001|Overall Study|Withdrawal by Subject|4
6031826|NCT00307801|9628016|FG000|Overall Study|Non-compliance, not taken all tablets|1
6031827|NCT00307801|9628017|FG001|Overall Study|Non-compliance, not taken all tablets|2
6031828|NCT00307801|9628016|FG000|Overall Study|Adverse event (AE)/Withdrawal of consent|2
6031829|NCT00307801|9628017|FG001|Overall Study|Adverse event (AE)/Withdrawal of consent|0
6031830|NCT00307801|9628016|FG000|Overall Study|Decreased Libido (AE at discontinuation)|0
6031831|NCT00307801|9628017|FG001|Overall Study|Decreased Libido (AE at discontinuation)|1
6031832|NCT00307801|9628016|FG000|Overall Study|Wrong Randomization|1
6031833|NCT00307801|9628017|FG001|Overall Study|Wrong Randomization|0
6031834|NCT00307801|9628016|FG000|Overall Study|Lack of Efficacy|0
6031835|NCT00307801|9628017|FG001|Overall Study|Lack of Efficacy|2
6031836|NCT00307801|9628016|FG000|Overall Study|Lost to Follow-up, moved abroad|1
6031837|NCT00307801|9628017|FG001|Overall Study|Lost to Follow-up, moved abroad|1
6031838|NCT00307801|9628016|FG000|Overall Study|Frustration with e-diary|1
6031839|NCT00307801|9628017|FG001|Overall Study|Frustration with e-diary|0
6031840|NCT00307801|9628016|FG000|Overall Study|Protocol Violation|3
6031841|NCT00307801|9628017|FG001|Overall Study|Protocol Violation|2
6031842|NCT00307801|9628016|FG000|Overall Study|No reason specified|2
6031843|NCT00307801|9628017|FG001|Overall Study|No reason specified|0
6031844|NCT00307801|9628016|FG000|Overall Study|Pregnancy|0
6031845|NCT00307801|9628017|FG001|Overall Study|Pregnancy|1
6031846|NCT00307931|9628024|FG000|Overall Study|Adverse Event|1
6031847|NCT00308074|9628038|FG000|Overall Study|Withdrawal by Subject|1
6031848|NCT00308087|9628044|FG000|Overall Study|Progressive Disease|19
6031849|NCT00308087|9628045|FG001|Overall Study|Progressive Disease|21
6031850|NCT00308087|9628044|FG000|Overall Study|Study Closure|11
6031851|NCT00308087|9628045|FG001|Overall Study|Study Closure|12
6031852|NCT00308087|9628044|FG000|Overall Study|Withdrawal by Subject|2
6031853|NCT00308087|9628045|FG001|Overall Study|Withdrawal by Subject|1
6031854|NCT00308087|9628044|FG000|Overall Study|Other|4
6031855|NCT00308087|9628045|FG001|Overall Study|Other|3
6031856|NCT00308139|9628053|FG000|Overall Study|Adverse Event|20
6031857|NCT00308139|9628054|FG001|Overall Study|Adverse Event|14
6031858|NCT00308139|9628053|FG000|Overall Study|Lost to Follow-up|13
6031859|NCT00308139|9628054|FG001|Overall Study|Lost to Follow-up|8
6031860|NCT00308139|9628053|FG000|Overall Study|Protocol Violation|3
6031861|NCT00308139|9628054|FG001|Overall Study|Protocol Violation|2
6031862|NCT00308139|9628053|FG000|Overall Study|Withdrawal of Consent|40
6031863|NCT00308139|9628054|FG001|Overall Study|Withdrawal of Consent|42
6031864|NCT00308139|9628053|FG000|Overall Study|Investigator Decision|11
6031865|NCT00308139|9628054|FG001|Overall Study|Investigator Decision|10
6031866|NCT00308139|9628053|FG000|Overall Study|Loss of Glucose Control|5
6031867|NCT00308139|9628054|FG001|Overall Study|Loss of Glucose Control|7
6031868|NCT00308139|9628053|FG000|Overall Study|Administrative|1
6031869|NCT00308139|9628054|FG001|Overall Study|Administrative|4
6031870|NCT00308139|9628053|FG000|Overall Study|Other|1
6031871|NCT00308139|9628054|FG001|Overall Study|Other|0
6031872|NCT00308308|9628115|FG000|Overall Study|Adverse Event|17
6031873|NCT00308308|9628116|FG001|Overall Study|Adverse Event|2
6031874|NCT00308308|9628115|FG000|Overall Study|Lost to Follow-up|5
6031875|NCT00308308|9628116|FG001|Overall Study|Lost to Follow-up|5
6031876|NCT00308308|9628115|FG000|Overall Study|Physician Decision|15
6031877|NCT00308308|9628116|FG001|Overall Study|Physician Decision|7
6031878|NCT00308308|9628115|FG000|Overall Study|Protocol Violation|3
6031879|NCT00308308|9628116|FG001|Overall Study|Protocol Violation|14
6031880|NCT00308308|9628115|FG000|Overall Study|Withdrawal by Subject|47
6031881|NCT00308308|9628116|FG001|Overall Study|Withdrawal by Subject|19
6031882|NCT00308308|9628115|FG000|Overall Study|Various|7
6031883|NCT00308308|9628116|FG001|Overall Study|Various|5
6031884|NCT00308308|9628115|FG000|Overall Study|Randomized but not dosed|8
6031885|NCT00308308|9628116|FG001|Overall Study|Randomized but not dosed|16
6031886|NCT00308308|9628115|FG000|Overall Study|Other|1
6031887|NCT00308308|9628116|FG001|Overall Study|Other|0
6031888|NCT00308555|9628124|FG000|Overall Study|Withdrawal by Subject|1
6031889|NCT00308555|9628125|FG001|Overall Study|Withdrawal by Subject|0
6031890|NCT00308555|9628124|FG000|Overall Study|Physician Decision|2
6031891|NCT00308555|9628125|FG001|Overall Study|Physician Decision|0
6031892|NCT00308581|9628131|FG000|Induction Phase|Adverse Event|0
6031893|NCT00308581|9628132|FG001|Induction Phase|Adverse Event|0
6031894|NCT00308581|9628133|FG002|Induction Phase|Adverse Event|37
6031895|NCT00308581|9628131|FG000|Induction Phase|Lack of Efficacy|0
6031896|NCT00308581|9628132|FG001|Induction Phase|Lack of Efficacy|0
6031897|NCT00308581|9628133|FG002|Induction Phase|Lack of Efficacy|121
6031898|NCT00308581|9628131|FG000|Induction Phase|Withdrawal by Subject|0
6031899|NCT00308581|9628132|FG001|Induction Phase|Withdrawal by Subject|0
6031900|NCT00308581|9628133|FG002|Induction Phase|Withdrawal by Subject|5
6031901|NCT00308581|9628131|FG000|Induction Phase|Unknown reason|0
6031902|NCT00308581|9628132|FG001|Induction Phase|Unknown reason|0
6031903|NCT00308581|9628133|FG002|Induction Phase|Unknown reason|3
6031904|NCT00308581|9628131|FG000|Randomized Maintenance Phase|Adverse Event|10
6031905|NCT00308581|9628132|FG001|Randomized Maintenance Phase|Adverse Event|17
6031906|NCT00308581|9628133|FG002|Randomized Maintenance Phase|Adverse Event|0
6031907|NCT00308581|9628131|FG000|Randomized Maintenance Phase|Lack of Efficacy|9
6031908|NCT00308581|9628132|FG001|Randomized Maintenance Phase|Lack of Efficacy|21
6031909|NCT00308581|9628133|FG002|Randomized Maintenance Phase|Lack of Efficacy|0
6031910|NCT00308581|9628131|FG000|Randomized Maintenance Phase|Lost to Follow-up|0
6031911|NCT00308581|9628132|FG001|Randomized Maintenance Phase|Lost to Follow-up|2
6031912|NCT00308581|9628133|FG002|Randomized Maintenance Phase|Lost to Follow-up|0
6031913|NCT00308581|9628131|FG000|Randomized Maintenance Phase|Withdrawal by Subject|1
6031914|NCT00308581|9628132|FG001|Randomized Maintenance Phase|Withdrawal by Subject|4
6031915|NCT00308581|9628133|FG002|Randomized Maintenance Phase|Withdrawal by Subject|0
6031916|NCT00308581|9628131|FG000|Randomized Maintenance Phase|Switched to Q2W open-label treatment|82
6031917|NCT00308581|9628132|FG001|Randomized Maintenance Phase|Switched to Q2W open-label treatment|59
6031918|NCT00308581|9628133|FG002|Randomized Maintenance Phase|Switched to Q2W open-label treatment|0
6031919|NCT00308581|9628131|FG000|Randomized Maintenance Phase|Unknown reason|3
6031920|NCT00308581|9628132|FG001|Randomized Maintenance Phase|Unknown reason|0
6031921|NCT00308581|9628133|FG002|Randomized Maintenance Phase|Unknown reason|0
6031922|NCT00308620|9628144|FG000|Overall Study|Death|1
6031923|NCT00308620|9628145|FG001|Overall Study|Death|1
6031924|NCT00308620|9628146|FG002|Overall Study|Death|0
6031925|NCT00308620|9628144|FG000|Overall Study|Lost to Follow-up|0
6031926|NCT00308620|9628145|FG001|Overall Study|Lost to Follow-up|0
6031927|NCT00308620|9628146|FG002|Overall Study|Lost to Follow-up|1
6031928|NCT00308711|9628157|FG000|Overall Study|Withdrawal by Subject|1
6031929|NCT00308711|9628158|FG001|Overall Study|Withdrawal by Subject|0
6031930|NCT00308711|9628159|FG002|Overall Study|Withdrawal by Subject|1
6031931|NCT00308711|9628157|FG000|Overall Study|Protocol Violation|0
6031932|NCT00308711|9628158|FG001|Overall Study|Protocol Violation|1
6031933|NCT00308711|9628159|FG002|Overall Study|Protocol Violation|1
6031934|NCT00308711|9628157|FG000|Overall Study|Lost to Follow-up|0
6031935|NCT00308711|9628158|FG001|Overall Study|Lost to Follow-up|1
6031936|NCT00308711|9628159|FG002|Overall Study|Lost to Follow-up|0
6031937|NCT00308711|9628157|FG000|Overall Study|Baby not born within 7 days of treatment|1
6031938|NCT00308711|9628158|FG001|Overall Study|Baby not born within 7 days of treatment|2
6031939|NCT00308711|9628159|FG002|Overall Study|Baby not born within 7 days of treatment|2
6031940|NCT00308711|9628157|FG000|Overall Study|Subject incarcerated, data not allowed|0
6031941|NCT00308711|9628158|FG001|Overall Study|Subject incarcerated, data not allowed|0
6031942|NCT00308711|9628159|FG002|Overall Study|Subject incarcerated, data not allowed|1
6031943|NCT00308737|9628170|FG000|Overall Study|Adverse Event|104
6309557|NCT02640612|10038247|FG000|Overall Study|Protocol Violation|0
6309558|NCT02640612|10038248|FG001|Overall Study|Protocol Violation|2
6146824|NCT01079182|9781813|FG000|Overall Study|Lost to Follow-up|1634
6146825|NCT01079182|9781813|FG000|Overall Study|Adverse Drug Reaction (ADR)|261
6146826|NCT01079182|9781813|FG000|Overall Study|Lack of Efficacy|514
6146827|NCT01079182|9781813|FG000|Overall Study|ADR and Lack of Effectiveness|39
6146828|NCT01079182|9781813|FG000|Overall Study|Reasons not Evaluated|271
6146829|NCT01079195|9781817|FG000|Overall Study|No Documentation of Tarka Therapy|739
6146830|NCT01079195|9781817|FG000|Overall Study|No Documentation Available|437
6146831|NCT01079195|9781817|FG000|Overall Study|Adverse Event|157
6146832|NCT01079195|9781817|FG000|Overall Study|Reason Unknown|39
6146833|NCT01079195|9781817|FG000|Overall Study|Withdrawal by Subject|18
6146834|NCT01079195|9781817|FG000|Overall Study|Financial Reasons|15
6146835|NCT01079195|9781817|FG000|Overall Study|Lack of Effectiveness|12
6146836|NCT01079195|9781817|FG000|Overall Study|Physician Decision|4
6146837|NCT01079195|9781817|FG000|Overall Study|Improved Status of Participant|4
6146838|NCT01079195|9781817|FG000|Overall Study|No Follow-up Documentation Available|4
6146839|NCT01079195|9781817|FG000|Overall Study|Non-compliance|2
6146840|NCT01079234|9781824|FG000|Main: Week 0 to 26|Adverse Event|5
6146841|NCT01079234|9781825|FG001|Main: Week 0 to 26|Adverse Event|4
6146842|NCT01079234|9781826|FG002|Main: Week 0 to 26|Adverse Event|1
6146843|NCT01079234|9781827|FG003|Main: Week 0 to 26|Adverse Event|0
6146844|NCT01079234|9781824|FG000|Main: Week 0 to 26|Lack of Efficacy|2
6031944|NCT00308737|9628171|FG001|Overall Study|Adverse Event|9
6031945|NCT00308737|9628172|FG002|Overall Study|Adverse Event|0
6031946|NCT00308737|9628170|FG000|Overall Study|Death|4
6031947|NCT00308737|9628171|FG001|Overall Study|Death|3
6031948|NCT00308737|9628172|FG002|Overall Study|Death|0
6031949|NCT00308737|9628170|FG000|Overall Study|Lost to Follow-up|56
6031950|NCT00308737|9628171|FG001|Overall Study|Lost to Follow-up|80
6031951|NCT00308737|9628172|FG002|Overall Study|Lost to Follow-up|5
6031952|NCT00308737|9628170|FG000|Overall Study|Physician Decision|15
6031953|NCT00308737|9628171|FG001|Overall Study|Physician Decision|2
6146845|NCT01079234|9781825|FG001|Main: Week 0 to 26|Lack of Efficacy|1
6146846|NCT01079234|9781826|FG002|Main: Week 0 to 26|Lack of Efficacy|1
6031954|NCT00308737|9628172|FG002|Overall Study|Physician Decision|1
6031955|NCT00308737|9628170|FG000|Overall Study|Protocol Violation|34
6031956|NCT00308737|9628171|FG001|Overall Study|Protocol Violation|9
6031957|NCT00308737|9628172|FG002|Overall Study|Protocol Violation|5
6031958|NCT00308737|9628170|FG000|Overall Study|Withdrawal by Subject|218
6031959|NCT00308737|9628171|FG001|Overall Study|Withdrawal by Subject|166
6031960|NCT00308737|9628172|FG002|Overall Study|Withdrawal by Subject|18
6031961|NCT00308737|9628170|FG000|Overall Study|Various|32
6031962|NCT00308737|9628171|FG001|Overall Study|Various|20
6031963|NCT00308737|9628172|FG002|Overall Study|Various|8
6031964|NCT00308750|9628183|FG000|Overall Study|Adverse Event|9
6031965|NCT00308750|9628184|FG001|Overall Study|Adverse Event|9
6031966|NCT00308750|9628185|FG002|Overall Study|Adverse Event|13
6031967|NCT00308750|9628183|FG000|Overall Study|Withdrawal by Subject|6
6031968|NCT00308750|9628184|FG001|Overall Study|Withdrawal by Subject|2
6031969|NCT00308750|9628185|FG002|Overall Study|Withdrawal by Subject|3
6031970|NCT00308750|9628183|FG000|Overall Study|Physician Decision|3
6031971|NCT00308750|9628184|FG001|Overall Study|Physician Decision|4
6031972|NCT00308750|9628185|FG002|Overall Study|Physician Decision|3
6031973|NCT00308750|9628183|FG000|Overall Study|Sponsor Decision|1
6031974|NCT00308750|9628184|FG001|Overall Study|Sponsor Decision|0
6031975|NCT00308750|9628185|FG002|Overall Study|Sponsor Decision|0
6031976|NCT00308750|9628183|FG000|Overall Study|Disease Progression|47
6031977|NCT00308750|9628184|FG001|Overall Study|Disease Progression|24
6031978|NCT00308750|9628185|FG002|Overall Study|Disease Progression|28
6031979|NCT00308750|9628183|FG000|Overall Study|Unrelated Complication|3
6031980|NCT00308750|9628184|FG001|Overall Study|Unrelated Complication|0
6031981|NCT00308750|9628185|FG002|Overall Study|Unrelated Complication|1
6031982|NCT00308750|9628183|FG000|Overall Study|Death|1
6031983|NCT00308750|9628184|FG001|Overall Study|Death|0
6031984|NCT00308750|9628185|FG002|Overall Study|Death|1
6031985|NCT00308750|9628183|FG000|Overall Study|Protocol Violation|1
6031986|NCT00308750|9628184|FG001|Overall Study|Protocol Violation|0
6031987|NCT00308750|9628185|FG002|Overall Study|Protocol Violation|0
6031988|NCT00308750|9628183|FG000|Overall Study|New Primary Disease Identified|1
6031989|NCT00308750|9628184|FG001|Overall Study|New Primary Disease Identified|1
6031990|NCT00308750|9628185|FG002|Overall Study|New Primary Disease Identified|0
6048627|NCT00419744|9647907|FG001|Overall Study|Spirometry mouthpiece issues|1
6048628|NCT00419744|9647908|FG002|Overall Study|Spirometry mouthpiece issues|2
6048629|NCT00419744|9647906|FG000|Overall Study|Incorrect medication kit dispensed|0
6048630|NCT00419744|9647907|FG001|Overall Study|Incorrect medication kit dispensed|0
6048631|NCT00419744|9647908|FG002|Overall Study|Incorrect medication kit dispensed|1
6048632|NCT00419757|9647918|FG000|Overall Study|Adverse Event|1
6048633|NCT00419757|9647919|FG001|Overall Study|Adverse Event|4
6048634|NCT00419757|9647918|FG000|Overall Study|Lost to Follow-up|1
6048635|NCT00419757|9647919|FG001|Overall Study|Lost to Follow-up|4
6048636|NCT00419757|9647918|FG000|Overall Study|Withdrawal by Subject|7
6048637|NCT00419757|9647919|FG001|Overall Study|Withdrawal by Subject|1
6048638|NCT00419757|9647918|FG000|Overall Study|Protocol Violation|2
6048639|NCT00419757|9647919|FG001|Overall Study|Protocol Violation|3
6048640|NCT00419757|9647918|FG000|Overall Study|Study specific discontinuation criteria|4
6048641|NCT00419757|9647919|FG001|Overall Study|Study specific discontinuation criteria|8
6048642|NCT00419757|9647918|FG000|Overall Study|Multiple reasons|3
6048643|NCT00419757|9647919|FG001|Overall Study|Multiple reasons|1
6048644|NCT00419770|9647929|FG000|Overall Study|Withdrawal by Subject|5
6048645|NCT00419770|9647930|FG001|Overall Study|Withdrawal by Subject|1
6048646|NCT00419926|9647938|FG000|Overall Study|Withdrawal by Subject|7
6048647|NCT00419926|9647939|FG001|Overall Study|Withdrawal by Subject|3
6048648|NCT00419926|9647938|FG000|Overall Study|Administrative Problem|4
6048649|NCT00419926|9647939|FG001|Overall Study|Administrative Problem|4
6048650|NCT00419926|9647938|FG000|Overall Study|Lost to Follow-up|1
6048651|NCT00419926|9647939|FG001|Overall Study|Lost to Follow-up|2
6048652|NCT00419926|9647938|FG000|Overall Study|Death|2
6048653|NCT00419926|9647939|FG001|Overall Study|Death|1
6048654|NCT00419952|9647947|FG000|Overall Study|Adverse Event|8
6048655|NCT00419952|9647948|FG001|Overall Study|Adverse Event|10
6048656|NCT00419952|9647947|FG000|Overall Study|Withdrawal by Subject|44
6048657|NCT00419952|9647948|FG001|Overall Study|Withdrawal by Subject|43
6048658|NCT00419952|9647947|FG000|Overall Study|Lost to Follow-up|43
6048659|NCT00419952|9647948|FG001|Overall Study|Lost to Follow-up|34
6048660|NCT00419952|9647947|FG000|Overall Study|Protocol Violation|32
6048661|NCT00419952|9647948|FG001|Overall Study|Protocol Violation|24
6048662|NCT00419952|9647947|FG000|Overall Study|Pregnancy|4
6048663|NCT00419952|9647948|FG001|Overall Study|Pregnancy|2
6048664|NCT00419952|9647947|FG000|Overall Study|Physician Decision|1
6048665|NCT00419952|9647948|FG001|Overall Study|Physician Decision|3
6048666|NCT00419952|9647947|FG000|Overall Study|Incorrectly enrolled|10
6048667|NCT00419952|9647948|FG001|Overall Study|Incorrectly enrolled|3
6048668|NCT00419952|9647947|FG000|Overall Study|Intake of prohibited medication|2
6048669|NCT00419952|9647948|FG001|Overall Study|Intake of prohibited medication|2
6048670|NCT00419952|9647947|FG000|Overall Study|Occurence of 2 or more exacerbations|2
6048671|NCT00419952|9647948|FG001|Overall Study|Occurence of 2 or more exacerbations|0
6048672|NCT00419952|9647947|FG000|Overall Study|Diary or medication non-compliance|2
6048673|NCT00419952|9647948|FG001|Overall Study|Diary or medication non-compliance|4
6031991|NCT00308997|9628196|FG000|Overall Study|Subject feigned clinical data|0
6031992|NCT00308997|9628197|FG001|Overall Study|Subject feigned clinical data|1
6031993|NCT00308997|9628196|FG000|Overall Study|Unable to tolerate intervention|1
6031994|NCT00308997|9628197|FG001|Overall Study|Unable to tolerate intervention|0
6031995|NCT00309166|9628209|FG000|Overall Study|Adverse event, non-fatal|1
6031996|NCT00309166|9628210|FG001|Overall Study|Adverse event, non-fatal|0
6031997|NCT00309166|9628209|FG000|Overall Study|Withdrawal by Subject|4
6031998|NCT00309166|9628210|FG001|Overall Study|Withdrawal by Subject|3
6031999|NCT00309244|9628218|FG000|Overall Study|Adverse Event|29
6032000|NCT00309244|9628219|FG001|Overall Study|Adverse Event|12
6032001|NCT00309244|9628218|FG000|Overall Study|Lost to Follow-up|6
6032002|NCT00309244|9628219|FG001|Overall Study|Lost to Follow-up|22
6032003|NCT00309244|9628218|FG000|Overall Study|Physician Decision|5
6032004|NCT00309244|9628219|FG001|Overall Study|Physician Decision|8
6032005|NCT00309244|9628218|FG000|Overall Study|Protocol Violation|6
6032006|NCT00309244|9628219|FG001|Overall Study|Protocol Violation|3
6032007|NCT00309244|9628218|FG000|Overall Study|Withdrawal by Subject|50
6032008|NCT00309244|9628219|FG001|Overall Study|Withdrawal by Subject|32
6032009|NCT00309244|9628218|FG000|Overall Study|Various|7
6032010|NCT00309244|9628219|FG001|Overall Study|Various|7
6032011|NCT00309244|9628218|FG000|Overall Study|Randomized but not dosed|11
6032012|NCT00309244|9628219|FG001|Overall Study|Randomized but not dosed|12
6032013|NCT00309244|9628218|FG000|Overall Study|Death|4
6032014|NCT00309244|9628219|FG001|Overall Study|Death|1
6032015|NCT00309387|9628227|FG000|Overall Study|Death|72
6032016|NCT00309387|9628228|FG001|Overall Study|Death|73
6032017|NCT00309387|9628227|FG000|Overall Study|Lost to Follow-up|70
6032018|NCT00309387|9628228|FG001|Overall Study|Lost to Follow-up|86
6032019|NCT00309452|9628237|FG000|Overall Study|Withdrawal by Subject|3
6032020|NCT00309452|9628238|FG001|Overall Study|Withdrawal by Subject|0
6032021|NCT00309608|9628274|FG000|Overall Study|Adverse Event|1
6032022|NCT00309608|9628275|FG001|Overall Study|Adverse Event|5
6032023|NCT00309608|9628276|FG002|Overall Study|Adverse Event|3
6032024|NCT00309608|9628277|FG003|Overall Study|Adverse Event|2
6032025|NCT00309608|9628278|FG004|Overall Study|Adverse Event|3
6032026|NCT00309608|9628274|FG000|Overall Study|Protocol Violation|2
6032027|NCT00309608|9628275|FG001|Overall Study|Protocol Violation|0
6032028|NCT00309608|9628276|FG002|Overall Study|Protocol Violation|0
6032029|NCT00309608|9628277|FG003|Overall Study|Protocol Violation|0
6032030|NCT00309608|9628278|FG004|Overall Study|Protocol Violation|0
6032031|NCT00309608|9628274|FG000|Overall Study|Lost to Follow-up|0
6032032|NCT00309608|9628275|FG001|Overall Study|Lost to Follow-up|0
6032033|NCT00309608|9628276|FG002|Overall Study|Lost to Follow-up|2
6032034|NCT00309608|9628277|FG003|Overall Study|Lost to Follow-up|0
6032035|NCT00309608|9628278|FG004|Overall Study|Lost to Follow-up|1
6032036|NCT00309608|9628274|FG000|Overall Study|Withdrawal by Subject|1
6032037|NCT00309608|9628275|FG001|Overall Study|Withdrawal by Subject|4
6032038|NCT00309608|9628276|FG002|Overall Study|Withdrawal by Subject|2
6032039|NCT00309608|9628277|FG003|Overall Study|Withdrawal by Subject|0
6032040|NCT00309608|9628278|FG004|Overall Study|Withdrawal by Subject|0
6032041|NCT00309608|9628274|FG000|Overall Study|Other incl. Lack of efficacy|10
6032042|NCT00309608|9628275|FG001|Overall Study|Other incl. Lack of efficacy|4
6032043|NCT00309608|9628276|FG002|Overall Study|Other incl. Lack of efficacy|3
6032044|NCT00309608|9628277|FG003|Overall Study|Other incl. Lack of efficacy|4
6032045|NCT00309608|9628278|FG004|Overall Study|Other incl. Lack of efficacy|0
6032046|NCT00309777|9628312|FG000|Overall Study|Adverse Event|13
6032047|NCT00309777|9628313|FG001|Overall Study|Adverse Event|2
6032048|NCT00309777|9628314|FG002|Overall Study|Adverse Event|8
6032049|NCT00309777|9628315|FG003|Overall Study|Adverse Event|1
6032050|NCT00309777|9628312|FG000|Overall Study|Protocol Violation|4
6032051|NCT00309777|9628313|FG001|Overall Study|Protocol Violation|1
6032052|NCT00309777|9628314|FG002|Overall Study|Protocol Violation|3
6032053|NCT00309777|9628315|FG003|Overall Study|Protocol Violation|1
6032054|NCT00309777|9628312|FG000|Overall Study|Withdrawal by Subject|6
6032055|NCT00309777|9628313|FG001|Overall Study|Withdrawal by Subject|5
6032056|NCT00309777|9628314|FG002|Overall Study|Withdrawal by Subject|7
6032057|NCT00309777|9628315|FG003|Overall Study|Withdrawal by Subject|2
6032058|NCT00309777|9628312|FG000|Overall Study|Lost to Follow-up|0
6032059|NCT00309777|9628313|FG001|Overall Study|Lost to Follow-up|0
6032060|NCT00309777|9628314|FG002|Overall Study|Lost to Follow-up|1
6032061|NCT00309777|9628315|FG003|Overall Study|Lost to Follow-up|0
6032062|NCT00309777|9628312|FG000|Overall Study|Death|0
6032063|NCT00309777|9628313|FG001|Overall Study|Death|1
6032064|NCT00309777|9628314|FG002|Overall Study|Death|0
6032065|NCT00309777|9628315|FG003|Overall Study|Death|0
6032066|NCT00309842|9628325|FG000|Overall Study|Lost to Follow-up|1
6032067|NCT00309907|9628329|FG000|Overall Study|Death|4
6032068|NCT00309907|9628329|FG000|Overall Study|Physician Decision|1
6032069|NCT00309907|9628329|FG000|Overall Study|Ineligible|11
6032070|NCT00309907|9628329|FG000|Overall Study|Major infectious event|4
6032071|NCT00309946|9628334|FG000|Overall Study|Withdrawal by Subject|1
6032072|NCT00309959|9628338|FG000|Overall Study|Ineligible - no prior chemotherapy|2
6032073|NCT00310037|9628349|FG000|Overall Study|Adverse Event|7
6032074|NCT00310037|9628350|FG001|Overall Study|Adverse Event|14
6032075|NCT00310037|9628349|FG000|Overall Study|Withdrawal by Subject|4
6032076|NCT00310037|9628350|FG001|Overall Study|Withdrawal by Subject|3
6032077|NCT00310037|9628349|FG000|Overall Study|Progression|6
6032078|NCT00310037|9628350|FG001|Overall Study|Progression|0
6032079|NCT00310037|9628349|FG000|Overall Study|Non-protocol treatment|1
6032080|NCT00310037|9628350|FG001|Overall Study|Non-protocol treatment|0
6032081|NCT00310375|9628394|FG000|Primary Reporting Phase|Adverse Event|28
6032082|NCT00310375|9628395|FG001|Primary Reporting Phase|Adverse Event|22
6032083|NCT00310375|9628396|FG002|Primary Reporting Phase|Adverse Event|0
6032084|NCT00310375|9628394|FG000|Primary Reporting Phase|Lack of Efficacy|24
6032085|NCT00310375|9628395|FG001|Primary Reporting Phase|Lack of Efficacy|19
6032086|NCT00310375|9628396|FG002|Primary Reporting Phase|Lack of Efficacy|0
6032087|NCT00310375|9628394|FG000|Primary Reporting Phase|Pregnancy|2
6032088|NCT00310375|9628395|FG001|Primary Reporting Phase|Pregnancy|2
6032089|NCT00310375|9628396|FG002|Primary Reporting Phase|Pregnancy|0
6032090|NCT00310375|9628394|FG000|Primary Reporting Phase|Withdrawal by Subject|10
6032091|NCT00310375|9628395|FG001|Primary Reporting Phase|Withdrawal by Subject|7
6032092|NCT00310375|9628396|FG002|Primary Reporting Phase|Withdrawal by Subject|0
6032093|NCT00310375|9628394|FG000|Primary Reporting Phase|Protocol Violation|8
6032094|NCT00310375|9628395|FG001|Primary Reporting Phase|Protocol Violation|5
6032095|NCT00310375|9628396|FG002|Primary Reporting Phase|Protocol Violation|0
6032096|NCT00310375|9628394|FG000|Primary Reporting Phase|Change in Par medical condition|2
6032097|NCT00310375|9628395|FG001|Primary Reporting Phase|Change in Par medical condition|0
6032098|NCT00310375|9628396|FG002|Primary Reporting Phase|Change in Par medical condition|0
6032099|NCT00310375|9628394|FG000|Primary Reporting Phase|Transaminase >5 upper limit of normal|2
6032100|NCT00310375|9628395|FG001|Primary Reporting Phase|Transaminase >5 upper limit of normal|1
6032101|NCT00310375|9628396|FG002|Primary Reporting Phase|Transaminase >5 upper limit of normal|0
6032102|NCT00310375|9628394|FG000|Primary Reporting Phase|Physician Decision|5
6032103|NCT00310375|9628395|FG001|Primary Reporting Phase|Physician Decision|3
6032104|NCT00310375|9628396|FG002|Primary Reporting Phase|Physician Decision|0
6032105|NCT00310375|9628394|FG000|Primary Reporting Phase|Request of the sponsor|2
6032106|NCT00310375|9628395|FG001|Primary Reporting Phase|Request of the sponsor|2
6032107|NCT00310375|9628396|FG002|Primary Reporting Phase|Request of the sponsor|0
6032108|NCT00310375|9628394|FG000|Primary Reporting Phase|Failed to return|1
6032109|NCT00310375|9628395|FG001|Primary Reporting Phase|Failed to return|3
6032110|NCT00310375|9628396|FG002|Primary Reporting Phase|Failed to return|0
6032111|NCT00310375|9628394|FG000|Primary Reporting Phase|Participant request unrelated to study|1
6032112|NCT00310375|9628395|FG001|Primary Reporting Phase|Participant request unrelated to study|2
6032113|NCT00310375|9628396|FG002|Primary Reporting Phase|Participant request unrelated to study|0
6032114|NCT00310375|9628394|FG000|Primary Reporting Phase|Going for temporal lobectomy|1
6032115|NCT00310375|9628395|FG001|Primary Reporting Phase|Going for temporal lobectomy|0
6032116|NCT00310375|9628396|FG002|Primary Reporting Phase|Going for temporal lobectomy|0
6032117|NCT00310375|9628394|FG000|Primary Reporting Phase|Missed study drug >5 days|1
6032118|NCT00310375|9628395|FG001|Primary Reporting Phase|Missed study drug >5 days|0
6032119|NCT00310375|9628396|FG002|Primary Reporting Phase|Missed study drug >5 days|0
6032120|NCT00310375|9628394|FG000|Primary Reporting Phase|Site closure|3
6032121|NCT00310375|9628395|FG001|Primary Reporting Phase|Site closure|0
6032122|NCT00310375|9628396|FG002|Primary Reporting Phase|Site closure|0
6032123|NCT00310375|9628394|FG000|Primary Reporting Phase|Missed study drug for 2 months|1
6032124|NCT00310375|9628395|FG001|Primary Reporting Phase|Missed study drug for 2 months|0
6032125|NCT00310375|9628396|FG002|Primary Reporting Phase|Missed study drug for 2 months|0
6032126|NCT00310375|9628394|FG000|Primary Reporting Phase|Par. switched to commercial product|0
6032127|NCT00310375|9628395|FG001|Primary Reporting Phase|Par. switched to commercial product|1
6032128|NCT00310375|9628396|FG002|Primary Reporting Phase|Par. switched to commercial product|0
6032129|NCT00310375|9628394|FG000|Primary Reporting Phase|Request of Ethics Committee|0
6032130|NCT00310375|9628395|FG001|Primary Reporting Phase|Request of Ethics Committee|1
6032131|NCT00310375|9628396|FG002|Primary Reporting Phase|Request of Ethics Committee|0
6032132|NCT00310375|9628394|FG000|Safety Follow-up Continuation Phase|Lost to Follow-up|0
6032133|NCT00310375|9628395|FG001|Safety Follow-up Continuation Phase|Lost to Follow-up|0
6032134|NCT00310375|9628396|FG002|Safety Follow-up Continuation Phase|Lost to Follow-up|1
6032135|NCT00310440|9628427|FG000|Overall Study|Lost to Follow-up|17
6032136|NCT00310440|9628428|FG001|Overall Study|Lost to Follow-up|8
6032137|NCT00310440|9628427|FG000|Overall Study|Withdrawal by Subject|2
6032138|NCT00310440|9628428|FG001|Overall Study|Withdrawal by Subject|1
6032139|NCT00310440|9628427|FG000|Overall Study|Missed 12 Month Visit|7
6032140|NCT00310440|9628428|FG001|Overall Study|Missed 12 Month Visit|4
6032141|NCT00310804|9628454|FG000|Overall Study|Lost to Follow-up|2
6032142|NCT00310804|9628455|FG001|Overall Study|Lost to Follow-up|0
6032143|NCT00310804|9628454|FG000|Overall Study|Withdrawal by Subject|3
6032144|NCT00310804|9628455|FG001|Overall Study|Withdrawal by Subject|0
6032145|NCT00310817|9628479|FG000|Overall Study|AE or Death|3
6032146|NCT00310817|9628480|FG001|Overall Study|AE or Death|1
6032147|NCT00310817|9628481|FG002|Overall Study|AE or Death|0
6032148|NCT00310817|9628482|FG003|Overall Study|AE or Death|0
6032149|NCT00310817|9628479|FG000|Overall Study|Withdrawal by Subject|1
6032150|NCT00310817|9628480|FG001|Overall Study|Withdrawal by Subject|4
6032151|NCT00310817|9628481|FG002|Overall Study|Withdrawal by Subject|6
6032152|NCT00310817|9628482|FG003|Overall Study|Withdrawal by Subject|7
6032153|NCT00310817|9628479|FG000|Overall Study|Lost to Follow-up|2
6032154|NCT00310817|9628480|FG001|Overall Study|Lost to Follow-up|1
6032155|NCT00310817|9628481|FG002|Overall Study|Lost to Follow-up|0
6032156|NCT00310817|9628482|FG003|Overall Study|Lost to Follow-up|0
6032157|NCT00310817|9628479|FG000|Overall Study|Inappropriate Enrollment|1
6032158|NCT00310817|9628480|FG001|Overall Study|Inappropriate Enrollment|0
6032159|NCT00310817|9628481|FG002|Overall Study|Inappropriate Enrollment|1
6032160|NCT00310817|9628482|FG003|Overall Study|Inappropriate Enrollment|0
6032161|NCT00310817|9628479|FG000|Overall Study|Protocol Violation|1
6032162|NCT00310817|9628480|FG001|Overall Study|Protocol Violation|1
6032163|NCT00310817|9628481|FG002|Overall Study|Protocol Violation|1
6032164|NCT00310817|9628482|FG003|Overall Study|Protocol Violation|1
6032165|NCT00310817|9628479|FG000|Overall Study|Unable to classify|3
6032166|NCT00310817|9628480|FG001|Overall Study|Unable to classify|1
6032167|NCT00310817|9628481|FG002|Overall Study|Unable to classify|0
6032168|NCT00310817|9628482|FG003|Overall Study|Unable to classify|0
6032169|NCT00310856|9628528|FG000|Overall Study|Withdrawal by Subject|2
6032170|NCT00310856|9628529|FG001|Overall Study|Withdrawal by Subject|2
6032171|NCT00310856|9628530|FG002|Overall Study|Withdrawal by Subject|2
6032172|NCT00310856|9628528|FG000|Overall Study|Lost to Follow-up|1
6032173|NCT00310856|9628529|FG001|Overall Study|Lost to Follow-up|2
6032174|NCT00310856|9628530|FG002|Overall Study|Lost to Follow-up|6
6032175|NCT00310856|9628528|FG000|Overall Study|Inappropriate enrollment|1
6032176|NCT00310856|9628529|FG001|Overall Study|Inappropriate enrollment|1
6032177|NCT00310856|9628530|FG002|Overall Study|Inappropriate enrollment|0
6032178|NCT00310856|9628528|FG000|Overall Study|Unable to classify|1
6032179|NCT00310856|9628529|FG001|Overall Study|Unable to classify|0
6032180|NCT00310856|9628530|FG002|Overall Study|Unable to classify|0
6032181|NCT00311155|9628539|FG000|Overall Study|Adverse Event|21
6032182|NCT00311155|9628539|FG000|Overall Study|Withdrawal by Subject|17
6032183|NCT00311155|9628539|FG000|Overall Study|Did not meet entry criteria|55
6032184|NCT00311168|9628545|FG000|First Intervention|Withdrawal by Subject|2
6032185|NCT00311168|9628546|FG001|First Intervention|Withdrawal by Subject|2
6032186|NCT00311168|9628545|FG000|First Intervention|Lost to Follow-up|1
6032187|NCT00311168|9628546|FG001|First Intervention|Lost to Follow-up|1
6032188|NCT00311168|9628545|FG000|First Intervention|Protocol Violation|1
6032189|NCT00311168|9628546|FG001|First Intervention|Protocol Violation|1
6032190|NCT00311168|9628545|FG000|First Intervention|Adverse Event|1
6146847|NCT01079234|9781827|FG003|Main: Week 0 to 26|Lack of Efficacy|0
6146848|NCT01079234|9781824|FG000|Main: Week 0 to 26|Protocol Violation|6
6146849|NCT01079234|9781825|FG001|Main: Week 0 to 26|Protocol Violation|2
6146850|NCT01079234|9781826|FG002|Main: Week 0 to 26|Protocol Violation|4
6146851|NCT01079234|9781827|FG003|Main: Week 0 to 26|Protocol Violation|0
6032191|NCT00311168|9628546|FG001|First Intervention|Adverse Event|0
6032192|NCT00311168|9628545|FG000|First Intervention|Other|2
6032193|NCT00311168|9628546|FG001|First Intervention|Other|2
6032194|NCT00311168|9628545|FG000|Second Intervention|Lost to Follow-up|9
6032195|NCT00311168|9628546|FG001|Second Intervention|Lost to Follow-up|2
6032196|NCT00311168|9628545|FG000|Second Intervention|Withdrawal by Subject|0
6032197|NCT00311168|9628546|FG001|Second Intervention|Withdrawal by Subject|1
6032198|NCT00311168|9628545|FG000|Second Intervention|Other|1
6032199|NCT00311168|9628546|FG001|Second Intervention|Other|1
6032200|NCT00311181|9628554|FG000|Overall Study|Final DFTs were not obtained|96
6032201|NCT00311311|9628567|FG000|Overall Study|Adverse Event|3
6032202|NCT00311311|9628568|FG001|Overall Study|Adverse Event|2
6032203|NCT00311311|9628567|FG000|Overall Study|Withdrawal by Subject|1
6032204|NCT00311311|9628568|FG001|Overall Study|Withdrawal by Subject|1
6032205|NCT00311311|9628567|FG000|Overall Study|Noncompliance|0
6032206|NCT00311311|9628568|FG001|Overall Study|Noncompliance|1
6032207|NCT00311311|9628567|FG000|Overall Study|Study Termination by Sponsor|3
6032208|NCT00311311|9628568|FG001|Overall Study|Study Termination by Sponsor|4
6032209|NCT00311311|9628567|FG000|Overall Study|Death|1
6032210|NCT00311311|9628568|FG001|Overall Study|Death|0
6032211|NCT00311311|9628567|FG000|Overall Study|Lack of ancillary assistance|0
6032212|NCT00311311|9628568|FG001|Overall Study|Lack of ancillary assistance|1
6032213|NCT00311363|9628577|FG000|24-Week Single-Blind Treatment Period|Adverse Event|42
6032214|NCT00311363|9628578|FG001|24-Week Single-Blind Treatment Period|Adverse Event|0
6032215|NCT00311363|9628579|FG002|24-Week Single-Blind Treatment Period|Adverse Event|0
6032216|NCT00311363|9628577|FG000|24-Week Single-Blind Treatment Period|Lack of Efficacy|13
6032217|NCT00311363|9628578|FG001|24-Week Single-Blind Treatment Period|Lack of Efficacy|0
6032218|NCT00311363|9628579|FG002|24-Week Single-Blind Treatment Period|Lack of Efficacy|0
6032219|NCT00311363|9628577|FG000|24-Week Single-Blind Treatment Period|Withdrawal by Subject|27
6032220|NCT00311363|9628578|FG001|24-Week Single-Blind Treatment Period|Withdrawal by Subject|0
6032221|NCT00311363|9628579|FG002|24-Week Single-Blind Treatment Period|Withdrawal by Subject|0
6032222|NCT00311363|9628577|FG000|24-Week Single-Blind Treatment Period|Lost to Follow-up|12
6032223|NCT00311363|9628578|FG001|24-Week Single-Blind Treatment Period|Lost to Follow-up|0
6032224|NCT00311363|9628579|FG002|24-Week Single-Blind Treatment Period|Lost to Follow-up|0
6032225|NCT00311363|9628577|FG000|24-Week Single-Blind Treatment Period|Protocol Violation|8
6032226|NCT00311363|9628578|FG001|24-Week Single-Blind Treatment Period|Protocol Violation|0
6032227|NCT00311363|9628579|FG002|24-Week Single-Blind Treatment Period|Protocol Violation|0
6032228|NCT00311363|9628577|FG000|24-Week Single-Blind Treatment Period|Elective Surgery|1
6146852|NCT01079234|9781824|FG000|Main: Week 0 to 26|Withdrawal criteria|6
6032229|NCT00311363|9628578|FG001|24-Week Single-Blind Treatment Period|Elective Surgery|0
6032230|NCT00311363|9628579|FG002|24-Week Single-Blind Treatment Period|Elective Surgery|0
6032231|NCT00311363|9628577|FG000|24-Week Single-Blind Treatment Period|Work Shift Changed to Evenings|1
6032232|NCT00311363|9628578|FG001|24-Week Single-Blind Treatment Period|Work Shift Changed to Evenings|0
6032233|NCT00311363|9628579|FG002|24-Week Single-Blind Treatment Period|Work Shift Changed to Evenings|0
6032234|NCT00311363|9628577|FG000|24-Week Single-Blind Treatment Period|Pregnancy|1
6032235|NCT00311363|9628578|FG001|24-Week Single-Blind Treatment Period|Pregnancy|0
6032236|NCT00311363|9628579|FG002|24-Week Single-Blind Treatment Period|Pregnancy|0
6032237|NCT00311363|9628577|FG000|24-Week Single-Blind Treatment Period|Death|1
6032238|NCT00311363|9628578|FG001|24-Week Single-Blind Treatment Period|Death|0
6032239|NCT00311363|9628579|FG002|24-Week Single-Blind Treatment Period|Death|0
6032240|NCT00311363|9628577|FG000|12-Week Double-Blind Treatment Period|Adverse Event|0
6032241|NCT00311363|9628578|FG001|12-Week Double-Blind Treatment Period|Adverse Event|3
6032242|NCT00311363|9628579|FG002|12-Week Double-Blind Treatment Period|Adverse Event|0
6032243|NCT00311363|9628577|FG000|12-Week Double-Blind Treatment Period|Lost to Follow-up|0
6032244|NCT00311363|9628578|FG001|12-Week Double-Blind Treatment Period|Lost to Follow-up|1
6032245|NCT00311363|9628579|FG002|12-Week Double-Blind Treatment Period|Lost to Follow-up|2
6032246|NCT00311363|9628577|FG000|12-Week Double-Blind Treatment Period|Lack of Efficacy|0
6032247|NCT00311363|9628578|FG001|12-Week Double-Blind Treatment Period|Lack of Efficacy|6
6032248|NCT00311363|9628579|FG002|12-Week Double-Blind Treatment Period|Lack of Efficacy|4
6032249|NCT00311363|9628577|FG000|12-Week Double-Blind Treatment Period|Withdrawal by Subject|0
6032250|NCT00311363|9628578|FG001|12-Week Double-Blind Treatment Period|Withdrawal by Subject|2
6032251|NCT00311363|9628579|FG002|12-Week Double-Blind Treatment Period|Withdrawal by Subject|4
6032252|NCT00311363|9628577|FG000|12-Week Double-Blind Treatment Period|Protocol Violation|0
6032253|NCT00311363|9628578|FG001|12-Week Double-Blind Treatment Period|Protocol Violation|1
6032254|NCT00311363|9628579|FG002|12-Week Double-Blind Treatment Period|Protocol Violation|2
6032255|NCT00311363|9628577|FG000|12-Week Double-Blind Treatment Period|Per Sponsor, Unknown|0
6032256|NCT00311363|9628578|FG001|12-Week Double-Blind Treatment Period|Per Sponsor, Unknown|1
6032257|NCT00311363|9628579|FG002|12-Week Double-Blind Treatment Period|Per Sponsor, Unknown|0
6032258|NCT00311402|9628604|FG000|Overall Study|Adverse Event|118
6032259|NCT00311402|9628605|FG001|Overall Study|Adverse Event|105
6032260|NCT00311402|9628604|FG000|Overall Study|Lost to Follow-up|0
6032261|NCT00311402|9628605|FG001|Overall Study|Lost to Follow-up|3
6032262|NCT00311402|9628604|FG000|Overall Study|Withdrawal by Subject|17
6032263|NCT00311402|9628605|FG001|Overall Study|Withdrawal by Subject|18
6032264|NCT00311402|9628604|FG000|Overall Study|Lack of Efficacy|58
6032265|NCT00311402|9628605|FG001|Overall Study|Lack of Efficacy|42
6032266|NCT00311402|9628604|FG000|Overall Study|Protocol Violation|7
6032267|NCT00311402|9628605|FG001|Overall Study|Protocol Violation|6
6032268|NCT00311402|9628604|FG000|Overall Study|IRB's rejection etc.|10
6032269|NCT00311402|9628605|FG001|Overall Study|IRB's rejection etc.|3
6032270|NCT00311584|9628613|FG000|Overall Study|Death|1
6032271|NCT00311584|9628614|FG001|Overall Study|Death|0
6032272|NCT00311584|9628613|FG000|Overall Study|Lack of Efficacy|12
6032273|NCT00311584|9628614|FG001|Overall Study|Lack of Efficacy|15
6032274|NCT00311584|9628613|FG000|Overall Study|Physician Decision|4
6032275|NCT00311584|9628614|FG001|Overall Study|Physician Decision|5
6032276|NCT00311584|9628613|FG000|Overall Study|Withdrawal by Subject|1
6032277|NCT00311584|9628614|FG001|Overall Study|Withdrawal by Subject|1
6032278|NCT00311584|9628613|FG000|Overall Study|ineligible|2
6032279|NCT00311584|9628614|FG001|Overall Study|ineligible|2
6032280|NCT00311623|9628623|FG000|Overall Study|Physician Decision|0
6032281|NCT00311623|9628624|FG001|Overall Study|Physician Decision|0
6032282|NCT00311623|9628625|FG002|Overall Study|Physician Decision|2
6032283|NCT00312195|9628645|FG000|Overall Study|Adverse Event|4
6032284|NCT00312195|9628646|FG001|Overall Study|Adverse Event|6
6032285|NCT00312195|9628645|FG000|Overall Study|Lost to Follow-up|1
6032286|NCT00312195|9628646|FG001|Overall Study|Lost to Follow-up|0
6032287|NCT00312195|9628645|FG000|Overall Study|Protocol Violation|1
6032288|NCT00312195|9628646|FG001|Overall Study|Protocol Violation|0
6032289|NCT00312208|9628656|FG000|Overall Study|Adverse Event|97
6032290|NCT00312208|9628657|FG001|Overall Study|Adverse Event|61
6032291|NCT00312208|9628656|FG000|Overall Study|Protocol Violation|5
6032292|NCT00312208|9628657|FG001|Overall Study|Protocol Violation|3
6032293|NCT00312208|9628656|FG000|Overall Study|Death|2
6032294|NCT00312208|9628657|FG001|Overall Study|Death|1
6032295|NCT00312208|9628656|FG000|Overall Study|Lack of Efficacy|7
6032296|NCT00312208|9628657|FG001|Overall Study|Lack of Efficacy|4
6032297|NCT00312208|9628656|FG000|Overall Study|Lost to Follow-up|3
6032298|NCT00312208|9628657|FG001|Overall Study|Lost to Follow-up|5
6032299|NCT00312208|9628656|FG000|Overall Study|Withdrawal by Subject|53
6032300|NCT00312208|9628657|FG001|Overall Study|Withdrawal by Subject|42
6032301|NCT00312208|9628656|FG000|Overall Study|Other|5
6032302|NCT00312208|9628657|FG001|Overall Study|Other|7
6032303|NCT00312221|9628666|FG000|Open-label Run-in Period|Withdrawal by Subject|6
6032304|NCT00312221|9628667|FG001|Open-label Run-in Period|Withdrawal by Subject|0
6032305|NCT00312221|9628668|FG002|Open-label Run-in Period|Withdrawal by Subject|0
6032306|NCT00312221|9628669|FG003|Open-label Run-in Period|Withdrawal by Subject|0
6032307|NCT00312221|9628666|FG000|Open-label Run-in Period|Adverse Event|74
6032308|NCT00312221|9628667|FG001|Open-label Run-in Period|Adverse Event|0
6032309|NCT00312221|9628668|FG002|Open-label Run-in Period|Adverse Event|0
6032310|NCT00312221|9628669|FG003|Open-label Run-in Period|Adverse Event|0
6032311|NCT00312221|9628666|FG000|Open-label Run-in Period|Lost to Follow-up|5
6032312|NCT00312221|9628667|FG001|Open-label Run-in Period|Lost to Follow-up|0
6032313|NCT00312221|9628668|FG002|Open-label Run-in Period|Lost to Follow-up|0
6032314|NCT00312221|9628669|FG003|Open-label Run-in Period|Lost to Follow-up|0
6032315|NCT00312221|9628666|FG000|Open-label Run-in Period|Administrative|42
6032316|NCT00312221|9628667|FG001|Open-label Run-in Period|Administrative|0
6032317|NCT00312221|9628668|FG002|Open-label Run-in Period|Administrative|0
6032318|NCT00312221|9628669|FG003|Open-label Run-in Period|Administrative|0
6032319|NCT00312221|9628666|FG000|Open-label Run-in Period|Lack of Efficacy|102
6032320|NCT00312221|9628667|FG001|Open-label Run-in Period|Lack of Efficacy|0
6032321|NCT00312221|9628668|FG002|Open-label Run-in Period|Lack of Efficacy|0
6032322|NCT00312221|9628669|FG003|Open-label Run-in Period|Lack of Efficacy|0
6032323|NCT00312221|9628666|FG000|Open-label Run-in Period|Did not qualify|5
6032324|NCT00312221|9628667|FG001|Open-label Run-in Period|Did not qualify|0
6032325|NCT00312221|9628668|FG002|Open-label Run-in Period|Did not qualify|0
6032326|NCT00312221|9628669|FG003|Open-label Run-in Period|Did not qualify|0
6032327|NCT00312221|9628666|FG000|Double-blind Phase|Withdrawal by Subject|0
6032328|NCT00312221|9628667|FG001|Double-blind Phase|Withdrawal by Subject|6
6032329|NCT00312221|9628668|FG002|Double-blind Phase|Withdrawal by Subject|8
6032330|NCT00312221|9628669|FG003|Double-blind Phase|Withdrawal by Subject|7
6032331|NCT00312221|9628666|FG000|Double-blind Phase|Adverse Event|0
6032332|NCT00312221|9628667|FG001|Double-blind Phase|Adverse Event|10
6032333|NCT00312221|9628668|FG002|Double-blind Phase|Adverse Event|19
6032334|NCT00312221|9628669|FG003|Double-blind Phase|Adverse Event|18
6032335|NCT00312221|9628666|FG000|Double-blind Phase|Lost to Follow-up|0
6032336|NCT00312221|9628667|FG001|Double-blind Phase|Lost to Follow-up|0
6032337|NCT00312221|9628668|FG002|Double-blind Phase|Lost to Follow-up|2
6032338|NCT00312221|9628669|FG003|Double-blind Phase|Lost to Follow-up|2
6032339|NCT00312221|9628666|FG000|Double-blind Phase|Administrative|0
6032340|NCT00312221|9628667|FG001|Double-blind Phase|Administrative|26
6032341|NCT00312221|9628668|FG002|Double-blind Phase|Administrative|37
6032342|NCT00312221|9628669|FG003|Double-blind Phase|Administrative|33
6032343|NCT00312221|9628666|FG000|Double-blind Phase|Lack of Efficacy|0
6032344|NCT00312221|9628667|FG001|Double-blind Phase|Lack of Efficacy|17
6032345|NCT00312221|9628668|FG002|Double-blind Phase|Lack of Efficacy|6
6032346|NCT00312221|9628669|FG003|Double-blind Phase|Lack of Efficacy|10
6032347|NCT00312338|9628680|FG000|Overall Study|Adverse Event|7
6032348|NCT00312338|9628681|FG001|Overall Study|Adverse Event|2
6032349|NCT00312338|9628680|FG000|Overall Study|Lost to Follow-up|9
6032350|NCT00312338|9628681|FG001|Overall Study|Lost to Follow-up|1
6032351|NCT00312338|9628680|FG000|Overall Study|Withdrawal by Subject|4
6032352|NCT00312338|9628681|FG001|Overall Study|Withdrawal by Subject|0
6032353|NCT00312338|9628680|FG000|Overall Study|Subsequent infection|2
6032354|NCT00312338|9628681|FG001|Overall Study|Subsequent infection|0
6032355|NCT00312377|9628689|FG000|Overall Study|Death|403
6032356|NCT00312377|9628690|FG001|Overall Study|Death|418
6032357|NCT00312377|9628689|FG000|Overall Study|Withdrawal by Subject|23
6032358|NCT00312377|9628690|FG001|Overall Study|Withdrawal by Subject|30
6032359|NCT00312377|9628689|FG000|Overall Study|Lost to Follow-up|9
6032360|NCT00312377|9628690|FG001|Overall Study|Lost to Follow-up|12
6032361|NCT00312377|9628689|FG000|Overall Study|Non-compliance|0
6032362|NCT00312377|9628690|FG001|Overall Study|Non-compliance|2
6032363|NCT00312377|9628689|FG000|Overall Study|Randomised but never received treatment|6
6032364|NCT00312377|9628690|FG001|Overall Study|Randomised but never received treatment|6
6032365|NCT00312377|9628689|FG000|Overall Study|Discontinue treatment survival follow up|202
6032366|NCT00312377|9628690|FG001|Overall Study|Discontinue treatment survival follow up|200
6032367|NCT00312377|9628689|FG000|Overall Study|Site ended participation in study|1
6032368|NCT00312377|9628690|FG001|Overall Study|Site ended participation in study|0
6032369|NCT00312494|9628699|FG000|Overall Study|Randomized; not treated with study drug|9
6032370|NCT00312494|9628700|FG001|Overall Study|Randomized; not treated with study drug|10
6032371|NCT00312494|9628701|FG002|Overall Study|Randomized; not treated with study drug|5
6032372|NCT00312494|9628699|FG000|Overall Study|Adverse Event|33
6032373|NCT00312494|9628700|FG001|Overall Study|Adverse Event|15
6032374|NCT00312494|9628701|FG002|Overall Study|Adverse Event|11
6032375|NCT00312494|9628699|FG000|Overall Study|Lack of Efficacy|4
6032376|NCT00312494|9628700|FG001|Overall Study|Lack of Efficacy|6
6032377|NCT00312494|9628701|FG002|Overall Study|Lack of Efficacy|8
6032378|NCT00312494|9628699|FG000|Overall Study|Laboratory abnormality|1
6032379|NCT00312494|9628700|FG001|Overall Study|Laboratory abnormality|0
6032380|NCT00312494|9628701|FG002|Overall Study|Laboratory abnormality|0
6032381|NCT00312494|9628699|FG000|Overall Study|Lost to Follow-up|8
6032382|NCT00312494|9628700|FG001|Overall Study|Lost to Follow-up|8
6032383|NCT00312494|9628701|FG002|Overall Study|Lost to Follow-up|8
6032384|NCT00312494|9628699|FG000|Overall Study|Withdrawal by Subject|6
6032385|NCT00312494|9628700|FG001|Overall Study|Withdrawal by Subject|9
6032386|NCT00312494|9628701|FG002|Overall Study|Withdrawal by Subject|10
6032387|NCT00312494|9628699|FG000|Overall Study|Other|10
6032388|NCT00312494|9628700|FG001|Overall Study|Other|10
6032389|NCT00312494|9628701|FG002|Overall Study|Other|1
6032390|NCT00312572|9628711|FG000|Overall Study|Adverse Event|10
6032391|NCT00312572|9628712|FG001|Overall Study|Adverse Event|16
6032392|NCT00312572|9628711|FG000|Overall Study|Lost to Follow-up|1
6032393|NCT00312572|9628712|FG001|Overall Study|Lost to Follow-up|1
6032394|NCT00312572|9628711|FG000|Overall Study|Administrative|4
6032395|NCT00312572|9628712|FG001|Overall Study|Administrative|2
6032396|NCT00312572|9628711|FG000|Overall Study|Lack of Efficacy|1
6032397|NCT00312572|9628712|FG001|Overall Study|Lack of Efficacy|2
6032398|NCT00312663|9628723|FG000|Immunization Phase|Adverse Event|0
6032399|NCT00312663|9628724|FG001|Immunization Phase|Adverse Event|1
6032400|NCT00312663|9628725|FG002|Immunization Phase|Adverse Event|0
6032401|NCT00312702|9628737|FG000|Immunization Phase|Lost to Follow-up|0
6032402|NCT00312702|9628738|FG001|Immunization Phase|Lost to Follow-up|1
6032403|NCT00312702|9628739|FG002|Immunization Phase|Lost to Follow-up|0
6032404|NCT00312728|9628747|FG000|Overall Study|Progressive disease|53
6032405|NCT00312728|9628747|FG000|Overall Study|Adverse Event|32
6032406|NCT00312728|9628747|FG000|Overall Study|Withdrawal by Subject|10
6032407|NCT00312728|9628747|FG000|Overall Study|Required non-protocol cancer treatment|2
6032408|NCT00312728|9628747|FG000|Overall Study|Protocol Violation|2
6032409|NCT00312728|9628747|FG000|Overall Study|Other|10
6032410|NCT00312728|9628747|FG000|Overall Study|Other|1
6032411|NCT00312845|9628753|FG000|Overall Study|Adverse Event|19
6032412|NCT00312845|9628754|FG001|Overall Study|Adverse Event|5
6032413|NCT00312845|9628753|FG000|Overall Study|Death|2
6032414|NCT00312845|9628754|FG001|Overall Study|Death|2
6032415|NCT00312845|9628753|FG000|Overall Study|Withdrawal by Subject|14
6032416|NCT00312845|9628754|FG001|Overall Study|Withdrawal by Subject|6
6032417|NCT00312845|9628753|FG000|Overall Study|Disease Progression|56
6032418|NCT00312845|9628754|FG001|Overall Study|Disease Progression|77
6032419|NCT00312845|9628753|FG000|Overall Study|Lost to Follow-up|2
6032420|NCT00312845|9628754|FG001|Overall Study|Lost to Follow-up|0
6032421|NCT00312845|9628753|FG000|Overall Study|Other|6
6032422|NCT00312845|9628754|FG001|Overall Study|Other|5
6032423|NCT00312858|9628762|FG000|Overall Study|Adverse Event|0
6032424|NCT00312858|9628763|FG001|Overall Study|Adverse Event|1
6032425|NCT00312858|9628762|FG000|Overall Study|Lost to Follow-up|25
6032426|NCT00312858|9628763|FG001|Overall Study|Lost to Follow-up|42
6032427|NCT00312858|9628762|FG000|Overall Study|Protocol Violation|3
6032428|NCT00312858|9628763|FG001|Overall Study|Protocol Violation|8
6032429|NCT00312858|9628762|FG000|Overall Study|Withdraw by Participant|20
6032430|NCT00312858|9628763|FG001|Overall Study|Withdraw by Participant|20
6032431|NCT00312858|9628762|FG000|Overall Study|Participant Moved|11
6032432|NCT00312858|9628763|FG001|Overall Study|Participant Moved|10
6032433|NCT00312858|9628762|FG000|Overall Study|Other|9
6032434|NCT00312858|9628763|FG001|Overall Study|Other|12
6032435|NCT00312897|9628780|FG000|Overall Study|Adverse Event|1
6032436|NCT00312897|9628781|FG001|Overall Study|Adverse Event|0
6032437|NCT00312897|9628780|FG000|Overall Study|Lost to Follow-up|2
6032438|NCT00312897|9628781|FG001|Overall Study|Lost to Follow-up|0
6032439|NCT00312897|9628780|FG000|Overall Study|Physician Decision|1
6032440|NCT00312897|9628781|FG001|Overall Study|Physician Decision|0
6032441|NCT00312897|9628780|FG000|Overall Study|Withdrawal by Subject|1
6032442|NCT00312897|9628781|FG001|Overall Study|Withdrawal by Subject|3
6032443|NCT00312897|9628780|FG000|Overall Study|Pregnancy|1
6032444|NCT00312897|9628781|FG001|Overall Study|Pregnancy|0
6032445|NCT00312897|9628780|FG000|Overall Study|discontinued prior to getting treatment|0
6032446|NCT00312897|9628781|FG001|Overall Study|discontinued prior to getting treatment|3
6032447|NCT00313014|9628799|FG000|Overall Study|Withdrawal by Subject|11
6032448|NCT00313014|9628800|FG001|Overall Study|Withdrawal by Subject|7
6032449|NCT00313014|9628801|FG002|Overall Study|Withdrawal by Subject|5
6032450|NCT00313014|9628799|FG000|Overall Study|Adverse Event|14
6032451|NCT00313014|9628800|FG001|Overall Study|Adverse Event|29
6032452|NCT00313014|9628801|FG002|Overall Study|Adverse Event|16
6032453|NCT00313014|9628799|FG000|Overall Study|Lost to Follow-up|7
6032454|NCT00313014|9628800|FG001|Overall Study|Lost to Follow-up|6
6032455|NCT00313014|9628801|FG002|Overall Study|Lost to Follow-up|10
6032456|NCT00313014|9628799|FG000|Overall Study|Administrative|9
6032457|NCT00313014|9628800|FG001|Overall Study|Administrative|6
6032458|NCT00313014|9628801|FG002|Overall Study|Administrative|14
6146853|NCT01079234|9781825|FG001|Main: Week 0 to 26|Withdrawal criteria|6
6032459|NCT00313014|9628799|FG000|Overall Study|Lack of Efficacy|52
6032460|NCT00313014|9628800|FG001|Overall Study|Lack of Efficacy|25
6032461|NCT00313014|9628801|FG002|Overall Study|Lack of Efficacy|16
6032462|NCT00313144|9628810|FG000|Overall Study|Discontinue Aralast ≥4 consecutive doses|12
6032463|NCT00313144|9628810|FG000|Overall Study|Death|7
6032464|NCT00313144|9628810|FG000|Overall Study|Lost to Follow-up|5
6032465|NCT00313144|9628810|FG000|Overall Study|Withdrawal by Subject|4
6032466|NCT00313144|9628810|FG000|Overall Study|Terminated by sponsor/ homecare provider|4
6032467|NCT00313144|9628810|FG000|Overall Study|Physician Decision|4
6032468|NCT00313144|9628810|FG000|Overall Study|Adverse event - transient|5
6032469|NCT00313144|9628810|FG000|Overall Study|Liver transplant|1
6032470|NCT00313144|9628810|FG000|Overall Study|Insurance (homecare provider) change|1
6032471|NCT00313144|9628810|FG000|Overall Study|Change to different product|1
6032472|NCT00313144|9628810|FG000|Overall Study|Due to termination of the study|66
6032473|NCT00313170|9628826|FG000|Overall Study|Death|2
6032474|NCT00313170|9628827|FG001|Overall Study|Death|4
6032475|NCT00313170|9628828|FG002|Overall Study|Death|2
6032476|NCT00313170|9628826|FG000|Overall Study|Adverse Event|1
6032477|NCT00313170|9628827|FG001|Overall Study|Adverse Event|2
6032478|NCT00313170|9628828|FG002|Overall Study|Adverse Event|0
6032479|NCT00313170|9628826|FG000|Overall Study|Disease progression|31
6032480|NCT00313170|9628827|FG001|Overall Study|Disease progression|26
6032481|NCT00313170|9628828|FG002|Overall Study|Disease progression|27
6032482|NCT00313170|9628826|FG000|Overall Study|Withdrawal by Subject|1
6032483|NCT00313170|9628827|FG001|Overall Study|Withdrawal by Subject|0
6032484|NCT00313170|9628828|FG002|Overall Study|Withdrawal by Subject|1
6032485|NCT00313170|9628826|FG000|Overall Study|Incorrect enrollment|0
6032486|NCT00313170|9628827|FG001|Overall Study|Incorrect enrollment|2
6032487|NCT00313170|9628828|FG002|Overall Study|Incorrect enrollment|1
6032488|NCT00313170|9628826|FG000|Overall Study|Lost to Follow-up|0
6032489|NCT00313170|9628827|FG001|Overall Study|Lost to Follow-up|0
6032490|NCT00313170|9628828|FG002|Overall Study|Lost to Follow-up|1
6032491|NCT00313170|9628826|FG000|Overall Study|Progression (investigators opinion)|1
6032492|NCT00313170|9628827|FG001|Overall Study|Progression (investigators opinion)|0
6032493|NCT00313170|9628828|FG002|Overall Study|Progression (investigators opinion)|0
6032494|NCT00313300|9628851|FG000|Randomized in Phase A (26 Weeks)|Adverse Event|19
6032495|NCT00313300|9628852|FG001|Randomized in Phase A (26 Weeks)|Adverse Event|14
6032496|NCT00313300|9628853|FG002|Randomized in Phase A (26 Weeks)|Adverse Event|17
6032497|NCT00313300|9628854|FG003|Randomized in Phase A (26 Weeks)|Adverse Event|0
6032498|NCT00313300|9628855|FG004|Randomized in Phase A (26 Weeks)|Adverse Event|0
6032499|NCT00313300|9628851|FG000|Randomized in Phase A (26 Weeks)|Withdrawal by Subject|20
6032500|NCT00313300|9628852|FG001|Randomized in Phase A (26 Weeks)|Withdrawal by Subject|12
6032501|NCT00313300|9628853|FG002|Randomized in Phase A (26 Weeks)|Withdrawal by Subject|13
6032502|NCT00313300|9628854|FG003|Randomized in Phase A (26 Weeks)|Withdrawal by Subject|0
6032503|NCT00313300|9628855|FG004|Randomized in Phase A (26 Weeks)|Withdrawal by Subject|0
6032504|NCT00313300|9628851|FG000|Randomized in Phase A (26 Weeks)|Death|3
6032505|NCT00313300|9628852|FG001|Randomized in Phase A (26 Weeks)|Death|4
6032506|NCT00313300|9628853|FG002|Randomized in Phase A (26 Weeks)|Death|0
6032507|NCT00313300|9628854|FG003|Randomized in Phase A (26 Weeks)|Death|0
6032508|NCT00313300|9628855|FG004|Randomized in Phase A (26 Weeks)|Death|0
6032509|NCT00313300|9628851|FG000|Randomized in Phase A (26 Weeks)|Lost to Follow-up|4
6032510|NCT00313300|9628852|FG001|Randomized in Phase A (26 Weeks)|Lost to Follow-up|4
6032511|NCT00313300|9628853|FG002|Randomized in Phase A (26 Weeks)|Lost to Follow-up|2
6032512|NCT00313300|9628854|FG003|Randomized in Phase A (26 Weeks)|Lost to Follow-up|0
6032513|NCT00313300|9628855|FG004|Randomized in Phase A (26 Weeks)|Lost to Follow-up|0
6032514|NCT00313300|9628851|FG000|Randomized in Phase A (26 Weeks)|Poor/non-compliance|3
6032515|NCT00313300|9628852|FG001|Randomized in Phase A (26 Weeks)|Poor/non-compliance|2
6032516|NCT00313300|9628853|FG002|Randomized in Phase A (26 Weeks)|Poor/non-compliance|1
6032517|NCT00313300|9628854|FG003|Randomized in Phase A (26 Weeks)|Poor/non-compliance|0
6032518|NCT00313300|9628855|FG004|Randomized in Phase A (26 Weeks)|Poor/non-compliance|0
6032519|NCT00313300|9628851|FG000|Randomized in Phase A (26 Weeks)|no longer meets criteria|4
6032520|NCT00313300|9628852|FG001|Randomized in Phase A (26 Weeks)|no longer meets criteria|3
6032521|NCT00313300|9628853|FG002|Randomized in Phase A (26 Weeks)|no longer meets criteria|2
6032522|NCT00313300|9628854|FG003|Randomized in Phase A (26 Weeks)|no longer meets criteria|0
6032523|NCT00313300|9628855|FG004|Randomized in Phase A (26 Weeks)|no longer meets criteria|0
6032524|NCT00313300|9628851|FG000|Randomized in Phase A (26 Weeks)|Administrative reason (arm terminated)|1
6032525|NCT00313300|9628852|FG001|Randomized in Phase A (26 Weeks)|Administrative reason (arm terminated)|0
6032526|NCT00313300|9628853|FG002|Randomized in Phase A (26 Weeks)|Administrative reason (arm terminated)|0
6032527|NCT00313300|9628854|FG003|Randomized in Phase A (26 Weeks)|Administrative reason (arm terminated)|0
6032528|NCT00313300|9628855|FG004|Randomized in Phase A (26 Weeks)|Administrative reason (arm terminated)|0
6032529|NCT00313300|9628851|FG000|Randomized in Phase B (26 Weeks)|Adverse Event|34
6032530|NCT00313300|9628852|FG001|Randomized in Phase B (26 Weeks)|Adverse Event|9
6032531|NCT00313300|9628853|FG002|Randomized in Phase B (26 Weeks)|Adverse Event|12
6032532|NCT00313300|9628854|FG003|Randomized in Phase B (26 Weeks)|Adverse Event|23
6032533|NCT00313300|9628855|FG004|Randomized in Phase B (26 Weeks)|Adverse Event|19
6032534|NCT00313300|9628851|FG000|Randomized in Phase B (26 Weeks)|Withdrawal by Subject|35
6032535|NCT00313300|9628852|FG001|Randomized in Phase B (26 Weeks)|Withdrawal by Subject|14
6032536|NCT00313300|9628853|FG002|Randomized in Phase B (26 Weeks)|Withdrawal by Subject|19
6032537|NCT00313300|9628854|FG003|Randomized in Phase B (26 Weeks)|Withdrawal by Subject|15
6032538|NCT00313300|9628855|FG004|Randomized in Phase B (26 Weeks)|Withdrawal by Subject|19
6032539|NCT00313300|9628851|FG000|Randomized in Phase B (26 Weeks)|Death|5
6032540|NCT00313300|9628852|FG001|Randomized in Phase B (26 Weeks)|Death|3
6032541|NCT00313300|9628853|FG002|Randomized in Phase B (26 Weeks)|Death|1
6032542|NCT00313300|9628854|FG003|Randomized in Phase B (26 Weeks)|Death|0
6032543|NCT00313300|9628855|FG004|Randomized in Phase B (26 Weeks)|Death|1
6032544|NCT00313300|9628851|FG000|Randomized in Phase B (26 Weeks)|Lost to Follow-up|5
6032545|NCT00313300|9628852|FG001|Randomized in Phase B (26 Weeks)|Lost to Follow-up|2
6032546|NCT00313300|9628853|FG002|Randomized in Phase B (26 Weeks)|Lost to Follow-up|3
6032547|NCT00313300|9628854|FG003|Randomized in Phase B (26 Weeks)|Lost to Follow-up|2
6032548|NCT00313300|9628855|FG004|Randomized in Phase B (26 Weeks)|Lost to Follow-up|3
6032549|NCT00313300|9628851|FG000|Randomized in Phase B (26 Weeks)|poor/non-compliance|3
6032550|NCT00313300|9628852|FG001|Randomized in Phase B (26 Weeks)|poor/non-compliance|1
6032551|NCT00313300|9628853|FG002|Randomized in Phase B (26 Weeks)|poor/non-compliance|3
6032552|NCT00313300|9628854|FG003|Randomized in Phase B (26 Weeks)|poor/non-compliance|0
6032553|NCT00313300|9628855|FG004|Randomized in Phase B (26 Weeks)|poor/non-compliance|0
6032554|NCT00313300|9628851|FG000|Randomized in Phase B (26 Weeks)|no longer meets criteria|9
6032555|NCT00313300|9628852|FG001|Randomized in Phase B (26 Weeks)|no longer meets criteria|3
6032556|NCT00313300|9628853|FG002|Randomized in Phase B (26 Weeks)|no longer meets criteria|2
6032557|NCT00313300|9628854|FG003|Randomized in Phase B (26 Weeks)|no longer meets criteria|0
6032558|NCT00313300|9628855|FG004|Randomized in Phase B (26 Weeks)|no longer meets criteria|2
6032559|NCT00313300|9628851|FG000|Randomized in Phase B (26 Weeks)|Administrative reason by Sponsor|2
6032560|NCT00313300|9628852|FG001|Randomized in Phase B (26 Weeks)|Administrative reason by Sponsor|1
6032561|NCT00313300|9628853|FG002|Randomized in Phase B (26 Weeks)|Administrative reason by Sponsor|0
6032562|NCT00313300|9628854|FG003|Randomized in Phase B (26 Weeks)|Administrative reason by Sponsor|193
6032563|NCT00313300|9628855|FG004|Randomized in Phase B (26 Weeks)|Administrative reason by Sponsor|164
6032564|NCT00313300|9628851|FG000|Randomized in Phase B (26 Weeks)|non-specified|1
6032565|NCT00313300|9628852|FG001|Randomized in Phase B (26 Weeks)|non-specified|0
6032566|NCT00313300|9628853|FG002|Randomized in Phase B (26 Weeks)|non-specified|0
6032567|NCT00313300|9628854|FG003|Randomized in Phase B (26 Weeks)|non-specified|0
6032568|NCT00313300|9628855|FG004|Randomized in Phase B (26 Weeks)|non-specified|0
6032569|NCT00313300|9628851|FG000|Follow-Up(30days)-Randomized Phase A|Withdrawal by Subject|5
6032570|NCT00313300|9628852|FG001|Follow-Up(30days)-Randomized Phase A|Withdrawal by Subject|5
6032571|NCT00313300|9628853|FG002|Follow-Up(30days)-Randomized Phase A|Withdrawal by Subject|2
6032572|NCT00313300|9628854|FG003|Follow-Up(30days)-Randomized Phase A|Withdrawal by Subject|0
6032573|NCT00313300|9628855|FG004|Follow-Up(30days)-Randomized Phase A|Withdrawal by Subject|0
6032574|NCT00313300|9628851|FG000|Follow-Up(30days)-Randomized Phase A|Death|0
6032575|NCT00313300|9628852|FG001|Follow-Up(30days)-Randomized Phase A|Death|1
6032576|NCT00313300|9628853|FG002|Follow-Up(30days)-Randomized Phase A|Death|0
6032577|NCT00313300|9628854|FG003|Follow-Up(30days)-Randomized Phase A|Death|0
6032578|NCT00313300|9628855|FG004|Follow-Up(30days)-Randomized Phase A|Death|0
6032579|NCT00313300|9628851|FG000|Follow-Up(30days)-Randomized Phase B|Withdrawal by Subject|1
6032580|NCT00313300|9628852|FG001|Follow-Up(30days)-Randomized Phase B|Withdrawal by Subject|0
6032581|NCT00313300|9628853|FG002|Follow-Up(30days)-Randomized Phase B|Withdrawal by Subject|2
6032582|NCT00313300|9628854|FG003|Follow-Up(30days)-Randomized Phase B|Withdrawal by Subject|1
6032583|NCT00313300|9628855|FG004|Follow-Up(30days)-Randomized Phase B|Withdrawal by Subject|1
6032584|NCT00313300|9628851|FG000|Follow-Up(30days)-Randomized Phase B|Death|1
6032585|NCT00313300|9628852|FG001|Follow-Up(30days)-Randomized Phase B|Death|0
6032586|NCT00313300|9628853|FG002|Follow-Up(30days)-Randomized Phase B|Death|0
6032587|NCT00313300|9628854|FG003|Follow-Up(30days)-Randomized Phase B|Death|0
6032588|NCT00313300|9628855|FG004|Follow-Up(30days)-Randomized Phase B|Death|0
6032589|NCT00313300|9628851|FG000|Follow-Up(30days)-Randomized Phase B|Lost to Follow-up|0
6032590|NCT00313300|9628852|FG001|Follow-Up(30days)-Randomized Phase B|Lost to Follow-up|0
6032591|NCT00313300|9628853|FG002|Follow-Up(30days)-Randomized Phase B|Lost to Follow-up|0
6032592|NCT00313300|9628854|FG003|Follow-Up(30days)-Randomized Phase B|Lost to Follow-up|2
6032593|NCT00313300|9628855|FG004|Follow-Up(30days)-Randomized Phase B|Lost to Follow-up|1
6032594|NCT00313300|9628851|FG000|Follow-Up(30days)-Randomized Phase B|missing end of study status|1
6032595|NCT00313300|9628852|FG001|Follow-Up(30days)-Randomized Phase B|missing end of study status|0
6032596|NCT00313300|9628853|FG002|Follow-Up(30days)-Randomized Phase B|missing end of study status|0
6032597|NCT00313300|9628854|FG003|Follow-Up(30days)-Randomized Phase B|missing end of study status|2
6032598|NCT00313300|9628855|FG004|Follow-Up(30days)-Randomized Phase B|missing end of study status|0
6032599|NCT00313313|9628876|FG000|Overall Study|Lack of Efficacy|14
6032600|NCT00313313|9628877|FG001|Overall Study|Lack of Efficacy|9
6032601|NCT00313313|9628878|FG002|Overall Study|Lack of Efficacy|20
6032602|NCT00313313|9628876|FG000|Overall Study|Withdrawal of consent by subject|18
6032603|NCT00313313|9628877|FG001|Overall Study|Withdrawal of consent by subject|17
6032604|NCT00313313|9628878|FG002|Overall Study|Withdrawal of consent by subject|31
6032605|NCT00313313|9628876|FG000|Overall Study|Lost to Follow-up|10
6032606|NCT00313313|9628877|FG001|Overall Study|Lost to Follow-up|7
6032607|NCT00313313|9628878|FG002|Overall Study|Lost to Follow-up|9
6032608|NCT00313313|9628876|FG000|Overall Study|Adverse Event|15
6032609|NCT00313313|9628877|FG001|Overall Study|Adverse Event|16
6032610|NCT00313313|9628878|FG002|Overall Study|Adverse Event|12
6032611|NCT00313313|9628876|FG000|Overall Study|Physician Decision|2
6032612|NCT00313313|9628877|FG001|Overall Study|Physician Decision|6
6032613|NCT00313313|9628878|FG002|Overall Study|Physician Decision|4
6032614|NCT00313313|9628876|FG000|Overall Study|Poor/Noncompliance|3
6032615|NCT00313313|9628877|FG001|Overall Study|Poor/Noncompliance|6
6032616|NCT00313313|9628878|FG002|Overall Study|Poor/Noncompliance|2
6032617|NCT00313313|9628876|FG000|Overall Study|Pregnancy|1
6032618|NCT00313313|9628877|FG001|Overall Study|Pregnancy|2
6032619|NCT00313313|9628878|FG002|Overall Study|Pregnancy|0
6032620|NCT00313313|9628876|FG000|Overall Study|Death|0
6032621|NCT00313313|9628877|FG001|Overall Study|Death|0
6032622|NCT00313313|9628878|FG002|Overall Study|Death|2
6032623|NCT00313313|9628876|FG000|Overall Study|Subject No Longer Meets Study Criteria|0
6032624|NCT00313313|9628877|FG001|Overall Study|Subject No Longer Meets Study Criteria|3
6032625|NCT00313313|9628878|FG002|Overall Study|Subject No Longer Meets Study Criteria|2
6032626|NCT00313586|9628902|FG000|Overall Study|Disease progression|14
6032627|NCT00313586|9628903|FG001|Overall Study|Disease progression|19
6032628|NCT00313586|9628904|FG002|Overall Study|Disease progression|10
6032629|NCT00313586|9628905|FG003|Overall Study|Disease progression|3
6032630|NCT00313586|9628902|FG000|Overall Study|Adverse Event|12
6032631|NCT00313586|9628903|FG001|Overall Study|Adverse Event|18
6032632|NCT00313586|9628904|FG002|Overall Study|Adverse Event|3
6032633|NCT00313586|9628905|FG003|Overall Study|Adverse Event|10
6032634|NCT00313586|9628902|FG000|Overall Study|Death|11
6032635|NCT00313586|9628903|FG001|Overall Study|Death|8
6032636|NCT00313586|9628904|FG002|Overall Study|Death|1
6032637|NCT00313586|9628905|FG003|Overall Study|Death|7
6032638|NCT00313586|9628902|FG000|Overall Study|Withdrawal by Subject|13
6032639|NCT00313586|9628903|FG001|Overall Study|Withdrawal by Subject|6
6032640|NCT00313586|9628904|FG002|Overall Study|Withdrawal by Subject|6
6032641|NCT00313586|9628905|FG003|Overall Study|Withdrawal by Subject|2
6032642|NCT00313586|9628902|FG000|Overall Study|Alternative therapy|3
6032643|NCT00313586|9628903|FG001|Overall Study|Alternative therapy|6
6032644|NCT00313586|9628904|FG002|Overall Study|Alternative therapy|2
6032645|NCT00313586|9628905|FG003|Overall Study|Alternative therapy|0
6032646|NCT00313586|9628902|FG000|Overall Study|Other complicating disease|2
6032647|NCT00313586|9628903|FG001|Overall Study|Other complicating disease|2
6032648|NCT00313586|9628904|FG002|Overall Study|Other complicating disease|0
6032649|NCT00313586|9628905|FG003|Overall Study|Other complicating disease|0
6032650|NCT00313586|9628902|FG000|Overall Study|Did not achieve HI-major/better response|10
6032651|NCT00313586|9628903|FG001|Overall Study|Did not achieve HI-major/better response|7
6032652|NCT00313586|9628904|FG002|Overall Study|Did not achieve HI-major/better response|2
6032653|NCT00313586|9628905|FG003|Overall Study|Did not achieve HI-major/better response|1
6032654|NCT00313586|9628902|FG000|Overall Study|Physician Decision|2
6032655|NCT00313586|9628903|FG001|Overall Study|Physician Decision|1
6032656|NCT00313586|9628904|FG002|Overall Study|Physician Decision|0
6032657|NCT00313586|9628905|FG003|Overall Study|Physician Decision|0
6032658|NCT00313586|9628902|FG000|Overall Study|Absolute neutrophil count not recovered|2
6032659|NCT00313586|9628903|FG001|Overall Study|Absolute neutrophil count not recovered|1
6032660|NCT00313586|9628904|FG002|Overall Study|Absolute neutrophil count not recovered|0
6032661|NCT00313586|9628905|FG003|Overall Study|Absolute neutrophil count not recovered|0
6032662|NCT00313586|9628902|FG000|Overall Study|Lost insurance|0
6032663|NCT00313586|9628903|FG001|Overall Study|Lost insurance|1
6032664|NCT00313586|9628904|FG002|Overall Study|Lost insurance|0
6032665|NCT00313586|9628905|FG003|Overall Study|Lost insurance|0
6032666|NCT00313586|9628902|FG000|Overall Study|Moved|0
6032667|NCT00313586|9628903|FG001|Overall Study|Moved|1
6032668|NCT00313586|9628904|FG002|Overall Study|Moved|0
6032669|NCT00313586|9628905|FG003|Overall Study|Moved|0
6032670|NCT00313586|9628902|FG000|Overall Study|Death before starting treatment|1
6032671|NCT00313586|9628903|FG001|Overall Study|Death before starting treatment|0
6032672|NCT00313586|9628904|FG002|Overall Study|Death before starting treatment|0
6032673|NCT00313586|9628905|FG003|Overall Study|Death before starting treatment|0
6032674|NCT00313612|9628915|FG000|Overall Study|Patient never received treatment|0
6032675|NCT00313612|9628916|FG001|Overall Study|Patient never received treatment|1
6032676|NCT00313703|9628926|FG000|Overall Study|Lost to Follow-up|11
6032677|NCT00313703|9628927|FG001|Overall Study|Lost to Follow-up|2
6032678|NCT00313703|9628928|FG002|Overall Study|Lost to Follow-up|5
6032679|NCT00313703|9628929|FG003|Overall Study|Lost to Follow-up|12
6032680|NCT00313716|9628945|FG000|Overall Study|Death|3
6032681|NCT00313716|9628946|FG001|Overall Study|Death|2
6032682|NCT00313716|9628947|FG002|Overall Study|Death|9
6032683|NCT00313716|9628948|FG003|Overall Study|Death|3
6032684|NCT00313716|9628949|FG004|Overall Study|Death|5
6032685|NCT00313716|9628950|FG005|Overall Study|Death|9
6032686|NCT00313716|9628945|FG000|Overall Study|Lost to Follow-up|2
6032687|NCT00313716|9628946|FG001|Overall Study|Lost to Follow-up|5
6032688|NCT00313716|9628947|FG002|Overall Study|Lost to Follow-up|2
6032689|NCT00313716|9628948|FG003|Overall Study|Lost to Follow-up|1
6032690|NCT00313716|9628949|FG004|Overall Study|Lost to Follow-up|0
6032691|NCT00313716|9628950|FG005|Overall Study|Lost to Follow-up|4
6032692|NCT00313716|9628945|FG000|Overall Study|Withdrawal by Subject|0
6032693|NCT00313716|9628946|FG001|Overall Study|Withdrawal by Subject|1
6032694|NCT00313716|9628947|FG002|Overall Study|Withdrawal by Subject|1
6032695|NCT00313716|9628948|FG003|Overall Study|Withdrawal by Subject|0
6032696|NCT00313716|9628949|FG004|Overall Study|Withdrawal by Subject|1
6032697|NCT00313716|9628950|FG005|Overall Study|Withdrawal by Subject|0
6032698|NCT00313781|9628974|FG000|Before Crossover|Death|22
6032699|NCT00313781|9628975|FG001|Before Crossover|Death|8
6032700|NCT00313781|9628976|FG002|Before Crossover|Death|0
6032701|NCT00313781|9628974|FG000|Before Crossover|Lost to Follow-up|0
6032702|NCT00313781|9628975|FG001|Before Crossover|Lost to Follow-up|3
6032703|NCT00313781|9628976|FG002|Before Crossover|Lost to Follow-up|0
6032704|NCT00313781|9628974|FG000|Before Crossover|Withdrawal by Subject|3
6032705|NCT00313781|9628975|FG001|Before Crossover|Withdrawal by Subject|1
6032706|NCT00313781|9628976|FG002|Before Crossover|Withdrawal by Subject|0
6032707|NCT00313781|9628974|FG000|Before Crossover|Other|45
6032708|NCT00313781|9628975|FG001|Before Crossover|Other|30
6032709|NCT00313781|9628976|FG002|Before Crossover|Other|0
6032710|NCT00313781|9628974|FG000|Before Crossover|Crossover|0
6032711|NCT00313781|9628975|FG001|Before Crossover|Crossover|37
6032712|NCT00313781|9628976|FG002|Before Crossover|Crossover|0
6032713|NCT00313781|9628974|FG000|Before Crossover|Randomized, not treated|5
6032714|NCT00313781|9628975|FG001|Before Crossover|Randomized, not treated|0
6032715|NCT00313781|9628976|FG002|Before Crossover|Randomized, not treated|0
6032716|NCT00313781|9628974|FG000|After Crossover|Death|0
6032717|NCT00313781|9628975|FG001|After Crossover|Death|0
6032718|NCT00313781|9628976|FG002|After Crossover|Death|6
6032719|NCT00313781|9628974|FG000|After Crossover|Withdrawal by Subject|0
6032720|NCT00313781|9628975|FG001|After Crossover|Withdrawal by Subject|0
6032721|NCT00313781|9628976|FG002|After Crossover|Withdrawal by Subject|3
6032722|NCT00313781|9628974|FG000|After Crossover|Other|0
6032723|NCT00313781|9628975|FG001|After Crossover|Other|0
6032724|NCT00313781|9628976|FG002|After Crossover|Other|18
6032725|NCT00313820|9628987|FG000|Assigned to Treatment|Other|1
6032726|NCT00313820|9628988|FG001|Assigned to Treatment|Other|0
6032727|NCT00313820|9628987|FG000|Pregabalin or Placebo Treatment Period|Adverse Event|9
6032728|NCT00313820|9628988|FG001|Pregabalin or Placebo Treatment Period|Adverse Event|4
6032729|NCT00313820|9628987|FG000|Pregabalin or Placebo Treatment Period|Lack of Efficacy|0
6032730|NCT00313820|9628988|FG001|Pregabalin or Placebo Treatment Period|Lack of Efficacy|1
6032731|NCT00313820|9628987|FG000|Pregabalin or Placebo Treatment Period|Lost to Follow-up|0
6032732|NCT00313820|9628988|FG001|Pregabalin or Placebo Treatment Period|Lost to Follow-up|7
6032733|NCT00313820|9628987|FG000|Pregabalin or Placebo Treatment Period|Withdrawal by Subject|6
6032734|NCT00313820|9628988|FG001|Pregabalin or Placebo Treatment Period|Withdrawal by Subject|4
6032735|NCT00313820|9628987|FG000|Pregabalin or Placebo Treatment Period|Other|2
6032736|NCT00313820|9628988|FG001|Pregabalin or Placebo Treatment Period|Other|3
6032737|NCT00313846|9628996|FG000|Overall Study|Withdrawal by Subject|2
6032738|NCT00313846|9628997|FG001|Overall Study|Withdrawal by Subject|0
6032739|NCT00313846|9628996|FG000|Overall Study|Adverse Event|1
6032740|NCT00313846|9628997|FG001|Overall Study|Adverse Event|8
6032741|NCT00313846|9628996|FG000|Overall Study|Administrative|2
6032742|NCT00313846|9628997|FG001|Overall Study|Administrative|3
6032743|NCT00313911|9629006|FG000|Overall Study|Serious adverse event|6
6032744|NCT00313911|9629007|FG001|Overall Study|Serious adverse event|1
6032745|NCT00313911|9629006|FG000|Overall Study|Adverse Event|2
6032746|NCT00313911|9629007|FG001|Overall Study|Adverse Event|3
6032747|NCT00313911|9629006|FG000|Overall Study|Protocol Violation|19
6032748|NCT00313911|9629007|FG001|Overall Study|Protocol Violation|10
6032749|NCT00313911|9629006|FG000|Overall Study|Lost to Follow-up|27
6032750|NCT00313911|9629007|FG001|Overall Study|Lost to Follow-up|14
6032751|NCT00313911|9629006|FG000|Overall Study|Withdrawal by Subject|39
6032752|NCT00313911|9629007|FG001|Overall Study|Withdrawal by Subject|12
6032753|NCT00313911|9629006|FG000|Overall Study|Did not meet age criteria|1
6032754|NCT00313911|9629007|FG001|Overall Study|Did not meet age criteria|1
6032755|NCT00314132|9629024|FG000|Overall Study|Lost to Follow-up|3
6032756|NCT00314132|9629025|FG001|Overall Study|Lost to Follow-up|13
6032757|NCT00314132|9629024|FG000|Overall Study|Withdrawal by Subject|3
6032758|NCT00314132|9629025|FG001|Overall Study|Withdrawal by Subject|5
6032759|NCT00314132|9629024|FG000|Overall Study|Adverse Event|1
6032760|NCT00314132|9629025|FG001|Overall Study|Adverse Event|0
6032761|NCT00314132|9629024|FG000|Overall Study|Physician Decision|1
6032762|NCT00314132|9629025|FG001|Overall Study|Physician Decision|0
6032763|NCT00314145|9629035|FG000|Overall Study|Withdrawal by Subject|8
6032764|NCT00314145|9629036|FG001|Overall Study|Withdrawal by Subject|10
6032765|NCT00314145|9629035|FG000|Overall Study|Lost to Follow-up|5
6032766|NCT00314145|9629036|FG001|Overall Study|Lost to Follow-up|12
6032767|NCT00314145|9629035|FG000|Overall Study|Physician Decision|3
6032768|NCT00314145|9629036|FG001|Overall Study|Physician Decision|4
6032769|NCT00314145|9629035|FG000|Overall Study|Adverse Event|0
6032770|NCT00314145|9629036|FG001|Overall Study|Adverse Event|3
6032771|NCT00314145|9629035|FG000|Overall Study|Protocol Violation|3
6032772|NCT00314145|9629036|FG001|Overall Study|Protocol Violation|0
6032773|NCT00314145|9629035|FG000|Overall Study|Sponsor Decision|2
6032774|NCT00314145|9629036|FG001|Overall Study|Sponsor Decision|0
6032775|NCT00314249|9629054|FG000|Overall Study|Adverse Event|73
6032776|NCT00314249|9629055|FG001|Overall Study|Adverse Event|94
6032777|NCT00314249|9629054|FG000|Overall Study|Lack of Efficacy|33
6032778|NCT00314249|9629055|FG001|Overall Study|Lack of Efficacy|24
6032779|NCT00314249|9629054|FG000|Overall Study|Withdrawal by Subject|21
6032780|NCT00314249|9629055|FG001|Overall Study|Withdrawal by Subject|28
6032781|NCT00314249|9629054|FG000|Overall Study|Lost to Follow-up|15
6032782|NCT00314249|9629055|FG001|Overall Study|Lost to Follow-up|9
6032783|NCT00314249|9629054|FG000|Overall Study|Physician Decision|1
6032784|NCT00314249|9629055|FG001|Overall Study|Physician Decision|1
6032785|NCT00314249|9629054|FG000|Overall Study|Withdrawn for other reasons|4
6032786|NCT00314249|9629055|FG001|Overall Study|Withdrawn for other reasons|1
6032787|NCT00314249|9629054|FG000|Overall Study|Non-Compliant|5
6032788|NCT00314249|9629055|FG001|Overall Study|Non-Compliant|6
6032789|NCT00314262|9629061|FG000|Overall Study|Adverse Event|2
6032790|NCT00314262|9629061|FG000|Overall Study|Withdrawal by Subject|2
6032791|NCT00314262|9629061|FG000|Overall Study|Physician Decision|1
6032792|NCT00314340|9629065|FG000|Overall Study|lost interest|1
6032793|NCT00314574|9629073|FG000|Overall Study|Death|3
6032794|NCT00314574|9629074|FG001|Overall Study|Death|0
6032795|NCT00314574|9629073|FG000|Overall Study|Adverse Event|11
6032796|NCT00314574|9629074|FG001|Overall Study|Adverse Event|16
6032797|NCT00314574|9629073|FG000|Overall Study|Lost to Follow-up|19
6032798|NCT00314574|9629074|FG001|Overall Study|Lost to Follow-up|25
6032799|NCT00314574|9629073|FG000|Overall Study|Withdrawal by Subject|33
6032800|NCT00314574|9629074|FG001|Overall Study|Withdrawal by Subject|22
6032801|NCT00314574|9629073|FG000|Overall Study|Physician Decision|22
6032802|NCT00314574|9629074|FG001|Overall Study|Physician Decision|15
6032803|NCT00314574|9629073|FG000|Overall Study|Pregnancy|6
6032804|NCT00314574|9629074|FG001|Overall Study|Pregnancy|4
6032805|NCT00314574|9629073|FG000|Overall Study|Data unknown at database lock|0
6032806|NCT00314574|9629074|FG001|Overall Study|Data unknown at database lock|1
6032807|NCT00314795|9629080|FG000|Overall Study|Adverse Event|8
6032808|NCT00314795|9629080|FG000|Overall Study|Death|4
6032809|NCT00314795|9629080|FG000|Overall Study|Reason not Specified|3
6032810|NCT00314795|9629080|FG000|Overall Study|Renal Transplant|3
6032811|NCT00314795|9629080|FG000|Overall Study|Participants Withdrew Consent|2
6032812|NCT00314808|9629084|FG000|Overall Study|Disease Progression without AE|4
6032813|NCT00314808|9629084|FG000|Overall Study|Withdrawal by Subject/PI without AE|4
6032814|NCT00314951|9629090|FG000|Treatment|Didn't meet criteria for mITT population|16
6032815|NCT00314951|9629091|FG001|Treatment|Didn't meet criteria for mITT population|11
6032816|NCT00314951|9629090|FG000|Follow-up|mITT failure|44
6032817|NCT00314951|9629091|FG001|Follow-up|mITT failure|34
6032818|NCT00315055|9629099|FG000|Overall Study|Protocol Violation|2
6032819|NCT00315055|9629100|FG001|Overall Study|Protocol Violation|4
6032820|NCT00315055|9629099|FG000|Overall Study|Lost to Follow-up|1
6032821|NCT00315055|9629100|FG001|Overall Study|Lost to Follow-up|1
6032822|NCT00315445|9629195|FG000|Overall Study|Adverse Event|7
6032823|NCT00315445|9629196|FG001|Overall Study|Adverse Event|12
6032824|NCT00315445|9629197|FG002|Overall Study|Adverse Event|15
6032825|NCT00315445|9629195|FG000|Overall Study|Lack of Efficacy|16
6032826|NCT00315445|9629196|FG001|Overall Study|Lack of Efficacy|1
6032827|NCT00315445|9629197|FG002|Overall Study|Lack of Efficacy|7
6032828|NCT00315445|9629195|FG000|Overall Study|Lost to Follow-up|1
6032829|NCT00315445|9629196|FG001|Overall Study|Lost to Follow-up|0
6032830|NCT00315445|9629197|FG002|Overall Study|Lost to Follow-up|1
6032831|NCT00315445|9629195|FG000|Overall Study|Protocol Violation|2
6032832|NCT00315445|9629196|FG001|Overall Study|Protocol Violation|0
6032833|NCT00315445|9629197|FG002|Overall Study|Protocol Violation|1
6032834|NCT00315445|9629195|FG000|Overall Study|Other|1
6032835|NCT00315445|9629196|FG001|Overall Study|Other|3
6032836|NCT00315445|9629197|FG002|Overall Study|Other|0
6032837|NCT00315458|9629207|FG000|Overall Study|Administrative|0
6032838|NCT00315458|9629208|FG001|Overall Study|Administrative|3
6032839|NCT00315458|9629209|FG002|Overall Study|Administrative|8
6032840|NCT00315458|9629210|FG003|Overall Study|Administrative|21
6032841|NCT00315458|9629207|FG000|Overall Study|Adverse Event|2
6032842|NCT00315458|9629208|FG001|Overall Study|Adverse Event|4
6032843|NCT00315458|9629209|FG002|Overall Study|Adverse Event|23
6032844|NCT00315458|9629210|FG003|Overall Study|Adverse Event|3
6032845|NCT00315458|9629207|FG000|Overall Study|Lost to Follow-up|1
6032846|NCT00315458|9629208|FG001|Overall Study|Lost to Follow-up|2
6032847|NCT00315458|9629209|FG002|Overall Study|Lost to Follow-up|0
6032848|NCT00315458|9629210|FG003|Overall Study|Lost to Follow-up|2
6032849|NCT00315458|9629207|FG000|Overall Study|Withdrawal by Subject|0
6032850|NCT00315458|9629208|FG001|Overall Study|Withdrawal by Subject|3
6032851|NCT00315458|9629209|FG002|Overall Study|Withdrawal by Subject|0
6032852|NCT00315458|9629210|FG003|Overall Study|Withdrawal by Subject|2
6032853|NCT00315458|9629207|FG000|Overall Study|Lack of Efficacy|0
6032854|NCT00315458|9629208|FG001|Overall Study|Lack of Efficacy|0
6032855|NCT00315458|9629209|FG002|Overall Study|Lack of Efficacy|20
6032856|NCT00315458|9629210|FG003|Overall Study|Lack of Efficacy|1
6032857|NCT00315458|9629207|FG000|Overall Study|Did not qualify|0
6032858|NCT00315458|9629208|FG001|Overall Study|Did not qualify|0
6032859|NCT00315458|9629209|FG002|Overall Study|Did not qualify|1
6032860|NCT00315458|9629210|FG003|Overall Study|Did not qualify|0
6032861|NCT00315705|9629239|FG000|Phase 1|Refused further treatment|1
6032862|NCT00315705|9629239|FG000|Phase 1|Failure to achieve response|8
6032863|NCT00315705|9629239|FG000|Phase 1|Disease relapse|4
6032864|NCT00315705|9629239|FG000|Phase 1|Scheduled for transplant|9
6032865|NCT00315705|9629239|FG000|Phase 1|Death|3
6032866|NCT00315705|9629239|FG000|Phase 2|Physician Decision|4
6032867|NCT00315705|9629239|FG000|Phase 2|Adverse Event|1
6032868|NCT00315705|9629239|FG000|Phase 2|Failure to achieve response|3
6080215|NCT00615030|9687420|FG003|Period I|Abnormal laboratory value(s)|0
6080216|NCT00615030|9687421|FG004|Period I|Abnormal laboratory value(s)|0
6032869|NCT00315705|9629239|FG000|Phase 2|Disease relapse|1
6032870|NCT00315705|9629239|FG000|Phase 2|Scheduled for transplant|8
6032871|NCT00315705|9629239|FG000|Phase 2|Other|1
6032872|NCT00315705|9629239|FG000|Phase 2|Death|7
6032873|NCT00315731|9629256|FG000|Overall Study|Lost to Follow-up|1
6032874|NCT00315731|9629256|FG000|Overall Study|Death|5
6032875|NCT00316004|9629282|FG000|Overall Study|Subject was not given study fluid.|14
6032876|NCT00316004|9629283|FG001|Overall Study|Subject was not given study fluid.|14
6032877|NCT00316004|9629284|FG002|Overall Study|Subject was not given study fluid.|21
6032878|NCT00316017|9629295|FG000|Overall Study|Protocol Violation|11
6032879|NCT00316017|9629296|FG001|Overall Study|Protocol Violation|13
6032880|NCT00316017|9629297|FG002|Overall Study|Protocol Violation|19
6048674|NCT00419952|9647947|FG000|Overall Study|Abnormal ECG|1
6048675|NCT00419952|9647948|FG001|Overall Study|Abnormal ECG|0
6048676|NCT00420004|9647957|FG000|Overall Study|Adverse Event|4
6048677|NCT00420004|9647958|FG001|Overall Study|Adverse Event|1
6048678|NCT00420004|9647959|FG002|Overall Study|Adverse Event|1
6048679|NCT00420004|9647957|FG000|Overall Study|Lack of Efficacy|5
6048680|NCT00420004|9647958|FG001|Overall Study|Lack of Efficacy|4
6048681|NCT00420004|9647959|FG002|Overall Study|Lack of Efficacy|1
6048682|NCT00420004|9647957|FG000|Overall Study|Lost to Follow-up|31
6048683|NCT00420004|9647958|FG001|Overall Study|Lost to Follow-up|12
6048684|NCT00420004|9647959|FG002|Overall Study|Lost to Follow-up|10
6048685|NCT00420004|9647957|FG000|Overall Study|Entry Criteria Not Met|0
6048686|NCT00420004|9647958|FG001|Overall Study|Entry Criteria Not Met|1
6048687|NCT00420004|9647959|FG002|Overall Study|Entry Criteria Not Met|0
6048688|NCT00420004|9647957|FG000|Overall Study|Physician Decision|14
6048689|NCT00420004|9647958|FG001|Overall Study|Physician Decision|4
6048690|NCT00420004|9647959|FG002|Overall Study|Physician Decision|2
6048691|NCT00420004|9647957|FG000|Overall Study|Protocol Violation|5
6048692|NCT00420004|9647958|FG001|Overall Study|Protocol Violation|4
6048693|NCT00420004|9647959|FG002|Overall Study|Protocol Violation|3
6048694|NCT00420004|9647957|FG000|Overall Study|Withdrawal by Subject|67
6048695|NCT00420004|9647958|FG001|Overall Study|Withdrawal by Subject|42
6048696|NCT00420004|9647959|FG002|Overall Study|Withdrawal by Subject|14
6048697|NCT00420004|9647957|FG000|Overall Study|Sponsor Decision|3
6048698|NCT00420004|9647958|FG001|Overall Study|Sponsor Decision|3
6048699|NCT00420004|9647959|FG002|Overall Study|Sponsor Decision|1
6048700|NCT00420056|9647980|FG000|Overall Study|Objective progression or relapse|17
6048701|NCT00420095|9647986|FG000|Overall Study|Adverse Event|1
6048702|NCT00420095|9647987|FG001|Overall Study|Adverse Event|0
6048703|NCT00420095|9647986|FG000|Overall Study|Protocol Violation|1
6048704|NCT00420095|9647987|FG001|Overall Study|Protocol Violation|1
6048705|NCT00420095|9647986|FG000|Overall Study|Lost to Follow-up|1
6048706|NCT00420095|9647987|FG001|Overall Study|Lost to Follow-up|0
6048707|NCT00420199|9648004|FG000|Overall Study|Participant no longer met study criteria|1
6048708|NCT00420199|9648005|FG001|Overall Study|Participant no longer met study criteria|0
6048709|NCT00420212|9648019|FG000|Overall Study|Adverse Event|22
6048710|NCT00420212|9648020|FG001|Overall Study|Adverse Event|40
6048711|NCT00420212|9648021|FG002|Overall Study|Adverse Event|36
6048712|NCT00420212|9648019|FG000|Overall Study|Lost to Follow-up|9
6048713|NCT00420212|9648020|FG001|Overall Study|Lost to Follow-up|11
6048714|NCT00420212|9648021|FG002|Overall Study|Lost to Follow-up|11
6048715|NCT00420212|9648019|FG000|Overall Study|Withdrawal by Subject|31
6048716|NCT00420212|9648020|FG001|Overall Study|Withdrawal by Subject|22
6048717|NCT00420212|9648021|FG002|Overall Study|Withdrawal by Subject|19
6048718|NCT00420212|9648019|FG000|Overall Study|Physician Decision|4
6048719|NCT00420212|9648020|FG001|Overall Study|Physician Decision|4
6048720|NCT00420212|9648021|FG002|Overall Study|Physician Decision|3
6048721|NCT00420212|9648019|FG000|Overall Study|Protocol Violation|4
6048722|NCT00420212|9648020|FG001|Overall Study|Protocol Violation|4
6048723|NCT00420212|9648021|FG002|Overall Study|Protocol Violation|8
6048724|NCT00420212|9648019|FG000|Overall Study|Death|0
6048725|NCT00420212|9648020|FG001|Overall Study|Death|0
6048726|NCT00420212|9648021|FG002|Overall Study|Death|1
6048727|NCT00420212|9648019|FG000|Overall Study|Other-Unspecified|21
6048728|NCT00420212|9648020|FG001|Overall Study|Other-Unspecified|14
6048729|NCT00420212|9648021|FG002|Overall Study|Other-Unspecified|18
6048730|NCT00420238|9648034|FG000|12 Week Double-Blind Treatment Period 1|Adverse Event|1
6048731|NCT00420238|9648035|FG001|12 Week Double-Blind Treatment Period 1|Adverse Event|0
6048732|NCT00420238|9648034|FG000|12 Week Double-Blind Treatment Period 1|Lack of Efficacy|0
6048733|NCT00420238|9648035|FG001|12 Week Double-Blind Treatment Period 1|Lack of Efficacy|2
6048734|NCT00420238|9648034|FG000|12 Week Double-Blind Treatment Period 1|Lost to Follow-up|0
6048735|NCT00420238|9648035|FG001|12 Week Double-Blind Treatment Period 1|Lost to Follow-up|1
6048736|NCT00420238|9648034|FG000|12 Week Double-Blind Treatment Period 1|Withdrawal of Consent|0
6048737|NCT00420238|9648035|FG001|12 Week Double-Blind Treatment Period 1|Withdrawal of Consent|1
6048738|NCT00420238|9648034|FG000|12 Week Open-Label Treatment Period 2|Lost to Follow-up|1
6048739|NCT00420238|9648035|FG001|12 Week Open-Label Treatment Period 2|Lost to Follow-up|0
6048740|NCT00420238|9648034|FG000|12 Week Open-Label Treatment Period 2|Withdrawal of Consent|1
6048741|NCT00420238|9648035|FG001|12 Week Open-Label Treatment Period 2|Withdrawal of Consent|1
6048742|NCT00420290|9648049|FG000|Overall Study|Adverse Event|3
6048743|NCT00420290|9648050|FG001|Overall Study|Adverse Event|1
6048744|NCT00420290|9648049|FG000|Overall Study|Withdrawal by Subject|0
6048745|NCT00420290|9648050|FG001|Overall Study|Withdrawal by Subject|2
6048746|NCT00420290|9648049|FG000|Overall Study|did not meet inclusion/exclusion|1
6048747|NCT00420290|9648050|FG001|Overall Study|did not meet inclusion/exclusion|1
6048748|NCT00420303|9648058|FG000|Overall Study|Serious Adverse Event|1
6048749|NCT00420303|9648059|FG001|Overall Study|Serious Adverse Event|0
6048750|NCT00420303|9648058|FG000|Overall Study|Lack of Efficacy|0
6032881|NCT00316082|9629310|FG000|Overall Study|Lack of Efficacy|2
6032882|NCT00316082|9629311|FG001|Overall Study|Lack of Efficacy|3
6032883|NCT00316082|9629312|FG002|Overall Study|Lack of Efficacy|3
6032884|NCT00316082|9629313|FG003|Overall Study|Lack of Efficacy|4
6032885|NCT00316082|9629314|FG004|Overall Study|Lack of Efficacy|6
6032886|NCT00316082|9629310|FG000|Overall Study|Withdrawal of Consent by Subject|10
6032887|NCT00316082|9629311|FG001|Overall Study|Withdrawal of Consent by Subject|8
6032888|NCT00316082|9629312|FG002|Overall Study|Withdrawal of Consent by Subject|2
6032889|NCT00316082|9629313|FG003|Overall Study|Withdrawal of Consent by Subject|9
6032890|NCT00316082|9629314|FG004|Overall Study|Withdrawal of Consent by Subject|5
6032891|NCT00316082|9629310|FG000|Overall Study|Lost to Follow-up|7
6032892|NCT00316082|9629311|FG001|Overall Study|Lost to Follow-up|6
6032893|NCT00316082|9629312|FG002|Overall Study|Lost to Follow-up|7
6032894|NCT00316082|9629313|FG003|Overall Study|Lost to Follow-up|8
6032895|NCT00316082|9629314|FG004|Overall Study|Lost to Follow-up|6
6032896|NCT00316082|9629310|FG000|Overall Study|Poor/noncompliance|6
6032897|NCT00316082|9629311|FG001|Overall Study|Poor/noncompliance|1
6032898|NCT00316082|9629312|FG002|Overall Study|Poor/noncompliance|4
6032899|NCT00316082|9629313|FG003|Overall Study|Poor/noncompliance|1
6032900|NCT00316082|9629314|FG004|Overall Study|Poor/noncompliance|4
6032901|NCT00316082|9629310|FG000|Overall Study|Adverse Event|4
6032902|NCT00316082|9629311|FG001|Overall Study|Adverse Event|2
6032903|NCT00316082|9629312|FG002|Overall Study|Adverse Event|5
6032904|NCT00316082|9629313|FG003|Overall Study|Adverse Event|1
6032905|NCT00316082|9629314|FG004|Overall Study|Adverse Event|3
6032906|NCT00316082|9629310|FG000|Overall Study|Subject no longer meets study criteria|3
6032907|NCT00316082|9629311|FG001|Overall Study|Subject no longer meets study criteria|1
6032908|NCT00316082|9629312|FG002|Overall Study|Subject no longer meets study criteria|2
6032909|NCT00316082|9629313|FG003|Overall Study|Subject no longer meets study criteria|2
6032910|NCT00316082|9629314|FG004|Overall Study|Subject no longer meets study criteria|1
6032911|NCT00316082|9629310|FG000|Overall Study|Physician Decision|1
6032912|NCT00316082|9629311|FG001|Overall Study|Physician Decision|1
6032913|NCT00316082|9629312|FG002|Overall Study|Physician Decision|2
6032914|NCT00316082|9629313|FG003|Overall Study|Physician Decision|1
6032915|NCT00316082|9629314|FG004|Overall Study|Physician Decision|1
6032916|NCT00316082|9629310|FG000|Overall Study|Death|0
6032917|NCT00316082|9629311|FG001|Overall Study|Death|0
6032918|NCT00316082|9629312|FG002|Overall Study|Death|1
6032919|NCT00316082|9629313|FG003|Overall Study|Death|0
6032920|NCT00316082|9629314|FG004|Overall Study|Death|0
6032921|NCT00316082|9629310|FG000|Overall Study|Administrative reason by sponsor|0
6032922|NCT00316082|9629311|FG001|Overall Study|Administrative reason by sponsor|0
6032923|NCT00316082|9629312|FG002|Overall Study|Administrative reason by sponsor|1
6032924|NCT00316082|9629313|FG003|Overall Study|Administrative reason by sponsor|0
6032925|NCT00316082|9629314|FG004|Overall Study|Administrative reason by sponsor|0
6032926|NCT00316121|9629332|FG000|Overall Study|Death|1
6032927|NCT00316121|9629333|FG001|Overall Study|Death|0
6032928|NCT00316121|9629332|FG000|Overall Study|Lost to Follow-up|14
6032929|NCT00316121|9629333|FG001|Overall Study|Lost to Follow-up|8
6032930|NCT00316121|9629332|FG000|Overall Study|Withdrawal by Subject|2
6032931|NCT00316121|9629333|FG001|Overall Study|Withdrawal by Subject|0
6032932|NCT00316121|9629332|FG000|Overall Study|Reason is missing|1
6032933|NCT00316121|9629333|FG001|Overall Study|Reason is missing|0
6032934|NCT00316121|9629332|FG000|Overall Study|Subject relocated|1
6032935|NCT00316121|9629333|FG001|Overall Study|Subject relocated|1
6032936|NCT00316121|9629332|FG000|Overall Study|Subject refused to return|1
6032937|NCT00316121|9629333|FG001|Overall Study|Subject refused to return|0
6032938|NCT00316121|9629332|FG000|Overall Study|Subject no show for visit x 3|1
6032939|NCT00316121|9629333|FG001|Overall Study|Subject no show for visit x 3|0
6032940|NCT00316121|9629332|FG000|Overall Study|Subject did not have 24 month visit|1
6032941|NCT00316121|9629333|FG001|Overall Study|Subject did not have 24 month visit|0
6032942|NCT00316173|9629341|FG000|Run-in Phase|Adverse Event|1
6032943|NCT00316173|9629342|FG001|Run-in Phase|Adverse Event|0
6032944|NCT00316173|9629341|FG000|Run-in Phase|Protocol Violation|1
6032945|NCT00316173|9629342|FG001|Run-in Phase|Protocol Violation|0
6032946|NCT00316173|9629341|FG000|Run-in Phase|Study Follow-up Stopped|5
6032947|NCT00316173|9629342|FG001|Run-in Phase|Study Follow-up Stopped|0
6032948|NCT00316173|9629341|FG000|Treatment Phase|Adverse Event|0
6146854|NCT01079234|9781826|FG002|Main: Week 0 to 26|Withdrawal criteria|2
6146855|NCT01079234|9781827|FG003|Main: Week 0 to 26|Withdrawal criteria|0
6146856|NCT01079234|9781824|FG000|Main: Week 0 to 26|Unclassified|7
6146857|NCT01079234|9781825|FG001|Main: Week 0 to 26|Unclassified|13
6146858|NCT01079234|9781826|FG002|Main: Week 0 to 26|Unclassified|4
6146859|NCT01079234|9781827|FG003|Main: Week 0 to 26|Unclassified|0
6146860|NCT01079234|9781824|FG000|Extension: Week 27 to 52|Adverse Event|0
6146861|NCT01079234|9781825|FG001|Extension: Week 27 to 52|Adverse Event|0
6146862|NCT01079234|9781826|FG002|Extension: Week 27 to 52|Adverse Event|1
6146863|NCT01079234|9781827|FG003|Extension: Week 27 to 52|Adverse Event|0
6032949|NCT00316173|9629342|FG001|Treatment Phase|Adverse Event|1
6032950|NCT00316173|9629341|FG000|Treatment Phase|Lack of Efficacy|0
6032951|NCT00316173|9629342|FG001|Treatment Phase|Lack of Efficacy|3
6032952|NCT00316173|9629341|FG000|Treatment Phase|Lost to Follow-up|0
6146864|NCT01079234|9781824|FG000|Extension: Week 27 to 52|Lack of Efficacy|0
6146865|NCT01079234|9781825|FG001|Extension: Week 27 to 52|Lack of Efficacy|0
6032953|NCT00316173|9629342|FG001|Treatment Phase|Lost to Follow-up|3
6032954|NCT00316173|9629341|FG000|Treatment Phase|Withdrawal by Subject|0
6032955|NCT00316173|9629342|FG001|Treatment Phase|Withdrawal by Subject|1
6032956|NCT00316173|9629341|FG000|Treatment Phase|Study Follow-up Stopped|0
6032957|NCT00316173|9629342|FG001|Treatment Phase|Study Follow-up Stopped|34
6032958|NCT00316186|9629347|FG000|Overall Study|Adverse Event|6
6032959|NCT00316186|9629347|FG000|Overall Study|Disease Progression|4
6032960|NCT00316186|9629347|FG000|Overall Study|Lost to Follow-up|1
6032961|NCT00316186|9629347|FG000|Overall Study|Other|1
6032962|NCT00316199|9629351|FG000|Overall Study|Adverse Event|2
6032963|NCT00316199|9629351|FG000|Overall Study|Death|8
6032964|NCT00316199|9629351|FG000|Overall Study|Lost to Follow-up|2
6032965|NCT00316225|9629355|FG000|Overall Study|Adverse Event|2
6032966|NCT00316225|9629355|FG000|Overall Study|Physician Decision|3
6032967|NCT00316225|9629355|FG000|Overall Study|Progressive Disease|15
6146866|NCT01079234|9781826|FG002|Extension: Week 27 to 52|Lack of Efficacy|0
6146867|NCT01079234|9781827|FG003|Extension: Week 27 to 52|Lack of Efficacy|2
6146868|NCT01079234|9781824|FG000|Extension: Week 27 to 52|Protocol Violation|0
6032968|NCT00316225|9629355|FG000|Overall Study|Withdrawal by Subject|3
6032969|NCT00316225|9629355|FG000|Overall Study|Death|2
6032970|NCT00316264|9629362|FG000|Overall Study|Lost to Follow-up|0
6032971|NCT00316264|9629363|FG001|Overall Study|Lost to Follow-up|1
6032972|NCT00316264|9629364|FG002|Overall Study|Lost to Follow-up|0
6032973|NCT00316264|9629362|FG000|Overall Study|Withdrawal of Consent|3
6032974|NCT00316264|9629363|FG001|Overall Study|Withdrawal of Consent|5
6032975|NCT00316264|9629364|FG002|Overall Study|Withdrawal of Consent|6
6032976|NCT00316264|9629362|FG000|Overall Study|Death|2
6032977|NCT00316264|9629363|FG001|Overall Study|Death|0
6032978|NCT00316264|9629364|FG002|Overall Study|Death|0
6032979|NCT00316264|9629362|FG000|Overall Study|Other|1
6032980|NCT00316264|9629363|FG001|Overall Study|Other|1
6032981|NCT00316264|9629364|FG002|Overall Study|Other|0
6032982|NCT00316277|9629374|FG000|Phase 1 (12 Weeks)|Lost to Follow-up|88
6032983|NCT00316277|9629375|FG001|Phase 1 (12 Weeks)|Lost to Follow-up|75
6032984|NCT00316277|9629374|FG000|Phase 1 (12 Weeks)|Investigator-initiated termination|2
6032985|NCT00316277|9629375|FG001|Phase 1 (12 Weeks)|Investigator-initiated termination|0
6032986|NCT00316277|9629374|FG000|Phase 1 (12 Weeks)|Eligible for Phase 2|220
6032987|NCT00316277|9629375|FG001|Phase 1 (12 Weeks)|Eligible for Phase 2|225
6032988|NCT00316277|9629374|FG000|Phase 2 (24 Weeks)|Lost to Follow-up prior to wk 13|19
6032989|NCT00316277|9629375|FG001|Phase 2 (24 Weeks)|Lost to Follow-up prior to wk 13|18
6032990|NCT00316277|9629374|FG000|Phase 2 (24 Weeks)|Discontinued intervention (jailed)|0
6032991|NCT00316277|9629375|FG001|Phase 2 (24 Weeks)|Discontinued intervention (jailed)|1
6032992|NCT00316303|9629391|FG000|Overall Study|Lost to Follow-up|11
6032993|NCT00316303|9629392|FG001|Overall Study|Lost to Follow-up|16
6032994|NCT00316589|9629435|FG000|Overall Study|Withdrawal by Subject|0
6146869|NCT01079234|9781825|FG001|Extension: Week 27 to 52|Protocol Violation|0
6146870|NCT01079234|9781826|FG002|Extension: Week 27 to 52|Protocol Violation|2
6032995|NCT00316589|9629436|FG001|Overall Study|Withdrawal by Subject|5
6032996|NCT00316589|9629437|FG002|Overall Study|Withdrawal by Subject|0
6032997|NCT00316589|9629438|FG003|Overall Study|Withdrawal by Subject|1
6032998|NCT00316589|9629435|FG000|Overall Study|Subject unwilling/unable to comply|0
6032999|NCT00316589|9629436|FG001|Overall Study|Subject unwilling/unable to comply|6
6033000|NCT00316589|9629437|FG002|Overall Study|Subject unwilling/unable to comply|0
6033001|NCT00316589|9629438|FG003|Overall Study|Subject unwilling/unable to comply|2
6033002|NCT00316589|9629435|FG000|Overall Study|Adverse Event|1
6033003|NCT00316589|9629436|FG001|Overall Study|Adverse Event|0
6033004|NCT00316589|9629437|FG002|Overall Study|Adverse Event|0
6033005|NCT00316589|9629438|FG003|Overall Study|Adverse Event|1
6033006|NCT00316589|9629435|FG000|Overall Study|Physician Decision|0
6033007|NCT00316589|9629436|FG001|Overall Study|Physician Decision|1
6033008|NCT00316589|9629437|FG002|Overall Study|Physician Decision|0
6033009|NCT00316589|9629438|FG003|Overall Study|Physician Decision|0
6033010|NCT00316589|9629435|FG000|Overall Study|Other reason|0
6033011|NCT00316589|9629436|FG001|Overall Study|Other reason|12
6033012|NCT00316589|9629437|FG002|Overall Study|Other reason|1
6146871|NCT01079234|9781827|FG003|Extension: Week 27 to 52|Protocol Violation|5
6146872|NCT01079234|9781824|FG000|Extension: Week 27 to 52|Withdrawal criteria|0
6146873|NCT01079234|9781825|FG001|Extension: Week 27 to 52|Withdrawal criteria|0
6146874|NCT01079234|9781826|FG002|Extension: Week 27 to 52|Withdrawal criteria|4
6146875|NCT01079234|9781827|FG003|Extension: Week 27 to 52|Withdrawal criteria|2
6033013|NCT00316589|9629438|FG003|Overall Study|Other reason|1
6033014|NCT00316602|9629452|FG000|Overall Study|Withdrawal by Subject|3
6033015|NCT00316602|9629453|FG001|Overall Study|Withdrawal by Subject|2
6033016|NCT00316602|9629452|FG000|Overall Study|Subject unwilling/unable to comply with|3
6033017|NCT00316602|9629453|FG001|Overall Study|Subject unwilling/unable to comply with|17
6033018|NCT00316602|9629452|FG000|Overall Study|Adverse Event|1
6033019|NCT00316602|9629453|FG001|Overall Study|Adverse Event|0
6146876|NCT01079234|9781824|FG000|Extension: Week 27 to 52|Unclassified|0
6033020|NCT00316602|9629452|FG000|Overall Study|Other|3
6033021|NCT00316602|9629453|FG001|Overall Study|Other|6
6033022|NCT00316693|9629461|FG000|Overall Study|Adverse Event|6
6146877|NCT01079234|9781825|FG001|Extension: Week 27 to 52|Unclassified|0
6146878|NCT01079234|9781826|FG002|Extension: Week 27 to 52|Unclassified|4
6033023|NCT00316693|9629462|FG001|Overall Study|Adverse Event|1
6033024|NCT00316693|9629461|FG000|Overall Study|Protocol Violation|1
6033025|NCT00316693|9629462|FG001|Overall Study|Protocol Violation|0
6033026|NCT00316693|9629461|FG000|Overall Study|Withdrawal by Subject|6
6033027|NCT00316693|9629462|FG001|Overall Study|Withdrawal by Subject|6
6033028|NCT00316693|9629461|FG000|Overall Study|Lost to Follow-up|26
6146879|NCT01079234|9781827|FG003|Extension: Week 27 to 52|Unclassified|7
6146880|NCT01079663|9781862|FG000|Overall Study|Adverse Event|0
6146881|NCT01079663|9781863|FG001|Overall Study|Adverse Event|2
6146882|NCT01079663|9781862|FG000|Overall Study|Protocol Violation|0
6146883|NCT01079663|9781863|FG001|Overall Study|Protocol Violation|2
6033029|NCT00316693|9629462|FG001|Overall Study|Lost to Follow-up|34
6033030|NCT00316693|9629461|FG000|Overall Study|Other|38
6033031|NCT00316693|9629462|FG001|Overall Study|Other|44
6033032|NCT00316706|9629470|FG000|Overall Study|Lost to Follow-up|38
6033033|NCT00316706|9629471|FG001|Overall Study|Lost to Follow-up|48
6033034|NCT00316719|9629479|FG000|Overall Study|Adverse Event|0
6033035|NCT00316719|9629480|FG001|Overall Study|Adverse Event|6
6033036|NCT00316719|9629479|FG000|Overall Study|Consent withdrawn|2
6033037|NCT00316719|9629480|FG001|Overall Study|Consent withdrawn|0
6033038|NCT00316888|9629492|FG000|Overall Study|Adverse Event|4
6033039|NCT00316888|9629493|FG001|Overall Study|Adverse Event|5
6033040|NCT00316888|9629492|FG000|Overall Study|Withdrawal by Subject|2
6033041|NCT00316888|9629493|FG001|Overall Study|Withdrawal by Subject|2
6033042|NCT00316888|9629492|FG000|Overall Study|Not start protocol therapy|0
6033043|NCT00316888|9629493|FG001|Overall Study|Not start protocol therapy|1
6033044|NCT00316914|9629501|FG000|Overall Study|Withdrawal by Subject|5
6033045|NCT00316914|9629502|FG001|Overall Study|Withdrawal by Subject|3
6033046|NCT00316914|9629501|FG000|Overall Study|Adverse Event|8
6033047|NCT00316914|9629502|FG001|Overall Study|Adverse Event|7
6033048|NCT00316914|9629501|FG000|Overall Study|Other Problems|6
6033049|NCT00316914|9629502|FG001|Overall Study|Other Problems|11
6033050|NCT00316914|9629501|FG000|Overall Study|Missing end of treatment documentation|14
6033051|NCT00316914|9629502|FG001|Overall Study|Missing end of treatment documentation|15
6033052|NCT00317044|9629511|FG000|Overall Study|Protocol Violation|28
6033053|NCT00317044|9629512|FG001|Overall Study|Protocol Violation|22
6033054|NCT00317044|9629513|FG002|Overall Study|Protocol Violation|20
6033055|NCT00317044|9629511|FG000|Overall Study|Adverse Event|4
6033056|NCT00317044|9629512|FG001|Overall Study|Adverse Event|7
6033057|NCT00317044|9629513|FG002|Overall Study|Adverse Event|4
6033058|NCT00317044|9629511|FG000|Overall Study|Withdrawal by Subject|10
6033059|NCT00317044|9629512|FG001|Overall Study|Withdrawal by Subject|7
6033060|NCT00317044|9629513|FG002|Overall Study|Withdrawal by Subject|12
6033061|NCT00317044|9629511|FG000|Overall Study|Lost to Follow-up|0
6033062|NCT00317044|9629512|FG001|Overall Study|Lost to Follow-up|2
6033063|NCT00317044|9629513|FG002|Overall Study|Lost to Follow-up|3
6033064|NCT00317044|9629511|FG000|Overall Study|Multiple Reasons|6
6033065|NCT00317044|9629512|FG001|Overall Study|Multiple Reasons|2
6033066|NCT00317044|9629513|FG002|Overall Study|Multiple Reasons|6
6033067|NCT00317109|9629523|FG000|Overall Study|Withdrawal by Subject|2
6033068|NCT00317109|9629524|FG001|Overall Study|Withdrawal by Subject|0
6033069|NCT00317109|9629523|FG000|Overall Study|Migated/moved from study area|1
6033070|NCT00317109|9629524|FG001|Overall Study|Migated/moved from study area|0
6033071|NCT00317356|9629547|FG000|Overall Study|Adverse Event|0
6033072|NCT00317356|9629548|FG001|Overall Study|Adverse Event|0
6033073|NCT00317356|9629549|FG002|Overall Study|Adverse Event|1
6033074|NCT00317356|9629550|FG003|Overall Study|Adverse Event|0
6033075|NCT00317356|9629547|FG000|Overall Study|Lack of Efficacy|1
6033076|NCT00317356|9629548|FG001|Overall Study|Lack of Efficacy|1
6033077|NCT00317356|9629549|FG002|Overall Study|Lack of Efficacy|0
6033078|NCT00317356|9629550|FG003|Overall Study|Lack of Efficacy|3
6033079|NCT00317356|9629547|FG000|Overall Study|Physician Decision|0
6033080|NCT00317356|9629548|FG001|Overall Study|Physician Decision|1
6033081|NCT00317356|9629549|FG002|Overall Study|Physician Decision|0
6033082|NCT00317356|9629550|FG003|Overall Study|Physician Decision|0
6033083|NCT00317369|9629563|FG000|Overall Study|Adverse Event|2
6033084|NCT00317369|9629564|FG001|Overall Study|Adverse Event|1
6033085|NCT00317369|9629565|FG002|Overall Study|Adverse Event|0
6033086|NCT00317369|9629563|FG000|Overall Study|Lack of Efficacy|0
6033087|NCT00317369|9629564|FG001|Overall Study|Lack of Efficacy|1
6033088|NCT00317369|9629565|FG002|Overall Study|Lack of Efficacy|1
6033089|NCT00317369|9629563|FG000|Overall Study|Withdrawal by Subject|0
6033090|NCT00317369|9629564|FG001|Overall Study|Withdrawal by Subject|0
6033091|NCT00317369|9629565|FG002|Overall Study|Withdrawal by Subject|1
6033092|NCT00317473|9629579|FG000|Overall Study|Withdrawal by Subject|2
6033093|NCT00317473|9629580|FG001|Overall Study|Withdrawal by Subject|1
6033094|NCT00317473|9629581|FG002|Overall Study|Withdrawal by Subject|2
6033095|NCT00317473|9629582|FG003|Overall Study|Withdrawal by Subject|1
6033096|NCT00317473|9629583|FG004|Overall Study|Withdrawal by Subject|3
6146884|NCT01079741|9781874|FG000|Cohort 2: Dose Level 2 (Weeks 13-24)|Disease Progression|0
6033097|NCT00317473|9629584|FG005|Overall Study|Withdrawal by Subject|1
6033098|NCT00317473|9629579|FG000|Overall Study|Relocation|1
6033099|NCT00317473|9629580|FG001|Overall Study|Relocation|0
6033100|NCT00317473|9629581|FG002|Overall Study|Relocation|1
6033101|NCT00317473|9629582|FG003|Overall Study|Relocation|1
6033102|NCT00317473|9629583|FG004|Overall Study|Relocation|5
6033103|NCT00317473|9629584|FG005|Overall Study|Relocation|2
6033104|NCT00317473|9629579|FG000|Overall Study|Death|1
6033105|NCT00317473|9629580|FG001|Overall Study|Death|0
6033106|NCT00317473|9629581|FG002|Overall Study|Death|0
6033107|NCT00317473|9629582|FG003|Overall Study|Death|0
6033108|NCT00317473|9629583|FG004|Overall Study|Death|0
6033109|NCT00317473|9629584|FG005|Overall Study|Death|0
6033110|NCT00317473|9629579|FG000|Overall Study|Other|0
6033111|NCT00317473|9629580|FG001|Overall Study|Other|2
6033112|NCT00317473|9629581|FG002|Overall Study|Other|0
6033113|NCT00317473|9629582|FG003|Overall Study|Other|0
6033114|NCT00317473|9629583|FG004|Overall Study|Other|0
6033115|NCT00317473|9629584|FG005|Overall Study|Other|0
6033116|NCT00317603|9629608|FG000|Overall Study|Progressive Disease|3
6033117|NCT00317642|9629614|FG000|Overall Study|Not Received Either Study Drug|1
6033118|NCT00317642|9629615|FG001|Overall Study|Not Received Either Study Drug|3
6033119|NCT00317642|9629614|FG000|Overall Study|Physician Decision|15
6033120|NCT00317642|9629615|FG001|Overall Study|Physician Decision|7
6033121|NCT00317642|9629614|FG000|Overall Study|Participant declined treatment|14
6033122|NCT00317642|9629615|FG001|Overall Study|Participant declined treatment|3
6033123|NCT00317642|9629614|FG000|Overall Study|Adverse Event|17
6033124|NCT00317642|9629615|FG001|Overall Study|Adverse Event|5
6033125|NCT00317642|9629614|FG000|Overall Study|Treatment Failure|56
6033126|NCT00317642|9629615|FG001|Overall Study|Treatment Failure|102
6033127|NCT00317642|9629614|FG000|Overall Study|Disease Recurrence|1
6033128|NCT00317642|9629615|FG001|Overall Study|Disease Recurrence|2
6033129|NCT00317642|9629614|FG000|Overall Study|Death|14
6033130|NCT00317642|9629615|FG001|Overall Study|Death|7
6033131|NCT00317642|9629614|FG000|Overall Study|Not Continue to Consolidation|2
6033132|NCT00317642|9629615|FG001|Overall Study|Not Continue to Consolidation|0
6033133|NCT00317642|9629614|FG000|Overall Study|Withdrawal by Subject|0
6033134|NCT00317642|9629615|FG001|Overall Study|Withdrawal by Subject|1
6033135|NCT00317642|9629614|FG000|Overall Study|Referred For Transplantation|1
6033136|NCT00317642|9629615|FG001|Overall Study|Referred For Transplantation|0
6033137|NCT00317642|9629614|FG000|Overall Study|AML Not Centrally Confirmed|1
6033138|NCT00317642|9629615|FG001|Overall Study|AML Not Centrally Confirmed|5
6033139|NCT00318149|9629656|FG000|Overall Study|Adverse Event|0
6033140|NCT00318149|9629657|FG001|Overall Study|Adverse Event|0
6033141|NCT00318149|9629658|FG002|Overall Study|Adverse Event|0
6033142|NCT00318149|9629659|FG003|Overall Study|Adverse Event|0
6033143|NCT00318149|9629660|FG004|Overall Study|Adverse Event|0
6033144|NCT00318149|9629661|FG005|Overall Study|Adverse Event|2
6033145|NCT00318370|9629695|FG000|Period 1|Lack of Efficacy|5
6033146|NCT00318370|9629696|FG001|Period 1|Lack of Efficacy|0
6033147|NCT00318370|9629697|FG002|Period 1|Lack of Efficacy|0
6033148|NCT00318370|9629695|FG000|Period 1|Physician Decision|1
6033149|NCT00318370|9629696|FG001|Period 1|Physician Decision|0
6033150|NCT00318370|9629697|FG002|Period 1|Physician Decision|0
6033151|NCT00318370|9629695|FG000|Period 1|Withdrawal by Subject|1
6033152|NCT00318370|9629696|FG001|Period 1|Withdrawal by Subject|0
6033153|NCT00318370|9629697|FG002|Period 1|Withdrawal by Subject|0
6033154|NCT00318370|9629695|FG000|Period 2|Adverse Event|0
6033155|NCT00318370|9629696|FG001|Period 2|Adverse Event|3
6033156|NCT00318370|9629697|FG002|Period 2|Adverse Event|0
6033157|NCT00318370|9629695|FG000|Period 2|Lack of Efficacy|0
6033158|NCT00318370|9629696|FG001|Period 2|Lack of Efficacy|5
6033159|NCT00318370|9629697|FG002|Period 2|Lack of Efficacy|0
6033160|NCT00318370|9629695|FG000|Period 2|Physician Decision|0
6033161|NCT00318370|9629696|FG001|Period 2|Physician Decision|1
6033162|NCT00318370|9629697|FG002|Period 2|Physician Decision|0
6033163|NCT00318370|9629695|FG000|Period 2|Withdrawal by Subject|0
6033164|NCT00318370|9629696|FG001|Period 2|Withdrawal by Subject|1
6033165|NCT00318370|9629697|FG002|Period 2|Withdrawal by Subject|0
6033166|NCT00318370|9629695|FG000|Period 2|Other|0
6033167|NCT00318370|9629696|FG001|Period 2|Other|1
6033168|NCT00318370|9629697|FG002|Period 2|Other|0
6033169|NCT00318370|9629695|FG000|Period 3|Adverse Event|0
6033170|NCT00318370|9629696|FG001|Period 3|Adverse Event|0
6033171|NCT00318370|9629697|FG002|Period 3|Adverse Event|1
6033172|NCT00318370|9629695|FG000|Period 3|Lack of Efficacy|0
6033173|NCT00318370|9629696|FG001|Period 3|Lack of Efficacy|0
6033174|NCT00318370|9629697|FG002|Period 3|Lack of Efficacy|24
6033175|NCT00318370|9629695|FG000|Period 3|Death|0
6033176|NCT00318370|9629696|FG001|Period 3|Death|0
6033177|NCT00318370|9629697|FG002|Period 3|Death|1
6033178|NCT00318370|9629695|FG000|Period 3|Physician Decision|0
6033179|NCT00318370|9629696|FG001|Period 3|Physician Decision|0
6033180|NCT00318370|9629697|FG002|Period 3|Physician Decision|1
6033181|NCT00318370|9629695|FG000|Period 3|Withdrawal by Subject|0
6033182|NCT00318370|9629696|FG001|Period 3|Withdrawal by Subject|0
6033183|NCT00318370|9629697|FG002|Period 3|Withdrawal by Subject|3
6033184|NCT00318370|9629695|FG000|Period 3|Other|0
6033185|NCT00318370|9629696|FG001|Period 3|Other|0
6033186|NCT00318370|9629697|FG002|Period 3|Other|3
6033187|NCT00318461|9629718|FG000|Double-Blind, 6 Months|Adverse Event|11
6033188|NCT00318461|9629719|FG001|Double-Blind, 6 Months|Adverse Event|23
6033189|NCT00318461|9629720|FG002|Double-Blind, 6 Months|Adverse Event|29
6033190|NCT00318461|9629721|FG003|Double-Blind, 6 Months|Adverse Event|2
6033191|NCT00318461|9629722|FG004|Double-Blind, 6 Months|Adverse Event|8
6033192|NCT00318461|9629718|FG000|Double-Blind, 6 Months|Lack of Efficacy|19
6033193|NCT00318461|9629719|FG001|Double-Blind, 6 Months|Lack of Efficacy|8
6033194|NCT00318461|9629720|FG002|Double-Blind, 6 Months|Lack of Efficacy|13
6033195|NCT00318461|9629721|FG003|Double-Blind, 6 Months|Lack of Efficacy|29
6033196|NCT00318461|9629722|FG004|Double-Blind, 6 Months|Lack of Efficacy|9
6033197|NCT00318461|9629718|FG000|Double-Blind, 6 Months|Protocol Violation|2
6033198|NCT00318461|9629719|FG001|Double-Blind, 6 Months|Protocol Violation|4
6033199|NCT00318461|9629720|FG002|Double-Blind, 6 Months|Protocol Violation|4
6033200|NCT00318461|9629721|FG003|Double-Blind, 6 Months|Protocol Violation|4
6033201|NCT00318461|9629722|FG004|Double-Blind, 6 Months|Protocol Violation|5
6033202|NCT00318461|9629718|FG000|Double-Blind, 6 Months|Lost to follow up|0
6033203|NCT00318461|9629719|FG001|Double-Blind, 6 Months|Lost to follow up|1
6033204|NCT00318461|9629720|FG002|Double-Blind, 6 Months|Lost to follow up|0
6033205|NCT00318461|9629721|FG003|Double-Blind, 6 Months|Lost to follow up|0
6033206|NCT00318461|9629722|FG004|Double-Blind, 6 Months|Lost to follow up|0
6033207|NCT00318461|9629718|FG000|Double-Blind, 6 Months|Poor compliance/Non-compliance|0
6033208|NCT00318461|9629719|FG001|Double-Blind, 6 Months|Poor compliance/Non-compliance|1
6033209|NCT00318461|9629720|FG002|Double-Blind, 6 Months|Poor compliance/Non-compliance|0
6033210|NCT00318461|9629721|FG003|Double-Blind, 6 Months|Poor compliance/Non-compliance|0
6033211|NCT00318461|9629722|FG004|Double-Blind, 6 Months|Poor compliance/Non-compliance|0
6033212|NCT00318461|9629718|FG000|Double-Blind, 6 Months|Consent withdrawn|0
6033213|NCT00318461|9629719|FG001|Double-Blind, 6 Months|Consent withdrawn|3
6033214|NCT00318461|9629720|FG002|Double-Blind, 6 Months|Consent withdrawn|4
6033215|NCT00318461|9629721|FG003|Double-Blind, 6 Months|Consent withdrawn|10
6033216|NCT00318461|9629722|FG004|Double-Blind, 6 Months|Consent withdrawn|4
6033217|NCT00318461|9629718|FG000|Double-Blind, 6 Months|Subject decision/No wish to continue|0
6033218|NCT00318461|9629719|FG001|Double-Blind, 6 Months|Subject decision/No wish to continue|2
6033219|NCT00318461|9629720|FG002|Double-Blind, 6 Months|Subject decision/No wish to continue|1
6033220|NCT00318461|9629721|FG003|Double-Blind, 6 Months|Subject decision/No wish to continue|0
6033221|NCT00318461|9629722|FG004|Double-Blind, 6 Months|Subject decision/No wish to continue|2
6033222|NCT00318461|9629718|FG000|Double-Blind, 6 Months|Move|0
6033223|NCT00318461|9629719|FG001|Double-Blind, 6 Months|Move|1
6033224|NCT00318461|9629720|FG002|Double-Blind, 6 Months|Move|0
6033225|NCT00318461|9629721|FG003|Double-Blind, 6 Months|Move|0
6033226|NCT00318461|9629722|FG004|Double-Blind, 6 Months|Move|0
6033227|NCT00318461|9629718|FG000|Double-Blind, 6 Months|Tendency to low blood glucose levels|0
6033228|NCT00318461|9629719|FG001|Double-Blind, 6 Months|Tendency to low blood glucose levels|0
6033229|NCT00318461|9629720|FG002|Double-Blind, 6 Months|Tendency to low blood glucose levels|0
6033230|NCT00318461|9629721|FG003|Double-Blind, 6 Months|Tendency to low blood glucose levels|0
6033231|NCT00318461|9629722|FG004|Double-Blind, 6 Months|Tendency to low blood glucose levels|1
6033232|NCT00318461|9629718|FG000|Double-Blind, 6 Months|FPG exceeds limits/too high|1
6033233|NCT00318461|9629719|FG001|Double-Blind, 6 Months|FPG exceeds limits/too high|0
6033234|NCT00318461|9629720|FG002|Double-Blind, 6 Months|FPG exceeds limits/too high|0
6033235|NCT00318461|9629721|FG003|Double-Blind, 6 Months|FPG exceeds limits/too high|2
6033236|NCT00318461|9629722|FG004|Double-Blind, 6 Months|FPG exceeds limits/too high|0
6033237|NCT00318461|9629718|FG000|Double-Blind, 6 Months|Work commitment|0
6033238|NCT00318461|9629719|FG001|Double-Blind, 6 Months|Work commitment|0
6033239|NCT00318461|9629720|FG002|Double-Blind, 6 Months|Work commitment|0
6033240|NCT00318461|9629721|FG003|Double-Blind, 6 Months|Work commitment|0
6033241|NCT00318461|9629722|FG004|Double-Blind, 6 Months|Work commitment|1
6033242|NCT00318461|9629718|FG000|Double-Blind, 6 Months|Investigator decision|0
6033243|NCT00318461|9629719|FG001|Double-Blind, 6 Months|Investigator decision|0
6033244|NCT00318461|9629720|FG002|Double-Blind, 6 Months|Investigator decision|0
6033245|NCT00318461|9629721|FG003|Double-Blind, 6 Months|Investigator decision|0
6033246|NCT00318461|9629722|FG004|Double-Blind, 6 Months|Investigator decision|1
6033247|NCT00318461|9629718|FG000|Double-Blind, 6 Months|Lack of time|1
6033248|NCT00318461|9629719|FG001|Double-Blind, 6 Months|Lack of time|0
6033249|NCT00318461|9629720|FG002|Double-Blind, 6 Months|Lack of time|0
6033250|NCT00318461|9629721|FG003|Double-Blind, 6 Months|Lack of time|0
6033251|NCT00318461|9629722|FG004|Double-Blind, 6 Months|Lack of time|0
6033252|NCT00318461|9629718|FG000|Double-Blind, 6 Months|Hypoglycaemia/Hypoglycemia|0
6033253|NCT00318461|9629719|FG001|Double-Blind, 6 Months|Hypoglycaemia/Hypoglycemia|0
6033254|NCT00318461|9629720|FG002|Double-Blind, 6 Months|Hypoglycaemia/Hypoglycemia|0
6033255|NCT00318461|9629721|FG003|Double-Blind, 6 Months|Hypoglycaemia/Hypoglycemia|0
6033256|NCT00318461|9629722|FG004|Double-Blind, 6 Months|Hypoglycaemia/Hypoglycemia|2
6033257|NCT00318461|9629718|FG000|Double-Blind, 6 Months|Hyperglicaemia|0
6033258|NCT00318461|9629719|FG001|Double-Blind, 6 Months|Hyperglicaemia|0
6033259|NCT00318461|9629720|FG002|Double-Blind, 6 Months|Hyperglicaemia|0
6033260|NCT00318461|9629721|FG003|Double-Blind, 6 Months|Hyperglicaemia|1
6033261|NCT00318461|9629722|FG004|Double-Blind, 6 Months|Hyperglicaemia|0
6033262|NCT00318461|9629718|FG000|Double-Blind, 6 Months|metformin titrated <1500 mg or >2000 mg|0
6033263|NCT00318461|9629719|FG001|Double-Blind, 6 Months|metformin titrated <1500 mg or >2000 mg|0
6033264|NCT00318461|9629720|FG002|Double-Blind, 6 Months|metformin titrated <1500 mg or >2000 mg|0
6033265|NCT00318461|9629721|FG003|Double-Blind, 6 Months|metformin titrated <1500 mg or >2000 mg|0
6033266|NCT00318461|9629722|FG004|Double-Blind, 6 Months|metformin titrated <1500 mg or >2000 mg|1
6033267|NCT00318461|9629718|FG000|Double-Blind, 6 Months|Fear of experiencing AE again|0
6033268|NCT00318461|9629719|FG001|Double-Blind, 6 Months|Fear of experiencing AE again|1
6033269|NCT00318461|9629720|FG002|Double-Blind, 6 Months|Fear of experiencing AE again|0
6033270|NCT00318461|9629721|FG003|Double-Blind, 6 Months|Fear of experiencing AE again|0
6033271|NCT00318461|9629722|FG004|Double-Blind, 6 Months|Fear of experiencing AE again|0
6033272|NCT00318461|9629718|FG000|Open-Label Extension, 18 Months|Withdrawals between 6 and 24 months|19
6033273|NCT00318461|9629719|FG001|Open-Label Extension, 18 Months|Withdrawals between 6 and 24 months|14
6033274|NCT00318461|9629720|FG002|Open-Label Extension, 18 Months|Withdrawals between 6 and 24 months|27
6033275|NCT00318461|9629721|FG003|Open-Label Extension, 18 Months|Withdrawals between 6 and 24 months|11
6033276|NCT00318461|9629722|FG004|Open-Label Extension, 18 Months|Withdrawals between 6 and 24 months|22
6033277|NCT00318461|9629718|FG000|Open-Label Extension, 18 Months|Adverse Event|11
6033278|NCT00318461|9629719|FG001|Open-Label Extension, 18 Months|Adverse Event|8
6033279|NCT00318461|9629720|FG002|Open-Label Extension, 18 Months|Adverse Event|6
6033280|NCT00318461|9629721|FG003|Open-Label Extension, 18 Months|Adverse Event|1
6033281|NCT00318461|9629722|FG004|Open-Label Extension, 18 Months|Adverse Event|6
6033282|NCT00318461|9629718|FG000|Open-Label Extension, 18 Months|Lack of Efficacy|41
6033283|NCT00318461|9629719|FG001|Open-Label Extension, 18 Months|Lack of Efficacy|33
6033284|NCT00318461|9629720|FG002|Open-Label Extension, 18 Months|Lack of Efficacy|37
6033285|NCT00318461|9629721|FG003|Open-Label Extension, 18 Months|Lack of Efficacy|27
6033286|NCT00318461|9629722|FG004|Open-Label Extension, 18 Months|Lack of Efficacy|63
6033287|NCT00318461|9629718|FG000|Open-Label Extension, 18 Months|Protocol Violation|7
6033288|NCT00318461|9629719|FG001|Open-Label Extension, 18 Months|Protocol Violation|5
6033289|NCT00318461|9629720|FG002|Open-Label Extension, 18 Months|Protocol Violation|3
6033290|NCT00318461|9629721|FG003|Open-Label Extension, 18 Months|Protocol Violation|4
6033291|NCT00318461|9629722|FG004|Open-Label Extension, 18 Months|Protocol Violation|6
6033292|NCT00318474|9629736|FG000|Overall Study|Adverse Event|1
6033293|NCT00318474|9629737|FG001|Overall Study|Adverse Event|1
6033294|NCT00318474|9629736|FG000|Overall Study|Lost to Follow-up|0
6033295|NCT00318474|9629737|FG001|Overall Study|Lost to Follow-up|1
6033296|NCT00318474|9629736|FG000|Overall Study|Pregnancy|0
6033297|NCT00318474|9629737|FG001|Overall Study|Pregnancy|2
6033298|NCT00318474|9629736|FG000|Overall Study|Protocol Violation|1
6033299|NCT00318474|9629737|FG001|Overall Study|Protocol Violation|0
6033300|NCT00318474|9629736|FG000|Overall Study|Withdrawal by Subject|3
6033301|NCT00318474|9629737|FG001|Overall Study|Withdrawal by Subject|2
6033302|NCT00318474|9629736|FG000|Overall Study|Fall in GFR|3
6033303|NCT00318474|9629737|FG001|Overall Study|Fall in GFR|3
6033304|NCT00318474|9629736|FG000|Overall Study|Post-therapy hyperflycemia|0
6033305|NCT00318474|9629737|FG001|Overall Study|Post-therapy hyperflycemia|1
6033306|NCT00318474|9629736|FG000|Overall Study|Trial terminated|10
6033307|NCT00318474|9629737|FG001|Overall Study|Trial terminated|7
6033308|NCT00318565|9629743|FG000|Overall Study|Excluded per protocol|24
6033309|NCT00318643|9629763|FG000|Overall Study|Adverse Event|0
6033310|NCT00318643|9629764|FG001|Overall Study|Adverse Event|0
6033311|NCT00318643|9629765|FG002|Overall Study|Adverse Event|0
6033312|NCT00318643|9629766|FG003|Overall Study|Adverse Event|0
6033313|NCT00318643|9629767|FG004|Overall Study|Adverse Event|1
6033314|NCT00318643|9629763|FG000|Overall Study|Participant's Decision|0
6033315|NCT00318643|9629764|FG001|Overall Study|Participant's Decision|0
6033316|NCT00318643|9629765|FG002|Overall Study|Participant's Decision|0
6033317|NCT00318643|9629766|FG003|Overall Study|Participant's Decision|0
6033318|NCT00318643|9629767|FG004|Overall Study|Participant's Decision|1
6033319|NCT00318643|9629763|FG000|Overall Study|Investigator's Decision|0
6033320|NCT00318643|9629764|FG001|Overall Study|Investigator's Decision|0
6033321|NCT00318643|9629765|FG002|Overall Study|Investigator's Decision|0
6033322|NCT00318643|9629766|FG003|Overall Study|Investigator's Decision|0
6033323|NCT00318643|9629767|FG004|Overall Study|Investigator's Decision|1
6033324|NCT00319020|9629808|FG000|Overall Study|Death|2
6033325|NCT00319020|9629809|FG001|Overall Study|Death|2
6033326|NCT00319020|9629808|FG000|Overall Study|Withdrawal by Subject|4
6033327|NCT00319020|9629809|FG001|Overall Study|Withdrawal by Subject|1
6033328|NCT00319020|9629808|FG000|Overall Study|F-1 completed but not enrolled in F-2|1
6033329|NCT00319020|9629809|FG001|Overall Study|F-1 completed but not enrolled in F-2|0
6033330|NCT00319020|9629808|FG000|Overall Study|Administrative reason|0
6033331|NCT00319020|9629809|FG001|Overall Study|Administrative reason|5
6033332|NCT00319020|9629808|FG000|Overall Study|Disease progression|0
6033333|NCT00319020|9629809|FG001|Overall Study|Disease progression|2
6033334|NCT00319020|9629808|FG000|Overall Study|Transplant|0
6033335|NCT00319020|9629809|FG001|Overall Study|Transplant|1
6033336|NCT00319020|9629808|FG000|Overall Study|Treatment failure|0
6033337|NCT00319020|9629809|FG001|Overall Study|Treatment failure|1
6033338|NCT00319020|9629808|FG000|Overall Study|Adverse Event|0
6033339|NCT00319020|9629809|FG001|Overall Study|Adverse Event|1
6033340|NCT00319046|9629817|FG000|Overall Study|withdrawal of subject's consent|7
6033341|NCT00319046|9629817|FG000|Overall Study|administrative reason|1
6033342|NCT00319098|9629825|FG000|Overall Study|Serious adverse event|3
6033343|NCT00319098|9629826|FG001|Overall Study|Serious adverse event|0
6033344|NCT00319098|9629825|FG000|Overall Study|Adverse Event|20
6033345|NCT00319098|9629826|FG001|Overall Study|Adverse Event|1
6033346|NCT00319098|9629825|FG000|Overall Study|Withdrawal by Subject|37
6033347|NCT00319098|9629826|FG001|Overall Study|Withdrawal by Subject|8
6033348|NCT00319098|9629825|FG000|Overall Study|Migrated/moved from study area|2
6033349|NCT00319098|9629826|FG001|Overall Study|Migrated/moved from study area|1
6033350|NCT00319098|9629825|FG000|Overall Study|Lost to Follow-up|37
6033351|NCT00319098|9629826|FG001|Overall Study|Lost to Follow-up|13
6033352|NCT00319098|9629825|FG000|Overall Study|Others|33
6033353|NCT00319098|9629826|FG001|Overall Study|Others|8
6033354|NCT00319098|9629825|FG000|Overall Study|Protocol Violation|3
6033355|NCT00319098|9629826|FG001|Overall Study|Protocol Violation|1
6033356|NCT00319111|9629836|FG000|Overall Study|Adverse Event|20
6033357|NCT00319111|9629836|FG000|Overall Study|Withdrawal of consent|11
6033358|NCT00319111|9629836|FG000|Overall Study|Death|9
6033359|NCT00319111|9629836|FG000|Overall Study|Lack of clinical improvement|4
6033360|NCT00319111|9629836|FG000|Overall Study|Administrative|2
6033361|NCT00319111|9629836|FG000|Overall Study|Treatment failure|1
6033362|NCT00319254|9629840|FG000|Overall Study|Withdrawal by Subject|4
6033363|NCT00319254|9629840|FG000|Overall Study|Death|46
6033364|NCT00319254|9629840|FG000|Overall Study|Lost to Follow-up|2
6033365|NCT00319254|9629840|FG000|Overall Study|Enrolled, Not Treated|2
6033366|NCT00319436|9629846|FG000|Overall Study|Withdrawal by Subject|6
6033367|NCT00319436|9629847|FG001|Overall Study|Withdrawal by Subject|7
6033368|NCT00319501|9629855|FG000|Double-blind Period|Withdrawal by Subject|0
6033369|NCT00319501|9629856|FG001|Double-blind Period|Withdrawal by Subject|3
6033370|NCT00319501|9629855|FG000|Double-blind Period|Sponsor Request|1
6033371|NCT00319501|9629856|FG001|Double-blind Period|Sponsor Request|0
6033372|NCT00319501|9629855|FG000|Double-blind Period|Did not receive treatment|42
6033373|NCT00319501|9629856|FG001|Double-blind Period|Did not receive treatment|29
6033374|NCT00319501|9629855|FG000|Open-label Period|Adverse Event|5
6033375|NCT00319501|9629856|FG001|Open-label Period|Adverse Event|0
6033376|NCT00319501|9629855|FG000|Open-label Period|Protocol Violation|6
6033377|NCT00319501|9629856|FG001|Open-label Period|Protocol Violation|0
6033378|NCT00319501|9629855|FG000|Open-label Period|Withdrawal by Subject|38
6033379|NCT00319501|9629856|FG001|Open-label Period|Withdrawal by Subject|0
6033380|NCT00319501|9629855|FG000|Open-label Period|Principal Investigator decision|6
6033381|NCT00319501|9629856|FG001|Open-label Period|Principal Investigator decision|0
6033382|NCT00319501|9629855|FG000|Open-label Period|Sponsor request|12
6033383|NCT00319501|9629856|FG001|Open-label Period|Sponsor request|0
6033384|NCT00319501|9629855|FG000|Open-label Period|Lost to Follow-up|5
6033385|NCT00319501|9629856|FG001|Open-label Period|Lost to Follow-up|0
6033386|NCT00319501|9629855|FG000|Open-label Period|Did not receive treatment|33
6033387|NCT00319501|9629856|FG001|Open-label Period|Did not receive treatment|0
6033388|NCT00319501|9629855|FG000|Open-label Period|Other|11
6033389|NCT00319501|9629856|FG001|Open-label Period|Other|0
6033390|NCT00319501|9629855|FG000|Open-label Extension Period|Adverse Event|2
6033391|NCT00319501|9629856|FG001|Open-label Extension Period|Adverse Event|0
6033392|NCT00319501|9629855|FG000|Open-label Extension Period|Did not receive treatment|18
6033393|NCT00319501|9629856|FG001|Open-label Extension Period|Did not receive treatment|0
6033394|NCT00319501|9629855|FG000|Open-label Extension Period|Other|1
6033395|NCT00319501|9629856|FG001|Open-label Extension Period|Other|0
6033396|NCT00319501|9629855|FG000|Open-label Extension Period|Principal investigator decision|2
6033397|NCT00319501|9629856|FG001|Open-label Extension Period|Principal investigator decision|0
6033398|NCT00319501|9629855|FG000|Open-label Extension Period|Sponsor request|26
6033399|NCT00319501|9629856|FG001|Open-label Extension Period|Sponsor request|0
6033400|NCT00319501|9629855|FG000|Open-label Extension Period|Withdrawal by Subject|2
6033401|NCT00319501|9629856|FG001|Open-label Extension Period|Withdrawal by Subject|0
6033402|NCT00319553|9629869|FG000|Overall Study|Protocol Violation|1
6033403|NCT00319553|9629870|FG001|Overall Study|Protocol Violation|2
6033404|NCT00319553|9629869|FG000|Overall Study|Lost to Follow-up|2
6033405|NCT00319553|9629870|FG001|Overall Study|Lost to Follow-up|1
6033406|NCT00319553|9629869|FG000|Overall Study|Withdrawal by Subject|1
6033407|NCT00319553|9629870|FG001|Overall Study|Withdrawal by Subject|1
6033408|NCT00319592|9629878|FG000|Overall Study|Protocol Violation|1
6033409|NCT00319592|9629879|FG001|Overall Study|Protocol Violation|0
6033410|NCT00319592|9629878|FG000|Overall Study|Physician Decision|0
6033411|NCT00319592|9629879|FG001|Overall Study|Physician Decision|1
6033412|NCT00319696|9629894|FG000|Overall Study|Adverse Event|36
6033413|NCT00319696|9629894|FG000|Overall Study|withdrawal of consent|14
6033414|NCT00319696|9629894|FG000|Overall Study|administrative|7
6033415|NCT00319696|9629894|FG000|Overall Study|Lost to Follow-up|3
6033416|NCT00319735|9629904|FG000|Overall Study|Death|2
6033417|NCT00319956|9629921|FG000|Overall Study|Death|20
6033418|NCT00319956|9629922|FG001|Overall Study|Death|24
6033419|NCT00319982|9629930|FG000|Overall Study|Withdrawal by Subject|1
6033420|NCT00319982|9629931|FG001|Overall Study|Withdrawal by Subject|0
6033421|NCT00320112|9629939|FG000|Overall Study|Lost to Follow-up|3
6033422|NCT00320112|9629940|FG001|Overall Study|Lost to Follow-up|4
6033423|NCT00320112|9629939|FG000|Overall Study|Withdrawal by Subject|3
6033424|NCT00320112|9629940|FG001|Overall Study|Withdrawal by Subject|0
6033425|NCT00320112|9629939|FG000|Overall Study|Death|2
6033426|NCT00320112|9629940|FG001|Overall Study|Death|1
6033427|NCT00320190|9629954|FG000|First 12 Months|Completed but did not enter extension|5
6033428|NCT00320190|9629955|FG001|First 12 Months|Completed but did not enter extension|3
6033429|NCT00320190|9629954|FG000|First 12 Months|Sponsor terminated study|2
6033430|NCT00320190|9629955|FG001|First 12 Months|Sponsor terminated study|2
6033431|NCT00320190|9629954|FG000|First 12 Months|Lost to Follow-up|0
6033432|NCT00320190|9629955|FG001|First 12 Months|Lost to Follow-up|1
6033433|NCT00320190|9629954|FG000|First 12 Months|Enrollment failure|0
6033434|NCT00320190|9629955|FG001|First 12 Months|Enrollment failure|1
6033435|NCT00320190|9629954|FG000|First 12 Months|Adverse event unrelated to study drug|1
6033436|NCT00320190|9629955|FG001|First 12 Months|Adverse event unrelated to study drug|0
6033437|NCT00320190|9629954|FG000|First 12 Months|Investigator request|0
6033438|NCT00320190|9629955|FG001|First 12 Months|Investigator request|1
6033439|NCT00320190|9629954|FG000|First 12 Months|Study drug toxicity|0
6033440|NCT00320190|9629955|FG001|First 12 Months|Study drug toxicity|1
6033441|NCT00320190|9629954|FG000|First 12 Months|Withdrawal by Subject|0
6033442|NCT00320190|9629955|FG001|First 12 Months|Withdrawal by Subject|1
6033443|NCT00320190|9629954|FG000|Long-term (12-month) Extension|Sponsor terminated study|7
6033444|NCT00320190|9629955|FG001|Long-term (12-month) Extension|Sponsor terminated study|0
6033445|NCT00320190|9629954|FG000|Long-term (12-month) Extension|Lack of major molecular response|1
6033446|NCT00320190|9629955|FG001|Long-term (12-month) Extension|Lack of major molecular response|2
6033447|NCT00320190|9629954|FG000|Long-term (12-month) Extension|Withdrawal by Subject|1
6033448|NCT00320190|9629955|FG001|Long-term (12-month) Extension|Withdrawal by Subject|0
6033449|NCT00320216|9629966|FG000|Overall Study|Adverse Event|0
6033450|NCT00320216|9629967|FG001|Overall Study|Adverse Event|6
6033451|NCT00320216|9629968|FG002|Overall Study|Adverse Event|0
6033452|NCT00320216|9629969|FG003|Overall Study|Adverse Event|2
6033453|NCT00320216|9629970|FG004|Overall Study|Adverse Event|2
6033454|NCT00320216|9629966|FG000|Overall Study|Lack of Efficacy|6
6033455|NCT00320216|9629967|FG001|Overall Study|Lack of Efficacy|2
6033456|NCT00320216|9629968|FG002|Overall Study|Lack of Efficacy|1
6033457|NCT00320216|9629969|FG003|Overall Study|Lack of Efficacy|0
6033458|NCT00320216|9629970|FG004|Overall Study|Lack of Efficacy|1
6033459|NCT00320216|9629966|FG000|Overall Study|Lost to Follow-up|3
6033460|NCT00320216|9629967|FG001|Overall Study|Lost to Follow-up|0
6033461|NCT00320216|9629968|FG002|Overall Study|Lost to Follow-up|0
6033462|NCT00320216|9629969|FG003|Overall Study|Lost to Follow-up|0
6033463|NCT00320216|9629970|FG004|Overall Study|Lost to Follow-up|0
6033464|NCT00320216|9629966|FG000|Overall Study|Other|7
6033465|NCT00320216|9629967|FG001|Overall Study|Other|2
6033466|NCT00320216|9629968|FG002|Overall Study|Other|5
6033467|NCT00320216|9629969|FG003|Overall Study|Other|1
6033468|NCT00320216|9629970|FG004|Overall Study|Other|3
6033469|NCT00320255|9630001|FG000|Overall Study|Lack of Efficacy|1
6033470|NCT00320255|9630002|FG001|Overall Study|Lack of Efficacy|0
6033471|NCT00320255|9630003|FG002|Overall Study|Lack of Efficacy|0
6033472|NCT00320255|9630004|FG003|Overall Study|Lack of Efficacy|0
6033473|NCT00320255|9630005|FG004|Overall Study|Lack of Efficacy|0
6033474|NCT00320255|9630006|FG005|Overall Study|Lack of Efficacy|0
6033475|NCT00320255|9630001|FG000|Overall Study|Adverse Event|5
6033476|NCT00320255|9630002|FG001|Overall Study|Adverse Event|2
6033477|NCT00320255|9630003|FG002|Overall Study|Adverse Event|3
6033478|NCT00320255|9630004|FG003|Overall Study|Adverse Event|2
6033479|NCT00320255|9630005|FG004|Overall Study|Adverse Event|0
6033480|NCT00320255|9630006|FG005|Overall Study|Adverse Event|0
6033481|NCT00320255|9630001|FG000|Overall Study|Withdrawal by Subject|1
6033482|NCT00320255|9630002|FG001|Overall Study|Withdrawal by Subject|2
6033483|NCT00320255|9630003|FG002|Overall Study|Withdrawal by Subject|2
6033484|NCT00320255|9630004|FG003|Overall Study|Withdrawal by Subject|4
6033485|NCT00320255|9630005|FG004|Overall Study|Withdrawal by Subject|0
6033486|NCT00320255|9630006|FG005|Overall Study|Withdrawal by Subject|0
6033487|NCT00320255|9630001|FG000|Overall Study|Poor compliance/noncompliance|1
6033488|NCT00320255|9630002|FG001|Overall Study|Poor compliance/noncompliance|1
6033489|NCT00320255|9630003|FG002|Overall Study|Poor compliance/noncompliance|0
6033490|NCT00320255|9630004|FG003|Overall Study|Poor compliance/noncompliance|1
6033491|NCT00320255|9630005|FG004|Overall Study|Poor compliance/noncompliance|0
6033492|NCT00320255|9630006|FG005|Overall Study|Poor compliance/noncompliance|0
6033493|NCT00320255|9630001|FG000|Overall Study|No longer meets study criteria|0
6033494|NCT00320255|9630002|FG001|Overall Study|No longer meets study criteria|0
6033495|NCT00320255|9630003|FG002|Overall Study|No longer meets study criteria|0
6033496|NCT00320255|9630004|FG003|Overall Study|No longer meets study criteria|1
6033497|NCT00320255|9630005|FG004|Overall Study|No longer meets study criteria|0
6033498|NCT00320255|9630006|FG005|Overall Study|No longer meets study criteria|0
6033499|NCT00320255|9630001|FG000|Overall Study|Other|3
6033500|NCT00320255|9630002|FG001|Overall Study|Other|2
6033501|NCT00320255|9630003|FG002|Overall Study|Other|1
6033502|NCT00320255|9630004|FG003|Overall Study|Other|0
6033503|NCT00320255|9630005|FG004|Overall Study|Other|0
6033504|NCT00320255|9630006|FG005|Overall Study|Other|0
6033505|NCT00320372|9630035|FG000|Overall Study|Physician Decision|4
6033506|NCT00320372|9630036|FG001|Overall Study|Physician Decision|7
6033507|NCT00320372|9630035|FG000|Overall Study|Death|7
6033508|NCT00320372|9630036|FG001|Overall Study|Death|8
6033509|NCT00320372|9630035|FG000|Overall Study|Withdrawal by Subject|55
6033510|NCT00320372|9630036|FG001|Overall Study|Withdrawal by Subject|37
6033511|NCT00320372|9630035|FG000|Overall Study|Non-Compliance|40
6033512|NCT00320372|9630036|FG001|Overall Study|Non-Compliance|39
6033513|NCT00320372|9630035|FG000|Overall Study|Did not Meet (I/E)|3
6033514|NCT00320372|9630036|FG001|Overall Study|Did not Meet (I/E)|1
6033515|NCT00320372|9630035|FG000|Overall Study|Other (i.e. lost to f/u, site closure)|86
6033516|NCT00320372|9630036|FG001|Overall Study|Other (i.e. lost to f/u, site closure)|71
6033517|NCT00320385|9630052|FG000|Overall Study|Lost to Follow-up|7
6033518|NCT00320385|9630053|FG001|Overall Study|Lost to Follow-up|10
6033519|NCT00320385|9630052|FG000|Overall Study|Withdrawal by Subject|6
6033520|NCT00320385|9630053|FG001|Overall Study|Withdrawal by Subject|7
6033521|NCT00320385|9630052|FG000|Overall Study|Sponsor Terminated Study|2
6033522|NCT00320385|9630053|FG001|Overall Study|Sponsor Terminated Study|1
6033523|NCT00320385|9630052|FG000|Overall Study|Investigator Decision|0
6033524|NCT00320385|9630053|FG001|Overall Study|Investigator Decision|1
6033525|NCT00320385|9630052|FG000|Overall Study|Death|1
6033526|NCT00320385|9630053|FG001|Overall Study|Death|2
6033527|NCT00320385|9630052|FG000|Overall Study|Serious Adverse Event|1
6033528|NCT00320385|9630053|FG001|Overall Study|Serious Adverse Event|0
6033529|NCT00320385|9630052|FG000|Overall Study|Withdrew Consent|1
6033530|NCT00320385|9630053|FG001|Overall Study|Withdrew Consent|0
6033531|NCT00320385|9630052|FG000|Overall Study|Adverse Event|0
6033532|NCT00320385|9630053|FG001|Overall Study|Adverse Event|1
6033533|NCT00320398|9630061|FG000|Overall Study|Adverse Event|1
6033534|NCT00320398|9630062|FG001|Overall Study|Adverse Event|4
6033535|NCT00320398|9630061|FG000|Overall Study|Other|1
6033536|NCT00320398|9630062|FG001|Overall Study|Other|0
6033537|NCT00320411|9630069|FG000|Overall Study|No investigational product admin.|4
6033538|NCT00320424|9630073|FG000|Overall Study|Adverse Event|3
6033539|NCT00320424|9630073|FG000|Overall Study|Other|3
6033540|NCT00320489|9630079|FG000|Overall Study|Adverse Event|26
6033541|NCT00320489|9630080|FG001|Overall Study|Adverse Event|25
6033542|NCT00320489|9630079|FG000|Overall Study|Clinical Relapse|26
6033543|NCT00320489|9630080|FG001|Overall Study|Clinical Relapse|20
6033544|NCT00320489|9630079|FG000|Overall Study|Death|0
6033545|NCT00320489|9630080|FG001|Overall Study|Death|2
6033546|NCT00320489|9630079|FG000|Overall Study|Entry Criteria Exclusion|2
6033547|NCT00320489|9630080|FG001|Overall Study|Entry Criteria Exclusion|4
6033548|NCT00320489|9630079|FG000|Overall Study|Lack of Efficacy|16
6033549|NCT00320489|9630080|FG001|Overall Study|Lack of Efficacy|7
6033550|NCT00320489|9630079|FG000|Overall Study|Lost to Follow-up|21
6033551|NCT00320489|9630080|FG001|Overall Study|Lost to Follow-up|22
6033552|NCT00320489|9630079|FG000|Overall Study|Physician Decision|8
6033553|NCT00320489|9630080|FG001|Overall Study|Physician Decision|8
6033554|NCT00320489|9630079|FG000|Overall Study|Protocol Violation|4
6033555|NCT00320489|9630080|FG001|Overall Study|Protocol Violation|4
6033556|NCT00320489|9630079|FG000|Overall Study|Sponsor Decision|3
6033557|NCT00320489|9630080|FG001|Overall Study|Sponsor Decision|3
6033558|NCT00320489|9630079|FG000|Overall Study|Withdrawal by Subject|39
6033559|NCT00320489|9630080|FG001|Overall Study|Withdrawal by Subject|41
6033560|NCT00320515|9630086|FG000|Overall Study|Death|33
6033561|NCT00320515|9630086|FG000|Overall Study|Lost to Follow-up|6
6033562|NCT00320515|9630086|FG000|Overall Study|Physician Decision|2
6033563|NCT00320515|9630086|FG000|Overall Study|Withdrawal by Subject|8
6033564|NCT00320528|9630093|FG000|Study Period II|Adverse Event|3
6033565|NCT00320528|9630094|FG001|Study Period II|Adverse Event|4
6033566|NCT00320528|9630095|FG002|Study Period II|Adverse Event|8
6033567|NCT00320528|9630093|FG000|Study Period II|Parent/Caregiver Decision|8
6033568|NCT00320528|9630094|FG001|Study Period II|Parent/Caregiver Decision|3
6033569|NCT00320528|9630095|FG002|Study Period II|Parent/Caregiver Decision|11
6033570|NCT00320528|9630093|FG000|Study Period II|Withdrawal by Subject|0
6033571|NCT00320528|9630094|FG001|Study Period II|Withdrawal by Subject|1
6033572|NCT00320528|9630095|FG002|Study Period II|Withdrawal by Subject|1
6033573|NCT00320528|9630093|FG000|Study Period II|Entry Criteria Exclusion|0
6033574|NCT00320528|9630094|FG001|Study Period II|Entry Criteria Exclusion|2
6033575|NCT00320528|9630095|FG002|Study Period II|Entry Criteria Exclusion|2
6033576|NCT00320528|9630093|FG000|Study Period III|Adverse Event|1
6033577|NCT00320528|9630094|FG001|Study Period III|Adverse Event|0
6033578|NCT00320528|9630095|FG002|Study Period III|Adverse Event|0
6033579|NCT00320528|9630093|FG000|Study Period III|Lost to Follow-up|1
6033580|NCT00320528|9630094|FG001|Study Period III|Lost to Follow-up|0
6033581|NCT00320528|9630095|FG002|Study Period III|Lost to Follow-up|0
6033582|NCT00320528|9630093|FG000|Study Period III|Withdrawal by Subject|1
6033583|NCT00320528|9630094|FG001|Study Period III|Withdrawal by Subject|1
6033584|NCT00320528|9630095|FG002|Study Period III|Withdrawal by Subject|2
6033585|NCT00320528|9630093|FG000|Study Period III|Lack of Efficacy|2
6033586|NCT00320528|9630094|FG001|Study Period III|Lack of Efficacy|0
6033587|NCT00320528|9630095|FG002|Study Period III|Lack of Efficacy|0
6033588|NCT00320528|9630093|FG000|Study Period III|Parent/Caregiver Decision|14
6033589|NCT00320528|9630094|FG001|Study Period III|Parent/Caregiver Decision|3
6033590|NCT00320528|9630095|FG002|Study Period III|Parent/Caregiver Decision|11
6033591|NCT00320528|9630093|FG000|Study Period III|Protocol Violation|0
6033592|NCT00320528|9630094|FG001|Study Period III|Protocol Violation|1
6033593|NCT00320528|9630095|FG002|Study Period III|Protocol Violation|0
6033594|NCT00320528|9630093|FG000|Study Period III|Physician Decision|0
6033595|NCT00320528|9630094|FG001|Study Period III|Physician Decision|1
6033596|NCT00320528|9630095|FG002|Study Period III|Physician Decision|2
6033597|NCT00320528|9630093|FG000|Study Period III|Sponsor Decision|0
6033598|NCT00320528|9630094|FG001|Study Period III|Sponsor Decision|0
6033599|NCT00320528|9630095|FG002|Study Period III|Sponsor Decision|1
6033600|NCT00320528|9630093|FG000|Study Period III|Atomoxetine Commercially Available|68
6033601|NCT00320528|9630094|FG001|Study Period III|Atomoxetine Commercially Available|25
6033602|NCT00320528|9630095|FG002|Study Period III|Atomoxetine Commercially Available|90
6033603|NCT00320541|9630105|FG000|Overall Study|Adverse Event|21
6033604|NCT00320541|9630106|FG001|Overall Study|Adverse Event|19
6033605|NCT00320541|9630105|FG000|Overall Study|Protocol Violation|0
6033606|NCT00320541|9630106|FG001|Overall Study|Protocol Violation|1
6033607|NCT00320541|9630105|FG000|Overall Study|Withdrawal by Subject|12
6033608|NCT00320541|9630106|FG001|Overall Study|Withdrawal by Subject|16
6033609|NCT00320541|9630105|FG000|Overall Study|Physician Decision|9
6033610|NCT00320541|9630106|FG001|Overall Study|Physician Decision|13
6033611|NCT00320541|9630105|FG000|Overall Study|Other|3
6033612|NCT00320541|9630106|FG001|Overall Study|Other|4
6033613|NCT00320541|9630105|FG000|Overall Study|Sponsor Decision|2
6033614|NCT00320541|9630106|FG001|Overall Study|Sponsor Decision|1
6033615|NCT00320541|9630105|FG000|Overall Study|Death due to Study Disease|1
6033616|NCT00320541|9630106|FG001|Overall Study|Death due to Study Disease|3
6033617|NCT00320541|9630105|FG000|Overall Study|Death due to Adverse Event(s)|1
6033618|NCT00320541|9630106|FG001|Overall Study|Death due to Adverse Event(s)|0
6033619|NCT00320541|9630105|FG000|Overall Study|Protocol Entry Criterion Not Met|1
6033620|NCT00320541|9630106|FG001|Overall Study|Protocol Entry Criterion Not Met|0
6033621|NCT00320593|9630114|FG000|Overall Study|Lost to Follow-up|3
6033622|NCT00320593|9630115|FG001|Overall Study|Lost to Follow-up|0
6033623|NCT00320593|9630114|FG000|Overall Study|Moved to another state|1
6033624|NCT00320593|9630115|FG001|Overall Study|Moved to another state|0
6033625|NCT00320593|9630114|FG000|Overall Study|Withdrawal by Subject|2
6033626|NCT00320593|9630115|FG001|Overall Study|Withdrawal by Subject|1
6033627|NCT00320593|9630114|FG000|Overall Study|Withdrawal by clinical center|1
6033628|NCT00320593|9630115|FG001|Overall Study|Withdrawal by clinical center|0
6033629|NCT00320606|9630121|FG000|Overall Study|Adverse Event|1
6033630|NCT00320606|9630121|FG000|Overall Study|Protocol Violation|1
6033631|NCT00320606|9630121|FG000|Overall Study|Withdrawal by Subject|1
6033632|NCT00320710|9630138|FG000|Overall Study|Disease progression|24
6033633|NCT00320710|9630139|FG001|Overall Study|Disease progression|19
6033634|NCT00320710|9630140|FG002|Overall Study|Disease progression|2
6033635|NCT00320710|9630138|FG000|Overall Study|Death|10
6033636|NCT00320710|9630139|FG001|Overall Study|Death|7
6033637|NCT00320710|9630140|FG002|Overall Study|Death|1
6033638|NCT00320710|9630138|FG000|Overall Study|Administrative problems|1
6033639|NCT00320710|9630139|FG001|Overall Study|Administrative problems|2
6033640|NCT00320710|9630140|FG002|Overall Study|Administrative problems|0
6033641|NCT00320710|9630138|FG000|Overall Study|Withdrawal by Subject|20
6033642|NCT00320710|9630139|FG001|Overall Study|Withdrawal by Subject|26
6033643|NCT00320710|9630140|FG002|Overall Study|Withdrawal by Subject|1
6033644|NCT00320710|9630138|FG000|Overall Study|Protocol Violation|6
6033645|NCT00320710|9630139|FG001|Overall Study|Protocol Violation|5
6033646|NCT00320710|9630140|FG002|Overall Study|Protocol Violation|0
6033647|NCT00320710|9630138|FG000|Overall Study|Abnormal test procedure result(s)|2
6033648|NCT00320710|9630139|FG001|Overall Study|Abnormal test procedure result(s)|0
6033649|NCT00320710|9630140|FG002|Overall Study|Abnormal test procedure result(s)|0
6033650|NCT00320710|9630138|FG000|Overall Study|Abnormal laboratory value(s)|12
6033651|NCT00320710|9630139|FG001|Overall Study|Abnormal laboratory value(s)|3
6033652|NCT00320710|9630140|FG002|Overall Study|Abnormal laboratory value(s)|0
6033653|NCT00320710|9630138|FG000|Overall Study|Adverse Event|18
6033654|NCT00320710|9630139|FG001|Overall Study|Adverse Event|14
6033655|NCT00320710|9630140|FG002|Overall Study|Adverse Event|1
6033656|NCT00320710|9630138|FG000|Overall Study|Lost to Follow-up|1
6033657|NCT00320710|9630139|FG001|Overall Study|Lost to Follow-up|0
6033658|NCT00320710|9630140|FG002|Overall Study|Lost to Follow-up|0
6033659|NCT00320788|9630159|FG000|Overall Study|Adverse Event|0
6033660|NCT00320788|9630160|FG001|Overall Study|Adverse Event|0
6033661|NCT00320788|9630161|FG002|Overall Study|Adverse Event|0
6033662|NCT00320788|9630162|FG003|Overall Study|Adverse Event|1
6033663|NCT00320788|9630163|FG004|Overall Study|Adverse Event|0
6033664|NCT00320788|9630159|FG000|Overall Study|Death|0
6033665|NCT00320788|9630160|FG001|Overall Study|Death|0
6033666|NCT00320788|9630161|FG002|Overall Study|Death|1
6033667|NCT00320788|9630162|FG003|Overall Study|Death|0
6033668|NCT00320788|9630163|FG004|Overall Study|Death|1
6033669|NCT00320788|9630159|FG000|Overall Study|Lost to Follow-up|0
6033670|NCT00320788|9630160|FG001|Overall Study|Lost to Follow-up|2
6033671|NCT00320788|9630161|FG002|Overall Study|Lost to Follow-up|1
6033672|NCT00320788|9630162|FG003|Overall Study|Lost to Follow-up|0
6033673|NCT00320788|9630163|FG004|Overall Study|Lost to Follow-up|0
6033674|NCT00320788|9630159|FG000|Overall Study|Decision by the Sponsor|1
6033675|NCT00320788|9630160|FG001|Overall Study|Decision by the Sponsor|1
6033676|NCT00320788|9630161|FG002|Overall Study|Decision by the Sponsor|0
6033677|NCT00320788|9630162|FG003|Overall Study|Decision by the Sponsor|0
6033678|NCT00320788|9630163|FG004|Overall Study|Decision by the Sponsor|1
6033679|NCT00320788|9630159|FG000|Overall Study|Other|1
6033680|NCT00320788|9630160|FG001|Overall Study|Other|2
6033681|NCT00320788|9630161|FG002|Overall Study|Other|1
6033682|NCT00320788|9630162|FG003|Overall Study|Other|1
6033683|NCT00320788|9630163|FG004|Overall Study|Other|1
6033684|NCT00320788|9630159|FG000|Overall Study|Physician Decision|1
6033685|NCT00320788|9630160|FG001|Overall Study|Physician Decision|1
6033686|NCT00320788|9630161|FG002|Overall Study|Physician Decision|0
6033687|NCT00320788|9630162|FG003|Overall Study|Physician Decision|0
6033688|NCT00320788|9630163|FG004|Overall Study|Physician Decision|0
6033689|NCT00320788|9630159|FG000|Overall Study|Protocol Violation|0
6033690|NCT00320788|9630160|FG001|Overall Study|Protocol Violation|0
6033691|NCT00320788|9630161|FG002|Overall Study|Protocol Violation|0
6033692|NCT00320788|9630162|FG003|Overall Study|Protocol Violation|0
6033693|NCT00320788|9630163|FG004|Overall Study|Protocol Violation|1
6033694|NCT00320788|9630159|FG000|Overall Study|Withdrawal by Subject|3
6033695|NCT00320788|9630160|FG001|Overall Study|Withdrawal by Subject|0
6033696|NCT00320788|9630161|FG002|Overall Study|Withdrawal by Subject|0
6033697|NCT00320788|9630162|FG003|Overall Study|Withdrawal by Subject|3
6033698|NCT00320788|9630163|FG004|Overall Study|Withdrawal by Subject|1
6033699|NCT00320801|9630183|FG000|Open-label Run-in Period|Withdrawal by Subject|2
6033700|NCT00320801|9630184|FG001|Open-label Run-in Period|Withdrawal by Subject|0
6033701|NCT00320801|9630185|FG002|Open-label Run-in Period|Withdrawal by Subject|0
6033702|NCT00320801|9630186|FG003|Open-label Run-in Period|Withdrawal by Subject|0
6033703|NCT00320801|9630183|FG000|Open-label Run-in Period|Adverse Event|33
6033704|NCT00320801|9630184|FG001|Open-label Run-in Period|Adverse Event|0
6033705|NCT00320801|9630185|FG002|Open-label Run-in Period|Adverse Event|0
6033706|NCT00320801|9630186|FG003|Open-label Run-in Period|Adverse Event|0
6033707|NCT00320801|9630183|FG000|Open-label Run-in Period|Administrative|10
6033708|NCT00320801|9630184|FG001|Open-label Run-in Period|Administrative|0
6033709|NCT00320801|9630185|FG002|Open-label Run-in Period|Administrative|0
6033710|NCT00320801|9630186|FG003|Open-label Run-in Period|Administrative|0
6033711|NCT00320801|9630183|FG000|Open-label Run-in Period|Lack of Efficacy|44
6033712|NCT00320801|9630184|FG001|Open-label Run-in Period|Lack of Efficacy|0
6033713|NCT00320801|9630185|FG002|Open-label Run-in Period|Lack of Efficacy|0
6033714|NCT00320801|9630186|FG003|Open-label Run-in Period|Lack of Efficacy|0
6033715|NCT00320801|9630183|FG000|Open-label Run-in Period|Lost to Follow-up|2
6033716|NCT00320801|9630184|FG001|Open-label Run-in Period|Lost to Follow-up|0
6033717|NCT00320801|9630185|FG002|Open-label Run-in Period|Lost to Follow-up|0
6033718|NCT00320801|9630186|FG003|Open-label Run-in Period|Lost to Follow-up|0
6033719|NCT00320801|9630183|FG000|Open-label Run-in Period|Did not qualify|1
6033720|NCT00320801|9630184|FG001|Open-label Run-in Period|Did not qualify|0
6033721|NCT00320801|9630185|FG002|Open-label Run-in Period|Did not qualify|0
6033722|NCT00320801|9630186|FG003|Open-label Run-in Period|Did not qualify|0
6033723|NCT00320801|9630183|FG000|Double-blind Phase|Withdrawal by Subject|0
6033724|NCT00320801|9630184|FG001|Double-blind Phase|Withdrawal by Subject|0
6033725|NCT00320801|9630185|FG002|Double-blind Phase|Withdrawal by Subject|1
6033726|NCT00320801|9630186|FG003|Double-blind Phase|Withdrawal by Subject|0
6033727|NCT00320801|9630183|FG000|Double-blind Phase|Adverse Event|0
6033728|NCT00320801|9630184|FG001|Double-blind Phase|Adverse Event|2
6033729|NCT00320801|9630185|FG002|Double-blind Phase|Adverse Event|8
6033730|NCT00320801|9630186|FG003|Double-blind Phase|Adverse Event|0
6033731|NCT00320801|9630183|FG000|Double-blind Phase|Administrative|0
6033732|NCT00320801|9630184|FG001|Double-blind Phase|Administrative|0
6033733|NCT00320801|9630185|FG002|Double-blind Phase|Administrative|4
6033734|NCT00320801|9630186|FG003|Double-blind Phase|Administrative|0
6033735|NCT00320801|9630183|FG000|Double-blind Phase|Lack of Efficacy|0
6033736|NCT00320801|9630184|FG001|Double-blind Phase|Lack of Efficacy|9
6033737|NCT00320801|9630185|FG002|Double-blind Phase|Lack of Efficacy|1
6033738|NCT00320801|9630186|FG003|Double-blind Phase|Lack of Efficacy|0
6033739|NCT00320801|9630183|FG000|Extension Phase|Withdrawal by Subject|0
6033740|NCT00320801|9630184|FG001|Extension Phase|Withdrawal by Subject|0
6033741|NCT00320801|9630185|FG002|Extension Phase|Withdrawal by Subject|0
6033742|NCT00320801|9630186|FG003|Extension Phase|Withdrawal by Subject|6
6033743|NCT00320801|9630183|FG000|Extension Phase|Adverse Event|0
6033744|NCT00320801|9630184|FG001|Extension Phase|Adverse Event|0
6033745|NCT00320801|9630185|FG002|Extension Phase|Adverse Event|0
6033746|NCT00320801|9630186|FG003|Extension Phase|Adverse Event|8
6033747|NCT00320801|9630183|FG000|Extension Phase|Administrative|0
6033748|NCT00320801|9630184|FG001|Extension Phase|Administrative|0
6033749|NCT00320801|9630185|FG002|Extension Phase|Administrative|0
6033750|NCT00320801|9630186|FG003|Extension Phase|Administrative|29
6033751|NCT00320801|9630183|FG000|Extension Phase|Lack of Efficacy|0
6033752|NCT00320801|9630184|FG001|Extension Phase|Lack of Efficacy|0
6033753|NCT00320801|9630185|FG002|Extension Phase|Lack of Efficacy|0
6033754|NCT00320801|9630186|FG003|Extension Phase|Lack of Efficacy|2
6033755|NCT00320801|9630183|FG000|Extension Phase|Lost to Follow-up|0
6033756|NCT00320801|9630184|FG001|Extension Phase|Lost to Follow-up|0
6033757|NCT00320801|9630185|FG002|Extension Phase|Lost to Follow-up|0
6033758|NCT00320801|9630186|FG003|Extension Phase|Lost to Follow-up|3
6033759|NCT00321048|9630198|FG000|Overall Study|Withdrawal by Subject|6
6033760|NCT00321048|9630199|FG001|Overall Study|Withdrawal by Subject|8
6033761|NCT00321373|9630223|FG000|Overall Study|Adverse Event|0
6033762|NCT00321373|9630224|FG001|Overall Study|Adverse Event|0
6033763|NCT00321373|9630225|FG002|Overall Study|Adverse Event|1
6033764|NCT00321373|9630223|FG000|Overall Study|Lost to Follow-up|1
6033765|NCT00321373|9630224|FG001|Overall Study|Lost to Follow-up|0
6033766|NCT00321373|9630225|FG002|Overall Study|Lost to Follow-up|1
6033767|NCT00321373|9630223|FG000|Overall Study|Withdrawal by Subject|1
6033768|NCT00321373|9630224|FG001|Overall Study|Withdrawal by Subject|0
6033769|NCT00321373|9630225|FG002|Overall Study|Withdrawal by Subject|0
6033770|NCT00321373|9630223|FG000|Overall Study|Other|0
6033771|NCT00321373|9630224|FG001|Overall Study|Other|0
6033772|NCT00321373|9630225|FG002|Overall Study|Other|1
6033773|NCT00321464|9630235|FG000|Overall Study|Death|169
6033774|NCT00321464|9630236|FG001|Overall Study|Death|174
6033775|NCT00321464|9630235|FG000|Overall Study|Disease progression|124
6033776|NCT00321464|9630236|FG001|Overall Study|Disease progression|124
6033777|NCT00321464|9630235|FG000|Overall Study|Withdrawal by Subject|117
6033778|NCT00321464|9630236|FG001|Overall Study|Withdrawal by Subject|118
6033779|NCT00321464|9630235|FG000|Overall Study|Participant request|57
6033780|NCT00321464|9630236|FG001|Overall Study|Participant request|61
6033781|NCT00321464|9630235|FG000|Overall Study|Adverse Event|43
6033782|NCT00321464|9630236|FG001|Overall Study|Adverse Event|28
6033783|NCT00321464|9630235|FG000|Overall Study|Physician Decision|15
6033784|NCT00321464|9630236|FG001|Overall Study|Physician Decision|14
6033785|NCT00321464|9630235|FG000|Overall Study|Noncompliance|4
6033786|NCT00321464|9630236|FG001|Overall Study|Noncompliance|10
6033787|NCT00321464|9630235|FG000|Overall Study|Lost to Follow-up|7
6033788|NCT00321464|9630236|FG001|Overall Study|Lost to Follow-up|8
6033789|NCT00321464|9630235|FG000|Overall Study|Protocol deviation|0
6033790|NCT00321464|9630236|FG001|Overall Study|Protocol deviation|2
6033791|NCT00321464|9630235|FG000|Overall Study|Ineligibility determined|2
6033792|NCT00321464|9630236|FG001|Overall Study|Ineligibility determined|1
6033793|NCT00321464|9630235|FG000|Overall Study|Other|21
6033794|NCT00321464|9630236|FG001|Overall Study|Other|18
6033795|NCT00321620|9630262|FG000|Overall Study|Death|269
6033796|NCT00321620|9630263|FG001|Overall Study|Death|294
6033797|NCT00321620|9630262|FG000|Overall Study|Withdrawal by Subject|164
6033798|NCT00321620|9630263|FG001|Overall Study|Withdrawal by Subject|147
6033799|NCT00321620|9630262|FG000|Overall Study|Disease progression|113
6033800|NCT00321620|9630263|FG001|Overall Study|Disease progression|117
6033801|NCT00321620|9630262|FG000|Overall Study|Adverse Event|43
6033802|NCT00321620|9630263|FG001|Overall Study|Adverse Event|56
6033803|NCT00321620|9630262|FG000|Overall Study|Lost to Follow-up|13
6033804|NCT00321620|9630263|FG001|Overall Study|Lost to Follow-up|9
6033805|NCT00321620|9630262|FG000|Overall Study|Physician Decision|4
6033806|NCT00321620|9630263|FG001|Overall Study|Physician Decision|1
6033807|NCT00321620|9630262|FG000|Overall Study|Noncompliance|14
6033808|NCT00321620|9630263|FG001|Overall Study|Noncompliance|7
6033809|NCT00321620|9630262|FG000|Overall Study|Protocol deviation|4
6033810|NCT00321620|9630263|FG001|Overall Study|Protocol deviation|3
6033811|NCT00321620|9630262|FG000|Overall Study|Ineligibility determined|2
6033812|NCT00321620|9630263|FG001|Overall Study|Ineligibility determined|3
6033813|NCT00321620|9630262|FG000|Overall Study|Participant request|75
6033814|NCT00321620|9630263|FG001|Overall Study|Participant request|52
6033815|NCT00321620|9630262|FG000|Overall Study|Other|42
6033816|NCT00321620|9630263|FG001|Overall Study|Other|33
6033817|NCT00321646|9630269|FG000|Neoadjuvant Chemotherapy|Withdrawal by Subject|1
6033818|NCT00321646|9630269|FG000|Neoadjuvant Chemotherapy|Adverse Event|2
6033819|NCT00321646|9630269|FG000|Neoadjuvant Chemotherapy|Disease progression|1
6033820|NCT00321672|9630277|FG000|Overall Study|Withdrawal by Subject|5
6033821|NCT00321672|9630278|FG001|Overall Study|Withdrawal by Subject|1
6033822|NCT00321672|9630279|FG002|Overall Study|Withdrawal by Subject|2
6033823|NCT00321672|9630280|FG003|Overall Study|Withdrawal by Subject|0
6033824|NCT00321672|9630277|FG000|Overall Study|Noncompliance|1
6033825|NCT00321672|9630278|FG001|Overall Study|Noncompliance|2
6033826|NCT00321672|9630279|FG002|Overall Study|Noncompliance|1
6033827|NCT00321672|9630280|FG003|Overall Study|Noncompliance|0
6033828|NCT00321672|9630277|FG000|Overall Study|Adverse Event|1
6033829|NCT00321672|9630278|FG001|Overall Study|Adverse Event|1
6033830|NCT00321672|9630279|FG002|Overall Study|Adverse Event|0
6033831|NCT00321672|9630280|FG003|Overall Study|Adverse Event|0
6033832|NCT00321672|9630277|FG000|Overall Study|Lack of Efficacy|1
6033833|NCT00321672|9630278|FG001|Overall Study|Lack of Efficacy|1
6033834|NCT00321672|9630279|FG002|Overall Study|Lack of Efficacy|0
6033835|NCT00321672|9630280|FG003|Overall Study|Lack of Efficacy|0
6033836|NCT00321672|9630277|FG000|Overall Study|Lost to Follow-up|2
6033837|NCT00321672|9630278|FG001|Overall Study|Lost to Follow-up|0
6033838|NCT00321672|9630279|FG002|Overall Study|Lost to Follow-up|4
6033839|NCT00321672|9630280|FG003|Overall Study|Lost to Follow-up|2
6033840|NCT00321672|9630277|FG000|Overall Study|Death|1
6033841|NCT00321672|9630278|FG001|Overall Study|Death|0
6033842|NCT00321672|9630279|FG002|Overall Study|Death|0
6033843|NCT00321672|9630280|FG003|Overall Study|Death|0
6033844|NCT00321672|9630277|FG000|Overall Study|Too far to travel for visits|1
6033845|NCT00321672|9630278|FG001|Overall Study|Too far to travel for visits|0
6033846|NCT00321672|9630279|FG002|Overall Study|Too far to travel for visits|0
6033847|NCT00321672|9630280|FG003|Overall Study|Too far to travel for visits|0
6033848|NCT00321672|9630277|FG000|Overall Study|Incarcerated|0
6033849|NCT00321672|9630278|FG001|Overall Study|Incarcerated|0
6033850|NCT00321672|9630279|FG002|Overall Study|Incarcerated|2
6033851|NCT00321672|9630280|FG003|Overall Study|Incarcerated|0
6033852|NCT00321672|9630277|FG000|Overall Study|Moved out of state|0
6033853|NCT00321672|9630278|FG001|Overall Study|Moved out of state|1
6033854|NCT00321672|9630279|FG002|Overall Study|Moved out of state|1
6033855|NCT00321672|9630280|FG003|Overall Study|Moved out of state|0
6033856|NCT00321672|9630277|FG000|Overall Study|Protocol Violation|0
6033857|NCT00321672|9630278|FG001|Overall Study|Protocol Violation|0
6033858|NCT00321672|9630279|FG002|Overall Study|Protocol Violation|1
6033859|NCT00321672|9630280|FG003|Overall Study|Protocol Violation|0
6033860|NCT00321672|9630277|FG000|Overall Study|Diagnosis of testicular cancer|0
6033861|NCT00321672|9630278|FG001|Overall Study|Diagnosis of testicular cancer|1
6033862|NCT00321672|9630279|FG002|Overall Study|Diagnosis of testicular cancer|0
6033863|NCT00321672|9630280|FG003|Overall Study|Diagnosis of testicular cancer|0
6033864|NCT00321672|9630277|FG000|Overall Study|Extensive travel required for new job|0
6033865|NCT00321672|9630278|FG001|Overall Study|Extensive travel required for new job|1
6033866|NCT00321672|9630279|FG002|Overall Study|Extensive travel required for new job|0
6033867|NCT00321672|9630280|FG003|Overall Study|Extensive travel required for new job|0
6033868|NCT00321685|9630294|FG000|Overall Study|Adverse Event|18
6033869|NCT00321685|9630294|FG000|Overall Study|Death|2
6033870|NCT00321685|9630294|FG000|Overall Study|Withdrawal by Subject|8
6033871|NCT00321685|9630294|FG000|Overall Study|Alternative therapy|1
6033872|NCT00321685|9630294|FG000|Overall Study|Complicating disese|1
6033873|NCT00321685|9630294|FG000|Overall Study|Other|5
6033874|NCT00321685|9630294|FG000|Overall Study|Not start protocol therapy|2
6033875|NCT00321685|9630294|FG000|Overall Study|Ineligible|2
6033876|NCT00321711|9630303|FG000|Part A|Adverse Event|3
6033877|NCT00321711|9630304|FG001|Part A|Adverse Event|3
6033878|NCT00321711|9630305|FG002|Part A|Adverse Event|2
6033879|NCT00321711|9630306|FG003|Part A|Adverse Event|0
6033880|NCT00321711|9630307|FG004|Part A|Adverse Event|0
6033881|NCT00321711|9630303|FG000|Part A|Withdrawal by Subject|1
6033882|NCT00321711|9630304|FG001|Part A|Withdrawal by Subject|1
6033883|NCT00321711|9630305|FG002|Part A|Withdrawal by Subject|1
6033884|NCT00321711|9630306|FG003|Part A|Withdrawal by Subject|0
6033885|NCT00321711|9630307|FG004|Part A|Withdrawal by Subject|0
6033886|NCT00321711|9630303|FG000|Part A|Disease progression|0
6033887|NCT00321711|9630304|FG001|Part A|Disease progression|1
6033888|NCT00321711|9630305|FG002|Part A|Disease progression|0
6033889|NCT00321711|9630306|FG003|Part A|Disease progression|0
6033890|NCT00321711|9630307|FG004|Part A|Disease progression|0
6033891|NCT00321711|9630303|FG000|Part A|Requirement for alternative therapy|0
6033892|NCT00321711|9630304|FG001|Part A|Requirement for alternative therapy|2
6033893|NCT00321711|9630305|FG002|Part A|Requirement for alternative therapy|1
6033894|NCT00321711|9630306|FG003|Part A|Requirement for alternative therapy|0
6033895|NCT00321711|9630307|FG004|Part A|Requirement for alternative therapy|0
6033896|NCT00321711|9630303|FG000|Part A|Physician Decision|0
6033897|NCT00321711|9630304|FG001|Part A|Physician Decision|1
6033898|NCT00321711|9630305|FG002|Part A|Physician Decision|3
6033899|NCT00321711|9630306|FG003|Part A|Physician Decision|0
6033900|NCT00321711|9630307|FG004|Part A|Physician Decision|0
6033901|NCT00321711|9630303|FG000|Part A|Other|1
6033902|NCT00321711|9630304|FG001|Part A|Other|2
6033903|NCT00321711|9630305|FG002|Part A|Other|3
6033904|NCT00321711|9630306|FG003|Part A|Other|0
6033905|NCT00321711|9630307|FG004|Part A|Other|0
6033906|NCT00321711|9630303|FG000|Part A|Protocol deviation|0
6033907|NCT00321711|9630304|FG001|Part A|Protocol deviation|0
6033908|NCT00321711|9630305|FG002|Part A|Protocol deviation|1
6033909|NCT00321711|9630306|FG003|Part A|Protocol deviation|0
6033910|NCT00321711|9630307|FG004|Part A|Protocol deviation|0
6033911|NCT00321711|9630303|FG000|Part B|Noncompliance|0
6033912|NCT00321711|9630304|FG001|Part B|Noncompliance|0
6033913|NCT00321711|9630305|FG002|Part B|Noncompliance|0
6033914|NCT00321711|9630306|FG003|Part B|Noncompliance|0
6033915|NCT00321711|9630307|FG004|Part B|Noncompliance|1
6033916|NCT00321711|9630303|FG000|Part B|Adverse Event|0
6033917|NCT00321711|9630304|FG001|Part B|Adverse Event|0
6033918|NCT00321711|9630305|FG002|Part B|Adverse Event|0
6033919|NCT00321711|9630306|FG003|Part B|Adverse Event|2
6033920|NCT00321711|9630307|FG004|Part B|Adverse Event|1
6033921|NCT00321711|9630303|FG000|Part B|Disease progression|0
6033922|NCT00321711|9630304|FG001|Part B|Disease progression|0
6033923|NCT00321711|9630305|FG002|Part B|Disease progression|0
6033924|NCT00321711|9630306|FG003|Part B|Disease progression|1
6033925|NCT00321711|9630307|FG004|Part B|Disease progression|0
6033926|NCT00321711|9630303|FG000|Part B|Physician Decision|0
6033927|NCT00321711|9630304|FG001|Part B|Physician Decision|0
6033928|NCT00321711|9630305|FG002|Part B|Physician Decision|0
6033929|NCT00321711|9630306|FG003|Part B|Physician Decision|1
6033930|NCT00321711|9630307|FG004|Part B|Physician Decision|2
6033931|NCT00321711|9630303|FG000|Part B|Death|0
6033932|NCT00321711|9630304|FG001|Part B|Death|0
6033933|NCT00321711|9630305|FG002|Part B|Death|0
6033934|NCT00321711|9630306|FG003|Part B|Death|2
6033935|NCT00321711|9630307|FG004|Part B|Death|1
6033936|NCT00321737|9630322|FG000|Overall Study|Relapse of Erosive Esophagitis|76
6033937|NCT00321737|9630323|FG001|Overall Study|Relapse of Erosive Esophagitis|25
6033938|NCT00321737|9630324|FG002|Overall Study|Relapse of Erosive Esophagitis|19
6033939|NCT00321737|9630322|FG000|Overall Study|Adverse Event|11
6033940|NCT00321737|9630323|FG001|Overall Study|Adverse Event|3
6033941|NCT00321737|9630324|FG002|Overall Study|Adverse Event|6
6033942|NCT00321737|9630322|FG000|Overall Study|Lost to Follow-up|5
6033943|NCT00321737|9630323|FG001|Overall Study|Lost to Follow-up|5
6033944|NCT00321737|9630324|FG002|Overall Study|Lost to Follow-up|6
6033945|NCT00321737|9630322|FG000|Overall Study|Withdrawal by Subject|19
6033946|NCT00321737|9630323|FG001|Overall Study|Withdrawal by Subject|12
6033947|NCT00321737|9630324|FG002|Overall Study|Withdrawal by Subject|17
6033948|NCT00321737|9630322|FG000|Overall Study|Protocol Violation|0
6033949|NCT00321737|9630323|FG001|Overall Study|Protocol Violation|0
6033950|NCT00321737|9630324|FG002|Overall Study|Protocol Violation|1
6033951|NCT00321737|9630322|FG000|Overall Study|Unmet Inclusion/Exclusion Criteria|1
6033952|NCT00321737|9630323|FG001|Overall Study|Unmet Inclusion/Exclusion Criteria|0
6033953|NCT00321737|9630324|FG002|Overall Study|Unmet Inclusion/Exclusion Criteria|0
6033954|NCT00321737|9630322|FG000|Overall Study|Possible Barrett's Esophagus|2
6033955|NCT00321737|9630323|FG001|Overall Study|Possible Barrett's Esophagus|1
6033956|NCT00321737|9630324|FG002|Overall Study|Possible Barrett's Esophagus|1
6033957|NCT00321737|9630322|FG000|Overall Study|Therapeutic Failure|6
6033958|NCT00321737|9630323|FG001|Overall Study|Therapeutic Failure|0
6033959|NCT00321737|9630324|FG002|Overall Study|Therapeutic Failure|2
6033960|NCT00321737|9630322|FG000|Overall Study|Pregnancy|0
6033961|NCT00321737|9630323|FG001|Overall Study|Pregnancy|2
6033962|NCT00321737|9630324|FG002|Overall Study|Pregnancy|0
6033963|NCT00321737|9630322|FG000|Overall Study|Noncompliance|2
6033964|NCT00321737|9630323|FG001|Overall Study|Noncompliance|0
6033965|NCT00321737|9630324|FG002|Overall Study|Noncompliance|0
6033966|NCT00321737|9630322|FG000|Overall Study|Subject Request/ Subject Unavailable|0
6033967|NCT00321737|9630323|FG001|Overall Study|Subject Request/ Subject Unavailable|0
6033968|NCT00321737|9630324|FG002|Overall Study|Subject Request/ Subject Unavailable|2
6033969|NCT00321763|9630336|FG000|Overall Study|Adverse Event|1
6033970|NCT00321763|9630337|FG001|Overall Study|Adverse Event|1
6033971|NCT00321763|9630338|FG002|Overall Study|Adverse Event|0
6033972|NCT00321763|9630339|FG003|Overall Study|Adverse Event|1
6033973|NCT00321763|9630336|FG000|Overall Study|Withdrawal by Subject|2
6033974|NCT00321763|9630337|FG001|Overall Study|Withdrawal by Subject|0
6033975|NCT00321763|9630338|FG002|Overall Study|Withdrawal by Subject|1
6033976|NCT00321763|9630339|FG003|Overall Study|Withdrawal by Subject|0
6033977|NCT00321763|9630336|FG000|Overall Study|Lost to Follow-up|3
6033978|NCT00321763|9630337|FG001|Overall Study|Lost to Follow-up|1
6033979|NCT00321763|9630338|FG002|Overall Study|Lost to Follow-up|5
6033980|NCT00321763|9630339|FG003|Overall Study|Lost to Follow-up|4
6033981|NCT00321789|9630353|FG000|Overall Study|Lost to Follow-up|4
6033982|NCT00321789|9630354|FG001|Overall Study|Lost to Follow-up|7
6033983|NCT00321789|9630353|FG000|Overall Study|Withdrawal by Subject|6
6033984|NCT00321789|9630354|FG001|Overall Study|Withdrawal by Subject|6
6033985|NCT00321789|9630353|FG000|Overall Study|Protocol Violation|5
6033986|NCT00321789|9630354|FG001|Overall Study|Protocol Violation|3
6033987|NCT00321828|9630360|FG000|Overall Study|Ineligible|3
6033988|NCT00321828|9630360|FG000|Overall Study|No follow up data|1
6033989|NCT00321854|9630366|FG000|Overall Study|Adverse Event|41
6033990|NCT00321854|9630367|FG001|Overall Study|Adverse Event|43
6033991|NCT00321854|9630366|FG000|Overall Study|Lack of Efficacy|9
6033992|NCT00321854|9630367|FG001|Overall Study|Lack of Efficacy|14
6033993|NCT00321854|9630366|FG000|Overall Study|Protocol Violation|6
6033994|NCT00321854|9630367|FG001|Overall Study|Protocol Violation|5
6033995|NCT00321854|9630366|FG000|Overall Study|Lost to Follow-up|0
6033996|NCT00321854|9630367|FG001|Overall Study|Lost to Follow-up|2
6033997|NCT00321854|9630366|FG000|Overall Study|Withdrawal by Subject|6
6033998|NCT00321854|9630367|FG001|Overall Study|Withdrawal by Subject|17
6033999|NCT00321854|9630366|FG000|Overall Study|Other|1
6034000|NCT00321854|9630367|FG001|Overall Study|Other|1
6034001|NCT00321893|9630377|FG000|Overall Study|Non-Compliance/Refusal|16
6034002|NCT00321893|9630378|FG001|Overall Study|Non-Compliance/Refusal|10
6034003|NCT00321893|9630377|FG000|Overall Study|Lost to Follow-up|2
6034004|NCT00321893|9630378|FG001|Overall Study|Lost to Follow-up|1
6034005|NCT00321893|9630377|FG000|Overall Study|Adverse Event|6
6034006|NCT00321893|9630378|FG001|Overall Study|Adverse Event|3
6034007|NCT00321906|9630386|FG000|Overall Study|Adverse Event|36
6034008|NCT00321906|9630387|FG001|Overall Study|Adverse Event|44
6034009|NCT00321906|9630386|FG000|Overall Study|Death|9
6034010|NCT00321906|9630387|FG001|Overall Study|Death|6
6034011|NCT00321906|9630386|FG000|Overall Study|Lost to Follow-up|1
6034012|NCT00321906|9630387|FG001|Overall Study|Lost to Follow-up|2
6034013|NCT00321906|9630386|FG000|Overall Study|Withdrawal by Subject|0
6034014|NCT00321906|9630387|FG001|Overall Study|Withdrawal by Subject|4
6034015|NCT00321919|9630395|FG000|Overall Study|Adverse Event|17
6034016|NCT00321919|9630396|FG001|Overall Study|Adverse Event|10
6034017|NCT00321919|9630395|FG000|Overall Study|Death|21
6034018|NCT00321919|9630396|FG001|Overall Study|Death|17
6034019|NCT00321919|9630395|FG000|Overall Study|Insufficient Therapeutic Response|1
6034020|NCT00321919|9630396|FG001|Overall Study|Insufficient Therapeutic Response|0
6034021|NCT00321919|9630395|FG000|Overall Study|Violation of Selection Criteria at Entry|1
6034022|NCT00321919|9630396|FG001|Overall Study|Violation of Selection Criteria at Entry|1
6034023|NCT00321919|9630395|FG000|Overall Study|Refused Treatment|23
6034024|NCT00321919|9630396|FG001|Overall Study|Refused Treatment|14
6034025|NCT00321919|9630395|FG000|Overall Study|Other Protocol Violation|2
6034026|NCT00321919|9630396|FG001|Overall Study|Other Protocol Violation|3
6034027|NCT00321919|9630395|FG000|Overall Study|Failure to Return|3
6034028|NCT00321919|9630396|FG001|Overall Study|Failure to Return|1
6034029|NCT00321919|9630395|FG000|Overall Study|Other withdrawal reason|7
6034030|NCT00321919|9630396|FG001|Overall Study|Other withdrawal reason|6
6048751|NCT00420303|9648059|FG001|Overall Study|Lack of Efficacy|3
6048752|NCT00420303|9648058|FG000|Overall Study|Physician Decision|0
6048753|NCT00420303|9648059|FG001|Overall Study|Physician Decision|1
6048754|NCT00420316|9648067|FG000|Overall Study|Withdrawal by Subject|0
6048755|NCT00420316|9648068|FG001|Overall Study|Withdrawal by Subject|1
6048756|NCT00420316|9648067|FG000|Overall Study|Lost to Follow-up|12
6146885|NCT01079741|9781875|FG001|Cohort 2: Dose Level 2 (Weeks 13-24)|Disease Progression|1
6146886|NCT01079741|9781876|FG002|Cohort 2: Dose Level 2 (Weeks 13-24)|Disease Progression|0
6048757|NCT00420316|9648068|FG001|Overall Study|Lost to Follow-up|8
6048758|NCT00420342|9648077|FG000|Overall Study|Lost to Follow-up|1
6048759|NCT00420342|9648078|FG001|Overall Study|Lost to Follow-up|0
6048760|NCT00420342|9648079|FG002|Overall Study|Lost to Follow-up|1
6048761|NCT00420342|9648077|FG000|Overall Study|Withdrawal by Subject|0
6048762|NCT00420342|9648078|FG001|Overall Study|Withdrawal by Subject|2
6048763|NCT00420342|9648079|FG002|Overall Study|Withdrawal by Subject|0
6048764|NCT00420381|9648087|FG000|Overall Study|Protocol Violation|1
6048765|NCT00420407|9648093|FG000|Overall Study|Lost to Follow-up|0
6048766|NCT00420407|9648094|FG001|Overall Study|Lost to Follow-up|3
6048767|NCT00420407|9648093|FG000|Overall Study|Physician Decision|2
6048768|NCT00420407|9648094|FG001|Overall Study|Physician Decision|1
6048769|NCT00420407|9648093|FG000|Overall Study|subject identified as detainee|1
6048770|NCT00420407|9648094|FG001|Overall Study|subject identified as detainee|0
6048771|NCT00420407|9648093|FG000|Overall Study|subject identified as Jehovah's witness|1
6048772|NCT00420407|9648094|FG001|Overall Study|subject identified as Jehovah's witness|0
6048773|NCT00420407|9648093|FG000|Overall Study|Withdrawal by Subject|0
6048774|NCT00420407|9648094|FG001|Overall Study|Withdrawal by Subject|2
6048775|NCT00420420|9648103|FG000|Overall Study|Adverse Event|5
6048776|NCT00420420|9648104|FG001|Overall Study|Adverse Event|3
6048777|NCT00420420|9648103|FG000|Overall Study|Protocol Violation|1
6048778|NCT00420420|9648104|FG001|Overall Study|Protocol Violation|1
6048779|NCT00420420|9648103|FG000|Overall Study|Withdrawal by Subject|1
6048780|NCT00420420|9648104|FG001|Overall Study|Withdrawal by Subject|0
6048781|NCT00420420|9648103|FG000|Overall Study|sponsor decision (abnormal ECG @ screen)|1
6048782|NCT00420420|9648104|FG001|Overall Study|sponsor decision (abnormal ECG @ screen)|0
6048783|NCT00420511|9648118|FG000|Overall Study|Adverse Event|1
6048784|NCT00420511|9648119|FG001|Overall Study|Adverse Event|1
6048785|NCT00420511|9648118|FG000|Overall Study|Lost to Follow-up|1
6048786|NCT00420511|9648119|FG001|Overall Study|Lost to Follow-up|0
6048787|NCT00420628|9648129|FG000|Overall Study|Withdrawn by parent or gaurdian|5
6048788|NCT00420628|9648130|FG001|Overall Study|Withdrawn by parent or gaurdian|2
6048789|NCT00420628|9648129|FG000|Overall Study|Lost to Follow-up|3
6048790|NCT00420628|9648130|FG001|Overall Study|Lost to Follow-up|2
6048791|NCT00420628|9648129|FG000|Overall Study|Adverse Event|1
6048792|NCT00420628|9648130|FG001|Overall Study|Adverse Event|0
6048793|NCT00420641|9648139|FG000|Overall Study|Adverse Event|3
6146887|NCT01079741|9781877|FG003|Cohort 2: Dose Level 2 (Weeks 13-24)|Disease Progression|0
6146888|NCT01079741|9781878|FG004|Cohort 2: Dose Level 2 (Weeks 13-24)|Disease Progression|0
6146889|NCT01079741|9781874|FG000|Phase 2 (Weeks 37-48)|Withdrawal by Subject|0
6146890|NCT01079741|9781875|FG001|Phase 2 (Weeks 37-48)|Withdrawal by Subject|0
6146891|NCT01079741|9781876|FG002|Phase 2 (Weeks 37-48)|Withdrawal by Subject|0
6146892|NCT01079741|9781877|FG003|Phase 2 (Weeks 37-48)|Withdrawal by Subject|0
6146893|NCT01079741|9781878|FG004|Phase 2 (Weeks 37-48)|Withdrawal by Subject|3
6146894|NCT01079806|9781892|FG000|Day 1 to Week 96|Adverse Event|0
6146895|NCT01079806|9781893|FG001|Day 1 to Week 96|Adverse Event|3
6146896|NCT01079806|9781892|FG000|Day 1 to Week 96|Withdrawal by Subject|3
6146897|NCT01079806|9781893|FG001|Day 1 to Week 96|Withdrawal by Subject|2
6146898|NCT01079806|9781892|FG000|Day 1 to Week 96|Pregnancy|0
6146899|NCT01079806|9781893|FG001|Day 1 to Week 96|Pregnancy|1
6146900|NCT01079806|9781892|FG000|Day 1 to Week 96|Poor compliance or noncompliance|2
6146901|NCT01079806|9781893|FG001|Day 1 to Week 96|Poor compliance or noncompliance|0
6146902|NCT01079806|9781892|FG000|Day 1 to Week 96|Lost to Follow-up|1
6146903|NCT01079806|9781893|FG001|Day 1 to Week 96|Lost to Follow-up|0
6146904|NCT01079806|9781892|FG000|Day 1 to Week 96|Subject request to stop study treatment|1
6146905|NCT01079806|9781893|FG001|Day 1 to Week 96|Subject request to stop study treatment|0
6146906|NCT01079806|9781892|FG000|Day 1 to Week 96|Removal by Medical Monitor|0
6146907|NCT01079806|9781893|FG001|Day 1 to Week 96|Removal by Medical Monitor|1
6146908|NCT01079806|9781892|FG000|Long-term Follow-up: Day 1-End of Study|Withdrawal by Subject|13
6146909|NCT01079806|9781893|FG001|Long-term Follow-up: Day 1-End of Study|Withdrawal by Subject|8
6146910|NCT01079806|9781892|FG000|Long-term Follow-up: Day 1-End of Study|Investigator Left Institution|0
6146911|NCT01079806|9781893|FG001|Long-term Follow-up: Day 1-End of Study|Investigator Left Institution|1
6146912|NCT01079806|9781892|FG000|Long-term Follow-up: Day 1-End of Study|Lost to Follow-up|6
6048794|NCT00420641|9648140|FG001|Overall Study|Adverse Event|25
6048795|NCT00420641|9648141|FG002|Overall Study|Adverse Event|10
6048796|NCT00420641|9648139|FG000|Overall Study|Lost to Follow-up|2
6048797|NCT00420641|9648140|FG001|Overall Study|Lost to Follow-up|4
6048798|NCT00420641|9648141|FG002|Overall Study|Lost to Follow-up|2
6048799|NCT00420641|9648139|FG000|Overall Study|Protocol Violation|8
6048800|NCT00420641|9648140|FG001|Overall Study|Protocol Violation|8
6048801|NCT00420641|9648141|FG002|Overall Study|Protocol Violation|7
6034031|NCT00321932|9630405|FG000|Overall Study|Death|3
6034032|NCT00321932|9630406|FG001|Overall Study|Death|6
6034033|NCT00321932|9630405|FG000|Overall Study|Withdrawal by Subject|3
6034034|NCT00321932|9630406|FG001|Overall Study|Withdrawal by Subject|6
6034035|NCT00321932|9630405|FG000|Overall Study|Early relapse|2
6034036|NCT00321932|9630406|FG001|Overall Study|Early relapse|8
6034037|NCT00321932|9630405|FG000|Overall Study|Missing data|2
6034038|NCT00321932|9630406|FG001|Overall Study|Missing data|1
6034039|NCT00321984|9630425|FG000|Overall Study|Adverse Event|9
6034040|NCT00321984|9630426|FG001|Overall Study|Adverse Event|6
6034041|NCT00321984|9630427|FG002|Overall Study|Adverse Event|8
6034042|NCT00321984|9630425|FG000|Overall Study|Protocol Violation|0
6034043|NCT00321984|9630426|FG001|Overall Study|Protocol Violation|1
6034044|NCT00321984|9630427|FG002|Overall Study|Protocol Violation|1
6034045|NCT00321984|9630425|FG000|Overall Study|Lost to Follow-up|2
6034046|NCT00321984|9630426|FG001|Overall Study|Lost to Follow-up|4
6034047|NCT00321984|9630427|FG002|Overall Study|Lost to Follow-up|2
6034048|NCT00321984|9630425|FG000|Overall Study|Withdrawal by Subject|8
6034049|NCT00321984|9630426|FG001|Overall Study|Withdrawal by Subject|6
6034050|NCT00321984|9630427|FG002|Overall Study|Withdrawal by Subject|5
6034051|NCT00321984|9630425|FG000|Overall Study|Unmet Inclusion/Exclusion Criteria|3
6034052|NCT00321984|9630426|FG001|Overall Study|Unmet Inclusion/Exclusion Criteria|1
6034053|NCT00321984|9630427|FG002|Overall Study|Unmet Inclusion/Exclusion Criteria|5
6034054|NCT00321984|9630425|FG000|Overall Study|Lack of Efficacy|3
6034055|NCT00321984|9630426|FG001|Overall Study|Lack of Efficacy|1
6034056|NCT00321984|9630427|FG002|Overall Study|Lack of Efficacy|3
6034057|NCT00321984|9630425|FG000|Overall Study|Noncompliant|0
6034058|NCT00321984|9630426|FG001|Overall Study|Noncompliant|0
6034059|NCT00321984|9630427|FG002|Overall Study|Noncompliant|2
6034060|NCT00321984|9630425|FG000|Overall Study|Pregnancy|0
6034061|NCT00321984|9630426|FG001|Overall Study|Pregnancy|1
6034062|NCT00321984|9630427|FG002|Overall Study|Pregnancy|0
6034063|NCT00321984|9630425|FG000|Overall Study|Per Subject Request|1
6034064|NCT00321984|9630426|FG001|Overall Study|Per Subject Request|0
6034065|NCT00321984|9630427|FG002|Overall Study|Per Subject Request|0
6034066|NCT00321984|9630425|FG000|Overall Study|Per Investigator Request|1
6034067|NCT00321984|9630426|FG001|Overall Study|Per Investigator Request|0
6034068|NCT00321984|9630427|FG002|Overall Study|Per Investigator Request|0
6034069|NCT00321984|9630425|FG000|Overall Study|Per Sponsor Due to High Baseline Gastrin|0
6034070|NCT00321984|9630426|FG001|Overall Study|Per Sponsor Due to High Baseline Gastrin|1
6034071|NCT00321984|9630427|FG002|Overall Study|Per Sponsor Due to High Baseline Gastrin|0
6034072|NCT00322023|9630438|FG000|Overall Study|various|0
6034073|NCT00322023|9630439|FG001|Overall Study|various|2
6034074|NCT00322023|9630440|FG002|Overall Study|various|6
6034075|NCT00322049|9630452|FG000|Overall Study|Moved out of area|0
6034076|NCT00322049|9630453|FG001|Overall Study|Moved out of area|0
6034077|NCT00322049|9630454|FG002|Overall Study|Moved out of area|0
6034078|NCT00322049|9630455|FG003|Overall Study|Moved out of area|1
6034079|NCT00322049|9630452|FG000|Overall Study|Infected with Dengue during study|0
6034080|NCT00322049|9630453|FG001|Overall Study|Infected with Dengue during study|1
6034081|NCT00322049|9630454|FG002|Overall Study|Infected with Dengue during study|0
6034082|NCT00322049|9630455|FG003|Overall Study|Infected with Dengue during study|0
6034083|NCT00322153|9630485|FG000|Overall Study|Adverse Event|21
6034084|NCT00322153|9630486|FG001|Overall Study|Adverse Event|34
6034085|NCT00322153|9630485|FG000|Overall Study|Protocol Violation|6
6034086|NCT00322153|9630486|FG001|Overall Study|Protocol Violation|14
6034087|NCT00322153|9630485|FG000|Overall Study|Withdrawal by Subject|18
6034088|NCT00322153|9630486|FG001|Overall Study|Withdrawal by Subject|10
6034089|NCT00322153|9630485|FG000|Overall Study|Lack of Efficacy|8
6034090|NCT00322153|9630486|FG001|Overall Study|Lack of Efficacy|3
6034091|NCT00322153|9630485|FG000|Overall Study|Lost to Follow-up|5
6034092|NCT00322153|9630486|FG001|Overall Study|Lost to Follow-up|4
6034093|NCT00322153|9630485|FG000|Overall Study|Withdrawn for other reasons|5
6034094|NCT00322153|9630486|FG001|Overall Study|Withdrawn for other reasons|4
6034095|NCT00322348|9630532|FG000|Overall Study|Adverse Event|0
6034096|NCT00322348|9630533|FG001|Overall Study|Adverse Event|1
6034097|NCT00322348|9630532|FG000|Overall Study|Withdrawal by Subject|1
6034098|NCT00322348|9630533|FG001|Overall Study|Withdrawal by Subject|4
6034099|NCT00322348|9630532|FG000|Overall Study|Lost to Follow-up|1
6034100|NCT00322348|9630533|FG001|Overall Study|Lost to Follow-up|0
6034101|NCT00322348|9630532|FG000|Overall Study|Death|0
6034102|NCT00322348|9630533|FG001|Overall Study|Death|2
6034103|NCT00322348|9630532|FG000|Overall Study|Disease Progression|30
6034104|NCT00322348|9630533|FG001|Overall Study|Disease Progression|25
6034105|NCT00322348|9630532|FG000|Overall Study|Reasons not specified|5
6034106|NCT00322348|9630533|FG001|Overall Study|Reasons not specified|1
6034107|NCT00322374|9630542|FG000|Starting Dose|Physician Decision|2
6309559|NCT02640612|10038249|FG002|Overall Study|Protocol Violation|0
6309560|NCT02640612|10038247|FG000|Overall Study|Lack of Efficacy|1
6309561|NCT02640612|10038248|FG001|Overall Study|Lack of Efficacy|1
6034108|NCT00322374|9630543|FG001|Starting Dose|Physician Decision|0
6034109|NCT00322374|9630544|FG002|Starting Dose|Physician Decision|0
6034110|NCT00322374|9630545|FG003|Starting Dose|Physician Decision|0
6034111|NCT00322374|9630542|FG000|Starting Dose|Study Drug Toxicity|4
6034112|NCT00322374|9630543|FG001|Starting Dose|Study Drug Toxicity|0
6034113|NCT00322374|9630544|FG002|Starting Dose|Study Drug Toxicity|0
6034114|NCT00322374|9630545|FG003|Starting Dose|Study Drug Toxicity|0
6034115|NCT00322374|9630542|FG000|First Escalation|Documented Disease Progression|0
6034116|NCT00322374|9630543|FG001|First Escalation|Documented Disease Progression|6
6034117|NCT00322374|9630544|FG002|First Escalation|Documented Disease Progression|0
6034118|NCT00322374|9630545|FG003|First Escalation|Documented Disease Progression|0
6034119|NCT00322374|9630542|FG000|First Escalation|Physician Decision|0
6034120|NCT00322374|9630543|FG001|First Escalation|Physician Decision|12
6034121|NCT00322374|9630544|FG002|First Escalation|Physician Decision|0
6034122|NCT00322374|9630545|FG003|First Escalation|Physician Decision|0
6034123|NCT00322374|9630542|FG000|First Escalation|Study Drug Toxicity|0
6034124|NCT00322374|9630543|FG001|First Escalation|Study Drug Toxicity|11
6034125|NCT00322374|9630544|FG002|First Escalation|Study Drug Toxicity|0
6034126|NCT00322374|9630545|FG003|First Escalation|Study Drug Toxicity|0
6034127|NCT00322374|9630542|FG000|First Escalation|Participant Request|0
6034128|NCT00322374|9630543|FG001|First Escalation|Participant Request|1
6034129|NCT00322374|9630544|FG002|First Escalation|Participant Request|0
6034130|NCT00322374|9630545|FG003|First Escalation|Participant Request|0
6034131|NCT00322374|9630542|FG000|Second Escalation|Physician Decision|0
6034132|NCT00322374|9630543|FG001|Second Escalation|Physician Decision|0
6034133|NCT00322374|9630544|FG002|Second Escalation|Physician Decision|5
6034134|NCT00322374|9630545|FG003|Second Escalation|Physician Decision|0
6034135|NCT00322374|9630542|FG000|Second Escalation|Study Drug Toxicity|0
6034136|NCT00322374|9630543|FG001|Second Escalation|Study Drug Toxicity|0
6034137|NCT00322374|9630544|FG002|Second Escalation|Study Drug Toxicity|1
6034138|NCT00322374|9630545|FG003|Second Escalation|Study Drug Toxicity|0
6034139|NCT00322387|9630560|FG000|Treatment Period|Adverse Event|0
6034140|NCT00322387|9630561|FG001|Treatment Period|Adverse Event|1
6034141|NCT00322387|9630560|FG000|Follow-up Period|Final assessment not done|1
6034142|NCT00322387|9630561|FG001|Follow-up Period|Final assessment not done|3
6034143|NCT00322387|9630560|FG000|Follow-up Period|Death|1
6034144|NCT00322387|9630561|FG001|Follow-up Period|Death|0
6034145|NCT00322452|9630584|FG000|Overall Study|Eligibility criteria not fulfilled|0
6034146|NCT00322452|9630585|FG001|Overall Study|Eligibility criteria not fulfilled|1
6034147|NCT00322452|9630584|FG000|Overall Study|Lost to Follow-up|5
6034148|NCT00322452|9630585|FG001|Overall Study|Lost to Follow-up|2
6034149|NCT00322452|9630584|FG000|Overall Study|Withdrawal by Subject|19
6034150|NCT00322452|9630585|FG001|Overall Study|Withdrawal by Subject|46
6034151|NCT00322452|9630584|FG000|Overall Study|Death|223
6034152|NCT00322452|9630585|FG001|Overall Study|Death|227
6034153|NCT00322491|9630613|FG000|Overall Study|Adverse Event|1
6034154|NCT00322491|9630614|FG001|Overall Study|Adverse Event|0
6034155|NCT00322491|9630613|FG000|Overall Study|Death|1
6034156|NCT00322491|9630614|FG001|Overall Study|Death|2
6034157|NCT00322556|9630621|FG000|Overall Study|Adverse Event|1
6034158|NCT00322556|9630621|FG000|Overall Study|Withdrawal by Subject|1
6034159|NCT00322556|9630621|FG000|Overall Study|Lost to Follow-up|3
6034160|NCT00322556|9630621|FG000|Overall Study|Other Reason|7
6034161|NCT00322621|9630628|FG000|Period II - Acute Therapy Phase|Adverse Event|20
6034162|NCT00322621|9630629|FG001|Period II - Acute Therapy Phase|Adverse Event|0
6034163|NCT00322621|9630630|FG002|Period II - Acute Therapy Phase|Adverse Event|0
6034164|NCT00322621|9630628|FG000|Period II - Acute Therapy Phase|Lack of Efficacy|1
6034165|NCT00322621|9630629|FG001|Period II - Acute Therapy Phase|Lack of Efficacy|0
6034166|NCT00322621|9630630|FG002|Period II - Acute Therapy Phase|Lack of Efficacy|0
6034167|NCT00322621|9630628|FG000|Period II - Acute Therapy Phase|Withdrawal by Subject|8
6034168|NCT00322621|9630629|FG001|Period II - Acute Therapy Phase|Withdrawal by Subject|0
6034169|NCT00322621|9630630|FG002|Period II - Acute Therapy Phase|Withdrawal by Subject|0
6034170|NCT00322621|9630628|FG000|Period II - Acute Therapy Phase|Protocol Violation|2
6034171|NCT00322621|9630629|FG001|Period II - Acute Therapy Phase|Protocol Violation|0
6034172|NCT00322621|9630630|FG002|Period II - Acute Therapy Phase|Protocol Violation|0
6034173|NCT00322621|9630628|FG000|Period II - Acute Therapy Phase|Physician Decision|1
6034174|NCT00322621|9630629|FG001|Period II - Acute Therapy Phase|Physician Decision|0
6034175|NCT00322621|9630630|FG002|Period II - Acute Therapy Phase|Physician Decision|0
6034176|NCT00322621|9630628|FG000|Period III - Maintenance / Rescue Phase|Adverse Event|0
6309562|NCT02640612|10038249|FG002|Overall Study|Lack of Efficacy|0
6309563|NCT02640755|10038268|FG000|Multiple Dose Period (Day 8 - EoS)|Condition under investigation worsened|0
6309564|NCT02640755|10038269|FG001|Multiple Dose Period (Day 8 - EoS)|Condition under investigation worsened|1
6309565|NCT02640755|10038268|FG000|Multiple Dose Period (Day 8 - EoS)|Subjective progression of disease|1
6309566|NCT02640755|10038269|FG001|Multiple Dose Period (Day 8 - EoS)|Subjective progression of disease|0
6309567|NCT02640755|10038268|FG000|Multiple Dose Period (Day 8 - EoS)|Withdrawal by Subject|1
6309568|NCT02640755|10038269|FG001|Multiple Dose Period (Day 8 - EoS)|Withdrawal by Subject|0
6309569|NCT02641080|10038300|FG000|Overall Study|Physician Decision|2
6309570|NCT02641080|10038301|FG001|Overall Study|Physician Decision|0
6309571|NCT02641080|10038300|FG000|Overall Study|Withdrawal by Subject|0
6309572|NCT02641080|10038301|FG001|Overall Study|Withdrawal by Subject|1
6309573|NCT02641080|10038300|FG000|Overall Study|Rehab Center denied use of pumps|0
6309574|NCT02641080|10038301|FG001|Overall Study|Rehab Center denied use of pumps|3
6034177|NCT00322621|9630629|FG001|Period III - Maintenance / Rescue Phase|Adverse Event|14
6034178|NCT00322621|9630630|FG002|Period III - Maintenance / Rescue Phase|Adverse Event|5
6309575|NCT02641080|10038300|FG000|Overall Study|Lost to Follow-up|0
6309576|NCT02641080|10038301|FG001|Overall Study|Lost to Follow-up|3
6309577|NCT02641379|10038339|FG000|Overall Study|Exclusion criterion during screening|1
6309578|NCT02641379|10038340|FG001|Overall Study|Exclusion criterion during screening|0
6309579|NCT02641379|10038341|FG002|Overall Study|Exclusion criterion during screening|0
6309580|NCT02641379|10038342|FG003|Overall Study|Exclusion criterion during screening|1
6309581|NCT02641379|10038343|FG004|Overall Study|Exclusion criterion during screening|2
6309582|NCT02641379|10038344|FG005|Overall Study|Exclusion criterion during screening|0
6309583|NCT02641379|10038345|FG006|Overall Study|Exclusion criterion during screening|0
6309584|NCT02641379|10038346|FG007|Overall Study|Exclusion criterion during screening|0
6309585|NCT02641379|10038347|FG008|Overall Study|Exclusion criterion during screening|0
6309586|NCT02641379|10038348|FG009|Overall Study|Exclusion criterion during screening|0
6309587|NCT02641379|10038349|FG010|Overall Study|Exclusion criterion during screening|0
6034179|NCT00322621|9630628|FG000|Period III - Maintenance / Rescue Phase|Lack of Efficacy|0
6034180|NCT00322621|9630629|FG001|Period III - Maintenance / Rescue Phase|Lack of Efficacy|4
6034181|NCT00322621|9630630|FG002|Period III - Maintenance / Rescue Phase|Lack of Efficacy|24
6034182|NCT00322621|9630628|FG000|Period III - Maintenance / Rescue Phase|Withdrawal by Subject|0
6034183|NCT00322621|9630629|FG001|Period III - Maintenance / Rescue Phase|Withdrawal by Subject|7
6034184|NCT00322621|9630630|FG002|Period III - Maintenance / Rescue Phase|Withdrawal by Subject|1
6034185|NCT00322621|9630628|FG000|Period III - Maintenance / Rescue Phase|Protocol Violation|0
6034186|NCT00322621|9630629|FG001|Period III - Maintenance / Rescue Phase|Protocol Violation|2
6034187|NCT00322621|9630630|FG002|Period III - Maintenance / Rescue Phase|Protocol Violation|5
6034188|NCT00322621|9630628|FG000|Period III - Maintenance / Rescue Phase|Death|0
6034189|NCT00322621|9630629|FG001|Period III - Maintenance / Rescue Phase|Death|1
6034190|NCT00322621|9630630|FG002|Period III - Maintenance / Rescue Phase|Death|0
6034191|NCT00322621|9630628|FG000|Period III - Maintenance / Rescue Phase|Lost to Follow-up|0
6034192|NCT00322621|9630629|FG001|Period III - Maintenance / Rescue Phase|Lost to Follow-up|1
6034193|NCT00322621|9630630|FG002|Period III - Maintenance / Rescue Phase|Lost to Follow-up|1
6034194|NCT00322712|9630643|FG000|Overall Study|treated with bevacizumab not cetuximab|1
6034195|NCT00322842|9630658|FG000|Overall Study|Withdrawal by Subject|0
6034196|NCT00322842|9630659|FG001|Overall Study|Withdrawal by Subject|1
6034197|NCT00322842|9630658|FG000|Overall Study|Lost to Follow-up|0
6034198|NCT00322842|9630659|FG001|Overall Study|Lost to Follow-up|1
6034199|NCT00322842|9630658|FG000|Overall Study|Refused transplant|1
6034200|NCT00322842|9630659|FG001|Overall Study|Refused transplant|0
6034201|NCT00322842|9630658|FG000|Overall Study|Death|1
6034202|NCT00322842|9630659|FG001|Overall Study|Death|0
6034203|NCT00322868|9630666|FG000|Overall Study|disease progression|1
6034204|NCT00322881|9630671|FG000|Overall Study|Death|2
6034205|NCT00322881|9630671|FG000|Overall Study|Adverse Event|1
6034206|NCT00322881|9630671|FG000|Overall Study|Disease Progression|2
6034207|NCT00323063|9630677|FG000|Overall Study|Adverse Event|1
6034208|NCT00323063|9630678|FG001|Overall Study|Adverse Event|0
6034209|NCT00323063|9630677|FG000|Overall Study|brain mets discovered prior to treatment|1
6034210|NCT00323063|9630678|FG001|Overall Study|brain mets discovered prior to treatment|0
6034211|NCT00323115|9630684|FG000|Vaccine Administration|Adverse Event|1
6034212|NCT00323115|9630684|FG000|Adjuvant Therapy & Survival Follow-Up|Death|8
6034213|NCT00323258|9630704|FG000|Primary Outcome (Phone Call at 6 Months)|Death|1
6034214|NCT00323258|9630705|FG001|Primary Outcome (Phone Call at 6 Months)|Death|2
6034215|NCT00323258|9630704|FG000|Primary Outcome (Phone Call at 6 Months)|Lost to Follow-up|12
6034216|NCT00323258|9630705|FG001|Primary Outcome (Phone Call at 6 Months)|Lost to Follow-up|11
6034217|NCT00323258|9630704|FG000|Primary Outcome (Phone Call at 6 Months)|Withdrawal by Subject|1
6034218|NCT00323258|9630705|FG001|Primary Outcome (Phone Call at 6 Months)|Withdrawal by Subject|5
6034219|NCT00323258|9630704|FG000|Primary Outcome (Phone Call at 6 Months)|Died between 180-240 days (call period)|2
6034220|NCT00323258|9630705|FG001|Primary Outcome (Phone Call at 6 Months)|Died between 180-240 days (call period)|1
6034221|NCT00323258|9630704|FG000|Secondary Outcome (6 Mon Refill Records)|Death|1
6034222|NCT00323258|9630705|FG001|Secondary Outcome (6 Mon Refill Records)|Death|2
6034223|NCT00323258|9630704|FG000|Secondary Outcome (6 Mon Refill Records)|Lost to Follow-up|12
6034224|NCT00323258|9630705|FG001|Secondary Outcome (6 Mon Refill Records)|Lost to Follow-up|10
6034225|NCT00323258|9630704|FG000|Secondary Outcome (6 Mon Refill Records)|Withdrawal by Subject|1
6034226|NCT00323258|9630705|FG001|Secondary Outcome (6 Mon Refill Records)|Withdrawal by Subject|2
6034227|NCT00323297|9630731|FG000|Part A (Double Blind Randomized)|Reason unspecified|0
6034228|NCT00323297|9630732|FG001|Part A (Double Blind Randomized)|Reason unspecified|1
6034229|NCT00323297|9630731|FG000|Part A (Double Blind Randomized)|Death|0
6034230|NCT00323297|9630732|FG001|Part A (Double Blind Randomized)|Death|1
6034231|NCT00323297|9630731|FG000|Part A (Double Blind Randomized)|Protocol Violation|1
6034232|NCT00323297|9630732|FG001|Part A (Double Blind Randomized)|Protocol Violation|3
6034233|NCT00323297|9630731|FG000|Part A (Double Blind Randomized)|Unrelated adverse event|1
6034234|NCT00323297|9630732|FG001|Part A (Double Blind Randomized)|Unrelated adverse event|0
6034235|NCT00323297|9630731|FG000|Part A (Double Blind Randomized)|Related and Unrelated adverse event|1
6034236|NCT00323297|9630732|FG001|Part A (Double Blind Randomized)|Related and Unrelated adverse event|0
6309588|NCT02641379|10038339|FG000|Overall Study|Withdrawal of informed consent|0
6034237|NCT00323297|9630731|FG000|Part A (Double Blind Randomized)|Related adverse event|2
6034238|NCT00323297|9630732|FG001|Part A (Double Blind Randomized)|Related adverse event|2
6034239|NCT00323297|9630731|FG000|Part B (Open-label)|Death|0
6034240|NCT00323297|9630732|FG001|Part B (Open-label)|Death|1
6146913|NCT01079806|9781893|FG001|Long-term Follow-up: Day 1-End of Study|Lost to Follow-up|6
6146914|NCT01079832|9781901|FG000|Overall Study|Withdrawal by Subject|1
6146915|NCT01079936|9781909|FG000|Phase I: MTD|First Remission Status|2
6146916|NCT01079936|9781910|FG001|Phase I: MTD|First Remission Status|0
6146917|NCT01079936|9781911|FG002|Phase I: MTD|First Remission Status|0
6146918|NCT01079936|9781912|FG003|Phase I: MTD|First Remission Status|0
6034241|NCT00323297|9630731|FG000|Part B (Open-label)|Reason unspecified|0
6034242|NCT00323297|9630732|FG001|Part B (Open-label)|Reason unspecified|1
6034243|NCT00323297|9630731|FG000|Part B (Open-label)|Withdrawal by Subject|1
6034244|NCT00323297|9630732|FG001|Part B (Open-label)|Withdrawal by Subject|3
6034245|NCT00323297|9630731|FG000|Part B (Open-label)|Lack of Efficacy|3
6034246|NCT00323297|9630732|FG001|Part B (Open-label)|Lack of Efficacy|1
6034247|NCT00323297|9630731|FG000|Part B (Open-label)|Adverse Event|5
6034248|NCT00323297|9630732|FG001|Part B (Open-label)|Adverse Event|5
6034249|NCT00323297|9630731|FG000|Part B (Open-label)|Protocol Violation|0
6034250|NCT00323297|9630732|FG001|Part B (Open-label)|Protocol Violation|1
6034251|NCT00323310|9630738|FG000|Overall Study|Withdrawal by Subject|1
6034252|NCT00323310|9630738|FG000|Overall Study|a parent refused blood draw|1
6034253|NCT00323310|9630738|FG000|Overall Study|did not complete the 24-hr f-up visit|1
6034254|NCT00323414|9630748|FG000|Overall Study|Withdrawal by Subject|0
6034255|NCT00323414|9630749|FG001|Overall Study|Withdrawal by Subject|1
6034256|NCT00323479|9630773|FG000|Overall Study|Adverse Event|2
6034257|NCT00323479|9630773|FG000|Overall Study|Withdrawal by Subject|2
6034258|NCT00323479|9630773|FG000|Overall Study|Protocol Violation|3
6034259|NCT00323479|9630773|FG000|Overall Study|house moving|1
6034260|NCT00323492|9630779|FG000|Study Phase 1|Adverse Event|2
6034261|NCT00323492|9630780|FG001|Study Phase 1|Adverse Event|0
6034262|NCT00323492|9630781|FG002|Study Phase 1|Adverse Event|0
6034263|NCT00323492|9630779|FG000|Study Phase 2|Adverse Event|1
6034264|NCT00323492|9630780|FG001|Study Phase 2|Adverse Event|0
6034265|NCT00323492|9630781|FG002|Study Phase 2|Adverse Event|0
6034266|NCT00323492|9630779|FG000|Study Phase 2|Physician Decision|1
6034267|NCT00323492|9630780|FG001|Study Phase 2|Physician Decision|0
6034268|NCT00323492|9630781|FG002|Study Phase 2|Physician Decision|0
6034269|NCT00323492|9630779|FG000|Study Phase 2|Lost to Follow-up|1
6034270|NCT00323492|9630780|FG001|Study Phase 2|Lost to Follow-up|0
6034271|NCT00323492|9630781|FG002|Study Phase 2|Lost to Follow-up|0
6034272|NCT00323492|9630779|FG000|Study Phase 2|Withdrawal by Subject|0
6034273|NCT00323492|9630780|FG001|Study Phase 2|Withdrawal by Subject|1
6034274|NCT00323492|9630781|FG002|Study Phase 2|Withdrawal by Subject|0
6034275|NCT00323492|9630779|FG000|Study Phase 2|Noncompliance with study schedule|0
6034276|NCT00323492|9630780|FG001|Study Phase 2|Noncompliance with study schedule|0
6034277|NCT00323492|9630781|FG002|Study Phase 2|Noncompliance with study schedule|1
6034278|NCT00323492|9630779|FG000|Study Phase 2|Protocol Violation|1
6034279|NCT00323492|9630780|FG001|Study Phase 2|Protocol Violation|0
6034280|NCT00323492|9630781|FG002|Study Phase 2|Protocol Violation|0
6034281|NCT00323557|9630790|FG000|Overall Study|Physician Decision|1
6034282|NCT00323557|9630791|FG001|Overall Study|Physician Decision|0
6034283|NCT00323609|9630800|FG000|Overall Study|Death|16
6034284|NCT00323609|9630801|FG001|Overall Study|Death|21
6034285|NCT00323609|9630802|FG002|Overall Study|Death|0
6034286|NCT00323609|9630803|FG003|Overall Study|Death|0
6034287|NCT00323609|9630800|FG000|Overall Study|Lost to Follow-up|9
6034288|NCT00323609|9630801|FG001|Overall Study|Lost to Follow-up|10
6034289|NCT00323609|9630802|FG002|Overall Study|Lost to Follow-up|0
6034290|NCT00323609|9630803|FG003|Overall Study|Lost to Follow-up|0
6034291|NCT00323609|9630800|FG000|Overall Study|Physician Decision|2
6034292|NCT00323609|9630801|FG001|Overall Study|Physician Decision|0
6034293|NCT00323609|9630802|FG002|Overall Study|Physician Decision|0
6034294|NCT00323609|9630803|FG003|Overall Study|Physician Decision|1
6034295|NCT00323609|9630800|FG000|Overall Study|Withdrawal by Subject|11
6034296|NCT00323609|9630801|FG001|Overall Study|Withdrawal by Subject|23
6034297|NCT00323609|9630802|FG002|Overall Study|Withdrawal by Subject|4
6034298|NCT00323609|9630803|FG003|Overall Study|Withdrawal by Subject|4
6034299|NCT00323609|9630800|FG000|Overall Study|Other non-VCF-related medical condition|3
6034300|NCT00323609|9630801|FG001|Overall Study|Other non-VCF-related medical condition|2
6034301|NCT00323609|9630802|FG002|Overall Study|Other non-VCF-related medical condition|0
6034302|NCT00323609|9630803|FG003|Overall Study|Other non-VCF-related medical condition|0
6034303|NCT00323609|9630800|FG000|Overall Study|Sponsor discontinued trial|29
6034304|NCT00323609|9630801|FG001|Overall Study|Sponsor discontinued trial|29
6034305|NCT00323609|9630802|FG002|Overall Study|Sponsor discontinued trial|0
6034306|NCT00323609|9630803|FG003|Overall Study|Sponsor discontinued trial|0
6034307|NCT00323609|9630800|FG000|Overall Study|Unrelenting or severe back pain|1
6034308|NCT00323609|9630801|FG001|Overall Study|Unrelenting or severe back pain|1
6034309|NCT00323609|9630802|FG002|Overall Study|Unrelenting or severe back pain|0
6034310|NCT00323609|9630803|FG003|Overall Study|Unrelenting or severe back pain|0
6034311|NCT00323609|9630800|FG000|Overall Study|Logistical withdrawal|9
6146919|NCT01079936|9781913|FG004|Phase I: MTD|First Remission Status|0
6034312|NCT00323609|9630801|FG001|Overall Study|Logistical withdrawal|5
6034313|NCT00323609|9630802|FG002|Overall Study|Logistical withdrawal|0
6034314|NCT00323609|9630803|FG003|Overall Study|Logistical withdrawal|1
6034315|NCT00323609|9630800|FG000|Overall Study|Other reason|11
6034316|NCT00323609|9630801|FG001|Overall Study|Other reason|8
6034317|NCT00323609|9630802|FG002|Overall Study|Other reason|4
6034318|NCT00323609|9630803|FG003|Overall Study|Other reason|9
6034319|NCT00323622|9630817|FG000|Overall Study|Other|30
6034320|NCT00323622|9630818|FG001|Overall Study|Other|91
6034321|NCT00323622|9630819|FG002|Overall Study|Other|4
6034322|NCT00323622|9630820|FG003|Overall Study|Other|12
6034323|NCT00323622|9630821|FG004|Overall Study|Other|32
6309589|NCT02641379|10038340|FG001|Overall Study|Withdrawal of informed consent|1
6309590|NCT02641379|10038341|FG002|Overall Study|Withdrawal of informed consent|0
6309591|NCT02641379|10038342|FG003|Overall Study|Withdrawal of informed consent|0
6034324|NCT00323622|9630822|FG005|Overall Study|Other|74
6034325|NCT00323622|9630823|FG006|Overall Study|Other|5
6034326|NCT00323622|9630824|FG007|Overall Study|Other|13
6034327|NCT00323622|9630817|FG000|Overall Study|Death|1
6034328|NCT00323622|9630818|FG001|Overall Study|Death|1
6034329|NCT00323622|9630819|FG002|Overall Study|Death|0
6034330|NCT00323622|9630820|FG003|Overall Study|Death|0
6034331|NCT00323622|9630821|FG004|Overall Study|Death|7
6034332|NCT00323622|9630822|FG005|Overall Study|Death|0
6034333|NCT00323622|9630823|FG006|Overall Study|Death|0
6034334|NCT00323622|9630824|FG007|Overall Study|Death|2
6034335|NCT00323869|9630854|FG000|Overall Study|Death|1
6034336|NCT00323882|9630863|FG000|Overall Study|Adverse Event|2
6034337|NCT00323882|9630864|FG001|Overall Study|Adverse Event|1
6034338|NCT00323882|9630865|FG002|Overall Study|Adverse Event|1
6034339|NCT00323882|9630866|FG003|Overall Study|Adverse Event|1
6034340|NCT00323882|9630867|FG004|Overall Study|Adverse Event|3
6034341|NCT00323882|9630863|FG000|Overall Study|Disease Progression|6
6034342|NCT00323882|9630864|FG001|Overall Study|Disease Progression|4
6034343|NCT00323882|9630865|FG002|Overall Study|Disease Progression|10
6034344|NCT00323882|9630866|FG003|Overall Study|Disease Progression|5
6034345|NCT00323882|9630867|FG004|Overall Study|Disease Progression|22
6034346|NCT00323882|9630863|FG000|Overall Study|Death|0
6034347|NCT00323882|9630864|FG001|Overall Study|Death|1
6034348|NCT00323882|9630865|FG002|Overall Study|Death|1
6034349|NCT00323882|9630866|FG003|Overall Study|Death|0
6034350|NCT00323882|9630867|FG004|Overall Study|Death|5
6034351|NCT00323882|9630863|FG000|Overall Study|Lost to Follow-up|0
6034352|NCT00323882|9630864|FG001|Overall Study|Lost to Follow-up|0
6034353|NCT00323882|9630865|FG002|Overall Study|Lost to Follow-up|1
6034354|NCT00323882|9630866|FG003|Overall Study|Lost to Follow-up|0
6034355|NCT00323882|9630867|FG004|Overall Study|Lost to Follow-up|1
6034356|NCT00323882|9630863|FG000|Overall Study|Other|0
6034357|NCT00323882|9630864|FG001|Overall Study|Other|0
6034358|NCT00323882|9630865|FG002|Overall Study|Other|0
6034359|NCT00323882|9630866|FG003|Overall Study|Other|1
6034360|NCT00323882|9630867|FG004|Overall Study|Other|1
6034361|NCT00324038|9630906|FG000|Overall Study|Adverse Event|38
6034362|NCT00324038|9630907|FG001|Overall Study|Adverse Event|23
6034363|NCT00324038|9630906|FG000|Overall Study|Lack of Efficacy|5
6034364|NCT00324038|9630907|FG001|Overall Study|Lack of Efficacy|13
6034365|NCT00324038|9630906|FG000|Overall Study|Lost to Follow-up|0
6034366|NCT00324038|9630907|FG001|Overall Study|Lost to Follow-up|2
6034367|NCT00324038|9630906|FG000|Overall Study|Other|6
6034368|NCT00324038|9630907|FG001|Overall Study|Other|13
6034369|NCT00324116|9630913|FG000|Overall Study|Adverse Event|5
6034370|NCT00324116|9630913|FG000|Overall Study|Lack of Efficacy|17
6034371|NCT00324116|9630913|FG000|Overall Study|Withdrawal by Subject|5
6034372|NCT00324116|9630913|FG000|Overall Study|Other|5
6034373|NCT00324155|9630919|FG000|Enrolled and Randomized|No longer met study criteria|3
6034374|NCT00324155|9630920|FG001|Enrolled and Randomized|No longer met study criteria|0
6034375|NCT00324155|9630919|FG000|Enrolled and Randomized|Lost to Follow-up|0
6034376|NCT00324155|9630920|FG001|Enrolled and Randomized|Lost to Follow-up|1
6034377|NCT00324155|9630919|FG000|Received Treatment in Induction Phase|Disease Progression|88
6034378|NCT00324155|9630920|FG001|Received Treatment in Induction Phase|Disease Progression|152
6034379|NCT00324155|9630919|FG000|Received Treatment in Induction Phase|Study Drug Toxicity|83
6034380|NCT00324155|9630920|FG001|Received Treatment in Induction Phase|Study Drug Toxicity|10
6034381|NCT00324155|9630919|FG000|Received Treatment in Induction Phase|Death|8
6034382|NCT00324155|9630920|FG001|Received Treatment in Induction Phase|Death|15
6034383|NCT00324155|9630919|FG000|Received Treatment in Induction Phase|Deterioration/Undocumented Progression|9
6034384|NCT00324155|9630920|FG001|Received Treatment in Induction Phase|Deterioration/Undocumented Progression|8
6034385|NCT00324155|9630919|FG000|Received Treatment in Induction Phase|Adverse Event|6
6034386|NCT00324155|9630920|FG001|Received Treatment in Induction Phase|Adverse Event|7
6034387|NCT00324155|9630919|FG000|Received Treatment in Induction Phase|Withdrawal by Subject|6
6034388|NCT00324155|9630920|FG001|Received Treatment in Induction Phase|Withdrawal by Subject|5
6034389|NCT00324155|9630919|FG000|Received Treatment in Induction Phase|Physician Decision|2
6309592|NCT02641379|10038343|FG004|Overall Study|Withdrawal of informed consent|0
6034390|NCT00324155|9630920|FG001|Received Treatment in Induction Phase|Physician Decision|0
6034391|NCT00324155|9630919|FG000|Received Treatment in Maintenance Phase|Disease Progression|26
6034392|NCT00324155|9630920|FG001|Received Treatment in Maintenance Phase|Disease Progression|41
6034393|NCT00324155|9630919|FG000|Received Treatment in Maintenance Phase|Study Drug Toxicity|4
6034394|NCT00324155|9630920|FG001|Received Treatment in Maintenance Phase|Study Drug Toxicity|0
6034395|NCT00324155|9630919|FG000|Received Treatment in Maintenance Phase|Withdrawal by Subject|1
6034396|NCT00324155|9630920|FG001|Received Treatment in Maintenance Phase|Withdrawal by Subject|3
6034397|NCT00324155|9630919|FG000|Received Treatment in Maintenance Phase|Adverse Event|0
6034398|NCT00324155|9630920|FG001|Received Treatment in Maintenance Phase|Adverse Event|3
6034399|NCT00324155|9630919|FG000|Received Treatment in Maintenance Phase|Deterioration/Undocumented Progression|1
6034400|NCT00324155|9630920|FG001|Received Treatment in Maintenance Phase|Deterioration/Undocumented Progression|0
6034401|NCT00324155|9630919|FG000|Follow-up Phase|On-going participants still on drug|11
6034402|NCT00324155|9630920|FG001|Follow-up Phase|On-going participants still on drug|6
6034403|NCT00324168|9630941|FG000|Overall Study|Lost to Follow-up|19
6034404|NCT00324168|9630942|FG001|Overall Study|Lost to Follow-up|18
6034405|NCT00324168|9630941|FG000|Overall Study|Death|3
6034406|NCT00324168|9630942|FG001|Overall Study|Death|3
6034407|NCT00324168|9630941|FG000|Overall Study|Patient did not visit in f/u window|6
6034408|NCT00324168|9630942|FG001|Overall Study|Patient did not visit in f/u window|9
6034409|NCT00324233|9630950|FG000|First Period|unable to insert catheter|1
6034410|NCT00324233|9630951|FG001|First Period|unable to insert catheter|0
6034411|NCT00324233|9630950|FG000|Second Period|unable to insert catheter|1
6034412|NCT00324233|9630951|FG001|Second Period|unable to insert catheter|1
6034413|NCT00324233|9630950|FG000|Second Period|Protocol Violation|4
6034414|NCT00324233|9630951|FG001|Second Period|Protocol Violation|6
6034415|NCT00324649|9631001|FG000|Overall Study|Adverse Event|1
6034416|NCT00324649|9631002|FG001|Overall Study|Adverse Event|4
6034417|NCT00324649|9631001|FG000|Overall Study|Withdrawal by Subject|0
6034418|NCT00324649|9631002|FG001|Overall Study|Withdrawal by Subject|1
6034419|NCT00324649|9631001|FG000|Overall Study|Noncompliance|1
6034420|NCT00324649|9631002|FG001|Overall Study|Noncompliance|0
6034421|NCT00324675|9631010|FG000|Overall Study|Adverse Event|1
6034422|NCT00324675|9631011|FG001|Overall Study|Adverse Event|0
6034423|NCT00324740|9631026|FG000|Overall Study|Withdrawal by Subject|1
6034424|NCT00324740|9631027|FG001|Overall Study|Withdrawal by Subject|0
6034425|NCT00324740|9631028|FG002|Overall Study|Withdrawal by Subject|1
6034426|NCT00324961|9631080|FG000|Overall Study|Adverse Event|5
6034427|NCT00324961|9631080|FG000|Overall Study|Consent Withdrawn|11
6034428|NCT00324961|9631080|FG000|Overall Study|Lost to Follow-up|22
6034429|NCT00324961|9631080|FG000|Overall Study|Protocol Violation|3
6034430|NCT00324961|9631080|FG000|Overall Study|Other|2
6034431|NCT00324987|9631088|FG000|Overall Study|Adverse Event|2
6034432|NCT00324987|9631089|FG001|Overall Study|Adverse Event|1
6034433|NCT00324987|9631088|FG000|Overall Study|Withdrawal by Subject|1
6034434|NCT00324987|9631089|FG001|Overall Study|Withdrawal by Subject|1
6034435|NCT00324987|9631088|FG000|Overall Study|Progression|1
6034436|NCT00324987|9631089|FG001|Overall Study|Progression|1
6034437|NCT00324987|9631088|FG000|Overall Study|symptomatic deterioration, toxicity, etc|2
6034438|NCT00324987|9631089|FG001|Overall Study|symptomatic deterioration, toxicity, etc|3
6034439|NCT00325039|9631097|FG000|Overall Study|Lost to Follow-up|18
6034440|NCT00325039|9631098|FG001|Overall Study|Lost to Follow-up|14
6034441|NCT00325130|9631120|FG000|Overall Study|Lost to Follow-up|6
6034442|NCT00325130|9631121|FG001|Overall Study|Lost to Follow-up|14
6034443|NCT00325130|9631120|FG000|Overall Study|Withdrawal by Subject|12
6034444|NCT00325130|9631121|FG001|Overall Study|Withdrawal by Subject|14
6034445|NCT00325130|9631120|FG000|Overall Study|Protocol Deviation|0
6034446|NCT00325130|9631121|FG001|Overall Study|Protocol Deviation|1
6034447|NCT00325130|9631120|FG000|Overall Study|Moved|0
6034448|NCT00325130|9631121|FG001|Overall Study|Moved|1
6034449|NCT00325130|9631120|FG000|Overall Study|Patient Discontinued for Other|1
6034450|NCT00325130|9631121|FG001|Overall Study|Patient Discontinued for Other|0
6034451|NCT00325143|9631127|FG000|Overall Study|Lost to follow-up(complete vacc. course)|13
6034452|NCT00325143|9631127|FG000|Overall Study|Migrated/moved from study area|1
6034453|NCT00325143|9631127|FG000|Overall Study|Lost to follow-up(incompl. vacc. course)|4
6034454|NCT00325143|9631127|FG000|Overall Study|Withdrawal by Subject|8
6034455|NCT00325156|9631131|FG000|Overall Study|Protocol Violation|8
6034456|NCT00325156|9631131|FG000|Overall Study|Lost to follow-up (complete vaccination)|41
6034457|NCT00325156|9631131|FG000|Overall Study|Migrated/moved from study area|12
6034458|NCT00325156|9631131|FG000|Overall Study|Adverse event, non-fatal|3
6034459|NCT00325156|9631131|FG000|Overall Study|Lost to follow-up (incompl. vaccination)|16
6034460|NCT00325156|9631131|FG000|Overall Study|Other|1
6034461|NCT00325156|9631131|FG000|Overall Study|Withdrawal by Subject|31
6034462|NCT00325195|9631138|FG000|Randomized|Not dosed|5
6034463|NCT00325195|9631139|FG001|Randomized|Not dosed|5
6034464|NCT00325195|9631140|FG002|Randomized|Not dosed|3
6034465|NCT00325195|9631138|FG000|Received Intervention: ITT Population|Adverse Event|15
6034466|NCT00325195|9631139|FG001|Received Intervention: ITT Population|Adverse Event|17
6034467|NCT00325195|9631140|FG002|Received Intervention: ITT Population|Adverse Event|1
6034468|NCT00325195|9631138|FG000|Received Intervention: ITT Population|Death|3
6034469|NCT00325195|9631139|FG001|Received Intervention: ITT Population|Death|1
6034470|NCT00325195|9631140|FG002|Received Intervention: ITT Population|Death|0
6048802|NCT00420641|9648139|FG000|Overall Study|Withdrawal by Subject|15
6034471|NCT00325195|9631138|FG000|Received Intervention: ITT Population|Withdrawal by Subject|7
6034472|NCT00325195|9631139|FG001|Received Intervention: ITT Population|Withdrawal by Subject|6
6034473|NCT00325195|9631140|FG002|Received Intervention: ITT Population|Withdrawal by Subject|1
6034474|NCT00325195|9631138|FG000|Received Intervention: ITT Population|Lost to Follow-up|0
6034475|NCT00325195|9631139|FG001|Received Intervention: ITT Population|Lost to Follow-up|0
6034476|NCT00325195|9631140|FG002|Received Intervention: ITT Population|Lost to Follow-up|2
6034477|NCT00325195|9631138|FG000|Received Intervention: ITT Population|Protocol violation/non-compliance|1
6034478|NCT00325195|9631139|FG001|Received Intervention: ITT Population|Protocol violation/non-compliance|1
6034479|NCT00325195|9631140|FG002|Received Intervention: ITT Population|Protocol violation/non-compliance|0
6034480|NCT00325234|9631150|FG000|Overall Study|Adverse Event|10
6034481|NCT00325234|9631151|FG001|Overall Study|Adverse Event|7
6034482|NCT00325234|9631150|FG000|Overall Study|Death due to Study Disease|1
6034483|NCT00325234|9631151|FG001|Overall Study|Death due to Study Disease|0
6034484|NCT00325234|9631150|FG000|Overall Study|Entry Criteria Not Met|1
6034485|NCT00325234|9631151|FG001|Overall Study|Entry Criteria Not Met|2
6034486|NCT00325234|9631150|FG000|Overall Study|Subject Decision|6
6034487|NCT00325234|9631151|FG001|Overall Study|Subject Decision|8
6034488|NCT00325234|9631150|FG000|Overall Study|Physician Decision|17
6034489|NCT00325234|9631151|FG001|Overall Study|Physician Decision|12
6034490|NCT00325234|9631150|FG000|Overall Study|Progressive Disease|34
6034491|NCT00325234|9631151|FG001|Overall Study|Progressive Disease|37
6034492|NCT00325416|9631172|FG000|Phase I: Dose Escalation|Pre-transplant screen failure|8
6034493|NCT00325416|9631173|FG001|Phase I: Dose Escalation|Pre-transplant screen failure|9
6034494|NCT00325416|9631172|FG000|Phase I: Dose Escalation|Denial of insurance coverage|7
6034495|NCT00325416|9631173|FG001|Phase I: Dose Escalation|Denial of insurance coverage|4
6034496|NCT00325416|9631172|FG000|Phase I: Dose Escalation|Withdrawal by Subject|7
6034497|NCT00325416|9631173|FG001|Phase I: Dose Escalation|Withdrawal by Subject|2
6034498|NCT00325416|9631172|FG000|Phase I: Dose Escalation|Inability to collect adequate stem cells|0
6034499|NCT00325416|9631173|FG001|Phase I: Dose Escalation|Inability to collect adequate stem cells|1
6034500|NCT00325416|9631172|FG000|Phase II: Treatment at MTD|denial of insurance coverage|0
6034501|NCT00325416|9631173|FG001|Phase II: Treatment at MTD|denial of insurance coverage|1
6034502|NCT00325416|9631172|FG000|Phase II: Treatment at MTD|Withdrawal by Subject|0
6034503|NCT00325416|9631173|FG001|Phase II: Treatment at MTD|Withdrawal by Subject|1
6034504|NCT00325468|9631196|FG000|Overall Study|Adverse Event|1
6034505|NCT00325468|9631197|FG001|Overall Study|Adverse Event|1
6034506|NCT00325468|9631198|FG002|Overall Study|Adverse Event|0
6034507|NCT00325468|9631199|FG003|Overall Study|Adverse Event|5
6034508|NCT00325468|9631200|FG004|Overall Study|Adverse Event|1
6034509|NCT00325468|9631196|FG000|Overall Study|Death|2
6034510|NCT00325468|9631197|FG001|Overall Study|Death|0
6034511|NCT00325468|9631198|FG002|Overall Study|Death|2
6034512|NCT00325468|9631199|FG003|Overall Study|Death|4
6034513|NCT00325468|9631200|FG004|Overall Study|Death|0
6034514|NCT00325468|9631196|FG000|Overall Study|Lost to Follow-up|0
6034515|NCT00325468|9631197|FG001|Overall Study|Lost to Follow-up|0
6034516|NCT00325468|9631198|FG002|Overall Study|Lost to Follow-up|1
6034517|NCT00325468|9631199|FG003|Overall Study|Lost to Follow-up|2
6034518|NCT00325468|9631200|FG004|Overall Study|Lost to Follow-up|2
6034519|NCT00325468|9631196|FG000|Overall Study|Physician Decision|1
6034520|NCT00325468|9631197|FG001|Overall Study|Physician Decision|1
6034521|NCT00325468|9631198|FG002|Overall Study|Physician Decision|0
6034522|NCT00325468|9631199|FG003|Overall Study|Physician Decision|1
6034523|NCT00325468|9631200|FG004|Overall Study|Physician Decision|0
6034524|NCT00325468|9631196|FG000|Overall Study|Withdrawal by Subject|3
6034525|NCT00325468|9631197|FG001|Overall Study|Withdrawal by Subject|1
6034526|NCT00325468|9631198|FG002|Overall Study|Withdrawal by Subject|0
6034527|NCT00325468|9631199|FG003|Overall Study|Withdrawal by Subject|14
6034528|NCT00325468|9631200|FG004|Overall Study|Withdrawal by Subject|4
6034529|NCT00325468|9631196|FG000|Overall Study|site closure etc|4
6034530|NCT00325468|9631197|FG001|Overall Study|site closure etc|2
6034531|NCT00325468|9631198|FG002|Overall Study|site closure etc|1
6034532|NCT00325468|9631199|FG003|Overall Study|site closure etc|8
6034533|NCT00325468|9631200|FG004|Overall Study|site closure etc|1
6034534|NCT00325754|9631226|FG000|Overall Study|Adverse Event|4
6034535|NCT00325754|9631227|FG001|Overall Study|Adverse Event|1
6034536|NCT00325819|9631239|FG000|Overall Study|Study product lost in mail|2
6034537|NCT00325819|9631240|FG001|Overall Study|Study product lost in mail|1
6034538|NCT00325819|9631239|FG000|Overall Study|Did not take a dose of study product|4
6034539|NCT00325819|9631240|FG001|Overall Study|Did not take a dose of study product|9
6034540|NCT00325819|9631239|FG000|Overall Study|Lost to Follow-up|3
6034541|NCT00325819|9631240|FG001|Overall Study|Lost to Follow-up|3
6034542|NCT00325897|9631250|FG000|Overall Study|Lost to Follow-up|12
6034543|NCT00325897|9631251|FG001|Overall Study|Lost to Follow-up|13
6146920|NCT01079936|9781909|FG000|Phase I: MTD|No Stem Cell Transplantation|2
6146921|NCT01079936|9781910|FG001|Phase I: MTD|No Stem Cell Transplantation|0
6146922|NCT01079936|9781911|FG002|Phase I: MTD|No Stem Cell Transplantation|0
6146923|NCT01079936|9781912|FG003|Phase I: MTD|No Stem Cell Transplantation|0
6146924|NCT01079936|9781913|FG004|Phase I: MTD|No Stem Cell Transplantation|0
6146925|NCT01079936|9781909|FG000|Phase II|Adverse Event|0
6146926|NCT01079936|9781910|FG001|Phase II|Adverse Event|0
6146927|NCT01079936|9781911|FG002|Phase II|Adverse Event|1
6034544|NCT00326001|9631262|FG000|Overall Study|Adverse Event|4
6034545|NCT00326001|9631263|FG001|Overall Study|Adverse Event|5
6034546|NCT00326001|9631262|FG000|Overall Study|Physician Decision|3
6034547|NCT00326001|9631263|FG001|Overall Study|Physician Decision|3
6034548|NCT00326118|9631271|FG000|Active Phase|Withdrawal by Subject|4
6034549|NCT00326118|9631272|FG001|Active Phase|Withdrawal by Subject|1
6034550|NCT00326209|9631292|FG000|Overall Study|Adverse Event|28
6034551|NCT00326209|9631292|FG000|Overall Study|Withdrawal by Subject|22
6034552|NCT00326209|9631292|FG000|Overall Study|Lack of Efficacy|31
6034553|NCT00326209|9631292|FG000|Overall Study|Lost to Follow-up|18
6034554|NCT00326209|9631292|FG000|Overall Study|Participant non-compliant|6
6034555|NCT00326209|9631292|FG000|Overall Study|Sponsor closed study|173
6034556|NCT00326209|9631292|FG000|Overall Study|Prohibited medication use|1
6146928|NCT01079936|9781912|FG003|Phase II|Adverse Event|0
6146929|NCT01079936|9781913|FG004|Phase II|Adverse Event|0
6146930|NCT01079936|9781909|FG000|Phase II|Insurance Issue|0
6146931|NCT01079936|9781910|FG001|Phase II|Insurance Issue|0
6146932|NCT01079936|9781911|FG002|Phase II|Insurance Issue|0
6146933|NCT01079936|9781912|FG003|Phase II|Insurance Issue|0
6146934|NCT01079936|9781913|FG004|Phase II|Insurance Issue|1
6034557|NCT00326209|9631292|FG000|Overall Study|Violation of entry criteria|1
6034558|NCT00326209|9631292|FG000|Overall Study|Withdrawn in error|1
6034559|NCT00326209|9631292|FG000|Overall Study|Pregnancy|1
6034560|NCT00326417|9631298|FG000|Overall Study|Withdrawal by Subject|0
6034561|NCT00326417|9631299|FG001|Overall Study|Withdrawal by Subject|0
6034562|NCT00326417|9631300|FG002|Overall Study|Withdrawal by Subject|1
6034563|NCT00326417|9631301|FG003|Overall Study|Withdrawal by Subject|0
6034564|NCT00326417|9631298|FG000|Overall Study|Arm Closed|7
6034565|NCT00326417|9631299|FG001|Overall Study|Arm Closed|0
6034566|NCT00326417|9631300|FG002|Overall Study|Arm Closed|0
6034567|NCT00326417|9631301|FG003|Overall Study|Arm Closed|3
6034568|NCT00326417|9631298|FG000|Overall Study|Death|7
6034569|NCT00326417|9631299|FG001|Overall Study|Death|0
6034570|NCT00326417|9631300|FG002|Overall Study|Death|0
6034571|NCT00326417|9631301|FG003|Overall Study|Death|0
6034572|NCT00326495|9631309|FG000|Overall Study|Switched to alternative treatment|1
6034573|NCT00326495|9631309|FG000|Overall Study|Disease progression before treatment|1
6034574|NCT00326495|9631309|FG000|Overall Study|Refused further treatment|2
6034575|NCT00326495|9631309|FG000|Overall Study|Subject off study before assessment|1
6034576|NCT00326599|9631317|FG000|Overall Study|Withdrawal by Subject|1
6034577|NCT00326599|9631318|FG001|Overall Study|Withdrawal by Subject|0
6034578|NCT00326599|9631319|FG002|Overall Study|Withdrawal by Subject|5
6034579|NCT00326599|9631320|FG003|Overall Study|Withdrawal by Subject|2
6034580|NCT00326599|9631317|FG000|Overall Study|Adverse Event|1
6034581|NCT00326599|9631318|FG001|Overall Study|Adverse Event|0
6034582|NCT00326599|9631319|FG002|Overall Study|Adverse Event|32
6034583|NCT00326599|9631320|FG003|Overall Study|Adverse Event|3
6034584|NCT00326599|9631317|FG000|Overall Study|Disease Progression|3
6034585|NCT00326599|9631318|FG001|Overall Study|Disease Progression|1
6034586|NCT00326599|9631319|FG002|Overall Study|Disease Progression|13
6034587|NCT00326599|9631320|FG003|Overall Study|Disease Progression|11
6034588|NCT00326599|9631317|FG000|Overall Study|Alternate Treatment|1
6034589|NCT00326599|9631318|FG001|Overall Study|Alternate Treatment|0
6034590|NCT00326599|9631319|FG002|Overall Study|Alternate Treatment|0
6034591|NCT00326599|9631320|FG003|Overall Study|Alternate Treatment|0
6034592|NCT00326599|9631317|FG000|Overall Study|Death|0
6034593|NCT00326599|9631318|FG001|Overall Study|Death|0
6034594|NCT00326599|9631319|FG002|Overall Study|Death|1
6034595|NCT00326599|9631320|FG003|Overall Study|Death|2
6034596|NCT00326599|9631317|FG000|Overall Study|Other Unspecified Reason|0
6034597|NCT00326599|9631318|FG001|Overall Study|Other Unspecified Reason|0
6034598|NCT00326599|9631319|FG002|Overall Study|Other Unspecified Reason|2
6034599|NCT00326599|9631320|FG003|Overall Study|Other Unspecified Reason|1
6034600|NCT00326612|9631331|FG000|Overall Study|They did not have a seizure requiring tx|129
6034601|NCT00326612|9631332|FG001|Overall Study|They did not have a seizure requiring tx|137
6034602|NCT00326625|9631344|FG000|Overall Study|Adverse Event|20
6034603|NCT00326625|9631345|FG001|Overall Study|Adverse Event|9
6034604|NCT00326625|9631344|FG000|Overall Study|Withdrawal by Subject|15
6034605|NCT00326625|9631345|FG001|Overall Study|Withdrawal by Subject|12
6034606|NCT00326625|9631344|FG000|Overall Study|Death|18
6034607|NCT00326625|9631345|FG001|Overall Study|Death|16
6034608|NCT00326625|9631344|FG000|Overall Study|Lost to Follow-up|1
6034609|NCT00326625|9631345|FG001|Overall Study|Lost to Follow-up|0
6034610|NCT00326625|9631344|FG000|Overall Study|prescheduled medical intervention|0
6034611|NCT00326625|9631345|FG001|Overall Study|prescheduled medical intervention|1
6034612|NCT00326716|9631353|FG000|Pre-Natal Mothers|Discontinued ATV Before Delivery|1
6034613|NCT00326716|9631354|FG001|Pre-Natal Mothers|Discontinued ATV Before Delivery|2
6034614|NCT00326716|9631355|FG002|Pre-Natal Mothers|Discontinued ATV Before Delivery|0
6146935|NCT01079949|9781926|FG000|Overall Study|Withdrawal before r-hCG administration|2
6034615|NCT00326716|9631356|FG003|Pre-Natal Mothers|Discontinued ATV Before Delivery|0
6034616|NCT00326885|9631399|FG000|Overall Study|Adverse Event|1
6034617|NCT00326885|9631399|FG000|Overall Study|Withdrawal by Subject|3
6034618|NCT00326885|9631399|FG000|Overall Study|Physician Decision|1
6146936|NCT01079949|9781927|FG001|Overall Study|Withdrawal before r-hCG administration|3
6146937|NCT01079949|9781926|FG000|Overall Study|Withdrawal between rhCG-ovum pickup(OPU)|4
6034619|NCT00326885|9631399|FG000|Overall Study|Hospice withdrew consent|2
6034620|NCT00326911|9631406|FG000|Overall Study|Hospitalization prior to treatment|0
6034621|NCT00326911|9631407|FG001|Overall Study|Hospitalization prior to treatment|1
6034622|NCT00326911|9631406|FG000|Overall Study|Physician decision prior to treatment|1
6034623|NCT00326911|9631407|FG001|Overall Study|Physician decision prior to treatment|0
6034624|NCT00326911|9631406|FG000|Overall Study|Withdrawal by subject prior to treatment|0
6034625|NCT00326911|9631407|FG001|Overall Study|Withdrawal by subject prior to treatment|1
6034626|NCT00326950|9631422|FG000|Overall Study|Progressive Disease|1
6034627|NCT00326963|9631426|FG000|Overall Study|Adverse Event|2
6034628|NCT00326963|9631426|FG000|Overall Study|Injection site reaction|1
6034629|NCT00326963|9631426|FG000|Overall Study|Death|1
6034630|NCT00326963|9631426|FG000|Overall Study|Failure to return|10
6034631|NCT00326963|9631426|FG000|Overall Study|Withdrawal by Subject|10
6034632|NCT00326963|9631426|FG000|Overall Study|Refused treatment / did not cooperate|5
6034633|NCT00326963|9631426|FG000|Overall Study|Violation of selection criteria at entry|2
6146938|NCT01079949|9781927|FG001|Overall Study|Withdrawal between rhCG-ovum pickup(OPU)|8
6146939|NCT01079949|9781926|FG000|Overall Study|Withdrawal between OPU - embryo transfer|8
6146940|NCT01079949|9781927|FG001|Overall Study|Withdrawal between OPU - embryo transfer|2
6146941|NCT01079949|9781926|FG000|Overall Study|Randomized but not treated|1
6146942|NCT01079949|9781927|FG001|Overall Study|Randomized but not treated|0
6034634|NCT00326963|9631426|FG000|Overall Study|Other protocol violation|1
6034635|NCT00326963|9631426|FG000|Overall Study|Administrative / other|1
6034636|NCT00327015|9631435|FG000|Overall Study|Lack of Efficacy|18
6034637|NCT00327015|9631436|FG001|Overall Study|Lack of Efficacy|18
6034638|NCT00327015|9631437|FG002|Overall Study|Lack of Efficacy|35
6034639|NCT00327015|9631438|FG003|Overall Study|Lack of Efficacy|29
6034640|NCT00327015|9631435|FG000|Overall Study|Withdrawal of Consent by Subject|20
6034641|NCT00327015|9631436|FG001|Overall Study|Withdrawal of Consent by Subject|24
6034642|NCT00327015|9631437|FG002|Overall Study|Withdrawal of Consent by Subject|28
6034643|NCT00327015|9631438|FG003|Overall Study|Withdrawal of Consent by Subject|25
6034644|NCT00327015|9631435|FG000|Overall Study|Lost to Follow-up|22
6034645|NCT00327015|9631436|FG001|Overall Study|Lost to Follow-up|23
6034646|NCT00327015|9631437|FG002|Overall Study|Lost to Follow-up|29
6034647|NCT00327015|9631438|FG003|Overall Study|Lost to Follow-up|22
6034648|NCT00327015|9631435|FG000|Overall Study|Adverse Event|14
6034649|NCT00327015|9631436|FG001|Overall Study|Adverse Event|10
6034650|NCT00327015|9631437|FG002|Overall Study|Adverse Event|14
6034651|NCT00327015|9631438|FG003|Overall Study|Adverse Event|14
6034652|NCT00327015|9631435|FG000|Overall Study|Subject no longer meets study criteria|4
6034653|NCT00327015|9631436|FG001|Overall Study|Subject no longer meets study criteria|2
6034654|NCT00327015|9631437|FG002|Overall Study|Subject no longer meets study criteria|8
6034655|NCT00327015|9631438|FG003|Overall Study|Subject no longer meets study criteria|7
6034656|NCT00327015|9631435|FG000|Overall Study|Poor/Noncompliance|11
6034657|NCT00327015|9631436|FG001|Overall Study|Poor/Noncompliance|8
6034658|NCT00327015|9631437|FG002|Overall Study|Poor/Noncompliance|4
6034659|NCT00327015|9631438|FG003|Overall Study|Poor/Noncompliance|5
6034660|NCT00327015|9631435|FG000|Overall Study|Physician Decision|0
6034661|NCT00327015|9631436|FG001|Overall Study|Physician Decision|1
6034662|NCT00327015|9631437|FG002|Overall Study|Physician Decision|3
6034663|NCT00327015|9631438|FG003|Overall Study|Physician Decision|2
6034664|NCT00327015|9631435|FG000|Overall Study|Death|1
6034665|NCT00327015|9631436|FG001|Overall Study|Death|2
6034666|NCT00327015|9631437|FG002|Overall Study|Death|2
6034667|NCT00327015|9631438|FG003|Overall Study|Death|3
6034668|NCT00327015|9631435|FG000|Overall Study|Pregnancy|0
6034669|NCT00327015|9631436|FG001|Overall Study|Pregnancy|2
6034670|NCT00327015|9631437|FG002|Overall Study|Pregnancy|1
6034671|NCT00327015|9631438|FG003|Overall Study|Pregnancy|1
6034672|NCT00327015|9631435|FG000|Overall Study|Administrative Reason by Sponsor|1
6034673|NCT00327015|9631436|FG001|Overall Study|Administrative Reason by Sponsor|2
6034674|NCT00327015|9631437|FG002|Overall Study|Administrative Reason by Sponsor|2
6034675|NCT00327015|9631438|FG003|Overall Study|Administrative Reason by Sponsor|1
6034676|NCT00327171|9631450|FG000|Overall Study|Did not receive study medication|3
6034677|NCT00327171|9631451|FG001|Overall Study|Did not receive study medication|0
6034678|NCT00327171|9631450|FG000|Overall Study|Adverse Event|23
6034679|NCT00327171|9631451|FG001|Overall Study|Adverse Event|23
6034680|NCT00327171|9631450|FG000|Overall Study|Disease progression/lack of efficacy|68
6034681|NCT00327171|9631451|FG001|Overall Study|Disease progression/lack of efficacy|69
6034682|NCT00327171|9631450|FG000|Overall Study|Investigator/participant request|1
6034683|NCT00327171|9631451|FG001|Overall Study|Investigator/participant request|8
6034684|NCT00327171|9631450|FG000|Overall Study|Clinical progression|12
6034685|NCT00327171|9631451|FG001|Overall Study|Clinical progression|8
6034686|NCT00327171|9631450|FG000|Overall Study|Undisclosed history of ischemia|0
6034687|NCT00327171|9631451|FG001|Overall Study|Undisclosed history of ischemia|1
6034688|NCT00327171|9631450|FG000|Overall Study|Other|1
6034689|NCT00327171|9631451|FG001|Overall Study|Other|0
6048803|NCT00420641|9648140|FG001|Overall Study|Withdrawal by Subject|21
6146943|NCT01079962|9781935|FG000|Overall Study|Adverse Event|2
6048804|NCT00420641|9648141|FG002|Overall Study|Withdrawal by Subject|14
6048805|NCT00420641|9648139|FG000|Overall Study|Lack of Efficacy|6
6048806|NCT00420641|9648140|FG001|Overall Study|Lack of Efficacy|5
6034690|NCT00327340|9631459|FG000|Overall Study|Withdrawal by Subject|1
6034691|NCT00327340|9631460|FG001|Overall Study|Withdrawal by Subject|5
6034692|NCT00327340|9631459|FG000|Overall Study|Physician Decision|1
6034693|NCT00327340|9631460|FG001|Overall Study|Physician Decision|1
6034694|NCT00327340|9631459|FG000|Overall Study|Disease Progression|10
6034695|NCT00327340|9631460|FG001|Overall Study|Disease Progression|19
6034696|NCT00327340|9631459|FG000|Overall Study|Symptomatic Disease|0
6034697|NCT00327340|9631460|FG001|Overall Study|Symptomatic Disease|2
6034698|NCT00327340|9631459|FG000|Overall Study|Adverse Event|3
6034699|NCT00327340|9631460|FG001|Overall Study|Adverse Event|3
6034700|NCT00327444|9631474|FG000|Double Blind Treatment (DB) Period|Disease progression|10
6034701|NCT00327444|9631475|FG001|Double Blind Treatment (DB) Period|Disease progression|13
6034702|NCT00327444|9631474|FG000|Double Blind Treatment (DB) Period|Adverse Event|5
6034703|NCT00327444|9631475|FG001|Double Blind Treatment (DB) Period|Adverse Event|5
6034704|NCT00327444|9631474|FG000|Double Blind Treatment (DB) Period|Subject request|0
6034705|NCT00327444|9631475|FG001|Double Blind Treatment (DB) Period|Subject request|1
6034706|NCT00327444|9631474|FG000|Double Blind Treatment (DB) Period|Withdrew DB and continued to OL|11
6034707|NCT00327444|9631475|FG001|Double Blind Treatment (DB) Period|Withdrew DB and continued to OL|10
6034708|NCT00327444|9631474|FG000|Open Label Treatment (OL) Period|Disease progression|8
6034709|NCT00327444|9631475|FG001|Open Label Treatment (OL) Period|Disease progression|7
6034710|NCT00327444|9631474|FG000|Open Label Treatment (OL) Period|Adverse Event|2
6034711|NCT00327444|9631475|FG001|Open Label Treatment (OL) Period|Adverse Event|2
6034712|NCT00327444|9631474|FG000|Open Label Treatment (OL) Period|Worsening dyspnea|0
6034713|NCT00327444|9631475|FG001|Open Label Treatment (OL) Period|Worsening dyspnea|1
6034714|NCT00327444|9631474|FG000|Open Label Treatment (OL) Period|Ongoing Treatment|1
6034715|NCT00327444|9631475|FG001|Open Label Treatment (OL) Period|Ongoing Treatment|0
6034716|NCT00327470|9631485|FG000|Overall Study|Randomized, but not treated|0
6034717|NCT00327470|9631486|FG001|Overall Study|Randomized, but not treated|2
6034718|NCT00327470|9631485|FG000|Overall Study|Adverse Event|9
6034719|NCT00327470|9631486|FG001|Overall Study|Adverse Event|14
6034720|NCT00327470|9631485|FG000|Overall Study|Lack of Efficacy|7
6034721|NCT00327470|9631486|FG001|Overall Study|Lack of Efficacy|19
6034722|NCT00327470|9631485|FG000|Overall Study|Other|5
6034723|NCT00327470|9631486|FG001|Overall Study|Other|9
6034724|NCT00327470|9631485|FG000|Overall Study|Lost to Follow-up|1
6034725|NCT00327470|9631486|FG001|Overall Study|Lost to Follow-up|3
6034726|NCT00327470|9631485|FG000|Overall Study|Withdrawal by Subject|6
6034727|NCT00327470|9631486|FG001|Overall Study|Withdrawal by Subject|12
6034728|NCT00327470|9631485|FG000|Overall Study|Death|1
6034729|NCT00327470|9631486|FG001|Overall Study|Death|4
6034730|NCT00327717|9631494|FG000|Overall Study|Adverse Event|6
6034731|NCT00327717|9631495|FG001|Overall Study|Adverse Event|6
6034732|NCT00327717|9631494|FG000|Overall Study|Lack of Efficacy|0
6034733|NCT00327717|9631495|FG001|Overall Study|Lack of Efficacy|1
6034734|NCT00327717|9631494|FG000|Overall Study|Withdrawal by Subject|3
6034735|NCT00327717|9631495|FG001|Overall Study|Withdrawal by Subject|7
6034736|NCT00328094|9631524|FG000|Overall Study|Physician Decision|3
6034737|NCT00328094|9631525|FG001|Overall Study|Physician Decision|3
6034738|NCT00328172|9631536|FG000|Overall Study|Adverse Event|3
6034739|NCT00328172|9631537|FG001|Overall Study|Adverse Event|2
6034740|NCT00328172|9631538|FG002|Overall Study|Adverse Event|1
6034741|NCT00328172|9631539|FG003|Overall Study|Adverse Event|2
6034742|NCT00328172|9631540|FG004|Overall Study|Adverse Event|1
6034743|NCT00328172|9631536|FG000|Overall Study|Protocol Violation|0
6034744|NCT00328172|9631537|FG001|Overall Study|Protocol Violation|1
6034745|NCT00328172|9631538|FG002|Overall Study|Protocol Violation|1
6034746|NCT00328172|9631539|FG003|Overall Study|Protocol Violation|0
6034747|NCT00328172|9631540|FG004|Overall Study|Protocol Violation|0
6034748|NCT00328172|9631536|FG000|Overall Study|Lost to Follow-up|1
6034749|NCT00328172|9631537|FG001|Overall Study|Lost to Follow-up|1
6034750|NCT00328172|9631538|FG002|Overall Study|Lost to Follow-up|2
6034751|NCT00328172|9631539|FG003|Overall Study|Lost to Follow-up|1
6034752|NCT00328172|9631540|FG004|Overall Study|Lost to Follow-up|1
6034753|NCT00328172|9631536|FG000|Overall Study|Withdrawal by Subject|1
6034754|NCT00328172|9631537|FG001|Overall Study|Withdrawal by Subject|1
6034755|NCT00328172|9631538|FG002|Overall Study|Withdrawal by Subject|1
6034756|NCT00328172|9631539|FG003|Overall Study|Withdrawal by Subject|6
6034757|NCT00328172|9631540|FG004|Overall Study|Withdrawal by Subject|0
6034758|NCT00328172|9631536|FG000|Overall Study|Lack of Efficacy|14
6034759|NCT00328172|9631537|FG001|Overall Study|Lack of Efficacy|9
6034760|NCT00328172|9631538|FG002|Overall Study|Lack of Efficacy|4
6034761|NCT00328172|9631539|FG003|Overall Study|Lack of Efficacy|4
6034762|NCT00328172|9631540|FG004|Overall Study|Lack of Efficacy|3
6034763|NCT00328172|9631536|FG000|Overall Study|Other reason (not specified)|3
6034764|NCT00328172|9631537|FG001|Overall Study|Other reason (not specified)|0
6034765|NCT00328172|9631538|FG002|Overall Study|Other reason (not specified)|1
6034766|NCT00328172|9631539|FG003|Overall Study|Other reason (not specified)|0
6034767|NCT00328172|9631540|FG004|Overall Study|Other reason (not specified)|0
6034768|NCT00328198|9631552|FG000|Treatment|Adverse Event|21
6034769|NCT00328198|9631552|FG000|Treatment|Death|1
6034770|NCT00328198|9631552|FG000|Treatment|Physician Decision|5
6034771|NCT00328198|9631552|FG000|Treatment|Withdrawal by Subject|5
6034772|NCT00328198|9631552|FG000|Treatment|Evidence of disease progression|2
6034773|NCT00328198|9631552|FG000|Treatment|Non-compliance|1
6034774|NCT00328198|9631552|FG000|Treatment|Confirmed complete response, MRD -|3
6034775|NCT00328198|9631552|FG000|Follow-up|Lost to Follow-up|4
6034776|NCT00328198|9631552|FG000|Follow-up|Death|31
6034777|NCT00328510|9631567|FG000|Overall Study|Gag disorder, could not use frame|4
6034778|NCT00328510|9631568|FG001|Overall Study|Gag disorder, could not use frame|0
6034779|NCT00328510|9631567|FG000|Overall Study|Dentition problems, could not use frame|1
6034780|NCT00328510|9631568|FG001|Overall Study|Dentition problems, could not use frame|0
6034781|NCT00328510|9631567|FG000|Overall Study|Withdrawal by Subject|4
6034782|NCT00328510|9631568|FG001|Overall Study|Withdrawal by Subject|2
6034783|NCT00328510|9631567|FG000|Overall Study|Severe kyphosis, could not use mask|0
6034784|NCT00328510|9631568|FG001|Overall Study|Severe kyphosis, could not use mask|1
6034785|NCT00328510|9631567|FG000|Overall Study|Treatment changed to a single fraction|1
6034786|NCT00328510|9631568|FG001|Overall Study|Treatment changed to a single fraction|1
6034787|NCT00328562|9631574|FG000|Overall Study|Disease progression|1
6034788|NCT00328627|9631610|FG000|Overall Study|Hyperglycemic Rescue|41
6034789|NCT00328627|9631611|FG001|Overall Study|Hyperglycemic Rescue|18
6034790|NCT00328627|9631612|FG002|Overall Study|Hyperglycemic Rescue|16
6034791|NCT00328627|9631613|FG003|Overall Study|Hyperglycemic Rescue|13
6034792|NCT00328627|9631614|FG004|Overall Study|Hyperglycemic Rescue|6
6034793|NCT00328627|9631615|FG005|Overall Study|Hyperglycemic Rescue|5
6034794|NCT00328627|9631616|FG006|Overall Study|Hyperglycemic Rescue|19
6034795|NCT00328627|9631617|FG007|Overall Study|Hyperglycemic Rescue|6
6034796|NCT00328627|9631618|FG008|Overall Study|Hyperglycemic Rescue|6
6034797|NCT00328627|9631619|FG009|Overall Study|Hyperglycemic Rescue|11
6034798|NCT00328627|9631620|FG010|Overall Study|Hyperglycemic Rescue|3
6034799|NCT00328627|9631621|FG011|Overall Study|Hyperglycemic Rescue|2
6034800|NCT00328627|9631610|FG000|Overall Study|Adverse Event|3
6034801|NCT00328627|9631611|FG001|Overall Study|Adverse Event|1
6034802|NCT00328627|9631612|FG002|Overall Study|Adverse Event|2
6034803|NCT00328627|9631613|FG003|Overall Study|Adverse Event|3
6034804|NCT00328627|9631614|FG004|Overall Study|Adverse Event|1
6034805|NCT00328627|9631615|FG005|Overall Study|Adverse Event|2
6034806|NCT00328627|9631616|FG006|Overall Study|Adverse Event|1
6034807|NCT00328627|9631617|FG007|Overall Study|Adverse Event|2
6034808|NCT00328627|9631618|FG008|Overall Study|Adverse Event|0
6034809|NCT00328627|9631619|FG009|Overall Study|Adverse Event|7
6034810|NCT00328627|9631620|FG010|Overall Study|Adverse Event|5
6034811|NCT00328627|9631621|FG011|Overall Study|Adverse Event|4
6034812|NCT00328627|9631610|FG000|Overall Study|Protocol Violation|2
6034813|NCT00328627|9631611|FG001|Overall Study|Protocol Violation|2
6034814|NCT00328627|9631612|FG002|Overall Study|Protocol Violation|2
6034815|NCT00328627|9631613|FG003|Overall Study|Protocol Violation|8
6034816|NCT00328627|9631614|FG004|Overall Study|Protocol Violation|5
6034817|NCT00328627|9631615|FG005|Overall Study|Protocol Violation|5
6034818|NCT00328627|9631616|FG006|Overall Study|Protocol Violation|6
6034819|NCT00328627|9631617|FG007|Overall Study|Protocol Violation|2
6034820|NCT00328627|9631618|FG008|Overall Study|Protocol Violation|1
6034821|NCT00328627|9631619|FG009|Overall Study|Protocol Violation|4
6034822|NCT00328627|9631620|FG010|Overall Study|Protocol Violation|6
6034823|NCT00328627|9631621|FG011|Overall Study|Protocol Violation|2
6034824|NCT00328627|9631610|FG000|Overall Study|Lost to Follow-up|4
6034825|NCT00328627|9631611|FG001|Overall Study|Lost to Follow-up|2
6034826|NCT00328627|9631612|FG002|Overall Study|Lost to Follow-up|2
6034827|NCT00328627|9631613|FG003|Overall Study|Lost to Follow-up|4
6034828|NCT00328627|9631614|FG004|Overall Study|Lost to Follow-up|0
6034829|NCT00328627|9631615|FG005|Overall Study|Lost to Follow-up|2
6034830|NCT00328627|9631616|FG006|Overall Study|Lost to Follow-up|3
6034831|NCT00328627|9631617|FG007|Overall Study|Lost to Follow-up|0
6034832|NCT00328627|9631618|FG008|Overall Study|Lost to Follow-up|3
6034833|NCT00328627|9631619|FG009|Overall Study|Lost to Follow-up|2
6034834|NCT00328627|9631620|FG010|Overall Study|Lost to Follow-up|0
6034835|NCT00328627|9631621|FG011|Overall Study|Lost to Follow-up|1
6034836|NCT00328627|9631610|FG000|Overall Study|Withdrawal by Subject|5
6034837|NCT00328627|9631611|FG001|Overall Study|Withdrawal by Subject|4
6034838|NCT00328627|9631612|FG002|Overall Study|Withdrawal by Subject|5
6034839|NCT00328627|9631613|FG003|Overall Study|Withdrawal by Subject|6
6034840|NCT00328627|9631614|FG004|Overall Study|Withdrawal by Subject|2
6034841|NCT00328627|9631615|FG005|Overall Study|Withdrawal by Subject|5
6034842|NCT00328627|9631616|FG006|Overall Study|Withdrawal by Subject|4
6034843|NCT00328627|9631617|FG007|Overall Study|Withdrawal by Subject|4
6034844|NCT00328627|9631618|FG008|Overall Study|Withdrawal by Subject|4
6034845|NCT00328627|9631619|FG009|Overall Study|Withdrawal by Subject|5
6034846|NCT00328627|9631620|FG010|Overall Study|Withdrawal by Subject|2
6034847|NCT00328627|9631621|FG011|Overall Study|Withdrawal by Subject|7
6034848|NCT00328627|9631610|FG000|Overall Study|Pregnancy|0
6034849|NCT00328627|9631611|FG001|Overall Study|Pregnancy|1
6034850|NCT00328627|9631612|FG002|Overall Study|Pregnancy|0
6034851|NCT00328627|9631613|FG003|Overall Study|Pregnancy|0
6034852|NCT00328627|9631614|FG004|Overall Study|Pregnancy|0
6034853|NCT00328627|9631615|FG005|Overall Study|Pregnancy|0
6034854|NCT00328627|9631616|FG006|Overall Study|Pregnancy|0
6034855|NCT00328627|9631617|FG007|Overall Study|Pregnancy|0
6034856|NCT00328627|9631618|FG008|Overall Study|Pregnancy|0
6034857|NCT00328627|9631619|FG009|Overall Study|Pregnancy|0
6034858|NCT00328627|9631620|FG010|Overall Study|Pregnancy|0
6034859|NCT00328627|9631621|FG011|Overall Study|Pregnancy|0
6034860|NCT00328627|9631610|FG000|Overall Study|Physician Decision|4
6034861|NCT00328627|9631611|FG001|Overall Study|Physician Decision|3
6034862|NCT00328627|9631612|FG002|Overall Study|Physician Decision|1
6034863|NCT00328627|9631613|FG003|Overall Study|Physician Decision|2
6034864|NCT00328627|9631614|FG004|Overall Study|Physician Decision|1
6034865|NCT00328627|9631615|FG005|Overall Study|Physician Decision|1
6034866|NCT00328627|9631616|FG006|Overall Study|Physician Decision|1
6034867|NCT00328627|9631617|FG007|Overall Study|Physician Decision|0
6034868|NCT00328627|9631618|FG008|Overall Study|Physician Decision|3
6034869|NCT00328627|9631619|FG009|Overall Study|Physician Decision|2
6034870|NCT00328627|9631620|FG010|Overall Study|Physician Decision|1
6034871|NCT00328627|9631621|FG011|Overall Study|Physician Decision|0
6034872|NCT00328627|9631610|FG000|Overall Study|Other|0
6034873|NCT00328627|9631611|FG001|Overall Study|Other|0
6034874|NCT00328627|9631612|FG002|Overall Study|Other|0
6034875|NCT00328627|9631613|FG003|Overall Study|Other|1
6034876|NCT00328627|9631614|FG004|Overall Study|Other|0
6034877|NCT00328627|9631615|FG005|Overall Study|Other|0
6034878|NCT00328627|9631616|FG006|Overall Study|Other|1
6034879|NCT00328627|9631617|FG007|Overall Study|Other|0
6034880|NCT00328627|9631618|FG008|Overall Study|Other|0
6034881|NCT00328627|9631619|FG009|Overall Study|Other|1
6034882|NCT00328627|9631620|FG010|Overall Study|Other|1
6034883|NCT00328627|9631621|FG011|Overall Study|Other|0
6034884|NCT00328783|9631660|FG000|Overall Study|Could not tolerate ABC|21
6034885|NCT00328783|9631660|FG000|Overall Study|No heart in RT field|4
6034886|NCT00328783|9631660|FG000|Overall Study|Withdrawal by Subject|1
6034887|NCT00328926|9631678|FG000|Overall Study|Pregnancy|2
6034888|NCT00328926|9631679|FG001|Overall Study|Pregnancy|1
6034889|NCT00328926|9631680|FG002|Overall Study|Pregnancy|0
6034890|NCT00328926|9631678|FG000|Overall Study|Lost to Follow-up|0
6034891|NCT00328926|9631679|FG001|Overall Study|Lost to Follow-up|1
6034892|NCT00328926|9631680|FG002|Overall Study|Lost to Follow-up|0
6034893|NCT00328926|9631678|FG000|Overall Study|Death|0
6034894|NCT00328926|9631679|FG001|Overall Study|Death|0
6034895|NCT00328926|9631680|FG002|Overall Study|Death|1
6034896|NCT00328926|9631678|FG000|Overall Study|In vitro fertilization treatment|0
6034897|NCT00328926|9631679|FG001|Overall Study|In vitro fertilization treatment|0
6034898|NCT00328926|9631680|FG002|Overall Study|In vitro fertilization treatment|1
6034899|NCT00328926|9631678|FG000|Overall Study|Lack of ovarian response|0
6034900|NCT00328926|9631679|FG001|Overall Study|Lack of ovarian response|1
6034901|NCT00328926|9631680|FG002|Overall Study|Lack of ovarian response|0
6034902|NCT00329030|9631690|FG000|Overall Study|Withdrawal by Subject|1
6034903|NCT00329030|9631691|FG001|Overall Study|Withdrawal by Subject|3
6034904|NCT00329030|9631690|FG000|Overall Study|Progressive Disease|6
6034905|NCT00329030|9631691|FG001|Overall Study|Progressive Disease|2
6034906|NCT00329030|9631690|FG000|Overall Study|Ineligible Pathology|1
6034907|NCT00329030|9631691|FG001|Overall Study|Ineligible Pathology|1
6034908|NCT00329160|9631697|FG000|Overall Study|Adverse Event|27
6034909|NCT00329160|9631697|FG000|Overall Study|Withdrawal by Subject|13
6034910|NCT00329160|9631697|FG000|Overall Study|Protocol Violation|2
6034911|NCT00329160|9631697|FG000|Overall Study|Did not Receive Study Drug|1
6034912|NCT00329160|9631697|FG000|Overall Study|Incomplete IVUS|45
6034913|NCT00329238|9631703|FG000|Overall Study|Adverse Event|147
6034914|NCT00329238|9631704|FG001|Overall Study|Adverse Event|129
6034915|NCT00329238|9631703|FG000|Overall Study|Protocol Violation|23
6034916|NCT00329238|9631704|FG001|Overall Study|Protocol Violation|34
6034917|NCT00329238|9631703|FG000|Overall Study|Lost to Follow-up|2
6034918|NCT00329238|9631704|FG001|Overall Study|Lost to Follow-up|6
6034919|NCT00329238|9631703|FG000|Overall Study|Withdrawal by Subject|64
6034920|NCT00329238|9631704|FG001|Overall Study|Withdrawal by Subject|58
6034921|NCT00329238|9631703|FG000|Overall Study|Other reason (not specified)|40
6034922|NCT00329238|9631704|FG001|Overall Study|Other reason (not specified)|54
6034923|NCT00329303|9631714|FG000|Overall Study|Lack of Efficacy|1
6034924|NCT00329303|9631715|FG001|Overall Study|Lack of Efficacy|0
6034925|NCT00329303|9631714|FG000|Overall Study|Decision of the sponsor|0
6034926|NCT00329303|9631715|FG001|Overall Study|Decision of the sponsor|1
6034927|NCT00329303|9631714|FG000|Overall Study|Patient no longer available|1
6034928|NCT00329303|9631715|FG001|Overall Study|Patient no longer available|0
6034929|NCT00329303|9631714|FG000|Overall Study|Patient relocated|0
6034930|NCT00329303|9631715|FG001|Overall Study|Patient relocated|1
6034931|NCT00329407|9631722|FG000|Overall Study|Withdrawal by Subject|1
6034932|NCT00329420|9631729|FG000|Re-induction Phase|Lack of Efficacy|0
6034933|NCT00329420|9631730|FG001|Re-induction Phase|Lack of Efficacy|1
6034934|NCT00329420|9631731|FG002|Re-induction Phase|Lack of Efficacy|0
6034935|NCT00329420|9631729|FG000|Re-induction Phase|Withdrawal of Consent|0
6034936|NCT00329420|9631730|FG001|Re-induction Phase|Withdrawal of Consent|0
6034937|NCT00329420|9631731|FG002|Re-induction Phase|Withdrawal of Consent|1
6034938|NCT00329420|9631729|FG000|Re-induction Phase|Did not respond to re-induction|6
6034939|NCT00329420|9631730|FG001|Re-induction Phase|Did not respond to re-induction|5
6034940|NCT00329420|9631731|FG002|Re-induction Phase|Did not respond to re-induction|7
6034941|NCT00329420|9631729|FG000|4-weekly Dosing Phase (Responders Only)|Adverse Event|2
6034942|NCT00329420|9631730|FG001|4-weekly Dosing Phase (Responders Only)|Adverse Event|1
6034943|NCT00329420|9631731|FG002|4-weekly Dosing Phase (Responders Only)|Adverse Event|1
6034944|NCT00329420|9631729|FG000|4-weekly Dosing Phase (Responders Only)|Lack of Efficacy|1
6034945|NCT00329420|9631730|FG001|4-weekly Dosing Phase (Responders Only)|Lack of Efficacy|1
6034946|NCT00329420|9631731|FG002|4-weekly Dosing Phase (Responders Only)|Lack of Efficacy|0
6034947|NCT00329420|9631729|FG000|4-weekly Dosing Phase (Responders Only)|Withdrawal of Consent|1
6034948|NCT00329420|9631730|FG001|4-weekly Dosing Phase (Responders Only)|Withdrawal of Consent|0
6034949|NCT00329420|9631731|FG002|4-weekly Dosing Phase (Responders Only)|Withdrawal of Consent|0
6034950|NCT00329550|9631757|FG000|Overall Study|Adverse Event|3
6034951|NCT00329550|9631758|FG001|Overall Study|Adverse Event|4
6034952|NCT00329550|9631759|FG002|Overall Study|Adverse Event|2
6034953|NCT00329550|9631757|FG000|Overall Study|Withdrawal of Consent|1
6034954|NCT00329550|9631758|FG001|Overall Study|Withdrawal of Consent|0
6034955|NCT00329550|9631759|FG002|Overall Study|Withdrawal of Consent|1
6034956|NCT00329550|9631757|FG000|Overall Study|Due to Relocation|0
6034957|NCT00329550|9631758|FG001|Overall Study|Due to Relocation|0
6034958|NCT00329550|9631759|FG002|Overall Study|Due to Relocation|1
6034959|NCT00329602|9631771|FG000|26-Week Double-Blind Treatment Phase|Did not complete phase; reason unknown|119
6034960|NCT00329602|9631772|FG001|26-Week Double-Blind Treatment Phase|Did not complete phase; reason unknown|99
6034961|NCT00329602|9631773|FG002|26-Week Double-Blind Treatment Phase|Did not complete phase; reason unknown|0
6034962|NCT00329602|9631771|FG000|40-Week Open-Label Treatment Phase|Adverse Event|0
6034963|NCT00329602|9631772|FG001|40-Week Open-Label Treatment Phase|Adverse Event|0
6034964|NCT00329602|9631773|FG002|40-Week Open-Label Treatment Phase|Adverse Event|20
6034965|NCT00329602|9631771|FG000|40-Week Open-Label Treatment Phase|Lost to Follow-up|0
6034966|NCT00329602|9631772|FG001|40-Week Open-Label Treatment Phase|Lost to Follow-up|0
6034967|NCT00329602|9631773|FG002|40-Week Open-Label Treatment Phase|Lost to Follow-up|1
6034968|NCT00329602|9631771|FG000|40-Week Open-Label Treatment Phase|Protocol Violation|0
6034969|NCT00329602|9631772|FG001|40-Week Open-Label Treatment Phase|Protocol Violation|0
6034970|NCT00329602|9631773|FG002|40-Week Open-Label Treatment Phase|Protocol Violation|2
6034971|NCT00329602|9631771|FG000|40-Week Open-Label Treatment Phase|Lack of Efficacy|0
6034972|NCT00329602|9631772|FG001|40-Week Open-Label Treatment Phase|Lack of Efficacy|0
6034973|NCT00329602|9631773|FG002|40-Week Open-Label Treatment Phase|Lack of Efficacy|9
6034974|NCT00329602|9631771|FG000|40-Week Open-Label Treatment Phase|Captured as Other|0
6034975|NCT00329602|9631772|FG001|40-Week Open-Label Treatment Phase|Captured as Other|0
6034976|NCT00329602|9631773|FG002|40-Week Open-Label Treatment Phase|Captured as Other|4
6034977|NCT00329641|9631789|FG000|Overall Study|Did not start treatment|1
6034978|NCT00329641|9631789|FG000|Overall Study|Not eligible|1
6034979|NCT00329641|9631789|FG000|Overall Study|Adverse Event|3
6034980|NCT00329641|9631789|FG000|Overall Study|Other reason, not protocol specified|1
6034981|NCT00329719|9631798|FG000|Overall Study|Lost to Follow-up|0
6034982|NCT00329719|9631799|FG001|Overall Study|Lost to Follow-up|0
6034983|NCT00329719|9631800|FG002|Overall Study|Lost to Follow-up|0
6034984|NCT00329719|9631801|FG003|Overall Study|Lost to Follow-up|1
6034985|NCT00329745|9631813|FG000|Overall Study|Protocol Violation|1
6034986|NCT00329745|9631814|FG001|Overall Study|Protocol Violation|0
6034987|NCT00329745|9631813|FG000|Overall Study|Withdrawal by Subject|0
6034988|NCT00329745|9631814|FG001|Overall Study|Withdrawal by Subject|1
6034989|NCT00329745|9631813|FG000|Overall Study|Lost to Follow-up|86
6034990|NCT00329745|9631814|FG001|Overall Study|Lost to Follow-up|101
6034991|NCT00329784|9631828|FG000|Overall Study|Lost to Follow-up|0
6034992|NCT00329784|9631829|FG001|Overall Study|Lost to Follow-up|1
6034993|NCT00329784|9631830|FG002|Overall Study|Lost to Follow-up|0
6034994|NCT00329784|9631831|FG003|Overall Study|Lost to Follow-up|0
6034995|NCT00329784|9631828|FG000|Overall Study|Withdrawal by Subject|4
6034996|NCT00329784|9631829|FG001|Overall Study|Withdrawal by Subject|2
6034997|NCT00329784|9631830|FG002|Overall Study|Withdrawal by Subject|0
6034998|NCT00329784|9631831|FG003|Overall Study|Withdrawal by Subject|0
6034999|NCT00329784|9631828|FG000|Overall Study|Other|1
6035000|NCT00329784|9631829|FG001|Overall Study|Other|2
6035001|NCT00329784|9631830|FG002|Overall Study|Other|0
6035002|NCT00329784|9631831|FG003|Overall Study|Other|0
6035003|NCT00329797|9631845|FG000|Overall Study|Protocol Violation|1
6035004|NCT00329797|9631846|FG001|Overall Study|Protocol Violation|0
6035005|NCT00329797|9631845|FG000|Overall Study|Withdrawal by Subject|6
6035006|NCT00329797|9631846|FG001|Overall Study|Withdrawal by Subject|6
6035007|NCT00329849|9631858|FG000|Overall Study|Withdrawal by Subject|6
6035008|NCT00329849|9631859|FG001|Overall Study|Withdrawal by Subject|4
6035009|NCT00329901|9631872|FG000|Overall Study|Withdrawal by Subject|4
6035010|NCT00329901|9631873|FG001|Overall Study|Withdrawal by Subject|3
6035011|NCT00329901|9631874|FG002|Overall Study|Withdrawal by Subject|2
6035012|NCT00329901|9631872|FG000|Overall Study|Lost to Follow-up|2
6035013|NCT00329901|9631873|FG001|Overall Study|Lost to Follow-up|0
6035014|NCT00329901|9631874|FG002|Overall Study|Lost to Follow-up|1
6035015|NCT00329901|9631872|FG000|Overall Study|Protocol Violation|1
6035016|NCT00329901|9631873|FG001|Overall Study|Protocol Violation|0
6035017|NCT00329901|9631874|FG002|Overall Study|Protocol Violation|1
6035018|NCT00329901|9631872|FG000|Overall Study|Unable to classify|2
6035019|NCT00329901|9631873|FG001|Overall Study|Unable to classify|2
6035020|NCT00329901|9631874|FG002|Overall Study|Unable to classify|0
6035021|NCT00330174|9631892|FG000|Overall Study|Withdrawal by Subject|7
6035022|NCT00330174|9631893|FG001|Overall Study|Withdrawal by Subject|7
6035023|NCT00330174|9631892|FG000|Overall Study|Lost to Follow-up|4
6035024|NCT00330174|9631893|FG001|Overall Study|Lost to Follow-up|1
6035025|NCT00330174|9631892|FG000|Overall Study|Clinical deterioration|1
6035026|NCT00330174|9631893|FG001|Overall Study|Clinical deterioration|2
6035027|NCT00330174|9631892|FG000|Overall Study|Excessive missed visits|3
6035028|NCT00330174|9631893|FG001|Overall Study|Excessive missed visits|8
6035029|NCT00330174|9631892|FG000|Overall Study|Miscellaneous reasons|7
6035030|NCT00330174|9631893|FG001|Overall Study|Miscellaneous reasons|1
6035031|NCT00330187|9631903|FG000|Overall Study|Lost to Follow-up|12
6035032|NCT00330187|9631904|FG001|Overall Study|Lost to Follow-up|13
6035033|NCT00330187|9631905|FG002|Overall Study|Lost to Follow-up|14
6035034|NCT00330187|9631906|FG003|Overall Study|Lost to Follow-up|10
6035035|NCT00330187|9631903|FG000|Overall Study|Withdrawal by Subject|8
6035036|NCT00330187|9631904|FG001|Overall Study|Withdrawal by Subject|5
6035037|NCT00330187|9631905|FG002|Overall Study|Withdrawal by Subject|4
6035038|NCT00330187|9631906|FG003|Overall Study|Withdrawal by Subject|4
6035039|NCT00330343|9631916|FG000|Overall Study|Lost to Follow-up|5
6035040|NCT00330460|9631937|FG000|Overall Study|Physician Decision|1
6035041|NCT00330460|9631938|FG001|Overall Study|Physician Decision|0
6035042|NCT00330460|9631937|FG000|Overall Study|Adverse Event|10
6035043|NCT00330460|9631938|FG001|Overall Study|Adverse Event|8
6035044|NCT00330460|9631937|FG000|Overall Study|Withdrawal by Subject|18
6035045|NCT00330460|9631938|FG001|Overall Study|Withdrawal by Subject|17
6035046|NCT00330460|9631937|FG000|Overall Study|Death|1
6035047|NCT00330460|9631938|FG001|Overall Study|Death|1
6035048|NCT00330460|9631937|FG000|Overall Study|Ineligibility determined|1
6035049|NCT00330460|9631938|FG001|Overall Study|Ineligibility determined|3
6035050|NCT00330460|9631937|FG000|Overall Study|Lost to Follow-up|8
6035051|NCT00330460|9631938|FG001|Overall Study|Lost to Follow-up|3
6035052|NCT00330460|9631937|FG000|Overall Study|Noncompliance|2
6035053|NCT00330460|9631938|FG001|Overall Study|Noncompliance|1
6035054|NCT00330460|9631937|FG000|Overall Study|Other|1
6035055|NCT00330460|9631938|FG001|Overall Study|Other|0
6035056|NCT00330616|9631959|FG000|Overall Study|Adverse Event|13
6035057|NCT00330616|9631959|FG000|Overall Study|Lack of Efficacy|1
6035058|NCT00330616|9631959|FG000|Overall Study|Lost to Follow-up|2
6035059|NCT00330616|9631959|FG000|Overall Study|Withdrawal by Subject|4
6035060|NCT00330616|9631959|FG000|Overall Study|Other|1
6035061|NCT00330668|9631963|FG000|BID Dosing Period|Adverse Event|1
6035062|NCT00330668|9631963|FG000|BID Dosing Period|Lost to Follow-up|7
6035063|NCT00330668|9631963|FG000|BID Dosing Period|Non-Compliance|5
6035064|NCT00330668|9631963|FG000|BID Dosing Period|Withdrawal by Subject|19
6035065|NCT00330668|9631963|FG000|BID Dosing Period|Sponsor's decision|1
6035066|NCT00330668|9631963|FG000|BID Dosing Period|Other|3
6035067|NCT00330668|9631963|FG000|QD Dosing Period|Sponsor decision to terminate study|74
6035068|NCT00330668|9631963|FG000|QD Dosing Period|Other|1
6035069|NCT00330668|9631963|FG000|QD Dosing Period|Withdrawal by Subject|1
6146944|NCT01079962|9781936|FG001|Overall Study|Adverse Event|2
6146945|NCT01079962|9781935|FG000|Overall Study|Withdrawal by Subject|5
6035070|NCT00330668|9631963|FG000|QD Dosing Period|Lost to Follow-up|2
6035071|NCT00330681|9631969|FG000|Overall Study|Adverse Event|3
6035072|NCT00330681|9631970|FG001|Overall Study|Adverse Event|6
6035073|NCT00330681|9631969|FG000|Overall Study|Protocol Violation|0
6035074|NCT00330681|9631970|FG001|Overall Study|Protocol Violation|1
6035075|NCT00330681|9631969|FG000|Overall Study|Withdrawal by Subject|5
6035076|NCT00330681|9631970|FG001|Overall Study|Withdrawal by Subject|5
6035077|NCT00330681|9631969|FG000|Overall Study|Tracheotomy due to worsening of ALS|1
6035078|NCT00330681|9631970|FG001|Overall Study|Tracheotomy due to worsening of ALS|2
6035079|NCT00330759|9631987|FG000|Overall Study|Death|316
6035080|NCT00330759|9631988|FG001|Overall Study|Death|310
6035081|NCT00330759|9631987|FG000|Overall Study|Disease progression|104
6035082|NCT00330759|9631988|FG001|Overall Study|Disease progression|126
6035083|NCT00330759|9631987|FG000|Overall Study|Withdrawal by Subject|143
6035084|NCT00330759|9631988|FG001|Overall Study|Withdrawal by Subject|124
6035085|NCT00330759|9631987|FG000|Overall Study|Adverse Event|48
6035086|NCT00330759|9631988|FG001|Overall Study|Adverse Event|36
6035087|NCT00330759|9631987|FG000|Overall Study|Participant request|31
6035088|NCT00330759|9631988|FG001|Overall Study|Participant request|22
6035089|NCT00330759|9631987|FG000|Overall Study|Lost to Follow-up|16
6035090|NCT00330759|9631988|FG001|Overall Study|Lost to Follow-up|22
6035091|NCT00330759|9631987|FG000|Overall Study|Noncompliance|15
6035092|NCT00330759|9631988|FG001|Overall Study|Noncompliance|17
6035093|NCT00330759|9631987|FG000|Overall Study|Physician Decision|1
6035094|NCT00330759|9631988|FG001|Overall Study|Physician Decision|2
6035095|NCT00330759|9631987|FG000|Overall Study|Protocol deviation|0
6035096|NCT00330759|9631988|FG001|Overall Study|Protocol deviation|2
6035097|NCT00330759|9631987|FG000|Overall Study|Ineligibility determined|2
6035098|NCT00330759|9631988|FG001|Overall Study|Ineligibility determined|1
6035099|NCT00330759|9631987|FG000|Overall Study|Other|36
6035100|NCT00330759|9631988|FG001|Overall Study|Other|44
6035101|NCT00330928|9632014|FG000|Overall Study|Lost to Follow-up|6
6035102|NCT00330928|9632014|FG000|Overall Study|Physician Decision|9
6035103|NCT00330928|9632014|FG000|Overall Study|Death|1
6035104|NCT00330928|9632014|FG000|Overall Study|IVUS could not be performed.|1
6035105|NCT00330967|9632020|FG000|Overall Study|Withdrawal by Subject|0
6035106|NCT00330967|9632021|FG001|Overall Study|Withdrawal by Subject|5
6035107|NCT00330967|9632020|FG000|Overall Study|Physician Decision|0
6035108|NCT00330967|9632021|FG001|Overall Study|Physician Decision|9
6035109|NCT00331006|9632027|FG000|Screening Phase|Withdrawal by Subject|1
6035110|NCT00331006|9632027|FG000|Screening Phase|enrollment halted|1
6035111|NCT00331006|9632027|FG000|Screening Phase|Lost to Follow-up|1
6035112|NCT00331006|9632027|FG000|Screening Phase|Ineligible for treatment phase|4
6035113|NCT00331006|9632027|FG000|Treatment Phase|Withdrawal by Subject|1
6035114|NCT00331006|9632027|FG000|Follow-Up Phase I|Lost to Follow-up|1
6035115|NCT00331006|9632027|FG000|Follow-Up Phase II|Lost to Follow-up|3
6035116|NCT00331136|9632035|FG000|Overall Study|Adverse Event|3
6035117|NCT00331136|9632036|FG001|Overall Study|Adverse Event|5
6035118|NCT00331136|9632037|FG002|Overall Study|Adverse Event|0
6035119|NCT00331136|9632038|FG003|Overall Study|Adverse Event|1
6035120|NCT00331136|9632035|FG000|Overall Study|Withdrawal by Subject|0
6035121|NCT00331136|9632036|FG001|Overall Study|Withdrawal by Subject|1
6035122|NCT00331136|9632037|FG002|Overall Study|Withdrawal by Subject|0
6035123|NCT00331136|9632038|FG003|Overall Study|Withdrawal by Subject|0
6035124|NCT00331136|9632035|FG000|Overall Study|Lost to Follow-up|0
6035125|NCT00331136|9632036|FG001|Overall Study|Lost to Follow-up|1
6035126|NCT00331136|9632037|FG002|Overall Study|Lost to Follow-up|0
6035127|NCT00331136|9632038|FG003|Overall Study|Lost to Follow-up|0
6035128|NCT00331136|9632035|FG000|Overall Study|Protocol Violation|1
6035129|NCT00331136|9632036|FG001|Overall Study|Protocol Violation|0
6035130|NCT00331136|9632037|FG002|Overall Study|Protocol Violation|0
6035131|NCT00331136|9632038|FG003|Overall Study|Protocol Violation|0
6035132|NCT00331136|9632035|FG000|Overall Study|Not treated|1
6035133|NCT00331136|9632036|FG001|Overall Study|Not treated|0
6035134|NCT00331136|9632037|FG002|Overall Study|Not treated|0
6035135|NCT00331136|9632038|FG003|Overall Study|Not treated|0
6035136|NCT00331344|9632057|FG000|Phase I|Adverse Event|0
6035137|NCT00331344|9632058|FG001|Phase I|Adverse Event|0
6035138|NCT00331344|9632059|FG002|Phase I|Adverse Event|0
6035139|NCT00331344|9632060|FG003|Phase I|Adverse Event|1
6035140|NCT00331344|9632061|FG004|Phase I|Adverse Event|2
6035141|NCT00331344|9632062|FG005|Phase I|Adverse Event|2
6035142|NCT00331344|9632063|FG006|Phase I|Adverse Event|0
6035143|NCT00331344|9632064|FG007|Phase I|Adverse Event|1
6035144|NCT00331344|9632065|FG008|Phase I|Adverse Event|0
6146946|NCT01079962|9781936|FG001|Overall Study|Withdrawal by Subject|7
6146947|NCT01079962|9781935|FG000|Overall Study|Protocol Violation|2
6146948|NCT01079962|9781936|FG001|Overall Study|Protocol Violation|2
6146949|NCT01079962|9781935|FG000|Overall Study|No blood pressure (BP) control|3
6146950|NCT01079962|9781936|FG001|Overall Study|No blood pressure (BP) control|0
6146951|NCT01079962|9781935|FG000|Overall Study|Inclusion/exclusion criteria|1
6146952|NCT01079962|9781936|FG001|Overall Study|Inclusion/exclusion criteria|3
6146953|NCT01079962|9781935|FG000|Overall Study|Participant not returning for next visit|1
6146954|NCT01079962|9781936|FG001|Overall Study|Participant not returning for next visit|0
6146955|NCT01079962|9781935|FG000|Overall Study|Due to arrhythmia/bradycardia|1
6146956|NCT01079962|9781936|FG001|Overall Study|Due to arrhythmia/bradycardia|1
6146957|NCT01079988|9781947|FG000|Overall Study|Lost to Follow-up|0
6146958|NCT01079988|9781948|FG001|Overall Study|Lost to Follow-up|0
6146959|NCT01079988|9781949|FG002|Overall Study|Lost to Follow-up|0
6146960|NCT01079988|9781950|FG003|Overall Study|Lost to Follow-up|1
6146961|NCT01079988|9781951|FG004|Overall Study|Lost to Follow-up|0
6146962|NCT01079988|9781947|FG000|Overall Study|Lack of Efficacy|1
6146963|NCT01079988|9781948|FG001|Overall Study|Lack of Efficacy|0
6146964|NCT01079988|9781949|FG002|Overall Study|Lack of Efficacy|0
6146965|NCT01079988|9781950|FG003|Overall Study|Lack of Efficacy|0
6146966|NCT01079988|9781951|FG004|Overall Study|Lack of Efficacy|0
6146967|NCT01079988|9781947|FG000|Overall Study|Other|0
6146968|NCT01079988|9781948|FG001|Overall Study|Other|0
6146969|NCT01079988|9781949|FG002|Overall Study|Other|0
6146970|NCT01079988|9781950|FG003|Overall Study|Other|2
6146971|NCT01079988|9781951|FG004|Overall Study|Other|1
6191306|NCT01421342|9847961|FG001|Continuation of Treatment (Week 12 - 36)|Other reason for withdrawal|0
6191307|NCT01421342|9847962|FG002|Continuation of Treatment (Week 12 - 36)|Other reason for withdrawal|7
6191308|NCT01421459|9847976|FG000|Overall Study|Adverse Event|6
6191309|NCT01421459|9847977|FG001|Overall Study|Adverse Event|10
6191310|NCT01421459|9847976|FG000|Overall Study|Death|1
6191311|NCT01421459|9847977|FG001|Overall Study|Death|1
6191312|NCT01421459|9847976|FG000|Overall Study|Lack of Efficacy|1
6191313|NCT01421459|9847977|FG001|Overall Study|Lack of Efficacy|2
6035145|NCT00331344|9632057|FG000|Phase II|Death|0
6035146|NCT00331344|9632058|FG001|Phase II|Death|0
6035147|NCT00331344|9632059|FG002|Phase II|Death|0
6035148|NCT00331344|9632060|FG003|Phase II|Death|0
6191314|NCT01421459|9847976|FG000|Overall Study|Lost to Follow-up|8
6191315|NCT01421459|9847977|FG001|Overall Study|Lost to Follow-up|9
6191316|NCT01421459|9847976|FG000|Overall Study|Physician Decision|9
6191317|NCT01421459|9847977|FG001|Overall Study|Physician Decision|9
6191318|NCT01421459|9847976|FG000|Overall Study|Protocol Violation|8
6191319|NCT01421459|9847977|FG001|Overall Study|Protocol Violation|5
6035149|NCT00331344|9632061|FG004|Phase II|Death|0
6035150|NCT00331344|9632062|FG005|Phase II|Death|0
6035151|NCT00331344|9632063|FG006|Phase II|Death|0
6035152|NCT00331344|9632064|FG007|Phase II|Death|0
6035153|NCT00331344|9632065|FG008|Phase II|Death|4
6035154|NCT00331409|9632078|FG000|Overall Study|Lack of Efficacy|4
6035155|NCT00331422|9632082|FG000|Overall Study|Did not receive entire study regimen|5
6035156|NCT00331552|9632089|FG000|Period 3: Phase II|Neurological Symptoms|1
6035157|NCT00331552|9632090|FG001|Period 3: Phase II|Neurological Symptoms|0
6035158|NCT00331552|9632089|FG000|Period 3: Phase II|Severe Nausea|1
6035159|NCT00331552|9632090|FG001|Period 3: Phase II|Severe Nausea|0
6035160|NCT00331630|9632101|FG000|Evaluated for and Completed SOC Surgery|Progressive Disease|1
6035161|NCT00331630|9632101|FG000|Evaluated for and Completed SOC Surgery|Lost to Follow-up|1
6035162|NCT00331630|9632101|FG000|Follow up for 5 Years|Death|5
6035163|NCT00331630|9632101|FG000|Follow up for 5 Years|Data collection was stopped|24
6035164|NCT00331682|9632105|FG000|Overall Study|Adverse Event|1
6035165|NCT00331760|9632111|FG000|Overall Study|Ineligible / no protocol treatment|15
6035166|NCT00331760|9632112|FG001|Overall Study|Ineligible / no protocol treatment|8
6035167|NCT00331799|9632119|FG000|Overall Study|Withdrawal by Subject|2
6035168|NCT00331799|9632119|FG000|Overall Study|Sedation|1
6035169|NCT00331864|9632125|FG000|Overall Study|Adverse Event|30
6035170|NCT00331864|9632126|FG001|Overall Study|Adverse Event|1
6035171|NCT00331864|9632125|FG000|Overall Study|Lack of Efficacy|4
6035172|NCT00331864|9632126|FG001|Overall Study|Lack of Efficacy|0
6035173|NCT00331864|9632125|FG000|Overall Study|Protocol Violation|3
6035174|NCT00331864|9632126|FG001|Overall Study|Protocol Violation|0
6035175|NCT00331864|9632125|FG000|Overall Study|Withdrawal by Subject|10
6035176|NCT00331864|9632126|FG001|Overall Study|Withdrawal by Subject|0
6035177|NCT00331864|9632125|FG000|Overall Study|Lost to Follow-up|4
6035178|NCT00331864|9632126|FG001|Overall Study|Lost to Follow-up|3
6035179|NCT00331864|9632125|FG000|Overall Study|Administrative Problems|1
6035180|NCT00331864|9632126|FG001|Overall Study|Administrative Problems|0
6035181|NCT00331864|9632125|FG000|Overall Study|Death|6
6035182|NCT00331864|9632126|FG001|Overall Study|Death|0
6035183|NCT00332189|9632141|FG000|Overall Study|Adverse Event|3
6146972|NCT01080131|9781976|FG000|Core Study (0- 12 Weeks)|Abnormal laboratory value(s)|1
6146973|NCT01080131|9781977|FG001|Core Study (0- 12 Weeks)|Abnormal laboratory value(s)|1
6146974|NCT01080131|9781976|FG000|Core Study (0- 12 Weeks)|Patient withdrew consent|6
6146975|NCT01080131|9781977|FG001|Core Study (0- 12 Weeks)|Patient withdrew consent|4
6146976|NCT01080131|9781976|FG000|Core Study (0- 12 Weeks)|Lost to Follow-up|5
6146977|NCT01080131|9781977|FG001|Core Study (0- 12 Weeks)|Lost to Follow-up|3
6146978|NCT01080131|9781976|FG000|Core Study (0- 12 Weeks)|Administrative problems|0
6146979|NCT01080131|9781977|FG001|Core Study (0- 12 Weeks)|Administrative problems|1
6146980|NCT01080131|9781976|FG000|Core Study (0- 12 Weeks)|Death|1
6146981|NCT01080131|9781977|FG001|Core Study (0- 12 Weeks)|Death|0
6146982|NCT01080131|9781976|FG000|Core Study (0- 12 Weeks)|Protocol deviation|0
6146983|NCT01080131|9781977|FG001|Core Study (0- 12 Weeks)|Protocol deviation|2
6146984|NCT01080131|9781976|FG000|Extension Study 1 (12 -24 Weeks)|Adverse Event|1
6146985|NCT01080131|9781977|FG001|Extension Study 1 (12 -24 Weeks)|Adverse Event|0
6146986|NCT01080131|9781976|FG000|Extension Study 1 (12 -24 Weeks)|Unsatisfactory Therapeutic Effect|0
6146987|NCT01080131|9781977|FG001|Extension Study 1 (12 -24 Weeks)|Unsatisfactory Therapeutic Effect|1
6146988|NCT01080131|9781976|FG000|Extension Study 1 (12 -24 Weeks)|Withdrawal by Subject|4
6146989|NCT01080131|9781977|FG001|Extension Study 1 (12 -24 Weeks)|Withdrawal by Subject|3
6146990|NCT01080131|9781976|FG000|Extension Study 1 (12 -24 Weeks)|Lost to Follow-up|1
6146991|NCT01080131|9781977|FG001|Extension Study 1 (12 -24 Weeks)|Lost to Follow-up|0
6146992|NCT01080131|9781976|FG000|Extension Study 2 (25-72 Weeks)|Adverse Event|1
6146993|NCT01080131|9781977|FG001|Extension Study 2 (25-72 Weeks)|Adverse Event|2
6146994|NCT01080131|9781976|FG000|Extension Study 2 (25-72 Weeks)|Withdrawal by Subject|3
6146995|NCT01080131|9781977|FG001|Extension Study 2 (25-72 Weeks)|Withdrawal by Subject|4
6146996|NCT01080131|9781976|FG000|Extension Study 2 (25-72 Weeks)|Lost to Follow-up|4
6146997|NCT01080131|9781977|FG001|Extension Study 2 (25-72 Weeks)|Lost to Follow-up|5
6146998|NCT01080300|9782051|FG000|Overall Study|Adverse Event|49
6146999|NCT01080300|9782052|FG001|Overall Study|Adverse Event|35
6147000|NCT01080300|9782051|FG000|Overall Study|Lack of Efficacy|12
6147001|NCT01080300|9782052|FG001|Overall Study|Lack of Efficacy|15
6147002|NCT01080300|9782051|FG000|Overall Study|Protocol Violation|7
6147003|NCT01080300|9782052|FG001|Overall Study|Protocol Violation|13
6147004|NCT01080300|9782051|FG000|Overall Study|Lost to Follow-up|10
6147005|NCT01080300|9782052|FG001|Overall Study|Lost to Follow-up|6
6147006|NCT01080300|9782051|FG000|Overall Study|Death|0
6147007|NCT01080300|9782052|FG001|Overall Study|Death|1
6147008|NCT01080300|9782051|FG000|Overall Study|Withdrawal by Subject|12
6147009|NCT01080300|9782052|FG001|Overall Study|Withdrawal by Subject|28
6147010|NCT01080300|9782051|FG000|Overall Study|Reasons not specified|4
6035184|NCT00332189|9632141|FG000|Overall Study|Uncooperative/Noncompliant|3
6147011|NCT01080300|9782052|FG001|Overall Study|Reasons not specified|6
6147012|NCT01080326|9782060|FG000|Overall Study|Patient deterioration prior to procedure|3
6147013|NCT01080326|9782060|FG000|Overall Study|Surgeon decision|1
6147014|NCT01080391|9782066|FG000|Overall Study|Randomized but not treated|7
6147015|NCT01080391|9782067|FG001|Overall Study|Randomized but not treated|4
6035185|NCT00332189|9632141|FG000|Overall Study|Withdrawal by Subject|9
6035186|NCT00332189|9632141|FG000|Overall Study|Lack of Efficacy|4
6035187|NCT00332189|9632141|FG000|Overall Study|Moved out of country|2
6035188|NCT00332202|9632148|FG000|Overall Study|Adverse Event|72
6147016|NCT01080625|9782076|FG000|Overall Study|Physician Decision|0
6035189|NCT00332202|9632149|FG001|Overall Study|Adverse Event|28
6035190|NCT00332202|9632148|FG000|Overall Study|Lost to Follow-up|2
6035191|NCT00332202|9632149|FG001|Overall Study|Lost to Follow-up|1
6035192|NCT00332202|9632148|FG000|Overall Study|Physician Decision|6
6035193|NCT00332202|9632149|FG001|Overall Study|Physician Decision|8
6035194|NCT00332202|9632148|FG000|Overall Study|Protocol Entry Criteria Not Met|6
6035195|NCT00332202|9632149|FG001|Overall Study|Protocol Entry Criteria Not Met|5
6035196|NCT00332202|9632148|FG000|Overall Study|Protocol Violation|7
6035197|NCT00332202|9632149|FG001|Overall Study|Protocol Violation|2
6035198|NCT00332202|9632148|FG000|Overall Study|Sponsor Decision|1
6035199|NCT00332202|9632149|FG001|Overall Study|Sponsor Decision|2
6035200|NCT00332202|9632148|FG000|Overall Study|Withdrawal by Subject|36
6035201|NCT00332202|9632149|FG001|Overall Study|Withdrawal by Subject|17
6035202|NCT00332202|9632148|FG000|Overall Study|Progressive Disease|106
6035203|NCT00332202|9632149|FG001|Overall Study|Progressive Disease|60
6035204|NCT00332202|9632148|FG000|Overall Study|Death|5
6035205|NCT00332202|9632149|FG001|Overall Study|Death|2
6035206|NCT00332241|9632166|FG000|Overall Study|Lack of Efficacy|6
6035207|NCT00332241|9632167|FG001|Overall Study|Lack of Efficacy|1
6035208|NCT00332241|9632166|FG000|Overall Study|Adverse Event|3
6035209|NCT00332241|9632167|FG001|Overall Study|Adverse Event|5
6035210|NCT00332241|9632166|FG000|Overall Study|Withdrawal by Subject|2
6035211|NCT00332241|9632167|FG001|Overall Study|Withdrawal by Subject|1
6035212|NCT00332241|9632166|FG000|Overall Study|Lost to Follow-up|4
6035213|NCT00332241|9632167|FG001|Overall Study|Lost to Follow-up|1
6035214|NCT00332332|9632173|FG000|Overall Study|Adverse Event|13
6035215|NCT00332332|9632173|FG000|Overall Study|Death|1
6035216|NCT00332332|9632173|FG000|Overall Study|Withdrawal by Subject|8
6035217|NCT00332332|9632173|FG000|Overall Study|Physician Decision|1
6035218|NCT00332332|9632173|FG000|Overall Study|Lost to Follow-up|3
6035219|NCT00332332|9632173|FG000|Overall Study|Protocol deviation|4
6035220|NCT00332332|9632173|FG000|Overall Study|Noncompliance|2
6035221|NCT00332332|9632173|FG000|Overall Study|Disease progression|2
6035222|NCT00332332|9632173|FG000|Overall Study|Other|18
6035223|NCT00332332|9632173|FG000|Overall Study|Did not receive study treatment|16
6035224|NCT00332462|9632177|FG000|Overall Study|Adverse Event|5
6035225|NCT00332462|9632177|FG000|Overall Study|Abnormal Lab Value|1
6035226|NCT00332462|9632177|FG000|Overall Study|Unsatisfactory therapeutic effect|4
6035227|NCT00332462|9632177|FG000|Overall Study|no longer requires study drug|1
6035228|NCT00332462|9632177|FG000|Overall Study|Death|3
6035229|NCT00332462|9632177|FG000|Overall Study|Graft Loss|2
6035230|NCT00332488|9632187|FG000|Initial Treatment Phase (Weeks 0 - 12)|Adverse Event|8
6035231|NCT00332488|9632188|FG001|Initial Treatment Phase (Weeks 0 - 12)|Adverse Event|2
6035232|NCT00332488|9632189|FG002|Initial Treatment Phase (Weeks 0 - 12)|Adverse Event|6
6035233|NCT00332488|9632187|FG000|Initial Treatment Phase (Weeks 0 - 12)|Physician Decision|13
6035234|NCT00332488|9632188|FG001|Initial Treatment Phase (Weeks 0 - 12)|Physician Decision|2
6035235|NCT00332488|9632189|FG002|Initial Treatment Phase (Weeks 0 - 12)|Physician Decision|10
6035236|NCT00332488|9632187|FG000|Initial Treatment Phase (Weeks 0 - 12)|Withdrawal by Subject|21
6035237|NCT00332488|9632188|FG001|Initial Treatment Phase (Weeks 0 - 12)|Withdrawal by Subject|10
6035238|NCT00332488|9632189|FG002|Initial Treatment Phase (Weeks 0 - 12)|Withdrawal by Subject|20
6035239|NCT00332488|9632187|FG000|Initial Treatment Phase (Weeks 0 - 12)|Various|4
6035240|NCT00332488|9632188|FG001|Initial Treatment Phase (Weeks 0 - 12)|Various|0
6035241|NCT00332488|9632189|FG002|Initial Treatment Phase (Weeks 0 - 12)|Various|20
6035242|NCT00332488|9632187|FG000|Initial Treatment Phase (Weeks 0 - 12)|Lost to Follow-up|1
6035243|NCT00332488|9632188|FG001|Initial Treatment Phase (Weeks 0 - 12)|Lost to Follow-up|3
6035244|NCT00332488|9632189|FG002|Initial Treatment Phase (Weeks 0 - 12)|Lost to Follow-up|0
6035245|NCT00332488|9632187|FG000|Initial Treatment Phase (Weeks 0 - 12)|Protocol Violation|3
6035246|NCT00332488|9632188|FG001|Initial Treatment Phase (Weeks 0 - 12)|Protocol Violation|1
6035247|NCT00332488|9632189|FG002|Initial Treatment Phase (Weeks 0 - 12)|Protocol Violation|0
6035248|NCT00332488|9632187|FG000|Transfer Treatment Phase (Weeks 12 - 24)|Adverse Event|0
6035249|NCT00332488|9632188|FG001|Transfer Treatment Phase (Weeks 12 - 24)|Adverse Event|0
6035250|NCT00332488|9632189|FG002|Transfer Treatment Phase (Weeks 12 - 24)|Adverse Event|3
6035251|NCT00332488|9632187|FG000|Transfer Treatment Phase (Weeks 12 - 24)|Lost to Follow-up|0
6035252|NCT00332488|9632188|FG001|Transfer Treatment Phase (Weeks 12 - 24)|Lost to Follow-up|0
6035253|NCT00332488|9632189|FG002|Transfer Treatment Phase (Weeks 12 - 24)|Lost to Follow-up|1
6035254|NCT00332488|9632187|FG000|Transfer Treatment Phase (Weeks 12 - 24)|Physician Decision|0
6035255|NCT00332488|9632188|FG001|Transfer Treatment Phase (Weeks 12 - 24)|Physician Decision|0
6035256|NCT00332488|9632189|FG002|Transfer Treatment Phase (Weeks 12 - 24)|Physician Decision|3
6035257|NCT00332488|9632187|FG000|Transfer Treatment Phase (Weeks 12 - 24)|Protocol Violation|0
6035258|NCT00332488|9632188|FG001|Transfer Treatment Phase (Weeks 12 - 24)|Protocol Violation|0
6035259|NCT00332488|9632189|FG002|Transfer Treatment Phase (Weeks 12 - 24)|Protocol Violation|1
6035260|NCT00332488|9632187|FG000|Transfer Treatment Phase (Weeks 12 - 24)|Withdrawal by Subject|2
6035261|NCT00332488|9632188|FG001|Transfer Treatment Phase (Weeks 12 - 24)|Withdrawal by Subject|2
6035262|NCT00332488|9632189|FG002|Transfer Treatment Phase (Weeks 12 - 24)|Withdrawal by Subject|8
6035263|NCT00332488|9632187|FG000|Transfer Treatment Phase (Weeks 12 - 24)|Various|0
6035264|NCT00332488|9632188|FG001|Transfer Treatment Phase (Weeks 12 - 24)|Various|0
6035265|NCT00332488|9632189|FG002|Transfer Treatment Phase (Weeks 12 - 24)|Various|5
6035266|NCT00332696|9632248|FG000|Overall Study|Death|24
6035267|NCT00332696|9632249|FG001|Overall Study|Death|14
6035268|NCT00332696|9632248|FG000|Overall Study|Insufficient therapeutic effect|4
6035269|NCT00332696|9632249|FG001|Overall Study|Insufficient therapeutic effect|11
6035270|NCT00332696|9632248|FG000|Overall Study|Adverse Event|1
6035271|NCT00332696|9632249|FG001|Overall Study|Adverse Event|2
6035272|NCT00332696|9632248|FG000|Overall Study|Condition does not justify treatment|0
6035273|NCT00332696|9632249|FG001|Overall Study|Condition does not justify treatment|2
6035274|NCT00332696|9632248|FG000|Overall Study|Lost to Follow-up|0
6035275|NCT00332696|9632249|FG001|Overall Study|Lost to Follow-up|1
6035276|NCT00332696|9632248|FG000|Overall Study|Withdrawal by Subject|1
6035277|NCT00332696|9632249|FG001|Overall Study|Withdrawal by Subject|0
6035278|NCT00332709|9632257|FG000|Overall Study|Adverse Event|11
6035279|NCT00332709|9632258|FG001|Overall Study|Adverse Event|14
6035280|NCT00332709|9632257|FG000|Overall Study|Withdrawal by Subject|2
6035281|NCT00332709|9632258|FG001|Overall Study|Withdrawal by Subject|3
6035282|NCT00332709|9632257|FG000|Overall Study|Lost to Follow-up|2
6035283|NCT00332709|9632258|FG001|Overall Study|Lost to Follow-up|0
6035284|NCT00332709|9632257|FG000|Overall Study|Administrative Problems|0
6035285|NCT00332709|9632258|FG001|Overall Study|Administrative Problems|3
6035286|NCT00332709|9632257|FG000|Overall Study|Abnormal test procedure result|1
6035287|NCT00332709|9632258|FG001|Overall Study|Abnormal test procedure result|0
6035288|NCT00332839|9632275|FG000|Core (Months 0 - 12)|Administrative problems|1
6035289|NCT00332839|9632276|FG001|Core (Months 0 - 12)|Administrative problems|1
6035290|NCT00332839|9632275|FG000|Core (Months 0 - 12)|Withdrawal by Subject|3
6035291|NCT00332839|9632276|FG001|Core (Months 0 - 12)|Withdrawal by Subject|1
6035292|NCT00332839|9632275|FG000|Core (Months 0 - 12)|Protocol deviation|1
6035293|NCT00332839|9632276|FG001|Core (Months 0 - 12)|Protocol deviation|1
6035294|NCT00332839|9632275|FG000|Core (Months 0 - 12)|Adverse Event|5
6035295|NCT00332839|9632276|FG001|Core (Months 0 - 12)|Adverse Event|15
6035296|NCT00332839|9632275|FG000|Follow-up (Months 12 - 60)|Withdrawal by Subject|1
6035297|NCT00332839|9632276|FG001|Follow-up (Months 12 - 60)|Withdrawal by Subject|1
6035298|NCT00332839|9632275|FG000|Follow-up (Months 12 - 60)|Lost to Follow-up|2
6035299|NCT00332839|9632276|FG001|Follow-up (Months 12 - 60)|Lost to Follow-up|1
6035300|NCT00332839|9632275|FG000|Follow-up (Months 12 - 60)|Death|1
6035301|NCT00332839|9632276|FG001|Follow-up (Months 12 - 60)|Death|1
6035302|NCT00333138|9632285|FG000|Core Study (6 Months)|Adverse Event|4
6035303|NCT00333138|9632286|FG001|Core Study (6 Months)|Adverse Event|5
6035304|NCT00333138|9632287|FG002|Core Study (6 Months)|Adverse Event|8
6035305|NCT00333138|9632285|FG000|Core Study (6 Months)|Withdrawal by Subject|1
6035306|NCT00333138|9632286|FG001|Core Study (6 Months)|Withdrawal by Subject|1
6035307|NCT00333138|9632287|FG002|Core Study (6 Months)|Withdrawal by Subject|2
6035308|NCT00333138|9632285|FG000|Core Study (6 Months)|Lack of Efficacy|1
6035309|NCT00333138|9632286|FG001|Core Study (6 Months)|Lack of Efficacy|0
6035310|NCT00333138|9632287|FG002|Core Study (6 Months)|Lack of Efficacy|0
6035311|NCT00333138|9632285|FG000|Core Study (6 Months)|Protocol Violation|1
6035312|NCT00333138|9632286|FG001|Core Study (6 Months)|Protocol Violation|0
6035313|NCT00333138|9632287|FG002|Core Study (6 Months)|Protocol Violation|1
6035314|NCT00333138|9632285|FG000|Core Study (6 Months)|Laboratory abnormality|0
6035315|NCT00333138|9632286|FG001|Core Study (6 Months)|Laboratory abnormality|0
6035316|NCT00333138|9632287|FG002|Core Study (6 Months)|Laboratory abnormality|1
6035317|NCT00333138|9632285|FG000|Extension Study (Month6 to End of Study)|Abnormal laboratory value|3
6035318|NCT00333138|9632286|FG001|Extension Study (Month6 to End of Study)|Abnormal laboratory value|2
6035319|NCT00333138|9632287|FG002|Extension Study (Month6 to End of Study)|Abnormal laboratory value|2
6035320|NCT00333138|9632285|FG000|Extension Study (Month6 to End of Study)|Administrative problems|1
6035321|NCT00333138|9632286|FG001|Extension Study (Month6 to End of Study)|Administrative problems|1
6035322|NCT00333138|9632287|FG002|Extension Study (Month6 to End of Study)|Administrative problems|2
6035323|NCT00333138|9632285|FG000|Extension Study (Month6 to End of Study)|Adverse Event|15
6035324|NCT00333138|9632286|FG001|Extension Study (Month6 to End of Study)|Adverse Event|19
6035325|NCT00333138|9632287|FG002|Extension Study (Month6 to End of Study)|Adverse Event|15
6035326|NCT00333138|9632285|FG000|Extension Study (Month6 to End of Study)|Protocol Violation|0
6035327|NCT00333138|9632286|FG001|Extension Study (Month6 to End of Study)|Protocol Violation|0
6035328|NCT00333138|9632287|FG002|Extension Study (Month6 to End of Study)|Protocol Violation|3
6035329|NCT00333138|9632285|FG000|Extension Study (Month6 to End of Study)|Withdrawal by Subject|14
6035330|NCT00333138|9632286|FG001|Extension Study (Month6 to End of Study)|Withdrawal by Subject|13
6035331|NCT00333138|9632287|FG002|Extension Study (Month6 to End of Study)|Withdrawal by Subject|14
6035332|NCT00333138|9632285|FG000|Extension Study (Month6 to End of Study)|Lack of Efficacy|7
6035333|NCT00333138|9632286|FG001|Extension Study (Month6 to End of Study)|Lack of Efficacy|4
6035334|NCT00333138|9632287|FG002|Extension Study (Month6 to End of Study)|Lack of Efficacy|7
6035335|NCT00333138|9632285|FG000|Extension Study (Month6 to End of Study)|Patient no longer required study drug|2
6035336|NCT00333138|9632286|FG001|Extension Study (Month6 to End of Study)|Patient no longer required study drug|1
6147017|NCT01080625|9782077|FG001|Overall Study|Physician Decision|2
6035337|NCT00333138|9632287|FG002|Extension Study (Month6 to End of Study)|Patient no longer required study drug|0
6035338|NCT00333138|9632285|FG000|Extension Study (Month6 to End of Study)|Lost to Follow-up|1
6048807|NCT00420641|9648141|FG002|Overall Study|Lack of Efficacy|4
6035339|NCT00333138|9632286|FG001|Extension Study (Month6 to End of Study)|Lost to Follow-up|1
6035340|NCT00333138|9632287|FG002|Extension Study (Month6 to End of Study)|Lost to Follow-up|0
6035341|NCT00333138|9632285|FG000|Extension Study (Month6 to End of Study)|Death|0
6035342|NCT00333138|9632286|FG001|Extension Study (Month6 to End of Study)|Death|1
6035343|NCT00333138|9632287|FG002|Extension Study (Month6 to End of Study)|Death|0
6035344|NCT00333359|9632318|FG000|Overall Study|Adverse Event|29
6035345|NCT00333359|9632319|FG001|Overall Study|Adverse Event|35
6035346|NCT00333359|9632318|FG000|Overall Study|Withdrawal by Subject|19
6035347|NCT00333359|9632319|FG001|Overall Study|Withdrawal by Subject|37
6035348|NCT00333359|9632318|FG000|Overall Study|Physician Decision|2
6035349|NCT00333359|9632319|FG001|Overall Study|Physician Decision|2
6035350|NCT00333359|9632318|FG000|Overall Study|Protocol Non-compliance|2
6035351|NCT00333359|9632319|FG001|Overall Study|Protocol Non-compliance|8
6035352|NCT00333359|9632318|FG000|Overall Study|Lost to Follow-up|15
6035353|NCT00333359|9632319|FG001|Overall Study|Lost to Follow-up|25
6035354|NCT00333359|9632318|FG000|Overall Study|Termination or Withdrawal by Sponsor|1
6035355|NCT00333359|9632319|FG001|Overall Study|Termination or Withdrawal by Sponsor|1
6035356|NCT00333359|9632318|FG000|Overall Study|Treatment Failure|3
6035357|NCT00333359|9632319|FG001|Overall Study|Treatment Failure|8
6035358|NCT00333359|9632318|FG000|Overall Study|Withdrew before Receiving One Dose|2
6035359|NCT00333359|9632319|FG001|Overall Study|Withdrew before Receiving One Dose|6
6035360|NCT00333619|9632345|FG000|Overall Study|Death|12
6035361|NCT00333619|9632346|FG001|Overall Study|Death|6
6035362|NCT00333619|9632345|FG000|Overall Study|Withdrawal by Subject|6
6035363|NCT00333619|9632346|FG001|Overall Study|Withdrawal by Subject|1
6035364|NCT00333619|9632345|FG000|Overall Study|Lost to Follow-up|3
6035365|NCT00333619|9632346|FG001|Overall Study|Lost to Follow-up|3
6035366|NCT00333775|9632370|FG000|Overall Study|Death|144
6035367|NCT00333775|9632371|FG001|Overall Study|Death|149
6035368|NCT00333775|9632372|FG002|Overall Study|Death|143
6035369|NCT00333775|9632370|FG000|Overall Study|In Follow-up When Study Stopped|87
6035370|NCT00333775|9632371|FG001|Overall Study|In Follow-up When Study Stopped|92
6035371|NCT00333775|9632372|FG002|Overall Study|In Follow-up When Study Stopped|96
6035372|NCT00333775|9632370|FG000|Overall Study|Lost to Follow-up|10
6035373|NCT00333775|9632371|FG001|Overall Study|Lost to Follow-up|7
6035374|NCT00333775|9632372|FG002|Overall Study|Lost to Follow-up|8
6035375|NCT00333788|9632380|FG000|Overall Study|Adverse Event|44
6035376|NCT00333788|9632380|FG000|Overall Study|Lack of Efficacy|80
6035377|NCT00333788|9632380|FG000|Overall Study|Lost to Follow-up|2
6035378|NCT00333788|9632380|FG000|Overall Study|Withdrawal by Subject|24
6035379|NCT00333788|9632380|FG000|Overall Study|Other: Non-compliance|2
6035380|NCT00333788|9632380|FG000|Overall Study|Other: Moved|2
6035381|NCT00333788|9632380|FG000|Overall Study|Other: Recurrent squamaous cell cancer|1
6035382|NCT00333788|9632380|FG000|Overall Study|Other: Investigator decision|1
6035383|NCT00333788|9632380|FG000|Overall Study|Other: Quality of life concern|1
6035384|NCT00333788|9632380|FG000|Overall Study|Other: Sponsor decision|1
6035385|NCT00333788|9632380|FG000|Overall Study|Other: Subject in need of an Entocort|1
6035386|NCT00333788|9632380|FG000|Overall Study|Other: Medical monitor decision|1
6035387|NCT00333788|9632380|FG000|Overall Study|Other: Physician decision|1
6035388|NCT00333788|9632380|FG000|Overall Study|Other: Signed consent for another study|1
6035389|NCT00333801|9632386|FG000|Overall Study|Moved to another state|5
6035390|NCT00333801|9632387|FG001|Overall Study|Moved to another state|3
6035391|NCT00333801|9632386|FG000|Overall Study|Lost to Follow-up|2
6035392|NCT00333801|9632387|FG001|Overall Study|Lost to Follow-up|0
6035393|NCT00333801|9632386|FG000|Overall Study|Incarcerated|1
6035394|NCT00333801|9632387|FG001|Overall Study|Incarcerated|2
6035395|NCT00333801|9632386|FG000|Overall Study|Withdrawal by Subject|0
6035396|NCT00333801|9632387|FG001|Overall Study|Withdrawal by Subject|1
6035397|NCT00333840|9632408|FG000|First-line Treatment Period|Adverse Event|38
6035398|NCT00333840|9632409|FG001|First-line Treatment Period|Adverse Event|37
6035399|NCT00333840|9632410|FG002|First-line Treatment Period|Adverse Event|0
6035400|NCT00333840|9632411|FG003|First-line Treatment Period|Adverse Event|0
6035401|NCT00333840|9632408|FG000|First-line Treatment Period|Abnormal laboratory values|3
6035402|NCT00333840|9632409|FG001|First-line Treatment Period|Abnormal laboratory values|1
6035403|NCT00333840|9632410|FG002|First-line Treatment Period|Abnormal laboratory values|0
6035404|NCT00333840|9632411|FG003|First-line Treatment Period|Abnormal laboratory values|0
6035405|NCT00333840|9632408|FG000|First-line Treatment Period|Abnormal procedure|2
6035406|NCT00333840|9632409|FG001|First-line Treatment Period|Abnormal procedure|0
6035407|NCT00333840|9632410|FG002|First-line Treatment Period|Abnormal procedure|0
6035408|NCT00333840|9632411|FG003|First-line Treatment Period|Abnormal procedure|0
6035409|NCT00333840|9632408|FG000|First-line Treatment Period|Unsatisfactory therapeutic effect|88
6035410|NCT00333840|9632409|FG001|First-line Treatment Period|Unsatisfactory therapeutic effect|29
6035411|NCT00333840|9632410|FG002|First-line Treatment Period|Unsatisfactory therapeutic effect|0
6035412|NCT00333840|9632411|FG003|First-line Treatment Period|Unsatisfactory therapeutic effect|0
6035413|NCT00333840|9632408|FG000|First-line Treatment Period|No longer required study drug|21
6035414|NCT00333840|9632409|FG001|First-line Treatment Period|No longer required study drug|8
6035415|NCT00333840|9632410|FG002|First-line Treatment Period|No longer required study drug|0
6035416|NCT00333840|9632411|FG003|First-line Treatment Period|No longer required study drug|0
6035417|NCT00333840|9632408|FG000|First-line Treatment Period|Protocol Violation|17
6035418|NCT00333840|9632409|FG001|First-line Treatment Period|Protocol Violation|17
6035419|NCT00333840|9632410|FG002|First-line Treatment Period|Protocol Violation|0
6035420|NCT00333840|9632411|FG003|First-line Treatment Period|Protocol Violation|0
6035421|NCT00333840|9632408|FG000|First-line Treatment Period|Subject withdrew consent|57
6035422|NCT00333840|9632409|FG001|First-line Treatment Period|Subject withdrew consent|77
6147018|NCT01080625|9782078|FG002|Overall Study|Physician Decision|1
6147019|NCT01080716|9782103|FG000|Part 1|Physician Decision|1
6147020|NCT01080716|9782104|FG001|Part 1|Physician Decision|0
6147021|NCT01080716|9782105|FG002|Part 1|Physician Decision|0
6147022|NCT01080716|9782106|FG003|Part 1|Physician Decision|0
6147023|NCT01080807|9782139|FG000|Overall Study|Adverse Event|9
6147024|NCT01080807|9782140|FG001|Overall Study|Adverse Event|1
6147025|NCT01080807|9782139|FG000|Overall Study|Lack of Efficacy|0
6147026|NCT01080807|9782140|FG001|Overall Study|Lack of Efficacy|1
6147027|NCT01080807|9782139|FG000|Overall Study|Withdrawal by Subject|7
6035423|NCT00333840|9632410|FG002|First-line Treatment Period|Subject withdrew consent|0
6035424|NCT00333840|9632411|FG003|First-line Treatment Period|Subject withdrew consent|0
6035425|NCT00333840|9632408|FG000|First-line Treatment Period|Lost to Follow-up|15
6035426|NCT00333840|9632409|FG001|First-line Treatment Period|Lost to Follow-up|6
6035427|NCT00333840|9632410|FG002|First-line Treatment Period|Lost to Follow-up|0
6035428|NCT00333840|9632411|FG003|First-line Treatment Period|Lost to Follow-up|0
6035429|NCT00333840|9632408|FG000|First-line Treatment Period|Administrative problems|12
6035430|NCT00333840|9632409|FG001|First-line Treatment Period|Administrative problems|6
6035431|NCT00333840|9632410|FG002|First-line Treatment Period|Administrative problems|0
6035432|NCT00333840|9632411|FG003|First-line Treatment Period|Administrative problems|0
6035433|NCT00333840|9632408|FG000|First-line Treatment Period|Death|19
6035434|NCT00333840|9632409|FG001|First-line Treatment Period|Death|2
6035435|NCT00333840|9632410|FG002|First-line Treatment Period|Death|0
6035436|NCT00333840|9632411|FG003|First-line Treatment Period|Death|0
6035437|NCT00333840|9632408|FG000|First-line Treatment Period|Crossed over to other treatment arm|14
6035438|NCT00333840|9632409|FG001|First-line Treatment Period|Crossed over to other treatment arm|363
6035439|NCT00333840|9632410|FG002|First-line Treatment Period|Crossed over to other treatment arm|0
6035440|NCT00333840|9632411|FG003|First-line Treatment Period|Crossed over to other treatment arm|0
6035441|NCT00333840|9632408|FG000|Second-line Treatment Period|Adverse Event|0
6035442|NCT00333840|9632409|FG001|Second-line Treatment Period|Adverse Event|0
6035443|NCT00333840|9632410|FG002|Second-line Treatment Period|Adverse Event|3
6035444|NCT00333840|9632411|FG003|Second-line Treatment Period|Adverse Event|34
6035445|NCT00333840|9632408|FG000|Second-line Treatment Period|Abnormal Laboratory Values|0
6035446|NCT00333840|9632409|FG001|Second-line Treatment Period|Abnormal Laboratory Values|0
6035447|NCT00333840|9632410|FG002|Second-line Treatment Period|Abnormal Laboratory Values|0
6035448|NCT00333840|9632411|FG003|Second-line Treatment Period|Abnormal Laboratory Values|3
6035449|NCT00333840|9632408|FG000|Second-line Treatment Period|Abnormal procedure|0
6035450|NCT00333840|9632409|FG001|Second-line Treatment Period|Abnormal procedure|0
6035451|NCT00333840|9632410|FG002|Second-line Treatment Period|Abnormal procedure|0
6035452|NCT00333840|9632411|FG003|Second-line Treatment Period|Abnormal procedure|1
6035453|NCT00333840|9632408|FG000|Second-line Treatment Period|Unsatisfactory therapeutic effect|0
6035454|NCT00333840|9632409|FG001|Second-line Treatment Period|Unsatisfactory therapeutic effect|0
6035455|NCT00333840|9632410|FG002|Second-line Treatment Period|Unsatisfactory therapeutic effect|9
6035456|NCT00333840|9632411|FG003|Second-line Treatment Period|Unsatisfactory therapeutic effect|70
6035457|NCT00333840|9632408|FG000|Second-line Treatment Period|No longer required study drug|0
6035458|NCT00333840|9632409|FG001|Second-line Treatment Period|No longer required study drug|0
6035459|NCT00333840|9632410|FG002|Second-line Treatment Period|No longer required study drug|1
6035460|NCT00333840|9632411|FG003|Second-line Treatment Period|No longer required study drug|14
6035461|NCT00333840|9632408|FG000|Second-line Treatment Period|Protocol Violation|0
6035462|NCT00333840|9632409|FG001|Second-line Treatment Period|Protocol Violation|0
6035463|NCT00333840|9632410|FG002|Second-line Treatment Period|Protocol Violation|1
6035464|NCT00333840|9632411|FG003|Second-line Treatment Period|Protocol Violation|10
6035465|NCT00333840|9632408|FG000|Second-line Treatment Period|Subject withdrew consent|0
6035466|NCT00333840|9632409|FG001|Second-line Treatment Period|Subject withdrew consent|0
6035467|NCT00333840|9632410|FG002|Second-line Treatment Period|Subject withdrew consent|0
6035468|NCT00333840|9632411|FG003|Second-line Treatment Period|Subject withdrew consent|34
6035469|NCT00333840|9632408|FG000|Second-line Treatment Period|Lost to Follow-up|0
6035470|NCT00333840|9632409|FG001|Second-line Treatment Period|Lost to Follow-up|0
6147028|NCT01080807|9782140|FG001|Overall Study|Withdrawal by Subject|2
6147029|NCT01080807|9782139|FG000|Overall Study|Protocol Violation|7
6147030|NCT01080807|9782140|FG001|Overall Study|Protocol Violation|6
6147031|NCT01080807|9782139|FG000|Overall Study|Lost to Follow-up|6
6147032|NCT01080807|9782140|FG001|Overall Study|Lost to Follow-up|4
6147033|NCT01080807|9782139|FG000|Overall Study|Noncompliance with drug administration|1
6147034|NCT01080807|9782140|FG001|Overall Study|Noncompliance with drug administration|1
6147035|NCT01080807|9782139|FG000|Overall Study|Noncompliance to study procedures|1
6147036|NCT01080807|9782140|FG001|Overall Study|Noncompliance to study procedures|1
6147037|NCT01080807|9782139|FG000|Overall Study|Began working day shift|0
6147038|NCT01080807|9782140|FG001|Overall Study|Began working day shift|2
6147039|NCT01080807|9782139|FG000|Overall Study|Laid off or terminated from job|1
6035471|NCT00333840|9632410|FG002|Second-line Treatment Period|Lost to Follow-up|0
6035472|NCT00333840|9632411|FG003|Second-line Treatment Period|Lost to Follow-up|6
6035473|NCT00333840|9632408|FG000|Second-line Treatment Period|Administrative problems|0
6035474|NCT00333840|9632409|FG001|Second-line Treatment Period|Administrative problems|0
6035475|NCT00333840|9632410|FG002|Second-line Treatment Period|Administrative problems|0
6035476|NCT00333840|9632411|FG003|Second-line Treatment Period|Administrative problems|7
6035477|NCT00333840|9632408|FG000|Second-line Treatment Period|Death|0
6035478|NCT00333840|9632409|FG001|Second-line Treatment Period|Death|0
6035479|NCT00333840|9632410|FG002|Second-line Treatment Period|Death|0
6035480|NCT00333840|9632411|FG003|Second-line Treatment Period|Death|9
6035481|NCT00333866|9632429|FG000|Overall Study|Adverse Event|23
6035482|NCT00333866|9632430|FG001|Overall Study|Adverse Event|37
6035483|NCT00333866|9632431|FG002|Overall Study|Adverse Event|38
6035484|NCT00333866|9632432|FG003|Overall Study|Adverse Event|47
6035485|NCT00333866|9632429|FG000|Overall Study|Other|3
6035486|NCT00333866|9632430|FG001|Overall Study|Other|2
6035487|NCT00333866|9632431|FG002|Overall Study|Other|2
6035488|NCT00333866|9632432|FG003|Overall Study|Other|2
6035489|NCT00333866|9632429|FG000|Overall Study|Lack of Efficacy|8
6035490|NCT00333866|9632430|FG001|Overall Study|Lack of Efficacy|6
6035491|NCT00333866|9632431|FG002|Overall Study|Lack of Efficacy|3
6035492|NCT00333866|9632432|FG003|Overall Study|Lack of Efficacy|5
6035493|NCT00333866|9632429|FG000|Overall Study|Lost to Follow-up|1
6035494|NCT00333866|9632430|FG001|Overall Study|Lost to Follow-up|2
6035495|NCT00333866|9632431|FG002|Overall Study|Lost to Follow-up|2
6035496|NCT00333866|9632432|FG003|Overall Study|Lost to Follow-up|2
6035497|NCT00333866|9632429|FG000|Overall Study|Withdrawal by Subject|8
6035498|NCT00333866|9632430|FG001|Overall Study|Withdrawal by Subject|14
6035499|NCT00333866|9632431|FG002|Overall Study|Withdrawal by Subject|4
6035500|NCT00333866|9632432|FG003|Overall Study|Withdrawal by Subject|9
6035501|NCT00333866|9632429|FG000|Overall Study|Randomized but not Treated|5
6035502|NCT00333866|9632430|FG001|Overall Study|Randomized but not Treated|3
6035503|NCT00333866|9632431|FG002|Overall Study|Randomized but not Treated|2
6035504|NCT00333866|9632432|FG003|Overall Study|Randomized but not Treated|1
6035505|NCT00333970|9632448|FG000|Overall Study|Withdrawal by Subject|13
6035506|NCT00333970|9632449|FG001|Overall Study|Withdrawal by Subject|7
6035507|NCT00333983|9632458|FG000|Overall Study|Lost to Follow-up|2
6035508|NCT00333983|9632459|FG001|Overall Study|Lost to Follow-up|1
6035509|NCT00333983|9632460|FG002|Overall Study|Lost to Follow-up|0
6035510|NCT00333983|9632458|FG000|Overall Study|Adverse Event|1
6035511|NCT00333983|9632459|FG001|Overall Study|Adverse Event|1
6035512|NCT00333983|9632460|FG002|Overall Study|Adverse Event|1
6035513|NCT00333983|9632458|FG000|Overall Study|Withdrawal by Subject|0
6035514|NCT00333983|9632459|FG001|Overall Study|Withdrawal by Subject|3
6035515|NCT00333983|9632460|FG002|Overall Study|Withdrawal by Subject|1
6048808|NCT00420641|9648139|FG000|Overall Study|Non-compliance|7
6048809|NCT00420641|9648140|FG001|Overall Study|Non-compliance|5
6048810|NCT00420641|9648141|FG002|Overall Study|Non-compliance|4
6048811|NCT00420641|9648139|FG000|Overall Study|Other|4
6048812|NCT00420641|9648140|FG001|Overall Study|Other|4
6048813|NCT00420641|9648141|FG002|Overall Study|Other|3
6048814|NCT00420745|9648151|FG000|Overall Study|Adverse Event|2
6048815|NCT00420745|9648152|FG001|Overall Study|Adverse Event|2
6048816|NCT00420745|9648151|FG000|Overall Study|Lost to Follow-up|10
6048817|NCT00420745|9648152|FG001|Overall Study|Lost to Follow-up|2
6048818|NCT00420745|9648151|FG000|Overall Study|Protocol Violation|1
6048819|NCT00420745|9648152|FG001|Overall Study|Protocol Violation|0
6048820|NCT00420745|9648151|FG000|Overall Study|Physician Decision|1
6048821|NCT00420745|9648152|FG001|Overall Study|Physician Decision|1
6048822|NCT00420745|9648151|FG000|Overall Study|Recurrent pneumonia & bronchitis|0
6048823|NCT00420745|9648152|FG001|Overall Study|Recurrent pneumonia & bronchitis|1
6048824|NCT00420745|9648151|FG000|Overall Study|Age limit exceeded for Dose 2|1
6048825|NCT00420745|9648152|FG001|Overall Study|Age limit exceeded for Dose 2|0
6048826|NCT00420784|9648171|FG000|Overall Study|Adverse Event|11
6048827|NCT00420784|9648172|FG001|Overall Study|Adverse Event|29
6048828|NCT00420784|9648173|FG002|Overall Study|Adverse Event|10
6048829|NCT00420784|9648174|FG003|Overall Study|Adverse Event|5
6048830|NCT00420784|9648171|FG000|Overall Study|Withdrawal by Subject|0
6048831|NCT00420784|9648172|FG001|Overall Study|Withdrawal by Subject|1
6048832|NCT00420784|9648173|FG002|Overall Study|Withdrawal by Subject|0
6048833|NCT00420784|9648174|FG003|Overall Study|Withdrawal by Subject|0
6048834|NCT00420784|9648171|FG000|Overall Study|Lost to Follow-up|0
6048835|NCT00420784|9648172|FG001|Overall Study|Lost to Follow-up|0
6048836|NCT00420784|9648173|FG002|Overall Study|Lost to Follow-up|2
6048837|NCT00420784|9648174|FG003|Overall Study|Lost to Follow-up|1
6048838|NCT00420784|9648171|FG000|Overall Study|Virologic Stopping Rule|17
6048839|NCT00420784|9648172|FG001|Overall Study|Virologic Stopping Rule|26
6048840|NCT00420784|9648173|FG002|Overall Study|Virologic Stopping Rule|41
6048841|NCT00420784|9648174|FG003|Overall Study|Virologic Stopping Rule|67
6048842|NCT00420784|9648171|FG000|Overall Study|Other|1
6048843|NCT00420784|9648172|FG001|Overall Study|Other|2
6048844|NCT00420784|9648173|FG002|Overall Study|Other|0
6048845|NCT00420784|9648174|FG003|Overall Study|Other|5
6048846|NCT00420849|9648185|FG000|Overall Study|Lack of Efficacy|154
6048847|NCT00420849|9648185|FG000|Overall Study|Adverse Event|107
6035516|NCT00334113|9632479|FG000|Overall Study|Lost to Follow-up|2
6035517|NCT00334113|9632480|FG001|Overall Study|Lost to Follow-up|2
6035518|NCT00334113|9632479|FG000|Overall Study|Withdrawal by Subject|0
6035519|NCT00334113|9632480|FG001|Overall Study|Withdrawal by Subject|1
6035520|NCT00334282|9632493|FG000|Overall Study|Lost to Follow-up|11
6035521|NCT00334282|9632494|FG001|Overall Study|Lost to Follow-up|5
6035522|NCT00334282|9632493|FG000|Overall Study|Withdrawal by Subject|17
6035523|NCT00334282|9632494|FG001|Overall Study|Withdrawal by Subject|3
6035524|NCT00334282|9632493|FG000|Overall Study|Death|194
6035525|NCT00334282|9632494|FG001|Overall Study|Death|100
6035526|NCT00334295|9632504|FG000|Overall Study|Patients received fewer than 3 injection|5
6035527|NCT00334542|9632508|FG000|Overall Study|Adverse Event|3
6035528|NCT00334542|9632508|FG000|Overall Study|Withdrawal by Subject|1
6035529|NCT00334542|9632508|FG000|Overall Study|New cancer diagnosis|1
6035530|NCT00334737|9632532|FG000|Hospital Phase|Death|1
6035531|NCT00334737|9632533|FG001|Hospital Phase|Death|2
6035532|NCT00334737|9632534|FG002|Hospital Phase|Death|3
6035533|NCT00334737|9632532|FG000|Hospital Phase|Withdrawal by Subject|0
6035534|NCT00334737|9632533|FG001|Hospital Phase|Withdrawal by Subject|0
6035535|NCT00334737|9632534|FG002|Hospital Phase|Withdrawal by Subject|1
6035536|NCT00334737|9632532|FG000|Hospital Phase|Did not receive study drug|1
6035537|NCT00334737|9632533|FG001|Hospital Phase|Did not receive study drug|0
6035538|NCT00334737|9632534|FG002|Hospital Phase|Did not receive study drug|0
6035539|NCT00334737|9632532|FG000|Follow up Phase|Lost to Follow-up|5
6035540|NCT00334737|9632533|FG001|Follow up Phase|Lost to Follow-up|3
6035541|NCT00334737|9632534|FG002|Follow up Phase|Lost to Follow-up|6
6035542|NCT00334802|9632544|FG000|Overall Study|Progressive Disease|2
6035543|NCT00334802|9632545|FG001|Overall Study|Progressive Disease|24
6035544|NCT00334802|9632544|FG000|Overall Study|Toxicity|1
6035545|NCT00334802|9632545|FG001|Overall Study|Toxicity|5
6035546|NCT00334802|9632544|FG000|Overall Study|Lack of Efficacy|1
6035547|NCT00334802|9632545|FG001|Overall Study|Lack of Efficacy|3
6035548|NCT00334802|9632544|FG000|Overall Study|Patient Condition Aggrevated|1
6035549|NCT00334802|9632545|FG001|Overall Study|Patient Condition Aggrevated|0
6035550|NCT00334802|9632544|FG000|Overall Study|Physician Decision|1
6035551|NCT00334802|9632545|FG001|Overall Study|Physician Decision|0
6035552|NCT00334802|9632544|FG000|Overall Study|Withdrawal by Subject|0
6035553|NCT00334802|9632545|FG001|Overall Study|Withdrawal by Subject|4
6035554|NCT00334802|9632544|FG000|Overall Study|Adverse Event|0
6035555|NCT00334802|9632545|FG001|Overall Study|Adverse Event|3
6035556|NCT00334802|9632544|FG000|Overall Study|Criteria for Starting Next Cycle Not Met|0
6035557|NCT00334802|9632545|FG001|Overall Study|Criteria for Starting Next Cycle Not Met|1
6035558|NCT00334893|9632556|FG000|Overall Study|Not Treated|1
6035559|NCT00334893|9632557|FG001|Overall Study|Not Treated|0
6035560|NCT00334958|9632567|FG000|Overall Study|Medication Noncompliance|0
6035561|NCT00334958|9632568|FG001|Overall Study|Medication Noncompliance|3
6035562|NCT00334958|9632567|FG000|Overall Study|Protocol Violation|2
6035563|NCT00334958|9632568|FG001|Overall Study|Protocol Violation|2
6035564|NCT00334958|9632567|FG000|Overall Study|Request of the investigator or sponsor|0
6035565|NCT00334958|9632568|FG001|Overall Study|Request of the investigator or sponsor|1
6035566|NCT00334958|9632567|FG000|Overall Study|Withdrawal by Subject|7
6035567|NCT00334958|9632568|FG001|Overall Study|Withdrawal by Subject|4
6035568|NCT00334958|9632567|FG000|Overall Study|Adverse Event|27
6035569|NCT00334958|9632568|FG001|Overall Study|Adverse Event|12
6035570|NCT00334958|9632567|FG000|Overall Study|Other|1
6035571|NCT00334958|9632568|FG001|Overall Study|Other|2
6035572|NCT00335140|9632574|FG000|Overall Study|Ineligible|1
6035573|NCT00335153|9632578|FG000|Nasojejunal (NJ) Test Period|Adverse Event|5
6035574|NCT00335153|9632578|FG000|Nasojejunal (NJ) Test Period|Lack of Efficacy|5
6035575|NCT00335153|9632578|FG000|Nasojejunal (NJ) Test Period|Withdrawal by Subject|12
6035576|NCT00335153|9632578|FG000|Nasojejunal (NJ) Test Period|Administrative|1
6035577|NCT00335153|9632578|FG000|Nasojejunal (NJ) Test Period|Protocol Violation|7
6035578|NCT00335153|9632578|FG000|Post-PEG-J Long-Term Treatment Period|Adverse Event|22
6035579|NCT00335153|9632578|FG000|Post-PEG-J Long-Term Treatment Period|Lack of Efficacy|2
6035580|NCT00335153|9632578|FG000|Post-PEG-J Long-Term Treatment Period|Withdrawal by Subject|13
6035581|NCT00335153|9632578|FG000|Post-PEG-J Long-Term Treatment Period|Administrative|13
6035582|NCT00335153|9632578|FG000|Post-PEG-J Long-Term Treatment Period|Protocol Violation|2
6035583|NCT00335322|9632613|FG000|Overall Study|Randomised but withdrew prior to ART sta|1
6035584|NCT00335322|9632614|FG001|Overall Study|Randomised but withdrew prior to ART sta|2
6035585|NCT00335322|9632615|FG002|Overall Study|Randomised but withdrew prior to ART sta|2
6035586|NCT00335452|9632630|FG000|Overall Study|Death|156
6035587|NCT00335452|9632631|FG001|Overall Study|Death|144
6035588|NCT00335452|9632632|FG002|Overall Study|Death|158
6035589|NCT00335452|9632633|FG003|Overall Study|Death|129
6035590|NCT00335452|9632630|FG000|Overall Study|Lost to Follow-up|2
6035591|NCT00335452|9632631|FG001|Overall Study|Lost to Follow-up|3
6035592|NCT00335452|9632632|FG002|Overall Study|Lost to Follow-up|1
6035593|NCT00335452|9632633|FG003|Overall Study|Lost to Follow-up|2
6035594|NCT00335556|9632679|FG000|Overall Study|Death|0
6035595|NCT00335556|9632680|FG001|Overall Study|Death|5
6035596|NCT00335556|9632681|FG002|Overall Study|Death|0
6035597|NCT00335556|9632682|FG003|Overall Study|Death|0
6035598|NCT00335556|9632683|FG004|Overall Study|Death|1
6035599|NCT00335556|9632684|FG005|Overall Study|Death|0
6035600|NCT00335556|9632679|FG000|Overall Study|Lack of Efficacy|0
6035601|NCT00335556|9632680|FG001|Overall Study|Lack of Efficacy|19
6035602|NCT00335556|9632681|FG002|Overall Study|Lack of Efficacy|3
6035603|NCT00335556|9632682|FG003|Overall Study|Lack of Efficacy|3
6035604|NCT00335556|9632683|FG004|Overall Study|Lack of Efficacy|0
6035605|NCT00335556|9632684|FG005|Overall Study|Lack of Efficacy|1
6035606|NCT00335556|9632679|FG000|Overall Study|Physician Decision|0
6035607|NCT00335556|9632680|FG001|Overall Study|Physician Decision|6
6035608|NCT00335556|9632681|FG002|Overall Study|Physician Decision|2
6035609|NCT00335556|9632682|FG003|Overall Study|Physician Decision|1
6035610|NCT00335556|9632683|FG004|Overall Study|Physician Decision|0
6035611|NCT00335556|9632684|FG005|Overall Study|Physician Decision|0
6035612|NCT00335556|9632679|FG000|Overall Study|Ineligible|2
6035613|NCT00335556|9632680|FG001|Overall Study|Ineligible|0
6035614|NCT00335556|9632681|FG002|Overall Study|Ineligible|0
6035615|NCT00335556|9632682|FG003|Overall Study|Ineligible|0
6035616|NCT00335556|9632683|FG004|Overall Study|Ineligible|0
6035617|NCT00335556|9632684|FG005|Overall Study|Ineligible|0
6035618|NCT00335556|9632679|FG000|Overall Study|Refusal of further protocol therapy|0
6035619|NCT00335556|9632680|FG001|Overall Study|Refusal of further protocol therapy|4
6035620|NCT00335556|9632681|FG002|Overall Study|Refusal of further protocol therapy|0
6035621|NCT00335556|9632682|FG003|Overall Study|Refusal of further protocol therapy|1
6035622|NCT00335556|9632683|FG004|Overall Study|Refusal of further protocol therapy|0
6035623|NCT00335556|9632684|FG005|Overall Study|Refusal of further protocol therapy|0
6035624|NCT00335738|9632715|FG000|Overall Study|Physician Decision|6
6035625|NCT00335738|9632716|FG001|Overall Study|Physician Decision|0
6035626|NCT00335738|9632715|FG000|Overall Study|Withdrawal by Subject|2
6035627|NCT00335738|9632716|FG001|Overall Study|Withdrawal by Subject|0
6035628|NCT00335738|9632715|FG000|Overall Study|Ineligible|3
6035629|NCT00335738|9632716|FG001|Overall Study|Ineligible|4
6035630|NCT00335764|9632728|FG000|Overall Study|wrong histology|1
6035631|NCT00335764|9632729|FG001|Overall Study|wrong histology|0
6035632|NCT00335764|9632730|FG002|Overall Study|wrong histology|0
6035633|NCT00335764|9632731|FG003|Overall Study|wrong histology|0
6035634|NCT00335764|9632732|FG004|Overall Study|wrong histology|1
6035635|NCT00335829|9632768|FG000|Overall Study|Withdrawal by Subject|1
6035636|NCT00335829|9632768|FG000|Overall Study|Lost to Follow-up|1
6035637|NCT00335829|9632768|FG000|Overall Study|Adverse Event|1
6035638|NCT00335959|9632772|FG000|Overall Study|Adverse Event|2
6035639|NCT00335959|9632772|FG000|Overall Study|Ineligible|1
6035640|NCT00335972|9632779|FG000|Overall Study|not given treatments|0
6035641|NCT00335972|9632780|FG001|Overall Study|not given treatments|3
6035642|NCT00336024|9632788|FG000|Overall Study|Death|2
6035643|NCT00336024|9632789|FG001|Overall Study|Death|1
6035644|NCT00336024|9632788|FG000|Overall Study|Physician Decision|4
6035645|NCT00336024|9632789|FG001|Overall Study|Physician Decision|1
6035646|NCT00336024|9632788|FG000|Overall Study|Protocol Violation|1
6035647|NCT00336024|9632789|FG001|Overall Study|Protocol Violation|0
6035648|NCT00336024|9632788|FG000|Overall Study|Withdrawal by Subject|1
6035649|NCT00336024|9632789|FG001|Overall Study|Withdrawal by Subject|2
6035650|NCT00336024|9632788|FG000|Overall Study|Failure to fulfill consolidation|1
6035651|NCT00336024|9632789|FG001|Overall Study|Failure to fulfill consolidation|1
6035652|NCT00336024|9632788|FG000|Overall Study|Progressive Disease|4
6035653|NCT00336024|9632789|FG001|Overall Study|Progressive Disease|7
6035654|NCT00336024|9632788|FG000|Overall Study|Ineligible|7
6035655|NCT00336024|9632789|FG001|Overall Study|Ineligible|7
6035656|NCT00336284|9632801|FG000|Overall Study|Death|52
6035657|NCT00336284|9632802|FG001|Overall Study|Death|26
6035658|NCT00336284|9632801|FG000|Overall Study|Lost to Follow-up|82
6035659|NCT00336284|9632802|FG001|Overall Study|Lost to Follow-up|61
6035660|NCT00336284|9632801|FG000|Overall Study|Withdrawal by Physician or Subject|102
6035661|NCT00336284|9632802|FG001|Overall Study|Withdrawal by Physician or Subject|64
6035662|NCT00336479|9632837|FG000|Overall Study|Adverse Event|8
6035663|NCT00336479|9632838|FG001|Overall Study|Adverse Event|11
6035664|NCT00336479|9632839|FG002|Overall Study|Adverse Event|18
6035665|NCT00336479|9632840|FG003|Overall Study|Adverse Event|4
6035666|NCT00336479|9632837|FG000|Overall Study|Noncompliant|1
6035667|NCT00336479|9632838|FG001|Overall Study|Noncompliant|7
6035668|NCT00336479|9632839|FG002|Overall Study|Noncompliant|3
6035669|NCT00336479|9632840|FG003|Overall Study|Noncompliant|0
6035670|NCT00336479|9632837|FG000|Overall Study|Physician Decision|2
6035671|NCT00336479|9632838|FG001|Overall Study|Physician Decision|3
6035672|NCT00336479|9632839|FG002|Overall Study|Physician Decision|1
6035673|NCT00336479|9632840|FG003|Overall Study|Physician Decision|0
6035674|NCT00336479|9632837|FG000|Overall Study|Lost to Follow-up|3
6035675|NCT00336479|9632838|FG001|Overall Study|Lost to Follow-up|2
6035676|NCT00336479|9632839|FG002|Overall Study|Lost to Follow-up|0
6035677|NCT00336479|9632840|FG003|Overall Study|Lost to Follow-up|0
6035678|NCT00336479|9632837|FG000|Overall Study|Withdrawal by Subject|3
6035679|NCT00336479|9632838|FG001|Overall Study|Withdrawal by Subject|2
6035680|NCT00336479|9632839|FG002|Overall Study|Withdrawal by Subject|3
6035681|NCT00336479|9632840|FG003|Overall Study|Withdrawal by Subject|0
6035682|NCT00336479|9632837|FG000|Overall Study|Other|0
6035683|NCT00336479|9632838|FG001|Overall Study|Other|0
6035684|NCT00336479|9632839|FG002|Overall Study|Other|1
6035685|NCT00336479|9632840|FG003|Overall Study|Other|0
6035686|NCT00336479|9632837|FG000|Overall Study|Virologic Stopping Rule|20
6035687|NCT00336479|9632838|FG001|Overall Study|Virologic Stopping Rule|0
6035688|NCT00336479|9632839|FG002|Overall Study|Virologic Stopping Rule|0
6035689|NCT00336479|9632840|FG003|Overall Study|Virologic Stopping Rule|0
6035690|NCT00336492|9632854|FG000|Overall Study|Adverse Event|4
6035691|NCT00336492|9632855|FG001|Overall Study|Adverse Event|3
6035692|NCT00336492|9632856|FG002|Overall Study|Adverse Event|6
6035693|NCT00336492|9632854|FG000|Overall Study|Lack of Efficacy|6
6035694|NCT00336492|9632855|FG001|Overall Study|Lack of Efficacy|1
6035695|NCT00336492|9632856|FG002|Overall Study|Lack of Efficacy|4
6035696|NCT00336492|9632854|FG000|Overall Study|Other|5
6035697|NCT00336492|9632855|FG001|Overall Study|Other|0
6035698|NCT00336492|9632856|FG002|Overall Study|Other|1
6035699|NCT00336505|9632866|FG000|Overall Study|Adverse Event|10
6035700|NCT00336505|9632867|FG001|Overall Study|Adverse Event|9
6035701|NCT00336505|9632866|FG000|Overall Study|Lack of Efficacy|8
6035702|NCT00336505|9632867|FG001|Overall Study|Lack of Efficacy|4
6035703|NCT00336505|9632866|FG000|Overall Study|Lost to Follow-up|7
6035704|NCT00336505|9632867|FG001|Overall Study|Lost to Follow-up|4
6035705|NCT00336505|9632866|FG000|Overall Study|Withdrawal by Subject|5
6035706|NCT00336505|9632867|FG001|Overall Study|Withdrawal by Subject|3
6035707|NCT00336505|9632866|FG000|Overall Study|Other|7
6035708|NCT00336505|9632867|FG001|Overall Study|Other|7
6035709|NCT00336544|9632875|FG000|Overall Study|Lack of Efficacy|8
6035710|NCT00336544|9632876|FG001|Overall Study|Lack of Efficacy|5
6035711|NCT00336544|9632875|FG000|Overall Study|Adverse Event|4
6035712|NCT00336544|9632876|FG001|Overall Study|Adverse Event|9
6035713|NCT00336544|9632875|FG000|Overall Study|Withdrawal by Subject|4
6035714|NCT00336544|9632876|FG001|Overall Study|Withdrawal by Subject|3
6035715|NCT00336544|9632875|FG000|Overall Study|Other|3
6035716|NCT00336544|9632876|FG001|Overall Study|Other|5
6035717|NCT00336583|9632882|FG000|Overall Study|Lost to Follow-up|1
6035718|NCT00336583|9632882|FG000|Overall Study|Death|1
6035719|NCT00336856|9632901|FG000|Overall Study|Withdrawal by Subject|3
6035720|NCT00336856|9632901|FG000|Overall Study|Found ineligible at time of analysis|1
6035721|NCT00336895|9632905|FG000|Overall Study|diarrhea|1
6035722|NCT00336895|9632905|FG000|Overall Study|nausea and upset stomach|1
6035723|NCT00336895|9632905|FG000|Overall Study|Physician Decision|1
6035724|NCT00336895|9632905|FG000|Overall Study|screen failed|1
6035725|NCT00337077|9632912|FG000|Overall Study|Progressive disease|25
6035726|NCT00337077|9632913|FG001|Overall Study|Progressive disease|37
6035727|NCT00337077|9632914|FG002|Overall Study|Progressive disease|19
6035728|NCT00337077|9632912|FG000|Overall Study|Adverse Event|7
6035729|NCT00337077|9632913|FG001|Overall Study|Adverse Event|7
6035730|NCT00337077|9632914|FG002|Overall Study|Adverse Event|1
6035731|NCT00337077|9632912|FG000|Overall Study|Death|0
6035732|NCT00337077|9632913|FG001|Overall Study|Death|1
6035733|NCT00337077|9632914|FG002|Overall Study|Death|0
6035734|NCT00337077|9632912|FG000|Overall Study|Withdrawal by Subject|7
6035735|NCT00337077|9632913|FG001|Overall Study|Withdrawal by Subject|2
6035736|NCT00337077|9632914|FG002|Overall Study|Withdrawal by Subject|2
6035737|NCT00337077|9632912|FG000|Overall Study|Alternative therapy|1
6035738|NCT00337077|9632913|FG001|Overall Study|Alternative therapy|0
6035739|NCT00337077|9632914|FG002|Overall Study|Alternative therapy|0
6035740|NCT00337077|9632912|FG000|Overall Study|Physician Decision|1
6035741|NCT00337077|9632913|FG001|Overall Study|Physician Decision|4
6035742|NCT00337077|9632914|FG002|Overall Study|Physician Decision|2
6035743|NCT00337077|9632912|FG000|Overall Study|Never started treatment|1
6035744|NCT00337077|9632913|FG001|Overall Study|Never started treatment|1
6035745|NCT00337077|9632914|FG002|Overall Study|Never started treatment|0
6035746|NCT00337077|9632912|FG000|Overall Study|Ineligible|1
6035747|NCT00337077|9632913|FG001|Overall Study|Ineligible|1
6035748|NCT00337077|9632914|FG002|Overall Study|Ineligible|1
6035749|NCT00337103|9632922|FG000|Overall Study|Progressive Disease|414
6035750|NCT00337103|9632923|FG001|Overall Study|Progressive Disease|410
6035751|NCT00337103|9632922|FG000|Overall Study|Adverse Event|45
6035752|NCT00337103|9632923|FG001|Overall Study|Adverse Event|59
6035753|NCT00337103|9632922|FG000|Overall Study|Subject Choice|34
6035754|NCT00337103|9632923|FG001|Overall Study|Subject Choice|27
6035755|NCT00337103|9632922|FG000|Overall Study|Clinical Progression|27
6035756|NCT00337103|9632923|FG001|Overall Study|Clinical Progression|24
6035757|NCT00337103|9632922|FG000|Overall Study|Physician Decision|15
6035758|NCT00337103|9632923|FG001|Overall Study|Physician Decision|14
6035759|NCT00337103|9632922|FG000|Overall Study|Withdrawal by Subject|8
6035760|NCT00337103|9632923|FG001|Overall Study|Withdrawal by Subject|5
6035761|NCT00337103|9632922|FG000|Overall Study|Other|5
6035762|NCT00337103|9632923|FG001|Overall Study|Other|6
6035763|NCT00337103|9632922|FG000|Overall Study|Entry Criteria Not Met|4
6035764|NCT00337103|9632923|FG001|Overall Study|Entry Criteria Not Met|1
6035765|NCT00337103|9632922|FG000|Overall Study|Lost to Follow-up|1
6035766|NCT00337103|9632923|FG001|Overall Study|Lost to Follow-up|2
6035767|NCT00337103|9632922|FG000|Overall Study|Death|1
6035768|NCT00337103|9632923|FG001|Overall Study|Death|0
6035769|NCT00337129|9632930|FG000|Overall Study|Adverse Event|4
6035770|NCT00337129|9632930|FG000|Overall Study|Withdrawal by Subject|1
6035771|NCT00337129|9632930|FG000|Overall Study|Lack of Efficacy|32
6035772|NCT00337129|9632930|FG000|Overall Study|Death|2
6035773|NCT00337129|9632930|FG000|Overall Study|not protocol specified|1
6035774|NCT00337168|9632934|FG000|Overall Study|Death|5
6035775|NCT00337168|9632934|FG000|Overall Study|Not protocol specified|2
6035776|NCT00337168|9632934|FG000|Overall Study|Did not start therapy|1
6035777|NCT00337194|9632950|FG000|Overall Study|Adverse Event|5
6035778|NCT00337194|9632951|FG001|Overall Study|Adverse Event|1
6035779|NCT00337194|9632950|FG000|Overall Study|Death|2
6035780|NCT00337194|9632951|FG001|Overall Study|Death|0
6035781|NCT00337194|9632950|FG000|Overall Study|Withdrawal by Subject|1
6035782|NCT00337194|9632951|FG001|Overall Study|Withdrawal by Subject|0
6035783|NCT00337194|9632950|FG000|Overall Study|Disease progression|1
6035784|NCT00337194|9632951|FG001|Overall Study|Disease progression|2
6035785|NCT00337194|9632950|FG000|Overall Study|Subsequent non-protocol therapy|3
6035786|NCT00337194|9632951|FG001|Overall Study|Subsequent non-protocol therapy|1
6035787|NCT00337207|9632959|FG000|Overall Study|Withdrawal by Subject|3
6035788|NCT00337272|9632966|FG000|Screening Period (Pre-randomization)|Withdrawal by Subject|2
6035789|NCT00337272|9632967|FG001|Screening Period (Pre-randomization)|Withdrawal by Subject|0
6035790|NCT00337272|9632966|FG000|Screening Period (Pre-randomization)|Non-compliance|1
6035791|NCT00337272|9632967|FG001|Screening Period (Pre-randomization)|Non-compliance|0
6035792|NCT00337272|9632966|FG000|Screening Period (Pre-randomization)|Screen failure|3
6035793|NCT00337272|9632967|FG001|Screening Period (Pre-randomization)|Screen failure|0
6035794|NCT00337272|9632966|FG000|Treatment Period|Non-compliance|1
6035795|NCT00337272|9632967|FG001|Treatment Period|Non-compliance|1
6035796|NCT00337272|9632966|FG000|Treatment Period|Withdrawal by Subject|0
6035797|NCT00337272|9632967|FG001|Treatment Period|Withdrawal by Subject|1
6035798|NCT00337272|9632966|FG000|Withdrawal Period|Non-compliance|0
6035799|NCT00337272|9632967|FG001|Withdrawal Period|Non-compliance|1
6035800|NCT00337285|9632973|FG000|Overall Study|Withdrawal by Subject|42
6035801|NCT00337285|9632973|FG000|Overall Study|Lost to Follow-up|41
6035802|NCT00337285|9632973|FG000|Overall Study|Adverse Event|28
6035803|NCT00337285|9632973|FG000|Overall Study|Protocol Violation|27
6035804|NCT00337285|9632973|FG000|Overall Study|Lack of Efficacy|11
6035805|NCT00337285|9632973|FG000|Overall Study|Death|1
6035806|NCT00337285|9632973|FG000|Overall Study|Physician Decision|1
6035807|NCT00337285|9632973|FG000|Overall Study|Lack of protocol compliance|7
6035808|NCT00337428|9632988|FG000|Overall Study|Withdrawal by Subject|1
6035809|NCT00337428|9632989|FG001|Overall Study|Withdrawal by Subject|2
6035810|NCT00337428|9632988|FG000|Overall Study|Lack of Time|1
6035811|NCT00337428|9632989|FG001|Overall Study|Lack of Time|1
6035812|NCT00337428|9632988|FG000|Overall Study|Unwilling to Continue|1
6035813|NCT00337428|9632989|FG001|Overall Study|Unwilling to Continue|0
6035814|NCT00337428|9632988|FG000|Overall Study|Anorexia|1
6035815|NCT00337428|9632989|FG001|Overall Study|Anorexia|0
6035816|NCT00337467|9632995|FG000|Overall Study|Adverse Event|3
6035817|NCT00337467|9632995|FG000|Overall Study|Subject Withdrew Consent|2
6035818|NCT00337467|9632995|FG000|Overall Study|Pregnancy|1
6035819|NCT00337467|9632995|FG000|Overall Study|Lost to Follow-up|2
6035820|NCT00337467|9632995|FG000|Overall Study|Subject No Longer Met Study Criteria|2
6035821|NCT00337571|9633006|FG000|Overall Study|Lack of Efficacy|3
6035822|NCT00337571|9633007|FG001|Overall Study|Lack of Efficacy|0
6035823|NCT00337571|9633008|FG002|Overall Study|Lack of Efficacy|0
6035824|NCT00337571|9633009|FG003|Overall Study|Lack of Efficacy|0
6035825|NCT00337571|9633006|FG000|Overall Study|Adverse Event|4
6035826|NCT00337571|9633007|FG001|Overall Study|Adverse Event|5
6035827|NCT00337571|9633008|FG002|Overall Study|Adverse Event|8
6035828|NCT00337571|9633009|FG003|Overall Study|Adverse Event|4
6035829|NCT00337571|9633006|FG000|Overall Study|Withdrawal by Subject|2
6035830|NCT00337571|9633007|FG001|Overall Study|Withdrawal by Subject|2
6035831|NCT00337571|9633008|FG002|Overall Study|Withdrawal by Subject|1
6035832|NCT00337571|9633009|FG003|Overall Study|Withdrawal by Subject|0
6035833|NCT00337571|9633006|FG000|Overall Study|Lost to Follow-up|3
6035834|NCT00337571|9633007|FG001|Overall Study|Lost to Follow-up|1
6035835|NCT00337571|9633008|FG002|Overall Study|Lost to Follow-up|0
6035836|NCT00337571|9633009|FG003|Overall Study|Lost to Follow-up|1
6035837|NCT00337571|9633006|FG000|Overall Study|Poor/noncompliance|1
6035838|NCT00337571|9633007|FG001|Overall Study|Poor/noncompliance|1
6035839|NCT00337571|9633008|FG002|Overall Study|Poor/noncompliance|1
6035840|NCT00337571|9633009|FG003|Overall Study|Poor/noncompliance|1
6035841|NCT00337571|9633006|FG000|Overall Study|No longer met study criteria|1
6035842|NCT00337571|9633007|FG001|Overall Study|No longer met study criteria|0
6035843|NCT00337571|9633008|FG002|Overall Study|No longer met study criteria|0
6035844|NCT00337571|9633009|FG003|Overall Study|No longer met study criteria|0
6035845|NCT00337571|9633006|FG000|Overall Study|High Potassium level|0
6035846|NCT00337571|9633007|FG001|Overall Study|High Potassium level|0
6035847|NCT00337571|9633008|FG002|Overall Study|High Potassium level|0
6035848|NCT00337571|9633009|FG003|Overall Study|High Potassium level|1
6035849|NCT00337610|9633021|FG000|Overall Study|Adverse Event|2
6035850|NCT00337610|9633022|FG001|Overall Study|Adverse Event|2
6035851|NCT00337610|9633021|FG000|Overall Study|Death|0
6035852|NCT00337610|9633022|FG001|Overall Study|Death|1
6035853|NCT00337610|9633021|FG000|Overall Study|Lack of Efficacy|6
6035854|NCT00337610|9633022|FG001|Overall Study|Lack of Efficacy|3
6035855|NCT00337610|9633021|FG000|Overall Study|Lost to Follow-up|3
6035856|NCT00337610|9633022|FG001|Overall Study|Lost to Follow-up|3
6035857|NCT00337610|9633021|FG000|Overall Study|Withdrawal by Subject|6
6035858|NCT00337610|9633022|FG001|Overall Study|Withdrawal by Subject|5
6035859|NCT00337662|9633031|FG000|Study Period II|Lost to Follow-up|0
6035860|NCT00337662|9633032|FG001|Study Period II|Lost to Follow-up|0
6035861|NCT00337662|9633033|FG002|Study Period II|Lost to Follow-up|0
6035862|NCT00337662|9633034|FG003|Study Period II|Lost to Follow-up|35
6035863|NCT00337662|9633031|FG000|Study Period II|Withdrawal by Subject|0
6035864|NCT00337662|9633032|FG001|Study Period II|Withdrawal by Subject|0
6035865|NCT00337662|9633033|FG002|Study Period II|Withdrawal by Subject|0
6035866|NCT00337662|9633034|FG003|Study Period II|Withdrawal by Subject|20
6035867|NCT00337662|9633031|FG000|Study Period II|Adverse Event|0
6035868|NCT00337662|9633032|FG001|Study Period II|Adverse Event|0
6035869|NCT00337662|9633033|FG002|Study Period II|Adverse Event|0
6035870|NCT00337662|9633034|FG003|Study Period II|Adverse Event|16
6035871|NCT00337662|9633031|FG000|Study Period II|Physician Decision|0
6035872|NCT00337662|9633032|FG001|Study Period II|Physician Decision|0
6035873|NCT00337662|9633033|FG002|Study Period II|Physician Decision|0
6035874|NCT00337662|9633034|FG003|Study Period II|Physician Decision|13
6035875|NCT00337662|9633031|FG000|Study Period II|Entry Criteria Not Met|0
6035876|NCT00337662|9633032|FG001|Study Period II|Entry Criteria Not Met|0
6035877|NCT00337662|9633033|FG002|Study Period II|Entry Criteria Not Met|0
6035878|NCT00337662|9633034|FG003|Study Period II|Entry Criteria Not Met|6
6035879|NCT00337662|9633031|FG000|Study Period II|Protocol Violation|0
6035880|NCT00337662|9633032|FG001|Study Period II|Protocol Violation|0
6035881|NCT00337662|9633033|FG002|Study Period II|Protocol Violation|0
6035882|NCT00337662|9633034|FG003|Study Period II|Protocol Violation|6
6035883|NCT00337662|9633031|FG000|Study Period II|Lack of Efficacy|0
6035884|NCT00337662|9633032|FG001|Study Period II|Lack of Efficacy|0
6035885|NCT00337662|9633033|FG002|Study Period II|Lack of Efficacy|0
6035886|NCT00337662|9633034|FG003|Study Period II|Lack of Efficacy|7
6035887|NCT00337662|9633031|FG000|Study Period II|Sponsor Decision|0
6035888|NCT00337662|9633032|FG001|Study Period II|Sponsor Decision|0
6035889|NCT00337662|9633033|FG002|Study Period II|Sponsor Decision|0
6035890|NCT00337662|9633034|FG003|Study Period II|Sponsor Decision|2
6035891|NCT00337662|9633031|FG000|Study Period II|Parent/Caregiver Decision|0
6035892|NCT00337662|9633032|FG001|Study Period II|Parent/Caregiver Decision|0
6035893|NCT00337662|9633033|FG002|Study Period II|Parent/Caregiver Decision|0
6035894|NCT00337662|9633034|FG003|Study Period II|Parent/Caregiver Decision|1
6035895|NCT00337662|9633031|FG000|Study Period III|Lost to Follow-up|14
6035896|NCT00337662|9633032|FG001|Study Period III|Lost to Follow-up|16
6035897|NCT00337662|9633033|FG002|Study Period III|Lost to Follow-up|14
6035898|NCT00337662|9633034|FG003|Study Period III|Lost to Follow-up|0
6035899|NCT00337662|9633031|FG000|Study Period III|Withdrawal by Subject|18
6035900|NCT00337662|9633032|FG001|Study Period III|Withdrawal by Subject|14
6035901|NCT00337662|9633033|FG002|Study Period III|Withdrawal by Subject|12
6035902|NCT00337662|9633034|FG003|Study Period III|Withdrawal by Subject|0
6035903|NCT00337662|9633031|FG000|Study Period III|Adverse Event|9
6035904|NCT00337662|9633032|FG001|Study Period III|Adverse Event|10
6035905|NCT00337662|9633033|FG002|Study Period III|Adverse Event|8
6035906|NCT00337662|9633034|FG003|Study Period III|Adverse Event|0
6035907|NCT00337662|9633031|FG000|Study Period III|Protocol Violation|3
6035908|NCT00337662|9633032|FG001|Study Period III|Protocol Violation|8
6035909|NCT00337662|9633033|FG002|Study Period III|Protocol Violation|2
6035910|NCT00337662|9633034|FG003|Study Period III|Protocol Violation|0
6035911|NCT00337662|9633031|FG000|Study Period III|Physician Decision|6
6035912|NCT00337662|9633032|FG001|Study Period III|Physician Decision|5
6035913|NCT00337662|9633033|FG002|Study Period III|Physician Decision|0
6035914|NCT00337662|9633034|FG003|Study Period III|Physician Decision|0
6035915|NCT00337662|9633031|FG000|Study Period III|Entry Criteria Not Met|4
6035916|NCT00337662|9633032|FG001|Study Period III|Entry Criteria Not Met|1
6035917|NCT00337662|9633033|FG002|Study Period III|Entry Criteria Not Met|3
6035918|NCT00337662|9633034|FG003|Study Period III|Entry Criteria Not Met|0
6035919|NCT00337662|9633031|FG000|Study Period III|Lack of Efficacy|4
6035920|NCT00337662|9633032|FG001|Study Period III|Lack of Efficacy|4
6035921|NCT00337662|9633033|FG002|Study Period III|Lack of Efficacy|2
6035922|NCT00337662|9633034|FG003|Study Period III|Lack of Efficacy|0
6035923|NCT00337662|9633031|FG000|Study Period III|Parent/Caregiver Decision|0
6035924|NCT00337662|9633032|FG001|Study Period III|Parent/Caregiver Decision|0
6035925|NCT00337662|9633033|FG002|Study Period III|Parent/Caregiver Decision|2
6035926|NCT00337662|9633034|FG003|Study Period III|Parent/Caregiver Decision|0
6035927|NCT00337662|9633031|FG000|Study Period III|Sponsor Decision|1
6035928|NCT00337662|9633032|FG001|Study Period III|Sponsor Decision|0
6035929|NCT00337662|9633033|FG002|Study Period III|Sponsor Decision|1
6035930|NCT00337662|9633034|FG003|Study Period III|Sponsor Decision|0
6035931|NCT00337662|9633031|FG000|Study Period III|Clinical Relapse|1
6035932|NCT00337662|9633032|FG001|Study Period III|Clinical Relapse|0
6035933|NCT00337662|9633033|FG002|Study Period III|Clinical Relapse|0
6035934|NCT00337662|9633034|FG003|Study Period III|Clinical Relapse|0
6035935|NCT00337727|9633047|FG000|Overall Study|Adverse Event|5
6035936|NCT00337727|9633048|FG001|Overall Study|Adverse Event|3
6035937|NCT00337727|9633047|FG000|Overall Study|Lost to Follow-up|5
6035938|NCT00337727|9633048|FG001|Overall Study|Lost to Follow-up|4
6035939|NCT00337727|9633047|FG000|Overall Study|Physician Decision|1
6035940|NCT00337727|9633048|FG001|Overall Study|Physician Decision|0
6035941|NCT00337727|9633047|FG000|Overall Study|Protocol Violation|4
6035942|NCT00337727|9633048|FG001|Overall Study|Protocol Violation|0
6035943|NCT00337727|9633047|FG000|Overall Study|Withdrawal by Subject|3
6035944|NCT00337727|9633048|FG001|Overall Study|Withdrawal by Subject|5
6035945|NCT00337779|9633056|FG000|Overall Study|Withdrawal by Subject|10
6035946|NCT00337779|9633057|FG001|Overall Study|Withdrawal by Subject|12
6035947|NCT00337779|9633056|FG000|Overall Study|Sponsor decision|1
6035948|NCT00337779|9633057|FG001|Overall Study|Sponsor decision|1
6035949|NCT00337779|9633056|FG000|Overall Study|Physician Decision|3
6035950|NCT00337779|9633057|FG001|Overall Study|Physician Decision|6
6035951|NCT00337779|9633056|FG000|Overall Study|Protocol Violation|1
6035952|NCT00337779|9633057|FG001|Overall Study|Protocol Violation|1
6035953|NCT00337779|9633056|FG000|Overall Study|Lost to Follow-up|6
6035954|NCT00337779|9633057|FG001|Overall Study|Lost to Follow-up|5
6035955|NCT00337779|9633056|FG000|Overall Study|Adverse Event|28
6035956|NCT00337779|9633057|FG001|Overall Study|Adverse Event|51
6035957|NCT00337779|9633056|FG000|Overall Study|Pregnancy|3
6035958|NCT00337779|9633057|FG001|Overall Study|Pregnancy|2
6035959|NCT00337779|9633056|FG000|Overall Study|Death|0
6035960|NCT00337779|9633057|FG001|Overall Study|Death|1
6035961|NCT00337818|9633066|FG000|Overall Study|Lost to Follow-up|289
6035962|NCT00337818|9633067|FG001|Overall Study|Lost to Follow-up|91
6035963|NCT00337818|9633068|FG002|Overall Study|Lost to Follow-up|107
6035964|NCT00337935|9633078|FG000|Overall Study|Adverse Event|2
6035965|NCT00337935|9633079|FG001|Overall Study|Adverse Event|5
6035966|NCT00337935|9633078|FG000|Overall Study|Death|2
6035967|NCT00337935|9633079|FG001|Overall Study|Death|8
6035968|NCT00337935|9633078|FG000|Overall Study|Physician Decision|1
6035969|NCT00337935|9633079|FG001|Overall Study|Physician Decision|1
6035970|NCT00337935|9633078|FG000|Overall Study|Lost to Follow-up|0
6035971|NCT00337935|9633079|FG001|Overall Study|Lost to Follow-up|1
6035972|NCT00337935|9633078|FG000|Overall Study|Protocol Violation|4
6035973|NCT00337935|9633079|FG001|Overall Study|Protocol Violation|3
6035974|NCT00337935|9633078|FG000|Overall Study|Withdrawal by Subject|1
6035975|NCT00337935|9633079|FG001|Overall Study|Withdrawal by Subject|7
6035976|NCT00337935|9633078|FG000|Overall Study|Other|0
6035977|NCT00337935|9633079|FG001|Overall Study|Other|1
6035978|NCT00337935|9633078|FG000|Overall Study|Lack of Efficacy|0
6035979|NCT00337935|9633079|FG001|Overall Study|Lack of Efficacy|1
6035980|NCT00338286|9633096|FG000|Overall Study|Withdrawal by Subject|50
6035981|NCT00338286|9633097|FG001|Overall Study|Withdrawal by Subject|54
6035982|NCT00338286|9633096|FG000|Overall Study|Lost to Follow-up|80
6035983|NCT00338286|9633097|FG001|Overall Study|Lost to Follow-up|66
6035984|NCT00338286|9633096|FG000|Overall Study|Other|103
6035985|NCT00338286|9633097|FG001|Overall Study|Other|93
6035986|NCT00338728|9633112|FG000|Overall Study|Screen Failure|14
6035987|NCT00338741|9633118|FG000|Overall Study|Lost to Follow-up|2
6035988|NCT00338741|9633119|FG001|Overall Study|Lost to Follow-up|0
6035989|NCT00338806|9633127|FG000|Acute Phase|Withdrawal by Subject|0
6035990|NCT00338806|9633128|FG001|Acute Phase|Withdrawal by Subject|1
6035991|NCT00338806|9633127|FG000|Follow-up|Lost to Follow-up|1
6035992|NCT00338806|9633128|FG001|Follow-up|Lost to Follow-up|3
6035993|NCT00338884|9633136|FG000|Overall Study|Objective Disease Progression or Relapse|44
6035994|NCT00338884|9633136|FG000|Overall Study|Adverse Event|14
6035995|NCT00338884|9633136|FG000|Overall Study|Death|8
6035996|NCT00338884|9633136|FG000|Overall Study|Other|4
6035997|NCT00338884|9633136|FG000|Overall Study|Global Deterioration of Health Status|3
6035998|NCT00338884|9633136|FG000|Overall Study|Withdrawal by Subject|3
6035999|NCT00338884|9633136|FG000|Overall Study|Lost to Follow-up|1
6036000|NCT00338884|9633136|FG000|Overall Study|Randomized But Did Not Receive Treatment|1
6036001|NCT00338949|9633142|FG000|Subject Screening|Screen failures|11
6036002|NCT00338949|9633143|FG001|Subject Screening|Screen failures|11
6036003|NCT00338949|9633142|FG000|Randomization|Withdrawal by Subject|1
6036004|NCT00338949|9633143|FG001|Randomization|Withdrawal by Subject|0
6036005|NCT00338949|9633142|FG000|Randomization|Adverse Event|0
6036006|NCT00338949|9633143|FG001|Randomization|Adverse Event|5
6036007|NCT00338962|9633153|FG000|Overall Study|Lost to Follow-up|3
6036008|NCT00338962|9633154|FG001|Overall Study|Lost to Follow-up|3
6036009|NCT00338962|9633155|FG002|Overall Study|Lost to Follow-up|2
6036010|NCT00338962|9633156|FG003|Overall Study|Lost to Follow-up|3
6036011|NCT00338962|9633153|FG000|Overall Study|Withdrawal by Subject|1
6036012|NCT00338962|9633154|FG001|Overall Study|Withdrawal by Subject|0
6036013|NCT00338962|9633155|FG002|Overall Study|Withdrawal by Subject|0
6036014|NCT00338962|9633156|FG003|Overall Study|Withdrawal by Subject|0
6036015|NCT00338962|9633153|FG000|Overall Study|No Transportation|2
6036016|NCT00338962|9633154|FG001|Overall Study|No Transportation|0
6036017|NCT00338962|9633155|FG002|Overall Study|No Transportation|0
6036018|NCT00338962|9633156|FG003|Overall Study|No Transportation|0
6036019|NCT00338962|9633153|FG000|Overall Study|Time Constraint|2
6036020|NCT00338962|9633154|FG001|Overall Study|Time Constraint|0
6036021|NCT00338962|9633155|FG002|Overall Study|Time Constraint|0
6036022|NCT00338962|9633156|FG003|Overall Study|Time Constraint|0
6036023|NCT00338962|9633153|FG000|Overall Study|Moved|0
6036024|NCT00338962|9633154|FG001|Overall Study|Moved|1
6036025|NCT00338962|9633155|FG002|Overall Study|Moved|0
6036026|NCT00338962|9633156|FG003|Overall Study|Moved|0
6036027|NCT00338962|9633153|FG000|Overall Study|Adverse Event|0
6036028|NCT00338962|9633154|FG001|Overall Study|Adverse Event|0
6036029|NCT00338962|9633155|FG002|Overall Study|Adverse Event|2
6036030|NCT00338962|9633156|FG003|Overall Study|Adverse Event|0
6036031|NCT00338962|9633153|FG000|Overall Study|Poor Compliance|0
6036032|NCT00338962|9633154|FG001|Overall Study|Poor Compliance|0
6036033|NCT00338962|9633155|FG002|Overall Study|Poor Compliance|2
6036034|NCT00338962|9633156|FG003|Overall Study|Poor Compliance|0
6036035|NCT00339040|9633173|FG000|Stage I|Not able to attend clinic|1
6036036|NCT00339040|9633174|FG001|Stage I|Not able to attend clinic|0
6036037|NCT00339040|9633173|FG000|Stage I|Protocol Violation|1
6036038|NCT00339040|9633174|FG001|Stage I|Protocol Violation|1
6036039|NCT00339040|9633173|FG000|Stage II|Lost to Follow-up|3
6036040|NCT00339040|9633174|FG001|Stage II|Lost to Follow-up|0
6036041|NCT00339040|9633173|FG000|Stage II|Withdrawal by Subject|1
6036042|NCT00339040|9633174|FG001|Stage II|Withdrawal by Subject|2
6036043|NCT00339040|9633173|FG000|Stage II|Protocol Violation|3
6036044|NCT00339040|9633174|FG001|Stage II|Protocol Violation|0
6036045|NCT00339040|9633173|FG000|Stage II|Not able to attend clinic|1
6036046|NCT00339040|9633174|FG001|Stage II|Not able to attend clinic|0
6036047|NCT00339040|9633173|FG000|Stage II|Site closing|2
6036048|NCT00339040|9633174|FG001|Stage II|Site closing|0
6036049|NCT00339144|9633204|FG000|Overall Study|Disease progression|5
6036050|NCT00339144|9633205|FG001|Overall Study|Disease progression|2
6036051|NCT00339144|9633206|FG002|Overall Study|Disease progression|2
6036052|NCT00339144|9633204|FG000|Overall Study|Study drug toxicity|3
6036053|NCT00339144|9633205|FG001|Overall Study|Study drug toxicity|1
6036054|NCT00339144|9633206|FG002|Overall Study|Study drug toxicity|1
6036055|NCT00339144|9633204|FG000|Overall Study|Participant's request to discontinuation|1
6036056|NCT00339144|9633205|FG001|Overall Study|Participant's request to discontinuation|0
6036057|NCT00339144|9633206|FG002|Overall Study|Participant's request to discontinuation|1
6036058|NCT00339183|9633217|FG000|Overall Study|Adverse Event|5
6036059|NCT00339183|9633218|FG001|Overall Study|Adverse Event|3
6036060|NCT00339183|9633217|FG000|Overall Study|Withdrawal by Subject|16
6036061|NCT00339183|9633218|FG001|Overall Study|Withdrawal by Subject|19
6036062|NCT00339183|9633217|FG000|Overall Study|Physician Decision|2
6036063|NCT00339183|9633218|FG001|Overall Study|Physician Decision|4
6036064|NCT00339183|9633217|FG000|Overall Study|Lost to Follow-up|17
6036065|NCT00339183|9633218|FG001|Overall Study|Lost to Follow-up|17
6036066|NCT00339183|9633217|FG000|Overall Study|Protocol-specified criteria|12
6036067|NCT00339183|9633218|FG001|Overall Study|Protocol-specified criteria|8
6036068|NCT00339183|9633217|FG000|Overall Study|Missing reason|3
6036069|NCT00339183|9633218|FG001|Overall Study|Missing reason|1
6036070|NCT00339183|9633217|FG000|Overall Study|Other|46
6036071|NCT00339183|9633218|FG001|Overall Study|Other|40
6036072|NCT00339183|9633217|FG000|Overall Study|Ongoing|20
6036073|NCT00339183|9633218|FG001|Overall Study|Ongoing|13
6036074|NCT00339833|9633230|FG000|Overall Study|Withdrawal by Subject|1
6036075|NCT00339833|9633231|FG001|Overall Study|Withdrawal by Subject|2
6036076|NCT00339833|9633230|FG000|Overall Study|toothache|0
6036077|NCT00339833|9633231|FG001|Overall Study|toothache|1
6036078|NCT00339833|9633230|FG000|Overall Study|indigestion|0
6036079|NCT00339833|9633231|FG001|Overall Study|indigestion|1
6036080|NCT00339833|9633230|FG000|Overall Study|Chest pain|0
6036081|NCT00339833|9633231|FG001|Overall Study|Chest pain|1
6036082|NCT00339833|9633230|FG000|Overall Study|minor infection|0
6036083|NCT00339833|9633231|FG001|Overall Study|minor infection|1
6036084|NCT00339833|9633230|FG000|Overall Study|Poor venous access|2
6036085|NCT00339833|9633231|FG001|Overall Study|Poor venous access|2
6036086|NCT00339833|9633230|FG000|Overall Study|anaemia or excess drop in glycaemia|2
6036087|NCT00339833|9633231|FG001|Overall Study|anaemia or excess drop in glycaemia|0
6036088|NCT00339833|9633230|FG000|Overall Study|Error in data records|1
6036089|NCT00339833|9633231|FG001|Overall Study|Error in data records|0
6036090|NCT00340678|9633250|FG000|Overall Study|Lost to Follow-up|1
6036091|NCT00340678|9633251|FG001|Overall Study|Lost to Follow-up|0
6036092|NCT00340678|9633252|FG002|Overall Study|Lost to Follow-up|0
6036093|NCT00340678|9633253|FG003|Overall Study|Lost to Follow-up|0
6036094|NCT00340704|9633270|FG000|PK Study|Adverse Event|0
6036095|NCT00340704|9633271|FG001|PK Study|Adverse Event|1
6036096|NCT00340704|9633272|FG002|PK Study|Adverse Event|0
6036097|NCT00340704|9633273|FG003|PK Study|Adverse Event|0
6036098|NCT00340704|9633274|FG004|PK Study|Adverse Event|0
6036099|NCT00340704|9633275|FG005|PK Study|Adverse Event|0
6036100|NCT00340704|9633276|FG006|PK Study|Adverse Event|0
6036101|NCT00340704|9633277|FG007|PK Study|Adverse Event|0
6036102|NCT00340704|9633278|FG008|PK Study|Adverse Event|0
6036103|NCT00340704|9633270|FG000|PK Study|Not treated|0
6036104|NCT00340704|9633271|FG001|PK Study|Not treated|0
6036105|NCT00340704|9633272|FG002|PK Study|Not treated|1
6036106|NCT00340704|9633273|FG003|PK Study|Not treated|0
6036107|NCT00340704|9633274|FG004|PK Study|Not treated|0
6036108|NCT00340704|9633275|FG005|PK Study|Not treated|0
6036109|NCT00340704|9633276|FG006|PK Study|Not treated|0
6036110|NCT00340704|9633277|FG007|PK Study|Not treated|0
6036111|NCT00340704|9633278|FG008|PK Study|Not treated|0
6036112|NCT00340704|9633270|FG000|Group D- Denovo & 527.51 Rollover Study|Adverse Event|0
6036113|NCT00340704|9633271|FG001|Group D- Denovo & 527.51 Rollover Study|Adverse Event|0
6036114|NCT00340704|9633272|FG002|Group D- Denovo & 527.51 Rollover Study|Adverse Event|0
6036115|NCT00340704|9633273|FG003|Group D- Denovo & 527.51 Rollover Study|Adverse Event|2
6036116|NCT00340704|9633274|FG004|Group D- Denovo & 527.51 Rollover Study|Adverse Event|4
6048848|NCT00420849|9648185|FG000|Overall Study|Withdrawal by Subject|28
6036117|NCT00340704|9633275|FG005|Group D- Denovo & 527.51 Rollover Study|Adverse Event|0
6036118|NCT00340704|9633276|FG006|Group D- Denovo & 527.51 Rollover Study|Adverse Event|0
6036119|NCT00340704|9633277|FG007|Group D- Denovo & 527.51 Rollover Study|Adverse Event|1
6036120|NCT00340704|9633278|FG008|Group D- Denovo & 527.51 Rollover Study|Adverse Event|1
6036121|NCT00340704|9633270|FG000|Group D- Denovo & 527.51 Rollover Study|Protocol Violation|0
6036122|NCT00340704|9633271|FG001|Group D- Denovo & 527.51 Rollover Study|Protocol Violation|0
6036123|NCT00340704|9633272|FG002|Group D- Denovo & 527.51 Rollover Study|Protocol Violation|0
6036124|NCT00340704|9633273|FG003|Group D- Denovo & 527.51 Rollover Study|Protocol Violation|0
6036125|NCT00340704|9633274|FG004|Group D- Denovo & 527.51 Rollover Study|Protocol Violation|0
6036126|NCT00340704|9633275|FG005|Group D- Denovo & 527.51 Rollover Study|Protocol Violation|1
6036127|NCT00340704|9633276|FG006|Group D- Denovo & 527.51 Rollover Study|Protocol Violation|0
6036128|NCT00340704|9633277|FG007|Group D- Denovo & 527.51 Rollover Study|Protocol Violation|0
6036129|NCT00340704|9633278|FG008|Group D- Denovo & 527.51 Rollover Study|Protocol Violation|0
6036130|NCT00340704|9633270|FG000|Group D- Denovo & 527.51 Rollover Study|Withdrawal by Subject|0
6036131|NCT00340704|9633271|FG001|Group D- Denovo & 527.51 Rollover Study|Withdrawal by Subject|0
6036132|NCT00340704|9633272|FG002|Group D- Denovo & 527.51 Rollover Study|Withdrawal by Subject|0
6036133|NCT00340704|9633273|FG003|Group D- Denovo & 527.51 Rollover Study|Withdrawal by Subject|0
6036134|NCT00340704|9633274|FG004|Group D- Denovo & 527.51 Rollover Study|Withdrawal by Subject|1
6036135|NCT00340704|9633275|FG005|Group D- Denovo & 527.51 Rollover Study|Withdrawal by Subject|3
6036136|NCT00340704|9633276|FG006|Group D- Denovo & 527.51 Rollover Study|Withdrawal by Subject|0
6036137|NCT00340704|9633277|FG007|Group D- Denovo & 527.51 Rollover Study|Withdrawal by Subject|0
6036138|NCT00340704|9633278|FG008|Group D- Denovo & 527.51 Rollover Study|Withdrawal by Subject|0
6036139|NCT00340704|9633270|FG000|Group D- Denovo & 527.51 Rollover Study|Other reason not defined above|0
6036140|NCT00340704|9633271|FG001|Group D- Denovo & 527.51 Rollover Study|Other reason not defined above|0
6036141|NCT00340704|9633272|FG002|Group D- Denovo & 527.51 Rollover Study|Other reason not defined above|0
6036142|NCT00340704|9633273|FG003|Group D- Denovo & 527.51 Rollover Study|Other reason not defined above|0
6036143|NCT00340704|9633274|FG004|Group D- Denovo & 527.51 Rollover Study|Other reason not defined above|0
6036144|NCT00340704|9633275|FG005|Group D- Denovo & 527.51 Rollover Study|Other reason not defined above|3
6036145|NCT00340704|9633276|FG006|Group D- Denovo & 527.51 Rollover Study|Other reason not defined above|53
6036146|NCT00340704|9633277|FG007|Group D- Denovo & 527.51 Rollover Study|Other reason not defined above|11
6036147|NCT00340704|9633278|FG008|Group D- Denovo & 527.51 Rollover Study|Other reason not defined above|28
6036148|NCT00340834|9633309|FG000|Core Phase of Study|Adverse Event|26
6036149|NCT00340834|9633310|FG001|Core Phase of Study|Adverse Event|9
6036150|NCT00340834|9633311|FG002|Core Phase of Study|Adverse Event|9
6036151|NCT00340834|9633312|FG003|Core Phase of Study|Adverse Event|0
6036152|NCT00340834|9633313|FG004|Core Phase of Study|Adverse Event|0
6036153|NCT00340834|9633309|FG000|Core Phase of Study|Withdrawal by Subject|11
6036154|NCT00340834|9633310|FG001|Core Phase of Study|Withdrawal by Subject|9
6036155|NCT00340834|9633311|FG002|Core Phase of Study|Withdrawal by Subject|16
6036156|NCT00340834|9633312|FG003|Core Phase of Study|Withdrawal by Subject|0
6036157|NCT00340834|9633313|FG004|Core Phase of Study|Withdrawal by Subject|0
6036158|NCT00340834|9633309|FG000|Core Phase of Study|Administrative Problems|6
6036159|NCT00340834|9633310|FG001|Core Phase of Study|Administrative Problems|2
6036160|NCT00340834|9633311|FG002|Core Phase of Study|Administrative Problems|7
6036161|NCT00340834|9633312|FG003|Core Phase of Study|Administrative Problems|0
6036162|NCT00340834|9633313|FG004|Core Phase of Study|Administrative Problems|0
6036163|NCT00340834|9633309|FG000|Core Phase of Study|Lack of Efficacy|3
6036164|NCT00340834|9633310|FG001|Core Phase of Study|Lack of Efficacy|3
6036165|NCT00340834|9633311|FG002|Core Phase of Study|Lack of Efficacy|7
6036166|NCT00340834|9633312|FG003|Core Phase of Study|Lack of Efficacy|0
6036167|NCT00340834|9633313|FG004|Core Phase of Study|Lack of Efficacy|0
6036168|NCT00340834|9633309|FG000|Core Phase of Study|Abnormal laboratory value(s)|4
6036169|NCT00340834|9633310|FG001|Core Phase of Study|Abnormal laboratory value(s)|6
6036170|NCT00340834|9633311|FG002|Core Phase of Study|Abnormal laboratory value(s)|1
6036171|NCT00340834|9633312|FG003|Core Phase of Study|Abnormal laboratory value(s)|0
6036172|NCT00340834|9633313|FG004|Core Phase of Study|Abnormal laboratory value(s)|0
6036173|NCT00340834|9633309|FG000|Core Phase of Study|Abnormal test procedure result(s)|4
6036174|NCT00340834|9633310|FG001|Core Phase of Study|Abnormal test procedure result(s)|3
6036175|NCT00340834|9633311|FG002|Core Phase of Study|Abnormal test procedure result(s)|3
6036176|NCT00340834|9633312|FG003|Core Phase of Study|Abnormal test procedure result(s)|0
6036177|NCT00340834|9633313|FG004|Core Phase of Study|Abnormal test procedure result(s)|0
6036178|NCT00340834|9633309|FG000|Core Phase of Study|Lost to Follow-up|1
6036179|NCT00340834|9633310|FG001|Core Phase of Study|Lost to Follow-up|1
6036180|NCT00340834|9633311|FG002|Core Phase of Study|Lost to Follow-up|4
6036181|NCT00340834|9633312|FG003|Core Phase of Study|Lost to Follow-up|0
6036182|NCT00340834|9633313|FG004|Core Phase of Study|Lost to Follow-up|0
6036183|NCT00340834|9633309|FG000|Core Phase of Study|Death|2
6036184|NCT00340834|9633310|FG001|Core Phase of Study|Death|0
6036185|NCT00340834|9633311|FG002|Core Phase of Study|Death|0
6036186|NCT00340834|9633312|FG003|Core Phase of Study|Death|0
6036187|NCT00340834|9633313|FG004|Core Phase of Study|Death|0
6036188|NCT00340834|9633309|FG000|Core Phase of Study|Protocol Violation|0
6036189|NCT00340834|9633310|FG001|Core Phase of Study|Protocol Violation|0
6036190|NCT00340834|9633311|FG002|Core Phase of Study|Protocol Violation|2
6036191|NCT00340834|9633312|FG003|Core Phase of Study|Protocol Violation|0
6036192|NCT00340834|9633313|FG004|Core Phase of Study|Protocol Violation|0
6036193|NCT00340834|9633309|FG000|Extension Phase of Study|Subject did not receive study drug|0
6036194|NCT00340834|9633310|FG001|Extension Phase of Study|Subject did not receive study drug|1
6036195|NCT00340834|9633311|FG002|Extension Phase of Study|Subject did not receive study drug|0
6036196|NCT00340834|9633312|FG003|Extension Phase of Study|Subject did not receive study drug|2
6036197|NCT00340834|9633313|FG004|Extension Phase of Study|Subject did not receive study drug|0
6036198|NCT00340834|9633309|FG000|Extension Phase of Study|Subject withdrew consent|26
6036199|NCT00340834|9633310|FG001|Extension Phase of Study|Subject withdrew consent|31
6036200|NCT00340834|9633311|FG002|Extension Phase of Study|Subject withdrew consent|0
6036201|NCT00340834|9633312|FG003|Extension Phase of Study|Subject withdrew consent|12
6036202|NCT00340834|9633313|FG004|Extension Phase of Study|Subject withdrew consent|15
6036203|NCT00340834|9633309|FG000|Extension Phase of Study|Adverse Event|21
6036204|NCT00340834|9633310|FG001|Extension Phase of Study|Adverse Event|22
6036205|NCT00340834|9633311|FG002|Extension Phase of Study|Adverse Event|0
6036206|NCT00340834|9633312|FG003|Extension Phase of Study|Adverse Event|19
6036207|NCT00340834|9633313|FG004|Extension Phase of Study|Adverse Event|7
6036208|NCT00340834|9633309|FG000|Extension Phase of Study|Abnormal laboratory value(s)|14
6036209|NCT00340834|9633310|FG001|Extension Phase of Study|Abnormal laboratory value(s)|13
6036210|NCT00340834|9633311|FG002|Extension Phase of Study|Abnormal laboratory value(s)|0
6036211|NCT00340834|9633312|FG003|Extension Phase of Study|Abnormal laboratory value(s)|13
6036212|NCT00340834|9633313|FG004|Extension Phase of Study|Abnormal laboratory value(s)|4
6036213|NCT00340834|9633309|FG000|Extension Phase of Study|Unsatisfactory therapeutic effect|13
6036214|NCT00340834|9633310|FG001|Extension Phase of Study|Unsatisfactory therapeutic effect|7
6036215|NCT00340834|9633311|FG002|Extension Phase of Study|Unsatisfactory therapeutic effect|0
6036216|NCT00340834|9633312|FG003|Extension Phase of Study|Unsatisfactory therapeutic effect|4
6036217|NCT00340834|9633313|FG004|Extension Phase of Study|Unsatisfactory therapeutic effect|9
6036218|NCT00340834|9633309|FG000|Extension Phase of Study|Lost to Follow-up|1
6036219|NCT00340834|9633310|FG001|Extension Phase of Study|Lost to Follow-up|1
6036220|NCT00340834|9633311|FG002|Extension Phase of Study|Lost to Follow-up|0
6036221|NCT00340834|9633312|FG003|Extension Phase of Study|Lost to Follow-up|2
6036222|NCT00340834|9633313|FG004|Extension Phase of Study|Lost to Follow-up|3
6036223|NCT00340834|9633309|FG000|Extension Phase of Study|Subject no longer requires study drug|4
6036224|NCT00340834|9633310|FG001|Extension Phase of Study|Subject no longer requires study drug|0
6036225|NCT00340834|9633311|FG002|Extension Phase of Study|Subject no longer requires study drug|0
6036226|NCT00340834|9633312|FG003|Extension Phase of Study|Subject no longer requires study drug|0
6036227|NCT00340834|9633313|FG004|Extension Phase of Study|Subject no longer requires study drug|2
6036228|NCT00340834|9633309|FG000|Extension Phase of Study|Administrative problems|3
6036229|NCT00340834|9633310|FG001|Extension Phase of Study|Administrative problems|0
6036230|NCT00340834|9633311|FG002|Extension Phase of Study|Administrative problems|0
6036231|NCT00340834|9633312|FG003|Extension Phase of Study|Administrative problems|1
6036232|NCT00340834|9633313|FG004|Extension Phase of Study|Administrative problems|1
6036233|NCT00340834|9633309|FG000|Extension Phase of Study|Abnormal test procedure result(s)|0
6036234|NCT00340834|9633310|FG001|Extension Phase of Study|Abnormal test procedure result(s)|1
6036235|NCT00340834|9633311|FG002|Extension Phase of Study|Abnormal test procedure result(s)|0
6036236|NCT00340834|9633312|FG003|Extension Phase of Study|Abnormal test procedure result(s)|0
6036237|NCT00340834|9633313|FG004|Extension Phase of Study|Abnormal test procedure result(s)|2
6036238|NCT00340834|9633309|FG000|Extension Phase of Study|Protocol Violation|3
6036239|NCT00340834|9633310|FG001|Extension Phase of Study|Protocol Violation|0
6036240|NCT00340834|9633311|FG002|Extension Phase of Study|Protocol Violation|0
6036241|NCT00340834|9633312|FG003|Extension Phase of Study|Protocol Violation|0
6036242|NCT00340834|9633313|FG004|Extension Phase of Study|Protocol Violation|0
6036243|NCT00340834|9633309|FG000|Extension Phase of Study|Death|0
6036244|NCT00340834|9633310|FG001|Extension Phase of Study|Death|0
6036245|NCT00340834|9633311|FG002|Extension Phase of Study|Death|0
6036246|NCT00340834|9633312|FG003|Extension Phase of Study|Death|0
6036247|NCT00340834|9633313|FG004|Extension Phase of Study|Death|1
6036248|NCT00342628|9633362|FG000|Overall Study|Withdrawal by Subject|19
6036249|NCT00342628|9633363|FG001|Overall Study|Withdrawal by Subject|19
6036250|NCT00342628|9633364|FG002|Overall Study|Withdrawal by Subject|18
6036251|NCT00342628|9633362|FG000|Overall Study|Death|1
6036252|NCT00342628|9633363|FG001|Overall Study|Death|1
6036253|NCT00342628|9633364|FG002|Overall Study|Death|0
6036254|NCT00342628|9633362|FG000|Overall Study|moved residence|0
6036255|NCT00342628|9633363|FG001|Overall Study|moved residence|1
6036256|NCT00342628|9633364|FG002|Overall Study|moved residence|1
6036257|NCT00343252|9633383|FG000|6 Months (All Treated Participants)|Adverse Event|17
6036258|NCT00343252|9633384|FG001|6 Months (All Treated Participants)|Adverse Event|11
6036259|NCT00343252|9633383|FG000|6 Months (All Treated Participants)|Death|0
6036260|NCT00343252|9633384|FG001|6 Months (All Treated Participants)|Death|2
6036261|NCT00343252|9633383|FG000|6 Months (All Treated Participants)|Entry Criteria Not Met|10
6036262|NCT00343252|9633384|FG001|6 Months (All Treated Participants)|Entry Criteria Not Met|8
6036263|NCT00343252|9633383|FG000|6 Months (All Treated Participants)|Lack of Efficacy|0
6036264|NCT00343252|9633384|FG001|6 Months (All Treated Participants)|Lack of Efficacy|1
6036265|NCT00343252|9633383|FG000|6 Months (All Treated Participants)|Lost to Follow-up|0
6036266|NCT00343252|9633384|FG001|6 Months (All Treated Participants)|Lost to Follow-up|4
6036267|NCT00343252|9633383|FG000|6 Months (All Treated Participants)|Physician Decision|1
6036268|NCT00343252|9633384|FG001|6 Months (All Treated Participants)|Physician Decision|3
6036269|NCT00343252|9633383|FG000|6 Months (All Treated Participants)|Protocol Violation|2
6036270|NCT00343252|9633384|FG001|6 Months (All Treated Participants)|Protocol Violation|2
6036271|NCT00343252|9633383|FG000|6 Months (All Treated Participants)|Sponsor Decision|7
6036272|NCT00343252|9633384|FG001|6 Months (All Treated Participants)|Sponsor Decision|4
6036273|NCT00343252|9633383|FG000|6 Months (All Treated Participants)|Withdrawal by Subject|19
6036274|NCT00343252|9633384|FG001|6 Months (All Treated Participants)|Withdrawal by Subject|9
6036275|NCT00343252|9633383|FG000|12 Months (All Treated Participants)|Adverse Event|22
6036276|NCT00343252|9633384|FG001|12 Months (All Treated Participants)|Adverse Event|20
6036277|NCT00343252|9633383|FG000|12 Months (All Treated Participants)|Death|3
6036278|NCT00343252|9633384|FG001|12 Months (All Treated Participants)|Death|3
6036279|NCT00343252|9633383|FG000|12 Months (All Treated Participants)|Entry Criteria Not Met|10
6036280|NCT00343252|9633384|FG001|12 Months (All Treated Participants)|Entry Criteria Not Met|10
6036281|NCT00343252|9633383|FG000|12 Months (All Treated Participants)|Lack of Efficacy|1
6036282|NCT00343252|9633384|FG001|12 Months (All Treated Participants)|Lack of Efficacy|1
6036283|NCT00343252|9633383|FG000|12 Months (All Treated Participants)|Lost to Follow-up|1
6036284|NCT00343252|9633384|FG001|12 Months (All Treated Participants)|Lost to Follow-up|5
6036285|NCT00343252|9633383|FG000|12 Months (All Treated Participants)|Physician Decision|4
6036286|NCT00343252|9633384|FG001|12 Months (All Treated Participants)|Physician Decision|5
6036287|NCT00343252|9633383|FG000|12 Months (All Treated Participants)|Protocol Violation|3
6036288|NCT00343252|9633384|FG001|12 Months (All Treated Participants)|Protocol Violation|2
6036289|NCT00343252|9633383|FG000|12 Months (All Treated Participants)|Sponsor Decision|9
6036290|NCT00343252|9633384|FG001|12 Months (All Treated Participants)|Sponsor Decision|6
6036291|NCT00343252|9633383|FG000|12 Months (All Treated Participants)|Withdrawal by Subject|33
6036292|NCT00343252|9633384|FG001|12 Months (All Treated Participants)|Withdrawal by Subject|17
6036293|NCT00343252|9633383|FG000|18 Months (All Treated Participants)|Adverse Event|31
6036294|NCT00343252|9633384|FG001|18 Months (All Treated Participants)|Adverse Event|23
6036295|NCT00343252|9633383|FG000|18 Months (All Treated Participants)|Death|4
6036296|NCT00343252|9633384|FG001|18 Months (All Treated Participants)|Death|5
6036297|NCT00343252|9633383|FG000|18 Months (All Treated Participants)|Entry Criteria Not Met|11
6036298|NCT00343252|9633384|FG001|18 Months (All Treated Participants)|Entry Criteria Not Met|10
6036299|NCT00343252|9633383|FG000|18 Months (All Treated Participants)|Lack of Efficacy|1
6036300|NCT00343252|9633384|FG001|18 Months (All Treated Participants)|Lack of Efficacy|1
6036301|NCT00343252|9633383|FG000|18 Months (All Treated Participants)|Lost to Follow-up|3
6036302|NCT00343252|9633384|FG001|18 Months (All Treated Participants)|Lost to Follow-up|7
6036303|NCT00343252|9633383|FG000|18 Months (All Treated Participants)|Physician Decision|4
6036304|NCT00343252|9633384|FG001|18 Months (All Treated Participants)|Physician Decision|7
6036305|NCT00343252|9633383|FG000|18 Months (All Treated Participants)|Protocol Violation|3
6036306|NCT00343252|9633384|FG001|18 Months (All Treated Participants)|Protocol Violation|3
6036307|NCT00343252|9633383|FG000|18 Months (All Treated Participants)|Sponsor Decision|8
6036308|NCT00343252|9633384|FG001|18 Months (All Treated Participants)|Sponsor Decision|5
6036309|NCT00343252|9633383|FG000|18 Months (All Treated Participants)|Withdrawal by Subject|36
6036310|NCT00343252|9633384|FG001|18 Months (All Treated Participants)|Withdrawal by Subject|20
6036311|NCT00343291|9633392|FG000|Overall Study|Adverse Event|13
6036312|NCT00343291|9633393|FG001|Overall Study|Adverse Event|13
6036313|NCT00343291|9633392|FG000|Overall Study|Death|3
6036314|NCT00343291|9633393|FG001|Overall Study|Death|2
6036315|NCT00343291|9633392|FG000|Overall Study|Progressive disease|33
6036316|NCT00343291|9633393|FG001|Overall Study|Progressive disease|34
6036317|NCT00343291|9633392|FG000|Overall Study|Withdrawal by Subject|0
6036318|NCT00343291|9633393|FG001|Overall Study|Withdrawal by Subject|2
6036319|NCT00343291|9633392|FG000|Overall Study|Other|8
6036320|NCT00343291|9633393|FG001|Overall Study|Other|5
6036321|NCT00343382|9633402|FG000|Overall Study|Adverse Event|2
6036322|NCT00343382|9633403|FG001|Overall Study|Adverse Event|10
6036323|NCT00343382|9633404|FG002|Overall Study|Adverse Event|7
6036324|NCT00343382|9633402|FG000|Overall Study|Withdrawal by Subject|1
6036325|NCT00343382|9633403|FG001|Overall Study|Withdrawal by Subject|2
6036326|NCT00343382|9633404|FG002|Overall Study|Withdrawal by Subject|6
6036327|NCT00343382|9633402|FG000|Overall Study|Other Reason Not Specified|1
6036328|NCT00343382|9633403|FG001|Overall Study|Other Reason Not Specified|2
6036329|NCT00343382|9633404|FG002|Overall Study|Other Reason Not Specified|4
6036330|NCT00343512|9633438|FG000|Overall Study|Withdrawal by Subject|2
6036331|NCT00343642|9633562|FG000|Overall Study|Lost to Follow-up|0
6036332|NCT00343642|9633563|FG001|Overall Study|Lost to Follow-up|1
6036333|NCT00343642|9633564|FG002|Overall Study|Lost to Follow-up|0
6036334|NCT00343642|9633562|FG000|Overall Study|Pregnancy|1
6036335|NCT00343642|9633563|FG001|Overall Study|Pregnancy|0
6036336|NCT00343642|9633564|FG002|Overall Study|Pregnancy|2
6036337|NCT00343642|9633562|FG000|Overall Study|Withdrawal by Subject|2
6036338|NCT00343642|9633563|FG001|Overall Study|Withdrawal by Subject|3
6036339|NCT00343642|9633564|FG002|Overall Study|Withdrawal by Subject|4
6036340|NCT00343642|9633562|FG000|Overall Study|Adverse Event|0
6036341|NCT00343642|9633563|FG001|Overall Study|Adverse Event|0
6036342|NCT00343642|9633564|FG002|Overall Study|Adverse Event|1
6036343|NCT00343642|9633562|FG000|Overall Study|Flare up|6
6036344|NCT00343642|9633563|FG001|Overall Study|Flare up|4
6036345|NCT00343642|9633564|FG002|Overall Study|Flare up|0
6036346|NCT00343889|9633593|FG000|Overall Study|Lost to Follow-up|2
6036347|NCT00343889|9633594|FG001|Overall Study|Lost to Follow-up|0
6036348|NCT00343889|9633593|FG000|Overall Study|Withdrawal by Subject|0
6036349|NCT00343889|9633594|FG001|Overall Study|Withdrawal by Subject|1
6036350|NCT00343889|9633593|FG000|Overall Study|Protocol Violation|1
6036351|NCT00343889|9633594|FG001|Overall Study|Protocol Violation|0
6036352|NCT00343915|9633602|FG000|Primary Study|Withdrawal by Subject|1
6036353|NCT00343915|9633603|FG001|Primary Study|Withdrawal by Subject|0
6036354|NCT00343915|9633602|FG000|Primary Study|Lost to Follow-up|2
6036355|NCT00343915|9633603|FG001|Primary Study|Lost to Follow-up|3
6036356|NCT00343915|9633602|FG000|Primary Study|Other|1
6036357|NCT00343915|9633603|FG001|Primary Study|Other|0
6036358|NCT00344032|9633614|FG000|Overall Study|Adverse Event|0
6036359|NCT00344032|9633615|FG001|Overall Study|Adverse Event|1
6036360|NCT00344032|9633614|FG000|Overall Study|Withdrawal by Subject|6
6036361|NCT00344032|9633615|FG001|Overall Study|Withdrawal by Subject|2
6036362|NCT00344032|9633614|FG000|Overall Study|Lost to Follow-up|4
6036363|NCT00344032|9633615|FG001|Overall Study|Lost to Follow-up|6
6036364|NCT00344032|9633614|FG000|Overall Study|Physician Decision|4
6036365|NCT00344032|9633615|FG001|Overall Study|Physician Decision|1
6036366|NCT00344305|9633632|FG000|Overall Study|Lost to Follow-up|2
6036367|NCT00344305|9633633|FG001|Overall Study|Lost to Follow-up|0
6036368|NCT00344305|9633632|FG000|Overall Study|Participant was not contacted in window|0
6036369|NCT00344305|9633633|FG001|Overall Study|Participant was not contacted in window|1
6036370|NCT00344318|9633644|FG000|Overall Study|Adverse Event|0
6036371|NCT00344318|9633645|FG001|Overall Study|Adverse Event|3
6036372|NCT00344318|9633646|FG002|Overall Study|Adverse Event|0
6036373|NCT00344318|9633647|FG003|Overall Study|Adverse Event|1
6036374|NCT00344318|9633644|FG000|Overall Study|Withdrawal by Subject|2
6036375|NCT00344318|9633645|FG001|Overall Study|Withdrawal by Subject|2
6036376|NCT00344318|9633646|FG002|Overall Study|Withdrawal by Subject|0
6036377|NCT00344318|9633647|FG003|Overall Study|Withdrawal by Subject|2
6036378|NCT00344318|9633644|FG000|Overall Study|Lost to Follow-up|2
6036379|NCT00344318|9633645|FG001|Overall Study|Lost to Follow-up|0
6036380|NCT00344318|9633646|FG002|Overall Study|Lost to Follow-up|1
6036381|NCT00344318|9633647|FG003|Overall Study|Lost to Follow-up|0
6048849|NCT00420849|9648185|FG000|Overall Study|Death|18
6048850|NCT00420849|9648185|FG000|Overall Study|Other|14
6048851|NCT00420849|9648185|FG000|Overall Study|Transplant|8
6048852|NCT00420849|9648185|FG000|Overall Study|Protocol Violation|1
6048853|NCT00420849|9648185|FG000|Overall Study|Lost to Follow-up|1
6048854|NCT00420927|9648199|FG000|Period 1|Adverse Event|19
6048855|NCT00420927|9648200|FG001|Period 1|Adverse Event|15
6048856|NCT00420927|9648201|FG002|Period 1|Adverse Event|0
6048857|NCT00420927|9648202|FG003|Period 1|Adverse Event|0
6048858|NCT00420927|9648203|FG004|Period 1|Adverse Event|0
6048859|NCT00420927|9648204|FG005|Period 1|Adverse Event|0
6048860|NCT00420927|9648205|FG006|Period 1|Adverse Event|0
6048861|NCT00420927|9648199|FG000|Period 1|Withdrawal by Subject|7
6048862|NCT00420927|9648200|FG001|Period 1|Withdrawal by Subject|12
6048863|NCT00420927|9648201|FG002|Period 1|Withdrawal by Subject|0
6048864|NCT00420927|9648202|FG003|Period 1|Withdrawal by Subject|0
6048865|NCT00420927|9648203|FG004|Period 1|Withdrawal by Subject|0
6048866|NCT00420927|9648204|FG005|Period 1|Withdrawal by Subject|0
6048867|NCT00420927|9648205|FG006|Period 1|Withdrawal by Subject|0
6048868|NCT00420927|9648199|FG000|Period 1|Lost to Follow-up|8
6048869|NCT00420927|9648200|FG001|Period 1|Lost to Follow-up|6
6048870|NCT00420927|9648201|FG002|Period 1|Lost to Follow-up|0
6048871|NCT00420927|9648202|FG003|Period 1|Lost to Follow-up|0
6048872|NCT00420927|9648203|FG004|Period 1|Lost to Follow-up|0
6048873|NCT00420927|9648204|FG005|Period 1|Lost to Follow-up|0
6048874|NCT00420927|9648205|FG006|Period 1|Lost to Follow-up|0
6048875|NCT00420927|9648199|FG000|Period 1|Lack of efficacy/Loss of efficacy|1
6048876|NCT00420927|9648200|FG001|Period 1|Lack of efficacy/Loss of efficacy|6
6048877|NCT00420927|9648201|FG002|Period 1|Lack of efficacy/Loss of efficacy|0
6147040|NCT01080807|9782140|FG001|Overall Study|Laid off or terminated from job|2
6147041|NCT01080807|9782139|FG000|Overall Study|Stopped working consistent night shifts|0
6147042|NCT01080807|9782140|FG001|Overall Study|Stopped working consistent night shifts|1
6147043|NCT01080807|9782139|FG000|Overall Study|Work schedule changing|1
6147044|NCT01080807|9782140|FG001|Overall Study|Work schedule changing|1
6147045|NCT01080807|9782139|FG000|Overall Study|Work schedule and travel|0
6048878|NCT00420927|9648202|FG003|Period 1|Lack of efficacy/Loss of efficacy|0
6048879|NCT00420927|9648203|FG004|Period 1|Lack of efficacy/Loss of efficacy|0
6048880|NCT00420927|9648204|FG005|Period 1|Lack of efficacy/Loss of efficacy|0
6048881|NCT00420927|9648205|FG006|Period 1|Lack of efficacy/Loss of efficacy|0
6048882|NCT00420927|9648199|FG000|Period 1|Death|2
6048883|NCT00420927|9648200|FG001|Period 1|Death|0
6048884|NCT00420927|9648201|FG002|Period 1|Death|0
6036382|NCT00344448|9633670|FG000|Screening|Withdrawal by Subject|0
6036383|NCT00344448|9633671|FG001|Screening|Withdrawal by Subject|1
6036384|NCT00344448|9633670|FG000|Double Blind, Placebo Controlled|Withdrawal by Subject|1
6036385|NCT00344448|9633671|FG001|Double Blind, Placebo Controlled|Withdrawal by Subject|0
6036386|NCT00344448|9633670|FG000|Double Blind, Placebo Controlled|Study terminated|1
6036387|NCT00344448|9633671|FG001|Double Blind, Placebo Controlled|Study terminated|0
6036388|NCT00344448|9633670|FG000|Open Label|Withdrawal by Subject|1
6036389|NCT00344448|9633671|FG001|Open Label|Withdrawal by Subject|1
6036390|NCT00344448|9633670|FG000|Open Label|Study terminated|1
6036391|NCT00344448|9633671|FG001|Open Label|Study terminated|0
6036392|NCT00344461|9633677|FG000|Overall Study|Adverse Event|6
6036393|NCT00344461|9633677|FG000|Overall Study|Death|1
6036394|NCT00344461|9633677|FG000|Overall Study|Lack of Efficacy|2
6036395|NCT00344461|9633677|FG000|Overall Study|Lost to Follow-up|2
6036396|NCT00344461|9633677|FG000|Overall Study|Physician Decision|2
6036397|NCT00344461|9633677|FG000|Overall Study|Protocol Violation|6
6036398|NCT00344461|9633677|FG000|Overall Study|Withdrawal by Subject|2
6036399|NCT00344500|9633684|FG000|Overall Study|Adverse Event|6
6036400|NCT00344500|9633685|FG001|Overall Study|Adverse Event|2
6036401|NCT00344500|9633686|FG002|Overall Study|Adverse Event|0
6036402|NCT00344500|9633684|FG000|Overall Study|Lost to Follow-up|5
6036403|NCT00344500|9633685|FG001|Overall Study|Lost to Follow-up|13
6036404|NCT00344500|9633686|FG002|Overall Study|Lost to Follow-up|1
6036405|NCT00344500|9633684|FG000|Overall Study|Withdrawal by Subject|7
6036406|NCT00344500|9633685|FG001|Overall Study|Withdrawal by Subject|10
6036407|NCT00344500|9633686|FG002|Overall Study|Withdrawal by Subject|0
6036408|NCT00344500|9633684|FG000|Overall Study|Protocol Violation|4
6036409|NCT00344500|9633685|FG001|Overall Study|Protocol Violation|7
6036410|NCT00344500|9633686|FG002|Overall Study|Protocol Violation|1
6036411|NCT00344500|9633684|FG000|Overall Study|Not Noted|1
6036412|NCT00344500|9633685|FG001|Overall Study|Not Noted|3
6036413|NCT00344500|9633686|FG002|Overall Study|Not Noted|0
6036414|NCT00344773|9633702|FG000|Overall Study|Adverse Event|2
6036415|NCT00344773|9633702|FG000|Overall Study|Objective Disease Progression|16
6036416|NCT00344773|9633702|FG000|Overall Study|Withdrawal by Subject|1
6036417|NCT00344773|9633702|FG000|Overall Study|Not Eligible for the study|2
6036418|NCT00344968|9633709|FG000|Overall Study|Adverse Event|5
6036419|NCT00344968|9633710|FG001|Overall Study|Adverse Event|4
6036420|NCT00344968|9633711|FG002|Overall Study|Adverse Event|15
6036421|NCT00344968|9633709|FG000|Overall Study|Unsatisfactory Therapeutic Effect|3
6036422|NCT00344968|9633710|FG001|Overall Study|Unsatisfactory Therapeutic Effect|0
6036423|NCT00344968|9633711|FG002|Overall Study|Unsatisfactory Therapeutic Effect|1
6036424|NCT00344968|9633709|FG000|Overall Study|Protocol Violation|2
6036425|NCT00344968|9633710|FG001|Overall Study|Protocol Violation|2
6147046|NCT01080807|9782140|FG001|Overall Study|Work schedule and travel|1
6147047|NCT01080807|9782139|FG000|Overall Study|Switched to first shift|1
6147048|NCT01080807|9782140|FG001|Overall Study|Switched to first shift|0
6147049|NCT01080807|9782139|FG000|Overall Study|Moved away without notifying center|1
6036426|NCT00344968|9633711|FG002|Overall Study|Protocol Violation|5
6036427|NCT00344968|9633709|FG000|Overall Study|Withdrawal by Subject|14
6036428|NCT00344968|9633710|FG001|Overall Study|Withdrawal by Subject|31
6036429|NCT00344968|9633711|FG002|Overall Study|Withdrawal by Subject|27
6036430|NCT00344968|9633709|FG000|Overall Study|Lost to Follow-up|24
6036431|NCT00344968|9633710|FG001|Overall Study|Lost to Follow-up|37
6036432|NCT00344968|9633711|FG002|Overall Study|Lost to Follow-up|37
6036433|NCT00344968|9633709|FG000|Overall Study|Death|11
6036434|NCT00344968|9633710|FG001|Overall Study|Death|27
6036435|NCT00344968|9633711|FG002|Overall Study|Death|31
6036436|NCT00344968|9633709|FG000|Overall Study|Other|0
6036437|NCT00344968|9633710|FG001|Overall Study|Other|1
6036438|NCT00344968|9633711|FG002|Overall Study|Other|0
6036439|NCT00345046|9633732|FG000|Overall Study|Protocol Violation|1
6036440|NCT00345046|9633733|FG001|Overall Study|Protocol Violation|1
6036441|NCT00345046|9633734|FG002|Overall Study|Protocol Violation|2
6036442|NCT00345293|9633770|FG000|Overall Study|Unable to access line for sample|1
6036443|NCT00345293|9633771|FG001|Overall Study|Unable to access line for sample|0
6036444|NCT00345293|9633770|FG000|Overall Study|Withdrawal by Subject|1
6036445|NCT00345293|9633771|FG001|Overall Study|Withdrawal by Subject|0
6036446|NCT00345397|9633806|FG000|Overall Study|Death|1
6036447|NCT00345540|9633811|FG000|Overall Study|Withdrawal by Subject|1
6036448|NCT00345579|9633817|FG000|Overall Study|Adverse Event|9
6036449|NCT00345579|9633818|FG001|Overall Study|Adverse Event|6
6036450|NCT00345579|9633817|FG000|Overall Study|Protocol Violation|14
6036451|NCT00345579|9633818|FG001|Overall Study|Protocol Violation|5
6036452|NCT00345579|9633817|FG000|Overall Study|Withdrawal by Subject|50
6036453|NCT00345579|9633818|FG001|Overall Study|Withdrawal by Subject|17
6036454|NCT00345579|9633817|FG000|Overall Study|Lost to Follow-up|82
6036455|NCT00345579|9633818|FG001|Overall Study|Lost to Follow-up|36
6036456|NCT00345579|9633817|FG000|Overall Study|Other|9
6036457|NCT00345579|9633818|FG001|Overall Study|Other|1
6036458|NCT00345592|9633827|FG000|Overall Study|Death|14
6036459|NCT00345592|9633828|FG001|Overall Study|Death|16
6036460|NCT00345592|9633827|FG000|Overall Study|Withdrawal by Subject|11
6036461|NCT00345592|9633828|FG001|Overall Study|Withdrawal by Subject|8
6036462|NCT00345605|9633834|FG000|Arm 1|Adverse Event|0
6036463|NCT00345605|9633835|FG001|Arm 1|Adverse Event|1
6036464|NCT00345605|9633834|FG000|Arm 2, Opposite Treatment|Adverse Event|1
6036465|NCT00345605|9633835|FG001|Arm 2, Opposite Treatment|Adverse Event|0
6036466|NCT00345631|9633846|FG000|Overall Study|Withdrawal by Subject|1
6036467|NCT00345631|9633847|FG001|Overall Study|Withdrawal by Subject|0
6036468|NCT00345631|9633848|FG002|Overall Study|Withdrawal by Subject|1
6036469|NCT00345631|9633846|FG000|Overall Study|Adverse Event|0
6036470|NCT00345631|9633847|FG001|Overall Study|Adverse Event|1
6036471|NCT00345631|9633848|FG002|Overall Study|Adverse Event|0
6036472|NCT00345631|9633846|FG000|Overall Study|Lost to Follow-up|3
6036473|NCT00345631|9633847|FG001|Overall Study|Lost to Follow-up|7
6036474|NCT00345631|9633848|FG002|Overall Study|Lost to Follow-up|4
6036475|NCT00345631|9633846|FG000|Overall Study|Other reasons|0
6036476|NCT00345631|9633847|FG001|Overall Study|Other reasons|0
6036477|NCT00345631|9633848|FG002|Overall Study|Other reasons|1
6036478|NCT00345683|9633860|FG000|Overall Study|Lost to Follow-up|19
6036479|NCT00345683|9633861|FG001|Overall Study|Lost to Follow-up|7
6036480|NCT00345683|9633860|FG000|Overall Study|Other|6
6036481|NCT00345683|9633861|FG001|Overall Study|Other|2
6036482|NCT00345839|9633869|FG000|Overall Study|Withdrawal by Subject|91
6036483|NCT00345839|9633870|FG001|Overall Study|Withdrawal by Subject|98
6036484|NCT00345839|9633869|FG000|Overall Study|Lost to Follow-up|58
6147050|NCT01080807|9782140|FG001|Overall Study|Moved away without notifying center|0
6147051|NCT01081132|9782175|FG000|Overall Study|Lack of Efficacy|25
6147052|NCT01081132|9782176|FG001|Overall Study|Lack of Efficacy|9
6147053|NCT01081132|9782175|FG000|Overall Study|Withdrawal by Subject|13
6147054|NCT01081132|9782176|FG001|Overall Study|Withdrawal by Subject|16
6147055|NCT01081132|9782175|FG000|Overall Study|Lost to Follow-up|4
6147056|NCT01081132|9782176|FG001|Overall Study|Lost to Follow-up|11
6147057|NCT01081132|9782175|FG000|Overall Study|Adverse Event|3
6147058|NCT01081132|9782176|FG001|Overall Study|Adverse Event|9
6147059|NCT01081132|9782175|FG000|Overall Study|Non Compliance|4
6147060|NCT01081132|9782176|FG001|Overall Study|Non Compliance|2
6147061|NCT01081132|9782175|FG000|Overall Study|Lack Of Compliance|0
6147062|NCT01081132|9782176|FG001|Overall Study|Lack Of Compliance|1
6147063|NCT01081132|9782175|FG000|Overall Study|Missed Visits|1
6147064|NCT01081132|9782176|FG001|Overall Study|Missed Visits|1
6147065|NCT01081132|9782175|FG000|Overall Study|Stopped Taking Meds|2
6147066|NCT01081132|9782176|FG001|Overall Study|Stopped Taking Meds|0
6147067|NCT01081132|9782175|FG000|Overall Study|Patient Did Not Complete Wk14 and 15|0
6147068|NCT01081132|9782176|FG001|Overall Study|Patient Did Not Complete Wk14 and 15|1
6147069|NCT01081132|9782175|FG000|Overall Study|Declined Taper Phase|0
6147070|NCT01081132|9782176|FG001|Overall Study|Declined Taper Phase|1
6036485|NCT00345839|9633870|FG001|Overall Study|Lost to Follow-up|61
6036486|NCT00345878|9633899|FG000|Overall Study|Adverse Event|1
6036487|NCT00345878|9633900|FG001|Overall Study|Adverse Event|0
6036488|NCT00345878|9633899|FG000|Overall Study|Lost to Follow-up|2
6036489|NCT00345878|9633900|FG001|Overall Study|Lost to Follow-up|1
6036490|NCT00345878|9633899|FG000|Overall Study|Other|1
6036491|NCT00345878|9633900|FG001|Overall Study|Other|0
6036492|NCT00346034|9633915|FG000|Overall Study|Adverse Event|34
6036493|NCT00346034|9633915|FG000|Overall Study|Lack of Efficacy|8
6036494|NCT00346034|9633915|FG000|Overall Study|Withdrawal by Subject|13
6036495|NCT00346034|9633915|FG000|Overall Study|Patient Stopped Taking Study Drug|1
6036496|NCT00346034|9633915|FG000|Overall Study|Not Willing to Follow Dosing Regimen|1
6036497|NCT00346073|9633921|FG000|Overall Study|Serious Adverse Event|2
6036498|NCT00346073|9633922|FG001|Overall Study|Serious Adverse Event|0
6036499|NCT00346073|9633921|FG000|Overall Study|Lost to Follow-up|39
6036500|NCT00346073|9633922|FG001|Overall Study|Lost to Follow-up|24
6036501|NCT00346151|9633928|FG000|Overall Study|Withdrawal by Subject|3
6036502|NCT00346216|9633935|FG000|Overall Study|Other|181
6036503|NCT00346216|9633936|FG001|Overall Study|Other|231
6036504|NCT00346216|9633937|FG002|Overall Study|Other|205
6036505|NCT00346216|9633935|FG000|Overall Study|No longer willing to participate|600
6036506|NCT00346216|9633936|FG001|Overall Study|No longer willing to participate|606
6036507|NCT00346216|9633937|FG002|Overall Study|No longer willing to participate|585
6036508|NCT00346216|9633935|FG000|Overall Study|Withdrawal by Subject|661
6036509|NCT00346216|9633936|FG001|Overall Study|Withdrawal by Subject|692
6036510|NCT00346216|9633937|FG002|Overall Study|Withdrawal by Subject|651
6036511|NCT00346216|9633935|FG000|Overall Study|Lost to Follow-up|611
6036512|NCT00346216|9633936|FG001|Overall Study|Lost to Follow-up|588
6036513|NCT00346216|9633937|FG002|Overall Study|Lost to Follow-up|542
6036514|NCT00346216|9633935|FG000|Overall Study|Physician Decision|80
6036515|NCT00346216|9633936|FG001|Overall Study|Physician Decision|76
6036516|NCT00346216|9633937|FG002|Overall Study|Physician Decision|59
6036517|NCT00346216|9633935|FG000|Overall Study|Does not meet entrance criteria|13
6036518|NCT00346216|9633936|FG001|Overall Study|Does not meet entrance criteria|10
6036519|NCT00346216|9633937|FG002|Overall Study|Does not meet entrance criteria|8
6036520|NCT00346216|9633935|FG000|Overall Study|Death|189
6036521|NCT00346216|9633936|FG001|Overall Study|Death|192
6036522|NCT00346216|9633937|FG002|Overall Study|Death|228
6036523|NCT00346216|9633935|FG000|Overall Study|Study terminated by sponsor|11
6036524|NCT00346216|9633936|FG001|Overall Study|Study terminated by sponsor|4
6036525|NCT00346216|9633937|FG002|Overall Study|Study terminated by sponsor|8
6147071|NCT01081132|9782175|FG000|Overall Study|Protocol Violation|3
6147072|NCT01081132|9782176|FG001|Overall Study|Protocol Violation|1
6036526|NCT00346216|9633935|FG000|Overall Study|Missing Subject Summary Status|62
6036527|NCT00346216|9633936|FG001|Overall Study|Missing Subject Summary Status|61
6036528|NCT00346216|9633937|FG002|Overall Study|Missing Subject Summary Status|62
6036529|NCT00346268|9633947|FG000|Overall Study|Adverse Event|1
6036530|NCT00346268|9633948|FG001|Overall Study|Adverse Event|0
6036531|NCT00346268|9633947|FG000|Overall Study|Protocol Violation|1
6036532|NCT00346268|9633948|FG001|Overall Study|Protocol Violation|0
6036533|NCT00346268|9633947|FG000|Overall Study|Participant refused|0
6036534|NCT00346268|9633948|FG001|Overall Study|Participant refused|3
6036535|NCT00346333|9633956|FG000|Overall Study|Death|1
6036536|NCT00346333|9633957|FG001|Overall Study|Death|0
6036537|NCT00346333|9633956|FG000|Overall Study|unwilling or unable to continue|4
6036538|NCT00346333|9633957|FG001|Overall Study|unwilling or unable to continue|8
6036539|NCT00346398|9633967|FG000|Overall Study|Lost to Follow-up|3
6036540|NCT00346398|9633968|FG001|Overall Study|Lost to Follow-up|0
6036541|NCT00346398|9633967|FG000|Overall Study|Withdrawal by Subject|0
6036542|NCT00346398|9633968|FG001|Overall Study|Withdrawal by Subject|2
6036543|NCT00346632|9633980|FG000|Overall Study|Progressive Disease|2
6036544|NCT00346632|9633981|FG001|Overall Study|Progressive Disease|2
6036545|NCT00346632|9633982|FG002|Overall Study|Progressive Disease|4
6036546|NCT00346632|9633983|FG003|Overall Study|Progressive Disease|3
6036547|NCT00346632|9633984|FG004|Overall Study|Progressive Disease|3
6036548|NCT00346632|9633985|FG005|Overall Study|Progressive Disease|1
6036549|NCT00346632|9633986|FG006|Overall Study|Progressive Disease|2
6036550|NCT00346632|9633987|FG007|Overall Study|Progressive Disease|2
6036551|NCT00346632|9633988|FG008|Overall Study|Progressive Disease|2
6036552|NCT00346632|9633989|FG009|Overall Study|Progressive Disease|2
6036553|NCT00346632|9633980|FG000|Overall Study|Adverse Event|0
6036554|NCT00346632|9633981|FG001|Overall Study|Adverse Event|0
6036555|NCT00346632|9633982|FG002|Overall Study|Adverse Event|0
6036556|NCT00346632|9633983|FG003|Overall Study|Adverse Event|0
6036557|NCT00346632|9633984|FG004|Overall Study|Adverse Event|1
6036558|NCT00346632|9633985|FG005|Overall Study|Adverse Event|1
6036559|NCT00346632|9633986|FG006|Overall Study|Adverse Event|1
6036560|NCT00346632|9633987|FG007|Overall Study|Adverse Event|0
6036561|NCT00346632|9633988|FG008|Overall Study|Adverse Event|0
6036562|NCT00346632|9633989|FG009|Overall Study|Adverse Event|0
6036563|NCT00346632|9633980|FG000|Overall Study|Death|0
6036564|NCT00346632|9633981|FG001|Overall Study|Death|0
6036565|NCT00346632|9633982|FG002|Overall Study|Death|1
6036566|NCT00346632|9633983|FG003|Overall Study|Death|0
6036567|NCT00346632|9633984|FG004|Overall Study|Death|0
6036568|NCT00346632|9633985|FG005|Overall Study|Death|0
6036569|NCT00346632|9633986|FG006|Overall Study|Death|0
6036570|NCT00346632|9633987|FG007|Overall Study|Death|0
6036571|NCT00346632|9633988|FG008|Overall Study|Death|0
6036572|NCT00346632|9633989|FG009|Overall Study|Death|0
6036573|NCT00346632|9633980|FG000|Overall Study|Protocol Violation|0
6147073|NCT01081145|9782182|FG000|Open-Label Phase|Lack of Efficacy|56
6147074|NCT01081145|9782183|FG001|Open-Label Phase|Lack of Efficacy|0
6147075|NCT01081145|9782182|FG000|Open-Label Phase|Response criteria not met|46
6147076|NCT01081145|9782183|FG001|Open-Label Phase|Response criteria not met|0
6147077|NCT01081145|9782182|FG000|Open-Label Phase|Adverse Event|42
6147078|NCT01081145|9782183|FG001|Open-Label Phase|Adverse Event|0
6147079|NCT01081145|9782182|FG000|Open-Label Phase|Withdrawal by Subject|41
6147080|NCT01081145|9782183|FG001|Open-Label Phase|Withdrawal by Subject|0
6147081|NCT01081145|9782182|FG000|Open-Label Phase|Other|12
6147082|NCT01081145|9782183|FG001|Open-Label Phase|Other|0
6147083|NCT01081145|9782182|FG000|Open-Label Phase|Lost to Follow-up|11
6147084|NCT01081145|9782183|FG001|Open-Label Phase|Lost to Follow-up|0
6147085|NCT01081145|9782182|FG000|Open-Label Phase|Protocol Violation|4
6147086|NCT01081145|9782183|FG001|Open-Label Phase|Protocol Violation|0
6147087|NCT01081145|9782182|FG000|Double-Blind Randomized-Withdrawal Phase|Adverse Event|3
6147088|NCT01081145|9782183|FG001|Double-Blind Randomized-Withdrawal Phase|Adverse Event|2
6147089|NCT01081145|9782182|FG000|Double-Blind Randomized-Withdrawal Phase|Protocol Violation|1
6147090|NCT01081145|9782183|FG001|Double-Blind Randomized-Withdrawal Phase|Protocol Violation|0
6147091|NCT01081145|9782182|FG000|Double-Blind Randomized-Withdrawal Phase|Withdrawal by Subject|10
6147092|NCT01081145|9782183|FG001|Double-Blind Randomized-Withdrawal Phase|Withdrawal by Subject|8
6147093|NCT01081145|9782182|FG000|Double-Blind Randomized-Withdrawal Phase|Lost to Follow-up|3
6147094|NCT01081145|9782183|FG001|Double-Blind Randomized-Withdrawal Phase|Lost to Follow-up|2
6147095|NCT01081145|9782182|FG000|Double-Blind Randomized-Withdrawal Phase|Lack of Efficacy|13
6147096|NCT01081145|9782183|FG001|Double-Blind Randomized-Withdrawal Phase|Lack of Efficacy|20
6147097|NCT01081145|9782182|FG000|Double-Blind Randomized-Withdrawal Phase|Treatment failure criteria met|47
6147098|NCT01081145|9782183|FG001|Double-Blind Randomized-Withdrawal Phase|Treatment failure criteria met|71
6147099|NCT01081145|9782182|FG000|Double-Blind Randomized-Withdrawal Phase|Other|4
6147100|NCT01081145|9782183|FG001|Double-Blind Randomized-Withdrawal Phase|Other|3
6036574|NCT00346632|9633981|FG001|Overall Study|Protocol Violation|0
6036575|NCT00346632|9633982|FG002|Overall Study|Protocol Violation|0
6147101|NCT01081249|9782191|FG000|Overall Study|Diagnosed with Bipolar Disorder|0
6036576|NCT00346632|9633983|FG003|Overall Study|Protocol Violation|0
6036577|NCT00346632|9633984|FG004|Overall Study|Protocol Violation|0
6036578|NCT00346632|9633985|FG005|Overall Study|Protocol Violation|0
6036579|NCT00346632|9633986|FG006|Overall Study|Protocol Violation|1
6036580|NCT00346632|9633987|FG007|Overall Study|Protocol Violation|0
6036581|NCT00346632|9633988|FG008|Overall Study|Protocol Violation|0
6036582|NCT00346632|9633989|FG009|Overall Study|Protocol Violation|0
6036583|NCT00346632|9633980|FG000|Overall Study|Withdrawal by Subject|0
6036584|NCT00346632|9633981|FG001|Overall Study|Withdrawal by Subject|0
6036585|NCT00346632|9633982|FG002|Overall Study|Withdrawal by Subject|0
6036586|NCT00346632|9633983|FG003|Overall Study|Withdrawal by Subject|0
6036587|NCT00346632|9633984|FG004|Overall Study|Withdrawal by Subject|0
6036588|NCT00346632|9633985|FG005|Overall Study|Withdrawal by Subject|0
6036589|NCT00346632|9633986|FG006|Overall Study|Withdrawal by Subject|1
6036590|NCT00346632|9633987|FG007|Overall Study|Withdrawal by Subject|0
6036591|NCT00346632|9633988|FG008|Overall Study|Withdrawal by Subject|0
6036592|NCT00346632|9633989|FG009|Overall Study|Withdrawal by Subject|0
6036593|NCT00346632|9633980|FG000|Overall Study|Switched to alternative treatment|0
6036594|NCT00346632|9633981|FG001|Overall Study|Switched to alternative treatment|0
6036595|NCT00346632|9633982|FG002|Overall Study|Switched to alternative treatment|1
6036596|NCT00346632|9633983|FG003|Overall Study|Switched to alternative treatment|0
6036597|NCT00346632|9633984|FG004|Overall Study|Switched to alternative treatment|0
6036598|NCT00346632|9633985|FG005|Overall Study|Switched to alternative treatment|0
6036599|NCT00346632|9633986|FG006|Overall Study|Switched to alternative treatment|0
6036600|NCT00346632|9633987|FG007|Overall Study|Switched to alternative treatment|0
6036601|NCT00346632|9633988|FG008|Overall Study|Switched to alternative treatment|0
6036602|NCT00346632|9633989|FG009|Overall Study|Switched to alternative treatment|0
6036603|NCT00346632|9633980|FG000|Overall Study|Not Stated|1
6036604|NCT00346632|9633981|FG001|Overall Study|Not Stated|1
6036605|NCT00346632|9633982|FG002|Overall Study|Not Stated|0
6036606|NCT00346632|9633983|FG003|Overall Study|Not Stated|0
6036607|NCT00346632|9633984|FG004|Overall Study|Not Stated|0
6036608|NCT00346632|9633985|FG005|Overall Study|Not Stated|0
6036609|NCT00346632|9633986|FG006|Overall Study|Not Stated|0
6036610|NCT00346632|9633987|FG007|Overall Study|Not Stated|2
6036611|NCT00346632|9633988|FG008|Overall Study|Not Stated|2
6036612|NCT00346632|9633989|FG009|Overall Study|Not Stated|1
6036613|NCT00346697|9634053|FG000|Overall Study|Lost to Follow-up|0
6036614|NCT00346697|9634054|FG001|Overall Study|Lost to Follow-up|1
6036615|NCT00346775|9634062|FG000|Period 1: Intervention Period 1|Lost to Follow-up|1
6036616|NCT00346775|9634063|FG001|Period 1: Intervention Period 1|Lost to Follow-up|1
6036617|NCT00346775|9634062|FG000|Period 1: Intervention Period 1|Protocol Violation|3
6036618|NCT00346775|9634063|FG001|Period 1: Intervention Period 1|Protocol Violation|2
6036619|NCT00346775|9634062|FG000|Period 1: Intervention Period 1|Participant had nasal congestion score<2|1
6036620|NCT00346775|9634063|FG001|Period 1: Intervention Period 1|Participant had nasal congestion score<2|0
6036621|NCT00347009|9634077|FG000|Overall Study|Death|1
6036622|NCT00347009|9634077|FG000|Overall Study|Adverse Event|6
6036623|NCT00347009|9634077|FG000|Overall Study|Withdrawal by Subject|3
6036624|NCT00347009|9634077|FG000|Overall Study|Physician Decision|5
6036625|NCT00347009|9634077|FG000|Overall Study|Lost to Follow-up|4
6036626|NCT00347009|9634077|FG000|Overall Study|Protocol Violation|2
6036627|NCT00347009|9634077|FG000|Overall Study|Adverse Laboratory Experience|1
6036628|NCT00347009|9634077|FG000|Overall Study|Insufficient Viral Suppression|3
6036629|NCT00347009|9634077|FG000|Overall Study|Increased ALT/HBV DNA|1
6036630|NCT00347009|9634077|FG000|Overall Study|Serious Adverse Event|1
6036631|NCT00347269|9634092|FG000|Overall Study|Lost to Follow-up|74
6036632|NCT00347269|9634093|FG001|Overall Study|Lost to Follow-up|65
6036633|NCT00347269|9634092|FG000|Overall Study|Withdrawal by Subject|18
6036634|NCT00347269|9634093|FG001|Overall Study|Withdrawal by Subject|38
6036635|NCT00347269|9634092|FG000|Overall Study|Death|2
6036636|NCT00347269|9634093|FG001|Overall Study|Death|3
6036637|NCT00347360|9634118|FG000|Overall Study|Adverse Event|1
6036638|NCT00347360|9634119|FG001|Overall Study|Adverse Event|2
6036639|NCT00347360|9634120|FG002|Overall Study|Adverse Event|0
6147102|NCT01081249|9782192|FG001|Overall Study|Diagnosed with Bipolar Disorder|1
6147103|NCT01081301|9782198|FG000|Overall Study|Bereaved|3
6036640|NCT00347360|9634121|FG003|Overall Study|Adverse Event|4
6036641|NCT00347360|9634122|FG004|Overall Study|Adverse Event|1
6036642|NCT00347360|9634123|FG005|Overall Study|Adverse Event|2
6036643|NCT00347360|9634124|FG006|Overall Study|Adverse Event|2
6036644|NCT00347360|9634125|FG007|Overall Study|Adverse Event|0
6036645|NCT00347360|9634126|FG008|Overall Study|Adverse Event|2
6036646|NCT00347360|9634127|FG009|Overall Study|Adverse Event|3
6147104|NCT01081301|9782198|FG000|Overall Study|Too busy|5
6036647|NCT00347360|9634128|FG010|Overall Study|Adverse Event|3
6036648|NCT00347360|9634129|FG011|Overall Study|Adverse Event|1
6036649|NCT00347360|9634130|FG012|Overall Study|Adverse Event|3
6036650|NCT00347360|9634131|FG013|Overall Study|Adverse Event|2
6036651|NCT00347360|9634132|FG014|Overall Study|Adverse Event|2
6036652|NCT00347360|9634118|FG000|Overall Study|Lost to Follow-up|0
6036653|NCT00347360|9634119|FG001|Overall Study|Lost to Follow-up|0
6036654|NCT00347360|9634120|FG002|Overall Study|Lost to Follow-up|0
6036655|NCT00347360|9634121|FG003|Overall Study|Lost to Follow-up|2
6036656|NCT00347360|9634122|FG004|Overall Study|Lost to Follow-up|1
6147105|NCT01081301|9782198|FG000|Overall Study|Patient too ill|2
6036657|NCT00347360|9634123|FG005|Overall Study|Lost to Follow-up|1
6036658|NCT00347360|9634124|FG006|Overall Study|Lost to Follow-up|0
6147106|NCT01081301|9782198|FG000|Overall Study|Lost to Follow-up|4
6036659|NCT00347360|9634125|FG007|Overall Study|Lost to Follow-up|1
6036660|NCT00347360|9634126|FG008|Overall Study|Lost to Follow-up|1
6036661|NCT00347360|9634127|FG009|Overall Study|Lost to Follow-up|2
6036662|NCT00347360|9634128|FG010|Overall Study|Lost to Follow-up|0
6036663|NCT00347360|9634129|FG011|Overall Study|Lost to Follow-up|0
6036664|NCT00347360|9634130|FG012|Overall Study|Lost to Follow-up|1
6036665|NCT00347360|9634131|FG013|Overall Study|Lost to Follow-up|0
6036666|NCT00347360|9634132|FG014|Overall Study|Lost to Follow-up|0
6036667|NCT00347360|9634118|FG000|Overall Study|Protocol Violation|2
6036668|NCT00347360|9634119|FG001|Overall Study|Protocol Violation|3
6036669|NCT00347360|9634120|FG002|Overall Study|Protocol Violation|1
6036670|NCT00347360|9634121|FG003|Overall Study|Protocol Violation|2
6036671|NCT00347360|9634122|FG004|Overall Study|Protocol Violation|1
6036672|NCT00347360|9634123|FG005|Overall Study|Protocol Violation|2
6036673|NCT00347360|9634124|FG006|Overall Study|Protocol Violation|0
6036674|NCT00347360|9634125|FG007|Overall Study|Protocol Violation|0
6036675|NCT00347360|9634126|FG008|Overall Study|Protocol Violation|1
6036676|NCT00347360|9634127|FG009|Overall Study|Protocol Violation|2
6036677|NCT00347360|9634128|FG010|Overall Study|Protocol Violation|0
6036678|NCT00347360|9634129|FG011|Overall Study|Protocol Violation|0
6036679|NCT00347360|9634130|FG012|Overall Study|Protocol Violation|0
6036680|NCT00347360|9634131|FG013|Overall Study|Protocol Violation|1
6036681|NCT00347360|9634132|FG014|Overall Study|Protocol Violation|0
6036682|NCT00347360|9634118|FG000|Overall Study|Withdrawal by Subject|0
6036683|NCT00347360|9634119|FG001|Overall Study|Withdrawal by Subject|1
6036684|NCT00347360|9634120|FG002|Overall Study|Withdrawal by Subject|2
6036685|NCT00347360|9634121|FG003|Overall Study|Withdrawal by Subject|4
6036686|NCT00347360|9634122|FG004|Overall Study|Withdrawal by Subject|1
6036687|NCT00347360|9634123|FG005|Overall Study|Withdrawal by Subject|2
6036688|NCT00347360|9634124|FG006|Overall Study|Withdrawal by Subject|1
6036689|NCT00347360|9634125|FG007|Overall Study|Withdrawal by Subject|1
6036690|NCT00347360|9634126|FG008|Overall Study|Withdrawal by Subject|1
6036691|NCT00347360|9634127|FG009|Overall Study|Withdrawal by Subject|1
6036692|NCT00347360|9634128|FG010|Overall Study|Withdrawal by Subject|0
6036693|NCT00347360|9634129|FG011|Overall Study|Withdrawal by Subject|3
6036694|NCT00347360|9634130|FG012|Overall Study|Withdrawal by Subject|4
6036695|NCT00347360|9634131|FG013|Overall Study|Withdrawal by Subject|2
6036696|NCT00347360|9634132|FG014|Overall Study|Withdrawal by Subject|1
6036697|NCT00347360|9634118|FG000|Overall Study|Lack of Efficacy|1
6036698|NCT00347360|9634119|FG001|Overall Study|Lack of Efficacy|1
6036699|NCT00347360|9634120|FG002|Overall Study|Lack of Efficacy|3
6036700|NCT00347360|9634121|FG003|Overall Study|Lack of Efficacy|1
6036701|NCT00347360|9634122|FG004|Overall Study|Lack of Efficacy|0
6036702|NCT00347360|9634123|FG005|Overall Study|Lack of Efficacy|1
6036703|NCT00347360|9634124|FG006|Overall Study|Lack of Efficacy|0
6036704|NCT00347360|9634125|FG007|Overall Study|Lack of Efficacy|1
6036705|NCT00347360|9634126|FG008|Overall Study|Lack of Efficacy|1
6036706|NCT00347360|9634127|FG009|Overall Study|Lack of Efficacy|0
6036707|NCT00347360|9634128|FG010|Overall Study|Lack of Efficacy|0
6036708|NCT00347360|9634129|FG011|Overall Study|Lack of Efficacy|0
6036709|NCT00347360|9634130|FG012|Overall Study|Lack of Efficacy|0
6036710|NCT00347360|9634131|FG013|Overall Study|Lack of Efficacy|0
6036711|NCT00347360|9634132|FG014|Overall Study|Lack of Efficacy|0
6036712|NCT00347360|9634118|FG000|Overall Study|Reason not listed/blank|1
6036713|NCT00347360|9634119|FG001|Overall Study|Reason not listed/blank|0
6036714|NCT00347360|9634120|FG002|Overall Study|Reason not listed/blank|0
6036715|NCT00347360|9634121|FG003|Overall Study|Reason not listed/blank|0
6036716|NCT00347360|9634122|FG004|Overall Study|Reason not listed/blank|0
6036717|NCT00347360|9634123|FG005|Overall Study|Reason not listed/blank|0
6036718|NCT00347360|9634124|FG006|Overall Study|Reason not listed/blank|1
6036719|NCT00347360|9634125|FG007|Overall Study|Reason not listed/blank|0
6036720|NCT00347360|9634126|FG008|Overall Study|Reason not listed/blank|0
6036721|NCT00347360|9634127|FG009|Overall Study|Reason not listed/blank|0
6036722|NCT00347360|9634128|FG010|Overall Study|Reason not listed/blank|0
6036723|NCT00347360|9634129|FG011|Overall Study|Reason not listed/blank|0
6036724|NCT00347360|9634130|FG012|Overall Study|Reason not listed/blank|0
6036725|NCT00347360|9634131|FG013|Overall Study|Reason not listed/blank|1
6036726|NCT00347360|9634132|FG014|Overall Study|Reason not listed/blank|0
6036727|NCT00347360|9634118|FG000|Overall Study|Per sponsors instruction|0
6036728|NCT00347360|9634119|FG001|Overall Study|Per sponsors instruction|1
6036729|NCT00347360|9634120|FG002|Overall Study|Per sponsors instruction|0
6036730|NCT00347360|9634121|FG003|Overall Study|Per sponsors instruction|0
6036731|NCT00347360|9634122|FG004|Overall Study|Per sponsors instruction|0
6036732|NCT00347360|9634123|FG005|Overall Study|Per sponsors instruction|0
6036733|NCT00347360|9634124|FG006|Overall Study|Per sponsors instruction|0
6036734|NCT00347360|9634125|FG007|Overall Study|Per sponsors instruction|0
6036735|NCT00347360|9634126|FG008|Overall Study|Per sponsors instruction|0
6036736|NCT00347360|9634127|FG009|Overall Study|Per sponsors instruction|0
6036737|NCT00347360|9634128|FG010|Overall Study|Per sponsors instruction|0
6036738|NCT00347360|9634129|FG011|Overall Study|Per sponsors instruction|0
6036739|NCT00347360|9634130|FG012|Overall Study|Per sponsors instruction|0
6036740|NCT00347360|9634131|FG013|Overall Study|Per sponsors instruction|0
6036741|NCT00347360|9634132|FG014|Overall Study|Per sponsors instruction|0
6036742|NCT00347360|9634118|FG000|Overall Study|P.I. recommended due to blood pressure|0
6036743|NCT00347360|9634119|FG001|Overall Study|P.I. recommended due to blood pressure|0
6036744|NCT00347360|9634120|FG002|Overall Study|P.I. recommended due to blood pressure|0
6036745|NCT00347360|9634121|FG003|Overall Study|P.I. recommended due to blood pressure|0
6036746|NCT00347360|9634122|FG004|Overall Study|P.I. recommended due to blood pressure|1
6036747|NCT00347360|9634123|FG005|Overall Study|P.I. recommended due to blood pressure|0
6036748|NCT00347360|9634124|FG006|Overall Study|P.I. recommended due to blood pressure|0
6036749|NCT00347360|9634125|FG007|Overall Study|P.I. recommended due to blood pressure|0
6036750|NCT00347360|9634126|FG008|Overall Study|P.I. recommended due to blood pressure|0
6036751|NCT00347360|9634127|FG009|Overall Study|P.I. recommended due to blood pressure|0
6036752|NCT00347360|9634128|FG010|Overall Study|P.I. recommended due to blood pressure|0
6036753|NCT00347360|9634129|FG011|Overall Study|P.I. recommended due to blood pressure|0
6036754|NCT00347360|9634130|FG012|Overall Study|P.I. recommended due to blood pressure|0
6036755|NCT00347360|9634131|FG013|Overall Study|P.I. recommended due to blood pressure|0
6036756|NCT00347360|9634132|FG014|Overall Study|P.I. recommended due to blood pressure|0
6036757|NCT00347360|9634118|FG000|Overall Study|Subject did not meet end of study ABPM|0
6036758|NCT00347360|9634119|FG001|Overall Study|Subject did not meet end of study ABPM|0
6036759|NCT00347360|9634120|FG002|Overall Study|Subject did not meet end of study ABPM|0
6036760|NCT00347360|9634121|FG003|Overall Study|Subject did not meet end of study ABPM|0
6036761|NCT00347360|9634122|FG004|Overall Study|Subject did not meet end of study ABPM|0
6036762|NCT00347360|9634123|FG005|Overall Study|Subject did not meet end of study ABPM|0
6036763|NCT00347360|9634124|FG006|Overall Study|Subject did not meet end of study ABPM|1
6036764|NCT00347360|9634125|FG007|Overall Study|Subject did not meet end of study ABPM|0
6036765|NCT00347360|9634126|FG008|Overall Study|Subject did not meet end of study ABPM|0
6036766|NCT00347360|9634127|FG009|Overall Study|Subject did not meet end of study ABPM|0
6036767|NCT00347360|9634128|FG010|Overall Study|Subject did not meet end of study ABPM|1
6036768|NCT00347360|9634129|FG011|Overall Study|Subject did not meet end of study ABPM|0
6036769|NCT00347360|9634130|FG012|Overall Study|Subject did not meet end of study ABPM|1
6036770|NCT00347360|9634131|FG013|Overall Study|Subject did not meet end of study ABPM|1
6036771|NCT00347360|9634132|FG014|Overall Study|Subject did not meet end of study ABPM|0
6036772|NCT00347360|9634118|FG000|Overall Study|Abnormal lab values|0
6036773|NCT00347360|9634119|FG001|Overall Study|Abnormal lab values|0
6036774|NCT00347360|9634120|FG002|Overall Study|Abnormal lab values|0
6036775|NCT00347360|9634121|FG003|Overall Study|Abnormal lab values|0
6036776|NCT00347360|9634122|FG004|Overall Study|Abnormal lab values|0
6036777|NCT00347360|9634123|FG005|Overall Study|Abnormal lab values|0
6036778|NCT00347360|9634124|FG006|Overall Study|Abnormal lab values|1
6036779|NCT00347360|9634125|FG007|Overall Study|Abnormal lab values|0
6036780|NCT00347360|9634126|FG008|Overall Study|Abnormal lab values|0
6036781|NCT00347360|9634127|FG009|Overall Study|Abnormal lab values|0
6036782|NCT00347360|9634128|FG010|Overall Study|Abnormal lab values|0
6036783|NCT00347360|9634129|FG011|Overall Study|Abnormal lab values|0
6036784|NCT00347360|9634130|FG012|Overall Study|Abnormal lab values|0
6036785|NCT00347360|9634131|FG013|Overall Study|Abnormal lab values|0
6036786|NCT00347360|9634132|FG014|Overall Study|Abnormal lab values|0
6036787|NCT00347360|9634118|FG000|Overall Study|PI recommended early withdrawal|0
6036788|NCT00347360|9634119|FG001|Overall Study|PI recommended early withdrawal|0
6036789|NCT00347360|9634120|FG002|Overall Study|PI recommended early withdrawal|0
6036790|NCT00347360|9634121|FG003|Overall Study|PI recommended early withdrawal|0
6036791|NCT00347360|9634122|FG004|Overall Study|PI recommended early withdrawal|0
6036792|NCT00347360|9634123|FG005|Overall Study|PI recommended early withdrawal|0
6036793|NCT00347360|9634124|FG006|Overall Study|PI recommended early withdrawal|0
6036794|NCT00347360|9634125|FG007|Overall Study|PI recommended early withdrawal|0
6036795|NCT00347360|9634126|FG008|Overall Study|PI recommended early withdrawal|0
6036796|NCT00347360|9634127|FG009|Overall Study|PI recommended early withdrawal|1
6036797|NCT00347360|9634128|FG010|Overall Study|PI recommended early withdrawal|0
6036798|NCT00347360|9634129|FG011|Overall Study|PI recommended early withdrawal|0
6036799|NCT00347360|9634130|FG012|Overall Study|PI recommended early withdrawal|0
6036800|NCT00347360|9634131|FG013|Overall Study|PI recommended early withdrawal|0
6036801|NCT00347360|9634132|FG014|Overall Study|PI recommended early withdrawal|0
6036802|NCT00347360|9634118|FG000|Overall Study|Did not meet criteria before ABPM|0
6036803|NCT00347360|9634119|FG001|Overall Study|Did not meet criteria before ABPM|0
6036804|NCT00347360|9634120|FG002|Overall Study|Did not meet criteria before ABPM|0
6036805|NCT00347360|9634121|FG003|Overall Study|Did not meet criteria before ABPM|0
6036806|NCT00347360|9634122|FG004|Overall Study|Did not meet criteria before ABPM|0
6036807|NCT00347360|9634123|FG005|Overall Study|Did not meet criteria before ABPM|0
6036808|NCT00347360|9634124|FG006|Overall Study|Did not meet criteria before ABPM|0
6036809|NCT00347360|9634125|FG007|Overall Study|Did not meet criteria before ABPM|0
6036810|NCT00347360|9634126|FG008|Overall Study|Did not meet criteria before ABPM|0
6036811|NCT00347360|9634127|FG009|Overall Study|Did not meet criteria before ABPM|0
6036812|NCT00347360|9634128|FG010|Overall Study|Did not meet criteria before ABPM|1
6036813|NCT00347360|9634129|FG011|Overall Study|Did not meet criteria before ABPM|0
6036814|NCT00347360|9634130|FG012|Overall Study|Did not meet criteria before ABPM|0
6036815|NCT00347360|9634131|FG013|Overall Study|Did not meet criteria before ABPM|0
6036816|NCT00347360|9634132|FG014|Overall Study|Did not meet criteria before ABPM|0
6036817|NCT00347360|9634118|FG000|Overall Study|Randomized in error|0
6036818|NCT00347360|9634119|FG001|Overall Study|Randomized in error|0
6036819|NCT00347360|9634120|FG002|Overall Study|Randomized in error|0
6036820|NCT00347360|9634121|FG003|Overall Study|Randomized in error|0
6036821|NCT00347360|9634122|FG004|Overall Study|Randomized in error|0
6036822|NCT00347360|9634123|FG005|Overall Study|Randomized in error|0
6036823|NCT00347360|9634124|FG006|Overall Study|Randomized in error|0
6036824|NCT00347360|9634125|FG007|Overall Study|Randomized in error|0
6036825|NCT00347360|9634126|FG008|Overall Study|Randomized in error|0
6036826|NCT00347360|9634127|FG009|Overall Study|Randomized in error|0
6036827|NCT00347360|9634128|FG010|Overall Study|Randomized in error|0
6036828|NCT00347360|9634129|FG011|Overall Study|Randomized in error|1
6036829|NCT00347360|9634130|FG012|Overall Study|Randomized in error|0
6036830|NCT00347360|9634131|FG013|Overall Study|Randomized in error|0
6036831|NCT00347360|9634132|FG014|Overall Study|Randomized in error|0
6036832|NCT00347360|9634118|FG000|Overall Study|Failed inclusion criteria #4|0
6036833|NCT00347360|9634119|FG001|Overall Study|Failed inclusion criteria #4|0
6036834|NCT00347360|9634120|FG002|Overall Study|Failed inclusion criteria #4|0
6036835|NCT00347360|9634121|FG003|Overall Study|Failed inclusion criteria #4|0
6036836|NCT00347360|9634122|FG004|Overall Study|Failed inclusion criteria #4|0
6036837|NCT00347360|9634123|FG005|Overall Study|Failed inclusion criteria #4|0
6036838|NCT00347360|9634124|FG006|Overall Study|Failed inclusion criteria #4|0
6036839|NCT00347360|9634125|FG007|Overall Study|Failed inclusion criteria #4|0
6036840|NCT00347360|9634126|FG008|Overall Study|Failed inclusion criteria #4|0
6036841|NCT00347360|9634127|FG009|Overall Study|Failed inclusion criteria #4|0
6036842|NCT00347360|9634128|FG010|Overall Study|Failed inclusion criteria #4|0
6036843|NCT00347360|9634129|FG011|Overall Study|Failed inclusion criteria #4|1
6036844|NCT00347360|9634130|FG012|Overall Study|Failed inclusion criteria #4|0
6036845|NCT00347360|9634131|FG013|Overall Study|Failed inclusion criteria #4|0
6036846|NCT00347360|9634132|FG014|Overall Study|Failed inclusion criteria #4|0
6036847|NCT00347360|9634118|FG000|Overall Study|Prolonged duration between visits|0
6147107|NCT01081626|9782221|FG000|Overall Study|Dosing error|1
6147108|NCT01081626|9782222|FG001|Overall Study|Dosing error|1
6147109|NCT01081626|9782221|FG000|Overall Study|Missing Estradiol|25
6309593|NCT02641379|10038344|FG005|Overall Study|Withdrawal of informed consent|0
6309594|NCT02641379|10038345|FG006|Overall Study|Withdrawal of informed consent|0
6309595|NCT02641379|10038346|FG007|Overall Study|Withdrawal of informed consent|1
6147110|NCT01081626|9782222|FG001|Overall Study|Missing Estradiol|28
6147111|NCT01081626|9782221|FG000|Overall Study|Low antral follicle count|1
6147112|NCT01081626|9782222|FG001|Overall Study|Low antral follicle count|0
6147113|NCT01081626|9782221|FG000|Overall Study|Overstimulation|0
6147114|NCT01081626|9782222|FG001|Overall Study|Overstimulation|1
6147115|NCT01081626|9782221|FG000|Overall Study|Lost to Follow-up|0
6147116|NCT01081626|9782222|FG001|Overall Study|Lost to Follow-up|1
6147117|NCT01081626|9782221|FG000|Overall Study|Other|33
6147118|NCT01081626|9782222|FG001|Overall Study|Other|30
6147119|NCT01081665|9782228|FG000|Overall Study|Death|41
6147120|NCT01081665|9782228|FG000|Overall Study|Lost to Follow-up|18
6147121|NCT01081665|9782228|FG000|Overall Study|Withdrawal by Subject|17
6147122|NCT01081665|9782228|FG000|Overall Study|Change of dialysis unit|10
6147123|NCT01081665|9782228|FG000|Overall Study|Regulation of iPTH|5
6147124|NCT01081665|9782228|FG000|Overall Study|Change in renal replacement therapy|2
6147125|NCT01081665|9782228|FG000|Overall Study|Adverse Event|1
6147126|NCT01081665|9782228|FG000|Overall Study|Lack of Efficacy|1
6147127|NCT01081678|9782236|FG000|Overall Study|Ineligibility Determined|0
6147128|NCT01081678|9782237|FG001|Overall Study|Ineligibility Determined|0
6147129|NCT01081678|9782238|FG002|Overall Study|Ineligibility Determined|1
6147130|NCT01081678|9782239|FG003|Overall Study|Ineligibility Determined|1
6147131|NCT01081678|9782236|FG000|Overall Study|Noncompliance|3
6147132|NCT01081678|9782237|FG001|Overall Study|Noncompliance|4
6147133|NCT01081678|9782238|FG002|Overall Study|Noncompliance|5
6147134|NCT01081678|9782239|FG003|Overall Study|Noncompliance|2
6147135|NCT01081678|9782236|FG000|Overall Study|Adverse Event|2
6147136|NCT01081678|9782237|FG001|Overall Study|Adverse Event|1
6147137|NCT01081678|9782238|FG002|Overall Study|Adverse Event|2
6147138|NCT01081678|9782239|FG003|Overall Study|Adverse Event|2
6147139|NCT01081678|9782236|FG000|Overall Study|Withdrawal by Subject|15
6147140|NCT01081678|9782237|FG001|Overall Study|Withdrawal by Subject|7
6147141|NCT01081678|9782238|FG002|Overall Study|Withdrawal by Subject|17
6147142|NCT01081678|9782239|FG003|Overall Study|Withdrawal by Subject|14
6147143|NCT01081678|9782236|FG000|Overall Study|Administrative Decision|1
6147144|NCT01081678|9782237|FG001|Overall Study|Administrative Decision|0
6147145|NCT01081678|9782238|FG002|Overall Study|Administrative Decision|0
6147146|NCT01081678|9782239|FG003|Overall Study|Administrative Decision|1
6147147|NCT01081678|9782236|FG000|Overall Study|Lost to Follow-up|4
6147148|NCT01081678|9782237|FG001|Overall Study|Lost to Follow-up|1
6147149|NCT01081678|9782238|FG002|Overall Study|Lost to Follow-up|4
6147150|NCT01081678|9782239|FG003|Overall Study|Lost to Follow-up|3
6309596|NCT02641379|10038347|FG008|Overall Study|Withdrawal of informed consent|0
6036848|NCT00347360|9634119|FG001|Overall Study|Prolonged duration between visits|0
6036849|NCT00347360|9634120|FG002|Overall Study|Prolonged duration between visits|0
6147151|NCT01081678|9782236|FG000|Overall Study|Death|2
6147152|NCT01081678|9782237|FG001|Overall Study|Death|2
6147153|NCT01081678|9782238|FG002|Overall Study|Death|2
6147154|NCT01081678|9782239|FG003|Overall Study|Death|6
6147155|NCT01081678|9782236|FG000|Overall Study|Other|0
6147156|NCT01081678|9782237|FG001|Overall Study|Other|1
6147157|NCT01081678|9782238|FG002|Overall Study|Other|0
6147158|NCT01081678|9782239|FG003|Overall Study|Other|0
6147159|NCT01081769|9782251|FG000|Whole Intent-to-Treat|Missing Responder Assessment|10
6147160|NCT01081769|9782252|FG001|Whole Intent-to-Treat|Missing Responder Assessment|12
6147161|NCT01081769|9782251|FG000|Whole Intent-to-Treat|Stopped; non-responder after 2 weeks|6
6147162|NCT01081769|9782252|FG001|Whole Intent-to-Treat|Stopped; non-responder after 2 weeks|6
6147163|NCT01081769|9782251|FG000|Whole Intent-to-Treat|Deviation; non-responder after 2 weeks|6
6147164|NCT01081769|9782252|FG001|Whole Intent-to-Treat|Deviation; non-responder after 2 weeks|7
6147165|NCT01081769|9782251|FG000|Whole Intent-to-Treat|Responder after 2 weeks, but stopped|2
6147166|NCT01081769|9782252|FG001|Whole Intent-to-Treat|Responder after 2 weeks, but stopped|0
6147167|NCT01081769|9782251|FG000|CORE Intent-To-Treat|Adverse Event|14
6147168|NCT01081769|9782252|FG001|CORE Intent-To-Treat|Adverse Event|11
6147169|NCT01081769|9782251|FG000|CORE Intent-To-Treat|Death|1
6147170|NCT01081769|9782252|FG001|CORE Intent-To-Treat|Death|1
6147171|NCT01081769|9782251|FG000|CORE Intent-To-Treat|Lack of Efficacy|2
6147172|NCT01081769|9782252|FG001|CORE Intent-To-Treat|Lack of Efficacy|6
6147173|NCT01081769|9782251|FG000|CORE Intent-To-Treat|Lost to Follow-up|4
6147174|NCT01081769|9782252|FG001|CORE Intent-To-Treat|Lost to Follow-up|5
6147175|NCT01081769|9782251|FG000|CORE Intent-To-Treat|Pregnancy|1
6036850|NCT00347360|9634121|FG003|Overall Study|Prolonged duration between visits|0
6036851|NCT00347360|9634122|FG004|Overall Study|Prolonged duration between visits|0
6036852|NCT00347360|9634123|FG005|Overall Study|Prolonged duration between visits|0
6036853|NCT00347360|9634124|FG006|Overall Study|Prolonged duration between visits|0
6036854|NCT00347360|9634125|FG007|Overall Study|Prolonged duration between visits|0
6036855|NCT00347360|9634126|FG008|Overall Study|Prolonged duration between visits|0
6036856|NCT00347360|9634127|FG009|Overall Study|Prolonged duration between visits|0
6036857|NCT00347360|9634128|FG010|Overall Study|Prolonged duration between visits|0
6036858|NCT00347360|9634129|FG011|Overall Study|Prolonged duration between visits|0
6036859|NCT00347360|9634130|FG012|Overall Study|Prolonged duration between visits|1
6036860|NCT00347360|9634131|FG013|Overall Study|Prolonged duration between visits|0
6036861|NCT00347360|9634132|FG014|Overall Study|Prolonged duration between visits|0
6036862|NCT00347360|9634118|FG000|Overall Study|Subject left town, ran out of study drug|0
6036863|NCT00347360|9634119|FG001|Overall Study|Subject left town, ran out of study drug|0
6036864|NCT00347360|9634120|FG002|Overall Study|Subject left town, ran out of study drug|0
6036865|NCT00347360|9634121|FG003|Overall Study|Subject left town, ran out of study drug|0
6036866|NCT00347360|9634122|FG004|Overall Study|Subject left town, ran out of study drug|0
6036867|NCT00347360|9634123|FG005|Overall Study|Subject left town, ran out of study drug|0
6036868|NCT00347360|9634124|FG006|Overall Study|Subject left town, ran out of study drug|0
6036869|NCT00347360|9634125|FG007|Overall Study|Subject left town, ran out of study drug|0
6036870|NCT00347360|9634126|FG008|Overall Study|Subject left town, ran out of study drug|0
6036871|NCT00347360|9634127|FG009|Overall Study|Subject left town, ran out of study drug|0
6036872|NCT00347360|9634128|FG010|Overall Study|Subject left town, ran out of study drug|0
6036873|NCT00347360|9634129|FG011|Overall Study|Subject left town, ran out of study drug|0
6036874|NCT00347360|9634130|FG012|Overall Study|Subject left town, ran out of study drug|0
6036875|NCT00347360|9634131|FG013|Overall Study|Subject left town, ran out of study drug|1
6036876|NCT00347360|9634132|FG014|Overall Study|Subject left town, ran out of study drug|0
6036877|NCT00347360|9634118|FG000|Overall Study|Subject refuse to sign updated consent|0
6036878|NCT00347360|9634119|FG001|Overall Study|Subject refuse to sign updated consent|0
6036879|NCT00347360|9634120|FG002|Overall Study|Subject refuse to sign updated consent|0
6036880|NCT00347360|9634121|FG003|Overall Study|Subject refuse to sign updated consent|0
6036881|NCT00347360|9634122|FG004|Overall Study|Subject refuse to sign updated consent|0
6036882|NCT00347360|9634123|FG005|Overall Study|Subject refuse to sign updated consent|0
6036883|NCT00347360|9634124|FG006|Overall Study|Subject refuse to sign updated consent|0
6036884|NCT00347360|9634125|FG007|Overall Study|Subject refuse to sign updated consent|0
6036885|NCT00347360|9634126|FG008|Overall Study|Subject refuse to sign updated consent|0
6036886|NCT00347360|9634127|FG009|Overall Study|Subject refuse to sign updated consent|0
6036887|NCT00347360|9634128|FG010|Overall Study|Subject refuse to sign updated consent|0
6036888|NCT00347360|9634129|FG011|Overall Study|Subject refuse to sign updated consent|0
6036889|NCT00347360|9634130|FG012|Overall Study|Subject refuse to sign updated consent|0
6036890|NCT00347360|9634131|FG013|Overall Study|Subject refuse to sign updated consent|0
6036891|NCT00347360|9634132|FG014|Overall Study|Subject refuse to sign updated consent|1
6036892|NCT00347360|9634118|FG000|Overall Study|Visits conflicted with new job|0
6036893|NCT00347360|9634119|FG001|Overall Study|Visits conflicted with new job|0
6036894|NCT00347360|9634120|FG002|Overall Study|Visits conflicted with new job|0
6036895|NCT00347360|9634121|FG003|Overall Study|Visits conflicted with new job|0
6036896|NCT00347360|9634122|FG004|Overall Study|Visits conflicted with new job|0
6147176|NCT01081769|9782252|FG001|CORE Intent-To-Treat|Pregnancy|0
6147177|NCT01081769|9782251|FG000|CORE Intent-To-Treat|Withdrawal by Subject|52
6147178|NCT01081769|9782252|FG001|CORE Intent-To-Treat|Withdrawal by Subject|60
6147179|NCT01081769|9782251|FG000|CORE Intent-To-Treat|Noncompliance With Study Drug|0
6036897|NCT00347360|9634123|FG005|Overall Study|Visits conflicted with new job|0
6036898|NCT00347360|9634124|FG006|Overall Study|Visits conflicted with new job|1
6036899|NCT00347360|9634125|FG007|Overall Study|Visits conflicted with new job|0
6036900|NCT00347360|9634126|FG008|Overall Study|Visits conflicted with new job|0
6036901|NCT00347360|9634127|FG009|Overall Study|Visits conflicted with new job|0
6036902|NCT00347360|9634128|FG010|Overall Study|Visits conflicted with new job|0
6036903|NCT00347360|9634129|FG011|Overall Study|Visits conflicted with new job|0
6036904|NCT00347360|9634130|FG012|Overall Study|Visits conflicted with new job|0
6036905|NCT00347360|9634131|FG013|Overall Study|Visits conflicted with new job|0
6036906|NCT00347360|9634132|FG014|Overall Study|Visits conflicted with new job|0
6036907|NCT00347438|9634164|FG000|Overall Study|Withdrawal by Subject|1
6036908|NCT00347438|9634164|FG000|Overall Study|Physician Decision|1
6036909|NCT00347776|9634171|FG000|1.5 Month Follow-up|Death|2
6036910|NCT00347776|9634172|FG001|1.5 Month Follow-up|Death|0
6036911|NCT00347776|9634173|FG002|1.5 Month Follow-up|Death|0
6036912|NCT00347776|9634171|FG000|1.5 Month Follow-up|reached the endpoint|12
6036913|NCT00347776|9634172|FG001|1.5 Month Follow-up|reached the endpoint|8
6036914|NCT00347776|9634173|FG002|1.5 Month Follow-up|reached the endpoint|12
6036915|NCT00347776|9634171|FG000|6 Month Follow-up|Death|2
6036916|NCT00347776|9634172|FG001|6 Month Follow-up|Death|1
6036917|NCT00347776|9634173|FG002|6 Month Follow-up|Death|3
6036918|NCT00347776|9634171|FG000|6 Month Follow-up|reached endpont|20
6036919|NCT00347776|9634172|FG001|6 Month Follow-up|reached endpont|12
6036920|NCT00347776|9634173|FG002|6 Month Follow-up|reached endpont|15
6036921|NCT00347776|9634171|FG000|12 Month Follow-up|Lost to Follow-up|7
6036922|NCT00347776|9634172|FG001|12 Month Follow-up|Lost to Follow-up|6
6036923|NCT00347776|9634173|FG002|12 Month Follow-up|Lost to Follow-up|6
6036924|NCT00347776|9634171|FG000|12 Month Follow-up|Death|3
6036925|NCT00347776|9634172|FG001|12 Month Follow-up|Death|4
6036926|NCT00347776|9634173|FG002|12 Month Follow-up|Death|4
6036927|NCT00347776|9634171|FG000|12 Month Follow-up|Reached endpoint|13
6036928|NCT00347776|9634172|FG001|12 Month Follow-up|Reached endpoint|6
6036929|NCT00347776|9634173|FG002|12 Month Follow-up|Reached endpoint|9
6036930|NCT00347919|9634184|FG000|Overall Study|Lost to Follow-up|11
6036931|NCT00347919|9634185|FG001|Overall Study|Lost to Follow-up|13
6036932|NCT00347919|9634186|FG002|Overall Study|Lost to Follow-up|0
6036933|NCT00347919|9634184|FG000|Overall Study|Withdrawal by Subject|6
6036934|NCT00347919|9634185|FG001|Overall Study|Withdrawal by Subject|8
6036935|NCT00347919|9634186|FG002|Overall Study|Withdrawal by Subject|0
6036936|NCT00347919|9634184|FG000|Overall Study|Physician Decision|1
6036937|NCT00347919|9634185|FG001|Overall Study|Physician Decision|1
6036938|NCT00347919|9634186|FG002|Overall Study|Physician Decision|0
6036939|NCT00347919|9634184|FG000|Overall Study|Sponsor terminated study|15
6036940|NCT00347919|9634185|FG001|Overall Study|Sponsor terminated study|10
6036941|NCT00347919|9634186|FG002|Overall Study|Sponsor terminated study|16
6036942|NCT00347919|9634184|FG000|Overall Study|Death|35
6036943|NCT00347919|9634185|FG001|Overall Study|Death|42
6036944|NCT00347919|9634186|FG002|Overall Study|Death|19
6036945|NCT00347919|9634184|FG000|Overall Study|Par. Started Other Treatment|1
6036946|NCT00347919|9634185|FG001|Overall Study|Par. Started Other Treatment|1
6036947|NCT00347919|9634186|FG002|Overall Study|Par. Started Other Treatment|1
6036948|NCT00347919|9634184|FG000|Overall Study|Missing|2
6036949|NCT00347919|9634185|FG001|Overall Study|Missing|1
6036950|NCT00347919|9634186|FG002|Overall Study|Missing|2
6036951|NCT00347932|9634198|FG000|Overall Study|Adverse Event|4
6036952|NCT00347932|9634199|FG001|Overall Study|Adverse Event|5
6147180|NCT01081769|9782252|FG001|CORE Intent-To-Treat|Noncompliance With Study Drug|5
6147181|NCT01081769|9782251|FG000|CORE Intent-To-Treat|Other|0
6147182|NCT01081769|9782252|FG001|CORE Intent-To-Treat|Other|1
6147183|NCT01081769|9782251|FG000|CORE Intent-To-Treat|Ineligibility|3
6147184|NCT01081769|9782252|FG001|CORE Intent-To-Treat|Ineligibility|4
6147185|NCT01081769|9782251|FG000|CORE Intent-To-Treat|Visit Schedule Issues|1
6147186|NCT01081769|9782252|FG001|CORE Intent-To-Treat|Visit Schedule Issues|2
6147187|NCT01081769|9782251|FG000|CORE Intent-To-Treat|Patient Moved|2
6147188|NCT01081769|9782252|FG001|CORE Intent-To-Treat|Patient Moved|2
6147189|NCT01081795|9782261|FG000|Overall Study|Adverse Event|18
6147190|NCT01081795|9782262|FG001|Overall Study|Adverse Event|23
6147191|NCT01081795|9782263|FG002|Overall Study|Adverse Event|6
6147192|NCT01081795|9782261|FG000|Overall Study|Lack of Efficacy|7
6147193|NCT01081795|9782262|FG001|Overall Study|Lack of Efficacy|5
6147194|NCT01081795|9782263|FG002|Overall Study|Lack of Efficacy|19
6147195|NCT01081795|9782261|FG000|Overall Study|Subject's schedule|1
6147196|NCT01081795|9782262|FG001|Overall Study|Subject's schedule|1
6147197|NCT01081795|9782263|FG002|Overall Study|Subject's schedule|2
6147198|NCT01081795|9782261|FG000|Overall Study|Revocation of informed consent|2
6036953|NCT00347932|9634198|FG000|Overall Study|Lack of Efficacy|3
6036954|NCT00347932|9634199|FG001|Overall Study|Lack of Efficacy|14
6036955|NCT00347932|9634198|FG000|Overall Study|Lost to Follow-up|10
6036956|NCT00347932|9634199|FG001|Overall Study|Lost to Follow-up|9
6036957|NCT00347932|9634198|FG000|Overall Study|Withdrawal by Subject|10
6036958|NCT00347932|9634199|FG001|Overall Study|Withdrawal by Subject|16
6147199|NCT01081795|9782262|FG001|Overall Study|Revocation of informed consent|0
6036959|NCT00347932|9634198|FG000|Overall Study|Did not meet inclusion criteria|4
6036960|NCT00347932|9634199|FG001|Overall Study|Did not meet inclusion criteria|8
6036961|NCT00347958|9634205|FG000|Overall Study|Adverse Event|1
6036962|NCT00347958|9634205|FG000|Overall Study|Protocol Violation|2
6036963|NCT00347958|9634205|FG000|Overall Study|Withdrawal by Subject|1
6036964|NCT00348140|9634212|FG000|Overall Study|Adverse Event|46
6036965|NCT00348140|9634213|FG001|Overall Study|Adverse Event|49
6036966|NCT00348140|9634214|FG002|Overall Study|Adverse Event|78
6036967|NCT00348140|9634212|FG000|Overall Study|Lost to Follow-up|4
6036968|NCT00348140|9634213|FG001|Overall Study|Lost to Follow-up|4
6036969|NCT00348140|9634214|FG002|Overall Study|Lost to Follow-up|4
6036970|NCT00348140|9634212|FG000|Overall Study|Protocol Violation|12
6036971|NCT00348140|9634213|FG001|Overall Study|Protocol Violation|13
6036972|NCT00348140|9634214|FG002|Overall Study|Protocol Violation|14
6036973|NCT00348140|9634212|FG000|Overall Study|Withdrawal by Subject|32
6036974|NCT00348140|9634213|FG001|Overall Study|Withdrawal by Subject|40
6036975|NCT00348140|9634214|FG002|Overall Study|Withdrawal by Subject|40
6036976|NCT00348140|9634212|FG000|Overall Study|Non-compliance|8
6036977|NCT00348140|9634213|FG001|Overall Study|Non-compliance|13
6036978|NCT00348140|9634214|FG002|Overall Study|Non-compliance|5
6036979|NCT00348140|9634212|FG000|Overall Study|Participant at risk due to study drug|2
6036980|NCT00348140|9634213|FG001|Overall Study|Participant at risk due to study drug|0
6036981|NCT00348140|9634214|FG002|Overall Study|Participant at risk due to study drug|0
6036982|NCT00348140|9634212|FG000|Overall Study|Conditional medication increased dose|1
6036983|NCT00348140|9634213|FG001|Overall Study|Conditional medication increased dose|0
6036984|NCT00348140|9634214|FG002|Overall Study|Conditional medication increased dose|0
6036985|NCT00348140|9634212|FG000|Overall Study|Caregiver related|4
6036986|NCT00348140|9634213|FG001|Overall Study|Caregiver related|7
6036987|NCT00348140|9634214|FG002|Overall Study|Caregiver related|3
6036988|NCT00348140|9634212|FG000|Overall Study|Participant hospitalised|3
6036989|NCT00348140|9634213|FG001|Overall Study|Participant hospitalised|0
6036990|NCT00348140|9634214|FG002|Overall Study|Participant hospitalised|0
6036991|NCT00348140|9634212|FG000|Overall Study|Efficacy related|1
6036992|NCT00348140|9634213|FG001|Overall Study|Efficacy related|1
6036993|NCT00348140|9634214|FG002|Overall Study|Efficacy related|0
6036994|NCT00348140|9634212|FG000|Overall Study|Administration related|3
6036995|NCT00348140|9634213|FG001|Overall Study|Administration related|1
6036996|NCT00348140|9634214|FG002|Overall Study|Administration related|1
6036997|NCT00348140|9634212|FG000|Overall Study|Unmet inclusion-exclusion criteria|1
6036998|NCT00348140|9634213|FG001|Overall Study|Unmet inclusion-exclusion criteria|0
6036999|NCT00348140|9634214|FG002|Overall Study|Unmet inclusion-exclusion criteria|1
6037000|NCT00348140|9634212|FG000|Overall Study|Participant unwell|1
6037001|NCT00348140|9634213|FG001|Overall Study|Participant unwell|0
6037002|NCT00348140|9634214|FG002|Overall Study|Participant unwell|0
6037003|NCT00348140|9634212|FG000|Overall Study|Screen failure|1
6037004|NCT00348140|9634213|FG001|Overall Study|Screen failure|0
6037005|NCT00348140|9634214|FG002|Overall Study|Screen failure|0
6037006|NCT00348140|9634212|FG000|Overall Study|Investigator decided to discontinue|4
6037007|NCT00348140|9634213|FG001|Overall Study|Investigator decided to discontinue|1
6037008|NCT00348140|9634214|FG002|Overall Study|Investigator decided to discontinue|4
6037009|NCT00348140|9634212|FG000|Overall Study|Decided to discontinue on their own|1
6037010|NCT00348140|9634213|FG001|Overall Study|Decided to discontinue on their own|4
6037011|NCT00348140|9634214|FG002|Overall Study|Decided to discontinue on their own|1
6037012|NCT00348140|9634212|FG000|Overall Study|Use of prohibited drug|1
6037013|NCT00348140|9634213|FG001|Overall Study|Use of prohibited drug|0
6037014|NCT00348140|9634214|FG002|Overall Study|Use of prohibited drug|2
6037015|NCT00348140|9634212|FG000|Overall Study|Disease progression|1
6037016|NCT00348140|9634213|FG001|Overall Study|Disease progression|2
6037017|NCT00348140|9634214|FG002|Overall Study|Disease progression|5
6037018|NCT00348140|9634212|FG000|Overall Study|Increased risk of cardiac infarction|0
6037019|NCT00348140|9634213|FG001|Overall Study|Increased risk of cardiac infarction|1
6037020|NCT00348140|9634214|FG002|Overall Study|Increased risk of cardiac infarction|0
6037021|NCT00348140|9634212|FG000|Overall Study|Serious adverse event|0
6037022|NCT00348140|9634213|FG001|Overall Study|Serious adverse event|1
6037023|NCT00348140|9634214|FG002|Overall Study|Serious adverse event|0
6037024|NCT00348140|9634212|FG000|Overall Study|Abnormal ECG|0
6037025|NCT00348140|9634213|FG001|Overall Study|Abnormal ECG|1
6037026|NCT00348140|9634214|FG002|Overall Study|Abnormal ECG|3
6037027|NCT00348140|9634212|FG000|Overall Study|Participant died|0
6037028|NCT00348140|9634213|FG001|Overall Study|Participant died|1
6037029|NCT00348140|9634214|FG002|Overall Study|Participant died|0
6037030|NCT00348140|9634212|FG000|Overall Study|Exclusion criteria met|0
6037031|NCT00348140|9634213|FG001|Overall Study|Exclusion criteria met|0
6037032|NCT00348140|9634214|FG002|Overall Study|Exclusion criteria met|1
6037033|NCT00348140|9634212|FG000|Overall Study|Memory declined|0
6037034|NCT00348140|9634213|FG001|Overall Study|Memory declined|0
6037035|NCT00348140|9634214|FG002|Overall Study|Memory declined|1
6037036|NCT00348283|9634229|FG000|Induction|Adverse Event|0
6037037|NCT00348283|9634230|FG001|Induction|Adverse Event|2
6037038|NCT00348283|9634229|FG000|Induction|Protocol Violation|0
6037039|NCT00348283|9634230|FG001|Induction|Protocol Violation|4
6037040|NCT00348283|9634229|FG000|Double Blind|Adverse Event|2
6037041|NCT00348283|9634230|FG001|Double Blind|Adverse Event|5
6037042|NCT00348283|9634229|FG000|Double Blind|Withdrawal by Subject|1
6037043|NCT00348283|9634230|FG001|Double Blind|Withdrawal by Subject|1
6037044|NCT00348283|9634229|FG000|Double Blind|Protocol Violation|0
6037045|NCT00348283|9634230|FG001|Double Blind|Protocol Violation|1
6037046|NCT00348283|9634229|FG000|Double Blind|Lack of Efficacy|2
6037047|NCT00348283|9634230|FG001|Double Blind|Lack of Efficacy|2
6037048|NCT00348283|9634229|FG000|Double Blind|Pregnancy|0
6037049|NCT00348283|9634230|FG001|Double Blind|Pregnancy|1
6037050|NCT00348283|9634229|FG000|Open Label|Adverse Event|0
6037051|NCT00348283|9634230|FG001|Open Label|Adverse Event|8
6037052|NCT00348283|9634229|FG000|Open Label|Withdrawal by Subject|0
6037053|NCT00348283|9634230|FG001|Open Label|Withdrawal by Subject|4
6037054|NCT00348283|9634229|FG000|Open Label|Lost to Follow-up|0
6037055|NCT00348283|9634230|FG001|Open Label|Lost to Follow-up|1
6037056|NCT00348283|9634229|FG000|Open Label|Lack of Efficacy|0
6037057|NCT00348283|9634230|FG001|Open Label|Lack of Efficacy|13
6037058|NCT00348283|9634229|FG000|Open Label|Administrative reasons|0
6037059|NCT00348283|9634230|FG001|Open Label|Administrative reasons|5
6037060|NCT00348283|9634229|FG000|Open Label|Subject moved to the United States|0
6037061|NCT00348283|9634230|FG001|Open Label|Subject moved to the United States|1
6037062|NCT00348283|9634229|FG000|Open Label|Pregnancy|0
6037063|NCT00348283|9634230|FG001|Open Label|Pregnancy|1
6037064|NCT00348283|9634229|FG000|Open Label|Sponsor decision|0
6037065|NCT00348283|9634230|FG001|Open Label|Sponsor decision|1
6037066|NCT00348309|9634239|FG000|Overall Study|Adverse Event|56
6037067|NCT00348309|9634240|FG001|Overall Study|Adverse Event|28
6037068|NCT00348309|9634241|FG002|Overall Study|Adverse Event|63
6037069|NCT00348309|9634239|FG000|Overall Study|Lost to Follow-up|6
6037070|NCT00348309|9634240|FG001|Overall Study|Lost to Follow-up|7
6037071|NCT00348309|9634241|FG002|Overall Study|Lost to Follow-up|4
6037072|NCT00348309|9634239|FG000|Overall Study|Protocol Violation|7
6037073|NCT00348309|9634240|FG001|Overall Study|Protocol Violation|12
6037074|NCT00348309|9634241|FG002|Overall Study|Protocol Violation|7
6037075|NCT00348309|9634239|FG000|Overall Study|Withdrawal by Subject|33
6037076|NCT00348309|9634240|FG001|Overall Study|Withdrawal by Subject|37
6037077|NCT00348309|9634241|FG002|Overall Study|Withdrawal by Subject|40
6037078|NCT00348309|9634239|FG000|Overall Study|Non-compliance|8
6037079|NCT00348309|9634240|FG001|Overall Study|Non-compliance|6
6037080|NCT00348309|9634241|FG002|Overall Study|Non-compliance|8
6037081|NCT00348309|9634239|FG000|Overall Study|Death of caregiver|1
6037082|NCT00348309|9634240|FG001|Overall Study|Death of caregiver|0
6037083|NCT00348309|9634241|FG002|Overall Study|Death of caregiver|1
6037084|NCT00348309|9634239|FG000|Overall Study|Lack of insight, dementia|1
6037085|NCT00348309|9634240|FG001|Overall Study|Lack of insight, dementia|0
6037086|NCT00348309|9634241|FG002|Overall Study|Lack of insight, dementia|0
6037087|NCT00348309|9634239|FG000|Overall Study|Wrong bottle allocated|1
6037088|NCT00348309|9634240|FG001|Overall Study|Wrong bottle allocated|0
6037089|NCT00348309|9634241|FG002|Overall Study|Wrong bottle allocated|0
6037090|NCT00348309|9634239|FG000|Overall Study|Caregiver sick|1
6037091|NCT00348309|9634240|FG001|Overall Study|Caregiver sick|0
6037092|NCT00348309|9634241|FG002|Overall Study|Caregiver sick|0
6037093|NCT00348309|9634239|FG000|Overall Study|Use of prohibited medication|5
6037094|NCT00348309|9634240|FG001|Overall Study|Use of prohibited medication|2
6037095|NCT00348309|9634241|FG002|Overall Study|Use of prohibited medication|2
6037096|NCT00348309|9634239|FG000|Overall Study|Caregiver withdrawal|3
6037097|NCT00348309|9634240|FG001|Overall Study|Caregiver withdrawal|0
6037098|NCT00348309|9634241|FG002|Overall Study|Caregiver withdrawal|7
6147200|NCT01081795|9782263|FG002|Overall Study|Revocation of informed consent|0
6147201|NCT01081795|9782261|FG000|Overall Study|Ineligible for participation|1
6147202|NCT01081795|9782262|FG001|Overall Study|Ineligible for participation|0
6147203|NCT01081795|9782263|FG002|Overall Study|Ineligible for participation|0
6147204|NCT01081795|9782261|FG000|Overall Study|Use of a prohibited concomitant drug|1
6147205|NCT01081795|9782262|FG001|Overall Study|Use of a prohibited concomitant drug|1
6147206|NCT01081795|9782263|FG002|Overall Study|Use of a prohibited concomitant drug|1
6147207|NCT01081795|9782261|FG000|Overall Study|Using drug with restricted days of use|2
6147208|NCT01081795|9782262|FG001|Overall Study|Using drug with restricted days of use|3
6147209|NCT01081795|9782263|FG002|Overall Study|Using drug with restricted days of use|2
6147210|NCT01081795|9782261|FG000|Overall Study|Other|1
6147211|NCT01081795|9782262|FG001|Overall Study|Other|2
6147212|NCT01081795|9782263|FG002|Overall Study|Other|0
6147213|NCT01081834|9782276|FG000|Core Period: Baseline to Week 26|Pregnancy|1
6147214|NCT01081834|9782277|FG001|Core Period: Baseline to Week 26|Pregnancy|0
6147215|NCT01081834|9782278|FG002|Core Period: Baseline to Week 26|Pregnancy|0
6037099|NCT00348309|9634239|FG000|Overall Study|Unable to complete ET visit|1
6037100|NCT00348309|9634240|FG001|Overall Study|Unable to complete ET visit|0
6037101|NCT00348309|9634241|FG002|Overall Study|Unable to complete ET visit|0
6037102|NCT00348309|9634239|FG000|Overall Study|PI closing medical practice|1
6037103|NCT00348309|9634240|FG001|Overall Study|PI closing medical practice|0
6147216|NCT01081834|9782279|FG003|Core Period: Baseline to Week 26|Pregnancy|0
6147217|NCT01081834|9782280|FG004|Core Period: Baseline to Week 26|Pregnancy|0
6147218|NCT01081834|9782276|FG000|Core Period: Baseline to Week 26|Adverse Event|2
6037104|NCT00348309|9634241|FG002|Overall Study|PI closing medical practice|0
6037105|NCT00348309|9634239|FG000|Overall Study|Principal investigator's decision|1
6037106|NCT00348309|9634240|FG001|Overall Study|Principal investigator's decision|0
6037107|NCT00348309|9634241|FG002|Overall Study|Principal investigator's decision|0
6037108|NCT00348309|9634239|FG000|Overall Study|No disponibility of medication|1
6037109|NCT00348309|9634240|FG001|Overall Study|No disponibility of medication|0
6037110|NCT00348309|9634241|FG002|Overall Study|No disponibility of medication|0
6037111|NCT00348309|9634239|FG000|Overall Study|Worsened neurodegenerative disease|1
6037112|NCT00348309|9634240|FG001|Overall Study|Worsened neurodegenerative disease|0
6037113|NCT00348309|9634241|FG002|Overall Study|Worsened neurodegenerative disease|0
6037114|NCT00348309|9634239|FG000|Overall Study|Cognitive and behaviour worsening|2
6037115|NCT00348309|9634240|FG001|Overall Study|Cognitive and behaviour worsening|0
6037116|NCT00348309|9634241|FG002|Overall Study|Cognitive and behaviour worsening|0
6037117|NCT00348309|9634239|FG000|Overall Study|Worsening of alzheimer|1
6037118|NCT00348309|9634240|FG001|Overall Study|Worsening of alzheimer|0
6037119|NCT00348309|9634241|FG002|Overall Study|Worsening of alzheimer|1
6037120|NCT00348309|9634239|FG000|Overall Study|Did not appear in time for Visit 3|1
6037121|NCT00348309|9634240|FG001|Overall Study|Did not appear in time for Visit 3|0
6037122|NCT00348309|9634241|FG002|Overall Study|Did not appear in time for Visit 3|0
6037123|NCT00348309|9634239|FG000|Overall Study|Participant died|2
6037124|NCT00348309|9634240|FG001|Overall Study|Participant died|1
6037125|NCT00348309|9634241|FG002|Overall Study|Participant died|1
6037126|NCT00348309|9634239|FG000|Overall Study|Decision of sponsor|1
6037127|NCT00348309|9634240|FG001|Overall Study|Decision of sponsor|0
6037128|NCT00348309|9634241|FG002|Overall Study|Decision of sponsor|0
6037129|NCT00348309|9634239|FG000|Overall Study|Ineffectiveness of treatment|0
6037130|NCT00348309|9634240|FG001|Overall Study|Ineffectiveness of treatment|1
6037131|NCT00348309|9634241|FG002|Overall Study|Ineffectiveness of treatment|0
6037132|NCT00348309|9634239|FG000|Overall Study|A foul of exclusion criteria|0
6037133|NCT00348309|9634240|FG001|Overall Study|A foul of exclusion criteria|1
6037134|NCT00348309|9634241|FG002|Overall Study|A foul of exclusion criteria|0
6037135|NCT00348309|9634239|FG000|Overall Study|Participant was hospitalized|0
6037136|NCT00348309|9634240|FG001|Overall Study|Participant was hospitalized|1
6037137|NCT00348309|9634241|FG002|Overall Study|Participant was hospitalized|0
6037138|NCT00348309|9634239|FG000|Overall Study|Sponsor refuseal|0
6037139|NCT00348309|9634240|FG001|Overall Study|Sponsor refuseal|1
6037140|NCT00348309|9634241|FG002|Overall Study|Sponsor refuseal|1
6037141|NCT00348309|9634239|FG000|Overall Study|Forgot often medication|0
6037142|NCT00348309|9634240|FG001|Overall Study|Forgot often medication|1
6037143|NCT00348309|9634241|FG002|Overall Study|Forgot often medication|0
6037144|NCT00348309|9634239|FG000|Overall Study|Medical Monitor decision|0
6037145|NCT00348309|9634240|FG001|Overall Study|Medical Monitor decision|0
6037146|NCT00348309|9634241|FG002|Overall Study|Medical Monitor decision|1
6037147|NCT00348309|9634239|FG000|Overall Study|Increased dose of Aricept|0
6037148|NCT00348309|9634240|FG001|Overall Study|Increased dose of Aricept|0
6037149|NCT00348309|9634241|FG002|Overall Study|Increased dose of Aricept|1
6037150|NCT00348309|9634239|FG000|Overall Study|Site closure|0
6037151|NCT00348309|9634240|FG001|Overall Study|Site closure|0
6037152|NCT00348309|9634241|FG002|Overall Study|Site closure|1
6037153|NCT00348309|9634239|FG000|Overall Study|Adverse event not attended|0
6037154|NCT00348309|9634240|FG001|Overall Study|Adverse event not attended|0
6037155|NCT00348309|9634241|FG002|Overall Study|Adverse event not attended|1
6037156|NCT00348309|9634239|FG000|Overall Study|ECG abnormal|0
6037157|NCT00348309|9634240|FG001|Overall Study|ECG abnormal|0
6037158|NCT00348309|9634241|FG002|Overall Study|ECG abnormal|2
6037159|NCT00348309|9634239|FG000|Overall Study|Cardiologist recommendations|0
6037160|NCT00348309|9634240|FG001|Overall Study|Cardiologist recommendations|0
6037161|NCT00348309|9634241|FG002|Overall Study|Cardiologist recommendations|1
6037162|NCT00348309|9634239|FG000|Overall Study|HCV career|0
6037163|NCT00348309|9634240|FG001|Overall Study|HCV career|0
6037164|NCT00348309|9634241|FG002|Overall Study|HCV career|1
6037165|NCT00348348|9634252|FG000|Overall Study|Adverse event - unrelated to study drug|0
6037166|NCT00348348|9634253|FG001|Overall Study|Adverse event - unrelated to study drug|1
6037167|NCT00348348|9634252|FG000|Overall Study|Lack of Efficacy|1
6037168|NCT00348348|9634253|FG001|Overall Study|Lack of Efficacy|1
6037169|NCT00348348|9634252|FG000|Overall Study|Lost to Follow-up|8
6037170|NCT00348348|9634253|FG001|Overall Study|Lost to Follow-up|10
6037171|NCT00348348|9634252|FG000|Overall Study|Withdrawal by Subject|4
6037172|NCT00348348|9634253|FG001|Overall Study|Withdrawal by Subject|1
6037173|NCT00348348|9634252|FG000|Overall Study|Other|7
6037174|NCT00348348|9634253|FG001|Overall Study|Other|4
6037175|NCT00348348|9634252|FG000|Overall Study|Dissallowed Meds - unrelated to study|1
6037176|NCT00348348|9634253|FG001|Overall Study|Dissallowed Meds - unrelated to study|3
6037177|NCT00348348|9634252|FG000|Overall Study|Dissallowed Meds - unlikley related|1
6037178|NCT00348348|9634253|FG001|Overall Study|Dissallowed Meds - unlikley related|1
6037179|NCT00348348|9634252|FG000|Overall Study|Dissallowed Meds - possibly releated|1
6037180|NCT00348348|9634253|FG001|Overall Study|Dissallowed Meds - possibly releated|1
6037181|NCT00348348|9634252|FG000|Overall Study|Worsening of BC - Unrelated to study|0
6037182|NCT00348348|9634253|FG001|Overall Study|Worsening of BC - Unrelated to study|3
6037183|NCT00348348|9634252|FG000|Overall Study|Worsening of BC - Unlikely related|1
6037184|NCT00348348|9634253|FG001|Overall Study|Worsening of BC - Unlikely related|2
6037185|NCT00348348|9634252|FG000|Overall Study|Adverse event probably related to study|1
6037186|NCT00348348|9634253|FG001|Overall Study|Adverse event probably related to study|0
6037187|NCT00348374|9634261|FG000|Overall Study|Adverse Event|1
6037188|NCT00348374|9634262|FG001|Overall Study|Adverse Event|4
6037189|NCT00348374|9634261|FG000|Overall Study|Lost to Follow-up|1
6037190|NCT00348374|9634262|FG001|Overall Study|Lost to Follow-up|3
6037191|NCT00348374|9634261|FG000|Overall Study|Withdrawal by Subject|5
6037192|NCT00348374|9634262|FG001|Overall Study|Withdrawal by Subject|5
6037193|NCT00348374|9634261|FG000|Overall Study|Other|11
6037194|NCT00348374|9634262|FG001|Overall Study|Other|12
6037195|NCT00348374|9634261|FG000|Overall Study|ongoing at date of cutoff|1
6037196|NCT00348374|9634262|FG001|Overall Study|ongoing at date of cutoff|1
6037197|NCT00348374|9634261|FG000|Overall Study|randomized but did not receive treatment|0
6037198|NCT00348374|9634262|FG001|Overall Study|randomized but did not receive treatment|7
6037199|NCT00348595|9634271|FG000|Overall Study|Adverse Event|5
6037200|NCT00348595|9634272|FG001|Overall Study|Adverse Event|8
6037201|NCT00348673|9634286|FG000|Stage 1|Randomized but not Treated|0
6037202|NCT00348673|9634287|FG001|Stage 1|Randomized but not Treated|0
6037203|NCT00348673|9634288|FG002|Stage 1|Randomized but not Treated|1
6037204|NCT00348673|9634289|FG003|Stage 1|Randomized but not Treated|0
6037205|NCT00348673|9634290|FG004|Stage 1|Randomized but not Treated|0
6037206|NCT00348673|9634291|FG005|Stage 1|Randomized but not Treated|0
6037207|NCT00348673|9634292|FG006|Stage 1|Randomized but not Treated|0
6037208|NCT00348673|9634293|FG007|Stage 1|Randomized but not Treated|0
6037209|NCT00348673|9634294|FG008|Stage 1|Randomized but not Treated|0
6037210|NCT00348686|9634312|FG000|Overall Study|Withdrawal by Subject|45
6037211|NCT00348686|9634312|FG000|Overall Study|Adverse Event|5
6037212|NCT00348686|9634312|FG000|Overall Study|Protocol Violation|6
6037213|NCT00348686|9634312|FG000|Overall Study|Lost to Follow-up|2
6037214|NCT00348686|9634312|FG000|Overall Study|Multiple Reasons|8
6037215|NCT00348790|9634316|FG000|Completed Treatment|Withdrawal by Subject|4
6037216|NCT00348790|9634316|FG000|Completed Treatment|Disease progression|14
6037217|NCT00348790|9634316|FG000|Completed Treatment|Adverse Event|4
6037218|NCT00348790|9634316|FG000|Completed Treatment|Required surgery|2
6037219|NCT00348790|9634316|FG000|Completed Treatment|Unable to travel to study site|1
6037220|NCT00348816|9634321|FG000|Overall Study|Noncompliance with radiation treatment|1
6037221|NCT00348881|9634329|FG000|Overall Study|Lost to Follow-up|12
6037222|NCT00348881|9634330|FG001|Overall Study|Lost to Follow-up|6
6037223|NCT00348881|9634329|FG000|Overall Study|Withdrawal by Subject|3
6037224|NCT00348881|9634330|FG001|Overall Study|Withdrawal by Subject|4
6037225|NCT00348881|9634329|FG000|Overall Study|Adverse Event|2
6037226|NCT00348881|9634330|FG001|Overall Study|Adverse Event|0
6037227|NCT00348881|9634329|FG000|Overall Study|Serious Adverse Event|0
6037228|NCT00348881|9634330|FG001|Overall Study|Serious Adverse Event|2
6037229|NCT00348933|9634340|FG000|Overall Study|Withdrawal by Subject|10
6037230|NCT00348933|9634340|FG000|Overall Study|Lost to Follow-up|6
6037231|NCT00348933|9634340|FG000|Overall Study|Protocol Violation|2
6037232|NCT00348933|9634340|FG000|Overall Study|Adverse Event|7
6037233|NCT00349349|9634368|FG000|Overall Study|Adverse Event|5
6037234|NCT00349349|9634369|FG001|Overall Study|Adverse Event|6
6037235|NCT00349349|9634370|FG002|Overall Study|Adverse Event|2
6037236|NCT00349349|9634368|FG000|Overall Study|Withdrawal by Subject|5
6037237|NCT00349349|9634369|FG001|Overall Study|Withdrawal by Subject|2
6037238|NCT00349349|9634370|FG002|Overall Study|Withdrawal by Subject|1
6037239|NCT00349349|9634368|FG000|Overall Study|Withdrawn due to Disease Progression|27
6037240|NCT00349349|9634369|FG001|Overall Study|Withdrawn due to Disease Progression|37
6037241|NCT00349349|9634370|FG002|Overall Study|Withdrawn due to Disease Progression|1
6037242|NCT00349349|9634368|FG000|Overall Study|Death|13
6037243|NCT00349349|9634369|FG001|Overall Study|Death|10
6037244|NCT00349349|9634370|FG002|Overall Study|Death|1
6037245|NCT00349349|9634368|FG000|Overall Study|Other Treatment Selected|2
6037246|NCT00349349|9634369|FG001|Overall Study|Other Treatment Selected|0
6037247|NCT00349349|9634370|FG002|Overall Study|Other Treatment Selected|0
6037248|NCT00349349|9634368|FG000|Overall Study|Participant Reduced General Condition|0
6037249|NCT00349349|9634369|FG001|Overall Study|Participant Reduced General Condition|1
6037250|NCT00349349|9634370|FG002|Overall Study|Participant Reduced General Condition|0
6037251|NCT00349349|9634368|FG000|Overall Study|Physician Decision|1
6037252|NCT00349349|9634369|FG001|Overall Study|Physician Decision|2
6037253|NCT00349349|9634370|FG002|Overall Study|Physician Decision|1
6037254|NCT00349349|9634368|FG000|Overall Study|No Response|0
6037255|NCT00349349|9634369|FG001|Overall Study|No Response|3
6037256|NCT00349349|9634370|FG002|Overall Study|No Response|0
6037257|NCT00349349|9634368|FG000|Overall Study|New Malignancy (Bladder Cancer)|0
6037258|NCT00349349|9634369|FG001|Overall Study|New Malignancy (Bladder Cancer)|1
6037259|NCT00349349|9634370|FG002|Overall Study|New Malignancy (Bladder Cancer)|0
6037260|NCT00349622|9634391|FG000|Overall Study|Death|168
6037261|NCT00349622|9634392|FG001|Overall Study|Death|86
6037262|NCT00349622|9634391|FG000|Overall Study|Lost to Follow-up|5
6037263|NCT00349622|9634392|FG001|Overall Study|Lost to Follow-up|1
6037264|NCT00349622|9634391|FG000|Overall Study|Withdrawal by Subject|5
6037265|NCT00349622|9634392|FG001|Overall Study|Withdrawal by Subject|9
6037266|NCT00349752|9634413|FG000|Overall Study|Adverse Event|8
6037267|NCT00349752|9634414|FG001|Overall Study|Adverse Event|12
6037268|NCT00349752|9634413|FG000|Overall Study|Lack of Efficacy|37
6037269|NCT00349752|9634414|FG001|Overall Study|Lack of Efficacy|42
6037270|NCT00349752|9634413|FG000|Overall Study|Lost to Follow-up|4
6037271|NCT00349752|9634414|FG001|Overall Study|Lost to Follow-up|2
6037272|NCT00349752|9634413|FG000|Overall Study|Personal reasons|6
6037273|NCT00349752|9634414|FG001|Overall Study|Personal reasons|5
6037274|NCT00349752|9634413|FG000|Overall Study|Other: Required exclusionary medication|0
6037275|NCT00349752|9634414|FG001|Overall Study|Other: Required exclusionary medication|1
6037276|NCT00349752|9634413|FG000|Overall Study|Other: Non compliance|0
6037277|NCT00349752|9634414|FG001|Overall Study|Other: Non compliance|1
6037278|NCT00349752|9634413|FG000|Overall Study|Other: Patient stopped steroids|0
6037279|NCT00349752|9634414|FG001|Overall Study|Other: Patient stopped steroids|1
6037280|NCT00349752|9634413|FG000|Overall Study|Other: Patient's steroid use|1
6037281|NCT00349752|9634414|FG001|Overall Study|Other: Patient's steroid use|0
6037282|NCT00349752|9634413|FG000|Overall Study|Other: Ineligible|1
6037283|NCT00349752|9634414|FG001|Overall Study|Other: Ineligible|0
6037284|NCT00349752|9634413|FG000|Overall Study|Other: Inadvertently unblinded|1
6037285|NCT00349752|9634414|FG001|Overall Study|Other: Inadvertently unblinded|0
6037286|NCT00349752|9634413|FG000|Overall Study|Other:History of squamous cell carcinoma|1
6037287|NCT00349752|9634414|FG001|Overall Study|Other:History of squamous cell carcinoma|0
6037288|NCT00349908|9634426|FG000|Overall Study|Withdrawal by Subject|0
6037289|NCT00349908|9634427|FG001|Overall Study|Withdrawal by Subject|4
6037290|NCT00349921|9634438|FG000|First Spinal Injection|Physician Decision|1
6037291|NCT00349921|9634439|FG001|First Spinal Injection|Physician Decision|0
6037292|NCT00349921|9634440|FG002|First Spinal Injection|Physician Decision|0
6037293|NCT00349921|9634441|FG003|First Spinal Injection|Physician Decision|0
6037294|NCT00349921|9634438|FG000|First Spinal Injection|Adverse Event|0
6037295|NCT00349921|9634439|FG001|First Spinal Injection|Adverse Event|0
6037296|NCT00349921|9634440|FG002|First Spinal Injection|Adverse Event|1
6037297|NCT00349921|9634441|FG003|First Spinal Injection|Adverse Event|0
6037298|NCT00349973|9634452|FG000|Overall Study|Adverse Event|3
6037299|NCT00349973|9634453|FG001|Overall Study|Adverse Event|3
6037300|NCT00349973|9634452|FG000|Overall Study|Withdrawal by Subject|1
6037301|NCT00349973|9634453|FG001|Overall Study|Withdrawal by Subject|0
6037302|NCT00350207|9634476|FG000|Overall Study|Adverse Event|5
6037303|NCT00350207|9634477|FG001|Overall Study|Adverse Event|2
6037304|NCT00350207|9634478|FG002|Overall Study|Adverse Event|2
6037305|NCT00350207|9634476|FG000|Overall Study|Lack of Efficacy|1
6037306|NCT00350207|9634477|FG001|Overall Study|Lack of Efficacy|0
6037307|NCT00350207|9634478|FG002|Overall Study|Lack of Efficacy|2
6037308|NCT00350207|9634476|FG000|Overall Study|Lost to Follow-up|1
6037309|NCT00350207|9634477|FG001|Overall Study|Lost to Follow-up|0
6037310|NCT00350207|9634478|FG002|Overall Study|Lost to Follow-up|1
6037311|NCT00350207|9634476|FG000|Overall Study|Withdrawal by Subject|0
6037312|NCT00350207|9634477|FG001|Overall Study|Withdrawal by Subject|1
6037313|NCT00350207|9634478|FG002|Overall Study|Withdrawal by Subject|1
6037314|NCT00350207|9634476|FG000|Overall Study|Other|1
6037315|NCT00350207|9634477|FG001|Overall Study|Other|3
6037316|NCT00350207|9634478|FG002|Overall Study|Other|1
6037317|NCT00350272|9634497|FG000|Blinded 12 Week Treatment|Adverse Event|1
6037318|NCT00350272|9634498|FG001|Blinded 12 Week Treatment|Adverse Event|0
6037319|NCT00350272|9634497|FG000|Blinded 12 Week Treatment|Death|1
6037320|NCT00350272|9634498|FG001|Blinded 12 Week Treatment|Death|0
6037321|NCT00350272|9634497|FG000|Blinded 12 Week Treatment|Lost to Follow-up|2
6037322|NCT00350272|9634498|FG001|Blinded 12 Week Treatment|Lost to Follow-up|0
6037323|NCT00350272|9634497|FG000|Blinded 12 Week Treatment|Withdrawal by Subject|3
6037324|NCT00350272|9634498|FG001|Blinded 12 Week Treatment|Withdrawal by Subject|0
6037325|NCT00350272|9634497|FG000|Blinded 12 Week Treatment|Physician Decision|2
6037326|NCT00350272|9634498|FG001|Blinded 12 Week Treatment|Physician Decision|1
6037327|NCT00350272|9634497|FG000|Blinded 12 Week Treatment|Sponsor decision|0
6037328|NCT00350272|9634498|FG001|Blinded 12 Week Treatment|Sponsor decision|1
6037329|NCT00350272|9634497|FG000|Open-Label 84 Week Treatment|Adverse Event|2
6037330|NCT00350272|9634498|FG001|Open-Label 84 Week Treatment|Adverse Event|1
6037331|NCT00350272|9634497|FG000|Open-Label 84 Week Treatment|Lost to Follow-up|3
6037332|NCT00350272|9634498|FG001|Open-Label 84 Week Treatment|Lost to Follow-up|2
6037333|NCT00350272|9634497|FG000|Open-Label 84 Week Treatment|Withdrawal by Subject|1
6037334|NCT00350272|9634498|FG001|Open-Label 84 Week Treatment|Withdrawal by Subject|2
6037335|NCT00350272|9634497|FG000|Open-Label 84 Week Treatment|Physician Decision|1
6037336|NCT00350272|9634498|FG001|Open-Label 84 Week Treatment|Physician Decision|2
6037337|NCT00350272|9634497|FG000|Open-Label 84 Week Treatment|Sponsor decision|2
6037338|NCT00350272|9634498|FG001|Open-Label 84 Week Treatment|Sponsor decision|1
6037339|NCT00350298|9634508|FG000|Overall Study|Death|7
6037340|NCT00350298|9634509|FG001|Overall Study|Death|8
6037341|NCT00350298|9634508|FG000|Overall Study|Lost to Follow-up|1
6037342|NCT00350298|9634509|FG001|Overall Study|Lost to Follow-up|2
6037343|NCT00350298|9634508|FG000|Overall Study|Withdrawal by Subject|1
6037344|NCT00350298|9634509|FG001|Overall Study|Withdrawal by Subject|3
6037345|NCT00350402|9634539|FG000|Overall Study|Lost to Follow-up|1
6037346|NCT00350402|9634540|FG001|Overall Study|Lost to Follow-up|1
6037347|NCT00350519|9634554|FG000|Overall Study|Death|0
6037348|NCT00350519|9634555|FG001|Overall Study|Death|1
6037349|NCT00350519|9634554|FG000|Overall Study|Physician Decision|0
6037350|NCT00350519|9634555|FG001|Overall Study|Physician Decision|1
6037351|NCT00350519|9634554|FG000|Overall Study|Protocol Violation|1
6037352|NCT00350519|9634555|FG001|Overall Study|Protocol Violation|2
6037353|NCT00350519|9634554|FG000|Overall Study|Withdrawal by Subject|3
6037354|NCT00350519|9634555|FG001|Overall Study|Withdrawal by Subject|2
6037355|NCT00350545|9634570|FG000|Overall Study|Withdrawal by Subject|2
6037356|NCT00350636|9634576|FG000|Overall Study|Adverse Event|19
6037357|NCT00350636|9634577|FG001|Overall Study|Adverse Event|13
6037358|NCT00350636|9634576|FG000|Overall Study|Protocol Violation|1
6037359|NCT00350636|9634577|FG001|Overall Study|Protocol Violation|3
6037360|NCT00350636|9634576|FG000|Overall Study|Withdrawal by Subject|13
6037361|NCT00350636|9634577|FG001|Overall Study|Withdrawal by Subject|17
6037362|NCT00350636|9634576|FG000|Overall Study|Lost to Follow-up|9
6037363|NCT00350636|9634577|FG001|Overall Study|Lost to Follow-up|8
6037364|NCT00350636|9634576|FG000|Overall Study|Physician Decision|0
6037365|NCT00350636|9634577|FG001|Overall Study|Physician Decision|2
6037366|NCT00350636|9634576|FG000|Overall Study|Other|1
6037367|NCT00350636|9634577|FG001|Overall Study|Other|2
6037368|NCT00350727|9634586|FG000|Phase I: Dose Escalation|Adverse Event|4
6037369|NCT00350727|9634587|FG001|Phase I: Dose Escalation|Adverse Event|0
6037370|NCT00350727|9634588|FG002|Phase I: Dose Escalation|Adverse Event|0
6037371|NCT00350727|9634586|FG000|Phase I: Dose Escalation|Lack of Efficacy|25
6037372|NCT00350727|9634587|FG001|Phase I: Dose Escalation|Lack of Efficacy|0
6037373|NCT00350727|9634588|FG002|Phase I: Dose Escalation|Lack of Efficacy|0
6037374|NCT00350727|9634586|FG000|Phase I: Dose Escalation|Death|1
6037375|NCT00350727|9634587|FG001|Phase I: Dose Escalation|Death|0
6037376|NCT00350727|9634588|FG002|Phase I: Dose Escalation|Death|0
6037377|NCT00350727|9634586|FG000|Phase I: Dose Escalation|Physician Decision|1
6037378|NCT00350727|9634587|FG001|Phase I: Dose Escalation|Physician Decision|0
6037379|NCT00350727|9634588|FG002|Phase I: Dose Escalation|Physician Decision|0
6037380|NCT00350727|9634586|FG000|Phase I: Dose Escalation|Transition to Extension Phase|3
6037381|NCT00350727|9634587|FG001|Phase I: Dose Escalation|Transition to Extension Phase|0
6037382|NCT00350727|9634588|FG002|Phase I: Dose Escalation|Transition to Extension Phase|0
6037383|NCT00350727|9634586|FG000|Phase II|Disease Progression|0
6037384|NCT00350727|9634587|FG001|Phase II|Disease Progression|15
6037385|NCT00350727|9634588|FG002|Phase II|Disease Progression|16
6037386|NCT00350727|9634586|FG000|Phase II|Clinical Deterioration|0
6037387|NCT00350727|9634587|FG001|Phase II|Clinical Deterioration|1
6037388|NCT00350727|9634588|FG002|Phase II|Clinical Deterioration|0
6147219|NCT01081834|9782277|FG001|Core Period: Baseline to Week 26|Adverse Event|5
6147220|NCT01081834|9782278|FG002|Core Period: Baseline to Week 26|Adverse Event|3
6147221|NCT01081834|9782279|FG003|Core Period: Baseline to Week 26|Adverse Event|1
6147222|NCT01081834|9782280|FG004|Core Period: Baseline to Week 26|Adverse Event|1
6147223|NCT01081834|9782276|FG000|Core Period: Baseline to Week 26|Death|1
6147224|NCT01081834|9782277|FG001|Core Period: Baseline to Week 26|Death|0
6147225|NCT01081834|9782278|FG002|Core Period: Baseline to Week 26|Death|0
6147226|NCT01081834|9782279|FG003|Core Period: Baseline to Week 26|Death|0
6147227|NCT01081834|9782280|FG004|Core Period: Baseline to Week 26|Death|0
6147228|NCT01081834|9782276|FG000|Core Period: Baseline to Week 26|Lost to Follow-up|2
6147229|NCT01081834|9782277|FG001|Core Period: Baseline to Week 26|Lost to Follow-up|2
6147230|NCT01081834|9782278|FG002|Core Period: Baseline to Week 26|Lost to Follow-up|5
6147231|NCT01081834|9782279|FG003|Core Period: Baseline to Week 26|Lost to Follow-up|0
6147232|NCT01081834|9782280|FG004|Core Period: Baseline to Week 26|Lost to Follow-up|0
6147233|NCT01081834|9782276|FG000|Core Period: Baseline to Week 26|Protocol Violation|0
6147234|NCT01081834|9782277|FG001|Core Period: Baseline to Week 26|Protocol Violation|4
6147235|NCT01081834|9782278|FG002|Core Period: Baseline to Week 26|Protocol Violation|0
6147236|NCT01081834|9782279|FG003|Core Period: Baseline to Week 26|Protocol Violation|0
6147237|NCT01081834|9782280|FG004|Core Period: Baseline to Week 26|Protocol Violation|2
6147238|NCT01081834|9782276|FG000|Core Period: Baseline to Week 26|Withdrawal by Subject|15
6037389|NCT00350727|9634586|FG000|Phase II|Withdrawal by Subject|0
6037390|NCT00350727|9634587|FG001|Phase II|Withdrawal by Subject|2
6037391|NCT00350727|9634588|FG002|Phase II|Withdrawal by Subject|1
6037392|NCT00350727|9634586|FG000|Phase II|Adverse Event|0
6037393|NCT00350727|9634587|FG001|Phase II|Adverse Event|1
6037394|NCT00350727|9634588|FG002|Phase II|Adverse Event|1
6037395|NCT00350727|9634586|FG000|Phase II|Death|0
6037396|NCT00350727|9634587|FG001|Phase II|Death|0
6037397|NCT00350727|9634588|FG002|Phase II|Death|2
6147239|NCT01081834|9782277|FG001|Core Period: Baseline to Week 26|Withdrawal by Subject|3
6147240|NCT01081834|9782278|FG002|Core Period: Baseline to Week 26|Withdrawal by Subject|9
6037398|NCT00350727|9634586|FG000|Phase II|Sponsor Terminated Study|0
6037399|NCT00350727|9634587|FG001|Phase II|Sponsor Terminated Study|0
6037400|NCT00350727|9634588|FG002|Phase II|Sponsor Terminated Study|1
6037401|NCT00350727|9634586|FG000|Phase II|Enrolled in Rollover Study|0
6037402|NCT00350727|9634587|FG001|Phase II|Enrolled in Rollover Study|0
6037403|NCT00350727|9634588|FG002|Phase II|Enrolled in Rollover Study|1
6037404|NCT00350779|9634609|FG000|Overall Study|Adverse Event|4
6037405|NCT00350779|9634610|FG001|Overall Study|Adverse Event|2
6037406|NCT00350779|9634609|FG000|Overall Study|Lack of Efficacy|0
6037407|NCT00350779|9634610|FG001|Overall Study|Lack of Efficacy|4
6037408|NCT00350779|9634609|FG000|Overall Study|Lost to Follow-up|2
6037409|NCT00350779|9634610|FG001|Overall Study|Lost to Follow-up|0
6037410|NCT00350779|9634609|FG000|Overall Study|Physician Decision|2
6037411|NCT00350779|9634610|FG001|Overall Study|Physician Decision|4
6037412|NCT00350779|9634609|FG000|Overall Study|Protocol Violation|3
6037413|NCT00350779|9634610|FG001|Overall Study|Protocol Violation|1
6037414|NCT00350779|9634609|FG000|Overall Study|Withdrawal by Subject|9
6037415|NCT00350779|9634610|FG001|Overall Study|Withdrawal by Subject|8
6037416|NCT00350779|9634609|FG000|Overall Study|Patient Moved|2
6037417|NCT00350779|9634610|FG001|Overall Study|Patient Moved|1
6037418|NCT00350779|9634609|FG000|Overall Study|Non-compliance with study procedures|0
6037419|NCT00350779|9634610|FG001|Overall Study|Non-compliance with study procedures|1
6037420|NCT00350792|9634618|FG000|Overall Study|Adverse Event|11
6037421|NCT00350792|9634618|FG000|Overall Study|Death from Study Disease|1
6037422|NCT00350792|9634618|FG000|Overall Study|Death from Study Drug Toxicity|1
6037423|NCT00350792|9634618|FG000|Overall Study|Death Not Study Drug Related|2
6037424|NCT00350792|9634618|FG000|Overall Study|Protocol Violation|1
6037425|NCT00350792|9634618|FG000|Overall Study|Withdrawal by Subject|4
6037426|NCT00350792|9634618|FG000|Overall Study|Physician Decision|2
6037427|NCT00350792|9634618|FG000|Overall Study|Lack of Efficacy|11
6037428|NCT00350870|9634626|FG000|Overall Study|Withdrawal by Subject|21
6037429|NCT00350870|9634627|FG001|Overall Study|Withdrawal by Subject|17
6037430|NCT00350870|9634628|FG002|Overall Study|Withdrawal by Subject|15
6037431|NCT00350870|9634629|FG003|Overall Study|Withdrawal by Subject|14
6037432|NCT00350870|9634626|FG000|Overall Study|Physician Decision|1
6037433|NCT00350870|9634627|FG001|Overall Study|Physician Decision|0
6037434|NCT00350870|9634628|FG002|Overall Study|Physician Decision|1
6037435|NCT00350870|9634629|FG003|Overall Study|Physician Decision|1
6037436|NCT00351273|9634654|FG000|Overall Study|Lost to Follow-up|1
6037437|NCT00351273|9634655|FG001|Overall Study|Lost to Follow-up|2
6037438|NCT00351273|9634656|FG002|Overall Study|Lost to Follow-up|5
6037439|NCT00351351|9634684|FG000|Overall Study|surgical access pbs; device issues|9
6037440|NCT00351351|9634685|FG001|Overall Study|surgical access pbs; device issues|4
6037441|NCT00351377|9634691|FG000|Overall Study|Adverse Event|5
6037442|NCT00351377|9634691|FG000|Overall Study|Death|1
6037443|NCT00351377|9634691|FG000|Overall Study|Unsatisfactory therapeutic effect|1
6037444|NCT00351468|9634704|FG000|Overall Study|Adverse Event|42
6037445|NCT00351468|9634704|FG000|Overall Study|Withdrawal by Subject|39
6037446|NCT00351468|9634704|FG000|Overall Study|Various -follow up w clinical team|39
6037447|NCT00351468|9634704|FG000|Overall Study|Lack of Efficacy|32
6037448|NCT00351468|9634704|FG000|Overall Study|Non-compliance|8
6037449|NCT00351468|9634704|FG000|Overall Study|Lost to Follow-up|4
6037450|NCT00351468|9634704|FG000|Overall Study|Protocol Violation|3
6037451|NCT00351533|9634711|FG000|Overall Study|Extubated before first BAL|1
6037452|NCT00351533|9634712|FG001|Overall Study|Extubated before first BAL|0
6037453|NCT00351533|9634711|FG000|Overall Study|Lost to Follow-up|1
6037454|NCT00351533|9634712|FG001|Overall Study|Lost to Follow-up|3
6309597|NCT02641379|10038348|FG009|Overall Study|Withdrawal of informed consent|0
6037455|NCT00351533|9634711|FG000|Overall Study|Physician Decision|0
6037456|NCT00351533|9634712|FG001|Overall Study|Physician Decision|1
6037457|NCT00351533|9634711|FG000|Overall Study|Withdrawal by Subject|0
6037458|NCT00351533|9634712|FG001|Overall Study|Withdrawal by Subject|1
6037459|NCT00351611|9634720|FG000|Overall Study|Adverse Event|11
6037460|NCT00351611|9634721|FG001|Overall Study|Adverse Event|3
6037461|NCT00351611|9634720|FG000|Overall Study|Death|1
6037462|NCT00351611|9634721|FG001|Overall Study|Death|0
6037463|NCT00351611|9634720|FG000|Overall Study|Lost to Follow-up|1
6037464|NCT00351611|9634721|FG001|Overall Study|Lost to Follow-up|0
6037465|NCT00351611|9634720|FG000|Overall Study|No Longer Willing to Participate in Study|0
6037466|NCT00351611|9634721|FG001|Overall Study|No Longer Willing to Participate in Study|5
6037467|NCT00351611|9634720|FG000|Overall Study|Other|1
6037468|NCT00351611|9634721|FG001|Overall Study|Other|0
6037469|NCT00351611|9634720|FG000|Overall Study|Protocol Violation|0
6037470|NCT00351611|9634721|FG001|Overall Study|Protocol Violation|2
6037471|NCT00351819|9634738|FG000|Overall Study|Lost to Follow-up|4
6037472|NCT00351819|9634739|FG001|Overall Study|Lost to Follow-up|4
6037473|NCT00351819|9634738|FG000|Overall Study|Withdrawal by Subject|0
6037474|NCT00351819|9634739|FG001|Overall Study|Withdrawal by Subject|4
6037475|NCT00351819|9634738|FG000|Overall Study|Elevated PSA|1
6037476|NCT00351819|9634739|FG001|Overall Study|Elevated PSA|1
6037477|NCT00351819|9634738|FG000|Overall Study|Traumatic ankle fracture|1
6037478|NCT00351819|9634739|FG001|Overall Study|Traumatic ankle fracture|0
6037479|NCT00351819|9634738|FG000|Overall Study|Unprofessional behavior|1
6037480|NCT00351819|9634739|FG001|Overall Study|Unprofessional behavior|0
6037481|NCT00351819|9634738|FG000|Overall Study|Non-compliance|0
6037482|NCT00351819|9634739|FG001|Overall Study|Non-compliance|1
6037483|NCT00351819|9634738|FG000|Overall Study|Incarcerated|0
6037484|NCT00351819|9634739|FG001|Overall Study|Incarcerated|1
6037485|NCT00351819|9634738|FG000|Overall Study|Enrolled in another trial|0
6037486|NCT00351819|9634739|FG001|Overall Study|Enrolled in another trial|1
6048885|NCT00420927|9648202|FG003|Period 1|Death|0
6048886|NCT00420927|9648203|FG004|Period 1|Death|0
6048887|NCT00420927|9648204|FG005|Period 1|Death|0
6048888|NCT00420927|9648205|FG006|Period 1|Death|0
6048889|NCT00420927|9648199|FG000|Period 1|Subject moved/relocated|0
6048890|NCT00420927|9648200|FG001|Period 1|Subject moved/relocated|2
6048891|NCT00420927|9648201|FG002|Period 1|Subject moved/relocated|0
6037487|NCT00352053|9634756|FG000|Double-Blind Phase (Through Week 48)|Virologic Failure|14
6037488|NCT00352053|9634757|FG001|Double-Blind Phase (Through Week 48)|Virologic Failure|10
6037489|NCT00352053|9634756|FG000|Double-Blind Phase (Through Week 48)|Physician Decision|2
6037490|NCT00352053|9634757|FG001|Double-Blind Phase (Through Week 48)|Physician Decision|2
6037491|NCT00352053|9634756|FG000|Double-Blind Phase (Through Week 48)|Adverse Event|1
6037492|NCT00352053|9634757|FG001|Double-Blind Phase (Through Week 48)|Adverse Event|0
6037493|NCT00352053|9634756|FG000|Double-Blind Phase (Through Week 48)|Withdrawal by Subject|0
6037494|NCT00352053|9634757|FG001|Double-Blind Phase (Through Week 48)|Withdrawal by Subject|1
6037495|NCT00352053|9634756|FG000|Double-Blind Phase (Through Week 48)|Intolerance to Antiretroviral Regimen|1
6037496|NCT00352053|9634757|FG001|Double-Blind Phase (Through Week 48)|Intolerance to Antiretroviral Regimen|0
6037497|NCT00352053|9634756|FG000|First Extension Phase (Weeks 48-144)|Physician Decision|9
6037498|NCT00352053|9634757|FG001|First Extension Phase (Weeks 48-144)|Physician Decision|13
6037499|NCT00352053|9634756|FG000|First Extension Phase (Weeks 48-144)|Lack of Efficacy|1
6037500|NCT00352053|9634757|FG001|First Extension Phase (Weeks 48-144)|Lack of Efficacy|4
6037501|NCT00352053|9634756|FG000|First Extension Phase (Weeks 48-144)|Pregnancy|1
6037502|NCT00352053|9634757|FG001|First Extension Phase (Weeks 48-144)|Pregnancy|0
6037503|NCT00352053|9634756|FG000|First Extension Phase (Weeks 48-144)|Lost to Follow-up|1
6037504|NCT00352053|9634757|FG001|First Extension Phase (Weeks 48-144)|Lost to Follow-up|0
6037505|NCT00352053|9634756|FG000|Second Extension Phase (Weeks 144-240)|Physician Decision|4
6147241|NCT01081834|9782279|FG003|Core Period: Baseline to Week 26|Withdrawal by Subject|3
6147242|NCT01081834|9782280|FG004|Core Period: Baseline to Week 26|Withdrawal by Subject|1
6147243|NCT01081834|9782276|FG000|Core Period: Baseline to Week 26|Noncompliance with study drug|3
6147244|NCT01081834|9782277|FG001|Core Period: Baseline to Week 26|Noncompliance with study drug|4
6147245|NCT01081834|9782278|FG002|Core Period: Baseline to Week 26|Noncompliance with study drug|2
6147246|NCT01081834|9782279|FG003|Core Period: Baseline to Week 26|Noncompliance with study drug|2
6147247|NCT01081834|9782280|FG004|Core Period: Baseline to Week 26|Noncompliance with study drug|0
6147248|NCT01081834|9782276|FG000|Core Period: Baseline to Week 26|Unable to take rescue therapy|1
6147249|NCT01081834|9782277|FG001|Core Period: Baseline to Week 26|Unable to take rescue therapy|0
6147250|NCT01081834|9782278|FG002|Core Period: Baseline to Week 26|Unable to take rescue therapy|0
6147251|NCT01081834|9782279|FG003|Core Period: Baseline to Week 26|Unable to take rescue therapy|0
6147252|NCT01081834|9782280|FG004|Core Period: Baseline to Week 26|Unable to take rescue therapy|0
6147253|NCT01081834|9782276|FG000|Core Period: Baseline to Week 26|Other|4
6147254|NCT01081834|9782277|FG001|Core Period: Baseline to Week 26|Other|4
6147255|NCT01081834|9782278|FG002|Core Period: Baseline to Week 26|Other|3
6147256|NCT01081834|9782279|FG003|Core Period: Baseline to Week 26|Other|1
6147257|NCT01081834|9782280|FG004|Core Period: Baseline to Week 26|Other|0
6147258|NCT01081834|9782276|FG000|Core Period: Baseline to Week 26|Lack of efficacy on rescue therapy|3
6147259|NCT01081834|9782277|FG001|Core Period: Baseline to Week 26|Lack of efficacy on rescue therapy|1
6147260|NCT01081834|9782278|FG002|Core Period: Baseline to Week 26|Lack of efficacy on rescue therapy|0
6147261|NCT01081834|9782279|FG003|Core Period: Baseline to Week 26|Lack of efficacy on rescue therapy|0
6147262|NCT01081834|9782280|FG004|Core Period: Baseline to Week 26|Lack of efficacy on rescue therapy|0
6147263|NCT01081834|9782276|FG000|Extension Period: Week 26 to Week 52|Adverse Event|1
6147264|NCT01081834|9782277|FG001|Extension Period: Week 26 to Week 52|Adverse Event|0
6147265|NCT01081834|9782278|FG002|Extension Period: Week 26 to Week 52|Adverse Event|0
6147266|NCT01081834|9782279|FG003|Extension Period: Week 26 to Week 52|Adverse Event|0
6147267|NCT01081834|9782280|FG004|Extension Period: Week 26 to Week 52|Adverse Event|0
6147268|NCT01081834|9782276|FG000|Extension Period: Week 26 to Week 52|Death|1
6147269|NCT01081834|9782277|FG001|Extension Period: Week 26 to Week 52|Death|0
6147270|NCT01081834|9782278|FG002|Extension Period: Week 26 to Week 52|Death|0
6147271|NCT01081834|9782279|FG003|Extension Period: Week 26 to Week 52|Death|0
6147272|NCT01081834|9782280|FG004|Extension Period: Week 26 to Week 52|Death|0
6147273|NCT01081834|9782276|FG000|Extension Period: Week 26 to Week 52|Lost to Follow-up|4
6147274|NCT01081834|9782277|FG001|Extension Period: Week 26 to Week 52|Lost to Follow-up|4
6147275|NCT01081834|9782278|FG002|Extension Period: Week 26 to Week 52|Lost to Follow-up|0
6147276|NCT01081834|9782279|FG003|Extension Period: Week 26 to Week 52|Lost to Follow-up|0
6147277|NCT01081834|9782280|FG004|Extension Period: Week 26 to Week 52|Lost to Follow-up|0
6147278|NCT01081834|9782276|FG000|Extension Period: Week 26 to Week 52|Protocol Violation|0
6147279|NCT01081834|9782277|FG001|Extension Period: Week 26 to Week 52|Protocol Violation|1
6147280|NCT01081834|9782278|FG002|Extension Period: Week 26 to Week 52|Protocol Violation|0
6147281|NCT01081834|9782279|FG003|Extension Period: Week 26 to Week 52|Protocol Violation|0
6147282|NCT01081834|9782280|FG004|Extension Period: Week 26 to Week 52|Protocol Violation|0
6147283|NCT01081834|9782276|FG000|Extension Period: Week 26 to Week 52|Withdrawal by Subject|1
6147284|NCT01081834|9782277|FG001|Extension Period: Week 26 to Week 52|Withdrawal by Subject|2
6147285|NCT01081834|9782278|FG002|Extension Period: Week 26 to Week 52|Withdrawal by Subject|0
6147286|NCT01081834|9782279|FG003|Extension Period: Week 26 to Week 52|Withdrawal by Subject|0
6147287|NCT01081834|9782280|FG004|Extension Period: Week 26 to Week 52|Withdrawal by Subject|0
6147288|NCT01081834|9782276|FG000|Extension Period: Week 26 to Week 52|Unable to take rescue therapy|1
6147289|NCT01081834|9782277|FG001|Extension Period: Week 26 to Week 52|Unable to take rescue therapy|0
6147290|NCT01081834|9782278|FG002|Extension Period: Week 26 to Week 52|Unable to take rescue therapy|1
6037506|NCT00352053|9634757|FG001|Second Extension Phase (Weeks 144-240)|Physician Decision|4
6037507|NCT00352053|9634756|FG000|Second Extension Phase (Weeks 144-240)|Withdrawal by Subject|1
6037508|NCT00352053|9634757|FG001|Second Extension Phase (Weeks 144-240)|Withdrawal by Subject|1
6037509|NCT00352053|9634756|FG000|Third Extension Phase (Weeks 240-294)|Lack of Efficacy|1
6037510|NCT00352053|9634757|FG001|Third Extension Phase (Weeks 240-294)|Lack of Efficacy|1
6037511|NCT00352053|9634756|FG000|Third Extension Phase (Weeks 240-294)|Withdrawal by Subject|0
6037512|NCT00352053|9634757|FG001|Third Extension Phase (Weeks 240-294)|Withdrawal by Subject|1
6037513|NCT00352105|9634771|FG000|Overall Study|Death|5
6037514|NCT00352105|9634771|FG000|Overall Study|Withdrawal by Subject|5
6037515|NCT00352105|9634771|FG000|Overall Study|Lack of Efficacy|9
6037516|NCT00352105|9634771|FG000|Overall Study|Adverse Event|19
6037517|NCT00352105|9634771|FG000|Overall Study|Protocol Violation|2
6037518|NCT00352365|9634775|FG000|Induction Therapy|Adverse Event|7
6037519|NCT00352365|9634775|FG000|Induction Therapy|Progression/Relapse|8
6037520|NCT00352365|9634775|FG000|Induction Therapy|Death|7
6037521|NCT00352365|9634775|FG000|Induction Therapy|Not protocol specified|1
6037522|NCT00352365|9634775|FG000|Induction Therapy|Not eligible|3
6037523|NCT00352365|9634775|FG000|Induction Therapy|Death before starting protocol therapy|1
6037524|NCT00352365|9634775|FG000|Maintenance Therapy|Progression/Relapse|3
6037525|NCT00352365|9634775|FG000|Maintenance Therapy|Death|2
6037526|NCT00352365|9634775|FG000|Maintenance Therapy|Not protocol specified|3
6037527|NCT00352365|9634775|FG000|Maintenance Therapy|Not eligible|4
6037528|NCT00352417|9634785|FG000|Overall Study|Adverse Event|1
6037529|NCT00352417|9634786|FG001|Overall Study|Adverse Event|0
6037530|NCT00352417|9634785|FG000|Overall Study|Protocol Violation|0
6037531|NCT00352417|9634786|FG001|Overall Study|Protocol Violation|2
6037532|NCT00352417|9634785|FG000|Overall Study|Withdrawal by Subject|1
6037533|NCT00352417|9634786|FG001|Overall Study|Withdrawal by Subject|2
6037534|NCT00352417|9634785|FG000|Overall Study|Lost to Follow-up|1
6037535|NCT00352417|9634786|FG001|Overall Study|Lost to Follow-up|0
6037536|NCT00352417|9634785|FG000|Overall Study|Schedule Change|2
6037537|NCT00352417|9634786|FG001|Overall Study|Schedule Change|1
6037538|NCT00352664|9634803|FG000|Overall Study|Withdrawal by Subject|7
6037539|NCT00352664|9634804|FG001|Overall Study|Withdrawal by Subject|0
6037540|NCT00352690|9634812|FG000|Overall Study|Determined to be ineligible|2
6037541|NCT00352690|9634813|FG001|Overall Study|Determined to be ineligible|0
6037542|NCT00352755|9634819|FG000|Overall Study|Physician Decision|1
6037543|NCT00352755|9634819|FG000|Overall Study|Adverse Event|1
6037544|NCT00352846|9634833|FG000|Overall Study|Disease progression|0
6037545|NCT00352846|9634834|FG001|Overall Study|Disease progression|2
6037546|NCT00352846|9634833|FG000|Overall Study|Withdrawal by Subject|3
6037547|NCT00352846|9634834|FG001|Overall Study|Withdrawal by Subject|8
6037548|NCT00352846|9634833|FG000|Overall Study|Ineligible|3
6037549|NCT00352846|9634834|FG001|Overall Study|Ineligible|2
6037550|NCT00352846|9634833|FG000|Overall Study|Non-compliance|2
6037551|NCT00352846|9634834|FG001|Overall Study|Non-compliance|0
6037552|NCT00352846|9634833|FG000|Overall Study|Death|0
6037553|NCT00352846|9634834|FG001|Overall Study|Death|1
6037554|NCT00352885|9634842|FG000|Overall Study|Withdrawal by Subject|0
6037555|NCT00352885|9634843|FG001|Overall Study|Withdrawal by Subject|3
6037556|NCT00352885|9634842|FG000|Overall Study|Development of major depression|0
6037557|NCT00352885|9634843|FG001|Overall Study|Development of major depression|1
6037558|NCT00352885|9634842|FG000|Overall Study|Progression of metastatic melanoma|5
6037559|NCT00352885|9634843|FG001|Overall Study|Progression of metastatic melanoma|3
6037560|NCT00352885|9634842|FG000|Overall Study|Side effects of IL-2 administration|1
6037561|NCT00352885|9634843|FG001|Overall Study|Side effects of IL-2 administration|0
6037562|NCT00353262|9634875|FG000|Overall Study|Adverse Event|8
6037563|NCT00353262|9634875|FG000|Overall Study|Withdrawal by Subject|2
6037564|NCT00353262|9634875|FG000|Overall Study|Insufficient Therapeutic Response|13
6037565|NCT00353262|9634875|FG000|Overall Study|Progression|1
6037566|NCT00353262|9634875|FG000|Overall Study|Surgery|4
6037567|NCT00353262|9634875|FG000|Overall Study|Break from Chemotherapy|1
6037568|NCT00353366|9634883|FG000|Overall Study|Adverse Event|8
6037569|NCT00353366|9634883|FG000|Overall Study|Protocol Violation|12
6037570|NCT00353366|9634883|FG000|Overall Study|Withdrawal by Subject|12
6037571|NCT00353366|9634883|FG000|Overall Study|Lost to Follow-up|92
6037572|NCT00353366|9634883|FG000|Overall Study|Other|19
6037573|NCT00353496|9634907|FG000|Overall Study|Adverse Event|1
6037574|NCT00353496|9634908|FG001|Overall Study|Adverse Event|0
6037575|NCT00353496|9634907|FG000|Overall Study|Protocol Violation|2
6037576|NCT00353496|9634908|FG001|Overall Study|Protocol Violation|2
6037577|NCT00353496|9634907|FG000|Overall Study|Withdrawal by Subject|3
6037578|NCT00353496|9634908|FG001|Overall Study|Withdrawal by Subject|4
6037579|NCT00353496|9634907|FG000|Overall Study|Physician Decision|6
6037580|NCT00353496|9634908|FG001|Overall Study|Physician Decision|9
6037581|NCT00353496|9634907|FG000|Overall Study|Not otherwise specified|4
6037582|NCT00353496|9634908|FG001|Overall Study|Not otherwise specified|2
6037583|NCT00353704|9634950|FG000|Overall Study|Protocol Violation|3
6037584|NCT00353704|9634951|FG001|Overall Study|Protocol Violation|1
6037585|NCT00353873|9634972|FG000|Overall Study|Protocol Violation|1
6037586|NCT00353873|9634973|FG001|Overall Study|Protocol Violation|2
6037587|NCT00353873|9634972|FG000|Overall Study|Exacerbation|1
6037588|NCT00353873|9634973|FG001|Overall Study|Exacerbation|0
6037589|NCT00353873|9634972|FG000|Overall Study|Adverse Event|1
6037590|NCT00353873|9634973|FG001|Overall Study|Adverse Event|0
6037591|NCT00353873|9634972|FG000|Overall Study|Physician Decision|2
6037592|NCT00353873|9634973|FG001|Overall Study|Physician Decision|0
6037593|NCT00353873|9634972|FG000|Overall Study|Withdrawal by Subject|1
6037594|NCT00353873|9634973|FG001|Overall Study|Withdrawal by Subject|1
6037595|NCT00354029|9634985|FG000|Overall Study|Protocol Violation|4
6037596|NCT00354029|9634986|FG001|Overall Study|Protocol Violation|2
6037597|NCT00354107|9634992|FG000|Overall Study|Adverse Event|2
6037598|NCT00354107|9634992|FG000|Overall Study|Physician Decision|2
6037599|NCT00354107|9634992|FG000|Overall Study|Withdrawal by Subject|1
6037600|NCT00354159|9634998|FG000|Randomized Study Period|Withdrawal by Subject|5
6037601|NCT00354159|9634999|FG001|Randomized Study Period|Withdrawal by Subject|3
6037602|NCT00354159|9634998|FG000|Randomized Study Period|Physician Decision|6
6037603|NCT00354159|9634999|FG001|Randomized Study Period|Physician Decision|10
6037604|NCT00354159|9634998|FG000|Randomized Study Period|Lost to Follow-up|4
6037605|NCT00354159|9634999|FG001|Randomized Study Period|Lost to Follow-up|0
6037606|NCT00354159|9634998|FG000|Randomized Study Period|Death|7
6037607|NCT00354159|9634999|FG001|Randomized Study Period|Death|9
6037608|NCT00354159|9634998|FG000|Long-term Follow-up|Withdrawal by Subject|9
6037609|NCT00354159|9634999|FG001|Long-term Follow-up|Withdrawal by Subject|9
6037610|NCT00354159|9634998|FG000|Long-term Follow-up|Physician Decision|127
6037611|NCT00354159|9634999|FG001|Long-term Follow-up|Physician Decision|122
6037612|NCT00354159|9634998|FG000|Long-term Follow-up|Lost to Follow-up|1
6037613|NCT00354159|9634999|FG001|Long-term Follow-up|Lost to Follow-up|0
6037614|NCT00354159|9634998|FG000|Long-term Follow-up|Death|14
6037615|NCT00354159|9634999|FG001|Long-term Follow-up|Death|11
6037616|NCT00354159|9634998|FG000|Long-term Follow-up|Study Closed|29
6037617|NCT00354159|9634999|FG001|Long-term Follow-up|Study Closed|34
6037618|NCT00354172|9635012|FG000|Overall Study|Did not receive transplant|1
6037619|NCT00354341|9635022|FG000|Overall Study|Adverse Event|1
6037620|NCT00354341|9635023|FG001|Overall Study|Adverse Event|0
6037621|NCT00354341|9635022|FG000|Overall Study|Death|0
6037622|NCT00354341|9635023|FG001|Overall Study|Death|2
6037623|NCT00354341|9635022|FG000|Overall Study|Refused treatment|1
6037624|NCT00354341|9635023|FG001|Overall Study|Refused treatment|2
6037625|NCT00354341|9635022|FG000|Overall Study|Failure to return|0
6037626|NCT00354341|9635023|FG001|Overall Study|Failure to return|1
6037627|NCT00354341|9635022|FG000|Overall Study|Other|1
6037628|NCT00354341|9635023|FG001|Overall Study|Other|2
6037629|NCT00354432|9635033|FG000|Overall Study|Adverse Event|3
6037630|NCT00354432|9635034|FG001|Overall Study|Adverse Event|1
6037631|NCT00354432|9635035|FG002|Overall Study|Adverse Event|5
6037632|NCT00354432|9635036|FG003|Overall Study|Adverse Event|5
6037633|NCT00354432|9635033|FG000|Overall Study|Off/Toxicity|3
6037634|NCT00354432|9635034|FG001|Overall Study|Off/Toxicity|7
6037635|NCT00354432|9635035|FG002|Overall Study|Off/Toxicity|5
6037636|NCT00354432|9635036|FG003|Overall Study|Off/Toxicity|5
6037637|NCT00354601|9635055|FG000|Overall Study|Protocol Violation|1
6037638|NCT00354601|9635055|FG000|Overall Study|progression|1
6037639|NCT00354614|9635059|FG000|Overall Study|Lack of Efficacy|28
6037640|NCT00354679|9635067|FG000|Overall Study|Patient Not Treated|1
6037641|NCT00354744|9635071|FG000|Overall Study|Adverse Event|2
6037642|NCT00354744|9635071|FG000|Overall Study|Death|2
6037643|NCT00354744|9635071|FG000|Overall Study|Lack of Efficacy|11
6037644|NCT00354744|9635071|FG000|Overall Study|Lost to Follow-up|2
6037645|NCT00354744|9635071|FG000|Overall Study|Physician Decision|11
6037646|NCT00354744|9635071|FG000|Overall Study|Withdrawal by Subject|14
6037647|NCT00355030|9635100|FG000|Study Period 1 Treatment|Adverse Event|1
6037648|NCT00355030|9635101|FG001|Study Period 1 Treatment|Adverse Event|1
6037649|NCT00355030|9635100|FG000|Study Period 1 Treatment|Lost to Follow-up|3
6037650|NCT00355030|9635101|FG001|Study Period 1 Treatment|Lost to Follow-up|0
6037651|NCT00355030|9635100|FG000|Study Period 1 Treatment|Withdrawal by Subject|4
6037652|NCT00355030|9635101|FG001|Study Period 1 Treatment|Withdrawal by Subject|1
6037653|NCT00355030|9635100|FG000|Study Period 1 Treatment|Parent/Caregiver Decision|1
6037654|NCT00355030|9635101|FG001|Study Period 1 Treatment|Parent/Caregiver Decision|2
6037655|NCT00355030|9635100|FG000|Study Period 1 Treatment|Physician Decision|0
6037656|NCT00355030|9635101|FG001|Study Period 1 Treatment|Physician Decision|1
6037657|NCT00355030|9635100|FG000|Study Period 1 Treatment|Sponsor Decision|34
6037658|NCT00355030|9635101|FG001|Study Period 1 Treatment|Sponsor Decision|32
6037659|NCT00355030|9635100|FG000|Study Period 1 Treatment|Protocol Entry Criterion Not Met|0
6037660|NCT00355030|9635101|FG001|Study Period 1 Treatment|Protocol Entry Criterion Not Met|1
6037661|NCT00355030|9635100|FG000|Study Period 1 Treatment|Other|2
6037662|NCT00355030|9635101|FG001|Study Period 1 Treatment|Other|6
6037663|NCT00355030|9635100|FG000|Study Period 2 Long Term Follow-Up|Lost to Follow-up|0
6037664|NCT00355030|9635101|FG001|Study Period 2 Long Term Follow-Up|Lost to Follow-up|1
6037665|NCT00355030|9635100|FG000|Study Period 2 Long Term Follow-Up|Withdrawal by Subject|1
6037666|NCT00355030|9635101|FG001|Study Period 2 Long Term Follow-Up|Withdrawal by Subject|1
6037667|NCT00355056|9635109|FG000|Randomization Period|Early Termination|4
6037668|NCT00355056|9635110|FG001|Randomization Period|Early Termination|6
6037669|NCT00355082|9635126|FG000|Double-Blind (DB) Treatment Phase|Adverse Event|4
6037670|NCT00355082|9635127|FG001|Double-Blind (DB) Treatment Phase|Adverse Event|10
6037671|NCT00355082|9635128|FG002|Double-Blind (DB) Treatment Phase|Adverse Event|0
6037672|NCT00355082|9635126|FG000|Double-Blind (DB) Treatment Phase|Withdrawal by Subject|9
6037673|NCT00355082|9635127|FG001|Double-Blind (DB) Treatment Phase|Withdrawal by Subject|8
6037674|NCT00355082|9635128|FG002|Double-Blind (DB) Treatment Phase|Withdrawal by Subject|0
6037675|NCT00355082|9635126|FG000|Double-Blind (DB) Treatment Phase|Lack of Efficacy|6
6037676|NCT00355082|9635127|FG001|Double-Blind (DB) Treatment Phase|Lack of Efficacy|7
6037677|NCT00355082|9635128|FG002|Double-Blind (DB) Treatment Phase|Lack of Efficacy|0
6037678|NCT00355082|9635126|FG000|Double-Blind (DB) Treatment Phase|Lost to Follow-up|0
6037679|NCT00355082|9635127|FG001|Double-Blind (DB) Treatment Phase|Lost to Follow-up|4
6037680|NCT00355082|9635128|FG002|Double-Blind (DB) Treatment Phase|Lost to Follow-up|0
6037681|NCT00355082|9635126|FG000|Double-Blind (DB) Treatment Phase|Protocol Violation|0
6037682|NCT00355082|9635127|FG001|Double-Blind (DB) Treatment Phase|Protocol Violation|4
6037683|NCT00355082|9635128|FG002|Double-Blind (DB) Treatment Phase|Protocol Violation|0
6037684|NCT00355082|9635126|FG000|Double-Blind (DB) Treatment Phase|Pregnancy|0
6037685|NCT00355082|9635127|FG001|Double-Blind (DB) Treatment Phase|Pregnancy|1
6037686|NCT00355082|9635128|FG002|Double-Blind (DB) Treatment Phase|Pregnancy|0
6037687|NCT00355082|9635126|FG000|Continuation Phase|Adverse Event|2
6037688|NCT00355082|9635127|FG001|Continuation Phase|Adverse Event|0
6037689|NCT00355082|9635128|FG002|Continuation Phase|Adverse Event|1
6037690|NCT00355082|9635126|FG000|Continuation Phase|Lost to Follow-up|2
6037691|NCT00355082|9635127|FG001|Continuation Phase|Lost to Follow-up|0
6037692|NCT00355082|9635128|FG002|Continuation Phase|Lost to Follow-up|1
6037693|NCT00355082|9635126|FG000|Continuation Phase|Protocol Violation|1
6037694|NCT00355082|9635127|FG001|Continuation Phase|Protocol Violation|0
6037695|NCT00355082|9635128|FG002|Continuation Phase|Protocol Violation|1
6037696|NCT00355082|9635126|FG000|Continuation Phase|Withdrawal by Subject|4
6037697|NCT00355082|9635127|FG001|Continuation Phase|Withdrawal by Subject|0
6037698|NCT00355082|9635128|FG002|Continuation Phase|Withdrawal by Subject|0
6037699|NCT00355082|9635126|FG000|Continuation Phase|Lack of Efficacy|5
6037700|NCT00355082|9635127|FG001|Continuation Phase|Lack of Efficacy|0
6037701|NCT00355082|9635128|FG002|Continuation Phase|Lack of Efficacy|0
6037702|NCT00355082|9635126|FG000|Continuation Phase|Site Closed by Sponsor|8
6037703|NCT00355082|9635127|FG001|Continuation Phase|Site Closed by Sponsor|0
6037704|NCT00355082|9635128|FG002|Continuation Phase|Site Closed by Sponsor|0
6037705|NCT00355082|9635126|FG000|Continuation Phase|Scheduling Error|1
6037706|NCT00355082|9635127|FG001|Continuation Phase|Scheduling Error|0
6037707|NCT00355082|9635128|FG002|Continuation Phase|Scheduling Error|0
6037708|NCT00355082|9635126|FG000|Continuation Phase|Ran Out of Drug Due to Travel|1
6037709|NCT00355082|9635127|FG001|Continuation Phase|Ran Out of Drug Due to Travel|0
6037710|NCT00355082|9635128|FG002|Continuation Phase|Ran Out of Drug Due to Travel|0
6037711|NCT00355121|9635142|FG000|Overall Study|Did not receive study vaccine|1
6037712|NCT00355121|9635143|FG001|Overall Study|Did not receive study vaccine|0
6037713|NCT00355121|9635144|FG002|Overall Study|Did not receive study vaccine|1
6037714|NCT00355121|9635142|FG000|Overall Study|Adverse Event|0
6037715|NCT00355121|9635143|FG001|Overall Study|Adverse Event|1
6037716|NCT00355121|9635144|FG002|Overall Study|Adverse Event|0
6037717|NCT00355121|9635142|FG000|Overall Study|Protocol Violation|7
6037718|NCT00355121|9635143|FG001|Overall Study|Protocol Violation|9
6037719|NCT00355121|9635144|FG002|Overall Study|Protocol Violation|1
6037720|NCT00355121|9635142|FG000|Overall Study|Lost to Follow-up|4
6037721|NCT00355121|9635143|FG001|Overall Study|Lost to Follow-up|7
6037722|NCT00355121|9635144|FG002|Overall Study|Lost to Follow-up|1
6037723|NCT00355121|9635142|FG000|Overall Study|Withdrawal by Subject|9
6037724|NCT00355121|9635143|FG001|Overall Study|Withdrawal by Subject|10
6037725|NCT00355121|9635144|FG002|Overall Study|Withdrawal by Subject|2
6037726|NCT00355121|9635142|FG000|Overall Study|Serious adverse events|0
6037727|NCT00355121|9635143|FG001|Overall Study|Serious adverse events|2
6037728|NCT00355121|9635144|FG002|Overall Study|Serious adverse events|0
6037729|NCT00355134|9635160|FG000|Core Phase|Withdrawal by Subject|35
6037730|NCT00355134|9635161|FG001|Core Phase|Withdrawal by Subject|24
6037731|NCT00355134|9635162|FG002|Core Phase|Withdrawal by Subject|35
6037732|NCT00355134|9635163|FG003|Core Phase|Withdrawal by Subject|0
6037733|NCT00355134|9635164|FG004|Core Phase|Withdrawal by Subject|0
6037734|NCT00355134|9635160|FG000|Core Phase|Adverse Event|28
6037735|NCT00355134|9635161|FG001|Core Phase|Adverse Event|22
6037736|NCT00355134|9635162|FG002|Core Phase|Adverse Event|16
6037737|NCT00355134|9635163|FG003|Core Phase|Adverse Event|0
6037738|NCT00355134|9635164|FG004|Core Phase|Adverse Event|0
6037739|NCT00355134|9635160|FG000|Core Phase|Lost to Follow-up|17
6037740|NCT00355134|9635161|FG001|Core Phase|Lost to Follow-up|13
6037741|NCT00355134|9635162|FG002|Core Phase|Lost to Follow-up|21
6037742|NCT00355134|9635163|FG003|Core Phase|Lost to Follow-up|0
6037743|NCT00355134|9635164|FG004|Core Phase|Lost to Follow-up|0
6037744|NCT00355134|9635160|FG000|Core Phase|Abnormal laboratory value(s)|19
6037745|NCT00355134|9635161|FG001|Core Phase|Abnormal laboratory value(s)|14
6037746|NCT00355134|9635162|FG002|Core Phase|Abnormal laboratory value(s)|2
6037747|NCT00355134|9635163|FG003|Core Phase|Abnormal laboratory value(s)|0
6037748|NCT00355134|9635164|FG004|Core Phase|Abnormal laboratory value(s)|0
6037749|NCT00355134|9635160|FG000|Core Phase|Unsatisfactory therapeutic effect|10
6037750|NCT00355134|9635161|FG001|Core Phase|Unsatisfactory therapeutic effect|6
6037751|NCT00355134|9635162|FG002|Core Phase|Unsatisfactory therapeutic effect|17
6037752|NCT00355134|9635163|FG003|Core Phase|Unsatisfactory therapeutic effect|0
6037753|NCT00355134|9635164|FG004|Core Phase|Unsatisfactory therapeutic effect|0
6037754|NCT00355134|9635160|FG000|Core Phase|Administrative problems|5
6037755|NCT00355134|9635161|FG001|Core Phase|Administrative problems|3
6037756|NCT00355134|9635162|FG002|Core Phase|Administrative problems|5
6037757|NCT00355134|9635163|FG003|Core Phase|Administrative problems|0
6037758|NCT00355134|9635164|FG004|Core Phase|Administrative problems|0
6037759|NCT00355134|9635160|FG000|Core Phase|Protocol Violation|3
6037760|NCT00355134|9635161|FG001|Core Phase|Protocol Violation|2
6037761|NCT00355134|9635162|FG002|Core Phase|Protocol Violation|2
6037762|NCT00355134|9635163|FG003|Core Phase|Protocol Violation|0
6037763|NCT00355134|9635164|FG004|Core Phase|Protocol Violation|0
6037764|NCT00355134|9635160|FG000|Core Phase|Abnormal test procedure result(s)|1
6037765|NCT00355134|9635161|FG001|Core Phase|Abnormal test procedure result(s)|2
6037766|NCT00355134|9635162|FG002|Core Phase|Abnormal test procedure result(s)|1
6037767|NCT00355134|9635163|FG003|Core Phase|Abnormal test procedure result(s)|0
6037768|NCT00355134|9635164|FG004|Core Phase|Abnormal test procedure result(s)|0
6037769|NCT00355134|9635160|FG000|Core Phase|Condition no longer requires study drug|1
6037770|NCT00355134|9635161|FG001|Core Phase|Condition no longer requires study drug|0
6037771|NCT00355134|9635162|FG002|Core Phase|Condition no longer requires study drug|1
6037772|NCT00355134|9635163|FG003|Core Phase|Condition no longer requires study drug|0
6037773|NCT00355134|9635164|FG004|Core Phase|Condition no longer requires study drug|0
6037774|NCT00355134|9635160|FG000|Extension Phase|Withdrawal by Subject|7
6037775|NCT00355134|9635161|FG001|Extension Phase|Withdrawal by Subject|11
6037776|NCT00355134|9635162|FG002|Extension Phase|Withdrawal by Subject|0
6037777|NCT00355134|9635163|FG003|Extension Phase|Withdrawal by Subject|7
6037778|NCT00355134|9635164|FG004|Extension Phase|Withdrawal by Subject|5
6037779|NCT00355134|9635160|FG000|Extension Phase|Adverse Event|13
6037780|NCT00355134|9635161|FG001|Extension Phase|Adverse Event|9
6037781|NCT00355134|9635162|FG002|Extension Phase|Adverse Event|0
6037782|NCT00355134|9635163|FG003|Extension Phase|Adverse Event|3
6037783|NCT00355134|9635164|FG004|Extension Phase|Adverse Event|5
6037784|NCT00355134|9635160|FG000|Extension Phase|Lost to Follow-up|2
6037785|NCT00355134|9635161|FG001|Extension Phase|Lost to Follow-up|6
6037786|NCT00355134|9635162|FG002|Extension Phase|Lost to Follow-up|0
6037787|NCT00355134|9635163|FG003|Extension Phase|Lost to Follow-up|2
6037788|NCT00355134|9635164|FG004|Extension Phase|Lost to Follow-up|4
6037789|NCT00355134|9635160|FG000|Extension Phase|Abnormal laboratory value(s)|4
6037790|NCT00355134|9635161|FG001|Extension Phase|Abnormal laboratory value(s)|2
6037791|NCT00355134|9635162|FG002|Extension Phase|Abnormal laboratory value(s)|0
6037792|NCT00355134|9635163|FG003|Extension Phase|Abnormal laboratory value(s)|2
6037793|NCT00355134|9635164|FG004|Extension Phase|Abnormal laboratory value(s)|2
6037794|NCT00355134|9635160|FG000|Extension Phase|Administrative problems|2
6037795|NCT00355134|9635161|FG001|Extension Phase|Administrative problems|4
6037796|NCT00355134|9635162|FG002|Extension Phase|Administrative problems|0
6037797|NCT00355134|9635163|FG003|Extension Phase|Administrative problems|1
6037798|NCT00355134|9635164|FG004|Extension Phase|Administrative problems|1
6037799|NCT00355134|9635160|FG000|Extension Phase|Unsatisfactory therapeutic effect|3
6037800|NCT00355134|9635161|FG001|Extension Phase|Unsatisfactory therapeutic effect|4
6037801|NCT00355134|9635162|FG002|Extension Phase|Unsatisfactory therapeutic effect|0
6037802|NCT00355134|9635163|FG003|Extension Phase|Unsatisfactory therapeutic effect|0
6037803|NCT00355134|9635164|FG004|Extension Phase|Unsatisfactory therapeutic effect|1
6037804|NCT00355134|9635160|FG000|Extension Phase|Abnormal test procedure result(s)|0
6037805|NCT00355134|9635161|FG001|Extension Phase|Abnormal test procedure result(s)|1
6037806|NCT00355134|9635162|FG002|Extension Phase|Abnormal test procedure result(s)|0
6037807|NCT00355134|9635163|FG003|Extension Phase|Abnormal test procedure result(s)|0
6037808|NCT00355134|9635164|FG004|Extension Phase|Abnormal test procedure result(s)|1
6037809|NCT00355134|9635160|FG000|Extension Phase|Protocol Violation|0
6037810|NCT00355134|9635161|FG001|Extension Phase|Protocol Violation|0
6037811|NCT00355134|9635162|FG002|Extension Phase|Protocol Violation|0
6037812|NCT00355134|9635163|FG003|Extension Phase|Protocol Violation|1
6037813|NCT00355134|9635164|FG004|Extension Phase|Protocol Violation|0
6037814|NCT00355147|9635176|FG000|Overall Study|Lost to Follow-up|10
6037815|NCT00355147|9635177|FG001|Overall Study|Lost to Follow-up|8
6037816|NCT00355147|9635176|FG000|Overall Study|Withdrawal by Subject|8
6037817|NCT00355147|9635177|FG001|Overall Study|Withdrawal by Subject|12
6037818|NCT00355264|9635196|FG000|Extension (Variable Duration)|Adverse Event|1
6037819|NCT00355264|9635196|FG000|Extension (Variable Duration)|Withdrew Consent|1
6037820|NCT00355342|9635207|FG000|Overall Study|Adverse Event|13
6037821|NCT00355342|9635208|FG001|Overall Study|Adverse Event|15
6037822|NCT00355342|9635207|FG000|Overall Study|Lost to Follow-up|4
6037823|NCT00355342|9635208|FG001|Overall Study|Lost to Follow-up|2
6037824|NCT00355342|9635207|FG000|Overall Study|Withdrawal by Subject|14
6037825|NCT00355342|9635208|FG001|Overall Study|Withdrawal by Subject|11
6037826|NCT00355342|9635207|FG000|Overall Study|Sponsor terminated study|2
6037827|NCT00355342|9635208|FG001|Overall Study|Sponsor terminated study|2
6037828|NCT00355342|9635207|FG000|Overall Study|Overcompliant-PI discretion|1
6037829|NCT00355342|9635208|FG001|Overall Study|Overcompliant-PI discretion|0
6037830|NCT00355342|9635207|FG000|Overall Study|Use of prohibited medication|1
6037831|NCT00355342|9635208|FG001|Overall Study|Use of prohibited medication|0
6037832|NCT00355342|9635207|FG000|Overall Study|COPD exacerbation|1
6037833|NCT00355342|9635208|FG001|Overall Study|COPD exacerbation|1
6037834|NCT00355342|9635207|FG000|Overall Study|Dispensed wrong study drug kit|1
6037835|NCT00355342|9635208|FG001|Overall Study|Dispensed wrong study drug kit|0
6037836|NCT00355342|9635207|FG000|Overall Study|Non-compliance with Dexa scans|1
6037837|NCT00355342|9635208|FG001|Overall Study|Non-compliance with Dexa scans|0
6037838|NCT00355342|9635207|FG000|Overall Study|Withdrawal by participant and physician|1
6037839|NCT00355342|9635208|FG001|Overall Study|Withdrawal by participant and physician|0
6037840|NCT00355342|9635207|FG000|Overall Study|Participant relocated|0
6037841|NCT00355342|9635208|FG001|Overall Study|Participant relocated|1
6037842|NCT00355342|9635207|FG000|Overall Study|Participant discontinued study drug|0
6037843|NCT00355342|9635208|FG001|Overall Study|Participant discontinued study drug|1
6037844|NCT00355342|9635207|FG000|Overall Study|Study management|0
6037845|NCT00355342|9635208|FG001|Overall Study|Study management|1
6037846|NCT00355342|9635207|FG000|Overall Study|Protocol Violation|0
6037847|NCT00355342|9635208|FG001|Overall Study|Protocol Violation|1
6037848|NCT00355342|9635207|FG000|Overall Study|Use of protocol excluded medication|0
6037849|NCT00355342|9635208|FG001|Overall Study|Use of protocol excluded medication|1
6037850|NCT00355368|9635216|FG000|Overall Study|Protocol Violation|8
6037851|NCT00355368|9635217|FG001|Overall Study|Protocol Violation|7
6037852|NCT00355368|9635216|FG000|Overall Study|cardiac arrest prior to intubation|2
6037853|NCT00355368|9635217|FG001|Overall Study|cardiac arrest prior to intubation|2
6037854|NCT00355472|9635234|FG000|Overall Study|Physician Decision|1
6037855|NCT00355615|9635250|FG000|Randomized Double Blind Period|Adverse Event|1
6037856|NCT00355615|9635251|FG001|Randomized Double Blind Period|Adverse Event|0
6037857|NCT00355615|9635252|FG002|Randomized Double Blind Period|Adverse Event|0
6037858|NCT00355615|9635253|FG003|Randomized Double Blind Period|Adverse Event|0
6037859|NCT00355615|9635254|FG004|Randomized Double Blind Period|Adverse Event|0
6037860|NCT00355615|9635250|FG000|Randomized Double Blind Period|Protocol Violation|0
6037861|NCT00355615|9635251|FG001|Randomized Double Blind Period|Protocol Violation|0
6037862|NCT00355615|9635252|FG002|Randomized Double Blind Period|Protocol Violation|1
6037863|NCT00355615|9635253|FG003|Randomized Double Blind Period|Protocol Violation|1
6147291|NCT01081834|9782279|FG003|Extension Period: Week 26 to Week 52|Unable to take rescue therapy|0
6147292|NCT01081834|9782280|FG004|Extension Period: Week 26 to Week 52|Unable to take rescue therapy|0
6147293|NCT01081834|9782276|FG000|Extension Period: Week 26 to Week 52|Creatinine or eGFR withdrawal criteria|1
6147294|NCT01081834|9782277|FG001|Extension Period: Week 26 to Week 52|Creatinine or eGFR withdrawal criteria|4
6147295|NCT01081834|9782278|FG002|Extension Period: Week 26 to Week 52|Creatinine or eGFR withdrawal criteria|0
6147296|NCT01081834|9782279|FG003|Extension Period: Week 26 to Week 52|Creatinine or eGFR withdrawal criteria|0
6147297|NCT01081834|9782280|FG004|Extension Period: Week 26 to Week 52|Creatinine or eGFR withdrawal criteria|0
6147298|NCT01081834|9782276|FG000|Extension Period: Week 26 to Week 52|Other|4
6147299|NCT01081834|9782277|FG001|Extension Period: Week 26 to Week 52|Other|5
6147300|NCT01081834|9782278|FG002|Extension Period: Week 26 to Week 52|Other|4
6147301|NCT01081834|9782279|FG003|Extension Period: Week 26 to Week 52|Other|0
6147302|NCT01081834|9782280|FG004|Extension Period: Week 26 to Week 52|Other|0
6147303|NCT01081834|9782276|FG000|Extension Period: Week 26 to Week 52|Lack of efficacy on rescue therapy|7
6147304|NCT01081834|9782277|FG001|Extension Period: Week 26 to Week 52|Lack of efficacy on rescue therapy|1
6147305|NCT01081834|9782278|FG002|Extension Period: Week 26 to Week 52|Lack of efficacy on rescue therapy|0
6147306|NCT01081834|9782279|FG003|Extension Period: Week 26 to Week 52|Lack of efficacy on rescue therapy|0
6147307|NCT01081834|9782280|FG004|Extension Period: Week 26 to Week 52|Lack of efficacy on rescue therapy|0
6147308|NCT01081834|9782276|FG000|Extension Period: Week 26 to Week 52|Physician Decision|0
6147309|NCT01081834|9782277|FG001|Extension Period: Week 26 to Week 52|Physician Decision|1
6147310|NCT01081834|9782278|FG002|Extension Period: Week 26 to Week 52|Physician Decision|0
6147311|NCT01081834|9782279|FG003|Extension Period: Week 26 to Week 52|Physician Decision|0
6147312|NCT01081834|9782280|FG004|Extension Period: Week 26 to Week 52|Physician Decision|0
6147313|NCT01081873|9782299|FG000|Overall Study|Death|86
6147314|NCT01081873|9782299|FG000|Overall Study|Withdrawal by Subject|10
6147315|NCT01081873|9782299|FG000|Overall Study|Lost to Follow-up|142
6147316|NCT01081873|9782299|FG000|Overall Study|Progression of prostate cancer|13
6147317|NCT01081873|9782299|FG000|Overall Study|Other|47
6147318|NCT01081912|9782328|FG000|Conversion/Titration|Adverse Event|47
6147319|NCT01081912|9782329|FG001|Conversion/Titration|Adverse Event|0
6147320|NCT01081912|9782330|FG002|Conversion/Titration|Adverse Event|0
6147321|NCT01081912|9782328|FG000|Conversion/Titration|Lack of Efficacy|17
6147322|NCT01081912|9782329|FG001|Conversion/Titration|Lack of Efficacy|0
6147323|NCT01081912|9782330|FG002|Conversion/Titration|Lack of Efficacy|0
6147324|NCT01081912|9782328|FG000|Conversion/Titration|Lost to Follow-up|5
6147325|NCT01081912|9782329|FG001|Conversion/Titration|Lost to Follow-up|0
6147326|NCT01081912|9782330|FG002|Conversion/Titration|Lost to Follow-up|0
6147327|NCT01081912|9782328|FG000|Conversion/Titration|Physician Decision|2
6147328|NCT01081912|9782329|FG001|Conversion/Titration|Physician Decision|0
6147329|NCT01081912|9782330|FG002|Conversion/Titration|Physician Decision|0
6037864|NCT00355615|9635254|FG004|Randomized Double Blind Period|Protocol Violation|0
6037865|NCT00355615|9635250|FG000|40-week Rosuvastatin Open Label Period|Adverse Event|0
6037866|NCT00355615|9635251|FG001|40-week Rosuvastatin Open Label Period|Adverse Event|0
6037867|NCT00355615|9635252|FG002|40-week Rosuvastatin Open Label Period|Adverse Event|0
6037868|NCT00355615|9635253|FG003|40-week Rosuvastatin Open Label Period|Adverse Event|0
6037869|NCT00355615|9635254|FG004|40-week Rosuvastatin Open Label Period|Adverse Event|4
6037870|NCT00355615|9635250|FG000|40-week Rosuvastatin Open Label Period|Protocol Violation|0
6037871|NCT00355615|9635251|FG001|40-week Rosuvastatin Open Label Period|Protocol Violation|0
6037872|NCT00355615|9635252|FG002|40-week Rosuvastatin Open Label Period|Protocol Violation|0
6037873|NCT00355615|9635253|FG003|40-week Rosuvastatin Open Label Period|Protocol Violation|0
6037874|NCT00355615|9635254|FG004|40-week Rosuvastatin Open Label Period|Protocol Violation|1
6037875|NCT00355615|9635250|FG000|40-week Rosuvastatin Open Label Period|Withdrawal by Subject|0
6037876|NCT00355615|9635251|FG001|40-week Rosuvastatin Open Label Period|Withdrawal by Subject|0
6037877|NCT00355615|9635252|FG002|40-week Rosuvastatin Open Label Period|Withdrawal by Subject|0
6037878|NCT00355615|9635253|FG003|40-week Rosuvastatin Open Label Period|Withdrawal by Subject|0
6037879|NCT00355615|9635254|FG004|40-week Rosuvastatin Open Label Period|Withdrawal by Subject|3
6037880|NCT00355615|9635250|FG000|40-week Rosuvastatin Open Label Period|investigational site closed|0
6037881|NCT00355615|9635251|FG001|40-week Rosuvastatin Open Label Period|investigational site closed|0
6037882|NCT00355615|9635252|FG002|40-week Rosuvastatin Open Label Period|investigational site closed|0
6037883|NCT00355615|9635253|FG003|40-week Rosuvastatin Open Label Period|investigational site closed|0
6037884|NCT00355615|9635254|FG004|40-week Rosuvastatin Open Label Period|investigational site closed|1
6037885|NCT00355784|9635279|FG000|Overall Study|Withdrawal by Subject|0
6037886|NCT00355784|9635280|FG001|Overall Study|Withdrawal by Subject|0
6037887|NCT00355784|9635281|FG002|Overall Study|Withdrawal by Subject|2
6037888|NCT00356122|9635337|FG000|TREATMENT|Lack of Efficacy|26
6037889|NCT00356122|9635337|FG000|TREATMENT|Adverse Event|10
6037890|NCT00356122|9635337|FG000|TREATMENT|Subject's request|4
6037891|NCT00356122|9635337|FG000|TREATMENT|Other|4
6037892|NCT00356122|9635337|FG000|TREATMENT|Did not receive study medication|1
6037893|NCT00356122|9635337|FG000|FOLLOW-UP|Death|37
6037894|NCT00356122|9635337|FG000|FOLLOW-UP|Lost to Follow-up|2
6037895|NCT00356122|9635337|FG000|FOLLOW-UP|Other|2
6037896|NCT00356135|9635344|FG000|Overall Study|Protocol Violation|1
6309598|NCT02641379|10038349|FG010|Overall Study|Withdrawal of informed consent|0
6309599|NCT02641379|10038339|FG000|Overall Study|Adverse Event|7
6309600|NCT02641379|10038340|FG001|Overall Study|Adverse Event|8
6309601|NCT02641379|10038341|FG002|Overall Study|Adverse Event|2
6037897|NCT00356135|9635345|FG001|Overall Study|Protocol Violation|0
6037898|NCT00356135|9635346|FG002|Overall Study|Protocol Violation|0
6037899|NCT00356135|9635344|FG000|Overall Study|Adverse Event|1
6037900|NCT00356135|9635345|FG001|Overall Study|Adverse Event|0
6037901|NCT00356135|9635346|FG002|Overall Study|Adverse Event|0
6037902|NCT00356135|9635344|FG000|Overall Study|Lost to Follow-up|0
6037903|NCT00356135|9635345|FG001|Overall Study|Lost to Follow-up|0
6037904|NCT00356135|9635346|FG002|Overall Study|Lost to Follow-up|1
6037905|NCT00356135|9635344|FG000|Overall Study|Physician Decision|1
6037906|NCT00356135|9635345|FG001|Overall Study|Physician Decision|1
6037907|NCT00356135|9635346|FG002|Overall Study|Physician Decision|1
6037908|NCT00356135|9635344|FG000|Overall Study|Subject non-compliance|1
6037909|NCT00356135|9635345|FG001|Overall Study|Subject non-compliance|1
6037910|NCT00356135|9635346|FG002|Overall Study|Subject non-compliance|3
6037911|NCT00356148|9635358|FG000|Overall Study|Reoperation within 30 days|2
6037912|NCT00356148|9635359|FG001|Overall Study|Reoperation within 30 days|1
6037913|NCT00356200|9635368|FG000|Cohort 1: 10 ug/ml|Lack of Efficacy|1
6037914|NCT00356200|9635369|FG001|Cohort 1: 10 ug/ml|Lack of Efficacy|0
6037915|NCT00356200|9635368|FG000|Cohort 2: 100 ug/ml (New Patients)|Lack of Efficacy|0
6037916|NCT00356200|9635369|FG001|Cohort 2: 100 ug/ml (New Patients)|Lack of Efficacy|2
6037917|NCT00356265|9635384|FG000|Overall Study|Withdrawal by Subject|0
6037918|NCT00356265|9635385|FG001|Overall Study|Withdrawal by Subject|0
6037919|NCT00356265|9635386|FG002|Overall Study|Withdrawal by Subject|1
6037920|NCT00356278|9635398|FG000|Overall Study|Withdrawal by Subject|25
6037921|NCT00356278|9635399|FG001|Overall Study|Withdrawal by Subject|15
6037922|NCT00356278|9635400|FG002|Overall Study|Withdrawal by Subject|19
6037923|NCT00356369|9635419|FG000|Active Phase|Withdrawal by Subject|2
6037924|NCT00356369|9635420|FG001|Active Phase|Withdrawal by Subject|1
6037925|NCT00356408|9635430|FG000|Overall Study|Adverse Event|9
6037926|NCT00356408|9635430|FG000|Overall Study|Lack of Efficacy|36
6037927|NCT00356408|9635430|FG000|Overall Study|Lost to Follow-up|2
6037928|NCT00356408|9635430|FG000|Overall Study|Withdrawal by Subject|6
6037929|NCT00356408|9635430|FG000|Overall Study|Other: Principal investigator discretion|3
6037930|NCT00356408|9635430|FG000|Overall Study|Other: Sponsor request|1
6037931|NCT00356408|9635430|FG000|Overall Study|Other: Azathioprine stopped|1
6037932|NCT00356408|9635430|FG000|Overall Study|Other: Failed to meet Inc/Exc criteria|1
6037933|NCT00356408|9635430|FG000|Overall Study|Other: Subject chose commerical dosing|1
6037934|NCT00356525|9635455|FG000|Overall Study|Progressive Disease|8
6037935|NCT00356525|9635456|FG001|Overall Study|Progressive Disease|5
6037936|NCT00356525|9635457|FG002|Overall Study|Progressive Disease|4
6037937|NCT00356525|9635458|FG003|Overall Study|Progressive Disease|2
6037938|NCT00356525|9635455|FG000|Overall Study|Adverse Event|1
6309602|NCT02641379|10038342|FG003|Overall Study|Adverse Event|2
6309603|NCT02641379|10038343|FG004|Overall Study|Adverse Event|5
6037939|NCT00356525|9635456|FG001|Overall Study|Adverse Event|3
6037940|NCT00356525|9635457|FG002|Overall Study|Adverse Event|1
6037941|NCT00356525|9635458|FG003|Overall Study|Adverse Event|1
6037942|NCT00356525|9635455|FG000|Overall Study|Lost to Follow-up|1
6037943|NCT00356525|9635456|FG001|Overall Study|Lost to Follow-up|0
6037944|NCT00356525|9635457|FG002|Overall Study|Lost to Follow-up|0
6037945|NCT00356525|9635458|FG003|Overall Study|Lost to Follow-up|0
6037946|NCT00356525|9635455|FG000|Overall Study|Physician Decision|2
6037947|NCT00356525|9635456|FG001|Overall Study|Physician Decision|2
6037948|NCT00356525|9635457|FG002|Overall Study|Physician Decision|2
6037949|NCT00356525|9635458|FG003|Overall Study|Physician Decision|1
6037950|NCT00356525|9635455|FG000|Overall Study|Protocol Entry Criteria Not Met|1
6037951|NCT00356525|9635456|FG001|Overall Study|Protocol Entry Criteria Not Met|0
6037952|NCT00356525|9635457|FG002|Overall Study|Protocol Entry Criteria Not Met|0
6037953|NCT00356525|9635458|FG003|Overall Study|Protocol Entry Criteria Not Met|0
6037954|NCT00356525|9635455|FG000|Overall Study|Withdrawal by Subject|1
6037955|NCT00356525|9635456|FG001|Overall Study|Withdrawal by Subject|1
6037956|NCT00356525|9635457|FG002|Overall Study|Withdrawal by Subject|0
6037957|NCT00356525|9635458|FG003|Overall Study|Withdrawal by Subject|3
6037958|NCT00356525|9635455|FG000|Overall Study|Death|0
6037959|NCT00356525|9635456|FG001|Overall Study|Death|0
6037960|NCT00356525|9635457|FG002|Overall Study|Death|0
6037961|NCT00356525|9635458|FG003|Overall Study|Death|1
6037962|NCT00356525|9635455|FG000|Overall Study|Sponsor Decision|0
6037963|NCT00356525|9635456|FG001|Overall Study|Sponsor Decision|0
6037964|NCT00356525|9635457|FG002|Overall Study|Sponsor Decision|0
6037965|NCT00356525|9635458|FG003|Overall Study|Sponsor Decision|1
6037966|NCT00356590|9635468|FG000|Overall Study|Adverse Event|54
6037967|NCT00356590|9635468|FG000|Overall Study|Death|10
6037968|NCT00356590|9635468|FG000|Overall Study|Lost to Follow-up|35
6037969|NCT00356590|9635468|FG000|Overall Study|Physician Decision|46
6037970|NCT00356590|9635468|FG000|Overall Study|Withdrawal by Subject|41
6037971|NCT00356590|9635468|FG000|Overall Study|Completed month 12 only|2
6037972|NCT00356590|9635468|FG000|Overall Study|Protocol issues|6
6037973|NCT00356590|9635468|FG000|Overall Study|Response status|28
6037974|NCT00356590|9635468|FG000|Overall Study|Other|52
6037975|NCT00356603|9635474|FG000|Overall Study|Other|6
6037976|NCT00356603|9635475|FG001|Overall Study|Other|3
6037977|NCT00356759|9635485|FG000|Overall Study|Death|5
6037978|NCT00356759|9635486|FG001|Overall Study|Death|2
6037979|NCT00356759|9635485|FG000|Overall Study|Withdrawal by Subject|2
6037980|NCT00356759|9635486|FG001|Overall Study|Withdrawal by Subject|2
6037981|NCT00356759|9635485|FG000|Overall Study|Adverse Event|1
6037982|NCT00356759|9635486|FG001|Overall Study|Adverse Event|3
6037983|NCT00356759|9635485|FG000|Overall Study|Lost to Follow-up|1
6037984|NCT00356759|9635486|FG001|Overall Study|Lost to Follow-up|1
6037985|NCT00356759|9635485|FG000|Overall Study|Intercurrent disease or persistent extre|5
6037986|NCT00356759|9635486|FG001|Overall Study|Intercurrent disease or persistent extre|2
6037987|NCT00356811|9635492|FG000|Overall Study|Death|35
6037988|NCT00356811|9635492|FG000|Overall Study|Lost to Follow-up|2
6037989|NCT00356811|9635492|FG000|Overall Study|Withdrawal by Subject|6
6037990|NCT00356811|9635492|FG000|Overall Study|Participant Could Not Make a Checkup|1
6037991|NCT00356811|9635492|FG000|Overall Study|Study Is Terminating|3
6037992|NCT00356811|9635492|FG000|Overall Study|Site Closed during Follow-up|2
6037993|NCT00356863|9635499|FG000|Overall Study|Death|16
6037994|NCT00356863|9635500|FG001|Overall Study|Death|32
6037995|NCT00356863|9635499|FG000|Overall Study|Lost to Follow-up|76
6037996|NCT00356863|9635500|FG001|Overall Study|Lost to Follow-up|43
6037997|NCT00356889|9635510|FG000|Overall Study|Protocol Violation|2
6037998|NCT00356889|9635510|FG000|Overall Study|Adverse Event|1
6037999|NCT00356915|9635518|FG000|Overall Study|Non compliance|1
6038000|NCT00356915|9635519|FG001|Overall Study|Non compliance|2
6038001|NCT00356915|9635520|FG002|Overall Study|Non compliance|1
6038002|NCT00356915|9635518|FG000|Overall Study|Protocol Violation|2
6038003|NCT00356915|9635519|FG001|Overall Study|Protocol Violation|3
6038004|NCT00356915|9635520|FG002|Overall Study|Protocol Violation|2
6038005|NCT00356915|9635518|FG000|Overall Study|Withdrawal by Subject|14
6038006|NCT00356915|9635519|FG001|Overall Study|Withdrawal by Subject|14
6038007|NCT00356915|9635520|FG002|Overall Study|Withdrawal by Subject|10
6038008|NCT00356915|9635518|FG000|Overall Study|Lack of Efficacy|0
6038009|NCT00356915|9635519|FG001|Overall Study|Lack of Efficacy|0
6038010|NCT00356915|9635520|FG002|Overall Study|Lack of Efficacy|3
6038011|NCT00356915|9635518|FG000|Overall Study|Lost to Follow-up|27
6038012|NCT00356915|9635519|FG001|Overall Study|Lost to Follow-up|34
6038013|NCT00356915|9635520|FG002|Overall Study|Lost to Follow-up|14
6038014|NCT00356915|9635518|FG000|Overall Study|Administrative Decision|0
6038015|NCT00356915|9635519|FG001|Overall Study|Administrative Decision|0
6038016|NCT00356915|9635520|FG002|Overall Study|Administrative Decision|1
6038017|NCT00356915|9635518|FG000|Overall Study|Physician Decision|0
6038018|NCT00356915|9635519|FG001|Overall Study|Physician Decision|2
6038019|NCT00356915|9635520|FG002|Overall Study|Physician Decision|0
6038020|NCT00356915|9635518|FG000|Overall Study|Adverse Event|21
6038021|NCT00356915|9635519|FG001|Overall Study|Adverse Event|31
6038022|NCT00356915|9635520|FG002|Overall Study|Adverse Event|8
6038023|NCT00356915|9635518|FG000|Overall Study|Miscellaneous reasons|11
6038024|NCT00356915|9635519|FG001|Overall Study|Miscellaneous reasons|8
6147330|NCT01081912|9782328|FG000|Conversion/Titration|Protocol Violation|67
6147331|NCT01081912|9782329|FG001|Conversion/Titration|Protocol Violation|0
6147332|NCT01081912|9782330|FG002|Conversion/Titration|Protocol Violation|0
6147333|NCT01081912|9782328|FG000|Conversion/Titration|Withdrawal by Subject|23
6147334|NCT01081912|9782329|FG001|Conversion/Titration|Withdrawal by Subject|0
6038025|NCT00356915|9635520|FG002|Overall Study|Miscellaneous reasons|3
6038026|NCT00357006|9635541|FG000|Overall Study|Lost to Follow-up|1
6038027|NCT00357006|9635542|FG001|Overall Study|Lost to Follow-up|2
6038028|NCT00357006|9635543|FG002|Overall Study|Lost to Follow-up|1
6038029|NCT00357006|9635541|FG000|Overall Study|Withdrawal by Subject|1
6038030|NCT00357006|9635542|FG001|Overall Study|Withdrawal by Subject|3
6038031|NCT00357006|9635543|FG002|Overall Study|Withdrawal by Subject|2
6038032|NCT00357097|9635557|FG000|Overall Study|Did not meet inclusion criteria|5
6038033|NCT00357097|9635558|FG001|Overall Study|Did not meet inclusion criteria|3
6038034|NCT00357097|9635557|FG000|Overall Study|Adverse Event|34
6038035|NCT00357097|9635558|FG001|Overall Study|Adverse Event|6
6038036|NCT00357097|9635557|FG000|Overall Study|Withdrawal by Subject|8
6038037|NCT00357097|9635558|FG001|Overall Study|Withdrawal by Subject|7
6147335|NCT01081912|9782330|FG002|Conversion/Titration|Withdrawal by Subject|0
6147336|NCT01081912|9782328|FG000|Conversion/Titration|Non-Compliance|47
6147337|NCT01081912|9782329|FG001|Conversion/Titration|Non-Compliance|0
6147338|NCT01081912|9782330|FG002|Conversion/Titration|Non-Compliance|0
6147339|NCT01081912|9782328|FG000|Maintenance Treatment|Adverse Event|0
6147340|NCT01081912|9782329|FG001|Maintenance Treatment|Adverse Event|2
6147341|NCT01081912|9782330|FG002|Maintenance Treatment|Adverse Event|12
6147342|NCT01081912|9782328|FG000|Maintenance Treatment|Lack of Efficacy|0
6147343|NCT01081912|9782329|FG001|Maintenance Treatment|Lack of Efficacy|14
6147344|NCT01081912|9782330|FG002|Maintenance Treatment|Lack of Efficacy|64
6147345|NCT01081912|9782328|FG000|Maintenance Treatment|Lost to Follow-up|0
6147346|NCT01081912|9782329|FG001|Maintenance Treatment|Lost to Follow-up|1
6038038|NCT00357097|9635557|FG000|Overall Study|Non-compliance|1
6038039|NCT00357097|9635558|FG001|Overall Study|Non-compliance|2
6038040|NCT00357097|9635557|FG000|Overall Study|Lack of Efficacy|2
6038041|NCT00357097|9635558|FG001|Overall Study|Lack of Efficacy|8
6038042|NCT00357097|9635557|FG000|Overall Study|Met Exclusion Criteria|3
6038043|NCT00357097|9635558|FG001|Overall Study|Met Exclusion Criteria|1
6147347|NCT01081912|9782330|FG002|Maintenance Treatment|Lost to Follow-up|0
6147348|NCT01081912|9782328|FG000|Maintenance Treatment|Physician Decision|0
6147349|NCT01081912|9782329|FG001|Maintenance Treatment|Physician Decision|0
6147350|NCT01081912|9782330|FG002|Maintenance Treatment|Physician Decision|1
6147351|NCT01081912|9782328|FG000|Maintenance Treatment|Protocol Violation|0
6147352|NCT01081912|9782329|FG001|Maintenance Treatment|Protocol Violation|1
6147353|NCT01081912|9782330|FG002|Maintenance Treatment|Protocol Violation|2
6147354|NCT01081912|9782328|FG000|Maintenance Treatment|Withdrawal by Subject|0
6147355|NCT01081912|9782329|FG001|Maintenance Treatment|Withdrawal by Subject|5
6147356|NCT01081912|9782330|FG002|Maintenance Treatment|Withdrawal by Subject|5
6147357|NCT01081912|9782328|FG000|Maintenance Treatment|Non-Compliance|0
6147358|NCT01081912|9782329|FG001|Maintenance Treatment|Non-Compliance|4
6147359|NCT01081912|9782330|FG002|Maintenance Treatment|Non-Compliance|7
6147360|NCT01081912|9782328|FG000|Maintenance Treatment|Withdrawal by Medical Monitor|0
6147361|NCT01081912|9782329|FG001|Maintenance Treatment|Withdrawal by Medical Monitor|0
6147362|NCT01081912|9782330|FG002|Maintenance Treatment|Withdrawal by Medical Monitor|1
6147363|NCT01082081|9782340|FG000|Overall Study|Lost to Follow-up|0
6147364|NCT01082081|9782341|FG001|Overall Study|Lost to Follow-up|0
6147365|NCT01082081|9782342|FG002|Overall Study|Lost to Follow-up|1
6147366|NCT01082081|9782340|FG000|Overall Study|Withdrawal by Subject|0
6147367|NCT01082081|9782341|FG001|Overall Study|Withdrawal by Subject|0
6147368|NCT01082081|9782342|FG002|Overall Study|Withdrawal by Subject|1
6147369|NCT01082081|9782340|FG000|Overall Study|Other Reason|0
6147370|NCT01082081|9782341|FG001|Overall Study|Other Reason|1
6147371|NCT01082081|9782342|FG002|Overall Study|Other Reason|0
6147372|NCT01082211|9782355|FG000|Overall Study|Protocol Violation|4
6147373|NCT01082211|9782355|FG000|Overall Study|No protocol treatment received|3
6147374|NCT01082328|9782362|FG000|Overall Study|Adverse Event|1
6147375|NCT01082367|9782368|FG000|Double-blind Period|Administrative problems|0
6147376|NCT01082367|9782369|FG001|Double-blind Period|Administrative problems|1
6147377|NCT01082367|9782368|FG000|Double-blind Period|Lack of Efficacy|5
6147378|NCT01082367|9782369|FG001|Double-blind Period|Lack of Efficacy|11
6147379|NCT01082367|9782368|FG000|Double-blind Period|Adverse Event|0
6147380|NCT01082367|9782369|FG001|Double-blind Period|Adverse Event|1
6038044|NCT00357097|9635557|FG000|Overall Study|Other|1
6038045|NCT00357097|9635558|FG001|Overall Study|Other|1
6147381|NCT01082367|9782368|FG000|Follow-up (F-U) Period|Administrative problems|1
6147382|NCT01082367|9782369|FG001|Follow-up (F-U) Period|Administrative problems|0
6147383|NCT01082367|9782368|FG000|Follow-up (F-U) Period|Abnormal lab values|1
6147384|NCT01082367|9782369|FG001|Follow-up (F-U) Period|Abnormal lab values|0
6147385|NCT01082367|9782368|FG000|Follow-up (F-U) Period|Adverse Event|0
6147386|NCT01082367|9782369|FG001|Follow-up (F-U) Period|Adverse Event|1
6147387|NCT01082614|9782398|FG000|Overall Study|Adverse Event|1
6038046|NCT00357097|9635557|FG000|Overall Study|Increase of RLS Symptoms|0
6038047|NCT00357097|9635558|FG001|Overall Study|Increase of RLS Symptoms|1
6038048|NCT00357110|9635566|FG000|Overall Study|Early study termination|5
6038049|NCT00357110|9635567|FG001|Overall Study|Early study termination|5
6038050|NCT00357370|9635606|FG000|Cohort 2|Lack of Efficacy|0
6038051|NCT00357370|9635607|FG001|Cohort 2|Lack of Efficacy|2
6038052|NCT00357370|9635608|FG002|Cohort 2|Lack of Efficacy|1
6038053|NCT00357370|9635606|FG000|Cohort 2|Adverse Event|1
6038054|NCT00357370|9635607|FG001|Cohort 2|Adverse Event|1
6038055|NCT00357370|9635608|FG002|Cohort 2|Adverse Event|1
6038056|NCT00357370|9635606|FG000|Cohort 2|Lost to Follow-up|0
6038057|NCT00357370|9635607|FG001|Cohort 2|Lost to Follow-up|1
6038058|NCT00357370|9635608|FG002|Cohort 2|Lost to Follow-up|0
6038059|NCT00357370|9635606|FG000|Cohort 2|non-compliance, not met criteria, etc|1
6038060|NCT00357370|9635607|FG001|Cohort 2|non-compliance, not met criteria, etc|1
6038061|NCT00357370|9635608|FG002|Cohort 2|non-compliance, not met criteria, etc|0
6038062|NCT00357370|9635606|FG000|Cohort 2|Withdrawal by Subject|0
6038063|NCT00357370|9635607|FG001|Cohort 2|Withdrawal by Subject|2
6038064|NCT00357370|9635608|FG002|Cohort 2|Withdrawal by Subject|0
6038065|NCT00357396|9635618|FG000|Overall Study|Adverse Event|1
6038066|NCT00357396|9635619|FG001|Overall Study|Adverse Event|0
6038067|NCT00357500|9635624|FG000|Overall Study|Adverse Event|3
6038068|NCT00357500|9635624|FG000|Overall Study|Withdrawal by Subject|5
6038069|NCT00357500|9635624|FG000|Overall Study|Progressive Disease|65
6038070|NCT00357500|9635624|FG000|Overall Study|Not Started Protocol Therapy|4
6038071|NCT00357552|9635628|FG000|Screening|Did not meet eligibility criteria|84
6038072|NCT00357552|9635628|FG000|Weeks 0 to 24|Death|1
6038073|NCT00357552|9635628|FG000|Weeks 24 to 104|Death|3
6038074|NCT00357552|9635628|FG000|Weeks 24 to 104|Not able to get to clinic|2
6038075|NCT00357656|9635638|FG000|Overall Study|Other, No surgery performed|0
6038076|NCT00357656|9635639|FG001|Overall Study|Other, No surgery performed|3
6038077|NCT00357760|9635663|FG000|Overall Study|Disease progression|44
6038078|NCT00357760|9635664|FG001|Overall Study|Disease progression|17
6038079|NCT00357760|9635663|FG000|Overall Study|Adverse Event|10
6038080|NCT00357760|9635664|FG001|Overall Study|Adverse Event|7
6038081|NCT00357760|9635663|FG000|Overall Study|Death|0
6038082|NCT00357760|9635664|FG001|Overall Study|Death|3
6038083|NCT00357760|9635663|FG000|Overall Study|Alternative therapy|1
6038084|NCT00357760|9635664|FG001|Overall Study|Alternative therapy|0
6038085|NCT00357760|9635663|FG000|Overall Study|Withdrawal by Subject|0
6038086|NCT00357760|9635664|FG001|Overall Study|Withdrawal by Subject|2
6038087|NCT00357760|9635663|FG000|Overall Study|Never started treatment|2
6038088|NCT00357760|9635664|FG001|Overall Study|Never started treatment|1
6038089|NCT00357760|9635663|FG000|Overall Study|Ineligible|0
6038090|NCT00357760|9635664|FG001|Overall Study|Ineligible|2
6038091|NCT00357760|9635663|FG000|Overall Study|Physician Decision|2
6038092|NCT00357760|9635664|FG001|Overall Study|Physician Decision|1
6038093|NCT00357760|9635663|FG000|Overall Study|Protocol Violation|0
6038094|NCT00357760|9635664|FG001|Overall Study|Protocol Violation|1
6038095|NCT00357760|9635663|FG000|Overall Study|To receive hospice care|0
6038096|NCT00357760|9635664|FG001|Overall Study|To receive hospice care|1
6038097|NCT00357877|9635672|FG000|Overall Study|Death|2
6038098|NCT00357877|9635673|FG001|Overall Study|Death|1
6038099|NCT00357877|9635672|FG000|Overall Study|Lost to Follow-up|20
6038100|NCT00357877|9635673|FG001|Overall Study|Lost to Follow-up|23
6038101|NCT00357877|9635672|FG000|Overall Study|Withdrawal by Subject|3
6038102|NCT00357877|9635673|FG001|Overall Study|Withdrawal by Subject|3
6038103|NCT00357877|9635672|FG000|Overall Study|Administrative withdrawal|1
6038104|NCT00357877|9635673|FG001|Overall Study|Administrative withdrawal|1
6038105|NCT00357877|9635672|FG000|Overall Study|Other|0
6038106|NCT00357877|9635673|FG001|Overall Study|Other|2
6048892|NCT00420927|9648202|FG003|Period 1|Subject moved/relocated|0
6048893|NCT00420927|9648203|FG004|Period 1|Subject moved/relocated|0
6048894|NCT00420927|9648204|FG005|Period 1|Subject moved/relocated|0
6048895|NCT00420927|9648205|FG006|Period 1|Subject moved/relocated|0
6048896|NCT00420927|9648199|FG000|Period 1|Noncompliant with study drug|1
6048897|NCT00420927|9648200|FG001|Period 1|Noncompliant with study drug|1
6048898|NCT00420927|9648201|FG002|Period 1|Noncompliant with study drug|0
6048899|NCT00420927|9648202|FG003|Period 1|Noncompliant with study drug|0
6048900|NCT00420927|9648203|FG004|Period 1|Noncompliant with study drug|0
6048901|NCT00420927|9648204|FG005|Period 1|Noncompliant with study drug|0
6048902|NCT00420927|9648205|FG006|Period 1|Noncompliant with study drug|0
6048903|NCT00420927|9648199|FG000|Period 1|Randomization error|1
6048904|NCT00420927|9648200|FG001|Period 1|Randomization error|0
6048905|NCT00420927|9648201|FG002|Period 1|Randomization error|0
6048906|NCT00420927|9648202|FG003|Period 1|Randomization error|0
6048907|NCT00420927|9648203|FG004|Period 1|Randomization error|0
6048908|NCT00420927|9648204|FG005|Period 1|Randomization error|0
6048909|NCT00420927|9648205|FG006|Period 1|Randomization error|0
6048910|NCT00420927|9648199|FG000|Period 1|Suspected tuberculosis/positive test|1
6048911|NCT00420927|9648200|FG001|Period 1|Suspected tuberculosis/positive test|1
6048912|NCT00420927|9648201|FG002|Period 1|Suspected tuberculosis/positive test|0
6048913|NCT00420927|9648202|FG003|Period 1|Suspected tuberculosis/positive test|0
6048914|NCT00420927|9648203|FG004|Period 1|Suspected tuberculosis/positive test|0
6048915|NCT00420927|9648204|FG005|Period 1|Suspected tuberculosis/positive test|0
6048916|NCT00420927|9648205|FG006|Period 1|Suspected tuberculosis/positive test|0
6048917|NCT00420927|9648199|FG000|Period 1|Study site closure|0
6048918|NCT00420927|9648200|FG001|Period 1|Study site closure|1
6038107|NCT00357903|9635683|FG000|Overall Study|Adverse Event|87
6038108|NCT00357903|9635684|FG001|Overall Study|Adverse Event|4
6038109|NCT00357903|9635683|FG000|Overall Study|Death|33
6038110|NCT00357903|9635684|FG001|Overall Study|Death|0
6038111|NCT00357903|9635683|FG000|Overall Study|Lost to Follow-up|23
6038112|NCT00357903|9635684|FG001|Overall Study|Lost to Follow-up|4
6038113|NCT00357903|9635683|FG000|Overall Study|Physician Decision|39
6038114|NCT00357903|9635684|FG001|Overall Study|Physician Decision|5
6038115|NCT00357903|9635683|FG000|Overall Study|Withdrawal by Subject|57
6038116|NCT00357903|9635684|FG001|Overall Study|Withdrawal by Subject|7
6038117|NCT00357903|9635683|FG000|Overall Study|Completed month 12 only|0
6038118|NCT00357903|9635684|FG001|Overall Study|Completed month 12 only|1
6038119|NCT00357903|9635683|FG000|Overall Study|Protocol issues|14
6038120|NCT00357903|9635684|FG001|Overall Study|Protocol issues|3
6038121|NCT00357903|9635683|FG000|Overall Study|Response status|61
6038122|NCT00357903|9635684|FG001|Overall Study|Response status|9
6038123|NCT00357903|9635683|FG000|Overall Study|Other|49
6038124|NCT00357903|9635684|FG001|Overall Study|Other|10
6038125|NCT00357968|9635702|FG000|First Maintenance Dose Phase|Not a PCI patient|47
6038126|NCT00357968|9635703|FG001|First Maintenance Dose Phase|Not a PCI patient|42
6038127|NCT00357968|9635702|FG000|First Maintenance Dose Phase|Withdrawal by Subject|1
6038128|NCT00357968|9635703|FG001|First Maintenance Dose Phase|Withdrawal by Subject|2
6038129|NCT00357994|9635726|FG000|Overall Study|Adverse Event|1
6038130|NCT00357994|9635727|FG001|Overall Study|Adverse Event|2
6038131|NCT00357994|9635726|FG000|Overall Study|Lack of Efficacy|0
6038132|NCT00357994|9635727|FG001|Overall Study|Lack of Efficacy|1
6038133|NCT00357994|9635726|FG000|Overall Study|Protocol Violation|1
6038134|NCT00357994|9635727|FG001|Overall Study|Protocol Violation|0
6038135|NCT00358150|9635737|FG000|Overall Study|Adverse Event|3
6038136|NCT00358150|9635737|FG000|Overall Study|Withdrawal by Subject|1
6038137|NCT00358150|9635737|FG000|Overall Study|Undefined|3
6038138|NCT00358215|9635746|FG000|Overall Study|Ineligibility determined|4
6038139|NCT00358215|9635747|FG001|Overall Study|Ineligibility determined|3
6038140|NCT00358215|9635746|FG000|Overall Study|Adverse Event|83
6038141|NCT00358215|9635747|FG001|Overall Study|Adverse Event|65
6038142|NCT00358215|9635746|FG000|Overall Study|Withdrawal by Subject|111
6038143|NCT00358215|9635747|FG001|Overall Study|Withdrawal by Subject|102
6038144|NCT00358215|9635746|FG000|Overall Study|Participant request|65
6038145|NCT00358215|9635747|FG001|Overall Study|Participant request|64
6038146|NCT00358215|9635746|FG000|Overall Study|Physician Decision|47
6038147|NCT00358215|9635747|FG001|Overall Study|Physician Decision|39
6038148|NCT00358215|9635746|FG000|Overall Study|Lost to Follow-up|16
6038149|NCT00358215|9635747|FG001|Overall Study|Lost to Follow-up|22
6038150|NCT00358215|9635746|FG000|Overall Study|Death|265
6038151|NCT00358215|9635747|FG001|Overall Study|Death|281
6147388|NCT01082614|9782399|FG001|Overall Study|Adverse Event|4
6147389|NCT01082614|9782398|FG000|Overall Study|Equipment Malfunction|0
6147390|NCT01082614|9782399|FG001|Overall Study|Equipment Malfunction|1
6147391|NCT01082614|9782398|FG000|Overall Study|Physician Decision|2
6147392|NCT01082614|9782399|FG001|Overall Study|Physician Decision|0
6147393|NCT01082640|9782408|FG000|Overall Study|Adverse Event|9
6147394|NCT01082640|9782409|FG001|Overall Study|Adverse Event|5
6147395|NCT01082640|9782410|FG002|Overall Study|Adverse Event|3
6147396|NCT01082640|9782408|FG000|Overall Study|Withdrawal by Subject|3
6147397|NCT01082640|9782409|FG001|Overall Study|Withdrawal by Subject|3
6147398|NCT01082640|9782410|FG002|Overall Study|Withdrawal by Subject|2
6147399|NCT01082640|9782408|FG000|Overall Study|Major protocol deviation|3
6147400|NCT01082640|9782409|FG001|Overall Study|Major protocol deviation|3
6147401|NCT01082640|9782410|FG002|Overall Study|Major protocol deviation|0
6147402|NCT01082640|9782408|FG000|Overall Study|Lost to Follow-up|0
6147403|NCT01082640|9782409|FG001|Overall Study|Lost to Follow-up|3
6147404|NCT01082640|9782410|FG002|Overall Study|Lost to Follow-up|0
6147405|NCT01082640|9782408|FG000|Overall Study|Other|2
6147406|NCT01082640|9782409|FG001|Overall Study|Other|1
6147407|NCT01082640|9782410|FG002|Overall Study|Other|3
6147408|NCT01082874|9782425|FG000|Overall Study|Lost to Follow-up|10
6147409|NCT01082874|9782426|FG001|Overall Study|Lost to Follow-up|10
6147410|NCT01082874|9782427|FG002|Overall Study|Lost to Follow-up|6
6147411|NCT01082874|9782428|FG003|Overall Study|Lost to Follow-up|10
6147412|NCT01082874|9782425|FG000|Overall Study|Withdrawal by Subject|1
6038152|NCT00358215|9635746|FG000|Overall Study|Protocol Violation|64
6038153|NCT00358215|9635747|FG001|Overall Study|Protocol Violation|59
6038154|NCT00358215|9635746|FG000|Overall Study|Pregnancy|1
6147413|NCT01082874|9782426|FG001|Overall Study|Withdrawal by Subject|2
6147414|NCT01082874|9782427|FG002|Overall Study|Withdrawal by Subject|5
6147415|NCT01082874|9782428|FG003|Overall Study|Withdrawal by Subject|3
6147416|NCT01082965|9782453|FG000|Overall Study|Protocol Violation|0
6147417|NCT01082965|9782454|FG001|Overall Study|Protocol Violation|1
6147418|NCT01082965|9782453|FG000|Overall Study|Other|1
6147419|NCT01082965|9782454|FG001|Overall Study|Other|1
6147420|NCT01083121|9782460|FG000|Overall Study|Use of Humira outside the approved label|81
6147421|NCT01083160|9782468|FG000|Overall Study|Adverse Event|1
6038155|NCT00358215|9635747|FG001|Overall Study|Pregnancy|0
6038156|NCT00358215|9635746|FG000|Overall Study|Other|21
6038157|NCT00358215|9635747|FG001|Overall Study|Other|14
6038158|NCT00358215|9635746|FG000|Overall Study|Did not receive investigational product|2
6038159|NCT00358215|9635747|FG001|Overall Study|Did not receive investigational product|3
6038160|NCT00358436|9635772|FG000|Overall Study|Adverse Event|29
6038161|NCT00358436|9635773|FG001|Overall Study|Adverse Event|13
6038162|NCT00358436|9635772|FG000|Overall Study|Lack of Efficacy|34
6038163|NCT00358436|9635773|FG001|Overall Study|Lack of Efficacy|36
6038164|NCT00358436|9635772|FG000|Overall Study|Lost to Follow-up|11
6038165|NCT00358436|9635773|FG001|Overall Study|Lost to Follow-up|6
6038166|NCT00358436|9635772|FG000|Overall Study|Protocol Violation|8
6038167|NCT00358436|9635773|FG001|Overall Study|Protocol Violation|3
6038168|NCT00358436|9635772|FG000|Overall Study|Withdrawal by Subject|40
6038169|NCT00358436|9635773|FG001|Overall Study|Withdrawal by Subject|17
6038170|NCT00358436|9635772|FG000|Overall Study|Non-fulfilment of inclusion/exclusion|4
6038171|NCT00358436|9635773|FG001|Overall Study|Non-fulfilment of inclusion/exclusion|0
6038172|NCT00358436|9635772|FG000|Overall Study|COPD exacerbation|22
6038173|NCT00358436|9635773|FG001|Overall Study|COPD exacerbation|10
6038174|NCT00358436|9635772|FG000|Overall Study|Other|6
6038175|NCT00358436|9635773|FG001|Overall Study|Other|1
6038176|NCT00358449|9635784|FG000|Overall Study|Adverse Event|1
6038177|NCT00358449|9635785|FG001|Overall Study|Adverse Event|0
6038178|NCT00358449|9635786|FG002|Overall Study|Adverse Event|1
6038179|NCT00358449|9635784|FG000|Overall Study|Lost to Follow-up|1
6038180|NCT00358449|9635785|FG001|Overall Study|Lost to Follow-up|0
6038181|NCT00358449|9635786|FG002|Overall Study|Lost to Follow-up|0
6038182|NCT00358449|9635784|FG000|Overall Study|Withdrawal by Subject|2
6038183|NCT00358449|9635785|FG001|Overall Study|Withdrawal by Subject|0
6038184|NCT00358449|9635786|FG002|Overall Study|Withdrawal by Subject|0
6038185|NCT00358449|9635784|FG000|Overall Study|Lack of Efficacy|0
6038186|NCT00358449|9635785|FG001|Overall Study|Lack of Efficacy|1
6038187|NCT00358449|9635786|FG002|Overall Study|Lack of Efficacy|0
6038188|NCT00358449|9635784|FG000|Overall Study|Steriod Inhaler was Increased|0
6038189|NCT00358449|9635785|FG001|Overall Study|Steriod Inhaler was Increased|0
6038190|NCT00358449|9635786|FG002|Overall Study|Steriod Inhaler was Increased|1
6038191|NCT00358644|9635834|FG000|Overall Study|Progressive Disease|21
6038192|NCT00358644|9635834|FG000|Overall Study|Adverse Event|7
6038193|NCT00358644|9635834|FG000|Overall Study|Death|11
6147422|NCT01083173|9782472|FG000|Main Surveillance: Safety Group|Violation of inclusion/exclusion crit.|14
6147423|NCT01083173|9782473|FG001|Main Surveillance: Safety Group|Violation of inclusion/exclusion crit.|0
6147424|NCT01083173|9782472|FG000|Main Surveillance: Safety Group|Violation of the use/dosage|1
6147425|NCT01083173|9782473|FG001|Main Surveillance: Safety Group|Violation of the use/dosage|0
6147426|NCT01083173|9782472|FG000|Main Surveillance: Effectiveness Group|No follow-up at 24 ±4 wks|201
6147427|NCT01083173|9782473|FG001|Main Surveillance: Effectiveness Group|No follow-up at 24 ±4 wks|0
6147428|NCT01083173|9782472|FG000|Main Surveillance: Effectiveness Group|No viral load data at 24 ±4 wks|168
6147429|NCT01083173|9782473|FG001|Main Surveillance: Effectiveness Group|No viral load data at 24 ±4 wks|0
6147430|NCT01083173|9782472|FG000|Main Surveillance: Effectiveness Group|Administration of Kaletra <24 wks|13
6147431|NCT01083173|9782473|FG001|Main Surveillance: Effectiveness Group|Administration of Kaletra <24 wks|0
6147432|NCT01083173|9782472|FG000|Long-term Surveillance: Safety Group|Violation of inclusion/exclusion crit.|0
6147433|NCT01083173|9782473|FG001|Long-term Surveillance: Safety Group|Violation of inclusion/exclusion crit.|14
6147434|NCT01083173|9782472|FG000|Long-term Surveillance: Safety Group|Violation of the dosage|0
6147435|NCT01083173|9782473|FG001|Long-term Surveillance: Safety Group|Violation of the dosage|1
6147436|NCT01083173|9782472|FG000|Long-term Surveillance: Safety Group|Administration of Kaletra <20 wks|0
6147437|NCT01083173|9782473|FG001|Long-term Surveillance: Safety Group|Administration of Kaletra <20 wks|101
6147438|NCT01083173|9782472|FG000|Long-term Surveillance: Effectiveness Gr|No follow-up at 48 ±4 wks|0
6147439|NCT01083173|9782473|FG001|Long-term Surveillance: Effectiveness Gr|No follow-up at 48 ±4 wks|195
6147440|NCT01083173|9782472|FG000|Long-term Surveillance: Effectiveness Gr|No viral load data at 48 ±4 wks|0
6147441|NCT01083173|9782473|FG001|Long-term Surveillance: Effectiveness Gr|No viral load data at 48 ±4 wks|136
6147442|NCT01083173|9782472|FG000|Long-term Surveillance: Effectiveness Gr|Administration of Kaletra <48 wks|0
6147443|NCT01083173|9782473|FG001|Long-term Surveillance: Effectiveness Gr|Administration of Kaletra <48 wks|46
6147444|NCT01083186|9782482|FG000|Overall Study|Lost to Follow-up|48
6147445|NCT01083186|9782482|FG000|Overall Study|Consent Withdrawal|7
6147446|NCT01083186|9782482|FG000|Overall Study|Death|3
6147447|NCT01083186|9782482|FG000|Overall Study|Adverse Event|3
6147448|NCT01083186|9782482|FG000|Overall Study|Lack of Efficacy|2
6147449|NCT01083186|9782482|FG000|Overall Study|Hemodialysis Initiation|28
6147450|NCT01083186|9782482|FG000|Overall Study|Administrative Reasons|2
6147451|NCT01083186|9782482|FG000|Overall Study|Non-compliance to Study Treatment|1
6147452|NCT01083316|9782511|FG000|Overall Study|Adverse Event|2
6038194|NCT00358644|9635834|FG000|Overall Study|Withdrawal by Subject|4
6147453|NCT01083316|9782511|FG000|Overall Study|Withdrawal by Subject|1
6147454|NCT01083485|9782531|FG000|Overall Study|Adverse Event|0
6038195|NCT00358644|9635834|FG000|Overall Study|Physician Decision|6
6038196|NCT00358644|9635834|FG000|Overall Study|Patient not eligible for study|1
6038197|NCT00358670|9635844|FG000|Overall Study|Adverse Event|26
6038198|NCT00358670|9635845|FG001|Overall Study|Adverse Event|29
6038199|NCT00358670|9635844|FG000|Overall Study|Lack of Efficacy|20
6038200|NCT00358670|9635845|FG001|Overall Study|Lack of Efficacy|23
6038201|NCT00358670|9635844|FG000|Overall Study|Protocol Violation|6
6038202|NCT00358670|9635845|FG001|Overall Study|Protocol Violation|9
6038203|NCT00358670|9635844|FG000|Overall Study|Lost to Follow-up|4
6038204|NCT00358670|9635845|FG001|Overall Study|Lost to Follow-up|5
6038205|NCT00358670|9635844|FG000|Overall Study|Withdrawal by Subject|13
6038206|NCT00358670|9635845|FG001|Overall Study|Withdrawal by Subject|24
6038207|NCT00358670|9635844|FG000|Overall Study|Protocol Defined Clinical Event|0
6038208|NCT00358670|9635845|FG001|Overall Study|Protocol Defined Clinical Event|1
6038209|NCT00358670|9635844|FG000|Overall Study|Did Not Meet Protocol Eligibility|0
6038210|NCT00358670|9635845|FG001|Overall Study|Did Not Meet Protocol Eligibility|3
6038211|NCT00358670|9635844|FG000|Overall Study|Administrative|153
6038212|NCT00358670|9635845|FG001|Overall Study|Administrative|125
6038213|NCT00358826|9635864|FG000|Core Study|Adverse Event|1
6038214|NCT00358826|9635865|FG001|Core Study|Adverse Event|3
6038215|NCT00358826|9635866|FG002|Core Study|Adverse Event|1
6038216|NCT00358826|9635867|FG003|Core Study|Adverse Event|1
6038217|NCT00358826|9635868|FG004|Core Study|Adverse Event|0
6147455|NCT01083485|9782532|FG001|Overall Study|Adverse Event|1
6147456|NCT01083485|9782531|FG000|Overall Study|Protocol Violation|1
6147457|NCT01083485|9782532|FG001|Overall Study|Protocol Violation|0
6147458|NCT01083485|9782531|FG000|Overall Study|Withdrawal by Subject|5
6147459|NCT01083485|9782532|FG001|Overall Study|Withdrawal by Subject|2
6147460|NCT01083485|9782531|FG000|Overall Study|Other|1
6147461|NCT01083485|9782532|FG001|Overall Study|Other|0
6147462|NCT01083576|9782542|FG000|Overall Study|Treatment Failure|6
6147463|NCT01083576|9782543|FG001|Overall Study|Treatment Failure|1
6147464|NCT01083602|9782550|FG000|Overall Study|Adverse Event|11
6147465|NCT01083602|9782550|FG000|Overall Study|New Cancer Therapy|2
6147466|NCT01083602|9782550|FG000|Overall Study|Death|1
6147467|NCT01083602|9782550|FG000|Overall Study|Withdrawal by Subject|5
6147468|NCT01083602|9782550|FG000|Overall Study|Lack of Efficacy|36
6147469|NCT01083641|9782563|FG000|Overall Study|Withdrawal by Subject|2
6147470|NCT01083680|9782580|FG000|Overall Study|Lost to Follow-up|2758
6147471|NCT01083680|9782580|FG000|Overall Study|Withdrawal by Subject|1086
6147472|NCT01083693|9782587|FG000|Overall Study|Adverse Event|1
6147473|NCT01083693|9782588|FG001|Overall Study|Adverse Event|1
6147474|NCT01083693|9782589|FG002|Overall Study|Adverse Event|0
6147475|NCT01083693|9782587|FG000|Overall Study|Lost to Follow-up|2
6147476|NCT01083693|9782588|FG001|Overall Study|Lost to Follow-up|0
6147477|NCT01083693|9782589|FG002|Overall Study|Lost to Follow-up|2
6147478|NCT01083693|9782587|FG000|Overall Study|Lack of effectiveness|13
6147479|NCT01083693|9782588|FG001|Overall Study|Lack of effectiveness|2
6147480|NCT01083693|9782589|FG002|Overall Study|Lack of effectiveness|2
6147481|NCT01083693|9782587|FG000|Overall Study|Patient Moved|0
6147482|NCT01083693|9782588|FG001|Overall Study|Patient Moved|1
6147483|NCT01083693|9782589|FG002|Overall Study|Patient Moved|0
6147484|NCT01083693|9782587|FG000|Overall Study|Complete remission|0
6147485|NCT01083693|9782588|FG001|Overall Study|Complete remission|1
6147486|NCT01083693|9782589|FG002|Overall Study|Complete remission|0
6147487|NCT01083693|9782587|FG000|Overall Study|Other medical condition/surgery|1
6147488|NCT01083693|9782588|FG001|Overall Study|Other medical condition/surgery|1
6147489|NCT01083693|9782589|FG002|Overall Study|Other medical condition/surgery|0
6147490|NCT01083693|9782587|FG000|Overall Study|Withdrawal by Subject|3
6147491|NCT01083693|9782588|FG001|Overall Study|Withdrawal by Subject|0
6147492|NCT01083693|9782589|FG002|Overall Study|Withdrawal by Subject|2
6147493|NCT01083693|9782587|FG000|Overall Study|Reason unknown|0
6147494|NCT01083693|9782588|FG001|Overall Study|Reason unknown|0
6147495|NCT01083693|9782589|FG002|Overall Study|Reason unknown|1
6147496|NCT01083810|9782628|FG000|Overall Study|Lost to Follow-up|23
6147497|NCT01083810|9782629|FG001|Overall Study|Lost to Follow-up|11
6147498|NCT01083810|9782630|FG002|Overall Study|Lost to Follow-up|4
6147499|NCT01083810|9782628|FG000|Overall Study|Adverse Event|15
6147500|NCT01083810|9782629|FG001|Overall Study|Adverse Event|11
6147501|NCT01083810|9782630|FG002|Overall Study|Adverse Event|4
6147502|NCT01083810|9782628|FG000|Overall Study|Withdrawal by Subject|7
6147503|NCT01083810|9782629|FG001|Overall Study|Withdrawal by Subject|2
6147504|NCT01083810|9782630|FG002|Overall Study|Withdrawal by Subject|4
6147505|NCT01083810|9782628|FG000|Overall Study|Reason not reported|6
6147506|NCT01083810|9782629|FG001|Overall Study|Reason not reported|1
6147507|NCT01083810|9782630|FG002|Overall Study|Reason not reported|1
6147508|NCT01083810|9782628|FG000|Overall Study|Non-compliance|4
6147509|NCT01083810|9782629|FG001|Overall Study|Non-compliance|7
6147510|NCT01083810|9782630|FG002|Overall Study|Non-compliance|2
6147511|NCT01083810|9782628|FG000|Overall Study|Simplification|4
6038218|NCT00358826|9635869|FG005|Core Study|Adverse Event|0
6038219|NCT00358826|9635870|FG006|Core Study|Adverse Event|0
6147512|NCT01083810|9782629|FG001|Overall Study|Simplification|1
6147513|NCT01083810|9782630|FG002|Overall Study|Simplification|0
6147514|NCT01083810|9782628|FG000|Overall Study|Death|2
6147515|NCT01083810|9782629|FG001|Overall Study|Death|2
6147516|NCT01083810|9782630|FG002|Overall Study|Death|3
6147517|NCT01083810|9782628|FG000|Overall Study|Co-morbidities|1
6038220|NCT00358826|9635871|FG007|Core Study|Adverse Event|0
6038221|NCT00358826|9635864|FG000|Core Study|Withdrawal by Subject|2
6038222|NCT00358826|9635865|FG001|Core Study|Withdrawal by Subject|2
6038223|NCT00358826|9635866|FG002|Core Study|Withdrawal by Subject|0
6147518|NCT01083810|9782629|FG001|Overall Study|Co-morbidities|0
6147519|NCT01083810|9782630|FG002|Overall Study|Co-morbidities|0
6038224|NCT00358826|9635867|FG003|Core Study|Withdrawal by Subject|0
6038225|NCT00358826|9635868|FG004|Core Study|Withdrawal by Subject|0
6038226|NCT00358826|9635869|FG005|Core Study|Withdrawal by Subject|0
6038227|NCT00358826|9635870|FG006|Core Study|Withdrawal by Subject|0
6038228|NCT00358826|9635871|FG007|Core Study|Withdrawal by Subject|0
6038229|NCT00358826|9635864|FG000|Core Study|Lost to Follow-up|0
6038230|NCT00358826|9635865|FG001|Core Study|Lost to Follow-up|0
6038231|NCT00358826|9635866|FG002|Core Study|Lost to Follow-up|0
6038232|NCT00358826|9635867|FG003|Core Study|Lost to Follow-up|1
6038233|NCT00358826|9635868|FG004|Core Study|Lost to Follow-up|0
6038234|NCT00358826|9635869|FG005|Core Study|Lost to Follow-up|0
6038235|NCT00358826|9635870|FG006|Core Study|Lost to Follow-up|0
6038236|NCT00358826|9635871|FG007|Core Study|Lost to Follow-up|0
6038237|NCT00358826|9635864|FG000|Core Study|Physician Decision|0
6038238|NCT00358826|9635865|FG001|Core Study|Physician Decision|0
6038239|NCT00358826|9635866|FG002|Core Study|Physician Decision|1
6038240|NCT00358826|9635867|FG003|Core Study|Physician Decision|0
6038241|NCT00358826|9635868|FG004|Core Study|Physician Decision|0
6038242|NCT00358826|9635869|FG005|Core Study|Physician Decision|0
6038243|NCT00358826|9635870|FG006|Core Study|Physician Decision|0
6038244|NCT00358826|9635871|FG007|Core Study|Physician Decision|0
6038245|NCT00358826|9635864|FG000|MDCT Substudy|Adverse Event|0
6038246|NCT00358826|9635865|FG001|MDCT Substudy|Adverse Event|0
6038247|NCT00358826|9635866|FG002|MDCT Substudy|Adverse Event|0
6038248|NCT00358826|9635867|FG003|MDCT Substudy|Adverse Event|0
6038249|NCT00358826|9635868|FG004|MDCT Substudy|Adverse Event|1
6038250|NCT00358826|9635869|FG005|MDCT Substudy|Adverse Event|0
6038251|NCT00358826|9635870|FG006|MDCT Substudy|Adverse Event|0
6038252|NCT00358826|9635871|FG007|MDCT Substudy|Adverse Event|0
6038253|NCT00358826|9635864|FG000|MDCT Substudy|Lost to Follow-up|0
6038254|NCT00358826|9635865|FG001|MDCT Substudy|Lost to Follow-up|0
6038255|NCT00358826|9635866|FG002|MDCT Substudy|Lost to Follow-up|0
6038256|NCT00358826|9635867|FG003|MDCT Substudy|Lost to Follow-up|0
6038257|NCT00358826|9635868|FG004|MDCT Substudy|Lost to Follow-up|0
6038258|NCT00358826|9635869|FG005|MDCT Substudy|Lost to Follow-up|1
6038259|NCT00358826|9635870|FG006|MDCT Substudy|Lost to Follow-up|0
6038260|NCT00358826|9635871|FG007|MDCT Substudy|Lost to Follow-up|0
6038261|NCT00358826|9635864|FG000|MDCT Substudy|Withdrawal by Subject|0
6038262|NCT00358826|9635865|FG001|MDCT Substudy|Withdrawal by Subject|0
6038263|NCT00358826|9635866|FG002|MDCT Substudy|Withdrawal by Subject|0
6038264|NCT00358826|9635867|FG003|MDCT Substudy|Withdrawal by Subject|0
6038265|NCT00358826|9635868|FG004|MDCT Substudy|Withdrawal by Subject|0
6038266|NCT00358826|9635869|FG005|MDCT Substudy|Withdrawal by Subject|1
6038267|NCT00358826|9635870|FG006|MDCT Substudy|Withdrawal by Subject|0
6038268|NCT00358826|9635871|FG007|MDCT Substudy|Withdrawal by Subject|0
6038269|NCT00358917|9635887|FG000|Overall Study|Adverse Event|14
6038270|NCT00358917|9635888|FG001|Overall Study|Adverse Event|21
6038271|NCT00358917|9635887|FG000|Overall Study|Withdrawal by Subject|5
6038272|NCT00358917|9635888|FG001|Overall Study|Withdrawal by Subject|7
6038273|NCT00358917|9635887|FG000|Overall Study|Lost to Follow-up|20
6038274|NCT00358917|9635888|FG001|Overall Study|Lost to Follow-up|17
6038275|NCT00358917|9635887|FG000|Overall Study|Noncompliance|12
6038276|NCT00358917|9635888|FG001|Overall Study|Noncompliance|11
6038277|NCT00358917|9635887|FG000|Overall Study|Death|2
6038278|NCT00358917|9635888|FG001|Overall Study|Death|3
6038279|NCT00358917|9635887|FG000|Overall Study|Virologic failure|11
6038280|NCT00358917|9635888|FG001|Overall Study|Virologic failure|8
6038281|NCT00358917|9635887|FG000|Overall Study|Unable to Continue Participation|2
6038282|NCT00358917|9635888|FG001|Overall Study|Unable to Continue Participation|2
6038283|NCT00358956|9635896|FG000|Overall Study|Adverse Event|3
6038284|NCT00358956|9635896|FG000|Overall Study|condition under investigation worsened|4
6038285|NCT00358956|9635896|FG000|Overall Study|Withdrawal by Subject|1
6038286|NCT00359021|9635902|FG000|Overall Study|Adverse Event|26
6038287|NCT00359021|9635903|FG001|Overall Study|Adverse Event|8
6038288|NCT00359021|9635902|FG000|Overall Study|Subject Non-Compliant|1
6038289|NCT00359021|9635903|FG001|Overall Study|Subject Non-Compliant|2
6038290|NCT00359021|9635902|FG000|Overall Study|Subject Ineligible To Continue The Trial|1
6038291|NCT00359021|9635903|FG001|Overall Study|Subject Ineligible To Continue The Trial|0
6038292|NCT00359021|9635902|FG000|Overall Study|Subject Reached A Virologic Endpoint|45
6038293|NCT00359021|9635903|FG001|Overall Study|Subject Reached A Virologic Endpoint|32
6038294|NCT00359021|9635902|FG000|Overall Study|Withdrawal by Subject|2
6038295|NCT00359021|9635903|FG001|Overall Study|Withdrawal by Subject|9
6038296|NCT00359021|9635902|FG000|Overall Study|Lost to Follow-up|1
6038297|NCT00359021|9635903|FG001|Overall Study|Lost to Follow-up|0
6038298|NCT00359021|9635902|FG000|Overall Study|Other|4
6038299|NCT00359021|9635903|FG001|Overall Study|Other|1
6038300|NCT00359021|9635902|FG000|Overall Study|Pregnancy|1
6038301|NCT00359021|9635903|FG001|Overall Study|Pregnancy|0
6038302|NCT00359073|9635913|FG000|Overall Study|Withdrawal by Subject|1
6038303|NCT00359073|9635914|FG001|Overall Study|Withdrawal by Subject|1
6038304|NCT00359073|9635913|FG000|Overall Study|Eligibility criteria no longer met|3
6038305|NCT00359073|9635914|FG001|Overall Study|Eligibility criteria no longer met|0
6038306|NCT00359073|9635913|FG000|Overall Study|developed RV16 antibody|0
6038307|NCT00359073|9635914|FG001|Overall Study|developed RV16 antibody|1
6038308|NCT00359281|9635940|FG000|Overall Study|Adverse Event|1
6038309|NCT00359281|9635941|FG001|Overall Study|Adverse Event|0
6038310|NCT00359281|9635942|FG002|Overall Study|Adverse Event|0
6038311|NCT00359281|9635943|FG003|Overall Study|Adverse Event|0
6038312|NCT00359281|9635944|FG004|Overall Study|Adverse Event|0
6038313|NCT00359281|9635945|FG005|Overall Study|Adverse Event|0
6038314|NCT00359281|9635946|FG006|Overall Study|Adverse Event|1
6038315|NCT00359281|9635947|FG007|Overall Study|Adverse Event|0
6038316|NCT00359281|9635948|FG008|Overall Study|Adverse Event|0
6038317|NCT00359281|9635940|FG000|Overall Study|Withdrawal by Subject|0
6038318|NCT00359281|9635941|FG001|Overall Study|Withdrawal by Subject|0
6038319|NCT00359281|9635942|FG002|Overall Study|Withdrawal by Subject|0
6038320|NCT00359281|9635943|FG003|Overall Study|Withdrawal by Subject|0
6038321|NCT00359281|9635944|FG004|Overall Study|Withdrawal by Subject|0
6038322|NCT00359281|9635945|FG005|Overall Study|Withdrawal by Subject|0
6038323|NCT00359281|9635946|FG006|Overall Study|Withdrawal by Subject|1
6038324|NCT00359281|9635947|FG007|Overall Study|Withdrawal by Subject|0
6038325|NCT00359281|9635948|FG008|Overall Study|Withdrawal by Subject|0
6038326|NCT00359294|9635980|FG000|Overall Study|Progressive disease|1
6038327|NCT00359294|9635981|FG001|Overall Study|Progressive disease|1
6038328|NCT00359294|9635982|FG002|Overall Study|Progressive disease|2
6038329|NCT00359294|9635983|FG003|Overall Study|Progressive disease|3
6038330|NCT00359294|9635984|FG004|Overall Study|Progressive disease|2
6038331|NCT00359294|9635980|FG000|Overall Study|Withdrawal by Subject|0
6038332|NCT00359294|9635981|FG001|Overall Study|Withdrawal by Subject|0
6038333|NCT00359294|9635982|FG002|Overall Study|Withdrawal by Subject|0
6038334|NCT00359294|9635983|FG003|Overall Study|Withdrawal by Subject|0
6038335|NCT00359294|9635984|FG004|Overall Study|Withdrawal by Subject|1
6038336|NCT00359294|9635980|FG000|Overall Study|Not treated|0
6038337|NCT00359294|9635981|FG001|Overall Study|Not treated|0
6038338|NCT00359294|9635982|FG002|Overall Study|Not treated|0
6038339|NCT00359294|9635983|FG003|Overall Study|Not treated|1
6038340|NCT00359294|9635984|FG004|Overall Study|Not treated|0
6038341|NCT00359294|9635980|FG000|Overall Study|Physician Decision|0
6038342|NCT00359294|9635981|FG001|Overall Study|Physician Decision|0
6038343|NCT00359294|9635982|FG002|Overall Study|Physician Decision|1
6147520|NCT01083810|9782628|FG000|Overall Study|Participation in study|1
6147521|NCT01083810|9782629|FG001|Overall Study|Participation in study|0
6147522|NCT01083810|9782630|FG002|Overall Study|Participation in study|0
6147523|NCT01083810|9782628|FG000|Overall Study|Therapy break|1
6147524|NCT01083810|9782629|FG001|Overall Study|Therapy break|2
6147525|NCT01083810|9782630|FG002|Overall Study|Therapy break|2
6147526|NCT01083810|9782628|FG000|Overall Study|Virologic failure|1
6147527|NCT01083810|9782629|FG001|Overall Study|Virologic failure|8
6147528|NCT01083810|9782630|FG002|Overall Study|Virologic failure|0
6147529|NCT01084005|9782667|FG000|Overall Study|Adverse Event|1
6147530|NCT01084005|9782668|FG001|Overall Study|Adverse Event|8
6147531|NCT01084005|9782667|FG000|Overall Study|Protocol Violation|3
6147532|NCT01084005|9782668|FG001|Overall Study|Protocol Violation|7
6147533|NCT01084005|9782667|FG000|Overall Study|Withdrawal by Subject|1
6147534|NCT01084005|9782668|FG001|Overall Study|Withdrawal by Subject|1
6147535|NCT01084083|9782674|FG000|Overall Study|Adverse Event|5
6147536|NCT01084083|9782674|FG000|Overall Study|Death|1
6147537|NCT01084083|9782674|FG000|Overall Study|Withdrawal by Subject|2
6147538|NCT01084083|9782674|FG000|Overall Study|Complicating disease|1
6147539|NCT01084083|9782674|FG000|Overall Study|Other|2
6147540|NCT01084083|9782674|FG000|Overall Study|Never started assigned therapy|1
6147541|NCT01084135|9782683|FG000|20 Week|Physician Decision|0
6147542|NCT01084135|9782684|FG001|20 Week|Physician Decision|1
6147543|NCT01084174|9782705|FG000|Overall Study|gastrointestinal symptoms|1
6147544|NCT01084174|9782706|FG001|Overall Study|gastrointestinal symptoms|1
6147545|NCT01084174|9782705|FG000|Overall Study|Eosinophilic esophagitis|0
6147546|NCT01084174|9782706|FG001|Overall Study|Eosinophilic esophagitis|1
6147547|NCT01084174|9782705|FG000|Overall Study|Anaphylaxis|0
6147548|NCT01084174|9782706|FG001|Overall Study|Anaphylaxis|1
6147549|NCT01084174|9782705|FG000|Overall Study|Participant noncompliance|0
6147550|NCT01084174|9782706|FG001|Overall Study|Participant noncompliance|1
6147551|NCT01084239|9782714|FG000|28-Day Follow-up|Lost to Follow-up|4
6147552|NCT01084239|9782715|FG001|28-Day Follow-up|Lost to Follow-up|9
6147553|NCT01084538|9782759|FG000|Overall Study|Drug not available|30
6147554|NCT01084538|9782759|FG000|Overall Study|Adverse Event|9
6147555|NCT01084538|9782759|FG000|Overall Study|Kidney transplant|6
6147556|NCT01084538|9782759|FG000|Overall Study|Serious Adverse Event|3
6147557|NCT01084538|9782759|FG000|Overall Study|Lack of effectiveness|2
6147558|NCT01084538|9782759|FG000|Overall Study|Patient noncompliance|2
6147559|NCT01084538|9782759|FG000|Overall Study|Hyperphosphatemia|2
6147560|NCT01084538|9782759|FG000|Overall Study|Nodular hyperplasia of parathyroid gland|2
6038344|NCT00359294|9635983|FG003|Overall Study|Physician Decision|0
6038345|NCT00359294|9635984|FG004|Overall Study|Physician Decision|0
6147561|NCT01084538|9782759|FG000|Overall Study|Change of residence|2
6038346|NCT00359424|9635994|FG000|Overall Study|Death|99
6038347|NCT00359424|9635995|FG001|Overall Study|Death|58
6038348|NCT00359424|9635994|FG000|Overall Study|Lost to Follow-up|19
6038349|NCT00359424|9635995|FG001|Overall Study|Lost to Follow-up|7
6038350|NCT00359424|9635994|FG000|Overall Study|Withdrawal by Subject|10
6038351|NCT00359424|9635995|FG001|Overall Study|Withdrawal by Subject|2
6038352|NCT00359424|9635994|FG000|Overall Study|follow up not conducted|2
6038353|NCT00359424|9635995|FG001|Overall Study|follow up not conducted|0
6038354|NCT00359619|9636008|FG000|Overall Study|Adverse Event|0
6038355|NCT00359619|9636009|FG001|Overall Study|Adverse Event|0
6038356|NCT00359619|9636010|FG002|Overall Study|Adverse Event|1
6038357|NCT00359619|9636011|FG003|Overall Study|Adverse Event|0
6038358|NCT00359619|9636012|FG004|Overall Study|Adverse Event|0
6038359|NCT00359619|9636013|FG005|Overall Study|Adverse Event|0
6038360|NCT00359619|9636014|FG006|Overall Study|Adverse Event|1
6038361|NCT00359619|9636008|FG000|Overall Study|Withdrawal by Subject|3
6038362|NCT00359619|9636009|FG001|Overall Study|Withdrawal by Subject|1
6038363|NCT00359619|9636010|FG002|Overall Study|Withdrawal by Subject|4
6038364|NCT00359619|9636011|FG003|Overall Study|Withdrawal by Subject|2
6038365|NCT00359619|9636012|FG004|Overall Study|Withdrawal by Subject|2
6038366|NCT00359619|9636013|FG005|Overall Study|Withdrawal by Subject|0
6147562|NCT01084538|9782759|FG000|Overall Study|Over-suppression of parathyroid gland|2
6147563|NCT01084538|9782759|FG000|Overall Study|Reason unknown|8
6147564|NCT01084551|9782766|FG000|Overall Study|Adverse Event|2
6147565|NCT01084551|9782767|FG001|Overall Study|Adverse Event|9
6147566|NCT01084551|9782768|FG002|Overall Study|Adverse Event|4
6147567|NCT01084551|9782766|FG000|Overall Study|Lack of Efficacy|2
6147568|NCT01084551|9782767|FG001|Overall Study|Lack of Efficacy|0
6147569|NCT01084551|9782768|FG002|Overall Study|Lack of Efficacy|1
6147570|NCT01084551|9782766|FG000|Overall Study|Withdrawal by Subject|2
6147571|NCT01084551|9782767|FG001|Overall Study|Withdrawal by Subject|1
6147572|NCT01084551|9782768|FG002|Overall Study|Withdrawal by Subject|0
6147573|NCT01084551|9782766|FG000|Overall Study|Protocol Violation|2
6147574|NCT01084551|9782767|FG001|Overall Study|Protocol Violation|4
6147575|NCT01084551|9782768|FG002|Overall Study|Protocol Violation|0
6147576|NCT01084551|9782766|FG000|Overall Study|Lost to Follow-up|0
6147577|NCT01084551|9782767|FG001|Overall Study|Lost to Follow-up|0
6147578|NCT01084551|9782768|FG002|Overall Study|Lost to Follow-up|3
6147579|NCT01084551|9782766|FG000|Overall Study|Physician Decision|1
6147580|NCT01084551|9782767|FG001|Overall Study|Physician Decision|0
6147581|NCT01084551|9782768|FG002|Overall Study|Physician Decision|0
6147582|NCT01084603|9782776|FG000|Baseline|Withdrawal by Subject|2
6147583|NCT01084603|9782776|FG000|NiQuitinTM Lozenge|Withdrawal by Subject|1
6147584|NCT01084603|9782776|FG000|Nicorette® Gum|Withdrawal by Subject|1
6147585|NCT01084603|9782776|FG000|Oral Nicotine 1|Withdrawal by Subject|1
6147586|NCT01084603|9782776|FG000|Washout Period 4|Adverse Event|1
6147587|NCT01084655|9782792|FG000|Overall Study|Radiographic disease progression|3
6147588|NCT01084655|9782793|FG001|Overall Study|Radiographic disease progression|2
6147589|NCT01084655|9782794|FG002|Overall Study|Radiographic disease progression|8
6147590|NCT01084655|9782792|FG000|Overall Study|Withdrawal by Subject|1
6147591|NCT01084655|9782793|FG001|Overall Study|Withdrawal by Subject|0
6147592|NCT01084655|9782794|FG002|Overall Study|Withdrawal by Subject|4
6147593|NCT01084655|9782792|FG000|Overall Study|Adverse Event|2
6147594|NCT01084655|9782793|FG001|Overall Study|Adverse Event|1
6147595|NCT01084655|9782794|FG002|Overall Study|Adverse Event|2
6147596|NCT01084655|9782792|FG000|Overall Study|Other|0
6147597|NCT01084655|9782793|FG001|Overall Study|Other|3
6147598|NCT01084655|9782794|FG002|Overall Study|Other|2
6147599|NCT01084655|9782792|FG000|Overall Study|Symptomatic deterioration|0
6147600|NCT01084655|9782793|FG001|Overall Study|Symptomatic deterioration|0
6147601|NCT01084655|9782794|FG002|Overall Study|Symptomatic deterioration|2
6147602|NCT01084655|9782792|FG000|Overall Study|Prostate-specificAntigen(PSA)progression|0
6147603|NCT01084655|9782793|FG001|Overall Study|Prostate-specificAntigen(PSA)progression|0
6147604|NCT01084655|9782794|FG002|Overall Study|Prostate-specificAntigen(PSA)progression|1
6147605|NCT01084668|9782806|FG000|Overall Study|Lack of Efficacy|5
6147606|NCT01084668|9782806|FG000|Overall Study|Withdrawal by Subject|2
6147607|NCT01084668|9782806|FG000|Overall Study|Pregnancy|1
6147608|NCT01084668|9782806|FG000|Overall Study|Non-compliance|1
6147609|NCT01084694|9782814|FG000|Overall Study|Withdrawal by Subject|2
6147610|NCT01084694|9782815|FG001|Overall Study|Withdrawal by Subject|1
6147611|NCT01084694|9782814|FG000|Overall Study|Death|2
6147612|NCT01084694|9782815|FG001|Overall Study|Death|12
6147613|NCT01084694|9782814|FG000|Overall Study|eligibility not maintained|2
6147614|NCT01084694|9782815|FG001|Overall Study|eligibility not maintained|7
6147615|NCT01084707|9782829|FG000|Overall Study|Withdrawal by Subject|6
6147616|NCT01084772|9782847|FG000|Baseline|Withdrawal by Subject|7
6147617|NCT01084772|9782848|FG001|Baseline|Withdrawal by Subject|6
6147618|NCT01084772|9782847|FG000|3 Months|Death|1
6147619|NCT01084772|9782848|FG001|3 Months|Death|0
6147620|NCT01084772|9782847|FG000|3 Months|Study Termination|2
6147621|NCT01084772|9782848|FG001|3 Months|Study Termination|2
6147622|NCT01084772|9782847|FG000|1 Year|Withdrawal by Subject|0
6038367|NCT00359619|9636014|FG006|Overall Study|Withdrawal by Subject|3
6038368|NCT00359619|9636008|FG000|Overall Study|Other|1
6147623|NCT01084772|9782848|FG001|1 Year|Withdrawal by Subject|1
6147624|NCT01084772|9782847|FG000|1 Year|Lost to Follow-up|3
6147625|NCT01084772|9782848|FG001|1 Year|Lost to Follow-up|0
6147626|NCT01084772|9782847|FG000|1 Year|Study Termination|0
6147627|NCT01084772|9782848|FG001|1 Year|Study Termination|7
6038369|NCT00359619|9636009|FG001|Overall Study|Other|0
6038370|NCT00359619|9636010|FG002|Overall Study|Other|0
6038371|NCT00359619|9636011|FG003|Overall Study|Other|0
6038372|NCT00359619|9636012|FG004|Overall Study|Other|0
6038373|NCT00359619|9636013|FG005|Overall Study|Other|0
6038374|NCT00359619|9636014|FG006|Overall Study|Other|0
6038375|NCT00359619|9636008|FG000|Overall Study|Lost to Follow-up|4
6038376|NCT00359619|9636009|FG001|Overall Study|Lost to Follow-up|4
6038377|NCT00359619|9636010|FG002|Overall Study|Lost to Follow-up|2
6038378|NCT00359619|9636011|FG003|Overall Study|Lost to Follow-up|1
6038379|NCT00359619|9636012|FG004|Overall Study|Lost to Follow-up|1
6038380|NCT00359619|9636013|FG005|Overall Study|Lost to Follow-up|5
6038381|NCT00359619|9636014|FG006|Overall Study|Lost to Follow-up|0
6038382|NCT00359632|9636032|FG000|Overall Study|Death|2
6038383|NCT00359632|9636033|FG001|Overall Study|Death|0
6038384|NCT00359632|9636032|FG000|Overall Study|Adverse Event|1
6038385|NCT00359632|9636033|FG001|Overall Study|Adverse Event|0
6038386|NCT00359632|9636032|FG000|Overall Study|Non-compliance with visit schedule|1
6038387|NCT00359632|9636033|FG001|Overall Study|Non-compliance with visit schedule|0
6038388|NCT00359762|9636052|FG000|Period II|Adverse Event|17
6038389|NCT00359762|9636053|FG001|Period II|Adverse Event|0
6038390|NCT00359762|9636054|FG002|Period II|Adverse Event|0
6038391|NCT00359762|9636055|FG003|Period II|Adverse Event|0
6038392|NCT00359762|9636056|FG004|Period II|Adverse Event|49
6038393|NCT00359762|9636052|FG000|Period II|Protocol Violation|18
6038394|NCT00359762|9636053|FG001|Period II|Protocol Violation|0
6038395|NCT00359762|9636054|FG002|Period II|Protocol Violation|0
6038396|NCT00359762|9636055|FG003|Period II|Protocol Violation|0
6038397|NCT00359762|9636056|FG004|Period II|Protocol Violation|11
6038398|NCT00359762|9636052|FG000|Period II|Physician Decision|17
6038399|NCT00359762|9636053|FG001|Period II|Physician Decision|0
6038400|NCT00359762|9636054|FG002|Period II|Physician Decision|0
6038401|NCT00359762|9636055|FG003|Period II|Physician Decision|0
6038402|NCT00359762|9636056|FG004|Period II|Physician Decision|23
6038403|NCT00359762|9636052|FG000|Period II|Death|2
6038404|NCT00359762|9636053|FG001|Period II|Death|0
6038405|NCT00359762|9636054|FG002|Period II|Death|0
6038406|NCT00359762|9636055|FG003|Period II|Death|0
6038407|NCT00359762|9636056|FG004|Period II|Death|4
6038408|NCT00359762|9636052|FG000|Period II|Lack of Efficacy|11
6038409|NCT00359762|9636053|FG001|Period II|Lack of Efficacy|0
6038410|NCT00359762|9636054|FG002|Period II|Lack of Efficacy|0
6038411|NCT00359762|9636055|FG003|Period II|Lack of Efficacy|0
6038412|NCT00359762|9636056|FG004|Period II|Lack of Efficacy|8
6038413|NCT00359762|9636052|FG000|Period II|Lost to follow up|5
6038414|NCT00359762|9636053|FG001|Period II|Lost to follow up|0
6038415|NCT00359762|9636054|FG002|Period II|Lost to follow up|0
6038416|NCT00359762|9636055|FG003|Period II|Lost to follow up|0
6038417|NCT00359762|9636056|FG004|Period II|Lost to follow up|5
6038418|NCT00359762|9636052|FG000|Period II|Entry Criteria Not Met|8
6038419|NCT00359762|9636053|FG001|Period II|Entry Criteria Not Met|0
6038420|NCT00359762|9636054|FG002|Period II|Entry Criteria Not Met|0
6038421|NCT00359762|9636055|FG003|Period II|Entry Criteria Not Met|0
6038422|NCT00359762|9636056|FG004|Period II|Entry Criteria Not Met|4
6038423|NCT00359762|9636052|FG000|Period II|Subject Decision|50
6038424|NCT00359762|9636053|FG001|Period II|Subject Decision|0
6038425|NCT00359762|9636054|FG002|Period II|Subject Decision|0
6038426|NCT00359762|9636055|FG003|Period II|Subject Decision|0
6038427|NCT00359762|9636056|FG004|Period II|Subject Decision|70
6038428|NCT00359762|9636052|FG000|Period III|Protocol Violation|0
6038429|NCT00359762|9636053|FG001|Period III|Protocol Violation|5
6038430|NCT00359762|9636054|FG002|Period III|Protocol Violation|3
6038431|NCT00359762|9636055|FG003|Period III|Protocol Violation|8
6038432|NCT00359762|9636056|FG004|Period III|Protocol Violation|0
6038433|NCT00359762|9636052|FG000|Period III|Adverse Event|0
6038434|NCT00359762|9636053|FG001|Period III|Adverse Event|3
6038435|NCT00359762|9636054|FG002|Period III|Adverse Event|4
6038436|NCT00359762|9636055|FG003|Period III|Adverse Event|10
6038437|NCT00359762|9636056|FG004|Period III|Adverse Event|0
6038438|NCT00359762|9636052|FG000|Period III|Physician Decision|0
6038439|NCT00359762|9636053|FG001|Period III|Physician Decision|5
6038440|NCT00359762|9636054|FG002|Period III|Physician Decision|9
6038441|NCT00359762|9636055|FG003|Period III|Physician Decision|15
6038442|NCT00359762|9636056|FG004|Period III|Physician Decision|0
6038443|NCT00359762|9636052|FG000|Period III|Lack of Efficacy|0
6038444|NCT00359762|9636053|FG001|Period III|Lack of Efficacy|7
6038445|NCT00359762|9636054|FG002|Period III|Lack of Efficacy|5
6038446|NCT00359762|9636055|FG003|Period III|Lack of Efficacy|9
6038447|NCT00359762|9636056|FG004|Period III|Lack of Efficacy|0
6038448|NCT00359762|9636052|FG000|Period III|Lost to follow up|0
6038449|NCT00359762|9636053|FG001|Period III|Lost to follow up|1
6038450|NCT00359762|9636054|FG002|Period III|Lost to follow up|1
6038451|NCT00359762|9636055|FG003|Period III|Lost to follow up|2
6038452|NCT00359762|9636056|FG004|Period III|Lost to follow up|0
6038453|NCT00359762|9636052|FG000|Period III|Entry Criteria Not Met|0
6038454|NCT00359762|9636053|FG001|Period III|Entry Criteria Not Met|1
6038455|NCT00359762|9636054|FG002|Period III|Entry Criteria Not Met|0
6038456|NCT00359762|9636055|FG003|Period III|Entry Criteria Not Met|1
6038457|NCT00359762|9636056|FG004|Period III|Entry Criteria Not Met|0
6038458|NCT00359762|9636052|FG000|Period III|Subject Decision|0
6038459|NCT00359762|9636053|FG001|Period III|Subject Decision|7
6038460|NCT00359762|9636054|FG002|Period III|Subject Decision|8
6038461|NCT00359762|9636055|FG003|Period III|Subject Decision|20
6147628|NCT01084772|9782847|FG000|2 Years|Withdrawal by Subject|1
6147629|NCT01084772|9782848|FG001|2 Years|Withdrawal by Subject|0
6147630|NCT01084772|9782847|FG000|2 Years|Lost to Follow-up|5
6147631|NCT01084772|9782848|FG001|2 Years|Lost to Follow-up|2
6147632|NCT01084772|9782847|FG000|2 Years|Study Termination|3
6147633|NCT01084772|9782848|FG001|2 Years|Study Termination|2
6147634|NCT01085045|9782863|FG000|Part A|Withdrawal by Subject|4
6147635|NCT01085045|9782863|FG000|Part A|Adverse Event|6
6147636|NCT01085045|9782863|FG000|Part A|Protocol Violation|1
6147637|NCT01085045|9782863|FG000|Part A|Protocol Specified Criteria|7
6147638|NCT01085045|9782863|FG000|Part B|Withdrawal by Subject|2
6147639|NCT01085045|9782863|FG000|Part B|Protocol Specified Criteria|6
6147640|NCT01085045|9782863|FG000|Part B|Lost to Follow-up|1
6147641|NCT01085045|9782863|FG000|Part B|Adverse Event|6
6147642|NCT01085136|9782883|FG000|Part A|Other Adverse event|223
6147643|NCT01085136|9782884|FG001|Part A|Other Adverse event|0
6147644|NCT01085136|9782885|FG002|Part A|Other Adverse event|0
6147645|NCT01085136|9782883|FG000|Part A|Protocol Violation|3
6147646|NCT01085136|9782884|FG001|Part A|Protocol Violation|0
6147647|NCT01085136|9782885|FG002|Part A|Protocol Violation|0
6147648|NCT01085136|9782883|FG000|Part A|Lost to Follow-up|3
6147649|NCT01085136|9782884|FG001|Part A|Lost to Follow-up|0
6147650|NCT01085136|9782885|FG002|Part A|Lost to Follow-up|0
6147651|NCT01085136|9782883|FG000|Part A|Refusal to continue trial medication|64
6147652|NCT01085136|9782884|FG001|Part A|Refusal to continue trial medication|0
6147653|NCT01085136|9782885|FG002|Part A|Refusal to continue trial medication|0
6147654|NCT01085136|9782883|FG000|Part A|Other reason not defined above|30
6147655|NCT01085136|9782884|FG001|Part A|Other reason not defined above|0
6147656|NCT01085136|9782885|FG002|Part A|Other reason not defined above|0
6038462|NCT00359762|9636056|FG004|Period III|Subject Decision|0
6147657|NCT01085136|9782883|FG000|Part B|Other AE|0
6147658|NCT01085136|9782884|FG001|Part B|Other AE|29
6147659|NCT01085136|9782885|FG002|Part B|Other AE|8
6147660|NCT01085136|9782883|FG000|Part B|Refusal to continue trial medication|0
6147661|NCT01085136|9782884|FG001|Part B|Refusal to continue trial medication|12
6147662|NCT01085136|9782885|FG002|Part B|Refusal to continue trial medication|7
6147663|NCT01085136|9782883|FG000|Part B|Not treated|0
6147664|NCT01085136|9782884|FG001|Part B|Not treated|4
6147665|NCT01085136|9782885|FG002|Part B|Not treated|8
6147666|NCT01085136|9782883|FG000|Part B|Other reason not defined above|0
6147667|NCT01085136|9782884|FG001|Part B|Other reason not defined above|6
6147668|NCT01085136|9782885|FG002|Part B|Other reason not defined above|3
6147669|NCT01085201|9782900|FG000|Overall Study|Scheduling conflict|1
6147670|NCT01085201|9782901|FG001|Overall Study|Scheduling conflict|0
6147671|NCT01085201|9782902|FG002|Overall Study|Scheduling conflict|1
6147672|NCT01085201|9782903|FG003|Overall Study|Scheduling conflict|0
6147673|NCT01085201|9782904|FG004|Overall Study|Scheduling conflict|0
6147674|NCT01085201|9782900|FG000|Overall Study|Unknown- no study drug|2
6147675|NCT01085201|9782901|FG001|Overall Study|Unknown- no study drug|0
6147676|NCT01085201|9782902|FG002|Overall Study|Unknown- no study drug|0
6147677|NCT01085201|9782903|FG003|Overall Study|Unknown- no study drug|0
6147678|NCT01085201|9782904|FG004|Overall Study|Unknown- no study drug|0
6147679|NCT01085201|9782900|FG000|Overall Study|Fond ineligible after consent|0
6147680|NCT01085201|9782901|FG001|Overall Study|Fond ineligible after consent|1
6147681|NCT01085201|9782902|FG002|Overall Study|Fond ineligible after consent|1
6147682|NCT01085201|9782903|FG003|Overall Study|Fond ineligible after consent|0
6147683|NCT01085201|9782904|FG004|Overall Study|Fond ineligible after consent|0
6147684|NCT01085214|9782921|FG000|Overall Study|Alternate treatment required|1
6147685|NCT01085357|9782953|FG000|Overall Study|Adverse Event|1
6147686|NCT01085357|9782954|FG001|Overall Study|Adverse Event|1
6147687|NCT01085357|9782953|FG000|Overall Study|Subject Decision|4
6147688|NCT01085357|9782954|FG001|Overall Study|Subject Decision|3
6147689|NCT01085357|9782953|FG000|Overall Study|Investigator Decision|1
6147690|NCT01085357|9782954|FG001|Overall Study|Investigator Decision|1
6147691|NCT01085357|9782953|FG000|Overall Study|Death|11
6147692|NCT01085357|9782954|FG001|Overall Study|Death|1
6147693|NCT01085357|9782953|FG000|Overall Study|Lost to Follow-up|2
6147694|NCT01085357|9782954|FG001|Overall Study|Lost to Follow-up|0
6147695|NCT01085591|9782985|FG000|Overall Study|Adverse Event|0
6147696|NCT01085591|9782986|FG001|Overall Study|Adverse Event|1
6147697|NCT01085591|9782987|FG002|Overall Study|Adverse Event|3
6147698|NCT01085591|9782985|FG000|Overall Study|Physician Decision|1
6147699|NCT01085591|9782986|FG001|Overall Study|Physician Decision|0
6147700|NCT01085591|9782987|FG002|Overall Study|Physician Decision|1
6147701|NCT01085591|9782985|FG000|Overall Study|Withdrawal by Subject|0
6147702|NCT01085591|9782986|FG001|Overall Study|Withdrawal by Subject|2
6147703|NCT01085591|9782987|FG002|Overall Study|Withdrawal by Subject|1
6147704|NCT01085591|9782985|FG000|Overall Study|Lost to Follow-up|0
6147705|NCT01085591|9782986|FG001|Overall Study|Lost to Follow-up|1
6147706|NCT01085591|9782987|FG002|Overall Study|Lost to Follow-up|1
6147707|NCT01085591|9782985|FG000|Overall Study|Protocol Violation|1
6147708|NCT01085591|9782986|FG001|Overall Study|Protocol Violation|1
6147709|NCT01085591|9782987|FG002|Overall Study|Protocol Violation|1
6147710|NCT01085591|9782985|FG000|Overall Study|Other|0
6147711|NCT01085591|9782986|FG001|Overall Study|Other|1
6038463|NCT00359788|9636072|FG000|Overall Study|Adverse Event|11
6038464|NCT00359788|9636073|FG001|Overall Study|Adverse Event|10
6038465|NCT00359788|9636072|FG000|Overall Study|Lack of Efficacy|1
6038466|NCT00359788|9636073|FG001|Overall Study|Lack of Efficacy|2
6038467|NCT00359788|9636072|FG000|Overall Study|Lost to Follow-up|3
6038468|NCT00359788|9636073|FG001|Overall Study|Lost to Follow-up|2
6038469|NCT00359788|9636072|FG000|Overall Study|Withdrawal by Subject|4
6038470|NCT00359788|9636073|FG001|Overall Study|Withdrawal by Subject|1
6038471|NCT00359788|9636072|FG000|Overall Study|Protocol Violation|4
6038472|NCT00359788|9636073|FG001|Overall Study|Protocol Violation|2
6038473|NCT00359801|9636081|FG000|Overall Study|Lost to Follow-up|72
6038474|NCT00359801|9636082|FG001|Overall Study|Lost to Follow-up|58
6038475|NCT00359801|9636081|FG000|Overall Study|Withdrawal by Subject|143
6038476|NCT00359801|9636082|FG001|Overall Study|Withdrawal by Subject|96
6038477|NCT00359801|9636081|FG000|Overall Study|Other|66
6038478|NCT00359801|9636082|FG001|Overall Study|Other|46
6038479|NCT00359801|9636081|FG000|Overall Study|Final Status Unknown: missing data|7
6038480|NCT00359801|9636082|FG001|Overall Study|Final Status Unknown: missing data|4
6038481|NCT00359801|9636081|FG000|Overall Study|Sponsor Decision|17
6038482|NCT00359801|9636082|FG001|Overall Study|Sponsor Decision|16
6038483|NCT00360230|9636138|FG000|Overall Study|Withdrawal by Subject|1
6038484|NCT00360230|9636139|FG001|Overall Study|Withdrawal by Subject|1
6038485|NCT00360230|9636140|FG002|Overall Study|Withdrawal by Subject|0
6038486|NCT00360230|9636141|FG003|Overall Study|Withdrawal by Subject|1
6038487|NCT00360230|9636142|FG004|Overall Study|Withdrawal by Subject|1
6038488|NCT00360230|9636143|FG005|Overall Study|Withdrawal by Subject|1
6038489|NCT00360230|9636144|FG006|Overall Study|Withdrawal by Subject|0
6038490|NCT00360230|9636138|FG000|Overall Study|Migrated|4
6038491|NCT00360230|9636139|FG001|Overall Study|Migrated|1
6038492|NCT00360230|9636140|FG002|Overall Study|Migrated|3
6038493|NCT00360230|9636141|FG003|Overall Study|Migrated|1
6038494|NCT00360230|9636142|FG004|Overall Study|Migrated|4
6038495|NCT00360230|9636143|FG005|Overall Study|Migrated|1
6038496|NCT00360230|9636144|FG006|Overall Study|Migrated|1
6038497|NCT00360230|9636138|FG000|Overall Study|Other|1
6038498|NCT00360230|9636139|FG001|Overall Study|Other|0
6038499|NCT00360230|9636140|FG002|Overall Study|Other|0
6038500|NCT00360230|9636141|FG003|Overall Study|Other|0
6038501|NCT00360230|9636142|FG004|Overall Study|Other|0
6038502|NCT00360230|9636143|FG005|Overall Study|Other|0
6038503|NCT00360230|9636144|FG006|Overall Study|Other|0
6038504|NCT00360230|9636138|FG000|Overall Study|Protocol Violation|0
6038505|NCT00360230|9636139|FG001|Overall Study|Protocol Violation|0
6038506|NCT00360230|9636140|FG002|Overall Study|Protocol Violation|0
6038507|NCT00360230|9636141|FG003|Overall Study|Protocol Violation|0
6038508|NCT00360230|9636142|FG004|Overall Study|Protocol Violation|0
6038509|NCT00360230|9636143|FG005|Overall Study|Protocol Violation|1
6038510|NCT00360230|9636144|FG006|Overall Study|Protocol Violation|0
6038511|NCT00360230|9636138|FG000|Overall Study|Death|0
6309604|NCT02641379|10038344|FG005|Overall Study|Adverse Event|1
6309605|NCT02641379|10038345|FG006|Overall Study|Adverse Event|5
6309606|NCT02641379|10038346|FG007|Overall Study|Adverse Event|0
6309607|NCT02641379|10038347|FG008|Overall Study|Adverse Event|1
6309608|NCT02641379|10038348|FG009|Overall Study|Adverse Event|1
6309609|NCT02641379|10038349|FG010|Overall Study|Adverse Event|5
6309610|NCT02641379|10038339|FG000|Overall Study|Lack of Efficacy|0
6038512|NCT00360230|9636139|FG001|Overall Study|Death|1
6038513|NCT00360230|9636140|FG002|Overall Study|Death|0
6038514|NCT00360230|9636141|FG003|Overall Study|Death|0
6038515|NCT00360230|9636142|FG004|Overall Study|Death|0
6038516|NCT00360230|9636143|FG005|Overall Study|Death|1
6038517|NCT00360230|9636144|FG006|Overall Study|Death|1
6038518|NCT00360269|9636181|FG000|Overall Study|Lost to Follow-up|7
6038519|NCT00360269|9636182|FG001|Overall Study|Lost to Follow-up|9
6038520|NCT00360269|9636181|FG000|Overall Study|Physician Decision|1
6038521|NCT00360269|9636182|FG001|Overall Study|Physician Decision|2
6038522|NCT00360269|9636181|FG000|Overall Study|Adverse Event|1
6038523|NCT00360269|9636182|FG001|Overall Study|Adverse Event|0
6038524|NCT00360269|9636181|FG000|Overall Study|Withdrawal by Subject|1
6038525|NCT00360269|9636182|FG001|Overall Study|Withdrawal by Subject|1
6309611|NCT02641379|10038340|FG001|Overall Study|Lack of Efficacy|0
6038526|NCT00360282|9636188|FG000|Washout 1-3 Weeks|Lost to Follow-up|0
6038527|NCT00360282|9636189|FG001|Washout 1-3 Weeks|Lost to Follow-up|0
6038528|NCT00360282|9636190|FG002|Washout 1-3 Weeks|Lost to Follow-up|1
6038529|NCT00360282|9636191|FG003|Washout 1-3 Weeks|Lost to Follow-up|0
6038530|NCT00360282|9636188|FG000|Second Intervention|Adverse Event|0
6038531|NCT00360282|9636189|FG001|Second Intervention|Adverse Event|1
6038532|NCT00360282|9636190|FG002|Second Intervention|Adverse Event|0
6038533|NCT00360282|9636191|FG003|Second Intervention|Adverse Event|0
6038534|NCT00360308|9636202|FG000|Overall Study|Adverse Event|15
6038535|NCT00360308|9636203|FG001|Overall Study|Adverse Event|14
6038536|NCT00360308|9636204|FG002|Overall Study|Adverse Event|25
6038537|NCT00360308|9636202|FG000|Overall Study|Abnormal Laboratory Value(s)|0
6038538|NCT00360308|9636203|FG001|Overall Study|Abnormal Laboratory Value(s)|1
6038539|NCT00360308|9636204|FG002|Overall Study|Abnormal Laboratory Value(s)|0
6038540|NCT00360308|9636202|FG000|Overall Study|Protocol Violation|2
6309612|NCT02641379|10038341|FG002|Overall Study|Lack of Efficacy|2
6309613|NCT02641379|10038342|FG003|Overall Study|Lack of Efficacy|0
6038541|NCT00360308|9636203|FG001|Overall Study|Protocol Violation|1
6038542|NCT00360308|9636204|FG002|Overall Study|Protocol Violation|2
6038543|NCT00360308|9636202|FG000|Overall Study|Withdrawal by Subject|11
6038544|NCT00360308|9636203|FG001|Overall Study|Withdrawal by Subject|7
6038545|NCT00360308|9636204|FG002|Overall Study|Withdrawal by Subject|14
6038546|NCT00360308|9636202|FG000|Overall Study|Lack of Efficacy|3
6038547|NCT00360308|9636203|FG001|Overall Study|Lack of Efficacy|0
6038548|NCT00360308|9636204|FG002|Overall Study|Lack of Efficacy|2
6038549|NCT00360308|9636202|FG000|Overall Study|Other|2
6038550|NCT00360308|9636203|FG001|Overall Study|Other|1
6038551|NCT00360308|9636204|FG002|Overall Study|Other|1
6038552|NCT00360308|9636202|FG000|Overall Study|Study termination by sponsor|43
6147712|NCT01085591|9782987|FG002|Overall Study|Other|0
6147713|NCT01085591|9782985|FG000|Overall Study|Not Properly Consented|1
6147714|NCT01085591|9782986|FG001|Overall Study|Not Properly Consented|0
6147715|NCT01085591|9782987|FG002|Overall Study|Not Properly Consented|0
6147716|NCT01085630|9782998|FG000|Overall Study|Insufficient data|1
6147717|NCT01085630|9782999|FG001|Overall Study|Insufficient data|0
6147718|NCT01085630|9782998|FG000|Overall Study|Ineligible|3
6147719|NCT01085630|9782999|FG001|Overall Study|Ineligible|0
6147720|NCT01085682|9783007|FG000|Overall Study|Withdrawal by Subject|25
6147721|NCT01085682|9783008|FG001|Overall Study|Withdrawal by Subject|25
6147722|NCT01085734|9783016|FG000|Overall Study|Adverse Event|0
6147723|NCT01085734|9783017|FG001|Overall Study|Adverse Event|2
6147724|NCT01085734|9783016|FG000|Overall Study|Death|1
6147725|NCT01085734|9783017|FG001|Overall Study|Death|0
6147726|NCT01085734|9783016|FG000|Overall Study|Lost to Follow-up|0
6147727|NCT01085734|9783017|FG001|Overall Study|Lost to Follow-up|1
6147728|NCT01085734|9783016|FG000|Overall Study|Withdrawal by Subject|0
6147729|NCT01085734|9783017|FG001|Overall Study|Withdrawal by Subject|1
6191320|NCT01421459|9847976|FG000|Overall Study|Withdrawal by Subject|12
6191321|NCT01421459|9847977|FG001|Overall Study|Withdrawal by Subject|16
6191322|NCT01421511|9848011|FG000|Overall Study|Lost to Follow-up|11
6191323|NCT01421511|9848012|FG001|Overall Study|Lost to Follow-up|14
6191324|NCT01421511|9848011|FG000|Overall Study|Randomized but didn't receive study drug|1
6191325|NCT01421511|9848012|FG001|Overall Study|Randomized but didn't receive study drug|7
6191326|NCT01421511|9848011|FG000|Overall Study|Physician Decision|0
6191327|NCT01421511|9848012|FG001|Overall Study|Physician Decision|1
6191328|NCT01421511|9848011|FG000|Overall Study|Withdrawal by Subject|6
6191329|NCT01421511|9848012|FG001|Overall Study|Withdrawal by Subject|5
6191330|NCT01421511|9848011|FG000|Overall Study|Death|1
6191331|NCT01421511|9848012|FG001|Overall Study|Death|1
6191332|NCT01421641|9848026|FG000|Overall Study|Protocol Violation|2
6191333|NCT01421641|9848027|FG001|Overall Study|Protocol Violation|2
6191334|NCT01421667|9848046|FG000|Overall Study|Withdrawal by Subject|0
6191335|NCT01421667|9848047|FG001|Overall Study|Withdrawal by Subject|1
6191336|NCT01421667|9848048|FG002|Overall Study|Withdrawal by Subject|2
6191337|NCT01421667|9848049|FG003|Overall Study|Withdrawal by Subject|1
6191338|NCT01421667|9848046|FG000|Overall Study|Lost to Follow-up|0
6191339|NCT01421667|9848047|FG001|Overall Study|Lost to Follow-up|1
6191340|NCT01421667|9848048|FG002|Overall Study|Lost to Follow-up|0
6191341|NCT01421667|9848049|FG003|Overall Study|Lost to Follow-up|0
6191342|NCT01421719|9848067|FG000|Overall Study|Withdrawal by Subject|4
6191343|NCT01422187|9848111|FG000|Overall Study|Personal reason|1
6191344|NCT01422187|9848112|FG001|Overall Study|Personal reason|0
6191345|NCT01422187|9848113|FG002|Overall Study|Personal reason|0
6191346|NCT01422187|9848111|FG000|Overall Study|Lost to Follow-up|0
6191347|NCT01422187|9848112|FG001|Overall Study|Lost to Follow-up|1
6191348|NCT01422187|9848113|FG002|Overall Study|Lost to Follow-up|0
6191349|NCT01422213|9848135|FG000|Overall Study|Adverse Event|8
6191350|NCT01422213|9848136|FG001|Overall Study|Adverse Event|7
6191351|NCT01422213|9848137|FG002|Overall Study|Adverse Event|11
6191352|NCT01422213|9848135|FG000|Overall Study|Lack of Efficacy|10
6191353|NCT01422213|9848136|FG001|Overall Study|Lack of Efficacy|2
6191354|NCT01422213|9848137|FG002|Overall Study|Lack of Efficacy|2
6191355|NCT01422213|9848135|FG000|Overall Study|Non-compliance with study drug|0
6191356|NCT01422213|9848136|FG001|Overall Study|Non-compliance with study drug|1
6191357|NCT01422213|9848137|FG002|Overall Study|Non-compliance with study drug|0
6191358|NCT01422213|9848135|FG000|Overall Study|Protocol Violation|0
6191359|NCT01422213|9848136|FG001|Overall Study|Protocol Violation|2
6191360|NCT01422213|9848137|FG002|Overall Study|Protocol Violation|4
6191361|NCT01422213|9848135|FG000|Overall Study|Withdrawal of Consent|7
6191362|NCT01422213|9848136|FG001|Overall Study|Withdrawal of Consent|3
6191363|NCT01422213|9848137|FG002|Overall Study|Withdrawal of Consent|5
6191364|NCT01422213|9848135|FG000|Overall Study|Lost to Follow-up|3
6191365|NCT01422213|9848136|FG001|Overall Study|Lost to Follow-up|3
6191366|NCT01422213|9848137|FG002|Overall Study|Lost to Follow-up|5
6038553|NCT00360308|9636203|FG001|Overall Study|Study termination by sponsor|55
6191367|NCT01422213|9848135|FG000|Overall Study|Administrative or Other Reason(s)|5
6191368|NCT01422213|9848136|FG001|Overall Study|Administrative or Other Reason(s)|4
6191369|NCT01422213|9848137|FG002|Overall Study|Administrative or Other Reason(s)|2
6191370|NCT01422239|9848156|FG000|Overall Study|Lost to Follow-up|4
6191371|NCT01422239|9848157|FG001|Overall Study|Lost to Follow-up|3
6191372|NCT01422304|9848165|FG000|Overall Study|Adverse Event|0
6191373|NCT01422304|9848166|FG001|Overall Study|Adverse Event|1
6038554|NCT00360308|9636204|FG002|Overall Study|Study termination by sponsor|44
6038555|NCT00360334|9636218|FG000|Overall Study|Adverse Event|7
6038556|NCT00360334|9636219|FG001|Overall Study|Adverse Event|4
6038557|NCT00360334|9636218|FG000|Overall Study|Protocol Violation|1
6038558|NCT00360334|9636219|FG001|Overall Study|Protocol Violation|1
6038559|NCT00360334|9636218|FG000|Overall Study|Physician Decision|2
6038560|NCT00360334|9636219|FG001|Overall Study|Physician Decision|3
6038561|NCT00360334|9636218|FG000|Overall Study|Lack of Efficacy|0
6038562|NCT00360334|9636219|FG001|Overall Study|Lack of Efficacy|1
6038563|NCT00360334|9636218|FG000|Overall Study|Entry criterion not met|1
6038564|NCT00360334|9636219|FG001|Overall Study|Entry criterion not met|2
6038565|NCT00360334|9636218|FG000|Overall Study|Subject decision|8
6038566|NCT00360334|9636219|FG001|Overall Study|Subject decision|2
6038567|NCT00360412|9636244|FG000|Overall Study|Adverse Event|37
6038568|NCT00360412|9636245|FG001|Overall Study|Adverse Event|65
6038569|NCT00360412|9636244|FG000|Overall Study|Protocol Violation|2
6038570|NCT00360412|9636245|FG001|Overall Study|Protocol Violation|5
6038571|NCT00360412|9636244|FG000|Overall Study|Patient withdrew consent|27
6038572|NCT00360412|9636245|FG001|Overall Study|Patient withdrew consent|52
6038573|NCT00360412|9636244|FG000|Overall Study|Lack of therapeutic efficacy|46
6038574|NCT00360412|9636245|FG001|Overall Study|Lack of therapeutic efficacy|61
6038575|NCT00360412|9636244|FG000|Overall Study|Physician Decision|2
6038576|NCT00360412|9636245|FG001|Overall Study|Physician Decision|4
6038577|NCT00360412|9636244|FG000|Overall Study|Other|5
6038578|NCT00360412|9636245|FG001|Overall Study|Other|6
6038579|NCT00360412|9636244|FG000|Overall Study|Study termination by Sponsor|214
6038580|NCT00360412|9636245|FG001|Overall Study|Study termination by Sponsor|469
6038581|NCT00360490|9636253|FG000|Overall Study|Adverse Event|4
6038582|NCT00360490|9636254|FG001|Overall Study|Adverse Event|2
6038583|NCT00360490|9636253|FG000|Overall Study|Lost to Follow-up|2
6038584|NCT00360490|9636254|FG001|Overall Study|Lost to Follow-up|1
6038585|NCT00360490|9636253|FG000|Overall Study|Physician Decision|2
6038586|NCT00360490|9636254|FG001|Overall Study|Physician Decision|1
6038587|NCT00360490|9636253|FG000|Overall Study|Protocol Violation|0
6038588|NCT00360490|9636254|FG001|Overall Study|Protocol Violation|4
6038589|NCT00360490|9636253|FG000|Overall Study|Withdrawal by Subject|1
6038590|NCT00360490|9636254|FG001|Overall Study|Withdrawal by Subject|3
6038591|NCT00360529|9636263|FG000|Overall Study|Adverse Event|10
6038592|NCT00360529|9636264|FG001|Overall Study|Adverse Event|23
6038593|NCT00360529|9636265|FG002|Overall Study|Adverse Event|33
6038594|NCT00360529|9636263|FG000|Overall Study|Protocol Violation|3
6038595|NCT00360529|9636264|FG001|Overall Study|Protocol Violation|3
6038596|NCT00360529|9636265|FG002|Overall Study|Protocol Violation|11
6038597|NCT00360529|9636263|FG000|Overall Study|Lost to Follow-up|14
6038598|NCT00360529|9636264|FG001|Overall Study|Lost to Follow-up|10
6038599|NCT00360529|9636265|FG002|Overall Study|Lost to Follow-up|13
6038600|NCT00360529|9636263|FG000|Overall Study|Withdrawal by Subject|22
6038601|NCT00360529|9636264|FG001|Overall Study|Withdrawal by Subject|14
6038602|NCT00360529|9636265|FG002|Overall Study|Withdrawal by Subject|18
6038603|NCT00360529|9636263|FG000|Overall Study|Lack of Efficacy|8
6038604|NCT00360529|9636264|FG001|Overall Study|Lack of Efficacy|6
6038605|NCT00360529|9636265|FG002|Overall Study|Lack of Efficacy|5
6038606|NCT00360529|9636263|FG000|Overall Study|Reason discontinued not explained above|4
6038607|NCT00360529|9636264|FG001|Overall Study|Reason discontinued not explained above|9
6038608|NCT00360529|9636265|FG002|Overall Study|Reason discontinued not explained above|11
6038609|NCT00360568|9636292|FG000|Overall Study|Adverse Event|1
6147730|NCT01085812|9783050|FG000|Open-Label Period|Adverse Event|0
6147731|NCT01085812|9783051|FG001|Open-Label Period|Adverse Event|80
6147732|NCT01085812|9783050|FG000|Open-Label Period|Lack of Efficacy|0
6147733|NCT01085812|9783051|FG001|Open-Label Period|Lack of Efficacy|26
6147734|NCT01085812|9783050|FG000|Open-Label Period|Protocol Violation|0
6147735|NCT01085812|9783051|FG001|Open-Label Period|Protocol Violation|39
6147736|NCT01085812|9783050|FG000|Open-Label Period|Withdrawal by Subject|0
6147737|NCT01085812|9783051|FG001|Open-Label Period|Withdrawal by Subject|53
6147738|NCT01085812|9783050|FG000|Open-Label Period|Lost to Follow-up|0
6147739|NCT01085812|9783051|FG001|Open-Label Period|Lost to Follow-up|42
6147740|NCT01085812|9783050|FG000|Double-Blind Period|Adverse Event|3
6147741|NCT01085812|9783051|FG001|Double-Blind Period|Adverse Event|8
6147742|NCT01085812|9783050|FG000|Double-Blind Period|Protocol Violation|2
6147743|NCT01085812|9783051|FG001|Double-Blind Period|Protocol Violation|7
6147744|NCT01085812|9783050|FG000|Double-Blind Period|Withdrawal by Subject|11
6147745|NCT01085812|9783051|FG001|Double-Blind Period|Withdrawal by Subject|24
6147746|NCT01085812|9783050|FG000|Double-Blind Period|Lost to Follow-up|5
6038610|NCT00360568|9636293|FG001|Overall Study|Adverse Event|2
6038611|NCT00360568|9636292|FG000|Overall Study|Lack of Efficacy|1
6038612|NCT00360568|9636293|FG001|Overall Study|Lack of Efficacy|0
6038613|NCT00360568|9636292|FG000|Overall Study|Withdrawal by Subject|0
6038614|NCT00360568|9636293|FG001|Overall Study|Withdrawal by Subject|3
6038615|NCT00360698|9636317|FG000|Run-In|Physician Decision|0
6038616|NCT00360698|9636318|FG001|Run-In|Physician Decision|1
6038617|NCT00360698|9636317|FG000|Run-In|Withdrawal by Subject|0
6038618|NCT00360698|9636318|FG001|Run-In|Withdrawal by Subject|2
6147747|NCT01085812|9783051|FG001|Double-Blind Period|Lost to Follow-up|17
6038619|NCT00360698|9636317|FG000|Run-In|Non compliance with treatment procedure|0
6038620|NCT00360698|9636318|FG001|Run-In|Non compliance with treatment procedure|1
6038621|NCT00360698|9636317|FG000|Run-In|Sponsor request|0
6038622|NCT00360698|9636318|FG001|Run-In|Sponsor request|2
6038623|NCT00360698|9636317|FG000|Run-In|Patient did not meet inclusion criteria|0
6038624|NCT00360698|9636318|FG001|Run-In|Patient did not meet inclusion criteria|1
6038625|NCT00360698|9636317|FG000|Run-In|Patient personal reasons|0
6038626|NCT00360698|9636318|FG001|Run-In|Patient personal reasons|2
6038627|NCT00360698|9636317|FG000|Run-In|Need of insulin with meals|0
6038628|NCT00360698|9636318|FG001|Run-In|Need of insulin with meals|1
6038629|NCT00360698|9636317|FG000|Treatment Period|Non compliance with treatment procedure|1
6038630|NCT00360698|9636318|FG001|Treatment Period|Non compliance with treatment procedure|0
6038631|NCT00360698|9636317|FG000|Treatment Period|Early termination by error|0
6038632|NCT00360698|9636318|FG001|Treatment Period|Early termination by error|1
6038633|NCT00361218|9636362|FG000|Overall Study|Lost to Follow-up|11
6038634|NCT00361218|9636362|FG000|Overall Study|Personal Reasons|7
6038635|NCT00361218|9636362|FG000|Overall Study|terminated / withdrawn due to toxicity /|5
6038636|NCT00361231|9636366|FG000|Overall Study|Physician Decision|3
6038637|NCT00361231|9636366|FG000|Overall Study|Symptomatic deterioration|5
6038638|NCT00361231|9636366|FG000|Overall Study|Radiographic disease progression|16
6038639|NCT00361231|9636366|FG000|Overall Study|Withdrawal by Subject|4
6038640|NCT00361231|9636366|FG000|Overall Study|Adverse Event|6
6038641|NCT00361270|9636385|FG000|Overall Study|Death|0
6038642|NCT00361270|9636386|FG001|Overall Study|Death|0
6038643|NCT00361270|9636387|FG002|Overall Study|Death|0
6038644|NCT00361270|9636388|FG003|Overall Study|Death|2
6038645|NCT00361270|9636385|FG000|Overall Study|Lost to Follow-up|4
6038646|NCT00361270|9636386|FG001|Overall Study|Lost to Follow-up|1
6038647|NCT00361270|9636387|FG002|Overall Study|Lost to Follow-up|0
6038648|NCT00361270|9636388|FG003|Overall Study|Lost to Follow-up|0
6038649|NCT00361270|9636385|FG000|Overall Study|Physician Decision|0
6038650|NCT00361270|9636386|FG001|Overall Study|Physician Decision|0
6038651|NCT00361270|9636387|FG002|Overall Study|Physician Decision|1
6038652|NCT00361270|9636388|FG003|Overall Study|Physician Decision|0
6147748|NCT01085812|9783050|FG000|Double-Blind Period|Other Reasons|0
6147749|NCT01085812|9783051|FG001|Double-Blind Period|Other Reasons|2
6147750|NCT01085812|9783050|FG000|Double-blind Intent-to-treat Population|Adverse Event|3
6147751|NCT01085812|9783051|FG001|Double-blind Intent-to-treat Population|Adverse Event|8
6147752|NCT01085812|9783050|FG000|Double-blind Intent-to-treat Population|Protocol Violation|2
6147753|NCT01085812|9783051|FG001|Double-blind Intent-to-treat Population|Protocol Violation|7
6147754|NCT01085812|9783050|FG000|Double-blind Intent-to-treat Population|Withdrawal by Subject|11
6147755|NCT01085812|9783051|FG001|Double-blind Intent-to-treat Population|Withdrawal by Subject|22
6147756|NCT01085812|9783050|FG000|Double-blind Intent-to-treat Population|Lost to Follow-up|4
6147757|NCT01085812|9783051|FG001|Double-blind Intent-to-treat Population|Lost to Follow-up|17
6147758|NCT01085812|9783050|FG000|Double-blind Intent-to-treat Population|Positive serum pregnancy test result|0
6147759|NCT01085812|9783051|FG001|Double-blind Intent-to-treat Population|Positive serum pregnancy test result|2
6147760|NCT01086033|9783099|FG000|Overall Study|Lack of efficacy/Exacerbation of RA|86
6147761|NCT01086033|9783099|FG000|Overall Study|Lost to Follow-up|86
6147762|NCT01086033|9783099|FG000|Overall Study|Adverse Event|42
6147763|NCT01086033|9783099|FG000|Overall Study|Withdrawal by Subject|41
6147764|NCT01086033|9783099|FG000|Overall Study|Other|14
6147765|NCT01086033|9783099|FG000|Overall Study|Other|13
6147766|NCT01086033|9783099|FG000|Overall Study|AE and Withdrew Consent|5
6147767|NCT01086033|9783099|FG000|Overall Study|Withdrew Consent and Lack of Efficacy|5
6147768|NCT01086033|9783099|FG000|Overall Study|Withdrew consent and Other Reason|4
6147769|NCT01086033|9783099|FG000|Overall Study|AE and Lack of Efficacy|4
6147770|NCT01086033|9783099|FG000|Overall Study|Death|1
6147771|NCT01086033|9783099|FG000|Overall Study|AE and Lost to Follow-up|1
6147772|NCT01086033|9783099|FG000|Overall Study|AE and Other Reason|1
6147773|NCT01086033|9783099|FG000|Overall Study|AE, Withdrew Consent & Lack of Efficacy|1
6147774|NCT01086150|9783109|FG000|Overall Study|Withdrawal by Subject|0
6038653|NCT00361270|9636385|FG000|Overall Study|Protocol Violation|9
6038654|NCT00361270|9636386|FG001|Overall Study|Protocol Violation|4
6038655|NCT00361270|9636387|FG002|Overall Study|Protocol Violation|5
6038656|NCT00361270|9636388|FG003|Overall Study|Protocol Violation|4
6038657|NCT00361270|9636385|FG000|Overall Study|Withdrawal by Subject|6
6038658|NCT00361270|9636386|FG001|Overall Study|Withdrawal by Subject|6
6038659|NCT00361270|9636387|FG002|Overall Study|Withdrawal by Subject|3
6147775|NCT01086150|9783110|FG001|Overall Study|Withdrawal by Subject|4
6147776|NCT01086150|9783111|FG002|Overall Study|Withdrawal by Subject|1
6038660|NCT00361270|9636388|FG003|Overall Study|Withdrawal by Subject|7
6038661|NCT00361270|9636385|FG000|Overall Study|Afraid of Hypnosis|1
6038662|NCT00361270|9636386|FG001|Overall Study|Afraid of Hypnosis|2
6038663|NCT00361270|9636387|FG002|Overall Study|Afraid of Hypnosis|0
6038664|NCT00361270|9636388|FG003|Overall Study|Afraid of Hypnosis|0
6038665|NCT00361270|9636385|FG000|Overall Study|Problems with Transportation|4
6038666|NCT00361270|9636386|FG001|Overall Study|Problems with Transportation|0
6147777|NCT01086150|9783109|FG000|Overall Study|Lost to Follow-up|0
6147778|NCT01086150|9783110|FG001|Overall Study|Lost to Follow-up|1
6147779|NCT01086150|9783111|FG002|Overall Study|Lost to Follow-up|0
6147780|NCT01086150|9783109|FG000|Overall Study|Screen Failure|0
6038667|NCT00361270|9636387|FG002|Overall Study|Problems with Transportation|0
6038668|NCT00361270|9636388|FG003|Overall Study|Problems with Transportation|0
6038669|NCT00361270|9636385|FG000|Overall Study|Adverse Event|0
6038670|NCT00361270|9636386|FG001|Overall Study|Adverse Event|1
6038671|NCT00361270|9636387|FG002|Overall Study|Adverse Event|1
6038672|NCT00361270|9636388|FG003|Overall Study|Adverse Event|0
6038673|NCT00361283|9636405|FG000|Overall Study|Lost to Follow-up|27
6038674|NCT00361296|9636409|FG000|Overall Study|Physician Decision|1
6038675|NCT00361296|9636409|FG000|Overall Study|Lack of Efficacy|2
6038676|NCT00361335|9636418|FG000|IV Period: Baseline to E0|Adverse Event|9
6038677|NCT00361335|9636419|FG001|IV Period: Baseline to E0|Adverse Event|4
6038678|NCT00361335|9636420|FG002|IV Period: Baseline to E0|Adverse Event|5
6038679|NCT00361335|9636421|FG003|IV Period: Baseline to E0|Adverse Event|9
6038680|NCT00361335|9636422|FG004|IV Period: Baseline to E0|Adverse Event|8
6038681|NCT00361335|9636423|FG005|IV Period: Baseline to E0|Adverse Event|0
6038682|NCT00361335|9636424|FG006|IV Period: Baseline to E0|Adverse Event|0
6038683|NCT00361335|9636418|FG000|IV Period: Baseline to E0|Lost to Follow-up|1
6038684|NCT00361335|9636419|FG001|IV Period: Baseline to E0|Lost to Follow-up|0
6038685|NCT00361335|9636420|FG002|IV Period: Baseline to E0|Lost to Follow-up|0
6038686|NCT00361335|9636421|FG003|IV Period: Baseline to E0|Lost to Follow-up|2
6038687|NCT00361335|9636422|FG004|IV Period: Baseline to E0|Lost to Follow-up|2
6038688|NCT00361335|9636423|FG005|IV Period: Baseline to E0|Lost to Follow-up|0
6038689|NCT00361335|9636424|FG006|IV Period: Baseline to E0|Lost to Follow-up|0
6038690|NCT00361335|9636418|FG000|IV Period: Baseline to E0|Death|1
6038691|NCT00361335|9636419|FG001|IV Period: Baseline to E0|Death|1
6038692|NCT00361335|9636420|FG002|IV Period: Baseline to E0|Death|1
6038693|NCT00361335|9636421|FG003|IV Period: Baseline to E0|Death|1
6038694|NCT00361335|9636422|FG004|IV Period: Baseline to E0|Death|0
6147781|NCT01086150|9783110|FG001|Overall Study|Screen Failure|1
6147782|NCT01086150|9783111|FG002|Overall Study|Screen Failure|0
6147783|NCT01086215|9783123|FG000|Overall Study|Death|14
6147784|NCT01086215|9783124|FG001|Overall Study|Death|8
6147785|NCT01086215|9783125|FG002|Overall Study|Death|8
6147786|NCT01086215|9783126|FG003|Overall Study|Death|1
6147787|NCT01086215|9783123|FG000|Overall Study|Lost to Follow-up|22
6147788|NCT01086215|9783124|FG001|Overall Study|Lost to Follow-up|39
6147789|NCT01086215|9783125|FG002|Overall Study|Lost to Follow-up|18
6147790|NCT01086215|9783126|FG003|Overall Study|Lost to Follow-up|2
6147791|NCT01086358|9783140|FG000|First Intervention|Lost to Follow-up|9
6147792|NCT01086358|9783141|FG001|First Intervention|Lost to Follow-up|4
6147793|NCT01086358|9783140|FG000|First Intervention|Withdrawal by Subject|0
6147794|NCT01086358|9783141|FG001|First Intervention|Withdrawal by Subject|1
6147795|NCT01086358|9783140|FG000|Second Intervention|Lost to Follow-up|4
6147796|NCT01086358|9783141|FG001|Second Intervention|Lost to Follow-up|4
6147797|NCT01086384|9783149|FG000|2-week Run-in Period|Adverse Event|1
6147798|NCT01086384|9783150|FG001|2-week Run-in Period|Adverse Event|0
6147799|NCT01086384|9783151|FG002|2-week Run-in Period|Adverse Event|0
6147800|NCT01086384|9783149|FG000|2-week Run-in Period|Protocol Violation|1
6147801|NCT01086384|9783150|FG001|2-week Run-in Period|Protocol Violation|0
6147802|NCT01086384|9783151|FG002|2-week Run-in Period|Protocol Violation|0
6147803|NCT01086384|9783149|FG000|2-week Run-in Period|Lost to Follow-up|1
6147804|NCT01086384|9783150|FG001|2-week Run-in Period|Lost to Follow-up|0
6147805|NCT01086384|9783151|FG002|2-week Run-in Period|Lost to Follow-up|0
6147806|NCT01086384|9783149|FG000|2-week Run-in Period|Physician Decision|6
6147807|NCT01086384|9783150|FG001|2-week Run-in Period|Physician Decision|0
6147808|NCT01086384|9783151|FG002|2-week Run-in Period|Physician Decision|0
6147809|NCT01086384|9783149|FG000|2-week Run-in Period|Withdrawal by Subject|19
6147810|NCT01086384|9783150|FG001|2-week Run-in Period|Withdrawal by Subject|0
6147811|NCT01086384|9783151|FG002|2-week Run-in Period|Withdrawal by Subject|0
6147812|NCT01086384|9783149|FG000|2-week Run-in Period|Study Closed/Terminated|42
6147813|NCT01086384|9783150|FG001|2-week Run-in Period|Study Closed/Terminated|0
6147814|NCT01086384|9783151|FG002|2-week Run-in Period|Study Closed/Terminated|0
6147815|NCT01086384|9783149|FG000|2-week Run-in Period|Continuation Criteria Not Met|92
6147816|NCT01086384|9783150|FG001|2-week Run-in Period|Continuation Criteria Not Met|0
6147817|NCT01086384|9783151|FG002|2-week Run-in Period|Continuation Criteria Not Met|0
6147818|NCT01086384|9783149|FG000|2-week Run-in Period|Randomized in Error|1
6147819|NCT01086384|9783150|FG001|2-week Run-in Period|Randomized in Error|0
6147820|NCT01086384|9783151|FG002|2-week Run-in Period|Randomized in Error|0
6147821|NCT01086384|9783149|FG000|Treatment Period|Withdrawal by Subject|0
6147822|NCT01086384|9783150|FG001|Treatment Period|Withdrawal by Subject|53
6147823|NCT01086384|9783151|FG002|Treatment Period|Withdrawal by Subject|55
6147824|NCT01086384|9783149|FG000|Treatment Period|Protocol Violation|0
6147825|NCT01086384|9783150|FG001|Treatment Period|Protocol Violation|26
6147826|NCT01086384|9783151|FG002|Treatment Period|Protocol Violation|17
6038695|NCT00361335|9636423|FG005|IV Period: Baseline to E0|Death|0
6147827|NCT01086384|9783149|FG000|Treatment Period|Lack of Efficacy|0
6147828|NCT01086384|9783150|FG001|Treatment Period|Lack of Efficacy|22
6147829|NCT01086384|9783151|FG002|Treatment Period|Lack of Efficacy|13
6147830|NCT01086384|9783149|FG000|Treatment Period|Adverse Event|0
6038696|NCT00361335|9636424|FG006|IV Period: Baseline to E0|Death|0
6038697|NCT00361335|9636418|FG000|IV Period: Baseline to E0|Discontinued oral study agent|2
6048919|NCT00420927|9648201|FG002|Period 1|Study site closure|0
6147831|NCT01086384|9783150|FG001|Treatment Period|Adverse Event|19
6038698|NCT00361335|9636419|FG001|IV Period: Baseline to E0|Discontinued oral study agent|1
6038699|NCT00361335|9636420|FG002|IV Period: Baseline to E0|Discontinued oral study agent|1
6038700|NCT00361335|9636421|FG003|IV Period: Baseline to E0|Discontinued oral study agent|1
6038701|NCT00361335|9636422|FG004|IV Period: Baseline to E0|Discontinued oral study agent|2
6038702|NCT00361335|9636423|FG005|IV Period: Baseline to E0|Discontinued oral study agent|0
6038703|NCT00361335|9636424|FG006|IV Period: Baseline to E0|Discontinued oral study agent|0
6038704|NCT00361335|9636418|FG000|IV Period: Baseline to E0|Protocol-prohibited medications|0
6038705|NCT00361335|9636419|FG001|IV Period: Baseline to E0|Protocol-prohibited medications|0
6038706|NCT00361335|9636420|FG002|IV Period: Baseline to E0|Protocol-prohibited medications|1
6038707|NCT00361335|9636421|FG003|IV Period: Baseline to E0|Protocol-prohibited medications|0
6038708|NCT00361335|9636422|FG004|IV Period: Baseline to E0|Protocol-prohibited medications|0
6038709|NCT00361335|9636423|FG005|IV Period: Baseline to E0|Protocol-prohibited medications|0
6038710|NCT00361335|9636424|FG006|IV Period: Baseline to E0|Protocol-prohibited medications|0
6038711|NCT00361335|9636418|FG000|IV Period: Baseline to E0|Worsening of RA|0
6038712|NCT00361335|9636419|FG001|IV Period: Baseline to E0|Worsening of RA|5
6038713|NCT00361335|9636420|FG002|IV Period: Baseline to E0|Worsening of RA|1
6038714|NCT00361335|9636421|FG003|IV Period: Baseline to E0|Worsening of RA|4
6038715|NCT00361335|9636422|FG004|IV Period: Baseline to E0|Worsening of RA|2
6038716|NCT00361335|9636423|FG005|IV Period: Baseline to E0|Worsening of RA|0
6038717|NCT00361335|9636424|FG006|IV Period: Baseline to E0|Worsening of RA|0
6038718|NCT00361335|9636418|FG000|IV Period: Baseline to E0|Other|2
6038719|NCT00361335|9636419|FG001|IV Period: Baseline to E0|Other|9
6038720|NCT00361335|9636420|FG002|IV Period: Baseline to E0|Other|9
6038721|NCT00361335|9636421|FG003|IV Period: Baseline to E0|Other|3
6038722|NCT00361335|9636422|FG004|IV Period: Baseline to E0|Other|2
6038723|NCT00361335|9636423|FG005|IV Period: Baseline to E0|Other|0
6038724|NCT00361335|9636424|FG006|IV Period: Baseline to E0|Other|0
6038725|NCT00361335|9636418|FG000|IV Period: Baseline to E0|Lack of Efficacy|5
6038726|NCT00361335|9636419|FG001|IV Period: Baseline to E0|Lack of Efficacy|9
6038727|NCT00361335|9636420|FG002|IV Period: Baseline to E0|Lack of Efficacy|3
6038728|NCT00361335|9636421|FG003|IV Period: Baseline to E0|Lack of Efficacy|7
6038729|NCT00361335|9636422|FG004|IV Period: Baseline to E0|Lack of Efficacy|8
6038730|NCT00361335|9636423|FG005|IV Period: Baseline to E0|Lack of Efficacy|0
6038731|NCT00361335|9636424|FG006|IV Period: Baseline to E0|Lack of Efficacy|0
6038732|NCT00361335|9636418|FG000|SC Period: Week E0 to Week E24|Adverse Event|0
6038733|NCT00361335|9636419|FG001|SC Period: Week E0 to Week E24|Adverse Event|2
6038734|NCT00361335|9636420|FG002|SC Period: Week E0 to Week E24|Adverse Event|1
6147832|NCT01086384|9783151|FG002|Treatment Period|Adverse Event|15
6147833|NCT01086384|9783149|FG000|Treatment Period|Lost to Follow-up|0
6147834|NCT01086384|9783150|FG001|Treatment Period|Lost to Follow-up|11
6147835|NCT01086384|9783151|FG002|Treatment Period|Lost to Follow-up|9
6147836|NCT01086384|9783149|FG000|Treatment Period|Physician Decision|0
6147837|NCT01086384|9783150|FG001|Treatment Period|Physician Decision|9
6147838|NCT01086384|9783151|FG002|Treatment Period|Physician Decision|6
6147839|NCT01086384|9783149|FG000|Treatment Period|Study Closed/Terminated|0
6147840|NCT01086384|9783150|FG001|Treatment Period|Study Closed/Terminated|7
6147841|NCT01086384|9783151|FG002|Treatment Period|Study Closed/Terminated|8
6147842|NCT01086384|9783149|FG000|Treatment Period|Protocol-Defined Stopping Criteria|0
6147843|NCT01086384|9783150|FG001|Treatment Period|Protocol-Defined Stopping Criteria|0
6147844|NCT01086384|9783151|FG002|Treatment Period|Protocol-Defined Stopping Criteria|1
6147845|NCT01086384|9783149|FG000|Treatment Period|Received Treatment in Error|0
6147846|NCT01086384|9783150|FG001|Treatment Period|Received Treatment in Error|1
6147847|NCT01086384|9783151|FG002|Treatment Period|Received Treatment in Error|0
6147848|NCT01086410|9783161|FG000|Overall Study|Adverse Event|1
6147849|NCT01086410|9783162|FG001|Overall Study|Adverse Event|0
6147850|NCT01086410|9783163|FG002|Overall Study|Adverse Event|0
6147851|NCT01086410|9783164|FG003|Overall Study|Adverse Event|2
6147852|NCT01086410|9783161|FG000|Overall Study|Lack of Efficacy|1
6147853|NCT01086410|9783162|FG001|Overall Study|Lack of Efficacy|1
6147854|NCT01086410|9783163|FG002|Overall Study|Lack of Efficacy|0
6147855|NCT01086410|9783164|FG003|Overall Study|Lack of Efficacy|0
6147856|NCT01086410|9783161|FG000|Overall Study|Protocol Violation|1
6147857|NCT01086410|9783162|FG001|Overall Study|Protocol Violation|1
6147858|NCT01086410|9783163|FG002|Overall Study|Protocol Violation|0
6147859|NCT01086410|9783164|FG003|Overall Study|Protocol Violation|0
6147860|NCT01086410|9783161|FG000|Overall Study|Lost to Follow-up|0
6147861|NCT01086410|9783162|FG001|Overall Study|Lost to Follow-up|0
6147862|NCT01086410|9783163|FG002|Overall Study|Lost to Follow-up|1
6147863|NCT01086410|9783164|FG003|Overall Study|Lost to Follow-up|0
6147864|NCT01086423|9783177|FG000|Overall Study|Protocol Violation|0
6147865|NCT01086423|9783178|FG001|Overall Study|Protocol Violation|0
6147866|NCT01086423|9783179|FG002|Overall Study|Protocol Violation|1
6038735|NCT00361335|9636421|FG003|SC Period: Week E0 to Week E24|Adverse Event|2
6038736|NCT00361335|9636422|FG004|SC Period: Week E0 to Week E24|Adverse Event|0
6038737|NCT00361335|9636423|FG005|SC Period: Week E0 to Week E24|Adverse Event|0
6038738|NCT00361335|9636424|FG006|SC Period: Week E0 to Week E24|Adverse Event|2
6038739|NCT00361335|9636418|FG000|SC Period: Week E0 to Week E24|Lost to Follow-up|1
6038740|NCT00361335|9636419|FG001|SC Period: Week E0 to Week E24|Lost to Follow-up|0
6147867|NCT01086423|9783177|FG000|Overall Study|Migrated/moved from study area|2
6038741|NCT00361335|9636420|FG002|SC Period: Week E0 to Week E24|Lost to Follow-up|1
6038742|NCT00361335|9636421|FG003|SC Period: Week E0 to Week E24|Lost to Follow-up|0
6038743|NCT00361335|9636422|FG004|SC Period: Week E0 to Week E24|Lost to Follow-up|0
6038744|NCT00361335|9636423|FG005|SC Period: Week E0 to Week E24|Lost to Follow-up|0
6038745|NCT00361335|9636424|FG006|SC Period: Week E0 to Week E24|Lost to Follow-up|1
6038746|NCT00361335|9636418|FG000|SC Period: Week E0 to Week E24|Death|0
6038747|NCT00361335|9636419|FG001|SC Period: Week E0 to Week E24|Death|0
6038748|NCT00361335|9636420|FG002|SC Period: Week E0 to Week E24|Death|0
6038749|NCT00361335|9636421|FG003|SC Period: Week E0 to Week E24|Death|0
6038750|NCT00361335|9636422|FG004|SC Period: Week E0 to Week E24|Death|0
6147868|NCT01086423|9783178|FG001|Overall Study|Migrated/moved from study area|0
6147869|NCT01086423|9783179|FG002|Overall Study|Migrated/moved from study area|4
6147870|NCT01086423|9783177|FG000|Overall Study|Adverse event, fatal|1
6147871|NCT01086423|9783178|FG001|Overall Study|Adverse event, fatal|1
6147872|NCT01086423|9783179|FG002|Overall Study|Adverse event, fatal|0
6147873|NCT01086423|9783177|FG000|Overall Study|Adverse event, non-fatal|2
6147874|NCT01086423|9783178|FG001|Overall Study|Adverse event, non-fatal|1
6147875|NCT01086423|9783179|FG002|Overall Study|Adverse event, non-fatal|0
6147876|NCT01086423|9783177|FG000|Overall Study|Withdrawal by Subject|5
6147877|NCT01086423|9783178|FG001|Overall Study|Withdrawal by Subject|1
6147878|NCT01086423|9783179|FG002|Overall Study|Withdrawal by Subject|3
6147879|NCT01086423|9783177|FG000|Overall Study|Lost to Follow-up|0
6147880|NCT01086423|9783178|FG001|Overall Study|Lost to Follow-up|0
6147881|NCT01086423|9783179|FG002|Overall Study|Lost to Follow-up|1
6147882|NCT01086540|9783198|FG000|Overall Study|Death|3
6147883|NCT01086540|9783199|FG001|Overall Study|Death|1
6147884|NCT01086540|9783198|FG000|Overall Study|Physician Decision|2
6147885|NCT01086540|9783199|FG001|Overall Study|Physician Decision|1
6147886|NCT01086540|9783198|FG000|Overall Study|Addition of new therapy for PAH|1
6147887|NCT01086540|9783199|FG001|Overall Study|Addition of new therapy for PAH|0
6147888|NCT01086969|9783246|FG000|Overall Study|Withdrawal by Subject|1
6147889|NCT01086969|9783247|FG001|Overall Study|Withdrawal by Subject|2
6147890|NCT01086969|9783248|FG002|Overall Study|Withdrawal by Subject|0
6147891|NCT01087489|9783256|FG000|Overall Study|enrolled in another VA study|0
6147892|NCT01087489|9783257|FG001|Overall Study|enrolled in another VA study|1
6147893|NCT01087489|9783256|FG000|Overall Study|Death|0
6147894|NCT01087489|9783257|FG001|Overall Study|Death|1
6147895|NCT01087489|9783256|FG000|Overall Study|unable to survey by telephone|0
6147896|NCT01087489|9783257|FG001|Overall Study|unable to survey by telephone|1
6309614|NCT02641379|10038343|FG004|Overall Study|Lack of Efficacy|0
6309615|NCT02641379|10038344|FG005|Overall Study|Lack of Efficacy|2
6309616|NCT02641379|10038345|FG006|Overall Study|Lack of Efficacy|0
6309617|NCT02641379|10038346|FG007|Overall Study|Lack of Efficacy|5
6309618|NCT02641379|10038347|FG008|Overall Study|Lack of Efficacy|0
6309619|NCT02641379|10038348|FG009|Overall Study|Lack of Efficacy|0
6309620|NCT02641379|10038349|FG010|Overall Study|Lack of Efficacy|0
6309621|NCT02641379|10038339|FG000|Overall Study|Participant unable to attend study visit|4
6309622|NCT02641379|10038340|FG001|Overall Study|Participant unable to attend study visit|10
6309623|NCT02641379|10038341|FG002|Overall Study|Participant unable to attend study visit|1
6309624|NCT02641379|10038342|FG003|Overall Study|Participant unable to attend study visit|2
6309625|NCT02641379|10038343|FG004|Overall Study|Participant unable to attend study visit|5
6309626|NCT02641379|10038344|FG005|Overall Study|Participant unable to attend study visit|1
6147897|NCT01087502|9783265|FG000|Up to Interim Analysis (Week 12)|Adverse Event|5
6147898|NCT01087502|9783266|FG001|Up to Interim Analysis (Week 12)|Adverse Event|4
6147899|NCT01087502|9783265|FG000|Up to Interim Analysis (Week 12)|Protocol Violation|1
6147900|NCT01087502|9783266|FG001|Up to Interim Analysis (Week 12)|Protocol Violation|1
6147901|NCT01087502|9783265|FG000|Up to Interim Analysis (Week 12)|Withdrawal by Subject|1
6147902|NCT01087502|9783266|FG001|Up to Interim Analysis (Week 12)|Withdrawal by Subject|1
6147903|NCT01087502|9783265|FG000|Up to Interim Analysis (Week 12)|Lack of Efficacy|1
6147904|NCT01087502|9783266|FG001|Up to Interim Analysis (Week 12)|Lack of Efficacy|0
6147905|NCT01087502|9783265|FG000|Up to Interim Analysis (Week 12)|Other reason not described above|1
6147906|NCT01087502|9783266|FG001|Up to Interim Analysis (Week 12)|Other reason not described above|2
6147907|NCT01087502|9783265|FG000|Up to Final Analysis (Week 52)|Adverse Event|17
6147908|NCT01087502|9783266|FG001|Up to Final Analysis (Week 52)|Adverse Event|10
6147909|NCT01087502|9783265|FG000|Up to Final Analysis (Week 52)|Lack of Efficacy|1
6147910|NCT01087502|9783266|FG001|Up to Final Analysis (Week 52)|Lack of Efficacy|2
6147911|NCT01087502|9783265|FG000|Up to Final Analysis (Week 52)|Protocol Violation|4
6147912|NCT01087502|9783266|FG001|Up to Final Analysis (Week 52)|Protocol Violation|0
6147913|NCT01087502|9783265|FG000|Up to Final Analysis (Week 52)|Lost to Follow-up|2
6147914|NCT01087502|9783266|FG001|Up to Final Analysis (Week 52)|Lost to Follow-up|0
6147915|NCT01087502|9783265|FG000|Up to Final Analysis (Week 52)|Withdrawal by Subject|3
6147916|NCT01087502|9783266|FG001|Up to Final Analysis (Week 52)|Withdrawal by Subject|2
6038751|NCT00361335|9636423|FG005|SC Period: Week E0 to Week E24|Death|0
6147917|NCT01087502|9783265|FG000|Up to Final Analysis (Week 52)|Study site excluded from analysis|1
6147918|NCT01087502|9783266|FG001|Up to Final Analysis (Week 52)|Study site excluded from analysis|5
6038752|NCT00361335|9636424|FG006|SC Period: Week E0 to Week E24|Death|1
6038753|NCT00361335|9636418|FG000|SC Period: Week E0 to Week E24|Worsening of RA|0
6038754|NCT00361335|9636419|FG001|SC Period: Week E0 to Week E24|Worsening of RA|1
6038755|NCT00361335|9636420|FG002|SC Period: Week E0 to Week E24|Worsening of RA|1
6038756|NCT00361335|9636421|FG003|SC Period: Week E0 to Week E24|Worsening of RA|1
6038757|NCT00361335|9636422|FG004|SC Period: Week E0 to Week E24|Worsening of RA|0
6038758|NCT00361335|9636423|FG005|SC Period: Week E0 to Week E24|Worsening of RA|0
6038759|NCT00361335|9636424|FG006|SC Period: Week E0 to Week E24|Worsening of RA|0
6038760|NCT00361335|9636418|FG000|SC Period: Week E0 to Week E24|Other|1
6038761|NCT00361335|9636419|FG001|SC Period: Week E0 to Week E24|Other|0
6038762|NCT00361335|9636420|FG002|SC Period: Week E0 to Week E24|Other|0
6038763|NCT00361335|9636421|FG003|SC Period: Week E0 to Week E24|Other|1
6038764|NCT00361335|9636422|FG004|SC Period: Week E0 to Week E24|Other|0
6038765|NCT00361335|9636423|FG005|SC Period: Week E0 to Week E24|Other|1
6038766|NCT00361335|9636424|FG006|SC Period: Week E0 to Week E24|Other|2
6038767|NCT00361335|9636418|FG000|SC Period: Week E0 to Week E24|Lack of Efficacy|0
6038768|NCT00361335|9636419|FG001|SC Period: Week E0 to Week E24|Lack of Efficacy|0
6038769|NCT00361335|9636420|FG002|SC Period: Week E0 to Week E24|Lack of Efficacy|2
6147919|NCT01087502|9783265|FG000|Up to Final Analysis (Week 52)|Other reason not described above|5
6147920|NCT01087502|9783266|FG001|Up to Final Analysis (Week 52)|Other reason not described above|4
6147921|NCT01087528|9783274|FG000|Overall Study|Withdrawal by Subject|1
6147922|NCT01087528|9783274|FG000|Overall Study|Incomplete CE procedure|6
6147923|NCT01087723|9783291|FG000|Overall Study|1 Year Visit Too Early (<335 days)|0
6147924|NCT01087723|9783292|FG001|Overall Study|1 Year Visit Too Early (<335 days)|1
6147925|NCT01087723|9783291|FG000|Overall Study|Withdrawal by Subject|10
6147926|NCT01087723|9783292|FG001|Overall Study|Withdrawal by Subject|13
6147927|NCT01087723|9783291|FG000|Overall Study|Physician Decision|2
6147928|NCT01087723|9783292|FG001|Overall Study|Physician Decision|0
6147929|NCT01087723|9783291|FG000|Overall Study|Lost to Follow-up|1
6147930|NCT01087723|9783292|FG001|Overall Study|Lost to Follow-up|4
6147931|NCT01087723|9783291|FG000|Overall Study|Reason Not Specified|1
6147932|NCT01087723|9783292|FG001|Overall Study|Reason Not Specified|2
6147933|NCT01087736|9783300|FG000|Overall Study|Lost to Follow-up|1
6147934|NCT01087736|9783301|FG001|Overall Study|Lost to Follow-up|0
6147935|NCT01087736|9783300|FG000|Overall Study|Death|0
6147936|NCT01087736|9783301|FG001|Overall Study|Death|1
6147937|NCT01087736|9783300|FG000|Overall Study|Withdrawal by Subject|0
6147938|NCT01087736|9783301|FG001|Overall Study|Withdrawal by Subject|1
6147939|NCT01087762|9783310|FG000|Double Blind Period (Weeks 0-24)|Lack of Efficacy|2
6147940|NCT01087762|9783311|FG001|Double Blind Period (Weeks 0-24)|Lack of Efficacy|0
6147941|NCT01087762|9783312|FG002|Double Blind Period (Weeks 0-24)|Lack of Efficacy|3
6147942|NCT01087762|9783313|FG003|Double Blind Period (Weeks 0-24)|Lack of Efficacy|0
6147943|NCT01087762|9783314|FG004|Double Blind Period (Weeks 0-24)|Lack of Efficacy|0
6147944|NCT01087762|9783310|FG000|Double Blind Period (Weeks 0-24)|Protocol Violation|6
6147945|NCT01087762|9783311|FG001|Double Blind Period (Weeks 0-24)|Protocol Violation|0
6147946|NCT01087762|9783312|FG002|Double Blind Period (Weeks 0-24)|Protocol Violation|1
6147947|NCT01087762|9783313|FG003|Double Blind Period (Weeks 0-24)|Protocol Violation|0
6147948|NCT01087762|9783314|FG004|Double Blind Period (Weeks 0-24)|Protocol Violation|0
6147949|NCT01087762|9783310|FG000|Double Blind Period (Weeks 0-24)|Lost to Follow-up|1
6147950|NCT01087762|9783311|FG001|Double Blind Period (Weeks 0-24)|Lost to Follow-up|2
6147951|NCT01087762|9783312|FG002|Double Blind Period (Weeks 0-24)|Lost to Follow-up|1
6147952|NCT01087762|9783313|FG003|Double Blind Period (Weeks 0-24)|Lost to Follow-up|0
6147953|NCT01087762|9783314|FG004|Double Blind Period (Weeks 0-24)|Lost to Follow-up|0
6147954|NCT01087762|9783310|FG000|Double Blind Period (Weeks 0-24)|Withdrawal by Subject|1
6147955|NCT01087762|9783311|FG001|Double Blind Period (Weeks 0-24)|Withdrawal by Subject|2
6147956|NCT01087762|9783312|FG002|Double Blind Period (Weeks 0-24)|Withdrawal by Subject|1
6147957|NCT01087762|9783313|FG003|Double Blind Period (Weeks 0-24)|Withdrawal by Subject|0
6147958|NCT01087762|9783314|FG004|Double Blind Period (Weeks 0-24)|Withdrawal by Subject|0
6147959|NCT01087762|9783310|FG000|Double Blind Period (Weeks 0-24)|SAE, non-fatal|2
6147960|NCT01087762|9783311|FG001|Double Blind Period (Weeks 0-24)|SAE, non-fatal|2
6147961|NCT01087762|9783312|FG002|Double Blind Period (Weeks 0-24)|SAE, non-fatal|3
6147962|NCT01087762|9783313|FG003|Double Blind Period (Weeks 0-24)|SAE, non-fatal|0
6147963|NCT01087762|9783314|FG004|Double Blind Period (Weeks 0-24)|SAE, non-fatal|0
6147964|NCT01087762|9783310|FG000|Open-Label Period (Weeks 48-204)|Lack of Efficacy|0
6147965|NCT01087762|9783311|FG001|Open-Label Period (Weeks 48-204)|Lack of Efficacy|0
6147966|NCT01087762|9783312|FG002|Open-Label Period (Weeks 48-204)|Lack of Efficacy|0
6147967|NCT01087762|9783313|FG003|Open-Label Period (Weeks 48-204)|Lack of Efficacy|4
6147968|NCT01087762|9783314|FG004|Open-Label Period (Weeks 48-204)|Lack of Efficacy|14
6147969|NCT01087762|9783310|FG000|Open-Label Period (Weeks 48-204)|Protocol Violation|0
6038770|NCT00361335|9636421|FG003|SC Period: Week E0 to Week E24|Lack of Efficacy|0
6038771|NCT00361335|9636422|FG004|SC Period: Week E0 to Week E24|Lack of Efficacy|0
6147970|NCT01087762|9783311|FG001|Open-Label Period (Weeks 48-204)|Protocol Violation|0
6147971|NCT01087762|9783312|FG002|Open-Label Period (Weeks 48-204)|Protocol Violation|0
6147972|NCT01087762|9783313|FG003|Open-Label Period (Weeks 48-204)|Protocol Violation|1
6147973|NCT01087762|9783314|FG004|Open-Label Period (Weeks 48-204)|Protocol Violation|1
6147974|NCT01087762|9783310|FG000|Open-Label Period (Weeks 48-204)|Lost to Follow-up|0
6147975|NCT01087762|9783311|FG001|Open-Label Period (Weeks 48-204)|Lost to Follow-up|0
6038772|NCT00361335|9636423|FG005|SC Period: Week E0 to Week E24|Lack of Efficacy|0
6147976|NCT01087762|9783312|FG002|Open-Label Period (Weeks 48-204)|Lost to Follow-up|0
6147977|NCT01087762|9783313|FG003|Open-Label Period (Weeks 48-204)|Lost to Follow-up|5
6147978|NCT01087762|9783314|FG004|Open-Label Period (Weeks 48-204)|Lost to Follow-up|2
6147979|NCT01087762|9783310|FG000|Open-Label Period (Weeks 48-204)|Withdrawal by Subject|0
6147980|NCT01087762|9783311|FG001|Open-Label Period (Weeks 48-204)|Withdrawal by Subject|0
6147981|NCT01087762|9783312|FG002|Open-Label Period (Weeks 48-204)|Withdrawal by Subject|0
6147982|NCT01087762|9783313|FG003|Open-Label Period (Weeks 48-204)|Withdrawal by Subject|22
6147983|NCT01087762|9783314|FG004|Open-Label Period (Weeks 48-204)|Withdrawal by Subject|15
6147984|NCT01087762|9783310|FG000|Open-Label Period (Weeks 48-204)|Other|0
6147985|NCT01087762|9783311|FG001|Open-Label Period (Weeks 48-204)|Other|0
6147986|NCT01087762|9783312|FG002|Open-Label Period (Weeks 48-204)|Other|0
6147987|NCT01087762|9783313|FG003|Open-Label Period (Weeks 48-204)|Other|2
6147988|NCT01087762|9783314|FG004|Open-Label Period (Weeks 48-204)|Other|4
6147989|NCT01087762|9783310|FG000|Open-Label Period (Weeks 48-204)|SAE, non-fatal|0
6147990|NCT01087762|9783311|FG001|Open-Label Period (Weeks 48-204)|SAE, non-fatal|0
6309627|NCT02641379|10038345|FG006|Overall Study|Participant unable to attend study visit|1
6309628|NCT02641379|10038346|FG007|Overall Study|Participant unable to attend study visit|1
6309629|NCT02641379|10038347|FG008|Overall Study|Participant unable to attend study visit|0
6309630|NCT02641379|10038348|FG009|Overall Study|Participant unable to attend study visit|2
6309631|NCT02641379|10038349|FG010|Overall Study|Participant unable to attend study visit|0
6309632|NCT02641379|10038339|FG000|Overall Study|Participant's compliance|0
6309633|NCT02641379|10038340|FG001|Overall Study|Participant's compliance|1
6147991|NCT01087762|9783312|FG002|Open-Label Period (Weeks 48-204)|SAE, non-fatal|0
6147992|NCT01087762|9783313|FG003|Open-Label Period (Weeks 48-204)|SAE, non-fatal|7
6147993|NCT01087762|9783314|FG004|Open-Label Period (Weeks 48-204)|SAE, non-fatal|4
6147994|NCT01087762|9783310|FG000|Open-Label Period (Weeks 48-204)|AE, non-serious non-fatal|0
6147995|NCT01087762|9783311|FG001|Open-Label Period (Weeks 48-204)|AE, non-serious non-fatal|0
6147996|NCT01087762|9783312|FG002|Open-Label Period (Weeks 48-204)|AE, non-serious non-fatal|0
6147997|NCT01087762|9783313|FG003|Open-Label Period (Weeks 48-204)|AE, non-serious non-fatal|16
6147998|NCT01087762|9783314|FG004|Open-Label Period (Weeks 48-204)|AE, non-serious non-fatal|13
6147999|NCT01087762|9783310|FG000|Open-Label Period (Weeks 48-204)|SAE, non-fatal + AE, non-serious/fatal|0
6148000|NCT01087762|9783311|FG001|Open-Label Period (Weeks 48-204)|SAE, non-fatal + AE, non-serious/fatal|0
6148001|NCT01087762|9783312|FG002|Open-Label Period (Weeks 48-204)|SAE, non-fatal + AE, non-serious/fatal|0
6148002|NCT01087762|9783313|FG003|Open-Label Period (Weeks 48-204)|SAE, non-fatal + AE, non-serious/fatal|2
6148003|NCT01087762|9783314|FG004|Open-Label Period (Weeks 48-204)|SAE, non-fatal + AE, non-serious/fatal|4
6148004|NCT01087775|9783324|FG000|Overall Study|failed inclusion criteria|2
6148005|NCT01087788|9783332|FG000|24-weeks Double-blind Period|Lack of Efficacy|2
6148006|NCT01087788|9783333|FG001|24-weeks Double-blind Period|Lack of Efficacy|0
6148007|NCT01087788|9783334|FG002|24-weeks Double-blind Period|Lack of Efficacy|1
6148008|NCT01087788|9783332|FG000|24-weeks Double-blind Period|Protocol Violation|0
6148009|NCT01087788|9783333|FG001|24-weeks Double-blind Period|Protocol Violation|1
6148010|NCT01087788|9783334|FG002|24-weeks Double-blind Period|Protocol Violation|0
6148011|NCT01087788|9783332|FG000|24-weeks Double-blind Period|Lost to Follow-up|4
6148012|NCT01087788|9783333|FG001|24-weeks Double-blind Period|Lost to Follow-up|1
6148013|NCT01087788|9783334|FG002|24-weeks Double-blind Period|Lost to Follow-up|1
6148014|NCT01087788|9783332|FG000|24-weeks Double-blind Period|Withdrawal by Subject|7
6148015|NCT01087788|9783333|FG001|24-weeks Double-blind Period|Withdrawal by Subject|2
6148016|NCT01087788|9783334|FG002|24-weeks Double-blind Period|Withdrawal by Subject|5
6148017|NCT01087788|9783332|FG000|24-weeks Double-blind Period|AE, serious fatal|0
6148018|NCT01087788|9783333|FG001|24-weeks Double-blind Period|AE, serious fatal|1
6148019|NCT01087788|9783334|FG002|24-weeks Double-blind Period|AE, serious fatal|1
6148020|NCT01087788|9783332|FG000|24-weeks Double-blind Period|AE, serious non-fatal|0
6148021|NCT01087788|9783333|FG001|24-weeks Double-blind Period|AE, serious non-fatal|2
6148022|NCT01087788|9783334|FG002|24-weeks Double-blind Period|AE, serious non-fatal|3
6148023|NCT01087788|9783332|FG000|24-weeks Double-blind Period|AE, non-serious non-fatal|2
6148024|NCT01087788|9783333|FG001|24-weeks Double-blind Period|AE, non-serious non-fatal|1
6148025|NCT01087788|9783334|FG002|24-weeks Double-blind Period|AE, non-serious non-fatal|2
6148026|NCT01087788|9783332|FG000|24-weeks Double-blind Period|AE, unknown type|0
6148027|NCT01087788|9783333|FG001|24-weeks Double-blind Period|AE, unknown type|0
6148028|NCT01087788|9783334|FG002|24-weeks Double-blind Period|AE, unknown type|1
6148029|NCT01087788|9783332|FG000|24-weeks Double-blind Period|Patient (P) does not want to attend|1
6148030|NCT01087788|9783333|FG001|24-weeks Double-blind Period|Patient (P) does not want to attend|0
6148031|NCT01087788|9783334|FG002|24-weeks Double-blind Period|Patient (P) does not want to attend|0
6148032|NCT01087788|9783332|FG000|24-weeks Double-blind Period|Protocol violation (decision of monitor)|0
6148033|NCT01087788|9783333|FG001|24-weeks Double-blind Period|Protocol violation (decision of monitor)|1
6309634|NCT02641379|10038341|FG002|Overall Study|Participant's compliance|0
6309635|NCT02641379|10038342|FG003|Overall Study|Participant's compliance|1
6038773|NCT00361335|9636424|FG006|SC Period: Week E0 to Week E24|Lack of Efficacy|3
6148034|NCT01087788|9783334|FG002|24-weeks Double-blind Period|Protocol violation (decision of monitor)|0
6148035|NCT01087788|9783332|FG000|24-weeks Double-blind Period|Exclusion criteria were not met|0
6038774|NCT00361504|9636464|FG000|Overall Study|Withdrawal by Subject|94
6038775|NCT00361504|9636465|FG001|Overall Study|Withdrawal by Subject|31
6038776|NCT00361504|9636464|FG000|Overall Study|Lost to Follow-up|40
6038777|NCT00361504|9636465|FG001|Overall Study|Lost to Follow-up|7
6038778|NCT00361504|9636464|FG000|Overall Study|Adverse Event|203
6038779|NCT00361504|9636465|FG001|Overall Study|Adverse Event|82
6038780|NCT00361504|9636464|FG000|Overall Study|Lack of Efficacy|72
6038781|NCT00361504|9636465|FG001|Overall Study|Lack of Efficacy|7
6038782|NCT00361504|9636464|FG000|Overall Study|Resolution of Pain|2
6038783|NCT00361504|9636465|FG001|Overall Study|Resolution of Pain|0
6038784|NCT00361504|9636464|FG000|Overall Study|Study medication non compliant|42
6038785|NCT00361504|9636465|FG001|Overall Study|Study medication non compliant|15
6038786|NCT00361504|9636464|FG000|Overall Study|All other|28
6038787|NCT00361504|9636465|FG001|Overall Study|All other|3
6038788|NCT00361569|9636475|FG000|Overall Study|Protocol Violation|3
6038789|NCT00361569|9636476|FG001|Overall Study|Protocol Violation|2
6038790|NCT00361569|9636477|FG002|Overall Study|Protocol Violation|4
6038791|NCT00361569|9636478|FG003|Overall Study|Protocol Violation|2
6038792|NCT00361569|9636475|FG000|Overall Study|Withdrawal by Subject|2
6038793|NCT00361569|9636476|FG001|Overall Study|Withdrawal by Subject|1
6038794|NCT00361569|9636477|FG002|Overall Study|Withdrawal by Subject|9
6038795|NCT00361569|9636478|FG003|Overall Study|Withdrawal by Subject|14
6038796|NCT00361569|9636475|FG000|Overall Study|Adverse Event|3
6038797|NCT00361569|9636476|FG001|Overall Study|Adverse Event|5
6038798|NCT00361569|9636477|FG002|Overall Study|Adverse Event|2
6038799|NCT00361569|9636478|FG003|Overall Study|Adverse Event|2
6038800|NCT00361569|9636475|FG000|Overall Study|Lost to Follow-up|2
6038801|NCT00361569|9636476|FG001|Overall Study|Lost to Follow-up|3
6038802|NCT00361569|9636477|FG002|Overall Study|Lost to Follow-up|3
6038803|NCT00361569|9636478|FG003|Overall Study|Lost to Follow-up|2
6038804|NCT00361569|9636475|FG000|Overall Study|Not specified by investigator|2
6038805|NCT00361569|9636476|FG001|Overall Study|Not specified by investigator|0
6038806|NCT00361569|9636477|FG002|Overall Study|Not specified by investigator|0
6038807|NCT00361569|9636478|FG003|Overall Study|Not specified by investigator|1
6038808|NCT00361634|9636492|FG000|Overall Study|Lost to Follow-up|1
6038809|NCT00361634|9636492|FG000|Overall Study|Withdrawal by Subject|1
6038810|NCT00361842|9636507|FG000|Overall Study|Withdrawal by Subject|2
6038811|NCT00361842|9636508|FG001|Overall Study|Withdrawal by Subject|3
6038812|NCT00361842|9636507|FG000|Overall Study|Death|2
6038813|NCT00361842|9636508|FG001|Overall Study|Death|1
6038814|NCT00361842|9636507|FG000|Overall Study|Disease progression|19
6038815|NCT00361842|9636508|FG001|Overall Study|Disease progression|20
6038816|NCT00361842|9636507|FG000|Overall Study|Adverse Event|2
6038817|NCT00361842|9636508|FG001|Overall Study|Adverse Event|3
6038818|NCT00361842|9636507|FG000|Overall Study|Occurrence of unacceptable toxicity|1
6038819|NCT00361842|9636508|FG001|Overall Study|Occurrence of unacceptable toxicity|5
6038820|NCT00361842|9636507|FG000|Overall Study|Other|1
6038821|NCT00361842|9636508|FG001|Overall Study|Other|0
6038822|NCT00361842|9636507|FG000|Overall Study|Other|0
6038823|NCT00361842|9636508|FG001|Overall Study|Other|2
6038824|NCT00362115|9636533|FG000|Overall Study|Adverse Event|0
6038825|NCT00362115|9636534|FG001|Overall Study|Adverse Event|1
6038826|NCT00362115|9636535|FG002|Overall Study|Adverse Event|1
6038827|NCT00362115|9636536|FG003|Overall Study|Adverse Event|1
6038828|NCT00362115|9636537|FG004|Overall Study|Adverse Event|2
6038829|NCT00362115|9636538|FG005|Overall Study|Adverse Event|2
6038830|NCT00362115|9636539|FG006|Overall Study|Adverse Event|1
6038831|NCT00362115|9636533|FG000|Overall Study|Protocol Violation|0
6038832|NCT00362115|9636534|FG001|Overall Study|Protocol Violation|0
6038833|NCT00362115|9636535|FG002|Overall Study|Protocol Violation|0
6038834|NCT00362115|9636536|FG003|Overall Study|Protocol Violation|0
6038835|NCT00362115|9636537|FG004|Overall Study|Protocol Violation|0
6038836|NCT00362115|9636538|FG005|Overall Study|Protocol Violation|1
6038837|NCT00362115|9636539|FG006|Overall Study|Protocol Violation|0
6038838|NCT00362115|9636533|FG000|Overall Study|Lost to Follow-up|0
6038839|NCT00362115|9636534|FG001|Overall Study|Lost to Follow-up|1
6038840|NCT00362115|9636535|FG002|Overall Study|Lost to Follow-up|0
6038841|NCT00362115|9636536|FG003|Overall Study|Lost to Follow-up|0
6038842|NCT00362115|9636537|FG004|Overall Study|Lost to Follow-up|2
6038843|NCT00362115|9636538|FG005|Overall Study|Lost to Follow-up|0
6038844|NCT00362115|9636539|FG006|Overall Study|Lost to Follow-up|1
6038845|NCT00362115|9636533|FG000|Overall Study|Withdrawal by Subject|1
6038846|NCT00362115|9636534|FG001|Overall Study|Withdrawal by Subject|3
6038847|NCT00362115|9636535|FG002|Overall Study|Withdrawal by Subject|1
6038848|NCT00362115|9636536|FG003|Overall Study|Withdrawal by Subject|0
6038849|NCT00362115|9636537|FG004|Overall Study|Withdrawal by Subject|1
6038850|NCT00362115|9636538|FG005|Overall Study|Withdrawal by Subject|3
6038851|NCT00362115|9636539|FG006|Overall Study|Withdrawal by Subject|4
6038852|NCT00362115|9636533|FG000|Overall Study|Lack of Efficacy|1
6038853|NCT00362115|9636534|FG001|Overall Study|Lack of Efficacy|0
6038854|NCT00362115|9636535|FG002|Overall Study|Lack of Efficacy|5
6038855|NCT00362115|9636536|FG003|Overall Study|Lack of Efficacy|2
6038856|NCT00362115|9636537|FG004|Overall Study|Lack of Efficacy|2
6038857|NCT00362115|9636538|FG005|Overall Study|Lack of Efficacy|0
6038858|NCT00362115|9636539|FG006|Overall Study|Lack of Efficacy|3
6038859|NCT00362115|9636533|FG000|Overall Study|Physician Decision|0
6038860|NCT00362115|9636534|FG001|Overall Study|Physician Decision|0
6038861|NCT00362115|9636535|FG002|Overall Study|Physician Decision|0
6038862|NCT00362115|9636536|FG003|Overall Study|Physician Decision|0
6038863|NCT00362115|9636537|FG004|Overall Study|Physician Decision|0
6038864|NCT00362115|9636538|FG005|Overall Study|Physician Decision|0
6038865|NCT00362115|9636539|FG006|Overall Study|Physician Decision|3
6038866|NCT00362115|9636533|FG000|Overall Study|Other|0
6038867|NCT00362115|9636534|FG001|Overall Study|Other|1
6038868|NCT00362115|9636535|FG002|Overall Study|Other|0
6038869|NCT00362115|9636536|FG003|Overall Study|Other|1
6038870|NCT00362115|9636537|FG004|Overall Study|Other|0
6038871|NCT00362115|9636538|FG005|Overall Study|Other|1
6038872|NCT00362115|9636539|FG006|Overall Study|Other|0
6038873|NCT00362180|9636568|FG000|Treated Period|Withdrawal by Subject|1
6038874|NCT00362180|9636569|FG001|Treated Period|Withdrawal by Subject|0
6038875|NCT00362180|9636570|FG002|Treated Period|Withdrawal by Subject|0
6038876|NCT00362180|9636571|FG003|Treated Period|Withdrawal by Subject|0
6038877|NCT00362180|9636572|FG004|Treated Period|Withdrawal by Subject|0
6038878|NCT00362180|9636573|FG005|Treated Period|Withdrawal by Subject|0
6038879|NCT00362180|9636574|FG006|Treated Period|Withdrawal by Subject|0
6038880|NCT00362180|9636575|FG007|Treated Period|Withdrawal by Subject|0
6038881|NCT00362180|9636576|FG008|Treated Period|Withdrawal by Subject|0
6038882|NCT00362180|9636568|FG000|Treated Period|Adverse Event|0
6038883|NCT00362180|9636569|FG001|Treated Period|Adverse Event|0
6038884|NCT00362180|9636570|FG002|Treated Period|Adverse Event|0
6038885|NCT00362180|9636571|FG003|Treated Period|Adverse Event|0
6038886|NCT00362180|9636572|FG004|Treated Period|Adverse Event|0
6038887|NCT00362180|9636573|FG005|Treated Period|Adverse Event|1
6038888|NCT00362180|9636574|FG006|Treated Period|Adverse Event|0
6038889|NCT00362180|9636575|FG007|Treated Period|Adverse Event|1
6038890|NCT00362180|9636576|FG008|Treated Period|Adverse Event|0
6038891|NCT00362232|9636596|FG000|Treatment (12 +/- 2 Days)|Adverse Event|62
6038892|NCT00362232|9636597|FG001|Treatment (12 +/- 2 Days)|Adverse Event|56
6038893|NCT00362232|9636596|FG000|Treatment (12 +/- 2 Days)|Death|1
6038894|NCT00362232|9636597|FG001|Treatment (12 +/- 2 Days)|Death|3
6038895|NCT00362232|9636596|FG000|Treatment (12 +/- 2 Days)|Lost to Follow-up|3
6038896|NCT00362232|9636597|FG001|Treatment (12 +/- 2 Days)|Lost to Follow-up|1
6038897|NCT00362232|9636596|FG000|Treatment (12 +/- 2 Days)|Physician Decision|2
6038898|NCT00362232|9636597|FG001|Treatment (12 +/- 2 Days)|Physician Decision|5
6038899|NCT00362232|9636596|FG000|Treatment (12 +/- 2 Days)|Protocol Violation|22
6038900|NCT00362232|9636597|FG001|Treatment (12 +/- 2 Days)|Protocol Violation|21
6038901|NCT00362232|9636596|FG000|Treatment (12 +/- 2 Days)|Withdrawal by Subject|49
6038902|NCT00362232|9636597|FG001|Treatment (12 +/- 2 Days)|Withdrawal by Subject|47
6038903|NCT00362232|9636596|FG000|Treatment (12 +/- 2 Days)|Noncompliance to Study Drug|9
6038904|NCT00362232|9636597|FG001|Treatment (12 +/- 2 Days)|Noncompliance to Study Drug|0
6038905|NCT00362232|9636596|FG000|Treatment (12 +/- 2 Days)|Technical Problems|1
6038906|NCT00362232|9636597|FG001|Treatment (12 +/- 2 Days)|Technical Problems|0
6038907|NCT00362232|9636596|FG000|Treatment (12 +/- 2 Days)|Clinical Endpoint Reached|10
6038908|NCT00362232|9636597|FG001|Treatment (12 +/- 2 Days)|Clinical Endpoint Reached|18
6038909|NCT00362232|9636596|FG000|Follow-up (30 (+ 5) Days)|Adverse Event|2
6038910|NCT00362232|9636597|FG001|Follow-up (30 (+ 5) Days)|Adverse Event|3
6038911|NCT00362232|9636596|FG000|Follow-up (30 (+ 5) Days)|Death|1
6038912|NCT00362232|9636597|FG001|Follow-up (30 (+ 5) Days)|Death|1
6038913|NCT00362232|9636596|FG000|Follow-up (30 (+ 5) Days)|Lost to Follow-up|27
6038914|NCT00362232|9636597|FG001|Follow-up (30 (+ 5) Days)|Lost to Follow-up|28
6038915|NCT00362232|9636596|FG000|Follow-up (30 (+ 5) Days)|Withdrawal by Subject|8
6038916|NCT00362232|9636597|FG001|Follow-up (30 (+ 5) Days)|Withdrawal by Subject|7
6038917|NCT00362297|9636605|FG000|Treatment 1 (Initial Drug Assignment)|Lost to Follow-up|0
6038918|NCT00362297|9636606|FG001|Treatment 1 (Initial Drug Assignment)|Lost to Follow-up|4
6038919|NCT00362336|9636615|FG000|Overall Study|Serious Adverse Event|1
6038920|NCT00362336|9636616|FG001|Overall Study|Serious Adverse Event|0
6038921|NCT00362336|9636617|FG002|Overall Study|Serious Adverse Event|1
6038922|NCT00362336|9636615|FG000|Overall Study|Protocol Violation|0
6038923|NCT00362336|9636616|FG001|Overall Study|Protocol Violation|0
6038924|NCT00362336|9636617|FG002|Overall Study|Protocol Violation|1
6038925|NCT00362336|9636615|FG000|Overall Study|Lost to Follow-up|6
6038926|NCT00362336|9636616|FG001|Overall Study|Lost to Follow-up|4
6038927|NCT00362336|9636617|FG002|Overall Study|Lost to Follow-up|0
6038928|NCT00362336|9636615|FG000|Overall Study|Withdrawal by Subject|3
6038929|NCT00362336|9636616|FG001|Overall Study|Withdrawal by Subject|3
6038930|NCT00362336|9636617|FG002|Overall Study|Withdrawal by Subject|1
6038931|NCT00362375|9636634|FG000|Overall Study|Lost to Follow-up|40
6038932|NCT00362375|9636635|FG001|Overall Study|Lost to Follow-up|35
6038933|NCT00362414|9636641|FG000|Overall Study|Death|2
6038934|NCT00362414|9636641|FG000|Overall Study|Adverse Event|1
6038935|NCT00362609|9636677|FG000|Overall Study|Withdrawal by Subject|0
6038936|NCT00362609|9636678|FG001|Overall Study|Withdrawal by Subject|1
6038937|NCT00362609|9636677|FG000|Overall Study|Protocol Violation|0
6038938|NCT00362609|9636678|FG001|Overall Study|Protocol Violation|1
6038939|NCT00362648|9636688|FG000|Overall Study|Adverse Event|12
6038940|NCT00362648|9636689|FG001|Overall Study|Adverse Event|21
6038941|NCT00362648|9636690|FG002|Overall Study|Adverse Event|1
6038942|NCT00362648|9636691|FG003|Overall Study|Adverse Event|0
6038943|NCT00362648|9636688|FG000|Overall Study|Lost to Follow-up|62
6038944|NCT00362648|9636689|FG001|Overall Study|Lost to Follow-up|69
6038945|NCT00362648|9636690|FG002|Overall Study|Lost to Follow-up|4
6038946|NCT00362648|9636691|FG003|Overall Study|Lost to Follow-up|3
6038947|NCT00362648|9636688|FG000|Overall Study|Protocol Violation|4
6038948|NCT00362648|9636689|FG001|Overall Study|Protocol Violation|2
6038949|NCT00362648|9636690|FG002|Overall Study|Protocol Violation|2
6038950|NCT00362648|9636691|FG003|Overall Study|Protocol Violation|2
6038951|NCT00362648|9636688|FG000|Overall Study|Withdrawal by Subject|48
6038952|NCT00362648|9636689|FG001|Overall Study|Withdrawal by Subject|42
6038953|NCT00362648|9636690|FG002|Overall Study|Withdrawal by Subject|2
6038954|NCT00362648|9636691|FG003|Overall Study|Withdrawal by Subject|6
6038955|NCT00363051|9636721|FG000|Overall Study|Adminstrative problems|1
6038956|NCT00363051|9636722|FG001|Overall Study|Adminstrative problems|1
6038957|NCT00363051|9636721|FG000|Overall Study|Adverse Event|21
6038958|NCT00363051|9636722|FG001|Overall Study|Adverse Event|12
6038959|NCT00363051|9636721|FG000|Overall Study|New Cancer Therapy|2
6038960|NCT00363051|9636722|FG001|Overall Study|New Cancer Therapy|1
6038961|NCT00363051|9636721|FG000|Overall Study|Withdrawal by Subject|11
6038962|NCT00363051|9636722|FG001|Overall Study|Withdrawal by Subject|3
6038963|NCT00363051|9636721|FG000|Overall Study|Lost to Follow-up|0
6038964|NCT00363051|9636722|FG001|Overall Study|Lost to Follow-up|1
6038965|NCT00363051|9636721|FG000|Overall Study|Protocol Violation|0
6148036|NCT01087788|9783333|FG001|24-weeks Double-blind Period|Exclusion criteria were not met|1
6148037|NCT01087788|9783334|FG002|24-weeks Double-blind Period|Exclusion criteria were not met|0
6148038|NCT01087788|9783332|FG000|24-weeks Double-blind Period|P cannot comply with scheduled visits|0
6148039|NCT01087788|9783333|FG001|24-weeks Double-blind Period|P cannot comply with scheduled visits|0
6148040|NCT01087788|9783334|FG002|24-weeks Double-blind Period|P cannot comply with scheduled visits|1
6148041|NCT01087788|9783332|FG000|24-weeks Dose-blind Period|Lack of Efficacy|0
6148042|NCT01087788|9783333|FG001|24-weeks Dose-blind Period|Lack of Efficacy|2
6148043|NCT01087788|9783334|FG002|24-weeks Dose-blind Period|Lack of Efficacy|1
6148044|NCT01087788|9783332|FG000|24-weeks Dose-blind Period|Lost to Follow-up|1
6148045|NCT01087788|9783333|FG001|24-weeks Dose-blind Period|Lost to Follow-up|0
6148046|NCT01087788|9783334|FG002|24-weeks Dose-blind Period|Lost to Follow-up|1
6148047|NCT01087788|9783332|FG000|24-weeks Dose-blind Period|Withdrawal by Subject|1
6148048|NCT01087788|9783333|FG001|24-weeks Dose-blind Period|Withdrawal by Subject|0
6148049|NCT01087788|9783334|FG002|24-weeks Dose-blind Period|Withdrawal by Subject|0
6148050|NCT01087788|9783332|FG000|24-weeks Dose-blind Period|AE, serious fatal|0
6148051|NCT01087788|9783333|FG001|24-weeks Dose-blind Period|AE, serious fatal|1
6148052|NCT01087788|9783334|FG002|24-weeks Dose-blind Period|AE, serious fatal|0
6148053|NCT01087788|9783332|FG000|24-weeks Dose-blind Period|AE, serious non-fatal|2
6148054|NCT01087788|9783333|FG001|24-weeks Dose-blind Period|AE, serious non-fatal|1
6148055|NCT01087788|9783334|FG002|24-weeks Dose-blind Period|AE, serious non-fatal|2
6148056|NCT01087788|9783332|FG000|24-weeks Dose-blind Period|AE, non-serious non-fatal|2
6148057|NCT01087788|9783333|FG001|24-weeks Dose-blind Period|AE, non-serious non-fatal|1
6148058|NCT01087788|9783334|FG002|24-weeks Dose-blind Period|AE, non-serious non-fatal|1
6148059|NCT01087788|9783332|FG000|24-weeks Dose-blind Period|Sponsor decision following missed visits|1
6148060|NCT01087788|9783333|FG001|24-weeks Dose-blind Period|Sponsor decision following missed visits|0
6148061|NCT01087788|9783334|FG002|24-weeks Dose-blind Period|Sponsor decision following missed visits|0
6148062|NCT01087788|9783332|FG000|24-weeks Dose-blind Period|Patient moved|0
6148063|NCT01087788|9783333|FG001|24-weeks Dose-blind Period|Patient moved|0
6148064|NCT01087788|9783334|FG002|24-weeks Dose-blind Period|Patient moved|1
6148065|NCT01087788|9783332|FG000|Open-Label Period (OL-P)|Lack of Efficacy|4
6148066|NCT01087788|9783333|FG001|Open-Label Period (OL-P)|Lack of Efficacy|2
6148067|NCT01087788|9783334|FG002|Open-Label Period (OL-P)|Lack of Efficacy|3
6148068|NCT01087788|9783332|FG000|Open-Label Period (OL-P)|Protocol Violation|2
6148069|NCT01087788|9783333|FG001|Open-Label Period (OL-P)|Protocol Violation|1
6148070|NCT01087788|9783334|FG002|Open-Label Period (OL-P)|Protocol Violation|0
6148071|NCT01087788|9783332|FG000|Open-Label Period (OL-P)|Lost to Follow-up|0
6148072|NCT01087788|9783333|FG001|Open-Label Period (OL-P)|Lost to Follow-up|4
6148073|NCT01087788|9783334|FG002|Open-Label Period (OL-P)|Lost to Follow-up|2
6148074|NCT01087788|9783332|FG000|Open-Label Period (OL-P)|Withdrawal by Subject|13
6148075|NCT01087788|9783333|FG001|Open-Label Period (OL-P)|Withdrawal by Subject|8
6148076|NCT01087788|9783334|FG002|Open-Label Period (OL-P)|Withdrawal by Subject|10
6148077|NCT01087788|9783332|FG000|Open-Label Period (OL-P)|AE, serious fatal|2
6148078|NCT01087788|9783333|FG001|Open-Label Period (OL-P)|AE, serious fatal|0
6148079|NCT01087788|9783334|FG002|Open-Label Period (OL-P)|AE, serious fatal|1
6148080|NCT01087788|9783332|FG000|Open-Label Period (OL-P)|AE, serious non-fatal|1
6148081|NCT01087788|9783333|FG001|Open-Label Period (OL-P)|AE, serious non-fatal|3
6148082|NCT01087788|9783334|FG002|Open-Label Period (OL-P)|AE, serious non-fatal|4
6038966|NCT00363051|9636722|FG001|Overall Study|Protocol Violation|2
6038967|NCT00363051|9636721|FG000|Overall Study|Death|3
6148083|NCT01087788|9783332|FG000|Open-Label Period (OL-P)|AE, non-serious non-fatal|6
6148084|NCT01087788|9783333|FG001|Open-Label Period (OL-P)|AE, non-serious non-fatal|4
6191374|NCT01422304|9848165|FG000|Overall Study|Lost to Follow-up|14
6038968|NCT00363051|9636722|FG001|Overall Study|Death|2
6038969|NCT00363129|9636741|FG000|Overall Study|Withdrawal by Subject|11
6038970|NCT00363129|9636742|FG001|Overall Study|Withdrawal by Subject|18
6038971|NCT00363129|9636741|FG000|Overall Study|Adverse Event|8
6038972|NCT00363129|9636742|FG001|Overall Study|Adverse Event|3
6038973|NCT00363129|9636741|FG000|Overall Study|Alternate Treatment|2
6038974|NCT00363129|9636742|FG001|Overall Study|Alternate Treatment|4
6038975|NCT00363129|9636741|FG000|Overall Study|Other Medical Problems|2
6038976|NCT00363129|9636742|FG001|Overall Study|Other Medical Problems|4
6038977|NCT00363129|9636741|FG000|Overall Study|Death|0
6038978|NCT00363129|9636742|FG001|Overall Study|Death|1
6038979|NCT00363129|9636741|FG000|Overall Study|Other Reasons|6
6038980|NCT00363129|9636742|FG001|Overall Study|Other Reasons|3
6038981|NCT00363142|9636750|FG000|Overall Study|Adverse Event|2
6038982|NCT00363142|9636751|FG001|Overall Study|Adverse Event|0
6038983|NCT00363142|9636750|FG000|Overall Study|Lack of Efficacy|0
6038984|NCT00363142|9636751|FG001|Overall Study|Lack of Efficacy|1
6038985|NCT00363142|9636750|FG000|Overall Study|Lost to Follow-up|1
6038986|NCT00363142|9636751|FG001|Overall Study|Lost to Follow-up|0
6038987|NCT00363142|9636750|FG000|Overall Study|Non-compliance|1
6148085|NCT01087788|9783334|FG002|Open-Label Period (OL-P)|AE, non-serious non-fatal|4
6148086|NCT01087788|9783332|FG000|Open-Label Period (OL-P)|SAE, non-fatal+AE, non-serious non-fatal|0
6148087|NCT01087788|9783333|FG001|Open-Label Period (OL-P)|SAE, non-fatal+AE, non-serious non-fatal|1
6148088|NCT01087788|9783334|FG002|Open-Label Period (OL-P)|SAE, non-fatal+AE, non-serious non-fatal|0
6148089|NCT01087788|9783332|FG000|Open-Label Period (OL-P)|AE, non-serious unknown|1
6148090|NCT01087788|9783333|FG001|Open-Label Period (OL-P)|AE, non-serious unknown|0
6148091|NCT01087788|9783334|FG002|Open-Label Period (OL-P)|AE, non-serious unknown|0
6148092|NCT01087788|9783332|FG000|Open-Label Period (OL-P)|Sponsor request|1
6148093|NCT01087788|9783333|FG001|Open-Label Period (OL-P)|Sponsor request|0
6148094|NCT01087788|9783334|FG002|Open-Label Period (OL-P)|Sponsor request|0
6148095|NCT01087788|9783332|FG000|Open-Label Period (OL-P)|Principal investigator decision|0
6148096|NCT01087788|9783333|FG001|Open-Label Period (OL-P)|Principal investigator decision|1
6148097|NCT01087788|9783334|FG002|Open-Label Period (OL-P)|Principal investigator decision|2
6148098|NCT01087788|9783332|FG000|Open-Label Period (OL-P)|No participation in study extension|0
6148099|NCT01087788|9783333|FG001|Open-Label Period (OL-P)|No participation in study extension|0
6148100|NCT01087788|9783334|FG002|Open-Label Period (OL-P)|No participation in study extension|1
6148101|NCT01087788|9783332|FG000|Open-Label Period (OL-P)|Personal reasons|0
6148102|NCT01087788|9783333|FG001|Open-Label Period (OL-P)|Personal reasons|0
6148103|NCT01087788|9783334|FG002|Open-Label Period (OL-P)|Personal reasons|1
6148104|NCT01087814|9783354|FG000|First Intervention (5 Days)|Withdrawal by Subject|3
6148105|NCT01087814|9783355|FG001|First Intervention (5 Days)|Withdrawal by Subject|1
6148106|NCT01087814|9783354|FG000|Second Intervention (5 Days)|Physician Decision|1
6148107|NCT01087814|9783355|FG001|Second Intervention (5 Days)|Physician Decision|0
6148108|NCT01087905|9783369|FG000|Overall Study|Lost to Follow-up|24
6148109|NCT01087905|9783370|FG001|Overall Study|Lost to Follow-up|28
6148110|NCT01087905|9783371|FG002|Overall Study|Lost to Follow-up|18
6148111|NCT01087905|9783372|FG003|Overall Study|Lost to Follow-up|31
6148112|NCT01087905|9783373|FG004|Overall Study|Lost to Follow-up|27
6148113|NCT01087905|9783374|FG005|Overall Study|Lost to Follow-up|25
6148114|NCT01087905|9783375|FG006|Overall Study|Lost to Follow-up|20
6148115|NCT01087905|9783376|FG007|Overall Study|Lost to Follow-up|24
6148116|NCT01087905|9783369|FG000|Overall Study|Withdrawal by Subject|5
6148117|NCT01087905|9783370|FG001|Overall Study|Withdrawal by Subject|4
6148118|NCT01087905|9783371|FG002|Overall Study|Withdrawal by Subject|4
6148119|NCT01087905|9783372|FG003|Overall Study|Withdrawal by Subject|5
6148120|NCT01087905|9783373|FG004|Overall Study|Withdrawal by Subject|4
6148121|NCT01087905|9783374|FG005|Overall Study|Withdrawal by Subject|3
6148122|NCT01087905|9783375|FG006|Overall Study|Withdrawal by Subject|3
6148123|NCT01087905|9783376|FG007|Overall Study|Withdrawal by Subject|5
6148124|NCT01087944|9783414|FG000|Period 1 (Week 1-3)|Adverse Event|1
6148125|NCT01087944|9783415|FG001|Period 1 (Week 1-3)|Adverse Event|0
6148126|NCT01087944|9783414|FG000|Period 2 (Week 4-6)|Adverse Event|0
6148127|NCT01087944|9783415|FG001|Period 2 (Week 4-6)|Adverse Event|2
6148128|NCT01087957|9783423|FG000|Overall Study|Death|2
6148129|NCT01087957|9783424|FG001|Overall Study|Death|2
6148130|NCT01087957|9783423|FG000|Overall Study|Lost to Follow-up|3
6148131|NCT01087957|9783424|FG001|Overall Study|Lost to Follow-up|4
6148132|NCT01087957|9783423|FG000|Overall Study|Protocol Violation|13
6148133|NCT01087957|9783424|FG001|Overall Study|Protocol Violation|25
6148134|NCT01087957|9783423|FG000|Overall Study|Withdrawal by Subject|18
6038988|NCT00363142|9636751|FG001|Overall Study|Non-compliance|1
6038989|NCT00363142|9636750|FG000|Overall Study|Withdrawal by Subject|3
6148135|NCT01087957|9783424|FG001|Overall Study|Withdrawal by Subject|15
6148136|NCT01087957|9783423|FG000|Overall Study|Physician Decision|5
6148137|NCT01087957|9783424|FG001|Overall Study|Physician Decision|9
6148138|NCT01087970|9783430|FG000|Overall Study|Protocol Violation|2
6148139|NCT01088048|9783454|FG000|Overall Study|Adverse Event|7
6148140|NCT01088048|9783455|FG001|Overall Study|Adverse Event|9
6148141|NCT01088048|9783456|FG002|Overall Study|Adverse Event|7
6148142|NCT01088048|9783457|FG003|Overall Study|Adverse Event|5
6148143|NCT01088048|9783458|FG004|Overall Study|Adverse Event|6
6038990|NCT00363142|9636751|FG001|Overall Study|Withdrawal by Subject|1
6038991|NCT00363246|9636769|FG000|Overall Study|Death|40
6038992|NCT00363246|9636769|FG000|Overall Study|Withdrawal by Subject|19
6038993|NCT00363246|9636769|FG000|Overall Study|Lost to Follow-up|14
6038994|NCT00363246|9636769|FG000|Overall Study|Bad health|6
6038995|NCT00363246|9636769|FG000|Overall Study|Stopped using wheelchair|11
6038996|NCT00363246|9636769|FG000|Overall Study|Subject expressed security concerns|2
6038997|NCT00363246|9636769|FG000|Overall Study|Eligibility changed due to Hospice move|5
6038998|NCT00363298|9636776|FG000|First Study Week|Lack of Efficacy|6
6038999|NCT00363298|9636777|FG001|First Study Week|Lack of Efficacy|5
6039000|NCT00363298|9636776|FG000|4-week Study Continuation Phase|Lack of Efficacy|1
6039001|NCT00363298|9636777|FG001|4-week Study Continuation Phase|Lack of Efficacy|0
6039002|NCT00363311|9636786|FG000|Overall Study|Adverse Event|6
6039003|NCT00363311|9636787|FG001|Overall Study|Adverse Event|4
6039004|NCT00363311|9636786|FG000|Overall Study|Lost to Follow-up|3
6039005|NCT00363311|9636787|FG001|Overall Study|Lost to Follow-up|0
6039006|NCT00363311|9636786|FG000|Overall Study|Protocol Violation|1
6039007|NCT00363311|9636787|FG001|Overall Study|Protocol Violation|2
6039008|NCT00363311|9636786|FG000|Overall Study|Withdrawal by Subject|12
6039009|NCT00363311|9636787|FG001|Overall Study|Withdrawal by Subject|6
6039010|NCT00363311|9636786|FG000|Overall Study|Physician Decision|1
6039011|NCT00363311|9636787|FG001|Overall Study|Physician Decision|1
6039012|NCT00363311|9636786|FG000|Overall Study|Sponsor Terminated Study|2
6039013|NCT00363311|9636787|FG001|Overall Study|Sponsor Terminated Study|2
6039014|NCT00363311|9636786|FG000|Overall Study|Disease Progression|46
6039015|NCT00363311|9636787|FG001|Overall Study|Disease Progression|26
6039016|NCT00363311|9636786|FG000|Overall Study|Non-Compliance|1
6039017|NCT00363311|9636787|FG001|Overall Study|Non-Compliance|1
6039018|NCT00363311|9636786|FG000|Overall Study|Participant Refused Biopsy|1
6039019|NCT00363311|9636787|FG001|Overall Study|Participant Refused Biopsy|0
6039020|NCT00363311|9636786|FG000|Overall Study|Prostate Volume/PSA Doubled|1
6039021|NCT00363311|9636787|FG001|Overall Study|Prostate Volume/PSA Doubled|0
6039022|NCT00363311|9636786|FG000|Overall Study|Participant Opted for Treatment|1
6039023|NCT00363311|9636787|FG001|Overall Study|Participant Opted for Treatment|0
6039024|NCT00363311|9636786|FG000|Overall Study|Participant Moved to Another Country|1
6039025|NCT00363311|9636787|FG001|Overall Study|Participant Moved to Another Country|0
6039026|NCT00363311|9636786|FG000|Overall Study|Participant Withdrew Waiting for Surgery|0
6039027|NCT00363311|9636787|FG001|Overall Study|Participant Withdrew Waiting for Surgery|1
6039028|NCT00363311|9636786|FG000|Overall Study|Withdrawn per Instructions of Monitor|0
6039029|NCT00363311|9636787|FG001|Overall Study|Withdrawn per Instructions of Monitor|1
6039030|NCT00363311|9636786|FG000|Overall Study|Participant Moved to Louisiana|0
6039031|NCT00363311|9636787|FG001|Overall Study|Participant Moved to Louisiana|1
6039032|NCT00363415|9636795|FG000|Overall Study|Progressive Disease|196
6039033|NCT00363415|9636796|FG001|Overall Study|Progressive Disease|107
6039034|NCT00363415|9636795|FG000|Overall Study|Sponsor Decision|67
6039035|NCT00363415|9636796|FG001|Overall Study|Sponsor Decision|31
6039036|NCT00363415|9636795|FG000|Overall Study|Death|32
6039037|NCT00363415|9636796|FG001|Overall Study|Death|29
6148144|NCT01088048|9783459|FG005|Overall Study|Adverse Event|3
6148145|NCT01088048|9783460|FG006|Overall Study|Adverse Event|3
6148146|NCT01088048|9783461|FG007|Overall Study|Adverse Event|0
6148147|NCT01088048|9783462|FG008|Overall Study|Adverse Event|2
6148148|NCT01088048|9783463|FG009|Overall Study|Adverse Event|2
6148149|NCT01088048|9783454|FG000|Overall Study|Withdrew Consent|1
6148150|NCT01088048|9783455|FG001|Overall Study|Withdrew Consent|1
6148151|NCT01088048|9783456|FG002|Overall Study|Withdrew Consent|1
6148152|NCT01088048|9783457|FG003|Overall Study|Withdrew Consent|1
6148153|NCT01088048|9783458|FG004|Overall Study|Withdrew Consent|2
6148154|NCT01088048|9783459|FG005|Overall Study|Withdrew Consent|1
6148155|NCT01088048|9783460|FG006|Overall Study|Withdrew Consent|0
6148156|NCT01088048|9783461|FG007|Overall Study|Withdrew Consent|2
6148157|NCT01088048|9783462|FG008|Overall Study|Withdrew Consent|2
6148158|NCT01088048|9783463|FG009|Overall Study|Withdrew Consent|1
6148159|NCT01088048|9783454|FG000|Overall Study|Concomitant Medication Prohibited|1
6148160|NCT01088048|9783455|FG001|Overall Study|Concomitant Medication Prohibited|0
6148161|NCT01088048|9783456|FG002|Overall Study|Concomitant Medication Prohibited|0
6148162|NCT01088048|9783457|FG003|Overall Study|Concomitant Medication Prohibited|0
6148163|NCT01088048|9783458|FG004|Overall Study|Concomitant Medication Prohibited|0
6148164|NCT01088048|9783459|FG005|Overall Study|Concomitant Medication Prohibited|0
6148165|NCT01088048|9783460|FG006|Overall Study|Concomitant Medication Prohibited|0
6148166|NCT01088048|9783461|FG007|Overall Study|Concomitant Medication Prohibited|0
6148167|NCT01088048|9783462|FG008|Overall Study|Concomitant Medication Prohibited|0
6148168|NCT01088048|9783463|FG009|Overall Study|Concomitant Medication Prohibited|0
6148169|NCT01088048|9783454|FG000|Overall Study|Investigator Request|2
6148170|NCT01088048|9783455|FG001|Overall Study|Investigator Request|2
6039038|NCT00363415|9636795|FG000|Overall Study|Adverse Event|24
6039039|NCT00363415|9636796|FG001|Overall Study|Adverse Event|15
6039040|NCT00363415|9636795|FG000|Overall Study|Physician Decision|18
6148171|NCT01088048|9783456|FG002|Overall Study|Investigator Request|0
6148172|NCT01088048|9783457|FG003|Overall Study|Investigator Request|0
6148173|NCT01088048|9783458|FG004|Overall Study|Investigator Request|3
6148174|NCT01088048|9783459|FG005|Overall Study|Investigator Request|1
6148175|NCT01088048|9783460|FG006|Overall Study|Investigator Request|1
6148176|NCT01088048|9783461|FG007|Overall Study|Investigator Request|0
6148177|NCT01088048|9783462|FG008|Overall Study|Investigator Request|0
6039041|NCT00363415|9636796|FG001|Overall Study|Physician Decision|35
6039042|NCT00363415|9636795|FG000|Overall Study|Entry Criteria Not Met|11
6039043|NCT00363415|9636796|FG001|Overall Study|Entry Criteria Not Met|10
6039044|NCT00363415|9636795|FG000|Overall Study|Withdrawal by Subject|9
6039045|NCT00363415|9636796|FG001|Overall Study|Withdrawal by Subject|15
6039046|NCT00363415|9636795|FG000|Overall Study|Lost to Follow-up|3
6039047|NCT00363415|9636796|FG001|Overall Study|Lost to Follow-up|3
6039048|NCT00363415|9636795|FG000|Overall Study|Protocol Violation|1
6039049|NCT00363415|9636796|FG001|Overall Study|Protocol Violation|4
6039050|NCT00363467|9636802|FG000|Overall Study|Physician Decision|1
6039051|NCT00363480|9636806|FG000|Overall Study|Criteria for treatment period not fulfil|1
6039052|NCT00363480|9636806|FG000|Overall Study|Adverse Event|4
6039053|NCT00363480|9636806|FG000|Overall Study|Lost to Follow-up|5
6039054|NCT00363480|9636806|FG000|Overall Study|Withdrawal by Subject|5
6039055|NCT00363480|9636806|FG000|Overall Study|Non-compliance of subject|1
6039056|NCT00363480|9636806|FG000|Overall Study|Participant discontinued on its own|1
6039057|NCT00363545|9636812|FG000|Overall Study|Serious Adverse Event|0
6039058|NCT00363545|9636813|FG001|Overall Study|Serious Adverse Event|1
6039059|NCT00363545|9636812|FG000|Overall Study|Withdrawal by Subject|12
6039060|NCT00363545|9636813|FG001|Overall Study|Withdrawal by Subject|15
6039061|NCT00363545|9636812|FG000|Overall Study|Migrated/moved from study area|3
6039062|NCT00363545|9636813|FG001|Overall Study|Migrated/moved from study area|6
6039063|NCT00363545|9636812|FG000|Overall Study|Lost to follow-up (incompl. vaccination)|14
6039064|NCT00363545|9636813|FG001|Overall Study|Lost to follow-up (incompl. vaccination)|18
6039065|NCT00363545|9636812|FG000|Overall Study|Lost to follow-up (complete vaccination)|14
6039066|NCT00363545|9636813|FG001|Overall Study|Lost to follow-up (complete vaccination)|17
6039067|NCT00363545|9636812|FG000|Overall Study|Others|1
6039068|NCT00363545|9636813|FG001|Overall Study|Others|0
6039069|NCT00363649|9636821|FG000|Overall Study|Withdrawal by Subject|1
6039070|NCT00363649|9636822|FG001|Overall Study|Withdrawal by Subject|1
6039071|NCT00363649|9636821|FG000|Overall Study|Adverse Event|6
6039072|NCT00363649|9636822|FG001|Overall Study|Adverse Event|0
6048920|NCT00420927|9648202|FG003|Period 1|Study site closure|0
6048921|NCT00420927|9648203|FG004|Period 1|Study site closure|0
6048922|NCT00420927|9648204|FG005|Period 1|Study site closure|0
6048923|NCT00420927|9648205|FG006|Period 1|Study site closure|0
6048924|NCT00420927|9648199|FG000|Period 1|Subject received new diagnosis|0
6048925|NCT00420927|9648200|FG001|Period 1|Subject received new diagnosis|2
6309636|NCT02641379|10038343|FG004|Overall Study|Participant's compliance|0
6309637|NCT02641379|10038344|FG005|Overall Study|Participant's compliance|2
6309638|NCT02641379|10038345|FG006|Overall Study|Participant's compliance|0
6309639|NCT02641379|10038346|FG007|Overall Study|Participant's compliance|0
6309640|NCT02641379|10038347|FG008|Overall Study|Participant's compliance|1
6309641|NCT02641379|10038348|FG009|Overall Study|Participant's compliance|1
6309642|NCT02641379|10038349|FG010|Overall Study|Participant's compliance|1
6309643|NCT02641379|10038339|FG000|Overall Study|Participant cannot be reached|4
6309644|NCT02641379|10038340|FG001|Overall Study|Participant cannot be reached|4
6309645|NCT02641379|10038341|FG002|Overall Study|Participant cannot be reached|0
6309646|NCT02641379|10038342|FG003|Overall Study|Participant cannot be reached|8
6309647|NCT02641379|10038343|FG004|Overall Study|Participant cannot be reached|2
6309648|NCT02641379|10038344|FG005|Overall Study|Participant cannot be reached|1
6309649|NCT02641379|10038345|FG006|Overall Study|Participant cannot be reached|0
6309650|NCT02641379|10038346|FG007|Overall Study|Participant cannot be reached|1
6148178|NCT01088048|9783463|FG009|Overall Study|Investigator Request|0
6148179|NCT01088048|9783454|FG000|Overall Study|Patient Non-compliance|0
6148180|NCT01088048|9783455|FG001|Overall Study|Patient Non-compliance|1
6148181|NCT01088048|9783456|FG002|Overall Study|Patient Non-compliance|0
6148182|NCT01088048|9783457|FG003|Overall Study|Patient Non-compliance|0
6148183|NCT01088048|9783458|FG004|Overall Study|Patient Non-compliance|0
6148184|NCT01088048|9783459|FG005|Overall Study|Patient Non-compliance|0
6148185|NCT01088048|9783460|FG006|Overall Study|Patient Non-compliance|0
6148186|NCT01088048|9783461|FG007|Overall Study|Patient Non-compliance|0
6148187|NCT01088048|9783462|FG008|Overall Study|Patient Non-compliance|0
6148188|NCT01088048|9783463|FG009|Overall Study|Patient Non-compliance|0
6148189|NCT01088048|9783454|FG000|Overall Study|Disease Progression|7
6148190|NCT01088048|9783455|FG001|Overall Study|Disease Progression|4
6148191|NCT01088048|9783456|FG002|Overall Study|Disease Progression|3
6148192|NCT01088048|9783457|FG003|Overall Study|Disease Progression|5
6148193|NCT01088048|9783458|FG004|Overall Study|Disease Progression|3
6309651|NCT02641379|10038347|FG008|Overall Study|Participant cannot be reached|0
6309652|NCT02641379|10038348|FG009|Overall Study|Participant cannot be reached|2
6048926|NCT00420927|9648201|FG002|Period 1|Subject received new diagnosis|0
6048927|NCT00420927|9648202|FG003|Period 1|Subject received new diagnosis|0
6048928|NCT00420927|9648203|FG004|Period 1|Subject received new diagnosis|0
6048929|NCT00420927|9648204|FG005|Period 1|Subject received new diagnosis|0
6048930|NCT00420927|9648205|FG006|Period 1|Subject received new diagnosis|0
6048931|NCT00420927|9648199|FG000|Period 1|Received wrong treatment/incorrect dose|0
6148194|NCT01088048|9783459|FG005|Overall Study|Disease Progression|3
6048932|NCT00420927|9648200|FG001|Period 1|Received wrong treatment/incorrect dose|1
6148195|NCT01088048|9783460|FG006|Overall Study|Disease Progression|2
6148196|NCT01088048|9783461|FG007|Overall Study|Disease Progression|1
6039073|NCT00363766|9636835|FG000|Overall Study|Progressive Disease|15
6039074|NCT00363766|9636836|FG001|Overall Study|Progressive Disease|9
6148197|NCT01088048|9783462|FG008|Overall Study|Disease Progression|0
6148198|NCT01088048|9783463|FG009|Overall Study|Disease Progression|0
6148199|NCT01088048|9783454|FG000|Overall Study|Death|1
6148200|NCT01088048|9783455|FG001|Overall Study|Death|5
6148201|NCT01088048|9783456|FG002|Overall Study|Death|3
6148202|NCT01088048|9783457|FG003|Overall Study|Death|3
6148203|NCT01088048|9783458|FG004|Overall Study|Death|1
6148204|NCT01088048|9783459|FG005|Overall Study|Death|3
6148205|NCT01088048|9783460|FG006|Overall Study|Death|0
6148206|NCT01088048|9783461|FG007|Overall Study|Death|0
6148207|NCT01088048|9783462|FG008|Overall Study|Death|3
6148208|NCT01088048|9783463|FG009|Overall Study|Death|1
6148209|NCT01088048|9783454|FG000|Overall Study|Other|3
6148210|NCT01088048|9783455|FG001|Overall Study|Other|5
6148211|NCT01088048|9783456|FG002|Overall Study|Other|0
6148212|NCT01088048|9783457|FG003|Overall Study|Other|0
6148213|NCT01088048|9783458|FG004|Overall Study|Other|2
6148214|NCT01088048|9783459|FG005|Overall Study|Other|0
6148215|NCT01088048|9783460|FG006|Overall Study|Other|0
6148216|NCT01088048|9783461|FG007|Overall Study|Other|2
6148217|NCT01088048|9783462|FG008|Overall Study|Other|0
6148218|NCT01088048|9783463|FG009|Overall Study|Other|0
6148219|NCT01088243|9783498|FG000|Overall Study|Adverse Event|1
6148220|NCT01088243|9783499|FG001|Overall Study|Adverse Event|0
6148221|NCT01088399|9783512|FG000|Overall Study|Adverse Event|211
6148222|NCT01088399|9783513|FG001|Overall Study|Adverse Event|16
6148223|NCT01088399|9783514|FG002|Overall Study|Adverse Event|0
6148224|NCT01088399|9783512|FG000|Overall Study|Death|204
6148225|NCT01088399|9783513|FG001|Overall Study|Death|45
6148226|NCT01088399|9783514|FG002|Overall Study|Death|0
6148227|NCT01088399|9783512|FG000|Overall Study|Lack of Efficacy|298
6148228|NCT01088399|9783513|FG001|Overall Study|Lack of Efficacy|7
6148229|NCT01088399|9783514|FG002|Overall Study|Lack of Efficacy|5
6148230|NCT01088399|9783512|FG000|Overall Study|Lost to Follow-up|1070
6148231|NCT01088399|9783513|FG001|Overall Study|Lost to Follow-up|278
6148232|NCT01088399|9783514|FG002|Overall Study|Lost to Follow-up|58
6148233|NCT01088399|9783512|FG000|Overall Study|Physician Decision|531
6148234|NCT01088399|9783513|FG001|Overall Study|Physician Decision|88
6148235|NCT01088399|9783514|FG002|Overall Study|Physician Decision|16
6148236|NCT01088399|9783512|FG000|Overall Study|Withdrawal by Subject|544
6148237|NCT01088399|9783513|FG001|Overall Study|Withdrawal by Subject|195
6148238|NCT01088399|9783514|FG002|Overall Study|Withdrawal by Subject|33
6148239|NCT01088399|9783512|FG000|Overall Study|Change to or start of somatropin therapy|234
6148240|NCT01088399|9783513|FG001|Overall Study|Change to or start of somatropin therapy|17
6148241|NCT01088399|9783514|FG002|Overall Study|Change to or start of somatropin therapy|12
6148242|NCT01088399|9783512|FG000|Overall Study|Sponsor decision|1573
6148243|NCT01088399|9783513|FG001|Overall Study|Sponsor decision|298
6148244|NCT01088399|9783514|FG002|Overall Study|Sponsor decision|7
6148245|NCT01088399|9783512|FG000|Overall Study|Protocol Violation|10
6148246|NCT01088399|9783513|FG001|Overall Study|Protocol Violation|1
6148247|NCT01088399|9783514|FG002|Overall Study|Protocol Violation|0
6148248|NCT01088399|9783512|FG000|Overall Study|Enrollment criteria not met|48
6148249|NCT01088399|9783513|FG001|Overall Study|Enrollment criteria not met|119
6148250|NCT01088399|9783514|FG002|Overall Study|Enrollment criteria not met|70
6148251|NCT01088399|9783512|FG000|Overall Study|Study summary visit not completed|2398
6148252|NCT01088399|9783513|FG001|Overall Study|Study summary visit not completed|283
6148253|NCT01088399|9783514|FG002|Overall Study|Study summary visit not completed|80
6148254|NCT01088412|9783525|FG000|Overall Study|Adverse Event|38
6148255|NCT01088412|9783526|FG001|Overall Study|Adverse Event|0
6148256|NCT01088412|9783527|FG002|Overall Study|Adverse Event|0
6148257|NCT01088412|9783525|FG000|Overall Study|Death|42
6148258|NCT01088412|9783526|FG001|Overall Study|Death|6
6148259|NCT01088412|9783527|FG002|Overall Study|Death|0
6148260|NCT01088412|9783525|FG000|Overall Study|Other Reason per Case Report Form|2089
6148261|NCT01088412|9783526|FG001|Overall Study|Other Reason per Case Report Form|103
6148262|NCT01088412|9783527|FG002|Overall Study|Other Reason per Case Report Form|9
6148263|NCT01088412|9783525|FG000|Overall Study|Withdrawal by Subject|1761
6039075|NCT00363766|9636835|FG000|Overall Study|Adverse Event|10
6148264|NCT01088412|9783526|FG001|Overall Study|Withdrawal by Subject|25
6148265|NCT01088412|9783527|FG002|Overall Study|Withdrawal by Subject|1
6148266|NCT01088412|9783525|FG000|Overall Study|Received Another GH Product|79
6148267|NCT01088412|9783526|FG001|Overall Study|Received Another GH Product|0
6148268|NCT01088412|9783527|FG002|Overall Study|Received Another GH Product|0
6148269|NCT01088412|9783525|FG000|Overall Study|Participant Moved|601
6148270|NCT01088412|9783526|FG001|Overall Study|Participant Moved|21
6148271|NCT01088412|9783527|FG002|Overall Study|Participant Moved|2
6148272|NCT01088412|9783525|FG000|Overall Study|Physician Decision|1041
6148273|NCT01088412|9783526|FG001|Overall Study|Physician Decision|8
6148274|NCT01088412|9783527|FG002|Overall Study|Physician Decision|4
6148275|NCT01088412|9783525|FG000|Overall Study|Sponsor Decision|4467
6148276|NCT01088412|9783526|FG001|Overall Study|Sponsor Decision|79
6148277|NCT01088412|9783527|FG002|Overall Study|Sponsor Decision|23
6148278|NCT01088412|9783525|FG000|Overall Study|Third Party Required to Change Brand|487
6148279|NCT01088412|9783526|FG001|Overall Study|Third Party Required to Change Brand|0
6148280|NCT01088412|9783527|FG002|Overall Study|Third Party Required to Change Brand|0
6039076|NCT00363766|9636836|FG001|Overall Study|Adverse Event|2
6039077|NCT00363766|9636835|FG000|Overall Study|Disease Related Death|1
6039078|NCT00363766|9636836|FG001|Overall Study|Disease Related Death|3
6039079|NCT00363766|9636835|FG000|Overall Study|Not Disease Related Death|3
6039080|NCT00363766|9636836|FG001|Overall Study|Not Disease Related Death|4
6039081|NCT00363766|9636835|FG000|Overall Study|Withdrawal by Subject|2
6039082|NCT00363766|9636836|FG001|Overall Study|Withdrawal by Subject|0
6039083|NCT00363766|9636835|FG000|Overall Study|Physician Decision|1
6039084|NCT00363766|9636836|FG001|Overall Study|Physician Decision|2
6039085|NCT00363896|9636866|FG000|Overall Study|Withdrawal by Subject|29
6039086|NCT00363896|9636867|FG001|Overall Study|Withdrawal by Subject|16
6039087|NCT00363896|9636866|FG000|Overall Study|Adverse Event|24
6039088|NCT00363896|9636867|FG001|Overall Study|Adverse Event|13
6039089|NCT00363896|9636866|FG000|Overall Study|COPD exacerbation|13
6039090|NCT00363896|9636867|FG001|Overall Study|COPD exacerbation|7
6039091|NCT00363896|9636866|FG000|Overall Study|Lack of Efficacy|12
6309653|NCT02641379|10038349|FG010|Overall Study|Participant cannot be reached|1
6309654|NCT02641379|10038339|FG000|Overall Study|PCR positive at Week 24|15
6309655|NCT02641379|10038340|FG001|Overall Study|PCR positive at Week 24|21
6309656|NCT02641379|10038341|FG002|Overall Study|PCR positive at Week 24|62
6309657|NCT02641379|10038342|FG003|Overall Study|PCR positive at Week 24|0
6309658|NCT02641379|10038343|FG004|Overall Study|PCR positive at Week 24|0
6309659|NCT02641379|10038344|FG005|Overall Study|PCR positive at Week 24|6
6309660|NCT02641379|10038345|FG006|Overall Study|PCR positive at Week 24|3
6309661|NCT02641379|10038346|FG007|Overall Study|PCR positive at Week 24|8
6309662|NCT02641379|10038347|FG008|Overall Study|PCR positive at Week 24|0
6309663|NCT02641379|10038348|FG009|Overall Study|PCR positive at Week 24|1
6309664|NCT02641379|10038349|FG010|Overall Study|PCR positive at Week 24|0
6309665|NCT02641379|10038339|FG000|Overall Study|PCR positive at follow up 2|1
6039092|NCT00363896|9636867|FG001|Overall Study|Lack of Efficacy|8
6039093|NCT00363896|9636866|FG000|Overall Study|Protocol Violation|6
6039094|NCT00363896|9636867|FG001|Overall Study|Protocol Violation|1
6039095|NCT00363896|9636866|FG000|Overall Study|Lost to Follow-up|3
6039096|NCT00363896|9636867|FG001|Overall Study|Lost to Follow-up|0
6039097|NCT00363896|9636866|FG000|Overall Study|Non-fulfilment of entry criteria|1
6039098|NCT00363896|9636867|FG001|Overall Study|Non-fulfilment of entry criteria|0
6039099|NCT00363896|9636866|FG000|Overall Study|Other|1
6039100|NCT00363896|9636867|FG001|Overall Study|Other|2
6039101|NCT00364013|9636878|FG000|Overall Study|Ineligibility determined|4
6039102|NCT00364013|9636879|FG001|Overall Study|Ineligibility determined|2
6039103|NCT00364013|9636878|FG000|Overall Study|Adverse Event|4
6039104|NCT00364013|9636879|FG001|Overall Study|Adverse Event|3
6039105|NCT00364013|9636878|FG000|Overall Study|Withdrawal by Subject|13
6039106|NCT00364013|9636879|FG001|Overall Study|Withdrawal by Subject|18
6039107|NCT00364013|9636878|FG000|Overall Study|Physician Decision|3
6039108|NCT00364013|9636879|FG001|Overall Study|Physician Decision|3
6039109|NCT00364013|9636878|FG000|Overall Study|Lost to Follow-up|10
6039110|NCT00364013|9636879|FG001|Overall Study|Lost to Follow-up|3
6039111|NCT00364013|9636878|FG000|Overall Study|Protocol-specified criteria|6
6039112|NCT00364013|9636879|FG001|Overall Study|Protocol-specified criteria|6
6039113|NCT00364013|9636878|FG000|Overall Study|Other|41
6039114|NCT00364013|9636879|FG001|Overall Study|Other|47
6039115|NCT00364013|9636878|FG000|Overall Study|Ongoing|20
6039116|NCT00364013|9636879|FG001|Overall Study|Ongoing|13
6039117|NCT00364130|9636891|FG000|Intervention Period|Lost to Follow-up|4
6039118|NCT00364130|9636892|FG001|Intervention Period|Lost to Follow-up|3
6039119|NCT00364130|9636891|FG000|Intervention Period|Pregnancy|1
6080217|NCT00615030|9687422|FG005|Period I|Abnormal laboratory value(s)|1
6309666|NCT02641379|10038340|FG001|Overall Study|PCR positive at follow up 2|0
6309667|NCT02641379|10038341|FG002|Overall Study|PCR positive at follow up 2|0
6309668|NCT02641379|10038342|FG003|Overall Study|PCR positive at follow up 2|0
6309669|NCT02641379|10038343|FG004|Overall Study|PCR positive at follow up 2|0
6309670|NCT02641379|10038344|FG005|Overall Study|PCR positive at follow up 2|0
6309671|NCT02641379|10038345|FG006|Overall Study|PCR positive at follow up 2|0
6039120|NCT00364130|9636892|FG001|Intervention Period|Pregnancy|0
6039121|NCT00364130|9636891|FG000|Intervention Period|Withdrawal by Subject|4
6039122|NCT00364130|9636892|FG001|Intervention Period|Withdrawal by Subject|5
6039123|NCT00364130|9636891|FG000|Post Intervention Follow-up Period|Lost to Follow-up|5
6039124|NCT00364130|9636892|FG001|Post Intervention Follow-up Period|Lost to Follow-up|11
6039125|NCT00364156|9636902|FG000|Overall Study|Withdrawal by Subject|73
6039126|NCT00364156|9636903|FG001|Overall Study|Withdrawal by Subject|80
6039127|NCT00364156|9636902|FG000|Overall Study|Protocol Violation|6
6039128|NCT00364156|9636903|FG001|Overall Study|Protocol Violation|1
6039129|NCT00364182|9636912|FG000|First Intervention|Secondary prophylaxis|1
6039130|NCT00364182|9636913|FG001|First Intervention|Secondary prophylaxis|0
6039131|NCT00364182|9636914|FG002|First Intervention|Secondary prophylaxis|0
6039132|NCT00364182|9636912|FG000|First Intervention|Withdrawal by Subject|2
6039133|NCT00364182|9636913|FG001|First Intervention|Withdrawal by Subject|0
6039134|NCT00364182|9636914|FG002|First Intervention|Withdrawal by Subject|0
6039135|NCT00364182|9636912|FG000|Second Intervention|non-compliance|0
6080218|NCT00615030|9687423|FG006|Period I|Abnormal laboratory value(s)|0
6080219|NCT00615030|9687424|FG007|Period I|Abnormal laboratory value(s)|0
6080220|NCT00615030|9687425|FG008|Period I|Abnormal laboratory value(s)|0
6148281|NCT01088412|9783525|FG000|Overall Study|Lost to Follow-up|3052
6148282|NCT01088412|9783526|FG001|Overall Study|Lost to Follow-up|130
6148283|NCT01088412|9783527|FG002|Overall Study|Lost to Follow-up|11
6148284|NCT01088412|9783525|FG000|Overall Study|Study Summary Not Completed|4360
6148285|NCT01088412|9783526|FG001|Overall Study|Study Summary Not Completed|64
6148286|NCT01088412|9783527|FG002|Overall Study|Study Summary Not Completed|22
6148287|NCT01088438|9783540|FG000|Overall Study|Withdrawal by Subject|11
6148288|NCT01088438|9783541|FG001|Overall Study|Withdrawal by Subject|6
6148289|NCT01088438|9783540|FG000|Overall Study|Lost to Follow-up|18
6148290|NCT01088438|9783541|FG001|Overall Study|Lost to Follow-up|30
6148291|NCT01088503|9783563|FG000|Overall Study|Withdrawal by Subject|118
6148292|NCT01088503|9783564|FG001|Overall Study|Withdrawal by Subject|327
6148293|NCT01088503|9783565|FG002|Overall Study|Withdrawal by Subject|10
6148294|NCT01088503|9783563|FG000|Overall Study|Death|64
6148295|NCT01088503|9783564|FG001|Overall Study|Death|358
6148296|NCT01088503|9783565|FG002|Overall Study|Death|7
6148297|NCT01088529|9783573|FG000|Overall Study|Did not receive study treatment|0
6148298|NCT01088529|9783574|FG001|Overall Study|Did not receive study treatment|1
6148299|NCT01088984|9783610|FG000|Phase 1|Death|2
6148300|NCT01088984|9783611|FG001|Phase 1|Death|1
6148301|NCT01088984|9783610|FG000|Phase 1|Disease Progression|2
6148302|NCT01088984|9783611|FG001|Phase 1|Disease Progression|4
6309672|NCT02641379|10038346|FG007|Overall Study|PCR positive at follow up 2|0
6309673|NCT02641379|10038347|FG008|Overall Study|PCR positive at follow up 2|0
6039136|NCT00364182|9636913|FG001|Second Intervention|non-compliance|1
6039137|NCT00364182|9636914|FG002|Second Intervention|non-compliance|1
6039138|NCT00364182|9636912|FG000|Second Intervention|Protocol Violation|0
6039139|NCT00364182|9636913|FG001|Second Intervention|Protocol Violation|1
6039140|NCT00364182|9636914|FG002|Second Intervention|Protocol Violation|0
6039141|NCT00364182|9636912|FG000|Second Intervention|Adverse Event|0
6039142|NCT00364182|9636913|FG001|Second Intervention|Adverse Event|0
6039143|NCT00364182|9636914|FG002|Second Intervention|Adverse Event|1
6039144|NCT00364182|9636912|FG000|Third Intervention|non-compliance|0
6039145|NCT00364182|9636913|FG001|Third Intervention|non-compliance|1
6039146|NCT00364182|9636914|FG002|Third Intervention|non-compliance|0
6039147|NCT00364182|9636912|FG000|Third Intervention|Lost to Follow-up|0
6039148|NCT00364182|9636913|FG001|Third Intervention|Lost to Follow-up|0
6039149|NCT00364182|9636914|FG002|Third Intervention|Lost to Follow-up|1
6039150|NCT00364286|9636924|FG000|Overall Study|Withdrawal by Subject|1
6039151|NCT00364286|9636924|FG000|Overall Study|Adverse Event|2
6039152|NCT00364351|9636930|FG000|Overall Study|Adverse Event|90
6039153|NCT00364351|9636931|FG001|Overall Study|Adverse Event|44
6039154|NCT00364351|9636930|FG000|Overall Study|Condition under investigation worsened|469
6039155|NCT00364351|9636931|FG001|Overall Study|Condition under investigation worsened|497
6039156|NCT00364351|9636930|FG000|Overall Study|Prohibited concomitant medication|0
6039157|NCT00364351|9636931|FG001|Overall Study|Prohibited concomitant medication|2
6039158|NCT00364351|9636930|FG000|Overall Study|Lost to Follow-up|1
6039159|NCT00364351|9636931|FG001|Overall Study|Lost to Follow-up|1
6039160|NCT00364351|9636930|FG000|Overall Study|Withdrawal by Subject|30
6309674|NCT02641379|10038348|FG009|Overall Study|PCR positive at follow up 2|0
6039161|NCT00364351|9636931|FG001|Overall Study|Withdrawal by Subject|29
6039162|NCT00364351|9636930|FG000|Overall Study|Incorrect enrollment|1
6039163|NCT00364351|9636931|FG001|Overall Study|Incorrect enrollment|1
6039164|NCT00364351|9636930|FG000|Overall Study|Sponsor decision|1
6039165|NCT00364351|9636931|FG001|Overall Study|Sponsor decision|0
6039166|NCT00364351|9636930|FG000|Overall Study|Poor treatment compliance|0
6039167|NCT00364351|9636931|FG001|Overall Study|Poor treatment compliance|3
6039168|NCT00364351|9636930|FG000|Overall Study|Investigator error|0
6039169|NCT00364351|9636931|FG001|Overall Study|Investigator error|2
6039170|NCT00364351|9636930|FG000|Overall Study|Patient could not travel to site|0
6039171|NCT00364351|9636931|FG001|Overall Study|Patient could not travel to site|1
6039172|NCT00364351|9636930|FG000|Overall Study|Randomised treatment not started|0
6039173|NCT00364351|9636931|FG001|Overall Study|Randomised treatment not started|3
6039174|NCT00364533|9636951|FG000|Overall Study|Adverse Event|8
6039175|NCT00364533|9636952|FG001|Overall Study|Adverse Event|7
6039176|NCT00364533|9636953|FG002|Overall Study|Adverse Event|15
6039177|NCT00364533|9636954|FG003|Overall Study|Adverse Event|5
6039178|NCT00364533|9636955|FG004|Overall Study|Adverse Event|2
6148303|NCT01088984|9783610|FG000|Phase 1|Other|1
6148304|NCT01088984|9783611|FG001|Phase 1|Other|1
6148305|NCT01088984|9783610|FG000|Phase 2|Death|0
6148306|NCT01088984|9783611|FG001|Phase 2|Death|5
6309675|NCT02641379|10038349|FG010|Overall Study|PCR positive at follow up 2|0
6039179|NCT00364533|9636951|FG000|Overall Study|Withdrawal by Subject|4
6039180|NCT00364533|9636952|FG001|Overall Study|Withdrawal by Subject|8
6039181|NCT00364533|9636953|FG002|Overall Study|Withdrawal by Subject|6
6039182|NCT00364533|9636954|FG003|Overall Study|Withdrawal by Subject|6
6039183|NCT00364533|9636955|FG004|Overall Study|Withdrawal by Subject|6
6039184|NCT00364533|9636951|FG000|Overall Study|Lack of Efficacy|22
6039185|NCT00364533|9636952|FG001|Overall Study|Lack of Efficacy|22
6039186|NCT00364533|9636953|FG002|Overall Study|Lack of Efficacy|21
6039187|NCT00364533|9636954|FG003|Overall Study|Lack of Efficacy|17
6039188|NCT00364533|9636955|FG004|Overall Study|Lack of Efficacy|42
6080221|NCT00615030|9687426|FG009|Period I|Abnormal laboratory value(s)|0
6148307|NCT01088984|9783610|FG000|Phase 2|Withdrawal by Subject|0
6039189|NCT00364533|9636951|FG000|Overall Study|Subject discharged from hospital|4
6039190|NCT00364533|9636952|FG001|Overall Study|Subject discharged from hospital|1
6039191|NCT00364533|9636953|FG002|Overall Study|Subject discharged from hospital|2
6039192|NCT00364533|9636954|FG003|Overall Study|Subject discharged from hospital|3
6039193|NCT00364533|9636955|FG004|Overall Study|Subject discharged from hospital|1
6039194|NCT00364533|9636951|FG000|Overall Study|Variations in drug compliance|2
6039195|NCT00364533|9636952|FG001|Overall Study|Variations in drug compliance|1
6039196|NCT00364533|9636953|FG002|Overall Study|Variations in drug compliance|1
6039197|NCT00364533|9636954|FG003|Overall Study|Variations in drug compliance|0
6039198|NCT00364533|9636955|FG004|Overall Study|Variations in drug compliance|0
6039199|NCT00364533|9636951|FG000|Overall Study|Non-compliance|1
6039200|NCT00364533|9636952|FG001|Overall Study|Non-compliance|0
6039201|NCT00364533|9636953|FG002|Overall Study|Non-compliance|0
6039202|NCT00364533|9636954|FG003|Overall Study|Non-compliance|0
6039203|NCT00364533|9636955|FG004|Overall Study|Non-compliance|0
6039204|NCT00364533|9636951|FG000|Overall Study|Protocol Violation|1
6039205|NCT00364533|9636952|FG001|Overall Study|Protocol Violation|1
6039206|NCT00364533|9636953|FG002|Overall Study|Protocol Violation|0
6039207|NCT00364533|9636954|FG003|Overall Study|Protocol Violation|0
6039208|NCT00364533|9636955|FG004|Overall Study|Protocol Violation|0
6039209|NCT00364611|9636969|FG000|Overall Study|Did not receive study medication|0
6039210|NCT00364611|9636970|FG001|Overall Study|Did not receive study medication|1
6039211|NCT00364611|9636969|FG000|Overall Study|Adverse Event|7
6039212|NCT00364611|9636970|FG001|Overall Study|Adverse Event|4
6039213|NCT00364611|9636969|FG000|Overall Study|Participant's Request|3
6039214|NCT00364611|9636970|FG001|Overall Study|Participant's Request|4
6039215|NCT00364611|9636969|FG000|Overall Study|Disease Progression|38
6039216|NCT00364611|9636970|FG001|Overall Study|Disease Progression|8
6039217|NCT00364611|9636969|FG000|Overall Study|Investigator decision|2
6039218|NCT00364611|9636970|FG001|Overall Study|Investigator decision|2
6039219|NCT00364611|9636969|FG000|Overall Study|Found Ineligible|1
6039220|NCT00364611|9636970|FG001|Overall Study|Found Ineligible|0
6039221|NCT00364611|9636969|FG000|Overall Study|Presumed CR on Study|0
6039222|NCT00364611|9636970|FG001|Overall Study|Presumed CR on Study|1
6039223|NCT00364611|9636969|FG000|Overall Study|Receiving Liver Ablation|0
6039224|NCT00364611|9636970|FG001|Overall Study|Receiving Liver Ablation|1
6039225|NCT00364793|9636980|FG000|Overall Study|Adverse Event|2
6039226|NCT00364793|9636981|FG001|Overall Study|Adverse Event|0
6039227|NCT00364793|9636982|FG002|Overall Study|Adverse Event|0
6039228|NCT00364793|9636983|FG003|Overall Study|Adverse Event|0
6039229|NCT00364793|9636980|FG000|Overall Study|Death|1
6039230|NCT00364793|9636981|FG001|Overall Study|Death|0
6039231|NCT00364793|9636982|FG002|Overall Study|Death|1
6039232|NCT00364793|9636983|FG003|Overall Study|Death|0
6039233|NCT00364793|9636980|FG000|Overall Study|Lack of Efficacy|3
6039234|NCT00364793|9636981|FG001|Overall Study|Lack of Efficacy|3
6309676|NCT02641379|10038339|FG000|Overall Study|Participant showed relapse|1
6309677|NCT02641379|10038340|FG001|Overall Study|Participant showed relapse|0
6309678|NCT02641379|10038341|FG002|Overall Study|Participant showed relapse|0
6309679|NCT02641379|10038342|FG003|Overall Study|Participant showed relapse|0
6309680|NCT02641379|10038343|FG004|Overall Study|Participant showed relapse|0
6309681|NCT02641379|10038344|FG005|Overall Study|Participant showed relapse|0
6309682|NCT02641379|10038345|FG006|Overall Study|Participant showed relapse|1
6309683|NCT02641379|10038346|FG007|Overall Study|Participant showed relapse|0
6309684|NCT02641379|10038347|FG008|Overall Study|Participant showed relapse|0
6309685|NCT02641379|10038348|FG009|Overall Study|Participant showed relapse|0
6309686|NCT02641379|10038349|FG010|Overall Study|Participant showed relapse|0
6309687|NCT02641379|10038339|FG000|Overall Study|Participant stopped study/treatment|1
6039235|NCT00364793|9636982|FG002|Overall Study|Lack of Efficacy|1
6039236|NCT00364793|9636983|FG003|Overall Study|Lack of Efficacy|1
6309688|NCT02641379|10038340|FG001|Overall Study|Participant stopped study/treatment|3
6039237|NCT00364793|9636980|FG000|Overall Study|Lost to Follow-up|1
6039238|NCT00364793|9636981|FG001|Overall Study|Lost to Follow-up|0
6039239|NCT00364793|9636982|FG002|Overall Study|Lost to Follow-up|2
6039240|NCT00364793|9636983|FG003|Overall Study|Lost to Follow-up|0
6039241|NCT00364793|9636980|FG000|Overall Study|Poor or non-compliance|1
6039242|NCT00364793|9636981|FG001|Overall Study|Poor or non-compliance|1
6039243|NCT00364793|9636982|FG002|Overall Study|Poor or non-compliance|0
6039244|NCT00364793|9636983|FG003|Overall Study|Poor or non-compliance|1
6039245|NCT00364793|9636980|FG000|Overall Study|No longer meets criteria|0
6039246|NCT00364793|9636981|FG001|Overall Study|No longer meets criteria|0
6039247|NCT00364793|9636982|FG002|Overall Study|No longer meets criteria|0
6039248|NCT00364793|9636983|FG003|Overall Study|No longer meets criteria|1
6039249|NCT00364793|9636980|FG000|Overall Study|Withdrawal by Subject|0
6039250|NCT00364793|9636981|FG001|Overall Study|Withdrawal by Subject|1
6039251|NCT00364793|9636982|FG002|Overall Study|Withdrawal by Subject|0
6039252|NCT00364793|9636983|FG003|Overall Study|Withdrawal by Subject|0
6039253|NCT00364832|9637009|FG000|Core Period|Early Withdrawals|2
6039254|NCT00364832|9637010|FG001|Core Period|Early Withdrawals|2
6039255|NCT00364832|9637011|FG002|Core Period|Early Withdrawals|1
6039256|NCT00364832|9637012|FG003|Core Period|Early Withdrawals|1
6039257|NCT00364832|9637013|FG004|Core Period|Early Withdrawals|0
6039258|NCT00364832|9637014|FG005|Core Period|Early Withdrawals|0
6039259|NCT00364832|9637015|FG006|Core Period|Early Withdrawals|4
6039260|NCT00364832|9637016|FG007|Core Period|Early Withdrawals|1
6039261|NCT00364832|9637017|FG008|Core Period|Early Withdrawals|0
6039262|NCT00364832|9637018|FG009|Core Period|Early Withdrawals|0
6039263|NCT00364832|9637019|FG010|Core Period|Early Withdrawals|0
6039264|NCT00364832|9637020|FG011|Core Period|Early Withdrawals|0
6039265|NCT00364832|9637009|FG000|Extension Year 1|Early Withdrawals|0
6039266|NCT00364832|9637010|FG001|Extension Year 1|Early Withdrawals|0
6039267|NCT00364832|9637011|FG002|Extension Year 1|Early Withdrawals|0
6039268|NCT00364832|9637012|FG003|Extension Year 1|Early Withdrawals|0
6039269|NCT00364832|9637013|FG004|Extension Year 1|Early Withdrawals|0
6039270|NCT00364832|9637014|FG005|Extension Year 1|Early Withdrawals|0
6039271|NCT00364832|9637015|FG006|Extension Year 1|Early Withdrawals|0
6039272|NCT00364832|9637016|FG007|Extension Year 1|Early Withdrawals|0
6039273|NCT00364832|9637017|FG008|Extension Year 1|Early Withdrawals|0
6039274|NCT00364832|9637018|FG009|Extension Year 1|Early Withdrawals|4
6039275|NCT00364832|9637019|FG010|Extension Year 1|Early Withdrawals|2
6039276|NCT00364832|9637020|FG011|Extension Year 1|Early Withdrawals|10
6039277|NCT00364832|9637009|FG000|Extension Year 2|Early Withdrawals|0
6039278|NCT00364832|9637010|FG001|Extension Year 2|Early Withdrawals|0
6039279|NCT00364832|9637011|FG002|Extension Year 2|Early Withdrawals|0
6039280|NCT00364832|9637012|FG003|Extension Year 2|Early Withdrawals|0
6039281|NCT00364832|9637013|FG004|Extension Year 2|Early Withdrawals|0
6039282|NCT00364832|9637014|FG005|Extension Year 2|Early Withdrawals|0
6039283|NCT00364832|9637015|FG006|Extension Year 2|Early Withdrawals|0
6039284|NCT00364832|9637016|FG007|Extension Year 2|Early Withdrawals|0
6039285|NCT00364832|9637017|FG008|Extension Year 2|Early Withdrawals|0
6039286|NCT00364832|9637018|FG009|Extension Year 2|Early Withdrawals|5
6039287|NCT00364832|9637019|FG010|Extension Year 2|Early Withdrawals|5
6039288|NCT00364832|9637020|FG011|Extension Year 2|Early Withdrawals|3
6039289|NCT00364845|9637039|FG000|Overall Study|Adverse Event|1
6039290|NCT00364845|9637040|FG001|Overall Study|Adverse Event|0
6039291|NCT00364845|9637039|FG000|Overall Study|Withdrawal by Subject|2
6039292|NCT00364845|9637040|FG001|Overall Study|Withdrawal by Subject|1
6039293|NCT00364845|9637039|FG000|Overall Study|Physician Decision|8
6039294|NCT00364845|9637040|FG001|Overall Study|Physician Decision|8
6039295|NCT00364845|9637039|FG000|Overall Study|Lost to Follow-up|0
6039296|NCT00364845|9637040|FG001|Overall Study|Lost to Follow-up|1
6039297|NCT00364845|9637039|FG000|Overall Study|Death|0
6039298|NCT00364845|9637040|FG001|Overall Study|Death|1
6039299|NCT00364858|9637048|FG000|Overall Study|Adverse Event|1
6039300|NCT00364858|9637049|FG001|Overall Study|Adverse Event|5
6039301|NCT00364858|9637048|FG000|Overall Study|Withdrawal by Subject|1
6039302|NCT00364858|9637049|FG001|Overall Study|Withdrawal by Subject|1
6039303|NCT00364858|9637048|FG000|Overall Study|Pregnancy|1
6039304|NCT00364858|9637049|FG001|Overall Study|Pregnancy|1
6039305|NCT00364858|9637048|FG000|Overall Study|Clinical failure|2
6039306|NCT00364858|9637049|FG001|Overall Study|Clinical failure|13
6039307|NCT00364858|9637048|FG000|Overall Study|Discontinuation at baseline|1
6039308|NCT00364858|9637049|FG001|Overall Study|Discontinuation at baseline|0
6039309|NCT00364858|9637048|FG000|Overall Study|Non-compliant|1
6039310|NCT00364858|9637049|FG001|Overall Study|Non-compliant|0
6039311|NCT00364858|9637048|FG000|Overall Study|Return to Q2 regimen|0
6039312|NCT00364858|9637049|FG001|Overall Study|Return to Q2 regimen|1
6039313|NCT00364858|9637048|FG000|Overall Study|Clinical baseline issue|0
6039314|NCT00364858|9637049|FG001|Overall Study|Clinical baseline issue|1
6039315|NCT00364923|9637056|FG000|Treatment With Pralatrexate|Treatment with pralatrexate ongoing|4
6039316|NCT00364923|9637056|FG000|Survival Follow-up, After Pralatrexate|Pts still in follow-up at data cutoff|24
6039317|NCT00365105|9637075|FG000|Overall Study|Protocol Violation|5
6039318|NCT00365105|9637076|FG001|Overall Study|Protocol Violation|8
6039319|NCT00365300|9637109|FG000|Open-label Phase|Adverse Event|4
6039320|NCT00365300|9637110|FG001|Open-label Phase|Adverse Event|0
6039321|NCT00365300|9637109|FG000|Open-label Phase|Failed to Return|1
6039322|NCT00365300|9637110|FG001|Open-label Phase|Failed to Return|0
6039323|NCT00365300|9637109|FG000|Open-label Phase|Physician Decision|1
6039324|NCT00365300|9637110|FG001|Open-label Phase|Physician Decision|0
6039325|NCT00365300|9637109|FG000|Open-label Phase|Noncompliance|9
6039326|NCT00365300|9637110|FG001|Open-label Phase|Noncompliance|0
6039327|NCT00365300|9637109|FG000|Open-label Phase|Parent/Legal Guardian Request|4
6039328|NCT00365300|9637110|FG001|Open-label Phase|Parent/Legal Guardian Request|0
6039329|NCT00365300|9637109|FG000|Open-label Phase|Protocol Violation|1
6039330|NCT00365300|9637110|FG001|Open-label Phase|Protocol Violation|0
6039331|NCT00365300|9637109|FG000|Open-label Phase|Lack of Efficacy|1
6039332|NCT00365300|9637110|FG001|Open-label Phase|Lack of Efficacy|0
6039333|NCT00365300|9637109|FG000|Open-label Phase|Patient skipped open label phase|1
6039334|NCT00365300|9637110|FG001|Open-label Phase|Patient skipped open label phase|0
6039335|NCT00365300|9637109|FG000|Double-blind Phase|Failed to return|1
6309689|NCT02641379|10038341|FG002|Overall Study|Participant stopped study/treatment|1
6309690|NCT02641379|10038342|FG003|Overall Study|Participant stopped study/treatment|0
6309691|NCT02641379|10038343|FG004|Overall Study|Participant stopped study/treatment|0
6309692|NCT02641379|10038344|FG005|Overall Study|Participant stopped study/treatment|1
6309693|NCT02641379|10038345|FG006|Overall Study|Participant stopped study/treatment|2
6309694|NCT02641379|10038346|FG007|Overall Study|Participant stopped study/treatment|0
6309695|NCT02641379|10038347|FG008|Overall Study|Participant stopped study/treatment|1
6309696|NCT02641379|10038348|FG009|Overall Study|Participant stopped study/treatment|0
6309697|NCT02641379|10038349|FG010|Overall Study|Participant stopped study/treatment|0
6309698|NCT02641379|10038339|FG000|Overall Study|Therapy stopped due to misunderstanding|1
6309699|NCT02641379|10038340|FG001|Overall Study|Therapy stopped due to misunderstanding|0
6309700|NCT02641379|10038341|FG002|Overall Study|Therapy stopped due to misunderstanding|0
6309701|NCT02641379|10038342|FG003|Overall Study|Therapy stopped due to misunderstanding|0
6309702|NCT02641379|10038343|FG004|Overall Study|Therapy stopped due to misunderstanding|0
6309703|NCT02641379|10038344|FG005|Overall Study|Therapy stopped due to misunderstanding|0
6309704|NCT02641379|10038345|FG006|Overall Study|Therapy stopped due to misunderstanding|0
6309705|NCT02641379|10038346|FG007|Overall Study|Therapy stopped due to misunderstanding|0
6309706|NCT02641379|10038347|FG008|Overall Study|Therapy stopped due to misunderstanding|0
6309707|NCT02641379|10038348|FG009|Overall Study|Therapy stopped due to misunderstanding|0
6309708|NCT02641379|10038349|FG010|Overall Study|Therapy stopped due to misunderstanding|0
6309709|NCT02641379|10038339|FG000|Overall Study|Financial problems|0
6309710|NCT02641379|10038340|FG001|Overall Study|Financial problems|1
6309711|NCT02641379|10038341|FG002|Overall Study|Financial problems|0
6309712|NCT02641379|10038342|FG003|Overall Study|Financial problems|0
6309713|NCT02641379|10038343|FG004|Overall Study|Financial problems|0
6309714|NCT02641379|10038344|FG005|Overall Study|Financial problems|0
6309715|NCT02641379|10038345|FG006|Overall Study|Financial problems|0
6309716|NCT02641379|10038346|FG007|Overall Study|Financial problems|0
6309717|NCT02641379|10038347|FG008|Overall Study|Financial problems|0
6309718|NCT02641379|10038348|FG009|Overall Study|Financial problems|0
6309719|NCT02641379|10038349|FG010|Overall Study|Financial problems|0
6309720|NCT02641379|10038339|FG000|Overall Study|PCR positive at Week 68|0
6309721|NCT02641379|10038340|FG001|Overall Study|PCR positive at Week 68|1
6309722|NCT02641379|10038341|FG002|Overall Study|PCR positive at Week 68|0
6309723|NCT02641379|10038342|FG003|Overall Study|PCR positive at Week 68|0
6309724|NCT02641379|10038343|FG004|Overall Study|PCR positive at Week 68|0
6309725|NCT02641379|10038344|FG005|Overall Study|PCR positive at Week 68|0
6309726|NCT02641379|10038345|FG006|Overall Study|PCR positive at Week 68|0
6309727|NCT02641379|10038346|FG007|Overall Study|PCR positive at Week 68|0
6309728|NCT02641379|10038347|FG008|Overall Study|PCR positive at Week 68|0
6309729|NCT02641379|10038348|FG009|Overall Study|PCR positive at Week 68|0
6309730|NCT02641379|10038349|FG010|Overall Study|PCR positive at Week 68|0
6309731|NCT02641379|10038339|FG000|Overall Study|PCR positive at Week 48|0
6309732|NCT02641379|10038340|FG001|Overall Study|PCR positive at Week 48|1
6309733|NCT02641379|10038341|FG002|Overall Study|PCR positive at Week 48|0
6309734|NCT02641379|10038342|FG003|Overall Study|PCR positive at Week 48|0
6309735|NCT02641379|10038343|FG004|Overall Study|PCR positive at Week 48|0
6309736|NCT02641379|10038344|FG005|Overall Study|PCR positive at Week 48|0
6309737|NCT02641379|10038345|FG006|Overall Study|PCR positive at Week 48|0
6309738|NCT02641379|10038346|FG007|Overall Study|PCR positive at Week 48|0
6309739|NCT02641379|10038347|FG008|Overall Study|PCR positive at Week 48|0
6309740|NCT02641379|10038348|FG009|Overall Study|PCR positive at Week 48|0
6309741|NCT02641379|10038349|FG010|Overall Study|PCR positive at Week 48|0
6309742|NCT02641379|10038339|FG000|Overall Study|PCR not performed at Week 12|0
6309743|NCT02641379|10038340|FG001|Overall Study|PCR not performed at Week 12|0
6309744|NCT02641379|10038341|FG002|Overall Study|PCR not performed at Week 12|1
6309745|NCT02641379|10038342|FG003|Overall Study|PCR not performed at Week 12|0
6309746|NCT02641379|10038343|FG004|Overall Study|PCR not performed at Week 12|0
6309747|NCT02641379|10038344|FG005|Overall Study|PCR not performed at Week 12|0
6309748|NCT02641379|10038345|FG006|Overall Study|PCR not performed at Week 12|0
6309749|NCT02641379|10038346|FG007|Overall Study|PCR not performed at Week 12|0
6309750|NCT02641379|10038347|FG008|Overall Study|PCR not performed at Week 12|0
6039336|NCT00365300|9637110|FG001|Double-blind Phase|Failed to return|0
6309751|NCT02641379|10038348|FG009|Overall Study|PCR not performed at Week 12|0
6039337|NCT00365300|9637109|FG000|Double-blind Phase|Noncompliance|1
6039338|NCT00365300|9637110|FG001|Double-blind Phase|Noncompliance|1
6039339|NCT00365300|9637109|FG000|Double-blind Phase|Withdrawal by Subject|0
6039340|NCT00365300|9637110|FG001|Double-blind Phase|Withdrawal by Subject|1
6039341|NCT00365300|9637109|FG000|Double-blind Phase|Protocol Violation|3
6039342|NCT00365300|9637110|FG001|Double-blind Phase|Protocol Violation|1
6039343|NCT00365300|9637109|FG000|Double-blind Phase|Lack of Efficacy|6
6039344|NCT00365300|9637110|FG001|Double-blind Phase|Lack of Efficacy|6
6039345|NCT00365352|9637122|FG000|Overall Study|Adverse Event|6
6039346|NCT00365352|9637123|FG001|Overall Study|Adverse Event|7
6039347|NCT00365352|9637124|FG002|Overall Study|Adverse Event|8
6039348|NCT00365352|9637122|FG000|Overall Study|Participant Withdrew Consent|8
6039349|NCT00365352|9637123|FG001|Overall Study|Participant Withdrew Consent|3
6039350|NCT00365352|9637124|FG002|Overall Study|Participant Withdrew Consent|4
6039351|NCT00365352|9637122|FG000|Overall Study|Lack of Efficacy|3
6039352|NCT00365352|9637123|FG001|Overall Study|Lack of Efficacy|0
6039353|NCT00365352|9637124|FG002|Overall Study|Lack of Efficacy|0
6039354|NCT00365352|9637122|FG000|Overall Study|Ineligible (Did Not Meet Entry Criteria)|0
6039355|NCT00365352|9637123|FG001|Overall Study|Ineligible (Did Not Meet Entry Criteria)|0
6039356|NCT00365352|9637124|FG002|Overall Study|Ineligible (Did Not Meet Entry Criteria)|2
6039357|NCT00365352|9637122|FG000|Overall Study|Non-Compliance (after Randomization)|1
6039358|NCT00365352|9637123|FG001|Overall Study|Non-Compliance (after Randomization)|0
6039359|NCT00365352|9637124|FG002|Overall Study|Non-Compliance (after Randomization)|1
6039360|NCT00365352|9637122|FG000|Overall Study|Lost to Follow-up|1
6039361|NCT00365352|9637123|FG001|Overall Study|Lost to Follow-up|1
6309752|NCT02641379|10038349|FG010|Overall Study|PCR not performed at Week 12|0
6309753|NCT02641379|10038339|FG000|Overall Study|No PCR at baseline|0
6309754|NCT02641379|10038340|FG001|Overall Study|No PCR at baseline|0
6309755|NCT02641379|10038341|FG002|Overall Study|No PCR at baseline|1
6309756|NCT02641379|10038342|FG003|Overall Study|No PCR at baseline|0
6309757|NCT02641379|10038343|FG004|Overall Study|No PCR at baseline|0
6309758|NCT02641379|10038344|FG005|Overall Study|No PCR at baseline|0
6309759|NCT02641379|10038345|FG006|Overall Study|No PCR at baseline|0
6309760|NCT02641379|10038346|FG007|Overall Study|No PCR at baseline|0
6309761|NCT02641379|10038347|FG008|Overall Study|No PCR at baseline|0
6309762|NCT02641379|10038348|FG009|Overall Study|No PCR at baseline|0
6309763|NCT02641379|10038349|FG010|Overall Study|No PCR at baseline|0
6309764|NCT02641379|10038339|FG000|Overall Study|PCR positive at Week 28|0
6309765|NCT02641379|10038340|FG001|Overall Study|PCR positive at Week 28|0
6309766|NCT02641379|10038341|FG002|Overall Study|PCR positive at Week 28|1
6309767|NCT02641379|10038342|FG003|Overall Study|PCR positive at Week 28|0
6309768|NCT02641379|10038343|FG004|Overall Study|PCR positive at Week 28|0
6309769|NCT02641379|10038344|FG005|Overall Study|PCR positive at Week 28|0
6309770|NCT02641379|10038345|FG006|Overall Study|PCR positive at Week 28|0
6309771|NCT02641379|10038346|FG007|Overall Study|PCR positive at Week 28|0
6309772|NCT02641379|10038347|FG008|Overall Study|PCR positive at Week 28|0
6309773|NCT02641379|10038348|FG009|Overall Study|PCR positive at Week 28|0
6309774|NCT02641379|10038349|FG010|Overall Study|PCR positive at Week 28|0
6309775|NCT02641379|10038339|FG000|Overall Study|PCR sample for Week 4 not drawn|0
6309776|NCT02641379|10038340|FG001|Overall Study|PCR sample for Week 4 not drawn|0
6309777|NCT02641379|10038341|FG002|Overall Study|PCR sample for Week 4 not drawn|0
6309778|NCT02641379|10038342|FG003|Overall Study|PCR sample for Week 4 not drawn|1
6309779|NCT02641379|10038343|FG004|Overall Study|PCR sample for Week 4 not drawn|0
6309780|NCT02641379|10038344|FG005|Overall Study|PCR sample for Week 4 not drawn|0
6309781|NCT02641379|10038345|FG006|Overall Study|PCR sample for Week 4 not drawn|0
6309782|NCT02641379|10038346|FG007|Overall Study|PCR sample for Week 4 not drawn|0
6309783|NCT02641379|10038347|FG008|Overall Study|PCR sample for Week 4 not drawn|0
6309784|NCT02641379|10038348|FG009|Overall Study|PCR sample for Week 4 not drawn|0
6309785|NCT02641379|10038349|FG010|Overall Study|PCR sample for Week 4 not drawn|0
6309786|NCT02641379|10038339|FG000|Overall Study|Inclusion criteria not fulfilled|0
6309787|NCT02641379|10038340|FG001|Overall Study|Inclusion criteria not fulfilled|0
6309788|NCT02641379|10038341|FG002|Overall Study|Inclusion criteria not fulfilled|0
6309789|NCT02641379|10038342|FG003|Overall Study|Inclusion criteria not fulfilled|1
6309790|NCT02641379|10038343|FG004|Overall Study|Inclusion criteria not fulfilled|0
6309791|NCT02641379|10038344|FG005|Overall Study|Inclusion criteria not fulfilled|0
6309792|NCT02641379|10038345|FG006|Overall Study|Inclusion criteria not fulfilled|0
6309793|NCT02641379|10038346|FG007|Overall Study|Inclusion criteria not fulfilled|0
6309794|NCT02641379|10038347|FG008|Overall Study|Inclusion criteria not fulfilled|0
6309795|NCT02641379|10038348|FG009|Overall Study|Inclusion criteria not fulfilled|0
6309796|NCT02641379|10038349|FG010|Overall Study|Inclusion criteria not fulfilled|0
6309797|NCT02641379|10038339|FG000|Overall Study|Baseline viral load unavailable|0
6309798|NCT02641379|10038340|FG001|Overall Study|Baseline viral load unavailable|0
6039362|NCT00365352|9637124|FG002|Overall Study|Lost to Follow-up|0
6039363|NCT00365352|9637122|FG000|Overall Study|Withdrawal of Participant by Sponsor|1
6039364|NCT00365352|9637123|FG001|Overall Study|Withdrawal of Participant by Sponsor|0
6039365|NCT00365352|9637124|FG002|Overall Study|Withdrawal of Participant by Sponsor|0
6039366|NCT00365365|9637138|FG000|Overall Study|Randomized but not treated|0
6039367|NCT00365365|9637139|FG001|Overall Study|Randomized but not treated|2
6039368|NCT00365365|9637140|FG002|Overall Study|Randomized but not treated|0
6039369|NCT00365365|9637138|FG000|Overall Study|Poor compliance to protocol|0
6309799|NCT02641379|10038341|FG002|Overall Study|Baseline viral load unavailable|0
6039370|NCT00365365|9637139|FG001|Overall Study|Poor compliance to protocol|1
6039371|NCT00365365|9637140|FG002|Overall Study|Poor compliance to protocol|0
6039372|NCT00365365|9637138|FG000|Overall Study|Lost to Follow-up|3
6039373|NCT00365365|9637139|FG001|Overall Study|Lost to Follow-up|3
6039374|NCT00365365|9637140|FG002|Overall Study|Lost to Follow-up|3
6039375|NCT00365365|9637138|FG000|Overall Study|Death|1
6039376|NCT00365365|9637139|FG001|Overall Study|Death|3
6039377|NCT00365365|9637140|FG002|Overall Study|Death|0
6039378|NCT00365365|9637138|FG000|Overall Study|Subject's request|11
6039379|NCT00365365|9637139|FG001|Overall Study|Subject's request|13
6039380|NCT00365365|9637140|FG002|Overall Study|Subject's request|1
6039381|NCT00365365|9637138|FG000|Overall Study|Disease progression/relapse|9
6039382|NCT00365365|9637139|FG001|Overall Study|Disease progression/relapse|6
6039383|NCT00365365|9637140|FG002|Overall Study|Disease progression/relapse|7
6039384|NCT00365365|9637138|FG000|Overall Study|Adverse Event|6
6039385|NCT00365365|9637139|FG001|Overall Study|Adverse Event|6
6039386|NCT00365365|9637140|FG002|Overall Study|Adverse Event|3
6039387|NCT00365365|9637138|FG000|Overall Study|Moved|2
6039388|NCT00365365|9637139|FG001|Overall Study|Moved|0
6039389|NCT00365365|9637140|FG002|Overall Study|Moved|0
6039390|NCT00365365|9637138|FG000|Overall Study|New cancer|1
6039391|NCT00365365|9637139|FG001|Overall Study|New cancer|0
6039392|NCT00365365|9637140|FG002|Overall Study|New cancer|0
6039393|NCT00365365|9637138|FG000|Overall Study|Withdrew consent|1
6039394|NCT00365365|9637139|FG001|Overall Study|Withdrew consent|1
6039395|NCT00365365|9637140|FG002|Overall Study|Withdrew consent|0
6039396|NCT00365365|9637138|FG000|Overall Study|Second malignancy|0
6309800|NCT02641379|10038342|FG003|Overall Study|Baseline viral load unavailable|1
6039397|NCT00365365|9637139|FG001|Overall Study|Second malignancy|1
6148308|NCT01088984|9783611|FG001|Phase 2|Withdrawal by Subject|1
6039398|NCT00365365|9637140|FG002|Overall Study|Second malignancy|0
6148309|NCT01088984|9783610|FG000|Phase 2|DIsease Progression|0
6148310|NCT01088984|9783611|FG001|Phase 2|DIsease Progression|25
6148311|NCT01088984|9783610|FG000|Phase 2|Other|0
6148312|NCT01088984|9783611|FG001|Phase 2|Other|1
6148313|NCT01088997|9783622|FG000|Overall Study|Physician Decision|1
6148314|NCT01088997|9783623|FG001|Overall Study|Physician Decision|1
6148315|NCT01088997|9783622|FG000|Overall Study|Req. Extracorporeal membrane oxygenation|1
6148316|NCT01088997|9783623|FG001|Overall Study|Req. Extracorporeal membrane oxygenation|1
6039399|NCT00365365|9637138|FG000|Overall Study|Patient/physician decision|0
6039400|NCT00365365|9637139|FG001|Overall Study|Patient/physician decision|0
6039401|NCT00365365|9637140|FG002|Overall Study|Patient/physician decision|1
6039402|NCT00365378|9637150|FG000|Vaccination (Day 1 to Month 7)|Randomized Not Vaccinated|11
6039403|NCT00365378|9637151|FG001|Vaccination (Day 1 to Month 7)|Randomized Not Vaccinated|7
6039404|NCT00365378|9637152|FG002|Vaccination (Day 1 to Month 7)|Randomized Not Vaccinated|0
6039405|NCT00365378|9637150|FG000|Vaccination (Day 1 to Month 7)|Adverse Event|4
6039406|NCT00365378|9637151|FG001|Vaccination (Day 1 to Month 7)|Adverse Event|5
6039407|NCT00365378|9637152|FG002|Vaccination (Day 1 to Month 7)|Adverse Event|0
6039408|NCT00365378|9637150|FG000|Vaccination (Day 1 to Month 7)|Lost to Follow-up|88
6039409|NCT00365378|9637151|FG001|Vaccination (Day 1 to Month 7)|Lost to Follow-up|75
6039410|NCT00365378|9637152|FG002|Vaccination (Day 1 to Month 7)|Lost to Follow-up|0
6039411|NCT00365378|9637150|FG000|Vaccination (Day 1 to Month 7)|Pregnancy|19
6039412|NCT00365378|9637151|FG001|Vaccination (Day 1 to Month 7)|Pregnancy|14
6039413|NCT00365378|9637152|FG002|Vaccination (Day 1 to Month 7)|Pregnancy|0
6039414|NCT00365378|9637150|FG000|Vaccination (Day 1 to Month 7)|Protocol Violation|22
6039415|NCT00365378|9637151|FG001|Vaccination (Day 1 to Month 7)|Protocol Violation|13
6039416|NCT00365378|9637152|FG002|Vaccination (Day 1 to Month 7)|Protocol Violation|0
6039417|NCT00365378|9637150|FG000|Vaccination (Day 1 to Month 7)|Withdrawal by Subject|50
6039418|NCT00365378|9637151|FG001|Vaccination (Day 1 to Month 7)|Withdrawal by Subject|44
6039419|NCT00365378|9637152|FG002|Vaccination (Day 1 to Month 7)|Withdrawal by Subject|0
6039420|NCT00365378|9637150|FG000|Vaccination (Day 1 to Month 7)|Other|17
6309801|NCT02641379|10038343|FG004|Overall Study|Baseline viral load unavailable|0
6039421|NCT00365378|9637151|FG001|Vaccination (Day 1 to Month 7)|Other|9
6039422|NCT00365378|9637152|FG002|Vaccination (Day 1 to Month 7)|Other|0
6039423|NCT00365378|9637150|FG000|Follow-up (Month 7 Though Month 48)|Moved|6
6039424|NCT00365378|9637151|FG001|Follow-up (Month 7 Though Month 48)|Moved|5
6039425|NCT00365378|9637152|FG002|Follow-up (Month 7 Though Month 48)|Moved|0
6039426|NCT00365378|9637150|FG000|Follow-up (Month 7 Though Month 48)|Lost to Follow-up|67
6148317|NCT01088997|9783622|FG000|Overall Study|Excluded prior to receiving drug|1
6148318|NCT01088997|9783623|FG001|Overall Study|Excluded prior to receiving drug|1
6148319|NCT01089023|9783632|FG000|Overall Study|Lost to Follow-up|3
6148320|NCT01089023|9783632|FG000|Overall Study|Adverse Event|1
6148321|NCT01089023|9783632|FG000|Overall Study|Withdrawal by Subject|1
6148322|NCT01089023|9783632|FG000|Overall Study|Protocol Violation|1
6148323|NCT01089023|9783632|FG000|Overall Study|Lack of Efficacy|1
6148324|NCT01089127|9783662|FG000|Overall Study|Adverse Event|5
6148325|NCT01089127|9783663|FG001|Overall Study|Adverse Event|1
6148326|NCT01089127|9783664|FG002|Overall Study|Adverse Event|1
6148327|NCT01089127|9783665|FG003|Overall Study|Adverse Event|0
6148328|NCT01089127|9783666|FG004|Overall Study|Adverse Event|0
6039427|NCT00365378|9637151|FG001|Follow-up (Month 7 Though Month 48)|Lost to Follow-up|69
6039428|NCT00365378|9637152|FG002|Follow-up (Month 7 Though Month 48)|Lost to Follow-up|0
6039429|NCT00365378|9637150|FG000|Follow-up (Month 7 Though Month 48)|Pregnancy|0
6039430|NCT00365378|9637151|FG001|Follow-up (Month 7 Though Month 48)|Pregnancy|1
6039431|NCT00365378|9637152|FG002|Follow-up (Month 7 Though Month 48)|Pregnancy|0
6039432|NCT00365378|9637150|FG000|Follow-up (Month 7 Though Month 48)|Protocol Violation|1
6039433|NCT00365378|9637151|FG001|Follow-up (Month 7 Though Month 48)|Protocol Violation|2
6039434|NCT00365378|9637152|FG002|Follow-up (Month 7 Though Month 48)|Protocol Violation|0
6039435|NCT00365378|9637150|FG000|Follow-up (Month 7 Though Month 48)|Withdrawal by Subject|73
6039436|NCT00365378|9637151|FG001|Follow-up (Month 7 Though Month 48)|Withdrawal by Subject|104
6039437|NCT00365378|9637152|FG002|Follow-up (Month 7 Though Month 48)|Withdrawal by Subject|0
6148329|NCT01089127|9783667|FG005|Overall Study|Adverse Event|1
6148330|NCT01089127|9783662|FG000|Overall Study|Subject withdrew consent|0
6148331|NCT01089127|9783663|FG001|Overall Study|Subject withdrew consent|1
6148332|NCT01089127|9783664|FG002|Overall Study|Subject withdrew consent|1
6148333|NCT01089127|9783665|FG003|Overall Study|Subject withdrew consent|1
6148334|NCT01089127|9783666|FG004|Overall Study|Subject withdrew consent|0
6148335|NCT01089127|9783667|FG005|Overall Study|Subject withdrew consent|2
6148336|NCT01089127|9783662|FG000|Overall Study|Abnormal test procedure result(s)|2
6148337|NCT01089127|9783663|FG001|Overall Study|Abnormal test procedure result(s)|1
6039438|NCT00365378|9637150|FG000|Follow-up (Month 7 Though Month 48)|Other|11
6039439|NCT00365378|9637151|FG001|Follow-up (Month 7 Though Month 48)|Other|21
6039440|NCT00365378|9637152|FG002|Follow-up (Month 7 Though Month 48)|Other|0
6039441|NCT00365378|9637150|FG000|Extension|Adverse Event|0
6039442|NCT00365378|9637151|FG001|Extension|Adverse Event|0
6039443|NCT00365378|9637152|FG002|Extension|Adverse Event|1
6039444|NCT00365378|9637150|FG000|Extension|Moved|0
6039445|NCT00365378|9637151|FG001|Extension|Moved|0
6039446|NCT00365378|9637152|FG002|Extension|Moved|8
6039447|NCT00365378|9637150|FG000|Extension|Lost to Follow-up|0
6039448|NCT00365378|9637151|FG001|Extension|Lost to Follow-up|0
6039449|NCT00365378|9637152|FG002|Extension|Lost to Follow-up|57
6039450|NCT00365378|9637150|FG000|Extension|Protocol Violation|0
6039451|NCT00365378|9637151|FG001|Extension|Protocol Violation|0
6039452|NCT00365378|9637152|FG002|Extension|Protocol Violation|2
6039453|NCT00365378|9637150|FG000|Extension|Withdrawal by Subject|0
6039454|NCT00365378|9637151|FG001|Extension|Withdrawal by Subject|0
6039455|NCT00365378|9637152|FG002|Extension|Withdrawal by Subject|98
6039456|NCT00365378|9637150|FG000|Extension|Other|0
6039457|NCT00365378|9637151|FG001|Extension|Other|0
6039458|NCT00365378|9637152|FG002|Extension|Other|31
6039459|NCT00365456|9637168|FG000|Trial Period I (12 Months)|Adverse Event|84
6039460|NCT00365456|9637169|FG001|Trial Period I (12 Months)|Adverse Event|0
6039461|NCT00365456|9637168|FG000|Trial Period I (12 Months)|Non-compliance|3
6039462|NCT00365456|9637169|FG001|Trial Period I (12 Months)|Non-compliance|0
6039463|NCT00365456|9637168|FG000|Trial Period I (12 Months)|Withdrawal by Subject|27
6039464|NCT00365456|9637169|FG001|Trial Period I (12 Months)|Withdrawal by Subject|0
6039465|NCT00365456|9637168|FG000|Trial Period I (12 Months)|Other|11
6039466|NCT00365456|9637169|FG001|Trial Period I (12 Months)|Other|0
6039467|NCT00365456|9637168|FG000|Trial Period II (12 Months)|Adverse Event|0
6039468|NCT00365456|9637169|FG001|Trial Period II (12 Months)|Adverse Event|6
6039469|NCT00365456|9637168|FG000|Trial Period II (12 Months)|Non-compliance|0
6039470|NCT00365456|9637169|FG001|Trial Period II (12 Months)|Non-compliance|2
6039471|NCT00365456|9637168|FG000|Trial Period II (12 Months)|Withdrawal by Subject|0
6039472|NCT00365456|9637169|FG001|Trial Period II (12 Months)|Withdrawal by Subject|5
6039473|NCT00365456|9637168|FG000|Trial Period II (12 Months)|Other|0
6039474|NCT00365456|9637169|FG001|Trial Period II (12 Months)|Other|1
6039475|NCT00365456|9637168|FG000|Trial Period III (12 Months)|Adverse Event|13
6039476|NCT00365456|9637169|FG001|Trial Period III (12 Months)|Adverse Event|3
6039477|NCT00365456|9637168|FG000|Trial Period III (12 Months)|Withdrawal by Subject|4
6039478|NCT00365456|9637169|FG001|Trial Period III (12 Months)|Withdrawal by Subject|1
6039479|NCT00365456|9637168|FG000|Trial Period III (12 Months)|Other|1
6039480|NCT00365456|9637169|FG001|Trial Period III (12 Months)|Other|1
6039481|NCT00365508|9637177|FG000|Overall Study|Lost to Follow-up|139
6039482|NCT00365508|9637178|FG001|Overall Study|Lost to Follow-up|154
6039483|NCT00365547|9637184|FG000|Overall Study|Insurance did not cover Avastin|1
6039484|NCT00365547|9637184|FG000|Overall Study|Screen failure|1
6039485|NCT00365547|9637184|FG000|Overall Study|Withdrawal by Subject|1
6039486|NCT00365716|9637200|FG000|Base Study (Day 1 to Month 7)|Randomized Not Vaccinated|1
6039487|NCT00365716|9637201|FG001|Base Study (Day 1 to Month 7)|Randomized Not Vaccinated|2
6039488|NCT00365716|9637202|FG002|Base Study (Day 1 to Month 7)|Randomized Not Vaccinated|0
6039489|NCT00365716|9637203|FG003|Base Study (Day 1 to Month 7)|Randomized Not Vaccinated|0
6039490|NCT00365716|9637204|FG004|Base Study (Day 1 to Month 7)|Randomized Not Vaccinated|0
6039491|NCT00365716|9637205|FG005|Base Study (Day 1 to Month 7)|Randomized Not Vaccinated|0
6039492|NCT00365716|9637206|FG006|Base Study (Day 1 to Month 7)|Randomized Not Vaccinated|0
6039493|NCT00365716|9637200|FG000|Base Study (Day 1 to Month 7)|Adverse Event|0
6039494|NCT00365716|9637201|FG001|Base Study (Day 1 to Month 7)|Adverse Event|2
6039495|NCT00365716|9637202|FG002|Base Study (Day 1 to Month 7)|Adverse Event|0
6148338|NCT01089127|9783664|FG002|Overall Study|Abnormal test procedure result(s)|0
6148339|NCT01089127|9783665|FG003|Overall Study|Abnormal test procedure result(s)|0
6148340|NCT01089127|9783666|FG004|Overall Study|Abnormal test procedure result(s)|0
6227291|NCT01716520|9900043|FG002|Washout Period 1 (10 to 14 Days)|Withdrawal by Subject|1
6039496|NCT00365716|9637203|FG003|Base Study (Day 1 to Month 7)|Adverse Event|0
6039497|NCT00365716|9637204|FG004|Base Study (Day 1 to Month 7)|Adverse Event|1
6039498|NCT00365716|9637205|FG005|Base Study (Day 1 to Month 7)|Adverse Event|0
6039499|NCT00365716|9637206|FG006|Base Study (Day 1 to Month 7)|Adverse Event|0
6039500|NCT00365716|9637200|FG000|Base Study (Day 1 to Month 7)|Lost to Follow-up|4
6039501|NCT00365716|9637201|FG001|Base Study (Day 1 to Month 7)|Lost to Follow-up|6
6039502|NCT00365716|9637202|FG002|Base Study (Day 1 to Month 7)|Lost to Follow-up|6
6039503|NCT00365716|9637203|FG003|Base Study (Day 1 to Month 7)|Lost to Follow-up|4
6039504|NCT00365716|9637204|FG004|Base Study (Day 1 to Month 7)|Lost to Follow-up|0
6039505|NCT00365716|9637205|FG005|Base Study (Day 1 to Month 7)|Lost to Follow-up|0
6039506|NCT00365716|9637206|FG006|Base Study (Day 1 to Month 7)|Lost to Follow-up|0
6039507|NCT00365716|9637200|FG000|Base Study (Day 1 to Month 7)|Other|0
6039508|NCT00365716|9637201|FG001|Base Study (Day 1 to Month 7)|Other|1
6039509|NCT00365716|9637202|FG002|Base Study (Day 1 to Month 7)|Other|0
6039510|NCT00365716|9637203|FG003|Base Study (Day 1 to Month 7)|Other|0
6039511|NCT00365716|9637204|FG004|Base Study (Day 1 to Month 7)|Other|0
6039512|NCT00365716|9637205|FG005|Base Study (Day 1 to Month 7)|Other|0
6039513|NCT00365716|9637206|FG006|Base Study (Day 1 to Month 7)|Other|0
6039514|NCT00365716|9637200|FG000|Base Study (Day 1 to Month 7)|Pregnancy|3
6039515|NCT00365716|9637201|FG001|Base Study (Day 1 to Month 7)|Pregnancy|2
6039516|NCT00365716|9637202|FG002|Base Study (Day 1 to Month 7)|Pregnancy|3
6039517|NCT00365716|9637203|FG003|Base Study (Day 1 to Month 7)|Pregnancy|1
6039518|NCT00365716|9637204|FG004|Base Study (Day 1 to Month 7)|Pregnancy|1
6039519|NCT00365716|9637205|FG005|Base Study (Day 1 to Month 7)|Pregnancy|0
6309802|NCT02641379|10038344|FG005|Overall Study|Baseline viral load unavailable|0
6039520|NCT00365716|9637206|FG006|Base Study (Day 1 to Month 7)|Pregnancy|0
6039521|NCT00365716|9637200|FG000|Base Study (Day 1 to Month 7)|Protocol Violation|1
6309803|NCT02641379|10038345|FG006|Overall Study|Baseline viral load unavailable|0
6309804|NCT02641379|10038346|FG007|Overall Study|Baseline viral load unavailable|0
6309805|NCT02641379|10038347|FG008|Overall Study|Baseline viral load unavailable|0
6309806|NCT02641379|10038348|FG009|Overall Study|Baseline viral load unavailable|0
6309807|NCT02641379|10038349|FG010|Overall Study|Baseline viral load unavailable|0
6309808|NCT02641379|10038339|FG000|Overall Study|Blood could not be drawn|0
6309809|NCT02641379|10038340|FG001|Overall Study|Blood could not be drawn|0
6309810|NCT02641379|10038341|FG002|Overall Study|Blood could not be drawn|0
6309811|NCT02641379|10038342|FG003|Overall Study|Blood could not be drawn|0
6309812|NCT02641379|10038343|FG004|Overall Study|Blood could not be drawn|1
6309813|NCT02641379|10038344|FG005|Overall Study|Blood could not be drawn|0
6309814|NCT02641379|10038345|FG006|Overall Study|Blood could not be drawn|0
6309815|NCT02641379|10038346|FG007|Overall Study|Blood could not be drawn|0
6309816|NCT02641379|10038347|FG008|Overall Study|Blood could not be drawn|0
6039522|NCT00365716|9637201|FG001|Base Study (Day 1 to Month 7)|Protocol Violation|2
6039523|NCT00365716|9637202|FG002|Base Study (Day 1 to Month 7)|Protocol Violation|0
6039524|NCT00365716|9637203|FG003|Base Study (Day 1 to Month 7)|Protocol Violation|1
6039525|NCT00365716|9637204|FG004|Base Study (Day 1 to Month 7)|Protocol Violation|2
6039526|NCT00365716|9637205|FG005|Base Study (Day 1 to Month 7)|Protocol Violation|0
6039527|NCT00365716|9637206|FG006|Base Study (Day 1 to Month 7)|Protocol Violation|0
6039528|NCT00365716|9637200|FG000|Base Study (Day 1 to Month 7)|Withdrawal by Subject|12
6039529|NCT00365716|9637201|FG001|Base Study (Day 1 to Month 7)|Withdrawal by Subject|9
6039530|NCT00365716|9637202|FG002|Base Study (Day 1 to Month 7)|Withdrawal by Subject|12
6039531|NCT00365716|9637203|FG003|Base Study (Day 1 to Month 7)|Withdrawal by Subject|4
6039532|NCT00365716|9637204|FG004|Base Study (Day 1 to Month 7)|Withdrawal by Subject|3
6039533|NCT00365716|9637205|FG005|Base Study (Day 1 to Month 7)|Withdrawal by Subject|0
6039534|NCT00365716|9637206|FG006|Base Study (Day 1 to Month 7)|Withdrawal by Subject|0
6039535|NCT00365716|9637200|FG000|Long Term Follow-up (Month 7 toMonth 36)|Proceeded to Extension 1|114
6039536|NCT00365716|9637201|FG001|Long Term Follow-up (Month 7 toMonth 36)|Proceeded to Extension 1|0
6039537|NCT00365716|9637202|FG002|Long Term Follow-up (Month 7 toMonth 36)|Proceeded to Extension 1|0
6039538|NCT00365716|9637203|FG003|Long Term Follow-up (Month 7 toMonth 36)|Proceeded to Extension 1|69
6039539|NCT00365716|9637204|FG004|Long Term Follow-up (Month 7 toMonth 36)|Proceeded to Extension 1|75
6039540|NCT00365716|9637205|FG005|Long Term Follow-up (Month 7 toMonth 36)|Proceeded to Extension 1|0
6039541|NCT00365716|9637206|FG006|Long Term Follow-up (Month 7 toMonth 36)|Proceeded to Extension 1|0
6039542|NCT00365716|9637200|FG000|Long Term Follow-up (Month 7 toMonth 36)|Lost to Follow-up|6
6039543|NCT00365716|9637201|FG001|Long Term Follow-up (Month 7 toMonth 36)|Lost to Follow-up|8
6039544|NCT00365716|9637202|FG002|Long Term Follow-up (Month 7 toMonth 36)|Lost to Follow-up|5
6309817|NCT02641379|10038348|FG009|Overall Study|Blood could not be drawn|0
6309818|NCT02641379|10038349|FG010|Overall Study|Blood could not be drawn|0
6309819|NCT02641379|10038339|FG000|Overall Study|Protocol Violation|0
6309820|NCT02641379|10038340|FG001|Overall Study|Protocol Violation|0
6309821|NCT02641379|10038341|FG002|Overall Study|Protocol Violation|0
6309822|NCT02641379|10038342|FG003|Overall Study|Protocol Violation|0
6309823|NCT02641379|10038343|FG004|Overall Study|Protocol Violation|2
6309824|NCT02641379|10038344|FG005|Overall Study|Protocol Violation|0
6309825|NCT02641379|10038345|FG006|Overall Study|Protocol Violation|0
6309826|NCT02641379|10038346|FG007|Overall Study|Protocol Violation|0
6309827|NCT02641379|10038347|FG008|Overall Study|Protocol Violation|1
6080222|NCT00615030|9687427|FG010|Period I|Abnormal laboratory value(s)|0
6039545|NCT00365716|9637203|FG003|Long Term Follow-up (Month 7 toMonth 36)|Lost to Follow-up|4
6039546|NCT00365716|9637204|FG004|Long Term Follow-up (Month 7 toMonth 36)|Lost to Follow-up|3
6039547|NCT00365716|9637205|FG005|Long Term Follow-up (Month 7 toMonth 36)|Lost to Follow-up|0
6039548|NCT00365716|9637206|FG006|Long Term Follow-up (Month 7 toMonth 36)|Lost to Follow-up|0
6039549|NCT00365716|9637200|FG000|Long Term Follow-up (Month 7 toMonth 36)|Moved|3
6039550|NCT00365716|9637201|FG001|Long Term Follow-up (Month 7 toMonth 36)|Moved|2
6039551|NCT00365716|9637202|FG002|Long Term Follow-up (Month 7 toMonth 36)|Moved|1
6039552|NCT00365716|9637203|FG003|Long Term Follow-up (Month 7 toMonth 36)|Moved|2
6039553|NCT00365716|9637204|FG004|Long Term Follow-up (Month 7 toMonth 36)|Moved|0
6039554|NCT00365716|9637205|FG005|Long Term Follow-up (Month 7 toMonth 36)|Moved|0
6039555|NCT00365716|9637206|FG006|Long Term Follow-up (Month 7 toMonth 36)|Moved|0
6039556|NCT00365716|9637200|FG000|Long Term Follow-up (Month 7 toMonth 36)|Other|2
6039557|NCT00365716|9637201|FG001|Long Term Follow-up (Month 7 toMonth 36)|Other|0
6039558|NCT00365716|9637202|FG002|Long Term Follow-up (Month 7 toMonth 36)|Other|0
6039559|NCT00365716|9637203|FG003|Long Term Follow-up (Month 7 toMonth 36)|Other|0
6039560|NCT00365716|9637204|FG004|Long Term Follow-up (Month 7 toMonth 36)|Other|1
6039561|NCT00365716|9637205|FG005|Long Term Follow-up (Month 7 toMonth 36)|Other|0
6309828|NCT02641379|10038348|FG009|Overall Study|Protocol Violation|0
6309829|NCT02641379|10038349|FG010|Overall Study|Protocol Violation|0
6309830|NCT02641379|10038339|FG000|Overall Study|Participation in sili rescue study|0
6309831|NCT02641379|10038340|FG001|Overall Study|Participation in sili rescue study|0
6309832|NCT02641379|10038341|FG002|Overall Study|Participation in sili rescue study|0
6309833|NCT02641379|10038342|FG003|Overall Study|Participation in sili rescue study|0
6309834|NCT02641379|10038343|FG004|Overall Study|Participation in sili rescue study|0
6309835|NCT02641379|10038344|FG005|Overall Study|Participation in sili rescue study|1
6309836|NCT02641379|10038345|FG006|Overall Study|Participation in sili rescue study|0
6309837|NCT02641379|10038346|FG007|Overall Study|Participation in sili rescue study|0
6309838|NCT02641379|10038347|FG008|Overall Study|Participation in sili rescue study|0
6309839|NCT02641379|10038348|FG009|Overall Study|Participation in sili rescue study|0
6309840|NCT02641379|10038349|FG010|Overall Study|Participation in sili rescue study|0
6309841|NCT02641379|10038339|FG000|Overall Study|Lost to Follow-up|0
6309842|NCT02641379|10038340|FG001|Overall Study|Lost to Follow-up|0
6309843|NCT02641379|10038341|FG002|Overall Study|Lost to Follow-up|0
6309844|NCT02641379|10038342|FG003|Overall Study|Lost to Follow-up|0
6309845|NCT02641379|10038343|FG004|Overall Study|Lost to Follow-up|0
6309846|NCT02641379|10038344|FG005|Overall Study|Lost to Follow-up|0
6309847|NCT02641379|10038345|FG006|Overall Study|Lost to Follow-up|0
6309848|NCT02641379|10038346|FG007|Overall Study|Lost to Follow-up|0
6309849|NCT02641379|10038347|FG008|Overall Study|Lost to Follow-up|1
6309850|NCT02641379|10038348|FG009|Overall Study|Lost to Follow-up|0
6309851|NCT02641379|10038349|FG010|Overall Study|Lost to Follow-up|0
6309852|NCT02641379|10038339|FG000|Overall Study|Source data not found|0
6309853|NCT02641379|10038340|FG001|Overall Study|Source data not found|0
6309854|NCT02641379|10038341|FG002|Overall Study|Source data not found|0
6309855|NCT02641379|10038342|FG003|Overall Study|Source data not found|0
6309856|NCT02641379|10038343|FG004|Overall Study|Source data not found|0
6309857|NCT02641379|10038344|FG005|Overall Study|Source data not found|1
6309858|NCT02641379|10038345|FG006|Overall Study|Source data not found|0
6309859|NCT02641379|10038346|FG007|Overall Study|Source data not found|0
6309860|NCT02641379|10038347|FG008|Overall Study|Source data not found|0
6309861|NCT02641379|10038348|FG009|Overall Study|Source data not found|0
6309862|NCT02641379|10038349|FG010|Overall Study|Source data not found|0
6309863|NCT02641379|10038339|FG000|Overall Study|Participant showed weight reduction|0
6309864|NCT02641379|10038340|FG001|Overall Study|Participant showed weight reduction|0
6309865|NCT02641379|10038341|FG002|Overall Study|Participant showed weight reduction|0
6309866|NCT02641379|10038342|FG003|Overall Study|Participant showed weight reduction|0
6309867|NCT02641379|10038343|FG004|Overall Study|Participant showed weight reduction|0
6309868|NCT02641379|10038344|FG005|Overall Study|Participant showed weight reduction|0
6309869|NCT02641379|10038345|FG006|Overall Study|Participant showed weight reduction|0
6309870|NCT02641379|10038346|FG007|Overall Study|Participant showed weight reduction|1
6309871|NCT02641379|10038347|FG008|Overall Study|Participant showed weight reduction|0
6309872|NCT02641379|10038348|FG009|Overall Study|Participant showed weight reduction|0
6309873|NCT02641379|10038349|FG010|Overall Study|Participant showed weight reduction|0
6309874|NCT02641379|10038339|FG000|Overall Study|Non-response Week 12|0
6309875|NCT02641379|10038340|FG001|Overall Study|Non-response Week 12|0
6309876|NCT02641379|10038341|FG002|Overall Study|Non-response Week 12|0
6309877|NCT02641379|10038342|FG003|Overall Study|Non-response Week 12|0
6309878|NCT02641379|10038343|FG004|Overall Study|Non-response Week 12|0
6309879|NCT02641379|10038344|FG005|Overall Study|Non-response Week 12|0
6309880|NCT02641379|10038345|FG006|Overall Study|Non-response Week 12|0
6309881|NCT02641379|10038346|FG007|Overall Study|Non-response Week 12|1
6309882|NCT02641379|10038347|FG008|Overall Study|Non-response Week 12|0
6309883|NCT02641379|10038348|FG009|Overall Study|Non-response Week 12|0
6309884|NCT02641379|10038349|FG010|Overall Study|Non-response Week 12|0
6309885|NCT02641379|10038339|FG000|Overall Study|No 2 Log drop at Week 12|0
6309886|NCT02641379|10038340|FG001|Overall Study|No 2 Log drop at Week 12|0
6039562|NCT00365716|9637206|FG006|Long Term Follow-up (Month 7 toMonth 36)|Other|0
6039563|NCT00365716|9637200|FG000|Long Term Follow-up (Month 7 toMonth 36)|Protocol Violation|0
6039564|NCT00365716|9637201|FG001|Long Term Follow-up (Month 7 toMonth 36)|Protocol Violation|1
6039565|NCT00365716|9637202|FG002|Long Term Follow-up (Month 7 toMonth 36)|Protocol Violation|1
6039566|NCT00365716|9637203|FG003|Long Term Follow-up (Month 7 toMonth 36)|Protocol Violation|0
6039567|NCT00365716|9637204|FG004|Long Term Follow-up (Month 7 toMonth 36)|Protocol Violation|0
6039568|NCT00365716|9637205|FG005|Long Term Follow-up (Month 7 toMonth 36)|Protocol Violation|0
6039569|NCT00365716|9637206|FG006|Long Term Follow-up (Month 7 toMonth 36)|Protocol Violation|0
6039570|NCT00365716|9637200|FG000|Long Term Follow-up (Month 7 toMonth 36)|Withdrawal by Subject|7
6039571|NCT00365716|9637201|FG001|Long Term Follow-up (Month 7 toMonth 36)|Withdrawal by Subject|4
6039572|NCT00365716|9637202|FG002|Long Term Follow-up (Month 7 toMonth 36)|Withdrawal by Subject|13
6039573|NCT00365716|9637203|FG003|Long Term Follow-up (Month 7 toMonth 36)|Withdrawal by Subject|4
6039574|NCT00365716|9637204|FG004|Long Term Follow-up (Month 7 toMonth 36)|Withdrawal by Subject|3
6039575|NCT00365716|9637205|FG005|Long Term Follow-up (Month 7 toMonth 36)|Withdrawal by Subject|0
6039576|NCT00365716|9637206|FG006|Long Term Follow-up (Month 7 toMonth 36)|Withdrawal by Subject|0
6039577|NCT00365716|9637200|FG000|Extension 1|Lost to Follow-up|0
6039578|NCT00365716|9637201|FG001|Extension 1|Lost to Follow-up|0
6039579|NCT00365716|9637202|FG002|Extension 1|Lost to Follow-up|0
6039580|NCT00365716|9637203|FG003|Extension 1|Lost to Follow-up|0
6039581|NCT00365716|9637204|FG004|Extension 1|Lost to Follow-up|0
6039582|NCT00365716|9637205|FG005|Extension 1|Lost to Follow-up|1
6039583|NCT00365716|9637206|FG006|Extension 1|Lost to Follow-up|0
6039584|NCT00365716|9637200|FG000|Extension 1|Other|0
6039585|NCT00365716|9637201|FG001|Extension 1|Other|0
6039586|NCT00365716|9637202|FG002|Extension 1|Other|0
6039587|NCT00365716|9637203|FG003|Extension 1|Other|0
6039588|NCT00365716|9637204|FG004|Extension 1|Other|0
6039589|NCT00365716|9637205|FG005|Extension 1|Other|9
6039590|NCT00365716|9637206|FG006|Extension 1|Other|0
6039591|NCT00365716|9637200|FG000|Extension 1|Moved|0
6039592|NCT00365716|9637201|FG001|Extension 1|Moved|0
6039593|NCT00365716|9637202|FG002|Extension 1|Moved|0
6039594|NCT00365716|9637203|FG003|Extension 1|Moved|0
6039595|NCT00365716|9637204|FG004|Extension 1|Moved|0
6039596|NCT00365716|9637205|FG005|Extension 1|Moved|4
6148341|NCT01089127|9783667|FG005|Overall Study|Abnormal test procedure result(s)|0
6148342|NCT01089127|9783662|FG000|Overall Study|Lost to Follow-up|1
6148343|NCT01089127|9783663|FG001|Overall Study|Lost to Follow-up|1
6148344|NCT01089127|9783664|FG002|Overall Study|Lost to Follow-up|0
6148345|NCT01089127|9783665|FG003|Overall Study|Lost to Follow-up|0
6148346|NCT01089127|9783666|FG004|Overall Study|Lost to Follow-up|1
6148347|NCT01089127|9783667|FG005|Overall Study|Lost to Follow-up|0
6148348|NCT01089127|9783662|FG000|Overall Study|Protocol deviation|0
6309887|NCT02641379|10038341|FG002|Overall Study|No 2 Log drop at Week 12|0
6309888|NCT02641379|10038342|FG003|Overall Study|No 2 Log drop at Week 12|0
6309889|NCT02641379|10038343|FG004|Overall Study|No 2 Log drop at Week 12|0
6309890|NCT02641379|10038344|FG005|Overall Study|No 2 Log drop at Week 12|0
6309891|NCT02641379|10038345|FG006|Overall Study|No 2 Log drop at Week 12|0
6309892|NCT02641379|10038346|FG007|Overall Study|No 2 Log drop at Week 12|0
6309893|NCT02641379|10038347|FG008|Overall Study|No 2 Log drop at Week 12|0
6309894|NCT02641379|10038348|FG009|Overall Study|No 2 Log drop at Week 12|0
6309895|NCT02641379|10038349|FG010|Overall Study|No 2 Log drop at Week 12|1
6309896|NCT02641379|10038339|FG000|Overall Study|Negative PCR result|0
6309897|NCT02641379|10038340|FG001|Overall Study|Negative PCR result|0
6309898|NCT02641379|10038341|FG002|Overall Study|Negative PCR result|0
6309899|NCT02641379|10038342|FG003|Overall Study|Negative PCR result|0
6309900|NCT02641379|10038343|FG004|Overall Study|Negative PCR result|0
6309901|NCT02641379|10038344|FG005|Overall Study|Negative PCR result|0
6309902|NCT02641379|10038345|FG006|Overall Study|Negative PCR result|0
6309903|NCT02641379|10038346|FG007|Overall Study|Negative PCR result|0
6309904|NCT02641379|10038347|FG008|Overall Study|Negative PCR result|0
6309905|NCT02641379|10038348|FG009|Overall Study|Negative PCR result|1
6309906|NCT02641379|10038349|FG010|Overall Study|Negative PCR result|0
6309907|NCT02641379|10038339|FG000|Overall Study|Participant's PCR high|0
6309908|NCT02641379|10038340|FG001|Overall Study|Participant's PCR high|0
6039597|NCT00365716|9637206|FG006|Extension 1|Moved|0
6039598|NCT00365716|9637200|FG000|Extension 1|Withdrawal by Subject|0
6039599|NCT00365716|9637201|FG001|Extension 1|Withdrawal by Subject|0
6148349|NCT01089127|9783663|FG001|Overall Study|Protocol deviation|1
6148350|NCT01089127|9783664|FG002|Overall Study|Protocol deviation|0
6148351|NCT01089127|9783665|FG003|Overall Study|Protocol deviation|0
6148352|NCT01089127|9783666|FG004|Overall Study|Protocol deviation|1
6148353|NCT01089127|9783667|FG005|Overall Study|Protocol deviation|0
6148354|NCT01089361|9783700|FG000|Overall Study|Death|1
6039600|NCT00365716|9637202|FG002|Extension 1|Withdrawal by Subject|0
6039601|NCT00365716|9637203|FG003|Extension 1|Withdrawal by Subject|0
6148355|NCT01089361|9783701|FG001|Overall Study|Death|0
6148356|NCT01089413|9783712|FG000|Overall Study|Lost to Follow-up|1
6148357|NCT01089413|9783712|FG000|Overall Study|Progressive Disease|93
6309909|NCT02641379|10038341|FG002|Overall Study|Participant's PCR high|0
6309910|NCT02641379|10038342|FG003|Overall Study|Participant's PCR high|0
6309911|NCT02641379|10038343|FG004|Overall Study|Participant's PCR high|0
6039602|NCT00365716|9637204|FG004|Extension 1|Withdrawal by Subject|0
6039603|NCT00365716|9637205|FG005|Extension 1|Withdrawal by Subject|3
6039604|NCT00365716|9637206|FG006|Extension 1|Withdrawal by Subject|0
6039605|NCT00365716|9637200|FG000|Extension 1|Pregnancy|0
6039606|NCT00365716|9637201|FG001|Extension 1|Pregnancy|0
6039607|NCT00365716|9637202|FG002|Extension 1|Pregnancy|0
6039608|NCT00365716|9637203|FG003|Extension 1|Pregnancy|0
6039609|NCT00365716|9637204|FG004|Extension 1|Pregnancy|0
6039610|NCT00365716|9637205|FG005|Extension 1|Pregnancy|4
6039611|NCT00365716|9637206|FG006|Extension 1|Pregnancy|0
6039612|NCT00365716|9637200|FG000|Extension 1|Protocol Violation|0
6039613|NCT00365716|9637201|FG001|Extension 1|Protocol Violation|0
6039614|NCT00365716|9637202|FG002|Extension 1|Protocol Violation|0
6039615|NCT00365716|9637203|FG003|Extension 1|Protocol Violation|0
6039616|NCT00365716|9637204|FG004|Extension 1|Protocol Violation|0
6039617|NCT00365716|9637205|FG005|Extension 1|Protocol Violation|1
6039618|NCT00365716|9637206|FG006|Extension 1|Protocol Violation|0
6039619|NCT00365716|9637200|FG000|Extension 2|Lost to Follow-up|0
6039620|NCT00365716|9637201|FG001|Extension 2|Lost to Follow-up|0
6039621|NCT00365716|9637202|FG002|Extension 2|Lost to Follow-up|0
6039622|NCT00365716|9637203|FG003|Extension 2|Lost to Follow-up|0
6039623|NCT00365716|9637204|FG004|Extension 2|Lost to Follow-up|0
6039624|NCT00365716|9637205|FG005|Extension 2|Lost to Follow-up|0
6039625|NCT00365716|9637206|FG006|Extension 2|Lost to Follow-up|2
6039626|NCT00365716|9637200|FG000|Extension 2|Other|0
6039627|NCT00365716|9637201|FG001|Extension 2|Other|0
6039628|NCT00365716|9637202|FG002|Extension 2|Other|0
6039629|NCT00365716|9637203|FG003|Extension 2|Other|0
6039630|NCT00365716|9637204|FG004|Extension 2|Other|0
6039631|NCT00365716|9637205|FG005|Extension 2|Other|0
6039632|NCT00365716|9637206|FG006|Extension 2|Other|3
6039633|NCT00365716|9637200|FG000|Extension 2|Withdrawal by Subject|0
6039634|NCT00365716|9637201|FG001|Extension 2|Withdrawal by Subject|0
6039635|NCT00365716|9637202|FG002|Extension 2|Withdrawal by Subject|0
6039636|NCT00365716|9637203|FG003|Extension 2|Withdrawal by Subject|0
6039637|NCT00365716|9637204|FG004|Extension 2|Withdrawal by Subject|0
6039638|NCT00365716|9637205|FG005|Extension 2|Withdrawal by Subject|0
6039639|NCT00365716|9637206|FG006|Extension 2|Withdrawal by Subject|5
6039640|NCT00365794|9637229|FG000|Overall Study|Withdrawal by Subject|2
6039641|NCT00365846|9637234|FG000|Overall Study|Lost to Follow-up|1
6039642|NCT00365976|9637269|FG000|Overall Study|Withdrawal by Subject|1
6039643|NCT00365976|9637270|FG001|Overall Study|Withdrawal by Subject|5
6039644|NCT00365989|9637276|FG000|Overall Study|Withdrawal by Subject|1
6039645|NCT00365989|9637276|FG000|Overall Study|Non-compliance|1
6039646|NCT00366249|9637298|FG000|Overall Study|Adverse Event|53
6039647|NCT00366249|9637299|FG001|Overall Study|Adverse Event|28
6039648|NCT00366249|9637298|FG000|Overall Study|Death|0
6039649|NCT00366249|9637299|FG001|Overall Study|Death|1
6039650|NCT00366249|9637298|FG000|Overall Study|Physician Decision|5
6039651|NCT00366249|9637299|FG001|Overall Study|Physician Decision|2
6039652|NCT00366249|9637298|FG000|Overall Study|Lost to Follow-up|2
6039653|NCT00366249|9637299|FG001|Overall Study|Lost to Follow-up|0
6039654|NCT00366249|9637298|FG000|Overall Study|Protocol Violation|1
6039655|NCT00366249|9637299|FG001|Overall Study|Protocol Violation|2
6039656|NCT00366249|9637298|FG000|Overall Study|Withdrawal by Subject|18
6039657|NCT00366249|9637299|FG001|Overall Study|Withdrawal by Subject|4
6309912|NCT02641379|10038344|FG005|Overall Study|Participant's PCR high|0
6309913|NCT02641379|10038345|FG006|Overall Study|Participant's PCR high|0
6309914|NCT02641379|10038346|FG007|Overall Study|Participant's PCR high|1
6309915|NCT02641379|10038347|FG008|Overall Study|Participant's PCR high|0
6309916|NCT02641379|10038348|FG009|Overall Study|Participant's PCR high|0
6309917|NCT02641379|10038349|FG010|Overall Study|Participant's PCR high|0
6309918|NCT02641379|10038339|FG000|Overall Study|Participant treated after Week 24|0
6309919|NCT02641379|10038340|FG001|Overall Study|Participant treated after Week 24|0
6309920|NCT02641379|10038341|FG002|Overall Study|Participant treated after Week 24|0
6309921|NCT02641379|10038342|FG003|Overall Study|Participant treated after Week 24|0
6309922|NCT02641379|10038343|FG004|Overall Study|Participant treated after Week 24|0
6309923|NCT02641379|10038344|FG005|Overall Study|Participant treated after Week 24|0
6309924|NCT02641379|10038345|FG006|Overall Study|Participant treated after Week 24|0
6309925|NCT02641379|10038346|FG007|Overall Study|Participant treated after Week 24|0
6039658|NCT00366249|9637298|FG000|Overall Study|Lack of Efficacy|21
6039659|NCT00366249|9637299|FG001|Overall Study|Lack of Efficacy|21
6039660|NCT00366249|9637298|FG000|Overall Study|Most due to osteomylitis status|31
6039661|NCT00366249|9637299|FG001|Overall Study|Most due to osteomylitis status|20
6039662|NCT00366301|9637313|FG000|Overall Study|Lost to Follow-up|4
6039663|NCT00366301|9637314|FG001|Overall Study|Lost to Follow-up|4
6039664|NCT00366301|9637315|FG002|Overall Study|Lost to Follow-up|3
6039665|NCT00366301|9637316|FG003|Overall Study|Lost to Follow-up|7
6039666|NCT00366301|9637313|FG000|Overall Study|Withdrawal by Subject|4
6039667|NCT00366301|9637314|FG001|Overall Study|Withdrawal by Subject|2
6039668|NCT00366301|9637315|FG002|Overall Study|Withdrawal by Subject|1
6039669|NCT00366301|9637316|FG003|Overall Study|Withdrawal by Subject|1
6039670|NCT00366340|9637328|FG000|Infant Series|Protocol Violation|3
6039671|NCT00366340|9637329|FG001|Infant Series|Protocol Violation|4
6039672|NCT00366340|9637328|FG000|Infant Series|Withdrawal by Subject|3
6039673|NCT00366340|9637329|FG001|Infant Series|Withdrawal by Subject|3
6039674|NCT00366340|9637328|FG000|Infant Series|Adverse Event|0
6039675|NCT00366340|9637329|FG001|Infant Series|Adverse Event|2
6039676|NCT00366340|9637328|FG000|Infant Series|Lost to Follow-up|1
6039677|NCT00366340|9637329|FG001|Infant Series|Lost to Follow-up|1
6039678|NCT00366340|9637328|FG000|Infant Series|Failure to return|1
6039679|NCT00366340|9637329|FG001|Infant Series|Failure to return|0
6039680|NCT00366340|9637328|FG000|After the Infant Series|Parent/legal guardian request|1
6039681|NCT00366340|9637329|FG001|After the Infant Series|Parent/legal guardian request|1
6039682|NCT00366340|9637328|FG000|After the Infant Series|Failed to return|0
6039683|NCT00366340|9637329|FG001|After the Infant Series|Failed to return|1
6039684|NCT00366340|9637328|FG000|After the Infant Series|Protocol Violation|2
6039685|NCT00366340|9637329|FG001|After the Infant Series|Protocol Violation|2
6039686|NCT00366340|9637328|FG000|After the Infant Series|Adverse Event|0
6039687|NCT00366340|9637329|FG001|After the Infant Series|Adverse Event|1
6039688|NCT00366340|9637328|FG000|After the Infant Series|Lost to Follow-up|0
6039689|NCT00366340|9637329|FG001|After the Infant Series|Lost to Follow-up|1
6039690|NCT00366340|9637328|FG000|Toddler Dose|Failed to return|1
6039691|NCT00366340|9637329|FG001|Toddler Dose|Failed to return|0
6039692|NCT00366340|9637328|FG000|Toddler Dose|Parent/legal guardian request|0
6039693|NCT00366340|9637329|FG001|Toddler Dose|Parent/legal guardian request|1
6039694|NCT00366444|9637361|FG000|Overall Study|Withdrawal by Subject|1
6039695|NCT00366444|9637362|FG001|Overall Study|Withdrawal by Subject|1
6039696|NCT00366444|9637361|FG000|Overall Study|Lack of Efficacy|0
6039697|NCT00366444|9637362|FG001|Overall Study|Lack of Efficacy|1
6039698|NCT00366457|9637368|FG000|Overall Study|never began study therapy|2
6039699|NCT00366535|9637374|FG000|First Phase: 12 Weeks|Adverse Event|1
6039700|NCT00366535|9637375|FG001|First Phase: 12 Weeks|Adverse Event|3
6039701|NCT00366535|9637374|FG000|First Phase: 12 Weeks|Withdrawal by Subject|2
6039702|NCT00366535|9637375|FG001|First Phase: 12 Weeks|Withdrawal by Subject|5
6039703|NCT00366535|9637374|FG000|Second Phase: 12 Weeks|Adverse Event|1
6039704|NCT00366535|9637375|FG001|Second Phase: 12 Weeks|Adverse Event|1
6039705|NCT00366535|9637374|FG000|Second Phase: 12 Weeks|Withdrawal by Subject|2
6039706|NCT00366535|9637375|FG001|Second Phase: 12 Weeks|Withdrawal by Subject|2
6039707|NCT00366548|9637391|FG000|Infant Series|Adverse Event|1
6039708|NCT00366548|9637392|FG001|Infant Series|Adverse Event|3
6039709|NCT00366548|9637391|FG000|Infant Series|Protocol Violation|0
6039710|NCT00366548|9637392|FG001|Infant Series|Protocol Violation|1
6039711|NCT00366548|9637391|FG000|Infant Series|Withdrawal by Subject|3
6039712|NCT00366548|9637392|FG001|Infant Series|Withdrawal by Subject|1
6039713|NCT00366548|9637391|FG000|After Infant Series|Withdrawal by Subject|3
6039714|NCT00366548|9637392|FG001|After Infant Series|Withdrawal by Subject|1
6039715|NCT00366548|9637391|FG000|After Infant Series|Adverse Event|2
6039716|NCT00366548|9637392|FG001|After Infant Series|Adverse Event|0
6039717|NCT00366548|9637391|FG000|After Infant Series|Lost to Follow-up|1
6039718|NCT00366548|9637392|FG001|After Infant Series|Lost to Follow-up|0
6039719|NCT00366678|9637429|FG000|Infant Series|Withdrawal by Subject|8
6039720|NCT00366678|9637430|FG001|Infant Series|Withdrawal by Subject|6
6039721|NCT00366678|9637431|FG002|Infant Series|Withdrawal by Subject|0
6039722|NCT00366678|9637429|FG000|Infant Series|Protocol Violation|4
6039723|NCT00366678|9637430|FG001|Infant Series|Protocol Violation|3
6039724|NCT00366678|9637431|FG002|Infant Series|Protocol Violation|0
6039725|NCT00366678|9637429|FG000|Infant Series|Failed to return|1
6039726|NCT00366678|9637430|FG001|Infant Series|Failed to return|1
6039727|NCT00366678|9637431|FG002|Infant Series|Failed to return|0
6039728|NCT00366678|9637429|FG000|Infant Series|Adverse Event|1
6039729|NCT00366678|9637430|FG001|Infant Series|Adverse Event|0
6039730|NCT00366678|9637431|FG002|Infant Series|Adverse Event|0
6039731|NCT00366678|9637429|FG000|After Infant|Withdrawal by Subject|8
6039732|NCT00366678|9637430|FG001|After Infant|Withdrawal by Subject|4
6039733|NCT00366678|9637431|FG002|After Infant|Withdrawal by Subject|0
6039734|NCT00366678|9637429|FG000|After Infant|Lost to Follow-up|2
6039735|NCT00366678|9637430|FG001|After Infant|Lost to Follow-up|1
6039736|NCT00366678|9637431|FG002|After Infant|Lost to Follow-up|0
6039737|NCT00366678|9637429|FG000|After Infant|Failed to return|5
6039738|NCT00366678|9637430|FG001|After Infant|Failed to return|5
6039739|NCT00366678|9637431|FG002|After Infant|Failed to return|0
6039740|NCT00366678|9637429|FG000|After Infant|Adverse Event|1
6039741|NCT00366678|9637430|FG001|After Infant|Adverse Event|0
6039742|NCT00366678|9637431|FG002|After Infant|Adverse Event|0
6039743|NCT00366678|9637429|FG000|After Infant|Protocol Violation|1
6039744|NCT00366678|9637430|FG001|After Infant|Protocol Violation|0
6039745|NCT00366678|9637431|FG002|After Infant|Protocol Violation|0
6039746|NCT00366678|9637429|FG000|Toddler Dose|Protocol Violation|2
6039747|NCT00366678|9637430|FG001|Toddler Dose|Protocol Violation|1
6039748|NCT00366678|9637431|FG002|Toddler Dose|Protocol Violation|0
6039749|NCT00366678|9637429|FG000|Toddler Dose|Failed to return|1
6039750|NCT00366678|9637430|FG001|Toddler Dose|Failed to return|0
6039751|NCT00366678|9637431|FG002|Toddler Dose|Failed to return|0
6039752|NCT00366678|9637429|FG000|Toddler Dose|Withdrawal by Subject|1
6039753|NCT00366678|9637430|FG001|Toddler Dose|Withdrawal by Subject|0
6039754|NCT00366678|9637431|FG002|Toddler Dose|Withdrawal by Subject|0
6039755|NCT00366678|9637429|FG000|Toddler Dose|protocol deviation|1
6039756|NCT00366678|9637430|FG001|Toddler Dose|protocol deviation|0
6039757|NCT00366678|9637431|FG002|Toddler Dose|protocol deviation|0
6039758|NCT00366899|9637478|FG000|Infant Series|Withdrawal by Subject|4
6039759|NCT00366899|9637479|FG001|Infant Series|Withdrawal by Subject|7
6039760|NCT00366899|9637478|FG000|Infant Series|Protocol Violation|2
6039761|NCT00366899|9637479|FG001|Infant Series|Protocol Violation|1
6039762|NCT00366899|9637478|FG000|Infant Series|Failed to return|1
6039763|NCT00366899|9637479|FG001|Infant Series|Failed to return|1
6039764|NCT00366899|9637478|FG000|Infant Series|Lost to Follow-up|0
6039765|NCT00366899|9637479|FG001|Infant Series|Lost to Follow-up|2
6039766|NCT00366899|9637478|FG000|Infant Series|Adverse Event|0
6039767|NCT00366899|9637479|FG001|Infant Series|Adverse Event|1
6039768|NCT00366899|9637478|FG000|Infant Series|Physician Decision|1
6039769|NCT00366899|9637479|FG001|Infant Series|Physician Decision|0
6039770|NCT00366899|9637478|FG000|Infant Series|Randomized but not consented|1
6039771|NCT00366899|9637479|FG001|Infant Series|Randomized but not consented|0
6039772|NCT00366899|9637478|FG000|After Infant Series|Lost to Follow-up|4
6039773|NCT00366899|9637479|FG001|After Infant Series|Lost to Follow-up|3
6039774|NCT00366899|9637478|FG000|After Infant Series|Withdrawal by Subject|1
6039775|NCT00366899|9637479|FG001|After Infant Series|Withdrawal by Subject|4
6039776|NCT00366899|9637478|FG000|After Infant Series|Adverse Event|1
6039777|NCT00366899|9637479|FG001|After Infant Series|Adverse Event|2
6039778|NCT00366899|9637478|FG000|After Infant Series|Protocol Violation|1
6039779|NCT00366899|9637479|FG001|After Infant Series|Protocol Violation|0
6039780|NCT00366899|9637478|FG000|Toddler Dose|Withdrawal by Subject|1
6039781|NCT00366899|9637479|FG001|Toddler Dose|Withdrawal by Subject|1
6039782|NCT00366899|9637478|FG000|Toddler Dose|Protocol Violation|1
6039783|NCT00366899|9637479|FG001|Toddler Dose|Protocol Violation|0
6039784|NCT00367055|9637528|FG000|Overall Study|Adverse Event|6
6039785|NCT00367055|9637529|FG001|Overall Study|Adverse Event|3
6039786|NCT00367055|9637528|FG000|Overall Study|Patient's Willing|3
6039787|NCT00367055|9637529|FG001|Overall Study|Patient's Willing|2
6039788|NCT00367055|9637528|FG000|Overall Study|Lack of Efficacy|1
6039789|NCT00367055|9637529|FG001|Overall Study|Lack of Efficacy|2
6039790|NCT00367055|9637528|FG000|Overall Study|Lost to Follow-up|1
6039791|NCT00367055|9637529|FG001|Overall Study|Lost to Follow-up|1
6309926|NCT02641379|10038347|FG008|Overall Study|Participant treated after Week 24|1
6309927|NCT02641379|10038348|FG009|Overall Study|Participant treated after Week 24|0
6309928|NCT02641379|10038349|FG010|Overall Study|Participant treated after Week 24|0
6309929|NCT02641379|10038339|FG000|Overall Study|Missing PCR result at Week 8|0
6309930|NCT02641379|10038340|FG001|Overall Study|Missing PCR result at Week 8|0
6309931|NCT02641379|10038341|FG002|Overall Study|Missing PCR result at Week 8|0
6309932|NCT02641379|10038342|FG003|Overall Study|Missing PCR result at Week 8|0
6309933|NCT02641379|10038343|FG004|Overall Study|Missing PCR result at Week 8|0
6309934|NCT02641379|10038344|FG005|Overall Study|Missing PCR result at Week 8|0
6309935|NCT02641379|10038345|FG006|Overall Study|Missing PCR result at Week 8|0
6309936|NCT02641379|10038346|FG007|Overall Study|Missing PCR result at Week 8|0
6309937|NCT02641379|10038347|FG008|Overall Study|Missing PCR result at Week 8|0
6309938|NCT02641379|10038348|FG009|Overall Study|Missing PCR result at Week 8|1
6309939|NCT02641379|10038349|FG010|Overall Study|Missing PCR result at Week 8|0
6309940|NCT02641379|10038339|FG000|Overall Study|PCR positive|0
6309941|NCT02641379|10038340|FG001|Overall Study|PCR positive|0
6309942|NCT02641379|10038341|FG002|Overall Study|PCR positive|0
6309943|NCT02641379|10038342|FG003|Overall Study|PCR positive|0
6309944|NCT02641379|10038343|FG004|Overall Study|PCR positive|0
6309945|NCT02641379|10038344|FG005|Overall Study|PCR positive|0
6309946|NCT02641379|10038345|FG006|Overall Study|PCR positive|1
6309947|NCT02641379|10038346|FG007|Overall Study|PCR positive|0
6309948|NCT02641379|10038347|FG008|Overall Study|PCR positive|0
6309949|NCT02641379|10038348|FG009|Overall Study|PCR positive|0
6309950|NCT02641379|10038349|FG010|Overall Study|PCR positive|0
6309951|NCT02641392|10038381|FG000|Overall Study|Lost to Follow-up|0
6309952|NCT02641392|10038382|FG001|Overall Study|Lost to Follow-up|0
6309953|NCT02641392|10038383|FG002|Overall Study|Lost to Follow-up|2
6309954|NCT02641392|10038381|FG000|Overall Study|Withdrawal by Subject|0
6309955|NCT02641392|10038382|FG001|Overall Study|Withdrawal by Subject|0
6309956|NCT02641392|10038383|FG002|Overall Study|Withdrawal by Subject|17
6309957|NCT02641392|10038381|FG000|Overall Study|Adverse Event|0
6309958|NCT02641392|10038382|FG001|Overall Study|Adverse Event|1
6309959|NCT02641392|10038383|FG002|Overall Study|Adverse Event|25
6309960|NCT02641392|10038381|FG000|Overall Study|Study Terminated by Sponsor|4
6309961|NCT02641392|10038382|FG001|Overall Study|Study Terminated by Sponsor|12
6309962|NCT02641392|10038383|FG002|Overall Study|Study Terminated by Sponsor|144
6309963|NCT02641392|10038381|FG000|Overall Study|Lack of Efficacy|0
6309964|NCT02641392|10038382|FG001|Overall Study|Lack of Efficacy|0
6309965|NCT02641392|10038383|FG002|Overall Study|Lack of Efficacy|101
6309966|NCT02641392|10038381|FG000|Overall Study|Miscellaneous|0
6309967|NCT02641392|10038382|FG001|Overall Study|Miscellaneous|0
6039792|NCT00367055|9637528|FG000|Overall Study|Protocol Violation|0
6039793|NCT00367055|9637529|FG001|Overall Study|Protocol Violation|1
6039794|NCT00367055|9637528|FG000|Overall Study|Stopping Criterion Met|0
6039795|NCT00367055|9637529|FG001|Overall Study|Stopping Criterion Met|1
6039796|NCT00367055|9637528|FG000|Overall Study|Participant Living too Far from Hospital|0
6039797|NCT00367055|9637529|FG001|Overall Study|Participant Living too Far from Hospital|1
6039798|NCT00367133|9637538|FG000|2 Years|Death|20
6039799|NCT00367133|9637539|FG001|2 Years|Death|12
6039800|NCT00367133|9637540|FG002|2 Years|Death|12
6039801|NCT00367133|9637538|FG000|2 Years|Dropped|34
6039802|NCT00367133|9637539|FG001|2 Years|Dropped|19
6039803|NCT00367133|9637540|FG002|2 Years|Dropped|33
6039804|NCT00367133|9637538|FG000|2 Years|Missed visit|4
6039805|NCT00367133|9637539|FG001|2 Years|Missed visit|5
6039806|NCT00367133|9637540|FG002|2 Years|Missed visit|4
6039807|NCT00367237|9637550|FG000|Overall Study|Adverse Event|7
6039808|NCT00367237|9637551|FG001|Overall Study|Adverse Event|2
6039809|NCT00367237|9637550|FG000|Overall Study|Lost to Follow-up|1
6148358|NCT01089413|9783712|FG000|Overall Study|Participant Withdrew Consent|1
6148359|NCT01089413|9783712|FG000|Overall Study|Unacceptable Toxicity|12
6309968|NCT02641392|10038383|FG002|Overall Study|Miscellaneous|3
6309969|NCT02641392|10038381|FG000|Overall Study|Death|0
6309970|NCT02641392|10038382|FG001|Overall Study|Death|0
6309971|NCT02641392|10038383|FG002|Overall Study|Death|1
6309972|NCT02641587|10038415|FG000|Confinement Period|Adverse Event|1
6309973|NCT02641587|10038416|FG001|Confinement Period|Adverse Event|0
6309974|NCT02641587|10038415|FG000|Confinement Period|Withdrawal by Subject|2
6309975|NCT02641587|10038416|FG001|Confinement Period|Withdrawal by Subject|1
6309976|NCT02641587|10038415|FG000|Ambulatory Period|Withdrawal by Subject|1
6309977|NCT02641587|10038416|FG001|Ambulatory Period|Withdrawal by Subject|0
6309978|NCT02641730|10038442|FG000|Placebo Controlled Period (Week 0 - 16)|Adverse Event|2
6309979|NCT02641730|10038443|FG001|Placebo Controlled Period (Week 0 - 16)|Adverse Event|0
6309980|NCT02641730|10038444|FG002|Placebo Controlled Period (Week 0 - 16)|Adverse Event|0
6309981|NCT02641730|10038445|FG003|Placebo Controlled Period (Week 0 - 16)|Adverse Event|1
6309982|NCT02641730|10038446|FG004|Placebo Controlled Period (Week 0 - 16)|Adverse Event|2
6309983|NCT02641730|10038442|FG000|After Controlled Period (Week 16 - 52)|Adverse Event|0
6309984|NCT02641730|10038443|FG001|After Controlled Period (Week 16 - 52)|Adverse Event|1
6309985|NCT02641730|10038444|FG002|After Controlled Period (Week 16 - 52)|Adverse Event|1
6309986|NCT02641730|10038445|FG003|After Controlled Period (Week 16 - 52)|Adverse Event|5
6309987|NCT02641730|10038446|FG004|After Controlled Period (Week 16 - 52)|Adverse Event|4
6309988|NCT02641730|10038442|FG000|After Controlled Period (Week 16 - 52)|Lack of Efficacy|0
6309989|NCT02641730|10038443|FG001|After Controlled Period (Week 16 - 52)|Lack of Efficacy|2
6309990|NCT02641730|10038444|FG002|After Controlled Period (Week 16 - 52)|Lack of Efficacy|0
6309991|NCT02641730|10038445|FG003|After Controlled Period (Week 16 - 52)|Lack of Efficacy|2
6309992|NCT02641730|10038446|FG004|After Controlled Period (Week 16 - 52)|Lack of Efficacy|0
6039810|NCT00367237|9637551|FG001|Overall Study|Lost to Follow-up|0
6039811|NCT00367237|9637550|FG000|Overall Study|Withdrawal by Subject|0
6039812|NCT00367237|9637551|FG001|Overall Study|Withdrawal by Subject|4
6039813|NCT00367237|9637550|FG000|Overall Study|Protocol Violation|2
6039814|NCT00367237|9637551|FG001|Overall Study|Protocol Violation|5
6148360|NCT01089413|9783712|FG000|Overall Study|Death|10
6039815|NCT00367341|9637559|FG000|Overall Study|Physician Decision|1
6309993|NCT02641730|10038442|FG000|After Controlled Period (Week 16 - 52)|Pregnancy|0
6309994|NCT02641730|10038443|FG001|After Controlled Period (Week 16 - 52)|Pregnancy|0
6309995|NCT02641730|10038444|FG002|After Controlled Period (Week 16 - 52)|Pregnancy|0
6309996|NCT02641730|10038445|FG003|After Controlled Period (Week 16 - 52)|Pregnancy|1
6309997|NCT02641730|10038446|FG004|After Controlled Period (Week 16 - 52)|Pregnancy|1
6309998|NCT02641730|10038442|FG000|After Controlled Period (Week 16 - 52)|Other|0
6309999|NCT02641730|10038443|FG001|After Controlled Period (Week 16 - 52)|Other|1
6310000|NCT02641730|10038444|FG002|After Controlled Period (Week 16 - 52)|Other|1
6310001|NCT02641730|10038445|FG003|After Controlled Period (Week 16 - 52)|Other|0
6310002|NCT02641730|10038446|FG004|After Controlled Period (Week 16 - 52)|Other|1
6310003|NCT02641730|10038442|FG000|Observational Period (Week 60 - Week 84)|Other|0
6310004|NCT02641730|10038443|FG001|Observational Period (Week 60 - Week 84)|Other|0
6310005|NCT02641730|10038444|FG002|Observational Period (Week 60 - Week 84)|Other|0
6310006|NCT02641730|10038445|FG003|Observational Period (Week 60 - Week 84)|Other|0
6310007|NCT02641730|10038446|FG004|Observational Period (Week 60 - Week 84)|Other|1
6310008|NCT02642159|10038485|FG000|Overall Study|Randomized but not treated|1
6310009|NCT02642159|10038486|FG001|Overall Study|Randomized but not treated|0
6310010|NCT02642159|10038485|FG000|Overall Study|Adverse Event|10
6310011|NCT02642159|10038486|FG001|Overall Study|Adverse Event|4
6310012|NCT02642159|10038485|FG000|Overall Study|Withdrawal by Subject|9
6310013|NCT02642159|10038486|FG001|Overall Study|Withdrawal by Subject|1
6310014|NCT02642159|10038485|FG000|Overall Study|Poor compliance to study protocol|1
6310015|NCT02642159|10038486|FG001|Overall Study|Poor compliance to study protocol|0
6310016|NCT02642159|10038485|FG000|Overall Study|Other than specified above|10
6310017|NCT02642159|10038486|FG001|Overall Study|Other than specified above|3
6310018|NCT02642432|10038511|FG000|Overall Study|Adverse Event|2
6310019|NCT02642432|10038511|FG000|Overall Study|Withdrew Consent|1
6310020|NCT02642432|10038511|FG000|Overall Study|Lost to Follow-up|2
6310021|NCT02642432|10038511|FG000|Overall Study|Other|3
6310022|NCT02642614|10038532|FG000|Overall Study|Adverse Event|1
6310023|NCT02642614|10038533|FG001|Overall Study|Adverse Event|1
6310024|NCT02642614|10038534|FG002|Overall Study|Adverse Event|2
6310025|NCT02642614|10038535|FG003|Overall Study|Adverse Event|2
6310026|NCT02642614|10038532|FG000|Overall Study|Lost to Follow-up|1
6310027|NCT02642614|10038533|FG001|Overall Study|Lost to Follow-up|0
6310028|NCT02642614|10038534|FG002|Overall Study|Lost to Follow-up|0
6310029|NCT02642614|10038535|FG003|Overall Study|Lost to Follow-up|0
6310030|NCT02642614|10038532|FG000|Overall Study|Withdrawal by Subject|1
6310031|NCT02642614|10038533|FG001|Overall Study|Withdrawal by Subject|1
6310032|NCT02642614|10038534|FG002|Overall Study|Withdrawal by Subject|0
6310033|NCT02642614|10038535|FG003|Overall Study|Withdrawal by Subject|0
6310034|NCT02642653|10038555|FG000|Overall Study|Adverse Event|2
6310035|NCT02642653|10038556|FG001|Overall Study|Adverse Event|0
6310036|NCT02642679|10038562|FG000|Overall Study|Withdrawal by Subject|1
6310037|NCT02642679|10038562|FG000|Overall Study|Physician Decision|1
6310038|NCT02642679|10038562|FG000|Overall Study|Physician Decision|1
6310039|NCT02643082|10038596|FG000|Period 1|Adverse Event|1
6310040|NCT02643082|10038597|FG001|Period 1|Adverse Event|0
6310041|NCT02643251|10038624|FG000|Overall Study|Adverse Event|3
6310042|NCT02643251|10038625|FG001|Overall Study|Adverse Event|1
6310043|NCT02643251|10038624|FG000|Overall Study|Withdrawal by Subject|2
6310044|NCT02643251|10038625|FG001|Overall Study|Withdrawal by Subject|0
6310045|NCT02643251|10038624|FG000|Overall Study|Lost to Follow-up|4
6310046|NCT02643251|10038625|FG001|Overall Study|Lost to Follow-up|1
6310047|NCT02643251|10038624|FG000|Overall Study|Protocol Violation|1
6310048|NCT02643251|10038625|FG001|Overall Study|Protocol Violation|0
6310049|NCT02643251|10038624|FG000|Overall Study|PI Decision to terminate patient|1
6310050|NCT02643251|10038625|FG001|Overall Study|PI Decision to terminate patient|0
6310051|NCT02643355|10038633|FG000|Overall Study|Withdrawal by Subject|1
6310052|NCT02643355|10038634|FG001|Overall Study|Withdrawal by Subject|3
6310053|NCT02643355|10038633|FG000|Overall Study|Protocol Violation|0
6310054|NCT02643355|10038634|FG001|Overall Study|Protocol Violation|2
6310055|NCT02643394|10038642|FG000|Overall Study|Protocol Violation|4
6310056|NCT02643394|10038643|FG001|Overall Study|Protocol Violation|5
6310057|NCT02643472|10038661|FG000|Overall Study|Death|2
6310058|NCT02643472|10038662|FG001|Overall Study|Death|5
6310059|NCT02643472|10038661|FG000|Overall Study|Withdrawal by Subject|3
6310060|NCT02643472|10038662|FG001|Overall Study|Withdrawal by Subject|2
6310061|NCT02643472|10038661|FG000|Overall Study|Protocol Violation|0
6310062|NCT02643472|10038662|FG001|Overall Study|Protocol Violation|1
6310063|NCT02643472|10038661|FG000|Overall Study|Lost to Follow-up|22
6310064|NCT02643472|10038662|FG001|Overall Study|Lost to Follow-up|26
6310065|NCT02643628|10038682|FG000|Overall Study|Lost to Follow-up|1
6310066|NCT02643628|10038683|FG001|Overall Study|Lost to Follow-up|4
6039816|NCT00367341|9637560|FG001|Overall Study|Physician Decision|0
6039817|NCT00367341|9637559|FG000|Overall Study|Protocol Violation|1
6310067|NCT02643628|10038682|FG000|Overall Study|Withdrawal by Subject|0
6310068|NCT02643628|10038683|FG001|Overall Study|Withdrawal by Subject|1
6310069|NCT02643628|10038682|FG000|Overall Study|Relocated out of state|0
6039818|NCT00367341|9637560|FG001|Overall Study|Protocol Violation|0
6039819|NCT00367432|9637579|FG000|First Period (16 Weeks)|Adverse Event|6
6039820|NCT00367432|9637580|FG001|First Period (16 Weeks)|Adverse Event|0
6039821|NCT00367432|9637579|FG000|First Period (16 Weeks)|Lack of Efficacy|24
6039822|NCT00367432|9637580|FG001|First Period (16 Weeks)|Lack of Efficacy|0
6039823|NCT00367432|9637579|FG000|First Period (16 Weeks)|Withdrawal by Subject|6
6039824|NCT00367432|9637580|FG001|First Period (16 Weeks)|Withdrawal by Subject|0
6039825|NCT00367432|9637579|FG000|First Period (16 Weeks)|Other Reason|2
6039826|NCT00367432|9637580|FG001|First Period (16 Weeks)|Other Reason|0
6039827|NCT00367432|9637579|FG000|Second Period (up to 54 Months)|Adverse Event|14
6039828|NCT00367432|9637580|FG001|Second Period (up to 54 Months)|Adverse Event|3
6039829|NCT00367432|9637579|FG000|Second Period (up to 54 Months)|Lack of Efficacy|59
6039830|NCT00367432|9637580|FG001|Second Period (up to 54 Months)|Lack of Efficacy|5
6039831|NCT00367432|9637579|FG000|Second Period (up to 54 Months)|Lost to Follow-up|0
6039832|NCT00367432|9637580|FG001|Second Period (up to 54 Months)|Lost to Follow-up|1
6039833|NCT00367432|9637579|FG000|Second Period (up to 54 Months)|Withdrawal by Subject|8
6039834|NCT00367432|9637580|FG001|Second Period (up to 54 Months)|Withdrawal by Subject|5
6039835|NCT00367432|9637579|FG000|Second Period (up to 54 Months)|Other Reason|6
6039836|NCT00367432|9637580|FG001|Second Period (up to 54 Months)|Other Reason|2
6039837|NCT00367458|9637586|FG000|First Intervention - 8 Weeks|Adverse Event|2
6039838|NCT00367458|9637587|FG001|First Intervention - 8 Weeks|Adverse Event|0
6039839|NCT00367484|9637593|FG000|Overall Study|Adverse Event|7
6039840|NCT00367484|9637593|FG000|Overall Study|Withdrew informed consent|5
6039841|NCT00367484|9637593|FG000|Overall Study|Travel to USA|1
6039842|NCT00367484|9637593|FG000|Overall Study|Lost to Follow-up|1
6039843|NCT00367484|9637593|FG000|Overall Study|Protocol Violation|1
6039844|NCT00367484|9637593|FG000|Overall Study|The choice of the patient|1
6039845|NCT00367484|9637593|FG000|Overall Study|Lack of Efficacy|1
6039846|NCT00367640|9637606|FG000|Overall Study|Adverse Event|3
6039847|NCT00367640|9637607|FG001|Overall Study|Adverse Event|6
6039848|NCT00367640|9637608|FG002|Overall Study|Adverse Event|8
6039849|NCT00367640|9637609|FG003|Overall Study|Adverse Event|0
6039850|NCT00367640|9637606|FG000|Overall Study|Withdrawal by Subject|8
6039851|NCT00367640|9637607|FG001|Overall Study|Withdrawal by Subject|11
6039852|NCT00367640|9637608|FG002|Overall Study|Withdrawal by Subject|8
6148361|NCT01089413|9783712|FG000|Overall Study|Metastasectomy|13
6148362|NCT01089413|9783712|FG000|Overall Study|Other|71
6148363|NCT01089504|9783724|FG000|Overall Study|Lost to Follow-up|1
6310070|NCT02643628|10038683|FG001|Overall Study|Relocated out of state|1
6310071|NCT02643693|10038691|FG000|Overall Study|Physician Decision|0
6310072|NCT02643693|10038692|FG001|Overall Study|Physician Decision|1
6310073|NCT02643693|10038693|FG002|Overall Study|Physician Decision|0
6310074|NCT02643693|10038694|FG003|Overall Study|Physician Decision|0
6310075|NCT02643693|10038695|FG004|Overall Study|Physician Decision|0
6310076|NCT02643693|10038696|FG005|Overall Study|Physician Decision|0
6310077|NCT02643693|10038691|FG000|Overall Study|Withdrawal by Subject|0
6310078|NCT02643693|10038692|FG001|Overall Study|Withdrawal by Subject|1
6310079|NCT02643693|10038693|FG002|Overall Study|Withdrawal by Subject|0
6310080|NCT02643693|10038694|FG003|Overall Study|Withdrawal by Subject|0
6310081|NCT02643693|10038695|FG004|Overall Study|Withdrawal by Subject|0
6310082|NCT02643693|10038696|FG005|Overall Study|Withdrawal by Subject|0
6310083|NCT02643693|10038691|FG000|Overall Study|Protocol Adherence Issues|2
6148364|NCT01089504|9783725|FG001|Overall Study|Lost to Follow-up|1
6148365|NCT01089504|9783724|FG000|Overall Study|Withdrawal by Subject|2
6148366|NCT01089504|9783725|FG001|Overall Study|Withdrawal by Subject|0
6148367|NCT01089543|9783748|FG000|Overall Study|Withdrawal by Subject|2
6148368|NCT01089543|9783749|FG001|Overall Study|Withdrawal by Subject|3
6148369|NCT01089543|9783750|FG002|Overall Study|Withdrawal by Subject|3
6148370|NCT01089543|9783751|FG003|Overall Study|Withdrawal by Subject|1
6148371|NCT01089543|9783748|FG000|Overall Study|Physician Decision|1
6148372|NCT01089543|9783749|FG001|Overall Study|Physician Decision|0
6148373|NCT01089543|9783750|FG002|Overall Study|Physician Decision|0
6148374|NCT01089543|9783751|FG003|Overall Study|Physician Decision|1
6148375|NCT01089543|9783748|FG000|Overall Study|Adverse Event|0
6148376|NCT01089543|9783749|FG001|Overall Study|Adverse Event|1
6310084|NCT02643693|10038692|FG001|Overall Study|Protocol Adherence Issues|0
6310085|NCT02643693|10038693|FG002|Overall Study|Protocol Adherence Issues|1
6310086|NCT02643693|10038694|FG003|Overall Study|Protocol Adherence Issues|0
6310087|NCT02643693|10038695|FG004|Overall Study|Protocol Adherence Issues|0
6310088|NCT02643693|10038696|FG005|Overall Study|Protocol Adherence Issues|1
6310089|NCT02644096|10038733|FG000|Overall Study|Withdrawal by Subject|28
6039853|NCT00367640|9637609|FG003|Overall Study|Withdrawal by Subject|6
6039854|NCT00367640|9637606|FG000|Overall Study|Any other reason not above-mentioned|7
6039855|NCT00367640|9637607|FG001|Overall Study|Any other reason not above-mentioned|5
6039856|NCT00367640|9637608|FG002|Overall Study|Any other reason not above-mentioned|3
6148377|NCT01089543|9783750|FG002|Overall Study|Adverse Event|0
6148378|NCT01089543|9783751|FG003|Overall Study|Adverse Event|0
6148379|NCT01089556|9783763|FG000|Study Period II (Weeks 1-8)|Adverse Event|35
6148380|NCT01089556|9783764|FG001|Study Period II (Weeks 1-8)|Adverse Event|39
6148381|NCT01089556|9783765|FG002|Study Period II (Weeks 1-8)|Adverse Event|0
6148382|NCT01089556|9783766|FG003|Study Period II (Weeks 1-8)|Adverse Event|0
6148383|NCT01089556|9783767|FG004|Study Period II (Weeks 1-8)|Adverse Event|0
6039857|NCT00367640|9637609|FG003|Overall Study|Any other reason not above-mentioned|4
6039858|NCT00367744|9637627|FG000|Overall Study|Lost to Follow-up|4
6039859|NCT00367744|9637628|FG001|Overall Study|Lost to Follow-up|5
6039860|NCT00367770|9637635|FG000|Overall Study|Adverse Event|1
6039861|NCT00367770|9637635|FG000|Overall Study|Withdrawal by Subject|1
6039862|NCT00367835|9637641|FG000|Overall Study|Adverse Event|14
6039863|NCT00367835|9637642|FG001|Overall Study|Adverse Event|1
6039864|NCT00367835|9637641|FG000|Overall Study|Protocol Violation|1
6039865|NCT00367835|9637642|FG001|Overall Study|Protocol Violation|7
6039866|NCT00367835|9637641|FG000|Overall Study|Withdrawal by Subject|7
6039867|NCT00367835|9637642|FG001|Overall Study|Withdrawal by Subject|6
6039868|NCT00367835|9637641|FG000|Overall Study|Lost to Follow-up|1
6310090|NCT02644096|10038734|FG001|Overall Study|Withdrawal by Subject|25
6310091|NCT02644109|10038742|FG000|Overall Study|Adverse Event|0
6310092|NCT02644109|10038743|FG001|Overall Study|Adverse Event|4
6310093|NCT02644122|10038749|FG000|Overall Study|Withdrawal by Subject|1
6310094|NCT02644343|10038771|FG000|Overall Study|Withdrawal by Subject|1
6310095|NCT02644356|10038775|FG000|Overall Study|Withdrawal by Subject|2
6310096|NCT02644668|10038782|FG000|Overall Study|Adverse Event|2
6310097|NCT02644668|10038783|FG001|Overall Study|Adverse Event|0
6310098|NCT02644668|10038784|FG002|Overall Study|Adverse Event|1
6310099|NCT02644668|10038782|FG000|Overall Study|Protocol Violation|0
6310100|NCT02644668|10038783|FG001|Overall Study|Protocol Violation|0
6310101|NCT02644668|10038784|FG002|Overall Study|Protocol Violation|1
6310102|NCT02644668|10038782|FG000|Overall Study|Withdrawal by Subject|0
6310103|NCT02644668|10038783|FG001|Overall Study|Withdrawal by Subject|0
6310104|NCT02644668|10038784|FG002|Overall Study|Withdrawal by Subject|1
6039869|NCT00367835|9637642|FG001|Overall Study|Lost to Follow-up|4
6039870|NCT00367835|9637641|FG000|Overall Study|Lack of Efficacy|3
6039871|NCT00367835|9637642|FG001|Overall Study|Lack of Efficacy|12
6039872|NCT00367835|9637641|FG000|Overall Study|Subject in juvenile detention center|1
6039873|NCT00367835|9637642|FG001|Overall Study|Subject in juvenile detention center|0
6039874|NCT00367835|9637641|FG000|Overall Study|refused blood collection|1
6039875|NCT00367835|9637642|FG001|Overall Study|refused blood collection|0
6039876|NCT00367835|9637641|FG000|Overall Study|Did not respond to calls|1
6039877|NCT00367835|9637642|FG001|Overall Study|Did not respond to calls|0
6039878|NCT00367835|9637641|FG000|Overall Study|History of lead poisoning|0
6039879|NCT00367835|9637642|FG001|Overall Study|History of lead poisoning|1
6310105|NCT02645409|10038852|FG000|Overall Study|Withdrawal by Subject|3
6310106|NCT02645409|10038853|FG001|Overall Study|Withdrawal by Subject|0
6310107|NCT02645409|10038852|FG000|Overall Study|Physician Decision|1
6310108|NCT02645409|10038853|FG001|Overall Study|Physician Decision|0
6310109|NCT02646124|10038874|FG000|Overall Study|Lost to Follow-up|0
6310110|NCT02646124|10038875|FG001|Overall Study|Lost to Follow-up|2
6310111|NCT02646332|10038883|FG000|Overall Study|Lost to Follow-up|0
6310112|NCT02646332|10038884|FG001|Overall Study|Lost to Follow-up|3
6310113|NCT02646423|10038901|FG000|Overall Study|Adverse Event|5
6310114|NCT02646423|10038902|FG001|Overall Study|Adverse Event|7
6310115|NCT02646423|10038901|FG000|Overall Study|Ineligible|2
6310116|NCT02646423|10038902|FG001|Overall Study|Ineligible|1
6310117|NCT02646566|10038920|FG000|Overall Study|Lost to Follow-up|5
6310118|NCT02646566|10038921|FG001|Overall Study|Lost to Follow-up|4
6310119|NCT02646566|10038922|FG002|Overall Study|Lost to Follow-up|5
6310120|NCT02646566|10038920|FG000|Overall Study|Treatment failure|1
6310121|NCT02646566|10038921|FG001|Overall Study|Treatment failure|0
6310122|NCT02646566|10038922|FG002|Overall Study|Treatment failure|0
6310123|NCT02646618|10038932|FG000|Overall Study|Lost to Follow-up|10
6310124|NCT02646618|10038933|FG001|Overall Study|Lost to Follow-up|14
6310125|NCT02646891|10038977|FG000|Overall Study|Adverse Event|0
6310126|NCT02646891|10038978|FG001|Overall Study|Adverse Event|1
6310127|NCT02646891|10038979|FG002|Overall Study|Adverse Event|0
6310128|NCT02646891|10038980|FG003|Overall Study|Adverse Event|0
6310129|NCT02646891|10038981|FG004|Overall Study|Adverse Event|0
6310130|NCT02646891|10038982|FG005|Overall Study|Adverse Event|0
6310131|NCT02646891|10038983|FG006|Overall Study|Adverse Event|0
6310132|NCT02646891|10038984|FG007|Overall Study|Adverse Event|0
6310133|NCT02646891|10038985|FG008|Overall Study|Adverse Event|0
6310134|NCT02646891|10038986|FG009|Overall Study|Adverse Event|0
6310135|NCT02646891|10038977|FG000|Overall Study|Lost to Follow-up|0
6310136|NCT02646891|10038978|FG001|Overall Study|Lost to Follow-up|0
6310137|NCT02646891|10038979|FG002|Overall Study|Lost to Follow-up|0
6310138|NCT02646891|10038980|FG003|Overall Study|Lost to Follow-up|0
6310139|NCT02646891|10038981|FG004|Overall Study|Lost to Follow-up|0
6310140|NCT02646891|10038982|FG005|Overall Study|Lost to Follow-up|0
6310141|NCT02646891|10038983|FG006|Overall Study|Lost to Follow-up|2
6310142|NCT02646891|10038984|FG007|Overall Study|Lost to Follow-up|2
6310143|NCT02646891|10038985|FG008|Overall Study|Lost to Follow-up|2
6310144|NCT02646891|10038986|FG009|Overall Study|Lost to Follow-up|2
6310145|NCT02646891|10038977|FG000|Overall Study|Protocol Violation|0
6310146|NCT02646891|10038978|FG001|Overall Study|Protocol Violation|0
6310147|NCT02646891|10038979|FG002|Overall Study|Protocol Violation|0
6310148|NCT02646891|10038980|FG003|Overall Study|Protocol Violation|0
6310149|NCT02646891|10038981|FG004|Overall Study|Protocol Violation|0
6310150|NCT02646891|10038982|FG005|Overall Study|Protocol Violation|0
6310151|NCT02646891|10038983|FG006|Overall Study|Protocol Violation|1
6310152|NCT02646891|10038984|FG007|Overall Study|Protocol Violation|1
6310153|NCT02646891|10038985|FG008|Overall Study|Protocol Violation|0
6310154|NCT02646891|10038986|FG009|Overall Study|Protocol Violation|0
6310155|NCT02646891|10038977|FG000|Overall Study|Withdrawal by Subject|2
6310156|NCT02646891|10038978|FG001|Overall Study|Withdrawal by Subject|0
6310157|NCT02646891|10038979|FG002|Overall Study|Withdrawal by Subject|1
6310158|NCT02646891|10038980|FG003|Overall Study|Withdrawal by Subject|0
6310159|NCT02646891|10038981|FG004|Overall Study|Withdrawal by Subject|0
6310160|NCT02646891|10038982|FG005|Overall Study|Withdrawal by Subject|0
6310161|NCT02646891|10038983|FG006|Overall Study|Withdrawal by Subject|5
6310162|NCT02646891|10038984|FG007|Overall Study|Withdrawal by Subject|9
6310163|NCT02646891|10038985|FG008|Overall Study|Withdrawal by Subject|7
6310164|NCT02646891|10038986|FG009|Overall Study|Withdrawal by Subject|3
6310165|NCT02646891|10038977|FG000|Overall Study|Death|0
6039880|NCT00367991|9637650|FG000|Overall Study|Withdrawal by Subject|1
6310166|NCT02646891|10038978|FG001|Overall Study|Death|0
6310167|NCT02646891|10038979|FG002|Overall Study|Death|0
6310168|NCT02646891|10038980|FG003|Overall Study|Death|0
6310169|NCT02646891|10038981|FG004|Overall Study|Death|0
6310170|NCT02646891|10038982|FG005|Overall Study|Death|0
6310171|NCT02646891|10038983|FG006|Overall Study|Death|1
6310172|NCT02646891|10038984|FG007|Overall Study|Death|1
6310173|NCT02646891|10038985|FG008|Overall Study|Death|1
6310174|NCT02646891|10038986|FG009|Overall Study|Death|0
6310175|NCT02647281|10039052|FG000|Multiple-Ascending Dose(Part 2-115 Days)|Withdrawal by Subject|0
6310176|NCT02647281|10039053|FG001|Multiple-Ascending Dose(Part 2-115 Days)|Withdrawal by Subject|0
6310177|NCT02647281|10039054|FG002|Multiple-Ascending Dose(Part 2-115 Days)|Withdrawal by Subject|0
6310178|NCT02647281|10039055|FG003|Multiple-Ascending Dose(Part 2-115 Days)|Withdrawal by Subject|0
6310179|NCT02647281|10039056|FG004|Multiple-Ascending Dose(Part 2-115 Days)|Withdrawal by Subject|0
6039881|NCT00367991|9637651|FG001|Overall Study|Withdrawal by Subject|1
6039882|NCT00367991|9637650|FG000|Overall Study|Adverse Event|1
6039883|NCT00367991|9637651|FG001|Overall Study|Adverse Event|1
6310180|NCT02647281|10039057|FG005|Multiple-Ascending Dose(Part 2-115 Days)|Withdrawal by Subject|0
6310181|NCT02647281|10039058|FG006|Multiple-Ascending Dose(Part 2-115 Days)|Withdrawal by Subject|0
6039884|NCT00368069|9637659|FG000|Overall Study|Adverse Event|5
6039885|NCT00368069|9637660|FG001|Overall Study|Adverse Event|2
6039886|NCT00368069|9637659|FG000|Overall Study|Lack of Efficacy|0
6310182|NCT02647281|10039059|FG007|Multiple-Ascending Dose(Part 2-115 Days)|Withdrawal by Subject|0
6310183|NCT02647281|10039060|FG008|Multiple-Ascending Dose(Part 2-115 Days)|Withdrawal by Subject|1
6310184|NCT02647320|10039094|FG000|Overall Study|Adverse Event|0
6310185|NCT02647320|10039095|FG001|Overall Study|Adverse Event|1
6310186|NCT02647320|10039096|FG002|Overall Study|Adverse Event|3
6310187|NCT02647320|10039097|FG003|Overall Study|Adverse Event|2
6310188|NCT02647320|10039098|FG004|Overall Study|Adverse Event|1
6310189|NCT02647320|10039094|FG000|Overall Study|Protocol Violation|0
6310190|NCT02647320|10039095|FG001|Overall Study|Protocol Violation|0
6310191|NCT02647320|10039096|FG002|Overall Study|Protocol Violation|3
6310192|NCT02647320|10039097|FG003|Overall Study|Protocol Violation|0
6310193|NCT02647320|10039098|FG004|Overall Study|Protocol Violation|0
6310194|NCT02647320|10039094|FG000|Overall Study|Withdrawal by Subject|7
6310195|NCT02647320|10039095|FG001|Overall Study|Withdrawal by Subject|4
6310196|NCT02647320|10039096|FG002|Overall Study|Withdrawal by Subject|2
6310197|NCT02647320|10039097|FG003|Overall Study|Withdrawal by Subject|2
6310198|NCT02647320|10039098|FG004|Overall Study|Withdrawal by Subject|7
6310199|NCT02647320|10039094|FG000|Overall Study|Persistent hyperglycemia|0
6310200|NCT02647320|10039095|FG001|Overall Study|Persistent hyperglycemia|1
6310201|NCT02647320|10039096|FG002|Overall Study|Persistent hyperglycemia|1
6310202|NCT02647320|10039097|FG003|Overall Study|Persistent hyperglycemia|1
6310203|NCT02647320|10039098|FG004|Overall Study|Persistent hyperglycemia|1
6310204|NCT02647320|10039094|FG000|Overall Study|Study terminated by sponsor|1
6310205|NCT02647320|10039095|FG001|Overall Study|Study terminated by sponsor|1
6310206|NCT02647320|10039096|FG002|Overall Study|Study terminated by sponsor|1
6310207|NCT02647320|10039097|FG003|Overall Study|Study terminated by sponsor|1
6310208|NCT02647320|10039098|FG004|Overall Study|Study terminated by sponsor|2
6310209|NCT02647320|10039094|FG000|Overall Study|Reason not provided|0
6310210|NCT02647320|10039095|FG001|Overall Study|Reason not provided|0
6310211|NCT02647320|10039096|FG002|Overall Study|Reason not provided|1
6310212|NCT02647320|10039097|FG003|Overall Study|Reason not provided|0
6310213|NCT02647320|10039098|FG004|Overall Study|Reason not provided|2
6310214|NCT02647320|10039094|FG000|Overall Study|Lost to Follow-up|1
6310215|NCT02647320|10039095|FG001|Overall Study|Lost to Follow-up|1
6310216|NCT02647320|10039096|FG002|Overall Study|Lost to Follow-up|0
6310217|NCT02647320|10039097|FG003|Overall Study|Lost to Follow-up|0
6310218|NCT02647320|10039098|FG004|Overall Study|Lost to Follow-up|0
6310219|NCT02647320|10039094|FG000|Overall Study|Develop anemia|1
6310220|NCT02647320|10039095|FG001|Overall Study|Develop anemia|0
6310221|NCT02647320|10039096|FG002|Overall Study|Develop anemia|0
6310222|NCT02647320|10039097|FG003|Overall Study|Develop anemia|0
6310223|NCT02647320|10039098|FG004|Overall Study|Develop anemia|0
6310224|NCT02647320|10039094|FG000|Overall Study|Lack of Efficacy|0
6310225|NCT02647320|10039095|FG001|Overall Study|Lack of Efficacy|0
6310226|NCT02647320|10039096|FG002|Overall Study|Lack of Efficacy|0
6310227|NCT02647320|10039097|FG003|Overall Study|Lack of Efficacy|1
6310228|NCT02647320|10039098|FG004|Overall Study|Lack of Efficacy|0
6310229|NCT02647320|10039094|FG000|Overall Study|Disposition Missing Due to Fire at Site|2
6310230|NCT02647320|10039095|FG001|Overall Study|Disposition Missing Due to Fire at Site|3
6310231|NCT02647320|10039096|FG002|Overall Study|Disposition Missing Due to Fire at Site|4
6310232|NCT02647320|10039097|FG003|Overall Study|Disposition Missing Due to Fire at Site|3
6310233|NCT02647320|10039098|FG004|Overall Study|Disposition Missing Due to Fire at Site|4
6310234|NCT02647645|10039118|FG000|Overall Study|Lost to Follow-up|2
6310235|NCT02647645|10039119|FG001|Overall Study|Lost to Follow-up|1
6310236|NCT02647658|10039127|FG000|Overall Study|Consent refusal|15
6310237|NCT02647658|10039128|FG001|Overall Study|Consent refusal|24
6310238|NCT02647788|10039136|FG000|Overall Study|Lost to Follow-up|13
6310239|NCT02647788|10039137|FG001|Overall Study|Lost to Follow-up|11
6310240|NCT02647788|10039136|FG000|Overall Study|Did not want opiate|0
6039887|NCT00368069|9637660|FG001|Overall Study|Lack of Efficacy|1
6310241|NCT02647788|10039137|FG001|Overall Study|Did not want opiate|1
6310242|NCT02647788|10039136|FG000|Overall Study|Withdrawal by Subject|1
6310243|NCT02647788|10039137|FG001|Overall Study|Withdrawal by Subject|0
6310244|NCT02647788|10039136|FG000|Overall Study|Felt itchy with assigned medication|1
6310245|NCT02647788|10039137|FG001|Overall Study|Felt itchy with assigned medication|0
6310246|NCT02647788|10039136|FG000|Overall Study|Felt nauseous with assigned medication|1
6310247|NCT02647788|10039137|FG001|Overall Study|Felt nauseous with assigned medication|1
6310248|NCT02647866|10039148|FG000|Overall Study|Adverse Event|0
6310249|NCT02647866|10039149|FG001|Overall Study|Adverse Event|0
6310250|NCT02647866|10039150|FG002|Overall Study|Adverse Event|2
6310251|NCT02647866|10039151|FG003|Overall Study|Adverse Event|2
6310252|NCT02647866|10039152|FG004|Overall Study|Adverse Event|1
6310253|NCT02647866|10039148|FG000|Overall Study|Disease Worsening|3
6310254|NCT02647866|10039149|FG001|Overall Study|Disease Worsening|1
6310255|NCT02647866|10039150|FG002|Overall Study|Disease Worsening|0
6039888|NCT00368069|9637659|FG000|Overall Study|Lost to Follow-up|1
6039889|NCT00368069|9637660|FG001|Overall Study|Lost to Follow-up|0
6039890|NCT00368069|9637659|FG000|Overall Study|Protocol Violation|0
6039891|NCT00368069|9637660|FG001|Overall Study|Protocol Violation|2
6039892|NCT00368069|9637659|FG000|Overall Study|Withdrawal of Consent|2
6039893|NCT00368069|9637660|FG001|Overall Study|Withdrawal of Consent|1
6039894|NCT00368069|9637659|FG000|Overall Study|no blood sampling possible|0
6039895|NCT00368069|9637660|FG001|Overall Study|no blood sampling possible|1
6039896|NCT00368108|9637669|FG000|Overall Study|Adverse Event|38
6310256|NCT02647866|10039151|FG003|Overall Study|Disease Worsening|0
6310257|NCT02647866|10039152|FG004|Overall Study|Disease Worsening|1
6310258|NCT02647866|10039148|FG000|Overall Study|Withdrawal by Subject|1
6310259|NCT02647866|10039149|FG001|Overall Study|Withdrawal by Subject|1
6310260|NCT02647866|10039150|FG002|Overall Study|Withdrawal by Subject|2
6310261|NCT02647866|10039151|FG003|Overall Study|Withdrawal by Subject|4
6310262|NCT02647866|10039152|FG004|Overall Study|Withdrawal by Subject|4
6310263|NCT02647866|10039148|FG000|Overall Study|Physician Decision|0
6310264|NCT02647866|10039149|FG001|Overall Study|Physician Decision|1
6310265|NCT02647866|10039150|FG002|Overall Study|Physician Decision|1
6310266|NCT02647866|10039151|FG003|Overall Study|Physician Decision|0
6310267|NCT02647866|10039152|FG004|Overall Study|Physician Decision|2
6310268|NCT02647866|10039148|FG000|Overall Study|Death|0
6310269|NCT02647866|10039149|FG001|Overall Study|Death|1
6310270|NCT02647866|10039150|FG002|Overall Study|Death|0
6310271|NCT02647866|10039151|FG003|Overall Study|Death|0
6310272|NCT02647866|10039152|FG004|Overall Study|Death|0
6310273|NCT02647866|10039148|FG000|Overall Study|Subject moved to different country|1
6310274|NCT02647866|10039149|FG001|Overall Study|Subject moved to different country|0
6310275|NCT02647866|10039150|FG002|Overall Study|Subject moved to different country|0
6310276|NCT02647866|10039151|FG003|Overall Study|Subject moved to different country|0
6310277|NCT02647866|10039152|FG004|Overall Study|Subject moved to different country|0
6310278|NCT02647905|10039172|FG000|Overall Study|Lost to Follow-up|1
6310279|NCT02647905|10039172|FG000|Overall Study|Withdrawal by Subject|2
6310280|NCT02647944|10039178|FG000|Overall Study|Withdrawal by Subject|0
6310281|NCT02647944|10039179|FG001|Overall Study|Withdrawal by Subject|3
6310282|NCT02647944|10039178|FG000|Overall Study|Adverse Event|2
6310283|NCT02647944|10039179|FG001|Overall Study|Adverse Event|0
6310284|NCT02648204|10039202|FG000|Overall Study|Withdrawal by Subject|12
6310285|NCT02648204|10039203|FG001|Overall Study|Withdrawal by Subject|8
6310286|NCT02648204|10039204|FG002|Overall Study|Withdrawal by Subject|2
6310287|NCT02648204|10039205|FG003|Overall Study|Withdrawal by Subject|6
6310288|NCT02648204|10039202|FG000|Overall Study|Lost to Follow-up|5
6310289|NCT02648204|10039203|FG001|Overall Study|Lost to Follow-up|8
6310290|NCT02648204|10039204|FG002|Overall Study|Lost to Follow-up|4
6310291|NCT02648204|10039205|FG003|Overall Study|Lost to Follow-up|6
6310292|NCT02648204|10039202|FG000|Overall Study|Missing follow-up information|4
6310293|NCT02648204|10039203|FG001|Overall Study|Missing follow-up information|4
6310294|NCT02648204|10039204|FG002|Overall Study|Missing follow-up information|4
6310295|NCT02648204|10039205|FG003|Overall Study|Missing follow-up information|2
6310296|NCT02648204|10039202|FG000|Overall Study|Death|1
6310297|NCT02648204|10039203|FG001|Overall Study|Death|1
6310298|NCT02648204|10039204|FG002|Overall Study|Death|2
6310299|NCT02648204|10039205|FG003|Overall Study|Death|2
6310300|NCT02648204|10039202|FG000|Overall Study|Adverse Event|0
6310301|NCT02648204|10039203|FG001|Overall Study|Adverse Event|0
6310302|NCT02648204|10039204|FG002|Overall Study|Adverse Event|1
6310303|NCT02648204|10039205|FG003|Overall Study|Adverse Event|0
6310304|NCT02648217|10039217|FG000|Overall Study|Adverse Event|0
6310305|NCT02648217|10039218|FG001|Overall Study|Adverse Event|1
6310306|NCT02648217|10039217|FG000|Overall Study|Lost to Follow-up|1
6310307|NCT02648217|10039218|FG001|Overall Study|Lost to Follow-up|1
6310308|NCT02648217|10039217|FG000|Overall Study|Withdrawal by Subject|4
6310309|NCT02648217|10039218|FG001|Overall Study|Withdrawal by Subject|3
6310310|NCT02648217|10039217|FG000|Overall Study|Unclassified|5
6310311|NCT02648217|10039218|FG001|Overall Study|Unclassified|0
6310312|NCT02648438|10039231|FG000|Overall Study|Eligibility criteria not fulfilled|0
6310313|NCT02648438|10039232|FG001|Overall Study|Eligibility criteria not fulfilled|2
6310314|NCT02648438|10039233|FG002|Overall Study|Eligibility criteria not fulfilled|0
6310315|NCT02648438|10039231|FG000|Overall Study|Protocol Violation|2
6310316|NCT02648438|10039232|FG001|Overall Study|Protocol Violation|0
6310317|NCT02648438|10039233|FG002|Overall Study|Protocol Violation|0
6039897|NCT00368108|9637670|FG001|Overall Study|Adverse Event|26
6039898|NCT00368108|9637671|FG002|Overall Study|Adverse Event|44
6310318|NCT02648438|10039231|FG000|Overall Study|Withdrawal by Subject|1
6310319|NCT02648438|10039232|FG001|Overall Study|Withdrawal by Subject|1
6310320|NCT02648438|10039233|FG002|Overall Study|Withdrawal by Subject|0
6310321|NCT02648932|10039264|FG000|Overall Study|No transplant|3
6310322|NCT02648932|10039265|FG001|Overall Study|No transplant|1
6039899|NCT00368108|9637669|FG000|Overall Study|Abnormal Laboratory Value|0
6039900|NCT00368108|9637670|FG001|Overall Study|Abnormal Laboratory Value|0
6310323|NCT02649218|10039318|FG000|Overall Study|Adverse Event|8
6310324|NCT02649218|10039318|FG000|Overall Study|Lack of Efficacy|8
6310325|NCT02649218|10039318|FG000|Overall Study|Pregnancy|3
6310326|NCT02649218|10039318|FG000|Overall Study|Protocol Violation|3
6310327|NCT02649218|10039318|FG000|Overall Study|Physician Decision|1
6039901|NCT00368108|9637671|FG002|Overall Study|Abnormal Laboratory Value|3
6039902|NCT00368108|9637669|FG000|Overall Study|Protocol Violation|5
6148384|NCT01089556|9783768|FG005|Study Period II (Weeks 1-8)|Adverse Event|0
6310328|NCT02649218|10039318|FG000|Overall Study|Withdrawal by Subject|2
6310329|NCT02649231|10039327|FG000|Overall Study|Adverse Event|0
6310330|NCT02649231|10039328|FG001|Overall Study|Adverse Event|0
6310331|NCT02649231|10039329|FG002|Overall Study|Adverse Event|0
6310332|NCT02649231|10039330|FG003|Overall Study|Adverse Event|1
6310333|NCT02649231|10039327|FG000|Overall Study|Lost to Follow-up|2
6310334|NCT02649231|10039328|FG001|Overall Study|Lost to Follow-up|1
6310335|NCT02649231|10039329|FG002|Overall Study|Lost to Follow-up|1
6310336|NCT02649231|10039330|FG003|Overall Study|Lost to Follow-up|0
6310337|NCT02649231|10039327|FG000|Overall Study|Withdrawal by Subject|0
6148385|NCT01089556|9783763|FG000|Study Period II (Weeks 1-8)|Entry Criteria Not Met|12
6148386|NCT01089556|9783764|FG001|Study Period II (Weeks 1-8)|Entry Criteria Not Met|8
6148387|NCT01089556|9783765|FG002|Study Period II (Weeks 1-8)|Entry Criteria Not Met|0
6148388|NCT01089556|9783766|FG003|Study Period II (Weeks 1-8)|Entry Criteria Not Met|0
6148389|NCT01089556|9783767|FG004|Study Period II (Weeks 1-8)|Entry Criteria Not Met|0
6148390|NCT01089556|9783768|FG005|Study Period II (Weeks 1-8)|Entry Criteria Not Met|0
6148391|NCT01089556|9783763|FG000|Study Period II (Weeks 1-8)|Lack of Efficacy|1
6148392|NCT01089556|9783764|FG001|Study Period II (Weeks 1-8)|Lack of Efficacy|2
6148393|NCT01089556|9783765|FG002|Study Period II (Weeks 1-8)|Lack of Efficacy|0
6148394|NCT01089556|9783766|FG003|Study Period II (Weeks 1-8)|Lack of Efficacy|0
6148395|NCT01089556|9783767|FG004|Study Period II (Weeks 1-8)|Lack of Efficacy|0
6148396|NCT01089556|9783768|FG005|Study Period II (Weeks 1-8)|Lack of Efficacy|0
6148397|NCT01089556|9783763|FG000|Study Period II (Weeks 1-8)|Lost to Follow-up|0
6148398|NCT01089556|9783764|FG001|Study Period II (Weeks 1-8)|Lost to Follow-up|3
6148399|NCT01089556|9783765|FG002|Study Period II (Weeks 1-8)|Lost to Follow-up|0
6148400|NCT01089556|9783766|FG003|Study Period II (Weeks 1-8)|Lost to Follow-up|0
6148401|NCT01089556|9783767|FG004|Study Period II (Weeks 1-8)|Lost to Follow-up|0
6148402|NCT01089556|9783768|FG005|Study Period II (Weeks 1-8)|Lost to Follow-up|0
6148403|NCT01089556|9783763|FG000|Study Period II (Weeks 1-8)|Physician Decision|4
6148404|NCT01089556|9783764|FG001|Study Period II (Weeks 1-8)|Physician Decision|0
6148405|NCT01089556|9783765|FG002|Study Period II (Weeks 1-8)|Physician Decision|0
6148406|NCT01089556|9783766|FG003|Study Period II (Weeks 1-8)|Physician Decision|0
6148407|NCT01089556|9783767|FG004|Study Period II (Weeks 1-8)|Physician Decision|0
6148408|NCT01089556|9783768|FG005|Study Period II (Weeks 1-8)|Physician Decision|0
6148409|NCT01089556|9783763|FG000|Study Period II (Weeks 1-8)|Protocol Violation|4
6148410|NCT01089556|9783764|FG001|Study Period II (Weeks 1-8)|Protocol Violation|4
6148411|NCT01089556|9783765|FG002|Study Period II (Weeks 1-8)|Protocol Violation|0
6148412|NCT01089556|9783766|FG003|Study Period II (Weeks 1-8)|Protocol Violation|0
6148413|NCT01089556|9783767|FG004|Study Period II (Weeks 1-8)|Protocol Violation|0
6148414|NCT01089556|9783768|FG005|Study Period II (Weeks 1-8)|Protocol Violation|0
6148415|NCT01089556|9783763|FG000|Study Period II (Weeks 1-8)|Withdrawal by Subject|12
6148416|NCT01089556|9783764|FG001|Study Period II (Weeks 1-8)|Withdrawal by Subject|14
6148417|NCT01089556|9783765|FG002|Study Period II (Weeks 1-8)|Withdrawal by Subject|0
6148418|NCT01089556|9783766|FG003|Study Period II (Weeks 1-8)|Withdrawal by Subject|0
6148419|NCT01089556|9783767|FG004|Study Period II (Weeks 1-8)|Withdrawal by Subject|0
6310338|NCT02649231|10039328|FG001|Overall Study|Withdrawal by Subject|1
6310339|NCT02649231|10039329|FG002|Overall Study|Withdrawal by Subject|0
6310340|NCT02649231|10039330|FG003|Overall Study|Withdrawal by Subject|1
6310341|NCT02649231|10039327|FG000|Overall Study|Protocol Violation|2
6310342|NCT02649231|10039328|FG001|Overall Study|Protocol Violation|1
6310343|NCT02649231|10039329|FG002|Overall Study|Protocol Violation|1
6310344|NCT02649231|10039330|FG003|Overall Study|Protocol Violation|0
6310345|NCT02649439|10039351|FG000|Overall Study|Switched to alternative treatment|6
6310346|NCT02649439|10039352|FG001|Overall Study|Switched to alternative treatment|4
6310347|NCT02649439|10039351|FG000|Overall Study|Patient decision|1
6310348|NCT02649439|10039352|FG001|Overall Study|Patient decision|0
6310349|NCT02649439|10039351|FG000|Overall Study|Patient going out of country|1
6310350|NCT02649439|10039352|FG001|Overall Study|Patient going out of country|0
6310351|NCT02649439|10039351|FG000|Overall Study|To start finasteride|1
6310352|NCT02649439|10039352|FG001|Overall Study|To start finasteride|0
6310353|NCT02649439|10039351|FG000|Overall Study|Physician Decision|1
6148420|NCT01089556|9783768|FG005|Study Period II (Weeks 1-8)|Withdrawal by Subject|0
6148421|NCT01089556|9783763|FG000|Study Period II (Weeks 1-8)|Not received any study drug|3
6310354|NCT02649439|10039352|FG001|Overall Study|Physician Decision|0
6310355|NCT02649439|10039351|FG000|Overall Study|Disease progression on study|12
6310356|NCT02649439|10039352|FG001|Overall Study|Disease progression on study|13
6310357|NCT02649439|10039351|FG000|Overall Study|Refused further treatment|1
6310358|NCT02649439|10039352|FG001|Overall Study|Refused further treatment|0
6310359|NCT02649439|10039351|FG000|Overall Study|Refused further follow up|2
6039903|NCT00368108|9637670|FG001|Overall Study|Protocol Violation|9
6148422|NCT01089556|9783764|FG001|Study Period II (Weeks 1-8)|Not received any study drug|4
6148423|NCT01089556|9783765|FG002|Study Period II (Weeks 1-8)|Not received any study drug|0
6148424|NCT01089556|9783766|FG003|Study Period II (Weeks 1-8)|Not received any study drug|0
6148425|NCT01089556|9783767|FG004|Study Period II (Weeks 1-8)|Not received any study drug|0
6039904|NCT00368108|9637671|FG002|Overall Study|Protocol Violation|9
6039905|NCT00368108|9637669|FG000|Overall Study|Withdrawal by Subject|9
6039906|NCT00368108|9637670|FG001|Overall Study|Withdrawal by Subject|3
6039907|NCT00368108|9637671|FG002|Overall Study|Withdrawal by Subject|5
6039908|NCT00368108|9637669|FG000|Overall Study|Lack of Efficacy|7
6039909|NCT00368108|9637670|FG001|Overall Study|Lack of Efficacy|8
6039910|NCT00368108|9637671|FG002|Overall Study|Lack of Efficacy|5
6039911|NCT00368108|9637669|FG000|Overall Study|Physician Decision|2
6039912|NCT00368108|9637670|FG001|Overall Study|Physician Decision|0
6039913|NCT00368108|9637671|FG002|Overall Study|Physician Decision|1
6039914|NCT00368108|9637669|FG000|Overall Study|Other|3
6039915|NCT00368108|9637670|FG001|Overall Study|Other|7
6039916|NCT00368108|9637671|FG002|Overall Study|Other|1
6039917|NCT00368251|9637682|FG000|Overall Study|SAE, non-fatal|1
6039918|NCT00368251|9637683|FG001|Overall Study|SAE, non-fatal|0
6039919|NCT00368251|9637684|FG002|Overall Study|SAE, non-fatal|0
6039920|NCT00368251|9637682|FG000|Overall Study|AE, non-serious non-fatal|0
6039921|NCT00368251|9637683|FG001|Overall Study|AE, non-serious non-fatal|0
6039922|NCT00368251|9637684|FG002|Overall Study|AE, non-serious non-fatal|1
6039923|NCT00368277|9637694|FG000|Overall Study|Adverse Event|33
6039924|NCT00368277|9637695|FG001|Overall Study|Adverse Event|49
6039925|NCT00368277|9637694|FG000|Overall Study|Death|2
6039926|NCT00368277|9637695|FG001|Overall Study|Death|1
6039927|NCT00368277|9637694|FG000|Overall Study|Unsatisfactory therapeutic effect|31
6310360|NCT02649439|10039352|FG001|Overall Study|Refused further follow up|7
6310361|NCT02649439|10039351|FG000|Overall Study|Completed treatment phase but refused the protocol specified follow up|1
6310362|NCT02649439|10039352|FG001|Overall Study|Completed treatment phase but refused the protocol specified follow up|0
6310363|NCT02649439|10039351|FG000|Overall Study|No treatment, per protocol|1
6310364|NCT02649439|10039352|FG001|Overall Study|No treatment, per protocol|0
6310365|NCT02649439|10039351|FG000|Overall Study|PSA DT makes ineligible|0
6310366|NCT02649439|10039352|FG001|Overall Study|PSA DT makes ineligible|1
6310367|NCT02649439|10039351|FG000|Overall Study|Rising PSA No Mets|0
6310368|NCT02649439|10039352|FG001|Overall Study|Rising PSA No Mets|1
6310369|NCT02649439|10039351|FG000|Overall Study|Rising PSA|0
6310370|NCT02649439|10039352|FG001|Overall Study|Rising PSA|1
6310371|NCT02649439|10039351|FG000|Overall Study|Signed follow up protocol|0
6310372|NCT02649439|10039352|FG001|Overall Study|Signed follow up protocol|1
6310373|NCT02649634|10039419|FG000|Overall Study|Withdrawal by Subject|3
6310374|NCT02649634|10039420|FG001|Overall Study|Withdrawal by Subject|5
6310375|NCT02649634|10039419|FG000|Overall Study|Lost to Follow-up|0
6310376|NCT02649634|10039420|FG001|Overall Study|Lost to Follow-up|1
6310377|NCT02649894|10039434|FG000|Overall Study|Adverse Event|1
6310378|NCT02649894|10039435|FG001|Overall Study|Adverse Event|0
6310379|NCT02649894|10039434|FG000|Overall Study|Physician Decision|0
6310380|NCT02649894|10039435|FG001|Overall Study|Physician Decision|1
6310381|NCT02649894|10039434|FG000|Overall Study|Withdrawal by Subject|5
6310382|NCT02649894|10039435|FG001|Overall Study|Withdrawal by Subject|2
6310383|NCT02649894|10039434|FG000|Overall Study|Lost to Follow-up|2
6310384|NCT02649894|10039435|FG001|Overall Study|Lost to Follow-up|1
6310385|NCT02649894|10039434|FG000|Overall Study|Death|30
6310386|NCT02649894|10039435|FG001|Overall Study|Death|7
6310387|NCT02649894|10039434|FG000|Overall Study|Other, not specified|6
6310388|NCT02649894|10039435|FG001|Overall Study|Other, not specified|0
6310389|NCT02650128|10039441|FG000|Overall Study|Death|2
6310390|NCT02650466|10039478|FG000|Overall Study|Physician Decision|1
6310391|NCT02650466|10039478|FG000|Overall Study|Withdrawal by Subject|5
6310392|NCT02650466|10039478|FG000|Overall Study|Lost to Follow-up|1
6310393|NCT02650895|10039499|FG000|Overall Study|Withdrawal by Subject|0
6310394|NCT02650895|10039500|FG001|Overall Study|Withdrawal by Subject|1
6310395|NCT02650895|10039501|FG002|Overall Study|Withdrawal by Subject|0
6310396|NCT02650895|10039502|FG003|Overall Study|Withdrawal by Subject|0
6310397|NCT02650895|10039503|FG004|Overall Study|Withdrawal by Subject|0
6310398|NCT02650895|10039504|FG005|Overall Study|Withdrawal by Subject|0
6310399|NCT02650921|10039523|FG000|Overall Study|Withdrawal by Subject|4
6310400|NCT02650921|10039523|FG000|Overall Study|Lost to Follow-up|2
6310401|NCT02650921|10039523|FG000|Overall Study|Adverse Event|1
6310402|NCT02650921|10039523|FG000|Overall Study|Due to Medical Condition|1
6310403|NCT02651116|10039539|FG000|Overall Study|Adverse Event|0
6310404|NCT02651116|10039540|FG001|Overall Study|Adverse Event|1
6039928|NCT00368277|9637695|FG001|Overall Study|Unsatisfactory therapeutic effect|24
6039929|NCT00368277|9637694|FG000|Overall Study|Protocol deviation|7
6039930|NCT00368277|9637695|FG001|Overall Study|Protocol deviation|0
6039931|NCT00368277|9637694|FG000|Overall Study|Patient withdrew consent|32
6039932|NCT00368277|9637695|FG001|Overall Study|Patient withdrew consent|28
6039933|NCT00368277|9637694|FG000|Overall Study|Lost to Follow-up|8
6310405|NCT02651116|10039539|FG000|Overall Study|No Longer Willing To Participate In Study|1
6310406|NCT02651116|10039540|FG001|Overall Study|No Longer Willing To Participate In Study|0
6310407|NCT02651155|10039548|FG000|Overall Study|Pretreatment Event/Adverse Event|1
6310408|NCT02651155|10039549|FG001|Overall Study|Pretreatment Event/Adverse Event|2
6310409|NCT02651155|10039548|FG000|Overall Study|Voluntary Withdrawal|5
6039934|NCT00368277|9637695|FG001|Overall Study|Lost to Follow-up|6
6039935|NCT00368355|9637721|FG000|Overall Study|Adverse Event|1
6039936|NCT00368355|9637722|FG001|Overall Study|Adverse Event|0
6310410|NCT02651155|10039549|FG001|Overall Study|Voluntary Withdrawal|0
6310411|NCT02651194|10039555|FG000|Overall Study|Lost to Follow-up|3
6310412|NCT02651194|10039555|FG000|Overall Study|Other|2
6310413|NCT02651220|10039562|FG000|Overall Study|Adverse Event|1
6310414|NCT02651220|10039563|FG001|Overall Study|Adverse Event|5
6310415|NCT02651220|10039564|FG002|Overall Study|Adverse Event|1
6310416|NCT02651220|10039562|FG000|Overall Study|Lost to Follow-up|8
6310417|NCT02651220|10039563|FG001|Overall Study|Lost to Follow-up|14
6310418|NCT02651220|10039564|FG002|Overall Study|Lost to Follow-up|14
6310419|NCT02651220|10039562|FG000|Overall Study|Non-Compliance with Study Drug|4
6310420|NCT02651220|10039563|FG001|Overall Study|Non-Compliance with Study Drug|0
6310421|NCT02651220|10039564|FG002|Overall Study|Non-Compliance with Study Drug|1
6310422|NCT02651220|10039562|FG000|Overall Study|Pregnancy|1
6310423|NCT02651220|10039563|FG001|Overall Study|Pregnancy|0
6310424|NCT02651220|10039564|FG002|Overall Study|Pregnancy|1
6310425|NCT02651220|10039562|FG000|Overall Study|Protocol Violation|0
6310426|NCT02651220|10039563|FG001|Overall Study|Protocol Violation|0
6310427|NCT02651220|10039564|FG002|Overall Study|Protocol Violation|1
6310428|NCT02651220|10039562|FG000|Overall Study|Withdrawal by Subject|5
6310429|NCT02651220|10039563|FG001|Overall Study|Withdrawal by Subject|6
6310430|NCT02651220|10039564|FG002|Overall Study|Withdrawal by Subject|8
6310431|NCT02651220|10039562|FG000|Overall Study|Miscellaneous|4
6310432|NCT02651220|10039563|FG001|Overall Study|Miscellaneous|1
6310433|NCT02651220|10039564|FG002|Overall Study|Miscellaneous|2
6310434|NCT02651220|10039562|FG000|Overall Study|Withdrawal by Parent/Guardian|0
6310435|NCT02651220|10039563|FG001|Overall Study|Withdrawal by Parent/Guardian|1
6310436|NCT02651220|10039564|FG002|Overall Study|Withdrawal by Parent/Guardian|1
6310437|NCT02651467|10039613|FG000|Overall Study|Withdrawal by Subject|0
6310438|NCT02651467|10039614|FG001|Overall Study|Withdrawal by Subject|0
6310439|NCT02651467|10039615|FG002|Overall Study|Withdrawal by Subject|2
6310440|NCT02651467|10039613|FG000|Overall Study|Other (Not specified)|1
6310441|NCT02651467|10039614|FG001|Overall Study|Other (Not specified)|0
6310442|NCT02651467|10039615|FG002|Overall Study|Other (Not specified)|2
6310443|NCT02651688|10039648|FG000|Overall Study|Non-compliance|0
6310444|NCT02651688|10039649|FG001|Overall Study|Non-compliance|0
6310445|NCT02651688|10039650|FG002|Overall Study|Non-compliance|1
6310446|NCT02651688|10039648|FG000|Overall Study|Principal Investigator (PI) decision|0
6310447|NCT02651688|10039649|FG001|Overall Study|Principal Investigator (PI) decision|2
6310448|NCT02651688|10039650|FG002|Overall Study|Principal Investigator (PI) decision|0
6310449|NCT02651688|10039648|FG000|Overall Study|Lost to Follow-up|1
6310450|NCT02651688|10039649|FG001|Overall Study|Lost to Follow-up|3
6310451|NCT02651688|10039650|FG002|Overall Study|Lost to Follow-up|0
6310452|NCT02651688|10039648|FG000|Overall Study|Withdrawal by Subject|1
6310453|NCT02651688|10039649|FG001|Overall Study|Withdrawal by Subject|0
6310454|NCT02651688|10039650|FG002|Overall Study|Withdrawal by Subject|2
6310455|NCT02651922|10039658|FG000|Overall Study|due to exclusion criteria|2
6310456|NCT02651987|10039664|FG000|Overall Study|Adverse Event|2
6310457|NCT02651987|10039665|FG001|Overall Study|Adverse Event|2
6310458|NCT02651987|10039664|FG000|Overall Study|Consent Withdrawn|2
6310459|NCT02651987|10039665|FG001|Overall Study|Consent Withdrawn|0
6310460|NCT02651987|10039664|FG000|Overall Study|Local PD|0
6310461|NCT02651987|10039665|FG001|Overall Study|Local PD|2
6310462|NCT02651987|10039664|FG000|Overall Study|Investigator Decision|1
6310463|NCT02651987|10039665|FG001|Overall Study|Investigator Decision|1
6310464|NCT02652156|10039677|FG000|Overall Study|Physician Decision|1
6310465|NCT02652156|10039678|FG001|Overall Study|Physician Decision|0
6310466|NCT02652156|10039679|FG002|Overall Study|Physician Decision|0
6310467|NCT02652260|10039703|FG000|Overall Study|Pregnancy|0
6310468|NCT02652260|10039704|FG001|Overall Study|Pregnancy|1
6310469|NCT02652260|10039703|FG000|Overall Study|Withdrawal by Subject|0
6310470|NCT02652260|10039704|FG001|Overall Study|Withdrawal by Subject|1
6310471|NCT02652442|10039749|FG000|Centrifugation - Distance|Lost to Follow-up|1
6310472|NCT02652624|10039767|FG000|Randomized Phase|Pregnancy|3
6310473|NCT02652624|10039768|FG001|Randomized Phase|Pregnancy|1
6310474|NCT02652624|10039767|FG000|Randomized Phase|Investigator's Discretion|0
6310475|NCT02652624|10039768|FG001|Randomized Phase|Investigator's Discretion|2
6310476|NCT02652624|10039767|FG000|Randomized Phase|Death|0
6310477|NCT02652624|10039768|FG001|Randomized Phase|Death|1
6310478|NCT02652624|10039767|FG000|Randomized Phase|Lost to Follow-up|0
6310479|NCT02652624|10039768|FG001|Randomized Phase|Lost to Follow-up|1
6310480|NCT02652624|10039767|FG000|Extension Phase|Lost to Follow-up|3
6310481|NCT02652624|10039768|FG001|Extension Phase|Lost to Follow-up|1
6310482|NCT02652624|10039767|FG000|Extension Phase|Pregnancy|1
6310483|NCT02652624|10039768|FG001|Extension Phase|Pregnancy|1
6310484|NCT02652624|10039767|FG000|Extension Phase|Adverse Event|0
6310485|NCT02652624|10039768|FG001|Extension Phase|Adverse Event|1
6310486|NCT02652624|10039767|FG000|Extension Phase|Withdrew Consent|0
6310487|NCT02652624|10039768|FG001|Extension Phase|Withdrew Consent|1
6310488|NCT02652767|10039776|FG000|Overall Study|Death|2
6310489|NCT02652767|10039776|FG000|Overall Study|Lost to Follow-up|1
6310490|NCT02652767|10039776|FG000|Overall Study|Withdrawal by Subject|1
6310491|NCT02653170|10039805|FG000|Overall Study|Withdrawal by Subject|3
6310492|NCT02653170|10039806|FG001|Overall Study|Withdrawal by Subject|8
6310493|NCT02653170|10039807|FG002|Overall Study|Withdrawal by Subject|3
6310494|NCT02653170|10039805|FG000|Overall Study|withdrawn by study team|2
6310495|NCT02653170|10039806|FG001|Overall Study|withdrawn by study team|4
6310496|NCT02653170|10039807|FG002|Overall Study|withdrawn by study team|5
6310497|NCT02653170|10039805|FG000|Overall Study|Lost to Follow-up|12
6310498|NCT02653170|10039806|FG001|Overall Study|Lost to Follow-up|4
6310499|NCT02653170|10039807|FG002|Overall Study|Lost to Follow-up|10
6310500|NCT02653300|10039824|FG000|Overall Study|Withdrawal by Subject|2
6310501|NCT02653326|10039830|FG000|Overall Study|Lost to Follow-up|10
6310502|NCT02653326|10039831|FG001|Overall Study|Lost to Follow-up|7
6310503|NCT02653625|10039925|FG000|Overall Study|Adverse Event|1
6310504|NCT02653625|10039925|FG000|Overall Study|Non-compliance with Study Drug|1
6310505|NCT02653625|10039925|FG000|Overall Study|Protocol Violation|1
6310506|NCT02653625|10039925|FG000|Overall Study|Suspected Drug Induced Liver Injury|1
6310507|NCT02653664|10039932|FG000|Post-Treatment|Withdrawal by Subject|6
6310508|NCT02653664|10039933|FG001|Post-Treatment|Withdrawal by Subject|5
6310509|NCT02653664|10039934|FG002|Post-Treatment|Withdrawal by Subject|7
6310510|NCT02653664|10039932|FG000|Post-Treatment|Lost to Follow-up|8
6310511|NCT02653664|10039933|FG001|Post-Treatment|Lost to Follow-up|1
6310512|NCT02653664|10039934|FG002|Post-Treatment|Lost to Follow-up|7
6310513|NCT02653664|10039932|FG000|3 Month Follow-Up|Withdrawal by Subject|9
6310514|NCT02653664|10039933|FG001|3 Month Follow-Up|Withdrawal by Subject|5
6310515|NCT02653664|10039934|FG002|3 Month Follow-Up|Withdrawal by Subject|9
6310516|NCT02653664|10039932|FG000|3 Month Follow-Up|Lost to Follow-up|9
6310517|NCT02653664|10039933|FG001|3 Month Follow-Up|Lost to Follow-up|8
6310518|NCT02653664|10039934|FG002|3 Month Follow-Up|Lost to Follow-up|16
6310519|NCT02653664|10039932|FG000|3 Month Follow-Up|Investigator Withdrawn, Behavioral Issues|0
6310520|NCT02653664|10039933|FG001|3 Month Follow-Up|Investigator Withdrawn, Behavioral Issues|2
6310521|NCT02653664|10039934|FG002|3 Month Follow-Up|Investigator Withdrawn, Behavioral Issues|0
6310522|NCT02653664|10039932|FG000|3 Month Follow-Up|Subject Declined Assessment Period, Remained Enrolled in Trial|3
6310523|NCT02653664|10039933|FG001|3 Month Follow-Up|Subject Declined Assessment Period, Remained Enrolled in Trial|0
6148426|NCT01089556|9783768|FG005|Study Period II (Weeks 1-8)|Not received any study drug|0
6148427|NCT01089556|9783763|FG000|Study Period III (Weeks 9-16)|Adverse Event|0
6148428|NCT01089556|9783764|FG001|Study Period III (Weeks 9-16)|Adverse Event|0
6148429|NCT01089556|9783765|FG002|Study Period III (Weeks 9-16)|Adverse Event|4
6148430|NCT01089556|9783766|FG003|Study Period III (Weeks 9-16)|Adverse Event|2
6148431|NCT01089556|9783767|FG004|Study Period III (Weeks 9-16)|Adverse Event|4
6148432|NCT01089556|9783768|FG005|Study Period III (Weeks 9-16)|Adverse Event|3
6148433|NCT01089556|9783763|FG000|Study Period III (Weeks 9-16)|Entry Criteria Not Met|0
6148434|NCT01089556|9783764|FG001|Study Period III (Weeks 9-16)|Entry Criteria Not Met|0
6148435|NCT01089556|9783765|FG002|Study Period III (Weeks 9-16)|Entry Criteria Not Met|1
6148436|NCT01089556|9783766|FG003|Study Period III (Weeks 9-16)|Entry Criteria Not Met|1
6148437|NCT01089556|9783767|FG004|Study Period III (Weeks 9-16)|Entry Criteria Not Met|1
6148438|NCT01089556|9783768|FG005|Study Period III (Weeks 9-16)|Entry Criteria Not Met|1
6148439|NCT01089556|9783763|FG000|Study Period III (Weeks 9-16)|Lack of Efficacy|0
6148440|NCT01089556|9783764|FG001|Study Period III (Weeks 9-16)|Lack of Efficacy|0
6148441|NCT01089556|9783765|FG002|Study Period III (Weeks 9-16)|Lack of Efficacy|0
6148442|NCT01089556|9783766|FG003|Study Period III (Weeks 9-16)|Lack of Efficacy|2
6310524|NCT02653664|10039934|FG002|3 Month Follow-Up|Subject Declined Assessment Period, Remained Enrolled in Trial|0
6310525|NCT02653664|10039932|FG000|6 Month Follow-Up|Withdrawal by Subject|13
6310526|NCT02653664|10039933|FG001|6 Month Follow-Up|Withdrawal by Subject|7
6310527|NCT02653664|10039934|FG002|6 Month Follow-Up|Withdrawal by Subject|14
6310528|NCT02653664|10039932|FG000|6 Month Follow-Up|Lost to Follow-up|10
6310529|NCT02653664|10039933|FG001|6 Month Follow-Up|Lost to Follow-up|11
6310530|NCT02653664|10039934|FG002|6 Month Follow-Up|Lost to Follow-up|9
6310531|NCT02653664|10039932|FG000|6 Month Follow-Up|Investigator Withdrawn, Behavioral Issues|0
6310532|NCT02653664|10039933|FG001|6 Month Follow-Up|Investigator Withdrawn, Behavioral Issues|2
6310533|NCT02653664|10039934|FG002|6 Month Follow-Up|Investigator Withdrawn, Behavioral Issues|0
6310534|NCT02653664|10039932|FG000|6 Month Follow-Up|Subject Declined Assessment Period|0
6310535|NCT02653664|10039933|FG001|6 Month Follow-Up|Subject Declined Assessment Period|1
6310536|NCT02653664|10039934|FG002|6 Month Follow-Up|Subject Declined Assessment Period|0
6310537|NCT02654002|10039977|FG000|Overall Study|Adverse Event|0
6310538|NCT02654002|10039978|FG001|Overall Study|Adverse Event|0
6310539|NCT02654002|10039979|FG002|Overall Study|Adverse Event|0
6310540|NCT02654002|10039980|FG003|Overall Study|Adverse Event|0
6310541|NCT02654002|10039981|FG004|Overall Study|Adverse Event|0
6310542|NCT02654002|10039982|FG005|Overall Study|Adverse Event|0
6310543|NCT02654002|10039983|FG006|Overall Study|Adverse Event|1
6310544|NCT02654002|10039984|FG007|Overall Study|Adverse Event|0
6310545|NCT02654002|10039985|FG008|Overall Study|Adverse Event|0
6310546|NCT02654002|10039977|FG000|Overall Study|Withdrew Consent|0
6310547|NCT02654002|10039978|FG001|Overall Study|Withdrew Consent|0
6310548|NCT02654002|10039979|FG002|Overall Study|Withdrew Consent|0
6310549|NCT02654002|10039980|FG003|Overall Study|Withdrew Consent|0
6310550|NCT02654002|10039981|FG004|Overall Study|Withdrew Consent|0
6148443|NCT01089556|9783767|FG004|Study Period III (Weeks 9-16)|Lack of Efficacy|1
6310551|NCT02654002|10039982|FG005|Overall Study|Withdrew Consent|1
6310552|NCT02654002|10039983|FG006|Overall Study|Withdrew Consent|0
6310553|NCT02654002|10039984|FG007|Overall Study|Withdrew Consent|1
6310554|NCT02654002|10039985|FG008|Overall Study|Withdrew Consent|0
6310555|NCT02654054|10040023|FG000|Post-Treatment Follow-Up Period|Withdrawal by Subject|2
6310556|NCT02654054|10040024|FG001|Post-Treatment Follow-Up Period|Withdrawal by Subject|6
6310557|NCT02654054|10040025|FG002|Post-Treatment Follow-Up Period|Withdrawal by Subject|7
6310558|NCT02654054|10040023|FG000|Post-Treatment Follow-Up Period|Lost to Follow-up|3
6310559|NCT02654054|10040024|FG001|Post-Treatment Follow-Up Period|Lost to Follow-up|0
6310560|NCT02654054|10040025|FG002|Post-Treatment Follow-Up Period|Lost to Follow-up|13
6310561|NCT02654054|10040023|FG000|Post-Treatment Follow-Up Period|Required Surgery/Invasive Intervention|2
6310562|NCT02654054|10040024|FG001|Post-Treatment Follow-Up Period|Required Surgery/Invasive Intervention|2
6310563|NCT02654054|10040025|FG002|Post-Treatment Follow-Up Period|Required Surgery/Invasive Intervention|2
6310564|NCT02654054|10040023|FG000|Post-Treatment Follow-Up Period|Other|1
6310565|NCT02654054|10040024|FG001|Post-Treatment Follow-Up Period|Other|0
6310566|NCT02654054|10040025|FG002|Post-Treatment Follow-Up Period|Other|4
6310567|NCT02654054|10040023|FG000|Post-Treatment Follow-Up Period|Non-Compliance|0
6310568|NCT02654054|10040024|FG001|Post-Treatment Follow-Up Period|Non-Compliance|0
6310569|NCT02654054|10040025|FG002|Post-Treatment Follow-Up Period|Non-Compliance|4
6310570|NCT02654145|10040034|FG000|Overall Study|Lack of Efficacy|1
6310571|NCT02654145|10040034|FG000|Overall Study|Protocol Violation|1
6310572|NCT02654145|10040034|FG000|Overall Study|Withdrawal by Subject|5
6310573|NCT02654717|10040068|FG000|Overall Study|Adverse Event|2
6310574|NCT02654717|10040069|FG001|Overall Study|Adverse Event|2
6310575|NCT02654717|10040068|FG000|Overall Study|Protocol Violation|1
6310576|NCT02654717|10040069|FG001|Overall Study|Protocol Violation|2
6310577|NCT02654717|10040068|FG000|Overall Study|Withdrawal by Subject|0
6310578|NCT02654717|10040069|FG001|Overall Study|Withdrawal by Subject|1
6310579|NCT02654717|10040068|FG000|Overall Study|Non-permitted medication|3
6310580|NCT02654717|10040069|FG001|Overall Study|Non-permitted medication|0
6310581|NCT02654977|10040126|FG000|Overall Study|Death|1
6310582|NCT02654977|10040126|FG000|Overall Study|Lost to Follow-up|1
6310583|NCT02654977|10040126|FG000|Overall Study|Adverse Event|1
6310584|NCT02654977|10040126|FG000|Overall Study|Withdrawal by Subject|1
6310585|NCT02654977|10040126|FG000|Overall Study|Lack of Efficacy|3
6310586|NCT02655224|10040132|FG000|Overall Study|Adverse Event|1
6310587|NCT02655224|10040133|FG001|Overall Study|Adverse Event|1
6310588|NCT02655237|10040141|FG000|Overall Study|Adverse Event|10
6310589|NCT02655237|10040142|FG001|Overall Study|Adverse Event|7
6310590|NCT02655237|10040141|FG000|Overall Study|Protocol Deviation|2
6310591|NCT02655237|10040142|FG001|Overall Study|Protocol Deviation|0
6310592|NCT02655237|10040141|FG000|Overall Study|Withdrawal by Participant|1
6310593|NCT02655237|10040142|FG001|Overall Study|Withdrawal by Participant|2
6310594|NCT02655237|10040141|FG000|Overall Study|Lack of Efficacy|0
6310595|NCT02655237|10040142|FG001|Overall Study|Lack of Efficacy|1
6310596|NCT02655237|10040141|FG000|Overall Study|Recovery Leading to Surgery|2
6310597|NCT02655237|10040142|FG001|Overall Study|Recovery Leading to Surgery|1
6310598|NCT02655237|10040141|FG000|Overall Study|Reduction of Hemoglobin Concentration|1
6310599|NCT02655237|10040142|FG001|Overall Study|Reduction of Hemoglobin Concentration|0
6310600|NCT02655237|10040141|FG000|Overall Study|Randomized but Not Treated|1
6310601|NCT02655237|10040142|FG001|Overall Study|Randomized but Not Treated|0
6310602|NCT02655419|10040159|FG000|Overall Study|Enrolled but not treated|1
6310603|NCT02655419|10040160|FG001|Overall Study|Enrolled but not treated|5
6310604|NCT02655419|10040159|FG000|Overall Study|Withdrawal by Subject|4
6310605|NCT02655419|10040160|FG001|Overall Study|Withdrawal by Subject|1
6310606|NCT02655419|10040159|FG000|Overall Study|Other|0
6310607|NCT02655419|10040160|FG001|Overall Study|Other|1
6310608|NCT02655666|10040198|FG000|Overall Study|Sponsor stopped this clinical research.|12
6310609|NCT02655679|10040207|FG000|Overall Study|Adverse Event|0
6310610|NCT02655679|10040208|FG001|Overall Study|Adverse Event|1
6310611|NCT02655679|10040209|FG002|Overall Study|Adverse Event|0
6310612|NCT02655679|10040210|FG003|Overall Study|Adverse Event|0
6310613|NCT02655679|10040211|FG004|Overall Study|Adverse Event|0
6310614|NCT02655679|10040207|FG000|Overall Study|Withdrawal by Subject|1
6310615|NCT02655679|10040208|FG001|Overall Study|Withdrawal by Subject|1
6310616|NCT02655679|10040209|FG002|Overall Study|Withdrawal by Subject|0
6310617|NCT02655679|10040210|FG003|Overall Study|Withdrawal by Subject|3
6310618|NCT02655679|10040211|FG004|Overall Study|Withdrawal by Subject|1
6310619|NCT02655679|10040207|FG000|Overall Study|Inability to Comply with the Protocol|1
6310620|NCT02655679|10040208|FG001|Overall Study|Inability to Comply with the Protocol|0
6310621|NCT02655679|10040209|FG002|Overall Study|Inability to Comply with the Protocol|0
6310622|NCT02655679|10040210|FG003|Overall Study|Inability to Comply with the Protocol|0
6310623|NCT02655679|10040211|FG004|Overall Study|Inability to Comply with the Protocol|0
6310624|NCT02655679|10040207|FG000|Overall Study|Lost to Follow-up|0
6310625|NCT02655679|10040208|FG001|Overall Study|Lost to Follow-up|1
6310626|NCT02655679|10040209|FG002|Overall Study|Lost to Follow-up|1
6310627|NCT02655679|10040210|FG003|Overall Study|Lost to Follow-up|1
6310628|NCT02655679|10040211|FG004|Overall Study|Lost to Follow-up|0
6310629|NCT02655679|10040207|FG000|Overall Study|Other Miscellaneous Reasons|1
6310630|NCT02655679|10040208|FG001|Overall Study|Other Miscellaneous Reasons|0
6310631|NCT02655679|10040209|FG002|Overall Study|Other Miscellaneous Reasons|0
6310632|NCT02655679|10040210|FG003|Overall Study|Other Miscellaneous Reasons|0
6310633|NCT02655679|10040211|FG004|Overall Study|Other Miscellaneous Reasons|0
6310634|NCT02655887|10040224|FG000|Overall Study|Lost to Follow-up|3
6310635|NCT02655887|10040224|FG000|Overall Study|Death|4
6310636|NCT02655887|10040224|FG000|Overall Study|Withdrawal by Subject|3
6310637|NCT02655887|10040224|FG000|Overall Study|Missed 12-month follow-up visit|4
6310638|NCT02656173|10040246|FG000|Overall Study|Deviation from the Eligible Criteria|3
6310639|NCT02656173|10040247|FG001|Overall Study|Deviation from the Eligible Criteria|2
6310640|NCT02656173|10040246|FG000|Overall Study|Adverse Event|7
6310641|NCT02656173|10040247|FG001|Overall Study|Adverse Event|5
6310642|NCT02656173|10040246|FG000|Overall Study|Withdrawal by Subject|1
6310643|NCT02656173|10040247|FG001|Overall Study|Withdrawal by Subject|3
6310644|NCT02656173|10040246|FG000|Overall Study|Protocol Violation|0
6310645|NCT02656173|10040247|FG001|Overall Study|Protocol Violation|1
6310646|NCT02656173|10040246|FG000|Overall Study|Miscellaneous|2
6310647|NCT02656173|10040247|FG001|Overall Study|Miscellaneous|0
6310648|NCT02656329|10040257|FG000|Overall Study|Lost to Follow-up|2
6310649|NCT02656329|10040258|FG001|Overall Study|Lost to Follow-up|3
6310650|NCT02656329|10040257|FG000|Overall Study|Withdrawal by Subject|7
6310651|NCT02656329|10040258|FG001|Overall Study|Withdrawal by Subject|6
6310652|NCT02656329|10040257|FG000|Overall Study|Study termination by Sponsor|150
6310653|NCT02656329|10040258|FG001|Overall Study|Study termination by Sponsor|142
6310654|NCT02656329|10040257|FG000|Overall Study|Other than specified above|5
6310655|NCT02656329|10040258|FG001|Overall Study|Other than specified above|6
6310656|NCT02656680|10040305|FG000|Overall Study|Lost to Follow-up|0
6310657|NCT02656680|10040306|FG001|Overall Study|Lost to Follow-up|1
6310658|NCT02656693|10040317|FG000|Overall Study|Pregnancy|1
6310659|NCT02656693|10040318|FG001|Overall Study|Pregnancy|1
6310660|NCT02656693|10040319|FG002|Overall Study|Pregnancy|1
6310661|NCT02656693|10040317|FG000|Overall Study|Bariatric surgery|0
6310662|NCT02656693|10040318|FG001|Overall Study|Bariatric surgery|1
6310663|NCT02656693|10040319|FG002|Overall Study|Bariatric surgery|2
6310664|NCT02657031|10040344|FG000|Overall Study|Adverse Event|1
6310665|NCT02657031|10040345|FG001|Overall Study|Adverse Event|2
6310666|NCT02657369|10040367|FG000|Overall Study|Death|27
6310667|NCT02657369|10040367|FG000|Overall Study|Study terminated by sponsor|7
6310668|NCT02657408|10040373|FG000|Overall Study|Adverse Event|3
6310669|NCT02657408|10040374|FG001|Overall Study|Adverse Event|7
6310670|NCT02657889|10040405|FG000|Overall Study|Death|5
6310671|NCT02657889|10040406|FG001|Overall Study|Death|2
6310672|NCT02657889|10040407|FG002|Overall Study|Death|20
6310673|NCT02657889|10040408|FG003|Overall Study|Death|34
6310674|NCT02657889|10040405|FG000|Overall Study|Lost to Follow-up|2
6310675|NCT02657889|10040406|FG001|Overall Study|Lost to Follow-up|0
6310676|NCT02657889|10040407|FG002|Overall Study|Lost to Follow-up|1
6310677|NCT02657889|10040408|FG003|Overall Study|Lost to Follow-up|2
6310678|NCT02657889|10040405|FG000|Overall Study|Withdrawal by Subject|0
6310679|NCT02657889|10040406|FG001|Overall Study|Withdrawal by Subject|0
6310680|NCT02657889|10040407|FG002|Overall Study|Withdrawal by Subject|8
6310681|NCT02657889|10040408|FG003|Overall Study|Withdrawal by Subject|0
6310682|NCT02657889|10040405|FG000|Overall Study|Ongoing in Study|0
6148444|NCT01089556|9783768|FG005|Study Period III (Weeks 9-16)|Lack of Efficacy|0
6148445|NCT01089556|9783763|FG000|Study Period III (Weeks 9-16)|Lost to Follow-up|0
6148446|NCT01089556|9783764|FG001|Study Period III (Weeks 9-16)|Lost to Follow-up|0
6148447|NCT01089556|9783765|FG002|Study Period III (Weeks 9-16)|Lost to Follow-up|1
6148448|NCT01089556|9783766|FG003|Study Period III (Weeks 9-16)|Lost to Follow-up|0
6148449|NCT01089556|9783767|FG004|Study Period III (Weeks 9-16)|Lost to Follow-up|0
6148450|NCT01089556|9783768|FG005|Study Period III (Weeks 9-16)|Lost to Follow-up|0
6148451|NCT01089556|9783763|FG000|Study Period III (Weeks 9-16)|Protocol Violation|0
6148452|NCT01089556|9783764|FG001|Study Period III (Weeks 9-16)|Protocol Violation|0
6148453|NCT01089556|9783765|FG002|Study Period III (Weeks 9-16)|Protocol Violation|1
6148454|NCT01089556|9783766|FG003|Study Period III (Weeks 9-16)|Protocol Violation|1
6148455|NCT01089556|9783767|FG004|Study Period III (Weeks 9-16)|Protocol Violation|1
6148456|NCT01089556|9783768|FG005|Study Period III (Weeks 9-16)|Protocol Violation|0
6148457|NCT01089556|9783763|FG000|Study Period III (Weeks 9-16)|Satisfactory Response|0
6148458|NCT01089556|9783764|FG001|Study Period III (Weeks 9-16)|Satisfactory Response|0
6148459|NCT01089556|9783765|FG002|Study Period III (Weeks 9-16)|Satisfactory Response|4
6148460|NCT01089556|9783766|FG003|Study Period III (Weeks 9-16)|Satisfactory Response|3
6148461|NCT01089556|9783767|FG004|Study Period III (Weeks 9-16)|Satisfactory Response|4
6148462|NCT01089556|9783768|FG005|Study Period III (Weeks 9-16)|Satisfactory Response|1
6148463|NCT01089556|9783763|FG000|Study Period III (Weeks 9-16)|Withdrawal by Subject|0
6148464|NCT01089556|9783764|FG001|Study Period III (Weeks 9-16)|Withdrawal by Subject|0
6148465|NCT01089556|9783765|FG002|Study Period III (Weeks 9-16)|Withdrawal by Subject|3
6148466|NCT01089556|9783766|FG003|Study Period III (Weeks 9-16)|Withdrawal by Subject|0
6148467|NCT01089556|9783767|FG004|Study Period III (Weeks 9-16)|Withdrawal by Subject|1
6148468|NCT01089556|9783768|FG005|Study Period III (Weeks 9-16)|Withdrawal by Subject|2
6148469|NCT01089582|9783793|FG000|Overall Study|Death|2
6148470|NCT01089582|9783793|FG000|Overall Study|Adverse Event|15
6148471|NCT01089582|9783793|FG000|Overall Study|Lost to Follow-up|8
6148472|NCT01089582|9783793|FG000|Overall Study|Other|4
6148473|NCT01089582|9783793|FG000|Overall Study|Withdrawal by Subject|1
6148474|NCT01089608|9783810|FG000|Overall Study|Adverse Event|0
6148475|NCT01089608|9783811|FG001|Overall Study|Adverse Event|4
6148476|NCT01089608|9783810|FG000|Overall Study|Lost to Follow-up|0
6148477|NCT01089608|9783811|FG001|Overall Study|Lost to Follow-up|2
6148478|NCT01089647|9783819|FG000|Overall Study|Lost to Follow-up|2
6148479|NCT01089647|9783820|FG001|Overall Study|Lost to Follow-up|2
6148480|NCT01089647|9783819|FG000|Overall Study|Withdrawal by Subject|2
6148481|NCT01089647|9783820|FG001|Overall Study|Withdrawal by Subject|1
6148482|NCT01089647|9783819|FG000|Overall Study|Adverse Event|0
6148483|NCT01089647|9783820|FG001|Overall Study|Adverse Event|1
6148484|NCT01089725|9783831|FG000|Overall Study|Adverse Event|1
6148485|NCT01089725|9783832|FG001|Overall Study|Adverse Event|1
6148486|NCT01089725|9783833|FG002|Overall Study|Adverse Event|0
6148487|NCT01089725|9783834|FG003|Overall Study|Adverse Event|0
6148488|NCT01089725|9783835|FG004|Overall Study|Adverse Event|2
6148489|NCT01089725|9783831|FG000|Overall Study|Lack of Efficacy|4
6310683|NCT02657889|10040406|FG001|Overall Study|Ongoing in Study|5
6310684|NCT02657889|10040407|FG002|Overall Study|Ongoing in Study|24
6310685|NCT02657889|10040408|FG003|Overall Study|Ongoing in Study|19
6310686|NCT02658019|10040439|FG000|Overall Study|Adverse Event|1
6310687|NCT02658084|10040445|FG000|Overall Study|Withdrawal by Subject|1
6148490|NCT01089725|9783832|FG001|Overall Study|Lack of Efficacy|3
6148491|NCT01089725|9783833|FG002|Overall Study|Lack of Efficacy|1
6310688|NCT02658084|10040446|FG001|Overall Study|Withdrawal by Subject|0
6310689|NCT02658084|10040445|FG000|Overall Study|Study Termination|1
6310690|NCT02658084|10040446|FG001|Overall Study|Study Termination|0
6148492|NCT01089725|9783834|FG003|Overall Study|Lack of Efficacy|0
6148493|NCT01089725|9783835|FG004|Overall Study|Lack of Efficacy|4
6148494|NCT01089725|9783831|FG000|Overall Study|Lost to Follow-up|2
6148495|NCT01089725|9783832|FG001|Overall Study|Lost to Follow-up|2
6227292|NCT01716520|9900044|FG003|Washout Period 1 (10 to 14 Days)|Withdrawal by Subject|0
6227293|NCT01716520|9900045|FG004|Washout Period 1 (10 to 14 Days)|Withdrawal by Subject|0
6310691|NCT02658149|10040453|FG000|Overall Study|Physician Decision|1
6310692|NCT02658149|10040454|FG001|Overall Study|Physician Decision|0
6310693|NCT02658175|10040463|FG000|Treatment Period: Weeks 1 to 52|Investigator Judgment|1
6310694|NCT02658175|10040464|FG001|Treatment Period: Weeks 1 to 52|Investigator Judgment|0
6310695|NCT02658175|10040465|FG002|Treatment Period: Weeks 1 to 52|Investigator Judgment|0
6310696|NCT02658175|10040463|FG000|Treatment Period: Weeks 1 to 52|Voluntary Withdrawal|6
6310697|NCT02658175|10040464|FG001|Treatment Period: Weeks 1 to 52|Voluntary Withdrawal|2
6310698|NCT02658175|10040465|FG002|Treatment Period: Weeks 1 to 52|Voluntary Withdrawal|0
6310699|NCT02658175|10040463|FG000|Treatment Period: Weeks 1 to 52|Adverse Event or Serious Adverse Event (SAE)|8
6310700|NCT02658175|10040464|FG001|Treatment Period: Weeks 1 to 52|Adverse Event or Serious Adverse Event (SAE)|5
6310701|NCT02658175|10040465|FG002|Treatment Period: Weeks 1 to 52|Adverse Event or Serious Adverse Event (SAE)|0
6310702|NCT02658175|10040463|FG000|1st Extended Treatment: Weeks 53 to 104|Investigator Judgment|1
6310703|NCT02658175|10040464|FG001|1st Extended Treatment: Weeks 53 to 104|Investigator Judgment|0
6310704|NCT02658175|10040465|FG002|1st Extended Treatment: Weeks 53 to 104|Investigator Judgment|0
6310705|NCT02658175|10040463|FG000|1st Extended Treatment: Weeks 53 to 104|Voluntary Withdrawal|4
6310706|NCT02658175|10040464|FG001|1st Extended Treatment: Weeks 53 to 104|Voluntary Withdrawal|0
6310707|NCT02658175|10040465|FG002|1st Extended Treatment: Weeks 53 to 104|Voluntary Withdrawal|1
6310708|NCT02658175|10040463|FG000|1st Extended Treatment: Weeks 53 to 104|Adverse Event or SAE|7
6310709|NCT02658175|10040464|FG001|1st Extended Treatment: Weeks 53 to 104|Adverse Event or SAE|0
6310710|NCT02658175|10040465|FG002|1st Extended Treatment: Weeks 53 to 104|Adverse Event or SAE|0
6310711|NCT02658175|10040463|FG000|1st Extended Treatment: Weeks 53 to 104|Other|1
6310712|NCT02658175|10040464|FG001|1st Extended Treatment: Weeks 53 to 104|Other|0
6310713|NCT02658175|10040465|FG002|1st Extended Treatment: Weeks 53 to 104|Other|1
6310714|NCT02658175|10040463|FG000|1st Extended Treatment: Weeks 53 to 104|Transferred to Early Access Programs|8
6310715|NCT02658175|10040464|FG001|1st Extended Treatment: Weeks 53 to 104|Transferred to Early Access Programs|2
6310716|NCT02658175|10040465|FG002|1st Extended Treatment: Weeks 53 to 104|Transferred to Early Access Programs|0
6310717|NCT02658175|10040463|FG000|2nd Extended Treatment: Weeks 105 to156|Adverse Event or SAE|0
6310718|NCT02658175|10040464|FG001|2nd Extended Treatment: Weeks 105 to156|Adverse Event or SAE|0
6310719|NCT02658175|10040465|FG002|2nd Extended Treatment: Weeks 105 to156|Adverse Event or SAE|1
6310720|NCT02658175|10040463|FG000|2nd Extended Treatment: Weeks 105 to156|Transferred to Commercial Treatment|1
6310721|NCT02658175|10040464|FG001|2nd Extended Treatment: Weeks 105 to156|Transferred to Commercial Treatment|0
6310722|NCT02658175|10040465|FG002|2nd Extended Treatment: Weeks 105 to156|Transferred to Commercial Treatment|0
6310723|NCT02658448|10040482|FG000|Overall Study|Lost to Follow-up|1
6310724|NCT02658487|10040501|FG000|Overall Study|Death|2
6310725|NCT02658487|10040501|FG000|Overall Study|Disease progression|10
6310726|NCT02658487|10040501|FG000|Overall Study|Alternative therapy|1
6310727|NCT02658487|10040501|FG000|Overall Study|Adverse Event|1
6310728|NCT02658487|10040501|FG000|Overall Study|Treatment Failure, circulating blasts|1
6310729|NCT02658487|10040501|FG000|Overall Study|Refractory AML|1
6310730|NCT02658630|10040506|FG000|Overall Study|Withdrawal by Subject|4
6148496|NCT01089725|9783833|FG002|Overall Study|Lost to Follow-up|0
6148497|NCT01089725|9783834|FG003|Overall Study|Lost to Follow-up|3
6148498|NCT01089725|9783835|FG004|Overall Study|Lost to Follow-up|0
6148499|NCT01089725|9783831|FG000|Overall Study|Protocol Violation|0
6148500|NCT01089725|9783832|FG001|Overall Study|Protocol Violation|0
6148501|NCT01089725|9783833|FG002|Overall Study|Protocol Violation|1
6148502|NCT01089725|9783834|FG003|Overall Study|Protocol Violation|1
6148503|NCT01089725|9783835|FG004|Overall Study|Protocol Violation|0
6148504|NCT01089725|9783831|FG000|Overall Study|Withdrawal by Subject|5
6148505|NCT01089725|9783832|FG001|Overall Study|Withdrawal by Subject|5
6148506|NCT01089725|9783833|FG002|Overall Study|Withdrawal by Subject|4
6148507|NCT01089725|9783834|FG003|Overall Study|Withdrawal by Subject|5
6148508|NCT01089725|9783835|FG004|Overall Study|Withdrawal by Subject|4
6148509|NCT01089725|9783831|FG000|Overall Study|Study Terminated by Sponsor|51
6148510|NCT01089725|9783832|FG001|Overall Study|Study Terminated by Sponsor|56
6148511|NCT01089725|9783833|FG002|Overall Study|Study Terminated by Sponsor|53
6148512|NCT01089725|9783834|FG003|Overall Study|Study Terminated by Sponsor|68
6148513|NCT01089725|9783835|FG004|Overall Study|Study Terminated by Sponsor|68
6148514|NCT01089725|9783831|FG000|Overall Study|Randomized, but not treated|0
6148515|NCT01089725|9783832|FG001|Overall Study|Randomized, but not treated|1
6227294|NCT01716520|9900046|FG005|Washout Period 1 (10 to 14 Days)|Withdrawal by Subject|1
6227295|NCT01716520|9900041|FG000|Treatment Period 2 (14 Days)|Adverse Event|0
6227296|NCT01716520|9900042|FG001|Treatment Period 2 (14 Days)|Adverse Event|0
6227297|NCT01716520|9900043|FG002|Treatment Period 2 (14 Days)|Adverse Event|0
6227298|NCT01716520|9900044|FG003|Treatment Period 2 (14 Days)|Adverse Event|0
6148516|NCT01089725|9783833|FG002|Overall Study|Randomized, but not treated|2
6148517|NCT01089725|9783834|FG003|Overall Study|Randomized, but not treated|1
6148518|NCT01089725|9783835|FG004|Overall Study|Randomized, but not treated|2
6310731|NCT02658734|10040510|FG000|Overall Study|Adverse Event|2
6310732|NCT02658734|10040510|FG000|Overall Study|Death|4
6310733|NCT02658734|10040510|FG000|Overall Study|Lost to Follow-up|7
6310734|NCT02658734|10040510|FG000|Overall Study|Withdrawal of Consent|16
6310735|NCT02658734|10040510|FG000|Overall Study|Disease Progression|28
6310736|NCT02659098|10040532|FG000|Overall Study|Withdrawal by Subject|7
6310737|NCT02659150|10040536|FG000|Subject Enrollment|Physician Decision|3
6310738|NCT02659150|10040536|FG000|Subject Enrollment|Withdrawal by Subject|2
6310739|NCT02659150|10040536|FG000|Baseline Imaging|Withdrawal by Subject|1
6310740|NCT02659150|10040536|FG000|Baseline Imaging|Physician Decision|1
6310741|NCT02659150|10040536|FG000|Study Drug Dosing|Adverse Event|1
6310742|NCT02659540|10040552|FG000|Overall Study|Adverse Event|3
6310743|NCT02659540|10040553|FG001|Overall Study|Adverse Event|2
6310744|NCT02659540|10040552|FG000|Overall Study|Death|1
6310745|NCT02659540|10040553|FG001|Overall Study|Death|0
6310746|NCT02659540|10040552|FG000|Overall Study|Progressive disease|2
6310747|NCT02659540|10040553|FG001|Overall Study|Progressive disease|6
6310748|NCT02659631|10040569|FG000|Overall Study|Lost to Follow-up|0
6310749|NCT02659631|10040570|FG001|Overall Study|Lost to Follow-up|0
6310750|NCT02659631|10040571|FG002|Overall Study|Lost to Follow-up|2
6310751|NCT02659631|10040572|FG003|Overall Study|Lost to Follow-up|0
6310752|NCT02659631|10040573|FG004|Overall Study|Lost to Follow-up|0
6310753|NCT02659631|10040574|FG005|Overall Study|Lost to Follow-up|1
6310754|NCT02659631|10040575|FG006|Overall Study|Lost to Follow-up|0
6310755|NCT02659631|10040576|FG007|Overall Study|Lost to Follow-up|0
6310756|NCT02659631|10040577|FG008|Overall Study|Lost to Follow-up|0
6310757|NCT02659631|10040578|FG009|Overall Study|Lost to Follow-up|0
6310758|NCT02659631|10040569|FG000|Overall Study|Withdrawal prior to treatment|0
6310759|NCT02659631|10040570|FG001|Overall Study|Withdrawal prior to treatment|0
6310760|NCT02659631|10040571|FG002|Overall Study|Withdrawal prior to treatment|0
6310761|NCT02659631|10040572|FG003|Overall Study|Withdrawal prior to treatment|0
6310762|NCT02659631|10040573|FG004|Overall Study|Withdrawal prior to treatment|1
6310763|NCT02659631|10040574|FG005|Overall Study|Withdrawal prior to treatment|0
6310764|NCT02659631|10040575|FG006|Overall Study|Withdrawal prior to treatment|0
6310765|NCT02659631|10040576|FG007|Overall Study|Withdrawal prior to treatment|0
6310766|NCT02659631|10040577|FG008|Overall Study|Withdrawal prior to treatment|0
6310767|NCT02659631|10040578|FG009|Overall Study|Withdrawal prior to treatment|0
6310768|NCT02659631|10040569|FG000|Overall Study|Participant refused further follow-up|0
6310769|NCT02659631|10040570|FG001|Overall Study|Participant refused further follow-up|0
6310770|NCT02659631|10040571|FG002|Overall Study|Participant refused further follow-up|0
6310771|NCT02659631|10040572|FG003|Overall Study|Participant refused further follow-up|1
6310772|NCT02659631|10040573|FG004|Overall Study|Participant refused further follow-up|0
6310773|NCT02659631|10040574|FG005|Overall Study|Participant refused further follow-up|0
6310774|NCT02659631|10040575|FG006|Overall Study|Participant refused further follow-up|0
6310775|NCT02659631|10040576|FG007|Overall Study|Participant refused further follow-up|0
6310776|NCT02659631|10040577|FG008|Overall Study|Participant refused further follow-up|1
6310777|NCT02659631|10040578|FG009|Overall Study|Participant refused further follow-up|0
6310778|NCT02659631|10040569|FG000|Overall Study|Death (follow-up phase)|1
6310779|NCT02659631|10040570|FG001|Overall Study|Death (follow-up phase)|2
6310780|NCT02659631|10040571|FG002|Overall Study|Death (follow-up phase)|1
6310781|NCT02659631|10040572|FG003|Overall Study|Death (follow-up phase)|1
6310782|NCT02659631|10040573|FG004|Overall Study|Death (follow-up phase)|3
6310783|NCT02659631|10040574|FG005|Overall Study|Death (follow-up phase)|2
6310784|NCT02659631|10040575|FG006|Overall Study|Death (follow-up phase)|0
6310785|NCT02659631|10040576|FG007|Overall Study|Death (follow-up phase)|3
6310786|NCT02659631|10040577|FG008|Overall Study|Death (follow-up phase)|1
6310787|NCT02659631|10040578|FG009|Overall Study|Death (follow-up phase)|0
6310788|NCT02659631|10040569|FG000|Overall Study|Death (treatment phase)|0
6310789|NCT02659631|10040570|FG001|Overall Study|Death (treatment phase)|0
6310790|NCT02659631|10040571|FG002|Overall Study|Death (treatment phase)|0
6310791|NCT02659631|10040572|FG003|Overall Study|Death (treatment phase)|0
6310792|NCT02659631|10040573|FG004|Overall Study|Death (treatment phase)|1
6310793|NCT02659631|10040574|FG005|Overall Study|Death (treatment phase)|0
6310794|NCT02659631|10040575|FG006|Overall Study|Death (treatment phase)|1
6310795|NCT02659631|10040576|FG007|Overall Study|Death (treatment phase)|0
6310796|NCT02659631|10040577|FG008|Overall Study|Death (treatment phase)|0
6310797|NCT02659631|10040578|FG009|Overall Study|Death (treatment phase)|0
6310798|NCT02659943|10040620|FG000|Overall Study|Switched to alternative treatment|1
6310799|NCT02659943|10040621|FG001|Overall Study|Switched to alternative treatment|1
6310800|NCT02659943|10040622|FG002|Overall Study|Switched to alternative treatment|0
6310801|NCT02659943|10040623|FG003|Overall Study|Switched to alternative treatment|2
6310802|NCT02659943|10040624|FG004|Overall Study|Switched to alternative treatment|1
6310803|NCT02659943|10040625|FG005|Overall Study|Switched to alternative treatment|0
6310804|NCT02659943|10040626|FG006|Overall Study|Switched to alternative treatment|1
6310805|NCT02659943|10040620|FG000|Overall Study|Disease progression on study|0
6310806|NCT02659943|10040621|FG001|Overall Study|Disease progression on study|1
6310807|NCT02659943|10040622|FG002|Overall Study|Disease progression on study|1
6310808|NCT02659943|10040623|FG003|Overall Study|Disease progression on study|1
6310809|NCT02659943|10040624|FG004|Overall Study|Disease progression on study|1
6310810|NCT02659943|10040625|FG005|Overall Study|Disease progression on study|4
6310811|NCT02659943|10040626|FG006|Overall Study|Disease progression on study|0
6310812|NCT02659943|10040620|FG000|Overall Study|Patient's condition per principal investigator|0
6310813|NCT02659943|10040621|FG001|Overall Study|Patient's condition per principal investigator|0
6310814|NCT02659943|10040622|FG002|Overall Study|Patient's condition per principal investigator|0
6310815|NCT02659943|10040623|FG003|Overall Study|Patient's condition per principal investigator|0
6310816|NCT02659943|10040624|FG004|Overall Study|Patient's condition per principal investigator|0
6310817|NCT02659943|10040625|FG005|Overall Study|Patient's condition per principal investigator|1
6310818|NCT02659943|10040626|FG006|Overall Study|Patient's condition per principal investigator|0
6310819|NCT02659943|10040620|FG000|Overall Study|Ineligible|0
6310820|NCT02659943|10040621|FG001|Overall Study|Ineligible|0
6310821|NCT02659943|10040622|FG002|Overall Study|Ineligible|0
6310822|NCT02659943|10040623|FG003|Overall Study|Ineligible|0
6310823|NCT02659943|10040624|FG004|Overall Study|Ineligible|0
6310824|NCT02659943|10040625|FG005|Overall Study|Ineligible|0
6310825|NCT02659943|10040626|FG006|Overall Study|Ineligible|1
6310826|NCT02659943|10040620|FG000|Overall Study|No longer meets eligibility|0
6310827|NCT02659943|10040621|FG001|Overall Study|No longer meets eligibility|0
6310828|NCT02659943|10040622|FG002|Overall Study|No longer meets eligibility|0
6310829|NCT02659943|10040623|FG003|Overall Study|No longer meets eligibility|0
6310830|NCT02659943|10040624|FG004|Overall Study|No longer meets eligibility|0
6310831|NCT02659943|10040625|FG005|Overall Study|No longer meets eligibility|0
6310832|NCT02659943|10040626|FG006|Overall Study|No longer meets eligibility|1
6310833|NCT02659943|10040620|FG000|Overall Study|No treatment, per protocol|0
6310834|NCT02659943|10040621|FG001|Overall Study|No treatment, per protocol|0
6310835|NCT02659943|10040622|FG002|Overall Study|No treatment, per protocol|0
6310836|NCT02659943|10040623|FG003|Overall Study|No treatment, per protocol|0
6310837|NCT02659943|10040624|FG004|Overall Study|No treatment, per protocol|0
6310838|NCT02659943|10040625|FG005|Overall Study|No treatment, per protocol|0
6310839|NCT02659943|10040626|FG006|Overall Study|No treatment, per protocol|3
6310840|NCT02660138|10040654|FG000|Overall Study|Adverse Event|0
6310841|NCT02660138|10040655|FG001|Overall Study|Adverse Event|3
6310842|NCT02660138|10040656|FG002|Overall Study|Adverse Event|2
6310843|NCT02660138|10040654|FG000|Overall Study|Lack of Efficacy|1
6310844|NCT02660138|10040655|FG001|Overall Study|Lack of Efficacy|2
6310845|NCT02660138|10040656|FG002|Overall Study|Lack of Efficacy|1
6310846|NCT02660138|10040654|FG000|Overall Study|Withdrawal by Subject|7
6310847|NCT02660138|10040655|FG001|Overall Study|Withdrawal by Subject|6
6310848|NCT02660138|10040656|FG002|Overall Study|Withdrawal by Subject|6
6310849|NCT02660138|10040654|FG000|Overall Study|Lost to Follow-up|4
6310850|NCT02660138|10040655|FG001|Overall Study|Lost to Follow-up|4
6310851|NCT02660138|10040656|FG002|Overall Study|Lost to Follow-up|1
6310852|NCT02660138|10040654|FG000|Overall Study|Sponsor Decision to Terminate Study|57
6310853|NCT02660138|10040655|FG001|Overall Study|Sponsor Decision to Terminate Study|57
6310854|NCT02660138|10040656|FG002|Overall Study|Sponsor Decision to Terminate Study|62
6310855|NCT02660138|10040654|FG000|Overall Study|Other|1
6310856|NCT02660138|10040655|FG001|Overall Study|Other|1
6310857|NCT02660138|10040656|FG002|Overall Study|Other|0
6310858|NCT02660138|10040654|FG000|Overall Study|Not treated|0
6310859|NCT02660138|10040655|FG001|Overall Study|Not treated|1
6310860|NCT02660138|10040656|FG002|Overall Study|Not treated|0
6310861|NCT02660229|10040669|FG000|Overall Study|Adverse Event|2
6310862|NCT02660229|10040670|FG001|Overall Study|Adverse Event|0
6310863|NCT02660229|10040669|FG000|Overall Study|Withdrawal by Subject|0
6310864|NCT02660229|10040670|FG001|Overall Study|Withdrawal by Subject|1
6310865|NCT02660242|10040676|FG000|Glucose Tabs|Lost to Follow-up|1
6310866|NCT02660242|10040676|FG000|Glucagon Injection|Lost to Follow-up|1
6310867|NCT02660359|10040692|FG000|Overall Study|Protocol Deviation|0
6310868|NCT02660359|10040693|FG001|Overall Study|Protocol Deviation|0
6310869|NCT02660359|10040694|FG002|Overall Study|Protocol Deviation|1
6310870|NCT02660359|10040692|FG000|Overall Study|Sponsor Decision to Terminate Study|73
6310871|NCT02660359|10040693|FG001|Overall Study|Sponsor Decision to Terminate Study|75
6310872|NCT02660359|10040694|FG002|Overall Study|Sponsor Decision to Terminate Study|71
6310873|NCT02660359|10040692|FG000|Overall Study|Lack of Efficacy|1
6310874|NCT02660359|10040693|FG001|Overall Study|Lack of Efficacy|1
6310875|NCT02660359|10040694|FG002|Overall Study|Lack of Efficacy|1
6310876|NCT02660359|10040692|FG000|Overall Study|Adverse Event|0
6310877|NCT02660359|10040693|FG001|Overall Study|Adverse Event|1
6310878|NCT02660359|10040694|FG002|Overall Study|Adverse Event|0
6310879|NCT02660359|10040692|FG000|Overall Study|Other|2
6310880|NCT02660359|10040693|FG001|Overall Study|Other|1
6310881|NCT02660359|10040694|FG002|Overall Study|Other|3
6310882|NCT02660359|10040692|FG000|Overall Study|Withdrawal by Subject|7
6310883|NCT02660359|10040693|FG001|Overall Study|Withdrawal by Subject|5
6310884|NCT02660359|10040694|FG002|Overall Study|Withdrawal by Subject|8
6310885|NCT02660359|10040692|FG000|Overall Study|Lost to Follow-up|3
6310886|NCT02660359|10040693|FG001|Overall Study|Lost to Follow-up|3
6310887|NCT02660359|10040694|FG002|Overall Study|Lost to Follow-up|0
6310888|NCT02660489|10040704|FG000|Overall Study|Lost to Follow-up|1
6310889|NCT02660489|10040705|FG001|Overall Study|Lost to Follow-up|1
6310890|NCT02660489|10040704|FG000|Overall Study|Adverse Event|1
6310891|NCT02660489|10040705|FG001|Overall Study|Adverse Event|3
6310892|NCT02660489|10040704|FG000|Overall Study|no rhinovirus infection|4
6310893|NCT02660489|10040705|FG001|Overall Study|no rhinovirus infection|4
6310894|NCT02660580|10040713|FG000|Core Treatment Period (Week 1 to 16)|Randomized, not treated|1
6310895|NCT02660580|10040714|FG001|Core Treatment Period (Week 1 to 16)|Randomized, not treated|1
6310896|NCT02660580|10040715|FG002|Core Treatment Period (Week 1 to 16)|Randomized, not treated|0
6310897|NCT02660580|10040716|FG003|Core Treatment Period (Week 1 to 16)|Randomized, not treated|0
6310898|NCT02660580|10040717|FG004|Core Treatment Period (Week 1 to 16)|Randomized, not treated|0
6310899|NCT02660580|10040713|FG000|Core Treatment Period (Week 1 to 16)|Protocol Violation|3
6310900|NCT02660580|10040714|FG001|Core Treatment Period (Week 1 to 16)|Protocol Violation|1
6310901|NCT02660580|10040715|FG002|Core Treatment Period (Week 1 to 16)|Protocol Violation|0
6310902|NCT02660580|10040716|FG003|Core Treatment Period (Week 1 to 16)|Protocol Violation|0
6310903|NCT02660580|10040717|FG004|Core Treatment Period (Week 1 to 16)|Protocol Violation|0
6310904|NCT02660580|10040713|FG000|Core Treatment Period (Week 1 to 16)|Other un-specified|1
6310905|NCT02660580|10040714|FG001|Core Treatment Period (Week 1 to 16)|Other un-specified|0
6310906|NCT02660580|10040715|FG002|Core Treatment Period (Week 1 to 16)|Other un-specified|0
6310907|NCT02660580|10040716|FG003|Core Treatment Period (Week 1 to 16)|Other un-specified|0
6310908|NCT02660580|10040717|FG004|Core Treatment Period (Week 1 to 16)|Other un-specified|0
6310909|NCT02660580|10040713|FG000|Core Treatment Period (Week 1 to 16)|Lack of Efficacy|0
6310910|NCT02660580|10040714|FG001|Core Treatment Period (Week 1 to 16)|Lack of Efficacy|2
6310911|NCT02660580|10040715|FG002|Core Treatment Period (Week 1 to 16)|Lack of Efficacy|0
6310912|NCT02660580|10040716|FG003|Core Treatment Period (Week 1 to 16)|Lack of Efficacy|0
6310913|NCT02660580|10040717|FG004|Core Treatment Period (Week 1 to 16)|Lack of Efficacy|0
6310914|NCT02660580|10040713|FG000|Core Treatment Period (Week 1 to 16)|Adverse Event|2
6310915|NCT02660580|10040714|FG001|Core Treatment Period (Week 1 to 16)|Adverse Event|9
6310916|NCT02660580|10040715|FG002|Core Treatment Period (Week 1 to 16)|Adverse Event|0
6310917|NCT02660580|10040716|FG003|Core Treatment Period (Week 1 to 16)|Adverse Event|0
6310918|NCT02660580|10040717|FG004|Core Treatment Period (Week 1 to 16)|Adverse Event|0
6310919|NCT02660580|10040713|FG000|Core Treatment Period (Week 1 to 16)|Withdrawal by Subject|1
6310920|NCT02660580|10040714|FG001|Core Treatment Period (Week 1 to 16)|Withdrawal by Subject|4
6310921|NCT02660580|10040715|FG002|Core Treatment Period (Week 1 to 16)|Withdrawal by Subject|0
6310922|NCT02660580|10040716|FG003|Core Treatment Period (Week 1 to 16)|Withdrawal by Subject|0
6310923|NCT02660580|10040717|FG004|Core Treatment Period (Week 1 to 16)|Withdrawal by Subject|0
6310924|NCT02660580|10040713|FG000|Core Treatment Period (Week 1 to 16)|Lost to Follow-up|1
6310925|NCT02660580|10040714|FG001|Core Treatment Period (Week 1 to 16)|Lost to Follow-up|2
6310926|NCT02660580|10040715|FG002|Core Treatment Period (Week 1 to 16)|Lost to Follow-up|0
6310927|NCT02660580|10040716|FG003|Core Treatment Period (Week 1 to 16)|Lost to Follow-up|0
6310928|NCT02660580|10040717|FG004|Core Treatment Period (Week 1 to 16)|Lost to Follow-up|0
6310929|NCT02660580|10040713|FG000|Extended Treatment Period(Week 16 to 52)|Protocol Violation|0
6310930|NCT02660580|10040714|FG001|Extended Treatment Period(Week 16 to 52)|Protocol Violation|0
6310931|NCT02660580|10040715|FG002|Extended Treatment Period(Week 16 to 52)|Protocol Violation|2
6310932|NCT02660580|10040716|FG003|Extended Treatment Period(Week 16 to 52)|Protocol Violation|0
6310933|NCT02660580|10040717|FG004|Extended Treatment Period(Week 16 to 52)|Protocol Violation|1
6310934|NCT02660580|10040713|FG000|Extended Treatment Period(Week 16 to 52)|Other un-specified|0
6310935|NCT02660580|10040714|FG001|Extended Treatment Period(Week 16 to 52)|Other un-specified|0
6310936|NCT02660580|10040715|FG002|Extended Treatment Period(Week 16 to 52)|Other un-specified|1
6310937|NCT02660580|10040716|FG003|Extended Treatment Period(Week 16 to 52)|Other un-specified|0
6310938|NCT02660580|10040717|FG004|Extended Treatment Period(Week 16 to 52)|Other un-specified|1
6310939|NCT02660580|10040713|FG000|Extended Treatment Period(Week 16 to 52)|Lack of Efficacy|0
6310940|NCT02660580|10040714|FG001|Extended Treatment Period(Week 16 to 52)|Lack of Efficacy|0
6310941|NCT02660580|10040715|FG002|Extended Treatment Period(Week 16 to 52)|Lack of Efficacy|4
6310942|NCT02660580|10040716|FG003|Extended Treatment Period(Week 16 to 52)|Lack of Efficacy|2
6310943|NCT02660580|10040717|FG004|Extended Treatment Period(Week 16 to 52)|Lack of Efficacy|2
6310944|NCT02660580|10040713|FG000|Extended Treatment Period(Week 16 to 52)|Adverse Event|0
6310945|NCT02660580|10040714|FG001|Extended Treatment Period(Week 16 to 52)|Adverse Event|0
6310946|NCT02660580|10040715|FG002|Extended Treatment Period(Week 16 to 52)|Adverse Event|8
6310947|NCT02660580|10040716|FG003|Extended Treatment Period(Week 16 to 52)|Adverse Event|6
6310948|NCT02660580|10040717|FG004|Extended Treatment Period(Week 16 to 52)|Adverse Event|4
6310949|NCT02660580|10040713|FG000|Extended Treatment Period(Week 16 to 52)|Withdrawal by Subject|0
6310950|NCT02660580|10040714|FG001|Extended Treatment Period(Week 16 to 52)|Withdrawal by Subject|0
6310951|NCT02660580|10040715|FG002|Extended Treatment Period(Week 16 to 52)|Withdrawal by Subject|3
6310952|NCT02660580|10040716|FG003|Extended Treatment Period(Week 16 to 52)|Withdrawal by Subject|2
6310953|NCT02660580|10040717|FG004|Extended Treatment Period(Week 16 to 52)|Withdrawal by Subject|2
6310954|NCT02660580|10040713|FG000|Extended Treatment Period(Week 16 to 52)|Lost to Follow-up|0
6310955|NCT02660580|10040714|FG001|Extended Treatment Period(Week 16 to 52)|Lost to Follow-up|0
6310956|NCT02660580|10040715|FG002|Extended Treatment Period(Week 16 to 52)|Lost to Follow-up|0
6310957|NCT02660580|10040716|FG003|Extended Treatment Period(Week 16 to 52)|Lost to Follow-up|1
6310958|NCT02660580|10040717|FG004|Extended Treatment Period(Week 16 to 52)|Lost to Follow-up|1
6310959|NCT02660944|10040768|FG000|Overall Study|Adverse Event|3
6310960|NCT02660944|10040769|FG001|Overall Study|Adverse Event|4
6310961|NCT02660944|10040768|FG000|Overall Study|Physician Decision|3
6310962|NCT02660944|10040769|FG001|Overall Study|Physician Decision|1
6310963|NCT02660944|10040768|FG000|Overall Study|Withdrawal by Subject|5
6310964|NCT02660944|10040769|FG001|Overall Study|Withdrawal by Subject|3
6310965|NCT02660944|10040768|FG000|Overall Study|Lost to Follow-up|4
6310966|NCT02660944|10040769|FG001|Overall Study|Lost to Follow-up|1
6310967|NCT02660944|10040768|FG000|Overall Study|Subject schedule|0
6310968|NCT02660944|10040769|FG001|Overall Study|Subject schedule|1
6310969|NCT02660944|10040768|FG000|Overall Study|Exclusion criteria met|2
6310970|NCT02660944|10040769|FG001|Overall Study|Exclusion criteria met|0
6310971|NCT02660983|10040777|FG000|Double-blind (DB) Phase (24 Weeks)|Protocol Violation|1
6310972|NCT02660983|10040778|FG001|Double-blind (DB) Phase (24 Weeks)|Protocol Violation|5
6310973|NCT02660983|10040777|FG000|Double-blind (DB) Phase (24 Weeks)|Withdrawal by Subject|15
6310974|NCT02660983|10040778|FG001|Double-blind (DB) Phase (24 Weeks)|Withdrawal by Subject|12
6310975|NCT02660983|10040777|FG000|Double-blind (DB) Phase (24 Weeks)|Adverse Event|8
6310976|NCT02660983|10040778|FG001|Double-blind (DB) Phase (24 Weeks)|Adverse Event|9
6310977|NCT02660983|10040777|FG000|Open Label Extension Phase (24 Weeks)|Protocol Violation|1
6310978|NCT02660983|10040778|FG001|Open Label Extension Phase (24 Weeks)|Protocol Violation|1
6310979|NCT02660983|10040777|FG000|Open Label Extension Phase (24 Weeks)|Withdrawal by Subject|1
6310980|NCT02660983|10040778|FG001|Open Label Extension Phase (24 Weeks)|Withdrawal by Subject|4
6310981|NCT02660983|10040777|FG000|Open Label Extension Phase (24 Weeks)|Adverse Event|1
6310982|NCT02660983|10040778|FG001|Open Label Extension Phase (24 Weeks)|Adverse Event|3
6310983|NCT02660983|10040777|FG000|Open Label Extension Phase (24 Weeks)|Other|0
6310984|NCT02660983|10040778|FG001|Open Label Extension Phase (24 Weeks)|Other|1
6310985|NCT02661061|10040787|FG000|Overall Study|Lack of Efficacy|1
6310986|NCT02661061|10040788|FG001|Overall Study|Lack of Efficacy|1
6310987|NCT02661061|10040787|FG000|Overall Study|Withdrawal by Subject|1
6310988|NCT02661061|10040788|FG001|Overall Study|Withdrawal by Subject|1
6310989|NCT02661178|10040818|FG000|Part 1|Protocol Violation|1
6310990|NCT02661178|10040819|FG001|Part 1|Protocol Violation|0
6310991|NCT02661178|10040820|FG002|Part 1|Protocol Violation|0
6310992|NCT02661178|10040821|FG003|Part 1|Protocol Violation|0
6310993|NCT02661178|10040822|FG004|Part 1|Protocol Violation|0
6310994|NCT02661178|10040823|FG005|Part 1|Protocol Violation|0
6310995|NCT02661178|10040824|FG006|Part 1|Protocol Violation|0
6310996|NCT02661178|10040825|FG007|Part 1|Protocol Violation|0
6310997|NCT02661178|10040826|FG008|Part 1|Protocol Violation|0
6310998|NCT02661178|10040827|FG009|Part 1|Protocol Violation|0
6310999|NCT02661178|10040828|FG010|Part 1|Protocol Violation|0
6311000|NCT02661178|10040829|FG011|Part 1|Protocol Violation|0
6311001|NCT02661178|10040830|FG012|Part 1|Protocol Violation|0
6311002|NCT02661178|10040831|FG013|Part 1|Protocol Violation|0
6311003|NCT02661178|10040832|FG014|Part 1|Protocol Violation|0
6311004|NCT02661217|10040884|FG000|Overall Study|Physician Decision|12
6311005|NCT02661217|10040885|FG001|Overall Study|Physician Decision|15
6311006|NCT02661217|10040884|FG000|Overall Study|Lost to Follow-up|1
6311007|NCT02661217|10040885|FG001|Overall Study|Lost to Follow-up|4
6311008|NCT02661217|10040884|FG000|Overall Study|Protocol Deviation|0
6311009|NCT02661217|10040885|FG001|Overall Study|Protocol Deviation|4
6311010|NCT02661217|10040884|FG000|Overall Study|Non-compliance with study treatment|5
6311011|NCT02661217|10040885|FG001|Overall Study|Non-compliance with study treatment|5
6311012|NCT02661217|10040884|FG000|Overall Study|Death|21
6311013|NCT02661217|10040885|FG001|Overall Study|Death|15
6311014|NCT02661217|10040884|FG000|Overall Study|Adverse Event|10
6311015|NCT02661217|10040885|FG001|Overall Study|Adverse Event|8
6311016|NCT02661217|10040884|FG000|Overall Study|Withdrawal by Subject|15
6311017|NCT02661217|10040885|FG001|Overall Study|Withdrawal by Subject|19
6311018|NCT02661217|10040884|FG000|Overall Study|Did not enter follow-up epoch|7
6311019|NCT02661217|10040885|FG001|Overall Study|Did not enter follow-up epoch|10
6311020|NCT02661217|10040884|FG000|Overall Study|Death - no study drug received|1
6311021|NCT02661217|10040885|FG001|Overall Study|Death - no study drug received|2
6311022|NCT02661217|10040884|FG000|Overall Study|Mis-randomized (not in treatment epoch)|3
6311023|NCT02661217|10040885|FG001|Overall Study|Mis-randomized (not in treatment epoch)|1
6311024|NCT02661490|10040903|FG000|Overall Study|Lost to Follow-up|0
6311025|NCT02661490|10040904|FG001|Overall Study|Lost to Follow-up|1
6311026|NCT02661490|10040905|FG002|Overall Study|Lost to Follow-up|0
6311027|NCT02661490|10040906|FG003|Overall Study|Lost to Follow-up|0
6311028|NCT02661490|10040907|FG004|Overall Study|Lost to Follow-up|2
6311029|NCT02661490|10040903|FG000|Overall Study|Withdrawal by Subject|2
6311030|NCT02661490|10040904|FG001|Overall Study|Withdrawal by Subject|0
6311031|NCT02661490|10040905|FG002|Overall Study|Withdrawal by Subject|2
6311032|NCT02661490|10040906|FG003|Overall Study|Withdrawal by Subject|0
6311033|NCT02661490|10040907|FG004|Overall Study|Withdrawal by Subject|0
6311034|NCT02661490|10040903|FG000|Overall Study|Death|1
6311035|NCT02661490|10040904|FG001|Overall Study|Death|1
6311036|NCT02661490|10040905|FG002|Overall Study|Death|0
6311037|NCT02661490|10040906|FG003|Overall Study|Death|1
6311038|NCT02661490|10040907|FG004|Overall Study|Death|0
6311039|NCT02661490|10040903|FG000|Overall Study|Reason not Specified|0
6311040|NCT02661490|10040904|FG001|Overall Study|Reason not Specified|0
6311041|NCT02661490|10040905|FG002|Overall Study|Reason not Specified|0
6311042|NCT02661490|10040906|FG003|Overall Study|Reason not Specified|0
6311043|NCT02661490|10040907|FG004|Overall Study|Reason not Specified|1
6311044|NCT02661594|10040923|FG000|Overall Study|Protocol Violation|1
6311045|NCT02661594|10040924|FG001|Overall Study|Protocol Violation|0
6311046|NCT02661594|10040925|FG002|Overall Study|Protocol Violation|1
6311047|NCT02661594|10040926|FG003|Overall Study|Protocol Violation|0
6311048|NCT02661815|10040944|FG000|Overall Study|Withdrawal by Subject|1
6311049|NCT02661815|10040945|FG001|Overall Study|Withdrawal by Subject|0
6311050|NCT02661815|10040946|FG002|Overall Study|Withdrawal by Subject|0
6311051|NCT02661815|10040947|FG003|Overall Study|Withdrawal by Subject|0
6148519|NCT01089725|9783831|FG000|Overall Study|Other|3
6148520|NCT01089725|9783832|FG001|Overall Study|Other|0
6148521|NCT01089725|9783833|FG002|Overall Study|Other|0
6148522|NCT01089725|9783834|FG003|Overall Study|Other|1
6148523|NCT01089725|9783835|FG004|Overall Study|Other|0
6148524|NCT01090011|9783860|FG000|Overall Study|Progressive disease|128
6148525|NCT01090011|9783860|FG000|Overall Study|Adverse Event|32
6148526|NCT01090011|9783860|FG000|Overall Study|Protocol Violation|1
6148527|NCT01090011|9783860|FG000|Overall Study|Refusal to start/continue medication|5
6148528|NCT01090011|9783860|FG000|Overall Study|Other reason not defined above|5
6148529|NCT01090050|9783874|FG000|Overall Study|Lost to Follow-up|0
6148530|NCT01090050|9783875|FG001|Overall Study|Lost to Follow-up|1
6148531|NCT01090050|9783874|FG000|Overall Study|Lack of Efficacy|1
6148532|NCT01090050|9783875|FG001|Overall Study|Lack of Efficacy|5
6148533|NCT01090050|9783874|FG000|Overall Study|Physician Decision|0
6148534|NCT01090050|9783875|FG001|Overall Study|Physician Decision|1
6148535|NCT01090063|9783885|FG000|Screen|Screen Failed|4
6148536|NCT01090063|9783885|FG000|Treatment|Withdrawal by Subject|4
6311052|NCT02662556|10041004|FG000|Overall Study|Adverse Event|4
6311053|NCT02662556|10041004|FG000|Overall Study|Lack of Efficacy|4
6311054|NCT02662569|10041013|FG000|Overall Study|Withdrawal by Subject|6
6311055|NCT02662569|10041014|FG001|Overall Study|Withdrawal by Subject|1
6311056|NCT02662569|10041015|FG002|Overall Study|Withdrawal by Subject|6
6311057|NCT02662569|10041016|FG003|Overall Study|Withdrawal by Subject|4
6311058|NCT02662569|10041013|FG000|Overall Study|Lost to Follow-up|1
6311059|NCT02662569|10041014|FG001|Overall Study|Lost to Follow-up|0
6311060|NCT02662569|10041015|FG002|Overall Study|Lost to Follow-up|0
6311061|NCT02662569|10041016|FG003|Overall Study|Lost to Follow-up|0
6311062|NCT02662582|10041028|FG000|Treatment Period 1 (14 Days)|Adverse Event|3
6311063|NCT02662582|10041029|FG001|Treatment Period 1 (14 Days)|Adverse Event|2
6311064|NCT02662582|10041028|FG000|Treatment Period 1 (14 Days)|Miscellaneous|0
6311065|NCT02662582|10041029|FG001|Treatment Period 1 (14 Days)|Miscellaneous|1
6311066|NCT02662582|10041028|FG000|Treatment Period 1 (14 Days)|Protocol Deviation|1
6311067|NCT02662582|10041029|FG001|Treatment Period 1 (14 Days)|Protocol Deviation|0
6311068|NCT02662582|10041028|FG000|Treatment Period 1 (14 Days)|Withdrawal by Subject|1
6311069|NCT02662582|10041029|FG001|Treatment Period 1 (14 Days)|Withdrawal by Subject|1
6311070|NCT02662764|10041040|FG000|Overall Study|Adverse Event|6
6311071|NCT02662764|10041040|FG000|Overall Study|Lack of Efficacy|8
6311072|NCT02662764|10041040|FG000|Overall Study|Protocol Violation|1
6311073|NCT02662764|10041040|FG000|Overall Study|Withdrawal by Subject|5
6311074|NCT02662764|10041040|FG000|Overall Study|Device failure|4
6311075|NCT02662764|10041040|FG000|Overall Study|Patient changed treatment|1
6311076|NCT02662764|10041040|FG000|Overall Study|Patient discharged prior to 24 hrs|5
6311077|NCT02663128|10041051|FG000|Period 2|Physician Decision|0
6311078|NCT02663128|10041052|FG001|Period 2|Physician Decision|0
6311079|NCT02663128|10041053|FG002|Period 2|Physician Decision|0
6311080|NCT02663128|10041054|FG003|Period 2|Physician Decision|0
6311081|NCT02663128|10041055|FG004|Period 2|Physician Decision|1
6311082|NCT02663128|10041056|FG005|Period 2|Physician Decision|0
6311083|NCT02663453|10041071|FG000|Overall Study|Death|4
6311084|NCT02663453|10041072|FG001|Overall Study|Death|4
6311085|NCT02663453|10041071|FG000|Overall Study|Withdrawal by Subject|1
6311086|NCT02663453|10041072|FG001|Overall Study|Withdrawal by Subject|0
6311087|NCT02663674|10041080|FG000|Overall Study|Lost to Follow-up|5
6311088|NCT02663674|10041081|FG001|Overall Study|Lost to Follow-up|4
6311089|NCT02663674|10041080|FG000|Overall Study|Withdrawal by Subject|1
6311090|NCT02663674|10041081|FG001|Overall Study|Withdrawal by Subject|4
6148537|NCT01090076|9783901|FG000|Overall Study|Death|1
6148538|NCT01090076|9783902|FG001|Overall Study|Death|1
6148539|NCT01090076|9783901|FG000|Overall Study|Withdrawal by Subject|0
6148540|NCT01090076|9783902|FG001|Overall Study|Withdrawal by Subject|1
6148541|NCT01090102|9783912|FG000|First 12 Weeks|Withdrawal by Subject|1
6311091|NCT02663674|10041080|FG000|Overall Study|Physician Decision|1
6311092|NCT02663674|10041081|FG001|Overall Study|Physician Decision|1
6311093|NCT02663674|10041080|FG000|Overall Study|Other Event (Health Related)|0
6311094|NCT02663674|10041081|FG001|Overall Study|Other Event (Health Related)|1
6311095|NCT02663687|10041092|FG000|Overall Study|Adverse Event|1
6311096|NCT02663687|10041093|FG001|Overall Study|Adverse Event|0
6311097|NCT02663687|10041094|FG002|Overall Study|Adverse Event|0
6311098|NCT02663687|10041095|FG003|Overall Study|Adverse Event|0
6311099|NCT02663687|10041096|FG004|Overall Study|Adverse Event|0
6311100|NCT02663687|10041092|FG000|Overall Study|Other|1
6311101|NCT02663687|10041093|FG001|Overall Study|Other|0
6311102|NCT02663687|10041094|FG002|Overall Study|Other|1
6311103|NCT02663687|10041095|FG003|Overall Study|Other|0
6311104|NCT02663687|10041096|FG004|Overall Study|Other|0
6311105|NCT02663817|10041121|FG000|Overall Study|Screen failure|2
6311106|NCT02663882|10041129|FG000|Overall Study|Lost to Follow-up|4
6311107|NCT02663882|10041130|FG001|Overall Study|Lost to Follow-up|2
6311108|NCT02663895|10041136|FG000|Overall Study|Adverse Event|3
6311109|NCT02663895|10041136|FG000|Overall Study|Physician Decision|2
6311110|NCT02663895|10041136|FG000|Overall Study|Progressive Systemic Sclerosis (SSc)|1
6311111|NCT02663895|10041136|FG000|Overall Study|Withdrawal by Subject|1
6311112|NCT02664272|10041150|FG000|Overall Study|Fluoroscopic images not made available|2
6148542|NCT01090102|9783913|FG001|First 12 Weeks|Withdrawal by Subject|1
6148543|NCT01090102|9783912|FG000|First 12 Weeks|Adverse Event|2
6148544|NCT01090102|9783913|FG001|First 12 Weeks|Adverse Event|0
6148545|NCT01090102|9783912|FG000|First 12 Weeks|Death|1
6148546|NCT01090102|9783913|FG001|First 12 Weeks|Death|1
6148547|NCT01090102|9783912|FG000|Second 12 Weeks|Withdrawal by Subject|0
6148548|NCT01090102|9783913|FG001|Second 12 Weeks|Withdrawal by Subject|1
6148549|NCT01090310|9783932|FG000|Core Study|Adverse Event|2
6148550|NCT01090310|9783933|FG001|Core Study|Adverse Event|2
6148551|NCT01090310|9783934|FG002|Core Study|Adverse Event|1
6148552|NCT01090310|9783935|FG003|Core Study|Adverse Event|1
6148553|NCT01090310|9783932|FG000|Core Study|Subject withdrew consent|0
6148554|NCT01090310|9783933|FG001|Core Study|Subject withdrew consent|3
6148555|NCT01090310|9783934|FG002|Core Study|Subject withdrew consent|1
6148556|NCT01090310|9783935|FG003|Core Study|Subject withdrew consent|1
6148557|NCT01090310|9783932|FG000|Core Study|Abnormal test procedure result|0
6148558|NCT01090310|9783933|FG001|Core Study|Abnormal test procedure result|0
6148559|NCT01090310|9783934|FG002|Core Study|Abnormal test procedure result|1
6148560|NCT01090310|9783935|FG003|Core Study|Abnormal test procedure result|0
6148561|NCT01090310|9783932|FG000|Core Study|Administrative reasons|5
6148562|NCT01090310|9783933|FG001|Core Study|Administrative reasons|6
6148563|NCT01090310|9783934|FG002|Core Study|Administrative reasons|4
6148564|NCT01090310|9783935|FG003|Core Study|Administrative reasons|4
6148565|NCT01090310|9783932|FG000|Core Study|Protocol deviation|1
6148566|NCT01090310|9783933|FG001|Core Study|Protocol deviation|0
6148567|NCT01090310|9783934|FG002|Core Study|Protocol deviation|0
6148568|NCT01090310|9783935|FG003|Core Study|Protocol deviation|1
6148569|NCT01090310|9783932|FG000|Extension Study|Aministrative problems|13
6148570|NCT01090310|9783933|FG001|Extension Study|Aministrative problems|15
6148571|NCT01090310|9783934|FG002|Extension Study|Aministrative problems|14
6148572|NCT01090310|9783935|FG003|Extension Study|Aministrative problems|18
6148573|NCT01090310|9783932|FG000|Extension Study|Adverse Event|0
6148574|NCT01090310|9783933|FG001|Extension Study|Adverse Event|0
6148575|NCT01090310|9783934|FG002|Extension Study|Adverse Event|0
6148576|NCT01090310|9783935|FG003|Extension Study|Adverse Event|1
6148577|NCT01090310|9783932|FG000|Extension Study|Unsatisfactory therapeutic effect|1
6148578|NCT01090310|9783933|FG001|Extension Study|Unsatisfactory therapeutic effect|0
6148579|NCT01090310|9783934|FG002|Extension Study|Unsatisfactory therapeutic effect|1
6148580|NCT01090310|9783935|FG003|Extension Study|Unsatisfactory therapeutic effect|1
6148581|NCT01090310|9783932|FG000|Extension Study|Subject withdrew consent|0
6148582|NCT01090310|9783933|FG001|Extension Study|Subject withdrew consent|1
6148583|NCT01090310|9783934|FG002|Extension Study|Subject withdrew consent|0
6148584|NCT01090310|9783935|FG003|Extension Study|Subject withdrew consent|0
6148585|NCT01090323|9783947|FG000|Overall Study|Adverse Event|12
6148586|NCT01090323|9783948|FG001|Overall Study|Adverse Event|2
6148587|NCT01090323|9783947|FG000|Overall Study|Abnormal Lab Values|3
6148588|NCT01090323|9783948|FG001|Overall Study|Abnormal Lab Values|1
6148589|NCT01090323|9783947|FG000|Overall Study|Abnormal Test Procedure Results|2
6148590|NCT01090323|9783948|FG001|Overall Study|Abnormal Test Procedure Results|0
6148591|NCT01090323|9783947|FG000|Overall Study|Unsatisfactory therapeutic effect|4
6148592|NCT01090323|9783948|FG001|Overall Study|Unsatisfactory therapeutic effect|2
6148593|NCT01090323|9783947|FG000|Overall Study|Condition no longer requires drug|5
6148594|NCT01090323|9783948|FG001|Overall Study|Condition no longer requires drug|4
6148595|NCT01090323|9783947|FG000|Overall Study|Protocol Violation|2
6148596|NCT01090323|9783948|FG001|Overall Study|Protocol Violation|1
6148597|NCT01090323|9783947|FG000|Overall Study|Withdrew consent|33
6148598|NCT01090323|9783948|FG001|Overall Study|Withdrew consent|11
6148599|NCT01090323|9783947|FG000|Overall Study|Lost to Follow-up|11
6148600|NCT01090323|9783948|FG001|Overall Study|Lost to Follow-up|6
6148601|NCT01090323|9783947|FG000|Overall Study|Administrative problems|6
6148602|NCT01090323|9783948|FG001|Overall Study|Administrative problems|4
6148603|NCT01090323|9783947|FG000|Overall Study|Death|1
6148604|NCT01090323|9783948|FG001|Overall Study|Death|2
6148605|NCT01090323|9783947|FG000|Overall Study|Stopped end of core|7
6148606|NCT01090323|9783948|FG001|Overall Study|Stopped end of core|0
6148607|NCT01090323|9783947|FG000|Overall Study|Stopped end of extension 1#|3
6148608|NCT01090323|9783948|FG001|Overall Study|Stopped end of extension 1#|1
6311113|NCT02664415|10041169|FG000|Overall Study|Adverse Event|1
6311114|NCT02664415|10041170|FG001|Overall Study|Adverse Event|0
6311115|NCT02665052|10041232|FG000|Overall Study|Lost to Follow-up|1
6311116|NCT02665052|10041233|FG001|Overall Study|Lost to Follow-up|0
6311117|NCT02665052|10041234|FG002|Overall Study|Lost to Follow-up|0
6311118|NCT02665052|10041235|FG003|Overall Study|Lost to Follow-up|0
6311119|NCT02665052|10041232|FG000|Overall Study|Withdrawal by Subject|1
6311120|NCT02665052|10041233|FG001|Overall Study|Withdrawal by Subject|1
6311121|NCT02665052|10041234|FG002|Overall Study|Withdrawal by Subject|0
6311122|NCT02665052|10041235|FG003|Overall Study|Withdrawal by Subject|5
6311123|NCT02665052|10041232|FG000|Overall Study|Adverse Event|1
6311124|NCT02665052|10041233|FG001|Overall Study|Adverse Event|1
6311125|NCT02665052|10041234|FG002|Overall Study|Adverse Event|0
6311126|NCT02665052|10041235|FG003|Overall Study|Adverse Event|0
6311127|NCT02665286|10041279|FG000|Overall Study|Lost to Follow-up|3
6311128|NCT02665286|10041280|FG001|Overall Study|Lost to Follow-up|2
6311129|NCT02665286|10041281|FG002|Overall Study|Lost to Follow-up|1
6311130|NCT02665455|10041298|FG000|Overall Study|Withdrawal by Subject|6
6311131|NCT02665455|10041298|FG000|Overall Study|Lost to Follow-up|1
6311132|NCT02665455|10041298|FG000|Overall Study|Adverse Event|1
6311133|NCT02665455|10041298|FG000|Overall Study|Protocol Violation|1
6311134|NCT02665689|10041313|FG000|Overall Study|Adverse Event|1
6311135|NCT02665689|10041314|FG001|Overall Study|Adverse Event|0
6311136|NCT02665689|10041313|FG000|Overall Study|Trial termination|1
6311137|NCT02665689|10041314|FG001|Overall Study|Trial termination|1
6311138|NCT02665689|10041313|FG000|Overall Study|Lost to Follow-up|0
6311139|NCT02665689|10041314|FG001|Overall Study|Lost to Follow-up|1
6311140|NCT02666222|10041346|FG000|Overall Study|Death|2
6311141|NCT02666664|10041386|FG000|Overall Study|Physician Decision|0
6311142|NCT02666664|10041387|FG001|Overall Study|Physician Decision|1
6311143|NCT02666664|10041386|FG000|Overall Study|Protocol Violation|0
6311144|NCT02666664|10041387|FG001|Overall Study|Protocol Violation|2
6311145|NCT02666664|10041386|FG000|Overall Study|Other|0
6311146|NCT02666664|10041387|FG001|Overall Study|Other|1
6311147|NCT02666664|10041386|FG000|Overall Study|Adverse Event|12
6311148|NCT02666664|10041387|FG001|Overall Study|Adverse Event|37
6311149|NCT02666664|10041386|FG000|Overall Study|Withdrawal by participant|23
6311150|NCT02666664|10041387|FG001|Overall Study|Withdrawal by participant|40
6311151|NCT02666664|10041386|FG000|Overall Study|Sponsor decision|0
6311152|NCT02666664|10041387|FG001|Overall Study|Sponsor decision|1
6311153|NCT02666664|10041386|FG000|Overall Study|Lost to Follow-up|1
6311154|NCT02666664|10041387|FG001|Overall Study|Lost to Follow-up|2
6311155|NCT02667236|10041445|FG000|Overall Study|Adverse Event|1
6311156|NCT02667236|10041446|FG001|Overall Study|Adverse Event|1
6311157|NCT02667236|10041445|FG000|Overall Study|Withdrawal by Subject|2
6311158|NCT02667236|10041446|FG001|Overall Study|Withdrawal by Subject|0
6311159|NCT02667275|10041454|FG000|Overall Study|Protocol Violation|11
6311160|NCT02667275|10041455|FG001|Overall Study|Protocol Violation|7
6311161|NCT02667275|10041454|FG000|Overall Study|Lost to Follow-up|0
6311162|NCT02667275|10041455|FG001|Overall Study|Lost to Follow-up|2
6311163|NCT02667275|10041454|FG000|Overall Study|Withdrawal by Subject|0
6311164|NCT02667275|10041455|FG001|Overall Study|Withdrawal by Subject|5
6311165|NCT02667275|10041454|FG000|Overall Study|Discontinued early without completing|0
6311166|NCT02667275|10041455|FG001|Overall Study|Discontinued early without completing|1
6311167|NCT02667288|10041461|FG000|Overall Study|Protocol Violation|5
6311168|NCT02667288|10041461|FG000|Overall Study|Lost to Follow-up|3
6311169|NCT02667288|10041461|FG000|Overall Study|Withdrawal by Subject|5
6311170|NCT02667301|10041465|FG000|Overall Study|Adverse Event|1
6311171|NCT02667301|10041465|FG000|Overall Study|Lack of Efficacy|1
6311172|NCT02667457|10041477|FG000|Overall Study|Withdrawal by Subject|1
6311173|NCT02667457|10041478|FG001|Overall Study|Withdrawal by Subject|0
6311174|NCT02667457|10041477|FG000|Overall Study|Other Reason|0
6311175|NCT02667457|10041478|FG001|Overall Study|Other Reason|2
6311176|NCT02667626|10041487|FG000|Overall Study|Withdrawal by Subject|0
6311177|NCT02667626|10041488|FG001|Overall Study|Withdrawal by Subject|1
6311178|NCT02667912|10041511|FG000|Overall Study|Death|3
6311179|NCT02667912|10041512|FG001|Overall Study|Death|1
6311180|NCT02667912|10041511|FG000|Overall Study|Withdrawal by Subject|1
6311181|NCT02667912|10041512|FG001|Overall Study|Withdrawal by Subject|2
6311182|NCT02667912|10041511|FG000|Overall Study|Withdrawal by Subject|1
6311183|NCT02667912|10041512|FG001|Overall Study|Withdrawal by Subject|0
6148609|NCT01090414|9783958|FG000|Study 101-99|Progressive Disease|28
6311184|NCT02668185|10041536|FG000|First Intervention (4 Weeks)|Physician Decision|2
6148610|NCT01090414|9783959|FG001|Study 101-99|Progressive Disease|48
6148611|NCT01090414|9783960|FG002|Study 101-99|Progressive Disease|10
6148612|NCT01090414|9783961|FG003|Study 101-99|Progressive Disease|4
6311185|NCT02668185|10041537|FG001|First Intervention (4 Weeks)|Physician Decision|0
6311186|NCT02668185|10041536|FG000|Washout Period (2 Weeks)|Adverse Event|1
6311187|NCT02668185|10041537|FG001|Washout Period (2 Weeks)|Adverse Event|0
6311188|NCT02668185|10041536|FG000|Washout Period (2 Weeks)|Physician Decision|0
6311189|NCT02668185|10041537|FG001|Washout Period (2 Weeks)|Physician Decision|2
6311190|NCT02668185|10041536|FG000|Second Intervention (4 Weeks)|Physician Decision|1
6311191|NCT02668185|10041537|FG001|Second Intervention (4 Weeks)|Physician Decision|3
6311192|NCT02668302|10041550|FG000|Overall Study|Withdrawal by Subject|1
6311193|NCT02668302|10041551|FG001|Overall Study|Withdrawal by Subject|0
6311194|NCT02668393|10041559|FG000|Overall Study|Progressive disease|6
6311195|NCT02668393|10041560|FG001|Overall Study|Progressive disease|3
6311196|NCT02668393|10041559|FG000|Overall Study|Adverse Event|0
6311197|NCT02668393|10041560|FG001|Overall Study|Adverse Event|2
6311198|NCT02668393|10041559|FG000|Overall Study|Withdrawal from the trial|0
6311199|NCT02668393|10041560|FG001|Overall Study|Withdrawal from the trial|1
6311200|NCT02668393|10041559|FG000|Overall Study|Lack of benefit and side effects|1
6311201|NCT02668393|10041560|FG001|Overall Study|Lack of benefit and side effects|0
6311202|NCT02668640|10041576|FG000|Overall Study|Lost to Follow-up|13
6311203|NCT02668640|10041576|FG000|Overall Study|Other, not specified|1
6311204|NCT02668692|10041582|FG000|Overall Study|Adverse Event|1
6311205|NCT02668692|10041583|FG001|Overall Study|Adverse Event|0
6311206|NCT02669017|10041607|FG000|Overall Study|Death|1
6311207|NCT02669017|10041608|FG001|Overall Study|Death|2
6311208|NCT02669017|10041609|FG002|Overall Study|Death|2
6311209|NCT02669017|10041610|FG003|Overall Study|Death|3
6311210|NCT02669017|10041611|FG004|Overall Study|Death|8
6311211|NCT02669017|10041612|FG005|Overall Study|Death|18
6311212|NCT02669017|10041613|FG006|Overall Study|Death|10
6311213|NCT02669017|10041614|FG007|Overall Study|Death|47
6311214|NCT02669017|10041615|FG008|Overall Study|Death|20
6311215|NCT02669017|10041607|FG000|Overall Study|Withdrawal by Subject|0
6311216|NCT02669017|10041608|FG001|Overall Study|Withdrawal by Subject|0
6311217|NCT02669017|10041609|FG002|Overall Study|Withdrawal by Subject|0
6311218|NCT02669017|10041610|FG003|Overall Study|Withdrawal by Subject|1
6311219|NCT02669017|10041611|FG004|Overall Study|Withdrawal by Subject|2
6311220|NCT02669017|10041612|FG005|Overall Study|Withdrawal by Subject|0
6311221|NCT02669017|10041613|FG006|Overall Study|Withdrawal by Subject|0
6311222|NCT02669017|10041614|FG007|Overall Study|Withdrawal by Subject|2
6311223|NCT02669017|10041615|FG008|Overall Study|Withdrawal by Subject|2
6311224|NCT02669017|10041607|FG000|Overall Study|Lost to Follow-up|0
6311225|NCT02669017|10041608|FG001|Overall Study|Lost to Follow-up|0
6311226|NCT02669017|10041609|FG002|Overall Study|Lost to Follow-up|0
6311227|NCT02669017|10041610|FG003|Overall Study|Lost to Follow-up|0
6311228|NCT02669017|10041611|FG004|Overall Study|Lost to Follow-up|0
6311229|NCT02669017|10041612|FG005|Overall Study|Lost to Follow-up|0
6311230|NCT02669017|10041613|FG006|Overall Study|Lost to Follow-up|0
6311231|NCT02669017|10041614|FG007|Overall Study|Lost to Follow-up|0
6311232|NCT02669017|10041615|FG008|Overall Study|Lost to Follow-up|1
6311233|NCT02669017|10041607|FG000|Overall Study|Miscellaneous|0
6311234|NCT02669017|10041608|FG001|Overall Study|Miscellaneous|0
6311235|NCT02669017|10041609|FG002|Overall Study|Miscellaneous|0
6311236|NCT02669017|10041610|FG003|Overall Study|Miscellaneous|0
6311237|NCT02669017|10041611|FG004|Overall Study|Miscellaneous|2
6311238|NCT02669017|10041612|FG005|Overall Study|Miscellaneous|1
6311239|NCT02669017|10041613|FG006|Overall Study|Miscellaneous|1
6311240|NCT02669017|10041614|FG007|Overall Study|Miscellaneous|13
6311241|NCT02669017|10041615|FG008|Overall Study|Miscellaneous|2
6311242|NCT02669043|10041643|FG000|Overall Study|Didn't meet I/E criteria|4
6311243|NCT02669082|10041647|FG000|Overall Study|Adverse Event|1
6311244|NCT02669095|10041653|FG000|Overall Study|Adverse Event|1
6311245|NCT02669095|10041654|FG001|Overall Study|Adverse Event|0
6311246|NCT02669095|10041653|FG000|Overall Study|Unsatisfactory Lens Fitting|0
6311247|NCT02669095|10041654|FG001|Overall Study|Unsatisfactory Lens Fitting|1
6311248|NCT02669095|10041653|FG000|Overall Study|Torn Lens|0
6311249|NCT02669095|10041654|FG001|Overall Study|Torn Lens|1
6311250|NCT02669095|10041653|FG000|Overall Study|Visit 5 assessments not completed|0
6311251|NCT02669095|10041654|FG001|Overall Study|Visit 5 assessments not completed|1
6311252|NCT02669121|10041662|FG000|Overall Study|Adverse Event|4
6311253|NCT02669121|10041663|FG001|Overall Study|Adverse Event|5
6311254|NCT02669121|10041662|FG000|Overall Study|Lost to Follow-up|15
6311255|NCT02669121|10041663|FG001|Overall Study|Lost to Follow-up|27
6311256|NCT02669121|10041662|FG000|Overall Study|Withdrawal by Subject|132
6311257|NCT02669121|10041663|FG001|Overall Study|Withdrawal by Subject|140
6311258|NCT02669121|10041662|FG000|Overall Study|Pregnancy|0
6311259|NCT02669121|10041663|FG001|Overall Study|Pregnancy|1
6311260|NCT02669121|10041662|FG000|Overall Study|Discharged from US Military Active Service|117
6311261|NCT02669121|10041663|FG001|Overall Study|Discharged from US Military Active Service|91
6311262|NCT02669121|10041662|FG000|Overall Study|Reason not Specified|22
6311263|NCT02669121|10041663|FG001|Overall Study|Reason not Specified|18
6311264|NCT02669264|10041676|FG000|Overall Study|Death|5
6311265|NCT02669264|10041677|FG001|Overall Study|Death|5
6311266|NCT02669264|10041678|FG002|Overall Study|Death|3
6311267|NCT02669264|10041679|FG003|Overall Study|Death|3
6311268|NCT02669264|10041680|FG004|Overall Study|Death|3
6311269|NCT02669264|10041681|FG005|Overall Study|Death|6
6311270|NCT02669264|10041682|FG006|Overall Study|Death|3
6311271|NCT02669264|10041676|FG000|Overall Study|Withdrawal by Subject|0
6311272|NCT02669264|10041677|FG001|Overall Study|Withdrawal by Subject|1
6311273|NCT02669264|10041678|FG002|Overall Study|Withdrawal by Subject|0
6311274|NCT02669264|10041679|FG003|Overall Study|Withdrawal by Subject|0
6311275|NCT02669264|10041680|FG004|Overall Study|Withdrawal by Subject|1
6311276|NCT02669264|10041681|FG005|Overall Study|Withdrawal by Subject|0
6311277|NCT02669264|10041682|FG006|Overall Study|Withdrawal by Subject|0
6311278|NCT02669264|10041676|FG000|Overall Study|Lost to Follow-up|0
6311279|NCT02669264|10041677|FG001|Overall Study|Lost to Follow-up|0
6311280|NCT02669264|10041678|FG002|Overall Study|Lost to Follow-up|0
6311281|NCT02669264|10041679|FG003|Overall Study|Lost to Follow-up|0
6311282|NCT02669264|10041680|FG004|Overall Study|Lost to Follow-up|1
6311283|NCT02669264|10041681|FG005|Overall Study|Lost to Follow-up|0
6311284|NCT02669264|10041682|FG006|Overall Study|Lost to Follow-up|0
6311285|NCT02669264|10041676|FG000|Overall Study|Miscellaneous|0
6311286|NCT02669264|10041677|FG001|Overall Study|Miscellaneous|0
6311287|NCT02669264|10041678|FG002|Overall Study|Miscellaneous|0
6311288|NCT02669264|10041679|FG003|Overall Study|Miscellaneous|0
6311289|NCT02669264|10041680|FG004|Overall Study|Miscellaneous|0
6311290|NCT02669264|10041681|FG005|Overall Study|Miscellaneous|0
6311291|NCT02669264|10041682|FG006|Overall Study|Miscellaneous|2
6311292|NCT02669407|10041704|FG000|Overall Study|Physician Decision|3
6311293|NCT02669433|10041711|FG000|Overall Study|Protocol Violation|0
6311294|NCT02669433|10041712|FG001|Overall Study|Protocol Violation|4
6311295|NCT02669433|10041713|FG002|Overall Study|Protocol Violation|1
6311296|NCT02669433|10041711|FG000|Overall Study|Disease Progression|1
6311297|NCT02669433|10041712|FG001|Overall Study|Disease Progression|0
6311298|NCT02669433|10041713|FG002|Overall Study|Disease Progression|0
6311299|NCT02669433|10041711|FG000|Overall Study|Physician Decision|1
6311300|NCT02669433|10041712|FG001|Overall Study|Physician Decision|1
6311301|NCT02669433|10041713|FG002|Overall Study|Physician Decision|0
6311302|NCT02669433|10041711|FG000|Overall Study|Adverse Event|6
6311303|NCT02669433|10041712|FG001|Overall Study|Adverse Event|7
6311304|NCT02669433|10041713|FG002|Overall Study|Adverse Event|10
6311305|NCT02669433|10041711|FG000|Overall Study|Sponsor Termination|1
6311306|NCT02669433|10041712|FG001|Overall Study|Sponsor Termination|0
6311307|NCT02669433|10041713|FG002|Overall Study|Sponsor Termination|1
6311308|NCT02669433|10041711|FG000|Overall Study|Withdrawal by Subject|5
6311309|NCT02669433|10041712|FG001|Overall Study|Withdrawal by Subject|1
6311310|NCT02669433|10041713|FG002|Overall Study|Withdrawal by Subject|0
6311311|NCT02669433|10041711|FG000|Overall Study|Withdrawal by Caregiver|1
6311312|NCT02669433|10041712|FG001|Overall Study|Withdrawal by Caregiver|0
6311313|NCT02669433|10041713|FG002|Overall Study|Withdrawal by Caregiver|2
6311314|NCT02669433|10041711|FG000|Overall Study|Death|0
6311315|NCT02669433|10041712|FG001|Overall Study|Death|1
6311316|NCT02669433|10041713|FG002|Overall Study|Death|1
6311317|NCT02669667|10041732|FG000|Overall Study|Lost to Follow-up|0
6311318|NCT02669667|10041733|FG001|Overall Study|Lost to Follow-up|0
6311319|NCT02669667|10041734|FG002|Overall Study|Lost to Follow-up|0
6311320|NCT02669667|10041735|FG003|Overall Study|Lost to Follow-up|0
6311321|NCT02669667|10041736|FG004|Overall Study|Lost to Follow-up|0
6311322|NCT02669667|10041737|FG005|Overall Study|Lost to Follow-up|1
6311323|NCT02669667|10041738|FG006|Overall Study|Lost to Follow-up|0
6311324|NCT02669758|10041760|FG000|Overall Study|Withdrawal by Subject|43
6311325|NCT02669758|10041760|FG000|Overall Study|Lost to Follow-up|19
6311326|NCT02669758|10041760|FG000|Overall Study|Adverse Event|16
6311327|NCT02669758|10041760|FG000|Overall Study|Non-Compliance with Study Drug|8
6311328|NCT02669758|10041760|FG000|Overall Study|Lack of Efficacy|5
6311329|NCT02669758|10041760|FG000|Overall Study|Pregnancy|1
6311330|NCT02669758|10041760|FG000|Overall Study|Study noncompliance|1
6311331|NCT02669758|10041760|FG000|Overall Study|Protocol Violation|1
6311332|NCT02669849|10041776|FG000|Overall Study|Withdrawal of Consent (not due to AE)|0
6311333|NCT02669849|10041777|FG001|Overall Study|Withdrawal of Consent (not due to AE)|0
6311334|NCT02669849|10041778|FG002|Overall Study|Withdrawal of Consent (not due to AE)|3
6311335|NCT02669849|10041776|FG000|Overall Study|Lost to Follow-up|1
6311336|NCT02669849|10041777|FG001|Overall Study|Lost to Follow-up|0
6311337|NCT02669849|10041778|FG002|Overall Study|Lost to Follow-up|3
6311338|NCT02669849|10041776|FG000|Overall Study|Death|1
6311339|NCT02669849|10041777|FG001|Overall Study|Death|1
6311340|NCT02669849|10041778|FG002|Overall Study|Death|2
6311341|NCT02669849|10041776|FG000|Overall Study|Study terminated by sponsor|16
6311342|NCT02669849|10041777|FG001|Overall Study|Study terminated by sponsor|1
6311343|NCT02669849|10041778|FG002|Overall Study|Study terminated by sponsor|14
6311344|NCT02669849|10041776|FG000|Overall Study|Other|0
6311345|NCT02669849|10041777|FG001|Overall Study|Other|0
6311346|NCT02669849|10041778|FG002|Overall Study|Other|2
6311347|NCT02669862|10041789|FG000|Overall Study|Lost to Follow-up|0
6311348|NCT02669862|10041790|FG001|Overall Study|Lost to Follow-up|2
6311349|NCT02669862|10041791|FG002|Overall Study|Lost to Follow-up|1
6311350|NCT02669862|10041789|FG000|Overall Study|Withdrawal by Subject|2
6311351|NCT02669862|10041790|FG001|Overall Study|Withdrawal by Subject|2
6311352|NCT02669862|10041791|FG002|Overall Study|Withdrawal by Subject|3
6311353|NCT02669862|10041789|FG000|Overall Study|moved|0
6311354|NCT02669862|10041790|FG001|Overall Study|moved|1
6311355|NCT02669862|10041791|FG002|Overall Study|moved|0
6311356|NCT02669862|10041789|FG000|Overall Study|Protocol Violation|0
6311357|NCT02669862|10041790|FG001|Overall Study|Protocol Violation|0
6311358|NCT02669862|10041791|FG002|Overall Study|Protocol Violation|1
6311359|NCT02669940|10041817|FG000|Overall Study|Failure to return|0
6311360|NCT02669940|10041818|FG001|Overall Study|Failure to return|3
6311361|NCT02669940|10041817|FG000|Overall Study|Insufficient follow-up data|1
6311362|NCT02669940|10041818|FG001|Overall Study|Insufficient follow-up data|0
6311363|NCT02670083|10041833|FG000|Overall Study|Adverse Event|16
6311364|NCT02670083|10041834|FG001|Overall Study|Adverse Event|13
6311365|NCT02670083|10041833|FG000|Overall Study|Death|4
6311366|NCT02670083|10041834|FG001|Overall Study|Death|6
6311367|NCT02670083|10041833|FG000|Overall Study|Lost to Follow-up|2
6311368|NCT02670083|10041834|FG001|Overall Study|Lost to Follow-up|2
6311369|NCT02670083|10041833|FG000|Overall Study|Multiple Reasons|9
6311370|NCT02670083|10041834|FG001|Overall Study|Multiple Reasons|9
6311371|NCT02670083|10041833|FG000|Overall Study|Physician Decision|0
6311372|NCT02670083|10041834|FG001|Overall Study|Physician Decision|2
6311373|NCT02670083|10041833|FG000|Overall Study|Study Terminated By Sponsor|257
6311374|NCT02670083|10041834|FG001|Overall Study|Study Terminated By Sponsor|254
6311375|NCT02670083|10041833|FG000|Overall Study|Symptomatic Deterioration|0
6311376|NCT02670083|10041834|FG001|Overall Study|Symptomatic Deterioration|2
6311377|NCT02670083|10041833|FG000|Overall Study|Withdrawal by Subject|32
6311378|NCT02670083|10041834|FG001|Overall Study|Withdrawal by Subject|31
6311379|NCT02670083|10041833|FG000|Overall Study|Non-Compliance With Study Drug|1
6311380|NCT02670083|10041834|FG001|Overall Study|Non-Compliance With Study Drug|0
6311381|NCT02670122|10041841|FG000|Overall Study|Lost to Follow-up|4
6311382|NCT02670330|10041854|FG000|Overall Study|Protocol Deviation|1
6311383|NCT02670330|10041855|FG001|Overall Study|Protocol Deviation|0
6311384|NCT02670330|10041854|FG000|Overall Study|Study Terminated By Sponsor|36
6311385|NCT02670330|10041855|FG001|Overall Study|Study Terminated By Sponsor|43
6311386|NCT02670330|10041854|FG000|Overall Study|Adverse Event|1
6311387|NCT02670330|10041855|FG001|Overall Study|Adverse Event|3
6311388|NCT02670330|10041854|FG000|Overall Study|Withdrawal by Subject|34
6311389|NCT02670330|10041855|FG001|Overall Study|Withdrawal by Subject|29
6311390|NCT02670330|10041854|FG000|Overall Study|Lost to Follow-up|3
6311391|NCT02670330|10041855|FG001|Overall Study|Lost to Follow-up|2
6311392|NCT02670382|10041865|FG000|Placebo lead-in Phase|Withdrawal by Subject|2
6311393|NCT02670382|10041866|FG001|Placebo lead-in Phase|Withdrawal by Subject|1
6311394|NCT02670473|10041874|FG000|Overall Study|Withdrawal by Subject|1
6311395|NCT02670538|10041890|FG000|Overall Study|Withdrawal of Consent|8
6311396|NCT02670538|10041891|FG001|Overall Study|Withdrawal of Consent|6
6311397|NCT02670538|10041892|FG002|Overall Study|Withdrawal of Consent|5
6311398|NCT02670538|10041890|FG000|Overall Study|Lost to Follow-up|8
6311399|NCT02670538|10041891|FG001|Overall Study|Lost to Follow-up|12
6311400|NCT02670538|10041892|FG002|Overall Study|Lost to Follow-up|7
6311401|NCT02670538|10041890|FG000|Overall Study|Adverse Event|5
6311402|NCT02670538|10041891|FG001|Overall Study|Adverse Event|5
6311403|NCT02670538|10041892|FG002|Overall Study|Adverse Event|11
6311404|NCT02670538|10041890|FG000|Overall Study|Lack of Efficacy|7
6311405|NCT02670538|10041891|FG001|Overall Study|Lack of Efficacy|1
6311406|NCT02670538|10041892|FG002|Overall Study|Lack of Efficacy|2
6311407|NCT02670538|10041890|FG000|Overall Study|Protocol Violation|3
6311408|NCT02670538|10041891|FG001|Overall Study|Protocol Violation|4
6311409|NCT02670538|10041892|FG002|Overall Study|Protocol Violation|1
6311410|NCT02670538|10041890|FG000|Overall Study|Noncompliance with Study Drug|1
6311411|NCT02670538|10041891|FG001|Overall Study|Noncompliance with Study Drug|3
6311412|NCT02670538|10041892|FG002|Overall Study|Noncompliance with Study Drug|2
6311413|NCT02670538|10041890|FG000|Overall Study|Other Miscellaneous Reasons|0
6311414|NCT02670538|10041891|FG001|Overall Study|Other Miscellaneous Reasons|1
6311415|NCT02670538|10041892|FG002|Overall Study|Other Miscellaneous Reasons|2
6311416|NCT02670551|10041903|FG000|Overall Study|Adverse Event|4
6311417|NCT02670551|10041904|FG001|Overall Study|Adverse Event|7
6311418|NCT02670551|10041905|FG002|Overall Study|Adverse Event|9
6311419|NCT02670551|10041903|FG000|Overall Study|Lack of Efficacy|2
6311420|NCT02670551|10041904|FG001|Overall Study|Lack of Efficacy|0
6311421|NCT02670551|10041905|FG002|Overall Study|Lack of Efficacy|3
6311422|NCT02670551|10041903|FG000|Overall Study|Withdrawal of Consent|6
6311423|NCT02670551|10041904|FG001|Overall Study|Withdrawal of Consent|3
6311424|NCT02670551|10041905|FG002|Overall Study|Withdrawal of Consent|8
6311425|NCT02670551|10041903|FG000|Overall Study|Lost to Follow-up|5
6311426|NCT02670551|10041904|FG001|Overall Study|Lost to Follow-up|7
6311427|NCT02670551|10041905|FG002|Overall Study|Lost to Follow-up|6
6311428|NCT02670551|10041903|FG000|Overall Study|Protocol Violation|1
6311429|NCT02670551|10041904|FG001|Overall Study|Protocol Violation|0
6311430|NCT02670551|10041905|FG002|Overall Study|Protocol Violation|0
6311431|NCT02670551|10041903|FG000|Overall Study|Noncompliance with study drug|3
6311432|NCT02670551|10041904|FG001|Overall Study|Noncompliance with study drug|3
6311433|NCT02670551|10041905|FG002|Overall Study|Noncompliance with study drug|2
6311434|NCT02670551|10041903|FG000|Overall Study|Other Miscellaneous Reasons|2
6311435|NCT02670551|10041904|FG001|Overall Study|Other Miscellaneous Reasons|3
6311436|NCT02670551|10041905|FG002|Overall Study|Other Miscellaneous Reasons|3
6311437|NCT02670551|10041903|FG000|Overall Study|Did Not Receive Treatment|5
6311438|NCT02670551|10041904|FG001|Overall Study|Did Not Receive Treatment|3
6311439|NCT02670551|10041905|FG002|Overall Study|Did Not Receive Treatment|0
6311440|NCT02670915|10041934|FG000|Overall Study|Withdrawal by Subject|0
6311441|NCT02670915|10041935|FG001|Overall Study|Withdrawal by Subject|1
6311442|NCT02670915|10041936|FG002|Overall Study|Withdrawal by Subject|4
6311443|NCT02670915|10041934|FG000|Overall Study|Withdrawal by parent/guardian|4
6311444|NCT02670915|10041935|FG001|Overall Study|Withdrawal by parent/guardian|4
6311445|NCT02670915|10041936|FG002|Overall Study|Withdrawal by parent/guardian|1
6311446|NCT02670915|10041934|FG000|Overall Study|Unclassified|0
6311447|NCT02670915|10041935|FG001|Overall Study|Unclassified|3
6311448|NCT02670915|10041936|FG002|Overall Study|Unclassified|0
6311449|NCT02670928|10041946|FG000|Overall Study|Adverse Event|3
6311450|NCT02670928|10041947|FG001|Overall Study|Adverse Event|1
6311451|NCT02670928|10041946|FG000|Overall Study|Withdrawal by Subject|4
6311452|NCT02670928|10041947|FG001|Overall Study|Withdrawal by Subject|0
6311453|NCT02670928|10041946|FG000|Overall Study|Lost to Follow-up|1
6311454|NCT02670928|10041947|FG001|Overall Study|Lost to Follow-up|0
6311455|NCT02670928|10041946|FG000|Overall Study|Miss 3 classes in a row in first 12 wks|2
6311456|NCT02670928|10041947|FG001|Overall Study|Miss 3 classes in a row in first 12 wks|0
6311457|NCT02671266|10041959|FG000|Overall Study|Withdrawal by Subject|1
6311458|NCT02671266|10041960|FG001|Overall Study|Withdrawal by Subject|1
6311459|NCT02671422|10041966|FG000|Overall Study|Lost to Follow-up|1
6311460|NCT02671422|10041966|FG000|Overall Study|Adverse Event|68
6311461|NCT02671422|10041966|FG000|Overall Study|Lack of Efficacy|1
6311462|NCT02671422|10041966|FG000|Overall Study|Lost to Follow-up|4
6311463|NCT02671422|10041966|FG000|Overall Study|Withdrawal by Subject|7
6311464|NCT02671422|10041966|FG000|Overall Study|Progressive Disease|156
6311465|NCT02671422|10041966|FG000|Overall Study|Worsening of Disease|4
6311466|NCT02671422|10041966|FG000|Overall Study|Sponsor decision|5
6311467|NCT02671422|10041966|FG000|Overall Study|Adverse Event unrelated to Vargatef®|8
6311468|NCT02671422|10041966|FG000|Overall Study|Not treated with Vargatef®|3
6311469|NCT02671422|10041966|FG000|Overall Study|Other not defined above|3
6311470|NCT02671500|10041970|FG000|Overall Study|Lack of Efficacy|12
6311471|NCT02671500|10041970|FG000|Overall Study|Lost to Follow-up|2
6311472|NCT02671760|10041978|FG000|Overall Study|Lost to Follow-up|0
6311473|NCT02671760|10041979|FG001|Overall Study|Lost to Follow-up|1
6311474|NCT02671760|10041980|FG002|Overall Study|Lost to Follow-up|0
6311475|NCT02672423|10042013|FG000|Period 1|Adverse Event|0
6311476|NCT02672423|10042014|FG001|Period 1|Adverse Event|0
6311477|NCT02672423|10042015|FG002|Period 1|Adverse Event|0
6311478|NCT02672423|10042016|FG003|Period 1|Adverse Event|0
6311479|NCT02672423|10042017|FG004|Period 1|Adverse Event|1
6311480|NCT02672423|10042018|FG005|Period 1|Adverse Event|0
6311481|NCT02672423|10042019|FG006|Period 1|Adverse Event|0
6311482|NCT02672423|10042020|FG007|Period 1|Adverse Event|0
6311483|NCT02672423|10042021|FG008|Period 1|Adverse Event|0
6311484|NCT02672423|10042022|FG009|Period 1|Adverse Event|0
6311485|NCT02672423|10042013|FG000|Period 2|Withdrawal by Subject|0
6311486|NCT02672423|10042014|FG001|Period 2|Withdrawal by Subject|0
6311487|NCT02672423|10042015|FG002|Period 2|Withdrawal by Subject|1
6311488|NCT02672423|10042016|FG003|Period 2|Withdrawal by Subject|0
6311489|NCT02672423|10042017|FG004|Period 2|Withdrawal by Subject|0
6311490|NCT02672423|10042018|FG005|Period 2|Withdrawal by Subject|0
6311491|NCT02672423|10042019|FG006|Period 2|Withdrawal by Subject|0
6311492|NCT02672423|10042020|FG007|Period 2|Withdrawal by Subject|0
6311493|NCT02672423|10042021|FG008|Period 2|Withdrawal by Subject|0
6311494|NCT02672423|10042022|FG009|Period 2|Withdrawal by Subject|0
6311495|NCT02672423|10042013|FG000|Period 3|Withdrawal by Subject|0
6311496|NCT02672423|10042014|FG001|Period 3|Withdrawal by Subject|0
6311497|NCT02672423|10042015|FG002|Period 3|Withdrawal by Subject|0
6311498|NCT02672423|10042016|FG003|Period 3|Withdrawal by Subject|0
6311499|NCT02672423|10042017|FG004|Period 3|Withdrawal by Subject|0
6311500|NCT02672423|10042018|FG005|Period 3|Withdrawal by Subject|0
6311501|NCT02672423|10042019|FG006|Period 3|Withdrawal by Subject|0
6311502|NCT02672423|10042020|FG007|Period 3|Withdrawal by Subject|1
6311503|NCT02672423|10042021|FG008|Period 3|Withdrawal by Subject|0
6311504|NCT02672423|10042022|FG009|Period 3|Withdrawal by Subject|0
6311505|NCT02672423|10042013|FG000|Period 3|Physician Decision|0
6311506|NCT02672423|10042014|FG001|Period 3|Physician Decision|0
6311507|NCT02672423|10042015|FG002|Period 3|Physician Decision|0
6311508|NCT02672423|10042016|FG003|Period 3|Physician Decision|0
6311509|NCT02672423|10042017|FG004|Period 3|Physician Decision|0
6311510|NCT02672423|10042018|FG005|Period 3|Physician Decision|1
6311511|NCT02672423|10042019|FG006|Period 3|Physician Decision|0
6311512|NCT02672423|10042020|FG007|Period 3|Physician Decision|0
6311513|NCT02672423|10042021|FG008|Period 3|Physician Decision|0
6311514|NCT02672423|10042022|FG009|Period 3|Physician Decision|0
6311515|NCT02672553|10042054|FG000|Overall Study|Death|3
6311516|NCT02672553|10042055|FG001|Overall Study|Death|5
6311517|NCT02672553|10042054|FG000|Overall Study|Valve Explant|1
6311518|NCT02672553|10042055|FG001|Overall Study|Valve Explant|0
6311519|NCT02672553|10042054|FG000|Overall Study|Conversion to Commercial Valve|3
6311520|NCT02672553|10042055|FG001|Overall Study|Conversion to Commercial Valve|0
6311521|NCT02672553|10042054|FG000|Overall Study|Withdrawal by Subject|3
6311522|NCT02672553|10042055|FG001|Overall Study|Withdrawal by Subject|3
6311523|NCT02672553|10042054|FG000|Overall Study|Intraoperative screen failure|2
6311524|NCT02672553|10042055|FG001|Overall Study|Intraoperative screen failure|0
6311525|NCT02672852|10042064|FG000|Part A1|Disease Worsening|1
6311526|NCT02672852|10042065|FG001|Part A1|Disease Worsening|0
6311527|NCT02672852|10042066|FG002|Part A1|Disease Worsening|0
6311528|NCT02672852|10042067|FG003|Part A1|Disease Worsening|0
6311529|NCT02672852|10042068|FG004|Part A1|Disease Worsening|0
6311530|NCT02672852|10042069|FG005|Part A1|Disease Worsening|0
6311531|NCT02672852|10042070|FG006|Part A1|Disease Worsening|0
6311532|NCT02672852|10042064|FG000|Part A1|Adverse Event|0
6311533|NCT02672852|10042065|FG001|Part A1|Adverse Event|1
6311534|NCT02672852|10042066|FG002|Part A1|Adverse Event|0
6311535|NCT02672852|10042067|FG003|Part A1|Adverse Event|0
6311536|NCT02672852|10042068|FG004|Part A1|Adverse Event|0
6311537|NCT02672852|10042069|FG005|Part A1|Adverse Event|0
6311538|NCT02672852|10042070|FG006|Part A1|Adverse Event|0
6311539|NCT02672852|10042064|FG000|Part A1|Lost to Follow-up|1
6311540|NCT02672852|10042065|FG001|Part A1|Lost to Follow-up|2
6311541|NCT02672852|10042066|FG002|Part A1|Lost to Follow-up|0
6311542|NCT02672852|10042067|FG003|Part A1|Lost to Follow-up|0
6311543|NCT02672852|10042068|FG004|Part A1|Lost to Follow-up|0
6311544|NCT02672852|10042069|FG005|Part A1|Lost to Follow-up|0
6311545|NCT02672852|10042070|FG006|Part A1|Lost to Follow-up|0
6311546|NCT02672852|10042064|FG000|Part A1|Withdrawal by Subject|1
6311547|NCT02672852|10042065|FG001|Part A1|Withdrawal by Subject|1
6311548|NCT02672852|10042066|FG002|Part A1|Withdrawal by Subject|0
6311549|NCT02672852|10042067|FG003|Part A1|Withdrawal by Subject|0
6311550|NCT02672852|10042068|FG004|Part A1|Withdrawal by Subject|0
6311551|NCT02672852|10042069|FG005|Part A1|Withdrawal by Subject|0
6311552|NCT02672852|10042070|FG006|Part A1|Withdrawal by Subject|0
6311553|NCT02672852|10042064|FG000|Part A2|Disease worsening|0
6311554|NCT02672852|10042065|FG001|Part A2|Disease worsening|0
6311555|NCT02672852|10042066|FG002|Part A2|Disease worsening|1
6311556|NCT02672852|10042067|FG003|Part A2|Disease worsening|0
6311557|NCT02672852|10042068|FG004|Part A2|Disease worsening|0
6311558|NCT02672852|10042069|FG005|Part A2|Disease worsening|0
6311559|NCT02672852|10042070|FG006|Part A2|Disease worsening|0
6311560|NCT02672852|10042064|FG000|Part A2|Adverse Event|0
6311561|NCT02672852|10042065|FG001|Part A2|Adverse Event|0
6311562|NCT02672852|10042066|FG002|Part A2|Adverse Event|3
6311563|NCT02672852|10042067|FG003|Part A2|Adverse Event|0
6311564|NCT02672852|10042068|FG004|Part A2|Adverse Event|0
6311565|NCT02672852|10042069|FG005|Part A2|Adverse Event|0
6311566|NCT02672852|10042070|FG006|Part A2|Adverse Event|0
6311567|NCT02672852|10042064|FG000|Part A2|Lost to Follow-up|0
6311568|NCT02672852|10042065|FG001|Part A2|Lost to Follow-up|0
6311569|NCT02672852|10042066|FG002|Part A2|Lost to Follow-up|2
6311570|NCT02672852|10042067|FG003|Part A2|Lost to Follow-up|0
6311571|NCT02672852|10042068|FG004|Part A2|Lost to Follow-up|0
6311572|NCT02672852|10042069|FG005|Part A2|Lost to Follow-up|0
6311573|NCT02672852|10042070|FG006|Part A2|Lost to Follow-up|0
6311574|NCT02672852|10042064|FG000|Part A2|Withdrawal by Subject|0
6311575|NCT02672852|10042065|FG001|Part A2|Withdrawal by Subject|0
6311576|NCT02672852|10042066|FG002|Part A2|Withdrawal by Subject|1
6311577|NCT02672852|10042067|FG003|Part A2|Withdrawal by Subject|0
6311578|NCT02672852|10042068|FG004|Part A2|Withdrawal by Subject|0
6311579|NCT02672852|10042069|FG005|Part A2|Withdrawal by Subject|0
6311580|NCT02672852|10042070|FG006|Part A2|Withdrawal by Subject|0
6311581|NCT02672852|10042064|FG000|Part A2|Other|0
6311582|NCT02672852|10042065|FG001|Part A2|Other|0
6311583|NCT02672852|10042066|FG002|Part A2|Other|3
6311584|NCT02672852|10042067|FG003|Part A2|Other|0
6311585|NCT02672852|10042068|FG004|Part A2|Other|0
6311586|NCT02672852|10042069|FG005|Part A2|Other|0
6311587|NCT02672852|10042070|FG006|Part A2|Other|0
6311588|NCT02672852|10042064|FG000|Part A2|Not entered in Part B|0
6311589|NCT02672852|10042065|FG001|Part A2|Not entered in Part B|0
6311590|NCT02672852|10042066|FG002|Part A2|Not entered in Part B|0
6311591|NCT02672852|10042067|FG003|Part A2|Not entered in Part B|4
6311592|NCT02672852|10042068|FG004|Part A2|Not entered in Part B|0
6311593|NCT02672852|10042069|FG005|Part A2|Not entered in Part B|0
6311594|NCT02672852|10042070|FG006|Part A2|Not entered in Part B|0
6311595|NCT02672852|10042064|FG000|Part B|Disease worsening|0
6311596|NCT02672852|10042065|FG001|Part B|Disease worsening|0
6311597|NCT02672852|10042066|FG002|Part B|Disease worsening|0
6311598|NCT02672852|10042067|FG003|Part B|Disease worsening|0
6311599|NCT02672852|10042068|FG004|Part B|Disease worsening|1
6311600|NCT02672852|10042069|FG005|Part B|Disease worsening|0
6311601|NCT02672852|10042070|FG006|Part B|Disease worsening|1
6311602|NCT02672852|10042064|FG000|Part B|Worsening pre-existing condition|0
6311603|NCT02672852|10042065|FG001|Part B|Worsening pre-existing condition|0
6311604|NCT02672852|10042066|FG002|Part B|Worsening pre-existing condition|0
6311605|NCT02672852|10042067|FG003|Part B|Worsening pre-existing condition|0
6311606|NCT02672852|10042068|FG004|Part B|Worsening pre-existing condition|0
6311607|NCT02672852|10042069|FG005|Part B|Worsening pre-existing condition|1
6311608|NCT02672852|10042070|FG006|Part B|Worsening pre-existing condition|0
6311609|NCT02672852|10042064|FG000|Part B|Other adverse event|0
6311610|NCT02672852|10042065|FG001|Part B|Other adverse event|0
6311611|NCT02672852|10042066|FG002|Part B|Other adverse event|0
6311612|NCT02672852|10042067|FG003|Part B|Other adverse event|0
6311613|NCT02672852|10042068|FG004|Part B|Other adverse event|3
6311614|NCT02672852|10042069|FG005|Part B|Other adverse event|5
6311615|NCT02672852|10042070|FG006|Part B|Other adverse event|1
6311616|NCT02672852|10042064|FG000|Part B|Lost to Follow-up|0
6311617|NCT02672852|10042065|FG001|Part B|Lost to Follow-up|0
6311618|NCT02672852|10042066|FG002|Part B|Lost to Follow-up|0
6311619|NCT02672852|10042067|FG003|Part B|Lost to Follow-up|0
6311620|NCT02672852|10042068|FG004|Part B|Lost to Follow-up|3
6311621|NCT02672852|10042069|FG005|Part B|Lost to Follow-up|4
6311622|NCT02672852|10042070|FG006|Part B|Lost to Follow-up|1
6311623|NCT02672852|10042064|FG000|Part B|Withdrawal by Subject|0
6311624|NCT02672852|10042065|FG001|Part B|Withdrawal by Subject|0
6311625|NCT02672852|10042066|FG002|Part B|Withdrawal by Subject|0
6311626|NCT02672852|10042067|FG003|Part B|Withdrawal by Subject|0
6311627|NCT02672852|10042068|FG004|Part B|Withdrawal by Subject|5
6311628|NCT02672852|10042069|FG005|Part B|Withdrawal by Subject|0
6148613|NCT01090414|9783958|FG000|Study 101-99|Adverse Event|10
6148614|NCT01090414|9783959|FG001|Study 101-99|Adverse Event|28
6148615|NCT01090414|9783960|FG002|Study 101-99|Adverse Event|18
6148616|NCT01090414|9783961|FG003|Study 101-99|Adverse Event|0
6148617|NCT01090414|9783958|FG000|Study 101-99|Investigator Request|1
6148618|NCT01090414|9783959|FG001|Study 101-99|Investigator Request|11
6148619|NCT01090414|9783960|FG002|Study 101-99|Investigator Request|4
6148620|NCT01090414|9783961|FG003|Study 101-99|Investigator Request|0
6148621|NCT01090414|9783958|FG000|Study 101-99|Death|3
6148622|NCT01090414|9783959|FG001|Study 101-99|Death|8
6148623|NCT01090414|9783960|FG002|Study 101-99|Death|1
6148624|NCT01090414|9783961|FG003|Study 101-99|Death|0
6148625|NCT01090414|9783958|FG000|Study 101-99|Sponsor Discontinued Study|0
6148626|NCT01090414|9783959|FG001|Study 101-99|Sponsor Discontinued Study|7
6148627|NCT01090414|9783960|FG002|Study 101-99|Sponsor Discontinued Study|5
6148628|NCT01090414|9783961|FG003|Study 101-99|Sponsor Discontinued Study|0
6148629|NCT01090414|9783958|FG000|Study 101-99|Other (Unknown Reasons)|3
6148630|NCT01090414|9783959|FG001|Study 101-99|Other (Unknown Reasons)|3
6148631|NCT01090414|9783960|FG002|Study 101-99|Other (Unknown Reasons)|0
6148632|NCT01090414|9783961|FG003|Study 101-99|Other (Unknown Reasons)|0
6148633|NCT01090414|9783958|FG000|Study 101-99|Withdrew Consent|0
6148634|NCT01090414|9783959|FG001|Study 101-99|Withdrew Consent|2
6148635|NCT01090414|9783960|FG002|Study 101-99|Withdrew Consent|3
6148636|NCT01090414|9783961|FG003|Study 101-99|Withdrew Consent|1
6148637|NCT01090414|9783958|FG000|Study 101-99|Participant Request|3
6148638|NCT01090414|9783959|FG001|Study 101-99|Participant Request|1
6148639|NCT01090414|9783960|FG002|Study 101-99|Participant Request|0
6148640|NCT01090414|9783961|FG003|Study 101-99|Participant Request|0
6148641|NCT01090427|9783986|FG000|After Controlled Period|Death|0
6148642|NCT01090427|9783987|FG001|After Controlled Period|Death|0
6148643|NCT01090427|9783988|FG002|After Controlled Period|Death|0
6148644|NCT01090427|9783989|FG003|After Controlled Period|Death|0
6148645|NCT01090427|9783990|FG004|After Controlled Period|Death|0
6148646|NCT01090427|9783991|FG005|After Controlled Period|Death|1
6311629|NCT02672852|10042070|FG006|Part B|Withdrawal by Subject|7
6311630|NCT02672852|10042064|FG000|Part B|Other|0
6311631|NCT02672852|10042065|FG001|Part B|Other|0
6311632|NCT02672852|10042066|FG002|Part B|Other|0
6311633|NCT02672852|10042067|FG003|Part B|Other|0
6311634|NCT02672852|10042068|FG004|Part B|Other|4
6311635|NCT02672852|10042069|FG005|Part B|Other|1
6311636|NCT02672852|10042070|FG006|Part B|Other|2
6148647|NCT01090427|9783992|FG006|After Controlled Period|Death|0
6148648|NCT01090427|9783986|FG000|After Controlled Period|Lack of Efficacy|0
6148649|NCT01090427|9783987|FG001|After Controlled Period|Lack of Efficacy|0
6148650|NCT01090427|9783988|FG002|After Controlled Period|Lack of Efficacy|0
6148651|NCT01090427|9783989|FG003|After Controlled Period|Lack of Efficacy|0
6148652|NCT01090427|9783990|FG004|After Controlled Period|Lack of Efficacy|0
6148653|NCT01090427|9783991|FG005|After Controlled Period|Lack of Efficacy|3
6148654|NCT01090427|9783992|FG006|After Controlled Period|Lack of Efficacy|2
6148655|NCT01090427|9783986|FG000|After Controlled Period|Adverse Event|0
6148656|NCT01090427|9783987|FG001|After Controlled Period|Adverse Event|0
6148657|NCT01090427|9783988|FG002|After Controlled Period|Adverse Event|0
6148658|NCT01090427|9783989|FG003|After Controlled Period|Adverse Event|2
6148659|NCT01090427|9783990|FG004|After Controlled Period|Adverse Event|0
6148660|NCT01090427|9783991|FG005|After Controlled Period|Adverse Event|1
6148661|NCT01090427|9783992|FG006|After Controlled Period|Adverse Event|0
6148662|NCT01090453|9784006|FG000|Overall Study|Withdrawal by Subject|1
6148663|NCT01090453|9784007|FG001|Overall Study|Withdrawal by Subject|2
6148664|NCT01090453|9784006|FG000|Overall Study|Lost to Follow-up|7
6148665|NCT01090453|9784007|FG001|Overall Study|Lost to Follow-up|7
6148666|NCT01090453|9784006|FG000|Overall Study|Non serious AEs|1
6148667|NCT01090453|9784007|FG001|Overall Study|Non serious AEs|0
6311637|NCT02673489|10042098|FG000|Treatment Period|Lost to Follow-up|3
6311638|NCT02673489|10042099|FG001|Treatment Period|Lost to Follow-up|0
6311639|NCT02673489|10042098|FG000|Treatment Period|Participant request to discontinue|1
6311640|NCT02673489|10042099|FG001|Treatment Period|Participant request to discontinue|1
6039937|NCT00368355|9637721|FG000|Overall Study|Death|2
6039938|NCT00368355|9637722|FG001|Overall Study|Death|4
6311641|NCT02673489|10042098|FG000|Treatment Period|Participant moved to another province|1
6311642|NCT02673489|10042099|FG001|Treatment Period|Participant moved to another province|0
6311643|NCT02673489|10042098|FG000|Treatment Period|Participant was incarcerated|0
6311644|NCT02673489|10042099|FG001|Treatment Period|Participant was incarcerated|1
6311645|NCT02673489|10042098|FG000|Treatment Period|Adverse Event|0
6311646|NCT02673489|10042099|FG001|Treatment Period|Adverse Event|1
6311647|NCT02673489|10042098|FG000|Follow Up Period|Unable to return for week 24 follow-up|0
6311648|NCT02673489|10042099|FG001|Follow Up Period|Unable to return for week 24 follow-up|1
6311649|NCT02673489|10042098|FG000|Follow Up Period|Unable to return for follow-up|0
6148668|NCT01090453|9784006|FG000|Overall Study|Protocol Violation|2
6311650|NCT02673489|10042099|FG001|Follow Up Period|Unable to return for follow-up|1
6311651|NCT02673515|10042108|FG000|Overall Study|Lack of motivation|2
6311652|NCT02673515|10042109|FG001|Overall Study|Lack of motivation|1
6311653|NCT02673619|10042128|FG000|Overall Study|Lost to Follow-up|1
6311654|NCT02673619|10042129|FG001|Overall Study|Lost to Follow-up|0
6311655|NCT02673619|10042130|FG002|Overall Study|Lost to Follow-up|0
6311656|NCT02673619|10042131|FG003|Overall Study|Lost to Follow-up|0
6311657|NCT02673619|10042128|FG000|Overall Study|Withdrawal by Subject|1
6311658|NCT02673619|10042129|FG001|Overall Study|Withdrawal by Subject|1
6311659|NCT02673619|10042130|FG002|Overall Study|Withdrawal by Subject|1
6311660|NCT02673619|10042131|FG003|Overall Study|Withdrawal by Subject|0
6311661|NCT02673619|10042128|FG000|Overall Study|Adverse Event|0
6311662|NCT02673619|10042129|FG001|Overall Study|Adverse Event|0
6311663|NCT02673619|10042130|FG002|Overall Study|Adverse Event|1
6311664|NCT02673619|10042131|FG003|Overall Study|Adverse Event|0
6311665|NCT02673619|10042128|FG000|Overall Study|Lack of Efficacy|0
6311666|NCT02673619|10042129|FG001|Overall Study|Lack of Efficacy|0
6311667|NCT02673619|10042130|FG002|Overall Study|Lack of Efficacy|1
6311668|NCT02673619|10042131|FG003|Overall Study|Lack of Efficacy|0
6311669|NCT02674334|10042160|FG000|Overall Study|Lost to Follow-up|5
6311670|NCT02674334|10042161|FG001|Overall Study|Lost to Follow-up|3
6311671|NCT02674334|10042160|FG000|Overall Study|participant difficulty breathing|1
6311672|NCT02674334|10042161|FG001|Overall Study|participant difficulty breathing|0
6311673|NCT02674334|10042160|FG000|Overall Study|NIRS not recording|1
6311674|NCT02674334|10042161|FG001|Overall Study|NIRS not recording|0
6311675|NCT02674386|10042170|FG000|Overall Study|Lost to Follow-up|0
6311676|NCT02674386|10042171|FG001|Overall Study|Lost to Follow-up|1
6311677|NCT02674386|10042172|FG002|Overall Study|Lost to Follow-up|1
6311678|NCT02674386|10042170|FG000|Overall Study|Withdrawal by Subject|0
6311679|NCT02674386|10042171|FG001|Overall Study|Withdrawal by Subject|4
6311680|NCT02674386|10042172|FG002|Overall Study|Withdrawal by Subject|0
6311681|NCT02674386|10042170|FG000|Overall Study|Other|0
6311682|NCT02674386|10042171|FG001|Overall Study|Other|1
6311683|NCT02674386|10042172|FG002|Overall Study|Other|0
6311684|NCT02674386|10042170|FG000|Overall Study|Enrolled but not evaluated|0
6311685|NCT02674386|10042171|FG001|Overall Study|Enrolled but not evaluated|4
6311686|NCT02674386|10042172|FG002|Overall Study|Enrolled but not evaluated|0
6311687|NCT02674399|10042187|FG000|Overall Study|Lost to Follow-up|2
6311688|NCT02674399|10042188|FG001|Overall Study|Lost to Follow-up|0
6311689|NCT02674477|10042204|FG000|Overall Study|Protocol Violation|8
6311690|NCT02674477|10042205|FG001|Overall Study|Protocol Violation|2
6311691|NCT02674568|10042211|FG000|Overall Study|Withdrawal by Subject|5
6311692|NCT02674568|10042211|FG000|Overall Study|Death|303
6311693|NCT02674568|10042211|FG000|Overall Study|Physician Decision|2
6148669|NCT01090453|9784007|FG001|Overall Study|Protocol Violation|0
6148670|NCT01090453|9784006|FG000|Overall Study|Other|2
6148671|NCT01090453|9784007|FG001|Overall Study|Other|4
6148672|NCT01090453|9784006|FG000|Overall Study|Eligibility Criteria|0
6148673|NCT01090453|9784007|FG001|Overall Study|Eligibility Criteria|1
6148674|NCT01090492|9784030|FG000|First Intervention Period (4 Weeks)|Protocol Violation|1
6148675|NCT01090492|9784031|FG001|First Intervention Period (4 Weeks)|Protocol Violation|1
6148676|NCT01090492|9784032|FG002|First Intervention Period (4 Weeks)|Protocol Violation|1
6148677|NCT01090492|9784033|FG003|First Intervention Period (4 Weeks)|Protocol Violation|2
6148678|NCT01090492|9784034|FG004|First Intervention Period (4 Weeks)|Protocol Violation|0
6148679|NCT01090492|9784035|FG005|First Intervention Period (4 Weeks)|Protocol Violation|0
6148680|NCT01090492|9784036|FG006|First Intervention Period (4 Weeks)|Protocol Violation|1
6148681|NCT01090492|9784037|FG007|First Intervention Period (4 Weeks)|Protocol Violation|0
6148682|NCT01090492|9784030|FG000|First Intervention Period (4 Weeks)|Did not meet inclusion criteria|0
6148683|NCT01090492|9784031|FG001|First Intervention Period (4 Weeks)|Did not meet inclusion criteria|2
6148684|NCT01090492|9784032|FG002|First Intervention Period (4 Weeks)|Did not meet inclusion criteria|0
6148685|NCT01090492|9784033|FG003|First Intervention Period (4 Weeks)|Did not meet inclusion criteria|0
6148686|NCT01090492|9784034|FG004|First Intervention Period (4 Weeks)|Did not meet inclusion criteria|0
6148687|NCT01090492|9784035|FG005|First Intervention Period (4 Weeks)|Did not meet inclusion criteria|0
6148688|NCT01090492|9784036|FG006|First Intervention Period (4 Weeks)|Did not meet inclusion criteria|0
6148689|NCT01090492|9784037|FG007|First Intervention Period (4 Weeks)|Did not meet inclusion criteria|1
6148690|NCT01090492|9784030|FG000|First Intervention Period (4 Weeks)|Lost to Follow-up|0
6148691|NCT01090492|9784031|FG001|First Intervention Period (4 Weeks)|Lost to Follow-up|0
6148692|NCT01090492|9784032|FG002|First Intervention Period (4 Weeks)|Lost to Follow-up|1
6148693|NCT01090492|9784033|FG003|First Intervention Period (4 Weeks)|Lost to Follow-up|0
6148694|NCT01090492|9784034|FG004|First Intervention Period (4 Weeks)|Lost to Follow-up|0
6148695|NCT01090492|9784035|FG005|First Intervention Period (4 Weeks)|Lost to Follow-up|0
6148696|NCT01090492|9784036|FG006|First Intervention Period (4 Weeks)|Lost to Follow-up|0
6148697|NCT01090492|9784037|FG007|First Intervention Period (4 Weeks)|Lost to Follow-up|0
6148698|NCT01090492|9784030|FG000|First Intervention Period (4 Weeks)|Other|0
6148699|NCT01090492|9784031|FG001|First Intervention Period (4 Weeks)|Other|0
6311694|NCT02674568|10042211|FG000|Overall Study|Lost to Follow-up|9
6311695|NCT02674568|10042211|FG000|Overall Study|Other, Not Specified|20
6311696|NCT02674633|10042222|FG000|Overall Study|Lost to Follow-up|3
6311697|NCT02674633|10042223|FG001|Overall Study|Lost to Follow-up|2
6311698|NCT02674633|10042222|FG000|Overall Study|Physician Decision|1
6311699|NCT02674633|10042223|FG001|Overall Study|Physician Decision|0
6311700|NCT02674633|10042222|FG000|Overall Study|Withdrawal by Parent/Guardian|1
6311701|NCT02674633|10042223|FG001|Overall Study|Withdrawal by Parent/Guardian|2
6311702|NCT02674685|10042238|FG000|Overall Study|Protocol Violation|4
6311703|NCT02674854|10042245|FG000|Overall Study|Adverse Event|17
6311704|NCT02674854|10042246|FG001|Overall Study|Adverse Event|15
6311705|NCT02674854|10042247|FG002|Overall Study|Adverse Event|5
6311706|NCT02674854|10042245|FG000|Overall Study|Withdrawal by Subject|1
6311707|NCT02674854|10042246|FG001|Overall Study|Withdrawal by Subject|5
6311708|NCT02674854|10042247|FG002|Overall Study|Withdrawal by Subject|4
6311709|NCT02674854|10042245|FG000|Overall Study|No-compliant subject|1
6311710|NCT02674854|10042246|FG001|Overall Study|No-compliant subject|0
6311711|NCT02674854|10042247|FG002|Overall Study|No-compliant subject|1
6311712|NCT02674854|10042245|FG000|Overall Study|Lost to Follow-up|1
6311713|NCT02674854|10042246|FG001|Overall Study|Lost to Follow-up|0
6311714|NCT02674854|10042247|FG002|Overall Study|Lost to Follow-up|2
6311715|NCT02674854|10042245|FG000|Overall Study|Lack of Efficacy|0
6311716|NCT02674854|10042246|FG001|Overall Study|Lack of Efficacy|3
6311717|NCT02674854|10042247|FG002|Overall Study|Lack of Efficacy|0
6311718|NCT02674854|10042245|FG000|Overall Study|Disallowed Concurrent Medication|2
6311719|NCT02674854|10042246|FG001|Overall Study|Disallowed Concurrent Medication|2
6311720|NCT02674854|10042247|FG002|Overall Study|Disallowed Concurrent Medication|0
6311721|NCT02674854|10042245|FG000|Overall Study|Protocol Violation|1
6311722|NCT02674854|10042246|FG001|Overall Study|Protocol Violation|1
6311723|NCT02674854|10042247|FG002|Overall Study|Protocol Violation|2
6311724|NCT02674854|10042245|FG000|Overall Study|Death|0
6311725|NCT02674854|10042246|FG001|Overall Study|Death|1
6311726|NCT02674854|10042247|FG002|Overall Study|Death|0
6311727|NCT02674854|10042245|FG000|Overall Study|Subject missed V6.2|1
6311728|NCT02674854|10042246|FG001|Overall Study|Subject missed V6.2|0
6311729|NCT02674854|10042247|FG002|Overall Study|Subject missed V6.2|0
6311730|NCT02675075|10042257|FG000|Overall Study|Lost to Follow-up|3
6311731|NCT02675075|10042258|FG001|Overall Study|Lost to Follow-up|0
6311732|NCT02675517|10042266|FG000|Overall Study|No evaluable PF-10 questionnaire at all|8
6311733|NCT02675517|10042266|FG000|Overall Study|Evaluable PF-10 questionnaire at visit1|151
6311734|NCT02675634|10042279|FG000|Test Period 1|Adverse Event|0
6311735|NCT02675634|10042280|FG001|Test Period 1|Adverse Event|1
6311736|NCT02675634|10042281|FG002|Test Period 1|Adverse Event|0
6311737|NCT02675634|10042282|FG003|Test Period 1|Adverse Event|1
6148700|NCT01090492|9784032|FG002|First Intervention Period (4 Weeks)|Other|1
6148701|NCT01090492|9784033|FG003|First Intervention Period (4 Weeks)|Other|1
6148702|NCT01090492|9784034|FG004|First Intervention Period (4 Weeks)|Other|2
6148703|NCT01090492|9784035|FG005|First Intervention Period (4 Weeks)|Other|0
6311738|NCT02675634|10042283|FG004|Test Period 1|Adverse Event|0
6311739|NCT02675634|10042284|FG005|Test Period 1|Adverse Event|0
6311740|NCT02675634|10042279|FG000|Test Period 1|Device deficiency that did not lead to A|0
6311741|NCT02675634|10042280|FG001|Test Period 1|Device deficiency that did not lead to A|0
6311742|NCT02675634|10042281|FG002|Test Period 1|Device deficiency that did not lead to A|1
6311743|NCT02675634|10042282|FG003|Test Period 1|Device deficiency that did not lead to A|0
6311744|NCT02675634|10042283|FG004|Test Period 1|Device deficiency that did not lead to A|0
6311745|NCT02675634|10042284|FG005|Test Period 1|Device deficiency that did not lead to A|0
6311746|NCT02675634|10042279|FG000|Test Period 2|Lack of Efficacy|1
6311747|NCT02675634|10042280|FG001|Test Period 2|Lack of Efficacy|0
6311748|NCT02675634|10042281|FG002|Test Period 2|Lack of Efficacy|0
6311749|NCT02675634|10042282|FG003|Test Period 2|Lack of Efficacy|0
6311750|NCT02675634|10042283|FG004|Test Period 2|Lack of Efficacy|0
6311751|NCT02675634|10042284|FG005|Test Period 2|Lack of Efficacy|0
6311752|NCT02675634|10042279|FG000|Test Period 2|Adverse Event|0
6311753|NCT02675634|10042280|FG001|Test Period 2|Adverse Event|0
6311754|NCT02675634|10042281|FG002|Test Period 2|Adverse Event|0
6311755|NCT02675634|10042282|FG003|Test Period 2|Adverse Event|0
6311756|NCT02675634|10042283|FG004|Test Period 2|Adverse Event|0
6311757|NCT02675634|10042284|FG005|Test Period 2|Adverse Event|1
6311758|NCT02675907|10042303|FG000|Treatment Phase (48 Hours Post-Dose 1)|Lack of Efficacy|4
6311759|NCT02675907|10042304|FG001|Treatment Phase (48 Hours Post-Dose 1)|Lack of Efficacy|4
6311760|NCT02675907|10042303|FG000|Treatment Phase (48 Hours Post-Dose 1)|Withdrawal by Subject|1
6311761|NCT02675907|10042304|FG001|Treatment Phase (48 Hours Post-Dose 1)|Withdrawal by Subject|1
6311762|NCT02675907|10042303|FG000|Study Overall|Lack of Efficacy|1
6311763|NCT02675907|10042304|FG001|Study Overall|Lack of Efficacy|0
6311764|NCT02675907|10042303|FG000|Study Overall|Withdrawal by Subject|2
6311765|NCT02675907|10042304|FG001|Study Overall|Withdrawal by Subject|2
6311766|NCT02675907|10042303|FG000|Study Overall|Lost to Follow-up|0
6311767|NCT02675907|10042304|FG001|Study Overall|Lost to Follow-up|2
6311768|NCT02675998|10042314|FG000|8-Week Treatment Period|Adverse Event|6
6311769|NCT02675998|10042315|FG001|8-Week Treatment Period|Adverse Event|5
6311770|NCT02675998|10042316|FG002|8-Week Treatment Period|Adverse Event|6
6311771|NCT02675998|10042317|FG003|8-Week Treatment Period|Adverse Event|0
6311772|NCT02675998|10042314|FG000|8-Week Treatment Period|Withdrawal by Subject|3
6311773|NCT02675998|10042315|FG001|8-Week Treatment Period|Withdrawal by Subject|3
6311774|NCT02675998|10042316|FG002|8-Week Treatment Period|Withdrawal by Subject|3
6311775|NCT02675998|10042317|FG003|8-Week Treatment Period|Withdrawal by Subject|0
6311776|NCT02675998|10042314|FG000|8-Week Treatment Period|Lack of Efficacy|2
6311777|NCT02675998|10042315|FG001|8-Week Treatment Period|Lack of Efficacy|5
6311778|NCT02675998|10042316|FG002|8-Week Treatment Period|Lack of Efficacy|3
6311779|NCT02675998|10042317|FG003|8-Week Treatment Period|Lack of Efficacy|0
6311780|NCT02675998|10042314|FG000|8-Week Treatment Period|Physician Decision|1
6311781|NCT02675998|10042315|FG001|8-Week Treatment Period|Physician Decision|0
6311782|NCT02675998|10042316|FG002|8-Week Treatment Period|Physician Decision|2
6311783|NCT02675998|10042317|FG003|8-Week Treatment Period|Physician Decision|0
6311784|NCT02675998|10042314|FG000|8-Week Treatment Period|GI side Effects|1
6148704|NCT01090492|9784036|FG006|First Intervention Period (4 Weeks)|Other|0
6311785|NCT02675998|10042315|FG001|8-Week Treatment Period|GI side Effects|4
6311786|NCT02675998|10042316|FG002|8-Week Treatment Period|GI side Effects|2
6311787|NCT02675998|10042317|FG003|8-Week Treatment Period|GI side Effects|0
6311788|NCT02675998|10042314|FG000|8-Week Treatment Period|Protocol Violation|1
6311789|NCT02675998|10042315|FG001|8-Week Treatment Period|Protocol Violation|1
6311790|NCT02675998|10042316|FG002|8-Week Treatment Period|Protocol Violation|1
6311791|NCT02675998|10042317|FG003|8-Week Treatment Period|Protocol Violation|0
6311792|NCT02675998|10042314|FG000|8-Week Treatment Period|Other|3
6311793|NCT02675998|10042315|FG001|8-Week Treatment Period|Other|1
6311794|NCT02675998|10042316|FG002|8-Week Treatment Period|Other|2
6311795|NCT02675998|10042317|FG003|8-Week Treatment Period|Other|0
6311796|NCT02675998|10042314|FG000|4-Week Randomized Withdrawal Period|Lack of Efficacy|0
6311797|NCT02675998|10042315|FG001|4-Week Randomized Withdrawal Period|Lack of Efficacy|1
6311798|NCT02675998|10042316|FG002|4-Week Randomized Withdrawal Period|Lack of Efficacy|1
6311799|NCT02675998|10042317|FG003|4-Week Randomized Withdrawal Period|Lack of Efficacy|3
6311800|NCT02675998|10042314|FG000|4-Week Randomized Withdrawal Period|Adverse Event|0
6311801|NCT02675998|10042315|FG001|4-Week Randomized Withdrawal Period|Adverse Event|0
6311802|NCT02675998|10042316|FG002|4-Week Randomized Withdrawal Period|Adverse Event|1
6311803|NCT02675998|10042317|FG003|4-Week Randomized Withdrawal Period|Adverse Event|3
6311804|NCT02675998|10042314|FG000|4-Week Randomized Withdrawal Period|Protocol Violation|0
6311805|NCT02675998|10042315|FG001|4-Week Randomized Withdrawal Period|Protocol Violation|0
6311806|NCT02675998|10042316|FG002|4-Week Randomized Withdrawal Period|Protocol Violation|0
6311807|NCT02675998|10042317|FG003|4-Week Randomized Withdrawal Period|Protocol Violation|1
6311808|NCT02675998|10042314|FG000|4-Week Randomized Withdrawal Period|Physician Decision|1
6311809|NCT02675998|10042315|FG001|4-Week Randomized Withdrawal Period|Physician Decision|0
6311810|NCT02675998|10042316|FG002|4-Week Randomized Withdrawal Period|Physician Decision|0
6311811|NCT02675998|10042317|FG003|4-Week Randomized Withdrawal Period|Physician Decision|0
6311812|NCT02675998|10042314|FG000|4-Week Randomized Withdrawal Period|Withdrawal by Subject|0
6311813|NCT02675998|10042315|FG001|4-Week Randomized Withdrawal Period|Withdrawal by Subject|0
6311814|NCT02675998|10042316|FG002|4-Week Randomized Withdrawal Period|Withdrawal by Subject|0
6311815|NCT02675998|10042317|FG003|4-Week Randomized Withdrawal Period|Withdrawal by Subject|1
6311816|NCT02676466|10042348|FG000|Overall Study|Death|0
6311817|NCT02676466|10042349|FG001|Overall Study|Death|2
6311818|NCT02676466|10042350|FG002|Overall Study|Death|1
6311819|NCT02676466|10042351|FG003|Overall Study|Death|0
6311820|NCT02676466|10042352|FG004|Overall Study|Death|0
6311821|NCT02676466|10042353|FG005|Overall Study|Death|0
6311822|NCT02676466|10042354|FG006|Overall Study|Death|0
6311823|NCT02676466|10042355|FG007|Overall Study|Death|0
6311824|NCT02676466|10042348|FG000|Overall Study|Withdrawal by Subject|4
6311825|NCT02676466|10042349|FG001|Overall Study|Withdrawal by Subject|3
6311826|NCT02676466|10042350|FG002|Overall Study|Withdrawal by Subject|1
6311827|NCT02676466|10042351|FG003|Overall Study|Withdrawal by Subject|0
6311828|NCT02676466|10042352|FG004|Overall Study|Withdrawal by Subject|3
6311829|NCT02676466|10042353|FG005|Overall Study|Withdrawal by Subject|1
6311830|NCT02676466|10042354|FG006|Overall Study|Withdrawal by Subject|1
6311831|NCT02676466|10042355|FG007|Overall Study|Withdrawal by Subject|1
6311832|NCT02676778|10042380|FG000|Overall Study|Disease Progression|7
6311833|NCT02676778|10042381|FG001|Overall Study|Disease Progression|3
6311834|NCT02676778|10042382|FG002|Overall Study|Disease Progression|1
6311835|NCT02676778|10042380|FG000|Overall Study|Couldn't Start Cycle After Planned Date|1
6311836|NCT02676778|10042381|FG001|Overall Study|Couldn't Start Cycle After Planned Date|1
6311837|NCT02676778|10042382|FG002|Overall Study|Couldn't Start Cycle After Planned Date|0
6311838|NCT02676778|10042380|FG000|Overall Study|Withdrawal by Subject|3
6311839|NCT02676778|10042381|FG001|Overall Study|Withdrawal by Subject|2
6311840|NCT02676778|10042382|FG002|Overall Study|Withdrawal by Subject|0
6311841|NCT02676778|10042380|FG000|Overall Study|Other|4
6311842|NCT02676778|10042381|FG001|Overall Study|Other|3
6311843|NCT02676778|10042382|FG002|Overall Study|Other|0
6311844|NCT02676778|10042380|FG000|Overall Study|Adverse Event|2
6311845|NCT02676778|10042381|FG001|Overall Study|Adverse Event|3
6311846|NCT02676778|10042382|FG002|Overall Study|Adverse Event|0
6311847|NCT02676882|10042398|FG000|Overall Study|Adverse Event|1
6148705|NCT01090492|9784037|FG007|First Intervention Period (4 Weeks)|Other|0
6148706|NCT01090492|9784030|FG000|First Intervention Period (4 Weeks)|Pregnancy|0
6148707|NCT01090492|9784031|FG001|First Intervention Period (4 Weeks)|Pregnancy|0
6148708|NCT01090492|9784032|FG002|First Intervention Period (4 Weeks)|Pregnancy|0
6148709|NCT01090492|9784033|FG003|First Intervention Period (4 Weeks)|Pregnancy|0
6148710|NCT01090492|9784034|FG004|First Intervention Period (4 Weeks)|Pregnancy|1
6148711|NCT01090492|9784035|FG005|First Intervention Period (4 Weeks)|Pregnancy|0
6148712|NCT01090492|9784036|FG006|First Intervention Period (4 Weeks)|Pregnancy|0
6148713|NCT01090492|9784037|FG007|First Intervention Period (4 Weeks)|Pregnancy|0
6148714|NCT01090492|9784030|FG000|First Intervention Period (4 Weeks)|Adverse Event|0
6148715|NCT01090492|9784031|FG001|First Intervention Period (4 Weeks)|Adverse Event|2
6311848|NCT02676882|10042399|FG001|Overall Study|Adverse Event|0
6311849|NCT02676882|10042398|FG000|Overall Study|Lost to Follow-up|1
6311850|NCT02676882|10042399|FG001|Overall Study|Lost to Follow-up|0
6311851|NCT02676882|10042398|FG000|Overall Study|Withdrawal by Subject|1
6311852|NCT02676882|10042399|FG001|Overall Study|Withdrawal by Subject|2
6148716|NCT01090492|9784032|FG002|First Intervention Period (4 Weeks)|Adverse Event|0
6311853|NCT02676895|10042408|FG000|Overall Study|Administrative reason|1
6311854|NCT02676895|10042409|FG001|Overall Study|Administrative reason|0
6311855|NCT02676895|10042410|FG002|Overall Study|Administrative reason|0
6311856|NCT02676895|10042408|FG000|Overall Study|Protocol Violation|1
6311857|NCT02676895|10042409|FG001|Overall Study|Protocol Violation|0
6311858|NCT02676895|10042410|FG002|Overall Study|Protocol Violation|0
6311859|NCT02676895|10042408|FG000|Overall Study|Adverse Event|0
6311860|NCT02676895|10042409|FG001|Overall Study|Adverse Event|3
6311861|NCT02676895|10042410|FG002|Overall Study|Adverse Event|1
6311862|NCT02676895|10042408|FG000|Overall Study|Lost to Follow-up|0
6311863|NCT02676895|10042409|FG001|Overall Study|Lost to Follow-up|0
6311864|NCT02676895|10042410|FG002|Overall Study|Lost to Follow-up|1
6311865|NCT02676895|10042408|FG000|Overall Study|Withdrawal by Subject|0
6311866|NCT02676895|10042409|FG001|Overall Study|Withdrawal by Subject|0
6311867|NCT02676895|10042410|FG002|Overall Study|Withdrawal by Subject|1
6311868|NCT02677116|10042428|FG000|Overall Study|Adverse Event|0
6311869|NCT02677116|10042429|FG001|Overall Study|Adverse Event|1
6311870|NCT02677116|10042430|FG002|Overall Study|Adverse Event|0
6311871|NCT02677116|10042431|FG003|Overall Study|Adverse Event|0
6311872|NCT02677116|10042432|FG004|Overall Study|Adverse Event|0
6039939|NCT00368355|9637721|FG000|Overall Study|Relapse|6
6039940|NCT00368355|9637722|FG001|Overall Study|Relapse|10
6039941|NCT00368355|9637721|FG000|Overall Study|Subsequent transplant|0
6039942|NCT00368355|9637722|FG001|Overall Study|Subsequent transplant|3
6039943|NCT00368355|9637721|FG000|Overall Study|Treatment - hematopoietic cell product|2
6039944|NCT00368355|9637722|FG001|Overall Study|Treatment - hematopoietic cell product|0
6039945|NCT00368472|9637737|FG000|Overall Study|Adverse Event|22
6039946|NCT00368472|9637737|FG000|Overall Study|Medication non-compliance|4
6039947|NCT00368472|9637737|FG000|Overall Study|Protocol Violation|2
6039948|NCT00368472|9637737|FG000|Overall Study|Request of Investigator or Sponsor|3
6039949|NCT00368472|9637737|FG000|Overall Study|Withdrawal by Subject|40
6039950|NCT00368472|9637737|FG000|Overall Study|Diary non-compliance|1
6039951|NCT00368472|9637737|FG000|Overall Study|Other|32
6039952|NCT00368472|9637737|FG000|Overall Study|Missing Final Disposition Date|1
6039953|NCT00368537|9637743|FG000|Randomization|No study drug dosed|13
6039954|NCT00368537|9637744|FG001|Randomization|No study drug dosed|6
6039955|NCT00368537|9637743|FG000|Baseline Participants|Lost to Follow-up|16
6311873|NCT02677116|10042433|FG005|Overall Study|Adverse Event|1
6311874|NCT02677116|10042434|FG006|Overall Study|Adverse Event|1
6311875|NCT02677116|10042435|FG007|Overall Study|Adverse Event|0
6311876|NCT02677116|10042436|FG008|Overall Study|Adverse Event|0
6311877|NCT02677116|10042428|FG000|Overall Study|Physician Decision|0
6311878|NCT02677116|10042429|FG001|Overall Study|Physician Decision|2
6311879|NCT02677116|10042430|FG002|Overall Study|Physician Decision|3
6311880|NCT02677116|10042431|FG003|Overall Study|Physician Decision|2
6311881|NCT02677116|10042432|FG004|Overall Study|Physician Decision|1
6311882|NCT02677116|10042433|FG005|Overall Study|Physician Decision|3
6311883|NCT02677116|10042434|FG006|Overall Study|Physician Decision|1
6311884|NCT02677116|10042435|FG007|Overall Study|Physician Decision|1
6039956|NCT00368537|9637744|FG001|Baseline Participants|Lost to Follow-up|17
6039957|NCT00368537|9637743|FG000|Baseline Participants|Withdrawal by Subject|6
6039958|NCT00368537|9637744|FG001|Baseline Participants|Withdrawal by Subject|4
6039959|NCT00368537|9637743|FG000|Baseline Participants|Death|1
6039960|NCT00368537|9637744|FG001|Baseline Participants|Death|2
6039961|NCT00368537|9637743|FG000|Baseline Participants|No susceptibility|1
6039962|NCT00368537|9637744|FG001|Baseline Participants|No susceptibility|0
6039963|NCT00368537|9637743|FG000|Baseline Participants|Patient uncompliant|0
6039964|NCT00368537|9637744|FG001|Baseline Participants|Patient uncompliant|1
6039965|NCT00368550|9637752|FG000|Overall Study|Adverse Event|7
6039966|NCT00368550|9637753|FG001|Overall Study|Adverse Event|4
6039967|NCT00368550|9637752|FG000|Overall Study|Lack of Efficacy|4
6311885|NCT02677116|10042436|FG008|Overall Study|Physician Decision|2
6311886|NCT02677116|10042428|FG000|Overall Study|Withdrawal by parent or guardian|2
6311887|NCT02677116|10042429|FG001|Overall Study|Withdrawal by parent or guardian|1
6311888|NCT02677116|10042430|FG002|Overall Study|Withdrawal by parent or guardian|0
6311889|NCT02677116|10042431|FG003|Overall Study|Withdrawal by parent or guardian|1
6311890|NCT02677116|10042432|FG004|Overall Study|Withdrawal by parent or guardian|0
6311891|NCT02677116|10042433|FG005|Overall Study|Withdrawal by parent or guardian|0
6311892|NCT02677116|10042434|FG006|Overall Study|Withdrawal by parent or guardian|2
6311893|NCT02677116|10042435|FG007|Overall Study|Withdrawal by parent or guardian|1
6311894|NCT02677116|10042436|FG008|Overall Study|Withdrawal by parent or guardian|0
6311895|NCT02677116|10042428|FG000|Overall Study|Withdrawal by Subject|1
6311896|NCT02677116|10042429|FG001|Overall Study|Withdrawal by Subject|0
6311897|NCT02677116|10042430|FG002|Overall Study|Withdrawal by Subject|0
6311898|NCT02677116|10042431|FG003|Overall Study|Withdrawal by Subject|0
6311899|NCT02677116|10042432|FG004|Overall Study|Withdrawal by Subject|0
6311900|NCT02677116|10042433|FG005|Overall Study|Withdrawal by Subject|0
6311901|NCT02677116|10042434|FG006|Overall Study|Withdrawal by Subject|0
6311902|NCT02677116|10042435|FG007|Overall Study|Withdrawal by Subject|0
6311903|NCT02677116|10042436|FG008|Overall Study|Withdrawal by Subject|0
6311904|NCT02677220|10042479|FG000|Overall Study|Adverse Event|1
6311905|NCT02677714|10042537|FG000|Overall Study|Withdrawal by Subject|2
6311906|NCT02677714|10042538|FG001|Overall Study|Withdrawal by Subject|0
6311907|NCT02677844|10042582|FG000|Period 3|Withdrawal by Subject|0
6311908|NCT02677844|10042583|FG001|Period 3|Withdrawal by Subject|0
6311909|NCT02677844|10042584|FG002|Period 3|Withdrawal by Subject|0
6311910|NCT02677844|10042585|FG003|Period 3|Withdrawal by Subject|1
6311911|NCT02677844|10042586|FG004|Period 3|Withdrawal by Subject|0
6311912|NCT02677844|10042587|FG005|Period 3|Withdrawal by Subject|0
6311913|NCT02677844|10042588|FG006|Period 3|Withdrawal by Subject|0
6311914|NCT02678000|10042612|FG000|PART 2|Adverse Event|0
6311915|NCT02678000|10042613|FG001|PART 2|Adverse Event|0
6311916|NCT02678000|10042614|FG002|PART 2|Adverse Event|2
6311917|NCT02678000|10042615|FG003|PART 2|Adverse Event|1
6311918|NCT02678000|10042616|FG004|PART 2|Adverse Event|0
6311919|NCT02678000|10042612|FG000|PART 2|Withdrawal by Subject|0
6311920|NCT02678000|10042613|FG001|PART 2|Withdrawal by Subject|0
6311921|NCT02678000|10042614|FG002|PART 2|Withdrawal by Subject|1
6311922|NCT02678000|10042615|FG003|PART 2|Withdrawal by Subject|0
6311923|NCT02678000|10042616|FG004|PART 2|Withdrawal by Subject|0
6311924|NCT02678247|10042652|FG000|First Intervention (7 Weeks)|Withdrawal by Subject|0
6311925|NCT02678247|10042653|FG001|First Intervention (7 Weeks)|Withdrawal by Subject|2
6311926|NCT02678247|10042652|FG000|First Intervention (7 Weeks)|Adverse Event|1
6311927|NCT02678247|10042653|FG001|First Intervention (7 Weeks)|Adverse Event|2
6311928|NCT02678247|10042652|FG000|First Intervention (7 Weeks)|Physician Decision|1
6311929|NCT02678247|10042653|FG001|First Intervention (7 Weeks)|Physician Decision|0
6311930|NCT02678247|10042652|FG000|Second Intervention (7 Weeks)|Withdrawal by Subject|1
6311931|NCT02678247|10042653|FG001|Second Intervention (7 Weeks)|Withdrawal by Subject|1
6311932|NCT02678247|10042652|FG000|Second Intervention (7 Weeks)|Adverse Event|2
6311933|NCT02678247|10042653|FG001|Second Intervention (7 Weeks)|Adverse Event|1
6311934|NCT02678247|10042652|FG000|Second Intervention (7 Weeks)|Physician Decision|1
6311935|NCT02678247|10042653|FG001|Second Intervention (7 Weeks)|Physician Decision|0
6311936|NCT02678286|10042666|FG000|Treatment Phase (48 Hours Post-Dose 1)|Lack of Efficacy|2
6311937|NCT02678286|10042667|FG001|Treatment Phase (48 Hours Post-Dose 1)|Lack of Efficacy|1
6311938|NCT02678286|10042666|FG000|Treatment Phase (48 Hours Post-Dose 1)|Adverse Event|0
6311939|NCT02678286|10042667|FG001|Treatment Phase (48 Hours Post-Dose 1)|Adverse Event|1
6311940|NCT02678286|10042666|FG000|Study Overall (28 Day Follow-Up)|Lack of Efficacy|1
6311941|NCT02678286|10042667|FG001|Study Overall (28 Day Follow-Up)|Lack of Efficacy|0
6311942|NCT02678286|10042666|FG000|Study Overall (28 Day Follow-Up)|Withdrawal by Subject|3
6311943|NCT02678286|10042667|FG001|Study Overall (28 Day Follow-Up)|Withdrawal by Subject|2
6311944|NCT02678286|10042666|FG000|Study Overall (28 Day Follow-Up)|Lost to Follow-up|2
6311945|NCT02678286|10042667|FG001|Study Overall (28 Day Follow-Up)|Lost to Follow-up|2
6311946|NCT02678390|10042675|FG000|AE (1 Day)|Withdrawal by Subject|0
6311947|NCT02678390|10042676|FG001|AE (1 Day)|Withdrawal by Subject|1
6311948|NCT02678416|10042684|FG000|Part 1|Withdrawal by Subject|1
6311949|NCT02678416|10042684|FG000|Part 2|Adverse Event|2
6311950|NCT02678416|10042684|FG000|Part 2|Withdrawal by Subject|1
6311951|NCT02678676|10042713|FG000|Overall Study|Death|619
6311952|NCT02678676|10042714|FG001|Overall Study|Death|649
6311953|NCT02678676|10042713|FG000|Overall Study|Withdrawal by Subject|13
6311954|NCT02678676|10042714|FG001|Overall Study|Withdrawal by Subject|5
6311955|NCT02678676|10042713|FG000|Overall Study|Lost to Follow-up|171
6311956|NCT02678676|10042714|FG001|Overall Study|Lost to Follow-up|151
6311957|NCT02678676|10042713|FG000|Overall Study|Unconfirmed for lost to follow-up|85
6311958|NCT02678676|10042714|FG001|Overall Study|Unconfirmed for lost to follow-up|67
6311959|NCT02678923|10042722|FG000|Overall Study|Protocol Deviation (Not Dosed)|1
6311960|NCT02678923|10042723|FG001|Overall Study|Protocol Deviation (Not Dosed)|3
6311961|NCT02678923|10042722|FG000|Overall Study|Withdrawal by Subject|3
6311962|NCT02678923|10042723|FG001|Overall Study|Withdrawal by Subject|2
6311963|NCT02678923|10042722|FG000|Overall Study|Lost to Follow-up|1
6039968|NCT00368550|9637753|FG001|Overall Study|Lack of Efficacy|9
6039969|NCT00368550|9637752|FG000|Overall Study|Withdrawal by Subject|17
6039970|NCT00368550|9637753|FG001|Overall Study|Withdrawal by Subject|10
6039971|NCT00368641|9637761|FG000|Overall Study|Adverse Event|2
6039972|NCT00368641|9637762|FG001|Overall Study|Adverse Event|1
6039973|NCT00368641|9637761|FG000|Overall Study|Death|1
6039974|NCT00368641|9637762|FG001|Overall Study|Death|0
6039975|NCT00368641|9637761|FG000|Overall Study|Withdrawal by Subject|1
6311964|NCT02678923|10042723|FG001|Overall Study|Lost to Follow-up|0
6311965|NCT02678923|10042722|FG000|Overall Study|Did Not Return for Study Visits|1
6311966|NCT02678923|10042723|FG001|Overall Study|Did Not Return for Study Visits|0
6311967|NCT02679079|10042732|FG000|Overall Study|Adverse Event|2
6311968|NCT02679079|10042733|FG001|Overall Study|Adverse Event|0
6311969|NCT02679079|10042734|FG002|Overall Study|Adverse Event|2
6311970|NCT02679079|10042732|FG000|Overall Study|Protocol Violation|0
6311971|NCT02679079|10042733|FG001|Overall Study|Protocol Violation|1
6311972|NCT02679079|10042734|FG002|Overall Study|Protocol Violation|0
6311973|NCT02679079|10042732|FG000|Overall Study|Withdrawal by Subject|2
6311974|NCT02679079|10042733|FG001|Overall Study|Withdrawal by Subject|1
6039976|NCT00368641|9637762|FG001|Overall Study|Withdrawal by Subject|0
6039977|NCT00368641|9637761|FG000|Overall Study|Sponsor decision to terminate study|2
6039978|NCT00368641|9637762|FG001|Overall Study|Sponsor decision to terminate study|5
6039979|NCT00368745|9637770|FG000|Double-blind Treatment Period|Adverse Event|6
6039980|NCT00368745|9637771|FG001|Double-blind Treatment Period|Adverse Event|6
6039981|NCT00368745|9637770|FG000|Double-blind Treatment Period|Lack of Efficacy|7
6039982|NCT00368745|9637771|FG001|Double-blind Treatment Period|Lack of Efficacy|16
6039983|NCT00368745|9637770|FG000|Double-blind Treatment Period|Lost to Follow-up|1
6039984|NCT00368745|9637771|FG001|Double-blind Treatment Period|Lost to Follow-up|0
6039985|NCT00368745|9637770|FG000|Double-blind Treatment Period|Withdrawal by Subject|5
6039986|NCT00368745|9637771|FG001|Double-blind Treatment Period|Withdrawal by Subject|3
6039987|NCT00368745|9637770|FG000|Double-blind Treatment Period|Other|7
6039988|NCT00368745|9637771|FG001|Double-blind Treatment Period|Other|6
6039989|NCT00368849|9637777|FG000|Overall Study|Withdrawal by Subject|0
6039990|NCT00368849|9637778|FG001|Overall Study|Withdrawal by Subject|1
6039991|NCT00368849|9637777|FG000|Overall Study|Physician Decision|0
6039992|NCT00368849|9637778|FG001|Overall Study|Physician Decision|1
6039993|NCT00368875|9637785|FG000|Overall Study|Adverse Event|0
6039994|NCT00368875|9637786|FG001|Overall Study|Adverse Event|12
6039995|NCT00368875|9637785|FG000|Overall Study|Progressive disease|3
6039996|NCT00368875|9637786|FG001|Overall Study|Progressive disease|27
6039997|NCT00368875|9637785|FG000|Overall Study|Withdrawal by Subject|2
6039998|NCT00368875|9637786|FG001|Overall Study|Withdrawal by Subject|6
6039999|NCT00368875|9637785|FG000|Overall Study|Other Reason|0
6040000|NCT00368875|9637786|FG001|Overall Study|Other Reason|2
6040001|NCT00368875|9637785|FG000|Overall Study|Alternative Therapy|1
6040002|NCT00368875|9637786|FG001|Overall Study|Alternative Therapy|1
6040003|NCT00368927|9637794|FG000|Overall Study|Lost to Follow-up|2
6040004|NCT00368927|9637795|FG001|Overall Study|Lost to Follow-up|0
6040005|NCT00368927|9637794|FG000|Overall Study|Adverse Event|1
6040006|NCT00368927|9637795|FG001|Overall Study|Adverse Event|1
6040007|NCT00368927|9637794|FG000|Overall Study|Withdrawal by Subject|1
6040008|NCT00368927|9637795|FG001|Overall Study|Withdrawal by Subject|2
6040009|NCT00368927|9637794|FG000|Overall Study|Physician Decision|1
6040010|NCT00368927|9637795|FG001|Overall Study|Physician Decision|0
6311975|NCT02679079|10042734|FG002|Overall Study|Withdrawal by Subject|0
6311976|NCT02679222|10042742|FG000|Overall Study|No time for project|1
6311977|NCT02679235|10042754|FG000|Overall Study|Withdrawal by Subject|3
6311978|NCT02679235|10042754|FG000|Overall Study|Adverse Event|1
6311979|NCT02679274|10042760|FG000|Overall Study|Withdrawal by Subject|1
6311980|NCT02679274|10042761|FG001|Overall Study|Withdrawal by Subject|0
6311981|NCT02679287|10042769|FG000|Period 1: Randomization-Study Session 1|Regimen not compatible with study|2
6311982|NCT02679287|10042770|FG001|Period 1: Randomization-Study Session 1|Regimen not compatible with study|1
6311983|NCT02679287|10042769|FG000|Period 1: Randomization-Study Session 1|Work or scheduling conflict|2
6311984|NCT02679287|10042770|FG001|Period 1: Randomization-Study Session 1|Work or scheduling conflict|3
6311985|NCT02679287|10042769|FG000|Period 1: Randomization-Study Session 1|Disliked mobile system|0
6311986|NCT02679287|10042770|FG001|Period 1: Randomization-Study Session 1|Disliked mobile system|1
6311987|NCT02679287|10042769|FG000|Period 1: Randomization-Study Session 1|Adverse Event prior to intervention|0
6311988|NCT02679287|10042770|FG001|Period 1: Randomization-Study Session 1|Adverse Event prior to intervention|1
6311989|NCT02679287|10042769|FG000|Period 2|Work/Scheduling Conflict|1
6311990|NCT02679287|10042770|FG001|Period 2|Work/Scheduling Conflict|0
6311991|NCT02679287|10042769|FG000|Period 2|Disliked Mobile System|2
6311992|NCT02679287|10042770|FG001|Period 2|Disliked Mobile System|0
6311993|NCT02679287|10042769|FG000|Period 3|Work/Scheduling Conflict|0
6311994|NCT02679287|10042770|FG001|Period 3|Work/Scheduling Conflict|1
6311995|NCT02679573|10042788|FG000|Overall Study|Adverse Event|13
6311996|NCT02679573|10042789|FG001|Overall Study|Adverse Event|6
6311997|NCT02679573|10042788|FG000|Overall Study|Lack of Efficacy|12
6311998|NCT02679573|10042789|FG001|Overall Study|Lack of Efficacy|15
6311999|NCT02679573|10042788|FG000|Overall Study|Could not complete required study visits|6
6312000|NCT02679573|10042789|FG001|Overall Study|Could not complete required study visits|2
6312001|NCT02679573|10042788|FG000|Overall Study|Withdrawal by Subject|2
6312002|NCT02679573|10042789|FG001|Overall Study|Withdrawal by Subject|9
6312003|NCT02679573|10042788|FG000|Overall Study|Death|2
6312004|NCT02679573|10042789|FG001|Overall Study|Death|0
6312005|NCT02679573|10042788|FG000|Overall Study|Physician Decision|2
6040011|NCT00368966|9637813|FG000|Infant Series|Withdrawal by Subject|11
6040012|NCT00368966|9637814|FG001|Infant Series|Withdrawal by Subject|6
6040013|NCT00368966|9637813|FG000|Infant Series|Protocol Violation|2
6040014|NCT00368966|9637814|FG001|Infant Series|Protocol Violation|1
6312006|NCT02679573|10042789|FG001|Overall Study|Physician Decision|4
6312007|NCT02679573|10042788|FG000|Overall Study|Lost to Follow-up|0
6312008|NCT02679573|10042789|FG001|Overall Study|Lost to Follow-up|3
6312009|NCT02679729|10042810|FG000|Overall Study|Lost to Follow-up|0
6312010|NCT02679729|10042811|FG001|Overall Study|Lost to Follow-up|1
6312011|NCT02679729|10042812|FG002|Overall Study|Lost to Follow-up|0
6312012|NCT02679729|10042813|FG003|Overall Study|Lost to Follow-up|0
6312013|NCT02679729|10042814|FG004|Overall Study|Lost to Follow-up|1
6312014|NCT02679729|10042815|FG005|Overall Study|Lost to Follow-up|0
6312015|NCT02679729|10042816|FG006|Overall Study|Lost to Follow-up|0
6312016|NCT02679729|10042817|FG007|Overall Study|Lost to Follow-up|0
6312017|NCT02679729|10042818|FG008|Overall Study|Lost to Follow-up|0
6312018|NCT02679729|10042810|FG000|Overall Study|Participant decision|0
6312019|NCT02679729|10042811|FG001|Overall Study|Participant decision|1
6312020|NCT02679729|10042812|FG002|Overall Study|Participant decision|0
6312021|NCT02679729|10042813|FG003|Overall Study|Participant decision|0
6227299|NCT01716520|9900045|FG004|Treatment Period 2 (14 Days)|Adverse Event|1
6227300|NCT01716520|9900046|FG005|Treatment Period 2 (14 Days)|Adverse Event|0
6227301|NCT01716520|9900041|FG000|Treatment Period 2 (14 Days)|Protocol Violation|0
6227302|NCT01716520|9900042|FG001|Treatment Period 2 (14 Days)|Protocol Violation|0
6227303|NCT01716520|9900043|FG002|Treatment Period 2 (14 Days)|Protocol Violation|0
6227304|NCT01716520|9900044|FG003|Treatment Period 2 (14 Days)|Protocol Violation|0
6227305|NCT01716520|9900045|FG004|Treatment Period 2 (14 Days)|Protocol Violation|1
6227306|NCT01716520|9900046|FG005|Treatment Period 2 (14 Days)|Protocol Violation|0
6227307|NCT01716520|9900041|FG000|Treatment Period 2 (14 Days)|Protocol-defined Stopping Criteria|0
6227308|NCT01716520|9900042|FG001|Treatment Period 2 (14 Days)|Protocol-defined Stopping Criteria|0
6227309|NCT01716520|9900043|FG002|Treatment Period 2 (14 Days)|Protocol-defined Stopping Criteria|0
6227310|NCT01716520|9900044|FG003|Treatment Period 2 (14 Days)|Protocol-defined Stopping Criteria|1
6227311|NCT01716520|9900045|FG004|Treatment Period 2 (14 Days)|Protocol-defined Stopping Criteria|0
6227312|NCT01716520|9900046|FG005|Treatment Period 2 (14 Days)|Protocol-defined Stopping Criteria|0
6227313|NCT01716520|9900041|FG000|Washout Period 2 (10 to 14 Days)|Adverse Event|1
6227314|NCT01716520|9900042|FG001|Washout Period 2 (10 to 14 Days)|Adverse Event|0
6227315|NCT01716520|9900043|FG002|Washout Period 2 (10 to 14 Days)|Adverse Event|1
6227316|NCT01716520|9900044|FG003|Washout Period 2 (10 to 14 Days)|Adverse Event|0
6227317|NCT01716520|9900045|FG004|Washout Period 2 (10 to 14 Days)|Adverse Event|0
6227318|NCT01716520|9900046|FG005|Washout Period 2 (10 to 14 Days)|Adverse Event|1
6040015|NCT00368966|9637813|FG000|Infant Series|Lost to Follow-up|2
6040016|NCT00368966|9637814|FG001|Infant Series|Lost to Follow-up|0
6040017|NCT00368966|9637813|FG000|Infant Series|Randomization error|0
6040018|NCT00368966|9637814|FG001|Infant Series|Randomization error|1
6040019|NCT00368966|9637813|FG000|Infant Series|Failed to meet eligibility criteria|0
6040020|NCT00368966|9637814|FG001|Infant Series|Failed to meet eligibility criteria|1
6040021|NCT00368966|9637813|FG000|Infant Series|Adverse Event|0
6040022|NCT00368966|9637814|FG001|Infant Series|Adverse Event|1
6040023|NCT00368966|9637813|FG000|Infant Series|Failed to return|1
6040024|NCT00368966|9637814|FG001|Infant Series|Failed to return|0
6040025|NCT00368966|9637813|FG000|After Infant|Failed to return|3
6040026|NCT00368966|9637814|FG001|After Infant|Failed to return|1
6312022|NCT02679729|10042814|FG004|Overall Study|Participant decision|0
6312023|NCT02679729|10042815|FG005|Overall Study|Participant decision|0
6312024|NCT02679729|10042816|FG006|Overall Study|Participant decision|1
6312025|NCT02679729|10042817|FG007|Overall Study|Participant decision|0
6312026|NCT02679729|10042818|FG008|Overall Study|Participant decision|0
6312027|NCT02679755|10042852|FG000|Overall Study|Death|0
6040027|NCT00368966|9637813|FG000|After Infant|Adverse Event|1
6040028|NCT00368966|9637814|FG001|After Infant|Adverse Event|2
6040029|NCT00368966|9637813|FG000|After Infant|Withdrawal by Subject|1
6040030|NCT00368966|9637814|FG001|After Infant|Withdrawal by Subject|1
6040031|NCT00368966|9637813|FG000|After Infant|Death|1
6040032|NCT00368966|9637814|FG001|After Infant|Death|0
6040033|NCT00368966|9637813|FG000|After Infant|Lost to Follow-up|0
6040034|NCT00368966|9637814|FG001|After Infant|Lost to Follow-up|1
6040035|NCT00368966|9637813|FG000|Toddler Dose|Withdrawal by Subject|1
6040036|NCT00368966|9637814|FG001|Toddler Dose|Withdrawal by Subject|1
6040037|NCT00368966|9637813|FG000|Toddler Dose|Lost to Follow-up|0
6040038|NCT00368966|9637814|FG001|Toddler Dose|Lost to Follow-up|2
6040039|NCT00368979|9637847|FG000|Overall Study|Adverse Event|9
6040040|NCT00368979|9637848|FG001|Overall Study|Adverse Event|16
6040041|NCT00368979|9637847|FG000|Overall Study|Lack of Efficacy|5
6040042|NCT00368979|9637848|FG001|Overall Study|Lack of Efficacy|3
6040043|NCT00368979|9637847|FG000|Overall Study|Other|3
6040044|NCT00368979|9637848|FG001|Overall Study|Other|1
6040045|NCT00368979|9637847|FG000|Overall Study|Lost to Follow-up|1
6040046|NCT00368979|9637848|FG001|Overall Study|Lost to Follow-up|0
6040047|NCT00368979|9637847|FG000|Overall Study|Protocol Violation|2
6040048|NCT00368979|9637848|FG001|Overall Study|Protocol Violation|1
6040049|NCT00368979|9637847|FG000|Overall Study|Withdrawal by Subject|5
6040050|NCT00368979|9637848|FG001|Overall Study|Withdrawal by Subject|9
6040051|NCT00368992|9637854|FG000|Overall Study|Ineligible|5
6040052|NCT00368992|9637854|FG000|Overall Study|Refused treatment|3
6040053|NCT00368992|9637854|FG000|Overall Study|Lack of Efficacy|63
6040054|NCT00368992|9637854|FG000|Overall Study|Adverse Event|26
6040055|NCT00368992|9637854|FG000|Overall Study|Death|4
6040056|NCT00368992|9637854|FG000|Overall Study|Other|9
6040057|NCT00369122|9637859|FG000|Overall Study|Ineligible|10
6040058|NCT00369122|9637859|FG000|Overall Study|No protocol treatment|1
6080223|NCT00615030|9687428|FG011|Period I|Abnormal laboratory value(s)|0
6312028|NCT02679755|10042853|FG001|Overall Study|Death|3
6312029|NCT02679755|10042852|FG000|Overall Study|Global deterioration of health status|1
6312030|NCT02679755|10042853|FG001|Overall Study|Global deterioration of health status|8
6312031|NCT02679755|10042852|FG000|Overall Study|Lost to Follow-up|1
6312032|NCT02679755|10042853|FG001|Overall Study|Lost to Follow-up|0
6312033|NCT02679755|10042852|FG000|Overall Study|Objective progression or relapse|24
6312034|NCT02679755|10042853|FG001|Overall Study|Objective progression or relapse|83
6312035|NCT02679755|10042852|FG000|Overall Study|Not defined|0
6040059|NCT00369161|9637865|FG000|Overall Study|Adverse Event|15
6040060|NCT00369161|9637866|FG001|Overall Study|Adverse Event|13
6040061|NCT00369161|9637865|FG000|Overall Study|Abnormal laboratory value|0
6040062|NCT00369161|9637866|FG001|Overall Study|Abnormal laboratory value|1
6040063|NCT00369161|9637865|FG000|Overall Study|Lack of Efficacy|3
6040064|NCT00369161|9637866|FG001|Overall Study|Lack of Efficacy|1
6040065|NCT00369161|9637865|FG000|Overall Study|Protocol Violation|0
6040066|NCT00369161|9637866|FG001|Overall Study|Protocol Violation|2
6040067|NCT00369161|9637865|FG000|Overall Study|Withdrawal by Subject|2
6040068|NCT00369161|9637866|FG001|Overall Study|Withdrawal by Subject|3
6040069|NCT00369161|9637865|FG000|Overall Study|Death|1
6040070|NCT00369161|9637866|FG001|Overall Study|Death|2
6040071|NCT00369161|9637865|FG000|Overall Study|Graft loss|4
6040072|NCT00369161|9637866|FG001|Overall Study|Graft loss|0
6040073|NCT00369161|9637865|FG000|Overall Study|Administrative Problem|2
6040074|NCT00369161|9637866|FG001|Overall Study|Administrative Problem|2
6040075|NCT00369278|9637886|FG000|Overall Study|Adverse Event|14
6040076|NCT00369278|9637887|FG001|Overall Study|Adverse Event|11
6040077|NCT00369278|9637886|FG000|Overall Study|Unsatisfactory therapeutic effect|4
6040078|NCT00369278|9637887|FG001|Overall Study|Unsatisfactory therapeutic effect|5
6040079|NCT00369278|9637886|FG000|Overall Study|Protocol Violation|2
6040080|NCT00369278|9637887|FG001|Overall Study|Protocol Violation|1
6040081|NCT00369278|9637886|FG000|Overall Study|Withdrawal by Subject|2
6040082|NCT00369278|9637887|FG001|Overall Study|Withdrawal by Subject|2
6040083|NCT00369278|9637886|FG000|Overall Study|Lost to Follow-up|1
6040084|NCT00369278|9637887|FG001|Overall Study|Lost to Follow-up|0
6040085|NCT00369278|9637886|FG000|Overall Study|Graft loss|1
6040086|NCT00369278|9637887|FG001|Overall Study|Graft loss|2
6048933|NCT00420927|9648201|FG002|Period 1|Received wrong treatment/incorrect dose|0
6048934|NCT00420927|9648202|FG003|Period 1|Received wrong treatment/incorrect dose|0
6048935|NCT00420927|9648203|FG004|Period 1|Received wrong treatment/incorrect dose|0
6048936|NCT00420927|9648204|FG005|Period 1|Received wrong treatment/incorrect dose|0
6048937|NCT00420927|9648205|FG006|Period 1|Received wrong treatment/incorrect dose|0
6048938|NCT00420927|9648199|FG000|Period 1|Failed to meet entry criteria|8
6048939|NCT00420927|9648200|FG001|Period 1|Failed to meet entry criteria|7
6048940|NCT00420927|9648201|FG002|Period 1|Failed to meet entry criteria|0
6048941|NCT00420927|9648202|FG003|Period 1|Failed to meet entry criteria|0
6048942|NCT00420927|9648203|FG004|Period 1|Failed to meet entry criteria|0
6048943|NCT00420927|9648204|FG005|Period 1|Failed to meet entry criteria|0
6048944|NCT00420927|9648205|FG006|Period 1|Failed to meet entry criteria|0
6048945|NCT00420927|9648199|FG000|Period 1|Took prohibited medication|1
6048946|NCT00420927|9648200|FG001|Period 1|Took prohibited medication|3
6048947|NCT00420927|9648201|FG002|Period 1|Took prohibited medication|0
6048948|NCT00420927|9648202|FG003|Period 1|Took prohibited medication|0
6048949|NCT00420927|9648203|FG004|Period 1|Took prohibited medication|0
6048950|NCT00420927|9648204|FG005|Period 1|Took prohibited medication|0
6048951|NCT00420927|9648205|FG006|Period 1|Took prohibited medication|0
6048952|NCT00420927|9648199|FG000|Period 2|Adverse Event|0
6048953|NCT00420927|9648200|FG001|Period 2|Adverse Event|0
6312036|NCT02679755|10042853|FG001|Overall Study|Not defined|2
6312037|NCT02679755|10042852|FG000|Overall Study|Withdrawal by participant|6
6312038|NCT02679755|10042853|FG001|Overall Study|Withdrawal by participant|3
6312039|NCT02679755|10042852|FG000|Overall Study|Adverse Event|1
6312040|NCT02679755|10042853|FG001|Overall Study|Adverse Event|4
6312041|NCT02679755|10042852|FG000|Overall Study|Adverse events not related to study drug|1
6312042|NCT02679755|10042853|FG001|Overall Study|Adverse events not related to study drug|2
6312043|NCT02680002|10042887|FG000|Overall Study|Lost to Follow-up|5
6312044|NCT02680002|10042888|FG001|Overall Study|Lost to Follow-up|1
6312045|NCT02680002|10042889|FG002|Overall Study|Lost to Follow-up|4
6312046|NCT02680002|10042890|FG003|Overall Study|Lost to Follow-up|2
6312047|NCT02680002|10042891|FG004|Overall Study|Lost to Follow-up|0
6312048|NCT02680002|10042892|FG005|Overall Study|Lost to Follow-up|2
6312049|NCT02680002|10042887|FG000|Overall Study|Physician Decision|5
6312050|NCT02680002|10042888|FG001|Overall Study|Physician Decision|1
6312051|NCT02680002|10042889|FG002|Overall Study|Physician Decision|1
6312052|NCT02680002|10042890|FG003|Overall Study|Physician Decision|1
6312053|NCT02680002|10042891|FG004|Overall Study|Physician Decision|1
6312054|NCT02680002|10042892|FG005|Overall Study|Physician Decision|1
6312055|NCT02680002|10042887|FG000|Overall Study|Protocol Violation|1
6312056|NCT02680002|10042888|FG001|Overall Study|Protocol Violation|0
6312057|NCT02680002|10042889|FG002|Overall Study|Protocol Violation|1
6312058|NCT02680002|10042890|FG003|Overall Study|Protocol Violation|0
6312059|NCT02680002|10042891|FG004|Overall Study|Protocol Violation|1
6048954|NCT00420927|9648201|FG002|Period 2|Adverse Event|7
6048955|NCT00420927|9648202|FG003|Period 2|Adverse Event|3
6048956|NCT00420927|9648203|FG004|Period 2|Adverse Event|17
6048957|NCT00420927|9648204|FG005|Period 2|Adverse Event|6
6048958|NCT00420927|9648205|FG006|Period 2|Adverse Event|20
6048959|NCT00420927|9648199|FG000|Period 2|Withdrawal by Subject|0
6048960|NCT00420927|9648200|FG001|Period 2|Withdrawal by Subject|0
6048961|NCT00420927|9648201|FG002|Period 2|Withdrawal by Subject|1
6048962|NCT00420927|9648202|FG003|Period 2|Withdrawal by Subject|3
6048963|NCT00420927|9648203|FG004|Period 2|Withdrawal by Subject|11
6048964|NCT00420927|9648204|FG005|Period 2|Withdrawal by Subject|2
6048965|NCT00420927|9648205|FG006|Period 2|Withdrawal by Subject|12
6048966|NCT00420927|9648199|FG000|Period 2|Lost to Follow-up|0
6312060|NCT02680002|10042892|FG005|Overall Study|Protocol Violation|2
6312061|NCT02680002|10042887|FG000|Overall Study|Withdrawal by Subject|0
6312062|NCT02680002|10042888|FG001|Overall Study|Withdrawal by Subject|0
6312063|NCT02680002|10042889|FG002|Overall Study|Withdrawal by Subject|1
6312064|NCT02680002|10042890|FG003|Overall Study|Withdrawal by Subject|0
6312065|NCT02680002|10042891|FG004|Overall Study|Withdrawal by Subject|2
6312066|NCT02680002|10042892|FG005|Overall Study|Withdrawal by Subject|2
6312067|NCT02680002|10042887|FG000|Overall Study|Missed Visit 8 (Day 201)|2
6312068|NCT02680002|10042888|FG001|Overall Study|Missed Visit 8 (Day 201)|1
6312069|NCT02680002|10042889|FG002|Overall Study|Missed Visit 8 (Day 201)|3
6312070|NCT02680002|10042890|FG003|Overall Study|Missed Visit 8 (Day 201)|1
6312071|NCT02680002|10042891|FG004|Overall Study|Missed Visit 8 (Day 201)|5
6312072|NCT02680002|10042892|FG005|Overall Study|Missed Visit 8 (Day 201)|0
6312073|NCT02680002|10042887|FG000|Overall Study|Other|0
6312074|NCT02680002|10042888|FG001|Overall Study|Other|1
6312075|NCT02680002|10042889|FG002|Overall Study|Other|0
6312076|NCT02680002|10042890|FG003|Overall Study|Other|0
6312077|NCT02680002|10042891|FG004|Overall Study|Other|1
6312078|NCT02680002|10042892|FG005|Overall Study|Other|0
6312079|NCT02680002|10042887|FG000|Overall Study|Adverse Event|0
6312080|NCT02680002|10042888|FG001|Overall Study|Adverse Event|0
6312081|NCT02680002|10042889|FG002|Overall Study|Adverse Event|0
6312082|NCT02680002|10042890|FG003|Overall Study|Adverse Event|0
6312083|NCT02680002|10042891|FG004|Overall Study|Adverse Event|1
6312084|NCT02680002|10042892|FG005|Overall Study|Adverse Event|2
6312085|NCT02680041|10042909|FG000|Overall Study|Withdrawal prior to 18F-fluciclovine PET|8
6312086|NCT02680041|10042909|FG000|Overall Study|Lost to Follow-up|2
6312087|NCT02680639|10042966|FG000|Screening Period|Screen Failure|7
6312088|NCT02680639|10042967|FG001|Screening Period|Screen Failure|0
6312089|NCT02680639|10042968|FG002|Screening Period|Screen Failure|0
6312090|NCT02680665|10042978|FG000|Overall Study|No visit after the first prescription|5
6312091|NCT02680756|10042984|FG000|Overall Study|Adverse Event|10
6312092|NCT02680756|10042985|FG001|Overall Study|Adverse Event|2
6312093|NCT02680756|10042984|FG000|Overall Study|Lost to Follow-up|7
6312094|NCT02680756|10042985|FG001|Overall Study|Lost to Follow-up|6
6312095|NCT02680756|10042984|FG000|Overall Study|Withdrawal by Subject|5
6312096|NCT02680756|10042985|FG001|Overall Study|Withdrawal by Subject|5
6312097|NCT02680756|10042984|FG000|Overall Study|Physician Decision|4
6312098|NCT02680756|10042985|FG001|Overall Study|Physician Decision|1
6312099|NCT02680756|10042984|FG000|Overall Study|Hb ≤7.5 g/dL|0
6312100|NCT02680756|10042985|FG001|Overall Study|Hb ≤7.5 g/dL|2
6312101|NCT02680756|10042984|FG000|Overall Study|Blood transfusion for any reason|0
6312102|NCT02680756|10042985|FG001|Overall Study|Blood transfusion for any reason|1
6312103|NCT02680756|10042984|FG000|Overall Study|Death|1
6312104|NCT02680756|10042985|FG001|Overall Study|Death|0
6312105|NCT02680756|10042984|FG000|Overall Study|Protocol Violation|1
6312106|NCT02680756|10042985|FG001|Overall Study|Protocol Violation|0
6312107|NCT02680756|10042984|FG000|Overall Study|TSAT above 60% or a ferritin above 800 m|1
6312108|NCT02680756|10042985|FG001|Overall Study|TSAT above 60% or a ferritin above 800 m|0
6312109|NCT02680756|10042984|FG000|Overall Study|None of above or not recorded|3
6312110|NCT02680756|10042985|FG001|Overall Study|None of above or not recorded|2
6312111|NCT02680834|10042993|FG000|Overall Study|Physician Decision|5
6312112|NCT02680834|10042994|FG001|Overall Study|Physician Decision|2
6312113|NCT02680834|10042993|FG000|Overall Study|Withdrawal by Subject|6
6312114|NCT02680834|10042994|FG001|Overall Study|Withdrawal by Subject|0
6312115|NCT02680834|10042993|FG000|Overall Study|Lost to Follow-up|0
6312116|NCT02680834|10042994|FG001|Overall Study|Lost to Follow-up|1
6312117|NCT02680847|10043003|FG000|Overall Study|Other|2
6312118|NCT02680847|10043004|FG001|Overall Study|Other|0
6312119|NCT02680847|10043005|FG002|Overall Study|Other|0
6312120|NCT02680847|10043003|FG000|Overall Study|No longer met eligibility criteria|2
6312121|NCT02680847|10043004|FG001|Overall Study|No longer met eligibility criteria|2
6312122|NCT02680847|10043005|FG002|Overall Study|No longer met eligibility criteria|0
6312123|NCT02680847|10043003|FG000|Overall Study|Unwilling to participate in study|1
6312124|NCT02680847|10043004|FG001|Overall Study|Unwilling to participate in study|1
6312125|NCT02680847|10043005|FG002|Overall Study|Unwilling to participate in study|0
6312126|NCT02680847|10043003|FG000|Overall Study|Lack of Efficacy|0
6312127|NCT02680847|10043004|FG001|Overall Study|Lack of Efficacy|0
6312128|NCT02680847|10043005|FG002|Overall Study|Lack of Efficacy|2
6312129|NCT02680847|10043003|FG000|Overall Study|Adverse Event|0
6312130|NCT02680847|10043004|FG001|Overall Study|Adverse Event|0
6312131|NCT02680847|10043005|FG002|Overall Study|Adverse Event|1
6312132|NCT02681094|10043016|FG000|1 -Modified Enrolled Participants Set|Participant decision|7
6312133|NCT02681094|10043017|FG001|1 -Modified Enrolled Participants Set|Participant decision|10
6312134|NCT02681094|10043018|FG002|1 -Modified Enrolled Participants Set|Participant decision|9
6312135|NCT02681094|10043016|FG000|1 -Modified Enrolled Participants Set|Adverse Event|10
6312136|NCT02681094|10043017|FG001|1 -Modified Enrolled Participants Set|Adverse Event|4
6312137|NCT02681094|10043018|FG002|1 -Modified Enrolled Participants Set|Adverse Event|1
6312138|NCT02681094|10043016|FG000|1 -Modified Enrolled Participants Set|Severe non-compliance to protocol|2
6312139|NCT02681094|10043017|FG001|1 -Modified Enrolled Participants Set|Severe non-compliance to protocol|0
6312140|NCT02681094|10043018|FG002|1 -Modified Enrolled Participants Set|Severe non-compliance to protocol|1
6312141|NCT02681094|10043016|FG000|1 -Modified Enrolled Participants Set|Lack of therapeutic response|1
6312142|NCT02681094|10043017|FG001|1 -Modified Enrolled Participants Set|Lack of therapeutic response|5
6312143|NCT02681094|10043018|FG002|1 -Modified Enrolled Participants Set|Lack of therapeutic response|14
6312144|NCT02681094|10043016|FG000|1 -Modified Enrolled Participants Set|Study-specific discontinuation criteria|11
6312145|NCT02681094|10043017|FG001|1 -Modified Enrolled Participants Set|Study-specific discontinuation criteria|13
6312146|NCT02681094|10043018|FG002|1 -Modified Enrolled Participants Set|Study-specific discontinuation criteria|20
6312147|NCT02681094|10043016|FG000|1 -Modified Enrolled Participants Set|Other|6
6312148|NCT02681094|10043017|FG001|1 -Modified Enrolled Participants Set|Other|6
6312149|NCT02681094|10043018|FG002|1 -Modified Enrolled Participants Set|Other|7
6312150|NCT02681094|10043016|FG000|1 -Modified Enrolled Participants Set|No treatment given|0
6312151|NCT02681094|10043017|FG001|1 -Modified Enrolled Participants Set|No treatment given|1
6312152|NCT02681094|10043018|FG002|1 -Modified Enrolled Participants Set|No treatment given|1
6312153|NCT02681094|10043016|FG000|2 - Enrolled Participants Set|Participant decision|7
6312154|NCT02681094|10043017|FG001|2 - Enrolled Participants Set|Participant decision|10
6312155|NCT02681094|10043018|FG002|2 - Enrolled Participants Set|Participant decision|9
6312156|NCT02681094|10043016|FG000|2 - Enrolled Participants Set|Adverse Event|10
6312157|NCT02681094|10043017|FG001|2 - Enrolled Participants Set|Adverse Event|4
6312158|NCT02681094|10043018|FG002|2 - Enrolled Participants Set|Adverse Event|1
6312159|NCT02681094|10043016|FG000|2 - Enrolled Participants Set|Severe non-compliance to protocol|2
6312160|NCT02681094|10043017|FG001|2 - Enrolled Participants Set|Severe non-compliance to protocol|0
6312161|NCT02681094|10043018|FG002|2 - Enrolled Participants Set|Severe non-compliance to protocol|1
6312162|NCT02681094|10043016|FG000|2 - Enrolled Participants Set|Lack of therapeutic response|1
6312163|NCT02681094|10043017|FG001|2 - Enrolled Participants Set|Lack of therapeutic response|5
6312164|NCT02681094|10043018|FG002|2 - Enrolled Participants Set|Lack of therapeutic response|14
6312165|NCT02681094|10043016|FG000|2 - Enrolled Participants Set|Study specific discontinuation criteria|14
6312166|NCT02681094|10043017|FG001|2 - Enrolled Participants Set|Study specific discontinuation criteria|15
6312167|NCT02681094|10043018|FG002|2 - Enrolled Participants Set|Study specific discontinuation criteria|21
6312168|NCT02681094|10043016|FG000|2 - Enrolled Participants Set|Other|6
6312169|NCT02681094|10043017|FG001|2 - Enrolled Participants Set|Other|6
6312170|NCT02681094|10043018|FG002|2 - Enrolled Participants Set|Other|7
6312171|NCT02681094|10043016|FG000|2 - Enrolled Participants Set|No treatment given|0
6312172|NCT02681094|10043017|FG001|2 - Enrolled Participants Set|No treatment given|1
6312173|NCT02681094|10043018|FG002|2 - Enrolled Participants Set|No treatment given|1
6312174|NCT02681510|10043040|FG000|Overall Study|Withdrawal by Subject|1
6312175|NCT02681510|10043040|FG000|Overall Study|Lost to Follow-up|9
6312176|NCT02681523|10043044|FG000|Overall Study|Adverse Event|1
6312177|NCT02681523|10043044|FG000|Overall Study|Patient Non-compliance|1
6312178|NCT02682264|10043099|FG000|Overall Study|Withdrawal by Subject|56
6312179|NCT02682264|10043100|FG001|Overall Study|Withdrawal by Subject|45
6312180|NCT02682264|10043099|FG000|Overall Study|Lost to Follow-up|49
6312181|NCT02682264|10043100|FG001|Overall Study|Lost to Follow-up|41
6312182|NCT02682264|10043099|FG000|Overall Study|Lack of Efficacy|14
6312183|NCT02682264|10043100|FG001|Overall Study|Lack of Efficacy|16
6312184|NCT02682264|10043099|FG000|Overall Study|Withdrawal by Parent|6
6312185|NCT02682264|10043100|FG001|Overall Study|Withdrawal by Parent|7
6312186|NCT02682264|10043099|FG000|Overall Study|Adverse Event|9
6312187|NCT02682264|10043100|FG001|Overall Study|Adverse Event|0
6312188|NCT02682264|10043099|FG000|Overall Study|Noncompliance with study drug|1
6312189|NCT02682264|10043100|FG001|Overall Study|Noncompliance with study drug|4
6312190|NCT02682264|10043099|FG000|Overall Study|Pregnancy|1
6312191|NCT02682264|10043100|FG001|Overall Study|Pregnancy|2
6312192|NCT02682264|10043099|FG000|Overall Study|Recovery|1
6312193|NCT02682264|10043100|FG001|Overall Study|Recovery|2
6312194|NCT02682264|10043099|FG000|Overall Study|Progressive Disease|1
6312195|NCT02682264|10043100|FG001|Overall Study|Progressive Disease|0
6312196|NCT02682264|10043099|FG000|Overall Study|Technical Problems|0
6312197|NCT02682264|10043100|FG001|Overall Study|Technical Problems|1
6312198|NCT02682264|10043099|FG000|Overall Study|Moved abroad and unable to continue|0
6312199|NCT02682264|10043100|FG001|Overall Study|Moved abroad and unable to continue|3
6312200|NCT02682264|10043099|FG000|Overall Study|Stopped test article application|0
6312201|NCT02682264|10043100|FG001|Overall Study|Stopped test article application|1
6312202|NCT02682602|10043151|FG000|Pre-operative Diseased & Normal Hips|Unusable images|1
6312203|NCT02682602|10043152|FG001|Pre-operative Diseased & Normal Hips|Unusable images|0
6312204|NCT02682602|10043151|FG000|Post-operative Fluoroscopy for Implanted|Lost to Follow-up|3
6312205|NCT02682602|10043152|FG001|Post-operative Fluoroscopy for Implanted|Lost to Follow-up|0
6312206|NCT02682784|10043166|FG000|Overall Study|Withdrawal by Subject|0
6312207|NCT02682784|10043167|FG001|Overall Study|Withdrawal by Subject|2
6312208|NCT02682784|10043168|FG002|Overall Study|Withdrawal by Subject|1
6312209|NCT02682784|10043169|FG003|Overall Study|Withdrawal by Subject|2
6312210|NCT02682784|10043166|FG000|Overall Study|Physician Decision|1
6312211|NCT02682784|10043167|FG001|Overall Study|Physician Decision|0
6312212|NCT02682784|10043168|FG002|Overall Study|Physician Decision|1
6312213|NCT02682784|10043169|FG003|Overall Study|Physician Decision|1
6312214|NCT02682823|10043184|FG000|Overall Study|Withdrawal by Subject|0
6312215|NCT02682823|10043185|FG001|Overall Study|Withdrawal by Subject|0
6312216|NCT02682823|10043186|FG002|Overall Study|Withdrawal by Subject|1
6312217|NCT02682823|10043187|FG003|Overall Study|Withdrawal by Subject|0
6312218|NCT02682823|10043188|FG004|Overall Study|Withdrawal by Subject|1
6312219|NCT02682823|10043184|FG000|Overall Study|Protocol Deviation|0
6312220|NCT02682823|10043185|FG001|Overall Study|Protocol Deviation|1
6312221|NCT02682823|10043186|FG002|Overall Study|Protocol Deviation|0
6312222|NCT02682823|10043187|FG003|Overall Study|Protocol Deviation|0
6312223|NCT02682823|10043188|FG004|Overall Study|Protocol Deviation|0
6312224|NCT02682823|10043184|FG000|Overall Study|Adverse Event|0
6312225|NCT02682823|10043185|FG001|Overall Study|Adverse Event|0
6312226|NCT02682823|10043186|FG002|Overall Study|Adverse Event|0
6312227|NCT02682823|10043187|FG003|Overall Study|Adverse Event|1
6312228|NCT02682823|10043188|FG004|Overall Study|Adverse Event|0
6312229|NCT02683109|10043206|FG000|Overall Study|Adverse Event|1
6040087|NCT00369343|9637895|FG000|Double-blind Phase|Adverse Event|19
6040088|NCT00369343|9637896|FG001|Double-blind Phase|Adverse Event|4
6040089|NCT00369343|9637895|FG000|Double-blind Phase|Failed to return|2
6040090|NCT00369343|9637896|FG001|Double-blind Phase|Failed to return|0
6040091|NCT00369343|9637895|FG000|Double-blind Phase|Lost to Follow-up|9
6040092|NCT00369343|9637896|FG001|Double-blind Phase|Lost to Follow-up|2
6312230|NCT02683109|10043207|FG001|Overall Study|Adverse Event|0
6312231|NCT02683187|10043223|FG000|Overall Study|Failed IV access|3
6040093|NCT00369343|9637895|FG000|Double-blind Phase|Protocol Violation|2
6312232|NCT02683187|10043223|FG000|Overall Study|Withdrawal by Subject|5
6312233|NCT02683525|10043248|FG000|Overall Study|Lost to Follow-up|1
6312234|NCT02683525|10043248|FG000|Overall Study|Physician Decision|1
6312235|NCT02683525|10043248|FG000|Overall Study|Disease Progression|6
6312236|NCT02683668|10043267|FG000|Period 2|Withdrawal by Subject|0
6312237|NCT02683668|10043268|FG001|Period 2|Withdrawal by Subject|1
6312238|NCT02683668|10043269|FG002|Period 2|Withdrawal by Subject|0
6312239|NCT02683746|10043286|FG000|Overall Study|Adverse Event|3
6312240|NCT02683746|10043287|FG001|Overall Study|Adverse Event|2
6312241|NCT02683746|10043286|FG000|Overall Study|Lost to Follow-up|5
6312242|NCT02683746|10043287|FG001|Overall Study|Lost to Follow-up|6
6312243|NCT02683746|10043286|FG000|Overall Study|Withdrawal by Subject|6
6312244|NCT02683746|10043287|FG001|Overall Study|Withdrawal by Subject|5
6312245|NCT02683746|10043286|FG000|Overall Study|Physician Decision|2
6312246|NCT02683746|10043287|FG001|Overall Study|Physician Decision|1
6312247|NCT02683785|10043306|FG000|Overall Study|Withdrawal by Subject|1
6312248|NCT02683785|10043307|FG001|Overall Study|Withdrawal by Subject|1
6312249|NCT02683785|10043306|FG000|Overall Study|Lost to Follow-up|0
6312250|NCT02683785|10043307|FG001|Overall Study|Lost to Follow-up|1
6312251|NCT02683785|10043306|FG000|Overall Study|Adverse Event|0
6312252|NCT02683785|10043307|FG001|Overall Study|Adverse Event|2
6312253|NCT02683876|10043317|FG000|Overall Study|samples damaged during shipping|2
6312254|NCT02683876|10043318|FG001|Overall Study|samples damaged during shipping|0
6040094|NCT00369343|9637896|FG001|Double-blind Phase|Protocol Violation|0
6040095|NCT00369343|9637895|FG000|Double-blind Phase|Withdrawal by Subject|8
6040096|NCT00369343|9637896|FG001|Double-blind Phase|Withdrawal by Subject|6
6148717|NCT01090492|9784033|FG003|First Intervention Period (4 Weeks)|Adverse Event|3
6148718|NCT01090492|9784034|FG004|First Intervention Period (4 Weeks)|Adverse Event|1
6148719|NCT01090492|9784035|FG005|First Intervention Period (4 Weeks)|Adverse Event|2
6040097|NCT00369343|9637895|FG000|Double-blind Phase|Lack of Efficacy|0
6148720|NCT01090492|9784036|FG006|First Intervention Period (4 Weeks)|Adverse Event|0
6148721|NCT01090492|9784037|FG007|First Intervention Period (4 Weeks)|Adverse Event|5
6148722|NCT01090492|9784030|FG000|Second Intervention Period (4 Weeks)|Protocol Violation|1
6148723|NCT01090492|9784031|FG001|Second Intervention Period (4 Weeks)|Protocol Violation|0
6148724|NCT01090492|9784032|FG002|Second Intervention Period (4 Weeks)|Protocol Violation|0
6148725|NCT01090492|9784033|FG003|Second Intervention Period (4 Weeks)|Protocol Violation|0
6148726|NCT01090492|9784034|FG004|Second Intervention Period (4 Weeks)|Protocol Violation|1
6148727|NCT01090492|9784035|FG005|Second Intervention Period (4 Weeks)|Protocol Violation|0
6148728|NCT01090492|9784036|FG006|Second Intervention Period (4 Weeks)|Protocol Violation|1
6148729|NCT01090492|9784037|FG007|Second Intervention Period (4 Weeks)|Protocol Violation|1
6148730|NCT01090492|9784030|FG000|Second Intervention Period (4 Weeks)|Non-compliance|0
6148731|NCT01090492|9784031|FG001|Second Intervention Period (4 Weeks)|Non-compliance|1
6148732|NCT01090492|9784032|FG002|Second Intervention Period (4 Weeks)|Non-compliance|0
6148733|NCT01090492|9784033|FG003|Second Intervention Period (4 Weeks)|Non-compliance|0
6312255|NCT02683941|10043337|FG000|Double-blind Phase|Adverse Event|0
6312256|NCT02683941|10043338|FG001|Double-blind Phase|Adverse Event|1
6312257|NCT02683941|10043337|FG000|Double-blind Phase|Withdrawal by Subject|4
6312258|NCT02683941|10043338|FG001|Double-blind Phase|Withdrawal by Subject|2
6312259|NCT02683941|10043337|FG000|Double-blind Phase|Lost to Follow-up|1
6312260|NCT02683941|10043338|FG001|Double-blind Phase|Lost to Follow-up|0
6312261|NCT02683941|10043337|FG000|Double-blind Phase|Disease Progression|5
6312262|NCT02683941|10043338|FG001|Double-blind Phase|Disease Progression|2
6312263|NCT02683941|10043337|FG000|Open-label Treatment Phase|Withdrawal by Subject|0
6312264|NCT02683941|10043338|FG001|Open-label Treatment Phase|Withdrawal by Subject|2
6312265|NCT02683941|10043337|FG000|Open-label Treatment Phase|Disease Progression|1
6312266|NCT02683941|10043338|FG001|Open-label Treatment Phase|Disease Progression|2
6312267|NCT02683941|10043337|FG000|Open-label Treatment Phase|Study Termination by the Sponsor|18
6312268|NCT02683941|10043338|FG001|Open-label Treatment Phase|Study Termination by the Sponsor|9
6312269|NCT02683941|10043337|FG000|Open-label Treatment Phase|Other|1
6312270|NCT02683941|10043338|FG001|Open-label Treatment Phase|Other|0
6312271|NCT02683941|10043337|FG000|Open-label Follow-up Phase|Withdrawal by Subject|3
6312272|NCT02683941|10043338|FG001|Open-label Follow-up Phase|Withdrawal by Subject|3
6312273|NCT02683941|10043337|FG000|Open-label Follow-up Phase|Lost to Follow-up|1
6312274|NCT02683941|10043338|FG001|Open-label Follow-up Phase|Lost to Follow-up|0
6312275|NCT02683941|10043337|FG000|Open-label Follow-up Phase|Study Termination by the Sponsor|6
6312276|NCT02683941|10043338|FG001|Open-label Follow-up Phase|Study Termination by the Sponsor|4
6312277|NCT02683941|10043337|FG000|Open-label Follow-up Phase|Other|8
6312278|NCT02683941|10043338|FG001|Open-label Follow-up Phase|Other|1
6312279|NCT02684097|10043359|FG000|Overall Study|Lack of Efficacy|13
6312280|NCT02684097|10043360|FG001|Overall Study|Lack of Efficacy|6
6312281|NCT02684279|10043385|FG000|Overall Study|Adverse Event|87
6312282|NCT02684279|10043385|FG000|Overall Study|Lack of Efficacy|4
6312283|NCT02684279|10043385|FG000|Overall Study|Lost to Follow-up|61
6312284|NCT02684279|10043385|FG000|Overall Study|Protocol Violation|6
6312285|NCT02684279|10043385|FG000|Overall Study|Pregnancy|8
6312286|NCT02684279|10043385|FG000|Overall Study|Withdrawal by Subject|92
6312287|NCT02684279|10043385|FG000|Overall Study|non-compliance with study drug|9
6312288|NCT02684279|10043385|FG000|Overall Study|non compliance with study visits|2
6312289|NCT02684279|10043385|FG000|Overall Study|subject to have surgery|1
6312290|NCT02684279|10043385|FG000|Overall Study|family emergency|1
6312291|NCT02684279|10043385|FG000|Overall Study|Site closures|7
6312292|NCT02684279|10043385|FG000|Overall Study|Physician Decision|1
6312293|NCT02684344|10043391|FG000|Overall Study|Withdrawal by Subject|0
6312294|NCT02684344|10043392|FG001|Overall Study|Withdrawal by Subject|1
6312295|NCT02684357|10043401|FG000|Part A|Adverse Event (Worsening of Disease)|1
6312296|NCT02684357|10043402|FG001|Part A|Adverse Event (Worsening of Disease)|0
6312297|NCT02684357|10043403|FG002|Part A|Adverse Event (Worsening of Disease)|0
6312298|NCT02684357|10043404|FG003|Part A|Adverse Event (Worsening of Disease)|0
6312299|NCT02684357|10043405|FG004|Part A|Adverse Event (Worsening of Disease)|0
6312300|NCT02684357|10043406|FG005|Part A|Adverse Event (Worsening of Disease)|0
6312301|NCT02684357|10043401|FG000|Part A|Lost to Follow-up|0
6312302|NCT02684357|10043402|FG001|Part A|Lost to Follow-up|2
6312303|NCT02684357|10043403|FG002|Part A|Lost to Follow-up|2
6312304|NCT02684357|10043404|FG003|Part A|Lost to Follow-up|0
6312305|NCT02684357|10043405|FG004|Part A|Lost to Follow-up|0
6312306|NCT02684357|10043406|FG005|Part A|Lost to Follow-up|0
6312307|NCT02684357|10043401|FG000|Part A|Withdrawal by Subject|3
6312308|NCT02684357|10043402|FG001|Part A|Withdrawal by Subject|0
6312309|NCT02684357|10043403|FG002|Part A|Withdrawal by Subject|0
6312310|NCT02684357|10043404|FG003|Part A|Withdrawal by Subject|0
6312311|NCT02684357|10043405|FG004|Part A|Withdrawal by Subject|0
6312312|NCT02684357|10043406|FG005|Part A|Withdrawal by Subject|0
6312313|NCT02684357|10043401|FG000|Part A|Other|0
6312314|NCT02684357|10043402|FG001|Part A|Other|1
6312315|NCT02684357|10043403|FG002|Part A|Other|0
6312316|NCT02684357|10043404|FG003|Part A|Other|0
6312317|NCT02684357|10043405|FG004|Part A|Other|0
6312318|NCT02684357|10043406|FG005|Part A|Other|0
6312319|NCT02684357|10043401|FG000|Part B|Adverse Event (Other)|0
6312320|NCT02684357|10043402|FG001|Part B|Adverse Event (Other)|0
6312321|NCT02684357|10043403|FG002|Part B|Adverse Event (Other)|0
6312322|NCT02684357|10043404|FG003|Part B|Adverse Event (Other)|1
6312323|NCT02684357|10043405|FG004|Part B|Adverse Event (Other)|1
6312324|NCT02684357|10043406|FG005|Part B|Adverse Event (Other)|1
6312325|NCT02684357|10043401|FG000|Part B|Lost to Follow-up|0
6312326|NCT02684357|10043402|FG001|Part B|Lost to Follow-up|0
6312327|NCT02684357|10043403|FG002|Part B|Lost to Follow-up|0
6312328|NCT02684357|10043404|FG003|Part B|Lost to Follow-up|1
6312329|NCT02684357|10043405|FG004|Part B|Lost to Follow-up|1
6312330|NCT02684357|10043406|FG005|Part B|Lost to Follow-up|7
6312331|NCT02684357|10043401|FG000|Part B|Withdrawal by Subject|0
6312332|NCT02684357|10043402|FG001|Part B|Withdrawal by Subject|0
6312333|NCT02684357|10043403|FG002|Part B|Withdrawal by Subject|0
6312334|NCT02684357|10043404|FG003|Part B|Withdrawal by Subject|0
6312335|NCT02684357|10043405|FG004|Part B|Withdrawal by Subject|2
6312336|NCT02684357|10043406|FG005|Part B|Withdrawal by Subject|4
6312337|NCT02684357|10043401|FG000|Part B|Other|0
6312338|NCT02684357|10043402|FG001|Part B|Other|0
6312339|NCT02684357|10043403|FG002|Part B|Other|0
6312340|NCT02684357|10043404|FG003|Part B|Other|1
6312341|NCT02684357|10043405|FG004|Part B|Other|0
6312342|NCT02684357|10043406|FG005|Part B|Other|1
6312343|NCT02684370|10043422|FG000|Part A|Adverse Event|2
6312344|NCT02684370|10043423|FG001|Part A|Adverse Event|0
6312345|NCT02684370|10043424|FG002|Part A|Adverse Event|1
6312346|NCT02684370|10043425|FG003|Part A|Adverse Event|0
6312347|NCT02684370|10043426|FG004|Part A|Adverse Event|0
6312348|NCT02684370|10043427|FG005|Part A|Adverse Event|0
6312349|NCT02684370|10043422|FG000|Part A|Lost to Follow-up|1
6312350|NCT02684370|10043423|FG001|Part A|Lost to Follow-up|1
6312351|NCT02684370|10043424|FG002|Part A|Lost to Follow-up|0
6312352|NCT02684370|10043425|FG003|Part A|Lost to Follow-up|0
6312353|NCT02684370|10043426|FG004|Part A|Lost to Follow-up|0
6312354|NCT02684370|10043427|FG005|Part A|Lost to Follow-up|0
6312355|NCT02684370|10043422|FG000|Part A|Subject Withdrawal|1
6312356|NCT02684370|10043423|FG001|Part A|Subject Withdrawal|0
6312357|NCT02684370|10043424|FG002|Part A|Subject Withdrawal|3
6312358|NCT02684370|10043425|FG003|Part A|Subject Withdrawal|0
6312359|NCT02684370|10043426|FG004|Part A|Subject Withdrawal|0
6312360|NCT02684370|10043427|FG005|Part A|Subject Withdrawal|0
6312361|NCT02684370|10043422|FG000|Part A|Other|0
6312362|NCT02684370|10043423|FG001|Part A|Other|0
6312363|NCT02684370|10043424|FG002|Part A|Other|1
6312364|NCT02684370|10043425|FG003|Part A|Other|0
6312365|NCT02684370|10043426|FG004|Part A|Other|0
6312366|NCT02684370|10043427|FG005|Part A|Other|0
6312367|NCT02684370|10043422|FG000|Part B|Adverse Event|0
6312368|NCT02684370|10043423|FG001|Part B|Adverse Event|0
6312369|NCT02684370|10043424|FG002|Part B|Adverse Event|0
6312370|NCT02684370|10043425|FG003|Part B|Adverse Event|0
6312371|NCT02684370|10043426|FG004|Part B|Adverse Event|2
6312372|NCT02684370|10043427|FG005|Part B|Adverse Event|1
6312373|NCT02684370|10043422|FG000|Part B|Lost to Follow-up|0
6312374|NCT02684370|10043423|FG001|Part B|Lost to Follow-up|0
6312375|NCT02684370|10043424|FG002|Part B|Lost to Follow-up|0
6312376|NCT02684370|10043425|FG003|Part B|Lost to Follow-up|1
6312377|NCT02684370|10043426|FG004|Part B|Lost to Follow-up|2
6312378|NCT02684370|10043427|FG005|Part B|Lost to Follow-up|5
6312379|NCT02684370|10043422|FG000|Part B|Subject Withdrawal|0
6312380|NCT02684370|10043423|FG001|Part B|Subject Withdrawal|0
6312381|NCT02684370|10043424|FG002|Part B|Subject Withdrawal|0
6312382|NCT02684370|10043425|FG003|Part B|Subject Withdrawal|1
6312383|NCT02684370|10043426|FG004|Part B|Subject Withdrawal|1
6312384|NCT02684370|10043427|FG005|Part B|Subject Withdrawal|2
6312385|NCT02684617|10043491|FG000|Overall Study|Adverse Event|1
6312386|NCT02684617|10043492|FG001|Overall Study|Adverse Event|0
6312387|NCT02684617|10043493|FG002|Overall Study|Adverse Event|1
6312388|NCT02684617|10043491|FG000|Overall Study|Death|8
6312389|NCT02684617|10043492|FG001|Overall Study|Death|16
6312390|NCT02684617|10043493|FG002|Overall Study|Death|28
6312391|NCT02684617|10043491|FG000|Overall Study|Withdrawal by Subject|2
6312392|NCT02684617|10043492|FG001|Overall Study|Withdrawal by Subject|0
6312393|NCT02684617|10043493|FG002|Overall Study|Withdrawal by Subject|4
6312394|NCT02684617|10043491|FG000|Overall Study|Screen Failure|1
6312395|NCT02684617|10043492|FG001|Overall Study|Screen Failure|0
6312396|NCT02684617|10043493|FG002|Overall Study|Screen Failure|2
6312397|NCT02684617|10043491|FG000|Overall Study|Study Terminated by Sponsor|6
6312398|NCT02684617|10043492|FG001|Overall Study|Study Terminated by Sponsor|1
6148734|NCT01090492|9784034|FG004|Second Intervention Period (4 Weeks)|Non-compliance|0
6312399|NCT02684617|10043493|FG002|Overall Study|Study Terminated by Sponsor|5
6312400|NCT02684981|10043531|FG000|Overall Study|Permanently discontinued the treatment|157
6312401|NCT02684981|10043532|FG001|Overall Study|Permanently discontinued the treatment|161
6312402|NCT02684981|10043533|FG002|Overall Study|Permanently discontinued the treatment|110
6312403|NCT02684981|10043531|FG000|Overall Study|Other|83
6312404|NCT02684981|10043532|FG001|Overall Study|Other|49
6312405|NCT02684981|10043533|FG002|Overall Study|Other|17
6312406|NCT02685033|10043553|FG000|Overall Study|Withdrawal of Consent|0
6312407|NCT02685033|10043554|FG001|Overall Study|Withdrawal of Consent|1
6312408|NCT02685033|10043553|FG000|Overall Study|Lost to Follow-up|2
6312409|NCT02685033|10043554|FG001|Overall Study|Lost to Follow-up|1
6312410|NCT02685033|10043553|FG000|Overall Study|Adverse Event|1
6312411|NCT02685033|10043554|FG001|Overall Study|Adverse Event|0
6312412|NCT02685072|10043562|FG000|Treatment Period|Lost to Follow-up|12
6312413|NCT02685072|10043563|FG001|Treatment Period|Lost to Follow-up|6
6312414|NCT02685072|10043562|FG000|Treatment Period|Withdrawal by Subject|1
6312415|NCT02685072|10043563|FG001|Treatment Period|Withdrawal by Subject|3
6312416|NCT02685072|10043562|FG000|1-Month Follow-Up|Withdrawal by Subject|1
6312417|NCT02685072|10043563|FG001|1-Month Follow-Up|Withdrawal by Subject|0
6312418|NCT02685488|10043592|FG000|Overall Study|Withdrawal by Subject|0
6312419|NCT02685488|10043593|FG001|Overall Study|Withdrawal by Subject|1
6312420|NCT02685826|10043611|FG000|Overall Study|Adverse Event|2
6312421|NCT02685826|10043612|FG001|Overall Study|Adverse Event|0
6312422|NCT02685826|10043613|FG002|Overall Study|Adverse Event|1
6312423|NCT02685826|10043611|FG000|Overall Study|Progressive Disease|2
6312424|NCT02685826|10043612|FG001|Overall Study|Progressive Disease|1
6312425|NCT02685826|10043613|FG002|Overall Study|Progressive Disease|0
6312426|NCT02685826|10043611|FG000|Overall Study|Withdrawal by Subject|2
6312427|NCT02685826|10043612|FG001|Overall Study|Withdrawal by Subject|0
6312428|NCT02685826|10043613|FG002|Overall Study|Withdrawal by Subject|0
6312429|NCT02685826|10043611|FG000|Overall Study|Full Clinical Hold by FDA|19
6312430|NCT02685826|10043612|FG001|Overall Study|Full Clinical Hold by FDA|9
6312431|NCT02685826|10043613|FG002|Overall Study|Full Clinical Hold by FDA|20
6312432|NCT02685995|10043634|FG000|Overall Study|Insertion of immediately puncturable graft.|1
6312433|NCT02685995|10043635|FG001|Overall Study|Insertion of immediately puncturable graft.|1
6312434|NCT02686034|10043643|FG000|Run-In Period 1|Eligibility|12
6312435|NCT02686034|10043644|FG001|Run-In Period 1|Eligibility|10
6312436|NCT02686034|10043643|FG000|Run-In Period 1|Withdrawal by Subject|4
6312437|NCT02686034|10043644|FG001|Run-In Period 1|Withdrawal by Subject|3
6312438|NCT02686034|10043643|FG000|Run-In Period 1|Lost to Follow-up|4
6312439|NCT02686034|10043644|FG001|Run-In Period 1|Lost to Follow-up|4
6312440|NCT02686034|10043643|FG000|Randomized Controlled Period 2|Lost to Follow-up|1
6312441|NCT02686034|10043644|FG001|Randomized Controlled Period 2|Lost to Follow-up|2
6312442|NCT02686034|10043643|FG000|Randomized Controlled Period 2|Withdrawal by Subject|3
6312443|NCT02686034|10043644|FG001|Randomized Controlled Period 2|Withdrawal by Subject|0
6312444|NCT02686034|10043643|FG000|Randomized Controlled Period 2|Adverse Event|0
6312445|NCT02686034|10043644|FG001|Randomized Controlled Period 2|Adverse Event|2
6312446|NCT02686034|10043643|FG000|Randomized Controlled Period 2|Spontaneous reduction in migraines|1
6312447|NCT02686034|10043644|FG001|Randomized Controlled Period 2|Spontaneous reduction in migraines|0
6312448|NCT02686034|10043643|FG000|Open Label Period 3|Lost to Follow-up|0
6312449|NCT02686034|10043644|FG001|Open Label Period 3|Lost to Follow-up|1
6312450|NCT02686164|10043659|FG000|Overall Study|Adverse Event|1
6312451|NCT02686164|10043659|FG000|Overall Study|Withdrawal of consent|1
6312452|NCT02686164|10043659|FG000|Overall Study|Clinical progression|1
6312453|NCT02687035|10043675|FG000|Overall Study|Withdrawal by Subject|1
6312454|NCT02687035|10043675|FG000|Overall Study|Death|87
6312455|NCT02687035|10043675|FG000|Overall Study|Lost to Follow-up|1
6312456|NCT02687035|10043675|FG000|Overall Study|Missed Visit|87
6312457|NCT02687035|10043675|FG000|Overall Study|Did not receive Study Device|8
6312458|NCT02687191|10043696|FG000|Overall Study|Death|0
6312459|NCT02687191|10043697|FG001|Overall Study|Death|1
6312460|NCT02687191|10043698|FG002|Overall Study|Death|1
6312461|NCT02687191|10043699|FG003|Overall Study|Death|0
6312462|NCT02687191|10043700|FG004|Overall Study|Death|1
6312463|NCT02687191|10043701|FG005|Overall Study|Death|1
6312464|NCT02687191|10043696|FG000|Overall Study|Withdrawal by Subject|0
6312465|NCT02687191|10043697|FG001|Overall Study|Withdrawal by Subject|0
6312466|NCT02687191|10043698|FG002|Overall Study|Withdrawal by Subject|0
6312467|NCT02687191|10043699|FG003|Overall Study|Withdrawal by Subject|1
6312468|NCT02687191|10043700|FG004|Overall Study|Withdrawal by Subject|0
6312469|NCT02687191|10043701|FG005|Overall Study|Withdrawal by Subject|0
6312470|NCT02687451|10043739|FG000|Overall Study|Withdrawal by Subject|1
6312471|NCT02687451|10043740|FG001|Overall Study|Withdrawal by Subject|0
6312472|NCT02687451|10043741|FG002|Overall Study|Withdrawal by Subject|0
6312473|NCT02687451|10043742|FG003|Overall Study|Withdrawal by Subject|0
6312474|NCT02687451|10043743|FG004|Overall Study|Withdrawal by Subject|0
6312475|NCT02687451|10043744|FG005|Overall Study|Withdrawal by Subject|1
6312476|NCT02687542|10043774|FG000|Overall Study|Medication error without associated AEs|0
6312477|NCT02687542|10043775|FG001|Overall Study|Medication error without associated AEs|0
6312478|NCT02687542|10043776|FG002|Overall Study|Medication error without associated AEs|0
6312479|NCT02687542|10043777|FG003|Overall Study|Medication error without associated AEs|0
6312480|NCT02687542|10043778|FG004|Overall Study|Medication error without associated AEs|1
6312481|NCT02687542|10043774|FG000|Overall Study|Lost to Follow-up|0
6312482|NCT02687542|10043775|FG001|Overall Study|Lost to Follow-up|0
6312483|NCT02687542|10043776|FG002|Overall Study|Lost to Follow-up|0
6312484|NCT02687542|10043777|FG003|Overall Study|Lost to Follow-up|0
6312485|NCT02687542|10043778|FG004|Overall Study|Lost to Follow-up|1
6312486|NCT02687542|10043774|FG000|Overall Study|Protocol Violation|0
6312487|NCT02687542|10043775|FG001|Overall Study|Protocol Violation|1
6312488|NCT02687542|10043776|FG002|Overall Study|Protocol Violation|0
6312489|NCT02687542|10043777|FG003|Overall Study|Protocol Violation|0
6312490|NCT02687542|10043778|FG004|Overall Study|Protocol Violation|0
6312491|NCT02687542|10043774|FG000|Overall Study|Other|5
6312492|NCT02687542|10043775|FG001|Overall Study|Other|9
6312493|NCT02687542|10043776|FG002|Overall Study|Other|10
6312494|NCT02687542|10043777|FG003|Overall Study|Other|6
6312495|NCT02687542|10043778|FG004|Overall Study|Other|5
6312496|NCT02687542|10043774|FG000|Overall Study|Adverse Event|3
6312497|NCT02687542|10043775|FG001|Overall Study|Adverse Event|1
6312498|NCT02687542|10043776|FG002|Overall Study|Adverse Event|3
6312499|NCT02687542|10043777|FG003|Overall Study|Adverse Event|2
6312500|NCT02687542|10043778|FG004|Overall Study|Adverse Event|9
6312501|NCT02687542|10043774|FG000|Overall Study|Withdrawal by Subject|0
6312502|NCT02687542|10043775|FG001|Overall Study|Withdrawal by Subject|1
6312503|NCT02687542|10043776|FG002|Overall Study|Withdrawal by Subject|1
6312504|NCT02687542|10043777|FG003|Overall Study|Withdrawal by Subject|2
6312505|NCT02687542|10043778|FG004|Overall Study|Withdrawal by Subject|4
6312506|NCT02687711|10043790|FG000|Overall Study|Adverse Event|89
6312507|NCT02687711|10043790|FG000|Overall Study|Lack of Efficacy|70
6312508|NCT02687711|10043790|FG000|Overall Study|Lost to Follow-up|20
6312509|NCT02687711|10043790|FG000|Overall Study|Consent withdrawn|15
6312510|NCT02687711|10043790|FG000|Overall Study|Participant moved to another country and continued treatment for epilepsy in that country|1
6312511|NCT02687711|10043790|FG000|Overall Study|Too expensive|4
6312512|NCT02687711|10043790|FG000|Overall Study|Participant moved abroad|1
6312513|NCT02687711|10043790|FG000|Overall Study|Progression of other medical condition (dementia, pneumonia)|1
6312514|NCT02687711|10043790|FG000|Overall Study|Perceived increase in seizures but diary records show no increase compared to pre-study|1
6312515|NCT02687711|10043790|FG000|Overall Study|Disliked taste|1
6312516|NCT02687711|10043790|FG000|Overall Study|Low mood|1
6312517|NCT02687711|10043790|FG000|Overall Study|Side effects|1
6312518|NCT02687711|10043790|FG000|Overall Study|Change of Hospital|1
6312519|NCT02687711|10043790|FG000|Overall Study|Liver Encephalopathy|1
6148735|NCT01090492|9784035|FG005|Second Intervention Period (4 Weeks)|Non-compliance|0
6148736|NCT01090492|9784036|FG006|Second Intervention Period (4 Weeks)|Non-compliance|0
6148737|NCT01090492|9784037|FG007|Second Intervention Period (4 Weeks)|Non-compliance|0
6148738|NCT01090492|9784030|FG000|Second Intervention Period (4 Weeks)|Other|0
6148739|NCT01090492|9784031|FG001|Second Intervention Period (4 Weeks)|Other|1
6148740|NCT01090492|9784032|FG002|Second Intervention Period (4 Weeks)|Other|1
6148741|NCT01090492|9784033|FG003|Second Intervention Period (4 Weeks)|Other|0
6148742|NCT01090492|9784034|FG004|Second Intervention Period (4 Weeks)|Other|0
6148743|NCT01090492|9784035|FG005|Second Intervention Period (4 Weeks)|Other|0
6148744|NCT01090492|9784036|FG006|Second Intervention Period (4 Weeks)|Other|0
6148745|NCT01090492|9784037|FG007|Second Intervention Period (4 Weeks)|Other|0
6148746|NCT01090492|9784030|FG000|Second Intervention Period (4 Weeks)|Adverse Event|0
6148747|NCT01090492|9784031|FG001|Second Intervention Period (4 Weeks)|Adverse Event|0
6148748|NCT01090492|9784032|FG002|Second Intervention Period (4 Weeks)|Adverse Event|1
6148749|NCT01090492|9784033|FG003|Second Intervention Period (4 Weeks)|Adverse Event|0
6148750|NCT01090492|9784034|FG004|Second Intervention Period (4 Weeks)|Adverse Event|1
6148751|NCT01090492|9784035|FG005|Second Intervention Period (4 Weeks)|Adverse Event|1
6148752|NCT01090492|9784036|FG006|Second Intervention Period (4 Weeks)|Adverse Event|7
6148753|NCT01090492|9784037|FG007|Second Intervention Period (4 Weeks)|Adverse Event|1
6148754|NCT01090492|9784030|FG000|Second Intervention Period (4 Weeks)|Lost to Follow-up|0
6148755|NCT01090492|9784031|FG001|Second Intervention Period (4 Weeks)|Lost to Follow-up|0
6148756|NCT01090492|9784032|FG002|Second Intervention Period (4 Weeks)|Lost to Follow-up|0
6148757|NCT01090492|9784033|FG003|Second Intervention Period (4 Weeks)|Lost to Follow-up|0
6148758|NCT01090492|9784034|FG004|Second Intervention Period (4 Weeks)|Lost to Follow-up|0
6148759|NCT01090492|9784035|FG005|Second Intervention Period (4 Weeks)|Lost to Follow-up|0
6148760|NCT01090492|9784036|FG006|Second Intervention Period (4 Weeks)|Lost to Follow-up|1
6148761|NCT01090492|9784037|FG007|Second Intervention Period (4 Weeks)|Lost to Follow-up|0
6148762|NCT01090739|9784056|FG000|Enrollment|Withdrawal by Subject|24
6227319|NCT01716520|9900041|FG000|Washout Period 2 (10 to 14 Days)|Lack of Efficacy|1
6227320|NCT01716520|9900042|FG001|Washout Period 2 (10 to 14 Days)|Lack of Efficacy|0
6227321|NCT01716520|9900043|FG002|Washout Period 2 (10 to 14 Days)|Lack of Efficacy|0
6227322|NCT01716520|9900044|FG003|Washout Period 2 (10 to 14 Days)|Lack of Efficacy|0
6227323|NCT01716520|9900045|FG004|Washout Period 2 (10 to 14 Days)|Lack of Efficacy|0
6227324|NCT01716520|9900046|FG005|Washout Period 2 (10 to 14 Days)|Lack of Efficacy|0
6227325|NCT01716520|9900041|FG000|Washout Period 2 (10 to 14 Days)|Protocol-defined Stopping Criteria|0
6227326|NCT01716520|9900042|FG001|Washout Period 2 (10 to 14 Days)|Protocol-defined Stopping Criteria|0
6227327|NCT01716520|9900043|FG002|Washout Period 2 (10 to 14 Days)|Protocol-defined Stopping Criteria|0
6227328|NCT01716520|9900044|FG003|Washout Period 2 (10 to 14 Days)|Protocol-defined Stopping Criteria|0
6227329|NCT01716520|9900045|FG004|Washout Period 2 (10 to 14 Days)|Protocol-defined Stopping Criteria|0
6227330|NCT01716520|9900046|FG005|Washout Period 2 (10 to 14 Days)|Protocol-defined Stopping Criteria|1
6227331|NCT01716520|9900041|FG000|Washout Period 2 (10 to 14 Days)|Withdrawal by Subject|0
6227332|NCT01716520|9900042|FG001|Washout Period 2 (10 to 14 Days)|Withdrawal by Subject|1
6227333|NCT01716520|9900043|FG002|Washout Period 2 (10 to 14 Days)|Withdrawal by Subject|0
6227334|NCT01716520|9900044|FG003|Washout Period 2 (10 to 14 Days)|Withdrawal by Subject|0
6227335|NCT01716520|9900045|FG004|Washout Period 2 (10 to 14 Days)|Withdrawal by Subject|0
6227336|NCT01716520|9900046|FG005|Washout Period 2 (10 to 14 Days)|Withdrawal by Subject|0
6227337|NCT01716520|9900041|FG000|Treatment Period 3 (14 Days)|Lack of Efficacy|0
6227338|NCT01716520|9900042|FG001|Treatment Period 3 (14 Days)|Lack of Efficacy|0
6148763|NCT01090739|9784056|FG000|Enrollment|Protocol Violation|14
6148764|NCT01090739|9784056|FG000|Enrollment|Lost to Follow-up|5
6148765|NCT01090739|9784056|FG000|Enrollment|Physician Decision|5
6148766|NCT01090739|9784056|FG000|Enrollment|Sponsor termination of site|4
6148767|NCT01090739|9784056|FG000|Enrollment|Study implant limit reached|2
6148768|NCT01090739|9784056|FG000|Enrollment|Adverse Event|1
6148769|NCT01090739|9784056|FG000|12 Month Follow-up|Withdrawal by Subject|2
6148770|NCT01090739|9784056|FG000|12 Month Follow-up|Lost to Follow-up|1
6148771|NCT01090739|9784056|FG000|12 Month Follow-up|Physician Decision|1
6148772|NCT01090739|9784056|FG000|12 Month Follow-up|Death|1
6148773|NCT01090739|9784056|FG000|24 Month Follow-up|Withdrawal by Subject|7
6148774|NCT01090739|9784056|FG000|24 Month Follow-up|Lost to Follow-up|1
6148775|NCT01090739|9784056|FG000|24 Month Follow-up|Death|1
6148776|NCT01090739|9784056|FG000|36 Month Follow-up|Withdrawal by Subject|6
6148777|NCT01090739|9784056|FG000|36 Month Follow-up|Visit still pending|17
6148778|NCT01090765|9784076|FG000|Overall Study|Patient withdrew consent|0
6148779|NCT01090765|9784077|FG001|Overall Study|Patient withdrew consent|0
6148780|NCT01090765|9784078|FG002|Overall Study|Patient withdrew consent|0
6148781|NCT01090765|9784079|FG003|Overall Study|Patient withdrew consent|0
6148782|NCT01090765|9784080|FG004|Overall Study|Patient withdrew consent|1
6148783|NCT01090765|9784081|FG005|Overall Study|Patient withdrew consent|1
6312520|NCT02687711|10043790|FG000|Overall Study|Participant experience side effects, fatigue. Most likely not related to investigational product|1
6312521|NCT02687711|10043790|FG000|Overall Study|Withdrawn due to intake interruption|1
6312522|NCT02687711|10043790|FG000|Overall Study|Stopped in preparation for epilepsy surgery|1
6312523|NCT02687711|10043790|FG000|Overall Study|Diagnosis epilepsy revised to psychogenic seizures|1
6312524|NCT02687711|10043790|FG000|Overall Study|Participant was not able to come in our clinic because participant could not find a car driver|1
6312525|NCT02687815|10043796|FG000|Overall Study|Lost to Follow-up|2
6312526|NCT02687815|10043797|FG001|Overall Study|Lost to Follow-up|4
6312527|NCT02687815|10043796|FG000|Overall Study|Withdrawal by Subject|2
6312528|NCT02687815|10043797|FG001|Overall Study|Withdrawal by Subject|4
6312529|NCT02687919|10043805|FG000|Overall Study|Withdrawal by Subject|6
6312530|NCT02687919|10043806|FG001|Overall Study|Withdrawal by Subject|6
6312531|NCT02687919|10043805|FG000|Overall Study|Protocol Violation|2
6312532|NCT02687919|10043806|FG001|Overall Study|Protocol Violation|0
6312533|NCT02688153|10043814|FG000|Overall Study|Death|7
6312534|NCT02688153|10043815|FG001|Overall Study|Death|5
6312535|NCT02688153|10043814|FG000|Overall Study|Withdrawal by Subject|4
6312536|NCT02688153|10043815|FG001|Overall Study|Withdrawal by Subject|2
6312537|NCT02688153|10043814|FG000|Overall Study|Valve Explant|1
6312538|NCT02688153|10043815|FG001|Overall Study|Valve Explant|0
6312539|NCT02688153|10043814|FG000|Overall Study|Conversion to Commercial Valve|3
6312540|NCT02688153|10043815|FG001|Overall Study|Conversion to Commercial Valve|0
6312541|NCT02688192|10043824|FG000|Overall Study|Lost to Follow-up|11
6312542|NCT02688192|10043825|FG001|Overall Study|Lost to Follow-up|5
6312543|NCT02688192|10043824|FG000|Overall Study|Physician Decision|1
6312544|NCT02688192|10043825|FG001|Overall Study|Physician Decision|0
6312545|NCT02688387|10043845|FG000|Part 1, Period 1 (up to 6 Days)|Adverse Event|0
6312546|NCT02688387|10043846|FG001|Part 1, Period 1 (up to 6 Days)|Adverse Event|0
6312547|NCT02688387|10043847|FG002|Part 1, Period 1 (up to 6 Days)|Adverse Event|1
6312548|NCT02688387|10043848|FG003|Part 1, Period 1 (up to 6 Days)|Adverse Event|0
6312549|NCT02688387|10043849|FG004|Part 1, Period 1 (up to 6 Days)|Adverse Event|0
6312550|NCT02688387|10043850|FG005|Part 1, Period 1 (up to 6 Days)|Adverse Event|0
6312551|NCT02688387|10043851|FG006|Part 1, Period 1 (up to 6 Days)|Adverse Event|0
6312552|NCT02688387|10043852|FG007|Part 1, Period 1 (up to 6 Days)|Adverse Event|0
6312553|NCT02688387|10043853|FG008|Part 1, Period 1 (up to 6 Days)|Adverse Event|0
6312554|NCT02688387|10043854|FG009|Part 1, Period 1 (up to 6 Days)|Adverse Event|0
6312555|NCT02688387|10043855|FG010|Part 1, Period 1 (up to 6 Days)|Adverse Event|0
6312556|NCT02688387|10043856|FG011|Part 1, Period 1 (up to 6 Days)|Adverse Event|0
6312557|NCT02688387|10043857|FG012|Part 1, Period 1 (up to 6 Days)|Adverse Event|0
6312558|NCT02688387|10043858|FG013|Part 1, Period 1 (up to 6 Days)|Adverse Event|0
6312559|NCT02688387|10043859|FG014|Part 1, Period 1 (up to 6 Days)|Adverse Event|0
6312560|NCT02688387|10043860|FG015|Part 1, Period 1 (up to 6 Days)|Adverse Event|0
6312561|NCT02688387|10043861|FG016|Part 1, Period 1 (up to 6 Days)|Adverse Event|0
6312562|NCT02688387|10043862|FG017|Part 1, Period 1 (up to 6 Days)|Adverse Event|0
6312563|NCT02688387|10043863|FG018|Part 1, Period 1 (up to 6 Days)|Adverse Event|0
6312564|NCT02688387|10043864|FG019|Part 1, Period 1 (up to 6 Days)|Adverse Event|0
6312565|NCT02688387|10043865|FG020|Part 1, Period 1 (up to 6 Days)|Adverse Event|0
6312566|NCT02688387|10043866|FG021|Part 1, Period 1 (up to 6 Days)|Adverse Event|0
6312567|NCT02688387|10043845|FG000|Part 1, Period 1 (up to 6 Days)|Withdrawal by Subject|0
6312568|NCT02688387|10043846|FG001|Part 1, Period 1 (up to 6 Days)|Withdrawal by Subject|0
6312569|NCT02688387|10043847|FG002|Part 1, Period 1 (up to 6 Days)|Withdrawal by Subject|0
6312570|NCT02688387|10043848|FG003|Part 1, Period 1 (up to 6 Days)|Withdrawal by Subject|1
6312571|NCT02688387|10043849|FG004|Part 1, Period 1 (up to 6 Days)|Withdrawal by Subject|0
6312572|NCT02688387|10043850|FG005|Part 1, Period 1 (up to 6 Days)|Withdrawal by Subject|0
6312573|NCT02688387|10043851|FG006|Part 1, Period 1 (up to 6 Days)|Withdrawal by Subject|0
6312574|NCT02688387|10043852|FG007|Part 1, Period 1 (up to 6 Days)|Withdrawal by Subject|0
6312575|NCT02688387|10043853|FG008|Part 1, Period 1 (up to 6 Days)|Withdrawal by Subject|0
6312576|NCT02688387|10043854|FG009|Part 1, Period 1 (up to 6 Days)|Withdrawal by Subject|0
6312577|NCT02688387|10043855|FG010|Part 1, Period 1 (up to 6 Days)|Withdrawal by Subject|0
6312578|NCT02688387|10043856|FG011|Part 1, Period 1 (up to 6 Days)|Withdrawal by Subject|0
6312579|NCT02688387|10043857|FG012|Part 1, Period 1 (up to 6 Days)|Withdrawal by Subject|0
6312580|NCT02688387|10043858|FG013|Part 1, Period 1 (up to 6 Days)|Withdrawal by Subject|0
6312581|NCT02688387|10043859|FG014|Part 1, Period 1 (up to 6 Days)|Withdrawal by Subject|0
6312582|NCT02688387|10043860|FG015|Part 1, Period 1 (up to 6 Days)|Withdrawal by Subject|0
6312583|NCT02688387|10043861|FG016|Part 1, Period 1 (up to 6 Days)|Withdrawal by Subject|0
6312584|NCT02688387|10043862|FG017|Part 1, Period 1 (up to 6 Days)|Withdrawal by Subject|0
6312585|NCT02688387|10043863|FG018|Part 1, Period 1 (up to 6 Days)|Withdrawal by Subject|0
6312586|NCT02688387|10043864|FG019|Part 1, Period 1 (up to 6 Days)|Withdrawal by Subject|0
6312587|NCT02688387|10043865|FG020|Part 1, Period 1 (up to 6 Days)|Withdrawal by Subject|0
6312588|NCT02688387|10043866|FG021|Part 1, Period 1 (up to 6 Days)|Withdrawal by Subject|0
6312589|NCT02688387|10043845|FG000|Part 1, Washout Period 1 (7 Days)|Protocol defined stop criteria reached|0
6312590|NCT02688387|10043846|FG001|Part 1, Washout Period 1 (7 Days)|Protocol defined stop criteria reached|1
6312591|NCT02688387|10043847|FG002|Part 1, Washout Period 1 (7 Days)|Protocol defined stop criteria reached|0
6312592|NCT02688387|10043848|FG003|Part 1, Washout Period 1 (7 Days)|Protocol defined stop criteria reached|0
6312593|NCT02688387|10043849|FG004|Part 1, Washout Period 1 (7 Days)|Protocol defined stop criteria reached|0
6312594|NCT02688387|10043850|FG005|Part 1, Washout Period 1 (7 Days)|Protocol defined stop criteria reached|0
6312595|NCT02688387|10043851|FG006|Part 1, Washout Period 1 (7 Days)|Protocol defined stop criteria reached|0
6312596|NCT02688387|10043852|FG007|Part 1, Washout Period 1 (7 Days)|Protocol defined stop criteria reached|0
6312597|NCT02688387|10043853|FG008|Part 1, Washout Period 1 (7 Days)|Protocol defined stop criteria reached|0
6312598|NCT02688387|10043854|FG009|Part 1, Washout Period 1 (7 Days)|Protocol defined stop criteria reached|0
6312599|NCT02688387|10043855|FG010|Part 1, Washout Period 1 (7 Days)|Protocol defined stop criteria reached|0
6312600|NCT02688387|10043856|FG011|Part 1, Washout Period 1 (7 Days)|Protocol defined stop criteria reached|0
6312601|NCT02688387|10043857|FG012|Part 1, Washout Period 1 (7 Days)|Protocol defined stop criteria reached|0
6312602|NCT02688387|10043858|FG013|Part 1, Washout Period 1 (7 Days)|Protocol defined stop criteria reached|0
6312603|NCT02688387|10043859|FG014|Part 1, Washout Period 1 (7 Days)|Protocol defined stop criteria reached|0
6312604|NCT02688387|10043860|FG015|Part 1, Washout Period 1 (7 Days)|Protocol defined stop criteria reached|0
6312605|NCT02688387|10043861|FG016|Part 1, Washout Period 1 (7 Days)|Protocol defined stop criteria reached|0
6312606|NCT02688387|10043862|FG017|Part 1, Washout Period 1 (7 Days)|Protocol defined stop criteria reached|0
6312607|NCT02688387|10043863|FG018|Part 1, Washout Period 1 (7 Days)|Protocol defined stop criteria reached|0
6312608|NCT02688387|10043864|FG019|Part 1, Washout Period 1 (7 Days)|Protocol defined stop criteria reached|0
6312609|NCT02688387|10043865|FG020|Part 1, Washout Period 1 (7 Days)|Protocol defined stop criteria reached|0
6312610|NCT02688387|10043866|FG021|Part 1, Washout Period 1 (7 Days)|Protocol defined stop criteria reached|0
6312611|NCT02688387|10043845|FG000|Part 1, Period 2 (up to 6 Days)|Protocol defined stop criteria reached|0
6312612|NCT02688387|10043846|FG001|Part 1, Period 2 (up to 6 Days)|Protocol defined stop criteria reached|0
6312613|NCT02688387|10043847|FG002|Part 1, Period 2 (up to 6 Days)|Protocol defined stop criteria reached|1
6312614|NCT02688387|10043848|FG003|Part 1, Period 2 (up to 6 Days)|Protocol defined stop criteria reached|0
6312615|NCT02688387|10043849|FG004|Part 1, Period 2 (up to 6 Days)|Protocol defined stop criteria reached|1
6312616|NCT02688387|10043850|FG005|Part 1, Period 2 (up to 6 Days)|Protocol defined stop criteria reached|0
6312617|NCT02688387|10043851|FG006|Part 1, Period 2 (up to 6 Days)|Protocol defined stop criteria reached|0
6312618|NCT02688387|10043852|FG007|Part 1, Period 2 (up to 6 Days)|Protocol defined stop criteria reached|0
6312619|NCT02688387|10043853|FG008|Part 1, Period 2 (up to 6 Days)|Protocol defined stop criteria reached|0
6312620|NCT02688387|10043854|FG009|Part 1, Period 2 (up to 6 Days)|Protocol defined stop criteria reached|0
6312621|NCT02688387|10043855|FG010|Part 1, Period 2 (up to 6 Days)|Protocol defined stop criteria reached|0
6312622|NCT02688387|10043856|FG011|Part 1, Period 2 (up to 6 Days)|Protocol defined stop criteria reached|0
6312623|NCT02688387|10043857|FG012|Part 1, Period 2 (up to 6 Days)|Protocol defined stop criteria reached|0
6312624|NCT02688387|10043858|FG013|Part 1, Period 2 (up to 6 Days)|Protocol defined stop criteria reached|0
6312625|NCT02688387|10043859|FG014|Part 1, Period 2 (up to 6 Days)|Protocol defined stop criteria reached|0
6312626|NCT02688387|10043860|FG015|Part 1, Period 2 (up to 6 Days)|Protocol defined stop criteria reached|0
6312627|NCT02688387|10043861|FG016|Part 1, Period 2 (up to 6 Days)|Protocol defined stop criteria reached|0
6312628|NCT02688387|10043862|FG017|Part 1, Period 2 (up to 6 Days)|Protocol defined stop criteria reached|0
6312629|NCT02688387|10043863|FG018|Part 1, Period 2 (up to 6 Days)|Protocol defined stop criteria reached|0
6312630|NCT02688387|10043864|FG019|Part 1, Period 2 (up to 6 Days)|Protocol defined stop criteria reached|0
6312631|NCT02688387|10043865|FG020|Part 1, Period 2 (up to 6 Days)|Protocol defined stop criteria reached|0
6312632|NCT02688387|10043866|FG021|Part 1, Period 2 (up to 6 Days)|Protocol defined stop criteria reached|0
6312633|NCT02688387|10043845|FG000|Part 1, Washout Period 3 (7 Days)|Protocol Violation|1
6312634|NCT02688387|10043846|FG001|Part 1, Washout Period 3 (7 Days)|Protocol Violation|0
6312635|NCT02688387|10043847|FG002|Part 1, Washout Period 3 (7 Days)|Protocol Violation|0
6312636|NCT02688387|10043848|FG003|Part 1, Washout Period 3 (7 Days)|Protocol Violation|0
6312637|NCT02688387|10043849|FG004|Part 1, Washout Period 3 (7 Days)|Protocol Violation|0
6312638|NCT02688387|10043850|FG005|Part 1, Washout Period 3 (7 Days)|Protocol Violation|0
6312639|NCT02688387|10043851|FG006|Part 1, Washout Period 3 (7 Days)|Protocol Violation|0
6312640|NCT02688387|10043852|FG007|Part 1, Washout Period 3 (7 Days)|Protocol Violation|0
6312641|NCT02688387|10043853|FG008|Part 1, Washout Period 3 (7 Days)|Protocol Violation|0
6312642|NCT02688387|10043854|FG009|Part 1, Washout Period 3 (7 Days)|Protocol Violation|0
6312643|NCT02688387|10043855|FG010|Part 1, Washout Period 3 (7 Days)|Protocol Violation|0
6312644|NCT02688387|10043856|FG011|Part 1, Washout Period 3 (7 Days)|Protocol Violation|0
6312645|NCT02688387|10043857|FG012|Part 1, Washout Period 3 (7 Days)|Protocol Violation|0
6312646|NCT02688387|10043858|FG013|Part 1, Washout Period 3 (7 Days)|Protocol Violation|0
6312647|NCT02688387|10043859|FG014|Part 1, Washout Period 3 (7 Days)|Protocol Violation|0
6312648|NCT02688387|10043860|FG015|Part 1, Washout Period 3 (7 Days)|Protocol Violation|0
6312649|NCT02688387|10043861|FG016|Part 1, Washout Period 3 (7 Days)|Protocol Violation|0
6312650|NCT02688387|10043862|FG017|Part 1, Washout Period 3 (7 Days)|Protocol Violation|0
6312651|NCT02688387|10043863|FG018|Part 1, Washout Period 3 (7 Days)|Protocol Violation|0
6312652|NCT02688387|10043864|FG019|Part 1, Washout Period 3 (7 Days)|Protocol Violation|0
6312653|NCT02688387|10043865|FG020|Part 1, Washout Period 3 (7 Days)|Protocol Violation|0
6312654|NCT02688387|10043866|FG021|Part 1, Washout Period 3 (7 Days)|Protocol Violation|0
6312655|NCT02688387|10043845|FG000|Part 2, Period 1 (up to 6 Days)|Adverse Event|0
6312656|NCT02688387|10043846|FG001|Part 2, Period 1 (up to 6 Days)|Adverse Event|0
6312657|NCT02688387|10043847|FG002|Part 2, Period 1 (up to 6 Days)|Adverse Event|0
6312658|NCT02688387|10043848|FG003|Part 2, Period 1 (up to 6 Days)|Adverse Event|0
6312659|NCT02688387|10043849|FG004|Part 2, Period 1 (up to 6 Days)|Adverse Event|0
6312660|NCT02688387|10043850|FG005|Part 2, Period 1 (up to 6 Days)|Adverse Event|0
6312661|NCT02688387|10043851|FG006|Part 2, Period 1 (up to 6 Days)|Adverse Event|0
6312662|NCT02688387|10043852|FG007|Part 2, Period 1 (up to 6 Days)|Adverse Event|0
6312663|NCT02688387|10043853|FG008|Part 2, Period 1 (up to 6 Days)|Adverse Event|0
6312664|NCT02688387|10043854|FG009|Part 2, Period 1 (up to 6 Days)|Adverse Event|0
6312665|NCT02688387|10043855|FG010|Part 2, Period 1 (up to 6 Days)|Adverse Event|1
6312666|NCT02688387|10043856|FG011|Part 2, Period 1 (up to 6 Days)|Adverse Event|0
6312667|NCT02688387|10043857|FG012|Part 2, Period 1 (up to 6 Days)|Adverse Event|0
6312668|NCT02688387|10043858|FG013|Part 2, Period 1 (up to 6 Days)|Adverse Event|0
6312669|NCT02688387|10043859|FG014|Part 2, Period 1 (up to 6 Days)|Adverse Event|0
6312670|NCT02688387|10043860|FG015|Part 2, Period 1 (up to 6 Days)|Adverse Event|0
6312671|NCT02688387|10043861|FG016|Part 2, Period 1 (up to 6 Days)|Adverse Event|0
6312672|NCT02688387|10043862|FG017|Part 2, Period 1 (up to 6 Days)|Adverse Event|0
6312673|NCT02688387|10043863|FG018|Part 2, Period 1 (up to 6 Days)|Adverse Event|0
6312674|NCT02688387|10043864|FG019|Part 2, Period 1 (up to 6 Days)|Adverse Event|0
6312675|NCT02688387|10043865|FG020|Part 2, Period 1 (up to 6 Days)|Adverse Event|0
6312676|NCT02688387|10043866|FG021|Part 2, Period 1 (up to 6 Days)|Adverse Event|0
6312677|NCT02688387|10043845|FG000|Part 3A, Period 1 (up to 6 Days)|Withdrawal by Subject|0
6312678|NCT02688387|10043846|FG001|Part 3A, Period 1 (up to 6 Days)|Withdrawal by Subject|0
6312679|NCT02688387|10043847|FG002|Part 3A, Period 1 (up to 6 Days)|Withdrawal by Subject|0
6312680|NCT02688387|10043848|FG003|Part 3A, Period 1 (up to 6 Days)|Withdrawal by Subject|0
6312681|NCT02688387|10043849|FG004|Part 3A, Period 1 (up to 6 Days)|Withdrawal by Subject|0
6312682|NCT02688387|10043850|FG005|Part 3A, Period 1 (up to 6 Days)|Withdrawal by Subject|0
6312683|NCT02688387|10043851|FG006|Part 3A, Period 1 (up to 6 Days)|Withdrawal by Subject|0
6312684|NCT02688387|10043852|FG007|Part 3A, Period 1 (up to 6 Days)|Withdrawal by Subject|0
6312685|NCT02688387|10043853|FG008|Part 3A, Period 1 (up to 6 Days)|Withdrawal by Subject|0
6312686|NCT02688387|10043854|FG009|Part 3A, Period 1 (up to 6 Days)|Withdrawal by Subject|0
6312687|NCT02688387|10043855|FG010|Part 3A, Period 1 (up to 6 Days)|Withdrawal by Subject|0
6312688|NCT02688387|10043856|FG011|Part 3A, Period 1 (up to 6 Days)|Withdrawal by Subject|0
6312689|NCT02688387|10043857|FG012|Part 3A, Period 1 (up to 6 Days)|Withdrawal by Subject|0
6312690|NCT02688387|10043858|FG013|Part 3A, Period 1 (up to 6 Days)|Withdrawal by Subject|0
6312691|NCT02688387|10043859|FG014|Part 3A, Period 1 (up to 6 Days)|Withdrawal by Subject|1
6312692|NCT02688387|10043860|FG015|Part 3A, Period 1 (up to 6 Days)|Withdrawal by Subject|0
6312693|NCT02688387|10043861|FG016|Part 3A, Period 1 (up to 6 Days)|Withdrawal by Subject|0
6312694|NCT02688387|10043862|FG017|Part 3A, Period 1 (up to 6 Days)|Withdrawal by Subject|0
6312695|NCT02688387|10043863|FG018|Part 3A, Period 1 (up to 6 Days)|Withdrawal by Subject|0
6312696|NCT02688387|10043864|FG019|Part 3A, Period 1 (up to 6 Days)|Withdrawal by Subject|0
6312697|NCT02688387|10043865|FG020|Part 3A, Period 1 (up to 6 Days)|Withdrawal by Subject|0
6312698|NCT02688387|10043866|FG021|Part 3A, Period 1 (up to 6 Days)|Withdrawal by Subject|0
6312699|NCT02688387|10043845|FG000|Part 3B, Period 3 (up to 6 Days)|Physician Decision|0
6312700|NCT02688387|10043846|FG001|Part 3B, Period 3 (up to 6 Days)|Physician Decision|0
6312701|NCT02688387|10043847|FG002|Part 3B, Period 3 (up to 6 Days)|Physician Decision|0
6312702|NCT02688387|10043848|FG003|Part 3B, Period 3 (up to 6 Days)|Physician Decision|0
6312703|NCT02688387|10043849|FG004|Part 3B, Period 3 (up to 6 Days)|Physician Decision|0
6312704|NCT02688387|10043850|FG005|Part 3B, Period 3 (up to 6 Days)|Physician Decision|0
6312705|NCT02688387|10043851|FG006|Part 3B, Period 3 (up to 6 Days)|Physician Decision|0
6312706|NCT02688387|10043852|FG007|Part 3B, Period 3 (up to 6 Days)|Physician Decision|0
6312707|NCT02688387|10043853|FG008|Part 3B, Period 3 (up to 6 Days)|Physician Decision|0
6312708|NCT02688387|10043854|FG009|Part 3B, Period 3 (up to 6 Days)|Physician Decision|0
6312709|NCT02688387|10043855|FG010|Part 3B, Period 3 (up to 6 Days)|Physician Decision|0
6312710|NCT02688387|10043856|FG011|Part 3B, Period 3 (up to 6 Days)|Physician Decision|0
6312711|NCT02688387|10043857|FG012|Part 3B, Period 3 (up to 6 Days)|Physician Decision|0
6312712|NCT02688387|10043858|FG013|Part 3B, Period 3 (up to 6 Days)|Physician Decision|0
6312713|NCT02688387|10043859|FG014|Part 3B, Period 3 (up to 6 Days)|Physician Decision|0
6312714|NCT02688387|10043860|FG015|Part 3B, Period 3 (up to 6 Days)|Physician Decision|0
6312715|NCT02688387|10043861|FG016|Part 3B, Period 3 (up to 6 Days)|Physician Decision|0
6312716|NCT02688387|10043862|FG017|Part 3B, Period 3 (up to 6 Days)|Physician Decision|0
6312717|NCT02688387|10043863|FG018|Part 3B, Period 3 (up to 6 Days)|Physician Decision|0
6312718|NCT02688387|10043864|FG019|Part 3B, Period 3 (up to 6 Days)|Physician Decision|0
6312719|NCT02688387|10043865|FG020|Part 3B, Period 3 (up to 6 Days)|Physician Decision|1
6312720|NCT02688387|10043866|FG021|Part 3B, Period 3 (up to 6 Days)|Physician Decision|0
6312721|NCT02688387|10043845|FG000|Part 3B, Washout Period 3 (10 Days)|Adverse Event|0
6312722|NCT02688387|10043846|FG001|Part 3B, Washout Period 3 (10 Days)|Adverse Event|0
6312723|NCT02688387|10043847|FG002|Part 3B, Washout Period 3 (10 Days)|Adverse Event|0
6312724|NCT02688387|10043848|FG003|Part 3B, Washout Period 3 (10 Days)|Adverse Event|0
6312725|NCT02688387|10043849|FG004|Part 3B, Washout Period 3 (10 Days)|Adverse Event|0
6312726|NCT02688387|10043850|FG005|Part 3B, Washout Period 3 (10 Days)|Adverse Event|0
6312727|NCT02688387|10043851|FG006|Part 3B, Washout Period 3 (10 Days)|Adverse Event|0
6312728|NCT02688387|10043852|FG007|Part 3B, Washout Period 3 (10 Days)|Adverse Event|0
6312729|NCT02688387|10043853|FG008|Part 3B, Washout Period 3 (10 Days)|Adverse Event|0
6312730|NCT02688387|10043854|FG009|Part 3B, Washout Period 3 (10 Days)|Adverse Event|0
6312731|NCT02688387|10043855|FG010|Part 3B, Washout Period 3 (10 Days)|Adverse Event|0
6312732|NCT02688387|10043856|FG011|Part 3B, Washout Period 3 (10 Days)|Adverse Event|0
6312733|NCT02688387|10043857|FG012|Part 3B, Washout Period 3 (10 Days)|Adverse Event|0
6312734|NCT02688387|10043858|FG013|Part 3B, Washout Period 3 (10 Days)|Adverse Event|0
6312735|NCT02688387|10043859|FG014|Part 3B, Washout Period 3 (10 Days)|Adverse Event|0
6312736|NCT02688387|10043860|FG015|Part 3B, Washout Period 3 (10 Days)|Adverse Event|0
6312737|NCT02688387|10043861|FG016|Part 3B, Washout Period 3 (10 Days)|Adverse Event|0
6312738|NCT02688387|10043862|FG017|Part 3B, Washout Period 3 (10 Days)|Adverse Event|0
6312739|NCT02688387|10043863|FG018|Part 3B, Washout Period 3 (10 Days)|Adverse Event|1
6312740|NCT02688387|10043864|FG019|Part 3B, Washout Period 3 (10 Days)|Adverse Event|0
6312741|NCT02688387|10043865|FG020|Part 3B, Washout Period 3 (10 Days)|Adverse Event|1
6312742|NCT02688387|10043866|FG021|Part 3B, Washout Period 3 (10 Days)|Adverse Event|0
6312743|NCT02688387|10043845|FG000|Part 3B, Washout Period 3 (10 Days)|Study terminated|0
6312744|NCT02688387|10043846|FG001|Part 3B, Washout Period 3 (10 Days)|Study terminated|0
6312745|NCT02688387|10043847|FG002|Part 3B, Washout Period 3 (10 Days)|Study terminated|0
6312746|NCT02688387|10043848|FG003|Part 3B, Washout Period 3 (10 Days)|Study terminated|0
6312747|NCT02688387|10043849|FG004|Part 3B, Washout Period 3 (10 Days)|Study terminated|0
6312748|NCT02688387|10043850|FG005|Part 3B, Washout Period 3 (10 Days)|Study terminated|0
6312749|NCT02688387|10043851|FG006|Part 3B, Washout Period 3 (10 Days)|Study terminated|0
6312750|NCT02688387|10043852|FG007|Part 3B, Washout Period 3 (10 Days)|Study terminated|0
6312751|NCT02688387|10043853|FG008|Part 3B, Washout Period 3 (10 Days)|Study terminated|0
6312752|NCT02688387|10043854|FG009|Part 3B, Washout Period 3 (10 Days)|Study terminated|0
6312753|NCT02688387|10043855|FG010|Part 3B, Washout Period 3 (10 Days)|Study terminated|0
6312754|NCT02688387|10043856|FG011|Part 3B, Washout Period 3 (10 Days)|Study terminated|0
6312755|NCT02688387|10043857|FG012|Part 3B, Washout Period 3 (10 Days)|Study terminated|0
6312756|NCT02688387|10043858|FG013|Part 3B, Washout Period 3 (10 Days)|Study terminated|0
6312757|NCT02688387|10043859|FG014|Part 3B, Washout Period 3 (10 Days)|Study terminated|0
6312758|NCT02688387|10043860|FG015|Part 3B, Washout Period 3 (10 Days)|Study terminated|0
6312759|NCT02688387|10043861|FG016|Part 3B, Washout Period 3 (10 Days)|Study terminated|0
6312760|NCT02688387|10043862|FG017|Part 3B, Washout Period 3 (10 Days)|Study terminated|0
6312761|NCT02688387|10043863|FG018|Part 3B, Washout Period 3 (10 Days)|Study terminated|0
6312762|NCT02688387|10043864|FG019|Part 3B, Washout Period 3 (10 Days)|Study terminated|1
6312763|NCT02688387|10043865|FG020|Part 3B, Washout Period 3 (10 Days)|Study terminated|0
6312764|NCT02688387|10043866|FG021|Part 3B, Washout Period 3 (10 Days)|Study terminated|0
6312765|NCT02688621|10043923|FG000|Overall Study|Pregnancy|1
6312766|NCT02688621|10043924|FG001|Overall Study|Pregnancy|3
6312767|NCT02688621|10043923|FG000|Overall Study|Lost to Follow-up|38
6312768|NCT02688621|10043924|FG001|Overall Study|Lost to Follow-up|15
6312769|NCT02688621|10043923|FG000|Overall Study|Withdrawal by Subject|1
6312770|NCT02688621|10043924|FG001|Overall Study|Withdrawal by Subject|0
6312771|NCT02688764|10043935|FG000|Overall Study|Adverse Event|3
6312772|NCT02688764|10043936|FG001|Overall Study|Adverse Event|3
6312773|NCT02688764|10043935|FG000|Overall Study|AE/Kidney transplant|1
6312774|NCT02688764|10043936|FG001|Overall Study|AE/Kidney transplant|0
6312775|NCT02688764|10043935|FG000|Overall Study|AE/Lack of efficacy|1
6312776|NCT02688764|10043936|FG001|Overall Study|AE/Lack of efficacy|0
6148784|NCT01090765|9784076|FG000|Overall Study|Developed a DVT, needed anticoagulation|0
6148785|NCT01090765|9784077|FG001|Overall Study|Developed a DVT, needed anticoagulation|0
6148786|NCT01090765|9784078|FG002|Overall Study|Developed a DVT, needed anticoagulation|0
6148787|NCT01090765|9784079|FG003|Overall Study|Developed a DVT, needed anticoagulation|1
6148788|NCT01090765|9784080|FG004|Overall Study|Developed a DVT, needed anticoagulation|0
6148789|NCT01090765|9784081|FG005|Overall Study|Developed a DVT, needed anticoagulation|0
6148790|NCT01090765|9784076|FG000|Overall Study|Vasovagal reaction with first infusion|0
6148791|NCT01090765|9784077|FG001|Overall Study|Vasovagal reaction with first infusion|0
6312777|NCT02688764|10043935|FG000|Overall Study|AE/Non-compl.|1
6312778|NCT02688764|10043936|FG001|Overall Study|AE/Non-compl.|0
6312779|NCT02688764|10043935|FG000|Overall Study|AE/Non-compl./Withd. parent|0
6312780|NCT02688764|10043936|FG001|Overall Study|AE/Non-compl./Withd. parent|1
6312781|NCT02688764|10043935|FG000|Overall Study|AE/Other|0
6312782|NCT02688764|10043936|FG001|Overall Study|AE/Other|1
6312783|NCT02688764|10043935|FG000|Overall Study|AE/Physician decision|1
6312784|NCT02688764|10043936|FG001|Overall Study|AE/Physician decision|0
6312785|NCT02688764|10043935|FG000|Overall Study|AE/Withd. parent|3
6312786|NCT02688764|10043936|FG001|Overall Study|AE/Withd. parent|0
6312787|NCT02688764|10043935|FG000|Overall Study|AE/Withd. parent/Withd. subject|1
6312788|NCT02688764|10043936|FG001|Overall Study|AE/Withd. parent/Withd. subject|1
6312789|NCT02688764|10043935|FG000|Overall Study|AE/Withd. subject|1
6312790|NCT02688764|10043936|FG001|Overall Study|AE/Withd. subject|0
6312791|NCT02688764|10043935|FG000|Overall Study|Kidney transplant|10
6312792|NCT02688764|10043936|FG001|Overall Study|Kidney transplant|4
6312793|NCT02688764|10043935|FG000|Overall Study|Lack of Efficacy|3
6312794|NCT02688764|10043936|FG001|Overall Study|Lack of Efficacy|2
6312795|NCT02688764|10043935|FG000|Overall Study|Lack of efficacy/Physician decision|0
6312796|NCT02688764|10043936|FG001|Overall Study|Lack of efficacy/Physician decision|1
6312797|NCT02688764|10043935|FG000|Overall Study|Non-compliance with study drug|4
6312798|NCT02688764|10043936|FG001|Overall Study|Non-compliance with study drug|0
6312799|NCT02688764|10043935|FG000|Overall Study|Non-compl./Physician decision|2
6312800|NCT02688764|10043936|FG001|Overall Study|Non-compl./Physician decision|0
6312801|NCT02688764|10043935|FG000|Overall Study|Non-compl./Ph. decision/Withd. subject|1
6312802|NCT02688764|10043936|FG001|Overall Study|Non-compl./Ph. decision/Withd. subject|1
6312803|NCT02688764|10043935|FG000|Overall Study|Non-compl./Withd. subject|0
6312804|NCT02688764|10043936|FG001|Overall Study|Non-compl./Withd. subject|2
6312805|NCT02688764|10043935|FG000|Overall Study|Phosphorus level outside safe range|0
6312806|NCT02688764|10043936|FG001|Overall Study|Phosphorus level outside safe range|1
6312807|NCT02688764|10043935|FG000|Overall Study|Phosphorus >7 mg/dL - Withd. by sponsor|1
6312808|NCT02688764|10043936|FG001|Overall Study|Phosphorus >7 mg/dL - Withd. by sponsor|0
6312809|NCT02688764|10043935|FG000|Overall Study|Study drug taste/Withd. parent|1
6312810|NCT02688764|10043936|FG001|Overall Study|Study drug taste/Withd. parent|0
6312811|NCT02688764|10043935|FG000|Overall Study|Subject moving out|2
6312812|NCT02688764|10043936|FG001|Overall Study|Subject moving out|0
6312813|NCT02688764|10043935|FG000|Overall Study|Subject taken off dialysis|1
6312814|NCT02688764|10043936|FG001|Overall Study|Subject taken off dialysis|0
6312815|NCT02688764|10043935|FG000|Overall Study|Withdrawal by parent|3
6312816|NCT02688764|10043936|FG001|Overall Study|Withdrawal by parent|0
6312817|NCT02689076|10043977|FG000|Overall Study|Did not have a non-VA encounter during study period (includes death before a non-VA encounter)|172
6312818|NCT02689076|10043978|FG001|Overall Study|Did not have a non-VA encounter during study period (includes death before a non-VA encounter)|213
6312819|NCT02689076|10043979|FG002|Overall Study|Did not have a non-VA encounter during study period (includes death before a non-VA encounter)|0
6312820|NCT02689076|10043977|FG000|Overall Study|Discharged from non-VA facility to long-term care facility for an indefinite period|3
6312821|NCT02689076|10043978|FG001|Overall Study|Discharged from non-VA facility to long-term care facility for an indefinite period|1
6312822|NCT02689076|10043979|FG002|Overall Study|Discharged from non-VA facility to long-term care facility for an indefinite period|0
6312823|NCT02689076|10043977|FG000|Overall Study|Did not have an HIE match|2
6312824|NCT02689076|10043978|FG001|Overall Study|Did not have an HIE match|0
6312825|NCT02689076|10043979|FG002|Overall Study|Did not have an HIE match|0
6312826|NCT02689076|10043977|FG000|Overall Study|Death during non-VA encounter|2
6312827|NCT02689076|10043978|FG001|Overall Study|Death during non-VA encounter|5
6312828|NCT02689076|10043979|FG002|Overall Study|Death during non-VA encounter|0
6148792|NCT01090765|9784078|FG002|Overall Study|Vasovagal reaction with first infusion|0
6148793|NCT01090765|9784079|FG003|Overall Study|Vasovagal reaction with first infusion|0
6148794|NCT01090765|9784080|FG004|Overall Study|Vasovagal reaction with first infusion|1
6148795|NCT01090765|9784081|FG005|Overall Study|Vasovagal reaction with first infusion|0
6148796|NCT01090973|9784100|FG000|Overall Study|Disease progression|1
6148797|NCT01091103|9784104|FG000|Overall Study|Adverse Event|1
6148798|NCT01091103|9784104|FG000|Overall Study|Progressive Disease|3
6148799|NCT01091168|9784137|FG000|Overall Study|Progressive disease|250
6148800|NCT01091168|9784138|FG001|Overall Study|Progressive disease|234
6148801|NCT01091168|9784137|FG000|Overall Study|Adverse Event|21
6148802|NCT01091168|9784138|FG001|Overall Study|Adverse Event|24
6148803|NCT01091168|9784137|FG000|Overall Study|Lost to Follow-up|0
6148804|NCT01091168|9784138|FG001|Overall Study|Lost to Follow-up|1
6148805|NCT01091168|9784137|FG000|Overall Study|Physician, patient's decision, other|27
6148806|NCT01091168|9784138|FG001|Overall Study|Physician, patient's decision, other|37
6148807|NCT01091246|9784147|FG000|Overall Study|Lost to Follow-up|23
6148808|NCT01091246|9784148|FG001|Overall Study|Lost to Follow-up|11
6148809|NCT01091246|9784149|FG002|Overall Study|Lost to Follow-up|7
6148810|NCT01091246|9784147|FG000|Overall Study|Adverse Event|1
6148811|NCT01091246|9784148|FG001|Overall Study|Adverse Event|0
6148812|NCT01091246|9784149|FG002|Overall Study|Adverse Event|1
6148813|NCT01091246|9784147|FG000|Overall Study|Withdrawal by Subject|9
6148814|NCT01091246|9784148|FG001|Overall Study|Withdrawal by Subject|5
6148815|NCT01091246|9784149|FG002|Overall Study|Withdrawal by Subject|4
6148816|NCT01091246|9784147|FG000|Overall Study|Subject not dosed|2
6148817|NCT01091246|9784148|FG001|Overall Study|Subject not dosed|0
6312829|NCT02689076|10043977|FG000|Overall Study|Provider declined to participate after participant assignment|1
6312830|NCT02689076|10043978|FG001|Overall Study|Provider declined to participate after participant assignment|1
6148818|NCT01091246|9784149|FG002|Overall Study|Subject not dosed|1
6148819|NCT01091259|9784159|FG000|Overall Study|Adverse Event|3
6148820|NCT01091259|9784159|FG000|Overall Study|Lack of Efficacy|2
6148821|NCT01091363|9784165|FG000|Overall Study|Withdrawal by Subject|11
6312831|NCT02689076|10043979|FG002|Overall Study|Provider declined to participate after participant assignment|0
6312832|NCT02689076|10043977|FG000|Overall Study|Participant no longer active in VA system|1
6312833|NCT02689076|10043978|FG001|Overall Study|Participant no longer active in VA system|0
6312834|NCT02689076|10043979|FG002|Overall Study|Participant no longer active in VA system|0
6312835|NCT02689076|10043977|FG000|Overall Study|Enrolled in GRACE or hospice during non-VA encounter|0
6312836|NCT02689076|10043978|FG001|Overall Study|Enrolled in GRACE or hospice during non-VA encounter|2
6312837|NCT02689076|10043979|FG002|Overall Study|Enrolled in GRACE or hospice during non-VA encounter|0
6312838|NCT02689206|10043996|FG000|Overall Study|Adverse Event|0
6312839|NCT02689206|10043997|FG001|Overall Study|Adverse Event|0
6312840|NCT02689206|10043998|FG002|Overall Study|Adverse Event|1
6312841|NCT02689206|10043999|FG003|Overall Study|Adverse Event|0
6312842|NCT02689206|10044000|FG004|Overall Study|Adverse Event|2
6312843|NCT02689206|10043996|FG000|Overall Study|Protocol Violation|1
6312844|NCT02689206|10043997|FG001|Overall Study|Protocol Violation|0
6312845|NCT02689206|10043998|FG002|Overall Study|Protocol Violation|0
6312846|NCT02689206|10043999|FG003|Overall Study|Protocol Violation|1
6312847|NCT02689206|10044000|FG004|Overall Study|Protocol Violation|2
6312848|NCT02689206|10043996|FG000|Overall Study|Other: Reached stopping criteria|0
6312849|NCT02689206|10043997|FG001|Overall Study|Other: Reached stopping criteria|1
6312850|NCT02689206|10043998|FG002|Overall Study|Other: Reached stopping criteria|2
6312851|NCT02689206|10043999|FG003|Overall Study|Other: Reached stopping criteria|3
6312852|NCT02689206|10044000|FG004|Overall Study|Other: Reached stopping criteria|4
6312853|NCT02689206|10043996|FG000|Overall Study|Physician Decision|1
6312854|NCT02689206|10043997|FG001|Overall Study|Physician Decision|0
6312855|NCT02689206|10043998|FG002|Overall Study|Physician Decision|0
6312856|NCT02689206|10043999|FG003|Overall Study|Physician Decision|0
6312857|NCT02689206|10044000|FG004|Overall Study|Physician Decision|0
6312858|NCT02689206|10043996|FG000|Overall Study|Withdrawal by Subject|1
6312859|NCT02689206|10043997|FG001|Overall Study|Withdrawal by Subject|0
6312860|NCT02689206|10043998|FG002|Overall Study|Withdrawal by Subject|1
6312861|NCT02689206|10043999|FG003|Overall Study|Withdrawal by Subject|0
6312862|NCT02689206|10044000|FG004|Overall Study|Withdrawal by Subject|0
6312863|NCT02689219|10044018|FG000|Overall Study|Death|1
6312864|NCT02689219|10044019|FG001|Overall Study|Death|1
6312865|NCT02689219|10044018|FG000|Overall Study|Disease Progression|10
6312866|NCT02689219|10044019|FG001|Overall Study|Disease Progression|6
6312867|NCT02689492|10044025|FG000|Overall Study|Lost to Follow-up|61
6312868|NCT02689492|10044025|FG000|Overall Study|Withdrawal by Subject|11
6148822|NCT01091363|9784166|FG001|Overall Study|Withdrawal by Subject|15
6148823|NCT01091363|9784165|FG000|Overall Study|Lost to Follow-up|2
6148824|NCT01091363|9784166|FG001|Overall Study|Lost to Follow-up|2
6148825|NCT01091428|9784176|FG000|Phase 1|Progressive Disease|24
6148826|NCT01091428|9784177|FG001|Phase 1|Progressive Disease|8
6148827|NCT01091428|9784178|FG002|Phase 1|Progressive Disease|0
6148828|NCT01091428|9784179|FG003|Phase 1|Progressive Disease|0
6148829|NCT01091428|9784176|FG000|Phase 1|Symptomatic Deterioration|3
6312869|NCT02689492|10044025|FG000|Overall Study|Death|9
6312870|NCT02689492|10044025|FG000|Overall Study|Physician Decision|2
6312871|NCT02689492|10044025|FG000|Overall Study|Withdrawal/Loss To Follow-Up|1
6312872|NCT02689492|10044025|FG000|Overall Study|Withdrawal/ Physician's Decision|1
6312873|NCT02689492|10044025|FG000|Overall Study|Other than listed|1
6312874|NCT02689804|10044034|FG000|Overall Study|Withdrawal by Subject|2
6312875|NCT02689804|10044035|FG001|Overall Study|Withdrawal by Subject|0
6312876|NCT02690194|10044095|FG000|Overall Study|Withdrawal by Subject|1
6312877|NCT02690194|10044096|FG001|Overall Study|Withdrawal by Subject|4
6312878|NCT02690194|10044097|FG002|Overall Study|Withdrawal by Subject|0
6312879|NCT02690207|10044105|FG000|Overall Study|Lost to Follow-up|48
6312880|NCT02690207|10044105|FG000|Overall Study|Withdrawal by Subject|46
6312881|NCT02690207|10044105|FG000|Overall Study|Protocol Violation|2
6312882|NCT02690207|10044105|FG000|Overall Study|Serious adverse event|110
6312883|NCT02690207|10044105|FG000|Overall Study|Non-serious Adverse Event|18
6312884|NCT02690207|10044105|FG000|Overall Study|Migrated/moved from study area|5
6312885|NCT02690207|10044105|FG000|Overall Study|Suspected HZ Episode|1
6312886|NCT02690207|10044105|FG000|Overall Study|Other reasons for withdrawal|23
6312887|NCT02690649|10044115|FG000|Overall Study|Withdrawal by Subject|1
6312888|NCT02690649|10044116|FG001|Overall Study|Withdrawal by Subject|1
6312889|NCT02690649|10044115|FG000|Overall Study|Protocol Violation|0
6312890|NCT02690649|10044116|FG001|Overall Study|Protocol Violation|3
6312891|NCT02690701|10044126|FG000|Treatment Period 1|Adverse Event|2
6312892|NCT02690701|10044127|FG001|Treatment Period 1|Adverse Event|2
6312893|NCT02690701|10044126|FG000|Treatment Period 1|Withdrawal by Subject|0
6312894|NCT02690701|10044127|FG001|Treatment Period 1|Withdrawal by Subject|1
6312895|NCT02690701|10044126|FG000|Treatment Period 2|Adverse Event|2
6312896|NCT02690701|10044127|FG001|Treatment Period 2|Adverse Event|0
6312897|NCT02690701|10044126|FG000|Treatment Period 2|Lack of Efficacy|1
6312898|NCT02690701|10044127|FG001|Treatment Period 2|Lack of Efficacy|0
6312899|NCT02690701|10044126|FG000|Treatment Period 2|Lost to Follow-up|0
6312900|NCT02690701|10044127|FG001|Treatment Period 2|Lost to Follow-up|2
6312901|NCT02690701|10044126|FG000|Treatment Period 2|Withdrawal by Subject|0
6312902|NCT02690701|10044127|FG001|Treatment Period 2|Withdrawal by Subject|2
6312903|NCT02690701|10044126|FG000|Treatment Period 2|Protocol Violation|0
6312904|NCT02690701|10044127|FG001|Treatment Period 2|Protocol Violation|1
6312905|NCT02690714|10044134|FG000|Post-Wk 48: Safety Week 48 to EoS Visit|Physician Decision|1
6312906|NCT02690714|10044134|FG000|Post-Wk 48: Safety Week 48 to EoS Visit|Withdrawal by Subject|1
6312907|NCT02690727|10044142|FG000|Overall Study|Adverse Event|2
6312908|NCT02690727|10044143|FG001|Overall Study|Adverse Event|2
6312909|NCT02690974|10044169|FG000|Overall Study|Adverse Event|16
6312910|NCT02690974|10044169|FG000|Overall Study|Death|9
6312911|NCT02690974|10044169|FG000|Overall Study|Subject/guardian decision|4
6312912|NCT02690974|10044169|FG000|Overall Study|Lost to Follow-up|3
6312913|NCT02690974|10044169|FG000|Overall Study|Withdrawal of Informed Consent|3
6312914|NCT02690974|10044169|FG000|Overall Study|Physician Decision|2
6312915|NCT02690974|10044169|FG000|Overall Study|Non-compliance with study treatment|1
6312916|NCT02690974|10044169|FG000|Overall Study|Protocol-defined stopping criteria|1
6312917|NCT02690974|10044169|FG000|Overall Study|Protocol Deviation|1
6312918|NCT02691247|10044185|FG000|Overall Study|Withdrawal by Subject|1
6312919|NCT02691247|10044186|FG001|Overall Study|Withdrawal by Subject|2
6312920|NCT02691247|10044187|FG002|Overall Study|Withdrawal by Subject|2
6312921|NCT02691247|10044185|FG000|Overall Study|Lost to Follow-up|2
6312922|NCT02691247|10044186|FG001|Overall Study|Lost to Follow-up|0
6312923|NCT02691247|10044187|FG002|Overall Study|Lost to Follow-up|1
6312924|NCT02691455|10044227|FG000|Overall Study|Withdrawal by Subject|1
6312925|NCT02691455|10044228|FG001|Overall Study|Withdrawal by Subject|2
6312926|NCT02691455|10044227|FG000|Overall Study|Lost to Follow-up|15
6312927|NCT02691455|10044228|FG001|Overall Study|Lost to Follow-up|15
6312928|NCT02691468|10044236|FG000|Overall Study|Bronchial blocker use|2
6312929|NCT02691468|10044237|FG001|Overall Study|Bronchial blocker use|1
6312930|NCT02691468|10044236|FG000|Overall Study|Lost to Follow-up|2
6312931|NCT02691468|10044237|FG001|Overall Study|Lost to Follow-up|1
6148830|NCT01091428|9784177|FG001|Phase 1|Symptomatic Deterioration|2
6312932|NCT02691468|10044236|FG000|Overall Study|Failure to advance FOB|2
6148831|NCT01091428|9784178|FG002|Phase 1|Symptomatic Deterioration|0
6312933|NCT02691468|10044237|FG001|Overall Study|Failure to advance FOB|0
6312934|NCT02691494|10044246|FG000|Post-Treatment Follow-Up Period|Withdrawal by Subject|1
6312935|NCT02691494|10044247|FG001|Post-Treatment Follow-Up Period|Withdrawal by Subject|2
6312936|NCT02691494|10044248|FG002|Post-Treatment Follow-Up Period|Withdrawal by Subject|8
6312937|NCT02691494|10044246|FG000|Post-Treatment Follow-Up Period|Lost to Follow-up|2
6312938|NCT02691494|10044247|FG001|Post-Treatment Follow-Up Period|Lost to Follow-up|3
6312939|NCT02691494|10044248|FG002|Post-Treatment Follow-Up Period|Lost to Follow-up|4
6312940|NCT02691494|10044246|FG000|Post-Treatment Follow-Up Period|Other|2
6312941|NCT02691494|10044247|FG001|Post-Treatment Follow-Up Period|Other|1
6312942|NCT02691494|10044248|FG002|Post-Treatment Follow-Up Period|Other|1
6312943|NCT02691494|10044246|FG000|Post-Treatment Follow-Up Period|Required Surgery/Invasive Intervention|0
6312944|NCT02691494|10044247|FG001|Post-Treatment Follow-Up Period|Required Surgery/Invasive Intervention|0
6312945|NCT02691494|10044248|FG002|Post-Treatment Follow-Up Period|Required Surgery/Invasive Intervention|3
6312946|NCT02691494|10044246|FG000|Post-Treatment Follow-Up Period|Non-Compliance|0
6312947|NCT02691494|10044247|FG001|Post-Treatment Follow-Up Period|Non-Compliance|1
6312948|NCT02691494|10044248|FG002|Post-Treatment Follow-Up Period|Non-Compliance|1
6312949|NCT02691507|10044258|FG000|Overall Study|Missed Visit 3|0
6312950|NCT02691507|10044259|FG001|Overall Study|Missed Visit 3|1
6312951|NCT02691572|10044267|FG000|Overall Study|Withdrawal by Subject|1
6312952|NCT02691572|10044268|FG001|Overall Study|Withdrawal by Subject|0
6312953|NCT02691572|10044267|FG000|Overall Study|Protocol Violation|0
6312954|NCT02691572|10044268|FG001|Overall Study|Protocol Violation|1
6148832|NCT01091428|9784179|FG003|Phase 1|Symptomatic Deterioration|0
6148833|NCT01091428|9784176|FG000|Phase 1|Adverse Event|2
6148834|NCT01091428|9784177|FG001|Phase 1|Adverse Event|0
6148835|NCT01091428|9784178|FG002|Phase 1|Adverse Event|0
6148836|NCT01091428|9784179|FG003|Phase 1|Adverse Event|0
6148837|NCT01091428|9784176|FG000|Phase 1|Withdrawal by Subject|7
6148838|NCT01091428|9784177|FG001|Phase 1|Withdrawal by Subject|0
6312955|NCT02691702|10044285|FG000|Overall Study|Adverse Event|1
6312956|NCT02691702|10044286|FG001|Overall Study|Adverse Event|0
6312957|NCT02691702|10044287|FG002|Overall Study|Adverse Event|0
6312958|NCT02691702|10044288|FG003|Overall Study|Adverse Event|0
6312959|NCT02691702|10044289|FG004|Overall Study|Adverse Event|0
6312960|NCT02691702|10044290|FG005|Overall Study|Adverse Event|0
6312961|NCT02691702|10044291|FG006|Overall Study|Adverse Event|0
6312962|NCT02691702|10044292|FG007|Overall Study|Adverse Event|0
6312963|NCT02691702|10044293|FG008|Overall Study|Adverse Event|1
6312964|NCT02691702|10044294|FG009|Overall Study|Adverse Event|0
6312965|NCT02691702|10044295|FG010|Overall Study|Adverse Event|1
6312966|NCT02691702|10044285|FG000|Overall Study|Lost to Follow-up|0
6312967|NCT02691702|10044286|FG001|Overall Study|Lost to Follow-up|0
6312968|NCT02691702|10044287|FG002|Overall Study|Lost to Follow-up|1
6312969|NCT02691702|10044288|FG003|Overall Study|Lost to Follow-up|0
6312970|NCT02691702|10044289|FG004|Overall Study|Lost to Follow-up|0
6312971|NCT02691702|10044290|FG005|Overall Study|Lost to Follow-up|2
6312972|NCT02691702|10044291|FG006|Overall Study|Lost to Follow-up|0
6312973|NCT02691702|10044292|FG007|Overall Study|Lost to Follow-up|0
6312974|NCT02691702|10044293|FG008|Overall Study|Lost to Follow-up|0
6312975|NCT02691702|10044294|FG009|Overall Study|Lost to Follow-up|0
6312976|NCT02691702|10044295|FG010|Overall Study|Lost to Follow-up|1
6312977|NCT02691702|10044285|FG000|Overall Study|Withdrawal by Subject|1
6312978|NCT02691702|10044286|FG001|Overall Study|Withdrawal by Subject|1
6148839|NCT01091428|9784178|FG002|Phase 1|Withdrawal by Subject|0
6148840|NCT01091428|9784179|FG003|Phase 1|Withdrawal by Subject|0
6312979|NCT02691702|10044287|FG002|Overall Study|Withdrawal by Subject|0
6312980|NCT02691702|10044288|FG003|Overall Study|Withdrawal by Subject|0
6312981|NCT02691702|10044289|FG004|Overall Study|Withdrawal by Subject|0
6312982|NCT02691702|10044290|FG005|Overall Study|Withdrawal by Subject|1
6312983|NCT02691702|10044291|FG006|Overall Study|Withdrawal by Subject|2
6312984|NCT02691702|10044292|FG007|Overall Study|Withdrawal by Subject|0
6312985|NCT02691702|10044293|FG008|Overall Study|Withdrawal by Subject|0
6312986|NCT02691702|10044294|FG009|Overall Study|Withdrawal by Subject|0
6312987|NCT02691702|10044295|FG010|Overall Study|Withdrawal by Subject|0
6312988|NCT02691702|10044285|FG000|Overall Study|Other|0
6312989|NCT02691702|10044286|FG001|Overall Study|Other|0
6312990|NCT02691702|10044287|FG002|Overall Study|Other|0
6312991|NCT02691702|10044288|FG003|Overall Study|Other|0
6312992|NCT02691702|10044289|FG004|Overall Study|Other|0
6312993|NCT02691702|10044290|FG005|Overall Study|Other|0
6312994|NCT02691702|10044291|FG006|Overall Study|Other|1
6312995|NCT02691702|10044292|FG007|Overall Study|Other|0
6312996|NCT02691702|10044293|FG008|Overall Study|Other|1
6312997|NCT02691702|10044294|FG009|Overall Study|Other|0
6312998|NCT02691702|10044295|FG010|Overall Study|Other|0
6312999|NCT02691702|10044285|FG000|Overall Study|Protocol Violation|0
6313000|NCT02691702|10044286|FG001|Overall Study|Protocol Violation|0
6313001|NCT02691702|10044287|FG002|Overall Study|Protocol Violation|0
6313002|NCT02691702|10044288|FG003|Overall Study|Protocol Violation|0
6313003|NCT02691702|10044289|FG004|Overall Study|Protocol Violation|0
6313004|NCT02691702|10044290|FG005|Overall Study|Protocol Violation|0
6313005|NCT02691702|10044291|FG006|Overall Study|Protocol Violation|0
6313006|NCT02691702|10044292|FG007|Overall Study|Protocol Violation|0
6313007|NCT02691702|10044293|FG008|Overall Study|Protocol Violation|0
6313008|NCT02691702|10044294|FG009|Overall Study|Protocol Violation|2
6313009|NCT02691702|10044295|FG010|Overall Study|Protocol Violation|0
6313010|NCT02691741|10044329|FG000|Overall Study|Adverse Event|0
6313011|NCT02691741|10044330|FG001|Overall Study|Adverse Event|2
6313012|NCT02691741|10044329|FG000|Overall Study|Lost to Follow-up|1
6313013|NCT02691741|10044330|FG001|Overall Study|Lost to Follow-up|0
6313014|NCT02691741|10044329|FG000|Overall Study|Physician Decision|0
6313015|NCT02691741|10044330|FG001|Overall Study|Physician Decision|1
6313016|NCT02691741|10044329|FG000|Overall Study|Withdrawal by Subject|0
6313017|NCT02691741|10044330|FG001|Overall Study|Withdrawal by Subject|4
6313018|NCT02691936|10044343|FG000|Overall Study|Withdrawal by Subject|2
6313019|NCT02691936|10044344|FG001|Overall Study|Withdrawal by Subject|5
6313020|NCT02692040|10044372|FG000|Overall Study|Protocol Violation|0
6313021|NCT02692040|10044373|FG001|Overall Study|Protocol Violation|0
6313022|NCT02692040|10044374|FG002|Overall Study|Protocol Violation|0
6313023|NCT02692040|10044375|FG003|Overall Study|Protocol Violation|0
6313024|NCT02692040|10044376|FG004|Overall Study|Protocol Violation|0
6313025|NCT02692040|10044377|FG005|Overall Study|Protocol Violation|0
6313026|NCT02692040|10044378|FG006|Overall Study|Protocol Violation|0
6313027|NCT02692040|10044379|FG007|Overall Study|Protocol Violation|0
6313028|NCT02692040|10044380|FG008|Overall Study|Protocol Violation|0
6313029|NCT02692040|10044381|FG009|Overall Study|Protocol Violation|0
6313030|NCT02692040|10044382|FG010|Overall Study|Protocol Violation|0
6313031|NCT02692040|10044383|FG011|Overall Study|Protocol Violation|0
6313032|NCT02692040|10044384|FG012|Overall Study|Protocol Violation|1
6313033|NCT02692040|10044385|FG013|Overall Study|Protocol Violation|0
6313034|NCT02692040|10044386|FG014|Overall Study|Protocol Violation|0
6313035|NCT02692040|10044387|FG015|Overall Study|Protocol Violation|0
6313036|NCT02692040|10044388|FG016|Overall Study|Protocol Violation|0
6313037|NCT02692040|10044372|FG000|Overall Study|Adverse Event|0
6313038|NCT02692040|10044373|FG001|Overall Study|Adverse Event|0
6313039|NCT02692040|10044374|FG002|Overall Study|Adverse Event|0
6313040|NCT02692040|10044375|FG003|Overall Study|Adverse Event|0
6313041|NCT02692040|10044376|FG004|Overall Study|Adverse Event|0
6313042|NCT02692040|10044377|FG005|Overall Study|Adverse Event|0
6313043|NCT02692040|10044378|FG006|Overall Study|Adverse Event|0
6313044|NCT02692040|10044379|FG007|Overall Study|Adverse Event|0
6313045|NCT02692040|10044380|FG008|Overall Study|Adverse Event|0
6313046|NCT02692040|10044381|FG009|Overall Study|Adverse Event|0
6313047|NCT02692040|10044382|FG010|Overall Study|Adverse Event|0
6313048|NCT02692040|10044383|FG011|Overall Study|Adverse Event|0
6313049|NCT02692040|10044384|FG012|Overall Study|Adverse Event|0
6313050|NCT02692040|10044385|FG013|Overall Study|Adverse Event|3
6313051|NCT02692040|10044386|FG014|Overall Study|Adverse Event|1
6313052|NCT02692040|10044387|FG015|Overall Study|Adverse Event|1
6313053|NCT02692040|10044388|FG016|Overall Study|Adverse Event|0
6313054|NCT02692235|10044473|FG000|Overall Study|Withdrawal by Subject|2
6313055|NCT02692235|10044474|FG001|Overall Study|Withdrawal by Subject|1
6313056|NCT02692235|10044473|FG000|Overall Study|Adverse Event|1
6313057|NCT02692235|10044474|FG001|Overall Study|Adverse Event|2
6313058|NCT02692417|10044491|FG000|Overall Study|Withdrawal by Subject|5
6313059|NCT02692417|10044492|FG001|Overall Study|Withdrawal by Subject|1
6313060|NCT02692417|10044491|FG000|Overall Study|Adverse Event|1
6313061|NCT02692417|10044492|FG001|Overall Study|Adverse Event|0
6313062|NCT02692482|10044500|FG000|Overall Study|Death|2
6313063|NCT02692482|10044501|FG001|Overall Study|Death|2
6313064|NCT02692482|10044500|FG000|Overall Study|Withdrawal by Subject|1
6313065|NCT02692482|10044501|FG001|Overall Study|Withdrawal by Subject|2
6313066|NCT02692560|10044523|FG000|Overall Study|Withdrawal by Subject|0
6313067|NCT02692560|10044524|FG001|Overall Study|Withdrawal by Subject|6
6313068|NCT02692586|10044530|FG000|Overall Study|Death from undiagnosed breast cancer through 30-day follow-up|1
6313069|NCT02692586|10044530|FG000|Overall Study|Received adjunctive thrombolytics|2
6313070|NCT02692703|10044534|FG000|Overall Study|Lost to Follow-up|1
6313071|NCT02692703|10044534|FG000|Overall Study|Other|1
6313072|NCT02692716|10044540|FG000|Overall Study|Lost to Follow-up|2
6313073|NCT02692716|10044541|FG001|Overall Study|Lost to Follow-up|5
6313074|NCT02692716|10044540|FG000|Overall Study|Withdrawal by Subject|3
6313075|NCT02692716|10044541|FG001|Overall Study|Withdrawal by Subject|1
6148841|NCT01091428|9784176|FG000|Phase 1|Reason not specified|0
6148842|NCT01091428|9784177|FG001|Phase 1|Reason not specified|1
6148843|NCT01091428|9784178|FG002|Phase 1|Reason not specified|0
6148844|NCT01091428|9784179|FG003|Phase 1|Reason not specified|0
6148845|NCT01091428|9784176|FG000|Phase 1|Single-Patient IND|2
6148846|NCT01091428|9784177|FG001|Phase 1|Single-Patient IND|0
6148847|NCT01091428|9784178|FG002|Phase 1|Single-Patient IND|0
6148848|NCT01091428|9784179|FG003|Phase 1|Single-Patient IND|0
6148849|NCT01091428|9784176|FG000|Phase 2|Progressive Disease|0
6148850|NCT01091428|9784177|FG001|Phase 2|Progressive Disease|0
6148851|NCT01091428|9784178|FG002|Phase 2|Progressive Disease|44
6148852|NCT01091428|9784179|FG003|Phase 2|Progressive Disease|46
6148853|NCT01091428|9784176|FG000|Phase 2|Symptomatic Deterioration|0
6148854|NCT01091428|9784177|FG001|Phase 2|Symptomatic Deterioration|0
6148855|NCT01091428|9784178|FG002|Phase 2|Symptomatic Deterioration|1
6148856|NCT01091428|9784179|FG003|Phase 2|Symptomatic Deterioration|6
6148857|NCT01091428|9784176|FG000|Phase 2|Adverse Event|0
6148858|NCT01091428|9784177|FG001|Phase 2|Adverse Event|0
6148859|NCT01091428|9784178|FG002|Phase 2|Adverse Event|12
6148860|NCT01091428|9784179|FG003|Phase 2|Adverse Event|5
6040098|NCT00369343|9637896|FG001|Double-blind Phase|Lack of Efficacy|4
6040099|NCT00369343|9637895|FG000|Double-blind Phase|Protocol deviation|4
6040100|NCT00369343|9637896|FG001|Double-blind Phase|Protocol deviation|0
6040101|NCT00369343|9637895|FG000|Open-label Phase|Adverse Event|19
6040102|NCT00369343|9637896|FG001|Open-label Phase|Adverse Event|7
6040103|NCT00369343|9637895|FG000|Open-label Phase|Failed to return|4
6040104|NCT00369343|9637896|FG001|Open-label Phase|Failed to return|0
6040105|NCT00369343|9637895|FG000|Open-label Phase|Physician Decision|2
6040106|NCT00369343|9637896|FG001|Open-label Phase|Physician Decision|0
6148861|NCT01091428|9784176|FG000|Phase 2|Withdrawal by Subject|0
6148862|NCT01091428|9784177|FG001|Phase 2|Withdrawal by Subject|0
6148863|NCT01091428|9784178|FG002|Phase 2|Withdrawal by Subject|9
6148864|NCT01091428|9784179|FG003|Phase 2|Withdrawal by Subject|8
6040107|NCT00369343|9637895|FG000|Open-label Phase|Lost to Follow-up|5
6040108|NCT00369343|9637896|FG001|Open-label Phase|Lost to Follow-up|3
6148865|NCT01091428|9784176|FG000|Phase 2|Unsatisfactory Therapeutic Response|0
6148866|NCT01091428|9784177|FG001|Phase 2|Unsatisfactory Therapeutic Response|0
6313076|NCT02693106|10044561|FG000|Overall Study|No time|3
6313077|NCT02693119|10044573|FG000|Open-Label Period|Withdrawal by Subject|0
6313078|NCT02693119|10044574|FG001|Open-Label Period|Withdrawal by Subject|1
6313079|NCT02693418|10044635|FG000|Overall Study|Lost to Follow-up|1
6313080|NCT02693418|10044636|FG001|Overall Study|Lost to Follow-up|2
6313081|NCT02693418|10044637|FG002|Overall Study|Lost to Follow-up|0
6313082|NCT02693418|10044638|FG003|Overall Study|Lost to Follow-up|0
6313083|NCT02693418|10044639|FG004|Overall Study|Lost to Follow-up|0
6313084|NCT02693418|10044635|FG000|Overall Study|Menses during study period|0
6313085|NCT02693418|10044636|FG001|Overall Study|Menses during study period|0
6313086|NCT02693418|10044637|FG002|Overall Study|Menses during study period|2
6313087|NCT02693418|10044638|FG003|Overall Study|Menses during study period|0
6313088|NCT02693418|10044639|FG004|Overall Study|Menses during study period|0
6313089|NCT02693834|10044668|FG000|Baseline Measurement|Withdrawal by Subject|1
6313090|NCT02693834|10044669|FG001|Baseline Measurement|Withdrawal by Subject|0
6313091|NCT02693834|10044668|FG000|Baseline Measurement|Adverse Event|1
6313092|NCT02693834|10044669|FG001|Baseline Measurement|Adverse Event|0
6313093|NCT02693834|10044668|FG000|Week 2 Practice|Adverse Event|0
6313094|NCT02693834|10044669|FG001|Week 2 Practice|Adverse Event|1
6313095|NCT02694328|10044698|FG000|Overall Study|Adverse Event|27
6313096|NCT02694328|10044699|FG001|Overall Study|Adverse Event|33
6313097|NCT02694328|10044698|FG000|Overall Study|Withdrawal by Subject|27
6313098|NCT02694328|10044699|FG001|Overall Study|Withdrawal by Subject|23
6313099|NCT02694328|10044698|FG000|Overall Study|Lost to Follow-up|26
6313100|NCT02694328|10044699|FG001|Overall Study|Lost to Follow-up|22
6313101|NCT02694328|10044698|FG000|Overall Study|Noncompliant with study drug|11
6040109|NCT00369343|9637895|FG000|Open-label Phase|inadvertently reported study completers|3
6040110|NCT00369343|9637896|FG001|Open-label Phase|inadvertently reported study completers|2
6040111|NCT00369343|9637895|FG000|Open-label Phase|Protocol Violation|1
6040112|NCT00369343|9637896|FG001|Open-label Phase|Protocol Violation|3
6040113|NCT00369343|9637895|FG000|Open-label Phase|Withdrawal by Subject|15
6040114|NCT00369343|9637896|FG001|Open-label Phase|Withdrawal by Subject|6
6040115|NCT00369343|9637895|FG000|Open-label Phase|Lack of Efficacy|4
6040116|NCT00369343|9637896|FG001|Open-label Phase|Lack of Efficacy|3
6148867|NCT01091428|9784178|FG002|Phase 2|Unsatisfactory Therapeutic Response|1
6313102|NCT02694328|10044699|FG001|Overall Study|Noncompliant with study drug|8
6313103|NCT02694328|10044698|FG000|Overall Study|Incarceration|1
6313104|NCT02694328|10044699|FG001|Overall Study|Incarceration|1
6313105|NCT02694328|10044698|FG000|Overall Study|Lack of Efficacy|1
6313106|NCT02694328|10044699|FG001|Overall Study|Lack of Efficacy|2
6313107|NCT02694328|10044698|FG000|Overall Study|Pregnancy|1
6313108|NCT02694328|10044699|FG001|Overall Study|Pregnancy|1
6313109|NCT02694328|10044698|FG000|Overall Study|Protocol Violation|6
6313110|NCT02694328|10044699|FG001|Overall Study|Protocol Violation|5
6313111|NCT02694328|10044698|FG000|Overall Study|Abnormal Laboratory Value|0
6148868|NCT01091428|9784179|FG003|Phase 2|Unsatisfactory Therapeutic Response|1
6148869|NCT01091428|9784176|FG000|Phase 2|Reason not specified|0
6148870|NCT01091428|9784177|FG001|Phase 2|Reason not specified|0
6148871|NCT01091428|9784178|FG002|Phase 2|Reason not specified|4
6148872|NCT01091428|9784179|FG003|Phase 2|Reason not specified|3
6148873|NCT01091428|9784176|FG000|Phase 2|Physician Decision|0
6148874|NCT01091428|9784177|FG001|Phase 2|Physician Decision|0
6148875|NCT01091428|9784178|FG002|Phase 2|Physician Decision|2
6148876|NCT01091428|9784179|FG003|Phase 2|Physician Decision|0
6148877|NCT01091454|9784198|FG000|Overall Study|Ineligible|1
6148878|NCT01091519|9784204|FG000|Overall Study|Adverse Event|12
6148879|NCT01091519|9784205|FG001|Overall Study|Adverse Event|16
6148880|NCT01091519|9784204|FG000|Overall Study|Death|1
6148881|NCT01091519|9784205|FG001|Overall Study|Death|0
6313112|NCT02694328|10044699|FG001|Overall Study|Abnormal Laboratory Value|3
6313113|NCT02694523|10044711|FG000|Part A|Adverse Event|7
6313114|NCT02694523|10044712|FG001|Part A|Adverse Event|3
6313115|NCT02694523|10044713|FG002|Part A|Adverse Event|0
6313116|NCT02694523|10044714|FG003|Part A|Adverse Event|0
6313117|NCT02694523|10044715|FG004|Part A|Adverse Event|0
6313118|NCT02694523|10044716|FG005|Part A|Adverse Event|0
6313119|NCT02694523|10044717|FG006|Part A|Adverse Event|0
6313120|NCT02694523|10044711|FG000|Part A|Protocol Violation|1
6313121|NCT02694523|10044712|FG001|Part A|Protocol Violation|0
6313122|NCT02694523|10044713|FG002|Part A|Protocol Violation|0
6313123|NCT02694523|10044714|FG003|Part A|Protocol Violation|0
6313124|NCT02694523|10044715|FG004|Part A|Protocol Violation|0
6313125|NCT02694523|10044716|FG005|Part A|Protocol Violation|0
6313126|NCT02694523|10044717|FG006|Part A|Protocol Violation|0
6313127|NCT02694523|10044711|FG000|Part A|Lost to Follow-up|1
6313128|NCT02694523|10044712|FG001|Part A|Lost to Follow-up|2
6313129|NCT02694523|10044713|FG002|Part A|Lost to Follow-up|0
6040117|NCT00369343|9637895|FG000|Open-label Phase|Lack of continuance tolerability|3
6048967|NCT00420927|9648200|FG001|Period 2|Lost to Follow-up|0
6148882|NCT01091519|9784204|FG000|Overall Study|Lack of Efficacy|16
6148883|NCT01091519|9784205|FG001|Overall Study|Lack of Efficacy|19
6148884|NCT01091519|9784204|FG000|Overall Study|Lost to Follow-up|14
6148885|NCT01091519|9784205|FG001|Overall Study|Lost to Follow-up|24
6313130|NCT02694523|10044714|FG003|Part A|Lost to Follow-up|0
6313131|NCT02694523|10044715|FG004|Part A|Lost to Follow-up|0
6313132|NCT02694523|10044716|FG005|Part A|Lost to Follow-up|0
6313133|NCT02694523|10044717|FG006|Part A|Lost to Follow-up|0
6313134|NCT02694523|10044711|FG000|Part A|Withdrawal by Subject|3
6313135|NCT02694523|10044712|FG001|Part A|Withdrawal by Subject|1
6313136|NCT02694523|10044713|FG002|Part A|Withdrawal by Subject|0
6313137|NCT02694523|10044714|FG003|Part A|Withdrawal by Subject|0
6313138|NCT02694523|10044715|FG004|Part A|Withdrawal by Subject|0
6313139|NCT02694523|10044716|FG005|Part A|Withdrawal by Subject|0
6313140|NCT02694523|10044717|FG006|Part A|Withdrawal by Subject|0
6313141|NCT02694523|10044711|FG000|Part A|Other|1
6313142|NCT02694523|10044712|FG001|Part A|Other|1
6313143|NCT02694523|10044713|FG002|Part A|Other|0
6313144|NCT02694523|10044714|FG003|Part A|Other|0
6313145|NCT02694523|10044715|FG004|Part A|Other|0
6313146|NCT02694523|10044716|FG005|Part A|Other|0
6313147|NCT02694523|10044717|FG006|Part A|Other|0
6313148|NCT02694523|10044711|FG000|Part B|Adverse Event|0
6313149|NCT02694523|10044712|FG001|Part B|Adverse Event|0
6313150|NCT02694523|10044713|FG002|Part B|Adverse Event|7
6313151|NCT02694523|10044714|FG003|Part B|Adverse Event|1
6313152|NCT02694523|10044715|FG004|Part B|Adverse Event|1
6313153|NCT02694523|10044716|FG005|Part B|Adverse Event|2
6313154|NCT02694523|10044717|FG006|Part B|Adverse Event|0
6313155|NCT02694523|10044711|FG000|Part B|Protocol Violation|0
6313156|NCT02694523|10044712|FG001|Part B|Protocol Violation|0
6313157|NCT02694523|10044713|FG002|Part B|Protocol Violation|1
6313158|NCT02694523|10044714|FG003|Part B|Protocol Violation|0
6313159|NCT02694523|10044715|FG004|Part B|Protocol Violation|0
6148886|NCT01091519|9784204|FG000|Overall Study|Withdrawal by Subject|2
6148887|NCT01091519|9784205|FG001|Overall Study|Withdrawal by Subject|2
6148888|NCT01091519|9784204|FG000|Overall Study|Other|6
6148889|NCT01091519|9784205|FG001|Overall Study|Other|8
6148890|NCT01091519|9784204|FG000|Overall Study|Randomized not treated|4
6148891|NCT01091519|9784205|FG001|Overall Study|Randomized not treated|4
6148892|NCT01091662|9784213|FG000|Overall Study|Adverse Event|1
6148893|NCT01091662|9784214|FG001|Overall Study|Adverse Event|9
6148894|NCT01091662|9784213|FG000|Overall Study|Physician Decision|1
6148895|NCT01091662|9784214|FG001|Overall Study|Physician Decision|1
6148896|NCT01091662|9784213|FG000|Overall Study|Withdrawal by Subject|7
6148897|NCT01091662|9784214|FG001|Overall Study|Withdrawal by Subject|6
6148898|NCT01091662|9784213|FG000|Overall Study|met exit criteria|7
6148899|NCT01091662|9784214|FG001|Overall Study|met exit criteria|13
6148900|NCT01091662|9784213|FG000|Overall Study|met exclusion criteria|1
6148901|NCT01091662|9784214|FG001|Overall Study|met exclusion criteria|0
6148902|NCT01091662|9784213|FG000|Overall Study|Lost to Follow-up|0
6148903|NCT01091662|9784214|FG001|Overall Study|Lost to Follow-up|1
6148904|NCT01091662|9784213|FG000|Overall Study|Pregnancy|0
6148905|NCT01091662|9784214|FG001|Overall Study|Pregnancy|1
6148906|NCT01091662|9784213|FG000|Overall Study|Protocol Violation|0
6148907|NCT01091662|9784214|FG001|Overall Study|Protocol Violation|2
6148908|NCT01091662|9784213|FG000|Overall Study|unable to swallow capsule|0
6148909|NCT01091662|9784214|FG001|Overall Study|unable to swallow capsule|1
6148910|NCT01091675|9784225|FG000|Overall Study|Adverse Event|7
6148911|NCT01091675|9784225|FG000|Overall Study|Lack of Efficacy|27
6148912|NCT01091974|9784243|FG000|Overall Study|Did not start intervention|3
6148913|NCT01091974|9784244|FG001|Overall Study|Did not start intervention|1
6148914|NCT01091974|9784245|FG002|Overall Study|Did not start intervention|3
6148915|NCT01091974|9784246|FG003|Overall Study|Did not start intervention|1
6148916|NCT01091974|9784243|FG000|Overall Study|resumed sleep medication|0
6148917|NCT01091974|9784244|FG001|Overall Study|resumed sleep medication|0
6148918|NCT01091974|9784245|FG002|Overall Study|resumed sleep medication|1
6148919|NCT01091974|9784246|FG003|Overall Study|resumed sleep medication|2
6148920|NCT01091974|9784243|FG000|Overall Study|Withdrawal by Subject|1
6313160|NCT02694523|10044716|FG005|Part B|Protocol Violation|0
6313161|NCT02694523|10044717|FG006|Part B|Protocol Violation|0
6313162|NCT02694523|10044711|FG000|Part B|Lost to Follow-up|0
6313163|NCT02694523|10044712|FG001|Part B|Lost to Follow-up|0
6313164|NCT02694523|10044713|FG002|Part B|Lost to Follow-up|2
6313165|NCT02694523|10044714|FG003|Part B|Lost to Follow-up|3
6313166|NCT02694523|10044715|FG004|Part B|Lost to Follow-up|2
6313167|NCT02694523|10044716|FG005|Part B|Lost to Follow-up|0
6313168|NCT02694523|10044717|FG006|Part B|Lost to Follow-up|1
6313169|NCT02694523|10044711|FG000|Part B|Withdrawal by Subject|0
6148921|NCT01091974|9784244|FG001|Overall Study|Withdrawal by Subject|3
6148922|NCT01091974|9784245|FG002|Overall Study|Withdrawal by Subject|2
6148923|NCT01091974|9784246|FG003|Overall Study|Withdrawal by Subject|2
6148924|NCT01091974|9784243|FG000|Overall Study|side-effects|1
6148925|NCT01091974|9784244|FG001|Overall Study|side-effects|1
6313170|NCT02694523|10044712|FG001|Part B|Withdrawal by Subject|0
6313171|NCT02694523|10044713|FG002|Part B|Withdrawal by Subject|9
6313172|NCT02694523|10044714|FG003|Part B|Withdrawal by Subject|0
6313173|NCT02694523|10044715|FG004|Part B|Withdrawal by Subject|1
6313174|NCT02694523|10044716|FG005|Part B|Withdrawal by Subject|3
6313175|NCT02694523|10044717|FG006|Part B|Withdrawal by Subject|0
6313176|NCT02694523|10044711|FG000|Part B|Other|0
6313177|NCT02694523|10044712|FG001|Part B|Other|0
6313178|NCT02694523|10044713|FG002|Part B|Other|1
6313179|NCT02694523|10044714|FG003|Part B|Other|0
6313180|NCT02694523|10044715|FG004|Part B|Other|0
6313181|NCT02694523|10044716|FG005|Part B|Other|0
6313182|NCT02694523|10044717|FG006|Part B|Other|1
6313183|NCT02694536|10044729|FG000|Overall Study|Progressive Disease|40
6313184|NCT02694536|10044729|FG000|Overall Study|Lost to Follow-up|1
6313185|NCT02694536|10044729|FG000|Overall Study|Study Drug-Related Adverse Event|1
6313186|NCT02694536|10044729|FG000|Overall Study|Withdrawal by Subject|8
6313187|NCT02694536|10044729|FG000|Overall Study|Death|8
6313188|NCT02694536|10044729|FG000|Overall Study|Other|22
6313189|NCT02694549|10044733|FG000|Overall Study|screen failures|2
6313190|NCT02694562|10044737|FG000|Overall Study|Death|8
6313191|NCT02694562|10044737|FG000|Overall Study|Protocol Violation|4
6313192|NCT02694562|10044737|FG000|Overall Study|Lost to Follow-up|3
6313193|NCT02694562|10044737|FG000|Overall Study|Screen Failure|2
6313194|NCT02694562|10044737|FG000|Overall Study|Physician Decision|1
6313195|NCT02694718|10044745|FG000|Overall Study|Death|1
6313196|NCT02694718|10044745|FG000|Overall Study|Withdrawal by Subject|1
6313197|NCT02694744|10044751|FG000|Overall Study|Adverse Event|2
6313198|NCT02694744|10044752|FG001|Overall Study|Adverse Event|1
6313199|NCT02694744|10044751|FG000|Overall Study|Withdrawal by Subject|2
6313200|NCT02694744|10044752|FG001|Overall Study|Withdrawal by Subject|1
6313201|NCT02694744|10044751|FG000|Overall Study|Physician Decision|1
6313202|NCT02694744|10044752|FG001|Overall Study|Physician Decision|2
6313203|NCT02694744|10044751|FG000|Overall Study|Lost to Follow-up|1
6313204|NCT02694744|10044752|FG001|Overall Study|Lost to Follow-up|0
6313205|NCT02694744|10044751|FG000|Overall Study|Taking potassium supplement: exclusion 6|0
6313206|NCT02694744|10044752|FG001|Overall Study|Taking potassium supplement: exclusion 6|1
6313207|NCT02694978|10044771|FG000|Overall Study|Adverse Event|10
6313208|NCT02694978|10044772|FG001|Overall Study|Adverse Event|9
6313209|NCT02694978|10044771|FG000|Overall Study|Withdrawal by Subject|22
6313210|NCT02694978|10044772|FG001|Overall Study|Withdrawal by Subject|19
6313211|NCT02694978|10044771|FG000|Overall Study|Lost to Follow-up|14
6313212|NCT02694978|10044772|FG001|Overall Study|Lost to Follow-up|17
6313213|NCT02694978|10044771|FG000|Overall Study|Death|4
6313214|NCT02694978|10044772|FG001|Overall Study|Death|1
6313215|NCT02694978|10044771|FG000|Overall Study|Other-Decision of Participant|6
6313216|NCT02694978|10044772|FG001|Overall Study|Other-Decision of Participant|1
6313217|NCT02694978|10044771|FG000|Overall Study|Other-Investigator's decision|1
6313218|NCT02694978|10044772|FG001|Overall Study|Other-Investigator's decision|0
6313219|NCT02694978|10044771|FG000|Overall Study|Other-Unable to be reached|0
6313220|NCT02694978|10044772|FG001|Overall Study|Other-Unable to be reached|1
6313221|NCT02694978|10044771|FG000|Overall Study|Other-Protocol noncompliant|2
6313222|NCT02694978|10044772|FG001|Overall Study|Other-Protocol noncompliant|1
6313223|NCT02694978|10044771|FG000|Overall Study|Other-Personal reasons|3
6313224|NCT02694978|10044772|FG001|Overall Study|Other-Personal reasons|3
6313225|NCT02694978|10044771|FG000|Overall Study|Other-Withdrew prior to dosing|9
6313226|NCT02694978|10044772|FG001|Overall Study|Other-Withdrew prior to dosing|8
6313227|NCT02695329|10044784|FG000|Overall Study|Adverse Event|1
6313228|NCT02695329|10044785|FG001|Overall Study|Adverse Event|0
6313229|NCT02695329|10044784|FG000|Overall Study|Poor X-ray quality for measurement|4
6313230|NCT02695329|10044785|FG001|Overall Study|Poor X-ray quality for measurement|5
6313231|NCT02695420|10044795|FG000|Overall Study|Death|0
6313232|NCT02695420|10044796|FG001|Overall Study|Death|1
6313233|NCT02695420|10044797|FG002|Overall Study|Death|0
6313234|NCT02695420|10044798|FG003|Overall Study|Death|0
6313235|NCT02695524|10044817|FG000|Overall Study|Lost to Follow-up|3
6313236|NCT02695524|10044818|FG001|Overall Study|Lost to Follow-up|2
6313237|NCT02695524|10044817|FG000|Overall Study|Death|0
6313238|NCT02695524|10044818|FG001|Overall Study|Death|1
6313239|NCT02695537|10044824|FG000|Overall Study|Adverse Event|3
6313240|NCT02695537|10044824|FG000|Overall Study|Lack of Efficacy|28
6313241|NCT02695537|10044824|FG000|Overall Study|Withdrawal by Subject|4
6313242|NCT02695537|10044824|FG000|Overall Study|Protocol Violation|3
6313243|NCT02695628|10044828|FG000|Overall Study|Withdrawal by Subject|1
6313244|NCT02695719|10044834|FG000|Overall Study|Pretreatment Event/Adverse Event|2
6313245|NCT02695719|10044835|FG001|Overall Study|Pretreatment Event/Adverse Event|9
6313246|NCT02695719|10044834|FG000|Overall Study|Significant Protocol Deviation|0
6313247|NCT02695719|10044835|FG001|Overall Study|Significant Protocol Deviation|1
6313248|NCT02695719|10044834|FG000|Overall Study|Voluntary Withdrawal|1
6313249|NCT02695719|10044835|FG001|Overall Study|Voluntary Withdrawal|0
6313250|NCT02696317|10044877|FG000|Habitual, 10 Days of Wear|Withdrawal by Subject|2
6313251|NCT02696317|10044878|FG001|Habitual, 10 Days of Wear|Withdrawal by Subject|4
6313252|NCT02696317|10044877|FG000|Period 2, 10 Days of Wear|Withdrawal by Subject|1
6313253|NCT02696317|10044878|FG001|Period 2, 10 Days of Wear|Withdrawal by Subject|0
6313254|NCT02696434|10044888|FG000|Overall Study|Adverse Event|3
6313255|NCT02696434|10044889|FG001|Overall Study|Adverse Event|1
6313256|NCT02696434|10044888|FG000|Overall Study|Lost to Follow-up|5
6313257|NCT02696434|10044889|FG001|Overall Study|Lost to Follow-up|4
6313258|NCT02696434|10044888|FG000|Overall Study|Withdrawal by Subject|14
6313259|NCT02696434|10044889|FG001|Overall Study|Withdrawal by Subject|12
6313260|NCT02696434|10044888|FG000|Overall Study|Physician Decision|0
6313261|NCT02696434|10044889|FG001|Overall Study|Physician Decision|1
6313262|NCT02696785|10044899|FG000|Blinded Treatment Period|Adverse Event|0
6313263|NCT02696785|10044900|FG001|Blinded Treatment Period|Adverse Event|1
6313264|NCT02696785|10044901|FG002|Blinded Treatment Period|Adverse Event|3
6313265|NCT02696785|10044902|FG003|Blinded Treatment Period|Adverse Event|0
6313266|NCT02696785|10044899|FG000|Blinded Treatment Period|Withdrawal by Subject|0
6313267|NCT02696785|10044900|FG001|Blinded Treatment Period|Withdrawal by Subject|1
6313268|NCT02696785|10044901|FG002|Blinded Treatment Period|Withdrawal by Subject|1
6313269|NCT02696785|10044902|FG003|Blinded Treatment Period|Withdrawal by Subject|2
6313270|NCT02696785|10044899|FG000|Blinded Treatment Period|Lack of Efficacy|0
6313271|NCT02696785|10044900|FG001|Blinded Treatment Period|Lack of Efficacy|0
6313272|NCT02696785|10044901|FG002|Blinded Treatment Period|Lack of Efficacy|0
6313273|NCT02696785|10044902|FG003|Blinded Treatment Period|Lack of Efficacy|1
6313274|NCT02696785|10044899|FG000|Blinded Treatment Period|Screen Failure|1
6313275|NCT02696785|10044900|FG001|Blinded Treatment Period|Screen Failure|0
6313276|NCT02696785|10044901|FG002|Blinded Treatment Period|Screen Failure|0
6313277|NCT02696785|10044902|FG003|Blinded Treatment Period|Screen Failure|0
6313278|NCT02696785|10044899|FG000|Washout Period|Withdrawal by Subject|0
6313279|NCT02696785|10044900|FG001|Washout Period|Withdrawal by Subject|1
6313280|NCT02696785|10044901|FG002|Washout Period|Withdrawal by Subject|0
6313281|NCT02696785|10044902|FG003|Washout Period|Withdrawal by Subject|0
6313282|NCT02696785|10044899|FG000|Washout Period|Lack of Efficacy|0
6313283|NCT02696785|10044900|FG001|Washout Period|Lack of Efficacy|1
6313284|NCT02696785|10044901|FG002|Washout Period|Lack of Efficacy|0
6313285|NCT02696785|10044902|FG003|Washout Period|Lack of Efficacy|0
6313286|NCT02696785|10044899|FG000|Extended Treatment Period|Adverse Event|2
6313287|NCT02696785|10044900|FG001|Extended Treatment Period|Adverse Event|3
6313288|NCT02696785|10044901|FG002|Extended Treatment Period|Adverse Event|2
6040118|NCT00369343|9637896|FG001|Open-label Phase|Lack of continuance tolerability|4
6040119|NCT00369343|9637895|FG000|Open-label Phase|did not take study drug|1
6040120|NCT00369343|9637896|FG001|Open-label Phase|did not take study drug|2
6040121|NCT00369382|9637911|FG000|Overall Study|Death|0
6040122|NCT00369382|9637912|FG001|Overall Study|Death|2
6040123|NCT00369382|9637911|FG000|Overall Study|Physician Decision|2
6040124|NCT00369382|9637912|FG001|Overall Study|Physician Decision|1
6040125|NCT00369382|9637911|FG000|Overall Study|Withdrawal by Subject|5
6040126|NCT00369382|9637912|FG001|Overall Study|Withdrawal by Subject|0
6040127|NCT00369382|9637911|FG000|Overall Study|Randomized, not treated|2
6040128|NCT00369382|9637912|FG001|Overall Study|Randomized, not treated|0
6040129|NCT00369382|9637911|FG000|Overall Study|Other|1
6040130|NCT00369382|9637912|FG001|Overall Study|Other|0
6040131|NCT00369486|9637924|FG000|4-Week Visit|Missed visit|2
6040132|NCT00369486|9637925|FG001|4-Week Visit|Missed visit|2
6040133|NCT00369486|9637926|FG002|4-Week Visit|Missed visit|0
6040134|NCT00369486|9637927|FG003|4-Week Visit|Missed visit|2
6040135|NCT00369486|9637928|FG004|4-Week Visit|Missed visit|1
6040136|NCT00369486|9637924|FG000|4-Week Visit|Dropped|0
6040137|NCT00369486|9637925|FG001|4-Week Visit|Dropped|0
6040138|NCT00369486|9637926|FG002|4-Week Visit|Dropped|1
6040139|NCT00369486|9637927|FG003|4-Week Visit|Dropped|0
6040140|NCT00369486|9637928|FG004|4-Week Visit|Dropped|0
6040141|NCT00369486|9637924|FG000|8-Week Visit|Missed visit|0
6313289|NCT02696785|10044902|FG003|Extended Treatment Period|Adverse Event|1
6313290|NCT02696785|10044899|FG000|Extended Treatment Period|Lack of Efficacy|0
6040142|NCT00369486|9637925|FG001|8-Week Visit|Missed visit|1
6040143|NCT00369486|9637926|FG002|8-Week Visit|Missed visit|0
6040144|NCT00369486|9637927|FG003|8-Week Visit|Missed visit|0
6040145|NCT00369486|9637928|FG004|8-Week Visit|Missed visit|1
6040146|NCT00369486|9637924|FG000|8-Week Visit|Dropped|0
6040147|NCT00369486|9637925|FG001|8-Week Visit|Dropped|0
6040148|NCT00369486|9637926|FG002|8-Week Visit|Dropped|0
6040149|NCT00369486|9637927|FG003|8-Week Visit|Dropped|1
6040150|NCT00369486|9637928|FG004|8-Week Visit|Dropped|0
6040151|NCT00369486|9637924|FG000|17-Week Visit|Missed visit|0
6040152|NCT00369486|9637925|FG001|17-Week Visit|Missed visit|0
6040153|NCT00369486|9637926|FG002|17-Week Visit|Missed visit|1
6040154|NCT00369486|9637927|FG003|17-Week Visit|Missed visit|1
6040155|NCT00369486|9637928|FG004|17-Week Visit|Missed visit|1
6040156|NCT00369486|9637924|FG000|34-Week Visit|Dropped|0
6040157|NCT00369486|9637925|FG001|34-Week Visit|Dropped|1
6040158|NCT00369486|9637926|FG002|34-Week Visit|Dropped|1
6040159|NCT00369486|9637927|FG003|34-Week Visit|Dropped|3
6040160|NCT00369486|9637928|FG004|34-Week Visit|Dropped|3
6040161|NCT00369577|9637960|FG000|Overall Study|Withdrawal by Subject|0
6313291|NCT02696785|10044900|FG001|Extended Treatment Period|Lack of Efficacy|1
6313292|NCT02696785|10044901|FG002|Extended Treatment Period|Lack of Efficacy|0
6313293|NCT02696785|10044902|FG003|Extended Treatment Period|Lack of Efficacy|0
6313294|NCT02696785|10044899|FG000|Extended Treatment Period|Withdrawal by Subject|1
6313295|NCT02696785|10044900|FG001|Extended Treatment Period|Withdrawal by Subject|2
6313296|NCT02696785|10044901|FG002|Extended Treatment Period|Withdrawal by Subject|3
6313297|NCT02696785|10044902|FG003|Extended Treatment Period|Withdrawal by Subject|5
6313298|NCT02696785|10044899|FG000|Follow-up Period|Adverse Event|0
6313299|NCT02696785|10044900|FG001|Follow-up Period|Adverse Event|0
6313300|NCT02696785|10044901|FG002|Follow-up Period|Adverse Event|8
6313301|NCT02696785|10044902|FG003|Follow-up Period|Adverse Event|2
6313302|NCT02696785|10044899|FG000|Follow-up Period|Lost to Follow-up|0
6313303|NCT02696785|10044900|FG001|Follow-up Period|Lost to Follow-up|0
6313304|NCT02696785|10044901|FG002|Follow-up Period|Lost to Follow-up|0
6313305|NCT02696785|10044902|FG003|Follow-up Period|Lost to Follow-up|1
6313306|NCT02696785|10044899|FG000|Follow-up Period|Lack of Efficacy|0
6313307|NCT02696785|10044900|FG001|Follow-up Period|Lack of Efficacy|0
6313308|NCT02696785|10044901|FG002|Follow-up Period|Lack of Efficacy|0
6313309|NCT02696785|10044902|FG003|Follow-up Period|Lack of Efficacy|1
6313310|NCT02696785|10044899|FG000|Follow-up Period|Withdrawal by Subject|1
6313311|NCT02696785|10044900|FG001|Follow-up Period|Withdrawal by Subject|0
6313312|NCT02696785|10044901|FG002|Follow-up Period|Withdrawal by Subject|5
6313313|NCT02696785|10044902|FG003|Follow-up Period|Withdrawal by Subject|4
6313314|NCT02696798|10044933|FG000|Blinded Treatment Dosing Period|Adverse Event|2
6313315|NCT02696798|10044934|FG001|Blinded Treatment Dosing Period|Adverse Event|9
6040162|NCT00369577|9637961|FG001|Overall Study|Withdrawal by Subject|0
6040163|NCT00369577|9637962|FG002|Overall Study|Withdrawal by Subject|1
6040164|NCT00369629|9637978|FG000|Treated 2 Cycles/Reached First Response|Physician Decision|0
6040165|NCT00369629|9637979|FG001|Treated 2 Cycles/Reached First Response|Physician Decision|1
6313316|NCT02696798|10044935|FG002|Blinded Treatment Dosing Period|Adverse Event|2
6313317|NCT02696798|10044933|FG000|Blinded Treatment Dosing Period|Death|0
6313318|NCT02696798|10044934|FG001|Blinded Treatment Dosing Period|Death|0
6313319|NCT02696798|10044935|FG002|Blinded Treatment Dosing Period|Death|1
6040166|NCT00369629|9637980|FG002|Treated 2 Cycles/Reached First Response|Physician Decision|1
6040167|NCT00369629|9637981|FG003|Treated 2 Cycles/Reached First Response|Physician Decision|0
6040168|NCT00369629|9637978|FG000|Treated 2 Cycles/Reached First Response|Adverse Event|0
6313320|NCT02696798|10044933|FG000|Blinded Treatment Dosing Period|Lack of Efficacy|2
6313321|NCT02696798|10044934|FG001|Blinded Treatment Dosing Period|Lack of Efficacy|1
6313322|NCT02696798|10044935|FG002|Blinded Treatment Dosing Period|Lack of Efficacy|1
6313323|NCT02696798|10044933|FG000|Blinded Treatment Dosing Period|Lost to Follow-up|0
6313324|NCT02696798|10044934|FG001|Blinded Treatment Dosing Period|Lost to Follow-up|1
6313325|NCT02696798|10044935|FG002|Blinded Treatment Dosing Period|Lost to Follow-up|0
6313326|NCT02696798|10044933|FG000|Blinded Treatment Dosing Period|Physician Decision|0
6313327|NCT02696798|10044934|FG001|Blinded Treatment Dosing Period|Physician Decision|1
6313328|NCT02696798|10044935|FG002|Blinded Treatment Dosing Period|Physician Decision|0
6313329|NCT02696798|10044933|FG000|Blinded Treatment Dosing Period|Withdrawal by Subject|7
6313330|NCT02696798|10044934|FG001|Blinded Treatment Dosing Period|Withdrawal by Subject|3
6313331|NCT02696798|10044935|FG002|Blinded Treatment Dosing Period|Withdrawal by Subject|4
6313332|NCT02696798|10044933|FG000|Extended Treatment Period|Adverse Event|1
6313333|NCT02696798|10044934|FG001|Extended Treatment Period|Adverse Event|4
6313334|NCT02696798|10044935|FG002|Extended Treatment Period|Adverse Event|5
6313335|NCT02696798|10044933|FG000|Extended Treatment Period|Lack of Efficacy|7
6313336|NCT02696798|10044934|FG001|Extended Treatment Period|Lack of Efficacy|2
6313337|NCT02696798|10044935|FG002|Extended Treatment Period|Lack of Efficacy|2
6313338|NCT02696798|10044933|FG000|Extended Treatment Period|Lost to Follow-up|1
6313339|NCT02696798|10044934|FG001|Extended Treatment Period|Lost to Follow-up|0
6313340|NCT02696798|10044935|FG002|Extended Treatment Period|Lost to Follow-up|0
6313341|NCT02696798|10044933|FG000|Extended Treatment Period|Physician Decision|0
6313342|NCT02696798|10044934|FG001|Extended Treatment Period|Physician Decision|1
6313343|NCT02696798|10044935|FG002|Extended Treatment Period|Physician Decision|0
6313344|NCT02696798|10044933|FG000|Extended Treatment Period|Withdrawal by Subject|3
6313345|NCT02696798|10044934|FG001|Extended Treatment Period|Withdrawal by Subject|2
6313346|NCT02696798|10044935|FG002|Extended Treatment Period|Withdrawal by Subject|3
6313347|NCT02696798|10044933|FG000|Post-treatment Follow-up Period|Adverse Event|2
6313348|NCT02696798|10044934|FG001|Post-treatment Follow-up Period|Adverse Event|12
6313349|NCT02696798|10044935|FG002|Post-treatment Follow-up Period|Adverse Event|6
6313350|NCT02696798|10044933|FG000|Post-treatment Follow-up Period|Lost to Follow-up|0
6313351|NCT02696798|10044934|FG001|Post-treatment Follow-up Period|Lost to Follow-up|1
6313352|NCT02696798|10044935|FG002|Post-treatment Follow-up Period|Lost to Follow-up|1
6313353|NCT02696798|10044933|FG000|Post-treatment Follow-up Period|Lack of Efficacy|1
6313354|NCT02696798|10044934|FG001|Post-treatment Follow-up Period|Lack of Efficacy|2
6313355|NCT02696798|10044935|FG002|Post-treatment Follow-up Period|Lack of Efficacy|0
6313356|NCT02696798|10044933|FG000|Post-treatment Follow-up Period|Withdrawal by Subject|2
6313357|NCT02696798|10044934|FG001|Post-treatment Follow-up Period|Withdrawal by Subject|8
6313358|NCT02696798|10044935|FG002|Post-treatment Follow-up Period|Withdrawal by Subject|12
6313359|NCT02696798|10044933|FG000|Post-treatment Follow-up Period|Physician Decision|0
6313360|NCT02696798|10044934|FG001|Post-treatment Follow-up Period|Physician Decision|2
6313361|NCT02696798|10044935|FG002|Post-treatment Follow-up Period|Physician Decision|0
6313362|NCT02696798|10044933|FG000|Post-treatment Follow-up Period|No progressive improvement|0
6313363|NCT02696798|10044934|FG001|Post-treatment Follow-up Period|No progressive improvement|1
6313364|NCT02696798|10044935|FG002|Post-treatment Follow-up Period|No progressive improvement|0
6313365|NCT02696850|10044959|FG000|Overall Study|Withdrawal by Subject|3
6313366|NCT02696850|10044960|FG001|Overall Study|Withdrawal by Subject|3
6313367|NCT02696850|10044959|FG000|Overall Study|Lost to Follow-up|8
6313368|NCT02696850|10044960|FG001|Overall Study|Lost to Follow-up|5
6313369|NCT02696902|10044969|FG000|Overall Study|Lost to Follow-up|0
6313370|NCT02696902|10044970|FG001|Overall Study|Lost to Follow-up|1
6313371|NCT02696902|10044971|FG002|Overall Study|Lost to Follow-up|1
6313372|NCT02696902|10044969|FG000|Overall Study|Withdrawal by Subject|0
6313373|NCT02696902|10044970|FG001|Overall Study|Withdrawal by Subject|0
6313374|NCT02696902|10044971|FG002|Overall Study|Withdrawal by Subject|1
6313375|NCT02696902|10044969|FG000|Overall Study|Death|19
6313376|NCT02696902|10044970|FG001|Overall Study|Death|3
6313377|NCT02696902|10044971|FG002|Overall Study|Death|24
6313378|NCT02696902|10044969|FG000|Overall Study|Participant not fit post-randomization|0
6313379|NCT02696902|10044970|FG001|Overall Study|Participant not fit post-randomization|0
6313380|NCT02696902|10044971|FG002|Overall Study|Participant not fit post-randomization|1
6313381|NCT02696902|10044969|FG000|Overall Study|Participant not eligible (negative PCR)|0
6313382|NCT02696902|10044970|FG001|Overall Study|Participant not eligible (negative PCR)|0
6313383|NCT02696902|10044971|FG002|Overall Study|Participant not eligible (negative PCR)|1
6040169|NCT00369629|9637979|FG001|Treated 2 Cycles/Reached First Response|Adverse Event|0
6040170|NCT00369629|9637980|FG002|Treated 2 Cycles/Reached First Response|Adverse Event|1
6040171|NCT00369629|9637981|FG003|Treated 2 Cycles/Reached First Response|Adverse Event|0
6040172|NCT00369629|9637978|FG000|Treated 2 Cycles/Reached First Response|Progressive disease|2
6040173|NCT00369629|9637979|FG001|Treated 2 Cycles/Reached First Response|Progressive disease|0
6040174|NCT00369629|9637980|FG002|Treated 2 Cycles/Reached First Response|Progressive disease|0
6040175|NCT00369629|9637981|FG003|Treated 2 Cycles/Reached First Response|Progressive disease|0
6313384|NCT02696902|10044969|FG000|Overall Study|Principal investigator's decision|1
6313385|NCT02696902|10044970|FG001|Overall Study|Principal investigator's decision|0
6313386|NCT02696902|10044971|FG002|Overall Study|Principal investigator's decision|0
6313387|NCT02696902|10044969|FG000|Overall Study|Sponsor's decision|1
6313388|NCT02696902|10044970|FG001|Overall Study|Sponsor's decision|0
6313389|NCT02696902|10044971|FG002|Overall Study|Sponsor's decision|0
6313390|NCT02696902|10044969|FG000|Overall Study|Transferred to other hospital|1
6313391|NCT02696902|10044970|FG001|Overall Study|Transferred to other hospital|0
6313392|NCT02696902|10044971|FG002|Overall Study|Transferred to other hospital|0
6313393|NCT02697435|10045050|FG000|Overall Study|Withdrawal by Subject|1
6313394|NCT02697435|10045051|FG001|Overall Study|Withdrawal by Subject|0
6313395|NCT02697435|10045050|FG000|Overall Study|Physician Decision|0
6313396|NCT02697435|10045051|FG001|Overall Study|Physician Decision|4
6313397|NCT02697591|10045068|FG000|Overall Study|Lost to Follow-up|0
6313398|NCT02697591|10045069|FG001|Overall Study|Lost to Follow-up|0
6313399|NCT02697591|10045070|FG002|Overall Study|Lost to Follow-up|0
6313400|NCT02697591|10045071|FG003|Overall Study|Lost to Follow-up|0
6313401|NCT02697591|10045072|FG004|Overall Study|Lost to Follow-up|0
6313402|NCT02697591|10045073|FG005|Overall Study|Lost to Follow-up|1
6313403|NCT02697591|10045074|FG006|Overall Study|Lost to Follow-up|1
6313404|NCT02697591|10045075|FG007|Overall Study|Lost to Follow-up|0
6313405|NCT02697591|10045076|FG008|Overall Study|Lost to Follow-up|0
6313406|NCT02697591|10045077|FG009|Overall Study|Lost to Follow-up|1
6313407|NCT02697591|10045068|FG000|Overall Study|Withdrawal by Subject|1
6313408|NCT02697591|10045069|FG001|Overall Study|Withdrawal by Subject|1
6313409|NCT02697591|10045070|FG002|Overall Study|Withdrawal by Subject|2
6313410|NCT02697591|10045071|FG003|Overall Study|Withdrawal by Subject|1
6313411|NCT02697591|10045072|FG004|Overall Study|Withdrawal by Subject|7
6313412|NCT02697591|10045073|FG005|Overall Study|Withdrawal by Subject|6
6313413|NCT02697591|10045074|FG006|Overall Study|Withdrawal by Subject|9
6313414|NCT02697591|10045075|FG007|Overall Study|Withdrawal by Subject|1
6313415|NCT02697591|10045076|FG008|Overall Study|Withdrawal by Subject|6
6313416|NCT02697591|10045077|FG009|Overall Study|Withdrawal by Subject|10
6313417|NCT02697591|10045068|FG000|Overall Study|Physician Decision|1
6313418|NCT02697591|10045069|FG001|Overall Study|Physician Decision|0
6313419|NCT02697591|10045070|FG002|Overall Study|Physician Decision|0
6313420|NCT02697591|10045071|FG003|Overall Study|Physician Decision|0
6313421|NCT02697591|10045072|FG004|Overall Study|Physician Decision|1
6313422|NCT02697591|10045073|FG005|Overall Study|Physician Decision|2
6313423|NCT02697591|10045074|FG006|Overall Study|Physician Decision|0
6313424|NCT02697591|10045075|FG007|Overall Study|Physician Decision|0
6313425|NCT02697591|10045076|FG008|Overall Study|Physician Decision|1
6313426|NCT02697591|10045077|FG009|Overall Study|Physician Decision|1
6313427|NCT02697591|10045068|FG000|Overall Study|Death|2
6313428|NCT02697591|10045069|FG001|Overall Study|Death|3
6313429|NCT02697591|10045070|FG002|Overall Study|Death|1
6313430|NCT02697591|10045071|FG003|Overall Study|Death|1
6313431|NCT02697591|10045072|FG004|Overall Study|Death|4
6313432|NCT02697591|10045073|FG005|Overall Study|Death|5
6313433|NCT02697591|10045074|FG006|Overall Study|Death|3
6313434|NCT02697591|10045075|FG007|Overall Study|Death|1
6313435|NCT02697591|10045076|FG008|Overall Study|Death|1
6313436|NCT02697591|10045077|FG009|Overall Study|Death|5
6313437|NCT02697591|10045068|FG000|Overall Study|Reason not Specified|0
6313438|NCT02697591|10045069|FG001|Overall Study|Reason not Specified|0
6040176|NCT00369629|9637978|FG000|Moved on to 4 More Cycles|Progressive Disease|0
6313439|NCT02697591|10045070|FG002|Overall Study|Reason not Specified|0
6313440|NCT02697591|10045071|FG003|Overall Study|Reason not Specified|1
6313441|NCT02697591|10045072|FG004|Overall Study|Reason not Specified|1
6313442|NCT02697591|10045073|FG005|Overall Study|Reason not Specified|2
6313443|NCT02697591|10045074|FG006|Overall Study|Reason not Specified|3
6313444|NCT02697591|10045075|FG007|Overall Study|Reason not Specified|1
6313445|NCT02697591|10045076|FG008|Overall Study|Reason not Specified|1
6313446|NCT02697591|10045077|FG009|Overall Study|Reason not Specified|3
6313447|NCT02697617|10045100|FG000|Overall Study|Withdrawal by Subject|0
6313448|NCT02697617|10045101|FG001|Overall Study|Withdrawal by Subject|2
6313449|NCT02697617|10045100|FG000|Overall Study|Pregnancy|1
6313450|NCT02697617|10045101|FG001|Overall Study|Pregnancy|0
6313451|NCT02697734|10045113|FG000|Core Phase - up to Week 48|Withdrawal by Subject|4
6313452|NCT02697734|10045114|FG001|Core Phase - up to Week 48|Withdrawal by Subject|0
6313453|NCT02697734|10045113|FG000|Core Phase - up to Week 48|Adverse Event|1
6313454|NCT02697734|10045114|FG001|Core Phase - up to Week 48|Adverse Event|2
6313455|NCT02697734|10045113|FG000|Core Phase - up to Week 48|Physician Decision|1
6313456|NCT02697734|10045114|FG001|Core Phase - up to Week 48|Physician Decision|0
6313457|NCT02697734|10045113|FG000|Optional Extension Phase|Adverse Event|5
6313458|NCT02697734|10045114|FG001|Optional Extension Phase|Adverse Event|1
6313459|NCT02697734|10045113|FG000|Optional Extension Phase|Physician Decision|0
6313460|NCT02697734|10045114|FG001|Optional Extension Phase|Physician Decision|1
6313461|NCT02697773|10045131|FG000|Overall Study|Adverse Event|2
6313462|NCT02697773|10045132|FG001|Overall Study|Adverse Event|1
6313463|NCT02697773|10045133|FG002|Overall Study|Adverse Event|2
6313464|NCT02697773|10045131|FG000|Overall Study|Death|0
6313465|NCT02697773|10045132|FG001|Overall Study|Death|0
6313466|NCT02697773|10045133|FG002|Overall Study|Death|2
6313467|NCT02697773|10045131|FG000|Overall Study|Lack of Efficacy|4
6313468|NCT02697773|10045132|FG001|Overall Study|Lack of Efficacy|6
6313469|NCT02697773|10045133|FG002|Overall Study|Lack of Efficacy|6
6313470|NCT02697773|10045131|FG000|Overall Study|Lost to Follow-up|5
6313471|NCT02697773|10045132|FG001|Overall Study|Lost to Follow-up|5
6313472|NCT02697773|10045133|FG002|Overall Study|Lost to Follow-up|7
6313473|NCT02697773|10045131|FG000|Overall Study|Other|15
6313474|NCT02697773|10045132|FG001|Overall Study|Other|11
6148926|NCT01091974|9784245|FG002|Overall Study|side-effects|0
6148927|NCT01091974|9784246|FG003|Overall Study|side-effects|2
6148928|NCT01092182|9784259|FG000|Overall Study|Death|0
6148929|NCT01092182|9784260|FG001|Overall Study|Death|5
6148930|NCT01092182|9784261|FG002|Overall Study|Death|3
6148931|NCT01092182|9784259|FG000|Overall Study|participant safety|1
6313475|NCT02697773|10045133|FG002|Overall Study|Other|10
6313476|NCT02697773|10045131|FG000|Overall Study|Protocol Violation|1
6313477|NCT02697773|10045132|FG001|Overall Study|Protocol Violation|1
6313478|NCT02697773|10045133|FG002|Overall Study|Protocol Violation|0
6313479|NCT02697773|10045131|FG000|Overall Study|Withdrawal by Subject|10
6313480|NCT02697773|10045132|FG001|Overall Study|Withdrawal by Subject|13
6313481|NCT02697773|10045133|FG002|Overall Study|Withdrawal by Subject|13
6313482|NCT02697773|10045131|FG000|Overall Study|Randomized but not treated|1
6313483|NCT02697773|10045132|FG001|Overall Study|Randomized but not treated|1
6313484|NCT02697773|10045133|FG002|Overall Study|Randomized but not treated|0
6313485|NCT02697916|10045152|FG000|Overall Study|Death|357
6313486|NCT02697916|10045153|FG001|Overall Study|Death|315
6313487|NCT02697916|10045152|FG000|Overall Study|Withdrawal by Subject|221
6313488|NCT02697916|10045153|FG001|Overall Study|Withdrawal by Subject|393
6313489|NCT02698176|10045166|FG000|Overall Study|Progressive disease|4
6313490|NCT02698176|10045167|FG001|Overall Study|Progressive disease|3
6148932|NCT01092182|9784260|FG001|Overall Study|participant safety|2
6148933|NCT01092182|9784261|FG002|Overall Study|participant safety|0
6148934|NCT01092182|9784259|FG000|Overall Study|Physician Decision|0
6148935|NCT01092182|9784260|FG001|Overall Study|Physician Decision|6
6148936|NCT01092182|9784261|FG002|Overall Study|Physician Decision|0
6148937|NCT01092182|9784259|FG000|Overall Study|Did not meet criteria|0
6148938|NCT01092182|9784260|FG001|Overall Study|Did not meet criteria|0
6148939|NCT01092182|9784261|FG002|Overall Study|Did not meet criteria|25
6148940|NCT01092182|9784259|FG000|Overall Study|Non-compliance|0
6148941|NCT01092182|9784260|FG001|Overall Study|Non-compliance|3
6148942|NCT01092182|9784261|FG002|Overall Study|Non-compliance|0
6148943|NCT01092182|9784259|FG000|Overall Study|Participant refused follow-up|0
6148944|NCT01092182|9784260|FG001|Overall Study|Participant refused follow-up|2
6148945|NCT01092182|9784261|FG002|Overall Study|Participant refused follow-up|0
6191375|NCT01422304|9848166|FG001|Overall Study|Lost to Follow-up|20
6191376|NCT01422304|9848165|FG000|Overall Study|Never Entered Follow-up|2
6191377|NCT01422304|9848166|FG001|Overall Study|Never Entered Follow-up|1
6191378|NCT01422304|9848165|FG000|Overall Study|Protocol Violation|1
6191379|NCT01422304|9848166|FG001|Overall Study|Protocol Violation|0
6313491|NCT02698176|10045168|FG002|Overall Study|Progressive disease|1
6313492|NCT02698176|10045169|FG003|Overall Study|Progressive disease|0
6313493|NCT02698176|10045166|FG000|Overall Study|Adverse Event|2
6313494|NCT02698176|10045167|FG001|Overall Study|Adverse Event|0
6313495|NCT02698176|10045168|FG002|Overall Study|Adverse Event|0
6313496|NCT02698176|10045169|FG003|Overall Study|Adverse Event|0
6313497|NCT02698176|10045166|FG000|Overall Study|Clinical progression|3
6313498|NCT02698176|10045167|FG001|Overall Study|Clinical progression|0
6313499|NCT02698176|10045168|FG002|Overall Study|Clinical progression|0
6313500|NCT02698176|10045169|FG003|Overall Study|Clinical progression|0
6313501|NCT02698189|10045182|FG000|Overall Study|Progressive disease|3
6313502|NCT02698189|10045183|FG001|Overall Study|Progressive disease|5
6313503|NCT02698189|10045182|FG000|Overall Study|Still ongoing in the study|0
6313504|NCT02698189|10045183|FG001|Overall Study|Still ongoing in the study|1
6313505|NCT02698241|10045200|FG000|Overall Study|Inclusion/exclusion criteria not met|4
6313506|NCT02698241|10045200|FG000|Overall Study|Screening not met|7
6313507|NCT02698241|10045200|FG000|Overall Study|Withdrawal by Subject|7
6313508|NCT02698241|10045200|FG000|Overall Study|Physician Decision|2
6313509|NCT02698241|10045200|FG000|Overall Study|Subject underwent system modification|2
6313510|NCT02698241|10045200|FG000|Overall Study|Lost to Follow-up|3
6313511|NCT02698241|10045200|FG000|Overall Study|Subject on inodrip not safe to continue|6
6313512|NCT02698241|10045200|FG000|Overall Study|geographic and licensing issue|1
6313513|NCT02698241|10045200|FG000|Overall Study|Death|2
6313514|NCT02698371|10045204|FG000|All Participants Flow|Lost to Follow-up|3
6313515|NCT02698371|10045204|FG000|FBDC-SE (G1; Control) Arm/Group Flow|Lost to Follow-up|3
6313516|NCT02698371|10045204|FG000|FBDC-SE-EE (G2; Control ) Arm/Group Flow|Lost to Follow-up|3
6313517|NCT02698371|10045204|FG000|FBU-ER (G3) Arm/Group Flow|Lost to Follow-up|3
6313518|NCT02698371|10045204|FG000|FBU-SE (G4) Arm/Group Flow|Lost to Follow-up|3
6313519|NCT02698371|10045204|FG000|ADU-ER (G5) Arm/Group Flow|Lost to Follow-up|3
6313520|NCT02698371|10045204|FG000|ADU-SE (G6) Arm/Group Flow|Lost to Follow-up|2
6313521|NCT02698410|10045220|FG000|Overall Study|Adverse Event|2
6313522|NCT02698410|10045220|FG000|Overall Study|Withdrawal by Subject|1
6313523|NCT02698410|10045220|FG000|Overall Study|Other|1
6313524|NCT02698423|10045226|FG000|Overall Study|Lost to Follow-up|19
6313525|NCT02698423|10045227|FG001|Overall Study|Lost to Follow-up|24
6313526|NCT02698436|10045237|FG000|Overall Study|Adverse Event|1
6313527|NCT02698436|10045238|FG001|Overall Study|Adverse Event|0
6313528|NCT02698436|10045237|FG000|Overall Study|Withdrawal by Subject|3
6313529|NCT02698436|10045238|FG001|Overall Study|Withdrawal by Subject|3
6313530|NCT02698436|10045237|FG000|Overall Study|Lost to Follow-up|2
6313531|NCT02698436|10045238|FG001|Overall Study|Lost to Follow-up|4
6313532|NCT02698436|10045237|FG000|Overall Study|Non-compliance with study regimen|1
6313533|NCT02698436|10045238|FG001|Overall Study|Non-compliance with study regimen|0
6313534|NCT02698475|10045244|FG000|Main Study Period|Lack of Efficacy|1
6313535|NCT02698475|10045244|FG000|Main Study Period|Protocol Violation|2
6313536|NCT02698475|10045244|FG000|Long-Term Extension Period|Lost to Follow-up|1
6313537|NCT02698475|10045244|FG000|Long-Term Extension Period|Trial Site Terminated by Sponsor|1
6313538|NCT02698475|10045244|FG000|Long-Term Extension Period|Withdrawal by Subject|3
6313539|NCT02698475|10045244|FG000|Long-Term Extension Period|Due to Long Term Extension Protocol-Specified Criteria|22
6313540|NCT02698475|10045244|FG000|Long-Term Extension Period|Other|1
6313541|NCT02698787|10045268|FG000|Second Intervention (3 Months)|Withdrawal by Subject|0
6313542|NCT02698787|10045269|FG001|Second Intervention (3 Months)|Withdrawal by Subject|1
6313543|NCT02699099|10045286|FG000|Overall Study|Adverse Event|1
6313544|NCT02699099|10045287|FG001|Overall Study|Adverse Event|0
6313545|NCT02699099|10045288|FG002|Overall Study|Adverse Event|2
6313546|NCT02699099|10045286|FG000|Overall Study|Lost to Follow-up|0
6313547|NCT02699099|10045287|FG001|Overall Study|Lost to Follow-up|1
6313548|NCT02699099|10045288|FG002|Overall Study|Lost to Follow-up|0
6313549|NCT02699099|10045286|FG000|Overall Study|CONSENT WITHDRAWAL NOT DUE TO ADV. EVENT|7
6313550|NCT02699099|10045287|FG001|Overall Study|CONSENT WITHDRAWAL NOT DUE TO ADV. EVENT|2
6313551|NCT02699099|10045288|FG002|Overall Study|CONSENT WITHDRAWAL NOT DUE TO ADV. EVENT|4
6313552|NCT02699125|10045298|FG000|Placebo|Lost to Follow-up|2
6313553|NCT02699125|10045299|FG001|Placebo|Lost to Follow-up|0
6313554|NCT02699125|10045298|FG000|Placebo|Protocol Violation|1
6313555|NCT02699125|10045299|FG001|Placebo|Protocol Violation|0
6313556|NCT02699125|10045298|FG000|Placebo|Withdrawal by Subject|0
6313557|NCT02699125|10045299|FG001|Placebo|Withdrawal by Subject|4
6313558|NCT02699125|10045298|FG000|Second Intervention (6 Weeks).|Withdrawal by Subject|7
6313559|NCT02699125|10045299|FG001|Second Intervention (6 Weeks).|Withdrawal by Subject|2
6313560|NCT02699450|10045312|FG000|Overall Study|Death|2
6313561|NCT02699450|10045313|FG001|Overall Study|Death|1
6313562|NCT02699450|10045314|FG002|Overall Study|Death|2
6313563|NCT02699450|10045312|FG000|Overall Study|Met Criteria for Study Exit|0
6313564|NCT02699450|10045313|FG001|Overall Study|Met Criteria for Study Exit|0
6313565|NCT02699450|10045314|FG002|Overall Study|Met Criteria for Study Exit|1
6313566|NCT02699450|10045312|FG000|Overall Study|Protocol Violation|4
6313567|NCT02699450|10045313|FG001|Overall Study|Protocol Violation|3
6313568|NCT02699450|10045314|FG002|Overall Study|Protocol Violation|5
6313569|NCT02699450|10045312|FG000|Overall Study|Lost to Follow-up|3
6313570|NCT02699450|10045313|FG001|Overall Study|Lost to Follow-up|0
6313571|NCT02699450|10045314|FG002|Overall Study|Lost to Follow-up|5
6313572|NCT02699450|10045312|FG000|Overall Study|Physician Decision|2
6313573|NCT02699450|10045313|FG001|Overall Study|Physician Decision|0
6313574|NCT02699450|10045314|FG002|Overall Study|Physician Decision|0
6313575|NCT02699450|10045312|FG000|Overall Study|Withdrawal by Subject|3
6313576|NCT02699450|10045313|FG001|Overall Study|Withdrawal by Subject|1
6313577|NCT02699450|10045314|FG002|Overall Study|Withdrawal by Subject|2
6313578|NCT02699450|10045312|FG000|Overall Study|Adverse Event|1
6313579|NCT02699450|10045313|FG001|Overall Study|Adverse Event|0
6313580|NCT02699450|10045314|FG002|Overall Study|Adverse Event|0
6313581|NCT02699463|10045325|FG000|Overall Study|Lost to Follow-up|11
6313582|NCT02699463|10045326|FG001|Overall Study|Lost to Follow-up|8
6313583|NCT02699463|10045325|FG000|Overall Study|Withdrawal by Subject|4
6313584|NCT02699463|10045326|FG001|Overall Study|Withdrawal by Subject|1
6313585|NCT02699593|10045332|FG000|Period 1|Unsatisfactory Visual Response|0
6313586|NCT02699593|10045333|FG001|Period 1|Unsatisfactory Visual Response|1
6313587|NCT02699593|10045332|FG000|Period 1|Torn Contact Len|4
6313588|NCT02699593|10045333|FG001|Period 1|Torn Contact Len|3
6313589|NCT02699593|10045332|FG000|Period 1|Protocol Violation|0
6313590|NCT02699593|10045333|FG001|Period 1|Protocol Violation|1
6313591|NCT02699593|10045332|FG000|Period 1|Withdrawal by Subject|0
6313592|NCT02699593|10045333|FG001|Period 1|Withdrawal by Subject|1
6313593|NCT02699593|10045332|FG000|Period 1|Adverse Event|1
6313594|NCT02699593|10045333|FG001|Period 1|Adverse Event|1
6313595|NCT02699593|10045332|FG000|Period 2|Adverse Event|1
6313596|NCT02699593|10045333|FG001|Period 2|Adverse Event|1
6313597|NCT02699593|10045332|FG000|Period 2|Lost Contact Lens|0
6313598|NCT02699593|10045333|FG001|Period 2|Lost Contact Lens|1
6313599|NCT02699593|10045332|FG000|Period 2|Torn Contact Lens|1
6313600|NCT02699593|10045333|FG001|Period 2|Torn Contact Lens|0
6313601|NCT02699684|10045346|FG000|Period 2, Second 30 Days of Wear|Adverse Event|1
6313602|NCT02699684|10045347|FG001|Period 2, Second 30 Days of Wear|Adverse Event|0
6313603|NCT02699749|10045368|FG000|Overall Study|Other|0
6313604|NCT02699749|10045369|FG001|Overall Study|Other|0
6313605|NCT02699749|10045370|FG002|Overall Study|Other|2
6313606|NCT02699749|10045371|FG003|Overall Study|Other|0
6313607|NCT02699749|10045372|FG004|Overall Study|Other|0
6313608|NCT02699749|10045373|FG005|Overall Study|Other|1
6313609|NCT02699749|10045374|FG006|Overall Study|Other|1
6313610|NCT02699749|10045375|FG007|Overall Study|Other|0
6313611|NCT02699749|10045376|FG008|Overall Study|Other|0
6313612|NCT02699749|10045377|FG009|Overall Study|Other|0
6313613|NCT02699749|10045378|FG010|Overall Study|Other|1
6040177|NCT00369629|9637979|FG001|Moved on to 4 More Cycles|Progressive Disease|0
6040178|NCT00369629|9637980|FG002|Moved on to 4 More Cycles|Progressive Disease|1
6040179|NCT00369629|9637981|FG003|Moved on to 4 More Cycles|Progressive Disease|0
6040180|NCT00369629|9637978|FG000|Completed 4 More Cycles|Withdrawal by Subject|2
6040181|NCT00369629|9637979|FG001|Completed 4 More Cycles|Withdrawal by Subject|1
6313614|NCT02699749|10045379|FG011|Overall Study|Other|0
6313615|NCT02699749|10045380|FG012|Overall Study|Other|0
6313616|NCT02699749|10045381|FG013|Overall Study|Other|0
6040182|NCT00369629|9637980|FG002|Completed 4 More Cycles|Withdrawal by Subject|0
6313617|NCT02699749|10045368|FG000|Overall Study|Progressive Disease|3
6313618|NCT02699749|10045369|FG001|Overall Study|Progressive Disease|3
6313619|NCT02699749|10045370|FG002|Overall Study|Progressive Disease|14
6313620|NCT02699749|10045371|FG003|Overall Study|Progressive Disease|3
6313621|NCT02699749|10045372|FG004|Overall Study|Progressive Disease|3
6313622|NCT02699749|10045373|FG005|Overall Study|Progressive Disease|7
6313623|NCT02699749|10045374|FG006|Overall Study|Progressive Disease|5
6313624|NCT02699749|10045375|FG007|Overall Study|Progressive Disease|5
6313625|NCT02699749|10045376|FG008|Overall Study|Progressive Disease|6
6313626|NCT02699749|10045377|FG009|Overall Study|Progressive Disease|6
6313627|NCT02699749|10045378|FG010|Overall Study|Progressive Disease|5
6313628|NCT02699749|10045379|FG011|Overall Study|Progressive Disease|4
6313629|NCT02699749|10045380|FG012|Overall Study|Progressive Disease|3
6313630|NCT02699749|10045381|FG013|Overall Study|Progressive Disease|5
6313631|NCT02699749|10045368|FG000|Overall Study|Death|0
6313632|NCT02699749|10045369|FG001|Overall Study|Death|0
6313633|NCT02699749|10045370|FG002|Overall Study|Death|0
6313634|NCT02699749|10045371|FG003|Overall Study|Death|0
6313635|NCT02699749|10045372|FG004|Overall Study|Death|0
6313636|NCT02699749|10045373|FG005|Overall Study|Death|0
6313637|NCT02699749|10045374|FG006|Overall Study|Death|0
6313638|NCT02699749|10045375|FG007|Overall Study|Death|0
6313639|NCT02699749|10045376|FG008|Overall Study|Death|0
6313640|NCT02699749|10045377|FG009|Overall Study|Death|0
6313641|NCT02699749|10045378|FG010|Overall Study|Death|0
6313642|NCT02699749|10045379|FG011|Overall Study|Death|0
6313643|NCT02699749|10045380|FG012|Overall Study|Death|0
6313644|NCT02699749|10045381|FG013|Overall Study|Death|1
6148946|NCT01092416|9784304|FG000|Enrollment|Atherectomy device not inserted|3
6148947|NCT01092416|9784304|FG000|30-Day Follow-up|Death|2
6148948|NCT01092416|9784304|FG000|30-Day Follow-up|Missed 30-day follow-up|3
6148949|NCT01092416|9784304|FG000|30-Day Follow-up|Data collected after close of 30D window|5
6148950|NCT01092416|9784304|FG000|12-Month Follow-up|Death|16
6148951|NCT01092416|9784304|FG000|12-Month Follow-up|Lost to Follow-up|4
6148952|NCT01092416|9784304|FG000|12-Month Follow-up|Withdrawal by Subject|2
6148953|NCT01092416|9784304|FG000|12-Month Follow-up|Missed 1-year follow-up|1
6148954|NCT01092416|9784304|FG000|12-Month Follow-up|Data collected after close of 1Y window|2
6148955|NCT01092507|9784327|FG000|Overall Study|Withdrawal by Subject|2
6148956|NCT01092507|9784328|FG001|Overall Study|Withdrawal by Subject|0
6148957|NCT01092546|9784334|FG000|Overall Study|Subjects withdrawn prior to dosing|4
6148958|NCT01092637|9784344|FG000|Overall Study|Death|47
6148959|NCT01092637|9784345|FG001|Overall Study|Death|49
6148960|NCT01092663|9784354|FG000|Overall Study|Withdrawal by Subject|3
6148961|NCT01092663|9784355|FG001|Overall Study|Withdrawal by Subject|2
6148962|NCT01092663|9784354|FG000|Overall Study|Glucose >300mg/dL|1
6148963|NCT01092663|9784355|FG001|Overall Study|Glucose >300mg/dL|0
6148964|NCT01092663|9784354|FG000|Overall Study|High fasting triglyceride|2
6148965|NCT01092663|9784355|FG001|Overall Study|High fasting triglyceride|0
6148966|NCT01092663|9784354|FG000|Overall Study|Adverse Event|1
6148967|NCT01092663|9784355|FG001|Overall Study|Adverse Event|1
6148968|NCT01092663|9784354|FG000|Overall Study|Protocol Violation|0
6148969|NCT01092663|9784355|FG001|Overall Study|Protocol Violation|1
6148970|NCT01092702|9784375|FG000|Overall Study|Withdrawal by Subject|7
6148971|NCT01092702|9784375|FG000|Overall Study|Lost to Follow-up|2
6148972|NCT01092728|9784381|FG000|Overall Study|Withdrawal by Subject|2
6148973|NCT01092728|9784382|FG001|Overall Study|Withdrawal by Subject|0
6148974|NCT01092728|9784381|FG000|Overall Study|Adverse Event|0
6148975|NCT01092728|9784382|FG001|Overall Study|Adverse Event|1
6148976|NCT01092728|9784381|FG000|Overall Study|Disease Progression|1
6148977|NCT01092728|9784382|FG001|Overall Study|Disease Progression|13
6148978|NCT01092728|9784381|FG000|Overall Study|Prohibited Concomitant Medications|1
6313645|NCT02699749|10045368|FG000|Overall Study|Lost to Follow-up|0
6313646|NCT02699749|10045369|FG001|Overall Study|Lost to Follow-up|0
6313647|NCT02699749|10045370|FG002|Overall Study|Lost to Follow-up|0
6313648|NCT02699749|10045371|FG003|Overall Study|Lost to Follow-up|0
6313649|NCT02699749|10045372|FG004|Overall Study|Lost to Follow-up|0
6313650|NCT02699749|10045373|FG005|Overall Study|Lost to Follow-up|1
6313651|NCT02699749|10045374|FG006|Overall Study|Lost to Follow-up|0
6313652|NCT02699749|10045375|FG007|Overall Study|Lost to Follow-up|1
6313653|NCT02699749|10045376|FG008|Overall Study|Lost to Follow-up|0
6313654|NCT02699749|10045377|FG009|Overall Study|Lost to Follow-up|0
6313655|NCT02699749|10045378|FG010|Overall Study|Lost to Follow-up|0
6313656|NCT02699749|10045379|FG011|Overall Study|Lost to Follow-up|0
6313657|NCT02699749|10045380|FG012|Overall Study|Lost to Follow-up|0
6313658|NCT02699749|10045381|FG013|Overall Study|Lost to Follow-up|0
6313659|NCT02699866|10045411|FG000|Overall Study|Withdrawal by Subject|3
6313660|NCT02699866|10045411|FG000|Overall Study|Physician Decision|2
6313661|NCT02699866|10045411|FG000|Overall Study|Adverse Event|3
6313662|NCT02699892|10045415|FG000|Overall Study|Other|36
6313663|NCT02699983|10045426|FG000|Overall Study|Withdrawal by Subject|1
6313664|NCT02699983|10045427|FG001|Overall Study|Withdrawal by Subject|0
6313665|NCT02699996|10045439|FG000|Overall Study|Withdrawal by Subject|5
6313666|NCT02699996|10045440|FG001|Overall Study|Withdrawal by Subject|2
6313667|NCT02700412|10045461|FG000|Overall Study|Adverse Event|6
6313668|NCT02700412|10045461|FG000|Overall Study|Death|1
6313669|NCT02700412|10045461|FG000|Overall Study|Lack of Efficacy|19
6313670|NCT02700412|10045461|FG000|Overall Study|Protocol Violation|5
6313671|NCT02700412|10045461|FG000|Overall Study|Withdrawal by Subject|2
6313672|NCT02700815|10045478|FG000|Overall Study|Adverse Event|0
6313673|NCT02700815|10045479|FG001|Overall Study|Adverse Event|6
6313674|NCT02700815|10045480|FG002|Overall Study|Adverse Event|2
6313675|NCT02700815|10045481|FG003|Overall Study|Adverse Event|3
6313676|NCT02700815|10045478|FG000|Overall Study|Lack of Efficacy|0
6313677|NCT02700815|10045479|FG001|Overall Study|Lack of Efficacy|0
6313678|NCT02700815|10045480|FG002|Overall Study|Lack of Efficacy|1
6313679|NCT02700815|10045481|FG003|Overall Study|Lack of Efficacy|2
6313680|NCT02700815|10045478|FG000|Overall Study|Lost to Follow-up|1
6313681|NCT02700815|10045479|FG001|Overall Study|Lost to Follow-up|0
6313682|NCT02700815|10045480|FG002|Overall Study|Lost to Follow-up|0
6313683|NCT02700815|10045481|FG003|Overall Study|Lost to Follow-up|1
6313684|NCT02700815|10045478|FG000|Overall Study|Refusal to continue medication|0
6313685|NCT02700815|10045479|FG001|Overall Study|Refusal to continue medication|1
6313686|NCT02700815|10045480|FG002|Overall Study|Refusal to continue medication|0
6313687|NCT02700815|10045481|FG003|Overall Study|Refusal to continue medication|1
6313688|NCT02700815|10045478|FG000|Overall Study|Withdrawal by Subject|0
6313689|NCT02700815|10045479|FG001|Overall Study|Withdrawal by Subject|0
6313690|NCT02700815|10045480|FG002|Overall Study|Withdrawal by Subject|1
6313691|NCT02700815|10045481|FG003|Overall Study|Withdrawal by Subject|0
6313692|NCT02700919|10045494|FG000|Overall Study|Physician Decision|1
6313693|NCT02700919|10045495|FG001|Overall Study|Physician Decision|0
6313694|NCT02700919|10045496|FG002|Overall Study|Physician Decision|0
6313695|NCT02700919|10045494|FG000|Overall Study|Protocol Violation|1
6313696|NCT02700919|10045495|FG001|Overall Study|Protocol Violation|0
6313697|NCT02700919|10045496|FG002|Overall Study|Protocol Violation|0
6313698|NCT02700919|10045494|FG000|Overall Study|Adverse Event|1
6313699|NCT02700919|10045495|FG001|Overall Study|Adverse Event|3
6313700|NCT02700919|10045496|FG002|Overall Study|Adverse Event|1
6313701|NCT02700919|10045494|FG000|Overall Study|Withdrawal by Subject|5
6148979|NCT01092728|9784382|FG001|Overall Study|Prohibited Concomitant Medications|0
6148980|NCT01092780|9784392|FG000|Washout Period 1|Adverse Event|0
6148981|NCT01092780|9784393|FG001|Washout Period 1|Adverse Event|1
6148982|NCT01092780|9784394|FG002|Washout Period 1|Adverse Event|0
6148983|NCT01092780|9784395|FG003|Washout Period 1|Adverse Event|0
6148984|NCT01092780|9784392|FG000|Washout Period 1|Noncompliance with nCPAP|1
6148985|NCT01092780|9784393|FG001|Washout Period 1|Noncompliance with nCPAP|0
6148986|NCT01092780|9784394|FG002|Washout Period 1|Noncompliance with nCPAP|0
6148987|NCT01092780|9784395|FG003|Washout Period 1|Noncompliance with nCPAP|0
6148988|NCT01092780|9784392|FG000|Washout Period 2|Adverse Event|0
6148989|NCT01092780|9784393|FG001|Washout Period 2|Adverse Event|1
6148990|NCT01092780|9784394|FG002|Washout Period 2|Adverse Event|1
6148991|NCT01092780|9784395|FG003|Washout Period 2|Adverse Event|0
6148992|NCT01092832|9784407|FG000|Overall Study|Other|1
6148993|NCT01092832|9784408|FG001|Overall Study|Other|0
6148994|NCT01093222|9784459|FG000|Overall Study|Ineligible|6
6148995|NCT01093222|9784459|FG000|Overall Study|Adverse Event|7
6148996|NCT01093222|9784459|FG000|Overall Study|Progression/relapse|24
6148997|NCT01093222|9784459|FG000|Overall Study|Death|2
6148998|NCT01093222|9784459|FG000|Overall Study|Not protocol specified|1
6148999|NCT01093534|9784498|FG000|Overall Study|Adverse Event|2
6149000|NCT01093534|9784499|FG001|Overall Study|Adverse Event|5
6149001|NCT01093534|9784500|FG002|Overall Study|Adverse Event|2
6149002|NCT01093534|9784498|FG000|Overall Study|Lack of Efficacy|2
6149003|NCT01093534|9784499|FG001|Overall Study|Lack of Efficacy|1
6149004|NCT01093534|9784500|FG002|Overall Study|Lack of Efficacy|1
6149005|NCT01093534|9784498|FG000|Overall Study|Withdrawal by Subject|5
6149006|NCT01093534|9784499|FG001|Overall Study|Withdrawal by Subject|7
6149007|NCT01093534|9784500|FG002|Overall Study|Withdrawal by Subject|2
6149008|NCT01093534|9784498|FG000|Overall Study|Other|1
6149009|NCT01093534|9784499|FG001|Overall Study|Other|3
6149010|NCT01093534|9784500|FG002|Overall Study|Other|4
6149011|NCT01093573|9784512|FG000|Overall Study|Physician Decision|0
6149012|NCT01093573|9784513|FG001|Overall Study|Physician Decision|0
6149013|NCT01093573|9784514|FG002|Overall Study|Physician Decision|1
6149014|NCT01093573|9784512|FG000|Overall Study|Insurance Denied|0
6149015|NCT01093573|9784513|FG001|Overall Study|Insurance Denied|0
6149016|NCT01093573|9784514|FG002|Overall Study|Insurance Denied|1
6149017|NCT01093586|9784525|FG000|Overall Study|Failed to engraft|3
6149018|NCT01093599|9784531|FG000|Overall Study|Lost to Follow-up|32
6313702|NCT02700919|10045495|FG001|Overall Study|Withdrawal by Subject|8
6313703|NCT02700919|10045496|FG002|Overall Study|Withdrawal by Subject|2
6313704|NCT02700919|10045494|FG000|Overall Study|Lost to Follow-up|2
6313705|NCT02700919|10045495|FG001|Overall Study|Lost to Follow-up|0
6313706|NCT02700919|10045496|FG002|Overall Study|Lost to Follow-up|0
6313707|NCT02700919|10045494|FG000|Overall Study|Other|2
6313708|NCT02700919|10045495|FG001|Overall Study|Other|1
6313709|NCT02700919|10045496|FG002|Overall Study|Other|1
6313710|NCT02700984|10045506|FG000|Overall Study|Death|2
6313711|NCT02700984|10045507|FG001|Overall Study|Death|1
6313712|NCT02700984|10045506|FG000|Overall Study|Lost to Follow-up|2
6149019|NCT01093599|9784532|FG001|Overall Study|Lost to Follow-up|46
6313713|NCT02700984|10045507|FG001|Overall Study|Lost to Follow-up|1
6313714|NCT02700984|10045506|FG000|Overall Study|Physician Decision|0
6313715|NCT02700984|10045507|FG001|Overall Study|Physician Decision|1
6313716|NCT02700984|10045506|FG000|Overall Study|Withdrawal by Subject|8
6313717|NCT02700984|10045507|FG001|Overall Study|Withdrawal by Subject|9
6313718|NCT02700984|10045506|FG000|Overall Study|Reason not specified|3
6313719|NCT02700984|10045507|FG001|Overall Study|Reason not specified|2
6313720|NCT02700997|10045523|FG000|Overall Study|Did not undergo CT imaging|1
6313721|NCT02700997|10045523|FG000|Overall Study|No CT measurement - pelvic calcification|1
6313722|NCT02701296|10045607|FG000|Overall Study|Incomplete Data|0
6313723|NCT02701296|10045608|FG001|Overall Study|Incomplete Data|2
6313724|NCT02701361|10045617|FG000|Overall Study|Lost to Follow-up|5
6313725|NCT02701361|10045618|FG001|Overall Study|Lost to Follow-up|2
6313726|NCT02701361|10045619|FG002|Overall Study|Lost to Follow-up|1
6313727|NCT02701361|10045617|FG000|Overall Study|Withdrawal by Subject|4
6313728|NCT02701361|10045618|FG001|Overall Study|Withdrawal by Subject|0
6313729|NCT02701361|10045619|FG002|Overall Study|Withdrawal by Subject|0
6313730|NCT02701361|10045617|FG000|Overall Study|timed out in rehab center|0
6313731|NCT02701361|10045618|FG001|Overall Study|timed out in rehab center|1
6313732|NCT02701361|10045619|FG002|Overall Study|timed out in rehab center|0
6313733|NCT02701361|10045617|FG000|Overall Study|incarceration|0
6313734|NCT02701361|10045618|FG001|Overall Study|incarceration|0
6313735|NCT02701361|10045619|FG002|Overall Study|incarceration|1
6313736|NCT02701413|10045646|FG000|Overall Study|Withdrawal by Subject|7
6313737|NCT02701413|10045647|FG001|Overall Study|Withdrawal by Subject|11
6313738|NCT02701634|10045666|FG000|Overall Study|Adverse Event|2
6313739|NCT02701634|10045667|FG001|Overall Study|Adverse Event|3
6313740|NCT02701634|10045666|FG000|Overall Study|Death|1
6313741|NCT02701634|10045667|FG001|Overall Study|Death|0
6313742|NCT02701634|10045666|FG000|Overall Study|Investigator's Discretion|7
6313743|NCT02701634|10045667|FG001|Overall Study|Investigator's Discretion|4
6313744|NCT02701634|10045666|FG000|Overall Study|Study terminated by Sponsor|15
6313745|NCT02701634|10045667|FG001|Overall Study|Study terminated by Sponsor|17
6313746|NCT02701634|10045666|FG000|Overall Study|Withdrew Consent|6
6313747|NCT02701634|10045667|FG001|Overall Study|Withdrew Consent|7
6313748|NCT02701634|10045666|FG000|Overall Study|Randomized but not treated|1
6313749|NCT02701634|10045667|FG001|Overall Study|Randomized but not treated|0
6313750|NCT02701764|10045695|FG000|Overall Study|Lost to Follow-up|0
6313751|NCT02701764|10045696|FG001|Overall Study|Lost to Follow-up|1
6313752|NCT02701985|10045718|FG000|Overall Study|Withdrawal by Subject|1
6313753|NCT02701985|10045719|FG001|Overall Study|Withdrawal by Subject|1
6313754|NCT02701985|10045718|FG000|Overall Study|Lost to Follow-up|1
6313755|NCT02701985|10045719|FG001|Overall Study|Lost to Follow-up|0
6313756|NCT02701985|10045718|FG000|Overall Study|Death|1
6313757|NCT02701985|10045719|FG001|Overall Study|Death|0
6313758|NCT02701985|10045718|FG000|Overall Study|Adverse Event|0
6313759|NCT02701985|10045719|FG001|Overall Study|Adverse Event|5
6313760|NCT02702011|10045730|FG000|Overall Study|Withdrawal by Subject|0
6313761|NCT02702011|10045731|FG001|Overall Study|Withdrawal by Subject|1
6313762|NCT02702011|10045732|FG002|Overall Study|Withdrawal by Subject|0
6313763|NCT02702011|10045733|FG003|Overall Study|Withdrawal by Subject|0
6313764|NCT02702193|10045745|FG000|Baseline Assessment/Randomization|Withdrawal by Subject|1
6313765|NCT02702193|10045746|FG001|Baseline Assessment/Randomization|Withdrawal by Subject|0
6313766|NCT02702193|10045745|FG000|4 Month Follow up|Withdrawal by Subject|1
6313767|NCT02702193|10045746|FG001|4 Month Follow up|Withdrawal by Subject|0
6313768|NCT02702193|10045745|FG000|4 Month Follow up|Lost to Follow-up|17
6313769|NCT02702193|10045746|FG001|4 Month Follow up|Lost to Follow-up|18
6313770|NCT02702193|10045745|FG000|8 Month Follow up|Withdrawal by Subject|1
6313771|NCT02702193|10045746|FG001|8 Month Follow up|Withdrawal by Subject|0
6040183|NCT00369629|9637981|FG003|Completed 4 More Cycles|Withdrawal by Subject|0
6040184|NCT00369629|9637978|FG000|Completed 4 More Cycles|Progressive disease|2
6040185|NCT00369629|9637979|FG001|Completed 4 More Cycles|Progressive disease|1
6040186|NCT00369629|9637980|FG002|Completed 4 More Cycles|Progressive disease|2
6040187|NCT00369629|9637981|FG003|Completed 4 More Cycles|Progressive disease|0
6040188|NCT00369629|9637978|FG000|Follow up for 1 Year|Death|2
6040189|NCT00369629|9637979|FG001|Follow up for 1 Year|Death|1
6040190|NCT00369629|9637980|FG002|Follow up for 1 Year|Death|1
6040191|NCT00369629|9637981|FG003|Follow up for 1 Year|Death|0
6040192|NCT00369629|9637978|FG000|Follow up for 1 Year|Lost to Follow-up|0
6313772|NCT02702193|10045745|FG000|8 Month Follow up|Lost to Follow-up|14
6313773|NCT02702193|10045746|FG001|8 Month Follow up|Lost to Follow-up|18
6313774|NCT02702193|10045745|FG000|12 Month Follow up|Withdrawal by Subject|1
6313775|NCT02702193|10045746|FG001|12 Month Follow up|Withdrawal by Subject|0
6313776|NCT02702193|10045745|FG000|12 Month Follow up|Lost to Follow-up|16
6313777|NCT02702193|10045746|FG001|12 Month Follow up|Lost to Follow-up|18
6313778|NCT02702388|10045754|FG000|Overall Study|Disease Progression|18
6313779|NCT02702388|10045755|FG001|Overall Study|Disease Progression|25
6313780|NCT02702388|10045754|FG000|Overall Study|Withdrawal by Subject|9
6313781|NCT02702388|10045755|FG001|Overall Study|Withdrawal by Subject|7
6313782|NCT02702388|10045754|FG000|Overall Study|Adverse Event|11
6313783|NCT02702388|10045755|FG001|Overall Study|Adverse Event|15
6313784|NCT02702388|10045754|FG000|Overall Study|Other|2
6313785|NCT02702388|10045755|FG001|Overall Study|Other|4
6313786|NCT02702401|10045772|FG000|Overall Study|Death|180
6313787|NCT02702401|10045773|FG001|Overall Study|Death|101
6313788|NCT02702401|10045772|FG000|Overall Study|Withdrawal by Subject|4
6313789|NCT02702401|10045773|FG001|Overall Study|Withdrawal by Subject|0
6313790|NCT02702401|10045772|FG000|Overall Study|Ongoing in study|94
6313791|NCT02702401|10045773|FG001|Overall Study|Ongoing in study|34
6313792|NCT02702518|10045781|FG000|Overall Study|Lost to Follow-up|3
6313793|NCT02702518|10045782|FG001|Overall Study|Lost to Follow-up|4
6313794|NCT02702609|10045790|FG000|Overall Study|Lost to Follow-up|8
6313795|NCT02702609|10045791|FG001|Overall Study|Lost to Follow-up|4
6313796|NCT02702609|10045790|FG000|Overall Study|Physician Decision|1
6313797|NCT02702609|10045791|FG001|Overall Study|Physician Decision|0
6313798|NCT02703259|10045817|FG000|24 Hours Postoperative Assessment|Lost to Follow-up|1
6313799|NCT02703259|10045818|FG001|24 Hours Postoperative Assessment|Lost to Follow-up|4
6313800|NCT02703259|10045817|FG000|24 Hours Postoperative Assessment|excluded from analysis per protocol|1
6313801|NCT02703259|10045818|FG001|24 Hours Postoperative Assessment|excluded from analysis per protocol|2
6313802|NCT02703259|10045817|FG000|2 Weeks Postoperative Assessment|Lost to Follow-up|10
6313803|NCT02703259|10045818|FG001|2 Weeks Postoperative Assessment|Lost to Follow-up|10
6313804|NCT02703311|10045824|FG000|Overall Study|Death|5
6313805|NCT02703311|10045824|FG000|Overall Study|Withdrawal by Subject|3
6313806|NCT02703324|10045828|FG000|Period Two|Withdrawal by Subject|0
6313807|NCT02703324|10045829|FG001|Period Two|Withdrawal by Subject|0
6313808|NCT02703324|10045830|FG002|Period Two|Withdrawal by Subject|1
6313809|NCT02703324|10045831|FG003|Period Two|Withdrawal by Subject|0
6313810|NCT02703324|10045832|FG004|Period Two|Withdrawal by Subject|0
6040193|NCT00369629|9637979|FG001|Follow up for 1 Year|Lost to Follow-up|1
6040194|NCT00369629|9637980|FG002|Follow up for 1 Year|Lost to Follow-up|0
6313811|NCT02703324|10045833|FG005|Period Two|Withdrawal by Subject|0
6313812|NCT02703337|10045842|FG000|Period One (Part A)|Withdrawal by Subject|0
6313813|NCT02703337|10045843|FG001|Period One (Part A)|Withdrawal by Subject|0
6313814|NCT02703337|10045844|FG002|Period One (Part A)|Withdrawal by Subject|0
6313815|NCT02703337|10045845|FG003|Period One (Part A)|Withdrawal by Subject|0
6313816|NCT02703337|10045846|FG004|Period One (Part A)|Withdrawal by Subject|1
6313817|NCT02703337|10045847|FG005|Period One (Part A)|Withdrawal by Subject|0
6313818|NCT02703337|10045848|FG006|Period One (Part A)|Withdrawal by Subject|0
6313819|NCT02703337|10045849|FG007|Period One (Part A)|Withdrawal by Subject|0
6313820|NCT02703454|10045894|FG000|Overall Study|Not treated|1
6313821|NCT02703454|10045895|FG001|Overall Study|Not treated|3
6313822|NCT02703454|10045894|FG000|Overall Study|Withdrawal by Subject|4
6313823|NCT02703454|10045895|FG001|Overall Study|Withdrawal by Subject|3
6313824|NCT02703454|10045894|FG000|Overall Study|Lost to Follow-up|1
6313825|NCT02703454|10045895|FG001|Overall Study|Lost to Follow-up|2
6313826|NCT02703454|10045894|FG000|Overall Study|Study discontinuation|5
6313827|NCT02703454|10045895|FG001|Overall Study|Study discontinuation|8
6313828|NCT02703532|10045922|FG000|Overall Study|Withdrawal by Subject|0
6313829|NCT02703532|10045923|FG001|Overall Study|Withdrawal by Subject|1
6313830|NCT02703532|10045924|FG002|Overall Study|Withdrawal by Subject|0
6313831|NCT02703532|10045925|FG003|Overall Study|Withdrawal by Subject|1
6313832|NCT02703532|10045922|FG000|Overall Study|Lost to Follow-up|2
6313833|NCT02703532|10045923|FG001|Overall Study|Lost to Follow-up|0
6313834|NCT02703532|10045924|FG002|Overall Study|Lost to Follow-up|2
6313835|NCT02703532|10045925|FG003|Overall Study|Lost to Follow-up|0
6313836|NCT02703636|10045935|FG000|Overall Study|Adverse Event|14
6313837|NCT02703636|10045935|FG000|Overall Study|Study stopped by sponsor|1
6313838|NCT02703636|10045935|FG000|Overall Study|Withdrawal by Subject|1
6313839|NCT02704091|10045982|FG000|Overall Study|Adverse Event|4
6313840|NCT02704091|10045983|FG001|Overall Study|Adverse Event|3
6313841|NCT02704091|10045982|FG000|Overall Study|Protocol Violation|5
6313842|NCT02704091|10045983|FG001|Overall Study|Protocol Violation|3
6313843|NCT02704091|10045982|FG000|Overall Study|Consent withdrawn|4
6313844|NCT02704091|10045983|FG001|Overall Study|Consent withdrawn|4
6313845|NCT02704091|10045982|FG000|Overall Study|Lost to Follow-up|13
6313846|NCT02704091|10045983|FG001|Overall Study|Lost to Follow-up|5
6313847|NCT02704091|10045982|FG000|Overall Study|Other|2
6313848|NCT02704091|10045983|FG001|Overall Study|Other|8
6313849|NCT02704143|10045997|FG000|Overall Study|disease progression|10
6313850|NCT02704689|10046001|FG000|Overall Study|Physician Decision|1
6313851|NCT02704689|10046001|FG000|Overall Study|Study device not implanted|2
6313852|NCT02705105|10046042|FG000|Treatment|Objective Disease Progression|1
6313853|NCT02705105|10046043|FG001|Treatment|Objective Disease Progression|50
6313854|NCT02705105|10046042|FG000|Treatment|Withdrawal by Subject|3
6313855|NCT02705105|10046043|FG001|Treatment|Withdrawal by Subject|5
6313856|NCT02705105|10046042|FG000|Treatment|Adverse Event|0
6313857|NCT02705105|10046043|FG001|Treatment|Adverse Event|17
6313858|NCT02705105|10046042|FG000|Treatment|Clinical Disease Progression|0
6313859|NCT02705105|10046043|FG001|Treatment|Clinical Disease Progression|32
6313860|NCT02705105|10046042|FG000|Treatment|Physician Decision|0
6313861|NCT02705105|10046043|FG001|Treatment|Physician Decision|3
6313862|NCT02705105|10046042|FG000|Treatment|Ongoing w/ Treatment at time of data cut|0
6313863|NCT02705105|10046043|FG001|Treatment|Ongoing w/ Treatment at time of data cut|2
6313864|NCT02705105|10046042|FG000|Follow-Up|Death|3
6313865|NCT02705105|10046043|FG001|Follow-Up|Death|68
6313866|NCT02705105|10046042|FG000|Follow-Up|Withdrawal by Subject|1
6313867|NCT02705105|10046043|FG001|Follow-Up|Withdrawal by Subject|14
6313868|NCT02705105|10046042|FG000|Follow-Up|Study Terminated|0
6313869|NCT02705105|10046043|FG001|Follow-Up|Study Terminated|26
6313870|NCT02705105|10046042|FG000|Follow-Up|Discontinued per Amendment 3|0
6313871|NCT02705105|10046043|FG001|Follow-Up|Discontinued per Amendment 3|2
6313872|NCT02705586|10046079|FG000|Overall Study|Health Issues|2
6313873|NCT02705586|10046079|FG000|Overall Study|Transportation Difficulties|5
6313874|NCT02705586|10046079|FG000|Overall Study|Vacation/Planned Absence|1
6313875|NCT02705625|10046086|FG000|Overall Study|Protocol Violation|1
6313876|NCT02705625|10046087|FG001|Overall Study|Protocol Violation|0
6313877|NCT02705625|10046088|FG002|Overall Study|Protocol Violation|0
6313878|NCT02705625|10046086|FG000|Overall Study|Adverse Event|6
6313879|NCT02705625|10046087|FG001|Overall Study|Adverse Event|5
6313880|NCT02705625|10046088|FG002|Overall Study|Adverse Event|2
6313881|NCT02705625|10046086|FG000|Overall Study|Death|0
6313882|NCT02705625|10046087|FG001|Overall Study|Death|0
6313883|NCT02705625|10046088|FG002|Overall Study|Death|1
6313884|NCT02705625|10046086|FG000|Overall Study|Withdrawal by Subject|1
6313885|NCT02705625|10046087|FG001|Overall Study|Withdrawal by Subject|4
6313886|NCT02705625|10046088|FG002|Overall Study|Withdrawal by Subject|5
6313887|NCT02705625|10046086|FG000|Overall Study|Lost to Follow-up|0
6313888|NCT02705625|10046087|FG001|Overall Study|Lost to Follow-up|0
6313889|NCT02705625|10046088|FG002|Overall Study|Lost to Follow-up|1
6313890|NCT02705625|10046086|FG000|Overall Study|Non-compliance|0
6313891|NCT02705625|10046087|FG001|Overall Study|Non-compliance|1
6313892|NCT02705625|10046088|FG002|Overall Study|Non-compliance|1
6313893|NCT02705625|10046086|FG000|Overall Study|Overdosing|0
6313894|NCT02705625|10046087|FG001|Overall Study|Overdosing|0
6313895|NCT02705625|10046088|FG002|Overall Study|Overdosing|1
6313896|NCT02705716|10046098|FG000|Overall Study|Adverse Event|0
6313897|NCT02705716|10046099|FG001|Overall Study|Adverse Event|1
6313898|NCT02705716|10046098|FG000|Overall Study|Protocol Violation|3
6313899|NCT02705716|10046099|FG001|Overall Study|Protocol Violation|0
6313900|NCT02705716|10046098|FG000|Overall Study|Withdrawal of Consent|1
6313901|NCT02705716|10046099|FG001|Overall Study|Withdrawal of Consent|1
6313902|NCT02706327|10046132|FG000|Overall Study|Lost to Follow-up|1
6313903|NCT02706327|10046133|FG001|Overall Study|Lost to Follow-up|1
6313904|NCT02706327|10046134|FG002|Overall Study|Lost to Follow-up|2
6313905|NCT02706483|10046142|FG000|Overall Study|Adverse Event|97
6313906|NCT02706483|10046142|FG000|Overall Study|Death|1
6313907|NCT02706483|10046142|FG000|Overall Study|Lack of Efficacy|39
6313908|NCT02706483|10046142|FG000|Overall Study|Lost to Follow-up|101
6313909|NCT02706483|10046142|FG000|Overall Study|Non-compliance with study drug|15
6313910|NCT02706483|10046142|FG000|Overall Study|Physician Decision|6
6313911|NCT02706483|10046142|FG000|Overall Study|Pregnancy|6
6313912|NCT02706483|10046142|FG000|Overall Study|Protocol Violation|18
6313913|NCT02706483|10046142|FG000|Overall Study|Withdrawal by Subject|136
6313914|NCT02706483|10046142|FG000|Overall Study|Non-compliance with visits|6
6313915|NCT02706483|10046142|FG000|Overall Study|Site closure|4
6313916|NCT02706483|10046142|FG000|Overall Study|Subject moved|1
6313917|NCT02706717|10046148|FG000|Overall Study|Withdrawal by Subject|1
6313918|NCT02706717|10046149|FG001|Overall Study|Withdrawal by Subject|8
6313919|NCT02706717|10046148|FG000|Overall Study|Lost to Follow-up|0
6313920|NCT02706717|10046149|FG001|Overall Study|Lost to Follow-up|1
6313921|NCT02706717|10046148|FG000|Overall Study|Physician Decision|0
6313922|NCT02706717|10046149|FG001|Overall Study|Physician Decision|1
6313923|NCT02706717|10046148|FG000|Overall Study|Death|0
6313924|NCT02706717|10046149|FG001|Overall Study|Death|1
6313925|NCT02706834|10046166|FG000|Overall Study|Pretreatment Event/Adverse Event|0
6313926|NCT02706834|10046167|FG001|Overall Study|Pretreatment Event/Adverse Event|1
6313927|NCT02706834|10046168|FG002|Overall Study|Pretreatment Event/Adverse Event|0
6313928|NCT02706834|10046169|FG003|Overall Study|Pretreatment Event/Adverse Event|0
6149020|NCT01093625|9784540|FG000|Baseline and Dispensed|Withdrawal by Subject|2
6149021|NCT01093625|9784541|FG001|Baseline and Dispensed|Withdrawal by Subject|0
6149022|NCT01093625|9784540|FG000|2-Week Visit|Withdrawal by Subject|1
6149023|NCT01093625|9784541|FG001|2-Week Visit|Withdrawal by Subject|0
6149024|NCT01093625|9784540|FG000|1-Month Visit|Lost to Follow-up|2
6149025|NCT01093625|9784541|FG001|1-Month Visit|Lost to Follow-up|0
6149026|NCT01093625|9784540|FG000|3-Month Visit|Lost to Follow-up|2
6149027|NCT01093625|9784541|FG001|3-Month Visit|Lost to Follow-up|0
6149028|NCT01093625|9784540|FG000|6-Month Visit|Withdrawal by Subject|6
6149029|NCT01093625|9784541|FG001|6-Month Visit|Withdrawal by Subject|7
6149030|NCT01093625|9784540|FG000|6-Month Visit|Lost to Follow-up|2
6149031|NCT01093625|9784541|FG001|6-Month Visit|Lost to Follow-up|2
6149032|NCT01093625|9784540|FG000|1-Year Visit|Lost to Follow-up|5
6149033|NCT01093625|9784541|FG001|1-Year Visit|Lost to Follow-up|3
6149034|NCT01093755|9784567|FG000|Overall Study|Withdrawal by Subject|3
6149035|NCT01093755|9784568|FG001|Overall Study|Withdrawal by Subject|4
6149036|NCT01093885|9784587|FG000|Overall Study|Adverse Event|4
6149037|NCT01093885|9784587|FG000|Overall Study|Lost to Follow-up|1
6149038|NCT01094119|9784607|FG000|Overall Study|Lack of Efficacy|2
6149039|NCT01094119|9784608|FG001|Overall Study|Lack of Efficacy|4
6149040|NCT01094171|9784614|FG000|Overall Study|Lost to Follow-up|2
6149041|NCT01094171|9784614|FG000|Overall Study|Informed consent withdrawal|4
6149042|NCT01094171|9784614|FG000|Overall Study|Migration from the study area|3
6149043|NCT01094171|9784614|FG000|Overall Study|Other|1
6149044|NCT01094184|9784620|FG000|Overall Study|Death|35
6149045|NCT01094184|9784621|FG001|Overall Study|Death|11
6149046|NCT01094288|9784635|FG000|Overall Study|Adverse Event|0
6149047|NCT01094288|9784636|FG001|Overall Study|Adverse Event|3
6149048|NCT01094288|9784637|FG002|Overall Study|Adverse Event|1
6149049|NCT01094288|9784638|FG003|Overall Study|Adverse Event|1
6149050|NCT01094288|9784639|FG004|Overall Study|Adverse Event|0
6149051|NCT01094288|9784640|FG005|Overall Study|Adverse Event|0
6149052|NCT01094288|9784641|FG006|Overall Study|Adverse Event|0
6149053|NCT01094288|9784642|FG007|Overall Study|Adverse Event|0
6149054|NCT01094288|9784635|FG000|Overall Study|Withdrawal by Subject|0
6149055|NCT01094288|9784636|FG001|Overall Study|Withdrawal by Subject|1
6149056|NCT01094288|9784637|FG002|Overall Study|Withdrawal by Subject|2
6149057|NCT01094288|9784638|FG003|Overall Study|Withdrawal by Subject|0
6149058|NCT01094288|9784639|FG004|Overall Study|Withdrawal by Subject|0
6149059|NCT01094288|9784640|FG005|Overall Study|Withdrawal by Subject|0
6149060|NCT01094288|9784641|FG006|Overall Study|Withdrawal by Subject|0
6149061|NCT01094288|9784642|FG007|Overall Study|Withdrawal by Subject|2
6149062|NCT01094288|9784635|FG000|Overall Study|Initiation of Alternative Therapy|0
6149063|NCT01094288|9784636|FG001|Overall Study|Initiation of Alternative Therapy|0
6149064|NCT01094288|9784637|FG002|Overall Study|Initiation of Alternative Therapy|1
6149065|NCT01094288|9784638|FG003|Overall Study|Initiation of Alternative Therapy|0
6149066|NCT01094288|9784639|FG004|Overall Study|Initiation of Alternative Therapy|0
6149067|NCT01094288|9784640|FG005|Overall Study|Initiation of Alternative Therapy|0
6149068|NCT01094288|9784641|FG006|Overall Study|Initiation of Alternative Therapy|0
6149069|NCT01094288|9784642|FG007|Overall Study|Initiation of Alternative Therapy|0
6149070|NCT01094288|9784635|FG000|Overall Study|Reason not Specified|2
6149071|NCT01094288|9784636|FG001|Overall Study|Reason not Specified|3
6149072|NCT01094288|9784637|FG002|Overall Study|Reason not Specified|0
6149073|NCT01094288|9784638|FG003|Overall Study|Reason not Specified|1
6149074|NCT01094288|9784639|FG004|Overall Study|Reason not Specified|0
6149075|NCT01094288|9784640|FG005|Overall Study|Reason not Specified|0
6149076|NCT01094288|9784641|FG006|Overall Study|Reason not Specified|0
6149077|NCT01094288|9784642|FG007|Overall Study|Reason not Specified|0
6313929|NCT02706834|10046170|FG004|Overall Study|Pretreatment Event/Adverse Event|0
6313930|NCT02706834|10046171|FG005|Overall Study|Pretreatment Event/Adverse Event|0
6313931|NCT02706834|10046172|FG006|Overall Study|Pretreatment Event/Adverse Event|0
6313932|NCT02706834|10046173|FG007|Overall Study|Pretreatment Event/Adverse Event|0
6313933|NCT02706834|10046174|FG008|Overall Study|Pretreatment Event/Adverse Event|0
6313934|NCT02706834|10046175|FG009|Overall Study|Pretreatment Event/Adverse Event|0
6313935|NCT02706834|10046176|FG010|Overall Study|Pretreatment Event/Adverse Event|1
6313936|NCT02706834|10046166|FG000|Overall Study|Lost to Follow-up|0
6313937|NCT02706834|10046167|FG001|Overall Study|Lost to Follow-up|0
6313938|NCT02706834|10046168|FG002|Overall Study|Lost to Follow-up|1
6313939|NCT02706834|10046169|FG003|Overall Study|Lost to Follow-up|0
6313940|NCT02706834|10046170|FG004|Overall Study|Lost to Follow-up|0
6313941|NCT02706834|10046171|FG005|Overall Study|Lost to Follow-up|0
6313942|NCT02706834|10046172|FG006|Overall Study|Lost to Follow-up|0
6313943|NCT02706834|10046173|FG007|Overall Study|Lost to Follow-up|0
6313944|NCT02706834|10046174|FG008|Overall Study|Lost to Follow-up|0
6149078|NCT01094288|9784635|FG000|Overall Study|Ongoing Participants|0
6149079|NCT01094288|9784636|FG001|Overall Study|Ongoing Participants|3
6149080|NCT01094288|9784637|FG002|Overall Study|Ongoing Participants|0
6149081|NCT01094288|9784638|FG003|Overall Study|Ongoing Participants|0
6149082|NCT01094288|9784639|FG004|Overall Study|Ongoing Participants|0
6149083|NCT01094288|9784640|FG005|Overall Study|Ongoing Participants|0
6149084|NCT01094288|9784641|FG006|Overall Study|Ongoing Participants|0
6149085|NCT01094288|9784642|FG007|Overall Study|Ongoing Participants|0
6149086|NCT01094301|9784664|FG000|Trial Stage|Withdrawal by Subject|1
6149087|NCT01094301|9784664|FG000|Implant Stage|Adverse Event|1
6149088|NCT01094301|9784664|FG000|Implant Stage|Protocol Violation|1
6149089|NCT01094301|9784664|FG000|Implant Stage|Withdrawal by Subject|2
6149090|NCT01094301|9784664|FG000|Implant Stage|No return of pain|4
6149091|NCT01094730|9784741|FG000|Period 1 (14 Days)|Lost to Follow-up|0
6149092|NCT01094730|9784742|FG001|Period 1 (14 Days)|Lost to Follow-up|1
6149093|NCT01094730|9784741|FG000|Period 1 (14 Days)|Withdrawal by Subject|0
6149094|NCT01094730|9784742|FG001|Period 1 (14 Days)|Withdrawal by Subject|1
6149095|NCT01094730|9784741|FG000|Period 1 (14 Days)|No time for the follow-up visit|1
6149096|NCT01094730|9784742|FG001|Period 1 (14 Days)|No time for the follow-up visit|0
6149097|NCT01094730|9784741|FG000|Period 1 (14 Days)|Unsatisfactory visual response|1
6149098|NCT01094730|9784742|FG001|Period 1 (14 Days)|Unsatisfactory visual response|0
6149099|NCT01094730|9784741|FG000|Period 2 (14 Days)|Protocol Violation|2
6149100|NCT01094730|9784742|FG001|Period 2 (14 Days)|Protocol Violation|0
6149101|NCT01094730|9784741|FG000|Period 2 (14 Days)|No time for the follow-up visit|1
6149102|NCT01094730|9784742|FG001|Period 2 (14 Days)|No time for the follow-up visit|0
6149103|NCT01094730|9784741|FG000|Period 2 (14 Days)|Adverse Event|0
6149104|NCT01094730|9784742|FG001|Period 2 (14 Days)|Adverse Event|1
6149105|NCT01094730|9784741|FG000|Period 2 (14 Days)|Unsatisfactory lens fitting|0
6149106|NCT01094730|9784742|FG001|Period 2 (14 Days)|Unsatisfactory lens fitting|1
6149107|NCT01094743|9784749|FG000|Period 1|Unsatisfactory comfort at lens fitting|2
6149108|NCT01094808|9784757|FG000|Overall Study|Withdrawal by Subject|1
6149109|NCT01094808|9784758|FG001|Overall Study|Withdrawal by Subject|1
6149110|NCT01094808|9784759|FG002|Overall Study|Withdrawal by Subject|0
6149111|NCT01094886|9784767|FG000|Overall Study|Adverse Event|2
6149112|NCT01094886|9784767|FG000|Overall Study|Withdrawal by Subject|5
6149113|NCT01095094|9784771|FG000|Overall Study|Withdrawal by Subject|1
6149114|NCT01095094|9784771|FG000|Overall Study|Death|1
6149115|NCT01095094|9784771|FG000|Overall Study|Physician Decision|1
6149116|NCT01095653|9784806|FG000|Overall Study|Lack of Efficacy|3
6149117|NCT01095653|9784807|FG001|Overall Study|Lack of Efficacy|0
6149118|NCT01095653|9784808|FG002|Overall Study|Lack of Efficacy|0
6149119|NCT01095653|9784806|FG000|Overall Study|Adverse Event|1
6149120|NCT01095653|9784807|FG001|Overall Study|Adverse Event|4
6149121|NCT01095653|9784808|FG002|Overall Study|Adverse Event|4
6149122|NCT01095653|9784806|FG000|Overall Study|Lost to Follow-up|1
6149123|NCT01095653|9784807|FG001|Overall Study|Lost to Follow-up|0
6149124|NCT01095653|9784808|FG002|Overall Study|Lost to Follow-up|4
6149125|NCT01095653|9784806|FG000|Overall Study|Withdrawal by Subject|4
6149126|NCT01095653|9784807|FG001|Overall Study|Withdrawal by Subject|5
6149127|NCT01095653|9784808|FG002|Overall Study|Withdrawal by Subject|3
6149128|NCT01095653|9784806|FG000|Overall Study|non-compliance, not met criteria, etc.|10
6149129|NCT01095653|9784807|FG001|Overall Study|non-compliance, not met criteria, etc.|6
6313945|NCT02706834|10046175|FG009|Overall Study|Lost to Follow-up|0
6313946|NCT02706834|10046176|FG010|Overall Study|Lost to Follow-up|0
6313947|NCT02706834|10046166|FG000|Overall Study|Voluntary Withdrawal|1
6313948|NCT02706834|10046167|FG001|Overall Study|Voluntary Withdrawal|0
6313949|NCT02706834|10046168|FG002|Overall Study|Voluntary Withdrawal|0
6313950|NCT02706834|10046169|FG003|Overall Study|Voluntary Withdrawal|0
6313951|NCT02706834|10046170|FG004|Overall Study|Voluntary Withdrawal|0
6313952|NCT02706834|10046171|FG005|Overall Study|Voluntary Withdrawal|0
6313953|NCT02706834|10046172|FG006|Overall Study|Voluntary Withdrawal|0
6313954|NCT02706834|10046173|FG007|Overall Study|Voluntary Withdrawal|0
6149130|NCT01095653|9784808|FG002|Overall Study|non-compliance, not met criteria, etc.|5
6149131|NCT01095666|9784819|FG000|Overall Study|Lack of Efficacy|0
6313955|NCT02706834|10046174|FG008|Overall Study|Voluntary Withdrawal|0
6313956|NCT02706834|10046175|FG009|Overall Study|Voluntary Withdrawal|1
6149132|NCT01095666|9784820|FG001|Overall Study|Lack of Efficacy|0
6149133|NCT01095666|9784821|FG002|Overall Study|Lack of Efficacy|1
6149134|NCT01095666|9784819|FG000|Overall Study|Adverse Event|2
6149135|NCT01095666|9784820|FG001|Overall Study|Adverse Event|1
6149136|NCT01095666|9784821|FG002|Overall Study|Adverse Event|3
6149137|NCT01095666|9784819|FG000|Overall Study|Lost to Follow-up|2
6149138|NCT01095666|9784820|FG001|Overall Study|Lost to Follow-up|2
6149139|NCT01095666|9784821|FG002|Overall Study|Lost to Follow-up|0
6149140|NCT01095666|9784819|FG000|Overall Study|Withdrawal by Subject|6
6149141|NCT01095666|9784820|FG001|Overall Study|Withdrawal by Subject|6
6149142|NCT01095666|9784821|FG002|Overall Study|Withdrawal by Subject|1
6149143|NCT01095666|9784819|FG000|Overall Study|Non-compliance, not met criteria etc.|7
6149144|NCT01095666|9784820|FG001|Overall Study|Non-compliance, not met criteria etc.|2
6149145|NCT01095666|9784821|FG002|Overall Study|Non-compliance, not met criteria etc.|2
6149146|NCT01095796|9784836|FG000|Overall Study|Randomized but Not Treated|5
6149147|NCT01095796|9784837|FG001|Overall Study|Randomized but Not Treated|2
6149148|NCT01095796|9784836|FG000|Overall Study|Adverse Event|9
6149149|NCT01095796|9784837|FG001|Overall Study|Adverse Event|19
6149150|NCT01095796|9784836|FG000|Overall Study|Death|3
6149151|NCT01095796|9784837|FG001|Overall Study|Death|2
6149152|NCT01095796|9784836|FG000|Overall Study|Pregnancy|2
6149153|NCT01095796|9784837|FG001|Overall Study|Pregnancy|0
6149154|NCT01095796|9784836|FG000|Overall Study|Lack of Efficacy|5
6149155|NCT01095796|9784837|FG001|Overall Study|Lack of Efficacy|3
6149156|NCT01095796|9784836|FG000|Overall Study|Investigator's Discretion|7
6149157|NCT01095796|9784837|FG001|Overall Study|Investigator's Discretion|2
6149158|NCT01095796|9784836|FG000|Overall Study|Withdrew Consent|16
6149159|NCT01095796|9784837|FG001|Overall Study|Withdrew Consent|22
6149160|NCT01095796|9784836|FG000|Overall Study|Lost to Follow-up|27
6149161|NCT01095796|9784837|FG001|Overall Study|Lost to Follow-up|29
6149162|NCT01095796|9784836|FG000|Overall Study|Participant Noncompliance|5
6149163|NCT01095796|9784837|FG001|Overall Study|Participant Noncompliance|10
6149164|NCT01095796|9784836|FG000|Overall Study|Protocol Violation|1
6149165|NCT01095796|9784837|FG001|Overall Study|Protocol Violation|0
6149166|NCT01095796|9784836|FG000|Overall Study|Participant Transferred to Another Study|215
6149167|NCT01095796|9784837|FG001|Overall Study|Participant Transferred to Another Study|200
6149168|NCT01095835|9784846|FG000|Overall Study|Adverse Event|8
6149169|NCT01095835|9784847|FG001|Overall Study|Adverse Event|6
6149170|NCT01095835|9784848|FG002|Overall Study|Adverse Event|6
6149171|NCT01095835|9784846|FG000|Overall Study|Lack of Efficacy|0
6149172|NCT01095835|9784847|FG001|Overall Study|Lack of Efficacy|1
6149173|NCT01095835|9784848|FG002|Overall Study|Lack of Efficacy|0
6149174|NCT01095835|9784846|FG000|Overall Study|Physician Decision|0
6149175|NCT01095835|9784847|FG001|Overall Study|Physician Decision|0
6149176|NCT01095835|9784848|FG002|Overall Study|Physician Decision|1
6149177|NCT01095835|9784846|FG000|Overall Study|Withdrawal by Subject|1
6149178|NCT01095835|9784847|FG001|Overall Study|Withdrawal by Subject|3
6149179|NCT01095835|9784848|FG002|Overall Study|Withdrawal by Subject|0
6149180|NCT01095835|9784846|FG000|Overall Study|Non study compliance|0
6149181|NCT01095835|9784847|FG001|Overall Study|Non study compliance|0
6149182|NCT01095835|9784848|FG002|Overall Study|Non study compliance|1
6149183|NCT01095835|9784846|FG000|Overall Study|Protocol Violation|1
6149184|NCT01095835|9784847|FG001|Overall Study|Protocol Violation|2
6149185|NCT01095835|9784848|FG002|Overall Study|Protocol Violation|0
6149186|NCT01095978|9784861|FG000|Overall Study|Did not take Klacid SR|2
6149187|NCT01095978|9784861|FG000|Overall Study|Adverse Event|1
6149188|NCT01096017|9784867|FG000|Treatment Period 2|Eligibility criteria not fulfilled|1
6149189|NCT01096017|9784868|FG001|Treatment Period 2|Eligibility criteria not fulfilled|1
6149190|NCT01096056|9784876|FG000|Overall Study|Lost to Follow-up|0
6149191|NCT01096056|9784877|FG001|Overall Study|Lost to Follow-up|1
6149192|NCT01096160|9784893|FG000|Overall Study|Adverse Event|0
6149193|NCT01096160|9784894|FG001|Overall Study|Adverse Event|0
6149194|NCT01096160|9784895|FG002|Overall Study|Adverse Event|1
6149195|NCT01096160|9784896|FG003|Overall Study|Adverse Event|0
6149196|NCT01096160|9784897|FG004|Overall Study|Adverse Event|0
6149197|NCT01096160|9784898|FG005|Overall Study|Adverse Event|0
6149198|NCT01096160|9784899|FG006|Overall Study|Adverse Event|0
6149199|NCT01096160|9784900|FG007|Overall Study|Adverse Event|0
6149200|NCT01096160|9784901|FG008|Overall Study|Adverse Event|0
6149201|NCT01096160|9784902|FG009|Overall Study|Adverse Event|1
6149202|NCT01096160|9784893|FG000|Overall Study|Met stopping criteria per protocol|0
6149203|NCT01096160|9784894|FG001|Overall Study|Met stopping criteria per protocol|0
6149204|NCT01096160|9784895|FG002|Overall Study|Met stopping criteria per protocol|0
6191380|NCT01422304|9848165|FG000|Overall Study|Withdrawal by Subject|4
6313957|NCT02706834|10046176|FG010|Overall Study|Voluntary Withdrawal|0
6313958|NCT02706834|10046166|FG000|Overall Study|Other Reason Not Specified|1
6313959|NCT02706834|10046167|FG001|Overall Study|Other Reason Not Specified|0
6313960|NCT02706834|10046168|FG002|Overall Study|Other Reason Not Specified|0
6313961|NCT02706834|10046169|FG003|Overall Study|Other Reason Not Specified|0
6313962|NCT02706834|10046170|FG004|Overall Study|Other Reason Not Specified|1
6313963|NCT02706834|10046171|FG005|Overall Study|Other Reason Not Specified|0
6313964|NCT02706834|10046172|FG006|Overall Study|Other Reason Not Specified|0
6313965|NCT02706834|10046173|FG007|Overall Study|Other Reason Not Specified|0
6313966|NCT02706834|10046174|FG008|Overall Study|Other Reason Not Specified|0
6313967|NCT02706834|10046175|FG009|Overall Study|Other Reason Not Specified|0
6313968|NCT02706834|10046176|FG010|Overall Study|Other Reason Not Specified|0
6313969|NCT02706873|10046225|FG000|Overall Study|Adverse Event|13
6313970|NCT02706873|10046226|FG001|Overall Study|Adverse Event|3
6313971|NCT02706873|10046227|FG002|Overall Study|Adverse Event|13
6313972|NCT02706873|10046228|FG003|Overall Study|Adverse Event|12
6313973|NCT02706873|10046225|FG000|Overall Study|Withdrawal by Subject|15
6313974|NCT02706873|10046226|FG001|Overall Study|Withdrawal by Subject|0
6313975|NCT02706873|10046227|FG002|Overall Study|Withdrawal by Subject|8
6313976|NCT02706873|10046228|FG003|Overall Study|Withdrawal by Subject|11
6313977|NCT02706873|10046225|FG000|Overall Study|Lost to Follow-up|3
6313978|NCT02706873|10046226|FG001|Overall Study|Lost to Follow-up|0
6313979|NCT02706873|10046227|FG002|Overall Study|Lost to Follow-up|4
6313980|NCT02706873|10046228|FG003|Overall Study|Lost to Follow-up|2
6313981|NCT02706873|10046225|FG000|Overall Study|Lack of Efficacy|10
6313982|NCT02706873|10046226|FG001|Overall Study|Lack of Efficacy|0
6313983|NCT02706873|10046227|FG002|Overall Study|Lack of Efficacy|0
6313984|NCT02706873|10046228|FG003|Overall Study|Lack of Efficacy|3
6313985|NCT02706873|10046225|FG000|Overall Study|Other|5
6313986|NCT02706873|10046226|FG001|Overall Study|Other|1
6313987|NCT02706873|10046227|FG002|Overall Study|Other|2
6313988|NCT02706873|10046228|FG003|Overall Study|Other|3
6313989|NCT02706873|10046225|FG000|Overall Study|Not Dosed|1
6313990|NCT02706873|10046226|FG001|Overall Study|Not Dosed|0
6313991|NCT02706873|10046227|FG002|Overall Study|Not Dosed|0
6313992|NCT02706873|10046228|FG003|Overall Study|Not Dosed|1
6313993|NCT02706873|10046225|FG000|Overall Study|Ongoing|0
6313994|NCT02706873|10046226|FG001|Overall Study|Ongoing|0
6313995|NCT02706873|10046227|FG002|Overall Study|Ongoing|0
6313996|NCT02706873|10046228|FG003|Overall Study|Ongoing|1
6313997|NCT02706886|10046249|FG000|Part A: SAD Period|Withdrawal by Subject|0
6313998|NCT02706886|10046250|FG001|Part A: SAD Period|Withdrawal by Subject|0
6313999|NCT02706886|10046251|FG002|Part A: SAD Period|Withdrawal by Subject|0
6314000|NCT02706886|10046252|FG003|Part A: SAD Period|Withdrawal by Subject|2
6314001|NCT02706886|10046253|FG004|Part A: SAD Period|Withdrawal by Subject|0
6314002|NCT02706886|10046254|FG005|Part A: SAD Period|Withdrawal by Subject|0
6314003|NCT02706886|10046255|FG006|Part A: SAD Period|Withdrawal by Subject|0
6314004|NCT02706886|10046256|FG007|Part A: SAD Period|Withdrawal by Subject|0
6314005|NCT02706886|10046257|FG008|Part A: SAD Period|Withdrawal by Subject|0
6314006|NCT02706899|10046302|FG000|Overall Study|Withdrawal by Subject|1
6314007|NCT02706899|10046303|FG001|Overall Study|Withdrawal by Subject|0
6314008|NCT02706899|10046302|FG000|Overall Study|Death|8
6314009|NCT02706899|10046303|FG001|Overall Study|Death|0
6314010|NCT02706899|10046302|FG000|Overall Study|Study Termination by Sponsor|4
6314011|NCT02706899|10046303|FG001|Overall Study|Study Termination by Sponsor|6
6314012|NCT02706938|10046356|FG000|First Period, 6 Weeks|Adverse Event|8
6314013|NCT02706938|10046357|FG001|First Period, 6 Weeks|Adverse Event|0
6314014|NCT02706938|10046356|FG000|First Period, 6 Weeks|Lost to Follow-up|2
6314015|NCT02706938|10046357|FG001|First Period, 6 Weeks|Lost to Follow-up|2
6314016|NCT02706938|10046356|FG000|First Period, 6 Weeks|Withdrawal by Subject|1
6314017|NCT02706938|10046357|FG001|First Period, 6 Weeks|Withdrawal by Subject|0
6314018|NCT02706938|10046356|FG000|Second Period, 6 Weeks|Adverse Event|0
6314019|NCT02706938|10046357|FG001|Second Period, 6 Weeks|Adverse Event|7
6314020|NCT02706938|10046356|FG000|Second Period, 6 Weeks|Withdrawal by Subject|0
6314021|NCT02706938|10046357|FG001|Second Period, 6 Weeks|Withdrawal by Subject|3
6314022|NCT02706951|10046367|FG000|Overall Study|Adverse Event|1
6314023|NCT02706951|10046368|FG001|Overall Study|Adverse Event|5
6314024|NCT02706951|10046369|FG002|Overall Study|Adverse Event|3
6314025|NCT02706951|10046367|FG000|Overall Study|Withdrawal by Subject|11
6314026|NCT02706951|10046368|FG001|Overall Study|Withdrawal by Subject|6
6314027|NCT02706951|10046369|FG002|Overall Study|Withdrawal by Subject|6
6314028|NCT02706951|10046367|FG000|Overall Study|Lost to Follow-up|0
6149205|NCT01096160|9784896|FG003|Overall Study|Met stopping criteria per protocol|0
6314029|NCT02706951|10046368|FG001|Overall Study|Lost to Follow-up|4
6314030|NCT02706951|10046369|FG002|Overall Study|Lost to Follow-up|1
6314031|NCT02706951|10046367|FG000|Overall Study|Other|2
6314032|NCT02706951|10046368|FG001|Overall Study|Other|1
6314033|NCT02706951|10046369|FG002|Overall Study|Other|0
6314034|NCT02707601|10046415|FG000|Overall Study|Death|0
6314035|NCT02707601|10046416|FG001|Overall Study|Death|1
6314036|NCT02707601|10046415|FG000|Overall Study|Lack of Efficacy|0
6314037|NCT02707601|10046416|FG001|Overall Study|Lack of Efficacy|1
6314038|NCT02707601|10046415|FG000|Overall Study|Investigator's Discretion|1
6314039|NCT02707601|10046416|FG001|Overall Study|Investigator's Discretion|0
6314040|NCT02707601|10046415|FG000|Overall Study|Withdrew Consent|0
6314041|NCT02707601|10046416|FG001|Overall Study|Withdrew Consent|1
6314042|NCT02707601|10046415|FG000|Overall Study|Lost to Follow-up|1
6314043|NCT02707601|10046416|FG001|Overall Study|Lost to Follow-up|1
6314044|NCT02707601|10046415|FG000|Overall Study|Participants Randomized but Not Treated|2
6314045|NCT02707601|10046416|FG001|Overall Study|Participants Randomized but Not Treated|0
6314046|NCT02707640|10046428|FG000|Overall Study|Adverse Event|4
6314047|NCT02707640|10046429|FG001|Overall Study|Adverse Event|2
6314048|NCT02707640|10046428|FG000|Overall Study|Death|1
6314049|NCT02707640|10046429|FG001|Overall Study|Death|2
6314050|NCT02707640|10046428|FG000|Overall Study|Physician Decision|2
6314051|NCT02707640|10046429|FG001|Overall Study|Physician Decision|0
6314052|NCT02707640|10046428|FG000|Overall Study|Withdrawal by Subject|0
6314053|NCT02707640|10046429|FG001|Overall Study|Withdrawal by Subject|1
6314054|NCT02707640|10046428|FG000|Overall Study|Participant's Personal Decision|1
6314055|NCT02707640|10046429|FG001|Overall Study|Participant's Personal Decision|2
6040195|NCT00369629|9637981|FG003|Follow up for 1 Year|Lost to Follow-up|0
6040196|NCT00369629|9637978|FG000|Follow up for 1 Year|stopped being followed as study closed|0
6040197|NCT00369629|9637979|FG001|Follow up for 1 Year|stopped being followed as study closed|0
6040198|NCT00369629|9637980|FG002|Follow up for 1 Year|stopped being followed as study closed|2
6040199|NCT00369629|9637981|FG003|Follow up for 1 Year|stopped being followed as study closed|0
6040200|NCT00369655|9637991|FG000|Overall Study|Refusal of further treatment|2
6149206|NCT01096160|9784897|FG004|Overall Study|Met stopping criteria per protocol|1
6314056|NCT02707640|10046428|FG000|Overall Study|Sponsor Discretion|1
6314057|NCT02707640|10046429|FG001|Overall Study|Sponsor Discretion|0
6314058|NCT02707757|10046437|FG000|Overall Study|Protocol Violation|3
6314059|NCT02707757|10046438|FG001|Overall Study|Protocol Violation|2
6314060|NCT02707757|10046437|FG000|Overall Study|Withdrawal by Subject|2
6314061|NCT02707757|10046438|FG001|Overall Study|Withdrawal by Subject|0
6314062|NCT02707757|10046437|FG000|Overall Study|Death|0
6314063|NCT02707757|10046438|FG001|Overall Study|Death|1
6314064|NCT02707757|10046437|FG000|Overall Study|Adverse Event|6
6314065|NCT02707757|10046438|FG001|Overall Study|Adverse Event|4
6314066|NCT02707757|10046437|FG000|Overall Study|Renal transplant/elective operation|1
6314067|NCT02707757|10046438|FG001|Overall Study|Renal transplant/elective operation|5
6314068|NCT02707861|10046457|FG000|Overall Study|Went onto commercial drug|30
6314069|NCT02707861|10046458|FG001|Overall Study|Went onto commercial drug|23
6314070|NCT02707861|10046457|FG000|Overall Study|Adverse Event|2
6314071|NCT02707861|10046458|FG001|Overall Study|Adverse Event|3
6149207|NCT01096160|9784898|FG005|Overall Study|Met stopping criteria per protocol|0
6149208|NCT01096160|9784899|FG006|Overall Study|Met stopping criteria per protocol|2
6149209|NCT01096160|9784900|FG007|Overall Study|Met stopping criteria per protocol|0
6149210|NCT01096160|9784901|FG008|Overall Study|Met stopping criteria per protocol|2
6149211|NCT01096160|9784902|FG009|Overall Study|Met stopping criteria per protocol|0
6149212|NCT01096186|9784937|FG000|Overall Study|Adverse Event|16
6149213|NCT01096186|9784937|FG000|Overall Study|Death|4
6314072|NCT02707861|10046457|FG000|Overall Study|Death|5
6314073|NCT02707861|10046458|FG001|Overall Study|Death|2
6314074|NCT02707861|10046457|FG000|Overall Study|Lack of Efficacy|0
6314075|NCT02707861|10046458|FG001|Overall Study|Lack of Efficacy|2
6314076|NCT02707861|10046457|FG000|Overall Study|Physician Decision|1
6314077|NCT02707861|10046458|FG001|Overall Study|Physician Decision|4
6314078|NCT02707861|10046457|FG000|Overall Study|Withdrawal by Subject|2
6314079|NCT02707861|10046458|FG001|Overall Study|Withdrawal by Subject|1
6314080|NCT02707861|10046457|FG000|Overall Study|Lost to Follow-up|1
6314081|NCT02707861|10046458|FG001|Overall Study|Lost to Follow-up|3
6314082|NCT02707952|10046468|FG000|Overall Study|Adverse Event|1
6314083|NCT02707952|10046469|FG001|Overall Study|Adverse Event|0
6314084|NCT02707952|10046470|FG002|Overall Study|Adverse Event|0
6314085|NCT02707952|10046471|FG003|Overall Study|Adverse Event|0
6314086|NCT02707952|10046468|FG000|Overall Study|Lost to Follow-up|1
6314087|NCT02707952|10046469|FG001|Overall Study|Lost to Follow-up|0
6314088|NCT02707952|10046470|FG002|Overall Study|Lost to Follow-up|0
6314089|NCT02707952|10046471|FG003|Overall Study|Lost to Follow-up|0
6314090|NCT02707952|10046468|FG000|Overall Study|Withdrawal by Subject|0
6314091|NCT02707952|10046469|FG001|Overall Study|Withdrawal by Subject|1
6314092|NCT02707952|10046470|FG002|Overall Study|Withdrawal by Subject|2
6314093|NCT02707952|10046471|FG003|Overall Study|Withdrawal by Subject|0
6314094|NCT02707965|10046492|FG000|Overall Study|Withdrawal by Subject|0
6314095|NCT02707965|10046493|FG001|Overall Study|Withdrawal by Subject|0
6314096|NCT02707965|10046494|FG002|Overall Study|Withdrawal by Subject|1
6314097|NCT02707965|10046495|FG003|Overall Study|Withdrawal by Subject|0
6314098|NCT02707965|10046496|FG004|Overall Study|Withdrawal by Subject|0
6314099|NCT02707965|10046497|FG005|Overall Study|Withdrawal by Subject|0
6314100|NCT02707965|10046498|FG006|Overall Study|Withdrawal by Subject|0
6314101|NCT02707965|10046499|FG007|Overall Study|Withdrawal by Subject|2
6314102|NCT02707965|10046500|FG008|Overall Study|Withdrawal by Subject|0
6314103|NCT02707965|10046501|FG009|Overall Study|Withdrawal by Subject|0
6314104|NCT02707965|10046502|FG010|Overall Study|Withdrawal by Subject|0
6314105|NCT02707965|10046503|FG011|Overall Study|Withdrawal by Subject|0
6149214|NCT01096186|9784937|FG000|Overall Study|Lack of Efficacy|4
6314106|NCT02707965|10046504|FG012|Overall Study|Withdrawal by Subject|0
6314107|NCT02707965|10046505|FG013|Overall Study|Withdrawal by Subject|0
6314108|NCT02707965|10046506|FG014|Overall Study|Withdrawal by Subject|0
6314109|NCT02707965|10046507|FG015|Overall Study|Withdrawal by Subject|0
6314110|NCT02707965|10046492|FG000|Overall Study|PI decisions|0
6314111|NCT02707965|10046493|FG001|Overall Study|PI decisions|0
6080224|NCT00615030|9687417|FG000|Period II|Adverse Event|0
6080225|NCT00615030|9687418|FG001|Period II|Adverse Event|0
6080226|NCT00615030|9687419|FG002|Period II|Adverse Event|1
6080227|NCT00615030|9687420|FG003|Period II|Adverse Event|0
6080228|NCT00615030|9687421|FG004|Period II|Adverse Event|0
6080229|NCT00615030|9687422|FG005|Period II|Adverse Event|0
6314112|NCT02707965|10046494|FG002|Overall Study|PI decisions|0
6314113|NCT02707965|10046495|FG003|Overall Study|PI decisions|0
6080230|NCT00615030|9687423|FG006|Period II|Adverse Event|0
6080231|NCT00615030|9687424|FG007|Period II|Adverse Event|0
6080232|NCT00615030|9687425|FG008|Period II|Adverse Event|1
6080233|NCT00615030|9687426|FG009|Period II|Adverse Event|0
6080234|NCT00615030|9687427|FG010|Period II|Adverse Event|0
6080235|NCT00615030|9687428|FG011|Period II|Adverse Event|0
6080236|NCT00615030|9687417|FG000|Period II|Subject withdrew consent|0
6080237|NCT00615030|9687418|FG001|Period II|Subject withdrew consent|0
6080238|NCT00615030|9687419|FG002|Period II|Subject withdrew consent|0
6080239|NCT00615030|9687420|FG003|Period II|Subject withdrew consent|1
6080240|NCT00615030|9687421|FG004|Period II|Subject withdrew consent|0
6080241|NCT00615030|9687422|FG005|Period II|Subject withdrew consent|0
6314114|NCT02707965|10046496|FG004|Overall Study|PI decisions|0
6314115|NCT02707965|10046497|FG005|Overall Study|PI decisions|0
6314116|NCT02707965|10046498|FG006|Overall Study|PI decisions|0
6314117|NCT02707965|10046499|FG007|Overall Study|PI decisions|0
6314118|NCT02707965|10046500|FG008|Overall Study|PI decisions|0
6314119|NCT02707965|10046501|FG009|Overall Study|PI decisions|0
6314120|NCT02707965|10046502|FG010|Overall Study|PI decisions|0
6314121|NCT02707965|10046503|FG011|Overall Study|PI decisions|0
6314122|NCT02707965|10046504|FG012|Overall Study|PI decisions|0
6314123|NCT02707965|10046505|FG013|Overall Study|PI decisions|0
6314124|NCT02707965|10046506|FG014|Overall Study|PI decisions|2
6314125|NCT02707965|10046507|FG015|Overall Study|PI decisions|0
6314126|NCT02707965|10046492|FG000|Overall Study|Protocol deviation|1
6314127|NCT02707965|10046493|FG001|Overall Study|Protocol deviation|1
6314128|NCT02707965|10046494|FG002|Overall Study|Protocol deviation|0
6314129|NCT02707965|10046495|FG003|Overall Study|Protocol deviation|0
6314130|NCT02707965|10046496|FG004|Overall Study|Protocol deviation|0
6314131|NCT02707965|10046497|FG005|Overall Study|Protocol deviation|0
6314132|NCT02707965|10046498|FG006|Overall Study|Protocol deviation|0
6080242|NCT00615030|9687423|FG006|Period II|Subject withdrew consent|1
6080243|NCT00615030|9687424|FG007|Period II|Subject withdrew consent|0
6080244|NCT00615030|9687425|FG008|Period II|Subject withdrew consent|0
6080245|NCT00615030|9687426|FG009|Period II|Subject withdrew consent|0
6080246|NCT00615030|9687427|FG010|Period II|Subject withdrew consent|0
6080247|NCT00615030|9687428|FG011|Period II|Subject withdrew consent|0
6080248|NCT00615030|9687417|FG000|Period III|Administrative problems|1
6080249|NCT00615030|9687418|FG001|Period III|Administrative problems|0
6080250|NCT00615030|9687419|FG002|Period III|Administrative problems|0
6080251|NCT00615030|9687420|FG003|Period III|Administrative problems|1
6080252|NCT00615030|9687421|FG004|Period III|Administrative problems|0
6080253|NCT00615030|9687422|FG005|Period III|Administrative problems|0
6080254|NCT00615030|9687423|FG006|Period III|Administrative problems|0
6080255|NCT00615030|9687424|FG007|Period III|Administrative problems|0
6080256|NCT00615030|9687425|FG008|Period III|Administrative problems|0
6080257|NCT00615030|9687426|FG009|Period III|Administrative problems|0
6080258|NCT00615030|9687427|FG010|Period III|Administrative problems|0
6080259|NCT00615030|9687428|FG011|Period III|Administrative problems|0
6080260|NCT00615056|9687446|FG000|Overall Study|Death|31
6080261|NCT00615056|9687447|FG001|Overall Study|Death|31
6080262|NCT00615056|9687448|FG002|Overall Study|Death|21
6080263|NCT00615056|9687449|FG003|Overall Study|Death|23
6149215|NCT01096186|9784937|FG000|Overall Study|Lost to Follow-up|2
6149216|NCT01096186|9784937|FG000|Overall Study|Withdrawal by Subject|22
6149217|NCT01096186|9784937|FG000|Overall Study|Physician Decision|1
6149218|NCT01096186|9784937|FG000|Overall Study|Noncompliance with study drug|1
6149219|NCT01096316|9784952|FG000|Overall Study|Lost to Follow-up|15
6149220|NCT01096316|9784953|FG001|Overall Study|Lost to Follow-up|9
6149221|NCT01096342|9784959|FG000|Overall Study|Protocol Violation|1
6149222|NCT01096446|9784965|FG000|Overall Study|Death|1
6149223|NCT01096446|9784966|FG001|Overall Study|Death|0
6149224|NCT01096446|9784965|FG000|Overall Study|Protocol Violation|2
6149225|NCT01096446|9784966|FG001|Overall Study|Protocol Violation|0
6149226|NCT01096550|9784973|FG000|Overall Study|discontinued site|10
6149227|NCT01096550|9784974|FG001|Overall Study|discontinued site|11
6149228|NCT01096550|9784973|FG000|Overall Study|non-regular treatment track at clinic|1
6149229|NCT01096550|9784974|FG001|Overall Study|non-regular treatment track at clinic|1
6149230|NCT01096550|9784973|FG000|Overall Study|clinic readmission|1
6149231|NCT01096550|9784974|FG001|Overall Study|clinic readmission|1
6149232|NCT01096550|9784973|FG000|Overall Study|Withdrawal by Subject|0
6149233|NCT01096550|9784974|FG001|Overall Study|Withdrawal by Subject|1
6149234|NCT01096550|9784973|FG000|Overall Study|non-African American participant|13
6149235|NCT01096550|9784974|FG001|Overall Study|non-African American participant|6
6149236|NCT01096550|9784973|FG000|Overall Study|Lost to Follow-up|12
6149237|NCT01096550|9784974|FG001|Overall Study|Lost to Follow-up|9
6149238|NCT01096589|9784984|FG000|Overall Study|Adverse Event|2
6149239|NCT01096589|9784985|FG001|Overall Study|Adverse Event|1
6149240|NCT01096589|9784986|FG002|Overall Study|Adverse Event|2
6149241|NCT01096589|9784987|FG003|Overall Study|Adverse Event|1
6149242|NCT01096589|9784984|FG000|Overall Study|Withdrawal by Subject|2
6149243|NCT01096589|9784985|FG001|Overall Study|Withdrawal by Subject|1
6149244|NCT01096589|9784986|FG002|Overall Study|Withdrawal by Subject|1
6149245|NCT01096589|9784987|FG003|Overall Study|Withdrawal by Subject|1
6149246|NCT01096589|9784984|FG000|Overall Study|Compliance with protocol|0
6149247|NCT01096589|9784985|FG001|Overall Study|Compliance with protocol|0
6149248|NCT01096589|9784986|FG002|Overall Study|Compliance with protocol|1
6149249|NCT01096589|9784987|FG003|Overall Study|Compliance with protocol|0
6149250|NCT01096589|9784984|FG000|Overall Study|found treatment exhausting|0
6149251|NCT01096589|9784985|FG001|Overall Study|found treatment exhausting|0
6149252|NCT01096589|9784986|FG002|Overall Study|found treatment exhausting|0
6149253|NCT01096589|9784987|FG003|Overall Study|found treatment exhausting|1
6314133|NCT02707965|10046499|FG007|Overall Study|Protocol deviation|1
6314134|NCT02707965|10046500|FG008|Overall Study|Protocol deviation|0
6314135|NCT02707965|10046501|FG009|Overall Study|Protocol deviation|0
6314136|NCT02707965|10046502|FG010|Overall Study|Protocol deviation|0
6314137|NCT02707965|10046503|FG011|Overall Study|Protocol deviation|0
6314138|NCT02707965|10046504|FG012|Overall Study|Protocol deviation|0
6314139|NCT02707965|10046505|FG013|Overall Study|Protocol deviation|0
6314140|NCT02707965|10046506|FG014|Overall Study|Protocol deviation|0
6314141|NCT02707965|10046507|FG015|Overall Study|Protocol deviation|0
6314142|NCT02707991|10046542|FG000|Overall Study|Protocol Violation|1
6314143|NCT02707991|10046543|FG001|Overall Study|Protocol Violation|0
6314144|NCT02707991|10046542|FG000|Overall Study|Became ineligible|0
6314145|NCT02707991|10046543|FG001|Overall Study|Became ineligible|1
6314146|NCT02708095|10046552|FG000|Overall Study|Adverse Event|4
6314147|NCT02708095|10046553|FG001|Overall Study|Adverse Event|10
6314148|NCT02708095|10046554|FG002|Overall Study|Adverse Event|11
6314149|NCT02708095|10046552|FG000|Overall Study|Lack of Efficacy|9
6314150|NCT02708095|10046553|FG001|Overall Study|Lack of Efficacy|3
6314151|NCT02708095|10046554|FG002|Overall Study|Lack of Efficacy|0
6314152|NCT02708095|10046552|FG000|Overall Study|Lost to Follow-up|2
6314153|NCT02708095|10046553|FG001|Overall Study|Lost to Follow-up|0
6314154|NCT02708095|10046554|FG002|Overall Study|Lost to Follow-up|0
6314155|NCT02708095|10046552|FG000|Overall Study|Physician Decision|2
6314156|NCT02708095|10046553|FG001|Overall Study|Physician Decision|3
6314157|NCT02708095|10046554|FG002|Overall Study|Physician Decision|2
6314158|NCT02708095|10046552|FG000|Overall Study|Protocol Violation|0
6314159|NCT02708095|10046553|FG001|Overall Study|Protocol Violation|0
6314160|NCT02708095|10046554|FG002|Overall Study|Protocol Violation|1
6314161|NCT02708095|10046552|FG000|Overall Study|Withdrawal by Subject|5
6314162|NCT02708095|10046553|FG001|Overall Study|Withdrawal by Subject|3
6149254|NCT01096667|9785006|FG000|Overall Study|Lost to Follow-up|1
6149255|NCT01096667|9785007|FG001|Overall Study|Lost to Follow-up|1
6149256|NCT01096667|9785008|FG002|Overall Study|Lost to Follow-up|1
6149257|NCT01096667|9785009|FG003|Overall Study|Lost to Follow-up|0
6149258|NCT01096667|9785010|FG004|Overall Study|Lost to Follow-up|0
6149259|NCT01096667|9785006|FG000|Overall Study|Withdrawal by Subject|1
6149260|NCT01096667|9785007|FG001|Overall Study|Withdrawal by Subject|0
6149261|NCT01096667|9785008|FG002|Overall Study|Withdrawal by Subject|0
6149262|NCT01096667|9785009|FG003|Overall Study|Withdrawal by Subject|1
6149263|NCT01096667|9785010|FG004|Overall Study|Withdrawal by Subject|0
6149264|NCT01096667|9785006|FG000|Overall Study|Reason not available|0
6149265|NCT01096667|9785007|FG001|Overall Study|Reason not available|1
6149266|NCT01096667|9785008|FG002|Overall Study|Reason not available|1
6149267|NCT01096667|9785009|FG003|Overall Study|Reason not available|1
6149268|NCT01096667|9785010|FG004|Overall Study|Reason not available|0
6149269|NCT01096667|9785006|FG000|Overall Study|Protocol Violation|0
6149270|NCT01096667|9785007|FG001|Overall Study|Protocol Violation|0
6149271|NCT01096667|9785008|FG002|Overall Study|Protocol Violation|0
6149272|NCT01096667|9785009|FG003|Overall Study|Protocol Violation|1
6149273|NCT01096667|9785010|FG004|Overall Study|Protocol Violation|0
6149274|NCT01096667|9785006|FG000|Overall Study|Not treated|1
6149275|NCT01096667|9785007|FG001|Overall Study|Not treated|0
6149276|NCT01096667|9785008|FG002|Overall Study|Not treated|0
6149277|NCT01096667|9785009|FG003|Overall Study|Not treated|0
6149278|NCT01096667|9785010|FG004|Overall Study|Not treated|0
6149279|NCT01096784|9785055|FG000|Overall Study|Withdrawal by Subject|2
6314163|NCT02708095|10046554|FG002|Overall Study|Withdrawal by Subject|4
6314164|NCT02708121|10046566|FG000|Overall Study|Withdrawn by Study Team|1
6314165|NCT02708121|10046567|FG001|Overall Study|Withdrawn by Study Team|1
6314166|NCT02708121|10046566|FG000|Overall Study|Withdrawal by Subject|0
6314167|NCT02708121|10046567|FG001|Overall Study|Withdrawal by Subject|4
6314168|NCT02708277|10046610|FG000|Overall Study|Lost to Follow-up|7
6314169|NCT02708277|10046611|FG001|Overall Study|Lost to Follow-up|4
6314170|NCT02708355|10046629|FG000|Overall Study|Adverse Event|1
6314171|NCT02708355|10046630|FG001|Overall Study|Adverse Event|0
6314172|NCT02708355|10046631|FG002|Overall Study|Adverse Event|0
6314173|NCT02708485|10046648|FG000|Overall Study|Withdrawal by Subject|3
6314174|NCT02708485|10046649|FG001|Overall Study|Withdrawal by Subject|2
6314175|NCT02708498|10046663|FG000|Overall Study|Death|20
6314176|NCT02708498|10046664|FG001|Overall Study|Death|19
6314177|NCT02708498|10046665|FG002|Overall Study|Death|0
6314178|NCT02708498|10046666|FG003|Overall Study|Death|0
6314179|NCT02708498|10046667|FG004|Overall Study|Death|1
6314180|NCT02708498|10046668|FG005|Overall Study|Death|0
6314181|NCT02708498|10046669|FG006|Overall Study|Death|0
6314182|NCT02708498|10046670|FG007|Overall Study|Death|0
6314183|NCT02708498|10046663|FG000|Overall Study|Unknown reason, missing data|0
6314184|NCT02708498|10046664|FG001|Overall Study|Unknown reason, missing data|0
6314185|NCT02708498|10046665|FG002|Overall Study|Unknown reason, missing data|62
6314186|NCT02708498|10046666|FG003|Overall Study|Unknown reason, missing data|51
6314187|NCT02708498|10046667|FG004|Overall Study|Unknown reason, missing data|195
6314188|NCT02708498|10046668|FG005|Overall Study|Unknown reason, missing data|132
6314189|NCT02708498|10046669|FG006|Overall Study|Unknown reason, missing data|0
6314190|NCT02708498|10046670|FG007|Overall Study|Unknown reason, missing data|0
6314191|NCT02708524|10046690|FG000|Overall Study|Adverse Event|0
6314192|NCT02708524|10046691|FG001|Overall Study|Adverse Event|1
6314193|NCT02708524|10046692|FG002|Overall Study|Adverse Event|0
6314194|NCT02708524|10046693|FG003|Overall Study|Adverse Event|0
6314195|NCT02708524|10046690|FG000|Overall Study|Lens Discomfort|1
6314196|NCT02708524|10046691|FG001|Overall Study|Lens Discomfort|0
6149280|NCT01096784|9785056|FG001|Overall Study|Withdrawal by Subject|1
6149281|NCT01096784|9785055|FG000|Overall Study|Adverse Event|11
6149282|NCT01096784|9785056|FG001|Overall Study|Adverse Event|9
6149283|NCT01096784|9785055|FG000|Overall Study|Protocol Deviation|2
6149284|NCT01096784|9785056|FG001|Overall Study|Protocol Deviation|2
6149285|NCT01096784|9785055|FG000|Overall Study|Administrative Decision|0
6149286|NCT01096784|9785056|FG001|Overall Study|Administrative Decision|1
6149287|NCT01096784|9785055|FG000|Overall Study|Other Unspecified|0
6149288|NCT01096784|9785056|FG001|Overall Study|Other Unspecified|1
6149289|NCT01096849|9785080|FG000|Overall Study|Consent Withdrawn|1
6149290|NCT01096849|9785081|FG001|Overall Study|Consent Withdrawn|4
6149291|NCT01096849|9785082|FG002|Overall Study|Consent Withdrawn|2
6149292|NCT01096849|9785080|FG000|Overall Study|Lack of Efficacy|0
6149293|NCT01096849|9785081|FG001|Overall Study|Lack of Efficacy|2
6149294|NCT01096849|9785082|FG002|Overall Study|Lack of Efficacy|0
6314197|NCT02708524|10046692|FG002|Overall Study|Lens Discomfort|1
6314198|NCT02708524|10046693|FG003|Overall Study|Lens Discomfort|0
6314199|NCT02708524|10046690|FG000|Overall Study|Lost to Follow-up|1
6314200|NCT02708524|10046691|FG001|Overall Study|Lost to Follow-up|1
6314201|NCT02708524|10046692|FG002|Overall Study|Lost to Follow-up|1
6314202|NCT02708524|10046693|FG003|Overall Study|Lost to Follow-up|0
6149295|NCT01096849|9785080|FG000|Overall Study|Unacceptable/ Intolerable AE(s)|0
6149296|NCT01096849|9785081|FG001|Overall Study|Unacceptable/ Intolerable AE(s)|1
6149297|NCT01096849|9785082|FG002|Overall Study|Unacceptable/ Intolerable AE(s)|1
6149298|NCT01096849|9785080|FG000|Overall Study|Investigator or Medical Monitor Decision|0
6149299|NCT01096849|9785081|FG001|Overall Study|Investigator or Medical Monitor Decision|1
6149300|NCT01096849|9785082|FG002|Overall Study|Investigator or Medical Monitor Decision|0
6149301|NCT01096849|9785080|FG000|Overall Study|Administrative Reasons|0
6149302|NCT01096849|9785081|FG001|Overall Study|Administrative Reasons|1
6149303|NCT01096849|9785082|FG002|Overall Study|Administrative Reasons|2
6149304|NCT01096849|9785080|FG000|Overall Study|Lost to Follow-up|1
6149305|NCT01096849|9785081|FG001|Overall Study|Lost to Follow-up|3
6227339|NCT01716520|9900043|FG002|Treatment Period 3 (14 Days)|Lack of Efficacy|0
6314203|NCT02708524|10046690|FG000|Overall Study|Protocol Violation|0
6314204|NCT02708524|10046691|FG001|Overall Study|Protocol Violation|1
6314205|NCT02708524|10046692|FG002|Overall Study|Protocol Violation|0
6314206|NCT02708524|10046693|FG003|Overall Study|Protocol Violation|0
6314207|NCT02708524|10046690|FG000|Overall Study|Withdrawal by Subject|1
6314208|NCT02708524|10046691|FG001|Overall Study|Withdrawal by Subject|1
6314209|NCT02708524|10046692|FG002|Overall Study|Withdrawal by Subject|0
6314210|NCT02708524|10046693|FG003|Overall Study|Withdrawal by Subject|0
6314211|NCT02708524|10046690|FG000|Overall Study|Dispensed incorrect study lens|0
6314212|NCT02708524|10046691|FG001|Overall Study|Dispensed incorrect study lens|1
6314213|NCT02708524|10046692|FG002|Overall Study|Dispensed incorrect study lens|1
6314214|NCT02708524|10046693|FG003|Overall Study|Dispensed incorrect study lens|0
6314215|NCT02708524|10046690|FG000|Overall Study|Did not wear lens at final visit|0
6314216|NCT02708524|10046691|FG001|Overall Study|Did not wear lens at final visit|1
6314217|NCT02708524|10046692|FG002|Overall Study|Did not wear lens at final visit|0
6314218|NCT02708524|10046693|FG003|Overall Study|Did not wear lens at final visit|0
6314219|NCT02708524|10046690|FG000|Overall Study|Subject lost study lens|1
6314220|NCT02708524|10046691|FG001|Overall Study|Subject lost study lens|0
6314221|NCT02708524|10046692|FG002|Overall Study|Subject lost study lens|0
6314222|NCT02708524|10046693|FG003|Overall Study|Subject lost study lens|0
6314223|NCT02708966|10046735|FG000|Overall Study|Lost to Follow-up|2
6314224|NCT02708966|10046736|FG001|Overall Study|Lost to Follow-up|2
6314225|NCT02709005|10046744|FG000|Overall Study|Lost to Follow-up|1
6314226|NCT02709005|10046745|FG001|Overall Study|Lost to Follow-up|1
6314227|NCT02709005|10046744|FG000|Overall Study|Withdrawal by Subject|3
6314228|NCT02709005|10046745|FG001|Overall Study|Withdrawal by Subject|0
6314229|NCT02709096|10046764|FG000|Overall Study|non-compliance|1
6314230|NCT02709096|10046765|FG001|Overall Study|non-compliance|1
6314231|NCT02709109|10046775|FG000|Treatment Period 1 (28 Days)|Adverse Event|3
6314232|NCT02709109|10046776|FG001|Treatment Period 1 (28 Days)|Adverse Event|3
6314233|NCT02709109|10046777|FG002|Treatment Period 1 (28 Days)|Adverse Event|1
6314234|NCT02709109|10046778|FG003|Treatment Period 1 (28 Days)|Adverse Event|0
6314235|NCT02709109|10046775|FG000|Treatment Period 1 (28 Days)|Participant refused further dosing|0
6314236|NCT02709109|10046776|FG001|Treatment Period 1 (28 Days)|Participant refused further dosing|2
6314237|NCT02709109|10046777|FG002|Treatment Period 1 (28 Days)|Participant refused further dosing|0
6314238|NCT02709109|10046778|FG003|Treatment Period 1 (28 Days)|Participant refused further dosing|0
6314239|NCT02709109|10046775|FG000|Treatment Period 1 (28 Days)|Non-compliance with study drug|1
6314240|NCT02709109|10046776|FG001|Treatment Period 1 (28 Days)|Non-compliance with study drug|0
6314241|NCT02709109|10046777|FG002|Treatment Period 1 (28 Days)|Non-compliance with study drug|0
6314242|NCT02709109|10046778|FG003|Treatment Period 1 (28 Days)|Non-compliance with study drug|0
6314243|NCT02709109|10046775|FG000|Washout Period (28 Days)|Other|2
6314244|NCT02709109|10046776|FG001|Washout Period (28 Days)|Other|2
6314245|NCT02709109|10046777|FG002|Washout Period (28 Days)|Other|3
6314246|NCT02709109|10046778|FG003|Washout Period (28 Days)|Other|0
6314247|NCT02709109|10046775|FG000|Treatment Period 2 (28 Days)|Adverse Event|2
6314248|NCT02709109|10046776|FG001|Treatment Period 2 (28 Days)|Adverse Event|3
6040201|NCT00369668|9637998|FG000|Overall Study|Lack of Efficacy|4
6040202|NCT00369668|9637999|FG001|Overall Study|Lack of Efficacy|5
6040203|NCT00369668|9638000|FG002|Overall Study|Lack of Efficacy|7
6040204|NCT00369681|9638011|FG000|Overall Study|Death|1
6040205|NCT00369707|9638015|FG000|Induction Part B (2 Cycles)|Adverse Event|3
6149306|NCT01096849|9785082|FG002|Overall Study|Lost to Follow-up|1
6040206|NCT00369707|9638015|FG000|Induction Part B (2 Cycles)|Withdrawal by Subject|2
6040207|NCT00369707|9638015|FG000|Induction Part B (2 Cycles)|Inadequate response/MD decision|1
6040208|NCT00369707|9638015|FG000|Induction Part B (2 Cycles)|Progressive disease|1
6040209|NCT00369707|9638015|FG000|Maintenance Period (up to 4 Cycles)|Withdrawal by Subject|2
6040210|NCT00369707|9638015|FG000|Maintenance Period (up to 4 Cycles)|inadequate response/MD decision|2
6040211|NCT00369707|9638015|FG000|Maintenance Period (up to 4 Cycles)|Progressive disease|4
6040212|NCT00369707|9638015|FG000|Follow up for 2 Years After Treatment|Death|1
6040213|NCT00369707|9638015|FG000|Follow up for 2 Years After Treatment|Other|2
6040214|NCT00369785|9638030|FG000|Overall Study|Physician Decision|3
6040215|NCT00369785|9638031|FG001|Overall Study|Physician Decision|2
6040216|NCT00369785|9638030|FG000|Overall Study|Death|1
6040217|NCT00369785|9638031|FG001|Overall Study|Death|2
6040218|NCT00369785|9638030|FG000|Overall Study|Withdrawal by Subject|7
6040219|NCT00369785|9638031|FG001|Overall Study|Withdrawal by Subject|6
6040220|NCT00369785|9638030|FG000|Overall Study|Toxicity|6
6040221|NCT00369785|9638031|FG001|Overall Study|Toxicity|4
6040222|NCT00369785|9638030|FG000|Overall Study|Never started|0
6040223|NCT00369785|9638031|FG001|Overall Study|Never started|2
6040224|NCT00369785|9638030|FG000|Overall Study|Progression|4
6040225|NCT00369785|9638031|FG001|Overall Study|Progression|4
6040226|NCT00369785|9638030|FG000|Overall Study|Multiple reasons|6
6040227|NCT00369785|9638031|FG001|Overall Study|Multiple reasons|5
6040228|NCT00369824|9638043|FG000|Overall Study|Adverse Event|0
6040229|NCT00369824|9638044|FG001|Overall Study|Adverse Event|2
6040230|NCT00369824|9638045|FG002|Overall Study|Adverse Event|0
6040231|NCT00369824|9638046|FG003|Overall Study|Adverse Event|0
6040232|NCT00369824|9638047|FG004|Overall Study|Adverse Event|1
6040233|NCT00369824|9638048|FG005|Overall Study|Adverse Event|0
6040234|NCT00369824|9638043|FG000|Overall Study|Protocol Violation|0
6040235|NCT00369824|9638044|FG001|Overall Study|Protocol Violation|1
6040236|NCT00369824|9638045|FG002|Overall Study|Protocol Violation|0
6040237|NCT00369824|9638046|FG003|Overall Study|Protocol Violation|1
6149307|NCT01097044|9785125|FG000|Overall Study|Withdrawal by Subject|4
6040238|NCT00369824|9638047|FG004|Overall Study|Protocol Violation|1
6040239|NCT00369824|9638048|FG005|Overall Study|Protocol Violation|0
6314249|NCT02709109|10046777|FG002|Treatment Period 2 (28 Days)|Adverse Event|0
6314250|NCT02709109|10046778|FG003|Treatment Period 2 (28 Days)|Adverse Event|0
6314251|NCT02709109|10046775|FG000|Treatment Period 2 (28 Days)|Other non-compliance|0
6314252|NCT02709109|10046776|FG001|Treatment Period 2 (28 Days)|Other non-compliance|1
6314253|NCT02709109|10046777|FG002|Treatment Period 2 (28 Days)|Other non-compliance|1
6314254|NCT02709109|10046778|FG003|Treatment Period 2 (28 Days)|Other non-compliance|0
6314255|NCT02709109|10046775|FG000|Treatment Period 2 (28 Days)|Requires prohibited medication|0
6314256|NCT02709109|10046776|FG001|Treatment Period 2 (28 Days)|Requires prohibited medication|0
6149308|NCT01097044|9785126|FG001|Overall Study|Withdrawal by Subject|4
6149309|NCT01097044|9785125|FG000|Overall Study|Lost to Follow-up|1
6149310|NCT01097044|9785126|FG001|Overall Study|Lost to Follow-up|0
6149311|NCT01097044|9785125|FG000|Overall Study|Withdrawal by Sponsor|0
6149312|NCT01097044|9785126|FG001|Overall Study|Withdrawal by Sponsor|1
6149313|NCT01097057|9785134|FG000|Overall Study|Physician Decision|3
6149314|NCT01097330|9785145|FG000|Overall Study|Study terminated early|7
6149315|NCT01097330|9785146|FG001|Overall Study|Study terminated early|5
6149316|NCT01097421|9785168|FG000|Overall Study|Adverse Event|8
6149317|NCT01097421|9785168|FG000|Overall Study|Protocol Violation|2
6149318|NCT01097421|9785168|FG000|Overall Study|Lost to Follow-up|1
6149319|NCT01097421|9785168|FG000|Overall Study|Withdrawal by Subject|3
6149320|NCT01097577|9785178|FG000|Overall Study|Adverse Event|0
6149321|NCT01097577|9785179|FG001|Overall Study|Adverse Event|1
6149322|NCT01097616|9785188|FG000|Double-Blind (DB) Treatment (TRT) Phase|Adverse Event|6
6149323|NCT01097616|9785189|FG001|Double-Blind (DB) Treatment (TRT) Phase|Adverse Event|15
6149324|NCT01097616|9785190|FG002|Double-Blind (DB) Treatment (TRT) Phase|Adverse Event|21
6149325|NCT01097616|9785191|FG003|Double-Blind (DB) Treatment (TRT) Phase|Adverse Event|0
6149326|NCT01097616|9785192|FG004|Double-Blind (DB) Treatment (TRT) Phase|Adverse Event|0
6149327|NCT01097616|9785193|FG005|Double-Blind (DB) Treatment (TRT) Phase|Adverse Event|0
6149328|NCT01097616|9785194|FG006|Double-Blind (DB) Treatment (TRT) Phase|Adverse Event|0
6149329|NCT01097616|9785195|FG007|Double-Blind (DB) Treatment (TRT) Phase|Adverse Event|0
6149330|NCT01097616|9785188|FG000|Double-Blind (DB) Treatment (TRT) Phase|Withdrawal by Subject|6
6149331|NCT01097616|9785189|FG001|Double-Blind (DB) Treatment (TRT) Phase|Withdrawal by Subject|8
6149332|NCT01097616|9785190|FG002|Double-Blind (DB) Treatment (TRT) Phase|Withdrawal by Subject|12
6149333|NCT01097616|9785191|FG003|Double-Blind (DB) Treatment (TRT) Phase|Withdrawal by Subject|0
6149334|NCT01097616|9785192|FG004|Double-Blind (DB) Treatment (TRT) Phase|Withdrawal by Subject|0
6149335|NCT01097616|9785193|FG005|Double-Blind (DB) Treatment (TRT) Phase|Withdrawal by Subject|0
6149336|NCT01097616|9785194|FG006|Double-Blind (DB) Treatment (TRT) Phase|Withdrawal by Subject|0
6149337|NCT01097616|9785195|FG007|Double-Blind (DB) Treatment (TRT) Phase|Withdrawal by Subject|0
6149338|NCT01097616|9785188|FG000|Double-Blind (DB) Treatment (TRT) Phase|Protocol Violation|5
6149339|NCT01097616|9785189|FG001|Double-Blind (DB) Treatment (TRT) Phase|Protocol Violation|3
6149340|NCT01097616|9785190|FG002|Double-Blind (DB) Treatment (TRT) Phase|Protocol Violation|1
6149341|NCT01097616|9785191|FG003|Double-Blind (DB) Treatment (TRT) Phase|Protocol Violation|0
6149342|NCT01097616|9785192|FG004|Double-Blind (DB) Treatment (TRT) Phase|Protocol Violation|0
6149343|NCT01097616|9785193|FG005|Double-Blind (DB) Treatment (TRT) Phase|Protocol Violation|0
6149344|NCT01097616|9785194|FG006|Double-Blind (DB) Treatment (TRT) Phase|Protocol Violation|0
6149345|NCT01097616|9785195|FG007|Double-Blind (DB) Treatment (TRT) Phase|Protocol Violation|0
6149346|NCT01097616|9785188|FG000|Double-Blind (DB) Treatment (TRT) Phase|Lost to Follow-up|1
6149347|NCT01097616|9785189|FG001|Double-Blind (DB) Treatment (TRT) Phase|Lost to Follow-up|1
6149348|NCT01097616|9785190|FG002|Double-Blind (DB) Treatment (TRT) Phase|Lost to Follow-up|0
6149349|NCT01097616|9785191|FG003|Double-Blind (DB) Treatment (TRT) Phase|Lost to Follow-up|0
6149350|NCT01097616|9785192|FG004|Double-Blind (DB) Treatment (TRT) Phase|Lost to Follow-up|0
6149351|NCT01097616|9785193|FG005|Double-Blind (DB) Treatment (TRT) Phase|Lost to Follow-up|0
6149352|NCT01097616|9785194|FG006|Double-Blind (DB) Treatment (TRT) Phase|Lost to Follow-up|0
6149353|NCT01097616|9785195|FG007|Double-Blind (DB) Treatment (TRT) Phase|Lost to Follow-up|0
6149354|NCT01097616|9785188|FG000|Double-Blind (DB) Treatment (TRT) Phase|Lack of Efficacy|1
6149355|NCT01097616|9785189|FG001|Double-Blind (DB) Treatment (TRT) Phase|Lack of Efficacy|7
6149356|NCT01097616|9785190|FG002|Double-Blind (DB) Treatment (TRT) Phase|Lack of Efficacy|9
6149357|NCT01097616|9785191|FG003|Double-Blind (DB) Treatment (TRT) Phase|Lack of Efficacy|0
6191381|NCT01422304|9848166|FG001|Overall Study|Withdrawal by Subject|2
6314257|NCT02709109|10046777|FG002|Treatment Period 2 (28 Days)|Requires prohibited medication|1
6314258|NCT02709109|10046778|FG003|Treatment Period 2 (28 Days)|Requires prohibited medication|0
6314259|NCT02709109|10046775|FG000|Treatment Period 2 (28 Days)|Other|0
6314260|NCT02709109|10046776|FG001|Treatment Period 2 (28 Days)|Other|0
6314261|NCT02709109|10046777|FG002|Treatment Period 2 (28 Days)|Other|1
6314262|NCT02709109|10046778|FG003|Treatment Period 2 (28 Days)|Other|0
6314263|NCT02709330|10046789|FG000|Overall Study|Death|5
6149358|NCT01097616|9785192|FG004|Double-Blind (DB) Treatment (TRT) Phase|Lack of Efficacy|0
6149359|NCT01097616|9785193|FG005|Double-Blind (DB) Treatment (TRT) Phase|Lack of Efficacy|0
6149360|NCT01097616|9785194|FG006|Double-Blind (DB) Treatment (TRT) Phase|Lack of Efficacy|0
6149361|NCT01097616|9785195|FG007|Double-Blind (DB) Treatment (TRT) Phase|Lack of Efficacy|0
6149362|NCT01097616|9785188|FG000|Double-Blind (DB) Treatment (TRT) Phase|Pregnancy|1
6149363|NCT01097616|9785189|FG001|Double-Blind (DB) Treatment (TRT) Phase|Pregnancy|1
6149364|NCT01097616|9785190|FG002|Double-Blind (DB) Treatment (TRT) Phase|Pregnancy|0
6149365|NCT01097616|9785191|FG003|Double-Blind (DB) Treatment (TRT) Phase|Pregnancy|0
6149366|NCT01097616|9785192|FG004|Double-Blind (DB) Treatment (TRT) Phase|Pregnancy|0
6149367|NCT01097616|9785193|FG005|Double-Blind (DB) Treatment (TRT) Phase|Pregnancy|0
6149368|NCT01097616|9785194|FG006|Double-Blind (DB) Treatment (TRT) Phase|Pregnancy|0
6149369|NCT01097616|9785195|FG007|Double-Blind (DB) Treatment (TRT) Phase|Pregnancy|0
6149370|NCT01097616|9785188|FG000|Double-Blind (DB) Treatment (TRT) Phase|Physician Decision|4
6149371|NCT01097616|9785189|FG001|Double-Blind (DB) Treatment (TRT) Phase|Physician Decision|3
6149372|NCT01097616|9785190|FG002|Double-Blind (DB) Treatment (TRT) Phase|Physician Decision|0
6149373|NCT01097616|9785191|FG003|Double-Blind (DB) Treatment (TRT) Phase|Physician Decision|0
6149374|NCT01097616|9785192|FG004|Double-Blind (DB) Treatment (TRT) Phase|Physician Decision|0
6149375|NCT01097616|9785193|FG005|Double-Blind (DB) Treatment (TRT) Phase|Physician Decision|0
6149376|NCT01097616|9785194|FG006|Double-Blind (DB) Treatment (TRT) Phase|Physician Decision|0
6149377|NCT01097616|9785195|FG007|Double-Blind (DB) Treatment (TRT) Phase|Physician Decision|0
6149378|NCT01097616|9785188|FG000|Double-Blind (DB) Treatment (TRT) Phase|Not Treated|0
6149379|NCT01097616|9785189|FG001|Double-Blind (DB) Treatment (TRT) Phase|Not Treated|0
6149380|NCT01097616|9785190|FG002|Double-Blind (DB) Treatment (TRT) Phase|Not Treated|1
6149381|NCT01097616|9785191|FG003|Double-Blind (DB) Treatment (TRT) Phase|Not Treated|0
6149382|NCT01097616|9785192|FG004|Double-Blind (DB) Treatment (TRT) Phase|Not Treated|0
6149383|NCT01097616|9785193|FG005|Double-Blind (DB) Treatment (TRT) Phase|Not Treated|0
6149384|NCT01097616|9785194|FG006|Double-Blind (DB) Treatment (TRT) Phase|Not Treated|0
6149385|NCT01097616|9785195|FG007|Double-Blind (DB) Treatment (TRT) Phase|Not Treated|0
6149386|NCT01097616|9785188|FG000|Optional DB EXT Phase|Adverse Event|0
6149387|NCT01097616|9785189|FG001|Optional DB EXT Phase|Adverse Event|7
6149388|NCT01097616|9785190|FG002|Optional DB EXT Phase|Adverse Event|2
6149389|NCT01097616|9785191|FG003|Optional DB EXT Phase|Adverse Event|0
6149390|NCT01097616|9785192|FG004|Optional DB EXT Phase|Adverse Event|0
6149391|NCT01097616|9785193|FG005|Optional DB EXT Phase|Adverse Event|0
6149392|NCT01097616|9785194|FG006|Optional DB EXT Phase|Adverse Event|0
6149393|NCT01097616|9785195|FG007|Optional DB EXT Phase|Adverse Event|0
6149394|NCT01097616|9785188|FG000|Optional DB EXT Phase|Withdrawal by Subject|12
6149395|NCT01097616|9785189|FG001|Optional DB EXT Phase|Withdrawal by Subject|6
6149396|NCT01097616|9785190|FG002|Optional DB EXT Phase|Withdrawal by Subject|3
6149397|NCT01097616|9785191|FG003|Optional DB EXT Phase|Withdrawal by Subject|0
6149398|NCT01097616|9785192|FG004|Optional DB EXT Phase|Withdrawal by Subject|0
6149399|NCT01097616|9785193|FG005|Optional DB EXT Phase|Withdrawal by Subject|0
6271921|NCT02169336|9974036|FG002|Overall Study|Withdrawal by Subject|0
6271922|NCT02169336|9974034|FG000|Overall Study|Physician Decision|0
6314264|NCT02709330|10046790|FG001|Overall Study|Death|0
6314265|NCT02709330|10046789|FG000|Overall Study|Lost to Follow-up|2
6314266|NCT02709330|10046790|FG001|Overall Study|Lost to Follow-up|0
6314267|NCT02709330|10046789|FG000|Overall Study|Physician Decision|2
6314268|NCT02709330|10046790|FG001|Overall Study|Physician Decision|0
6314269|NCT02709330|10046789|FG000|Overall Study|Withdrawal by Subject|4
6314270|NCT02709330|10046790|FG001|Overall Study|Withdrawal by Subject|0
6314271|NCT02709369|10046796|FG000|Overall Study|Lost to Follow-up|15
6314272|NCT02709369|10046796|FG000|Overall Study|Withdrawal by Subject|10
6314273|NCT02709369|10046796|FG000|Overall Study|Did not received intervention|2
6314274|NCT02709486|10046803|FG000|Overall Study|Adverse Event|2
6314275|NCT02709486|10046804|FG001|Overall Study|Adverse Event|5
6314276|NCT02709486|10046805|FG002|Overall Study|Adverse Event|3
6314277|NCT02709486|10046803|FG000|Overall Study|Death|0
6314278|NCT02709486|10046804|FG001|Overall Study|Death|0
6314279|NCT02709486|10046805|FG002|Overall Study|Death|2
6314280|NCT02709486|10046803|FG000|Overall Study|Insufficient clinical response|7
6314281|NCT02709486|10046804|FG001|Overall Study|Insufficient clinical response|3
6314282|NCT02709486|10046805|FG002|Overall Study|Insufficient clinical response|3
6149400|NCT01097616|9785194|FG006|Optional DB EXT Phase|Withdrawal by Subject|0
6149401|NCT01097616|9785195|FG007|Optional DB EXT Phase|Withdrawal by Subject|0
6149402|NCT01097616|9785188|FG000|Optional DB EXT Phase|Protocol Violation|0
6149403|NCT01097616|9785189|FG001|Optional DB EXT Phase|Protocol Violation|2
6149404|NCT01097616|9785190|FG002|Optional DB EXT Phase|Protocol Violation|3
6149405|NCT01097616|9785191|FG003|Optional DB EXT Phase|Protocol Violation|0
6149406|NCT01097616|9785192|FG004|Optional DB EXT Phase|Protocol Violation|0
6149407|NCT01097616|9785193|FG005|Optional DB EXT Phase|Protocol Violation|0
6149408|NCT01097616|9785194|FG006|Optional DB EXT Phase|Protocol Violation|0
6149409|NCT01097616|9785195|FG007|Optional DB EXT Phase|Protocol Violation|0
6149410|NCT01097616|9785188|FG000|Optional DB EXT Phase|Lost to Follow-up|1
6149411|NCT01097616|9785189|FG001|Optional DB EXT Phase|Lost to Follow-up|5
6149412|NCT01097616|9785190|FG002|Optional DB EXT Phase|Lost to Follow-up|1
6149413|NCT01097616|9785191|FG003|Optional DB EXT Phase|Lost to Follow-up|0
6149414|NCT01097616|9785192|FG004|Optional DB EXT Phase|Lost to Follow-up|0
6149415|NCT01097616|9785193|FG005|Optional DB EXT Phase|Lost to Follow-up|0
6149416|NCT01097616|9785194|FG006|Optional DB EXT Phase|Lost to Follow-up|0
6149417|NCT01097616|9785195|FG007|Optional DB EXT Phase|Lost to Follow-up|0
6149418|NCT01097616|9785188|FG000|Optional DB EXT Phase|Lack of Efficacy|1
6149419|NCT01097616|9785189|FG001|Optional DB EXT Phase|Lack of Efficacy|1
6149420|NCT01097616|9785190|FG002|Optional DB EXT Phase|Lack of Efficacy|1
6149421|NCT01097616|9785191|FG003|Optional DB EXT Phase|Lack of Efficacy|0
6149422|NCT01097616|9785192|FG004|Optional DB EXT Phase|Lack of Efficacy|0
6314283|NCT02709486|10046803|FG000|Overall Study|Lost to Follow-up|3
6314284|NCT02709486|10046804|FG001|Overall Study|Lost to Follow-up|2
6314285|NCT02709486|10046805|FG002|Overall Study|Lost to Follow-up|2
6149423|NCT01097616|9785193|FG005|Optional DB EXT Phase|Lack of Efficacy|0
6149424|NCT01097616|9785194|FG006|Optional DB EXT Phase|Lack of Efficacy|0
6149425|NCT01097616|9785195|FG007|Optional DB EXT Phase|Lack of Efficacy|0
6149426|NCT01097616|9785188|FG000|Optional DB EXT Phase|Physician Decision|1
6149427|NCT01097616|9785189|FG001|Optional DB EXT Phase|Physician Decision|0
6314286|NCT02709486|10046803|FG000|Overall Study|Other|0
6314287|NCT02709486|10046804|FG001|Overall Study|Other|2
6314288|NCT02709486|10046805|FG002|Overall Study|Other|3
6314289|NCT02709486|10046803|FG000|Overall Study|Withdrawal by Subject|32
6314290|NCT02709486|10046804|FG001|Overall Study|Withdrawal by Subject|22
6149428|NCT01097616|9785190|FG002|Optional DB EXT Phase|Physician Decision|0
6149429|NCT01097616|9785191|FG003|Optional DB EXT Phase|Physician Decision|0
6149430|NCT01097616|9785192|FG004|Optional DB EXT Phase|Physician Decision|0
6149431|NCT01097616|9785193|FG005|Optional DB EXT Phase|Physician Decision|0
6149432|NCT01097616|9785194|FG006|Optional DB EXT Phase|Physician Decision|0
6149433|NCT01097616|9785195|FG007|Optional DB EXT Phase|Physician Decision|0
6149434|NCT01097616|9785188|FG000|DB RO Phase|Adverse Event|0
6149435|NCT01097616|9785189|FG001|DB RO Phase|Adverse Event|0
6149436|NCT01097616|9785190|FG002|DB RO Phase|Adverse Event|0
6149437|NCT01097616|9785191|FG003|DB RO Phase|Adverse Event|0
6149438|NCT01097616|9785192|FG004|DB RO Phase|Adverse Event|0
6149439|NCT01097616|9785193|FG005|DB RO Phase|Adverse Event|0
6149440|NCT01097616|9785194|FG006|DB RO Phase|Adverse Event|1
6149441|NCT01097616|9785195|FG007|DB RO Phase|Adverse Event|0
6149442|NCT01097616|9785188|FG000|DB RO Phase|Withdrawal by Subject|0
6149443|NCT01097616|9785189|FG001|DB RO Phase|Withdrawal by Subject|0
6149444|NCT01097616|9785190|FG002|DB RO Phase|Withdrawal by Subject|0
6149445|NCT01097616|9785191|FG003|DB RO Phase|Withdrawal by Subject|0
6149446|NCT01097616|9785192|FG004|DB RO Phase|Withdrawal by Subject|0
6149447|NCT01097616|9785193|FG005|DB RO Phase|Withdrawal by Subject|1
6149448|NCT01097616|9785194|FG006|DB RO Phase|Withdrawal by Subject|0
6149449|NCT01097616|9785195|FG007|DB RO Phase|Withdrawal by Subject|0
6149450|NCT01097616|9785188|FG000|DB RO Phase|Lost to Follow-up|0
6149451|NCT01097616|9785189|FG001|DB RO Phase|Lost to Follow-up|0
6149452|NCT01097616|9785190|FG002|DB RO Phase|Lost to Follow-up|0
6149453|NCT01097616|9785191|FG003|DB RO Phase|Lost to Follow-up|1
6149454|NCT01097616|9785192|FG004|DB RO Phase|Lost to Follow-up|1
6149455|NCT01097616|9785193|FG005|DB RO Phase|Lost to Follow-up|0
6149456|NCT01097616|9785194|FG006|DB RO Phase|Lost to Follow-up|0
6149457|NCT01097616|9785195|FG007|DB RO Phase|Lost to Follow-up|1
6149458|NCT01097616|9785188|FG000|DB RO Phase|Not Treated in RO|0
6149459|NCT01097616|9785189|FG001|DB RO Phase|Not Treated in RO|0
6149460|NCT01097616|9785190|FG002|DB RO Phase|Not Treated in RO|0
6149461|NCT01097616|9785191|FG003|DB RO Phase|Not Treated in RO|0
6149462|NCT01097616|9785192|FG004|DB RO Phase|Not Treated in RO|0
6149463|NCT01097616|9785193|FG005|DB RO Phase|Not Treated in RO|1
6149464|NCT01097616|9785194|FG006|DB RO Phase|Not Treated in RO|0
6149465|NCT01097616|9785195|FG007|DB RO Phase|Not Treated in RO|0
6149466|NCT01097629|9785224|FG000|Double-Blind (DB) Treatment (TRT) Phase|Adverse Event|10
6149467|NCT01097629|9785225|FG001|Double-Blind (DB) Treatment (TRT) Phase|Adverse Event|19
6149468|NCT01097629|9785226|FG002|Double-Blind (DB) Treatment (TRT) Phase|Adverse Event|17
6149469|NCT01097629|9785227|FG003|Double-Blind (DB) Treatment (TRT) Phase|Adverse Event|0
6149470|NCT01097629|9785228|FG004|Double-Blind (DB) Treatment (TRT) Phase|Adverse Event|0
6149471|NCT01097629|9785229|FG005|Double-Blind (DB) Treatment (TRT) Phase|Adverse Event|0
6149472|NCT01097629|9785230|FG006|Double-Blind (DB) Treatment (TRT) Phase|Adverse Event|0
6149473|NCT01097629|9785231|FG007|Double-Blind (DB) Treatment (TRT) Phase|Adverse Event|0
6149474|NCT01097629|9785224|FG000|Double-Blind (DB) Treatment (TRT) Phase|Withdrawal by Subject|8
6149475|NCT01097629|9785225|FG001|Double-Blind (DB) Treatment (TRT) Phase|Withdrawal by Subject|9
6149476|NCT01097629|9785226|FG002|Double-Blind (DB) Treatment (TRT) Phase|Withdrawal by Subject|19
6149477|NCT01097629|9785227|FG003|Double-Blind (DB) Treatment (TRT) Phase|Withdrawal by Subject|0
6149478|NCT01097629|9785228|FG004|Double-Blind (DB) Treatment (TRT) Phase|Withdrawal by Subject|0
6149479|NCT01097629|9785229|FG005|Double-Blind (DB) Treatment (TRT) Phase|Withdrawal by Subject|0
6149480|NCT01097629|9785230|FG006|Double-Blind (DB) Treatment (TRT) Phase|Withdrawal by Subject|0
6149481|NCT01097629|9785231|FG007|Double-Blind (DB) Treatment (TRT) Phase|Withdrawal by Subject|0
6149482|NCT01097629|9785224|FG000|Double-Blind (DB) Treatment (TRT) Phase|Protocol Violation|5
6149483|NCT01097629|9785225|FG001|Double-Blind (DB) Treatment (TRT) Phase|Protocol Violation|4
6149484|NCT01097629|9785226|FG002|Double-Blind (DB) Treatment (TRT) Phase|Protocol Violation|8
6149485|NCT01097629|9785227|FG003|Double-Blind (DB) Treatment (TRT) Phase|Protocol Violation|0
6149486|NCT01097629|9785228|FG004|Double-Blind (DB) Treatment (TRT) Phase|Protocol Violation|0
6149487|NCT01097629|9785229|FG005|Double-Blind (DB) Treatment (TRT) Phase|Protocol Violation|0
6149488|NCT01097629|9785230|FG006|Double-Blind (DB) Treatment (TRT) Phase|Protocol Violation|0
6149489|NCT01097629|9785231|FG007|Double-Blind (DB) Treatment (TRT) Phase|Protocol Violation|0
6149490|NCT01097629|9785224|FG000|Double-Blind (DB) Treatment (TRT) Phase|Lost to Follow-up|2
6149491|NCT01097629|9785225|FG001|Double-Blind (DB) Treatment (TRT) Phase|Lost to Follow-up|4
6149492|NCT01097629|9785226|FG002|Double-Blind (DB) Treatment (TRT) Phase|Lost to Follow-up|1
6149493|NCT01097629|9785227|FG003|Double-Blind (DB) Treatment (TRT) Phase|Lost to Follow-up|0
6149494|NCT01097629|9785228|FG004|Double-Blind (DB) Treatment (TRT) Phase|Lost to Follow-up|0
6314291|NCT02709486|10046805|FG002|Overall Study|Withdrawal by Subject|32
6314292|NCT02709538|10046816|FG000|Overall Study|Adverse Event|13
6314293|NCT02709538|10046817|FG001|Overall Study|Adverse Event|2
6314294|NCT02709538|10046818|FG002|Overall Study|Adverse Event|3
6314295|NCT02709538|10046816|FG000|Overall Study|Lack of Efficacy|1
6314296|NCT02709538|10046817|FG001|Overall Study|Lack of Efficacy|0
6314297|NCT02709538|10046818|FG002|Overall Study|Lack of Efficacy|0
6314298|NCT02709538|10046816|FG000|Overall Study|Lost to Follow-up|24
6314299|NCT02709538|10046817|FG001|Overall Study|Lost to Follow-up|8
6314300|NCT02709538|10046818|FG002|Overall Study|Lost to Follow-up|4
6314301|NCT02709538|10046816|FG000|Overall Study|Physician Decision|1
6314302|NCT02709538|10046817|FG001|Overall Study|Physician Decision|0
6314303|NCT02709538|10046818|FG002|Overall Study|Physician Decision|0
6314304|NCT02709538|10046816|FG000|Overall Study|Withdrawal by Subject|40
6314305|NCT02709538|10046817|FG001|Overall Study|Withdrawal by Subject|7
6314306|NCT02709538|10046818|FG002|Overall Study|Withdrawal by Subject|4
6314307|NCT02709538|10046816|FG000|Overall Study|Non-compliance with study procedures|5
6314308|NCT02709538|10046817|FG001|Overall Study|Non-compliance with study procedures|0
6314309|NCT02709538|10046818|FG002|Overall Study|Non-compliance with study procedures|0
6314310|NCT02709538|10046816|FG000|Overall Study|Non-compliance with study drug|2
6314311|NCT02709538|10046817|FG001|Overall Study|Non-compliance with study drug|0
6314312|NCT02709538|10046818|FG002|Overall Study|Non-compliance with study drug|0
6314313|NCT02709538|10046816|FG000|Overall Study|Protocol deviation|10
6314314|NCT02709538|10046817|FG001|Overall Study|Protocol deviation|4
6314315|NCT02709538|10046818|FG002|Overall Study|Protocol deviation|4
6314316|NCT02709538|10046816|FG000|Overall Study|Withdrawal by Parent or Legal Guardian|1
6314317|NCT02709538|10046817|FG001|Overall Study|Withdrawal by Parent or Legal Guardian|0
6314318|NCT02709538|10046818|FG002|Overall Study|Withdrawal by Parent or Legal Guardian|0
6314319|NCT02709538|10046816|FG000|Overall Study|Other|16
6314320|NCT02709538|10046817|FG001|Overall Study|Other|7
6314321|NCT02709538|10046818|FG002|Overall Study|Other|5
6314322|NCT02709577|10046828|FG000|Overall Study|non-accommodating anatomy|0
6314323|NCT02709577|10046829|FG001|Overall Study|non-accommodating anatomy|1
6314324|NCT02709577|10046830|FG002|Overall Study|non-accommodating anatomy|0
6149495|NCT01097629|9785229|FG005|Double-Blind (DB) Treatment (TRT) Phase|Lost to Follow-up|0
6149496|NCT01097629|9785230|FG006|Double-Blind (DB) Treatment (TRT) Phase|Lost to Follow-up|0
6149497|NCT01097629|9785231|FG007|Double-Blind (DB) Treatment (TRT) Phase|Lost to Follow-up|0
6149498|NCT01097629|9785224|FG000|Double-Blind (DB) Treatment (TRT) Phase|Lack of Efficacy|7
6149499|NCT01097629|9785225|FG001|Double-Blind (DB) Treatment (TRT) Phase|Lack of Efficacy|4
6149500|NCT01097629|9785226|FG002|Double-Blind (DB) Treatment (TRT) Phase|Lack of Efficacy|8
6149501|NCT01097629|9785227|FG003|Double-Blind (DB) Treatment (TRT) Phase|Lack of Efficacy|0
6149502|NCT01097629|9785228|FG004|Double-Blind (DB) Treatment (TRT) Phase|Lack of Efficacy|0
6149503|NCT01097629|9785229|FG005|Double-Blind (DB) Treatment (TRT) Phase|Lack of Efficacy|0
6149504|NCT01097629|9785230|FG006|Double-Blind (DB) Treatment (TRT) Phase|Lack of Efficacy|0
6149505|NCT01097629|9785231|FG007|Double-Blind (DB) Treatment (TRT) Phase|Lack of Efficacy|0
6149506|NCT01097629|9785224|FG000|Double-Blind (DB) Treatment (TRT) Phase|Physician Decision|2
6149507|NCT01097629|9785225|FG001|Double-Blind (DB) Treatment (TRT) Phase|Physician Decision|1
6149508|NCT01097629|9785226|FG002|Double-Blind (DB) Treatment (TRT) Phase|Physician Decision|0
6149509|NCT01097629|9785227|FG003|Double-Blind (DB) Treatment (TRT) Phase|Physician Decision|0
6149510|NCT01097629|9785228|FG004|Double-Blind (DB) Treatment (TRT) Phase|Physician Decision|0
6149511|NCT01097629|9785229|FG005|Double-Blind (DB) Treatment (TRT) Phase|Physician Decision|0
6149512|NCT01097629|9785230|FG006|Double-Blind (DB) Treatment (TRT) Phase|Physician Decision|0
6149513|NCT01097629|9785231|FG007|Double-Blind (DB) Treatment (TRT) Phase|Physician Decision|0
6149514|NCT01097629|9785224|FG000|Double-Blind (DB) Treatment (TRT) Phase|Not Treated|1
6149515|NCT01097629|9785225|FG001|Double-Blind (DB) Treatment (TRT) Phase|Not Treated|5
6149516|NCT01097629|9785226|FG002|Double-Blind (DB) Treatment (TRT) Phase|Not Treated|4
6149517|NCT01097629|9785227|FG003|Double-Blind (DB) Treatment (TRT) Phase|Not Treated|0
6149518|NCT01097629|9785228|FG004|Double-Blind (DB) Treatment (TRT) Phase|Not Treated|0
6149519|NCT01097629|9785229|FG005|Double-Blind (DB) Treatment (TRT) Phase|Not Treated|0
6149520|NCT01097629|9785230|FG006|Double-Blind (DB) Treatment (TRT) Phase|Not Treated|0
6149521|NCT01097629|9785231|FG007|Double-Blind (DB) Treatment (TRT) Phase|Not Treated|0
6149522|NCT01097629|9785224|FG000|DB RO Phase|Withdrawal by Subject|0
6149523|NCT01097629|9785225|FG001|DB RO Phase|Withdrawal by Subject|0
6149524|NCT01097629|9785226|FG002|DB RO Phase|Withdrawal by Subject|0
6149525|NCT01097629|9785227|FG003|DB RO Phase|Withdrawal by Subject|0
6149526|NCT01097629|9785228|FG004|DB RO Phase|Withdrawal by Subject|0
6149527|NCT01097629|9785229|FG005|DB RO Phase|Withdrawal by Subject|0
6149528|NCT01097629|9785230|FG006|DB RO Phase|Withdrawal by Subject|0
6149529|NCT01097629|9785231|FG007|DB RO Phase|Withdrawal by Subject|1
6149530|NCT01097629|9785224|FG000|DB RO Phase|Protocol Violation|0
6149531|NCT01097629|9785225|FG001|DB RO Phase|Protocol Violation|0
6149532|NCT01097629|9785226|FG002|DB RO Phase|Protocol Violation|0
6149533|NCT01097629|9785227|FG003|DB RO Phase|Protocol Violation|1
6149534|NCT01097629|9785228|FG004|DB RO Phase|Protocol Violation|0
6149535|NCT01097629|9785229|FG005|DB RO Phase|Protocol Violation|1
6314325|NCT02709577|10046831|FG003|Overall Study|non-accommodating anatomy|0
6314326|NCT02709577|10046828|FG000|Overall Study|procedural complication|0
6149536|NCT01097629|9785230|FG006|DB RO Phase|Protocol Violation|1
6314327|NCT02709577|10046829|FG001|Overall Study|procedural complication|1
6314328|NCT02709577|10046830|FG002|Overall Study|procedural complication|0
6314329|NCT02709577|10046831|FG003|Overall Study|procedural complication|0
6149537|NCT01097629|9785231|FG007|DB RO Phase|Protocol Violation|0
6149538|NCT01097629|9785224|FG000|DB RO Phase|Lost to Follow-up|0
6149539|NCT01097629|9785225|FG001|DB RO Phase|Lost to Follow-up|0
6149540|NCT01097629|9785226|FG002|DB RO Phase|Lost to Follow-up|0
6149541|NCT01097629|9785227|FG003|DB RO Phase|Lost to Follow-up|0
6149542|NCT01097629|9785228|FG004|DB RO Phase|Lost to Follow-up|0
6314330|NCT02709577|10046828|FG000|Overall Study|Withdrawal by Subject|2
6314331|NCT02709577|10046829|FG001|Overall Study|Withdrawal by Subject|3
6314332|NCT02709577|10046830|FG002|Overall Study|Withdrawal by Subject|2
6314333|NCT02709577|10046831|FG003|Overall Study|Withdrawal by Subject|0
6314334|NCT02709746|10046861|FG000|Phase A (Single-blind Treatment Period)|Protocol Violation|4
6314335|NCT02709746|10046862|FG001|Phase A (Single-blind Treatment Period)|Protocol Violation|0
6314336|NCT02709746|10046863|FG002|Phase A (Single-blind Treatment Period)|Protocol Violation|0
6314337|NCT02709746|10046864|FG003|Phase A (Single-blind Treatment Period)|Protocol Violation|0
6314338|NCT02709746|10046865|FG004|Phase A (Single-blind Treatment Period)|Protocol Violation|0
6314339|NCT02709746|10046861|FG000|Phase A (Single-blind Treatment Period)|Not sepcified|14
6314340|NCT02709746|10046862|FG001|Phase A (Single-blind Treatment Period)|Not sepcified|0
6314341|NCT02709746|10046863|FG002|Phase A (Single-blind Treatment Period)|Not sepcified|0
6314342|NCT02709746|10046864|FG003|Phase A (Single-blind Treatment Period)|Not sepcified|0
6314343|NCT02709746|10046865|FG004|Phase A (Single-blind Treatment Period)|Not sepcified|0
6314344|NCT02709746|10046861|FG000|Phase A (Single-blind Treatment Period)|Non-compliance with study drug|12
6314345|NCT02709746|10046862|FG001|Phase A (Single-blind Treatment Period)|Non-compliance with study drug|0
6314346|NCT02709746|10046863|FG002|Phase A (Single-blind Treatment Period)|Non-compliance with study drug|0
6314347|NCT02709746|10046864|FG003|Phase A (Single-blind Treatment Period)|Non-compliance with study drug|0
6149543|NCT01097629|9785229|FG005|DB RO Phase|Lost to Follow-up|0
6149544|NCT01097629|9785230|FG006|DB RO Phase|Lost to Follow-up|2
6149545|NCT01097629|9785231|FG007|DB RO Phase|Lost to Follow-up|0
6149546|NCT01097655|9785263|FG000|Overall Study|Withdrawal by Subject|1
6149547|NCT01097655|9785263|FG000|Overall Study|Subject Documented Twice|1
6149548|NCT01097655|9785263|FG000|Overall Study|Did Not Meet Inclusion Criteria|8
6149549|NCT01097668|9785269|FG000|Overall Study|Withdrawal by Subject|1
6149550|NCT01097668|9785270|FG001|Overall Study|Withdrawal by Subject|2
6149551|NCT01097668|9785269|FG000|Overall Study|Lost to Follow-up|1
6149552|NCT01097668|9785270|FG001|Overall Study|Lost to Follow-up|0
6149553|NCT01097694|9785282|FG000|Overall Study|Adverse Event|5
6149554|NCT01097694|9785283|FG001|Overall Study|Adverse Event|0
6149555|NCT01097694|9785282|FG000|Overall Study|Lost to Follow-up|0
6149556|NCT01097694|9785283|FG001|Overall Study|Lost to Follow-up|3
6149557|NCT01097694|9785282|FG000|Overall Study|Withdrawal by Subject|3
6149558|NCT01097694|9785283|FG001|Overall Study|Withdrawal by Subject|1
6149559|NCT01097707|9785294|FG000|Overall Study|Abnormal Lab/Electrocardiogram Result|0
6149560|NCT01097707|9785295|FG001|Overall Study|Abnormal Lab/Electrocardiogram Result|0
6149561|NCT01097707|9785296|FG002|Overall Study|Abnormal Lab/Electrocardiogram Result|1
6149562|NCT01097707|9785297|FG003|Overall Study|Abnormal Lab/Electrocardiogram Result|1
6149563|NCT01097707|9785298|FG004|Overall Study|Abnormal Lab/Electrocardiogram Result|1
6149564|NCT01097707|9785294|FG000|Overall Study|Adverse Event|4
6149565|NCT01097707|9785295|FG001|Overall Study|Adverse Event|2
6149566|NCT01097707|9785296|FG002|Overall Study|Adverse Event|3
6149567|NCT01097707|9785297|FG003|Overall Study|Adverse Event|1
6149568|NCT01097707|9785298|FG004|Overall Study|Adverse Event|3
6149569|NCT01097707|9785294|FG000|Overall Study|Entry Criteria Not Met|2
6149570|NCT01097707|9785295|FG001|Overall Study|Entry Criteria Not Met|1
6149571|NCT01097707|9785296|FG002|Overall Study|Entry Criteria Not Met|1
6149572|NCT01097707|9785297|FG003|Overall Study|Entry Criteria Not Met|0
6149573|NCT01097707|9785298|FG004|Overall Study|Entry Criteria Not Met|1
6149574|NCT01097707|9785294|FG000|Overall Study|Lack of Efficacy|1
6149575|NCT01097707|9785295|FG001|Overall Study|Lack of Efficacy|0
6149576|NCT01097707|9785296|FG002|Overall Study|Lack of Efficacy|0
6149577|NCT01097707|9785297|FG003|Overall Study|Lack of Efficacy|1
6149578|NCT01097707|9785298|FG004|Overall Study|Lack of Efficacy|0
6149579|NCT01097707|9785294|FG000|Overall Study|Lost to Follow-up|1
6149580|NCT01097707|9785295|FG001|Overall Study|Lost to Follow-up|1
6149581|NCT01097707|9785296|FG002|Overall Study|Lost to Follow-up|2
6149582|NCT01097707|9785297|FG003|Overall Study|Lost to Follow-up|0
6149583|NCT01097707|9785298|FG004|Overall Study|Lost to Follow-up|3
6149584|NCT01097707|9785294|FG000|Overall Study|Protocol Violation|2
6149585|NCT01097707|9785295|FG001|Overall Study|Protocol Violation|2
6149586|NCT01097707|9785296|FG002|Overall Study|Protocol Violation|3
6149587|NCT01097707|9785297|FG003|Overall Study|Protocol Violation|2
6149588|NCT01097707|9785298|FG004|Overall Study|Protocol Violation|2
6149589|NCT01097707|9785294|FG000|Overall Study|Sponsor Decision|31
6149590|NCT01097707|9785295|FG001|Overall Study|Sponsor Decision|31
6149591|NCT01097707|9785296|FG002|Overall Study|Sponsor Decision|34
6149592|NCT01097707|9785297|FG003|Overall Study|Sponsor Decision|35
6149593|NCT01097707|9785298|FG004|Overall Study|Sponsor Decision|36
6149594|NCT01097707|9785294|FG000|Overall Study|Withdrawal by Subject|3
6314348|NCT02709746|10046865|FG004|Phase A (Single-blind Treatment Period)|Non-compliance with study drug|0
6314349|NCT02709746|10046861|FG000|Phase A (Single-blind Treatment Period)|Lack of Efficacy|7
6314350|NCT02709746|10046862|FG001|Phase A (Single-blind Treatment Period)|Lack of Efficacy|0
6314351|NCT02709746|10046863|FG002|Phase A (Single-blind Treatment Period)|Lack of Efficacy|0
6314352|NCT02709746|10046864|FG003|Phase A (Single-blind Treatment Period)|Lack of Efficacy|0
6314353|NCT02709746|10046865|FG004|Phase A (Single-blind Treatment Period)|Lack of Efficacy|0
6314354|NCT02709746|10046861|FG000|Phase A (Single-blind Treatment Period)|Adverse Event|2
6314355|NCT02709746|10046862|FG001|Phase A (Single-blind Treatment Period)|Adverse Event|0
6314356|NCT02709746|10046863|FG002|Phase A (Single-blind Treatment Period)|Adverse Event|0
6314357|NCT02709746|10046864|FG003|Phase A (Single-blind Treatment Period)|Adverse Event|0
6314358|NCT02709746|10046865|FG004|Phase A (Single-blind Treatment Period)|Adverse Event|0
6314359|NCT02709746|10046861|FG000|Phase A (Single-blind Treatment Period)|Withdrawal by Subject|12
6314360|NCT02709746|10046862|FG001|Phase A (Single-blind Treatment Period)|Withdrawal by Subject|0
6314361|NCT02709746|10046863|FG002|Phase A (Single-blind Treatment Period)|Withdrawal by Subject|0
6314362|NCT02709746|10046864|FG003|Phase A (Single-blind Treatment Period)|Withdrawal by Subject|0
6314363|NCT02709746|10046865|FG004|Phase A (Single-blind Treatment Period)|Withdrawal by Subject|0
6314364|NCT02709746|10046861|FG000|Phase A (Single-blind Treatment Period)|Enrolled not treated|7
6149595|NCT01097707|9785295|FG001|Overall Study|Withdrawal by Subject|6
6149596|NCT01097707|9785296|FG002|Overall Study|Withdrawal by Subject|1
6149597|NCT01097707|9785297|FG003|Overall Study|Withdrawal by Subject|4
6149598|NCT01097707|9785298|FG004|Overall Study|Withdrawal by Subject|3
6149599|NCT01097707|9785294|FG000|Overall Study|Reason unknown|0
6149600|NCT01097707|9785295|FG001|Overall Study|Reason unknown|0
6149601|NCT01097707|9785296|FG002|Overall Study|Reason unknown|0
6149602|NCT01097707|9785297|FG003|Overall Study|Reason unknown|0
6149603|NCT01097707|9785298|FG004|Overall Study|Reason unknown|1
6149604|NCT01097863|9785323|FG000|Overall Study|Discomfort|1
6149605|NCT01097863|9785324|FG001|Overall Study|Discomfort|0
6149606|NCT01097863|9785325|FG002|Overall Study|Discomfort|1
6149607|NCT01097863|9785323|FG000|Overall Study|Did not return for final visit|0
6149608|NCT01097863|9785324|FG001|Overall Study|Did not return for final visit|0
6149609|NCT01097863|9785325|FG002|Overall Study|Did not return for final visit|1
6191382|NCT01422304|9848165|FG000|Overall Study|Did Not Meet Protocol Eligibility|0
6191383|NCT01422304|9848166|FG001|Overall Study|Did Not Meet Protocol Eligibility|2
6191384|NCT01422304|9848165|FG000|Overall Study|Not Treated|3
6191385|NCT01422304|9848166|FG001|Overall Study|Not Treated|11
6191386|NCT01422382|9848181|FG000|NK-104 4mg QD and Diltiazem 240 mg QD|personal reasons|1
6191387|NCT01422408|9848185|FG000|Overall Study|Adverse Event|1
6191388|NCT01422408|9848185|FG000|Overall Study|Withdrawal by Subject|3
6191389|NCT01422538|9848205|FG000|Overall Study|Lost to Follow-up|0
6191390|NCT01422538|9848206|FG001|Overall Study|Lost to Follow-up|1
6191391|NCT01422538|9848207|FG002|Overall Study|Lost to Follow-up|1
6191392|NCT01422538|9848205|FG000|Overall Study|Missed visit|0
6191393|NCT01422538|9848206|FG001|Overall Study|Missed visit|1
6191394|NCT01422538|9848207|FG002|Overall Study|Missed visit|1
6191395|NCT01422720|9848216|FG000|Overall Study|Adverse Event|16
6191396|NCT01422720|9848216|FG000|Overall Study|Lack of Efficacy|1
6191397|NCT01422720|9848216|FG000|Overall Study|Withdrawal by Subject|4
6191398|NCT01422720|9848216|FG000|Overall Study|Ineligibility|1
6191399|NCT01422824|9848224|FG000|Overall Study|Case record form not evaluated|1
6191400|NCT01422824|9848224|FG000|Overall Study|Lost to Follow-up|37
6191401|NCT01422850|9848228|FG000|Overall Study|Physician Decision|3
6191402|NCT01422876|9848244|FG000|Week 24|Lost to Follow-up|1
6191403|NCT01422876|9848245|FG001|Week 24|Lost to Follow-up|1
6191404|NCT01422876|9848246|FG002|Week 24|Lost to Follow-up|2
6191405|NCT01422876|9848247|FG003|Week 24|Lost to Follow-up|4
6191406|NCT01422876|9848248|FG004|Week 24|Lost to Follow-up|2
6191407|NCT01422876|9848249|FG005|Week 24|Lost to Follow-up|0
6191408|NCT01422876|9848250|FG006|Week 24|Lost to Follow-up|1
6191409|NCT01422876|9848251|FG007|Week 24|Lost to Follow-up|3
6191410|NCT01422876|9848252|FG008|Week 24|Lost to Follow-up|3
6191411|NCT01422876|9848253|FG009|Week 24|Lost to Follow-up|4
6191412|NCT01422876|9848244|FG000|Week 24|Consent withdrawn|5
6191413|NCT01422876|9848245|FG001|Week 24|Consent withdrawn|1
6191414|NCT01422876|9848246|FG002|Week 24|Consent withdrawn|3
6191415|NCT01422876|9848247|FG003|Week 24|Consent withdrawn|4
6191416|NCT01422876|9848248|FG004|Week 24|Consent withdrawn|5
6314365|NCT02709746|10046862|FG001|Phase A (Single-blind Treatment Period)|Enrolled not treated|0
6191417|NCT01422876|9848249|FG005|Week 24|Consent withdrawn|6
6191418|NCT01422876|9848250|FG006|Week 24|Consent withdrawn|5
6191419|NCT01422876|9848251|FG007|Week 24|Consent withdrawn|4
6191420|NCT01422876|9848252|FG008|Week 24|Consent withdrawn|3
6191421|NCT01422876|9848253|FG009|Week 24|Consent withdrawn|6
6191422|NCT01422876|9848244|FG000|Week 24|Death|0
6191423|NCT01422876|9848245|FG001|Week 24|Death|1
6191424|NCT01422876|9848246|FG002|Week 24|Death|0
6191425|NCT01422876|9848247|FG003|Week 24|Death|0
6191426|NCT01422876|9848248|FG004|Week 24|Death|0
6191427|NCT01422876|9848249|FG005|Week 24|Death|0
6191428|NCT01422876|9848250|FG006|Week 24|Death|0
6191429|NCT01422876|9848251|FG007|Week 24|Death|0
6191430|NCT01422876|9848252|FG008|Week 24|Death|0
6191431|NCT01422876|9848253|FG009|Week 24|Death|0
6191432|NCT01422876|9848244|FG000|Week 52|Lost to Follow-up|3
6314366|NCT02709746|10046863|FG002|Phase A (Single-blind Treatment Period)|Enrolled not treated|0
6314367|NCT02709746|10046864|FG003|Phase A (Single-blind Treatment Period)|Enrolled not treated|0
6314368|NCT02709746|10046865|FG004|Phase A (Single-blind Treatment Period)|Enrolled not treated|0
6314369|NCT02709746|10046861|FG000|Phase A (Single-blind Treatment Period)|Lost to Follow-up|7
6314370|NCT02709746|10046862|FG001|Phase A (Single-blind Treatment Period)|Lost to Follow-up|0
6314371|NCT02709746|10046863|FG002|Phase A (Single-blind Treatment Period)|Lost to Follow-up|0
6314372|NCT02709746|10046864|FG003|Phase A (Single-blind Treatment Period)|Lost to Follow-up|0
6314373|NCT02709746|10046865|FG004|Phase A (Single-blind Treatment Period)|Lost to Follow-up|0
6314374|NCT02709746|10046861|FG000|Phase A (Single-blind Treatment Period)|Do not fulfill rand criteria for DBT|103
6314375|NCT02709746|10046862|FG001|Phase A (Single-blind Treatment Period)|Do not fulfill rand criteria for DBT|0
6314376|NCT02709746|10046863|FG002|Phase A (Single-blind Treatment Period)|Do not fulfill rand criteria for DBT|0
6314377|NCT02709746|10046864|FG003|Phase A (Single-blind Treatment Period)|Do not fulfill rand criteria for DBT|0
6314378|NCT02709746|10046865|FG004|Phase A (Single-blind Treatment Period)|Do not fulfill rand criteria for DBT|0
6314379|NCT02709746|10046861|FG000|Phase B (Double-blind Treatment Period)|Protocol Violation|0
6314380|NCT02709746|10046862|FG001|Phase B (Double-blind Treatment Period)|Protocol Violation|1
6314381|NCT02709746|10046863|FG002|Phase B (Double-blind Treatment Period)|Protocol Violation|0
6314382|NCT02709746|10046864|FG003|Phase B (Double-blind Treatment Period)|Protocol Violation|0
6314383|NCT02709746|10046865|FG004|Phase B (Double-blind Treatment Period)|Protocol Violation|2
6149610|NCT01098097|9785370|FG000|Overall Study|Adverse Event|17
6149611|NCT01098097|9785370|FG000|Overall Study|Lost to Follow-up|18
6149612|NCT01098097|9785370|FG000|Overall Study|Status unknown|16
6149613|NCT01098097|9785370|FG000|Overall Study|No reason reported|31
6149614|NCT01098162|9785374|FG000|Overall Study|Adverse Event|37
6149615|NCT01098162|9785374|FG000|Overall Study|Lack of Efficacy|4
6149616|NCT01098162|9785374|FG000|Overall Study|Wish of Patient|7
6149617|NCT01098162|9785374|FG000|Overall Study|Lost to Follow-up|9
6149618|NCT01098162|9785374|FG000|Overall Study|Lack of Efficacy & Wish of Patient|5
6149619|NCT01098162|9785374|FG000|Overall Study|Adverse Event & Lack of Efficacy|6
6149620|NCT01098162|9785374|FG000|Overall Study|Adverse Event & Wish of Patient|13
6149621|NCT01098162|9785374|FG000|Overall Study|Adverse Event & Lost to Follow-up|2
6149622|NCT01098162|9785374|FG000|Overall Study|AE & Lack of Efficacy & Wish of Patient|1
6149623|NCT01098162|9785374|FG000|Overall Study|Wish of Patient & Lost to Follow-up|1
6149624|NCT01098162|9785374|FG000|Overall Study|Other Reason|1
6149625|NCT01098162|9785374|FG000|Overall Study|Reason Unknown|26
6149626|NCT01098240|9785378|FG000|Open-Label Phase|Study Terminated by Sponsor|27
6149627|NCT01098240|9785379|FG001|Open-Label Phase|Study Terminated by Sponsor|0
6149628|NCT01098240|9785380|FG002|Open-Label Phase|Study Terminated by Sponsor|0
6149629|NCT01098240|9785378|FG000|Open-Label Phase|Protocol Violation|4
6149630|NCT01098240|9785379|FG001|Open-Label Phase|Protocol Violation|0
6149631|NCT01098240|9785380|FG002|Open-Label Phase|Protocol Violation|0
6149632|NCT01098240|9785378|FG000|Open-Label Phase|Lost to Follow-up|13
6149633|NCT01098240|9785379|FG001|Open-Label Phase|Lost to Follow-up|0
6149634|NCT01098240|9785380|FG002|Open-Label Phase|Lost to Follow-up|0
6149635|NCT01098240|9785378|FG000|Open-Label Phase|Other|19
6149636|NCT01098240|9785379|FG001|Open-Label Phase|Other|0
6149637|NCT01098240|9785380|FG002|Open-Label Phase|Other|0
6149638|NCT01098240|9785378|FG000|Open-Label Phase|Did Not Meet Entrance Criteria|50
6149639|NCT01098240|9785379|FG001|Open-Label Phase|Did Not Meet Entrance Criteria|0
6149640|NCT01098240|9785380|FG002|Open-Label Phase|Did Not Meet Entrance Criteria|0
6149641|NCT01098240|9785378|FG000|Open-Label Phase|Pregnancy|1
6149642|NCT01098240|9785379|FG001|Open-Label Phase|Pregnancy|0
6149643|NCT01098240|9785380|FG002|Open-Label Phase|Pregnancy|0
6149644|NCT01098240|9785378|FG000|Open-Label Phase|Withdrawal by Subject|9
6149645|NCT01098240|9785379|FG001|Open-Label Phase|Withdrawal by Subject|0
6149646|NCT01098240|9785380|FG002|Open-Label Phase|Withdrawal by Subject|0
6149647|NCT01098240|9785378|FG000|Open-Label Phase|Adverse Event|12
6149648|NCT01098240|9785379|FG001|Open-Label Phase|Adverse Event|0
6149649|NCT01098240|9785380|FG002|Open-Label Phase|Adverse Event|0
6149650|NCT01098240|9785378|FG000|Double-Blind Phase|Study Terminated by Sponsor|0
6149651|NCT01098240|9785379|FG001|Double-Blind Phase|Study Terminated by Sponsor|5
6149652|NCT01098240|9785380|FG002|Double-Blind Phase|Study Terminated by Sponsor|8
6149653|NCT01098240|9785378|FG000|Double-Blind Phase|Protocol Violation|0
6149654|NCT01098240|9785379|FG001|Double-Blind Phase|Protocol Violation|2
6149655|NCT01098240|9785380|FG002|Double-Blind Phase|Protocol Violation|4
6149656|NCT01098240|9785378|FG000|Double-Blind Phase|Lost to Follow-up|0
6149657|NCT01098240|9785379|FG001|Double-Blind Phase|Lost to Follow-up|2
6149658|NCT01098240|9785380|FG002|Double-Blind Phase|Lost to Follow-up|0
6149659|NCT01098240|9785378|FG000|Double-Blind Phase|Other|0
6149660|NCT01098240|9785379|FG001|Double-Blind Phase|Other|2
6149661|NCT01098240|9785380|FG002|Double-Blind Phase|Other|2
6149662|NCT01098240|9785378|FG000|Double-Blind Phase|Did Not Meet Entrance Criteria|0
6149663|NCT01098240|9785379|FG001|Double-Blind Phase|Did Not Meet Entrance Criteria|1
6149664|NCT01098240|9785380|FG002|Double-Blind Phase|Did Not Meet Entrance Criteria|0
6149665|NCT01098240|9785378|FG000|Double-Blind Phase|Insufficient Clinical Response|0
6149666|NCT01098240|9785379|FG001|Double-Blind Phase|Insufficient Clinical Response|1
6149667|NCT01098240|9785380|FG002|Double-Blind Phase|Insufficient Clinical Response|2
6314384|NCT02709746|10046861|FG000|Phase B (Double-blind Treatment Period)|Other|0
6314385|NCT02709746|10046862|FG001|Phase B (Double-blind Treatment Period)|Other|6
6314386|NCT02709746|10046863|FG002|Phase B (Double-blind Treatment Period)|Other|5
6314387|NCT02709746|10046864|FG003|Phase B (Double-blind Treatment Period)|Other|6
6314388|NCT02709746|10046865|FG004|Phase B (Double-blind Treatment Period)|Other|7
6314389|NCT02709746|10046861|FG000|Phase B (Double-blind Treatment Period)|Non-compliance with study drug|0
6314390|NCT02709746|10046862|FG001|Phase B (Double-blind Treatment Period)|Non-compliance with study drug|1
6314391|NCT02709746|10046863|FG002|Phase B (Double-blind Treatment Period)|Non-compliance with study drug|4
6314392|NCT02709746|10046864|FG003|Phase B (Double-blind Treatment Period)|Non-compliance with study drug|1
6314393|NCT02709746|10046865|FG004|Phase B (Double-blind Treatment Period)|Non-compliance with study drug|0
6314394|NCT02709746|10046861|FG000|Phase B (Double-blind Treatment Period)|Lack of Efficacy|0
6314395|NCT02709746|10046862|FG001|Phase B (Double-blind Treatment Period)|Lack of Efficacy|3
6314396|NCT02709746|10046863|FG002|Phase B (Double-blind Treatment Period)|Lack of Efficacy|0
6314397|NCT02709746|10046864|FG003|Phase B (Double-blind Treatment Period)|Lack of Efficacy|1
6314398|NCT02709746|10046865|FG004|Phase B (Double-blind Treatment Period)|Lack of Efficacy|2
6314399|NCT02709746|10046861|FG000|Phase B (Double-blind Treatment Period)|Adverse Event|0
6314400|NCT02709746|10046862|FG001|Phase B (Double-blind Treatment Period)|Adverse Event|4
6149668|NCT01098240|9785378|FG000|Double-Blind Phase|Withdrawal by Subject|0
6149669|NCT01098240|9785379|FG001|Double-Blind Phase|Withdrawal by Subject|1
6149670|NCT01098240|9785380|FG002|Double-Blind Phase|Withdrawal by Subject|3
6149671|NCT01098240|9785378|FG000|Double-Blind Phase|Adverse Event|0
6149672|NCT01098240|9785379|FG001|Double-Blind Phase|Adverse Event|3
6149673|NCT01098240|9785380|FG002|Double-Blind Phase|Adverse Event|3
6149674|NCT01098266|9785398|FG000|Overall Study|Physician Decision|1
6149675|NCT01098266|9785399|FG001|Overall Study|Physician Decision|0
6149676|NCT01098266|9785398|FG000|Overall Study|Death|3
6149677|NCT01098266|9785399|FG001|Overall Study|Death|2
6149678|NCT01098266|9785398|FG000|Overall Study|Withdrawal by Subject|3
6149679|NCT01098266|9785399|FG001|Overall Study|Withdrawal by Subject|5
6149680|NCT01098305|9785407|FG000|Overall Study|Lost to Follow-up|31
6149681|NCT01098305|9785408|FG001|Overall Study|Lost to Follow-up|33
6149682|NCT01098461|9785435|FG000|Treatment Period (TP) (16 Weeks)|Persistent Hypoglycemia|10
6149683|NCT01098461|9785436|FG001|Treatment Period (TP) (16 Weeks)|Persistent Hypoglycemia|2
6149684|NCT01098461|9785437|FG002|Treatment Period (TP) (16 Weeks)|Persistent Hypoglycemia|0
6149685|NCT01098461|9785438|FG003|Treatment Period (TP) (16 Weeks)|Persistent Hypoglycemia|0
6149686|NCT01098461|9785435|FG000|Treatment Period (TP) (16 Weeks)|Adverse Event|1
6149687|NCT01098461|9785436|FG001|Treatment Period (TP) (16 Weeks)|Adverse Event|2
6149688|NCT01098461|9785437|FG002|Treatment Period (TP) (16 Weeks)|Adverse Event|1
6149689|NCT01098461|9785438|FG003|Treatment Period (TP) (16 Weeks)|Adverse Event|3
6149690|NCT01098461|9785435|FG000|Treatment Period (TP) (16 Weeks)|Withdrawal by Subject|1
6149691|NCT01098461|9785436|FG001|Treatment Period (TP) (16 Weeks)|Withdrawal by Subject|2
6149692|NCT01098461|9785437|FG002|Treatment Period (TP) (16 Weeks)|Withdrawal by Subject|0
6149693|NCT01098461|9785438|FG003|Treatment Period (TP) (16 Weeks)|Withdrawal by Subject|0
6149694|NCT01098461|9785435|FG000|Treatment Period (TP) (16 Weeks)|Transferred to Oita (Japan)|0
6149695|NCT01098461|9785436|FG001|Treatment Period (TP) (16 Weeks)|Transferred to Oita (Japan)|1
6149696|NCT01098461|9785437|FG002|Treatment Period (TP) (16 Weeks)|Transferred to Oita (Japan)|0
6149697|NCT01098461|9785438|FG003|Treatment Period (TP) (16 Weeks)|Transferred to Oita (Japan)|0
6149698|NCT01098461|9785435|FG000|Follow-up (FU) Period (8 Weeks)|Withdrawal by Subject|0
6149699|NCT01098461|9785436|FG001|Follow-up (FU) Period (8 Weeks)|Withdrawal by Subject|1
6149700|NCT01098461|9785437|FG002|Follow-up (FU) Period (8 Weeks)|Withdrawal by Subject|0
6149701|NCT01098461|9785438|FG003|Follow-up (FU) Period (8 Weeks)|Withdrawal by Subject|0
6149702|NCT01098461|9785435|FG000|Follow-up (FU) Period (8 Weeks)|Transferred to Oita (Japan)|0
6149703|NCT01098461|9785436|FG001|Follow-up (FU) Period (8 Weeks)|Transferred to Oita (Japan)|1
6149704|NCT01098461|9785437|FG002|Follow-up (FU) Period (8 Weeks)|Transferred to Oita (Japan)|0
6149705|NCT01098461|9785438|FG003|Follow-up (FU) Period (8 Weeks)|Transferred to Oita (Japan)|0
6149706|NCT01098461|9785435|FG000|Follow-up (FU) Period (8 Weeks)|Follow-up Not Conducted Due to Earthquak|0
6149707|NCT01098461|9785436|FG001|Follow-up (FU) Period (8 Weeks)|Follow-up Not Conducted Due to Earthquak|1
6149708|NCT01098461|9785437|FG002|Follow-up (FU) Period (8 Weeks)|Follow-up Not Conducted Due to Earthquak|1
6149709|NCT01098461|9785438|FG003|Follow-up (FU) Period (8 Weeks)|Follow-up Not Conducted Due to Earthquak|0
6149710|NCT01098474|9785455|FG000|Active Phase|Other|0
6149711|NCT01098474|9785456|FG001|Active Phase|Other|0
6149712|NCT01098474|9785457|FG002|Active Phase|Other|3
6149713|NCT01098474|9785458|FG003|Active Phase|Other|0
6149714|NCT01098474|9785459|FG004|Active Phase|Other|0
6149715|NCT01098474|9785460|FG005|Active Phase|Other|0
6149716|NCT01098474|9785455|FG000|Active Phase|Withdrawal by Subject|1
6149717|NCT01098474|9785456|FG001|Active Phase|Withdrawal by Subject|1
6149718|NCT01098474|9785457|FG002|Active Phase|Withdrawal by Subject|2
6149719|NCT01098474|9785458|FG003|Active Phase|Withdrawal by Subject|0
6314401|NCT02709746|10046863|FG002|Phase B (Double-blind Treatment Period)|Adverse Event|8
6040240|NCT00369824|9638043|FG000|Overall Study|Withdrawal by Subject|9
6040241|NCT00369824|9638044|FG001|Overall Study|Withdrawal by Subject|5
6040242|NCT00369824|9638045|FG002|Overall Study|Withdrawal by Subject|5
6040243|NCT00369824|9638046|FG003|Overall Study|Withdrawal by Subject|4
6040244|NCT00369824|9638047|FG004|Overall Study|Withdrawal by Subject|6
6040245|NCT00369824|9638048|FG005|Overall Study|Withdrawal by Subject|2
6040246|NCT00369824|9638043|FG000|Overall Study|Lost to Follow-up|6
6040247|NCT00369824|9638044|FG001|Overall Study|Lost to Follow-up|11
6040248|NCT00369824|9638045|FG002|Overall Study|Lost to Follow-up|7
6040249|NCT00369824|9638046|FG003|Overall Study|Lost to Follow-up|8
6040250|NCT00369824|9638047|FG004|Overall Study|Lost to Follow-up|9
6040251|NCT00369824|9638048|FG005|Overall Study|Lost to Follow-up|6
6040252|NCT00369824|9638043|FG000|Overall Study|Other|0
6040253|NCT00369824|9638044|FG001|Overall Study|Other|0
6040254|NCT00369824|9638045|FG002|Overall Study|Other|0
6040255|NCT00369824|9638046|FG003|Overall Study|Other|2
6040256|NCT00369824|9638047|FG004|Overall Study|Other|1
6040257|NCT00369824|9638048|FG005|Overall Study|Other|3
6040258|NCT00369915|9638064|FG000|Overall Study|expected side effects|2
6040259|NCT00369915|9638065|FG001|Overall Study|expected side effects|1
6040260|NCT00369915|9638064|FG000|Overall Study|Withdrawal by Subject|4
6040261|NCT00369915|9638065|FG001|Overall Study|Withdrawal by Subject|1
6040262|NCT00369915|9638064|FG000|Overall Study|W/drawl by investigators|0
6040263|NCT00369915|9638065|FG001|Overall Study|W/drawl by investigators|1
6040264|NCT00369941|9638086|FG000|Overall Study|Never Treated|1
6040265|NCT00369941|9638087|FG001|Overall Study|Never Treated|2
6149720|NCT01098474|9785459|FG004|Active Phase|Withdrawal by Subject|0
6149721|NCT01098474|9785460|FG005|Active Phase|Withdrawal by Subject|0
6149722|NCT01098474|9785455|FG000|Active Phase|Lost to Follow-up|1
6149723|NCT01098474|9785456|FG001|Active Phase|Lost to Follow-up|0
6149724|NCT01098474|9785457|FG002|Active Phase|Lost to Follow-up|0
6149725|NCT01098474|9785458|FG003|Active Phase|Lost to Follow-up|0
6314402|NCT02709746|10046864|FG003|Phase B (Double-blind Treatment Period)|Adverse Event|5
6314403|NCT02709746|10046865|FG004|Phase B (Double-blind Treatment Period)|Adverse Event|2
6314404|NCT02709746|10046861|FG000|Phase B (Double-blind Treatment Period)|Withdrawal by Subject|0
6314405|NCT02709746|10046862|FG001|Phase B (Double-blind Treatment Period)|Withdrawal by Subject|2
6314406|NCT02709746|10046863|FG002|Phase B (Double-blind Treatment Period)|Withdrawal by Subject|2
6314407|NCT02709746|10046864|FG003|Phase B (Double-blind Treatment Period)|Withdrawal by Subject|2
6314408|NCT02709746|10046865|FG004|Phase B (Double-blind Treatment Period)|Withdrawal by Subject|1
6314409|NCT02709746|10046861|FG000|Phase B (Double-blind Treatment Period)|enrolled not treated|0
6314410|NCT02709746|10046862|FG001|Phase B (Double-blind Treatment Period)|enrolled not treated|0
6314411|NCT02709746|10046863|FG002|Phase B (Double-blind Treatment Period)|enrolled not treated|1
6314412|NCT02709746|10046864|FG003|Phase B (Double-blind Treatment Period)|enrolled not treated|0
6314413|NCT02709746|10046865|FG004|Phase B (Double-blind Treatment Period)|enrolled not treated|0
6314414|NCT02709746|10046861|FG000|Phase B (Double-blind Treatment Period)|Lost to Follow-up|0
6314415|NCT02709746|10046862|FG001|Phase B (Double-blind Treatment Period)|Lost to Follow-up|4
6149726|NCT01098474|9785459|FG004|Active Phase|Lost to Follow-up|0
6149727|NCT01098474|9785460|FG005|Active Phase|Lost to Follow-up|0
6149728|NCT01098474|9785455|FG000|Follow Up Phase|Travelled out of study area|0
6149729|NCT01098474|9785456|FG001|Follow Up Phase|Travelled out of study area|0
6149730|NCT01098474|9785457|FG002|Follow Up Phase|Travelled out of study area|0
6149731|NCT01098474|9785458|FG003|Follow Up Phase|Travelled out of study area|0
6149732|NCT01098474|9785459|FG004|Follow Up Phase|Travelled out of study area|1
6149733|NCT01098474|9785460|FG005|Follow Up Phase|Travelled out of study area|0
6149734|NCT01098474|9785455|FG000|Follow Up Phase|Other|0
6149735|NCT01098474|9785456|FG001|Follow Up Phase|Other|0
6149736|NCT01098474|9785457|FG002|Follow Up Phase|Other|0
6149737|NCT01098474|9785458|FG003|Follow Up Phase|Other|0
6149738|NCT01098474|9785459|FG004|Follow Up Phase|Other|0
6149739|NCT01098474|9785460|FG005|Follow Up Phase|Other|4
6149740|NCT01098474|9785455|FG000|Follow Up Phase|Withdrawal by Subject|0
6149741|NCT01098474|9785456|FG001|Follow Up Phase|Withdrawal by Subject|0
6314416|NCT02709746|10046863|FG002|Phase B (Double-blind Treatment Period)|Lost to Follow-up|2
6314417|NCT02709746|10046864|FG003|Phase B (Double-blind Treatment Period)|Lost to Follow-up|0
6314418|NCT02709746|10046865|FG004|Phase B (Double-blind Treatment Period)|Lost to Follow-up|2
6314419|NCT02709785|10046880|FG000|Overall Study|Withdrawal by Subject|1
6314420|NCT02709785|10046881|FG001|Overall Study|Withdrawal by Subject|2
6040266|NCT00369941|9638086|FG000|Overall Study|Adverse Event|14
6040267|NCT00369941|9638087|FG001|Overall Study|Adverse Event|28
6040268|NCT00369941|9638086|FG000|Overall Study|Lack of Efficacy|6
6040269|NCT00369941|9638087|FG001|Overall Study|Lack of Efficacy|10
6040270|NCT00369941|9638086|FG000|Overall Study|Lost to Follow-up|12
6040271|NCT00369941|9638087|FG001|Overall Study|Lost to Follow-up|22
6040272|NCT00369941|9638086|FG000|Overall Study|Protocol Violation|5
6040273|NCT00369941|9638087|FG001|Overall Study|Protocol Violation|3
6040274|NCT00369941|9638086|FG000|Overall Study|Withdrawal by Subject|5
6149742|NCT01098474|9785457|FG002|Follow Up Phase|Withdrawal by Subject|0
6149743|NCT01098474|9785458|FG003|Follow Up Phase|Withdrawal by Subject|2
6149744|NCT01098474|9785459|FG004|Follow Up Phase|Withdrawal by Subject|0
6314421|NCT02709785|10046882|FG002|Overall Study|Withdrawal by Subject|1
6314422|NCT02709889|10046898|FG000|Overall Study|Withdrawal by Subject|11
6314423|NCT02709889|10046899|FG001|Overall Study|Withdrawal by Subject|10
6149745|NCT01098474|9785460|FG005|Follow Up Phase|Withdrawal by Subject|1
6149746|NCT01098474|9785455|FG000|Follow Up Phase|Lost to Follow-up|0
6149747|NCT01098474|9785456|FG001|Follow Up Phase|Lost to Follow-up|0
6149748|NCT01098474|9785457|FG002|Follow Up Phase|Lost to Follow-up|0
6149749|NCT01098474|9785458|FG003|Follow Up Phase|Lost to Follow-up|0
6149750|NCT01098474|9785459|FG004|Follow Up Phase|Lost to Follow-up|1
6149751|NCT01098474|9785460|FG005|Follow Up Phase|Lost to Follow-up|0
6149752|NCT01098487|9785484|FG000|Overall Study|Adverse Event|22
6149753|NCT01098487|9785484|FG000|Overall Study|Lack of Efficacy|11
6149754|NCT01098487|9785484|FG000|Overall Study|Withdrawal by Subject|7
6149755|NCT01098487|9785484|FG000|Overall Study|Lost to Follow-up|3
6149756|NCT01098487|9785484|FG000|Overall Study|Physician Decision|1
6149757|NCT01098539|9785494|FG000|Overall Study|Adverse Event|26
6149758|NCT01098539|9785495|FG001|Overall Study|Adverse Event|26
6149759|NCT01098539|9785494|FG000|Overall Study|Protocol Violation|1
6149760|NCT01098539|9785495|FG001|Overall Study|Protocol Violation|4
6149761|NCT01098539|9785494|FG000|Overall Study|Noncompliance|3
6149762|NCT01098539|9785495|FG001|Overall Study|Noncompliance|5
6149763|NCT01098539|9785494|FG000|Overall Study|Lost to Follow-up|4
6149764|NCT01098539|9785495|FG001|Overall Study|Lost to Follow-up|4
6149765|NCT01098539|9785494|FG000|Overall Study|Withdrawal by Subject|12
6149766|NCT01098539|9785495|FG001|Overall Study|Withdrawal by Subject|26
6149767|NCT01098539|9785494|FG000|Overall Study|Physician Decision|5
6149768|NCT01098539|9785495|FG001|Overall Study|Physician Decision|3
6149769|NCT01098812|9785526|FG000|Overall Study|Death|2
6149770|NCT01098812|9785527|FG001|Overall Study|Death|0
6149771|NCT01098812|9785528|FG002|Overall Study|Death|1
6149772|NCT01098812|9785526|FG000|Overall Study|Lost to Follow-up|0
6149773|NCT01098812|9785527|FG001|Overall Study|Lost to Follow-up|1
6149774|NCT01098812|9785528|FG002|Overall Study|Lost to Follow-up|0
6149775|NCT01098851|9785537|FG000|Overall Study|Equipment failure|1
6149776|NCT01098851|9785538|FG001|Overall Study|Equipment failure|0
6149777|NCT01099215|9785577|FG000|Overall Study|Withdrawal by Subject|1
6149778|NCT01099215|9785578|FG001|Overall Study|Withdrawal by Subject|0
6149779|NCT01099215|9785577|FG000|Overall Study|Adverse Event|0
6149780|NCT01099215|9785578|FG001|Overall Study|Adverse Event|1
6149781|NCT01099267|9785584|FG000|MDS-003 Study|Adverse Event|37
6149782|NCT01099267|9785584|FG000|MDS-003 Study|Lack of Efficacy|52
6149783|NCT01099267|9785584|FG000|MDS-003 Study|Withdrawal by Subject|8
6149784|NCT01099267|9785584|FG000|MDS-003 Study|Lost to Follow-up|1
6149785|NCT01099267|9785584|FG000|MDS-003 Study|Death|11
6149786|NCT01099267|9785584|FG000|MDS-003 Study|Study Closed by Sponsor|2
6149787|NCT01099267|9785584|FG000|MDS-003 Study|Disease Progression|7
6149788|NCT01099267|9785584|FG000|MDS-003 Study|Investigator Decision|2
6149789|NCT01099267|9785584|FG000|MDS-003 Study|Non-Compliance|2
6149790|NCT01099267|9785584|FG000|MDS-003 Study|Loss of Response|1
6149791|NCT01099267|9785584|FG000|MDS-003 Study|Secondary Malign Disease|1
6149792|NCT01099397|9785602|FG000|Overall Study|Lost to Follow-up|4
6149793|NCT01099397|9785602|FG000|Overall Study|Protocol Violation|4
6149794|NCT01099397|9785602|FG000|Overall Study|Withdrawal by Subject|5
6149795|NCT01099579|9785645|FG000|Stage 1 (ATV Powder Formulation)|Adverse Event|4
6149796|NCT01099579|9785646|FG001|Stage 1 (ATV Powder Formulation)|Adverse Event|1
6149797|NCT01099579|9785647|FG002|Stage 1 (ATV Powder Formulation)|Adverse Event|0
6149798|NCT01099579|9785645|FG000|Stage 1 (ATV Powder Formulation)|Withdrawal by Subject|0
6149799|NCT01099579|9785646|FG001|Stage 1 (ATV Powder Formulation)|Withdrawal by Subject|0
6149800|NCT01099579|9785647|FG002|Stage 1 (ATV Powder Formulation)|Withdrawal by Subject|1
6149801|NCT01099579|9785645|FG000|Stage 1 (ATV Powder Formulation)|Lack of Efficacy|0
6149802|NCT01099579|9785646|FG001|Stage 1 (ATV Powder Formulation)|Lack of Efficacy|2
6149803|NCT01099579|9785647|FG002|Stage 1 (ATV Powder Formulation)|Lack of Efficacy|0
6149804|NCT01099579|9785645|FG000|Stage 1 (ATV Powder Formulation)|Poor compliance/noncompliance|0
6149805|NCT01099579|9785646|FG001|Stage 1 (ATV Powder Formulation)|Poor compliance/noncompliance|2
6149806|NCT01099579|9785647|FG002|Stage 1 (ATV Powder Formulation)|Poor compliance/noncompliance|0
6149807|NCT01099579|9785645|FG000|Stage 2 (ATV Capsule)|No longer met study criteria|2
6149808|NCT01099579|9785646|FG001|Stage 2 (ATV Capsule)|No longer met study criteria|2
6149809|NCT01099579|9785647|FG002|Stage 2 (ATV Capsule)|No longer met study criteria|1
6149810|NCT01099579|9785645|FG000|Stage 2 (ATV Capsule)|Lost to Follow-up|1
6149811|NCT01099579|9785646|FG001|Stage 2 (ATV Capsule)|Lost to Follow-up|1
6149812|NCT01099579|9785647|FG002|Stage 2 (ATV Capsule)|Lost to Follow-up|1
6149813|NCT01099579|9785645|FG000|Stage 2 (ATV Capsule)|Lack of Efficacy|0
6149814|NCT01099579|9785646|FG001|Stage 2 (ATV Capsule)|Lack of Efficacy|0
6149815|NCT01099579|9785647|FG002|Stage 2 (ATV Capsule)|Lack of Efficacy|2
6149816|NCT01099579|9785645|FG000|Stage 2 (ATV Capsule)|Withdrawal by Subject|1
6149817|NCT01099579|9785646|FG001|Stage 2 (ATV Capsule)|Withdrawal by Subject|1
6149818|NCT01099579|9785647|FG002|Stage 2 (ATV Capsule)|Withdrawal by Subject|1
6149819|NCT01099579|9785645|FG000|Stage 2 (ATV Capsule)|Poor/Non-Compliance|2
6149820|NCT01099579|9785646|FG001|Stage 2 (ATV Capsule)|Poor/Non-Compliance|0
6314424|NCT02709889|10046900|FG002|Overall Study|Withdrawal by Subject|2
6314425|NCT02709889|10046901|FG003|Overall Study|Withdrawal by Subject|12
6314426|NCT02709889|10046898|FG000|Overall Study|Death|25
6314427|NCT02709889|10046899|FG001|Overall Study|Death|38
6314428|NCT02709889|10046900|FG002|Overall Study|Death|4
6314429|NCT02709889|10046901|FG003|Overall Study|Death|44
6314430|NCT02709889|10046898|FG000|Overall Study|Physician Decision|1
6314431|NCT02709889|10046899|FG001|Overall Study|Physician Decision|2
6314432|NCT02709889|10046900|FG002|Overall Study|Physician Decision|3
6314433|NCT02709889|10046901|FG003|Overall Study|Physician Decision|5
6314434|NCT02709889|10046898|FG000|Overall Study|Lost to Follow-up|2
6314435|NCT02709889|10046899|FG001|Overall Study|Lost to Follow-up|0
6314436|NCT02709889|10046900|FG002|Overall Study|Lost to Follow-up|0
6314437|NCT02709889|10046901|FG003|Overall Study|Lost to Follow-up|4
6314438|NCT02709889|10046898|FG000|Overall Study|Study Terminated by Sponsor|4
6314439|NCT02709889|10046899|FG001|Overall Study|Study Terminated by Sponsor|6
6314440|NCT02709889|10046900|FG002|Overall Study|Study Terminated by Sponsor|2
6314441|NCT02709889|10046901|FG003|Overall Study|Study Terminated by Sponsor|17
6314442|NCT02709889|10046898|FG000|Overall Study|Other, Not Specified|0
6314443|NCT02709889|10046899|FG001|Overall Study|Other, Not Specified|1
6314444|NCT02709889|10046900|FG002|Overall Study|Other, Not Specified|1
6314445|NCT02709889|10046901|FG003|Overall Study|Other, Not Specified|6
6314446|NCT02710045|10046949|FG000|Overall Study|Death|1
6314447|NCT02710045|10046950|FG001|Overall Study|Death|2
6314448|NCT02710045|10046951|FG002|Overall Study|Death|0
6314449|NCT02710045|10046949|FG000|Overall Study|Withdrawal by Subject|6
6314450|NCT02710045|10046950|FG001|Overall Study|Withdrawal by Subject|6
6314451|NCT02710045|10046951|FG002|Overall Study|Withdrawal by Subject|2
6040275|NCT00369941|9638087|FG001|Overall Study|Withdrawal by Subject|18
6040276|NCT00369941|9638086|FG000|Overall Study|Pregnancy|4
6040277|NCT00369941|9638087|FG001|Overall Study|Pregnancy|2
6040278|NCT00369941|9638086|FG000|Overall Study|Completed, Did Not Enter Extension|5
6314452|NCT02710045|10046949|FG000|Overall Study|Protocol Violation|1
6040279|NCT00369941|9638087|FG001|Overall Study|Completed, Did Not Enter Extension|6
6040280|NCT00369941|9638086|FG000|Overall Study|Moved|11
6040281|NCT00369941|9638087|FG001|Overall Study|Moved|5
6040282|NCT00369941|9638086|FG000|Overall Study|Treatment with Prohibited Medication|3
6048968|NCT00420927|9648201|FG002|Period 2|Lost to Follow-up|2
6080264|NCT00615056|9687446|FG000|Overall Study|Lost to Follow-up|1
6080265|NCT00615056|9687447|FG001|Overall Study|Lost to Follow-up|2
6080266|NCT00615056|9687448|FG002|Overall Study|Lost to Follow-up|4
6080267|NCT00615056|9687449|FG003|Overall Study|Lost to Follow-up|5
6080268|NCT00615056|9687446|FG000|Overall Study|Other|13
6080269|NCT00615056|9687447|FG001|Overall Study|Other|15
6080270|NCT00615056|9687448|FG002|Overall Study|Other|10
6080271|NCT00615056|9687449|FG003|Overall Study|Other|7
6080272|NCT00615056|9687446|FG000|Overall Study|Objective progression or relapse|0
6080273|NCT00615056|9687447|FG001|Overall Study|Objective progression or relapse|2
6080274|NCT00615056|9687448|FG002|Overall Study|Objective progression or relapse|0
6080275|NCT00615056|9687449|FG003|Overall Study|Objective progression or relapse|0
6080276|NCT00615056|9687446|FG000|Overall Study|Withdrawal by Subject|0
6080277|NCT00615056|9687447|FG001|Overall Study|Withdrawal by Subject|1
6080278|NCT00615056|9687448|FG002|Overall Study|Withdrawal by Subject|1
6080279|NCT00615056|9687449|FG003|Overall Study|Withdrawal by Subject|0
6080280|NCT00615056|9687446|FG000|Overall Study|Discontinued by Sponsor|1
6080281|NCT00615056|9687447|FG001|Overall Study|Discontinued by Sponsor|0
6080282|NCT00615056|9687448|FG002|Overall Study|Discontinued by Sponsor|0
6080283|NCT00615056|9687449|FG003|Overall Study|Discontinued by Sponsor|0
6080284|NCT00615056|9687446|FG000|Overall Study|Randomized but not treated|3
6080285|NCT00615056|9687447|FG001|Overall Study|Randomized but not treated|0
6080286|NCT00615056|9687448|FG002|Overall Study|Randomized but not treated|0
6080287|NCT00615056|9687449|FG003|Overall Study|Randomized but not treated|0
6080288|NCT00615069|9687459|FG000|Overall Study|Death|10
6080289|NCT00615069|9687459|FG000|Overall Study|Physician Decision|2
6080290|NCT00615069|9687459|FG000|Overall Study|Withdrawal by Subject|4
6080291|NCT00615108|9687463|FG000|Overall Study|Adverse Event|122
6080292|NCT00615108|9687463|FG000|Overall Study|Other|370
6080293|NCT00615108|9687463|FG000|Overall Study|Lost to Follow-up|15
6080294|NCT00615199|9687473|FG000|Overall Study|Adverse Event|3
6080295|NCT00615199|9687474|FG001|Overall Study|Adverse Event|1
6080296|NCT00615199|9687475|FG002|Overall Study|Adverse Event|1
6080297|NCT00615199|9687476|FG003|Overall Study|Adverse Event|0
6080298|NCT00615199|9687473|FG000|Overall Study|Lack of Efficacy|2
6080299|NCT00615199|9687474|FG001|Overall Study|Lack of Efficacy|0
6080300|NCT00615199|9687475|FG002|Overall Study|Lack of Efficacy|0
6080301|NCT00615199|9687476|FG003|Overall Study|Lack of Efficacy|1
6080302|NCT00615199|9687473|FG000|Overall Study|Lost to Follow-up|1
6080303|NCT00615199|9687474|FG001|Overall Study|Lost to Follow-up|0
6080304|NCT00615199|9687475|FG002|Overall Study|Lost to Follow-up|0
6080305|NCT00615199|9687476|FG003|Overall Study|Lost to Follow-up|0
6080306|NCT00615199|9687473|FG000|Overall Study|Other|0
6314453|NCT02710045|10046950|FG001|Overall Study|Protocol Violation|2
6314454|NCT02710045|10046951|FG002|Overall Study|Protocol Violation|3
6314455|NCT02710045|10046949|FG000|Overall Study|Lost to Follow-up|3
6314456|NCT02710045|10046950|FG001|Overall Study|Lost to Follow-up|6
6314457|NCT02710045|10046951|FG002|Overall Study|Lost to Follow-up|7
6314458|NCT02710045|10046949|FG000|Overall Study|Physician Decision|0
6314459|NCT02710045|10046950|FG001|Overall Study|Physician Decision|0
6314460|NCT02710045|10046951|FG002|Overall Study|Physician Decision|1
6314461|NCT02710045|10046949|FG000|Overall Study|Poor Attendance|0
6314462|NCT02710045|10046950|FG001|Overall Study|Poor Attendance|1
6314463|NCT02710045|10046951|FG002|Overall Study|Poor Attendance|0
6314464|NCT02710071|10046961|FG000|First Intervention (6 Weeks).|Withdrawal by Subject|3
6314465|NCT02710071|10046962|FG001|First Intervention (6 Weeks).|Withdrawal by Subject|4
6040283|NCT00369941|9638087|FG001|Overall Study|Treatment with Prohibited Medication|1
6040284|NCT00369941|9638086|FG000|Overall Study|Employment Interfered with Study Visits|1
6040285|NCT00369941|9638087|FG001|Overall Study|Employment Interfered with Study Visits|0
6149821|NCT01099579|9785647|FG002|Stage 2 (ATV Capsule)|Poor/Non-Compliance|1
6149822|NCT01099579|9785645|FG000|Stage 2 (ATV Capsule)|Adverse Event|0
6149823|NCT01099579|9785646|FG001|Stage 2 (ATV Capsule)|Adverse Event|1
6149824|NCT01099579|9785647|FG002|Stage 2 (ATV Capsule)|Adverse Event|0
6149825|NCT01099709|9785701|FG000|Period 1|Withdrawal by Subject|0
6149826|NCT01099709|9785702|FG001|Period 1|Withdrawal by Subject|1
6149827|NCT01099709|9785701|FG000|Period 1|Positive cotinine test|0
6149828|NCT01099709|9785702|FG001|Period 1|Positive cotinine test|1
6149829|NCT01099709|9785701|FG000|Period 1|Adverse Event|1
6149830|NCT01099709|9785702|FG001|Period 1|Adverse Event|0
6149831|NCT01099917|9785734|FG000|Overall Study|Adverse Event|3
6149832|NCT01099917|9785734|FG000|Overall Study|Not Treated|24
6149833|NCT01100034|9785755|FG000|Overall Study|Lost to Follow-up|11
6149834|NCT01100034|9785755|FG000|Overall Study|Withdrawal of parent/guardian consent|1
6149835|NCT01100034|9785755|FG000|Overall Study|Withdrawal by Subject|4
6149836|NCT01100034|9785755|FG000|Overall Study|Sponsor decision|21
6149837|NCT01100034|9785755|FG000|Overall Study|Participated in another clinical trial|1
6149838|NCT01100034|9785755|FG000|Overall Study|Participants moved to another hospital|4
6149839|NCT01100034|9785755|FG000|Overall Study|Site closed due to non-responsiveness|1
6149840|NCT01100073|9785759|FG000|Overall Study|Lack of Efficacy|4
6149841|NCT01100073|9785759|FG000|Overall Study|Insufficient Tolerability|21
6149842|NCT01100073|9785759|FG000|Overall Study|Withdrawal by Subject|13
6149843|NCT01100073|9785759|FG000|Overall Study|Lost to Follow-up|39
6149844|NCT01100073|9785759|FG000|Overall Study|Lack of effect + patient's wish|2
6149845|NCT01100073|9785759|FG000|Overall Study|Insufficient tolerability +patients wish|8
6149846|NCT01100073|9785759|FG000|Overall Study|Other|8
6149847|NCT01100073|9785759|FG000|Overall Study|Missing|5
6149848|NCT01100086|9785763|FG000|Period 1|Withdrawal by Subject|1
6149849|NCT01100086|9785764|FG001|Period 1|Withdrawal by Subject|0
6149850|NCT01100307|9785793|FG000|Double Masked Phase (Up to Week 24)|Lack of Efficacy|1
6149851|NCT01100307|9785794|FG001|Double Masked Phase (Up to Week 24)|Lack of Efficacy|1
6149852|NCT01100307|9785793|FG000|Double Masked Phase (Up to Week 24)|Withdrawal by Subject|0
6149853|NCT01100307|9785794|FG001|Double Masked Phase (Up to Week 24)|Withdrawal by Subject|1
6149854|NCT01100307|9785793|FG000|Double Masked Phase (Up to Week 24)|Adverse Event|5
6149855|NCT01100307|9785794|FG001|Double Masked Phase (Up to Week 24)|Adverse Event|2
6149856|NCT01100307|9785793|FG000|Open Phase (Week 24 up to Week 54)|Lack of Efficacy|1
6149857|NCT01100307|9785794|FG001|Open Phase (Week 24 up to Week 54)|Lack of Efficacy|2
6149858|NCT01100307|9785793|FG000|Open Phase (Week 24 up to Week 54)|Withdrawal by Subject|2
6149859|NCT01100307|9785794|FG001|Open Phase (Week 24 up to Week 54)|Withdrawal by Subject|3
6149860|NCT01100307|9785793|FG000|Open Phase (Week 24 up to Week 54)|Adverse Event|3
6149861|NCT01100307|9785794|FG001|Open Phase (Week 24 up to Week 54)|Adverse Event|8
6149862|NCT01100320|9785802|FG000|Period 1|Withdrawal by Subject|2
6149863|NCT01100320|9785803|FG001|Period 1|Withdrawal by Subject|4
6040286|NCT00369941|9638086|FG000|Overall Study|Study Site Terminated|2
6040287|NCT00369941|9638087|FG001|Overall Study|Study Site Terminated|0
6040288|NCT00369941|9638086|FG000|Overall Study|Miscellaneous|3
6040289|NCT00369941|9638087|FG001|Overall Study|Miscellaneous|3
6040290|NCT00369967|9638096|FG000|Overall Study|Lost to Follow-up|23
6040291|NCT00369967|9638097|FG001|Overall Study|Lost to Follow-up|12
6040292|NCT00370032|9638109|FG000|Treatment Period 1|Unable to perform sigmoidoscopy on Day 6|0
6040293|NCT00370032|9638110|FG001|Treatment Period 1|Unable to perform sigmoidoscopy on Day 6|1
6040294|NCT00370032|9638109|FG000|Washout Period|Withdrawal by Subject|0
6040295|NCT00370032|9638110|FG001|Washout Period|Withdrawal by Subject|1
6040296|NCT00370032|9638109|FG000|Washout Period|Lost to Follow-up|0
6040297|NCT00370032|9638110|FG001|Washout Period|Lost to Follow-up|1
6040298|NCT00370032|9638109|FG000|Washout Period|Adverse Event|1
6040299|NCT00370032|9638110|FG001|Washout Period|Adverse Event|0
6040300|NCT00370032|9638109|FG000|Follow-up Period|Withdrawal by Subject|1
6040301|NCT00370032|9638110|FG001|Follow-up Period|Withdrawal by Subject|0
6040302|NCT00370071|9638125|FG000|Overall Study|Withdrawal by Subject|2
6040303|NCT00370149|9638131|FG000|Overall Study|Physician Decision|16
6149864|NCT01100320|9785802|FG000|Period 1|Positive Drug Screen|1
6314466|NCT02710071|10046961|FG000|Second Intervention (6 Weeks).|Withdrawal by Subject|1
6040304|NCT00370149|9638132|FG001|Overall Study|Physician Decision|16
6040305|NCT00370149|9638131|FG000|Overall Study|Protocol Violation|1
6149865|NCT01100320|9785803|FG001|Period 1|Positive Drug Screen|1
6149866|NCT01100320|9785802|FG000|Period 1|Adverse Event|2
6149867|NCT01100320|9785803|FG001|Period 1|Adverse Event|2
6314467|NCT02710071|10046962|FG001|Second Intervention (6 Weeks).|Withdrawal by Subject|2
6314468|NCT02710136|10046971|FG000|Phase 1a[Refer to Arm/Group Description]|Adverse Event|1
6314469|NCT02710136|10046972|FG001|Phase 1a[Refer to Arm/Group Description]|Adverse Event|0
6314470|NCT02710214|10046981|FG000|Overall Study|Lost to Follow-up|1
6314471|NCT02710214|10046982|FG001|Overall Study|Lost to Follow-up|0
6314472|NCT02710214|10046981|FG000|Overall Study|Lack of Efficacy|0
6314473|NCT02710214|10046982|FG001|Overall Study|Lack of Efficacy|1
6314474|NCT02710214|10046981|FG000|Overall Study|Death|0
6314475|NCT02710214|10046982|FG001|Overall Study|Death|1
6314476|NCT02710292|10046992|FG000|Period 1, First 10 Days of Wear|Adverse Event|0
6314477|NCT02710292|10046993|FG001|Period 1, First 10 Days of Wear|Adverse Event|1
6314478|NCT02710292|10046992|FG000|Period 1, First 10 Days of Wear|Withdrawal by Subject|1
6314479|NCT02710292|10046993|FG001|Period 1, First 10 Days of Wear|Withdrawal by Subject|2
6314480|NCT02710422|10047002|FG000|Overall Study|Termination of study|9
6314481|NCT02710422|10047003|FG001|Overall Study|Termination of study|9
6314482|NCT02710669|10047077|FG000|Overall Study|Physician Decision|2
6314483|NCT02710669|10047078|FG001|Overall Study|Physician Decision|1
6314484|NCT02710669|10047079|FG002|Overall Study|Physician Decision|0
6314485|NCT02710669|10047077|FG000|Overall Study|Institutional delays (including COVID)|2
6314486|NCT02710669|10047078|FG001|Overall Study|Institutional delays (including COVID)|2
6314487|NCT02710669|10047079|FG002|Overall Study|Institutional delays (including COVID)|0
6314488|NCT02710669|10047077|FG000|Overall Study|arrived in afib/aflutter|10
6314489|NCT02710669|10047078|FG001|Overall Study|arrived in afib/aflutter|8
6314490|NCT02710669|10047079|FG002|Overall Study|arrived in afib/aflutter|2
6149868|NCT01100320|9785802|FG000|Period 2|Withdrawal by Subject|1
6149869|NCT01100320|9785803|FG001|Period 2|Withdrawal by Subject|1
6149870|NCT01100437|9785809|FG000|Titration/Stabilization|Adverse Event|0
6149871|NCT01100437|9785810|FG001|Titration/Stabilization|Adverse Event|0
6149872|NCT01100437|9785811|FG002|Titration/Stabilization|Adverse Event|4
6149873|NCT01100437|9785809|FG000|Titration/Stabilization|Non-compliance|0
6149874|NCT01100437|9785810|FG001|Titration/Stabilization|Non-compliance|0
6149875|NCT01100437|9785811|FG002|Titration/Stabilization|Non-compliance|1
6149876|NCT01100437|9785809|FG000|Titration/Stabilization|Sponsor canceled study|0
6149877|NCT01100437|9785810|FG001|Titration/Stabilization|Sponsor canceled study|0
6149878|NCT01100437|9785811|FG002|Titration/Stabilization|Sponsor canceled study|1
6149879|NCT01100437|9785809|FG000|Maintenance|Withdrawal by Subject|0
6149880|NCT01100437|9785810|FG001|Maintenance|Withdrawal by Subject|0
6149881|NCT01100437|9785811|FG002|Maintenance|Withdrawal by Subject|1
6314491|NCT02711306|10047107|FG000|Overall Study|Withdrawal by Subject|2
6314492|NCT02711306|10047108|FG001|Overall Study|Withdrawal by Subject|2
6314493|NCT02711345|10047124|FG000|Overall Study|Adverse Event|0
6314494|NCT02711345|10047125|FG001|Overall Study|Adverse Event|0
6314495|NCT02711345|10047126|FG002|Overall Study|Adverse Event|0
6314496|NCT02711345|10047127|FG003|Overall Study|Adverse Event|1
6314497|NCT02711345|10047128|FG004|Overall Study|Adverse Event|1
6314498|NCT02711345|10047129|FG005|Overall Study|Adverse Event|2
6314499|NCT02711345|10047130|FG006|Overall Study|Adverse Event|1
6314500|NCT02711345|10047131|FG007|Overall Study|Adverse Event|0
6314501|NCT02711345|10047132|FG008|Overall Study|Adverse Event|0
6314502|NCT02711345|10047133|FG009|Overall Study|Adverse Event|2
6314503|NCT02711345|10047124|FG000|Overall Study|Physician Decision|0
6314504|NCT02711345|10047125|FG001|Overall Study|Physician Decision|0
6314505|NCT02711345|10047126|FG002|Overall Study|Physician Decision|1
6314506|NCT02711345|10047127|FG003|Overall Study|Physician Decision|0
6314507|NCT02711345|10047128|FG004|Overall Study|Physician Decision|0
6314508|NCT02711345|10047129|FG005|Overall Study|Physician Decision|0
6314509|NCT02711345|10047130|FG006|Overall Study|Physician Decision|0
6314510|NCT02711345|10047131|FG007|Overall Study|Physician Decision|0
6314511|NCT02711345|10047132|FG008|Overall Study|Physician Decision|1
6314512|NCT02711345|10047133|FG009|Overall Study|Physician Decision|0
6314513|NCT02711345|10047124|FG000|Overall Study|Progressive disease|1
6314514|NCT02711345|10047125|FG001|Overall Study|Progressive disease|3
6314515|NCT02711345|10047126|FG002|Overall Study|Progressive disease|5
6314516|NCT02711345|10047127|FG003|Overall Study|Progressive disease|3
6314517|NCT02711345|10047128|FG004|Overall Study|Progressive disease|7
6314518|NCT02711345|10047129|FG005|Overall Study|Progressive disease|2
6314519|NCT02711345|10047130|FG006|Overall Study|Progressive disease|8
6314520|NCT02711345|10047131|FG007|Overall Study|Progressive disease|4
6314521|NCT02711345|10047132|FG008|Overall Study|Progressive disease|5
6314522|NCT02711345|10047133|FG009|Overall Study|Progressive disease|6
6314523|NCT02711345|10047124|FG000|Overall Study|Subject/guardian decision|0
6314524|NCT02711345|10047125|FG001|Overall Study|Subject/guardian decision|0
6314525|NCT02711345|10047126|FG002|Overall Study|Subject/guardian decision|0
6314526|NCT02711345|10047127|FG003|Overall Study|Subject/guardian decision|0
6314527|NCT02711345|10047128|FG004|Overall Study|Subject/guardian decision|0
6314528|NCT02711345|10047129|FG005|Overall Study|Subject/guardian decision|2
6314529|NCT02711345|10047130|FG006|Overall Study|Subject/guardian decision|3
6314530|NCT02711345|10047131|FG007|Overall Study|Subject/guardian decision|1
6314531|NCT02711345|10047132|FG008|Overall Study|Subject/guardian decision|0
6314532|NCT02711345|10047133|FG009|Overall Study|Subject/guardian decision|4
6314533|NCT02711345|10047124|FG000|Overall Study|Death|1
6314534|NCT02711345|10047125|FG001|Overall Study|Death|0
6314535|NCT02711345|10047126|FG002|Overall Study|Death|0
6314536|NCT02711345|10047127|FG003|Overall Study|Death|0
6314537|NCT02711345|10047128|FG004|Overall Study|Death|0
6314538|NCT02711345|10047129|FG005|Overall Study|Death|0
6314539|NCT02711345|10047130|FG006|Overall Study|Death|0
6314540|NCT02711345|10047131|FG007|Overall Study|Death|1
6314541|NCT02711345|10047132|FG008|Overall Study|Death|0
6314542|NCT02711345|10047133|FG009|Overall Study|Death|0
6314543|NCT02711553|10047164|FG000|Overall Study|Withdrawal by Subject|2
6314544|NCT02711553|10047165|FG001|Overall Study|Withdrawal by Subject|1
6314545|NCT02711553|10047166|FG002|Overall Study|Withdrawal by Subject|1
6314546|NCT02711553|10047167|FG003|Overall Study|Withdrawal by Subject|0
6314547|NCT02711553|10047164|FG000|Overall Study|Lost to Follow-up|3
6314548|NCT02711553|10047165|FG001|Overall Study|Lost to Follow-up|3
6149882|NCT01100437|9785809|FG000|Maintenance|Sponsor termination of study|0
6314549|NCT02711553|10047166|FG002|Overall Study|Lost to Follow-up|6
6314550|NCT02711553|10047167|FG003|Overall Study|Lost to Follow-up|3
6314551|NCT02711553|10047164|FG000|Overall Study|On Study Treatment at Study Conclusion|1
6314552|NCT02711553|10047165|FG001|Overall Study|On Study Treatment at Study Conclusion|1
6314553|NCT02711553|10047166|FG002|Overall Study|On Study Treatment at Study Conclusion|3
6314554|NCT02711553|10047167|FG003|Overall Study|On Study Treatment at Study Conclusion|1
6314555|NCT02711800|10047179|FG000|Overall Study|Lost to Follow-up|1
6314556|NCT02711800|10047179|FG000|Overall Study|Withdrawal by Subject|1
6314557|NCT02711956|10047207|FG000|Overall Study|Adverse Event|0
6314558|NCT02711956|10047208|FG001|Overall Study|Adverse Event|0
6314559|NCT02711956|10047209|FG002|Overall Study|Adverse Event|0
6314560|NCT02711956|10047210|FG003|Overall Study|Adverse Event|1
6314561|NCT02711956|10047211|FG004|Overall Study|Adverse Event|2
6314562|NCT02711956|10047212|FG005|Overall Study|Adverse Event|0
6314563|NCT02711956|10047213|FG006|Overall Study|Adverse Event|0
6314564|NCT02711956|10047214|FG007|Overall Study|Adverse Event|1
6314565|NCT02711956|10047215|FG008|Overall Study|Adverse Event|1
6314566|NCT02711956|10047216|FG009|Overall Study|Adverse Event|1
6314567|NCT02711956|10047217|FG010|Overall Study|Adverse Event|1
6314568|NCT02711956|10047218|FG011|Overall Study|Adverse Event|0
6314569|NCT02711956|10047219|FG012|Overall Study|Adverse Event|0
6314570|NCT02711956|10047220|FG013|Overall Study|Adverse Event|0
6314571|NCT02711956|10047221|FG014|Overall Study|Adverse Event|2
6314572|NCT02711956|10047207|FG000|Overall Study|Physician Decision|0
6314573|NCT02711956|10047208|FG001|Overall Study|Physician Decision|0
6314574|NCT02711956|10047209|FG002|Overall Study|Physician Decision|0
6314575|NCT02711956|10047210|FG003|Overall Study|Physician Decision|2
6314576|NCT02711956|10047211|FG004|Overall Study|Physician Decision|0
6314577|NCT02711956|10047212|FG005|Overall Study|Physician Decision|0
6314578|NCT02711956|10047213|FG006|Overall Study|Physician Decision|0
6314579|NCT02711956|10047214|FG007|Overall Study|Physician Decision|0
6314580|NCT02711956|10047215|FG008|Overall Study|Physician Decision|0
6314581|NCT02711956|10047216|FG009|Overall Study|Physician Decision|0
6314582|NCT02711956|10047217|FG010|Overall Study|Physician Decision|0
6314583|NCT02711956|10047218|FG011|Overall Study|Physician Decision|0
6314584|NCT02711956|10047219|FG012|Overall Study|Physician Decision|0
6314585|NCT02711956|10047220|FG013|Overall Study|Physician Decision|0
6314586|NCT02711956|10047221|FG014|Overall Study|Physician Decision|0
6314587|NCT02711956|10047207|FG000|Overall Study|Withdrawal by Subject|0
6314588|NCT02711956|10047208|FG001|Overall Study|Withdrawal by Subject|0
6314589|NCT02711956|10047209|FG002|Overall Study|Withdrawal by Subject|0
6314590|NCT02711956|10047210|FG003|Overall Study|Withdrawal by Subject|0
6314591|NCT02711956|10047211|FG004|Overall Study|Withdrawal by Subject|0
6314592|NCT02711956|10047212|FG005|Overall Study|Withdrawal by Subject|0
6314593|NCT02711956|10047213|FG006|Overall Study|Withdrawal by Subject|1
6314594|NCT02711956|10047214|FG007|Overall Study|Withdrawal by Subject|0
6314595|NCT02711956|10047215|FG008|Overall Study|Withdrawal by Subject|0
6314596|NCT02711956|10047216|FG009|Overall Study|Withdrawal by Subject|0
6314597|NCT02711956|10047217|FG010|Overall Study|Withdrawal by Subject|0
6314598|NCT02711956|10047218|FG011|Overall Study|Withdrawal by Subject|1
6314599|NCT02711956|10047219|FG012|Overall Study|Withdrawal by Subject|6
6314600|NCT02711956|10047220|FG013|Overall Study|Withdrawal by Subject|0
6314601|NCT02711956|10047221|FG014|Overall Study|Withdrawal by Subject|1
6314602|NCT02711956|10047207|FG000|Overall Study|Clinical progression|1
6314603|NCT02711956|10047208|FG001|Overall Study|Clinical progression|0
6314604|NCT02711956|10047209|FG002|Overall Study|Clinical progression|0
6314605|NCT02711956|10047210|FG003|Overall Study|Clinical progression|0
6314606|NCT02711956|10047211|FG004|Overall Study|Clinical progression|0
6314607|NCT02711956|10047212|FG005|Overall Study|Clinical progression|0
6314608|NCT02711956|10047213|FG006|Overall Study|Clinical progression|1
6314609|NCT02711956|10047214|FG007|Overall Study|Clinical progression|0
6314610|NCT02711956|10047215|FG008|Overall Study|Clinical progression|1
6314611|NCT02711956|10047216|FG009|Overall Study|Clinical progression|0
6314612|NCT02711956|10047217|FG010|Overall Study|Clinical progression|0
6314613|NCT02711956|10047218|FG011|Overall Study|Clinical progression|2
6314614|NCT02711956|10047219|FG012|Overall Study|Clinical progression|4
6314615|NCT02711956|10047220|FG013|Overall Study|Clinical progression|1
6314616|NCT02711956|10047221|FG014|Overall Study|Clinical progression|1
6314617|NCT02711956|10047207|FG000|Overall Study|Radiographic progression|1
6314618|NCT02711956|10047208|FG001|Overall Study|Radiographic progression|1
6314619|NCT02711956|10047209|FG002|Overall Study|Radiographic progression|2
6314620|NCT02711956|10047210|FG003|Overall Study|Radiographic progression|0
6314621|NCT02711956|10047211|FG004|Overall Study|Radiographic progression|1
6314622|NCT02711956|10047212|FG005|Overall Study|Radiographic progression|0
6314623|NCT02711956|10047213|FG006|Overall Study|Radiographic progression|0
6314624|NCT02711956|10047214|FG007|Overall Study|Radiographic progression|0
6314625|NCT02711956|10047215|FG008|Overall Study|Radiographic progression|2
6314626|NCT02711956|10047216|FG009|Overall Study|Radiographic progression|1
6314627|NCT02711956|10047217|FG010|Overall Study|Radiographic progression|0
6314628|NCT02711956|10047218|FG011|Overall Study|Radiographic progression|5
6314629|NCT02711956|10047219|FG012|Overall Study|Radiographic progression|3
6314630|NCT02711956|10047220|FG013|Overall Study|Radiographic progression|0
6314631|NCT02711956|10047221|FG014|Overall Study|Radiographic progression|1
6314632|NCT02711956|10047207|FG000|Overall Study|PSA progression with clinical progression|0
6314633|NCT02711956|10047208|FG001|Overall Study|PSA progression with clinical progression|0
6314634|NCT02711956|10047209|FG002|Overall Study|PSA progression with clinical progression|0
6314635|NCT02711956|10047210|FG003|Overall Study|PSA progression with clinical progression|0
6314636|NCT02711956|10047211|FG004|Overall Study|PSA progression with clinical progression|1
6314637|NCT02711956|10047212|FG005|Overall Study|PSA progression with clinical progression|0
6314638|NCT02711956|10047213|FG006|Overall Study|PSA progression with clinical progression|0
6314639|NCT02711956|10047214|FG007|Overall Study|PSA progression with clinical progression|0
6314640|NCT02711956|10047215|FG008|Overall Study|PSA progression with clinical progression|0
6314641|NCT02711956|10047216|FG009|Overall Study|PSA progression with clinical progression|0
6314642|NCT02711956|10047217|FG010|Overall Study|PSA progression with clinical progression|0
6314643|NCT02711956|10047218|FG011|Overall Study|PSA progression with clinical progression|0
6314644|NCT02711956|10047219|FG012|Overall Study|PSA progression with clinical progression|1
6314645|NCT02711956|10047220|FG013|Overall Study|PSA progression with clinical progression|1
6314646|NCT02711956|10047221|FG014|Overall Study|PSA progression with clinical progression|0
6314647|NCT02711956|10047207|FG000|Overall Study|PSA progression with radiographic progression|0
6314648|NCT02711956|10047208|FG001|Overall Study|PSA progression with radiographic progression|1
6314649|NCT02711956|10047209|FG002|Overall Study|PSA progression with radiographic progression|0
6314650|NCT02711956|10047210|FG003|Overall Study|PSA progression with radiographic progression|0
6314651|NCT02711956|10047211|FG004|Overall Study|PSA progression with radiographic progression|0
6314652|NCT02711956|10047212|FG005|Overall Study|PSA progression with radiographic progression|2
6314653|NCT02711956|10047213|FG006|Overall Study|PSA progression with radiographic progression|2
6314654|NCT02711956|10047214|FG007|Overall Study|PSA progression with radiographic progression|1
6314655|NCT02711956|10047215|FG008|Overall Study|PSA progression with radiographic progression|0
6314656|NCT02711956|10047216|FG009|Overall Study|PSA progression with radiographic progression|1
6314657|NCT02711956|10047217|FG010|Overall Study|PSA progression with radiographic progression|0
6314658|NCT02711956|10047218|FG011|Overall Study|PSA progression with radiographic progression|1
6314659|NCT02711956|10047219|FG012|Overall Study|PSA progression with radiographic progression|2
6314660|NCT02711956|10047220|FG013|Overall Study|PSA progression with radiographic progression|3
6314661|NCT02711956|10047221|FG014|Overall Study|PSA progression with radiographic progression|3
6314662|NCT02711995|10047262|FG000|Washout (90 Days)|Conflicting medication|1
6314663|NCT02712008|10047271|FG000|Baseline (Day 1) up to Week 12|Death|3
6314664|NCT02712008|10047272|FG001|Baseline (Day 1) up to Week 12|Death|0
6314665|NCT02712008|10047273|FG002|Baseline (Day 1) up to Week 12|Death|0
6314666|NCT02712008|10047274|FG003|Baseline (Day 1) up to Week 12|Death|0
6314667|NCT02712008|10047275|FG004|Baseline (Day 1) up to Week 12|Death|0
6314668|NCT02712008|10047276|FG005|Baseline (Day 1) up to Week 12|Death|0
6314669|NCT02712008|10047277|FG006|Baseline (Day 1) up to Week 12|Death|0
6314670|NCT02712008|10047278|FG007|Baseline (Day 1) up to Week 12|Death|0
6314671|NCT02712008|10047271|FG000|Baseline (Day 1) up to Week 12|Withdrawal by Subject|0
6149883|NCT01100437|9785810|FG001|Maintenance|Sponsor termination of study|0
6149884|NCT01100437|9785811|FG002|Maintenance|Sponsor termination of study|1
6149885|NCT01100502|9785822|FG000|Overall Study|Withdrawal by Subject|18
6149886|NCT01100502|9785823|FG001|Overall Study|Withdrawal by Subject|25
6149887|NCT01100502|9785822|FG000|Overall Study|Lost to Follow-up|13
6149888|NCT01100502|9785823|FG001|Overall Study|Lost to Follow-up|28
6149889|NCT01100502|9785822|FG000|Overall Study|Site request to end participation in study|0
6149890|NCT01100502|9785823|FG001|Overall Study|Site request to end participation in study|1
6149891|NCT01100502|9785822|FG000|Overall Study|Death|45
6149892|NCT01100502|9785823|FG001|Overall Study|Death|40
6149893|NCT01100528|9785829|FG000|Overall Study|Death|1
6149894|NCT01100528|9785829|FG000|Overall Study|Withdrawal by Subject|2
6149895|NCT01100567|9785835|FG000|Overall Study|Withdrawal by Subject|5
6149896|NCT01100567|9785836|FG001|Overall Study|Withdrawal by Subject|8
6149897|NCT01100567|9785835|FG000|Overall Study|Early Hospital Discharge|6
6149898|NCT01100567|9785836|FG001|Overall Study|Early Hospital Discharge|4
6149899|NCT01100567|9785835|FG000|Overall Study|Lost to Follow-up|1
6149900|NCT01100567|9785836|FG001|Overall Study|Lost to Follow-up|2
6149901|NCT01100567|9785835|FG000|Overall Study|Physician Decision|0
6149902|NCT01100567|9785836|FG001|Overall Study|Physician Decision|1
6149903|NCT01100567|9785835|FG000|Overall Study|Deemed ineligible after consent|0
6149904|NCT01100567|9785836|FG001|Overall Study|Deemed ineligible after consent|1
6149905|NCT01100853|9785866|FG000|Overall Study|Lost to Follow-up|11
6149906|NCT01100853|9785867|FG001|Overall Study|Lost to Follow-up|6
6149907|NCT01100853|9785866|FG000|Overall Study|Received <4 study injections|10
6149908|NCT01100853|9785867|FG001|Overall Study|Received <4 study injections|13
6149909|NCT01100853|9785866|FG000|Overall Study|Withdrawal by Subject|6
6149910|NCT01100853|9785867|FG001|Overall Study|Withdrawal by Subject|4
6149911|NCT01100944|9785883|FG000|Dose Escalation Phase 1 Dose Level 1|Adverse Event|2
6149912|NCT01100944|9785884|FG001|Dose Escalation Phase 1 Dose Level 1|Adverse Event|0
6149913|NCT01100944|9785885|FG002|Dose Escalation Phase 1 Dose Level 1|Adverse Event|0
6149914|NCT01100944|9785883|FG000|Dose Escalation Phase 1 Dose Level 1|Discontinued due to treatment delay|1
6149915|NCT01100944|9785884|FG001|Dose Escalation Phase 1 Dose Level 1|Discontinued due to treatment delay|0
6149916|NCT01100944|9785885|FG002|Dose Escalation Phase 1 Dose Level 1|Discontinued due to treatment delay|0
6149917|NCT01100944|9785883|FG000|Dose Escalation Phase 1 Dose Level 1|Progressive Disease|1
6149918|NCT01100944|9785884|FG001|Dose Escalation Phase 1 Dose Level 1|Progressive Disease|0
6149919|NCT01100944|9785885|FG002|Dose Escalation Phase 1 Dose Level 1|Progressive Disease|0
6149920|NCT01100944|9785883|FG000|Dose Escalation Phase 1 Dose Level 2|Adverse Event|0
6149921|NCT01100944|9785884|FG001|Dose Escalation Phase 1 Dose Level 2|Adverse Event|2
6149922|NCT01100944|9785885|FG002|Dose Escalation Phase 1 Dose Level 2|Adverse Event|0
6149923|NCT01101022|9785908|FG000|Overall Study|Adverse Event|6
6149924|NCT01101022|9785909|FG001|Overall Study|Adverse Event|2
6149925|NCT01101022|9785908|FG000|Overall Study|Protocol Violation|4
6149926|NCT01101022|9785909|FG001|Overall Study|Protocol Violation|3
6149927|NCT01101022|9785908|FG000|Overall Study|Withdrawal by Subject|3
6149928|NCT01101022|9785909|FG001|Overall Study|Withdrawal by Subject|8
6149929|NCT01101022|9785908|FG000|Overall Study|Lost to Follow-up|1
6149930|NCT01101022|9785909|FG001|Overall Study|Lost to Follow-up|4
6149931|NCT01101022|9785908|FG000|Overall Study|Lack of Efficacy|0
6149932|NCT01101022|9785909|FG001|Overall Study|Lack of Efficacy|7
6149933|NCT01101022|9785908|FG000|Overall Study|Sponsor decision|1
6149934|NCT01101022|9785909|FG001|Overall Study|Sponsor decision|1
6149935|NCT01101022|9785908|FG000|Overall Study|Non-compliance|1
6149936|NCT01101022|9785909|FG001|Overall Study|Non-compliance|0
6149937|NCT01101022|9785908|FG000|Overall Study|Work schedule|1
6149938|NCT01101022|9785909|FG001|Overall Study|Work schedule|1
6149939|NCT01101022|9785908|FG000|Overall Study|Vacation|0
6149940|NCT01101022|9785909|FG001|Overall Study|Vacation|1
6149941|NCT01101035|9785917|FG000|Overall Study|Adverse Event|191
6149942|NCT01101035|9785918|FG001|Overall Study|Adverse Event|172
6149943|NCT01101035|9785917|FG000|Overall Study|Major Protocol Deviation|52
6149944|NCT01101035|9785918|FG001|Overall Study|Major Protocol Deviation|46
6149945|NCT01101035|9785917|FG000|Overall Study|Lost to Follow-up|226
6149946|NCT01101035|9785918|FG001|Overall Study|Lost to Follow-up|223
6149947|NCT01101035|9785917|FG000|Overall Study|Voluntary Withdrawal|595
6149948|NCT01101035|9785918|FG001|Overall Study|Voluntary Withdrawal|587
6149949|NCT01101035|9785917|FG000|Overall Study|Reason not Specified|333
6149950|NCT01101035|9785918|FG001|Overall Study|Reason not Specified|363
6149951|NCT01101061|9785930|FG000|Overall Study|Adverse Event|0
6149952|NCT01101061|9785931|FG001|Overall Study|Adverse Event|0
6149953|NCT01101061|9785932|FG002|Overall Study|Adverse Event|1
6149954|NCT01101061|9785933|FG003|Overall Study|Adverse Event|0
6149955|NCT01101061|9785934|FG004|Overall Study|Adverse Event|0
6149956|NCT01101061|9785935|FG005|Overall Study|Adverse Event|0
6149957|NCT01101165|9785958|FG000|Period 1|Adverse Event|1
6149958|NCT01101165|9785959|FG001|Period 1|Adverse Event|2
6149959|NCT01101165|9785958|FG000|Period 1|Withdrawal by Subject|0
6149960|NCT01101165|9785959|FG001|Period 1|Withdrawal by Subject|2
6149961|NCT01101165|9785958|FG000|Period 1|Positive Drug Screen|0
6149962|NCT01101165|9785959|FG001|Period 1|Positive Drug Screen|1
6149963|NCT01101165|9785958|FG000|Period 1|Lost to Follow-up|1
6149964|NCT01101165|9785959|FG001|Period 1|Lost to Follow-up|0
6149965|NCT01101165|9785958|FG000|Period 2|Withdrawal by Subject|3
6149966|NCT01101165|9785959|FG001|Period 2|Withdrawal by Subject|1
6149967|NCT01101165|9785958|FG000|Period 2|Adverse Event|1
6149968|NCT01101165|9785959|FG001|Period 2|Adverse Event|0
6149969|NCT01101178|9785965|FG000|Period 1|Withdrawal by Subject|1
6149970|NCT01101178|9785966|FG001|Period 1|Withdrawal by Subject|2
6314672|NCT02712008|10047272|FG001|Baseline (Day 1) up to Week 12|Withdrawal by Subject|2
6314673|NCT02712008|10047273|FG002|Baseline (Day 1) up to Week 12|Withdrawal by Subject|1
6314674|NCT02712008|10047274|FG003|Baseline (Day 1) up to Week 12|Withdrawal by Subject|0
6314675|NCT02712008|10047275|FG004|Baseline (Day 1) up to Week 12|Withdrawal by Subject|0
6314676|NCT02712008|10047276|FG005|Baseline (Day 1) up to Week 12|Withdrawal by Subject|0
6314677|NCT02712008|10047277|FG006|Baseline (Day 1) up to Week 12|Withdrawal by Subject|0
6314678|NCT02712008|10047278|FG007|Baseline (Day 1) up to Week 12|Withdrawal by Subject|0
6314679|NCT02712008|10047271|FG000|Baseline (Day 1) up to Week 12|Lost to Follow-up|1
6314680|NCT02712008|10047272|FG001|Baseline (Day 1) up to Week 12|Lost to Follow-up|0
6314681|NCT02712008|10047273|FG002|Baseline (Day 1) up to Week 12|Lost to Follow-up|2
6314682|NCT02712008|10047274|FG003|Baseline (Day 1) up to Week 12|Lost to Follow-up|0
6314683|NCT02712008|10047275|FG004|Baseline (Day 1) up to Week 12|Lost to Follow-up|0
6314684|NCT02712008|10047276|FG005|Baseline (Day 1) up to Week 12|Lost to Follow-up|0
6314685|NCT02712008|10047277|FG006|Baseline (Day 1) up to Week 12|Lost to Follow-up|0
6314686|NCT02712008|10047278|FG007|Baseline (Day 1) up to Week 12|Lost to Follow-up|0
6314687|NCT02712008|10047271|FG000|Baseline (Day 1) up to Week 12|Protocol Violation|0
6314688|NCT02712008|10047272|FG001|Baseline (Day 1) up to Week 12|Protocol Violation|0
6314689|NCT02712008|10047273|FG002|Baseline (Day 1) up to Week 12|Protocol Violation|1
6314690|NCT02712008|10047274|FG003|Baseline (Day 1) up to Week 12|Protocol Violation|0
6314691|NCT02712008|10047275|FG004|Baseline (Day 1) up to Week 12|Protocol Violation|0
6314692|NCT02712008|10047276|FG005|Baseline (Day 1) up to Week 12|Protocol Violation|0
6314693|NCT02712008|10047277|FG006|Baseline (Day 1) up to Week 12|Protocol Violation|0
6314694|NCT02712008|10047278|FG007|Baseline (Day 1) up to Week 12|Protocol Violation|0
6314695|NCT02712008|10047271|FG000|Baseline (Day 1) up to Week 12|Other Unspecified|0
6314696|NCT02712008|10047272|FG001|Baseline (Day 1) up to Week 12|Other Unspecified|1
6314697|NCT02712008|10047273|FG002|Baseline (Day 1) up to Week 12|Other Unspecified|0
6314698|NCT02712008|10047274|FG003|Baseline (Day 1) up to Week 12|Other Unspecified|0
6314699|NCT02712008|10047275|FG004|Baseline (Day 1) up to Week 12|Other Unspecified|0
6314700|NCT02712008|10047276|FG005|Baseline (Day 1) up to Week 12|Other Unspecified|0
6314701|NCT02712008|10047277|FG006|Baseline (Day 1) up to Week 12|Other Unspecified|0
6314702|NCT02712008|10047278|FG007|Baseline (Day 1) up to Week 12|Other Unspecified|0
6314703|NCT02712008|10047271|FG000|From Week 12 up to Week 36|Adverse Event|0
6314704|NCT02712008|10047272|FG001|From Week 12 up to Week 36|Adverse Event|0
6314705|NCT02712008|10047273|FG002|From Week 12 up to Week 36|Adverse Event|0
6314706|NCT02712008|10047274|FG003|From Week 12 up to Week 36|Adverse Event|0
6314707|NCT02712008|10047275|FG004|From Week 12 up to Week 36|Adverse Event|1
6314708|NCT02712008|10047276|FG005|From Week 12 up to Week 36|Adverse Event|0
6314709|NCT02712008|10047277|FG006|From Week 12 up to Week 36|Adverse Event|0
6314710|NCT02712008|10047278|FG007|From Week 12 up to Week 36|Adverse Event|2
6314711|NCT02712008|10047271|FG000|From Week 12 up to Week 36|Death|1
6314712|NCT02712008|10047272|FG001|From Week 12 up to Week 36|Death|0
6314713|NCT02712008|10047273|FG002|From Week 12 up to Week 36|Death|0
6314714|NCT02712008|10047274|FG003|From Week 12 up to Week 36|Death|0
6314715|NCT02712008|10047275|FG004|From Week 12 up to Week 36|Death|0
6314716|NCT02712008|10047276|FG005|From Week 12 up to Week 36|Death|0
6314717|NCT02712008|10047277|FG006|From Week 12 up to Week 36|Death|1
6314718|NCT02712008|10047278|FG007|From Week 12 up to Week 36|Death|0
6314719|NCT02712008|10047271|FG000|From Week 12 up to Week 36|Lost to Follow-up|0
6149971|NCT01101178|9785965|FG000|Period 1|Positive drug screen|1
6149972|NCT01101178|9785966|FG001|Period 1|Positive drug screen|1
6149973|NCT01101178|9785965|FG000|Period 1|Adverse Event|2
6149974|NCT01101178|9785966|FG001|Period 1|Adverse Event|1
6149975|NCT01101178|9785965|FG000|Period 2|Withdrawal by Subject|0
6149976|NCT01101178|9785966|FG001|Period 2|Withdrawal by Subject|1
6149977|NCT01101191|9785973|FG000|Period 1|Withdrawal by Subject|1
6314720|NCT02712008|10047272|FG001|From Week 12 up to Week 36|Lost to Follow-up|0
6314721|NCT02712008|10047273|FG002|From Week 12 up to Week 36|Lost to Follow-up|0
6314722|NCT02712008|10047274|FG003|From Week 12 up to Week 36|Lost to Follow-up|1
6314723|NCT02712008|10047275|FG004|From Week 12 up to Week 36|Lost to Follow-up|0
6314724|NCT02712008|10047276|FG005|From Week 12 up to Week 36|Lost to Follow-up|0
6314725|NCT02712008|10047277|FG006|From Week 12 up to Week 36|Lost to Follow-up|1
6314726|NCT02712008|10047278|FG007|From Week 12 up to Week 36|Lost to Follow-up|0
6314727|NCT02712008|10047271|FG000|From Week 12 up to Week 36|Physician Decision|0
6314728|NCT02712008|10047272|FG001|From Week 12 up to Week 36|Physician Decision|0
6314729|NCT02712008|10047273|FG002|From Week 12 up to Week 36|Physician Decision|0
6314730|NCT02712008|10047274|FG003|From Week 12 up to Week 36|Physician Decision|1
6314731|NCT02712008|10047275|FG004|From Week 12 up to Week 36|Physician Decision|1
6314732|NCT02712008|10047276|FG005|From Week 12 up to Week 36|Physician Decision|0
6314733|NCT02712008|10047277|FG006|From Week 12 up to Week 36|Physician Decision|0
6314734|NCT02712008|10047278|FG007|From Week 12 up to Week 36|Physician Decision|0
6314735|NCT02712008|10047271|FG000|From Week 12 up to Week 36|Withdrawal by Subject|0
6314736|NCT02712008|10047272|FG001|From Week 12 up to Week 36|Withdrawal by Subject|0
6314737|NCT02712008|10047273|FG002|From Week 12 up to Week 36|Withdrawal by Subject|0
6314738|NCT02712008|10047274|FG003|From Week 12 up to Week 36|Withdrawal by Subject|0
6314739|NCT02712008|10047275|FG004|From Week 12 up to Week 36|Withdrawal by Subject|0
6314740|NCT02712008|10047276|FG005|From Week 12 up to Week 36|Withdrawal by Subject|0
6314741|NCT02712008|10047277|FG006|From Week 12 up to Week 36|Withdrawal by Subject|3
6314742|NCT02712008|10047278|FG007|From Week 12 up to Week 36|Withdrawal by Subject|2
6314743|NCT02712320|10047308|FG000|Overall Study|Lost to Follow-up|1
6314744|NCT02712320|10047308|FG000|Overall Study|Withdrawal by Subject|1
6314745|NCT02712320|10047308|FG000|Overall Study|Transferred to another facility|1
6314746|NCT02712320|10047308|FG000|Overall Study|Treating with the prohibited medications|2
6314747|NCT02712333|10047314|FG000|First Period|Withdrawal by Subject|3
6314748|NCT02712333|10047315|FG001|First Period|Withdrawal by Subject|2
6314749|NCT02712398|10047343|FG000|Overall Study|Withdrawal by Subject|6
6149978|NCT01101191|9785974|FG001|Period 1|Withdrawal by Subject|0
6149979|NCT01101191|9785973|FG000|Period 1|Adverse Event|1
6149980|NCT01101191|9785974|FG001|Period 1|Adverse Event|2
6149981|NCT01101308|9785981|FG000|Period 1|Adverse Event|2
6149982|NCT01101308|9785982|FG001|Period 1|Adverse Event|1
6149983|NCT01101308|9785981|FG000|Period 1|Positive for cotinine|1
6149984|NCT01101308|9785982|FG001|Period 1|Positive for cotinine|0
6149985|NCT01101321|9785989|FG000|Period 1|Withdrawal by Subject|1
6149986|NCT01101321|9785990|FG001|Period 1|Withdrawal by Subject|1
6149987|NCT01101321|9785989|FG000|Period 1|Adverse Event|3
6149988|NCT01101321|9785990|FG001|Period 1|Adverse Event|3
6149989|NCT01101334|9785998|FG000|Overall Study|Adverse Event|9
6149990|NCT01101334|9785999|FG001|Overall Study|Adverse Event|4
6149991|NCT01101334|9785998|FG000|Overall Study|Death|7
6149992|NCT01101334|9785999|FG001|Overall Study|Death|1
6149993|NCT01101334|9785998|FG000|Overall Study|Withdrawal by Subject|4
6149994|NCT01101334|9785999|FG001|Overall Study|Withdrawal by Subject|3
6149995|NCT01101334|9785998|FG000|Overall Study|Withdrawal by Sponsor|1
6149996|NCT01101334|9785999|FG001|Overall Study|Withdrawal by Sponsor|1
6149997|NCT01101334|9785998|FG000|Overall Study|Progressive Disease|22
6149998|NCT01101334|9785999|FG001|Overall Study|Progressive Disease|35
6149999|NCT01101334|9785998|FG000|Overall Study|Other|2
6150000|NCT01101334|9785999|FG001|Overall Study|Other|1
6150001|NCT01101477|9786008|FG000|Overall Study|Protocol Violation|5
6150002|NCT01101477|9786009|FG001|Overall Study|Protocol Violation|3
6150003|NCT01101477|9786010|FG002|Overall Study|Protocol Violation|1
6150004|NCT01101542|9786018|FG000|Year 3 Surveillance Period|Lost to Follow-up|7
6150005|NCT01101542|9786018|FG000|Year 3 Surveillance Period|Withdrawal by Subject|4
6314750|NCT02712398|10047343|FG000|Overall Study|Lost to Follow-up|6
6314751|NCT02712398|10047343|FG000|Overall Study|Sponsor Decision|1
6314752|NCT02712398|10047343|FG000|Overall Study|Physician Decision|1
6314753|NCT02712398|10047343|FG000|Overall Study|Death|2
6040306|NCT00370149|9638132|FG001|Overall Study|Protocol Violation|0
6040307|NCT00370149|9638131|FG000|Overall Study|Catheter inserted in wrong vessel-|2
6040308|NCT00370149|9638132|FG001|Overall Study|Catheter inserted in wrong vessel-|1
6314754|NCT02712398|10047343|FG000|Overall Study|Re-operation|21
6314755|NCT02712424|10047349|FG000|Overall Study|Lost to Follow-up|34
6314756|NCT02712424|10047350|FG001|Overall Study|Lost to Follow-up|32
6314757|NCT02712554|10047358|FG000|Part B: Qualification Phase|Drug Discrimination Failure|0
6314758|NCT02712554|10047359|FG001|Part B: Qualification Phase|Drug Discrimination Failure|13
6314759|NCT02712554|10047358|FG000|Part B: Qualification Phase|Sponsor Decision|0
6314760|NCT02712554|10047359|FG001|Part B: Qualification Phase|Sponsor Decision|4
6314761|NCT02712554|10047358|FG000|Part B: Qualification Phase|Withdrawal by Subject|0
6150006|NCT01101542|9786018|FG000|Year 4 Surveillance Period|Other|287
6150007|NCT01101542|9786018|FG000|Year 5 Surveillance Period|Lost to Follow-up|140
6150008|NCT01101542|9786018|FG000|Year 5 Surveillance Period|Pregnancy|1
6150009|NCT01101542|9786018|FG000|Year 6 Surveillance Period|Lost to Follow-up|986
6150010|NCT01101542|9786018|FG000|Year 6 Surveillance Period|Pregnancy|1
6040309|NCT00370149|9638131|FG000|Overall Study|Pre-existing infection|0
6150011|NCT01101542|9786018|FG000|Year 6 Surveillance Period|Withdrawal by Subject|4
6150012|NCT01101841|9786028|FG000|Overall Study|Adverse Event|15
6150013|NCT01101841|9786029|FG001|Overall Study|Adverse Event|15
6150014|NCT01101841|9786028|FG000|Overall Study|Lost to Follow-up|9
6150015|NCT01101841|9786029|FG001|Overall Study|Lost to Follow-up|3
6150016|NCT01101841|9786028|FG000|Overall Study|Withdrawal by Subject|21
6150017|NCT01101841|9786029|FG001|Overall Study|Withdrawal by Subject|40
6227340|NCT01716520|9900044|FG003|Treatment Period 3 (14 Days)|Lack of Efficacy|0
6227341|NCT01716520|9900045|FG004|Treatment Period 3 (14 Days)|Lack of Efficacy|0
6227342|NCT01716520|9900046|FG005|Treatment Period 3 (14 Days)|Lack of Efficacy|2
6227343|NCT01716520|9900041|FG000|Treatment Period 3 (14 Days)|Withdrawal by Subject|0
6227344|NCT01716520|9900042|FG001|Treatment Period 3 (14 Days)|Withdrawal by Subject|0
6227345|NCT01716520|9900043|FG002|Treatment Period 3 (14 Days)|Withdrawal by Subject|1
6227346|NCT01716520|9900044|FG003|Treatment Period 3 (14 Days)|Withdrawal by Subject|0
6040310|NCT00370149|9638132|FG001|Overall Study|Pre-existing infection|1
6150018|NCT01101841|9786028|FG000|Overall Study|Protocol Violation|1
6314762|NCT02712554|10047359|FG001|Part B: Qualification Phase|Withdrawal by Subject|3
6314763|NCT02712554|10047358|FG000|Part B: Qualification Phase|Adverse Event|0
6314764|NCT02712554|10047359|FG001|Part B: Qualification Phase|Adverse Event|1
6314765|NCT02712554|10047358|FG000|Part B: Treatment Phase|Adverse Event|0
6314766|NCT02712554|10047359|FG001|Part B: Treatment Phase|Adverse Event|1
6314767|NCT02712554|10047358|FG000|Part B: Treatment Phase|Withdrawal by Subject|0
6314768|NCT02712554|10047359|FG001|Part B: Treatment Phase|Withdrawal by Subject|1
6314769|NCT02712554|10047358|FG000|Part B: Treatment Phase|Other|0
6314770|NCT02712554|10047359|FG001|Part B: Treatment Phase|Other|1
6314771|NCT02712788|10047384|FG000|Overall Study|Physician Decision|1
6314772|NCT02712788|10047385|FG001|Overall Study|Physician Decision|0
6314773|NCT02712788|10047384|FG000|Overall Study|Protocol Violation|1
6314774|NCT02712788|10047385|FG001|Overall Study|Protocol Violation|0
6314775|NCT02712983|10047400|FG000|Treatment Phase|Adverse Event|3
6314776|NCT02712983|10047401|FG001|Treatment Phase|Adverse Event|1
6314777|NCT02712983|10047402|FG002|Treatment Phase|Adverse Event|1
6314778|NCT02712983|10047403|FG003|Treatment Phase|Adverse Event|4
6314779|NCT02712983|10047404|FG004|Treatment Phase|Adverse Event|3
6314780|NCT02712983|10047405|FG005|Treatment Phase|Adverse Event|0
6314781|NCT02712983|10047406|FG006|Treatment Phase|Adverse Event|6
6314782|NCT02712983|10047407|FG007|Treatment Phase|Adverse Event|6
6314783|NCT02712983|10047408|FG008|Treatment Phase|Adverse Event|1
6314784|NCT02712983|10047400|FG000|Treatment Phase|Protocol Deviation|0
6314785|NCT02712983|10047401|FG001|Treatment Phase|Protocol Deviation|0
6314786|NCT02712983|10047402|FG002|Treatment Phase|Protocol Deviation|0
6314787|NCT02712983|10047403|FG003|Treatment Phase|Protocol Deviation|2
6314788|NCT02712983|10047404|FG004|Treatment Phase|Protocol Deviation|0
6314789|NCT02712983|10047405|FG005|Treatment Phase|Protocol Deviation|0
6314790|NCT02712983|10047406|FG006|Treatment Phase|Protocol Deviation|1
6314791|NCT02712983|10047407|FG007|Treatment Phase|Protocol Deviation|0
6314792|NCT02712983|10047408|FG008|Treatment Phase|Protocol Deviation|0
6314793|NCT02712983|10047400|FG000|Treatment Phase|Technical Problems|0
6314794|NCT02712983|10047401|FG001|Treatment Phase|Technical Problems|0
6314795|NCT02712983|10047402|FG002|Treatment Phase|Technical Problems|0
6314796|NCT02712983|10047403|FG003|Treatment Phase|Technical Problems|0
6314797|NCT02712983|10047404|FG004|Treatment Phase|Technical Problems|0
6314798|NCT02712983|10047405|FG005|Treatment Phase|Technical Problems|0
6314799|NCT02712983|10047406|FG006|Treatment Phase|Technical Problems|1
6314800|NCT02712983|10047407|FG007|Treatment Phase|Technical Problems|0
6314801|NCT02712983|10047408|FG008|Treatment Phase|Technical Problems|0
6314802|NCT02712983|10047400|FG000|Treatment Phase|Physician Decision|0
6314803|NCT02712983|10047401|FG001|Treatment Phase|Physician Decision|0
6314804|NCT02712983|10047402|FG002|Treatment Phase|Physician Decision|0
6314805|NCT02712983|10047403|FG003|Treatment Phase|Physician Decision|0
6314806|NCT02712983|10047404|FG004|Treatment Phase|Physician Decision|0
6314807|NCT02712983|10047405|FG005|Treatment Phase|Physician Decision|0
6314808|NCT02712983|10047406|FG006|Treatment Phase|Physician Decision|0
6314809|NCT02712983|10047407|FG007|Treatment Phase|Physician Decision|1
6314810|NCT02712983|10047408|FG008|Treatment Phase|Physician Decision|1
6314811|NCT02712983|10047400|FG000|Treatment Phase|Subject Decision|2
6314812|NCT02712983|10047401|FG001|Treatment Phase|Subject Decision|0
6314813|NCT02712983|10047402|FG002|Treatment Phase|Subject Decision|0
6314814|NCT02712983|10047403|FG003|Treatment Phase|Subject Decision|2
6314815|NCT02712983|10047404|FG004|Treatment Phase|Subject Decision|1
6150019|NCT01101841|9786029|FG001|Overall Study|Protocol Violation|1
6150020|NCT01101841|9786028|FG000|Overall Study|Physician Decision|0
6150021|NCT01101841|9786029|FG001|Overall Study|Physician Decision|2
6150022|NCT01101841|9786028|FG000|Overall Study|Lack of Efficacy|0
6150023|NCT01101841|9786029|FG001|Overall Study|Lack of Efficacy|2
6150024|NCT01101841|9786028|FG000|Overall Study|Other|0
6150025|NCT01101841|9786029|FG001|Overall Study|Other|1
6150026|NCT01101841|9786028|FG000|Overall Study|Suicidality Tracking Scale|3
6150027|NCT01101841|9786029|FG001|Overall Study|Suicidality Tracking Scale|1
6150028|NCT01101841|9786028|FG000|Overall Study|Eligibility Criteria|1
6150029|NCT01101841|9786029|FG001|Overall Study|Eligibility Criteria|2
6150030|NCT01101997|9786066|FG000|Overall Study|Withdrawal by Subject|2
6314816|NCT02712983|10047405|FG005|Treatment Phase|Subject Decision|0
6314817|NCT02712983|10047406|FG006|Treatment Phase|Subject Decision|1
6314818|NCT02712983|10047407|FG007|Treatment Phase|Subject Decision|2
6314819|NCT02712983|10047408|FG008|Treatment Phase|Subject Decision|0
6314820|NCT02712983|10047400|FG000|Post-Treatment Efficacy Follow-Up Phase|Adverse Event|0
6314821|NCT02712983|10047401|FG001|Post-Treatment Efficacy Follow-Up Phase|Adverse Event|1
6314822|NCT02712983|10047402|FG002|Post-Treatment Efficacy Follow-Up Phase|Adverse Event|0
6314823|NCT02712983|10047403|FG003|Post-Treatment Efficacy Follow-Up Phase|Adverse Event|0
6314824|NCT02712983|10047404|FG004|Post-Treatment Efficacy Follow-Up Phase|Adverse Event|0
6314825|NCT02712983|10047405|FG005|Post-Treatment Efficacy Follow-Up Phase|Adverse Event|0
6314826|NCT02712983|10047406|FG006|Post-Treatment Efficacy Follow-Up Phase|Adverse Event|1
6314827|NCT02712983|10047407|FG007|Post-Treatment Efficacy Follow-Up Phase|Adverse Event|1
6150031|NCT01102231|9786081|FG000|Overall Study|Protocol Violation|3
6150032|NCT01102231|9786081|FG000|Overall Study|Lack of Efficacy|2
6314828|NCT02712983|10047408|FG008|Post-Treatment Efficacy Follow-Up Phase|Adverse Event|0
6314829|NCT02712983|10047400|FG000|Post-Treatment Efficacy Follow-Up Phase|Lost to Follow-up|0
6314830|NCT02712983|10047401|FG001|Post-Treatment Efficacy Follow-Up Phase|Lost to Follow-up|0
6314831|NCT02712983|10047402|FG002|Post-Treatment Efficacy Follow-Up Phase|Lost to Follow-up|0
6314832|NCT02712983|10047403|FG003|Post-Treatment Efficacy Follow-Up Phase|Lost to Follow-up|1
6314833|NCT02712983|10047404|FG004|Post-Treatment Efficacy Follow-Up Phase|Lost to Follow-up|0
6314834|NCT02712983|10047405|FG005|Post-Treatment Efficacy Follow-Up Phase|Lost to Follow-up|0
6314835|NCT02712983|10047406|FG006|Post-Treatment Efficacy Follow-Up Phase|Lost to Follow-up|0
6314836|NCT02712983|10047407|FG007|Post-Treatment Efficacy Follow-Up Phase|Lost to Follow-up|0
6314837|NCT02712983|10047408|FG008|Post-Treatment Efficacy Follow-Up Phase|Lost to Follow-up|0
6314838|NCT02712983|10047400|FG000|Post-Treatment Efficacy Follow-Up Phase|Subject Decision|0
6314839|NCT02712983|10047401|FG001|Post-Treatment Efficacy Follow-Up Phase|Subject Decision|0
6314840|NCT02712983|10047402|FG002|Post-Treatment Efficacy Follow-Up Phase|Subject Decision|0
6314841|NCT02712983|10047403|FG003|Post-Treatment Efficacy Follow-Up Phase|Subject Decision|0
6314842|NCT02712983|10047404|FG004|Post-Treatment Efficacy Follow-Up Phase|Subject Decision|2
6314843|NCT02712983|10047405|FG005|Post-Treatment Efficacy Follow-Up Phase|Subject Decision|1
6314844|NCT02712983|10047406|FG006|Post-Treatment Efficacy Follow-Up Phase|Subject Decision|1
6314845|NCT02712983|10047407|FG007|Post-Treatment Efficacy Follow-Up Phase|Subject Decision|2
6314846|NCT02712983|10047408|FG008|Post-Treatment Efficacy Follow-Up Phase|Subject Decision|0
6314847|NCT02712996|10047430|FG000|Second Intervention (Study Days 43-84)|Adverse Event|0
6314848|NCT02712996|10047431|FG001|Second Intervention (Study Days 43-84)|Adverse Event|1
6314849|NCT02713204|10047455|FG000|Baseline (Day 1) up to Week 12|Adverse Event|1
6314850|NCT02713204|10047456|FG001|Baseline (Day 1) up to Week 12|Adverse Event|0
6314851|NCT02713204|10047457|FG002|Baseline (Day 1) up to Week 12|Adverse Event|1
6314852|NCT02713204|10047458|FG003|Baseline (Day 1) up to Week 12|Adverse Event|0
6314853|NCT02713204|10047459|FG004|Baseline (Day 1) up to Week 12|Adverse Event|0
6314854|NCT02713204|10047460|FG005|Baseline (Day 1) up to Week 12|Adverse Event|0
6314855|NCT02713204|10047461|FG006|Baseline (Day 1) up to Week 12|Adverse Event|0
6314856|NCT02713204|10047462|FG007|Baseline (Day 1) up to Week 12|Adverse Event|0
6314857|NCT02713204|10047455|FG000|Baseline (Day 1) up to Week 12|Withdrawal by Subject|0
6314858|NCT02713204|10047456|FG001|Baseline (Day 1) up to Week 12|Withdrawal by Subject|0
6314859|NCT02713204|10047457|FG002|Baseline (Day 1) up to Week 12|Withdrawal by Subject|1
6314860|NCT02713204|10047458|FG003|Baseline (Day 1) up to Week 12|Withdrawal by Subject|0
6314861|NCT02713204|10047459|FG004|Baseline (Day 1) up to Week 12|Withdrawal by Subject|0
6314862|NCT02713204|10047460|FG005|Baseline (Day 1) up to Week 12|Withdrawal by Subject|0
6314863|NCT02713204|10047461|FG006|Baseline (Day 1) up to Week 12|Withdrawal by Subject|0
6314864|NCT02713204|10047462|FG007|Baseline (Day 1) up to Week 12|Withdrawal by Subject|0
6314865|NCT02713204|10047455|FG000|Baseline (Day 1) up to Week 12|Lost to Follow-up|0
6314866|NCT02713204|10047456|FG001|Baseline (Day 1) up to Week 12|Lost to Follow-up|1
6314867|NCT02713204|10047457|FG002|Baseline (Day 1) up to Week 12|Lost to Follow-up|0
6314868|NCT02713204|10047458|FG003|Baseline (Day 1) up to Week 12|Lost to Follow-up|0
6314869|NCT02713204|10047459|FG004|Baseline (Day 1) up to Week 12|Lost to Follow-up|0
6314870|NCT02713204|10047460|FG005|Baseline (Day 1) up to Week 12|Lost to Follow-up|0
6314871|NCT02713204|10047461|FG006|Baseline (Day 1) up to Week 12|Lost to Follow-up|0
6314872|NCT02713204|10047462|FG007|Baseline (Day 1) up to Week 12|Lost to Follow-up|0
6314873|NCT02713204|10047455|FG000|From Week 12 up to Week 36|Adverse Event|1
6314874|NCT02713204|10047456|FG001|From Week 12 up to Week 36|Adverse Event|0
6314875|NCT02713204|10047457|FG002|From Week 12 up to Week 36|Adverse Event|0
6314876|NCT02713204|10047458|FG003|From Week 12 up to Week 36|Adverse Event|1
6314877|NCT02713204|10047459|FG004|From Week 12 up to Week 36|Adverse Event|1
6314878|NCT02713204|10047460|FG005|From Week 12 up to Week 36|Adverse Event|0
6314879|NCT02713204|10047461|FG006|From Week 12 up to Week 36|Adverse Event|2
6314880|NCT02713204|10047462|FG007|From Week 12 up to Week 36|Adverse Event|1
6314881|NCT02713204|10047455|FG000|From Week 12 up to Week 36|Death|0
6314882|NCT02713204|10047456|FG001|From Week 12 up to Week 36|Death|0
6314883|NCT02713204|10047457|FG002|From Week 12 up to Week 36|Death|0
6314884|NCT02713204|10047458|FG003|From Week 12 up to Week 36|Death|1
6314885|NCT02713204|10047459|FG004|From Week 12 up to Week 36|Death|0
6314886|NCT02713204|10047460|FG005|From Week 12 up to Week 36|Death|1
6314887|NCT02713204|10047461|FG006|From Week 12 up to Week 36|Death|0
6314888|NCT02713204|10047462|FG007|From Week 12 up to Week 36|Death|3
6314889|NCT02713204|10047455|FG000|From Week 12 up to Week 36|Lost to Follow-up|0
6314890|NCT02713204|10047456|FG001|From Week 12 up to Week 36|Lost to Follow-up|0
6314891|NCT02713204|10047457|FG002|From Week 12 up to Week 36|Lost to Follow-up|0
6314892|NCT02713204|10047458|FG003|From Week 12 up to Week 36|Lost to Follow-up|2
6314893|NCT02713204|10047459|FG004|From Week 12 up to Week 36|Lost to Follow-up|0
6150033|NCT01102231|9786081|FG000|Overall Study|Death|2
6150034|NCT01102231|9786081|FG000|Overall Study|Adverse Event|3
6150035|NCT01102231|9786081|FG000|Overall Study|Withdrawal by Subject|1
6150036|NCT01102231|9786081|FG000|Overall Study|Did not received the treatment|4
6150037|NCT01102257|9786088|FG000|Overall Study|Adverse Event|1
6150038|NCT01102257|9786089|FG001|Overall Study|Adverse Event|0
6150039|NCT01102257|9786088|FG000|Overall Study|Adverse Event|1
6150040|NCT01102257|9786089|FG001|Overall Study|Adverse Event|0
6150041|NCT01102374|9786104|FG000|Overall Study|Death|9
6150042|NCT01102374|9786105|FG001|Overall Study|Death|13
6150043|NCT01102374|9786104|FG000|Overall Study|Lost to Follow-up|7
6150044|NCT01102374|9786105|FG001|Overall Study|Lost to Follow-up|6
6150045|NCT01102426|9786122|FG000|Overall Study|Randomized but not treated|4
6150046|NCT01102426|9786123|FG001|Overall Study|Randomized but not treated|1
6150047|NCT01102426|9786122|FG000|Overall Study|Adverse Events (treatment-related)|15
6150048|NCT01102426|9786123|FG001|Overall Study|Adverse Events (treatment-related)|8
6150049|NCT01102426|9786122|FG000|Overall Study|Physician Decision|9
6150050|NCT01102426|9786123|FG001|Overall Study|Physician Decision|6
6150051|NCT01102426|9786122|FG000|Overall Study|Progressive Disease|85
6150052|NCT01102426|9786123|FG001|Overall Study|Progressive Disease|44
6150053|NCT01102426|9786122|FG000|Overall Study|Adverse Events (unrelated to|9
6150054|NCT01102426|9786123|FG001|Overall Study|Adverse Events (unrelated to|1
6150055|NCT01102426|9786122|FG000|Overall Study|Patient Refusal|24
6150056|NCT01102426|9786123|FG001|Overall Study|Patient Refusal|12
6150057|NCT01102426|9786122|FG000|Overall Study|Death (due to adverse events|0
6150058|NCT01102426|9786123|FG001|Overall Study|Death (due to adverse events|1
6150059|NCT01102426|9786122|FG000|Overall Study|Death (non-related to the study|19
6150060|NCT01102426|9786123|FG001|Overall Study|Death (non-related to the study|8
6150061|NCT01102491|9786131|FG000|Overall Study|Protocol Violation|11
6150062|NCT01102491|9786132|FG001|Overall Study|Protocol Violation|12
6150063|NCT01102777|9786153|FG000|Overall Study|Death|2
6150064|NCT01102777|9786154|FG001|Overall Study|Death|6
6150065|NCT01102777|9786153|FG000|Overall Study|Lost to Follow-up|7
6150066|NCT01102777|9786154|FG001|Overall Study|Lost to Follow-up|10
6150067|NCT01102803|9786163|FG000|Baseline to Post-Treatment|Lost to Follow-up|3
6150068|NCT01102803|9786164|FG001|Baseline to Post-Treatment|Lost to Follow-up|0
6150069|NCT01102803|9786163|FG000|Post to Follow-Up|Lost to Follow-up|1
6150070|NCT01102803|9786164|FG001|Post to Follow-Up|Lost to Follow-up|3
6227347|NCT01716520|9900045|FG004|Treatment Period 3 (14 Days)|Withdrawal by Subject|0
6227348|NCT01716520|9900046|FG005|Treatment Period 3 (14 Days)|Withdrawal by Subject|0
6227349|NCT01716533|9900058|FG000|Overall Study|Failure of antibiotic treatment to treat|0
6227350|NCT01716533|9900059|FG001|Overall Study|Failure of antibiotic treatment to treat|0
6227351|NCT01716533|9900060|FG002|Overall Study|Failure of antibiotic treatment to treat|5
6227352|NCT01716533|9900061|FG003|Overall Study|Failure of antibiotic treatment to treat|0
6227353|NCT01716533|9900058|FG000|Overall Study|Withdrawal by Subject|0
6227354|NCT01716533|9900059|FG001|Overall Study|Withdrawal by Subject|0
6227355|NCT01716533|9900060|FG002|Overall Study|Withdrawal by Subject|0
6227356|NCT01716533|9900061|FG003|Overall Study|Withdrawal by Subject|5
6227357|NCT01716533|9900058|FG000|Overall Study|Death|0
6227358|NCT01716533|9900059|FG001|Overall Study|Death|0
6227359|NCT01716533|9900060|FG002|Overall Study|Death|0
6227360|NCT01716533|9900061|FG003|Overall Study|Death|2
6227361|NCT01716533|9900058|FG000|Overall Study|Immunosuppressants>14days past 6months|0
6227362|NCT01716533|9900059|FG001|Overall Study|Immunosuppressants>14days past 6months|0
6227363|NCT01716533|9900060|FG002|Overall Study|Immunosuppressants>14days past 6months|0
6227364|NCT01716533|9900061|FG003|Overall Study|Immunosuppressants>14days past 6months|1
6227365|NCT01716559|9900075|FG000|Overall Study|Adverse Event|11
6314894|NCT02713204|10047460|FG005|From Week 12 up to Week 36|Lost to Follow-up|0
6314895|NCT02713204|10047461|FG006|From Week 12 up to Week 36|Lost to Follow-up|0
6314896|NCT02713204|10047462|FG007|From Week 12 up to Week 36|Lost to Follow-up|0
6150071|NCT01102972|9786180|FG000|Overall Study|Adverse Event|8
6150072|NCT01102972|9786181|FG001|Overall Study|Adverse Event|2
6150073|NCT01102972|9786180|FG000|Overall Study|Lack of Efficacy|2
6314897|NCT02713204|10047455|FG000|From Week 12 up to Week 36|Participant Re-located|0
6314898|NCT02713204|10047456|FG001|From Week 12 up to Week 36|Participant Re-located|0
6314899|NCT02713204|10047457|FG002|From Week 12 up to Week 36|Participant Re-located|0
6314900|NCT02713204|10047458|FG003|From Week 12 up to Week 36|Participant Re-located|0
6314901|NCT02713204|10047459|FG004|From Week 12 up to Week 36|Participant Re-located|1
6314902|NCT02713204|10047460|FG005|From Week 12 up to Week 36|Participant Re-located|0
6314903|NCT02713204|10047461|FG006|From Week 12 up to Week 36|Participant Re-located|0
6314904|NCT02713204|10047462|FG007|From Week 12 up to Week 36|Participant Re-located|0
6314905|NCT02713243|10047493|FG000|Overall Study|Abnormal laboratory value(s)#|1
6314906|NCT02713243|10047494|FG001|Overall Study|Abnormal laboratory value(s)#|0
6314907|NCT02713243|10047493|FG000|Overall Study|Administrative problems|0
6150074|NCT01102972|9786181|FG001|Overall Study|Lack of Efficacy|1
6150075|NCT01102972|9786180|FG000|Overall Study|Protocol Violation|1
6150076|NCT01102972|9786181|FG001|Overall Study|Protocol Violation|0
6150077|NCT01102972|9786180|FG000|Overall Study|Lost to Follow-up|10
6150078|NCT01102972|9786181|FG001|Overall Study|Lost to Follow-up|5
6150079|NCT01102972|9786180|FG000|Overall Study|Investigator Discretion|2
6150080|NCT01102972|9786181|FG001|Overall Study|Investigator Discretion|0
6314908|NCT02713243|10047494|FG001|Overall Study|Administrative problems|1
6314909|NCT02713243|10047493|FG000|Overall Study|Protocol deviation|0
6314910|NCT02713243|10047494|FG001|Overall Study|Protocol deviation|1
6314911|NCT02713490|10047510|FG000|Overall Study|Withdrawal by Subject|2
6314912|NCT02713490|10047511|FG001|Overall Study|Withdrawal by Subject|1
6314913|NCT02713490|10047510|FG000|Overall Study|Did not receive study drug|1
6314914|NCT02713490|10047511|FG001|Overall Study|Did not receive study drug|0
6314915|NCT02713490|10047510|FG000|Overall Study|Met exclusion criteria|0
6314916|NCT02713490|10047511|FG001|Overall Study|Met exclusion criteria|1
6314917|NCT02713529|10047524|FG000|Overall Study|Withdrawal by Subject|3
6150081|NCT01102972|9786180|FG000|Overall Study|Withdrawal by Subject|6
6150082|NCT01102972|9786181|FG001|Overall Study|Withdrawal by Subject|6
6314918|NCT02713529|10047525|FG001|Overall Study|Withdrawal by Subject|1
6040311|NCT00370149|9638131|FG000|Overall Study|Antibiotic coated dressing placed|0
6040312|NCT00370149|9638132|FG001|Overall Study|Antibiotic coated dressing placed|1
6040313|NCT00370292|9638143|FG000|Overall Study|Disease Progression|4
6040314|NCT00370292|9638143|FG000|Overall Study|Adverse Event|7
6040315|NCT00370292|9638143|FG000|Overall Study|Physician Decision|2
6048969|NCT00420927|9648202|FG003|Period 2|Lost to Follow-up|2
6048970|NCT00420927|9648203|FG004|Period 2|Lost to Follow-up|6
6048971|NCT00420927|9648204|FG005|Period 2|Lost to Follow-up|3
6048972|NCT00420927|9648205|FG006|Period 2|Lost to Follow-up|9
6048973|NCT00420927|9648199|FG000|Period 2|Lack of efficacy/Loss of efficacy|0
6048974|NCT00420927|9648200|FG001|Period 2|Lack of efficacy/Loss of efficacy|0
6048975|NCT00420927|9648201|FG002|Period 2|Lack of efficacy/Loss of efficacy|2
6048976|NCT00420927|9648202|FG003|Period 2|Lack of efficacy/Loss of efficacy|1
6048977|NCT00420927|9648203|FG004|Period 2|Lack of efficacy/Loss of efficacy|6
6048978|NCT00420927|9648204|FG005|Period 2|Lack of efficacy/Loss of efficacy|2
6048979|NCT00420927|9648205|FG006|Period 2|Lack of efficacy/Loss of efficacy|6
6048980|NCT00420927|9648199|FG000|Period 2|Received wrong treatment/incorrect dose|0
6048981|NCT00420927|9648200|FG001|Period 2|Received wrong treatment/incorrect dose|0
6048982|NCT00420927|9648201|FG002|Period 2|Received wrong treatment/incorrect dose|0
6048983|NCT00420927|9648202|FG003|Period 2|Received wrong treatment/incorrect dose|0
6314919|NCT02713529|10047526|FG002|Overall Study|Withdrawal by Subject|4
6048984|NCT00420927|9648203|FG004|Period 2|Received wrong treatment/incorrect dose|0
6048985|NCT00420927|9648204|FG005|Period 2|Received wrong treatment/incorrect dose|0
6048986|NCT00420927|9648205|FG006|Period 2|Received wrong treatment/incorrect dose|1
6150083|NCT01103063|9786189|FG000|Overall Study|Adverse Event|3
6150084|NCT01103063|9786190|FG001|Overall Study|Adverse Event|1
6150085|NCT01103063|9786189|FG000|Overall Study|Lost to Follow-up|68
6150086|NCT01103063|9786190|FG001|Overall Study|Lost to Follow-up|51
6150087|NCT01103063|9786189|FG000|Overall Study|Withdrawal by Subject|60
6150088|NCT01103063|9786190|FG001|Overall Study|Withdrawal by Subject|15
6150089|NCT01103063|9786189|FG000|Overall Study|Other|16
6150090|NCT01103063|9786190|FG001|Overall Study|Other|11
6150091|NCT01103063|9786189|FG000|Overall Study|Protocol Violation|1
6150092|NCT01103063|9786190|FG001|Overall Study|Protocol Violation|0
6150093|NCT01103063|9786189|FG000|Overall Study|Study terminated by Sponsor|326
6150094|NCT01103063|9786190|FG001|Overall Study|Study terminated by Sponsor|342
6150095|NCT01103063|9786189|FG000|Overall Study|Death|3
6150096|NCT01103063|9786190|FG001|Overall Study|Death|1
6150097|NCT01103141|9786200|FG000|Overall Study|Death|0
6150098|NCT01103141|9786201|FG001|Overall Study|Death|1
6150099|NCT01103141|9786200|FG000|Overall Study|Lost to Follow-up|2
6150100|NCT01103141|9786201|FG001|Overall Study|Lost to Follow-up|1
6150101|NCT01103232|9786209|FG000|Overall Study|Withdrawal by Subject|1
6150102|NCT01103232|9786210|FG001|Overall Study|Withdrawal by Subject|1
6150103|NCT01103232|9786209|FG000|Overall Study|Protocol Violation|0
6150104|NCT01103232|9786210|FG001|Overall Study|Protocol Violation|1
6150105|NCT01103245|9786220|FG000|Overall Study|Withdrawal by Subject|1
6150106|NCT01103245|9786221|FG001|Overall Study|Withdrawal by Subject|0
6150107|NCT01103245|9786222|FG002|Overall Study|Withdrawal by Subject|3
6150108|NCT01103245|9786223|FG003|Overall Study|Withdrawal by Subject|0
6150109|NCT01103245|9786220|FG000|Overall Study|Inadequate IV access|1
6150110|NCT01103245|9786221|FG001|Overall Study|Inadequate IV access|0
6150111|NCT01103245|9786222|FG002|Overall Study|Inadequate IV access|0
6150112|NCT01103245|9786223|FG003|Overall Study|Inadequate IV access|0
6150113|NCT01103245|9786220|FG000|Overall Study|Adverse Event|0
6150114|NCT01103245|9786221|FG001|Overall Study|Adverse Event|2
6150115|NCT01103245|9786222|FG002|Overall Study|Adverse Event|1
6150116|NCT01103245|9786223|FG003|Overall Study|Adverse Event|0
6314920|NCT02713529|10047527|FG003|Overall Study|Withdrawal by Subject|2
6314921|NCT02713529|10047528|FG004|Overall Study|Withdrawal by Subject|0
6314922|NCT02713529|10047529|FG005|Overall Study|Withdrawal by Subject|1
6314923|NCT02713529|10047530|FG006|Overall Study|Withdrawal by Subject|1
6314924|NCT02713529|10047524|FG000|Overall Study|Lost to Follow-up|1
6314925|NCT02713529|10047525|FG001|Overall Study|Lost to Follow-up|0
6314926|NCT02713529|10047526|FG002|Overall Study|Lost to Follow-up|1
6314927|NCT02713529|10047527|FG003|Overall Study|Lost to Follow-up|0
6314928|NCT02713529|10047528|FG004|Overall Study|Lost to Follow-up|0
6314929|NCT02713529|10047529|FG005|Overall Study|Lost to Follow-up|0
6314930|NCT02713529|10047530|FG006|Overall Study|Lost to Follow-up|0
6314931|NCT02713529|10047524|FG000|Overall Study|Death|3
6314932|NCT02713529|10047525|FG001|Overall Study|Death|3
6314933|NCT02713529|10047526|FG002|Overall Study|Death|26
6314934|NCT02713529|10047527|FG003|Overall Study|Death|27
6314935|NCT02713529|10047528|FG004|Overall Study|Death|3
6314936|NCT02713529|10047529|FG005|Overall Study|Death|13
6314937|NCT02713529|10047530|FG006|Overall Study|Death|3
6314938|NCT02713542|10047552|FG000|Overall Study|Use of prohibited medication|14
6314939|NCT02713542|10047553|FG001|Overall Study|Use of prohibited medication|5
6314940|NCT02713542|10047552|FG000|Overall Study|Withdrawal by Subject|4
6314941|NCT02713542|10047553|FG001|Overall Study|Withdrawal by Subject|1
6314942|NCT02713594|10047561|FG000|Overall Study|Withdrawal by Subject|32
6314943|NCT02713594|10047562|FG001|Overall Study|Withdrawal by Subject|22
6314944|NCT02713594|10047561|FG000|Overall Study|Lost to Follow-up|358
6314945|NCT02713594|10047562|FG001|Overall Study|Lost to Follow-up|374
6314946|NCT02713789|10047611|FG000|Overall Study|Lost to Follow-up|0
6314947|NCT02713789|10047612|FG001|Overall Study|Lost to Follow-up|1
6314948|NCT02713789|10047613|FG002|Overall Study|Lost to Follow-up|1
6314949|NCT02713828|10047623|FG000|Overall Study|Death|2
6314950|NCT02713828|10047624|FG001|Overall Study|Death|0
6314951|NCT02713828|10047623|FG000|Overall Study|Withdrawal by Subject|1
6314952|NCT02713828|10047624|FG001|Overall Study|Withdrawal by Subject|0
6314953|NCT02713828|10047623|FG000|Overall Study|study terminated but patient allowed to|2
6314954|NCT02713828|10047624|FG001|Overall Study|study terminated but patient allowed to|0
6314955|NCT02714153|10047629|FG000|Overall Study|Death|1
6314956|NCT02714426|10047655|FG000|Overall Study|Withdrawal by Subject|2
6314957|NCT02714426|10047656|FG001|Overall Study|Withdrawal by Subject|2
6314958|NCT02714569|10047682|FG000|Part A Second Intervention|Withdrawal by Subject|0
6314959|NCT02714569|10047683|FG001|Part A Second Intervention|Withdrawal by Subject|1
6150117|NCT01103245|9786220|FG000|Overall Study|Physician Decision|1
6150118|NCT01103245|9786221|FG001|Overall Study|Physician Decision|0
6150119|NCT01103245|9786222|FG002|Overall Study|Physician Decision|0
6150120|NCT01103245|9786223|FG003|Overall Study|Physician Decision|0
6150121|NCT01103284|9786245|FG000|Overall Study|Death|2
6314960|NCT02714569|10047684|FG002|Part A Second Intervention|Withdrawal by Subject|0
6150122|NCT01103284|9786246|FG001|Overall Study|Death|0
6150123|NCT01103284|9786245|FG000|Overall Study|Lost to Follow-up|9
6314961|NCT02714569|10047685|FG003|Part A Second Intervention|Withdrawal by Subject|0
6314962|NCT02714569|10047686|FG004|Part A Second Intervention|Withdrawal by Subject|0
6314963|NCT02714569|10047687|FG005|Part A Second Intervention|Withdrawal by Subject|0
6314964|NCT02714569|10047688|FG006|Part A Second Intervention|Withdrawal by Subject|0
6314965|NCT02714569|10047689|FG007|Part A Second Intervention|Withdrawal by Subject|0
6314966|NCT02714569|10047690|FG008|Part A Second Intervention|Withdrawal by Subject|0
6314967|NCT02714569|10047691|FG009|Part A Second Intervention|Withdrawal by Subject|0
6314968|NCT02714569|10047692|FG010|Part A Second Intervention|Withdrawal by Subject|0
6314969|NCT02714569|10047682|FG000|Part A Third Intervention|Positive Urine Drug Screen (UDS)|0
6314970|NCT02714569|10047683|FG001|Part A Third Intervention|Positive Urine Drug Screen (UDS)|0
6314971|NCT02714569|10047684|FG002|Part A Third Intervention|Positive Urine Drug Screen (UDS)|0
6314972|NCT02714569|10047685|FG003|Part A Third Intervention|Positive Urine Drug Screen (UDS)|1
6314973|NCT02714569|10047686|FG004|Part A Third Intervention|Positive Urine Drug Screen (UDS)|0
6314974|NCT02714569|10047687|FG005|Part A Third Intervention|Positive Urine Drug Screen (UDS)|0
6314975|NCT02714569|10047688|FG006|Part A Third Intervention|Positive Urine Drug Screen (UDS)|0
6314976|NCT02714569|10047689|FG007|Part A Third Intervention|Positive Urine Drug Screen (UDS)|0
6314977|NCT02714569|10047690|FG008|Part A Third Intervention|Positive Urine Drug Screen (UDS)|0
6314978|NCT02714569|10047691|FG009|Part A Third Intervention|Positive Urine Drug Screen (UDS)|0
6314979|NCT02714569|10047692|FG010|Part A Third Intervention|Positive Urine Drug Screen (UDS)|0
6314980|NCT02714569|10047682|FG000|Part A Third Intervention|Adverse Event|0
6314981|NCT02714569|10047683|FG001|Part A Third Intervention|Adverse Event|0
6314982|NCT02714569|10047684|FG002|Part A Third Intervention|Adverse Event|1
6314983|NCT02714569|10047685|FG003|Part A Third Intervention|Adverse Event|0
6314984|NCT02714569|10047686|FG004|Part A Third Intervention|Adverse Event|0
6314985|NCT02714569|10047687|FG005|Part A Third Intervention|Adverse Event|0
6314986|NCT02714569|10047688|FG006|Part A Third Intervention|Adverse Event|0
6314987|NCT02714569|10047689|FG007|Part A Third Intervention|Adverse Event|0
6314988|NCT02714569|10047690|FG008|Part A Third Intervention|Adverse Event|0
6314989|NCT02714569|10047691|FG009|Part A Third Intervention|Adverse Event|0
6314990|NCT02714569|10047692|FG010|Part A Third Intervention|Adverse Event|0
6314991|NCT02714569|10047682|FG000|Part A Fourth Intervention|Positive Urinary Drug Screen (UDS)|1
6314992|NCT02714569|10047683|FG001|Part A Fourth Intervention|Positive Urinary Drug Screen (UDS)|0
6314993|NCT02714569|10047684|FG002|Part A Fourth Intervention|Positive Urinary Drug Screen (UDS)|0
6314994|NCT02714569|10047685|FG003|Part A Fourth Intervention|Positive Urinary Drug Screen (UDS)|0
6314995|NCT02714569|10047686|FG004|Part A Fourth Intervention|Positive Urinary Drug Screen (UDS)|0
6314996|NCT02714569|10047687|FG005|Part A Fourth Intervention|Positive Urinary Drug Screen (UDS)|1
6314997|NCT02714569|10047688|FG006|Part A Fourth Intervention|Positive Urinary Drug Screen (UDS)|0
6314998|NCT02714569|10047689|FG007|Part A Fourth Intervention|Positive Urinary Drug Screen (UDS)|0
6314999|NCT02714569|10047690|FG008|Part A Fourth Intervention|Positive Urinary Drug Screen (UDS)|0
6315000|NCT02714569|10047691|FG009|Part A Fourth Intervention|Positive Urinary Drug Screen (UDS)|0
6315001|NCT02714569|10047692|FG010|Part A Fourth Intervention|Positive Urinary Drug Screen (UDS)|0
6315002|NCT02714569|10047682|FG000|Part B (Overall)|Lost to Follow-up|0
6315003|NCT02714569|10047683|FG001|Part B (Overall)|Lost to Follow-up|0
6315004|NCT02714569|10047684|FG002|Part B (Overall)|Lost to Follow-up|0
6315005|NCT02714569|10047685|FG003|Part B (Overall)|Lost to Follow-up|0
6315006|NCT02714569|10047686|FG004|Part B (Overall)|Lost to Follow-up|0
6315007|NCT02714569|10047687|FG005|Part B (Overall)|Lost to Follow-up|0
6315008|NCT02714569|10047688|FG006|Part B (Overall)|Lost to Follow-up|1
6315009|NCT02714569|10047689|FG007|Part B (Overall)|Lost to Follow-up|0
6315010|NCT02714569|10047690|FG008|Part B (Overall)|Lost to Follow-up|0
6315011|NCT02714569|10047691|FG009|Part B (Overall)|Lost to Follow-up|0
6315012|NCT02714569|10047692|FG010|Part B (Overall)|Lost to Follow-up|0
6315013|NCT02714569|10047682|FG000|Part B (Overall)|Withdrawal by Subject|0
6315014|NCT02714569|10047683|FG001|Part B (Overall)|Withdrawal by Subject|0
6315015|NCT02714569|10047684|FG002|Part B (Overall)|Withdrawal by Subject|0
6315016|NCT02714569|10047685|FG003|Part B (Overall)|Withdrawal by Subject|0
6315017|NCT02714569|10047686|FG004|Part B (Overall)|Withdrawal by Subject|0
6315018|NCT02714569|10047687|FG005|Part B (Overall)|Withdrawal by Subject|0
6315019|NCT02714569|10047688|FG006|Part B (Overall)|Withdrawal by Subject|0
6315020|NCT02714569|10047689|FG007|Part B (Overall)|Withdrawal by Subject|1
6315021|NCT02714569|10047690|FG008|Part B (Overall)|Withdrawal by Subject|0
6315022|NCT02714569|10047691|FG009|Part B (Overall)|Withdrawal by Subject|1
6315023|NCT02714569|10047692|FG010|Part B (Overall)|Withdrawal by Subject|0
6315024|NCT02714569|10047682|FG000|Part B (Overall)|Adverse Event|0
6315025|NCT02714569|10047683|FG001|Part B (Overall)|Adverse Event|0
6315026|NCT02714569|10047684|FG002|Part B (Overall)|Adverse Event|0
6315027|NCT02714569|10047685|FG003|Part B (Overall)|Adverse Event|0
6315028|NCT02714569|10047686|FG004|Part B (Overall)|Adverse Event|0
6315029|NCT02714569|10047687|FG005|Part B (Overall)|Adverse Event|0
6315030|NCT02714569|10047688|FG006|Part B (Overall)|Adverse Event|0
6315031|NCT02714569|10047689|FG007|Part B (Overall)|Adverse Event|0
6315032|NCT02714569|10047690|FG008|Part B (Overall)|Adverse Event|0
6315033|NCT02714569|10047691|FG009|Part B (Overall)|Adverse Event|1
6315034|NCT02714569|10047692|FG010|Part B (Overall)|Adverse Event|0
6315035|NCT02714595|10047754|FG000|Overall Study|Lost to Follow-up|1
6315036|NCT02714595|10047755|FG001|Overall Study|Lost to Follow-up|0
6315037|NCT02714595|10047754|FG000|Overall Study|Withdrawal by Subject|1
6315038|NCT02714595|10047755|FG001|Overall Study|Withdrawal by Subject|2
6315039|NCT02714595|10047754|FG000|Overall Study|Lack of Efficacy|0
6315040|NCT02714595|10047755|FG001|Overall Study|Lack of Efficacy|1
6315041|NCT02714595|10047754|FG000|Overall Study|Death|30
6315042|NCT02714595|10047755|FG001|Overall Study|Death|9
6315043|NCT02714595|10047754|FG000|Overall Study|Other-Miscellaneous|0
6315044|NCT02714595|10047755|FG001|Overall Study|Other-Miscellaneous|1
6315045|NCT02714868|10047781|FG000|Overall Study|Withdrawal by Subject|3
6315046|NCT02714868|10047782|FG001|Overall Study|Withdrawal by Subject|0
6315047|NCT02714868|10047781|FG000|Overall Study|PI withdrawal safety risk self/others|1
6315048|NCT02714868|10047782|FG001|Overall Study|PI withdrawal safety risk self/others|0
6315049|NCT02714868|10047781|FG000|Overall Study|PI withdraw did not meet inclusion|1
6315050|NCT02714868|10047782|FG001|Overall Study|PI withdraw did not meet inclusion|0
6315051|NCT02715258|10047816|FG000|Overall Study|Withdrawal by Subject|6
6315052|NCT02715258|10047817|FG001|Overall Study|Withdrawal by Subject|1
6315053|NCT02715258|10047816|FG000|Overall Study|Lost to Follow-up|7
6315054|NCT02715258|10047817|FG001|Overall Study|Lost to Follow-up|1
6315055|NCT02715258|10047816|FG000|Overall Study|Terminated by Sponsor|0
6315056|NCT02715258|10047817|FG001|Overall Study|Terminated by Sponsor|1
6315057|NCT02715258|10047816|FG000|Overall Study|Death|0
6315058|NCT02715258|10047817|FG001|Overall Study|Death|1
6315059|NCT02715258|10047816|FG000|Overall Study|Subject non-compliant|1
6315060|NCT02715258|10047817|FG001|Overall Study|Subject non-compliant|1
6315061|NCT02715258|10047816|FG000|Overall Study|GCP violation|2
6315062|NCT02715258|10047817|FG001|Overall Study|GCP violation|1
6315063|NCT02715726|10047833|FG000|Overall Study|Adverse Event|2
6315064|NCT02715726|10047834|FG001|Overall Study|Adverse Event|6
6315065|NCT02715726|10047833|FG000|Overall Study|Protocol Violation|1
6315066|NCT02715726|10047834|FG001|Overall Study|Protocol Violation|0
6315067|NCT02715726|10047833|FG000|Overall Study|Death|2
6315068|NCT02715726|10047834|FG001|Overall Study|Death|1
6315069|NCT02715726|10047833|FG000|Overall Study|Participant moved|1
6315070|NCT02715726|10047834|FG001|Overall Study|Participant moved|3
6315071|NCT02715726|10047833|FG000|Overall Study|Other than specified above|11
6315072|NCT02715726|10047834|FG001|Overall Study|Other than specified above|15
6315073|NCT02715726|10047833|FG000|Overall Study|Randomized but not treated|1
6315074|NCT02715726|10047834|FG001|Overall Study|Randomized but not treated|2
6315075|NCT02715804|10047842|FG000|Overall Study|Death|222
6315076|NCT02715804|10047843|FG001|Overall Study|Death|106
6315077|NCT02715804|10047842|FG000|Overall Study|Withdrawal by Subject|5
6315078|NCT02715804|10047843|FG001|Overall Study|Withdrawal by Subject|4
6315079|NCT02715804|10047842|FG000|Overall Study|Other than specified|2
6315080|NCT02715804|10047843|FG001|Overall Study|Other than specified|3
6315081|NCT02716194|10047852|FG000|Period 1 - ADVATE|Withdrawal by Subject|1
6315082|NCT02716194|10047853|FG001|Period 1 - ADVATE|Withdrawal by Subject|1
6315083|NCT02716194|10047854|FG002|Period 1 - ADVATE|Withdrawal by Subject|0
6315084|NCT02716298|10047875|FG000|First Intervention (1 Month)|Lens discomfort|1
6315085|NCT02716298|10047876|FG001|First Intervention (1 Month)|Lens discomfort|1
6315086|NCT02716584|10047902|FG000|Overall Study|Lost to Follow-up|8
6315087|NCT02716584|10047903|FG001|Overall Study|Lost to Follow-up|5
6315088|NCT02716779|10047934|FG000|Monotherapy|Adverse Event|0
6315089|NCT02716779|10047935|FG001|Monotherapy|Adverse Event|1
6315090|NCT02716779|10047936|FG002|Monotherapy|Adverse Event|1
6315091|NCT02716779|10047934|FG000|Combination Therapy|Adverse Event|0
6315092|NCT02716779|10047935|FG001|Combination Therapy|Adverse Event|2
6315093|NCT02716779|10047936|FG002|Combination Therapy|Adverse Event|1
6315094|NCT02716805|10047950|FG000|Overall Study|Progressive disease|2
6315095|NCT02716805|10047951|FG001|Overall Study|Progressive disease|0
6315096|NCT02716805|10047952|FG002|Overall Study|Progressive disease|0
6315097|NCT02716805|10047953|FG003|Overall Study|Progressive disease|0
6315098|NCT02716896|10047990|FG000|Overall Study|Physician Decision|0
6315099|NCT02716896|10047991|FG001|Overall Study|Physician Decision|1
6315100|NCT02716987|10048003|FG000|Overall Study|Ligand synthesis failure|0
6315101|NCT02716987|10048004|FG001|Overall Study|Ligand synthesis failure|0
6315102|NCT02716987|10048005|FG002|Overall Study|Ligand synthesis failure|1
6315103|NCT02716987|10048006|FG003|Overall Study|Ligand synthesis failure|0
6315104|NCT02716987|10048007|FG004|Overall Study|Ligand synthesis failure|0
6315105|NCT02716987|10048008|FG005|Overall Study|Ligand synthesis failure|0
6315106|NCT02716987|10048003|FG000|Overall Study|Withdrawal by Subject|0
6315107|NCT02716987|10048004|FG001|Overall Study|Withdrawal by Subject|0
6315108|NCT02716987|10048005|FG002|Overall Study|Withdrawal by Subject|0
6315109|NCT02716987|10048006|FG003|Overall Study|Withdrawal by Subject|0
6315110|NCT02716987|10048007|FG004|Overall Study|Withdrawal by Subject|1
6315111|NCT02716987|10048008|FG005|Overall Study|Withdrawal by Subject|1
6315112|NCT02717195|10048037|FG000|Prospective Confirmation (PC) Period|Adverse Event|19
6315113|NCT02717195|10048038|FG001|Prospective Confirmation (PC) Period|Adverse Event|7
6315114|NCT02717195|10048039|FG002|Prospective Confirmation (PC) Period|Adverse Event|0
6315115|NCT02717195|10048040|FG003|Prospective Confirmation (PC) Period|Adverse Event|0
6315116|NCT02717195|10048041|FG004|Prospective Confirmation (PC) Period|Adverse Event|0
6315117|NCT02717195|10048037|FG000|Prospective Confirmation (PC) Period|Lack of Efficacy|2
6315118|NCT02717195|10048038|FG001|Prospective Confirmation (PC) Period|Lack of Efficacy|1
6315119|NCT02717195|10048039|FG002|Prospective Confirmation (PC) Period|Lack of Efficacy|0
6315120|NCT02717195|10048040|FG003|Prospective Confirmation (PC) Period|Lack of Efficacy|0
6315121|NCT02717195|10048041|FG004|Prospective Confirmation (PC) Period|Lack of Efficacy|0
6315122|NCT02717195|10048037|FG000|Prospective Confirmation (PC) Period|Non-compliance with IMP|7
6315123|NCT02717195|10048038|FG001|Prospective Confirmation (PC) Period|Non-compliance with IMP|1
6315124|NCT02717195|10048039|FG002|Prospective Confirmation (PC) Period|Non-compliance with IMP|0
6315125|NCT02717195|10048040|FG003|Prospective Confirmation (PC) Period|Non-compliance with IMP|0
6315126|NCT02717195|10048041|FG004|Prospective Confirmation (PC) Period|Non-compliance with IMP|0
6315127|NCT02717195|10048037|FG000|Prospective Confirmation (PC) Period|Protocol Violation|3
6315128|NCT02717195|10048038|FG001|Prospective Confirmation (PC) Period|Protocol Violation|1
6315129|NCT02717195|10048039|FG002|Prospective Confirmation (PC) Period|Protocol Violation|0
6315130|NCT02717195|10048040|FG003|Prospective Confirmation (PC) Period|Protocol Violation|0
6315131|NCT02717195|10048041|FG004|Prospective Confirmation (PC) Period|Protocol Violation|0
6315132|NCT02717195|10048037|FG000|Prospective Confirmation (PC) Period|Withdrawal by Subject|43
6315133|NCT02717195|10048038|FG001|Prospective Confirmation (PC) Period|Withdrawal by Subject|12
6315134|NCT02717195|10048039|FG002|Prospective Confirmation (PC) Period|Withdrawal by Subject|0
6315135|NCT02717195|10048040|FG003|Prospective Confirmation (PC) Period|Withdrawal by Subject|0
6315136|NCT02717195|10048041|FG004|Prospective Confirmation (PC) Period|Withdrawal by Subject|0
6315137|NCT02717195|10048037|FG000|Prospective Confirmation (PC) Period|Lost to Follow-up|9
6315138|NCT02717195|10048038|FG001|Prospective Confirmation (PC) Period|Lost to Follow-up|4
6315139|NCT02717195|10048039|FG002|Prospective Confirmation (PC) Period|Lost to Follow-up|0
6315140|NCT02717195|10048040|FG003|Prospective Confirmation (PC) Period|Lost to Follow-up|0
6315141|NCT02717195|10048041|FG004|Prospective Confirmation (PC) Period|Lost to Follow-up|0
6315142|NCT02717195|10048037|FG000|Prospective Confirmation (PC) Period|Did not fulfill rand criteria for DBT|189
6315143|NCT02717195|10048038|FG001|Prospective Confirmation (PC) Period|Did not fulfill rand criteria for DBT|75
6315144|NCT02717195|10048039|FG002|Prospective Confirmation (PC) Period|Did not fulfill rand criteria for DBT|0
6315145|NCT02717195|10048040|FG003|Prospective Confirmation (PC) Period|Did not fulfill rand criteria for DBT|0
6315146|NCT02717195|10048041|FG004|Prospective Confirmation (PC) Period|Did not fulfill rand criteria for DBT|0
6315147|NCT02717195|10048037|FG000|Prospective Confirmation (PC) Period|Enrolled but not treated|3
6315148|NCT02717195|10048038|FG001|Prospective Confirmation (PC) Period|Enrolled but not treated|3
6315149|NCT02717195|10048039|FG002|Prospective Confirmation (PC) Period|Enrolled but not treated|0
6315150|NCT02717195|10048040|FG003|Prospective Confirmation (PC) Period|Enrolled but not treated|0
6315151|NCT02717195|10048041|FG004|Prospective Confirmation (PC) Period|Enrolled but not treated|0
6315152|NCT02717195|10048037|FG000|Prospective Confirmation (PC) Period|Lack of results for blood levels|1
6315153|NCT02717195|10048038|FG001|Prospective Confirmation (PC) Period|Lack of results for blood levels|0
6315154|NCT02717195|10048039|FG002|Prospective Confirmation (PC) Period|Lack of results for blood levels|0
6315155|NCT02717195|10048040|FG003|Prospective Confirmation (PC) Period|Lack of results for blood levels|0
6315156|NCT02717195|10048041|FG004|Prospective Confirmation (PC) Period|Lack of results for blood levels|0
6315157|NCT02717195|10048037|FG000|Prospective Confirmation (PC) Period|Technical error|1
6315158|NCT02717195|10048038|FG001|Prospective Confirmation (PC) Period|Technical error|0
6315159|NCT02717195|10048039|FG002|Prospective Confirmation (PC) Period|Technical error|0
6315160|NCT02717195|10048040|FG003|Prospective Confirmation (PC) Period|Technical error|0
6315161|NCT02717195|10048041|FG004|Prospective Confirmation (PC) Period|Technical error|0
6315162|NCT02717195|10048037|FG000|Prospective Confirmation (PC) Period|Patient decision|5
6315163|NCT02717195|10048038|FG001|Prospective Confirmation (PC) Period|Patient decision|2
6315164|NCT02717195|10048039|FG002|Prospective Confirmation (PC) Period|Patient decision|0
6315165|NCT02717195|10048040|FG003|Prospective Confirmation (PC) Period|Patient decision|0
6315166|NCT02717195|10048041|FG004|Prospective Confirmation (PC) Period|Patient decision|0
6315167|NCT02717195|10048037|FG000|Prospective Confirmation (PC) Period|Low level of drug in the blood|1
6315168|NCT02717195|10048038|FG001|Prospective Confirmation (PC) Period|Low level of drug in the blood|0
6315169|NCT02717195|10048039|FG002|Prospective Confirmation (PC) Period|Low level of drug in the blood|0
6315170|NCT02717195|10048040|FG003|Prospective Confirmation (PC) Period|Low level of drug in the blood|0
6315171|NCT02717195|10048041|FG004|Prospective Confirmation (PC) Period|Low level of drug in the blood|0
6315172|NCT02717195|10048037|FG000|Prospective Confirmation (PC) Period|Change of place of residence|1
6315173|NCT02717195|10048038|FG001|Prospective Confirmation (PC) Period|Change of place of residence|0
6315174|NCT02717195|10048039|FG002|Prospective Confirmation (PC) Period|Change of place of residence|0
6315175|NCT02717195|10048040|FG003|Prospective Confirmation (PC) Period|Change of place of residence|0
6315176|NCT02717195|10048041|FG004|Prospective Confirmation (PC) Period|Change of place of residence|0
6315177|NCT02717195|10048037|FG000|Prospective Confirmation (PC) Period|Apato Abulcasis Syndrome|0
6315178|NCT02717195|10048038|FG001|Prospective Confirmation (PC) Period|Apato Abulcasis Syndrome|1
6315179|NCT02717195|10048039|FG002|Prospective Confirmation (PC) Period|Apato Abulcasis Syndrome|0
6315180|NCT02717195|10048040|FG003|Prospective Confirmation (PC) Period|Apato Abulcasis Syndrome|0
6315181|NCT02717195|10048041|FG004|Prospective Confirmation (PC) Period|Apato Abulcasis Syndrome|0
6315182|NCT02717195|10048037|FG000|Prospective Confirmation (PC) Period|Investigator decision|2
6315183|NCT02717195|10048038|FG001|Prospective Confirmation (PC) Period|Investigator decision|1
6315184|NCT02717195|10048039|FG002|Prospective Confirmation (PC) Period|Investigator decision|0
6315185|NCT02717195|10048040|FG003|Prospective Confirmation (PC) Period|Investigator decision|0
6315186|NCT02717195|10048041|FG004|Prospective Confirmation (PC) Period|Investigator decision|0
6315187|NCT02717195|10048037|FG000|Prospective Confirmation (PC) Period|Subject took exclusionary medication|0
6150124|NCT01103284|9786246|FG001|Overall Study|Lost to Follow-up|10
6150125|NCT01103284|9786245|FG000|Overall Study|Pregnancy|3
6150126|NCT01103284|9786246|FG001|Overall Study|Pregnancy|1
6150127|NCT01103284|9786245|FG000|Overall Study|Protocol Violation|12
6150128|NCT01103284|9786246|FG001|Overall Study|Protocol Violation|5
6150129|NCT01103284|9786245|FG000|Overall Study|Adverse Event|0
6150130|NCT01103284|9786246|FG001|Overall Study|Adverse Event|5
6150131|NCT01103284|9786245|FG000|Overall Study|Withdrawal by Subject|14
6150132|NCT01103284|9786246|FG001|Overall Study|Withdrawal by Subject|18
6150133|NCT01103284|9786245|FG000|Overall Study|Dermal Hypersensitivity|0
6150134|NCT01103284|9786246|FG001|Overall Study|Dermal Hypersensitivity|1
6150135|NCT01103284|9786245|FG000|Overall Study|Termination by the Sponsor|0
6150136|NCT01103284|9786246|FG001|Overall Study|Termination by the Sponsor|1
6150137|NCT01103284|9786245|FG000|Overall Study|Not described|2
6150138|NCT01103284|9786246|FG001|Overall Study|Not described|1
6150139|NCT01103284|9786245|FG000|Overall Study|Missing CRF entries for study completion|0
6150140|NCT01103284|9786246|FG001|Overall Study|Missing CRF entries for study completion|2
6150141|NCT01103323|9786254|FG000|Without/Before Drug Switch|Adverse Event|50
6150142|NCT01103323|9786255|FG001|Without/Before Drug Switch|Adverse Event|7
6150143|NCT01103323|9786254|FG000|Without/Before Drug Switch|Withdrawal by Subject|17
6150144|NCT01103323|9786255|FG001|Without/Before Drug Switch|Withdrawal by Subject|5
6150145|NCT01103323|9786254|FG000|Without/Before Drug Switch|Protocol Violation|2
6150146|NCT01103323|9786255|FG001|Without/Before Drug Switch|Protocol Violation|0
6150147|NCT01103323|9786254|FG000|Without/Before Drug Switch|Physician Decision|2
6150148|NCT01103323|9786255|FG001|Without/Before Drug Switch|Physician Decision|0
6150149|NCT01103323|9786254|FG000|Without/Before Drug Switch|did not receive study treatment|5
6150150|NCT01103323|9786255|FG001|Without/Before Drug Switch|did not receive study treatment|2
6150151|NCT01103323|9786254|FG000|Without/Before Drug Switch|Switch to Regorafenib|0
6150152|NCT01103323|9786255|FG001|Without/Before Drug Switch|Switch to Regorafenib|4
6150153|NCT01103323|9786254|FG000|Switched From Placebo to Regorafenib|Adverse Event|0
6150154|NCT01103323|9786255|FG001|Switched From Placebo to Regorafenib|Adverse Event|1
6150155|NCT01103362|9786262|FG000|Overall Study|study terminated|596
6150156|NCT01103466|9786296|FG000|First Period (14 +/- 3 Days)|Protocol Violation|2
6150157|NCT01103466|9786297|FG001|First Period (14 +/- 3 Days)|Protocol Violation|0
6150158|NCT01103466|9786298|FG002|First Period (14 +/- 3 Days)|Protocol Violation|0
6150159|NCT01103466|9786296|FG000|Second Period (14 +/- 3 Days)|Adverse Event|2
6150160|NCT01103466|9786297|FG001|Second Period (14 +/- 3 Days)|Adverse Event|1
6150161|NCT01103466|9786298|FG002|Second Period (14 +/- 3 Days)|Adverse Event|0
6150162|NCT01103466|9786296|FG000|Second Period (14 +/- 3 Days)|Lack of Efficacy|0
6150163|NCT01103466|9786297|FG001|Second Period (14 +/- 3 Days)|Lack of Efficacy|1
6150164|NCT01103466|9786298|FG002|Second Period (14 +/- 3 Days)|Lack of Efficacy|1
6150165|NCT01103466|9786296|FG000|Third Period (14 +/- 3 Days)|Adverse Event|1
6150166|NCT01103466|9786297|FG001|Third Period (14 +/- 3 Days)|Adverse Event|0
6150167|NCT01103466|9786298|FG002|Third Period (14 +/- 3 Days)|Adverse Event|0
6150168|NCT01103466|9786296|FG000|Third Period (14 +/- 3 Days)|Lack of Efficacy|1
6150169|NCT01103466|9786297|FG001|Third Period (14 +/- 3 Days)|Lack of Efficacy|0
6150170|NCT01103466|9786298|FG002|Third Period (14 +/- 3 Days)|Lack of Efficacy|0
6150171|NCT01103466|9786296|FG000|Third Period (14 +/- 3 Days)|not satisfied with product|0
6150172|NCT01103466|9786297|FG001|Third Period (14 +/- 3 Days)|not satisfied with product|0
6150173|NCT01103466|9786298|FG002|Third Period (14 +/- 3 Days)|not satisfied with product|1
6150174|NCT01103479|9786309|FG000|Overall Study|Up to date with CRC screening|1
6150175|NCT01103479|9786310|FG001|Overall Study|Up to date with CRC screening|9
6150176|NCT01103479|9786311|FG002|Overall Study|Up to date with CRC screening|12
6150177|NCT01103479|9786309|FG000|Overall Study|Family history of CRC|1
6150178|NCT01103479|9786310|FG001|Overall Study|Family history of CRC|0
6150179|NCT01103479|9786311|FG002|Overall Study|Family history of CRC|2
6150180|NCT01103479|9786309|FG000|Overall Study|Active cancer|1
6315188|NCT02717195|10048038|FG001|Prospective Confirmation (PC) Period|Subject took exclusionary medication|1
6040316|NCT04876274|9638156|FG000|Overall Study|Lost to Follow-up|9
6040317|NCT04876274|9638157|FG001|Overall Study|Lost to Follow-up|12
6040318|NCT04656691|9638163|FG000|Overall Study|Adverse Event|1
6040319|NCT04555096|9638178|FG000|Overall Study|Death|4
6040320|NCT04555096|9638179|FG001|Overall Study|Death|4
6040321|NCT04555096|9638178|FG000|Overall Study|Withdrawal by Subject|1
6040322|NCT04555096|9638179|FG001|Overall Study|Withdrawal by Subject|0
6040323|NCT04555096|9638178|FG000|Overall Study|Other|0
6150181|NCT01103479|9786310|FG001|Overall Study|Active cancer|0
6150182|NCT01103479|9786311|FG002|Overall Study|Active cancer|0
6150183|NCT01103479|9786309|FG000|Overall Study|Saw non-study physician|2
6150184|NCT01103479|9786310|FG001|Overall Study|Saw non-study physician|0
6150185|NCT01103479|9786311|FG002|Overall Study|Saw non-study physician|0
6191433|NCT01422876|9848245|FG001|Week 52|Lost to Follow-up|5
6191434|NCT01422876|9848246|FG002|Week 52|Lost to Follow-up|7
6191435|NCT01422876|9848247|FG003|Week 52|Lost to Follow-up|5
6191436|NCT01422876|9848248|FG004|Week 52|Lost to Follow-up|8
6040324|NCT04555096|9638179|FG001|Overall Study|Other|1
6040325|NCT04150341|9638185|FG000|Overall Study|Physician Decision|0
6040326|NCT04150341|9638186|FG001|Overall Study|Physician Decision|0
6040327|NCT04150341|9638187|FG002|Overall Study|Physician Decision|1
6040328|NCT04150341|9638188|FG003|Overall Study|Physician Decision|0
6040329|NCT04150341|9638189|FG004|Overall Study|Physician Decision|0
6040330|NCT04150341|9638190|FG005|Overall Study|Physician Decision|0
6040331|NCT04150341|9638185|FG000|Overall Study|Adverse Event|0
6040332|NCT04150341|9638186|FG001|Overall Study|Adverse Event|0
6040333|NCT04150341|9638187|FG002|Overall Study|Adverse Event|0
6040334|NCT04150341|9638188|FG003|Overall Study|Adverse Event|0
6040335|NCT04150341|9638189|FG004|Overall Study|Adverse Event|1
6040336|NCT04150341|9638190|FG005|Overall Study|Adverse Event|0
6040337|NCT04115839|9638203|FG000|Main Study (Up to 16 Weeks)|Study Terminated by Sponsor|14
6040338|NCT04115839|9638204|FG001|Main Study (Up to 16 Weeks)|Study Terminated by Sponsor|13
6040339|NCT04115839|9638205|FG002|Main Study (Up to 16 Weeks)|Study Terminated by Sponsor|14
6040340|NCT04115839|9638206|FG003|Main Study (Up to 16 Weeks)|Study Terminated by Sponsor|0
6040341|NCT04115839|9638207|FG004|Main Study (Up to 16 Weeks)|Study Terminated by Sponsor|0
6040342|NCT04115839|9638208|FG005|Main Study (Up to 16 Weeks)|Study Terminated by Sponsor|0
6040343|NCT04115839|9638209|FG006|Main Study (Up to 16 Weeks)|Study Terminated by Sponsor|0
6040344|NCT04115839|9638203|FG000|Main Study (Up to 16 Weeks)|Withdrew Consent|2
6040345|NCT04115839|9638204|FG001|Main Study (Up to 16 Weeks)|Withdrew Consent|1
6040346|NCT04115839|9638205|FG002|Main Study (Up to 16 Weeks)|Withdrew Consent|3
6040347|NCT04115839|9638206|FG003|Main Study (Up to 16 Weeks)|Withdrew Consent|0
6040348|NCT04115839|9638207|FG004|Main Study (Up to 16 Weeks)|Withdrew Consent|0
6040349|NCT04115839|9638208|FG005|Main Study (Up to 16 Weeks)|Withdrew Consent|0
6315189|NCT02717195|10048039|FG002|Prospective Confirmation (PC) Period|Subject took exclusionary medication|0
6315190|NCT02717195|10048040|FG003|Prospective Confirmation (PC) Period|Subject took exclusionary medication|0
6315191|NCT02717195|10048041|FG004|Prospective Confirmation (PC) Period|Subject took exclusionary medication|0
6315192|NCT02717195|10048037|FG000|Prospective Confirmation (PC) Period|Sub therapeutic blood levels Olanzapine|1
6315193|NCT02717195|10048038|FG001|Prospective Confirmation (PC) Period|Sub therapeutic blood levels Olanzapine|0
6315194|NCT02717195|10048039|FG002|Prospective Confirmation (PC) Period|Sub therapeutic blood levels Olanzapine|0
6315195|NCT02717195|10048040|FG003|Prospective Confirmation (PC) Period|Sub therapeutic blood levels Olanzapine|0
6315196|NCT02717195|10048041|FG004|Prospective Confirmation (PC) Period|Sub therapeutic blood levels Olanzapine|0
6315197|NCT02717195|10048037|FG000|Prospective Confirmation (PC) Period|Positive Urine Drug Screen|0
6315198|NCT02717195|10048038|FG001|Prospective Confirmation (PC) Period|Positive Urine Drug Screen|1
6315199|NCT02717195|10048039|FG002|Prospective Confirmation (PC) Period|Positive Urine Drug Screen|0
6315200|NCT02717195|10048040|FG003|Prospective Confirmation (PC) Period|Positive Urine Drug Screen|0
6315201|NCT02717195|10048041|FG004|Prospective Confirmation (PC) Period|Positive Urine Drug Screen|0
6315202|NCT02717195|10048037|FG000|Prospective Confirmation (PC) Period|Duplicate subject|1
6315203|NCT02717195|10048038|FG001|Prospective Confirmation (PC) Period|Duplicate subject|0
6315204|NCT02717195|10048039|FG002|Prospective Confirmation (PC) Period|Duplicate subject|0
6315205|NCT02717195|10048040|FG003|Prospective Confirmation (PC) Period|Duplicate subject|0
6315206|NCT02717195|10048041|FG004|Prospective Confirmation (PC) Period|Duplicate subject|0
6315207|NCT02717195|10048037|FG000|Prospective Confirmation (PC) Period|Sponsor requested|0
6315208|NCT02717195|10048038|FG001|Prospective Confirmation (PC) Period|Sponsor requested|1
6315209|NCT02717195|10048039|FG002|Prospective Confirmation (PC) Period|Sponsor requested|0
6315210|NCT02717195|10048040|FG003|Prospective Confirmation (PC) Period|Sponsor requested|0
6315211|NCT02717195|10048041|FG004|Prospective Confirmation (PC) Period|Sponsor requested|0
6315212|NCT02717195|10048037|FG000|Prospective Confirmation (PC) Period|Patient fraud with payment|1
6315213|NCT02717195|10048038|FG001|Prospective Confirmation (PC) Period|Patient fraud with payment|0
6315214|NCT02717195|10048039|FG002|Prospective Confirmation (PC) Period|Patient fraud with payment|0
6315215|NCT02717195|10048040|FG003|Prospective Confirmation (PC) Period|Patient fraud with payment|0
6315216|NCT02717195|10048041|FG004|Prospective Confirmation (PC) Period|Patient fraud with payment|0
6315217|NCT02717195|10048037|FG000|Prospective Confirmation (PC) Period|Noncompliance with protocol|1
6315218|NCT02717195|10048038|FG001|Prospective Confirmation (PC) Period|Noncompliance with protocol|0
6315219|NCT02717195|10048039|FG002|Prospective Confirmation (PC) Period|Noncompliance with protocol|0
6315220|NCT02717195|10048040|FG003|Prospective Confirmation (PC) Period|Noncompliance with protocol|0
6315221|NCT02717195|10048041|FG004|Prospective Confirmation (PC) Period|Noncompliance with protocol|0
6315222|NCT02717195|10048037|FG000|Double-blind Treatment (DBT) Period|Adverse Event|0
6315223|NCT02717195|10048038|FG001|Double-blind Treatment (DBT) Period|Adverse Event|0
6315224|NCT02717195|10048039|FG002|Double-blind Treatment (DBT) Period|Adverse Event|10
6315225|NCT02717195|10048040|FG003|Double-blind Treatment (DBT) Period|Adverse Event|11
6315226|NCT02717195|10048041|FG004|Double-blind Treatment (DBT) Period|Adverse Event|8
6315227|NCT02717195|10048037|FG000|Double-blind Treatment (DBT) Period|Lack of Efficacy|0
6315228|NCT02717195|10048038|FG001|Double-blind Treatment (DBT) Period|Lack of Efficacy|0
6315229|NCT02717195|10048039|FG002|Double-blind Treatment (DBT) Period|Lack of Efficacy|6
6040350|NCT04115839|9638209|FG006|Main Study (Up to 16 Weeks)|Withdrew Consent|0
6040351|NCT04115839|9638203|FG000|Main Study (Up to 16 Weeks)|Adverse Event|2
6040352|NCT04115839|9638204|FG001|Main Study (Up to 16 Weeks)|Adverse Event|0
6040353|NCT04115839|9638205|FG002|Main Study (Up to 16 Weeks)|Adverse Event|0
6040354|NCT04115839|9638206|FG003|Main Study (Up to 16 Weeks)|Adverse Event|0
6040355|NCT04115839|9638207|FG004|Main Study (Up to 16 Weeks)|Adverse Event|0
6315230|NCT02717195|10048040|FG003|Double-blind Treatment (DBT) Period|Lack of Efficacy|9
6315231|NCT02717195|10048041|FG004|Double-blind Treatment (DBT) Period|Lack of Efficacy|2
6315232|NCT02717195|10048037|FG000|Double-blind Treatment (DBT) Period|Non-compliance with IMP|0
6315233|NCT02717195|10048038|FG001|Double-blind Treatment (DBT) Period|Non-compliance with IMP|0
6315234|NCT02717195|10048039|FG002|Double-blind Treatment (DBT) Period|Non-compliance with IMP|4
6315235|NCT02717195|10048040|FG003|Double-blind Treatment (DBT) Period|Non-compliance with IMP|3
6315236|NCT02717195|10048041|FG004|Double-blind Treatment (DBT) Period|Non-compliance with IMP|2
6315237|NCT02717195|10048037|FG000|Double-blind Treatment (DBT) Period|Protocol Violation|0
6315238|NCT02717195|10048038|FG001|Double-blind Treatment (DBT) Period|Protocol Violation|0
6315239|NCT02717195|10048039|FG002|Double-blind Treatment (DBT) Period|Protocol Violation|1
6315240|NCT02717195|10048040|FG003|Double-blind Treatment (DBT) Period|Protocol Violation|0
6315241|NCT02717195|10048041|FG004|Double-blind Treatment (DBT) Period|Protocol Violation|1
6315242|NCT02717195|10048037|FG000|Double-blind Treatment (DBT) Period|Withdrawal by Subject|0
6315243|NCT02717195|10048038|FG001|Double-blind Treatment (DBT) Period|Withdrawal by Subject|0
6315244|NCT02717195|10048039|FG002|Double-blind Treatment (DBT) Period|Withdrawal by Subject|14
6315245|NCT02717195|10048040|FG003|Double-blind Treatment (DBT) Period|Withdrawal by Subject|13
6315246|NCT02717195|10048041|FG004|Double-blind Treatment (DBT) Period|Withdrawal by Subject|8
6315247|NCT02717195|10048037|FG000|Double-blind Treatment (DBT) Period|Lost to Follow-up|0
6315248|NCT02717195|10048038|FG001|Double-blind Treatment (DBT) Period|Lost to Follow-up|0
6315249|NCT02717195|10048039|FG002|Double-blind Treatment (DBT) Period|Lost to Follow-up|0
6315250|NCT02717195|10048040|FG003|Double-blind Treatment (DBT) Period|Lost to Follow-up|3
6315251|NCT02717195|10048041|FG004|Double-blind Treatment (DBT) Period|Lost to Follow-up|2
6315252|NCT02717195|10048037|FG000|Double-blind Treatment (DBT) Period|Enrolled but not treated|0
6315253|NCT02717195|10048038|FG001|Double-blind Treatment (DBT) Period|Enrolled but not treated|0
6315254|NCT02717195|10048039|FG002|Double-blind Treatment (DBT) Period|Enrolled but not treated|1
6315255|NCT02717195|10048040|FG003|Double-blind Treatment (DBT) Period|Enrolled but not treated|0
6315256|NCT02717195|10048041|FG004|Double-blind Treatment (DBT) Period|Enrolled but not treated|0
6315257|NCT02717195|10048037|FG000|Double-blind Treatment (DBT) Period|Patient decision|0
6315258|NCT02717195|10048038|FG001|Double-blind Treatment (DBT) Period|Patient decision|0
6315259|NCT02717195|10048039|FG002|Double-blind Treatment (DBT) Period|Patient decision|0
6315260|NCT02717195|10048040|FG003|Double-blind Treatment (DBT) Period|Patient decision|2
6315261|NCT02717195|10048041|FG004|Double-blind Treatment (DBT) Period|Patient decision|2
6315262|NCT02717195|10048037|FG000|Double-blind Treatment (DBT) Period|Investigator decision|0
6315263|NCT02717195|10048038|FG001|Double-blind Treatment (DBT) Period|Investigator decision|0
6315264|NCT02717195|10048039|FG002|Double-blind Treatment (DBT) Period|Investigator decision|0
6315265|NCT02717195|10048040|FG003|Double-blind Treatment (DBT) Period|Investigator decision|1
6040356|NCT04115839|9638208|FG005|Main Study (Up to 16 Weeks)|Adverse Event|0
6040357|NCT04115839|9638209|FG006|Main Study (Up to 16 Weeks)|Adverse Event|0
6040358|NCT04115839|9638203|FG000|Main Study (Up to 16 Weeks)|Investigator's Discretion|0
6315266|NCT02717195|10048041|FG004|Double-blind Treatment (DBT) Period|Investigator decision|1
6315267|NCT02717195|10048037|FG000|Double-blind Treatment (DBT) Period|Family circumstances|0
6315268|NCT02717195|10048038|FG001|Double-blind Treatment (DBT) Period|Family circumstances|0
6315269|NCT02717195|10048039|FG002|Double-blind Treatment (DBT) Period|Family circumstances|0
6315270|NCT02717195|10048040|FG003|Double-blind Treatment (DBT) Period|Family circumstances|0
6315271|NCT02717195|10048041|FG004|Double-blind Treatment (DBT) Period|Family circumstances|1
6315272|NCT02717195|10048037|FG000|Double-blind Treatment (DBT) Period|Change of residence|0
6315273|NCT02717195|10048038|FG001|Double-blind Treatment (DBT) Period|Change of residence|0
6315274|NCT02717195|10048039|FG002|Double-blind Treatment (DBT) Period|Change of residence|0
6315275|NCT02717195|10048040|FG003|Double-blind Treatment (DBT) Period|Change of residence|1
6315276|NCT02717195|10048041|FG004|Double-blind Treatment (DBT) Period|Change of residence|1
6315277|NCT02717195|10048037|FG000|Double-blind Treatment (DBT) Period|Needed antidepressant medication|0
6315278|NCT02717195|10048038|FG001|Double-blind Treatment (DBT) Period|Needed antidepressant medication|0
6315279|NCT02717195|10048039|FG002|Double-blind Treatment (DBT) Period|Needed antidepressant medication|0
6315280|NCT02717195|10048040|FG003|Double-blind Treatment (DBT) Period|Needed antidepressant medication|0
6315281|NCT02717195|10048041|FG004|Double-blind Treatment (DBT) Period|Needed antidepressant medication|1
6315282|NCT02717195|10048037|FG000|Double-blind Treatment (DBT) Period|Psychosocial issues|0
6315283|NCT02717195|10048038|FG001|Double-blind Treatment (DBT) Period|Psychosocial issues|0
6315284|NCT02717195|10048039|FG002|Double-blind Treatment (DBT) Period|Psychosocial issues|1
6315285|NCT02717195|10048040|FG003|Double-blind Treatment (DBT) Period|Psychosocial issues|0
6315286|NCT02717195|10048041|FG004|Double-blind Treatment (DBT) Period|Psychosocial issues|0
6315287|NCT02717195|10048037|FG000|Double-blind Treatment (DBT) Period|Patient missed required visits|0
6315288|NCT02717195|10048038|FG001|Double-blind Treatment (DBT) Period|Patient missed required visits|0
6315289|NCT02717195|10048039|FG002|Double-blind Treatment (DBT) Period|Patient missed required visits|0
6315290|NCT02717195|10048040|FG003|Double-blind Treatment (DBT) Period|Patient missed required visits|1
6315291|NCT02717195|10048041|FG004|Double-blind Treatment (DBT) Period|Patient missed required visits|1
6315292|NCT02717494|10048066|FG000|First Intervention (Step 1)|Lost to Follow-up|4
6315293|NCT02717494|10048067|FG001|First Intervention (Step 1)|Lost to Follow-up|7
6315294|NCT02717494|10048068|FG002|First Intervention (Step 1)|Lost to Follow-up|3
6315295|NCT02717494|10048066|FG000|First Intervention (Step 1)|Withdrawal by Subject|2
6315296|NCT02717494|10048067|FG001|First Intervention (Step 1)|Withdrawal by Subject|0
6315297|NCT02717494|10048068|FG002|First Intervention (Step 1)|Withdrawal by Subject|1
6315298|NCT02717494|10048066|FG000|First Intervention (Step 1)|Death|0
6315299|NCT02717494|10048067|FG001|First Intervention (Step 1)|Death|0
6315300|NCT02717494|10048068|FG002|First Intervention (Step 1)|Death|1
6315301|NCT02717494|10048066|FG000|Second Intervention (Step 2 or Step 3)|Lost to Follow-up|0
6315302|NCT02717494|10048067|FG001|Second Intervention (Step 2 or Step 3)|Lost to Follow-up|0
6315303|NCT02717494|10048068|FG002|Second Intervention (Step 2 or Step 3)|Lost to Follow-up|4
6315304|NCT02717546|10048094|FG000|Overall Study|Lost to Follow-up|12
6315305|NCT02717754|10048104|FG000|Overall Study|Incorrect Infusion Duration|0
6315306|NCT02717754|10048105|FG001|Overall Study|Incorrect Infusion Duration|0
6315307|NCT02717754|10048106|FG002|Overall Study|Incorrect Infusion Duration|0
6315308|NCT02717754|10048107|FG003|Overall Study|Incorrect Infusion Duration|10
6315309|NCT02717754|10048108|FG004|Overall Study|Incorrect Infusion Duration|20
6315310|NCT02717754|10048109|FG005|Overall Study|Incorrect Infusion Duration|20
6315311|NCT02718131|10048134|FG000|Overall Study|Withdrawal by Subject|1
6315312|NCT02718131|10048135|FG001|Overall Study|Withdrawal by Subject|0
6315313|NCT02718131|10048134|FG000|Overall Study|Adverse Event|1
6315314|NCT02718131|10048135|FG001|Overall Study|Adverse Event|0
6040359|NCT04115839|9638204|FG001|Main Study (Up to 16 Weeks)|Investigator's Discretion|0
6080307|NCT00615199|9687474|FG001|Overall Study|Other|0
6315315|NCT02718131|10048134|FG000|Overall Study|Data was incomplete. Patient was inevaluable|1
6315316|NCT02718131|10048135|FG001|Overall Study|Data was incomplete. Patient was inevaluable|0
6315317|NCT02718326|10048154|FG000|Overall Study|Adverse Event|4
6315318|NCT02718326|10048155|FG001|Overall Study|Adverse Event|9
6315319|NCT02718326|10048156|FG002|Overall Study|Adverse Event|0
6315320|NCT02718326|10048154|FG000|Overall Study|Death|8
6315321|NCT02718326|10048155|FG001|Overall Study|Death|1
6315322|NCT02718326|10048156|FG002|Overall Study|Death|2
6315323|NCT02718326|10048154|FG000|Overall Study|Withdrawal by Subject|4
6315324|NCT02718326|10048155|FG001|Overall Study|Withdrawal by Subject|9
6315325|NCT02718326|10048156|FG002|Overall Study|Withdrawal by Subject|6
6315326|NCT02718326|10048154|FG000|Overall Study|Lost to Follow-up|18
6315327|NCT02718326|10048155|FG001|Overall Study|Lost to Follow-up|5
6315328|NCT02718326|10048156|FG002|Overall Study|Lost to Follow-up|14
6315329|NCT02718326|10048154|FG000|Overall Study|Protocol Deviation|1
6315330|NCT02718326|10048155|FG001|Overall Study|Protocol Deviation|0
6315331|NCT02718326|10048156|FG002|Overall Study|Protocol Deviation|0
6315332|NCT02718326|10048154|FG000|Overall Study|Pregnancy|1
6315333|NCT02718326|10048155|FG001|Overall Study|Pregnancy|0
6315334|NCT02718326|10048156|FG002|Overall Study|Pregnancy|0
6315335|NCT02718417|10048169|FG000|Chemotherapy Phase (CP)|Adverse Event|9
6315336|NCT02718417|10048170|FG001|Chemotherapy Phase (CP)|Adverse Event|14
6315337|NCT02718417|10048171|FG002|Chemotherapy Phase (CP)|Adverse Event|13
6315338|NCT02718417|10048169|FG000|Chemotherapy Phase (CP)|Death leading to discontinuation|5
6315339|NCT02718417|10048170|FG001|Chemotherapy Phase (CP)|Death leading to discontinuation|4
6315340|NCT02718417|10048171|FG002|Chemotherapy Phase (CP)|Death leading to discontinuation|1
6315341|NCT02718417|10048169|FG000|Chemotherapy Phase (CP)|Global deterioration of health status|3
6315342|NCT02718417|10048170|FG001|Chemotherapy Phase (CP)|Global deterioration of health status|2
6150186|NCT01103713|9786341|FG000|Overall Study|Lost to Follow-up|2
6150187|NCT01103713|9786341|FG000|Overall Study|Withdrawal by Subject|8
6150188|NCT01103713|9786341|FG000|Overall Study|Study terminated by sponsor|2
6150189|NCT01103713|9786341|FG000|Overall Study|Other|1
6150190|NCT01103778|9786348|FG000|Overall Study|Lost to Follow-up|1
6150191|NCT01103778|9786348|FG000|Overall Study|Proteinuria improved prior to enrollment|1
6150192|NCT01103778|9786348|FG000|Overall Study|Screen failure|1
6150193|NCT01103960|9786365|FG000|Overall Study|Adverse Event|2
6150194|NCT01103960|9786366|FG001|Overall Study|Adverse Event|1
6150195|NCT01103960|9786365|FG000|Overall Study|Withdrawal by Subject|2
6150196|NCT01103960|9786366|FG001|Overall Study|Withdrawal by Subject|1
6150197|NCT01103960|9786365|FG000|Overall Study|Other|1
6150198|NCT01103960|9786366|FG001|Overall Study|Other|0
6150199|NCT01104155|9786407|FG000|Overall Study|Adverse Event|15
6150200|NCT01104155|9786408|FG001|Overall Study|Adverse Event|8
6150201|NCT01104155|9786407|FG000|Overall Study|Participant choice|6
6150202|NCT01104155|9786408|FG001|Overall Study|Participant choice|5
6150203|NCT01104155|9786407|FG000|Overall Study|Withdrawal of consent|1
6150204|NCT01104155|9786408|FG001|Overall Study|Withdrawal of consent|1
6150205|NCT01104155|9786407|FG000|Overall Study|Other|3
6150206|NCT01104155|9786408|FG001|Overall Study|Other|4
6150207|NCT01104246|9786423|FG000|Overall Study|Withdrawal by Subject|1
6150208|NCT01104246|9786423|FG000|Overall Study|did not meet inclusion criteria|4
6150209|NCT01104311|9786438|FG000|Overall Study|Withdrawal by Subject|6
6150210|NCT01104311|9786439|FG001|Overall Study|Withdrawal by Subject|6
6150211|NCT01104311|9786438|FG000|Overall Study|Protocol Violation|0
6150212|NCT01104311|9786439|FG001|Overall Study|Protocol Violation|1
6150213|NCT01104311|9786438|FG000|Overall Study|Physician Decision|2
6150214|NCT01104311|9786439|FG001|Overall Study|Physician Decision|2
6150215|NCT01104311|9786438|FG000|Overall Study|low compliance|1
6150216|NCT01104311|9786439|FG001|Overall Study|low compliance|1
6150217|NCT01104311|9786438|FG000|Overall Study|Adverse Event|1
6150218|NCT01104311|9786439|FG001|Overall Study|Adverse Event|2
6150219|NCT01104376|9786449|FG000|Overall Study|Withdrawal by Subject|15
6150220|NCT01104376|9786449|FG000|Overall Study|Consented but excluded after labs|13
6150221|NCT01104415|9786462|FG000|Core Phase|Consent withdrawn by subjects|1
6150222|NCT01104415|9786463|FG001|Core Phase|Consent withdrawn by subjects|0
6150223|NCT01104415|9786462|FG000|Extension Period|Progressive disease|0
6150224|NCT01104415|9786463|FG001|Extension Period|Progressive disease|4
6150225|NCT01104415|9786462|FG000|Extension Period|Death|0
6150226|NCT01104415|9786463|FG001|Extension Period|Death|1
6150227|NCT01104415|9786462|FG000|Extension Period|Physician Decision|0
6150228|NCT01104415|9786463|FG001|Extension Period|Physician Decision|1
6150229|NCT01104415|9786462|FG000|Extension Period|Transition to Study LX1606.302|0
6150230|NCT01104415|9786463|FG001|Extension Period|Transition to Study LX1606.302|4
6150231|NCT01104415|9786462|FG000|Extension Period|Heart surgery/feeling miserable|0
6150232|NCT01104415|9786463|FG001|Extension Period|Heart surgery/feeling miserable|1
6315343|NCT02718417|10048171|FG002|Chemotherapy Phase (CP)|Global deterioration of health status|1
6150233|NCT01104493|9786472|FG000|Overall Study|Lost to Follow-up|0
6150234|NCT01104493|9786473|FG001|Overall Study|Lost to Follow-up|2
6150235|NCT01104545|9786482|FG000|Overall Study|Adverse Event|0
6315344|NCT02718417|10048169|FG000|Chemotherapy Phase (CP)|No longer met eligibility criteria|4
6315345|NCT02718417|10048170|FG001|Chemotherapy Phase (CP)|No longer met eligibility criteria|2
6315346|NCT02718417|10048171|FG002|Chemotherapy Phase (CP)|No longer met eligibility criteria|1
6315347|NCT02718417|10048169|FG000|Chemotherapy Phase (CP)|Physician's decision|5
6315348|NCT02718417|10048170|FG001|Chemotherapy Phase (CP)|Physician's decision|0
6315349|NCT02718417|10048171|FG002|Chemotherapy Phase (CP)|Physician's decision|4
6315350|NCT02718417|10048169|FG000|Chemotherapy Phase (CP)|Progressive disease|11
6315351|NCT02718417|10048170|FG001|Chemotherapy Phase (CP)|Progressive disease|7
6315352|NCT02718417|10048171|FG002|Chemotherapy Phase (CP)|Progressive disease|10
6315353|NCT02718417|10048169|FG000|Chemotherapy Phase (CP)|Withdrawal by Subject|13
6315354|NCT02718417|10048170|FG001|Chemotherapy Phase (CP)|Withdrawal by Subject|8
6315355|NCT02718417|10048171|FG002|Chemotherapy Phase (CP)|Withdrawal by Subject|15
6315356|NCT02718417|10048169|FG000|Chemotherapy Phase (CP)|Other|2
6315357|NCT02718417|10048170|FG001|Chemotherapy Phase (CP)|Other|0
6315358|NCT02718417|10048171|FG002|Chemotherapy Phase (CP)|Other|1
6315359|NCT02718417|10048169|FG000|Maintenance Phase (MP)|Adverse Event|21
6315360|NCT02718417|10048170|FG001|Maintenance Phase (MP)|Adverse Event|26
6315361|NCT02718417|10048171|FG002|Maintenance Phase (MP)|Adverse Event|0
6315362|NCT02718417|10048169|FG000|Maintenance Phase (MP)|Death leading to discontinuation|1
6315363|NCT02718417|10048170|FG001|Maintenance Phase (MP)|Death leading to discontinuation|1
6315364|NCT02718417|10048171|FG002|Maintenance Phase (MP)|Death leading to discontinuation|0
6315365|NCT02718417|10048169|FG000|Maintenance Phase (MP)|Global deterioration of health status|5
6315366|NCT02718417|10048170|FG001|Maintenance Phase (MP)|Global deterioration of health status|3
6315367|NCT02718417|10048171|FG002|Maintenance Phase (MP)|Global deterioration of health status|0
6315368|NCT02718417|10048169|FG000|Maintenance Phase (MP)|No longer met eligibility criteria|0
6315369|NCT02718417|10048170|FG001|Maintenance Phase (MP)|No longer met eligibility criteria|1
6315370|NCT02718417|10048171|FG002|Maintenance Phase (MP)|No longer met eligibility criteria|0
6315371|NCT02718417|10048169|FG000|Maintenance Phase (MP)|Physician's decision|6
6315372|NCT02718417|10048170|FG001|Maintenance Phase (MP)|Physician's decision|7
6315373|NCT02718417|10048171|FG002|Maintenance Phase (MP)|Physician's decision|0
6315374|NCT02718417|10048169|FG000|Maintenance Phase (MP)|Progressive disease|100
6315375|NCT02718417|10048170|FG001|Maintenance Phase (MP)|Progressive disease|88
6315376|NCT02718417|10048171|FG002|Maintenance Phase (MP)|Progressive disease|0
6315377|NCT02718417|10048169|FG000|Maintenance Phase (MP)|Other|2
6315378|NCT02718417|10048170|FG001|Maintenance Phase (MP)|Other|1
6315379|NCT02718417|10048171|FG002|Maintenance Phase (MP)|Other|0
6315380|NCT02718417|10048169|FG000|Maintenance Phase (MP)|Withdrawal by Subject|17
6315381|NCT02718417|10048170|FG001|Maintenance Phase (MP)|Withdrawal by Subject|20
6315382|NCT02718417|10048171|FG002|Maintenance Phase (MP)|Withdrawal by Subject|0
6315383|NCT02718417|10048169|FG000|Maintenance Phase (MP)|Study terminated by sponsor|114
6315384|NCT02718417|10048170|FG001|Maintenance Phase (MP)|Study terminated by sponsor|140
6315385|NCT02718417|10048171|FG002|Maintenance Phase (MP)|Study terminated by sponsor|0
6315386|NCT02718417|10048169|FG000|Observation Phase (OP)|Adverse Event|0
6315387|NCT02718417|10048170|FG001|Observation Phase (OP)|Adverse Event|0
6315388|NCT02718417|10048171|FG002|Observation Phase (OP)|Adverse Event|1
6315389|NCT02718417|10048169|FG000|Observation Phase (OP)|Death leading to discontinuation|0
6315390|NCT02718417|10048170|FG001|Observation Phase (OP)|Death leading to discontinuation|0
6315391|NCT02718417|10048171|FG002|Observation Phase (OP)|Death leading to discontinuation|2
6315392|NCT02718417|10048169|FG000|Observation Phase (OP)|Lost to Follow-up|0
6315393|NCT02718417|10048170|FG001|Observation Phase (OP)|Lost to Follow-up|0
6315394|NCT02718417|10048171|FG002|Observation Phase (OP)|Lost to Follow-up|1
6315395|NCT02718417|10048169|FG000|Observation Phase (OP)|Physician Decision|0
6315396|NCT02718417|10048170|FG001|Observation Phase (OP)|Physician Decision|0
6315397|NCT02718417|10048171|FG002|Observation Phase (OP)|Physician Decision|9
6315398|NCT02718417|10048169|FG000|Observation Phase (OP)|Progressive disease|0
6315399|NCT02718417|10048170|FG001|Observation Phase (OP)|Progressive disease|0
6315400|NCT02718417|10048171|FG002|Observation Phase (OP)|Progressive disease|92
6315401|NCT02718417|10048169|FG000|Observation Phase (OP)|Study terminated by sponsor|0
6315402|NCT02718417|10048170|FG001|Observation Phase (OP)|Study terminated by sponsor|0
6315403|NCT02718417|10048171|FG002|Observation Phase (OP)|Study terminated by sponsor|135
6315404|NCT02718417|10048169|FG000|Observation Phase (OP)|Withdrawal by Subject|0
6315405|NCT02718417|10048170|FG001|Observation Phase (OP)|Withdrawal by Subject|0
6315406|NCT02718417|10048171|FG002|Observation Phase (OP)|Withdrawal by Subject|34
6315407|NCT02718417|10048169|FG000|Observation Phase (OP)|Global deterioration of health status|0
6315408|NCT02718417|10048170|FG001|Observation Phase (OP)|Global deterioration of health status|0
6315409|NCT02718417|10048171|FG002|Observation Phase (OP)|Global deterioration of health status|1
6315410|NCT02718417|10048169|FG000|Observation Phase (OP)|Other|0
6315411|NCT02718417|10048170|FG001|Observation Phase (OP)|Other|0
6315412|NCT02718417|10048171|FG002|Observation Phase (OP)|Other|7
6315413|NCT02718417|10048169|FG000|Follow-up Phase|Adverse Event|3
6315414|NCT02718417|10048170|FG001|Follow-up Phase|Adverse Event|1
6315415|NCT02718417|10048171|FG002|Follow-up Phase|Adverse Event|1
6315416|NCT02718417|10048169|FG000|Follow-up Phase|Other|4
6315417|NCT02718417|10048170|FG001|Follow-up Phase|Other|6
6315418|NCT02718417|10048171|FG002|Follow-up Phase|Other|4
6315419|NCT02718417|10048169|FG000|Follow-up Phase|Withdrawal by Subject|19
6315420|NCT02718417|10048170|FG001|Follow-up Phase|Withdrawal by Subject|17
6315421|NCT02718417|10048171|FG002|Follow-up Phase|Withdrawal by Subject|5
6315422|NCT02718417|10048169|FG000|Follow-up Phase|Study terminated by sponsor|100
6315423|NCT02718417|10048170|FG001|Follow-up Phase|Study terminated by sponsor|138
6315424|NCT02718417|10048171|FG002|Follow-up Phase|Study terminated by sponsor|6
6315425|NCT02718417|10048169|FG000|Follow-up Phase|Lost to Follow-up|2
6315426|NCT02718417|10048170|FG001|Follow-up Phase|Lost to Follow-up|3
6315427|NCT02718417|10048171|FG002|Follow-up Phase|Lost to Follow-up|0
6315428|NCT02718417|10048169|FG000|Follow-up Phase|Death leading to discontinuation|7
6315429|NCT02718417|10048170|FG001|Follow-up Phase|Death leading to discontinuation|7
6315430|NCT02718417|10048171|FG002|Follow-up Phase|Death leading to discontinuation|3
6315431|NCT02718417|10048169|FG000|Long-term Follow-up Phase|Death leading to discontinuation|20
6315432|NCT02718417|10048170|FG001|Long-term Follow-up Phase|Death leading to discontinuation|17
6315433|NCT02718417|10048171|FG002|Long-term Follow-up Phase|Death leading to discontinuation|11
6315434|NCT02718417|10048169|FG000|Long-term Follow-up Phase|Lost to Follow-up|8
6315435|NCT02718417|10048170|FG001|Long-term Follow-up Phase|Lost to Follow-up|4
6315436|NCT02718417|10048171|FG002|Long-term Follow-up Phase|Lost to Follow-up|3
6315437|NCT02718417|10048169|FG000|Long-term Follow-up Phase|Study terminated by sponsor|105
6315438|NCT02718417|10048170|FG001|Long-term Follow-up Phase|Study terminated by sponsor|80
6315439|NCT02718417|10048171|FG002|Long-term Follow-up Phase|Study terminated by sponsor|112
6315440|NCT02718417|10048169|FG000|Long-term Follow-up Phase|Withdrawal by Subject|6
6315441|NCT02718417|10048170|FG001|Long-term Follow-up Phase|Withdrawal by Subject|9
6315442|NCT02718417|10048171|FG002|Long-term Follow-up Phase|Withdrawal by Subject|9
6315443|NCT02718417|10048169|FG000|Long-term Follow-up Phase|Other|0
6315444|NCT02718417|10048170|FG001|Long-term Follow-up Phase|Other|2
6315445|NCT02718417|10048171|FG002|Long-term Follow-up Phase|Other|0
6315446|NCT02718625|10048188|FG000|Overall Study|Adverse Event|0
6315447|NCT02718625|10048189|FG001|Overall Study|Adverse Event|1
6315448|NCT02718625|10048188|FG000|Overall Study|Termination of Study by Sponsor|0
6315449|NCT02718625|10048189|FG001|Overall Study|Termination of Study by Sponsor|1
6315450|NCT02718898|10048197|FG000|Blinded Treatment Period|Adverse Event|5
6315451|NCT02718898|10048198|FG001|Blinded Treatment Period|Adverse Event|1
6315452|NCT02718898|10048199|FG002|Blinded Treatment Period|Adverse Event|0
6315453|NCT02718898|10048200|FG003|Blinded Treatment Period|Adverse Event|0
6315454|NCT02718898|10048201|FG004|Blinded Treatment Period|Adverse Event|0
6315455|NCT02718898|10048202|FG005|Blinded Treatment Period|Adverse Event|0
6315456|NCT02718898|10048203|FG006|Blinded Treatment Period|Adverse Event|0
6150236|NCT01104545|9786483|FG001|Overall Study|Adverse Event|1
6150237|NCT01104545|9786484|FG002|Overall Study|Adverse Event|2
6150238|NCT01104558|9786529|FG000|Overall Study|Protocol Violation|6
6150239|NCT01104558|9786529|FG000|Overall Study|Missing of primary efficacy assessment|10
6150240|NCT01104558|9786529|FG000|Overall Study|Missing of genetic analysis results|1
6150241|NCT01104584|9786533|FG000|Overall Study|Study drug never administered|21
6150242|NCT01104584|9786533|FG000|Overall Study|Study prematurely discontinued|2
6150243|NCT01104636|9786555|FG000|Overall Study|Lack of Efficacy|43
6150244|NCT01104636|9786555|FG000|Overall Study|Lost to Follow-up|24
6150245|NCT01104636|9786555|FG000|Overall Study|Withdrawal by Subject|4
6150246|NCT01104636|9786555|FG000|Overall Study|Other|43
6150247|NCT01104636|9786555|FG000|Overall Study|Study terminated by sponsor|1
6150248|NCT01104636|9786555|FG000|Overall Study|Pregnancy|2
6150249|NCT01104636|9786555|FG000|Overall Study|Adverse Event|40
6150250|NCT01104636|9786555|FG000|Overall Study|Ongoing|21
6315457|NCT02718898|10048197|FG000|Blinded Treatment Period|Physician Decision|1
6315458|NCT02718898|10048198|FG001|Blinded Treatment Period|Physician Decision|0
6315459|NCT02718898|10048199|FG002|Blinded Treatment Period|Physician Decision|0
6315460|NCT02718898|10048200|FG003|Blinded Treatment Period|Physician Decision|0
6315461|NCT02718898|10048201|FG004|Blinded Treatment Period|Physician Decision|0
6315462|NCT02718898|10048202|FG005|Blinded Treatment Period|Physician Decision|0
6315463|NCT02718898|10048203|FG006|Blinded Treatment Period|Physician Decision|0
6315464|NCT02718898|10048197|FG000|Blinded Treatment Period|Lack of Efficacy|1
6315465|NCT02718898|10048198|FG001|Blinded Treatment Period|Lack of Efficacy|0
6315466|NCT02718898|10048199|FG002|Blinded Treatment Period|Lack of Efficacy|0
6315467|NCT02718898|10048200|FG003|Blinded Treatment Period|Lack of Efficacy|0
6315468|NCT02718898|10048201|FG004|Blinded Treatment Period|Lack of Efficacy|0
6315469|NCT02718898|10048202|FG005|Blinded Treatment Period|Lack of Efficacy|0
6315470|NCT02718898|10048203|FG006|Blinded Treatment Period|Lack of Efficacy|0
6315471|NCT02718898|10048197|FG000|Blinded Treatment Period|Lost to Follow-up|2
6315472|NCT02718898|10048198|FG001|Blinded Treatment Period|Lost to Follow-up|0
6315473|NCT02718898|10048199|FG002|Blinded Treatment Period|Lost to Follow-up|0
6315474|NCT02718898|10048200|FG003|Blinded Treatment Period|Lost to Follow-up|0
6315475|NCT02718898|10048201|FG004|Blinded Treatment Period|Lost to Follow-up|0
6315476|NCT02718898|10048202|FG005|Blinded Treatment Period|Lost to Follow-up|0
6315477|NCT02718898|10048203|FG006|Blinded Treatment Period|Lost to Follow-up|0
6315478|NCT02718898|10048197|FG000|Open Label Treatment Period (OLTP)|Adverse Event|0
6315479|NCT02718898|10048198|FG001|Open Label Treatment Period (OLTP)|Adverse Event|0
6315480|NCT02718898|10048199|FG002|Open Label Treatment Period (OLTP)|Adverse Event|1
6315481|NCT02718898|10048200|FG003|Open Label Treatment Period (OLTP)|Adverse Event|1
6315482|NCT02718898|10048201|FG004|Open Label Treatment Period (OLTP)|Adverse Event|0
6315483|NCT02718898|10048202|FG005|Open Label Treatment Period (OLTP)|Adverse Event|0
6315484|NCT02718898|10048203|FG006|Open Label Treatment Period (OLTP)|Adverse Event|0
6315485|NCT02718898|10048197|FG000|Open Label Treatment Period (OLTP)|Lost to Follow-up|0
6150251|NCT01104662|9786567|FG000|Overall Study|Adverse Event|2
6150252|NCT01104662|9786568|FG001|Overall Study|Adverse Event|2
6150253|NCT01104662|9786569|FG002|Overall Study|Adverse Event|0
6315486|NCT02718898|10048198|FG001|Open Label Treatment Period (OLTP)|Lost to Follow-up|0
6315487|NCT02718898|10048199|FG002|Open Label Treatment Period (OLTP)|Lost to Follow-up|0
6040360|NCT04115839|9638205|FG002|Main Study (Up to 16 Weeks)|Investigator's Discretion|1
6315488|NCT02718898|10048200|FG003|Open Label Treatment Period (OLTP)|Lost to Follow-up|2
6315489|NCT02718898|10048201|FG004|Open Label Treatment Period (OLTP)|Lost to Follow-up|0
6315490|NCT02718898|10048202|FG005|Open Label Treatment Period (OLTP)|Lost to Follow-up|0
6315491|NCT02718898|10048203|FG006|Open Label Treatment Period (OLTP)|Lost to Follow-up|0
6315492|NCT02718898|10048197|FG000|Open Label Treatment Period (OLTP)|Withdrawal by Subject|0
6315493|NCT02718898|10048198|FG001|Open Label Treatment Period (OLTP)|Withdrawal by Subject|0
6315494|NCT02718898|10048199|FG002|Open Label Treatment Period (OLTP)|Withdrawal by Subject|1
6315495|NCT02718898|10048200|FG003|Open Label Treatment Period (OLTP)|Withdrawal by Subject|3
6315496|NCT02718898|10048201|FG004|Open Label Treatment Period (OLTP)|Withdrawal by Subject|0
6315497|NCT02718898|10048202|FG005|Open Label Treatment Period (OLTP)|Withdrawal by Subject|0
6315498|NCT02718898|10048203|FG006|Open Label Treatment Period (OLTP)|Withdrawal by Subject|0
6315499|NCT02718898|10048197|FG000|Open Label Treatment Period (OLTP)|Lack of Efficacy|0
6315500|NCT02718898|10048198|FG001|Open Label Treatment Period (OLTP)|Lack of Efficacy|0
6315501|NCT02718898|10048199|FG002|Open Label Treatment Period (OLTP)|Lack of Efficacy|1
6315502|NCT02718898|10048200|FG003|Open Label Treatment Period (OLTP)|Lack of Efficacy|2
6315503|NCT02718898|10048201|FG004|Open Label Treatment Period (OLTP)|Lack of Efficacy|0
6315504|NCT02718898|10048202|FG005|Open Label Treatment Period (OLTP)|Lack of Efficacy|0
6315505|NCT02718898|10048203|FG006|Open Label Treatment Period (OLTP)|Lack of Efficacy|0
6315506|NCT02718898|10048197|FG000|Open Label Treatment Period (OLTP)|Subject discontinued in OLTP|0
6315507|NCT02718898|10048198|FG001|Open Label Treatment Period (OLTP)|Subject discontinued in OLTP|0
6315508|NCT02718898|10048199|FG002|Open Label Treatment Period (OLTP)|Subject discontinued in OLTP|0
6315509|NCT02718898|10048200|FG003|Open Label Treatment Period (OLTP)|Subject discontinued in OLTP|1
6315510|NCT02718898|10048201|FG004|Open Label Treatment Period (OLTP)|Subject discontinued in OLTP|0
6315511|NCT02718898|10048202|FG005|Open Label Treatment Period (OLTP)|Subject discontinued in OLTP|0
6315512|NCT02718898|10048203|FG006|Open Label Treatment Period (OLTP)|Subject discontinued in OLTP|0
6315513|NCT02718898|10048197|FG000|Open Label Treatment Period (OLTP)|Ttt of undisclosed addiction-Pt withdrew|0
6315514|NCT02718898|10048198|FG001|Open Label Treatment Period (OLTP)|Ttt of undisclosed addiction-Pt withdrew|0
6315515|NCT02718898|10048199|FG002|Open Label Treatment Period (OLTP)|Ttt of undisclosed addiction-Pt withdrew|0
6315516|NCT02718898|10048200|FG003|Open Label Treatment Period (OLTP)|Ttt of undisclosed addiction-Pt withdrew|1
6315517|NCT02718898|10048201|FG004|Open Label Treatment Period (OLTP)|Ttt of undisclosed addiction-Pt withdrew|0
6315518|NCT02718898|10048202|FG005|Open Label Treatment Period (OLTP)|Ttt of undisclosed addiction-Pt withdrew|0
6315519|NCT02718898|10048203|FG006|Open Label Treatment Period (OLTP)|Ttt of undisclosed addiction-Pt withdrew|0
6315520|NCT02718898|10048197|FG000|Post Treatment Follow-up Period|Adverse Event|0
6315521|NCT02718898|10048198|FG001|Post Treatment Follow-up Period|Adverse Event|0
6315522|NCT02718898|10048199|FG002|Post Treatment Follow-up Period|Adverse Event|0
6315523|NCT02718898|10048200|FG003|Post Treatment Follow-up Period|Adverse Event|0
6315524|NCT02718898|10048201|FG004|Post Treatment Follow-up Period|Adverse Event|0
6315525|NCT02718898|10048202|FG005|Post Treatment Follow-up Period|Adverse Event|1
6315526|NCT02718898|10048203|FG006|Post Treatment Follow-up Period|Adverse Event|1
6315527|NCT02718898|10048197|FG000|Post Treatment Follow-up Period|Lost to Follow-up|0
6315528|NCT02718898|10048198|FG001|Post Treatment Follow-up Period|Lost to Follow-up|0
6315529|NCT02718898|10048199|FG002|Post Treatment Follow-up Period|Lost to Follow-up|0
6315530|NCT02718898|10048200|FG003|Post Treatment Follow-up Period|Lost to Follow-up|0
6315531|NCT02718898|10048201|FG004|Post Treatment Follow-up Period|Lost to Follow-up|1
6315532|NCT02718898|10048202|FG005|Post Treatment Follow-up Period|Lost to Follow-up|5
6315533|NCT02718898|10048203|FG006|Post Treatment Follow-up Period|Lost to Follow-up|1
6315534|NCT02718898|10048197|FG000|Post Treatment Follow-up Period|Withdrawal by Subject|0
6315535|NCT02718898|10048198|FG001|Post Treatment Follow-up Period|Withdrawal by Subject|0
6315536|NCT02718898|10048199|FG002|Post Treatment Follow-up Period|Withdrawal by Subject|0
6315537|NCT02718898|10048200|FG003|Post Treatment Follow-up Period|Withdrawal by Subject|0
6315538|NCT02718898|10048201|FG004|Post Treatment Follow-up Period|Withdrawal by Subject|0
6315539|NCT02718898|10048202|FG005|Post Treatment Follow-up Period|Withdrawal by Subject|5
6315540|NCT02718898|10048203|FG006|Post Treatment Follow-up Period|Withdrawal by Subject|3
6315541|NCT02719028|10048229|FG000|Overall Study|Adverse Event|2
6315542|NCT02719028|10048230|FG001|Overall Study|Adverse Event|1
6315543|NCT02719028|10048231|FG002|Overall Study|Adverse Event|4
6315544|NCT02719028|10048232|FG003|Overall Study|Adverse Event|8
6315545|NCT02719028|10048229|FG000|Overall Study|Physician Decision|0
6315546|NCT02719028|10048230|FG001|Overall Study|Physician Decision|1
6315547|NCT02719028|10048231|FG002|Overall Study|Physician Decision|1
6315548|NCT02719028|10048232|FG003|Overall Study|Physician Decision|1
6315549|NCT02719028|10048229|FG000|Overall Study|Use of prohibited medication|0
6315550|NCT02719028|10048230|FG001|Overall Study|Use of prohibited medication|0
6315551|NCT02719028|10048231|FG002|Overall Study|Use of prohibited medication|1
6315552|NCT02719028|10048232|FG003|Overall Study|Use of prohibited medication|0
6315553|NCT02719028|10048229|FG000|Overall Study|Protocol Violation|0
6315554|NCT02719028|10048230|FG001|Overall Study|Protocol Violation|0
6040361|NCT04115839|9638206|FG003|Main Study (Up to 16 Weeks)|Investigator's Discretion|0
6040362|NCT04115839|9638207|FG004|Main Study (Up to 16 Weeks)|Investigator's Discretion|0
6315555|NCT02719028|10048231|FG002|Overall Study|Protocol Violation|0
6315556|NCT02719028|10048232|FG003|Overall Study|Protocol Violation|1
6315557|NCT02719171|10048260|FG000|Overall Study|Adverse Event|1
6315558|NCT02719171|10048261|FG001|Overall Study|Adverse Event|2
6315559|NCT02719171|10048262|FG002|Overall Study|Adverse Event|0
6315560|NCT02719171|10048263|FG003|Overall Study|Adverse Event|0
6315561|NCT02719171|10048264|FG004|Overall Study|Adverse Event|2
6315562|NCT02719171|10048260|FG000|Overall Study|Lost to Follow-up|0
6315563|NCT02719171|10048261|FG001|Overall Study|Lost to Follow-up|0
6315564|NCT02719171|10048262|FG002|Overall Study|Lost to Follow-up|1
6315565|NCT02719171|10048263|FG003|Overall Study|Lost to Follow-up|0
6315566|NCT02719171|10048264|FG004|Overall Study|Lost to Follow-up|0
6315567|NCT02719171|10048260|FG000|Overall Study|Subject Withdrawal|0
6315568|NCT02719171|10048261|FG001|Overall Study|Subject Withdrawal|2
6315569|NCT02719171|10048262|FG002|Overall Study|Subject Withdrawal|2
6315570|NCT02719171|10048263|FG003|Overall Study|Subject Withdrawal|1
6315571|NCT02719171|10048264|FG004|Overall Study|Subject Withdrawal|0
6315572|NCT02719171|10048260|FG000|Overall Study|Other|0
6315573|NCT02719171|10048261|FG001|Overall Study|Other|0
6315574|NCT02719171|10048262|FG002|Overall Study|Other|0
6315575|NCT02719171|10048263|FG003|Overall Study|Other|1
6315576|NCT02719171|10048264|FG004|Overall Study|Other|0
6315577|NCT02719353|10048279|FG000|First Intervention|Physician Decision|0
6315578|NCT02719353|10048280|FG001|First Intervention|Physician Decision|1
6315579|NCT02719743|10048308|FG000|Overall Study|Consent withdrawal|0
6315580|NCT02719743|10048309|FG001|Overall Study|Consent withdrawal|2
6315581|NCT02719743|10048310|FG002|Overall Study|Consent withdrawal|0
6315582|NCT02719743|10048311|FG003|Overall Study|Consent withdrawal|1
6315583|NCT02719743|10048312|FG004|Overall Study|Consent withdrawal|0
6315584|NCT02719743|10048308|FG000|Overall Study|Migrated/moved from study area|0
6315585|NCT02719743|10048309|FG001|Overall Study|Migrated/moved from study area|0
6315586|NCT02719743|10048310|FG002|Overall Study|Migrated/moved from study area|0
6315587|NCT02719743|10048311|FG003|Overall Study|Migrated/moved from study area|0
6315588|NCT02719743|10048312|FG004|Overall Study|Migrated/moved from study area|2
6315589|NCT02719743|10048308|FG000|Overall Study|Lost to Follow-up|1
6315590|NCT02719743|10048309|FG001|Overall Study|Lost to Follow-up|1
6315591|NCT02719743|10048310|FG002|Overall Study|Lost to Follow-up|0
6315592|NCT02719743|10048311|FG003|Overall Study|Lost to Follow-up|0
6315593|NCT02719743|10048312|FG004|Overall Study|Lost to Follow-up|0
6315594|NCT02720042|10048333|FG000|Overall Study|Death|3
6315595|NCT02720042|10048333|FG000|Overall Study|Lost to Follow-up|4
6315596|NCT02720042|10048333|FG000|Overall Study|Withdrawal by Subject|1
6315597|NCT02720042|10048333|FG000|Overall Study|Physician Decision|3
6315598|NCT02720042|10048333|FG000|Overall Study|Phasix Mesh explanted|1
6315599|NCT02720042|10048333|FG000|Overall Study|unable due to non-study-related illness|3
6315600|NCT02720081|10048339|FG000|Overall Study|Adverse Event|0
6315601|NCT02720081|10048340|FG001|Overall Study|Adverse Event|3
6315602|NCT02720081|10048339|FG000|Overall Study|Protocol Violation|4
6315603|NCT02720081|10048340|FG001|Overall Study|Protocol Violation|1
6315604|NCT02720198|10048352|FG000|Overall Study|Withdrawal by Subject|0
6315605|NCT02720198|10048353|FG001|Overall Study|Withdrawal by Subject|1
6315606|NCT02720484|10048363|FG000|Treatment on Study|Adverse Event|1
6315607|NCT02720484|10048363|FG000|Treatment on Study|Withdrawal by Subject|1
6315608|NCT02720484|10048363|FG000|Treatment on Study|Progressive Disease|4
6315609|NCT02720484|10048363|FG000|Follow Up for 2 Years|Withdrawal by Subject|1
6315610|NCT02720484|10048363|FG000|Follow Up for 2 Years|Death|3
6315611|NCT02720484|10048363|FG000|Follow Up for 2 Years|Lost to Follow-up|2
6315612|NCT02720523|10048371|FG000|Period 1: Placebo-controlled Period|Adverse Event|0
6315613|NCT02720523|10048372|FG001|Period 1: Placebo-controlled Period|Adverse Event|0
6315614|NCT02720523|10048373|FG002|Period 1: Placebo-controlled Period|Adverse Event|1
6315615|NCT02720523|10048374|FG003|Period 1: Placebo-controlled Period|Adverse Event|5
6315616|NCT02720523|10048375|FG004|Period 1: Placebo-controlled Period|Adverse Event|0
6315617|NCT02720523|10048376|FG005|Period 1: Placebo-controlled Period|Adverse Event|0
6315618|NCT02720523|10048377|FG006|Period 1: Placebo-controlled Period|Adverse Event|0
6315619|NCT02720523|10048371|FG000|Period 1: Placebo-controlled Period|Withdrawal by Subject|1
6315620|NCT02720523|10048372|FG001|Period 1: Placebo-controlled Period|Withdrawal by Subject|0
6315621|NCT02720523|10048373|FG002|Period 1: Placebo-controlled Period|Withdrawal by Subject|0
6315622|NCT02720523|10048374|FG003|Period 1: Placebo-controlled Period|Withdrawal by Subject|0
6315623|NCT02720523|10048375|FG004|Period 1: Placebo-controlled Period|Withdrawal by Subject|0
6315624|NCT02720523|10048376|FG005|Period 1: Placebo-controlled Period|Withdrawal by Subject|0
6315625|NCT02720523|10048377|FG006|Period 1: Placebo-controlled Period|Withdrawal by Subject|0
6315626|NCT02720523|10048371|FG000|Period 1: Placebo-controlled Period|Lack of Efficacy|1
6315627|NCT02720523|10048372|FG001|Period 1: Placebo-controlled Period|Lack of Efficacy|0
6315628|NCT02720523|10048373|FG002|Period 1: Placebo-controlled Period|Lack of Efficacy|0
6315629|NCT02720523|10048374|FG003|Period 1: Placebo-controlled Period|Lack of Efficacy|0
6315630|NCT02720523|10048375|FG004|Period 1: Placebo-controlled Period|Lack of Efficacy|0
6315631|NCT02720523|10048376|FG005|Period 1: Placebo-controlled Period|Lack of Efficacy|0
6315632|NCT02720523|10048377|FG006|Period 1: Placebo-controlled Period|Lack of Efficacy|0
6315633|NCT02720523|10048371|FG000|Period 1: Placebo-controlled Period|Other|0
6315634|NCT02720523|10048372|FG001|Period 1: Placebo-controlled Period|Other|0
6315635|NCT02720523|10048373|FG002|Period 1: Placebo-controlled Period|Other|1
6315636|NCT02720523|10048374|FG003|Period 1: Placebo-controlled Period|Other|1
6315637|NCT02720523|10048375|FG004|Period 1: Placebo-controlled Period|Other|0
6315638|NCT02720523|10048376|FG005|Period 1: Placebo-controlled Period|Other|0
6315639|NCT02720523|10048377|FG006|Period 1: Placebo-controlled Period|Other|0
6315640|NCT02720523|10048371|FG000|Period 2: Long-term Extension Period|Ongoing|0
6315641|NCT02720523|10048372|FG001|Period 2: Long-term Extension Period|Ongoing|0
6150254|NCT01104662|9786570|FG003|Overall Study|Adverse Event|1
6150255|NCT01104662|9786571|FG004|Overall Study|Adverse Event|1
6150256|NCT01104662|9786572|FG005|Overall Study|Adverse Event|1
6150257|NCT01104662|9786573|FG006|Overall Study|Adverse Event|0
6150258|NCT01104662|9786574|FG007|Overall Study|Adverse Event|0
6315642|NCT02720523|10048373|FG002|Period 2: Long-term Extension Period|Ongoing|0
6315643|NCT02720523|10048374|FG003|Period 2: Long-term Extension Period|Ongoing|0
6315644|NCT02720523|10048375|FG004|Period 2: Long-term Extension Period|Ongoing|57
6315645|NCT02720523|10048376|FG005|Period 2: Long-term Extension Period|Ongoing|54
6315646|NCT02720523|10048377|FG006|Period 2: Long-term Extension Period|Ongoing|45
6315647|NCT02720523|10048371|FG000|Period 2: Long-term Extension Period|Adverse Event|0
6315648|NCT02720523|10048372|FG001|Period 2: Long-term Extension Period|Adverse Event|0
6315649|NCT02720523|10048373|FG002|Period 2: Long-term Extension Period|Adverse Event|0
6315650|NCT02720523|10048374|FG003|Period 2: Long-term Extension Period|Adverse Event|0
6315651|NCT02720523|10048375|FG004|Period 2: Long-term Extension Period|Adverse Event|4
6315652|NCT02720523|10048376|FG005|Period 2: Long-term Extension Period|Adverse Event|7
6315653|NCT02720523|10048377|FG006|Period 2: Long-term Extension Period|Adverse Event|11
6315654|NCT02720523|10048371|FG000|Period 2: Long-term Extension Period|Withdrawal by Subject|0
6315655|NCT02720523|10048372|FG001|Period 2: Long-term Extension Period|Withdrawal by Subject|0
6315656|NCT02720523|10048373|FG002|Period 2: Long-term Extension Period|Withdrawal by Subject|0
6315657|NCT02720523|10048374|FG003|Period 2: Long-term Extension Period|Withdrawal by Subject|0
6315658|NCT02720523|10048375|FG004|Period 2: Long-term Extension Period|Withdrawal by Subject|2
6315659|NCT02720523|10048376|FG005|Period 2: Long-term Extension Period|Withdrawal by Subject|1
6315660|NCT02720523|10048377|FG006|Period 2: Long-term Extension Period|Withdrawal by Subject|1
6315661|NCT02720523|10048371|FG000|Period 2: Long-term Extension Period|Other|0
6315662|NCT02720523|10048372|FG001|Period 2: Long-term Extension Period|Other|0
6040363|NCT04115839|9638208|FG005|Main Study (Up to 16 Weeks)|Investigator's Discretion|0
6040364|NCT04115839|9638209|FG006|Main Study (Up to 16 Weeks)|Investigator's Discretion|0
6315663|NCT02720523|10048373|FG002|Period 2: Long-term Extension Period|Other|0
6315664|NCT02720523|10048374|FG003|Period 2: Long-term Extension Period|Other|0
6315665|NCT02720523|10048375|FG004|Period 2: Long-term Extension Period|Other|2
6315666|NCT02720523|10048376|FG005|Period 2: Long-term Extension Period|Other|0
6315667|NCT02720523|10048377|FG006|Period 2: Long-term Extension Period|Other|3
6315668|NCT02720536|10048390|FG000|Overall Study|Primary reason (PR) - subject withdrawal|11
6315669|NCT02720536|10048390|FG000|Overall Study|PR - pregnancy|2
6315670|NCT02720536|10048390|FG000|Overall Study|PR - unsatisfactory therapeutic effect|2
6315671|NCT02720536|10048390|FG000|Overall Study|PR - death|1
6315672|NCT02720536|10048390|FG000|Overall Study|PR - adverse event|1
6315673|NCT02720536|10048390|FG000|Overall Study|PR - abnormal lab value(s)|1
6315674|NCT02720536|10048390|FG000|Overall Study|PR- unwilling to comply with procedures|1
6315675|NCT02720757|10048404|FG000|Overall Study|Other reason|5
6315676|NCT02720757|10048404|FG000|Overall Study|Loss of contact|4
6315677|NCT02720757|10048404|FG000|Overall Study|Informed consent withdrawal|1
6315678|NCT02720757|10048404|FG000|Overall Study|Patients wish to withdraw|2
6315679|NCT02720757|10048404|FG000|Overall Study|Missing|3
6315680|NCT02720757|10048404|FG000|Overall Study|General exclusion|3
6315681|NCT02721147|10048422|FG000|Overall Study|Lost to Follow-up|2
6315682|NCT02721147|10048423|FG001|Overall Study|Lost to Follow-up|0
6315683|NCT02721147|10048424|FG002|Overall Study|Lost to Follow-up|0
6315684|NCT02721251|10048435|FG000|Overall Study|Withdrawal by Subject|8
6315685|NCT02721251|10048436|FG001|Overall Study|Withdrawal by Subject|7
6315686|NCT02721251|10048437|FG002|Overall Study|Withdrawal by Subject|9
6315687|NCT02721251|10048435|FG000|Overall Study|poor adherence|2
6315688|NCT02721251|10048436|FG001|Overall Study|poor adherence|2
6315689|NCT02721251|10048437|FG002|Overall Study|poor adherence|2
6315690|NCT02721355|10048448|FG000|Overall Study|Lost to Follow-up|6
6315691|NCT02721355|10048449|FG001|Overall Study|Lost to Follow-up|1
6040365|NCT04115839|9638203|FG000|LTE Phase (After Week 16 to Week 63)|Study Terminated by Sponsor|0
6040366|NCT04115839|9638204|FG001|LTE Phase (After Week 16 to Week 63)|Study Terminated by Sponsor|0
6040367|NCT04115839|9638205|FG002|LTE Phase (After Week 16 to Week 63)|Study Terminated by Sponsor|0
6150259|NCT01104662|9786567|FG000|Overall Study|Clinical Failure|1
6150260|NCT01104662|9786568|FG001|Overall Study|Clinical Failure|0
6315692|NCT02721875|10048461|FG000|Overall Study|Progressive disease/relapse|1
6315693|NCT02721875|10048462|FG001|Overall Study|Progressive disease/relapse|0
6315694|NCT02721966|10048471|FG000|Overall Study|Protocol Violation|1
6315695|NCT02721966|10048472|FG001|Overall Study|Protocol Violation|0
6315696|NCT02721966|10048473|FG002|Overall Study|Protocol Violation|0
6315697|NCT02721966|10048474|FG003|Overall Study|Protocol Violation|0
6315698|NCT02721966|10048475|FG004|Overall Study|Protocol Violation|0
6315699|NCT02721966|10048471|FG000|Overall Study|Withdrawal by Subject|9
6315700|NCT02721966|10048472|FG001|Overall Study|Withdrawal by Subject|2
6315701|NCT02721966|10048473|FG002|Overall Study|Withdrawal by Subject|3
6315702|NCT02721966|10048474|FG003|Overall Study|Withdrawal by Subject|7
6315703|NCT02721966|10048475|FG004|Overall Study|Withdrawal by Subject|0
6315704|NCT02721966|10048471|FG000|Overall Study|Adverse Event|4
6315705|NCT02721966|10048472|FG001|Overall Study|Adverse Event|4
6315706|NCT02721966|10048473|FG002|Overall Study|Adverse Event|3
6315707|NCT02721966|10048474|FG003|Overall Study|Adverse Event|0
6040368|NCT04115839|9638206|FG003|LTE Phase (After Week 16 to Week 63)|Study Terminated by Sponsor|17
6040369|NCT04115839|9638207|FG004|LTE Phase (After Week 16 to Week 63)|Study Terminated by Sponsor|19
6040370|NCT04115839|9638208|FG005|LTE Phase (After Week 16 to Week 63)|Study Terminated by Sponsor|10
6040371|NCT04115839|9638209|FG006|LTE Phase (After Week 16 to Week 63)|Study Terminated by Sponsor|8
6040372|NCT04115839|9638203|FG000|LTE Phase (After Week 16 to Week 63)|Adverse Event|0
6040373|NCT04115839|9638204|FG001|LTE Phase (After Week 16 to Week 63)|Adverse Event|0
6040374|NCT04115839|9638205|FG002|LTE Phase (After Week 16 to Week 63)|Adverse Event|0
6040375|NCT04115839|9638206|FG003|LTE Phase (After Week 16 to Week 63)|Adverse Event|1
6150261|NCT01104662|9786569|FG002|Overall Study|Clinical Failure|0
6150262|NCT01104662|9786570|FG003|Overall Study|Clinical Failure|0
6315708|NCT02721966|10048475|FG004|Overall Study|Adverse Event|0
6315709|NCT02721966|10048471|FG000|Overall Study|Death|1
6315710|NCT02721966|10048472|FG001|Overall Study|Death|0
6315711|NCT02721966|10048473|FG002|Overall Study|Death|0
6315712|NCT02721966|10048474|FG003|Overall Study|Death|0
6315713|NCT02721966|10048475|FG004|Overall Study|Death|0
6315714|NCT02721966|10048471|FG000|Overall Study|Lack of Efficacy|7
6315715|NCT02721966|10048472|FG001|Overall Study|Lack of Efficacy|4
6315716|NCT02721966|10048473|FG002|Overall Study|Lack of Efficacy|0
6315717|NCT02721966|10048474|FG003|Overall Study|Lack of Efficacy|0
6315718|NCT02721966|10048475|FG004|Overall Study|Lack of Efficacy|0
6315719|NCT02721966|10048471|FG000|Overall Study|Lost to Follow-up|0
6315720|NCT02721966|10048472|FG001|Overall Study|Lost to Follow-up|0
6315721|NCT02721966|10048473|FG002|Overall Study|Lost to Follow-up|3
6315722|NCT02721966|10048474|FG003|Overall Study|Lost to Follow-up|0
6315723|NCT02721966|10048475|FG004|Overall Study|Lost to Follow-up|0
6315724|NCT02721966|10048471|FG000|Overall Study|Physician Decision|1
6315725|NCT02721966|10048472|FG001|Overall Study|Physician Decision|1
6315726|NCT02721966|10048473|FG002|Overall Study|Physician Decision|0
6315727|NCT02721966|10048474|FG003|Overall Study|Physician Decision|0
6315728|NCT02721966|10048475|FG004|Overall Study|Physician Decision|0
6315729|NCT02721966|10048471|FG000|Overall Study|Pregnancy|1
6315730|NCT02721966|10048472|FG001|Overall Study|Pregnancy|0
6315731|NCT02721966|10048473|FG002|Overall Study|Pregnancy|0
6315732|NCT02721966|10048474|FG003|Overall Study|Pregnancy|0
6315733|NCT02721966|10048475|FG004|Overall Study|Pregnancy|0
6315734|NCT02721966|10048471|FG000|Overall Study|Did not continue to period 2|5
6315735|NCT02721966|10048472|FG001|Overall Study|Did not continue to period 2|12
6315736|NCT02721966|10048473|FG002|Overall Study|Did not continue to period 2|0
6315737|NCT02721966|10048474|FG003|Overall Study|Did not continue to period 2|0
6315738|NCT02721966|10048475|FG004|Overall Study|Did not continue to period 2|5
6315739|NCT02722044|10048483|FG000|Overall Study|Adverse Event|2
6315740|NCT02722044|10048483|FG000|Overall Study|Physician Decision|1
6315741|NCT02722044|10048483|FG000|Overall Study|Withdrawal by Subject|1
6315742|NCT02722044|10048483|FG000|Overall Study|Did Not Meet Criteria at Week 14|1
6315743|NCT02722148|10048488|FG000|Overall Study|Lost to Follow-up|2
6315744|NCT02722148|10048488|FG000|Overall Study|Non compliant with treatment regimen|3
6315745|NCT02722278|10048504|FG000|Overall Study|Withdrawal by Subject|5
6315746|NCT02722278|10048505|FG001|Overall Study|Withdrawal by Subject|3
6315747|NCT02722278|10048504|FG000|Overall Study|Adverse Event|4
6315748|NCT02722278|10048505|FG001|Overall Study|Adverse Event|1
6315749|NCT02722278|10048504|FG000|Overall Study|Lost to Follow-up|2
6315750|NCT02722278|10048505|FG001|Overall Study|Lost to Follow-up|0
6315751|NCT02722278|10048504|FG000|Overall Study|Protocol Violation|1
6315752|NCT02722278|10048505|FG001|Overall Study|Protocol Violation|0
6315753|NCT02722278|10048504|FG000|Overall Study|High PSA pre-study/ not eligible|0
6315754|NCT02722278|10048505|FG001|Overall Study|High PSA pre-study/ not eligible|1
6315755|NCT02722278|10048504|FG000|Overall Study|Subject declined after tx assignment|0
6315756|NCT02722278|10048505|FG001|Overall Study|Subject declined after tx assignment|1
6315757|NCT02722278|10048504|FG000|Overall Study|Site closure not study related|0
6315758|NCT02722278|10048505|FG001|Overall Study|Site closure not study related|1
6315759|NCT02722304|10048518|FG000|Overall Study|Study Terminated by Sponsor|1
6315760|NCT02722304|10048519|FG001|Overall Study|Study Terminated by Sponsor|0
6315761|NCT02722304|10048520|FG002|Overall Study|Study Terminated by Sponsor|2
6315762|NCT02722304|10048521|FG003|Overall Study|Study Terminated by Sponsor|1
6315763|NCT02722304|10048522|FG004|Overall Study|Study Terminated by Sponsor|1
6315764|NCT02722304|10048518|FG000|Overall Study|Other|0
6315765|NCT02722304|10048519|FG001|Overall Study|Other|0
6315766|NCT02722304|10048520|FG002|Overall Study|Other|0
6315767|NCT02722304|10048521|FG003|Overall Study|Other|1
6315768|NCT02722304|10048522|FG004|Overall Study|Other|1
6315769|NCT02722499|10048549|FG000|Overall Study|Lost to Follow-up|2
6315770|NCT02722499|10048550|FG001|Overall Study|Lost to Follow-up|0
6315771|NCT02722499|10048551|FG002|Overall Study|Lost to Follow-up|1
6315772|NCT02722928|10048578|FG000|Overall Study|Standard CT was not as required per prot|5
6315773|NCT02722928|10048579|FG001|Overall Study|Standard CT was not as required per prot|13
6315774|NCT02722928|10048578|FG000|Overall Study|Required Intraoperative MRI|5
6315775|NCT02722928|10048579|FG001|Overall Study|Required Intraoperative MRI|7
6315776|NCT02722967|10048592|FG000|Overall Study|Adverse Event|1
6315777|NCT02722967|10048593|FG001|Overall Study|Adverse Event|0
6315778|NCT02722967|10048594|FG002|Overall Study|Adverse Event|0
6315779|NCT02722967|10048592|FG000|Overall Study|Lost to Follow-up|0
6315780|NCT02722967|10048593|FG001|Overall Study|Lost to Follow-up|1
6315781|NCT02722967|10048594|FG002|Overall Study|Lost to Follow-up|0
6315782|NCT02722967|10048592|FG000|Overall Study|Non-compliance with patch wearing|2
6315783|NCT02722967|10048593|FG001|Overall Study|Non-compliance with patch wearing|1
6315784|NCT02722967|10048594|FG002|Overall Study|Non-compliance with patch wearing|1
6315785|NCT02722967|10048592|FG000|Overall Study|Withdrawal by Subject|1
6315786|NCT02722967|10048593|FG001|Overall Study|Withdrawal by Subject|0
6315787|NCT02722967|10048594|FG002|Overall Study|Withdrawal by Subject|1
6315788|NCT02722967|10048592|FG000|Overall Study|Physician Decision|1
6315789|NCT02722967|10048593|FG001|Overall Study|Physician Decision|0
6315790|NCT02722967|10048594|FG002|Overall Study|Physician Decision|0
6315791|NCT02722967|10048592|FG000|Overall Study|Non-adherence of the patch to the skin|0
6315792|NCT02722967|10048593|FG001|Overall Study|Non-adherence of the patch to the skin|0
6315793|NCT02722967|10048594|FG002|Overall Study|Non-adherence of the patch to the skin|2
6315794|NCT02723006|10048605|FG000|Overall Study|Withdrawal by Subject|0
6315795|NCT02723006|10048606|FG001|Overall Study|Withdrawal by Subject|1
6315796|NCT02723006|10048607|FG002|Overall Study|Withdrawal by Subject|1
6315797|NCT02723006|10048605|FG000|Overall Study|Study Terminated by Sponsor|1
6315798|NCT02723006|10048606|FG001|Overall Study|Study Terminated by Sponsor|6
6315799|NCT02723006|10048607|FG002|Overall Study|Study Terminated by Sponsor|6
6315800|NCT02723084|10048617|FG000|Overall Study|Withdrawal by Subject|1
6315801|NCT02723084|10048618|FG001|Overall Study|Withdrawal by Subject|1
6315802|NCT02723084|10048617|FG000|Overall Study|Lost to Follow-up|3
6315803|NCT02723084|10048618|FG001|Overall Study|Lost to Follow-up|0
6315804|NCT02723175|10048626|FG000|Overall Study|Lost to 1 Month Follow Up|3
6315805|NCT02723175|10048627|FG001|Overall Study|Lost to 1 Month Follow Up|2
6315806|NCT02723175|10048626|FG000|Overall Study|Lost to 3 Month Follow Up|1
6315807|NCT02723175|10048627|FG001|Overall Study|Lost to 3 Month Follow Up|1
6315808|NCT02723188|10048636|FG000|Overall Study|Withdrawal by Subject|1
6040376|NCT04115839|9638207|FG004|LTE Phase (After Week 16 to Week 63)|Adverse Event|1
6040377|NCT04115839|9638208|FG005|LTE Phase (After Week 16 to Week 63)|Adverse Event|0
6040378|NCT04115839|9638209|FG006|LTE Phase (After Week 16 to Week 63)|Adverse Event|0
6048987|NCT00420927|9648199|FG000|Period 2|Subject unable to find transportation|0
6048988|NCT00420927|9648200|FG001|Period 2|Subject unable to find transportation|0
6048989|NCT00420927|9648201|FG002|Period 2|Subject unable to find transportation|0
6315809|NCT02723188|10048637|FG001|Overall Study|Withdrawal by Subject|0
6315810|NCT02723188|10048638|FG002|Overall Study|Withdrawal by Subject|0
6315811|NCT02723201|10048649|FG000|Second Intervention Period|Protocol Violation|1
6315812|NCT02723201|10048650|FG001|Second Intervention Period|Protocol Violation|0
6315813|NCT02723201|10048651|FG002|Second Intervention Period|Protocol Violation|0
6315814|NCT02723201|10048649|FG000|Second Intervention Period|Adverse Event|1
6315815|NCT02723201|10048650|FG001|Second Intervention Period|Adverse Event|0
6315816|NCT02723201|10048651|FG002|Second Intervention Period|Adverse Event|0
6315817|NCT02723344|10048667|FG000|Overall Study|Lost to Follow-up|0
6315818|NCT02723344|10048668|FG001|Overall Study|Lost to Follow-up|4
6315819|NCT02723591|10048676|FG000|Overall Study|Adverse Event|48
6315820|NCT02723591|10048677|FG001|Overall Study|Adverse Event|40
6315821|NCT02723591|10048676|FG000|Overall Study|Death|2
6315822|NCT02723591|10048677|FG001|Overall Study|Death|2
6315823|NCT02723591|10048676|FG000|Overall Study|Lack of Efficacy|4
6315824|NCT02723591|10048677|FG001|Overall Study|Lack of Efficacy|3
6315825|NCT02723591|10048676|FG000|Overall Study|Lost to Follow-up|1
6315826|NCT02723591|10048677|FG001|Overall Study|Lost to Follow-up|7
6315827|NCT02723591|10048676|FG000|Overall Study|Protocol Violation|20
6315828|NCT02723591|10048677|FG001|Overall Study|Protocol Violation|23
6315829|NCT02723591|10048676|FG000|Overall Study|Withdrawal by Subject|4
6315830|NCT02723591|10048677|FG001|Overall Study|Withdrawal by Subject|8
6315831|NCT02723591|10048676|FG000|Overall Study|Randomized but Never Received StudyDrug|12
6315832|NCT02723591|10048677|FG001|Overall Study|Randomized but Never Received StudyDrug|12
6315833|NCT02723591|10048676|FG000|Overall Study|Miscellaneous|5
6315834|NCT02723591|10048677|FG001|Overall Study|Miscellaneous|6
6315835|NCT02723630|10048689|FG000|Intervention Period 1|Adverse Event|1
6315836|NCT02723630|10048690|FG001|Intervention Period 1|Adverse Event|0
6315837|NCT02723630|10048691|FG002|Intervention Period 1|Adverse Event|0
6315838|NCT02723630|10048692|FG003|Intervention Period 1|Adverse Event|0
6315839|NCT02723630|10048693|FG004|Intervention Period 1|Adverse Event|0
6315840|NCT02723630|10048694|FG005|Intervention Period 1|Adverse Event|0
6315841|NCT02723630|10048689|FG000|Intervention Period 3|consumption of restricted item|0
6315842|NCT02723630|10048690|FG001|Intervention Period 3|consumption of restricted item|1
6315843|NCT02723630|10048691|FG002|Intervention Period 3|consumption of restricted item|0
6315844|NCT02723630|10048692|FG003|Intervention Period 3|consumption of restricted item|0
6315845|NCT02723630|10048693|FG004|Intervention Period 3|consumption of restricted item|0
6315846|NCT02723630|10048694|FG005|Intervention Period 3|consumption of restricted item|0
6315847|NCT02723786|10048707|FG000|Overall Study|Lost to Follow-up|1
6315848|NCT02724020|10048734|FG000|Overall Study|Death|16
6315849|NCT02724020|10048735|FG001|Overall Study|Death|18
6315850|NCT02724020|10048736|FG002|Overall Study|Death|19
6315851|NCT02724020|10048734|FG000|Overall Study|Lost to Follow-up|0
6315852|NCT02724020|10048735|FG001|Overall Study|Lost to Follow-up|3
6315853|NCT02724020|10048736|FG002|Overall Study|Lost to Follow-up|0
6315854|NCT02724020|10048734|FG000|Overall Study|Site Terminated by Sponsor|15
6315855|NCT02724020|10048735|FG001|Overall Study|Site Terminated by Sponsor|8
6315856|NCT02724020|10048736|FG002|Overall Study|Site Terminated by Sponsor|8
6315857|NCT02724020|10048734|FG000|Overall Study|Withdrawal by Subject|1
6315858|NCT02724020|10048735|FG001|Overall Study|Withdrawal by Subject|3
6315859|NCT02724020|10048736|FG002|Overall Study|Withdrawal by Subject|5
6315860|NCT02724111|10048759|FG000|Overall Study|Protocol Violation|2
6315861|NCT02724111|10048760|FG001|Overall Study|Protocol Violation|5
6315862|NCT02724462|10048777|FG000|3 Month Follow-up Survey|Lost to Follow-up|171
6315863|NCT02724462|10048778|FG001|3 Month Follow-up Survey|Lost to Follow-up|151
6315864|NCT02724462|10048777|FG000|3 Month Follow-up Survey|Excluded as ineligible after randomization|40
6315865|NCT02724462|10048778|FG001|3 Month Follow-up Survey|Excluded as ineligible after randomization|48
6315866|NCT02724462|10048777|FG000|6 Month Follow-up Survey|Lost to Follow-up|156
6315867|NCT02724462|10048778|FG001|6 Month Follow-up Survey|Lost to Follow-up|123
6315868|NCT02724462|10048777|FG000|6 Month Follow-up Survey|Excluded as ineligible after randomization|40
6315869|NCT02724462|10048778|FG001|6 Month Follow-up Survey|Excluded as ineligible after randomization|48
6315870|NCT02724462|10048777|FG000|12 Month Follow-up Survey|Lost to Follow-up|174
6315871|NCT02724462|10048778|FG001|12 Month Follow-up Survey|Lost to Follow-up|134
6315872|NCT02724462|10048777|FG000|12 Month Follow-up Survey|Excluded as ineligible after randomization|40
6315873|NCT02724462|10048778|FG001|12 Month Follow-up Survey|Excluded as ineligible after randomization|48
6315874|NCT02724592|10048786|FG000|Overall Study|Lost to Follow-up|4
6315875|NCT02724592|10048787|FG001|Overall Study|Lost to Follow-up|1
6315876|NCT02724644|10048795|FG000|Overall Study|Adverse Event|7
6315877|NCT02724644|10048796|FG001|Overall Study|Adverse Event|1
6315878|NCT02724644|10048795|FG000|Overall Study|Lost to Follow-up|6
6315879|NCT02724644|10048796|FG001|Overall Study|Lost to Follow-up|2
6315880|NCT02724644|10048795|FG000|Overall Study|Withdrawal by Subject|7
6315881|NCT02724644|10048796|FG001|Overall Study|Withdrawal by Subject|1
6315882|NCT02724644|10048795|FG000|Overall Study|Administrative|1
6315883|NCT02724644|10048796|FG001|Overall Study|Administrative|0
6315884|NCT02724839|10048818|FG000|Overall Study|Withdrawal by Subject|1
6315885|NCT02724839|10048819|FG001|Overall Study|Withdrawal by Subject|1
6315886|NCT02724839|10048820|FG002|Overall Study|Withdrawal by Subject|0
6315887|NCT02724839|10048818|FG000|Overall Study|Lost to Follow-up|0
6315888|NCT02724839|10048819|FG001|Overall Study|Lost to Follow-up|3
6315889|NCT02724839|10048820|FG002|Overall Study|Lost to Follow-up|2
6315890|NCT02724839|10048818|FG000|Overall Study|Physician Decision|0
6315891|NCT02724839|10048819|FG001|Overall Study|Physician Decision|0
6315892|NCT02724839|10048820|FG002|Overall Study|Physician Decision|3
6315893|NCT02724956|10048837|FG000|Overall Study|Physician Decision|1
6315894|NCT02724956|10048838|FG001|Overall Study|Physician Decision|0
6315895|NCT02724956|10048837|FG000|Overall Study|Lack of Efficacy|0
6315896|NCT02724956|10048838|FG001|Overall Study|Lack of Efficacy|1
6315897|NCT02724956|10048837|FG000|Overall Study|Withdrawal by Subject|0
6315898|NCT02724956|10048838|FG001|Overall Study|Withdrawal by Subject|1
6315899|NCT02725008|10048846|FG000|Overall Study|Lost to Follow-up|7
6315900|NCT02725008|10048847|FG001|Overall Study|Lost to Follow-up|9
6315901|NCT02725008|10048846|FG000|Overall Study|Withdrawal by Subject|2
6315902|NCT02725008|10048847|FG001|Overall Study|Withdrawal by Subject|2
6315903|NCT02725008|10048846|FG000|Overall Study|Admitted to hospital|0
6315904|NCT02725008|10048847|FG001|Overall Study|Admitted to hospital|1
6315905|NCT02725268|10048857|FG000|Overall Study|Death|58
6315906|NCT02725268|10048858|FG001|Overall Study|Death|59
6315907|NCT02725268|10048859|FG002|Overall Study|Death|30
6315908|NCT02725268|10048860|FG003|Overall Study|Death|16
6315909|NCT02725268|10048857|FG000|Overall Study|Lost to Follow-up|4
6315910|NCT02725268|10048858|FG001|Overall Study|Lost to Follow-up|3
6315911|NCT02725268|10048859|FG002|Overall Study|Lost to Follow-up|0
6315912|NCT02725268|10048860|FG003|Overall Study|Lost to Follow-up|1
6315913|NCT02725268|10048857|FG000|Overall Study|Site Terminated by Sponsor|0
6315914|NCT02725268|10048858|FG001|Overall Study|Site Terminated by Sponsor|1
6315915|NCT02725268|10048859|FG002|Overall Study|Site Terminated by Sponsor|0
6315916|NCT02725268|10048860|FG003|Overall Study|Site Terminated by Sponsor|0
6315917|NCT02725268|10048857|FG000|Overall Study|Withdrawal by Subject|8
6315918|NCT02725268|10048858|FG001|Overall Study|Withdrawal by Subject|6
6315919|NCT02725268|10048859|FG002|Overall Study|Withdrawal by Subject|8
6315920|NCT02725268|10048860|FG003|Overall Study|Withdrawal by Subject|1
6315921|NCT02725268|10048857|FG000|Overall Study|Reason not Specified|2
6315922|NCT02725268|10048858|FG001|Overall Study|Reason not Specified|1
6315923|NCT02725268|10048859|FG002|Overall Study|Reason not Specified|0
6315924|NCT02725268|10048860|FG003|Overall Study|Reason not Specified|0
6315925|NCT02725411|10048873|FG000|Treatment Period (56 Weeks)|Adverse Event|3
6315926|NCT02725411|10048874|FG001|Treatment Period (56 Weeks)|Adverse Event|5
6315927|NCT02725411|10048875|FG002|Treatment Period (56 Weeks)|Adverse Event|4
6315928|NCT02725411|10048873|FG000|Treatment Period (56 Weeks)|Lack of Efficacy|1
6315929|NCT02725411|10048874|FG001|Treatment Period (56 Weeks)|Lack of Efficacy|4
6315930|NCT02725411|10048875|FG002|Treatment Period (56 Weeks)|Lack of Efficacy|1
6315931|NCT02725411|10048873|FG000|Treatment Period (56 Weeks)|Lost to Follow-up|0
6315932|NCT02725411|10048874|FG001|Treatment Period (56 Weeks)|Lost to Follow-up|1
6315933|NCT02725411|10048875|FG002|Treatment Period (56 Weeks)|Lost to Follow-up|0
6315934|NCT02725411|10048873|FG000|Treatment Period (56 Weeks)|Other|1
6315935|NCT02725411|10048874|FG001|Treatment Period (56 Weeks)|Other|4
6315936|NCT02725411|10048875|FG002|Treatment Period (56 Weeks)|Other|5
6315937|NCT02725411|10048873|FG000|Treatment Period (56 Weeks)|Withdrawal by Subject|0
6315938|NCT02725411|10048874|FG001|Treatment Period (56 Weeks)|Withdrawal by Subject|1
6315939|NCT02725411|10048875|FG002|Treatment Period (56 Weeks)|Withdrawal by Subject|4
6315940|NCT02725411|10048873|FG000|Treatment Period (56 Weeks)|Not Met Protocol-Specified Criteria|25
6315941|NCT02725411|10048874|FG001|Treatment Period (56 Weeks)|Not Met Protocol-Specified Criteria|35
6315942|NCT02725411|10048875|FG002|Treatment Period (56 Weeks)|Not Met Protocol-Specified Criteria|35
6315943|NCT02725411|10048873|FG000|Follow-up Period (24 Weeks)|Adverse Event|1
6315944|NCT02725411|10048874|FG001|Follow-up Period (24 Weeks)|Adverse Event|1
6315945|NCT02725411|10048875|FG002|Follow-up Period (24 Weeks)|Adverse Event|0
6315946|NCT02725411|10048873|FG000|Follow-up Period (24 Weeks)|Lack of Efficacy|0
6315947|NCT02725411|10048874|FG001|Follow-up Period (24 Weeks)|Lack of Efficacy|2
6315948|NCT02725411|10048875|FG002|Follow-up Period (24 Weeks)|Lack of Efficacy|0
6315949|NCT02725411|10048873|FG000|Follow-up Period (24 Weeks)|Lost to Follow-up|1
6315950|NCT02725411|10048874|FG001|Follow-up Period (24 Weeks)|Lost to Follow-up|1
6315951|NCT02725411|10048875|FG002|Follow-up Period (24 Weeks)|Lost to Follow-up|0
6315952|NCT02725411|10048873|FG000|Follow-up Period (24 Weeks)|Other|1
6315953|NCT02725411|10048874|FG001|Follow-up Period (24 Weeks)|Other|4
6315954|NCT02725411|10048875|FG002|Follow-up Period (24 Weeks)|Other|2
6315955|NCT02725411|10048873|FG000|Follow-up Period (24 Weeks)|Withdrawal by Subject|1
6315956|NCT02725411|10048874|FG001|Follow-up Period (24 Weeks)|Withdrawal by Subject|3
6315957|NCT02725411|10048875|FG002|Follow-up Period (24 Weeks)|Withdrawal by Subject|3
6040379|NCT04078126|9638234|FG000|Washout|Study put on hold due to COVID-19|0
6040380|NCT04078126|9638235|FG001|Washout|Study put on hold due to COVID-19|2
6040381|NCT04078126|9638234|FG000|Period 2|Study put on hold due to COVID-19|1
6040382|NCT04078126|9638235|FG001|Period 2|Study put on hold due to COVID-19|1
6040383|NCT03825341|9638243|FG000|Overall Study|Withdrawal by Subject|0
6040384|NCT03825341|9638244|FG001|Overall Study|Withdrawal by Subject|1
6040385|NCT03751631|9638252|FG000|Overall Study|Withdrawal by Subject|0
6315958|NCT02725476|10048885|FG000|Overall Study|Physician Decision|2
6315959|NCT02725476|10048886|FG001|Overall Study|Physician Decision|0
6315960|NCT02725476|10048885|FG000|Overall Study|Adverse Event|1
6315961|NCT02725476|10048886|FG001|Overall Study|Adverse Event|1
6315962|NCT02725515|10048894|FG000|Overall Study|Refused infusion (no study treatment)|1
6315963|NCT02725515|10048895|FG001|Overall Study|Refused infusion (no study treatment)|0
6315964|NCT02725515|10048894|FG000|Overall Study|Loss of Improvement per Protocol|14
6315965|NCT02725515|10048895|FG001|Overall Study|Loss of Improvement per Protocol|25
6315966|NCT02725515|10048894|FG000|Overall Study|Withdrawal by Subject|2
6315967|NCT02725515|10048895|FG001|Overall Study|Withdrawal by Subject|1
6315968|NCT02725515|10048894|FG000|Overall Study|Non-Compliance With Study Drug|0
6315969|NCT02725515|10048895|FG001|Overall Study|Non-Compliance With Study Drug|3
6315970|NCT02725515|10048894|FG000|Overall Study|Lost to Follow-up|1
6040386|NCT03751631|9638253|FG001|Overall Study|Withdrawal by Subject|0
6315971|NCT02725515|10048895|FG001|Overall Study|Lost to Follow-up|1
6315972|NCT02725515|10048894|FG000|Overall Study|Adverse Event|7
6315973|NCT02725515|10048895|FG001|Overall Study|Adverse Event|2
6315974|NCT02725515|10048894|FG000|Overall Study|No Documented Disease Improvement|0
6315975|NCT02725515|10048895|FG001|Overall Study|No Documented Disease Improvement|1
6315976|NCT02725515|10048894|FG000|Overall Study|Completed Study Under Original Protocol|0
6315977|NCT02725515|10048895|FG001|Overall Study|Completed Study Under Original Protocol|1
6315978|NCT02725515|10048894|FG000|Overall Study|Lack of Response|0
6315979|NCT02725515|10048895|FG001|Overall Study|Lack of Response|1
6315980|NCT02725710|10048907|FG000|Overall Study|Lost to Follow-up|1
6315981|NCT02725710|10048908|FG001|Overall Study|Lost to Follow-up|0
6315982|NCT02725788|10048916|FG000|Overall Study|Lost to Follow-up|1
6315983|NCT02725788|10048917|FG001|Overall Study|Lost to Follow-up|1
6315984|NCT02725788|10048916|FG000|Overall Study|Protocol Violation|0
6315985|NCT02725788|10048917|FG001|Overall Study|Protocol Violation|1
6315986|NCT02725866|10048932|FG000|Overall Study|Failure to return|6
6315987|NCT02725866|10048932|FG000|Overall Study|Withdrew consent|3
6315988|NCT02725866|10048932|FG000|Overall Study|Insufficient virological response|1
6315989|NCT02725866|10048932|FG000|Overall Study|Other, not specified|4
6315990|NCT02726022|10048936|FG000|Overall Study|Adverse Event|14
6315991|NCT02726022|10048936|FG000|Overall Study|Treatment Failure|8
6315992|NCT02726022|10048936|FG000|Overall Study|Poor Compliance|13
6315993|NCT02726022|10048936|FG000|Overall Study|Treatment Failure and Poor Compliance|1
6315994|NCT02726074|10048940|FG000|Overall Study|Withdrawal by Subject|4
6315995|NCT02726074|10048940|FG000|Overall Study|Adverse Event|14
6315996|NCT02726074|10048940|FG000|Overall Study|Protocol Violation|3
6315997|NCT02726074|10048940|FG000|Overall Study|Lost to Follow-up|2
6315998|NCT02726074|10048940|FG000|Overall Study|Others|3
6315999|NCT02726113|10048946|FG000|Total Enrollment|Physician Decision|0
6316000|NCT02726113|10048947|FG001|Total Enrollment|Physician Decision|1
6316001|NCT02726113|10048946|FG000|Total Enrollment|Protocol Violation|1
6316002|NCT02726113|10048947|FG001|Total Enrollment|Protocol Violation|0
6316003|NCT02726113|10048946|FG000|Total Enrollment|Withdrawal by Subject|2
6316004|NCT02726113|10048947|FG001|Total Enrollment|Withdrawal by Subject|1
6316005|NCT02726113|10048946|FG000|Total Enrollment|Insurance non-coverage for surgery|1
6316006|NCT02726113|10048947|FG001|Total Enrollment|Insurance non-coverage for surgery|1
6316007|NCT02726113|10048946|FG000|Genomic Analysis|Protocol Violation|1
6316008|NCT02726113|10048947|FG001|Genomic Analysis|Protocol Violation|0
6316009|NCT02726113|10048946|FG000|Genomic Analysis|Withdrawal by Subject|2
6316010|NCT02726113|10048947|FG001|Genomic Analysis|Withdrawal by Subject|1
6316011|NCT02726113|10048946|FG000|Genomic Analysis|Insurance non-coverage for surgery|1
6316012|NCT02726113|10048947|FG001|Genomic Analysis|Insurance non-coverage for surgery|1
6316013|NCT02726945|10049000|FG000|Overall Study|Withdrawal by Subject|0
6316014|NCT02726945|10049001|FG001|Overall Study|Withdrawal by Subject|0
6316015|NCT02726945|10049002|FG002|Overall Study|Withdrawal by Subject|1
6316016|NCT02726945|10049000|FG000|Overall Study|Elected to have total knee replacement|0
6316017|NCT02726945|10049001|FG001|Overall Study|Elected to have total knee replacement|1
6316018|NCT02726945|10049002|FG002|Overall Study|Elected to have total knee replacement|0
6316019|NCT02727192|10049021|FG000|Overall Study|Lost to Follow-up|1
6316020|NCT02727192|10049022|FG001|Overall Study|Lost to Follow-up|0
6316021|NCT02727192|10049023|FG002|Overall Study|Lost to Follow-up|0
6316022|NCT02727322|10049032|FG000|Overall Study|Withdrawal by Subject|1
6316023|NCT02727322|10049033|FG001|Overall Study|Withdrawal by Subject|1
6316024|NCT02727322|10049032|FG000|Overall Study|Protocol Violation|1
6316025|NCT02727322|10049033|FG001|Overall Study|Protocol Violation|0
6316026|NCT02727660|10049046|FG000|Overall Study|Lack of Efficacy|40
6316027|NCT02727660|10049047|FG001|Overall Study|Lack of Efficacy|40
6316028|NCT02727660|10049048|FG002|Overall Study|Lack of Efficacy|70
6316029|NCT02727660|10049046|FG000|Overall Study|Adverse Event|28
6316030|NCT02727660|10049047|FG001|Overall Study|Adverse Event|21
6316031|NCT02727660|10049048|FG002|Overall Study|Adverse Event|32
6316032|NCT02727660|10049046|FG000|Overall Study|Withdrawal by Subject|26
6316033|NCT02727660|10049047|FG001|Overall Study|Withdrawal by Subject|25
6316034|NCT02727660|10049048|FG002|Overall Study|Withdrawal by Subject|30
6316035|NCT02727660|10049046|FG000|Overall Study|Physician Decision|3
6316036|NCT02727660|10049047|FG001|Overall Study|Physician Decision|8
6316037|NCT02727660|10049048|FG002|Overall Study|Physician Decision|14
6316038|NCT02727660|10049046|FG000|Overall Study|Lost to Follow-up|5
6316039|NCT02727660|10049047|FG001|Overall Study|Lost to Follow-up|9
6316040|NCT02727660|10049048|FG002|Overall Study|Lost to Follow-up|8
6316041|NCT02727660|10049046|FG000|Overall Study|Protocol Violation|7
6316042|NCT02727660|10049047|FG001|Overall Study|Protocol Violation|5
6316043|NCT02727660|10049048|FG002|Overall Study|Protocol Violation|5
6316044|NCT02727660|10049046|FG000|Overall Study|Protocol Specified Disc. Criteria|5
6316045|NCT02727660|10049047|FG001|Overall Study|Protocol Specified Disc. Criteria|5
6316046|NCT02727660|10049048|FG002|Overall Study|Protocol Specified Disc. Criteria|2
6316047|NCT02727660|10049046|FG000|Overall Study|Administrative Reasons|2
6316048|NCT02727660|10049047|FG001|Overall Study|Administrative Reasons|3
6316049|NCT02727660|10049048|FG002|Overall Study|Administrative Reasons|4
6316050|NCT02727777|10049063|FG000|Overall Study|Screen Failure|2
6316051|NCT02727777|10049064|FG001|Overall Study|Screen Failure|0
6316052|NCT02727777|10049065|FG002|Overall Study|Screen Failure|0
6316053|NCT02727777|10049063|FG000|Overall Study|Progressive disease|2
6316054|NCT02727777|10049064|FG001|Overall Study|Progressive disease|0
6316055|NCT02727777|10049065|FG002|Overall Study|Progressive disease|0
6316056|NCT02728089|10049109|FG000|Overall Study|Physician Decision|2
6316057|NCT02728089|10049109|FG000|Overall Study|Withdrawal by Subject|1
6316058|NCT02728102|10049116|FG000|Overall Study|Death|1
6316059|NCT02728102|10049117|FG001|Overall Study|Death|0
6316060|NCT02728102|10049118|FG002|Overall Study|Death|0
6316061|NCT02728102|10049116|FG000|Overall Study|Withdrawal by Subject|0
6316062|NCT02728102|10049117|FG001|Overall Study|Withdrawal by Subject|2
6316063|NCT02728102|10049118|FG002|Overall Study|Withdrawal by Subject|2
6316064|NCT02728206|10049125|FG000|Overall Study|Death|1
6316065|NCT02728830|10049129|FG000|Overall Study|Exclusionary Surgery|9
6316066|NCT02728830|10049129|FG000|Overall Study|Exclusionary Pathology|6
6316067|NCT02728830|10049129|FG000|Overall Study|Physician Decision|3
6316068|NCT02728830|10049129|FG000|Overall Study|Withdrawal by Subject|2
6316069|NCT02728830|10049129|FG000|Overall Study|Lost to Follow-up|1
6316070|NCT02728830|10049129|FG000|Overall Study|Exclusionary Lab Values|1
6316071|NCT02728830|10049129|FG000|Overall Study|Contraindicated Illness|1
6316072|NCT02728830|10049129|FG000|Overall Study|Language Barrier|1
6316073|NCT02728895|10049135|FG000|Overall Study|Other|1
6316074|NCT02728895|10049136|FG001|Overall Study|Other|2
6316075|NCT02728895|10049135|FG000|Overall Study|Withdrawal by Subject|0
6316076|NCT02728895|10049136|FG001|Overall Study|Withdrawal by Subject|3
6316077|NCT02729025|10049144|FG000|Overall Study|Sponsor Decision|0
6316078|NCT02729025|10049145|FG001|Overall Study|Sponsor Decision|1
6316079|NCT02729051|10049177|FG000|Overall Study|Adverse Event|21
6316080|NCT02729051|10049178|FG001|Overall Study|Adverse Event|11
6316081|NCT02729051|10049177|FG000|Overall Study|Lack of Efficacy|1
6316082|NCT02729051|10049178|FG001|Overall Study|Lack of Efficacy|1
6316083|NCT02729051|10049177|FG000|Overall Study|Lost to Follow-up|1
6316084|NCT02729051|10049178|FG001|Overall Study|Lost to Follow-up|2
6316085|NCT02729051|10049177|FG000|Overall Study|Physician Decision|1
6316086|NCT02729051|10049178|FG001|Overall Study|Physician Decision|1
6316087|NCT02729051|10049177|FG000|Overall Study|Withdrawal by Subject|6
6316088|NCT02729051|10049178|FG001|Overall Study|Withdrawal by Subject|17
6316089|NCT02729194|10049184|FG000|Overall Study|Withdrawal by Subject|3
6316090|NCT02729545|10049190|FG000|Overall Study|Pregnancy|1
6316091|NCT02729545|10049191|FG001|Overall Study|Pregnancy|1
6316092|NCT02729545|10049190|FG000|Overall Study|Lost to Follow-up|0
6316093|NCT02729545|10049191|FG001|Overall Study|Lost to Follow-up|1
6316094|NCT02729545|10049190|FG000|Overall Study|Withdrawal by Subject|2
6316095|NCT02729545|10049191|FG001|Overall Study|Withdrawal by Subject|3
6316096|NCT02729740|10049197|FG000|Overall Study|Early Termination|130
6316097|NCT02729740|10049197|FG000|Overall Study|Other|1
6316098|NCT02729831|10049205|FG000|Baseline (Post Decision Aid, Pre-visit)|Ineligible post completion|38
6316099|NCT02729831|10049206|FG001|Baseline (Post Decision Aid, Pre-visit)|Ineligible post completion|23
6316100|NCT02729831|10049207|FG002|Baseline (Post Decision Aid, Pre-visit)|Ineligible post completion|18
6316101|NCT02729831|10049208|FG003|Baseline (Post Decision Aid, Pre-visit)|Ineligible post completion|17
6316102|NCT02729831|10049205|FG000|1 Week Post-visit|Lost to Follow-up|43
6316103|NCT02729831|10049206|FG001|1 Week Post-visit|Lost to Follow-up|40
6316104|NCT02729831|10049207|FG002|1 Week Post-visit|Lost to Follow-up|38
6316105|NCT02729831|10049208|FG003|1 Week Post-visit|Lost to Follow-up|36
6316106|NCT02729831|10049205|FG000|6 Month Follow-up|Lost to Follow-up|54
6316107|NCT02729831|10049206|FG001|6 Month Follow-up|Lost to Follow-up|51
6316108|NCT02729831|10049207|FG002|6 Month Follow-up|Lost to Follow-up|48
6316109|NCT02729831|10049208|FG003|6 Month Follow-up|Lost to Follow-up|42
6316110|NCT02729831|10049205|FG000|6 Month Follow-up|Death|1
6316111|NCT02729831|10049206|FG001|6 Month Follow-up|Death|3
6316112|NCT02729831|10049207|FG002|6 Month Follow-up|Death|0
6316113|NCT02729831|10049208|FG003|6 Month Follow-up|Death|1
6316114|NCT02729896|10049221|FG000|Overall Study|Death|0
6316115|NCT02729896|10049222|FG001|Overall Study|Death|2
6316116|NCT02729896|10049223|FG002|Overall Study|Death|13
6316117|NCT02729896|10049221|FG000|Overall Study|Lost to Follow-up|0
6316118|NCT02729896|10049222|FG001|Overall Study|Lost to Follow-up|2
6316119|NCT02729896|10049223|FG002|Overall Study|Lost to Follow-up|3
6316120|NCT02729896|10049221|FG000|Overall Study|Other|0
6316121|NCT02729896|10049222|FG001|Overall Study|Other|2
6316122|NCT02729896|10049223|FG002|Overall Study|Other|0
6316123|NCT02729896|10049221|FG000|Overall Study|Physician Decision|1
6316124|NCT02729896|10049222|FG001|Overall Study|Physician Decision|2
6316125|NCT02729896|10049223|FG002|Overall Study|Physician Decision|3
6316126|NCT02729896|10049221|FG000|Overall Study|Progressive Disease|0
6316127|NCT02729896|10049222|FG001|Overall Study|Progressive Disease|1
6316128|NCT02729896|10049223|FG002|Overall Study|Progressive Disease|0
6316129|NCT02729896|10049221|FG000|Overall Study|Withdrawal by Subject|1
6316130|NCT02729896|10049222|FG001|Overall Study|Withdrawal by Subject|0
6316131|NCT02729896|10049223|FG002|Overall Study|Withdrawal by Subject|3
6316132|NCT02729909|10049234|FG000|Overall Study|Lost to Follow-up|0
6316133|NCT02729909|10049235|FG001|Overall Study|Lost to Follow-up|1
6316134|NCT02729909|10049234|FG000|Overall Study|Lack of Efficacy|0
6316135|NCT02729909|10049235|FG001|Overall Study|Lack of Efficacy|2
6316136|NCT02729909|10049234|FG000|Overall Study|Significant Protocol Deviation|0
6316137|NCT02729909|10049235|FG001|Overall Study|Significant Protocol Deviation|2
6316138|NCT02729909|10049234|FG000|Overall Study|Voluntary Withdrawal|1
6316139|NCT02729909|10049235|FG001|Overall Study|Voluntary Withdrawal|0
6316140|NCT02730169|10049245|FG000|Overall Study|Protocol Violation|1
6316141|NCT02730169|10049246|FG001|Overall Study|Protocol Violation|0
6316142|NCT02730169|10049247|FG002|Overall Study|Protocol Violation|0
6316143|NCT02730169|10049248|FG003|Overall Study|Protocol Violation|1
6316144|NCT02730169|10049245|FG000|Overall Study|Adverse Event|2
6316145|NCT02730169|10049246|FG001|Overall Study|Adverse Event|3
6316146|NCT02730169|10049247|FG002|Overall Study|Adverse Event|3
6316147|NCT02730169|10049248|FG003|Overall Study|Adverse Event|0
6316148|NCT02730169|10049245|FG000|Overall Study|Adverse Event of Special Interest|0
6316149|NCT02730169|10049246|FG001|Overall Study|Adverse Event of Special Interest|1
6316150|NCT02730169|10049247|FG002|Overall Study|Adverse Event of Special Interest|2
6316151|NCT02730169|10049248|FG003|Overall Study|Adverse Event of Special Interest|0
6316152|NCT02730169|10049245|FG000|Overall Study|Withdrawal by Subject|6
6316153|NCT02730169|10049246|FG001|Overall Study|Withdrawal by Subject|11
6316154|NCT02730169|10049247|FG002|Overall Study|Withdrawal by Subject|6
6316155|NCT02730169|10049248|FG003|Overall Study|Withdrawal by Subject|8
6316156|NCT02730169|10049245|FG000|Overall Study|Lost to Follow-up|5
6316157|NCT02730169|10049246|FG001|Overall Study|Lost to Follow-up|6
6316158|NCT02730169|10049247|FG002|Overall Study|Lost to Follow-up|5
6316159|NCT02730169|10049248|FG003|Overall Study|Lost to Follow-up|6
6316160|NCT02730169|10049245|FG000|Overall Study|Other|0
6316161|NCT02730169|10049246|FG001|Overall Study|Other|0
6316162|NCT02730169|10049247|FG002|Overall Study|Other|1
6316163|NCT02730169|10049248|FG003|Overall Study|Other|1
6316164|NCT02730195|10049258|FG000|Overall Study|Withdrawal by Subject|1
6316165|NCT02730208|10049264|FG000|Overall Study|Withdrawal of consent (not due to AE)|0
6316166|NCT02730208|10049265|FG001|Overall Study|Withdrawal of consent (not due to AE)|1
6316167|NCT02730351|10049288|FG000|Treatment Period 1 (2 Weeks)|Adverse Event|1
6316168|NCT02730351|10049289|FG001|Treatment Period 1 (2 Weeks)|Adverse Event|0
6316169|NCT02730351|10049288|FG000|Wash-out Period (2 Weeks)|Protocol Violation|0
6316170|NCT02730351|10049289|FG001|Wash-out Period (2 Weeks)|Protocol Violation|1
6316171|NCT02730351|10049288|FG000|Wash-out Period (2 Weeks)|Withdrawal by Subject|1
6316172|NCT02730351|10049289|FG001|Wash-out Period (2 Weeks)|Withdrawal by Subject|0
6316173|NCT02730351|10049288|FG000|Treatment Period 2 (2 Weeks)|Adverse Event|1
6316174|NCT02730351|10049289|FG001|Treatment Period 2 (2 Weeks)|Adverse Event|0
6316175|NCT02730351|10049288|FG000|Treatment Period 2 (2 Weeks)|Lack of Efficacy|1
6316176|NCT02730351|10049289|FG001|Treatment Period 2 (2 Weeks)|Lack of Efficacy|0
6316177|NCT02730377|10049297|FG000|Overall Study|Other|5
6316178|NCT02730377|10049298|FG001|Overall Study|Other|4
6316179|NCT02730377|10049297|FG000|Overall Study|Death|1
6316180|NCT02730377|10049298|FG001|Overall Study|Death|8
6316181|NCT02730377|10049297|FG000|Overall Study|Inadequate glycaemic control|368
6316182|NCT02730377|10049298|FG001|Overall Study|Inadequate glycaemic control|473
6316183|NCT02730377|10049297|FG000|Overall Study|Adverse Event|79
6316184|NCT02730377|10049298|FG001|Overall Study|Adverse Event|41
6316185|NCT02730377|10049297|FG000|Overall Study|Protocol Violation|23
6316186|NCT02730377|10049298|FG001|Overall Study|Protocol Violation|30
6316187|NCT02730377|10049297|FG000|Overall Study|Lack of Efficacy|4
6316188|NCT02730377|10049298|FG001|Overall Study|Lack of Efficacy|13
6316189|NCT02730377|10049297|FG000|Overall Study|Pregnancy|0
6316190|NCT02730377|10049298|FG001|Overall Study|Pregnancy|1
6316191|NCT02730377|10049297|FG000|Overall Study|Withdrawal by Subject|45
6316192|NCT02730377|10049298|FG001|Overall Study|Withdrawal by Subject|42
6316193|NCT02730377|10049297|FG000|Overall Study|Lost to Follow-up|25
6316194|NCT02730377|10049298|FG001|Overall Study|Lost to Follow-up|21
6316195|NCT02730455|10049312|FG000|Overall Study|Death|5
6316196|NCT02730455|10049313|FG001|Overall Study|Death|6
6316197|NCT02730455|10049314|FG002|Overall Study|Death|4
6316198|NCT02730455|10049312|FG000|Overall Study|Consent withdrawn|2
6316199|NCT02730455|10049313|FG001|Overall Study|Consent withdrawn|4
6316200|NCT02730455|10049314|FG002|Overall Study|Consent withdrawn|1
6316201|NCT02730455|10049312|FG000|Overall Study|Lost to Follow-up|3
6316202|NCT02730455|10049313|FG001|Overall Study|Lost to Follow-up|1
6316203|NCT02730455|10049314|FG002|Overall Study|Lost to Follow-up|4
6316204|NCT02730455|10049312|FG000|Overall Study|Other|1
6316205|NCT02730455|10049313|FG001|Overall Study|Other|1
6316206|NCT02730455|10049314|FG002|Overall Study|Other|2
6316207|NCT02730455|10049312|FG000|Overall Study|Other|2
6316208|NCT02730455|10049313|FG001|Overall Study|Other|2
6316209|NCT02730455|10049314|FG002|Overall Study|Other|0
6316210|NCT02730598|10049324|FG000|Overall Study|Withdrawal by Subject|3
6316211|NCT02730598|10049325|FG001|Overall Study|Withdrawal by Subject|3
6316212|NCT02730598|10049324|FG000|Overall Study|Protocol Violation|0
6316213|NCT02730598|10049325|FG001|Overall Study|Protocol Violation|1
6316214|NCT02730598|10049324|FG000|Overall Study|Unrelated Injury affecting outcomes.|1
6316215|NCT02730598|10049325|FG001|Overall Study|Unrelated Injury affecting outcomes.|0
6316216|NCT02730728|10049338|FG000|Overall Study|Withdrawal by Subject|0
6316217|NCT02730728|10049339|FG001|Overall Study|Withdrawal by Subject|1
6316218|NCT02730728|10049340|FG002|Overall Study|Withdrawal by Subject|0
6316219|NCT02730728|10049338|FG000|Overall Study|Lack of Efficacy|0
6316220|NCT02730728|10049339|FG001|Overall Study|Lack of Efficacy|1
6316221|NCT02730728|10049340|FG002|Overall Study|Lack of Efficacy|1
6316222|NCT02730819|10049348|FG000|Overall Study|Lost to Follow-up|9
6316223|NCT02730871|10049354|FG000|Overall Study|Adverse Event|6
6316224|NCT02730871|10049355|FG001|Overall Study|Adverse Event|0
6316225|NCT02731131|10049385|FG000|Overall Study|Psychiatric Disorder|0
6316226|NCT02731131|10049386|FG001|Overall Study|Psychiatric Disorder|1
6316227|NCT02731131|10049385|FG000|Overall Study|Refused Therapy|0
6316228|NCT02731131|10049386|FG001|Overall Study|Refused Therapy|1
6316229|NCT02731157|10049392|FG000|First Rejuvenated RCE|Withdrawal by Subject|1
6316230|NCT02731638|10049458|FG000|Overall Study|Lost to Follow-up|6
6316231|NCT02731638|10049459|FG001|Overall Study|Lost to Follow-up|9
6316232|NCT02731690|10049465|FG000|Overall Study|Adverse Event|1
6316233|NCT02731690|10049465|FG000|Overall Study|Withdrawal by Subject|3
6040387|NCT03751631|9638254|FG002|Overall Study|Withdrawal by Subject|1
6316234|NCT02731690|10049465|FG000|Overall Study|Discontinuation of Study by Sponsor|26
6316235|NCT02731729|10049471|FG000|Overall Study|Death|2
6316236|NCT02731729|10049472|FG001|Overall Study|Death|2
6040388|NCT03751631|9638255|FG003|Overall Study|Withdrawal by Subject|1
6316237|NCT02731729|10049471|FG000|Overall Study|Study terminated by Sponsor|6
6316238|NCT02731729|10049472|FG001|Overall Study|Study terminated by Sponsor|6
6316239|NCT02731729|10049471|FG000|Overall Study|Withdrawal by Subject|1
6316240|NCT02731729|10049472|FG001|Overall Study|Withdrawal by Subject|0
6316241|NCT02731742|10049482|FG000|Overall Study|Death|1
6316242|NCT02731742|10049483|FG001|Overall Study|Death|2
6316243|NCT02731742|10049484|FG002|Overall Study|Death|5
6316244|NCT02731742|10049485|FG003|Overall Study|Death|0
6316245|NCT02731742|10049482|FG000|Overall Study|Physician Decision|0
6316246|NCT02731742|10049483|FG001|Overall Study|Physician Decision|0
6316247|NCT02731742|10049484|FG002|Overall Study|Physician Decision|0
6316248|NCT02731742|10049485|FG003|Overall Study|Physician Decision|1
6316249|NCT02731742|10049482|FG000|Overall Study|Study Terminated by Sponsor|2
6316250|NCT02731742|10049483|FG001|Overall Study|Study Terminated by Sponsor|1
6316251|NCT02731742|10049484|FG002|Overall Study|Study Terminated by Sponsor|1
6316252|NCT02731742|10049485|FG003|Overall Study|Study Terminated by Sponsor|1
6316253|NCT02731755|10049495|FG000|First Intervention|Withdrawal by Subject|0
6316254|NCT02731755|10049496|FG001|First Intervention|Withdrawal by Subject|2
6316255|NCT02732015|10049522|FG000|Overall Study|Lost to Follow-up|0
6316256|NCT02732015|10049523|FG001|Overall Study|Lost to Follow-up|1
6316257|NCT02732119|10049534|FG000|Phase I|Adverse Event|1
6316258|NCT02732119|10049535|FG001|Phase I|Adverse Event|3
6316259|NCT02732119|10049536|FG002|Phase I|Adverse Event|1
6316260|NCT02732119|10049537|FG003|Phase I|Adverse Event|0
6316261|NCT02732119|10049538|FG004|Phase I|Adverse Event|0
6316262|NCT02732119|10049534|FG000|Phase I|Progressive disease|7
6316263|NCT02732119|10049535|FG001|Phase I|Progressive disease|3
6316264|NCT02732119|10049536|FG002|Phase I|Progressive disease|2
6316265|NCT02732119|10049537|FG003|Phase I|Progressive disease|0
6316266|NCT02732119|10049538|FG004|Phase I|Progressive disease|0
6316267|NCT02732119|10049534|FG000|Phase I|Protocol deviation|0
6316268|NCT02732119|10049535|FG001|Phase I|Protocol deviation|1
6316269|NCT02732119|10049536|FG002|Phase I|Protocol deviation|0
6316270|NCT02732119|10049537|FG003|Phase I|Protocol deviation|0
6316271|NCT02732119|10049538|FG004|Phase I|Protocol deviation|0
6316272|NCT02732119|10049534|FG000|Phase I|Physician Decision|0
6316273|NCT02732119|10049535|FG001|Phase I|Physician Decision|3
6316274|NCT02732119|10049536|FG002|Phase I|Physician Decision|4
6316275|NCT02732119|10049537|FG003|Phase I|Physician Decision|0
6316276|NCT02732119|10049538|FG004|Phase I|Physician Decision|0
6316277|NCT02732119|10049534|FG000|Phase II|Adverse Event|0
6316278|NCT02732119|10049535|FG001|Phase II|Adverse Event|0
6316279|NCT02732119|10049536|FG002|Phase II|Adverse Event|0
6316280|NCT02732119|10049537|FG003|Phase II|Adverse Event|3
6316281|NCT02732119|10049538|FG004|Phase II|Adverse Event|3
6316282|NCT02732119|10049534|FG000|Phase II|Death|0
6316283|NCT02732119|10049535|FG001|Phase II|Death|0
6316284|NCT02732119|10049536|FG002|Phase II|Death|0
6316285|NCT02732119|10049537|FG003|Phase II|Death|1
6316286|NCT02732119|10049538|FG004|Phase II|Death|0
6316287|NCT02732119|10049534|FG000|Phase II|Progressive dissease|0
6316288|NCT02732119|10049535|FG001|Phase II|Progressive dissease|0
6316289|NCT02732119|10049536|FG002|Phase II|Progressive dissease|0
6316290|NCT02732119|10049537|FG003|Phase II|Progressive dissease|30
6316291|NCT02732119|10049538|FG004|Phase II|Progressive dissease|23
6316292|NCT02732119|10049534|FG000|Phase II|Study terminated by sponsor|0
6316293|NCT02732119|10049535|FG001|Phase II|Study terminated by sponsor|0
6316294|NCT02732119|10049536|FG002|Phase II|Study terminated by sponsor|0
6316295|NCT02732119|10049537|FG003|Phase II|Study terminated by sponsor|2
6316296|NCT02732119|10049538|FG004|Phase II|Study terminated by sponsor|2
6316297|NCT02732119|10049534|FG000|Phase II|Other|0
6316298|NCT02732119|10049535|FG001|Phase II|Other|0
6316299|NCT02732119|10049536|FG002|Phase II|Other|0
6316300|NCT02732119|10049537|FG003|Phase II|Other|2
6316301|NCT02732119|10049538|FG004|Phase II|Other|0
6316302|NCT02732119|10049534|FG000|Phase II|Physician Decision|0
6316303|NCT02732119|10049535|FG001|Phase II|Physician Decision|0
6316304|NCT02732119|10049536|FG002|Phase II|Physician Decision|0
6316305|NCT02732119|10049537|FG003|Phase II|Physician Decision|8
6316306|NCT02732119|10049538|FG004|Phase II|Physician Decision|5
6316307|NCT02732210|10049589|FG000|Overall Study|Site Closed|0
6316308|NCT02732210|10049590|FG001|Overall Study|Site Closed|11
6316309|NCT02732210|10049589|FG000|Overall Study|Study Ended|13
6150263|NCT01104662|9786571|FG004|Overall Study|Clinical Failure|0
6150264|NCT01104662|9786572|FG005|Overall Study|Clinical Failure|1
6150265|NCT01104662|9786573|FG006|Overall Study|Clinical Failure|0
6316310|NCT02732210|10049590|FG001|Overall Study|Study Ended|13
6316311|NCT02732210|10049589|FG000|Overall Study|Withdrawal by Subject|28
6316312|NCT02732210|10049590|FG001|Overall Study|Withdrawal by Subject|87
6316313|NCT02732210|10049589|FG000|Overall Study|Lost to Follow-up|5
6316314|NCT02732210|10049590|FG001|Overall Study|Lost to Follow-up|57
6150266|NCT01104662|9786574|FG007|Overall Study|Clinical Failure|0
6316315|NCT02732210|10049589|FG000|Overall Study|Death|4
6316316|NCT02732210|10049590|FG001|Overall Study|Death|15
6316317|NCT02732210|10049589|FG000|Overall Study|Other|35
6316318|NCT02732210|10049590|FG001|Overall Study|Other|103
6150267|NCT01104662|9786567|FG000|Overall Study|Participant left investigator's care|1
6150268|NCT01104662|9786568|FG001|Overall Study|Participant left investigator's care|1
6150269|NCT01104662|9786569|FG002|Overall Study|Participant left investigator's care|0
6150270|NCT01104662|9786570|FG003|Overall Study|Participant left investigator's care|0
6150271|NCT01104662|9786571|FG004|Overall Study|Participant left investigator's care|0
6150272|NCT01104662|9786572|FG005|Overall Study|Participant left investigator's care|0
6150273|NCT01104662|9786573|FG006|Overall Study|Participant left investigator's care|0
6150274|NCT01104662|9786574|FG007|Overall Study|Participant left investigator's care|0
6150275|NCT01104662|9786567|FG000|Overall Study|Reason not specified|3
6150276|NCT01104662|9786568|FG001|Overall Study|Reason not specified|3
6150277|NCT01104662|9786569|FG002|Overall Study|Reason not specified|0
6150278|NCT01104662|9786570|FG003|Overall Study|Reason not specified|0
6150279|NCT01104662|9786571|FG004|Overall Study|Reason not specified|0
6150280|NCT01104662|9786572|FG005|Overall Study|Reason not specified|1
6150281|NCT01104662|9786573|FG006|Overall Study|Reason not specified|0
6150282|NCT01104662|9786574|FG007|Overall Study|Reason not specified|0
6150283|NCT01104662|9786567|FG000|Overall Study|Randomized but not treated|3
6150284|NCT01104662|9786568|FG001|Overall Study|Randomized but not treated|4
6150285|NCT01104662|9786569|FG002|Overall Study|Randomized but not treated|1
6150286|NCT01104662|9786570|FG003|Overall Study|Randomized but not treated|0
6150287|NCT01104662|9786571|FG004|Overall Study|Randomized but not treated|0
6150288|NCT01104662|9786572|FG005|Overall Study|Randomized but not treated|1
6150289|NCT01104662|9786573|FG006|Overall Study|Randomized but not treated|0
6150290|NCT01104662|9786574|FG007|Overall Study|Randomized but not treated|0
6150291|NCT01104701|9786597|FG000|Overall Study|Withdrawal by Subject|0
6150292|NCT01104701|9786598|FG001|Overall Study|Withdrawal by Subject|1
6150293|NCT01104701|9786599|FG002|Overall Study|Withdrawal by Subject|2
6150294|NCT01104701|9786600|FG003|Overall Study|Withdrawal by Subject|1
6150295|NCT01104701|9786597|FG000|Overall Study|Adverse Event|0
6150296|NCT01104701|9786598|FG001|Overall Study|Adverse Event|0
6150297|NCT01104701|9786599|FG002|Overall Study|Adverse Event|0
6150298|NCT01104701|9786600|FG003|Overall Study|Adverse Event|1
6150299|NCT01104701|9786597|FG000|Overall Study|Physician Decision|0
6150300|NCT01104701|9786598|FG001|Overall Study|Physician Decision|2
6150301|NCT01104701|9786599|FG002|Overall Study|Physician Decision|0
6150302|NCT01104701|9786600|FG003|Overall Study|Physician Decision|0
6150303|NCT01104766|9786614|FG000|Overall Study|Did not meet inc/exc criteria|1
6150304|NCT01104766|9786615|FG001|Overall Study|Did not meet inc/exc criteria|0
6150305|NCT01104766|9786616|FG002|Overall Study|Did not meet inc/exc criteria|0
6150306|NCT01104766|9786617|FG003|Overall Study|Did not meet inc/exc criteria|0
6150307|NCT01104766|9786614|FG000|Overall Study|Adverse Event|17
6150308|NCT01104766|9786615|FG001|Overall Study|Adverse Event|15
6150309|NCT01104766|9786616|FG002|Overall Study|Adverse Event|20
6150310|NCT01104766|9786617|FG003|Overall Study|Adverse Event|14
6150311|NCT01104766|9786614|FG000|Overall Study|Lack of Efficacy|20
6150312|NCT01104766|9786615|FG001|Overall Study|Lack of Efficacy|15
6150313|NCT01104766|9786616|FG002|Overall Study|Lack of Efficacy|14
6150314|NCT01104766|9786617|FG003|Overall Study|Lack of Efficacy|8
6150315|NCT01104766|9786614|FG000|Overall Study|Protocol Violation|2
6150316|NCT01104766|9786615|FG001|Overall Study|Protocol Violation|0
6150317|NCT01104766|9786616|FG002|Overall Study|Protocol Violation|0
6150318|NCT01104766|9786617|FG003|Overall Study|Protocol Violation|0
6316319|NCT02732210|10049589|FG000|Overall Study|Missing|0
6316320|NCT02732210|10049590|FG001|Overall Study|Missing|8
6316321|NCT02732561|10049610|FG000|Overall Study|Lost to Follow-up|1
6316322|NCT02732561|10049611|FG001|Overall Study|Lost to Follow-up|1
6316323|NCT02732561|10049610|FG000|Overall Study|Withdrawal by Subject|1
6316324|NCT02732561|10049611|FG001|Overall Study|Withdrawal by Subject|0
6316325|NCT02732639|10049631|FG000|Overall Study|Lost to Follow-up|1
6316326|NCT02732847|10049637|FG000|Overall Study|some filled early|42
6316327|NCT02732847|10049638|FG001|Overall Study|some filled early|42
6316328|NCT02732912|10049655|FG000|Overall Study|Discharged before night|2
6316329|NCT02732912|10049656|FG001|Overall Study|Discharged before night|6
6316330|NCT02732912|10049655|FG000|Overall Study|Incomplete completion of questionnaire|2
6316331|NCT02732912|10049656|FG001|Overall Study|Incomplete completion of questionnaire|3
6316332|NCT02732912|10049655|FG000|Overall Study|No outcome; discharged or refused|6
6316333|NCT02732912|10049656|FG001|Overall Study|No outcome; discharged or refused|9
6150319|NCT01104766|9786614|FG000|Overall Study|Withdrawal by Subject|17
6150320|NCT01104766|9786615|FG001|Overall Study|Withdrawal by Subject|19
6150321|NCT01104766|9786616|FG002|Overall Study|Withdrawal by Subject|25
6150322|NCT01104766|9786617|FG003|Overall Study|Withdrawal by Subject|15
6150323|NCT01104766|9786614|FG000|Overall Study|Lost to Follow-up|1
6150324|NCT01104766|9786615|FG001|Overall Study|Lost to Follow-up|2
6150325|NCT01104766|9786616|FG002|Overall Study|Lost to Follow-up|1
6040389|NCT03751631|9638256|FG004|Overall Study|Withdrawal by Subject|0
6040390|NCT03751631|9638257|FG005|Overall Study|Withdrawal by Subject|0
6150326|NCT01104766|9786617|FG003|Overall Study|Lost to Follow-up|1
6150327|NCT01104779|9786630|FG000|Overall Study|Protocol Violation|1
6150328|NCT01104779|9786631|FG001|Overall Study|Protocol Violation|2
6150329|NCT01104779|9786632|FG002|Overall Study|Protocol Violation|2
6150330|NCT01104779|9786630|FG000|Overall Study|Lack of Efficacy|26
6150331|NCT01104779|9786631|FG001|Overall Study|Lack of Efficacy|12
6150332|NCT01104779|9786632|FG002|Overall Study|Lack of Efficacy|13
6150333|NCT01104779|9786630|FG000|Overall Study|Adverse Event|13
6150334|NCT01104779|9786631|FG001|Overall Study|Adverse Event|14
6150335|NCT01104779|9786632|FG002|Overall Study|Adverse Event|13
6150336|NCT01104779|9786630|FG000|Overall Study|Did not meet inc/exc criteria|1
6150337|NCT01104779|9786631|FG001|Overall Study|Did not meet inc/exc criteria|1
6150338|NCT01104779|9786632|FG002|Overall Study|Did not meet inc/exc criteria|1
6150339|NCT01104779|9786630|FG000|Overall Study|Other reasons|0
6150340|NCT01104779|9786631|FG001|Overall Study|Other reasons|1
6150341|NCT01104779|9786632|FG002|Overall Study|Other reasons|0
6150342|NCT01104779|9786630|FG000|Overall Study|Lost to Follow-up|2
6150343|NCT01104779|9786631|FG001|Overall Study|Lost to Follow-up|0
6150344|NCT01104779|9786632|FG002|Overall Study|Lost to Follow-up|1
6150345|NCT01104779|9786630|FG000|Overall Study|Withdrawal by Subject|16
6150346|NCT01104779|9786631|FG001|Overall Study|Withdrawal by Subject|25
6150347|NCT01104779|9786632|FG002|Overall Study|Withdrawal by Subject|32
6150348|NCT01104792|9786640|FG000|Overall Study|Adverse Event|77
6150349|NCT01104792|9786640|FG000|Overall Study|Insufficient Therapeutic Response|22
6150350|NCT01104792|9786640|FG000|Overall Study|Protocol Violation|45
6150351|NCT01104792|9786640|FG000|Overall Study|Withdrawal of Consent|179
6150352|NCT01104792|9786640|FG000|Overall Study|Lost to Follow-up|43
6150353|NCT01104792|9786640|FG000|Overall Study|Reasons Not Specified|27
6150354|NCT01104792|9786640|FG000|Overall Study|Did Not Meet Eligibility Criteria|133
6150355|NCT01104870|9786647|FG000|Overall Study|Adverse Event|1
6150356|NCT01104870|9786648|FG001|Overall Study|Adverse Event|1
6150357|NCT01104870|9786649|FG002|Overall Study|Adverse Event|0
6150358|NCT01104870|9786647|FG000|Overall Study|Death|0
6150359|NCT01104870|9786648|FG001|Overall Study|Death|0
6150360|NCT01104870|9786649|FG002|Overall Study|Death|1
6150361|NCT01104870|9786647|FG000|Overall Study|Withdrawal by Subject|0
6040391|NCT03751098|9638268|FG000|Overall Study|Withdrawal by Subject|0
6150362|NCT01104870|9786648|FG001|Overall Study|Withdrawal by Subject|0
6150363|NCT01104870|9786649|FG002|Overall Study|Withdrawal by Subject|1
6150364|NCT01105065|9786657|FG000|Overall Study|Adverse Event|5
6150365|NCT01105065|9786657|FG000|Overall Study|Technical Problems|1
6040392|NCT03751098|9638269|FG001|Overall Study|Withdrawal by Subject|1
6040393|NCT03673345|9638285|FG000|Overall Study|Lost to Follow-up|1
6150366|NCT01105091|9786665|FG000|Overall Study|Death|2
6040394|NCT03673345|9638286|FG001|Overall Study|Lost to Follow-up|0
6150367|NCT01105091|9786666|FG001|Overall Study|Death|0
6150368|NCT01105130|9786686|FG000|Overall Study|Withdrawal by Subject|4
6150369|NCT01105130|9786687|FG001|Overall Study|Withdrawal by Subject|6
6150370|NCT01105130|9786688|FG002|Overall Study|Withdrawal by Subject|2
6150371|NCT01105130|9786686|FG000|Overall Study|Never Started|2
6150372|NCT01105130|9786687|FG001|Overall Study|Never Started|2
6150373|NCT01105130|9786688|FG002|Overall Study|Never Started|4
6150374|NCT01105130|9786686|FG000|Overall Study|Toxicity|1
6150375|NCT01105130|9786687|FG001|Overall Study|Toxicity|3
6150376|NCT01105130|9786688|FG002|Overall Study|Toxicity|2
6227366|NCT01716559|9900075|FG000|Overall Study|Death|21
6227367|NCT01716559|9900075|FG000|Overall Study|Withdrawal by Subject|4
6227368|NCT01716559|9900075|FG000|Overall Study|Other withdrawal reason|75
6227369|NCT01716585|9900081|FG000|Double-blind Treatment|Did Not Receive Study Drug|4
6227370|NCT01716585|9900082|FG001|Double-blind Treatment|Did Not Receive Study Drug|1
6227371|NCT01716585|9900081|FG000|Double-blind Treatment|Adverse Event|2
6227372|NCT01716585|9900082|FG001|Double-blind Treatment|Adverse Event|1
6227373|NCT01716585|9900081|FG000|Double-blind Treatment|Withdrawal by Subject|3
6227374|NCT01716585|9900082|FG001|Double-blind Treatment|Withdrawal by Subject|0
6227375|NCT01716585|9900081|FG000|Double-blind Treatment|Lost to Follow-up|2
6227376|NCT01716585|9900082|FG001|Double-blind Treatment|Lost to Follow-up|0
6227377|NCT01716585|9900081|FG000|Double-blind Treatment|Subject Noncompliant|1
6227378|NCT01716585|9900082|FG001|Double-blind Treatment|Subject Noncompliant|0
6150377|NCT01105130|9786686|FG000|Overall Study|Multiple Reasons|3
6150378|NCT01105130|9786687|FG001|Overall Study|Multiple Reasons|0
6150379|NCT01105130|9786688|FG002|Overall Study|Multiple Reasons|2
6150380|NCT01105377|9786725|FG000|Overall Study|Withdrawal by Subject|0
6150381|NCT01105377|9786726|FG001|Overall Study|Withdrawal by Subject|1
6150382|NCT01105533|9786732|FG000|Overall Study|Death|0
6150383|NCT01105533|9786733|FG001|Overall Study|Death|0
6150384|NCT01105533|9786734|FG002|Overall Study|Death|0
6150385|NCT01105533|9786735|FG003|Overall Study|Death|0
6150386|NCT01105533|9786736|FG004|Overall Study|Death|1
6150387|NCT01105533|9786737|FG005|Overall Study|Death|0
6150388|NCT01105533|9786738|FG006|Overall Study|Death|0
6150389|NCT01105533|9786739|FG007|Overall Study|Death|0
6150390|NCT01105533|9786740|FG008|Overall Study|Death|0
6150391|NCT01105533|9786732|FG000|Overall Study|Lack of Efficacy|1
6150392|NCT01105533|9786733|FG001|Overall Study|Lack of Efficacy|1
6150393|NCT01105533|9786734|FG002|Overall Study|Lack of Efficacy|3
6150394|NCT01105533|9786735|FG003|Overall Study|Lack of Efficacy|3
6150395|NCT01105533|9786736|FG004|Overall Study|Lack of Efficacy|4
6150396|NCT01105533|9786737|FG005|Overall Study|Lack of Efficacy|5
6150397|NCT01105533|9786738|FG006|Overall Study|Lack of Efficacy|3
6150398|NCT01105533|9786739|FG007|Overall Study|Lack of Efficacy|2
6150399|NCT01105533|9786740|FG008|Overall Study|Lack of Efficacy|9
6150400|NCT01105533|9786732|FG000|Overall Study|Adverse Event|0
6150401|NCT01105533|9786733|FG001|Overall Study|Adverse Event|0
6150402|NCT01105533|9786734|FG002|Overall Study|Adverse Event|0
6150403|NCT01105533|9786735|FG003|Overall Study|Adverse Event|0
6150404|NCT01105533|9786736|FG004|Overall Study|Adverse Event|1
6150405|NCT01105533|9786737|FG005|Overall Study|Adverse Event|2
6150406|NCT01105533|9786738|FG006|Overall Study|Adverse Event|2
6150407|NCT01105533|9786739|FG007|Overall Study|Adverse Event|0
6150408|NCT01105533|9786740|FG008|Overall Study|Adverse Event|1
6150409|NCT01105533|9786732|FG000|Overall Study|Other|0
6150410|NCT01105533|9786733|FG001|Overall Study|Other|0
6150411|NCT01105533|9786734|FG002|Overall Study|Other|0
6150412|NCT01105533|9786735|FG003|Overall Study|Other|0
6150413|NCT01105533|9786736|FG004|Overall Study|Other|1
6150414|NCT01105533|9786737|FG005|Overall Study|Other|0
6150415|NCT01105533|9786738|FG006|Overall Study|Other|3
6150416|NCT01105533|9786739|FG007|Overall Study|Other|1
6150417|NCT01105533|9786740|FG008|Overall Study|Other|2
6150418|NCT01105533|9786732|FG000|Overall Study|Physician Decision|0
6150419|NCT01105533|9786733|FG001|Overall Study|Physician Decision|0
6150420|NCT01105533|9786734|FG002|Overall Study|Physician Decision|0
6150421|NCT01105533|9786735|FG003|Overall Study|Physician Decision|0
6150422|NCT01105533|9786736|FG004|Overall Study|Physician Decision|0
6150423|NCT01105533|9786737|FG005|Overall Study|Physician Decision|0
6150424|NCT01105533|9786738|FG006|Overall Study|Physician Decision|0
6150425|NCT01105533|9786739|FG007|Overall Study|Physician Decision|1
6150426|NCT01105533|9786740|FG008|Overall Study|Physician Decision|0
6150427|NCT01105767|9786785|FG000|Overall Study|Lost to Follow-up|1160
6150428|NCT01105767|9786786|FG001|Overall Study|Lost to Follow-up|1614
6150429|NCT01105767|9786787|FG002|Overall Study|Lost to Follow-up|1184
6150430|NCT01105936|9786795|FG000|Period 1|Adverse Event|0
6227379|NCT01716585|9900081|FG000|Double-blind Treatment|Other|1
6150431|NCT01105936|9786796|FG001|Period 1|Adverse Event|0
6150432|NCT01105936|9786797|FG002|Period 1|Adverse Event|0
6150433|NCT01105936|9786798|FG003|Period 1|Adverse Event|1
6150434|NCT01105936|9786795|FG000|Period 2|Adverse Event|1
6150435|NCT01105936|9786796|FG001|Period 2|Adverse Event|0
6227380|NCT01716585|9900082|FG001|Double-blind Treatment|Other|0
6150436|NCT01105936|9786797|FG002|Period 2|Adverse Event|0
6150437|NCT01105936|9786798|FG003|Period 2|Adverse Event|0
6150438|NCT01105936|9786795|FG000|Period 3|Protocol Violation|0
6150439|NCT01105936|9786796|FG001|Period 3|Protocol Violation|2
6150440|NCT01105936|9786797|FG002|Period 3|Protocol Violation|0
6150441|NCT01105936|9786798|FG003|Period 3|Protocol Violation|0
6150442|NCT01105975|9786817|FG000|Overall Study|Adverse Event|2
6150443|NCT01105975|9786818|FG001|Overall Study|Adverse Event|1
6150444|NCT01105975|9786819|FG002|Overall Study|Adverse Event|5
6150445|NCT01105975|9786820|FG003|Overall Study|Adverse Event|1
6150446|NCT01105975|9786821|FG004|Overall Study|Adverse Event|0
6150447|NCT01105975|9786822|FG005|Overall Study|Adverse Event|1
6150448|NCT01105975|9786823|FG006|Overall Study|Adverse Event|2
6150449|NCT01105975|9786824|FG007|Overall Study|Adverse Event|4
6150450|NCT01105975|9786825|FG008|Overall Study|Adverse Event|1
6150451|NCT01105975|9786826|FG009|Overall Study|Adverse Event|4
6150452|NCT01105975|9786817|FG000|Overall Study|Withdrawal by Subject|2
6150453|NCT01105975|9786818|FG001|Overall Study|Withdrawal by Subject|2
6150454|NCT01105975|9786819|FG002|Overall Study|Withdrawal by Subject|2
6150455|NCT01105975|9786820|FG003|Overall Study|Withdrawal by Subject|0
6150456|NCT01105975|9786821|FG004|Overall Study|Withdrawal by Subject|4
6150457|NCT01105975|9786822|FG005|Overall Study|Withdrawal by Subject|1
6150458|NCT01105975|9786823|FG006|Overall Study|Withdrawal by Subject|2
6150459|NCT01105975|9786824|FG007|Overall Study|Withdrawal by Subject|1
6150460|NCT01105975|9786825|FG008|Overall Study|Withdrawal by Subject|0
6150461|NCT01105975|9786826|FG009|Overall Study|Withdrawal by Subject|3
6150462|NCT01105975|9786817|FG000|Overall Study|Lost to Follow-up|1
6150463|NCT01105975|9786818|FG001|Overall Study|Lost to Follow-up|0
6150464|NCT01105975|9786819|FG002|Overall Study|Lost to Follow-up|0
6150465|NCT01105975|9786820|FG003|Overall Study|Lost to Follow-up|1
6150466|NCT01105975|9786821|FG004|Overall Study|Lost to Follow-up|1
6150467|NCT01105975|9786822|FG005|Overall Study|Lost to Follow-up|0
6150468|NCT01105975|9786823|FG006|Overall Study|Lost to Follow-up|0
6150469|NCT01105975|9786824|FG007|Overall Study|Lost to Follow-up|0
6150470|NCT01105975|9786825|FG008|Overall Study|Lost to Follow-up|1
6150471|NCT01105975|9786826|FG009|Overall Study|Lost to Follow-up|0
6150472|NCT01105975|9786817|FG000|Overall Study|Physician Decision|0
6150473|NCT01105975|9786818|FG001|Overall Study|Physician Decision|0
6150474|NCT01105975|9786819|FG002|Overall Study|Physician Decision|0
6150475|NCT01105975|9786820|FG003|Overall Study|Physician Decision|0
6150476|NCT01105975|9786821|FG004|Overall Study|Physician Decision|0
6150477|NCT01105975|9786822|FG005|Overall Study|Physician Decision|0
6150478|NCT01105975|9786823|FG006|Overall Study|Physician Decision|2
6150479|NCT01105975|9786824|FG007|Overall Study|Physician Decision|0
6150480|NCT01105975|9786825|FG008|Overall Study|Physician Decision|0
6150481|NCT01105975|9786826|FG009|Overall Study|Physician Decision|0
6150482|NCT01105975|9786817|FG000|Overall Study|Protocol Violation|0
6150483|NCT01105975|9786818|FG001|Overall Study|Protocol Violation|2
6150484|NCT01105975|9786819|FG002|Overall Study|Protocol Violation|2
6150485|NCT01105975|9786820|FG003|Overall Study|Protocol Violation|0
6150486|NCT01105975|9786821|FG004|Overall Study|Protocol Violation|1
6150487|NCT01105975|9786822|FG005|Overall Study|Protocol Violation|1
6150488|NCT01105975|9786823|FG006|Overall Study|Protocol Violation|1
6150489|NCT01105975|9786824|FG007|Overall Study|Protocol Violation|1
6150490|NCT01105975|9786825|FG008|Overall Study|Protocol Violation|2
6150491|NCT01105975|9786826|FG009|Overall Study|Protocol Violation|2
6150492|NCT01105975|9786817|FG000|Overall Study|Abnormal Lab/Electrocardiogram Result|0
6150493|NCT01105975|9786818|FG001|Overall Study|Abnormal Lab/Electrocardiogram Result|0
6150494|NCT01105975|9786819|FG002|Overall Study|Abnormal Lab/Electrocardiogram Result|1
6150495|NCT01105975|9786820|FG003|Overall Study|Abnormal Lab/Electrocardiogram Result|0
6150496|NCT01105975|9786821|FG004|Overall Study|Abnormal Lab/Electrocardiogram Result|0
6150497|NCT01105975|9786822|FG005|Overall Study|Abnormal Lab/Electrocardiogram Result|2
6150498|NCT01105975|9786823|FG006|Overall Study|Abnormal Lab/Electrocardiogram Result|1
6150499|NCT01105975|9786824|FG007|Overall Study|Abnormal Lab/Electrocardiogram Result|1
6150500|NCT01105975|9786825|FG008|Overall Study|Abnormal Lab/Electrocardiogram Result|2
6150501|NCT01105975|9786826|FG009|Overall Study|Abnormal Lab/Electrocardiogram Result|0
6150502|NCT01106014|9786869|FG000|Overall Study|Morbidity or Mortality primary endpoint|155
6150503|NCT01106014|9786870|FG001|Overall Study|Morbidity or Mortality primary endpoint|242
6150504|NCT01106014|9786869|FG000|Overall Study|Adverse Event|78
6150505|NCT01106014|9786870|FG001|Overall Study|Adverse Event|42
6150506|NCT01106014|9786869|FG000|Overall Study|Withdrawal by Subject|43
6150507|NCT01106014|9786870|FG001|Overall Study|Withdrawal by Subject|37
6150508|NCT01106014|9786869|FG000|Overall Study|Administrative reason|7
6150509|NCT01106014|9786870|FG001|Overall Study|Administrative reason|6
6150510|NCT01106014|9786869|FG000|Overall Study|Lost to Follow-up|2
6150511|NCT01106014|9786870|FG001|Overall Study|Lost to Follow-up|3
6150512|NCT01106027|9786876|FG000|Overall Study|Lost graft early, discontinued|1
6150513|NCT01106092|9786889|FG000|Overall Study|Withdrawal by Subject|0
6150514|NCT01106092|9786890|FG001|Overall Study|Withdrawal by Subject|0
6150515|NCT01106092|9786891|FG002|Overall Study|Withdrawal by Subject|0
6150516|NCT01106092|9786892|FG003|Overall Study|Withdrawal by Subject|1
6150517|NCT01106157|9786904|FG000|Overall Study|Withdrawal by Subject|1
6150518|NCT01106157|9786905|FG001|Overall Study|Withdrawal by Subject|0
6150519|NCT01106248|9786911|FG000|Overall Study|Adverse Event|1
6150520|NCT01106248|9786911|FG000|Overall Study|Administrative|2
6150521|NCT01106287|9786919|FG000|Overall Study|Adverse Event|1
6150522|NCT01106287|9786920|FG001|Overall Study|Adverse Event|0
6150523|NCT01106287|9786921|FG002|Overall Study|Adverse Event|0
6150524|NCT01106287|9786922|FG003|Overall Study|Adverse Event|0
6150525|NCT01106352|9786947|FG000|Overall Study|Subjects untreated|0
6150526|NCT01106352|9786948|FG001|Overall Study|Subjects untreated|0
6150527|NCT01106352|9786949|FG002|Overall Study|Subjects untreated|0
6150528|NCT01106352|9786950|FG003|Overall Study|Subjects untreated|3
6150529|NCT01106352|9786951|FG004|Overall Study|Subjects untreated|4
6150530|NCT01106352|9786947|FG000|Overall Study|Sponsor Decision|1
6150531|NCT01106352|9786948|FG001|Overall Study|Sponsor Decision|0
6150532|NCT01106352|9786949|FG002|Overall Study|Sponsor Decision|0
6150533|NCT01106352|9786950|FG003|Overall Study|Sponsor Decision|0
6150534|NCT01106352|9786951|FG004|Overall Study|Sponsor Decision|0
6150535|NCT01106352|9786947|FG000|Overall Study|Too ill to come in for the visit|0
6150536|NCT01106352|9786948|FG001|Overall Study|Too ill to come in for the visit|0
6150537|NCT01106352|9786949|FG002|Overall Study|Too ill to come in for the visit|1
6150538|NCT01106352|9786950|FG003|Overall Study|Too ill to come in for the visit|0
6150539|NCT01106352|9786951|FG004|Overall Study|Too ill to come in for the visit|0
6150540|NCT01106352|9786947|FG000|Overall Study|Lost to Follow-up|0
6150541|NCT01106352|9786948|FG001|Overall Study|Lost to Follow-up|0
6150542|NCT01106352|9786949|FG002|Overall Study|Lost to Follow-up|0
6150543|NCT01106352|9786950|FG003|Overall Study|Lost to Follow-up|0
6150544|NCT01106352|9786951|FG004|Overall Study|Lost to Follow-up|1
6150545|NCT01106352|9786947|FG000|Overall Study|Death|0
6150546|NCT01106352|9786948|FG001|Overall Study|Death|0
6150547|NCT01106352|9786949|FG002|Overall Study|Death|1
6150548|NCT01106352|9786950|FG003|Overall Study|Death|3
6150549|NCT01106352|9786951|FG004|Overall Study|Death|1
6150550|NCT01106352|9786947|FG000|Overall Study|Disease progression|0
6150551|NCT01106352|9786948|FG001|Overall Study|Disease progression|0
6150552|NCT01106352|9786949|FG002|Overall Study|Disease progression|0
6150553|NCT01106352|9786950|FG003|Overall Study|Disease progression|1
6150554|NCT01106352|9786951|FG004|Overall Study|Disease progression|0
6150555|NCT01106352|9786947|FG000|Overall Study|Withdrawal by Subject|0
6150556|NCT01106352|9786948|FG001|Overall Study|Withdrawal by Subject|0
6150557|NCT01106352|9786949|FG002|Overall Study|Withdrawal by Subject|0
6150558|NCT01106352|9786950|FG003|Overall Study|Withdrawal by Subject|3
6150559|NCT01106352|9786951|FG004|Overall Study|Withdrawal by Subject|2
6150560|NCT01106352|9786947|FG000|Overall Study|Went on hospice|0
6316334|NCT02732938|10049664|FG000|Overall Study|Death|0
6316335|NCT02732938|10049665|FG001|Overall Study|Death|11
6316336|NCT02732938|10049666|FG002|Overall Study|Death|0
6316337|NCT02732938|10049664|FG000|Overall Study|Randomized but did not receive treatment|0
6316338|NCT02732938|10049665|FG001|Overall Study|Randomized but did not receive treatment|1
6316339|NCT02732938|10049666|FG002|Overall Study|Randomized but did not receive treatment|0
6316340|NCT02732938|10049664|FG000|Overall Study|Refused further follow-up|1
6316341|NCT02732938|10049665|FG001|Overall Study|Refused further follow-up|0
6316342|NCT02732938|10049666|FG002|Overall Study|Refused further follow-up|0
6316343|NCT02732938|10049664|FG000|Overall Study|Study terminated by sponsor|3
6316344|NCT02732938|10049665|FG001|Overall Study|Study terminated by sponsor|6
6316345|NCT02732938|10049666|FG002|Overall Study|Study terminated by sponsor|0
6316346|NCT02732951|10049676|FG000|Overall Study|Other than listed|1
6316347|NCT02732951|10049677|FG001|Overall Study|Other than listed|0
6316348|NCT02732951|10049676|FG000|Overall Study|Lost to Follow-up|0
6316349|NCT02732951|10049677|FG001|Overall Study|Lost to Follow-up|1
6316350|NCT02732951|10049676|FG000|Overall Study|Adverse Event|4
6316351|NCT02732951|10049677|FG001|Overall Study|Adverse Event|4
6316352|NCT02732951|10049676|FG000|Overall Study|Protocol Violation|0
6316353|NCT02732951|10049677|FG001|Overall Study|Protocol Violation|1
6316354|NCT02733367|10049683|FG000|Overall Study|Withdrawal by Subject|6
6316355|NCT02733627|10049696|FG000|Overall Study|Adverse Event|0
6316356|NCT02733627|10049697|FG001|Overall Study|Adverse Event|1
6316357|NCT02733627|10049698|FG002|Overall Study|Adverse Event|1
6316358|NCT02733627|10049699|FG003|Overall Study|Adverse Event|0
6316359|NCT02733627|10049696|FG000|Overall Study|Withdrawn due laboratory reason concerning neutrophils in agreement with the sponsor|0
6316360|NCT02733627|10049697|FG001|Overall Study|Withdrawn due laboratory reason concerning neutrophils in agreement with the sponsor|0
6316361|NCT02733627|10049698|FG002|Overall Study|Withdrawn due laboratory reason concerning neutrophils in agreement with the sponsor|1
6316362|NCT02733627|10049699|FG003|Overall Study|Withdrawn due laboratory reason concerning neutrophils in agreement with the sponsor|0
6316363|NCT02733991|10049732|FG000|Overall Study|Adverse Event|1
6316364|NCT02733991|10049733|FG001|Overall Study|Adverse Event|0
6316365|NCT02733991|10049732|FG000|Overall Study|Withdrawal by Subject|0
6316366|NCT02733991|10049733|FG001|Overall Study|Withdrawal by Subject|5
6316367|NCT02734212|10049759|FG000|Overall Study|Lost to Follow-up|5
6316368|NCT02734212|10049760|FG001|Overall Study|Lost to Follow-up|10
6316369|NCT02734693|10049805|FG000|Overall Study|Adverse Event|1
6316370|NCT02734693|10049806|FG001|Overall Study|Adverse Event|3
6316371|NCT02734693|10049807|FG002|Overall Study|Adverse Event|3
6316372|NCT02734693|10049805|FG000|Overall Study|Lack of Efficacy|1
6316373|NCT02734693|10049806|FG001|Overall Study|Lack of Efficacy|0
6316374|NCT02734693|10049807|FG002|Overall Study|Lack of Efficacy|0
6316375|NCT02734693|10049805|FG000|Overall Study|Lost to Follow-up|2
6316376|NCT02734693|10049806|FG001|Overall Study|Lost to Follow-up|0
6316377|NCT02734693|10049807|FG002|Overall Study|Lost to Follow-up|0
6316378|NCT02734693|10049805|FG000|Overall Study|Protocol Violation|1
6316379|NCT02734693|10049806|FG001|Overall Study|Protocol Violation|0
6316380|NCT02734693|10049807|FG002|Overall Study|Protocol Violation|0
6316381|NCT02734693|10049805|FG000|Overall Study|Withdrawal by Subject|1
6316382|NCT02734693|10049806|FG001|Overall Study|Withdrawal by Subject|0
6316383|NCT02734693|10049807|FG002|Overall Study|Withdrawal by Subject|0
6316384|NCT02734810|10049817|FG000|Overall Study|Adverse Event|1
6316385|NCT02734810|10049818|FG001|Overall Study|Adverse Event|0
6316386|NCT02734810|10049817|FG000|Overall Study|Lack of Efficacy|1
6316387|NCT02734810|10049818|FG001|Overall Study|Lack of Efficacy|0
6316388|NCT02734862|10049840|FG000|Part A|Death|3
6150561|NCT01106352|9786948|FG001|Overall Study|Went on hospice|0
6150562|NCT01106352|9786949|FG002|Overall Study|Went on hospice|0
6150563|NCT01106352|9786950|FG003|Overall Study|Went on hospice|1
6150564|NCT01106352|9786951|FG004|Overall Study|Went on hospice|0
6150565|NCT01106352|9786947|FG000|Overall Study|Subject entered hospice|0
6150566|NCT01106352|9786948|FG001|Overall Study|Subject entered hospice|0
6150567|NCT01106352|9786949|FG002|Overall Study|Subject entered hospice|0
6150568|NCT01106352|9786950|FG003|Overall Study|Subject entered hospice|1
6150569|NCT01106352|9786951|FG004|Overall Study|Subject entered hospice|0
6150570|NCT01106352|9786947|FG000|Overall Study|Home hospice since July 2013|0
6150571|NCT01106352|9786948|FG001|Overall Study|Home hospice since July 2013|0
6150572|NCT01106352|9786949|FG002|Overall Study|Home hospice since July 2013|0
6150573|NCT01106352|9786950|FG003|Overall Study|Home hospice since July 2013|1
6150574|NCT01106352|9786951|FG004|Overall Study|Home hospice since July 2013|0
6316389|NCT02734862|10049841|FG001|Part A|Death|4
6316390|NCT02734862|10049842|FG002|Part A|Death|6
6316391|NCT02734862|10049840|FG000|Part A|Lost to Follow-up|2
6316392|NCT02734862|10049841|FG001|Part A|Lost to Follow-up|1
6316393|NCT02734862|10049842|FG002|Part A|Lost to Follow-up|1
6316394|NCT02734862|10049840|FG000|Part A|Withdrawal by Subject|1
6316395|NCT02734862|10049841|FG001|Part A|Withdrawal by Subject|1
6316396|NCT02734862|10049842|FG002|Part A|Withdrawal by Subject|2
6316397|NCT02734862|10049840|FG000|Part A|Physician Decision|2
6316398|NCT02734862|10049841|FG001|Part A|Physician Decision|0
6316399|NCT02734862|10049842|FG002|Part A|Physician Decision|1
6316400|NCT02734862|10049840|FG000|Part A|Adverse Event|2
6316401|NCT02734862|10049841|FG001|Part A|Adverse Event|0
6316402|NCT02734862|10049842|FG002|Part A|Adverse Event|1
6316403|NCT02734862|10049840|FG000|Part A|Noncompliance|1
6316404|NCT02734862|10049841|FG001|Part A|Noncompliance|1
6316405|NCT02734862|10049842|FG002|Part A|Noncompliance|0
6316406|NCT02734862|10049840|FG000|Part A|Other|1
6316407|NCT02734862|10049841|FG001|Part A|Other|1
6316408|NCT02734862|10049842|FG002|Part A|Other|3
6316409|NCT02734862|10049840|FG000|Part B|Death|8
6316410|NCT02734862|10049841|FG001|Part B|Death|3
6316411|NCT02734862|10049842|FG002|Part B|Death|5
6316412|NCT02734862|10049840|FG000|Part B|Lost to Follow-up|2
6316413|NCT02734862|10049841|FG001|Part B|Lost to Follow-up|2
6316414|NCT02734862|10049842|FG002|Part B|Lost to Follow-up|0
6316415|NCT02734862|10049840|FG000|Part B|Withdrawal by Subject|3
6040395|NCT03673345|9638287|FG002|Overall Study|Lost to Follow-up|3
6316416|NCT02734862|10049841|FG001|Part B|Withdrawal by Subject|1
6316417|NCT02734862|10049842|FG002|Part B|Withdrawal by Subject|0
6316418|NCT02734862|10049840|FG000|Part B|Other|0
6316419|NCT02734862|10049841|FG001|Part B|Other|1
6316420|NCT02734862|10049842|FG002|Part B|Other|0
6316421|NCT02735096|10049867|FG000|Overall Study|No symptoms in clinic/personal leave|1
6316422|NCT02735200|10049892|FG000|Overall Study|Lost to Follow-up|0
6316423|NCT02735200|10049893|FG001|Overall Study|Lost to Follow-up|5
6316424|NCT02735200|10049892|FG000|Overall Study|Withdrawal by Subject|8
6316425|NCT02735200|10049893|FG001|Overall Study|Withdrawal by Subject|0
6316426|NCT02735421|10049916|FG000|Overall Study|Adverse Event|2
6316427|NCT02735421|10049916|FG000|Overall Study|Withdrawal by Subject|6
6316428|NCT02735421|10049916|FG000|Overall Study|Lost to Follow-up|3
6316429|NCT02735421|10049916|FG000|Overall Study|Inadequate compliance to treatment|1
6316430|NCT02735421|10049916|FG000|Overall Study|Pregnancy|1
6316431|NCT02735577|10049936|FG000|Disulfiram Treatment|Lost to Follow-up|1
6316432|NCT02735577|10049936|FG000|Optional 28 Days of Disulfiram Treatment|Lost to Follow-up|2
6316433|NCT02735915|10049953|FG000|Overall Study|Not vaccinated but subject ID assigned|8
6316434|NCT02735915|10049953|FG000|Overall Study|Withdrawal following SAE|2
6316435|NCT02735915|10049953|FG000|Overall Study|Withdrawal by Subject|1
6316436|NCT02735980|10049962|FG000|Overall Study|Adverse Event|0
6316437|NCT02735980|10049963|FG001|Overall Study|Adverse Event|4
6316438|NCT02735980|10049964|FG002|Overall Study|Adverse Event|1
6316439|NCT02735980|10049962|FG000|Overall Study|Death|5
6316440|NCT02735980|10049963|FG001|Overall Study|Death|4
6316441|NCT02735980|10049964|FG002|Overall Study|Death|0
6316442|NCT02735980|10049962|FG000|Overall Study|Physician Decision|3
6316443|NCT02735980|10049963|FG001|Overall Study|Physician Decision|1
6316444|NCT02735980|10049964|FG002|Overall Study|Physician Decision|0
6316445|NCT02735980|10049962|FG000|Overall Study|Screen failure|1
6316446|NCT02735980|10049963|FG001|Overall Study|Screen failure|0
6316447|NCT02735980|10049964|FG002|Overall Study|Screen failure|0
6316448|NCT02735980|10049962|FG000|Overall Study|Withdrawal by Subject|1
6316449|NCT02735980|10049963|FG001|Overall Study|Withdrawal by Subject|2
6316450|NCT02735980|10049964|FG002|Overall Study|Withdrawal by Subject|0
6316451|NCT02736188|10049986|FG000|Overall Study|Discontinuation of Study by Sponsor|134
6316452|NCT02736188|10049986|FG000|Overall Study|Adverse Event|1
6316453|NCT02736188|10049986|FG000|Overall Study|Withdrawal by Subject|1
6316454|NCT02736188|10049986|FG000|Overall Study|Other|6
6316455|NCT02736409|10049996|FG000|Overall Study|Withdrawal by Subject|4
6316456|NCT02736409|10049997|FG001|Overall Study|Withdrawal by Subject|2
6316457|NCT02736409|10049998|FG002|Overall Study|Withdrawal by Subject|17
6316458|NCT02736409|10049999|FG003|Overall Study|Withdrawal by Subject|3
6316459|NCT02736409|10049996|FG000|Overall Study|Non-Compliance with Study Drug|0
6316460|NCT02736409|10049997|FG001|Overall Study|Non-Compliance with Study Drug|0
6316461|NCT02736409|10049998|FG002|Overall Study|Non-Compliance with Study Drug|0
6316462|NCT02736409|10049999|FG003|Overall Study|Non-Compliance with Study Drug|1
6316463|NCT02736409|10049996|FG000|Overall Study|Adverse Event|0
6316464|NCT02736409|10049997|FG001|Overall Study|Adverse Event|1
6316465|NCT02736409|10049998|FG002|Overall Study|Adverse Event|5
6316466|NCT02736409|10049999|FG003|Overall Study|Adverse Event|4
6316467|NCT02736409|10049996|FG000|Overall Study|Other|0
6316468|NCT02736409|10049997|FG001|Overall Study|Other|0
6316469|NCT02736409|10049998|FG002|Overall Study|Other|1
6316470|NCT02736409|10049999|FG003|Overall Study|Other|1
6316471|NCT02736409|10049996|FG000|Overall Study|Pregnancy|0
6316472|NCT02736409|10049997|FG001|Overall Study|Pregnancy|0
6316473|NCT02736409|10049998|FG002|Overall Study|Pregnancy|1
6316474|NCT02736409|10049999|FG003|Overall Study|Pregnancy|0
6316475|NCT02736409|10049996|FG000|Overall Study|Lost to Follow-up|0
6316476|NCT02736409|10049997|FG001|Overall Study|Lost to Follow-up|0
6316477|NCT02736409|10049998|FG002|Overall Study|Lost to Follow-up|2
6316478|NCT02736409|10049999|FG003|Overall Study|Lost to Follow-up|1
6316479|NCT02736409|10049996|FG000|Overall Study|Physician Decision|0
6316480|NCT02736409|10049997|FG001|Overall Study|Physician Decision|0
6316481|NCT02736409|10049998|FG002|Overall Study|Physician Decision|0
6316482|NCT02736409|10049999|FG003|Overall Study|Physician Decision|2
6316483|NCT02736474|10050012|FG000|Overall Study|Lost to Follow-up|0
6316484|NCT02736474|10050013|FG001|Overall Study|Lost to Follow-up|1
6316485|NCT02736578|10050021|FG000|Overall Study|Adverse Event|1
6316486|NCT02736578|10050022|FG001|Overall Study|Adverse Event|0
6316487|NCT02736721|10050032|FG000|Overall Study|Adverse Event|8
6316488|NCT02736721|10050032|FG000|Overall Study|Lost to Follow-up|3
6316489|NCT02736721|10050032|FG000|Overall Study|Other|5
6316490|NCT02736825|10050038|FG000|Overall Study|Lost to Follow-up|10
6316491|NCT02736825|10050039|FG001|Overall Study|Lost to Follow-up|11
6316492|NCT02736825|10050038|FG000|Overall Study|Early Termination|0
6316493|NCT02736825|10050039|FG001|Overall Study|Early Termination|1
6316494|NCT02736890|10050048|FG000|Crossover Next 12 Weeks|Lost to Follow-up|1
6316495|NCT02736890|10050049|FG001|Crossover Next 12 Weeks|Lost to Follow-up|2
6316496|NCT02736890|10050048|FG000|Crossover Next 12 Weeks|Withdrawal by Subject|1
6316497|NCT02736890|10050049|FG001|Crossover Next 12 Weeks|Withdrawal by Subject|0
6316498|NCT02737358|10050103|FG000|Overall Study|Withdrawal by Subject|7
6316499|NCT02737358|10050104|FG001|Overall Study|Withdrawal by Subject|12
6316500|NCT02737358|10050103|FG000|Overall Study|Lost to Follow-up|2
6316501|NCT02737358|10050104|FG001|Overall Study|Lost to Follow-up|3
6316502|NCT02737501|10050122|FG000|Randomized Phase|Died|41
6316503|NCT02737501|10050123|FG001|Randomized Phase|Died|29
6316504|NCT02737501|10050124|FG002|Randomized Phase|Died|0
6316505|NCT02737501|10050122|FG000|Randomized Phase|Withdrawal by Subject|16
6316506|NCT02737501|10050123|FG001|Randomized Phase|Withdrawal by Subject|6
6316507|NCT02737501|10050124|FG002|Randomized Phase|Withdrawal by Subject|0
6316508|NCT02737501|10050122|FG000|Randomized Phase|Lost to Follow-up|0
6316509|NCT02737501|10050123|FG001|Randomized Phase|Lost to Follow-up|1
6316510|NCT02737501|10050124|FG002|Randomized Phase|Lost to Follow-up|0
6316511|NCT02737501|10050122|FG000|Randomized Phase|Site Terminated by Sponsor|58
6316512|NCT02737501|10050123|FG001|Randomized Phase|Site Terminated by Sponsor|16
6316513|NCT02737501|10050124|FG002|Randomized Phase|Site Terminated by Sponsor|0
6316514|NCT02737501|10050122|FG000|Randomized Phase|Reason not Specified|1
6316515|NCT02737501|10050123|FG001|Randomized Phase|Reason not Specified|1
6316516|NCT02737501|10050124|FG002|Randomized Phase|Reason not Specified|0
6316517|NCT02737501|10050122|FG000|Randomized Phase|Never Treated|1
6316518|NCT02737501|10050123|FG001|Randomized Phase|Never Treated|1
6316519|NCT02737501|10050124|FG002|Randomized Phase|Never Treated|0
6316520|NCT02737501|10050122|FG000|Crossover Phase|Died|0
6316521|NCT02737501|10050123|FG001|Crossover Phase|Died|0
6316522|NCT02737501|10050124|FG002|Crossover Phase|Died|22
6316523|NCT02737501|10050122|FG000|Crossover Phase|Withdrew Consent|0
6316524|NCT02737501|10050123|FG001|Crossover Phase|Withdrew Consent|0
6316525|NCT02737501|10050124|FG002|Crossover Phase|Withdrew Consent|9
6316526|NCT02737501|10050122|FG000|Crossover Phase|Physician Decision|0
6316527|NCT02737501|10050123|FG001|Crossover Phase|Physician Decision|0
6316528|NCT02737501|10050124|FG002|Crossover Phase|Physician Decision|1
6316529|NCT02737501|10050122|FG000|Crossover Phase|Site Terminated by Sponsor|0
6316530|NCT02737501|10050123|FG001|Crossover Phase|Site Terminated by Sponsor|0
6316531|NCT02737501|10050124|FG002|Crossover Phase|Site Terminated by Sponsor|23
6316532|NCT02737592|10050132|FG000|Overall Study|Withdrawal by Subject|1
6316533|NCT02737618|10050136|FG000|Overall Study|Withdrawal by Subject|9
6316534|NCT02737722|10050148|FG000|Overall Study|Physician Decision|0
6316535|NCT02737722|10050149|FG001|Overall Study|Physician Decision|0
6316536|NCT02737722|10050150|FG002|Overall Study|Physician Decision|1
6316537|NCT02737722|10050151|FG003|Overall Study|Physician Decision|0
6316538|NCT02737826|10050161|FG000|Phase II - Randomization + Taper|Withdrawal by Subject|0
6316539|NCT02737826|10050162|FG001|Phase II - Randomization + Taper|Withdrawal by Subject|12
6316540|NCT02737826|10050163|FG002|Phase II - Randomization + Taper|Withdrawal by Subject|14
6316541|NCT02737852|10050172|FG000|Overall Study|Withdrawal by Subject|2
6316542|NCT02737930|10050196|FG000|Overall Study|Withdrawal by Subject|0
6316543|NCT02737930|10050197|FG001|Overall Study|Withdrawal by Subject|1
6316544|NCT02738008|10050206|FG000|Overall Study|Study Terminated by Sponsor|1
6316545|NCT02738008|10050207|FG001|Overall Study|Study Terminated by Sponsor|5
6150575|NCT01106404|9786973|FG000|Period I (First 6 Weeks)|Adverse Event|2
6150576|NCT01106404|9786974|FG001|Period I (First 6 Weeks)|Adverse Event|0
6316546|NCT02738008|10050208|FG002|Overall Study|Study Terminated by Sponsor|3
6316547|NCT02738008|10050206|FG000|Overall Study|Adverse Event|0
6316548|NCT02738008|10050207|FG001|Overall Study|Adverse Event|1
6316549|NCT02738008|10050208|FG002|Overall Study|Adverse Event|2
6316550|NCT02738138|10050230|FG000|Overall Study|Adverse Event|0
6316551|NCT02738138|10050231|FG001|Overall Study|Adverse Event|1
6316552|NCT02738138|10050230|FG000|Overall Study|Lost to Follow-up|2
6316553|NCT02738138|10050231|FG001|Overall Study|Lost to Follow-up|0
6316554|NCT02738138|10050230|FG000|Overall Study|Other - not further specified|1
6316555|NCT02738138|10050231|FG001|Overall Study|Other - not further specified|0
6316556|NCT02738151|10050238|FG000|Overall Study|Randomized but not treated|4
6316557|NCT02738151|10050239|FG001|Overall Study|Randomized but not treated|1
6316558|NCT02738151|10050238|FG000|Overall Study|Adverse Event|4
6316559|NCT02738151|10050239|FG001|Overall Study|Adverse Event|5
6316560|NCT02738151|10050238|FG000|Overall Study|Hypoglycemia|0
6316561|NCT02738151|10050239|FG001|Overall Study|Hypoglycemia|1
6316562|NCT02738151|10050238|FG000|Overall Study|Poor Compliance to Protocol|4
6316563|NCT02738151|10050239|FG001|Overall Study|Poor Compliance to Protocol|3
6316564|NCT02738151|10050238|FG000|Overall Study|Other than specified above|11
6316565|NCT02738151|10050239|FG001|Overall Study|Other than specified above|21
6316566|NCT02738203|10050247|FG000|Overall Study|Failed IUD Insertion|2
6316567|NCT02738203|10050248|FG001|Overall Study|Failed IUD Insertion|2
6316568|NCT02738203|10050247|FG000|Overall Study|Protocol Violation|0
6316569|NCT02738203|10050248|FG001|Overall Study|Protocol Violation|1
6316570|NCT02738333|10050257|FG000|Overall Study|Death|1
6316571|NCT02738333|10050258|FG001|Overall Study|Death|0
6316572|NCT02738333|10050259|FG002|Overall Study|Death|0
6316573|NCT02738333|10050257|FG000|Overall Study|Lost to Follow-up|1
6316574|NCT02738333|10050258|FG001|Overall Study|Lost to Follow-up|0
6316575|NCT02738333|10050259|FG002|Overall Study|Lost to Follow-up|0
6316576|NCT02738450|10050271|FG000|Overall Study|Withdrawal by Subject|0
6316577|NCT02738450|10050272|FG001|Overall Study|Withdrawal by Subject|2
6316578|NCT02738450|10050273|FG002|Overall Study|Withdrawal by Subject|0
6316579|NCT02738580|10050284|FG000|Overall Study|Adverse Event|1
6316580|NCT02738580|10050285|FG001|Overall Study|Adverse Event|0
6316581|NCT02738580|10050284|FG000|Overall Study|Lack of Efficacy|3
6316582|NCT02738580|10050285|FG001|Overall Study|Lack of Efficacy|2
6316583|NCT02738580|10050284|FG000|Overall Study|Withdrawal by Subject|0
6316584|NCT02738580|10050285|FG001|Overall Study|Withdrawal by Subject|1
6316585|NCT02738580|10050284|FG000|Overall Study|EXCLUDED FROM DONNOR PROGRAM|0
6316586|NCT02738580|10050285|FG001|Overall Study|EXCLUDED FROM DONNOR PROGRAM|1
6316587|NCT02738775|10050297|FG000|Overall Study|Withdrawal by Subject|0
6316588|NCT02738775|10050298|FG001|Overall Study|Withdrawal by Subject|1
6316589|NCT02738775|10050299|FG002|Overall Study|Withdrawal by Subject|0
6316590|NCT02738775|10050300|FG003|Overall Study|Withdrawal by Subject|0
6316591|NCT02738775|10050301|FG004|Overall Study|Withdrawal by Subject|0
6316592|NCT02738775|10050302|FG005|Overall Study|Withdrawal by Subject|0
6316593|NCT02738775|10050297|FG000|Overall Study|Adverse Event|0
6316594|NCT02738775|10050298|FG001|Overall Study|Adverse Event|0
6316595|NCT02738775|10050299|FG002|Overall Study|Adverse Event|0
6316596|NCT02738775|10050300|FG003|Overall Study|Adverse Event|1
6316597|NCT02738775|10050301|FG004|Overall Study|Adverse Event|0
6316598|NCT02738775|10050302|FG005|Overall Study|Adverse Event|0
6316599|NCT02738775|10050297|FG000|Overall Study|Pregnancy|0
6316600|NCT02738775|10050298|FG001|Overall Study|Pregnancy|1
6316601|NCT02738775|10050299|FG002|Overall Study|Pregnancy|0
6316602|NCT02738775|10050300|FG003|Overall Study|Pregnancy|0
6316603|NCT02738775|10050301|FG004|Overall Study|Pregnancy|0
6316604|NCT02738775|10050302|FG005|Overall Study|Pregnancy|0
6316605|NCT02738775|10050297|FG000|Overall Study|Missing|0
6316606|NCT02738775|10050298|FG001|Overall Study|Missing|0
6316607|NCT02738775|10050299|FG002|Overall Study|Missing|0
6316608|NCT02738775|10050300|FG003|Overall Study|Missing|0
6316609|NCT02738775|10050301|FG004|Overall Study|Missing|0
6316610|NCT02738775|10050302|FG005|Overall Study|Missing|1
6316611|NCT02738801|10050322|FG000|Overall Study|Adverse Event|1
6316612|NCT02738801|10050323|FG001|Overall Study|Adverse Event|1
6316613|NCT02738801|10050322|FG000|Overall Study|Withdrawal by Subject|0
6316614|NCT02738801|10050323|FG001|Overall Study|Withdrawal by Subject|1
6316615|NCT02738840|10050330|FG000|Overall Study|MRI Scan not Performed|5
6316616|NCT02738840|10050330|FG000|Overall Study|Lost to Follow-up|1
6316617|NCT02738840|10050330|FG000|Overall Study|Subject Participation Terminated by Investigator|1
6316618|NCT02738840|10050330|FG000|Overall Study|Subject Did not Meet Screening Inclusion/Exclusion Criteria|1
6316619|NCT02738879|10050336|FG000|Overall Study|Adverse Event|1
6316620|NCT02738879|10050337|FG001|Overall Study|Adverse Event|1
6316621|NCT02738879|10050336|FG000|Overall Study|Death|0
6316622|NCT02738879|10050337|FG001|Overall Study|Death|2
6316623|NCT02738879|10050336|FG000|Overall Study|Lost to Follow-up|1
6316624|NCT02738879|10050337|FG001|Overall Study|Lost to Follow-up|5
6316625|NCT02738879|10050336|FG000|Overall Study|Protocol Violation|1
6316626|NCT02738879|10050337|FG001|Overall Study|Protocol Violation|3
6316627|NCT02738879|10050336|FG000|Overall Study|Physician Decision|3
6316628|NCT02738879|10050337|FG001|Overall Study|Physician Decision|4
6316629|NCT02738879|10050336|FG000|Overall Study|Pregnancy|0
6316630|NCT02738879|10050337|FG001|Overall Study|Pregnancy|1
6316631|NCT02738879|10050336|FG000|Overall Study|Screen Failure|1
6316632|NCT02738879|10050337|FG001|Overall Study|Screen Failure|2
6316633|NCT02738879|10050336|FG000|Overall Study|Site Discontinued Study Participation|1
6316634|NCT02738879|10050337|FG001|Overall Study|Site Discontinued Study Participation|0
6316635|NCT02738879|10050336|FG000|Overall Study|Withdrawal by Subject|5
6316636|NCT02738879|10050337|FG001|Overall Study|Withdrawal by Subject|7
6316637|NCT02739269|10050353|FG000|Overall Study|Protocol Violation|5
6316638|NCT02739269|10050354|FG001|Overall Study|Protocol Violation|0
6316639|NCT02739269|10050353|FG000|Overall Study|Cycle cancellation|2
6316640|NCT02739269|10050354|FG001|Overall Study|Cycle cancellation|2
6316641|NCT02739269|10050353|FG000|Overall Study|Withdrawal by Subject|0
6316642|NCT02739269|10050354|FG001|Overall Study|Withdrawal by Subject|2
6316643|NCT02739321|10050362|FG000|Overall Study|Lack of Efficacy|1
6316644|NCT02739321|10050363|FG001|Overall Study|Lack of Efficacy|1
6316645|NCT02739321|10050362|FG000|Overall Study|Lost to Follow-up|1
6316646|NCT02739321|10050363|FG001|Overall Study|Lost to Follow-up|1
6316647|NCT02739321|10050362|FG000|Overall Study|Withdrawal by Subject|1
6316648|NCT02739321|10050363|FG001|Overall Study|Withdrawal by Subject|2
6316649|NCT02739360|10050378|FG000|Overall Study|Adverse Event|1
6316650|NCT02739360|10050378|FG000|Overall Study|Study terminated by Sponsor|2
6316651|NCT02739594|10050384|FG000|Overall Study|Undesired Event|3
6150577|NCT01106404|9786973|FG000|Period I (First 6 Weeks)|Physician Decision|1
6150578|NCT01106404|9786974|FG001|Period I (First 6 Weeks)|Physician Decision|0
6150579|NCT01106404|9786973|FG000|Period I (First 6 Weeks)|Lost to Follow-up|0
6316652|NCT02739594|10050385|FG001|Overall Study|Undesired Event|4
6316653|NCT02739594|10050384|FG000|Overall Study|Violation of Eligibility Criteria|1
6316654|NCT02739594|10050385|FG001|Overall Study|Violation of Eligibility Criteria|2
6316655|NCT02739594|10050384|FG000|Overall Study|Protocol Violation|5
6316656|NCT02739594|10050385|FG001|Overall Study|Protocol Violation|6
6316657|NCT02739594|10050384|FG000|Overall Study|Death|4
6316658|NCT02739594|10050385|FG001|Overall Study|Death|2
6316659|NCT02739594|10050384|FG000|Overall Study|Renal Insufficiency|4
6316660|NCT02739594|10050385|FG001|Overall Study|Renal Insufficiency|6
6316661|NCT02739594|10050384|FG000|Overall Study|Administrative Reasons|1
6316662|NCT02739594|10050385|FG001|Overall Study|Administrative Reasons|3
6316663|NCT02739594|10050384|FG000|Overall Study|Withdrawal by Subject|1
6316664|NCT02739594|10050385|FG001|Overall Study|Withdrawal by Subject|1
6316665|NCT02739594|10050384|FG000|Overall Study|Lost to Follow-up|0
6316666|NCT02739594|10050385|FG001|Overall Study|Lost to Follow-up|1
6316667|NCT02739594|10050384|FG000|Overall Study|Elevated Serum Creatinine|0
6316668|NCT02739594|10050385|FG001|Overall Study|Elevated Serum Creatinine|1
6316669|NCT02739594|10050384|FG000|Overall Study|Other|6
6316670|NCT02739594|10050385|FG001|Overall Study|Other|2
6316671|NCT02739828|10050410|FG000|Overall Study|Adverse Event|1
6316672|NCT02739828|10050410|FG000|Overall Study|Lost to Follow-up|4
6316673|NCT02739984|10050416|FG000|Overall Study|Sponsor Decision|1
6316674|NCT02739984|10050417|FG001|Overall Study|Sponsor Decision|0
6316675|NCT02739984|10050416|FG000|Overall Study|Withdrawal by Subject|1
6316676|NCT02739984|10050417|FG001|Overall Study|Withdrawal by Subject|1
6316677|NCT02739984|10050416|FG000|Overall Study|Death|0
6316678|NCT02739984|10050417|FG001|Overall Study|Death|1
6316679|NCT02739984|10050416|FG000|Overall Study|Lost to Follow-up|3
6316680|NCT02739984|10050417|FG001|Overall Study|Lost to Follow-up|0
6040396|NCT03673345|9638288|FG003|Overall Study|Lost to Follow-up|3
6040397|NCT03673345|9638289|FG004|Overall Study|Lost to Follow-up|2
6040398|NCT03673345|9638290|FG005|Overall Study|Lost to Follow-up|1
6040399|NCT03673345|9638291|FG006|Overall Study|Lost to Follow-up|0
6150580|NCT01106404|9786974|FG001|Period I (First 6 Weeks)|Lost to Follow-up|1
6040400|NCT03673345|9638292|FG007|Overall Study|Lost to Follow-up|0
6316681|NCT02739997|10050423|FG000|Overall Study|Death|1
6316682|NCT02739997|10050423|FG000|Overall Study|Withdrawal by Subject|1
6316683|NCT02740049|10050427|FG000|Overall Study|Isolated cells did not grow sufficiently|1
6316684|NCT02740478|10050459|FG000|Overall Study|Withdrawal by Subject|1
6316685|NCT02741076|10050515|FG000|Overall Study|Adverse Event|0
6316686|NCT02741076|10050516|FG001|Overall Study|Adverse Event|1
6316687|NCT02741076|10050517|FG002|Overall Study|Adverse Event|1
6316688|NCT02741076|10050518|FG003|Overall Study|Adverse Event|0
6316689|NCT02741076|10050515|FG000|Overall Study|Lack of Efficacy|1
6316690|NCT02741076|10050516|FG001|Overall Study|Lack of Efficacy|0
6316691|NCT02741076|10050517|FG002|Overall Study|Lack of Efficacy|0
6316692|NCT02741076|10050518|FG003|Overall Study|Lack of Efficacy|0
6316693|NCT02741076|10050515|FG000|Overall Study|Withdrawal by Subject|0
6316694|NCT02741076|10050516|FG001|Overall Study|Withdrawal by Subject|1
6316695|NCT02741076|10050517|FG002|Overall Study|Withdrawal by Subject|0
6316696|NCT02741076|10050518|FG003|Overall Study|Withdrawal by Subject|0
6316697|NCT02741076|10050515|FG000|Overall Study|Sponsor Request|2
6316698|NCT02741076|10050516|FG001|Overall Study|Sponsor Request|3
6316699|NCT02741076|10050517|FG002|Overall Study|Sponsor Request|0
6316700|NCT02741076|10050518|FG003|Overall Study|Sponsor Request|1
6316701|NCT02741076|10050515|FG000|Overall Study|No additional information available|0
6316702|NCT02741076|10050516|FG001|Overall Study|No additional information available|0
6316703|NCT02741076|10050517|FG002|Overall Study|No additional information available|1
6316704|NCT02741076|10050518|FG003|Overall Study|No additional information available|1
6316705|NCT02741310|10050546|FG000|Overall Study|Sponsor Decision|2
6316706|NCT02741310|10050547|FG001|Overall Study|Sponsor Decision|2
6316707|NCT02741518|10050563|FG000|Overall Study|Withdrawal by Subject|1
6316708|NCT02741518|10050564|FG001|Overall Study|Withdrawal by Subject|1
6316709|NCT02741596|10050572|FG000|Overall Study|Adverse Event|1
6316710|NCT02741596|10050573|FG001|Overall Study|Adverse Event|5
6316711|NCT02741596|10050572|FG000|Overall Study|Lost to Follow-up|1
6316712|NCT02741596|10050573|FG001|Overall Study|Lost to Follow-up|1
6316713|NCT02741596|10050572|FG000|Overall Study|Physician Decision|2
6316714|NCT02741596|10050573|FG001|Overall Study|Physician Decision|1
6316715|NCT02741596|10050572|FG000|Overall Study|Pregnancy|3
6316716|NCT02741596|10050573|FG001|Overall Study|Pregnancy|1
6316717|NCT02741596|10050572|FG000|Overall Study|Other (Unspecified)|0
6316718|NCT02741596|10050573|FG001|Overall Study|Other (Unspecified)|3
6316719|NCT02741596|10050572|FG000|Overall Study|Subject withdrawn-Other|17
6316720|NCT02741596|10050573|FG001|Overall Study|Subject withdrawn-Other|4
6316721|NCT02741596|10050572|FG000|Overall Study|Subject withdrawn-to commercial product|54
6316722|NCT02741596|10050573|FG001|Overall Study|Subject withdrawn-to commercial product|63
6316723|NCT02741635|10050579|FG000|Overall Study|Withdrawal by Subject|1
6316724|NCT02741713|10050595|FG000|Overall Study|Surgery type changed intra-operatively|2
6316725|NCT02741713|10050596|FG001|Overall Study|Surgery type changed intra-operatively|1
6316726|NCT02742103|10050609|FG000|Overall Study|Protocol Violation|1
6316727|NCT02742103|10050610|FG001|Overall Study|Protocol Violation|0
6316728|NCT02742103|10050609|FG000|Overall Study|Death|2
6316729|NCT02742103|10050610|FG001|Overall Study|Death|2
6316730|NCT02742103|10050609|FG000|Overall Study|Adverse Event|1
6316731|NCT02742103|10050610|FG001|Overall Study|Adverse Event|0
6316732|NCT02742103|10050609|FG000|Overall Study|Moved to another town|0
6316733|NCT02742103|10050610|FG001|Overall Study|Moved to another town|1
6316734|NCT02742103|10050609|FG000|Overall Study|Withdrawal by Subject|5
6316735|NCT02742103|10050610|FG001|Overall Study|Withdrawal by Subject|2
6316736|NCT02742441|10050630|FG000|Overall Study|Lost to Follow-up|4
6316737|NCT02742441|10050631|FG001|Overall Study|Lost to Follow-up|4
6316738|NCT02742441|10050630|FG000|Overall Study|Withdrawal by Subject|2
6316739|NCT02742441|10050631|FG001|Overall Study|Withdrawal by Subject|2
6316740|NCT02742441|10050630|FG000|Overall Study|Adverse Event|0
6316741|NCT02742441|10050631|FG001|Overall Study|Adverse Event|2
6316742|NCT02742519|10050639|FG000|Part 1 Treatment Period 2 (8 Weeks)|Availability of commercial drug|1
6316743|NCT02742519|10050640|FG001|Part 1 Treatment Period 2 (8 Weeks)|Availability of commercial drug|1
6316744|NCT02742519|10050641|FG002|Part 1 Treatment Period 2 (8 Weeks)|Availability of commercial drug|0
6316745|NCT02742519|10050639|FG000|Part 2 Open Label Period (32 Weeks)|Availability of commercial drug|0
6316746|NCT02742519|10050640|FG001|Part 2 Open Label Period (32 Weeks)|Availability of commercial drug|0
6316747|NCT02742519|10050641|FG002|Part 2 Open Label Period (32 Weeks)|Availability of commercial drug|9
6316748|NCT02742519|10050639|FG000|Part 2 Open Label Period (32 Weeks)|Other|0
6316749|NCT02742519|10050640|FG001|Part 2 Open Label Period (32 Weeks)|Other|0
6316750|NCT02742519|10050641|FG002|Part 2 Open Label Period (32 Weeks)|Other|1
6316751|NCT02742649|10050661|FG000|Pre-Randomization Washout Period|Washout/Randomization Failure|5
6316752|NCT02742649|10050662|FG001|Pre-Randomization Washout Period|Washout/Randomization Failure|0
6316753|NCT02742649|10050663|FG002|Pre-Randomization Washout Period|Washout/Randomization Failure|0
6316754|NCT02742649|10050664|FG003|Pre-Randomization Washout Period|Washout/Randomization Failure|0
6316755|NCT02742649|10050665|FG004|Pre-Randomization Washout Period|Washout/Randomization Failure|0
6316756|NCT02742649|10050661|FG000|Double-Blind Treatment Period|Adverse Event|0
6316757|NCT02742649|10050662|FG001|Double-Blind Treatment Period|Adverse Event|1
6316758|NCT02742649|10050663|FG002|Double-Blind Treatment Period|Adverse Event|0
6316759|NCT02742649|10050664|FG003|Double-Blind Treatment Period|Adverse Event|0
6316760|NCT02742649|10050665|FG004|Double-Blind Treatment Period|Adverse Event|0
6316761|NCT02742649|10050661|FG000|Open-Label Period|Lost to Follow-up|0
6316762|NCT02742649|10050662|FG001|Open-Label Period|Lost to Follow-up|0
6316763|NCT02742649|10050663|FG002|Open-Label Period|Lost to Follow-up|0
6316764|NCT02742649|10050664|FG003|Open-Label Period|Lost to Follow-up|0
6316765|NCT02742649|10050665|FG004|Open-Label Period|Lost to Follow-up|1
6316766|NCT02742766|10050695|FG000|Part 2 (Up to 22 Days)|Withdrawal by Subject|0
6316767|NCT02742766|10050696|FG001|Part 2 (Up to 22 Days)|Withdrawal by Subject|0
6316768|NCT02742766|10050697|FG002|Part 2 (Up to 22 Days)|Withdrawal by Subject|0
6316769|NCT02742766|10050698|FG003|Part 2 (Up to 22 Days)|Withdrawal by Subject|0
6316770|NCT02742766|10050699|FG004|Part 2 (Up to 22 Days)|Withdrawal by Subject|0
6316771|NCT02742766|10050700|FG005|Part 2 (Up to 22 Days)|Withdrawal by Subject|0
6316772|NCT02742766|10050701|FG006|Part 2 (Up to 22 Days)|Withdrawal by Subject|0
6316773|NCT02742766|10050702|FG007|Part 2 (Up to 22 Days)|Withdrawal by Subject|0
6316774|NCT02742766|10050703|FG008|Part 2 (Up to 22 Days)|Withdrawal by Subject|0
6316775|NCT02742766|10050704|FG009|Part 2 (Up to 22 Days)|Withdrawal by Subject|0
6316776|NCT02742766|10050705|FG010|Part 2 (Up to 22 Days)|Withdrawal by Subject|0
6316777|NCT02742766|10050706|FG011|Part 2 (Up to 22 Days)|Withdrawal by Subject|0
6316778|NCT02742766|10050707|FG012|Part 2 (Up to 22 Days)|Withdrawal by Subject|0
6316779|NCT02742766|10050708|FG013|Part 2 (Up to 22 Days)|Withdrawal by Subject|1
6316780|NCT02742766|10050709|FG014|Part 2 (Up to 22 Days)|Withdrawal by Subject|0
6316781|NCT02742766|10050710|FG015|Part 2 (Up to 22 Days)|Withdrawal by Subject|0
6316782|NCT02742766|10050711|FG016|Part 2 (Up to 22 Days)|Withdrawal by Subject|0
6316783|NCT02742766|10050712|FG017|Part 2 (Up to 22 Days)|Withdrawal by Subject|0
6316784|NCT02742766|10050713|FG018|Part 2 (Up to 22 Days)|Withdrawal by Subject|0
6316785|NCT02742766|10050695|FG000|Part 2 (Up to 22 Days)|Physician Decision|0
6316786|NCT02742766|10050696|FG001|Part 2 (Up to 22 Days)|Physician Decision|0
6316787|NCT02742766|10050697|FG002|Part 2 (Up to 22 Days)|Physician Decision|0
6316788|NCT02742766|10050698|FG003|Part 2 (Up to 22 Days)|Physician Decision|0
6316789|NCT02742766|10050699|FG004|Part 2 (Up to 22 Days)|Physician Decision|0
6316790|NCT02742766|10050700|FG005|Part 2 (Up to 22 Days)|Physician Decision|0
6316791|NCT02742766|10050701|FG006|Part 2 (Up to 22 Days)|Physician Decision|0
6316792|NCT02742766|10050702|FG007|Part 2 (Up to 22 Days)|Physician Decision|0
6316793|NCT02742766|10050703|FG008|Part 2 (Up to 22 Days)|Physician Decision|0
6316794|NCT02742766|10050704|FG009|Part 2 (Up to 22 Days)|Physician Decision|0
6316795|NCT02742766|10050705|FG010|Part 2 (Up to 22 Days)|Physician Decision|0
6316796|NCT02742766|10050706|FG011|Part 2 (Up to 22 Days)|Physician Decision|0
6316797|NCT02742766|10050707|FG012|Part 2 (Up to 22 Days)|Physician Decision|2
6316798|NCT02742766|10050708|FG013|Part 2 (Up to 22 Days)|Physician Decision|5
6316799|NCT02742766|10050709|FG014|Part 2 (Up to 22 Days)|Physician Decision|0
6316800|NCT02742766|10050710|FG015|Part 2 (Up to 22 Days)|Physician Decision|1
6316801|NCT02742766|10050711|FG016|Part 2 (Up to 22 Days)|Physician Decision|0
6316802|NCT02742766|10050712|FG017|Part 2 (Up to 22 Days)|Physician Decision|0
6316803|NCT02742766|10050713|FG018|Part 2 (Up to 22 Days)|Physician Decision|0
6316804|NCT02742818|10050775|FG000|Overall Study|Adverse Event|0
6316805|NCT02742818|10050776|FG001|Overall Study|Adverse Event|1
6316806|NCT02742818|10050775|FG000|Overall Study|Protocol Violation|0
6316807|NCT02742818|10050776|FG001|Overall Study|Protocol Violation|1
6316808|NCT02743117|10050799|FG000|Overall Study|Lost to Follow-up|0
6316809|NCT02743117|10050800|FG001|Overall Study|Lost to Follow-up|1
6316810|NCT02743117|10050799|FG000|Overall Study|Other|1
6316811|NCT02743117|10050800|FG001|Overall Study|Other|0
6316812|NCT02743221|10050808|FG000|Overall Study|Progressive disease|29
6316813|NCT02743221|10050809|FG001|Overall Study|Progressive disease|38
6316814|NCT02743221|10050808|FG000|Overall Study|Adverse Event|17
6316815|NCT02743221|10050809|FG001|Overall Study|Adverse Event|14
6316816|NCT02743221|10050808|FG000|Overall Study|non medical reason|8
6316817|NCT02743221|10050809|FG001|Overall Study|non medical reason|2
6316818|NCT02743221|10050808|FG000|Overall Study|Physician Decision|2
6316819|NCT02743221|10050809|FG001|Overall Study|Physician Decision|5
6316820|NCT02743221|10050808|FG000|Overall Study|Patient not eligible, not treated|0
6316821|NCT02743221|10050809|FG001|Overall Study|Patient not eligible, not treated|1
6316822|NCT02743520|10050847|FG000|Overall Study|Withdrawal by Subject|1
6316823|NCT02743780|10050865|FG000|Part 3 (7 Days)|Adverse Event|0
6316824|NCT02743780|10050866|FG001|Part 3 (7 Days)|Adverse Event|0
6316825|NCT02743780|10050867|FG002|Part 3 (7 Days)|Adverse Event|1
6316826|NCT02743780|10050868|FG003|Part 3 (7 Days)|Adverse Event|0
6316827|NCT02743780|10050869|FG004|Part 3 (7 Days)|Adverse Event|0
6316828|NCT02743793|10050891|FG000|Overall Study|Death|1
6316829|NCT02743793|10050892|FG001|Overall Study|Death|1
6316830|NCT02743793|10050891|FG000|Overall Study|Withdrawal by Subject|0
6316831|NCT02743793|10050892|FG001|Overall Study|Withdrawal by Subject|1
6316832|NCT02743793|10050891|FG000|Overall Study|Screen Failure|4
6316833|NCT02743793|10050892|FG001|Overall Study|Screen Failure|0
6316834|NCT02743793|10050891|FG000|Overall Study|No Primary Care Physician|0
6316835|NCT02743793|10050892|FG001|Overall Study|No Primary Care Physician|1
6316836|NCT02743793|10050891|FG000|Overall Study|Travel/remote visits could not be performed at nursing facility|0
6316837|NCT02743793|10050892|FG001|Overall Study|Travel/remote visits could not be performed at nursing facility|1
6316838|NCT02743793|10050891|FG000|Overall Study|Study stopped due to COVID-19 pandemic|0
6316839|NCT02743793|10050892|FG001|Overall Study|Study stopped due to COVID-19 pandemic|32
6316840|NCT02743949|10050909|FG000|Overall Study|Adverse Event|0
6316841|NCT02743949|10050910|FG001|Overall Study|Adverse Event|0
6316842|NCT02743949|10050911|FG002|Overall Study|Adverse Event|2
6316843|NCT02743949|10050909|FG000|Overall Study|Significant Protocol Deviation|2
6316844|NCT02743949|10050910|FG001|Overall Study|Significant Protocol Deviation|0
6316845|NCT02743949|10050911|FG002|Overall Study|Significant Protocol Deviation|1
6316846|NCT02743949|10050909|FG000|Overall Study|Voluntary Withdrawal|2
6316847|NCT02743949|10050910|FG001|Overall Study|Voluntary Withdrawal|1
6316848|NCT02743949|10050911|FG002|Overall Study|Voluntary Withdrawal|0
6316849|NCT02743962|10050921|FG000|Overall Study|Atrophic vaginitis diagnosed|1
6316850|NCT02743962|10050922|FG001|Overall Study|Atrophic vaginitis diagnosed|0
6316851|NCT02744066|10050933|FG000|Overall Study|Withdrawal by parent|0
6316852|NCT02744066|10050934|FG001|Overall Study|Withdrawal by parent|1
6316853|NCT02744066|10050933|FG000|Overall Study|Discharged from NICU prior to completion|0
6316854|NCT02744066|10050934|FG001|Overall Study|Discharged from NICU prior to completion|4
6316855|NCT02744391|10050942|FG000|Overall Study|Lost to Follow-up|9
6316856|NCT02744391|10050942|FG000|Overall Study|Physician Decision|2
6316857|NCT02744391|10050942|FG000|Overall Study|Withdrawal by Subject|3
6316858|NCT02744755|10050954|FG000|Study Period 1|Protocol Violation|2
6316859|NCT02744755|10050955|FG001|Study Period 1|Protocol Violation|1
6316860|NCT02744755|10050954|FG000|Study Period 1|not defined|0
6316861|NCT02744755|10050955|FG001|Study Period 1|not defined|1
6316862|NCT02744755|10050954|FG000|Study Period 1|Pregnancy|1
6316863|NCT02744755|10050955|FG001|Study Period 1|Pregnancy|0
6316864|NCT02744755|10050954|FG000|Study Period 1|Adverse Event|1
6316865|NCT02744755|10050955|FG001|Study Period 1|Adverse Event|1
6316866|NCT02744755|10050954|FG000|Study Period 1|Lost to Follow-up|1
6316867|NCT02744755|10050955|FG001|Study Period 1|Lost to Follow-up|1
6316868|NCT02744755|10050954|FG000|Study Period 1|Lack of Efficacy|1
6316869|NCT02744755|10050955|FG001|Study Period 1|Lack of Efficacy|0
6316870|NCT02744755|10050954|FG000|Study Period 1|Withdrawal by Subject|8
6316871|NCT02744755|10050955|FG001|Study Period 1|Withdrawal by Subject|4
6316872|NCT02744755|10050954|FG000|Study Period 2|Adverse Event|5
6150581|NCT01106404|9786973|FG000|Period I (First 6 Weeks)|Lack of Efficacy|0
6150582|NCT01106404|9786974|FG001|Period I (First 6 Weeks)|Lack of Efficacy|1
6150583|NCT01106430|9786988|FG000|Overall Study|Adverse Event|8
6150584|NCT01106430|9786989|FG001|Overall Study|Adverse Event|10
6150585|NCT01106430|9786988|FG000|Overall Study|Lack of Efficacy|2
6150586|NCT01106430|9786989|FG001|Overall Study|Lack of Efficacy|13
6316873|NCT02744755|10050955|FG001|Study Period 2|Adverse Event|0
6316874|NCT02744755|10050954|FG000|Study Period 2|Protocol Violation|1
6316875|NCT02744755|10050955|FG001|Study Period 2|Protocol Violation|0
6316876|NCT02744755|10050954|FG000|Study Period 2|not defined|3
6316877|NCT02744755|10050955|FG001|Study Period 2|not defined|2
6316878|NCT02744755|10050954|FG000|Study Period 2|Lost to Follow-up|0
6316879|NCT02744755|10050955|FG001|Study Period 2|Lost to Follow-up|2
6316880|NCT02744755|10050954|FG000|Study Period 2|Withdrawal by Subject|2
6316881|NCT02744755|10050955|FG001|Study Period 2|Withdrawal by Subject|2
6316882|NCT02744755|10050954|FG000|Study Period 2|Lack of Efficacy|3
6316883|NCT02744755|10050955|FG001|Study Period 2|Lack of Efficacy|2
6316884|NCT02744898|10050973|FG000|Overall Study|Progressive Disease|2
6316885|NCT02744898|10050973|FG000|Overall Study|Physician Decision|1
6316886|NCT02744898|10050973|FG000|Overall Study|Toxicity|1
6150587|NCT01106430|9786988|FG000|Overall Study|Lost to Follow-up|5
6150588|NCT01106430|9786989|FG001|Overall Study|Lost to Follow-up|1
6316887|NCT02745080|10050979|FG000|Overall Study|Adverse Event|13
6316888|NCT02745080|10050980|FG001|Overall Study|Adverse Event|21
6316889|NCT02745080|10050979|FG000|Overall Study|Lack of Efficacy|11
6316890|NCT02745080|10050980|FG001|Overall Study|Lack of Efficacy|23
6316891|NCT02745080|10050979|FG000|Overall Study|Lost to Follow-up|3
6316892|NCT02745080|10050980|FG001|Overall Study|Lost to Follow-up|3
6316893|NCT02745080|10050979|FG000|Overall Study|Physician Decision|3
6316894|NCT02745080|10050980|FG001|Overall Study|Physician Decision|0
6316895|NCT02745080|10050979|FG000|Overall Study|Protocol Violation|3
6316896|NCT02745080|10050980|FG001|Overall Study|Protocol Violation|1
6316897|NCT02745080|10050979|FG000|Overall Study|Withdrawal by Subject|22
6316898|NCT02745080|10050980|FG001|Overall Study|Withdrawal by Subject|41
6316899|NCT02745119|10050991|FG000|Overall Study|Adverse Event|1
6316900|NCT02745119|10050992|FG001|Overall Study|Adverse Event|0
6316901|NCT02745119|10050993|FG002|Overall Study|Adverse Event|1
6316902|NCT02745119|10050994|FG003|Overall Study|Adverse Event|3
6316903|NCT02745119|10050991|FG000|Overall Study|Death|3
6316904|NCT02745119|10050992|FG001|Overall Study|Death|3
6316905|NCT02745119|10050993|FG002|Overall Study|Death|0
6316906|NCT02745119|10050994|FG003|Overall Study|Death|4
6316907|NCT02745119|10050991|FG000|Overall Study|Lost to Follow-up|0
6316908|NCT02745119|10050992|FG001|Overall Study|Lost to Follow-up|0
6316909|NCT02745119|10050993|FG002|Overall Study|Lost to Follow-up|0
6316910|NCT02745119|10050994|FG003|Overall Study|Lost to Follow-up|1
6316911|NCT02745119|10050991|FG000|Overall Study|Protocol Deviation|0
6316912|NCT02745119|10050992|FG001|Overall Study|Protocol Deviation|0
6316913|NCT02745119|10050993|FG002|Overall Study|Protocol Deviation|0
6316914|NCT02745119|10050994|FG003|Overall Study|Protocol Deviation|1
6316915|NCT02745119|10050991|FG000|Overall Study|Withdrawal by Subject|7
6316916|NCT02745119|10050992|FG001|Overall Study|Withdrawal by Subject|15
6316917|NCT02745119|10050993|FG002|Overall Study|Withdrawal by Subject|8
6316918|NCT02745119|10050994|FG003|Overall Study|Withdrawal by Subject|14
6316919|NCT02745119|10050991|FG000|Overall Study|Study Terminated by Sponsor|134
6316920|NCT02745119|10050992|FG001|Overall Study|Study Terminated by Sponsor|252
6316921|NCT02745119|10050993|FG002|Overall Study|Study Terminated by Sponsor|135
6316922|NCT02745119|10050994|FG003|Overall Study|Study Terminated by Sponsor|251
6316923|NCT02745119|10050991|FG000|Overall Study|Physician Decision|0
6316924|NCT02745119|10050992|FG001|Overall Study|Physician Decision|2
6316925|NCT02745119|10050993|FG002|Overall Study|Physician Decision|2
6316926|NCT02745119|10050994|FG003|Overall Study|Physician Decision|2
6316927|NCT02745119|10050991|FG000|Overall Study|Reason Not Specified|0
6316928|NCT02745119|10050992|FG001|Overall Study|Reason Not Specified|2
6316929|NCT02745119|10050993|FG002|Overall Study|Reason Not Specified|0
6316930|NCT02745119|10050994|FG003|Overall Study|Reason Not Specified|1
6316931|NCT02745145|10051009|FG000|Overall Study|Adverse Event|1
6316932|NCT02745145|10051010|FG001|Overall Study|Adverse Event|0
6316933|NCT02745145|10051011|FG002|Overall Study|Adverse Event|0
6316934|NCT02745145|10051009|FG000|Overall Study|Death|0
6316935|NCT02745145|10051010|FG001|Overall Study|Death|1
6316936|NCT02745145|10051011|FG002|Overall Study|Death|0
6316937|NCT02745145|10051009|FG000|Overall Study|Progressive disease|0
6316938|NCT02745145|10051010|FG001|Overall Study|Progressive disease|0
6316939|NCT02745145|10051011|FG002|Overall Study|Progressive disease|1
6316940|NCT02745145|10051009|FG000|Overall Study|Withdrew consent|1
6316941|NCT02745145|10051010|FG001|Overall Study|Withdrew consent|1
6316942|NCT02745145|10051011|FG002|Overall Study|Withdrew consent|1
6316943|NCT02745145|10051009|FG000|Overall Study|Study Termination|8
6316944|NCT02745145|10051010|FG001|Overall Study|Study Termination|3
6316945|NCT02745145|10051011|FG002|Overall Study|Study Termination|7
6316946|NCT02745392|10051032|FG000|Overall Study|Lost to Follow-up|0
6316947|NCT02745392|10051033|FG001|Overall Study|Lost to Follow-up|1
6316948|NCT02745392|10051034|FG002|Overall Study|Lost to Follow-up|0
6316949|NCT02745392|10051035|FG003|Overall Study|Lost to Follow-up|0
6316950|NCT02746575|10051077|FG000|Overall Study|Surgery cancelled or time chaned|13
6316951|NCT02746575|10051077|FG000|Overall Study|Received epidural|10
6316952|NCT02746575|10051077|FG000|Overall Study|Withdrawal by Subject|3
6316953|NCT02746575|10051077|FG000|Overall Study|Bradycardia/hypotension|9
6316954|NCT02746575|10051077|FG000|Overall Study|Study paused|8
6316955|NCT02746575|10051077|FG000|Overall Study|put on beta-blocker|3
6316956|NCT02746575|10051077|FG000|Overall Study|type of surgery|1
6316957|NCT02746575|10051077|FG000|Overall Study|typ of surgery|1
6316958|NCT02746575|10051077|FG000|Overall Study|PI unavailable|1
6316959|NCT02746575|10051077|FG000|Overall Study|Unknown history of CVA|1
6316960|NCT02746627|10051084|FG000|Overall Study|Withdrawal by Subject|1
6316961|NCT02746627|10051085|FG001|Overall Study|Withdrawal by Subject|1
6316962|NCT02746627|10051086|FG002|Overall Study|Withdrawal by Subject|1
6316963|NCT02746679|10051096|FG000|Overall Study|Lost to Follow-up|4
6316964|NCT02746679|10051097|FG001|Overall Study|Lost to Follow-up|6
6316965|NCT02746705|10051105|FG000|Overall Study|Physician Decision|1
6316966|NCT02746705|10051106|FG001|Overall Study|Physician Decision|1
6316967|NCT02746705|10051105|FG000|Overall Study|Lost to Follow-up|1
6316968|NCT02746705|10051106|FG001|Overall Study|Lost to Follow-up|0
6316969|NCT02746705|10051105|FG000|Overall Study|outlier scores deemed not valid|0
6316970|NCT02746705|10051106|FG001|Overall Study|outlier scores deemed not valid|1
6316971|NCT02746874|10051114|FG000|Overall Study|Withdrawal by Subject|0
6316972|NCT02746874|10051115|FG001|Overall Study|Withdrawal by Subject|1
6316973|NCT02746874|10051114|FG000|Overall Study|Surgery Date Changed|0
6316974|NCT02746874|10051115|FG001|Overall Study|Surgery Date Changed|2
6316975|NCT02747004|10051135|FG000|Overall Study|Withdrawal by Subject|8
6316976|NCT02747004|10051136|FG001|Overall Study|Withdrawal by Subject|5
6316977|NCT02747004|10051137|FG002|Overall Study|Withdrawal by Subject|4
6316978|NCT02747004|10051135|FG000|Overall Study|Lost to Follow-up|1
6316979|NCT02747004|10051136|FG001|Overall Study|Lost to Follow-up|2
6316980|NCT02747004|10051137|FG002|Overall Study|Lost to Follow-up|2
6316981|NCT02747004|10051135|FG000|Overall Study|on study treatment/follow-up|48
6316982|NCT02747004|10051136|FG001|Overall Study|on study treatment/follow-up|42
6316983|NCT02747004|10051137|FG002|Overall Study|on study treatment/follow-up|41
6316984|NCT02747043|10051147|FG000|Overall Study|Other|1
6316985|NCT02747043|10051148|FG001|Overall Study|Other|1
6316986|NCT02747043|10051147|FG000|Overall Study|Adverse Event|3
6316987|NCT02747043|10051148|FG001|Overall Study|Adverse Event|1
6316988|NCT02747043|10051147|FG000|Overall Study|Withdrawal by Subject|1
6316989|NCT02747043|10051148|FG001|Overall Study|Withdrawal by Subject|1
6316990|NCT02747043|10051147|FG000|Overall Study|Physician Decision|1
6316991|NCT02747043|10051148|FG001|Overall Study|Physician Decision|1
6316992|NCT02747043|10051147|FG000|Overall Study|Protocol Violation|0
6316993|NCT02747043|10051148|FG001|Overall Study|Protocol Violation|1
6316994|NCT02747043|10051147|FG000|Overall Study|Disease progression|4
6316995|NCT02747043|10051148|FG001|Overall Study|Disease progression|0
6316996|NCT02747108|10051156|FG000|Overall Study|Death|2
6316997|NCT02747108|10051157|FG001|Overall Study|Death|2
6316998|NCT02747108|10051156|FG000|Overall Study|Withdrawal by Subject|1
6316999|NCT02747108|10051157|FG001|Overall Study|Withdrawal by Subject|0
6317000|NCT02747108|10051156|FG000|Overall Study|Protocol Violation|2
6317001|NCT02747108|10051157|FG001|Overall Study|Protocol Violation|0
6317002|NCT02747238|10051179|FG000|Overall Study|Lack of Efficacy|0
6317003|NCT02747238|10051180|FG001|Overall Study|Lack of Efficacy|1
6317004|NCT02747238|10051179|FG000|Overall Study|Data lost|3
6317005|NCT02747238|10051180|FG001|Overall Study|Data lost|5
6317006|NCT02747420|10051188|FG000|Overall Study|Lost to Follow-up|4
6317007|NCT02747420|10051189|FG001|Overall Study|Lost to Follow-up|2
6317008|NCT02747420|10051188|FG000|Overall Study|Withdrawal by Subject|3
6317009|NCT02747420|10051189|FG001|Overall Study|Withdrawal by Subject|2
6317010|NCT02747875|10051231|FG000|Overall Study|Physician Decision|1
6317011|NCT02747875|10051232|FG001|Overall Study|Physician Decision|0
6317012|NCT02747875|10051231|FG000|Overall Study|Adverse Event|0
6317013|NCT02747875|10051232|FG001|Overall Study|Adverse Event|1
6317014|NCT02747927|10051240|FG000|Overall Study|Adverse Event|5
6317015|NCT02747927|10051241|FG001|Overall Study|Adverse Event|14
6317016|NCT02747927|10051240|FG000|Overall Study|Lost to Follow-up|22
6317017|NCT02747927|10051241|FG001|Overall Study|Lost to Follow-up|43
6317018|NCT02747927|10051240|FG000|Overall Study|Pregnancy|34
6317019|NCT02747927|10051241|FG001|Overall Study|Pregnancy|66
6150589|NCT01106430|9786988|FG000|Overall Study|Early Termination Requested By Sponsor|1
6150590|NCT01106430|9786989|FG001|Overall Study|Early Termination Requested By Sponsor|0
6150591|NCT01106430|9786988|FG000|Overall Study|Moved Out Of State|0
6150592|NCT01106430|9786989|FG001|Overall Study|Moved Out Of State|1
6150593|NCT01106430|9786988|FG000|Overall Study|Refused To Take Medication|0
6150594|NCT01106430|9786989|FG001|Overall Study|Refused To Take Medication|1
6150595|NCT01106430|9786988|FG000|Overall Study|Noncompliance|0
6317020|NCT02747927|10051240|FG000|Overall Study|Protocol Violation|2
6317021|NCT02747927|10051241|FG001|Overall Study|Protocol Violation|4
6150596|NCT01106430|9786989|FG001|Overall Study|Noncompliance|1
6150597|NCT01106430|9786988|FG000|Overall Study|Hard Time Swallowing The Pills|1
6150598|NCT01106430|9786989|FG001|Overall Study|Hard Time Swallowing The Pills|0
6150599|NCT01106430|9786988|FG000|Overall Study|Previous Use Of Marijuana|1
6150600|NCT01106430|9786989|FG001|Overall Study|Previous Use Of Marijuana|0
6150601|NCT01106430|9786988|FG000|Overall Study|Protocol Violation|7
6150602|NCT01106430|9786989|FG001|Overall Study|Protocol Violation|2
6150603|NCT01106430|9786988|FG000|Overall Study|Withdrawal by Subject|8
6150604|NCT01106430|9786989|FG001|Overall Study|Withdrawal by Subject|4
6150605|NCT01106586|9787006|FG000|Overall Study|Adverse Event|9
6150606|NCT01106586|9787007|FG001|Overall Study|Adverse Event|15
6150607|NCT01106586|9787006|FG000|Overall Study|Death|1
6150608|NCT01106586|9787007|FG001|Overall Study|Death|3
6150609|NCT01106586|9787006|FG000|Overall Study|Pregnancy|2
6150610|NCT01106586|9787007|FG001|Overall Study|Pregnancy|2
6150611|NCT01106586|9787006|FG000|Overall Study|Lack of Efficacy|1
6150612|NCT01106586|9787007|FG001|Overall Study|Lack of Efficacy|0
6150613|NCT01106586|9787006|FG000|Overall Study|Investigator's Discretion|5
6150614|NCT01106586|9787007|FG001|Overall Study|Investigator's Discretion|8
6150615|NCT01106586|9787006|FG000|Overall Study|Withdrew Consent|18
6150616|NCT01106586|9787007|FG001|Overall Study|Withdrew Consent|30
6150617|NCT01106586|9787006|FG000|Overall Study|Lost to Follow-up|24
6150618|NCT01106586|9787007|FG001|Overall Study|Lost to Follow-up|20
6150619|NCT01106586|9787006|FG000|Overall Study|Participant Noncompliance|12
6150620|NCT01106586|9787007|FG001|Overall Study|Participant Noncompliance|10
6150621|NCT01106586|9787006|FG000|Overall Study|Protocol Violation|1
6150622|NCT01106586|9787007|FG001|Overall Study|Protocol Violation|0
6150623|NCT01106586|9787006|FG000|Overall Study|Participant Transferred to Another Study|212
6150624|NCT01106586|9787007|FG001|Overall Study|Participant Transferred to Another Study|197
6150625|NCT01106625|9787016|FG000|Core Period: Baseline to Week 26|Adverse Event|6
6150626|NCT01106625|9787017|FG001|Core Period: Baseline to Week 26|Adverse Event|8
6150627|NCT01106625|9787018|FG002|Core Period: Baseline to Week 26|Adverse Event|8
6150628|NCT01106625|9787016|FG000|Core Period: Baseline to Week 26|Lost to Follow-up|5
6150629|NCT01106625|9787017|FG001|Core Period: Baseline to Week 26|Lost to Follow-up|0
6317022|NCT02747927|10051240|FG000|Overall Study|Withdrawal by Participant and/or Participants Parent/Guardian|147
6317023|NCT02747927|10051241|FG001|Overall Study|Withdrawal by Participant and/or Participants Parent/Guardian|304
6317024|NCT02747927|10051240|FG000|Overall Study|Reason not Specified|11
6317025|NCT02747927|10051241|FG001|Overall Study|Reason not Specified|27
6317026|NCT02748213|10051267|FG000|Overall Study|Withdrawal Prior to Treatment|1
6317027|NCT02748213|10051268|FG001|Overall Study|Withdrawal Prior to Treatment|2
6317028|NCT02748213|10051267|FG000|Overall Study|Abnormal Laboratory Test|1
6317029|NCT02748213|10051268|FG001|Overall Study|Abnormal Laboratory Test|0
6317030|NCT02748213|10051267|FG000|Overall Study|Adverse Event or Intercurrent Illness|5
6317031|NCT02748213|10051268|FG001|Overall Study|Adverse Event or Intercurrent Illness|11
6317032|NCT02748213|10051267|FG000|Overall Study|Death|5
6317033|NCT02748213|10051268|FG001|Overall Study|Death|3
6317034|NCT02748213|10051267|FG000|Overall Study|Insufficient Therapeutic Response|56
6317035|NCT02748213|10051268|FG001|Overall Study|Insufficient Therapeutic Response|57
6317036|NCT02748213|10051267|FG000|Overall Study|Violation of Selection Criteria|2
6317037|NCT02748213|10051268|FG001|Overall Study|Violation of Selection Criteria|0
6317038|NCT02748213|10051267|FG000|Overall Study|Protocol Violation|6
6317039|NCT02748213|10051268|FG001|Overall Study|Protocol Violation|4
6317040|NCT02748213|10051267|FG000|Overall Study|Refused Treatment*|6
6317041|NCT02748213|10051268|FG001|Overall Study|Refused Treatment*|6
6317042|NCT02748213|10051267|FG000|Overall Study|Failure to Return|1
6317043|NCT02748213|10051268|FG001|Overall Study|Failure to Return|0
6317044|NCT02748213|10051267|FG000|Overall Study|Other|30
6317045|NCT02748213|10051268|FG001|Overall Study|Other|29
6317046|NCT02748317|10051274|FG000|Overall Study|Withdrawal by Subject|14
6317047|NCT02748317|10051274|FG000|Overall Study|Lost to Follow-up|8
6317048|NCT02748317|10051274|FG000|Overall Study|Death|1
6317049|NCT02748356|10051278|FG000|Overall Study|Withdrawal by Subject|1
6317050|NCT02748512|10051284|FG000|Overall Study|Lost to Follow-up|1
6317051|NCT02748512|10051285|FG001|Overall Study|Lost to Follow-up|1
6317052|NCT02748694|10051310|FG000|Overall Study|Voluntary Withdrawal|0
6317053|NCT02748694|10051311|FG001|Overall Study|Voluntary Withdrawal|0
6317054|NCT02748694|10051312|FG002|Overall Study|Voluntary Withdrawal|0
6317055|NCT02748694|10051313|FG003|Overall Study|Voluntary Withdrawal|0
6317056|NCT02748694|10051314|FG004|Overall Study|Voluntary Withdrawal|0
6317057|NCT02748694|10051315|FG005|Overall Study|Voluntary Withdrawal|0
6317058|NCT02748694|10051316|FG006|Overall Study|Voluntary Withdrawal|0
6317059|NCT02748694|10051317|FG007|Overall Study|Voluntary Withdrawal|0
6150630|NCT01106625|9787018|FG002|Core Period: Baseline to Week 26|Lost to Follow-up|4
6150631|NCT01106625|9787016|FG000|Core Period: Baseline to Week 26|Physician Decision|1
6150632|NCT01106625|9787017|FG001|Core Period: Baseline to Week 26|Physician Decision|0
6150633|NCT01106625|9787018|FG002|Core Period: Baseline to Week 26|Physician Decision|0
6150634|NCT01106625|9787016|FG000|Core Period: Baseline to Week 26|Protocol Violation|2
6150635|NCT01106625|9787017|FG001|Core Period: Baseline to Week 26|Protocol Violation|1
6150636|NCT01106625|9787018|FG002|Core Period: Baseline to Week 26|Protocol Violation|3
6150637|NCT01106625|9787016|FG000|Core Period: Baseline to Week 26|Withdrawal by Subject|6
6317060|NCT02748694|10051318|FG008|Overall Study|Voluntary Withdrawal|0
6317061|NCT02748694|10051319|FG009|Overall Study|Voluntary Withdrawal|0
6317062|NCT02748694|10051320|FG010|Overall Study|Voluntary Withdrawal|0
6317063|NCT02748694|10051321|FG011|Overall Study|Voluntary Withdrawal|0
6317064|NCT02748694|10051322|FG012|Overall Study|Voluntary Withdrawal|0
6317065|NCT02748694|10051323|FG013|Overall Study|Voluntary Withdrawal|0
6317066|NCT02748694|10051324|FG014|Overall Study|Voluntary Withdrawal|2
6317067|NCT02748863|10051400|FG000|Treatment Period 1|Adverse Event|0
6317068|NCT02748863|10051401|FG001|Treatment Period 1|Adverse Event|1
6317069|NCT02748863|10051402|FG002|Treatment Period 1|Adverse Event|0
6317070|NCT02748863|10051403|FG003|Treatment Period 1|Adverse Event|0
6317071|NCT02748863|10051404|FG004|Treatment Period 1|Adverse Event|0
6317072|NCT02748863|10051400|FG000|Treatment Period 1|Lack of Efficacy|0
6317073|NCT02748863|10051401|FG001|Treatment Period 1|Lack of Efficacy|0
6317074|NCT02748863|10051402|FG002|Treatment Period 1|Lack of Efficacy|1
6317075|NCT02748863|10051403|FG003|Treatment Period 1|Lack of Efficacy|0
6317076|NCT02748863|10051404|FG004|Treatment Period 1|Lack of Efficacy|0
6317077|NCT02748863|10051400|FG000|Treatment Period 1|Withdrawal by Subject|0
6317078|NCT02748863|10051401|FG001|Treatment Period 1|Withdrawal by Subject|1
6317079|NCT02748863|10051402|FG002|Treatment Period 1|Withdrawal by Subject|1
6317080|NCT02748863|10051403|FG003|Treatment Period 1|Withdrawal by Subject|0
6317081|NCT02748863|10051404|FG004|Treatment Period 1|Withdrawal by Subject|0
6317082|NCT02748863|10051400|FG000|Treatment Period 2|Lost to Follow-up|2
6317083|NCT02748863|10051401|FG001|Treatment Period 2|Lost to Follow-up|0
6317084|NCT02748863|10051402|FG002|Treatment Period 2|Lost to Follow-up|0
6317085|NCT02748863|10051403|FG003|Treatment Period 2|Lost to Follow-up|0
6317086|NCT02748863|10051404|FG004|Treatment Period 2|Lost to Follow-up|0
6317087|NCT02748863|10051400|FG000|Treatment Period 2|Adverse Event|3
6317088|NCT02748863|10051401|FG001|Treatment Period 2|Adverse Event|2
6317089|NCT02748863|10051402|FG002|Treatment Period 2|Adverse Event|0
6317090|NCT02748863|10051403|FG003|Treatment Period 2|Adverse Event|2
6317091|NCT02748863|10051404|FG004|Treatment Period 2|Adverse Event|0
6317092|NCT02748863|10051400|FG000|Treatment Period 2|Lack of Efficacy|0
6317093|NCT02748863|10051401|FG001|Treatment Period 2|Lack of Efficacy|1
6317094|NCT02748863|10051402|FG002|Treatment Period 2|Lack of Efficacy|0
6317095|NCT02748863|10051403|FG003|Treatment Period 2|Lack of Efficacy|0
6317096|NCT02748863|10051404|FG004|Treatment Period 2|Lack of Efficacy|0
6317097|NCT02748863|10051400|FG000|Treatment Period 2|Pregnancy|0
6317098|NCT02748863|10051401|FG001|Treatment Period 2|Pregnancy|0
6317099|NCT02748863|10051402|FG002|Treatment Period 2|Pregnancy|0
6317100|NCT02748863|10051403|FG003|Treatment Period 2|Pregnancy|0
6317101|NCT02748863|10051404|FG004|Treatment Period 2|Pregnancy|1
6317102|NCT02749370|10051435|FG000|Overall Study|Withdrawal by Subject|11
6317103|NCT02749370|10051435|FG000|Overall Study|Lost to Follow-up|3
6317104|NCT02749721|10051439|FG000|Screening|Withdrawal by Subject|1
6317105|NCT02749721|10051439|FG000|Screening|Lost to Follow-up|2
6317106|NCT02749721|10051439|FG000|Screening|Protocol Violation|3
6317107|NCT02749721|10051439|FG000|8-week Open-Label Treatment Phase|Lost to Follow-up|2
6317108|NCT02749721|10051439|FG000|8-week Open-Label Treatment Phase|Withdrawal by Subject|1
6317109|NCT02749799|10051445|FG000|Overall Study|Adverse Event|2
6317110|NCT02749799|10051445|FG000|Overall Study|Lost to Follow-up|4
6317111|NCT02749799|10051445|FG000|Overall Study|Protocol Violation|1
6317112|NCT02749799|10051445|FG000|Overall Study|Withdrawal by Subject|1
6317113|NCT02750306|10051466|FG000|Overall Study|Withdrawal by Subject|5
6317114|NCT02750306|10051467|FG001|Overall Study|Withdrawal by Subject|2
6317115|NCT02750306|10051466|FG000|Overall Study|Protocol Violation|1
6317116|NCT02750306|10051467|FG001|Overall Study|Protocol Violation|0
6317117|NCT02750332|10051473|FG000|Treatment Period 1|Withdrawal by Subject|0
6317118|NCT02750332|10051474|FG001|Treatment Period 1|Withdrawal by Subject|1
6317119|NCT02750345|10051480|FG000|Intervention 1|Adverse Event|0
6317120|NCT02750345|10051481|FG001|Intervention 1|Adverse Event|0
6317121|NCT02750345|10051482|FG002|Intervention 1|Adverse Event|0
6317122|NCT02750345|10051483|FG003|Intervention 1|Adverse Event|0
6150638|NCT01106625|9787017|FG001|Core Period: Baseline to Week 26|Withdrawal by Subject|9
6150639|NCT01106625|9787018|FG002|Core Period: Baseline to Week 26|Withdrawal by Subject|7
6150640|NCT01106625|9787016|FG000|Core Period: Baseline to Week 26|Unable to take rescue therapy|4
6150641|NCT01106625|9787017|FG001|Core Period: Baseline to Week 26|Unable to take rescue therapy|1
6150642|NCT01106625|9787018|FG002|Core Period: Baseline to Week 26|Unable to take rescue therapy|0
6150643|NCT01106625|9787016|FG000|Core Period: Baseline to Week 26|Creatinine, or eGFR withdrawal criteria|0
6150644|NCT01106625|9787017|FG001|Core Period: Baseline to Week 26|Creatinine, or eGFR withdrawal criteria|1
6150645|NCT01106625|9787018|FG002|Core Period: Baseline to Week 26|Creatinine, or eGFR withdrawal criteria|1
6150646|NCT01106625|9787016|FG000|Core Period: Baseline to Week 26|Noncompliance with study drug|1
6150647|NCT01106625|9787017|FG001|Core Period: Baseline to Week 26|Noncompliance with study drug|1
6150648|NCT01106625|9787018|FG002|Core Period: Baseline to Week 26|Noncompliance with study drug|0
6150649|NCT01106625|9787016|FG000|Core Period: Baseline to Week 26|Other|8
6150650|NCT01106625|9787017|FG001|Core Period: Baseline to Week 26|Other|7
6150651|NCT01106625|9787018|FG002|Core Period: Baseline to Week 26|Other|4
6150652|NCT01106625|9787016|FG000|Extension Period: Week 26 to Week 52|Adverse Event|2
6150653|NCT01106625|9787017|FG001|Extension Period: Week 26 to Week 52|Adverse Event|2
6150654|NCT01106625|9787018|FG002|Extension Period: Week 26 to Week 52|Adverse Event|3
6150655|NCT01106625|9787016|FG000|Extension Period: Week 26 to Week 52|Lost to Follow-up|1
6150656|NCT01106625|9787017|FG001|Extension Period: Week 26 to Week 52|Lost to Follow-up|3
6150657|NCT01106625|9787018|FG002|Extension Period: Week 26 to Week 52|Lost to Follow-up|2
6150658|NCT01106625|9787016|FG000|Extension Period: Week 26 to Week 52|Physician Decision|2
6150659|NCT01106625|9787017|FG001|Extension Period: Week 26 to Week 52|Physician Decision|0
6150660|NCT01106625|9787018|FG002|Extension Period: Week 26 to Week 52|Physician Decision|1
6150661|NCT01106625|9787016|FG000|Extension Period: Week 26 to Week 52|Protocol Violation|0
6150662|NCT01106625|9787017|FG001|Extension Period: Week 26 to Week 52|Protocol Violation|1
6150663|NCT01106625|9787018|FG002|Extension Period: Week 26 to Week 52|Protocol Violation|0
6150664|NCT01106625|9787016|FG000|Extension Period: Week 26 to Week 52|Withdrawal by Subject|4
6150665|NCT01106625|9787017|FG001|Extension Period: Week 26 to Week 52|Withdrawal by Subject|1
6150666|NCT01106625|9787018|FG002|Extension Period: Week 26 to Week 52|Withdrawal by Subject|1
6150667|NCT01106625|9787016|FG000|Extension Period: Week 26 to Week 52|Unable to take rescue therapy|14
6150668|NCT01106625|9787017|FG001|Extension Period: Week 26 to Week 52|Unable to take rescue therapy|5
6150669|NCT01106625|9787018|FG002|Extension Period: Week 26 to Week 52|Unable to take rescue therapy|4
6150670|NCT01106625|9787016|FG000|Extension Period: Week 26 to Week 52|Creatinine or eGFR withdrawal criteria|1
6150671|NCT01106625|9787017|FG001|Extension Period: Week 26 to Week 52|Creatinine or eGFR withdrawal criteria|1
6150672|NCT01106625|9787018|FG002|Extension Period: Week 26 to Week 52|Creatinine or eGFR withdrawal criteria|2
6150673|NCT01106625|9787016|FG000|Extension Period: Week 26 to Week 52|Other|5
6150674|NCT01106625|9787017|FG001|Extension Period: Week 26 to Week 52|Other|5
6150675|NCT01106625|9787018|FG002|Extension Period: Week 26 to Week 52|Other|4
6150676|NCT01106651|9787032|FG000|Overall Study|Adverse Event|17
6150677|NCT01106651|9787033|FG001|Overall Study|Adverse Event|9
6150678|NCT01106651|9787034|FG002|Overall Study|Adverse Event|23
6150679|NCT01106651|9787032|FG000|Overall Study|Lost to Follow-up|8
6150680|NCT01106651|9787033|FG001|Overall Study|Lost to Follow-up|2
6150681|NCT01106651|9787034|FG002|Overall Study|Lost to Follow-up|6
6150682|NCT01106651|9787032|FG000|Overall Study|Physician Decision|4
6150683|NCT01106651|9787033|FG001|Overall Study|Physician Decision|3
6317123|NCT02750345|10051484|FG004|Intervention 1|Adverse Event|1
6317124|NCT02750345|10051485|FG005|Intervention 1|Adverse Event|0
6317125|NCT02750410|10051497|FG000|Double-Blind Treatment Period|Adverse Event|2
6317126|NCT02750410|10051498|FG001|Double-Blind Treatment Period|Adverse Event|2
6317127|NCT02750410|10051497|FG000|Double-Blind Treatment Period|Withdrawal by Subject|0
6317128|NCT02750410|10051498|FG001|Double-Blind Treatment Period|Withdrawal by Subject|1
6317129|NCT02750410|10051497|FG000|Open-Label Extension Period|Adverse Event|5
6317130|NCT02750410|10051498|FG001|Open-Label Extension Period|Adverse Event|3
6317131|NCT02750410|10051497|FG000|Open-Label Extension Period|Protocol Violation|0
6317132|NCT02750410|10051498|FG001|Open-Label Extension Period|Protocol Violation|1
6040401|NCT03673345|9638285|FG000|Overall Study|Withdrawal by Subject|1
6040402|NCT03673345|9638286|FG001|Overall Study|Withdrawal by Subject|0
6040403|NCT03673345|9638287|FG002|Overall Study|Withdrawal by Subject|4
6040404|NCT03673345|9638288|FG003|Overall Study|Withdrawal by Subject|2
6040405|NCT03673345|9638289|FG004|Overall Study|Withdrawal by Subject|0
6040406|NCT03673345|9638290|FG005|Overall Study|Withdrawal by Subject|0
6040407|NCT03673345|9638291|FG006|Overall Study|Withdrawal by Subject|0
6040408|NCT03673345|9638292|FG007|Overall Study|Withdrawal by Subject|0
6040409|NCT03673345|9638285|FG000|Overall Study|Physician Decision|0
6040410|NCT03673345|9638286|FG001|Overall Study|Physician Decision|0
6317133|NCT02750410|10051497|FG000|Open-Label Extension Period|Withdrawal by Subject|1
6317134|NCT02750410|10051498|FG001|Open-Label Extension Period|Withdrawal by Subject|2
6040411|NCT03673345|9638287|FG002|Overall Study|Physician Decision|2
6040412|NCT03673345|9638288|FG003|Overall Study|Physician Decision|0
6040413|NCT03673345|9638289|FG004|Overall Study|Physician Decision|0
6040414|NCT03673345|9638290|FG005|Overall Study|Physician Decision|0
6040415|NCT03673345|9638291|FG006|Overall Study|Physician Decision|0
6040416|NCT03673345|9638292|FG007|Overall Study|Physician Decision|0
6040417|NCT03418675|9638312|FG000|Overall Study|Lost to Follow-up|13
6040418|NCT03418675|9638313|FG001|Overall Study|Lost to Follow-up|10
6040419|NCT03418675|9638312|FG000|Overall Study|Adverse Event|2
6040420|NCT03418675|9638313|FG001|Overall Study|Adverse Event|0
6040421|NCT03329690|9638328|FG000|Overall Study|Progressive disease per RECIST|85
6040422|NCT03329690|9638329|FG001|Overall Study|Progressive disease per RECIST|44
6040423|NCT03329690|9638330|FG002|Overall Study|Progressive disease per RECIST|6
6040424|NCT03329690|9638331|FG003|Overall Study|Progressive disease per RECIST|16
6040425|NCT03329690|9638332|FG004|Overall Study|Progressive disease per RECIST|20
6040426|NCT03329690|9638328|FG000|Overall Study|Clinical progression|7
6040427|NCT03329690|9638329|FG001|Overall Study|Clinical progression|4
6040428|NCT03329690|9638330|FG002|Overall Study|Clinical progression|1
6040429|NCT03329690|9638331|FG003|Overall Study|Clinical progression|1
6040430|NCT03329690|9638332|FG004|Overall Study|Clinical progression|1
6040431|NCT03329690|9638328|FG000|Overall Study|Adverse Event|22
6040432|NCT03329690|9638329|FG001|Overall Study|Adverse Event|4
6040433|NCT03329690|9638330|FG002|Overall Study|Adverse Event|0
6040434|NCT03329690|9638331|FG003|Overall Study|Adverse Event|1
6040435|NCT03329690|9638332|FG004|Overall Study|Adverse Event|2
6150684|NCT01106651|9787034|FG002|Overall Study|Physician Decision|1
6150685|NCT01106651|9787032|FG000|Overall Study|Protocol Violation|1
6150686|NCT01106651|9787033|FG001|Overall Study|Protocol Violation|2
6150687|NCT01106651|9787034|FG002|Overall Study|Protocol Violation|1
6150688|NCT01106651|9787032|FG000|Overall Study|Withdrawal by Subject|14
6150689|NCT01106651|9787033|FG001|Overall Study|Withdrawal by Subject|7
6040436|NCT03329690|9638328|FG000|Overall Study|Death|2
6040437|NCT03329690|9638329|FG001|Overall Study|Death|0
6040438|NCT03329690|9638330|FG002|Overall Study|Death|0
6040439|NCT03329690|9638331|FG003|Overall Study|Death|1
6040440|NCT03329690|9638332|FG004|Overall Study|Death|0
6040441|NCT03329690|9638328|FG000|Overall Study|Withdrawal by Subject|2
6040442|NCT03329690|9638329|FG001|Overall Study|Withdrawal by Subject|3
6040443|NCT03329690|9638330|FG002|Overall Study|Withdrawal by Subject|0
6040444|NCT03329690|9638331|FG003|Overall Study|Withdrawal by Subject|1
6040445|NCT03329690|9638332|FG004|Overall Study|Withdrawal by Subject|0
6040446|NCT03329690|9638328|FG000|Overall Study|Physician Decision|1
6040447|NCT03329690|9638329|FG001|Overall Study|Physician Decision|0
6040448|NCT03329690|9638330|FG002|Overall Study|Physician Decision|0
6040449|NCT03329690|9638331|FG003|Overall Study|Physician Decision|0
6040450|NCT03329690|9638332|FG004|Overall Study|Physician Decision|1
6040451|NCT03329690|9638328|FG000|Overall Study|Miscellaneous|6
6040452|NCT03329690|9638329|FG001|Overall Study|Miscellaneous|0
6040453|NCT03329690|9638330|FG002|Overall Study|Miscellaneous|0
6040454|NCT03329690|9638331|FG003|Overall Study|Miscellaneous|0
6040455|NCT03329690|9638332|FG004|Overall Study|Miscellaneous|0
6040456|NCT03329690|9638328|FG000|Overall Study|Did not receive treatment|1
6040457|NCT03329690|9638329|FG001|Overall Study|Did not receive treatment|0
6040458|NCT03329690|9638330|FG002|Overall Study|Did not receive treatment|0
6040459|NCT03329690|9638331|FG003|Overall Study|Did not receive treatment|1
6040460|NCT03329690|9638332|FG004|Overall Study|Did not receive treatment|0
6040461|NCT03320564|9638350|FG000|Overall Study|Protocol Violation|1
6040462|NCT03302234|9638356|FG000|Overall Study|Death|137
6040463|NCT03302234|9638357|FG001|Overall Study|Death|135
6040464|NCT03302234|9638356|FG000|Overall Study|Withdrawal by Subject|1
6040465|NCT03302234|9638357|FG001|Overall Study|Withdrawal by Subject|1
6040466|NCT03302234|9638356|FG000|Overall Study|Laryngeal carcinoma|0
6040467|NCT03302234|9638357|FG001|Overall Study|Laryngeal carcinoma|1
6040468|NCT03165955|9638378|FG000|Treatment|Withdrawal by Subject|3
6040469|NCT03165955|9638378|FG000|Treatment|Death|1
6040470|NCT03165955|9638378|FG000|Treatment|Adverse Event|1
6040471|NCT03165955|9638378|FG000|Treatment|Progressive disease|3
6040472|NCT03133793|9638386|FG000|Overall Study|Withdrawal by Subject|0
6040473|NCT03133793|9638387|FG001|Overall Study|Withdrawal by Subject|4
6040474|NCT03133793|9638388|FG002|Overall Study|Withdrawal by Subject|2
6040475|NCT03133793|9638389|FG003|Overall Study|Withdrawal by Subject|4
6040476|NCT03133793|9638386|FG000|Overall Study|Lost to Follow-up|1
6040477|NCT03133793|9638387|FG001|Overall Study|Lost to Follow-up|0
6040478|NCT03133793|9638388|FG002|Overall Study|Lost to Follow-up|2
6040479|NCT03133793|9638389|FG003|Overall Study|Lost to Follow-up|0
6040480|NCT03133793|9638386|FG000|Overall Study|Death|0
6040481|NCT03133793|9638387|FG001|Overall Study|Death|0
6040482|NCT03133793|9638388|FG002|Overall Study|Death|0
6040483|NCT03133793|9638389|FG003|Overall Study|Death|1
6048990|NCT00420927|9648202|FG003|Period 2|Subject unable to find transportation|0
6048991|NCT00420927|9648203|FG004|Period 2|Subject unable to find transportation|0
6048992|NCT00420927|9648204|FG005|Period 2|Subject unable to find transportation|0
6048993|NCT00420927|9648205|FG006|Period 2|Subject unable to find transportation|1
6048994|NCT00420927|9648199|FG000|Period 2|Physician Decision|0
6048995|NCT00420927|9648200|FG001|Period 2|Physician Decision|0
6048996|NCT00420927|9648201|FG002|Period 2|Physician Decision|0
6048997|NCT00420927|9648202|FG003|Period 2|Physician Decision|0
6048998|NCT00420927|9648203|FG004|Period 2|Physician Decision|1
6150690|NCT01106651|9787034|FG002|Overall Study|Withdrawal by Subject|4
6040484|NCT03103542|9638403|FG000|Overall Study|Physician Decision|2
6040485|NCT03103542|9638403|FG000|Overall Study|Adverse Event|2
6040486|NCT03103542|9638403|FG000|Overall Study|Other|2
6040487|NCT03103542|9638403|FG000|Overall Study|Withdrawal by Subject|1
6040488|NCT03063203|9638417|FG000|Overall Study|Chose alternative therapy|3
6040489|NCT03063203|9638417|FG000|Overall Study|Death|2
6040490|NCT03063203|9638417|FG000|Overall Study|Disease progression|4
6040491|NCT03063203|9638417|FG000|Overall Study|Physician Decision|5
6040492|NCT02676765|9638430|FG000|Overall Study|Lost to Follow-up|0
6317135|NCT02750501|10051508|FG000|Overall Study|Adverse Event|4
6317136|NCT02750501|10051508|FG000|Overall Study|Physician Decision|1
6317137|NCT02750501|10051508|FG000|Overall Study|Protocol Violation|1
6317138|NCT02750501|10051508|FG000|Overall Study|G-tube came out|1
6317139|NCT02750501|10051508|FG000|Overall Study|Non-compliant use of PERT|1
6040493|NCT02676765|9638431|FG001|Overall Study|Lost to Follow-up|1
6040494|NCT02362451|9638457|FG000|Overall Study|Withdrawal by Subject|0
6040495|NCT02362451|9638458|FG001|Overall Study|Withdrawal by Subject|1
6040496|NCT02362451|9638457|FG000|Overall Study|Lack of Efficacy|2
6150691|NCT01106651|9787032|FG000|Overall Study|Noncompliance with study drug|1
6150692|NCT01106651|9787033|FG001|Overall Study|Noncompliance with study drug|0
6150693|NCT01106651|9787034|FG002|Overall Study|Noncompliance with study drug|2
6150694|NCT01106651|9787032|FG000|Overall Study|Other|34
6317140|NCT02750514|10051521|FG000|Track 1|Disease progression|20
6317141|NCT02750514|10051522|FG001|Track 1|Disease progression|1
6317142|NCT02750514|10051523|FG002|Track 1|Disease progression|0
6317143|NCT02750514|10051524|FG003|Track 1|Disease progression|1
6317144|NCT02750514|10051525|FG004|Track 1|Disease progression|0
6317145|NCT02750514|10051521|FG000|Track 1|Adverse event unrelated to study drug|1
6317146|NCT02750514|10051522|FG001|Track 1|Adverse event unrelated to study drug|0
6317147|NCT02750514|10051523|FG002|Track 1|Adverse event unrelated to study drug|0
6317148|NCT02750514|10051524|FG003|Track 1|Adverse event unrelated to study drug|0
6317149|NCT02750514|10051525|FG004|Track 1|Adverse event unrelated to study drug|0
6040497|NCT02362451|9638458|FG001|Overall Study|Lack of Efficacy|0
6040498|NCT02362451|9638457|FG000|Overall Study|Progression|1
6040499|NCT02362451|9638458|FG001|Overall Study|Progression|0
6040500|NCT02362451|9638457|FG000|Overall Study|Participant chose other therapy.|1
6040501|NCT02362451|9638458|FG001|Overall Study|Participant chose other therapy.|0
6040502|NCT02282020|9638466|FG000|Overall Study|Objective Disease Progression|111
6040503|NCT02282020|9638467|FG001|Overall Study|Objective Disease Progression|30
6317150|NCT02750514|10051521|FG000|Track 1|Study drug toxicity|4
6317151|NCT02750514|10051522|FG001|Track 1|Study drug toxicity|1
6040504|NCT02282020|9638466|FG000|Overall Study|Adverse Event|13
6040505|NCT02282020|9638467|FG001|Overall Study|Adverse Event|15
6040506|NCT02282020|9638466|FG000|Overall Study|Withdrawal by Subject|5
6040507|NCT02282020|9638467|FG001|Overall Study|Withdrawal by Subject|10
6317152|NCT02750514|10051523|FG002|Track 1|Study drug toxicity|0
6317153|NCT02750514|10051524|FG003|Track 1|Study drug toxicity|1
6317154|NCT02750514|10051525|FG004|Track 1|Study drug toxicity|0
6317155|NCT02750514|10051521|FG000|Track 1|Participant request to discontinue|1
6317156|NCT02750514|10051522|FG001|Track 1|Participant request to discontinue|0
6317157|NCT02750514|10051523|FG002|Track 1|Participant request to discontinue|0
6317158|NCT02750514|10051524|FG003|Track 1|Participant request to discontinue|0
6317159|NCT02750514|10051525|FG004|Track 1|Participant request to discontinue|0
6317160|NCT02750514|10051521|FG000|Track 1|Other reasons|1
6317161|NCT02750514|10051522|FG001|Track 1|Other reasons|0
6317162|NCT02750514|10051523|FG002|Track 1|Other reasons|0
6317163|NCT02750514|10051524|FG003|Track 1|Other reasons|0
6317164|NCT02750514|10051525|FG004|Track 1|Other reasons|0
6317165|NCT02750514|10051521|FG000|Track 2|Disease progression|4
6317166|NCT02750514|10051522|FG001|Track 2|Disease progression|5
6317167|NCT02750514|10051523|FG002|Track 2|Disease progression|2
6317168|NCT02750514|10051524|FG003|Track 2|Disease progression|5
6317169|NCT02750514|10051525|FG004|Track 2|Disease progression|0
6317170|NCT02750514|10051521|FG000|Track 2|Adverse event unrelated to study drug|1
6317171|NCT02750514|10051522|FG001|Track 2|Adverse event unrelated to study drug|0
6317172|NCT02750514|10051523|FG002|Track 2|Adverse event unrelated to study drug|0
6317173|NCT02750514|10051524|FG003|Track 2|Adverse event unrelated to study drug|0
6317174|NCT02750514|10051525|FG004|Track 2|Adverse event unrelated to study drug|0
6317175|NCT02750514|10051521|FG000|Track 2|Study drug toxicity|1
6317176|NCT02750514|10051522|FG001|Track 2|Study drug toxicity|2
6317177|NCT02750514|10051523|FG002|Track 2|Study drug toxicity|0
6317178|NCT02750514|10051524|FG003|Track 2|Study drug toxicity|2
6317179|NCT02750514|10051525|FG004|Track 2|Study drug toxicity|0
6317180|NCT02750514|10051521|FG000|Track 2|Participant withdrew consent|0
6317181|NCT02750514|10051522|FG001|Track 2|Participant withdrew consent|1
6317182|NCT02750514|10051523|FG002|Track 2|Participant withdrew consent|0
6317183|NCT02750514|10051524|FG003|Track 2|Participant withdrew consent|0
6317184|NCT02750514|10051525|FG004|Track 2|Participant withdrew consent|0
6317185|NCT02750514|10051521|FG000|Track 3|Disease progression|0
6317186|NCT02750514|10051522|FG001|Track 3|Disease progression|24
6317187|NCT02750514|10051523|FG002|Track 3|Disease progression|13
6317188|NCT02750514|10051524|FG003|Track 3|Disease progression|14
6317189|NCT02750514|10051525|FG004|Track 3|Disease progression|0
6317190|NCT02750514|10051521|FG000|Track 3|Adverse event unrelated to study drug|0
6317191|NCT02750514|10051522|FG001|Track 3|Adverse event unrelated to study drug|1
6317192|NCT02750514|10051523|FG002|Track 3|Adverse event unrelated to study drug|1
6317193|NCT02750514|10051524|FG003|Track 3|Adverse event unrelated to study drug|1
6317194|NCT02750514|10051525|FG004|Track 3|Adverse event unrelated to study drug|0
6317195|NCT02750514|10051521|FG000|Track 3|Study drug toxicity|0
6317196|NCT02750514|10051522|FG001|Track 3|Study drug toxicity|3
6317197|NCT02750514|10051523|FG002|Track 3|Study drug toxicity|0
6317198|NCT02750514|10051524|FG003|Track 3|Study drug toxicity|1
6317199|NCT02750514|10051525|FG004|Track 3|Study drug toxicity|0
6317200|NCT02750514|10051521|FG000|Track 3|Participant request to discontinue|0
6317201|NCT02750514|10051522|FG001|Track 3|Participant request to discontinue|2
6317202|NCT02750514|10051523|FG002|Track 3|Participant request to discontinue|0
6317203|NCT02750514|10051524|FG003|Track 3|Participant request to discontinue|0
6317204|NCT02750514|10051525|FG004|Track 3|Participant request to discontinue|0
6317205|NCT02750514|10051521|FG000|Track 3|Participant withdrew consent|0
6317206|NCT02750514|10051522|FG001|Track 3|Participant withdrew consent|3
6317207|NCT02750514|10051523|FG002|Track 3|Participant withdrew consent|1
6317208|NCT02750514|10051524|FG003|Track 3|Participant withdrew consent|0
6317209|NCT02750514|10051525|FG004|Track 3|Participant withdrew consent|0
6317210|NCT02750514|10051521|FG000|Track 3|Other reasons|0
6317211|NCT02750514|10051522|FG001|Track 3|Other reasons|3
6317212|NCT02750514|10051523|FG002|Track 3|Other reasons|0
6317213|NCT02750514|10051524|FG003|Track 3|Other reasons|0
6317214|NCT02750514|10051525|FG004|Track 3|Other reasons|0
6317215|NCT02750514|10051521|FG000|Track 4|Study drug toxicity|0
6317216|NCT02750514|10051522|FG001|Track 4|Study drug toxicity|6
6317217|NCT02750514|10051523|FG002|Track 4|Study drug toxicity|0
6317218|NCT02750514|10051524|FG003|Track 4|Study drug toxicity|5
6317219|NCT02750514|10051525|FG004|Track 4|Study drug toxicity|0
6317220|NCT02750514|10051521|FG000|Track 4|Participant request to discontinue|0
6317221|NCT02750514|10051522|FG001|Track 4|Participant request to discontinue|1
6317222|NCT02750514|10051523|FG002|Track 4|Participant request to discontinue|0
6317223|NCT02750514|10051524|FG003|Track 4|Participant request to discontinue|1
6317224|NCT02750514|10051525|FG004|Track 4|Participant request to discontinue|0
6317225|NCT02750514|10051521|FG000|Track 4|Participant withdrew consent|0
6317226|NCT02750514|10051522|FG001|Track 4|Participant withdrew consent|1
6317227|NCT02750514|10051523|FG002|Track 4|Participant withdrew consent|0
6317228|NCT02750514|10051524|FG003|Track 4|Participant withdrew consent|0
6317229|NCT02750514|10051525|FG004|Track 4|Participant withdrew consent|0
6317230|NCT02750514|10051521|FG000|Track 4|Other reasons|0
6317231|NCT02750514|10051522|FG001|Track 4|Other reasons|5
6317232|NCT02750514|10051523|FG002|Track 4|Other reasons|0
6317233|NCT02750514|10051524|FG003|Track 4|Other reasons|3
6317234|NCT02750514|10051525|FG004|Track 4|Other reasons|0
6317235|NCT02750514|10051521|FG000|Track 4|Disease progression|0
6317236|NCT02750514|10051522|FG001|Track 4|Disease progression|33
6317237|NCT02750514|10051523|FG002|Track 4|Disease progression|0
6317238|NCT02750514|10051524|FG003|Track 4|Disease progression|32
6317239|NCT02750514|10051525|FG004|Track 4|Disease progression|0
6040508|NCT02282020|9638466|FG000|Overall Study|Miscellaneous|4
6040509|NCT02282020|9638467|FG001|Overall Study|Miscellaneous|17
6040510|NCT02282020|9638466|FG000|Overall Study|Severe Non-compliance to Protocol|1
6040511|NCT02282020|9638467|FG001|Overall Study|Severe Non-compliance to Protocol|0
6040512|NCT02282020|9638466|FG000|Overall Study|Developed Discontinuation Criteria|1
6040513|NCT02282020|9638467|FG001|Overall Study|Developed Discontinuation Criteria|3
6040514|NCT02282020|9638466|FG000|Overall Study|Withdrew Consent Prior to Dosing|0
6040515|NCT02282020|9638467|FG001|Overall Study|Withdrew Consent Prior to Dosing|12
6040516|NCT02180724|9638492|FG000|Overall Study|Death|12
6040517|NCT02180724|9638493|FG001|Overall Study|Death|1
6040518|NCT02180724|9638492|FG000|Overall Study|Lost to Follow-up|1
6040519|NCT02180724|9638493|FG001|Overall Study|Lost to Follow-up|0
6040520|NCT02180724|9638492|FG000|Overall Study|Withdrawal by Subject|1
6040521|NCT02180724|9638493|FG001|Overall Study|Withdrawal by Subject|2
6040522|NCT02180724|9638492|FG000|Overall Study|Ongoing Study|78
6040523|NCT02180724|9638493|FG001|Overall Study|Ongoing Study|11
6040524|NCT02038777|9638507|FG000|Overall Study|Death|0
6040525|NCT02038777|9638508|FG001|Overall Study|Death|2
6040526|NCT02038777|9638509|FG002|Overall Study|Death|0
6040527|NCT02038777|9638510|FG003|Overall Study|Death|1
6040528|NCT02038777|9638511|FG004|Overall Study|Death|2
6040529|NCT02038777|9638512|FG005|Overall Study|Death|4
6040530|NCT02038777|9638513|FG006|Overall Study|Death|0
6040531|NCT02038777|9638514|FG007|Overall Study|Death|10
6040532|NCT02038777|9638507|FG000|Overall Study|Lost to Follow-up|0
6040533|NCT02038777|9638508|FG001|Overall Study|Lost to Follow-up|0
6040534|NCT02038777|9638509|FG002|Overall Study|Lost to Follow-up|0
6040535|NCT02038777|9638510|FG003|Overall Study|Lost to Follow-up|1
6040536|NCT02038777|9638511|FG004|Overall Study|Lost to Follow-up|0
6040537|NCT02038777|9638512|FG005|Overall Study|Lost to Follow-up|0
6040538|NCT02038777|9638513|FG006|Overall Study|Lost to Follow-up|0
6040539|NCT02038777|9638514|FG007|Overall Study|Lost to Follow-up|0
6040540|NCT02038777|9638507|FG000|Overall Study|Other|0
6040541|NCT02038777|9638508|FG001|Overall Study|Other|1
6040542|NCT02038777|9638509|FG002|Overall Study|Other|0
6040543|NCT02038777|9638510|FG003|Overall Study|Other|2
6040544|NCT02038777|9638511|FG004|Overall Study|Other|1
6317240|NCT02750514|10051521|FG000|Track 4|Adverse event unrelated to study drug|0
6317241|NCT02750514|10051522|FG001|Track 4|Adverse event unrelated to study drug|5
6317242|NCT02750514|10051523|FG002|Track 4|Adverse event unrelated to study drug|0
6317243|NCT02750514|10051524|FG003|Track 4|Adverse event unrelated to study drug|0
6317244|NCT02750514|10051525|FG004|Track 4|Adverse event unrelated to study drug|0
6317245|NCT02750514|10051521|FG000|Track 4|Death|0
6317246|NCT02750514|10051522|FG001|Track 4|Death|0
6317247|NCT02750514|10051523|FG002|Track 4|Death|0
6317248|NCT02750514|10051524|FG003|Track 4|Death|1
6040545|NCT02038777|9638512|FG005|Overall Study|Other|0
6040546|NCT02038777|9638513|FG006|Overall Study|Other|0
6040547|NCT02038777|9638514|FG007|Overall Study|Other|0
6040548|NCT02038777|9638507|FG000|Overall Study|Randomized but not treated|0
6040549|NCT02038777|9638508|FG001|Overall Study|Randomized but not treated|1
6040550|NCT02038777|9638509|FG002|Overall Study|Randomized but not treated|0
6040551|NCT02038777|9638510|FG003|Overall Study|Randomized but not treated|0
6040552|NCT02038777|9638511|FG004|Overall Study|Randomized but not treated|0
6040553|NCT02038777|9638512|FG005|Overall Study|Randomized but not treated|0
6317249|NCT02750514|10051525|FG004|Track 4|Death|0
6317250|NCT02750514|10051521|FG000|Track 5|Disease progression|0
6317251|NCT02750514|10051522|FG001|Track 5|Disease progression|0
6317252|NCT02750514|10051523|FG002|Track 5|Disease progression|0
6317253|NCT02750514|10051524|FG003|Track 5|Disease progression|0
6317254|NCT02750514|10051525|FG004|Track 5|Disease progression|34
6317255|NCT02750514|10051521|FG000|Track 5|Adverse event unrelated to study drug|0
6317256|NCT02750514|10051522|FG001|Track 5|Adverse event unrelated to study drug|0
6317257|NCT02750514|10051523|FG002|Track 5|Adverse event unrelated to study drug|0
6317258|NCT02750514|10051524|FG003|Track 5|Adverse event unrelated to study drug|0
6317259|NCT02750514|10051525|FG004|Track 5|Adverse event unrelated to study drug|2
6317260|NCT02750514|10051521|FG000|Track 5|Study drug toxicity|0
6317261|NCT02750514|10051522|FG001|Track 5|Study drug toxicity|0
6317262|NCT02750514|10051523|FG002|Track 5|Study drug toxicity|0
6317263|NCT02750514|10051524|FG003|Track 5|Study drug toxicity|0
6317264|NCT02750514|10051525|FG004|Track 5|Study drug toxicity|2
6317265|NCT02750514|10051521|FG000|Track 5|Participant request to discontinue|0
6317266|NCT02750514|10051522|FG001|Track 5|Participant request to discontinue|0
6317267|NCT02750514|10051523|FG002|Track 5|Participant request to discontinue|0
6317268|NCT02750514|10051524|FG003|Track 5|Participant request to discontinue|0
6317269|NCT02750514|10051525|FG004|Track 5|Participant request to discontinue|3
6317270|NCT02750514|10051521|FG000|Track 5|Other reasons|0
6317271|NCT02750514|10051522|FG001|Track 5|Other reasons|0
6317272|NCT02750514|10051523|FG002|Track 5|Other reasons|0
6317273|NCT02750514|10051524|FG003|Track 5|Other reasons|0
6317274|NCT02750514|10051525|FG004|Track 5|Other reasons|2
6317275|NCT02750592|10051545|FG000|Overall Study|Adverse Event|3
6317276|NCT02750592|10051545|FG000|Overall Study|Lack of Efficacy|2
6317277|NCT02750618|10051549|FG000|Overall Study|Withdrawal by Subject|1
6317278|NCT02750709|10051553|FG000|Treatment Period 1|Adverse Event|0
6317279|NCT02750709|10051554|FG001|Treatment Period 1|Adverse Event|0
6317280|NCT02750709|10051555|FG002|Treatment Period 1|Adverse Event|0
6317281|NCT02750709|10051556|FG003|Treatment Period 1|Adverse Event|0
6317282|NCT02750709|10051557|FG004|Treatment Period 1|Adverse Event|0
6317283|NCT02750709|10051558|FG005|Treatment Period 1|Adverse Event|1
6317284|NCT02750761|10051572|FG000|Overall Study|Lost to Follow-up|0
6317285|NCT02750761|10051573|FG001|Overall Study|Lost to Follow-up|0
6317286|NCT02750761|10051574|FG002|Overall Study|Lost to Follow-up|1
6317287|NCT02750761|10051575|FG003|Overall Study|Lost to Follow-up|0
6317288|NCT02750761|10051576|FG004|Overall Study|Lost to Follow-up|0
6317289|NCT02750761|10051577|FG005|Overall Study|Lost to Follow-up|0
6317290|NCT02750800|10051601|FG000|Overall Study|Adverse Event|18
6317291|NCT02750800|10051601|FG000|Overall Study|Lost to Follow-up|12
6317292|NCT02750800|10051601|FG000|Overall Study|Investigator decision|53
6317293|NCT02750800|10051601|FG000|Overall Study|Patient request|12
6317294|NCT02750800|10051601|FG000|Overall Study|Other, not specified|3
6317295|NCT02750813|10051619|FG000|Period 1, First 14 Days of Wear|Withdrawal by Subject|1
6317296|NCT02750813|10051620|FG001|Period 1, First 14 Days of Wear|Withdrawal by Subject|0
6317297|NCT02750813|10051619|FG000|Period 1, First 14 Days of Wear|Reason not given|0
6317298|NCT02750813|10051620|FG001|Period 1, First 14 Days of Wear|Reason not given|1
6317299|NCT02750930|10051627|FG000|Overall Study|Study closed/terminated|8
6317300|NCT02750943|10051633|FG000|Overall Study|Lost to Follow-up|1
6317301|NCT02750943|10051634|FG001|Overall Study|Lost to Follow-up|2
6317302|NCT02750943|10051633|FG000|Overall Study|Withdrawal by Subject|5
6317303|NCT02750943|10051634|FG001|Overall Study|Withdrawal by Subject|7
6317304|NCT02751320|10051640|FG000|Overall Study|Adverse Event|2
6317305|NCT02751320|10051640|FG000|Overall Study|Withdrawal by Subject|1
6317306|NCT02751359|10051665|FG000|Overall Study|Lost to Follow-up|1
6317307|NCT02751424|10051693|FG000|Part 2|Adverse Event|0
6317308|NCT02751424|10051694|FG001|Part 2|Adverse Event|0
6317309|NCT02751424|10051695|FG002|Part 2|Adverse Event|0
6317310|NCT02751424|10051696|FG003|Part 2|Adverse Event|0
6317311|NCT02751424|10051697|FG004|Part 2|Adverse Event|0
6317312|NCT02751424|10051698|FG005|Part 2|Adverse Event|0
6317313|NCT02751424|10051699|FG006|Part 2|Adverse Event|0
6317314|NCT02751424|10051700|FG007|Part 2|Adverse Event|5
6317315|NCT02751424|10051701|FG008|Part 2|Adverse Event|0
6317316|NCT02751450|10051726|FG000|Overall Study|Adverse Event|1
6317317|NCT02751450|10051727|FG001|Overall Study|Adverse Event|0
6317318|NCT02751580|10051735|FG000|Overall Study|Lost to Follow-up|4
6317319|NCT02751580|10051735|FG000|Overall Study|Death|2
6317320|NCT02751827|10051742|FG000|Overall Study|Only patient treated by TKI without anti-angiogenic action. He was excluded due to selection bias.|0
6317321|NCT02751827|10051743|FG001|Overall Study|Only patient treated by TKI without anti-angiogenic action. He was excluded due to selection bias.|0
6317322|NCT02751827|10051744|FG002|Overall Study|Only patient treated by TKI without anti-angiogenic action. He was excluded due to selection bias.|1
6317323|NCT02751931|10051766|FG000|Overall Study|Adverse Event|3
6317324|NCT02751931|10051767|FG001|Overall Study|Adverse Event|0
6317325|NCT02751931|10051766|FG000|Overall Study|Other: Miscelleneous|10
6317326|NCT02751931|10051767|FG001|Overall Study|Other: Miscelleneous|8
6040554|NCT02038777|9638513|FG006|Overall Study|Randomized but not treated|0
6040555|NCT02038777|9638514|FG007|Overall Study|Randomized but not treated|0
6040556|NCT02038777|9638507|FG000|Overall Study|Started Chemotherapy|1
6040557|NCT02038777|9638508|FG001|Overall Study|Started Chemotherapy|0
6040558|NCT02038777|9638509|FG002|Overall Study|Started Chemotherapy|3
6040559|NCT02038777|9638510|FG003|Overall Study|Started Chemotherapy|0
6040560|NCT02038777|9638511|FG004|Overall Study|Started Chemotherapy|0
6150695|NCT01106651|9787033|FG001|Overall Study|Other|31
6317327|NCT02751983|10051781|FG000|Treatment|Stopped ACT, but Remained in study|2
6317328|NCT02751983|10051782|FG001|Treatment|Stopped ACT, but Remained in study|0
6317329|NCT02751983|10051781|FG000|Treatment|Discharged prior to beginning ACT|2
6317330|NCT02751983|10051782|FG001|Treatment|Discharged prior to beginning ACT|0
6317331|NCT02751983|10051781|FG000|Post-Treatment Assessment|Lost to Follow-up|5
6317332|NCT02751983|10051782|FG001|Post-Treatment Assessment|Lost to Follow-up|0
6317333|NCT02751983|10051781|FG000|One-Month Follow-Up Assessments|Lost to Follow-up|14
6317334|NCT02751983|10051782|FG001|One-Month Follow-Up Assessments|Lost to Follow-up|12
6317335|NCT02751983|10051781|FG000|Three-Month Follow-Up Assessments|Lost to Follow-up|12
6317336|NCT02751983|10051782|FG001|Three-Month Follow-Up Assessments|Lost to Follow-up|16
6317337|NCT02752048|10051791|FG000|Overall Study|Withdrawal by Subject|0
6317338|NCT02752048|10051792|FG001|Overall Study|Withdrawal by Subject|0
6150696|NCT01106651|9787034|FG002|Overall Study|Other|21
6150697|NCT01106651|9787032|FG000|Overall Study|Death|0
6317339|NCT02752048|10051793|FG002|Overall Study|Withdrawal by Subject|3
6317340|NCT02752074|10051803|FG000|Overall Study|Lost to Follow-up|1
6317341|NCT02752074|10051804|FG001|Overall Study|Lost to Follow-up|4
6317342|NCT02752074|10051803|FG000|Overall Study|Death|146
6317343|NCT02752074|10051804|FG001|Overall Study|Death|129
6317344|NCT02752074|10051803|FG000|Overall Study|Withdrawal by Subject|9
6317345|NCT02752074|10051804|FG001|Overall Study|Withdrawal by Subject|10
6317346|NCT02752087|10051810|FG000|Washout|Physician Decision|1
6040561|NCT02038777|9638512|FG005|Overall Study|Started Chemotherapy|0
6040562|NCT02038777|9638513|FG006|Overall Study|Started Chemotherapy|0
6317347|NCT02752087|10051811|FG001|Washout|Physician Decision|0
6317348|NCT02752633|10051835|FG000|Overall Study|Withdrawal by Subject|1
6317349|NCT02752776|10051842|FG000|Overall Study|Adverse Event|15
6317350|NCT02752776|10051843|FG001|Overall Study|Adverse Event|23
6317351|NCT02752776|10051844|FG002|Overall Study|Adverse Event|11
6317352|NCT02752776|10051842|FG000|Overall Study|Lack of Efficacy|2
6317353|NCT02752776|10051843|FG001|Overall Study|Lack of Efficacy|6
6317354|NCT02752776|10051844|FG002|Overall Study|Lack of Efficacy|14
6317355|NCT02752776|10051842|FG000|Overall Study|Lost to Follow-up|11
6317356|NCT02752776|10051843|FG001|Overall Study|Lost to Follow-up|12
6317357|NCT02752776|10051844|FG002|Overall Study|Lost to Follow-up|4
6317358|NCT02752776|10051842|FG000|Overall Study|Non-compliance with study treatment|0
6317359|NCT02752776|10051843|FG001|Overall Study|Non-compliance with study treatment|0
6317360|NCT02752776|10051844|FG002|Overall Study|Non-compliance with study treatment|1
6317361|NCT02752776|10051842|FG000|Overall Study|Physician Decision|2
6317362|NCT02752776|10051843|FG001|Overall Study|Physician Decision|6
6317363|NCT02752776|10051844|FG002|Overall Study|Physician Decision|2
6317364|NCT02752776|10051842|FG000|Overall Study|Pregnancy|1
6317365|NCT02752776|10051843|FG001|Overall Study|Pregnancy|6
6317366|NCT02752776|10051844|FG002|Overall Study|Pregnancy|3
6317367|NCT02752776|10051842|FG000|Overall Study|Protocol Violation|10
6317368|NCT02752776|10051843|FG001|Overall Study|Protocol Violation|13
6317369|NCT02752776|10051844|FG002|Overall Study|Protocol Violation|6
6317370|NCT02752776|10051842|FG000|Overall Study|Subject/guardian decision|8
6317371|NCT02752776|10051843|FG001|Overall Study|Subject/guardian decision|6
6317372|NCT02752776|10051844|FG002|Overall Study|Subject/guardian decision|4
6317373|NCT02752776|10051842|FG000|Overall Study|Death|0
6317374|NCT02752776|10051843|FG001|Overall Study|Death|0
6317375|NCT02752776|10051844|FG002|Overall Study|Death|1
6317376|NCT02752776|10051842|FG000|Overall Study|Withdrawal by Subject|3
6317377|NCT02752776|10051843|FG001|Overall Study|Withdrawal by Subject|4
6317378|NCT02752776|10051844|FG002|Overall Study|Withdrawal by Subject|2
6317379|NCT02752802|10051856|FG000|Overall Study|Contrast Volume Not Collected|1
6317380|NCT02752802|10051857|FG001|Overall Study|Contrast Volume Not Collected|0
6317381|NCT02752958|10051875|FG000|Overall Study|Adverse Event|3
6317382|NCT02752958|10051875|FG000|Overall Study|Lost to Follow-up|1
6317383|NCT02752958|10051875|FG000|Overall Study|Protocol Violation|1
6317384|NCT02752958|10051875|FG000|Overall Study|Withdrawal by Subject|2
6317385|NCT02752958|10051875|FG000|Overall Study|Other (Reason not specified)|2
6317386|NCT02753075|10051884|FG000|Overall Study|Adverse Event|2
6317387|NCT02753075|10051885|FG001|Overall Study|Adverse Event|1
6317388|NCT02753075|10051886|FG002|Overall Study|Adverse Event|0
6317389|NCT02753075|10051884|FG000|Overall Study|Lost to Follow-up|2
6317390|NCT02753075|10051885|FG001|Overall Study|Lost to Follow-up|0
6317391|NCT02753075|10051886|FG002|Overall Study|Lost to Follow-up|0
6317392|NCT02753075|10051884|FG000|Overall Study|Withdrawal of Consent|1
6317393|NCT02753075|10051885|FG001|Overall Study|Withdrawal of Consent|1
6317394|NCT02753075|10051886|FG002|Overall Study|Withdrawal of Consent|3
6317395|NCT02753075|10051884|FG000|Overall Study|Physician Decision|3
6317396|NCT02753075|10051885|FG001|Overall Study|Physician Decision|1
6317397|NCT02753075|10051886|FG002|Overall Study|Physician Decision|0
6317398|NCT02753400|10051897|FG000|Overall Study|Adverse Event|3
6317399|NCT02753400|10051898|FG001|Overall Study|Adverse Event|0
6317400|NCT02753400|10051897|FG000|Overall Study|Withdrawal by Subject|2
6317401|NCT02753400|10051898|FG001|Overall Study|Withdrawal by Subject|1
6317402|NCT02753595|10051915|FG000|Overall Study|Sponsor termination|2
6317403|NCT02753595|10051916|FG001|Overall Study|Sponsor termination|2
6317404|NCT02753816|10051939|FG000|Overall Study|Protocol Violation|0
6317405|NCT02753816|10051940|FG001|Overall Study|Protocol Violation|1
6317406|NCT02753816|10051941|FG002|Overall Study|Protocol Violation|0
6317407|NCT02753946|10052000|FG000|Overall Study|Adverse Event|7
6317408|NCT02753946|10052001|FG001|Overall Study|Adverse Event|6
6317409|NCT02753946|10052000|FG000|Overall Study|Withdrawal by Subject|6
6317410|NCT02753946|10052001|FG001|Overall Study|Withdrawal by Subject|1
6317411|NCT02753946|10052000|FG000|Overall Study|Lack of Efficacy|1
6317412|NCT02753946|10052001|FG001|Overall Study|Lack of Efficacy|0
6317413|NCT02753946|10052000|FG000|Overall Study|Physician Decision|0
6317414|NCT02753946|10052001|FG001|Overall Study|Physician Decision|2
6317415|NCT02754440|10052029|FG000|Overall Study|Protocol Violation|3
6317416|NCT02754440|10052030|FG001|Overall Study|Protocol Violation|2
6317417|NCT02754440|10052031|FG002|Overall Study|Protocol Violation|2
6317418|NCT02754440|10052032|FG003|Overall Study|Protocol Violation|6
6317419|NCT02754440|10052029|FG000|Overall Study|Adverse Event|3
6317420|NCT02754440|10052030|FG001|Overall Study|Adverse Event|1
6317421|NCT02754440|10052031|FG002|Overall Study|Adverse Event|0
6317422|NCT02754440|10052032|FG003|Overall Study|Adverse Event|9
6317423|NCT02754440|10052029|FG000|Overall Study|Withdrawal by Subject|0
6317424|NCT02754440|10052030|FG001|Overall Study|Withdrawal by Subject|0
6317425|NCT02754440|10052031|FG002|Overall Study|Withdrawal by Subject|0
6317426|NCT02754440|10052032|FG003|Overall Study|Withdrawal by Subject|1
6317427|NCT02754440|10052029|FG000|Overall Study|Equipment failure|0
6317428|NCT02754440|10052030|FG001|Overall Study|Equipment failure|5
6317429|NCT02754440|10052031|FG002|Overall Study|Equipment failure|5
6317430|NCT02754440|10052032|FG003|Overall Study|Equipment failure|7
6317431|NCT02754440|10052029|FG000|Overall Study|Subject issues not resulting in AE|0
6317432|NCT02754440|10052030|FG001|Overall Study|Subject issues not resulting in AE|0
6317433|NCT02754440|10052031|FG002|Overall Study|Subject issues not resulting in AE|0
6317434|NCT02754440|10052032|FG003|Overall Study|Subject issues not resulting in AE|12
6317435|NCT02754492|10052045|FG000|Overall Study|Protocol Violation|2
6317436|NCT02754492|10052046|FG001|Overall Study|Protocol Violation|2
6317437|NCT02754492|10052047|FG002|Overall Study|Protocol Violation|0
6317438|NCT02754492|10052048|FG003|Overall Study|Protocol Violation|1
6317439|NCT02754492|10052045|FG000|Overall Study|Withdrawal by Subject|2
6317440|NCT02754492|10052046|FG001|Overall Study|Withdrawal by Subject|0
6317441|NCT02754492|10052047|FG002|Overall Study|Withdrawal by Subject|0
6317442|NCT02754492|10052048|FG003|Overall Study|Withdrawal by Subject|0
6317443|NCT02754492|10052045|FG000|Overall Study|Equipment malfuntion|0
6317444|NCT02754492|10052046|FG001|Overall Study|Equipment malfuntion|0
6317445|NCT02754492|10052047|FG002|Overall Study|Equipment malfuntion|2
6317446|NCT02754492|10052048|FG003|Overall Study|Equipment malfuntion|5
6317447|NCT02754492|10052045|FG000|Overall Study|Adverse Event|0
6317448|NCT02754492|10052046|FG001|Overall Study|Adverse Event|0
6317449|NCT02754492|10052047|FG002|Overall Study|Adverse Event|0
6317450|NCT02754492|10052048|FG003|Overall Study|Adverse Event|13
6317451|NCT02754492|10052045|FG000|Overall Study|Venous access issues not resulting in AE|0
6317452|NCT02754492|10052046|FG001|Overall Study|Venous access issues not resulting in AE|0
6317453|NCT02754492|10052047|FG002|Overall Study|Venous access issues not resulting in AE|0
6317454|NCT02754492|10052048|FG003|Overall Study|Venous access issues not resulting in AE|4
6317455|NCT02755090|10052089|FG000|Overall Study|equipment malfunction|1
6317456|NCT02755090|10052090|FG001|Overall Study|equipment malfunction|0
6317457|NCT02755116|10052098|FG000|Overall Study|surgery converted to open, pt admitted|3
6317458|NCT02755116|10052099|FG001|Overall Study|surgery converted to open, pt admitted|1
6317459|NCT02755649|10052119|FG000|Overall Study|Transitioned into OLE study|99
6317460|NCT02755649|10052120|FG001|Overall Study|Transitioned into OLE study|98
6317461|NCT02755649|10052121|FG002|Overall Study|Transitioned into OLE study|100
6317462|NCT02755649|10052119|FG000|Overall Study|Did Not Complete Follow-up Visits|1
6317463|NCT02755649|10052120|FG001|Overall Study|Did Not Complete Follow-up Visits|0
6317464|NCT02755649|10052121|FG002|Overall Study|Did Not Complete Follow-up Visits|0
6317465|NCT02755649|10052119|FG000|Overall Study|Physician Decision|0
6317466|NCT02755649|10052120|FG001|Overall Study|Physician Decision|0
6317467|NCT02755649|10052121|FG002|Overall Study|Physician Decision|2
6317468|NCT02755649|10052119|FG000|Overall Study|Withdrawal by Subject|0
6317469|NCT02755649|10052120|FG001|Overall Study|Withdrawal by Subject|1
6317470|NCT02755649|10052121|FG002|Overall Study|Withdrawal by Subject|0
6317471|NCT02755649|10052119|FG000|Overall Study|Undecided|1
6317472|NCT02755649|10052120|FG001|Overall Study|Undecided|0
6317473|NCT02755649|10052121|FG002|Overall Study|Undecided|0
6317474|NCT02755805|10052131|FG000|Overall Study|Lost to Follow-up|1
6317475|NCT02755805|10052132|FG001|Overall Study|Lost to Follow-up|2
6317476|NCT02755805|10052131|FG000|Overall Study|Refused assessments|1
6317477|NCT02755805|10052132|FG001|Overall Study|Refused assessments|0
6317478|NCT02755805|10052131|FG000|Overall Study|Withdrawal by Subject|0
6317479|NCT02755805|10052132|FG001|Overall Study|Withdrawal by Subject|2
6317480|NCT02755818|10052142|FG000|Overall Study|Withdrawal by Subject|0
6317481|NCT02755818|10052143|FG001|Overall Study|Withdrawal by Subject|0
6317482|NCT02755818|10052144|FG002|Overall Study|Withdrawal by Subject|0
6317483|NCT02755818|10052145|FG003|Overall Study|Withdrawal by Subject|2
6317484|NCT02755818|10052142|FG000|Overall Study|withdrawal by PI|0
6040563|NCT02038777|9638514|FG007|Overall Study|Started Chemotherapy|0
6040564|NCT01927419|9638544|FG000|Pre-Treatment Period|Adverse event unrelated to study drug|0
6040565|NCT01927419|9638545|FG001|Pre-Treatment Period|Adverse event unrelated to study drug|1
6040566|NCT01927419|9638544|FG000|Pre-Treatment Period|Participants no longer meeting study criteria|1
6048999|NCT00420927|9648204|FG005|Period 2|Physician Decision|1
6317485|NCT02755818|10052143|FG001|Overall Study|withdrawal by PI|0
6317486|NCT02755818|10052144|FG002|Overall Study|withdrawal by PI|1
6317487|NCT02755818|10052145|FG003|Overall Study|withdrawal by PI|1
6317488|NCT02755831|10052159|FG000|Overall Study|Lost to Follow-up|3
6317489|NCT02755831|10052160|FG001|Overall Study|Lost to Follow-up|3
6317490|NCT02756013|10052170|FG000|Overall Study|Adverse Event|1
6317491|NCT02756013|10052170|FG000|Overall Study|Hypersensitivity|1
6317492|NCT02756078|10052174|FG000|Period 1|Unsatisfactory Lens Fitting|0
6317493|NCT02756078|10052175|FG001|Period 1|Unsatisfactory Lens Fitting|1
6317494|NCT02756078|10052174|FG000|Period 1|Lost to Follow-up|0
6317495|NCT02756078|10052175|FG001|Period 1|Lost to Follow-up|2
6317496|NCT02756078|10052174|FG000|Period 1|Protocol Violation|0
6317497|NCT02756078|10052175|FG001|Period 1|Protocol Violation|1
6317498|NCT02756078|10052174|FG000|Period 1|Adverse Event|1
6317499|NCT02756078|10052175|FG001|Period 1|Adverse Event|10
6317500|NCT02756078|10052174|FG000|Period 1|Withdrawal by Subject|6
6317501|NCT02756078|10052175|FG001|Period 1|Withdrawal by Subject|6
6317502|NCT02756078|10052174|FG000|Period 1|Lens Discomfort|2
6317503|NCT02756078|10052175|FG001|Period 1|Lens Discomfort|2
6317504|NCT02756078|10052174|FG000|Period 2|Adverse Event|3
6317505|NCT02756078|10052175|FG001|Period 2|Adverse Event|5
6317506|NCT02756078|10052174|FG000|Period 2|Unsatisfactory Lens Fitting|0
6317507|NCT02756078|10052175|FG001|Period 2|Unsatisfactory Lens Fitting|1
6317508|NCT02756078|10052174|FG000|Period 2|Withdrawal by Subject|3
6317509|NCT02756078|10052175|FG001|Period 2|Withdrawal by Subject|1
6317510|NCT02756182|10052181|FG000|Overall Study|StudyTechnical Difficulties|4
6317511|NCT02756338|10052187|FG000|Overall Study|Withdrawn by Investigator|1
6317512|NCT02756338|10052187|FG000|Overall Study|Device Replaced with Pacemaker|4
6317513|NCT02756364|10052203|FG000|Overall Study|Site Terminated by Sponsor|24
6317514|NCT02756364|10052204|FG001|Overall Study|Site Terminated by Sponsor|30
6317515|NCT02756364|10052205|FG002|Overall Study|Site Terminated by Sponsor|21
6317516|NCT02756364|10052203|FG000|Overall Study|Death|20
6317517|NCT02756364|10052204|FG001|Overall Study|Death|15
6317518|NCT02756364|10052205|FG002|Overall Study|Death|18
6040567|NCT01927419|9638545|FG001|Pre-Treatment Period|Participants no longer meeting study criteria|0
6040568|NCT01927419|9638544|FG000|Treatment Period|Disease progression|17
6040569|NCT01927419|9638545|FG001|Treatment Period|Disease progression|20
6040570|NCT01927419|9638544|FG000|Treatment Period|Study drug toxicity|48
6317519|NCT02756364|10052203|FG000|Overall Study|Withdrawal by Patient|2
6317520|NCT02756364|10052204|FG001|Overall Study|Withdrawal by Patient|1
6317521|NCT02756364|10052205|FG002|Overall Study|Withdrawal by Patient|8
6317522|NCT02756364|10052203|FG000|Overall Study|Lost to Follow-up|0
6317523|NCT02756364|10052204|FG001|Overall Study|Lost to Follow-up|1
6317524|NCT02756364|10052205|FG002|Overall Study|Lost to Follow-up|1
6317525|NCT02756637|10052233|FG000|Overall Study|Not eligible for initial SWOG study|10
6317526|NCT02756637|10052234|FG001|Overall Study|Not eligible for initial SWOG study|10
6317527|NCT02756637|10052233|FG000|Overall Study|No available NLR value|44
6317528|NCT02756637|10052234|FG001|Overall Study|No available NLR value|44
6317529|NCT02756637|10052233|FG000|Overall Study|Did not complete curative therapy|33
6317530|NCT02756637|10052234|FG001|Overall Study|Did not complete curative therapy|0
6317531|NCT02756650|10052240|FG000|Overall Study|Physician Decision|1
6317532|NCT02756650|10052240|FG000|Overall Study|Adverse Event|1
6317533|NCT02756819|10052287|FG000|Overall Study|Lost for observation|23
6317534|NCT02756819|10052287|FG000|Overall Study|Patient's unwillingness|16
6317535|NCT02756819|10052287|FG000|Overall Study|Insufficient efficacy|2
6317536|NCT02756819|10052287|FG000|Overall Study|Adverse Event|2
6317537|NCT02756819|10052287|FG000|Overall Study|Reason not Specified|9
6317538|NCT02756832|10052291|FG000|Overall Study|Lost for Observation after Baseline|6
6317539|NCT02756832|10052291|FG000|Overall Study|Lost for Observation|13
6317540|NCT02756832|10052291|FG000|Overall Study|Patient's Unwillingness|12
6317541|NCT02756832|10052291|FG000|Overall Study|Insufficient Efficacy|2
6317542|NCT02756832|10052291|FG000|Overall Study|Sponsor Decision/Regulatory Requirement|1
6317543|NCT02756832|10052291|FG000|Overall Study|Reason not Specified|9
6317544|NCT02756832|10052291|FG000|Overall Study|Protocol Deviation|10
6317545|NCT02757352|10052405|FG000|Double-Blind Period (Week 0 - Week 16)|Adverse Event|2
6317546|NCT02757352|10052406|FG001|Double-Blind Period (Week 0 - Week 16)|Adverse Event|0
6317547|NCT02757352|10052407|FG002|Double-Blind Period (Week 0 - Week 16)|Adverse Event|1
6317548|NCT02757352|10052408|FG003|Double-Blind Period (Week 0 - Week 16)|Adverse Event|0
6317549|NCT02757352|10052409|FG004|Double-Blind Period (Week 0 - Week 16)|Adverse Event|0
6317550|NCT02757352|10052410|FG005|Double-Blind Period (Week 0 - Week 16)|Adverse Event|0
6317551|NCT02757352|10052411|FG006|Double-Blind Period (Week 0 - Week 16)|Adverse Event|0
6317552|NCT02757352|10052412|FG007|Double-Blind Period (Week 0 - Week 16)|Adverse Event|0
6317553|NCT02757352|10052413|FG008|Double-Blind Period (Week 0 - Week 16)|Adverse Event|0
6317554|NCT02757352|10052414|FG009|Double-Blind Period (Week 0 - Week 16)|Adverse Event|0
6317555|NCT02757352|10052405|FG000|Double-Blind Period (Week 0 - Week 16)|Lost to Follow-up|0
6317556|NCT02757352|10052406|FG001|Double-Blind Period (Week 0 - Week 16)|Lost to Follow-up|0
6317557|NCT02757352|10052407|FG002|Double-Blind Period (Week 0 - Week 16)|Lost to Follow-up|1
6317558|NCT02757352|10052408|FG003|Double-Blind Period (Week 0 - Week 16)|Lost to Follow-up|0
6317559|NCT02757352|10052409|FG004|Double-Blind Period (Week 0 - Week 16)|Lost to Follow-up|0
6317560|NCT02757352|10052410|FG005|Double-Blind Period (Week 0 - Week 16)|Lost to Follow-up|0
6317561|NCT02757352|10052411|FG006|Double-Blind Period (Week 0 - Week 16)|Lost to Follow-up|0
6317562|NCT02757352|10052412|FG007|Double-Blind Period (Week 0 - Week 16)|Lost to Follow-up|0
6317563|NCT02757352|10052413|FG008|Double-Blind Period (Week 0 - Week 16)|Lost to Follow-up|0
6317564|NCT02757352|10052414|FG009|Double-Blind Period (Week 0 - Week 16)|Lost to Follow-up|0
6317565|NCT02757352|10052405|FG000|Double-Blind Period (Week 0 - Week 16)|Withdrawal by Subject|6
6317566|NCT02757352|10052406|FG001|Double-Blind Period (Week 0 - Week 16)|Withdrawal by Subject|1
6317567|NCT02757352|10052407|FG002|Double-Blind Period (Week 0 - Week 16)|Withdrawal by Subject|2
6317568|NCT02757352|10052408|FG003|Double-Blind Period (Week 0 - Week 16)|Withdrawal by Subject|0
6317569|NCT02757352|10052409|FG004|Double-Blind Period (Week 0 - Week 16)|Withdrawal by Subject|0
6317570|NCT02757352|10052410|FG005|Double-Blind Period (Week 0 - Week 16)|Withdrawal by Subject|0
6317571|NCT02757352|10052411|FG006|Double-Blind Period (Week 0 - Week 16)|Withdrawal by Subject|0
6317572|NCT02757352|10052412|FG007|Double-Blind Period (Week 0 - Week 16)|Withdrawal by Subject|0
6317573|NCT02757352|10052413|FG008|Double-Blind Period (Week 0 - Week 16)|Withdrawal by Subject|0
6317574|NCT02757352|10052414|FG009|Double-Blind Period (Week 0 - Week 16)|Withdrawal by Subject|0
6317575|NCT02757352|10052405|FG000|Double-Blind Period (Week 16 - Week 52)|Adverse Event|0
6317576|NCT02757352|10052406|FG001|Double-Blind Period (Week 16 - Week 52)|Adverse Event|1
6317577|NCT02757352|10052407|FG002|Double-Blind Period (Week 16 - Week 52)|Adverse Event|0
6317578|NCT02757352|10052408|FG003|Double-Blind Period (Week 16 - Week 52)|Adverse Event|0
6317579|NCT02757352|10052409|FG004|Double-Blind Period (Week 16 - Week 52)|Adverse Event|0
6317580|NCT02757352|10052410|FG005|Double-Blind Period (Week 16 - Week 52)|Adverse Event|0
6317581|NCT02757352|10052411|FG006|Double-Blind Period (Week 16 - Week 52)|Adverse Event|0
6317582|NCT02757352|10052412|FG007|Double-Blind Period (Week 16 - Week 52)|Adverse Event|0
6317583|NCT02757352|10052413|FG008|Double-Blind Period (Week 16 - Week 52)|Adverse Event|0
6317584|NCT02757352|10052414|FG009|Double-Blind Period (Week 16 - Week 52)|Adverse Event|0
6317585|NCT02757352|10052405|FG000|Double-Blind Period (Week 16 - Week 52)|Lack of Efficacy|0
6317586|NCT02757352|10052406|FG001|Double-Blind Period (Week 16 - Week 52)|Lack of Efficacy|1
6317587|NCT02757352|10052407|FG002|Double-Blind Period (Week 16 - Week 52)|Lack of Efficacy|0
6317588|NCT02757352|10052408|FG003|Double-Blind Period (Week 16 - Week 52)|Lack of Efficacy|0
6317589|NCT02757352|10052409|FG004|Double-Blind Period (Week 16 - Week 52)|Lack of Efficacy|0
6317590|NCT02757352|10052410|FG005|Double-Blind Period (Week 16 - Week 52)|Lack of Efficacy|0
6317591|NCT02757352|10052411|FG006|Double-Blind Period (Week 16 - Week 52)|Lack of Efficacy|0
6317592|NCT02757352|10052412|FG007|Double-Blind Period (Week 16 - Week 52)|Lack of Efficacy|0
6317593|NCT02757352|10052413|FG008|Double-Blind Period (Week 16 - Week 52)|Lack of Efficacy|0
6317594|NCT02757352|10052414|FG009|Double-Blind Period (Week 16 - Week 52)|Lack of Efficacy|0
6317595|NCT02757352|10052405|FG000|Double-Blind Period (Week 16 - Week 52)|Withdrawal by Subject|1
6317596|NCT02757352|10052406|FG001|Double-Blind Period (Week 16 - Week 52)|Withdrawal by Subject|1
6317597|NCT02757352|10052407|FG002|Double-Blind Period (Week 16 - Week 52)|Withdrawal by Subject|4
6317598|NCT02757352|10052408|FG003|Double-Blind Period (Week 16 - Week 52)|Withdrawal by Subject|0
6317599|NCT02757352|10052409|FG004|Double-Blind Period (Week 16 - Week 52)|Withdrawal by Subject|0
6317600|NCT02757352|10052410|FG005|Double-Blind Period (Week 16 - Week 52)|Withdrawal by Subject|0
6317601|NCT02757352|10052411|FG006|Double-Blind Period (Week 16 - Week 52)|Withdrawal by Subject|0
6317602|NCT02757352|10052412|FG007|Double-Blind Period (Week 16 - Week 52)|Withdrawal by Subject|0
6317603|NCT02757352|10052413|FG008|Double-Blind Period (Week 16 - Week 52)|Withdrawal by Subject|0
6317604|NCT02757352|10052414|FG009|Double-Blind Period (Week 16 - Week 52)|Withdrawal by Subject|0
6317605|NCT02757352|10052405|FG000|Double-Blind Period (Week 16 - Week 52)|Classified as Inadequate Responders (IR)|62
6317606|NCT02757352|10052406|FG001|Double-Blind Period (Week 16 - Week 52)|Classified as Inadequate Responders (IR)|40
6317607|NCT02757352|10052407|FG002|Double-Blind Period (Week 16 - Week 52)|Classified as Inadequate Responders (IR)|42
6317608|NCT02757352|10052408|FG003|Double-Blind Period (Week 16 - Week 52)|Classified as Inadequate Responders (IR)|0
6317609|NCT02757352|10052409|FG004|Double-Blind Period (Week 16 - Week 52)|Classified as Inadequate Responders (IR)|0
6317610|NCT02757352|10052410|FG005|Double-Blind Period (Week 16 - Week 52)|Classified as Inadequate Responders (IR)|0
6317611|NCT02757352|10052411|FG006|Double-Blind Period (Week 16 - Week 52)|Classified as Inadequate Responders (IR)|0
6317612|NCT02757352|10052412|FG007|Double-Blind Period (Week 16 - Week 52)|Classified as Inadequate Responders (IR)|0
6040571|NCT01927419|9638545|FG001|Treatment Period|Study drug toxicity|10
6040572|NCT01927419|9638544|FG000|Treatment Period|Death|0
6040573|NCT01927419|9638545|FG001|Treatment Period|Death|1
6317613|NCT02757352|10052413|FG008|Double-Blind Period (Week 16 - Week 52)|Classified as Inadequate Responders (IR)|0
6317614|NCT02757352|10052414|FG009|Double-Blind Period (Week 16 - Week 52)|Classified as Inadequate Responders (IR)|0
6317615|NCT02757352|10052405|FG000|IR-Open Label Period (Week 16 - Week 52)|Adverse Event|0
6317616|NCT02757352|10052406|FG001|IR-Open Label Period (Week 16 - Week 52)|Adverse Event|0
6317617|NCT02757352|10052407|FG002|IR-Open Label Period (Week 16 - Week 52)|Adverse Event|0
6317618|NCT02757352|10052408|FG003|IR-Open Label Period (Week 16 - Week 52)|Adverse Event|3
6317619|NCT02757352|10052409|FG004|IR-Open Label Period (Week 16 - Week 52)|Adverse Event|0
6317620|NCT02757352|10052410|FG005|IR-Open Label Period (Week 16 - Week 52)|Adverse Event|1
6317621|NCT02757352|10052411|FG006|IR-Open Label Period (Week 16 - Week 52)|Adverse Event|0
6317622|NCT02757352|10052412|FG007|IR-Open Label Period (Week 16 - Week 52)|Adverse Event|0
6317623|NCT02757352|10052413|FG008|IR-Open Label Period (Week 16 - Week 52)|Adverse Event|0
6317624|NCT02757352|10052414|FG009|IR-Open Label Period (Week 16 - Week 52)|Adverse Event|0
6317625|NCT02757352|10052405|FG000|IR-Open Label Period (Week 16 - Week 52)|Lack of Efficacy|0
6317626|NCT02757352|10052406|FG001|IR-Open Label Period (Week 16 - Week 52)|Lack of Efficacy|0
6317627|NCT02757352|10052407|FG002|IR-Open Label Period (Week 16 - Week 52)|Lack of Efficacy|0
6317628|NCT02757352|10052408|FG003|IR-Open Label Period (Week 16 - Week 52)|Lack of Efficacy|2
6317629|NCT02757352|10052409|FG004|IR-Open Label Period (Week 16 - Week 52)|Lack of Efficacy|1
6317630|NCT02757352|10052410|FG005|IR-Open Label Period (Week 16 - Week 52)|Lack of Efficacy|4
6317631|NCT02757352|10052411|FG006|IR-Open Label Period (Week 16 - Week 52)|Lack of Efficacy|0
6317632|NCT02757352|10052412|FG007|IR-Open Label Period (Week 16 - Week 52)|Lack of Efficacy|0
6317633|NCT02757352|10052413|FG008|IR-Open Label Period (Week 16 - Week 52)|Lack of Efficacy|0
6317634|NCT02757352|10052414|FG009|IR-Open Label Period (Week 16 - Week 52)|Lack of Efficacy|0
6317635|NCT02757352|10052405|FG000|IR-Open Label Period (Week 16 - Week 52)|Pregnancy|0
6317636|NCT02757352|10052406|FG001|IR-Open Label Period (Week 16 - Week 52)|Pregnancy|0
6317637|NCT02757352|10052407|FG002|IR-Open Label Period (Week 16 - Week 52)|Pregnancy|0
6317638|NCT02757352|10052408|FG003|IR-Open Label Period (Week 16 - Week 52)|Pregnancy|0
6317639|NCT02757352|10052409|FG004|IR-Open Label Period (Week 16 - Week 52)|Pregnancy|1
6317640|NCT02757352|10052410|FG005|IR-Open Label Period (Week 16 - Week 52)|Pregnancy|0
6317641|NCT02757352|10052411|FG006|IR-Open Label Period (Week 16 - Week 52)|Pregnancy|0
6317642|NCT02757352|10052412|FG007|IR-Open Label Period (Week 16 - Week 52)|Pregnancy|0
6317643|NCT02757352|10052413|FG008|IR-Open Label Period (Week 16 - Week 52)|Pregnancy|0
6317644|NCT02757352|10052414|FG009|IR-Open Label Period (Week 16 - Week 52)|Pregnancy|0
6317645|NCT02757352|10052405|FG000|IR-Open Label Period (Week 16 - Week 52)|Physician Decision|0
6317646|NCT02757352|10052406|FG001|IR-Open Label Period (Week 16 - Week 52)|Physician Decision|0
6317647|NCT02757352|10052407|FG002|IR-Open Label Period (Week 16 - Week 52)|Physician Decision|0
6317648|NCT02757352|10052408|FG003|IR-Open Label Period (Week 16 - Week 52)|Physician Decision|0
6317649|NCT02757352|10052409|FG004|IR-Open Label Period (Week 16 - Week 52)|Physician Decision|0
6317650|NCT02757352|10052410|FG005|IR-Open Label Period (Week 16 - Week 52)|Physician Decision|1
6317651|NCT02757352|10052411|FG006|IR-Open Label Period (Week 16 - Week 52)|Physician Decision|0
6317652|NCT02757352|10052412|FG007|IR-Open Label Period (Week 16 - Week 52)|Physician Decision|0
6317653|NCT02757352|10052413|FG008|IR-Open Label Period (Week 16 - Week 52)|Physician Decision|0
6317654|NCT02757352|10052414|FG009|IR-Open Label Period (Week 16 - Week 52)|Physician Decision|0
6317655|NCT02757352|10052405|FG000|IR-Open Label Period (Week 16 - Week 52)|Withdrawal by Subject|0
6317656|NCT02757352|10052406|FG001|IR-Open Label Period (Week 16 - Week 52)|Withdrawal by Subject|0
6317657|NCT02757352|10052407|FG002|IR-Open Label Period (Week 16 - Week 52)|Withdrawal by Subject|0
6317658|NCT02757352|10052408|FG003|IR-Open Label Period (Week 16 - Week 52)|Withdrawal by Subject|2
6317659|NCT02757352|10052409|FG004|IR-Open Label Period (Week 16 - Week 52)|Withdrawal by Subject|1
6317660|NCT02757352|10052410|FG005|IR-Open Label Period (Week 16 - Week 52)|Withdrawal by Subject|1
6317661|NCT02757352|10052411|FG006|IR-Open Label Period (Week 16 - Week 52)|Withdrawal by Subject|0
6317662|NCT02757352|10052412|FG007|IR-Open Label Period (Week 16 - Week 52)|Withdrawal by Subject|0
6317663|NCT02757352|10052413|FG008|IR-Open Label Period (Week 16 - Week 52)|Withdrawal by Subject|0
6317664|NCT02757352|10052414|FG009|IR-Open Label Period (Week 16 - Week 52)|Withdrawal by Subject|0
6317665|NCT02757352|10052405|FG000|Follow-Up Period|Adverse Event|0
6317666|NCT02757352|10052406|FG001|Follow-Up Period|Adverse Event|0
6317667|NCT02757352|10052407|FG002|Follow-Up Period|Adverse Event|0
6317668|NCT02757352|10052408|FG003|Follow-Up Period|Adverse Event|0
6317669|NCT02757352|10052409|FG004|Follow-Up Period|Adverse Event|0
6317670|NCT02757352|10052410|FG005|Follow-Up Period|Adverse Event|0
6317671|NCT02757352|10052411|FG006|Follow-Up Period|Adverse Event|1
6317672|NCT02757352|10052412|FG007|Follow-Up Period|Adverse Event|0
6317673|NCT02757352|10052413|FG008|Follow-Up Period|Adverse Event|2
6317674|NCT02757352|10052414|FG009|Follow-Up Period|Adverse Event|0
6317675|NCT02757352|10052405|FG000|Follow-Up Period|Lost to Follow-up|0
6317676|NCT02757352|10052406|FG001|Follow-Up Period|Lost to Follow-up|0
6317677|NCT02757352|10052407|FG002|Follow-Up Period|Lost to Follow-up|0
6317678|NCT02757352|10052408|FG003|Follow-Up Period|Lost to Follow-up|0
6317679|NCT02757352|10052409|FG004|Follow-Up Period|Lost to Follow-up|0
6317680|NCT02757352|10052410|FG005|Follow-Up Period|Lost to Follow-up|0
6040574|NCT01927419|9638544|FG000|Treatment Period|Adverse event unrelated to study drug|6
6040575|NCT01927419|9638545|FG001|Treatment Period|Adverse event unrelated to study drug|3
6040576|NCT01927419|9638544|FG000|Treatment Period|Participant request to discontinue|12
6317681|NCT02757352|10052411|FG006|Follow-Up Period|Lost to Follow-up|0
6317682|NCT02757352|10052412|FG007|Follow-Up Period|Lost to Follow-up|0
6317683|NCT02757352|10052413|FG008|Follow-Up Period|Lost to Follow-up|1
6317684|NCT02757352|10052414|FG009|Follow-Up Period|Lost to Follow-up|0
6317685|NCT02757352|10052405|FG000|Follow-Up Period|Lack of Efficacy|0
6317686|NCT02757352|10052406|FG001|Follow-Up Period|Lack of Efficacy|0
6317687|NCT02757352|10052407|FG002|Follow-Up Period|Lack of Efficacy|0
6317688|NCT02757352|10052408|FG003|Follow-Up Period|Lack of Efficacy|0
6317689|NCT02757352|10052409|FG004|Follow-Up Period|Lack of Efficacy|0
6317690|NCT02757352|10052410|FG005|Follow-Up Period|Lack of Efficacy|0
6317691|NCT02757352|10052411|FG006|Follow-Up Period|Lack of Efficacy|0
6317692|NCT02757352|10052412|FG007|Follow-Up Period|Lack of Efficacy|0
6317693|NCT02757352|10052413|FG008|Follow-Up Period|Lack of Efficacy|1
6317694|NCT02757352|10052414|FG009|Follow-Up Period|Lack of Efficacy|1
6317695|NCT02757352|10052405|FG000|Follow-Up Period|Withdrawal by Subject|0
6317696|NCT02757352|10052406|FG001|Follow-Up Period|Withdrawal by Subject|0
6317697|NCT02757352|10052407|FG002|Follow-Up Period|Withdrawal by Subject|0
6317698|NCT02757352|10052408|FG003|Follow-Up Period|Withdrawal by Subject|0
6317699|NCT02757352|10052409|FG004|Follow-Up Period|Withdrawal by Subject|0
6317700|NCT02757352|10052410|FG005|Follow-Up Period|Withdrawal by Subject|0
6317701|NCT02757352|10052411|FG006|Follow-Up Period|Withdrawal by Subject|0
6317702|NCT02757352|10052412|FG007|Follow-Up Period|Withdrawal by Subject|1
6317703|NCT02757352|10052413|FG008|Follow-Up Period|Withdrawal by Subject|6
6317704|NCT02757352|10052414|FG009|Follow-Up Period|Withdrawal by Subject|2
6317705|NCT02757430|10052445|FG000|Overall Study|Physician Decision|6
6317706|NCT02757430|10052445|FG000|Overall Study|Inclusion/Exclusion criteria not met|3
6317707|NCT02757430|10052445|FG000|Overall Study|No informed consent|1
6317708|NCT02757430|10052445|FG000|Overall Study|No procedure performed|2
6317709|NCT02757625|10052462|FG000|Overall Study|Investigator's discretion|0
6317710|NCT02757625|10052463|FG001|Overall Study|Investigator's discretion|0
6317711|NCT02757625|10052464|FG002|Overall Study|Investigator's discretion|1
6317712|NCT02757625|10052465|FG003|Overall Study|Investigator's discretion|0
6317713|NCT02757625|10052462|FG000|Overall Study|Adverse Event|0
6317714|NCT02757625|10052463|FG001|Overall Study|Adverse Event|0
6317715|NCT02757625|10052464|FG002|Overall Study|Adverse Event|1
6317716|NCT02757625|10052465|FG003|Overall Study|Adverse Event|0
6317717|NCT02757768|10052479|FG000|Overall Study|Randomized Never Received Study Drug|3
6317718|NCT02757768|10052480|FG001|Overall Study|Randomized Never Received Study Drug|4
6317719|NCT02757768|10052479|FG000|Overall Study|Adverse Event|5
6317720|NCT02757768|10052480|FG001|Overall Study|Adverse Event|3
6317721|NCT02757768|10052479|FG000|Overall Study|Lack of Efficacy|2
6317722|NCT02757768|10052480|FG001|Overall Study|Lack of Efficacy|1
6317723|NCT02757768|10052479|FG000|Overall Study|Lost to Follow-up|1
6317724|NCT02757768|10052480|FG001|Overall Study|Lost to Follow-up|0
6317725|NCT02757768|10052479|FG000|Overall Study|Protocol Deviation|2
6317726|NCT02757768|10052480|FG001|Overall Study|Protocol Deviation|9
6317727|NCT02757768|10052479|FG000|Overall Study|Withdrawal by Subject|16
6317728|NCT02757768|10052480|FG001|Overall Study|Withdrawal by Subject|9
6317729|NCT02757768|10052479|FG000|Overall Study|Miscellaneous|4
6317730|NCT02757768|10052480|FG001|Overall Study|Miscellaneous|2
6317731|NCT02757963|10052498|FG000|Overall Study|Adverse Event|3
6317732|NCT02757963|10052498|FG000|Overall Study|Reached Stopping Criteria|1054
6317733|NCT02757963|10052498|FG000|Overall Study|Lost to Follow-up|5
6317734|NCT02757963|10052498|FG000|Overall Study|Physician Decision|1
6317735|NCT02757963|10052498|FG000|Overall Study|Withdrawal by Subject|34
6317736|NCT02758171|10052526|FG000|Wash-out|Withdrawal by Subject|1
6317737|NCT02758171|10052527|FG001|Wash-out|Withdrawal by Subject|0
6317738|NCT02758171|10052526|FG000|Wash-out|Other reason|1
6317739|NCT02758171|10052527|FG001|Wash-out|Other reason|0
6317740|NCT02758301|10052539|FG000|Overall Study|Death|12
6317741|NCT02758301|10052540|FG001|Overall Study|Death|0
6317742|NCT02758301|10052539|FG000|Overall Study|Physician Decision|10
6317743|NCT02758301|10052540|FG001|Overall Study|Physician Decision|1
6317744|NCT02758301|10052539|FG000|Overall Study|Withdrawal by Subject|5
6317745|NCT02758301|10052540|FG001|Overall Study|Withdrawal by Subject|6
6317746|NCT02758301|10052539|FG000|Overall Study|Lost to Follow-up|7
6317747|NCT02758301|10052540|FG001|Overall Study|Lost to Follow-up|0
6317748|NCT02758301|10052539|FG000|Overall Study|Protocol Violation|0
6317749|NCT02758301|10052540|FG001|Overall Study|Protocol Violation|1
6317750|NCT02758613|10052550|FG000|Treatment|Physician and Sponsor Decision|1
6317751|NCT02758613|10052551|FG001|Treatment|Physician and Sponsor Decision|0
6317752|NCT02758613|10052552|FG002|Treatment|Physician and Sponsor Decision|0
6317753|NCT02758613|10052553|FG003|Treatment|Physician and Sponsor Decision|0
6317754|NCT02758613|10052550|FG000|Treatment|Withdrawal by Subject|1
6317755|NCT02758613|10052551|FG001|Treatment|Withdrawal by Subject|0
6317756|NCT02758613|10052552|FG002|Treatment|Withdrawal by Subject|1
6317757|NCT02758613|10052553|FG003|Treatment|Withdrawal by Subject|0
6317758|NCT02759016|10052577|FG000|Overall Study|Not treated with BI 836826|1
6317759|NCT02759016|10052578|FG001|Overall Study|Not treated with BI 836826|0
6317760|NCT02759016|10052577|FG000|Overall Study|Progressive disease|1
6317761|NCT02759016|10052578|FG001|Overall Study|Progressive disease|0
6317762|NCT02759016|10052577|FG000|Overall Study|SD, PR-MRDpos or PR-L|0
6317763|NCT02759016|10052578|FG001|Overall Study|SD, PR-MRDpos or PR-L|2
6317764|NCT02759016|10052577|FG000|Overall Study|Other not defined above|2
6317765|NCT02759016|10052578|FG001|Overall Study|Other not defined above|1
6317766|NCT02759055|10052587|FG000|Overall Study|Patients with no follow-up visit and/or age 18-39 were not included in analyses.|1927
6317767|NCT02759055|10052588|FG001|Overall Study|Patients with no follow-up visit and/or age 18-39 were not included in analyses.|1508
6317768|NCT02759120|10052596|FG000|Overall Study|Death|34
6317769|NCT02759120|10052597|FG001|Overall Study|Death|36
6317770|NCT02759120|10052596|FG000|Overall Study|Lost to Follow-up|4
6317771|NCT02759120|10052597|FG001|Overall Study|Lost to Follow-up|7
6317772|NCT02759120|10052596|FG000|Overall Study|Physician Decision|3
6317773|NCT02759120|10052597|FG001|Overall Study|Physician Decision|0
6317774|NCT02759120|10052596|FG000|Overall Study|Withdrawal by Subject|28
6317775|NCT02759120|10052597|FG001|Overall Study|Withdrawal by Subject|15
6317776|NCT02759120|10052596|FG000|Overall Study|Moved out of area|3
6317777|NCT02759120|10052597|FG001|Overall Study|Moved out of area|4
6317778|NCT02759120|10052596|FG000|Overall Study|Lung transplant|3
6317779|NCT02759120|10052597|FG001|Overall Study|Lung transplant|5
6317780|NCT02759120|10052596|FG000|Overall Study|Other reason not completed|10
6317781|NCT02759120|10052597|FG001|Overall Study|Other reason not completed|12
6317782|NCT02759315|10052636|FG000|Overall Study|Adverse Event|0
6317783|NCT02759315|10052637|FG001|Overall Study|Adverse Event|0
6317784|NCT02759315|10052638|FG002|Overall Study|Adverse Event|0
6317785|NCT02759315|10052639|FG003|Overall Study|Adverse Event|1
6317786|NCT02759315|10052640|FG004|Overall Study|Adverse Event|0
6317787|NCT02759315|10052636|FG000|Overall Study|Death|0
6317788|NCT02759315|10052637|FG001|Overall Study|Death|0
6317789|NCT02759315|10052638|FG002|Overall Study|Death|1
6317790|NCT02759315|10052639|FG003|Overall Study|Death|0
6317791|NCT02759315|10052640|FG004|Overall Study|Death|0
6317792|NCT02759315|10052636|FG000|Overall Study|Lost to Follow-up|2
6317793|NCT02759315|10052637|FG001|Overall Study|Lost to Follow-up|0
6317794|NCT02759315|10052638|FG002|Overall Study|Lost to Follow-up|4
6317795|NCT02759315|10052639|FG003|Overall Study|Lost to Follow-up|0
6317796|NCT02759315|10052640|FG004|Overall Study|Lost to Follow-up|0
6317797|NCT02759315|10052636|FG000|Overall Study|Protocol Violation|0
6317798|NCT02759315|10052637|FG001|Overall Study|Protocol Violation|1
6317799|NCT02759315|10052638|FG002|Overall Study|Protocol Violation|0
6317800|NCT02759315|10052639|FG003|Overall Study|Protocol Violation|0
6317801|NCT02759315|10052640|FG004|Overall Study|Protocol Violation|0
6317802|NCT02759315|10052636|FG000|Overall Study|Study terminated prior to completion|2
6317803|NCT02759315|10052637|FG001|Overall Study|Study terminated prior to completion|0
6317804|NCT02759315|10052638|FG002|Overall Study|Study terminated prior to completion|5
6317805|NCT02759315|10052639|FG003|Overall Study|Study terminated prior to completion|0
6317806|NCT02759315|10052640|FG004|Overall Study|Study terminated prior to completion|1
6317807|NCT02759471|10052673|FG000|Overall Study|discomfort|2
6317808|NCT02759562|10052681|FG000|Open-Label Treatment Period|Withdrew Consent|1
6317809|NCT02759562|10052682|FG001|Open-Label Treatment Period|Withdrew Consent|0
6317810|NCT02759562|10052681|FG000|Open-Label Treatment Period|Study Terminated by Sponsor|1
6317811|NCT02759562|10052682|FG001|Open-Label Treatment Period|Study Terminated by Sponsor|2
6317812|NCT02759692|10052693|FG000|Period 1|Test article no longer available|1
6317813|NCT02759692|10052694|FG001|Period 1|Test article no longer available|1
6317814|NCT02759692|10052693|FG000|Period 1|No longer meets eligibility criteria.|1
6317815|NCT02759692|10052694|FG001|Period 1|No longer meets eligibility criteria.|0
6317816|NCT02759692|10052693|FG000|Period 1|Miss-Randomized|1
6317817|NCT02759692|10052694|FG001|Period 1|Miss-Randomized|1
6317818|NCT02759692|10052693|FG000|Period 2|Lost to Follow-up|1
6317819|NCT02759692|10052694|FG001|Period 2|Lost to Follow-up|0
6317820|NCT02759692|10052693|FG000|Period 2|Test article no longer available|0
6317821|NCT02759692|10052694|FG001|Period 2|Test article no longer available|1
6317822|NCT02759939|10052704|FG000|Overall Study|Missing data on first outcome assessed|11
6317823|NCT02759939|10052705|FG001|Overall Study|Missing data on first outcome assessed|2
6317824|NCT02759939|10052706|FG002|Overall Study|Missing data on first outcome assessed|5
6317825|NCT02759939|10052707|FG003|Overall Study|Missing data on first outcome assessed|2
6317826|NCT02759939|10052704|FG000|Overall Study|Ineligible for T2 and T3|310
6317827|NCT02759939|10052705|FG001|Overall Study|Ineligible for T2 and T3|179
6317828|NCT02759939|10052706|FG002|Overall Study|Ineligible for T2 and T3|366
6317829|NCT02759939|10052707|FG003|Overall Study|Ineligible for T2 and T3|391
6317830|NCT02759939|10052704|FG000|Overall Study|Lost to Follow-up|735
6317831|NCT02759939|10052705|FG001|Overall Study|Lost to Follow-up|791
6317832|NCT02759939|10052706|FG002|Overall Study|Lost to Follow-up|783
6317833|NCT02759939|10052707|FG003|Overall Study|Lost to Follow-up|650
6317834|NCT02760069|10052730|FG000|Overall Study|Withdrawal by Subject|0
6317835|NCT02760069|10052731|FG001|Overall Study|Withdrawal by Subject|1
6317836|NCT02760069|10052732|FG002|Overall Study|Withdrawal by Subject|1
6317837|NCT02760368|10052778|FG000|Overall Study|Withdrawal by Subject|12
6317838|NCT02760368|10052779|FG001|Overall Study|Withdrawal by Subject|8
6317839|NCT02760368|10052780|FG002|Overall Study|Withdrawal by Subject|9
6317840|NCT02760368|10052778|FG000|Overall Study|Screen Failure|0
6317841|NCT02760368|10052779|FG001|Overall Study|Screen Failure|0
6317842|NCT02760368|10052780|FG002|Overall Study|Screen Failure|1
6317843|NCT02760368|10052778|FG000|Overall Study|Death|1
6317844|NCT02760368|10052779|FG001|Overall Study|Death|0
6317845|NCT02760368|10052780|FG002|Overall Study|Death|0
6317846|NCT02760368|10052778|FG000|Overall Study|Withdrawal by Sponsor|0
6317847|NCT02760368|10052779|FG001|Overall Study|Withdrawal by Sponsor|0
6317848|NCT02760368|10052780|FG002|Overall Study|Withdrawal by Sponsor|1
6317849|NCT02760407|10052792|FG000|Overall Study|Death|2
6317850|NCT02760407|10052793|FG001|Overall Study|Death|3
6317851|NCT02760407|10052794|FG002|Overall Study|Death|1
6317852|NCT02760407|10052795|FG003|Overall Study|Death|1
6317853|NCT02760407|10052792|FG000|Overall Study|Lost to Follow-up|1
6317854|NCT02760407|10052793|FG001|Overall Study|Lost to Follow-up|7
6317855|NCT02760407|10052794|FG002|Overall Study|Lost to Follow-up|4
6317856|NCT02760407|10052795|FG003|Overall Study|Lost to Follow-up|6
6317857|NCT02760407|10052792|FG000|Overall Study|Withdrawal by Subject|25
6317858|NCT02760407|10052793|FG001|Overall Study|Withdrawal by Subject|31
6317859|NCT02760407|10052794|FG002|Overall Study|Withdrawal by Subject|37
6317860|NCT02760407|10052795|FG003|Overall Study|Withdrawal by Subject|25
6317861|NCT02760407|10052792|FG000|Overall Study|Violation of Eligibility criteria|0
6317862|NCT02760407|10052793|FG001|Overall Study|Violation of Eligibility criteria|0
6317863|NCT02760407|10052794|FG002|Overall Study|Violation of Eligibility criteria|1
6317864|NCT02760407|10052795|FG003|Overall Study|Violation of Eligibility criteria|1
6317865|NCT02760407|10052792|FG000|Overall Study|Personal reasons|0
6317866|NCT02760407|10052793|FG001|Overall Study|Personal reasons|0
6317867|NCT02760407|10052794|FG002|Overall Study|Personal reasons|0
6317868|NCT02760407|10052795|FG003|Overall Study|Personal reasons|1
6317869|NCT02760407|10052792|FG000|Overall Study|The subject was early discontinued due to lab Adverse Event as per Investigator's decision|1
6317870|NCT02760407|10052793|FG001|Overall Study|The subject was early discontinued due to lab Adverse Event as per Investigator's decision|0
6317871|NCT02760407|10052794|FG002|Overall Study|The subject was early discontinued due to lab Adverse Event as per Investigator's decision|0
6317872|NCT02760407|10052795|FG003|Overall Study|The subject was early discontinued due to lab Adverse Event as per Investigator's decision|0
6317873|NCT02760407|10052792|FG000|Overall Study|Use of prohibited Medication|0
6317874|NCT02760407|10052793|FG001|Overall Study|Use of prohibited Medication|0
6317875|NCT02760407|10052794|FG002|Overall Study|Use of prohibited Medication|1
6317876|NCT02760407|10052795|FG003|Overall Study|Use of prohibited Medication|0
6317877|NCT02760407|10052792|FG000|Overall Study|Subject didn't Completed Visits Schedule After Serious Adverse Event|0
6317878|NCT02760407|10052793|FG001|Overall Study|Subject didn't Completed Visits Schedule After Serious Adverse Event|0
6317879|NCT02760407|10052794|FG002|Overall Study|Subject didn't Completed Visits Schedule After Serious Adverse Event|1
6317880|NCT02760407|10052795|FG003|Overall Study|Subject didn't Completed Visits Schedule After Serious Adverse Event|0
6317881|NCT02760407|10052792|FG000|Overall Study|Positive Quantiferon Testing, Patient Was Not Taken Prophylactic Medication|1
6317882|NCT02760407|10052793|FG001|Overall Study|Positive Quantiferon Testing, Patient Was Not Taken Prophylactic Medication|0
6317883|NCT02760407|10052794|FG002|Overall Study|Positive Quantiferon Testing, Patient Was Not Taken Prophylactic Medication|0
6317884|NCT02760407|10052795|FG003|Overall Study|Positive Quantiferon Testing, Patient Was Not Taken Prophylactic Medication|0
6317885|NCT02760407|10052792|FG000|Overall Study|Investigator's Decision (Adverse Event)|0
6317886|NCT02760407|10052793|FG001|Overall Study|Investigator's Decision (Adverse Event)|1
6317887|NCT02760407|10052794|FG002|Overall Study|Investigator's Decision (Adverse Event)|0
6317888|NCT02760407|10052795|FG003|Overall Study|Investigator's Decision (Adverse Event)|0
6317889|NCT02760407|10052792|FG000|Overall Study|Inadequately Enrolled|0
6317890|NCT02760407|10052793|FG001|Overall Study|Inadequately Enrolled|0
6317891|NCT02760407|10052794|FG002|Overall Study|Inadequately Enrolled|0
6317892|NCT02760407|10052795|FG003|Overall Study|Inadequately Enrolled|1
6317893|NCT02760407|10052792|FG000|Overall Study|Withdrawal By PI's Decision|0
6317894|NCT02760407|10052793|FG001|Overall Study|Withdrawal By PI's Decision|1
6317895|NCT02760407|10052794|FG002|Overall Study|Withdrawal By PI's Decision|0
6317896|NCT02760407|10052795|FG003|Overall Study|Withdrawal By PI's Decision|0
6317897|NCT02760407|10052792|FG000|Overall Study|Subject Did not attend treatment period visits due to misunderstanding of protocol|1
6317898|NCT02760407|10052793|FG001|Overall Study|Subject Did not attend treatment period visits due to misunderstanding of protocol|0
6317899|NCT02760407|10052794|FG002|Overall Study|Subject Did not attend treatment period visits due to misunderstanding of protocol|1
6317900|NCT02760407|10052795|FG003|Overall Study|Subject Did not attend treatment period visits due to misunderstanding of protocol|0
6317901|NCT02760407|10052792|FG000|Overall Study|Subject met permanent IP discontinuation criteria, did not agree for treatment period visits|0
6317902|NCT02760407|10052793|FG001|Overall Study|Subject met permanent IP discontinuation criteria, did not agree for treatment period visits|0
6317903|NCT02760407|10052794|FG002|Overall Study|Subject met permanent IP discontinuation criteria, did not agree for treatment period visits|1
6317904|NCT02760407|10052795|FG003|Overall Study|Subject met permanent IP discontinuation criteria, did not agree for treatment period visits|0
6317905|NCT02760407|10052792|FG000|Overall Study|Investigator recorded as Sponsor's decision - decreased lymphocyte level|1
6317906|NCT02760407|10052793|FG001|Overall Study|Investigator recorded as Sponsor's decision - decreased lymphocyte level|0
6317907|NCT02760407|10052794|FG002|Overall Study|Investigator recorded as Sponsor's decision - decreased lymphocyte level|0
6317908|NCT02760407|10052795|FG003|Overall Study|Investigator recorded as Sponsor's decision - decreased lymphocyte level|0
6317909|NCT02760407|10052792|FG000|Overall Study|Study Treatment Was Terminated At The Site|0
6317910|NCT02760407|10052793|FG001|Overall Study|Study Treatment Was Terminated At The Site|0
6317911|NCT02760407|10052794|FG002|Overall Study|Study Treatment Was Terminated At The Site|1
6317912|NCT02760407|10052795|FG003|Overall Study|Study Treatment Was Terminated At The Site|0
6317913|NCT02760407|10052792|FG000|Overall Study|Subject Taken Out Of Study Due To Sponsor Investigating Investigational Product.|1
6317914|NCT02760407|10052793|FG001|Overall Study|Subject Taken Out Of Study Due To Sponsor Investigating Investigational Product.|0
6317915|NCT02760407|10052794|FG002|Overall Study|Subject Taken Out Of Study Due To Sponsor Investigating Investigational Product.|0
6317916|NCT02760407|10052795|FG003|Overall Study|Subject Taken Out Of Study Due To Sponsor Investigating Investigational Product.|0
6317917|NCT02760407|10052792|FG000|Overall Study|Inadequately enrolled patient refused to Follow-Up|1
6317918|NCT02760407|10052793|FG001|Overall Study|Inadequately enrolled patient refused to Follow-Up|0
6317919|NCT02760407|10052794|FG002|Overall Study|Inadequately enrolled patient refused to Follow-Up|0
6317920|NCT02760407|10052795|FG003|Overall Study|Inadequately enrolled patient refused to Follow-Up|0
6317921|NCT02760407|10052792|FG000|Overall Study|Lack Of Efficacy Per PI|0
6317922|NCT02760407|10052793|FG001|Overall Study|Lack Of Efficacy Per PI|0
6317923|NCT02760407|10052794|FG002|Overall Study|Lack Of Efficacy Per PI|0
6317924|NCT02760407|10052795|FG003|Overall Study|Lack Of Efficacy Per PI|1
6317925|NCT02760407|10052792|FG000|Overall Study|Patient had an upper respiratory infection and took medication that was not allowed|1
6317926|NCT02760407|10052793|FG001|Overall Study|Patient had an upper respiratory infection and took medication that was not allowed|0
6317927|NCT02760407|10052794|FG002|Overall Study|Patient had an upper respiratory infection and took medication that was not allowed|0
6317928|NCT02760407|10052795|FG003|Overall Study|Patient had an upper respiratory infection and took medication that was not allowed|0
6317929|NCT02760407|10052792|FG000|Overall Study|Investigator recorded as Adverse Event|1
6317930|NCT02760407|10052793|FG001|Overall Study|Investigator recorded as Adverse Event|0
6317931|NCT02760407|10052794|FG002|Overall Study|Investigator recorded as Adverse Event|2
6317932|NCT02760407|10052795|FG003|Overall Study|Investigator recorded as Adverse Event|0
6317933|NCT02760433|10052811|FG000|Overall Study|Lost to Follow-up|1
6317934|NCT02760433|10052812|FG001|Overall Study|Lost to Follow-up|0
6317935|NCT02760433|10052813|FG002|Overall Study|Lost to Follow-up|1
6317936|NCT02760433|10052814|FG003|Overall Study|Lost to Follow-up|0
6317937|NCT02760433|10052815|FG004|Overall Study|Lost to Follow-up|0
6317938|NCT02760433|10052811|FG000|Overall Study|Withdrawal by Subject|23
6317939|NCT02760433|10052812|FG001|Overall Study|Withdrawal by Subject|9
6317940|NCT02760433|10052813|FG002|Overall Study|Withdrawal by Subject|0
6317941|NCT02760433|10052814|FG003|Overall Study|Withdrawal by Subject|2
6317942|NCT02760433|10052815|FG004|Overall Study|Withdrawal by Subject|9
6317943|NCT02760433|10052811|FG000|Overall Study|Lack of Response At Week 14|0
6317944|NCT02760433|10052812|FG001|Overall Study|Lack of Response At Week 14|0
6317945|NCT02760433|10052813|FG002|Overall Study|Lack of Response At Week 14|0
6317946|NCT02760433|10052814|FG003|Overall Study|Lack of Response At Week 14|0
6317947|NCT02760433|10052815|FG004|Overall Study|Lack of Response At Week 14|1
6317948|NCT02760433|10052811|FG000|Overall Study|Subject refused to continue the study|1
6317949|NCT02760433|10052812|FG001|Overall Study|Subject refused to continue the study|0
6317950|NCT02760433|10052813|FG002|Overall Study|Subject refused to continue the study|0
6317951|NCT02760433|10052814|FG003|Overall Study|Subject refused to continue the study|0
6317952|NCT02760433|10052815|FG004|Overall Study|Subject refused to continue the study|0
6317953|NCT02760433|10052811|FG000|Overall Study|Subject was taking prohibited medications and refused to stop.|2
6317954|NCT02760433|10052812|FG001|Overall Study|Subject was taking prohibited medications and refused to stop.|0
6317955|NCT02760433|10052813|FG002|Overall Study|Subject was taking prohibited medications and refused to stop.|0
6317956|NCT02760433|10052814|FG003|Overall Study|Subject was taking prohibited medications and refused to stop.|0
6317957|NCT02760433|10052815|FG004|Overall Study|Subject was taking prohibited medications and refused to stop.|0
6317958|NCT02760433|10052811|FG000|Overall Study|Ongoing Adverse Events (low platelet count) with long interruptions of investigational product|0
6317959|NCT02760433|10052812|FG001|Overall Study|Ongoing Adverse Events (low platelet count) with long interruptions of investigational product|1
6040577|NCT01927419|9638545|FG001|Treatment Period|Participant request to discontinue|4
6040578|NCT01927419|9638544|FG000|Treatment Period|Withdrawal by Subject|1
6040579|NCT01927419|9638545|FG001|Treatment Period|Withdrawal by Subject|1
6040580|NCT01927419|9638544|FG000|Treatment Period|Maximum Clinical Benefit|6
6040581|NCT01927419|9638545|FG001|Treatment Period|Maximum Clinical Benefit|2
6040582|NCT01927419|9638544|FG000|Treatment Period|Other reasons|3
6040583|NCT01927419|9638545|FG001|Treatment Period|Other reasons|4
6040584|NCT01927419|9638544|FG000|Treatment Period|Not Reported|1
6040585|NCT01927419|9638545|FG001|Treatment Period|Not Reported|1
6317960|NCT02760433|10052813|FG002|Overall Study|Ongoing Adverse Events (low platelet count) with long interruptions of investigational product|0
6317961|NCT02760433|10052814|FG003|Overall Study|Ongoing Adverse Events (low platelet count) with long interruptions of investigational product|0
6317962|NCT02760433|10052815|FG004|Overall Study|Ongoing Adverse Events (low platelet count) with long interruptions of investigational product|0
6317963|NCT02760654|10052834|FG000|Overall Study|Lost to Follow-up|3
6317964|NCT02760654|10052835|FG001|Overall Study|Lost to Follow-up|3
6317965|NCT02760654|10052834|FG000|Overall Study|Withdrawal by Subject|4
6317966|NCT02760654|10052835|FG001|Overall Study|Withdrawal by Subject|3
6317967|NCT02760810|10052841|FG000|Overall Study|Protocol Violation|1
6317968|NCT02760927|10052854|FG000|Overall Study|Tube Slippage from Device|1
6040586|NCT01924533|9638553|FG000|Overall Study|Death|181
6317969|NCT02761330|10052873|FG000|Treatment Week 1|Withdrawal by Subject|0
6317970|NCT02761330|10052874|FG001|Treatment Week 1|Withdrawal by Subject|0
6317971|NCT02761330|10052875|FG002|Treatment Week 1|Withdrawal by Subject|0
6317972|NCT02761330|10052876|FG003|Treatment Week 1|Withdrawal by Subject|1
6317973|NCT02761330|10052877|FG004|Treatment Week 1|Withdrawal by Subject|0
6317974|NCT02761330|10052878|FG005|Treatment Week 1|Withdrawal by Subject|1
6317975|NCT02761629|10052894|FG000|Overall Study|Adverse Event/Intercurrent Illness|7
6317976|NCT02761629|10052895|FG001|Overall Study|Adverse Event/Intercurrent Illness|5
6317977|NCT02761629|10052894|FG000|Overall Study|Insufficient Therapeutic Response|2
6317978|NCT02761629|10052895|FG001|Overall Study|Insufficient Therapeutic Response|7
6317979|NCT02761629|10052894|FG000|Overall Study|Failure to Return|2
6317980|NCT02761629|10052895|FG001|Overall Study|Failure to Return|4
6317981|NCT02761629|10052894|FG000|Overall Study|Did not Cooperate/Refused Treatment|2
6317982|NCT02761629|10052895|FG001|Overall Study|Did not Cooperate/Refused Treatment|4
6317983|NCT02761629|10052894|FG000|Overall Study|Protocol Violation|2
6317984|NCT02761629|10052895|FG001|Overall Study|Protocol Violation|2
6317985|NCT02761629|10052894|FG000|Overall Study|Withdrawal by Subject|0
6317986|NCT02761629|10052895|FG001|Overall Study|Withdrawal by Subject|3
6317987|NCT02761629|10052894|FG000|Overall Study|Other|0
6317988|NCT02761629|10052895|FG001|Overall Study|Other|2
6317989|NCT02761629|10052894|FG000|Overall Study|Lost to Follow-up|4
6317990|NCT02761629|10052895|FG001|Overall Study|Lost to Follow-up|1
6317991|NCT02761629|10052894|FG000|Overall Study|Randomized But Not Treated|8
6317992|NCT02761629|10052895|FG001|Overall Study|Randomized But Not Treated|4
6317993|NCT02761642|10052901|FG000|Overall Study|Did not Receive Study Treatment|3
6317994|NCT02761642|10052901|FG000|Overall Study|Adverse Event|13
6317995|NCT02761642|10052901|FG000|Overall Study|Withdrawal by Subject|2
6317996|NCT02761642|10052901|FG000|Overall Study|Non-compliant|7
6317997|NCT02761642|10052901|FG000|Overall Study|Death|3
6317998|NCT02761642|10052901|FG000|Overall Study|Lack of Efficacy|20
6317999|NCT02761642|10052901|FG000|Overall Study|Physician Decision|1
6318000|NCT02761642|10052901|FG000|Overall Study|Reason Unspecified|21
6318001|NCT02761733|10052909|FG000|Overall Study|Death|3
6318002|NCT02761733|10052910|FG001|Overall Study|Death|5
6318003|NCT02761733|10052911|FG002|Overall Study|Death|1
6318004|NCT02761733|10052912|FG003|Overall Study|Death|1
6318005|NCT02761733|10052909|FG000|Overall Study|Lost to Follow-up|6
6318006|NCT02761733|10052910|FG001|Overall Study|Lost to Follow-up|7
6318007|NCT02761733|10052911|FG002|Overall Study|Lost to Follow-up|0
6318008|NCT02761733|10052912|FG003|Overall Study|Lost to Follow-up|3
6318009|NCT02761733|10052909|FG000|Overall Study|Physician Decision|4
6318010|NCT02761733|10052910|FG001|Overall Study|Physician Decision|0
6318011|NCT02761733|10052911|FG002|Overall Study|Physician Decision|0
6318012|NCT02761733|10052912|FG003|Overall Study|Physician Decision|0
6318013|NCT02761733|10052909|FG000|Overall Study|Withdrawal by Subject|2
6318014|NCT02761733|10052910|FG001|Overall Study|Withdrawal by Subject|0
6318015|NCT02761733|10052911|FG002|Overall Study|Withdrawal by Subject|0
6318016|NCT02761733|10052912|FG003|Overall Study|Withdrawal by Subject|0
6318017|NCT02761733|10052909|FG000|Overall Study|Discharged from Study Site|10
6318018|NCT02761733|10052910|FG001|Overall Study|Discharged from Study Site|9
6318019|NCT02761733|10052911|FG002|Overall Study|Discharged from Study Site|25
6318020|NCT02761733|10052912|FG003|Overall Study|Discharged from Study Site|11
6318021|NCT02761733|10052909|FG000|Overall Study|Cognitive Impairment|5
6318022|NCT02761733|10052910|FG001|Overall Study|Cognitive Impairment|0
6318023|NCT02761733|10052911|FG002|Overall Study|Cognitive Impairment|1
6318024|NCT02761733|10052912|FG003|Overall Study|Cognitive Impairment|0
6318025|NCT02761915|10052928|FG000|Overall Study|Death|3
6318026|NCT02761915|10052929|FG001|Overall Study|Death|1
6318027|NCT02761915|10052930|FG002|Overall Study|Death|1
6318028|NCT02761915|10052931|FG003|Overall Study|Death|1
6318029|NCT02761915|10052932|FG004|Overall Study|Death|0
6040587|NCT01924533|9638554|FG001|Overall Study|Death|200
6040588|NCT01924533|9638553|FG000|Overall Study|Lost to Follow-up|0
6040589|NCT01924533|9638554|FG001|Overall Study|Lost to Follow-up|1
6040590|NCT01924533|9638553|FG000|Overall Study|Withdrawal by Subject|7
6040591|NCT01924533|9638554|FG001|Overall Study|Withdrawal by Subject|3
6040592|NCT01924533|9638553|FG000|Overall Study|Other Eligibility criteria|1
6040593|NCT01924533|9638554|FG001|Overall Study|Other Eligibility criteria|1
6040594|NCT01711879|9638580|FG000|Overall Study|Death|1
6040595|NCT01711879|9638581|FG001|Overall Study|Death|0
6040596|NCT01697267|9638591|FG000|Overall Study|Death|3
6040597|NCT01697267|9638592|FG001|Overall Study|Death|1
6040598|NCT01697267|9638591|FG000|Overall Study|Withdrawal by Subject|5
6040599|NCT01697267|9638592|FG001|Overall Study|Withdrawal by Subject|5
6040600|NCT01697267|9638591|FG000|Overall Study|Adverse Event|2
6150698|NCT01106651|9787033|FG001|Overall Study|Death|3
6150699|NCT01106651|9787034|FG002|Overall Study|Death|0
6150700|NCT01106677|9787049|FG000|Core Period: Baseline to Week 26|Adverse Event|7
6318030|NCT02761915|10052933|FG005|Overall Study|Death|1
6150701|NCT01106677|9787050|FG001|Core Period: Baseline to Week 26|Adverse Event|18
6318031|NCT02761915|10052928|FG000|Overall Study|Withdrawal by Subject|1
6318032|NCT02761915|10052929|FG001|Overall Study|Withdrawal by Subject|0
6318033|NCT02761915|10052930|FG002|Overall Study|Withdrawal by Subject|0
6318034|NCT02761915|10052931|FG003|Overall Study|Withdrawal by Subject|0
6318035|NCT02761915|10052932|FG004|Overall Study|Withdrawal by Subject|1
6150702|NCT01106677|9787051|FG002|Core Period: Baseline to Week 26|Adverse Event|6
6150703|NCT01106677|9787052|FG003|Core Period: Baseline to Week 26|Adverse Event|8
6150704|NCT01106677|9787049|FG000|Core Period: Baseline to Week 26|Death|0
6150705|NCT01106677|9787050|FG001|Core Period: Baseline to Week 26|Death|0
6318036|NCT02761915|10052933|FG005|Overall Study|Withdrawal by Subject|2
6318037|NCT02761915|10052928|FG000|Overall Study|Disease Progression|0
6318038|NCT02761915|10052929|FG001|Overall Study|Disease Progression|0
6318039|NCT02761915|10052930|FG002|Overall Study|Disease Progression|0
6318040|NCT02761915|10052931|FG003|Overall Study|Disease Progression|2
6318041|NCT02761915|10052932|FG004|Overall Study|Disease Progression|2
6318042|NCT02761915|10052933|FG005|Overall Study|Disease Progression|2
6318043|NCT02761980|10052967|FG000|Overall Study|Adverse Event|4
6150706|NCT01106677|9787051|FG002|Core Period: Baseline to Week 26|Death|1
6150707|NCT01106677|9787052|FG003|Core Period: Baseline to Week 26|Death|0
6150708|NCT01106677|9787049|FG000|Core Period: Baseline to Week 26|Lack of Efficacy|1
6150709|NCT01106677|9787050|FG001|Core Period: Baseline to Week 26|Lack of Efficacy|0
6150710|NCT01106677|9787051|FG002|Core Period: Baseline to Week 26|Lack of Efficacy|0
6150711|NCT01106677|9787052|FG003|Core Period: Baseline to Week 26|Lack of Efficacy|0
6150712|NCT01106677|9787049|FG000|Core Period: Baseline to Week 26|Lost to Follow-up|3
6150713|NCT01106677|9787050|FG001|Core Period: Baseline to Week 26|Lost to Follow-up|1
6150714|NCT01106677|9787051|FG002|Core Period: Baseline to Week 26|Lost to Follow-up|6
6150715|NCT01106677|9787052|FG003|Core Period: Baseline to Week 26|Lost to Follow-up|3
6150716|NCT01106677|9787049|FG000|Core Period: Baseline to Week 26|Physician Decision|2
6150717|NCT01106677|9787050|FG001|Core Period: Baseline to Week 26|Physician Decision|1
6150718|NCT01106677|9787051|FG002|Core Period: Baseline to Week 26|Physician Decision|3
6150719|NCT01106677|9787052|FG003|Core Period: Baseline to Week 26|Physician Decision|1
6150720|NCT01106677|9787049|FG000|Core Period: Baseline to Week 26|Protocol Violation|0
6150721|NCT01106677|9787050|FG001|Core Period: Baseline to Week 26|Protocol Violation|1
6150722|NCT01106677|9787051|FG002|Core Period: Baseline to Week 26|Protocol Violation|0
6150723|NCT01106677|9787052|FG003|Core Period: Baseline to Week 26|Protocol Violation|3
6150724|NCT01106677|9787049|FG000|Core Period: Baseline to Week 26|Withdrawal by Subject|5
6150725|NCT01106677|9787050|FG001|Core Period: Baseline to Week 26|Withdrawal by Subject|3
6040601|NCT01697267|9638592|FG001|Overall Study|Adverse Event|1
6150726|NCT01106677|9787051|FG002|Core Period: Baseline to Week 26|Withdrawal by Subject|15
6150727|NCT01106677|9787052|FG003|Core Period: Baseline to Week 26|Withdrawal by Subject|6
6150728|NCT01106677|9787049|FG000|Core Period: Baseline to Week 26|Creatinine or eGFR withdrawal criteria|1
6150729|NCT01106677|9787050|FG001|Core Period: Baseline to Week 26|Creatinine or eGFR withdrawal criteria|2
6150730|NCT01106677|9787051|FG002|Core Period: Baseline to Week 26|Creatinine or eGFR withdrawal criteria|2
6318044|NCT02761980|10052968|FG001|Overall Study|Adverse Event|6
6040602|NCT01697267|9638591|FG000|Overall Study|Lost to Follow-up|2
6040603|NCT01697267|9638592|FG001|Overall Study|Lost to Follow-up|4
6040604|NCT01697267|9638591|FG000|Overall Study|Physician Decision|2
6040605|NCT01697267|9638592|FG001|Overall Study|Physician Decision|4
6040606|NCT01527149|9638598|FG000|Overall Study|Death|2
6049000|NCT00420927|9648205|FG006|Period 2|Physician Decision|0
6049001|NCT00420927|9648199|FG000|Period 2|Sponsor decision|0
6049002|NCT00420927|9648200|FG001|Period 2|Sponsor decision|0
6049003|NCT00420927|9648201|FG002|Period 2|Sponsor decision|1
6049004|NCT00420927|9648202|FG003|Period 2|Sponsor decision|0
6150731|NCT01106677|9787052|FG003|Core Period: Baseline to Week 26|Creatinine or eGFR withdrawal criteria|3
6150732|NCT01106677|9787049|FG000|Core Period: Baseline to Week 26|Noncompliance with study drug|1
6150733|NCT01106677|9787050|FG001|Core Period: Baseline to Week 26|Noncompliance with study drug|3
6150734|NCT01106677|9787051|FG002|Core Period: Baseline to Week 26|Noncompliance with study drug|0
6318045|NCT02761980|10052969|FG002|Overall Study|Adverse Event|5
6318046|NCT02761980|10052970|FG003|Overall Study|Adverse Event|6
6040607|NCT00554840|9638628|FG000|Overall Study|Physician Decision|0
6040608|NCT00554840|9638629|FG001|Overall Study|Physician Decision|1
6040609|NCT00003656|9638639|FG000|Overall Study|Adverse Event|0
6040610|NCT00003656|9638640|FG001|Overall Study|Adverse Event|1
6040611|NCT00370331|9638649|FG000|Overall Study|Adverse Event|4
6040612|NCT00370331|9638650|FG001|Overall Study|Adverse Event|13
6040613|NCT00370331|9638649|FG000|Overall Study|Withdrawal by Subject|2
6040614|NCT00370331|9638650|FG001|Overall Study|Withdrawal by Subject|4
6040615|NCT00370331|9638649|FG000|Overall Study|Lost to Follow-up|0
6040616|NCT00370331|9638650|FG001|Overall Study|Lost to Follow-up|3
6040617|NCT00370331|9638649|FG000|Overall Study|Lack of Efficacy|0
6040618|NCT00370331|9638650|FG001|Overall Study|Lack of Efficacy|1
6040619|NCT00370331|9638649|FG000|Overall Study|Non-compliance|0
6040620|NCT00370331|9638650|FG001|Overall Study|Non-compliance|1
6040621|NCT00370331|9638649|FG000|Overall Study|Protocol Violation|1
6040622|NCT00370331|9638650|FG001|Overall Study|Protocol Violation|1
6040623|NCT00370396|9638659|FG000|Overall Study|Withdrawal by Subject|0
6040624|NCT00370396|9638660|FG001|Overall Study|Withdrawal by Subject|0
6040625|NCT00370396|9638661|FG002|Overall Study|Withdrawal by Subject|1
6040626|NCT00370396|9638659|FG000|Overall Study|Lost to Follow-up|11
6040627|NCT00370396|9638660|FG001|Overall Study|Lost to Follow-up|1
6040628|NCT00370396|9638661|FG002|Overall Study|Lost to Follow-up|0
6040629|NCT00370552|9638672|FG000|Overall Study|Adverse Event|2
6040630|NCT00370552|9638673|FG001|Overall Study|Adverse Event|2
6040631|NCT00370552|9638674|FG002|Overall Study|Adverse Event|2
6040632|NCT00370552|9638672|FG000|Overall Study|Disease progression|23
6040633|NCT00370552|9638673|FG001|Overall Study|Disease progression|23
6040634|NCT00370552|9638674|FG002|Overall Study|Disease progression|15
6318047|NCT02761980|10052967|FG000|Overall Study|Withdrawal by Subject|0
6318048|NCT02761980|10052968|FG001|Overall Study|Withdrawal by Subject|1
6318049|NCT02761980|10052969|FG002|Overall Study|Withdrawal by Subject|0
6318050|NCT02761980|10052970|FG003|Overall Study|Withdrawal by Subject|0
6318051|NCT02761980|10052967|FG000|Overall Study|Other|0
6318052|NCT02761980|10052968|FG001|Overall Study|Other|0
6318053|NCT02761980|10052969|FG002|Overall Study|Other|1
6318054|NCT02761980|10052970|FG003|Overall Study|Other|0
6318055|NCT02761993|10052983|FG000|Overall Study|Adverse Event|0
6318056|NCT02761993|10052984|FG001|Overall Study|Adverse Event|2
6318057|NCT02761993|10052985|FG002|Overall Study|Adverse Event|0
6318058|NCT02761993|10052983|FG000|Overall Study|Lost to Follow-up|1
6318059|NCT02761993|10052984|FG001|Overall Study|Lost to Follow-up|3
6318060|NCT02761993|10052985|FG002|Overall Study|Lost to Follow-up|2
6318061|NCT02761993|10052983|FG000|Overall Study|Withdrawal by Subject|1
6318062|NCT02761993|10052984|FG001|Overall Study|Withdrawal by Subject|1
6318063|NCT02761993|10052985|FG002|Overall Study|Withdrawal by Subject|2
6318064|NCT02762084|10053006|FG000|Overall Study|Withdrawal by Subject|1
6318065|NCT02762084|10053007|FG001|Overall Study|Withdrawal by Subject|0
6318066|NCT02762084|10053008|FG002|Overall Study|Withdrawal by Subject|0
6318067|NCT02762084|10053006|FG000|Overall Study|Adverse Event|0
6318068|NCT02762084|10053007|FG001|Overall Study|Adverse Event|0
6318069|NCT02762084|10053008|FG002|Overall Study|Adverse Event|1
6318070|NCT02762370|10053029|FG000|Overall Study|Protocol Violation|1
6318071|NCT02762370|10053030|FG001|Overall Study|Protocol Violation|0
6318072|NCT02762500|10053040|FG000|Overall Study|Lack of Efficacy|1
6318073|NCT02762500|10053041|FG001|Overall Study|Lack of Efficacy|0
6318074|NCT02762500|10053040|FG000|Overall Study|Withdrawal by Subject|1
6318075|NCT02762500|10053041|FG001|Overall Study|Withdrawal by Subject|1
6318076|NCT02762500|10053040|FG000|Overall Study|Adverse Event|0
6318077|NCT02762500|10053041|FG001|Overall Study|Adverse Event|2
6318078|NCT02762565|10053051|FG000|Overall Study|Missing iBE data: a result of incomplete data transfer from the iBE|11
6318079|NCT02762578|10053057|FG000|Overall Study|Adverse Event|1
6040635|NCT00370552|9638672|FG000|Overall Study|Maximum clinical benefit|3
6040636|NCT00370552|9638673|FG001|Overall Study|Maximum clinical benefit|5
6318080|NCT02762578|10053058|FG001|Overall Study|Adverse Event|6
6318081|NCT02762578|10053057|FG000|Overall Study|Protocol Violation|4
6318082|NCT02762578|10053058|FG001|Overall Study|Protocol Violation|2
6318083|NCT02762578|10053057|FG000|Overall Study|Withdrawal by Subject|4
6318084|NCT02762578|10053058|FG001|Overall Study|Withdrawal by Subject|2
6318085|NCT02762578|10053057|FG000|Overall Study|Unclassified|6
6318086|NCT02762578|10053058|FG001|Overall Study|Unclassified|0
6040637|NCT00370552|9638674|FG002|Overall Study|Maximum clinical benefit|5
6040638|NCT00370552|9638672|FG000|Overall Study|Poor or noncompliance|0
6040639|NCT00370552|9638673|FG001|Overall Study|Poor or noncompliance|0
6040640|NCT00370552|9638674|FG002|Overall Study|Poor or noncompliance|1
6040641|NCT00370552|9638672|FG000|Overall Study|Study drug toxicity|11
6040642|NCT00370552|9638673|FG001|Overall Study|Study drug toxicity|8
6040643|NCT00370552|9638674|FG002|Overall Study|Study drug toxicity|6
6318087|NCT02762994|10053097|FG000|Overall Study|Withdrawal by Subject|0
6318088|NCT02762994|10053098|FG001|Overall Study|Withdrawal by Subject|1
6318089|NCT02762994|10053099|FG002|Overall Study|Withdrawal by Subject|2
6318090|NCT02762994|10053100|FG003|Overall Study|Withdrawal by Subject|0
6318091|NCT02762994|10053097|FG000|Overall Study|Protocol Violation|1
6318092|NCT02762994|10053098|FG001|Overall Study|Protocol Violation|0
6318093|NCT02762994|10053099|FG002|Overall Study|Protocol Violation|0
6318094|NCT02762994|10053100|FG003|Overall Study|Protocol Violation|2
6318095|NCT02763046|10053117|FG000|Overall Study|Adverse Event|5
6318096|NCT02763046|10053118|FG001|Overall Study|Adverse Event|4
6318097|NCT02763046|10053119|FG002|Overall Study|Adverse Event|0
6318098|NCT02763046|10053117|FG000|Overall Study|Lack of Efficacy|1
6318099|NCT02763046|10053118|FG001|Overall Study|Lack of Efficacy|1
6227381|NCT01716585|9900081|FG000|Open-label Treatment|Adverse Event|0
6318100|NCT02763046|10053119|FG002|Overall Study|Lack of Efficacy|3
6318101|NCT02763046|10053117|FG000|Overall Study|Physician Decision|1
6318102|NCT02763046|10053118|FG001|Overall Study|Physician Decision|0
6318103|NCT02763046|10053119|FG002|Overall Study|Physician Decision|1
6318104|NCT02763046|10053117|FG000|Overall Study|Subject/guardian decision|2
6150735|NCT01106677|9787052|FG003|Core Period: Baseline to Week 26|Noncompliance with study drug|0
6150736|NCT01106677|9787049|FG000|Core Period: Baseline to Week 26|Study terminated by sponsor|0
6150737|NCT01106677|9787050|FG001|Core Period: Baseline to Week 26|Study terminated by sponsor|1
6150738|NCT01106677|9787051|FG002|Core Period: Baseline to Week 26|Study terminated by sponsor|2
6150739|NCT01106677|9787052|FG003|Core Period: Baseline to Week 26|Study terminated by sponsor|0
6150740|NCT01106677|9787049|FG000|Core Period: Baseline to Week 26|Product quality complaint|0
6150741|NCT01106677|9787050|FG001|Core Period: Baseline to Week 26|Product quality complaint|1
6150742|NCT01106677|9787051|FG002|Core Period: Baseline to Week 26|Product quality complaint|1
6150743|NCT01106677|9787052|FG003|Core Period: Baseline to Week 26|Product quality complaint|0
6150744|NCT01106677|9787049|FG000|Core Period: Baseline to Week 26|Other|8
6150745|NCT01106677|9787050|FG001|Core Period: Baseline to Week 26|Other|14
6150746|NCT01106677|9787051|FG002|Core Period: Baseline to Week 26|Other|8
6150747|NCT01106677|9787052|FG003|Core Period: Baseline to Week 26|Other|23
6150748|NCT01106677|9787049|FG000|Core Period: Baseline to Week 26|Pregnancy|0
6150749|NCT01106677|9787050|FG001|Core Period: Baseline to Week 26|Pregnancy|1
6150750|NCT01106677|9787051|FG002|Core Period: Baseline to Week 26|Pregnancy|0
6150751|NCT01106677|9787052|FG003|Core Period: Baseline to Week 26|Pregnancy|0
6150752|NCT01106677|9787049|FG000|Extension Period: Week 26 to Week 52|Adverse Event|1
6150753|NCT01106677|9787050|FG001|Extension Period: Week 26 to Week 52|Adverse Event|1
6150754|NCT01106677|9787051|FG002|Extension Period: Week 26 to Week 52|Adverse Event|5
6150755|NCT01106677|9787052|FG003|Extension Period: Week 26 to Week 52|Adverse Event|9
6150756|NCT01106677|9787049|FG000|Extension Period: Week 26 to Week 52|Death|0
6150757|NCT01106677|9787050|FG001|Extension Period: Week 26 to Week 52|Death|0
6150758|NCT01106677|9787051|FG002|Extension Period: Week 26 to Week 52|Death|0
6150759|NCT01106677|9787052|FG003|Extension Period: Week 26 to Week 52|Death|1
6150760|NCT01106677|9787049|FG000|Extension Period: Week 26 to Week 52|Lack of Efficacy|2
6150761|NCT01106677|9787050|FG001|Extension Period: Week 26 to Week 52|Lack of Efficacy|0
6150762|NCT01106677|9787051|FG002|Extension Period: Week 26 to Week 52|Lack of Efficacy|0
6150763|NCT01106677|9787052|FG003|Extension Period: Week 26 to Week 52|Lack of Efficacy|4
6318105|NCT02763046|10053118|FG001|Overall Study|Subject/guardian decision|0
6318106|NCT02763046|10053119|FG002|Overall Study|Subject/guardian decision|4
6318107|NCT02763215|10053137|FG000|Overall Study|Participants withdrew from study|3
6318108|NCT02763215|10053137|FG000|Overall Study|Missed visit|1
6318109|NCT02763215|10053137|FG000|Overall Study|Visit outside visit-window|1
6318110|NCT02763215|10053137|FG000|Overall Study|Death|1
6318111|NCT02763215|10053137|FG000|Overall Study|Lost to Follow-up|1
6318112|NCT02763254|10053141|FG000|Overall Study|Adverse Event|1
6318113|NCT02763566|10053149|FG000|Overall Study|Lost to Follow-up|1
6318114|NCT02763566|10053150|FG001|Overall Study|Lost to Follow-up|4
6318115|NCT02763566|10053151|FG002|Overall Study|Lost to Follow-up|0
6318116|NCT02763566|10053152|FG003|Overall Study|Lost to Follow-up|1
6150764|NCT01106677|9787049|FG000|Extension Period: Week 26 to Week 52|Lost to Follow-up|0
6150765|NCT01106677|9787050|FG001|Extension Period: Week 26 to Week 52|Lost to Follow-up|2
6150766|NCT01106677|9787051|FG002|Extension Period: Week 26 to Week 52|Lost to Follow-up|2
6150767|NCT01106677|9787052|FG003|Extension Period: Week 26 to Week 52|Lost to Follow-up|2
6150768|NCT01106677|9787049|FG000|Extension Period: Week 26 to Week 52|Physician Decision|2
6150769|NCT01106677|9787050|FG001|Extension Period: Week 26 to Week 52|Physician Decision|3
6150770|NCT01106677|9787051|FG002|Extension Period: Week 26 to Week 52|Physician Decision|2
6150771|NCT01106677|9787052|FG003|Extension Period: Week 26 to Week 52|Physician Decision|3
6150772|NCT01106677|9787049|FG000|Extension Period: Week 26 to Week 52|Protocol Violation|1
6318117|NCT02763566|10053149|FG000|Overall Study|On study treatment at study conclusion|114
6318118|NCT02763566|10053150|FG001|Overall Study|On study treatment at study conclusion|34
6318119|NCT02763566|10053151|FG002|Overall Study|On study treatment at study conclusion|54
6318120|NCT02763566|10053152|FG003|Overall Study|On study treatment at study conclusion|13
6318121|NCT02763566|10053149|FG000|Overall Study|Withdrawal by Subject|3
6318122|NCT02763566|10053150|FG001|Overall Study|Withdrawal by Subject|1
6318123|NCT02763566|10053151|FG002|Overall Study|Withdrawal by Subject|0
6318124|NCT02763566|10053152|FG003|Overall Study|Withdrawal by Subject|0
6318125|NCT02763644|10053168|FG000|Overall Study|Patient/guardian decision|1
6318126|NCT02763644|10053169|FG001|Overall Study|Patient/guardian decision|0
6318127|NCT02763644|10053168|FG000|Overall Study|Death|1
6318128|NCT02763644|10053169|FG001|Overall Study|Death|1
6318129|NCT02763644|10053168|FG000|Overall Study|Adverse Event|1
6318130|NCT02763644|10053169|FG001|Overall Study|Adverse Event|1
6318131|NCT02764151|10053224|FG000|Overall Study|Subject refused further follow-up|0
6318132|NCT02764151|10053225|FG001|Overall Study|Subject refused further follow-up|0
6318133|NCT02764151|10053226|FG002|Overall Study|Subject refused further follow-up|0
6318134|NCT02764151|10053227|FG003|Overall Study|Subject refused further follow-up|1
6318135|NCT02764151|10053224|FG000|Overall Study|Other|0
6318136|NCT02764151|10053225|FG001|Overall Study|Other|0
6318137|NCT02764151|10053226|FG002|Overall Study|Other|0
6318138|NCT02764151|10053227|FG003|Overall Study|Other|2
6318139|NCT02764190|10053243|FG000|Overall Study|Lost to Follow-up|17
6318140|NCT02764190|10053244|FG001|Overall Study|Lost to Follow-up|13
6318141|NCT02764229|10053250|FG000|Overall Study|Withdrawal by Subject|15
6318142|NCT02764229|10053250|FG000|Overall Study|Adverse Event|9
6318143|NCT02764229|10053250|FG000|Overall Study|Physician Decision|5
6318144|NCT02764229|10053250|FG000|Overall Study|Lost to Follow-up|3
6318145|NCT02764229|10053250|FG000|Overall Study|Lack of Efficacy|1
6318146|NCT02764229|10053250|FG000|Overall Study|Study Stopped by Sponsor|69
6318147|NCT02764320|10053256|FG000|Overall Study|Withdrawal by Subject|35
6318148|NCT02764320|10053257|FG001|Overall Study|Withdrawal by Subject|38
6318149|NCT02764320|10053256|FG000|Overall Study|Protocol Violation|11
6318150|NCT02764320|10053257|FG001|Overall Study|Protocol Violation|6
6318151|NCT02764320|10053256|FG000|Overall Study|Adverse Event|2
6318152|NCT02764320|10053257|FG001|Overall Study|Adverse Event|0
6318153|NCT02764320|10053256|FG000|Overall Study|Health Issues unable to continue|2
6318154|NCT02764320|10053257|FG001|Overall Study|Health Issues unable to continue|0
6318155|NCT02764320|10053256|FG000|Overall Study|Did not meet inclusion criteria|1
6318156|NCT02764320|10053257|FG001|Overall Study|Did not meet inclusion criteria|0
6318157|NCT02764320|10053256|FG000|Overall Study|Subject moved|0
6318158|NCT02764320|10053257|FG001|Overall Study|Subject moved|2
6318159|NCT02764320|10053256|FG000|Overall Study|Overused medication unavailable|0
6318160|NCT02764320|10053257|FG001|Overall Study|Overused medication unavailable|1
6318161|NCT02764320|10053256|FG000|Overall Study|Seeking care outside site|0
6318162|NCT02764320|10053257|FG001|Overall Study|Seeking care outside site|1
6318163|NCT02764320|10053256|FG000|Overall Study|Technology barriers|0
6318164|NCT02764320|10053257|FG001|Overall Study|Technology barriers|1
6318165|NCT02764333|10053263|FG000|Overall Study|Ineligible|1
6318166|NCT02764697|10053276|FG000|Overall Study|Lack of Efficacy|3
6318167|NCT02764762|10053280|FG000|Overall Study|Adverse Event|5
6318168|NCT02764762|10053280|FG000|Overall Study|Voluntary Withdrawal|3
6318169|NCT02764762|10053280|FG000|Overall Study|Significant Deviation|1
6318170|NCT02764775|10053284|FG000|Overall Study|Death|1
6318171|NCT02764775|10053284|FG000|Overall Study|Lost to Follow-up|2
6318172|NCT02764775|10053284|FG000|Overall Study|Withdrawal by Subject|3
6040644|NCT00370552|9638672|FG000|Overall Study|Withdrawal by Subject|2
6040645|NCT00370552|9638673|FG001|Overall Study|Withdrawal by Subject|0
6040646|NCT00370552|9638674|FG002|Overall Study|Withdrawal by Subject|1
6040647|NCT00370552|9638672|FG000|Overall Study|Still on treatment|1
6040648|NCT00370552|9638673|FG001|Overall Study|Still on treatment|3
6040649|NCT00370552|9638674|FG002|Overall Study|Still on treatment|2
6040650|NCT00370552|9638672|FG000|Overall Study|Never treated|1
6040651|NCT00370552|9638673|FG001|Overall Study|Never treated|0
6040652|NCT00370552|9638674|FG002|Overall Study|Never treated|0
6040653|NCT00370552|9638672|FG000|Overall Study|Physician Decision|1
6040654|NCT00370552|9638673|FG001|Overall Study|Physician Decision|1
6040655|NCT00370552|9638674|FG002|Overall Study|Physician Decision|0
6040656|NCT00370552|9638672|FG000|Overall Study|Investigator decision|2
6040657|NCT00370552|9638673|FG001|Overall Study|Investigator decision|1
6040658|NCT00370552|9638674|FG002|Overall Study|Investigator decision|0
6318173|NCT02765035|10053299|FG000|First Intervention (90 Days)|Adverse Event|1
6318174|NCT02765035|10053300|FG001|First Intervention (90 Days)|Adverse Event|1
6318175|NCT02765035|10053299|FG000|Second Intervention (30 Days)|Protocol Violation|2
6318176|NCT02765035|10053300|FG001|Second Intervention (30 Days)|Protocol Violation|2
6318177|NCT02765100|10053309|FG000|Overall Study|subject found ineligible after baseline|1
6318178|NCT02765100|10053310|FG001|Overall Study|subject found ineligible after baseline|1
6318179|NCT02765100|10053309|FG000|Overall Study|Lost to Follow-up|0
6318180|NCT02765100|10053310|FG001|Overall Study|Lost to Follow-up|1
6040659|NCT00370552|9638672|FG000|Overall Study|High risk of allergic reaction|0
6040660|NCT00370552|9638673|FG001|Overall Study|High risk of allergic reaction|1
6040661|NCT00370552|9638674|FG002|Overall Study|High risk of allergic reaction|0
6040662|NCT00370552|9638672|FG000|Overall Study|Planned radiation for palliation|0
6318181|NCT02765165|10053323|FG000|Treatment Period|Progressive disease|3
6318182|NCT02765165|10053324|FG001|Treatment Period|Progressive disease|2
6318183|NCT02765165|10053325|FG002|Treatment Period|Progressive disease|3
6318184|NCT02765165|10053326|FG003|Treatment Period|Progressive disease|3
6318185|NCT02765165|10053327|FG004|Treatment Period|Progressive disease|4
6318186|NCT02765165|10053328|FG005|Treatment Period|Progressive disease|2
6318187|NCT02765165|10053329|FG006|Treatment Period|Progressive disease|2
6318188|NCT02765165|10053323|FG000|Treatment Period|Physician Decision|0
6318189|NCT02765165|10053324|FG001|Treatment Period|Physician Decision|1
6318190|NCT02765165|10053325|FG002|Treatment Period|Physician Decision|0
6318191|NCT02765165|10053326|FG003|Treatment Period|Physician Decision|0
6318192|NCT02765165|10053327|FG004|Treatment Period|Physician Decision|0
6318193|NCT02765165|10053328|FG005|Treatment Period|Physician Decision|0
6318194|NCT02765165|10053329|FG006|Treatment Period|Physician Decision|0
6318195|NCT02765165|10053323|FG000|Treatment Period|Adverse Event|0
6318196|NCT02765165|10053324|FG001|Treatment Period|Adverse Event|1
6318197|NCT02765165|10053325|FG002|Treatment Period|Adverse Event|0
6318198|NCT02765165|10053326|FG003|Treatment Period|Adverse Event|0
6318199|NCT02765165|10053327|FG004|Treatment Period|Adverse Event|0
6318200|NCT02765165|10053328|FG005|Treatment Period|Adverse Event|0
6318201|NCT02765165|10053329|FG006|Treatment Period|Adverse Event|0
6318202|NCT02765165|10053323|FG000|Treatment Period|Withdrawal by Subject|0
6318203|NCT02765165|10053324|FG001|Treatment Period|Withdrawal by Subject|0
6318204|NCT02765165|10053325|FG002|Treatment Period|Withdrawal by Subject|0
6318205|NCT02765165|10053326|FG003|Treatment Period|Withdrawal by Subject|0
6318206|NCT02765165|10053327|FG004|Treatment Period|Withdrawal by Subject|2
6318207|NCT02765165|10053328|FG005|Treatment Period|Withdrawal by Subject|0
6318208|NCT02765165|10053329|FG006|Treatment Period|Withdrawal by Subject|0
6318209|NCT02765165|10053323|FG000|Treatment Period|Study terminated|0
6318210|NCT02765165|10053324|FG001|Treatment Period|Study terminated|0
6318211|NCT02765165|10053325|FG002|Treatment Period|Study terminated|0
6318212|NCT02765165|10053326|FG003|Treatment Period|Study terminated|0
6318213|NCT02765165|10053327|FG004|Treatment Period|Study terminated|0
6318214|NCT02765165|10053328|FG005|Treatment Period|Study terminated|1
6318215|NCT02765165|10053329|FG006|Treatment Period|Study terminated|2
6318216|NCT02765165|10053323|FG000|Post-treatment Follow-up|Death|1
6318217|NCT02765165|10053324|FG001|Post-treatment Follow-up|Death|2
6318218|NCT02765165|10053325|FG002|Post-treatment Follow-up|Death|1
6318219|NCT02765165|10053326|FG003|Post-treatment Follow-up|Death|1
6318220|NCT02765165|10053327|FG004|Post-treatment Follow-up|Death|1
6318221|NCT02765165|10053328|FG005|Post-treatment Follow-up|Death|1
6318222|NCT02765165|10053329|FG006|Post-treatment Follow-up|Death|0
6318223|NCT02765165|10053323|FG000|Post-treatment Follow-up|Lost to Follow-up|0
6318224|NCT02765165|10053324|FG001|Post-treatment Follow-up|Lost to Follow-up|0
6318225|NCT02765165|10053325|FG002|Post-treatment Follow-up|Lost to Follow-up|0
6318226|NCT02765165|10053326|FG003|Post-treatment Follow-up|Lost to Follow-up|1
6318227|NCT02765165|10053327|FG004|Post-treatment Follow-up|Lost to Follow-up|0
6318228|NCT02765165|10053328|FG005|Post-treatment Follow-up|Lost to Follow-up|0
6318229|NCT02765165|10053329|FG006|Post-treatment Follow-up|Lost to Follow-up|0
6318230|NCT02765165|10053323|FG000|Post-treatment Follow-up|Site terminated by sponsor|0
6318231|NCT02765165|10053324|FG001|Post-treatment Follow-up|Site terminated by sponsor|0
6318232|NCT02765165|10053325|FG002|Post-treatment Follow-up|Site terminated by sponsor|1
6318233|NCT02765165|10053326|FG003|Post-treatment Follow-up|Site terminated by sponsor|0
6318234|NCT02765165|10053327|FG004|Post-treatment Follow-up|Site terminated by sponsor|0
6318235|NCT02765165|10053328|FG005|Post-treatment Follow-up|Site terminated by sponsor|0
6318236|NCT02765165|10053329|FG006|Post-treatment Follow-up|Site terminated by sponsor|0
6318237|NCT02765165|10053323|FG000|Post-treatment Follow-up|Initiation of subsequent treatment|0
6318238|NCT02765165|10053324|FG001|Post-treatment Follow-up|Initiation of subsequent treatment|0
6318239|NCT02765165|10053325|FG002|Post-treatment Follow-up|Initiation of subsequent treatment|1
6318240|NCT02765165|10053326|FG003|Post-treatment Follow-up|Initiation of subsequent treatment|1
6318241|NCT02765165|10053327|FG004|Post-treatment Follow-up|Initiation of subsequent treatment|0
6318242|NCT02765165|10053328|FG005|Post-treatment Follow-up|Initiation of subsequent treatment|0
6318243|NCT02765165|10053329|FG006|Post-treatment Follow-up|Initiation of subsequent treatment|0
6318244|NCT02765165|10053323|FG000|Post-treatment Follow-up|Withdrawal by Subject|0
6318245|NCT02765165|10053324|FG001|Post-treatment Follow-up|Withdrawal by Subject|1
6318246|NCT02765165|10053325|FG002|Post-treatment Follow-up|Withdrawal by Subject|0
6318247|NCT02765165|10053326|FG003|Post-treatment Follow-up|Withdrawal by Subject|0
6318248|NCT02765165|10053327|FG004|Post-treatment Follow-up|Withdrawal by Subject|0
6318249|NCT02765165|10053328|FG005|Post-treatment Follow-up|Withdrawal by Subject|0
6318250|NCT02765165|10053329|FG006|Post-treatment Follow-up|Withdrawal by Subject|0
6318251|NCT02765165|10053323|FG000|Post-treatment Follow-up|Study terminated by the sponsor|0
6318252|NCT02765165|10053324|FG001|Post-treatment Follow-up|Study terminated by the sponsor|0
6318253|NCT02765165|10053325|FG002|Post-treatment Follow-up|Study terminated by the sponsor|0
6040663|NCT00370552|9638673|FG001|Overall Study|Planned radiation for palliation|1
6040664|NCT00370552|9638674|FG002|Overall Study|Planned radiation for palliation|0
6040665|NCT00370682|9638685|FG000|Overall Study|Moved from area|0
6040666|NCT00370682|9638686|FG001|Overall Study|Moved from area|2
6040667|NCT00370682|9638687|FG002|Overall Study|Moved from area|0
6040668|NCT00370682|9638685|FG000|Overall Study|Lost to Follow-up|0
6040669|NCT00370682|9638686|FG001|Overall Study|Lost to Follow-up|1
6040670|NCT00370682|9638687|FG002|Overall Study|Lost to Follow-up|1
6040671|NCT00371137|9638720|FG000|Overall Study|Adverse Event|20
6040672|NCT00371137|9638721|FG001|Overall Study|Adverse Event|35
6040673|NCT00371137|9638722|FG002|Overall Study|Adverse Event|42
6040674|NCT00371137|9638720|FG000|Overall Study|Withdrawal by Subject|11
6040675|NCT00371137|9638721|FG001|Overall Study|Withdrawal by Subject|10
6040676|NCT00371137|9638722|FG002|Overall Study|Withdrawal by Subject|15
6040677|NCT00371137|9638720|FG000|Overall Study|Lost to Follow-up|6
6040678|NCT00371137|9638721|FG001|Overall Study|Lost to Follow-up|3
6040679|NCT00371137|9638722|FG002|Overall Study|Lost to Follow-up|5
6040680|NCT00371137|9638720|FG000|Overall Study|Lack of Efficacy|30
6040681|NCT00371137|9638721|FG001|Overall Study|Lack of Efficacy|12
6040682|NCT00371137|9638722|FG002|Overall Study|Lack of Efficacy|13
6040683|NCT00371137|9638720|FG000|Overall Study|Sponsor Decision|2
6040684|NCT00371137|9638721|FG001|Overall Study|Sponsor Decision|1
6040685|NCT00371137|9638722|FG002|Overall Study|Sponsor Decision|2
6040686|NCT00371137|9638720|FG000|Overall Study|Physician Decision|1
6150773|NCT01106677|9787050|FG001|Extension Period: Week 26 to Week 52|Protocol Violation|0
6150774|NCT01106677|9787051|FG002|Extension Period: Week 26 to Week 52|Protocol Violation|0
6150775|NCT01106677|9787052|FG003|Extension Period: Week 26 to Week 52|Protocol Violation|0
6150776|NCT01106677|9787049|FG000|Extension Period: Week 26 to Week 52|Withdrawal by Subject|1
6150777|NCT01106677|9787050|FG001|Extension Period: Week 26 to Week 52|Withdrawal by Subject|3
6318254|NCT02765165|10053326|FG003|Post-treatment Follow-up|Study terminated by the sponsor|0
6318255|NCT02765165|10053327|FG004|Post-treatment Follow-up|Study terminated by the sponsor|2
6318256|NCT02765165|10053328|FG005|Post-treatment Follow-up|Study terminated by the sponsor|2
6318257|NCT02765165|10053329|FG006|Post-treatment Follow-up|Study terminated by the sponsor|1
6318258|NCT02765490|10053369|FG000|Overall Study|Lost to Follow-up|1
6318259|NCT02765490|10053370|FG001|Overall Study|Lost to Follow-up|1
6040687|NCT00371137|9638721|FG001|Overall Study|Physician Decision|1
6318260|NCT02765490|10053369|FG000|Overall Study|Other|0
6318261|NCT02765490|10053370|FG001|Overall Study|Other|1
6318262|NCT02765490|10053369|FG000|Overall Study|Death|0
6318263|NCT02765490|10053370|FG001|Overall Study|Death|1
6318264|NCT02766023|10053378|FG000|Overall Study|Lost to Follow-up|23
6318265|NCT02766023|10053379|FG001|Overall Study|Lost to Follow-up|11
6318266|NCT02766023|10053378|FG000|Overall Study|Pregnancy|1
6318267|NCT02766023|10053379|FG001|Overall Study|Pregnancy|0
6318268|NCT02766023|10053378|FG000|Overall Study|Adverse Event|1
6318269|NCT02766023|10053379|FG001|Overall Study|Adverse Event|0
6318270|NCT02766023|10053378|FG000|Overall Study|Withdrawal by Subject|4
6318271|NCT02766023|10053379|FG001|Overall Study|Withdrawal by Subject|5
6318272|NCT02766023|10053378|FG000|Overall Study|Physician Decision|1
6318273|NCT02766023|10053379|FG001|Overall Study|Physician Decision|0
6318274|NCT02766023|10053378|FG000|Overall Study|Not Eligible at Enrollment|0
6318275|NCT02766023|10053379|FG001|Overall Study|Not Eligible at Enrollment|1
6318276|NCT02766088|10053385|FG000|Overall Study|Sponsor study termination|498
6318277|NCT02766088|10053385|FG000|Overall Study|Migrated/moved from the study area|1
6318278|NCT02766088|10053385|FG000|Overall Study|Lost to Follow-up|5
6318279|NCT02766088|10053385|FG000|Overall Study|Other|1
6318280|NCT02766088|10053385|FG000|Overall Study|Death|1
6318281|NCT02766283|10053398|FG000|Overall Study|Lost to Follow-up|27
6318282|NCT02766400|10053417|FG000|Overall Study|Death|1
6318283|NCT02766400|10053418|FG001|Overall Study|Death|2
6318284|NCT02766400|10053417|FG000|Overall Study|Withdrawal by Subject|1
6318285|NCT02766400|10053418|FG001|Overall Study|Withdrawal by Subject|0
6318286|NCT02766608|10053442|FG000|Overall Study|Adverse Event|27
6318287|NCT02766608|10053443|FG001|Overall Study|Adverse Event|22
6318288|NCT02766608|10053444|FG002|Overall Study|Adverse Event|17
6318289|NCT02766608|10053445|FG003|Overall Study|Adverse Event|13
6318290|NCT02766608|10053446|FG004|Overall Study|Adverse Event|12
6318291|NCT02766608|10053442|FG000|Overall Study|Withdrawal by Subject|21
6318292|NCT02766608|10053443|FG001|Overall Study|Withdrawal by Subject|20
6318293|NCT02766608|10053444|FG002|Overall Study|Withdrawal by Subject|24
6040688|NCT00371137|9638722|FG002|Overall Study|Physician Decision|1
6040689|NCT00371137|9638720|FG000|Overall Study|Protocol Violation|2
6040690|NCT00371137|9638721|FG001|Overall Study|Protocol Violation|1
6040691|NCT00371137|9638722|FG002|Overall Study|Protocol Violation|1
6040692|NCT00371150|9638732|FG000|Overall Study|Lost to Follow-up|3
6040693|NCT00371150|9638733|FG001|Overall Study|Lost to Follow-up|2
6040694|NCT00371254|9638754|FG000|Overall Study|Disease progression|13
6040695|NCT00371254|9638755|FG001|Overall Study|Disease progression|13
6040696|NCT00371254|9638754|FG000|Overall Study|Study drug toxicity|3
6040697|NCT00371254|9638755|FG001|Overall Study|Study drug toxicity|5
6040698|NCT00371254|9638754|FG000|Overall Study|Subject request|5
6040699|NCT00371254|9638755|FG001|Overall Study|Subject request|0
6040700|NCT00371254|9638754|FG000|Overall Study|Investigator Decision|2
6040701|NCT00371254|9638755|FG001|Overall Study|Investigator Decision|0
6040702|NCT00371254|9638754|FG000|Overall Study|Adverse event unrelated to study drug|0
6049005|NCT00420927|9648203|FG004|Period 2|Sponsor decision|0
6318294|NCT02766608|10053445|FG003|Overall Study|Withdrawal by Subject|13
6318295|NCT02766608|10053446|FG004|Overall Study|Withdrawal by Subject|10
6318296|NCT02766608|10053442|FG000|Overall Study|Lack of Efficacy|16
6318297|NCT02766608|10053443|FG001|Overall Study|Lack of Efficacy|15
6318298|NCT02766608|10053444|FG002|Overall Study|Lack of Efficacy|32
6318299|NCT02766608|10053445|FG003|Overall Study|Lack of Efficacy|8
6318300|NCT02766608|10053446|FG004|Overall Study|Lack of Efficacy|2
6318301|NCT02766608|10053442|FG000|Overall Study|Lost to Follow-up|6
6318302|NCT02766608|10053443|FG001|Overall Study|Lost to Follow-up|3
6318303|NCT02766608|10053444|FG002|Overall Study|Lost to Follow-up|5
6318304|NCT02766608|10053445|FG003|Overall Study|Lost to Follow-up|2
6318305|NCT02766608|10053446|FG004|Overall Study|Lost to Follow-up|2
6318306|NCT02766608|10053442|FG000|Overall Study|Physician Decision|3
6318307|NCT02766608|10053443|FG001|Overall Study|Physician Decision|2
6318308|NCT02766608|10053444|FG002|Overall Study|Physician Decision|3
6318309|NCT02766608|10053445|FG003|Overall Study|Physician Decision|1
6318310|NCT02766608|10053446|FG004|Overall Study|Physician Decision|2
6318311|NCT02766608|10053442|FG000|Overall Study|Protocol disc criteria|3
6318312|NCT02766608|10053443|FG001|Overall Study|Protocol disc criteria|3
6318313|NCT02766608|10053444|FG002|Overall Study|Protocol disc criteria|4
6318314|NCT02766608|10053445|FG003|Overall Study|Protocol disc criteria|0
6318315|NCT02766608|10053446|FG004|Overall Study|Protocol disc criteria|0
6318316|NCT02766608|10053442|FG000|Overall Study|Protocol Violation|0
6318317|NCT02766608|10053443|FG001|Overall Study|Protocol Violation|4
6318318|NCT02766608|10053444|FG002|Overall Study|Protocol Violation|4
6318319|NCT02766608|10053445|FG003|Overall Study|Protocol Violation|0
6318320|NCT02766608|10053446|FG004|Overall Study|Protocol Violation|1
6318321|NCT02766608|10053442|FG000|Overall Study|Administrative Reasons|3
6318322|NCT02766608|10053443|FG001|Overall Study|Administrative Reasons|1
6318323|NCT02766608|10053444|FG002|Overall Study|Administrative Reasons|1
6318324|NCT02766608|10053445|FG003|Overall Study|Administrative Reasons|0
6318325|NCT02766608|10053446|FG004|Overall Study|Administrative Reasons|0
6318326|NCT02766777|10053474|FG000|Overall Study|Adverse Event|12
6318327|NCT02766777|10053474|FG000|Overall Study|Lost to Follow-up|16
6318328|NCT02766777|10053474|FG000|Overall Study|Non-Compliance With Study Drug|1
6318329|NCT02766777|10053474|FG000|Overall Study|Protocol Violation|1
6318330|NCT02766777|10053474|FG000|Overall Study|Withdrawal by Subject|4
6318331|NCT02767323|10053523|FG000|Overall Study|Withdrawal by Subject|17
6318332|NCT02767323|10053524|FG001|Overall Study|Withdrawal by Subject|5
6318333|NCT02767323|10053525|FG002|Overall Study|Withdrawal by Subject|13
6318334|NCT02767323|10053526|FG003|Overall Study|Withdrawal by Subject|0
6318335|NCT02767323|10053523|FG000|Overall Study|Contraindication, moving during the scan, low behavior, or Covid-19|17
6318336|NCT02767323|10053524|FG001|Overall Study|Contraindication, moving during the scan, low behavior, or Covid-19|20
6318337|NCT02767323|10053525|FG002|Overall Study|Contraindication, moving during the scan, low behavior, or Covid-19|17
6318338|NCT02767323|10053526|FG003|Overall Study|Contraindication, moving during the scan, low behavior, or Covid-19|0
6318339|NCT02767765|10053574|FG000|Overall Study|Adverse Event|4
6318340|NCT02767765|10053574|FG000|Overall Study|Death|1
6318341|NCT02767765|10053574|FG000|Overall Study|Insufficient response|1
6318342|NCT02767765|10053574|FG000|Overall Study|Lost to Follow-up|2
6318343|NCT02767765|10053574|FG000|Overall Study|Investigator decision|1
6318344|NCT02767765|10053574|FG000|Overall Study|Non-Compliance|1
6318345|NCT02767765|10053574|FG000|Overall Study|Withdrawal by Subject|1
6318346|NCT02768103|10053607|FG000|Overall Study|1 participant did not fit in the fMRI|1
6318347|NCT02768194|10053620|FG000|Period 1|Adverse Event|0
6150778|NCT01106677|9787051|FG002|Extension Period: Week 26 to Week 52|Withdrawal by Subject|2
6150779|NCT01106677|9787052|FG003|Extension Period: Week 26 to Week 52|Withdrawal by Subject|1
6150780|NCT01106677|9787049|FG000|Extension Period: Week 26 to Week 52|Creatinine or eGFR withdrawal criteria|2
6150781|NCT01106677|9787050|FG001|Extension Period: Week 26 to Week 52|Creatinine or eGFR withdrawal criteria|4
6150782|NCT01106677|9787051|FG002|Extension Period: Week 26 to Week 52|Creatinine or eGFR withdrawal criteria|3
6150783|NCT01106677|9787052|FG003|Extension Period: Week 26 to Week 52|Creatinine or eGFR withdrawal criteria|2
6150784|NCT01106677|9787049|FG000|Extension Period: Week 26 to Week 52|Unable to take rescue therapy|0
6150785|NCT01106677|9787050|FG001|Extension Period: Week 26 to Week 52|Unable to take rescue therapy|0
6150786|NCT01106677|9787051|FG002|Extension Period: Week 26 to Week 52|Unable to take rescue therapy|0
6318348|NCT02768194|10053621|FG001|Period 1|Adverse Event|0
6318349|NCT02768194|10053622|FG002|Period 1|Adverse Event|0
6318350|NCT02768194|10053623|FG003|Period 1|Adverse Event|1
6318351|NCT02768194|10053624|FG004|Period 1|Adverse Event|0
6318352|NCT02768194|10053625|FG005|Period 1|Adverse Event|0
6318353|NCT02768194|10053620|FG000|Period 2|Other (Reason not specified)|1
6318354|NCT02768194|10053621|FG001|Period 2|Other (Reason not specified)|0
6318355|NCT02768194|10053622|FG002|Period 2|Other (Reason not specified)|0
6318356|NCT02768194|10053623|FG003|Period 2|Other (Reason not specified)|0
6318357|NCT02768194|10053624|FG004|Period 2|Other (Reason not specified)|0
6318358|NCT02768194|10053625|FG005|Period 2|Other (Reason not specified)|0
6318359|NCT02768194|10053620|FG000|Period 3|Other (Reason not specified)|0
6318360|NCT02768194|10053621|FG001|Period 3|Other (Reason not specified)|1
6318361|NCT02768194|10053622|FG002|Period 3|Other (Reason not specified)|0
6318362|NCT02768194|10053623|FG003|Period 3|Other (Reason not specified)|0
6318363|NCT02768194|10053624|FG004|Period 3|Other (Reason not specified)|0
6318364|NCT02768194|10053625|FG005|Period 3|Other (Reason not specified)|0
6318365|NCT02768298|10053635|FG000|Overall Study|Adverse Event|1
6040703|NCT00371254|9638755|FG001|Overall Study|Adverse event unrelated to study drug|1
6040704|NCT00371254|9638754|FG000|Overall Study|Lost to Follow-up|0
6040705|NCT00371254|9638755|FG001|Overall Study|Lost to Follow-up|1
6040706|NCT00371254|9638754|FG000|Overall Study|Withdrawal by Subject|0
6040707|NCT00371254|9638755|FG001|Overall Study|Withdrawal by Subject|1
6040708|NCT00371345|9638786|FG000|Overall Study|Disease Progression|21
6040709|NCT00371345|9638787|FG001|Overall Study|Disease Progression|35
6040710|NCT00371345|9638786|FG000|Overall Study|Study Drug Toxicity|1
6040711|NCT00371345|9638787|FG001|Overall Study|Study Drug Toxicity|7
6040712|NCT00371345|9638786|FG000|Overall Study|Adverse event(AE Unrelated to Study Drug|1
6040713|NCT00371345|9638787|FG001|Overall Study|Adverse event(AE Unrelated to Study Drug|2
6040714|NCT00371345|9638786|FG000|Overall Study|Participant Request|1
6040715|NCT00371345|9638787|FG001|Overall Study|Participant Request|1
6040716|NCT00371345|9638786|FG000|Overall Study|Participant Withdrew Consent|0
6040717|NCT00371345|9638787|FG001|Overall Study|Participant Withdrew Consent|1
6040718|NCT00371397|9638807|FG000|Session 1|Withdrawal by Subject|1
6040719|NCT00371397|9638808|FG001|Session 1|Withdrawal by Subject|0
6040720|NCT00371397|9638809|FG002|Session 1|Withdrawal by Subject|0
6040721|NCT00371397|9638810|FG003|Session 1|Withdrawal by Subject|0
6040722|NCT00371397|9638811|FG004|Session 1|Withdrawal by Subject|0
6040723|NCT00371397|9638812|FG005|Session 1|Withdrawal by Subject|0
6040724|NCT00371397|9638813|FG006|Session 1|Withdrawal by Subject|0
6040725|NCT00371397|9638814|FG007|Session 1|Withdrawal by Subject|1
6040726|NCT00371397|9638815|FG008|Session 1|Withdrawal by Subject|0
6040727|NCT00371397|9638816|FG009|Session 1|Withdrawal by Subject|0
6040728|NCT00371397|9638817|FG010|Session 1|Withdrawal by Subject|0
6040729|NCT00371397|9638818|FG011|Session 1|Withdrawal by Subject|0
6040730|NCT00371566|9638850|FG000|Treatment Phase|Withdrawal by Subject|0
6040731|NCT00371566|9638851|FG001|Treatment Phase|Withdrawal by Subject|1
6040732|NCT00371566|9638850|FG000|Treatment Phase|Adverse Event|0
6040733|NCT00371566|9638851|FG001|Treatment Phase|Adverse Event|1
6040734|NCT00371566|9638850|FG000|Treatment Phase|Protocol Violation|0
6040735|NCT00371566|9638851|FG001|Treatment Phase|Protocol Violation|1
6040736|NCT00371566|9638850|FG000|Chemoradiation Phase|Physician Decision|2
6040737|NCT00371566|9638851|FG001|Chemoradiation Phase|Physician Decision|0
6040738|NCT00371566|9638850|FG000|Chemoradiation Phase|Withdrawal by Subject|0
6040739|NCT00371566|9638851|FG001|Chemoradiation Phase|Withdrawal by Subject|1
6040740|NCT00371566|9638850|FG000|Chemoradiation Phase|Non compliant|0
6040741|NCT00371566|9638851|FG001|Chemoradiation Phase|Non compliant|1
6040742|NCT00371566|9638850|FG000|Chemoradiation Phase|Progressive Disease|1
6040743|NCT00371566|9638851|FG001|Chemoradiation Phase|Progressive Disease|1
6040744|NCT00371566|9638850|FG000|Chemoradiation Phase|Death|2
6040745|NCT00371566|9638851|FG001|Chemoradiation Phase|Death|0
6040746|NCT00371566|9638850|FG000|Follow Up Phase|Death|0
6040747|NCT00371566|9638851|FG001|Follow Up Phase|Death|5
6040748|NCT00371566|9638850|FG000|Follow Up Phase|Disease progression|1
6040749|NCT00371566|9638851|FG001|Follow Up Phase|Disease progression|0
6040750|NCT00371566|9638850|FG000|Follow Up Phase|Withdrawal by Subject|0
6040751|NCT00371566|9638851|FG001|Follow Up Phase|Withdrawal by Subject|1
6040752|NCT00371566|9638850|FG000|Follow Up Phase|Physician Decision|1
6040753|NCT00371566|9638851|FG001|Follow Up Phase|Physician Decision|1
6040754|NCT00371566|9638850|FG000|Follow Up Phase|Lost to Follow-up|1
6040755|NCT00371566|9638851|FG001|Follow Up Phase|Lost to Follow-up|0
6040756|NCT00371683|9638872|FG000|DB Treatment Period-Randomized Patients|Death|1
6040757|NCT00371683|9638873|FG001|DB Treatment Period-Randomized Patients|Death|1
6040758|NCT00371683|9638872|FG000|DB Treatment Period-Randomized Patients|Adverse Event|60
6040759|NCT00371683|9638873|FG001|DB Treatment Period-Randomized Patients|Adverse Event|58
6040760|NCT00371683|9638872|FG000|DB Treatment Period-Randomized Patients|Withdrawal by Subject|18
6040761|NCT00371683|9638873|FG001|DB Treatment Period-Randomized Patients|Withdrawal by Subject|37
6040762|NCT00371683|9638872|FG000|DB Treatment Period-Randomized Patients|Lost to Follow-up|0
6040763|NCT00371683|9638873|FG001|DB Treatment Period-Randomized Patients|Lost to Follow-up|1
6040764|NCT00371683|9638872|FG000|DB Treatment Period-Randomized Patients|No longer meets study criteria|1
6040765|NCT00371683|9638873|FG001|DB Treatment Period-Randomized Patients|No longer meets study criteria|2
6040766|NCT00371683|9638872|FG000|DB Treatment Period-Randomized Patients|Administrative reason by sponsor|1
6040767|NCT00371683|9638873|FG001|DB Treatment Period-Randomized Patients|Administrative reason by sponsor|0
6150787|NCT01106677|9787052|FG003|Extension Period: Week 26 to Week 52|Unable to take rescue therapy|1
6150788|NCT01106677|9787049|FG000|Extension Period: Week 26 to Week 52|Other|6
6150789|NCT01106677|9787050|FG001|Extension Period: Week 26 to Week 52|Other|5
6150790|NCT01106677|9787051|FG002|Extension Period: Week 26 to Week 52|Other|8
6150791|NCT01106677|9787052|FG003|Extension Period: Week 26 to Week 52|Other|5
6150792|NCT01106690|9787072|FG000|Core Period: Baseline to Week 26|Adverse Event|6
6150793|NCT01106690|9787073|FG001|Core Period: Baseline to Week 26|Adverse Event|1
6150794|NCT01106690|9787074|FG002|Core Period: Baseline to Week 26|Adverse Event|4
6150795|NCT01106690|9787072|FG000|Core Period: Baseline to Week 26|Lost to Follow-up|1
6150796|NCT01106690|9787073|FG001|Core Period: Baseline to Week 26|Lost to Follow-up|1
6040768|NCT00371683|9638872|FG000|DB Treatment Period-Randomized Patients|non-specified|9
6318366|NCT02768298|10053636|FG001|Overall Study|Adverse Event|4
6040769|NCT00371683|9638873|FG001|DB Treatment Period-Randomized Patients|non-specified|8
6040770|NCT00371683|9638872|FG000|Follow-Up Period - Randomized Patients|Withdrawal by Subject|17
6040771|NCT00371683|9638873|FG001|Follow-Up Period - Randomized Patients|Withdrawal by Subject|19
6040772|NCT00371683|9638872|FG000|Follow-Up Period - Randomized Patients|Death|0
6040773|NCT00371683|9638873|FG001|Follow-Up Period - Randomized Patients|Death|2
6040774|NCT00371683|9638872|FG000|Follow-Up Period - Randomized Patients|Lost to Follow-up|38
6040775|NCT00371683|9638873|FG001|Follow-Up Period - Randomized Patients|Lost to Follow-up|39
6040776|NCT00371683|9638872|FG000|Follow-Up Period - Randomized Patients|non-specified|6
6040777|NCT00371683|9638873|FG001|Follow-Up Period - Randomized Patients|non-specified|12
6040778|NCT00371761|9638891|FG000|Overall Study|Adverse Event|1
6040779|NCT00371761|9638892|FG001|Overall Study|Adverse Event|1
6040780|NCT00371761|9638891|FG000|Overall Study|Withdrawal by Subject|1
6040781|NCT00371761|9638892|FG001|Overall Study|Withdrawal by Subject|3
6040782|NCT00371761|9638891|FG000|Overall Study|Investigator Judgment|2
6040783|NCT00371761|9638892|FG001|Overall Study|Investigator Judgment|3
6040784|NCT00371761|9638891|FG000|Overall Study|Study termination|4
6040785|NCT00371761|9638892|FG001|Overall Study|Study termination|3
6040786|NCT00371787|9638900|FG000|Overall Study|Withdrawal by Subject|3
6040787|NCT00371787|9638901|FG001|Overall Study|Withdrawal by Subject|1
6040788|NCT00371826|9638910|FG000|Core Phase (12 Months)|Adverse Event|15
6040789|NCT00371826|9638911|FG001|Core Phase (12 Months)|Adverse Event|4
6040790|NCT00371826|9638912|FG002|Core Phase (12 Months)|Adverse Event|9
6040791|NCT00371826|9638910|FG000|Core Phase (12 Months)|Abnormal test procedure result(s)|1
6040792|NCT00371826|9638911|FG001|Core Phase (12 Months)|Abnormal test procedure result(s)|0
6040793|NCT00371826|9638912|FG002|Core Phase (12 Months)|Abnormal test procedure result(s)|1
6040794|NCT00371826|9638910|FG000|Core Phase (12 Months)|Unsatisfactory therapeutic effect|6
6040795|NCT00371826|9638911|FG001|Core Phase (12 Months)|Unsatisfactory therapeutic effect|3
6040796|NCT00371826|9638912|FG002|Core Phase (12 Months)|Unsatisfactory therapeutic effect|2
6040797|NCT00371826|9638910|FG000|Core Phase (12 Months)|Protocol Violation|1
6040798|NCT00371826|9638911|FG001|Core Phase (12 Months)|Protocol Violation|0
6040799|NCT00371826|9638912|FG002|Core Phase (12 Months)|Protocol Violation|1
6040800|NCT00371826|9638910|FG000|Core Phase (12 Months)|Subject withdrew consent|0
6040801|NCT00371826|9638911|FG001|Core Phase (12 Months)|Subject withdrew consent|0
6040802|NCT00371826|9638912|FG002|Core Phase (12 Months)|Subject withdrew consent|3
6040803|NCT00371826|9638910|FG000|Core Phase (12 Months)|Administrative problems|1
6040804|NCT00371826|9638911|FG001|Core Phase (12 Months)|Administrative problems|0
6040805|NCT00371826|9638912|FG002|Core Phase (12 Months)|Administrative problems|8
6040806|NCT00371826|9638910|FG000|Core Phase (12 Months)|Graft Loss|0
6040807|NCT00371826|9638911|FG001|Core Phase (12 Months)|Graft Loss|1
6040808|NCT00371826|9638912|FG002|Core Phase (12 Months)|Graft Loss|0
6040809|NCT00371826|9638910|FG000|Extension Phase (24 Months)|Adverse Event|4
6040810|NCT00371826|9638911|FG001|Extension Phase (24 Months)|Adverse Event|5
6040811|NCT00371826|9638912|FG002|Extension Phase (24 Months)|Adverse Event|0
6040812|NCT00371826|9638910|FG000|Extension Phase (24 Months)|Abnormal test procedure result(s)|0
6040813|NCT00371826|9638911|FG001|Extension Phase (24 Months)|Abnormal test procedure result(s)|1
6040814|NCT00371826|9638912|FG002|Extension Phase (24 Months)|Abnormal test procedure result(s)|0
6040815|NCT00371826|9638910|FG000|Extension Phase (24 Months)|Unsatisfactory therapeutic effect|0
6150797|NCT01106690|9787074|FG002|Core Period: Baseline to Week 26|Lost to Follow-up|2
6318367|NCT02768298|10053635|FG000|Overall Study|Death|2
6318368|NCT02768298|10053636|FG001|Overall Study|Death|1
6318369|NCT02768298|10053635|FG000|Overall Study|Non-compliance with study treatment|0
6318370|NCT02768298|10053636|FG001|Overall Study|Non-compliance with study treatment|1
6318371|NCT02768298|10053635|FG000|Overall Study|Subject/guardian decision|1
6318372|NCT02768298|10053636|FG001|Overall Study|Subject/guardian decision|0
6318373|NCT02768298|10053635|FG000|Overall Study|Withdrawal of informed consent|0
6318374|NCT02768298|10053636|FG001|Overall Study|Withdrawal of informed consent|1
6318375|NCT02768792|10053660|FG000|Overall Study|Adverse Event|1
6318376|NCT02769065|10053694|FG000|Overall Study|Voluntary Withdrawal|1
6318377|NCT02769065|10053695|FG001|Overall Study|Voluntary Withdrawal|0
6318378|NCT02769065|10053696|FG002|Overall Study|Voluntary Withdrawal|0
6318379|NCT02769065|10053697|FG003|Overall Study|Voluntary Withdrawal|0
6318380|NCT02769065|10053698|FG004|Overall Study|Voluntary Withdrawal|0
6318381|NCT02769065|10053699|FG005|Overall Study|Voluntary Withdrawal|0
6318382|NCT02769065|10053700|FG006|Overall Study|Voluntary Withdrawal|0
6318383|NCT02769065|10053701|FG007|Overall Study|Voluntary Withdrawal|0
6318384|NCT02769065|10053702|FG008|Overall Study|Voluntary Withdrawal|0
6318385|NCT02769065|10053703|FG009|Overall Study|Voluntary Withdrawal|0
6318386|NCT02769065|10053704|FG010|Overall Study|Voluntary Withdrawal|0
6318387|NCT02769065|10053705|FG011|Overall Study|Voluntary Withdrawal|0
6150798|NCT01106690|9787072|FG000|Core Period: Baseline to Week 26|Protocol Violation|1
6150799|NCT01106690|9787073|FG001|Core Period: Baseline to Week 26|Protocol Violation|0
6150800|NCT01106690|9787074|FG002|Core Period: Baseline to Week 26|Protocol Violation|0
6150801|NCT01106690|9787072|FG000|Core Period: Baseline to Week 26|Withdrawal by Subject|4
6150802|NCT01106690|9787073|FG001|Core Period: Baseline to Week 26|Withdrawal by Subject|1
6318388|NCT02769065|10053706|FG012|Overall Study|Voluntary Withdrawal|0
6318389|NCT02769065|10053707|FG013|Overall Study|Voluntary Withdrawal|0
6318390|NCT02769065|10053708|FG014|Overall Study|Voluntary Withdrawal|0
6150803|NCT01106690|9787074|FG002|Core Period: Baseline to Week 26|Withdrawal by Subject|0
6318391|NCT02769065|10053709|FG015|Overall Study|Voluntary Withdrawal|0
6318392|NCT02769065|10053710|FG016|Overall Study|Voluntary Withdrawal|0
6318393|NCT02769065|10053711|FG017|Overall Study|Voluntary Withdrawal|0
6318394|NCT02769065|10053712|FG018|Overall Study|Voluntary Withdrawal|0
6318395|NCT02769065|10053713|FG019|Overall Study|Voluntary Withdrawal|0
6318396|NCT02769065|10053714|FG020|Overall Study|Voluntary Withdrawal|0
6318397|NCT02769065|10053715|FG021|Overall Study|Voluntary Withdrawal|0
6318398|NCT02769065|10053716|FG022|Overall Study|Voluntary Withdrawal|0
6318399|NCT02769065|10053717|FG023|Overall Study|Voluntary Withdrawal|0
6318400|NCT02769065|10053718|FG024|Overall Study|Voluntary Withdrawal|0
6318401|NCT02769065|10053719|FG025|Overall Study|Voluntary Withdrawal|0
6318402|NCT02769065|10053720|FG026|Overall Study|Voluntary Withdrawal|0
6318403|NCT02769065|10053721|FG027|Overall Study|Voluntary Withdrawal|0
6318404|NCT02769065|10053722|FG028|Overall Study|Voluntary Withdrawal|0
6318405|NCT02769065|10053723|FG029|Overall Study|Voluntary Withdrawal|0
6318406|NCT02769065|10053694|FG000|Overall Study|Reason Not Specified|0
6318407|NCT02769065|10053695|FG001|Overall Study|Reason Not Specified|0
6318408|NCT02769065|10053696|FG002|Overall Study|Reason Not Specified|0
6318409|NCT02769065|10053697|FG003|Overall Study|Reason Not Specified|0
6318410|NCT02769065|10053698|FG004|Overall Study|Reason Not Specified|0
6318411|NCT02769065|10053699|FG005|Overall Study|Reason Not Specified|0
6318412|NCT02769065|10053700|FG006|Overall Study|Reason Not Specified|1
6318413|NCT02769065|10053701|FG007|Overall Study|Reason Not Specified|0
6318414|NCT02769065|10053702|FG008|Overall Study|Reason Not Specified|0
6040816|NCT00371826|9638911|FG001|Extension Phase (24 Months)|Unsatisfactory therapeutic effect|2
6040817|NCT00371826|9638912|FG002|Extension Phase (24 Months)|Unsatisfactory therapeutic effect|0
6040818|NCT00371826|9638910|FG000|Extension Phase (24 Months)|Subject withdrew consent|1
6150804|NCT01106690|9787072|FG000|Core Period: Baseline to Week 26|Creatinine or eGFR withdrawal criteria|0
6150805|NCT01106690|9787073|FG001|Core Period: Baseline to Week 26|Creatinine or eGFR withdrawal criteria|3
6150806|NCT01106690|9787074|FG002|Core Period: Baseline to Week 26|Creatinine or eGFR withdrawal criteria|1
6150807|NCT01106690|9787072|FG000|Core Period: Baseline to Week 26|Noncompliance with study drug|0
6150808|NCT01106690|9787073|FG001|Core Period: Baseline to Week 26|Noncompliance with study drug|1
6150809|NCT01106690|9787074|FG002|Core Period: Baseline to Week 26|Noncompliance with study drug|0
6150810|NCT01106690|9787072|FG000|Core Period: Baseline to Week 26|Unable to take rescue therapy|1
6150811|NCT01106690|9787073|FG001|Core Period: Baseline to Week 26|Unable to take rescue therapy|0
6150812|NCT01106690|9787074|FG002|Core Period: Baseline to Week 26|Unable to take rescue therapy|0
6150813|NCT01106690|9787072|FG000|Core Period: Baseline to Week 26|Lack of efficacy on rescue therapy|1
6150814|NCT01106690|9787073|FG001|Core Period: Baseline to Week 26|Lack of efficacy on rescue therapy|0
6040819|NCT00371826|9638911|FG001|Extension Phase (24 Months)|Subject withdrew consent|2
6318415|NCT02769065|10053703|FG009|Overall Study|Reason Not Specified|0
6318416|NCT02769065|10053704|FG010|Overall Study|Reason Not Specified|0
6150815|NCT01106690|9787074|FG002|Core Period: Baseline to Week 26|Lack of efficacy on rescue therapy|0
6150816|NCT01106690|9787072|FG000|Core Period: Baseline to Week 26|Other|10
6150817|NCT01106690|9787073|FG001|Core Period: Baseline to Week 26|Other|2
6318417|NCT02769065|10053705|FG011|Overall Study|Reason Not Specified|0
6318418|NCT02769065|10053706|FG012|Overall Study|Reason Not Specified|0
6318419|NCT02769065|10053707|FG013|Overall Study|Reason Not Specified|0
6040820|NCT00371826|9638912|FG002|Extension Phase (24 Months)|Subject withdrew consent|0
6040821|NCT00371826|9638910|FG000|Extension Phase (24 Months)|Administrative problems|0
6318420|NCT02769065|10053708|FG014|Overall Study|Reason Not Specified|0
6318421|NCT02769065|10053709|FG015|Overall Study|Reason Not Specified|0
6318422|NCT02769065|10053710|FG016|Overall Study|Reason Not Specified|0
6318423|NCT02769065|10053711|FG017|Overall Study|Reason Not Specified|0
6318424|NCT02769065|10053712|FG018|Overall Study|Reason Not Specified|0
6318425|NCT02769065|10053713|FG019|Overall Study|Reason Not Specified|0
6318426|NCT02769065|10053714|FG020|Overall Study|Reason Not Specified|0
6318427|NCT02769065|10053715|FG021|Overall Study|Reason Not Specified|0
6318428|NCT02769065|10053716|FG022|Overall Study|Reason Not Specified|0
6318429|NCT02769065|10053717|FG023|Overall Study|Reason Not Specified|0
6318430|NCT02769065|10053718|FG024|Overall Study|Reason Not Specified|0
6040822|NCT00371826|9638911|FG001|Extension Phase (24 Months)|Administrative problems|0
6318431|NCT02769065|10053719|FG025|Overall Study|Reason Not Specified|0
6318432|NCT02769065|10053720|FG026|Overall Study|Reason Not Specified|0
6318433|NCT02769065|10053721|FG027|Overall Study|Reason Not Specified|0
6318434|NCT02769065|10053722|FG028|Overall Study|Reason Not Specified|0
6318435|NCT02769065|10053723|FG029|Overall Study|Reason Not Specified|0
6318436|NCT02769065|10053694|FG000|Overall Study|Pre-treatment Event/Adverse Event|0
6318437|NCT02769065|10053695|FG001|Overall Study|Pre-treatment Event/Adverse Event|0
6318438|NCT02769065|10053696|FG002|Overall Study|Pre-treatment Event/Adverse Event|0
6318439|NCT02769065|10053697|FG003|Overall Study|Pre-treatment Event/Adverse Event|0
6318440|NCT02769065|10053698|FG004|Overall Study|Pre-treatment Event/Adverse Event|0
6318441|NCT02769065|10053699|FG005|Overall Study|Pre-treatment Event/Adverse Event|0
6318442|NCT02769065|10053700|FG006|Overall Study|Pre-treatment Event/Adverse Event|0
6318443|NCT02769065|10053701|FG007|Overall Study|Pre-treatment Event/Adverse Event|0
6318444|NCT02769065|10053702|FG008|Overall Study|Pre-treatment Event/Adverse Event|0
6318445|NCT02769065|10053703|FG009|Overall Study|Pre-treatment Event/Adverse Event|0
6318446|NCT02769065|10053704|FG010|Overall Study|Pre-treatment Event/Adverse Event|1
6318447|NCT02769065|10053705|FG011|Overall Study|Pre-treatment Event/Adverse Event|0
6318448|NCT02769065|10053706|FG012|Overall Study|Pre-treatment Event/Adverse Event|0
6318449|NCT02769065|10053707|FG013|Overall Study|Pre-treatment Event/Adverse Event|0
6318450|NCT02769065|10053708|FG014|Overall Study|Pre-treatment Event/Adverse Event|0
6318451|NCT02769065|10053709|FG015|Overall Study|Pre-treatment Event/Adverse Event|0
6318452|NCT02769065|10053710|FG016|Overall Study|Pre-treatment Event/Adverse Event|0
6318453|NCT02769065|10053711|FG017|Overall Study|Pre-treatment Event/Adverse Event|0
6318454|NCT02769065|10053712|FG018|Overall Study|Pre-treatment Event/Adverse Event|0
6318455|NCT02769065|10053713|FG019|Overall Study|Pre-treatment Event/Adverse Event|0
6318456|NCT02769065|10053714|FG020|Overall Study|Pre-treatment Event/Adverse Event|0
6318457|NCT02769065|10053715|FG021|Overall Study|Pre-treatment Event/Adverse Event|0
6318458|NCT02769065|10053716|FG022|Overall Study|Pre-treatment Event/Adverse Event|0
6318459|NCT02769065|10053717|FG023|Overall Study|Pre-treatment Event/Adverse Event|0
6318460|NCT02769065|10053718|FG024|Overall Study|Pre-treatment Event/Adverse Event|0
6318461|NCT02769065|10053719|FG025|Overall Study|Pre-treatment Event/Adverse Event|0
6318462|NCT02769065|10053720|FG026|Overall Study|Pre-treatment Event/Adverse Event|0
6318463|NCT02769065|10053721|FG027|Overall Study|Pre-treatment Event/Adverse Event|0
6318464|NCT02769065|10053722|FG028|Overall Study|Pre-treatment Event/Adverse Event|0
6318465|NCT02769065|10053723|FG029|Overall Study|Pre-treatment Event/Adverse Event|0
6040823|NCT00371826|9638912|FG002|Extension Phase (24 Months)|Administrative problems|2
6150818|NCT01106690|9787074|FG002|Core Period: Baseline to Week 26|Other|6
6150819|NCT01106690|9787072|FG000|Extension Period: Week 26 to Week 52|Adverse Event|1
6150820|NCT01106690|9787073|FG001|Extension Period: Week 26 to Week 52|Adverse Event|1
6150821|NCT01106690|9787074|FG002|Extension Period: Week 26 to Week 52|Adverse Event|0
6150822|NCT01106690|9787072|FG000|Extension Period: Week 26 to Week 52|Withdrawal by Subject|1
6150823|NCT01106690|9787073|FG001|Extension Period: Week 26 to Week 52|Withdrawal by Subject|0
6150824|NCT01106690|9787074|FG002|Extension Period: Week 26 to Week 52|Withdrawal by Subject|0
6150825|NCT01106690|9787072|FG000|Extension Period: Week 26 to Week 52|Physician Decision|0
6150826|NCT01106690|9787073|FG001|Extension Period: Week 26 to Week 52|Physician Decision|2
6150827|NCT01106690|9787074|FG002|Extension Period: Week 26 to Week 52|Physician Decision|2
6150828|NCT01106690|9787072|FG000|Extension Period: Week 26 to Week 52|Noncompliance with study drug|0
6150829|NCT01106690|9787073|FG001|Extension Period: Week 26 to Week 52|Noncompliance with study drug|0
6150830|NCT01106690|9787074|FG002|Extension Period: Week 26 to Week 52|Noncompliance with study drug|1
6150831|NCT01106690|9787072|FG000|Extension Period: Week 26 to Week 52|Unable to take rescue therapy|1
6150832|NCT01106690|9787073|FG001|Extension Period: Week 26 to Week 52|Unable to take rescue therapy|1
6150833|NCT01106690|9787074|FG002|Extension Period: Week 26 to Week 52|Unable to take rescue therapy|0
6150834|NCT01106690|9787072|FG000|Extension Period: Week 26 to Week 52|Other|8
6150835|NCT01106690|9787073|FG001|Extension Period: Week 26 to Week 52|Other|3
6150836|NCT01106690|9787074|FG002|Extension Period: Week 26 to Week 52|Other|4
6318466|NCT02769247|10053820|FG000|Overall Study|Withdrawal by Subject|1
6318467|NCT02769247|10053821|FG001|Overall Study|Withdrawal by Subject|0
6318468|NCT02769247|10053822|FG002|Overall Study|Withdrawal by Subject|0
6318469|NCT02769247|10053823|FG003|Overall Study|Withdrawal by Subject|1
6318470|NCT02769247|10053820|FG000|Overall Study|Protocol Violation|0
6318471|NCT02769247|10053821|FG001|Overall Study|Protocol Violation|0
6318472|NCT02769247|10053822|FG002|Overall Study|Protocol Violation|1
6318473|NCT02769247|10053823|FG003|Overall Study|Protocol Violation|0
6318474|NCT02769247|10053820|FG000|Overall Study|Physician Decision|1
6318475|NCT02769247|10053821|FG001|Overall Study|Physician Decision|0
6318476|NCT02769247|10053822|FG002|Overall Study|Physician Decision|0
6318477|NCT02769247|10053823|FG003|Overall Study|Physician Decision|0
6318478|NCT02769312|10053839|FG000|Double-Blind (0-2 Weeks)|Withdrawal by Subject|1
6318479|NCT02769312|10053840|FG001|Double-Blind (0-2 Weeks)|Withdrawal by Subject|1
6318480|NCT02769312|10053839|FG000|Double-Blind (0-2 Weeks)|Adverse Event|1
6150837|NCT01106690|9787072|FG000|Extension Period: Week 26 to Week 52|Lost to Follow-up|1
6150838|NCT01106690|9787073|FG001|Extension Period: Week 26 to Week 52|Lost to Follow-up|0
6150839|NCT01106690|9787074|FG002|Extension Period: Week 26 to Week 52|Lost to Follow-up|0
6150840|NCT01106846|9787096|FG000|Overall Study|Change in surgical procedure|0
6150841|NCT01106846|9787097|FG001|Overall Study|Change in surgical procedure|1
6150842|NCT01106898|9787114|FG000|Overall Study|Adverse Event|6
6150843|NCT01106911|9787118|FG000|Overall Study|Physician Decision|2
6040824|NCT00371839|9638923|FG000|Overall Study|Death|4
6040825|NCT00371839|9638924|FG001|Overall Study|Death|0
6040826|NCT00371839|9638925|FG002|Overall Study|Death|0
6040827|NCT00371839|9638923|FG000|Overall Study|Withdrawal by Subject|7
6040828|NCT00371839|9638924|FG001|Overall Study|Withdrawal by Subject|4
6040829|NCT00371839|9638925|FG002|Overall Study|Withdrawal by Subject|0
6150844|NCT01106911|9787118|FG000|Overall Study|deemed ineligible after screening|3
6150845|NCT01106976|9787128|FG000|Overall Study|Lost to Follow-up|8
6318481|NCT02769312|10053840|FG001|Double-Blind (0-2 Weeks)|Adverse Event|0
6318482|NCT02769312|10053839|FG000|Unblinded (Optional 2-4 Weeks)|Withdrawal by Subject|1
6318483|NCT02769312|10053840|FG001|Unblinded (Optional 2-4 Weeks)|Withdrawal by Subject|0
6318484|NCT02769312|10053839|FG000|Unblinded (Optional 2-4 Weeks)|Lost to Follow-up|0
6318485|NCT02769312|10053840|FG001|Unblinded (Optional 2-4 Weeks)|Lost to Follow-up|1
6318486|NCT02769312|10053839|FG000|Follow-up|Lost to Follow-up|1
6040830|NCT00371839|9638923|FG000|Overall Study|Lost to Follow-up|6
6150846|NCT01107197|9787151|FG000|Overall Study|Death|12
6150847|NCT01107197|9787152|FG001|Overall Study|Death|10
6150848|NCT01107197|9787151|FG000|Overall Study|Lost to Follow-up|5
6150849|NCT01107197|9787152|FG001|Overall Study|Lost to Follow-up|8
6150850|NCT01107197|9787151|FG000|Overall Study|Withdrawal by Subject|3
6150851|NCT01107197|9787152|FG001|Overall Study|Withdrawal by Subject|5
6150852|NCT01107353|9787160|FG000|Overall Study|Positive Drug Screen|1
6150853|NCT01107353|9787161|FG001|Overall Study|Positive Drug Screen|0
6150854|NCT01107379|9787167|FG000|Overall Study|Withdrawal by Subject|18
6150855|NCT01107379|9787167|FG000|Overall Study|Lost to Follow-up|3
6150856|NCT01107392|9787173|FG000|Overall Study|Adverse Event|2
6150857|NCT01107392|9787174|FG001|Overall Study|Adverse Event|0
6150858|NCT01107392|9787173|FG000|Overall Study|Personal Reasons|2
6150859|NCT01107392|9787174|FG001|Overall Study|Personal Reasons|3
6150860|NCT01107392|9787173|FG000|Overall Study|Administrative decision|1
6150861|NCT01107392|9787174|FG001|Overall Study|Administrative decision|0
6150862|NCT01107405|9787185|FG000|Overall Study|Adverse Event|1
6150863|NCT01107405|9787186|FG001|Overall Study|Adverse Event|1
6150864|NCT01107405|9787187|FG002|Overall Study|Adverse Event|0
6150865|NCT01107405|9787188|FG003|Overall Study|Adverse Event|0
6150866|NCT01107405|9787189|FG004|Overall Study|Adverse Event|2
6150867|NCT01107405|9787185|FG000|Overall Study|Withdrawal by Subject|1
6150868|NCT01107405|9787186|FG001|Overall Study|Withdrawal by Subject|0
6150869|NCT01107405|9787187|FG002|Overall Study|Withdrawal by Subject|1
6150870|NCT01107405|9787188|FG003|Overall Study|Withdrawal by Subject|2
6150871|NCT01107405|9787189|FG004|Overall Study|Withdrawal by Subject|1
6150872|NCT01107405|9787185|FG000|Overall Study|Protocol Violation|0
6150873|NCT01107405|9787186|FG001|Overall Study|Protocol Violation|0
6150874|NCT01107405|9787187|FG002|Overall Study|Protocol Violation|1
6150875|NCT01107405|9787188|FG003|Overall Study|Protocol Violation|1
6150876|NCT01107405|9787189|FG004|Overall Study|Protocol Violation|0
6150877|NCT01107418|9787205|FG000|Overall Study|Disease Progression|45
6150878|NCT01107418|9787205|FG000|Overall Study|Adverse Event|3
6150879|NCT01107418|9787205|FG000|Overall Study|Withdrawal by Subject|1
6150880|NCT01107418|9787205|FG000|Overall Study|Study Closing|1
6150881|NCT01107418|9787205|FG000|Overall Study|Started Other Therapy|1
6150882|NCT01107418|9787205|FG000|Overall Study|Entered Extension Study|1
6150883|NCT01107444|9787222|FG000|Overall Study|Withdrawal by Subject|8
6150884|NCT01107444|9787223|FG001|Overall Study|Withdrawal by Subject|12
6150885|NCT01107444|9787222|FG000|Overall Study|Protocol Entry Criteria Not Met|0
6150886|NCT01107444|9787223|FG001|Overall Study|Protocol Entry Criteria Not Met|1
6150887|NCT01107457|9787237|FG000|Part A|Adverse Event|1
6150888|NCT01107457|9787238|FG001|Part A|Adverse Event|2
6150889|NCT01107457|9787239|FG002|Part A|Adverse Event|1
6040831|NCT00371839|9638924|FG001|Overall Study|Lost to Follow-up|3
6040832|NCT00371839|9638925|FG002|Overall Study|Lost to Follow-up|2
6040833|NCT00371865|9638933|FG000|Overall Study|Lack of Efficacy|0
6150890|NCT01107457|9787240|FG003|Part A|Adverse Event|0
6150891|NCT01107457|9787241|FG004|Part A|Adverse Event|0
6318487|NCT02769312|10053840|FG001|Follow-up|Lost to Follow-up|1
6318488|NCT02769481|10053863|FG000|Overall Study|Protocol Violation|1
6318489|NCT02769481|10053864|FG001|Overall Study|Protocol Violation|0
6318490|NCT02769481|10053863|FG000|Overall Study|Adverse Event|3
6318491|NCT02769481|10053864|FG001|Overall Study|Adverse Event|6
6318492|NCT02769481|10053863|FG000|Overall Study|Entry Criteria Not Met|1
6318493|NCT02769481|10053864|FG001|Overall Study|Entry Criteria Not Met|2
6318494|NCT02769481|10053863|FG000|Overall Study|Withdrawal by Subject|14
6318495|NCT02769481|10053864|FG001|Overall Study|Withdrawal by Subject|16
6318496|NCT02769481|10053863|FG000|Overall Study|Lost to Follow-up|9
6318497|NCT02769481|10053864|FG001|Overall Study|Lost to Follow-up|9
6318498|NCT02769481|10053863|FG000|Overall Study|Physician Decision|0
6318499|NCT02769481|10053864|FG001|Overall Study|Physician Decision|1
6318500|NCT02769481|10053863|FG000|Overall Study|Terminated by Sponsor|1
6318501|NCT02769481|10053864|FG001|Overall Study|Terminated by Sponsor|0
6318502|NCT02769481|10053863|FG000|Overall Study|Death|0
6318503|NCT02769481|10053864|FG001|Overall Study|Death|1
6318504|NCT02769481|10053863|FG000|Overall Study|Undefined|4
6318505|NCT02769481|10053864|FG001|Overall Study|Undefined|1
6318506|NCT02769624|10053870|FG000|Overall Study|Lost to Follow-up|0
6318507|NCT02769624|10053871|FG001|Overall Study|Lost to Follow-up|1
6318508|NCT02769858|10053881|FG000|Overall Study|Withdrawal by Subject|2
6318509|NCT02770170|10053894|FG000|Overall Study|Withdrawal by Subject|0
6318510|NCT02770170|10053895|FG001|Overall Study|Withdrawal by Subject|0
6318511|NCT02770170|10053896|FG002|Overall Study|Withdrawal by Subject|0
6318512|NCT02770170|10053897|FG003|Overall Study|Withdrawal by Subject|2
6318513|NCT02770170|10053894|FG000|Overall Study|due to pregnancy|1
6318514|NCT02770170|10053895|FG001|Overall Study|due to pregnancy|0
6318515|NCT02770170|10053896|FG002|Overall Study|due to pregnancy|0
6318516|NCT02770170|10053897|FG003|Overall Study|due to pregnancy|0
6318517|NCT02770170|10053894|FG000|Overall Study|Lack of Efficacy|2
6318518|NCT02770170|10053895|FG001|Overall Study|Lack of Efficacy|0
6318519|NCT02770170|10053896|FG002|Overall Study|Lack of Efficacy|0
6318520|NCT02770170|10053897|FG003|Overall Study|Lack of Efficacy|1
6318521|NCT02770170|10053894|FG000|Overall Study|Adverse Event|4
6318522|NCT02770170|10053895|FG001|Overall Study|Adverse Event|3
6318523|NCT02770170|10053896|FG002|Overall Study|Adverse Event|5
6318524|NCT02770170|10053897|FG003|Overall Study|Adverse Event|3
6318525|NCT02770170|10053894|FG000|Overall Study|due to disease worsening|0
6318526|NCT02770170|10053895|FG001|Overall Study|due to disease worsening|0
6318527|NCT02770170|10053896|FG002|Overall Study|due to disease worsening|0
6318528|NCT02770170|10053897|FG003|Overall Study|due to disease worsening|1
6318529|NCT02770248|10053909|FG000|Overall Study|Adverse Event|0
6318530|NCT02770248|10053910|FG001|Overall Study|Adverse Event|1
6318531|NCT02770248|10053909|FG000|Overall Study|Randomized in error, prior to treatment|0
6318532|NCT02770248|10053910|FG001|Overall Study|Randomized in error, prior to treatment|1
6318533|NCT02770547|10053963|FG000|Overall Study|Patient non-compliant|1
6318534|NCT02770547|10053964|FG001|Overall Study|Patient non-compliant|0
6318535|NCT02770547|10053963|FG000|Overall Study|Adverse Event|0
6318536|NCT02770547|10053964|FG001|Overall Study|Adverse Event|1
6318537|NCT02770612|10053970|FG000|Overall Study|Met exclusion criteria (postop LOS>7d)|1
6150892|NCT01107457|9787242|FG005|Part A|Adverse Event|0
6150893|NCT01107457|9787237|FG000|Part A|Withdrawal by Subject|3
6150894|NCT01107457|9787238|FG001|Part A|Withdrawal by Subject|3
6150895|NCT01107457|9787239|FG002|Part A|Withdrawal by Subject|0
6150896|NCT01107457|9787240|FG003|Part A|Withdrawal by Subject|3
6150897|NCT01107457|9787241|FG004|Part A|Withdrawal by Subject|1
6150898|NCT01107457|9787242|FG005|Part A|Withdrawal by Subject|0
6150899|NCT01107457|9787237|FG000|Part A|Lost to Follow-up|0
6150900|NCT01107457|9787238|FG001|Part A|Lost to Follow-up|1
6150901|NCT01107457|9787239|FG002|Part A|Lost to Follow-up|0
6150902|NCT01107457|9787240|FG003|Part A|Lost to Follow-up|0
6150903|NCT01107457|9787241|FG004|Part A|Lost to Follow-up|0
6150904|NCT01107457|9787242|FG005|Part A|Lost to Follow-up|0
6150905|NCT01107457|9787237|FG000|Part A|Lack of Efficacy|1
6150906|NCT01107457|9787238|FG001|Part A|Lack of Efficacy|0
6150907|NCT01107457|9787239|FG002|Part A|Lack of Efficacy|0
6150908|NCT01107457|9787240|FG003|Part A|Lack of Efficacy|0
6150909|NCT01107457|9787241|FG004|Part A|Lack of Efficacy|0
6150910|NCT01107457|9787242|FG005|Part A|Lack of Efficacy|0
6150911|NCT01107457|9787237|FG000|Part A|Protocol Violation|0
6150912|NCT01107457|9787238|FG001|Part A|Protocol Violation|1
6150913|NCT01107457|9787239|FG002|Part A|Protocol Violation|0
6150914|NCT01107457|9787240|FG003|Part A|Protocol Violation|0
6150915|NCT01107457|9787241|FG004|Part A|Protocol Violation|0
6150916|NCT01107457|9787242|FG005|Part A|Protocol Violation|0
6150917|NCT01107457|9787237|FG000|Part B and C|Adverse Event|0
6150918|NCT01107457|9787238|FG001|Part B and C|Adverse Event|0
6150919|NCT01107457|9787239|FG002|Part B and C|Adverse Event|0
6150920|NCT01107457|9787240|FG003|Part B and C|Adverse Event|0
6150921|NCT01107457|9787241|FG004|Part B and C|Adverse Event|0
6150922|NCT01107457|9787242|FG005|Part B and C|Adverse Event|12
6150923|NCT01107457|9787237|FG000|Part B and C|Inclusion/Exclusion Criteria Not Met|0
6150924|NCT01107457|9787238|FG001|Part B and C|Inclusion/Exclusion Criteria Not Met|0
6150925|NCT01107457|9787239|FG002|Part B and C|Inclusion/Exclusion Criteria Not Met|0
6150926|NCT01107457|9787240|FG003|Part B and C|Inclusion/Exclusion Criteria Not Met|0
6150927|NCT01107457|9787241|FG004|Part B and C|Inclusion/Exclusion Criteria Not Met|0
6150928|NCT01107457|9787242|FG005|Part B and C|Inclusion/Exclusion Criteria Not Met|1
6150929|NCT01107457|9787237|FG000|Part B and C|Physician Decision|0
6150930|NCT01107457|9787238|FG001|Part B and C|Physician Decision|0
6150931|NCT01107457|9787239|FG002|Part B and C|Physician Decision|0
6150932|NCT01107457|9787240|FG003|Part B and C|Physician Decision|0
6150933|NCT01107457|9787241|FG004|Part B and C|Physician Decision|0
6150934|NCT01107457|9787242|FG005|Part B and C|Physician Decision|3
6318538|NCT02770820|10053978|FG000|Overall Study|Death|1
6318539|NCT02770820|10053978|FG000|Overall Study|Physician Decision|2
6318540|NCT02771145|10054002|FG000|Overall Study|Adverse Event|3
6318541|NCT02771145|10054002|FG000|Overall Study|Lost to Follow-up|1
6318542|NCT02771210|10054024|FG000|Period 1|Adverse Event|5
6318543|NCT02771210|10054025|FG001|Period 1|Adverse Event|3
6318544|NCT02771210|10054024|FG000|Period 1|Lack of Efficacy|3
6318545|NCT02771210|10054025|FG001|Period 1|Lack of Efficacy|6
6318546|NCT02771210|10054024|FG000|Period 1|Lost to Follow-up|2
6318547|NCT02771210|10054025|FG001|Period 1|Lost to Follow-up|0
6318548|NCT02771210|10054024|FG000|Period 1|Physician Decision|0
6318549|NCT02771210|10054025|FG001|Period 1|Physician Decision|1
6318550|NCT02771210|10054024|FG000|Period 1|Withdrawal by Subject|0
6318551|NCT02771210|10054025|FG001|Period 1|Withdrawal by Subject|3
6318552|NCT02771210|10054024|FG000|Period 1|Withdrawal of informed consent|1
6318553|NCT02771210|10054025|FG001|Period 1|Withdrawal of informed consent|5
6318554|NCT02771210|10054024|FG000|Period 2|Adverse Event|1
6318555|NCT02771210|10054025|FG001|Period 2|Adverse Event|0
6318556|NCT02771210|10054024|FG000|Period 2|Lack of Efficacy|0
6318557|NCT02771210|10054025|FG001|Period 2|Lack of Efficacy|1
6318558|NCT02771210|10054024|FG000|Period 2|Withdrawal by Subject|1
6318559|NCT02771210|10054025|FG001|Period 2|Withdrawal by Subject|0
6318560|NCT02771210|10054024|FG000|Period 2|Withdrawal of informed consent|0
6318561|NCT02771210|10054025|FG001|Period 2|Withdrawal of informed consent|2
6318562|NCT02771366|10054046|FG000|Period 1|Withdrawal by Subject|0
6318563|NCT02771366|10054047|FG001|Period 1|Withdrawal by Subject|2
6040834|NCT00371865|9638934|FG001|Overall Study|Lack of Efficacy|2
6040835|NCT00371865|9638933|FG000|Overall Study|Protocol Violation|3
6040836|NCT00371865|9638934|FG001|Overall Study|Protocol Violation|2
6040837|NCT00371865|9638933|FG000|Overall Study|Withdrawal by Subject|12
6040838|NCT00371865|9638934|FG001|Overall Study|Withdrawal by Subject|10
6040839|NCT00372060|9638942|FG000|Period I - Double-blind (Weeks 0-12)|Adverse Event|2
6040840|NCT00372060|9638943|FG001|Period I - Double-blind (Weeks 0-12)|Adverse Event|0
6040841|NCT00372060|9638942|FG000|Period I - Double-blind (Weeks 0-12)|Lack of Efficacy|0
6040842|NCT00372060|9638943|FG001|Period I - Double-blind (Weeks 0-12)|Lack of Efficacy|1
6040843|NCT00372060|9638942|FG000|Period I - Double-blind (Weeks 0-12)|No improvement in hyperglycemia|1
6040844|NCT00372060|9638943|FG001|Period I - Double-blind (Weeks 0-12)|No improvement in hyperglycemia|0
6150935|NCT01107457|9787237|FG000|Part B and C|Lack of Efficacy|0
6150936|NCT01107457|9787238|FG001|Part B and C|Lack of Efficacy|0
6150937|NCT01107457|9787239|FG002|Part B and C|Lack of Efficacy|0
6150938|NCT01107457|9787240|FG003|Part B and C|Lack of Efficacy|0
6150939|NCT01107457|9787241|FG004|Part B and C|Lack of Efficacy|0
6150940|NCT01107457|9787242|FG005|Part B and C|Lack of Efficacy|7
6150941|NCT01107457|9787237|FG000|Part B and C|Lost to Follow-up|0
6150942|NCT01107457|9787238|FG001|Part B and C|Lost to Follow-up|0
6150943|NCT01107457|9787239|FG002|Part B and C|Lost to Follow-up|0
6150944|NCT01107457|9787240|FG003|Part B and C|Lost to Follow-up|0
6150945|NCT01107457|9787241|FG004|Part B and C|Lost to Follow-up|0
6150946|NCT01107457|9787242|FG005|Part B and C|Lost to Follow-up|10
6150947|NCT01107457|9787237|FG000|Part B and C|Protocol Violation|0
6150948|NCT01107457|9787238|FG001|Part B and C|Protocol Violation|0
6150949|NCT01107457|9787239|FG002|Part B and C|Protocol Violation|0
6150950|NCT01107457|9787240|FG003|Part B and C|Protocol Violation|0
6150951|NCT01107457|9787241|FG004|Part B and C|Protocol Violation|0
6150952|NCT01107457|9787242|FG005|Part B and C|Protocol Violation|1
6150953|NCT01107457|9787237|FG000|Part B and C|Sponsor Decision|0
6150954|NCT01107457|9787238|FG001|Part B and C|Sponsor Decision|0
6150955|NCT01107457|9787239|FG002|Part B and C|Sponsor Decision|0
6150956|NCT01107457|9787240|FG003|Part B and C|Sponsor Decision|0
6150957|NCT01107457|9787241|FG004|Part B and C|Sponsor Decision|0
6150958|NCT01107457|9787242|FG005|Part B and C|Sponsor Decision|66
6150959|NCT01107457|9787237|FG000|Part B and C|Withdrawal by Subject|0
6150960|NCT01107457|9787238|FG001|Part B and C|Withdrawal by Subject|0
6150961|NCT01107457|9787239|FG002|Part B and C|Withdrawal by Subject|0
6150962|NCT01107457|9787240|FG003|Part B and C|Withdrawal by Subject|0
6150963|NCT01107457|9787241|FG004|Part B and C|Withdrawal by Subject|0
6150964|NCT01107457|9787242|FG005|Part B and C|Withdrawal by Subject|16
6150965|NCT01107457|9787237|FG000|Part B and C|Clinical Relapse|0
6150966|NCT01107457|9787238|FG001|Part B and C|Clinical Relapse|0
6150967|NCT01107457|9787239|FG002|Part B and C|Clinical Relapse|0
6150968|NCT01107457|9787240|FG003|Part B and C|Clinical Relapse|0
6150969|NCT01107457|9787241|FG004|Part B and C|Clinical Relapse|0
6150970|NCT01107457|9787242|FG005|Part B and C|Clinical Relapse|4
6150971|NCT01107535|9787260|FG000|Overall Study|Death|5
6150972|NCT01107626|9787268|FG000|Step 1: Induction Therapy|Lack of Efficacy|167
6150973|NCT01107626|9787269|FG001|Step 1: Induction Therapy|Lack of Efficacy|0
6150974|NCT01107626|9787270|FG002|Step 1: Induction Therapy|Lack of Efficacy|0
6150975|NCT01107626|9787271|FG003|Step 1: Induction Therapy|Lack of Efficacy|0
6150976|NCT01107626|9787268|FG000|Step 1: Induction Therapy|Adverse Event|198
6150977|NCT01107626|9787269|FG001|Step 1: Induction Therapy|Adverse Event|0
6150978|NCT01107626|9787270|FG002|Step 1: Induction Therapy|Adverse Event|0
6150979|NCT01107626|9787271|FG003|Step 1: Induction Therapy|Adverse Event|0
6150980|NCT01107626|9787268|FG000|Step 1: Induction Therapy|Death|62
6150981|NCT01107626|9787269|FG001|Step 1: Induction Therapy|Death|0
6150982|NCT01107626|9787270|FG002|Step 1: Induction Therapy|Death|0
6318564|NCT02771366|10054046|FG000|Period 2 (Crossover)|Withdrawal by Subject|2
6318565|NCT02771366|10054047|FG001|Period 2 (Crossover)|Withdrawal by Subject|0
6318566|NCT02771522|10054054|FG000|Overall Study|Lost to Follow-up|3
6150983|NCT01107626|9787271|FG003|Step 1: Induction Therapy|Death|0
6150984|NCT01107626|9787268|FG000|Step 1: Induction Therapy|Withdrawal by Subject|54
6318567|NCT02771522|10054054|FG000|Overall Study|Withdrawal by Subject|2
6318568|NCT02771522|10054054|FG000|Overall Study|No white spot lesions|3
6318569|NCT02772757|10054113|FG000|Overall Study|Withdrawal by Subject|1
6318570|NCT02772757|10054114|FG001|Overall Study|Withdrawal by Subject|0
6318571|NCT02772757|10054115|FG002|Overall Study|Withdrawal by Subject|1
6318572|NCT02772757|10054113|FG000|Overall Study|Protocol Violation|0
6318573|NCT02772757|10054114|FG001|Overall Study|Protocol Violation|0
6318574|NCT02772757|10054115|FG002|Overall Study|Protocol Violation|1
6318575|NCT02772757|10054113|FG000|Overall Study|Physician Decision|0
6318576|NCT02772757|10054114|FG001|Overall Study|Physician Decision|3
6318577|NCT02772757|10054115|FG002|Overall Study|Physician Decision|3
6318578|NCT02772809|10054133|FG000|Overall Study|not completed some tasks|6
6318579|NCT02772978|10054142|FG000|Overall Study|Withdrawal by Subject|1
6318580|NCT02772978|10054143|FG001|Overall Study|Withdrawal by Subject|1
6318581|NCT02773368|10054150|FG000|Overall Study|Lost to Follow-up|4
6318582|NCT02773368|10054151|FG001|Overall Study|Lost to Follow-up|1
6318583|NCT02773368|10054150|FG000|Overall Study|Withdrawal by Subject|5
6318584|NCT02773368|10054151|FG001|Overall Study|Withdrawal by Subject|1
6318585|NCT02773368|10054150|FG000|Overall Study|Unclassified|1
6318586|NCT02773368|10054151|FG001|Overall Study|Unclassified|1
6318587|NCT02773368|10054150|FG000|Overall Study|Missing|0
6318588|NCT02773368|10054151|FG001|Overall Study|Missing|1
6318589|NCT02773446|10054163|FG000|First Admission|Withdrawal by Subject|0
6318590|NCT02773446|10054164|FG001|First Admission|Withdrawal by Subject|0
6318591|NCT02773446|10054165|FG002|First Admission|Withdrawal by Subject|0
6318592|NCT02773446|10054166|FG003|First Admission|Withdrawal by Subject|1
6318593|NCT02773446|10054167|FG004|First Admission|Withdrawal by Subject|0
6318594|NCT02773446|10054168|FG005|First Admission|Withdrawal by Subject|0
6318595|NCT02773446|10054163|FG000|First Admission|Lost to Follow-up|1
6040845|NCT00372060|9638942|FG000|Period II - Open-label (Weeks 12-52)|Adverse Event|3
6040846|NCT00372060|9638943|FG001|Period II - Open-label (Weeks 12-52)|Adverse Event|0
6040847|NCT00372060|9638942|FG000|Period II - Open-label (Weeks 12-52)|Lack of Efficacy|9
6040848|NCT00372060|9638943|FG001|Period II - Open-label (Weeks 12-52)|Lack of Efficacy|8
6040849|NCT00372060|9638942|FG000|Period II - Open-label (Weeks 12-52)|Withdrawal by Subject|2
6040850|NCT00372060|9638943|FG001|Period II - Open-label (Weeks 12-52)|Withdrawal by Subject|0
6040851|NCT00372112|9638956|FG000|Overall Study|Adverse Event|0
6040852|NCT00372112|9638957|FG001|Overall Study|Adverse Event|1
6040853|NCT00372112|9638958|FG002|Overall Study|Adverse Event|1
6040854|NCT00372112|9638959|FG003|Overall Study|Adverse Event|1
6227382|NCT01716585|9900082|FG001|Open-label Treatment|Adverse Event|2
6040855|NCT00372112|9638956|FG000|Overall Study|Withdrawal by Subject|0
6040856|NCT00372112|9638957|FG001|Overall Study|Withdrawal by Subject|0
6040857|NCT00372112|9638958|FG002|Overall Study|Withdrawal by Subject|2
6040858|NCT00372112|9638959|FG003|Overall Study|Withdrawal by Subject|1
6040859|NCT00372112|9638956|FG000|Overall Study|Exacerbation|0
6040860|NCT00372112|9638957|FG001|Overall Study|Exacerbation|0
6040861|NCT00372112|9638958|FG002|Overall Study|Exacerbation|0
6040862|NCT00372112|9638959|FG003|Overall Study|Exacerbation|1
6040863|NCT00372112|9638956|FG000|Overall Study|PR >240 at Visit 3|0
6040864|NCT00372112|9638957|FG001|Overall Study|PR >240 at Visit 3|0
6040865|NCT00372112|9638958|FG002|Overall Study|PR >240 at Visit 3|0
6040866|NCT00372112|9638959|FG003|Overall Study|PR >240 at Visit 3|1
6040867|NCT00372112|9638956|FG000|Overall Study|Hepatitis B|1
6040868|NCT00372112|9638957|FG001|Overall Study|Hepatitis B|0
6040869|NCT00372112|9638958|FG002|Overall Study|Hepatitis B|0
6040870|NCT00372112|9638959|FG003|Overall Study|Hepatitis B|0
6040871|NCT00372112|9638956|FG000|Overall Study|Other-protocol violation|0
6040872|NCT00372112|9638957|FG001|Overall Study|Other-protocol violation|0
6040873|NCT00372112|9638958|FG002|Overall Study|Other-protocol violation|1
6040874|NCT00372112|9638959|FG003|Overall Study|Other-protocol violation|0
6040875|NCT00372190|9638974|FG000|Overall Study|Lost to Follow-up|3
6040876|NCT00372190|9638975|FG001|Overall Study|Lost to Follow-up|1
6040877|NCT00372255|9638985|FG000|Overall Study|Withdrawn for other reasons|2
6040878|NCT00372255|9638986|FG001|Overall Study|Withdrawn for other reasons|1
6040879|NCT00372385|9638997|FG000|Overall Study|Adverse Event|6
6040880|NCT00372385|9638998|FG001|Overall Study|Adverse Event|11
6040881|NCT00372385|9638999|FG002|Overall Study|Adverse Event|9
6040882|NCT00372385|9639000|FG003|Overall Study|Adverse Event|7
6040883|NCT00372385|9638997|FG000|Overall Study|Noncompliance|0
6040884|NCT00372385|9638998|FG001|Overall Study|Noncompliance|1
6040885|NCT00372385|9638999|FG002|Overall Study|Noncompliance|1
6040886|NCT00372385|9639000|FG003|Overall Study|Noncompliance|1
6040887|NCT00372385|9638997|FG000|Overall Study|Physician Decision|1
6040888|NCT00372385|9638998|FG001|Overall Study|Physician Decision|0
6040889|NCT00372385|9638999|FG002|Overall Study|Physician Decision|0
6040890|NCT00372385|9639000|FG003|Overall Study|Physician Decision|0
6040891|NCT00372385|9638997|FG000|Overall Study|Lost to Follow-up|2
6040892|NCT00372385|9638998|FG001|Overall Study|Lost to Follow-up|0
6318596|NCT02773446|10054164|FG001|First Admission|Lost to Follow-up|0
6318597|NCT02773446|10054165|FG002|First Admission|Lost to Follow-up|0
6318598|NCT02773446|10054166|FG003|First Admission|Lost to Follow-up|0
6040893|NCT00372385|9638999|FG002|Overall Study|Lost to Follow-up|0
6040894|NCT00372385|9639000|FG003|Overall Study|Lost to Follow-up|0
6318599|NCT02773446|10054167|FG004|First Admission|Lost to Follow-up|0
6318600|NCT02773446|10054168|FG005|First Admission|Lost to Follow-up|0
6318601|NCT02773537|10054188|FG000|Overall Study|Lost to Follow-up|0
6318602|NCT02773537|10054189|FG001|Overall Study|Lost to Follow-up|1
6318603|NCT02773537|10054190|FG002|Overall Study|Lost to Follow-up|4
6318604|NCT02774278|10054251|FG000|Overall Study|Lack of Efficacy|199
6318605|NCT02774278|10054251|FG000|Overall Study|Death|29
6318606|NCT02774278|10054251|FG000|Overall Study|Adverse event/intercurrent illness|16
6318607|NCT02774278|10054251|FG000|Overall Study|Refused treatment/did not cooperate|9
6318608|NCT02774278|10054251|FG000|Overall Study|Administrative reasons|6
6318609|NCT02774278|10054251|FG000|Overall Study|Withdrawal by Subject|3
6318610|NCT02774278|10054251|FG000|Overall Study|Protocol Violation|2
6318611|NCT02774681|10054279|FG000|Treatment on Study|Progressive Disease|7
6318612|NCT02774681|10054279|FG000|Follow-Up for 3 Years|Death|11
6318613|NCT02774681|10054279|FG000|Follow-Up for 3 Years|Withdrawal by Subject|1
6318614|NCT02775344|10054322|FG000|Overall Study|No ovarian cyst identified|3
6150985|NCT01107626|9787269|FG001|Step 1: Induction Therapy|Withdrawal by Subject|0
6150986|NCT01107626|9787270|FG002|Step 1: Induction Therapy|Withdrawal by Subject|0
6150987|NCT01107626|9787271|FG003|Step 1: Induction Therapy|Withdrawal by Subject|0
6150988|NCT01107626|9787268|FG000|Step 1: Induction Therapy|Complicating disease|13
6150989|NCT01107626|9787269|FG001|Step 1: Induction Therapy|Complicating disease|0
6150990|NCT01107626|9787270|FG002|Step 1: Induction Therapy|Complicating disease|0
6150991|NCT01107626|9787271|FG003|Step 1: Induction Therapy|Complicating disease|0
6150992|NCT01107626|9787268|FG000|Step 1: Induction Therapy|Alternative therapy|12
6150993|NCT01107626|9787269|FG001|Step 1: Induction Therapy|Alternative therapy|0
6150994|NCT01107626|9787270|FG002|Step 1: Induction Therapy|Alternative therapy|0
6150995|NCT01107626|9787271|FG003|Step 1: Induction Therapy|Alternative therapy|0
6150996|NCT01107626|9787268|FG000|Step 1: Induction Therapy|Symptomatic deterioration|10
6150997|NCT01107626|9787269|FG001|Step 1: Induction Therapy|Symptomatic deterioration|0
6150998|NCT01107626|9787270|FG002|Step 1: Induction Therapy|Symptomatic deterioration|0
6150999|NCT01107626|9787271|FG003|Step 1: Induction Therapy|Symptomatic deterioration|0
6151000|NCT01107626|9787268|FG000|Step 1: Induction Therapy|Non-compliance|4
6151001|NCT01107626|9787269|FG001|Step 1: Induction Therapy|Non-compliance|0
6151002|NCT01107626|9787270|FG002|Step 1: Induction Therapy|Non-compliance|0
6151003|NCT01107626|9787271|FG003|Step 1: Induction Therapy|Non-compliance|0
6151004|NCT01107626|9787268|FG000|Step 1: Induction Therapy|Pain|4
6151005|NCT01107626|9787269|FG001|Step 1: Induction Therapy|Pain|0
6151006|NCT01107626|9787270|FG002|Step 1: Induction Therapy|Pain|0
6151007|NCT01107626|9787271|FG003|Step 1: Induction Therapy|Pain|0
6151008|NCT01107626|9787268|FG000|Step 1: Induction Therapy|Protocol Violation|1
6151009|NCT01107626|9787269|FG001|Step 1: Induction Therapy|Protocol Violation|0
6151010|NCT01107626|9787270|FG002|Step 1: Induction Therapy|Protocol Violation|0
6151011|NCT01107626|9787271|FG003|Step 1: Induction Therapy|Protocol Violation|0
6151012|NCT01107626|9787268|FG000|Step 1: Induction Therapy|Hospice care|1
6151013|NCT01107626|9787269|FG001|Step 1: Induction Therapy|Hospice care|0
6151014|NCT01107626|9787270|FG002|Step 1: Induction Therapy|Hospice care|0
6151015|NCT01107626|9787271|FG003|Step 1: Induction Therapy|Hospice care|0
6151016|NCT01107626|9787268|FG000|Step 1: Induction Therapy|Physician Decision|1
6151017|NCT01107626|9787269|FG001|Step 1: Induction Therapy|Physician Decision|0
6151018|NCT01107626|9787270|FG002|Step 1: Induction Therapy|Physician Decision|0
6151019|NCT01107626|9787271|FG003|Step 1: Induction Therapy|Physician Decision|0
6151020|NCT01107626|9787268|FG000|Step 1: Induction Therapy|Off treatment reason not reported|50
6151021|NCT01107626|9787269|FG001|Step 1: Induction Therapy|Off treatment reason not reported|0
6151022|NCT01107626|9787270|FG002|Step 1: Induction Therapy|Off treatment reason not reported|0
6318615|NCT02775344|10054323|FG001|Overall Study|No ovarian cyst identified|2
6318616|NCT02775864|10054342|FG000|Overall Study|Data ended end of 2010|1764
6318617|NCT02775864|10054343|FG001|Overall Study|Data ended end of 2010|2880
6318618|NCT02775864|10054344|FG002|Overall Study|Data ended end of 2010|1140
6318619|NCT02775864|10054345|FG003|Overall Study|Data ended end of 2010|1194
6318620|NCT02775864|10054342|FG000|Overall Study|Medicaid eligibility discontinued|1478
6318621|NCT02775864|10054343|FG001|Overall Study|Medicaid eligibility discontinued|2019
6318622|NCT02775864|10054344|FG002|Overall Study|Medicaid eligibility discontinued|720
6318623|NCT02775864|10054345|FG003|Overall Study|Medicaid eligibility discontinued|890
6318624|NCT02775903|10054360|FG000|Overall Study|Ongoing|14
6318625|NCT02775903|10054361|FG001|Overall Study|Ongoing|15
6318626|NCT02775903|10054362|FG002|Overall Study|Ongoing|15
6318627|NCT02775903|10054363|FG003|Overall Study|Ongoing|19
6318628|NCT02775903|10054360|FG000|Overall Study|Death|19
6318629|NCT02775903|10054361|FG001|Overall Study|Death|18
6318630|NCT02775903|10054362|FG002|Overall Study|Death|38
6318631|NCT02775903|10054363|FG003|Overall Study|Death|35
6318632|NCT02775903|10054360|FG000|Overall Study|Withdrawal by Subject|5
6318633|NCT02775903|10054361|FG001|Overall Study|Withdrawal by Subject|5
6318634|NCT02775903|10054362|FG002|Overall Study|Withdrawal by Subject|5
6318635|NCT02775903|10054363|FG003|Overall Study|Withdrawal by Subject|4
6318636|NCT02775903|10054360|FG000|Overall Study|Adverse Event|0
6318637|NCT02775903|10054361|FG001|Overall Study|Adverse Event|0
6318638|NCT02775903|10054362|FG002|Overall Study|Adverse Event|1
6318639|NCT02775903|10054363|FG003|Overall Study|Adverse Event|1
6318640|NCT02775903|10054360|FG000|Overall Study|Lost to Follow-up|0
6151023|NCT01107626|9787271|FG003|Step 1: Induction Therapy|Off treatment reason not reported|0
6151024|NCT01107626|9787268|FG000|Step 2: Maintenance Therapy|Lack of Efficacy|0
6151025|NCT01107626|9787269|FG001|Step 2: Maintenance Therapy|Lack of Efficacy|217
6151026|NCT01107626|9787270|FG002|Step 2: Maintenance Therapy|Lack of Efficacy|217
6151027|NCT01107626|9787271|FG003|Step 2: Maintenance Therapy|Lack of Efficacy|170
6151028|NCT01107626|9787268|FG000|Step 2: Maintenance Therapy|Adverse Event|0
6151029|NCT01107626|9787269|FG001|Step 2: Maintenance Therapy|Adverse Event|32
6151030|NCT01107626|9787270|FG002|Step 2: Maintenance Therapy|Adverse Event|29
6151031|NCT01107626|9787271|FG003|Step 2: Maintenance Therapy|Adverse Event|46
6151032|NCT01107626|9787268|FG000|Step 2: Maintenance Therapy|Death|0
6151033|NCT01107626|9787269|FG001|Step 2: Maintenance Therapy|Death|8
6151034|NCT01107626|9787270|FG002|Step 2: Maintenance Therapy|Death|2
6151035|NCT01107626|9787271|FG003|Step 2: Maintenance Therapy|Death|13
6151036|NCT01107626|9787268|FG000|Step 2: Maintenance Therapy|Withdrawal by Subject|0
6151037|NCT01107626|9787269|FG001|Step 2: Maintenance Therapy|Withdrawal by Subject|11
6151038|NCT01107626|9787270|FG002|Step 2: Maintenance Therapy|Withdrawal by Subject|21
6151039|NCT01107626|9787271|FG003|Step 2: Maintenance Therapy|Withdrawal by Subject|27
6151040|NCT01107626|9787268|FG000|Step 2: Maintenance Therapy|Alternative therapy|0
6151041|NCT01107626|9787269|FG001|Step 2: Maintenance Therapy|Alternative therapy|2
6151042|NCT01107626|9787270|FG002|Step 2: Maintenance Therapy|Alternative therapy|4
6151043|NCT01107626|9787271|FG003|Step 2: Maintenance Therapy|Alternative therapy|5
6151044|NCT01107626|9787268|FG000|Step 2: Maintenance Therapy|Other complicating disease|0
6151045|NCT01107626|9787269|FG001|Step 2: Maintenance Therapy|Other complicating disease|2
6151046|NCT01107626|9787270|FG002|Step 2: Maintenance Therapy|Other complicating disease|5
6151047|NCT01107626|9787271|FG003|Step 2: Maintenance Therapy|Other complicating disease|9
6151048|NCT01107626|9787268|FG000|Step 2: Maintenance Therapy|Symptomatic deterioration|0
6151049|NCT01107626|9787269|FG001|Step 2: Maintenance Therapy|Symptomatic deterioration|2
6151050|NCT01107626|9787270|FG002|Step 2: Maintenance Therapy|Symptomatic deterioration|4
6151051|NCT01107626|9787271|FG003|Step 2: Maintenance Therapy|Symptomatic deterioration|3
6151052|NCT01107626|9787268|FG000|Step 2: Maintenance Therapy|Exceeded maximum delay in treatment|0
6151053|NCT01107626|9787269|FG001|Step 2: Maintenance Therapy|Exceeded maximum delay in treatment|2
6151054|NCT01107626|9787270|FG002|Step 2: Maintenance Therapy|Exceeded maximum delay in treatment|2
6151055|NCT01107626|9787271|FG003|Step 2: Maintenance Therapy|Exceeded maximum delay in treatment|3
6151056|NCT01107626|9787268|FG000|Step 2: Maintenance Therapy|Diagnosis of progressive disease error|0
6151057|NCT01107626|9787269|FG001|Step 2: Maintenance Therapy|Diagnosis of progressive disease error|1
6151058|NCT01107626|9787270|FG002|Step 2: Maintenance Therapy|Diagnosis of progressive disease error|1
6151059|NCT01107626|9787271|FG003|Step 2: Maintenance Therapy|Diagnosis of progressive disease error|0
6151060|NCT01107626|9787268|FG000|Step 2: Maintenance Therapy|Financial reason|0
6151061|NCT01107626|9787269|FG001|Step 2: Maintenance Therapy|Financial reason|2
6151062|NCT01107626|9787270|FG002|Step 2: Maintenance Therapy|Financial reason|0
6151063|NCT01107626|9787271|FG003|Step 2: Maintenance Therapy|Financial reason|0
6151064|NCT01107626|9787268|FG000|Step 2: Maintenance Therapy|Physician Decision|0
6151065|NCT01107626|9787269|FG001|Step 2: Maintenance Therapy|Physician Decision|2
6151066|NCT01107626|9787270|FG002|Step 2: Maintenance Therapy|Physician Decision|3
6151067|NCT01107626|9787271|FG003|Step 2: Maintenance Therapy|Physician Decision|3
6151068|NCT01107626|9787268|FG000|Step 2: Maintenance Therapy|Hospice care|0
6151069|NCT01107626|9787269|FG001|Step 2: Maintenance Therapy|Hospice care|1
6151070|NCT01107626|9787270|FG002|Step 2: Maintenance Therapy|Hospice care|2
6151071|NCT01107626|9787271|FG003|Step 2: Maintenance Therapy|Hospice care|0
6318641|NCT02775903|10054361|FG001|Overall Study|Lost to Follow-up|0
6318642|NCT02775903|10054362|FG002|Overall Study|Lost to Follow-up|1
6318643|NCT02775903|10054363|FG003|Overall Study|Lost to Follow-up|1
6318644|NCT02775903|10054360|FG000|Overall Study|Other-Miscellaneous|4
6318645|NCT02775903|10054361|FG001|Overall Study|Other-Miscellaneous|3
6318646|NCT02775903|10054362|FG002|Overall Study|Other-Miscellaneous|4
6318647|NCT02775903|10054363|FG003|Overall Study|Other-Miscellaneous|5
6318648|NCT02775916|10054379|FG000|Overall Study|Adverse Event|1
6318649|NCT02775916|10054380|FG001|Overall Study|Adverse Event|0
6318650|NCT02775916|10054379|FG000|Overall Study|Subject/Guardian Decision|2
6318651|NCT02775916|10054380|FG001|Overall Study|Subject/Guardian Decision|0
6318652|NCT02776033|10054389|FG000|Overall Study|Withdrawal by Subject|0
6318653|NCT02776033|10054390|FG001|Overall Study|Withdrawal by Subject|0
6318654|NCT02776033|10054391|FG002|Overall Study|Withdrawal by Subject|2
6318655|NCT02776033|10054389|FG000|Overall Study|Physician Decision|2
6318656|NCT02776033|10054390|FG001|Overall Study|Physician Decision|0
6318657|NCT02776033|10054391|FG002|Overall Study|Physician Decision|0
6318658|NCT02776033|10054389|FG000|Overall Study|Lost to Follow-up|1
6318659|NCT02776033|10054390|FG001|Overall Study|Lost to Follow-up|0
6318660|NCT02776033|10054391|FG002|Overall Study|Lost to Follow-up|0
6318661|NCT02776033|10054389|FG000|Overall Study|Adverse Event|1
6318662|NCT02776033|10054390|FG001|Overall Study|Adverse Event|2
6318663|NCT02776033|10054391|FG002|Overall Study|Adverse Event|0
6318664|NCT02776553|10054407|FG000|Overall Study|Lost to Follow-up|1
6318665|NCT02776553|10054408|FG001|Overall Study|Lost to Follow-up|0
6318666|NCT02776553|10054407|FG000|Overall Study|got liver transplant|1
6318667|NCT02776553|10054408|FG001|Overall Study|got liver transplant|2
6318668|NCT02776553|10054407|FG000|Overall Study|had other surgery|1
6318669|NCT02776553|10054408|FG001|Overall Study|had other surgery|0
6151072|NCT01107626|9787268|FG000|Step 2: Maintenance Therapy|Non-compliance|0
6151073|NCT01107626|9787269|FG001|Step 2: Maintenance Therapy|Non-compliance|0
6151074|NCT01107626|9787270|FG002|Step 2: Maintenance Therapy|Non-compliance|0
6151075|NCT01107626|9787271|FG003|Step 2: Maintenance Therapy|Non-compliance|2
6151076|NCT01107626|9787268|FG000|Step 2: Maintenance Therapy|Pain|0
6151077|NCT01107626|9787269|FG001|Step 2: Maintenance Therapy|Pain|0
6151078|NCT01107626|9787270|FG002|Step 2: Maintenance Therapy|Pain|0
6151079|NCT01107626|9787271|FG003|Step 2: Maintenance Therapy|Pain|1
6151080|NCT01107626|9787268|FG000|Step 2: Maintenance Therapy|Off treatment reason not reported|0
6151081|NCT01107626|9787269|FG001|Step 2: Maintenance Therapy|Off treatment reason not reported|4
6151082|NCT01107626|9787270|FG002|Step 2: Maintenance Therapy|Off treatment reason not reported|4
6151083|NCT01107626|9787271|FG003|Step 2: Maintenance Therapy|Off treatment reason not reported|10
6151084|NCT01107743|9787299|FG000|Overall Study|Protocol Violation|46
6151085|NCT01107886|9787359|FG000|Overall Study|Lost to Follow-up|15
6151086|NCT01107886|9787360|FG001|Overall Study|Lost to Follow-up|13
6151087|NCT01107886|9787359|FG000|Overall Study|Withdrawal by Subject|180
6151088|NCT01107886|9787360|FG001|Overall Study|Withdrawal by Subject|196
6151089|NCT01107886|9787359|FG000|Overall Study|Administrative withdrawal of consent|7
6151090|NCT01107886|9787360|FG001|Overall Study|Administrative withdrawal of consent|5
6151091|NCT01107899|9787369|FG000|Overall Study|Physician Decision|5
6151092|NCT01107899|9787370|FG001|Overall Study|Physician Decision|0
6151093|NCT01107899|9787371|FG002|Overall Study|Physician Decision|3
6151094|NCT01107899|9787369|FG000|Overall Study|Withdrawal by Subject|0
6151095|NCT01107899|9787370|FG001|Overall Study|Withdrawal by Subject|0
6151096|NCT01107899|9787371|FG002|Overall Study|Withdrawal by Subject|1
6151097|NCT01107912|9787386|FG000|Period 1|Adverse Event|0
6151098|NCT01107912|9787387|FG001|Period 1|Adverse Event|0
6151099|NCT01107912|9787388|FG002|Period 1|Adverse Event|0
6151100|NCT01107912|9787389|FG003|Period 1|Adverse Event|0
6151101|NCT01107912|9787390|FG004|Period 1|Adverse Event|2
6151102|NCT01107912|9787391|FG005|Period 1|Adverse Event|0
6151103|NCT01107912|9787386|FG000|Period 1|Physician Decision|0
6151104|NCT01107912|9787387|FG001|Period 1|Physician Decision|0
6151105|NCT01107912|9787388|FG002|Period 1|Physician Decision|0
6151106|NCT01107912|9787389|FG003|Period 1|Physician Decision|0
6151107|NCT01107912|9787390|FG004|Period 1|Physician Decision|1
6151108|NCT01107912|9787391|FG005|Period 1|Physician Decision|0
6151109|NCT01107912|9787386|FG000|Period 1|Withdrawal by Subject|1
6318670|NCT02776553|10054407|FG000|Overall Study|Protocol Violation|0
6318671|NCT02776553|10054408|FG001|Overall Study|Protocol Violation|1
6318672|NCT02776670|10054425|FG000|Overall Study|Adverse Event|0
6318673|NCT02776670|10054426|FG001|Overall Study|Adverse Event|2
6318674|NCT02776670|10054425|FG000|Overall Study|Protocol Violation|0
6318675|NCT02776670|10054426|FG001|Overall Study|Protocol Violation|2
6318676|NCT02776670|10054425|FG000|Overall Study|Withdrawal by Subject|0
6318677|NCT02776670|10054426|FG001|Overall Study|Withdrawal by Subject|1
6318678|NCT02776670|10054425|FG000|Overall Study|Other - Reason not given|0
6318679|NCT02776670|10054426|FG001|Overall Study|Other - Reason not given|1
6318680|NCT02776683|10054432|FG000|Pre-switch Period|Protocol Violation|1
6318681|NCT02776683|10054433|FG001|Pre-switch Period|Protocol Violation|0
6318682|NCT02776683|10054432|FG000|Pre-switch Period|Adverse Event|21
6318683|NCT02776683|10054433|FG001|Pre-switch Period|Adverse Event|0
6318684|NCT02776683|10054432|FG000|Pre-switch Period|Withdrawal by Subject|9
6318685|NCT02776683|10054433|FG001|Pre-switch Period|Withdrawal by Subject|0
6318686|NCT02776683|10054432|FG000|Pre-switch Period|Physician Decision|7
6318687|NCT02776683|10054433|FG001|Pre-switch Period|Physician Decision|0
6318688|NCT02776683|10054432|FG000|Pre-switch Period|Progressive disease|39
6318689|NCT02776683|10054433|FG001|Pre-switch Period|Progressive disease|0
6318690|NCT02776683|10054432|FG000|Pre-switch Period|Other than listed|3
6040895|NCT00372385|9638997|FG000|Overall Study|Withdrawal by Subject|2
6151110|NCT01107912|9787387|FG001|Period 1|Withdrawal by Subject|0
6318691|NCT02776683|10054433|FG001|Pre-switch Period|Other than listed|0
6318692|NCT02776683|10054432|FG000|Post-switch Period|Adverse Event|0
6318693|NCT02776683|10054433|FG001|Post-switch Period|Adverse Event|3
6318694|NCT02776683|10054432|FG000|Post-switch Period|Withdrawal by Subject|0
6318695|NCT02776683|10054433|FG001|Post-switch Period|Withdrawal by Subject|2
6318696|NCT02776683|10054432|FG000|Post-switch Period|Physician Decision|0
6318697|NCT02776683|10054433|FG001|Post-switch Period|Physician Decision|3
6318698|NCT02776683|10054432|FG000|Post-switch Period|Progressive disease|0
6318699|NCT02776683|10054433|FG001|Post-switch Period|Progressive disease|20
6318700|NCT02776683|10054432|FG000|Post-switch Period|Other than listed|0
6318701|NCT02776683|10054433|FG001|Post-switch Period|Other than listed|15
6318702|NCT02777086|10054468|FG000|Overall Study|Lost to Follow-up|96
6318703|NCT02777086|10054469|FG001|Overall Study|Lost to Follow-up|99
6318704|NCT02777125|10054477|FG000|Overall Study|Consent form violation|14
6318705|NCT02777125|10054478|FG001|Overall Study|Consent form violation|12
6318706|NCT02777125|10054477|FG000|Overall Study|Assent form violation|21
6318707|NCT02777125|10054478|FG001|Overall Study|Assent form violation|23
6318708|NCT02777125|10054477|FG000|Overall Study|Protocol Violation|8
6318709|NCT02777125|10054478|FG001|Overall Study|Protocol Violation|12
6318710|NCT02777242|10054485|FG000|Overall Study|Other|2
6318711|NCT02777242|10054485|FG000|Overall Study|Lost to Follow-up|1
6318712|NCT02777242|10054485|FG000|Overall Study|Multiple|1
6318713|NCT02777242|10054485|FG000|Overall Study|Sponsor's request|1
6318714|NCT02777242|10054485|FG000|Overall Study|Withdrawal by Subject|1
6318715|NCT02777333|10054513|FG000|Overall Study|Withdrawal by Subject|0
6318716|NCT02777333|10054514|FG001|Overall Study|Withdrawal by Subject|1
6318717|NCT02777333|10054513|FG000|Overall Study|Lost to Follow-up|0
6318718|NCT02777333|10054514|FG001|Overall Study|Lost to Follow-up|1
6151111|NCT01107912|9787388|FG002|Period 1|Withdrawal by Subject|0
6151112|NCT01107912|9787389|FG003|Period 1|Withdrawal by Subject|0
6151113|NCT01107912|9787390|FG004|Period 1|Withdrawal by Subject|0
6151114|NCT01107912|9787391|FG005|Period 1|Withdrawal by Subject|0
6151115|NCT01107912|9787386|FG000|Period 2|Physician Decision|0
6151116|NCT01107912|9787387|FG001|Period 2|Physician Decision|0
6151117|NCT01107912|9787388|FG002|Period 2|Physician Decision|1
6151118|NCT01107912|9787389|FG003|Period 2|Physician Decision|0
6151119|NCT01107912|9787390|FG004|Period 2|Physician Decision|0
6151120|NCT01107912|9787391|FG005|Period 2|Physician Decision|0
6151121|NCT01107912|9787386|FG000|Period 3|Adverse Event|0
6151122|NCT01107912|9787387|FG001|Period 3|Adverse Event|1
6151123|NCT01107912|9787388|FG002|Period 3|Adverse Event|1
6151124|NCT01107912|9787389|FG003|Period 3|Adverse Event|0
6151125|NCT01107912|9787390|FG004|Period 3|Adverse Event|0
6151126|NCT01107912|9787391|FG005|Period 3|Adverse Event|0
6151127|NCT01107912|9787386|FG000|Period 3|Withdrawal by Subject|0
6151128|NCT01107912|9787387|FG001|Period 3|Withdrawal by Subject|0
6151129|NCT01107912|9787388|FG002|Period 3|Withdrawal by Subject|0
6151130|NCT01107912|9787389|FG003|Period 3|Withdrawal by Subject|1
6151131|NCT01107912|9787390|FG004|Period 3|Withdrawal by Subject|0
6151132|NCT01107912|9787391|FG005|Period 3|Withdrawal by Subject|0
6151133|NCT01107925|9787410|FG000|Period 1-Randomization up Through Day 12|Withdrawal by Subject|1
6151134|NCT01107925|9787411|FG001|Period 1-Randomization up Through Day 12|Withdrawal by Subject|0
6151135|NCT01107925|9787412|FG002|Period 1-Randomization up Through Day 12|Withdrawal by Subject|0
6151136|NCT01107925|9787413|FG003|Period 1-Randomization up Through Day 12|Withdrawal by Subject|0
6151137|NCT01107925|9787414|FG004|Period 1-Randomization up Through Day 12|Withdrawal by Subject|1
6151138|NCT01107925|9787415|FG005|Period 1-Randomization up Through Day 12|Withdrawal by Subject|0
6151139|NCT01107925|9787410|FG000|Period 2|Withdrawal by Subject|0
6151140|NCT01107925|9787411|FG001|Period 2|Withdrawal by Subject|1
6151141|NCT01107925|9787412|FG002|Period 2|Withdrawal by Subject|0
6151142|NCT01107925|9787413|FG003|Period 2|Withdrawal by Subject|0
6227383|NCT01716585|9900081|FG000|Open-label Treatment|Virologic Failure|0
6227384|NCT01716585|9900082|FG001|Open-label Treatment|Virologic Failure|2
6227385|NCT01716585|9900081|FG000|Open-label Treatment|Withdrawal by Subject|0
6227386|NCT01716585|9900082|FG001|Open-label Treatment|Withdrawal by Subject|3
6227387|NCT01716663|9900089|FG000|Overall Study|Withdrawn prior to procedure|4
6227388|NCT01716663|9900089|FG000|Overall Study|Treated with non-study catheter|2
6227389|NCT01716715|9900095|FG000|Overall Study|Never Treated|2
6227390|NCT01716715|9900096|FG001|Overall Study|Never Treated|4
6227391|NCT01716754|9900108|FG000|Overall Study|Death|0
6227392|NCT01716754|9900109|FG001|Overall Study|Death|0
6227393|NCT01716754|9900110|FG002|Overall Study|Death|0
6151143|NCT01107925|9787414|FG004|Period 2|Withdrawal by Subject|0
6151144|NCT01107925|9787415|FG005|Period 2|Withdrawal by Subject|1
6151145|NCT01108068|9787463|FG000|Overall Study|5 not started, 1 stop due to side effect|6
6151146|NCT01108068|9787464|FG001|Overall Study|5 not started, 1 stop due to side effect|0
6318719|NCT04952701|10054520|FG000|Control Lens|Physician Decision|4
6318720|NCT04952701|10054520|FG000|Test Lens|Physician Decision|1
6318721|NCT04074161|10054533|FG000|Overall Study|Withdrawal by Subject|2
6318722|NCT04074161|10054534|FG001|Overall Study|Withdrawal by Subject|4
6318723|NCT04074161|10054535|FG002|Overall Study|Withdrawal by Subject|1
6318724|NCT04074161|10054533|FG000|Overall Study|Lost to Follow-up|4
6318725|NCT04074161|10054534|FG001|Overall Study|Lost to Follow-up|5
6318726|NCT04074161|10054535|FG002|Overall Study|Lost to Follow-up|3
6318727|NCT04033432|10054543|FG000|Overall Study|Progressive Disease|8
6318728|NCT04033432|10054543|FG000|Overall Study|Adverse Event|4
6318729|NCT04033432|10054543|FG000|Overall Study|Death|1
6318730|NCT04030247|10054548|FG000|Overall Study|Withdrawal by Subject|4
6318731|NCT04030247|10054548|FG000|Overall Study|Lost to Follow-up|13
6318732|NCT03893565|10054557|FG000|Double-blind Induction Phase (10 Weeks)|Other|1
6318733|NCT03893565|10054558|FG001|Double-blind Induction Phase (10 Weeks)|Other|3
6318734|NCT03893565|10054559|FG002|Double-blind Induction Phase (10 Weeks)|Other|0
6318735|NCT03893565|10054560|FG003|Double-blind Induction Phase (10 Weeks)|Other|0
6318736|NCT03893565|10054561|FG004|Double-blind Induction Phase (10 Weeks)|Other|1
6318737|NCT03893565|10054562|FG005|Double-blind Induction Phase (10 Weeks)|Other|0
6318738|NCT03893565|10054563|FG006|Double-blind Induction Phase (10 Weeks)|Other|0
6318739|NCT03893565|10054564|FG007|Double-blind Induction Phase (10 Weeks)|Other|0
6318740|NCT03893565|10054565|FG008|Double-blind Induction Phase (10 Weeks)|Other|0
6151147|NCT01108094|9787492|FG000|Overall Study|Adverse Event|2
6151148|NCT01108094|9787493|FG001|Overall Study|Adverse Event|0
6151149|NCT01108094|9787494|FG002|Overall Study|Adverse Event|0
6151150|NCT01108094|9787495|FG003|Overall Study|Adverse Event|0
6151151|NCT01108094|9787492|FG000|Overall Study|Withdrawal by Subject|1
6151152|NCT01108094|9787493|FG001|Overall Study|Withdrawal by Subject|0
6151153|NCT01108094|9787494|FG002|Overall Study|Withdrawal by Subject|0
6151154|NCT01108094|9787495|FG003|Overall Study|Withdrawal by Subject|0
6151155|NCT01108185|9787508|FG000|Overall Study|Non-compliance|15
6151156|NCT01108185|9787508|FG000|Overall Study|Lost to Follow-up|12
6151157|NCT01108237|9787514|FG000|Overall Study|No alignment data|2
6151158|NCT01108237|9787515|FG001|Overall Study|No alignment data|17
6151159|NCT01108237|9787514|FG000|Overall Study|Did not meet criteria for analysis|7
6151160|NCT01108237|9787515|FG001|Overall Study|Did not meet criteria for analysis|0
6151161|NCT01108263|9787523|FG000|Overall Study|Adverse Event|0
6151162|NCT01108263|9787524|FG001|Overall Study|Adverse Event|1
6151163|NCT01108341|9787530|FG000|Overall Study|Death|2
6151164|NCT01108341|9787530|FG000|Overall Study|Withdrawal by Subject|1
6151165|NCT01108341|9787530|FG000|Overall Study|Lost to Follow-up|1
6151166|NCT01108341|9787530|FG000|Overall Study|Other|1
6151167|NCT01108458|9787549|FG000|Overall Study|Withdrawal by Subject|1
6151168|NCT01108510|9787555|FG000|Overall Study|Randomized but Not Treated|5
6151169|NCT01108510|9787556|FG001|Overall Study|Randomized but Not Treated|1
6151170|NCT01108510|9787555|FG000|Overall Study|Joined Another Gilead-sponsored Study|186
6151171|NCT01108510|9787556|FG001|Overall Study|Joined Another Gilead-sponsored Study|195
6151172|NCT01108510|9787555|FG000|Overall Study|Adverse Event|26
6151173|NCT01108510|9787556|FG001|Overall Study|Adverse Event|19
6151174|NCT01108510|9787555|FG000|Overall Study|Lost to Follow-up|20
6151175|NCT01108510|9787556|FG001|Overall Study|Lost to Follow-up|17
6151176|NCT01108510|9787555|FG000|Overall Study|Withdrew Consent|21
6151177|NCT01108510|9787556|FG001|Overall Study|Withdrew Consent|15
6151178|NCT01108510|9787555|FG000|Overall Study|Investigator's Discretion|12
6151179|NCT01108510|9787556|FG001|Overall Study|Investigator's Discretion|10
6151180|NCT01108510|9787555|FG000|Overall Study|Participant Noncompliance|5
6151181|NCT01108510|9787556|FG001|Overall Study|Participant Noncompliance|7
6151182|NCT01108510|9787555|FG000|Overall Study|Lack of Efficacy|3
6151183|NCT01108510|9787556|FG001|Overall Study|Lack of Efficacy|0
6151184|NCT01108510|9787555|FG000|Overall Study|Pregnancy|0
6151185|NCT01108510|9787556|FG001|Overall Study|Pregnancy|3
6151186|NCT01108510|9787555|FG000|Overall Study|Death|1
6151187|NCT01108510|9787556|FG001|Overall Study|Death|1
6151188|NCT01108718|9787564|FG000|Received Second Intervention (2 Months)|Withdrawal by Subject|1
6151189|NCT01108718|9787565|FG001|Received Second Intervention (2 Months)|Withdrawal by Subject|0
6151190|NCT01108731|9787572|FG000|Overall Study|Withdrawal by Subject|1
6151191|NCT01108731|9787573|FG001|Overall Study|Withdrawal by Subject|1
6151192|NCT01108731|9787572|FG000|Overall Study|Adverse Event|3
6151193|NCT01108731|9787573|FG001|Overall Study|Adverse Event|3
6191437|NCT01422876|9848249|FG005|Week 52|Lost to Follow-up|5
6191438|NCT01422876|9848250|FG006|Week 52|Lost to Follow-up|5
6191439|NCT01422876|9848251|FG007|Week 52|Lost to Follow-up|8
6191440|NCT01422876|9848252|FG008|Week 52|Lost to Follow-up|7
6191441|NCT01422876|9848253|FG009|Week 52|Lost to Follow-up|8
6191442|NCT01422876|9848244|FG000|Week 52|Consent withdrawn|9
6191443|NCT01422876|9848245|FG001|Week 52|Consent withdrawn|4
6191444|NCT01422876|9848246|FG002|Week 52|Consent withdrawn|6
6191445|NCT01422876|9848247|FG003|Week 52|Consent withdrawn|12
6191446|NCT01422876|9848248|FG004|Week 52|Consent withdrawn|7
6191447|NCT01422876|9848249|FG005|Week 52|Consent withdrawn|12
6191448|NCT01422876|9848250|FG006|Week 52|Consent withdrawn|10
6191449|NCT01422876|9848251|FG007|Week 52|Consent withdrawn|12
6191450|NCT01422876|9848252|FG008|Week 52|Consent withdrawn|13
6191451|NCT01422876|9848253|FG009|Week 52|Consent withdrawn|9
6191452|NCT01422876|9848244|FG000|Week 52|Death|0
6191453|NCT01422876|9848245|FG001|Week 52|Death|1
6191454|NCT01422876|9848246|FG002|Week 52|Death|0
6191455|NCT01422876|9848247|FG003|Week 52|Death|1
6191456|NCT01422876|9848248|FG004|Week 52|Death|0
6191457|NCT01422876|9848249|FG005|Week 52|Death|0
6191458|NCT01422876|9848250|FG006|Week 52|Death|1
6318741|NCT03893565|10054557|FG000|Double-blind Induction Phase (10 Weeks)|Physician Decision|0
6318742|NCT03893565|10054558|FG001|Double-blind Induction Phase (10 Weeks)|Physician Decision|1
6318743|NCT03893565|10054559|FG002|Double-blind Induction Phase (10 Weeks)|Physician Decision|0
6318744|NCT03893565|10054560|FG003|Double-blind Induction Phase (10 Weeks)|Physician Decision|0
6318745|NCT03893565|10054561|FG004|Double-blind Induction Phase (10 Weeks)|Physician Decision|0
6318746|NCT03893565|10054562|FG005|Double-blind Induction Phase (10 Weeks)|Physician Decision|0
6318747|NCT03893565|10054563|FG006|Double-blind Induction Phase (10 Weeks)|Physician Decision|0
6318748|NCT03893565|10054564|FG007|Double-blind Induction Phase (10 Weeks)|Physician Decision|0
6318749|NCT03893565|10054565|FG008|Double-blind Induction Phase (10 Weeks)|Physician Decision|0
6318750|NCT03893565|10054557|FG000|Double-blind Induction Phase (10 Weeks)|Withdrawal by Subject|0
6318751|NCT03893565|10054558|FG001|Double-blind Induction Phase (10 Weeks)|Withdrawal by Subject|2
6318752|NCT03893565|10054559|FG002|Double-blind Induction Phase (10 Weeks)|Withdrawal by Subject|0
6318753|NCT03893565|10054560|FG003|Double-blind Induction Phase (10 Weeks)|Withdrawal by Subject|1
6318754|NCT03893565|10054561|FG004|Double-blind Induction Phase (10 Weeks)|Withdrawal by Subject|0
6318755|NCT03893565|10054562|FG005|Double-blind Induction Phase (10 Weeks)|Withdrawal by Subject|0
6040896|NCT00372385|9638998|FG001|Overall Study|Withdrawal by Subject|1
6040897|NCT00372385|9638999|FG002|Overall Study|Withdrawal by Subject|0
6040898|NCT00372385|9639000|FG003|Overall Study|Withdrawal by Subject|0
6040899|NCT00372385|9638997|FG000|Overall Study|Refusal of Treatment|3
6040900|NCT00372385|9638998|FG001|Overall Study|Refusal of Treatment|6
6040901|NCT00372385|9638999|FG002|Overall Study|Refusal of Treatment|0
6040902|NCT00372385|9639000|FG003|Overall Study|Refusal of Treatment|0
6040903|NCT00372385|9638997|FG000|Overall Study|No Response|1
6040904|NCT00372385|9638998|FG001|Overall Study|No Response|1
6040905|NCT00372385|9638999|FG002|Overall Study|No Response|0
6151194|NCT01108796|9787592|FG000|Overall Study|Adverse Event|0
6151195|NCT01108796|9787593|FG001|Overall Study|Adverse Event|1
6318756|NCT03893565|10054563|FG006|Double-blind Induction Phase (10 Weeks)|Withdrawal by Subject|0
6318757|NCT03893565|10054564|FG007|Double-blind Induction Phase (10 Weeks)|Withdrawal by Subject|0
6318758|NCT03893565|10054565|FG008|Double-blind Induction Phase (10 Weeks)|Withdrawal by Subject|0
6318759|NCT03893565|10054557|FG000|Double-blind Induction Phase (10 Weeks)|Lost to Follow-up|0
6318760|NCT03893565|10054558|FG001|Double-blind Induction Phase (10 Weeks)|Lost to Follow-up|1
6318761|NCT03893565|10054559|FG002|Double-blind Induction Phase (10 Weeks)|Lost to Follow-up|0
6318762|NCT03893565|10054560|FG003|Double-blind Induction Phase (10 Weeks)|Lost to Follow-up|6
6318763|NCT03893565|10054561|FG004|Double-blind Induction Phase (10 Weeks)|Lost to Follow-up|0
6318764|NCT03893565|10054562|FG005|Double-blind Induction Phase (10 Weeks)|Lost to Follow-up|0
6318765|NCT03893565|10054563|FG006|Double-blind Induction Phase (10 Weeks)|Lost to Follow-up|0
6318766|NCT03893565|10054564|FG007|Double-blind Induction Phase (10 Weeks)|Lost to Follow-up|0
6318767|NCT03893565|10054565|FG008|Double-blind Induction Phase (10 Weeks)|Lost to Follow-up|0
6318768|NCT03893565|10054557|FG000|Double-blind Induction Phase (10 Weeks)|Study terminated by sponsor|5
6318769|NCT03893565|10054558|FG001|Double-blind Induction Phase (10 Weeks)|Study terminated by sponsor|5
6318770|NCT03893565|10054559|FG002|Double-blind Induction Phase (10 Weeks)|Study terminated by sponsor|9
6318771|NCT03893565|10054560|FG003|Double-blind Induction Phase (10 Weeks)|Study terminated by sponsor|0
6151196|NCT01108796|9787592|FG000|Overall Study|Lost to Follow-up|7
6151197|NCT01108796|9787593|FG001|Overall Study|Lost to Follow-up|6
6151198|NCT01108809|9787601|FG000|Overall Study|Adverse Event|3
6151199|NCT01108809|9787601|FG000|Overall Study|Lost to Follow-up|1
6151200|NCT01109173|9787656|FG000|Overall Study|Adverse Event|15
6151201|NCT01109173|9787657|FG001|Overall Study|Adverse Event|17
6151202|NCT01109173|9787658|FG002|Overall Study|Adverse Event|9
6151203|NCT01109173|9787659|FG003|Overall Study|Adverse Event|6
6151204|NCT01109173|9787656|FG000|Overall Study|Lost to Follow-up|0
6151205|NCT01109173|9787657|FG001|Overall Study|Lost to Follow-up|1
6151206|NCT01109173|9787658|FG002|Overall Study|Lost to Follow-up|0
6151207|NCT01109173|9787659|FG003|Overall Study|Lost to Follow-up|0
6151208|NCT01109173|9787656|FG000|Overall Study|Patient Decision Unrelated to Advrs Evnt|5
6151209|NCT01109173|9787657|FG001|Overall Study|Patient Decision Unrelated to Advrs Evnt|0
6151210|NCT01109173|9787658|FG002|Overall Study|Patient Decision Unrelated to Advrs Evnt|2
6151211|NCT01109173|9787659|FG003|Overall Study|Patient Decision Unrelated to Advrs Evnt|0
6151212|NCT01109173|9787656|FG000|Overall Study|Noncompliance|0
6151213|NCT01109173|9787657|FG001|Overall Study|Noncompliance|1
6151214|NCT01109173|9787658|FG002|Overall Study|Noncompliance|0
6151215|NCT01109173|9787659|FG003|Overall Study|Noncompliance|0
6151216|NCT01109173|9787656|FG000|Overall Study|Treatment Failure|25
6151217|NCT01109173|9787657|FG001|Overall Study|Treatment Failure|32
6151218|NCT01109173|9787658|FG002|Overall Study|Treatment Failure|69
6151219|NCT01109173|9787659|FG003|Overall Study|Treatment Failure|64
6151220|NCT01109173|9787656|FG000|Overall Study|Protocol Violation|4
6151221|NCT01109173|9787657|FG001|Overall Study|Protocol Violation|5
6151222|NCT01109173|9787658|FG002|Overall Study|Protocol Violation|1
6318772|NCT03893565|10054561|FG004|Double-blind Induction Phase (10 Weeks)|Study terminated by sponsor|6
6318773|NCT03893565|10054562|FG005|Double-blind Induction Phase (10 Weeks)|Study terminated by sponsor|0
6318774|NCT03893565|10054563|FG006|Double-blind Induction Phase (10 Weeks)|Study terminated by sponsor|0
6040906|NCT00372385|9639000|FG003|Overall Study|No Response|0
6318775|NCT03893565|10054564|FG007|Double-blind Induction Phase (10 Weeks)|Study terminated by sponsor|0
6318776|NCT03893565|10054565|FG008|Double-blind Induction Phase (10 Weeks)|Study terminated by sponsor|0
6318777|NCT03893565|10054557|FG000|Double-blind Induction Phase (10 Weeks)|Protocol-specified withdrawal criterion met|0
6318778|NCT03893565|10054558|FG001|Double-blind Induction Phase (10 Weeks)|Protocol-specified withdrawal criterion met|2
6318779|NCT03893565|10054559|FG002|Double-blind Induction Phase (10 Weeks)|Protocol-specified withdrawal criterion met|0
6318780|NCT03893565|10054560|FG003|Double-blind Induction Phase (10 Weeks)|Protocol-specified withdrawal criterion met|0
6318781|NCT03893565|10054561|FG004|Double-blind Induction Phase (10 Weeks)|Protocol-specified withdrawal criterion met|0
6318782|NCT03893565|10054562|FG005|Double-blind Induction Phase (10 Weeks)|Protocol-specified withdrawal criterion met|0
6318783|NCT03893565|10054563|FG006|Double-blind Induction Phase (10 Weeks)|Protocol-specified withdrawal criterion met|0
6318784|NCT03893565|10054564|FG007|Double-blind Induction Phase (10 Weeks)|Protocol-specified withdrawal criterion met|0
6318785|NCT03893565|10054565|FG008|Double-blind Induction Phase (10 Weeks)|Protocol-specified withdrawal criterion met|0
6151223|NCT01109173|9787659|FG003|Overall Study|Protocol Violation|2
6151224|NCT01109173|9787656|FG000|Overall Study|Patient Did Not Use Study Medication|34
6151225|NCT01109173|9787657|FG001|Overall Study|Patient Did Not Use Study Medication|26
6151226|NCT01109173|9787658|FG002|Overall Study|Patient Did Not Use Study Medication|11
6151227|NCT01109173|9787659|FG003|Overall Study|Patient Did Not Use Study Medication|7
6151228|NCT01109173|9787656|FG000|Overall Study|Not Specifiied|5
6151229|NCT01109173|9787657|FG001|Overall Study|Not Specifiied|4
6151230|NCT01109173|9787658|FG002|Overall Study|Not Specifiied|9
6151231|NCT01109173|9787659|FG003|Overall Study|Not Specifiied|14
6151232|NCT01109316|9787675|FG000|Study Period 1|Adverse Event|0
6151233|NCT01109316|9787676|FG001|Study Period 1|Adverse Event|0
6151234|NCT01109316|9787677|FG002|Study Period 1|Adverse Event|1
6151235|NCT01109316|9787678|FG003|Study Period 1|Adverse Event|0
6151236|NCT01109316|9787679|FG004|Study Period 1|Adverse Event|0
6151237|NCT01109316|9787680|FG005|Study Period 1|Adverse Event|0
6151238|NCT01109316|9787675|FG000|Study Period 1|Lost to Follow-up|0
6151239|NCT01109316|9787676|FG001|Study Period 1|Lost to Follow-up|0
6151240|NCT01109316|9787677|FG002|Study Period 1|Lost to Follow-up|1
6151241|NCT01109316|9787678|FG003|Study Period 1|Lost to Follow-up|1
6151242|NCT01109316|9787679|FG004|Study Period 1|Lost to Follow-up|0
6151243|NCT01109316|9787680|FG005|Study Period 1|Lost to Follow-up|0
6151244|NCT01109316|9787675|FG000|Study Period 1|Withdrawal by Subject|0
6151245|NCT01109316|9787676|FG001|Study Period 1|Withdrawal by Subject|0
6151246|NCT01109316|9787677|FG002|Study Period 1|Withdrawal by Subject|1
6151247|NCT01109316|9787678|FG003|Study Period 1|Withdrawal by Subject|0
6151248|NCT01109316|9787679|FG004|Study Period 1|Withdrawal by Subject|2
6151249|NCT01109316|9787680|FG005|Study Period 1|Withdrawal by Subject|0
6151250|NCT01109316|9787675|FG000|Study Period 1|Sponsor Decision|0
6151251|NCT01109316|9787676|FG001|Study Period 1|Sponsor Decision|0
6151252|NCT01109316|9787677|FG002|Study Period 1|Sponsor Decision|0
6151253|NCT01109316|9787678|FG003|Study Period 1|Sponsor Decision|0
6151254|NCT01109316|9787679|FG004|Study Period 1|Sponsor Decision|0
6151255|NCT01109316|9787680|FG005|Study Period 1|Sponsor Decision|2
6151256|NCT01109316|9787675|FG000|Study Period 2|Entry Criteria Not Met|0
6151257|NCT01109316|9787676|FG001|Study Period 2|Entry Criteria Not Met|1
6151258|NCT01109316|9787677|FG002|Study Period 2|Entry Criteria Not Met|0
6151259|NCT01109316|9787678|FG003|Study Period 2|Entry Criteria Not Met|0
6151260|NCT01109316|9787679|FG004|Study Period 2|Entry Criteria Not Met|0
6151261|NCT01109316|9787680|FG005|Study Period 2|Entry Criteria Not Met|0
6151262|NCT01109316|9787675|FG000|Study Period 2|Physician Decision|0
6151263|NCT01109316|9787676|FG001|Study Period 2|Physician Decision|0
6151264|NCT01109316|9787677|FG002|Study Period 2|Physician Decision|0
6151265|NCT01109316|9787678|FG003|Study Period 2|Physician Decision|1
6151266|NCT01109316|9787679|FG004|Study Period 2|Physician Decision|0
6151267|NCT01109316|9787680|FG005|Study Period 2|Physician Decision|0
6151268|NCT01109316|9787675|FG000|Study Period 2|Protocol Violation|1
6151269|NCT01109316|9787676|FG001|Study Period 2|Protocol Violation|0
6151270|NCT01109316|9787677|FG002|Study Period 2|Protocol Violation|0
6151271|NCT01109316|9787678|FG003|Study Period 2|Protocol Violation|0
6151272|NCT01109316|9787679|FG004|Study Period 2|Protocol Violation|0
6151273|NCT01109316|9787680|FG005|Study Period 2|Protocol Violation|0
6151274|NCT01109316|9787675|FG000|Study Period 2|Withdrawal by Subject|0
6151275|NCT01109316|9787676|FG001|Study Period 2|Withdrawal by Subject|0
6151276|NCT01109316|9787677|FG002|Study Period 2|Withdrawal by Subject|1
6151277|NCT01109316|9787678|FG003|Study Period 2|Withdrawal by Subject|0
6151278|NCT01109316|9787679|FG004|Study Period 2|Withdrawal by Subject|0
6151279|NCT01109316|9787680|FG005|Study Period 2|Withdrawal by Subject|1
6151280|NCT01109316|9787675|FG000|Study Period 3|Lost to Follow-up|0
6151281|NCT01109316|9787676|FG001|Study Period 3|Lost to Follow-up|0
6151282|NCT01109316|9787677|FG002|Study Period 3|Lost to Follow-up|0
6151283|NCT01109316|9787678|FG003|Study Period 3|Lost to Follow-up|0
6151284|NCT01109316|9787679|FG004|Study Period 3|Lost to Follow-up|1
6151285|NCT01109316|9787680|FG005|Study Period 3|Lost to Follow-up|0
6151286|NCT01109316|9787675|FG000|Study Period 3|Withdrawal by Subject|1
6151287|NCT01109316|9787676|FG001|Study Period 3|Withdrawal by Subject|0
6151288|NCT01109316|9787677|FG002|Study Period 3|Withdrawal by Subject|0
6151289|NCT01109316|9787678|FG003|Study Period 3|Withdrawal by Subject|0
6318786|NCT03893565|10054557|FG000|Double-blind Induction Phase (10 Weeks)|Lack of Efficacy|0
6318787|NCT03893565|10054558|FG001|Double-blind Induction Phase (10 Weeks)|Lack of Efficacy|0
6318788|NCT03893565|10054559|FG002|Double-blind Induction Phase (10 Weeks)|Lack of Efficacy|0
6318789|NCT03893565|10054560|FG003|Double-blind Induction Phase (10 Weeks)|Lack of Efficacy|1
6318790|NCT03893565|10054561|FG004|Double-blind Induction Phase (10 Weeks)|Lack of Efficacy|0
6318791|NCT03893565|10054562|FG005|Double-blind Induction Phase (10 Weeks)|Lack of Efficacy|0
6318792|NCT03893565|10054563|FG006|Double-blind Induction Phase (10 Weeks)|Lack of Efficacy|0
6318793|NCT03893565|10054564|FG007|Double-blind Induction Phase (10 Weeks)|Lack of Efficacy|0
6318794|NCT03893565|10054565|FG008|Double-blind Induction Phase (10 Weeks)|Lack of Efficacy|0
6318795|NCT03893565|10054557|FG000|Double-blind Induction Phase (10 Weeks)|Adverse Event|0
6318796|NCT03893565|10054558|FG001|Double-blind Induction Phase (10 Weeks)|Adverse Event|2
6318797|NCT03893565|10054559|FG002|Double-blind Induction Phase (10 Weeks)|Adverse Event|1
6318798|NCT03893565|10054560|FG003|Double-blind Induction Phase (10 Weeks)|Adverse Event|1
6318799|NCT03893565|10054561|FG004|Double-blind Induction Phase (10 Weeks)|Adverse Event|0
6318800|NCT03893565|10054562|FG005|Double-blind Induction Phase (10 Weeks)|Adverse Event|0
6318801|NCT03893565|10054563|FG006|Double-blind Induction Phase (10 Weeks)|Adverse Event|0
6318802|NCT03893565|10054564|FG007|Double-blind Induction Phase (10 Weeks)|Adverse Event|0
6318803|NCT03893565|10054565|FG008|Double-blind Induction Phase (10 Weeks)|Adverse Event|0
6318804|NCT03893565|10054557|FG000|Double-blind Extended Treatment(20weeks)|Other|0
6318805|NCT03893565|10054558|FG001|Double-blind Extended Treatment(20weeks)|Other|0
6318806|NCT03893565|10054559|FG002|Double-blind Extended Treatment(20weeks)|Other|0
6318807|NCT03893565|10054560|FG003|Double-blind Extended Treatment(20weeks)|Other|0
6318808|NCT03893565|10054561|FG004|Double-blind Extended Treatment(20weeks)|Other|0
6318809|NCT03893565|10054562|FG005|Double-blind Extended Treatment(20weeks)|Other|1
6318810|NCT03893565|10054563|FG006|Double-blind Extended Treatment(20weeks)|Other|1
6318811|NCT03893565|10054564|FG007|Double-blind Extended Treatment(20weeks)|Other|0
6318812|NCT03893565|10054565|FG008|Double-blind Extended Treatment(20weeks)|Other|0
6318813|NCT03893565|10054557|FG000|Double-blind Extended Treatment(20weeks)|Withdrawal by Subject|0
6318814|NCT03893565|10054558|FG001|Double-blind Extended Treatment(20weeks)|Withdrawal by Subject|0
6318815|NCT03893565|10054559|FG002|Double-blind Extended Treatment(20weeks)|Withdrawal by Subject|0
6151290|NCT01109316|9787679|FG004|Study Period 3|Withdrawal by Subject|1
6151291|NCT01109316|9787680|FG005|Study Period 3|Withdrawal by Subject|0
6151292|NCT01109524|9787694|FG000|Overall Study|Disease Progression|29
6151293|NCT01109524|9787694|FG000|Overall Study|Study Drug toxicity|6
6151294|NCT01109524|9787694|FG000|Overall Study|Adverse Event|4
6151295|NCT01109524|9787694|FG000|Overall Study|Withdrawal by Subject|2
6151296|NCT01109524|9787694|FG000|Overall Study|Maximum clinical benefit|3
6151297|NCT01109524|9787694|FG000|Overall Study|Death|2
6151298|NCT01109524|9787694|FG000|Overall Study|No longer meets criteria|2
6151299|NCT01109524|9787694|FG000|Overall Study|Participant requested to end treatment|4
6151300|NCT01109524|9787694|FG000|Overall Study|Other|5
6151301|NCT01109849|9787716|FG000|Initial Randomization: ADHD Treatment|Lost to Follow-up|9
6151302|NCT01109849|9787717|FG001|Initial Randomization: ADHD Treatment|Lost to Follow-up|35
6151303|NCT01109849|9787718|FG002|Initial Randomization: ADHD Treatment|Lost to Follow-up|0
6151304|NCT01109849|9787719|FG003|Initial Randomization: ADHD Treatment|Lost to Follow-up|0
6151305|NCT01109849|9787720|FG004|Initial Randomization: ADHD Treatment|Lost to Follow-up|0
6151306|NCT01109849|9787716|FG000|Initial Randomization: ADHD Treatment|Protocol Violation|1
6151307|NCT01109849|9787717|FG001|Initial Randomization: ADHD Treatment|Protocol Violation|0
6151308|NCT01109849|9787718|FG002|Initial Randomization: ADHD Treatment|Protocol Violation|0
6151309|NCT01109849|9787719|FG003|Initial Randomization: ADHD Treatment|Protocol Violation|0
6151310|NCT01109849|9787720|FG004|Initial Randomization: ADHD Treatment|Protocol Violation|0
6151311|NCT01109849|9787716|FG000|Initial Randomization: ADHD Treatment|Withdrawal by Subject|6
6151312|NCT01109849|9787717|FG001|Initial Randomization: ADHD Treatment|Withdrawal by Subject|7
6151313|NCT01109849|9787718|FG002|Initial Randomization: ADHD Treatment|Withdrawal by Subject|0
6151314|NCT01109849|9787719|FG003|Initial Randomization: ADHD Treatment|Withdrawal by Subject|0
6151315|NCT01109849|9787720|FG004|Initial Randomization: ADHD Treatment|Withdrawal by Subject|0
6151316|NCT01109849|9787716|FG000|Initial Randomization: ADHD Treatment|move away|2
6151317|NCT01109849|9787717|FG001|Initial Randomization: ADHD Treatment|move away|7
6151318|NCT01109849|9787718|FG002|Initial Randomization: ADHD Treatment|move away|0
6151319|NCT01109849|9787719|FG003|Initial Randomization: ADHD Treatment|move away|0
6318816|NCT03893565|10054560|FG003|Double-blind Extended Treatment(20weeks)|Withdrawal by Subject|0
6318817|NCT03893565|10054561|FG004|Double-blind Extended Treatment(20weeks)|Withdrawal by Subject|0
6318818|NCT03893565|10054562|FG005|Double-blind Extended Treatment(20weeks)|Withdrawal by Subject|0
6318819|NCT03893565|10054563|FG006|Double-blind Extended Treatment(20weeks)|Withdrawal by Subject|1
6318820|NCT03893565|10054564|FG007|Double-blind Extended Treatment(20weeks)|Withdrawal by Subject|0
6318821|NCT03893565|10054565|FG008|Double-blind Extended Treatment(20weeks)|Withdrawal by Subject|0
6318822|NCT03893565|10054557|FG000|Double-blind Extended Treatment(20weeks)|Study terminated by sponsor|0
6318823|NCT03893565|10054558|FG001|Double-blind Extended Treatment(20weeks)|Study terminated by sponsor|0
6318824|NCT03893565|10054559|FG002|Double-blind Extended Treatment(20weeks)|Study terminated by sponsor|0
6318825|NCT03893565|10054560|FG003|Double-blind Extended Treatment(20weeks)|Study terminated by sponsor|0
6318826|NCT03893565|10054561|FG004|Double-blind Extended Treatment(20weeks)|Study terminated by sponsor|0
6318827|NCT03893565|10054562|FG005|Double-blind Extended Treatment(20weeks)|Study terminated by sponsor|2
6318828|NCT03893565|10054563|FG006|Double-blind Extended Treatment(20weeks)|Study terminated by sponsor|2
6318829|NCT03893565|10054564|FG007|Double-blind Extended Treatment(20weeks)|Study terminated by sponsor|0
6318830|NCT03893565|10054565|FG008|Double-blind Extended Treatment(20weeks)|Study terminated by sponsor|0
6318831|NCT03893565|10054557|FG000|Open-label Induction Phase (10 Weeks)|Other|0
6318832|NCT03893565|10054558|FG001|Open-label Induction Phase (10 Weeks)|Other|0
6318833|NCT03893565|10054559|FG002|Open-label Induction Phase (10 Weeks)|Other|0
6318834|NCT03893565|10054560|FG003|Open-label Induction Phase (10 Weeks)|Other|0
6318835|NCT03893565|10054561|FG004|Open-label Induction Phase (10 Weeks)|Other|0
6318836|NCT03893565|10054562|FG005|Open-label Induction Phase (10 Weeks)|Other|0
6318837|NCT03893565|10054563|FG006|Open-label Induction Phase (10 Weeks)|Other|0
6318838|NCT03893565|10054564|FG007|Open-label Induction Phase (10 Weeks)|Other|3
6318839|NCT03893565|10054565|FG008|Open-label Induction Phase (10 Weeks)|Other|0
6318840|NCT03893565|10054557|FG000|Open-label Induction Phase (10 Weeks)|Withdrawal by Subject|0
6318841|NCT03893565|10054558|FG001|Open-label Induction Phase (10 Weeks)|Withdrawal by Subject|0
6318842|NCT03893565|10054559|FG002|Open-label Induction Phase (10 Weeks)|Withdrawal by Subject|0
6318843|NCT03893565|10054560|FG003|Open-label Induction Phase (10 Weeks)|Withdrawal by Subject|0
6318844|NCT03893565|10054561|FG004|Open-label Induction Phase (10 Weeks)|Withdrawal by Subject|0
6318845|NCT03893565|10054562|FG005|Open-label Induction Phase (10 Weeks)|Withdrawal by Subject|0
6318846|NCT03893565|10054563|FG006|Open-label Induction Phase (10 Weeks)|Withdrawal by Subject|0
6318847|NCT03893565|10054564|FG007|Open-label Induction Phase (10 Weeks)|Withdrawal by Subject|5
6318848|NCT03893565|10054565|FG008|Open-label Induction Phase (10 Weeks)|Withdrawal by Subject|0
6318849|NCT03893565|10054557|FG000|Open-label Induction Phase (10 Weeks)|Study terminated by sponsor|0
6318850|NCT03893565|10054558|FG001|Open-label Induction Phase (10 Weeks)|Study terminated by sponsor|0
6318851|NCT03893565|10054559|FG002|Open-label Induction Phase (10 Weeks)|Study terminated by sponsor|0
6318852|NCT03893565|10054560|FG003|Open-label Induction Phase (10 Weeks)|Study terminated by sponsor|0
6318853|NCT03893565|10054561|FG004|Open-label Induction Phase (10 Weeks)|Study terminated by sponsor|0
6318854|NCT03893565|10054562|FG005|Open-label Induction Phase (10 Weeks)|Study terminated by sponsor|0
6318855|NCT03893565|10054563|FG006|Open-label Induction Phase (10 Weeks)|Study terminated by sponsor|0
6318856|NCT03893565|10054564|FG007|Open-label Induction Phase (10 Weeks)|Study terminated by sponsor|15
6318857|NCT03893565|10054565|FG008|Open-label Induction Phase (10 Weeks)|Study terminated by sponsor|0
6318858|NCT03893565|10054557|FG000|Open-label Induction Phase (10 Weeks)|Lack of Efficacy|0
6318859|NCT03893565|10054558|FG001|Open-label Induction Phase (10 Weeks)|Lack of Efficacy|0
6318860|NCT03893565|10054559|FG002|Open-label Induction Phase (10 Weeks)|Lack of Efficacy|0
6318861|NCT03893565|10054560|FG003|Open-label Induction Phase (10 Weeks)|Lack of Efficacy|0
6318862|NCT03893565|10054561|FG004|Open-label Induction Phase (10 Weeks)|Lack of Efficacy|0
6318863|NCT03893565|10054562|FG005|Open-label Induction Phase (10 Weeks)|Lack of Efficacy|0
6318864|NCT03893565|10054563|FG006|Open-label Induction Phase (10 Weeks)|Lack of Efficacy|0
6318865|NCT03893565|10054564|FG007|Open-label Induction Phase (10 Weeks)|Lack of Efficacy|7
6318866|NCT03893565|10054565|FG008|Open-label Induction Phase (10 Weeks)|Lack of Efficacy|0
6318867|NCT03893565|10054557|FG000|Open-label Extended Treatment (20 Weeks)|Study terminated by sponsor|0
6318868|NCT03893565|10054558|FG001|Open-label Extended Treatment (20 Weeks)|Study terminated by sponsor|0
6318869|NCT03893565|10054559|FG002|Open-label Extended Treatment (20 Weeks)|Study terminated by sponsor|0
6318870|NCT03893565|10054560|FG003|Open-label Extended Treatment (20 Weeks)|Study terminated by sponsor|0
6318871|NCT03893565|10054561|FG004|Open-label Extended Treatment (20 Weeks)|Study terminated by sponsor|0
6318872|NCT03893565|10054562|FG005|Open-label Extended Treatment (20 Weeks)|Study terminated by sponsor|0
6318873|NCT03893565|10054563|FG006|Open-label Extended Treatment (20 Weeks)|Study terminated by sponsor|0
6318874|NCT03893565|10054564|FG007|Open-label Extended Treatment (20 Weeks)|Study terminated by sponsor|0
6318875|NCT03893565|10054565|FG008|Open-label Extended Treatment (20 Weeks)|Study terminated by sponsor|4
6318876|NCT03701516|10054584|FG000|Period 1|Lost to Follow-up|0
6318877|NCT03701516|10054585|FG001|Period 1|Lost to Follow-up|1
6318878|NCT03701516|10054584|FG000|Period 1|Adverse Event|0
6318879|NCT03701516|10054585|FG001|Period 1|Adverse Event|2
6318880|NCT03701516|10054584|FG000|Period 1|Unsatisfactory Lens Fitting due to Test Article|2
6318881|NCT03701516|10054585|FG001|Period 1|Unsatisfactory Lens Fitting due to Test Article|0
6318882|NCT03701516|10054584|FG000|Period 1|Non Compliance to Protocol|2
6318883|NCT03701516|10054585|FG001|Period 1|Non Compliance to Protocol|1
6318884|NCT03701516|10054584|FG000|Period 1|Withdrawal by Subject|0
6318885|NCT03701516|10054585|FG001|Period 1|Withdrawal by Subject|1
6318886|NCT03701516|10054584|FG000|Period 2|failed to meet all eligibility creiteria|1
6318887|NCT03701516|10054585|FG001|Period 2|failed to meet all eligibility creiteria|0
6318888|NCT03701516|10054584|FG000|Period 2|Unsatisfactory Lens Fitting due to Test Article|0
6318889|NCT03701516|10054585|FG001|Period 2|Unsatisfactory Lens Fitting due to Test Article|1
6318890|NCT03650556|10054591|FG000|Overall Study|Death|2
6318891|NCT03650556|10054591|FG000|Overall Study|Withdrawal by Subject|20
6318892|NCT03650556|10054591|FG000|Overall Study|Physician Decision|2
6318893|NCT03650556|10054591|FG000|Overall Study|Lost to Follow-up|8
6318894|NCT03650556|10054591|FG000|Overall Study|Subject did not complete follow-up but did not meet criteria for lost-to-follow-up|4
6318895|NCT03650556|10054591|FG000|Overall Study|Enrolled, but no ablation performed-investigational catheter was not inserted|1
6318896|NCT03639311|10054598|FG000|Overall Study|Ongoing at the time of analysis|88
6318897|NCT03639311|10054599|FG001|Overall Study|Ongoing at the time of analysis|0
6318898|NCT03639311|10054598|FG000|Overall Study|Lost to Follow-up|1
6318899|NCT03639311|10054599|FG001|Overall Study|Lost to Follow-up|0
6318900|NCT03639311|10054598|FG000|Overall Study|Adverse Event|1
6318901|NCT03639311|10054599|FG001|Overall Study|Adverse Event|0
6318902|NCT03628716|10054610|FG000|Overall Study|Adverse Event|1
6318903|NCT03628716|10054611|FG001|Overall Study|Adverse Event|1
6318904|NCT03628716|10054610|FG000|Overall Study|Death|1
6318905|NCT03628716|10054611|FG001|Overall Study|Death|0
6318906|NCT03628716|10054610|FG000|Overall Study|Lack of Efficacy|15
6318907|NCT03628716|10054611|FG001|Overall Study|Lack of Efficacy|20
6318908|NCT03628716|10054610|FG000|Overall Study|Withdrawal by Subject|1
6318909|NCT03628716|10054611|FG001|Overall Study|Withdrawal by Subject|2
6318910|NCT03628716|10054610|FG000|Overall Study|Study Terminated by Sponsor|1
6318911|NCT03628716|10054611|FG001|Overall Study|Study Terminated by Sponsor|0
6151320|NCT01109849|9787720|FG004|Initial Randomization: ADHD Treatment|move away|0
6151321|NCT01109849|9787716|FG000|Adaptive Randomization: Weight Recovery|Lost to Follow-up|0
6151322|NCT01109849|9787717|FG001|Adaptive Randomization: Weight Recovery|Lost to Follow-up|0
6151323|NCT01109849|9787718|FG002|Adaptive Randomization: Weight Recovery|Lost to Follow-up|1
6151324|NCT01109849|9787719|FG003|Adaptive Randomization: Weight Recovery|Lost to Follow-up|1
6151325|NCT01109849|9787720|FG004|Adaptive Randomization: Weight Recovery|Lost to Follow-up|1
6151326|NCT01109849|9787716|FG000|Adaptive Randomization: Weight Recovery|moved away|0
6151327|NCT01109849|9787717|FG001|Adaptive Randomization: Weight Recovery|moved away|0
6151328|NCT01109849|9787718|FG002|Adaptive Randomization: Weight Recovery|moved away|0
6151329|NCT01109849|9787719|FG003|Adaptive Randomization: Weight Recovery|moved away|2
6151330|NCT01109849|9787720|FG004|Adaptive Randomization: Weight Recovery|moved away|0
6151331|NCT01109940|9787744|FG000|Overall Study|Administrative problems|2
6151332|NCT01109940|9787745|FG001|Overall Study|Administrative problems|0
6151333|NCT01109940|9787746|FG002|Overall Study|Administrative problems|0
6151334|NCT01109940|9787747|FG003|Overall Study|Administrative problems|0
6151335|NCT01109940|9787744|FG000|Overall Study|Serious Adverse Event|2
6151336|NCT01109940|9787745|FG001|Overall Study|Serious Adverse Event|1
6318912|NCT03377699|10054621|FG000|Overall Study|Withdrawal by Subject|2
6318913|NCT03377699|10054622|FG001|Overall Study|Withdrawal by Subject|9
6318914|NCT03377699|10054621|FG000|Overall Study|Lost to Follow-up|1
6151337|NCT01109940|9787746|FG002|Overall Study|Serious Adverse Event|0
6151338|NCT01109940|9787747|FG003|Overall Study|Serious Adverse Event|0
6151339|NCT01109940|9787744|FG000|Overall Study|Lost to Follow-up|1
6151340|NCT01109940|9787745|FG001|Overall Study|Lost to Follow-up|0
6151341|NCT01109940|9787746|FG002|Overall Study|Lost to Follow-up|0
6151342|NCT01109940|9787747|FG003|Overall Study|Lost to Follow-up|0
6151343|NCT01109940|9787744|FG000|Overall Study|Patient withdrew consent|1
6151344|NCT01109940|9787745|FG001|Overall Study|Patient withdrew consent|1
6151345|NCT01109940|9787746|FG002|Overall Study|Patient withdrew consent|0
6151346|NCT01109940|9787747|FG003|Overall Study|Patient withdrew consent|0
6151347|NCT01109940|9787744|FG000|Overall Study|Unsatisfactory therapeutic effect|2
6151348|NCT01109940|9787745|FG001|Overall Study|Unsatisfactory therapeutic effect|0
6151349|NCT01109940|9787746|FG002|Overall Study|Unsatisfactory therapeutic effect|1
6151350|NCT01109940|9787747|FG003|Overall Study|Unsatisfactory therapeutic effect|0
6151351|NCT01109979|9787759|FG000|Overall Study|Physician Decision|2
6151352|NCT01109979|9787760|FG001|Overall Study|Physician Decision|0
6151353|NCT01109979|9787759|FG000|Overall Study|Withdrawal by Subject|0
6151354|NCT01109979|9787760|FG001|Overall Study|Withdrawal by Subject|1
6151355|NCT01109992|9787768|FG000|Overall Study|Withdrawal by Subject|0
6151356|NCT01109992|9787769|FG001|Overall Study|Withdrawal by Subject|1
6151357|NCT01109992|9787768|FG000|Overall Study|Movement during rest scan.|0
6151358|NCT01109992|9787769|FG001|Overall Study|Movement during rest scan.|1
6151359|NCT01110005|9787780|FG000|Overall Study|ineligible|1
6151360|NCT01110005|9787781|FG001|Overall Study|ineligible|2
6151361|NCT01110005|9787780|FG000|Overall Study|missing consent|3
6151362|NCT01110005|9787781|FG001|Overall Study|missing consent|2
6151363|NCT01110005|9787780|FG000|Overall Study|Withdrawal by Subject|0
6151364|NCT01110005|9787781|FG001|Overall Study|Withdrawal by Subject|1
6151365|NCT01110200|9787804|FG000|Overall Study|Adverse Event|28
6151366|NCT01110200|9787805|FG001|Overall Study|Adverse Event|28
6151367|NCT01110200|9787804|FG000|Overall Study|Withdrawal by Subject|25
6151368|NCT01110200|9787805|FG001|Overall Study|Withdrawal by Subject|32
6151369|NCT01110200|9787804|FG000|Overall Study|Lack of Efficacy|16
6151370|NCT01110200|9787805|FG001|Overall Study|Lack of Efficacy|25
6151371|NCT01110200|9787804|FG000|Overall Study|Protocol Violation|14
6151372|NCT01110200|9787805|FG001|Overall Study|Protocol Violation|12
6151373|NCT01110200|9787804|FG000|Overall Study|Physician Decision|13
6151374|NCT01110200|9787805|FG001|Overall Study|Physician Decision|17
6151375|NCT01110200|9787804|FG000|Overall Study|Lost to Follow-up|10
6151376|NCT01110200|9787805|FG001|Overall Study|Lost to Follow-up|7
6151377|NCT01110239|9787815|FG000|Sham Preconditioning|Withdrawal by Subject|0
6151378|NCT01110239|9787816|FG001|Sham Preconditioning|Withdrawal by Subject|0
6151379|NCT01110239|9787817|FG002|Sham Preconditioning|Withdrawal by Subject|1
6151380|NCT01110239|9787818|FG003|Sham Preconditioning|Withdrawal by Subject|0
6151381|NCT01110239|9787815|FG000|7.5 Min Ischemia|Withdrawal by Subject|0
6151382|NCT01110239|9787816|FG001|7.5 Min Ischemia|Withdrawal by Subject|0
6151383|NCT01110239|9787817|FG002|7.5 Min Ischemia|Withdrawal by Subject|1
6151384|NCT01110239|9787818|FG003|7.5 Min Ischemia|Withdrawal by Subject|0
6151385|NCT01110330|9787837|FG000|Overall Study|Adverse Event|0
6151386|NCT01110330|9787838|FG001|Overall Study|Adverse Event|4
6151387|NCT01110330|9787839|FG002|Overall Study|Adverse Event|3
6151388|NCT01110330|9787837|FG000|Overall Study|Lack of Efficacy|3
6151389|NCT01110330|9787838|FG001|Overall Study|Lack of Efficacy|1
6151390|NCT01110330|9787839|FG002|Overall Study|Lack of Efficacy|1
6151391|NCT01110330|9787837|FG000|Overall Study|Lost to Follow-up|9
6151392|NCT01110330|9787838|FG001|Overall Study|Lost to Follow-up|10
6151393|NCT01110330|9787839|FG002|Overall Study|Lost to Follow-up|15
6151394|NCT01110330|9787837|FG000|Overall Study|Physician Decision|0
6151395|NCT01110330|9787838|FG001|Overall Study|Physician Decision|1
6151396|NCT01110330|9787839|FG002|Overall Study|Physician Decision|0
6151397|NCT01110330|9787837|FG000|Overall Study|Protocol Violation|2
6151398|NCT01110330|9787838|FG001|Overall Study|Protocol Violation|0
6151399|NCT01110330|9787839|FG002|Overall Study|Protocol Violation|4
6151400|NCT01110330|9787837|FG000|Overall Study|Withdrawal by Subject|0
6151401|NCT01110330|9787838|FG001|Overall Study|Withdrawal by Subject|6
6151402|NCT01110330|9787839|FG002|Overall Study|Withdrawal by Subject|2
6151403|NCT01110330|9787837|FG000|Overall Study|Other|1
6151404|NCT01110330|9787838|FG001|Overall Study|Other|1
6151405|NCT01110330|9787839|FG002|Overall Study|Other|1
6318915|NCT03377699|10054622|FG001|Overall Study|Lost to Follow-up|1
6151406|NCT01110382|9787849|FG000|Overall Study|Withdrawal by Subject|0
6151407|NCT01110382|9787850|FG001|Overall Study|Withdrawal by Subject|1
6151408|NCT01110382|9787849|FG000|Overall Study|Protocol Violation|0
6318916|NCT03377699|10054621|FG000|Overall Study|Commencement of medical infertility treatment during the course of the trial|1
6151409|NCT01110382|9787850|FG001|Overall Study|Protocol Violation|1
6151410|NCT01110408|9787862|FG000|Overall Study|Protocol Violation|1
6151411|NCT01110408|9787863|FG001|Overall Study|Protocol Violation|0
6151412|NCT01110707|9787928|FG000|Overall Study|Protocol Violation|0
6151413|NCT01110707|9787929|FG001|Overall Study|Protocol Violation|3
6151414|NCT01110915|9787948|FG000|Overall Study|Death|2
6318917|NCT03377699|10054622|FG001|Overall Study|Commencement of medical infertility treatment during the course of the trial|0
6318918|NCT03377699|10054621|FG000|Overall Study|Non-pregnant subject initiating medication contraindicated during pregnancy|1
6318919|NCT03377699|10054622|FG001|Overall Study|Non-pregnant subject initiating medication contraindicated during pregnancy|1
6318920|NCT03377699|10054621|FG000|Overall Study|Randomised non-pregnant did not become pregnant and withdrawn from trial|11
6318921|NCT03377699|10054622|FG001|Overall Study|Randomised non-pregnant did not become pregnant and withdrawn from trial|8
6318922|NCT03377699|10054621|FG000|Overall Study|Randomised non-pregnant did not become pregnant and NOT withdrawn from trial|6
6318923|NCT03377699|10054622|FG001|Overall Study|Randomised non-pregnant did not become pregnant and NOT withdrawn from trial|6
6318924|NCT03275350|10054632|FG000|Overall Study|Lost to Follow-up|4
6318925|NCT03275350|10054633|FG001|Overall Study|Lost to Follow-up|6
6318926|NCT03275350|10054632|FG000|Overall Study|Death|2
6318927|NCT03275350|10054633|FG001|Overall Study|Death|1
6318928|NCT03275350|10054632|FG000|Overall Study|Physician Decision|1
6318929|NCT03275350|10054633|FG001|Overall Study|Physician Decision|0
6318930|NCT03275350|10054632|FG000|Overall Study|Incarcerated|1
6318931|NCT03275350|10054633|FG001|Overall Study|Incarcerated|1
6318932|NCT03272347|10054644|FG000|Overall Study|Death|0
6318933|NCT03272347|10054645|FG001|Overall Study|Death|0
6318934|NCT03272347|10054646|FG002|Overall Study|Death|0
6318935|NCT03272347|10054647|FG003|Overall Study|Death|1
6318936|NCT03272347|10054644|FG000|Overall Study|Lost to Follow-up|1
6318937|NCT03272347|10054645|FG001|Overall Study|Lost to Follow-up|0
6318938|NCT03272347|10054646|FG002|Overall Study|Lost to Follow-up|5
6151415|NCT01110915|9787949|FG001|Overall Study|Death|1
6151416|NCT01110915|9787948|FG000|Overall Study|Lost to Follow-up|1
6151417|NCT01110915|9787949|FG001|Overall Study|Lost to Follow-up|0
6151418|NCT01110915|9787948|FG000|Overall Study|Withdrawal by Subject|7
6151419|NCT01110915|9787949|FG001|Overall Study|Withdrawal by Subject|1
6151420|NCT01111123|9787971|FG000|Open- Label Phase|Failed to be clear or almost cleared|14
6151421|NCT01111123|9787972|FG001|Open- Label Phase|Failed to be clear or almost cleared|0
6151422|NCT01111123|9787971|FG000|Maintenance Phase|Lost to Follow-up|0
6151423|NCT01111123|9787972|FG001|Maintenance Phase|Lost to Follow-up|2
6151424|NCT01111149|9787983|FG000|Overall Study|Protocol Violation|1
6151425|NCT01111149|9787984|FG001|Overall Study|Protocol Violation|1
6151426|NCT01111149|9787985|FG002|Overall Study|Protocol Violation|2
6151427|NCT01111149|9787983|FG000|Overall Study|Withdrawal by Subject|1
6151428|NCT01111149|9787984|FG001|Overall Study|Withdrawal by Subject|0
6151429|NCT01111149|9787985|FG002|Overall Study|Withdrawal by Subject|2
6151430|NCT01111240|9787998|FG000|Overall Study|Adverse Event|190
6151431|NCT01111240|9787998|FG000|Overall Study|Lack of Efficacy|545
6151432|NCT01111240|9787998|FG000|Overall Study|Lack of Efficacy and Adverse Event|19
6151433|NCT01111240|9787998|FG000|Overall Study|Other|312
6151434|NCT01111292|9788004|FG000|Treatment|Physician Decision|1
6151435|NCT01111292|9788005|FG001|Treatment|Physician Decision|1
6151436|NCT01111461|9788043|FG000|Overall Study|Adverse Event|32
6151437|NCT01111461|9788043|FG000|Overall Study|Participant choice|11
6151438|NCT01111461|9788043|FG000|Overall Study|Lost to Follow-up|1
6151439|NCT01111461|9788043|FG000|Overall Study|Withdrawal by Subject|1
6151440|NCT01111461|9788043|FG000|Overall Study|Other|6
6151441|NCT01111474|9788047|FG000|Overall Study|Lost to Follow-up|12
6151442|NCT01111526|9788053|FG000|Overall Study|GVHD Disease Progression|0
6151443|NCT01111526|9788054|FG001|Overall Study|GVHD Disease Progression|1
6151444|NCT01111526|9788055|FG002|Overall Study|GVHD Disease Progression|2
6151445|NCT01111539|9788059|FG000|Phase B (Day 1 to Week 8)|Lost to Follow-up|6
6151446|NCT01111539|9788060|FG001|Phase B (Day 1 to Week 8)|Lost to Follow-up|0
6151447|NCT01111539|9788061|FG002|Phase B (Day 1 to Week 8)|Lost to Follow-up|0
6151448|NCT01111539|9788062|FG003|Phase B (Day 1 to Week 8)|Lost to Follow-up|0
6151449|NCT01111539|9788063|FG004|Phase B (Day 1 to Week 8)|Lost to Follow-up|0
6151450|NCT01111539|9788059|FG000|Phase B (Day 1 to Week 8)|Adverse Event|5
6151451|NCT01111539|9788060|FG001|Phase B (Day 1 to Week 8)|Adverse Event|0
6151452|NCT01111539|9788061|FG002|Phase B (Day 1 to Week 8)|Adverse Event|0
6151453|NCT01111539|9788062|FG003|Phase B (Day 1 to Week 8)|Adverse Event|0
6151454|NCT01111539|9788063|FG004|Phase B (Day 1 to Week 8)|Adverse Event|0
6151455|NCT01111539|9788059|FG000|Phase B (Day 1 to Week 8)|Sponsor Discontinued Study|60
6151456|NCT01111539|9788060|FG001|Phase B (Day 1 to Week 8)|Sponsor Discontinued Study|0
6151457|NCT01111539|9788061|FG002|Phase B (Day 1 to Week 8)|Sponsor Discontinued Study|0
6151458|NCT01111539|9788062|FG003|Phase B (Day 1 to Week 8)|Sponsor Discontinued Study|0
6151459|NCT01111539|9788063|FG004|Phase B (Day 1 to Week 8)|Sponsor Discontinued Study|0
6151460|NCT01111539|9788059|FG000|Phase B (Day 1 to Week 8)|Investigator Withdrew Subject|1
6151461|NCT01111539|9788060|FG001|Phase B (Day 1 to Week 8)|Investigator Withdrew Subject|0
6151462|NCT01111539|9788061|FG002|Phase B (Day 1 to Week 8)|Investigator Withdrew Subject|0
6151463|NCT01111539|9788062|FG003|Phase B (Day 1 to Week 8)|Investigator Withdrew Subject|0
6151464|NCT01111539|9788063|FG004|Phase B (Day 1 to Week 8)|Investigator Withdrew Subject|0
6151465|NCT01111539|9788059|FG000|Phase B (Day 1 to Week 8)|Subject Withdrew Consent|7
6151466|NCT01111539|9788060|FG001|Phase B (Day 1 to Week 8)|Subject Withdrew Consent|0
6151467|NCT01111539|9788061|FG002|Phase B (Day 1 to Week 8)|Subject Withdrew Consent|0
6318939|NCT03272347|10054647|FG003|Overall Study|Lost to Follow-up|1
6318940|NCT03272347|10054644|FG000|Overall Study|Physician Decision|4
6318941|NCT03272347|10054645|FG001|Overall Study|Physician Decision|2
6318942|NCT03272347|10054646|FG002|Overall Study|Physician Decision|5
6318943|NCT03272347|10054647|FG003|Overall Study|Physician Decision|4
6318944|NCT03272347|10054644|FG000|Overall Study|Screen Failure|1
6318945|NCT03272347|10054645|FG001|Overall Study|Screen Failure|0
6318946|NCT03272347|10054646|FG002|Overall Study|Screen Failure|0
6318947|NCT03272347|10054647|FG003|Overall Study|Screen Failure|0
6318948|NCT03272347|10054644|FG000|Overall Study|Withdrawal by Subject|3
6318949|NCT03272347|10054645|FG001|Overall Study|Withdrawal by Subject|1
6318950|NCT03272347|10054646|FG002|Overall Study|Withdrawal by Subject|2
6318951|NCT03272347|10054647|FG003|Overall Study|Withdrawal by Subject|1
6318952|NCT03272347|10054644|FG000|Overall Study|Status Not Recorded|22
6318953|NCT03272347|10054645|FG001|Overall Study|Status Not Recorded|26
6318954|NCT03272347|10054646|FG002|Overall Study|Status Not Recorded|19
6318955|NCT03272347|10054647|FG003|Overall Study|Status Not Recorded|22
6318956|NCT02853305|10054670|FG000|Overall Study|Death|244
6318957|NCT02853305|10054671|FG001|Overall Study|Death|207
6318958|NCT02853305|10054672|FG002|Overall Study|Death|263
6318959|NCT02853305|10054670|FG000|Overall Study|Withdrawal by Subject|2
6318960|NCT02853305|10054671|FG001|Overall Study|Withdrawal by Subject|4
6318961|NCT02853305|10054672|FG002|Overall Study|Withdrawal by Subject|2
6318962|NCT02853305|10054670|FG000|Overall Study|Ongoing in Trial|105
6318963|NCT02853305|10054671|FG001|Overall Study|Ongoing in Trial|96
6318964|NCT02853305|10054672|FG002|Overall Study|Ongoing in Trial|87
6151468|NCT01111539|9788062|FG003|Phase B (Day 1 to Week 8)|Subject Withdrew Consent|0
6151469|NCT01111539|9788063|FG004|Phase B (Day 1 to Week 8)|Subject Withdrew Consent|0
6151470|NCT01111539|9788059|FG000|Phase B (Day 1 to Week 8)|Protocol Deviation|2
6151471|NCT01111539|9788060|FG001|Phase B (Day 1 to Week 8)|Protocol Deviation|0
6151472|NCT01111539|9788061|FG002|Phase B (Day 1 to Week 8)|Protocol Deviation|0
6151473|NCT01111539|9788062|FG003|Phase B (Day 1 to Week 8)|Protocol Deviation|0
6151474|NCT01111539|9788063|FG004|Phase B (Day 1 to Week 8)|Protocol Deviation|0
6151475|NCT01111539|9788059|FG000|Phase B (Day 1 to Week 8)|Lack of Efficacy as Determined by the Investigator|1
6151476|NCT01111539|9788060|FG001|Phase B (Day 1 to Week 8)|Lack of Efficacy as Determined by the Investigator|0
6151477|NCT01111539|9788061|FG002|Phase B (Day 1 to Week 8)|Lack of Efficacy as Determined by the Investigator|0
6151478|NCT01111539|9788062|FG003|Phase B (Day 1 to Week 8)|Lack of Efficacy as Determined by the Investigator|0
6151479|NCT01111539|9788063|FG004|Phase B (Day 1 to Week 8)|Lack of Efficacy as Determined by the Investigator|0
6318965|NCT02674750|10054701|FG000|Overall Study|Death|4
6318966|NCT02674750|10054702|FG001|Overall Study|Death|5
6151480|NCT01111539|9788059|FG000|Phase B+ and Phase C (Weeks 9 to 14)|Lost to Follow-up|0
6151481|NCT01111539|9788060|FG001|Phase B+ and Phase C (Weeks 9 to 14)|Lost to Follow-up|0
6151482|NCT01111539|9788061|FG002|Phase B+ and Phase C (Weeks 9 to 14)|Lost to Follow-up|1
6151483|NCT01111539|9788062|FG003|Phase B+ and Phase C (Weeks 9 to 14)|Lost to Follow-up|0
6151484|NCT01111539|9788063|FG004|Phase B+ and Phase C (Weeks 9 to 14)|Lost to Follow-up|1
6151485|NCT01111539|9788059|FG000|Phase B+ and Phase C (Weeks 9 to 14)|Adverse Event|0
6151486|NCT01111539|9788060|FG001|Phase B+ and Phase C (Weeks 9 to 14)|Adverse Event|0
6151487|NCT01111539|9788061|FG002|Phase B+ and Phase C (Weeks 9 to 14)|Adverse Event|1
6151488|NCT01111539|9788062|FG003|Phase B+ and Phase C (Weeks 9 to 14)|Adverse Event|0
6151489|NCT01111539|9788063|FG004|Phase B+ and Phase C (Weeks 9 to 14)|Adverse Event|2
6151490|NCT01111539|9788059|FG000|Phase B+ and Phase C (Weeks 9 to 14)|Sponsor Discontinued Study|0
6151491|NCT01111539|9788060|FG001|Phase B+ and Phase C (Weeks 9 to 14)|Sponsor Discontinued Study|7
6151492|NCT01111539|9788061|FG002|Phase B+ and Phase C (Weeks 9 to 14)|Sponsor Discontinued Study|4
6151493|NCT01111539|9788062|FG003|Phase B+ and Phase C (Weeks 9 to 14)|Sponsor Discontinued Study|5
6151494|NCT01111539|9788063|FG004|Phase B+ and Phase C (Weeks 9 to 14)|Sponsor Discontinued Study|5
6151495|NCT01111539|9788059|FG000|Phase B+ and Phase C (Weeks 9 to 14)|Subject Met Withdrawal Criteria|0
6151496|NCT01111539|9788060|FG001|Phase B+ and Phase C (Weeks 9 to 14)|Subject Met Withdrawal Criteria|0
6151497|NCT01111539|9788061|FG002|Phase B+ and Phase C (Weeks 9 to 14)|Subject Met Withdrawal Criteria|0
6151498|NCT01111539|9788062|FG003|Phase B+ and Phase C (Weeks 9 to 14)|Subject Met Withdrawal Criteria|0
6151499|NCT01111539|9788063|FG004|Phase B+ and Phase C (Weeks 9 to 14)|Subject Met Withdrawal Criteria|1
6151500|NCT01111539|9788059|FG000|Phase B+ and Phase C (Weeks 9 to 14)|Investigator Withdrew Subject|0
6151501|NCT01111539|9788060|FG001|Phase B+ and Phase C (Weeks 9 to 14)|Investigator Withdrew Subject|0
6151502|NCT01111539|9788061|FG002|Phase B+ and Phase C (Weeks 9 to 14)|Investigator Withdrew Subject|0
6151503|NCT01111539|9788062|FG003|Phase B+ and Phase C (Weeks 9 to 14)|Investigator Withdrew Subject|1
6151504|NCT01111539|9788063|FG004|Phase B+ and Phase C (Weeks 9 to 14)|Investigator Withdrew Subject|0
6151505|NCT01111539|9788059|FG000|Phase B+ and Phase C (Weeks 9 to 14)|Subject Withdrew Consent|0
6151506|NCT01111539|9788060|FG001|Phase B+ and Phase C (Weeks 9 to 14)|Subject Withdrew Consent|0
6151507|NCT01111539|9788061|FG002|Phase B+ and Phase C (Weeks 9 to 14)|Subject Withdrew Consent|0
6151508|NCT01111539|9788062|FG003|Phase B+ and Phase C (Weeks 9 to 14)|Subject Withdrew Consent|2
6151509|NCT01111539|9788063|FG004|Phase B+ and Phase C (Weeks 9 to 14)|Subject Withdrew Consent|0
6151510|NCT01111539|9788059|FG000|Phase B+ and Phase C (Weeks 9 to 14)|Protocol Deviation|0
6151511|NCT01111539|9788060|FG001|Phase B+ and Phase C (Weeks 9 to 14)|Protocol Deviation|0
6151512|NCT01111539|9788061|FG002|Phase B+ and Phase C (Weeks 9 to 14)|Protocol Deviation|0
6151513|NCT01111539|9788062|FG003|Phase B+ and Phase C (Weeks 9 to 14)|Protocol Deviation|0
6151514|NCT01111539|9788063|FG004|Phase B+ and Phase C (Weeks 9 to 14)|Protocol Deviation|1
6151515|NCT01111552|9788073|FG000|Phase B (Day 1 to Week 8)|Lost to Follow-up|9
6151516|NCT01111552|9788074|FG001|Phase B (Day 1 to Week 8)|Lost to Follow-up|0
6151517|NCT01111552|9788075|FG002|Phase B (Day 1 to Week 8)|Lost to Follow-up|0
6151518|NCT01111552|9788076|FG003|Phase B (Day 1 to Week 8)|Lost to Follow-up|0
6151519|NCT01111552|9788077|FG004|Phase B (Day 1 to Week 8)|Lost to Follow-up|0
6151520|NCT01111552|9788073|FG000|Phase B (Day 1 to Week 8)|Adverse Event|4
6151521|NCT01111552|9788074|FG001|Phase B (Day 1 to Week 8)|Adverse Event|0
6151522|NCT01111552|9788075|FG002|Phase B (Day 1 to Week 8)|Adverse Event|0
6151523|NCT01111552|9788076|FG003|Phase B (Day 1 to Week 8)|Adverse Event|0
6151524|NCT01111552|9788077|FG004|Phase B (Day 1 to Week 8)|Adverse Event|0
6151525|NCT01111552|9788073|FG000|Phase B (Day 1 to Week 8)|Sponsor Discontinued Study|89
6151526|NCT01111552|9788074|FG001|Phase B (Day 1 to Week 8)|Sponsor Discontinued Study|0
6151527|NCT01111552|9788075|FG002|Phase B (Day 1 to Week 8)|Sponsor Discontinued Study|0
6151528|NCT01111552|9788076|FG003|Phase B (Day 1 to Week 8)|Sponsor Discontinued Study|0
6151529|NCT01111552|9788077|FG004|Phase B (Day 1 to Week 8)|Sponsor Discontinued Study|0
6151530|NCT01111552|9788073|FG000|Phase B (Day 1 to Week 8)|Participant Met Withdrawal Criteria|3
6151531|NCT01111552|9788074|FG001|Phase B (Day 1 to Week 8)|Participant Met Withdrawal Criteria|0
6151532|NCT01111552|9788075|FG002|Phase B (Day 1 to Week 8)|Participant Met Withdrawal Criteria|0
6151533|NCT01111552|9788076|FG003|Phase B (Day 1 to Week 8)|Participant Met Withdrawal Criteria|0
6151534|NCT01111552|9788077|FG004|Phase B (Day 1 to Week 8)|Participant Met Withdrawal Criteria|0
6151535|NCT01111552|9788073|FG000|Phase B (Day 1 to Week 8)|Investigator Withdrew Participant|3
6151536|NCT01111552|9788074|FG001|Phase B (Day 1 to Week 8)|Investigator Withdrew Participant|0
6151537|NCT01111552|9788075|FG002|Phase B (Day 1 to Week 8)|Investigator Withdrew Participant|0
6151538|NCT01111552|9788076|FG003|Phase B (Day 1 to Week 8)|Investigator Withdrew Participant|0
6151539|NCT01111552|9788077|FG004|Phase B (Day 1 to Week 8)|Investigator Withdrew Participant|0
6318967|NCT02674750|10054703|FG002|Overall Study|Death|8
6318968|NCT02674750|10054701|FG000|Overall Study|Lost to Follow-up|0
6318969|NCT02674750|10054702|FG001|Overall Study|Lost to Follow-up|8
6318970|NCT02674750|10054703|FG002|Overall Study|Lost to Follow-up|0
6318971|NCT02674750|10054701|FG000|Overall Study|Lack of Efficacy|1
6318972|NCT02674750|10054702|FG001|Overall Study|Lack of Efficacy|17
6151540|NCT01111552|9788073|FG000|Phase B (Day 1 to Week 8)|Participant Withdrew Consent|7
6151541|NCT01111552|9788074|FG001|Phase B (Day 1 to Week 8)|Participant Withdrew Consent|0
6151542|NCT01111552|9788075|FG002|Phase B (Day 1 to Week 8)|Participant Withdrew Consent|0
6151543|NCT01111552|9788076|FG003|Phase B (Day 1 to Week 8)|Participant Withdrew Consent|0
6151544|NCT01111552|9788077|FG004|Phase B (Day 1 to Week 8)|Participant Withdrew Consent|0
6151545|NCT01111552|9788073|FG000|Phase B (Day 1 to Week 8)|Protocol Deviation|1
6151546|NCT01111552|9788074|FG001|Phase B (Day 1 to Week 8)|Protocol Deviation|0
6151547|NCT01111552|9788075|FG002|Phase B (Day 1 to Week 8)|Protocol Deviation|0
6151548|NCT01111552|9788076|FG003|Phase B (Day 1 to Week 8)|Protocol Deviation|0
6151549|NCT01111552|9788077|FG004|Phase B (Day 1 to Week 8)|Protocol Deviation|0
6151550|NCT01111552|9788073|FG000|Phase B (Day 1 to Week 8)|Lack of Efficacy as Determined by Investigator|1
6151551|NCT01111552|9788074|FG001|Phase B (Day 1 to Week 8)|Lack of Efficacy as Determined by Investigator|0
6151552|NCT01111552|9788075|FG002|Phase B (Day 1 to Week 8)|Lack of Efficacy as Determined by Investigator|0
6151553|NCT01111552|9788076|FG003|Phase B (Day 1 to Week 8)|Lack of Efficacy as Determined by Investigator|0
6151554|NCT01111552|9788077|FG004|Phase B (Day 1 to Week 8)|Lack of Efficacy as Determined by Investigator|0
6151555|NCT01111552|9788073|FG000|Phase B+ and Phase C (Weeks 9 to 14)|Adverse Event|0
6151556|NCT01111552|9788074|FG001|Phase B+ and Phase C (Weeks 9 to 14)|Adverse Event|0
6151557|NCT01111552|9788075|FG002|Phase B+ and Phase C (Weeks 9 to 14)|Adverse Event|0
6151558|NCT01111552|9788076|FG003|Phase B+ and Phase C (Weeks 9 to 14)|Adverse Event|1
6151559|NCT01111552|9788077|FG004|Phase B+ and Phase C (Weeks 9 to 14)|Adverse Event|0
6151560|NCT01111552|9788073|FG000|Phase B+ and Phase C (Weeks 9 to 14)|Sponsor Discontinued Study|0
6151561|NCT01111552|9788074|FG001|Phase B+ and Phase C (Weeks 9 to 14)|Sponsor Discontinued Study|5
6151562|NCT01111552|9788075|FG002|Phase B+ and Phase C (Weeks 9 to 14)|Sponsor Discontinued Study|4
6151563|NCT01111552|9788076|FG003|Phase B+ and Phase C (Weeks 9 to 14)|Sponsor Discontinued Study|3
6151564|NCT01111552|9788077|FG004|Phase B+ and Phase C (Weeks 9 to 14)|Sponsor Discontinued Study|5
6151565|NCT01111552|9788073|FG000|Phase B+ and Phase C (Weeks 9 to 14)|Participant Met Withdrawal Criteria|0
6151566|NCT01111552|9788074|FG001|Phase B+ and Phase C (Weeks 9 to 14)|Participant Met Withdrawal Criteria|2
6151567|NCT01111552|9788075|FG002|Phase B+ and Phase C (Weeks 9 to 14)|Participant Met Withdrawal Criteria|0
6151568|NCT01111552|9788076|FG003|Phase B+ and Phase C (Weeks 9 to 14)|Participant Met Withdrawal Criteria|0
6151569|NCT01111552|9788077|FG004|Phase B+ and Phase C (Weeks 9 to 14)|Participant Met Withdrawal Criteria|0
6151570|NCT01111552|9788073|FG000|Phase B+ and Phase C (Weeks 9 to 14)|Investigator Withdrew Participant|0
6151571|NCT01111552|9788074|FG001|Phase B+ and Phase C (Weeks 9 to 14)|Investigator Withdrew Participant|1
6151572|NCT01111552|9788075|FG002|Phase B+ and Phase C (Weeks 9 to 14)|Investigator Withdrew Participant|0
6151573|NCT01111552|9788076|FG003|Phase B+ and Phase C (Weeks 9 to 14)|Investigator Withdrew Participant|0
6151574|NCT01111552|9788077|FG004|Phase B+ and Phase C (Weeks 9 to 14)|Investigator Withdrew Participant|0
6151575|NCT01111552|9788073|FG000|Phase B+ and Phase C (Weeks 9 to 14)|Participant Withdrew Consent|0
6151576|NCT01111552|9788074|FG001|Phase B+ and Phase C (Weeks 9 to 14)|Participant Withdrew Consent|1
6151577|NCT01111552|9788075|FG002|Phase B+ and Phase C (Weeks 9 to 14)|Participant Withdrew Consent|0
6151578|NCT01111552|9788076|FG003|Phase B+ and Phase C (Weeks 9 to 14)|Participant Withdrew Consent|0
6151579|NCT01111552|9788077|FG004|Phase B+ and Phase C (Weeks 9 to 14)|Participant Withdrew Consent|0
6151580|NCT01111552|9788073|FG000|Phase B+ and Phase C (Weeks 9 to 14)|Protocol Deviation|0
6151581|NCT01111552|9788074|FG001|Phase B+ and Phase C (Weeks 9 to 14)|Protocol Deviation|0
6151582|NCT01111552|9788075|FG002|Phase B+ and Phase C (Weeks 9 to 14)|Protocol Deviation|1
6151583|NCT01111552|9788076|FG003|Phase B+ and Phase C (Weeks 9 to 14)|Protocol Deviation|0
6151584|NCT01111552|9788077|FG004|Phase B+ and Phase C (Weeks 9 to 14)|Protocol Deviation|0
6151585|NCT01111604|9788090|FG000|Overall Study|Lost to Follow-up|0
6151586|NCT01111604|9788091|FG001|Overall Study|Lost to Follow-up|0
6151587|NCT01111604|9788092|FG002|Overall Study|Lost to Follow-up|1
6151588|NCT01111604|9788090|FG000|Overall Study|Withdrew Consent|3
6151589|NCT01111604|9788091|FG001|Overall Study|Withdrew Consent|0
6151590|NCT01111604|9788092|FG002|Overall Study|Withdrew Consent|2
6151591|NCT01111604|9788090|FG000|Overall Study|Withdrawal by Subject|2
6151592|NCT01111604|9788091|FG001|Overall Study|Withdrawal by Subject|0
6151593|NCT01111604|9788092|FG002|Overall Study|Withdrawal by Subject|0
6151594|NCT01111604|9788090|FG000|Overall Study|Death|1
6151595|NCT01111604|9788091|FG001|Overall Study|Death|0
6151596|NCT01111604|9788092|FG002|Overall Study|Death|0
6151597|NCT01111604|9788090|FG000|Overall Study|Met Exclusion Criteria|2
6151598|NCT01111604|9788091|FG001|Overall Study|Met Exclusion Criteria|0
6151599|NCT01111604|9788092|FG002|Overall Study|Met Exclusion Criteria|0
6151600|NCT01111825|9788122|FG000|Overall Study|Withdrawal by Subject|0
6151601|NCT01111825|9788123|FG001|Overall Study|Withdrawal by Subject|0
6151602|NCT01111825|9788124|FG002|Overall Study|Withdrawal by Subject|1
6151603|NCT01111825|9788125|FG003|Overall Study|Withdrawal by Subject|0
6151604|NCT01111825|9788122|FG000|Overall Study|Lost to Follow-up|0
6151605|NCT01111825|9788123|FG001|Overall Study|Lost to Follow-up|0
6151606|NCT01111825|9788124|FG002|Overall Study|Lost to Follow-up|3
6151607|NCT01111825|9788125|FG003|Overall Study|Lost to Follow-up|1
6318973|NCT02674750|10054703|FG002|Overall Study|Lack of Efficacy|3
6318974|NCT02674750|10054701|FG000|Overall Study|Withdrawal by Subject|0
6318975|NCT02674750|10054702|FG001|Overall Study|Withdrawal by Subject|7
6318976|NCT02674750|10054703|FG002|Overall Study|Withdrawal by Subject|1
6318977|NCT02674750|10054701|FG000|Overall Study|Other|0
6318978|NCT02674750|10054702|FG001|Overall Study|Other|8
6040907|NCT00372385|9638997|FG000|Overall Study|Ineligibility due to Exclusion Criterion|1
6040908|NCT00372385|9638998|FG001|Overall Study|Ineligibility due to Exclusion Criterion|0
6151608|NCT01111825|9788122|FG000|Overall Study|Adverse Event|2
6151609|NCT01111825|9788123|FG001|Overall Study|Adverse Event|1
6151610|NCT01111825|9788124|FG002|Overall Study|Adverse Event|4
6151611|NCT01111825|9788125|FG003|Overall Study|Adverse Event|0
6151612|NCT01111825|9788122|FG000|Overall Study|Disease Progression|1
6151613|NCT01111825|9788123|FG001|Overall Study|Disease Progression|0
6151614|NCT01111825|9788124|FG002|Overall Study|Disease Progression|0
6151615|NCT01111825|9788125|FG003|Overall Study|Disease Progression|0
6151616|NCT01111825|9788122|FG000|Overall Study|Discontinuation by Sponsor|0
6151617|NCT01111825|9788123|FG001|Overall Study|Discontinuation by Sponsor|0
6151618|NCT01111825|9788124|FG002|Overall Study|Discontinuation by Sponsor|0
6151619|NCT01111825|9788125|FG003|Overall Study|Discontinuation by Sponsor|20
6151620|NCT01111838|9788135|FG000|Overall Study|Patient Ineligible|2
6151621|NCT01111838|9788135|FG000|Overall Study|Not Treated|3
6151622|NCT01111838|9788135|FG000|Overall Study|Clinical deterioration|1
6151623|NCT01111838|9788135|FG000|Overall Study|Other Complicating Disease|1
6151624|NCT01111851|9788141|FG000|Overall Study|All planned PET scans were not obtained.|2
6151625|NCT01111851|9788142|FG001|Overall Study|All planned PET scans were not obtained.|0
6151626|NCT01112059|9788150|FG000|Overall Study|Withdrawal by Subject|1
6151627|NCT01112059|9788151|FG001|Overall Study|Withdrawal by Subject|0
6151628|NCT01112267|9788172|FG000|Overall Study|Adverse Event|24
6151629|NCT01112267|9788173|FG001|Overall Study|Adverse Event|6
6151630|NCT01112267|9788172|FG000|Overall Study|Withdrawal by Subject|3
6151631|NCT01112267|9788173|FG001|Overall Study|Withdrawal by Subject|5
6151632|NCT01112267|9788172|FG000|Overall Study|Protocol Violation|5
6151633|NCT01112267|9788173|FG001|Overall Study|Protocol Violation|3
6151634|NCT01112267|9788172|FG000|Overall Study|Participants not compliant|1
6151635|NCT01112267|9788173|FG001|Overall Study|Participants not compliant|2
6040909|NCT00372385|9638999|FG002|Overall Study|Ineligibility due to Exclusion Criterion|0
6040910|NCT00372385|9639000|FG003|Overall Study|Ineligibility due to Exclusion Criterion|0
6040911|NCT00372385|9638997|FG000|Overall Study|Virologic Stopping Rule|17
6040912|NCT00372385|9638998|FG001|Overall Study|Virologic Stopping Rule|0
6040913|NCT00372385|9638999|FG002|Overall Study|Virologic Stopping Rule|0
6040914|NCT00372385|9639000|FG003|Overall Study|Virologic Stopping Rule|0
6040915|NCT00372411|9639014|FG000|Overall Study|Withdrawal by Subject|3
6040916|NCT00372411|9639015|FG001|Overall Study|Withdrawal by Subject|4
6040917|NCT00372411|9639016|FG002|Overall Study|Withdrawal by Subject|1
6040918|NCT00372411|9639014|FG000|Overall Study|Death|0
6040919|NCT00372411|9639015|FG001|Overall Study|Death|2
6040920|NCT00372411|9639016|FG002|Overall Study|Death|1
6151636|NCT01112267|9788172|FG000|Overall Study|Participants not receive any study drug|1
6151637|NCT01112267|9788173|FG001|Overall Study|Participants not receive any study drug|2
6151638|NCT01112514|9788192|FG000|Overall Study|Lost to Follow-up|1
6151639|NCT01112579|9788198|FG000|Overall Study|Missed Visit|1
6151640|NCT01112579|9788199|FG001|Overall Study|Missed Visit|1
6151641|NCT01112579|9788198|FG000|Overall Study|Death|0
6151642|NCT01112579|9788199|FG001|Overall Study|Death|2
6151643|NCT01112917|9788247|FG000|Overall Study|Death|2
6151644|NCT01112917|9788248|FG001|Overall Study|Death|11
6151645|NCT01112917|9788247|FG000|Overall Study|Lost to Follow-up|1
6151646|NCT01112917|9788248|FG001|Overall Study|Lost to Follow-up|1
6151647|NCT01112917|9788247|FG000|Overall Study|Withdrawal by Subject|1
6151648|NCT01112917|9788248|FG001|Overall Study|Withdrawal by Subject|3
6151649|NCT01112917|9788247|FG000|Overall Study|Unable to Convert Filter|3
6151650|NCT01112917|9788248|FG001|Overall Study|Unable to Convert Filter|0
6151651|NCT01112982|9788252|FG000|Overall Study|Withdrawal by Subject|1
6151652|NCT01112982|9788252|FG000|Overall Study|exceeded weight limit to complete MRI|1
6151653|NCT01113463|9788276|FG000|Overall Study|Physician Decision|5
6151654|NCT01113502|9788285|FG000|Overall Study|Withdrawal by Subject|1
6151655|NCT01113502|9788286|FG001|Overall Study|Withdrawal by Subject|0
6151656|NCT01113502|9788287|FG002|Overall Study|Withdrawal by Subject|1
6151657|NCT01113502|9788288|FG003|Overall Study|Withdrawal by Subject|1
6151658|NCT01113502|9788289|FG004|Overall Study|Withdrawal by Subject|0
6151659|NCT01113502|9788285|FG000|Overall Study|Adverse Event|0
6151660|NCT01113502|9788286|FG001|Overall Study|Adverse Event|0
6151661|NCT01113502|9788287|FG002|Overall Study|Adverse Event|3
6151662|NCT01113502|9788288|FG003|Overall Study|Adverse Event|2
6151663|NCT01113502|9788289|FG004|Overall Study|Adverse Event|0
6151664|NCT01113541|9788302|FG000|Overall Study|Withdrawal by Subject|1
6151665|NCT01113541|9788302|FG000|Overall Study|Protocol Violation|1
6151666|NCT01113541|9788302|FG000|Overall Study|Study Terminated by Sponsor|7
6151667|NCT01113541|9788302|FG000|Overall Study|Adverse Event|4
6151668|NCT01113580|9788308|FG000|Overall Study|Protocol Violation|1
6151669|NCT01113580|9788309|FG001|Overall Study|Protocol Violation|0
6318979|NCT02674750|10054703|FG002|Overall Study|Other|0
6318980|NCT02440854|10054710|FG000|Overall Study|Relocation of patient|1
6040921|NCT00372411|9639014|FG000|Overall Study|Lost to Follow-up|1
6318981|NCT02440854|10054710|FG000|Overall Study|Death|6
6318982|NCT02440854|10054710|FG000|Overall Study|Lost to Follow-up|10
6318983|NCT02440854|10054710|FG000|Overall Study|Afatinib discontinuation|46
6318984|NCT02440854|10054710|FG000|Overall Study|stopped study at earlier timepoint|14
6318985|NCT02440854|10054710|FG000|Overall Study|Study medication not received|1
6318986|NCT02440854|10054710|FG000|Overall Study|Violation of inclusion criteria|2
6318987|NCT02154529|10054729|FG000|Overall Study|Death|1
6318988|NCT02154529|10054730|FG001|Overall Study|Death|1
6318989|NCT02154529|10054731|FG002|Overall Study|Death|5
6318990|NCT02154529|10054732|FG003|Overall Study|Death|1
6151670|NCT01113710|9788324|FG000|Overall Study|Adverse Event|64
6151671|NCT01113710|9788324|FG000|Overall Study|Lack of Efficacy|41
6151672|NCT01113710|9788324|FG000|Overall Study|No Information Available|40
6151673|NCT01113710|9788324|FG000|Overall Study|Withdrawal by Subject|28
6151674|NCT01113710|9788324|FG000|Overall Study|Lost to Follow-up|20
6151675|NCT01113710|9788324|FG000|Overall Study|Lack of Efficacy/Withdrawal by Subject|13
6151676|NCT01113710|9788324|FG000|Overall Study|Withdrawal by Subject/Adverse Event|11
6151677|NCT01113710|9788324|FG000|Overall Study|Lack of Patient's Compliance|8
6151678|NCT01113710|9788324|FG000|Overall Study|Other|7
6151679|NCT01113710|9788324|FG000|Overall Study|Adverse Event/Other|5
6151680|NCT01113710|9788324|FG000|Overall Study|Patient's Compliance/Lost to Follow up|5
6151681|NCT01113710|9788324|FG000|Overall Study|Lack of Efficacy/Other|4
6151682|NCT01113710|9788324|FG000|Overall Study|Patient Compliance/Withdrawal by Subject|4
6151683|NCT01113710|9788324|FG000|Overall Study|Lack of Efficacy/Adverse Event|3
6151684|NCT01113710|9788324|FG000|Overall Study|Efficacy/Subject Withdrawal/AE|2
6151685|NCT01113710|9788324|FG000|Overall Study|Compliance/Lost to Follow up/Pt Withdraw|2
6040922|NCT00372411|9639015|FG001|Overall Study|Lost to Follow-up|1
6151686|NCT01113710|9788324|FG000|Overall Study|Lost to Follow up/Withdrawal by Subject|2
6151687|NCT01113710|9788324|FG000|Overall Study|Efficacy/Withdrawal by Subject/Other|1
6151688|NCT01113710|9788324|FG000|Overall Study|Compliance/Efficacy/Adverse Event|1
6151689|NCT01113710|9788324|FG000|Overall Study|Compliance/Efficacy/AE/Other|1
6151690|NCT01113710|9788324|FG000|Overall Study|Compliance/Efficacy/Subject Withdrawal|1
6151691|NCT01113710|9788324|FG000|Overall Study|Compliance/Lost to Follow up/Efficacy/AE|1
6151692|NCT01113710|9788324|FG000|Overall Study|Lack of Patient's Compliance/Other|1
6151693|NCT01113710|9788324|FG000|Overall Study|Compliance/Subject Withdrawal/AE|1
6151694|NCT01113710|9788324|FG000|Overall Study|Subject Did Not Receive Neupro|3
6151695|NCT01113749|9788341|FG000|Overall Study|Lost to Follow-up|1
6151696|NCT01113749|9788342|FG001|Overall Study|Lost to Follow-up|2
6151697|NCT01113801|9788352|FG000|Overall Study|Adverse Event|4
6151698|NCT01113801|9788353|FG001|Overall Study|Adverse Event|0
6151699|NCT01113801|9788354|FG002|Overall Study|Adverse Event|2
6151700|NCT01113801|9788355|FG003|Overall Study|Adverse Event|6
6151701|NCT01113801|9788352|FG000|Overall Study|Death|4
6151702|NCT01113801|9788353|FG001|Overall Study|Death|5
6151703|NCT01113801|9788354|FG002|Overall Study|Death|3
6151704|NCT01113801|9788355|FG003|Overall Study|Death|4
6151705|NCT01113801|9788352|FG000|Overall Study|Protocol Violation|0
6151706|NCT01113801|9788353|FG001|Overall Study|Protocol Violation|1
6151707|NCT01113801|9788354|FG002|Overall Study|Protocol Violation|0
6151708|NCT01113801|9788355|FG003|Overall Study|Protocol Violation|0
6151709|NCT01113801|9788352|FG000|Overall Study|Withdrawal by Subject|9
6151710|NCT01113801|9788353|FG001|Overall Study|Withdrawal by Subject|7
6151711|NCT01113801|9788354|FG002|Overall Study|Withdrawal by Subject|7
6151712|NCT01113801|9788355|FG003|Overall Study|Withdrawal by Subject|8
6151713|NCT01113801|9788352|FG000|Overall Study|Physician Decision|2
6151714|NCT01113801|9788353|FG001|Overall Study|Physician Decision|2
6151715|NCT01113801|9788354|FG002|Overall Study|Physician Decision|3
6151716|NCT01113801|9788355|FG003|Overall Study|Physician Decision|3
6151717|NCT01113801|9788352|FG000|Overall Study|Sponsor Decision|15
6151718|NCT01113801|9788353|FG001|Overall Study|Sponsor Decision|21
6151719|NCT01113801|9788354|FG002|Overall Study|Sponsor Decision|20
6151720|NCT01113801|9788355|FG003|Overall Study|Sponsor Decision|15
6151721|NCT01113801|9788352|FG000|Overall Study|Clinical Endpoint (ESRD)|7
6151722|NCT01113801|9788353|FG001|Overall Study|Clinical Endpoint (ESRD)|4
6151723|NCT01113801|9788354|FG002|Overall Study|Clinical Endpoint (ESRD)|2
6151724|NCT01113801|9788355|FG003|Overall Study|Clinical Endpoint (ESRD)|5
6151725|NCT01113879|9788367|FG000|Period 1: Block 1|Withdrawal by Subject|2
6151726|NCT01113879|9788368|FG001|Period 1: Block 1|Withdrawal by Subject|0
6151727|NCT01113892|9788378|FG000|Overall Study|Lost to Follow-up|2
6151728|NCT01113892|9788379|FG001|Overall Study|Lost to Follow-up|2
6151729|NCT01113892|9788378|FG000|Overall Study|Withdrawal by Subject|1
6151730|NCT01113892|9788379|FG001|Overall Study|Withdrawal by Subject|1
6151731|NCT01113892|9788378|FG000|Overall Study|Death|2
6151732|NCT01113892|9788379|FG001|Overall Study|Death|4
6151733|NCT01113892|9788378|FG000|Overall Study|Graft no longer evaluable|9
6318991|NCT02154529|10054729|FG000|Overall Study|Termination of study by sponsor|2
6318992|NCT02154529|10054730|FG001|Overall Study|Termination of study by sponsor|2
6318993|NCT02154529|10054731|FG002|Overall Study|Termination of study by sponsor|3
6040923|NCT00372411|9639016|FG002|Overall Study|Lost to Follow-up|1
6151734|NCT01113892|9788379|FG001|Overall Study|Graft no longer evaluable|9
6151735|NCT01113931|9788387|FG000|Overall Study|Adverse Event|2
6151736|NCT01113931|9788388|FG001|Overall Study|Adverse Event|2
6318994|NCT02154529|10054732|FG003|Overall Study|Termination of study by sponsor|1
6318995|NCT02154529|10054729|FG000|Overall Study|Lost to Follow-up|1
6318996|NCT02154529|10054730|FG001|Overall Study|Lost to Follow-up|0
6318997|NCT02154529|10054731|FG002|Overall Study|Lost to Follow-up|0
6318998|NCT02154529|10054732|FG003|Overall Study|Lost to Follow-up|0
6080308|NCT00615199|9687475|FG002|Overall Study|Other|0
6080309|NCT00615199|9687476|FG003|Overall Study|Other|1
6080310|NCT00615199|9687473|FG000|Overall Study|Withdrawal by Subject|2
6080311|NCT00615199|9687474|FG001|Overall Study|Withdrawal by Subject|1
6151737|NCT01113931|9788387|FG000|Overall Study|Physician Decision|0
6151738|NCT01113931|9788388|FG001|Overall Study|Physician Decision|2
6151739|NCT01113931|9788387|FG000|Overall Study|Lost to Follow-up|12
6151740|NCT01113931|9788388|FG001|Overall Study|Lost to Follow-up|9
6151741|NCT01113931|9788387|FG000|Overall Study|Various|2
6151742|NCT01113931|9788388|FG001|Overall Study|Various|4
6151743|NCT01113931|9788387|FG000|Overall Study|Withdrawal by Subject|3
6151744|NCT01113931|9788388|FG001|Overall Study|Withdrawal by Subject|0
6151745|NCT01114360|9788413|FG000|Intervention 1 (4 Weeks)|Physician Decision|0
6151746|NCT01114360|9788414|FG001|Intervention 1 (4 Weeks)|Physician Decision|1
6151747|NCT01114373|9788434|FG000|Intervention 1 (4 Weeks)|Lost to Follow-up|1
6151748|NCT01114373|9788435|FG001|Intervention 1 (4 Weeks)|Lost to Follow-up|0
6151749|NCT01114373|9788434|FG000|Intervention 1 (4 Weeks)|Incarceration|1
6151750|NCT01114373|9788435|FG001|Intervention 1 (4 Weeks)|Incarceration|0
6151751|NCT01114373|9788434|FG000|Intervention 1 (4 Weeks)|Terminated by PI after protocol violatio|1
6151752|NCT01114373|9788435|FG001|Intervention 1 (4 Weeks)|Terminated by PI after protocol violatio|0
6151753|NCT01114373|9788434|FG000|Intervention 2 (4 Weeks)|Lost to Follow-up|0
6151754|NCT01114373|9788435|FG001|Intervention 2 (4 Weeks)|Lost to Follow-up|1
6080312|NCT00615199|9687475|FG002|Overall Study|Withdrawal by Subject|0
6080313|NCT00615199|9687476|FG003|Overall Study|Withdrawal by Subject|0
6080314|NCT00615264|9687488|FG000|Overall Study|Withdrawal by Subject|17
6080315|NCT00615264|9687489|FG001|Overall Study|Withdrawal by Subject|19
6080316|NCT00615264|9687488|FG000|Overall Study|Lost to Follow-up|6
6080317|NCT00615264|9687489|FG001|Overall Study|Lost to Follow-up|13
6080318|NCT00615264|9687488|FG000|Overall Study|Adverse Event|8
6080319|NCT00615264|9687489|FG001|Overall Study|Adverse Event|5
6080320|NCT00615264|9687488|FG000|Overall Study|Death|1
6080321|NCT00615264|9687489|FG001|Overall Study|Death|1
6080322|NCT00615264|9687488|FG000|Overall Study|Protocol Violation|11
6080323|NCT00615264|9687489|FG001|Overall Study|Protocol Violation|7
6080324|NCT00615264|9687488|FG000|Overall Study|Not defined|7
6080325|NCT00615264|9687489|FG001|Overall Study|Not defined|4
6080326|NCT00615264|9687488|FG000|Overall Study|Dermal Hypersensitivity|0
6080327|NCT00615264|9687489|FG001|Overall Study|Dermal Hypersensitivity|3
6080328|NCT00615290|9687495|FG000|Overall Study|Adverse Event|2
6080329|NCT00615290|9687495|FG000|Overall Study|Lost to Follow-up|3
6080330|NCT00615290|9687495|FG000|Overall Study|Withdrawal by Subject|1
6080331|NCT00615290|9687495|FG000|Overall Study|Other|2
6080332|NCT00615459|9687526|FG000|Period I|Adverse Event|2
6080333|NCT00615459|9687527|FG001|Period I|Adverse Event|0
6080334|NCT00615459|9687528|FG002|Period I|Adverse Event|1
6151755|NCT01114438|9788445|FG000|Overall Study|Adverse Event|10
6318999|NCT00788125|10054744|FG000|Overall Study|Death|6
6319000|NCT02777554|10054750|FG000|Overall Study|Adverse Event|4
6151756|NCT01114438|9788445|FG000|Overall Study|concomitant medication|1
6151757|NCT01114438|9788445|FG000|Overall Study|Physician Decision|1
6151758|NCT01114438|9788445|FG000|Overall Study|Withdrawal by Subject|2
6151759|NCT01114516|9788460|FG000|Overall Study|Lost to Follow-up|2
6151760|NCT01114516|9788461|FG001|Overall Study|Lost to Follow-up|1
6151761|NCT01114529|9788470|FG000|Completed Study Medication at Month 24|Adverse Event|87
6151762|NCT01114529|9788471|FG001|Completed Study Medication at Month 24|Adverse Event|18
6151763|NCT01114529|9788472|FG002|Completed Study Medication at Month 24|Adverse Event|17
6151764|NCT01114529|9788470|FG000|Completed Study Medication at Month 24|Abnormal laboratory value(s)|6
6151765|NCT01114529|9788471|FG001|Completed Study Medication at Month 24|Abnormal laboratory value(s)|0
6151766|NCT01114529|9788472|FG002|Completed Study Medication at Month 24|Abnormal laboratory value(s)|1
6151767|NCT01114529|9788470|FG000|Completed Study Medication at Month 24|Abnormal test procedure result(s)|3
6151768|NCT01114529|9788471|FG001|Completed Study Medication at Month 24|Abnormal test procedure result(s)|0
6151769|NCT01114529|9788472|FG002|Completed Study Medication at Month 24|Abnormal test procedure result(s)|1
6151770|NCT01114529|9788470|FG000|Completed Study Medication at Month 24|Lack of Efficacy|2
6151771|NCT01114529|9788471|FG001|Completed Study Medication at Month 24|Lack of Efficacy|1
6151772|NCT01114529|9788472|FG002|Completed Study Medication at Month 24|Lack of Efficacy|2
6151773|NCT01114529|9788470|FG000|Completed Study Medication at Month 24|Subject's no longer required drug|1
6151774|NCT01114529|9788471|FG001|Completed Study Medication at Month 24|Subject's no longer required drug|1
6151775|NCT01114529|9788472|FG002|Completed Study Medication at Month 24|Subject's no longer required drug|1
6151776|NCT01114529|9788470|FG000|Completed Study Medication at Month 24|Withdrawal by Subject|18
6151777|NCT01114529|9788471|FG001|Completed Study Medication at Month 24|Withdrawal by Subject|8
6151778|NCT01114529|9788472|FG002|Completed Study Medication at Month 24|Withdrawal by Subject|2
6151779|NCT01114529|9788470|FG000|Completed Study Medication at Month 24|Lost to Follow-up|1
6151780|NCT01114529|9788471|FG001|Completed Study Medication at Month 24|Lost to Follow-up|4
6151781|NCT01114529|9788472|FG002|Completed Study Medication at Month 24|Lost to Follow-up|2
6151782|NCT01114529|9788470|FG000|Completed Study Medication at Month 24|Administrative problems|2
6151783|NCT01114529|9788471|FG001|Completed Study Medication at Month 24|Administrative problems|1
6151784|NCT01114529|9788472|FG002|Completed Study Medication at Month 24|Administrative problems|2
6151785|NCT01114529|9788470|FG000|Completed Study Medication at Month 24|Death|2
6151786|NCT01114529|9788471|FG001|Completed Study Medication at Month 24|Death|1
6151787|NCT01114529|9788472|FG002|Completed Study Medication at Month 24|Death|2
6151788|NCT01114529|9788470|FG000|Completed Study Medication at Month 24|Graft loss|0
6151789|NCT01114529|9788471|FG001|Completed Study Medication at Month 24|Graft loss|2
6151790|NCT01114529|9788472|FG002|Completed Study Medication at Month 24|Graft loss|0
6151791|NCT01114529|9788470|FG000|Completed Study Medication at Month 24|Protocol Violation|0
6151792|NCT01114529|9788471|FG001|Completed Study Medication at Month 24|Protocol Violation|5
6151793|NCT01114529|9788472|FG002|Completed Study Medication at Month 24|Protocol Violation|2
6151794|NCT01114529|9788470|FG000|Completed Study Medication at Month 24|Missing|2
6151795|NCT01114529|9788471|FG001|Completed Study Medication at Month 24|Missing|0
6151796|NCT01114529|9788472|FG002|Completed Study Medication at Month 24|Missing|0
6151797|NCT01114529|9788470|FG000|Completed Study Phase at Month 24|Withdrawal by Subject|18
6151798|NCT01114529|9788471|FG001|Completed Study Phase at Month 24|Withdrawal by Subject|6
6151799|NCT01114529|9788472|FG002|Completed Study Phase at Month 24|Withdrawal by Subject|3
6151800|NCT01114529|9788470|FG000|Completed Study Phase at Month 24|Lost to Follow-up|10
6151801|NCT01114529|9788471|FG001|Completed Study Phase at Month 24|Lost to Follow-up|5
6151802|NCT01114529|9788472|FG002|Completed Study Phase at Month 24|Lost to Follow-up|7
6151803|NCT01114529|9788470|FG000|Completed Study Phase at Month 24|Death|8
6040924|NCT00372411|9639014|FG000|Overall Study|Adverse Event|1
6040925|NCT00372411|9639015|FG001|Overall Study|Adverse Event|1
6151804|NCT01114529|9788471|FG001|Completed Study Phase at Month 24|Death|5
6151805|NCT01114529|9788472|FG002|Completed Study Phase at Month 24|Death|4
6040926|NCT00372411|9639016|FG002|Overall Study|Adverse Event|0
6040927|NCT00372424|9639024|FG000|Overall Study|Adverse Event|2
6040928|NCT00372424|9639024|FG000|Overall Study|Withdrawal by Subject|1
6040929|NCT00372424|9639024|FG000|Overall Study|Death|1
6040930|NCT00372424|9639024|FG000|Overall Study|Objective Progression or Relapse|14
6040931|NCT00372424|9639024|FG000|Overall Study|Other|7
6040932|NCT00372424|9639024|FG000|Overall Study|Enrolled, Not Treated|1
6040933|NCT00372489|9639028|FG000|Overall Study|Adverse Event|18
6040934|NCT00372489|9639028|FG000|Overall Study|Lack of Efficacy|1
6040935|NCT00372489|9639028|FG000|Overall Study|Lost to Follow-up|3
6040936|NCT00372489|9639028|FG000|Overall Study|Physician Decision|3
6040937|NCT00372489|9639028|FG000|Overall Study|Withdrawal by Subject|5
6040938|NCT00372489|9639028|FG000|Overall Study|Patient Relocation|2
6040939|NCT00372489|9639028|FG000|Overall Study|Renal transplant|6
6040940|NCT00372489|9639028|FG000|Overall Study|Sponsor Decision to Terminate Study|41
6040941|NCT00372528|9639032|FG000|Overall Study|Lack of Efficacy|1
6040942|NCT00372528|9639032|FG000|Overall Study|Adverse Event|1
6151806|NCT01114529|9788470|FG000|Completed Study Phase at Month 24|Other|2
6151807|NCT01114529|9788471|FG001|Completed Study Phase at Month 24|Other|0
6040943|NCT00372528|9639032|FG000|Overall Study|Study Terminated by Sponsor|18
6319001|NCT02777554|10054751|FG001|Overall Study|Adverse Event|4
6319002|NCT02777554|10054752|FG002|Overall Study|Adverse Event|0
6319003|NCT02777554|10054753|FG003|Overall Study|Adverse Event|1
6319004|NCT02777554|10054754|FG004|Overall Study|Adverse Event|0
6319005|NCT02777554|10054755|FG005|Overall Study|Adverse Event|0
6319006|NCT02777554|10054750|FG000|Overall Study|Withdrawal by Subject|3
6319007|NCT02777554|10054751|FG001|Overall Study|Withdrawal by Subject|1
6319008|NCT02777554|10054752|FG002|Overall Study|Withdrawal by Subject|1
6151808|NCT01114529|9788472|FG002|Completed Study Phase at Month 24|Other|0
6151809|NCT01114529|9788470|FG000|Completed Study Phase at Month 24|Missing|2
6151810|NCT01114529|9788471|FG001|Completed Study Phase at Month 24|Missing|0
6151811|NCT01114529|9788472|FG002|Completed Study Phase at Month 24|Missing|0
6151812|NCT01114646|9788501|FG000|Overall Study|Withdrawal by Subject|3
6151813|NCT01114646|9788502|FG001|Overall Study|Withdrawal by Subject|2
6151814|NCT01114672|9788510|FG000|Overall Study|Death|0
6151815|NCT01114672|9788511|FG001|Overall Study|Death|1
6151816|NCT01114672|9788510|FG000|Overall Study|Withdrawal by Subject|2
6151817|NCT01114672|9788511|FG001|Overall Study|Withdrawal by Subject|1
6319009|NCT02777554|10054753|FG003|Overall Study|Withdrawal by Subject|0
6319010|NCT02777554|10054754|FG004|Overall Study|Withdrawal by Subject|0
6151818|NCT01114672|9788510|FG000|Overall Study|Lost to Follow-up|1
6151819|NCT01114672|9788511|FG001|Overall Study|Lost to Follow-up|0
6319011|NCT02777554|10054755|FG005|Overall Study|Withdrawal by Subject|0
6319012|NCT02777554|10054750|FG000|Overall Study|Discharged early due to hurricane|22
6319013|NCT02777554|10054751|FG001|Overall Study|Discharged early due to hurricane|20
6319014|NCT02777554|10054752|FG002|Overall Study|Discharged early due to hurricane|0
6319015|NCT02777554|10054753|FG003|Overall Study|Discharged early due to hurricane|0
6319016|NCT02777554|10054754|FG004|Overall Study|Discharged early due to hurricane|0
6319017|NCT02777554|10054755|FG005|Overall Study|Discharged early due to hurricane|0
6319018|NCT02777554|10054750|FG000|Overall Study|Other - Miscellaneous|1
6319019|NCT02777554|10054751|FG001|Overall Study|Other - Miscellaneous|0
6319020|NCT02777554|10054752|FG002|Overall Study|Other - Miscellaneous|0
6319021|NCT02777554|10054753|FG003|Overall Study|Other - Miscellaneous|0
6319022|NCT02777554|10054754|FG004|Overall Study|Other - Miscellaneous|0
6319023|NCT02777554|10054755|FG005|Overall Study|Other - Miscellaneous|0
6319024|NCT02777827|10054792|FG000|Washout Between Periods 3 and 4|Protocol Violation|0
6319025|NCT02777827|10054793|FG001|Washout Between Periods 3 and 4|Protocol Violation|0
6319026|NCT02777827|10054794|FG002|Washout Between Periods 3 and 4|Protocol Violation|1
6319027|NCT02777827|10054795|FG003|Washout Between Periods 3 and 4|Protocol Violation|0
6319028|NCT02777827|10054796|FG004|Washout Between Periods 3 and 4|Protocol Violation|0
6319029|NCT02777827|10054797|FG005|Washout Between Periods 3 and 4|Protocol Violation|0
6319030|NCT02777918|10054813|FG000|Overall Study|Medical reasons|1
6319031|NCT02777918|10054814|FG001|Overall Study|Medical reasons|2
6319032|NCT02777918|10054813|FG000|Overall Study|Too busy / stressed|1
6319033|NCT02777918|10054814|FG001|Overall Study|Too busy / stressed|1
6319034|NCT02777918|10054813|FG000|Overall Study|Withdrawal by Subject|1
6319035|NCT02777918|10054814|FG001|Overall Study|Withdrawal by Subject|1
6319036|NCT02777970|10054841|FG000|Overall Study|Lost to Follow-up|0
6319037|NCT02777970|10054842|FG001|Overall Study|Lost to Follow-up|1
6319038|NCT02777970|10054843|FG002|Overall Study|Lost to Follow-up|0
6151820|NCT01114672|9788510|FG000|Overall Study|transplanted|1
6151821|NCT01114672|9788511|FG001|Overall Study|transplanted|0
6151822|NCT01114724|9788517|FG000|Overall Study|Death|8
6151823|NCT01114724|9788517|FG000|Overall Study|Lost to Follow-up|1
6151824|NCT01114724|9788517|FG000|Overall Study|Withdrawal by Subject|1
6151825|NCT01114737|9788524|FG000|Randomized Treatment Period|Withdrawal by Subject|1
6151826|NCT01114737|9788525|FG001|Randomized Treatment Period|Withdrawal by Subject|0
6151827|NCT01114737|9788524|FG000|Randomized Treatment Period|Lost to Follow-up|1
6151828|NCT01114737|9788525|FG001|Randomized Treatment Period|Lost to Follow-up|1
6151829|NCT01114737|9788524|FG000|Randomized Treatment Period|Pregnancy|1
6319039|NCT02777970|10054841|FG000|Overall Study|Protocol Violation|1
6319040|NCT02777970|10054842|FG001|Overall Study|Protocol Violation|0
6319041|NCT02777970|10054843|FG002|Overall Study|Protocol Violation|0
6319042|NCT02778074|10054855|FG000|Overall Study|Lost to Follow-up|7
6319043|NCT02778074|10054856|FG001|Overall Study|Lost to Follow-up|10
6319044|NCT02778100|10054864|FG000|Period 1 (Common Cold)|Withdrawal by Subject|1
6319045|NCT02778100|10054865|FG001|Period 1 (Common Cold)|Withdrawal by Subject|0
6151830|NCT01114737|9788525|FG001|Randomized Treatment Period|Pregnancy|0
6151831|NCT01114737|9788524|FG000|Open-Label Treatment Period|Withdrawal by Subject|1
6151832|NCT01114737|9788525|FG001|Open-Label Treatment Period|Withdrawal by Subject|1
6151833|NCT01114737|9788524|FG000|Open-Label Treatment Period|Lost to Follow-up|3
6151834|NCT01114737|9788525|FG001|Open-Label Treatment Period|Lost to Follow-up|1
6151835|NCT01114737|9788524|FG000|Open-Label Treatment Period|Difficult Personal Events|1
6319046|NCT02778555|10054895|FG000|Overall Study|Withdrawal by Subject|55
6319047|NCT02778555|10054896|FG001|Overall Study|Withdrawal by Subject|32
6319048|NCT02778555|10054897|FG002|Overall Study|Withdrawal by Subject|107
6319049|NCT02778867|10054907|FG000|Phase 1|Withdrawal by Subject|2
6319050|NCT02778867|10054908|FG001|Phase 1|Withdrawal by Subject|3
6319051|NCT02778867|10054909|FG002|Phase 1|Withdrawal by Subject|0
6319052|NCT02778867|10054910|FG003|Phase 1|Withdrawal by Subject|0
6319053|NCT02778867|10054907|FG000|Phase 2|Withdrawal by Subject|0
6319054|NCT02778867|10054908|FG001|Phase 2|Withdrawal by Subject|0
6319055|NCT02778867|10054909|FG002|Phase 2|Withdrawal by Subject|1
6319056|NCT02778867|10054910|FG003|Phase 2|Withdrawal by Subject|0
6319057|NCT02778867|10054907|FG000|Phase 2|Physician Decision|0
6319058|NCT02778867|10054908|FG001|Phase 2|Physician Decision|0
6319059|NCT02778867|10054909|FG002|Phase 2|Physician Decision|0
6319060|NCT02778867|10054910|FG003|Phase 2|Physician Decision|1
6319061|NCT02778867|10054907|FG000|Phase 2|Adverse Event|0
6151836|NCT01114737|9788525|FG001|Open-Label Treatment Period|Difficult Personal Events|0
6319062|NCT02778867|10054908|FG001|Phase 2|Adverse Event|0
6319063|NCT02778867|10054909|FG002|Phase 2|Adverse Event|0
6319064|NCT02778867|10054910|FG003|Phase 2|Adverse Event|1
6319065|NCT02779075|10054940|FG000|Overall Study|Withdrawal by Subject|1
6319066|NCT02779075|10054941|FG001|Overall Study|Withdrawal by Subject|3
6319067|NCT02779075|10054940|FG000|Overall Study|IV lost during 2nd study|1
6319068|NCT02779075|10054941|FG001|Overall Study|IV lost during 2nd study|0
6319069|NCT02780115|10054988|FG000|Overall Study|Withdrawal by Subject|0
6319070|NCT02780115|10054989|FG001|Overall Study|Withdrawal by Subject|1
6319071|NCT02780115|10054990|FG002|Overall Study|Withdrawal by Subject|1
6151837|NCT01114828|9788544|FG000|Overall Study|Adverse Event|1
6151838|NCT01114828|9788545|FG001|Overall Study|Adverse Event|1
6151839|NCT01114828|9788544|FG000|Overall Study|Lack of Efficacy|0
6319072|NCT02780115|10054991|FG003|Overall Study|Withdrawal by Subject|0
6319073|NCT02780115|10054992|FG004|Overall Study|Withdrawal by Subject|0
6319074|NCT02780115|10054988|FG000|Overall Study|Adverse Event|0
6319075|NCT02780115|10054989|FG001|Overall Study|Adverse Event|0
6319076|NCT02780115|10054990|FG002|Overall Study|Adverse Event|0
6319077|NCT02780115|10054991|FG003|Overall Study|Adverse Event|1
6319078|NCT02780115|10054992|FG004|Overall Study|Adverse Event|1
6319079|NCT02780167|10055009|FG000|Overall Study|Adverse Event|9
6319080|NCT02780167|10055010|FG001|Overall Study|Adverse Event|8
6319081|NCT02780167|10055011|FG002|Overall Study|Adverse Event|8
6319082|NCT02780167|10055012|FG003|Overall Study|Adverse Event|12
6319083|NCT02780167|10055013|FG004|Overall Study|Adverse Event|8
6319084|NCT02780167|10055009|FG000|Overall Study|Lack of Efficacy|6
6319085|NCT02780167|10055010|FG001|Overall Study|Lack of Efficacy|5
6319086|NCT02780167|10055011|FG002|Overall Study|Lack of Efficacy|6
6319087|NCT02780167|10055012|FG003|Overall Study|Lack of Efficacy|1
6319088|NCT02780167|10055013|FG004|Overall Study|Lack of Efficacy|0
6319089|NCT02780167|10055009|FG000|Overall Study|Lost to Follow-up|2
6319090|NCT02780167|10055010|FG001|Overall Study|Lost to Follow-up|0
6319091|NCT02780167|10055011|FG002|Overall Study|Lost to Follow-up|1
6319092|NCT02780167|10055012|FG003|Overall Study|Lost to Follow-up|0
6319093|NCT02780167|10055013|FG004|Overall Study|Lost to Follow-up|0
6319094|NCT02780167|10055009|FG000|Overall Study|Does not meet entrance criteria|0
6319095|NCT02780167|10055010|FG001|Overall Study|Does not meet entrance criteria|0
6319096|NCT02780167|10055011|FG002|Overall Study|Does not meet entrance criteria|1
6319097|NCT02780167|10055012|FG003|Overall Study|Does not meet entrance criteria|0
6319098|NCT02780167|10055013|FG004|Overall Study|Does not meet entrance criteria|0
6319099|NCT02780167|10055009|FG000|Overall Study|No longer meets eligibility criteria|0
6319100|NCT02780167|10055010|FG001|Overall Study|No longer meets eligibility criteria|0
6319101|NCT02780167|10055011|FG002|Overall Study|No longer meets eligibility criteria|0
6319102|NCT02780167|10055012|FG003|Overall Study|No longer meets eligibility criteria|1
6319103|NCT02780167|10055013|FG004|Overall Study|No longer meets eligibility criteria|1
6319104|NCT02780167|10055009|FG000|Overall Study|Protocol Violation|5
6319105|NCT02780167|10055010|FG001|Overall Study|Protocol Violation|5
6319106|NCT02780167|10055011|FG002|Overall Study|Protocol Violation|1
6319107|NCT02780167|10055012|FG003|Overall Study|Protocol Violation|1
6319108|NCT02780167|10055013|FG004|Overall Study|Protocol Violation|2
6319109|NCT02780167|10055009|FG000|Overall Study|Withdrawal by Subject|6
6319110|NCT02780167|10055010|FG001|Overall Study|Withdrawal by Subject|4
6319111|NCT02780167|10055011|FG002|Overall Study|Withdrawal by Subject|4
6319112|NCT02780167|10055012|FG003|Overall Study|Withdrawal by Subject|3
6319113|NCT02780167|10055013|FG004|Overall Study|Withdrawal by Subject|4
6319114|NCT02780167|10055009|FG000|Overall Study|Other|0
6319115|NCT02780167|10055010|FG001|Overall Study|Other|0
6319116|NCT02780167|10055011|FG002|Overall Study|Other|3
6319117|NCT02780167|10055012|FG003|Overall Study|Other|1
6319118|NCT02780167|10055013|FG004|Overall Study|Other|2
6319119|NCT02780388|10055034|FG000|Overall Study|Lost to Follow-up|0
6319120|NCT02780388|10055035|FG001|Overall Study|Lost to Follow-up|1
6319121|NCT02780388|10055036|FG002|Overall Study|Lost to Follow-up|0
6319122|NCT02780388|10055037|FG003|Overall Study|Lost to Follow-up|0
6319123|NCT02780388|10055038|FG004|Overall Study|Lost to Follow-up|0
6319124|NCT02780388|10055034|FG000|Overall Study|Withdrawal by Subject|1
6319125|NCT02780388|10055035|FG001|Overall Study|Withdrawal by Subject|1
6319126|NCT02780388|10055036|FG002|Overall Study|Withdrawal by Subject|0
6319127|NCT02780388|10055037|FG003|Overall Study|Withdrawal by Subject|0
6319128|NCT02780388|10055038|FG004|Overall Study|Withdrawal by Subject|0
6319129|NCT02780687|10055072|FG000|Overall Study|Adverse Event|1
6319130|NCT02780687|10055073|FG001|Overall Study|Adverse Event|1
6319131|NCT02780687|10055072|FG000|Overall Study|Withdrawal by Subject|2
6319132|NCT02780687|10055073|FG001|Overall Study|Withdrawal by Subject|1
6319133|NCT02780687|10055072|FG000|Overall Study|Switched to commercial program (in CTP)|2
6319134|NCT02780687|10055073|FG001|Overall Study|Switched to commercial program (in CTP)|0
6319135|NCT02780687|10055072|FG000|Overall Study|progressive disease|29
6319136|NCT02780687|10055073|FG001|Overall Study|progressive disease|6
6319137|NCT02780700|10055078|FG000|Overall Study|Progressive disease|1
6319138|NCT02780713|10055082|FG000|Period 3: Variant B (100mg)|Withdrawal by Subject|0
6319139|NCT02780713|10055083|FG001|Period 3: Variant B (100mg)|Withdrawal by Subject|0
6319140|NCT02780713|10055084|FG002|Period 3: Variant B (100mg)|Withdrawal by Subject|2
6319141|NCT02780713|10055085|FG003|Period 3: Variant B (100mg)|Withdrawal by Subject|0
6319142|NCT02780713|10055086|FG004|Period 3: Variant B (100mg)|Withdrawal by Subject|0
6319143|NCT02780856|10055114|FG000|Overall Study|Lost to Follow-up|1
6319144|NCT02781311|10055138|FG000|Overall Study|Adverse Event|2
6319145|NCT02781311|10055139|FG001|Overall Study|Adverse Event|6
6319146|NCT02781311|10055140|FG002|Overall Study|Adverse Event|1
6319147|NCT02781311|10055138|FG000|Overall Study|Withdrawal of Consent|11
6319148|NCT02781311|10055139|FG001|Overall Study|Withdrawal of Consent|12
6319149|NCT02781311|10055140|FG002|Overall Study|Withdrawal of Consent|2
6319150|NCT02781311|10055138|FG000|Overall Study|Lost to Follow-up|11
6319151|NCT02781311|10055139|FG001|Overall Study|Lost to Follow-up|8
6319152|NCT02781311|10055140|FG002|Overall Study|Lost to Follow-up|1
6319153|NCT02781311|10055138|FG000|Overall Study|Non-Compliance with Study Drug|2
6319154|NCT02781311|10055139|FG001|Overall Study|Non-Compliance with Study Drug|0
6319155|NCT02781311|10055140|FG002|Overall Study|Non-Compliance with Study Drug|0
6319156|NCT02781324|10055149|FG000|Overall Study|Withdrawal by Subject|1
6319157|NCT02781324|10055150|FG001|Overall Study|Withdrawal by Subject|0
6319158|NCT02781324|10055149|FG000|Overall Study|Physician Decision|1
6319159|NCT02781324|10055150|FG001|Overall Study|Physician Decision|2
6319160|NCT02781558|10055186|FG000|Overall Study|Lost to Follow-up|2
6319161|NCT02781558|10055187|FG001|Overall Study|Lost to Follow-up|2
6319162|NCT02781558|10055186|FG000|Overall Study|Adverse Event|1
6319163|NCT02781558|10055187|FG001|Overall Study|Adverse Event|0
6319164|NCT02781818|10055231|FG000|Overall Study|Lost to Follow-up|4
6319165|NCT02781818|10055232|FG001|Overall Study|Lost to Follow-up|2
6319166|NCT02781818|10055233|FG002|Overall Study|Lost to Follow-up|1
6319167|NCT02781844|10055245|FG000|Treatment Period 1|Adverse Event|0
6319168|NCT02781844|10055246|FG001|Treatment Period 1|Adverse Event|0
6319169|NCT02781844|10055247|FG002|Treatment Period 1|Adverse Event|0
6319170|NCT02781844|10055248|FG003|Treatment Period 1|Adverse Event|0
6151840|NCT01114828|9788545|FG001|Overall Study|Lack of Efficacy|2
6040944|NCT00372528|9639032|FG000|Overall Study|Other|1
6040945|NCT00372567|9639039|FG000|Phase 3 Study|Adverse Event|5
6040946|NCT00372567|9639040|FG001|Phase 3 Study|Adverse Event|1
6040947|NCT00372567|9639041|FG002|Phase 3 Study|Adverse Event|1
6040948|NCT00372567|9639039|FG000|Phase 3 Study|Death|1
6040949|NCT00372567|9639040|FG001|Phase 3 Study|Death|1
6040950|NCT00372567|9639041|FG002|Phase 3 Study|Death|0
6040951|NCT00372567|9639039|FG000|Phase 3 Study|Protocol Violation|0
6151841|NCT01114828|9788544|FG000|Overall Study|Protocol Violation|2
6151842|NCT01114828|9788545|FG001|Overall Study|Protocol Violation|0
6151843|NCT01114828|9788544|FG000|Overall Study|Withdrawal by Subject|0
6319171|NCT02781844|10055249|FG004|Treatment Period 1|Adverse Event|0
6040952|NCT00372567|9639040|FG001|Phase 3 Study|Protocol Violation|0
6151844|NCT01114828|9788545|FG001|Overall Study|Withdrawal by Subject|1
6151845|NCT01114880|9788553|FG000|Period 1 (Week 0 to Week 12)|Adverse Event|4
6151846|NCT01114880|9788554|FG001|Period 1 (Week 0 to Week 12)|Adverse Event|0
6151847|NCT01114880|9788553|FG000|Period 1 (Week 0 to Week 12)|Withdrawal by Subject|1
6151848|NCT01114880|9788554|FG001|Period 1 (Week 0 to Week 12)|Withdrawal by Subject|0
6151849|NCT01114880|9788553|FG000|Period 1 (Week 0 to Week 12)|Lost to Follow-up|0
6151850|NCT01114880|9788554|FG001|Period 1 (Week 0 to Week 12)|Lost to Follow-up|1
6040953|NCT00372567|9639041|FG002|Phase 3 Study|Protocol Violation|1
6040954|NCT00372567|9639039|FG000|Phase 3 Study|Objective progression or relapse|10
6151851|NCT01114880|9788553|FG000|Period 1 (Week 0 to Week 12)|Poor subject compliance|0
6151852|NCT01114880|9788554|FG001|Period 1 (Week 0 to Week 12)|Poor subject compliance|1
6151853|NCT01114880|9788553|FG000|Period 2 (Week 12 to Week 24)|Adverse Event|3
6151854|NCT01114880|9788554|FG001|Period 2 (Week 12 to Week 24)|Adverse Event|0
6151855|NCT01114880|9788553|FG000|Period 2 (Week 12 to Week 24)|Lost to Follow-up|0
6151856|NCT01114880|9788554|FG001|Period 2 (Week 12 to Week 24)|Lost to Follow-up|2
6151857|NCT01115309|9788651|FG000|Procedure Safety (1-Month)|Lost to Follow-up|2
6151858|NCT01115309|9788651|FG000|Procedure Safety (1-Month)|Withdrawal by Subject|1
6151859|NCT01115309|9788651|FG000|Long-term Follow-up|Lost to Follow-up|6
6151860|NCT01115491|9788664|FG000|Overall Study|Death|22
6151861|NCT01115491|9788664|FG000|Overall Study|Adverse Event|3
6151862|NCT01115491|9788664|FG000|Overall Study|Lost to Follow-up|3
6151863|NCT01115491|9788664|FG000|Overall Study|Withdrawal by Subject|1
6319172|NCT02781844|10055250|FG005|Treatment Period 1|Adverse Event|1
6319173|NCT02781844|10055251|FG006|Treatment Period 1|Adverse Event|0
6319174|NCT02781844|10055252|FG007|Treatment Period 1|Adverse Event|0
6319175|NCT02782169|10055275|FG000|Overall Study|Lost to Follow-up|1
6319176|NCT02782169|10055276|FG001|Overall Study|Lost to Follow-up|2
6319177|NCT02782325|10055284|FG000|Blinded FMT Treatment (up to 24 Weeks)|Lack of Efficacy|4
6319178|NCT02782325|10055285|FG001|Blinded FMT Treatment (up to 24 Weeks)|Lack of Efficacy|2
6319179|NCT02782325|10055286|FG002|Blinded FMT Treatment (up to 24 Weeks)|Lack of Efficacy|0
6319180|NCT02782325|10055284|FG000|Open Label FMT Period (up to 24 Weeks)|Lack of Efficacy|0
6319181|NCT02782325|10055285|FG001|Open Label FMT Period (up to 24 Weeks)|Lack of Efficacy|0
6319182|NCT02782325|10055286|FG002|Open Label FMT Period (up to 24 Weeks)|Lack of Efficacy|4
6319183|NCT02782377|10055302|FG000|Overall Study|Physician Decision|5
6319184|NCT02782676|10055307|FG000|Overall Study|Lost to Follow-up|0
6319185|NCT02782676|10055308|FG001|Overall Study|Lost to Follow-up|1
6319186|NCT02782780|10055316|FG000|Overall Study|dropped out after randomization.|7
6319187|NCT02782780|10055317|FG001|Overall Study|dropped out after randomization.|5
6319188|NCT02782780|10055316|FG000|Overall Study|Protocol Violation|0
6319189|NCT02782780|10055317|FG001|Overall Study|Protocol Violation|2
6319190|NCT02782923|10055323|FG000|Overall Study|Lost to Follow-up|15
6319191|NCT02783066|10055336|FG000|Overall Study|Withdrawal by Subject|13
6319192|NCT02783170|10055343|FG000|Overall Study|Randomized but not Vaccinated|1
6319193|NCT02783170|10055344|FG001|Overall Study|Randomized but not Vaccinated|0
6319194|NCT02783573|10055367|FG000|Placebo-Controlled Treatment Period|Adverse Event|13
6319195|NCT02783573|10055368|FG001|Placebo-Controlled Treatment Period|Adverse Event|17
6319196|NCT02783573|10055369|FG002|Placebo-Controlled Treatment Period|Adverse Event|13
6319197|NCT02783573|10055367|FG000|Placebo-Controlled Treatment Period|Death|4
6319198|NCT02783573|10055368|FG001|Placebo-Controlled Treatment Period|Death|2
6319199|NCT02783573|10055369|FG002|Placebo-Controlled Treatment Period|Death|3
6319200|NCT02783573|10055367|FG000|Placebo-Controlled Treatment Period|Lack of Efficacy|0
6319201|NCT02783573|10055368|FG001|Placebo-Controlled Treatment Period|Lack of Efficacy|0
6319202|NCT02783573|10055369|FG002|Placebo-Controlled Treatment Period|Lack of Efficacy|2
6319203|NCT02783573|10055367|FG000|Placebo-Controlled Treatment Period|Lost to Follow-up|3
6319204|NCT02783573|10055368|FG001|Placebo-Controlled Treatment Period|Lost to Follow-up|3
6319205|NCT02783573|10055369|FG002|Placebo-Controlled Treatment Period|Lost to Follow-up|1
6319206|NCT02783573|10055367|FG000|Placebo-Controlled Treatment Period|Non-Compliance|0
6319207|NCT02783573|10055368|FG001|Placebo-Controlled Treatment Period|Non-Compliance|1
6319208|NCT02783573|10055369|FG002|Placebo-Controlled Treatment Period|Non-Compliance|0
6151864|NCT01115491|9788664|FG000|Overall Study|Physician Decision|1
6151865|NCT01115569|9788688|FG000|Conversion/Titration Phase|Adverse Event|59
6151866|NCT01115569|9788689|FG001|Conversion/Titration Phase|Adverse Event|0
6319209|NCT02783573|10055367|FG000|Placebo-Controlled Treatment Period|Other-determined by Investigator|0
6319210|NCT02783573|10055368|FG001|Placebo-Controlled Treatment Period|Other-determined by Investigator|1
6319211|NCT02783573|10055369|FG002|Placebo-Controlled Treatment Period|Other-determined by Investigator|2
6319212|NCT02783573|10055367|FG000|Placebo-Controlled Treatment Period|Physician Decision|3
6319213|NCT02783573|10055368|FG001|Placebo-Controlled Treatment Period|Physician Decision|1
6319214|NCT02783573|10055369|FG002|Placebo-Controlled Treatment Period|Physician Decision|3
6319215|NCT02783573|10055367|FG000|Placebo-Controlled Treatment Period|Protocol Violation|1
6319216|NCT02783573|10055368|FG001|Placebo-Controlled Treatment Period|Protocol Violation|2
6319217|NCT02783573|10055369|FG002|Placebo-Controlled Treatment Period|Protocol Violation|0
6319218|NCT02783573|10055367|FG000|Placebo-Controlled Treatment Period|Withdrawal by Subject|15
6151867|NCT01115569|9788688|FG000|Conversion/Titration Phase|Lost to Follow-up|3
6151868|NCT01115569|9788689|FG001|Conversion/Titration Phase|Lost to Follow-up|0
6151869|NCT01115569|9788688|FG000|Conversion/Titration Phase|Physician Decision|5
6040955|NCT00372567|9639040|FG001|Phase 3 Study|Objective progression or relapse|13
6319219|NCT02783573|10055368|FG001|Placebo-Controlled Treatment Period|Withdrawal by Subject|20
6319220|NCT02783573|10055369|FG002|Placebo-Controlled Treatment Period|Withdrawal by Subject|23
6319221|NCT02783573|10055367|FG000|Placebo-Controlled Treatment Period|Withdrawal due to Caregiver Circumstance|3
6319222|NCT02783573|10055368|FG001|Placebo-Controlled Treatment Period|Withdrawal due to Caregiver Circumstance|3
6319223|NCT02783573|10055369|FG002|Placebo-Controlled Treatment Period|Withdrawal due to Caregiver Circumstance|9
6319224|NCT02783573|10055367|FG000|Placebo-Controlled Treatment Period|Sponsor Decision|494
6319225|NCT02783573|10055368|FG001|Placebo-Controlled Treatment Period|Sponsor Decision|512
6319226|NCT02783573|10055369|FG002|Placebo-Controlled Treatment Period|Sponsor Decision|492
6319227|NCT02783573|10055367|FG000|Delayed-Start Period|Sponsor Decision|0
6319228|NCT02783573|10055368|FG001|Delayed-Start Period|Sponsor Decision|17
6319229|NCT02783573|10055369|FG002|Delayed-Start Period|Sponsor Decision|12
6319230|NCT02783599|10055380|FG000|Overall Study|Progressive disease|23
6319231|NCT02783599|10055380|FG000|Overall Study|Surgical Resection|10
6319232|NCT02783599|10055380|FG000|Overall Study|Adverse Event|4
6319233|NCT02783599|10055380|FG000|Overall Study|Physician Decision|2
6319234|NCT02783599|10055380|FG000|Overall Study|Death|1
6319235|NCT02783729|10055395|FG000|Overall Study|Lack of Efficacy|1
6319236|NCT02783729|10055396|FG001|Overall Study|Lack of Efficacy|0
6319237|NCT02783729|10055397|FG002|Overall Study|Lack of Efficacy|0
6319238|NCT02783729|10055398|FG003|Overall Study|Lack of Efficacy|0
6319239|NCT02783729|10055395|FG000|Overall Study|Adverse Event|2
6319240|NCT02783729|10055396|FG001|Overall Study|Adverse Event|6
6319241|NCT02783729|10055397|FG002|Overall Study|Adverse Event|2
6319242|NCT02783729|10055398|FG003|Overall Study|Adverse Event|3
6319243|NCT02783729|10055395|FG000|Overall Study|Other|1
6319244|NCT02783729|10055396|FG001|Overall Study|Other|6
6319245|NCT02783729|10055397|FG002|Overall Study|Other|2
6319246|NCT02783729|10055398|FG003|Overall Study|Other|3
6319247|NCT02783729|10055395|FG000|Overall Study|Withdrawal by Subject|2
6319248|NCT02783729|10055396|FG001|Overall Study|Withdrawal by Subject|3
6319249|NCT02783729|10055397|FG002|Overall Study|Withdrawal by Subject|1
6319250|NCT02783729|10055398|FG003|Overall Study|Withdrawal by Subject|2
6319251|NCT02783729|10055395|FG000|Overall Study|Participant's choice|2
6319252|NCT02783729|10055396|FG001|Overall Study|Participant's choice|1
6319253|NCT02783729|10055397|FG002|Overall Study|Participant's choice|2
6319254|NCT02783729|10055398|FG003|Overall Study|Participant's choice|1
6319255|NCT02783729|10055395|FG000|Overall Study|Lost to Follow-up|2
6319256|NCT02783729|10055396|FG001|Overall Study|Lost to Follow-up|1
6319257|NCT02783729|10055397|FG002|Overall Study|Lost to Follow-up|1
6319258|NCT02783729|10055398|FG003|Overall Study|Lost to Follow-up|0
6319259|NCT02783768|10055413|FG000|Overall Study|Lost to Follow-up|1
6319260|NCT02783768|10055414|FG001|Overall Study|Lost to Follow-up|0
6319261|NCT02783911|10055450|FG000|Overall Study|Lost to Follow-up|3
6319262|NCT02783911|10055451|FG001|Overall Study|Lost to Follow-up|32
6319263|NCT02784106|10055468|FG000|Double-Blind Treatment Period (12 Weeks)|Adverse Event|3
6319264|NCT02784106|10055469|FG001|Double-Blind Treatment Period (12 Weeks)|Adverse Event|5
6319265|NCT02784106|10055470|FG002|Double-Blind Treatment Period (12 Weeks)|Adverse Event|0
6319266|NCT02784106|10055471|FG003|Double-Blind Treatment Period (12 Weeks)|Adverse Event|0
6319267|NCT02784106|10055468|FG000|Double-Blind Treatment Period (12 Weeks)|Withdrawal by Subject|2
6319268|NCT02784106|10055469|FG001|Double-Blind Treatment Period (12 Weeks)|Withdrawal by Subject|1
6319269|NCT02784106|10055470|FG002|Double-Blind Treatment Period (12 Weeks)|Withdrawal by Subject|0
6319270|NCT02784106|10055471|FG003|Double-Blind Treatment Period (12 Weeks)|Withdrawal by Subject|0
6319271|NCT02784106|10055468|FG000|Double-Blind Treatment Period (12 Weeks)|Other|2
6319272|NCT02784106|10055469|FG001|Double-Blind Treatment Period (12 Weeks)|Other|0
6319273|NCT02784106|10055470|FG002|Double-Blind Treatment Period (12 Weeks)|Other|0
6319274|NCT02784106|10055471|FG003|Double-Blind Treatment Period (12 Weeks)|Other|0
6319275|NCT02784106|10055468|FG000|Double-Blind Treatment Period (12 Weeks)|Lack of Efficacy|1
6319276|NCT02784106|10055469|FG001|Double-Blind Treatment Period (12 Weeks)|Lack of Efficacy|0
6319277|NCT02784106|10055470|FG002|Double-Blind Treatment Period (12 Weeks)|Lack of Efficacy|0
6319278|NCT02784106|10055471|FG003|Double-Blind Treatment Period (12 Weeks)|Lack of Efficacy|0
6319279|NCT02784106|10055468|FG000|Open-Label Extension Period (26 Weeks)|Adverse Event|0
6319280|NCT02784106|10055469|FG001|Open-Label Extension Period (26 Weeks)|Adverse Event|0
6319281|NCT02784106|10055470|FG002|Open-Label Extension Period (26 Weeks)|Adverse Event|2
6319282|NCT02784106|10055471|FG003|Open-Label Extension Period (26 Weeks)|Adverse Event|1
6319283|NCT02784106|10055468|FG000|Open-Label Extension Period (26 Weeks)|Lack of Efficacy|0
6319284|NCT02784106|10055469|FG001|Open-Label Extension Period (26 Weeks)|Lack of Efficacy|0
6319285|NCT02784106|10055470|FG002|Open-Label Extension Period (26 Weeks)|Lack of Efficacy|1
6319286|NCT02784106|10055471|FG003|Open-Label Extension Period (26 Weeks)|Lack of Efficacy|1
6319287|NCT02784431|10055497|FG000|Overall Study|Unsuccessful Implant Attempt|1
6319288|NCT02784431|10055497|FG000|Overall Study|Early Study Termination|19
6319289|NCT02784834|10055531|FG000|Overall Study|Lack of Efficacy|1
6319290|NCT02785458|10055624|FG000|1 Month|Withdrawal by Subject|2
6319291|NCT02785458|10055625|FG001|1 Month|Withdrawal by Subject|1
6319292|NCT02785458|10055624|FG000|1 Month|Lost to Follow-up|38
6319293|NCT02785458|10055625|FG001|1 Month|Lost to Follow-up|31
6319294|NCT02785458|10055624|FG000|1 Month|Deemed Ineligible|1
6319295|NCT02785458|10055625|FG001|1 Month|Deemed Ineligible|0
6319296|NCT02785458|10055624|FG000|1 Month|Completed Evaluation by Baseline|42
6319297|NCT02785458|10055625|FG001|1 Month|Completed Evaluation by Baseline|39
6319298|NCT02785458|10055624|FG000|1 Month|Partial Interview|0
6319299|NCT02785458|10055625|FG001|1 Month|Partial Interview|4
6319300|NCT02785458|10055624|FG000|3 Months|Withdrawal by Subject|3
6319301|NCT02785458|10055625|FG001|3 Months|Withdrawal by Subject|1
6319302|NCT02785458|10055624|FG000|3 Months|Lost to Follow-up|25
6319303|NCT02785458|10055625|FG001|3 Months|Lost to Follow-up|21
6319304|NCT02785458|10055624|FG000|3 Months|Completed Evaluation at 1 Month|100
6319305|NCT02785458|10055625|FG001|3 Months|Completed Evaluation at 1 Month|89
6319306|NCT02785588|10055631|FG000|Phase 1: Initial Feasibility Assessment|Breakdown of investigational device|1
6319307|NCT02785588|10055631|FG000|Phase 1: Initial Feasibility Assessment|Withdrawal by Subject|1
6319308|NCT02785770|10055635|FG000|Intervention Period 2 (1 Day)|Adverse Event|0
6319309|NCT02785770|10055636|FG001|Intervention Period 2 (1 Day)|Adverse Event|1
6319310|NCT02785770|10055637|FG002|Intervention Period 2 (1 Day)|Adverse Event|0
6319311|NCT02785770|10055638|FG003|Intervention Period 2 (1 Day)|Adverse Event|0
6319312|NCT02785770|10055635|FG000|Intervention Period 2 (1 Day)|Family related obligations|0
6319313|NCT02785770|10055636|FG001|Intervention Period 2 (1 Day)|Family related obligations|0
6319314|NCT02785770|10055637|FG002|Intervention Period 2 (1 Day)|Family related obligations|1
6319315|NCT02785770|10055638|FG003|Intervention Period 2 (1 Day)|Family related obligations|0
6319316|NCT02785770|10055635|FG000|Intervention Period 3 (1 Day)|Adverse Event|0
6319317|NCT02785770|10055636|FG001|Intervention Period 3 (1 Day)|Adverse Event|0
6319318|NCT02785770|10055637|FG002|Intervention Period 3 (1 Day)|Adverse Event|0
6319319|NCT02785770|10055638|FG003|Intervention Period 3 (1 Day)|Adverse Event|1
6319320|NCT02785900|10055653|FG000|Overall Study|Study Termination by Sponsor|64
6319321|NCT02785900|10055654|FG001|Overall Study|Study Termination by Sponsor|81
6319322|NCT02785900|10055653|FG000|Overall Study|Death|46
6319323|NCT02785900|10055654|FG001|Overall Study|Death|32
6319324|NCT02785900|10055653|FG000|Overall Study|Withdrawal by Subject|4
6319325|NCT02785900|10055654|FG001|Overall Study|Withdrawal by Subject|8
6319326|NCT02785900|10055653|FG000|Overall Study|Physician Decision|3
6319327|NCT02785900|10055654|FG001|Overall Study|Physician Decision|2
6319328|NCT02785913|10055660|FG000|Overall Study|Adverse Event|5
6319329|NCT02785913|10055660|FG000|Overall Study|Death|2
6319330|NCT02785913|10055660|FG000|Overall Study|Progression|18
6319331|NCT02785913|10055660|FG000|Overall Study|Not protocol specified|1
6319332|NCT02785939|10055667|FG000|Overall Study|Progression|25
6319333|NCT02785939|10055668|FG001|Overall Study|Progression|8
6319334|NCT02785939|10055667|FG000|Overall Study|Adverse Event|3
6319335|NCT02785939|10055668|FG001|Overall Study|Adverse Event|1
6319336|NCT02785939|10055667|FG000|Overall Study|Death|1
6319337|NCT02785939|10055668|FG001|Overall Study|Death|0
6319338|NCT02785939|10055667|FG000|Overall Study|Refusal|1
6319339|NCT02785939|10055668|FG001|Overall Study|Refusal|0
6319340|NCT02785939|10055667|FG000|Overall Study|Deteriorating health|1
6319341|NCT02785939|10055668|FG001|Overall Study|Deteriorating health|0
6319342|NCT02785939|10055667|FG000|Overall Study|Not protocol specified|0
6319343|NCT02785939|10055668|FG001|Overall Study|Not protocol specified|1
6319344|NCT02786004|10055676|FG000|Overall Study|Withdrawal by Subject|0
6319345|NCT02786004|10055677|FG001|Overall Study|Withdrawal by Subject|1
6319346|NCT02786836|10055718|FG000|Overall Study|Death|1
6319347|NCT02786836|10055718|FG000|Overall Study|Lack of Efficacy|2
6319348|NCT02786836|10055718|FG000|Overall Study|Protocol Violation|3
6319349|NCT02786836|10055718|FG000|Overall Study|Withdrawal by Subject|3
6319350|NCT02786836|10055718|FG000|Overall Study|Liver Transplantation|2
6319351|NCT02786836|10055718|FG000|Overall Study|Device or Pharmacy Issues|3
6319352|NCT02786901|10055726|FG000|Overall Study|Adverse Event|1
6319353|NCT02786901|10055727|FG001|Overall Study|Adverse Event|1
6319354|NCT02786901|10055728|FG002|Overall Study|Adverse Event|2
6319355|NCT02786901|10055726|FG000|Overall Study|Physician Decision|1
6319356|NCT02786901|10055727|FG001|Overall Study|Physician Decision|0
6319357|NCT02786901|10055728|FG002|Overall Study|Physician Decision|0
6319358|NCT02786901|10055726|FG000|Overall Study|Rescue Therapy Use|71
6319359|NCT02786901|10055727|FG001|Overall Study|Rescue Therapy Use|49
6319360|NCT02786901|10055728|FG002|Overall Study|Rescue Therapy Use|33
6319361|NCT02786901|10055726|FG000|Overall Study|Subject Request/Lost to Follow up|1
6319362|NCT02786901|10055727|FG001|Overall Study|Subject Request/Lost to Follow up|5
6319363|NCT02786901|10055728|FG002|Overall Study|Subject Request/Lost to Follow up|5
6319364|NCT02786901|10055726|FG000|Overall Study|Disallowed medication|1
6319365|NCT02786901|10055727|FG001|Overall Study|Disallowed medication|1
6319366|NCT02786901|10055728|FG002|Overall Study|Disallowed medication|0
6319367|NCT02786901|10055726|FG000|Overall Study|Randomized in error|2
6319368|NCT02786901|10055727|FG001|Overall Study|Randomized in error|0
6319369|NCT02786901|10055728|FG002|Overall Study|Randomized in error|1
6319370|NCT02786927|10055736|FG000|Overall Study|Adverse Event|1
6319371|NCT02786927|10055736|FG000|Overall Study|Protocol Violation|4
6319372|NCT02786953|10055743|FG000|Overall Study|Withdrawal by Subject|3
6319373|NCT02786953|10055744|FG001|Overall Study|Withdrawal by Subject|0
6319374|NCT02786953|10055743|FG000|Overall Study|Physician Decision|0
6319375|NCT02786953|10055744|FG001|Overall Study|Physician Decision|1
6319376|NCT02787083|10055761|FG000|Overall Study|Adverse Event|1
6319377|NCT02787083|10055762|FG001|Overall Study|Adverse Event|0
6319378|NCT02787083|10055761|FG000|Overall Study|Withdrawal by Subject|2
6319379|NCT02787083|10055762|FG001|Overall Study|Withdrawal by Subject|2
6319380|NCT02787304|10055776|FG000|Overall Study|Adverse Event|9
6319381|NCT02787304|10055777|FG001|Overall Study|Adverse Event|3
6319382|NCT02787304|10055778|FG002|Overall Study|Adverse Event|8
6319383|NCT02787304|10055779|FG003|Overall Study|Adverse Event|1
6319384|NCT02787304|10055776|FG000|Overall Study|Withdrawal by Subject|1
6319385|NCT02787304|10055777|FG001|Overall Study|Withdrawal by Subject|4
6319386|NCT02787304|10055778|FG002|Overall Study|Withdrawal by Subject|0
6319387|NCT02787304|10055779|FG003|Overall Study|Withdrawal by Subject|0
6319388|NCT02787304|10055776|FG000|Overall Study|Lost to Follow-up|1
6319389|NCT02787304|10055777|FG001|Overall Study|Lost to Follow-up|0
6319390|NCT02787304|10055778|FG002|Overall Study|Lost to Follow-up|0
6319391|NCT02787304|10055779|FG003|Overall Study|Lost to Follow-up|1
6319392|NCT02787304|10055776|FG000|Overall Study|Noncompliance with study drug|0
6319393|NCT02787304|10055777|FG001|Overall Study|Noncompliance with study drug|0
6319394|NCT02787304|10055778|FG002|Overall Study|Noncompliance with study drug|1
6319395|NCT02787304|10055779|FG003|Overall Study|Noncompliance with study drug|0
6319396|NCT02787304|10055776|FG000|Overall Study|Physician Decision|0
6319397|NCT02787304|10055777|FG001|Overall Study|Physician Decision|0
6319398|NCT02787304|10055778|FG002|Overall Study|Physician Decision|1
6319399|NCT02787304|10055779|FG003|Overall Study|Physician Decision|0
6319400|NCT02787304|10055776|FG000|Overall Study|Study terminated by sponsor|25
6319401|NCT02787304|10055777|FG001|Overall Study|Study terminated by sponsor|31
6319402|NCT02787304|10055778|FG002|Overall Study|Study terminated by sponsor|31
6319403|NCT02787304|10055779|FG003|Overall Study|Study terminated by sponsor|32
6319404|NCT02787863|10055823|FG000|Overall Study|Death|1
6319405|NCT02787863|10055824|FG001|Overall Study|Death|0
6319406|NCT02787863|10055825|FG002|Overall Study|Death|1
6319407|NCT02787863|10055826|FG003|Overall Study|Death|0
6319408|NCT02787863|10055827|FG004|Overall Study|Death|0
6319409|NCT02787863|10055828|FG005|Overall Study|Death|0
6151870|NCT01115569|9788689|FG001|Conversion/Titration Phase|Physician Decision|0
6151871|NCT01115569|9788688|FG000|Conversion/Titration Phase|Protocol Violation|68
6151872|NCT01115569|9788689|FG001|Conversion/Titration Phase|Protocol Violation|0
6151873|NCT01115569|9788688|FG000|Conversion/Titration Phase|Withdrawal by Subject|26
6151874|NCT01115569|9788689|FG001|Conversion/Titration Phase|Withdrawal by Subject|0
6151875|NCT01115569|9788688|FG000|Conversion/Titration Phase|Non-Compliance with Study Drug|53
6151876|NCT01115569|9788689|FG001|Conversion/Titration Phase|Non-Compliance with Study Drug|0
6151877|NCT01115569|9788688|FG000|Maintenance Phase|Adverse Event|0
6151878|NCT01115569|9788689|FG001|Maintenance Phase|Adverse Event|43
6151879|NCT01115569|9788688|FG000|Maintenance Phase|Lost to Follow-up|0
6319410|NCT02787863|10055829|FG006|Overall Study|Death|0
6319411|NCT02787863|10055830|FG007|Overall Study|Death|0
6319412|NCT02787863|10055823|FG000|Overall Study|Withdrawal by Subject|0
6319413|NCT02787863|10055824|FG001|Overall Study|Withdrawal by Subject|1
6319414|NCT02787863|10055825|FG002|Overall Study|Withdrawal by Subject|1
6319415|NCT02787863|10055826|FG003|Overall Study|Withdrawal by Subject|0
6319416|NCT02787863|10055827|FG004|Overall Study|Withdrawal by Subject|0
6319417|NCT02787863|10055828|FG005|Overall Study|Withdrawal by Subject|0
6319418|NCT02787863|10055829|FG006|Overall Study|Withdrawal by Subject|0
6319419|NCT02787863|10055830|FG007|Overall Study|Withdrawal by Subject|0
6319420|NCT02788175|10055889|FG000|Overall Study|Protocol Violation|3
6319421|NCT02788175|10055889|FG000|Overall Study|Withdrawal by Subject|4
6319422|NCT02788175|10055889|FG000|Overall Study|Ineligible prior to study agent|6
6319423|NCT02788201|10055928|FG000|Overall Study|Death|1
6319424|NCT02788201|10055929|FG001|Overall Study|Death|1
6319425|NCT02788201|10055930|FG002|Overall Study|Death|1
6319426|NCT02788201|10055931|FG003|Overall Study|Death|1
6319427|NCT02788201|10055932|FG004|Overall Study|Death|0
6319428|NCT02788201|10055933|FG005|Overall Study|Death|1
6319429|NCT02788201|10055928|FG000|Overall Study|Ineligible|0
6319430|NCT02788201|10055929|FG001|Overall Study|Ineligible|0
6319431|NCT02788201|10055930|FG002|Overall Study|Ineligible|0
6319432|NCT02788201|10055931|FG003|Overall Study|Ineligible|0
6319433|NCT02788201|10055932|FG004|Overall Study|Ineligible|0
6319434|NCT02788201|10055933|FG005|Overall Study|Ineligible|1
6319435|NCT02788201|10055928|FG000|Overall Study|Withdrawal by Subject|0
6319436|NCT02788201|10055929|FG001|Overall Study|Withdrawal by Subject|0
6319437|NCT02788201|10055930|FG002|Overall Study|Withdrawal by Subject|0
6319438|NCT02788201|10055931|FG003|Overall Study|Withdrawal by Subject|0
6319439|NCT02788201|10055932|FG004|Overall Study|Withdrawal by Subject|0
6319440|NCT02788201|10055933|FG005|Overall Study|Withdrawal by Subject|1
6319441|NCT02788279|10055952|FG000|Overall Study|Death|62
6319442|NCT02788279|10055953|FG001|Overall Study|Death|136
6319443|NCT02788279|10055954|FG002|Overall Study|Death|72
6319444|NCT02788279|10055952|FG000|Overall Study|Withdrawal by Subject|10
6319445|NCT02788279|10055953|FG001|Overall Study|Withdrawal by Subject|15
6319446|NCT02788279|10055954|FG002|Overall Study|Withdrawal by Subject|5
6319447|NCT02788279|10055952|FG000|Overall Study|Lost to Follow-up|0
6319448|NCT02788279|10055953|FG001|Overall Study|Lost to Follow-up|3
6319449|NCT02788279|10055954|FG002|Overall Study|Lost to Follow-up|2
6319450|NCT02788279|10055952|FG000|Overall Study|Sponsor decision|18
6319451|NCT02788279|10055953|FG001|Overall Study|Sponsor decision|29
6319452|NCT02788279|10055954|FG002|Overall Study|Sponsor decision|11
6319453|NCT02788357|10055967|FG000|Overall Study|Lost to Follow-up|3
6319454|NCT02788357|10055968|FG001|Overall Study|Lost to Follow-up|0
6319455|NCT02788474|10055976|FG000|Double Blind Treatment Period|Not treated|1
6319456|NCT02788474|10055977|FG001|Double Blind Treatment Period|Not treated|0
6319457|NCT02788474|10055976|FG000|Double Blind Treatment Period|Patient's refusal|3
6319458|NCT02788474|10055977|FG001|Double Blind Treatment Period|Patient's refusal|0
6319459|NCT02788474|10055976|FG000|Double Blind Treatment Period|Adverse Event|6
6319460|NCT02788474|10055977|FG001|Double Blind Treatment Period|Adverse Event|4
6319461|NCT02788474|10055976|FG000|Open Label Treatment Period|Adverse Event|29
6319462|NCT02788474|10055977|FG001|Open Label Treatment Period|Adverse Event|9
6319463|NCT02788474|10055976|FG000|Open Label Treatment Period|Other than reason specified|1
6319464|NCT02788474|10055977|FG001|Open Label Treatment Period|Other than reason specified|0
6319465|NCT02788474|10055976|FG000|Open Label Treatment Period|Patient's refusal|1
6319466|NCT02788474|10055977|FG001|Open Label Treatment Period|Patient's refusal|3
6319467|NCT02788474|10055976|FG000|Open Label Treatment Period|Non-compliance|1
6319468|NCT02788474|10055977|FG001|Open Label Treatment Period|Non-compliance|0
6319469|NCT02788513|10055989|FG000|Overall Study|Withdrawal by Subject|3
6319470|NCT02788513|10055990|FG001|Overall Study|Withdrawal by Subject|0
6319471|NCT02788513|10055991|FG002|Overall Study|Withdrawal by Subject|2
6319472|NCT02788513|10055992|FG003|Overall Study|Withdrawal by Subject|3
6319473|NCT02788513|10055993|FG004|Overall Study|Withdrawal by Subject|1
6319474|NCT02788513|10055989|FG000|Overall Study|Lost to Follow-up|1
6319475|NCT02788513|10055990|FG001|Overall Study|Lost to Follow-up|0
6319476|NCT02788513|10055991|FG002|Overall Study|Lost to Follow-up|0
6319477|NCT02788513|10055992|FG003|Overall Study|Lost to Follow-up|0
6319478|NCT02788513|10055993|FG004|Overall Study|Lost to Follow-up|1
6319479|NCT02788513|10055989|FG000|Overall Study|Adverse Event|5
6319480|NCT02788513|10055990|FG001|Overall Study|Adverse Event|8
6319481|NCT02788513|10055991|FG002|Overall Study|Adverse Event|4
6319482|NCT02788513|10055992|FG003|Overall Study|Adverse Event|2
6319483|NCT02788513|10055993|FG004|Overall Study|Adverse Event|2
6319484|NCT02788513|10055989|FG000|Overall Study|Protocol Violation|0
6319485|NCT02788513|10055990|FG001|Overall Study|Protocol Violation|0
6319486|NCT02788513|10055991|FG002|Overall Study|Protocol Violation|1
6319487|NCT02788513|10055992|FG003|Overall Study|Protocol Violation|1
6319488|NCT02788513|10055993|FG004|Overall Study|Protocol Violation|0
6319489|NCT02788513|10055989|FG000|Overall Study|Subject decided to stop taking treatment|0
6319490|NCT02788513|10055990|FG001|Overall Study|Subject decided to stop taking treatment|0
6319491|NCT02788513|10055991|FG002|Overall Study|Subject decided to stop taking treatment|1
6319492|NCT02788513|10055992|FG003|Overall Study|Subject decided to stop taking treatment|0
6319493|NCT02788513|10055993|FG004|Overall Study|Subject decided to stop taking treatment|0
6319494|NCT02788513|10055989|FG000|Overall Study|Decision by the study team|0
6319495|NCT02788513|10055990|FG001|Overall Study|Decision by the study team|0
6319496|NCT02788513|10055991|FG002|Overall Study|Decision by the study team|0
6319497|NCT02788513|10055992|FG003|Overall Study|Decision by the study team|0
6319498|NCT02788513|10055993|FG004|Overall Study|Decision by the study team|1
6319499|NCT02788656|10056007|FG000|Overall Study|Withdrawal by Subject|1
6319500|NCT02788656|10056008|FG001|Overall Study|Withdrawal by Subject|0
6319501|NCT02788747|10056017|FG000|Overall Study|Adverse Event|1
6319502|NCT02788747|10056018|FG001|Overall Study|Adverse Event|0
6319503|NCT02788747|10056019|FG002|Overall Study|Adverse Event|0
6319504|NCT02789111|10056060|FG000|Overall Study|Withdrawal by Subject|1
6319505|NCT02789111|10056061|FG001|Overall Study|Withdrawal by Subject|4
6319506|NCT02789137|10056069|FG000|Overall Study|Dropped out/Died|58
6319507|NCT02789176|10056078|FG000|Overall Study|Death|0
6319508|NCT02789176|10056079|FG001|Overall Study|Death|0
6319509|NCT02789176|10056080|FG002|Overall Study|Death|3
6319510|NCT02789176|10056081|FG003|Overall Study|Death|0
6319511|NCT02789176|10056078|FG000|Overall Study|Withdrawal by Subject|0
6319512|NCT02789176|10056079|FG001|Overall Study|Withdrawal by Subject|0
6319513|NCT02789176|10056080|FG002|Overall Study|Withdrawal by Subject|1
6319514|NCT02789176|10056081|FG003|Overall Study|Withdrawal by Subject|0
6319515|NCT02789176|10056078|FG000|Overall Study|Lost to Follow-up|8
6319516|NCT02789176|10056079|FG001|Overall Study|Lost to Follow-up|2
6319517|NCT02789176|10056080|FG002|Overall Study|Lost to Follow-up|6
6319518|NCT02789176|10056081|FG003|Overall Study|Lost to Follow-up|1
6319519|NCT02790073|10056100|FG000|Overall Study|Death|1
6319520|NCT02790073|10056100|FG000|Overall Study|Withdrawal from HD|1
6319521|NCT02790073|10056100|FG000|Overall Study|Withdrawal by Subject|1
6319522|NCT02790437|10056110|FG000|Overall Study|Patient graft failure - nephrectomy|1
6319523|NCT02790437|10056111|FG001|Overall Study|Patient graft failure - nephrectomy|0
6319524|NCT02790437|10056110|FG000|Overall Study|Adverse Event|1
6319525|NCT02790437|10056111|FG001|Overall Study|Adverse Event|0
6319526|NCT02790437|10056110|FG000|Overall Study|Withdrawal by Subject|1
6319527|NCT02790437|10056111|FG001|Overall Study|Withdrawal by Subject|0
6319528|NCT02790606|10056133|FG000|Overall Study|Death|27
6319529|NCT02790606|10056133|FG000|Overall Study|Lost to Follow-up|4
6319530|NCT02790606|10056133|FG000|Overall Study|Physician Decision|3
6319531|NCT02790606|10056133|FG000|Overall Study|Withdrawal by Subject|1
6319532|NCT02791191|10056160|FG000|Overall Study|Adverse Event|2
6319533|NCT02791191|10056161|FG001|Overall Study|Adverse Event|4
6319534|NCT02791191|10056162|FG002|Overall Study|Adverse Event|5
6319535|NCT02791191|10056160|FG000|Overall Study|Lack of Efficacy|0
6319536|NCT02791191|10056161|FG001|Overall Study|Lack of Efficacy|1
6319537|NCT02791191|10056162|FG002|Overall Study|Lack of Efficacy|0
6319538|NCT02791191|10056160|FG000|Overall Study|Study Drug Non-Compliance|0
6319539|NCT02791191|10056161|FG001|Overall Study|Study Drug Non-Compliance|2
6319540|NCT02791191|10056162|FG002|Overall Study|Study Drug Non-Compliance|0
6319541|NCT02791191|10056160|FG000|Overall Study|Site Closed by Sponsor|1
6319542|NCT02791191|10056161|FG001|Overall Study|Site Closed by Sponsor|1
6319543|NCT02791191|10056162|FG002|Overall Study|Site Closed by Sponsor|3
6319544|NCT02791191|10056160|FG000|Overall Study|Progressive Disease|1
6319545|NCT02791191|10056161|FG001|Overall Study|Progressive Disease|0
6319546|NCT02791191|10056162|FG002|Overall Study|Progressive Disease|0
6319547|NCT02791191|10056160|FG000|Overall Study|Study Terminated by Sponsor|29
6319548|NCT02791191|10056161|FG001|Overall Study|Study Terminated by Sponsor|101
6319549|NCT02791191|10056162|FG002|Overall Study|Study Terminated by Sponsor|109
6319550|NCT02791191|10056160|FG000|Overall Study|Withdrawal by Subject|3
6319551|NCT02791191|10056161|FG001|Overall Study|Withdrawal by Subject|1
6319552|NCT02791191|10056162|FG002|Overall Study|Withdrawal by Subject|3
6319553|NCT02791191|10056160|FG000|Overall Study|Subject Withdrew Caregiver Circumstances|2
6319554|NCT02791191|10056161|FG001|Overall Study|Subject Withdrew Caregiver Circumstances|1
6319555|NCT02791191|10056162|FG002|Overall Study|Subject Withdrew Caregiver Circumstances|0
6319556|NCT02791269|10056172|FG000|Overall Study|Lost to Follow-up|0
6040956|NCT00372567|9639041|FG002|Phase 3 Study|Objective progression or relapse|4
6151880|NCT01115569|9788689|FG001|Maintenance Phase|Lost to Follow-up|8
6151881|NCT01115569|9788688|FG000|Maintenance Phase|Physician Decision|0
6151882|NCT01115569|9788689|FG001|Maintenance Phase|Physician Decision|3
6151883|NCT01115569|9788688|FG000|Maintenance Phase|Protocol Violation|0
6151884|NCT01115569|9788689|FG001|Maintenance Phase|Protocol Violation|9
6151885|NCT01115569|9788688|FG000|Maintenance Phase|Withdrawal by Subject|0
6151886|NCT01115569|9788689|FG001|Maintenance Phase|Withdrawal by Subject|27
6151887|NCT01115569|9788688|FG000|Maintenance Phase|Non-Compliance with Study Drug|0
6151888|NCT01115569|9788689|FG001|Maintenance Phase|Non-Compliance with Study Drug|48
6319557|NCT02791269|10056173|FG001|Overall Study|Lost to Follow-up|1
6040957|NCT00372567|9639039|FG000|Phase 3 Study|Global deterioration of health status|0
6040958|NCT00372567|9639040|FG001|Phase 3 Study|Global deterioration of health status|1
6040959|NCT00372567|9639041|FG002|Phase 3 Study|Global deterioration of health status|0
6040960|NCT00372567|9639039|FG000|Phase 3 Study|Other|2
6040961|NCT00372567|9639040|FG001|Phase 3 Study|Other|2
6040962|NCT00372567|9639041|FG002|Phase 3 Study|Other|1
6040963|NCT00372567|9639039|FG000|Phase 3 Study|study terminated by sponsor|13
6040964|NCT00372567|9639040|FG001|Phase 3 Study|study terminated by sponsor|8
6040965|NCT00372567|9639041|FG002|Phase 3 Study|study terminated by sponsor|5
6040966|NCT00372593|9639052|FG000|Overall Study|Adverse Event|43
6040967|NCT00372593|9639053|FG001|Overall Study|Adverse Event|45
6040968|NCT00372593|9639054|FG002|Overall Study|Adverse Event|0
6040969|NCT00372593|9639052|FG000|Overall Study|Death|16
6040970|NCT00372593|9639053|FG001|Overall Study|Death|20
6319558|NCT02791438|10056205|FG000|Treatment Period|Adverse Event|1
6040971|NCT00372593|9639054|FG002|Overall Study|Death|1
6319559|NCT02791438|10056206|FG001|Treatment Period|Adverse Event|0
6040972|NCT00372593|9639052|FG000|Overall Study|Lack of Efficacy|82
6319560|NCT02791438|10056205|FG000|Treatment Period|Withdrawal by Subject|0
6319561|NCT02791438|10056206|FG001|Treatment Period|Withdrawal by Subject|1
6319562|NCT02791438|10056205|FG000|Treatment Period|Withdrawal by Parent/Guardian|2
6319563|NCT02791438|10056206|FG001|Treatment Period|Withdrawal by Parent/Guardian|0
6319564|NCT02791490|10056214|FG000|Overall Study|Lost to Follow-up|1
6319565|NCT02791490|10056215|FG001|Overall Study|Lost to Follow-up|2
6319566|NCT02791490|10056214|FG000|Overall Study|Withdrawal by Subject|2
6319567|NCT02791490|10056215|FG001|Overall Study|Withdrawal by Subject|6
6319568|NCT02791516|10056223|FG000|Overall Study|Withdrawal by Subject|1
6319569|NCT02791516|10056224|FG001|Overall Study|Withdrawal by Subject|1
6319570|NCT02791659|10056232|FG000|Overall Study|Protocol Violation|0
6319571|NCT02791659|10056233|FG001|Overall Study|Protocol Violation|1
6319572|NCT02791763|10056242|FG000|Overall Study|Protocol Violation|0
6319573|NCT02791763|10056243|FG001|Overall Study|Protocol Violation|0
6319574|NCT02791763|10056244|FG002|Overall Study|Protocol Violation|1
6319575|NCT02791763|10056242|FG000|Overall Study|Withdrawal by Subject|5
6319576|NCT02791763|10056243|FG001|Overall Study|Withdrawal by Subject|1
6319577|NCT02791763|10056244|FG002|Overall Study|Withdrawal by Subject|0
6319578|NCT02791763|10056242|FG000|Overall Study|Physician Decision|0
6319579|NCT02791763|10056243|FG001|Overall Study|Physician Decision|1
6319580|NCT02791763|10056244|FG002|Overall Study|Physician Decision|0
6319581|NCT02791763|10056242|FG000|Overall Study|Needs maintenance/changes in dialysis|16
6319582|NCT02791763|10056243|FG001|Overall Study|Needs maintenance/changes in dialysis|19
6319583|NCT02791763|10056244|FG002|Overall Study|Needs maintenance/changes in dialysis|5
6319584|NCT02791763|10056242|FG000|Overall Study|Cancer event|1
6319585|NCT02791763|10056243|FG001|Overall Study|Cancer event|3
6319586|NCT02791763|10056244|FG002|Overall Study|Cancer event|0
6319587|NCT02791763|10056242|FG000|Overall Study|Participant had renal transplant|3
6319588|NCT02791763|10056243|FG001|Overall Study|Participant had renal transplant|0
6319589|NCT02791763|10056244|FG002|Overall Study|Participant had renal transplant|0
6319590|NCT02791763|10056242|FG000|Overall Study|Met hemoglobin stopping criteria|1
6319591|NCT02791763|10056243|FG001|Overall Study|Met hemoglobin stopping criteria|0
6319592|NCT02791763|10056244|FG002|Overall Study|Met hemoglobin stopping criteria|0
6319593|NCT02791763|10056242|FG000|Overall Study|Adverse Event|12
6319594|NCT02791763|10056243|FG001|Overall Study|Adverse Event|13
6319595|NCT02791763|10056244|FG002|Overall Study|Adverse Event|7
6319596|NCT02791893|10056263|FG000|Blinded Phase|Lost to Follow-up|2
6319597|NCT02791893|10056264|FG001|Blinded Phase|Lost to Follow-up|2
6319598|NCT02791893|10056263|FG000|Blinded Phase|Withdrawal by Subject|1
6319599|NCT02791893|10056264|FG001|Blinded Phase|Withdrawal by Subject|2
6319600|NCT02791893|10056263|FG000|Open Label Phase|Lost to Follow-up|3
6319601|NCT02791893|10056264|FG001|Open Label Phase|Lost to Follow-up|0
6319602|NCT02791893|10056263|FG000|Open Label Phase|Withdrawal by Subject|0
6319603|NCT02791893|10056264|FG001|Open Label Phase|Withdrawal by Subject|2
6319604|NCT02792062|10056307|FG000|Washout Period (at Least 14 Days)|Voluntary Withdrawal|1
6319605|NCT02792062|10056308|FG001|Washout Period (at Least 14 Days)|Voluntary Withdrawal|0
6319606|NCT02792062|10056309|FG002|Washout Period (at Least 14 Days)|Voluntary Withdrawal|0
6319607|NCT02792062|10056310|FG003|Washout Period (at Least 14 Days)|Voluntary Withdrawal|0
6319608|NCT02792062|10056311|FG004|Washout Period (at Least 14 Days)|Voluntary Withdrawal|0
6319609|NCT02792062|10056312|FG005|Washout Period (at Least 14 Days)|Voluntary Withdrawal|0
6319610|NCT02792192|10056324|FG000|Overall Study|Death|1
6040973|NCT00372593|9639053|FG001|Overall Study|Lack of Efficacy|71
6040974|NCT00372593|9639054|FG002|Overall Study|Lack of Efficacy|2
6319611|NCT02792192|10056325|FG001|Overall Study|Death|0
6319612|NCT02792192|10056326|FG002|Overall Study|Death|0
6319613|NCT02792192|10056327|FG003|Overall Study|Death|0
6319614|NCT02792192|10056324|FG000|Overall Study|Informed Consent Withdrawn|4
6319615|NCT02792192|10056325|FG001|Overall Study|Informed Consent Withdrawn|0
6319616|NCT02792192|10056326|FG002|Overall Study|Informed Consent Withdrawn|0
6319617|NCT02792192|10056327|FG003|Overall Study|Informed Consent Withdrawn|0
6319618|NCT02792192|10056324|FG000|Overall Study|Physician Decision|1
6319619|NCT02792192|10056325|FG001|Overall Study|Physician Decision|0
6319620|NCT02792192|10056326|FG002|Overall Study|Physician Decision|0
6319621|NCT02792192|10056327|FG003|Overall Study|Physician Decision|0
6319622|NCT02792192|10056324|FG000|Overall Study|Progressive Disease|0
6319623|NCT02792192|10056325|FG001|Overall Study|Progressive Disease|1
6319624|NCT02792192|10056326|FG002|Overall Study|Progressive Disease|0
6319625|NCT02792192|10056327|FG003|Overall Study|Progressive Disease|0
6319626|NCT02792192|10056324|FG000|Overall Study|Study Terminated By Sponsor|6
6319627|NCT02792192|10056325|FG001|Overall Study|Study Terminated By Sponsor|10
6319628|NCT02792192|10056326|FG002|Overall Study|Study Terminated By Sponsor|0
6319629|NCT02792192|10056327|FG003|Overall Study|Study Terminated By Sponsor|0
6319630|NCT02792218|10056340|FG000|Overall Study|Patient/guardian decision|15
6319631|NCT02792218|10056341|FG001|Overall Study|Patient/guardian decision|42
6319632|NCT02792218|10056340|FG000|Overall Study|Adverse Event|15
6319633|NCT02792218|10056341|FG001|Overall Study|Adverse Event|14
6319634|NCT02792218|10056340|FG000|Overall Study|Lost to Follow-up|10
6319635|NCT02792218|10056341|FG001|Overall Study|Lost to Follow-up|5
6319636|NCT02792218|10056340|FG000|Overall Study|Lack of Efficacy|1
6319637|NCT02792218|10056341|FG001|Overall Study|Lack of Efficacy|12
6319638|NCT02792218|10056340|FG000|Overall Study|Physician Decision|4
6319639|NCT02792218|10056341|FG001|Overall Study|Physician Decision|4
6319640|NCT02792218|10056340|FG000|Overall Study|Protocol deviation|3
6319641|NCT02792218|10056341|FG001|Overall Study|Protocol deviation|2
6319642|NCT02792218|10056340|FG000|Overall Study|New therapy for study indication|0
6319643|NCT02792218|10056341|FG001|Overall Study|New therapy for study indication|1
6319644|NCT02792218|10056340|FG000|Overall Study|Non-compliance with study treatment|0
6319645|NCT02792218|10056341|FG001|Overall Study|Non-compliance with study treatment|1
6319646|NCT02792218|10056340|FG000|Overall Study|Pregnancy|1
6319647|NCT02792218|10056341|FG001|Overall Study|Pregnancy|0
6319648|NCT02792231|10056349|FG000|Overall Study|Patient/guardian decision|32
6319649|NCT02792231|10056350|FG001|Overall Study|Patient/guardian decision|42
6319650|NCT02792231|10056349|FG000|Overall Study|Adverse Event|15
6319651|NCT02792231|10056350|FG001|Overall Study|Adverse Event|11
6319652|NCT02792231|10056349|FG000|Overall Study|Physician Decision|14
6319653|NCT02792231|10056350|FG001|Overall Study|Physician Decision|12
6319654|NCT02792231|10056349|FG000|Overall Study|Lack of Efficacy|7
6319655|NCT02792231|10056350|FG001|Overall Study|Lack of Efficacy|9
6319656|NCT02792231|10056349|FG000|Overall Study|Lost to Follow-up|9
6319657|NCT02792231|10056350|FG001|Overall Study|Lost to Follow-up|5
6319658|NCT02792231|10056349|FG000|Overall Study|Pregnancy|1
6319659|NCT02792231|10056350|FG001|Overall Study|Pregnancy|3
6319660|NCT02792231|10056349|FG000|Overall Study|Non-compliance with study treatment|2
6319661|NCT02792231|10056350|FG001|Overall Study|Non-compliance with study treatment|1
6319662|NCT02792231|10056349|FG000|Overall Study|Protocol deviation|2
6319663|NCT02792231|10056350|FG001|Overall Study|Protocol deviation|0
6319664|NCT02792231|10056349|FG000|Overall Study|Technical problems|0
6319665|NCT02792231|10056350|FG001|Overall Study|Technical problems|1
6319666|NCT02792504|10056356|FG000|Overall Study|Lost to Follow-up|24
6319667|NCT02792504|10056356|FG000|Overall Study|Violated inclusion/exclusion criteria|6
6040975|NCT00372593|9639052|FG000|Overall Study|Lost to Follow-up|1
6040976|NCT00372593|9639053|FG001|Overall Study|Lost to Follow-up|0
6151889|NCT01115569|9788688|FG000|Maintenance Phase|Administrative|0
6319668|NCT02792517|10056360|FG000|Overall Study|Withdrawal by Subject|10
6319669|NCT02792517|10056360|FG000|Overall Study|Decision by Sponsor|7
6319670|NCT02792517|10056360|FG000|Overall Study|Lost to Follow-up|3
6151890|NCT01115569|9788689|FG001|Maintenance Phase|Administrative|1
6151891|NCT01115738|9788723|FG000|Overall Study|Death|1
6319671|NCT02792699|10056367|FG000|Overall Study|Adverse Event|1
6319672|NCT02792699|10056368|FG001|Overall Study|Adverse Event|2
6319673|NCT02792699|10056369|FG002|Overall Study|Adverse Event|4
6319674|NCT02792699|10056367|FG000|Overall Study|Withdrawal by Subject|4
6319675|NCT02792699|10056368|FG001|Overall Study|Withdrawal by Subject|4
6319676|NCT02792699|10056369|FG002|Overall Study|Withdrawal by Subject|3
6319677|NCT02792699|10056367|FG000|Overall Study|Lost to Follow-up|0
6319678|NCT02792699|10056368|FG001|Overall Study|Lost to Follow-up|1
6319679|NCT02792699|10056369|FG002|Overall Study|Lost to Follow-up|2
6319680|NCT02792699|10056367|FG000|Overall Study|Physician Decision|2
6319681|NCT02792699|10056368|FG001|Overall Study|Physician Decision|0
6319682|NCT02792699|10056369|FG002|Overall Study|Physician Decision|0
6319683|NCT02792699|10056367|FG000|Overall Study|Dissatisfaction with Treatment Efficacy|1
6319684|NCT02792699|10056368|FG001|Overall Study|Dissatisfaction with Treatment Efficacy|3
6319685|NCT02792699|10056369|FG002|Overall Study|Dissatisfaction with Treatment Efficacy|1
6319686|NCT02792699|10056367|FG000|Overall Study|Other|1
6319687|NCT02792699|10056368|FG001|Overall Study|Other|0
6319688|NCT02792699|10056369|FG002|Overall Study|Other|0
6319689|NCT02792777|10056386|FG000|Overall Study|Withdrawal by Subject|2
6319690|NCT02792777|10056387|FG001|Overall Study|Withdrawal by Subject|0
6319691|NCT02792777|10056386|FG000|Overall Study|Recording malfunction|2
6319692|NCT02792777|10056387|FG001|Overall Study|Recording malfunction|0
6319693|NCT02792777|10056386|FG000|Overall Study|Later determined to be ineligible|2
6319694|NCT02792777|10056387|FG001|Overall Study|Later determined to be ineligible|0
6319695|NCT02792777|10056386|FG000|Overall Study|Participant interviewed twice|1
6319696|NCT02792777|10056387|FG001|Overall Study|Participant interviewed twice|0
6319697|NCT02792829|10056402|FG000|Treatment Period 2|Non compliance with alcohol prohibition|0
6319698|NCT02792829|10056403|FG001|Treatment Period 2|Non compliance with alcohol prohibition|1
6319699|NCT02792829|10056404|FG002|Treatment Period 2|Non compliance with alcohol prohibition|0
6319700|NCT02792829|10056405|FG003|Treatment Period 2|Non compliance with alcohol prohibition|0
6319701|NCT02792829|10056406|FG004|Treatment Period 2|Non compliance with alcohol prohibition|0
6319702|NCT02792829|10056407|FG005|Treatment Period 2|Non compliance with alcohol prohibition|0
6319703|NCT02792829|10056408|FG006|Treatment Period 2|Non compliance with alcohol prohibition|0
6319704|NCT02792829|10056409|FG007|Treatment Period 2|Non compliance with alcohol prohibition|0
6319705|NCT02792829|10056402|FG000|Treatment Period 2|Adverse Event|0
6319706|NCT02792829|10056403|FG001|Treatment Period 2|Adverse Event|0
6319707|NCT02792829|10056404|FG002|Treatment Period 2|Adverse Event|0
6319708|NCT02792829|10056405|FG003|Treatment Period 2|Adverse Event|0
6319709|NCT02792829|10056406|FG004|Treatment Period 2|Adverse Event|1
6319710|NCT02792829|10056407|FG005|Treatment Period 2|Adverse Event|0
6319711|NCT02792829|10056408|FG006|Treatment Period 2|Adverse Event|1
6319712|NCT02792829|10056409|FG007|Treatment Period 2|Adverse Event|1
6319713|NCT02792829|10056402|FG000|Treatment Period 2|Use of proscribed medications|0
6319714|NCT02792829|10056403|FG001|Treatment Period 2|Use of proscribed medications|0
6319715|NCT02792829|10056404|FG002|Treatment Period 2|Use of proscribed medications|0
6319716|NCT02792829|10056405|FG003|Treatment Period 2|Use of proscribed medications|0
6319717|NCT02792829|10056406|FG004|Treatment Period 2|Use of proscribed medications|0
6319718|NCT02792829|10056407|FG005|Treatment Period 2|Use of proscribed medications|0
6319719|NCT02792829|10056408|FG006|Treatment Period 2|Use of proscribed medications|0
6319720|NCT02792829|10056409|FG007|Treatment Period 2|Use of proscribed medications|1
6319721|NCT02792959|10056435|FG000|Overall Study|Protocol Violation|1
6319722|NCT02793128|10056439|FG000|Overall Study|Death|4
6319723|NCT02793128|10056439|FG000|Overall Study|Withdrawal by Subject|2
6319724|NCT02793128|10056439|FG000|Overall Study|Physician Decision|1
6319725|NCT02793128|10056439|FG000|Overall Study|Comorbid conditions and noncompliance|1
6319726|NCT02793128|10056439|FG000|Overall Study|Patient elected nephroureterectomy|1
6319727|NCT02793232|10056473|FG000|Period 1-Part A:5 Days; Part B,C:19 Days|Adverse Event|0
6319728|NCT02793232|10056474|FG001|Period 1-Part A:5 Days; Part B,C:19 Days|Adverse Event|0
6319729|NCT02793232|10056475|FG002|Period 1-Part A:5 Days; Part B,C:19 Days|Adverse Event|0
6319730|NCT02793232|10056476|FG003|Period 1-Part A:5 Days; Part B,C:19 Days|Adverse Event|0
6319731|NCT02793232|10056477|FG004|Period 1-Part A:5 Days; Part B,C:19 Days|Adverse Event|1
6319732|NCT02793232|10056478|FG005|Period 1-Part A:5 Days; Part B,C:19 Days|Adverse Event|0
6319733|NCT02793232|10056479|FG006|Period 1-Part A:5 Days; Part B,C:19 Days|Adverse Event|1
6319734|NCT02793232|10056480|FG007|Period 1-Part A:5 Days; Part B,C:19 Days|Adverse Event|0
6319735|NCT02793232|10056481|FG008|Period 1-Part A:5 Days; Part B,C:19 Days|Adverse Event|0
6319736|NCT02793622|10056517|FG000|Overall Study|Lost to Follow-up|31
6319737|NCT02793622|10056518|FG001|Overall Study|Lost to Follow-up|19
6319738|NCT02793622|10056517|FG000|Overall Study|Withdrawal by Subject|21
6319739|NCT02793622|10056518|FG001|Overall Study|Withdrawal by Subject|17
6319740|NCT02793622|10056517|FG000|Overall Study|Adverse Event|0
6319741|NCT02793622|10056518|FG001|Overall Study|Adverse Event|1
6319742|NCT02793622|10056517|FG000|Overall Study|Protocol Violation|1
6319743|NCT02793622|10056518|FG001|Overall Study|Protocol Violation|5
6319744|NCT02793947|10056595|FG000|Overall Study|Death|1
6319745|NCT02793947|10056596|FG001|Overall Study|Death|0
6319746|NCT02793947|10056595|FG000|Overall Study|Physician Decision|1
6319747|NCT02793947|10056596|FG001|Overall Study|Physician Decision|5
6319748|NCT02794103|10056602|FG000|Overall Study|Loss to follow up due to high sedation|3
6319749|NCT02794246|10056614|FG000|Overall Study|Withdrawal by Subject|2
6319750|NCT02794246|10056614|FG000|Overall Study|Physician Decision|4
6319751|NCT02794480|10056629|FG000|Period 1: Treatment Period 1 (28 Days)|Adverse Event|0
6319752|NCT02794480|10056630|FG001|Period 1: Treatment Period 1 (28 Days)|Adverse Event|0
6319753|NCT02794480|10056631|FG002|Period 1: Treatment Period 1 (28 Days)|Adverse Event|1
6319754|NCT02794480|10056632|FG003|Period 1: Treatment Period 1 (28 Days)|Adverse Event|0
6319755|NCT02794480|10056629|FG000|Period 1: Treatment Period 1 (28 Days)|Protocol Violation|0
6319756|NCT02794480|10056630|FG001|Period 1: Treatment Period 1 (28 Days)|Protocol Violation|0
6319757|NCT02794480|10056631|FG002|Period 1: Treatment Period 1 (28 Days)|Protocol Violation|1
6319758|NCT02794480|10056632|FG003|Period 1: Treatment Period 1 (28 Days)|Protocol Violation|0
6319759|NCT02794480|10056629|FG000|Period 1: Treatment Period 1 (28 Days)|Lost to Follow-up|0
6319760|NCT02794480|10056630|FG001|Period 1: Treatment Period 1 (28 Days)|Lost to Follow-up|0
6319761|NCT02794480|10056631|FG002|Period 1: Treatment Period 1 (28 Days)|Lost to Follow-up|0
6319762|NCT02794480|10056632|FG003|Period 1: Treatment Period 1 (28 Days)|Lost to Follow-up|2
6319763|NCT02794480|10056629|FG000|Period 1: Treatment Period 1 (28 Days)|Withdrawal by Subject|0
6319764|NCT02794480|10056630|FG001|Period 1: Treatment Period 1 (28 Days)|Withdrawal by Subject|2
6319765|NCT02794480|10056631|FG002|Period 1: Treatment Period 1 (28 Days)|Withdrawal by Subject|0
6319766|NCT02794480|10056632|FG003|Period 1: Treatment Period 1 (28 Days)|Withdrawal by Subject|1
6319767|NCT02794480|10056629|FG000|Period 2: Treatment Period 2 (28 Days)|Withdrawal by Subject|1
6319768|NCT02794480|10056630|FG001|Period 2: Treatment Period 2 (28 Days)|Withdrawal by Subject|0
6319769|NCT02794480|10056631|FG002|Period 2: Treatment Period 2 (28 Days)|Withdrawal by Subject|0
6319770|NCT02794480|10056632|FG003|Period 2: Treatment Period 2 (28 Days)|Withdrawal by Subject|1
6319771|NCT02794870|10056680|FG000|Overall Study|Withdrawal by Subject|2
6319772|NCT02794870|10056681|FG001|Overall Study|Withdrawal by Subject|0
6319773|NCT02794974|10056689|FG000|Overall Study|Physician Decision|0
6319774|NCT02794974|10056690|FG001|Overall Study|Physician Decision|1
6319775|NCT02795767|10056712|FG000|Overall Study|Received Commercial Emicizumab|1
6319776|NCT02795767|10056713|FG001|Overall Study|Received Commercial Emicizumab|0
6319777|NCT02795767|10056714|FG002|Overall Study|Received Commercial Emicizumab|0
6319778|NCT02795832|10056759|FG000|Overall Study|Adverse Event|0
6319779|NCT02795832|10056760|FG001|Overall Study|Adverse Event|0
6319780|NCT02795832|10056761|FG002|Overall Study|Adverse Event|0
6319781|NCT02795832|10056762|FG003|Overall Study|Adverse Event|0
6319782|NCT02795832|10056763|FG004|Overall Study|Adverse Event|0
6319783|NCT02795832|10056764|FG005|Overall Study|Adverse Event|3
6319784|NCT02796560|10056829|FG000|Overall Study|Adverse Event|2
6319785|NCT02796560|10056830|FG001|Overall Study|Adverse Event|0
6319786|NCT02796560|10056829|FG000|Overall Study|Withdrawal by Subject|2
6319787|NCT02796560|10056830|FG001|Overall Study|Withdrawal by Subject|2
6319788|NCT02796651|10056840|FG000|Overall Study|Adverse Event|6
6319789|NCT02796651|10056840|FG000|Overall Study|Lost to Follow-up|1
6319790|NCT02796651|10056840|FG000|Overall Study|Withdrawal by Subject|4
6319791|NCT02796651|10056840|FG000|Overall Study|Protocol Violation|4
6319792|NCT02796651|10056840|FG000|Overall Study|Lack of Efficacy|1
6319793|NCT02796651|10056840|FG000|Overall Study|Other|10
6319794|NCT02796664|10056857|FG000|Overall Study|Withdrawal by Subject|0
6319795|NCT02796664|10056858|FG001|Overall Study|Withdrawal by Subject|3
6319796|NCT02796664|10056857|FG000|Overall Study|Noncompliance|1
6319797|NCT02796664|10056858|FG001|Overall Study|Noncompliance|1
6319798|NCT02796664|10056857|FG000|Overall Study|Death|0
6319799|NCT02796664|10056858|FG001|Overall Study|Death|1
6319800|NCT02796677|10056870|FG000|Overall Study|Adverse Event|11
6319801|NCT02796677|10056871|FG001|Overall Study|Adverse Event|22
6319802|NCT02796677|10056872|FG002|Overall Study|Adverse Event|14
6319803|NCT02796677|10056873|FG003|Overall Study|Adverse Event|14
6319804|NCT02796677|10056870|FG000|Overall Study|Protocol Violation|7
6319805|NCT02796677|10056871|FG001|Overall Study|Protocol Violation|5
6319806|NCT02796677|10056872|FG002|Overall Study|Protocol Violation|4
6319807|NCT02796677|10056873|FG003|Overall Study|Protocol Violation|8
6319808|NCT02796677|10056870|FG000|Overall Study|Lost to Follow-up|1
6319809|NCT02796677|10056871|FG001|Overall Study|Lost to Follow-up|5
6319810|NCT02796677|10056872|FG002|Overall Study|Lost to Follow-up|2
6319811|NCT02796677|10056873|FG003|Overall Study|Lost to Follow-up|2
6319812|NCT02796677|10056870|FG000|Overall Study|Lack of Efficacy|7
6319813|NCT02796677|10056871|FG001|Overall Study|Lack of Efficacy|9
6319814|NCT02796677|10056872|FG002|Overall Study|Lack of Efficacy|14
6319815|NCT02796677|10056873|FG003|Overall Study|Lack of Efficacy|20
6319816|NCT02796677|10056870|FG000|Overall Study|Withdrawal by Subject|4
6319817|NCT02796677|10056871|FG001|Overall Study|Withdrawal by Subject|14
6319818|NCT02796677|10056872|FG002|Overall Study|Withdrawal by Subject|6
6319819|NCT02796677|10056873|FG003|Overall Study|Withdrawal by Subject|7
6319820|NCT02796677|10056870|FG000|Overall Study|Progressive disease|6
6319821|NCT02796677|10056871|FG001|Overall Study|Progressive disease|15
6319822|NCT02796677|10056872|FG002|Overall Study|Progressive disease|13
6319823|NCT02796677|10056873|FG003|Overall Study|Progressive disease|18
6319824|NCT02796677|10056870|FG000|Overall Study|Reason not mentioned|2
6319825|NCT02796677|10056871|FG001|Overall Study|Reason not mentioned|3
6319826|NCT02796677|10056872|FG002|Overall Study|Reason not mentioned|0
6319827|NCT02796677|10056873|FG003|Overall Study|Reason not mentioned|5
6319828|NCT02796755|10056887|FG000|Overall Study|Adverse Event|2
6319829|NCT02796755|10056888|FG001|Overall Study|Adverse Event|0
6319830|NCT02796963|10056902|FG000|Overall Study|Lost to Follow-up|89
6319831|NCT02796963|10056903|FG001|Overall Study|Lost to Follow-up|76
6319832|NCT02796963|10056904|FG002|Overall Study|Lost to Follow-up|69
6319833|NCT02796963|10056905|FG003|Overall Study|Lost to Follow-up|72
6319834|NCT02797080|10056928|FG000|Overall Study|Lost to Follow-up|1
6319835|NCT02797080|10056928|FG000|Overall Study|Withdrawal by Subject|1
6319836|NCT02797132|10056932|FG000|Part A (15 Days)|Adverse Event|1
6319837|NCT02797132|10056932|FG000|Part B (24 Weeks)|Adverse Event|3
6319838|NCT02797171|10056951|FG000|Overall Study|Lost to Follow-up|2
6319839|NCT02797171|10056952|FG001|Overall Study|Lost to Follow-up|0
6319840|NCT02797171|10056953|FG002|Overall Study|Lost to Follow-up|2
6319841|NCT02797171|10056954|FG003|Overall Study|Lost to Follow-up|1
6319842|NCT02797171|10056955|FG004|Overall Study|Lost to Follow-up|2
6319843|NCT02797171|10056956|FG005|Overall Study|Lost to Follow-up|0
6319844|NCT02797171|10056951|FG000|Overall Study|Withdrawal by Subject|1
6319845|NCT02797171|10056952|FG001|Overall Study|Withdrawal by Subject|1
6319846|NCT02797171|10056953|FG002|Overall Study|Withdrawal by Subject|0
6319847|NCT02797171|10056954|FG003|Overall Study|Withdrawal by Subject|0
6319848|NCT02797171|10056955|FG004|Overall Study|Withdrawal by Subject|0
6319849|NCT02797171|10056956|FG005|Overall Study|Withdrawal by Subject|0
6319850|NCT02797171|10056951|FG000|Overall Study|Protocol Violation|1
6319851|NCT02797171|10056952|FG001|Overall Study|Protocol Violation|0
6319852|NCT02797171|10056953|FG002|Overall Study|Protocol Violation|0
6319853|NCT02797171|10056954|FG003|Overall Study|Protocol Violation|0
6319854|NCT02797171|10056955|FG004|Overall Study|Protocol Violation|0
6319855|NCT02797171|10056956|FG005|Overall Study|Protocol Violation|0
6319856|NCT02797171|10056951|FG000|Overall Study|Participant unable to adhere|0
6319857|NCT02797171|10056952|FG001|Overall Study|Participant unable to adhere|1
6319858|NCT02797171|10056953|FG002|Overall Study|Participant unable to adhere|0
6319859|NCT02797171|10056954|FG003|Overall Study|Participant unable to adhere|0
6319860|NCT02797171|10056955|FG004|Overall Study|Participant unable to adhere|0
6040977|NCT00372593|9639054|FG002|Overall Study|Lost to Follow-up|0
6040978|NCT00372593|9639052|FG000|Overall Study|Physician Decision|42
6040979|NCT00372593|9639053|FG001|Overall Study|Physician Decision|41
6040980|NCT00372593|9639054|FG002|Overall Study|Physician Decision|0
6040981|NCT00372593|9639052|FG000|Overall Study|Ineligible|20
6040982|NCT00372593|9639053|FG001|Overall Study|Ineligible|21
6040983|NCT00372593|9639054|FG002|Overall Study|Ineligible|1
6040984|NCT00372619|9639070|FG000|Overall Study|Ineligible|0
6080335|NCT00615459|9687529|FG003|Period I|Adverse Event|0
6080336|NCT00615459|9687526|FG000|Period I|Subject withdrew consent|1
6080337|NCT00615459|9687527|FG001|Period I|Subject withdrew consent|0
6080338|NCT00615459|9687528|FG002|Period I|Subject withdrew consent|0
6080339|NCT00615459|9687529|FG003|Period I|Subject withdrew consent|1
6080340|NCT00615459|9687526|FG000|Period I|Abnormal test procedure results|1
6080341|NCT00615459|9687527|FG001|Period I|Abnormal test procedure results|1
6080342|NCT00615459|9687528|FG002|Period I|Abnormal test procedure results|1
6080343|NCT00615459|9687529|FG003|Period I|Abnormal test procedure results|0
6080344|NCT00615459|9687526|FG000|Period II|Adverse Event|1
6080345|NCT00615459|9687527|FG001|Period II|Adverse Event|0
6080346|NCT00615459|9687528|FG002|Period II|Adverse Event|0
6080347|NCT00615459|9687529|FG003|Period II|Adverse Event|0
6080348|NCT00615459|9687526|FG000|Period II|Lost to Follow-up|0
6080349|NCT00615459|9687527|FG001|Period II|Lost to Follow-up|0
6080350|NCT00615459|9687528|FG002|Period II|Lost to Follow-up|0
6080351|NCT00615459|9687529|FG003|Period II|Lost to Follow-up|1
6080352|NCT00615459|9687526|FG000|Period III|Adverse Event|0
6080353|NCT00615459|9687527|FG001|Period III|Adverse Event|1
6080354|NCT00615459|9687528|FG002|Period III|Adverse Event|0
6080355|NCT00615459|9687529|FG003|Period III|Adverse Event|0
6080356|NCT00615459|9687526|FG000|Period III|Administrative problems|0
6080357|NCT00615459|9687527|FG001|Period III|Administrative problems|1
6080358|NCT00615459|9687528|FG002|Period III|Administrative problems|1
6080359|NCT00615459|9687529|FG003|Period III|Administrative problems|0
6080360|NCT00615459|9687526|FG000|Period III|Unsatisfactory therapeutic effect|0
6080361|NCT00615459|9687527|FG001|Period III|Unsatisfactory therapeutic effect|1
6319861|NCT02797171|10056956|FG005|Overall Study|Participant unable to adhere|0
6319862|NCT02797171|10056951|FG000|Overall Study|Not Randomized|0
6319863|NCT02797171|10056952|FG001|Overall Study|Not Randomized|0
6319864|NCT02797171|10056953|FG002|Overall Study|Not Randomized|0
6319865|NCT02797171|10056954|FG003|Overall Study|Not Randomized|0
6319866|NCT02797171|10056955|FG004|Overall Study|Not Randomized|0
6319867|NCT02797171|10056956|FG005|Overall Study|Not Randomized|1
6319868|NCT02797522|10056981|FG000|Overall Study|Study Terminated by Sponsor|0
6319869|NCT02797522|10056982|FG001|Overall Study|Study Terminated by Sponsor|0
6319870|NCT02797522|10056983|FG002|Overall Study|Study Terminated by Sponsor|0
6319871|NCT02797522|10056984|FG003|Overall Study|Study Terminated by Sponsor|0
6319872|NCT02797522|10056985|FG004|Overall Study|Study Terminated by Sponsor|0
6319873|NCT02797522|10056986|FG005|Overall Study|Study Terminated by Sponsor|0
6319874|NCT02797522|10056987|FG006|Overall Study|Study Terminated by Sponsor|0
6319875|NCT02797522|10056988|FG007|Overall Study|Study Terminated by Sponsor|4
6319876|NCT02797522|10056989|FG008|Overall Study|Study Terminated by Sponsor|2
6319877|NCT02797522|10056990|FG009|Overall Study|Study Terminated by Sponsor|4
6319878|NCT02797522|10056991|FG010|Overall Study|Study Terminated by Sponsor|1
6319879|NCT02797678|10057028|FG000|Screening Phase|Meeting Inclusion/Exclusion criteria|25
6319880|NCT02797678|10057029|FG001|Screening Phase|Meeting Inclusion/Exclusion criteria|0
6319881|NCT02797678|10057030|FG002|Screening Phase|Meeting Inclusion/Exclusion criteria|0
6319882|NCT02797678|10057031|FG003|Screening Phase|Meeting Inclusion/Exclusion criteria|0
6319883|NCT02797678|10057028|FG000|First Intervention (5 Nights)|study/device use non-compliance|0
6319884|NCT02797678|10057029|FG001|First Intervention (5 Nights)|study/device use non-compliance|1
6319885|NCT02797678|10057030|FG002|First Intervention (5 Nights)|study/device use non-compliance|0
6319886|NCT02797678|10057031|FG003|First Intervention (5 Nights)|study/device use non-compliance|0
6319887|NCT02797678|10057028|FG000|Second Intervention (5 Nights)|study/device use non-compliance|0
6319888|NCT02797678|10057029|FG001|Second Intervention (5 Nights)|study/device use non-compliance|0
6319889|NCT02797678|10057030|FG002|Second Intervention (5 Nights)|study/device use non-compliance|1
6319890|NCT02797678|10057031|FG003|Second Intervention (5 Nights)|study/device use non-compliance|0
6319891|NCT02797808|10057046|FG000|Overall Study|Withdrawal by Subject|1
6319892|NCT02797808|10057047|FG001|Overall Study|Withdrawal by Subject|1
6319893|NCT02797808|10057046|FG000|Overall Study|Physician Decision|6
6319894|NCT02797808|10057047|FG001|Overall Study|Physician Decision|2
6319895|NCT02798211|10057069|FG000|Period 1|Adverse Event|1
6319896|NCT02798211|10057070|FG001|Period 1|Adverse Event|1
6319897|NCT02798211|10057071|FG002|Period 1|Adverse Event|0
6319898|NCT02798211|10057072|FG003|Period 1|Adverse Event|0
6319899|NCT02798211|10057073|FG004|Period 1|Adverse Event|0
6319900|NCT02798211|10057074|FG005|Period 1|Adverse Event|0
6319901|NCT02798211|10057069|FG000|Period 1|Lost to Follow-up|2
6319902|NCT02798211|10057070|FG001|Period 1|Lost to Follow-up|1
6319903|NCT02798211|10057071|FG002|Period 1|Lost to Follow-up|0
6319904|NCT02798211|10057072|FG003|Period 1|Lost to Follow-up|0
6319905|NCT02798211|10057073|FG004|Period 1|Lost to Follow-up|0
6319906|NCT02798211|10057074|FG005|Period 1|Lost to Follow-up|0
6319907|NCT02798211|10057069|FG000|Period 1|Protocol Violation|0
6319908|NCT02798211|10057070|FG001|Period 1|Protocol Violation|0
6319909|NCT02798211|10057071|FG002|Period 1|Protocol Violation|2
6319910|NCT02798211|10057072|FG003|Period 1|Protocol Violation|0
6319911|NCT02798211|10057073|FG004|Period 1|Protocol Violation|0
6319912|NCT02798211|10057074|FG005|Period 1|Protocol Violation|0
6319913|NCT02798211|10057069|FG000|Period 1|Withdrawal by Subject|1
6319914|NCT02798211|10057070|FG001|Period 1|Withdrawal by Subject|1
6319915|NCT02798211|10057071|FG002|Period 1|Withdrawal by Subject|0
6319916|NCT02798211|10057072|FG003|Period 1|Withdrawal by Subject|0
6319917|NCT02798211|10057073|FG004|Period 1|Withdrawal by Subject|0
6319918|NCT02798211|10057074|FG005|Period 1|Withdrawal by Subject|0
6319919|NCT02798211|10057069|FG000|Period 1|Death|0
6319920|NCT02798211|10057070|FG001|Period 1|Death|0
6319921|NCT02798211|10057071|FG002|Period 1|Death|1
6151892|NCT01115738|9788724|FG001|Overall Study|Death|0
6151893|NCT01115738|9788725|FG002|Overall Study|Death|0
6151894|NCT01115738|9788723|FG000|Overall Study|Lost to Follow-up|0
6151895|NCT01115738|9788724|FG001|Overall Study|Lost to Follow-up|0
6151896|NCT01115738|9788725|FG002|Overall Study|Lost to Follow-up|1
6151897|NCT01115738|9788723|FG000|Overall Study|Physician Decision|18
6151898|NCT01115738|9788724|FG001|Overall Study|Physician Decision|15
6151899|NCT01115738|9788725|FG002|Overall Study|Physician Decision|17
6151900|NCT01115738|9788723|FG000|Overall Study|Withdrawal by Subject|6
6151901|NCT01115738|9788724|FG001|Overall Study|Withdrawal by Subject|6
6151902|NCT01115738|9788725|FG002|Overall Study|Withdrawal by Subject|9
6151903|NCT01115803|9788748|FG000|Overall Study|Withdrawal by Subject|0
6151904|NCT01115803|9788749|FG001|Overall Study|Withdrawal by Subject|0
6151905|NCT01115803|9788750|FG002|Overall Study|Withdrawal by Subject|0
6151906|NCT01115803|9788751|FG003|Overall Study|Withdrawal by Subject|0
6151907|NCT01115803|9788752|FG004|Overall Study|Withdrawal by Subject|0
6151908|NCT01115803|9788753|FG005|Overall Study|Withdrawal by Subject|0
6151909|NCT01115803|9788754|FG006|Overall Study|Withdrawal by Subject|1
6151910|NCT01115803|9788748|FG000|Overall Study|Lost to Follow-up|0
6151911|NCT01115803|9788749|FG001|Overall Study|Lost to Follow-up|0
6151912|NCT01115803|9788750|FG002|Overall Study|Lost to Follow-up|1
6151913|NCT01115803|9788751|FG003|Overall Study|Lost to Follow-up|0
6319922|NCT02798211|10057072|FG003|Period 1|Death|0
6319923|NCT02798211|10057073|FG004|Period 1|Death|0
6319924|NCT02798211|10057074|FG005|Period 1|Death|0
6319925|NCT02798211|10057069|FG000|Period 1|Withdrawal of Informed Consent|2
6319926|NCT02798211|10057070|FG001|Period 1|Withdrawal of Informed Consent|7
6319927|NCT02798211|10057071|FG002|Period 1|Withdrawal of Informed Consent|3
6319928|NCT02798211|10057072|FG003|Period 1|Withdrawal of Informed Consent|0
6319929|NCT02798211|10057073|FG004|Period 1|Withdrawal of Informed Consent|0
6319930|NCT02798211|10057074|FG005|Period 1|Withdrawal of Informed Consent|0
6319931|NCT02798211|10057069|FG000|Period 2|Withdrawal by Subject|2
6319932|NCT02798211|10057070|FG001|Period 2|Withdrawal by Subject|0
6319933|NCT02798211|10057071|FG002|Period 2|Withdrawal by Subject|0
6319934|NCT02798211|10057072|FG003|Period 2|Withdrawal by Subject|0
6319935|NCT02798211|10057073|FG004|Period 2|Withdrawal by Subject|2
6319936|NCT02798211|10057074|FG005|Period 2|Withdrawal by Subject|2
6319937|NCT02798211|10057069|FG000|Period 2|Adverse Event|5
6319938|NCT02798211|10057070|FG001|Period 2|Adverse Event|0
6319939|NCT02798211|10057071|FG002|Period 2|Adverse Event|0
6319940|NCT02798211|10057072|FG003|Period 2|Adverse Event|0
6319941|NCT02798211|10057073|FG004|Period 2|Adverse Event|1
6319942|NCT02798211|10057074|FG005|Period 2|Adverse Event|0
6319943|NCT02798211|10057069|FG000|Period 2|Lack of Efficacy|1
6319944|NCT02798211|10057070|FG001|Period 2|Lack of Efficacy|0
6319945|NCT02798211|10057071|FG002|Period 2|Lack of Efficacy|0
6319946|NCT02798211|10057072|FG003|Period 2|Lack of Efficacy|1
6319947|NCT02798211|10057073|FG004|Period 2|Lack of Efficacy|0
6319948|NCT02798211|10057074|FG005|Period 2|Lack of Efficacy|1
6319949|NCT02798211|10057069|FG000|Period 2|Lost to Follow-up|3
6319950|NCT02798211|10057070|FG001|Period 2|Lost to Follow-up|0
6319951|NCT02798211|10057071|FG002|Period 2|Lost to Follow-up|0
6319952|NCT02798211|10057072|FG003|Period 2|Lost to Follow-up|0
6319953|NCT02798211|10057073|FG004|Period 2|Lost to Follow-up|2
6319954|NCT02798211|10057074|FG005|Period 2|Lost to Follow-up|0
6319955|NCT02798211|10057069|FG000|Period 2|Physician Decision|1
6319956|NCT02798211|10057070|FG001|Period 2|Physician Decision|0
6319957|NCT02798211|10057071|FG002|Period 2|Physician Decision|0
6319958|NCT02798211|10057072|FG003|Period 2|Physician Decision|1
6319959|NCT02798211|10057073|FG004|Period 2|Physician Decision|1
6319960|NCT02798211|10057074|FG005|Period 2|Physician Decision|0
6319961|NCT02798211|10057069|FG000|Period 2|Pregnancy|0
6319962|NCT02798211|10057070|FG001|Period 2|Pregnancy|0
6319963|NCT02798211|10057071|FG002|Period 2|Pregnancy|0
6319964|NCT02798211|10057072|FG003|Period 2|Pregnancy|2
6319965|NCT02798211|10057073|FG004|Period 2|Pregnancy|0
6319966|NCT02798211|10057074|FG005|Period 2|Pregnancy|0
6319967|NCT02798211|10057069|FG000|Period 2|Technical problems|1
6319968|NCT02798211|10057070|FG001|Period 2|Technical problems|0
6319969|NCT02798211|10057071|FG002|Period 2|Technical problems|0
6151914|NCT01115803|9788752|FG004|Overall Study|Lost to Follow-up|0
6151915|NCT01115803|9788753|FG005|Overall Study|Lost to Follow-up|0
6151916|NCT01115803|9788754|FG006|Overall Study|Lost to Follow-up|0
6151917|NCT01115803|9788748|FG000|Overall Study|Progressive Disease during Cycle1|0
6319970|NCT02798211|10057072|FG003|Period 2|Technical problems|1
6319971|NCT02798211|10057073|FG004|Period 2|Technical problems|0
6319972|NCT02798211|10057074|FG005|Period 2|Technical problems|0
6319973|NCT02798211|10057069|FG000|Period 2|Withdrawal of Informed Consent|1
6319974|NCT02798211|10057070|FG001|Period 2|Withdrawal of Informed Consent|0
6151918|NCT01115803|9788749|FG001|Overall Study|Progressive Disease during Cycle1|0
6151919|NCT01115803|9788750|FG002|Overall Study|Progressive Disease during Cycle1|0
6319975|NCT02798211|10057071|FG002|Period 2|Withdrawal of Informed Consent|0
6319976|NCT02798211|10057072|FG003|Period 2|Withdrawal of Informed Consent|2
6319977|NCT02798211|10057073|FG004|Period 2|Withdrawal of Informed Consent|2
6319978|NCT02798211|10057074|FG005|Period 2|Withdrawal of Informed Consent|3
6319979|NCT02798315|10057090|FG000|Overall Study|Failure to return|1
6319980|NCT02798835|10057129|FG000|Overall Study|Protocol Violation|0
6319981|NCT02798835|10057130|FG001|Overall Study|Protocol Violation|0
6319982|NCT02798835|10057131|FG002|Overall Study|Protocol Violation|3
6319983|NCT02798861|10057139|FG000|Overall Study|Lost to Follow-up|22
6319984|NCT02798861|10057139|FG000|Overall Study|Withdrawal by Subject|1
6319985|NCT02799069|10057185|FG000|Overall Study|Adverse Event|0
6319986|NCT02799069|10057186|FG001|Overall Study|Adverse Event|2
6319987|NCT02799069|10057187|FG002|Overall Study|Adverse Event|2
6319988|NCT02799069|10057185|FG000|Overall Study|Lack of Efficacy|2
6319989|NCT02799069|10057186|FG001|Overall Study|Lack of Efficacy|0
6319990|NCT02799069|10057187|FG002|Overall Study|Lack of Efficacy|0
6319991|NCT02799069|10057185|FG000|Overall Study|Lost to Follow-up|1
6319992|NCT02799069|10057186|FG001|Overall Study|Lost to Follow-up|1
6319993|NCT02799069|10057187|FG002|Overall Study|Lost to Follow-up|0
6319994|NCT02799069|10057185|FG000|Overall Study|Withdrawal by Subject|4
6319995|NCT02799069|10057186|FG001|Overall Study|Withdrawal by Subject|4
6319996|NCT02799069|10057187|FG002|Overall Study|Withdrawal by Subject|3
6319997|NCT02799069|10057185|FG000|Overall Study|Protocol Violation|1
6319998|NCT02799069|10057186|FG001|Overall Study|Protocol Violation|0
6319999|NCT02799069|10057187|FG002|Overall Study|Protocol Violation|2
6320000|NCT02799082|10057197|FG000|Overall Study|Refused second PDT or withdraw consent|4
6320001|NCT02799082|10057198|FG001|Overall Study|Refused second PDT or withdraw consent|3
6320002|NCT02799082|10057197|FG000|Overall Study|Protocol Violation|0
6320003|NCT02799082|10057198|FG001|Overall Study|Protocol Violation|1
6320004|NCT02799381|10057223|FG000|Overall Study|Withdrew consent|3
6320005|NCT02799381|10057224|FG001|Overall Study|Withdrew consent|2
6320006|NCT02799381|10057223|FG000|Overall Study|Adverse Event|0
6320007|NCT02799381|10057224|FG001|Overall Study|Adverse Event|1
6320008|NCT02799381|10057223|FG000|Overall Study|Participant did not take any study drug|1
6320009|NCT02799381|10057224|FG001|Overall Study|Participant did not take any study drug|0
6320010|NCT02799472|10057232|FG000|Overall Study|Withdrawal by Subject|2
6320011|NCT02799472|10057233|FG001|Overall Study|Withdrawal by Subject|4
6320012|NCT02799472|10057232|FG000|Overall Study|Lack of Efficacy|2
6320013|NCT02799472|10057233|FG001|Overall Study|Lack of Efficacy|0
6320014|NCT02799472|10057232|FG000|Overall Study|Lost to Follow-up|0
6320015|NCT02799472|10057233|FG001|Overall Study|Lost to Follow-up|1
6320016|NCT02799745|10057250|FG000|Overall Study|Participant moved out of state|1
6320017|NCT02799745|10057251|FG001|Overall Study|Participant moved out of state|0
6040985|NCT00372619|9639071|FG001|Overall Study|Ineligible|0
6040986|NCT00372619|9639072|FG002|Overall Study|Ineligible|0
6040987|NCT00372619|9639073|FG003|Overall Study|Ineligible|0
6040988|NCT00372619|9639074|FG004|Overall Study|Ineligible|0
6151920|NCT01115803|9788751|FG003|Overall Study|Progressive Disease during Cycle1|0
6151921|NCT01115803|9788752|FG004|Overall Study|Progressive Disease during Cycle1|0
6151922|NCT01115803|9788753|FG005|Overall Study|Progressive Disease during Cycle1|0
6151923|NCT01115803|9788754|FG006|Overall Study|Progressive Disease during Cycle1|1
6151924|NCT01115855|9788777|FG000|Overall Study|Adverse Event|16
6151925|NCT01115855|9788778|FG001|Overall Study|Adverse Event|18
6151926|NCT01115855|9788777|FG000|Overall Study|Death|6
6151927|NCT01115855|9788778|FG001|Overall Study|Death|5
6151928|NCT01115855|9788777|FG000|Overall Study|Lab Abnormality|1
6151929|NCT01115855|9788778|FG001|Overall Study|Lab Abnormality|1
6151930|NCT01115855|9788777|FG000|Overall Study|Protocol Violation|0
6151931|NCT01115855|9788778|FG001|Overall Study|Protocol Violation|1
6151932|NCT01115855|9788777|FG000|Overall Study|Withdrawal by Subject|5
6151933|NCT01115855|9788778|FG001|Overall Study|Withdrawal by Subject|5
6151934|NCT01115855|9788777|FG000|Overall Study|Other|8
6151935|NCT01115855|9788778|FG001|Overall Study|Other|6
6151936|NCT01115933|9788784|FG000|Overall Study|Did not receive XIENCE PRIME SV|1
6151937|NCT01115998|9788843|FG000|Overall Study|Lost to Follow-up|6
6151938|NCT01115998|9788844|FG001|Overall Study|Lost to Follow-up|6
6151939|NCT01116427|9788919|FG000|Core Phase|Adverse Event|0
6151940|NCT01116427|9788920|FG001|Core Phase|Adverse Event|1
6151941|NCT01116427|9788919|FG000|Core Phase|Lost to Follow-up|1
6151942|NCT01116427|9788920|FG001|Core Phase|Lost to Follow-up|0
6151943|NCT01116427|9788919|FG000|Core Phase|Withdrawal by Subject|3
6151944|NCT01116427|9788920|FG001|Core Phase|Withdrawal by Subject|0
6151945|NCT01116427|9788919|FG000|Core Phase|Worsening Multiple Sclerosis|1
6151946|NCT01116427|9788920|FG001|Core Phase|Worsening Multiple Sclerosis|0
6151947|NCT01116427|9788919|FG000|Extension Phase|Adverse Event|1
6320018|NCT02799745|10057250|FG000|Overall Study|Discontinued due to planned surgery|1
6040989|NCT00372619|9639075|FG005|Overall Study|Ineligible|2
6040990|NCT00372619|9639076|FG006|Overall Study|Ineligible|0
6040991|NCT00372619|9639070|FG000|Overall Study|Inevaluable|0
6040992|NCT00372619|9639071|FG001|Overall Study|Inevaluable|0
6040993|NCT00372619|9639072|FG002|Overall Study|Inevaluable|0
6040994|NCT00372619|9639073|FG003|Overall Study|Inevaluable|0
6040995|NCT00372619|9639074|FG004|Overall Study|Inevaluable|0
6040996|NCT00372619|9639075|FG005|Overall Study|Inevaluable|1
6151948|NCT01116427|9788920|FG001|Extension Phase|Adverse Event|1
6151949|NCT01116427|9788919|FG000|Extension Phase|Lost to Follow-up|2
6151950|NCT01116427|9788920|FG001|Extension Phase|Lost to Follow-up|0
6320019|NCT02799745|10057251|FG001|Overall Study|Discontinued due to planned surgery|0
6320020|NCT02799745|10057250|FG000|Overall Study|Withdrawal by Subject|16
6320021|NCT02799745|10057251|FG001|Overall Study|Withdrawal by Subject|25
6040997|NCT00372619|9639076|FG006|Overall Study|Inevaluable|0
6040998|NCT00372697|9639094|FG000|Overall Study|Protocol Violation|1
6040999|NCT00372697|9639095|FG001|Overall Study|Protocol Violation|1
6041000|NCT00372775|9639101|FG000|Overall Study|Adverse Event|8
6041001|NCT00372775|9639101|FG000|Overall Study|Death|15
6041002|NCT00372775|9639101|FG000|Overall Study|Objective progression or relapse|30
6041003|NCT00372775|9639101|FG000|Overall Study|Global deterioration of health status|6
6041004|NCT00372775|9639101|FG000|Overall Study|Withdrawal by Subject|1
6041005|NCT00372775|9639101|FG000|Overall Study|Other|1
6041006|NCT00372775|9639101|FG000|Overall Study|Not Treated|2
6041007|NCT00372905|9639105|FG000|Cohort 1: Dose Level 1.0mg/m2|Progressive Disease|2
6041008|NCT00372905|9639106|FG001|Cohort 1: Dose Level 1.0mg/m2|Progressive Disease|0
6041009|NCT00372905|9639107|FG002|Cohort 1: Dose Level 1.0mg/m2|Progressive Disease|0
6041010|NCT00372905|9639108|FG003|Cohort 1: Dose Level 1.0mg/m2|Progressive Disease|0
6041011|NCT00372905|9639105|FG000|Cohort 3: Dose Level 1.6mg/m2|Adverse Event|0
6041012|NCT00372905|9639106|FG001|Cohort 3: Dose Level 1.6mg/m2|Adverse Event|0
6041013|NCT00372905|9639107|FG002|Cohort 3: Dose Level 1.6mg/m2|Adverse Event|2
6041014|NCT00372905|9639108|FG003|Cohort 3: Dose Level 1.6mg/m2|Adverse Event|0
6041015|NCT00372905|9639105|FG000|Cohort 3: Dose Level 1.6mg/m2|Withdrawal by Subject|0
6041016|NCT00372905|9639106|FG001|Cohort 3: Dose Level 1.6mg/m2|Withdrawal by Subject|0
6041017|NCT00372905|9639107|FG002|Cohort 3: Dose Level 1.6mg/m2|Withdrawal by Subject|1
6041018|NCT00372905|9639108|FG003|Cohort 3: Dose Level 1.6mg/m2|Withdrawal by Subject|0
6041019|NCT00372905|9639105|FG000|Expansion Phase at Dose 1.3mg/m2|Adverse Event|0
6041020|NCT00372905|9639106|FG001|Expansion Phase at Dose 1.3mg/m2|Adverse Event|0
6041021|NCT00372905|9639107|FG002|Expansion Phase at Dose 1.3mg/m2|Adverse Event|0
6041022|NCT00372905|9639108|FG003|Expansion Phase at Dose 1.3mg/m2|Adverse Event|2
6041023|NCT00372905|9639105|FG000|Follow up Until Relapse or Progression|Study closed|0
6041024|NCT00372905|9639106|FG001|Follow up Until Relapse or Progression|Study closed|0
6041025|NCT00372905|9639107|FG002|Follow up Until Relapse or Progression|Study closed|0
6041026|NCT00372905|9639108|FG003|Follow up Until Relapse or Progression|Study closed|3
6041027|NCT00372905|9639105|FG000|Follow up Until Relapse or Progression|Other|0
6041028|NCT00372905|9639106|FG001|Follow up Until Relapse or Progression|Other|1
6041029|NCT00372905|9639107|FG002|Follow up Until Relapse or Progression|Other|0
6041030|NCT00372905|9639108|FG003|Follow up Until Relapse or Progression|Other|0
6041031|NCT00372996|9639144|FG000|Overall Study|Death|11
6041032|NCT00372996|9639145|FG001|Overall Study|Death|4
6041033|NCT00372996|9639146|FG002|Overall Study|Death|8
6041034|NCT00372996|9639147|FG003|Overall Study|Death|7
6041035|NCT00372996|9639144|FG000|Overall Study|Lost to Follow-up|0
6041036|NCT00372996|9639145|FG001|Overall Study|Lost to Follow-up|2
6041037|NCT00372996|9639146|FG002|Overall Study|Lost to Follow-up|0
6041038|NCT00372996|9639147|FG003|Overall Study|Lost to Follow-up|1
6041039|NCT00372996|9639144|FG000|Overall Study|Withdrawal by Subject|12
6041040|NCT00372996|9639145|FG001|Overall Study|Withdrawal by Subject|6
6041041|NCT00372996|9639146|FG002|Overall Study|Withdrawal by Subject|9
6041042|NCT00372996|9639147|FG003|Overall Study|Withdrawal by Subject|5
6041043|NCT00372996|9639144|FG000|Overall Study|Study Terminated by Sponsor|4
6041044|NCT00372996|9639145|FG001|Overall Study|Study Terminated by Sponsor|0
6041045|NCT00372996|9639146|FG002|Overall Study|Study Terminated by Sponsor|4
6041046|NCT00372996|9639147|FG003|Overall Study|Study Terminated by Sponsor|0
6041047|NCT00372996|9639144|FG000|Overall Study|Other|10
6041048|NCT00372996|9639145|FG001|Overall Study|Other|2
6041049|NCT00372996|9639146|FG002|Overall Study|Other|7
6041050|NCT00372996|9639147|FG003|Overall Study|Other|7
6041051|NCT00373113|9639159|FG000|Overall Study|Death|1
6041052|NCT00373113|9639160|FG001|Overall Study|Death|7
6041053|NCT00373113|9639159|FG000|Overall Study|Adverse Event|38
6041054|NCT00373113|9639160|FG001|Overall Study|Adverse Event|24
6041055|NCT00373113|9639159|FG000|Overall Study|Study terminated by sponsor|9
6041056|NCT00373113|9639160|FG001|Overall Study|Study terminated by sponsor|1
6041057|NCT00373113|9639159|FG000|Overall Study|Global deterioration of health status|10
6041058|NCT00373113|9639160|FG001|Overall Study|Global deterioration of health status|7
6041059|NCT00373113|9639159|FG000|Overall Study|Lost to Follow-up|1
6041060|NCT00373113|9639160|FG001|Overall Study|Lost to Follow-up|3
6041061|NCT00373113|9639159|FG000|Overall Study|Objective progression or relapse|150
6041062|NCT00373113|9639160|FG001|Overall Study|Objective progression or relapse|169
6041063|NCT00373113|9639159|FG000|Overall Study|Other|14
6041064|NCT00373113|9639160|FG001|Overall Study|Other|17
6041065|NCT00373113|9639159|FG000|Overall Study|Protocol Violation|5
6041066|NCT00373113|9639160|FG001|Overall Study|Protocol Violation|1
6041067|NCT00373113|9639159|FG000|Overall Study|Withdrawal by Subject|10
6041068|NCT00373113|9639160|FG001|Overall Study|Withdrawal by Subject|15
6041069|NCT00373256|9639168|FG000|Overall Study|Adverse Event (AE)|1
6041070|NCT00373256|9639169|FG001|Overall Study|Adverse Event (AE)|5
6041071|NCT00373256|9639168|FG000|Overall Study|Lost to Follow-up|2
6041072|NCT00373256|9639169|FG001|Overall Study|Lost to Follow-up|1
6041073|NCT00373256|9639168|FG000|Overall Study|Death|9
6041074|NCT00373256|9639169|FG001|Overall Study|Death|8
6041075|NCT00373256|9639168|FG000|Overall Study|Objective Progression or Relapse|111
6041076|NCT00373256|9639169|FG001|Overall Study|Objective Progression or Relapse|104
6041077|NCT00373256|9639168|FG000|Overall Study|Refused Treatment-Reason Other Than AE|4
6049006|NCT00420927|9648204|FG005|Period 2|Sponsor decision|0
6041078|NCT00373256|9639169|FG001|Overall Study|Refused Treatment-Reason Other Than AE|7
6041079|NCT00373256|9639168|FG000|Overall Study|Other|73
6041080|NCT00373256|9639169|FG001|Overall Study|Other|107
6041081|NCT00373256|9639168|FG000|Overall Study|Protocol Violation|0
6041082|NCT00373256|9639169|FG001|Overall Study|Protocol Violation|2
6041083|NCT00373256|9639168|FG000|Overall Study|Study Terminated by Sponsor|41
6041084|NCT00373256|9639169|FG001|Overall Study|Study Terminated by Sponsor|13
6041085|NCT00373295|9639184|FG000|Intervention 1 (8 Days)|Withdrawal by Subject|0
6041086|NCT00373295|9639185|FG001|Intervention 1 (8 Days)|Withdrawal by Subject|2
6041087|NCT00373295|9639186|FG002|Intervention 1 (8 Days)|Withdrawal by Subject|0
6041088|NCT00373295|9639187|FG003|Intervention 1 (8 Days)|Withdrawal by Subject|0
6041089|NCT00373295|9639188|FG004|Intervention 1 (8 Days)|Withdrawal by Subject|1
6041090|NCT00373295|9639189|FG005|Intervention 1 (8 Days)|Withdrawal by Subject|0
6041091|NCT00373425|9639238|FG000|Overall Study|Relapse of NSCLC|116
6041092|NCT00373425|9639239|FG001|Overall Study|Relapse of NSCLC|104
6320022|NCT02799745|10057250|FG000|Overall Study|Protocol Deviation|4
6320023|NCT02799745|10057251|FG001|Overall Study|Protocol Deviation|5
6320024|NCT02799745|10057250|FG000|Overall Study|Progressive Disease|28
6320025|NCT02799745|10057251|FG001|Overall Study|Progressive Disease|38
6320026|NCT02799745|10057250|FG000|Overall Study|Lost to Follow-up|3
6320027|NCT02799745|10057251|FG001|Overall Study|Lost to Follow-up|2
6320028|NCT02799745|10057250|FG000|Overall Study|Death|3
6320029|NCT02799745|10057251|FG001|Overall Study|Death|0
6320030|NCT02799745|10057250|FG000|Overall Study|Adverse Event|0
6320031|NCT02799745|10057251|FG001|Overall Study|Adverse Event|1
6320032|NCT02799784|10057257|FG000|Treatment Period 1 (TP1- 8 Weeks)|Lost to Follow-up|1
6320033|NCT02799784|10057258|FG001|Treatment Period 1 (TP1- 8 Weeks)|Lost to Follow-up|1
6320034|NCT02799784|10057257|FG000|Treatment Period 1 (TP1- 8 Weeks)|Withdrawal by Subject|5
6320035|NCT02799784|10057258|FG001|Treatment Period 1 (TP1- 8 Weeks)|Withdrawal by Subject|0
6320036|NCT02799784|10057257|FG000|Treatment Period 2 (TP2 - 8 Weeks)|Adverse Event|0
6320037|NCT02799784|10057258|FG001|Treatment Period 2 (TP2 - 8 Weeks)|Adverse Event|1
6041093|NCT00373425|9639240|FG002|Overall Study|Relapse of NSCLC|19
6041094|NCT00373425|9639241|FG003|Overall Study|Relapse of NSCLC|2
6041095|NCT00373425|9639242|FG004|Overall Study|Relapse of NSCLC|26
6041096|NCT00373425|9639238|FG000|Overall Study|Adverse Event|191
6320038|NCT02799784|10057257|FG000|Treatment Period 2 (TP2 - 8 Weeks)|Par. reached protocol stopping criteria|1
6320039|NCT02799784|10057258|FG001|Treatment Period 2 (TP2 - 8 Weeks)|Par. reached protocol stopping criteria|0
6320040|NCT02799784|10057257|FG000|Treatment Period 2 (TP2 - 8 Weeks)|Lost to Follow-up|0
6320041|NCT02799784|10057258|FG001|Treatment Period 2 (TP2 - 8 Weeks)|Lost to Follow-up|1
6320042|NCT02799784|10057257|FG000|Treatment Period 2 (TP2 - 8 Weeks)|Withdrawal by Subject|0
6320043|NCT02799784|10057258|FG001|Treatment Period 2 (TP2 - 8 Weeks)|Withdrawal by Subject|1
6320044|NCT02800642|10057290|FG000|Overall Study|Death|3
6320045|NCT02800642|10057290|FG000|Overall Study|Other|10
6320046|NCT02800642|10057290|FG000|Overall Study|Physician Decision|2
6320047|NCT02800642|10057290|FG000|Overall Study|Adverse Event|6
6320048|NCT02800642|10057290|FG000|Overall Study|Withdrawal by Subject|3
6320049|NCT02800642|10057290|FG000|Overall Study|Lost to Follow-up|1
6320050|NCT02800928|10057294|FG000|Overall Study|Withdrawal by Subject|1
6320051|NCT02800928|10057295|FG001|Overall Study|Withdrawal by Subject|1
6320052|NCT02800928|10057294|FG000|Overall Study|Protocol Violation|1
6320053|NCT02800928|10057295|FG001|Overall Study|Protocol Violation|1
6320054|NCT02801396|10057320|FG000|Period 1|Withdrawal by Subject|0
6320055|NCT02801396|10057321|FG001|Period 1|Withdrawal by Subject|0
6320056|NCT02801396|10057322|FG002|Period 1|Withdrawal by Subject|0
6320057|NCT02801396|10057323|FG003|Period 1|Withdrawal by Subject|0
6320058|NCT02801396|10057324|FG004|Period 1|Withdrawal by Subject|1
6320059|NCT02801396|10057325|FG005|Period 1|Withdrawal by Subject|0
6320060|NCT02801578|10057333|FG000|Overall Study|Adverse Event|2
6320061|NCT02801617|10057339|FG000|Overall Study|Protocol Violation|2
6320062|NCT02801617|10057340|FG001|Overall Study|Protocol Violation|6
6320063|NCT02801669|10057352|FG000|Overall Study|Death|66
6320064|NCT02801669|10057353|FG001|Overall Study|Death|69
6320065|NCT02801669|10057352|FG000|Overall Study|Withdrawal by Subject|81
6320066|NCT02801669|10057353|FG001|Overall Study|Withdrawal by Subject|77
6320067|NCT02801669|10057352|FG000|Overall Study|Other|4
6041097|NCT00373425|9639239|FG001|Overall Study|Adverse Event|22
6041098|NCT00373425|9639240|FG002|Overall Study|Adverse Event|59
6041099|NCT00373425|9639241|FG003|Overall Study|Adverse Event|0
6041100|NCT00373425|9639242|FG004|Overall Study|Adverse Event|34
6041101|NCT00373425|9639238|FG000|Overall Study|Patient request|35
6041102|NCT00373425|9639239|FG001|Overall Study|Patient request|18
6320068|NCT02801669|10057353|FG001|Overall Study|Other|6
6320069|NCT02801877|10057363|FG000|Overall Study|Lost to Follow-up|1
6320070|NCT02801877|10057364|FG001|Overall Study|Lost to Follow-up|1
6320071|NCT02801877|10057365|FG002|Overall Study|Lost to Follow-up|2
6320072|NCT02801877|10057366|FG003|Overall Study|Lost to Follow-up|0
6320073|NCT02801877|10057363|FG000|Overall Study|Never Started Treatment|2
6320074|NCT02801877|10057364|FG001|Overall Study|Never Started Treatment|0
6320075|NCT02801877|10057365|FG002|Overall Study|Never Started Treatment|4
6320076|NCT02801877|10057366|FG003|Overall Study|Never Started Treatment|0
6320077|NCT02802319|10057413|FG000|Overall Study|Physician Decision|2
6320078|NCT02802319|10057414|FG001|Overall Study|Physician Decision|1
6320079|NCT02802319|10057413|FG000|Overall Study|Lost to Follow-up|0
6320080|NCT02802319|10057414|FG001|Overall Study|Lost to Follow-up|4
6320081|NCT02802345|10057422|FG000|Overall Study|Not Treated|0
6320082|NCT02802345|10057423|FG001|Overall Study|Not Treated|1
6320083|NCT02802345|10057422|FG000|Overall Study|Adverse Event|28
6320084|NCT02802345|10057423|FG001|Overall Study|Adverse Event|20
6320085|NCT02802345|10057422|FG000|Overall Study|Withdrawal by Subject|3
6320086|NCT02802345|10057423|FG001|Overall Study|Withdrawal by Subject|3
6320087|NCT02802345|10057422|FG000|Overall Study|Protocol Violation|0
6320088|NCT02802345|10057423|FG001|Overall Study|Protocol Violation|1
6320089|NCT02802345|10057422|FG000|Overall Study|Other than listed|1
6320090|NCT02802345|10057423|FG001|Overall Study|Other than listed|5
6320091|NCT02802735|10057475|FG000|Overall Study|Withdrawal by Subject|0
6320092|NCT02802735|10057476|FG001|Overall Study|Withdrawal by Subject|1
6320093|NCT02802735|10057477|FG002|Overall Study|Withdrawal by Subject|0
6320094|NCT02802735|10057478|FG003|Overall Study|Withdrawal by Subject|0
6320095|NCT02802735|10057479|FG004|Overall Study|Withdrawal by Subject|0
6320096|NCT02802865|10057496|FG000|Overall Study|Pregnancy|1
6320097|NCT02802865|10057497|FG001|Overall Study|Pregnancy|1
6320098|NCT02802865|10057496|FG000|Overall Study|Ineliegible due to tuberculosis|0
6320099|NCT02802865|10057497|FG001|Overall Study|Ineliegible due to tuberculosis|1
6320100|NCT02802878|10057505|FG000|Overall Study|Withdrawal by Subject|3
6320101|NCT02802878|10057506|FG001|Overall Study|Withdrawal by Subject|3
6320102|NCT02802878|10057505|FG000|Overall Study|Protocol Violation|1
6320103|NCT02802878|10057506|FG001|Overall Study|Protocol Violation|0
6320104|NCT02803138|10057512|FG000|Overall Study|Failure to return|38
6320105|NCT02803138|10057512|FG000|Overall Study|Insufficient virological response|2
6320106|NCT02803138|10057512|FG000|Overall Study|Withdrawn consent|1
6320107|NCT02803138|10057512|FG000|Overall Study|Death|1
6320108|NCT02803138|10057512|FG000|Overall Study|Other, not specified|28
6320109|NCT02803580|10057538|FG000|Overall Study|Death|13
6320110|NCT02803580|10057538|FG000|Overall Study|Lost to Follow-up|19
6320111|NCT02803580|10057538|FG000|Overall Study|Withdrawal by Subject|3
6320112|NCT02803580|10057538|FG000|Overall Study|Inclusion in clinical trial|1
6320113|NCT02804178|10057551|FG000|Overall Study|Adverse Event|1
6320114|NCT02804399|10057555|FG000|Period 2|Adverse Event|0
6320115|NCT02804399|10057556|FG001|Period 2|Adverse Event|1
6320116|NCT02804750|10057576|FG000|Period 1|Adverse Event|0
6320117|NCT02804750|10057577|FG001|Period 1|Adverse Event|2
6320118|NCT02804750|10057576|FG000|Period 1|Withdrawal by Subject|0
6320119|NCT02804750|10057577|FG001|Period 1|Withdrawal by Subject|1
6320120|NCT02804750|10057576|FG000|Period 2|Adverse Event|1
6320121|NCT02804750|10057577|FG001|Period 2|Adverse Event|0
6320122|NCT02804750|10057576|FG000|Period 3|Adverse Event|0
6320123|NCT02804750|10057577|FG001|Period 3|Adverse Event|2
6320124|NCT02804750|10057576|FG000|Period 4|Adverse Event|0
6320125|NCT02804750|10057577|FG001|Period 4|Adverse Event|5
6320126|NCT02804763|10057589|FG000|Double-Blind Period (Week 1 to Week 24)|Adverse Event|1
6320127|NCT02804763|10057590|FG001|Double-Blind Period (Week 1 to Week 24)|Adverse Event|0
6320128|NCT02804763|10057591|FG002|Double-Blind Period (Week 1 to Week 24)|Adverse Event|0
6320129|NCT02804763|10057592|FG003|Double-Blind Period (Week 1 to Week 24)|Adverse Event|0
6320130|NCT02804763|10057589|FG000|Double-Blind Period (Week 1 to Week 24)|Withdrawal by Subject|0
6320131|NCT02804763|10057590|FG001|Double-Blind Period (Week 1 to Week 24)|Withdrawal by Subject|0
6320132|NCT02804763|10057591|FG002|Double-Blind Period (Week 1 to Week 24)|Withdrawal by Subject|1
6320133|NCT02804763|10057592|FG003|Double-Blind Period (Week 1 to Week 24)|Withdrawal by Subject|2
6041103|NCT00373425|9639240|FG002|Overall Study|Patient request|43
6041104|NCT00373425|9639241|FG003|Overall Study|Patient request|6
6041105|NCT00373425|9639242|FG004|Overall Study|Patient request|7
6041106|NCT00373425|9639238|FG000|Overall Study|Medical/ethical/noncompliance reason|21
6041107|NCT00373425|9639239|FG001|Overall Study|Medical/ethical/noncompliance reason|9
6041108|NCT00373425|9639240|FG002|Overall Study|Medical/ethical/noncompliance reason|10
6041109|NCT00373425|9639241|FG003|Overall Study|Medical/ethical/noncompliance reason|2
6041110|NCT00373425|9639242|FG004|Overall Study|Medical/ethical/noncompliance reason|5
6041111|NCT00373425|9639238|FG000|Overall Study|Death|7
6041112|NCT00373425|9639239|FG001|Overall Study|Death|0
6041113|NCT00373425|9639240|FG002|Overall Study|Death|3
6041114|NCT00373425|9639241|FG003|Overall Study|Death|1
6041115|NCT00373425|9639242|FG004|Overall Study|Death|0
6041116|NCT00373490|9639253|FG000|Overall Study|Adverse Event|0
6041117|NCT00373490|9639254|FG001|Overall Study|Adverse Event|1
6041118|NCT00373490|9639253|FG000|Overall Study|Lack of Efficacy|9
6041119|NCT00373490|9639254|FG001|Overall Study|Lack of Efficacy|4
6041120|NCT00373490|9639253|FG000|Overall Study|Withdrawal by Subject|0
6041121|NCT00373490|9639254|FG001|Overall Study|Withdrawal by Subject|1
6041122|NCT00373529|9639260|FG000|Overall Study|Physician Decision|19
6041123|NCT00373529|9639260|FG000|Overall Study|Withdrawal by Subject|7
6041124|NCT00373529|9639260|FG000|Overall Study|Adverse Event|7
6041125|NCT00373529|9639260|FG000|Overall Study|Treatment failure|36
6041126|NCT00373529|9639260|FG000|Overall Study|Disease recurrence|10
6041127|NCT00373529|9639260|FG000|Overall Study|Death|16
6041128|NCT00373529|9639260|FG000|Overall Study|Need for treatment prohibited by study|1
6320134|NCT02804763|10057589|FG000|Double-Blind Period (Week 1 to Week 24)|Consent withdrawal after Week 24|0
6320135|NCT02804763|10057590|FG001|Double-Blind Period (Week 1 to Week 24)|Consent withdrawal after Week 24|1
6320136|NCT02804763|10057591|FG002|Double-Blind Period (Week 1 to Week 24)|Consent withdrawal after Week 24|0
6320137|NCT02804763|10057592|FG003|Double-Blind Period (Week 1 to Week 24)|Consent withdrawal after Week 24|0
6320138|NCT02804763|10057589|FG000|Observational Period (Wk 24 to Wk 48)|Lost to Follow-up|2
6320139|NCT02804763|10057590|FG001|Observational Period (Wk 24 to Wk 48)|Lost to Follow-up|0
6320140|NCT02804763|10057591|FG002|Observational Period (Wk 24 to Wk 48)|Lost to Follow-up|1
6320141|NCT02804763|10057592|FG003|Observational Period (Wk 24 to Wk 48)|Lost to Follow-up|1
6320142|NCT02804763|10057589|FG000|Observational Period (Wk 24 to Wk 48)|Withdrawal by Subject|4
6320143|NCT02804763|10057590|FG001|Observational Period (Wk 24 to Wk 48)|Withdrawal by Subject|0
6320144|NCT02804763|10057591|FG002|Observational Period (Wk 24 to Wk 48)|Withdrawal by Subject|2
6320145|NCT02804763|10057592|FG003|Observational Period (Wk 24 to Wk 48)|Withdrawal by Subject|2
6320146|NCT02804763|10057589|FG000|Observational Period (Wk 24 to Wk 48)|Patient moved out of state|0
6320147|NCT02804763|10057590|FG001|Observational Period (Wk 24 to Wk 48)|Patient moved out of state|1
6320148|NCT02804763|10057591|FG002|Observational Period (Wk 24 to Wk 48)|Patient moved out of state|0
6320149|NCT02804763|10057592|FG003|Observational Period (Wk 24 to Wk 48)|Patient moved out of state|0
6320150|NCT02805309|10057613|FG000|Overall Study|Lost to Follow-up|2
6320151|NCT02805309|10057614|FG001|Overall Study|Lost to Follow-up|2
6320152|NCT02805309|10057615|FG002|Overall Study|Lost to Follow-up|2
6320153|NCT02805309|10057613|FG000|Overall Study|Post-Randomization Exclusion|0
6320154|NCT02805309|10057614|FG001|Overall Study|Post-Randomization Exclusion|2
6320155|NCT02805309|10057615|FG002|Overall Study|Post-Randomization Exclusion|1
6320156|NCT02805660|10057639|FG000|Overall Study|Death|5
6320157|NCT02805660|10057640|FG001|Overall Study|Death|2
6320158|NCT02805660|10057641|FG002|Overall Study|Death|9
6320159|NCT02805660|10057642|FG003|Overall Study|Death|5
6320160|NCT02805660|10057643|FG004|Overall Study|Death|0
6320161|NCT02805660|10057644|FG005|Overall Study|Death|14
6320162|NCT02805660|10057645|FG006|Overall Study|Death|12
6320163|NCT02805660|10057639|FG000|Overall Study|Lost to Follow-up|0
6320164|NCT02805660|10057640|FG001|Overall Study|Lost to Follow-up|1
6320165|NCT02805660|10057641|FG002|Overall Study|Lost to Follow-up|1
6320166|NCT02805660|10057642|FG003|Overall Study|Lost to Follow-up|2
6320167|NCT02805660|10057643|FG004|Overall Study|Lost to Follow-up|0
6320168|NCT02805660|10057644|FG005|Overall Study|Lost to Follow-up|0
6320169|NCT02805660|10057645|FG006|Overall Study|Lost to Follow-up|0
6320170|NCT02805660|10057639|FG000|Overall Study|Withdrawal by Subject|0
6320171|NCT02805660|10057640|FG001|Overall Study|Withdrawal by Subject|0
6320172|NCT02805660|10057641|FG002|Overall Study|Withdrawal by Subject|0
6320173|NCT02805660|10057642|FG003|Overall Study|Withdrawal by Subject|3
6320174|NCT02805660|10057643|FG004|Overall Study|Withdrawal by Subject|1
6320175|NCT02805660|10057644|FG005|Overall Study|Withdrawal by Subject|0
6320176|NCT02805660|10057645|FG006|Overall Study|Withdrawal by Subject|2
6320177|NCT02805660|10057639|FG000|Overall Study|Study terminated by Sponsor|0
6320178|NCT02805660|10057640|FG001|Overall Study|Study terminated by Sponsor|0
6320179|NCT02805660|10057641|FG002|Overall Study|Study terminated by Sponsor|1
6320180|NCT02805660|10057642|FG003|Overall Study|Study terminated by Sponsor|4
6320181|NCT02805660|10057643|FG004|Overall Study|Study terminated by Sponsor|2
6320182|NCT02805660|10057644|FG005|Overall Study|Study terminated by Sponsor|3
6320183|NCT02805660|10057645|FG006|Overall Study|Study terminated by Sponsor|1
6320184|NCT02805660|10057639|FG000|Overall Study|Miscellaneous|0
6320185|NCT02805660|10057640|FG001|Overall Study|Miscellaneous|1
6320186|NCT02805660|10057641|FG002|Overall Study|Miscellaneous|0
6320187|NCT02805660|10057642|FG003|Overall Study|Miscellaneous|4
6320188|NCT02805660|10057643|FG004|Overall Study|Miscellaneous|0
6320189|NCT02805660|10057644|FG005|Overall Study|Miscellaneous|6
6320190|NCT02805660|10057645|FG006|Overall Study|Miscellaneous|4
6320191|NCT02805790|10057676|FG000|Second Intervention (4 Weeks)|Physician Decision|0
6320192|NCT02805790|10057677|FG001|Second Intervention (4 Weeks)|Physician Decision|1
6320193|NCT02805907|10057685|FG000|Overall Study|Lost to Follow-up|3
6320194|NCT02805907|10057686|FG001|Overall Study|Lost to Follow-up|3
6320195|NCT02805972|10057694|FG000|Washout Period|Lost to Follow-up|3
6320196|NCT02805972|10057695|FG001|Washout Period|Lost to Follow-up|0
6320197|NCT02806024|10057713|FG000|Overall Study|Night Delivery|1
6320198|NCT02806024|10057714|FG001|Overall Study|Night Delivery|1
6320199|NCT02806024|10057713|FG000|Overall Study|DVT during antepartum admission|0
6320200|NCT02806024|10057714|FG001|Overall Study|DVT during antepartum admission|1
6320201|NCT02806232|10057729|FG000|Overall Study|Lost to Follow-up|1
6320202|NCT02806232|10057730|FG001|Overall Study|Lost to Follow-up|2
6320203|NCT02806232|10057731|FG002|Overall Study|Lost to Follow-up|1
6320204|NCT02806232|10057732|FG003|Overall Study|Lost to Follow-up|0
6320205|NCT02806232|10057733|FG004|Overall Study|Lost to Follow-up|0
6320206|NCT02806232|10057734|FG005|Overall Study|Lost to Follow-up|1
6320207|NCT02806232|10057735|FG006|Overall Study|Lost to Follow-up|0
6320208|NCT02806232|10057736|FG007|Overall Study|Lost to Follow-up|0
6320209|NCT02806232|10057737|FG008|Overall Study|Lost to Follow-up|0
6320210|NCT02806232|10057729|FG000|Overall Study|Withdrawal by Subject|0
6320211|NCT02806232|10057730|FG001|Overall Study|Withdrawal by Subject|2
6320212|NCT02806232|10057731|FG002|Overall Study|Withdrawal by Subject|0
6320213|NCT02806232|10057732|FG003|Overall Study|Withdrawal by Subject|0
6320214|NCT02806232|10057733|FG004|Overall Study|Withdrawal by Subject|2
6320215|NCT02806232|10057734|FG005|Overall Study|Withdrawal by Subject|1
6320216|NCT02806232|10057735|FG006|Overall Study|Withdrawal by Subject|0
6320217|NCT02806232|10057736|FG007|Overall Study|Withdrawal by Subject|0
6320218|NCT02806232|10057737|FG008|Overall Study|Withdrawal by Subject|0
6320219|NCT02806414|10057757|FG000|Overall Study|Lost to Follow-up|2
6320220|NCT02806505|10057763|FG000|Overall Study|Adverse event/intercurrent illness|1
6320221|NCT02806505|10057764|FG001|Overall Study|Adverse event/intercurrent illness|3
6320222|NCT02806505|10057763|FG000|Overall Study|Death|4
6320223|NCT02806505|10057764|FG001|Overall Study|Death|0
6320224|NCT02806505|10057763|FG000|Overall Study|Did not cooperate/refused treatment|3
6320225|NCT02806505|10057764|FG001|Overall Study|Did not cooperate/refused treatment|3
6320226|NCT02806505|10057763|FG000|Overall Study|Failure to return|0
6320227|NCT02806505|10057764|FG001|Overall Study|Failure to return|1
6320228|NCT02806505|10057763|FG000|Overall Study|Insufficient therapeutic response|2
6320229|NCT02806505|10057764|FG001|Overall Study|Insufficient therapeutic response|4
6320230|NCT02806713|10057776|FG000|Overall Study|Urethral injury during procedure|1
6320231|NCT02806713|10057777|FG001|Overall Study|Urethral injury during procedure|0
6320232|NCT02806713|10057776|FG000|Overall Study|cancelled surgery|1
6320233|NCT02806713|10057777|FG001|Overall Study|cancelled surgery|2
6320234|NCT02806726|10057783|FG000|Overall Study|Lost to Follow-up|1
6320235|NCT02806947|10057819|FG000|Overall Study|Withdrawal by Subject|5
6320236|NCT02806947|10057820|FG001|Overall Study|Withdrawal by Subject|1
6320237|NCT02806973|10057826|FG000|Period 1|Withdrawal by Subject|0
6320238|NCT02806973|10057827|FG001|Period 1|Withdrawal by Subject|2
6320239|NCT02806973|10057828|FG002|Period 1|Withdrawal by Subject|1
6320240|NCT02806973|10057829|FG003|Period 1|Withdrawal by Subject|1
6320241|NCT02806973|10057826|FG000|Period 1|Adverse Event|0
6320242|NCT02806973|10057827|FG001|Period 1|Adverse Event|0
6320243|NCT02806973|10057828|FG002|Period 1|Adverse Event|0
6320244|NCT02806973|10057829|FG003|Period 1|Adverse Event|1
6320245|NCT02806973|10057826|FG000|Period 3|Withdrawal by Subject|0
6320246|NCT02806973|10057827|FG001|Period 3|Withdrawal by Subject|0
6320247|NCT02806973|10057828|FG002|Period 3|Withdrawal by Subject|0
6320248|NCT02806973|10057829|FG003|Period 3|Withdrawal by Subject|3
6320249|NCT02806973|10057826|FG000|Period 3|Adverse Event|0
6320250|NCT02806973|10057827|FG001|Period 3|Adverse Event|0
6320251|NCT02806973|10057828|FG002|Period 3|Adverse Event|1
6320252|NCT02806973|10057829|FG003|Period 3|Adverse Event|0
6320253|NCT02806986|10057839|FG000|Treatment Stage 1|Adverse Event|1
6320254|NCT02806986|10057839|FG000|Treatment Stage 2|Adverse Event|3
6320255|NCT02806986|10057839|FG000|Treatment Stage 2|Withdrawal by Subject|2
6320256|NCT02807259|10057849|FG000|Baseline (3 Months)|migration, refusal, not available|77
6320257|NCT02807259|10057850|FG001|Baseline (3 Months)|migration, refusal, not available|112
6320258|NCT02807259|10057849|FG000|Midline (3 Months)|migration, refusal, not available|30
6320259|NCT02807259|10057850|FG001|Midline (3 Months)|migration, refusal, not available|34
6320260|NCT02807259|10057849|FG000|Endline (3 Months)|migration, refusal, not available|35
6320261|NCT02807259|10057850|FG001|Endline (3 Months)|migration, refusal, not available|87
6320262|NCT02807376|10057860|FG000|Overall Study|Intra-operative exclusion criteria|3
6320263|NCT02807376|10057861|FG001|Overall Study|Intra-operative exclusion criteria|0
6320264|NCT02807376|10057860|FG000|Overall Study|Lost to Follow-up|0
6320265|NCT02807376|10057861|FG001|Overall Study|Lost to Follow-up|1
6320266|NCT02807402|10057867|FG000|Overall Study|Failure to Return|1
6320267|NCT02807402|10057867|FG000|Overall Study|Death|3
6320268|NCT02807402|10057867|FG000|Overall Study|Other|2
6320269|NCT02807623|10057882|FG000|Overall Study|Lost to Follow-up|23
6320270|NCT02807623|10057883|FG001|Overall Study|Lost to Follow-up|18
6320271|NCT02807623|10057884|FG002|Overall Study|Lost to Follow-up|22
6320272|NCT02807623|10057882|FG000|Overall Study|Drug intolerance|0
6320273|NCT02807623|10057883|FG001|Overall Study|Drug intolerance|1
6320274|NCT02807623|10057884|FG002|Overall Study|Drug intolerance|0
6320275|NCT02807623|10057882|FG000|Overall Study|incomplete blood draw|0
6320276|NCT02807623|10057883|FG001|Overall Study|incomplete blood draw|2
6320277|NCT02807623|10057884|FG002|Overall Study|incomplete blood draw|1
6320278|NCT02807844|10057911|FG000|Overall Study|Physician Decision|0
6320279|NCT02807844|10057912|FG001|Overall Study|Physician Decision|0
6320280|NCT02807844|10057913|FG002|Overall Study|Physician Decision|0
6320281|NCT02807844|10057914|FG003|Overall Study|Physician Decision|0
6320282|NCT02807844|10057915|FG004|Overall Study|Physician Decision|0
6320283|NCT02807844|10057916|FG005|Overall Study|Physician Decision|0
6041129|NCT00373529|9639260|FG000|Overall Study|Other|8
6041130|NCT00373529|9639260|FG000|Overall Study|Failed independent confirmation of AML|3
6041131|NCT00373529|9639260|FG000|Overall Study|Consent violation|1
6041132|NCT00373685|9639266|FG000|Overall Study|Death|2
6041133|NCT00373685|9639267|FG001|Overall Study|Death|1
6041134|NCT00373685|9639266|FG000|Overall Study|Adverse Event|278
6041135|NCT00373685|9639267|FG001|Overall Study|Adverse Event|253
6041136|NCT00373685|9639266|FG000|Overall Study|Insufficient clinical response|169
6041137|NCT00373685|9639267|FG001|Overall Study|Insufficient clinical response|119
6041138|NCT00373685|9639266|FG000|Overall Study|Did not meet entrance criteria|167
6041139|NCT00373685|9639267|FG001|Overall Study|Did not meet entrance criteria|184
6041140|NCT00373685|9639266|FG000|Overall Study|Lost to follow up|83
6041141|NCT00373685|9639267|FG001|Overall Study|Lost to follow up|103
6320284|NCT02807844|10057917|FG006|Overall Study|Physician Decision|3
6320285|NCT02807844|10057918|FG007|Overall Study|Physician Decision|0
6320286|NCT02807844|10057919|FG008|Overall Study|Physician Decision|1
6041142|NCT00373685|9639266|FG000|Overall Study|No longer willing to participate|337
6041143|NCT00373685|9639267|FG001|Overall Study|No longer willing to participate|352
6320287|NCT02807844|10057920|FG009|Overall Study|Physician Decision|2
6320288|NCT02807844|10057911|FG000|Overall Study|Death|0
6320289|NCT02807844|10057912|FG001|Overall Study|Death|0
6320290|NCT02807844|10057913|FG002|Overall Study|Death|2
6320291|NCT02807844|10057914|FG003|Overall Study|Death|4
6320292|NCT02807844|10057915|FG004|Overall Study|Death|1
6320293|NCT02807844|10057916|FG005|Overall Study|Death|2
6320294|NCT02807844|10057917|FG006|Overall Study|Death|1
6320295|NCT02807844|10057918|FG007|Overall Study|Death|2
6320296|NCT02807844|10057919|FG008|Overall Study|Death|0
6320297|NCT02807844|10057920|FG009|Overall Study|Death|1
6320298|NCT02807844|10057911|FG000|Overall Study|Withdrawal by Subject|0
6320299|NCT02807844|10057912|FG001|Overall Study|Withdrawal by Subject|0
6320300|NCT02807844|10057913|FG002|Overall Study|Withdrawal by Subject|2
6320301|NCT02807844|10057914|FG003|Overall Study|Withdrawal by Subject|1
6320302|NCT02807844|10057915|FG004|Overall Study|Withdrawal by Subject|1
6320303|NCT02807844|10057916|FG005|Overall Study|Withdrawal by Subject|0
6320304|NCT02807844|10057917|FG006|Overall Study|Withdrawal by Subject|1
6320305|NCT02807844|10057918|FG007|Overall Study|Withdrawal by Subject|0
6320306|NCT02807844|10057919|FG008|Overall Study|Withdrawal by Subject|0
6320307|NCT02807844|10057920|FG009|Overall Study|Withdrawal by Subject|0
6320308|NCT02807844|10057911|FG000|Overall Study|Progressive disease|5
6320309|NCT02807844|10057912|FG001|Overall Study|Progressive disease|12
6320310|NCT02807844|10057913|FG002|Overall Study|Progressive disease|8
6320311|NCT02807844|10057914|FG003|Overall Study|Progressive disease|8
6320312|NCT02807844|10057915|FG004|Overall Study|Progressive disease|3
6320313|NCT02807844|10057916|FG005|Overall Study|Progressive disease|8
6320314|NCT02807844|10057917|FG006|Overall Study|Progressive disease|14
6320315|NCT02807844|10057918|FG007|Overall Study|Progressive disease|17
6320316|NCT02807844|10057919|FG008|Overall Study|Progressive disease|19
6320317|NCT02807844|10057920|FG009|Overall Study|Progressive disease|15
6320318|NCT02807844|10057911|FG000|Overall Study|Adverse Event|1
6320319|NCT02807844|10057912|FG001|Overall Study|Adverse Event|0
6320320|NCT02807844|10057913|FG002|Overall Study|Adverse Event|0
6320321|NCT02807844|10057914|FG003|Overall Study|Adverse Event|0
6320322|NCT02807844|10057915|FG004|Overall Study|Adverse Event|1
6320323|NCT02807844|10057916|FG005|Overall Study|Adverse Event|1
6320324|NCT02807844|10057917|FG006|Overall Study|Adverse Event|1
6320325|NCT02807844|10057918|FG007|Overall Study|Adverse Event|1
6320326|NCT02807844|10057919|FG008|Overall Study|Adverse Event|1
6320327|NCT02807844|10057920|FG009|Overall Study|Adverse Event|2
6320328|NCT02807857|10057946|FG000|Enrolled Set|Patients not suitable for follow-up.|551
6320329|NCT02807857|10057946|FG000|Follow-Up Set|Study Terminated By Sponsor|131
6320330|NCT02807857|10057946|FG000|Follow-Up Set|Withdrawal by Subject|8
6320331|NCT02807857|10057946|FG000|Follow-Up Set|Lost to Follow-up|7
6320332|NCT02807857|10057946|FG000|Follow-Up Set|Physician Decision|6
6320333|NCT02807857|10057946|FG000|Follow-Up Set|Adverse Event|3
6320334|NCT02807857|10057946|FG000|Follow-Up Set|Death|27
6320335|NCT02807857|10057946|FG000|Follow-Up Set|Relocation|2
6320336|NCT02807948|10057956|FG000|Overall Study|Physician Decision|1
6320337|NCT02807948|10057957|FG001|Overall Study|Physician Decision|0
6320338|NCT02808312|10058008|FG000|Overall Study|Enrolled but Never Treated|0
6320339|NCT02808312|10058009|FG001|Overall Study|Enrolled but Never Treated|0
6320340|NCT02808312|10058010|FG002|Overall Study|Enrolled but Never Treated|1
6320341|NCT02808312|10058011|FG003|Overall Study|Enrolled but Never Treated|0
6320342|NCT02808312|10058012|FG004|Overall Study|Enrolled but Never Treated|0
6320343|NCT02808338|10058029|FG000|Screening|Screen Failure|10
6320344|NCT02808338|10058029|FG000|Overnight In-lab Polysomonography|Withdrawal by Subject|1
6320345|NCT02808338|10058029|FG000|Overnight In-lab Polysomonography|Reason not given|1
6320346|NCT02808429|10058043|FG000|Overall Study|Lost to Follow-up|1
6320347|NCT02808429|10058044|FG001|Overall Study|Lost to Follow-up|0
6320348|NCT02808429|10058045|FG002|Overall Study|Lost to Follow-up|0
6320349|NCT02808429|10058043|FG000|Overall Study|Protocol Violation|0
6320350|NCT02808429|10058044|FG001|Overall Study|Protocol Violation|1
6320351|NCT02808429|10058045|FG002|Overall Study|Protocol Violation|0
6320352|NCT02808429|10058043|FG000|Overall Study|Premature study termination by sponsor|2
6320353|NCT02808429|10058044|FG001|Overall Study|Premature study termination by sponsor|0
6320354|NCT02808429|10058045|FG002|Overall Study|Premature study termination by sponsor|1
6320355|NCT02808429|10058043|FG000|Overall Study|Relocation|0
6320356|NCT02808429|10058044|FG001|Overall Study|Relocation|0
6320357|NCT02808429|10058045|FG002|Overall Study|Relocation|1
6320358|NCT02808819|10058055|FG000|Overall Study|eg. no treatment efficacy on asthma|5
6320359|NCT02808819|10058056|FG001|Overall Study|eg. no treatment efficacy on asthma|4
6320360|NCT02808819|10058055|FG000|Overall Study|Withdrawal by Subject|10
6320361|NCT02808819|10058056|FG001|Overall Study|Withdrawal by Subject|13
6320362|NCT02808819|10058055|FG000|Overall Study|Site terminated by sponsor|2
6320363|NCT02808819|10058056|FG001|Overall Study|Site terminated by sponsor|0
6320364|NCT02808819|10058055|FG000|Overall Study|Pregnancy|1
6320365|NCT02808819|10058056|FG001|Overall Study|Pregnancy|0
6320366|NCT02808819|10058055|FG000|Overall Study|Lost to Follow-up|1
6041144|NCT00373685|9639266|FG000|Overall Study|Other|149
6041145|NCT00373685|9639267|FG001|Overall Study|Other|146
6041146|NCT00373685|9639266|FG000|Overall Study|Protocol Violation|191
6320367|NCT02808819|10058056|FG001|Overall Study|Lost to Follow-up|6
6320368|NCT02808819|10058055|FG000|Overall Study|Protocol Violation|0
6320369|NCT02808819|10058056|FG001|Overall Study|Protocol Violation|1
6320370|NCT02808819|10058055|FG000|Overall Study|Development of study-specific withdrawal criteria|8
6320371|NCT02808819|10058056|FG001|Overall Study|Development of study-specific withdrawal criteria|3
6320372|NCT02808819|10058055|FG000|Overall Study|Death|1
6320373|NCT02808819|10058056|FG001|Overall Study|Death|0
6320374|NCT02808819|10058055|FG000|Overall Study|Adverse Event|3
6320375|NCT02808819|10058056|FG001|Overall Study|Adverse Event|4
6320376|NCT02808975|10058065|FG000|Overall Study|Adverse Event|3
6320377|NCT02808975|10058066|FG001|Overall Study|Adverse Event|4
6320378|NCT02808975|10058065|FG000|Overall Study|Withdrew consent|9
6320379|NCT02808975|10058066|FG001|Overall Study|Withdrew consent|8
6320380|NCT02808975|10058065|FG000|Overall Study|Lost to Follow-up|4
6320381|NCT02808975|10058066|FG001|Overall Study|Lost to Follow-up|6
6320382|NCT02808975|10058065|FG000|Overall Study|Planned HS surgery performed prior Wk 13|1
6320383|NCT02808975|10058066|FG001|Overall Study|Planned HS surgery performed prior Wk 13|0
6320384|NCT02808975|10058065|FG000|Overall Study|Other, not specified|5
6320385|NCT02808975|10058066|FG001|Overall Study|Other, not specified|1
6320386|NCT02809053|10058074|FG000|Overall Study|Death|0
6320387|NCT02809053|10058075|FG001|Overall Study|Death|1
6320388|NCT02809053|10058074|FG000|Overall Study|Lost to Follow-up|3
6320389|NCT02809053|10058075|FG001|Overall Study|Lost to Follow-up|1
6320390|NCT02809053|10058074|FG000|Overall Study|Withdrawal by Subject|2
6320391|NCT02809053|10058075|FG001|Overall Study|Withdrawal by Subject|3
6320392|NCT02809053|10058074|FG000|Overall Study|Disease Progression|2
6320393|NCT02809053|10058075|FG001|Overall Study|Disease Progression|1
6320394|NCT02809833|10058115|FG000|Overall Study|Death|3
6320395|NCT02809833|10058115|FG000|Overall Study|Intolerance|54
6320396|NCT02809833|10058115|FG000|Overall Study|Lack of Efficacy|89
6320397|NCT02809833|10058115|FG000|Overall Study|Remission/Treatment No Longer Needed|3
6320398|NCT02809833|10058115|FG000|Overall Study|Noncompliance|1
6320399|NCT02809833|10058115|FG000|Overall Study|Withdrawal by Subject|34
6320400|NCT02809833|10058115|FG000|Overall Study|Lost to Follow-up|35
6320401|NCT02809833|10058115|FG000|Overall Study|Adverse Event (AE)|24
6320402|NCT02809833|10058115|FG000|Overall Study|Other|5
6320403|NCT02809833|10058115|FG000|Overall Study|Missing Information|52
6320404|NCT02809976|10058141|FG000|Overall Study|Lost to Follow-up|1
6320405|NCT02809976|10058141|FG000|Overall Study|Withdrawal by Subject|1
6320406|NCT02810340|10058157|FG000|Overall Study|Withdrawal by Subject|1
6041147|NCT00373685|9639267|FG001|Overall Study|Protocol Violation|182
6041148|NCT00373685|9639266|FG000|Overall Study|Final Status Unknown|12
6041149|NCT00373685|9639267|FG001|Overall Study|Final Status Unknown|4
6041150|NCT00373685|9639266|FG000|Overall Study|Randomized, not treated|51
6041151|NCT00373685|9639267|FG001|Overall Study|Randomized, not treated|77
6041152|NCT00373880|9639284|FG000|Overall Study|Physician Decision|3
6041153|NCT00373880|9639284|FG000|Overall Study|Arrested|1
6041154|NCT00373880|9639284|FG000|Overall Study|Protocol Violation|14
6041155|NCT00373958|9639298|FG000|Infant Series|Withdrawal by Subject|13
6320407|NCT02810340|10058158|FG001|Overall Study|Withdrawal by Subject|0
6320408|NCT02810340|10058159|FG002|Overall Study|Withdrawal by Subject|0
6041156|NCT00373958|9639299|FG001|Infant Series|Withdrawal by Subject|15
6320409|NCT02810340|10058157|FG000|Overall Study|Incarceration|0
6151951|NCT01116427|9788919|FG000|Extension Phase|Withdrawal by Subject|5
6151952|NCT01116427|9788920|FG001|Extension Phase|Withdrawal by Subject|1
6151953|NCT01116427|9788919|FG000|Extension Phase|Not using appropriate birth control|1
6151954|NCT01116427|9788920|FG001|Extension Phase|Not using appropriate birth control|0
6151955|NCT01116440|9788932|FG000|Treatment|Withdrawal by Subject|2
6151956|NCT01116440|9788933|FG001|Treatment|Withdrawal by Subject|2
6151957|NCT01116440|9788932|FG000|Treatment|Lost to Follow-up|1
6151958|NCT01116440|9788933|FG001|Treatment|Lost to Follow-up|1
6151959|NCT01116440|9788932|FG000|Treatment|Protocol Violation|0
6151960|NCT01116440|9788933|FG001|Treatment|Protocol Violation|2
6151961|NCT01116440|9788932|FG000|Treatment|Lack of Efficacy|0
6151962|NCT01116440|9788933|FG001|Treatment|Lack of Efficacy|1
6320410|NCT02810340|10058158|FG001|Overall Study|Incarceration|1
6320411|NCT02810340|10058159|FG002|Overall Study|Incarceration|0
6320412|NCT02810340|10058157|FG000|Overall Study|Lost to Follow-up|0
6320413|NCT02810340|10058158|FG001|Overall Study|Lost to Follow-up|0
6320414|NCT02810340|10058159|FG002|Overall Study|Lost to Follow-up|1
6320415|NCT02810392|10058169|FG000|Overall Study|Subject too ill to continue|1
6320416|NCT02810392|10058170|FG001|Overall Study|Subject too ill to continue|0
6151963|NCT01116440|9788932|FG000|Treatment|Adverse Event|0
6151964|NCT01116440|9788933|FG001|Treatment|Adverse Event|1
6151965|NCT01116440|9788932|FG000|Withdrawal|Withdrawal by Subject|0
6151966|NCT01116440|9788933|FG001|Withdrawal|Withdrawal by Subject|1
6320417|NCT02810392|10058169|FG000|Overall Study|COVID 19 research restrictions|0
6320418|NCT02810392|10058170|FG001|Overall Study|COVID 19 research restrictions|1
6320419|NCT02810951|10058197|FG000|Overall Study|Adverse Event|1
6320420|NCT02810964|10058205|FG000|Double-Blind Treatment Phase (16 Weeks)|Withdrawal by Subject|1
6320421|NCT02810964|10058206|FG001|Double-Blind Treatment Phase (16 Weeks)|Withdrawal by Subject|2
6320422|NCT02810964|10058205|FG000|Double-Blind Treatment Phase (16 Weeks)|Lost to Follow-up|1
6320423|NCT02810964|10058206|FG001|Double-Blind Treatment Phase (16 Weeks)|Lost to Follow-up|0
6320424|NCT02810964|10058205|FG000|Double-Blind Treatment Phase (16 Weeks)|Protocol Violation|0
6320425|NCT02810964|10058206|FG001|Double-Blind Treatment Phase (16 Weeks)|Protocol Violation|1
6320426|NCT02810964|10058205|FG000|Double-Blind Treatment Phase (16 Weeks)|Relocation|1
6320427|NCT02810964|10058206|FG001|Double-Blind Treatment Phase (16 Weeks)|Relocation|0
6041157|NCT00373958|9639298|FG000|Infant Series|Failed to return|8
6320428|NCT02811159|10058212|FG000|Treatment Course 1|Lost to Follow-up|1
6320429|NCT02811640|10058239|FG000|Overall Study|Technology malfunction|2
6320430|NCT02812186|10058270|FG000|Period 1|Post randomization screen failure|5
6320431|NCT02812186|10058271|FG001|Period 1|Post randomization screen failure|9
6320432|NCT02812186|10058270|FG000|Period 1|nonevaluable data sets|6
6320433|NCT02812186|10058271|FG001|Period 1|nonevaluable data sets|6
6320434|NCT02813421|10058318|FG000|Overall Study|Withdrawal by Subject|1
6320435|NCT02813421|10058319|FG001|Overall Study|Withdrawal by Subject|2
6320436|NCT02813421|10058318|FG000|Overall Study|Lost to Follow-up|1
6320437|NCT02813421|10058319|FG001|Overall Study|Lost to Follow-up|1
6320438|NCT02813577|10058338|FG000|Overall Study|Study terminated|4
6320439|NCT02813681|10058345|FG000|Overall Study|Physician Decision|5
6320440|NCT02813681|10058346|FG001|Overall Study|Physician Decision|5
6320441|NCT02813681|10058347|FG002|Overall Study|Physician Decision|0
6320442|NCT02813681|10058345|FG000|Overall Study|Lost to Follow-up|0
6320443|NCT02813681|10058346|FG001|Overall Study|Lost to Follow-up|1
6320444|NCT02813681|10058347|FG002|Overall Study|Lost to Follow-up|0
6320445|NCT02813694|10058359|FG000|Overall Study|Physician Decision|0
6320446|NCT02813694|10058360|FG001|Overall Study|Physician Decision|1
6320447|NCT02813694|10058359|FG000|Overall Study|Withdrawal by Subject|10
6320448|NCT02813694|10058360|FG001|Overall Study|Withdrawal by Subject|9
6320449|NCT02813694|10058359|FG000|Overall Study|Lost to Follow-up|1
6320450|NCT02813694|10058360|FG001|Overall Study|Lost to Follow-up|1
6320451|NCT02813694|10058359|FG000|Overall Study|Death|3
6320452|NCT02813694|10058360|FG001|Overall Study|Death|3
6320453|NCT02813694|10058359|FG000|Overall Study|Randomized- did not receive study drug|2
6320454|NCT02813694|10058360|FG001|Overall Study|Randomized- did not receive study drug|0
6320455|NCT02813694|10058359|FG000|Overall Study|Patient hospitalized|1
6320456|NCT02813694|10058360|FG001|Overall Study|Patient hospitalized|0
6320457|NCT02814175|10058368|FG000|Part 1|Adverse Event|2
6320458|NCT02814175|10058369|FG001|Part 1|Adverse Event|3
6320459|NCT02814175|10058370|FG002|Part 1|Adverse Event|0
6320460|NCT02814175|10058371|FG003|Part 1|Adverse Event|0
6320461|NCT02814175|10058372|FG004|Part 1|Adverse Event|0
6320462|NCT02814175|10058373|FG005|Part 1|Adverse Event|0
6320463|NCT02814175|10058368|FG000|Part 1|Withdrawal Consent|8
6320464|NCT02814175|10058369|FG001|Part 1|Withdrawal Consent|1
6320465|NCT02814175|10058370|FG002|Part 1|Withdrawal Consent|0
6320466|NCT02814175|10058371|FG003|Part 1|Withdrawal Consent|0
6320467|NCT02814175|10058372|FG004|Part 1|Withdrawal Consent|0
6320468|NCT02814175|10058373|FG005|Part 1|Withdrawal Consent|0
6320469|NCT02814175|10058368|FG000|Part 1|Lost to Follow-up|1
6320470|NCT02814175|10058369|FG001|Part 1|Lost to Follow-up|0
6320471|NCT02814175|10058370|FG002|Part 1|Lost to Follow-up|0
6320472|NCT02814175|10058371|FG003|Part 1|Lost to Follow-up|0
6320473|NCT02814175|10058372|FG004|Part 1|Lost to Follow-up|0
6320474|NCT02814175|10058373|FG005|Part 1|Lost to Follow-up|0
6320475|NCT02814175|10058368|FG000|Part 1|Lack of Efficacy|1
6320476|NCT02814175|10058369|FG001|Part 1|Lack of Efficacy|2
6320477|NCT02814175|10058370|FG002|Part 1|Lack of Efficacy|0
6320478|NCT02814175|10058371|FG003|Part 1|Lack of Efficacy|0
6320479|NCT02814175|10058372|FG004|Part 1|Lack of Efficacy|0
6320480|NCT02814175|10058373|FG005|Part 1|Lack of Efficacy|0
6320481|NCT02814175|10058368|FG000|Part 2|Adverse Event|0
6320482|NCT02814175|10058369|FG001|Part 2|Adverse Event|0
6320483|NCT02814175|10058370|FG002|Part 2|Adverse Event|0
6320484|NCT02814175|10058371|FG003|Part 2|Adverse Event|1
6320485|NCT02814175|10058372|FG004|Part 2|Adverse Event|1
6320486|NCT02814175|10058373|FG005|Part 2|Adverse Event|2
6320487|NCT02814175|10058368|FG000|Part 2|Withdrawal Consent|0
6320488|NCT02814175|10058369|FG001|Part 2|Withdrawal Consent|0
6320489|NCT02814175|10058370|FG002|Part 2|Withdrawal Consent|0
6320490|NCT02814175|10058371|FG003|Part 2|Withdrawal Consent|2
6320491|NCT02814175|10058372|FG004|Part 2|Withdrawal Consent|1
6320492|NCT02814175|10058373|FG005|Part 2|Withdrawal Consent|1
6320493|NCT02814175|10058368|FG000|Part 2|Lost to Follow-up|0
6320494|NCT02814175|10058369|FG001|Part 2|Lost to Follow-up|0
6320495|NCT02814175|10058370|FG002|Part 2|Lost to Follow-up|0
6320496|NCT02814175|10058371|FG003|Part 2|Lost to Follow-up|1
6320497|NCT02814175|10058372|FG004|Part 2|Lost to Follow-up|0
6041158|NCT00373958|9639299|FG001|Infant Series|Failed to return|13
6320498|NCT02814175|10058373|FG005|Part 2|Lost to Follow-up|0
6320499|NCT02814175|10058368|FG000|Part 2|Lack of Efficacy|0
6320500|NCT02814175|10058369|FG001|Part 2|Lack of Efficacy|0
6320501|NCT02814175|10058370|FG002|Part 2|Lack of Efficacy|0
6320502|NCT02814175|10058371|FG003|Part 2|Lack of Efficacy|0
6320503|NCT02814175|10058372|FG004|Part 2|Lack of Efficacy|0
6320504|NCT02814175|10058373|FG005|Part 2|Lack of Efficacy|3
6320505|NCT02814565|10058423|FG000|Overall Study|Lack of Efficacy|0
6320506|NCT02814565|10058424|FG001|Overall Study|Lack of Efficacy|1
6320507|NCT02814565|10058423|FG000|Overall Study|Subject decision, caused by AE Influenza|1
6320508|NCT02814565|10058424|FG001|Overall Study|Subject decision, caused by AE Influenza|1
6320509|NCT02814643|10058432|FG000|Overall Study|Lost to Follow-up|0
6320510|NCT02814643|10058433|FG001|Overall Study|Lost to Follow-up|1
6320511|NCT02814643|10058432|FG000|Overall Study|Withdrawal by Subject|1
6320512|NCT02814643|10058433|FG001|Overall Study|Withdrawal by Subject|2
6320513|NCT02814838|10058458|FG000|Overall Study|3 agreed dates for the final visit missed|1
6320514|NCT02814838|10058459|FG001|Overall Study|3 agreed dates for the final visit missed|0
6320515|NCT02814838|10058458|FG000|Overall Study|Consent withdrawal|1
6320516|NCT02814838|10058459|FG001|Overall Study|Consent withdrawal|1
6320517|NCT02815293|10058483|FG000|Overall Study|Study termination by sponsor|10
6320518|NCT02815293|10058484|FG001|Overall Study|Study termination by sponsor|7
6320519|NCT02815293|10058485|FG002|Overall Study|Study termination by sponsor|0
6320520|NCT02815293|10058483|FG000|Overall Study|Participants not randomized|0
6320521|NCT02815293|10058484|FG001|Overall Study|Participants not randomized|0
6320522|NCT02815293|10058485|FG002|Overall Study|Participants not randomized|18
6320523|NCT02815293|10058483|FG000|Overall Study|Adverse Event|0
6320524|NCT02815293|10058484|FG001|Overall Study|Adverse Event|1
6320525|NCT02815293|10058485|FG002|Overall Study|Adverse Event|0
6320526|NCT02815670|10058500|FG000|Overall Study|Prematurely discontinued of the trial|1
6320527|NCT02815735|10058526|FG000|First Intervention (4 Weeks)|Discomfort|1
6320528|NCT02815735|10058527|FG001|First Intervention (4 Weeks)|Discomfort|0
6320529|NCT02815735|10058526|FG000|First Intervention (4 Weeks)|Lost to Follow-up|1
6320530|NCT02815735|10058527|FG001|First Intervention (4 Weeks)|Lost to Follow-up|0
6320531|NCT02815735|10058526|FG000|First Intervention (4 Weeks)|Poor fitting characteristics|0
6320532|NCT02815735|10058527|FG001|First Intervention (4 Weeks)|Poor fitting characteristics|1
6320533|NCT02815735|10058526|FG000|Second Intervention (4 Weeks)|Protocol Violation|1
6320534|NCT02815735|10058527|FG001|Second Intervention (4 Weeks)|Protocol Violation|0
6320535|NCT02816138|10058561|FG000|Overall Study|Adverse Event|1
6320536|NCT02816398|10058586|FG000|Overall Study|Death|5
6320537|NCT02816398|10058586|FG000|Overall Study|Lack of Efficacy|8
6320538|NCT02816398|10058586|FG000|Overall Study|Lost to Follow-up|1
6320539|NCT02817087|10058617|FG000|Overall Study|Withdrawal by Subject|2
6320540|NCT02817087|10058618|FG001|Overall Study|Withdrawal by Subject|0
6320541|NCT02817516|10058628|FG000|Overall Study|Other|0
6320542|NCT02817516|10058629|FG001|Overall Study|Other|0
6320543|NCT02817516|10058630|FG002|Overall Study|Other|1
6320544|NCT02817516|10058631|FG003|Overall Study|Other|0
6320545|NCT02817555|10058646|FG000|Overall Study|Death|1
6320546|NCT02817555|10058647|FG001|Overall Study|Death|3
6320547|NCT02817555|10058646|FG000|Overall Study|moved away|1
6320548|NCT02817555|10058647|FG001|Overall Study|moved away|0
6320549|NCT02817555|10058646|FG000|Overall Study|transplant|1
6320550|NCT02817555|10058647|FG001|Overall Study|transplant|1
6320551|NCT02817555|10058646|FG000|Overall Study|changed to Peritoneal Dialysis|0
6320552|NCT02817555|10058647|FG001|Overall Study|changed to Peritoneal Dialysis|1
6320553|NCT02817594|10058653|FG000|Overall Study|Withdrawal by Subject|1
6320554|NCT02817594|10058653|FG000|Overall Study|Other|1
6320555|NCT02817594|10058653|FG000|Overall Study|Did Not Receive Treatment|1
6320556|NCT02817776|10058670|FG000|Overall Study|Excluded|33
6320557|NCT02817776|10058670|FG000|Overall Study|Lost to Follow-up|20
6320558|NCT02817776|10058670|FG000|Overall Study|Withdrawal by Subject|33
6320559|NCT02817776|10058670|FG000|Overall Study|Death|2
6320560|NCT02817828|10058674|FG000|Overall Study|Lost to Follow-up|41
6320561|NCT02817828|10058674|FG000|Overall Study|Adverse event not related to bleeding|104
6320562|NCT02817828|10058674|FG000|Overall Study|Adverse event related to bleeding|53
6320563|NCT02817828|10058674|FG000|Overall Study|Protocol Violation|11
6320564|NCT02817828|10058674|FG000|Overall Study|Pregnancy|7
6320565|NCT02817828|10058674|FG000|Overall Study|Pregnancy wish|15
6320566|NCT02817828|10058674|FG000|Overall Study|Withdrawal by Subject|78
6320567|NCT02817828|10058674|FG000|Overall Study|Other|26
6320568|NCT02817841|10058683|FG000|Overall Study|Lost to Follow-up|287
6320569|NCT02817841|10058683|FG000|Overall Study|Withdrawal by Subject|183
6320570|NCT02817841|10058683|FG000|Overall Study|Adverse event not related to bleeding|131
6320571|NCT02817841|10058683|FG000|Overall Study|Adverse event related to bleeding|51
6320572|NCT02817841|10058683|FG000|Overall Study|Pregnancy|32
6320573|NCT02817841|10058683|FG000|Overall Study|Pregnancy wish|17
6320574|NCT02817841|10058683|FG000|Overall Study|Other reasons|53
6320575|NCT02817841|10058683|FG000|Overall Study|Protocol Violation|94
6320576|NCT02817906|10058693|FG000|Overall Study|Adverse Event|3
6320577|NCT02817906|10058694|FG001|Overall Study|Adverse Event|0
6320578|NCT02817906|10058693|FG000|Overall Study|Lack of Efficacy|1
6320579|NCT02817906|10058694|FG001|Overall Study|Lack of Efficacy|0
6320580|NCT02817906|10058693|FG000|Overall Study|Protocol Violation|1
6320581|NCT02817906|10058694|FG001|Overall Study|Protocol Violation|1
6320582|NCT02817906|10058693|FG000|Overall Study|Study Terminated by Sponsor|2
6320583|NCT02817906|10058694|FG001|Overall Study|Study Terminated by Sponsor|2
6320584|NCT02817906|10058693|FG000|Overall Study|Withdrawal by Subject|7
6320585|NCT02817906|10058694|FG001|Overall Study|Withdrawal by Subject|0
6320586|NCT02817906|10058693|FG000|Overall Study|Other|2
6320587|NCT02817906|10058694|FG001|Overall Study|Other|2
6320588|NCT02818036|10058702|FG000|Overall Study|head did not fit in fMRI scanner headres|1
6320589|NCT02818036|10058703|FG001|Overall Study|head did not fit in fMRI scanner headres|0
6320590|NCT02818036|10058702|FG000|Overall Study|Withdrawal by Subject|1
6320591|NCT02818036|10058703|FG001|Overall Study|Withdrawal by Subject|0
6320592|NCT02818777|10058741|FG000|Overall Study|Adverse Event|3
6320593|NCT02818998|10058754|FG000|Overall Study|Adverse Event|3
6320594|NCT02818998|10058755|FG001|Overall Study|Adverse Event|2
6320595|NCT02818998|10058756|FG002|Overall Study|Adverse Event|1
6320596|NCT02818998|10058754|FG000|Overall Study|Lost to Follow-up|4
6320597|NCT02818998|10058755|FG001|Overall Study|Lost to Follow-up|1
6320598|NCT02818998|10058756|FG002|Overall Study|Lost to Follow-up|2
6320599|NCT02818998|10058754|FG000|Overall Study|Withdrawal by sponsor|0
6320600|NCT02818998|10058755|FG001|Overall Study|Withdrawal by sponsor|1
6320601|NCT02818998|10058756|FG002|Overall Study|Withdrawal by sponsor|1
6320602|NCT02818998|10058754|FG000|Overall Study|Death|3
6151967|NCT01116440|9788932|FG000|Withdrawal|Lost to Follow-up|0
6320603|NCT02818998|10058755|FG001|Overall Study|Death|6
6320604|NCT02818998|10058756|FG002|Overall Study|Death|8
6320605|NCT02818998|10058754|FG000|Overall Study|Withdrawal by Subject|7
6320606|NCT02818998|10058755|FG001|Overall Study|Withdrawal by Subject|6
6320607|NCT02818998|10058756|FG002|Overall Study|Withdrawal by Subject|6
6320608|NCT02818998|10058754|FG000|Overall Study|Physician Decision|1
6320609|NCT02818998|10058755|FG001|Overall Study|Physician Decision|0
6320610|NCT02818998|10058756|FG002|Overall Study|Physician Decision|0
6320611|NCT02819297|10058785|FG000|Overall Study|Withdrawal by Subject|25
6320612|NCT02819297|10058786|FG001|Overall Study|Withdrawal by Subject|13
6320613|NCT02819297|10058785|FG000|Overall Study|Lost to Follow-up|12
6320614|NCT02819297|10058786|FG001|Overall Study|Lost to Follow-up|14
6320615|NCT02819297|10058785|FG000|Overall Study|Adverse Event|12
6320616|NCT02819297|10058786|FG001|Overall Study|Adverse Event|10
6320617|NCT02819297|10058785|FG000|Overall Study|Physician Decision|5
6320618|NCT02819297|10058786|FG001|Overall Study|Physician Decision|5
6320619|NCT02819297|10058785|FG000|Overall Study|Lack of Efficacy|5
6320620|NCT02819297|10058786|FG001|Overall Study|Lack of Efficacy|8
6320621|NCT02819297|10058785|FG000|Overall Study|Protocol Violation|1
6320622|NCT02819297|10058786|FG001|Overall Study|Protocol Violation|2
6320623|NCT02819310|10058792|FG000|Overall Study|Withdrawal by Subject|37
6320624|NCT02819310|10058792|FG000|Overall Study|Lost to Follow-up|16
6320625|NCT02819310|10058792|FG000|Overall Study|Adverse Event|13
6320626|NCT02819310|10058792|FG000|Overall Study|Lack of Efficacy|5
6320627|NCT02819310|10058792|FG000|Overall Study|Physician Decision|8
6320628|NCT02819310|10058792|FG000|Overall Study|Protocol Violation|30
6320629|NCT02819726|10058816|FG000|Part A (All Participants)|Lost to Follow-up|0
6320630|NCT02819726|10058817|FG001|Part A (All Participants)|Lost to Follow-up|1
6151968|NCT01116440|9788933|FG001|Withdrawal|Lost to Follow-up|1
6151969|NCT01116440|9788932|FG000|Follow-up|Lost to Follow-up|0
6320631|NCT02819726|10058818|FG002|Part A (All Participants)|Lost to Follow-up|0
6320632|NCT02819726|10058819|FG003|Part A (All Participants)|Lost to Follow-up|0
6320633|NCT02819726|10058816|FG000|Part A (All Participants)|Withdrawal by Subject|3
6320634|NCT02819726|10058817|FG001|Part A (All Participants)|Withdrawal by Subject|5
6320635|NCT02819726|10058818|FG002|Part A (All Participants)|Withdrawal by Subject|6
6320636|NCT02819726|10058819|FG003|Part A (All Participants)|Withdrawal by Subject|0
6320637|NCT02819726|10058816|FG000|Part A (All Participants)|Protocol non-compliance|3
6320638|NCT02819726|10058817|FG001|Part A (All Participants)|Protocol non-compliance|4
6320639|NCT02819726|10058818|FG002|Part A (All Participants)|Protocol non-compliance|5
6320640|NCT02819726|10058819|FG003|Part A (All Participants)|Protocol non-compliance|0
6320641|NCT02819726|10058816|FG000|Part B (All Participants)|Lost to Follow-up|1
6320642|NCT02819726|10058817|FG001|Part B (All Participants)|Lost to Follow-up|1
6320643|NCT02819726|10058818|FG002|Part B (All Participants)|Lost to Follow-up|2
6320644|NCT02819726|10058819|FG003|Part B (All Participants)|Lost to Follow-up|2
6320645|NCT02819726|10058816|FG000|Part B (All Participants)|Withdrawal by Subject|2
6320646|NCT02819726|10058817|FG001|Part B (All Participants)|Withdrawal by Subject|1
6320647|NCT02819726|10058818|FG002|Part B (All Participants)|Withdrawal by Subject|1
6320648|NCT02819726|10058819|FG003|Part B (All Participants)|Withdrawal by Subject|0
6320649|NCT02819726|10058816|FG000|Part B (All Participants)|Protocol non-compliance|0
6320650|NCT02819726|10058817|FG001|Part B (All Participants)|Protocol non-compliance|0
6320651|NCT02819726|10058818|FG002|Part B (All Participants)|Protocol non-compliance|1
6320652|NCT02819726|10058819|FG003|Part B (All Participants)|Protocol non-compliance|0
6320653|NCT02820038|10058850|FG000|Overall Study|Lost to Follow-up|7
6320654|NCT02820038|10058851|FG001|Overall Study|Lost to Follow-up|11
6320655|NCT02820038|10058852|FG002|Overall Study|Lost to Follow-up|2
6320656|NCT02820038|10058853|FG003|Overall Study|Lost to Follow-up|9
6320657|NCT02820038|10058850|FG000|Overall Study|Withdrawal by Subject|3
6320658|NCT02820038|10058851|FG001|Overall Study|Withdrawal by Subject|14
6320659|NCT02820038|10058852|FG002|Overall Study|Withdrawal by Subject|3
6320660|NCT02820038|10058853|FG003|Overall Study|Withdrawal by Subject|13
6320661|NCT02820298|10058875|FG000|Overall Study|Withdrawal by Subject|0
6320662|NCT02820298|10058876|FG001|Overall Study|Withdrawal by Subject|1
6320663|NCT02820298|10058875|FG000|Overall Study|Physician Decision|1
6320664|NCT02820298|10058876|FG001|Overall Study|Physician Decision|0
6320665|NCT02820298|10058875|FG000|Overall Study|Protocol Violation|0
6320666|NCT02820298|10058876|FG001|Overall Study|Protocol Violation|1
6320667|NCT02820597|10058909|FG000|Overall Study|Lost to Follow-up|12
6320668|NCT02820844|10058915|FG000|Double-blinded (Up to 48 Weeks)|Withdrawal by Subject|1
6320669|NCT02820844|10058916|FG001|Double-blinded (Up to 48 Weeks)|Withdrawal by Subject|3
6320670|NCT02820844|10058917|FG002|Double-blinded (Up to 48 Weeks)|Withdrawal by Subject|0
6320671|NCT02820844|10058918|FG003|Double-blinded (Up to 48 Weeks)|Withdrawal by Subject|0
6320672|NCT02820844|10058919|FG004|Double-blinded (Up to 48 Weeks)|Withdrawal by Subject|0
6320673|NCT02820844|10058920|FG005|Double-blinded (Up to 48 Weeks)|Withdrawal by Subject|0
6320674|NCT02820844|10058915|FG000|Double-blinded (Up to 48 Weeks)|Reached stopping criteria|1
6320675|NCT02820844|10058916|FG001|Double-blinded (Up to 48 Weeks)|Reached stopping criteria|2
6320676|NCT02820844|10058917|FG002|Double-blinded (Up to 48 Weeks)|Reached stopping criteria|0
6320677|NCT02820844|10058918|FG003|Double-blinded (Up to 48 Weeks)|Reached stopping criteria|0
6320678|NCT02820844|10058919|FG004|Double-blinded (Up to 48 Weeks)|Reached stopping criteria|0
6320679|NCT02820844|10058920|FG005|Double-blinded (Up to 48 Weeks)|Reached stopping criteria|0
6320680|NCT02820844|10058915|FG000|Double-blinded (Up to 48 Weeks)|Protocol Violation|0
6320681|NCT02820844|10058916|FG001|Double-blinded (Up to 48 Weeks)|Protocol Violation|3
6320682|NCT02820844|10058917|FG002|Double-blinded (Up to 48 Weeks)|Protocol Violation|0
6320683|NCT02820844|10058918|FG003|Double-blinded (Up to 48 Weeks)|Protocol Violation|0
6320684|NCT02820844|10058919|FG004|Double-blinded (Up to 48 Weeks)|Protocol Violation|0
6320685|NCT02820844|10058920|FG005|Double-blinded (Up to 48 Weeks)|Protocol Violation|0
6320686|NCT02820844|10058915|FG000|Double-blinded (Up to 48 Weeks)|Adverse Event|2
6320687|NCT02820844|10058916|FG001|Double-blinded (Up to 48 Weeks)|Adverse Event|1
6320688|NCT02820844|10058917|FG002|Double-blinded (Up to 48 Weeks)|Adverse Event|0
6320689|NCT02820844|10058918|FG003|Double-blinded (Up to 48 Weeks)|Adverse Event|0
6320690|NCT02820844|10058919|FG004|Double-blinded (Up to 48 Weeks)|Adverse Event|0
6320691|NCT02820844|10058920|FG005|Double-blinded (Up to 48 Weeks)|Adverse Event|0
6320692|NCT02820844|10058915|FG000|Double-blinded (Up to 48 Weeks)|Investigator discretion|1
6320693|NCT02820844|10058916|FG001|Double-blinded (Up to 48 Weeks)|Investigator discretion|0
6320694|NCT02820844|10058917|FG002|Double-blinded (Up to 48 Weeks)|Investigator discretion|0
6320695|NCT02820844|10058918|FG003|Double-blinded (Up to 48 Weeks)|Investigator discretion|0
6320696|NCT02820844|10058919|FG004|Double-blinded (Up to 48 Weeks)|Investigator discretion|0
6320697|NCT02820844|10058920|FG005|Double-blinded (Up to 48 Weeks)|Investigator discretion|0
6320698|NCT02820844|10058915|FG000|Open-label(2nd Treatment-Up to 48 Weeks)|Adverse Event|0
6320699|NCT02820844|10058916|FG001|Open-label(2nd Treatment-Up to 48 Weeks)|Adverse Event|0
6320700|NCT02820844|10058917|FG002|Open-label(2nd Treatment-Up to 48 Weeks)|Adverse Event|1
6320701|NCT02820844|10058918|FG003|Open-label(2nd Treatment-Up to 48 Weeks)|Adverse Event|2
6320702|NCT02820844|10058919|FG004|Open-label(2nd Treatment-Up to 48 Weeks)|Adverse Event|0
6320703|NCT02820844|10058920|FG005|Open-label(2nd Treatment-Up to 48 Weeks)|Adverse Event|0
6320704|NCT02820844|10058915|FG000|Open-label(2nd Treatment-Up to 48 Weeks)|Investigator discretion|0
6320705|NCT02820844|10058916|FG001|Open-label(2nd Treatment-Up to 48 Weeks)|Investigator discretion|0
6320706|NCT02820844|10058917|FG002|Open-label(2nd Treatment-Up to 48 Weeks)|Investigator discretion|1
6320707|NCT02820844|10058918|FG003|Open-label(2nd Treatment-Up to 48 Weeks)|Investigator discretion|0
6320708|NCT02820844|10058919|FG004|Open-label(2nd Treatment-Up to 48 Weeks)|Investigator discretion|0
6320709|NCT02820844|10058920|FG005|Open-label(2nd Treatment-Up to 48 Weeks)|Investigator discretion|0
6320710|NCT02820844|10058915|FG000|Open-label(2nd Treatment-Up to 48 Weeks)|Withdrawal by Subject|0
6320711|NCT02820844|10058916|FG001|Open-label(2nd Treatment-Up to 48 Weeks)|Withdrawal by Subject|0
6320712|NCT02820844|10058917|FG002|Open-label(2nd Treatment-Up to 48 Weeks)|Withdrawal by Subject|7
6320713|NCT02820844|10058918|FG003|Open-label(2nd Treatment-Up to 48 Weeks)|Withdrawal by Subject|2
6320714|NCT02820844|10058919|FG004|Open-label(2nd Treatment-Up to 48 Weeks)|Withdrawal by Subject|0
6320715|NCT02820844|10058920|FG005|Open-label(2nd Treatment-Up to 48 Weeks)|Withdrawal by Subject|0
6320716|NCT02820844|10058915|FG000|Open-label(3rd Treatment-Up to 48 Weeks)|Reached stopping criteria|0
6320717|NCT02820844|10058916|FG001|Open-label(3rd Treatment-Up to 48 Weeks)|Reached stopping criteria|0
6320718|NCT02820844|10058917|FG002|Open-label(3rd Treatment-Up to 48 Weeks)|Reached stopping criteria|0
6320719|NCT02820844|10058918|FG003|Open-label(3rd Treatment-Up to 48 Weeks)|Reached stopping criteria|0
6320720|NCT02820844|10058919|FG004|Open-label(3rd Treatment-Up to 48 Weeks)|Reached stopping criteria|2
6320721|NCT02820844|10058920|FG005|Open-label(3rd Treatment-Up to 48 Weeks)|Reached stopping criteria|0
6320722|NCT02820844|10058915|FG000|Open-label(3rd Treatment-Up to 48 Weeks)|Withdrawal by Subject|0
6320723|NCT02820844|10058916|FG001|Open-label(3rd Treatment-Up to 48 Weeks)|Withdrawal by Subject|0
6320724|NCT02820844|10058917|FG002|Open-label(3rd Treatment-Up to 48 Weeks)|Withdrawal by Subject|0
6320725|NCT02820844|10058918|FG003|Open-label(3rd Treatment-Up to 48 Weeks)|Withdrawal by Subject|0
6320726|NCT02820844|10058919|FG004|Open-label(3rd Treatment-Up to 48 Weeks)|Withdrawal by Subject|0
6320727|NCT02820844|10058920|FG005|Open-label(3rd Treatment-Up to 48 Weeks)|Withdrawal by Subject|1
6320728|NCT02821416|10058979|FG000|Overall Study|Adverse Event|0
6320729|NCT02821416|10058980|FG001|Overall Study|Adverse Event|1
6320730|NCT02821416|10058979|FG000|Overall Study|Withdrawal by Subject|2
6320731|NCT02821416|10058980|FG001|Overall Study|Withdrawal by Subject|0
6320732|NCT02821416|10058979|FG000|Overall Study|Lost to Follow-up|1
6320733|NCT02821416|10058980|FG001|Overall Study|Lost to Follow-up|0
6320734|NCT02821715|10058991|FG000|Overall Study|Protocol Violation|1
6320735|NCT02821715|10058992|FG001|Overall Study|Protocol Violation|0
6320736|NCT02821715|10058993|FG002|Overall Study|Protocol Violation|0
6320737|NCT02821715|10058994|FG003|Overall Study|Protocol Violation|0
6320738|NCT02821715|10058995|FG004|Overall Study|Protocol Violation|0
6320739|NCT02821715|10058996|FG005|Overall Study|Protocol Violation|0
6320740|NCT02821819|10059004|FG000|Overall Study|Protocol Violation|1
6320741|NCT02821910|10059014|FG000|Overall Study|Withdrawal by Subject|0
6320742|NCT02821910|10059015|FG001|Overall Study|Withdrawal by Subject|0
6320743|NCT02821910|10059016|FG002|Overall Study|Withdrawal by Subject|1
6320744|NCT02821910|10059017|FG003|Overall Study|Withdrawal by Subject|0
6320745|NCT02821910|10059018|FG004|Overall Study|Withdrawal by Subject|0
6320746|NCT02821910|10059019|FG005|Overall Study|Withdrawal by Subject|1
6320747|NCT02821910|10059014|FG000|Overall Study|Other than specified|1
6320748|NCT02821910|10059015|FG001|Overall Study|Other than specified|0
6320749|NCT02821910|10059016|FG002|Overall Study|Other than specified|1
6320750|NCT02821910|10059017|FG003|Overall Study|Other than specified|0
6320751|NCT02821910|10059018|FG004|Overall Study|Other than specified|0
6320752|NCT02821910|10059019|FG005|Overall Study|Other than specified|0
6320753|NCT02821962|10059035|FG000|Overall Study|Lost to Follow-up|2
6320754|NCT02821962|10059036|FG001|Overall Study|Lost to Follow-up|0
6041159|NCT00373958|9639298|FG000|Infant Series|Lost to Follow-up|6
6320755|NCT02822222|10059044|FG000|Overall Study|Protocol requirement SBP<110 mmHg|1
6320756|NCT02822222|10059045|FG001|Overall Study|Protocol requirement SBP<110 mmHg|0
6320757|NCT02822235|10059053|FG000|Cross-sectional Phase (Day 1)|Not Eligible for Prospective Follow-up|144
6320758|NCT02822235|10059054|FG001|Cross-sectional Phase (Day 1)|Not Eligible for Prospective Follow-up|107
6320759|NCT02822235|10059053|FG000|Cross-sectional Phase (Day 1)|Reason Not Specified|2
6320760|NCT02822235|10059054|FG001|Cross-sectional Phase (Day 1)|Reason Not Specified|0
6320761|NCT02822235|10059053|FG000|Prospective Phase (Day 1 up to Month 12)|Withdrawal of Consent|0
6320762|NCT02822235|10059054|FG001|Prospective Phase (Day 1 up to Month 12)|Withdrawal of Consent|1
6320763|NCT02822235|10059053|FG000|Prospective Phase (Day 1 up to Month 12)|Lost to Follow-up|4
6320764|NCT02822235|10059054|FG001|Prospective Phase (Day 1 up to Month 12)|Lost to Follow-up|0
6320765|NCT02822235|10059053|FG000|Prospective Phase (Day 1 up to Month 12)|Death|1
6320766|NCT02822235|10059054|FG001|Prospective Phase (Day 1 up to Month 12)|Death|0
6320767|NCT02822235|10059053|FG000|Prospective Phase (Day 1 up to Month 12)|Reason Not Specified|6
6320768|NCT02822235|10059054|FG001|Prospective Phase (Day 1 up to Month 12)|Reason Not Specified|1
6320769|NCT02822794|10059105|FG000|Overall Study|Withdrew Consent|1
6320770|NCT02822794|10059106|FG001|Overall Study|Withdrew Consent|0
6320771|NCT02823470|10059148|FG000|Overall Study|Adverse Event|1
6320772|NCT02823470|10059149|FG001|Overall Study|Adverse Event|0
6320773|NCT02823470|10059148|FG000|Overall Study|Study terminated by sponsor|8
6320774|NCT02823470|10059149|FG001|Overall Study|Study terminated by sponsor|15
6320775|NCT02823964|10059164|FG000|Overall Study|Adverse Event|2
6320776|NCT02823964|10059164|FG000|Overall Study|Physician Decision|1
6320777|NCT02823964|10059164|FG000|Overall Study|Lack of Efficacy|1
6320778|NCT02823964|10059164|FG000|Overall Study|Withdrawal by Subject|1
6041160|NCT00373958|9639299|FG001|Infant Series|Lost to Follow-up|5
6320779|NCT02824224|10059170|FG000|Overall Study|Discontinued, IUS expulsion|0
6320780|NCT02824224|10059171|FG001|Overall Study|Discontinued, IUS expulsion|1
6320781|NCT02824224|10059170|FG000|Overall Study|Did not show up for allocation visit|2
6320782|NCT02824224|10059171|FG001|Overall Study|Did not show up for allocation visit|0
6320783|NCT02824432|10059179|FG000|Overall Study|Major Protocol Deviation|1
6320784|NCT02824432|10059180|FG001|Overall Study|Major Protocol Deviation|0
6320785|NCT02824562|10059188|FG000|Overall Study|Lost to Follow-up|3
6320786|NCT02824562|10059189|FG001|Overall Study|Lost to Follow-up|4
6320787|NCT02824562|10059188|FG000|Overall Study|Death|0
6320788|NCT02824562|10059189|FG001|Overall Study|Death|1
6320789|NCT02825251|10059212|FG000|Overall Study|Adverse Event|0
6320790|NCT02825251|10059213|FG001|Overall Study|Adverse Event|1
6320791|NCT02825251|10059212|FG000|Overall Study|Lost to Follow-up|0
6320792|NCT02825251|10059213|FG001|Overall Study|Lost to Follow-up|1
6320793|NCT02825251|10059212|FG000|Overall Study|Withdrawal by Subject|1
6320794|NCT02825251|10059213|FG001|Overall Study|Withdrawal by Subject|4
6320795|NCT02825251|10059212|FG000|Overall Study|Unclassified|2
6320796|NCT02825251|10059213|FG001|Overall Study|Unclassified|0
6320797|NCT02825420|10059221|FG000|Overall Study|Death|30
6320798|NCT02825420|10059222|FG001|Overall Study|Death|12
6320799|NCT02825420|10059221|FG000|Overall Study|Progressive disease|6
6320800|NCT02825420|10059222|FG001|Overall Study|Progressive disease|1
6320801|NCT02825420|10059221|FG000|Overall Study|Lost to Follow-up|2
6320802|NCT02825420|10059222|FG001|Overall Study|Lost to Follow-up|2
6320803|NCT02825420|10059221|FG000|Overall Study|Withdrawal by Subject|1
6320804|NCT02825420|10059222|FG001|Overall Study|Withdrawal by Subject|1
6320805|NCT02825420|10059221|FG000|Overall Study|Protocol amendment not signed|1
6320806|NCT02825420|10059222|FG001|Overall Study|Protocol amendment not signed|1
6320807|NCT02825420|10059221|FG000|Overall Study|Physician Decision|1
6320808|NCT02825420|10059222|FG001|Overall Study|Physician Decision|0
6320809|NCT02825420|10059221|FG000|Overall Study|Did not receive PLD|2
6320810|NCT02825420|10059222|FG001|Overall Study|Did not receive PLD|0
6320811|NCT02825550|10059233|FG000|Overall Study|Physician Decision|1
6320812|NCT02825992|10059264|FG000|Overall Study|Withdrawal by Subject|4
6320813|NCT02825992|10059264|FG000|Overall Study|Lost to Follow-up|2
6320814|NCT02825992|10059264|FG000|Overall Study|Procedure terminated|2
6041161|NCT00373958|9639298|FG000|Infant Series|Protocol Violation|3
6320815|NCT02826421|10059278|FG000|Overall Study|Adverse Event|1
6320816|NCT02826421|10059279|FG001|Overall Study|Adverse Event|0
6320817|NCT02826421|10059280|FG002|Overall Study|Adverse Event|0
6320818|NCT02826421|10059281|FG003|Overall Study|Adverse Event|1
6320819|NCT02826421|10059278|FG000|Overall Study|Withdrawal by Subject|1
6320820|NCT02826421|10059279|FG001|Overall Study|Withdrawal by Subject|3
6320821|NCT02826421|10059280|FG002|Overall Study|Withdrawal by Subject|1
6320822|NCT02826421|10059281|FG003|Overall Study|Withdrawal by Subject|1
6320823|NCT02826421|10059278|FG000|Overall Study|Reason not given|1
6320824|NCT02826421|10059279|FG001|Overall Study|Reason not given|0
6320825|NCT02826421|10059280|FG002|Overall Study|Reason not given|1
6320826|NCT02826421|10059281|FG003|Overall Study|Reason not given|0
6320827|NCT02826603|10059294|FG000|Overall Study|Adverse Event|17
6320828|NCT02826603|10059295|FG001|Overall Study|Adverse Event|9
6320829|NCT02826603|10059294|FG000|Overall Study|Lack of Efficacy|4
6320830|NCT02826603|10059295|FG001|Overall Study|Lack of Efficacy|9
6320831|NCT02826603|10059294|FG000|Overall Study|Lost to Follow-up|13
6320832|NCT02826603|10059295|FG001|Overall Study|Lost to Follow-up|12
6320833|NCT02826603|10059294|FG000|Overall Study|Noncompliance with treatment|0
6320834|NCT02826603|10059295|FG001|Overall Study|Noncompliance with treatment|2
6320835|NCT02826603|10059294|FG000|Overall Study|Physician Decision|1
6320836|NCT02826603|10059295|FG001|Overall Study|Physician Decision|7
6320837|NCT02826603|10059294|FG000|Overall Study|Pregnancy|1
6320838|NCT02826603|10059295|FG001|Overall Study|Pregnancy|2
6320839|NCT02826603|10059294|FG000|Overall Study|Protocol Violation|3
6320840|NCT02826603|10059295|FG001|Overall Study|Protocol Violation|3
6320841|NCT02826603|10059294|FG000|Overall Study|Withdrawal by Subject|20
6320842|NCT02826603|10059295|FG001|Overall Study|Withdrawal by Subject|19
6320843|NCT02826603|10059294|FG000|Overall Study|Death|2
6320844|NCT02826603|10059295|FG001|Overall Study|Death|0
6320845|NCT02826603|10059294|FG000|Overall Study|New therapy for study indication|0
6320846|NCT02826603|10059295|FG001|Overall Study|New therapy for study indication|1
6320847|NCT02826798|10059318|FG000|Overall Study|Withdrawal by Subject|0
6320848|NCT02826798|10059319|FG001|Overall Study|Withdrawal by Subject|1
6320849|NCT02826798|10059320|FG002|Overall Study|Withdrawal by Subject|0
6320850|NCT02826798|10059321|FG003|Overall Study|Withdrawal by Subject|1
6320851|NCT02826798|10059322|FG004|Overall Study|Withdrawal by Subject|0
6320852|NCT02827500|10059336|FG000|Overall Study|Death|7
6320853|NCT02827500|10059337|FG001|Overall Study|Death|3
6320854|NCT02827500|10059336|FG000|Overall Study|Lost to Follow-up|1
6320855|NCT02827500|10059337|FG001|Overall Study|Lost to Follow-up|1
6320856|NCT02827500|10059336|FG000|Overall Study|Withdrawal by Subject|3
6320857|NCT02827500|10059337|FG001|Overall Study|Withdrawal by Subject|1
6320858|NCT02827500|10059336|FG000|Overall Study|Missing primary endpoint data|3
6320859|NCT02827500|10059337|FG001|Overall Study|Missing primary endpoint data|1
6320860|NCT02827500|10059336|FG000|Overall Study|Other|5
6320861|NCT02827500|10059337|FG001|Overall Study|Other|1
6320862|NCT02827708|10059345|FG000|Overall Study|Lost to Follow-up|3
6320863|NCT02827708|10059346|FG001|Overall Study|Lost to Follow-up|1
6320864|NCT02827708|10059345|FG000|Overall Study|Withdrawal by Subject|1
6320865|NCT02827708|10059346|FG001|Overall Study|Withdrawal by Subject|2
6320866|NCT02827708|10059345|FG000|Overall Study|Death|1
6320867|NCT02827708|10059346|FG001|Overall Study|Death|2
6320868|NCT02828020|10059355|FG000|Treatment Period|Adverse Event|3
6320869|NCT02828020|10059356|FG001|Treatment Period|Adverse Event|1
6320870|NCT02828020|10059357|FG002|Treatment Period|Adverse Event|1
6320871|NCT02828020|10059355|FG000|Treatment Period|Withdrawal of Consent|10
6320872|NCT02828020|10059356|FG001|Treatment Period|Withdrawal of Consent|14
6320873|NCT02828020|10059357|FG002|Treatment Period|Withdrawal of Consent|9
6320874|NCT02828020|10059355|FG000|Treatment Period|Lost to Follow-up|21
6320875|NCT02828020|10059356|FG001|Treatment Period|Lost to Follow-up|24
6320876|NCT02828020|10059357|FG002|Treatment Period|Lost to Follow-up|18
6320877|NCT02828020|10059355|FG000|Treatment Period|Lack of Qualifying Event|44
6041162|NCT00373958|9639299|FG001|Infant Series|Protocol Violation|7
6320878|NCT02828020|10059356|FG001|Treatment Period|Lack of Qualifying Event|53
6320879|NCT02828020|10059357|FG002|Treatment Period|Lack of Qualifying Event|43
6320880|NCT02828020|10059355|FG000|Treatment Period|Pregnancy|0
6320881|NCT02828020|10059356|FG001|Treatment Period|Pregnancy|2
6320882|NCT02828020|10059357|FG002|Treatment Period|Pregnancy|0
6320883|NCT02828020|10059355|FG000|Treatment Period|Protocol Violation|2
6320884|NCT02828020|10059356|FG001|Treatment Period|Protocol Violation|4
6320885|NCT02828020|10059357|FG002|Treatment Period|Protocol Violation|7
6320886|NCT02828020|10059355|FG000|Treatment Period|Other Miscellaneous Reasons|0
6320887|NCT02828020|10059356|FG001|Treatment Period|Other Miscellaneous Reasons|1
6041163|NCT00373958|9639298|FG000|Infant Series|Lost Kaiser coverage|4
6320888|NCT02828020|10059357|FG002|Treatment Period|Other Miscellaneous Reasons|0
6320889|NCT02828020|10059355|FG000|Safety Follow-up Period|Withdrawal of Consent|10
6320890|NCT02828020|10059356|FG001|Safety Follow-up Period|Withdrawal of Consent|8
6320891|NCT02828020|10059357|FG002|Safety Follow-up Period|Withdrawal of Consent|7
6320892|NCT02828020|10059355|FG000|Safety Follow-up Period|Lost to Follow-up|9
6320893|NCT02828020|10059356|FG001|Safety Follow-up Period|Lost to Follow-up|8
6320894|NCT02828020|10059357|FG002|Safety Follow-up Period|Lost to Follow-up|11
6320895|NCT02828020|10059355|FG000|Safety Follow-up Period|Protocol Violation|0
6320896|NCT02828020|10059356|FG001|Safety Follow-up Period|Protocol Violation|2
6320897|NCT02828020|10059357|FG002|Safety Follow-up Period|Protocol Violation|1
6320898|NCT02828020|10059355|FG000|Safety Follow-up Period|Other Miscellaneous Reasons|1
6320899|NCT02828020|10059356|FG001|Safety Follow-up Period|Other Miscellaneous Reasons|0
6320900|NCT02828020|10059357|FG002|Safety Follow-up Period|Other Miscellaneous Reasons|0
6320901|NCT02828111|10059370|FG000|Overall Study|Withdrawal by Subject|0
6320902|NCT02828111|10059371|FG001|Overall Study|Withdrawal by Subject|0
6320903|NCT02828111|10059372|FG002|Overall Study|Withdrawal by Subject|2
6320904|NCT02828111|10059373|FG003|Overall Study|Withdrawal by Subject|0
6320905|NCT02828111|10059374|FG004|Overall Study|Withdrawal by Subject|0
6320906|NCT02828111|10059370|FG000|Overall Study|Lost to Follow-up|0
6320907|NCT02828111|10059371|FG001|Overall Study|Lost to Follow-up|0
6320908|NCT02828111|10059372|FG002|Overall Study|Lost to Follow-up|0
6320909|NCT02828111|10059373|FG003|Overall Study|Lost to Follow-up|1
6320910|NCT02828111|10059374|FG004|Overall Study|Lost to Follow-up|1
6320911|NCT02828241|10059410|FG000|Overall Study|Adverse Event|7
6320912|NCT02828241|10059411|FG001|Overall Study|Adverse Event|2
6320913|NCT02828241|10059410|FG000|Overall Study|Protocol Violation|1
6320914|NCT02828241|10059411|FG001|Overall Study|Protocol Violation|0
6320915|NCT02828358|10059439|FG000|Overall Study|Physician Decision|7
6320916|NCT02828358|10059440|FG001|Overall Study|Physician Decision|1
6320917|NCT02828358|10059439|FG000|Overall Study|Treatment Failure|6
6320918|NCT02828358|10059440|FG001|Overall Study|Treatment Failure|0
6320919|NCT02828358|10059439|FG000|Overall Study|Patients without KMT2A rearrangement|0
6320920|NCT02828358|10059440|FG001|Overall Study|Patients without KMT2A rearrangement|21
6320921|NCT02828358|10059439|FG000|Overall Study|Refusal of further protocol therapy|2
6320922|NCT02828358|10059440|FG001|Overall Study|Refusal of further protocol therapy|0
6320923|NCT02828358|10059439|FG000|Overall Study|Relapse|25
6320924|NCT02828358|10059440|FG001|Overall Study|Relapse|0
6320925|NCT02828358|10059439|FG000|Overall Study|Still on therapy|5
6320926|NCT02828358|10059440|FG001|Overall Study|Still on therapy|0
6320927|NCT02828436|10059445|FG000|Period 1|Did Not Meet Inclusion Criteria|0
6320928|NCT02828436|10059446|FG001|Period 1|Did Not Meet Inclusion Criteria|3
6320929|NCT02828436|10059445|FG000|Period 1|Lost to Follow-up|0
6320930|NCT02828436|10059446|FG001|Period 1|Lost to Follow-up|1
6320931|NCT02828436|10059445|FG000|Period 2|Withdrawal by Subject|4
6320932|NCT02828436|10059446|FG001|Period 2|Withdrawal by Subject|0
6320933|NCT02828436|10059445|FG000|Period 2|Did Not Meet Inclusion Criteria|3
6041164|NCT00373958|9639299|FG001|Infant Series|Lost Kaiser coverage|0
6041165|NCT00373958|9639298|FG000|Infant Series|Child relocated|1
6320934|NCT02828436|10059446|FG001|Period 2|Did Not Meet Inclusion Criteria|0
6320935|NCT02828436|10059445|FG000|Period 2|Lost to Follow-up|1
6320936|NCT02828436|10059446|FG001|Period 2|Lost to Follow-up|0
6320937|NCT02828644|10059454|FG000|Overall Study|Lost to Follow-up|23
6320938|NCT02828644|10059455|FG001|Overall Study|Lost to Follow-up|22
6320939|NCT02829138|10059473|FG000|Overall Study|Withdrawal by Subject|1
6320940|NCT02829138|10059474|FG001|Overall Study|Withdrawal by Subject|0
6320941|NCT02829775|10059510|FG000|Overall Study|Death|1
6320942|NCT02829775|10059510|FG000|Overall Study|Withdrawal by Subject|3
6320943|NCT02829775|10059510|FG000|Overall Study|Disease remission|1
6320944|NCT02829944|10059517|FG000|Overall Study|Physician Decision|0
6320945|NCT02829944|10059518|FG001|Overall Study|Physician Decision|1
6320946|NCT02829944|10059517|FG000|Overall Study|Screen Failure|2
6320947|NCT02829944|10059518|FG001|Overall Study|Screen Failure|2
6320948|NCT02829944|10059517|FG000|Overall Study|Inadequate Neuraxial Block|1
6320949|NCT02829944|10059518|FG001|Overall Study|Inadequate Neuraxial Block|1
6320950|NCT02829944|10059517|FG000|Overall Study|Withdrawal by Subject|2
6320951|NCT02829944|10059518|FG001|Overall Study|Withdrawal by Subject|1
6320952|NCT02829944|10059517|FG000|Overall Study|Catheter Displacement|1
6320953|NCT02829944|10059518|FG001|Overall Study|Catheter Displacement|0
6320954|NCT02829944|10059517|FG000|Overall Study|Catheter broke|0
6320955|NCT02829944|10059518|FG001|Overall Study|Catheter broke|1
6320956|NCT02829944|10059517|FG000|Overall Study|Staff unavailable|0
6320957|NCT02829944|10059518|FG001|Overall Study|Staff unavailable|1
6320958|NCT02829996|10059538|FG000|Overall Study|Withdrawal by Subject|1
6320959|NCT02829996|10059539|FG001|Overall Study|Withdrawal by Subject|0
6320960|NCT02829996|10059540|FG002|Overall Study|Withdrawal by Subject|0
6320961|NCT02829996|10059541|FG003|Overall Study|Withdrawal by Subject|0
6320962|NCT02829996|10059542|FG004|Overall Study|Withdrawal by Subject|0
6320963|NCT02830087|10059570|FG000|Overall Study|No study staff to follow-up patients|4
6320964|NCT02830087|10059571|FG001|Overall Study|No study staff to follow-up patients|4
6320965|NCT02830087|10059572|FG002|Overall Study|No study staff to follow-up patients|4
6320966|NCT02830087|10059573|FG003|Overall Study|No study staff to follow-up patients|3
6320967|NCT02830087|10059574|FG004|Overall Study|No study staff to follow-up patients|3
6320968|NCT02830087|10059575|FG005|Overall Study|No study staff to follow-up patients|3
6320969|NCT02830776|10059593|FG000|Overall Study|Lost to Follow-up|1
6320970|NCT02830880|10059598|FG000|Overall Study|Adverse reaction to chemotherapy|1
6320971|NCT02830880|10059598|FG000|Overall Study|Death|1
6320972|NCT02830880|10059598|FG000|Overall Study|Physician Decision|1
6320973|NCT02830893|10059604|FG000|Overall Study|Relocation to out of the country|1
6320974|NCT02830893|10059605|FG001|Overall Study|Relocation to out of the country|0
6320975|NCT02830893|10059604|FG000|Overall Study|Lost to Follow-up|0
6320976|NCT02830893|10059605|FG001|Overall Study|Lost to Follow-up|2
6320977|NCT02830893|10059604|FG000|Overall Study|Discharged to SNF, no transportation.|0
6320978|NCT02830893|10059605|FG001|Overall Study|Discharged to SNF, no transportation.|1
6320979|NCT02831257|10059611|FG000|Overall Study|Lack of Efficacy|3
6320980|NCT02831257|10059611|FG000|Overall Study|Adverse Event|2
6320981|NCT02831257|10059611|FG000|Overall Study|Physician Decision|1
6320982|NCT02831257|10059611|FG000|Overall Study|Withdrawal by Subject|6
6320983|NCT02831387|10059617|FG000|Overall Study|Withdrawal by Subject|1
6320984|NCT02831387|10059618|FG001|Overall Study|Withdrawal by Subject|1
6320985|NCT02831387|10059617|FG000|Overall Study|Discontinued due to stock recovery|0
6320986|NCT02831387|10059618|FG001|Overall Study|Discontinued due to stock recovery|1
6320987|NCT02831855|10059643|FG000|Open Label Phase (24 Weeks)|Adverse Event|39
6320988|NCT02831855|10059644|FG001|Open Label Phase (24 Weeks)|Adverse Event|0
6320989|NCT02831855|10059645|FG002|Open Label Phase (24 Weeks)|Adverse Event|0
6320990|NCT02831855|10059643|FG000|Open Label Phase (24 Weeks)|Lost to Follow-up|8
6320991|NCT02831855|10059644|FG001|Open Label Phase (24 Weeks)|Lost to Follow-up|0
6320992|NCT02831855|10059645|FG002|Open Label Phase (24 Weeks)|Lost to Follow-up|0
6320993|NCT02831855|10059643|FG000|Open Label Phase (24 Weeks)|Insufficient Clinical Response|7
6320994|NCT02831855|10059644|FG001|Open Label Phase (24 Weeks)|Insufficient Clinical Response|0
6320995|NCT02831855|10059645|FG002|Open Label Phase (24 Weeks)|Insufficient Clinical Response|0
6320996|NCT02831855|10059643|FG000|Open Label Phase (24 Weeks)|Medication error,no linked adverse event|2
6320997|NCT02831855|10059644|FG001|Open Label Phase (24 Weeks)|Medication error,no linked adverse event|0
6320998|NCT02831855|10059645|FG002|Open Label Phase (24 Weeks)|Medication error,no linked adverse event|0
6320999|NCT02831855|10059643|FG000|Open Label Phase (24 Weeks)|Protocol Violation|5
6321000|NCT02831855|10059644|FG001|Open Label Phase (24 Weeks)|Protocol Violation|0
6321001|NCT02831855|10059645|FG002|Open Label Phase (24 Weeks)|Protocol Violation|0
6321002|NCT02831855|10059643|FG000|Open Label Phase (24 Weeks)|Withdrawal by Subject|6
6321003|NCT02831855|10059644|FG001|Open Label Phase (24 Weeks)|Withdrawal by Subject|0
6321004|NCT02831855|10059645|FG002|Open Label Phase (24 Weeks)|Withdrawal by Subject|0
6321005|NCT02831855|10059643|FG000|Open Label Phase (24 Weeks)|Other|4
6041166|NCT00373958|9639299|FG001|Infant Series|Child relocated|0
6321006|NCT02831855|10059644|FG001|Open Label Phase (24 Weeks)|Other|0
6321007|NCT02831855|10059645|FG002|Open Label Phase (24 Weeks)|Other|0
6321008|NCT02831855|10059643|FG000|Double Blind Phase (24 Weeks)|Adverse Event|0
6321009|NCT02831855|10059644|FG001|Double Blind Phase (24 Weeks)|Adverse Event|6
6321010|NCT02831855|10059645|FG002|Double Blind Phase (24 Weeks)|Adverse Event|6
6321011|NCT02831855|10059643|FG000|Double Blind Phase (24 Weeks)|Death|0
6321012|NCT02831855|10059644|FG001|Double Blind Phase (24 Weeks)|Death|0
6321013|NCT02831855|10059645|FG002|Double Blind Phase (24 Weeks)|Death|2
6321014|NCT02831855|10059643|FG000|Double Blind Phase (24 Weeks)|Lost to Follow-up|0
6321015|NCT02831855|10059644|FG001|Double Blind Phase (24 Weeks)|Lost to Follow-up|1
6321016|NCT02831855|10059645|FG002|Double Blind Phase (24 Weeks)|Lost to Follow-up|1
6321017|NCT02831855|10059643|FG000|Double Blind Phase (24 Weeks)|Screen Failure|0
6321018|NCT02831855|10059644|FG001|Double Blind Phase (24 Weeks)|Screen Failure|1
6321019|NCT02831855|10059645|FG002|Double Blind Phase (24 Weeks)|Screen Failure|0
6321020|NCT02831855|10059643|FG000|Double Blind Phase (24 Weeks)|Withdrawal by Subject|0
6321021|NCT02831855|10059644|FG001|Double Blind Phase (24 Weeks)|Withdrawal by Subject|5
6321022|NCT02831855|10059645|FG002|Double Blind Phase (24 Weeks)|Withdrawal by Subject|2
6321023|NCT02831855|10059643|FG000|Double Blind Phase (24 Weeks)|Other|0
6321024|NCT02831855|10059644|FG001|Double Blind Phase (24 Weeks)|Other|2
6321025|NCT02831855|10059645|FG002|Double Blind Phase (24 Weeks)|Other|5
6321026|NCT02831855|10059643|FG000|Double Blind Phase (24 Weeks)|Insufficient Clinical Response|0
6321027|NCT02831855|10059644|FG001|Double Blind Phase (24 Weeks)|Insufficient Clinical Response|6
6321028|NCT02831855|10059645|FG002|Double Blind Phase (24 Weeks)|Insufficient Clinical Response|1
6321029|NCT02831855|10059643|FG000|Double Blind Phase (24 Weeks)|Protocol Violation|0
6321030|NCT02831855|10059644|FG001|Double Blind Phase (24 Weeks)|Protocol Violation|5
6321031|NCT02831855|10059645|FG002|Double Blind Phase (24 Weeks)|Protocol Violation|2
6321032|NCT02831855|10059643|FG000|Double Blind Phase (24 Weeks)|Randomized but not Treated|0
6321033|NCT02831855|10059644|FG001|Double Blind Phase (24 Weeks)|Randomized but not Treated|3
6321034|NCT02831855|10059645|FG002|Double Blind Phase (24 Weeks)|Randomized but not Treated|0
6321035|NCT02832037|10059671|FG000|Overall Study|Administrative reasons|0
6321036|NCT02832037|10059672|FG001|Overall Study|Administrative reasons|0
6321037|NCT02832037|10059673|FG002|Overall Study|Administrative reasons|1
6321038|NCT02832037|10059674|FG003|Overall Study|Administrative reasons|0
6321039|NCT02832037|10059675|FG004|Overall Study|Administrative reasons|0
6321040|NCT02832037|10059671|FG000|Overall Study|Protocol Violation|3
6321041|NCT02832037|10059672|FG001|Overall Study|Protocol Violation|0
6321042|NCT02832037|10059673|FG002|Overall Study|Protocol Violation|4
6321043|NCT02832037|10059674|FG003|Overall Study|Protocol Violation|1
6321044|NCT02832037|10059675|FG004|Overall Study|Protocol Violation|2
6321045|NCT02832037|10059671|FG000|Overall Study|Lost to Follow-up|2
6321046|NCT02832037|10059672|FG001|Overall Study|Lost to Follow-up|0
6321047|NCT02832037|10059673|FG002|Overall Study|Lost to Follow-up|3
6321048|NCT02832037|10059674|FG003|Overall Study|Lost to Follow-up|0
6321049|NCT02832037|10059675|FG004|Overall Study|Lost to Follow-up|5
6321050|NCT02832037|10059671|FG000|Overall Study|Withdrawal by Subject|9
6321051|NCT02832037|10059672|FG001|Overall Study|Withdrawal by Subject|8
6321052|NCT02832037|10059673|FG002|Overall Study|Withdrawal by Subject|0
6321053|NCT02832037|10059674|FG003|Overall Study|Withdrawal by Subject|4
6321054|NCT02832037|10059675|FG004|Overall Study|Withdrawal by Subject|8
6321055|NCT02832037|10059671|FG000|Overall Study|Adverse Event|5
6321056|NCT02832037|10059672|FG001|Overall Study|Adverse Event|4
6321057|NCT02832037|10059673|FG002|Overall Study|Adverse Event|0
6321058|NCT02832037|10059674|FG003|Overall Study|Adverse Event|2
6321059|NCT02832037|10059675|FG004|Overall Study|Adverse Event|4
6321060|NCT02832375|10059706|FG000|Overall Study|Lost to Follow-up|1
6321061|NCT02832375|10059707|FG001|Overall Study|Lost to Follow-up|0
6321062|NCT02832375|10059706|FG000|Overall Study|Withdrawal of Consent|1
6321063|NCT02832375|10059707|FG001|Overall Study|Withdrawal of Consent|0
6321064|NCT02832622|10059714|FG000|Overall Study|MPP not programmed|1259
6321065|NCT02832622|10059714|FG000|Overall Study|Withdrawal by Subject|123
6321066|NCT02832622|10059714|FG000|Overall Study|Death|119
6321067|NCT02832622|10059714|FG000|Overall Study|Unsuccessful CRT implant|93
6321068|NCT02832622|10059714|FG000|Overall Study|Lost to Follow-up|45
6321069|NCT02832622|10059714|FG000|Overall Study|Patient non-compliance|42
6321070|NCT02832622|10059714|FG000|Overall Study|Withdrawal by other reasons|25
6321071|NCT02832622|10059714|FG000|Overall Study|System explant|24
6321072|NCT02832622|10059714|FG000|Overall Study|Physician Decision|6
6321073|NCT02833077|10059725|FG000|Overall Study|Adverse Event|1
6321074|NCT02833077|10059726|FG001|Overall Study|Adverse Event|2
6321075|NCT02833077|10059725|FG000|Overall Study|Lost to Follow-up|10
6321076|NCT02833077|10059726|FG001|Overall Study|Lost to Follow-up|1
6321077|NCT02833077|10059725|FG000|Overall Study|Personal Reasons|6
6321078|NCT02833077|10059726|FG001|Overall Study|Personal Reasons|4
6321079|NCT02833077|10059725|FG000|Overall Study|Protocol Deviation|0
6321080|NCT02833077|10059726|FG001|Overall Study|Protocol Deviation|1
6321081|NCT02833350|10059744|FG000|Overall Study|Adverse Event|0
6321082|NCT02833350|10059745|FG001|Overall Study|Adverse Event|3
6321083|NCT02833350|10059746|FG002|Overall Study|Adverse Event|4
6321084|NCT02833350|10059747|FG003|Overall Study|Adverse Event|4
6321085|NCT02833350|10059748|FG004|Overall Study|Adverse Event|1
6321086|NCT02833350|10059749|FG005|Overall Study|Adverse Event|0
6321087|NCT02833350|10059750|FG006|Overall Study|Adverse Event|1
6321088|NCT02833350|10059744|FG000|Overall Study|Death|0
6321089|NCT02833350|10059745|FG001|Overall Study|Death|0
6321090|NCT02833350|10059746|FG002|Overall Study|Death|1
6321091|NCT02833350|10059747|FG003|Overall Study|Death|0
6321092|NCT02833350|10059748|FG004|Overall Study|Death|0
6321093|NCT02833350|10059749|FG005|Overall Study|Death|0
6321094|NCT02833350|10059750|FG006|Overall Study|Death|0
6321095|NCT02833350|10059744|FG000|Overall Study|Lack of Efficacy|0
6321096|NCT02833350|10059745|FG001|Overall Study|Lack of Efficacy|2
6321097|NCT02833350|10059746|FG002|Overall Study|Lack of Efficacy|1
6321098|NCT02833350|10059747|FG003|Overall Study|Lack of Efficacy|4
6321099|NCT02833350|10059748|FG004|Overall Study|Lack of Efficacy|0
6321100|NCT02833350|10059749|FG005|Overall Study|Lack of Efficacy|1
6321101|NCT02833350|10059750|FG006|Overall Study|Lack of Efficacy|1
6321102|NCT02833350|10059744|FG000|Overall Study|Lost to Follow-up|0
6321103|NCT02833350|10059745|FG001|Overall Study|Lost to Follow-up|1
6321104|NCT02833350|10059746|FG002|Overall Study|Lost to Follow-up|0
6321105|NCT02833350|10059747|FG003|Overall Study|Lost to Follow-up|0
6321106|NCT02833350|10059748|FG004|Overall Study|Lost to Follow-up|0
6321107|NCT02833350|10059749|FG005|Overall Study|Lost to Follow-up|0
6321108|NCT02833350|10059750|FG006|Overall Study|Lost to Follow-up|1
6321109|NCT02833350|10059744|FG000|Overall Study|Withdrawal by Subject|3
6321110|NCT02833350|10059745|FG001|Overall Study|Withdrawal by Subject|3
6321111|NCT02833350|10059746|FG002|Overall Study|Withdrawal by Subject|2
6321112|NCT02833350|10059747|FG003|Overall Study|Withdrawal by Subject|0
6321113|NCT02833350|10059748|FG004|Overall Study|Withdrawal by Subject|2
6321114|NCT02833350|10059749|FG005|Overall Study|Withdrawal by Subject|0
6321115|NCT02833350|10059750|FG006|Overall Study|Withdrawal by Subject|2
6321116|NCT02833844|10059780|FG000|Double-Blind Period|Withdrawal by Subject|2
6321117|NCT02833844|10059781|FG001|Double-Blind Period|Withdrawal by Subject|3
6321118|NCT02833844|10059780|FG000|Double-Blind Period|Protocol Violation|0
6321119|NCT02833844|10059781|FG001|Double-Blind Period|Protocol Violation|4
6321120|NCT02833844|10059780|FG000|Open-Label Period|Death|0
6321121|NCT02833844|10059781|FG001|Open-Label Period|Death|2
6321122|NCT02833844|10059780|FG000|Open-Label Period|Lost to Follow-up|1
6321123|NCT02833844|10059781|FG001|Open-Label Period|Lost to Follow-up|0
6321124|NCT02833844|10059780|FG000|Open-Label Period|Withdrawal by Subject|1
6321125|NCT02833844|10059781|FG001|Open-Label Period|Withdrawal by Subject|0
6321126|NCT02833948|10059799|FG000|Overall Study|Death|2
6321127|NCT02833948|10059800|FG001|Overall Study|Death|3
6321128|NCT02833948|10059799|FG000|Overall Study|were not scanned|8
6321129|NCT02833948|10059800|FG001|Overall Study|were not scanned|13
6321130|NCT02833948|10059799|FG000|Overall Study|scans could not be evaluated|5
6321131|NCT02833948|10059800|FG001|Overall Study|scans could not be evaluated|2
6321132|NCT02833974|10059812|FG000|Overall Study|Lost to Follow-up|1
6321133|NCT02833974|10059813|FG001|Overall Study|Lost to Follow-up|0
6321134|NCT02833974|10059812|FG000|Overall Study|Adverse Event|0
6321135|NCT02833974|10059813|FG001|Overall Study|Adverse Event|3
6321136|NCT02834247|10059823|FG000|Dose Escalation Phase|Study Terminated by Sponsor|1
6321137|NCT02834247|10059824|FG001|Dose Escalation Phase|Study Terminated by Sponsor|2
6321138|NCT02834247|10059825|FG002|Dose Escalation Phase|Study Terminated by Sponsor|0
6321139|NCT02834247|10059826|FG003|Dose Escalation Phase|Study Terminated by Sponsor|0
6321140|NCT02834247|10059823|FG000|Dose Escalation Phase|Death|5
6321141|NCT02834247|10059824|FG001|Dose Escalation Phase|Death|6
6321142|NCT02834247|10059825|FG002|Dose Escalation Phase|Death|5
6321143|NCT02834247|10059826|FG003|Dose Escalation Phase|Death|0
6321144|NCT02834247|10059823|FG000|Dose Escalation Phase|Lost to Follow-up|0
6321145|NCT02834247|10059824|FG001|Dose Escalation Phase|Lost to Follow-up|1
6321146|NCT02834247|10059825|FG002|Dose Escalation Phase|Lost to Follow-up|0
6321147|NCT02834247|10059826|FG003|Dose Escalation Phase|Lost to Follow-up|0
6321148|NCT02834247|10059823|FG000|Dose Escalation Phase|Withdrawal by Subject|2
6321149|NCT02834247|10059824|FG001|Dose Escalation Phase|Withdrawal by Subject|2
6321150|NCT02834247|10059825|FG002|Dose Escalation Phase|Withdrawal by Subject|0
6321151|NCT02834247|10059826|FG003|Dose Escalation Phase|Withdrawal by Subject|0
6321152|NCT02834247|10059823|FG000|Dose Expansion Phase|Study Terminated by Sponsor|0
6321153|NCT02834247|10059824|FG001|Dose Expansion Phase|Study Terminated by Sponsor|0
6321154|NCT02834247|10059825|FG002|Dose Expansion Phase|Study Terminated by Sponsor|0
6321155|NCT02834247|10059826|FG003|Dose Expansion Phase|Study Terminated by Sponsor|7
6321156|NCT02834247|10059823|FG000|Dose Expansion Phase|Death|0
6321157|NCT02834247|10059824|FG001|Dose Expansion Phase|Death|0
6321158|NCT02834247|10059825|FG002|Dose Expansion Phase|Death|0
6321159|NCT02834247|10059826|FG003|Dose Expansion Phase|Death|8
6321160|NCT02834247|10059823|FG000|Dose Expansion Phase|Lost to Follow-up|0
6321161|NCT02834247|10059824|FG001|Dose Expansion Phase|Lost to Follow-up|0
6321162|NCT02834247|10059825|FG002|Dose Expansion Phase|Lost to Follow-up|0
6321163|NCT02834247|10059826|FG003|Dose Expansion Phase|Lost to Follow-up|1
6321164|NCT02834247|10059823|FG000|Dose Expansion Phase|Withdrawal by Subject|0
6321165|NCT02834247|10059824|FG001|Dose Expansion Phase|Withdrawal by Subject|0
6321166|NCT02834247|10059825|FG002|Dose Expansion Phase|Withdrawal by Subject|0
6321167|NCT02834247|10059826|FG003|Dose Expansion Phase|Withdrawal by Subject|1
6321168|NCT02834390|10059840|FG000|Induction Phase|Progressive disease|0
6321169|NCT02834390|10059841|FG001|Induction Phase|Progressive disease|1
6321170|NCT02834390|10059840|FG000|Induction Phase|CR, CRp, or CRi not achieved (Induction Cycle 2)|2
6321171|NCT02834390|10059841|FG001|Induction Phase|CR, CRp, or CRi not achieved (Induction Cycle 2)|0
6321172|NCT02834390|10059840|FG000|Induction Phase|Relapse after CR, CRp, or CRi|0
6321173|NCT02834390|10059841|FG001|Induction Phase|Relapse after CR, CRp, or CRi|1
6321174|NCT02834390|10059840|FG000|Consolidation Phase|Physician Decision|1
6321175|NCT02834390|10059841|FG001|Consolidation Phase|Physician Decision|1
6321176|NCT02834819|10059881|FG000|Overall Study|Did not complete 7 day follow up call.|5
6321177|NCT02834819|10059882|FG001|Overall Study|Did not complete 7 day follow up call.|0
6321178|NCT02835092|10059891|FG000|Overall Study|Withdrawal by Subject|3
6321179|NCT02835092|10059892|FG001|Overall Study|Withdrawal by Subject|6
6321180|NCT02835092|10059893|FG002|Overall Study|Withdrawal by Subject|3
6321181|NCT02835092|10059891|FG000|Overall Study|Lost to Follow-up|0
6321182|NCT02835092|10059892|FG001|Overall Study|Lost to Follow-up|2
6321183|NCT02835092|10059893|FG002|Overall Study|Lost to Follow-up|0
6321184|NCT02835339|10059912|FG000|Overall Study|Did not receive allocated intervention|13
6321185|NCT02835339|10059913|FG001|Overall Study|Did not receive allocated intervention|16
6321186|NCT02835495|10059921|FG000|Overall Study|Cancer diagnosis prior intervention|1
6321187|NCT02835495|10059922|FG001|Overall Study|Cancer diagnosis prior intervention|0
6321188|NCT02835495|10059921|FG000|Overall Study|Declined in-person follow-up visit|4
6321189|NCT02835495|10059922|FG001|Overall Study|Declined in-person follow-up visit|2
6321190|NCT02835820|10059946|FG000|Overall Study|Baseline Screen Failure|0
6321191|NCT02835820|10059947|FG001|Overall Study|Baseline Screen Failure|3
6321192|NCT02836496|10059959|FG000|Overall Study|Adverse Event|2
6321193|NCT02836496|10059960|FG001|Overall Study|Adverse Event|1
6321194|NCT02836496|10059959|FG000|Overall Study|Withdrawal by Subject|0
6321195|NCT02836496|10059960|FG001|Overall Study|Withdrawal by Subject|1
6321196|NCT02836613|10059968|FG000|Overall Study|Accidental drowning|1
6321197|NCT02836613|10059969|FG001|Overall Study|Accidental drowning|0
6321198|NCT02836613|10059968|FG000|Overall Study|Lost to Follow-up|0
6321199|NCT02836613|10059969|FG001|Overall Study|Lost to Follow-up|1
6321200|NCT02836613|10059968|FG000|Overall Study|Withdrawal by Subject|0
6041167|NCT00373958|9639298|FG000|Infant Series|Consent was not received|1
6041168|NCT00373958|9639299|FG001|Infant Series|Consent was not received|0
6321201|NCT02836613|10059969|FG001|Overall Study|Withdrawal by Subject|2
6321202|NCT02836652|10059977|FG000|Overall Study|Death|3
6321203|NCT02836652|10059978|FG001|Overall Study|Death|3
6321204|NCT02836652|10059977|FG000|Overall Study|Transplant/Explant|3
6321205|NCT02836652|10059978|FG001|Overall Study|Transplant/Explant|4
6321206|NCT02836652|10059977|FG000|Overall Study|Withdrawn|9
6321207|NCT02836652|10059978|FG001|Overall Study|Withdrawn|9
6321208|NCT02836652|10059977|FG000|Overall Study|Not on treatment regimen post-op day 15|3
6321209|NCT02836652|10059978|FG001|Overall Study|Not on treatment regimen post-op day 15|3
6321210|NCT02836769|10059984|FG000|Overall Study|Lost to Follow-up|10
6321211|NCT02836769|10059984|FG000|Overall Study|Medical withdrawal|2
6321212|NCT02836769|10059984|FG000|Overall Study|Withdrawal by Subject|3
6321213|NCT02836873|10059990|FG000|Overall Study|Protocol Violation|0
6321214|NCT02836873|10059991|FG001|Overall Study|Protocol Violation|1
6321215|NCT02836873|10059990|FG000|Overall Study|Adverse Event|1
6321216|NCT02836873|10059991|FG001|Overall Study|Adverse Event|4
6321217|NCT02836873|10059990|FG000|Overall Study|Withdrawal by Subject|2
6321218|NCT02836873|10059991|FG001|Overall Study|Withdrawal by Subject|2
6321219|NCT02836873|10059990|FG000|Overall Study|Lost to Follow-up|1
6321220|NCT02836873|10059991|FG001|Overall Study|Lost to Follow-up|3
6321221|NCT02836873|10059990|FG000|Overall Study|Physician Decision|0
6321222|NCT02836873|10059991|FG001|Overall Study|Physician Decision|1
6321223|NCT02836873|10059990|FG000|Overall Study|Other|1
6321224|NCT02836873|10059991|FG001|Overall Study|Other|0
6321225|NCT02837731|10060023|FG000|Allocation|Admitted to General Floor|3
6321226|NCT02837731|10060024|FG001|Allocation|Admitted to General Floor|4
6321227|NCT02837731|10060023|FG000|Allocation|Immediate surgery/withdrew|2
6321228|NCT02837731|10060024|FG001|Allocation|Immediate surgery/withdrew|0
6321229|NCT02837731|10060023|FG000|Allocation|Diabetic Ketoacidosis/withdrew|1
6321230|NCT02837731|10060024|FG001|Allocation|Diabetic Ketoacidosis/withdrew|0
6321231|NCT02837731|10060023|FG000|Allocation|Withdrawal by Subject|2
6321232|NCT02837731|10060024|FG001|Allocation|Withdrawal by Subject|0
6321233|NCT02837731|10060023|FG000|Allocation|Device not available|1
6321234|NCT02837731|10060024|FG001|Allocation|Device not available|0
6321235|NCT02837731|10060023|FG000|Allocation|Protocol not implemented|7
6321236|NCT02837731|10060024|FG001|Allocation|Protocol not implemented|0
6321237|NCT02837731|10060023|FG000|Allocation|Moribund/Do not resuscitate|2
6321238|NCT02837731|10060024|FG001|Allocation|Moribund/Do not resuscitate|0
6321239|NCT02837731|10060023|FG000|Allocation|Did not meet sepsis criteria|1
6321240|NCT02837731|10060024|FG001|Allocation|Did not meet sepsis criteria|2
6321241|NCT02837731|10060023|FG000|Allocation|Known aortic abnormalities|0
6321242|NCT02837731|10060024|FG001|Allocation|Known aortic abnormalities|1
6321243|NCT02837952|10060045|FG000|Overall Study|Adverse Event|0
6321244|NCT02837952|10060046|FG001|Overall Study|Adverse Event|1
6321245|NCT02837952|10060045|FG000|Overall Study|Withdrawal by Subject|4
6321246|NCT02837952|10060046|FG001|Overall Study|Withdrawal by Subject|5
6321247|NCT02837952|10060045|FG000|Overall Study|Medication Error|1
6321248|NCT02837952|10060046|FG001|Overall Study|Medication Error|0
6321249|NCT02838017|10060054|FG000|Overall Study|Lost to Follow-up|14
6321250|NCT02838017|10060055|FG001|Overall Study|Lost to Follow-up|11
6321251|NCT02838134|10060063|FG000|Overall Study|Lost to Follow-up|1
6321252|NCT02838134|10060064|FG001|Overall Study|Lost to Follow-up|2
6321253|NCT02838134|10060063|FG000|Overall Study|logistic problems|1
6321254|NCT02838134|10060064|FG001|Overall Study|logistic problems|1
6321255|NCT02838420|10060076|FG000|Overall Study|Ongoing in Study|113
6321256|NCT02838420|10060077|FG001|Overall Study|Ongoing in Study|45
6321257|NCT02838420|10060076|FG000|Overall Study|Lost to Follow-up|1
6321258|NCT02838420|10060077|FG001|Overall Study|Lost to Follow-up|0
6321259|NCT02838420|10060076|FG000|Overall Study|Withdrawal by Subject|3
6321260|NCT02838420|10060077|FG001|Overall Study|Withdrawal by Subject|4
6321261|NCT02838420|10060076|FG000|Overall Study|Death|8
6321262|NCT02838420|10060077|FG001|Overall Study|Death|13
6321263|NCT02838628|10060085|FG000|Recurrence Follow-up Period|AK Recurrence|18
6321264|NCT02838628|10060086|FG001|Recurrence Follow-up Period|AK Recurrence|13
6321265|NCT02838628|10060085|FG000|Recurrence Follow-up Period|Adverse Event|1
6321266|NCT02838628|10060086|FG001|Recurrence Follow-up Period|Adverse Event|0
6321267|NCT02838628|10060085|FG000|Recurrence Follow-up Period|Non-compliance|0
6321268|NCT02838628|10060086|FG001|Recurrence Follow-up Period|Non-compliance|1
6321269|NCT02838628|10060085|FG000|Recurrence Follow-up Period|Withdrawal by Subject|0
6321270|NCT02838628|10060086|FG001|Recurrence Follow-up Period|Withdrawal by Subject|2
6321271|NCT02838628|10060085|FG000|Recurrence Follow-up Period|Other un-specified|1
6321272|NCT02838628|10060086|FG001|Recurrence Follow-up Period|Other un-specified|1
6321273|NCT02838901|10060095|FG000|Overall Study|Withdrawal by Subject|1
6321274|NCT02838901|10060096|FG001|Overall Study|Withdrawal by Subject|1
6321275|NCT02838901|10060095|FG000|Overall Study|Lost to Follow-up|1
6321276|NCT02838901|10060096|FG001|Overall Study|Lost to Follow-up|1
6321277|NCT02839200|10060110|FG000|Overall Study|Withdrawal by Subject|2
6321278|NCT02839200|10060111|FG001|Overall Study|Withdrawal by Subject|0
6321279|NCT02839200|10060112|FG002|Overall Study|Withdrawal by Subject|1
6321280|NCT02839200|10060113|FG003|Overall Study|Withdrawal by Subject|0
6321281|NCT02839200|10060114|FG004|Overall Study|Withdrawal by Subject|0
6321282|NCT02839200|10060115|FG005|Overall Study|Withdrawal by Subject|1
6321283|NCT02839200|10060110|FG000|Overall Study|Lost to Follow-up|2
6321284|NCT02839200|10060111|FG001|Overall Study|Lost to Follow-up|0
6321285|NCT02839200|10060112|FG002|Overall Study|Lost to Follow-up|0
6321286|NCT02839200|10060113|FG003|Overall Study|Lost to Follow-up|0
6321287|NCT02839200|10060114|FG004|Overall Study|Lost to Follow-up|1
6321288|NCT02839200|10060115|FG005|Overall Study|Lost to Follow-up|0
6321289|NCT02839200|10060110|FG000|Overall Study|Adverse Event|0
6321290|NCT02839200|10060111|FG001|Overall Study|Adverse Event|0
6321291|NCT02839200|10060112|FG002|Overall Study|Adverse Event|0
6321292|NCT02839200|10060113|FG003|Overall Study|Adverse Event|0
6321293|NCT02839200|10060114|FG004|Overall Study|Adverse Event|1
6321294|NCT02839200|10060115|FG005|Overall Study|Adverse Event|0
6321295|NCT02839200|10060110|FG000|Overall Study|Randomized in error|0
6321296|NCT02839200|10060111|FG001|Overall Study|Randomized in error|1
6321297|NCT02839200|10060112|FG002|Overall Study|Randomized in error|0
6321298|NCT02839200|10060113|FG003|Overall Study|Randomized in error|0
6321299|NCT02839200|10060114|FG004|Overall Study|Randomized in error|0
6321300|NCT02839200|10060115|FG005|Overall Study|Randomized in error|0
6321301|NCT02839330|10060133|FG000|Overall Study|Adverse Event|0
6321302|NCT02839330|10060134|FG001|Overall Study|Adverse Event|1
6321303|NCT02839330|10060135|FG002|Overall Study|Adverse Event|2
6321304|NCT02839330|10060136|FG003|Overall Study|Adverse Event|2
6321305|NCT02839330|10060133|FG000|Overall Study|Death|4
6321306|NCT02839330|10060134|FG001|Overall Study|Death|6
6321307|NCT02839330|10060135|FG002|Overall Study|Death|1
6321308|NCT02839330|10060136|FG003|Overall Study|Death|1
6321309|NCT02839330|10060133|FG000|Overall Study|Withdrawal by Subject|27
6321310|NCT02839330|10060134|FG001|Overall Study|Withdrawal by Subject|19
6321311|NCT02839330|10060135|FG002|Overall Study|Withdrawal by Subject|11
6321312|NCT02839330|10060136|FG003|Overall Study|Withdrawal by Subject|13
6321313|NCT02839330|10060133|FG000|Overall Study|Lost to Follow-up|22
6321314|NCT02839330|10060134|FG001|Overall Study|Lost to Follow-up|27
6321315|NCT02839330|10060135|FG002|Overall Study|Lost to Follow-up|29
6321316|NCT02839330|10060136|FG003|Overall Study|Lost to Follow-up|25
6321317|NCT02839330|10060133|FG000|Overall Study|Administrative Reason|0
6321318|NCT02839330|10060134|FG001|Overall Study|Administrative Reason|0
6321319|NCT02839330|10060135|FG002|Overall Study|Administrative Reason|0
6321320|NCT02839330|10060136|FG003|Overall Study|Administrative Reason|1
6321321|NCT02839330|10060133|FG000|Overall Study|Protocol Violation|1
6321322|NCT02839330|10060134|FG001|Overall Study|Protocol Violation|2
6321323|NCT02839330|10060135|FG002|Overall Study|Protocol Violation|2
6321324|NCT02839330|10060136|FG003|Overall Study|Protocol Violation|3
6321325|NCT02839330|10060133|FG000|Overall Study|Other reason, not specified|4
6321326|NCT02839330|10060134|FG001|Overall Study|Other reason, not specified|3
6321327|NCT02839330|10060135|FG002|Overall Study|Other reason, not specified|3
6321328|NCT02839330|10060136|FG003|Overall Study|Other reason, not specified|6
6321329|NCT02839681|10060147|FG000|Overall Study|Death|2
6321330|NCT02839746|10060151|FG000|Overall Study|Not met selection criteria|12
6321331|NCT02839798|10060178|FG000|Overall Study|Withdrawal by Subject|2
6321332|NCT02839876|10060184|FG000|Overall Study|Protocol Violation|10
6321333|NCT02839876|10060185|FG001|Overall Study|Protocol Violation|11
6321334|NCT02840253|10060225|FG000|Overall Study|Unsuccessful block|4
6321335|NCT02840461|10060232|FG000|Overall Study|Adverse Event|1
6321336|NCT02840461|10060233|FG001|Overall Study|Adverse Event|5
6321337|NCT02840461|10060234|FG002|Overall Study|Adverse Event|3
6321338|NCT02840461|10060232|FG000|Overall Study|Lost to Follow-up|10
6321339|NCT02840461|10060233|FG001|Overall Study|Lost to Follow-up|7
6321340|NCT02840461|10060234|FG002|Overall Study|Lost to Follow-up|6
6321341|NCT02840461|10060232|FG000|Overall Study|Non-Comliance with Dosing Requirements|0
6321342|NCT02840461|10060233|FG001|Overall Study|Non-Comliance with Dosing Requirements|1
6321343|NCT02840461|10060234|FG002|Overall Study|Non-Comliance with Dosing Requirements|0
6321344|NCT02840461|10060232|FG000|Overall Study|Protocol Violation|2
6321345|NCT02840461|10060233|FG001|Overall Study|Protocol Violation|3
6321346|NCT02840461|10060234|FG002|Overall Study|Protocol Violation|1
6321347|NCT02840461|10060232|FG000|Overall Study|Withdrawal by Subject|10
6321348|NCT02840461|10060233|FG001|Overall Study|Withdrawal by Subject|6
6321349|NCT02840461|10060234|FG002|Overall Study|Withdrawal by Subject|2
6321350|NCT02840461|10060232|FG000|Overall Study|Worsening of Symptom & Kit Error|0
6321351|NCT02840461|10060233|FG001|Overall Study|Worsening of Symptom & Kit Error|0
6321352|NCT02840461|10060234|FG002|Overall Study|Worsening of Symptom & Kit Error|2
6321353|NCT02840474|10060245|FG000|Overall Study|Lost to Follow-up|1
6321354|NCT02840474|10060246|FG001|Overall Study|Lost to Follow-up|0
6321355|NCT02840721|10060252|FG000|Treatment Period|Adverse Event|1
6321356|NCT02840721|10060252|FG000|Follow-Up|Lack of Efficacy|1
6321357|NCT02840721|10060252|FG000|Follow-Up|Withdrawal by Subject|4
6321358|NCT02840721|10060252|FG000|Follow-Up|Withdrawal of Consent|2
6321359|NCT02841709|10060320|FG000|5th Intervention|Adverse Event|2
6321360|NCT02841709|10060321|FG001|5th Intervention|Adverse Event|0
6321361|NCT02841709|10060322|FG002|5th Intervention|Adverse Event|0
6321362|NCT02841709|10060323|FG003|5th Intervention|Adverse Event|0
6321363|NCT02841709|10060324|FG004|5th Intervention|Adverse Event|2
6321364|NCT02841787|10060340|FG000|Overall Study|Lost to Follow-up|1
6321365|NCT02841787|10060341|FG001|Overall Study|Lost to Follow-up|0
6321366|NCT02841787|10060342|FG002|Overall Study|Lost to Follow-up|0
6321367|NCT02841787|10060340|FG000|Overall Study|Symptoms dropped below threshold|1
6321368|NCT02841787|10060341|FG001|Overall Study|Symptoms dropped below threshold|0
6321369|NCT02841787|10060342|FG002|Overall Study|Symptoms dropped below threshold|0
6321370|NCT02841787|10060340|FG000|Overall Study|Withdrawal by Subject|1
6321371|NCT02841787|10060341|FG001|Overall Study|Withdrawal by Subject|4
6321372|NCT02841787|10060342|FG002|Overall Study|Withdrawal by Subject|0
6321373|NCT02842073|10060359|FG000|Overall Study|Withdrawal by Subject|1
6321374|NCT02842086|10060365|FG000|Overall Study|Randomized but Never Treated|6
6321375|NCT02842086|10060366|FG001|Overall Study|Randomized but Never Treated|6
6321376|NCT02842086|10060365|FG000|Overall Study|Still in Double-Blind Phase|7
6321377|NCT02842086|10060366|FG001|Overall Study|Still in Double-Blind Phase|3
6321378|NCT02842086|10060365|FG000|Overall Study|Adverse Event|18
6321379|NCT02842086|10060366|FG001|Overall Study|Adverse Event|20
6321380|NCT02842086|10060365|FG000|Overall Study|Death|3
6321381|NCT02842086|10060366|FG001|Overall Study|Death|3
6321382|NCT02842086|10060365|FG000|Overall Study|Investigator's Discretion|9
6321383|NCT02842086|10060366|FG001|Overall Study|Investigator's Discretion|13
6321384|NCT02842086|10060365|FG000|Overall Study|Non-Compliance with Study Drug|9
6321385|NCT02842086|10060366|FG001|Overall Study|Non-Compliance with Study Drug|8
6321386|NCT02842086|10060365|FG000|Overall Study|Protocol Violation|8
6321387|NCT02842086|10060366|FG001|Overall Study|Protocol Violation|4
6321388|NCT02842086|10060365|FG000|Overall Study|Withdrew Consent|205
6321389|NCT02842086|10060366|FG001|Overall Study|Withdrew Consent|194
6321390|NCT02842086|10060365|FG000|Overall Study|Lost to Follow-up|274
6321391|NCT02842086|10060366|FG001|Overall Study|Lost to Follow-up|236
6321392|NCT02842086|10060365|FG000|Overall Study|HIV-1 Infection|5
6321393|NCT02842086|10060366|FG001|Overall Study|HIV-1 Infection|6
6321394|NCT02842151|10060372|FG000|Overall Study|Adverse Event|1
6321395|NCT02842151|10060372|FG000|Overall Study|Subject moved too far away|1
6321396|NCT02842736|10060387|FG000|Overall Study|Lost to Follow-up|13
6321397|NCT02842736|10060387|FG000|Overall Study|Intervention for menstrual bleeding|17
6321398|NCT02842736|10060387|FG000|Overall Study|Withdrawal by Subject|4
6321399|NCT02842736|10060387|FG000|Overall Study|Pregnancy|3
6321400|NCT02842736|10060387|FG000|Overall Study|Hysterectomy for fibroids|2
6321401|NCT02842736|10060387|FG000|Overall Study|Hysterectomy for uterine prolapse|1
6321402|NCT02842736|10060387|FG000|Overall Study|IUD: Mirena|1
6321403|NCT02843178|10060395|FG000|Overall Study|Lost to Follow-up|8
6321404|NCT02843178|10060396|FG001|Overall Study|Lost to Follow-up|8
6321405|NCT02843178|10060397|FG002|Overall Study|Lost to Follow-up|6
6321406|NCT02843178|10060398|FG003|Overall Study|Lost to Follow-up|3
6321407|NCT02843178|10060395|FG000|Overall Study|Withdrawal by Subject|0
6321408|NCT02843178|10060396|FG001|Overall Study|Withdrawal by Subject|0
6321409|NCT02843178|10060397|FG002|Overall Study|Withdrawal by Subject|1
6321410|NCT02843178|10060398|FG003|Overall Study|Withdrawal by Subject|1
6321411|NCT02843659|10060420|FG000|Overall Study|Subject Withdrew Consent|0
6321412|NCT02843659|10060421|FG001|Overall Study|Subject Withdrew Consent|0
6321413|NCT02843659|10060422|FG002|Overall Study|Subject Withdrew Consent|1
6321414|NCT02843659|10060420|FG000|Overall Study|Administrative Reason by Sponsor|4
6321415|NCT02843659|10060421|FG001|Overall Study|Administrative Reason by Sponsor|5
6321416|NCT02843659|10060422|FG002|Overall Study|Administrative Reason by Sponsor|4
6321417|NCT02843659|10060420|FG000|Overall Study|Adverse Event|0
6321418|NCT02843659|10060421|FG001|Overall Study|Adverse Event|1
6321419|NCT02843659|10060422|FG002|Overall Study|Adverse Event|0
6151970|NCT01116440|9788933|FG001|Follow-up|Lost to Follow-up|1
6321420|NCT02844439|10060430|FG000|Overall Study|Withdrawal by Subject|1
6321421|NCT02844439|10060430|FG000|Overall Study|Lost to Follow-up|2
6321422|NCT02844439|10060430|FG000|Overall Study|Termination by Sponsor|4
6321423|NCT02844439|10060430|FG000|Overall Study|Death|28
6321424|NCT02844439|10060430|FG000|Overall Study|Other|5
6321425|NCT02844543|10060441|FG000|Overall Study|Withdrawal by Subject|4
6321426|NCT02844543|10060441|FG000|Overall Study|Did not meet eligibility criteria|1
6321427|NCT02844920|10060458|FG000|Overall Study|Lost to Follow-up|2
6321428|NCT02845336|10060477|FG000|Overall Study|Lost to Follow-up|3
6321429|NCT02845336|10060478|FG001|Overall Study|Lost to Follow-up|1
6321430|NCT02845336|10060477|FG000|Overall Study|Inability to get medication|2
6321431|NCT02845336|10060478|FG001|Overall Study|Inability to get medication|0
6321432|NCT02845375|10060487|FG000|Overall Study|upper airway obstruction|1
6321433|NCT02845375|10060488|FG001|Overall Study|upper airway obstruction|2
6321434|NCT02845375|10060489|FG002|Overall Study|upper airway obstruction|1
6321435|NCT02846324|10060537|FG000|Overall Study|Other|1
6321436|NCT02846324|10060538|FG001|Overall Study|Other|0
6321437|NCT02846324|10060539|FG002|Overall Study|Other|0
6321438|NCT02846324|10060540|FG003|Overall Study|Other|0
6321439|NCT02846324|10060537|FG000|Overall Study|Withdrawal by Subject|1
6321440|NCT02846324|10060538|FG001|Overall Study|Withdrawal by Subject|0
6321441|NCT02846324|10060539|FG002|Overall Study|Withdrawal by Subject|4
6321442|NCT02846324|10060540|FG003|Overall Study|Withdrawal by Subject|0
6321443|NCT02846415|10060561|FG000|Overall Study|Lost to Follow-up|2
6321444|NCT02846415|10060562|FG001|Overall Study|Lost to Follow-up|0
6321445|NCT02846415|10060561|FG000|Overall Study|Withdrawal by Subject|1
6321446|NCT02846415|10060562|FG001|Overall Study|Withdrawal by Subject|1
6321447|NCT02846558|10060572|FG000|Overall Study|Adverse Event|1
6321448|NCT02846558|10060573|FG001|Overall Study|Adverse Event|0
6321449|NCT02846558|10060574|FG002|Overall Study|Adverse Event|0
6321450|NCT02846558|10060575|FG003|Overall Study|Adverse Event|0
6321451|NCT02846558|10060572|FG000|Overall Study|Withdrawal by Subject|5
6321452|NCT02846558|10060573|FG001|Overall Study|Withdrawal by Subject|4
6321453|NCT02846558|10060574|FG002|Overall Study|Withdrawal by Subject|2
6321454|NCT02846558|10060575|FG003|Overall Study|Withdrawal by Subject|2
6321455|NCT02846558|10060572|FG000|Overall Study|Lost to Follow-up|2
6321456|NCT02846558|10060573|FG001|Overall Study|Lost to Follow-up|0
6321457|NCT02846558|10060574|FG002|Overall Study|Lost to Follow-up|0
6321458|NCT02846558|10060575|FG003|Overall Study|Lost to Follow-up|0
6321459|NCT02846779|10060608|FG000|Overall Study|Lost Enrollment|83
6321460|NCT02846779|10060609|FG001|Overall Study|Lost Enrollment|82
6321461|NCT02846779|10060610|FG002|Overall Study|Lost Enrollment|86
6321462|NCT02846779|10060608|FG000|Overall Study|Less than 31 days of follow-up|56
6321463|NCT02846779|10060609|FG001|Overall Study|Less than 31 days of follow-up|45
6321464|NCT02846779|10060610|FG002|Overall Study|Less than 31 days of follow-up|52
6321465|NCT02847182|10060646|FG000|Overall Study|Withdrawal by Subject|0
6321466|NCT02847182|10060647|FG001|Overall Study|Withdrawal by Subject|1
6321467|NCT02847260|10060659|FG000|Overall Study|Adverse Event|3
6321468|NCT02847260|10060659|FG000|Overall Study|Withdrawal by Subject|2
6321469|NCT02847260|10060659|FG000|Overall Study|Clinical Deterioration|1
6321470|NCT02847260|10060659|FG000|Overall Study|Physician Decision|1
6321471|NCT02847494|10060665|FG000|Overall Study|Lost to Follow-up|8
6321472|NCT02847494|10060666|FG001|Overall Study|Lost to Follow-up|5
6321473|NCT02847650|10060674|FG000|Overall Study|Adverse Event|2
6321474|NCT02847650|10060675|FG001|Overall Study|Adverse Event|4
6321475|NCT02847650|10060674|FG000|Overall Study|Lost to Follow-up|1
6321476|NCT02847650|10060675|FG001|Overall Study|Lost to Follow-up|0
6321477|NCT02847650|10060674|FG000|Overall Study|Protocol Violation|0
6321478|NCT02847650|10060675|FG001|Overall Study|Protocol Violation|1
6321479|NCT02847650|10060674|FG000|Overall Study|Withdrawal by Subject|1
6321480|NCT02847650|10060675|FG001|Overall Study|Withdrawal by Subject|1
6321481|NCT02847858|10060683|FG000|Overall Study|Lost to Follow-up|401
6321482|NCT02847858|10060684|FG001|Overall Study|Lost to Follow-up|269
6321483|NCT02848313|10060714|FG000|Overall Study|Adverse Event|1
6321484|NCT02848313|10060715|FG001|Overall Study|Adverse Event|2
6321485|NCT02848313|10060714|FG000|Overall Study|Lack of Efficacy|0
6321486|NCT02848313|10060715|FG001|Overall Study|Lack of Efficacy|1
6321487|NCT02848313|10060714|FG000|Overall Study|Withdrawal by Subject|1
6321488|NCT02848313|10060715|FG001|Overall Study|Withdrawal by Subject|1
6321489|NCT02848313|10060714|FG000|Overall Study|Lost to follow up|1
6321490|NCT02848313|10060715|FG001|Overall Study|Lost to follow up|0
6321491|NCT02848326|10060727|FG000|Treatment Period|Adverse Event|5
6321492|NCT02848326|10060728|FG001|Treatment Period|Adverse Event|4
6321493|NCT02848326|10060729|FG002|Treatment Period|Adverse Event|11
6321494|NCT02848326|10060730|FG003|Treatment Period|Adverse Event|6
6321495|NCT02848326|10060731|FG004|Treatment Period|Adverse Event|5
6321496|NCT02848326|10060732|FG005|Treatment Period|Adverse Event|7
6321497|NCT02848326|10060727|FG000|Treatment Period|Withdrawal of Consent|20
6321498|NCT02848326|10060728|FG001|Treatment Period|Withdrawal of Consent|6
6321499|NCT02848326|10060729|FG002|Treatment Period|Withdrawal of Consent|9
6321500|NCT02848326|10060730|FG003|Treatment Period|Withdrawal of Consent|6
6321501|NCT02848326|10060731|FG004|Treatment Period|Withdrawal of Consent|9
6321502|NCT02848326|10060732|FG005|Treatment Period|Withdrawal of Consent|6
6321503|NCT02848326|10060727|FG000|Treatment Period|Lost to Follow-up|5
6321504|NCT02848326|10060728|FG001|Treatment Period|Lost to Follow-up|1
6321505|NCT02848326|10060729|FG002|Treatment Period|Lost to Follow-up|11
6321506|NCT02848326|10060730|FG003|Treatment Period|Lost to Follow-up|7
6321507|NCT02848326|10060731|FG004|Treatment Period|Lost to Follow-up|2
6321508|NCT02848326|10060732|FG005|Treatment Period|Lost to Follow-up|3
6321509|NCT02848326|10060727|FG000|Treatment Period|Pregnancy|0
6321510|NCT02848326|10060728|FG001|Treatment Period|Pregnancy|0
6321511|NCT02848326|10060729|FG002|Treatment Period|Pregnancy|1
6321512|NCT02848326|10060730|FG003|Treatment Period|Pregnancy|1
6321513|NCT02848326|10060731|FG004|Treatment Period|Pregnancy|0
6321514|NCT02848326|10060732|FG005|Treatment Period|Pregnancy|1
6321515|NCT02848326|10060727|FG000|Treatment Period|Protocol Violation|4
6321516|NCT02848326|10060728|FG001|Treatment Period|Protocol Violation|3
6321517|NCT02848326|10060729|FG002|Treatment Period|Protocol Violation|4
6321518|NCT02848326|10060730|FG003|Treatment Period|Protocol Violation|2
6321519|NCT02848326|10060731|FG004|Treatment Period|Protocol Violation|3
6321520|NCT02848326|10060732|FG005|Treatment Period|Protocol Violation|3
6321521|NCT02848326|10060727|FG000|Treatment Period|Non-compliance with Study Drug|4
6321522|NCT02848326|10060728|FG001|Treatment Period|Non-compliance with Study Drug|0
6321523|NCT02848326|10060729|FG002|Treatment Period|Non-compliance with Study Drug|0
6321524|NCT02848326|10060730|FG003|Treatment Period|Non-compliance with Study Drug|1
6321525|NCT02848326|10060731|FG004|Treatment Period|Non-compliance with Study Drug|0
6321526|NCT02848326|10060732|FG005|Treatment Period|Non-compliance with Study Drug|0
6321527|NCT02848326|10060727|FG000|Safety Follow-up Period|Withdrawal of Consent|0
6321528|NCT02848326|10060728|FG001|Safety Follow-up Period|Withdrawal of Consent|1
6321529|NCT02848326|10060729|FG002|Safety Follow-up Period|Withdrawal of Consent|1
6321530|NCT02848326|10060730|FG003|Safety Follow-up Period|Withdrawal of Consent|0
6321531|NCT02848326|10060731|FG004|Safety Follow-up Period|Withdrawal of Consent|0
6321532|NCT02848326|10060732|FG005|Safety Follow-up Period|Withdrawal of Consent|2
6321533|NCT02848326|10060727|FG000|Safety Follow-up Period|Lost to Follow-up|4
6321534|NCT02848326|10060728|FG001|Safety Follow-up Period|Lost to Follow-up|0
6321535|NCT02848326|10060729|FG002|Safety Follow-up Period|Lost to Follow-up|2
6321536|NCT02848326|10060730|FG003|Safety Follow-up Period|Lost to Follow-up|0
6321537|NCT02848326|10060731|FG004|Safety Follow-up Period|Lost to Follow-up|1
6321538|NCT02848326|10060732|FG005|Safety Follow-up Period|Lost to Follow-up|3
6321539|NCT02848599|10060748|FG000|Overall Study|Protocol Violation|7
6321540|NCT02848599|10060749|FG001|Overall Study|Protocol Violation|9
6321541|NCT02848651|10060757|FG000|Overall Study|Death|85
6321542|NCT02848651|10060757|FG000|Overall Study|Lost to Follow-up|1
6321543|NCT02848651|10060757|FG000|Overall Study|Non-Compliance|1
6321544|NCT02848651|10060757|FG000|Overall Study|Symptomatic Deterioration|1
6321545|NCT02848651|10060757|FG000|Overall Study|Physician Decision|4
6321546|NCT02848651|10060757|FG000|Overall Study|Withdrawal by Subject|14
6321547|NCT02848664|10060777|FG000|Overall Study|Withdrawal by Subject|2
6321548|NCT02848664|10060777|FG000|Overall Study|Adverse Event|1
6321549|NCT02848664|10060777|FG000|Overall Study|no assistance for device training|1
6321550|NCT02848729|10060787|FG000|Overall Study|Withdrawal by Subject|1
6321551|NCT02848729|10060788|FG001|Overall Study|Withdrawal by Subject|0
6321552|NCT02848729|10060787|FG000|Overall Study|Emesis|15
6321553|NCT02848729|10060788|FG001|Overall Study|Emesis|11
6321554|NCT02848833|10060801|FG000|Overall Study|subject who are duplicated|1
6321555|NCT02848833|10060801|FG000|Overall Study|have not taken the study drug|11
6321556|NCT02848833|10060801|FG000|Overall Study|follow-up failure|6
6321557|NCT02848833|10060801|FG000|Overall Study|Protocol Violation|119
6321558|NCT02849080|10060807|FG000|Main Phase: 0 - 52 Weeks|Lost to Follow-up|7
6321559|NCT02849080|10060808|FG001|Main Phase: 0 - 52 Weeks|Lost to Follow-up|4
6321560|NCT02849080|10060809|FG002|Main Phase: 0 - 52 Weeks|Lost to Follow-up|0
6321561|NCT02849080|10060810|FG003|Main Phase: 0 - 52 Weeks|Lost to Follow-up|0
6321562|NCT02849080|10060807|FG000|Main Phase: 0 - 52 Weeks|Withdrawal by Subject|5
6321563|NCT02849080|10060808|FG001|Main Phase: 0 - 52 Weeks|Withdrawal by Subject|1
6321564|NCT02849080|10060809|FG002|Main Phase: 0 - 52 Weeks|Withdrawal by Subject|0
6321565|NCT02849080|10060810|FG003|Main Phase: 0 - 52 Weeks|Withdrawal by Subject|0
6321566|NCT02849080|10060807|FG000|Main Phase: 0 - 52 Weeks|Death|0
6321567|NCT02849080|10060808|FG001|Main Phase: 0 - 52 Weeks|Death|2
6321568|NCT02849080|10060809|FG002|Main Phase: 0 - 52 Weeks|Death|0
6321569|NCT02849080|10060810|FG003|Main Phase: 0 - 52 Weeks|Death|0
6321570|NCT02849080|10060807|FG000|Extension Phase: 53 - 104 Weeks|Lost to Follow-up|2
6321571|NCT02849080|10060808|FG001|Extension Phase: 53 - 104 Weeks|Lost to Follow-up|0
6321572|NCT02849080|10060809|FG002|Extension Phase: 53 - 104 Weeks|Lost to Follow-up|0
6321573|NCT02849080|10060810|FG003|Extension Phase: 53 - 104 Weeks|Lost to Follow-up|0
6321574|NCT02849080|10060807|FG000|Extension Phase: 53 - 104 Weeks|Other|0
6321575|NCT02849080|10060808|FG001|Extension Phase: 53 - 104 Weeks|Other|0
6321576|NCT02849080|10060809|FG002|Extension Phase: 53 - 104 Weeks|Other|1
6321577|NCT02849080|10060810|FG003|Extension Phase: 53 - 104 Weeks|Other|0
6321578|NCT02849080|10060807|FG000|Extension Phase: 53 - 104 Weeks|Withdrawal by Subject|1
6321579|NCT02849080|10060808|FG001|Extension Phase: 53 - 104 Weeks|Withdrawal by Subject|0
6321580|NCT02849080|10060809|FG002|Extension Phase: 53 - 104 Weeks|Withdrawal by Subject|0
6321581|NCT02849080|10060810|FG003|Extension Phase: 53 - 104 Weeks|Withdrawal by Subject|0
6321582|NCT02849509|10060857|FG000|Overall Study|Worsening of disease under study|1
6321583|NCT02849509|10060858|FG001|Overall Study|Worsening of disease under study|1
6321584|NCT02849509|10060859|FG002|Overall Study|Worsening of disease under study|1
6321585|NCT02849509|10060857|FG000|Overall Study|Worsening of other pre-existing disease|0
6321586|NCT02849509|10060858|FG001|Overall Study|Worsening of other pre-existing disease|1
6321587|NCT02849509|10060859|FG002|Overall Study|Worsening of other pre-existing disease|2
6041169|NCT00373958|9639298|FG000|Infant Series|Adverse Event|3
6041170|NCT00373958|9639299|FG001|Infant Series|Adverse Event|1
6321588|NCT02849509|10060857|FG000|Overall Study|Other adverse event|36
6321589|NCT02849509|10060858|FG001|Overall Study|Other adverse event|41
6321590|NCT02849509|10060859|FG002|Overall Study|Other adverse event|8
6321591|NCT02849509|10060857|FG000|Overall Study|Withdrawal by Subject|6
6321592|NCT02849509|10060858|FG001|Overall Study|Withdrawal by Subject|17
6321593|NCT02849509|10060859|FG002|Overall Study|Withdrawal by Subject|12
6321594|NCT02849509|10060857|FG000|Overall Study|Lost to Follow-up|27
6321595|NCT02849509|10060858|FG001|Overall Study|Lost to Follow-up|67
6321596|NCT02849509|10060859|FG002|Overall Study|Lost to Follow-up|36
6321597|NCT02849509|10060857|FG000|Overall Study|Other, reason not specified|14
6321598|NCT02849509|10060858|FG001|Overall Study|Other, reason not specified|29
6321599|NCT02849509|10060859|FG002|Overall Study|Other, reason not specified|25
6321600|NCT02849509|10060857|FG000|Overall Study|No inform. on termination of Pradaxa/VKA|6
6321601|NCT02849509|10060858|FG001|Overall Study|No inform. on termination of Pradaxa/VKA|10
6321602|NCT02849509|10060859|FG002|Overall Study|No inform. on termination of Pradaxa/VKA|1
6321603|NCT02849678|10060871|FG000|Overall Study|Protocol Violation|3
6321604|NCT02849678|10060872|FG001|Overall Study|Protocol Violation|6
6321605|NCT02849704|10060880|FG000|Assessment on PERT - CP Subj - 16 Days|Lost to Follow-up|1
6321606|NCT02849704|10060881|FG001|Assessment on PERT - CP Subj - 16 Days|Lost to Follow-up|0
6321607|NCT02849704|10060880|FG000|Assessment on PERT - CP Subj - 16 Days|Adverse Event|1
6321608|NCT02849704|10060881|FG001|Assessment on PERT - CP Subj - 16 Days|Adverse Event|0
6321609|NCT02849704|10060880|FG000|Assessment on PERT - CP Subj - 16 Days|Unable to complete study procedures|1
6321610|NCT02849704|10060881|FG001|Assessment on PERT - CP Subj - 16 Days|Unable to complete study procedures|0
6321611|NCT02850276|10060913|FG000|Overall Study|screen failure|43
6321612|NCT02850276|10060913|FG000|Overall Study|Withdrawal by Subject|14
6321613|NCT02850276|10060913|FG000|Overall Study|Physician Decision|2
6321614|NCT02850276|10060913|FG000|Overall Study|Lost to Follow-up|2
6321615|NCT02850965|10060929|FG000|Overall Study|Other than listed|3
6321616|NCT02850965|10060930|FG001|Overall Study|Other than listed|4
6321617|NCT02850965|10060929|FG000|Overall Study|Protocol Violation|0
6321618|NCT02850965|10060930|FG001|Overall Study|Protocol Violation|2
6321619|NCT02850965|10060929|FG000|Overall Study|Lost to Follow-up|5
6321620|NCT02850965|10060930|FG001|Overall Study|Lost to Follow-up|3
6321621|NCT02850965|10060929|FG000|Overall Study|Lack of Efficacy|4
6321622|NCT02850965|10060930|FG001|Overall Study|Lack of Efficacy|8
6321623|NCT02850965|10060929|FG000|Overall Study|Adverse Event|3
6321624|NCT02850965|10060930|FG001|Overall Study|Adverse Event|2
6321625|NCT02850965|10060929|FG000|Overall Study|Withdrawal by Subject|3
6321626|NCT02850965|10060930|FG001|Overall Study|Withdrawal by Subject|4
6321627|NCT02850965|10060929|FG000|Overall Study|Physician Decision|0
6321628|NCT02850965|10060930|FG001|Overall Study|Physician Decision|1
6321629|NCT02850965|10060929|FG000|Overall Study|Randomized but not treated|0
6321630|NCT02850965|10060930|FG001|Overall Study|Randomized but not treated|1
6321631|NCT02850978|10060936|FG000|Overall Study|Uncollectable CRF|27
6321632|NCT02850978|10060936|FG000|Overall Study|No visit since the first visit|35
6321633|NCT02850978|10060936|FG000|Overall Study|Adverse Event|81
6321634|NCT02850978|10060936|FG000|Overall Study|Lack of Efficacy|40
6321635|NCT02850978|10060936|FG000|Overall Study|Improvement in condition|34
6321636|NCT02850978|10060936|FG000|Overall Study|Lost to Follow-up|121
6321637|NCT02850978|10060936|FG000|Overall Study|Reason not listed|88
6321638|NCT02851069|10060940|FG000|Overall Study|Failure to Return|3
6321639|NCT02851069|10060940|FG000|Overall Study|Other|3
6321640|NCT02851615|10060956|FG000|Overall Study|Cognitive Issue|1
6321641|NCT02851615|10060957|FG001|Overall Study|Cognitive Issue|0
6321642|NCT02851615|10060956|FG000|Overall Study|Lost to Follow-up|0
6321643|NCT02851615|10060957|FG001|Overall Study|Lost to Follow-up|4
6321644|NCT02852005|10060975|FG000|Overall Study|Lost to Follow-up|0
6321645|NCT02852005|10060976|FG001|Overall Study|Lost to Follow-up|0
6321646|NCT02852005|10060977|FG002|Overall Study|Lost to Follow-up|0
6321647|NCT02852005|10060978|FG003|Overall Study|Lost to Follow-up|0
6321648|NCT02852005|10060979|FG004|Overall Study|Lost to Follow-up|1
6321649|NCT02852005|10060975|FG000|Overall Study|Withdrawal by Subject|1
6321650|NCT02852005|10060976|FG001|Overall Study|Withdrawal by Subject|0
6321651|NCT02852005|10060977|FG002|Overall Study|Withdrawal by Subject|0
6321652|NCT02852005|10060978|FG003|Overall Study|Withdrawal by Subject|0
6321653|NCT02852005|10060979|FG004|Overall Study|Withdrawal by Subject|0
6321654|NCT02852265|10060995|FG000|3-month Follow-up|Lost to Follow-up|1
6321655|NCT02852265|10060996|FG001|3-month Follow-up|Lost to Follow-up|1
6321656|NCT02852434|10061012|FG000|Overall Study|Withdrawal by Subject|0
6321657|NCT02852434|10061013|FG001|Overall Study|Withdrawal by Subject|1
6321658|NCT02852434|10061012|FG000|Overall Study|Unsuccessful Dilator Procedure|2
6321659|NCT02852434|10061013|FG001|Overall Study|Unsuccessful Dilator Procedure|0
6321660|NCT02853032|10061021|FG000|Overall Study|Adverse Event|4
6321661|NCT02853032|10061022|FG001|Overall Study|Adverse Event|0
6321662|NCT02853032|10061021|FG000|Overall Study|Withdrawal by Subject|3
6321663|NCT02853032|10061022|FG001|Overall Study|Withdrawal by Subject|1
6321664|NCT02853032|10061021|FG000|Overall Study|Requested to withdraw from all treatment|2
6321665|NCT02853032|10061022|FG001|Overall Study|Requested to withdraw from all treatment|2
6321666|NCT02853123|10061030|FG000|Treatment Period 1|Adverse Event|0
6041171|NCT00373958|9639298|FG000|Infant Series|Physician Decision|1
6041172|NCT00373958|9639299|FG001|Infant Series|Physician Decision|1
6041173|NCT00373958|9639298|FG000|Toddler Dose|Lost to Follow-up|5
6041174|NCT00373958|9639299|FG001|Toddler Dose|Lost to Follow-up|8
6041175|NCT00373958|9639298|FG000|Toddler Dose|Withdrawal by Subject|2
6041176|NCT00373958|9639299|FG001|Toddler Dose|Withdrawal by Subject|2
6041177|NCT00373958|9639298|FG000|Toddler Dose|Failed to return|1
6041178|NCT00373958|9639299|FG001|Toddler Dose|Failed to return|2
6041179|NCT00373958|9639298|FG000|Toddler Dose|Protocol Violation|0
6041180|NCT00373958|9639299|FG001|Toddler Dose|Protocol Violation|1
6041181|NCT00373958|9639298|FG000|Toddler Dose|Withdrawn after infant series|22
6041182|NCT00373958|9639299|FG001|Toddler Dose|Withdrawn after infant series|25
6041183|NCT00374127|9639337|FG000|Overall Study|Did not inhale during smoking procedure.|3
6041184|NCT00374127|9639337|FG000|Overall Study|Blood could not be drawn.|2
6041185|NCT00374127|9639337|FG000|Overall Study|Protocol Violation|5
6041186|NCT00374127|9639337|FG000|Overall Study|Pregnancy|1
6041187|NCT00374140|9639347|FG000|Overall Study|Lost to Follow-up|1
6041188|NCT00374140|9639347|FG000|Overall Study|Protocol Violation|1
6041189|NCT00374322|9639367|FG000|Overall Study|Lost to Follow-up|92
6041190|NCT00374322|9639368|FG001|Overall Study|Lost to Follow-up|90
6041191|NCT00374322|9639367|FG000|Overall Study|Protocol Violation|8
6041192|NCT00374322|9639368|FG001|Overall Study|Protocol Violation|3
6041193|NCT00374322|9639367|FG000|Overall Study|Withdrawal by Subject|235
6041194|NCT00374322|9639368|FG001|Overall Study|Withdrawal by Subject|167
6151971|NCT01116440|9788932|FG000|Follow-up|Withdrawal by Subject|0
6151972|NCT01116440|9788933|FG001|Follow-up|Withdrawal by Subject|1
6151973|NCT01116544|9788948|FG000|Overall Study|Protocol Violation|1
6151974|NCT01116544|9788949|FG001|Overall Study|Protocol Violation|0
6151975|NCT01116544|9788948|FG000|Overall Study|Withdrawal by Subject|1
6151976|NCT01116544|9788949|FG001|Overall Study|Withdrawal by Subject|1
6151977|NCT01116687|9788959|FG000|Overall Study|Withdrawal by Subject|4
6151978|NCT01116739|9788965|FG000|Overall Study|Child had 2 years of HS|110
6151979|NCT01116739|9788966|FG001|Overall Study|Child had 2 years of HS|128
6151980|NCT01116739|9788965|FG000|Overall Study|Withdrawal by Subject|6
6151981|NCT01116739|9788966|FG001|Overall Study|Withdrawal by Subject|0
6151982|NCT01116739|9788965|FG000|Overall Study|child too young|2
6151983|NCT01116739|9788966|FG001|Overall Study|child too young|6
6151984|NCT01116739|9788965|FG000|Overall Study|child not enrolled in head start|10
6151985|NCT01116739|9788966|FG001|Overall Study|child not enrolled in head start|2
6041195|NCT00374322|9639367|FG000|Overall Study|Sponsor Terminated Study|866
6041196|NCT00374322|9639368|FG001|Overall Study|Sponsor Terminated Study|990
6041197|NCT00374322|9639367|FG000|Overall Study|Physician Decision|36
6041198|NCT00374322|9639368|FG001|Overall Study|Physician Decision|32
6041199|NCT00374322|9639367|FG000|Overall Study|Par. Consented to Survival FU Only|3
6041200|NCT00374322|9639368|FG001|Overall Study|Par. Consented to Survival FU Only|1
6041201|NCT00374322|9639367|FG000|Overall Study|Sponsor Decision|2
6041202|NCT00374322|9639368|FG001|Overall Study|Sponsor Decision|3
6041203|NCT00374322|9639367|FG000|Overall Study|FU by a Non-Principal Investigator (PI)|2
6041204|NCT00374322|9639368|FG001|Overall Study|FU by a Non-Principal Investigator (PI)|3
6041205|NCT00374322|9639367|FG000|Overall Study|Seen in FU by a Non-Primary Investigator|1
6041206|NCT00374322|9639368|FG001|Overall Study|Seen in FU by a Non-Primary Investigator|0
6041207|NCT00374322|9639367|FG000|Overall Study|Severe Toxicity|1
6041208|NCT00374322|9639368|FG001|Overall Study|Severe Toxicity|0
6041209|NCT00374322|9639367|FG000|Overall Study|Site Closed|2
6041210|NCT00374322|9639368|FG001|Overall Study|Site Closed|2
6041211|NCT00374322|9639367|FG000|Overall Study|Participant Changed Physician|1
6041212|NCT00374322|9639368|FG001|Overall Study|Participant Changed Physician|0
6041213|NCT00374322|9639367|FG000|Overall Study|Started Another Chemotherapy Regimen|0
6321667|NCT02853123|10061031|FG001|Treatment Period 1|Adverse Event|3
6321668|NCT02853123|10061030|FG000|Washout Period|Worsening of COPD|0
6041214|NCT00374322|9639368|FG001|Overall Study|Started Another Chemotherapy Regimen|1
6041215|NCT00374322|9639367|FG000|Overall Study|Noncompliance with Study Requirements|0
6041216|NCT00374322|9639368|FG001|Overall Study|Noncompliance with Study Requirements|1
6041217|NCT00374322|9639367|FG000|Overall Study|Withdrew Consent During Follow-up|0
6041218|NCT00374322|9639368|FG001|Overall Study|Withdrew Consent During Follow-up|5
6151986|NCT01116739|9788965|FG000|Overall Study|enrolled caregiver not legal guardian|2
6151987|NCT01116739|9788966|FG001|Overall Study|enrolled caregiver not legal guardian|0
6151988|NCT01116882|9788974|FG000|30-day|Lost to Follow-up|50
6041219|NCT00374322|9639367|FG000|Overall Study|Did Not Receive Study Medication|8
6041220|NCT00374322|9639368|FG001|Overall Study|Did Not Receive Study Medication|6
6041221|NCT00374452|9639381|FG000|Overall Study|Left clinic before intervention started|4
6041222|NCT00374452|9639382|FG001|Overall Study|Left clinic before intervention started|1
6041223|NCT00374452|9639381|FG000|Overall Study|Change in job role before intervention|0
6041224|NCT00374452|9639382|FG001|Overall Study|Change in job role before intervention|1
6041225|NCT00374452|9639381|FG000|Overall Study|Left clinic after intervention started|1
6041226|NCT00374452|9639382|FG001|Overall Study|Left clinic after intervention started|1
6041227|NCT00374452|9639381|FG000|Overall Study|Withdrawal by Subject|0
6041228|NCT00374452|9639382|FG001|Overall Study|Withdrawal by Subject|2
6041229|NCT00374556|9639390|FG000|Overall Study|Lost to Follow-up|1
6041230|NCT00374556|9639391|FG001|Overall Study|Lost to Follow-up|0
6041231|NCT00374556|9639390|FG000|Overall Study|Removed at baseline due to medical cond|0
6041232|NCT00374556|9639391|FG001|Overall Study|Removed at baseline due to medical cond|1
6041233|NCT00374868|9639423|FG000|Overall Study|Adverse Event|12
6041234|NCT00374868|9639423|FG000|Overall Study|Progressive Disease|7
6041235|NCT00374868|9639423|FG000|Overall Study|Physician Decision|13
6041236|NCT00374868|9639423|FG000|Overall Study|Lost to Follow-up|1
6041237|NCT00374868|9639423|FG000|Overall Study|Death|2
6041238|NCT00374868|9639423|FG000|Overall Study|Other - Not Specified|1
6041239|NCT00374907|9639429|FG000|12-Week Short-term Period|Subject Withdrew Consent|3
6041240|NCT00374907|9639430|FG001|12-Week Short-term Period|Subject Withdrew Consent|1
6041241|NCT00374907|9639429|FG000|116-Week Short-term + Long-term Period|Subject Withdrew Consent|8
6041242|NCT00374907|9639430|FG001|116-Week Short-term + Long-term Period|Subject Withdrew Consent|9
6041243|NCT00374907|9639429|FG000|116-Week Short-term + Long-term Period|Lack of Efficacy|4
6041244|NCT00374907|9639430|FG001|116-Week Short-term + Long-term Period|Lack of Efficacy|2
6041245|NCT00374907|9639429|FG000|116-Week Short-term + Long-term Period|Adverse Event|0
6041246|NCT00374907|9639430|FG001|116-Week Short-term + Long-term Period|Adverse Event|2
6041247|NCT00374907|9639429|FG000|116-Week Short-term + Long-term Period|Lost to Follow-up|1
6041248|NCT00374907|9639430|FG001|116-Week Short-term + Long-term Period|Lost to Follow-up|1
6041249|NCT00375219|9639452|FG000|Overall Study|Failure to achieve a response|16
6151989|NCT01116882|9788975|FG001|30-day|Lost to Follow-up|21
6151990|NCT01116882|9788974|FG000|30-day|Withdrawal by Subject|2
6151991|NCT01116882|9788975|FG001|30-day|Withdrawal by Subject|4
6151992|NCT01116882|9788974|FG000|30-day|Other Reasons|16
6151993|NCT01116882|9788975|FG001|30-day|Other Reasons|6
6151994|NCT01116882|9788974|FG000|12-month|Lost to Follow-up|111
6151995|NCT01116882|9788975|FG001|12-month|Lost to Follow-up|42
6151996|NCT01116882|9788974|FG000|12-month|Other Reasons|151
6151997|NCT01116882|9788975|FG001|12-month|Other Reasons|49
6151998|NCT01116882|9788974|FG000|12-month|Withdrawal by Subject|5
6151999|NCT01116882|9788975|FG001|12-month|Withdrawal by Subject|8
6152000|NCT01117012|9789104|FG000|Overall Study|Adverse Event|0
6152001|NCT01117012|9789105|FG001|Overall Study|Adverse Event|1
6152002|NCT01117012|9789104|FG000|Overall Study|Death|1
6152003|NCT01117012|9789105|FG001|Overall Study|Death|1
6152004|NCT01117012|9789104|FG000|Overall Study|Withdrawal by Subject|3
6152005|NCT01117012|9789105|FG001|Overall Study|Withdrawal by Subject|0
6152006|NCT01117012|9789104|FG000|Overall Study|Undefined|4
6152007|NCT01117012|9789105|FG001|Overall Study|Undefined|3
6152008|NCT01117051|9789113|FG000|Overall Study|Withdrawal by Subject|5
6041250|NCT00375219|9639453|FG001|Overall Study|Failure to achieve a response|2
6041251|NCT00375219|9639454|FG002|Overall Study|Failure to achieve a response|0
6041252|NCT00375219|9639452|FG000|Overall Study|Adverse Event|8
6041253|NCT00375219|9639453|FG001|Overall Study|Adverse Event|2
6041254|NCT00375219|9639454|FG002|Overall Study|Adverse Event|1
6041255|NCT00375219|9639452|FG000|Overall Study|Protocol Violation|1
6041256|NCT00375219|9639453|FG001|Overall Study|Protocol Violation|0
6041257|NCT00375219|9639454|FG002|Overall Study|Protocol Violation|1
6041258|NCT00375219|9639452|FG000|Overall Study|Request of Patient, PI, Sponsor or RA|5
6321669|NCT02853123|10061031|FG001|Washout Period|Worsening of COPD|3
6321670|NCT02853123|10061030|FG000|Washout Period|Adverse Event|1
6041259|NCT00375219|9639453|FG001|Overall Study|Request of Patient, PI, Sponsor or RA|3
6041260|NCT00375219|9639454|FG002|Overall Study|Request of Patient, PI, Sponsor or RA|0
6041261|NCT00375219|9639452|FG000|Overall Study|Lost to Follow-up|1
6041262|NCT00375219|9639453|FG001|Overall Study|Lost to Follow-up|1
6041263|NCT00375219|9639454|FG002|Overall Study|Lost to Follow-up|0
6041264|NCT00375219|9639452|FG000|Overall Study|Disease progression|18
6041265|NCT00375219|9639453|FG001|Overall Study|Disease progression|9
6041266|NCT00375219|9639454|FG002|Overall Study|Disease progression|12
6152009|NCT01117051|9789114|FG001|Overall Study|Withdrawal by Subject|3
6152010|NCT01117051|9789113|FG000|Overall Study|Adverse Event|4
6152011|NCT01117051|9789114|FG001|Overall Study|Adverse Event|3
6041267|NCT00375219|9639452|FG000|Overall Study|Death|4
6041268|NCT00375219|9639453|FG001|Overall Study|Death|3
6152012|NCT01117051|9789113|FG000|Overall Study|Lost to Follow-up|0
6152013|NCT01117051|9789114|FG001|Overall Study|Lost to Follow-up|1
6152014|NCT01117051|9789113|FG000|Overall Study|Did not meet in-/exclusion criteria|0
6152015|NCT01117051|9789114|FG001|Overall Study|Did not meet in-/exclusion criteria|1
6152016|NCT01117051|9789113|FG000|Overall Study|Sponsor's decision|3
6152017|NCT01117051|9789114|FG001|Overall Study|Sponsor's decision|1
6321671|NCT02853123|10061031|FG001|Washout Period|Adverse Event|0
6321672|NCT02853318|10061038|FG000|Overall Study|Withdrawal by Subject|1
6321673|NCT02853435|10061045|FG000|Part 3, Washout Period 2 (3 Days)|Withdrawal by Subject|0
6321674|NCT02853435|10061046|FG001|Part 3, Washout Period 2 (3 Days)|Withdrawal by Subject|0
6321675|NCT02853435|10061047|FG002|Part 3, Washout Period 2 (3 Days)|Withdrawal by Subject|0
6321676|NCT02853435|10061048|FG003|Part 3, Washout Period 2 (3 Days)|Withdrawal by Subject|0
6321677|NCT02853435|10061049|FG004|Part 3, Washout Period 2 (3 Days)|Withdrawal by Subject|1
6321678|NCT02853435|10061050|FG005|Part 3, Washout Period 2 (3 Days)|Withdrawal by Subject|0
6321679|NCT02853929|10061082|FG000|Overall Study|Lost to Follow-up|3
6321680|NCT02853929|10061083|FG001|Overall Study|Lost to Follow-up|0
6321681|NCT02853929|10061082|FG000|Overall Study|Withdrawal by Subject|1
6321682|NCT02853929|10061083|FG001|Overall Study|Withdrawal by Subject|0
6321683|NCT02853929|10061082|FG000|Overall Study|Subjects enrolled but not vaccinated|7
6321684|NCT02853929|10061083|FG001|Overall Study|Subjects enrolled but not vaccinated|4
6321685|NCT02854527|10061108|FG000|Overall Study|Adverse Event|0
6321686|NCT02854527|10061109|FG001|Overall Study|Adverse Event|0
6321687|NCT02854527|10061110|FG002|Overall Study|Adverse Event|0
6321688|NCT02854527|10061111|FG003|Overall Study|Adverse Event|0
6321689|NCT02854527|10061112|FG004|Overall Study|Adverse Event|1
6321690|NCT02854527|10061113|FG005|Overall Study|Adverse Event|0
6321691|NCT02854527|10061114|FG006|Overall Study|Adverse Event|0
6321692|NCT02854527|10061115|FG007|Overall Study|Adverse Event|0
6321693|NCT02854527|10061116|FG008|Overall Study|Adverse Event|0
6321694|NCT02854527|10061117|FG009|Overall Study|Adverse Event|0
6321695|NCT02854527|10061108|FG000|Overall Study|Lost to Follow-up|0
6321696|NCT02854527|10061109|FG001|Overall Study|Lost to Follow-up|0
6321697|NCT02854527|10061110|FG002|Overall Study|Lost to Follow-up|0
6321698|NCT02854527|10061111|FG003|Overall Study|Lost to Follow-up|1
6321699|NCT02854527|10061112|FG004|Overall Study|Lost to Follow-up|0
6321700|NCT02854527|10061113|FG005|Overall Study|Lost to Follow-up|0
6321701|NCT02854527|10061114|FG006|Overall Study|Lost to Follow-up|0
6321702|NCT02854527|10061115|FG007|Overall Study|Lost to Follow-up|0
6321703|NCT02854527|10061116|FG008|Overall Study|Lost to Follow-up|0
6321704|NCT02854527|10061117|FG009|Overall Study|Lost to Follow-up|0
6321705|NCT02854605|10061138|FG000|Overall Study|Adverse Event|1
6321706|NCT02854605|10061139|FG001|Overall Study|Adverse Event|5
6321707|NCT02854605|10061140|FG002|Overall Study|Adverse Event|2
6321708|NCT02854605|10061138|FG000|Overall Study|Lost to Follow-up|0
6321709|NCT02854605|10061139|FG001|Overall Study|Lost to Follow-up|2
6321710|NCT02854605|10061140|FG002|Overall Study|Lost to Follow-up|0
6321711|NCT02854605|10061138|FG000|Overall Study|Withdrew Consent|1
6041269|NCT00375219|9639454|FG002|Overall Study|Death|7
6041270|NCT00375219|9639452|FG000|Overall Study|Hematologic resistance|1
6041271|NCT00375219|9639453|FG001|Overall Study|Hematologic resistance|0
6041272|NCT00375219|9639454|FG002|Overall Study|Hematologic resistance|0
6041273|NCT00375219|9639452|FG000|Overall Study|Specific tyrosine kinase inhibitor avail|1
6041274|NCT00375219|9639453|FG001|Overall Study|Specific tyrosine kinase inhibitor avail|0
6041275|NCT00375219|9639454|FG002|Overall Study|Specific tyrosine kinase inhibitor avail|0
6041276|NCT00375219|9639452|FG000|Overall Study|Allograft|2
6041277|NCT00375219|9639453|FG001|Overall Study|Allograft|0
6041278|NCT00375219|9639454|FG002|Overall Study|Allograft|0
6041279|NCT00375219|9639452|FG000|Overall Study|Cord blood transplantation|1
6041280|NCT00375219|9639453|FG001|Overall Study|Cord blood transplantation|0
6041281|NCT00375219|9639454|FG002|Overall Study|Cord blood transplantation|0
6041282|NCT00375219|9639452|FG000|Overall Study|Withdrawal by Subject|1
6041283|NCT00375219|9639453|FG001|Overall Study|Withdrawal by Subject|0
6041284|NCT00375219|9639454|FG002|Overall Study|Withdrawal by Subject|0
6041285|NCT00375427|9639463|FG000|Overall Study|Adverse Event|21
6041286|NCT00375427|9639464|FG001|Overall Study|Adverse Event|27
6041287|NCT00375427|9639463|FG000|Overall Study|Abnormal test procedure result(s)|0
6041288|NCT00375427|9639464|FG001|Overall Study|Abnormal test procedure result(s)|1
6041289|NCT00375427|9639463|FG000|Overall Study|Abnormal laboratory value(s)|1
6041290|NCT00375427|9639464|FG001|Overall Study|Abnormal laboratory value(s)|2
6041291|NCT00375427|9639463|FG000|Overall Study|Unsatisfactory therapeutic effect|4
6041292|NCT00375427|9639464|FG001|Overall Study|Unsatisfactory therapeutic effect|4
6041293|NCT00375427|9639463|FG000|Overall Study|Patient no longer requires study drug|3
6041294|NCT00375427|9639464|FG001|Overall Study|Patient no longer requires study drug|7
6041295|NCT00375427|9639463|FG000|Overall Study|Protocol Violation|10
6041296|NCT00375427|9639464|FG001|Overall Study|Protocol Violation|8
6152018|NCT01117051|9789113|FG000|Overall Study|Surgical procedure|0
6041297|NCT00375427|9639463|FG000|Overall Study|Withdrawal by Subject|9
6041298|NCT00375427|9639464|FG001|Overall Study|Withdrawal by Subject|13
6041299|NCT00375427|9639463|FG000|Overall Study|Lost to Follow-up|1
6041300|NCT00375427|9639464|FG001|Overall Study|Lost to Follow-up|1
6321712|NCT02854605|10061139|FG001|Overall Study|Withdrew Consent|0
6321713|NCT02854605|10061140|FG002|Overall Study|Withdrew Consent|1
6321714|NCT02854605|10061138|FG000|Overall Study|Investigator's Discretion|1
6321715|NCT02854605|10061139|FG001|Overall Study|Investigator's Discretion|0
6321716|NCT02854605|10061140|FG002|Overall Study|Investigator's Discretion|0
6321717|NCT02854605|10061138|FG000|Overall Study|Protocol Violation|0
6321718|NCT02854605|10061139|FG001|Overall Study|Protocol Violation|0
6321719|NCT02854605|10061140|FG002|Overall Study|Protocol Violation|1
6321720|NCT02854631|10061150|FG000|Overall Study|Adverse Event|1
6041301|NCT00375427|9639463|FG000|Overall Study|Administrative reasons|0
6041302|NCT00375427|9639464|FG001|Overall Study|Administrative reasons|1
6041303|NCT00375427|9639463|FG000|Overall Study|Death|11
6041304|NCT00375427|9639464|FG001|Overall Study|Death|10
6041305|NCT00375492|9639472|FG000|Overall Study|Adverse Event|4
6041306|NCT00375492|9639473|FG001|Overall Study|Adverse Event|5
6041307|NCT00375492|9639472|FG000|Overall Study|Entry Criteria Not Met|0
6321721|NCT02854631|10061151|FG001|Overall Study|Adverse Event|2
6321722|NCT02854631|10061150|FG000|Overall Study|Withdrew Consent|3
6321723|NCT02854631|10061151|FG001|Overall Study|Withdrew Consent|2
6321724|NCT02854631|10061150|FG000|Overall Study|Investigator's Discretion|2
6321725|NCT02854631|10061151|FG001|Overall Study|Investigator's Discretion|0
6321726|NCT02854631|10061150|FG000|Overall Study|Death|12
6321727|NCT02854631|10061151|FG001|Overall Study|Death|8
6321728|NCT02854631|10061150|FG000|Overall Study|Liver Biopsy Inconsistent With Diagnosis|2
6321729|NCT02854631|10061151|FG001|Overall Study|Liver Biopsy Inconsistent With Diagnosis|0
6321730|NCT02854631|10061150|FG000|Overall Study|Protocol Violation|0
6321731|NCT02854631|10061151|FG001|Overall Study|Protocol Violation|1
6321732|NCT02854631|10061150|FG000|Overall Study|Subjects Randomized but Never Treated|2
6321733|NCT02854631|10061151|FG001|Overall Study|Subjects Randomized but Never Treated|0
6321734|NCT02854631|10061150|FG000|Overall Study|Lost to Follow-up|4
6321735|NCT02854631|10061151|FG001|Overall Study|Lost to Follow-up|2
6321736|NCT02854800|10061160|FG000|Overall Study|Protocol Violation|16
6321737|NCT02854800|10061161|FG001|Overall Study|Protocol Violation|11
6321738|NCT02854800|10061162|FG002|Overall Study|Protocol Violation|3
6321739|NCT02854800|10061160|FG000|Overall Study|Withdrawal by Subject|4
6321740|NCT02854800|10061161|FG001|Overall Study|Withdrawal by Subject|2
6321741|NCT02854800|10061162|FG002|Overall Study|Withdrawal by Subject|3
6321742|NCT02855164|10061190|FG000|Parts A + B (Randomized Set)|Withdrawal by Subject|0
6321743|NCT02855164|10061191|FG001|Parts A + B (Randomized Set)|Withdrawal by Subject|0
6321744|NCT02855164|10061192|FG002|Parts A + B (Randomized Set)|Withdrawal by Subject|1
6321745|NCT02855164|10061193|FG003|Parts A + B (Randomized Set)|Withdrawal by Subject|2
6321746|NCT02855164|10061194|FG004|Parts A + B (Randomized Set)|Withdrawal by Subject|1
6321747|NCT02855164|10061195|FG005|Parts A + B (Randomized Set)|Withdrawal by Subject|0
6321748|NCT02855164|10061196|FG006|Parts A + B (Randomized Set)|Withdrawal by Subject|0
6321749|NCT02855164|10061197|FG007|Parts A + B (Randomized Set)|Withdrawal by Subject|0
6321750|NCT02855164|10061190|FG000|Parts A + B (Randomized Set)|Physician Decision|0
6321751|NCT02855164|10061191|FG001|Parts A + B (Randomized Set)|Physician Decision|0
6321752|NCT02855164|10061192|FG002|Parts A + B (Randomized Set)|Physician Decision|0
6321753|NCT02855164|10061193|FG003|Parts A + B (Randomized Set)|Physician Decision|2
6321754|NCT02855164|10061194|FG004|Parts A + B (Randomized Set)|Physician Decision|0
6321755|NCT02855164|10061195|FG005|Parts A + B (Randomized Set)|Physician Decision|0
6321756|NCT02855164|10061196|FG006|Parts A + B (Randomized Set)|Physician Decision|0
6321757|NCT02855164|10061197|FG007|Parts A + B (Randomized Set)|Physician Decision|0
6321758|NCT02855164|10061190|FG000|Parts A + B (Randomized Set)|Adverse Event|0
6321759|NCT02855164|10061191|FG001|Parts A + B (Randomized Set)|Adverse Event|0
6321760|NCT02855164|10061192|FG002|Parts A + B (Randomized Set)|Adverse Event|0
6321761|NCT02855164|10061193|FG003|Parts A + B (Randomized Set)|Adverse Event|4
6321762|NCT02855164|10061194|FG004|Parts A + B (Randomized Set)|Adverse Event|0
6321763|NCT02855164|10061195|FG005|Parts A + B (Randomized Set)|Adverse Event|0
6321764|NCT02855164|10061196|FG006|Parts A + B (Randomized Set)|Adverse Event|0
6321765|NCT02855164|10061197|FG007|Parts A + B (Randomized Set)|Adverse Event|0
6321766|NCT02855164|10061190|FG000|Part C (Randomized Set)|Adverse Event|0
6321767|NCT02855164|10061191|FG001|Part C (Randomized Set)|Adverse Event|0
6321768|NCT02855164|10061192|FG002|Part C (Randomized Set)|Adverse Event|0
6321769|NCT02855164|10061193|FG003|Part C (Randomized Set)|Adverse Event|0
6321770|NCT02855164|10061194|FG004|Part C (Randomized Set)|Adverse Event|0
6321771|NCT02855164|10061195|FG005|Part C (Randomized Set)|Adverse Event|5
6321772|NCT02855164|10061196|FG006|Part C (Randomized Set)|Adverse Event|9
6321773|NCT02855164|10061197|FG007|Part C (Randomized Set)|Adverse Event|2
6321774|NCT02855164|10061190|FG000|Part C (Randomized Set)|Lost to Follow-up|0
6321775|NCT02855164|10061191|FG001|Part C (Randomized Set)|Lost to Follow-up|0
6041308|NCT00375492|9639473|FG001|Overall Study|Entry Criteria Not Met|1
6041309|NCT00375492|9639472|FG000|Overall Study|Loss of Glucose Control|0
6041310|NCT00375492|9639473|FG001|Overall Study|Loss of Glucose Control|1
6041311|NCT00375492|9639472|FG000|Overall Study|Lost to Follow-up|10
6041312|NCT00375492|9639473|FG001|Overall Study|Lost to Follow-up|5
6041313|NCT00375492|9639472|FG000|Overall Study|Physician Decision|0
6321776|NCT02855164|10061192|FG002|Part C (Randomized Set)|Lost to Follow-up|0
6321777|NCT02855164|10061193|FG003|Part C (Randomized Set)|Lost to Follow-up|0
6321778|NCT02855164|10061194|FG004|Part C (Randomized Set)|Lost to Follow-up|0
6321779|NCT02855164|10061195|FG005|Part C (Randomized Set)|Lost to Follow-up|1
6321780|NCT02855164|10061196|FG006|Part C (Randomized Set)|Lost to Follow-up|1
6321781|NCT02855164|10061197|FG007|Part C (Randomized Set)|Lost to Follow-up|1
6321782|NCT02855164|10061190|FG000|Part C (Randomized Set)|Physician Decision|0
6321783|NCT02855164|10061191|FG001|Part C (Randomized Set)|Physician Decision|0
6321784|NCT02855164|10061192|FG002|Part C (Randomized Set)|Physician Decision|0
6321785|NCT02855164|10061193|FG003|Part C (Randomized Set)|Physician Decision|0
6321786|NCT02855164|10061194|FG004|Part C (Randomized Set)|Physician Decision|0
6321787|NCT02855164|10061195|FG005|Part C (Randomized Set)|Physician Decision|1
6321788|NCT02855164|10061196|FG006|Part C (Randomized Set)|Physician Decision|0
6321789|NCT02855164|10061197|FG007|Part C (Randomized Set)|Physician Decision|1
6321790|NCT02855164|10061190|FG000|Part C (Randomized Set)|Withdrawal by Subject|0
6321791|NCT02855164|10061191|FG001|Part C (Randomized Set)|Withdrawal by Subject|0
6321792|NCT02855164|10061192|FG002|Part C (Randomized Set)|Withdrawal by Subject|0
6321793|NCT02855164|10061193|FG003|Part C (Randomized Set)|Withdrawal by Subject|0
6321794|NCT02855164|10061194|FG004|Part C (Randomized Set)|Withdrawal by Subject|0
6321795|NCT02855164|10061195|FG005|Part C (Randomized Set)|Withdrawal by Subject|5
6321796|NCT02855164|10061196|FG006|Part C (Randomized Set)|Withdrawal by Subject|4
6041314|NCT00375492|9639473|FG001|Overall Study|Physician Decision|4
6041315|NCT00375492|9639472|FG000|Overall Study|Protocol Violation|6
6041316|NCT00375492|9639473|FG001|Overall Study|Protocol Violation|3
6041317|NCT00375492|9639472|FG000|Overall Study|Sponsor Decision|0
6041318|NCT00375492|9639473|FG001|Overall Study|Sponsor Decision|1
6041319|NCT00375492|9639472|FG000|Overall Study|Withdrawal by Subject|6
6041320|NCT00375492|9639473|FG001|Overall Study|Withdrawal by Subject|6
6041321|NCT00375505|9639481|FG000|Overall Study|Adverse Event|1
6041322|NCT00375505|9639482|FG001|Overall Study|Adverse Event|2
6041323|NCT00375518|9639490|FG000|Overall Study|Withdrawal by Subject|2
6041324|NCT00375518|9639491|FG001|Overall Study|Withdrawal by Subject|10
6041325|NCT00375518|9639490|FG000|Overall Study|Patient Not Treated|6
6152019|NCT01117051|9789114|FG001|Overall Study|Surgical procedure|1
6152020|NCT01117051|9789113|FG000|Overall Study|Randomized by mistake|0
6152021|NCT01117051|9789114|FG001|Overall Study|Randomized by mistake|1
6152022|NCT01117051|9789113|FG000|Overall Study|Convenience issue|1
6152023|NCT01117051|9789114|FG001|Overall Study|Convenience issue|0
6152024|NCT01117181|9789134|FG000|Overall Study|Lost to Follow-up|1
6152025|NCT01117181|9789135|FG001|Overall Study|Lost to Follow-up|0
6152026|NCT01117181|9789134|FG000|Overall Study|Withdrawal by Subject|0
6152027|NCT01117181|9789135|FG001|Overall Study|Withdrawal by Subject|2
6152028|NCT01117337|9789152|FG000|Overall Study|Lost to Follow-up|4
6152029|NCT01117337|9789153|FG001|Overall Study|Lost to Follow-up|0
6152030|NCT01117350|9789161|FG000|Comparative Period|Not Treated|5
6152031|NCT01117350|9789162|FG001|Comparative Period|Not Treated|8
6152032|NCT01117350|9789161|FG000|Comparative Period|Adverse Event|6
6152033|NCT01117350|9789162|FG001|Comparative Period|Adverse Event|33
6152034|NCT01117350|9789161|FG000|Comparative Period|Lost to Follow-up|11
6152035|NCT01117350|9789162|FG001|Comparative Period|Lost to Follow-up|7
6152036|NCT01117350|9789161|FG000|Comparative Period|Withdrawal by Subject|9
6152037|NCT01117350|9789162|FG001|Comparative Period|Withdrawal by Subject|13
6152038|NCT01117350|9789161|FG000|Comparative Period|Protocol Violation|8
6152039|NCT01117350|9789162|FG001|Comparative Period|Protocol Violation|12
6152040|NCT01117350|9789161|FG000|Comparative Period|Lack of Efficacy|1
6152041|NCT01117350|9789162|FG001|Comparative Period|Lack of Efficacy|0
6152042|NCT01117350|9789161|FG000|Comparative Period|Physician Decision|0
6152043|NCT01117350|9789162|FG001|Comparative Period|Physician Decision|1
6152044|NCT01117350|9789161|FG000|Comparative Period|Move to another city/country|2
6321797|NCT02855164|10061197|FG007|Part C (Randomized Set)|Withdrawal by Subject|3
6321798|NCT02855359|10061245|FG000|Overall Study|Death|2
6321799|NCT02855359|10061246|FG001|Overall Study|Death|2
6321800|NCT02855359|10061247|FG002|Overall Study|Death|0
6321801|NCT02855359|10061248|FG003|Overall Study|Death|0
6041326|NCT00375518|9639491|FG001|Overall Study|Patient Not Treated|6
6041327|NCT00375518|9639490|FG000|Overall Study|Death|0
6321802|NCT02855359|10061245|FG000|Overall Study|Study Termination by Sponsor|9
6321803|NCT02855359|10061246|FG001|Overall Study|Study Termination by Sponsor|11
6321804|NCT02855359|10061247|FG002|Overall Study|Study Termination by Sponsor|0
6321805|NCT02855359|10061248|FG003|Overall Study|Study Termination by Sponsor|0
6321806|NCT02855450|10061266|FG000|Overall Study|Adverse Event|1
6321807|NCT02855450|10061267|FG001|Overall Study|Adverse Event|0
6321808|NCT02855450|10061266|FG000|Overall Study|Lost to Follow-up|4
6321809|NCT02855450|10061267|FG001|Overall Study|Lost to Follow-up|0
6321810|NCT02855541|10061273|FG000|Overall Study|Change in health status|2
6321811|NCT02855541|10061273|FG000|Overall Study|Withdrawal by Subject|2
6321812|NCT02856282|10061290|FG000|Overall Study|Withdrawal by Subject|1
6321813|NCT02856555|10061310|FG000|Overall Study|Adverse Event|1
6321814|NCT02856555|10061311|FG001|Overall Study|Adverse Event|0
6321815|NCT02856555|10061312|FG002|Overall Study|Adverse Event|0
6321816|NCT02856555|10061310|FG000|Overall Study|Lost to Follow-up|1
6321817|NCT02856555|10061311|FG001|Overall Study|Lost to Follow-up|3
6041328|NCT00375518|9639491|FG001|Overall Study|Death|1
6041329|NCT00375609|9639500|FG000|Overall Study|Did not receive treatment|1
6041330|NCT00375609|9639501|FG001|Overall Study|Did not receive treatment|0
6321818|NCT02856555|10061312|FG002|Overall Study|Lost to Follow-up|0
6321819|NCT02856555|10061310|FG000|Overall Study|Withdrawal by Subject|3
6041331|NCT00375609|9639502|FG002|Overall Study|Did not receive treatment|0
6041332|NCT00375609|9639500|FG000|Overall Study|Adverse Event|0
6152045|NCT01117350|9789162|FG001|Comparative Period|Move to another city/country|1
6152046|NCT01117350|9789161|FG000|Extension Period|Not included in extension, not treated|0
6152047|NCT01117350|9789162|FG001|Extension Period|Not included in extension, not treated|50
6321820|NCT02856555|10061311|FG001|Overall Study|Withdrawal by Subject|0
6321821|NCT02856555|10061312|FG002|Overall Study|Withdrawal by Subject|0
6321822|NCT02856555|10061310|FG000|Overall Study|Randomized but Never Treated|0
6321823|NCT02856555|10061311|FG001|Overall Study|Randomized but Never Treated|1
6321824|NCT02856555|10061312|FG002|Overall Study|Randomized but Never Treated|0
6321825|NCT02856802|10061322|FG000|Double-Blind Treatment Period 1|Withdrawal by Subject|0
6321826|NCT02856802|10061323|FG001|Double-Blind Treatment Period 1|Withdrawal by Subject|2
6321827|NCT02856802|10061322|FG000|Double-Blind Treatment Period 1|Lost to Follow-up|1
6321828|NCT02856802|10061323|FG001|Double-Blind Treatment Period 1|Lost to Follow-up|0
6321829|NCT02856802|10061322|FG000|Double-Blind Treatment Period 1|Protocol Violation|0
6321830|NCT02856802|10061323|FG001|Double-Blind Treatment Period 1|Protocol Violation|1
6321831|NCT02856802|10061322|FG000|Double-Blind Treatment Period 1|Sponsor terminated|1
6321832|NCT02856802|10061323|FG001|Double-Blind Treatment Period 1|Sponsor terminated|0
6321833|NCT02856802|10061322|FG000|Double-Blind Treatment Period 1|Lack of diary compliance|0
6321834|NCT02856802|10061323|FG001|Double-Blind Treatment Period 1|Lack of diary compliance|2
6321835|NCT02856802|10061322|FG000|Double-Blind Treatment Period 2|Lost to Follow-up|1
6321836|NCT02856802|10061323|FG001|Double-Blind Treatment Period 2|Lost to Follow-up|0
6321837|NCT02856880|10061350|FG000|Overall Study|Withdrawal of consent|1
6321838|NCT02857283|10061371|FG000|First Exposure|Withdrawal by Subject|1
6321839|NCT02857283|10061372|FG001|First Exposure|Withdrawal by Subject|0
6321840|NCT02857816|10061379|FG000|Overall Study|Screen Failure|33
6321841|NCT02857816|10061379|FG000|Overall Study|Withdrawal by Subject|4
6321842|NCT02857816|10061379|FG000|Overall Study|Lost to Follow-up|1
6321843|NCT02858076|10061395|FG000|Overall Study|Death|6
6321844|NCT02858076|10061396|FG001|Overall Study|Death|3
6321845|NCT02858076|10061395|FG000|Overall Study|Withdrawal by Subject|1
6321846|NCT02858076|10061396|FG001|Overall Study|Withdrawal by Subject|5
6321847|NCT02858076|10061395|FG000|Overall Study|Lost to Follow-up|2
6321848|NCT02858076|10061396|FG001|Overall Study|Lost to Follow-up|7
6321849|NCT02858076|10061395|FG000|Overall Study|Completed Out of Window|1
6321850|NCT02858076|10061396|FG001|Overall Study|Completed Out of Window|3
6321851|NCT02858180|10061406|FG000|Overall Study|Lost to Follow-up|0
6321852|NCT02858180|10061407|FG001|Overall Study|Lost to Follow-up|2
6321853|NCT02858362|10061420|FG000|Overall Study|Protocol Violation|0
6321854|NCT02858362|10061421|FG001|Overall Study|Protocol Violation|1
6321855|NCT02858362|10061422|FG002|Overall Study|Protocol Violation|0
6321856|NCT02858362|10061420|FG000|Overall Study|Withdrawal by Subject|1
6321857|NCT02858362|10061421|FG001|Overall Study|Withdrawal by Subject|0
6321858|NCT02858362|10061422|FG002|Overall Study|Withdrawal by Subject|0
6321859|NCT02858362|10061420|FG000|Overall Study|Early Study Termination|0
6321860|NCT02858362|10061421|FG001|Overall Study|Early Study Termination|0
6321861|NCT02858362|10061422|FG002|Overall Study|Early Study Termination|3
6321862|NCT02858362|10061420|FG000|Overall Study|Lost to Follow-up|1
6321863|NCT02858362|10061421|FG001|Overall Study|Lost to Follow-up|0
6321864|NCT02858362|10061422|FG002|Overall Study|Lost to Follow-up|0
6321865|NCT02858401|10061442|FG000|Overall Study|Withdrew Consent|0
6152048|NCT01117350|9789161|FG000|Extension Period|Adverse Event|0
6152049|NCT01117350|9789162|FG001|Extension Period|Adverse Event|2
6152050|NCT01117350|9789161|FG000|Extension Period|Protocol Violation|0
6321866|NCT02858401|10061443|FG001|Overall Study|Withdrew Consent|0
6321867|NCT02858401|10061444|FG002|Overall Study|Withdrew Consent|0
6321868|NCT02858401|10061445|FG003|Overall Study|Withdrew Consent|0
6321869|NCT02858401|10061446|FG004|Overall Study|Withdrew Consent|0
6321870|NCT02858401|10061447|FG005|Overall Study|Withdrew Consent|1
6321871|NCT02858401|10061448|FG006|Overall Study|Withdrew Consent|0
6321872|NCT02858401|10061442|FG000|Overall Study|Lost to Follow-up|0
6321873|NCT02858401|10061443|FG001|Overall Study|Lost to Follow-up|1
6321874|NCT02858401|10061444|FG002|Overall Study|Lost to Follow-up|0
6321875|NCT02858401|10061445|FG003|Overall Study|Lost to Follow-up|0
6321876|NCT02858401|10061446|FG004|Overall Study|Lost to Follow-up|0
6321877|NCT02858401|10061447|FG005|Overall Study|Lost to Follow-up|0
6321878|NCT02858401|10061448|FG006|Overall Study|Lost to Follow-up|0
6321879|NCT02858440|10061473|FG000|Overall Study|Lost to Follow-up|3
6321880|NCT02858440|10061473|FG000|Overall Study|Protocol Violation|2
6321881|NCT02858440|10061473|FG000|Overall Study|Consent withdrawal|3
6321882|NCT02858440|10061473|FG000|Overall Study|Migrated/moved from study area|4
6321883|NCT02858492|10061481|FG000|Overall Study|Withdrawal by Subject|0
6321884|NCT02858492|10061482|FG001|Overall Study|Withdrawal by Subject|1
6321885|NCT02858492|10061483|FG002|Overall Study|Withdrawal by Subject|0
6321886|NCT02858492|10061484|FG003|Overall Study|Withdrawal by Subject|1
6321887|NCT02858492|10061481|FG000|Overall Study|Adverse Event|0
6321888|NCT02858492|10061482|FG001|Overall Study|Adverse Event|0
6321889|NCT02858492|10061483|FG002|Overall Study|Adverse Event|0
6321890|NCT02858492|10061484|FG003|Overall Study|Adverse Event|3
6321891|NCT02858492|10061481|FG000|Overall Study|Lack of Efficacy|0
6321892|NCT02858492|10061482|FG001|Overall Study|Lack of Efficacy|0
6321893|NCT02858492|10061483|FG002|Overall Study|Lack of Efficacy|0
6321894|NCT02858492|10061484|FG003|Overall Study|Lack of Efficacy|1
6321895|NCT02858492|10061481|FG000|Overall Study|Protocol defined stopping criteria|0
6321896|NCT02858492|10061482|FG001|Overall Study|Protocol defined stopping criteria|0
6321897|NCT02858492|10061483|FG002|Overall Study|Protocol defined stopping criteria|0
6321898|NCT02858492|10061484|FG003|Overall Study|Protocol defined stopping criteria|1
6321899|NCT02858726|10061513|FG000|Overall Study|Adverse Event|4
6321900|NCT02858726|10061514|FG001|Overall Study|Adverse Event|4
6321901|NCT02858726|10061515|FG002|Overall Study|Adverse Event|9
6321902|NCT02858726|10061516|FG003|Overall Study|Adverse Event|1
6321903|NCT02858726|10061513|FG000|Overall Study|Physician Decision|0
6321904|NCT02858726|10061514|FG001|Overall Study|Physician Decision|0
6321905|NCT02858726|10061515|FG002|Overall Study|Physician Decision|1
6321906|NCT02858726|10061516|FG003|Overall Study|Physician Decision|0
6321907|NCT02858726|10061513|FG000|Overall Study|Protocol Violation|0
6321908|NCT02858726|10061514|FG001|Overall Study|Protocol Violation|0
6321909|NCT02858726|10061515|FG002|Overall Study|Protocol Violation|0
6321910|NCT02858726|10061516|FG003|Overall Study|Protocol Violation|1
6321911|NCT02858726|10061513|FG000|Overall Study|Study Terminated by Sponsor|0
6321912|NCT02858726|10061514|FG001|Overall Study|Study Terminated by Sponsor|0
6321913|NCT02858726|10061515|FG002|Overall Study|Study Terminated by Sponsor|0
6321914|NCT02858726|10061516|FG003|Overall Study|Study Terminated by Sponsor|1
6321915|NCT02858726|10061513|FG000|Overall Study|Withdrawal by Subject|1
6321916|NCT02858726|10061514|FG001|Overall Study|Withdrawal by Subject|2
6321917|NCT02858726|10061515|FG002|Overall Study|Withdrawal by Subject|1
6321918|NCT02858726|10061516|FG003|Overall Study|Withdrawal by Subject|0
6321919|NCT02858726|10061513|FG000|Overall Study|Noncompliance|0
6041333|NCT00375609|9639501|FG001|Overall Study|Adverse Event|3
6041334|NCT00375609|9639502|FG002|Overall Study|Adverse Event|0
6321920|NCT02858726|10061514|FG001|Overall Study|Noncompliance|1
6321921|NCT02858726|10061515|FG002|Overall Study|Noncompliance|0
6321922|NCT02858726|10061516|FG003|Overall Study|Noncompliance|0
6321923|NCT02859142|10061532|FG000|Overall Study|Adverse Event|1
6321924|NCT02859142|10061533|FG001|Overall Study|Adverse Event|2
6321925|NCT02859142|10061532|FG000|Overall Study|Lost to Follow-up|1
6321926|NCT02859142|10061533|FG001|Overall Study|Lost to Follow-up|4
6321927|NCT02859142|10061532|FG000|Overall Study|Withdrawal by Subject|2
6321928|NCT02859142|10061533|FG001|Overall Study|Withdrawal by Subject|0
6321929|NCT02859142|10061532|FG000|Overall Study|Scheduling difficulties|0
6321930|NCT02859142|10061533|FG001|Overall Study|Scheduling difficulties|3
6321931|NCT02859246|10061539|FG000|Overall Study|Screen fails|3
6321932|NCT02859246|10061539|FG000|Overall Study|Adverse Event|1
6321933|NCT02859246|10061539|FG000|Overall Study|Withdrawal by Subject|1
6321934|NCT02859324|10061547|FG000|Overall Study|Death|4
6321935|NCT02859324|10061548|FG001|Overall Study|Death|6
6321936|NCT02859324|10061549|FG002|Overall Study|Death|5
6321937|NCT02859324|10061547|FG000|Overall Study|Other reasons|3
6321938|NCT02859324|10061548|FG001|Overall Study|Other reasons|3
6321939|NCT02859324|10061549|FG002|Overall Study|Other reasons|0
6321940|NCT02859454|10061578|FG000|Overall Study|PI discretion/off study prior to trtmt|1
6321941|NCT02860130|10061598|FG000|Overall Study|Adverse Event|2
6321942|NCT02860130|10061599|FG001|Overall Study|Adverse Event|3
6041335|NCT00375609|9639500|FG000|Overall Study|Lost to Follow-up|1
6321943|NCT02860130|10061598|FG000|Overall Study|Protocol Violation|1
6321944|NCT02860130|10061599|FG001|Overall Study|Protocol Violation|1
6321945|NCT02860130|10061598|FG000|Overall Study|Withdrawal by Subject|0
6321946|NCT02860130|10061599|FG001|Overall Study|Withdrawal by Subject|2
6321947|NCT02860130|10061598|FG000|Overall Study|Physician Decision|2
6321948|NCT02860130|10061599|FG001|Overall Study|Physician Decision|2
6321949|NCT02860130|10061598|FG000|Overall Study|Other|2
6321950|NCT02860130|10061599|FG001|Overall Study|Other|1
6321951|NCT02860546|10061632|FG000|Overall Study|Clinical Progression|6
6321952|NCT02860546|10061632|FG000|Overall Study|Radiological Progression|12
6041336|NCT00375609|9639501|FG001|Overall Study|Lost to Follow-up|0
6041337|NCT00375609|9639502|FG002|Overall Study|Lost to Follow-up|0
6321953|NCT02861534|10061680|FG000|Overall Study|Death|541
6321954|NCT02861534|10061681|FG001|Overall Study|Death|552
6321955|NCT02861534|10061680|FG000|Overall Study|Lost to Follow-up|14
6321956|NCT02861534|10061681|FG001|Overall Study|Lost to Follow-up|14
6321957|NCT02861534|10061680|FG000|Overall Study|Site Terminated by Sponsor|4
6321958|NCT02861534|10061681|FG001|Overall Study|Site Terminated by Sponsor|3
6321959|NCT02861534|10061680|FG000|Overall Study|Withdrawal by Subject|15
6321960|NCT02861534|10061681|FG001|Overall Study|Withdrawal by Subject|18
6321961|NCT02861586|10061695|FG000|Overall Study|Withdrawal by Subject|1
6321962|NCT02861586|10061696|FG001|Overall Study|Withdrawal by Subject|2
6321963|NCT02861586|10061697|FG002|Overall Study|Withdrawal by Subject|0
6321964|NCT02861586|10061698|FG003|Overall Study|Withdrawal by Subject|0
6321965|NCT02861586|10061699|FG004|Overall Study|Withdrawal by Subject|0
6321966|NCT02861586|10061700|FG005|Overall Study|Withdrawal by Subject|1
6321967|NCT02861586|10061701|FG006|Overall Study|Withdrawal by Subject|1
6321968|NCT02861586|10061702|FG007|Overall Study|Withdrawal by Subject|0
6321969|NCT02861586|10061695|FG000|Overall Study|Lost to Follow-up|3
6321970|NCT02861586|10061696|FG001|Overall Study|Lost to Follow-up|1
6321971|NCT02861586|10061697|FG002|Overall Study|Lost to Follow-up|1
6321972|NCT02861586|10061698|FG003|Overall Study|Lost to Follow-up|0
6321973|NCT02861586|10061699|FG004|Overall Study|Lost to Follow-up|0
6321974|NCT02861586|10061700|FG005|Overall Study|Lost to Follow-up|3
6321975|NCT02861586|10061701|FG006|Overall Study|Lost to Follow-up|0
6321976|NCT02861586|10061702|FG007|Overall Study|Lost to Follow-up|0
6321977|NCT02861586|10061695|FG000|Overall Study|Adverse Event|0
6321978|NCT02861586|10061696|FG001|Overall Study|Adverse Event|0
6321979|NCT02861586|10061697|FG002|Overall Study|Adverse Event|0
6321980|NCT02861586|10061698|FG003|Overall Study|Adverse Event|0
6321981|NCT02861586|10061699|FG004|Overall Study|Adverse Event|0
6321982|NCT02861586|10061700|FG005|Overall Study|Adverse Event|1
6321983|NCT02861586|10061701|FG006|Overall Study|Adverse Event|0
6321984|NCT02861586|10061702|FG007|Overall Study|Adverse Event|0
6321985|NCT02861664|10061727|FG000|Overall Study|Withdrawal of Consent|0
6321986|NCT02861664|10061728|FG001|Overall Study|Withdrawal of Consent|1
6321987|NCT02861807|10061736|FG000|Overall Study|Lost to Follow-up|7
6321988|NCT02861807|10061737|FG001|Overall Study|Lost to Follow-up|6
6321989|NCT02861807|10061736|FG000|Overall Study|Withdrawal by Subject|5
6321990|NCT02861807|10061737|FG001|Overall Study|Withdrawal by Subject|8
6321991|NCT02862106|10061778|FG000|Overall Study|Adverse Event|4
6321992|NCT02862106|10061779|FG001|Overall Study|Adverse Event|0
6321993|NCT02862106|10061778|FG000|Overall Study|Protocol Violation|16
6321994|NCT02862106|10061779|FG001|Overall Study|Protocol Violation|1
6321995|NCT02862106|10061778|FG000|Overall Study|Lost to Follow-up|15
6321996|NCT02862106|10061779|FG001|Overall Study|Lost to Follow-up|5
6321997|NCT02862106|10061778|FG000|Overall Study|Withdrawal by Subject|2
6321998|NCT02862106|10061779|FG001|Overall Study|Withdrawal by Subject|0
6152051|NCT01117350|9789162|FG001|Extension Period|Protocol Violation|2
6152052|NCT01117350|9789161|FG000|Extension Period|Lost to Follow-up|0
6152053|NCT01117350|9789162|FG001|Extension Period|Lost to Follow-up|2
6152054|NCT01117350|9789161|FG000|Extension Period|Withdrawal by Subject|0
6152055|NCT01117350|9789162|FG001|Extension Period|Withdrawal by Subject|3
6152056|NCT01117350|9789161|FG000|Extension Period|Lack of Efficacy|0
6152057|NCT01117350|9789162|FG001|Extension Period|Lack of Efficacy|2
6152058|NCT01117350|9789161|FG000|Extension Period|Inclusion criteria not respected|0
6152059|NCT01117350|9789162|FG001|Extension Period|Inclusion criteria not respected|1
6152060|NCT01117350|9789161|FG000|Extension Period|Prohibited medication|0
6152061|NCT01117350|9789162|FG001|Extension Period|Prohibited medication|1
6152062|NCT01117428|9789177|FG000|Overall Study|Lack of Efficacy|1
6152063|NCT01117428|9789178|FG001|Overall Study|Lack of Efficacy|0
6152064|NCT01117428|9789179|FG002|Overall Study|Lack of Efficacy|0
6152065|NCT01117428|9789180|FG003|Overall Study|Lack of Efficacy|0
6152066|NCT01117428|9789181|FG004|Overall Study|Lack of Efficacy|0
6152067|NCT01117428|9789182|FG005|Overall Study|Lack of Efficacy|0
6152068|NCT01117428|9789177|FG000|Overall Study|Adverse Event|4
6152069|NCT01117428|9789178|FG001|Overall Study|Adverse Event|0
6152070|NCT01117428|9789179|FG002|Overall Study|Adverse Event|0
6152071|NCT01117428|9789180|FG003|Overall Study|Adverse Event|0
6152072|NCT01117428|9789181|FG004|Overall Study|Adverse Event|1
6152073|NCT01117428|9789182|FG005|Overall Study|Adverse Event|2
6152074|NCT01117428|9789177|FG000|Overall Study|Death|0
6152075|NCT01117428|9789178|FG001|Overall Study|Death|1
6152076|NCT01117428|9789179|FG002|Overall Study|Death|2
6152077|NCT01117428|9789180|FG003|Overall Study|Death|0
6152078|NCT01117428|9789181|FG004|Overall Study|Death|0
6152079|NCT01117428|9789182|FG005|Overall Study|Death|1
6152080|NCT01117428|9789177|FG000|Overall Study|Physician Decision|0
6152081|NCT01117428|9789178|FG001|Overall Study|Physician Decision|1
6152082|NCT01117428|9789179|FG002|Overall Study|Physician Decision|0
6152083|NCT01117428|9789180|FG003|Overall Study|Physician Decision|0
6152084|NCT01117428|9789181|FG004|Overall Study|Physician Decision|0
6152085|NCT01117428|9789182|FG005|Overall Study|Physician Decision|0
6152086|NCT01117428|9789177|FG000|Overall Study|Withdrawal by Subject|0
6152087|NCT01117428|9789178|FG001|Overall Study|Withdrawal by Subject|0
6152088|NCT01117428|9789179|FG002|Overall Study|Withdrawal by Subject|1
6321999|NCT02862106|10061778|FG000|Overall Study|Subjects moved to other city|1
6322000|NCT02862106|10061779|FG001|Overall Study|Subjects moved to other city|0
6322001|NCT02862535|10061795|FG000|Overall Study|Death|7
6322002|NCT02862535|10061796|FG001|Overall Study|Death|3
6322003|NCT02862535|10061797|FG002|Overall Study|Death|2
6322004|NCT02862535|10061798|FG003|Overall Study|Death|5
6322005|NCT02862535|10061795|FG000|Overall Study|Study Terminated by Sponsor|1
6322006|NCT02862535|10061796|FG001|Overall Study|Study Terminated by Sponsor|3
6322007|NCT02862535|10061797|FG002|Overall Study|Study Terminated by Sponsor|8
6322008|NCT02862535|10061798|FG003|Overall Study|Study Terminated by Sponsor|5
6322009|NCT02862535|10061795|FG000|Overall Study|Enrolled, not Treated|1
6322010|NCT02862535|10061796|FG001|Overall Study|Enrolled, not Treated|0
6322011|NCT02862535|10061797|FG002|Overall Study|Enrolled, not Treated|0
6322012|NCT02862535|10061798|FG003|Overall Study|Enrolled, not Treated|1
6322013|NCT02862548|10061810|FG000|Open-Label Phase|Death|0
6322014|NCT02862548|10061811|FG001|Open-Label Phase|Death|1
6322015|NCT02862548|10061810|FG000|Open-Label Extension Phase|Still on Study|26
6322016|NCT02862548|10061811|FG001|Open-Label Extension Phase|Still on Study|24
6322017|NCT02862574|10061820|FG000|Double-Blind Treatment Period|Adverse Event|0
6322018|NCT02862574|10061821|FG001|Double-Blind Treatment Period|Adverse Event|1
6322019|NCT02862574|10061822|FG002|Double-Blind Treatment Period|Adverse Event|0
6322020|NCT02862574|10061820|FG000|Double-Blind Treatment Period|Study Terminated by Sponsor|3
6322021|NCT02862574|10061821|FG001|Double-Blind Treatment Period|Study Terminated by Sponsor|1
6322022|NCT02862574|10061822|FG002|Double-Blind Treatment Period|Study Terminated by Sponsor|4
6322023|NCT02862574|10061820|FG000|Open-Label Treatment Period|Study Terminated by Sponsor|2
6322024|NCT02862574|10061821|FG001|Open-Label Treatment Period|Study Terminated by Sponsor|3
6322025|NCT02862574|10061822|FG002|Open-Label Treatment Period|Study Terminated by Sponsor|1
6322026|NCT02862600|10061831|FG000|Period 1--Perhexiline-low Target Range|Lack of Efficacy|9
6322027|NCT02862600|10061831|FG000|Period 1--Perhexiline-low Target Range|Protocol Violation|3
6322028|NCT02862600|10061831|FG000|Period 1--Perhexiline-low Target Range|Withdrawal by Subject|1
6322029|NCT02862600|10061831|FG000|Period 2--Perhexiline-high Target Range|Lack of Efficacy|7
6322030|NCT02862730|10061837|FG000|Tslim Training Visit (2 Weeks)|Withdrawal by Subject|0
6322031|NCT02862730|10061838|FG001|Tslim Training Visit (2 Weeks)|Withdrawal by Subject|0
6322032|NCT02862730|10061839|FG002|Tslim Training Visit (2 Weeks)|Withdrawal by Subject|1
6322033|NCT02862730|10061840|FG003|Tslim Training Visit (2 Weeks)|Withdrawal by Subject|0
6322034|NCT02862730|10061841|FG004|Tslim Training Visit (2 Weeks)|Withdrawal by Subject|0
6322035|NCT02862730|10061842|FG005|Tslim Training Visit (2 Weeks)|Withdrawal by Subject|0
6322036|NCT02862730|10061843|FG006|Tslim Training Visit (2 Weeks)|Withdrawal by Subject|0
6322037|NCT02862730|10061837|FG000|Second Intervention (84 Hours)|Withdrawal by Subject|1
6322038|NCT02862730|10061838|FG001|Second Intervention (84 Hours)|Withdrawal by Subject|0
6322039|NCT02862730|10061839|FG002|Second Intervention (84 Hours)|Withdrawal by Subject|0
6322040|NCT02862730|10061840|FG003|Second Intervention (84 Hours)|Withdrawal by Subject|0
6322041|NCT02862730|10061841|FG004|Second Intervention (84 Hours)|Withdrawal by Subject|0
6322042|NCT02862730|10061842|FG005|Second Intervention (84 Hours)|Withdrawal by Subject|0
6322043|NCT02862730|10061843|FG006|Second Intervention (84 Hours)|Withdrawal by Subject|0
6322044|NCT02862730|10061837|FG000|Third Rest Period (7-45 Days)|Withdrawal by Subject|0
6322045|NCT02862730|10061838|FG001|Third Rest Period (7-45 Days)|Withdrawal by Subject|0
6322046|NCT02862730|10061839|FG002|Third Rest Period (7-45 Days)|Withdrawal by Subject|1
6322047|NCT02862730|10061840|FG003|Third Rest Period (7-45 Days)|Withdrawal by Subject|0
6322048|NCT02862730|10061841|FG004|Third Rest Period (7-45 Days)|Withdrawal by Subject|1
6322049|NCT02862730|10061842|FG005|Third Rest Period (7-45 Days)|Withdrawal by Subject|0
6322050|NCT02862730|10061843|FG006|Third Rest Period (7-45 Days)|Withdrawal by Subject|0
6322051|NCT02862730|10061837|FG000|Third Intervention (84 Hours)|diagnosis of gastroparesis|0
6322052|NCT02862730|10061838|FG001|Third Intervention (84 Hours)|diagnosis of gastroparesis|0
6322053|NCT02862730|10061839|FG002|Third Intervention (84 Hours)|diagnosis of gastroparesis|0
6322054|NCT02862730|10061840|FG003|Third Intervention (84 Hours)|diagnosis of gastroparesis|1
6322055|NCT02862730|10061841|FG004|Third Intervention (84 Hours)|diagnosis of gastroparesis|0
6322056|NCT02862730|10061842|FG005|Third Intervention (84 Hours)|diagnosis of gastroparesis|0
6322057|NCT02862730|10061843|FG006|Third Intervention (84 Hours)|diagnosis of gastroparesis|0
6322058|NCT02863328|10061894|FG000|Overall Study|Lost to Follow-up|4
6322059|NCT02863328|10061895|FG001|Overall Study|Lost to Follow-up|10
6322060|NCT02863328|10061894|FG000|Overall Study|Withdrawal by Subject|7
6322061|NCT02863328|10061895|FG001|Overall Study|Withdrawal by Subject|12
6322062|NCT02863328|10061894|FG000|Overall Study|Died|0
6322063|NCT02863328|10061895|FG001|Overall Study|Died|1
6322064|NCT02863354|10061903|FG000|Year 1|Lost to Follow-up|1
6322065|NCT02863354|10061904|FG001|Year 1|Lost to Follow-up|1
6322066|NCT02863354|10061903|FG000|Year 1|Withdrawal by Subject|3
6322067|NCT02863354|10061904|FG001|Year 1|Withdrawal by Subject|0
6322068|NCT02863354|10061903|FG000|Year 1|Death|0
6322069|NCT02863354|10061904|FG001|Year 1|Death|1
6322070|NCT02863354|10061903|FG000|Year 2|Lost to Follow-up|2
6322071|NCT02863354|10061904|FG001|Year 2|Lost to Follow-up|2
6322072|NCT02863419|10061913|FG000|Overall Study|Lost to Follow-up|0
6322073|NCT02863419|10061914|FG001|Overall Study|Lost to Follow-up|1
6322074|NCT02863419|10061915|FG002|Overall Study|Lost to Follow-up|4
6322075|NCT02863419|10061913|FG000|Overall Study|Withdrawal by Subject|5
6322076|NCT02863419|10061914|FG001|Overall Study|Withdrawal by Subject|5
6322077|NCT02863419|10061915|FG002|Overall Study|Withdrawal by Subject|3
6322078|NCT02863419|10061913|FG000|Overall Study|Died|3
6322079|NCT02863419|10061914|FG001|Overall Study|Died|4
6322080|NCT02863419|10061915|FG002|Overall Study|Died|1
6322081|NCT02863575|10061926|FG000|Overall Study|Participants Unable To Swallow Capsule|1
6322082|NCT02863575|10061927|FG001|Overall Study|Participants Unable To Swallow Capsule|0
6322083|NCT02863575|10061928|FG002|Overall Study|Participants Unable To Swallow Capsule|0
6322084|NCT02863575|10061926|FG000|Overall Study|Withdrawal by Subject|0
6322085|NCT02863575|10061927|FG001|Overall Study|Withdrawal by Subject|1
6322086|NCT02863575|10061928|FG002|Overall Study|Withdrawal by Subject|1
6322087|NCT02863575|10061926|FG000|Overall Study|Adverse Event|0
6322088|NCT02863575|10061927|FG001|Overall Study|Adverse Event|1
6322089|NCT02863575|10061928|FG002|Overall Study|Adverse Event|0
6322090|NCT02864082|10061951|FG000|Overall Study|Adverse Event|1
6322091|NCT02864082|10061952|FG001|Overall Study|Adverse Event|1
6322092|NCT02864082|10061951|FG000|Overall Study|Lost to Follow-up|0
6322093|NCT02864082|10061952|FG001|Overall Study|Lost to Follow-up|1
6322094|NCT02864082|10061951|FG000|Overall Study|Withdrawal by Subject|2
6322095|NCT02864082|10061952|FG001|Overall Study|Withdrawal by Subject|2
6322096|NCT02864316|10061974|FG000|Overall Study|Progressive Disease|2
6322097|NCT02864316|10061975|FG001|Overall Study|Progressive Disease|1
6322098|NCT02864316|10061974|FG000|Overall Study|Adverse Event|0
6322099|NCT02864316|10061975|FG001|Overall Study|Adverse Event|1
6322100|NCT02864342|10061983|FG000|Overall Study|Eligibility Criteria Deviation|2
6322101|NCT02864342|10061984|FG001|Overall Study|Eligibility Criteria Deviation|3
6322102|NCT02864342|10061983|FG000|Overall Study|Withdrawal by Subject|4
6322103|NCT02864342|10061984|FG001|Overall Study|Withdrawal by Subject|2
6322104|NCT02864342|10061983|FG000|Overall Study|Device Technology Issue|6
6322105|NCT02864342|10061984|FG001|Overall Study|Device Technology Issue|7
6322106|NCT02864342|10061983|FG000|Overall Study|Death|0
6322107|NCT02864342|10061984|FG001|Overall Study|Death|1
6322108|NCT02864342|10061983|FG000|Overall Study|Did Not Start Treatment with Symbicort|0
6322109|NCT02864342|10061984|FG001|Overall Study|Did Not Start Treatment with Symbicort|1
6322110|NCT02864342|10061983|FG000|Overall Study|Lost to Follow-up|1
6322111|NCT02864342|10061984|FG001|Overall Study|Lost to Follow-up|5
6322112|NCT02864342|10061983|FG000|Overall Study|Lost Device|1
6322113|NCT02864342|10061984|FG001|Overall Study|Lost Device|0
6322114|NCT02864342|10061983|FG000|Overall Study|Adverse Event|1
6322115|NCT02864342|10061984|FG001|Overall Study|Adverse Event|0
6322116|NCT02864381|10062028|FG000|Overall Study|Death|58
6322117|NCT02864381|10062029|FG001|Overall Study|Death|61
6322118|NCT02864381|10062028|FG000|Overall Study|Withdrew Consent|5
6322119|NCT02864381|10062029|FG001|Overall Study|Withdrew Consent|6
6322120|NCT02864381|10062028|FG000|Overall Study|Reason Unknown|7
6322121|NCT02864381|10062029|FG001|Overall Study|Reason Unknown|3
6322122|NCT02864381|10062028|FG000|Overall Study|Lost to Follow-up|1
6322123|NCT02864381|10062029|FG001|Overall Study|Lost to Follow-up|1
6322124|NCT02864381|10062028|FG000|Overall Study|Investigator's Discretion|1
6322125|NCT02864381|10062029|FG001|Overall Study|Investigator's Discretion|0
6322126|NCT02864381|10062028|FG000|Overall Study|Protocol Violation|0
6322127|NCT02864381|10062029|FG001|Overall Study|Protocol Violation|1
6322128|NCT02864394|10062037|FG000|Overall Study|Death|135
6041338|NCT00375609|9639500|FG000|Overall Study|Physician Decision|0
6041339|NCT00375609|9639501|FG001|Overall Study|Physician Decision|0
6041340|NCT00375609|9639502|FG002|Overall Study|Physician Decision|1
6041341|NCT00375609|9639500|FG000|Overall Study|Withdrawal by Subject|1
6041342|NCT00375609|9639501|FG001|Overall Study|Withdrawal by Subject|4
6041343|NCT00375609|9639502|FG002|Overall Study|Withdrawal by Subject|0
6041344|NCT00375609|9639500|FG000|Overall Study|Neurologist Wanted Pt to start Plavix|1
6041345|NCT00375609|9639501|FG001|Overall Study|Neurologist Wanted Pt to start Plavix|0
6041346|NCT00375609|9639502|FG002|Overall Study|Neurologist Wanted Pt to start Plavix|0
6041347|NCT00375674|9639512|FG000|Overall Study|Other|26
6322129|NCT02864394|10062038|FG001|Overall Study|Death|150
6322130|NCT02864394|10062037|FG000|Overall Study|Withdrawal by Subject|1
6322131|NCT02864394|10062038|FG001|Overall Study|Withdrawal by Subject|9
6322132|NCT02864394|10062037|FG000|Overall Study|Ongoing In Study|77
6322133|NCT02864394|10062038|FG001|Overall Study|Ongoing In Study|53
6322134|NCT02865499|10062125|FG000|Baseline|Adverse Event|1
6322135|NCT02865499|10062125|FG000|Baseline|Withdrawal by Subject|1
6322136|NCT02865538|10062134|FG000|Overall Study|Withdrawal by Subject|0
6322137|NCT02865538|10062135|FG001|Overall Study|Withdrawal by Subject|0
6322138|NCT02865538|10062136|FG002|Overall Study|Withdrawal by Subject|1
6322139|NCT02865538|10062137|FG003|Overall Study|Withdrawal by Subject|0
6322140|NCT02865538|10062138|FG004|Overall Study|Withdrawal by Subject|0
6322141|NCT02865538|10062134|FG000|Overall Study|Lost to Follow-up|1
6322142|NCT02865538|10062135|FG001|Overall Study|Lost to Follow-up|0
6322143|NCT02865538|10062136|FG002|Overall Study|Lost to Follow-up|0
6041348|NCT00375674|9639513|FG001|Overall Study|Other|18
6322144|NCT02865538|10062137|FG003|Overall Study|Lost to Follow-up|0
6322145|NCT02865538|10062138|FG004|Overall Study|Lost to Follow-up|0
6322146|NCT02866175|10062174|FG000|Overall Study|Adverse Event|56
6041349|NCT00375674|9639512|FG000|Overall Study|Death|67
6322147|NCT02866175|10062175|FG001|Overall Study|Adverse Event|54
6322148|NCT02866175|10062174|FG000|Overall Study|Withdrawal by Subject|31
6322149|NCT02866175|10062175|FG001|Overall Study|Withdrawal by Subject|52
6322150|NCT02866175|10062174|FG000|Overall Study|Death|30
6322151|NCT02866175|10062175|FG001|Overall Study|Death|23
6322152|NCT02866175|10062174|FG000|Overall Study|Other|7
6322153|NCT02866175|10062175|FG001|Overall Study|Other|14
6322154|NCT02866175|10062174|FG000|Overall Study|Progressive disease|1
6322155|NCT02866175|10062175|FG001|Overall Study|Progressive disease|1
6322156|NCT02866175|10062174|FG000|Overall Study|Lost to Follow-up|2
6322157|NCT02866175|10062175|FG001|Overall Study|Lost to Follow-up|0
6322158|NCT02866175|10062174|FG000|Overall Study|Lack of Efficacy|0
6322159|NCT02866175|10062175|FG001|Overall Study|Lack of Efficacy|1
6322160|NCT02866175|10062174|FG000|Overall Study|Physician Decision|3
6322161|NCT02866175|10062175|FG001|Overall Study|Physician Decision|15
6322162|NCT02866175|10062174|FG000|Overall Study|Did not receive treatment|5
6322163|NCT02866175|10062175|FG001|Overall Study|Did not receive treatment|15
6322164|NCT02866942|10062191|FG000|Overall Study|Invalid consent|1
6322165|NCT02867709|10062245|FG000|Treatment Period|Adverse Event|1
6322166|NCT02867709|10062246|FG001|Treatment Period|Adverse Event|1
6322167|NCT02867709|10062247|FG002|Treatment Period|Adverse Event|2
6322168|NCT02867709|10062245|FG000|Treatment Period|Withdrawal of Consent|7
6322169|NCT02867709|10062246|FG001|Treatment Period|Withdrawal of Consent|9
6322170|NCT02867709|10062247|FG002|Treatment Period|Withdrawal of Consent|8
6322171|NCT02867709|10062245|FG000|Treatment Period|Lost to Follow-up|17
6322172|NCT02867709|10062246|FG001|Treatment Period|Lost to Follow-up|20
6322173|NCT02867709|10062247|FG002|Treatment Period|Lost to Follow-up|20
6322174|NCT02867709|10062245|FG000|Treatment Period|Lack of Qualifying Event|42
6322175|NCT02867709|10062246|FG001|Treatment Period|Lack of Qualifying Event|55
6322176|NCT02867709|10062247|FG002|Treatment Period|Lack of Qualifying Event|42
6322177|NCT02867709|10062245|FG000|Treatment Period|Protocol Violation|3
6322178|NCT02867709|10062246|FG001|Treatment Period|Protocol Violation|2
6322179|NCT02867709|10062247|FG002|Treatment Period|Protocol Violation|3
6322180|NCT02867709|10062245|FG000|Safety Follow-up Period|Withdrawal of Consent|1
6322181|NCT02867709|10062246|FG001|Safety Follow-up Period|Withdrawal of Consent|8
6322182|NCT02867709|10062247|FG002|Safety Follow-up Period|Withdrawal of Consent|6
6322183|NCT02867709|10062245|FG000|Safety Follow-up Period|Lost to Follow-up|10
6322184|NCT02867709|10062246|FG001|Safety Follow-up Period|Lost to Follow-up|5
6322185|NCT02867709|10062247|FG002|Safety Follow-up Period|Lost to Follow-up|7
6322186|NCT02867709|10062245|FG000|Safety Follow-up Period|Pregnancy|0
6322187|NCT02867709|10062246|FG001|Safety Follow-up Period|Pregnancy|1
6322188|NCT02867709|10062247|FG002|Safety Follow-up Period|Pregnancy|0
6322189|NCT02867709|10062245|FG000|Safety Follow-up Period|Protocol Violation|0
6322190|NCT02867709|10062246|FG001|Safety Follow-up Period|Protocol Violation|1
6322191|NCT02867709|10062247|FG002|Safety Follow-up Period|Protocol Violation|1
6322192|NCT02867995|10062257|FG000|Overall Study|Withdrawal by Subject|0
6322193|NCT02867995|10062258|FG001|Overall Study|Withdrawal by Subject|1
6322194|NCT02867995|10062257|FG000|Overall Study|Lost to Follow-up|0
6322195|NCT02867995|10062258|FG001|Overall Study|Lost to Follow-up|2
6322196|NCT02868216|10062270|FG000|Overall Study|Death|0
6322197|NCT02868216|10062271|FG001|Overall Study|Death|1
6322198|NCT02868216|10062270|FG000|Overall Study|coronary artery bypass|1
6322199|NCT02868216|10062271|FG001|Overall Study|coronary artery bypass|0
6322200|NCT02868216|10062270|FG000|Overall Study|Withdrawal by Subject|7
6322201|NCT02868216|10062271|FG001|Overall Study|Withdrawal by Subject|5
6322202|NCT02868229|10062281|FG000|Overall Study|Adverse Event|1
6322203|NCT02868229|10062282|FG001|Overall Study|Adverse Event|0
6322204|NCT02868229|10062283|FG002|Overall Study|Adverse Event|0
6322205|NCT02868229|10062284|FG003|Overall Study|Adverse Event|1
6322206|NCT02868229|10062281|FG000|Overall Study|Death|0
6322207|NCT02868229|10062282|FG001|Overall Study|Death|0
6322208|NCT02868229|10062283|FG002|Overall Study|Death|1
6322209|NCT02868229|10062284|FG003|Overall Study|Death|1
6322210|NCT02868229|10062281|FG000|Overall Study|Missed dose|0
6322211|NCT02868229|10062282|FG001|Overall Study|Missed dose|0
6322212|NCT02868229|10062283|FG002|Overall Study|Missed dose|0
6322213|NCT02868229|10062284|FG003|Overall Study|Missed dose|3
6322214|NCT02868281|10062307|FG000|Overall Study|Adverse Event|2
6322215|NCT02868281|10062308|FG001|Overall Study|Adverse Event|2
6322216|NCT02868281|10062307|FG000|Overall Study|Protocol Violation|13
6322217|NCT02868281|10062308|FG001|Overall Study|Protocol Violation|10
6322218|NCT02868281|10062307|FG000|Overall Study|Lost to Follow-up|3
6322219|NCT02868281|10062308|FG001|Overall Study|Lost to Follow-up|6
6322220|NCT02868281|10062307|FG000|Overall Study|Withdrawal by Subject|11
6322221|NCT02868281|10062308|FG001|Overall Study|Withdrawal by Subject|15
6322222|NCT02868281|10062307|FG000|Overall Study|Physician Decision|2
6322223|NCT02868281|10062308|FG001|Overall Study|Physician Decision|0
6322224|NCT02868281|10062307|FG000|Overall Study|Had protocol-defined asthma exacerbation|8
6322225|NCT02868281|10062308|FG001|Overall Study|Had protocol-defined asthma exacerbation|8
6322226|NCT02868281|10062307|FG000|Overall Study|Inclusion/exclusion criteria violation|3
6322227|NCT02868281|10062308|FG001|Overall Study|Inclusion/exclusion criteria violation|2
6322228|NCT02868281|10062307|FG000|Overall Study|Long journey/moving away|1
6322229|NCT02868281|10062308|FG001|Overall Study|Long journey/moving away|1
6322230|NCT02868554|10062317|FG000|Overall Study|Lost to Follow-up|3
6322231|NCT02868554|10062318|FG001|Overall Study|Lost to Follow-up|0
6322232|NCT02868554|10062319|FG002|Overall Study|Lost to Follow-up|1
6322233|NCT02869438|10062359|FG000|Overall Study|Lost to Follow-up|1
6322234|NCT02869438|10062360|FG001|Overall Study|Lost to Follow-up|0
6322235|NCT02869438|10062359|FG000|Overall Study|Adverse Event|1
6322236|NCT02869438|10062360|FG001|Overall Study|Adverse Event|0
6322237|NCT02869438|10062359|FG000|Overall Study|Withdrawal by Subject|1
6322238|NCT02869438|10062360|FG001|Overall Study|Withdrawal by Subject|2
6322239|NCT02869893|10062370|FG000|Overall Study|participant aversion to IV|5
6322240|NCT02869893|10062370|FG000|Overall Study|participant fear of MRI scanner|2
6322241|NCT02870933|10062426|FG000|Overall Study|Death|2
6322242|NCT02870933|10062427|FG001|Overall Study|Death|1
6322243|NCT02870933|10062426|FG000|Overall Study|Withdrawal by Subject|0
6322244|NCT02870933|10062427|FG001|Overall Study|Withdrawal by Subject|1
6322245|NCT02870972|10062439|FG000|Overall Study|Adverse Event|1
6322246|NCT02870972|10062440|FG001|Overall Study|Adverse Event|0
6322247|NCT02870972|10062441|FG002|Overall Study|Adverse Event|0
6322248|NCT02870972|10062442|FG003|Overall Study|Adverse Event|0
6322249|NCT02870972|10062443|FG004|Overall Study|Adverse Event|0
6322250|NCT02871375|10062479|FG000|Period 1, First 14 Days of Wear|Inclusion criteria not met|0
6322251|NCT02871375|10062480|FG001|Period 1, First 14 Days of Wear|Inclusion criteria not met|1
6322252|NCT02871492|10062520|FG000|Overall Study|Lost to Follow-up|6
6322253|NCT02871492|10062521|FG001|Overall Study|Lost to Follow-up|3
6322254|NCT02871492|10062522|FG002|Overall Study|Lost to Follow-up|5
6322255|NCT02871492|10062520|FG000|Overall Study|Withdrawal by Subject|0
6322256|NCT02871492|10062521|FG001|Overall Study|Withdrawal by Subject|0
6322257|NCT02871492|10062522|FG002|Overall Study|Withdrawal by Subject|1
6322258|NCT02871635|10062541|FG000|Overall Study|Primary lack of efficacy|4
6322259|NCT02871635|10062542|FG001|Overall Study|Primary lack of efficacy|4
6322260|NCT02871635|10062541|FG000|Overall Study|Protocol Violation|3
6322261|NCT02871635|10062542|FG001|Overall Study|Protocol Violation|1
6322262|NCT02871635|10062541|FG000|Overall Study|Lost to Follow-up|1
6322263|NCT02871635|10062542|FG001|Overall Study|Lost to Follow-up|2
6322264|NCT02871635|10062541|FG000|Overall Study|Pregnancy|0
6322265|NCT02871635|10062542|FG001|Overall Study|Pregnancy|2
6322266|NCT02871635|10062541|FG000|Overall Study|Physician Decision|1
6322267|NCT02871635|10062542|FG001|Overall Study|Physician Decision|1
6322268|NCT02871635|10062541|FG000|Overall Study|Withdrawal by Subject|3
6322269|NCT02871635|10062542|FG001|Overall Study|Withdrawal by Subject|4
6322270|NCT02871635|10062541|FG000|Overall Study|Adverse Event|4
6322271|NCT02871635|10062542|FG001|Overall Study|Adverse Event|4
6322272|NCT02871635|10062541|FG000|Overall Study|Secondary lack of efficacy|2
6322273|NCT02871635|10062542|FG001|Overall Study|Secondary lack of efficacy|1
6322274|NCT02871739|10062554|FG000|Overall Study|Lost to Follow-up|3
6322275|NCT02871739|10062555|FG001|Overall Study|Lost to Follow-up|2
6322276|NCT02871739|10062556|FG002|Overall Study|Lost to Follow-up|0
6322277|NCT02871739|10062557|FG003|Overall Study|Lost to Follow-up|2
6322278|NCT02872012|10062572|FG000|Overall Study|Withdrawal by Subject|1
6322279|NCT02872012|10062573|FG001|Overall Study|Withdrawal by Subject|0
6322280|NCT02872012|10062574|FG002|Overall Study|Withdrawal by Subject|0
6322281|NCT02872012|10062575|FG003|Overall Study|Withdrawal by Subject|0
6322282|NCT02872012|10062576|FG004|Overall Study|Withdrawal by Subject|0
6322283|NCT02872142|10062601|FG000|Overall Study|Adverse Event|2
6322284|NCT02872142|10062601|FG000|Overall Study|Death|1
6322285|NCT02872142|10062601|FG000|Overall Study|Participant Decision|3
6322286|NCT02872285|10062607|FG000|Overall Study|Withdrawal by Subject|2
6322287|NCT02872285|10062608|FG001|Overall Study|Withdrawal by Subject|0
6322288|NCT02872285|10062607|FG000|Overall Study|Lost to Follow-up|2
6322289|NCT02872285|10062608|FG001|Overall Study|Lost to Follow-up|2
6322290|NCT02872285|10062607|FG000|Overall Study|Discontinued due to back surgery|1
6322291|NCT02872285|10062608|FG001|Overall Study|Discontinued due to back surgery|0
6322292|NCT02872311|10062619|FG000|Overall Study|Death|2
6322293|NCT02872311|10062620|FG001|Overall Study|Death|0
6322294|NCT02872311|10062621|FG002|Overall Study|Death|0
6322295|NCT02872311|10062622|FG003|Overall Study|Death|0
6322296|NCT02872311|10062623|FG004|Overall Study|Death|0
6322297|NCT02872311|10062619|FG000|Overall Study|Lost to Follow-up|2
6322298|NCT02872311|10062620|FG001|Overall Study|Lost to Follow-up|0
6322299|NCT02872311|10062621|FG002|Overall Study|Lost to Follow-up|0
6322300|NCT02872311|10062622|FG003|Overall Study|Lost to Follow-up|0
6322301|NCT02872311|10062623|FG004|Overall Study|Lost to Follow-up|0
6322302|NCT02872311|10062619|FG000|Overall Study|Protocol Violation|0
6322303|NCT02872311|10062620|FG001|Overall Study|Protocol Violation|2
6322304|NCT02872311|10062621|FG002|Overall Study|Protocol Violation|1
6322305|NCT02872311|10062622|FG003|Overall Study|Protocol Violation|0
6322306|NCT02872311|10062623|FG004|Overall Study|Protocol Violation|0
6322307|NCT02872935|10062673|FG000|Overall Study|Other|0
6322308|NCT02872935|10062674|FG001|Overall Study|Other|1
6322309|NCT02873208|10062689|FG000|Overall Study|Withdrawal by Subject|36
6322310|NCT02873208|10062689|FG000|Overall Study|Lost to Follow-up|22
6322311|NCT02873208|10062689|FG000|Overall Study|Adverse Event|15
6322312|NCT02873208|10062689|FG000|Overall Study|Non-compliance with study drug|12
6322313|NCT02873208|10062689|FG000|Overall Study|Protocol Violation|8
6322314|NCT02873208|10062689|FG000|Overall Study|Pregnancy|2
6322315|NCT02873208|10062689|FG000|Overall Study|Incarceration|1
6322316|NCT02873208|10062689|FG000|Overall Study|Lack of Efficacy|1
6322317|NCT02873208|10062689|FG000|Overall Study|Physician Decision|1
6322318|NCT02873221|10062696|FG000|Treatment Period|Other Miscellaneous Reasons|0
6322319|NCT02873221|10062697|FG001|Treatment Period|Other Miscellaneous Reasons|2
6322320|NCT02873221|10062698|FG002|Treatment Period|Other Miscellaneous Reasons|1
6322321|NCT02873221|10062696|FG000|Treatment Period|Non-Compliance with Study Drug|0
6322322|NCT02873221|10062697|FG001|Treatment Period|Non-Compliance with Study Drug|3
6322323|NCT02873221|10062698|FG002|Treatment Period|Non-Compliance with Study Drug|2
6322324|NCT02873221|10062696|FG000|Treatment Period|Protocol Violation|2
6322325|NCT02873221|10062697|FG001|Treatment Period|Protocol Violation|5
6322326|NCT02873221|10062698|FG002|Treatment Period|Protocol Violation|8
6322327|NCT02873221|10062696|FG000|Treatment Period|Pregnancy|4
6322328|NCT02873221|10062697|FG001|Treatment Period|Pregnancy|6
6322329|NCT02873221|10062698|FG002|Treatment Period|Pregnancy|3
6322330|NCT02873221|10062696|FG000|Treatment Period|Lack of Qualifying Event|0
6322331|NCT02873221|10062697|FG001|Treatment Period|Lack of Qualifying Event|3
6322332|NCT02873221|10062698|FG002|Treatment Period|Lack of Qualifying Event|1
6322333|NCT02873221|10062696|FG000|Treatment Period|Withdrawal of Consent|52
6322334|NCT02873221|10062697|FG001|Treatment Period|Withdrawal of Consent|51
6322335|NCT02873221|10062698|FG002|Treatment Period|Withdrawal of Consent|41
6322336|NCT02873221|10062696|FG000|Treatment Period|Lack of Efficacy|0
6322337|NCT02873221|10062697|FG001|Treatment Period|Lack of Efficacy|17
6322338|NCT02873221|10062698|FG002|Treatment Period|Lack of Efficacy|12
6322339|NCT02873221|10062696|FG000|Treatment Period|Adverse Event|4
6322340|NCT02873221|10062697|FG001|Treatment Period|Adverse Event|9
6322341|NCT02873221|10062698|FG002|Treatment Period|Adverse Event|11
6322342|NCT02873221|10062696|FG000|Treatment Period|Lost to Follow-up|26
6322343|NCT02873221|10062697|FG001|Treatment Period|Lost to Follow-up|30
6322344|NCT02873221|10062698|FG002|Treatment Period|Lost to Follow-up|26
6322345|NCT02873221|10062696|FG000|Safety Follow-up Period|Other Miscellaneous Reasons|0
6322346|NCT02873221|10062697|FG001|Safety Follow-up Period|Other Miscellaneous Reasons|2
6322347|NCT02873221|10062698|FG002|Safety Follow-up Period|Other Miscellaneous Reasons|0
6322348|NCT02873221|10062696|FG000|Safety Follow-up Period|Protocol Violation|0
6322349|NCT02873221|10062697|FG001|Safety Follow-up Period|Protocol Violation|0
6322350|NCT02873221|10062698|FG002|Safety Follow-up Period|Protocol Violation|1
6322351|NCT02873221|10062696|FG000|Safety Follow-up Period|Lost to Follow-up|3
6322352|NCT02873221|10062697|FG001|Safety Follow-up Period|Lost to Follow-up|5
6322353|NCT02873221|10062698|FG002|Safety Follow-up Period|Lost to Follow-up|5
6322354|NCT02873221|10062696|FG000|Safety Follow-up Period|Withdrawal of Consent|4
6322355|NCT02873221|10062697|FG001|Safety Follow-up Period|Withdrawal of Consent|10
6322356|NCT02873221|10062698|FG002|Safety Follow-up Period|Withdrawal of Consent|8
6322357|NCT02873338|10062730|FG000|Overall Study|Adverse Event|0
6322358|NCT02873338|10062731|FG001|Overall Study|Adverse Event|2
6322359|NCT02873338|10062732|FG002|Overall Study|Adverse Event|1
6322360|NCT02873338|10062730|FG000|Overall Study|Death|2
6322361|NCT02873338|10062731|FG001|Overall Study|Death|1
6322362|NCT02873338|10062732|FG002|Overall Study|Death|1
6322363|NCT02873338|10062730|FG000|Overall Study|Withdrawal by Subject|2
6322364|NCT02873338|10062731|FG001|Overall Study|Withdrawal by Subject|1
6322365|NCT02873338|10062732|FG002|Overall Study|Withdrawal by Subject|3
6322366|NCT02873338|10062730|FG000|Overall Study|Lack of Efficacy|0
6322367|NCT02873338|10062731|FG001|Overall Study|Lack of Efficacy|2
6322368|NCT02873338|10062732|FG002|Overall Study|Lack of Efficacy|0
6322369|NCT02873338|10062730|FG000|Overall Study|Other or Missing|14
6322370|NCT02873338|10062731|FG001|Overall Study|Other or Missing|15
6322371|NCT02873338|10062732|FG002|Overall Study|Other or Missing|13
6322372|NCT02873377|10062742|FG000|Period Title 2: 3 Months Follow up|Lost to Follow-up|22
6322373|NCT02873377|10062743|FG001|Period Title 2: 3 Months Follow up|Lost to Follow-up|22
6322374|NCT02873377|10062742|FG000|Period Title 3: 6 Months Follow up|Lost to Follow-up|15
6322375|NCT02873377|10062743|FG001|Period Title 3: 6 Months Follow up|Lost to Follow-up|23
6322376|NCT02873429|10062752|FG000|6-8 Weeks|Missed 6-8 week, eligible for 16 week|10
6322377|NCT02873429|10062753|FG001|6-8 Weeks|Missed 6-8 week, eligible for 16 week|1
6322378|NCT02873429|10062752|FG000|16 Weeks|Completed 6-8 week, missed 16 week|2
6322379|NCT02873429|10062753|FG001|16 Weeks|Completed 6-8 week, missed 16 week|2
6322380|NCT02873429|10062752|FG000|16 Weeks|Lost to Follow-up|3
6322381|NCT02873429|10062753|FG001|16 Weeks|Lost to Follow-up|0
6322382|NCT02873689|10062778|FG000|Overall Study|Lack of Efficacy|1
6322383|NCT02873689|10062779|FG001|Overall Study|Lack of Efficacy|0
6322384|NCT02873689|10062778|FG000|Overall Study|Withdrawal by Subject|2
6322385|NCT02873689|10062779|FG001|Overall Study|Withdrawal by Subject|2
6322386|NCT02873689|10062778|FG000|Overall Study|Protocol Violation|1
6322387|NCT02873689|10062779|FG001|Overall Study|Protocol Violation|0
6322388|NCT02873689|10062778|FG000|Overall Study|Adverse Event|2
6322389|NCT02873689|10062779|FG001|Overall Study|Adverse Event|2
6322390|NCT02873689|10062778|FG000|Overall Study|Randomized but not Treated|1
6322391|NCT02873689|10062779|FG001|Overall Study|Randomized but not Treated|1
6152089|NCT01117428|9789180|FG003|Overall Study|Withdrawal by Subject|0
6152090|NCT01117428|9789181|FG004|Overall Study|Withdrawal by Subject|0
6152091|NCT01117428|9789182|FG005|Overall Study|Withdrawal by Subject|0
6152092|NCT01117428|9789177|FG000|Overall Study|Progressive disease|15
6152093|NCT01117428|9789178|FG001|Overall Study|Progressive disease|27
6152094|NCT01117428|9789179|FG002|Overall Study|Progressive disease|10
6152095|NCT01117428|9789180|FG003|Overall Study|Progressive disease|12
6152096|NCT01117428|9789181|FG004|Overall Study|Progressive disease|16
6152097|NCT01117428|9789182|FG005|Overall Study|Progressive disease|17
6152098|NCT01117454|9789200|FG000|Overall Study|Pregnancy|0
6152099|NCT01117454|9789201|FG001|Overall Study|Pregnancy|1
6152100|NCT01117480|9789207|FG000|Overall Study|Protocol Violation|8
6152101|NCT01117480|9789207|FG000|Overall Study|Did Not Start Adalimumab Therapy|20
6152102|NCT01117623|9789219|FG000|Overall Study|Adverse Event|0
6152103|NCT01117623|9789220|FG001|Overall Study|Adverse Event|2
6152104|NCT01117623|9789221|FG002|Overall Study|Adverse Event|4
6152105|NCT01117623|9789222|FG003|Overall Study|Adverse Event|0
6152106|NCT01117623|9789223|FG004|Overall Study|Adverse Event|2
6152107|NCT01117623|9789224|FG005|Overall Study|Adverse Event|0
6152108|NCT01117623|9789225|FG006|Overall Study|Adverse Event|0
6152109|NCT01117623|9789226|FG007|Overall Study|Adverse Event|2
6152110|NCT01117623|9789219|FG000|Overall Study|Disease progression, recurrence, relapse|3
6152111|NCT01117623|9789220|FG001|Overall Study|Disease progression, recurrence, relapse|6
6152112|NCT01117623|9789221|FG002|Overall Study|Disease progression, recurrence, relapse|5
6152113|NCT01117623|9789222|FG003|Overall Study|Disease progression, recurrence, relapse|6
6152114|NCT01117623|9789223|FG004|Overall Study|Disease progression, recurrence, relapse|8
6152115|NCT01117623|9789224|FG005|Overall Study|Disease progression, recurrence, relapse|14
6152116|NCT01117623|9789225|FG006|Overall Study|Disease progression, recurrence, relapse|5
6152117|NCT01117623|9789226|FG007|Overall Study|Disease progression, recurrence, relapse|22
6152118|NCT01117623|9789219|FG000|Overall Study|Withdrawal by Subject|0
6152119|NCT01117623|9789220|FG001|Overall Study|Withdrawal by Subject|0
6152120|NCT01117623|9789221|FG002|Overall Study|Withdrawal by Subject|2
6152121|NCT01117623|9789222|FG003|Overall Study|Withdrawal by Subject|0
6152122|NCT01117623|9789223|FG004|Overall Study|Withdrawal by Subject|0
6152123|NCT01117623|9789224|FG005|Overall Study|Withdrawal by Subject|1
6152124|NCT01117623|9789225|FG006|Overall Study|Withdrawal by Subject|1
6152125|NCT01117623|9789226|FG007|Overall Study|Withdrawal by Subject|1
6152126|NCT01117623|9789219|FG000|Overall Study|Non-compliance with study medication|0
6152127|NCT01117623|9789220|FG001|Overall Study|Non-compliance with study medication|0
6152128|NCT01117623|9789221|FG002|Overall Study|Non-compliance with study medication|0
6152129|NCT01117623|9789222|FG003|Overall Study|Non-compliance with study medication|0
6152130|NCT01117623|9789223|FG004|Overall Study|Non-compliance with study medication|0
6152131|NCT01117623|9789224|FG005|Overall Study|Non-compliance with study medication|0
6152132|NCT01117623|9789225|FG006|Overall Study|Non-compliance with study medication|0
6152133|NCT01117623|9789226|FG007|Overall Study|Non-compliance with study medication|1
6152134|NCT01117623|9789219|FG000|Overall Study|Invest. text: completed all planned txs|0
6152135|NCT01117623|9789220|FG001|Overall Study|Invest. text: completed all planned txs|0
6152136|NCT01117623|9789221|FG002|Overall Study|Invest. text: completed all planned txs|0
6152137|NCT01117623|9789222|FG003|Overall Study|Invest. text: completed all planned txs|0
6152138|NCT01117623|9789223|FG004|Overall Study|Invest. text: completed all planned txs|0
6152139|NCT01117623|9789224|FG005|Overall Study|Invest. text: completed all planned txs|1
6152140|NCT01117623|9789225|FG006|Overall Study|Invest. text: completed all planned txs|0
6152141|NCT01117623|9789226|FG007|Overall Study|Invest. text: completed all planned txs|0
6152142|NCT01117766|9789251|FG000|First Intervention|Adverse Event|0
6152143|NCT01117766|9789252|FG001|First Intervention|Adverse Event|1
6152144|NCT01117766|9789251|FG000|First Intervention|Protocol Violation|1
6322392|NCT02873702|10062787|FG000|Healing Period (up to Week 8)|Adverse Event|1
6322393|NCT02873702|10062788|FG001|Healing Period (up to Week 8)|Adverse Event|0
6322394|NCT02873702|10062789|FG002|Healing Period (up to Week 8)|Adverse Event|0
6322395|NCT02873702|10062790|FG003|Healing Period (up to Week 8)|Adverse Event|0
6322396|NCT02873702|10062787|FG000|Healing Period (up to Week 8)|Withdrawal by Subject|0
6322397|NCT02873702|10062788|FG001|Healing Period (up to Week 8)|Withdrawal by Subject|1
6322398|NCT02873702|10062789|FG002|Healing Period (up to Week 8)|Withdrawal by Subject|0
6322399|NCT02873702|10062790|FG003|Healing Period (up to Week 8)|Withdrawal by Subject|0
6322400|NCT02873702|10062787|FG000|Maintenance Period (up to Month 6)|Adverse Event|0
6322401|NCT02873702|10062788|FG001|Maintenance Period (up to Month 6)|Adverse Event|0
6322402|NCT02873702|10062789|FG002|Maintenance Period (up to Month 6)|Adverse Event|1
6322403|NCT02873702|10062790|FG003|Maintenance Period (up to Month 6)|Adverse Event|0
6322404|NCT02873702|10062787|FG000|Maintenance Period (up to Month 6)|Relapse of EE|0
6322405|NCT02873702|10062788|FG001|Maintenance Period (up to Month 6)|Relapse of EE|0
6322406|NCT02873702|10062789|FG002|Maintenance Period (up to Month 6)|Relapse of EE|4
6322407|NCT02873702|10062790|FG003|Maintenance Period (up to Month 6)|Relapse of EE|1
6322408|NCT02873702|10062787|FG000|Maintenance Period (up to Month 6)|Withdrawal by Subject|0
6322409|NCT02873702|10062788|FG001|Maintenance Period (up to Month 6)|Withdrawal by Subject|0
6322410|NCT02873702|10062789|FG002|Maintenance Period (up to Month 6)|Withdrawal by Subject|2
6322411|NCT02873702|10062790|FG003|Maintenance Period (up to Month 6)|Withdrawal by Subject|1
6322412|NCT02873754|10062800|FG000|Overall Study|Lost to Follow-up|5
6322413|NCT02873754|10062800|FG000|Overall Study|Couldn't complete study procedures|1
6041350|NCT00375674|9639513|FG001|Overall Study|Death|76
6041351|NCT00375674|9639512|FG000|Overall Study|Participants refused further follow-up|31
6041352|NCT00375674|9639513|FG001|Overall Study|Participants refused further follow-up|30
6322414|NCT02873936|10062811|FG000|Overall Study|Withdrew Consent|4
6322415|NCT02873936|10062812|FG001|Overall Study|Withdrew Consent|11
6322416|NCT02873936|10062813|FG002|Overall Study|Withdrew Consent|20
6322417|NCT02873936|10062811|FG000|Overall Study|Investigator's Discretion|3
6322418|NCT02873936|10062812|FG001|Overall Study|Investigator's Discretion|5
6322419|NCT02873936|10062813|FG002|Overall Study|Investigator's Discretion|4
6322420|NCT02873936|10062811|FG000|Overall Study|Adverse Event|3
6322421|NCT02873936|10062812|FG001|Overall Study|Adverse Event|5
6322422|NCT02873936|10062813|FG002|Overall Study|Adverse Event|3
6322423|NCT02873936|10062811|FG000|Overall Study|Protocol Violation|0
6322424|NCT02873936|10062812|FG001|Overall Study|Protocol Violation|1
6322425|NCT02873936|10062813|FG002|Overall Study|Protocol Violation|3
6322426|NCT02873936|10062811|FG000|Overall Study|Lost to Follow-up|1
6322427|NCT02873936|10062812|FG001|Overall Study|Lost to Follow-up|1
6322428|NCT02873936|10062813|FG002|Overall Study|Lost to Follow-up|1
6322429|NCT02873936|10062811|FG000|Overall Study|Non-compliance With Study Drug|1
6322430|NCT02873936|10062812|FG001|Overall Study|Non-compliance With Study Drug|0
6322431|NCT02873936|10062813|FG002|Overall Study|Non-compliance With Study Drug|1
6322432|NCT02873936|10062811|FG000|Overall Study|Randomized but not Dosed|1
6322433|NCT02873936|10062812|FG001|Overall Study|Randomized but not Dosed|0
6322434|NCT02873936|10062813|FG002|Overall Study|Randomized but not Dosed|0
6322435|NCT02874534|10062840|FG000|Overall Study|Withdrawal by Subject|5
6322436|NCT02874534|10062841|FG001|Overall Study|Withdrawal by Subject|8
6322437|NCT02874534|10062840|FG000|Overall Study|Lost to Follow-up|2
6322438|NCT02874534|10062841|FG001|Overall Study|Lost to Follow-up|2
6322439|NCT02874534|10062840|FG000|Overall Study|Ongoing in study|1
6322440|NCT02874534|10062841|FG001|Overall Study|Ongoing in study|1
6322441|NCT02874794|10062849|FG000|Overall Study|Physician Decision|3
6322442|NCT02874794|10062850|FG001|Overall Study|Physician Decision|2
6322443|NCT02874794|10062849|FG000|Overall Study|Withdrawal by Subject|2
6322444|NCT02874794|10062850|FG001|Overall Study|Withdrawal by Subject|8
6041353|NCT00375674|9639512|FG000|Overall Study|Lost to Follow-up|17
6041354|NCT00375674|9639513|FG001|Overall Study|Lost to Follow-up|15
6041355|NCT00375674|9639512|FG000|Overall Study|Enrolled but not treated|3
6041356|NCT00375674|9639513|FG001|Overall Study|Enrolled but not treated|2
6041357|NCT00375752|9639530|FG000|Overall Study|Lack of Efficacy|4
6041358|NCT00375752|9639531|FG001|Overall Study|Lack of Efficacy|4
6041359|NCT00375752|9639530|FG000|Overall Study|Adverse Event|1
6041360|NCT00375752|9639531|FG001|Overall Study|Adverse Event|6
6041361|NCT00375752|9639530|FG000|Overall Study|Withdrawal by Subject|6
6322445|NCT02874794|10062849|FG000|Overall Study|Death|2
6322446|NCT02874794|10062850|FG001|Overall Study|Death|1
6322447|NCT02874924|10062872|FG000|Overall Study|Adverse Event|2
6322448|NCT02874924|10062873|FG001|Overall Study|Adverse Event|0
6322449|NCT02874924|10062874|FG002|Overall Study|Adverse Event|0
6322450|NCT02874924|10062872|FG000|Overall Study|Withdrawal by Subject|1
6322451|NCT02874924|10062873|FG001|Overall Study|Withdrawal by Subject|0
6322452|NCT02874924|10062874|FG002|Overall Study|Withdrawal by Subject|0
6322453|NCT02875028|10062884|FG000|Washout Period|Withdrawal by Subject|0
6322454|NCT02875028|10062885|FG001|Washout Period|Withdrawal by Subject|1
6322455|NCT02875080|10062896|FG000|Overall Study|Positive urine test for cotinine on Day 20 or Day 40|2
6322456|NCT02875080|10062897|FG001|Overall Study|Positive urine test for cotinine on Day 20 or Day 40|0
6322457|NCT02875080|10062898|FG002|Overall Study|Positive urine test for cotinine on Day 20 or Day 40|0
6322458|NCT02875340|10062906|FG000|Overall Study|Death|2
6322459|NCT02875340|10062906|FG000|Overall Study|Withdrawal by Subject|2
6322460|NCT02875340|10062906|FG000|Overall Study|Physician Decision|3
6322461|NCT02875340|10062906|FG000|Overall Study|Adverse Event|1
6322462|NCT02875366|10062918|FG000|Overall Study|Adverse Event|0
6322463|NCT02875366|10062919|FG001|Overall Study|Adverse Event|2
6322464|NCT02875366|10062918|FG000|Overall Study|Noncompliance|0
6322465|NCT02875366|10062919|FG001|Overall Study|Noncompliance|1
6041362|NCT00375752|9639531|FG001|Overall Study|Withdrawal by Subject|1
6041363|NCT00375752|9639530|FG000|Overall Study|Abnormal Laboratory Value(s)|1
6322466|NCT02875392|10062927|FG000|Overall Study|The subjects did not inform their Hepatobiliary disorders; hence, their data did not analyze|7
6322467|NCT02875392|10062928|FG001|Overall Study|The subjects did not inform their Hepatobiliary disorders; hence, their data did not analyze|8
6322468|NCT02875613|10062934|FG000|Overall Study|Withdrawal by Subject|1
6322469|NCT02875834|10062942|FG000|Open-label Phase|Withdrawal by Subject|3
6322470|NCT02875834|10062943|FG001|Open-label Phase|Withdrawal by Subject|0
6322471|NCT02875834|10062944|FG002|Open-label Phase|Withdrawal by Subject|0
6322472|NCT02875834|10062945|FG003|Open-label Phase|Withdrawal by Subject|0
6322473|NCT02875834|10062942|FG000|Open-label Phase|(Not collected)|4
6322474|NCT02875834|10062943|FG001|Open-label Phase|(Not collected)|0
6322475|NCT02875834|10062944|FG002|Open-label Phase|(Not collected)|0
6041364|NCT00375752|9639531|FG001|Overall Study|Abnormal Laboratory Value(s)|1
6041365|NCT00375752|9639530|FG000|Overall Study|Protocol Violation|0
6041366|NCT00375752|9639531|FG001|Overall Study|Protocol Violation|2
6041367|NCT00375752|9639530|FG000|Overall Study|Administrative Problems|0
6041368|NCT00375752|9639531|FG001|Overall Study|Administrative Problems|1
6041369|NCT00375934|9639564|FG000|Overall Study|Adverse Event|1
6041370|NCT00375934|9639565|FG001|Overall Study|Adverse Event|1
6041371|NCT00375934|9639564|FG000|Overall Study|Withdrawal by Subject|2
6322476|NCT02875834|10062945|FG003|Open-label Phase|(Not collected)|0
6322477|NCT02875834|10062942|FG000|Randomized Treatment Phase|Withdrawal by Subject|0
6322478|NCT02875834|10062943|FG001|Randomized Treatment Phase|Withdrawal by Subject|3
6322479|NCT02875834|10062944|FG002|Randomized Treatment Phase|Withdrawal by Subject|1
6322480|NCT02875834|10062945|FG003|Randomized Treatment Phase|Withdrawal by Subject|0
6322481|NCT02875834|10062942|FG000|Randomized Treatment Phase|Protocol Violation|0
6322482|NCT02875834|10062943|FG001|Randomized Treatment Phase|Protocol Violation|2
6322483|NCT02875834|10062944|FG002|Randomized Treatment Phase|Protocol Violation|0
6322484|NCT02875834|10062945|FG003|Randomized Treatment Phase|Protocol Violation|0
6322485|NCT02875834|10062942|FG000|Randomized Treatment Phase|(Not collected)|0
6322486|NCT02875834|10062943|FG001|Randomized Treatment Phase|(Not collected)|9
6322487|NCT02875834|10062944|FG002|Randomized Treatment Phase|(Not collected)|10
6322488|NCT02875834|10062945|FG003|Randomized Treatment Phase|(Not collected)|9
6322489|NCT02875977|10062957|FG000|Overall Study|Lost to Follow-up|42
6322490|NCT02875977|10062958|FG001|Overall Study|Lost to Follow-up|29
6322491|NCT02876601|10062998|FG000|Washout (Minimum of 6 Weeks)|unforeseen unavailability|0
6322492|NCT02876601|10062999|FG001|Washout (Minimum of 6 Weeks)|unforeseen unavailability|0
6322493|NCT02876601|10063000|FG002|Washout (Minimum of 6 Weeks)|unforeseen unavailability|1
6322494|NCT02876601|10063001|FG003|Washout (Minimum of 6 Weeks)|unforeseen unavailability|0
6322495|NCT02877004|10063093|FG000|Overall Study|Pregnancy|0
6322496|NCT02877004|10063094|FG001|Overall Study|Pregnancy|0
6322497|NCT02877004|10063095|FG002|Overall Study|Pregnancy|1
6322498|NCT02877082|10063103|FG000|Overall Study|Trial was closed early|5
6322499|NCT02877680|10063128|FG000|Overall Study|Lost to Follow-up|1
6322500|NCT02877680|10063129|FG001|Overall Study|Lost to Follow-up|1
6322501|NCT02877927|10063141|FG000|Overall Study|Adverse Event|1
6322502|NCT02877927|10063142|FG001|Overall Study|Adverse Event|0
6322503|NCT02877927|10063141|FG000|Overall Study|Lost to Follow-up|37
6322504|NCT02877927|10063142|FG001|Overall Study|Lost to Follow-up|38
6322505|NCT02877927|10063141|FG000|Overall Study|Withdrawal by Subject|11
6322506|NCT02877927|10063142|FG001|Overall Study|Withdrawal by Subject|12
6322507|NCT02877927|10063141|FG000|Overall Study|Physician Decision|0
6322508|NCT02877927|10063142|FG001|Overall Study|Physician Decision|1
6322509|NCT02877927|10063141|FG000|Overall Study|Missed EOT/PTE Visit|5
6322510|NCT02877927|10063142|FG001|Overall Study|Missed EOT/PTE Visit|6
6322511|NCT02878213|10063152|FG000|Overall Study|Withdrawal by Subject|2
6322512|NCT02878213|10063152|FG000|Overall Study|Adverse Event|1
6322513|NCT02878330|10063159|FG000|Overall Study|Death|3
6322514|NCT02878330|10063160|FG001|Overall Study|Death|2
6322515|NCT02878330|10063159|FG000|Overall Study|Lost to Follow-up|11
6322516|NCT02878330|10063160|FG001|Overall Study|Lost to Follow-up|26
6322517|NCT02878330|10063159|FG000|Overall Study|Withdrawal by Subject|11
6322518|NCT02878330|10063160|FG001|Overall Study|Withdrawal by Subject|21
6322519|NCT02878330|10063159|FG000|Overall Study|Other|4
6322520|NCT02878330|10063160|FG001|Overall Study|Other|7
6322521|NCT02878590|10063185|FG000|Overall Study|Withdrawal by Subject|2
6322522|NCT02879383|10063199|FG000|First 24 Weeks|Physician Decision|0
6322523|NCT02879383|10063200|FG001|First 24 Weeks|Physician Decision|1
6322524|NCT02879383|10063201|FG002|First 24 Weeks|Physician Decision|0
6322525|NCT02879383|10063202|FG003|First 24 Weeks|Physician Decision|0
6322526|NCT02879578|10063217|FG000|Overall Study|Adverse Event|1
6322527|NCT02879578|10063218|FG001|Overall Study|Adverse Event|2
6322528|NCT02879578|10063219|FG002|Overall Study|Adverse Event|14
6322529|NCT02879578|10063217|FG000|Overall Study|Protocol Violation|0
6322530|NCT02879578|10063218|FG001|Overall Study|Protocol Violation|1
6322531|NCT02879578|10063219|FG002|Overall Study|Protocol Violation|1
6322532|NCT02879578|10063217|FG000|Overall Study|Withdrawal by Subject|8
6322533|NCT02879578|10063218|FG001|Overall Study|Withdrawal by Subject|6
6322534|NCT02879578|10063219|FG002|Overall Study|Withdrawal by Subject|9
6322535|NCT02879578|10063217|FG000|Overall Study|Lost to Follow-up|1
6322536|NCT02879578|10063218|FG001|Overall Study|Lost to Follow-up|0
6322537|NCT02879578|10063219|FG002|Overall Study|Lost to Follow-up|4
6322538|NCT02879578|10063217|FG000|Overall Study|Physician Decision|0
6322539|NCT02879578|10063218|FG001|Overall Study|Physician Decision|0
6322540|NCT02879578|10063219|FG002|Overall Study|Physician Decision|4
6322541|NCT02879994|10063258|FG000|Overall Study|off treatment early|7
6322542|NCT02879994|10063258|FG000|Overall Study|Adverse Event|2
6322543|NCT02879994|10063258|FG000|Overall Study|Death|2
6322544|NCT02880761|10063313|FG000|Overall Study|Death|6
6322545|NCT02880761|10063314|FG001|Overall Study|Death|8
6322546|NCT02880761|10063313|FG000|Overall Study|Withdrawal by Subject|3
6322547|NCT02880761|10063314|FG001|Overall Study|Withdrawal by Subject|6
6322548|NCT02880761|10063313|FG000|Overall Study|Protocol Violation|4
6322549|NCT02880761|10063314|FG001|Overall Study|Protocol Violation|3
6322550|NCT02880761|10063313|FG000|Overall Study|Lost to Follow-up|3
6322551|NCT02880761|10063314|FG001|Overall Study|Lost to Follow-up|4
6322552|NCT02880865|10063326|FG000|Overall Study|Adverse Event|1
6322553|NCT02880865|10063327|FG001|Overall Study|Adverse Event|0
6322554|NCT02880865|10063326|FG000|Overall Study|Withdrawal by Subject|0
6322555|NCT02880865|10063327|FG001|Overall Study|Withdrawal by Subject|2
6322556|NCT02880865|10063326|FG000|Overall Study|Physician Decision|0
6322557|NCT02880865|10063327|FG001|Overall Study|Physician Decision|1
6322558|NCT02881047|10063382|FG000|Overall Study|Adverse Event|1
6322559|NCT02881047|10063382|FG000|Overall Study|Withdrawal by Subject|1
6322560|NCT02881567|10063390|FG000|Overall Study|Adverse Event|1
6322561|NCT02881567|10063390|FG000|Overall Study|Lost to Follow-up|3
6322562|NCT02881567|10063390|FG000|Overall Study|Consent withdrawn|1
6322563|NCT02881567|10063390|FG000|Overall Study|Investigator decision|1
6322564|NCT02881567|10063390|FG000|Overall Study|Study terminated by sponsor|9
6322565|NCT02881567|10063390|FG000|Overall Study|Reason not Specified|3
6322566|NCT02881957|10063418|FG000|Overall Study|Comfort care|0
6322567|NCT02881957|10063419|FG001|Overall Study|Comfort care|1
6322568|NCT02881957|10063418|FG000|Overall Study|Concurrent trial enrollment|0
6322569|NCT02881957|10063419|FG001|Overall Study|Concurrent trial enrollment|1
6322570|NCT02881957|10063418|FG000|Overall Study|Discharged within 48 hours|0
6322571|NCT02881957|10063419|FG001|Overall Study|Discharged within 48 hours|1
6322572|NCT02881957|10063418|FG000|Overall Study|Withdrawal by Subject|2
6322573|NCT02881957|10063419|FG001|Overall Study|Withdrawal by Subject|1
6322574|NCT02881957|10063418|FG000|Overall Study|Protocol Violation|1
6322575|NCT02881957|10063419|FG001|Overall Study|Protocol Violation|0
6322576|NCT02882152|10063436|FG000|Overall Study|Lost to Follow-up|1
6322577|NCT02882152|10063437|FG001|Overall Study|Lost to Follow-up|0
6322578|NCT02882854|10063462|FG000|Overall Study|Lost to Follow-up|1
6322579|NCT02882854|10063463|FG001|Overall Study|Lost to Follow-up|2
6322580|NCT02882854|10063462|FG000|Overall Study|Physician Decision|0
6322581|NCT02882854|10063463|FG001|Overall Study|Physician Decision|1
6322582|NCT02883244|10063471|FG000|Overall Study|Lost to Follow-up|0
6322583|NCT02883244|10063472|FG001|Overall Study|Lost to Follow-up|1
6322584|NCT02883452|10063484|FG000|Overall Study|Withdrawal by Subject|1
6322585|NCT02883452|10063485|FG001|Overall Study|Withdrawal by Subject|1
6322586|NCT02883452|10063486|FG002|Overall Study|Withdrawal by Subject|3
6322587|NCT02883452|10063487|FG003|Overall Study|Withdrawal by Subject|0
6322588|NCT02883452|10063488|FG004|Overall Study|Withdrawal by Subject|2
6322589|NCT02883452|10063489|FG005|Overall Study|Withdrawal by Subject|5
6322590|NCT02883452|10063484|FG000|Overall Study|Disease progression|1
6322591|NCT02883452|10063485|FG001|Overall Study|Disease progression|0
6322592|NCT02883452|10063486|FG002|Overall Study|Disease progression|0
6322593|NCT02883452|10063487|FG003|Overall Study|Disease progression|1
6322594|NCT02883452|10063488|FG004|Overall Study|Disease progression|4
6322595|NCT02883452|10063489|FG005|Overall Study|Disease progression|5
6322596|NCT02883452|10063484|FG000|Overall Study|Adverse Event|2
6322597|NCT02883452|10063485|FG001|Overall Study|Adverse Event|1
6322598|NCT02883452|10063486|FG002|Overall Study|Adverse Event|1
6322599|NCT02883452|10063487|FG003|Overall Study|Adverse Event|1
6322600|NCT02883452|10063488|FG004|Overall Study|Adverse Event|1
6322601|NCT02883452|10063489|FG005|Overall Study|Adverse Event|3
6322602|NCT02883452|10063484|FG000|Overall Study|Physician Decision|0
6322603|NCT02883452|10063485|FG001|Overall Study|Physician Decision|0
6322604|NCT02883452|10063486|FG002|Overall Study|Physician Decision|0
6322605|NCT02883452|10063487|FG003|Overall Study|Physician Decision|0
6322606|NCT02883452|10063488|FG004|Overall Study|Physician Decision|4
6322607|NCT02883452|10063489|FG005|Overall Study|Physician Decision|1
6322608|NCT02883452|10063484|FG000|Overall Study|Death|1
6322609|NCT02883452|10063485|FG001|Overall Study|Death|0
6322610|NCT02883452|10063486|FG002|Overall Study|Death|1
6322611|NCT02883452|10063487|FG003|Overall Study|Death|0
6322612|NCT02883452|10063488|FG004|Overall Study|Death|0
6322613|NCT02883452|10063489|FG005|Overall Study|Death|0
6322614|NCT02883452|10063484|FG000|Overall Study|Other|0
6322615|NCT02883452|10063485|FG001|Overall Study|Other|0
6322616|NCT02883452|10063486|FG002|Overall Study|Other|0
6322617|NCT02883452|10063487|FG003|Overall Study|Other|0
6322618|NCT02883452|10063488|FG004|Overall Study|Other|0
6322619|NCT02883452|10063489|FG005|Overall Study|Other|1
6322620|NCT02884089|10063504|FG000|Period 1|Dosing error|2
6322621|NCT02884089|10063505|FG001|Period 1|Dosing error|2
6322622|NCT02884089|10063506|FG002|Period 1|Dosing error|0
6322623|NCT02884089|10063507|FG003|Period 1|Dosing error|0
6322624|NCT02884089|10063504|FG000|Washout Period 1|Lost to Follow-up|0
6322625|NCT02884089|10063505|FG001|Washout Period 1|Lost to Follow-up|1
6322626|NCT02884089|10063506|FG002|Washout Period 1|Lost to Follow-up|0
6322627|NCT02884089|10063507|FG003|Washout Period 1|Lost to Follow-up|1
6322628|NCT02884089|10063504|FG000|Washout Period 1|Withdrawal by Subject|0
6322629|NCT02884089|10063505|FG001|Washout Period 1|Withdrawal by Subject|1
6322630|NCT02884089|10063506|FG002|Washout Period 1|Withdrawal by Subject|0
6322631|NCT02884089|10063507|FG003|Washout Period 1|Withdrawal by Subject|0
6322632|NCT02884089|10063504|FG000|Period 2|Adverse Event|1
6322633|NCT02884089|10063505|FG001|Period 2|Adverse Event|0
6322634|NCT02884089|10063506|FG002|Period 2|Adverse Event|0
6322635|NCT02884089|10063507|FG003|Period 2|Adverse Event|0
6322636|NCT02884089|10063504|FG000|Period 3|Withdrawal by Subject|0
6322637|NCT02884089|10063505|FG001|Period 3|Withdrawal by Subject|0
6322638|NCT02884089|10063506|FG002|Period 3|Withdrawal by Subject|1
6322639|NCT02884089|10063507|FG003|Period 3|Withdrawal by Subject|0
6322640|NCT02884089|10063504|FG000|Washout Period 3|Withdrawal by Subject|0
6322641|NCT02884089|10063505|FG001|Washout Period 3|Withdrawal by Subject|0
6322642|NCT02884089|10063506|FG002|Washout Period 3|Withdrawal by Subject|1
6322643|NCT02884089|10063507|FG003|Washout Period 3|Withdrawal by Subject|0
6322644|NCT02884089|10063504|FG000|Washout Period 3|Lost to Follow-up|0
6322645|NCT02884089|10063505|FG001|Washout Period 3|Lost to Follow-up|0
6322646|NCT02884089|10063506|FG002|Washout Period 3|Lost to Follow-up|0
6322647|NCT02884089|10063507|FG003|Washout Period 3|Lost to Follow-up|1
6322648|NCT02884089|10063504|FG000|Period 4|Withdrawal by Subject|0
6322649|NCT02884089|10063505|FG001|Period 4|Withdrawal by Subject|1
6322650|NCT02884089|10063506|FG002|Period 4|Withdrawal by Subject|0
6322651|NCT02884089|10063507|FG003|Period 4|Withdrawal by Subject|0
6322652|NCT02884089|10063504|FG000|Period 4|Lost to Follow-up|1
6322653|NCT02884089|10063505|FG001|Period 4|Lost to Follow-up|0
6322654|NCT02884089|10063506|FG002|Period 4|Lost to Follow-up|0
6322655|NCT02884089|10063507|FG003|Period 4|Lost to Follow-up|0
6322656|NCT02884089|10063504|FG000|Follow-up Visit|Withdrawal by Subject|1
6322657|NCT02884089|10063505|FG001|Follow-up Visit|Withdrawal by Subject|0
6322658|NCT02884089|10063506|FG002|Follow-up Visit|Withdrawal by Subject|0
6322659|NCT02884089|10063507|FG003|Follow-up Visit|Withdrawal by Subject|1
6322660|NCT02885181|10063577|FG000|Overall Study|Investigator's Discretion|0
6322661|NCT02885181|10063578|FG001|Overall Study|Investigator's Discretion|1
6322662|NCT02885181|10063579|FG002|Overall Study|Investigator's Discretion|0
6322663|NCT02885181|10063580|FG003|Overall Study|Investigator's Discretion|1
6322664|NCT02885181|10063577|FG000|Overall Study|Adverse Event|0
6322665|NCT02885181|10063578|FG001|Overall Study|Adverse Event|0
6322666|NCT02885181|10063579|FG002|Overall Study|Adverse Event|0
6322667|NCT02885181|10063580|FG003|Overall Study|Adverse Event|1
6322668|NCT02885181|10063577|FG000|Overall Study|Withdrawal by Subject|0
6322669|NCT02885181|10063578|FG001|Overall Study|Withdrawal by Subject|0
6322670|NCT02885181|10063579|FG002|Overall Study|Withdrawal by Subject|0
6322671|NCT02885181|10063580|FG003|Overall Study|Withdrawal by Subject|1
6322672|NCT02886338|10063676|FG000|Overall Study|Withdrawal by Subject|1
6322673|NCT02886494|10063682|FG000|Overall Study|Adverse Event|1
6322674|NCT02886494|10063683|FG001|Overall Study|Adverse Event|0
6322675|NCT02886494|10063682|FG000|Overall Study|Withdrawal by Subject|12
6322676|NCT02886494|10063683|FG001|Overall Study|Withdrawal by Subject|3
6322677|NCT02886494|10063682|FG000|Overall Study|Protocol Violation|4
6322678|NCT02886494|10063683|FG001|Overall Study|Protocol Violation|1
6322679|NCT02886624|10063692|FG000|12-week Post Treatment Follow-up|Death|1
6322680|NCT02886624|10063692|FG000|48-week Post Treatment Follow-up|Lost to Follow-up|1
6322681|NCT02886702|10063699|FG000|Overall Study|Other|4
6322682|NCT02886702|10063700|FG001|Overall Study|Other|3
6322683|NCT02886702|10063701|FG002|Overall Study|Other|9
6322684|NCT02886702|10063699|FG000|Overall Study|Withdrawal by Subject|24
6322685|NCT02886702|10063700|FG001|Overall Study|Withdrawal by Subject|18
6322686|NCT02886702|10063701|FG002|Overall Study|Withdrawal by Subject|22
6322687|NCT02886702|10063699|FG000|Overall Study|Significant Worsening of Condition|0
6322688|NCT02886702|10063700|FG001|Overall Study|Significant Worsening of Condition|1
6322689|NCT02886702|10063701|FG002|Overall Study|Significant Worsening of Condition|0
6322690|NCT02886702|10063699|FG000|Overall Study|Protocol Violation|2
6322691|NCT02886702|10063700|FG001|Overall Study|Protocol Violation|2
6322692|NCT02886702|10063701|FG002|Overall Study|Protocol Violation|1
6322693|NCT02886702|10063699|FG000|Overall Study|Non-Compliance With Study Drug|0
6322694|NCT02886702|10063700|FG001|Overall Study|Non-Compliance With Study Drug|1
6322695|NCT02886702|10063701|FG002|Overall Study|Non-Compliance With Study Drug|4
6322696|NCT02886702|10063699|FG000|Overall Study|Lost to Follow-up|11
6322697|NCT02886702|10063700|FG001|Overall Study|Lost to Follow-up|13
6322698|NCT02886702|10063701|FG002|Overall Study|Lost to Follow-up|8
6322699|NCT02886702|10063699|FG000|Overall Study|Lack of Efficacy|3
6322700|NCT02886702|10063700|FG001|Overall Study|Lack of Efficacy|4
6322701|NCT02886702|10063701|FG002|Overall Study|Lack of Efficacy|5
6322702|NCT02886702|10063699|FG000|Overall Study|Adverse Event|4
6322703|NCT02886702|10063700|FG001|Overall Study|Adverse Event|9
6322704|NCT02886702|10063701|FG002|Overall Study|Adverse Event|3
6322705|NCT02886702|10063699|FG000|Overall Study|Administrative Reasons|0
6322706|NCT02886702|10063700|FG001|Overall Study|Administrative Reasons|0
6322707|NCT02886702|10063701|FG002|Overall Study|Administrative Reasons|1
6322708|NCT02886715|10063712|FG000|Overall Study|Non-Compliance With Study Drug|0
6322709|NCT02886715|10063713|FG001|Overall Study|Non-Compliance With Study Drug|2
6041372|NCT00375934|9639565|FG001|Overall Study|Withdrawal by Subject|2
6322710|NCT02886715|10063714|FG002|Overall Study|Non-Compliance With Study Drug|0
6322711|NCT02886715|10063712|FG000|Overall Study|Adverse Event|4
6322712|NCT02886715|10063713|FG001|Overall Study|Adverse Event|2
6322713|NCT02886715|10063714|FG002|Overall Study|Adverse Event|0
6322714|NCT02886715|10063712|FG000|Overall Study|Lack of Efficacy|0
6322715|NCT02886715|10063713|FG001|Overall Study|Lack of Efficacy|2
6322716|NCT02886715|10063714|FG002|Overall Study|Lack of Efficacy|1
6322717|NCT02886715|10063712|FG000|Overall Study|Lost to Follow-up|29
6322718|NCT02886715|10063713|FG001|Overall Study|Lost to Follow-up|26
6322719|NCT02886715|10063714|FG002|Overall Study|Lost to Follow-up|10
6322720|NCT02886715|10063712|FG000|Overall Study|Pregnancy|1
6322721|NCT02886715|10063713|FG001|Overall Study|Pregnancy|1
6322722|NCT02886715|10063714|FG002|Overall Study|Pregnancy|1
6322723|NCT02886715|10063712|FG000|Overall Study|Protocol Violation|3
6322724|NCT02886715|10063713|FG001|Overall Study|Protocol Violation|2
6322725|NCT02886715|10063714|FG002|Overall Study|Protocol Violation|1
6322726|NCT02886715|10063712|FG000|Overall Study|Withdrawal by Subject|20
6322727|NCT02886715|10063713|FG001|Overall Study|Withdrawal by Subject|18
6322728|NCT02886715|10063714|FG002|Overall Study|Withdrawal by Subject|5
6322729|NCT02886715|10063712|FG000|Overall Study|missing|7
6322730|NCT02886715|10063713|FG001|Overall Study|missing|2
6322731|NCT02886715|10063714|FG002|Overall Study|missing|2
6322732|NCT02886728|10063726|FG000|Overall Study|Withdrew Consent|31
6322733|NCT02886728|10063727|FG001|Overall Study|Withdrew Consent|13
6322734|NCT02886728|10063728|FG002|Overall Study|Withdrew Consent|11
6322735|NCT02886728|10063729|FG003|Overall Study|Withdrew Consent|47
6322736|NCT02886728|10063726|FG000|Overall Study|Lost to Follow-up|12
6322737|NCT02886728|10063727|FG001|Overall Study|Lost to Follow-up|6
6322738|NCT02886728|10063728|FG002|Overall Study|Lost to Follow-up|13
6322739|NCT02886728|10063729|FG003|Overall Study|Lost to Follow-up|12
6322740|NCT02886728|10063726|FG000|Overall Study|Adverse Event|13
6322741|NCT02886728|10063727|FG001|Overall Study|Adverse Event|5
6322742|NCT02886728|10063728|FG002|Overall Study|Adverse Event|5
6322743|NCT02886728|10063729|FG003|Overall Study|Adverse Event|11
6322744|NCT02886728|10063726|FG000|Overall Study|Investigator's Discretion|11
6322745|NCT02886728|10063727|FG001|Overall Study|Investigator's Discretion|7
6322746|NCT02886728|10063728|FG002|Overall Study|Investigator's Discretion|5
6322747|NCT02886728|10063729|FG003|Overall Study|Investigator's Discretion|11
6322748|NCT02886728|10063726|FG000|Overall Study|Death|3
6322749|NCT02886728|10063727|FG001|Overall Study|Death|1
6322750|NCT02886728|10063728|FG002|Overall Study|Death|0
6322751|NCT02886728|10063729|FG003|Overall Study|Death|0
6322752|NCT02886728|10063726|FG000|Overall Study|Protocol Violation|0
6322753|NCT02886728|10063727|FG001|Overall Study|Protocol Violation|0
6322754|NCT02886728|10063728|FG002|Overall Study|Protocol Violation|0
6322755|NCT02886728|10063729|FG003|Overall Study|Protocol Violation|4
6322756|NCT02886728|10063726|FG000|Overall Study|Non-Compliance with Study Drug|1
6322757|NCT02886728|10063727|FG001|Overall Study|Non-Compliance with Study Drug|0
6322758|NCT02886728|10063728|FG002|Overall Study|Non-Compliance with Study Drug|1
6322759|NCT02886728|10063729|FG003|Overall Study|Non-Compliance with Study Drug|0
6322760|NCT02886728|10063726|FG000|Overall Study|Pregnancy|0
6322761|NCT02886728|10063727|FG001|Overall Study|Pregnancy|0
6322762|NCT02886728|10063728|FG002|Overall Study|Pregnancy|1
6322763|NCT02886728|10063729|FG003|Overall Study|Pregnancy|0
6322764|NCT02886728|10063726|FG000|Overall Study|Randomized but Not Dosed|1
6322765|NCT02886728|10063727|FG001|Overall Study|Randomized but Not Dosed|0
6322766|NCT02886728|10063728|FG002|Overall Study|Randomized but Not Dosed|0
6322767|NCT02886728|10063729|FG003|Overall Study|Randomized but Not Dosed|2
6322768|NCT02887183|10063746|FG000|Overall Study|Adverse Event|44
6322769|NCT02887183|10063746|FG000|Overall Study|Death|30
6322770|NCT02887183|10063746|FG000|Overall Study|Pregnancy|1
6322771|NCT02887183|10063746|FG000|Overall Study|Protocol Violation|6
6322772|NCT02887183|10063746|FG000|Overall Study|Technical Problems|2
6322773|NCT02887183|10063746|FG000|Overall Study|Lost to Follow-up|13
6322774|NCT02887183|10063746|FG000|Overall Study|Physician Decision|10
6322775|NCT02887183|10063746|FG000|Overall Study|Withdrawal by Subject|35
6322776|NCT02887521|10063762|FG000|Overall Study|Withdrawal by Subject|0
6322777|NCT02887521|10063763|FG001|Overall Study|Withdrawal by Subject|3
6322778|NCT02887989|10063771|FG000|Overall Study|Withdrawal by Subject|8
6322779|NCT02887989|10063772|FG001|Overall Study|Withdrawal by Subject|11
6322780|NCT02887989|10063771|FG000|Overall Study|Death|1
6322781|NCT02887989|10063772|FG001|Overall Study|Death|0
6322782|NCT02888080|10063780|FG000|Overall Study|Subject / Guardian decision|1
6322783|NCT02888080|10063781|FG001|Overall Study|Subject / Guardian decision|3
6322784|NCT02888080|10063780|FG000|Overall Study|New Therapy for study indication|1
6322785|NCT02888080|10063781|FG001|Overall Study|New Therapy for study indication|0
6322786|NCT02888080|10063780|FG000|Overall Study|Lack of Efficacy|0
6322787|NCT02888080|10063781|FG001|Overall Study|Lack of Efficacy|1
6322788|NCT02888080|10063780|FG000|Overall Study|Adverse Event|0
6322789|NCT02888080|10063781|FG001|Overall Study|Adverse Event|1
6322790|NCT02888106|10063804|FG000|Overall Study|Withdrawal by Subject|1
6322791|NCT02888106|10063805|FG001|Overall Study|Withdrawal by Subject|2
6322792|NCT02888106|10063806|FG002|Overall Study|Withdrawal by Subject|0
6322793|NCT02888106|10063807|FG003|Overall Study|Withdrawal by Subject|1
6322794|NCT02888106|10063808|FG004|Overall Study|Withdrawal by Subject|0
6322795|NCT02888106|10063809|FG005|Overall Study|Withdrawal by Subject|0
6322796|NCT02888106|10063804|FG000|Overall Study|Lost to Follow-up|1
6322797|NCT02888106|10063805|FG001|Overall Study|Lost to Follow-up|0
6322798|NCT02888106|10063806|FG002|Overall Study|Lost to Follow-up|0
6322799|NCT02888106|10063807|FG003|Overall Study|Lost to Follow-up|1
6322800|NCT02888106|10063808|FG004|Overall Study|Lost to Follow-up|0
6322801|NCT02888106|10063809|FG005|Overall Study|Lost to Follow-up|1
6322802|NCT02888106|10063804|FG000|Overall Study|Adverse Event|2
6322803|NCT02888106|10063805|FG001|Overall Study|Adverse Event|0
6322804|NCT02888106|10063806|FG002|Overall Study|Adverse Event|0
6322805|NCT02888106|10063807|FG003|Overall Study|Adverse Event|0
6322806|NCT02888106|10063808|FG004|Overall Study|Adverse Event|0
6322807|NCT02888106|10063809|FG005|Overall Study|Adverse Event|0
6322808|NCT02888106|10063804|FG000|Overall Study|Withdrawal of consent|0
6322809|NCT02888106|10063805|FG001|Overall Study|Withdrawal of consent|0
6322810|NCT02888106|10063806|FG002|Overall Study|Withdrawal of consent|0
6322811|NCT02888106|10063807|FG003|Overall Study|Withdrawal of consent|0
6322812|NCT02888106|10063808|FG004|Overall Study|Withdrawal of consent|1
6322813|NCT02888106|10063809|FG005|Overall Study|Withdrawal of consent|0
6322814|NCT02888106|10063804|FG000|Overall Study|Pregnancy|1
6322815|NCT02888106|10063805|FG001|Overall Study|Pregnancy|0
6322816|NCT02888106|10063806|FG002|Overall Study|Pregnancy|0
6322817|NCT02888106|10063807|FG003|Overall Study|Pregnancy|0
6322818|NCT02888106|10063808|FG004|Overall Study|Pregnancy|0
6322819|NCT02888106|10063809|FG005|Overall Study|Pregnancy|0
6322820|NCT02888171|10063831|FG000|Overall Study|Lost to Follow-up|2
6322821|NCT02888171|10063832|FG001|Overall Study|Lost to Follow-up|1
6322822|NCT02888171|10063831|FG000|Overall Study|Withdrawal by Subject|3
6322823|NCT02888171|10063832|FG001|Overall Study|Withdrawal by Subject|2
6322824|NCT02888171|10063831|FG000|Overall Study|Adverse Event|0
6322825|NCT02888171|10063832|FG001|Overall Study|Adverse Event|1
6322826|NCT02888756|10063862|FG000|Analytical Treatment Interruption|Physician Decision|10
6322827|NCT02888756|10063863|FG001|Analytical Treatment Interruption|Physician Decision|6
6322828|NCT02888756|10063864|FG002|Analytical Treatment Interruption|Physician Decision|5
6322829|NCT02889562|10063895|FG000|Overall Study|Physician Decision|0
6322830|NCT02889562|10063896|FG001|Overall Study|Physician Decision|1
6322831|NCT02889562|10063895|FG000|Overall Study|Withdrawal by Subject|0
6322832|NCT02889562|10063896|FG001|Overall Study|Withdrawal by Subject|1
6322833|NCT02889796|10063906|FG000|Overall Study|Withdrew Consent|18
6322834|NCT02889796|10063907|FG001|Overall Study|Withdrew Consent|29
6322835|NCT02889796|10063908|FG002|Overall Study|Withdrew Consent|20
6322836|NCT02889796|10063909|FG003|Overall Study|Withdrew Consent|1
6322837|NCT02889796|10063910|FG004|Overall Study|Withdrew Consent|2
6322838|NCT02889796|10063911|FG005|Overall Study|Withdrew Consent|35
6322839|NCT02889796|10063906|FG000|Overall Study|Investigator's Discretion|10
6322840|NCT02889796|10063907|FG001|Overall Study|Investigator's Discretion|9
6322841|NCT02889796|10063908|FG002|Overall Study|Investigator's Discretion|10
6322842|NCT02889796|10063909|FG003|Overall Study|Investigator's Discretion|3
6322843|NCT02889796|10063910|FG004|Overall Study|Investigator's Discretion|0
6322844|NCT02889796|10063911|FG005|Overall Study|Investigator's Discretion|15
6322845|NCT02889796|10063906|FG000|Overall Study|Adverse Event|17
6322846|NCT02889796|10063907|FG001|Overall Study|Adverse Event|8
6322847|NCT02889796|10063908|FG002|Overall Study|Adverse Event|8
6322848|NCT02889796|10063909|FG003|Overall Study|Adverse Event|4
6322849|NCT02889796|10063910|FG004|Overall Study|Adverse Event|1
6322850|NCT02889796|10063911|FG005|Overall Study|Adverse Event|7
6322851|NCT02889796|10063906|FG000|Overall Study|Lost to Follow-up|5
6322852|NCT02889796|10063907|FG001|Overall Study|Lost to Follow-up|7
6322853|NCT02889796|10063908|FG002|Overall Study|Lost to Follow-up|2
6322854|NCT02889796|10063909|FG003|Overall Study|Lost to Follow-up|0
6322855|NCT02889796|10063910|FG004|Overall Study|Lost to Follow-up|2
6322856|NCT02889796|10063911|FG005|Overall Study|Lost to Follow-up|6
6322857|NCT02889796|10063906|FG000|Overall Study|Protocol Violation|0
6322858|NCT02889796|10063907|FG001|Overall Study|Protocol Violation|1
6322859|NCT02889796|10063908|FG002|Overall Study|Protocol Violation|3
6322860|NCT02889796|10063909|FG003|Overall Study|Protocol Violation|0
6322861|NCT02889796|10063910|FG004|Overall Study|Protocol Violation|0
6322862|NCT02889796|10063911|FG005|Overall Study|Protocol Violation|4
6322863|NCT02889796|10063906|FG000|Overall Study|Non-compliance With Study Drug|0
6322864|NCT02889796|10063907|FG001|Overall Study|Non-compliance With Study Drug|2
6322865|NCT02889796|10063908|FG002|Overall Study|Non-compliance With Study Drug|0
6322866|NCT02889796|10063909|FG003|Overall Study|Non-compliance With Study Drug|0
6322867|NCT02889796|10063910|FG004|Overall Study|Non-compliance With Study Drug|1
6322868|NCT02889796|10063911|FG005|Overall Study|Non-compliance With Study Drug|2
6322869|NCT02889796|10063906|FG000|Overall Study|Death|1
6322870|NCT02889796|10063907|FG001|Overall Study|Death|1
6322871|NCT02889796|10063908|FG002|Overall Study|Death|0
6322872|NCT02889796|10063909|FG003|Overall Study|Death|1
6322873|NCT02889796|10063910|FG004|Overall Study|Death|0
6322874|NCT02889796|10063911|FG005|Overall Study|Death|1
6322875|NCT02889796|10063906|FG000|Overall Study|Pregnancy|0
6322876|NCT02889796|10063907|FG001|Overall Study|Pregnancy|1
6322877|NCT02889796|10063908|FG002|Overall Study|Pregnancy|1
6322878|NCT02889796|10063909|FG003|Overall Study|Pregnancy|0
6322879|NCT02889796|10063910|FG004|Overall Study|Pregnancy|0
6322880|NCT02889796|10063911|FG005|Overall Study|Pregnancy|0
6322881|NCT02889796|10063906|FG000|Overall Study|Randomized but not Dosed|2
6322882|NCT02889796|10063907|FG001|Overall Study|Randomized but not Dosed|0
6322883|NCT02889796|10063908|FG002|Overall Study|Randomized but not Dosed|0
6322884|NCT02889796|10063909|FG003|Overall Study|Randomized but not Dosed|0
6322885|NCT02889796|10063910|FG004|Overall Study|Randomized but not Dosed|0
6322886|NCT02889796|10063911|FG005|Overall Study|Randomized but not Dosed|2
6322887|NCT02889861|10063934|FG000|Overall Study|Ongoing in Survival Follow-up|2
6322888|NCT02890992|10063964|FG000|130 Weeks Open-Label Extension Period|Adverse Event|0
6322889|NCT02890992|10063965|FG001|130 Weeks Open-Label Extension Period|Adverse Event|1
6322890|NCT02890992|10063966|FG002|130 Weeks Open-Label Extension Period|Adverse Event|0
6322891|NCT02890992|10063967|FG003|130 Weeks Open-Label Extension Period|Adverse Event|0
6322892|NCT02890992|10063968|FG004|130 Weeks Open-Label Extension Period|Adverse Event|0
6322893|NCT02890992|10063969|FG005|130 Weeks Open-Label Extension Period|Adverse Event|0
6322894|NCT02890992|10063970|FG006|130 Weeks Open-Label Extension Period|Adverse Event|0
6322895|NCT02890992|10063971|FG007|130 Weeks Open-Label Extension Period|Adverse Event|0
6322896|NCT02890992|10063964|FG000|130 Weeks Open-Label Extension Period|Included but not treated|0
6322897|NCT02890992|10063965|FG001|130 Weeks Open-Label Extension Period|Included but not treated|0
6322898|NCT02890992|10063966|FG002|130 Weeks Open-Label Extension Period|Included but not treated|0
6322899|NCT02890992|10063967|FG003|130 Weeks Open-Label Extension Period|Included but not treated|0
6322900|NCT02890992|10063968|FG004|130 Weeks Open-Label Extension Period|Included but not treated|0
6322901|NCT02890992|10063969|FG005|130 Weeks Open-Label Extension Period|Included but not treated|0
6041373|NCT00375934|9639564|FG000|Overall Study|Lack of Efficacy|0
6041374|NCT00375934|9639565|FG001|Overall Study|Lack of Efficacy|2
6322902|NCT02890992|10063970|FG006|130 Weeks Open-Label Extension Period|Included but not treated|1
6322903|NCT02890992|10063971|FG007|130 Weeks Open-Label Extension Period|Included but not treated|1
6322904|NCT02890992|10063964|FG000|130 Weeks Open-Label Extension Period|Other than specified|0
6322905|NCT02890992|10063965|FG001|130 Weeks Open-Label Extension Period|Other than specified|2
6322906|NCT02890992|10063966|FG002|130 Weeks Open-Label Extension Period|Other than specified|0
6322907|NCT02890992|10063967|FG003|130 Weeks Open-Label Extension Period|Other than specified|0
6322908|NCT02890992|10063968|FG004|130 Weeks Open-Label Extension Period|Other than specified|0
6322909|NCT02890992|10063969|FG005|130 Weeks Open-Label Extension Period|Other than specified|0
6041375|NCT00375934|9639564|FG000|Overall Study|Physician Decision|0
6041376|NCT00375934|9639565|FG001|Overall Study|Physician Decision|1
6041377|NCT00376168|9639586|FG000|Overall Study|Adverse Event|1
6041378|NCT00376168|9639587|FG001|Overall Study|Adverse Event|1
6041379|NCT00376168|9639586|FG000|Overall Study|Pregnancy|1
6041380|NCT00376168|9639587|FG001|Overall Study|Pregnancy|0
6041381|NCT00376220|9639595|FG000|Overall Study|Lost to Follow-up|7
6041382|NCT00376220|9639596|FG001|Overall Study|Lost to Follow-up|10
6041383|NCT00376220|9639595|FG000|Overall Study|Withdrawal by Subject|3
6041384|NCT00376220|9639596|FG001|Overall Study|Withdrawal by Subject|2
6152145|NCT01117766|9789252|FG001|First Intervention|Protocol Violation|0
6152146|NCT01117766|9789251|FG000|Washout Period|Protocol Violation|0
6322910|NCT02890992|10063970|FG006|130 Weeks Open-Label Extension Period|Other than specified|0
6322911|NCT02890992|10063971|FG007|130 Weeks Open-Label Extension Period|Other than specified|0
6322912|NCT02891070|10063998|FG000|Overall Study|Adverse Event|1
6322913|NCT02891070|10063999|FG001|Overall Study|Adverse Event|0
6322914|NCT02891070|10063998|FG000|Overall Study|Physician Decision|0
6322915|NCT02891070|10063999|FG001|Overall Study|Physician Decision|1
6322916|NCT02891070|10063998|FG000|Overall Study|Lost to Follow-up|4
6322917|NCT02891070|10063999|FG001|Overall Study|Lost to Follow-up|4
6322918|NCT02891070|10063998|FG000|Overall Study|Other|1
6322919|NCT02891070|10063999|FG001|Overall Study|Other|0
6322920|NCT02891070|10063998|FG000|Overall Study|Protocol Violation|0
6322921|NCT02891070|10063999|FG001|Overall Study|Protocol Violation|1
6322922|NCT02891070|10063998|FG000|Overall Study|Withdrawal by Subject|1
6322923|NCT02891070|10063999|FG001|Overall Study|Withdrawal by Subject|2
6322924|NCT02891070|10063998|FG000|Overall Study|Death|3
6322925|NCT02891070|10063999|FG001|Overall Study|Death|0
6322926|NCT02891174|10064007|FG000|First Intervention (24 Hours)|Declined any study medication|1
6322927|NCT02891174|10064008|FG001|First Intervention (24 Hours)|Declined any study medication|5
6322928|NCT02891174|10064007|FG000|First Intervention (24 Hours)|Discharged prior to cross-over|0
6322929|NCT02891174|10064008|FG001|First Intervention (24 Hours)|Discharged prior to cross-over|2
6322930|NCT02891174|10064007|FG000|First Intervention (24 Hours)|Withdrew after receiving study drug|2
6322931|NCT02891174|10064008|FG001|First Intervention (24 Hours)|Withdrew after receiving study drug|6
6322932|NCT02891174|10064007|FG000|Second Intervention (24 Hours)|No blood pressure after cross-over|1
6322933|NCT02891174|10064008|FG001|Second Intervention (24 Hours)|No blood pressure after cross-over|0
6322934|NCT02891174|10064007|FG000|Second Intervention (24 Hours)|Discharged during second intervention|3
6322935|NCT02891174|10064008|FG001|Second Intervention (24 Hours)|Discharged during second intervention|5
6322936|NCT02891174|10064007|FG000|Second Intervention (24 Hours)|Withdrew after receiving study drug|2
6322937|NCT02891174|10064008|FG001|Second Intervention (24 Hours)|Withdrew after receiving study drug|1
6322938|NCT02891174|10064007|FG000|Second Intervention (24 Hours)|Protocol Violation|0
6322939|NCT02891174|10064008|FG001|Second Intervention (24 Hours)|Protocol Violation|1
6322940|NCT02891200|10064020|FG000|Overall Study|Lost to Follow-up|31
6322941|NCT02891200|10064021|FG001|Overall Study|Lost to Follow-up|36
6322942|NCT02891200|10064020|FG000|Overall Study|Death|10
6322943|NCT02891200|10064021|FG001|Overall Study|Death|9
6322944|NCT02891200|10064020|FG000|Overall Study|Withdrawal by Subject|1
6322945|NCT02891200|10064021|FG001|Overall Study|Withdrawal by Subject|4
6322946|NCT02891408|10064034|FG000|Overall Study|Lost to Follow-up|0
6322947|NCT02891408|10064035|FG001|Overall Study|Lost to Follow-up|0
6322948|NCT02891408|10064036|FG002|Overall Study|Lost to Follow-up|1
6322949|NCT02891408|10064037|FG003|Overall Study|Lost to Follow-up|0
6322950|NCT02891408|10064038|FG004|Overall Study|Lost to Follow-up|0
6322951|NCT02891408|10064039|FG005|Overall Study|Lost to Follow-up|0
6322952|NCT02891408|10064040|FG006|Overall Study|Lost to Follow-up|0
6322953|NCT02891681|10064078|FG000|Overall Study|Did not complete all timepoints in Endocrine Cohort|0
6322954|NCT02891681|10064079|FG001|Overall Study|Did not complete all timepoints in Endocrine Cohort|0
6322955|NCT02891681|10064080|FG002|Overall Study|Did not complete all timepoints in Endocrine Cohort|1
6322956|NCT02891681|10064078|FG000|Overall Study|Developed metastases prior to completing neoadjuvant therapy|2
6322957|NCT02891681|10064079|FG001|Overall Study|Developed metastases prior to completing neoadjuvant therapy|0
6322958|NCT02891681|10064080|FG002|Overall Study|Developed metastases prior to completing neoadjuvant therapy|0
6322959|NCT02891681|10064078|FG000|Overall Study|Taken off study after first imaging appointment|1
6322960|NCT02891681|10064079|FG001|Overall Study|Taken off study after first imaging appointment|0
6041385|NCT00376246|9639602|FG000|First Intervention (2 Weeks)|Adverse Event|2
6322961|NCT02891681|10064080|FG002|Overall Study|Taken off study after first imaging appointment|0
6322962|NCT02891850|10064090|FG000|Overall Study|Adverse Event|3
6322963|NCT02891850|10064091|FG001|Overall Study|Adverse Event|0
6322964|NCT02891850|10064090|FG000|Overall Study|Death|0
6322965|NCT02891850|10064091|FG001|Overall Study|Death|4
6322966|NCT02891850|10064090|FG000|Overall Study|Physician Decision|1
6322967|NCT02891850|10064091|FG001|Overall Study|Physician Decision|0
6322968|NCT02891850|10064090|FG000|Overall Study|Pregnancy|1
6322969|NCT02891850|10064091|FG001|Overall Study|Pregnancy|0
6322970|NCT02891850|10064090|FG000|Overall Study|Withdrawal by Subject|2
6322971|NCT02891850|10064091|FG001|Overall Study|Withdrawal by Subject|3
6041386|NCT00376246|9639603|FG001|First Intervention (2 Weeks)|Adverse Event|0
6322972|NCT02891915|10064103|FG000|Overall Study|Enrolled but Treatment Not Administered|6
6322973|NCT02891915|10064104|FG001|Overall Study|Enrolled but Treatment Not Administered|4
6322974|NCT02891915|10064103|FG000|Overall Study|Withdrawal by Subject|3
6322975|NCT02891915|10064104|FG001|Overall Study|Withdrawal by Subject|3
6322976|NCT02891915|10064103|FG000|Overall Study|Became Ineligible After Enrollment|2
6322977|NCT02891915|10064104|FG001|Overall Study|Became Ineligible After Enrollment|1
6322978|NCT02891915|10064103|FG000|Overall Study|Lost to Follow-up|1
6322979|NCT02891915|10064104|FG001|Overall Study|Lost to Follow-up|4
6322980|NCT02891915|10064103|FG000|Overall Study|Physician Decision|1
6322981|NCT02891915|10064104|FG001|Overall Study|Physician Decision|0
6322982|NCT02892019|10064112|FG000|Overall Study|randomized but not treated|0
6322983|NCT02892019|10064113|FG001|Overall Study|randomized but not treated|1
6322984|NCT02892019|10064112|FG000|Overall Study|Withdrawal by Subject|0
6322985|NCT02892019|10064113|FG001|Overall Study|Withdrawal by Subject|1
6322986|NCT02892019|10064112|FG000|Overall Study|Adverse Event|1
6322987|NCT02892019|10064113|FG001|Overall Study|Adverse Event|1
6322988|NCT02892344|10064130|FG000|Overall Study|Protocol deviation|3
6322989|NCT02892344|10064131|FG001|Overall Study|Protocol deviation|4
6322990|NCT02892344|10064130|FG000|Overall Study|Adverse Event|1
6322991|NCT02892344|10064131|FG001|Overall Study|Adverse Event|8
6322992|NCT02892344|10064130|FG000|Overall Study|Lost to Follow-up|0
6322993|NCT02892344|10064131|FG001|Overall Study|Lost to Follow-up|1
6322994|NCT02892344|10064130|FG000|Overall Study|Non-compliance with study treatment|0
6322995|NCT02892344|10064131|FG001|Overall Study|Non-compliance with study treatment|1
6322996|NCT02892344|10064130|FG000|Overall Study|Physician Decision|0
6322997|NCT02892344|10064131|FG001|Overall Study|Physician Decision|2
6322998|NCT02892344|10064130|FG000|Overall Study|Subject/guardian decision|0
6322999|NCT02892344|10064131|FG001|Overall Study|Subject/guardian decision|4
6323000|NCT02892344|10064130|FG000|Overall Study|Technical problems|0
6323001|NCT02892344|10064131|FG001|Overall Study|Technical problems|1
6323002|NCT02892409|10064139|FG000|Overall Study|Adverse Event|1
6323003|NCT02892409|10064140|FG001|Overall Study|Adverse Event|0
6323004|NCT02892409|10064139|FG000|Overall Study|Withdrawal by Subject|2
6323005|NCT02892409|10064140|FG001|Overall Study|Withdrawal by Subject|1
6041387|NCT00376246|9639602|FG000|First Intervention (2 Weeks)|Withdrawal by Subject|1
6152147|NCT01117766|9789252|FG001|Washout Period|Protocol Violation|2
6323006|NCT02892422|10064146|FG000|Overall Study|Enrolled not treated|4
6323007|NCT02892422|10064146|FG000|Overall Study|Adverse Event|38
6323008|NCT02892422|10064146|FG000|Overall Study|Lack of Efficacy|32
6323009|NCT02892422|10064146|FG000|Overall Study|Non-compliance with study drug|11
6323010|NCT02892422|10064146|FG000|Overall Study|Protocol Violation|4
6323011|NCT02892422|10064146|FG000|Overall Study|Withdrawal by Subject|56
6323012|NCT02892422|10064146|FG000|Overall Study|Lost to Follow-up|5
6323013|NCT02892422|10064146|FG000|Overall Study|sponsor information 16159A results|21
6323014|NCT02892422|10064146|FG000|Overall Study|withdrawal of consent|13
6152148|NCT01117766|9789251|FG000|Second Intervention|Lost to Follow-up|1
6152149|NCT01117766|9789252|FG001|Second Intervention|Lost to Follow-up|0
6152150|NCT01117766|9789251|FG000|Second Intervention|Other|1
6152151|NCT01117766|9789252|FG001|Second Intervention|Other|2
6152152|NCT01117766|9789251|FG000|Second Intervention|Adverse Event|0
6152153|NCT01117766|9789252|FG001|Second Intervention|Adverse Event|2
6152154|NCT01117766|9789251|FG000|Second Intervention|Withdrawal by Subject|0
6152155|NCT01117766|9789252|FG001|Second Intervention|Withdrawal by Subject|1
6152156|NCT01117792|9789258|FG000|Overall Study|Death|1
6152157|NCT01117792|9789258|FG000|Overall Study|Adverse Event|3
6152158|NCT01117857|9789262|FG000|Overall Study|Lost to Follow-up|4
6152159|NCT01117857|9789262|FG000|Overall Study|Withdrawal by Subject|4
6152160|NCT01117857|9789262|FG000|Overall Study|Physician Decision|1
6152161|NCT01117870|9789268|FG000|Overall Study|Inability to place needle|1
6152162|NCT01117870|9789269|FG001|Overall Study|Inability to place needle|0
6152163|NCT01117987|9789290|FG000|Overall Study|Protocol deviation|0
6152164|NCT01117987|9789291|FG001|Overall Study|Protocol deviation|1
6152165|NCT01117987|9789290|FG000|Overall Study|Subject no longer requires study drug|1
6152166|NCT01117987|9789291|FG001|Overall Study|Subject no longer requires study drug|0
6152167|NCT01117987|9789290|FG000|Overall Study|Lost to Follow-up|1
6152168|NCT01117987|9789291|FG001|Overall Study|Lost to Follow-up|1
6152169|NCT01117987|9789290|FG000|Overall Study|Abnormal test procedure result|2
6152170|NCT01117987|9789291|FG001|Overall Study|Abnormal test procedure result|0
6152171|NCT01117987|9789290|FG000|Overall Study|Lack of Efficacy|3
6152172|NCT01117987|9789291|FG001|Overall Study|Lack of Efficacy|4
6152173|NCT01117987|9789290|FG000|Overall Study|Death|5
6152174|NCT01117987|9789291|FG001|Overall Study|Death|10
6152175|NCT01117987|9789290|FG000|Overall Study|Withdrawal by Subject|5
6152176|NCT01117987|9789291|FG001|Overall Study|Withdrawal by Subject|10
6152177|NCT01117987|9789290|FG000|Overall Study|Adverse Event|19
6152178|NCT01117987|9789291|FG001|Overall Study|Adverse Event|26
6152179|NCT01117987|9789290|FG000|Overall Study|Administrative problems|25
6152180|NCT01117987|9789291|FG001|Overall Study|Administrative problems|22
6152181|NCT01118052|9789297|FG000|Overall Study|Never treated|2
6152182|NCT01118117|9789318|FG000|Overall Study|Death|8
6152183|NCT01118117|9789319|FG001|Overall Study|Death|0
6152184|NCT01118117|9789318|FG000|Overall Study|Lost to Follow-up|6
6152185|NCT01118117|9789319|FG001|Overall Study|Lost to Follow-up|0
6152186|NCT01118117|9789318|FG000|Overall Study|Missed 12 Month Visit|7
6152187|NCT01118117|9789319|FG001|Overall Study|Missed 12 Month Visit|0
6152188|NCT01118143|9789327|FG000|Overall Study|Withdrawal by Subject|2
6152189|NCT01118143|9789328|FG001|Overall Study|Withdrawal by Subject|5
6152190|NCT01118299|9789376|FG000|Overall Study|Death|7
6152191|NCT01118299|9789377|FG001|Overall Study|Death|5
6152192|NCT01118299|9789376|FG000|Overall Study|Withdrawal by Subject|8
6152193|NCT01118299|9789377|FG001|Overall Study|Withdrawal by Subject|8
6152194|NCT01118299|9789376|FG000|Overall Study|Lost to Follow-up|2
6152195|NCT01118299|9789377|FG001|Overall Study|Lost to Follow-up|1
6152196|NCT01118299|9789376|FG000|Overall Study|Enrollment Closure, Protocol Amendment|6
6152197|NCT01118299|9789377|FG001|Overall Study|Enrollment Closure, Protocol Amendment|15
6152198|NCT01118312|9789384|FG000|Overall Study|Lost to Follow-up|33
6152199|NCT01118312|9789385|FG001|Overall Study|Lost to Follow-up|32
6152200|NCT01118312|9789384|FG000|Overall Study|Withdrawal by Subject|1
6152201|NCT01118312|9789385|FG001|Overall Study|Withdrawal by Subject|3
6152202|NCT01118325|9789394|FG000|Overall Study|Adverse Event|1
6152203|NCT01118325|9789395|FG001|Overall Study|Adverse Event|0
6152204|NCT01118325|9789396|FG002|Overall Study|Adverse Event|1
6152205|NCT01118351|9789426|FG000|Overall Study|Adverse Event|3
6152206|NCT01118351|9789426|FG000|Overall Study|Withdrawal by Subject|1
6152207|NCT01118377|9789430|FG000|Overall Study|Did Not Receive Study Medication|1
6323015|NCT02892422|10064146|FG000|Overall Study|exclusion criteria met|3
6152208|NCT01118377|9789430|FG000|Overall Study|Death|38
6323016|NCT02892422|10064146|FG000|Overall Study|moving elsewhere|4
6152209|NCT01118377|9789430|FG000|Overall Study|Failure to Return|3
6323017|NCT02892422|10064146|FG000|Overall Study|non-compliance|10
6323018|NCT02892422|10064146|FG000|Overall Study|patient legally incapable|1
6323019|NCT02892422|10064146|FG000|Overall Study|patient decision|7
6323020|NCT02892422|10064146|FG000|Overall Study|Investigator decision|1
6323021|NCT02892448|10064153|FG000|Overall Study|Screening failure|2
6323022|NCT02892448|10064154|FG001|Overall Study|Screening failure|2
6323023|NCT02892448|10064155|FG002|Overall Study|Screening failure|1
6323024|NCT02892513|10064165|FG000|Overall Study|Withdrawal by Subject|0
6049007|NCT00420927|9648205|FG006|Period 2|Sponsor decision|1
6323025|NCT02892513|10064166|FG001|Overall Study|Withdrawal by Subject|1
6152210|NCT01118455|9789436|FG000|Baseline [Visits 1 & 2]|Adverse Event|1
6152211|NCT01118455|9789437|FG001|Baseline [Visits 1 & 2]|Adverse Event|0
6152212|NCT01118520|9789454|FG000|Overall Study|AAA repair|9
6152213|NCT01118520|9789455|FG001|Overall Study|AAA repair|7
6152214|NCT01118520|9789456|FG002|Overall Study|AAA repair|9
6152215|NCT01118520|9789454|FG000|Overall Study|Adverse Event|3
6152216|NCT01118520|9789455|FG001|Overall Study|Adverse Event|3
6152217|NCT01118520|9789456|FG002|Overall Study|Adverse Event|3
6152218|NCT01118520|9789454|FG000|Overall Study|Withdrawal by Subject|8
6152219|NCT01118520|9789455|FG001|Overall Study|Withdrawal by Subject|13
6152220|NCT01118520|9789456|FG002|Overall Study|Withdrawal by Subject|8
6152221|NCT01118663|9789470|FG000|Overall Study|Adverse Event|2
6152222|NCT01118663|9789471|FG001|Overall Study|Adverse Event|1
6152223|NCT01118663|9789470|FG000|Overall Study|Withdrawal by Subject|0
6152224|NCT01118663|9789471|FG001|Overall Study|Withdrawal by Subject|1
6152225|NCT01118728|9789507|FG000|Overall Study|Adverse Event|17
6152226|NCT01118728|9789507|FG000|Overall Study|Lack of Efficacy|27
6152227|NCT01118728|9789507|FG000|Overall Study|Sponsor's decision to discontinue study|172
6152228|NCT01118728|9789507|FG000|Overall Study|Withdrawal by Subject|3
6152229|NCT01118728|9789507|FG000|Overall Study|Lost to Follow-up|4
6152230|NCT01118780|9789524|FG000|Overall Study|Adverse Event|15
6152231|NCT01118780|9789525|FG001|Overall Study|Adverse Event|15
6152232|NCT01118780|9789524|FG000|Overall Study|Death|1
6152233|NCT01118780|9789525|FG001|Overall Study|Death|0
6152234|NCT01118780|9789524|FG000|Overall Study|Lack of Efficacy|2
6152235|NCT01118780|9789525|FG001|Overall Study|Lack of Efficacy|6
6152236|NCT01118780|9789524|FG000|Overall Study|Physician Decision|2
6152237|NCT01118780|9789525|FG001|Overall Study|Physician Decision|0
6152238|NCT01118780|9789524|FG000|Overall Study|Protocol Violation|3
6152239|NCT01118780|9789525|FG001|Overall Study|Protocol Violation|6
6152240|NCT01118780|9789524|FG000|Overall Study|Withdrawal by Subject|13
6152241|NCT01118780|9789525|FG001|Overall Study|Withdrawal by Subject|8
6323026|NCT02892734|10064172|FG000|Treatment on Study|Progressive Disease|2
6323027|NCT02892734|10064172|FG000|Follow up for 2 Years|Death|2
6323028|NCT02892734|10064172|FG000|Follow up for 2 Years|Study closed early|1
6323029|NCT02892760|10064176|FG000|Overall Study|Withdrawal by Subject|3
6323030|NCT02894502|10064199|FG000|Baseline|Withdrawal by Subject|24
6323031|NCT02894502|10064200|FG001|Baseline|Withdrawal by Subject|31
6323032|NCT02894502|10064201|FG002|Baseline|Withdrawal by Subject|36
6323033|NCT02894502|10064199|FG000|Baseline|Death|3
6323034|NCT02894502|10064200|FG001|Baseline|Death|1
6323035|NCT02894502|10064201|FG002|Baseline|Death|9
6323036|NCT02894502|10064199|FG000|First Follow up|Withdrawal by Subject|32
6323037|NCT02894502|10064200|FG001|First Follow up|Withdrawal by Subject|29
6323038|NCT02894502|10064201|FG002|First Follow up|Withdrawal by Subject|37
6323039|NCT02894502|10064199|FG000|First Follow up|Death|2
6323040|NCT02894502|10064200|FG001|First Follow up|Death|2
6323041|NCT02894502|10064201|FG002|First Follow up|Death|3
6323042|NCT02894502|10064199|FG000|Second Follow up|Withdrawal by Subject|13
6323043|NCT02894502|10064200|FG001|Second Follow up|Withdrawal by Subject|15
6323044|NCT02894502|10064201|FG002|Second Follow up|Withdrawal by Subject|13
6323045|NCT02894502|10064199|FG000|Second Follow up|Death|2
6323046|NCT02894502|10064200|FG001|Second Follow up|Death|3
6323047|NCT02894502|10064201|FG002|Second Follow up|Death|1
6323048|NCT02894502|10064199|FG000|Third Follow up|Withdrawal by Subject|5
6323049|NCT02894502|10064200|FG001|Third Follow up|Withdrawal by Subject|6
6323050|NCT02894502|10064201|FG002|Third Follow up|Withdrawal by Subject|3
6323051|NCT02894502|10064199|FG000|Third Follow up|Death|1
6323052|NCT02894502|10064200|FG001|Third Follow up|Death|1
6323053|NCT02894502|10064201|FG002|Third Follow up|Death|0
6323054|NCT02894840|10064216|FG000|Overall Study|Lost to Follow-up|1
6323055|NCT02894840|10064217|FG001|Overall Study|Lost to Follow-up|0
6323056|NCT02894840|10064218|FG002|Overall Study|Lost to Follow-up|3
6323057|NCT02894840|10064219|FG003|Overall Study|Lost to Follow-up|0
6323058|NCT02895295|10064261|FG000|Overall Study|Survey Non-response|71
6323059|NCT02895295|10064262|FG001|Overall Study|Survey Non-response|94
6323060|NCT02895295|10064263|FG002|Overall Study|Survey Non-response|92
6323061|NCT02895347|10064273|FG000|Overall Study|Withdrawal by Subject|3
6323062|NCT02895347|10064274|FG001|Overall Study|Withdrawal by Subject|1
6323063|NCT02895360|10064287|FG000|Phase 1 - 30 mg/m² Cohort|Progressive disease|4
6323064|NCT02895360|10064288|FG001|Phase 1 - 30 mg/m² Cohort|Progressive disease|0
6323065|NCT02895360|10064289|FG002|Phase 1 - 30 mg/m² Cohort|Progressive disease|0
6323066|NCT02895360|10064290|FG003|Phase 1 - 30 mg/m² Cohort|Progressive disease|0
6323067|NCT02895360|10064291|FG004|Phase 1 - 30 mg/m² Cohort|Progressive disease|0
6323068|NCT02895360|10064292|FG005|Phase 1 - 30 mg/m² Cohort|Progressive disease|0
6152242|NCT01118949|9789538|FG000|Overall Study|Adverse Event|5
6152243|NCT01118949|9789538|FG000|Overall Study|Withdrawal by Subject|4
6152244|NCT01118962|9789542|FG000|Overall Study|Adverse Event|2
6323069|NCT02895360|10064287|FG000|Phase 1 - 45 mg/m² Cohort|Progressive disease|0
6323070|NCT02895360|10064288|FG001|Phase 1 - 45 mg/m² Cohort|Progressive disease|3
6323071|NCT02895360|10064289|FG002|Phase 1 - 45 mg/m² Cohort|Progressive disease|0
6323072|NCT02895360|10064290|FG003|Phase 1 - 45 mg/m² Cohort|Progressive disease|0
6323073|NCT02895360|10064291|FG004|Phase 1 - 45 mg/m² Cohort|Progressive disease|0
6323074|NCT02895360|10064292|FG005|Phase 1 - 45 mg/m² Cohort|Progressive disease|0
6323075|NCT02895360|10064287|FG000|Phase 1 - 70 mg/m² Cohort|Adverse Event|0
6323076|NCT02895360|10064288|FG001|Phase 1 - 70 mg/m² Cohort|Adverse Event|0
6323077|NCT02895360|10064289|FG002|Phase 1 - 70 mg/m² Cohort|Adverse Event|2
6323078|NCT02895360|10064290|FG003|Phase 1 - 70 mg/m² Cohort|Adverse Event|0
6323079|NCT02895360|10064291|FG004|Phase 1 - 70 mg/m² Cohort|Adverse Event|0
6323080|NCT02895360|10064292|FG005|Phase 1 - 70 mg/m² Cohort|Adverse Event|0
6323081|NCT02895360|10064287|FG000|Phase 1 - 70 mg/m² Cohort|Progressive disease|0
6323082|NCT02895360|10064288|FG001|Phase 1 - 70 mg/m² Cohort|Progressive disease|0
6323083|NCT02895360|10064289|FG002|Phase 1 - 70 mg/m² Cohort|Progressive disease|7
6323084|NCT02895360|10064290|FG003|Phase 1 - 70 mg/m² Cohort|Progressive disease|0
6323085|NCT02895360|10064291|FG004|Phase 1 - 70 mg/m² Cohort|Progressive disease|0
6323086|NCT02895360|10064292|FG005|Phase 1 - 70 mg/m² Cohort|Progressive disease|0
6323087|NCT02895360|10064287|FG000|Phase 1 - 90 mg/m² Cohort|Progressive disease|0
6323088|NCT02895360|10064288|FG001|Phase 1 - 90 mg/m² Cohort|Progressive disease|0
6323089|NCT02895360|10064289|FG002|Phase 1 - 90 mg/m² Cohort|Progressive disease|0
6323090|NCT02895360|10064290|FG003|Phase 1 - 90 mg/m² Cohort|Progressive disease|4
6323091|NCT02895360|10064291|FG004|Phase 1 - 90 mg/m² Cohort|Progressive disease|0
6323092|NCT02895360|10064292|FG005|Phase 1 - 90 mg/m² Cohort|Progressive disease|0
6323093|NCT02895360|10064287|FG000|Phase 2a|Adverse Event|0
6323094|NCT02895360|10064288|FG001|Phase 2a|Adverse Event|0
6323095|NCT02895360|10064289|FG002|Phase 2a|Adverse Event|0
6323096|NCT02895360|10064290|FG003|Phase 2a|Adverse Event|0
6323097|NCT02895360|10064291|FG004|Phase 2a|Adverse Event|0
6323098|NCT02895360|10064292|FG005|Phase 2a|Adverse Event|1
6323099|NCT02895360|10064287|FG000|Phase 2a|Progressive disease|0
6323100|NCT02895360|10064288|FG001|Phase 2a|Progressive disease|0
6323101|NCT02895360|10064289|FG002|Phase 2a|Progressive disease|0
6323102|NCT02895360|10064290|FG003|Phase 2a|Progressive disease|0
6323103|NCT02895360|10064291|FG004|Phase 2a|Progressive disease|11
6323104|NCT02895360|10064292|FG005|Phase 2a|Progressive disease|11
6323105|NCT02895945|10064326|FG000|Overall Study|Physician Decision|2
6323106|NCT02895945|10064327|FG001|Overall Study|Physician Decision|1
6323107|NCT02896127|10064342|FG000|COMPLETED WEEK 52|Adverse Event|9
6323108|NCT02896127|10064343|FG001|COMPLETED WEEK 52|Adverse Event|2
6323109|NCT02896127|10064342|FG000|COMPLETED WEEK 52|Lack of Efficacy|2
6323110|NCT02896127|10064343|FG001|COMPLETED WEEK 52|Lack of Efficacy|3
6323111|NCT02896127|10064342|FG000|COMPLETED WEEK 52|Lost to Follow-up|0
6323112|NCT02896127|10064343|FG001|COMPLETED WEEK 52|Lost to Follow-up|1
6323113|NCT02896127|10064342|FG000|COMPLETED WEEK 52|Physician Decision|1
6323114|NCT02896127|10064343|FG001|COMPLETED WEEK 52|Physician Decision|1
6323115|NCT02896127|10064342|FG000|COMPLETED WEEK 52|Pregnancy|2
6323116|NCT02896127|10064343|FG001|COMPLETED WEEK 52|Pregnancy|0
6323117|NCT02896127|10064342|FG000|COMPLETED WEEK 52|Withdrawal by Subject|12
6323118|NCT02896127|10064343|FG001|COMPLETED WEEK 52|Withdrawal by Subject|4
6323119|NCT02896127|10064342|FG000|COMPLETED WEEK 52|Technical problems|1
6323120|NCT02896127|10064343|FG001|COMPLETED WEEK 52|Technical problems|0
6323121|NCT02896127|10064342|FG000|COMPLETED POST-TREATMENT FOLLOW UP|Withdrawal by Subject|2
6323122|NCT02896127|10064343|FG001|COMPLETED POST-TREATMENT FOLLOW UP|Withdrawal by Subject|3
6323123|NCT02896127|10064342|FG000|COMPLETED POST-TREATMENT FOLLOW UP|Lost to Follow-up|0
6323124|NCT02896127|10064343|FG001|COMPLETED POST-TREATMENT FOLLOW UP|Lost to Follow-up|1
6323125|NCT02896127|10064342|FG000|COMPLETED POST-TREATMENT FOLLOW UP|Physician Decision|1
6323126|NCT02896127|10064343|FG001|COMPLETED POST-TREATMENT FOLLOW UP|Physician Decision|0
6323127|NCT02896127|10064342|FG000|COMPLETED POST-TREATMENT FOLLOW UP|Pregnancy|1
6323128|NCT02896127|10064343|FG001|COMPLETED POST-TREATMENT FOLLOW UP|Pregnancy|0
6323129|NCT02896127|10064342|FG000|COMPLETED POST-TREATMENT FOLLOW UP|Protocol Violation|0
6323130|NCT02896127|10064343|FG001|COMPLETED POST-TREATMENT FOLLOW UP|Protocol Violation|1
6323131|NCT02896296|10064349|FG000|Overall Study|Adverse Event|1
6323132|NCT02896296|10064349|FG000|Overall Study|Lost to Follow-up|19
6323133|NCT02896296|10064349|FG000|Overall Study|Pregnancy|1
6323134|NCT02896296|10064349|FG000|Overall Study|Physician Decision|2
6323135|NCT02896296|10064349|FG000|Overall Study|Withdrawal by Subject|10
6323136|NCT02896296|10064349|FG000|Overall Study|Site closing|7
6323137|NCT02896296|10064349|FG000|Overall Study|Incarceration|1
6323138|NCT02896296|10064349|FG000|Overall Study|Relocation|1
6323139|NCT02896361|10064353|FG000|Third Intervention (2 Weeks)|Protocol Violation|1
6323140|NCT02896361|10064354|FG001|Third Intervention (2 Weeks)|Protocol Violation|0
6323141|NCT02896361|10064355|FG002|Third Intervention (2 Weeks)|Protocol Violation|0
6323142|NCT02896361|10064353|FG000|Third Intervention (2 Weeks)|emergenge of several new painful regions|0
6323143|NCT02896361|10064354|FG001|Third Intervention (2 Weeks)|emergenge of several new painful regions|1
6323144|NCT02896361|10064355|FG002|Third Intervention (2 Weeks)|emergenge of several new painful regions|0
6323145|NCT02896400|10064383|FG000|1 Month Follow-up|Lost to Follow-up|7
6323146|NCT02896400|10064384|FG001|1 Month Follow-up|Lost to Follow-up|7
6323147|NCT02896400|10064385|FG002|1 Month Follow-up|Lost to Follow-up|5
6323148|NCT02896400|10064386|FG003|1 Month Follow-up|Lost to Follow-up|8
6323149|NCT02896400|10064387|FG004|1 Month Follow-up|Lost to Follow-up|9
6323150|NCT02896400|10064388|FG005|1 Month Follow-up|Lost to Follow-up|6
6323151|NCT02896400|10064389|FG006|1 Month Follow-up|Lost to Follow-up|5
6323152|NCT02896400|10064390|FG007|1 Month Follow-up|Lost to Follow-up|6
6323153|NCT02896400|10064391|FG008|1 Month Follow-up|Lost to Follow-up|4
6323154|NCT02896400|10064392|FG009|1 Month Follow-up|Lost to Follow-up|7
6323155|NCT02896400|10064393|FG010|1 Month Follow-up|Lost to Follow-up|5
6323156|NCT02896400|10064394|FG011|1 Month Follow-up|Lost to Follow-up|5
6323157|NCT02896400|10064395|FG012|1 Month Follow-up|Lost to Follow-up|3
6323158|NCT02896400|10064396|FG013|1 Month Follow-up|Lost to Follow-up|4
6323159|NCT02896400|10064397|FG014|1 Month Follow-up|Lost to Follow-up|1
6323160|NCT02896400|10064398|FG015|1 Month Follow-up|Lost to Follow-up|2
6323161|NCT02896400|10064383|FG000|1 Month Follow-up|Death|0
6323162|NCT02896400|10064384|FG001|1 Month Follow-up|Death|0
6323163|NCT02896400|10064385|FG002|1 Month Follow-up|Death|0
6323164|NCT02896400|10064386|FG003|1 Month Follow-up|Death|0
6323165|NCT02896400|10064387|FG004|1 Month Follow-up|Death|0
6323166|NCT02896400|10064388|FG005|1 Month Follow-up|Death|0
6323167|NCT02896400|10064389|FG006|1 Month Follow-up|Death|0
6323168|NCT02896400|10064390|FG007|1 Month Follow-up|Death|0
6323169|NCT02896400|10064391|FG008|1 Month Follow-up|Death|0
6323170|NCT02896400|10064392|FG009|1 Month Follow-up|Death|0
6323171|NCT02896400|10064393|FG010|1 Month Follow-up|Death|0
6323172|NCT02896400|10064394|FG011|1 Month Follow-up|Death|0
6323173|NCT02896400|10064395|FG012|1 Month Follow-up|Death|0
6323174|NCT02896400|10064396|FG013|1 Month Follow-up|Death|0
6323175|NCT02896400|10064397|FG014|1 Month Follow-up|Death|0
6323176|NCT02896400|10064398|FG015|1 Month Follow-up|Death|1
6323177|NCT02896400|10064383|FG000|3 Month Follow-up|Lost to Follow-up|6
6323178|NCT02896400|10064384|FG001|3 Month Follow-up|Lost to Follow-up|3
6323179|NCT02896400|10064385|FG002|3 Month Follow-up|Lost to Follow-up|6
6323180|NCT02896400|10064386|FG003|3 Month Follow-up|Lost to Follow-up|11
6323181|NCT02896400|10064387|FG004|3 Month Follow-up|Lost to Follow-up|12
6323182|NCT02896400|10064388|FG005|3 Month Follow-up|Lost to Follow-up|6
6323183|NCT02896400|10064389|FG006|3 Month Follow-up|Lost to Follow-up|4
6323184|NCT02896400|10064390|FG007|3 Month Follow-up|Lost to Follow-up|3
6323185|NCT02896400|10064391|FG008|3 Month Follow-up|Lost to Follow-up|6
6323186|NCT02896400|10064392|FG009|3 Month Follow-up|Lost to Follow-up|5
6323187|NCT02896400|10064393|FG010|3 Month Follow-up|Lost to Follow-up|6
6323188|NCT02896400|10064394|FG011|3 Month Follow-up|Lost to Follow-up|6
6323189|NCT02896400|10064395|FG012|3 Month Follow-up|Lost to Follow-up|3
6323190|NCT02896400|10064396|FG013|3 Month Follow-up|Lost to Follow-up|5
6323191|NCT02896400|10064397|FG014|3 Month Follow-up|Lost to Follow-up|3
6323192|NCT02896400|10064398|FG015|3 Month Follow-up|Lost to Follow-up|2
6323193|NCT02896400|10064383|FG000|3 Month Follow-up|Death|0
6323194|NCT02896400|10064384|FG001|3 Month Follow-up|Death|0
6323195|NCT02896400|10064385|FG002|3 Month Follow-up|Death|0
6323196|NCT02896400|10064386|FG003|3 Month Follow-up|Death|0
6041388|NCT00376246|9639603|FG001|First Intervention (2 Weeks)|Withdrawal by Subject|2
6152245|NCT01118962|9789542|FG000|Overall Study|Lack of Efficacy|1
6323197|NCT02896400|10064387|FG004|3 Month Follow-up|Death|0
6323198|NCT02896400|10064388|FG005|3 Month Follow-up|Death|0
6323199|NCT02896400|10064389|FG006|3 Month Follow-up|Death|0
6323200|NCT02896400|10064390|FG007|3 Month Follow-up|Death|0
6323201|NCT02896400|10064391|FG008|3 Month Follow-up|Death|0
6323202|NCT02896400|10064392|FG009|3 Month Follow-up|Death|0
6323203|NCT02896400|10064393|FG010|3 Month Follow-up|Death|0
6323204|NCT02896400|10064394|FG011|3 Month Follow-up|Death|0
6152246|NCT01118962|9789542|FG000|Overall Study|Protocol Violation|1
6152247|NCT01118962|9789542|FG000|Overall Study|Withdrawal by Subject|4
6323205|NCT02896400|10064395|FG012|3 Month Follow-up|Death|0
6323206|NCT02896400|10064396|FG013|3 Month Follow-up|Death|1
6323207|NCT02896400|10064397|FG014|3 Month Follow-up|Death|1
6323208|NCT02896400|10064398|FG015|3 Month Follow-up|Death|0
6323209|NCT02896400|10064383|FG000|Biochemical Verification at 3 Months|Lost to Follow-up|1
6323210|NCT02896400|10064384|FG001|Biochemical Verification at 3 Months|Lost to Follow-up|0
6323211|NCT02896400|10064385|FG002|Biochemical Verification at 3 Months|Lost to Follow-up|1
6323212|NCT02896400|10064386|FG003|Biochemical Verification at 3 Months|Lost to Follow-up|1
6323213|NCT02896400|10064387|FG004|Biochemical Verification at 3 Months|Lost to Follow-up|0
6323214|NCT02896400|10064388|FG005|Biochemical Verification at 3 Months|Lost to Follow-up|1
6323215|NCT02896400|10064389|FG006|Biochemical Verification at 3 Months|Lost to Follow-up|3
6323216|NCT02896400|10064390|FG007|Biochemical Verification at 3 Months|Lost to Follow-up|2
6323217|NCT02896400|10064391|FG008|Biochemical Verification at 3 Months|Lost to Follow-up|1
6323218|NCT02896400|10064392|FG009|Biochemical Verification at 3 Months|Lost to Follow-up|1
6323219|NCT02896400|10064393|FG010|Biochemical Verification at 3 Months|Lost to Follow-up|0
6323220|NCT02896400|10064394|FG011|Biochemical Verification at 3 Months|Lost to Follow-up|0
6323221|NCT02896400|10064395|FG012|Biochemical Verification at 3 Months|Lost to Follow-up|1
6323222|NCT02896400|10064396|FG013|Biochemical Verification at 3 Months|Lost to Follow-up|0
6323223|NCT02896400|10064397|FG014|Biochemical Verification at 3 Months|Lost to Follow-up|3
6323224|NCT02896400|10064398|FG015|Biochemical Verification at 3 Months|Lost to Follow-up|1
6323225|NCT02896400|10064383|FG000|Biochemical Verification at 3 Months|participant was not eligible for biochem|45
6323226|NCT02896400|10064384|FG001|Biochemical Verification at 3 Months|participant was not eligible for biochem|48
6323227|NCT02896400|10064385|FG002|Biochemical Verification at 3 Months|participant was not eligible for biochem|46
6323228|NCT02896400|10064386|FG003|Biochemical Verification at 3 Months|participant was not eligible for biochem|40
6323229|NCT02896400|10064387|FG004|Biochemical Verification at 3 Months|participant was not eligible for biochem|45
6323230|NCT02896400|10064388|FG005|Biochemical Verification at 3 Months|participant was not eligible for biochem|48
6323231|NCT02896400|10064389|FG006|Biochemical Verification at 3 Months|participant was not eligible for biochem|48
6323232|NCT02896400|10064390|FG007|Biochemical Verification at 3 Months|participant was not eligible for biochem|47
6323233|NCT02896400|10064391|FG008|Biochemical Verification at 3 Months|participant was not eligible for biochem|44
6323234|NCT02896400|10064392|FG009|Biochemical Verification at 3 Months|participant was not eligible for biochem|52
6323235|NCT02896400|10064393|FG010|Biochemical Verification at 3 Months|participant was not eligible for biochem|55
6323236|NCT02896400|10064394|FG011|Biochemical Verification at 3 Months|participant was not eligible for biochem|41
6323237|NCT02896400|10064395|FG012|Biochemical Verification at 3 Months|participant was not eligible for biochem|52
6323238|NCT02896400|10064396|FG013|Biochemical Verification at 3 Months|participant was not eligible for biochem|48
6323239|NCT02896400|10064397|FG014|Biochemical Verification at 3 Months|participant was not eligible for biochem|52
6323240|NCT02896400|10064398|FG015|Biochemical Verification at 3 Months|participant was not eligible for biochem|56
6323241|NCT02896569|10064426|FG000|Overall Study|Lost to Follow-up|2
6323242|NCT02896569|10064427|FG001|Overall Study|Lost to Follow-up|1
6323243|NCT02896569|10064426|FG000|Overall Study|Physician Decision|1
6323244|NCT02896569|10064427|FG001|Overall Study|Physician Decision|3
6323245|NCT02896569|10064426|FG000|Overall Study|Adverse Event|0
6323246|NCT02896569|10064427|FG001|Overall Study|Adverse Event|1
6323247|NCT02896569|10064426|FG000|Overall Study|Withdrawal by Subject|1
6323248|NCT02896569|10064427|FG001|Overall Study|Withdrawal by Subject|0
6323249|NCT02897115|10064448|FG000|Overall Study|Early termination of study by sponsor|11
6323250|NCT02897115|10064449|FG001|Overall Study|Early termination of study by sponsor|8
6323251|NCT02897349|10064477|FG000|Overall Study|Lost to Follow-up|2
6323252|NCT02897349|10064478|FG001|Overall Study|Lost to Follow-up|2
6323253|NCT02897349|10064477|FG000|Overall Study|Adverse Event|3
6323254|NCT02897349|10064478|FG001|Overall Study|Adverse Event|3
6323255|NCT02897349|10064477|FG000|Overall Study|Other than listed above|0
6323256|NCT02897349|10064478|FG001|Overall Study|Other than listed above|1
6323257|NCT02898077|10064486|FG000|Overall Study|Adverse Event|21
6323258|NCT02898077|10064487|FG001|Overall Study|Adverse Event|7
6323259|NCT02898077|10064486|FG000|Overall Study|Withdrawal by Subject|51
6323260|NCT02898077|10064487|FG001|Overall Study|Withdrawal by Subject|14
6323261|NCT02898077|10064486|FG000|Overall Study|Physician Decision|12
6323262|NCT02898077|10064487|FG001|Overall Study|Physician Decision|4
6323263|NCT02898077|10064486|FG000|Overall Study|Non-compliance With Study Drug|3
6323264|NCT02898077|10064487|FG001|Overall Study|Non-compliance With Study Drug|2
6323265|NCT02898077|10064486|FG000|Overall Study|Protocol Deviation|3
6323266|NCT02898077|10064487|FG001|Overall Study|Protocol Deviation|0
6323267|NCT02898077|10064486|FG000|Overall Study|On Study Treatment|5
6323268|NCT02898077|10064487|FG001|Overall Study|On Study Treatment|3
6323269|NCT02898116|10064506|FG000|Overall Study|Adverse Event|1
6323270|NCT02898116|10064506|FG000|Overall Study|Progressive disease|1
6323271|NCT02898454|10064513|FG000|Overall Study|Adverse Event|4
6323272|NCT02898454|10064514|FG001|Overall Study|Adverse Event|1
6323273|NCT02898454|10064515|FG002|Overall Study|Adverse Event|2
6323274|NCT02898454|10064513|FG000|Overall Study|Protocol Violation|1
6323275|NCT02898454|10064514|FG001|Overall Study|Protocol Violation|0
6323276|NCT02898454|10064515|FG002|Overall Study|Protocol Violation|1
6323277|NCT02898454|10064513|FG000|Overall Study|Lack of Efficacy|4
6323278|NCT02898454|10064514|FG001|Overall Study|Lack of Efficacy|1
6323279|NCT02898454|10064515|FG002|Overall Study|Lack of Efficacy|0
6323280|NCT02898454|10064513|FG000|Overall Study|Withdrawal by Subject|6
6323281|NCT02898454|10064514|FG001|Overall Study|Withdrawal by Subject|3
6323282|NCT02898454|10064515|FG002|Overall Study|Withdrawal by Subject|3
6323283|NCT02898454|10064513|FG000|Overall Study|Lost to Follow-up|1
6323284|NCT02898454|10064514|FG001|Overall Study|Lost to Follow-up|0
6323285|NCT02898454|10064515|FG002|Overall Study|Lost to Follow-up|0
6323286|NCT02898454|10064513|FG000|Overall Study|Did Not Met Eligibility Criteria|1
6323287|NCT02898454|10064514|FG001|Overall Study|Did Not Met Eligibility Criteria|0
6323288|NCT02898454|10064515|FG002|Overall Study|Did Not Met Eligibility Criteria|0
6323289|NCT02898597|10064530|FG000|Overall Study|Protocol Violation|4
6323290|NCT02898597|10064531|FG001|Overall Study|Protocol Violation|2
6323291|NCT02898597|10064530|FG000|Overall Study|Lost to Follow-up|0
6323292|NCT02898597|10064531|FG001|Overall Study|Lost to Follow-up|9
6323293|NCT02898597|10064530|FG000|Overall Study|Death|0
6323294|NCT02898597|10064531|FG001|Overall Study|Death|1
6323295|NCT02898662|10064539|FG000|Overall Study|Adverse Event|1
6323296|NCT02898662|10064540|FG001|Overall Study|Adverse Event|0
6323297|NCT02898662|10064539|FG000|Overall Study|Loss of asthma control|23
6323298|NCT02898662|10064540|FG001|Overall Study|Loss of asthma control|24
6323299|NCT02898662|10064539|FG000|Overall Study|Withdrawal by Subject|4
6323300|NCT02898662|10064540|FG001|Overall Study|Withdrawal by Subject|1
6323301|NCT02898662|10064539|FG000|Overall Study|Technical issue|0
6323302|NCT02898662|10064540|FG001|Overall Study|Technical issue|1
6323303|NCT02898662|10064539|FG000|Overall Study|Randomized in error|0
6152248|NCT01118962|9789542|FG000|Overall Study|Pregnancy|1
6152249|NCT01118962|9789542|FG000|Overall Study|Non-compliance with Medicinal Product|1
6152250|NCT01118975|9789548|FG000|Overall Study|Adverse Event|0
6152251|NCT01118975|9789549|FG001|Overall Study|Adverse Event|1
6152252|NCT01119001|9789567|FG000|Overall Study|Withdrawal by Subject|2
6152253|NCT01119105|9789580|FG000|Overall Study|Withdrawal by Subject|1
6152254|NCT01119105|9789581|FG001|Overall Study|Withdrawal by Subject|1
6152255|NCT01119105|9789582|FG002|Overall Study|Withdrawal by Subject|1
6152256|NCT01119105|9789580|FG000|Overall Study|Lost to Follow-up|0
6152257|NCT01119105|9789581|FG001|Overall Study|Lost to Follow-up|2
6323304|NCT02898662|10064540|FG001|Overall Study|Randomized in error|1
6323305|NCT02898662|10064539|FG000|Overall Study|Subject decision|1
6323306|NCT02898662|10064540|FG001|Overall Study|Subject decision|0
6323307|NCT02898662|10064539|FG000|Overall Study|Other|0
6323308|NCT02898662|10064540|FG001|Overall Study|Other|1
6323309|NCT02899156|10064566|FG000|Overall Study|Death|1
6152258|NCT01119105|9789582|FG002|Overall Study|Lost to Follow-up|5
6152259|NCT01119105|9789580|FG000|Overall Study|Adverse Event|1
6152260|NCT01119105|9789581|FG001|Overall Study|Adverse Event|0
6152261|NCT01119105|9789582|FG002|Overall Study|Adverse Event|1
6323310|NCT02899156|10064567|FG001|Overall Study|Death|0
6323311|NCT02899156|10064566|FG000|Overall Study|Physician Decision|0
6323312|NCT02899156|10064567|FG001|Overall Study|Physician Decision|1
6323313|NCT02899195|10064573|FG000|Concurrent Durvalumab|Adverse Event|4
6323314|NCT02899195|10064573|FG000|Concurrent Durvalumab|Physician Decision|1
6323315|NCT02899195|10064573|FG000|Concurrent Durvalumab|Withdrawal by Subject|1
6323316|NCT02899195|10064573|FG000|Concurrent Durvalumab|Progressive Disease|5
6323317|NCT02899195|10064573|FG000|Maintenance Durvalumab|Adverse Event|1
6323318|NCT02899195|10064573|FG000|Maintenance Durvalumab|Physician Decision|1
6323319|NCT02899195|10064573|FG000|Maintenance Durvalumab|Withdrawal by Subject|1
6323320|NCT02899195|10064573|FG000|Maintenance Durvalumab|Progressive Disease|31
6323321|NCT02899338|10064579|FG000|Overall Study|Adverse Event|1
6323322|NCT02899338|10064580|FG001|Overall Study|Adverse Event|2
6323323|NCT02899338|10064579|FG000|Overall Study|Withdrawal by Subject|2
6323324|NCT02899338|10064580|FG001|Overall Study|Withdrawal by Subject|0
6323325|NCT02899377|10064588|FG000|Overall Study|Adverse Event|1
6323326|NCT02899377|10064589|FG001|Overall Study|Adverse Event|0
6323327|NCT02899962|10064625|FG000|Open-label Phase|Adverse Event|2
6323328|NCT02899962|10064626|FG001|Open-label Phase|Adverse Event|0
6323329|NCT02899962|10064627|FG002|Open-label Phase|Adverse Event|0
6323330|NCT02899962|10064625|FG000|Open-label Phase|Lost to Follow-up|9
6323331|NCT02899962|10064626|FG001|Open-label Phase|Lost to Follow-up|0
6323332|NCT02899962|10064627|FG002|Open-label Phase|Lost to Follow-up|0
6323333|NCT02899962|10064625|FG000|Open-label Phase|Other reasons|9
6323334|NCT02899962|10064626|FG001|Open-label Phase|Other reasons|0
6323335|NCT02899962|10064627|FG002|Open-label Phase|Other reasons|0
6323336|NCT02899962|10064625|FG000|Open-label Phase|Withdrawal by Subject|7
6323337|NCT02899962|10064626|FG001|Open-label Phase|Withdrawal by Subject|0
6323338|NCT02899962|10064627|FG002|Open-label Phase|Withdrawal by Subject|0
6152262|NCT01119105|9789580|FG000|Overall Study|study drug missed on 2 consecutive days|1
6152263|NCT01119105|9789581|FG001|Overall Study|study drug missed on 2 consecutive days|2
6152264|NCT01119105|9789582|FG002|Overall Study|study drug missed on 2 consecutive days|1
6152265|NCT01119105|9789580|FG000|Overall Study|Other|1
6152266|NCT01119105|9789581|FG001|Overall Study|Other|1
6152267|NCT01119105|9789582|FG002|Overall Study|Other|0
6152268|NCT01119118|9789590|FG000|Overall Study|Adverse Event|1
6152269|NCT01119131|9789597|FG000|Overall Study|Adverse Event|1
6152270|NCT01119131|9789598|FG001|Overall Study|Adverse Event|1
6152271|NCT01119131|9789599|FG002|Overall Study|Adverse Event|1
6152272|NCT01119131|9789597|FG000|Overall Study|Non-Compliance|1
6152273|NCT01119131|9789598|FG001|Overall Study|Non-Compliance|0
6152274|NCT01119131|9789599|FG002|Overall Study|Non-Compliance|4
6152275|NCT01119131|9789597|FG000|Overall Study|Physician Decision|0
6152276|NCT01119131|9789598|FG001|Overall Study|Physician Decision|0
6152277|NCT01119131|9789599|FG002|Overall Study|Physician Decision|1
6152278|NCT01119248|9789623|FG000|Overall Study|Physician Decision|5
6152279|NCT01119287|9789634|FG000|Overall Study|Patient Decision, not related to AE|0
6152280|NCT01119287|9789635|FG001|Overall Study|Patient Decision, not related to AE|0
6152281|NCT01119287|9789636|FG002|Overall Study|Patient Decision, not related to AE|2
6152282|NCT01119287|9789637|FG003|Overall Study|Patient Decision, not related to AE|2
6152283|NCT01119287|9789638|FG004|Overall Study|Patient Decision, not related to AE|1
6152284|NCT01119287|9789639|FG005|Overall Study|Patient Decision, not related to AE|0
6152285|NCT01119443|9789653|FG000|Crossover Period 1 (5 Days)|Adverse Event|0
6152286|NCT01119443|9789654|FG001|Crossover Period 1 (5 Days)|Adverse Event|1
6152287|NCT01119508|9789703|FG000|Overall Study|Adverse Event|56
6152288|NCT01119508|9789703|FG000|Overall Study|Withdrawal by Subject|2
6152289|NCT01119508|9789703|FG000|Overall Study|Died before tumor response evaluation|1
6152290|NCT01119625|9789709|FG000|Overall Study|Lost to Follow-up|1
6152291|NCT01119625|9789710|FG001|Overall Study|Lost to Follow-up|2
6152292|NCT01119625|9789709|FG000|Overall Study|Withdrawal by Subject|2
6152293|NCT01119625|9789710|FG001|Overall Study|Withdrawal by Subject|1
6152294|NCT01119625|9789709|FG000|Overall Study|Other|0
6152295|NCT01119625|9789710|FG001|Overall Study|Other|1
6152296|NCT01119703|9789718|FG000|Overall Study|Adverse Event|0
6152297|NCT01119703|9789719|FG001|Overall Study|Adverse Event|1
6152298|NCT01119768|9789738|FG000|Treatment Period|Lack of Efficacy|18
6152299|NCT01119768|9789739|FG001|Treatment Period|Lack of Efficacy|25
6152300|NCT01119846|9789752|FG000|Overall Study|Adverse Event|1
6152301|NCT01119846|9789753|FG001|Overall Study|Adverse Event|0
6152302|NCT01119846|9789754|FG002|Overall Study|Adverse Event|6
6323339|NCT02899962|10064625|FG000|Maintenance Phase|Adverse Event|0
6323340|NCT02899962|10064626|FG001|Maintenance Phase|Adverse Event|2
6323341|NCT02899962|10064627|FG002|Maintenance Phase|Adverse Event|1
6323342|NCT02899962|10064625|FG000|Maintenance Phase|Death|0
6323343|NCT02899962|10064626|FG001|Maintenance Phase|Death|0
6323344|NCT02899962|10064627|FG002|Maintenance Phase|Death|1
6323345|NCT02899962|10064625|FG000|Maintenance Phase|Lack of Efficacy|0
6323346|NCT02899962|10064626|FG001|Maintenance Phase|Lack of Efficacy|20
6152303|NCT01119846|9789752|FG000|Overall Study|Physician Decision|1
6152304|NCT01119846|9789753|FG001|Overall Study|Physician Decision|0
6152305|NCT01119846|9789754|FG002|Overall Study|Physician Decision|0
6323347|NCT02899962|10064627|FG002|Maintenance Phase|Lack of Efficacy|16
6152306|NCT01119846|9789752|FG000|Overall Study|Protocol Violation|0
6152307|NCT01119846|9789753|FG001|Overall Study|Protocol Violation|0
6152308|NCT01119846|9789754|FG002|Overall Study|Protocol Violation|1
6152309|NCT01119846|9789752|FG000|Overall Study|Withdrawal by Subject|0
6152310|NCT01119846|9789753|FG001|Overall Study|Withdrawal by Subject|0
6152311|NCT01119846|9789754|FG002|Overall Study|Withdrawal by Subject|4
6323348|NCT02899962|10064625|FG000|Maintenance Phase|Lost to Follow-up|0
6323349|NCT02899962|10064626|FG001|Maintenance Phase|Lost to Follow-up|12
6323350|NCT02899962|10064627|FG002|Maintenance Phase|Lost to Follow-up|14
6323351|NCT02899962|10064625|FG000|Maintenance Phase|Other reasons|0
6323352|NCT02899962|10064626|FG001|Maintenance Phase|Other reasons|9
6323353|NCT02899962|10064627|FG002|Maintenance Phase|Other reasons|13
6323354|NCT02899962|10064625|FG000|Maintenance Phase|Not achieve treatment success after Wk 4|0
6323355|NCT02899962|10064626|FG001|Maintenance Phase|Not achieve treatment success after Wk 4|3
6323356|NCT02899962|10064627|FG002|Maintenance Phase|Not achieve treatment success after Wk 4|2
6323357|NCT02899962|10064625|FG000|Maintenance Phase|Not clear/almost clear after rescue med|0
6323358|NCT02899962|10064626|FG001|Maintenance Phase|Not clear/almost clear after rescue med|65
6323359|NCT02899962|10064627|FG002|Maintenance Phase|Not clear/almost clear after rescue med|70
6323360|NCT02899962|10064625|FG000|Maintenance Phase|Withdrawal by Subject|0
6323361|NCT02899962|10064626|FG001|Maintenance Phase|Withdrawal by Subject|30
6323362|NCT02899962|10064627|FG002|Maintenance Phase|Withdrawal by Subject|36
6323363|NCT02899988|10064638|FG000|Induction Period (16 Weeks)|Withdrawal by Subject|2
6323364|NCT02899988|10064639|FG001|Induction Period (16 Weeks)|Withdrawal by Subject|1
6323365|NCT02899988|10064640|FG002|Induction Period (16 Weeks)|Withdrawal by Subject|0
6323366|NCT02899988|10064641|FG003|Induction Period (16 Weeks)|Withdrawal by Subject|0
6323367|NCT02899988|10064642|FG004|Induction Period (16 Weeks)|Withdrawal by Subject|0
6323368|NCT02899988|10064643|FG005|Induction Period (16 Weeks)|Withdrawal by Subject|0
6323369|NCT02899988|10064644|FG006|Induction Period (16 Weeks)|Withdrawal by Subject|0
6323370|NCT02899988|10064645|FG007|Induction Period (16 Weeks)|Withdrawal by Subject|0
6323371|NCT02899988|10064646|FG008|Induction Period (16 Weeks)|Withdrawal by Subject|0
6323372|NCT02899988|10064647|FG009|Induction Period (16 Weeks)|Withdrawal by Subject|0
6323373|NCT02899988|10064648|FG010|Induction Period (16 Weeks)|Withdrawal by Subject|0
6323374|NCT02899988|10064638|FG000|Induction Period (16 Weeks)|Adverse Event|0
6323375|NCT02899988|10064639|FG001|Induction Period (16 Weeks)|Adverse Event|0
6323376|NCT02899988|10064640|FG002|Induction Period (16 Weeks)|Adverse Event|0
6323377|NCT02899988|10064641|FG003|Induction Period (16 Weeks)|Adverse Event|2
6323378|NCT02899988|10064642|FG004|Induction Period (16 Weeks)|Adverse Event|0
6323379|NCT02899988|10064643|FG005|Induction Period (16 Weeks)|Adverse Event|0
6323380|NCT02899988|10064644|FG006|Induction Period (16 Weeks)|Adverse Event|0
6323381|NCT02899988|10064645|FG007|Induction Period (16 Weeks)|Adverse Event|0
6323382|NCT02899988|10064646|FG008|Induction Period (16 Weeks)|Adverse Event|0
6323383|NCT02899988|10064647|FG009|Induction Period (16 Weeks)|Adverse Event|0
6323384|NCT02899988|10064648|FG010|Induction Period (16 Weeks)|Adverse Event|0
6323385|NCT02899988|10064638|FG000|Induction Period (16 Weeks)|Physician Decision|0
6323386|NCT02899988|10064639|FG001|Induction Period (16 Weeks)|Physician Decision|1
6323387|NCT02899988|10064640|FG002|Induction Period (16 Weeks)|Physician Decision|0
6323388|NCT02899988|10064641|FG003|Induction Period (16 Weeks)|Physician Decision|0
6323389|NCT02899988|10064642|FG004|Induction Period (16 Weeks)|Physician Decision|0
6323390|NCT02899988|10064643|FG005|Induction Period (16 Weeks)|Physician Decision|0
6323391|NCT02899988|10064644|FG006|Induction Period (16 Weeks)|Physician Decision|0
6323392|NCT02899988|10064645|FG007|Induction Period (16 Weeks)|Physician Decision|0
6323393|NCT02899988|10064646|FG008|Induction Period (16 Weeks)|Physician Decision|0
6323394|NCT02899988|10064647|FG009|Induction Period (16 Weeks)|Physician Decision|0
6041389|NCT00376246|9639602|FG000|First Intervention (2 Weeks)|Lost to Follow-up|1
6152312|NCT01119859|9789791|FG000|Overall Study|Adverse Event|9
6323395|NCT02899988|10064648|FG010|Induction Period (16 Weeks)|Physician Decision|0
6323396|NCT02899988|10064638|FG000|Maintenance Period (88 Weeks)|Adverse Event|0
6323397|NCT02899988|10064639|FG001|Maintenance Period (88 Weeks)|Adverse Event|0
6323398|NCT02899988|10064640|FG002|Maintenance Period (88 Weeks)|Adverse Event|0
6323399|NCT02899988|10064641|FG003|Maintenance Period (88 Weeks)|Adverse Event|0
6323400|NCT02899988|10064642|FG004|Maintenance Period (88 Weeks)|Adverse Event|1
6323401|NCT02899988|10064643|FG005|Maintenance Period (88 Weeks)|Adverse Event|2
6323402|NCT02899988|10064644|FG006|Maintenance Period (88 Weeks)|Adverse Event|1
6323403|NCT02899988|10064645|FG007|Maintenance Period (88 Weeks)|Adverse Event|2
6323404|NCT02899988|10064646|FG008|Maintenance Period (88 Weeks)|Adverse Event|2
6323405|NCT02899988|10064647|FG009|Maintenance Period (88 Weeks)|Adverse Event|2
6323406|NCT02899988|10064648|FG010|Maintenance Period (88 Weeks)|Adverse Event|1
6323407|NCT02899988|10064638|FG000|Maintenance Period (88 Weeks)|Lost to Follow-up|0
6323408|NCT02899988|10064639|FG001|Maintenance Period (88 Weeks)|Lost to Follow-up|0
6323409|NCT02899988|10064640|FG002|Maintenance Period (88 Weeks)|Lost to Follow-up|0
6323410|NCT02899988|10064641|FG003|Maintenance Period (88 Weeks)|Lost to Follow-up|0
6323411|NCT02899988|10064642|FG004|Maintenance Period (88 Weeks)|Lost to Follow-up|0
6323412|NCT02899988|10064643|FG005|Maintenance Period (88 Weeks)|Lost to Follow-up|1
6323413|NCT02899988|10064644|FG006|Maintenance Period (88 Weeks)|Lost to Follow-up|0
6323414|NCT02899988|10064645|FG007|Maintenance Period (88 Weeks)|Lost to Follow-up|1
6323415|NCT02899988|10064646|FG008|Maintenance Period (88 Weeks)|Lost to Follow-up|0
6323416|NCT02899988|10064647|FG009|Maintenance Period (88 Weeks)|Lost to Follow-up|0
6323417|NCT02899988|10064648|FG010|Maintenance Period (88 Weeks)|Lost to Follow-up|0
6323418|NCT02899988|10064638|FG000|Maintenance Period (88 Weeks)|Withdrawal by Subject|0
6323419|NCT02899988|10064639|FG001|Maintenance Period (88 Weeks)|Withdrawal by Subject|0
6323420|NCT02899988|10064640|FG002|Maintenance Period (88 Weeks)|Withdrawal by Subject|0
6323421|NCT02899988|10064641|FG003|Maintenance Period (88 Weeks)|Withdrawal by Subject|0
6323422|NCT02899988|10064642|FG004|Maintenance Period (88 Weeks)|Withdrawal by Subject|1
6323423|NCT02899988|10064643|FG005|Maintenance Period (88 Weeks)|Withdrawal by Subject|0
6323424|NCT02899988|10064644|FG006|Maintenance Period (88 Weeks)|Withdrawal by Subject|3
6323425|NCT02899988|10064645|FG007|Maintenance Period (88 Weeks)|Withdrawal by Subject|2
6323426|NCT02899988|10064646|FG008|Maintenance Period (88 Weeks)|Withdrawal by Subject|2
6323427|NCT02899988|10064647|FG009|Maintenance Period (88 Weeks)|Withdrawal by Subject|0
6323428|NCT02899988|10064648|FG010|Maintenance Period (88 Weeks)|Withdrawal by Subject|1
6323429|NCT02900092|10064680|FG000|Overall Study|Adverse Event|1
6323430|NCT02900170|10064684|FG000|Overall Study|Lost to Follow-up|8
6323431|NCT02900378|10064690|FG000|Randomization (Visit 2)|Adverse Event|14
6323432|NCT02900378|10064691|FG001|Randomization (Visit 2)|Adverse Event|11
6323433|NCT02900378|10064690|FG000|Randomization (Visit 2)|Death|1
6323434|NCT02900378|10064691|FG001|Randomization (Visit 2)|Death|4
6323435|NCT02900378|10064690|FG000|Randomization (Visit 2)|Lost to Follow-up|1
6323436|NCT02900378|10064691|FG001|Randomization (Visit 2)|Lost to Follow-up|0
6323437|NCT02900378|10064690|FG000|Randomization (Visit 2)|Non-compliance with Study Drug|1
6323438|NCT02900378|10064691|FG001|Randomization (Visit 2)|Non-compliance with Study Drug|1
6323439|NCT02900378|10064690|FG000|Randomization (Visit 2)|Protocol Deviation|1
6323440|NCT02900378|10064691|FG001|Randomization (Visit 2)|Protocol Deviation|7
6323441|NCT02900378|10064690|FG000|Randomization (Visit 2)|Withdrawal by Parent/Guardian|5
6323442|NCT02900378|10064691|FG001|Randomization (Visit 2)|Withdrawal by Parent/Guardian|3
6323443|NCT02900378|10064690|FG000|Randomization (Visit 2)|Withdrawal of Informed Consent|0
6323444|NCT02900378|10064691|FG001|Randomization (Visit 2)|Withdrawal of Informed Consent|2
6323445|NCT02901054|10064697|FG000|Overall Study|Physician Decision|1
6323446|NCT02901054|10064697|FG000|Overall Study|Withdrawal by Subject|3
6323447|NCT02901431|10064731|FG000|PK Part|Adverse Event|0
6323448|NCT02901431|10064732|FG001|PK Part|Adverse Event|1
6323449|NCT02901431|10064733|FG002|PK Part|Adverse Event|0
6323450|NCT02901431|10064734|FG003|PK Part|Adverse Event|0
6323451|NCT02901431|10064735|FG004|PK Part|Adverse Event|0
6323452|NCT02901431|10064736|FG005|PK Part|Adverse Event|0
6323453|NCT02901431|10064737|FG006|PK Part|Adverse Event|0
6323454|NCT02901431|10064738|FG007|PK Part|Adverse Event|0
6323455|NCT02901431|10064739|FG008|PK Part|Adverse Event|0
6323456|NCT02901431|10064740|FG009|PK Part|Adverse Event|0
6323457|NCT02901431|10064741|FG010|PK Part|Adverse Event|0
6323458|NCT02901431|10064742|FG011|PK Part|Adverse Event|0
6323459|NCT02901431|10064743|FG012|PK Part|Adverse Event|0
6323460|NCT02901431|10064731|FG000|PK Part|Lost to Follow-up|0
6323461|NCT02901431|10064732|FG001|PK Part|Lost to Follow-up|0
6323462|NCT02901431|10064733|FG002|PK Part|Lost to Follow-up|1
6323463|NCT02901431|10064734|FG003|PK Part|Lost to Follow-up|0
6323464|NCT02901431|10064735|FG004|PK Part|Lost to Follow-up|0
6323465|NCT02901431|10064736|FG005|PK Part|Lost to Follow-up|0
6323466|NCT02901431|10064737|FG006|PK Part|Lost to Follow-up|0
6323467|NCT02901431|10064738|FG007|PK Part|Lost to Follow-up|0
6323468|NCT02901431|10064739|FG008|PK Part|Lost to Follow-up|0
6323469|NCT02901431|10064740|FG009|PK Part|Lost to Follow-up|0
6323470|NCT02901431|10064741|FG010|PK Part|Lost to Follow-up|0
6323471|NCT02901431|10064742|FG011|PK Part|Lost to Follow-up|0
6323472|NCT02901431|10064743|FG012|PK Part|Lost to Follow-up|0
6323473|NCT02901431|10064731|FG000|PK Part|Pending IMC/SOC Dose Confirmation|2
6323474|NCT02901431|10064732|FG001|PK Part|Pending IMC/SOC Dose Confirmation|0
6323475|NCT02901431|10064733|FG002|PK Part|Pending IMC/SOC Dose Confirmation|0
6323476|NCT02901431|10064734|FG003|PK Part|Pending IMC/SOC Dose Confirmation|0
6323477|NCT02901431|10064735|FG004|PK Part|Pending IMC/SOC Dose Confirmation|0
6323478|NCT02901431|10064736|FG005|PK Part|Pending IMC/SOC Dose Confirmation|0
6323479|NCT02901431|10064737|FG006|PK Part|Pending IMC/SOC Dose Confirmation|0
6323480|NCT02901431|10064738|FG007|PK Part|Pending IMC/SOC Dose Confirmation|0
6323481|NCT02901431|10064739|FG008|PK Part|Pending IMC/SOC Dose Confirmation|0
6323482|NCT02901431|10064740|FG009|PK Part|Pending IMC/SOC Dose Confirmation|0
6323483|NCT02901431|10064741|FG010|PK Part|Pending IMC/SOC Dose Confirmation|0
6323484|NCT02901431|10064742|FG011|PK Part|Pending IMC/SOC Dose Confirmation|0
6323485|NCT02901431|10064743|FG012|PK Part|Pending IMC/SOC Dose Confirmation|0
6323486|NCT02901431|10064731|FG000|PK Part|Pending dose confirmation|0
6323487|NCT02901431|10064732|FG001|PK Part|Pending dose confirmation|1
6323488|NCT02901431|10064733|FG002|PK Part|Pending dose confirmation|0
6323489|NCT02901431|10064734|FG003|PK Part|Pending dose confirmation|0
6323490|NCT02901431|10064735|FG004|PK Part|Pending dose confirmation|0
6323491|NCT02901431|10064736|FG005|PK Part|Pending dose confirmation|0
6323492|NCT02901431|10064737|FG006|PK Part|Pending dose confirmation|0
6323493|NCT02901431|10064738|FG007|PK Part|Pending dose confirmation|0
6323494|NCT02901431|10064739|FG008|PK Part|Pending dose confirmation|0
6323495|NCT02901431|10064740|FG009|PK Part|Pending dose confirmation|0
6323496|NCT02901431|10064741|FG010|PK Part|Pending dose confirmation|0
6323497|NCT02901431|10064742|FG011|PK Part|Pending dose confirmation|0
6323498|NCT02901431|10064743|FG012|PK Part|Pending dose confirmation|0
6323499|NCT02901431|10064731|FG000|PK Part|8 weeks of treatment ran out|2
6323500|NCT02901431|10064732|FG001|PK Part|8 weeks of treatment ran out|0
6323501|NCT02901431|10064733|FG002|PK Part|8 weeks of treatment ran out|0
6323502|NCT02901431|10064734|FG003|PK Part|8 weeks of treatment ran out|0
6323503|NCT02901431|10064735|FG004|PK Part|8 weeks of treatment ran out|0
6323504|NCT02901431|10064736|FG005|PK Part|8 weeks of treatment ran out|0
6323505|NCT02901431|10064737|FG006|PK Part|8 weeks of treatment ran out|0
6323506|NCT02901431|10064738|FG007|PK Part|8 weeks of treatment ran out|0
6323507|NCT02901431|10064739|FG008|PK Part|8 weeks of treatment ran out|0
6323508|NCT02901431|10064740|FG009|PK Part|8 weeks of treatment ran out|0
6323509|NCT02901431|10064741|FG010|PK Part|8 weeks of treatment ran out|0
6323510|NCT02901431|10064742|FG011|PK Part|8 weeks of treatment ran out|0
6323511|NCT02901431|10064743|FG012|PK Part|8 weeks of treatment ran out|0
6323512|NCT02901431|10064731|FG000|PK Part|Stopped treatment after 8 weeks|1
6323513|NCT02901431|10064732|FG001|PK Part|Stopped treatment after 8 weeks|0
6152313|NCT01119859|9789792|FG001|Overall Study|Adverse Event|10
6152314|NCT01119859|9789791|FG000|Overall Study|Death|2
6152315|NCT01119859|9789792|FG001|Overall Study|Death|0
6152316|NCT01119859|9789791|FG000|Overall Study|Insufficient therapeutic response|7
6323514|NCT02901431|10064733|FG002|PK Part|Stopped treatment after 8 weeks|1
6323515|NCT02901431|10064734|FG003|PK Part|Stopped treatment after 8 weeks|0
6323516|NCT02901431|10064735|FG004|PK Part|Stopped treatment after 8 weeks|0
6152317|NCT01119859|9789792|FG001|Overall Study|Insufficient therapeutic response|14
6152318|NCT01119859|9789791|FG000|Overall Study|Refused treatment|3
6323517|NCT02901431|10064736|FG005|PK Part|Stopped treatment after 8 weeks|0
6323518|NCT02901431|10064737|FG006|PK Part|Stopped treatment after 8 weeks|0
6323519|NCT02901431|10064738|FG007|PK Part|Stopped treatment after 8 weeks|0
6323520|NCT02901431|10064739|FG008|PK Part|Stopped treatment after 8 weeks|0
6323521|NCT02901431|10064740|FG009|PK Part|Stopped treatment after 8 weeks|0
6323522|NCT02901431|10064741|FG010|PK Part|Stopped treatment after 8 weeks|0
6323523|NCT02901431|10064742|FG011|PK Part|Stopped treatment after 8 weeks|0
6323524|NCT02901431|10064743|FG012|PK Part|Stopped treatment after 8 weeks|0
6323525|NCT02901431|10064731|FG000|PK Part|Stopped on Sponsor instruction pending dose confirmation|1
6323526|NCT02901431|10064732|FG001|PK Part|Stopped on Sponsor instruction pending dose confirmation|0
6323527|NCT02901431|10064733|FG002|PK Part|Stopped on Sponsor instruction pending dose confirmation|4
6323528|NCT02901431|10064734|FG003|PK Part|Stopped on Sponsor instruction pending dose confirmation|0
6323529|NCT02901431|10064735|FG004|PK Part|Stopped on Sponsor instruction pending dose confirmation|0
6323530|NCT02901431|10064736|FG005|PK Part|Stopped on Sponsor instruction pending dose confirmation|0
6323531|NCT02901431|10064737|FG006|PK Part|Stopped on Sponsor instruction pending dose confirmation|0
6323532|NCT02901431|10064738|FG007|PK Part|Stopped on Sponsor instruction pending dose confirmation|0
6323533|NCT02901431|10064739|FG008|PK Part|Stopped on Sponsor instruction pending dose confirmation|0
6323534|NCT02901431|10064740|FG009|PK Part|Stopped on Sponsor instruction pending dose confirmation|0
6323535|NCT02901431|10064741|FG010|PK Part|Stopped on Sponsor instruction pending dose confirmation|0
6323536|NCT02901431|10064742|FG011|PK Part|Stopped on Sponsor instruction pending dose confirmation|0
6323537|NCT02901431|10064743|FG012|PK Part|Stopped on Sponsor instruction pending dose confirmation|0
6323538|NCT02901431|10064731|FG000|PK Part|Discontinued per Sponsor|0
6323539|NCT02901431|10064732|FG001|PK Part|Discontinued per Sponsor|3
6323540|NCT02901431|10064733|FG002|PK Part|Discontinued per Sponsor|0
6323541|NCT02901431|10064734|FG003|PK Part|Discontinued per Sponsor|0
6323542|NCT02901431|10064735|FG004|PK Part|Discontinued per Sponsor|0
6323543|NCT02901431|10064736|FG005|PK Part|Discontinued per Sponsor|0
6323544|NCT02901431|10064737|FG006|PK Part|Discontinued per Sponsor|0
6323545|NCT02901431|10064738|FG007|PK Part|Discontinued per Sponsor|0
6323546|NCT02901431|10064739|FG008|PK Part|Discontinued per Sponsor|0
6323547|NCT02901431|10064740|FG009|PK Part|Discontinued per Sponsor|0
6323548|NCT02901431|10064741|FG010|PK Part|Discontinued per Sponsor|0
6323549|NCT02901431|10064742|FG011|PK Part|Discontinued per Sponsor|0
6323550|NCT02901431|10064743|FG012|PK Part|Discontinued per Sponsor|0
6323551|NCT02901431|10064731|FG000|PK Part|Withdrawal by Subject|1
6323552|NCT02901431|10064732|FG001|PK Part|Withdrawal by Subject|1
6323553|NCT02901431|10064733|FG002|PK Part|Withdrawal by Subject|3
6323554|NCT02901431|10064734|FG003|PK Part|Withdrawal by Subject|0
6323555|NCT02901431|10064735|FG004|PK Part|Withdrawal by Subject|0
6323556|NCT02901431|10064736|FG005|PK Part|Withdrawal by Subject|0
6152319|NCT01119859|9789792|FG001|Overall Study|Refused treatment|6
6152320|NCT01119859|9789791|FG000|Overall Study|Failure to return|3
6152321|NCT01119859|9789792|FG001|Overall Study|Failure to return|0
6191459|NCT01422876|9848251|FG007|Week 52|Death|3
6191460|NCT01422876|9848252|FG008|Week 52|Death|1
6191461|NCT01422876|9848253|FG009|Week 52|Death|0
6323557|NCT02901431|10064737|FG006|PK Part|Withdrawal by Subject|0
6323558|NCT02901431|10064738|FG007|PK Part|Withdrawal by Subject|0
6323559|NCT02901431|10064739|FG008|PK Part|Withdrawal by Subject|0
6323560|NCT02901431|10064740|FG009|PK Part|Withdrawal by Subject|0
6323561|NCT02901431|10064741|FG010|PK Part|Withdrawal by Subject|0
6323562|NCT02901431|10064742|FG011|PK Part|Withdrawal by Subject|0
6323563|NCT02901431|10064743|FG012|PK Part|Withdrawal by Subject|0
6323564|NCT02901431|10064731|FG000|Main Treatment Part|Adverse Event|0
6323565|NCT02901431|10064732|FG001|Main Treatment Part|Adverse Event|0
6323566|NCT02901431|10064733|FG002|Main Treatment Part|Adverse Event|0
6323567|NCT02901431|10064734|FG003|Main Treatment Part|Adverse Event|3
6323568|NCT02901431|10064735|FG004|Main Treatment Part|Adverse Event|3
6323569|NCT02901431|10064736|FG005|Main Treatment Part|Adverse Event|4
6323570|NCT02901431|10064737|FG006|Main Treatment Part|Adverse Event|1
6323571|NCT02901431|10064738|FG007|Main Treatment Part|Adverse Event|0
6323572|NCT02901431|10064739|FG008|Main Treatment Part|Adverse Event|0
6323573|NCT02901431|10064740|FG009|Main Treatment Part|Adverse Event|0
6323574|NCT02901431|10064741|FG010|Main Treatment Part|Adverse Event|0
6323575|NCT02901431|10064742|FG011|Main Treatment Part|Adverse Event|0
6323576|NCT02901431|10064743|FG012|Main Treatment Part|Adverse Event|0
6323577|NCT02901431|10064731|FG000|Main Treatment Part|Lack of Efficacy|0
6323578|NCT02901431|10064732|FG001|Main Treatment Part|Lack of Efficacy|0
6323579|NCT02901431|10064733|FG002|Main Treatment Part|Lack of Efficacy|0
6323580|NCT02901431|10064734|FG003|Main Treatment Part|Lack of Efficacy|1
6323581|NCT02901431|10064735|FG004|Main Treatment Part|Lack of Efficacy|0
6323582|NCT02901431|10064736|FG005|Main Treatment Part|Lack of Efficacy|0
6323583|NCT02901431|10064737|FG006|Main Treatment Part|Lack of Efficacy|0
6323584|NCT02901431|10064738|FG007|Main Treatment Part|Lack of Efficacy|0
6323585|NCT02901431|10064739|FG008|Main Treatment Part|Lack of Efficacy|0
6323586|NCT02901431|10064740|FG009|Main Treatment Part|Lack of Efficacy|0
6323587|NCT02901431|10064741|FG010|Main Treatment Part|Lack of Efficacy|0
6323588|NCT02901431|10064742|FG011|Main Treatment Part|Lack of Efficacy|0
6323589|NCT02901431|10064743|FG012|Main Treatment Part|Lack of Efficacy|0
6323590|NCT02901431|10064731|FG000|Main Treatment Part|Lost to Follow-up|0
6323591|NCT02901431|10064732|FG001|Main Treatment Part|Lost to Follow-up|0
6323592|NCT02901431|10064733|FG002|Main Treatment Part|Lost to Follow-up|0
6323593|NCT02901431|10064734|FG003|Main Treatment Part|Lost to Follow-up|3
6323594|NCT02901431|10064735|FG004|Main Treatment Part|Lost to Follow-up|1
6323595|NCT02901431|10064736|FG005|Main Treatment Part|Lost to Follow-up|2
6323596|NCT02901431|10064737|FG006|Main Treatment Part|Lost to Follow-up|3
6323597|NCT02901431|10064738|FG007|Main Treatment Part|Lost to Follow-up|0
6323598|NCT02901431|10064739|FG008|Main Treatment Part|Lost to Follow-up|0
6323599|NCT02901431|10064740|FG009|Main Treatment Part|Lost to Follow-up|0
6323600|NCT02901431|10064741|FG010|Main Treatment Part|Lost to Follow-up|0
6323601|NCT02901431|10064742|FG011|Main Treatment Part|Lost to Follow-up|0
6323602|NCT02901431|10064743|FG012|Main Treatment Part|Lost to Follow-up|0
6323603|NCT02901431|10064731|FG000|Main Treatment Part|Withdrawal by Caregiver|0
6323604|NCT02901431|10064732|FG001|Main Treatment Part|Withdrawal by Caregiver|0
6323605|NCT02901431|10064733|FG002|Main Treatment Part|Withdrawal by Caregiver|0
6323606|NCT02901431|10064734|FG003|Main Treatment Part|Withdrawal by Caregiver|0
6191462|NCT01422889|9848271|FG000|Overall Study|No Data Entered for Study Stent|9
6191463|NCT01422915|9848275|FG000|Overall Study|Adverse Event|1
6191464|NCT01423084|9848282|FG000|Overall Study|Adverse Event|0
6191465|NCT01423084|9848283|FG001|Overall Study|Adverse Event|1
6323607|NCT02901431|10064735|FG004|Main Treatment Part|Withdrawal by Caregiver|0
6323608|NCT02901431|10064736|FG005|Main Treatment Part|Withdrawal by Caregiver|1
6323609|NCT02901431|10064737|FG006|Main Treatment Part|Withdrawal by Caregiver|0
6323610|NCT02901431|10064738|FG007|Main Treatment Part|Withdrawal by Caregiver|0
6323611|NCT02901431|10064739|FG008|Main Treatment Part|Withdrawal by Caregiver|0
6323612|NCT02901431|10064740|FG009|Main Treatment Part|Withdrawal by Caregiver|0
6323613|NCT02901431|10064741|FG010|Main Treatment Part|Withdrawal by Caregiver|0
6323614|NCT02901431|10064742|FG011|Main Treatment Part|Withdrawal by Caregiver|0
6323615|NCT02901431|10064743|FG012|Main Treatment Part|Withdrawal by Caregiver|0
6323616|NCT02901431|10064731|FG000|Main Treatment Part|Physician Decision|0
6323617|NCT02901431|10064732|FG001|Main Treatment Part|Physician Decision|0
6323618|NCT02901431|10064733|FG002|Main Treatment Part|Physician Decision|0
6323619|NCT02901431|10064734|FG003|Main Treatment Part|Physician Decision|1
6323620|NCT02901431|10064735|FG004|Main Treatment Part|Physician Decision|0
6323621|NCT02901431|10064736|FG005|Main Treatment Part|Physician Decision|0
6323622|NCT02901431|10064737|FG006|Main Treatment Part|Physician Decision|1
6323623|NCT02901431|10064738|FG007|Main Treatment Part|Physician Decision|0
6323624|NCT02901431|10064739|FG008|Main Treatment Part|Physician Decision|0
6323625|NCT02901431|10064740|FG009|Main Treatment Part|Physician Decision|0
6323626|NCT02901431|10064741|FG010|Main Treatment Part|Physician Decision|0
6191466|NCT01423084|9848282|FG000|Overall Study|Withdrawal by Subject|2
6191467|NCT01423084|9848283|FG001|Overall Study|Withdrawal by Subject|3
6191468|NCT01423253|9848299|FG000|Overall Study|Adverse Event|2
6152322|NCT01119898|9789800|FG000|Overall Study|Adverse Event|4
6152323|NCT01119898|9789801|FG001|Overall Study|Adverse Event|5
6152324|NCT01119898|9789800|FG000|Overall Study|Withdrawal by Subject|1
6323627|NCT02901431|10064742|FG011|Main Treatment Part|Physician Decision|0
6323628|NCT02901431|10064743|FG012|Main Treatment Part|Physician Decision|0
6323629|NCT02901431|10064731|FG000|Main Treatment Part|Withdrawal by Subject|0
6323630|NCT02901431|10064732|FG001|Main Treatment Part|Withdrawal by Subject|0
6323631|NCT02901431|10064733|FG002|Main Treatment Part|Withdrawal by Subject|0
6323632|NCT02901431|10064734|FG003|Main Treatment Part|Withdrawal by Subject|18
6323633|NCT02901431|10064735|FG004|Main Treatment Part|Withdrawal by Subject|3
6323634|NCT02901431|10064736|FG005|Main Treatment Part|Withdrawal by Subject|5
6323635|NCT02901431|10064737|FG006|Main Treatment Part|Withdrawal by Subject|6
6323636|NCT02901431|10064738|FG007|Main Treatment Part|Withdrawal by Subject|0
6323637|NCT02901431|10064739|FG008|Main Treatment Part|Withdrawal by Subject|0
6323638|NCT02901431|10064740|FG009|Main Treatment Part|Withdrawal by Subject|0
6323639|NCT02901431|10064741|FG010|Main Treatment Part|Withdrawal by Subject|0
6323640|NCT02901431|10064742|FG011|Main Treatment Part|Withdrawal by Subject|0
6323641|NCT02901431|10064743|FG012|Main Treatment Part|Withdrawal by Subject|0
6323642|NCT02901431|10064731|FG000|Open Label Part|Adverse Event|0
6323643|NCT02901431|10064732|FG001|Open Label Part|Adverse Event|0
6323644|NCT02901431|10064733|FG002|Open Label Part|Adverse Event|0
6323645|NCT02901431|10064734|FG003|Open Label Part|Adverse Event|0
6323646|NCT02901431|10064735|FG004|Open Label Part|Adverse Event|0
6323647|NCT02901431|10064736|FG005|Open Label Part|Adverse Event|0
6323648|NCT02901431|10064737|FG006|Open Label Part|Adverse Event|0
6323649|NCT02901431|10064738|FG007|Open Label Part|Adverse Event|0
6323650|NCT02901431|10064739|FG008|Open Label Part|Adverse Event|4
6323651|NCT02901431|10064740|FG009|Open Label Part|Adverse Event|4
6323652|NCT02901431|10064741|FG010|Open Label Part|Adverse Event|0
6323653|NCT02901431|10064742|FG011|Open Label Part|Adverse Event|4
6323654|NCT02901431|10064743|FG012|Open Label Part|Adverse Event|1
6323655|NCT02901431|10064731|FG000|Open Label Part|Lost to Follow-up|0
6323656|NCT02901431|10064732|FG001|Open Label Part|Lost to Follow-up|0
6323657|NCT02901431|10064733|FG002|Open Label Part|Lost to Follow-up|0
6323658|NCT02901431|10064734|FG003|Open Label Part|Lost to Follow-up|0
6323659|NCT02901431|10064735|FG004|Open Label Part|Lost to Follow-up|0
6323660|NCT02901431|10064736|FG005|Open Label Part|Lost to Follow-up|0
6323661|NCT02901431|10064737|FG006|Open Label Part|Lost to Follow-up|0
6323662|NCT02901431|10064738|FG007|Open Label Part|Lost to Follow-up|0
6323663|NCT02901431|10064739|FG008|Open Label Part|Lost to Follow-up|2
6323664|NCT02901431|10064740|FG009|Open Label Part|Lost to Follow-up|2
6323665|NCT02901431|10064741|FG010|Open Label Part|Lost to Follow-up|1
6323666|NCT02901431|10064742|FG011|Open Label Part|Lost to Follow-up|1
6323667|NCT02901431|10064743|FG012|Open Label Part|Lost to Follow-up|1
6152325|NCT01119898|9789801|FG001|Overall Study|Withdrawal by Subject|4
6152326|NCT01119898|9789800|FG000|Overall Study|Lack of Efficacy|0
6152327|NCT01119898|9789801|FG001|Overall Study|Lack of Efficacy|2
6152328|NCT01119898|9789800|FG000|Overall Study|Protocol Violation|1
6152329|NCT01119898|9789801|FG001|Overall Study|Protocol Violation|1
6041390|NCT00376246|9639603|FG001|First Intervention (2 Weeks)|Lost to Follow-up|0
6041391|NCT00376259|9639613|FG000|Overall Study|Sponsor request - study termination|21
6041392|NCT00376259|9639614|FG001|Overall Study|Sponsor request - study termination|21
6041393|NCT00376259|9639613|FG000|Overall Study|Patient request|1
6152330|NCT01119898|9789800|FG000|Overall Study|Medical procedure|1
6323668|NCT02901431|10064731|FG000|Open Label Part|Physician Decision|0
6323669|NCT02901431|10064732|FG001|Open Label Part|Physician Decision|0
6323670|NCT02901431|10064733|FG002|Open Label Part|Physician Decision|0
6323671|NCT02901431|10064734|FG003|Open Label Part|Physician Decision|0
6323672|NCT02901431|10064735|FG004|Open Label Part|Physician Decision|0
6323673|NCT02901431|10064736|FG005|Open Label Part|Physician Decision|0
6323674|NCT02901431|10064737|FG006|Open Label Part|Physician Decision|0
6323675|NCT02901431|10064738|FG007|Open Label Part|Physician Decision|0
6323676|NCT02901431|10064739|FG008|Open Label Part|Physician Decision|1
6323677|NCT02901431|10064740|FG009|Open Label Part|Physician Decision|1
6323678|NCT02901431|10064741|FG010|Open Label Part|Physician Decision|0
6323679|NCT02901431|10064742|FG011|Open Label Part|Physician Decision|0
6323680|NCT02901431|10064743|FG012|Open Label Part|Physician Decision|0
6323681|NCT02901431|10064731|FG000|Open Label Part|Study Terminated By Sponsor|0
6323682|NCT02901431|10064732|FG001|Open Label Part|Study Terminated By Sponsor|0
6323683|NCT02901431|10064733|FG002|Open Label Part|Study Terminated By Sponsor|0
6323684|NCT02901431|10064734|FG003|Open Label Part|Study Terminated By Sponsor|0
6323685|NCT02901431|10064735|FG004|Open Label Part|Study Terminated By Sponsor|0
6323686|NCT02901431|10064736|FG005|Open Label Part|Study Terminated By Sponsor|0
6323687|NCT02901431|10064737|FG006|Open Label Part|Study Terminated By Sponsor|0
6323688|NCT02901431|10064738|FG007|Open Label Part|Study Terminated By Sponsor|0
6323689|NCT02901431|10064739|FG008|Open Label Part|Study Terminated By Sponsor|35
6323690|NCT02901431|10064740|FG009|Open Label Part|Study Terminated By Sponsor|12
6152331|NCT01119898|9789801|FG001|Overall Study|Medical procedure|0
6152332|NCT01119898|9789800|FG000|Overall Study|Randomized in error did not participate|1
6323691|NCT02901431|10064741|FG010|Open Label Part|Study Terminated By Sponsor|21
6323692|NCT02901431|10064742|FG011|Open Label Part|Study Terminated By Sponsor|31
6323693|NCT02901431|10064743|FG012|Open Label Part|Study Terminated By Sponsor|0
6323694|NCT02901431|10064731|FG000|Open Label Part|Withdrawal by Subject|0
6323695|NCT02901431|10064732|FG001|Open Label Part|Withdrawal by Subject|0
6323696|NCT02901431|10064733|FG002|Open Label Part|Withdrawal by Subject|0
6323697|NCT02901431|10064734|FG003|Open Label Part|Withdrawal by Subject|0
6323698|NCT02901431|10064735|FG004|Open Label Part|Withdrawal by Subject|0
6323699|NCT02901431|10064736|FG005|Open Label Part|Withdrawal by Subject|0
6323700|NCT02901431|10064737|FG006|Open Label Part|Withdrawal by Subject|0
6323701|NCT02901431|10064738|FG007|Open Label Part|Withdrawal by Subject|0
6323702|NCT02901431|10064739|FG008|Open Label Part|Withdrawal by Subject|6
6323703|NCT02901431|10064740|FG009|Open Label Part|Withdrawal by Subject|5
6323704|NCT02901431|10064741|FG010|Open Label Part|Withdrawal by Subject|7
6323705|NCT02901431|10064742|FG011|Open Label Part|Withdrawal by Subject|3
6323706|NCT02901431|10064743|FG012|Open Label Part|Withdrawal by Subject|1
6323707|NCT02902809|10064827|FG000|Overall Study|Discontinuation of asthma program|28
6323708|NCT02902965|10064839|FG000|Overall Study|Withdrawal by Subject|10
6323709|NCT02903030|10064846|FG000|First Intervention (8 Weeks)|Withdrawal by Subject|2
6323710|NCT02903030|10064847|FG001|First Intervention (8 Weeks)|Withdrawal by Subject|1
6323711|NCT02903238|10064865|FG000|Overall Study|Lost to Follow-up|4
6323712|NCT02903368|10064872|FG000|Overall Study|Not sprcified|4
6323713|NCT02903368|10064873|FG001|Overall Study|Not sprcified|0
6323714|NCT02903420|10064901|FG000|Overall Study|Death|3
6323715|NCT02903511|10064916|FG000|Overall Study|Withdrawal by Subject|1
6323716|NCT02903511|10064917|FG001|Overall Study|Withdrawal by Subject|0
6323717|NCT02903511|10064916|FG000|Overall Study|Lost to Follow-up|3
6323718|NCT02903511|10064917|FG001|Overall Study|Lost to Follow-up|2
6323719|NCT02903966|10064938|FG000|Part A (Day 1 to 43)|Adverse Event|1
6323720|NCT02903966|10064939|FG001|Part A (Day 1 to 43)|Adverse Event|0
6323721|NCT02903966|10064938|FG000|Part B (Day 44 to 112)|Lack of Efficacy|0
6323722|NCT02903966|10064939|FG001|Part B (Day 44 to 112)|Lack of Efficacy|1
6323723|NCT02903966|10064938|FG000|Part B (Day 44 to 112)|Withdrawal by Subject|0
6323724|NCT02903966|10064939|FG001|Part B (Day 44 to 112)|Withdrawal by Subject|1
6323725|NCT02904096|10064962|FG000|Overall Study|Adverse Event|1
6323726|NCT02904096|10064963|FG001|Overall Study|Adverse Event|0
6323727|NCT02904096|10064962|FG000|Overall Study|Withdrawal by Subject|4
6323728|NCT02904096|10064963|FG001|Overall Study|Withdrawal by Subject|3
6323729|NCT02904096|10064962|FG000|Overall Study|Lost to Follow-up|10
6323730|NCT02904096|10064963|FG001|Overall Study|Lost to Follow-up|17
6323731|NCT02904096|10064962|FG000|Overall Study|Non-compliant|3
6323732|NCT02904096|10064963|FG001|Overall Study|Non-compliant|1
6323733|NCT02904096|10064962|FG000|Overall Study|Sponsor instructed|1
6323734|NCT02904096|10064963|FG001|Overall Study|Sponsor instructed|0
6323735|NCT02904200|10064969|FG000|Overall Study|Withdrawal by Subject|1
6323736|NCT02904200|10064970|FG001|Overall Study|Withdrawal by Subject|0
6323737|NCT02904265|10065007|FG000|Overall Study|Physician Decision|1
6323738|NCT02904265|10065008|FG001|Overall Study|Physician Decision|2
6323739|NCT02904512|10065016|FG000|Overall Study|Withdrawal by Subject|1
6323740|NCT02904512|10065017|FG001|Overall Study|Withdrawal by Subject|0
6323741|NCT02904512|10065016|FG000|Overall Study|Transferred to ICU|1
6323742|NCT02904512|10065017|FG001|Overall Study|Transferred to ICU|0
6323743|NCT02904512|10065016|FG000|Overall Study|Minor Bleeding at site of device insertion|1
6323744|NCT02904512|10065017|FG001|Overall Study|Minor Bleeding at site of device insertion|0
6323745|NCT02904902|10065023|FG000|Overall Study|Withdrawal by Subject|1
6323746|NCT02904954|10065038|FG000|Neoadjuvant (Preoperative) to Surgery|Death|1
6323747|NCT02904954|10065039|FG001|Neoadjuvant (Preoperative) to Surgery|Death|1
6323748|NCT02904954|10065038|FG000|Neoadjuvant (Preoperative) to Surgery|Withdrawal by Subject|1
6323749|NCT02904954|10065039|FG001|Neoadjuvant (Preoperative) to Surgery|Withdrawal by Subject|0
6323750|NCT02904954|10065038|FG000|Neoadjuvant (Preoperative) to Surgery|Disease progression|2
6323751|NCT02904954|10065039|FG001|Neoadjuvant (Preoperative) to Surgery|Disease progression|3
6323752|NCT02904954|10065038|FG000|Adjuvant Durvalumab|Recurrence|2
6323753|NCT02904954|10065039|FG001|Adjuvant Durvalumab|Recurrence|0
6323754|NCT02904954|10065038|FG000|Adjuvant Durvalumab|Adverse Event|2
6323755|NCT02904954|10065039|FG001|Adjuvant Durvalumab|Adverse Event|6
6323756|NCT02904954|10065038|FG000|Adjuvant Durvalumab|Participant wishes|12
6323757|NCT02904954|10065039|FG001|Adjuvant Durvalumab|Participant wishes|5
6323758|NCT02904954|10065038|FG000|Adjuvant Durvalumab|Physician Decision|2
6323759|NCT02904954|10065039|FG001|Adjuvant Durvalumab|Physician Decision|1
6323760|NCT02904954|10065038|FG000|Adjuvant Durvalumab|Slow recovery after chemotherapy|1
6323761|NCT02904954|10065039|FG001|Adjuvant Durvalumab|Slow recovery after chemotherapy|0
6323762|NCT02904954|10065038|FG000|Adjuvant Durvalumab|Death|0
6323763|NCT02904954|10065039|FG001|Adjuvant Durvalumab|Death|1
6323764|NCT02904954|10065038|FG000|Adjuvant Durvalumab|Prostate cancer|1
6323765|NCT02904954|10065039|FG001|Adjuvant Durvalumab|Prostate cancer|0
6323766|NCT02904954|10065038|FG000|Adjuvant Durvalumab|Currently on treatment|1
6323767|NCT02904954|10065039|FG001|Adjuvant Durvalumab|Currently on treatment|3
6323768|NCT02905006|10065053|FG000|Overall Study|Adverse Event|1
6323769|NCT02905006|10065054|FG001|Overall Study|Adverse Event|1
6323770|NCT02905006|10065055|FG002|Overall Study|Adverse Event|1
6323771|NCT02905006|10065056|FG003|Overall Study|Adverse Event|1
6323772|NCT02905006|10065057|FG004|Overall Study|Adverse Event|0
6323773|NCT02905006|10065058|FG005|Overall Study|Adverse Event|1
6323774|NCT02905006|10065053|FG000|Overall Study|Lack of Efficacy|1
6323775|NCT02905006|10065054|FG001|Overall Study|Lack of Efficacy|0
6323776|NCT02905006|10065055|FG002|Overall Study|Lack of Efficacy|0
6323777|NCT02905006|10065056|FG003|Overall Study|Lack of Efficacy|0
6323778|NCT02905006|10065057|FG004|Overall Study|Lack of Efficacy|0
6323779|NCT02905006|10065058|FG005|Overall Study|Lack of Efficacy|0
6323780|NCT02905006|10065053|FG000|Overall Study|Protocol Violation|2
6323781|NCT02905006|10065054|FG001|Overall Study|Protocol Violation|0
6323782|NCT02905006|10065055|FG002|Overall Study|Protocol Violation|0
6323783|NCT02905006|10065056|FG003|Overall Study|Protocol Violation|0
6323784|NCT02905006|10065057|FG004|Overall Study|Protocol Violation|0
6323785|NCT02905006|10065058|FG005|Overall Study|Protocol Violation|0
6323786|NCT02905006|10065053|FG000|Overall Study|Lost to Follow-up|0
6323787|NCT02905006|10065054|FG001|Overall Study|Lost to Follow-up|0
6323788|NCT02905006|10065055|FG002|Overall Study|Lost to Follow-up|0
6323789|NCT02905006|10065056|FG003|Overall Study|Lost to Follow-up|1
6323790|NCT02905006|10065057|FG004|Overall Study|Lost to Follow-up|1
6323791|NCT02905006|10065058|FG005|Overall Study|Lost to Follow-up|0
6323792|NCT02905006|10065053|FG000|Overall Study|Withdrawal by Subject|0
6323793|NCT02905006|10065054|FG001|Overall Study|Withdrawal by Subject|0
6323794|NCT02905006|10065055|FG002|Overall Study|Withdrawal by Subject|1
6323795|NCT02905006|10065056|FG003|Overall Study|Withdrawal by Subject|1
6323796|NCT02905006|10065057|FG004|Overall Study|Withdrawal by Subject|0
6323797|NCT02905006|10065058|FG005|Overall Study|Withdrawal by Subject|1
6323798|NCT02905006|10065053|FG000|Overall Study|Screening exclusion criteria met|1
6323799|NCT02905006|10065054|FG001|Overall Study|Screening exclusion criteria met|0
6323800|NCT02905006|10065055|FG002|Overall Study|Screening exclusion criteria met|0
6323801|NCT02905006|10065056|FG003|Overall Study|Screening exclusion criteria met|0
6323802|NCT02905006|10065057|FG004|Overall Study|Screening exclusion criteria met|0
6323803|NCT02905006|10065058|FG005|Overall Study|Screening exclusion criteria met|0
6323804|NCT02905006|10065053|FG000|Overall Study|Lab withdrawal criterion met|0
6323805|NCT02905006|10065054|FG001|Overall Study|Lab withdrawal criterion met|1
6323806|NCT02905006|10065055|FG002|Overall Study|Lab withdrawal criterion met|2
6323807|NCT02905006|10065056|FG003|Overall Study|Lab withdrawal criterion met|2
6323808|NCT02905006|10065057|FG004|Overall Study|Lab withdrawal criterion met|2
6323809|NCT02905006|10065058|FG005|Overall Study|Lab withdrawal criterion met|1
6323810|NCT02905006|10065053|FG000|Overall Study|Positive for Tuberculosis|0
6323811|NCT02905006|10065054|FG001|Overall Study|Positive for Tuberculosis|1
6323812|NCT02905006|10065055|FG002|Overall Study|Positive for Tuberculosis|0
6323813|NCT02905006|10065056|FG003|Overall Study|Positive for Tuberculosis|0
6323814|NCT02905006|10065057|FG004|Overall Study|Positive for Tuberculosis|0
6323815|NCT02905006|10065058|FG005|Overall Study|Positive for Tuberculosis|0
6323816|NCT02905006|10065053|FG000|Overall Study|Subject positive for Hep B|0
6323817|NCT02905006|10065054|FG001|Overall Study|Subject positive for Hep B|0
6323818|NCT02905006|10065055|FG002|Overall Study|Subject positive for Hep B|1
6323819|NCT02905006|10065056|FG003|Overall Study|Subject positive for Hep B|0
6323820|NCT02905006|10065057|FG004|Overall Study|Subject positive for Hep B|0
6323821|NCT02905006|10065058|FG005|Overall Study|Subject positive for Hep B|0
6323822|NCT02905006|10065053|FG000|Overall Study|Patient moved abroad|0
6323823|NCT02905006|10065054|FG001|Overall Study|Patient moved abroad|0
6323824|NCT02905006|10065055|FG002|Overall Study|Patient moved abroad|0
6323825|NCT02905006|10065056|FG003|Overall Study|Patient moved abroad|1
6323826|NCT02905006|10065057|FG004|Overall Study|Patient moved abroad|0
6323827|NCT02905006|10065058|FG005|Overall Study|Patient moved abroad|0
6323828|NCT02905006|10065053|FG000|Overall Study|Patient randomized by mistake|0
6323829|NCT02905006|10065054|FG001|Overall Study|Patient randomized by mistake|0
6323830|NCT02905006|10065055|FG002|Overall Study|Patient randomized by mistake|0
6323831|NCT02905006|10065056|FG003|Overall Study|Patient randomized by mistake|0
6323832|NCT02905006|10065057|FG004|Overall Study|Patient randomized by mistake|0
6323833|NCT02905006|10065058|FG005|Overall Study|Patient randomized by mistake|1
6323834|NCT02905149|10065098|FG000|Overall Study|Lost to Follow-up|2
6323835|NCT02905149|10065099|FG001|Overall Study|Lost to Follow-up|0
6323836|NCT02905266|10065107|FG000|Treatment Phase Part 1|Participant Withdrew Consent|1
6323837|NCT02905266|10065108|FG001|Treatment Phase Part 1|Participant Withdrew Consent|0
6323838|NCT02905266|10065107|FG000|Treatment Phase Part 1|Disease Progression|6
6323839|NCT02905266|10065108|FG001|Treatment Phase Part 1|Disease Progression|7
6323840|NCT02905266|10065107|FG000|Treatment Phase Part 1|Study Drug Toxicity|22
6323841|NCT02905266|10065108|FG001|Treatment Phase Part 1|Study Drug Toxicity|16
6323842|NCT02905266|10065107|FG000|Transition From Part 1 to Part 2|Adverse event unrelated to study drug|1
6323843|NCT02905266|10065108|FG001|Transition From Part 1 to Part 2|Adverse event unrelated to study drug|0
6323844|NCT02905266|10065107|FG000|Transition From Part 1 to Part 2|Disease progression|2
6323845|NCT02905266|10065108|FG001|Transition From Part 1 to Part 2|Disease progression|1
6323846|NCT02905266|10065107|FG000|Transition From Part 1 to Part 2|Study drug toxicity|0
6323847|NCT02905266|10065108|FG001|Transition From Part 1 to Part 2|Study drug toxicity|4
6323848|NCT02905266|10065107|FG000|Transition From Part 1 to Part 2|Death|0
6323849|NCT02905266|10065108|FG001|Transition From Part 1 to Part 2|Death|1
6323850|NCT02905266|10065107|FG000|Transition From Part 1 to Part 2|Participant withdrew consent|0
6323851|NCT02905266|10065108|FG001|Transition From Part 1 to Part 2|Participant withdrew consent|1
6041394|NCT00376259|9639614|FG001|Overall Study|Patient request|0
6041395|NCT00376506|9639631|FG000|Overall Study|Death|0
6041396|NCT00376506|9639632|FG001|Overall Study|Death|2
6041397|NCT00376532|9639643|FG000|Overall Study|Lack sufficient blood sample|6
6041398|NCT00376532|9639644|FG001|Overall Study|Lack sufficient blood sample|6
6049008|NCT00420927|9648199|FG000|Period 2|Randomization error|0
6049009|NCT00420927|9648200|FG001|Period 2|Randomization error|0
6049010|NCT00420927|9648201|FG002|Period 2|Randomization error|0
6049011|NCT00420927|9648202|FG003|Period 2|Randomization error|0
6152333|NCT01119898|9789801|FG001|Overall Study|Randomized in error did not participate|0
6152334|NCT01119937|9789809|FG000|Overall Study|Adverse Event|11
6152335|NCT01119937|9789810|FG001|Overall Study|Adverse Event|5
6152336|NCT01119937|9789809|FG000|Overall Study|Protocol deviation|3
6152337|NCT01119937|9789810|FG001|Overall Study|Protocol deviation|1
6152338|NCT01119937|9789809|FG000|Overall Study|Unsatisfactory therapeutic effect|3
6152339|NCT01119937|9789810|FG001|Overall Study|Unsatisfactory therapeutic effect|0
6152340|NCT01119937|9789809|FG000|Overall Study|Withdrawal by Subject|2
6152341|NCT01119937|9789810|FG001|Overall Study|Withdrawal by Subject|1
6152342|NCT01119950|9789816|FG000|Overall Study|Adverse Event|25
6152343|NCT01119950|9789816|FG000|Overall Study|Withdrawal by Subject|9
6152344|NCT01119950|9789816|FG000|Overall Study|Protocol Violation|5
6152345|NCT01119950|9789816|FG000|Overall Study|Lost to Follow-up|4
6152346|NCT01119950|9789816|FG000|Overall Study|Administrative|2
6152347|NCT01119950|9789816|FG000|Overall Study|Abnormal lab value|1
6152348|NCT01119950|9789816|FG000|Overall Study|Death|1
6152349|NCT01119963|9789844|FG000|Overall Study|Lost to Follow-up|1
6152350|NCT01119963|9789845|FG001|Overall Study|Lost to Follow-up|1
6152351|NCT01120028|9789857|FG000|Period 1: Alemtuzumab or Basiliximab|Withdrawal by Subject|0
6152352|NCT01120028|9789858|FG001|Period 1: Alemtuzumab or Basiliximab|Withdrawal by Subject|5
6152353|NCT01120028|9789859|FG002|Period 1: Alemtuzumab or Basiliximab|Withdrawal by Subject|0
6041399|NCT00376675|9639673|FG000|Overall Study|Withdrawal by Subject|9
6041400|NCT00376675|9639674|FG001|Overall Study|Withdrawal by Subject|2
6041401|NCT00376675|9639673|FG000|Overall Study|Adverse Event|10
6152354|NCT01120028|9789860|FG003|Period 1: Alemtuzumab or Basiliximab|Withdrawal by Subject|0
6152355|NCT01120028|9789857|FG000|Period 1: Alemtuzumab or Basiliximab|Not transplanted|14
6152356|NCT01120028|9789858|FG001|Period 1: Alemtuzumab or Basiliximab|Not transplanted|18
6041402|NCT00376675|9639674|FG001|Overall Study|Adverse Event|5
6041403|NCT00376675|9639673|FG000|Overall Study|Other Reason|1
6041404|NCT00376675|9639674|FG001|Overall Study|Other Reason|7
6041405|NCT00376688|9639680|FG000|Overall Study|Adverse Event|3
6041406|NCT00376688|9639680|FG000|Overall Study|Death|1
6041407|NCT00376961|9639709|FG000|Initial Registration|Adverse Event|1
6041408|NCT00376961|9639710|FG001|Initial Registration|Adverse Event|0
6041409|NCT00376961|9639709|FG000|Initial Registration|Refusal Unrelated to Adverse Event|2
6041410|NCT00376961|9639710|FG001|Initial Registration|Refusal Unrelated to Adverse Event|0
6041411|NCT00376961|9639709|FG000|Initial Registration|Progression/relapse|1
6041412|NCT00376961|9639710|FG001|Initial Registration|Progression/relapse|0
6152357|NCT01120028|9789859|FG002|Period 1: Alemtuzumab or Basiliximab|Not transplanted|0
6152358|NCT01120028|9789860|FG003|Period 1: Alemtuzumab or Basiliximab|Not transplanted|0
6152359|NCT01120067|9789873|FG000|Overall Study|Lost to Follow-up|3
6152360|NCT01120067|9789874|FG001|Overall Study|Lost to Follow-up|1
6152361|NCT01120067|9789873|FG000|Overall Study|fail to engage >3 sessions|2
6152362|NCT01120067|9789874|FG001|Overall Study|fail to engage >3 sessions|0
6152363|NCT01120093|9789880|FG000|Treatment Period 1|Adverse Event|0
6152364|NCT01120093|9789881|FG001|Treatment Period 1|Adverse Event|0
6152365|NCT01120093|9789882|FG002|Treatment Period 1|Adverse Event|1
6152366|NCT01120093|9789883|FG003|Treatment Period 1|Adverse Event|0
6152367|NCT01120093|9789884|FG004|Treatment Period 1|Adverse Event|1
6152368|NCT01120093|9789880|FG000|Treatment Period 1|Withdrawal by Subject|0
6152369|NCT01120093|9789881|FG001|Treatment Period 1|Withdrawal by Subject|1
6152370|NCT01120093|9789882|FG002|Treatment Period 1|Withdrawal by Subject|0
6152371|NCT01120093|9789883|FG003|Treatment Period 1|Withdrawal by Subject|0
6152372|NCT01120093|9789884|FG004|Treatment Period 1|Withdrawal by Subject|0
6152373|NCT01120093|9789880|FG000|Treatment Period 2|Adverse Event|0
6152374|NCT01120093|9789881|FG001|Treatment Period 2|Adverse Event|0
6152375|NCT01120093|9789882|FG002|Treatment Period 2|Adverse Event|0
6152376|NCT01120093|9789883|FG003|Treatment Period 2|Adverse Event|1
6152377|NCT01120093|9789884|FG004|Treatment Period 2|Adverse Event|0
6152378|NCT01120093|9789880|FG000|Treatment Period 2|Withdrawal by Subject|0
6152379|NCT01120093|9789881|FG001|Treatment Period 2|Withdrawal by Subject|0
6152380|NCT01120093|9789882|FG002|Treatment Period 2|Withdrawal by Subject|0
6152381|NCT01120093|9789883|FG003|Treatment Period 2|Withdrawal by Subject|0
6152382|NCT01120093|9789884|FG004|Treatment Period 2|Withdrawal by Subject|1
6152383|NCT01120093|9789880|FG000|Treatment Period 3|Lack of Efficacy|0
6152384|NCT01120093|9789881|FG001|Treatment Period 3|Lack of Efficacy|0
6152385|NCT01120093|9789882|FG002|Treatment Period 3|Lack of Efficacy|0
6152386|NCT01120093|9789883|FG003|Treatment Period 3|Lack of Efficacy|1
6152387|NCT01120093|9789884|FG004|Treatment Period 3|Lack of Efficacy|0
6152388|NCT01120093|9789880|FG000|Treatment Period 3|Adverse Event|0
6152389|NCT01120093|9789881|FG001|Treatment Period 3|Adverse Event|0
6152390|NCT01120093|9789882|FG002|Treatment Period 3|Adverse Event|0
6152391|NCT01120093|9789883|FG003|Treatment Period 3|Adverse Event|0
6152392|NCT01120093|9789884|FG004|Treatment Period 3|Adverse Event|1
6152393|NCT01120093|9789880|FG000|Treatment Period 3|Withdrawal by Subject|0
6152394|NCT01120093|9789881|FG001|Treatment Period 3|Withdrawal by Subject|0
6152395|NCT01120093|9789882|FG002|Treatment Period 3|Withdrawal by Subject|1
6152396|NCT01120093|9789883|FG003|Treatment Period 3|Withdrawal by Subject|0
6152397|NCT01120093|9789884|FG004|Treatment Period 3|Withdrawal by Subject|0
6152398|NCT01120093|9789880|FG000|Treatment Period 4|Adverse Event|1
6152399|NCT01120093|9789881|FG001|Treatment Period 4|Adverse Event|0
6152400|NCT01120093|9789882|FG002|Treatment Period 4|Adverse Event|0
6152401|NCT01120093|9789883|FG003|Treatment Period 4|Adverse Event|0
6152402|NCT01120093|9789884|FG004|Treatment Period 4|Adverse Event|0
6152403|NCT01120093|9789880|FG000|Treatment Period 5|Adverse Event|0
6152404|NCT01120093|9789881|FG001|Treatment Period 5|Adverse Event|1
6152405|NCT01120093|9789882|FG002|Treatment Period 5|Adverse Event|0
6152406|NCT01120093|9789883|FG003|Treatment Period 5|Adverse Event|1
6152407|NCT01120093|9789884|FG004|Treatment Period 5|Adverse Event|0
6152408|NCT01120184|9789899|FG000|Overall Study|Adverse Event|0
6152409|NCT01120184|9789900|FG001|Overall Study|Adverse Event|1
6152410|NCT01120184|9789901|FG002|Overall Study|Adverse Event|0
6152411|NCT01120184|9789899|FG000|Overall Study|Lost to Follow-up|13
6152412|NCT01120184|9789900|FG001|Overall Study|Lost to Follow-up|13
6152413|NCT01120184|9789901|FG002|Overall Study|Lost to Follow-up|11
6152414|NCT01120184|9789899|FG000|Overall Study|Physician Decision|9
6152415|NCT01120184|9789900|FG001|Overall Study|Physician Decision|1
6152416|NCT01120184|9789901|FG002|Overall Study|Physician Decision|3
6152417|NCT01120184|9789899|FG000|Overall Study|Reason not Specified|8
6152418|NCT01120184|9789900|FG001|Overall Study|Reason not Specified|3
6152419|NCT01120184|9789901|FG002|Overall Study|Reason not Specified|12
6152420|NCT01120184|9789899|FG000|Overall Study|Sponsor Decision to Terminate Study|133
6152421|NCT01120184|9789900|FG001|Overall Study|Sponsor Decision to Terminate Study|144
6152422|NCT01120184|9789901|FG002|Overall Study|Sponsor Decision to Terminate Study|143
6152423|NCT01120184|9789899|FG000|Overall Study|Subject/ Guardian Decision to Withdraw|32
6152424|NCT01120184|9789900|FG001|Overall Study|Subject/ Guardian Decision to Withdraw|29
6152425|NCT01120184|9789901|FG002|Overall Study|Subject/ Guardian Decision to Withdraw|25
6152426|NCT01120184|9789899|FG000|Overall Study|Death|170
6152427|NCT01120184|9789900|FG001|Overall Study|Death|176
6152428|NCT01120184|9789901|FG002|Overall Study|Death|169
6152429|NCT01120210|9789921|FG000|MAIN INFUSION|Adverse Event|1
6152430|NCT01120210|9789922|FG001|MAIN INFUSION|Adverse Event|0
6152431|NCT01120210|9789921|FG000|MAIN INFUSION|Withdrawal by Subject|0
6152432|NCT01120210|9789922|FG001|MAIN INFUSION|Withdrawal by Subject|1
6152433|NCT01120275|9789949|FG000|Overall Study|Adverse Event|3
6152434|NCT01120275|9789949|FG000|Overall Study|Progression|27
6152435|NCT01120275|9789949|FG000|Overall Study|Ineligible|3
6152436|NCT01120275|9789949|FG000|Overall Study|Withdrawal by Subject|1
6152437|NCT01120275|9789949|FG000|Overall Study|Refusal|1
6152438|NCT01120275|9789949|FG000|Overall Study|Not specific|1
6152439|NCT01120379|9789954|FG000|One Year Timepoint|Withdrawal by Subject|41
6152440|NCT01120379|9789954|FG000|One Year Timepoint|Lost to Follow-up|115
6152441|NCT01120379|9789954|FG000|One Year Timepoint|Death|108
6152442|NCT01120379|9789954|FG000|One Year Timepoint|Physician Decision|9
6152443|NCT01120379|9789954|FG000|One Year Timepoint|Any other reason for early termination|5
6152444|NCT01120379|9789954|FG000|Two Year Timepoint|Withdrawal by Subject|11
6152445|NCT01120379|9789954|FG000|Two Year Timepoint|Lost to Follow-up|87
6152446|NCT01120379|9789954|FG000|Two Year Timepoint|Death|123
6152447|NCT01120379|9789954|FG000|Two Year Timepoint|Physician Decision|12
6152448|NCT01120379|9789954|FG000|Two Year Timepoint|Any other reason for early termination|4
6152449|NCT01120379|9789954|FG000|Three Year Timepoint|Withdrawal by Subject|25
6152450|NCT01120379|9789954|FG000|Three Year Timepoint|Lost to Follow-up|43
6152451|NCT01120379|9789954|FG000|Three Year Timepoint|Death|120
6152452|NCT01120379|9789954|FG000|Three Year Timepoint|Physician Decision|9
6152453|NCT01120379|9789954|FG000|Three Year Timepoint|Any other reason for early termination|17
6152454|NCT01120379|9789954|FG000|Four Year Timepoint|Withdrawal by Subject|5
6152455|NCT01120379|9789954|FG000|Four Year Timepoint|Lost to Follow-up|10
6152456|NCT01120379|9789954|FG000|Four Year Timepoint|Death|131
6152457|NCT01120379|9789954|FG000|Four Year Timepoint|Physician Decision|5
6152458|NCT01120379|9789954|FG000|Four Year Timepoint|Any other reason for early termination|217
6152459|NCT01120600|9789971|FG000|Overall Study|Adverse Event|7
6152460|NCT01120600|9789972|FG001|Overall Study|Adverse Event|7
6152461|NCT01120600|9789971|FG000|Overall Study|Excessive Bone Loss|0
6152462|NCT01120600|9789972|FG001|Overall Study|Excessive Bone Loss|4
6152463|NCT01120600|9789971|FG000|Overall Study|Lost to Follow-up|1
6152464|NCT01120600|9789972|FG001|Overall Study|Lost to Follow-up|3
6152465|NCT01120600|9789971|FG000|Overall Study|Physician Decision|1
6152466|NCT01120600|9789972|FG001|Overall Study|Physician Decision|3
6152467|NCT01120600|9789971|FG000|Overall Study|Protocol Violation|0
6152468|NCT01120600|9789972|FG001|Overall Study|Protocol Violation|4
6152469|NCT01120600|9789971|FG000|Overall Study|Withdrawal by Subject|10
6152470|NCT01120600|9789972|FG001|Overall Study|Withdrawal by Subject|11
6152471|NCT01120626|9789980|FG000|Overall Study|Withdrawal by Subject|1
6152472|NCT01120626|9789981|FG001|Overall Study|Withdrawal by Subject|0
6152473|NCT01120691|9790007|FG000|Overall Study|Adverse Event|59
6152474|NCT01120691|9790008|FG001|Overall Study|Adverse Event|67
6152475|NCT01120691|9790009|FG002|Overall Study|Adverse Event|47
6152476|NCT01120691|9790007|FG000|Overall Study|Subject withdrew consent|33
6152477|NCT01120691|9790008|FG001|Overall Study|Subject withdrew consent|50
6152478|NCT01120691|9790009|FG002|Overall Study|Subject withdrew consent|44
6152479|NCT01120691|9790007|FG000|Overall Study|Death|21
6152480|NCT01120691|9790008|FG001|Overall Study|Death|22
6152481|NCT01120691|9790009|FG002|Overall Study|Death|24
6152482|NCT01120691|9790007|FG000|Overall Study|Unsatisfactory therapeutic effect|18
6152483|NCT01120691|9790008|FG001|Overall Study|Unsatisfactory therapeutic effect|32
6152484|NCT01120691|9790009|FG002|Overall Study|Unsatisfactory therapeutic effect|38
6152485|NCT01120691|9790007|FG000|Overall Study|Administrative problems|15
6152486|NCT01120691|9790008|FG001|Overall Study|Administrative problems|8
6152487|NCT01120691|9790009|FG002|Overall Study|Administrative problems|9
6152488|NCT01120691|9790007|FG000|Overall Study|Protocol deviation|13
6152489|NCT01120691|9790008|FG001|Overall Study|Protocol deviation|12
6152490|NCT01120691|9790009|FG002|Overall Study|Protocol deviation|12
6152491|NCT01120691|9790007|FG000|Overall Study|Lost to Follow-up|5
6152492|NCT01120691|9790008|FG001|Overall Study|Lost to Follow-up|6
6152493|NCT01120691|9790009|FG002|Overall Study|Lost to Follow-up|4
6152494|NCT01120691|9790007|FG000|Overall Study|Abnormal test procedure result(s)|3
6152495|NCT01120691|9790008|FG001|Overall Study|Abnormal test procedure result(s)|2
6152496|NCT01120691|9790009|FG002|Overall Study|Abnormal test procedure result(s)|1
6152497|NCT01120691|9790007|FG000|Overall Study|Patient's inability to use the device|3
6152498|NCT01120691|9790008|FG001|Overall Study|Patient's inability to use the device|1
6152499|NCT01120691|9790009|FG002|Overall Study|Patient's inability to use the device|0
6152500|NCT01120691|9790007|FG000|Overall Study|Abnormal laboratory value(s)|1
6152501|NCT01120691|9790008|FG001|Overall Study|Abnormal laboratory value(s)|3
6152502|NCT01120691|9790009|FG002|Overall Study|Abnormal laboratory value(s)|4
6152503|NCT01120717|9790100|FG000|Overall Study|Withdrawal by Subject|11
6152504|NCT01120717|9790101|FG001|Overall Study|Withdrawal by Subject|6
6152505|NCT01120717|9790100|FG000|Overall Study|Adverse Event|10
6152506|NCT01120717|9790101|FG001|Overall Study|Adverse Event|6
6152507|NCT01120717|9790100|FG000|Overall Study|Protocol Deviation|2
6152508|NCT01120717|9790101|FG001|Overall Study|Protocol Deviation|5
6152509|NCT01120717|9790100|FG000|Overall Study|Unsatisfactory Therapeutic Effect|3
6152510|NCT01120717|9790101|FG001|Overall Study|Unsatisfactory Therapeutic Effect|3
6041413|NCT00376961|9639709|FG000|Initial Registration|Ineligible|3
6152511|NCT01120717|9790100|FG000|Overall Study|Lost to Follow-up|2
6152512|NCT01120717|9790101|FG001|Overall Study|Lost to Follow-up|3
6152513|NCT01120717|9790100|FG000|Overall Study|Death|3
6152514|NCT01120717|9790101|FG001|Overall Study|Death|1
6152515|NCT01120717|9790100|FG000|Overall Study|Abnormal Test Procedure Result(s)|1
6152516|NCT01120717|9790101|FG001|Overall Study|Abnormal Test Procedure Result(s)|0
6152517|NCT01120756|9790109|FG000|Overall Study|Withdrawal by Subject|1
6152518|NCT01120756|9790110|FG001|Overall Study|Withdrawal by Subject|1
6152519|NCT01120782|9790116|FG000|Overall Study|Test article shipping error|11
6152520|NCT01120899|9790128|FG000|Overall Study|Withdrawal by Subject|3
6152521|NCT01121146|9790138|FG000|Overall Study|Death|17
6152522|NCT01121146|9790139|FG001|Overall Study|Death|15
6152523|NCT01121146|9790138|FG000|Overall Study|Adverse Event|2
6152524|NCT01121146|9790139|FG001|Overall Study|Adverse Event|11
6152525|NCT01121146|9790138|FG000|Overall Study|Lost to Follow-up|7
6152526|NCT01121146|9790139|FG001|Overall Study|Lost to Follow-up|16
6152527|NCT01121185|9790158|FG000|Overall Study|Not infused|0
6152528|NCT01121185|9790159|FG001|Overall Study|Not infused|1
6152529|NCT01121185|9790158|FG000|Overall Study|Not transplanted|1
6152530|NCT01121185|9790159|FG001|Overall Study|Not transplanted|0
6152531|NCT01121263|9790200|FG000|Overall Study|Death|3
6152532|NCT01121263|9790201|FG001|Overall Study|Death|2
6152533|NCT01121263|9790200|FG000|Overall Study|Lost to Follow-up|22
6152534|NCT01121263|9790201|FG001|Overall Study|Lost to Follow-up|12
6152535|NCT01121263|9790200|FG000|Overall Study|Withdrawal by Subject|0
6152536|NCT01121263|9790201|FG001|Overall Study|Withdrawal by Subject|1
6152537|NCT01121393|9790211|FG000|Overall Study|Progressive disease|201
6152538|NCT01121393|9790212|FG001|Overall Study|Progressive disease|20
6152539|NCT01121393|9790211|FG000|Overall Study|Other Adverse events|24
6152540|NCT01121393|9790212|FG001|Overall Study|Other Adverse events|45
6152541|NCT01121393|9790211|FG000|Overall Study|Non-compliant with protocol|0
6152542|NCT01121393|9790212|FG001|Overall Study|Non-compliant with protocol|3
6152543|NCT01121393|9790211|FG000|Overall Study|Lost to Follow-up|1
6152544|NCT01121393|9790212|FG001|Overall Study|Lost to Follow-up|0
6152545|NCT01121393|9790211|FG000|Overall Study|Refused cont. medication|7
6152546|NCT01121393|9790212|FG001|Overall Study|Refused cont. medication|7
6041414|NCT00376961|9639710|FG001|Initial Registration|Ineligible|0
6152547|NCT01121393|9790211|FG000|Overall Study|Not treated|3
6152548|NCT01121393|9790212|FG001|Overall Study|Not treated|9
6152549|NCT01121393|9790211|FG000|Overall Study|Other than listed|6
6152550|NCT01121393|9790212|FG001|Overall Study|Other than listed|0
6152551|NCT01121406|9790226|FG000|Overall Study|Progressive disease RECIST|44
6152552|NCT01121406|9790227|FG001|Overall Study|Progressive disease RECIST|28
6152553|NCT01121406|9790226|FG000|Overall Study|Wors. or AE of underlying cancer disease|4
6152554|NCT01121406|9790227|FG001|Overall Study|Wors. or AE of underlying cancer disease|6
6152555|NCT01121406|9790226|FG000|Overall Study|Other AE|3
6152556|NCT01121406|9790227|FG001|Overall Study|Other AE|10
6152557|NCT01121406|9790226|FG000|Overall Study|Non-compliant with protocol|0
6152558|NCT01121406|9790227|FG001|Overall Study|Non-compliant with protocol|2
6152559|NCT01121406|9790226|FG000|Overall Study|Lost to Follow-up|0
6152560|NCT01121406|9790227|FG001|Overall Study|Lost to Follow-up|1
6152561|NCT01121406|9790226|FG000|Overall Study|Refused continuation of study med.|1
6152562|NCT01121406|9790227|FG001|Overall Study|Refused continuation of study med.|2
6152563|NCT01121406|9790226|FG000|Overall Study|Reason other than specified above|2
6152564|NCT01121406|9790227|FG001|Overall Study|Reason other than specified above|6
6152565|NCT01121406|9790226|FG000|Overall Study|Not treated|1
6152566|NCT01121406|9790227|FG001|Overall Study|Not treated|0
6152567|NCT01121484|9790238|FG000|Overall Study|Adverse Event|12
6152568|NCT01121484|9790239|FG001|Overall Study|Adverse Event|5
6152569|NCT01121484|9790238|FG000|Overall Study|Lack of Efficacy|3
6152570|NCT01121484|9790239|FG001|Overall Study|Lack of Efficacy|11
6152571|NCT01121484|9790238|FG000|Overall Study|Lost to Follow-up|5
6152572|NCT01121484|9790239|FG001|Overall Study|Lost to Follow-up|9
6152573|NCT01121484|9790238|FG000|Overall Study|Physician Decision|0
6152574|NCT01121484|9790239|FG001|Overall Study|Physician Decision|3
6152575|NCT01121484|9790238|FG000|Overall Study|Protocol Violation|1
6152576|NCT01121484|9790239|FG001|Overall Study|Protocol Violation|0
6152577|NCT01121484|9790238|FG000|Overall Study|Withdrawal by Subject|8
6152578|NCT01121484|9790239|FG001|Overall Study|Withdrawal by Subject|7
6152579|NCT01121484|9790238|FG000|Overall Study|Discontinuation of study by sponsor|0
6152580|NCT01121484|9790239|FG001|Overall Study|Discontinuation of study by sponsor|1
6152581|NCT01121484|9790238|FG000|Overall Study|Other|3
6152582|NCT01121484|9790239|FG001|Overall Study|Other|3
6152583|NCT01121484|9790238|FG000|Overall Study|Randomized, not treated|1
6152584|NCT01121484|9790239|FG001|Overall Study|Randomized, not treated|4
6152585|NCT01121536|9790245|FG000|Overall Study|Adverse Event|63
6152586|NCT01121536|9790245|FG000|Overall Study|Lack of Efficacy|35
6152587|NCT01121536|9790245|FG000|Overall Study|Withdrawal by Subject|65
6152588|NCT01121536|9790245|FG000|Overall Study|Protocol Violation|20
6152589|NCT01121536|9790245|FG000|Overall Study|Noncompliance with study medication|12
6152590|NCT01121536|9790245|FG000|Overall Study|Noncompliance with study procedures|9
6152591|NCT01121536|9790245|FG000|Overall Study|Lost to Follow-up|39
6041415|NCT00376961|9639709|FG000|Maintenance|Adverse Event|0
6041416|NCT00376961|9639710|FG001|Maintenance|Adverse Event|1
6041417|NCT00376961|9639709|FG000|Maintenance|Refusal Unrelated to Adverse Event|0
6041418|NCT00376961|9639710|FG001|Maintenance|Refusal Unrelated to Adverse Event|1
6041419|NCT00376961|9639709|FG000|Maintenance|Progression/relapse|0
6041420|NCT00376961|9639710|FG001|Maintenance|Progression/relapse|18
6041421|NCT00376961|9639709|FG000|Maintenance|Ineligible|0
6041422|NCT00376961|9639710|FG001|Maintenance|Ineligible|3
6041423|NCT00377156|9639720|FG000|Overall Study|Death|23
6041424|NCT00377156|9639721|FG001|Overall Study|Death|19
6041425|NCT00377156|9639720|FG000|Overall Study|Withdrawal by Subject|16
6041426|NCT00377156|9639721|FG001|Overall Study|Withdrawal by Subject|24
6041427|NCT00377156|9639720|FG000|Overall Study|Had follow-up <90 d|3
6041428|NCT00377156|9639721|FG001|Overall Study|Had follow-up <90 d|6
6041429|NCT00377156|9639720|FG000|Overall Study|Cancellation|1
6041430|NCT00377156|9639721|FG001|Overall Study|Cancellation|0
6041431|NCT00377156|9639720|FG000|Overall Study|Refused testing|0
6041432|NCT00377156|9639721|FG001|Overall Study|Refused testing|1
6041433|NCT00377156|9639720|FG000|Overall Study|Ineligible|0
6041434|NCT00377156|9639721|FG001|Overall Study|Ineligible|1
6041435|NCT00377156|9639720|FG000|Overall Study|Disability or language problem|0
6041436|NCT00377156|9639721|FG001|Overall Study|Disability or language problem|1
6041437|NCT00377156|9639720|FG000|Overall Study|Other|5
6041438|NCT00377156|9639721|FG001|Overall Study|Other|2
6152592|NCT01121536|9790245|FG000|Overall Study|Other|118
6152593|NCT01121549|9790249|FG000|Overall Study|Adverse Event|10
6152594|NCT01121549|9790249|FG000|Overall Study|Lack of Efficacy|11
6152595|NCT01121549|9790249|FG000|Overall Study|Lost to Follow-up|12
6152596|NCT01121549|9790249|FG000|Overall Study|Did not meet entrance criteria|9
6041439|NCT00377234|9639731|FG000|Overall Study|Adverse Event|14
6152597|NCT01121549|9790249|FG000|Overall Study|Study terminated by sponsor|197
6152598|NCT01121549|9790249|FG000|Overall Study|Pregnancy|1
6152599|NCT01121549|9790249|FG000|Overall Study|Protocol Violation|33
6152600|NCT01121549|9790249|FG000|Overall Study|Withdrawal by Subject|16
6152601|NCT01121549|9790249|FG000|Overall Study|Other|58
6152602|NCT01121562|9790253|FG000|Overall Study|Objective progression or relapse|8
6152603|NCT01121562|9790253|FG000|Overall Study|Withdrawal by Subject|1
6152604|NCT01121562|9790253|FG000|Overall Study|Adverse Event|1
6152605|NCT01121562|9790253|FG000|Overall Study|Sponsor Decision|1
6152606|NCT01121562|9790253|FG000|Overall Study|Met study discontinuation criteria|1
6152607|NCT01121575|9790263|FG000|Overall Study|Participant Refused Further Follow-Up|0
6152608|NCT01121575|9790264|FG001|Overall Study|Participant Refused Further Follow-Up|0
6152609|NCT01121575|9790265|FG002|Overall Study|Participant Refused Further Follow-Up|0
6152610|NCT01121575|9790266|FG003|Overall Study|Participant Refused Further Follow-Up|0
6041440|NCT00377234|9639732|FG001|Overall Study|Adverse Event|17
6041441|NCT00377234|9639731|FG000|Overall Study|Withdrawal by Subject|11
6152611|NCT01121575|9790267|FG004|Overall Study|Participant Refused Further Follow-Up|5
6041442|NCT00377234|9639732|FG001|Overall Study|Withdrawal by Subject|9
6041443|NCT00377234|9639731|FG000|Overall Study|Lost to Follow-up|4
6041444|NCT00377234|9639732|FG001|Overall Study|Lost to Follow-up|2
6041445|NCT00377234|9639731|FG000|Overall Study|Administrative|2
6041446|NCT00377234|9639732|FG001|Overall Study|Administrative|1
6041447|NCT00377234|9639731|FG000|Overall Study|Not assigned|3
6191469|NCT01423253|9848299|FG000|Overall Study|Lack of Efficacy|2
6152612|NCT01121575|9790268|FG005|Overall Study|Participant Refused Further Follow-Up|1
6152613|NCT01121575|9790263|FG000|Overall Study|Unspecified Reasons|8
6152614|NCT01121575|9790264|FG001|Overall Study|Unspecified Reasons|6
6152615|NCT01121575|9790265|FG002|Overall Study|Unspecified Reasons|7
6152616|NCT01121575|9790266|FG003|Overall Study|Unspecified Reasons|5
6152617|NCT01121575|9790267|FG004|Overall Study|Unspecified Reasons|13
6152618|NCT01121575|9790268|FG005|Overall Study|Unspecified Reasons|10
6152619|NCT01121575|9790263|FG000|Overall Study|Death|6
6152620|NCT01121575|9790264|FG001|Overall Study|Death|0
6152621|NCT01121575|9790265|FG002|Overall Study|Death|0
6152622|NCT01121575|9790266|FG003|Overall Study|Death|1
6152623|NCT01121575|9790267|FG004|Overall Study|Death|7
6152624|NCT01121575|9790268|FG005|Overall Study|Death|1
6152625|NCT01121666|9790289|FG000|Overall Study|Protocol Violation|29
6152626|NCT01121666|9790290|FG001|Overall Study|Protocol Violation|10
6152627|NCT01121757|9790298|FG000|First Drug|Death|1
6152628|NCT01121757|9790299|FG001|First Drug|Death|0
6152629|NCT01121757|9790298|FG000|First Drug|Disease Progression|0
6152630|NCT01121757|9790299|FG001|First Drug|Disease Progression|2
6152631|NCT01121757|9790298|FG000|Combination|Physician Decision|0
6152632|NCT01121757|9790299|FG001|Combination|Physician Decision|1
6152633|NCT01121757|9790298|FG000|Combination|Disease Progression|2
6152634|NCT01121757|9790299|FG001|Combination|Disease Progression|0
6152635|NCT01121900|9790307|FG000|First Intervention Period|Adverse Event|1
6152636|NCT01121900|9790308|FG001|First Intervention Period|Adverse Event|1
6152637|NCT01121900|9790307|FG000|Washout Period of 7 Days|Withdrawal by Subject|0
6152638|NCT01121900|9790308|FG001|Washout Period of 7 Days|Withdrawal by Subject|1
6152639|NCT01121913|9790314|FG000|First Intervention Period|Adverse Event|0
6152640|NCT01121913|9790315|FG001|First Intervention Period|Adverse Event|0
6152641|NCT01121913|9790316|FG002|First Intervention Period|Adverse Event|1
6152642|NCT01121913|9790317|FG003|First Intervention Period|Adverse Event|0
6152643|NCT01121913|9790314|FG000|First Washout Period|Withdrawal by Subject|1
6152644|NCT01121913|9790315|FG001|First Washout Period|Withdrawal by Subject|0
6152645|NCT01121913|9790316|FG002|First Washout Period|Withdrawal by Subject|0
6152646|NCT01121913|9790317|FG003|First Washout Period|Withdrawal by Subject|0
6152647|NCT01121913|9790314|FG000|Second Intervention Period|Adverse Event|0
6152648|NCT01121913|9790315|FG001|Second Intervention Period|Adverse Event|0
6152649|NCT01121913|9790316|FG002|Second Intervention Period|Adverse Event|1
6152650|NCT01121913|9790317|FG003|Second Intervention Period|Adverse Event|0
6152651|NCT01121913|9790314|FG000|Second Washout Period|Withdrawal by Subject|0
6152652|NCT01121913|9790315|FG001|Second Washout Period|Withdrawal by Subject|0
6152653|NCT01121913|9790316|FG002|Second Washout Period|Withdrawal by Subject|1
6152654|NCT01121913|9790317|FG003|Second Washout Period|Withdrawal by Subject|0
6152655|NCT01121913|9790314|FG000|Third Washout Period|Adverse Event|1
6152656|NCT01121913|9790315|FG001|Third Washout Period|Adverse Event|0
6152657|NCT01121913|9790316|FG002|Third Washout Period|Adverse Event|0
6152658|NCT01121913|9790317|FG003|Third Washout Period|Adverse Event|0
6152659|NCT01121926|9790327|FG000|First Intervention Period|Adverse Event|1
6152660|NCT01121926|9790328|FG001|First Intervention Period|Adverse Event|0
6152661|NCT01121926|9790327|FG000|Washout Period|Adverse Event|0
6152662|NCT01121926|9790328|FG001|Washout Period|Adverse Event|1
6152663|NCT01121926|9790327|FG000|Washout Period|Positive pregnancy test|0
6152664|NCT01121926|9790328|FG001|Washout Period|Positive pregnancy test|1
6152665|NCT01121991|9790341|FG000|Overall Study|Lack of Ovarian Response|2
6152666|NCT01121991|9790341|FG000|Overall Study|No Oocytes Retrieved|3
6152667|NCT01121991|9790341|FG000|Overall Study|No Fertilization|1
6152668|NCT01122173|9790396|FG000|Overall Study|Lost to Follow-up|3
6152669|NCT01122173|9790396|FG000|Overall Study|Withdrawal by Subject|3
6152670|NCT01122173|9790396|FG000|Overall Study|Left study for other reasons|3
6152671|NCT01122264|9790449|FG000|Overall Study|Adverse Event|6
6152672|NCT01122264|9790450|FG001|Overall Study|Adverse Event|5
6152673|NCT01122264|9790451|FG002|Overall Study|Adverse Event|7
6152674|NCT01122264|9790449|FG000|Overall Study|Death|1
6152675|NCT01122264|9790450|FG001|Overall Study|Death|0
6152676|NCT01122264|9790451|FG002|Overall Study|Death|0
6041448|NCT00377234|9639732|FG001|Overall Study|Not assigned|2
6041449|NCT00377260|9639746|FG000|Overall Study|Lost to Follow-up|0
6041450|NCT00377260|9639747|FG001|Overall Study|Lost to Follow-up|1
6152677|NCT01122264|9790449|FG000|Overall Study|Lost to Follow-up|5
6152678|NCT01122264|9790450|FG001|Overall Study|Lost to Follow-up|9
6152679|NCT01122264|9790451|FG002|Overall Study|Lost to Follow-up|13
6152680|NCT01122264|9790449|FG000|Overall Study|Entry Criteria Not Met|1
6152681|NCT01122264|9790450|FG001|Overall Study|Entry Criteria Not Met|0
6152682|NCT01122264|9790451|FG002|Overall Study|Entry Criteria Not Met|0
6152683|NCT01122264|9790449|FG000|Overall Study|Protocol Violation|7
6152684|NCT01122264|9790450|FG001|Overall Study|Protocol Violation|7
6152685|NCT01122264|9790451|FG002|Overall Study|Protocol Violation|9
6152686|NCT01122264|9790449|FG000|Overall Study|Withdrawal by Subject|6
6152687|NCT01122264|9790450|FG001|Overall Study|Withdrawal by Subject|6
6152688|NCT01122264|9790451|FG002|Overall Study|Withdrawal by Subject|16
6152689|NCT01122264|9790449|FG000|Overall Study|Physician Decision|3
6152690|NCT01122264|9790450|FG001|Overall Study|Physician Decision|1
6152691|NCT01122264|9790451|FG002|Overall Study|Physician Decision|1
6152692|NCT01122264|9790449|FG000|Overall Study|Lack of Efficacy|3
6152693|NCT01122264|9790450|FG001|Overall Study|Lack of Efficacy|1
6152694|NCT01122264|9790451|FG002|Overall Study|Lack of Efficacy|1
6152695|NCT01122394|9790469|FG000|Overall Study|Withdrawal by Subject|1
6152696|NCT01122394|9790470|FG001|Overall Study|Withdrawal by Subject|1
6152697|NCT01122394|9790469|FG000|Overall Study|Lost to Follow-up|2
6152698|NCT01122394|9790470|FG001|Overall Study|Lost to Follow-up|2
6152699|NCT01122394|9790469|FG000|Overall Study|Adverse Event|0
6152700|NCT01122394|9790470|FG001|Overall Study|Adverse Event|1
6152701|NCT01122576|9790490|FG000|Pre-Cataract Surgery|Withdrawal by Subject|0
6152702|NCT01122576|9790491|FG001|Pre-Cataract Surgery|Withdrawal by Subject|1
6152703|NCT01122576|9790492|FG002|Pre-Cataract Surgery|Withdrawal by Subject|2
6152704|NCT01122576|9790490|FG000|Post-Cataract Surgery|Central Macular Edema|0
6152705|NCT01122576|9790491|FG001|Post-Cataract Surgery|Central Macular Edema|0
6152706|NCT01122576|9790492|FG002|Post-Cataract Surgery|Central Macular Edema|1
6152707|NCT01122576|9790490|FG000|Post-Cataract Surgery|Fellow Eye Explanted|0
6152708|NCT01122576|9790491|FG001|Post-Cataract Surgery|Fellow Eye Explanted|0
6152709|NCT01122576|9790492|FG002|Post-Cataract Surgery|Fellow Eye Explanted|1
6152710|NCT01122680|9790503|FG000|Period 1 (4 Weeks)|Adverse Event|1
6152711|NCT01122680|9790504|FG001|Period 1 (4 Weeks)|Adverse Event|0
6152712|NCT01122680|9790505|FG002|Period 1 (4 Weeks)|Adverse Event|0
6152713|NCT01122680|9790506|FG003|Period 1 (4 Weeks)|Adverse Event|0
6152714|NCT01122680|9790503|FG000|Period 1 (4 Weeks)|Protocol Violation|1
6152715|NCT01122680|9790504|FG001|Period 1 (4 Weeks)|Protocol Violation|0
6152716|NCT01122680|9790505|FG002|Period 1 (4 Weeks)|Protocol Violation|0
6152717|NCT01122680|9790506|FG003|Period 1 (4 Weeks)|Protocol Violation|0
6152718|NCT01122680|9790503|FG000|Period 1 (4 Weeks)|Other|1
6152719|NCT01122680|9790504|FG001|Period 1 (4 Weeks)|Other|1
6152720|NCT01122680|9790505|FG002|Period 1 (4 Weeks)|Other|0
6152721|NCT01122680|9790506|FG003|Period 1 (4 Weeks)|Other|0
6152722|NCT01122680|9790503|FG000|Period 2 (4 Weeks)|Protocol Violation|0
6152723|NCT01122680|9790504|FG001|Period 2 (4 Weeks)|Protocol Violation|0
6152724|NCT01122680|9790505|FG002|Period 2 (4 Weeks)|Protocol Violation|0
6152725|NCT01122680|9790506|FG003|Period 2 (4 Weeks)|Protocol Violation|1
6152726|NCT01122680|9790503|FG000|Period 2 (4 Weeks)|Other|1
6152727|NCT01122680|9790504|FG001|Period 2 (4 Weeks)|Other|0
6152728|NCT01122680|9790505|FG002|Period 2 (4 Weeks)|Other|0
6152729|NCT01122680|9790506|FG003|Period 2 (4 Weeks)|Other|0
6152730|NCT01122680|9790503|FG000|Period 3 (4 Weeks)|Adverse Event|1
6152731|NCT01122680|9790504|FG001|Period 3 (4 Weeks)|Adverse Event|0
6152732|NCT01122680|9790505|FG002|Period 3 (4 Weeks)|Adverse Event|0
6152733|NCT01122680|9790506|FG003|Period 3 (4 Weeks)|Adverse Event|0
6041451|NCT00377260|9639746|FG000|Overall Study|Withdrawal by Subject|2
6041452|NCT00377260|9639747|FG001|Overall Study|Withdrawal by Subject|4
6041453|NCT00377299|9639755|FG000|Overall Study|Lost to Follow-up|14
6041454|NCT00377299|9639756|FG001|Overall Study|Lost to Follow-up|19
6041455|NCT00377299|9639755|FG000|Overall Study|Adverse Event|0
6041456|NCT00377299|9639756|FG001|Overall Study|Adverse Event|1
6041457|NCT00377299|9639755|FG000|Overall Study|Withdrawal by Subject|5
6041458|NCT00377299|9639756|FG001|Overall Study|Withdrawal by Subject|4
6041459|NCT00377312|9639765|FG000|Overall Study|Adverse Event|1
6041460|NCT00377312|9639766|FG001|Overall Study|Adverse Event|1
6041461|NCT00377364|9639774|FG000|Overall Study|Lost to Follow-up|1
6041462|NCT00377364|9639775|FG001|Overall Study|Lost to Follow-up|0
6041463|NCT00377364|9639774|FG000|Overall Study|Withdrawal by Subject|1
6041464|NCT00377364|9639775|FG001|Overall Study|Withdrawal by Subject|0
6041465|NCT00377403|9639785|FG000|Overall Study|Unable to contact for telephone intervie|4
6041466|NCT00377403|9639786|FG001|Overall Study|Unable to contact for telephone intervie|7
6041467|NCT00377429|9639792|FG000|Overall Study|Withdrawal by Subject|5
6041468|NCT00377429|9639792|FG000|Overall Study|Adverse Event|8
6041469|NCT00377429|9639792|FG000|Overall Study|Physician Decision|1
6041470|NCT00377429|9639792|FG000|Overall Study|Patient non-compliance|1
6041471|NCT00377520|9639796|FG000|Overall Study|Ineligible (Prior radiation)|1
6041472|NCT00377611|9639811|FG000|Overall Study|Adverse Event|2
6041473|NCT00377611|9639812|FG001|Overall Study|Adverse Event|9
6041474|NCT00377611|9639811|FG000|Overall Study|Protocol Violation|2
6041475|NCT00377611|9639812|FG001|Overall Study|Protocol Violation|0
6041476|NCT00377611|9639811|FG000|Overall Study|Withdrawal by Subject|0
6041477|NCT00377611|9639812|FG001|Overall Study|Withdrawal by Subject|5
6041478|NCT00377611|9639811|FG000|Overall Study|Lost to Follow-up|18
6041479|NCT00377611|9639812|FG001|Overall Study|Lost to Follow-up|16
6041480|NCT00377611|9639811|FG000|Overall Study|Other|0
6041481|NCT00377611|9639812|FG001|Overall Study|Other|3
6041482|NCT00377637|9639823|FG000|Induction Phase|Adverse Event|12
6041483|NCT00377637|9639824|FG001|Induction Phase|Adverse Event|21
6041484|NCT00377637|9639825|FG002|Induction Phase|Adverse Event|0
6041485|NCT00377637|9639826|FG003|Induction Phase|Adverse Event|0
6041486|NCT00377637|9639823|FG000|Induction Phase|Deterioration/serum creatinine|2
6041487|NCT00377637|9639824|FG001|Induction Phase|Deterioration/serum creatinine|0
6041488|NCT00377637|9639825|FG002|Induction Phase|Deterioration/serum creatinine|0
6041489|NCT00377637|9639826|FG003|Induction Phase|Deterioration/serum creatinine|0
6041490|NCT00377637|9639823|FG000|Induction Phase|Dose reduction of MMF < 2 g/day for 14 d|0
6041491|NCT00377637|9639824|FG001|Induction Phase|Dose reduction of MMF < 2 g/day for 14 d|1
6041492|NCT00377637|9639825|FG002|Induction Phase|Dose reduction of MMF < 2 g/day for 14 d|0
6041493|NCT00377637|9639826|FG003|Induction Phase|Dose reduction of MMF < 2 g/day for 14 d|0
6041494|NCT00377637|9639823|FG000|Induction Phase|Lost to Follow-up|2
6152734|NCT01122680|9790503|FG000|Period 3 (4 Weeks)|Withdrawal by Subject|0
6152735|NCT01122680|9790504|FG001|Period 3 (4 Weeks)|Withdrawal by Subject|1
6152736|NCT01122680|9790505|FG002|Period 3 (4 Weeks)|Withdrawal by Subject|0
6152737|NCT01122680|9790506|FG003|Period 3 (4 Weeks)|Withdrawal by Subject|0
6152738|NCT01122862|9790539|FG000|Period 1|Protocol Violation|0
6152739|NCT01122862|9790540|FG001|Period 1|Protocol Violation|1
6152740|NCT01122862|9790541|FG002|Period 1|Protocol Violation|0
6152741|NCT01122862|9790539|FG000|Period 2|Adverse Event|0
6152742|NCT01122862|9790540|FG001|Period 2|Adverse Event|0
6152743|NCT01122862|9790541|FG002|Period 2|Adverse Event|1
6152744|NCT01122927|9790564|FG000|Period 1 - Conversion Phase|Adverse Event|3
6152745|NCT01122927|9790565|FG001|Period 1 - Conversion Phase|Adverse Event|0
6152746|NCT01122927|9790564|FG000|Period 1 - Conversion Phase|Met Withdrawal Criteria|1
6152747|NCT01122927|9790565|FG001|Period 1 - Conversion Phase|Met Withdrawal Criteria|0
6152748|NCT01122927|9790564|FG000|Period 1 - Conversion Phase|Physician Decision|2
6152749|NCT01122927|9790565|FG001|Period 1 - Conversion Phase|Physician Decision|0
6152750|NCT01122927|9790564|FG000|Period 1 - Conversion Phase|Withdrawal by Subject|7
6152751|NCT01122927|9790565|FG001|Period 1 - Conversion Phase|Withdrawal by Subject|0
6152752|NCT01122927|9790564|FG000|Period 1 - Conversion Phase|Protocol Deviation|1
6152753|NCT01122927|9790565|FG001|Period 1 - Conversion Phase|Protocol Deviation|0
6152754|NCT01122927|9790564|FG000|Period 2- Open-label Treatment Phase|Lost to Follow-up|0
6152755|NCT01122927|9790565|FG001|Period 2- Open-label Treatment Phase|Lost to Follow-up|21
6152756|NCT01122927|9790564|FG000|Period 2- Open-label Treatment Phase|Adverse Event|0
6152757|NCT01122927|9790565|FG001|Period 2- Open-label Treatment Phase|Adverse Event|33
6152758|NCT01122927|9790564|FG000|Period 2- Open-label Treatment Phase|Sponsor Discontinued Trial|0
6152759|NCT01122927|9790565|FG001|Period 2- Open-label Treatment Phase|Sponsor Discontinued Trial|165
6152760|NCT01122927|9790564|FG000|Period 2- Open-label Treatment Phase|Met Withdrawal Criteria|0
6152761|NCT01122927|9790565|FG001|Period 2- Open-label Treatment Phase|Met Withdrawal Criteria|9
6152762|NCT01122927|9790564|FG000|Period 2- Open-label Treatment Phase|Physician Decision|0
6152763|NCT01122927|9790565|FG001|Period 2- Open-label Treatment Phase|Physician Decision|12
6152764|NCT01122927|9790564|FG000|Period 2- Open-label Treatment Phase|Withdrawal by Subject|0
6152765|NCT01122927|9790565|FG001|Period 2- Open-label Treatment Phase|Withdrawal by Subject|65
6152766|NCT01122927|9790564|FG000|Period 2- Open-label Treatment Phase|Lack of Efficacy|0
6152767|NCT01122927|9790565|FG001|Period 2- Open-label Treatment Phase|Lack of Efficacy|7
6152768|NCT01123070|9790579|FG000|Part B Double Blind Period|Protocol Violation|0
6152769|NCT01123070|9790580|FG001|Part B Double Blind Period|Protocol Violation|0
6152770|NCT01123070|9790581|FG002|Part B Double Blind Period|Protocol Violation|0
6152771|NCT01123070|9790582|FG003|Part B Double Blind Period|Protocol Violation|1
6152772|NCT01123070|9790579|FG000|Part B Double Blind Period|Adverse Event|0
6152773|NCT01123070|9790580|FG001|Part B Double Blind Period|Adverse Event|0
6152774|NCT01123070|9790581|FG002|Part B Double Blind Period|Adverse Event|2
6152775|NCT01123070|9790582|FG003|Part B Double Blind Period|Adverse Event|0
6152776|NCT01123070|9790579|FG000|Part B Double Blind Period|Sponsor's Decision|0
6152777|NCT01123070|9790580|FG001|Part B Double Blind Period|Sponsor's Decision|0
6152778|NCT01123070|9790581|FG002|Part B Double Blind Period|Sponsor's Decision|2
6152779|NCT01123070|9790582|FG003|Part B Double Blind Period|Sponsor's Decision|2
6152780|NCT01123083|9790595|FG000|Overall Study|Investigator recommendation|1
6152781|NCT01123083|9790596|FG001|Overall Study|Investigator recommendation|1
6152782|NCT01123083|9790595|FG000|Overall Study|Administrative reasons|0
6152783|NCT01123083|9790596|FG001|Overall Study|Administrative reasons|4
6152784|NCT01123083|9790595|FG000|Overall Study|Lost to Follow-up|2
6152785|NCT01123083|9790596|FG001|Overall Study|Lost to Follow-up|6
6152786|NCT01123083|9790595|FG000|Overall Study|Adverse Event|1
6152787|NCT01123083|9790596|FG001|Overall Study|Adverse Event|0
6152788|NCT01123083|9790595|FG000|Overall Study|Withdrew for another reason not covered|0
6152789|NCT01123083|9790596|FG001|Overall Study|Withdrew for another reason not covered|1
6152790|NCT01123083|9790595|FG000|Overall Study|Participant/legal representative request|7
6152791|NCT01123083|9790596|FG001|Overall Study|Participant/legal representative request|3
6152792|NCT01123148|9790602|FG000|Overall Study|Coughing caused unacceptable EEG quality|1
6152793|NCT01123148|9790602|FG000|Overall Study|Didn't meet milestone criteria|1
6152794|NCT01123161|9790608|FG000|Overall Study|Lost to Follow-up|1
6152795|NCT01123161|9790609|FG001|Overall Study|Lost to Follow-up|0
6152796|NCT01123161|9790608|FG000|Overall Study|Withdrawal by Subject|1
6152797|NCT01123161|9790609|FG001|Overall Study|Withdrawal by Subject|0
6152798|NCT01123200|9790618|FG000|Overall Study|Withdrawal by Subject|1
6152799|NCT01123356|9790622|FG000|Overall Study|Adverse Event|2
6152800|NCT01123356|9790622|FG000|Overall Study|Lack of Efficacy|4
6152801|NCT01123356|9790622|FG000|Overall Study|Withdrawal by Subject|1
6152802|NCT01123382|9790629|FG000|Overall Study|Withdrawal by Subject|1
6152803|NCT01123382|9790630|FG001|Overall Study|Withdrawal by Subject|4
6152804|NCT01123382|9790629|FG000|Overall Study|Lost to Follow-up|1
6152805|NCT01123382|9790630|FG001|Overall Study|Lost to Follow-up|2
6152806|NCT01123395|9790636|FG000|Washout Period of 14 Days|Withdrawal by Subject|0
6152807|NCT01123395|9790637|FG001|Washout Period of 14 Days|Withdrawal by Subject|1
6152808|NCT01123642|9790652|FG000|Overall Study|Lost to Follow-up|23
6152809|NCT01123642|9790652|FG000|Overall Study|Withdrawal by Subject|9
6152810|NCT01123642|9790652|FG000|Overall Study|ineligible at baseline assessment|36
6152811|NCT01123655|9790659|FG000|Overall Study|Medication for RA had to be changed|1
6152812|NCT01123655|9790660|FG001|Overall Study|Medication for RA had to be changed|0
6152813|NCT01123655|9790661|FG002|Overall Study|Medication for RA had to be changed|0
6152814|NCT01123655|9790659|FG000|Overall Study|new illness|0
6152815|NCT01123655|9790660|FG001|Overall Study|new illness|1
6152816|NCT01123655|9790661|FG002|Overall Study|new illness|0
6152817|NCT01123655|9790659|FG000|Overall Study|began prohibitive drug|0
6152818|NCT01123655|9790660|FG001|Overall Study|began prohibitive drug|0
6152819|NCT01123655|9790661|FG002|Overall Study|began prohibitive drug|1
6152820|NCT01123889|9790669|FG000|Overall Study|Lost to Follow-up|3
6152821|NCT01123889|9790670|FG001|Overall Study|Lost to Follow-up|1
6152822|NCT01123941|9790687|FG000|Overall Study|Lost to Follow-up|2
6152823|NCT01123941|9790688|FG001|Overall Study|Lost to Follow-up|1
6152824|NCT01123980|9790696|FG000|Overall Study|Adverse Event|1
6152825|NCT01123980|9790697|FG001|Overall Study|Adverse Event|1
6152826|NCT01123980|9790696|FG000|Overall Study|Lack of Efficacy|1
6152827|NCT01123980|9790697|FG001|Overall Study|Lack of Efficacy|0
6152828|NCT01123980|9790696|FG000|Overall Study|Physician Decision|0
6152829|NCT01123980|9790697|FG001|Overall Study|Physician Decision|1
6152830|NCT01123980|9790696|FG000|Overall Study|Lost to Follow-up|0
6152831|NCT01123980|9790697|FG001|Overall Study|Lost to Follow-up|6
6152832|NCT01123980|9790696|FG000|Overall Study|Protocol Violation|6
6152833|NCT01123980|9790697|FG001|Overall Study|Protocol Violation|6
6152834|NCT01123980|9790696|FG000|Overall Study|Withdrawal by Subject|5
6152835|NCT01123980|9790697|FG001|Overall Study|Withdrawal by Subject|3
6152836|NCT01123980|9790696|FG000|Overall Study|Unclassified|6
6152837|NCT01123980|9790697|FG001|Overall Study|Unclassified|7
6152838|NCT01124006|9790706|FG000|Overall Study|Withdrawal by Subject|2
6152839|NCT01124006|9790707|FG001|Overall Study|Withdrawal by Subject|2
6152840|NCT01124006|9790708|FG002|Overall Study|Withdrawal by Subject|0
6152841|NCT01124006|9790706|FG000|Overall Study|Lost to Follow-up|1
6152842|NCT01124006|9790707|FG001|Overall Study|Lost to Follow-up|0
6152843|NCT01124006|9790708|FG002|Overall Study|Lost to Follow-up|1
6152844|NCT01124006|9790706|FG000|Overall Study|Other|0
6152845|NCT01124006|9790707|FG001|Overall Study|Other|0
6152846|NCT01124006|9790708|FG002|Overall Study|Other|1
6191470|NCT01423253|9848299|FG000|Overall Study|Lost to Follow-up|1
6191471|NCT01423253|9848299|FG000|Overall Study|Protocol Violation|2
6191472|NCT01423253|9848299|FG000|Overall Study|Withdrawal by Subject|2
6191473|NCT01423604|9848306|FG000|Safety Run-In|Adverse Event|3
6191474|NCT01423604|9848307|FG001|Safety Run-In|Adverse Event|0
6191475|NCT01423604|9848306|FG000|Safety Run-In|Death|1
6191476|NCT01423604|9848307|FG001|Safety Run-In|Death|0
6191477|NCT01423604|9848306|FG000|Safety Run-In|Physician Decision|1
6191478|NCT01423604|9848307|FG001|Safety Run-In|Physician Decision|0
6191479|NCT01423604|9848306|FG000|Safety Run-In|Disease progression|3
6191480|NCT01423604|9848307|FG001|Safety Run-In|Disease progression|0
6191481|NCT01423604|9848306|FG000|Safety Run-In|Patient decision|1
6191482|NCT01423604|9848307|FG001|Safety Run-In|Patient decision|0
6191483|NCT01423604|9848306|FG000|Randomized|Adverse Event|4
6191484|NCT01423604|9848307|FG001|Randomized|Adverse Event|10
6191485|NCT01423604|9848306|FG000|Randomized|Death|1
6191486|NCT01423604|9848307|FG001|Randomized|Death|0
6191487|NCT01423604|9848306|FG000|Randomized|Physician Decision|16
6191488|NCT01423604|9848307|FG001|Randomized|Physician Decision|13
6191489|NCT01423604|9848306|FG000|Randomized|Other - unspecified|37
6191490|NCT01423604|9848307|FG001|Randomized|Other - unspecified|31
6191491|NCT01423604|9848306|FG000|Randomized|Patient decision|5
6191492|NCT01423604|9848307|FG001|Randomized|Patient decision|9
6191493|NCT01423617|9848316|FG000|Overall Study|Lost to Follow-up|0
6191494|NCT01423617|9848317|FG001|Overall Study|Lost to Follow-up|1
6191495|NCT01423812|9848341|FG000|Overall Study|Lost to Follow-up|2
6191496|NCT01423812|9848342|FG001|Overall Study|Lost to Follow-up|2
6191497|NCT01423812|9848341|FG000|Overall Study|Withdrawal by Subject|1
6191498|NCT01423812|9848342|FG001|Overall Study|Withdrawal by Subject|2
6191499|NCT01423916|9848353|FG000|Overall Study|Adverse Event|5
6191500|NCT01423916|9848354|FG001|Overall Study|Adverse Event|9
6191501|NCT01423916|9848355|FG002|Overall Study|Adverse Event|2
6191502|NCT01423916|9848353|FG000|Overall Study|Met Withdrawal Criteria|1
6191503|NCT01423916|9848354|FG001|Overall Study|Met Withdrawal Criteria|1
6191504|NCT01423916|9848355|FG002|Overall Study|Met Withdrawal Criteria|1
6191505|NCT01423916|9848353|FG000|Overall Study|Physician Decision|1
6191506|NCT01423916|9848354|FG001|Overall Study|Physician Decision|0
6191507|NCT01423916|9848355|FG002|Overall Study|Physician Decision|1
6191508|NCT01423916|9848353|FG000|Overall Study|Withdrawal by Subject|3
6191509|NCT01423916|9848354|FG001|Overall Study|Withdrawal by Subject|10
6191510|NCT01423916|9848355|FG002|Overall Study|Withdrawal by Subject|3
6191511|NCT01423916|9848353|FG000|Overall Study|Protocol Deviation|1
6191512|NCT01423916|9848354|FG001|Overall Study|Protocol Deviation|0
6191513|NCT01423916|9848355|FG002|Overall Study|Protocol Deviation|0
6191514|NCT01424189|9848393|FG000|Overall Study|Adverse Event|1
6191515|NCT01424189|9848394|FG001|Overall Study|Adverse Event|0
6191516|NCT01424189|9848393|FG000|Overall Study|Lost to Follow-up|4
6191517|NCT01424189|9848394|FG001|Overall Study|Lost to Follow-up|1
6191518|NCT01424189|9848393|FG000|Overall Study|Withdrawal by Subject|4
6191519|NCT01424189|9848394|FG001|Overall Study|Withdrawal by Subject|4
6191520|NCT01424189|9848393|FG000|Overall Study|Subject moved|1
6191521|NCT01424189|9848394|FG001|Overall Study|Subject moved|0
6191522|NCT01424189|9848393|FG000|Overall Study|Death|3
6191523|NCT01424189|9848394|FG001|Overall Study|Death|1
6191524|NCT01424228|9848411|FG000|Overall Study|Withdrawal by Subject|27
6191525|NCT01424228|9848412|FG001|Overall Study|Withdrawal by Subject|11
6191526|NCT01424228|9848411|FG000|Overall Study|Adverse Event|10
6191527|NCT01424228|9848412|FG001|Overall Study|Adverse Event|14
6191528|NCT01424228|9848411|FG000|Overall Study|Sponsor's decision|9
6191529|NCT01424228|9848412|FG001|Overall Study|Sponsor's decision|12
6191530|NCT01424228|9848411|FG000|Overall Study|Lack of Efficacy|5
6191531|NCT01424228|9848412|FG001|Overall Study|Lack of Efficacy|7
6191532|NCT01424228|9848411|FG000|Overall Study|inclusion/exclusion criteria not met|2
6191533|NCT01424228|9848412|FG001|Overall Study|inclusion/exclusion criteria not met|2
6191534|NCT01424228|9848411|FG000|Overall Study|Non-compliance|2
6191535|NCT01424228|9848412|FG001|Overall Study|Non-compliance|0
6191536|NCT01424228|9848411|FG000|Overall Study|Worsening of symptoms|1
6191537|NCT01424228|9848412|FG001|Overall Study|Worsening of symptoms|0
6191538|NCT01424228|9848411|FG000|Overall Study|Unplanned journey|0
6191539|NCT01424228|9848412|FG001|Overall Study|Unplanned journey|1
6191540|NCT01424306|9848422|FG000|Overall Study|Protocol Violation|0
6191541|NCT01424306|9848423|FG001|Overall Study|Protocol Violation|0
6191542|NCT01424306|9848424|FG002|Overall Study|Protocol Violation|0
6191543|NCT01424306|9848425|FG003|Overall Study|Protocol Violation|0
6191544|NCT01424306|9848426|FG004|Overall Study|Protocol Violation|1
6191545|NCT01424306|9848427|FG005|Overall Study|Protocol Violation|0
6152847|NCT01124045|9790718|FG000|Overall Study|Lost to Follow-up|0
6152848|NCT01124045|9790719|FG001|Overall Study|Lost to Follow-up|1
6152849|NCT01124045|9790718|FG000|Overall Study|Physician Decision|0
6152850|NCT01124045|9790719|FG001|Overall Study|Physician Decision|2
6152851|NCT01124097|9790729|FG000|Overall Study|Withdrawal by Subject|4
6152852|NCT01124097|9790730|FG001|Overall Study|Withdrawal by Subject|3
6152853|NCT01124097|9790731|FG002|Overall Study|Withdrawal by Subject|2
6152854|NCT01124097|9790732|FG003|Overall Study|Withdrawal by Subject|3
6152855|NCT01124097|9790729|FG000|Overall Study|Lack of Efficacy|2
6152856|NCT01124097|9790730|FG001|Overall Study|Lack of Efficacy|3
6152857|NCT01124097|9790731|FG002|Overall Study|Lack of Efficacy|1
6152858|NCT01124097|9790732|FG003|Overall Study|Lack of Efficacy|3
6152859|NCT01124097|9790729|FG000|Overall Study|Adverse Event|24
6152860|NCT01124097|9790730|FG001|Overall Study|Adverse Event|15
6152861|NCT01124097|9790731|FG002|Overall Study|Adverse Event|15
6152862|NCT01124097|9790732|FG003|Overall Study|Adverse Event|7
6152863|NCT01124097|9790729|FG000|Overall Study|Protocol Violation|2
6152864|NCT01124097|9790730|FG001|Overall Study|Protocol Violation|0
6152865|NCT01124097|9790731|FG002|Overall Study|Protocol Violation|2
6152866|NCT01124097|9790732|FG003|Overall Study|Protocol Violation|1
6152867|NCT01124097|9790729|FG000|Overall Study|Physician Decision|2
6152868|NCT01124097|9790730|FG001|Overall Study|Physician Decision|1
6152869|NCT01124097|9790731|FG002|Overall Study|Physician Decision|0
6152870|NCT01124097|9790732|FG003|Overall Study|Physician Decision|0
6152871|NCT01124149|9790742|FG000|Acute Phase|Withdrawal by Subject|22
6152872|NCT01124149|9790742|FG000|Acute Phase|Adverse Event|21
6152873|NCT01124149|9790742|FG000|Acute Phase|Lack of Efficacy|17
6152874|NCT01124149|9790742|FG000|Acute Phase|Protocol Violation|14
6152875|NCT01124149|9790742|FG000|Acute Phase|Lost to Follow-up|2
6152876|NCT01124149|9790742|FG000|Acute Phase|Prolonged antibiotic therapy|1
6152877|NCT01124149|9790742|FG000|Acute Phase|Sponsor request|1
6152878|NCT01124149|9790742|FG000|Acute Phase|UC symptoms not ameliorated|1
6152879|NCT01124149|9790742|FG000|Acute Phase|Non-compliance|1
6152880|NCT01124149|9790742|FG000|Acute Phase|Low hemoglobin|1
6152881|NCT01124149|9790742|FG000|Acute Phase|Travelling to another country|1
6152882|NCT01124149|9790742|FG000|Acute Phase|Sponsor decision|1
6152883|NCT01124149|9790742|FG000|Maintenance Phase|Lack of Efficacy|40
6152884|NCT01124149|9790742|FG000|Maintenance Phase|Adverse Event|24
6152885|NCT01124149|9790742|FG000|Maintenance Phase|Lost to Follow-up|15
6152886|NCT01124149|9790742|FG000|Maintenance Phase|Withdrawal by Subject|10
6152887|NCT01124149|9790742|FG000|Maintenance Phase|Protocol Violation|5
6152888|NCT01124149|9790742|FG000|Maintenance Phase|Coordinator error|1
6152889|NCT01124149|9790742|FG000|Maintenance Phase|Non-compliance|1
6152890|NCT01124162|9790751|FG000|First Intervention|Adverse Event|2
6152891|NCT01124162|9790752|FG001|First Intervention|Adverse Event|0
6152892|NCT01124162|9790751|FG000|Washout of 7 Days|Withdrawal by Subject|1
6152893|NCT01124162|9790752|FG001|Washout of 7 Days|Withdrawal by Subject|0
6152894|NCT01124175|9790760|FG000|Washout of 7 Days|Withdrawal by Subject|0
6152895|NCT01124175|9790761|FG001|Washout of 7 Days|Withdrawal by Subject|2
6152896|NCT01124292|9790779|FG000|Overall Study|Lost to Follow-up|2
6152897|NCT01124292|9790780|FG001|Overall Study|Lost to Follow-up|4
6152898|NCT01124292|9790781|FG002|Overall Study|Lost to Follow-up|3
6152899|NCT01124292|9790779|FG000|Overall Study|Physician Decision|0
6152900|NCT01124292|9790780|FG001|Overall Study|Physician Decision|3
6152901|NCT01124292|9790781|FG002|Overall Study|Physician Decision|2
6152902|NCT01124292|9790779|FG000|Overall Study|Withdrawal by Subject|0
6152903|NCT01124292|9790780|FG001|Overall Study|Withdrawal by Subject|6
6152904|NCT01124292|9790781|FG002|Overall Study|Withdrawal by Subject|2
6152905|NCT01124292|9790779|FG000|Overall Study|medical issue unrelated to the study|0
6152906|NCT01124292|9790780|FG001|Overall Study|medical issue unrelated to the study|0
6152907|NCT01124292|9790781|FG002|Overall Study|medical issue unrelated to the study|2
6152908|NCT01124292|9790779|FG000|Overall Study|piercing track closed|0
6152909|NCT01124292|9790780|FG001|Overall Study|piercing track closed|2
6152910|NCT01124292|9790781|FG002|Overall Study|piercing track closed|1
6152911|NCT01124422|9790807|FG000|4-Week Open-label Run-in Phase|Withdrawal by Subject|5
6152912|NCT01124422|9790808|FG001|4-Week Open-label Run-in Phase|Withdrawal by Subject|0
6152913|NCT01124422|9790809|FG002|4-Week Open-label Run-in Phase|Withdrawal by Subject|0
6152914|NCT01124422|9790807|FG000|4-Week Open-label Run-in Phase|Adverse Event|7
6152915|NCT01124422|9790808|FG001|4-Week Open-label Run-in Phase|Adverse Event|0
6152916|NCT01124422|9790809|FG002|4-Week Open-label Run-in Phase|Adverse Event|0
6152917|NCT01124422|9790807|FG000|4-Week Open-label Run-in Phase|Physician Decision|4
6152918|NCT01124422|9790808|FG001|4-Week Open-label Run-in Phase|Physician Decision|0
6152919|NCT01124422|9790809|FG002|4-Week Open-label Run-in Phase|Physician Decision|0
6152920|NCT01124422|9790807|FG000|4-Week Open-label Run-in Phase|Lost to Follow-up|1
6152921|NCT01124422|9790808|FG001|4-Week Open-label Run-in Phase|Lost to Follow-up|0
6152922|NCT01124422|9790809|FG002|4-Week Open-label Run-in Phase|Lost to Follow-up|0
6152923|NCT01124422|9790807|FG000|4-Week Open-label Run-in Phase|Did Not Meet Continuation Criteria|61
6152924|NCT01124422|9790808|FG001|4-Week Open-label Run-in Phase|Did Not Meet Continuation Criteria|0
6152925|NCT01124422|9790809|FG002|4-Week Open-label Run-in Phase|Did Not Meet Continuation Criteria|0
6152926|NCT01124422|9790807|FG000|4-Week Open-label Run-in Phase|Protocol Violation|5
6152927|NCT01124422|9790808|FG001|4-Week Open-label Run-in Phase|Protocol Violation|0
6152928|NCT01124422|9790809|FG002|4-Week Open-label Run-in Phase|Protocol Violation|0
6152929|NCT01124422|9790807|FG000|4-Week Double-blind Treatment Phase|Withdrawal by Subject|0
6152930|NCT01124422|9790808|FG001|4-Week Double-blind Treatment Phase|Withdrawal by Subject|0
6152931|NCT01124422|9790809|FG002|4-Week Double-blind Treatment Phase|Withdrawal by Subject|3
6152932|NCT01124422|9790807|FG000|4-Week Double-blind Treatment Phase|Adverse Event|0
6152933|NCT01124422|9790808|FG001|4-Week Double-blind Treatment Phase|Adverse Event|6
6152934|NCT01124422|9790809|FG002|4-Week Double-blind Treatment Phase|Adverse Event|3
6152935|NCT01124422|9790807|FG000|4-Week Double-blind Treatment Phase|Physician Decision|0
6152936|NCT01124422|9790808|FG001|4-Week Double-blind Treatment Phase|Physician Decision|5
6152937|NCT01124422|9790809|FG002|4-Week Double-blind Treatment Phase|Physician Decision|2
6152938|NCT01124422|9790807|FG000|4-Week Double-blind Treatment Phase|Lost to Follow-up|0
6152939|NCT01124422|9790808|FG001|4-Week Double-blind Treatment Phase|Lost to Follow-up|0
6152940|NCT01124422|9790809|FG002|4-Week Double-blind Treatment Phase|Lost to Follow-up|1
6152941|NCT01124448|9790818|FG000|Overall Study|Lost to Follow-up|0
6152942|NCT01124448|9790819|FG001|Overall Study|Lost to Follow-up|3
6152943|NCT01124448|9790818|FG000|Overall Study|Protocol Violation|2
6152944|NCT01124448|9790819|FG001|Overall Study|Protocol Violation|0
6152945|NCT01124604|9790827|FG000|Overall Study|Adverse Event|10
6152946|NCT01124604|9790828|FG001|Overall Study|Adverse Event|1
6152947|NCT01124604|9790827|FG000|Overall Study|Lack of Efficacy|1
6152948|NCT01124604|9790828|FG001|Overall Study|Lack of Efficacy|0
6152949|NCT01124604|9790827|FG000|Overall Study|Withdrawal by Subject|4
6152950|NCT01124604|9790828|FG001|Overall Study|Withdrawal by Subject|0
6152951|NCT01124604|9790827|FG000|Overall Study|Disease Progression|0
6152952|NCT01124604|9790828|FG001|Overall Study|Disease Progression|1
6152953|NCT01124617|9790836|FG000|Overall Study|Adverse Event|5
6152954|NCT01124617|9790837|FG001|Overall Study|Adverse Event|2
6152955|NCT01124617|9790836|FG000|Overall Study|Lack of Efficacy|2
6152956|NCT01124617|9790837|FG001|Overall Study|Lack of Efficacy|1
6152957|NCT01124617|9790836|FG000|Overall Study|Protocol Violation|1
6152958|NCT01124617|9790837|FG001|Overall Study|Protocol Violation|1
6152959|NCT01124617|9790836|FG000|Overall Study|Withdrawal by Subject|9
6152960|NCT01124617|9790837|FG001|Overall Study|Withdrawal by Subject|1
6152961|NCT01124617|9790836|FG000|Overall Study|Other|2
6152962|NCT01124617|9790837|FG001|Overall Study|Other|1
6152963|NCT01124643|9790843|FG000|Overall Study|Death|1
6152964|NCT01124734|9790847|FG000|Overall Study|Disease progression|13
6152965|NCT01124734|9790847|FG000|Overall Study|Adverse Event|1
6152966|NCT01124734|9790847|FG000|Overall Study|Withdrawal by Subject|1
6152967|NCT01124734|9790847|FG000|Overall Study|Elected for alternative treatment|2
6152968|NCT01124838|9790867|FG000|Overall Study|Miscellaneous|4
6152969|NCT01124838|9790868|FG001|Overall Study|Miscellaneous|2
6152970|NCT01124838|9790867|FG000|Overall Study|Adverse Event|7
6152971|NCT01124838|9790868|FG001|Overall Study|Adverse Event|11
6152972|NCT01124838|9790867|FG000|Overall Study|Lack of Efficacy|2
6152973|NCT01124838|9790868|FG001|Overall Study|Lack of Efficacy|0
6152974|NCT01124838|9790867|FG000|Overall Study|Withdrawal by Subject|3
6152975|NCT01124838|9790868|FG001|Overall Study|Withdrawal by Subject|2
6152976|NCT01124838|9790867|FG000|Overall Study|Lost to Follow-up|2
6152977|NCT01124838|9790868|FG001|Overall Study|Lost to Follow-up|0
6152978|NCT01124864|9790882|FG000|Overall Study|Follow up phase competed as per protocol|18
6152979|NCT01124864|9790883|FG001|Overall Study|Follow up phase competed as per protocol|22
6152980|NCT01124864|9790884|FG002|Overall Study|Follow up phase competed as per protocol|24
6152981|NCT01124864|9790885|FG003|Overall Study|Follow up phase competed as per protocol|18
6152982|NCT01124864|9790886|FG004|Overall Study|Follow up phase competed as per protocol|26
6152983|NCT01124864|9790887|FG005|Overall Study|Follow up phase competed as per protocol|2
6152984|NCT01124864|9790882|FG000|Overall Study|Death|6
6152985|NCT01124864|9790883|FG001|Overall Study|Death|9
6152986|NCT01124864|9790884|FG002|Overall Study|Death|6
6152987|NCT01124864|9790885|FG003|Overall Study|Death|2
6152988|NCT01124864|9790886|FG004|Overall Study|Death|1
6152989|NCT01124864|9790887|FG005|Overall Study|Death|0
6152990|NCT01124864|9790882|FG000|Overall Study|Withdrawal by Subject|2
6152991|NCT01124864|9790883|FG001|Overall Study|Withdrawal by Subject|3
6152992|NCT01124864|9790884|FG002|Overall Study|Withdrawal by Subject|4
6152993|NCT01124864|9790885|FG003|Overall Study|Withdrawal by Subject|0
6152994|NCT01124864|9790886|FG004|Overall Study|Withdrawal by Subject|2
6152995|NCT01124864|9790887|FG005|Overall Study|Withdrawal by Subject|1
6152996|NCT01124864|9790882|FG000|Overall Study|Lost to Follow-up|1
6152997|NCT01124864|9790883|FG001|Overall Study|Lost to Follow-up|1
6152998|NCT01124864|9790884|FG002|Overall Study|Lost to Follow-up|0
6152999|NCT01124864|9790885|FG003|Overall Study|Lost to Follow-up|1
6153000|NCT01124864|9790886|FG004|Overall Study|Lost to Follow-up|0
6153001|NCT01124864|9790887|FG005|Overall Study|Lost to Follow-up|0
6153002|NCT01124864|9790882|FG000|Overall Study|Protocol Violation|1
6153003|NCT01124864|9790883|FG001|Overall Study|Protocol Violation|0
6153004|NCT01124864|9790884|FG002|Overall Study|Protocol Violation|0
6153005|NCT01124864|9790885|FG003|Overall Study|Protocol Violation|0
6153006|NCT01124864|9790886|FG004|Overall Study|Protocol Violation|1
6153007|NCT01124864|9790887|FG005|Overall Study|Protocol Violation|0
6153008|NCT01124916|9790905|FG000|Overall Study|Lost to Follow-up|3
6153009|NCT01124916|9790906|FG001|Overall Study|Lost to Follow-up|2
6153010|NCT01125046|9790921|FG000|First 6 Months of Treatment|Death|1
6153011|NCT01125046|9790921|FG000|First 6 Months of Treatment|Withdrawal by Subject|2
6153012|NCT01125046|9790921|FG000|First 6 Months of Treatment|Non-compliance|1
6153013|NCT01125046|9790921|FG000|First 6 Months of Treatment|Surgery|1
6153014|NCT01125046|9790921|FG000|First 6 Months of Treatment|Progressive Disease|7
6153015|NCT01125046|9790921|FG000|First 6 Months of Treatment|Adverse Event|2
6153016|NCT01125046|9790921|FG000|Continued Treatment After 6 Months|Progressive Disease|2
6153017|NCT01125046|9790921|FG000|Continued Treatment After 6 Months|Adverse Event|1
6153018|NCT01125046|9790921|FG000|Follow-up/Data Cut Off Point|Death|29
6153019|NCT01125046|9790921|FG000|Follow-up/Data Cut Off Point|Lost to Follow-up|4
6191546|NCT01424397|9848471|FG000|Period-2 (8 Days)|Withdrawal by Subject|0
6191547|NCT01424397|9848472|FG001|Period-2 (8 Days)|Withdrawal by Subject|0
6191548|NCT01424397|9848473|FG002|Period-2 (8 Days)|Withdrawal by Subject|1
6191549|NCT01424397|9848474|FG003|Period-2 (8 Days)|Withdrawal by Subject|0
6191550|NCT01424397|9848475|FG004|Period-2 (8 Days)|Withdrawal by Subject|0
6191551|NCT01424397|9848476|FG005|Period-2 (8 Days)|Withdrawal by Subject|0
6191552|NCT01424397|9848477|FG006|Period-2 (8 Days)|Withdrawal by Subject|0
6191553|NCT01424397|9848478|FG007|Period-2 (8 Days)|Withdrawal by Subject|0
6191554|NCT01424397|9848479|FG008|Period-2 (8 Days)|Withdrawal by Subject|0
6191555|NCT01424397|9848480|FG009|Period-2 (8 Days)|Withdrawal by Subject|0
6191556|NCT01424397|9848481|FG010|Period-2 (8 Days)|Withdrawal by Subject|0
6191557|NCT01424397|9848482|FG011|Period-2 (8 Days)|Withdrawal by Subject|0
6191558|NCT01424501|9848502|FG000|Overall Study|Withdrawal by Subject|1
6191559|NCT01424501|9848503|FG001|Overall Study|Withdrawal by Subject|0
6191560|NCT01424501|9848504|FG002|Overall Study|Withdrawal by Subject|1
6191561|NCT01424501|9848505|FG003|Overall Study|Withdrawal by Subject|0
6191562|NCT01424501|9848506|FG004|Overall Study|Withdrawal by Subject|0
6191563|NCT01424501|9848507|FG005|Overall Study|Withdrawal by Subject|0
6191564|NCT01424501|9848502|FG000|Overall Study|Lost to Follow-up|0
6191565|NCT01424501|9848503|FG001|Overall Study|Lost to Follow-up|1
6191566|NCT01424501|9848504|FG002|Overall Study|Lost to Follow-up|1
6191567|NCT01424501|9848505|FG003|Overall Study|Lost to Follow-up|0
6191568|NCT01424501|9848506|FG004|Overall Study|Lost to Follow-up|0
6191569|NCT01424501|9848507|FG005|Overall Study|Lost to Follow-up|0
6191570|NCT01424514|9848522|FG000|Period 1:Intervention Period 1 (14 Days)|Protocol Violation|1
6191571|NCT01424514|9848523|FG001|Period 1:Intervention Period 1 (14 Days)|Protocol Violation|1
6191572|NCT01424514|9848522|FG000|Period 3:Intervention Period 2 (14 Days)|Protocol Violation|1
6191573|NCT01424514|9848523|FG001|Period 3:Intervention Period 2 (14 Days)|Protocol Violation|0
6191574|NCT01424566|9848534|FG000|Single-blind Treatment|Adverse Event|71
6191575|NCT01424566|9848535|FG001|Single-blind Treatment|Adverse Event|0
6191576|NCT01424566|9848536|FG002|Single-blind Treatment|Adverse Event|0
6191577|NCT01424566|9848534|FG000|Single-blind Treatment|Withdrawal by Subject|16
6191578|NCT01424566|9848535|FG001|Single-blind Treatment|Withdrawal by Subject|0
6191579|NCT01424566|9848536|FG002|Single-blind Treatment|Withdrawal by Subject|0
6191580|NCT01424566|9848534|FG000|Single-blind Treatment|Withdrawal by Investigator|2
6191581|NCT01424566|9848535|FG001|Single-blind Treatment|Withdrawal by Investigator|0
6191582|NCT01424566|9848536|FG002|Single-blind Treatment|Withdrawal by Investigator|0
6191583|NCT01424566|9848534|FG000|Single-blind Treatment|Did Not Meet Inclusion Criteria|108
6191584|NCT01424566|9848535|FG001|Single-blind Treatment|Did Not Meet Inclusion Criteria|0
6191585|NCT01424566|9848536|FG002|Single-blind Treatment|Did Not Meet Inclusion Criteria|0
6191586|NCT01424566|9848534|FG000|Single-blind Treatment|Met Exclusion Criteria|1
6191587|NCT01424566|9848535|FG001|Single-blind Treatment|Met Exclusion Criteria|0
6191588|NCT01424566|9848536|FG002|Single-blind Treatment|Met Exclusion Criteria|0
6191589|NCT01424566|9848534|FG000|Single-blind Treatment|Did Not Administer Any Study Drug|2
6191590|NCT01424566|9848535|FG001|Single-blind Treatment|Did Not Administer Any Study Drug|0
6191591|NCT01424566|9848536|FG002|Single-blind Treatment|Did Not Administer Any Study Drug|0
6191592|NCT01424566|9848534|FG000|Double-blind Treatment|Adverse Event|0
6191593|NCT01424566|9848535|FG001|Double-blind Treatment|Adverse Event|21
6191594|NCT01424566|9848536|FG002|Double-blind Treatment|Adverse Event|13
6191595|NCT01424566|9848534|FG000|Double-blind Treatment|Withdrawal by Subject|0
6191596|NCT01424566|9848535|FG001|Double-blind Treatment|Withdrawal by Subject|2
6191597|NCT01424566|9848536|FG002|Double-blind Treatment|Withdrawal by Subject|0
6191598|NCT01424566|9848534|FG000|Double-blind Treatment|Withdrawal by Investigator|0
6191599|NCT01424566|9848535|FG001|Double-blind Treatment|Withdrawal by Investigator|1
6191600|NCT01424566|9848536|FG002|Double-blind Treatment|Withdrawal by Investigator|1
6191601|NCT01424566|9848534|FG000|Double-blind Treatment|Lack of Efficacy|0
6191602|NCT01424566|9848535|FG001|Double-blind Treatment|Lack of Efficacy|1
6191603|NCT01424566|9848536|FG002|Double-blind Treatment|Lack of Efficacy|1
6191604|NCT01424644|9848545|FG000|Overall Study|Adverse Event|2
6191605|NCT01424644|9848546|FG001|Overall Study|Adverse Event|0
6191606|NCT01424644|9848545|FG000|Overall Study|Withdrawal by Subject|9
6191607|NCT01424644|9848546|FG001|Overall Study|Withdrawal by Subject|12
6041495|NCT00377637|9639824|FG001|Induction Phase|Lost to Follow-up|1
6041496|NCT00377637|9639825|FG002|Induction Phase|Lost to Follow-up|0
6153020|NCT01125189|9790947|FG000|Treatment Period|Lack of Efficacy|15
6153021|NCT01125189|9790948|FG001|Treatment Period|Lack of Efficacy|18
6153022|NCT01125189|9790949|FG002|Treatment Period|Lack of Efficacy|25
6153023|NCT01125189|9790947|FG000|Treatment Period|Adverse Event|7
6153024|NCT01125189|9790948|FG001|Treatment Period|Adverse Event|8
6153025|NCT01125189|9790949|FG002|Treatment Period|Adverse Event|8
6153026|NCT01125189|9790947|FG000|Treatment Period|Withdrawal by Subject|3
6153027|NCT01125189|9790948|FG001|Treatment Period|Withdrawal by Subject|1
6153028|NCT01125189|9790949|FG002|Treatment Period|Withdrawal by Subject|1
6153029|NCT01125189|9790947|FG000|Treatment Period|Death|1
6153030|NCT01125189|9790948|FG001|Treatment Period|Death|0
6153031|NCT01125189|9790949|FG002|Treatment Period|Death|0
6153032|NCT01125189|9790947|FG000|Treatment Period|Lost to Follow-up|1
6153033|NCT01125189|9790948|FG001|Treatment Period|Lost to Follow-up|2
6153034|NCT01125189|9790949|FG002|Treatment Period|Lost to Follow-up|1
6153035|NCT01125189|9790947|FG000|Treatment Period|Poor compliance/noncompliance|0
6153036|NCT01125189|9790948|FG001|Treatment Period|Poor compliance/noncompliance|1
6153037|NCT01125189|9790949|FG002|Treatment Period|Poor compliance/noncompliance|0
6153038|NCT01125189|9790947|FG000|Treatment Period|Participants requested to discontinue|1
6153039|NCT01125189|9790948|FG001|Treatment Period|Participants requested to discontinue|3
6153040|NCT01125189|9790949|FG002|Treatment Period|Participants requested to discontinue|4
6153041|NCT01125189|9790947|FG000|Treatment Period|Other reasons|1
6153042|NCT01125189|9790948|FG001|Treatment Period|Other reasons|1
6153043|NCT01125189|9790949|FG002|Treatment Period|Other reasons|0
6153044|NCT01125189|9790947|FG000|Treatment Period|Completed 24 week treatment period only|2
6153045|NCT01125189|9790948|FG001|Treatment Period|Completed 24 week treatment period only|1
6153046|NCT01125189|9790949|FG002|Treatment Period|Completed 24 week treatment period only|2
6153047|NCT01125189|9790947|FG000|Follow up Period|Withdrawal by Subject|3
6153048|NCT01125189|9790948|FG001|Follow up Period|Withdrawal by Subject|2
6153049|NCT01125189|9790949|FG002|Follow up Period|Withdrawal by Subject|5
6153050|NCT01125189|9790947|FG000|Follow up Period|Death|1
6153051|NCT01125189|9790948|FG001|Follow up Period|Death|0
6153052|NCT01125189|9790949|FG002|Follow up Period|Death|0
6153053|NCT01125189|9790947|FG000|Follow up Period|Lost to Follow-up|12
6153054|NCT01125189|9790948|FG001|Follow up Period|Lost to Follow-up|9
6153055|NCT01125189|9790949|FG002|Follow up Period|Lost to Follow-up|6
6153056|NCT01125189|9790947|FG000|Follow up Period|Other reasons|4
6153057|NCT01125189|9790948|FG001|Follow up Period|Other reasons|4
6153058|NCT01125189|9790949|FG002|Follow up Period|Other reasons|5
6153059|NCT01125293|9790975|FG000|Overall Study|Disease Progression|1
6153060|NCT01125293|9790976|FG001|Overall Study|Disease Progression|3
6153061|NCT01125293|9790977|FG002|Overall Study|Disease Progression|4
6153062|NCT01125293|9790978|FG003|Overall Study|Disease Progression|3
6153063|NCT01125293|9790979|FG004|Overall Study|Disease Progression|5
6153064|NCT01125293|9790980|FG005|Overall Study|Disease Progression|12
6153065|NCT01125293|9790975|FG000|Overall Study|Adverse Event|1
6153066|NCT01125293|9790976|FG001|Overall Study|Adverse Event|0
6153067|NCT01125293|9790977|FG002|Overall Study|Adverse Event|0
6153068|NCT01125293|9790978|FG003|Overall Study|Adverse Event|0
6153069|NCT01125293|9790979|FG004|Overall Study|Adverse Event|2
6153070|NCT01125293|9790980|FG005|Overall Study|Adverse Event|8
6153071|NCT01125293|9790975|FG000|Overall Study|Symptomatic Deterioration|1
6153072|NCT01125293|9790976|FG001|Overall Study|Symptomatic Deterioration|0
6153073|NCT01125293|9790977|FG002|Overall Study|Symptomatic Deterioration|0
6153074|NCT01125293|9790978|FG003|Overall Study|Symptomatic Deterioration|0
6153075|NCT01125293|9790979|FG004|Overall Study|Symptomatic Deterioration|0
6153076|NCT01125293|9790980|FG005|Overall Study|Symptomatic Deterioration|0
6153077|NCT01125293|9790975|FG000|Overall Study|Death|0
6041497|NCT00377637|9639826|FG003|Induction Phase|Lost to Follow-up|0
6041498|NCT00377637|9639823|FG000|Induction Phase|Death|1
6041499|NCT00377637|9639824|FG001|Induction Phase|Death|3
6153078|NCT01125293|9790976|FG001|Overall Study|Death|0
6153079|NCT01125293|9790977|FG002|Overall Study|Death|0
6153080|NCT01125293|9790978|FG003|Overall Study|Death|0
6153081|NCT01125293|9790979|FG004|Overall Study|Death|1
6153082|NCT01125293|9790980|FG005|Overall Study|Death|0
6153083|NCT01125293|9790975|FG000|Overall Study|Withdrawal by Subject|0
6153084|NCT01125293|9790976|FG001|Overall Study|Withdrawal by Subject|0
6153085|NCT01125293|9790977|FG002|Overall Study|Withdrawal by Subject|0
6153086|NCT01125293|9790978|FG003|Overall Study|Withdrawal by Subject|0
6153087|NCT01125293|9790979|FG004|Overall Study|Withdrawal by Subject|2
6153088|NCT01125293|9790980|FG005|Overall Study|Withdrawal by Subject|1
6153089|NCT01125293|9790975|FG000|Overall Study|Physician Decision|0
6153090|NCT01125293|9790976|FG001|Overall Study|Physician Decision|0
6153091|NCT01125293|9790977|FG002|Overall Study|Physician Decision|0
6153092|NCT01125293|9790978|FG003|Overall Study|Physician Decision|0
6153093|NCT01125293|9790979|FG004|Overall Study|Physician Decision|0
6153094|NCT01125293|9790980|FG005|Overall Study|Physician Decision|2
6153095|NCT01125358|9791001|FG000|Overall Study|Adverse Event|3
6153096|NCT01125358|9791002|FG001|Overall Study|Adverse Event|0
6153097|NCT01125358|9791003|FG002|Overall Study|Adverse Event|0
6153098|NCT01125358|9791004|FG003|Overall Study|Adverse Event|2
6153099|NCT01125358|9791001|FG000|Overall Study|Perceived Lack of Efficacy|6
6153100|NCT01125358|9791002|FG001|Overall Study|Perceived Lack of Efficacy|3
6153101|NCT01125358|9791003|FG002|Overall Study|Perceived Lack of Efficacy|7
6153102|NCT01125358|9791004|FG003|Overall Study|Perceived Lack of Efficacy|4
6153103|NCT01125358|9791001|FG000|Overall Study|Protocol Violation|1
6153104|NCT01125358|9791002|FG001|Overall Study|Protocol Violation|0
6153105|NCT01125358|9791003|FG002|Overall Study|Protocol Violation|0
6153106|NCT01125358|9791004|FG003|Overall Study|Protocol Violation|0
6153107|NCT01125358|9791001|FG000|Overall Study|Sponsor Decision|0
6153108|NCT01125358|9791002|FG001|Overall Study|Sponsor Decision|0
6153109|NCT01125358|9791003|FG002|Overall Study|Sponsor Decision|1
6153110|NCT01125358|9791004|FG003|Overall Study|Sponsor Decision|1
6153111|NCT01125358|9791001|FG000|Overall Study|Withdrawal by Subject|2
6153112|NCT01125358|9791002|FG001|Overall Study|Withdrawal by Subject|1
6153113|NCT01125358|9791003|FG002|Overall Study|Withdrawal by Subject|1
6153114|NCT01125358|9791004|FG003|Overall Study|Withdrawal by Subject|1
6191608|NCT01424644|9848545|FG000|Overall Study|Lost to Follow-up|16
6191609|NCT01424644|9848546|FG001|Overall Study|Lost to Follow-up|12
6191610|NCT01424644|9848545|FG000|Overall Study|Protocol Violation|4
6191611|NCT01424644|9848546|FG001|Overall Study|Protocol Violation|3
6191612|NCT01424644|9848545|FG000|Overall Study|Administrative Reason|1
6191613|NCT01424644|9848546|FG001|Overall Study|Administrative Reason|0
6191614|NCT01424644|9848545|FG000|Overall Study|Unable to Classify|1
6191615|NCT01424644|9848546|FG001|Overall Study|Unable to Classify|0
6191616|NCT01424670|9848554|FG000|6-Month Intensive Period (182 Days)|Adverse Event|2
6191617|NCT01424670|9848555|FG001|6-Month Intensive Period (182 Days)|Adverse Event|2
6191618|NCT01424670|9848554|FG000|6-Month Intensive Period (182 Days)|Lost to Follow-up|0
6191619|NCT01424670|9848555|FG001|6-Month Intensive Period (182 Days)|Lost to Follow-up|1
6191620|NCT01424670|9848554|FG000|6-Month Intensive Period (182 Days)|Met Protocol Withdrawal Criteria|2
6191621|NCT01424670|9848555|FG001|6-Month Intensive Period (182 Days)|Met Protocol Withdrawal Criteria|1
6191622|NCT01424670|9848554|FG000|6-Month Intensive Period (182 Days)|Physician Decision|2
6191623|NCT01424670|9848555|FG001|6-Month Intensive Period (182 Days)|Physician Decision|3
6191624|NCT01424670|9848554|FG000|6-Month Intensive Period (182 Days)|Withdrawal by Subject|13
6191625|NCT01424670|9848555|FG001|6-Month Intensive Period (182 Days)|Withdrawal by Subject|7
6191626|NCT01424670|9848554|FG000|Continuation Period|Adverse Event|13
6191627|NCT01424670|9848555|FG001|Continuation Period|Adverse Event|5
6191628|NCT01424670|9848554|FG000|Continuation Period|Lost to Follow-up|2
6191629|NCT01424670|9848555|FG001|Continuation Period|Lost to Follow-up|0
6191630|NCT01424670|9848554|FG000|Continuation Period|Met Protocol Withdrawal Criteria|1
6191631|NCT01424670|9848555|FG001|Continuation Period|Met Protocol Withdrawal Criteria|1
6191632|NCT01424670|9848554|FG000|Continuation Period|Physician Decision|5
6191633|NCT01424670|9848555|FG001|Continuation Period|Physician Decision|4
6191634|NCT01424670|9848554|FG000|Continuation Period|Withdrawal by Subject|13
6191635|NCT01424670|9848555|FG001|Continuation Period|Withdrawal by Subject|4
6191636|NCT01424722|9848563|FG000|Overall Study|Sponsor terminated investigation|2258
6191637|NCT01424813|9848569|FG000|Overall Study|Withdrawal by Subject|3
6191638|NCT01424813|9848570|FG001|Overall Study|Withdrawal by Subject|0
6191639|NCT01424813|9848569|FG000|Overall Study|Protocol Violation|1
6191640|NCT01424813|9848570|FG001|Overall Study|Protocol Violation|0
6191641|NCT01424813|9848569|FG000|Overall Study|Other|1
6191642|NCT01424813|9848570|FG001|Overall Study|Other|2
6191643|NCT01424930|9848578|FG000|Overall Study|Adverse Event|0
6041500|NCT00377637|9639825|FG002|Induction Phase|Death|0
6191644|NCT01424930|9848579|FG001|Overall Study|Adverse Event|1
6191645|NCT01424930|9848578|FG000|Overall Study|Death|1
6191646|NCT01424930|9848579|FG001|Overall Study|Death|0
6191647|NCT01424930|9848578|FG000|Overall Study|Progressive Disease|3
6153115|NCT04516746|9791037|FG000|Overall Study|Ongoing in the study at clinical DCO for the primary analysis.|21090
6153116|NCT04516746|9791038|FG001|Overall Study|Ongoing in the study at clinical DCO for the primary analysis.|10305
6153117|NCT04516746|9791037|FG000|Overall Study|Withdrawal by Subject|362
6153118|NCT04516746|9791038|FG001|Overall Study|Withdrawal by Subject|408
6153119|NCT04516746|9791037|FG000|Overall Study|Lost to Follow-up|157
6153120|NCT04516746|9791038|FG001|Overall Study|Lost to Follow-up|86
6153121|NCT04516746|9791037|FG000|Overall Study|Protocol deviation|18
6153122|NCT04516746|9791038|FG001|Overall Study|Protocol deviation|7
6153123|NCT04516746|9791037|FG000|Overall Study|Death|8
6153124|NCT04516746|9791038|FG001|Overall Study|Death|7
6153125|NCT04516746|9791037|FG000|Overall Study|Physician Decision|0
6153126|NCT04516746|9791038|FG001|Overall Study|Physician Decision|2
6153127|NCT04516746|9791037|FG000|Overall Study|Other|0
6153128|NCT04516746|9791038|FG001|Overall Study|Other|1
6153129|NCT04364737|9791050|FG000|Overall Study|Withdrawal by Subject|4
6153130|NCT04364737|9791051|FG001|Overall Study|Withdrawal by Subject|9
6153131|NCT04364737|9791050|FG000|Overall Study|Lost to Follow-up|1
6153132|NCT04364737|9791051|FG001|Overall Study|Lost to Follow-up|1
6153133|NCT04354155|9791057|FG000|Overall Study|Withdrawal by Subject|1
6153134|NCT04354155|9791057|FG000|Overall Study|Did not meet criteria for study intervention|1
6153135|NCT04085367|9791063|FG000|Overall Study|Adverse Event|1
6153136|NCT04085367|9791064|FG001|Overall Study|Adverse Event|1
6153137|NCT04085367|9791063|FG000|Overall Study|Withdrawal by Subject|13
6153138|NCT04085367|9791064|FG001|Overall Study|Withdrawal by Subject|4
6153139|NCT04085367|9791063|FG000|Overall Study|Lost to Follow-up|3
6153140|NCT04085367|9791064|FG001|Overall Study|Lost to Follow-up|1
6153141|NCT04085367|9791063|FG000|Overall Study|Other unspecified|2
6153142|NCT04085367|9791064|FG001|Overall Study|Other unspecified|1
6153143|NCT04085367|9791063|FG000|Overall Study|Status Unknown|1
6153144|NCT04085367|9791064|FG001|Overall Study|Status Unknown|1
6153145|NCT03621696|9791078|FG000|Overall Study|Not eligible|0
6153146|NCT03621696|9791079|FG001|Overall Study|Not eligible|0
6153147|NCT03621696|9791080|FG002|Overall Study|Not eligible|0
6153148|NCT03621696|9791081|FG003|Overall Study|Not eligible|5
6153149|NCT03621696|9791078|FG000|Overall Study|Withdrawal by Subject|1
6153150|NCT03621696|9791079|FG001|Overall Study|Withdrawal by Subject|1
6153151|NCT03621696|9791080|FG002|Overall Study|Withdrawal by Subject|1
6153152|NCT03621696|9791081|FG003|Overall Study|Withdrawal by Subject|0
6153153|NCT03621696|9791078|FG000|Overall Study|Physician Decision|0
6153154|NCT03621696|9791079|FG001|Overall Study|Physician Decision|0
6153155|NCT03621696|9791080|FG002|Overall Study|Physician Decision|1
6153156|NCT03621696|9791081|FG003|Overall Study|Physician Decision|0
6153157|NCT03544268|9791091|FG000|Overall Study|Did not meet full criteria for inclusion after enrollment|2
6153158|NCT03544268|9791092|FG001|Overall Study|Did not meet full criteria for inclusion after enrollment|0
6153159|NCT03038438|9791144|FG000|Overall Study|Death|2
6153160|NCT03038438|9791144|FG000|Overall Study|Lost to Follow-up|4
6153161|NCT03038438|9791144|FG000|Overall Study|Subject Incarceration|1
6153162|NCT03038438|9791144|FG000|Overall Study|Withdrawal by Subject|2
6153163|NCT03038438|9791144|FG000|Overall Study|No 24-Month Follow-Up|43
6153164|NCT02451943|9791159|FG000|Overall Study|On Treatment|4
6153165|NCT02451943|9791160|FG001|Overall Study|On Treatment|4
6153166|NCT02451943|9791159|FG000|Overall Study|Withdrawal by Subject|13
6153167|NCT02451943|9791160|FG001|Overall Study|Withdrawal by Subject|16
6153168|NCT02451943|9791159|FG000|Overall Study|Lost to Follow-up|3
6153169|NCT02451943|9791160|FG001|Overall Study|Lost to Follow-up|4
6153170|NCT02242942|9791169|FG000|Overall Study|Death|17
6153171|NCT02242942|9791170|FG001|Overall Study|Death|20
6153172|NCT02242942|9791171|FG002|Overall Study|Death|2
6153173|NCT02242942|9791169|FG000|Overall Study|Physician Decision|1
6153174|NCT02242942|9791170|FG001|Overall Study|Physician Decision|0
6153175|NCT02242942|9791171|FG002|Overall Study|Physician Decision|0
6153176|NCT02242942|9791169|FG000|Overall Study|Withdrawal by Subject|8
6153177|NCT02242942|9791170|FG001|Overall Study|Withdrawal by Subject|10
6153178|NCT02242942|9791171|FG002|Overall Study|Withdrawal by Subject|0
6153179|NCT02242942|9791169|FG000|Overall Study|On-going in Study|190
6153180|NCT02242942|9791170|FG001|Overall Study|On-going in Study|186
6153181|NCT02242942|9791171|FG002|Overall Study|On-going in Study|11
6153182|NCT02198794|9791181|FG000|Part A: Open-Label (158 Weeks)|Withdrawal by Subject|79
6153183|NCT02198794|9791182|FG001|Part A: Open-Label (158 Weeks)|Withdrawal by Subject|0
6153184|NCT02198794|9791183|FG002|Part A: Open-Label (158 Weeks)|Withdrawal by Subject|0
6153185|NCT02198794|9791184|FG003|Part A: Open-Label (158 Weeks)|Withdrawal by Subject|0
6153186|NCT02198794|9791181|FG000|Part A: Open-Label (158 Weeks)|Adverse Event|33
6153187|NCT02198794|9791182|FG001|Part A: Open-Label (158 Weeks)|Adverse Event|0
6153188|NCT02198794|9791183|FG002|Part A: Open-Label (158 Weeks)|Adverse Event|0
6153189|NCT02198794|9791184|FG003|Part A: Open-Label (158 Weeks)|Adverse Event|0
6153190|NCT02198794|9791181|FG000|Part A: Open-Label (158 Weeks)|Lost to Follow-up|24
6153191|NCT02198794|9791182|FG001|Part A: Open-Label (158 Weeks)|Lost to Follow-up|0
6153192|NCT02198794|9791183|FG002|Part A: Open-Label (158 Weeks)|Lost to Follow-up|0
6153193|NCT02198794|9791184|FG003|Part A: Open-Label (158 Weeks)|Lost to Follow-up|0
6153194|NCT02198794|9791181|FG000|Part A: Open-Label (158 Weeks)|Lack of Efficacy|9
6153195|NCT02198794|9791182|FG001|Part A: Open-Label (158 Weeks)|Lack of Efficacy|0
6153196|NCT02198794|9791183|FG002|Part A: Open-Label (158 Weeks)|Lack of Efficacy|0
6153197|NCT02198794|9791184|FG003|Part A: Open-Label (158 Weeks)|Lack of Efficacy|0
6153198|NCT02198794|9791181|FG000|Part A: Open-Label (158 Weeks)|Death|8
6153199|NCT02198794|9791182|FG001|Part A: Open-Label (158 Weeks)|Death|0
6153200|NCT02198794|9791183|FG002|Part A: Open-Label (158 Weeks)|Death|0
6153201|NCT02198794|9791184|FG003|Part A: Open-Label (158 Weeks)|Death|0
6153202|NCT02198794|9791181|FG000|Part A: Open-Label (158 Weeks)|Noncompliance with study drug|3
6153203|NCT02198794|9791182|FG001|Part A: Open-Label (158 Weeks)|Noncompliance with study drug|0
6153204|NCT02198794|9791183|FG002|Part A: Open-Label (158 Weeks)|Noncompliance with study drug|0
6153205|NCT02198794|9791184|FG003|Part A: Open-Label (158 Weeks)|Noncompliance with study drug|0
6153206|NCT02198794|9791181|FG000|Part A: Open-Label (158 Weeks)|Other than specified|5
6153207|NCT02198794|9791182|FG001|Part A: Open-Label (158 Weeks)|Other than specified|0
6153208|NCT02198794|9791183|FG002|Part A: Open-Label (158 Weeks)|Other than specified|0
6153209|NCT02198794|9791184|FG003|Part A: Open-Label (158 Weeks)|Other than specified|0
6153210|NCT02198794|9791181|FG000|Part A: Open-Label (158 Weeks)|Study terminated|1
6153211|NCT02198794|9791182|FG001|Part A: Open-Label (158 Weeks)|Study terminated|0
6153212|NCT02198794|9791183|FG002|Part A: Open-Label (158 Weeks)|Study terminated|0
6153213|NCT02198794|9791184|FG003|Part A: Open-Label (158 Weeks)|Study terminated|0
6153214|NCT02198794|9791181|FG000|Part A: Open-Label (158 Weeks)|Protocol deviation|1
6153215|NCT02198794|9791182|FG001|Part A: Open-Label (158 Weeks)|Protocol deviation|0
6153216|NCT02198794|9791183|FG002|Part A: Open-Label (158 Weeks)|Protocol deviation|0
6153217|NCT02198794|9791184|FG003|Part A: Open-Label (158 Weeks)|Protocol deviation|0
6153218|NCT02198794|9791181|FG000|Part A: Open-Label (158 Weeks)|Agreed to continue in Part B|142
6153219|NCT02198794|9791182|FG001|Part A: Open-Label (158 Weeks)|Agreed to continue in Part B|0
6153220|NCT02198794|9791183|FG002|Part A: Open-Label (158 Weeks)|Agreed to continue in Part B|0
6153221|NCT02198794|9791184|FG003|Part A: Open-Label (158 Weeks)|Agreed to continue in Part B|0
6153222|NCT02198794|9791181|FG000|Part B: Randomized (13 Weeks)|Withdrawal by Subject|0
6153223|NCT02198794|9791182|FG001|Part B: Randomized (13 Weeks)|Withdrawal by Subject|3
6153224|NCT02198794|9791183|FG002|Part B: Randomized (13 Weeks)|Withdrawal by Subject|1
6153225|NCT02198794|9791184|FG003|Part B: Randomized (13 Weeks)|Withdrawal by Subject|0
6153226|NCT02198794|9791181|FG000|Part B: Randomized (13 Weeks)|Lost to Follow-up|0
6153227|NCT02198794|9791182|FG001|Part B: Randomized (13 Weeks)|Lost to Follow-up|2
6153228|NCT02198794|9791183|FG002|Part B: Randomized (13 Weeks)|Lost to Follow-up|2
6153229|NCT02198794|9791184|FG003|Part B: Randomized (13 Weeks)|Lost to Follow-up|0
6153230|NCT02198794|9791181|FG000|Part C: Safety Assessment (52 Weeks)|Withdrawal by Subject|0
6153231|NCT02198794|9791182|FG001|Part C: Safety Assessment (52 Weeks)|Withdrawal by Subject|0
6153232|NCT02198794|9791183|FG002|Part C: Safety Assessment (52 Weeks)|Withdrawal by Subject|0
6153233|NCT02198794|9791184|FG003|Part C: Safety Assessment (52 Weeks)|Withdrawal by Subject|3
6153234|NCT02198794|9791181|FG000|Part C: Safety Assessment (52 Weeks)|Adverse Event|0
6153235|NCT02198794|9791182|FG001|Part C: Safety Assessment (52 Weeks)|Adverse Event|0
6153236|NCT02198794|9791183|FG002|Part C: Safety Assessment (52 Weeks)|Adverse Event|0
6153237|NCT02198794|9791184|FG003|Part C: Safety Assessment (52 Weeks)|Adverse Event|2
6153238|NCT02198794|9791181|FG000|Part C: Safety Assessment (52 Weeks)|Death|0
6153239|NCT02198794|9791182|FG001|Part C: Safety Assessment (52 Weeks)|Death|0
6153240|NCT02198794|9791183|FG002|Part C: Safety Assessment (52 Weeks)|Death|0
6153241|NCT02198794|9791184|FG003|Part C: Safety Assessment (52 Weeks)|Death|2
6153242|NCT01877655|9791195|FG000|Overall Study|Death|57
6153243|NCT01877655|9791196|FG001|Overall Study|Death|52
6153244|NCT01877655|9791195|FG000|Overall Study|Withdrawal by Subject|18
6153245|NCT01877655|9791196|FG001|Overall Study|Withdrawal by Subject|26
6153246|NCT01877655|9791195|FG000|Overall Study|Physician Decision|11
6153247|NCT01877655|9791196|FG001|Overall Study|Physician Decision|10
6153248|NCT01877655|9791195|FG000|Overall Study|Miscellaneous|4
6153249|NCT01877655|9791196|FG001|Overall Study|Miscellaneous|4
6153250|NCT01877655|9791195|FG000|Overall Study|Randomized but Never Received Drug|8
6153251|NCT01877655|9791196|FG001|Overall Study|Randomized but Never Received Drug|5
6153252|NCT00308685|9791204|FG000|Overall Study|Lost to Follow-up|1
6153253|NCT00308685|9791205|FG001|Overall Study|Lost to Follow-up|0
6153254|NCT00308685|9791204|FG000|Overall Study|Need to administer prohibited medication|1
6153255|NCT00308685|9791205|FG001|Overall Study|Need to administer prohibited medication|2
6153256|NCT00308685|9791204|FG000|Overall Study|Other than specified|1
6153257|NCT00308685|9791205|FG001|Overall Study|Other than specified|3
6153258|NCT01125514|9791211|FG000|Treatment Period 1 (Day 1 - Day 7)|Adverse Event|1
6153259|NCT01125514|9791211|FG000|Treatment Period 1 (Day 1 - Day 7)|Administrative problems|1
6153260|NCT01125514|9791211|FG000|Treatment Period 2 (Day 8 - Day 17)|Adverse Event|3
6153261|NCT01125514|9791211|FG000|Treatment Period2(Day9-Day27) and Day 28|Adverse Event|2
6153262|NCT01125514|9791211|FG000|Treatment Period2(Day9-Day27) and Day 28|Protocol Deviation|1
6153263|NCT01125514|9791211|FG000|Treatment Period2(Day9-Day27) and Day 28|Withdrawal by Subject|1
6191648|NCT01424930|9848579|FG001|Overall Study|Progressive Disease|6
6153264|NCT01125566|9791227|FG000|Patients Before the Switch (26Apr2013)|Progressive disease according to RECIST|182
6153265|NCT01125566|9791228|FG001|Patients Before the Switch (26Apr2013)|Progressive disease according to RECIST|119
6153266|NCT01125566|9791229|FG002|Patients Before the Switch (26Apr2013)|Progressive disease according to RECIST|0
6153267|NCT01125566|9791227|FG000|Patients Before the Switch (26Apr2013)|Worsening of underlying cancer disease|6
6153268|NCT01125566|9791228|FG001|Patients Before the Switch (26Apr2013)|Worsening of underlying cancer disease|6
6153269|NCT01125566|9791229|FG002|Patients Before the Switch (26Apr2013)|Worsening of underlying cancer disease|0
6153270|NCT01125566|9791227|FG000|Patients Before the Switch (26Apr2013)|Adverse Event|25
6153271|NCT01125566|9791228|FG001|Patients Before the Switch (26Apr2013)|Adverse Event|5
6153272|NCT01125566|9791229|FG002|Patients Before the Switch (26Apr2013)|Adverse Event|0
6153273|NCT01125566|9791227|FG000|Patients Before the Switch (26Apr2013)|Protocol Violation|0
6153274|NCT01125566|9791228|FG001|Patients Before the Switch (26Apr2013)|Protocol Violation|2
6153275|NCT01125566|9791229|FG002|Patients Before the Switch (26Apr2013)|Protocol Violation|0
6153276|NCT01125566|9791227|FG000|Patients Before the Switch (26Apr2013)|Refused to continue taking medication|24
6153277|NCT01125566|9791228|FG001|Patients Before the Switch (26Apr2013)|Refused to continue taking medication|23
6153278|NCT01125566|9791229|FG002|Patients Before the Switch (26Apr2013)|Refused to continue taking medication|0
6153279|NCT01125566|9791227|FG000|Patients Before the Switch (26Apr2013)|Not treated|2
6153280|NCT01125566|9791228|FG001|Patients Before the Switch (26Apr2013)|Not treated|0
6153281|NCT01125566|9791229|FG002|Patients Before the Switch (26Apr2013)|Not treated|0
6153282|NCT01125566|9791227|FG000|Patients Before the Switch (26Apr2013)|Other than listed above|25
6153283|NCT01125566|9791228|FG001|Patients Before the Switch (26Apr2013)|Other than listed above|13
6153284|NCT01125566|9791229|FG002|Patients Before the Switch (26Apr2013)|Other than listed above|0
6153285|NCT01125566|9791227|FG000|Patients Before the Switch (26Apr2013)|Lost to Follow-up|1
6153286|NCT01125566|9791228|FG001|Patients Before the Switch (26Apr2013)|Lost to Follow-up|1
6153287|NCT01125566|9791229|FG002|Patients Before the Switch (26Apr2013)|Lost to Follow-up|0
6153288|NCT01125566|9791227|FG000|Patients Who Switched From AV to TV|Progressive disease according to RECIST|0
6153289|NCT01125566|9791228|FG001|Patients Who Switched From AV to TV|Progressive disease according to RECIST|0
6153290|NCT01125566|9791229|FG002|Patients Who Switched From AV to TV|Progressive disease according to RECIST|59
6153291|NCT01125566|9791227|FG000|Patients Who Switched From AV to TV|Refused to continue taking medication|0
6153292|NCT01125566|9791228|FG001|Patients Who Switched From AV to TV|Refused to continue taking medication|0
6153293|NCT01125566|9791229|FG002|Patients Who Switched From AV to TV|Refused to continue taking medication|7
6153294|NCT01125566|9791227|FG000|Patients Who Switched From AV to TV|Worsening of underlying cancer disease|0
6153295|NCT01125566|9791228|FG001|Patients Who Switched From AV to TV|Worsening of underlying cancer disease|0
6153296|NCT01125566|9791229|FG002|Patients Who Switched From AV to TV|Worsening of underlying cancer disease|3
6153297|NCT01125566|9791227|FG000|Patients Who Switched From AV to TV|Other than listed above|0
6153298|NCT01125566|9791228|FG001|Patients Who Switched From AV to TV|Other than listed above|0
6153299|NCT01125566|9791229|FG002|Patients Who Switched From AV to TV|Other than listed above|4
6153300|NCT01125722|9791255|FG000|Overall Study|Withdrawal by Subject|2
6153301|NCT01125722|9791256|FG001|Overall Study|Withdrawal by Subject|1
6153302|NCT01125722|9791255|FG000|Overall Study|Lost to Follow-up|1
6153303|NCT01125722|9791256|FG001|Overall Study|Lost to Follow-up|0
6153304|NCT01125748|9791264|FG000|Overall Study|Adverse Event|0
6153305|NCT01125748|9791265|FG001|Overall Study|Adverse Event|2
6153306|NCT01125748|9791264|FG000|Overall Study|Lost to Follow-up|0
6041501|NCT00377637|9639826|FG003|Induction Phase|Death|0
6041502|NCT00377637|9639823|FG000|Induction Phase|Withdrawal by Subject|5
6041503|NCT00377637|9639824|FG001|Induction Phase|Withdrawal by Subject|6
6153307|NCT01125748|9791265|FG001|Overall Study|Lost to Follow-up|1
6153308|NCT01125748|9791264|FG000|Overall Study|Physician Decision|8
6153309|NCT01125748|9791265|FG001|Overall Study|Physician Decision|7
6153310|NCT01125748|9791264|FG000|Overall Study|Patient Decision to Withdraw|2
6153311|NCT01125748|9791265|FG001|Overall Study|Patient Decision to Withdraw|4
6153312|NCT01125800|9791287|FG000|Phase I|Protocol Violation|0
6153313|NCT01125800|9791288|FG001|Phase I|Protocol Violation|3
6153314|NCT01125800|9791289|FG002|Phase I|Protocol Violation|1
6153315|NCT01125800|9791290|FG003|Phase I|Protocol Violation|1
6153316|NCT01125800|9791291|FG004|Phase I|Protocol Violation|0
6153317|NCT01125800|9791287|FG000|Phase I|Adverse Event|2
6153318|NCT01125800|9791288|FG001|Phase I|Adverse Event|2
6153319|NCT01125800|9791289|FG002|Phase I|Adverse Event|1
6153320|NCT01125800|9791290|FG003|Phase I|Adverse Event|7
6153321|NCT01125800|9791291|FG004|Phase I|Adverse Event|0
6153322|NCT01125800|9791287|FG000|Phase I|Administrative problems|1
6153323|NCT01125800|9791288|FG001|Phase I|Administrative problems|0
6153324|NCT01125800|9791289|FG002|Phase I|Administrative problems|0
6153325|NCT01125800|9791290|FG003|Phase I|Administrative problems|0
6153326|NCT01125800|9791291|FG004|Phase I|Administrative problems|0
6153327|NCT01125800|9791287|FG000|Phase I|Withdrawal by Subject|0
6153328|NCT01125800|9791288|FG001|Phase I|Withdrawal by Subject|0
6153329|NCT01125800|9791289|FG002|Phase I|Withdrawal by Subject|1
6153330|NCT01125800|9791290|FG003|Phase I|Withdrawal by Subject|0
6153331|NCT01125800|9791291|FG004|Phase I|Withdrawal by Subject|0
6153332|NCT01125800|9791287|FG000|Phase I|Disease progression|5
6153333|NCT01125800|9791288|FG001|Phase I|Disease progression|4
6153334|NCT01125800|9791289|FG002|Phase I|Disease progression|1
6153335|NCT01125800|9791290|FG003|Phase I|Disease progression|3
6153336|NCT01125800|9791291|FG004|Phase I|Disease progression|0
6153337|NCT01125800|9791287|FG000|Phase II|Protocol Violation|0
6153338|NCT01125800|9791288|FG001|Phase II|Protocol Violation|0
6153339|NCT01125800|9791289|FG002|Phase II|Protocol Violation|0
6153340|NCT01125800|9791290|FG003|Phase II|Protocol Violation|0
6153341|NCT01125800|9791291|FG004|Phase II|Protocol Violation|1
6153342|NCT01125800|9791287|FG000|Phase II|Adverse Event|0
6153343|NCT01125800|9791288|FG001|Phase II|Adverse Event|0
6153344|NCT01125800|9791289|FG002|Phase II|Adverse Event|0
6153345|NCT01125800|9791290|FG003|Phase II|Adverse Event|0
6153346|NCT01125800|9791291|FG004|Phase II|Adverse Event|2
6153347|NCT01125800|9791287|FG000|Phase II|Disease progression|0
6153348|NCT01125800|9791288|FG001|Phase II|Disease progression|0
6153349|NCT01125800|9791289|FG002|Phase II|Disease progression|0
6153350|NCT01125800|9791290|FG003|Phase II|Disease progression|1
6153351|NCT01125800|9791291|FG004|Phase II|Disease progression|8
6153352|NCT01125813|9791306|FG000|Overall Study|Death|1
6153353|NCT01125813|9791306|FG000|Overall Study|Withdrawal by Subject|1
6153354|NCT01125813|9791306|FG000|Overall Study|Screen Failures|4
6153355|NCT01125917|9791310|FG000|Overall Study|Adverse Event|43
6153356|NCT01125917|9791310|FG000|Overall Study|Lost to Follow-up|23
6153357|NCT01125917|9791310|FG000|Overall Study|Withdrawal by Subject|31
6153358|NCT01125917|9791310|FG000|Overall Study|Administrative|223
6153359|NCT01125917|9791310|FG000|Overall Study|Lack of Efficacy|19
6153360|NCT01125930|9791316|FG000|Overall Study|Adverse Event|0
6153361|NCT01125930|9791317|FG001|Overall Study|Adverse Event|1
6153362|NCT01125930|9791316|FG000|Overall Study|Withdrawal by Subject|1
6153363|NCT01125930|9791317|FG001|Overall Study|Withdrawal by Subject|6
6153364|NCT01125930|9791316|FG000|Overall Study|Protocol Violation|0
6153365|NCT01125930|9791317|FG001|Overall Study|Protocol Violation|1
6153366|NCT01125930|9791316|FG000|Overall Study|Lost to Follow-up|0
6153367|NCT01125930|9791317|FG001|Overall Study|Lost to Follow-up|2
6153368|NCT01126060|9791341|FG000|Overall Study|Protocol Violation|0
6153369|NCT01126060|9791342|FG001|Overall Study|Protocol Violation|2
6153370|NCT01126268|9791357|FG000|Overall Study|Adverse Event|1
6153371|NCT01126359|9791361|FG000|First Intervention (20-minutes)|Physician Decision|0
6153372|NCT01126359|9791362|FG001|First Intervention (20-minutes)|Physician Decision|1
6153373|NCT01126424|9791378|FG000|Overall Study|Adverse Event|0
6153374|NCT01126424|9791379|FG001|Overall Study|Adverse Event|0
6153375|NCT01126424|9791380|FG002|Overall Study|Adverse Event|0
6153376|NCT01126424|9791381|FG003|Overall Study|Adverse Event|0
6153377|NCT01126424|9791382|FG004|Overall Study|Adverse Event|1
6153378|NCT01126424|9791383|FG005|Overall Study|Adverse Event|0
6153379|NCT01126424|9791378|FG000|Overall Study|Withdrawal by Subject|0
6153380|NCT01126424|9791379|FG001|Overall Study|Withdrawal by Subject|0
6153381|NCT01126424|9791380|FG002|Overall Study|Withdrawal by Subject|1
6153382|NCT01126424|9791381|FG003|Overall Study|Withdrawal by Subject|3
6153383|NCT01126424|9791382|FG004|Overall Study|Withdrawal by Subject|1
6153384|NCT01126424|9791383|FG005|Overall Study|Withdrawal by Subject|0
6153385|NCT01126437|9791394|FG000|Overall Study|Not treated|11
6153386|NCT01126437|9791395|FG001|Overall Study|Not treated|18
6153387|NCT01126437|9791396|FG002|Overall Study|Not treated|19
6153388|NCT01126437|9791394|FG000|Overall Study|Sites with data irregularities/fraud|6
6153389|NCT01126437|9791395|FG001|Overall Study|Sites with data irregularities/fraud|6
6153390|NCT01126437|9791396|FG002|Overall Study|Sites with data irregularities/fraud|7
6153391|NCT01126437|9791394|FG000|Overall Study|Adverse Event|602
6153392|NCT01126437|9791395|FG001|Overall Study|Adverse Event|606
6153393|NCT01126437|9791396|FG002|Overall Study|Adverse Event|635
6153394|NCT01126437|9791394|FG000|Overall Study|Lack of Efficacy|65
6153395|NCT01126437|9791395|FG001|Overall Study|Lack of Efficacy|60
6153396|NCT01126437|9791396|FG002|Overall Study|Lack of Efficacy|59
6153397|NCT01126437|9791394|FG000|Overall Study|Protocol Violation|64
6153398|NCT01126437|9791395|FG001|Overall Study|Protocol Violation|66
6153399|NCT01126437|9791396|FG002|Overall Study|Protocol Violation|41
6153400|NCT01126437|9791394|FG000|Overall Study|Lost to Follow-up|52
6153401|NCT01126437|9791395|FG001|Overall Study|Lost to Follow-up|63
6153402|NCT01126437|9791396|FG002|Overall Study|Lost to Follow-up|55
6153403|NCT01126437|9791394|FG000|Overall Study|Withdrawal by Subject|331
6153404|NCT01126437|9791395|FG001|Overall Study|Withdrawal by Subject|335
6153405|NCT01126437|9791396|FG002|Overall Study|Withdrawal by Subject|319
6153406|NCT01126437|9791394|FG000|Overall Study|Other reason not specified|210
6153407|NCT01126437|9791395|FG001|Overall Study|Other reason not specified|176
6153408|NCT01126437|9791396|FG002|Overall Study|Other reason not specified|178
6153409|NCT01126541|9791407|FG000|Overall Study|Adverse Event|0
6153410|NCT01126541|9791408|FG001|Overall Study|Adverse Event|2
6153411|NCT01126541|9791409|FG002|Overall Study|Adverse Event|4
6153412|NCT01126541|9791407|FG000|Overall Study|Death|0
6153413|NCT01126541|9791408|FG001|Overall Study|Death|1
6153414|NCT01126541|9791409|FG002|Overall Study|Death|0
6153415|NCT01126541|9791407|FG000|Overall Study|Lack of Efficacy|6
6153416|NCT01126541|9791408|FG001|Overall Study|Lack of Efficacy|1
6153417|NCT01126541|9791409|FG002|Overall Study|Lack of Efficacy|11
6153418|NCT01126541|9791407|FG000|Overall Study|Lost to Follow-up|1
6153419|NCT01126541|9791408|FG001|Overall Study|Lost to Follow-up|2
6153420|NCT01126541|9791409|FG002|Overall Study|Lost to Follow-up|2
6153421|NCT01126541|9791407|FG000|Overall Study|Withdrawal by Subject|2
6153422|NCT01126541|9791408|FG001|Overall Study|Withdrawal by Subject|5
6153423|NCT01126541|9791409|FG002|Overall Study|Withdrawal by Subject|6
6153424|NCT01126541|9791407|FG000|Overall Study|Protocol Violation|0
6153425|NCT01126541|9791408|FG001|Overall Study|Protocol Violation|0
6153426|NCT01126541|9791409|FG002|Overall Study|Protocol Violation|1
6153427|NCT01126541|9791407|FG000|Overall Study|Administrative reason or other|1
6153428|NCT01126541|9791408|FG001|Overall Study|Administrative reason or other|1
6153429|NCT01126541|9791409|FG002|Overall Study|Administrative reason or other|2
6153430|NCT01126580|9791422|FG000|Overall Study|Adverse Event|14
6153431|NCT01126580|9791423|FG001|Overall Study|Adverse Event|8
6153432|NCT01126580|9791424|FG002|Overall Study|Adverse Event|12
6153433|NCT01126580|9791422|FG000|Overall Study|Withdrawal by Subject|11
6153434|NCT01126580|9791423|FG001|Overall Study|Withdrawal by Subject|19
6153435|NCT01126580|9791424|FG002|Overall Study|Withdrawal by Subject|14
6153436|NCT01126580|9791422|FG000|Overall Study|Sponsor Decision|5
6153437|NCT01126580|9791423|FG001|Overall Study|Sponsor Decision|4
6153438|NCT01126580|9791424|FG002|Overall Study|Sponsor Decision|7
6153439|NCT01126580|9791422|FG000|Overall Study|Physician Decision|1
6153440|NCT01126580|9791423|FG001|Overall Study|Physician Decision|1
6153441|NCT01126580|9791424|FG002|Overall Study|Physician Decision|2
6153442|NCT01126580|9791422|FG000|Overall Study|Entry Criteria Not Met|1
6153443|NCT01126580|9791423|FG001|Overall Study|Entry Criteria Not Met|1
6153444|NCT01126580|9791424|FG002|Overall Study|Entry Criteria Not Met|2
6153445|NCT01126580|9791422|FG000|Overall Study|Lack of Efficacy|2
6153446|NCT01126580|9791423|FG001|Overall Study|Lack of Efficacy|3
6153447|NCT01126580|9791424|FG002|Overall Study|Lack of Efficacy|4
6153448|NCT01126580|9791422|FG000|Overall Study|Protocol Violation|0
6153449|NCT01126580|9791423|FG001|Overall Study|Protocol Violation|1
6153450|NCT01126580|9791424|FG002|Overall Study|Protocol Violation|2
6153451|NCT01126580|9791422|FG000|Overall Study|Lost to Follow-up|15
6153452|NCT01126580|9791423|FG001|Overall Study|Lost to Follow-up|13
6153453|NCT01126580|9791424|FG002|Overall Study|Lost to Follow-up|9
6153454|NCT01126580|9791422|FG000|Overall Study|Treatment Non-compliance|0
6153455|NCT01126580|9791423|FG001|Overall Study|Treatment Non-compliance|2
6153456|NCT01126580|9791424|FG002|Overall Study|Treatment Non-compliance|3
6153457|NCT01126619|9791446|FG000|Overall Study|Not eligible for the study|2
6153458|NCT01126619|9791446|FG000|Overall Study|Investigator decision|4
6153459|NCT01126619|9791446|FG000|Overall Study|Serious adverse event|1
6153460|NCT01126619|9791446|FG000|Overall Study|Withdrawal by Subject|9
6153461|NCT01126619|9791446|FG000|Overall Study|Non-compliance|1
6153462|NCT01127061|9791474|FG000|Overall Study|Lost to Follow-up|7
6153463|NCT01127061|9791475|FG001|Overall Study|Lost to Follow-up|10
6153464|NCT01127061|9791474|FG000|Overall Study|Physician Decision|3
6153465|NCT01127061|9791475|FG001|Overall Study|Physician Decision|3
6153466|NCT01127139|9791492|FG000|Overall Study|Adverse Event|40
6153467|NCT01127139|9791492|FG000|Overall Study|Incompliance|12
6153468|NCT01127139|9791492|FG000|Overall Study|Lack of Efficacy|4
6153469|NCT01127139|9791492|FG000|Overall Study|Reason not specified|1
6153470|NCT01127165|9791501|FG000|Overall Study|Adverse Event|2
6153471|NCT01127165|9791502|FG001|Overall Study|Adverse Event|2
6153472|NCT01127165|9791501|FG000|Overall Study|Lack of Efficacy|10
6153473|NCT01127165|9791502|FG001|Overall Study|Lack of Efficacy|8
6153474|NCT01127165|9791501|FG000|Overall Study|Lost to Follow-up|3
6153475|NCT01127165|9791502|FG001|Overall Study|Lost to Follow-up|5
6153476|NCT01127165|9791501|FG000|Overall Study|Withdrawal by Subject|1
6153477|NCT01127165|9791502|FG001|Overall Study|Withdrawal by Subject|3
6153478|NCT01127165|9791501|FG000|Overall Study|Protocol Violation|0
6153479|NCT01127165|9791502|FG001|Overall Study|Protocol Violation|1
6153480|NCT01127373|9791529|FG000|Overall Study|Not Treated|3
6153481|NCT01127373|9791529|FG000|Overall Study|Lost to Follow-up|7
6153482|NCT01127373|9791529|FG000|Overall Study|Withdrawal by Subject|1
6153483|NCT01127373|9791529|FG000|Overall Study|Disease progression|1
6153484|NCT01127607|9791565|FG000|Phase II (Between Subjects)|Lost to Follow-up|0
6153485|NCT01127607|9791566|FG001|Phase II (Between Subjects)|Lost to Follow-up|2
6153486|NCT01127607|9791565|FG000|Phase II (Between Subjects)|Withdrawal by Subject|1
6153487|NCT01127607|9791566|FG001|Phase II (Between Subjects)|Withdrawal by Subject|0
6153488|NCT01127633|9791591|FG000|Overall Study|Adverse Event|74
6153489|NCT01127633|9791592|FG001|Overall Study|Adverse Event|73
6153490|NCT01127633|9791591|FG000|Overall Study|Death|40
6153491|NCT01127633|9791592|FG001|Overall Study|Death|43
6153492|NCT01127633|9791591|FG000|Overall Study|Lost to Follow-up|4
6153493|NCT01127633|9791592|FG001|Overall Study|Lost to Follow-up|0
6153494|NCT01127633|9791591|FG000|Overall Study|Parent/Caregiver Decision|246
6153495|NCT01127633|9791592|FG001|Overall Study|Parent/Caregiver Decision|228
6153496|NCT01127633|9791591|FG000|Overall Study|Physician Decision|60
6153497|NCT01127633|9791592|FG001|Overall Study|Physician Decision|45
6153498|NCT01127633|9791591|FG000|Overall Study|Withdrawal by Subject|57
6153499|NCT01127633|9791592|FG001|Overall Study|Withdrawal by Subject|72
6153500|NCT01127633|9791591|FG000|Overall Study|Sponsor Decision|163
6153501|NCT01127633|9791592|FG001|Overall Study|Sponsor Decision|195
6153502|NCT01127633|9791591|FG000|Overall Study|Protocol Violation|8
6153503|NCT01127633|9791592|FG001|Overall Study|Protocol Violation|16
6153504|NCT01127633|9791591|FG000|Overall Study|Abnormal Lab/ECG Result|0
6153505|NCT01127633|9791592|FG001|Overall Study|Abnormal Lab/ECG Result|1
6153506|NCT01127633|9791591|FG000|Overall Study|Not treated|1
6153507|NCT01127633|9791592|FG001|Overall Study|Not treated|0
6153508|NCT01127646|9791600|FG000|Overall Study|Entry Criteria Not Met|1
6153509|NCT01127646|9791601|FG001|Overall Study|Entry Criteria Not Met|0
6153510|NCT01127646|9791600|FG000|Overall Study|Protocol Violation|0
6153511|NCT01127646|9791601|FG001|Overall Study|Protocol Violation|1
6153512|NCT01127763|9791643|FG000|Overall Study|Adverse Event|2
6153513|NCT01127763|9791643|FG000|Overall Study|Withdrawal by Subject|1
6153514|NCT01127763|9791643|FG000|Overall Study|Physician Decision|2
6153515|NCT01127893|9791651|FG000|Overall Study|Study Termination by the Sponsor|1
6153516|NCT01128153|9791670|FG000|Overall Study|Adverse Event|1
6153517|NCT01128153|9791671|FG001|Overall Study|Adverse Event|3
6153518|NCT01128153|9791670|FG000|Overall Study|Condition under investigation worsened|8
6153519|NCT01128153|9791671|FG001|Overall Study|Condition under investigation worsened|7
6041504|NCT00377637|9639825|FG002|Induction Phase|Withdrawal by Subject|0
6041505|NCT00377637|9639826|FG003|Induction Phase|Withdrawal by Subject|0
6153520|NCT01128153|9791670|FG000|Overall Study|Withdrawal by Subject|2
6153521|NCT01128153|9791671|FG001|Overall Study|Withdrawal by Subject|3
6041506|NCT00377637|9639823|FG000|Induction Phase|Physician Decision|3
6041507|NCT00377637|9639824|FG001|Induction Phase|Physician Decision|1
6041508|NCT00377637|9639825|FG002|Induction Phase|Physician Decision|0
6041509|NCT00377637|9639826|FG003|Induction Phase|Physician Decision|0
6041510|NCT00377637|9639823|FG000|Induction Phase|Sponsor decision|1
6041511|NCT00377637|9639824|FG001|Induction Phase|Sponsor decision|2
6041512|NCT00377637|9639825|FG002|Induction Phase|Sponsor decision|0
6041513|NCT00377637|9639826|FG003|Induction Phase|Sponsor decision|0
6041514|NCT00377637|9639823|FG000|Induction Phase|Non-Compliance|1
6041515|NCT00377637|9639824|FG001|Induction Phase|Non-Compliance|0
6153522|NCT01128153|9791670|FG000|Overall Study|Incorrect enrolment to study|2
6153523|NCT01128153|9791671|FG001|Overall Study|Incorrect enrolment to study|1
6153524|NCT01128153|9791670|FG000|Overall Study|Protocol Violation|2
6153525|NCT01128153|9791671|FG001|Overall Study|Protocol Violation|0
6153526|NCT01128153|9791670|FG000|Overall Study|Developed discontinuation criteria|1
6153527|NCT01128153|9791671|FG001|Overall Study|Developed discontinuation criteria|1
6153528|NCT01128179|9791679|FG000|Overall Study|Death|1
6153529|NCT01128179|9791680|FG001|Overall Study|Death|0
6153530|NCT01128179|9791679|FG000|Overall Study|Protocol Violation|1
6153531|NCT01128179|9791680|FG001|Overall Study|Protocol Violation|0
6153532|NCT01128244|9791701|FG000|Overall Study|Adverse Event|1
6153533|NCT01128244|9791701|FG000|Overall Study|Scheduling conflict|2
6041516|NCT00377637|9639825|FG002|Induction Phase|Non-Compliance|0
6153534|NCT01128296|9791721|FG000|Overall Study|Physician Decision|0
6041517|NCT00377637|9639826|FG003|Induction Phase|Non-Compliance|0
6041518|NCT00377637|9639823|FG000|Induction Phase|Reason for withdrawal is not noted|2
6041519|NCT00377637|9639824|FG001|Induction Phase|Reason for withdrawal is not noted|0
6041520|NCT00377637|9639825|FG002|Induction Phase|Reason for withdrawal is not noted|0
6041521|NCT00377637|9639826|FG003|Induction Phase|Reason for withdrawal is not noted|0
6041522|NCT00377637|9639823|FG000|Maintenance Phase|Adverse Event|0
6041523|NCT00377637|9639824|FG001|Maintenance Phase|Adverse Event|0
6041524|NCT00377637|9639825|FG002|Maintenance Phase|Adverse Event|29
6041525|NCT00377637|9639826|FG003|Maintenance Phase|Adverse Event|43
6041526|NCT00377637|9639823|FG000|Maintenance Phase|Physician Decision|0
6041527|NCT00377637|9639824|FG001|Maintenance Phase|Physician Decision|0
6153535|NCT01128296|9791722|FG001|Overall Study|Physician Decision|0
6153536|NCT01128296|9791723|FG002|Overall Study|Physician Decision|0
6153537|NCT01128296|9791724|FG003|Overall Study|Physician Decision|0
6153538|NCT01128296|9791725|FG004|Overall Study|Physician Decision|0
6153539|NCT01128296|9791726|FG005|Overall Study|Physician Decision|3
6153540|NCT01128296|9791721|FG000|Overall Study|Withdrawal by Subject|0
6153541|NCT01128296|9791722|FG001|Overall Study|Withdrawal by Subject|0
6153542|NCT01128296|9791723|FG002|Overall Study|Withdrawal by Subject|0
6153543|NCT01128296|9791724|FG003|Overall Study|Withdrawal by Subject|0
6153544|NCT01128296|9791725|FG004|Overall Study|Withdrawal by Subject|0
6153545|NCT01128296|9791726|FG005|Overall Study|Withdrawal by Subject|2
6153546|NCT01128361|9791739|FG000|Overall Study|Lost to Follow-up|0
6153547|NCT01128361|9791740|FG001|Overall Study|Lost to Follow-up|1
6153548|NCT01128361|9791739|FG000|Overall Study|Withdrawal by Subject|5
6153549|NCT01128361|9791740|FG001|Overall Study|Withdrawal by Subject|2
6153550|NCT01128387|9791748|FG000|Overall Study|Physician Decision|0
6153551|NCT01128387|9791749|FG001|Overall Study|Physician Decision|1
6153552|NCT01128400|9791758|FG000|Overall Study|Lost to Follow-up|1
6153553|NCT01128400|9791759|FG001|Overall Study|Lost to Follow-up|0
6153554|NCT01128400|9791760|FG002|Overall Study|Lost to Follow-up|1
6153555|NCT01128400|9791758|FG000|Overall Study|Screening failure|1
6153556|NCT01128400|9791759|FG001|Overall Study|Screening failure|0
6153557|NCT01128400|9791760|FG002|Overall Study|Screening failure|0
6153558|NCT01128400|9791758|FG000|Overall Study|were not invited to participate on taste|0
6153559|NCT01128400|9791759|FG001|Overall Study|were not invited to participate on taste|0
6153560|NCT01128400|9791760|FG002|Overall Study|were not invited to participate on taste|15
6153561|NCT01128400|9791758|FG000|Overall Study|Excluded due to sinus problems|0
6153562|NCT01128400|9791759|FG001|Overall Study|Excluded due to sinus problems|1
6153563|NCT01128400|9791760|FG002|Overall Study|Excluded due to sinus problems|0
6153564|NCT01128413|9791770|FG000|Overall Study|Withdrawal by Subject|1
6153565|NCT01128413|9791771|FG001|Overall Study|Withdrawal by Subject|0
6153566|NCT01128413|9791770|FG000|Overall Study|NICOM Monitor Problems|2
6153567|NCT01128413|9791771|FG001|Overall Study|NICOM Monitor Problems|1
6153568|NCT01128413|9791770|FG000|Overall Study|Pt made DNR|1
6153569|NCT01128413|9791771|FG001|Overall Study|Pt made DNR|0
6153570|NCT01128543|9791783|FG000|Overall Study|Withdrawal by Subject|3
6153571|NCT01128543|9791783|FG000|Overall Study|Protocol Violation|1
6153572|NCT01128569|9791787|FG000|Washout Period 1|Adverse Event|0
6153573|NCT01128569|9791788|FG001|Washout Period 1|Adverse Event|0
6153574|NCT01128569|9791789|FG002|Washout Period 1|Adverse Event|1
6153575|NCT01128569|9791790|FG003|Washout Period 1|Adverse Event|0
6153576|NCT01128569|9791791|FG004|Washout Period 1|Adverse Event|0
6153577|NCT01128569|9791792|FG005|Washout Period 1|Adverse Event|0
6153578|NCT01128569|9791787|FG000|Treatment Period 2|Withdrawal by Subject|0
6153579|NCT01128569|9791788|FG001|Treatment Period 2|Withdrawal by Subject|1
6153580|NCT01128569|9791789|FG002|Treatment Period 2|Withdrawal by Subject|0
6153581|NCT01128569|9791790|FG003|Treatment Period 2|Withdrawal by Subject|0
6153582|NCT01128569|9791791|FG004|Treatment Period 2|Withdrawal by Subject|0
6153583|NCT01128569|9791792|FG005|Treatment Period 2|Withdrawal by Subject|0
6153584|NCT01128595|9791800|FG000|Treatment Period 3|Withdrawal by Subject|0
6153585|NCT01128595|9791801|FG001|Treatment Period 3|Withdrawal by Subject|1
6153586|NCT01128595|9791802|FG002|Treatment Period 3|Withdrawal by Subject|0
6153587|NCT01128595|9791803|FG003|Treatment Period 3|Withdrawal by Subject|0
6153588|NCT01128621|9791816|FG000|Part B: GSK1292263 75 mg/300 mg/ 600 mg|Reached defined stopping criteria|0
6153589|NCT01128621|9791817|FG001|Part B: GSK1292263 75 mg/300 mg/ 600 mg|Reached defined stopping criteria|2
6153590|NCT01128738|9791841|FG000|First Treatment Phase (TP)|Lost to Follow-up|1
6153591|NCT01128738|9791842|FG001|First Treatment Phase (TP)|Lost to Follow-up|0
6153592|NCT01128738|9791841|FG000|First Treatment Phase (TP)|Withdrawal by Subject|3
6153593|NCT01128738|9791842|FG001|First Treatment Phase (TP)|Withdrawal by Subject|1
6153594|NCT01128738|9791841|FG000|Second TP|Lost to Follow-up|0
6153595|NCT01128738|9791842|FG001|Second TP|Lost to Follow-up|1
6153596|NCT01128738|9791841|FG000|Second TP|Withdrawal by Subject|0
6153597|NCT01128738|9791842|FG001|Second TP|Withdrawal by Subject|2
6153598|NCT01128842|9791854|FG000|Overall Study|Adverse Event|1
6153599|NCT01128842|9791854|FG000|Overall Study|Disease Progression|6
6153600|NCT01128894|9791861|FG000|Overall Study|Adverse Event|31
6153601|NCT01128894|9791862|FG001|Overall Study|Adverse Event|41
6153602|NCT01128894|9791861|FG000|Overall Study|Protocol Violation|2
6153603|NCT01128894|9791862|FG001|Overall Study|Protocol Violation|1
6153604|NCT01128894|9791861|FG000|Overall Study|Noncompliance|4
6153605|NCT01128894|9791862|FG001|Overall Study|Noncompliance|5
6153606|NCT01128894|9791861|FG000|Overall Study|Lost to Follow-up|8
6153607|NCT01128894|9791862|FG001|Overall Study|Lost to Follow-up|8
6153608|NCT01128894|9791861|FG000|Overall Study|Withdrawal by Subject|10
6153609|NCT01128894|9791862|FG001|Overall Study|Withdrawal by Subject|12
6153610|NCT01128894|9791861|FG000|Overall Study|Physician Decision|2
6153611|NCT01128894|9791862|FG001|Overall Study|Physician Decision|1
6153612|NCT01128894|9791861|FG000|Overall Study|Conflicting HbA1c Results at Screening|1
6153613|NCT01128894|9791862|FG001|Overall Study|Conflicting HbA1c Results at Screening|0
6153614|NCT01128946|9791868|FG000|Period I|Protocol Violation|0
6153615|NCT01128946|9791869|FG001|Period I|Protocol Violation|1
6153616|NCT01128946|9791870|FG002|Period I|Protocol Violation|0
6153617|NCT01128946|9791871|FG003|Period I|Protocol Violation|0
6153618|NCT01128946|9791868|FG000|Period I|Withdrawal by Subject|0
6153619|NCT01128946|9791869|FG001|Period I|Withdrawal by Subject|0
6153620|NCT01128946|9791870|FG002|Period I|Withdrawal by Subject|1
6153621|NCT01128946|9791871|FG003|Period I|Withdrawal by Subject|1
6153622|NCT01128946|9791868|FG000|Period II|Protocol Violation|0
6153623|NCT01128946|9791869|FG001|Period II|Protocol Violation|1
6153624|NCT01128946|9791870|FG002|Period II|Protocol Violation|0
6153625|NCT01128946|9791871|FG003|Period II|Protocol Violation|0
6153626|NCT01128946|9791868|FG000|Period II|Withdrawal by Subject|0
6153627|NCT01128946|9791869|FG001|Period II|Withdrawal by Subject|0
6153628|NCT01128946|9791870|FG002|Period II|Withdrawal by Subject|0
6153629|NCT01128946|9791871|FG003|Period II|Withdrawal by Subject|1
6153630|NCT01128946|9791868|FG000|Period III|Protocol Violation|1
6153631|NCT01128946|9791869|FG001|Period III|Protocol Violation|0
6153632|NCT01128946|9791870|FG002|Period III|Protocol Violation|0
6153633|NCT01128946|9791871|FG003|Period III|Protocol Violation|0
6153634|NCT01128959|9791882|FG000|Lead in Period|Adverse Event|3
6153635|NCT01128959|9791882|FG000|Treatment Period|Adverse Event|3
6153636|NCT01128959|9791882|FG000|Treatment Period|Withdrawal by Subject|1
6191649|NCT01424930|9848578|FG000|Overall Study|Screen Failure|0
6191650|NCT01424930|9848579|FG001|Overall Study|Screen Failure|1
6191651|NCT01424930|9848578|FG000|Overall Study|Reason not specified|0
6191652|NCT01424930|9848579|FG001|Overall Study|Reason not specified|6
6191653|NCT01425190|9848597|FG000|Overall Study|Full dose not consumed.|1
6191654|NCT01425190|9848598|FG001|Overall Study|Full dose not consumed.|0
6191655|NCT01425190|9848599|FG002|Overall Study|Full dose not consumed.|0
6191656|NCT01425203|9848609|FG000|Treatment Phase|DC during PR Lead-in Phase|3
6191657|NCT01425203|9848610|FG001|Treatment Phase|DC during PR Lead-in Phase|1
6191658|NCT01425203|9848611|FG002|Treatment Phase|DC during PR Lead-in Phase|0
6191659|NCT01425203|9848609|FG000|Treatment Phase|Failure at futility timepoint|8
6191660|NCT01425203|9848610|FG001|Treatment Phase|Failure at futility timepoint|27
6191661|NCT01425203|9848611|FG002|Treatment Phase|Failure at futility timepoint|0
6191662|NCT01425203|9848609|FG000|Treatment Phase|Other virologic failure criteria|5
6191663|NCT01425203|9848610|FG001|Treatment Phase|Other virologic failure criteria|3
6191664|NCT01425203|9848611|FG002|Treatment Phase|Other virologic failure criteria|0
6191665|NCT01425203|9848609|FG000|Treatment Phase|Unidentified reasons|11
6191666|NCT01425203|9848610|FG001|Treatment Phase|Unidentified reasons|5
6191667|NCT01425203|9848611|FG002|Treatment Phase|Unidentified reasons|0
6191668|NCT01425203|9848609|FG000|Treatment Phase|Did not receive treatment|0
6191669|NCT01425203|9848610|FG001|Treatment Phase|Did not receive treatment|1
6191670|NCT01425203|9848611|FG002|Treatment Phase|Did not receive treatment|0
6191671|NCT01425203|9848609|FG000|Crossover Phase|Failure at futility timepoint|0
6191672|NCT01425203|9848610|FG001|Crossover Phase|Failure at futility timepoint|0
6191673|NCT01425203|9848611|FG002|Crossover Phase|Failure at futility timepoint|3
6191674|NCT01425203|9848609|FG000|Crossover Phase|Other virologic failure criteria|0
6191675|NCT01425203|9848610|FG001|Crossover Phase|Other virologic failure criteria|0
6191676|NCT01425203|9848611|FG002|Crossover Phase|Other virologic failure criteria|3
6191677|NCT01425268|9848629|FG000|Overall Study|Withdrawal by Subject|2
6191678|NCT01425268|9848630|FG001|Overall Study|Withdrawal by Subject|0
6191679|NCT01425268|9848629|FG000|Overall Study|Sponsor Decision|5
6191680|NCT01425268|9848630|FG001|Overall Study|Sponsor Decision|0
6191681|NCT01425268|9848629|FG000|Overall Study|Physician Decision|1
6191682|NCT01425268|9848630|FG001|Overall Study|Physician Decision|0
6191683|NCT01425359|9848649|FG000|Overall Study|Randomized but Not Treated|2
6191684|NCT01425359|9848650|FG001|Overall Study|Randomized but Not Treated|3
6191685|NCT01425359|9848649|FG000|Overall Study|Adverse Event|9
6191686|NCT01425359|9848650|FG001|Overall Study|Adverse Event|8
6191687|NCT01425359|9848649|FG000|Overall Study|Revascularization|0
6191688|NCT01425359|9848650|FG001|Overall Study|Revascularization|1
6191689|NCT01425359|9848649|FG000|Overall Study|Death|0
6191690|NCT01425359|9848650|FG001|Overall Study|Death|1
6191691|NCT01425359|9848649|FG000|Overall Study|Unsatisfactory Response|1
6191692|NCT01425359|9848650|FG001|Overall Study|Unsatisfactory Response|0
6191693|NCT01425359|9848649|FG000|Overall Study|Protocol Violation|1
6191694|NCT01425359|9848650|FG001|Overall Study|Protocol Violation|2
6191695|NCT01425359|9848649|FG000|Overall Study|Subject Withdrew Consent|1
6191696|NCT01425359|9848650|FG001|Overall Study|Subject Withdrew Consent|2
6191697|NCT01425359|9848649|FG000|Overall Study|Investigator's Discretion|2
6191698|NCT01425359|9848650|FG001|Overall Study|Investigator's Discretion|0
6191699|NCT01425359|9848649|FG000|Overall Study|Did Not Meet Qualifying Criteria|3
6191700|NCT01425359|9848650|FG001|Overall Study|Did Not Meet Qualifying Criteria|5
6191701|NCT01425463|9848659|FG000|Overall Study|Adverse Event|5
6191702|NCT01425463|9848660|FG001|Overall Study|Adverse Event|7
6041528|NCT00377637|9639825|FG002|Maintenance Phase|Physician Decision|5
6041529|NCT00377637|9639826|FG003|Maintenance Phase|Physician Decision|4
6041530|NCT00377637|9639823|FG000|Maintenance Phase|Lost to Follow-up|0
6041531|NCT00377637|9639824|FG001|Maintenance Phase|Lost to Follow-up|0
6041532|NCT00377637|9639825|FG002|Maintenance Phase|Lost to Follow-up|3
6041533|NCT00377637|9639826|FG003|Maintenance Phase|Lost to Follow-up|1
6041534|NCT00377637|9639823|FG000|Maintenance Phase|Withdrawal by Subject|0
6041535|NCT00377637|9639824|FG001|Maintenance Phase|Withdrawal by Subject|0
6041536|NCT00377637|9639825|FG002|Maintenance Phase|Withdrawal by Subject|3
6153637|NCT01129024|9791910|FG000|Overall Study|Physician Decision|5
6153638|NCT01129024|9791910|FG000|Overall Study|Study Terminated by Sponsor|8
6153639|NCT01129024|9791910|FG000|Overall Study|Withdrawal by Subject|2
6153640|NCT01129024|9791910|FG000|Overall Study|Lack of Efficacy|3
6153641|NCT01129024|9791910|FG000|Overall Study|Needed a Platelet Transfusion|1
6153642|NCT01129102|9791917|FG000|Overall Study|No study drug treatment|2
6153643|NCT01129102|9791918|FG001|Overall Study|No study drug treatment|3
6153644|NCT01129102|9791919|FG002|Overall Study|No study drug treatment|1
6041537|NCT00377637|9639826|FG003|Maintenance Phase|Withdrawal by Subject|3
6041538|NCT00377637|9639823|FG000|Maintenance Phase|Sponsor decision|0
6041539|NCT00377637|9639824|FG001|Maintenance Phase|Sponsor decision|0
6041540|NCT00377637|9639825|FG002|Maintenance Phase|Sponsor decision|2
6041541|NCT00377637|9639826|FG003|Maintenance Phase|Sponsor decision|3
6041542|NCT00377637|9639823|FG000|Maintenance Phase|Non-compliance|0
6041543|NCT00377637|9639824|FG001|Maintenance Phase|Non-compliance|0
6041544|NCT00377637|9639825|FG002|Maintenance Phase|Non-compliance|1
6041545|NCT00377637|9639826|FG003|Maintenance Phase|Non-compliance|1
6041546|NCT00377637|9639823|FG000|Maintenance Phase|Study medication stopped > 14 days|0
6041547|NCT00377637|9639824|FG001|Maintenance Phase|Study medication stopped > 14 days|0
6041548|NCT00377637|9639825|FG002|Maintenance Phase|Study medication stopped > 14 days|0
6041549|NCT00377637|9639826|FG003|Maintenance Phase|Study medication stopped > 14 days|1
6041550|NCT00377637|9639823|FG000|Maintenance Phase|Death|0
6041551|NCT00377637|9639824|FG001|Maintenance Phase|Death|0
6041552|NCT00377637|9639825|FG002|Maintenance Phase|Death|0
6041553|NCT00377637|9639826|FG003|Maintenance Phase|Death|1
6041554|NCT00377676|9639842|FG000|Overall Study|Adverse Event|498
6041555|NCT00377676|9639843|FG001|Overall Study|Adverse Event|107
6041556|NCT00377676|9639842|FG000|Overall Study|Protocol Violation|33
6041557|NCT00377676|9639843|FG001|Overall Study|Protocol Violation|27
6041558|NCT00377676|9639842|FG000|Overall Study|Death|5
6041559|NCT00377676|9639843|FG001|Overall Study|Death|2
6041560|NCT00377676|9639842|FG000|Overall Study|Withdrawal by Subject|187
6041561|NCT00377676|9639843|FG001|Overall Study|Withdrawal by Subject|72
6041562|NCT00377676|9639842|FG000|Overall Study|Lost to Follow-up|120
6041563|NCT00377676|9639843|FG001|Overall Study|Lost to Follow-up|56
6041564|NCT00377676|9639842|FG000|Overall Study|Other|118
6041565|NCT00377676|9639843|FG001|Overall Study|Other|58
6041566|NCT00377819|9639860|FG000|Overall Study|Adverse Event|2
6041567|NCT00377819|9639861|FG001|Overall Study|Adverse Event|3
6153645|NCT01129102|9791917|FG000|Overall Study|Withdrawal by Subject|2
6041568|NCT00377819|9639860|FG000|Overall Study|Withdrawal by Subject|10
6041569|NCT00377819|9639861|FG001|Overall Study|Withdrawal by Subject|4
6041570|NCT00377819|9639860|FG000|Overall Study|Death|0
6041571|NCT00377819|9639861|FG001|Overall Study|Death|1
6041572|NCT00377819|9639860|FG000|Overall Study|Lost to Follow-up|0
6041573|NCT00377819|9639861|FG001|Overall Study|Lost to Follow-up|1
6041574|NCT00377819|9639860|FG000|Overall Study|Protocol Violation|1
6041575|NCT00377819|9639861|FG001|Overall Study|Protocol Violation|1
6041576|NCT00377858|9639881|FG000|Overall Study|Withdrawal by Subject|12
6041577|NCT00377858|9639882|FG001|Overall Study|Withdrawal by Subject|11
6041578|NCT00377858|9639881|FG000|Overall Study|Lost to Follow-up|6
6041579|NCT00377858|9639882|FG001|Overall Study|Lost to Follow-up|1
6041580|NCT00377858|9639881|FG000|Overall Study|Physician Decision|5
6041581|NCT00377858|9639882|FG001|Overall Study|Physician Decision|5
6153646|NCT01129102|9791918|FG001|Overall Study|Withdrawal by Subject|0
6153647|NCT01129102|9791919|FG002|Overall Study|Withdrawal by Subject|3
6153648|NCT01129102|9791917|FG000|Overall Study|Protocol Violation|0
6153649|NCT01129102|9791918|FG001|Overall Study|Protocol Violation|1
6153650|NCT01129102|9791919|FG002|Overall Study|Protocol Violation|1
6153651|NCT01129102|9791917|FG000|Overall Study|Pregnancy|0
6153652|NCT01129102|9791918|FG001|Overall Study|Pregnancy|0
6153653|NCT01129102|9791919|FG002|Overall Study|Pregnancy|1
6153654|NCT01129102|9791917|FG000|Overall Study|Adverse Event|2
6153655|NCT01129102|9791918|FG001|Overall Study|Adverse Event|2
6153656|NCT01129102|9791919|FG002|Overall Study|Adverse Event|1
6153657|NCT01129102|9791917|FG000|Overall Study|Lost to Follow-up|2
6153658|NCT01129102|9791918|FG001|Overall Study|Lost to Follow-up|0
6153659|NCT01129102|9791919|FG002|Overall Study|Lost to Follow-up|0
6153660|NCT01129115|9791930|FG000|Overall Study|Adverse Event|1
6153661|NCT01129115|9791931|FG001|Overall Study|Adverse Event|2
6153662|NCT01129115|9791932|FG002|Overall Study|Adverse Event|3
6153663|NCT01129115|9791933|FG003|Overall Study|Adverse Event|3
6153664|NCT01129115|9791930|FG000|Overall Study|Withdrawal by Subject|1
6153665|NCT01129115|9791931|FG001|Overall Study|Withdrawal by Subject|3
6153666|NCT01129115|9791932|FG002|Overall Study|Withdrawal by Subject|1
6153667|NCT01129115|9791933|FG003|Overall Study|Withdrawal by Subject|4
6153668|NCT01129115|9791930|FG000|Overall Study|Protocol Violation|0
6153669|NCT01129115|9791931|FG001|Overall Study|Protocol Violation|2
6153670|NCT01129115|9791932|FG002|Overall Study|Protocol Violation|2
6153671|NCT01129115|9791933|FG003|Overall Study|Protocol Violation|2
6153672|NCT01129128|9791946|FG000|Overall Study|Lost to Follow-up|2
6153673|NCT01129128|9791947|FG001|Overall Study|Lost to Follow-up|2
6153674|NCT01129128|9791948|FG002|Overall Study|Lost to Follow-up|1
6153675|NCT01129128|9791946|FG000|Overall Study|Protocol Violation|0
6153676|NCT01129128|9791947|FG001|Overall Study|Protocol Violation|1
6153677|NCT01129128|9791948|FG002|Overall Study|Protocol Violation|0
6153678|NCT01129128|9791946|FG000|Overall Study|Withdrawal by Subject|0
6153679|NCT01129128|9791947|FG001|Overall Study|Withdrawal by Subject|1
6153680|NCT01129128|9791948|FG002|Overall Study|Withdrawal by Subject|3
6153681|NCT01129128|9791946|FG000|Overall Study|Physician Decision|1
6153682|NCT01129128|9791947|FG001|Overall Study|Physician Decision|0
6153683|NCT01129128|9791948|FG002|Overall Study|Physician Decision|0
6153684|NCT01129284|9791987|FG000|Overall Study|Adverse Event|2
6153685|NCT01129284|9791988|FG001|Overall Study|Adverse Event|0
6153686|NCT01129284|9791989|FG002|Overall Study|Adverse Event|1
6153687|NCT01129336|9791999|FG000|Overall Study|Protocol Violation|1
6153688|NCT01129336|9792000|FG001|Overall Study|Protocol Violation|0
6153689|NCT01129336|9791999|FG000|Overall Study|Disease Progression|1
6153690|NCT01129336|9792000|FG001|Overall Study|Disease Progression|4
6153691|NCT01129336|9791999|FG000|Overall Study|Lost to Follow-up|1
6153692|NCT01129336|9792000|FG001|Overall Study|Lost to Follow-up|0
6153693|NCT01129336|9791999|FG000|Overall Study|Withdrawal by Subject|7
6153694|NCT01129336|9792000|FG001|Overall Study|Withdrawal by Subject|4
6087667|NCT00669942|9698116|FG000|Parts 2 and 3|Adverse Event|0
6153695|NCT01129336|9791999|FG000|Overall Study|Adverse Event|0
6153696|NCT01129336|9792000|FG001|Overall Study|Adverse Event|1
6153697|NCT01129336|9791999|FG000|Overall Study|Missing Study Completion Status|2
6153698|NCT01129336|9792000|FG001|Overall Study|Missing Study Completion Status|3
6153699|NCT01129336|9791999|FG000|Overall Study|Death|0
6153700|NCT01129336|9792000|FG001|Overall Study|Death|4
6153701|NCT01129557|9792036|FG000|Overall Study|Adverse Event|1
6153702|NCT01129557|9792037|FG001|Overall Study|Adverse Event|2
6153703|NCT01129557|9792038|FG002|Overall Study|Adverse Event|2
6153704|NCT01129557|9792036|FG000|Overall Study|Novartis terminated study early|3
6153705|NCT01129557|9792037|FG001|Overall Study|Novartis terminated study early|3
6153706|NCT01129557|9792038|FG002|Overall Study|Novartis terminated study early|2
6153707|NCT01129583|9792059|FG000|Overall Study|Death|1
6153708|NCT01129583|9792060|FG001|Overall Study|Death|0
6153709|NCT01129583|9792059|FG000|Overall Study|Lost to Follow-up|1
6153710|NCT01129583|9792060|FG001|Overall Study|Lost to Follow-up|1
6153711|NCT01129583|9792059|FG000|Overall Study|Ipsilateral Upper Extremity Injury|1
6153712|NCT01129583|9792060|FG001|Overall Study|Ipsilateral Upper Extremity Injury|1
6080362|NCT00615459|9687528|FG002|Period III|Unsatisfactory therapeutic effect|0
6153713|NCT01129622|9792070|FG000|Overall Study|Withdrawal by Subject|2
6153714|NCT01129882|9792092|FG000|Overall Study|Adverse Event|39
6153715|NCT01129882|9792092|FG000|Overall Study|Death|6
6153716|NCT01129882|9792092|FG000|Overall Study|Lack of Efficacy|5
6153717|NCT01129882|9792092|FG000|Overall Study|Lost to Follow-up|13
6153718|NCT01129882|9792092|FG000|Overall Study|Physician Decision|27
6153719|NCT01129882|9792092|FG000|Overall Study|Protocol Deviation|3
6153720|NCT01129882|9792092|FG000|Overall Study|Withdrawal Criteria Met|19
6153721|NCT01129882|9792092|FG000|Overall Study|Trial Termination by Sponsor|6
6153722|NCT01129882|9792092|FG000|Overall Study|Withdrawal by Subject|160
6153723|NCT01129921|9792098|FG000|After Sham Cross-over to Mild, One Year|Lost to Follow-up|2
6153724|NCT01129921|9792099|FG001|After Sham Cross-over to Mild, One Year|Lost to Follow-up|1
6153725|NCT01129921|9792098|FG000|After Sham Cross-over to Mild, One Year|Lack of Efficacy|0
6153726|NCT01129921|9792099|FG001|After Sham Cross-over to Mild, One Year|Lack of Efficacy|1
6153727|NCT01129921|9792098|FG000|After Sham Cross-over to Mild, One Year|Withdrawal by Subject|0
6153728|NCT01129921|9792099|FG001|After Sham Cross-over to Mild, One Year|Withdrawal by Subject|4
6153729|NCT01129921|9792098|FG000|After Sham Cross-over to Mild, One Year|pancreatic cancer progressed|0
6153730|NCT01129921|9792099|FG001|After Sham Cross-over to Mild, One Year|pancreatic cancer progressed|1
6153731|NCT01129960|9792113|FG000|Overall Study|Withdrawal by Subject|3
6153732|NCT01129960|9792114|FG001|Overall Study|Withdrawal by Subject|0
6153733|NCT01129960|9792115|FG002|Overall Study|Withdrawal by Subject|3
6153734|NCT01129960|9792116|FG003|Overall Study|Withdrawal by Subject|2
6153735|NCT01129960|9792113|FG000|Overall Study|Lack of Efficacy|1
6153736|NCT01129960|9792114|FG001|Overall Study|Lack of Efficacy|1
6153737|NCT01129960|9792115|FG002|Overall Study|Lack of Efficacy|1
6153738|NCT01129960|9792116|FG003|Overall Study|Lack of Efficacy|1
6153739|NCT01129960|9792113|FG000|Overall Study|Adverse Event|23
6153740|NCT01129960|9792114|FG001|Overall Study|Adverse Event|16
6153741|NCT01129960|9792115|FG002|Overall Study|Adverse Event|16
6153742|NCT01129960|9792116|FG003|Overall Study|Adverse Event|7
6153743|NCT01129960|9792113|FG000|Overall Study|Protocol Violation|1
6153744|NCT01129960|9792114|FG001|Overall Study|Protocol Violation|2
6153745|NCT01129960|9792115|FG002|Overall Study|Protocol Violation|3
6153746|NCT01129960|9792116|FG003|Overall Study|Protocol Violation|0
6153747|NCT01129960|9792113|FG000|Overall Study|Lost to Follow-up|0
6153748|NCT01129960|9792114|FG001|Overall Study|Lost to Follow-up|2
6153749|NCT01129960|9792115|FG002|Overall Study|Lost to Follow-up|3
6153750|NCT01129960|9792116|FG003|Overall Study|Lost to Follow-up|3
6153751|NCT01129960|9792113|FG000|Overall Study|Discontinuation of the study by Sponsor|0
6153752|NCT01129960|9792114|FG001|Overall Study|Discontinuation of the study by Sponsor|1
6153753|NCT01129960|9792115|FG002|Overall Study|Discontinuation of the study by Sponsor|0
6153754|NCT01129960|9792116|FG003|Overall Study|Discontinuation of the study by Sponsor|0
6153755|NCT01129960|9792113|FG000|Overall Study|Physician Decision|1
6153756|NCT01129960|9792114|FG001|Overall Study|Physician Decision|0
6153757|NCT01129960|9792115|FG002|Overall Study|Physician Decision|0
6153758|NCT01129960|9792116|FG003|Overall Study|Physician Decision|0
6153759|NCT01129960|9792113|FG000|Overall Study|Pregnancy|1
6153760|NCT01129960|9792114|FG001|Overall Study|Pregnancy|0
6153761|NCT01129960|9792115|FG002|Overall Study|Pregnancy|0
6153762|NCT01129960|9792116|FG003|Overall Study|Pregnancy|0
6153763|NCT01130051|9792126|FG000|Washout Period of 14 Days|Withdrawal by Subject|0
6153764|NCT01130051|9792127|FG001|Washout Period of 14 Days|Withdrawal by Subject|1
6153765|NCT01130051|9792126|FG000|Washout Period of 14 Days|Protocol Violation|1
6153766|NCT01130051|9792127|FG001|Washout Period of 14 Days|Protocol Violation|1
6153767|NCT01130103|9792135|FG000|Randomized Treatment|Adverse Event|1
6153768|NCT01130103|9792136|FG001|Randomized Treatment|Adverse Event|1
6153769|NCT01130103|9792135|FG000|Randomized Treatment|Lost to Follow-up|1
6153770|NCT01130103|9792136|FG001|Randomized Treatment|Lost to Follow-up|0
6153771|NCT01130103|9792135|FG000|Randomized Treatment|Protocol Violation|3
6153772|NCT01130103|9792136|FG001|Randomized Treatment|Protocol Violation|2
6153773|NCT01130103|9792135|FG000|Randomized Treatment|Withdrawal by Subject|1
6153774|NCT01130103|9792136|FG001|Randomized Treatment|Withdrawal by Subject|2
6153775|NCT01130103|9792135|FG000|Maintenance Treatment|Lack of Efficacy|0
6153776|NCT01130103|9792136|FG001|Maintenance Treatment|Lack of Efficacy|1
6153777|NCT01130103|9792135|FG000|Maintenance Treatment|Lost to Follow-up|1
6153778|NCT01130103|9792136|FG001|Maintenance Treatment|Lost to Follow-up|1
6153779|NCT01130103|9792135|FG000|Maintenance Treatment|Withdrawal by Subject|1
6153780|NCT01130103|9792136|FG001|Maintenance Treatment|Withdrawal by Subject|0
6153781|NCT01130168|9792142|FG000|Period 1|Withdrawal by Subject|0
6041582|NCT00377858|9639881|FG000|Overall Study|Protocol Violation|3
6041583|NCT00377858|9639882|FG001|Overall Study|Protocol Violation|4
6041584|NCT00377858|9639881|FG000|Overall Study|Adverse Event|2
6041585|NCT00377858|9639882|FG001|Overall Study|Adverse Event|1
6041586|NCT00377858|9639881|FG000|Overall Study|Entry Criteria Not Met|2
6041587|NCT00377858|9639882|FG001|Overall Study|Entry Criteria Not Met|0
6041588|NCT00377858|9639881|FG000|Overall Study|Sponsor Decision|1
6041589|NCT00377858|9639882|FG001|Overall Study|Sponsor Decision|2
6153782|NCT01130168|9792143|FG001|Period 1|Withdrawal by Subject|1
6153783|NCT01130168|9792144|FG002|Period 1|Withdrawal by Subject|0
6153784|NCT01130168|9792145|FG003|Period 1|Withdrawal by Subject|1
6153785|NCT01130168|9792146|FG004|Period 1|Withdrawal by Subject|0
6153786|NCT01130168|9792147|FG005|Period 1|Withdrawal by Subject|0
6153787|NCT01130168|9792142|FG000|Period 1|Discontinued For Other Reason|0
6153788|NCT01130168|9792143|FG001|Period 1|Discontinued For Other Reason|0
6153789|NCT01130168|9792144|FG002|Period 1|Discontinued For Other Reason|1
6153790|NCT01130168|9792145|FG003|Period 1|Discontinued For Other Reason|1
6153791|NCT01130168|9792146|FG004|Period 1|Discontinued For Other Reason|0
6153792|NCT01130168|9792147|FG005|Period 1|Discontinued For Other Reason|0
6153793|NCT01130168|9792142|FG000|Period 1|Adverse Event|0
6153794|NCT01130168|9792143|FG001|Period 1|Adverse Event|0
6153795|NCT01130168|9792144|FG002|Period 1|Adverse Event|0
6153796|NCT01130168|9792145|FG003|Period 1|Adverse Event|1
6153797|NCT01130168|9792146|FG004|Period 1|Adverse Event|0
6153798|NCT01130168|9792147|FG005|Period 1|Adverse Event|0
6153799|NCT01130272|9792161|FG000|Overall Study|Adverse Event|2
6041590|NCT00377858|9639881|FG000|Overall Study|Death|0
6153800|NCT01130272|9792162|FG001|Overall Study|Adverse Event|5
6153801|NCT01130272|9792163|FG002|Overall Study|Adverse Event|6
6153802|NCT01130272|9792164|FG003|Overall Study|Adverse Event|22
6153803|NCT01130272|9792165|FG004|Overall Study|Adverse Event|7
6153804|NCT01130272|9792161|FG000|Overall Study|IVRS-confirmed constipation|0
6153805|NCT01130272|9792162|FG001|Overall Study|IVRS-confirmed constipation|1
6153806|NCT01130272|9792163|FG002|Overall Study|IVRS-confirmed constipation|1
6153807|NCT01130272|9792164|FG003|Overall Study|IVRS-confirmed constipation|2
6153808|NCT01130272|9792165|FG004|Overall Study|IVRS-confirmed constipation|0
6153809|NCT01130272|9792161|FG000|Overall Study|Rescue medications due to diarrhea|3
6153810|NCT01130272|9792162|FG001|Overall Study|Rescue medications due to diarrhea|5
6153811|NCT01130272|9792163|FG002|Overall Study|Rescue medications due to diarrhea|8
6153812|NCT01130272|9792164|FG003|Overall Study|Rescue medications due to diarrhea|8
6153813|NCT01130272|9792165|FG004|Overall Study|Rescue medications due to diarrhea|6
6153814|NCT01130272|9792161|FG000|Overall Study|Lack of efficacy- uncontrolled diarrhea|1
6153815|NCT01130272|9792162|FG001|Overall Study|Lack of efficacy- uncontrolled diarrhea|1
6153816|NCT01130272|9792163|FG002|Overall Study|Lack of efficacy- uncontrolled diarrhea|0
6153817|NCT01130272|9792164|FG003|Overall Study|Lack of efficacy- uncontrolled diarrhea|0
6153818|NCT01130272|9792165|FG004|Overall Study|Lack of efficacy- uncontrolled diarrhea|2
6041591|NCT00377858|9639882|FG001|Overall Study|Death|3
6041592|NCT00377962|9639890|FG000|Core Study: 0-12 Months|Adverse Event|18
6041593|NCT00377962|9639891|FG001|Core Study: 0-12 Months|Adverse Event|2
6041594|NCT00377962|9639890|FG000|Core Study: 0-12 Months|Death|3
6041595|NCT00377962|9639891|FG001|Core Study: 0-12 Months|Death|0
6041596|NCT00377962|9639890|FG000|Core Study: 0-12 Months|Withdrew Consent|5
6041597|NCT00377962|9639891|FG001|Core Study: 0-12 Months|Withdrew Consent|2
6153819|NCT01130272|9792161|FG000|Overall Study|Lack of efficacy-uncontrolled IBS-d pain|0
6153820|NCT01130272|9792162|FG001|Overall Study|Lack of efficacy-uncontrolled IBS-d pain|0
6153821|NCT01130272|9792163|FG002|Overall Study|Lack of efficacy-uncontrolled IBS-d pain|0
6041598|NCT00377962|9639890|FG000|Core Study: 0-12 Months|Administrative Reason|1
6041599|NCT00377962|9639891|FG001|Core Study: 0-12 Months|Administrative Reason|1
6041600|NCT00377962|9639890|FG000|Core Study: 0-12 Months|Unspecified reasons|1
6041601|NCT00377962|9639891|FG001|Core Study: 0-12 Months|Unspecified reasons|4
6041602|NCT00377962|9639890|FG000|Extension Study: 12-24 Months|Death|1
6041603|NCT00377962|9639891|FG001|Extension Study: 12-24 Months|Death|1
6153822|NCT01130272|9792164|FG003|Overall Study|Lack of efficacy-uncontrolled IBS-d pain|1
6153823|NCT01130272|9792165|FG004|Overall Study|Lack of efficacy-uncontrolled IBS-d pain|0
6153824|NCT01130272|9792161|FG000|Overall Study|Protocol Violation|0
6153825|NCT01130272|9792162|FG001|Overall Study|Protocol Violation|0
6153826|NCT01130272|9792163|FG002|Overall Study|Protocol Violation|3
6153827|NCT01130272|9792164|FG003|Overall Study|Protocol Violation|5
6153828|NCT01130272|9792165|FG004|Overall Study|Protocol Violation|5
6153829|NCT01130272|9792161|FG000|Overall Study|Lost to Follow-up|4
6153830|NCT01130272|9792162|FG001|Overall Study|Lost to Follow-up|3
6153831|NCT01130272|9792163|FG002|Overall Study|Lost to Follow-up|4
6153832|NCT01130272|9792164|FG003|Overall Study|Lost to Follow-up|7
6153833|NCT01130272|9792165|FG004|Overall Study|Lost to Follow-up|6
6153834|NCT01130272|9792161|FG000|Overall Study|Withdrawal by Subject|4
6153835|NCT01130272|9792162|FG001|Overall Study|Withdrawal by Subject|11
6153836|NCT01130272|9792163|FG002|Overall Study|Withdrawal by Subject|10
6153837|NCT01130272|9792164|FG003|Overall Study|Withdrawal by Subject|9
6153838|NCT01130272|9792165|FG004|Overall Study|Withdrawal by Subject|8
6153839|NCT01130272|9792161|FG000|Overall Study|Physician Decision|1
6153840|NCT01130272|9792162|FG001|Overall Study|Physician Decision|1
6153841|NCT01130272|9792163|FG002|Overall Study|Physician Decision|0
6153842|NCT01130272|9792164|FG003|Overall Study|Physician Decision|1
6153843|NCT01130272|9792165|FG004|Overall Study|Physician Decision|2
6153844|NCT01130272|9792161|FG000|Overall Study|Sponsor decision|6
6153845|NCT01130272|9792162|FG001|Overall Study|Sponsor decision|15
6041604|NCT00377962|9639890|FG000|Extension Study: 12-24 Months|Adverse Event|8
6041605|NCT00377962|9639891|FG001|Extension Study: 12-24 Months|Adverse Event|0
6041606|NCT00377962|9639890|FG000|Extension Study: 12-24 Months|Abnormal laboratory value|1
6041607|NCT00377962|9639891|FG001|Extension Study: 12-24 Months|Abnormal laboratory value|0
6153846|NCT01130272|9792163|FG002|Overall Study|Sponsor decision|16
6153847|NCT01130272|9792164|FG003|Overall Study|Sponsor decision|13
6153848|NCT01130272|9792165|FG004|Overall Study|Sponsor decision|16
6153849|NCT01130272|9792161|FG000|Overall Study|Study arm discontinued|38
6153850|NCT01130272|9792162|FG001|Overall Study|Study arm discontinued|0
6153851|NCT01130272|9792163|FG002|Overall Study|Study arm discontinued|0
6153852|NCT01130272|9792164|FG003|Overall Study|Study arm discontinued|0
6153853|NCT01130272|9792165|FG004|Overall Study|Study arm discontinued|0
6323852|NCT02905266|10065107|FG000|Transition From Part 1 to Part 2|Adverse Event|1
6323853|NCT02905266|10065108|FG001|Transition From Part 1 to Part 2|Adverse Event|1
6323854|NCT02905266|10065107|FG000|Maintenance Phase Part 2|Disease Progression|9
6323855|NCT02905266|10065108|FG001|Maintenance Phase Part 2|Disease Progression|2
6323856|NCT02905266|10065107|FG000|Maintenance Phase Part 2|Study Drug Toxicity|3
6323857|NCT02905266|10065108|FG001|Maintenance Phase Part 2|Study Drug Toxicity|4
6323858|NCT02905266|10065107|FG000|Maintenance Phase Part 2|Maximum Clinical Benefit|0
6323859|NCT02905266|10065108|FG001|Maintenance Phase Part 2|Maximum Clinical Benefit|2
6323860|NCT02905331|10065116|FG000|Placebo Controlled Period(Week[wk] 0-16)|Adverse Event|1
6323861|NCT02905331|10065117|FG001|Placebo Controlled Period(Week[wk] 0-16)|Adverse Event|0
6323862|NCT02905331|10065118|FG002|Placebo Controlled Period(Week[wk] 0-16)|Adverse Event|0
6323863|NCT02905331|10065116|FG000|Placebo Controlled Period(Week[wk] 0-16)|Lack of Efficacy|2
6323864|NCT02905331|10065117|FG001|Placebo Controlled Period(Week[wk] 0-16)|Lack of Efficacy|0
6323865|NCT02905331|10065118|FG002|Placebo Controlled Period(Week[wk] 0-16)|Lack of Efficacy|0
6323866|NCT02905331|10065116|FG000|Placebo Controlled Period(Week[wk] 0-16)|Lost to Follow-up|0
6041608|NCT00377962|9639890|FG000|Extension Study: 12-24 Months|Unspecified reason|0
6041609|NCT00377962|9639891|FG001|Extension Study: 12-24 Months|Unspecified reason|3
6041610|NCT00378014|9639905|FG000|Core (Randomization to Month 11)|Adverse Event|1
6323867|NCT02905331|10065117|FG001|Placebo Controlled Period(Week[wk] 0-16)|Lost to Follow-up|1
6323868|NCT02905331|10065118|FG002|Placebo Controlled Period(Week[wk] 0-16)|Lost to Follow-up|0
6323869|NCT02905331|10065116|FG000|Active Treatment and Follow up (wk16-40)|Other|0
6323870|NCT02905331|10065117|FG001|Active Treatment and Follow up (wk16-40)|Other|6
6323871|NCT02905331|10065118|FG002|Active Treatment and Follow up (wk16-40)|Other|0
6323872|NCT02905331|10065116|FG000|Active Treatment and Follow up (wk16-40)|Withdrawal by Subject|0
6323873|NCT02905331|10065117|FG001|Active Treatment and Follow up (wk16-40)|Withdrawal by Subject|2
6323874|NCT02905331|10065118|FG002|Active Treatment and Follow up (wk16-40)|Withdrawal by Subject|0
6323875|NCT02905435|10065126|FG000|Overall Study|Death|2
6323876|NCT02905435|10065126|FG000|Overall Study|Physician Decision|1
6323877|NCT02905435|10065126|FG000|Overall Study|Lost to Follow-up|4
6323878|NCT02905825|10065131|FG000|Overall Study|Protocol Violation|11
6323879|NCT02905825|10065131|FG000|Overall Study|Device Malfunction|1
6323880|NCT02906358|10065141|FG000|Overall Study|Withdrawal by Subject|10
6323881|NCT02906358|10065142|FG001|Overall Study|Withdrawal by Subject|7
6323882|NCT02906358|10065141|FG000|Overall Study|Lost to Follow-up|12
6323883|NCT02906358|10065142|FG001|Overall Study|Lost to Follow-up|15
6323884|NCT02906579|10065159|FG000|Overall Study|Adverse Event|1
6323885|NCT02906579|10065159|FG000|Overall Study|Physician Decision|1
6041611|NCT00378014|9639906|FG001|Core (Randomization to Month 11)|Adverse Event|0
6041612|NCT00378014|9639905|FG000|Core (Randomization to Month 11)|Graft loss|1
6041613|NCT00378014|9639906|FG001|Core (Randomization to Month 11)|Graft loss|2
6041614|NCT00378014|9639905|FG000|Core (Randomization to Month 11)|Death|5
6080363|NCT00615459|9687529|FG003|Period III|Unsatisfactory therapeutic effect|0
6080364|NCT00615550|9687550|FG000|Overall Study|Lost to Follow-up|6
6080365|NCT00615550|9687551|FG001|Overall Study|Lost to Follow-up|1
6080366|NCT00615719|9687562|FG000|Overall Study|Physician Decision|5
6080367|NCT00615836|9687574|FG000|Extension Study (FE992026 CS31)|Adverse Event|7
6080368|NCT00615836|9687575|FG001|Extension Study (FE992026 CS31)|Adverse Event|12
6041615|NCT00378014|9639906|FG001|Core (Randomization to Month 11)|Death|3
6041616|NCT00378014|9639905|FG000|Core (Randomization to Month 11)|Administrative Problems|2
6041617|NCT00378014|9639906|FG001|Core (Randomization to Month 11)|Administrative Problems|2
6041618|NCT00378014|9639905|FG000|Core (Randomization to Month 11)|Lost to Follow-up|0
6041619|NCT00378014|9639906|FG001|Core (Randomization to Month 11)|Lost to Follow-up|1
6041620|NCT00378014|9639905|FG000|Core (Randomization to Month 11)|Withdrawal by Subject|5
6041621|NCT00378014|9639906|FG001|Core (Randomization to Month 11)|Withdrawal by Subject|2
6041622|NCT00378014|9639905|FG000|Core (Randomization to Month 11)|Protocol deviation|0
6041623|NCT00378014|9639906|FG001|Core (Randomization to Month 11)|Protocol deviation|1
6080369|NCT00615836|9687576|FG002|Extension Study (FE992026 CS31)|Adverse Event|15
6080370|NCT00615836|9687577|FG003|Extension Study (FE992026 CS31)|Adverse Event|13
6041624|NCT00378014|9639905|FG000|Core (Randomization to Month 11)|Lack of Efficacy|0
6049012|NCT00420927|9648203|FG004|Period 2|Randomization error|1
6153854|NCT01130337|9792177|FG000|Overall Study|Withdrawal by Subject|3
6153855|NCT01130337|9792177|FG000|Overall Study|Principal investigator decision|1
6153856|NCT01130337|9792177|FG000|Overall Study|Death|1
6153857|NCT01130337|9792177|FG000|Overall Study|Disease progression|1
6153858|NCT01130337|9792177|FG000|Overall Study|Toxicity, AE/intercurrent disease|7
6323886|NCT02906644|10065181|FG000|First 2 Weeks|Withdrawal by Subject|0
6323887|NCT02906644|10065182|FG001|First 2 Weeks|Withdrawal by Subject|2
6323888|NCT02906644|10065181|FG000|First 2 Weeks|Physician Decision|1
6323889|NCT02906644|10065182|FG001|First 2 Weeks|Physician Decision|1
6323890|NCT02906644|10065181|FG000|Weeks 3 to 14|Withdrawal by Subject|13
6323891|NCT02906644|10065182|FG001|Weeks 3 to 14|Withdrawal by Subject|7
6323892|NCT02906644|10065181|FG000|Weeks 3 to 14|Lost to Follow-up|3
6323893|NCT02906644|10065182|FG001|Weeks 3 to 14|Lost to Follow-up|4
6323894|NCT02906670|10065199|FG000|Cohort 1, QW|Radiological Progression|1
6323895|NCT02906670|10065200|FG001|Cohort 1, QW|Radiological Progression|0
6323896|NCT02906670|10065201|FG002|Cohort 1, QW|Radiological Progression|0
6323897|NCT02906670|10065202|FG003|Cohort 1, QW|Radiological Progression|0
6323898|NCT02906670|10065203|FG004|Cohort 1, QW|Radiological Progression|0
6323899|NCT02906670|10065204|FG005|Cohort 1, QW|Radiological Progression|0
6323900|NCT02906670|10065205|FG006|Cohort 1, QW|Radiological Progression|0
6323901|NCT02906670|10065206|FG007|Cohort 1, QW|Radiological Progression|0
6323902|NCT02906670|10065207|FG008|Cohort 1, QW|Radiological Progression|0
6323903|NCT02906670|10065208|FG009|Cohort 1, QW|Radiological Progression|0
6323904|NCT02906670|10065199|FG000|Cohort 2, QW|Radiological Progression|0
6323905|NCT02906670|10065200|FG001|Cohort 2, QW|Radiological Progression|1
6323906|NCT02906670|10065201|FG002|Cohort 2, QW|Radiological Progression|0
6323907|NCT02906670|10065202|FG003|Cohort 2, QW|Radiological Progression|0
6323908|NCT02906670|10065203|FG004|Cohort 2, QW|Radiological Progression|0
6323909|NCT02906670|10065204|FG005|Cohort 2, QW|Radiological Progression|0
6323910|NCT02906670|10065205|FG006|Cohort 2, QW|Radiological Progression|0
6323911|NCT02906670|10065206|FG007|Cohort 2, QW|Radiological Progression|0
6323912|NCT02906670|10065207|FG008|Cohort 2, QW|Radiological Progression|0
6323913|NCT02906670|10065208|FG009|Cohort 2, QW|Radiological Progression|0
6323914|NCT02906670|10065199|FG000|Cohort 3, QW|Radiological Progression|0
6323915|NCT02906670|10065200|FG001|Cohort 3, QW|Radiological Progression|0
6323916|NCT02906670|10065201|FG002|Cohort 3, QW|Radiological Progression|2
6323917|NCT02906670|10065202|FG003|Cohort 3, QW|Radiological Progression|0
6323918|NCT02906670|10065203|FG004|Cohort 3, QW|Radiological Progression|0
6323919|NCT02906670|10065204|FG005|Cohort 3, QW|Radiological Progression|0
6323920|NCT02906670|10065205|FG006|Cohort 3, QW|Radiological Progression|0
6323921|NCT02906670|10065206|FG007|Cohort 3, QW|Radiological Progression|0
6323922|NCT02906670|10065207|FG008|Cohort 3, QW|Radiological Progression|0
6323923|NCT02906670|10065208|FG009|Cohort 3, QW|Radiological Progression|0
6323924|NCT02906670|10065199|FG000|Cohort 3, QW|Lack of Clinical Benefit|0
6323925|NCT02906670|10065200|FG001|Cohort 3, QW|Lack of Clinical Benefit|0
6323926|NCT02906670|10065201|FG002|Cohort 3, QW|Lack of Clinical Benefit|2
6323927|NCT02906670|10065202|FG003|Cohort 3, QW|Lack of Clinical Benefit|0
6323928|NCT02906670|10065203|FG004|Cohort 3, QW|Lack of Clinical Benefit|0
6323929|NCT02906670|10065204|FG005|Cohort 3, QW|Lack of Clinical Benefit|0
6323930|NCT02906670|10065205|FG006|Cohort 3, QW|Lack of Clinical Benefit|0
6323931|NCT02906670|10065206|FG007|Cohort 3, QW|Lack of Clinical Benefit|0
6323932|NCT02906670|10065207|FG008|Cohort 3, QW|Lack of Clinical Benefit|0
6323933|NCT02906670|10065208|FG009|Cohort 3, QW|Lack of Clinical Benefit|0
6323934|NCT02906670|10065199|FG000|Cohort 4, Q2W|Radiological Progression|0
6323935|NCT02906670|10065200|FG001|Cohort 4, Q2W|Radiological Progression|0
6323936|NCT02906670|10065201|FG002|Cohort 4, Q2W|Radiological Progression|0
6323937|NCT02906670|10065202|FG003|Cohort 4, Q2W|Radiological Progression|0
6323938|NCT02906670|10065203|FG004|Cohort 4, Q2W|Radiological Progression|0
6323939|NCT02906670|10065204|FG005|Cohort 4, Q2W|Radiological Progression|1
6323940|NCT02906670|10065205|FG006|Cohort 4, Q2W|Radiological Progression|0
6323941|NCT02906670|10065206|FG007|Cohort 4, Q2W|Radiological Progression|0
6323942|NCT02906670|10065207|FG008|Cohort 4, Q2W|Radiological Progression|0
6323943|NCT02906670|10065208|FG009|Cohort 4, Q2W|Radiological Progression|0
6323944|NCT02906670|10065199|FG000|Cohort 4, Q2W|Clinical Progression|0
6323945|NCT02906670|10065200|FG001|Cohort 4, Q2W|Clinical Progression|0
6323946|NCT02906670|10065201|FG002|Cohort 4, Q2W|Clinical Progression|0
6323947|NCT02906670|10065202|FG003|Cohort 4, Q2W|Clinical Progression|0
6323948|NCT02906670|10065203|FG004|Cohort 4, Q2W|Clinical Progression|0
6323949|NCT02906670|10065204|FG005|Cohort 4, Q2W|Clinical Progression|2
6323950|NCT02906670|10065205|FG006|Cohort 4, Q2W|Clinical Progression|0
6323951|NCT02906670|10065206|FG007|Cohort 4, Q2W|Clinical Progression|0
6323952|NCT02906670|10065207|FG008|Cohort 4, Q2W|Clinical Progression|0
6323953|NCT02906670|10065208|FG009|Cohort 4, Q2W|Clinical Progression|0
6323954|NCT02906670|10065199|FG000|Cohort 5, Q2W|Radiological Progression|0
6323955|NCT02906670|10065200|FG001|Cohort 5, Q2W|Radiological Progression|0
6323956|NCT02906670|10065201|FG002|Cohort 5, Q2W|Radiological Progression|0
6323957|NCT02906670|10065202|FG003|Cohort 5, Q2W|Radiological Progression|0
6323958|NCT02906670|10065203|FG004|Cohort 5, Q2W|Radiological Progression|0
6323959|NCT02906670|10065204|FG005|Cohort 5, Q2W|Radiological Progression|0
6323960|NCT02906670|10065205|FG006|Cohort 5, Q2W|Radiological Progression|4
6323961|NCT02906670|10065206|FG007|Cohort 5, Q2W|Radiological Progression|0
6323962|NCT02906670|10065207|FG008|Cohort 5, Q2W|Radiological Progression|0
6323963|NCT02906670|10065208|FG009|Cohort 5, Q2W|Radiological Progression|0
6323964|NCT02906670|10065199|FG000|Cohort 5, Q2W|Clinical Progression|0
6323965|NCT02906670|10065200|FG001|Cohort 5, Q2W|Clinical Progression|0
6323966|NCT02906670|10065201|FG002|Cohort 5, Q2W|Clinical Progression|0
6323967|NCT02906670|10065202|FG003|Cohort 5, Q2W|Clinical Progression|0
6323968|NCT02906670|10065203|FG004|Cohort 5, Q2W|Clinical Progression|0
6323969|NCT02906670|10065204|FG005|Cohort 5, Q2W|Clinical Progression|0
6323970|NCT02906670|10065205|FG006|Cohort 5, Q2W|Clinical Progression|1
6323971|NCT02906670|10065206|FG007|Cohort 5, Q2W|Clinical Progression|0
6323972|NCT02906670|10065207|FG008|Cohort 5, Q2W|Clinical Progression|0
6323973|NCT02906670|10065208|FG009|Cohort 5, Q2W|Clinical Progression|0
6323974|NCT02906670|10065199|FG000|Cohort 5, Q2W|Adverse Event|0
6323975|NCT02906670|10065200|FG001|Cohort 5, Q2W|Adverse Event|0
6323976|NCT02906670|10065201|FG002|Cohort 5, Q2W|Adverse Event|0
6323977|NCT02906670|10065202|FG003|Cohort 5, Q2W|Adverse Event|0
6323978|NCT02906670|10065203|FG004|Cohort 5, Q2W|Adverse Event|0
6323979|NCT02906670|10065204|FG005|Cohort 5, Q2W|Adverse Event|0
6323980|NCT02906670|10065205|FG006|Cohort 5, Q2W|Adverse Event|1
6323981|NCT02906670|10065206|FG007|Cohort 5, Q2W|Adverse Event|0
6323982|NCT02906670|10065207|FG008|Cohort 5, Q2W|Adverse Event|0
6153859|NCT01130337|9792177|FG000|Overall Study|Surgical resection (R2)|1
6153860|NCT01130493|9792181|FG000|Open-label Dose Conversion to IPX066|Adverse Event|1
6153861|NCT01130493|9792182|FG001|Open-label Dose Conversion to IPX066|Adverse Event|0
6153862|NCT01130493|9792183|FG002|Open-label Dose Conversion to IPX066|Adverse Event|0
6153863|NCT01130493|9792181|FG000|Open-label Dose Conversion to IPX066|Protocol Violation|3
6323983|NCT02906670|10065208|FG009|Cohort 5, Q2W|Adverse Event|0
6323984|NCT02906670|10065199|FG000|Cohort 5, Q2W|Lack of Clinical Benefit|0
6323985|NCT02906670|10065200|FG001|Cohort 5, Q2W|Lack of Clinical Benefit|0
6323986|NCT02906670|10065201|FG002|Cohort 5, Q2W|Lack of Clinical Benefit|0
6323987|NCT02906670|10065202|FG003|Cohort 5, Q2W|Lack of Clinical Benefit|0
6323988|NCT02906670|10065203|FG004|Cohort 5, Q2W|Lack of Clinical Benefit|0
6323989|NCT02906670|10065204|FG005|Cohort 5, Q2W|Lack of Clinical Benefit|0
6323990|NCT02906670|10065205|FG006|Cohort 5, Q2W|Lack of Clinical Benefit|1
6323991|NCT02906670|10065206|FG007|Cohort 5, Q2W|Lack of Clinical Benefit|0
6323992|NCT02906670|10065207|FG008|Cohort 5, Q2W|Lack of Clinical Benefit|0
6323993|NCT02906670|10065208|FG009|Cohort 5, Q2W|Lack of Clinical Benefit|0
6323994|NCT02906670|10065199|FG000|Cohort 5P, Q2W|Radiological Progression|0
6323995|NCT02906670|10065200|FG001|Cohort 5P, Q2W|Radiological Progression|0
6323996|NCT02906670|10065201|FG002|Cohort 5P, Q2W|Radiological Progression|0
6323997|NCT02906670|10065202|FG003|Cohort 5P, Q2W|Radiological Progression|0
6323998|NCT02906670|10065203|FG004|Cohort 5P, Q2W|Radiological Progression|0
6323999|NCT02906670|10065204|FG005|Cohort 5P, Q2W|Radiological Progression|0
6324000|NCT02906670|10065205|FG006|Cohort 5P, Q2W|Radiological Progression|0
6324001|NCT02906670|10065206|FG007|Cohort 5P, Q2W|Radiological Progression|2
6324002|NCT02906670|10065207|FG008|Cohort 5P, Q2W|Radiological Progression|0
6324003|NCT02906670|10065208|FG009|Cohort 5P, Q2W|Radiological Progression|0
6324004|NCT02906670|10065199|FG000|Cohort 5P, Q2W|Adverse Event|0
6324005|NCT02906670|10065200|FG001|Cohort 5P, Q2W|Adverse Event|0
6324006|NCT02906670|10065201|FG002|Cohort 5P, Q2W|Adverse Event|0
6324007|NCT02906670|10065202|FG003|Cohort 5P, Q2W|Adverse Event|0
6324008|NCT02906670|10065203|FG004|Cohort 5P, Q2W|Adverse Event|0
6324009|NCT02906670|10065204|FG005|Cohort 5P, Q2W|Adverse Event|0
6324010|NCT02906670|10065205|FG006|Cohort 5P, Q2W|Adverse Event|0
6324011|NCT02906670|10065206|FG007|Cohort 5P, Q2W|Adverse Event|1
6324012|NCT02906670|10065207|FG008|Cohort 5P, Q2W|Adverse Event|0
6324013|NCT02906670|10065208|FG009|Cohort 5P, Q2W|Adverse Event|0
6324014|NCT02906670|10065199|FG000|Cohort 6P, Q2W|Radiological Progression|0
6324015|NCT02906670|10065200|FG001|Cohort 6P, Q2W|Radiological Progression|0
6324016|NCT02906670|10065201|FG002|Cohort 6P, Q2W|Radiological Progression|0
6324017|NCT02906670|10065202|FG003|Cohort 6P, Q2W|Radiological Progression|0
6324018|NCT02906670|10065203|FG004|Cohort 6P, Q2W|Radiological Progression|0
6324019|NCT02906670|10065204|FG005|Cohort 6P, Q2W|Radiological Progression|0
6324020|NCT02906670|10065205|FG006|Cohort 6P, Q2W|Radiological Progression|0
6324021|NCT02906670|10065206|FG007|Cohort 6P, Q2W|Radiological Progression|0
6324022|NCT02906670|10065207|FG008|Cohort 6P, Q2W|Radiological Progression|1
6324023|NCT02906670|10065208|FG009|Cohort 6P, Q2W|Radiological Progression|0
6153864|NCT01130493|9792182|FG001|Open-label Dose Conversion to IPX066|Protocol Violation|0
6324024|NCT02906670|10065199|FG000|Cohort 6P, Q2W|Clinical Progression|0
6324025|NCT02906670|10065200|FG001|Cohort 6P, Q2W|Clinical Progression|0
6324026|NCT02906670|10065201|FG002|Cohort 6P, Q2W|Clinical Progression|0
6324027|NCT02906670|10065202|FG003|Cohort 6P, Q2W|Clinical Progression|0
6324028|NCT02906670|10065203|FG004|Cohort 6P, Q2W|Clinical Progression|0
6324029|NCT02906670|10065204|FG005|Cohort 6P, Q2W|Clinical Progression|0
6324030|NCT02906670|10065205|FG006|Cohort 6P, Q2W|Clinical Progression|0
6324031|NCT02906670|10065206|FG007|Cohort 6P, Q2W|Clinical Progression|0
6324032|NCT02906670|10065207|FG008|Cohort 6P, Q2W|Clinical Progression|3
6324033|NCT02906670|10065208|FG009|Cohort 6P, Q2W|Clinical Progression|0
6324034|NCT02906670|10065199|FG000|Cohort 4P, QW|Radiological Progression|0
6324035|NCT02906670|10065200|FG001|Cohort 4P, QW|Radiological Progression|0
6324036|NCT02906670|10065201|FG002|Cohort 4P, QW|Radiological Progression|0
6324037|NCT02906670|10065202|FG003|Cohort 4P, QW|Radiological Progression|3
6324038|NCT02906670|10065203|FG004|Cohort 4P, QW|Radiological Progression|0
6324039|NCT02906670|10065204|FG005|Cohort 4P, QW|Radiological Progression|0
6324040|NCT02906670|10065205|FG006|Cohort 4P, QW|Radiological Progression|0
6324041|NCT02906670|10065206|FG007|Cohort 4P, QW|Radiological Progression|0
6324042|NCT02906670|10065207|FG008|Cohort 4P, QW|Radiological Progression|0
6324043|NCT02906670|10065208|FG009|Cohort 4P, QW|Radiological Progression|0
6324044|NCT02906670|10065199|FG000|Cohort 7P, Q2W|Adverse Event|0
6324045|NCT02906670|10065200|FG001|Cohort 7P, Q2W|Adverse Event|0
6324046|NCT02906670|10065201|FG002|Cohort 7P, Q2W|Adverse Event|0
6324047|NCT02906670|10065202|FG003|Cohort 7P, Q2W|Adverse Event|0
6324048|NCT02906670|10065203|FG004|Cohort 7P, Q2W|Adverse Event|0
6324049|NCT02906670|10065204|FG005|Cohort 7P, Q2W|Adverse Event|0
6324050|NCT02906670|10065205|FG006|Cohort 7P, Q2W|Adverse Event|0
6041625|NCT00378014|9639906|FG001|Core (Randomization to Month 11)|Lack of Efficacy|1
6041626|NCT00378014|9639905|FG000|Extension (Month 12 to Month 59)|Adverse Event|8
6324051|NCT02906670|10065206|FG007|Cohort 7P, Q2W|Adverse Event|0
6324052|NCT02906670|10065207|FG008|Cohort 7P, Q2W|Adverse Event|0
6324053|NCT02906670|10065208|FG009|Cohort 7P, Q2W|Adverse Event|1
6324054|NCT02906670|10065199|FG000|Cohort 7P, Q2W|Physician Decision|0
6041627|NCT00378014|9639906|FG001|Extension (Month 12 to Month 59)|Adverse Event|7
6041628|NCT00378014|9639905|FG000|Extension (Month 12 to Month 59)|Death|1
6041629|NCT00378014|9639906|FG001|Extension (Month 12 to Month 59)|Death|2
6324055|NCT02906670|10065200|FG001|Cohort 7P, Q2W|Physician Decision|0
6324056|NCT02906670|10065201|FG002|Cohort 7P, Q2W|Physician Decision|0
6324057|NCT02906670|10065202|FG003|Cohort 7P, Q2W|Physician Decision|0
6324058|NCT02906670|10065203|FG004|Cohort 7P, Q2W|Physician Decision|0
6324059|NCT02906670|10065204|FG005|Cohort 7P, Q2W|Physician Decision|0
6324060|NCT02906670|10065205|FG006|Cohort 7P, Q2W|Physician Decision|0
6324061|NCT02906670|10065206|FG007|Cohort 7P, Q2W|Physician Decision|0
6324062|NCT02906670|10065207|FG008|Cohort 7P, Q2W|Physician Decision|0
6324063|NCT02906670|10065208|FG009|Cohort 7P, Q2W|Physician Decision|1
6324064|NCT02906670|10065199|FG000|Cohort 7P, Q2W|More than 3 Dose-reduction of Pan-Her|0
6324065|NCT02906670|10065200|FG001|Cohort 7P, Q2W|More than 3 Dose-reduction of Pan-Her|0
6324066|NCT02906670|10065201|FG002|Cohort 7P, Q2W|More than 3 Dose-reduction of Pan-Her|0
6324067|NCT02906670|10065202|FG003|Cohort 7P, Q2W|More than 3 Dose-reduction of Pan-Her|0
6324068|NCT02906670|10065203|FG004|Cohort 7P, Q2W|More than 3 Dose-reduction of Pan-Her|0
6324069|NCT02906670|10065204|FG005|Cohort 7P, Q2W|More than 3 Dose-reduction of Pan-Her|0
6324070|NCT02906670|10065205|FG006|Cohort 7P, Q2W|More than 3 Dose-reduction of Pan-Her|0
6324071|NCT02906670|10065206|FG007|Cohort 7P, Q2W|More than 3 Dose-reduction of Pan-Her|0
6324072|NCT02906670|10065207|FG008|Cohort 7P, Q2W|More than 3 Dose-reduction of Pan-Her|0
6324073|NCT02906670|10065208|FG009|Cohort 7P, Q2W|More than 3 Dose-reduction of Pan-Her|1
6324074|NCT02906670|10065199|FG000|Cohort 5P, QW|Radiological Progression|0
6324075|NCT02906670|10065200|FG001|Cohort 5P, QW|Radiological Progression|0
6324076|NCT02906670|10065201|FG002|Cohort 5P, QW|Radiological Progression|0
6324077|NCT02906670|10065202|FG003|Cohort 5P, QW|Radiological Progression|0
6324078|NCT02906670|10065203|FG004|Cohort 5P, QW|Radiological Progression|3
6324079|NCT02906670|10065204|FG005|Cohort 5P, QW|Radiological Progression|0
6324080|NCT02906670|10065205|FG006|Cohort 5P, QW|Radiological Progression|0
6324081|NCT02906670|10065206|FG007|Cohort 5P, QW|Radiological Progression|0
6324082|NCT02906670|10065207|FG008|Cohort 5P, QW|Radiological Progression|0
6324083|NCT02906670|10065208|FG009|Cohort 5P, QW|Radiological Progression|0
6324084|NCT02906709|10065264|FG000|Phase A (Week 0 to Week 16)|Adverse Event|1
6324085|NCT02906709|10065265|FG001|Phase A (Week 0 to Week 16)|Adverse Event|2
6324086|NCT02906709|10065264|FG000|Phase A (Week 0 to Week 16)|Death|0
6324087|NCT02906709|10065265|FG001|Phase A (Week 0 to Week 16)|Death|1
6324088|NCT02906709|10065264|FG000|Phase B (Extension, Week 17 to Week 52)|Adverse Event|3
6324089|NCT02906709|10065265|FG001|Phase B (Extension, Week 17 to Week 52)|Adverse Event|0
6324090|NCT02906709|10065264|FG000|Phase B (Extension, Week 17 to Week 52)|Withdrawal by Subject|2
6324091|NCT02906709|10065265|FG001|Phase B (Extension, Week 17 to Week 52)|Withdrawal by Subject|0
6324092|NCT02906917|10065292|FG000|Initiation Period (Week 0-26)|Unclassified|1
6324093|NCT02906917|10065293|FG001|Initiation Period (Week 0-26)|Unclassified|3
6324094|NCT02906917|10065292|FG000|Initiation Period (Week 0-26)|Adverse Event|1
6324095|NCT02906917|10065293|FG001|Initiation Period (Week 0-26)|Adverse Event|0
6324096|NCT02906917|10065292|FG000|Initiation Period (Week 0-26)|Lost to Follow-up|1
6324097|NCT02906917|10065293|FG001|Initiation Period (Week 0-26)|Lost to Follow-up|4
6324098|NCT02906917|10065292|FG000|Initiation Period (Week 0-26)|Withdrawal by Subject|3
6324099|NCT02906917|10065293|FG001|Initiation Period (Week 0-26)|Withdrawal by Subject|4
6324100|NCT02906917|10065292|FG000|Intensification Period (Week 26-38)|Unclassified|3
6324101|NCT02906917|10065293|FG001|Intensification Period (Week 26-38)|Unclassified|2
6324102|NCT02906917|10065292|FG000|Intensification Period (Week 26-38)|Adverse Event|0
6324103|NCT02906917|10065293|FG001|Intensification Period (Week 26-38)|Adverse Event|2
6324104|NCT02906917|10065292|FG000|Intensification Period (Week 26-38)|Lost to Follow-up|3
6324105|NCT02906917|10065293|FG001|Intensification Period (Week 26-38)|Lost to Follow-up|1
6324106|NCT02906917|10065292|FG000|Intensification Period (Week 26-38)|Withdrawal by Subject|3
6324107|NCT02906917|10065293|FG001|Intensification Period (Week 26-38)|Withdrawal by Subject|2
6324108|NCT02906930|10065303|FG000|Overall Study|Withdrawal by Subject|0
6324109|NCT02906930|10065304|FG001|Overall Study|Withdrawal by Subject|5
6324110|NCT02906930|10065305|FG002|Overall Study|Withdrawal by Subject|5
6324111|NCT02906930|10065306|FG003|Overall Study|Withdrawal by Subject|4
6324112|NCT02906930|10065303|FG000|Overall Study|Lost to Follow-up|5
6324113|NCT02906930|10065304|FG001|Overall Study|Lost to Follow-up|7
6324114|NCT02906930|10065305|FG002|Overall Study|Lost to Follow-up|5
6324115|NCT02906930|10065306|FG003|Overall Study|Lost to Follow-up|2
6324116|NCT02906930|10065303|FG000|Overall Study|Death|0
6324117|NCT02906930|10065304|FG001|Overall Study|Death|0
6324118|NCT02906930|10065305|FG002|Overall Study|Death|1
6041630|NCT00378014|9639905|FG000|Extension (Month 12 to Month 59)|Administrative problems|1
6041631|NCT00378014|9639906|FG001|Extension (Month 12 to Month 59)|Administrative problems|0
6041632|NCT00378014|9639905|FG000|Extension (Month 12 to Month 59)|Lost to Follow-up|1
6153865|NCT01130493|9792183|FG002|Open-label Dose Conversion to IPX066|Protocol Violation|0
6153866|NCT01130493|9792181|FG000|Open-label Dose Conversion to IPX066|Lack of Efficacy|7
6153867|NCT01130493|9792182|FG001|Open-label Dose Conversion to IPX066|Lack of Efficacy|0
6153868|NCT01130493|9792183|FG002|Open-label Dose Conversion to IPX066|Lack of Efficacy|0
6153869|NCT01130493|9792181|FG000|Open-label Dose Conversion to IPX066|Withdrawal by Subject|7
6153870|NCT01130493|9792182|FG001|Open-label Dose Conversion to IPX066|Withdrawal by Subject|0
6191703|NCT01425463|9848659|FG000|Overall Study|Lack of Efficacy|1
6041633|NCT00378014|9639906|FG001|Extension (Month 12 to Month 59)|Lost to Follow-up|1
6041634|NCT00378014|9639905|FG000|Extension (Month 12 to Month 59)|Withdrawal by Subject|0
6041635|NCT00378014|9639906|FG001|Extension (Month 12 to Month 59)|Withdrawal by Subject|3
6041636|NCT00378014|9639905|FG000|Extension (Month 12 to Month 59)|Lack of Efficacy|3
6041637|NCT00378014|9639906|FG001|Extension (Month 12 to Month 59)|Lack of Efficacy|1
6041638|NCT00378079|9639917|FG000|Overall Study|Lost to Follow-up|6
6041639|NCT00378079|9639918|FG001|Overall Study|Lost to Follow-up|1
6041640|NCT00378079|9639919|FG002|Overall Study|Lost to Follow-up|0
6041641|NCT00378105|9639929|FG000|Overall Study|Adverse Event|3
6041642|NCT00378105|9639930|FG001|Overall Study|Adverse Event|1
6041643|NCT00378105|9639929|FG000|Overall Study|Withdrawal by Subject|3
6041644|NCT00378105|9639930|FG001|Overall Study|Withdrawal by Subject|3
6041645|NCT00378105|9639929|FG000|Overall Study|Death|1
6041646|NCT00378105|9639930|FG001|Overall Study|Death|0
6041647|NCT00378105|9639929|FG000|Overall Study|Going to transplant|7
6041648|NCT00378105|9639930|FG001|Overall Study|Going to transplant|8
6041649|NCT00378105|9639929|FG000|Overall Study|Progressive disease|3
6041650|NCT00378105|9639930|FG001|Overall Study|Progressive disease|3
6041651|NCT00378105|9639929|FG000|Overall Study|remain on study|3
6041652|NCT00378105|9639930|FG001|Overall Study|remain on study|11
6041653|NCT00378105|9639929|FG000|Overall Study|Physician Decision|0
6041654|NCT00378105|9639930|FG001|Overall Study|Physician Decision|2
6041655|NCT00378105|9639929|FG000|Overall Study|Going non-protocol therapy|0
6041656|NCT00378105|9639930|FG001|Overall Study|Going non-protocol therapy|1
6041657|NCT00378105|9639929|FG000|Overall Study|necessity to increase lenalidomide dose|0
6041658|NCT00378105|9639930|FG001|Overall Study|necessity to increase lenalidomide dose|1
6041659|NCT00378209|9639937|FG000|Overall Study|Progressive disease|11
6041660|NCT00378209|9639937|FG000|Overall Study|Adverse Event|3
6041661|NCT00378209|9639937|FG000|Overall Study|Initiation of non-protocol therapy|3
6041662|NCT00378209|9639937|FG000|Overall Study|Physician Decision|3
6041663|NCT00378209|9639937|FG000|Overall Study|Death|1
6041664|NCT00378209|9639937|FG000|Overall Study|Treatment delay|1
6041665|NCT00378508|9639965|FG000|Overall Study|Withdrawal by Subject|1
6041666|NCT00378508|9639966|FG001|Overall Study|Withdrawal by Subject|3
6041667|NCT00378508|9639965|FG000|Overall Study|Lost to Follow-up|1
6041668|NCT00378508|9639966|FG001|Overall Study|Lost to Follow-up|0
6041669|NCT00378534|9639975|FG000|Overall Study|Participants did not receive transplant|3
6041670|NCT00378534|9639976|FG001|Overall Study|Participants did not receive transplant|0
6041671|NCT00378560|9639983|FG000|Overall Study|Adverse Event|1
6041672|NCT00378560|9639984|FG001|Overall Study|Adverse Event|0
6041673|NCT00378560|9639983|FG000|Overall Study|Lost to Follow-up|24
6041674|NCT00378560|9639984|FG001|Overall Study|Lost to Follow-up|29
6041675|NCT00378560|9639983|FG000|Overall Study|Protocol Violation|2
6041676|NCT00378560|9639984|FG001|Overall Study|Protocol Violation|0
6041677|NCT00378560|9639983|FG000|Overall Study|Withdrawal by Subject|17
6041678|NCT00378560|9639984|FG001|Overall Study|Withdrawal by Subject|21
6041679|NCT00378560|9639983|FG000|Overall Study|Moved|4
6041680|NCT00378560|9639984|FG001|Overall Study|Moved|3
6041681|NCT00378560|9639983|FG000|Overall Study|Pregnancy|7
6041682|NCT00378560|9639984|FG001|Overall Study|Pregnancy|5
6041683|NCT00378560|9639983|FG000|Overall Study|Laboratory test values abnormal|1
6041684|NCT00378560|9639984|FG001|Overall Study|Laboratory test values abnormal|0
6041685|NCT00378573|9639990|FG000|Treatment Period|Adverse Event|9
6041686|NCT00378573|9639990|FG000|Treatment Period|Physician Decision|1
6041687|NCT00378573|9639990|FG000|Treatment Period|Withdrawal by Subject|2
6041688|NCT00378573|9639990|FG000|Treatment Period|Disease Progression|4
6041689|NCT00378573|9639990|FG000|Treatment Period|Sponsor decision to close study|1
6041690|NCT00378573|9639990|FG000|Follow-up|Death|12
6041691|NCT00378573|9639990|FG000|Follow-up|Lost to Follow-up|1
6041692|NCT00378573|9639990|FG000|Follow-up|Withdrawal by Subject|1
6041693|NCT00378599|9639994|FG000|Overall Study|Adverse Event|38
6041694|NCT00378599|9639994|FG000|Overall Study|Protocol Violation|2
6041695|NCT00378599|9639994|FG000|Overall Study|Treatment failure|7
6041696|NCT00378599|9639994|FG000|Overall Study|Withdrawal by Subject|5
6041697|NCT00378703|9640002|FG000|Overall Study|Disease progression|59
6041698|NCT00378703|9640003|FG001|Overall Study|Disease progression|43
6041699|NCT00378703|9640004|FG002|Overall Study|Disease progression|48
6041700|NCT00378703|9640005|FG003|Overall Study|Disease progression|49
6041701|NCT00378703|9640002|FG000|Overall Study|Adverse Event|11
6041702|NCT00378703|9640003|FG001|Overall Study|Adverse Event|17
6041703|NCT00378703|9640004|FG002|Overall Study|Adverse Event|20
6041704|NCT00378703|9640005|FG003|Overall Study|Adverse Event|18
6041705|NCT00378703|9640002|FG000|Overall Study|Death|2
6041706|NCT00378703|9640003|FG001|Overall Study|Death|2
6041707|NCT00378703|9640004|FG002|Overall Study|Death|4
6041708|NCT00378703|9640005|FG003|Overall Study|Death|3
6041709|NCT00378703|9640002|FG000|Overall Study|Withdrawal by Subject|4
6041710|NCT00378703|9640003|FG001|Overall Study|Withdrawal by Subject|8
6041711|NCT00378703|9640004|FG002|Overall Study|Withdrawal by Subject|5
6041712|NCT00378703|9640005|FG003|Overall Study|Withdrawal by Subject|7
6041713|NCT00378703|9640002|FG000|Overall Study|Physician Decision|1
6041714|NCT00378703|9640003|FG001|Overall Study|Physician Decision|4
6041715|NCT00378703|9640004|FG002|Overall Study|Physician Decision|1
6041716|NCT00378703|9640005|FG003|Overall Study|Physician Decision|0
6041717|NCT00378703|9640002|FG000|Overall Study|Alternative therapy|4
6041718|NCT00378703|9640003|FG001|Overall Study|Alternative therapy|2
6041719|NCT00378703|9640004|FG002|Overall Study|Alternative therapy|0
6041720|NCT00378703|9640005|FG003|Overall Study|Alternative therapy|0
6041721|NCT00378703|9640002|FG000|Overall Study|Other complicated disease|0
6041722|NCT00378703|9640003|FG001|Overall Study|Other complicated disease|2
6041723|NCT00378703|9640004|FG002|Overall Study|Other complicated disease|2
6041724|NCT00378703|9640005|FG003|Overall Study|Other complicated disease|0
6041725|NCT00378703|9640002|FG000|Overall Study|Symptomatic deterioration|0
6041726|NCT00378703|9640003|FG001|Overall Study|Symptomatic deterioration|1
6041727|NCT00378703|9640004|FG002|Overall Study|Symptomatic deterioration|0
6041728|NCT00378703|9640005|FG003|Overall Study|Symptomatic deterioration|2
6041729|NCT00378703|9640002|FG000|Overall Study|Surgery|1
6041730|NCT00378703|9640003|FG001|Overall Study|Surgery|0
6041731|NCT00378703|9640004|FG002|Overall Study|Surgery|0
6041732|NCT00378703|9640005|FG003|Overall Study|Surgery|1
6041733|NCT00378703|9640002|FG000|Overall Study|Joint decision of physician and patient|1
6041734|NCT00378703|9640003|FG001|Overall Study|Joint decision of physician and patient|0
6041735|NCT00378703|9640004|FG002|Overall Study|Joint decision of physician and patient|0
6041736|NCT00378703|9640005|FG003|Overall Study|Joint decision of physician and patient|0
6041737|NCT00378703|9640002|FG000|Overall Study|Adverse events and progressive disease|0
6041738|NCT00378703|9640003|FG001|Overall Study|Adverse events and progressive disease|0
6041739|NCT00378703|9640004|FG002|Overall Study|Adverse events and progressive disease|0
6041740|NCT00378703|9640005|FG003|Overall Study|Adverse events and progressive disease|1
6041741|NCT00378703|9640002|FG000|Overall Study|Relocation|0
6041742|NCT00378703|9640003|FG001|Overall Study|Relocation|0
6041743|NCT00378703|9640004|FG002|Overall Study|Relocation|1
6041744|NCT00378703|9640005|FG003|Overall Study|Relocation|0
6041745|NCT00378703|9640002|FG000|Overall Study|Ineligible|4
6041746|NCT00378703|9640003|FG001|Overall Study|Ineligible|7
6041747|NCT00378703|9640004|FG002|Overall Study|Ineligible|7
6041748|NCT00378703|9640005|FG003|Overall Study|Ineligible|7
6041749|NCT00378703|9640002|FG000|Overall Study|Never started treatment|1
6041750|NCT00378703|9640003|FG001|Overall Study|Never started treatment|4
6041751|NCT00378703|9640004|FG002|Overall Study|Never started treatment|0
6041752|NCT00378703|9640005|FG003|Overall Study|Never started treatment|0
6041753|NCT00378703|9640002|FG000|Overall Study|Other|1
6041754|NCT00378703|9640003|FG001|Overall Study|Other|1
6041755|NCT00378703|9640004|FG002|Overall Study|Other|2
6041756|NCT00378703|9640005|FG003|Overall Study|Other|3
6041757|NCT00378898|9640017|FG000|Overall Study|Withdrawal by Subject|10
6041758|NCT00378898|9640018|FG001|Overall Study|Withdrawal by Subject|5
6041759|NCT00378898|9640017|FG000|Overall Study|Protocol Violation|1
6041760|NCT00378898|9640018|FG001|Overall Study|Protocol Violation|1
6041761|NCT00379080|9640029|FG000|Overall Study|Withdrawal by Subject|0
6041762|NCT00379080|9640030|FG001|Overall Study|Withdrawal by Subject|4
6041763|NCT00379080|9640031|FG002|Overall Study|Withdrawal by Subject|0
6041764|NCT00379210|9640070|FG000|Overall Study|Withdrawal by Subject|10
6041765|NCT00379210|9640071|FG001|Overall Study|Withdrawal by Subject|7
6041766|NCT00379236|9640079|FG000|Double-blind|Adverse Event|11
6041767|NCT00379236|9640080|FG001|Double-blind|Adverse Event|6
6041768|NCT00379236|9640081|FG002|Double-blind|Adverse Event|0
6041769|NCT00379236|9640079|FG000|Double-blind|Protocol Violation|3
6041770|NCT00379236|9640080|FG001|Double-blind|Protocol Violation|3
6041771|NCT00379236|9640081|FG002|Double-blind|Protocol Violation|0
6041772|NCT00379236|9640079|FG000|Double-blind|Withdrawal by Subject|12
6041773|NCT00379236|9640080|FG001|Double-blind|Withdrawal by Subject|13
6041774|NCT00379236|9640081|FG002|Double-blind|Withdrawal by Subject|0
6041775|NCT00379236|9640079|FG000|Double-blind|Lost to Follow-up|4
6041776|NCT00379236|9640080|FG001|Double-blind|Lost to Follow-up|3
6041777|NCT00379236|9640081|FG002|Double-blind|Lost to Follow-up|0
6041778|NCT00379236|9640079|FG000|Double-blind|Use of exclusionary medication|1
6041779|NCT00379236|9640080|FG001|Double-blind|Use of exclusionary medication|2
6041780|NCT00379236|9640081|FG002|Double-blind|Use of exclusionary medication|0
6041781|NCT00379236|9640079|FG000|Double-blind|Other|3
6041782|NCT00379236|9640080|FG001|Double-blind|Other|7
6041783|NCT00379236|9640081|FG002|Double-blind|Other|0
6041784|NCT00379236|9640079|FG000|Double-blind|Data could not be retrieved|2
6041785|NCT00379236|9640080|FG001|Double-blind|Data could not be retrieved|2
6041786|NCT00379236|9640081|FG002|Double-blind|Data could not be retrieved|0
6041787|NCT00379236|9640079|FG000|Open-label Extension|Adverse Event|0
6041788|NCT00379236|9640080|FG001|Open-label Extension|Adverse Event|0
6041789|NCT00379236|9640081|FG002|Open-label Extension|Adverse Event|13
6041790|NCT00379236|9640079|FG000|Open-label Extension|Protocol Violation|0
6041791|NCT00379236|9640080|FG001|Open-label Extension|Protocol Violation|0
6041792|NCT00379236|9640081|FG002|Open-label Extension|Protocol Violation|7
6041793|NCT00379236|9640079|FG000|Open-label Extension|Withdrawal by Subject|0
6041794|NCT00379236|9640080|FG001|Open-label Extension|Withdrawal by Subject|0
6041795|NCT00379236|9640081|FG002|Open-label Extension|Withdrawal by Subject|13
6153871|NCT01130493|9792183|FG002|Open-label Dose Conversion to IPX066|Withdrawal by Subject|0
6153872|NCT01130493|9792181|FG000|Open-label Dose Conversion to IPX066|Diary imcomplete|1
6153873|NCT01130493|9792182|FG001|Open-label Dose Conversion to IPX066|Diary imcomplete|0
6153874|NCT01130493|9792183|FG002|Open-label Dose Conversion to IPX066|Diary imcomplete|0
6153875|NCT01130493|9792181|FG000|Part 1: Double-blind Treatment Period 1|Protocol Violation|0
6153876|NCT01130493|9792182|FG001|Part 1: Double-blind Treatment Period 1|Protocol Violation|1
6153877|NCT01130493|9792183|FG002|Part 1: Double-blind Treatment Period 1|Protocol Violation|0
6041796|NCT00379236|9640079|FG000|Open-label Extension|Lost to Follow-up|0
6041797|NCT00379236|9640080|FG001|Open-label Extension|Lost to Follow-up|0
6041798|NCT00379236|9640081|FG002|Open-label Extension|Lost to Follow-up|12
6041799|NCT00379236|9640079|FG000|Open-label Extension|Use of exclusionary medication|0
6041800|NCT00379236|9640080|FG001|Open-label Extension|Use of exclusionary medication|0
6041801|NCT00379236|9640081|FG002|Open-label Extension|Use of exclusionary medication|3
6153878|NCT01130493|9792181|FG000|Part 1: Double-blind Treatment Period 1|Lack of Efficacy|0
6153879|NCT01130493|9792182|FG001|Part 1: Double-blind Treatment Period 1|Lack of Efficacy|1
6153880|NCT01130493|9792183|FG002|Part 1: Double-blind Treatment Period 1|Lack of Efficacy|0
6153881|NCT01130493|9792181|FG000|Part 1: Open-Label IPX066 Washout|Lack of Efficacy|0
6153882|NCT01130493|9792182|FG001|Part 1: Open-Label IPX066 Washout|Lack of Efficacy|1
6153883|NCT01130493|9792183|FG002|Part 1: Open-Label IPX066 Washout|Lack of Efficacy|0
6153884|NCT01130493|9792181|FG000|Part 1: Open-Label IPX066 Washout|Adverse Event|0
6153885|NCT01130493|9792182|FG001|Part 1: Open-Label IPX066 Washout|Adverse Event|0
6153886|NCT01130493|9792183|FG002|Part 1: Open-Label IPX066 Washout|Adverse Event|1
6041802|NCT00379236|9640079|FG000|Open-label Extension|Other|0
6041803|NCT00379236|9640080|FG001|Open-label Extension|Other|0
6041804|NCT00379236|9640081|FG002|Open-label Extension|Other|7
6041805|NCT00379353|9640095|FG000|Overall Study|Hospitalization|3
6041806|NCT00379353|9640096|FG001|Overall Study|Hospitalization|3
6041807|NCT00379353|9640095|FG000|Overall Study|Withdrawal by Subject|5
6041808|NCT00379353|9640096|FG001|Overall Study|Withdrawal by Subject|2
6041809|NCT00379353|9640095|FG000|Overall Study|Death|1
6041810|NCT00379353|9640096|FG001|Overall Study|Death|0
6041811|NCT00379353|9640095|FG000|Overall Study|Cardiac Tamponade|1
6041812|NCT00379353|9640096|FG001|Overall Study|Cardiac Tamponade|0
6041813|NCT00379353|9640095|FG000|Overall Study|Non-compliance|1
6041814|NCT00379353|9640096|FG001|Overall Study|Non-compliance|0
6041815|NCT00379353|9640095|FG000|Overall Study|Conflicting drug treatment|0
6041816|NCT00379353|9640096|FG001|Overall Study|Conflicting drug treatment|1
6041817|NCT00379587|9640116|FG000|Overall Study|Lost to Follow-up|2
6041818|NCT00379639|9640125|FG000|Overall Study|Disease Progression|3
6041819|NCT00379639|9640126|FG001|Overall Study|Disease Progression|3
6041820|NCT00379639|9640127|FG002|Overall Study|Disease Progression|3
6041821|NCT00379639|9640128|FG003|Overall Study|Disease Progression|4
6041822|NCT00379639|9640129|FG004|Overall Study|Disease Progression|4
6041823|NCT00379639|9640125|FG000|Overall Study|Physician Decision|0
6041824|NCT00379639|9640126|FG001|Overall Study|Physician Decision|2
6324119|NCT02906930|10065306|FG003|Overall Study|Death|0
6324120|NCT02906930|10065303|FG000|Overall Study|Other|1
6324121|NCT02906930|10065304|FG001|Overall Study|Other|2
6324122|NCT02906930|10065305|FG002|Overall Study|Other|1
6324123|NCT02906930|10065306|FG003|Overall Study|Other|2
6324124|NCT02907177|10065331|FG000|Overall Study|Death|0
6324125|NCT02907177|10065332|FG001|Overall Study|Death|1
6324126|NCT02907177|10065331|FG000|Overall Study|Physician Decision|3
6324127|NCT02907177|10065332|FG001|Overall Study|Physician Decision|3
6324128|NCT02907177|10065331|FG000|Overall Study|Withdrawal by Subject|15
6324129|NCT02907177|10065332|FG001|Overall Study|Withdrawal by Subject|7
6324130|NCT02907177|10065331|FG000|Overall Study|Sponsor's Decision|50
6324131|NCT02907177|10065332|FG001|Overall Study|Sponsor's Decision|57
6324132|NCT02907216|10065340|FG000|Overall Study|No benefit to be obtained by continuing|0
6324133|NCT02907216|10065341|FG001|Overall Study|No benefit to be obtained by continuing|1
6324134|NCT02907216|10065340|FG000|Overall Study|Withdrawal by Subject|1
6324135|NCT02907216|10065341|FG001|Overall Study|Withdrawal by Subject|0
6324136|NCT02907463|10065355|FG000|Overall Study|Lost to Follow-up|17
6324137|NCT02907463|10065355|FG000|Overall Study|Death|10
6324138|NCT02907463|10065355|FG000|Overall Study|Withdrawal by Subject|4
6324139|NCT02907463|10065355|FG000|Overall Study|MIS Approach was not used|2
6324140|NCT02907463|10065355|FG000|Overall Study|Not Implanted with Study Device|2
6324141|NCT02907463|10065355|FG000|Overall Study|Device Explanted|1
6324142|NCT02907463|10065355|FG000|Overall Study|Missing Exit Form|1
6324143|NCT02907619|10065379|FG000|Overall Study|Study terminated by sponsor|18
6324144|NCT02907619|10065380|FG001|Overall Study|Study terminated by sponsor|18
6324145|NCT02907619|10065381|FG002|Overall Study|Study terminated by sponsor|19
6324146|NCT02907619|10065379|FG000|Overall Study|Death|0
6324147|NCT02907619|10065380|FG001|Overall Study|Death|0
6324148|NCT02907619|10065381|FG002|Overall Study|Death|1
6324149|NCT02907619|10065379|FG000|Overall Study|Withdrawal by Subject|1
6324150|NCT02907619|10065380|FG001|Overall Study|Withdrawal by Subject|1
6324151|NCT02907619|10065381|FG002|Overall Study|Withdrawal by Subject|0
6041825|NCT00379639|9640127|FG002|Overall Study|Physician Decision|1
6041826|NCT00379639|9640128|FG003|Overall Study|Physician Decision|1
6041827|NCT00379639|9640129|FG004|Overall Study|Physician Decision|0
6041828|NCT00379639|9640125|FG000|Overall Study|Symptomatic Deterioration|0
6041829|NCT00379639|9640126|FG001|Overall Study|Symptomatic Deterioration|0
6041830|NCT00379639|9640127|FG002|Overall Study|Symptomatic Deterioration|1
6041831|NCT00379639|9640128|FG003|Overall Study|Symptomatic Deterioration|0
6041832|NCT00379639|9640129|FG004|Overall Study|Symptomatic Deterioration|1
6041833|NCT00379639|9640125|FG000|Overall Study|Adverse Event|0
6041834|NCT00379639|9640126|FG001|Overall Study|Adverse Event|0
6041835|NCT00379639|9640127|FG002|Overall Study|Adverse Event|1
6041836|NCT00379639|9640128|FG003|Overall Study|Adverse Event|0
6041837|NCT00379639|9640129|FG004|Overall Study|Adverse Event|1
6041838|NCT00379639|9640125|FG000|Overall Study|Lost to Follow-up|0
6041839|NCT00379639|9640126|FG001|Overall Study|Lost to Follow-up|0
6041840|NCT00379639|9640127|FG002|Overall Study|Lost to Follow-up|0
6041841|NCT00379639|9640128|FG003|Overall Study|Lost to Follow-up|1
6041842|NCT00379639|9640129|FG004|Overall Study|Lost to Follow-up|0
6041843|NCT00379639|9640125|FG000|Overall Study|Other|0
6041844|NCT00379639|9640126|FG001|Overall Study|Other|0
6041845|NCT00379639|9640127|FG002|Overall Study|Other|3
6041846|NCT00379639|9640128|FG003|Overall Study|Other|0
6041847|NCT00379639|9640129|FG004|Overall Study|Other|0
6041848|NCT00379769|9640145|FG000|Main Study|Death|57
6041849|NCT00379769|9640146|FG001|Main Study|Death|67
6153887|NCT01130493|9792181|FG000|Part 1: Open-Label IPX066 Washout|Withdrawal by Subject|0
6153888|NCT01130493|9792182|FG001|Part 1: Open-Label IPX066 Washout|Withdrawal by Subject|0
6153889|NCT01130493|9792183|FG002|Part 1: Open-Label IPX066 Washout|Withdrawal by Subject|1
6153890|NCT01130493|9792181|FG000|Part 1: Double-blind Treatment Period 2|Withdrawal by Subject|0
6153891|NCT01130493|9792182|FG001|Part 1: Double-blind Treatment Period 2|Withdrawal by Subject|0
6153892|NCT01130493|9792183|FG002|Part 1: Double-blind Treatment Period 2|Withdrawal by Subject|1
6153893|NCT01130493|9792181|FG000|Part 1: Double-blind Treatment Period 2|Noncompliance|0
6153894|NCT01130493|9792182|FG001|Part 1: Double-blind Treatment Period 2|Noncompliance|0
6153895|NCT01130493|9792183|FG002|Part 1: Double-blind Treatment Period 2|Noncompliance|1
6153896|NCT01130493|9792181|FG000|Part 2: OLE|Adverse Event|0
6153897|NCT01130493|9792182|FG001|Part 2: OLE|Adverse Event|2
6153898|NCT01130493|9792183|FG002|Part 2: OLE|Adverse Event|1
6153899|NCT01130493|9792181|FG000|Part 2: OLE|Withdrawal by Subject|0
6153900|NCT01130493|9792182|FG001|Part 2: OLE|Withdrawal by Subject|1
6153901|NCT01130493|9792183|FG002|Part 2: OLE|Withdrawal by Subject|4
6153902|NCT01130532|9792197|FG000|Period III (Weeks 0-12)|Adverse Event|3
6153903|NCT01130532|9792198|FG001|Period III (Weeks 0-12)|Adverse Event|3
6153904|NCT01130532|9792199|FG002|Period III (Weeks 0-12)|Adverse Event|2
6153905|NCT01130532|9792200|FG003|Period III (Weeks 0-12)|Adverse Event|0
6153906|NCT01130532|9792197|FG000|Period III (Weeks 0-12)|Entry Criteria Not Met|4
6153907|NCT01130532|9792198|FG001|Period III (Weeks 0-12)|Entry Criteria Not Met|2
6153908|NCT01130532|9792199|FG002|Period III (Weeks 0-12)|Entry Criteria Not Met|4
6153909|NCT01130532|9792200|FG003|Period III (Weeks 0-12)|Entry Criteria Not Met|0
6153910|NCT01130532|9792197|FG000|Period III (Weeks 0-12)|Lack of Efficacy|2
6153911|NCT01130532|9792198|FG001|Period III (Weeks 0-12)|Lack of Efficacy|0
6153912|NCT01130532|9792199|FG002|Period III (Weeks 0-12)|Lack of Efficacy|1
6153913|NCT01130532|9792200|FG003|Period III (Weeks 0-12)|Lack of Efficacy|0
6153914|NCT01130532|9792197|FG000|Period III (Weeks 0-12)|Lost to Follow-up|2
6153915|NCT01130532|9792198|FG001|Period III (Weeks 0-12)|Lost to Follow-up|2
6153916|NCT01130532|9792199|FG002|Period III (Weeks 0-12)|Lost to Follow-up|3
6153917|NCT01130532|9792200|FG003|Period III (Weeks 0-12)|Lost to Follow-up|0
6153918|NCT01130532|9792197|FG000|Period III (Weeks 0-12)|Protocol Violation|0
6041850|NCT00379769|9640147|FG002|Main Study|Death|54
6041851|NCT00379769|9640148|FG003|Main Study|Death|72
6041852|NCT00379769|9640149|FG004|Main Study|Death|0
6041853|NCT00379769|9640150|FG005|Main Study|Death|0
6041854|NCT00379769|9640145|FG000|Main Study|Adverse Event|5
6041855|NCT00379769|9640146|FG001|Main Study|Adverse Event|8
6041856|NCT00379769|9640147|FG002|Main Study|Adverse Event|10
6041857|NCT00379769|9640148|FG003|Main Study|Adverse Event|11
6041858|NCT00379769|9640149|FG004|Main Study|Adverse Event|0
6041859|NCT00379769|9640150|FG005|Main Study|Adverse Event|0
6041860|NCT00379769|9640145|FG000|Main Study|Lost to Follow-up|29
6041861|NCT00379769|9640146|FG001|Main Study|Lost to Follow-up|29
6041862|NCT00379769|9640147|FG002|Main Study|Lost to Follow-up|25
6153919|NCT01130532|9792198|FG001|Period III (Weeks 0-12)|Protocol Violation|0
6153920|NCT01130532|9792199|FG002|Period III (Weeks 0-12)|Protocol Violation|1
6153921|NCT01130532|9792200|FG003|Period III (Weeks 0-12)|Protocol Violation|0
6153922|NCT01130532|9792197|FG000|Period III (Weeks 0-12)|Sponsor Decision|3
6153923|NCT01130532|9792198|FG001|Period III (Weeks 0-12)|Sponsor Decision|4
6153924|NCT01130532|9792199|FG002|Period III (Weeks 0-12)|Sponsor Decision|2
6153925|NCT01130532|9792200|FG003|Period III (Weeks 0-12)|Sponsor Decision|0
6153926|NCT01130532|9792197|FG000|Period III (Weeks 0-12)|Withdrawal by Subject|7
6153927|NCT01130532|9792198|FG001|Period III (Weeks 0-12)|Withdrawal by Subject|7
6153928|NCT01130532|9792199|FG002|Period III (Weeks 0-12)|Withdrawal by Subject|6
6153929|NCT01130532|9792200|FG003|Period III (Weeks 0-12)|Withdrawal by Subject|0
6153930|NCT01130532|9792197|FG000|Period IV (Weeks 13-16)|Adverse Event|0
6153931|NCT01130532|9792198|FG001|Period IV (Weeks 13-16)|Adverse Event|0
6153932|NCT01130532|9792199|FG002|Period IV (Weeks 13-16)|Adverse Event|0
6153933|NCT01130532|9792200|FG003|Period IV (Weeks 13-16)|Adverse Event|1
6153934|NCT01130532|9792197|FG000|Period IV (Weeks 13-16)|Entry Criteria Not Met|0
6153935|NCT01130532|9792198|FG001|Period IV (Weeks 13-16)|Entry Criteria Not Met|0
6153936|NCT01130532|9792199|FG002|Period IV (Weeks 13-16)|Entry Criteria Not Met|0
6153937|NCT01130532|9792200|FG003|Period IV (Weeks 13-16)|Entry Criteria Not Met|1
6153938|NCT01130532|9792197|FG000|Period IV (Weeks 13-16)|Lost to Follow-up|0
6153939|NCT01130532|9792198|FG001|Period IV (Weeks 13-16)|Lost to Follow-up|0
6153940|NCT01130532|9792199|FG002|Period IV (Weeks 13-16)|Lost to Follow-up|0
6153941|NCT01130532|9792200|FG003|Period IV (Weeks 13-16)|Lost to Follow-up|5
6153942|NCT01130532|9792197|FG000|Period IV (Weeks 13-16)|Withdrawal by Subject|0
6153943|NCT01130532|9792198|FG001|Period IV (Weeks 13-16)|Withdrawal by Subject|0
6041863|NCT00379769|9640148|FG003|Main Study|Lost to Follow-up|26
6041864|NCT00379769|9640149|FG004|Main Study|Lost to Follow-up|0
6041865|NCT00379769|9640150|FG005|Main Study|Lost to Follow-up|0
6041866|NCT00379769|9640145|FG000|Main Study|Withdrawal by Subject|46
6041867|NCT00379769|9640146|FG001|Main Study|Withdrawal by Subject|56
6041868|NCT00379769|9640147|FG002|Main Study|Withdrawal by Subject|72
6041869|NCT00379769|9640148|FG003|Main Study|Withdrawal by Subject|70
6041870|NCT00379769|9640149|FG004|Main Study|Withdrawal by Subject|0
6041871|NCT00379769|9640150|FG005|Main Study|Withdrawal by Subject|0
6041872|NCT00379769|9640145|FG000|Main Study|Moved to survival status follow-up only|27
6041873|NCT00379769|9640146|FG001|Main Study|Moved to survival status follow-up only|25
6041874|NCT00379769|9640147|FG002|Main Study|Moved to survival status follow-up only|32
6041875|NCT00379769|9640148|FG003|Main Study|Moved to survival status follow-up only|36
6041876|NCT00379769|9640149|FG004|Main Study|Moved to survival status follow-up only|0
6041877|NCT00379769|9640150|FG005|Main Study|Moved to survival status follow-up only|0
6041878|NCT00379769|9640145|FG000|Main Study|Participant moved|3
6041879|NCT00379769|9640146|FG001|Main Study|Participant moved|2
6041880|NCT00379769|9640147|FG002|Main Study|Participant moved|3
6153944|NCT01130532|9792199|FG002|Period IV (Weeks 13-16)|Withdrawal by Subject|0
6041881|NCT00379769|9640148|FG003|Main Study|Participant moved|3
6041882|NCT00379769|9640149|FG004|Main Study|Participant moved|0
6041883|NCT00379769|9640150|FG005|Main Study|Participant moved|0
6041884|NCT00379769|9640145|FG000|Main Study|Poor compliance|3
6041885|NCT00379769|9640146|FG001|Main Study|Poor compliance|2
6153945|NCT01130532|9792200|FG003|Period IV (Weeks 13-16)|Withdrawal by Subject|3
6153946|NCT01130597|9792212|FG000|Overall Study|Protocol-specified (High K+)|1
6153947|NCT01130597|9792212|FG000|Overall Study|Adverse Event|4
6153948|NCT01130597|9792212|FG000|Overall Study|Death|1
6153949|NCT01130597|9792212|FG000|Overall Study|Protocol Violation|1
6153950|NCT01130831|9792225|FG000|Overall Study|Withdrawal by Subject|7
6153951|NCT01130831|9792225|FG000|Overall Study|Death|4
6153952|NCT01130831|9792225|FG000|Overall Study|Information was missing|3
6153953|NCT01130883|9792257|FG000|Overall Study|Patient Noncompliance|6
6153954|NCT01130883|9792257|FG000|Overall Study|Reason Unknown|1
6153955|NCT01130883|9792257|FG000|Overall Study|Adverse Event|3
6153956|NCT01130974|9792267|FG000|Overall Study|Protocol Violation|10
6153957|NCT01130974|9792268|FG001|Overall Study|Protocol Violation|10
6153958|NCT01130974|9792267|FG000|Overall Study|Withdrawal by Subject|0
6153959|NCT01130974|9792268|FG001|Overall Study|Withdrawal by Subject|1
6153960|NCT01130974|9792267|FG000|Overall Study|Ineligibility criteria|5
6153961|NCT01130974|9792268|FG001|Overall Study|Ineligibility criteria|2
6153962|NCT01131078|9792291|FG000|Overall Study|Adverse Event|22
6153963|NCT01131078|9792292|FG001|Overall Study|Adverse Event|12
6153964|NCT01131078|9792293|FG002|Overall Study|Adverse Event|17
6153965|NCT01131078|9792291|FG000|Overall Study|Progressive Disease|58
6153966|NCT01131078|9792292|FG001|Overall Study|Progressive Disease|77
6153967|NCT01131078|9792293|FG002|Overall Study|Progressive Disease|71
6153968|NCT01131078|9792291|FG000|Overall Study|Protocol Violation|1
6153969|NCT01131078|9792292|FG001|Overall Study|Protocol Violation|0
6153970|NCT01131078|9792293|FG002|Overall Study|Protocol Violation|0
6153971|NCT01131078|9792291|FG000|Overall Study|Lost to Follow-up|1
6153972|NCT01131078|9792292|FG001|Overall Study|Lost to Follow-up|1
6153973|NCT01131078|9792293|FG002|Overall Study|Lost to Follow-up|1
6153974|NCT01131078|9792291|FG000|Overall Study|Withdrawal by Subject|2
6153975|NCT01131078|9792292|FG001|Overall Study|Withdrawal by Subject|4
6153976|NCT01131078|9792293|FG002|Overall Study|Withdrawal by Subject|3
6153977|NCT01131078|9792291|FG000|Overall Study|Non-compliance|3
6153978|NCT01131078|9792292|FG001|Overall Study|Non-compliance|0
6153979|NCT01131078|9792293|FG002|Overall Study|Non-compliance|0
6153980|NCT01131078|9792291|FG000|Overall Study|Physician Decision|10
6153981|NCT01131078|9792292|FG001|Overall Study|Physician Decision|6
6153982|NCT01131078|9792293|FG002|Overall Study|Physician Decision|8
6153983|NCT01131078|9792291|FG000|Overall Study|Death|4
6153984|NCT01131078|9792292|FG001|Overall Study|Death|0
6153985|NCT01131078|9792293|FG002|Overall Study|Death|2
6153986|NCT01131078|9792291|FG000|Overall Study|Other|0
6153987|NCT01131078|9792292|FG001|Overall Study|Other|1
6153988|NCT01131078|9792293|FG002|Overall Study|Other|0
6153989|NCT01131104|9792303|FG000|Overall Study|Withdrawal by Subject|3
6153990|NCT01131104|9792303|FG000|Overall Study|Physician Decision|4
6153991|NCT01131104|9792303|FG000|Overall Study|Information Not Available|5
6153992|NCT01131104|9792303|FG000|Overall Study|No Information on Index Date of Onset|1
6153993|NCT01131130|9792307|FG000|Period 1 - Baseline|Pregnancy|1
6153994|NCT01131130|9792307|FG000|Period 3- Crossover|+ Slit lamp finding|1
6153995|NCT01131182|9792317|FG000|Overall Study|Withdrawal by Subject|1
6153996|NCT01131182|9792318|FG001|Overall Study|Withdrawal by Subject|1
6153997|NCT01131182|9792317|FG000|Overall Study|Lost to Follow-up|14
6153998|NCT01131182|9792318|FG001|Overall Study|Lost to Follow-up|15
6153999|NCT01131182|9792317|FG000|Overall Study|Other Reason|1
6154000|NCT01131182|9792318|FG001|Overall Study|Other Reason|0
6154001|NCT01131260|9792326|FG000|Overall Study|Randomization error|5
6154002|NCT01131260|9792327|FG001|Overall Study|Randomization error|1
6154003|NCT01131260|9792326|FG000|Overall Study|Declined to continue participation|8
6154004|NCT01131260|9792327|FG001|Overall Study|Declined to continue participation|13
6154005|NCT01131260|9792326|FG000|Overall Study|Physician Decision|22
6154006|NCT01131260|9792327|FG001|Overall Study|Physician Decision|24
6154007|NCT01131260|9792326|FG000|Overall Study|Technical problems|7
6154008|NCT01131260|9792327|FG001|Overall Study|Technical problems|6
6154009|NCT01131260|9792326|FG000|Overall Study|Staff error|2
6154010|NCT01131260|9792327|FG001|Overall Study|Staff error|1
6154011|NCT01131260|9792326|FG000|Overall Study|Ineligible|0
6154012|NCT01131260|9792327|FG001|Overall Study|Ineligible|2
6154013|NCT01131299|9792335|FG000|Overall Study|Withdrawal by Subject|4
6324152|NCT02907619|10065379|FG000|Overall Study|Other|0
6324153|NCT02907619|10065380|FG001|Overall Study|Other|1
6324154|NCT02907619|10065381|FG002|Overall Study|Other|0
6324155|NCT02907892|10065402|FG000|Overall Study|Lost to Follow-up|27
6324156|NCT02907892|10065403|FG001|Overall Study|Lost to Follow-up|40
6324157|NCT02908100|10065419|FG000|Overall Study|Adverse Event|7
6324158|NCT02908100|10065420|FG001|Overall Study|Adverse Event|6
6324159|NCT02908100|10065421|FG002|Overall Study|Adverse Event|9
6324160|NCT02908100|10065419|FG000|Overall Study|Death|2
6324161|NCT02908100|10065420|FG001|Overall Study|Death|0
6324162|NCT02908100|10065421|FG002|Overall Study|Death|0
6324163|NCT02908100|10065419|FG000|Overall Study|Lack of Efficacy|2
6324164|NCT02908100|10065420|FG001|Overall Study|Lack of Efficacy|3
6041886|NCT00379769|9640147|FG002|Main Study|Poor compliance|2
6041887|NCT00379769|9640148|FG003|Main Study|Poor compliance|1
6041888|NCT00379769|9640149|FG004|Main Study|Poor compliance|0
6041889|NCT00379769|9640150|FG005|Main Study|Poor compliance|0
6041890|NCT00379769|9640145|FG000|Main Study|Prohibited glucose lowering medication|0
6041891|NCT00379769|9640146|FG001|Main Study|Prohibited glucose lowering medication|3
6041892|NCT00379769|9640147|FG002|Main Study|Prohibited glucose lowering medication|0
6041893|NCT00379769|9640148|FG003|Main Study|Prohibited glucose lowering medication|1
6041894|NCT00379769|9640149|FG004|Main Study|Prohibited glucose lowering medication|0
6041895|NCT00379769|9640150|FG005|Main Study|Prohibited glucose lowering medication|0
6041896|NCT00379769|9640145|FG000|Main Study|Site closed|4
6041897|NCT00379769|9640146|FG001|Main Study|Site closed|4
6041898|NCT00379769|9640147|FG002|Main Study|Site closed|4
6324165|NCT02908100|10065421|FG002|Overall Study|Lack of Efficacy|3
6324166|NCT02908100|10065419|FG000|Overall Study|Lost to Follow-up|0
6324167|NCT02908100|10065420|FG001|Overall Study|Lost to Follow-up|1
6324168|NCT02908100|10065421|FG002|Overall Study|Lost to Follow-up|2
6324169|NCT02908100|10065419|FG000|Overall Study|Non-Compliance With Study Drug|1
6324170|NCT02908100|10065420|FG001|Overall Study|Non-Compliance With Study Drug|1
6324171|NCT02908100|10065421|FG002|Overall Study|Non-Compliance With Study Drug|2
6324172|NCT02908100|10065419|FG000|Overall Study|Non-Compliance With Contraceptive Method|1
6324173|NCT02908100|10065420|FG001|Overall Study|Non-Compliance With Contraceptive Method|0
6324174|NCT02908100|10065421|FG002|Overall Study|Non-Compliance With Contraceptive Method|0
6324175|NCT02908100|10065419|FG000|Overall Study|Physician Decision|0
6324176|NCT02908100|10065420|FG001|Overall Study|Physician Decision|1
6324177|NCT02908100|10065421|FG002|Overall Study|Physician Decision|0
6324178|NCT02908100|10065419|FG000|Overall Study|Pregnancy|1
6324179|NCT02908100|10065420|FG001|Overall Study|Pregnancy|2
6324180|NCT02908100|10065421|FG002|Overall Study|Pregnancy|0
6324181|NCT02908100|10065419|FG000|Overall Study|Withdrawal by Subject|8
6324182|NCT02908100|10065420|FG001|Overall Study|Withdrawal by Subject|7
6324183|NCT02908100|10065421|FG002|Overall Study|Withdrawal by Subject|5
6324184|NCT02908100|10065419|FG000|Overall Study|Randomised in Error|1
6324185|NCT02908100|10065420|FG001|Overall Study|Randomised in Error|0
6324186|NCT02908100|10065421|FG002|Overall Study|Randomised in Error|0
6324187|NCT02908347|10065449|FG000|Overall Study|Adverse Event|0
6324188|NCT02908347|10065450|FG001|Overall Study|Adverse Event|1
6324189|NCT02908347|10065449|FG000|Overall Study|Lost to Follow-up|1
6324190|NCT02908347|10065450|FG001|Overall Study|Lost to Follow-up|0
6324191|NCT02908464|10065472|FG000|Overall Study|Withdrawal by Subject|2
6324192|NCT02908464|10065473|FG001|Overall Study|Withdrawal by Subject|1
6324193|NCT02908464|10065472|FG000|Overall Study|Found ineligible after randomization|0
6324194|NCT02908464|10065473|FG001|Overall Study|Found ineligible after randomization|2
6324195|NCT02908529|10065489|FG000|Overall Study|Lost to Follow-up|0
6324196|NCT02908529|10065490|FG001|Overall Study|Lost to Follow-up|2
6324197|NCT02908841|10065521|FG000|Overall Study|Physician Decision|4
6324198|NCT02908841|10065522|FG001|Overall Study|Physician Decision|0
6324199|NCT02908880|10065528|FG000|Overall Study|Lost to Follow-up|4
6324200|NCT02908880|10065528|FG000|Overall Study|Explantation of the device|1
6324201|NCT02908880|10065528|FG000|Overall Study|Withdrawal by Subject|17
6324202|NCT02908880|10065528|FG000|Overall Study|Death|5
6324203|NCT02909101|10065534|FG000|Overall Study|Lost to Follow-up|1
6324204|NCT02909101|10065535|FG001|Overall Study|Lost to Follow-up|1
6324205|NCT02909153|10065559|FG000|Overall Study|Withdrawal by Subject|0
6324206|NCT02909153|10065560|FG001|Overall Study|Withdrawal by Subject|1
6324207|NCT02909153|10065561|FG002|Overall Study|Withdrawal by Subject|0
6324208|NCT02909153|10065562|FG003|Overall Study|Withdrawal by Subject|0
6324209|NCT02909153|10065563|FG004|Overall Study|Withdrawal by Subject|0
6324210|NCT02909504|10065584|FG000|Overall Study|Adverse Event|2
6324211|NCT02909504|10065584|FG000|Overall Study|Lack of Efficacy|3
6324212|NCT02909504|10065584|FG000|Overall Study|Withdrawal by Subject|4
6324213|NCT02909504|10065584|FG000|Overall Study|Pregnancy|1
6324214|NCT02909504|10065584|FG000|Overall Study|Subject moved|1
6324215|NCT02909504|10065584|FG000|Overall Study|Lost to Follow-up|1
6324216|NCT02909907|10065603|FG000|Overall Study|Withdrawal by Subject|0
6324217|NCT02909907|10065604|FG001|Overall Study|Withdrawal by Subject|1
6324218|NCT02910011|10065619|FG000|Overall Study|Physician Decision|2
6324219|NCT02910037|10065625|FG000|Overall Study|Withdrawal by Subject|4
6324220|NCT02910037|10065625|FG000|Overall Study|Lost to Follow-up|6
6324221|NCT02910063|10065645|FG000|Phase 2|Withdrawal by Subject|3
6324222|NCT02910063|10065646|FG001|Phase 2|Withdrawal by Subject|0
6324223|NCT02910063|10065647|FG002|Phase 2|Withdrawal by Subject|0
6324224|NCT02910063|10065645|FG000|Phase 2|Lost to Follow-up|1
6324225|NCT02910063|10065646|FG001|Phase 2|Lost to Follow-up|0
6324226|NCT02910063|10065647|FG002|Phase 2|Lost to Follow-up|0
6324227|NCT02910063|10065645|FG000|Phase 2|Death|24
6324228|NCT02910063|10065646|FG001|Phase 2|Death|0
6324229|NCT02910063|10065647|FG002|Phase 2|Death|0
6324230|NCT02910089|10065658|FG000|Overall Study|Lost insurance eligibility|22
6324231|NCT02910089|10065659|FG001|Overall Study|Lost insurance eligibility|16
6324232|NCT02910167|10065679|FG000|Overall Study|Adverse Event|1
6324233|NCT02910167|10065679|FG000|Overall Study|Lost to Follow-up|18
6324234|NCT02910466|10065692|FG000|Overall Study|Adverse Event|1
6324235|NCT02910466|10065692|FG000|Overall Study|Withdrawal by Subject|3
6324236|NCT02910466|10065692|FG000|Overall Study|Lost to Follow-up|5
6324237|NCT02910466|10065692|FG000|Overall Study|Due to Food and Drug Administration (FDA) recall|29
6324238|NCT02910466|10065692|FG000|Overall Study|Participant didn't meet inclusion criteria|1
6324239|NCT02910713|10065701|FG000|Overall Study|Protocol Violation|2
6324240|NCT02910713|10065701|FG000|Overall Study|Subject Choice|4
6324241|NCT02910713|10065701|FG000|Overall Study|Received One Application|10
6324242|NCT02910713|10065701|FG000|Overall Study|Received Neither Application|18
6324243|NCT02910713|10065701|FG000|Overall Study|Enrollment cap|7
6324244|NCT02910713|10065701|FG000|Overall Study|Investigator Discretion|1
6324245|NCT02910739|10065708|FG000|Overall Study|Adverse Event|1
6041899|NCT00379769|9640148|FG003|Main Study|Site closed|8
6041900|NCT00379769|9640149|FG004|Main Study|Site closed|0
6041901|NCT00379769|9640150|FG005|Main Study|Site closed|0
6041902|NCT00379769|9640145|FG000|Main Study|Entry criteria violation|0
6041903|NCT00379769|9640146|FG001|Main Study|Entry criteria violation|0
6041904|NCT00379769|9640147|FG002|Main Study|Entry criteria violation|1
6041905|NCT00379769|9640148|FG003|Main Study|Entry criteria violation|1
6041906|NCT00379769|9640149|FG004|Main Study|Entry criteria violation|0
6041907|NCT00379769|9640150|FG005|Main Study|Entry criteria violation|0
6041908|NCT00379769|9640145|FG000|Main Study|Participant did not take study drug|0
6041909|NCT00379769|9640146|FG001|Main Study|Participant did not take study drug|0
6041910|NCT00379769|9640147|FG002|Main Study|Participant did not take study drug|1
6041911|NCT00379769|9640148|FG003|Main Study|Participant did not take study drug|0
6041912|NCT00379769|9640149|FG004|Main Study|Participant did not take study drug|0
6041913|NCT00379769|9640150|FG005|Main Study|Participant did not take study drug|0
6041914|NCT00379769|9640145|FG000|Main Study|Physician Decision|2
6041915|NCT00379769|9640146|FG001|Main Study|Physician Decision|2
6041916|NCT00379769|9640147|FG002|Main Study|Physician Decision|1
6041917|NCT00379769|9640148|FG003|Main Study|Physician Decision|1
6041918|NCT00379769|9640149|FG004|Main Study|Physician Decision|0
6041919|NCT00379769|9640150|FG005|Main Study|Physician Decision|0
6041920|NCT00379769|9640145|FG000|Main Study|Participant completed study at visit 27|1
6041921|NCT00379769|9640146|FG001|Main Study|Participant completed study at visit 27|0
6324246|NCT02910739|10065709|FG001|Overall Study|Adverse Event|0
6324247|NCT02910739|10065710|FG002|Overall Study|Adverse Event|0
6324248|NCT02910739|10065711|FG003|Overall Study|Adverse Event|0
6324249|NCT02911025|10065717|FG000|Overall Study|Lost to Follow-up|3
6324250|NCT02911116|10065723|FG000|Overall Study|Insufficient Therapeutic Response|1
6324251|NCT02911116|10065724|FG001|Overall Study|Insufficient Therapeutic Response|0
6324252|NCT02911116|10065723|FG000|Overall Study|Lost to Follow-up|0
6324253|NCT02911116|10065724|FG001|Overall Study|Lost to Follow-up|1
6324254|NCT02911285|10065732|FG000|Overall Study|Lost to Follow-up|8
6324255|NCT02911285|10065733|FG001|Overall Study|Lost to Follow-up|5
6324256|NCT02911285|10065732|FG000|Overall Study|Participant got a job and no longer had time to participate.|1
6324257|NCT02911285|10065733|FG001|Overall Study|Participant got a job and no longer had time to participate.|0
6324258|NCT02911519|10065755|FG000|Overall Study|Lost to Follow-up|2
6324259|NCT02911519|10065756|FG001|Overall Study|Lost to Follow-up|2
6324260|NCT02911519|10065755|FG000|Overall Study|Death|0
6324261|NCT02911519|10065756|FG001|Overall Study|Death|2
6041922|NCT00379769|9640147|FG002|Main Study|Participant completed study at visit 27|0
6324262|NCT02911688|10065764|FG000|Washout|Lost to Follow-up|1
6324263|NCT02911688|10065765|FG001|Washout|Lost to Follow-up|1
6154014|NCT01131299|9792336|FG001|Overall Study|Withdrawal by Subject|7
6154015|NCT01131312|9792344|FG000|Overall Study|Lost to Follow-up|425
6154016|NCT01131312|9792345|FG001|Overall Study|Lost to Follow-up|229
6154017|NCT01131312|9792346|FG002|Overall Study|Lost to Follow-up|351
6154018|NCT01131325|9792354|FG000|Overall Study|Adverse Event|1
6154019|NCT01131325|9792354|FG000|Overall Study|The participants discontinued the study as the study got terminated|2
6154020|NCT01131351|9792360|FG000|Overall Study|Adverse Event|0
6154021|NCT01131351|9792361|FG001|Overall Study|Adverse Event|2
6154022|NCT01131351|9792360|FG000|Overall Study|Protocol Deviation|0
6154023|NCT01131351|9792361|FG001|Overall Study|Protocol Deviation|1
6154024|NCT01131494|9792367|FG000|Overall Study|Withdrawal by Subject|2
6154025|NCT01131507|9792372|FG000|Overall Study|Adverse Event|1
6154026|NCT01131507|9792372|FG000|Overall Study|Lost to Follow-up|1
6154027|NCT01131507|9792372|FG000|Overall Study|Withdrawal by Subject|1
6154028|NCT01131520|9792378|FG000|Overall Study|Computer problem|1
6154029|NCT01131520|9792379|FG001|Overall Study|Computer problem|0
6154030|NCT01131520|9792378|FG000|Overall Study|Counselor not available|0
6154031|NCT01131520|9792379|FG001|Overall Study|Counselor not available|3
6154032|NCT01131520|9792378|FG000|Overall Study|Subject changed history after enrollment|0
6154033|NCT01131520|9792379|FG001|Overall Study|Subject changed history after enrollment|1
6154034|NCT01131585|9792387|FG000|Overall Study|Adverse Event|0
6154035|NCT01131585|9792388|FG001|Overall Study|Adverse Event|2
6154036|NCT01131585|9792387|FG000|Overall Study|Abnormal laboratory value|1
6154037|NCT01131585|9792388|FG001|Overall Study|Abnormal laboratory value|0
6154038|NCT01131585|9792387|FG000|Overall Study|Unsatisfactory therapeutic effect|0
6154039|NCT01131585|9792388|FG001|Overall Study|Unsatisfactory therapeutic effect|3
6154040|NCT01131585|9792387|FG000|Overall Study|Protocol Violation|2
6154041|NCT01131585|9792388|FG001|Overall Study|Protocol Violation|1
6154042|NCT01131585|9792387|FG000|Overall Study|Withdrawal by Subject|3
6154043|NCT01131585|9792388|FG001|Overall Study|Withdrawal by Subject|3
6154044|NCT01131585|9792387|FG000|Overall Study|Lost to Follow-up|0
6154045|NCT01131585|9792388|FG001|Overall Study|Lost to Follow-up|1
6154046|NCT01131585|9792387|FG000|Overall Study|Administrative problems|1
6154047|NCT01131585|9792388|FG001|Overall Study|Administrative problems|1
6154048|NCT01131585|9792387|FG000|Overall Study|Study termination|78
6154049|NCT01131585|9792388|FG001|Overall Study|Study termination|32
6154050|NCT01131676|9792397|FG000|Discontinuation From Treatment|Study drug stopped, reason missing|5
6154051|NCT01131676|9792398|FG001|Discontinuation From Treatment|Study drug stopped, reason missing|3
6154052|NCT01131676|9792399|FG002|Discontinuation From Treatment|Study drug stopped, reason missing|4
6154053|NCT01131676|9792397|FG000|Discontinuation From Treatment|Not treated|4
6154054|NCT01131676|9792398|FG001|Discontinuation From Treatment|Not treated|2
6154055|NCT01131676|9792399|FG002|Discontinuation From Treatment|Not treated|2
6154056|NCT01131676|9792397|FG000|Discontinuation From Treatment|Lack of Efficacy|11
6154057|NCT01131676|9792398|FG001|Discontinuation From Treatment|Lack of Efficacy|1
6154058|NCT01131676|9792399|FG002|Discontinuation From Treatment|Lack of Efficacy|0
6154059|NCT01131676|9792397|FG000|Discontinuation From Treatment|Non compliant with protocol|15
6154060|NCT01131676|9792398|FG001|Discontinuation From Treatment|Non compliant with protocol|15
6154061|NCT01131676|9792399|FG002|Discontinuation From Treatment|Non compliant with protocol|12
6154062|NCT01131676|9792397|FG000|Discontinuation From Treatment|Lost to Follow-up|15
6154063|NCT01131676|9792398|FG001|Discontinuation From Treatment|Lost to Follow-up|9
6154064|NCT01131676|9792399|FG002|Discontinuation From Treatment|Lost to Follow-up|6
6154065|NCT01131676|9792397|FG000|Discontinuation From Treatment|Refusal to continue, not due to AE|172
6154066|NCT01131676|9792398|FG001|Discontinuation From Treatment|Refusal to continue, not due to AE|118
6154067|NCT01131676|9792399|FG002|Discontinuation From Treatment|Refusal to continue, not due to AE|122
6154068|NCT01131676|9792397|FG000|Discontinuation From Treatment|Other than those specified|162
6154069|NCT01131676|9792398|FG001|Discontinuation From Treatment|Other than those specified|142
6154070|NCT01131676|9792399|FG002|Discontinuation From Treatment|Other than those specified|125
6154071|NCT01131676|9792397|FG000|Discontinuation From Treatment|Adverse Event|303
6154072|NCT01131676|9792398|FG001|Discontinuation From Treatment|Adverse Event|267
6154073|NCT01131676|9792399|FG002|Discontinuation From Treatment|Adverse Event|273
6154074|NCT01131676|9792397|FG000|Discontinuation From Study (Treated Set)|Consent withdrawn: Final VS available|23
6154075|NCT01131676|9792398|FG001|Discontinuation From Study (Treated Set)|Consent withdrawn: Final VS available|35
6154076|NCT01131676|9792399|FG002|Discontinuation From Study (Treated Set)|Consent withdrawn: Final VS available|25
6154077|NCT01131676|9792397|FG000|Discontinuation From Study (Treated Set)|Consent withdrawn:Final VS not available|8
6154078|NCT01131676|9792398|FG001|Discontinuation From Study (Treated Set)|Consent withdrawn:Final VS not available|6
6154079|NCT01131676|9792399|FG002|Discontinuation From Study (Treated Set)|Consent withdrawn:Final VS not available|5
6154080|NCT01131676|9792397|FG000|Discontinuation From Study (Treated Set)|Site closure: Final VS available|20
6154081|NCT01131676|9792398|FG001|Discontinuation From Study (Treated Set)|Site closure: Final VS available|21
6154082|NCT01131676|9792399|FG002|Discontinuation From Study (Treated Set)|Site closure: Final VS available|19
6154083|NCT01131676|9792397|FG000|Discontinuation From Study (Treated Set)|Site closure:Final VS not available (NA)|5
6154084|NCT01131676|9792398|FG001|Discontinuation From Study (Treated Set)|Site closure:Final VS not available (NA)|9
6154085|NCT01131676|9792399|FG002|Discontinuation From Study (Treated Set)|Site closure:Final VS not available (NA)|7
6154086|NCT01131676|9792397|FG000|Discontinuation From Study (Treated Set)|Lost to FU for 3PMACE:Final VS available|7
6154087|NCT01131676|9792398|FG001|Discontinuation From Study (Treated Set)|Lost to FU for 3PMACE:Final VS available|6
6154088|NCT01131676|9792399|FG002|Discontinuation From Study (Treated Set)|Lost to FU for 3PMACE:Final VS available|5
6154089|NCT01131676|9792397|FG000|Discontinuation From Study (Treated Set)|Lost to FU for 3P-MACE:Final VS NA|4
6154090|NCT01131676|9792398|FG001|Discontinuation From Study (Treated Set)|Lost to FU for 3P-MACE:Final VS NA|4
6154091|NCT01131676|9792399|FG002|Discontinuation From Study (Treated Set)|Lost to FU for 3P-MACE:Final VS NA|2
6154092|NCT01132118|9792410|FG000|First Intervention (8 Weeks)|Adverse Event|1
6154093|NCT01132118|9792411|FG001|First Intervention (8 Weeks)|Adverse Event|0
6154094|NCT01132118|9792410|FG000|First Intervention (8 Weeks)|Withdrawal by Subject|2
6154095|NCT01132118|9792411|FG001|First Intervention (8 Weeks)|Withdrawal by Subject|3
6154096|NCT01132118|9792410|FG000|Second Intervention (8 Weeks)|Adverse Event|0
6154097|NCT01132118|9792411|FG001|Second Intervention (8 Weeks)|Adverse Event|1
6154098|NCT01132313|9792440|FG000|Overall Study|Lack of Efficacy|1
6154099|NCT01132313|9792441|FG001|Overall Study|Lack of Efficacy|0
6154100|NCT01132313|9792442|FG002|Overall Study|Lack of Efficacy|0
6154101|NCT01132313|9792443|FG003|Overall Study|Lack of Efficacy|0
6154102|NCT01132313|9792444|FG004|Overall Study|Lack of Efficacy|0
6154103|NCT01132313|9792445|FG005|Overall Study|Lack of Efficacy|0
6154104|NCT01132313|9792446|FG006|Overall Study|Lack of Efficacy|0
6154105|NCT01132313|9792447|FG007|Overall Study|Lack of Efficacy|3
6154106|NCT01132313|9792448|FG008|Overall Study|Lack of Efficacy|14
6154107|NCT01132313|9792449|FG009|Overall Study|Lack of Efficacy|16
6154108|NCT01132313|9792450|FG010|Overall Study|Lack of Efficacy|0
6154109|NCT01132313|9792451|FG011|Overall Study|Lack of Efficacy|0
6154110|NCT01132313|9792440|FG000|Overall Study|Not treated|2
6154111|NCT01132313|9792441|FG001|Overall Study|Not treated|0
6154112|NCT01132313|9792442|FG002|Overall Study|Not treated|0
6154113|NCT01132313|9792443|FG003|Overall Study|Not treated|0
6154114|NCT01132313|9792444|FG004|Overall Study|Not treated|2
6154115|NCT01132313|9792445|FG005|Overall Study|Not treated|1
6154116|NCT01132313|9792446|FG006|Overall Study|Not treated|3
6154117|NCT01132313|9792447|FG007|Overall Study|Not treated|0
6154118|NCT01132313|9792448|FG008|Overall Study|Not treated|0
6154119|NCT01132313|9792449|FG009|Overall Study|Not treated|0
6154120|NCT01132313|9792450|FG010|Overall Study|Not treated|0
6154121|NCT01132313|9792451|FG011|Overall Study|Not treated|0
6154122|NCT01132313|9792440|FG000|Overall Study|Adverse Event|0
6154123|NCT01132313|9792441|FG001|Overall Study|Adverse Event|0
6154124|NCT01132313|9792442|FG002|Overall Study|Adverse Event|4
6154125|NCT01132313|9792443|FG003|Overall Study|Adverse Event|10
6154126|NCT01132313|9792444|FG004|Overall Study|Adverse Event|19
6154127|NCT01132313|9792445|FG005|Overall Study|Adverse Event|6
6154128|NCT01132313|9792446|FG006|Overall Study|Adverse Event|5
6154129|NCT01132313|9792447|FG007|Overall Study|Adverse Event|3
6154130|NCT01132313|9792448|FG008|Overall Study|Adverse Event|7
6154131|NCT01132313|9792449|FG009|Overall Study|Adverse Event|2
6154132|NCT01132313|9792450|FG010|Overall Study|Adverse Event|0
6154133|NCT01132313|9792451|FG011|Overall Study|Adverse Event|0
6154134|NCT01132313|9792440|FG000|Overall Study|Protocol Violation|0
6154135|NCT01132313|9792441|FG001|Overall Study|Protocol Violation|0
6154136|NCT01132313|9792442|FG002|Overall Study|Protocol Violation|0
6154137|NCT01132313|9792443|FG003|Overall Study|Protocol Violation|1
6154138|NCT01132313|9792444|FG004|Overall Study|Protocol Violation|0
6154139|NCT01132313|9792445|FG005|Overall Study|Protocol Violation|0
6154140|NCT01132313|9792446|FG006|Overall Study|Protocol Violation|0
6154141|NCT01132313|9792447|FG007|Overall Study|Protocol Violation|0
6154142|NCT01132313|9792448|FG008|Overall Study|Protocol Violation|0
6154143|NCT01132313|9792449|FG009|Overall Study|Protocol Violation|0
6154144|NCT01132313|9792450|FG010|Overall Study|Protocol Violation|0
6154145|NCT01132313|9792451|FG011|Overall Study|Protocol Violation|0
6154146|NCT01132313|9792440|FG000|Overall Study|Lost to Follow-up|0
6154147|NCT01132313|9792441|FG001|Overall Study|Lost to Follow-up|0
6154148|NCT01132313|9792442|FG002|Overall Study|Lost to Follow-up|1
6154149|NCT01132313|9792443|FG003|Overall Study|Lost to Follow-up|0
6154150|NCT01132313|9792444|FG004|Overall Study|Lost to Follow-up|0
6154151|NCT01132313|9792445|FG005|Overall Study|Lost to Follow-up|0
6154152|NCT01132313|9792446|FG006|Overall Study|Lost to Follow-up|0
6154153|NCT01132313|9792447|FG007|Overall Study|Lost to Follow-up|1
6154154|NCT01132313|9792448|FG008|Overall Study|Lost to Follow-up|0
6154155|NCT01132313|9792449|FG009|Overall Study|Lost to Follow-up|0
6154156|NCT01132313|9792450|FG010|Overall Study|Lost to Follow-up|0
6154157|NCT01132313|9792451|FG011|Overall Study|Lost to Follow-up|0
6154158|NCT01132313|9792440|FG000|Overall Study|Withdrawal by Subject|0
6154159|NCT01132313|9792441|FG001|Overall Study|Withdrawal by Subject|0
6154160|NCT01132313|9792442|FG002|Overall Study|Withdrawal by Subject|3
6154161|NCT01132313|9792443|FG003|Overall Study|Withdrawal by Subject|3
6154162|NCT01132313|9792444|FG004|Overall Study|Withdrawal by Subject|6
6154163|NCT01132313|9792445|FG005|Overall Study|Withdrawal by Subject|0
6154164|NCT01132313|9792446|FG006|Overall Study|Withdrawal by Subject|1
6154165|NCT01132313|9792447|FG007|Overall Study|Withdrawal by Subject|0
6154166|NCT01132313|9792448|FG008|Overall Study|Withdrawal by Subject|0
6154167|NCT01132313|9792449|FG009|Overall Study|Withdrawal by Subject|2
6154168|NCT01132313|9792450|FG010|Overall Study|Withdrawal by Subject|0
6154169|NCT01132313|9792451|FG011|Overall Study|Withdrawal by Subject|0
6154170|NCT01132313|9792440|FG000|Overall Study|Lack of antiviral response|0
6154171|NCT01132313|9792441|FG001|Overall Study|Lack of antiviral response|0
6154172|NCT01132313|9792442|FG002|Overall Study|Lack of antiviral response|12
6154173|NCT01132313|9792443|FG003|Overall Study|Lack of antiviral response|18
6154174|NCT01132313|9792444|FG004|Overall Study|Lack of antiviral response|18
6154175|NCT01132313|9792445|FG005|Overall Study|Lack of antiviral response|18
6154176|NCT01132313|9792446|FG006|Overall Study|Lack of antiviral response|21
6154177|NCT01132313|9792447|FG007|Overall Study|Lack of antiviral response|0
6324264|NCT02911688|10065764|FG000|Washout|Withdrawal by Subject|0
6324265|NCT02911688|10065765|FG001|Washout|Withdrawal by Subject|1
6324266|NCT02911948|10065864|FG000|Overall Study|Protocol Violation|0
6324267|NCT02911948|10065865|FG001|Overall Study|Protocol Violation|1
6324268|NCT02911948|10065864|FG000|Overall Study|Withdrawal by Subject|0
6154178|NCT01132313|9792448|FG008|Overall Study|Lack of antiviral response|0
6154179|NCT01132313|9792449|FG009|Overall Study|Lack of antiviral response|0
6154180|NCT01132313|9792450|FG010|Overall Study|Lack of antiviral response|1
6154181|NCT01132313|9792451|FG011|Overall Study|Lack of antiviral response|0
6154182|NCT01132313|9792440|FG000|Overall Study|Other reason not defined above|0
6154183|NCT01132313|9792441|FG001|Overall Study|Other reason not defined above|0
6154184|NCT01132313|9792442|FG002|Overall Study|Other reason not defined above|0
6154185|NCT01132313|9792443|FG003|Overall Study|Other reason not defined above|0
6154186|NCT01132313|9792444|FG004|Overall Study|Other reason not defined above|0
6154187|NCT01132313|9792445|FG005|Overall Study|Other reason not defined above|0
6154188|NCT01132313|9792446|FG006|Overall Study|Other reason not defined above|0
6154189|NCT01132313|9792447|FG007|Overall Study|Other reason not defined above|1
6154190|NCT01132313|9792448|FG008|Overall Study|Other reason not defined above|0
6154191|NCT01132313|9792449|FG009|Overall Study|Other reason not defined above|0
6154192|NCT01132313|9792450|FG010|Overall Study|Other reason not defined above|0
6154193|NCT01132313|9792451|FG011|Overall Study|Other reason not defined above|0
6154194|NCT01132326|9792482|FG000|Overall Study|Lack of Efficacy|25
6154195|NCT01132326|9792482|FG000|Overall Study|Adverse Event|37
6154196|NCT01132326|9792482|FG000|Overall Study|Protocol Violation|1
6154197|NCT01132326|9792482|FG000|Overall Study|Lost to Follow-up|16
6154198|NCT01132326|9792482|FG000|Overall Study|Withdrawal by Subject|40
6154199|NCT01132326|9792482|FG000|Overall Study|Physician Decision|10
6154200|NCT01132326|9792482|FG000|Overall Study|Study Termination|80
6154201|NCT01132326|9792482|FG000|Overall Study|Declining Health|1
6154202|NCT01132326|9792482|FG000|Overall Study|Pregnancy|1
6154203|NCT01132326|9792482|FG000|Overall Study|Caregiver Withdrew Consent|1
6154204|NCT01132326|9792482|FG000|Overall Study|Death|5
6154205|NCT01132326|9792482|FG000|Overall Study|Subject Unable to Come To Visits|1
6154206|NCT01132482|9792493|FG000|Overall Study|Adverse Event|1
6154207|NCT01132482|9792494|FG001|Overall Study|Adverse Event|0
6154208|NCT01132495|9792504|FG000|Overall Study|Various reasons|40
6154209|NCT01132495|9792505|FG001|Overall Study|Various reasons|38
6154210|NCT01132495|9792506|FG002|Overall Study|Various reasons|20
6154211|NCT01132495|9792507|FG003|Overall Study|Various reasons|12
6154212|NCT01132547|9792524|FG000|Overall Study|Withdrawal by Subject|3
6154213|NCT01132547|9792525|FG001|Overall Study|Withdrawal by Subject|1
6154214|NCT01132547|9792524|FG000|Overall Study|Death|1
6154215|NCT01132547|9792525|FG001|Overall Study|Death|0
6154216|NCT01132612|9792534|FG000|Overall Study|Death|0
6154217|NCT01132612|9792535|FG001|Overall Study|Death|0
6154218|NCT01132612|9792536|FG002|Overall Study|Death|1
6154219|NCT01132612|9792534|FG000|Overall Study|Protocol deviation|0
6154220|NCT01132612|9792535|FG001|Overall Study|Protocol deviation|0
6154221|NCT01132612|9792536|FG002|Overall Study|Protocol deviation|3
6154222|NCT01132612|9792534|FG000|Overall Study|Lost to Follow-up|2
6154223|NCT01132612|9792535|FG001|Overall Study|Lost to Follow-up|2
6154224|NCT01132612|9792536|FG002|Overall Study|Lost to Follow-up|7
6154225|NCT01132612|9792534|FG000|Overall Study|Adverse Event|5
6154226|NCT01132612|9792535|FG001|Overall Study|Adverse Event|2
6154227|NCT01132612|9792536|FG002|Overall Study|Adverse Event|15
6154228|NCT01132612|9792534|FG000|Overall Study|Withdrawal by Subject|5
6154229|NCT01132612|9792535|FG001|Overall Study|Withdrawal by Subject|8
6154230|NCT01132612|9792536|FG002|Overall Study|Withdrawal by Subject|19
6324269|NCT02911948|10065865|FG001|Overall Study|Withdrawal by Subject|2
6324270|NCT02911948|10065864|FG000|Overall Study|Lack of Efficacy|0
6324271|NCT02911948|10065865|FG001|Overall Study|Lack of Efficacy|1
6154231|NCT01132612|9792534|FG000|Overall Study|Administrative problems|5
6154232|NCT01132612|9792535|FG001|Overall Study|Administrative problems|1
6154233|NCT01132612|9792536|FG002|Overall Study|Administrative problems|52
6154234|NCT01132612|9792534|FG000|Overall Study|Lack of Efficacy|23
6154235|NCT01132612|9792535|FG001|Overall Study|Lack of Efficacy|22
6154236|NCT01132612|9792536|FG002|Overall Study|Lack of Efficacy|73
6154237|NCT01132651|9792546|FG000|Overall Study|Lost to Follow-up|1
6154238|NCT01132651|9792547|FG001|Overall Study|Lost to Follow-up|1
6154239|NCT01132664|9792558|FG000|Phase lb|Adverse Event|0
6154240|NCT01132664|9792559|FG001|Phase lb|Adverse Event|1
6154241|NCT01132664|9792560|FG002|Phase lb|Adverse Event|0
6154242|NCT01132664|9792561|FG003|Phase lb|Adverse Event|0
6154243|NCT01132664|9792562|FG004|Phase lb|Adverse Event|0
6154244|NCT01132664|9792558|FG000|Phase lb|Withdrawal by Subject|1
6154245|NCT01132664|9792559|FG001|Phase lb|Withdrawal by Subject|2
6154246|NCT01132664|9792560|FG002|Phase lb|Withdrawal by Subject|0
6324272|NCT02911948|10065864|FG000|Overall Study|Unclassified|0
6324273|NCT02911948|10065865|FG001|Overall Study|Unclassified|3
6324274|NCT02912455|10065892|FG000|Overall Study|Withdrawal by Subject|0
6324275|NCT02912455|10065893|FG001|Overall Study|Withdrawal by Subject|1
6324276|NCT02912455|10065892|FG000|Overall Study|Lack of Efficacy|0
6324277|NCT02912455|10065893|FG001|Overall Study|Lack of Efficacy|1
6324278|NCT02912455|10065892|FG000|Overall Study|Lost to Follow-up|2
6324279|NCT02912455|10065893|FG001|Overall Study|Lost to Follow-up|1
6324280|NCT02912468|10065901|FG000|Overall Study|Adverse Event|3
6324281|NCT02912468|10065902|FG001|Overall Study|Adverse Event|2
6324282|NCT02912468|10065901|FG000|Overall Study|Withdrawal by Subject|6
6324283|NCT02912468|10065902|FG001|Overall Study|Withdrawal by Subject|2
6324284|NCT02912468|10065901|FG000|Overall Study|Randomized and not treated|0
6324285|NCT02912468|10065902|FG001|Overall Study|Randomized and not treated|1
6324286|NCT02912650|10065913|FG000|Overall Study|Withdrawal by Subject|1
6324287|NCT02912650|10065914|FG001|Overall Study|Withdrawal by Subject|0
6324288|NCT02912650|10065915|FG002|Overall Study|Withdrawal by Subject|1
6324289|NCT02912650|10065916|FG003|Overall Study|Withdrawal by Subject|5
6324290|NCT02912650|10065913|FG000|Overall Study|Adverse Event|0
6324291|NCT02912650|10065914|FG001|Overall Study|Adverse Event|0
6324292|NCT02912650|10065915|FG002|Overall Study|Adverse Event|1
6324293|NCT02912650|10065916|FG003|Overall Study|Adverse Event|0
6324294|NCT02913105|10065929|FG000|Overall Study|Adverse Event|11
6324295|NCT02913105|10065930|FG001|Overall Study|Adverse Event|0
6324296|NCT02913105|10065931|FG002|Overall Study|Adverse Event|4
6324297|NCT02913105|10065929|FG000|Overall Study|Non-Compliance With Study Drug|0
6324298|NCT02913105|10065930|FG001|Overall Study|Non-Compliance With Study Drug|0
6324299|NCT02913105|10065931|FG002|Overall Study|Non-Compliance With Study Drug|1
6324300|NCT02913105|10065929|FG000|Overall Study|Reason Not Specified|3
6324301|NCT02913105|10065930|FG001|Overall Study|Reason Not Specified|1
6041923|NCT00379769|9640148|FG003|Main Study|Participant completed study at visit 27|0
6041924|NCT00379769|9640149|FG004|Main Study|Participant completed study at visit 27|0
6041925|NCT00379769|9640150|FG005|Main Study|Participant completed study at visit 27|0
6154247|NCT01132664|9792561|FG003|Phase lb|Withdrawal by Subject|0
6154248|NCT01132664|9792562|FG004|Phase lb|Withdrawal by Subject|0
6154249|NCT01132664|9792558|FG000|Phase lb|Disease Progression|4
6154250|NCT01132664|9792559|FG001|Phase lb|Disease Progression|9
6041926|NCT00379769|9640145|FG000|Main Study|Personal reasons|1
6041927|NCT00379769|9640146|FG001|Main Study|Personal reasons|0
6041928|NCT00379769|9640147|FG002|Main Study|Personal reasons|0
6041929|NCT00379769|9640148|FG003|Main Study|Personal reasons|0
6154251|NCT01132664|9792560|FG002|Phase lb|Disease Progression|0
6154252|NCT01132664|9792561|FG003|Phase lb|Disease Progression|0
6154253|NCT01132664|9792562|FG004|Phase lb|Disease Progression|0
6154254|NCT01132664|9792558|FG000|Phase ll|Death|0
6154255|NCT01132664|9792559|FG001|Phase ll|Death|0
6154256|NCT01132664|9792560|FG002|Phase ll|Death|2
6154257|NCT01132664|9792561|FG003|Phase ll|Death|0
6154258|NCT01132664|9792562|FG004|Phase ll|Death|0
6154259|NCT01132664|9792558|FG000|Phase ll|Adverse Event|0
6154260|NCT01132664|9792559|FG001|Phase ll|Adverse Event|0
6154261|NCT01132664|9792560|FG002|Phase ll|Adverse Event|10
6154262|NCT01132664|9792561|FG003|Phase ll|Adverse Event|0
6154263|NCT01132664|9792562|FG004|Phase ll|Adverse Event|0
6154264|NCT01132664|9792558|FG000|Phase ll|Withdrawal by Subject|0
6154265|NCT01132664|9792559|FG001|Phase ll|Withdrawal by Subject|0
6154266|NCT01132664|9792560|FG002|Phase ll|Withdrawal by Subject|3
6154267|NCT01132664|9792561|FG003|Phase ll|Withdrawal by Subject|0
6154268|NCT01132664|9792562|FG004|Phase ll|Withdrawal by Subject|0
6154269|NCT01132664|9792558|FG000|Phase ll|Disease progression|0
6154270|NCT01132664|9792559|FG001|Phase ll|Disease progression|0
6154271|NCT01132664|9792560|FG002|Phase ll|Disease progression|35
6154272|NCT01132664|9792561|FG003|Phase ll|Disease progression|0
6154273|NCT01132664|9792562|FG004|Phase ll|Disease progression|0
6154274|NCT01132664|9792558|FG000|BM Cohort|Disease progression|0
6154275|NCT01132664|9792559|FG001|BM Cohort|Disease progression|0
6154276|NCT01132664|9792560|FG002|BM Cohort|Disease progression|0
6154277|NCT01132664|9792561|FG003|BM Cohort|Disease progression|3
6154278|NCT01132664|9792562|FG004|BM Cohort|Disease progression|4
6154279|NCT01132664|9792558|FG000|BM Cohort|Adverse Event|0
6154280|NCT01132664|9792559|FG001|BM Cohort|Adverse Event|0
6154281|NCT01132664|9792560|FG002|BM Cohort|Adverse Event|0
6154282|NCT01132664|9792561|FG003|BM Cohort|Adverse Event|0
6154283|NCT01132664|9792562|FG004|BM Cohort|Adverse Event|1
6154284|NCT01132664|9792558|FG000|BM Cohort|Withdrawal by Subject|0
6154285|NCT01132664|9792559|FG001|BM Cohort|Withdrawal by Subject|0
6154286|NCT01132664|9792560|FG002|BM Cohort|Withdrawal by Subject|0
6154287|NCT01132664|9792561|FG003|BM Cohort|Withdrawal by Subject|0
6154288|NCT01132664|9792562|FG004|BM Cohort|Withdrawal by Subject|1
6154289|NCT01132755|9792583|FG000|Overall Study|Procedure not done due to medical reason|23
6154290|NCT01132755|9792583|FG000|Overall Study|Protocol Violation|15
6154291|NCT01132755|9792583|FG000|Overall Study|Withdrawal by Subject|4
6041930|NCT00379769|9640149|FG004|Main Study|Personal reasons|0
6041931|NCT00379769|9640150|FG005|Main Study|Personal reasons|0
6154292|NCT01132807|9792587|FG000|Initial ABVD Treatment (2 Cycles)|Withdrawal by Subject|9
6154293|NCT01132807|9792588|FG001|Initial ABVD Treatment (2 Cycles)|Withdrawal by Subject|0
6154294|NCT01132807|9792589|FG002|Initial ABVD Treatment (2 Cycles)|Withdrawal by Subject|0
6154295|NCT01132807|9792587|FG000|Initial ABVD Treatment (2 Cycles)|Ineligible|6
6154296|NCT01132807|9792588|FG001|Initial ABVD Treatment (2 Cycles)|Ineligible|0
6154297|NCT01132807|9792589|FG002|Initial ABVD Treatment (2 Cycles)|Ineligible|0
6154298|NCT01132820|9792597|FG000|Overall Study|Ineligible: wrong cell type|1
6154299|NCT01132820|9792597|FG000|Overall Study|Ineligible:Improper pre-protocol therapy|1
6041932|NCT00379769|9640145|FG000|Main Study|Risk of heart failure|0
6041933|NCT00379769|9640146|FG001|Main Study|Risk of heart failure|1
6154300|NCT01132820|9792597|FG000|Overall Study|Ineligible:Inadequate pathology|1
6154301|NCT01132820|9792597|FG000|Overall Study|Never treated|1
6154302|NCT01132820|9792597|FG000|Overall Study|Inadequate data|1
6154303|NCT01133067|9792616|FG000|Overall Study|Death|136
6154304|NCT01133067|9792616|FG000|Overall Study|Lost to Follow-up|3
6154305|NCT01133171|9792629|FG000|Overall Study|Withdrawal by Subject|1
6154306|NCT01133171|9792630|FG001|Overall Study|Withdrawal by Subject|2
6154307|NCT01133171|9792631|FG002|Overall Study|Withdrawal by Subject|0
6154308|NCT01133275|9792639|FG000|Overall Study|Withdrawal by Subject|1
6154309|NCT01133275|9792639|FG000|Overall Study|Cerebrovascular accident (CVA)|1
6154310|NCT01133379|9792646|FG000|Overall Study|Withdrawal by Subject|0
6154311|NCT01133379|9792647|FG001|Overall Study|Withdrawal by Subject|1
6154312|NCT01133379|9792648|FG002|Overall Study|Withdrawal by Subject|1
6154313|NCT01133379|9792646|FG000|Overall Study|Lost to Follow-up|1
6154314|NCT01133379|9792647|FG001|Overall Study|Lost to Follow-up|1
6154315|NCT01133379|9792648|FG002|Overall Study|Lost to Follow-up|1
6154316|NCT01133392|9792658|FG000|Interval Between Dosing (4-7 Days)|Withdrawal by Subject|0
6154317|NCT01133392|9792659|FG001|Interval Between Dosing (4-7 Days)|Withdrawal by Subject|1
6154318|NCT01133392|9792658|FG000|Interval Between Dosing (4-7 Days)|Protocol Violation|0
6154319|NCT01133392|9792659|FG001|Interval Between Dosing (4-7 Days)|Protocol Violation|1
6154320|NCT01133405|9792675|FG000|Period 1|Withdrawal by Subject|0
6154321|NCT01133405|9792676|FG001|Period 1|Withdrawal by Subject|1
6154322|NCT01133405|9792677|FG002|Period 1|Withdrawal by Subject|0
6154323|NCT01133405|9792678|FG003|Period 1|Withdrawal by Subject|1
6154324|NCT01133405|9792679|FG004|Period 1|Withdrawal by Subject|0
6154325|NCT01133405|9792680|FG005|Period 1|Withdrawal by Subject|1
6154326|NCT01133405|9792681|FG006|Period 1|Withdrawal by Subject|0
6154327|NCT01133405|9792682|FG007|Period 1|Withdrawal by Subject|0
6154328|NCT01133405|9792683|FG008|Period 1|Withdrawal by Subject|0
6154329|NCT01133405|9792684|FG009|Period 1|Withdrawal by Subject|0
6154330|NCT01133405|9792675|FG000|Period 1|Physician Decision|0
6154331|NCT01133405|9792676|FG001|Period 1|Physician Decision|0
6154332|NCT01133405|9792677|FG002|Period 1|Physician Decision|0
6154333|NCT01133405|9792678|FG003|Period 1|Physician Decision|1
6154334|NCT01133405|9792679|FG004|Period 1|Physician Decision|0
6154335|NCT01133405|9792680|FG005|Period 1|Physician Decision|0
6154336|NCT01133405|9792681|FG006|Period 1|Physician Decision|0
6154337|NCT01133405|9792682|FG007|Period 1|Physician Decision|0
6154338|NCT01133405|9792683|FG008|Period 1|Physician Decision|0
6154339|NCT01133405|9792684|FG009|Period 1|Physician Decision|0
6154340|NCT01133405|9792675|FG000|Period 1|Discontinued after randomization|1
6154341|NCT01133405|9792676|FG001|Period 1|Discontinued after randomization|0
6154342|NCT01133405|9792677|FG002|Period 1|Discontinued after randomization|0
6154343|NCT01133405|9792678|FG003|Period 1|Discontinued after randomization|0
6324302|NCT02913105|10065931|FG002|Overall Study|Reason Not Specified|1
6324303|NCT02913105|10065929|FG000|Overall Study|Physician Decision|1
6324304|NCT02913105|10065930|FG001|Overall Study|Physician Decision|1
6324305|NCT02913105|10065931|FG002|Overall Study|Physician Decision|0
6324306|NCT02913105|10065929|FG000|Overall Study|Withdrawal by Subject|0
6324307|NCT02913105|10065930|FG001|Overall Study|Withdrawal by Subject|3
6324308|NCT02913105|10065931|FG002|Overall Study|Withdrawal by Subject|1
6324309|NCT02913326|10065942|FG000|Overall Study|Reason not listed|0
6324310|NCT02913326|10065943|FG001|Overall Study|Reason not listed|1
6324311|NCT02913326|10065942|FG000|Overall Study|Lost to Follow-up|0
6324312|NCT02913326|10065943|FG001|Overall Study|Lost to Follow-up|1
6324313|NCT02913326|10065942|FG000|Overall Study|Adverse Event|1
6324314|NCT02913326|10065943|FG001|Overall Study|Adverse Event|0
6324315|NCT02914184|10065983|FG000|Overall Study|Lost to Follow-up|7
6324316|NCT02914184|10065984|FG001|Overall Study|Lost to Follow-up|10
6324317|NCT02914184|10065985|FG002|Overall Study|Lost to Follow-up|8
6324318|NCT02914184|10065986|FG003|Overall Study|Lost to Follow-up|7
6324319|NCT02914184|10065983|FG000|Overall Study|Withdrawal by Subject|4
6324320|NCT02914184|10065984|FG001|Overall Study|Withdrawal by Subject|2
6324321|NCT02914184|10065985|FG002|Overall Study|Withdrawal by Subject|7
6324322|NCT02914184|10065986|FG003|Overall Study|Withdrawal by Subject|3
6324323|NCT02914184|10065983|FG000|Overall Study|Other|1
6041934|NCT00379769|9640147|FG002|Main Study|Risk of heart failure|0
6154344|NCT01133405|9792679|FG004|Period 1|Discontinued after randomization|0
6154345|NCT01133405|9792680|FG005|Period 1|Discontinued after randomization|0
6154346|NCT01133405|9792681|FG006|Period 1|Discontinued after randomization|1
6154347|NCT01133405|9792682|FG007|Period 1|Discontinued after randomization|0
6154348|NCT01133405|9792683|FG008|Period 1|Discontinued after randomization|0
6154349|NCT01133405|9792684|FG009|Period 1|Discontinued after randomization|0
6154350|NCT01133405|9792675|FG000|Period 1|Received drug only in period 2|0
6154351|NCT01133405|9792676|FG001|Period 1|Received drug only in period 2|1
6154352|NCT01133405|9792677|FG002|Period 1|Received drug only in period 2|0
6154353|NCT01133405|9792678|FG003|Period 1|Received drug only in period 2|2
6154354|NCT01133405|9792679|FG004|Period 1|Received drug only in period 2|0
6154355|NCT01133405|9792680|FG005|Period 1|Received drug only in period 2|1
6154356|NCT01133405|9792681|FG006|Period 1|Received drug only in period 2|0
6154357|NCT01133405|9792682|FG007|Period 1|Received drug only in period 2|0
6154358|NCT01133405|9792683|FG008|Period 1|Received drug only in period 2|0
6154359|NCT01133405|9792684|FG009|Period 1|Received drug only in period 2|0
6154360|NCT01133405|9792675|FG000|Period 1|Received drug only in period 3|0
6154361|NCT01133405|9792676|FG001|Period 1|Received drug only in period 3|1
6324324|NCT02914184|10065984|FG001|Overall Study|Other|0
6324325|NCT02914184|10065985|FG002|Overall Study|Other|0
6324326|NCT02914184|10065986|FG003|Overall Study|Other|0
6154362|NCT01133405|9792677|FG002|Period 1|Received drug only in period 3|1
6154363|NCT01133405|9792678|FG003|Period 1|Received drug only in period 3|0
6324327|NCT02914184|10065983|FG000|Overall Study|Migrated/moved from the study area|2
6041935|NCT00379769|9640148|FG003|Main Study|Risk of heart failure|0
6041936|NCT00379769|9640149|FG004|Main Study|Risk of heart failure|0
6041937|NCT00379769|9640150|FG005|Main Study|Risk of heart failure|0
6041938|NCT00379769|9640145|FG000|Main Study|Investigator refused to log temperature|0
6041939|NCT00379769|9640146|FG001|Main Study|Investigator refused to log temperature|0
6154364|NCT01133405|9792679|FG004|Period 1|Received drug only in period 3|0
6154365|NCT01133405|9792680|FG005|Period 1|Received drug only in period 3|0
6154366|NCT01133405|9792681|FG006|Period 1|Received drug only in period 3|0
6154367|NCT01133405|9792682|FG007|Period 1|Received drug only in period 3|0
6154368|NCT01133405|9792683|FG008|Period 1|Received drug only in period 3|0
6154369|NCT01133405|9792684|FG009|Period 1|Received drug only in period 3|0
6154370|NCT01133405|9792675|FG000|Period 2|Adverse Event|0
6041940|NCT00379769|9640147|FG002|Main Study|Investigator refused to log temperature|1
6154371|NCT01133405|9792676|FG001|Period 2|Adverse Event|0
6154372|NCT01133405|9792677|FG002|Period 2|Adverse Event|1
6324328|NCT02914184|10065984|FG001|Overall Study|Migrated/moved from the study area|1
6324329|NCT02914184|10065985|FG002|Overall Study|Migrated/moved from the study area|2
6324330|NCT02914184|10065986|FG003|Overall Study|Migrated/moved from the study area|1
6324331|NCT02914236|10066007|FG000|Overall Study|Lost to Follow-up|1
6324332|NCT02914275|10066013|FG000|Overall Study|Lost to Follow-up|84
6324333|NCT02914275|10066014|FG001|Overall Study|Lost to Follow-up|29
6324334|NCT02914275|10066013|FG000|Overall Study|Withdrawal by Subject|26
6324335|NCT02914275|10066014|FG001|Overall Study|Withdrawal by Subject|10
6324336|NCT02914275|10066013|FG000|Overall Study|Protocol Violation|1
6324337|NCT02914275|10066014|FG001|Overall Study|Protocol Violation|1
6324338|NCT02914275|10066013|FG000|Overall Study|Physician Decision|3
6324339|NCT02914275|10066014|FG001|Overall Study|Physician Decision|1
6324340|NCT02914275|10066013|FG000|Overall Study|Other|4
6324341|NCT02914275|10066014|FG001|Overall Study|Other|1
6324342|NCT02914275|10066013|FG000|Overall Study|Excluded due to invalid informed consent|3
6324343|NCT02914275|10066014|FG001|Overall Study|Excluded due to invalid informed consent|0
6324344|NCT02914457|10066024|FG000|Overall Study|Withdrawal by Subject|1
6324345|NCT02914457|10066024|FG000|Overall Study|Physician Decision|1
6324346|NCT02914457|10066024|FG000|Overall Study|No veins available for lead placement|1
6324347|NCT02914457|10066024|FG000|Overall Study|Electrical instability of patient|1
6324348|NCT02914457|10066024|FG000|Overall Study|ECG acquisition error due to sweating|1
6324349|NCT02914457|10066024|FG000|Overall Study|Protocol Violation|1
6324350|NCT02914522|10066045|FG000|Induction Study: Up to Week 11|Adverse Event|5
6041941|NCT00379769|9640148|FG003|Main Study|Investigator refused to log temperature|0
6041942|NCT00379769|9640149|FG004|Main Study|Investigator refused to log temperature|0
6154373|NCT01133405|9792678|FG003|Period 2|Adverse Event|0
6154374|NCT01133405|9792679|FG004|Period 2|Adverse Event|0
6154375|NCT01133405|9792680|FG005|Period 2|Adverse Event|0
6154376|NCT01133405|9792681|FG006|Period 2|Adverse Event|0
6154377|NCT01133405|9792682|FG007|Period 2|Adverse Event|0
6154378|NCT01133405|9792683|FG008|Period 2|Adverse Event|0
6154379|NCT01133405|9792684|FG009|Period 2|Adverse Event|0
6154380|NCT01133405|9792675|FG000|Period 2|Withdrawal by Subject|0
6154381|NCT01133405|9792676|FG001|Period 2|Withdrawal by Subject|0
6154382|NCT01133405|9792677|FG002|Period 2|Withdrawal by Subject|0
6154383|NCT01133405|9792678|FG003|Period 2|Withdrawal by Subject|1
6154384|NCT01133405|9792679|FG004|Period 2|Withdrawal by Subject|0
6154385|NCT01133405|9792680|FG005|Period 2|Withdrawal by Subject|1
6154386|NCT01133405|9792681|FG006|Period 2|Withdrawal by Subject|0
6154387|NCT01133405|9792682|FG007|Period 2|Withdrawal by Subject|0
6154388|NCT01133405|9792683|FG008|Period 2|Withdrawal by Subject|0
6154389|NCT01133405|9792684|FG009|Period 2|Withdrawal by Subject|0
6154390|NCT01133405|9792675|FG000|Period 2|Entry Criteria Not Met|0
6154391|NCT01133405|9792676|FG001|Period 2|Entry Criteria Not Met|1
6154392|NCT01133405|9792677|FG002|Period 2|Entry Criteria Not Met|0
6324351|NCT02914522|10066046|FG001|Induction Study: Up to Week 11|Adverse Event|6
6324352|NCT02914522|10066047|FG002|Induction Study: Up to Week 11|Adverse Event|4
6324353|NCT02914522|10066048|FG003|Induction Study: Up to Week 11|Adverse Event|18
6324354|NCT02914522|10066049|FG004|Induction Study: Up to Week 11|Adverse Event|14
6324355|NCT02914522|10066050|FG005|Induction Study: Up to Week 11|Adverse Event|10
6324356|NCT02914522|10066051|FG006|Induction Study: Up to Week 11|Adverse Event|0
6154393|NCT01133405|9792678|FG003|Period 2|Entry Criteria Not Met|0
6154394|NCT01133405|9792679|FG004|Period 2|Entry Criteria Not Met|0
6154395|NCT01133405|9792680|FG005|Period 2|Entry Criteria Not Met|0
6154396|NCT01133405|9792681|FG006|Period 2|Entry Criteria Not Met|0
6154397|NCT01133405|9792682|FG007|Period 2|Entry Criteria Not Met|0
6154398|NCT01133405|9792683|FG008|Period 2|Entry Criteria Not Met|0
6154399|NCT01133405|9792684|FG009|Period 2|Entry Criteria Not Met|0
6154400|NCT01133405|9792675|FG000|Period 2|Physician Decision|0
6154401|NCT01133405|9792676|FG001|Period 2|Physician Decision|0
6154402|NCT01133405|9792677|FG002|Period 2|Physician Decision|0
6154403|NCT01133405|9792678|FG003|Period 2|Physician Decision|0
6154404|NCT01133405|9792679|FG004|Period 2|Physician Decision|0
6154405|NCT01133405|9792680|FG005|Period 2|Physician Decision|1
6154406|NCT01133405|9792681|FG006|Period 2|Physician Decision|0
6154407|NCT01133405|9792682|FG007|Period 2|Physician Decision|0
6154408|NCT01133405|9792683|FG008|Period 2|Physician Decision|0
6154409|NCT01133405|9792684|FG009|Period 2|Physician Decision|0
6154410|NCT01133418|9792716|FG000|Overall Study|Lost to Follow-up|5
6154411|NCT01133418|9792717|FG001|Overall Study|Lost to Follow-up|6
6154412|NCT01133522|9792733|FG000|Overall Study|Withdrawal by Subject|0
6154413|NCT01133522|9792734|FG001|Overall Study|Withdrawal by Subject|1
6154414|NCT01133522|9792735|FG002|Overall Study|Withdrawal by Subject|0
6154415|NCT01133522|9792736|FG003|Overall Study|Withdrawal by Subject|1
6154416|NCT01133522|9792737|FG004|Overall Study|Withdrawal by Subject|0
6154417|NCT01133522|9792738|FG005|Overall Study|Withdrawal by Subject|0
6154418|NCT01133522|9792739|FG006|Overall Study|Withdrawal by Subject|0
6154419|NCT01133522|9792740|FG007|Overall Study|Withdrawal by Subject|0
6154420|NCT01133522|9792741|FG008|Overall Study|Withdrawal by Subject|0
6154421|NCT01133522|9792742|FG009|Overall Study|Withdrawal by Subject|0
6154422|NCT01133522|9792733|FG000|Overall Study|Physician Decision|0
6154423|NCT01133522|9792734|FG001|Overall Study|Physician Decision|0
6154424|NCT01133522|9792735|FG002|Overall Study|Physician Decision|0
6154425|NCT01133522|9792736|FG003|Overall Study|Physician Decision|0
6154426|NCT01133522|9792737|FG004|Overall Study|Physician Decision|1
6154427|NCT01133522|9792738|FG005|Overall Study|Physician Decision|0
6154428|NCT01133522|9792739|FG006|Overall Study|Physician Decision|0
6154429|NCT01133522|9792740|FG007|Overall Study|Physician Decision|0
6154430|NCT01133522|9792741|FG008|Overall Study|Physician Decision|0
6154431|NCT01133522|9792742|FG009|Overall Study|Physician Decision|0
6154432|NCT01133626|9792774|FG000|Overall Study|Adverse Event|0
6154433|NCT01133626|9792775|FG001|Overall Study|Adverse Event|1
6154434|NCT01133626|9792776|FG002|Overall Study|Adverse Event|0
6324357|NCT02914522|10066052|FG007|Induction Study: Up to Week 11|Adverse Event|0
6324358|NCT02914522|10066053|FG008|Induction Study: Up to Week 11|Adverse Event|0
6324359|NCT02914522|10066054|FG009|Induction Study: Up to Week 11|Adverse Event|0
6324360|NCT02914522|10066055|FG010|Induction Study: Up to Week 11|Adverse Event|0
6324361|NCT02914522|10066045|FG000|Induction Study: Up to Week 11|Withdrew Consent|4
6324362|NCT02914522|10066046|FG001|Induction Study: Up to Week 11|Withdrew Consent|11
6324363|NCT02914522|10066047|FG002|Induction Study: Up to Week 11|Withdrew Consent|4
6324364|NCT02914522|10066048|FG003|Induction Study: Up to Week 11|Withdrew Consent|6
6324365|NCT02914522|10066049|FG004|Induction Study: Up to Week 11|Withdrew Consent|3
6324366|NCT02914522|10066050|FG005|Induction Study: Up to Week 11|Withdrew Consent|3
6324367|NCT02914522|10066051|FG006|Induction Study: Up to Week 11|Withdrew Consent|0
6324368|NCT02914522|10066052|FG007|Induction Study: Up to Week 11|Withdrew Consent|0
6324369|NCT02914522|10066053|FG008|Induction Study: Up to Week 11|Withdrew Consent|0
6324370|NCT02914522|10066054|FG009|Induction Study: Up to Week 11|Withdrew Consent|0
6324371|NCT02914522|10066055|FG010|Induction Study: Up to Week 11|Withdrew Consent|0
6324372|NCT02914522|10066045|FG000|Induction Study: Up to Week 11|Protocol Violation|0
6324373|NCT02914522|10066046|FG001|Induction Study: Up to Week 11|Protocol Violation|2
6324374|NCT02914522|10066047|FG002|Induction Study: Up to Week 11|Protocol Violation|1
6324375|NCT02914522|10066048|FG003|Induction Study: Up to Week 11|Protocol Violation|3
6324376|NCT02914522|10066049|FG004|Induction Study: Up to Week 11|Protocol Violation|4
6324377|NCT02914522|10066050|FG005|Induction Study: Up to Week 11|Protocol Violation|2
6154435|NCT01133626|9792774|FG000|Overall Study|Withdrawal by Subject|1
6154436|NCT01133626|9792775|FG001|Overall Study|Withdrawal by Subject|2
6154437|NCT01133626|9792776|FG002|Overall Study|Withdrawal by Subject|2
6154438|NCT01133626|9792774|FG000|Overall Study|Other|0
6154439|NCT01133626|9792775|FG001|Overall Study|Other|2
6154440|NCT01133626|9792776|FG002|Overall Study|Other|0
6154441|NCT01133665|9792784|FG000|Overall Study|Physician Decision|2
6154442|NCT01133678|9792790|FG000|Overall Study|Death|1
6154443|NCT01133678|9792791|FG001|Overall Study|Death|1
6154444|NCT01133704|9792799|FG000|Overall Study|Death|44
6154445|NCT01133704|9792800|FG001|Overall Study|Death|26
6154446|NCT01133704|9792799|FG000|Overall Study|Patient refused to continue|4
6154447|NCT01133704|9792800|FG001|Overall Study|Patient refused to continue|0
6154448|NCT01133704|9792799|FG000|Overall Study|Study Closure|1
6324378|NCT02914522|10066051|FG006|Induction Study: Up to Week 11|Protocol Violation|0
6154449|NCT01133704|9792800|FG001|Overall Study|Study Closure|0
6154450|NCT01133756|9792809|FG000|Overall Study|Adverse Event|1
6154451|NCT01133756|9792810|FG001|Overall Study|Adverse Event|2
6154452|NCT01133756|9792811|FG002|Overall Study|Adverse Event|1
6324379|NCT02914522|10066052|FG007|Induction Study: Up to Week 11|Protocol Violation|0
6324380|NCT02914522|10066053|FG008|Induction Study: Up to Week 11|Protocol Violation|0
6324381|NCT02914522|10066054|FG009|Induction Study: Up to Week 11|Protocol Violation|0
6324382|NCT02914522|10066055|FG010|Induction Study: Up to Week 11|Protocol Violation|0
6324383|NCT02914522|10066045|FG000|Induction Study: Up to Week 11|Lost to Follow-up|0
6324384|NCT02914522|10066046|FG001|Induction Study: Up to Week 11|Lost to Follow-up|2
6154453|NCT01133756|9792809|FG000|Overall Study|Investigator Decision|1
6154454|NCT01133756|9792810|FG001|Overall Study|Investigator Decision|0
6154455|NCT01133756|9792811|FG002|Overall Study|Investigator Decision|0
6154456|NCT01133756|9792809|FG000|Overall Study|Withdrawal by Subject|0
6154457|NCT01133756|9792810|FG001|Overall Study|Withdrawal by Subject|1
6154458|NCT01133756|9792811|FG002|Overall Study|Withdrawal by Subject|0
6154459|NCT01133756|9792809|FG000|Overall Study|Progression of Disease|0
6154460|NCT01133756|9792810|FG001|Overall Study|Progression of Disease|0
6154461|NCT01133756|9792811|FG002|Overall Study|Progression of Disease|1
6154462|NCT01133821|9792821|FG000|Overall Study|Lost to Follow-up|8
6154463|NCT01133821|9792822|FG001|Overall Study|Lost to Follow-up|11
6154464|NCT01133821|9792821|FG000|Overall Study|Withdrawal by Subject|8
6154465|NCT01133821|9792822|FG001|Overall Study|Withdrawal by Subject|3
6154466|NCT01133821|9792821|FG000|Overall Study|preferred other treatment|1
6154467|NCT01133821|9792822|FG001|Overall Study|preferred other treatment|1
6154468|NCT01133821|9792821|FG000|Overall Study|Protocol Violation|0
6154469|NCT01133821|9792822|FG001|Overall Study|Protocol Violation|1
6154470|NCT01133821|9792821|FG000|Overall Study|Refused participation|1
6154471|NCT01133821|9792822|FG001|Overall Study|Refused participation|3
6154472|NCT01133847|9792831|FG000|Active Treatment Phase (Weeks 1-16)|Withdrawal by Subject|5
6154473|NCT01133847|9792832|FG001|Active Treatment Phase (Weeks 1-16)|Withdrawal by Subject|1
6154474|NCT01133847|9792833|FG002|Active Treatment Phase (Weeks 1-16)|Withdrawal by Subject|3
6154475|NCT01133847|9792831|FG000|Follow-Up Phase|Lost to Follow-up|1
6154476|NCT01133847|9792832|FG001|Follow-Up Phase|Lost to Follow-up|3
6154477|NCT01133847|9792833|FG002|Follow-Up Phase|Lost to Follow-up|7
6154478|NCT01133977|9792852|FG000|Overall Study|Adverse Event|0
6154479|NCT01133977|9792853|FG001|Overall Study|Adverse Event|0
6154480|NCT01133977|9792854|FG002|Overall Study|Adverse Event|1
6154481|NCT01133977|9792855|FG003|Overall Study|Adverse Event|0
6154482|NCT01133977|9792856|FG004|Overall Study|Adverse Event|0
6154483|NCT01133977|9792852|FG000|Overall Study|Death|1
6154484|NCT01133977|9792853|FG001|Overall Study|Death|1
6154485|NCT01133977|9792854|FG002|Overall Study|Death|1
6154486|NCT01133977|9792855|FG003|Overall Study|Death|7
6154487|NCT01133977|9792856|FG004|Overall Study|Death|3
6154488|NCT01133977|9792852|FG000|Overall Study|Started a New Line of Therapy|2
6154489|NCT01133977|9792853|FG001|Overall Study|Started a New Line of Therapy|6
6154490|NCT01133977|9792854|FG002|Overall Study|Started a New Line of Therapy|4
6154491|NCT01133977|9792855|FG003|Overall Study|Started a New Line of Therapy|25
6154492|NCT01133977|9792856|FG004|Overall Study|Started a New Line of Therapy|33
6154493|NCT01133977|9792852|FG000|Overall Study|Lost to Follow-up|0
6154494|NCT01133977|9792853|FG001|Overall Study|Lost to Follow-up|0
6154495|NCT01133977|9792854|FG002|Overall Study|Lost to Follow-up|0
6154496|NCT01133977|9792855|FG003|Overall Study|Lost to Follow-up|2
6154497|NCT01133977|9792856|FG004|Overall Study|Lost to Follow-up|1
6154498|NCT01133977|9792852|FG000|Overall Study|Withdrawal by Subject|0
6041943|NCT00379769|9640150|FG005|Main Study|Investigator refused to log temperature|0
6041944|NCT00379769|9640145|FG000|Main Study|Reason unspecified|0
6041945|NCT00379769|9640146|FG001|Main Study|Reason unspecified|0
6154499|NCT01133977|9792853|FG001|Overall Study|Withdrawal by Subject|0
6154500|NCT01133977|9792854|FG002|Overall Study|Withdrawal by Subject|0
6154501|NCT01133977|9792855|FG003|Overall Study|Withdrawal by Subject|5
6154502|NCT01133977|9792856|FG004|Overall Study|Withdrawal by Subject|1
6154503|NCT01134042|9792907|FG000|Overall Study|Adverse Event|3
6154504|NCT01134042|9792908|FG001|Overall Study|Adverse Event|7
6154505|NCT01134042|9792909|FG002|Overall Study|Adverse Event|2
6154506|NCT01134042|9792907|FG000|Overall Study|Lack of Efficacy|21
6154507|NCT01134042|9792908|FG001|Overall Study|Lack of Efficacy|6
6154508|NCT01134042|9792909|FG002|Overall Study|Lack of Efficacy|18
6041946|NCT00379769|9640147|FG002|Main Study|Reason unspecified|1
6041947|NCT00379769|9640148|FG003|Main Study|Reason unspecified|0
6041948|NCT00379769|9640149|FG004|Main Study|Reason unspecified|0
6041949|NCT00379769|9640150|FG005|Main Study|Reason unspecified|0
6041950|NCT00379769|9640145|FG000|Observational Follow-up|Death|0
6041951|NCT00379769|9640146|FG001|Observational Follow-up|Death|0
6041952|NCT00379769|9640147|FG002|Observational Follow-up|Death|0
6041953|NCT00379769|9640148|FG003|Observational Follow-up|Death|0
6041954|NCT00379769|9640149|FG004|Observational Follow-up|Death|78
6041955|NCT00379769|9640150|FG005|Observational Follow-up|Death|70
6324385|NCT02914522|10066047|FG002|Induction Study: Up to Week 11|Lost to Follow-up|1
6324386|NCT02914522|10066048|FG003|Induction Study: Up to Week 11|Lost to Follow-up|1
6324387|NCT02914522|10066049|FG004|Induction Study: Up to Week 11|Lost to Follow-up|0
6324388|NCT02914522|10066050|FG005|Induction Study: Up to Week 11|Lost to Follow-up|0
6324389|NCT02914522|10066051|FG006|Induction Study: Up to Week 11|Lost to Follow-up|0
6324390|NCT02914522|10066052|FG007|Induction Study: Up to Week 11|Lost to Follow-up|0
6324391|NCT02914522|10066053|FG008|Induction Study: Up to Week 11|Lost to Follow-up|0
6324392|NCT02914522|10066054|FG009|Induction Study: Up to Week 11|Lost to Follow-up|0
6041956|NCT00379769|9640145|FG000|Observational Follow-up|Adverse Event|0
6041957|NCT00379769|9640146|FG001|Observational Follow-up|Adverse Event|0
6041958|NCT00379769|9640147|FG002|Observational Follow-up|Adverse Event|0
6041959|NCT00379769|9640148|FG003|Observational Follow-up|Adverse Event|0
6041960|NCT00379769|9640149|FG004|Observational Follow-up|Adverse Event|1
6041961|NCT00379769|9640150|FG005|Observational Follow-up|Adverse Event|0
6041962|NCT00379769|9640145|FG000|Observational Follow-up|Lost to Follow-up|0
6041963|NCT00379769|9640146|FG001|Observational Follow-up|Lost to Follow-up|0
6041964|NCT00379769|9640147|FG002|Observational Follow-up|Lost to Follow-up|0
6041965|NCT00379769|9640148|FG003|Observational Follow-up|Lost to Follow-up|0
6041966|NCT00379769|9640149|FG004|Observational Follow-up|Lost to Follow-up|25
6041967|NCT00379769|9640150|FG005|Observational Follow-up|Lost to Follow-up|27
6324393|NCT02914522|10066055|FG010|Induction Study: Up to Week 11|Lost to Follow-up|0
6041968|NCT00379769|9640145|FG000|Observational Follow-up|Withdrawal by Subject|0
6049013|NCT00420927|9648204|FG005|Period 2|Randomization error|1
6324394|NCT02914522|10066045|FG000|Induction Study: Up to Week 11|Investigator's Discretion|0
6324395|NCT02914522|10066046|FG001|Induction Study: Up to Week 11|Investigator's Discretion|0
6324396|NCT02914522|10066047|FG002|Induction Study: Up to Week 11|Investigator's Discretion|0
6324397|NCT02914522|10066048|FG003|Induction Study: Up to Week 11|Investigator's Discretion|0
6324398|NCT02914522|10066049|FG004|Induction Study: Up to Week 11|Investigator's Discretion|1
6324399|NCT02914522|10066050|FG005|Induction Study: Up to Week 11|Investigator's Discretion|0
6324400|NCT02914522|10066051|FG006|Induction Study: Up to Week 11|Investigator's Discretion|0
6324401|NCT02914522|10066052|FG007|Induction Study: Up to Week 11|Investigator's Discretion|0
6324402|NCT02914522|10066053|FG008|Induction Study: Up to Week 11|Investigator's Discretion|0
6324403|NCT02914522|10066054|FG009|Induction Study: Up to Week 11|Investigator's Discretion|0
6324404|NCT02914522|10066055|FG010|Induction Study: Up to Week 11|Investigator's Discretion|0
6324405|NCT02914522|10066045|FG000|Induction Study: Up to Week 11|Non-compliance With Study Drug|1
6324406|NCT02914522|10066046|FG001|Induction Study: Up to Week 11|Non-compliance With Study Drug|0
6324407|NCT02914522|10066047|FG002|Induction Study: Up to Week 11|Non-compliance With Study Drug|0
6324408|NCT02914522|10066048|FG003|Induction Study: Up to Week 11|Non-compliance With Study Drug|0
6324409|NCT02914522|10066049|FG004|Induction Study: Up to Week 11|Non-compliance With Study Drug|0
6324410|NCT02914522|10066050|FG005|Induction Study: Up to Week 11|Non-compliance With Study Drug|0
6324411|NCT02914522|10066051|FG006|Induction Study: Up to Week 11|Non-compliance With Study Drug|0
6324412|NCT02914522|10066052|FG007|Induction Study: Up to Week 11|Non-compliance With Study Drug|0
6041969|NCT00379769|9640146|FG001|Observational Follow-up|Withdrawal by Subject|0
6041970|NCT00379769|9640147|FG002|Observational Follow-up|Withdrawal by Subject|0
6041971|NCT00379769|9640148|FG003|Observational Follow-up|Withdrawal by Subject|0
6041972|NCT00379769|9640149|FG004|Observational Follow-up|Withdrawal by Subject|12
6041973|NCT00379769|9640150|FG005|Observational Follow-up|Withdrawal by Subject|12
6041974|NCT00379769|9640145|FG000|Observational Follow-up|Entered into Another Clinical Trial|0
6041975|NCT00379769|9640146|FG001|Observational Follow-up|Entered into Another Clinical Trial|0
6041976|NCT00379769|9640147|FG002|Observational Follow-up|Entered into Another Clinical Trial|0
6041977|NCT00379769|9640148|FG003|Observational Follow-up|Entered into Another Clinical Trial|0
6041978|NCT00379769|9640149|FG004|Observational Follow-up|Entered into Another Clinical Trial|18
6041979|NCT00379769|9640150|FG005|Observational Follow-up|Entered into Another Clinical Trial|22
6324413|NCT02914522|10066053|FG008|Induction Study: Up to Week 11|Non-compliance With Study Drug|0
6324414|NCT02914522|10066054|FG009|Induction Study: Up to Week 11|Non-compliance With Study Drug|0
6324415|NCT02914522|10066055|FG010|Induction Study: Up to Week 11|Non-compliance With Study Drug|0
6324416|NCT02914522|10066045|FG000|Induction Study: Up to Week 11|Pregnancy|0
6324417|NCT02914522|10066046|FG001|Induction Study: Up to Week 11|Pregnancy|0
6324418|NCT02914522|10066047|FG002|Induction Study: Up to Week 11|Pregnancy|0
6324419|NCT02914522|10066048|FG003|Induction Study: Up to Week 11|Pregnancy|0
6324420|NCT02914522|10066049|FG004|Induction Study: Up to Week 11|Pregnancy|1
6324421|NCT02914522|10066050|FG005|Induction Study: Up to Week 11|Pregnancy|0
6324422|NCT02914522|10066051|FG006|Induction Study: Up to Week 11|Pregnancy|0
6324423|NCT02914522|10066052|FG007|Induction Study: Up to Week 11|Pregnancy|0
6324424|NCT02914522|10066053|FG008|Induction Study: Up to Week 11|Pregnancy|0
6324425|NCT02914522|10066054|FG009|Induction Study: Up to Week 11|Pregnancy|0
6080371|NCT00615836|9687578|FG004|Extension Study (FE992026 CS31)|Adverse Event|0
6080372|NCT00615836|9687574|FG000|Extension Study (FE992026 CS31)|Serum sodium ≤125 mmol/L|1
6041980|NCT00379769|9640145|FG000|Observational Follow-up|Physician Decision|0
6041981|NCT00379769|9640146|FG001|Observational Follow-up|Physician Decision|0
6041982|NCT00379769|9640147|FG002|Observational Follow-up|Physician Decision|0
6041983|NCT00379769|9640148|FG003|Observational Follow-up|Physician Decision|0
6041984|NCT00379769|9640149|FG004|Observational Follow-up|Physician Decision|8
6041985|NCT00379769|9640150|FG005|Observational Follow-up|Physician Decision|8
6041986|NCT00379769|9640145|FG000|Observational Follow-up|Site Closed Early|0
6041987|NCT00379769|9640146|FG001|Observational Follow-up|Site Closed Early|0
6041988|NCT00379769|9640147|FG002|Observational Follow-up|Site Closed Early|0
6041989|NCT00379769|9640148|FG003|Observational Follow-up|Site Closed Early|0
6041990|NCT00379769|9640149|FG004|Observational Follow-up|Site Closed Early|6
6041991|NCT00379769|9640150|FG005|Observational Follow-up|Site Closed Early|7
6041992|NCT00379769|9640145|FG000|Observational Follow-up|Participant Moved|0
6041993|NCT00379769|9640146|FG001|Observational Follow-up|Participant Moved|0
6041994|NCT00379769|9640147|FG002|Observational Follow-up|Participant Moved|0
6041995|NCT00379769|9640148|FG003|Observational Follow-up|Participant Moved|0
6041996|NCT00379769|9640149|FG004|Observational Follow-up|Participant Moved|0
6041997|NCT00379769|9640150|FG005|Observational Follow-up|Participant Moved|1
6041998|NCT00379769|9640145|FG000|Observational Follow-up|Unknown; Reason Not Provided|0
6041999|NCT00379769|9640146|FG001|Observational Follow-up|Unknown; Reason Not Provided|0
6042000|NCT00379769|9640147|FG002|Observational Follow-up|Unknown; Reason Not Provided|0
6042001|NCT00379769|9640148|FG003|Observational Follow-up|Unknown; Reason Not Provided|0
6042002|NCT00379769|9640149|FG004|Observational Follow-up|Unknown; Reason Not Provided|1
6042003|NCT00379769|9640150|FG005|Observational Follow-up|Unknown; Reason Not Provided|1
6042004|NCT00379795|9640182|FG000|Overall Study|Death|31
6042005|NCT00379795|9640183|FG001|Overall Study|Death|8
6080373|NCT00615836|9687575|FG001|Extension Study (FE992026 CS31)|Serum sodium ≤125 mmol/L|0
6080374|NCT00615836|9687576|FG002|Extension Study (FE992026 CS31)|Serum sodium ≤125 mmol/L|3
6042006|NCT00379795|9640184|FG002|Overall Study|Death|6
6042007|NCT00379795|9640185|FG003|Overall Study|Death|4
6042008|NCT00379795|9640186|FG004|Overall Study|Death|7
6042009|NCT00379795|9640182|FG000|Overall Study|Adverse Event|17
6042010|NCT00379795|9640183|FG001|Overall Study|Adverse Event|3
6154509|NCT01134042|9792907|FG000|Overall Study|Protocol Violation|5
6154510|NCT01134042|9792908|FG001|Overall Study|Protocol Violation|3
6154511|NCT01134042|9792909|FG002|Overall Study|Protocol Violation|5
6154512|NCT01134042|9792907|FG000|Overall Study|Lost to Follow-up|2
6154513|NCT01134042|9792908|FG001|Overall Study|Lost to Follow-up|0
6154514|NCT01134042|9792909|FG002|Overall Study|Lost to Follow-up|1
6154515|NCT01134042|9792907|FG000|Overall Study|Physician Decision|4
6154516|NCT01134042|9792908|FG001|Overall Study|Physician Decision|8
6154517|NCT01134042|9792909|FG002|Overall Study|Physician Decision|1
6154518|NCT01134042|9792907|FG000|Overall Study|Withdrawal by Subject|13
6154519|NCT01134042|9792908|FG001|Overall Study|Withdrawal by Subject|4
6154520|NCT01134042|9792909|FG002|Overall Study|Withdrawal by Subject|7
6154521|NCT01134055|9792925|FG000|Overall Study|Adverse Event|5
6154522|NCT01134055|9792926|FG001|Overall Study|Adverse Event|2
6154523|NCT01134055|9792927|FG002|Overall Study|Adverse Event|2
6154524|NCT01134055|9792928|FG003|Overall Study|Adverse Event|2
6154525|NCT01134055|9792929|FG004|Overall Study|Adverse Event|5
6154526|NCT01134055|9792930|FG005|Overall Study|Adverse Event|7
6154527|NCT01134055|9792931|FG006|Overall Study|Adverse Event|2
6154528|NCT01134055|9792925|FG000|Overall Study|Lost to Follow-up|0
6154529|NCT01134055|9792926|FG001|Overall Study|Lost to Follow-up|1
6154530|NCT01134055|9792927|FG002|Overall Study|Lost to Follow-up|0
6154531|NCT01134055|9792928|FG003|Overall Study|Lost to Follow-up|1
6154532|NCT01134055|9792929|FG004|Overall Study|Lost to Follow-up|0
6154533|NCT01134055|9792930|FG005|Overall Study|Lost to Follow-up|0
6154534|NCT01134055|9792931|FG006|Overall Study|Lost to Follow-up|0
6154535|NCT01134055|9792925|FG000|Overall Study|Withdrawal by Subject|3
6154536|NCT01134055|9792926|FG001|Overall Study|Withdrawal by Subject|3
6154537|NCT01134055|9792927|FG002|Overall Study|Withdrawal by Subject|1
6154538|NCT01134055|9792928|FG003|Overall Study|Withdrawal by Subject|2
6154539|NCT01134055|9792929|FG004|Overall Study|Withdrawal by Subject|0
6154540|NCT01134055|9792930|FG005|Overall Study|Withdrawal by Subject|0
6154541|NCT01134055|9792931|FG006|Overall Study|Withdrawal by Subject|8
6154542|NCT01134055|9792925|FG000|Overall Study|Protocol Violation|0
6154543|NCT01134055|9792926|FG001|Overall Study|Protocol Violation|0
6154544|NCT01134055|9792927|FG002|Overall Study|Protocol Violation|0
6154545|NCT01134055|9792928|FG003|Overall Study|Protocol Violation|1
6154546|NCT01134055|9792929|FG004|Overall Study|Protocol Violation|1
6154547|NCT01134055|9792930|FG005|Overall Study|Protocol Violation|0
6154548|NCT01134055|9792931|FG006|Overall Study|Protocol Violation|0
6154549|NCT01134055|9792925|FG000|Overall Study|Physician Decision|0
6154550|NCT01134055|9792926|FG001|Overall Study|Physician Decision|0
6154551|NCT01134055|9792927|FG002|Overall Study|Physician Decision|0
6154552|NCT01134055|9792928|FG003|Overall Study|Physician Decision|0
6154553|NCT01134055|9792929|FG004|Overall Study|Physician Decision|0
6154554|NCT01134055|9792930|FG005|Overall Study|Physician Decision|0
6154555|NCT01134055|9792931|FG006|Overall Study|Physician Decision|1
6154556|NCT01134107|9792963|FG000|Period 1-First Treatment Intervention|Adverse Event|1
6154557|NCT01134107|9792964|FG001|Period 1-First Treatment Intervention|Adverse Event|0
6154558|NCT01134107|9792963|FG000|Period 1-First Treatment Intervention|Entry Criteria Not Met|1
6154559|NCT01134107|9792964|FG001|Period 1-First Treatment Intervention|Entry Criteria Not Met|1
6154560|NCT01134107|9792963|FG000|Period 1-First Treatment Intervention|Withdrawal by Subject|3
6154561|NCT01134107|9792964|FG001|Period 1-First Treatment Intervention|Withdrawal by Subject|4
6154562|NCT01134107|9792963|FG000|Period 1-First Treatment Intervention|Physician Decision|1
6154563|NCT01134107|9792964|FG001|Period 1-First Treatment Intervention|Physician Decision|0
6154564|NCT01134107|9792963|FG000|Period 2-Second Treatment Intervention|Withdrawal by Subject|2
6154565|NCT01134107|9792964|FG001|Period 2-Second Treatment Intervention|Withdrawal by Subject|0
6154566|NCT01134107|9792963|FG000|Period 2-Second Treatment Intervention|Physician Decision|1
6154567|NCT01134107|9792964|FG001|Period 2-Second Treatment Intervention|Physician Decision|0
6154568|NCT01134107|9792963|FG000|Period 2-Second Treatment Intervention|Sponsor Decision|1
6154569|NCT01134107|9792964|FG001|Period 2-Second Treatment Intervention|Sponsor Decision|0
6154570|NCT01134263|9792984|FG000|Overall Study|Serious adverse event|2
6154571|NCT01134263|9792985|FG001|Overall Study|Serious adverse event|1
6154572|NCT01134263|9792986|FG002|Overall Study|Serious adverse event|1
6154573|NCT01134263|9792987|FG003|Overall Study|Serious adverse event|1
6154574|NCT01134263|9792988|FG004|Overall Study|Serious adverse event|1
6154575|NCT01134263|9792984|FG000|Overall Study|Other adverse event|1
6154576|NCT01134263|9792985|FG001|Overall Study|Other adverse event|2
6154577|NCT01134263|9792986|FG002|Overall Study|Other adverse event|5
6154578|NCT01134263|9792987|FG003|Overall Study|Other adverse event|3
6154579|NCT01134263|9792988|FG004|Overall Study|Other adverse event|0
6154580|NCT01134263|9792984|FG000|Overall Study|Protocol Violation|8
6154581|NCT01134263|9792985|FG001|Overall Study|Protocol Violation|7
6154582|NCT01134263|9792986|FG002|Overall Study|Protocol Violation|2
6154583|NCT01134263|9792987|FG003|Overall Study|Protocol Violation|4
6154584|NCT01134263|9792988|FG004|Overall Study|Protocol Violation|2
6154585|NCT01134263|9792984|FG000|Overall Study|Lost to Follow-up|4
6154586|NCT01134263|9792985|FG001|Overall Study|Lost to Follow-up|3
6154587|NCT01134263|9792986|FG002|Overall Study|Lost to Follow-up|5
6154588|NCT01134263|9792987|FG003|Overall Study|Lost to Follow-up|3
6154589|NCT01134263|9792988|FG004|Overall Study|Lost to Follow-up|1
6154590|NCT01134263|9792984|FG000|Overall Study|Withdrawal by Subject|8
6154591|NCT01134263|9792985|FG001|Overall Study|Withdrawal by Subject|6
6154592|NCT01134263|9792986|FG002|Overall Study|Withdrawal by Subject|16
6154593|NCT01134263|9792987|FG003|Overall Study|Withdrawal by Subject|7
6154594|NCT01134263|9792988|FG004|Overall Study|Withdrawal by Subject|5
6154595|NCT01134263|9792984|FG000|Overall Study|Enrolled, but not treated|1
6154596|NCT01134263|9792985|FG001|Overall Study|Enrolled, but not treated|1
6154597|NCT01134263|9792986|FG002|Overall Study|Enrolled, but not treated|0
6154598|NCT01134263|9792987|FG003|Overall Study|Enrolled, but not treated|1
6154599|NCT01134263|9792988|FG004|Overall Study|Enrolled, but not treated|0
6154600|NCT01134315|9793020|FG000|Overall Study|Adverse Event|1
6154601|NCT01134315|9793021|FG001|Overall Study|Adverse Event|2
6154602|NCT01134315|9793020|FG000|Overall Study|Other Reason|8
6154603|NCT01134315|9793021|FG001|Overall Study|Other Reason|17
6154604|NCT01134393|9793044|FG000|Overall Study|Adverse Event|18
6154605|NCT01134393|9793044|FG000|Overall Study|Lack of Efficacy|2
6154606|NCT01134393|9793044|FG000|Overall Study|Protocol Violation|12
6154607|NCT01134393|9793044|FG000|Overall Study|Lost to Follow-up|3
6154608|NCT01134393|9793044|FG000|Overall Study|Withdrawal by Subject|11
6154609|NCT01134393|9793044|FG000|Overall Study|Other|6
6191704|NCT01425463|9848660|FG001|Overall Study|Lack of Efficacy|1
6191705|NCT01425463|9848659|FG000|Overall Study|Protocol Violation|2
6191706|NCT01425463|9848660|FG001|Overall Study|Protocol Violation|2
6191707|NCT01425463|9848659|FG000|Overall Study|Lost to Follow-up|5
6154610|NCT01129011|9793063|FG000|Overall Study|Adverse Event|20
6154611|NCT01129011|9793064|FG001|Overall Study|Adverse Event|30
6154612|NCT01129011|9793063|FG000|Overall Study|Withdrawal by Subject|24
6154613|NCT01129011|9793064|FG001|Overall Study|Withdrawal by Subject|8
6154614|NCT01129011|9793063|FG000|Overall Study|Lost to Follow-up|6
6154615|NCT01129011|9793064|FG001|Overall Study|Lost to Follow-up|7
6154616|NCT01129011|9793063|FG000|Overall Study|Duodenal Ulcer|2
6154617|NCT01129011|9793064|FG001|Overall Study|Duodenal Ulcer|8
6154618|NCT01129011|9793063|FG000|Overall Study|misc|7
6154619|NCT01129011|9793064|FG001|Overall Study|misc|4
6154620|NCT01134562|9793101|FG000|Overall Study|Adverse Event|0
6154621|NCT01134562|9793102|FG001|Overall Study|Adverse Event|1
6154622|NCT01134562|9793103|FG002|Overall Study|Adverse Event|0
6154623|NCT01134562|9793104|FG003|Overall Study|Adverse Event|0
6042011|NCT00379795|9640184|FG002|Overall Study|Adverse Event|3
6042012|NCT00379795|9640185|FG003|Overall Study|Adverse Event|1
6042013|NCT00379795|9640186|FG004|Overall Study|Adverse Event|4
6042014|NCT00379795|9640182|FG000|Overall Study|Lost to Follow-up|8
6042015|NCT00379795|9640183|FG001|Overall Study|Lost to Follow-up|1
6042016|NCT00379795|9640184|FG002|Overall Study|Lost to Follow-up|2
6042017|NCT00379795|9640185|FG003|Overall Study|Lost to Follow-up|1
6042018|NCT00379795|9640186|FG004|Overall Study|Lost to Follow-up|4
6042019|NCT00379795|9640182|FG000|Overall Study|Physician Decision|25
6042020|NCT00379795|9640183|FG001|Overall Study|Physician Decision|0
6042021|NCT00379795|9640184|FG002|Overall Study|Physician Decision|2
6042022|NCT00379795|9640185|FG003|Overall Study|Physician Decision|2
6042023|NCT00379795|9640186|FG004|Overall Study|Physician Decision|2
6042024|NCT00379795|9640182|FG000|Overall Study|Withdrawal by Subject|94
6042025|NCT00379795|9640183|FG001|Overall Study|Withdrawal by Subject|11
6042026|NCT00379795|9640184|FG002|Overall Study|Withdrawal by Subject|19
6042027|NCT00379795|9640185|FG003|Overall Study|Withdrawal by Subject|7
6042028|NCT00379795|9640186|FG004|Overall Study|Withdrawal by Subject|14
6042029|NCT00379795|9640182|FG000|Overall Study|Subject non-compliance|7
6042030|NCT00379795|9640183|FG001|Overall Study|Subject non-compliance|2
6324426|NCT02914522|10066055|FG010|Induction Study: Up to Week 11|Pregnancy|0
6324427|NCT02914522|10066045|FG000|Induction Study: Up to Week 11|Did not Receive Study Drug|0
6324428|NCT02914522|10066046|FG001|Induction Study: Up to Week 11|Did not Receive Study Drug|1
6324429|NCT02914522|10066047|FG002|Induction Study: Up to Week 11|Did not Receive Study Drug|0
6324430|NCT02914522|10066048|FG003|Induction Study: Up to Week 11|Did not Receive Study Drug|0
6324431|NCT02914522|10066049|FG004|Induction Study: Up to Week 11|Did not Receive Study Drug|1
6324432|NCT02914522|10066050|FG005|Induction Study: Up to Week 11|Did not Receive Study Drug|1
6324433|NCT02914522|10066051|FG006|Induction Study: Up to Week 11|Did not Receive Study Drug|0
6324434|NCT02914522|10066052|FG007|Induction Study: Up to Week 11|Did not Receive Study Drug|0
6324435|NCT02914522|10066053|FG008|Induction Study: Up to Week 11|Did not Receive Study Drug|0
6324436|NCT02914522|10066054|FG009|Induction Study: Up to Week 11|Did not Receive Study Drug|0
6324437|NCT02914522|10066055|FG010|Induction Study: Up to Week 11|Did not Receive Study Drug|0
6324438|NCT02914522|10066045|FG000|Maintenance Study: Week 11 to Week 58|Protocol-specified Disease Worsening|0
6324439|NCT02914522|10066046|FG001|Maintenance Study: Week 11 to Week 58|Protocol-specified Disease Worsening|0
6324440|NCT02914522|10066047|FG002|Maintenance Study: Week 11 to Week 58|Protocol-specified Disease Worsening|0
6324441|NCT02914522|10066048|FG003|Maintenance Study: Week 11 to Week 58|Protocol-specified Disease Worsening|0
6324442|NCT02914522|10066049|FG004|Maintenance Study: Week 11 to Week 58|Protocol-specified Disease Worsening|0
6042031|NCT00379795|9640184|FG002|Overall Study|Subject non-compliance|0
6042032|NCT00379795|9640185|FG003|Overall Study|Subject non-compliance|0
6042033|NCT00379795|9640186|FG004|Overall Study|Subject non-compliance|1
6042034|NCT00379795|9640182|FG000|Overall Study|Verteporfin photodynamic therapy in eye|3
6042035|NCT00379795|9640183|FG001|Overall Study|Verteporfin photodynamic therapy in eye|0
6042036|NCT00379795|9640184|FG002|Overall Study|Verteporfin photodynamic therapy in eye|0
6042037|NCT00379795|9640185|FG003|Overall Study|Verteporfin photodynamic therapy in eye|1
6042038|NCT00379795|9640186|FG004|Overall Study|Verteporfin photodynamic therapy in eye|0
6042039|NCT00379795|9640182|FG000|Overall Study|Subjects condition mandated intervention|34
6042040|NCT00379795|9640183|FG001|Overall Study|Subjects condition mandated intervention|9
6042041|NCT00379795|9640184|FG002|Overall Study|Subjects condition mandated intervention|7
6154624|NCT01134562|9793105|FG004|Overall Study|Adverse Event|0
6154625|NCT01134627|9793140|FG000|Overall Study|Adverse Event|47
6154626|NCT01134627|9793141|FG001|Overall Study|Adverse Event|31
6154627|NCT01134627|9793140|FG000|Overall Study|Lost to Follow-up|1
6154628|NCT01134627|9793141|FG001|Overall Study|Lost to Follow-up|2
6154629|NCT01134627|9793140|FG000|Overall Study|Protocol Violation|3
6154630|NCT01134627|9793141|FG001|Overall Study|Protocol Violation|5
6154631|NCT01134627|9793140|FG000|Overall Study|Lack of Efficacy|2
6154632|NCT01134627|9793141|FG001|Overall Study|Lack of Efficacy|12
6154633|NCT01134627|9793140|FG000|Overall Study|Withdrawal by Subject|4
6154634|NCT01134627|9793141|FG001|Overall Study|Withdrawal by Subject|3
6154635|NCT01134627|9793140|FG000|Overall Study|Planning to become pregnant/pregnancy|1
6154636|NCT01134627|9793141|FG001|Overall Study|Planning to become pregnant/pregnancy|0
6154637|NCT01134627|9793140|FG000|Overall Study|Other|11
6154638|NCT01134627|9793141|FG001|Overall Study|Other|14
6154639|NCT01134705|9793149|FG000|Overall Study|Adverse Event|1
6154640|NCT01134705|9793150|FG001|Overall Study|Adverse Event|7
6154641|NCT01134705|9793149|FG000|Overall Study|Withdrawal by Subject|6
6154642|NCT01134705|9793150|FG001|Overall Study|Withdrawal by Subject|6
6154643|NCT01134705|9793149|FG000|Overall Study|Pregnancy|1
6154644|NCT01134705|9793150|FG001|Overall Study|Pregnancy|0
6154645|NCT01134705|9793149|FG000|Overall Study|Lost to Follow-up|5
6154646|NCT01134705|9793150|FG001|Overall Study|Lost to Follow-up|2
6154647|NCT01134705|9793149|FG000|Overall Study|Protocol Violation|1
6154648|NCT01134705|9793150|FG001|Overall Study|Protocol Violation|1
6154649|NCT01134705|9793149|FG000|Overall Study|Other|1
6154650|NCT01134705|9793150|FG001|Overall Study|Other|6
6154651|NCT01134731|9793159|FG000|Overall Study|Adverse Event|3
6154652|NCT01134731|9793160|FG001|Overall Study|Adverse Event|2
6154653|NCT01134731|9793161|FG002|Overall Study|Adverse Event|1
6154654|NCT01134731|9793159|FG000|Overall Study|Physician Decision|2
6154655|NCT01134731|9793160|FG001|Overall Study|Physician Decision|2
6154656|NCT01134731|9793161|FG002|Overall Study|Physician Decision|2
6154657|NCT01134731|9793159|FG000|Overall Study|Lack of Efficacy|0
6154658|NCT01134731|9793160|FG001|Overall Study|Lack of Efficacy|0
6154659|NCT01134731|9793161|FG002|Overall Study|Lack of Efficacy|1
6154660|NCT01134731|9793159|FG000|Overall Study|Withdrawal by Subject|3
6154661|NCT01134731|9793160|FG001|Overall Study|Withdrawal by Subject|3
6154662|NCT01134731|9793161|FG002|Overall Study|Withdrawal by Subject|1
6154663|NCT01134731|9793159|FG000|Overall Study|Lost to Follow-up|5
6154664|NCT01134731|9793160|FG001|Overall Study|Lost to Follow-up|4
6154665|NCT01134731|9793161|FG002|Overall Study|Lost to Follow-up|3
6154666|NCT01134783|9793172|FG000|Overall Study|Pregnancy|16
6154667|NCT01134783|9793173|FG001|Overall Study|Pregnancy|8
6154668|NCT01134783|9793172|FG000|Overall Study|Withdrawal by Subject|15
6154669|NCT01134783|9793173|FG001|Overall Study|Withdrawal by Subject|9
6154670|NCT01134783|9793172|FG000|Overall Study|Lost to Follow-up|5
6154671|NCT01134783|9793173|FG001|Overall Study|Lost to Follow-up|20
6154672|NCT01134939|9793215|FG000|Overall Study|Adverse Event|9
6154673|NCT01134939|9793216|FG001|Overall Study|Adverse Event|3
6154674|NCT01134939|9793217|FG002|Overall Study|Adverse Event|4
6154675|NCT01134939|9793218|FG003|Overall Study|Adverse Event|5
6154676|NCT01134939|9793219|FG004|Overall Study|Adverse Event|5
6154677|NCT01134939|9793220|FG005|Overall Study|Adverse Event|5
6154678|NCT01134939|9793221|FG006|Overall Study|Adverse Event|1
6154679|NCT01134939|9793222|FG007|Overall Study|Adverse Event|0
6154680|NCT01134939|9793215|FG000|Overall Study|Lack of Efficacy|2
6154681|NCT01134939|9793216|FG001|Overall Study|Lack of Efficacy|5
6154682|NCT01134939|9793217|FG002|Overall Study|Lack of Efficacy|1
6154683|NCT01134939|9793218|FG003|Overall Study|Lack of Efficacy|0
6154684|NCT01134939|9793219|FG004|Overall Study|Lack of Efficacy|3
6154685|NCT01134939|9793220|FG005|Overall Study|Lack of Efficacy|0
6154686|NCT01134939|9793221|FG006|Overall Study|Lack of Efficacy|1
6154687|NCT01134939|9793222|FG007|Overall Study|Lack of Efficacy|0
6154688|NCT01134939|9793215|FG000|Overall Study|Lost to Follow-up|2
6154689|NCT01134939|9793216|FG001|Overall Study|Lost to Follow-up|3
6154690|NCT01134939|9793217|FG002|Overall Study|Lost to Follow-up|0
6154691|NCT01134939|9793218|FG003|Overall Study|Lost to Follow-up|1
6154692|NCT01134939|9793219|FG004|Overall Study|Lost to Follow-up|2
6154693|NCT01134939|9793220|FG005|Overall Study|Lost to Follow-up|1
6154694|NCT01134939|9793221|FG006|Overall Study|Lost to Follow-up|0
6154695|NCT01134939|9793222|FG007|Overall Study|Lost to Follow-up|0
6154696|NCT01134939|9793215|FG000|Overall Study|Death|0
6154697|NCT01134939|9793216|FG001|Overall Study|Death|1
6154698|NCT01134939|9793217|FG002|Overall Study|Death|0
6154699|NCT01134939|9793218|FG003|Overall Study|Death|0
6154700|NCT01134939|9793219|FG004|Overall Study|Death|0
6154701|NCT01134939|9793220|FG005|Overall Study|Death|0
6154702|NCT01134939|9793221|FG006|Overall Study|Death|0
6154703|NCT01134939|9793222|FG007|Overall Study|Death|0
6154704|NCT01134939|9793215|FG000|Overall Study|Termination page not available|4
6154705|NCT01134939|9793216|FG001|Overall Study|Termination page not available|6
6154706|NCT01134939|9793217|FG002|Overall Study|Termination page not available|5
6154707|NCT01134939|9793218|FG003|Overall Study|Termination page not available|8
6154708|NCT01134939|9793219|FG004|Overall Study|Termination page not available|0
6154709|NCT01134939|9793220|FG005|Overall Study|Termination page not available|3
6154710|NCT01134939|9793221|FG006|Overall Study|Termination page not available|7
6154711|NCT01134939|9793222|FG007|Overall Study|Termination page not available|0
6154712|NCT01135017|9793246|FG000|Overall Study|Adverse Event|3
6154713|NCT01135017|9793247|FG001|Overall Study|Adverse Event|8
6154714|NCT01135017|9793246|FG000|Overall Study|Other than above|3
6154715|NCT01135017|9793247|FG001|Overall Study|Other than above|4
6154716|NCT01135394|9793336|FG000|Screening|Lost to Follow-up|2
6154717|NCT01135394|9793336|FG000|Screening|Withdrawal by Subject|10
6154718|NCT01135394|9793336|FG000|Screening|Screening failure|16
6154719|NCT01135394|9793336|FG000|Screening|Physician Decision|5
6154720|NCT01135394|9793336|FG000|Baseline Assessment|Withdrawal by Subject|9
6154721|NCT01135394|9793336|FG000|Baseline Assessment|Physician Decision|3
6154722|NCT01135394|9793336|FG000|Baseline Assessment|Lost to Follow-up|2
6154723|NCT01135394|9793336|FG000|Baseline Assessment|Adverse Event|1
6154724|NCT01135394|9793336|FG000|Study Treatment|Withdrawal by Subject|1
6154725|NCT01135394|9793336|FG000|Study Treatment|Physician Decision|1
6154726|NCT01135394|9793336|FG000|Study Treatment|Adverse Event|2
6154727|NCT01135498|9793349|FG000|Overall Study|Adverse Event|20
6154728|NCT01135498|9793349|FG000|Overall Study|Progressive disease|38
6154729|NCT01135498|9793349|FG000|Overall Study|Investigator judgement|25
6154730|NCT01135498|9793349|FG000|Overall Study|Withdrawal by Subject|4
6154731|NCT01135498|9793349|FG000|Overall Study|Death|1
6154732|NCT01135498|9793349|FG000|Overall Study|Ongoing at time of analysis|2
6154733|NCT01135511|9793363|FG000|Overall Study|Adverse Event|0
6154734|NCT01135511|9793364|FG001|Overall Study|Adverse Event|1
6154735|NCT01135511|9793365|FG002|Overall Study|Adverse Event|2
6154736|NCT01135511|9793366|FG003|Overall Study|Adverse Event|0
6154737|NCT01135511|9793367|FG004|Overall Study|Adverse Event|0
6154738|NCT01135511|9793368|FG005|Overall Study|Adverse Event|1
6154739|NCT01135511|9793369|FG006|Overall Study|Adverse Event|0
6154740|NCT01135511|9793370|FG007|Overall Study|Adverse Event|1
6154741|NCT01135511|9793371|FG008|Overall Study|Adverse Event|0
6154742|NCT01135511|9793363|FG000|Overall Study|Lack of Efficacy|0
6154743|NCT01135511|9793364|FG001|Overall Study|Lack of Efficacy|1
6154744|NCT01135511|9793365|FG002|Overall Study|Lack of Efficacy|1
6154745|NCT01135511|9793366|FG003|Overall Study|Lack of Efficacy|2
6154746|NCT01135511|9793367|FG004|Overall Study|Lack of Efficacy|0
6154747|NCT01135511|9793368|FG005|Overall Study|Lack of Efficacy|0
6154748|NCT01135511|9793369|FG006|Overall Study|Lack of Efficacy|0
6154749|NCT01135511|9793370|FG007|Overall Study|Lack of Efficacy|0
6154750|NCT01135511|9793371|FG008|Overall Study|Lack of Efficacy|0
6154751|NCT01135511|9793363|FG000|Overall Study|Protocol Violation|0
6154752|NCT01135511|9793364|FG001|Overall Study|Protocol Violation|0
6154753|NCT01135511|9793365|FG002|Overall Study|Protocol Violation|3
6154754|NCT01135511|9793366|FG003|Overall Study|Protocol Violation|0
6154755|NCT01135511|9793367|FG004|Overall Study|Protocol Violation|0
6154756|NCT01135511|9793368|FG005|Overall Study|Protocol Violation|0
6154757|NCT01135511|9793369|FG006|Overall Study|Protocol Violation|0
6154758|NCT01135511|9793370|FG007|Overall Study|Protocol Violation|0
6154759|NCT01135511|9793371|FG008|Overall Study|Protocol Violation|0
6154760|NCT01135511|9793363|FG000|Overall Study|Pregnancy|0
6154761|NCT01135511|9793364|FG001|Overall Study|Pregnancy|0
6154762|NCT01135511|9793365|FG002|Overall Study|Pregnancy|0
6154763|NCT01135511|9793366|FG003|Overall Study|Pregnancy|1
6154764|NCT01135511|9793367|FG004|Overall Study|Pregnancy|0
6154765|NCT01135511|9793368|FG005|Overall Study|Pregnancy|0
6154766|NCT01135511|9793369|FG006|Overall Study|Pregnancy|0
6154767|NCT01135511|9793370|FG007|Overall Study|Pregnancy|0
6154768|NCT01135511|9793371|FG008|Overall Study|Pregnancy|0
6154769|NCT01135511|9793363|FG000|Overall Study|could not visit the clinic|0
6154770|NCT01135511|9793364|FG001|Overall Study|could not visit the clinic|1
6154771|NCT01135511|9793365|FG002|Overall Study|could not visit the clinic|2
6154772|NCT01135511|9793366|FG003|Overall Study|could not visit the clinic|0
6154773|NCT01135511|9793367|FG004|Overall Study|could not visit the clinic|0
6154774|NCT01135511|9793368|FG005|Overall Study|could not visit the clinic|0
6154775|NCT01135511|9793369|FG006|Overall Study|could not visit the clinic|0
6154776|NCT01135511|9793370|FG007|Overall Study|could not visit the clinic|0
6154777|NCT01135511|9793371|FG008|Overall Study|could not visit the clinic|0
6154778|NCT01135511|9793363|FG000|Overall Study|noncompliance with study drug taken|0
6154779|NCT01135511|9793364|FG001|Overall Study|noncompliance with study drug taken|0
6154780|NCT01135511|9793365|FG002|Overall Study|noncompliance with study drug taken|0
6154781|NCT01135511|9793366|FG003|Overall Study|noncompliance with study drug taken|0
6154782|NCT01135511|9793367|FG004|Overall Study|noncompliance with study drug taken|1
6154783|NCT01135511|9793368|FG005|Overall Study|noncompliance with study drug taken|0
6154784|NCT01135511|9793369|FG006|Overall Study|noncompliance with study drug taken|0
6154785|NCT01135511|9793370|FG007|Overall Study|noncompliance with study drug taken|0
6154786|NCT01135511|9793371|FG008|Overall Study|noncompliance with study drug taken|0
6154787|NCT01135511|9793363|FG000|Overall Study|Withdrawal by Subject|0
6154788|NCT01135511|9793364|FG001|Overall Study|Withdrawal by Subject|0
6154789|NCT01135511|9793365|FG002|Overall Study|Withdrawal by Subject|0
6154790|NCT01135511|9793366|FG003|Overall Study|Withdrawal by Subject|0
6154791|NCT01135511|9793367|FG004|Overall Study|Withdrawal by Subject|0
6154792|NCT01135511|9793368|FG005|Overall Study|Withdrawal by Subject|0
6154793|NCT01135511|9793369|FG006|Overall Study|Withdrawal by Subject|1
6154794|NCT01135511|9793370|FG007|Overall Study|Withdrawal by Subject|0
6154795|NCT01135511|9793371|FG008|Overall Study|Withdrawal by Subject|1
6154796|NCT01135524|9793391|FG000|Overall Study|Withdrawal by Subject|14
6154797|NCT01135524|9793391|FG000|Overall Study|Adverse Event|20
6154798|NCT01135524|9793391|FG000|Overall Study|Lost to Follow-up|3
6154799|NCT01135524|9793391|FG000|Overall Study|Administrative|151
6154800|NCT01135524|9793391|FG000|Overall Study|Lack of Efficacy|8
6154801|NCT01135914|9793402|FG000|Overall Study|Withdrawal by Subject|1
6154802|NCT01135914|9793403|FG001|Overall Study|Withdrawal by Subject|3
6154803|NCT01135914|9793404|FG002|Overall Study|Withdrawal by Subject|6
6154804|NCT01135914|9793402|FG000|Overall Study|Lost to Follow-up|1
6154805|NCT01135914|9793403|FG001|Overall Study|Lost to Follow-up|0
6154806|NCT01135914|9793404|FG002|Overall Study|Lost to Follow-up|1
6154807|NCT01135914|9793402|FG000|Overall Study|Protocol Violation|0
6154808|NCT01135914|9793403|FG001|Overall Study|Protocol Violation|0
6154809|NCT01135914|9793404|FG002|Overall Study|Protocol Violation|3
6154810|NCT01135914|9793402|FG000|Overall Study|Lack of Efficacy|2
6154811|NCT01135914|9793403|FG001|Overall Study|Lack of Efficacy|1
6154812|NCT01135914|9793404|FG002|Overall Study|Lack of Efficacy|10
6154813|NCT01135914|9793402|FG000|Overall Study|Adverse Event|0
6154814|NCT01135914|9793403|FG001|Overall Study|Adverse Event|1
6154815|NCT01135914|9793404|FG002|Overall Study|Adverse Event|2
6154816|NCT01135992|9793412|FG000|Overall Study|Adverse Event|1
6154817|NCT01135992|9793412|FG000|Overall Study|Lack of Efficacy|1
6154818|NCT01135992|9793412|FG000|Overall Study|Protocol Violation|2
6154819|NCT01135992|9793412|FG000|Overall Study|Withdrawal criteria|10
6154820|NCT01135992|9793412|FG000|Overall Study|Unclassified|7
6154821|NCT01136174|9793420|FG000|Overall Study|Adverse Event|0
6154822|NCT01136174|9793421|FG001|Overall Study|Adverse Event|0
6154823|NCT01136174|9793422|FG002|Overall Study|Adverse Event|0
6154824|NCT01136174|9793423|FG003|Overall Study|Adverse Event|4
6154825|NCT01136291|9793449|FG000|Overall Study|Lost to Follow-up|1
6154826|NCT01136291|9793450|FG001|Overall Study|Lost to Follow-up|1
6154827|NCT01136356|9793456|FG000|First 18-day Withdrawal|Withdrawal by Subject|3
6154828|NCT01136356|9793457|FG001|First 18-day Withdrawal|Withdrawal by Subject|0
6154829|NCT01136356|9793456|FG000|First 18-day Withdrawal|Physician Decision|1
6154830|NCT01136356|9793457|FG001|First 18-day Withdrawal|Physician Decision|0
6154831|NCT01136356|9793456|FG000|Second 18-day Withdrawal|Withdrawal by Subject|0
6154832|NCT01136356|9793457|FG001|Second 18-day Withdrawal|Withdrawal by Subject|1
6154833|NCT01136382|9793464|FG000|Overall Study|Other|8
6154834|NCT01136382|9793465|FG001|Overall Study|Other|3
6154835|NCT01136382|9793464|FG000|Overall Study|Study-Specific Withdrawal Criteria|48
6154836|NCT01136382|9793465|FG001|Overall Study|Study-Specific Withdrawal Criteria|25
6154837|NCT01136382|9793464|FG000|Overall Study|Severe Non-Compliance to Protocol|0
6154838|NCT01136382|9793465|FG001|Overall Study|Severe Non-Compliance to Protocol|2
6154839|NCT01136382|9793464|FG000|Overall Study|Withdrawal by Subject|4
6154840|NCT01136382|9793465|FG001|Overall Study|Withdrawal by Subject|1
6154841|NCT01136408|9793474|FG000|Overall Study|Adverse Event|4
6154842|NCT01136408|9793475|FG001|Overall Study|Adverse Event|8
6154843|NCT01136408|9793476|FG002|Overall Study|Adverse Event|4
6154844|NCT01136408|9793474|FG000|Overall Study|Protocol Violation|1
6154845|NCT01136408|9793475|FG001|Overall Study|Protocol Violation|1
6154846|NCT01136408|9793476|FG002|Overall Study|Protocol Violation|1
6154847|NCT01136655|9793492|FG000|Washout After BUD 160/FM 2.25 (7 Days)|Withdrawal by Subject|1
6154848|NCT01136655|9793492|FG000|Washout After BUD 160/FM 4.5 (7 Days)|Adverse Event|1
6154849|NCT01136655|9793492|FG000|Washout After BUD 160/FM 9.0 (7 Days)|Withdrawal by Subject|1
6154850|NCT01136655|9793492|FG000|Washout After BUD 160/FM 9.0 (7 Days)|Adverse Event|1
6154851|NCT01136733|9793512|FG000|Phase 1b|Adverse Event|0
6154852|NCT01136733|9793513|FG001|Phase 1b|Adverse Event|3
6154853|NCT01136733|9793514|FG002|Phase 1b|Adverse Event|1
6154854|NCT01136733|9793515|FG003|Phase 1b|Adverse Event|0
6154855|NCT01136733|9793516|FG004|Phase 1b|Adverse Event|0
6154856|NCT01136733|9793517|FG005|Phase 1b|Adverse Event|0
6154857|NCT01136733|9793518|FG006|Phase 1b|Adverse Event|0
6154858|NCT01136733|9793512|FG000|Phase 1b|Participant Choice|0
6154859|NCT01136733|9793513|FG001|Phase 1b|Participant Choice|0
6154860|NCT01136733|9793514|FG002|Phase 1b|Participant Choice|1
6154861|NCT01136733|9793515|FG003|Phase 1b|Participant Choice|0
6154862|NCT01136733|9793516|FG004|Phase 1b|Participant Choice|0
6154863|NCT01136733|9793517|FG005|Phase 1b|Participant Choice|0
6154864|NCT01136733|9793518|FG006|Phase 1b|Participant Choice|0
6154865|NCT01136733|9793512|FG000|Phase 1b|Administrative-Withdrew Consent|0
6154866|NCT01136733|9793513|FG001|Phase 1b|Administrative-Withdrew Consent|1
6154867|NCT01136733|9793514|FG002|Phase 1b|Administrative-Withdrew Consent|0
6154868|NCT01136733|9793515|FG003|Phase 1b|Administrative-Withdrew Consent|0
6154869|NCT01136733|9793516|FG004|Phase 1b|Administrative-Withdrew Consent|0
6154870|NCT01136733|9793517|FG005|Phase 1b|Administrative-Withdrew Consent|0
6154871|NCT01136733|9793518|FG006|Phase 1b|Administrative-Withdrew Consent|0
6154872|NCT01136733|9793512|FG000|Phase 1b|Clinical Progression|1
6154873|NCT01136733|9793513|FG001|Phase 1b|Clinical Progression|1
6154874|NCT01136733|9793514|FG002|Phase 1b|Clinical Progression|0
6154875|NCT01136733|9793515|FG003|Phase 1b|Clinical Progression|0
6154876|NCT01136733|9793516|FG004|Phase 1b|Clinical Progression|0
6154877|NCT01136733|9793517|FG005|Phase 1b|Clinical Progression|0
6154878|NCT01136733|9793518|FG006|Phase 1b|Clinical Progression|0
6154879|NCT01136733|9793512|FG000|Phase 2|Disease Progression|0
6154880|NCT01136733|9793513|FG001|Phase 2|Disease Progression|0
6154881|NCT01136733|9793514|FG002|Phase 2|Disease Progression|0
6154882|NCT01136733|9793515|FG003|Phase 2|Disease Progression|0
6154883|NCT01136733|9793516|FG004|Phase 2|Disease Progression|30
6154884|NCT01136733|9793517|FG005|Phase 2|Disease Progression|32
6154885|NCT01136733|9793518|FG006|Phase 2|Disease Progression|38
6154886|NCT01136733|9793512|FG000|Phase 2|Adverse Event|0
6154887|NCT01136733|9793513|FG001|Phase 2|Adverse Event|0
6154888|NCT01136733|9793514|FG002|Phase 2|Adverse Event|0
6154889|NCT01136733|9793515|FG003|Phase 2|Adverse Event|0
6154890|NCT01136733|9793516|FG004|Phase 2|Adverse Event|11
6154891|NCT01136733|9793517|FG005|Phase 2|Adverse Event|13
6154892|NCT01136733|9793518|FG006|Phase 2|Adverse Event|5
6154893|NCT01136733|9793512|FG000|Phase 2|Participant Choice|0
6154894|NCT01136733|9793513|FG001|Phase 2|Participant Choice|0
6154895|NCT01136733|9793514|FG002|Phase 2|Participant Choice|0
6154896|NCT01136733|9793515|FG003|Phase 2|Participant Choice|0
6154897|NCT01136733|9793516|FG004|Phase 2|Participant Choice|3
6154898|NCT01136733|9793517|FG005|Phase 2|Participant Choice|0
6154899|NCT01136733|9793518|FG006|Phase 2|Participant Choice|1
6154900|NCT01136733|9793512|FG000|Phase 2|Administrative-Withdrew Consent|0
6154901|NCT01136733|9793513|FG001|Phase 2|Administrative-Withdrew Consent|0
6154902|NCT01136733|9793514|FG002|Phase 2|Administrative-Withdrew Consent|0
6154903|NCT01136733|9793515|FG003|Phase 2|Administrative-Withdrew Consent|0
6154904|NCT01136733|9793516|FG004|Phase 2|Administrative-Withdrew Consent|1
6154905|NCT01136733|9793517|FG005|Phase 2|Administrative-Withdrew Consent|0
6154906|NCT01136733|9793518|FG006|Phase 2|Administrative-Withdrew Consent|0
6154907|NCT01136733|9793512|FG000|Phase 2|Other|0
6154908|NCT01136733|9793513|FG001|Phase 2|Other|0
6154909|NCT01136733|9793514|FG002|Phase 2|Other|0
6154910|NCT01136733|9793515|FG003|Phase 2|Other|0
6154911|NCT01136733|9793516|FG004|Phase 2|Other|6
6154912|NCT01136733|9793517|FG005|Phase 2|Other|7
6154913|NCT01136733|9793518|FG006|Phase 2|Other|6
6154914|NCT01136746|9793550|FG000|Overall Study|Lost to Follow-up|0
6154915|NCT01136746|9793551|FG001|Overall Study|Lost to Follow-up|2
6154916|NCT01136746|9793550|FG000|Overall Study|Protocol Violation|2
6154917|NCT01136746|9793551|FG001|Overall Study|Protocol Violation|1
6154918|NCT01136746|9793550|FG000|Overall Study|Death|1
6154919|NCT01136746|9793551|FG001|Overall Study|Death|0
6154920|NCT01136772|9793559|FG000|Overall Study|Adverse Event|15
6154921|NCT01136772|9793560|FG001|Overall Study|Adverse Event|14
6154922|NCT01136772|9793559|FG000|Overall Study|Lack of Efficacy|42
6154923|NCT01136772|9793560|FG001|Overall Study|Lack of Efficacy|39
6154924|NCT01136772|9793559|FG000|Overall Study|Administrative|14
6154925|NCT01136772|9793560|FG001|Overall Study|Administrative|12
6154926|NCT01136772|9793559|FG000|Overall Study|Withdrawal by Subject|33
6154927|NCT01136772|9793560|FG001|Overall Study|Withdrawal by Subject|36
6154928|NCT01136772|9793559|FG000|Overall Study|Did not receive injection|10
6154929|NCT01136772|9793560|FG001|Overall Study|Did not receive injection|7
6154930|NCT01136772|9793559|FG000|Overall Study|Did not follow up after first injection|2
6154931|NCT01136772|9793560|FG001|Overall Study|Did not follow up after first injection|2
6154932|NCT01136785|9793568|FG000|Overall Study|Protocol Violation|2
6154933|NCT01136785|9793569|FG001|Overall Study|Protocol Violation|1
6154934|NCT01136876|9793590|FG000|Overall Study|Lost to Follow-up|0
6154935|NCT01136876|9793591|FG001|Overall Study|Lost to Follow-up|1
6154936|NCT01136876|9793590|FG000|Overall Study|Physician Decision|3
6154937|NCT01136876|9793591|FG001|Overall Study|Physician Decision|5
6154938|NCT01136876|9793590|FG000|Overall Study|Missing NGAL measurement|2
6154939|NCT01136876|9793591|FG001|Overall Study|Missing NGAL measurement|5
6154940|NCT01136915|9793601|FG000|Overall Study|Lost to Follow-up|2
6154941|NCT01136915|9793602|FG001|Overall Study|Lost to Follow-up|0
6154942|NCT01136915|9793601|FG000|Overall Study|Exclusion criterion met|0
6154943|NCT01136915|9793602|FG001|Overall Study|Exclusion criterion met|1
6154944|NCT01136954|9793612|FG000|Overall Study|Adverse Event|3
6154945|NCT01136954|9793613|FG001|Overall Study|Adverse Event|2
6154946|NCT01136954|9793612|FG000|Overall Study|Withdrawal by Subject|6
6154947|NCT01136954|9793613|FG001|Overall Study|Withdrawal by Subject|2
6154948|NCT01136954|9793612|FG000|Overall Study|Lack of Efficacy|14
6154949|NCT01136954|9793613|FG001|Overall Study|Lack of Efficacy|13
6154950|NCT01136954|9793612|FG000|Overall Study|Physician Decision|0
6154951|NCT01136954|9793613|FG001|Overall Study|Physician Decision|1
6154952|NCT01136954|9793612|FG000|Overall Study|Other|1
6154953|NCT01136954|9793613|FG001|Overall Study|Other|3
6154954|NCT01137071|9793654|FG000|Overall Study|Disease Progression|11
6154955|NCT01137071|9793654|FG000|Overall Study|Withdrawal by Subject|2
6154956|NCT01137071|9793654|FG000|Overall Study|Wrongly Included|1
6154957|NCT01137110|9793665|FG000|Overall Study|Protocol Violation|1
6154958|NCT01137110|9793666|FG001|Overall Study|Protocol Violation|0
6154959|NCT01137292|9793672|FG000|Overall Study|Death|30
6154960|NCT01137292|9793672|FG000|Overall Study|Adverse Event|3
6154961|NCT01137292|9793672|FG000|Overall Study|Lack of Efficacy|13
6154962|NCT01137292|9793672|FG000|Overall Study|Lost to Follow-up|1
6154963|NCT01137292|9793672|FG000|Overall Study|Other|7
6154964|NCT01137474|9793698|FG000|Overall Study|Adverse Event|3
6154965|NCT01137474|9793699|FG001|Overall Study|Adverse Event|5
6154966|NCT01137474|9793700|FG002|Overall Study|Adverse Event|1
6154967|NCT01137474|9793701|FG003|Overall Study|Adverse Event|3
6154968|NCT01137474|9793698|FG000|Overall Study|Withdrawal by Subject|7
6154969|NCT01137474|9793699|FG001|Overall Study|Withdrawal by Subject|2
6154970|NCT01137474|9793700|FG002|Overall Study|Withdrawal by Subject|6
6154971|NCT01137474|9793701|FG003|Overall Study|Withdrawal by Subject|9
6154972|NCT01137474|9793698|FG000|Overall Study|No longer met study criteria|6
6154973|NCT01137474|9793699|FG001|Overall Study|No longer met study criteria|1
6154974|NCT01137474|9793700|FG002|Overall Study|No longer met study criteria|0
6154975|NCT01137474|9793701|FG003|Overall Study|No longer met study criteria|5
6154976|NCT01137474|9793698|FG000|Overall Study|Lost to Follow-up|5
6154977|NCT01137474|9793699|FG001|Overall Study|Lost to Follow-up|1
6154978|NCT01137474|9793700|FG002|Overall Study|Lost to Follow-up|0
6154979|NCT01137474|9793701|FG003|Overall Study|Lost to Follow-up|2
6154980|NCT01137474|9793698|FG000|Overall Study|Lack of Efficacy|0
6154981|NCT01137474|9793699|FG001|Overall Study|Lack of Efficacy|0
6154982|NCT01137474|9793700|FG002|Overall Study|Lack of Efficacy|0
6154983|NCT01137474|9793701|FG003|Overall Study|Lack of Efficacy|2
6154984|NCT01137474|9793698|FG000|Overall Study|Other|3
6154985|NCT01137474|9793699|FG001|Overall Study|Other|1
6154986|NCT01137474|9793700|FG002|Overall Study|Other|0
6154987|NCT01137474|9793701|FG003|Overall Study|Other|0
6154988|NCT01137474|9793698|FG000|Overall Study|Pregnancy|0
6154989|NCT01137474|9793699|FG001|Overall Study|Pregnancy|1
6154990|NCT01137474|9793700|FG002|Overall Study|Pregnancy|0
6154991|NCT01137474|9793701|FG003|Overall Study|Pregnancy|0
6154992|NCT01137474|9793698|FG000|Overall Study|Administrative reason by sponsor|0
6154993|NCT01137474|9793699|FG001|Overall Study|Administrative reason by sponsor|1
6154994|NCT01137474|9793700|FG002|Overall Study|Administrative reason by sponsor|0
6154995|NCT01137474|9793701|FG003|Overall Study|Administrative reason by sponsor|0
6154996|NCT01137578|9793715|FG000|Overall Study|Participant requested to Discontinue|3
6154997|NCT01137578|9793716|FG001|Overall Study|Participant requested to Discontinue|0
6154998|NCT01137578|9793717|FG002|Overall Study|Participant requested to Discontinue|0
6154999|NCT01137578|9793715|FG000|Overall Study|Withdrawal by Subject|1
6155000|NCT01137578|9793716|FG001|Overall Study|Withdrawal by Subject|0
6155001|NCT01137578|9793717|FG002|Overall Study|Withdrawal by Subject|0
6155002|NCT01137578|9793715|FG000|Overall Study|Other|12
6155003|NCT01137578|9793716|FG001|Overall Study|Other|2
6155004|NCT01137578|9793717|FG002|Overall Study|Other|6
6155005|NCT01137604|9793749|FG000|Overall Study|Adverse Event|1
6155006|NCT01137604|9793750|FG001|Overall Study|Adverse Event|6
6155007|NCT01137604|9793751|FG002|Overall Study|Adverse Event|9
6155008|NCT01137604|9793752|FG003|Overall Study|Adverse Event|9
6155009|NCT01137604|9793749|FG000|Overall Study|Withdrawal by Subject|0
6155010|NCT01137604|9793750|FG001|Overall Study|Withdrawal by Subject|2
6155011|NCT01137604|9793751|FG002|Overall Study|Withdrawal by Subject|2
6155012|NCT01137604|9793752|FG003|Overall Study|Withdrawal by Subject|1
6155013|NCT01137604|9793749|FG000|Overall Study|Clinical Progression|0
6155014|NCT01137604|9793750|FG001|Overall Study|Clinical Progression|2
6155015|NCT01137604|9793751|FG002|Overall Study|Clinical Progression|1
6155016|NCT01137604|9793752|FG003|Overall Study|Clinical Progression|0
6155017|NCT01137604|9793749|FG000|Overall Study|Participant's Decision|1
6155018|NCT01137604|9793750|FG001|Overall Study|Participant's Decision|0
6155019|NCT01137604|9793751|FG002|Overall Study|Participant's Decision|0
6155020|NCT01137604|9793752|FG003|Overall Study|Participant's Decision|0
6155021|NCT01137604|9793749|FG000|Overall Study|Clinical Decline|0
6155022|NCT01137604|9793750|FG001|Overall Study|Clinical Decline|0
6155023|NCT01137604|9793751|FG002|Overall Study|Clinical Decline|1
6155024|NCT01137604|9793752|FG003|Overall Study|Clinical Decline|1
6155025|NCT01137682|9793765|FG000|Overall Study|Adverse Event-CORE|2
6155026|NCT01137682|9793766|FG001|Overall Study|Adverse Event-CORE|4
6155027|NCT01137682|9793767|FG002|Overall Study|Adverse Event-CORE|0
6155028|NCT01137682|9793765|FG000|Overall Study|Withdrawal by Subject-CORE|2
6155029|NCT01137682|9793766|FG001|Overall Study|Withdrawal by Subject-CORE|2
6155030|NCT01137682|9793767|FG002|Overall Study|Withdrawal by Subject-CORE|2
6155031|NCT01137682|9793765|FG000|Overall Study|Administrative problems-CORE|2
6155032|NCT01137682|9793766|FG001|Overall Study|Administrative problems-CORE|1
6155033|NCT01137682|9793767|FG002|Overall Study|Administrative problems-CORE|0
6155034|NCT01137682|9793765|FG000|Overall Study|Protocol Violation-CORE|0
6155035|NCT01137682|9793766|FG001|Overall Study|Protocol Violation-CORE|1
6155036|NCT01137682|9793767|FG002|Overall Study|Protocol Violation-CORE|1
6155037|NCT01137682|9793765|FG000|Overall Study|Adverse Event-Extension|4
6155038|NCT01137682|9793766|FG001|Overall Study|Adverse Event-Extension|8
6155039|NCT01137682|9793767|FG002|Overall Study|Adverse Event-Extension|7
6155040|NCT01137682|9793765|FG000|Overall Study|Lack of Efficacy-Extension|15
6155041|NCT01137682|9793766|FG001|Overall Study|Lack of Efficacy-Extension|9
6155042|NCT01137682|9793767|FG002|Overall Study|Lack of Efficacy-Extension|13
6155043|NCT01137682|9793765|FG000|Overall Study|Withdrawal by Subject-Extension|6
6155044|NCT01137682|9793766|FG001|Overall Study|Withdrawal by Subject-Extension|8
6155045|NCT01137682|9793767|FG002|Overall Study|Withdrawal by Subject-Extension|8
6155046|NCT01137682|9793765|FG000|Overall Study|Lost to Follow Up-Extension|0
6155047|NCT01137682|9793766|FG001|Overall Study|Lost to Follow Up-Extension|1
6155048|NCT01137682|9793767|FG002|Overall Study|Lost to Follow Up-Extension|0
6155049|NCT01137682|9793765|FG000|Overall Study|Administrative problems-Extension|0
6155050|NCT01137682|9793766|FG001|Overall Study|Administrative problems-Extension|2
6155051|NCT01137682|9793767|FG002|Overall Study|Administrative problems-Extension|0
6155052|NCT01137682|9793765|FG000|Overall Study|Death-Extension|2
6155053|NCT01137682|9793766|FG001|Overall Study|Death-Extension|0
6155054|NCT01137682|9793767|FG002|Overall Study|Death-Extension|0
6155055|NCT01137682|9793765|FG000|Overall Study|Protocol Violation-Extension|2
6155056|NCT01137682|9793766|FG001|Overall Study|Protocol Violation-Extension|1
6155057|NCT01137682|9793767|FG002|Overall Study|Protocol Violation-Extension|0
6155058|NCT01137682|9793765|FG000|Overall Study|Did not enter extension|2
6155059|NCT01137682|9793766|FG001|Overall Study|Did not enter extension|3
6155060|NCT01137682|9793767|FG002|Overall Study|Did not enter extension|2
6155061|NCT01137682|9793765|FG000|Overall Study|Did not receive treatment in extension|0
6155062|NCT01137682|9793766|FG001|Overall Study|Did not receive treatment in extension|0
6155063|NCT01137682|9793767|FG002|Overall Study|Did not receive treatment in extension|1
6042042|NCT00379795|9640185|FG003|Overall Study|Subjects condition mandated intervention|5
6042043|NCT00379795|9640186|FG004|Overall Study|Subjects condition mandated intervention|7
6042044|NCT00379795|9640182|FG000|Overall Study|Sponsor's decision|257
6042045|NCT00379795|9640183|FG001|Overall Study|Sponsor's decision|17
6155064|NCT01137786|9793781|FG000|Overall Study|Lost to Follow-up|0
6155065|NCT01137786|9793782|FG001|Overall Study|Lost to Follow-up|2
6155066|NCT01137786|9793781|FG000|Overall Study|Withdrawal by Subject|1
6155067|NCT01137786|9793782|FG001|Overall Study|Withdrawal by Subject|1
6155068|NCT01137812|9793792|FG000|Overall Study|Adverse Event|21
6155069|NCT01137812|9793793|FG001|Overall Study|Adverse Event|14
6155070|NCT01137812|9793792|FG000|Overall Study|Lost to Follow-up|6
6155071|NCT01137812|9793793|FG001|Overall Study|Lost to Follow-up|8
6155072|NCT01137812|9793792|FG000|Overall Study|Physician Decision|25
6155073|NCT01137812|9793793|FG001|Overall Study|Physician Decision|17
6155074|NCT01137812|9793792|FG000|Overall Study|Protocol Violation|5
6155075|NCT01137812|9793793|FG001|Overall Study|Protocol Violation|4
6155076|NCT01137812|9793792|FG000|Overall Study|Withdrawal by Subject|5
6155077|NCT01137812|9793793|FG001|Overall Study|Withdrawal by Subject|13
6155078|NCT01137812|9793792|FG000|Overall Study|Death|2
6155079|NCT01137812|9793793|FG001|Overall Study|Death|0
6155080|NCT01137812|9793792|FG000|Overall Study|Patient met glycemic withdrawal criteria|40
6155081|NCT01137812|9793793|FG001|Overall Study|Patient met glycemic withdrawal criteria|85
6155082|NCT01137812|9793792|FG000|Overall Study|Other|19
6155083|NCT01137812|9793793|FG001|Overall Study|Other|27
6155084|NCT01138007|9793857|FG000|Overall Study|Adverse Event|4
6155085|NCT01138007|9793858|FG001|Overall Study|Adverse Event|12
6155086|NCT01138007|9793859|FG002|Overall Study|Adverse Event|9
6155087|NCT01138007|9793857|FG000|Overall Study|Lack of Efficacy|2
6155088|NCT01138007|9793858|FG001|Overall Study|Lack of Efficacy|0
6155089|NCT01138007|9793859|FG002|Overall Study|Lack of Efficacy|6
6155090|NCT01138007|9793857|FG000|Overall Study|Protocol Violation|2
6155091|NCT01138007|9793858|FG001|Overall Study|Protocol Violation|3
6155092|NCT01138007|9793859|FG002|Overall Study|Protocol Violation|2
6155093|NCT01138007|9793857|FG000|Overall Study|Protocol-Defined Stopping Criteria|6
6155094|NCT01138007|9793858|FG001|Overall Study|Protocol-Defined Stopping Criteria|1
6155095|NCT01138007|9793859|FG002|Overall Study|Protocol-Defined Stopping Criteria|8
6155096|NCT01138007|9793857|FG000|Overall Study|Lost to Follow-up|3
6155097|NCT01138007|9793858|FG001|Overall Study|Lost to Follow-up|3
6155098|NCT01138007|9793859|FG002|Overall Study|Lost to Follow-up|5
6155099|NCT01138007|9793857|FG000|Overall Study|Physician Decision|0
6042046|NCT00379795|9640184|FG002|Overall Study|Sponsor's decision|54
6155100|NCT01138007|9793858|FG001|Overall Study|Physician Decision|5
6155101|NCT01138007|9793859|FG002|Overall Study|Physician Decision|3
6155102|NCT01138007|9793857|FG000|Overall Study|Withdrawal by Subject|5
6155103|NCT01138007|9793858|FG001|Overall Study|Withdrawal by Subject|6
6155104|NCT01138007|9793859|FG002|Overall Study|Withdrawal by Subject|15
6155105|NCT01138046|9793869|FG000|Overall Study|Withdrawal due to death|6
6155106|NCT01138111|9793882|FG000|Overall Study|Withdrawal by Subject|5
6155107|NCT01138111|9793882|FG000|Overall Study|Adverse Event|1
6155108|NCT01138111|9793882|FG000|Overall Study|Death|1
6155109|NCT01138111|9793882|FG000|Overall Study|Lost to Follow-up|2
6155110|NCT01138150|9793928|FG000|Overall Study|blood unable to be processed|0
6155111|NCT01138150|9793929|FG001|Overall Study|blood unable to be processed|1
6155112|NCT01138150|9793928|FG000|Overall Study|Physician Decision|1
6155113|NCT01138150|9793929|FG001|Overall Study|Physician Decision|0
6155114|NCT01138501|9793964|FG000|Overall Study|Protocol Violation|2
6155115|NCT01138501|9793964|FG000|Overall Study|Withdrawal by Subject|3
6155116|NCT01138657|9793984|FG000|Overall Study|Adverse Event|3
6155117|NCT01138657|9793985|FG001|Overall Study|Adverse Event|10
6155118|NCT01138657|9793984|FG000|Overall Study|Lack of Efficacy|2
6155119|NCT01138657|9793985|FG001|Overall Study|Lack of Efficacy|1
6155120|NCT01138657|9793984|FG000|Overall Study|Lost to Follow-up|0
6155121|NCT01138657|9793985|FG001|Overall Study|Lost to Follow-up|3
6155122|NCT01138657|9793984|FG000|Overall Study|Miscellaneous Reasons|3
6155123|NCT01138657|9793985|FG001|Overall Study|Miscellaneous Reasons|4
6155124|NCT01138826|9794002|FG000|Washout Period I (of 16 Days)|Lost to Follow-up|1
6155125|NCT01138826|9794003|FG001|Washout Period I (of 16 Days)|Lost to Follow-up|1
6155126|NCT01138826|9794004|FG002|Washout Period I (of 16 Days)|Lost to Follow-up|0
6155127|NCT01138826|9794005|FG003|Washout Period I (of 16 Days)|Lost to Follow-up|0
6155128|NCT01138826|9794006|FG004|Washout Period I (of 16 Days)|Lost to Follow-up|1
6155129|NCT01138826|9794007|FG005|Washout Period I (of 16 Days)|Lost to Follow-up|0
6155130|NCT01139008|9794042|FG000|Overall Study|Withdrawal by Subject|5
6155131|NCT01139008|9794042|FG000|Overall Study|Non-compliant, lost product|1
6155132|NCT01139021|9794055|FG000|Overall Study|Adverse Event|0
6155133|NCT01139021|9794056|FG001|Overall Study|Adverse Event|0
6155134|NCT01139021|9794057|FG002|Overall Study|Adverse Event|0
6155135|NCT01139021|9794058|FG003|Overall Study|Adverse Event|0
6227394|NCT01716754|9900111|FG003|Overall Study|Death|1
6227395|NCT01716754|9900108|FG000|Overall Study|Protocol deviation|0
6227396|NCT01716754|9900109|FG001|Overall Study|Protocol deviation|2
6227397|NCT01716754|9900110|FG002|Overall Study|Protocol deviation|7
6227398|NCT01716754|9900111|FG003|Overall Study|Protocol deviation|2
6227399|NCT01716754|9900108|FG000|Overall Study|Non-compliance with study treatment|0
6227400|NCT01716754|9900109|FG001|Overall Study|Non-compliance with study treatment|0
6227401|NCT01716754|9900110|FG002|Overall Study|Non-compliance with study treatment|1
6227402|NCT01716754|9900111|FG003|Overall Study|Non-compliance with study treatment|0
6227403|NCT01716754|9900108|FG000|Overall Study|Physician Decision|1
6227404|NCT01716754|9900109|FG001|Overall Study|Physician Decision|0
6155136|NCT01139021|9794059|FG004|Overall Study|Adverse Event|1
6227405|NCT01716754|9900110|FG002|Overall Study|Physician Decision|0
6155137|NCT01139021|9794060|FG005|Overall Study|Adverse Event|0
6155138|NCT01139021|9794055|FG000|Overall Study|Lost to Follow-up|0
6155139|NCT01139021|9794056|FG001|Overall Study|Lost to Follow-up|0
6155140|NCT01139021|9794057|FG002|Overall Study|Lost to Follow-up|0
6155141|NCT01139021|9794058|FG003|Overall Study|Lost to Follow-up|0
6155142|NCT01139021|9794059|FG004|Overall Study|Lost to Follow-up|2
6155143|NCT01139021|9794060|FG005|Overall Study|Lost to Follow-up|0
6155144|NCT01139021|9794055|FG000|Overall Study|Protocol Violation|1
6155145|NCT01139021|9794056|FG001|Overall Study|Protocol Violation|0
6155146|NCT01139021|9794057|FG002|Overall Study|Protocol Violation|0
6155147|NCT01139021|9794058|FG003|Overall Study|Protocol Violation|0
6155148|NCT01139021|9794059|FG004|Overall Study|Protocol Violation|2
6155149|NCT01139021|9794060|FG005|Overall Study|Protocol Violation|0
6155150|NCT01139021|9794055|FG000|Overall Study|Withdrawal by Subject|0
6155151|NCT01139021|9794056|FG001|Overall Study|Withdrawal by Subject|0
6155152|NCT01139021|9794057|FG002|Overall Study|Withdrawal by Subject|0
6155153|NCT01139021|9794058|FG003|Overall Study|Withdrawal by Subject|1
6155154|NCT01139021|9794059|FG004|Overall Study|Withdrawal by Subject|4
6155155|NCT01139021|9794060|FG005|Overall Study|Withdrawal by Subject|0
6155156|NCT01139047|9794075|FG000|Overall Study|Withdrawal by Subject|1
6155157|NCT01139164|9794085|FG000|Overall Study|Withdrawn prior to study start|0
6155158|NCT01139164|9794086|FG001|Overall Study|Withdrawn prior to study start|2
6155159|NCT01139164|9794087|FG002|Overall Study|Withdrawn prior to study start|0
6155160|NCT01139450|9794118|FG000|Overall Study|Withdrawal by Subject|7
6155161|NCT01139450|9794119|FG001|Overall Study|Withdrawal by Subject|10
6155162|NCT01139450|9794120|FG002|Overall Study|Withdrawal by Subject|13
6155163|NCT01139450|9794118|FG000|Overall Study|Lack of Efficacy|3
6155164|NCT01139450|9794119|FG001|Overall Study|Lack of Efficacy|1
6155165|NCT01139450|9794120|FG002|Overall Study|Lack of Efficacy|8
6155166|NCT01139450|9794118|FG000|Overall Study|Protocol Violation|6
6155167|NCT01139450|9794119|FG001|Overall Study|Protocol Violation|5
6155168|NCT01139450|9794120|FG002|Overall Study|Protocol Violation|2
6155169|NCT01139450|9794118|FG000|Overall Study|Lost to Follow-up|9
6155170|NCT01139450|9794119|FG001|Overall Study|Lost to Follow-up|7
6155171|NCT01139450|9794120|FG002|Overall Study|Lost to Follow-up|11
6155172|NCT01139450|9794118|FG000|Overall Study|Administrative|0
6155173|NCT01139450|9794119|FG001|Overall Study|Administrative|0
6155174|NCT01139450|9794120|FG002|Overall Study|Administrative|1
6155175|NCT01139450|9794118|FG000|Overall Study|Adverse Event|2
6155176|NCT01139450|9794119|FG001|Overall Study|Adverse Event|2
6155177|NCT01139450|9794120|FG002|Overall Study|Adverse Event|3
6155178|NCT01139580|9794143|FG000|Overall Study|Adverse Event|5
6155179|NCT01139580|9794144|FG001|Overall Study|Adverse Event|4
6155180|NCT01139580|9794143|FG000|Overall Study|Lost to Follow-up|9
6155181|NCT01139580|9794144|FG001|Overall Study|Lost to Follow-up|1
6155182|NCT01139580|9794143|FG000|Overall Study|Lack of Efficacy|0
6155183|NCT01139580|9794144|FG001|Overall Study|Lack of Efficacy|2
6155184|NCT01139580|9794143|FG000|Overall Study|Withdrawal by Subject|6
6155185|NCT01139580|9794144|FG001|Overall Study|Withdrawal by Subject|9
6155186|NCT01139580|9794143|FG000|Overall Study|Used Excluded Medicine After Enrollment|1
6155187|NCT01139580|9794144|FG001|Overall Study|Used Excluded Medicine After Enrollment|0
6155188|NCT01139580|9794143|FG000|Overall Study|Did Not Meet Exclusion Criteria|1
6155189|NCT01139580|9794144|FG001|Overall Study|Did Not Meet Exclusion Criteria|0
6155190|NCT01139580|9794143|FG000|Overall Study|Misrandomized|1
6155191|NCT01139580|9794144|FG001|Overall Study|Misrandomized|0
6155192|NCT01139580|9794143|FG000|Overall Study|Beginning Study Exclusion Treatment|0
6155193|NCT01139580|9794144|FG001|Overall Study|Beginning Study Exclusion Treatment|1
6155194|NCT01139580|9794143|FG000|Overall Study|Participant Randomization in Error|0
6155195|NCT01139580|9794144|FG001|Overall Study|Participant Randomization in Error|1
6155196|NCT01139658|9794152|FG000|Overall Study|Adverse Event|10
6155197|NCT01139658|9794153|FG001|Overall Study|Adverse Event|27
6155198|NCT01139658|9794152|FG000|Overall Study|Lack of Efficacy|15
6155199|NCT01139658|9794153|FG001|Overall Study|Lack of Efficacy|7
6155200|NCT01139658|9794152|FG000|Overall Study|Withdrawal by Subject|2
6155201|NCT01139658|9794153|FG001|Overall Study|Withdrawal by Subject|4
6155202|NCT01139658|9794152|FG000|Overall Study|No documentation of treatment|1
6155203|NCT01139658|9794153|FG001|Overall Study|No documentation of treatment|0
6155204|NCT01139658|9794152|FG000|Overall Study|Other|28
6155205|NCT01139658|9794153|FG001|Overall Study|Other|75
6155206|NCT01139762|9794161|FG000|Washout and Placebo Lead-In Period|Entry Criteria Not Met|258
6155207|NCT01139762|9794162|FG001|Washout and Placebo Lead-In Period|Entry Criteria Not Met|0
6155208|NCT01139762|9794163|FG002|Washout and Placebo Lead-In Period|Entry Criteria Not Met|0
6155209|NCT01139762|9794161|FG000|Washout and Placebo Lead-In Period|Adverse Event|1
6155210|NCT01139762|9794162|FG001|Washout and Placebo Lead-In Period|Adverse Event|0
6155211|NCT01139762|9794163|FG002|Washout and Placebo Lead-In Period|Adverse Event|0
6155212|NCT01139762|9794161|FG000|Washout and Placebo Lead-In Period|Withdrawal by Subject|83
6155213|NCT01139762|9794162|FG001|Washout and Placebo Lead-In Period|Withdrawal by Subject|0
6155214|NCT01139762|9794163|FG002|Washout and Placebo Lead-In Period|Withdrawal by Subject|0
6155215|NCT01139762|9794161|FG000|Washout and Placebo Lead-In Period|Physician Decision|12
6155216|NCT01139762|9794162|FG001|Washout and Placebo Lead-In Period|Physician Decision|0
6155217|NCT01139762|9794163|FG002|Washout and Placebo Lead-In Period|Physician Decision|0
6191708|NCT01425463|9848660|FG001|Overall Study|Lost to Follow-up|2
6155218|NCT01139762|9794161|FG000|Washout and Placebo Lead-In Period|Sponsor Decision|10
6155219|NCT01139762|9794162|FG001|Washout and Placebo Lead-In Period|Sponsor Decision|0
6155220|NCT01139762|9794163|FG002|Washout and Placebo Lead-In Period|Sponsor Decision|0
6155221|NCT01139762|9794161|FG000|Washout and Placebo Lead-In Period|Lost to Follow-up|10
6155222|NCT01139762|9794162|FG001|Washout and Placebo Lead-In Period|Lost to Follow-up|0
6155223|NCT01139762|9794163|FG002|Washout and Placebo Lead-In Period|Lost to Follow-up|0
6155224|NCT01139762|9794161|FG000|Double-Blind Randomized Active Treatment|Adverse Event|0
6155225|NCT01139762|9794162|FG001|Double-Blind Randomized Active Treatment|Adverse Event|4
6155226|NCT01139762|9794163|FG002|Double-Blind Randomized Active Treatment|Adverse Event|10
6155227|NCT01139762|9794161|FG000|Double-Blind Randomized Active Treatment|Death|0
6155228|NCT01139762|9794162|FG001|Double-Blind Randomized Active Treatment|Death|1
6155229|NCT01139762|9794163|FG002|Double-Blind Randomized Active Treatment|Death|1
6155230|NCT01139762|9794161|FG000|Double-Blind Randomized Active Treatment|Entry Criteria Not Met|0
6155231|NCT01139762|9794162|FG001|Double-Blind Randomized Active Treatment|Entry Criteria Not Met|14
6155232|NCT01139762|9794163|FG002|Double-Blind Randomized Active Treatment|Entry Criteria Not Met|17
6155233|NCT01139762|9794161|FG000|Double-Blind Randomized Active Treatment|Protocol Violation|0
6155234|NCT01139762|9794162|FG001|Double-Blind Randomized Active Treatment|Protocol Violation|2
6155235|NCT01139762|9794163|FG002|Double-Blind Randomized Active Treatment|Protocol Violation|8
6155236|NCT01139762|9794161|FG000|Double-Blind Randomized Active Treatment|Withdrawal by Subject|0
6155237|NCT01139762|9794162|FG001|Double-Blind Randomized Active Treatment|Withdrawal by Subject|6
6155238|NCT01139762|9794163|FG002|Double-Blind Randomized Active Treatment|Withdrawal by Subject|13
6155239|NCT01139762|9794161|FG000|Double-Blind Randomized Active Treatment|Physician Decision|0
6155240|NCT01139762|9794162|FG001|Double-Blind Randomized Active Treatment|Physician Decision|2
6155241|NCT01139762|9794163|FG002|Double-Blind Randomized Active Treatment|Physician Decision|0
6155242|NCT01139762|9794161|FG000|Double-Blind Randomized Active Treatment|Sponsor Decision|0
6155243|NCT01139762|9794162|FG001|Double-Blind Randomized Active Treatment|Sponsor Decision|5
6155244|NCT01139762|9794163|FG002|Double-Blind Randomized Active Treatment|Sponsor Decision|6
6155245|NCT01139762|9794161|FG000|Double-Blind Randomized Active Treatment|Lack of Efficacy|0
6155246|NCT01139762|9794162|FG001|Double-Blind Randomized Active Treatment|Lack of Efficacy|3
6155247|NCT01139762|9794163|FG002|Double-Blind Randomized Active Treatment|Lack of Efficacy|5
6155248|NCT01139762|9794161|FG000|Double-Blind Randomized Active Treatment|Lost to Follow-up|0
6155249|NCT01139762|9794162|FG001|Double-Blind Randomized Active Treatment|Lost to Follow-up|3
6155250|NCT01139762|9794163|FG002|Double-Blind Randomized Active Treatment|Lost to Follow-up|4
6155251|NCT01139775|9794173|FG000|Overall Study|Adverse Event|0
6155252|NCT01139775|9794174|FG001|Overall Study|Adverse Event|6
6155253|NCT01139775|9794175|FG002|Overall Study|Adverse Event|2
6155254|NCT01139775|9794173|FG000|Overall Study|Protocol Violation|0
6155255|NCT01139775|9794174|FG001|Overall Study|Protocol Violation|5
6155256|NCT01139775|9794175|FG002|Overall Study|Protocol Violation|0
6155257|NCT01139775|9794173|FG000|Overall Study|Withdrawal by Subject|1
6155258|NCT01139775|9794174|FG001|Overall Study|Withdrawal by Subject|0
6155259|NCT01139775|9794175|FG002|Overall Study|Withdrawal by Subject|2
6155260|NCT01139775|9794173|FG000|Overall Study|Physician Decision|0
6155261|NCT01139775|9794174|FG001|Overall Study|Physician Decision|2
6155262|NCT01139775|9794175|FG002|Overall Study|Physician Decision|2
6155263|NCT01140061|9794215|FG000|Part I|Adverse Event|1
6155264|NCT01140061|9794216|FG001|Part I|Adverse Event|0
6155265|NCT01140061|9794217|FG002|Part I|Adverse Event|0
6155266|NCT01140061|9794218|FG003|Part I|Adverse Event|0
6155267|NCT01140061|9794219|FG004|Part I|Adverse Event|0
6155268|NCT01140061|9794220|FG005|Part I|Adverse Event|0
6155269|NCT01140061|9794221|FG006|Part I|Adverse Event|0
6155270|NCT01140061|9794222|FG007|Part I|Adverse Event|0
6155271|NCT01140061|9794223|FG008|Part I|Adverse Event|0
6155272|NCT01140061|9794224|FG009|Part I|Adverse Event|0
6155273|NCT01140061|9794215|FG000|Extension|Laboratory Adverse Event|0
6155274|NCT01140061|9794216|FG001|Extension|Laboratory Adverse Event|0
6155275|NCT01140061|9794217|FG002|Extension|Laboratory Adverse Event|0
6155276|NCT01140061|9794218|FG003|Extension|Laboratory Adverse Event|0
6155277|NCT01140061|9794219|FG004|Extension|Laboratory Adverse Event|0
6155278|NCT01140061|9794220|FG005|Extension|Laboratory Adverse Event|0
6155279|NCT01140061|9794221|FG006|Extension|Laboratory Adverse Event|0
6155280|NCT01140061|9794222|FG007|Extension|Laboratory Adverse Event|0
6155281|NCT01140061|9794223|FG008|Extension|Laboratory Adverse Event|0
6155282|NCT01140061|9794224|FG009|Extension|Laboratory Adverse Event|1
6155283|NCT01140347|9794256|FG000|Overall Study|Lost to Follow-up|5
6155284|NCT01140347|9794257|FG001|Overall Study|Lost to Follow-up|6
6155285|NCT01140347|9794256|FG000|Overall Study|Withdrawal by Subject|13
6155286|NCT01140347|9794257|FG001|Overall Study|Withdrawal by Subject|8
6155287|NCT01140477|9794269|FG000|Overall Study|Lost to Follow-up|4
6155288|NCT01140477|9794270|FG001|Overall Study|Lost to Follow-up|0
6155289|NCT01140477|9794269|FG000|Overall Study|Withdrawal by Subject|1
6155290|NCT01140477|9794270|FG001|Overall Study|Withdrawal by Subject|4
6155291|NCT01140477|9794269|FG000|Overall Study|Surgical complication preventing implant|2
6155292|NCT01140477|9794270|FG001|Overall Study|Surgical complication preventing implant|0
6155293|NCT01140477|9794269|FG000|Overall Study|Death|1
6155294|NCT01140477|9794270|FG001|Overall Study|Death|1
6155295|NCT01140477|9794269|FG000|Overall Study|Subject explanted|0
6155296|NCT01140477|9794270|FG001|Overall Study|Subject explanted|1
6155297|NCT01140503|9794276|FG000|Overall Study|Withdrawal by Subject|1
6155298|NCT01140568|9794280|FG000|Overall Study|disease progression|31
6155299|NCT01140568|9794280|FG000|Overall Study|Withdrawal by Subject|1
6155300|NCT01140568|9794280|FG000|Overall Study|Screen Fail|4
6155301|NCT01140646|9794284|FG000|Overall Study|Adverse Event|4
6155302|NCT01140646|9794284|FG000|Overall Study|Refused Further Treatment|5
6155303|NCT01140880|9794301|FG000|Overall Study|Death|0
6155304|NCT01140880|9794302|FG001|Overall Study|Death|1
6155305|NCT01140880|9794301|FG000|Overall Study|Withdrawal by Subject|6
6155306|NCT01140880|9794302|FG001|Overall Study|Withdrawal by Subject|3
6155307|NCT01140880|9794301|FG000|Overall Study|Lost to Follow-up|8
6155308|NCT01140880|9794302|FG001|Overall Study|Lost to Follow-up|10
6155309|NCT01140880|9794301|FG000|Overall Study|Protocol Violation|0
6155310|NCT01140880|9794302|FG001|Overall Study|Protocol Violation|30
6155311|NCT01140906|9794312|FG000|Overall Study|Adverse Event|7
6155312|NCT01140906|9794313|FG001|Overall Study|Adverse Event|10
6155313|NCT01140906|9794314|FG002|Overall Study|Adverse Event|17
6155314|NCT01140906|9794315|FG003|Overall Study|Adverse Event|7
6155315|NCT01140906|9794312|FG000|Overall Study|Lack of Efficacy|6
6155316|NCT01140906|9794313|FG001|Overall Study|Lack of Efficacy|8
6155317|NCT01140906|9794314|FG002|Overall Study|Lack of Efficacy|2
6155318|NCT01140906|9794315|FG003|Overall Study|Lack of Efficacy|1
6155319|NCT01140906|9794312|FG000|Overall Study|Non-compliance|0
6155320|NCT01140906|9794313|FG001|Overall Study|Non-compliance|1
6155321|NCT01140906|9794314|FG002|Overall Study|Non-compliance|0
6155322|NCT01140906|9794315|FG003|Overall Study|Non-compliance|1
6155323|NCT01140906|9794312|FG000|Overall Study|Protocol Violation|5
6155324|NCT01140906|9794313|FG001|Overall Study|Protocol Violation|3
6155325|NCT01140906|9794314|FG002|Overall Study|Protocol Violation|2
6155326|NCT01140906|9794315|FG003|Overall Study|Protocol Violation|1
6155327|NCT01140906|9794312|FG000|Overall Study|Withdrawal of consent|6
6155328|NCT01140906|9794313|FG001|Overall Study|Withdrawal of consent|6
6155329|NCT01140906|9794314|FG002|Overall Study|Withdrawal of consent|2
6155330|NCT01140906|9794315|FG003|Overall Study|Withdrawal of consent|2
6155331|NCT01140906|9794312|FG000|Overall Study|Lost to Follow-up|1
6155332|NCT01140906|9794313|FG001|Overall Study|Lost to Follow-up|1
6155333|NCT01140906|9794314|FG002|Overall Study|Lost to Follow-up|0
6155334|NCT01140906|9794315|FG003|Overall Study|Lost to Follow-up|2
6155335|NCT01140906|9794312|FG000|Overall Study|Administrative or other reason|0
6155336|NCT01140906|9794313|FG001|Overall Study|Administrative or other reason|5
6155337|NCT01140906|9794314|FG002|Overall Study|Administrative or other reason|3
6155338|NCT01140906|9794315|FG003|Overall Study|Administrative or other reason|2
6191709|NCT01425463|9848659|FG000|Overall Study|Withdrawal by Subject|7
6191710|NCT01425463|9848660|FG001|Overall Study|Withdrawal by Subject|5
6191711|NCT01425463|9848659|FG000|Overall Study|Unknown Reason|4
6191712|NCT01425463|9848660|FG001|Overall Study|Unknown Reason|7
6191713|NCT01425528|9848668|FG000|Overall Study|Withdrawal by Subject|1
6191714|NCT01425528|9848669|FG001|Overall Study|Withdrawal by Subject|1
6193347|NCT01437397|9850966|FG000|Overall Study|Site termination/COPD exacerbation/other|10
6193348|NCT01437397|9850967|FG001|Overall Study|Site termination/COPD exacerbation/other|8
6193349|NCT01437397|9850968|FG002|Overall Study|Site termination/COPD exacerbation/other|9
6193350|NCT01437397|9850969|FG003|Overall Study|Site termination/COPD exacerbation/other|9
6193351|NCT01437397|9850970|FG004|Overall Study|Site termination/COPD exacerbation/other|14
6193352|NCT01437540|9851006|FG000|Overall Study|Not listed below|7
6193353|NCT01437540|9851007|FG001|Overall Study|Not listed below|6
6193354|NCT01437540|9851006|FG000|Overall Study|COPD exacerbation|13
6193355|NCT01437540|9851007|FG001|Overall Study|COPD exacerbation|3
6193356|NCT01437540|9851006|FG000|Overall Study|Lost to Follow-up|3
6193357|NCT01437540|9851007|FG001|Overall Study|Lost to Follow-up|5
6193358|NCT01437540|9851006|FG000|Overall Study|Lack of Efficacy|23
6193359|NCT01437540|9851007|FG001|Overall Study|Lack of Efficacy|11
6042047|NCT00379795|9640185|FG003|Overall Study|Sponsor's decision|47
6042048|NCT00379795|9640186|FG004|Overall Study|Sponsor's decision|10
6042049|NCT00379808|9640201|FG000|Intervention Period 2 (4 Weeks)|Lost to Follow-up|0
6042050|NCT00379808|9640202|FG001|Intervention Period 2 (4 Weeks)|Lost to Follow-up|1
6042051|NCT00379834|9640232|FG000|Overall Study|Time constraints|2
6155339|NCT01141205|9794340|FG000|Overall Study|Physician Decision|1
6155340|NCT01141205|9794341|FG001|Overall Study|Physician Decision|1
6155341|NCT01141205|9794340|FG000|Overall Study|Lost to Follow-up|1
6155342|NCT01141205|9794341|FG001|Overall Study|Lost to Follow-up|0
6155343|NCT01141205|9794340|FG000|Overall Study|Withdrawal by Subject|1
6155344|NCT01141205|9794341|FG001|Overall Study|Withdrawal by Subject|1
6155345|NCT01141283|9794351|FG000|Overall Study|Adverse Event|56
6155346|NCT01141283|9794351|FG000|Overall Study|Lost to Follow-up|4
6155347|NCT01141283|9794351|FG000|Overall Study|Withdrawal by Subject|14
6155348|NCT01141283|9794351|FG000|Overall Study|Administrative|4
6155349|NCT01141283|9794351|FG000|Overall Study|Lack of Efficacy|10
6155350|NCT01141478|9794372|FG000|Overall Study|Withdrawal by Subject|1
6155351|NCT01141478|9794373|FG001|Overall Study|Withdrawal by Subject|1
6155352|NCT01141660|9794416|FG000|Overall Study|Physician Decision|0
6155353|NCT01141660|9794417|FG001|Overall Study|Physician Decision|12
6155354|NCT01142089|9794443|FG000|Overall Study|Physician Decision|1
6155355|NCT01142089|9794444|FG001|Overall Study|Physician Decision|0
6155356|NCT01142089|9794443|FG000|Overall Study|Withdrawal by Subject|1
6155357|NCT01142089|9794444|FG001|Overall Study|Withdrawal by Subject|2
6042052|NCT00379899|9640238|FG000|Overall Study|Adverse Event|7
6042053|NCT00379899|9640239|FG001|Overall Study|Adverse Event|3
6155358|NCT01142089|9794443|FG000|Overall Study|Use of prohibited medications|0
6155359|NCT01142089|9794444|FG001|Overall Study|Use of prohibited medications|1
6155360|NCT01142089|9794443|FG000|Overall Study|Noncompliance with study procedures|2
6155361|NCT01142089|9794444|FG001|Overall Study|Noncompliance with study procedures|1
6155362|NCT01142089|9794443|FG000|Overall Study|Patient required rescue medication|8
6155363|NCT01142089|9794444|FG001|Overall Study|Patient required rescue medication|17
6155364|NCT01142115|9794450|FG000|First Intervention|Lack of Efficacy|1
6155365|NCT01142115|9794451|FG001|First Intervention|Lack of Efficacy|1
6155366|NCT01142115|9794450|FG000|First Intervention|Adverse Event|1
6155367|NCT01142115|9794451|FG001|First Intervention|Adverse Event|0
6155368|NCT01142193|9794458|FG000|Overall Study|Adverse Event|12
6155369|NCT01142193|9794459|FG001|Overall Study|Adverse Event|4
6155370|NCT01142193|9794458|FG000|Overall Study|Lack of Efficacy|2
6155371|NCT01142193|9794459|FG001|Overall Study|Lack of Efficacy|1
6155372|NCT01142193|9794458|FG000|Overall Study|Physician Decision|1
6155373|NCT01142193|9794459|FG001|Overall Study|Physician Decision|1
6155374|NCT01142193|9794458|FG000|Overall Study|Withdrawal by Subject|4
6155375|NCT01142193|9794459|FG001|Overall Study|Withdrawal by Subject|3
6155376|NCT01142193|9794458|FG000|Overall Study|Protocol Discontinuation Criterion Met|1
6155377|NCT01142193|9794459|FG001|Overall Study|Protocol Discontinuation Criterion Met|0
6155378|NCT01142193|9794458|FG000|Overall Study|Other|1
6155379|NCT01142193|9794459|FG001|Overall Study|Other|2
6155380|NCT01142232|9794470|FG000|Overall Study|Adverse Event|1
6155381|NCT01142232|9794471|FG001|Overall Study|Adverse Event|2
6155382|NCT01142232|9794472|FG002|Overall Study|Adverse Event|1
6155383|NCT01142232|9794473|FG003|Overall Study|Adverse Event|0
6155384|NCT01142232|9794474|FG004|Overall Study|Adverse Event|4
6155385|NCT01142232|9794470|FG000|Overall Study|Death|0
6042054|NCT00379899|9640238|FG000|Overall Study|Death|10
6042055|NCT00379899|9640239|FG001|Overall Study|Death|10
6042056|NCT00379899|9640238|FG000|Overall Study|Lost to Follow-up|2
6042057|NCT00379899|9640239|FG001|Overall Study|Lost to Follow-up|4
6042058|NCT00379899|9640238|FG000|Overall Study|Physician Decision|3
6042059|NCT00379899|9640239|FG001|Overall Study|Physician Decision|4
6042060|NCT00379899|9640238|FG000|Overall Study|Withdrawal by Subject|5
6042061|NCT00379899|9640239|FG001|Overall Study|Withdrawal by Subject|5
6042062|NCT00379899|9640238|FG000|Overall Study|Ineligibility determined|0
6042063|NCT00379899|9640239|FG001|Overall Study|Ineligibility determined|1
6042064|NCT00379899|9640238|FG000|Overall Study|Noncompliance|1
6042065|NCT00379899|9640239|FG001|Overall Study|Noncompliance|1
6155386|NCT01142232|9794471|FG001|Overall Study|Death|0
6155387|NCT01142232|9794472|FG002|Overall Study|Death|0
6155388|NCT01142232|9794473|FG003|Overall Study|Death|0
6155389|NCT01142232|9794474|FG004|Overall Study|Death|1
6042066|NCT00379899|9640238|FG000|Overall Study|Parathyroidectomy|0
6042067|NCT00379899|9640239|FG001|Overall Study|Parathyroidectomy|2
6042068|NCT00379899|9640238|FG000|Overall Study|Renal transplantation|5
6042069|NCT00379899|9640239|FG001|Overall Study|Renal transplantation|4
6155390|NCT01142232|9794470|FG000|Overall Study|Disease Progression|2
6155391|NCT01142232|9794471|FG001|Overall Study|Disease Progression|0
6155392|NCT01142232|9794472|FG002|Overall Study|Disease Progression|1
6155393|NCT01142232|9794473|FG003|Overall Study|Disease Progression|2
6155394|NCT01142232|9794474|FG004|Overall Study|Disease Progression|12
6155395|NCT01142232|9794470|FG000|Overall Study|Withdrawal by Subject|0
6155396|NCT01142232|9794471|FG001|Overall Study|Withdrawal by Subject|0
6155397|NCT01142232|9794472|FG002|Overall Study|Withdrawal by Subject|0
6155398|NCT01142232|9794473|FG003|Overall Study|Withdrawal by Subject|1
6155399|NCT01142232|9794474|FG004|Overall Study|Withdrawal by Subject|3
6042070|NCT00379899|9640238|FG000|Overall Study|Coronary artery bypass graft|1
6042071|NCT00379899|9640239|FG001|Overall Study|Coronary artery bypass graft|1
6042072|NCT00379899|9640238|FG000|Overall Study|Other protocol-specified criteria|3
6042073|NCT00379899|9640239|FG001|Overall Study|Other protocol-specified criteria|4
6042074|NCT00379899|9640238|FG000|Overall Study|Other|3
6042075|NCT00379899|9640239|FG001|Overall Study|Other|1
6042076|NCT00379912|9640247|FG000|Overall Study|Lack of Efficacy|1
6042077|NCT00379912|9640248|FG001|Overall Study|Lack of Efficacy|0
6042078|NCT00380068|9640268|FG000|Overall Study|Adverse Event|40
6155400|NCT01142232|9794470|FG000|Overall Study|Physician Decision|0
6155401|NCT01142232|9794471|FG001|Overall Study|Physician Decision|1
6155402|NCT01142232|9794472|FG002|Overall Study|Physician Decision|0
6155403|NCT01142232|9794473|FG003|Overall Study|Physician Decision|2
6155404|NCT01142232|9794474|FG004|Overall Study|Physician Decision|10
6155405|NCT01142232|9794470|FG000|Overall Study|Alternative Therapy|0
6155406|NCT01142232|9794471|FG001|Overall Study|Alternative Therapy|1
6155407|NCT01142232|9794472|FG002|Overall Study|Alternative Therapy|1
6155408|NCT01142232|9794473|FG003|Overall Study|Alternative Therapy|0
6155409|NCT01142232|9794474|FG004|Overall Study|Alternative Therapy|1
6155410|NCT01142232|9794470|FG000|Overall Study|Off Trt for other complicating disease|0
6155411|NCT01142232|9794471|FG001|Overall Study|Off Trt for other complicating disease|0
6155412|NCT01142232|9794472|FG002|Overall Study|Off Trt for other complicating disease|0
6155413|NCT01142232|9794473|FG003|Overall Study|Off Trt for other complicating disease|0
6155414|NCT01142232|9794474|FG004|Overall Study|Off Trt for other complicating disease|1
6155415|NCT01142232|9794470|FG000|Overall Study|Noncompliance|0
6155416|NCT01142232|9794471|FG001|Overall Study|Noncompliance|0
6155417|NCT01142232|9794472|FG002|Overall Study|Noncompliance|0
6155418|NCT01142232|9794473|FG003|Overall Study|Noncompliance|0
6155419|NCT01142232|9794474|FG004|Overall Study|Noncompliance|2
6155420|NCT01142336|9794510|FG000|Overall Study|Adverse Event|1
6155421|NCT01142336|9794511|FG001|Overall Study|Adverse Event|1
6155422|NCT01142336|9794510|FG000|Overall Study|Lost to Follow-up|0
6155423|NCT01142336|9794511|FG001|Overall Study|Lost to Follow-up|1
6155424|NCT01142466|9794522|FG000|Overall Study|Adverse Event|2
6155425|NCT01142466|9794523|FG001|Overall Study|Adverse Event|1
6155426|NCT01142466|9794522|FG000|Overall Study|Withdrawal by Subject|1
6155427|NCT01142466|9794523|FG001|Overall Study|Withdrawal by Subject|1
6155428|NCT01142661|9794529|FG000|Overall Study|Adverse Event|2
6155429|NCT01142661|9794529|FG000|Overall Study|Withdrawal by Subject|1
6155430|NCT01142661|9794529|FG000|Overall Study|Physician Decision|1
6155431|NCT01142726|9794536|FG000|Treatment Phase: Day 1 Through Month 12|Adverse Event|5
6155432|NCT01142726|9794537|FG001|Treatment Phase: Day 1 Through Month 12|Adverse Event|8
6155433|NCT01142726|9794538|FG002|Treatment Phase: Day 1 Through Month 12|Adverse Event|5
6155434|NCT01142726|9794536|FG000|Treatment Phase: Day 1 Through Month 12|Withdrawal by Subject|4
6155435|NCT01142726|9794537|FG001|Treatment Phase: Day 1 Through Month 12|Withdrawal by Subject|9
6155436|NCT01142726|9794538|FG002|Treatment Phase: Day 1 Through Month 12|Withdrawal by Subject|3
6155437|NCT01142726|9794536|FG000|Treatment Phase: Day 1 Through Month 12|Lost to Follow-up|1
6155438|NCT01142726|9794537|FG001|Treatment Phase: Day 1 Through Month 12|Lost to Follow-up|2
6042079|NCT00380068|9640268|FG000|Overall Study|Withdrawal by Subject|10
6155439|NCT01142726|9794538|FG002|Treatment Phase: Day 1 Through Month 12|Lost to Follow-up|1
6155440|NCT01142726|9794536|FG000|Treatment Phase: Day 1 Through Month 12|Poor compliance/noncompliance|1
6155441|NCT01142726|9794537|FG001|Treatment Phase: Day 1 Through Month 12|Poor compliance/noncompliance|0
6155442|NCT01142726|9794538|FG002|Treatment Phase: Day 1 Through Month 12|Poor compliance/noncompliance|0
6042080|NCT00380068|9640268|FG000|Overall Study|Not compliant|6
6042081|NCT00380068|9640268|FG000|Overall Study|Lost to Follow-up|1
6042082|NCT00380068|9640268|FG000|Overall Study|Addition of other PAH therapeutic agent|1
6042083|NCT00380068|9640268|FG000|Overall Study|Lung transplant|3
6042084|NCT00380068|9640268|FG000|Overall Study|Physician Decision|2
6155443|NCT01142726|9794536|FG000|Treatment Phase: Day 1 Through Month 12|Lack of Efficacy|5
6155444|NCT01142726|9794537|FG001|Treatment Phase: Day 1 Through Month 12|Lack of Efficacy|6
6155445|NCT01142726|9794538|FG002|Treatment Phase: Day 1 Through Month 12|Lack of Efficacy|11
6155446|NCT01142726|9794536|FG000|Withdrawal Phase: Months 12 up to 24|Adverse Event|0
6155447|NCT01142726|9794537|FG001|Withdrawal Phase: Months 12 up to 24|Adverse Event|0
6155448|NCT01142726|9794538|FG002|Withdrawal Phase: Months 12 up to 24|Adverse Event|1
6155449|NCT01142726|9794536|FG000|Withdrawal Phase: Months 12 up to 24|Withdrawal by Subject|1
6155450|NCT01142726|9794537|FG001|Withdrawal Phase: Months 12 up to 24|Withdrawal by Subject|1
6155451|NCT01142726|9794538|FG002|Withdrawal Phase: Months 12 up to 24|Withdrawal by Subject|2
6155452|NCT01142726|9794536|FG000|Withdrawal Phase: Months 12 up to 24|Pregnancy|1
6155453|NCT01142726|9794537|FG001|Withdrawal Phase: Months 12 up to 24|Pregnancy|0
6155454|NCT01142726|9794538|FG002|Withdrawal Phase: Months 12 up to 24|Pregnancy|1
6155455|NCT01142726|9794536|FG000|Withdrawal Phase: Months 12 up to 24|Lost to Follow-up|2
6155456|NCT01142726|9794537|FG001|Withdrawal Phase: Months 12 up to 24|Lost to Follow-up|0
6155457|NCT01142726|9794538|FG002|Withdrawal Phase: Months 12 up to 24|Lost to Follow-up|0
6155458|NCT01142726|9794536|FG000|Withdrawal Phase: Months 12 up to 24|No longer met study criteria|1
6155459|NCT01142726|9794537|FG001|Withdrawal Phase: Months 12 up to 24|No longer met study criteria|0
6155460|NCT01142726|9794538|FG002|Withdrawal Phase: Months 12 up to 24|No longer met study criteria|0
6155461|NCT01142726|9794536|FG000|Withdrawal Phase: Months 12 up to 24|Lack of Efficacy|65
6155462|NCT01142726|9794537|FG001|Withdrawal Phase: Months 12 up to 24|Lack of Efficacy|54
6155463|NCT01142726|9794538|FG002|Withdrawal Phase: Months 12 up to 24|Lack of Efficacy|53
6155464|NCT01142726|9794536|FG000|Withdrawal Phase: Months 12 up to 24|non-specified|0
6155465|NCT01142726|9794537|FG001|Withdrawal Phase: Months 12 up to 24|non-specified|1
6155466|NCT01142726|9794538|FG002|Withdrawal Phase: Months 12 up to 24|non-specified|1
6155467|NCT01142726|9794536|FG000|Re-Exposure Phase: Months 24 up to 30|Adverse Event|0
6155468|NCT01142726|9794537|FG001|Re-Exposure Phase: Months 24 up to 30|Adverse Event|0
6155469|NCT01142726|9794538|FG002|Re-Exposure Phase: Months 24 up to 30|Adverse Event|1
6155470|NCT01142726|9794536|FG000|Re-Exposure Phase: Months 24 up to 30|Withdrawal by Subject|1
6155471|NCT01142726|9794537|FG001|Re-Exposure Phase: Months 24 up to 30|Withdrawal by Subject|1
6155472|NCT01142726|9794538|FG002|Re-Exposure Phase: Months 24 up to 30|Withdrawal by Subject|1
6155473|NCT01142726|9794536|FG000|Re-Exposure Phase: Months 24 up to 30|Pregnancy|0
6155474|NCT01142726|9794537|FG001|Re-Exposure Phase: Months 24 up to 30|Pregnancy|0
6155475|NCT01142726|9794538|FG002|Re-Exposure Phase: Months 24 up to 30|Pregnancy|1
6155476|NCT01142726|9794536|FG000|Re-Exposure Phase: Months 24 up to 30|Lack of Efficacy|0
6155477|NCT01142726|9794537|FG001|Re-Exposure Phase: Months 24 up to 30|Lack of Efficacy|1
6155478|NCT01142726|9794538|FG002|Re-Exposure Phase: Months 24 up to 30|Lack of Efficacy|0
6155479|NCT01142791|9794554|FG000|Overall Study|Alternative Treatment|1
6155480|NCT01142791|9794555|FG001|Overall Study|Alternative Treatment|0
6155481|NCT01142791|9794554|FG000|Overall Study|Lost to Follow-up|1
6155482|NCT01142791|9794555|FG001|Overall Study|Lost to Follow-up|0
6155483|NCT01142791|9794554|FG000|Overall Study|Withdrawal by Subject|5
6155484|NCT01142791|9794555|FG001|Overall Study|Withdrawal by Subject|0
6155485|NCT01142791|9794554|FG000|Overall Study|Received only 1 sonication|0
6155486|NCT01142791|9794555|FG001|Overall Study|Received only 1 sonication|6
6155487|NCT01142908|9794561|FG000|Overall Study|Lost to Follow-up|19
6155488|NCT01142908|9794562|FG001|Overall Study|Lost to Follow-up|13
6155489|NCT01142908|9794561|FG000|Overall Study|Death|1
6042085|NCT00380068|9640268|FG000|Overall Study|Partipant moved away|1
6042086|NCT00380068|9640268|FG000|Overall Study|Lack of Efficacy|5
6042087|NCT00380081|9640278|FG000|Overall Study|Withdrawal by Subject|0
6042088|NCT00380081|9640279|FG001|Overall Study|Withdrawal by Subject|0
6042089|NCT00380081|9640280|FG002|Overall Study|Withdrawal by Subject|0
6042090|NCT00380081|9640281|FG003|Overall Study|Withdrawal by Subject|0
6042091|NCT00380081|9640282|FG004|Overall Study|Withdrawal by Subject|1
6042092|NCT00380081|9640283|FG005|Overall Study|Withdrawal by Subject|0
6042093|NCT00380081|9640278|FG000|Overall Study|Family Emergency|0
6155490|NCT01142908|9794562|FG001|Overall Study|Death|4
6155491|NCT01142908|9794561|FG000|Overall Study|Excluded - did not meet criteria|9
6324443|NCT02914522|10066050|FG005|Maintenance Study: Week 11 to Week 58|Protocol-specified Disease Worsening|0
6324444|NCT02914522|10066051|FG006|Maintenance Study: Week 11 to Week 58|Protocol-specified Disease Worsening|34
6324445|NCT02914522|10066052|FG007|Maintenance Study: Week 11 to Week 58|Protocol-specified Disease Worsening|49
6324446|NCT02914522|10066053|FG008|Maintenance Study: Week 11 to Week 58|Protocol-specified Disease Worsening|53
6324447|NCT02914522|10066054|FG009|Maintenance Study: Week 11 to Week 58|Protocol-specified Disease Worsening|39
6324448|NCT02914522|10066055|FG010|Maintenance Study: Week 11 to Week 58|Protocol-specified Disease Worsening|21
6324449|NCT02914522|10066045|FG000|Maintenance Study: Week 11 to Week 58|Adverse Event|0
6324450|NCT02914522|10066046|FG001|Maintenance Study: Week 11 to Week 58|Adverse Event|0
6324451|NCT02914522|10066047|FG002|Maintenance Study: Week 11 to Week 58|Adverse Event|0
6324452|NCT02914522|10066048|FG003|Maintenance Study: Week 11 to Week 58|Adverse Event|0
6324453|NCT02914522|10066049|FG004|Maintenance Study: Week 11 to Week 58|Adverse Event|0
6324454|NCT02914522|10066050|FG005|Maintenance Study: Week 11 to Week 58|Adverse Event|0
6324455|NCT02914522|10066051|FG006|Maintenance Study: Week 11 to Week 58|Adverse Event|7
6324456|NCT02914522|10066052|FG007|Maintenance Study: Week 11 to Week 58|Adverse Event|2
6324457|NCT02914522|10066053|FG008|Maintenance Study: Week 11 to Week 58|Adverse Event|10
6324458|NCT02914522|10066054|FG009|Maintenance Study: Week 11 to Week 58|Adverse Event|4
6324459|NCT02914522|10066055|FG010|Maintenance Study: Week 11 to Week 58|Adverse Event|3
6324460|NCT02914522|10066045|FG000|Maintenance Study: Week 11 to Week 58|Protocol Violation|0
6324461|NCT02914522|10066046|FG001|Maintenance Study: Week 11 to Week 58|Protocol Violation|0
6324462|NCT02914522|10066047|FG002|Maintenance Study: Week 11 to Week 58|Protocol Violation|0
6324463|NCT02914522|10066048|FG003|Maintenance Study: Week 11 to Week 58|Protocol Violation|0
6324464|NCT02914522|10066049|FG004|Maintenance Study: Week 11 to Week 58|Protocol Violation|0
6324465|NCT02914522|10066050|FG005|Maintenance Study: Week 11 to Week 58|Protocol Violation|0
6324466|NCT02914522|10066051|FG006|Maintenance Study: Week 11 to Week 58|Protocol Violation|5
6324467|NCT02914522|10066052|FG007|Maintenance Study: Week 11 to Week 58|Protocol Violation|5
6324468|NCT02914522|10066053|FG008|Maintenance Study: Week 11 to Week 58|Protocol Violation|3
6155492|NCT01142908|9794562|FG001|Overall Study|Excluded - did not meet criteria|5
6155493|NCT01142908|9794561|FG000|Overall Study|Withdrawal by Subject|3
6155494|NCT01142908|9794562|FG001|Overall Study|Withdrawal by Subject|0
6155495|NCT01143038|9794572|FG000|Overall Study|Withdrawal by Subject|4
6155496|NCT01143038|9794572|FG000|Overall Study|Requirement for alternative therapy|5
6155497|NCT01143038|9794572|FG000|Overall Study|Adverse Event|3
6155498|NCT01143038|9794572|FG000|Overall Study|Lost to Follow-up|2
6155499|NCT01143038|9794572|FG000|Overall Study|Protocol Deviation|1
6155500|NCT01143038|9794572|FG000|Overall Study|Death|1
6155501|NCT01143051|9794582|FG000|3-14 Day Washout|Withdrawal by Subject|0
6042094|NCT00380081|9640279|FG001|Overall Study|Family Emergency|0
6042095|NCT00380081|9640280|FG002|Overall Study|Family Emergency|0
6042096|NCT00380081|9640281|FG003|Overall Study|Family Emergency|0
6042097|NCT00380081|9640282|FG004|Overall Study|Family Emergency|0
6042098|NCT00380081|9640283|FG005|Overall Study|Family Emergency|1
6042099|NCT00380250|9640293|FG000|Overall Study|Withdrawal by Subject|39
6042100|NCT00380250|9640294|FG001|Overall Study|Withdrawal by Subject|28
6042101|NCT00380250|9640293|FG000|Overall Study|Adverse Event|20
6042102|NCT00380250|9640294|FG001|Overall Study|Adverse Event|9
6042103|NCT00380250|9640293|FG000|Overall Study|Lack of Efficacy|10
6042104|NCT00380250|9640294|FG001|Overall Study|Lack of Efficacy|8
6042105|NCT00380250|9640293|FG000|Overall Study|Protocol Violation|15
6042106|NCT00380250|9640294|FG001|Overall Study|Protocol Violation|5
6042107|NCT00380250|9640293|FG000|Overall Study|Lost to Follow-up|14
6042108|NCT00380250|9640294|FG001|Overall Study|Lost to Follow-up|5
6042109|NCT00380250|9640293|FG000|Overall Study|Physician Decision|1
6042110|NCT00380250|9640294|FG001|Overall Study|Physician Decision|0
6042111|NCT00380367|9640300|FG000|Overall Study|Lost to Follow-up|1
6042112|NCT00380367|9640300|FG000|Overall Study|Withdrawal by Subject|1
6042113|NCT00380393|9640306|FG000|Month 8 (Cross-sectional Visit)|Withdrawal by Subject|6
6042114|NCT00380393|9640307|FG001|Month 8 (Cross-sectional Visit)|Withdrawal by Subject|5
6042115|NCT00380393|9640306|FG000|Month 8 (Cross-sectional Visit)|Lost to Follow-up|0
6042116|NCT00380393|9640307|FG001|Month 8 (Cross-sectional Visit)|Lost to Follow-up|1
6042117|NCT00380393|9640306|FG000|Month 8 (Cross-sectional Visit)|Migrated/moved from study area|37
6042118|NCT00380393|9640307|FG001|Month 8 (Cross-sectional Visit)|Migrated/moved from study area|29
6042119|NCT00380393|9640306|FG000|Month 8 (Cross-sectional Visit)|Serious Adverse Event|1
6042120|NCT00380393|9640307|FG001|Month 8 (Cross-sectional Visit)|Serious Adverse Event|1
6042121|NCT00380393|9640306|FG000|Month 8 (Cross-sectional Visit)|Others|5
6042122|NCT00380393|9640307|FG001|Month 8 (Cross-sectional Visit)|Others|4
6042123|NCT00380393|9640306|FG000|Month 14|Withdrawal by Subject|9
6042124|NCT00380393|9640307|FG001|Month 14|Withdrawal by Subject|7
6042125|NCT00380393|9640306|FG000|Month 14|Death|1
6042126|NCT00380393|9640307|FG001|Month 14|Death|0
6042127|NCT00380393|9640306|FG000|Month 14|Lost to Follow-up|0
6042128|NCT00380393|9640307|FG001|Month 14|Lost to Follow-up|1
6042129|NCT00380393|9640306|FG000|Month 14|Migrated/moved from study area|39
6155502|NCT01143051|9794583|FG001|3-14 Day Washout|Withdrawal by Subject|0
6155503|NCT01143051|9794584|FG002|3-14 Day Washout|Withdrawal by Subject|1
6155504|NCT01143051|9794585|FG003|3-14 Day Washout|Withdrawal by Subject|0
6155505|NCT01143051|9794586|FG004|3-14 Day Washout|Withdrawal by Subject|0
6155506|NCT01143051|9794587|FG005|3-14 Day Washout|Withdrawal by Subject|0
6155507|NCT01143051|9794582|FG000|3-14 Day Washout|Withdrawal by Subject|0
6042130|NCT00380393|9640307|FG001|Month 14|Migrated/moved from study area|42
6080375|NCT00615836|9687577|FG003|Extension Study (FE992026 CS31)|Serum sodium ≤125 mmol/L|3
6080376|NCT00615836|9687578|FG004|Extension Study (FE992026 CS31)|Serum sodium ≤125 mmol/L|0
6080377|NCT00615836|9687574|FG000|Extension Study (FE992026 CS31)|Use of exclusionary medication|1
6042131|NCT00380393|9640306|FG000|Month 14|Protocol Violation|2
6042132|NCT00380393|9640307|FG001|Month 14|Protocol Violation|0
6042133|NCT00380393|9640306|FG000|Month 14|Others|6
6042134|NCT00380393|9640307|FG001|Month 14|Others|6
6042135|NCT00380588|9640315|FG000|Overall Study|Unequivocal Disease Progression|25
6042136|NCT00380588|9640316|FG001|Overall Study|Unequivocal Disease Progression|34
6042137|NCT00380588|9640315|FG000|Overall Study|Next Cycle Not Started|4
6042138|NCT00380588|9640316|FG001|Overall Study|Next Cycle Not Started|0
6155508|NCT01143051|9794583|FG001|3-14 Day Washout|Withdrawal by Subject|0
6155509|NCT01143051|9794584|FG002|3-14 Day Washout|Withdrawal by Subject|0
6155510|NCT01143051|9794585|FG003|3-14 Day Washout|Withdrawal by Subject|0
6080378|NCT00615836|9687575|FG001|Extension Study (FE992026 CS31)|Use of exclusionary medication|2
6080379|NCT00615836|9687576|FG002|Extension Study (FE992026 CS31)|Use of exclusionary medication|1
6080380|NCT00615836|9687577|FG003|Extension Study (FE992026 CS31)|Use of exclusionary medication|0
6080381|NCT00615836|9687578|FG004|Extension Study (FE992026 CS31)|Use of exclusionary medication|0
6080382|NCT00615836|9687574|FG000|Extension Study (FE992026 CS31)|Protocol Violation|4
6080383|NCT00615836|9687575|FG001|Extension Study (FE992026 CS31)|Protocol Violation|5
6080384|NCT00615836|9687576|FG002|Extension Study (FE992026 CS31)|Protocol Violation|2
6080385|NCT00615836|9687577|FG003|Extension Study (FE992026 CS31)|Protocol Violation|3
6042139|NCT00380588|9640315|FG000|Overall Study|Adverse Event|7
6042140|NCT00380588|9640316|FG001|Overall Study|Adverse Event|3
6324469|NCT02914522|10066054|FG009|Maintenance Study: Week 11 to Week 58|Protocol Violation|0
6324470|NCT02914522|10066055|FG010|Maintenance Study: Week 11 to Week 58|Protocol Violation|1
6042141|NCT00380588|9640315|FG000|Overall Study|Withdrawal by Subject|1
6042142|NCT00380588|9640316|FG001|Overall Study|Withdrawal by Subject|3
6042143|NCT00380588|9640315|FG000|Overall Study|Physician Decision|2
6042144|NCT00380588|9640316|FG001|Overall Study|Physician Decision|0
6042145|NCT00380692|9640324|FG000|Study Period II - Double Blind|Adverse Event|1
6042146|NCT00380692|9640325|FG001|Study Period II - Double Blind|Adverse Event|0
6042147|NCT00380692|9640324|FG000|Study Period II - Double Blind|Protocol Violation|2
6042148|NCT00380692|9640325|FG001|Study Period II - Double Blind|Protocol Violation|2
6042149|NCT00380692|9640324|FG000|Study Period II - Double Blind|Withdrawal by Subject|0
6042150|NCT00380692|9640325|FG001|Study Period II - Double Blind|Withdrawal by Subject|0
6042151|NCT00380692|9640324|FG000|Study Period II - Double Blind|Physician Decision|0
6042152|NCT00380692|9640325|FG001|Study Period II - Double Blind|Physician Decision|1
6042153|NCT00380692|9640324|FG000|Study Period II - Double Blind|Lack of Efficacy|1
6042154|NCT00380692|9640325|FG001|Study Period II - Double Blind|Lack of Efficacy|0
6042155|NCT00380692|9640324|FG000|Study Period II - Double Blind|Parent/Caregiver Decision|1
6324471|NCT02914522|10066045|FG000|Maintenance Study: Week 11 to Week 58|Withdrew Consent|0
6324472|NCT02914522|10066046|FG001|Maintenance Study: Week 11 to Week 58|Withdrew Consent|0
6324473|NCT02914522|10066047|FG002|Maintenance Study: Week 11 to Week 58|Withdrew Consent|0
6324474|NCT02914522|10066048|FG003|Maintenance Study: Week 11 to Week 58|Withdrew Consent|0
6324475|NCT02914522|10066049|FG004|Maintenance Study: Week 11 to Week 58|Withdrew Consent|0
6324476|NCT02914522|10066050|FG005|Maintenance Study: Week 11 to Week 58|Withdrew Consent|0
6324477|NCT02914522|10066051|FG006|Maintenance Study: Week 11 to Week 58|Withdrew Consent|4
6324478|NCT02914522|10066052|FG007|Maintenance Study: Week 11 to Week 58|Withdrew Consent|1
6324479|NCT02914522|10066053|FG008|Maintenance Study: Week 11 to Week 58|Withdrew Consent|6
6324480|NCT02914522|10066054|FG009|Maintenance Study: Week 11 to Week 58|Withdrew Consent|3
6324481|NCT02914522|10066055|FG010|Maintenance Study: Week 11 to Week 58|Withdrew Consent|4
6324482|NCT02914522|10066045|FG000|Maintenance Study: Week 11 to Week 58|Death|0
6324483|NCT02914522|10066046|FG001|Maintenance Study: Week 11 to Week 58|Death|0
6324484|NCT02914522|10066047|FG002|Maintenance Study: Week 11 to Week 58|Death|0
6324485|NCT02914522|10066048|FG003|Maintenance Study: Week 11 to Week 58|Death|0
6324486|NCT02914522|10066049|FG004|Maintenance Study: Week 11 to Week 58|Death|0
6324487|NCT02914522|10066050|FG005|Maintenance Study: Week 11 to Week 58|Death|0
6324488|NCT02914522|10066051|FG006|Maintenance Study: Week 11 to Week 58|Death|2
6042156|NCT00380692|9640325|FG001|Study Period II - Double Blind|Parent/Caregiver Decision|0
6042157|NCT00380692|9640324|FG000|Study Period III - Open Label|Adverse Event|5
6087668|NCT00669942|9698117|FG001|Parts 2 and 3|Adverse Event|0
6049014|NCT00420927|9648205|FG006|Period 2|Randomization error|0
6080386|NCT00615836|9687578|FG004|Extension Study (FE992026 CS31)|Protocol Violation|0
6080387|NCT00615836|9687574|FG000|Extension Study (FE992026 CS31)|Withdrawal by Subject|37
6080388|NCT00615836|9687575|FG001|Extension Study (FE992026 CS31)|Withdrawal by Subject|42
6080389|NCT00615836|9687576|FG002|Extension Study (FE992026 CS31)|Withdrawal by Subject|38
6080390|NCT00615836|9687577|FG003|Extension Study (FE992026 CS31)|Withdrawal by Subject|43
6155511|NCT01143051|9794586|FG004|3-14 Day Washout|Withdrawal by Subject|0
6155512|NCT01143051|9794587|FG005|3-14 Day Washout|Withdrawal by Subject|1
6155513|NCT01143077|9794600|FG000|Overall Study|Lack of Efficacy|0
6155514|NCT01143077|9794601|FG001|Overall Study|Lack of Efficacy|2
6080391|NCT00615836|9687578|FG004|Extension Study (FE992026 CS31)|Withdrawal by Subject|0
6080392|NCT00615836|9687574|FG000|Extension Study (FE992026 CS31)|Lost to Follow-up|10
6155515|NCT01143077|9794602|FG002|Overall Study|Lack of Efficacy|1
6155516|NCT01143077|9794600|FG000|Overall Study|Adverse Event|5
6155517|NCT01143077|9794601|FG001|Overall Study|Adverse Event|6
6155518|NCT01143077|9794602|FG002|Overall Study|Adverse Event|5
6155519|NCT01143077|9794600|FG000|Overall Study|Lost to Follow-up|2
6155520|NCT01143077|9794601|FG001|Overall Study|Lost to Follow-up|3
6155521|NCT01143077|9794602|FG002|Overall Study|Lost to Follow-up|4
6155522|NCT01143077|9794600|FG000|Overall Study|Protocol Violation|2
6155523|NCT01143077|9794601|FG001|Overall Study|Protocol Violation|0
6324489|NCT02914522|10066052|FG007|Maintenance Study: Week 11 to Week 58|Death|0
6324490|NCT02914522|10066053|FG008|Maintenance Study: Week 11 to Week 58|Death|0
6324491|NCT02914522|10066054|FG009|Maintenance Study: Week 11 to Week 58|Death|0
6324492|NCT02914522|10066055|FG010|Maintenance Study: Week 11 to Week 58|Death|0
6324493|NCT02914522|10066045|FG000|Maintenance Study: Week 11 to Week 58|Investigator's Discretion|0
6324494|NCT02914522|10066046|FG001|Maintenance Study: Week 11 to Week 58|Investigator's Discretion|0
6324495|NCT02914522|10066047|FG002|Maintenance Study: Week 11 to Week 58|Investigator's Discretion|0
6324496|NCT02914522|10066048|FG003|Maintenance Study: Week 11 to Week 58|Investigator's Discretion|0
6324497|NCT02914522|10066049|FG004|Maintenance Study: Week 11 to Week 58|Investigator's Discretion|0
6324498|NCT02914522|10066050|FG005|Maintenance Study: Week 11 to Week 58|Investigator's Discretion|0
6324499|NCT02914522|10066051|FG006|Maintenance Study: Week 11 to Week 58|Investigator's Discretion|0
6324500|NCT02914522|10066052|FG007|Maintenance Study: Week 11 to Week 58|Investigator's Discretion|1
6324501|NCT02914522|10066053|FG008|Maintenance Study: Week 11 to Week 58|Investigator's Discretion|2
6324502|NCT02914522|10066054|FG009|Maintenance Study: Week 11 to Week 58|Investigator's Discretion|0
6155524|NCT01143077|9794602|FG002|Overall Study|Protocol Violation|0
6155525|NCT01143077|9794600|FG000|Overall Study|Withdrawal by Subject|4
6155526|NCT01143077|9794601|FG001|Overall Study|Withdrawal by Subject|3
6155527|NCT01143077|9794602|FG002|Overall Study|Withdrawal by Subject|3
6155528|NCT01143077|9794600|FG000|Overall Study|Non-compliance with study drug|0
6155529|NCT01143077|9794601|FG001|Overall Study|Non-compliance with study drug|1
6155530|NCT01143077|9794602|FG002|Overall Study|Non-compliance with study drug|1
6155531|NCT01143077|9794600|FG000|Overall Study|Administrative|1
6155532|NCT01143077|9794601|FG001|Overall Study|Administrative|0
6155533|NCT01143077|9794602|FG002|Overall Study|Administrative|0
6155534|NCT01143077|9794600|FG000|Overall Study|Principal Investigator Decision|2
6155535|NCT01143077|9794601|FG001|Overall Study|Principal Investigator Decision|0
6155536|NCT01143077|9794602|FG002|Overall Study|Principal Investigator Decision|1
6155537|NCT01143090|9794610|FG000|Overall Study|Lack of Efficacy|2
6155538|NCT01143090|9794610|FG000|Overall Study|Adverse Event|17
6155539|NCT01143090|9794610|FG000|Overall Study|Lost to Follow-up|9
6155540|NCT01143090|9794610|FG000|Overall Study|Protocol Violation|2
6155541|NCT01143090|9794610|FG000|Overall Study|Withdrawal by Subject|18
6155542|NCT01143090|9794610|FG000|Overall Study|Non-compliance with study drug|1
6155543|NCT01143090|9794610|FG000|Overall Study|Failure to meet eligibility criteria|1
6155544|NCT01143090|9794610|FG000|Overall Study|Administrative|1
6155545|NCT01143207|9794640|FG000|Overall Study|Lost to Follow-up|2
6155546|NCT01143259|9794646|FG000|Overall Study|Withdrawal by Subject|3
6324503|NCT02914522|10066055|FG010|Maintenance Study: Week 11 to Week 58|Investigator's Discretion|0
6324504|NCT02914522|10066045|FG000|Maintenance Study: Week 11 to Week 58|Pregnancy|0
6324505|NCT02914522|10066046|FG001|Maintenance Study: Week 11 to Week 58|Pregnancy|0
6324506|NCT02914522|10066047|FG002|Maintenance Study: Week 11 to Week 58|Pregnancy|0
6324507|NCT02914522|10066048|FG003|Maintenance Study: Week 11 to Week 58|Pregnancy|0
6324508|NCT02914522|10066049|FG004|Maintenance Study: Week 11 to Week 58|Pregnancy|0
6324509|NCT02914522|10066050|FG005|Maintenance Study: Week 11 to Week 58|Pregnancy|0
6324510|NCT02914522|10066051|FG006|Maintenance Study: Week 11 to Week 58|Pregnancy|0
6324511|NCT02914522|10066052|FG007|Maintenance Study: Week 11 to Week 58|Pregnancy|0
6324512|NCT02914522|10066053|FG008|Maintenance Study: Week 11 to Week 58|Pregnancy|1
6324513|NCT02914522|10066054|FG009|Maintenance Study: Week 11 to Week 58|Pregnancy|2
6324514|NCT02914522|10066055|FG010|Maintenance Study: Week 11 to Week 58|Pregnancy|0
6324515|NCT02914522|10066045|FG000|Maintenance Study: Week 11 to Week 58|Non-compliance With Study Drug|0
6324516|NCT02914522|10066046|FG001|Maintenance Study: Week 11 to Week 58|Non-compliance With Study Drug|0
6324517|NCT02914522|10066047|FG002|Maintenance Study: Week 11 to Week 58|Non-compliance With Study Drug|0
6324518|NCT02914522|10066048|FG003|Maintenance Study: Week 11 to Week 58|Non-compliance With Study Drug|0
6324519|NCT02914522|10066049|FG004|Maintenance Study: Week 11 to Week 58|Non-compliance With Study Drug|0
6324520|NCT02914522|10066050|FG005|Maintenance Study: Week 11 to Week 58|Non-compliance With Study Drug|0
6324521|NCT02914522|10066051|FG006|Maintenance Study: Week 11 to Week 58|Non-compliance With Study Drug|0
6324522|NCT02914522|10066052|FG007|Maintenance Study: Week 11 to Week 58|Non-compliance With Study Drug|0
6324523|NCT02914522|10066053|FG008|Maintenance Study: Week 11 to Week 58|Non-compliance With Study Drug|0
6324524|NCT02914522|10066054|FG009|Maintenance Study: Week 11 to Week 58|Non-compliance With Study Drug|1
6324525|NCT02914522|10066055|FG010|Maintenance Study: Week 11 to Week 58|Non-compliance With Study Drug|0
6324526|NCT02914548|10066085|FG000|Overall Study|Adverse Event|15
6324527|NCT02914548|10066086|FG001|Overall Study|Adverse Event|7
6324528|NCT02914548|10066087|FG002|Overall Study|Adverse Event|15
6324529|NCT02914548|10066085|FG000|Overall Study|Physician Decision|2
6324530|NCT02914548|10066086|FG001|Overall Study|Physician Decision|2
6324531|NCT02914548|10066087|FG002|Overall Study|Physician Decision|0
6324532|NCT02914548|10066085|FG000|Overall Study|Protocol Violation|1
6324533|NCT02914548|10066086|FG001|Overall Study|Protocol Violation|0
6324534|NCT02914548|10066087|FG002|Overall Study|Protocol Violation|0
6324535|NCT02914548|10066085|FG000|Overall Study|Withdrawal by Subject|3
6324536|NCT02914548|10066086|FG001|Overall Study|Withdrawal by Subject|4
6324537|NCT02914548|10066087|FG002|Overall Study|Withdrawal by Subject|4
6324538|NCT02914548|10066085|FG000|Overall Study|>40% of body surface area|0
6324539|NCT02914548|10066086|FG001|Overall Study|>40% of body surface area|1
6324540|NCT02914548|10066087|FG002|Overall Study|>40% of body surface area|1
6324541|NCT02914834|10066108|FG000|Overall Study|Study halted due to COVID|1
6324542|NCT02914834|10066109|FG001|Overall Study|Study halted due to COVID|1
6324543|NCT02914834|10066108|FG000|Overall Study|1 subject withdrew|0
6324544|NCT02914834|10066109|FG001|Overall Study|1 subject withdrew|1
6324545|NCT02915159|10066126|FG000|Overall Study|Participant no longer meets criteria|2
6324546|NCT02915159|10066127|FG001|Overall Study|Participant no longer meets criteria|0
6324547|NCT02915159|10066126|FG000|Overall Study|poor/non-compliance|1
6324548|NCT02915159|10066127|FG001|Overall Study|poor/non-compliance|0
6324549|NCT02915159|10066126|FG000|Overall Study|Participant withdrew consent|5
6324550|NCT02915159|10066127|FG001|Overall Study|Participant withdrew consent|1
6324551|NCT02915159|10066126|FG000|Overall Study|Request to discontinue treatment|1
6324552|NCT02915159|10066127|FG001|Overall Study|Request to discontinue treatment|2
6324553|NCT02915159|10066126|FG000|Overall Study|Adverse Event|2
6324554|NCT02915159|10066127|FG001|Overall Study|Adverse Event|2
6324555|NCT02915159|10066126|FG000|Overall Study|Lack of Efficacy|0
6324556|NCT02915159|10066127|FG001|Overall Study|Lack of Efficacy|3
6155547|NCT01143259|9794647|FG001|Overall Study|Withdrawal by Subject|2
6155548|NCT01143259|9794646|FG000|Overall Study|Protocol Violation|13
6155549|NCT01143259|9794647|FG001|Overall Study|Protocol Violation|9
6155550|NCT01143259|9794646|FG000|Overall Study|Screen Failure|7
6155551|NCT01143259|9794647|FG001|Overall Study|Screen Failure|9
6155552|NCT01143324|9794662|FG000|Overall Study|Lost to Follow-up|11
6155553|NCT01143324|9794662|FG000|Overall Study|Withdrawal by Subject|4
6324557|NCT02915835|10066162|FG000|Overall Study|Physician Decision|1
6155554|NCT01143324|9794662|FG000|Overall Study|Explant of the device|4
6155555|NCT01143337|9794668|FG000|Overall Study|Adverse Event|3
6155556|NCT01143337|9794669|FG001|Overall Study|Adverse Event|9
6155557|NCT01143337|9794670|FG002|Overall Study|Adverse Event|5
6155558|NCT01143337|9794668|FG000|Overall Study|Lack of Efficacy|6
6155559|NCT01143337|9794669|FG001|Overall Study|Lack of Efficacy|2
6155560|NCT01143337|9794670|FG002|Overall Study|Lack of Efficacy|1
6042158|NCT00380692|9640325|FG001|Study Period III - Open Label|Adverse Event|3
6042159|NCT00380692|9640324|FG000|Study Period III - Open Label|Protocol Violation|0
6042160|NCT00380692|9640325|FG001|Study Period III - Open Label|Protocol Violation|0
6042161|NCT00380692|9640324|FG000|Study Period III - Open Label|Withdrawal by Subject|0
6042162|NCT00380692|9640325|FG001|Study Period III - Open Label|Withdrawal by Subject|1
6155561|NCT01143337|9794668|FG000|Overall Study|Protocol Violation|1
6155562|NCT01143337|9794669|FG001|Overall Study|Protocol Violation|0
6324558|NCT02915835|10066163|FG001|Overall Study|Physician Decision|0
6324559|NCT02915835|10066162|FG000|Overall Study|Withdrawal by Subject|0
6324560|NCT02915835|10066163|FG001|Overall Study|Withdrawal by Subject|1
6324561|NCT02915874|10066171|FG000|Overall Study|Lost to Follow-up|5
6324562|NCT02915874|10066172|FG001|Overall Study|Lost to Follow-up|4
6324563|NCT02915874|10066171|FG000|Overall Study|Withdrawal by Subject|1
6324564|NCT02915874|10066172|FG001|Overall Study|Withdrawal by Subject|1
6324565|NCT02915874|10066171|FG000|Overall Study|Started New Anxiety Medication|0
6324566|NCT02915874|10066172|FG001|Overall Study|Started New Anxiety Medication|1
6324567|NCT02915978|10066181|FG000|Overall Study|Adverse Event|2
6324568|NCT02915978|10066182|FG001|Overall Study|Adverse Event|1
6324569|NCT02915978|10066183|FG002|Overall Study|Adverse Event|0
6324570|NCT02916056|10066191|FG000|Overall Study|Adverse Event|6
6324571|NCT02916056|10066191|FG000|Overall Study|Lost to Follow-up|1
6324572|NCT02916056|10066191|FG000|Overall Study|Other|12
6324573|NCT02916056|10066191|FG000|Overall Study|Protocol Violation|1
6324574|NCT02916056|10066191|FG000|Overall Study|Withdrawal by Subject|8
6324575|NCT02916056|10066191|FG000|Overall Study|Study Terminated by Sponsor|269
6324576|NCT02916433|10066206|FG000|Overall Study|Withdrawal by Subject|1
6324577|NCT02916433|10066207|FG001|Overall Study|Withdrawal by Subject|0
6324578|NCT02916433|10066206|FG000|Overall Study|Physician Decision|1
6324579|NCT02916433|10066207|FG001|Overall Study|Physician Decision|0
6324580|NCT02916693|10066229|FG000|Overall Study|Lost to Follow-up|7
6324581|NCT02916927|10066243|FG000|Overall Study|Discharged prior to study drug receipt|0
6324582|NCT02916927|10066244|FG001|Overall Study|Discharged prior to study drug receipt|2
6324583|NCT02916927|10066243|FG000|Overall Study|At radiology for 45 & 60 min time points|0
6324584|NCT02916927|10066244|FG001|Overall Study|At radiology for 45 & 60 min time points|1
6155563|NCT01143337|9794670|FG002|Overall Study|Protocol Violation|0
6155564|NCT01143337|9794668|FG000|Overall Study|Withdrawal by Subject|0
6155565|NCT01143337|9794669|FG001|Overall Study|Withdrawal by Subject|0
6155566|NCT01143337|9794670|FG002|Overall Study|Withdrawal by Subject|1
6324585|NCT02916927|10066243|FG000|Overall Study|Withdrawal before first time point|1
6155567|NCT01143337|9794668|FG000|Overall Study|Other reason|0
6155568|NCT01143337|9794669|FG001|Overall Study|Other reason|0
6155569|NCT01143337|9794670|FG002|Overall Study|Other reason|5
6155570|NCT01143389|9794678|FG000|Overall Study|Lost to Follow-up|26
6155571|NCT01143389|9794679|FG001|Overall Study|Lost to Follow-up|25
6155572|NCT01143402|9794688|FG000|Overall Study|Rapid clinical decline|1
6155573|NCT01143402|9794689|FG001|Overall Study|Rapid clinical decline|1
6155574|NCT01143402|9794690|FG002|Overall Study|Rapid clinical decline|0
6155575|NCT01143402|9794688|FG000|Overall Study|Not Treated|0
6155576|NCT01143402|9794689|FG001|Overall Study|Not Treated|0
6155577|NCT01143402|9794690|FG002|Overall Study|Not Treated|1
6155578|NCT01143714|9794767|FG000|Overall Study|Adverse Event|4
6155579|NCT01143714|9794768|FG001|Overall Study|Adverse Event|2
6155580|NCT01143714|9794767|FG000|Overall Study|Withdrawal by Subject|1
6155581|NCT01143714|9794768|FG001|Overall Study|Withdrawal by Subject|0
6155582|NCT01143714|9794767|FG000|Overall Study|Subject non-compliance|0
6155583|NCT01143714|9794768|FG001|Overall Study|Subject non-compliance|1
6155584|NCT01143714|9794767|FG000|Overall Study|wound closed = deemed healed|1
6155585|NCT01143714|9794768|FG001|Overall Study|wound closed = deemed healed|0
6042163|NCT00380692|9640324|FG000|Study Period III - Open Label|Physician Decision|0
6042164|NCT00380692|9640325|FG001|Study Period III - Open Label|Physician Decision|3
6042165|NCT00380692|9640324|FG000|Study Period III - Open Label|Lack of Efficacy|0
6042166|NCT00380692|9640325|FG001|Study Period III - Open Label|Lack of Efficacy|4
6042167|NCT00380692|9640324|FG000|Study Period III - Open Label|Parent/Caregiver Decision|1
6042168|NCT00380692|9640325|FG001|Study Period III - Open Label|Parent/Caregiver Decision|1
6155586|NCT01143714|9794767|FG000|Overall Study|wound size increased|1
6155587|NCT01143714|9794768|FG001|Overall Study|wound size increased|0
6155588|NCT01143896|9794846|FG000|Overall Study|Did not complete Baseline Interview|5
6155589|NCT01143896|9794847|FG001|Overall Study|Did not complete Baseline Interview|4
6155590|NCT01143896|9794846|FG000|Overall Study|Lost to Follow-up|18
6155591|NCT01143896|9794847|FG001|Overall Study|Lost to Follow-up|13
6155592|NCT01143896|9794846|FG000|Overall Study|Withdrawal by Subject|13
6155593|NCT01143896|9794847|FG001|Overall Study|Withdrawal by Subject|5
6324586|NCT02916927|10066244|FG001|Overall Study|Withdrawal before first time point|0
6324587|NCT02917031|10066253|FG000|Overall Study|Reason not specified|7
6324588|NCT02917031|10066254|FG001|Overall Study|Reason not specified|5
6324589|NCT02917031|10066255|FG002|Overall Study|Reason not specified|6
6324590|NCT02917031|10066253|FG000|Overall Study|Development of study-specific withdrawal criteria|1
6324591|NCT02917031|10066254|FG001|Overall Study|Development of study-specific withdrawal criteria|1
6324592|NCT02917031|10066255|FG002|Overall Study|Development of study-specific withdrawal criteria|0
6155594|NCT01143896|9794846|FG000|Overall Study|Death|6
6155595|NCT01143896|9794847|FG001|Overall Study|Death|3
6155596|NCT01144052|9794865|FG000|Overall Study|Withdrawal by Subject|1
6042169|NCT00380718|9640331|FG000|Overall Study|Adverse Event|1
6042170|NCT00380718|9640331|FG000|Overall Study|Death after 30-day post-therapy followup|17
6042171|NCT00380744|9640342|FG000|Overall Study|Death|0
6042172|NCT00380744|9640343|FG001|Overall Study|Death|0
6042173|NCT00380744|9640344|FG002|Overall Study|Death|0
6042174|NCT00380744|9640345|FG003|Overall Study|Death|0
6042175|NCT00380744|9640346|FG004|Overall Study|Death|0
6042176|NCT00380744|9640347|FG005|Overall Study|Death|0
6042177|NCT00380744|9640348|FG006|Overall Study|Death|1
6042178|NCT00380744|9640342|FG000|Overall Study|Withdrawal by Subject|1
6042179|NCT00380744|9640343|FG001|Overall Study|Withdrawal by Subject|0
6042180|NCT00380744|9640344|FG002|Overall Study|Withdrawal by Subject|0
6042181|NCT00380744|9640345|FG003|Overall Study|Withdrawal by Subject|0
6042182|NCT00380744|9640346|FG004|Overall Study|Withdrawal by Subject|0
6042183|NCT00380744|9640347|FG005|Overall Study|Withdrawal by Subject|0
6042184|NCT00380744|9640348|FG006|Overall Study|Withdrawal by Subject|0
6042185|NCT00380874|9640376|FG000|Overall Study|Adverse Event|7
6042186|NCT00380874|9640377|FG001|Overall Study|Adverse Event|7
6042187|NCT00380874|9640376|FG000|Overall Study|Death|1
6042188|NCT00380874|9640377|FG001|Overall Study|Death|0
6042189|NCT00380874|9640376|FG000|Overall Study|Withdrawal by Subject|2
6042190|NCT00380874|9640377|FG001|Overall Study|Withdrawal by Subject|1
6042191|NCT00380874|9640376|FG000|Overall Study|Not related to study drug|3
6042192|NCT00380874|9640377|FG001|Overall Study|Not related to study drug|2
6042193|NCT00380978|9640385|FG000|Overall Study|Refused allocated intervention|0
6042194|NCT00380978|9640386|FG001|Overall Study|Refused allocated intervention|6
6042195|NCT00380978|9640385|FG000|Overall Study|Wrong study envelope|0
6042196|NCT00380978|9640386|FG001|Overall Study|Wrong study envelope|2
6042197|NCT00380978|9640385|FG000|Overall Study|Allocation prior to analgesia request|1
6042198|NCT00380978|9640386|FG001|Overall Study|Allocation prior to analgesia request|2
6042199|NCT00380978|9640385|FG000|Overall Study|Parous patient|1
6042200|NCT00380978|9640386|FG001|Overall Study|Parous patient|0
6042201|NCT00381043|9640398|FG000|Overall Study|Lost to Follow-up|8
6042202|NCT00381043|9640399|FG001|Overall Study|Lost to Follow-up|6
6155597|NCT01144052|9794866|FG001|Overall Study|Withdrawal by Subject|1
6155598|NCT01144182|9794893|FG000|Overall Study|Death|5
6155599|NCT01144182|9794894|FG001|Overall Study|Death|6
6155600|NCT01144182|9794893|FG000|Overall Study|Withdrawal by Subject|3
6155601|NCT01144182|9794894|FG001|Overall Study|Withdrawal by Subject|6
6155602|NCT01144182|9794893|FG000|Overall Study|Lost to Follow-up|9
6155603|NCT01144182|9794894|FG001|Overall Study|Lost to Follow-up|9
6155604|NCT01144299|9794920|FG000|Overall Study|Lost to Follow-up|1
6155605|NCT01144299|9794921|FG001|Overall Study|Lost to Follow-up|0
6155606|NCT01144299|9794920|FG000|Overall Study|Withdrawal by Subject|1
6155607|NCT01144299|9794921|FG001|Overall Study|Withdrawal by Subject|0
6042203|NCT00381043|9640398|FG000|Overall Study|Withdrawal by Subject|3
6155608|NCT01144364|9794938|FG000|Induction Phase|Disease progression|14
6042204|NCT00381043|9640399|FG001|Overall Study|Withdrawal by Subject|1
6042205|NCT00381043|9640398|FG000|Overall Study|wanted more care|0
6042206|NCT00381043|9640399|FG001|Overall Study|wanted more care|1
6042207|NCT00381043|9640398|FG000|Overall Study|incarcerated|1
6042208|NCT00381043|9640399|FG001|Overall Study|incarcerated|0
6042209|NCT00381095|9640407|FG000|Overall Study|Death|3
6042210|NCT00381095|9640408|FG001|Overall Study|Death|4
6324593|NCT02917031|10066253|FG000|Overall Study|Withdrawal by Subject|3
6324594|NCT02917031|10066254|FG001|Overall Study|Withdrawal by Subject|3
6324595|NCT02917031|10066255|FG002|Overall Study|Withdrawal by Subject|0
6324596|NCT02917031|10066253|FG000|Overall Study|Physician Decision|1
6324597|NCT02917031|10066254|FG001|Overall Study|Physician Decision|0
6324598|NCT02917031|10066255|FG002|Overall Study|Physician Decision|0
6042211|NCT00381095|9640407|FG000|Overall Study|Lack of Efficacy|2
6324599|NCT02917031|10066253|FG000|Overall Study|Adverse Event|4
6324600|NCT02917031|10066254|FG001|Overall Study|Adverse Event|1
6324601|NCT02917031|10066255|FG002|Overall Study|Adverse Event|5
6324602|NCT02917031|10066253|FG000|Overall Study|Death|2
6324603|NCT02917031|10066254|FG001|Overall Study|Death|3
6324604|NCT02917031|10066255|FG002|Overall Study|Death|4
6324605|NCT02917265|10066275|FG000|Overall Study|Physician Decision|1
6324606|NCT02917265|10066276|FG001|Overall Study|Physician Decision|0
6324607|NCT02917265|10066275|FG000|Overall Study|Withdrawal by Subject|1
6324608|NCT02917265|10066276|FG001|Overall Study|Withdrawal by Subject|0
6324609|NCT02917941|10066321|FG000|Treatment Period|Adverse Event|11
6155609|NCT01144364|9794939|FG001|Induction Phase|Disease progression|0
6155610|NCT01144364|9794940|FG002|Induction Phase|Disease progression|0
6227406|NCT01716754|9900111|FG003|Overall Study|Physician Decision|0
5972182|NCT03923738|9557864|FG000|Period 1|Adverse Event|1
6155611|NCT01144364|9794938|FG000|Induction Phase|Adverse Event|9
6155612|NCT01144364|9794939|FG001|Induction Phase|Adverse Event|0
6155613|NCT01144364|9794940|FG002|Induction Phase|Adverse Event|0
6042212|NCT00381095|9640408|FG001|Overall Study|Lack of Efficacy|4
6042213|NCT00381095|9640407|FG000|Overall Study|Other|2
6042214|NCT00381095|9640408|FG001|Overall Study|Other|2
6042215|NCT00381095|9640407|FG000|Overall Study|Protocol Violation|1
6042216|NCT00381095|9640408|FG001|Overall Study|Protocol Violation|1
6042217|NCT00381095|9640407|FG000|Overall Study|Withdrawal by Subject|3
6155614|NCT01144364|9794938|FG000|Induction Phase|Death|1
6155615|NCT01144364|9794939|FG001|Induction Phase|Death|0
6155616|NCT01144364|9794940|FG002|Induction Phase|Death|0
6155617|NCT01144364|9794938|FG000|Induction Phase|Withdrawal by Subject|1
6155618|NCT01144364|9794939|FG001|Induction Phase|Withdrawal by Subject|0
6155619|NCT01144364|9794940|FG002|Induction Phase|Withdrawal by Subject|0
6155620|NCT01144364|9794938|FG000|Induction Phase|Lost to Follow-up|2
6155621|NCT01144364|9794939|FG001|Induction Phase|Lost to Follow-up|0
6042218|NCT00381095|9640408|FG001|Overall Study|Withdrawal by Subject|3
6042219|NCT00381095|9640407|FG000|Overall Study|Adverse Event|2
6042220|NCT00381095|9640408|FG001|Overall Study|Adverse Event|7
6042221|NCT00381238|9640414|FG000|Overall Study|Adverse Event|3
6042222|NCT00381238|9640414|FG000|Overall Study|Protocol Violation|1
6042223|NCT00381238|9640414|FG000|Overall Study|Withdrawal by Subject|4
6042224|NCT00381238|9640414|FG000|Overall Study|Lack of Efficacy|2
6042225|NCT00381238|9640414|FG000|Overall Study|Withdrew by physician|1
6155622|NCT01144364|9794940|FG002|Induction Phase|Lost to Follow-up|0
6155623|NCT01144364|9794938|FG000|Induction Phase|Physician Decision|1
6155624|NCT01144364|9794939|FG001|Induction Phase|Physician Decision|0
6155625|NCT01144364|9794940|FG002|Induction Phase|Physician Decision|0
6155626|NCT01144364|9794938|FG000|Induction Phase|Stable disease|2
6042226|NCT00381238|9640414|FG000|Overall Study|Disease progression|1
6042227|NCT00381303|9640420|FG000|Overall Study|Lost to Follow-up|25
6042228|NCT00381303|9640421|FG001|Overall Study|Lost to Follow-up|9
6042229|NCT00381303|9640420|FG000|Overall Study|AE/HIV-related event|22
6042230|NCT00381303|9640421|FG001|Overall Study|AE/HIV-related event|6
6155627|NCT01144364|9794939|FG001|Induction Phase|Stable disease|0
6042231|NCT00381303|9640420|FG000|Overall Study|Non-Adherence|13
6042232|NCT00381303|9640421|FG001|Overall Study|Non-Adherence|6
6042233|NCT00381303|9640420|FG000|Overall Study|Withdrawal by Subject|13
6042234|NCT00381303|9640421|FG001|Overall Study|Withdrawal by Subject|6
6042235|NCT00381303|9640420|FG000|Overall Study|Virologic failure|6
6042236|NCT00381303|9640421|FG001|Overall Study|Virologic failure|4
6042237|NCT00381303|9640420|FG000|Overall Study|Ineligible to continue the trial|2
6042238|NCT00381303|9640421|FG001|Overall Study|Ineligible to continue the trial|1
6042239|NCT00381303|9640420|FG000|Overall Study|Pregnancy|2
6042240|NCT00381303|9640421|FG001|Overall Study|Pregnancy|0
6042241|NCT00381303|9640420|FG000|Overall Study|Physician Decision|1
6042242|NCT00381303|9640421|FG001|Overall Study|Physician Decision|0
6042243|NCT00381303|9640420|FG000|Overall Study|Physician's decision to close the site|3
6042244|NCT00381303|9640421|FG001|Overall Study|Physician's decision to close the site|1
6042245|NCT00381303|9640420|FG000|Overall Study|Subject moved out of state|2
6042246|NCT00381303|9640421|FG001|Overall Study|Subject moved out of state|0
6042247|NCT00381303|9640420|FG000|Overall Study|Subject taking too many different meds|1
6042248|NCT00381303|9640421|FG001|Overall Study|Subject taking too many different meds|0
6042249|NCT00381303|9640420|FG000|Overall Study|No virologic response by week 12|1
6042250|NCT00381303|9640421|FG001|Overall Study|No virologic response by week 12|0
6042251|NCT00381303|9640420|FG000|Overall Study|Subject was too busy for appointments|1
6042252|NCT00381303|9640421|FG001|Overall Study|Subject was too busy for appointments|0
6042253|NCT00381303|9640420|FG000|Overall Study|Subject did not continue visits|1
6042254|NCT00381303|9640421|FG001|Overall Study|Subject did not continue visits|0
6042255|NCT00381303|9640420|FG000|Overall Study|Subject primary physician's decision|1
6042256|NCT00381303|9640421|FG001|Overall Study|Subject primary physician's decision|0
6042257|NCT00381563|9640445|FG000|Overall Study|Withdrawal by Subject|5
6042258|NCT00381563|9640446|FG001|Overall Study|Withdrawal by Subject|5
6042259|NCT00381563|9640445|FG000|Overall Study|Lost to Follow-up|2
6042260|NCT00381563|9640446|FG001|Overall Study|Lost to Follow-up|0
6042261|NCT00381563|9640445|FG000|Overall Study|Protocol Violation|0
6042262|NCT00381563|9640446|FG001|Overall Study|Protocol Violation|1
6042263|NCT00381615|9640455|FG000|Overall Study|Withdrawal by Subject|1
6042264|NCT00381615|9640456|FG001|Overall Study|Withdrawal by Subject|3
6042265|NCT00381615|9640457|FG002|Overall Study|Withdrawal by Subject|0
6042266|NCT00381615|9640458|FG003|Overall Study|Withdrawal by Subject|1
6042267|NCT00381615|9640455|FG000|Overall Study|Lost to Follow-up|3
6042268|NCT00381615|9640456|FG001|Overall Study|Lost to Follow-up|2
6042269|NCT00381615|9640457|FG002|Overall Study|Lost to Follow-up|0
6042270|NCT00381615|9640458|FG003|Overall Study|Lost to Follow-up|1
6042271|NCT00381615|9640455|FG000|Overall Study|Protocol Violation|0
6042272|NCT00381615|9640456|FG001|Overall Study|Protocol Violation|0
6042273|NCT00381615|9640457|FG002|Overall Study|Protocol Violation|1
6042274|NCT00381615|9640458|FG003|Overall Study|Protocol Violation|0
6042275|NCT00381680|9640489|FG000|Overall Study|Adverse Event|9
6042276|NCT00381680|9640490|FG001|Overall Study|Adverse Event|3
6042277|NCT00381680|9640489|FG000|Overall Study|Death|10
6042278|NCT00381680|9640490|FG001|Overall Study|Death|7
6042279|NCT00381680|9640489|FG000|Overall Study|Lost to Follow-up|3
6042280|NCT00381680|9640490|FG001|Overall Study|Lost to Follow-up|2
6042281|NCT00381680|9640489|FG000|Overall Study|Physician Decision|25
6042282|NCT00381680|9640490|FG001|Overall Study|Physician Decision|6
6042283|NCT00381680|9640489|FG000|Overall Study|Withdrawal by Subject|3
6042284|NCT00381680|9640490|FG001|Overall Study|Withdrawal by Subject|1
6042285|NCT00381680|9640489|FG000|Overall Study|Entry onto another COG Trial|1
6042286|NCT00381680|9640490|FG001|Overall Study|Entry onto another COG Trial|2
6042287|NCT00381680|9640489|FG000|Overall Study|Alternative Therapy|11
6042288|NCT00381680|9640490|FG001|Overall Study|Alternative Therapy|5
6042289|NCT00381680|9640489|FG000|Overall Study|Secondary Malignancy|3
6042290|NCT00381680|9640490|FG001|Overall Study|Secondary Malignancy|0
6042291|NCT00381680|9640489|FG000|Overall Study|Delay initiation|1
6042292|NCT00381680|9640490|FG001|Overall Study|Delay initiation|0
6042293|NCT00381680|9640489|FG000|Overall Study|Stem Cell Transplant|26
6042294|NCT00381680|9640490|FG001|Overall Study|Stem Cell Transplant|10
6042295|NCT00381680|9640489|FG000|Overall Study|Relapse|18
6042296|NCT00381680|9640490|FG001|Overall Study|Relapse|9
6042297|NCT00381680|9640489|FG000|Overall Study|Induction Failure|4
6042298|NCT00381680|9640490|FG001|Overall Study|Induction Failure|1
6042299|NCT00381680|9640489|FG000|Overall Study|Progression|1
6042300|NCT00381680|9640490|FG001|Overall Study|Progression|1
6042301|NCT00381680|9640489|FG000|Overall Study|Other not otherwise specified|7
6042302|NCT00381680|9640490|FG001|Overall Study|Other not otherwise specified|2
6042303|NCT00381680|9640489|FG000|Overall Study|Ineligible|3
6042304|NCT00381680|9640490|FG001|Overall Study|Ineligible|1
6042305|NCT00381693|9640500|FG000|Overall Study|Death|1
6042306|NCT00381693|9640500|FG000|Overall Study|Adverse Event|4
6042307|NCT00381693|9640500|FG000|Overall Study|Patient Choice|1
6042308|NCT00381693|9640500|FG000|Overall Study|Progression|2
6042309|NCT00381706|9640510|FG000|Overall Study|Never treated|7
6042310|NCT00381706|9640511|FG001|Overall Study|Never treated|2
6042311|NCT00381706|9640512|FG002|Overall Study|Never treated|1
6042312|NCT00381797|9640531|FG000|Overall Study|Withdrawal by Subject|1
6042313|NCT00381797|9640532|FG001|Overall Study|Withdrawal by Subject|1
6042314|NCT00381797|9640533|FG002|Overall Study|Withdrawal by Subject|0
6042315|NCT00381797|9640534|FG003|Overall Study|Withdrawal by Subject|0
6042316|NCT00381797|9640535|FG004|Overall Study|Withdrawal by Subject|2
6042317|NCT00381797|9640531|FG000|Overall Study|Ineligible|0
6042318|NCT00381797|9640532|FG001|Overall Study|Ineligible|0
6042319|NCT00381797|9640533|FG002|Overall Study|Ineligible|0
6042320|NCT00381797|9640534|FG003|Overall Study|Ineligible|1
6042321|NCT00381797|9640535|FG004|Overall Study|Ineligible|0
6042322|NCT00381849|9640574|FG000|Wash Out|Withdrawal by Subject|0
6042323|NCT00381849|9640575|FG001|Wash Out|Withdrawal by Subject|1
6042324|NCT00381888|9640585|FG000|Overall Study|Death|1
6042325|NCT00381888|9640585|FG000|Overall Study|Withdrawal by Subject|1
6042326|NCT00381888|9640585|FG000|Overall Study|Physician Decision|1
6042327|NCT00381888|9640585|FG000|Overall Study|Protocol Violation|9
6042328|NCT00381888|9640585|FG000|Overall Study|Had laparoscopic surgery|2
6042329|NCT00381888|9640585|FG000|Overall Study|Surgery was cancelled|2
6042330|NCT00381888|9640585|FG000|Overall Study|Adverse Event|1
6042331|NCT00381940|9640589|FG000|Overall Study|Lack of Efficacy|3
6042332|NCT00381940|9640589|FG000|Overall Study|Protocol Violation|1
6042333|NCT00381940|9640589|FG000|Overall Study|Ineligible|1
6042334|NCT00382018|9640601|FG000|Overall Study|Progression|0
6042335|NCT00382018|9640602|FG001|Overall Study|Progression|136
6042336|NCT00382018|9640603|FG002|Overall Study|Progression|51
6042337|NCT00382018|9640604|FG003|Overall Study|Progression|43
6042338|NCT00382018|9640601|FG000|Overall Study|Death|0
6042339|NCT00382018|9640602|FG001|Overall Study|Death|9
6042340|NCT00382018|9640603|FG002|Overall Study|Death|7
6042341|NCT00382018|9640604|FG003|Overall Study|Death|11
6042342|NCT00382018|9640601|FG000|Overall Study|Withdrawal by Subject|0
6042343|NCT00382018|9640602|FG001|Overall Study|Withdrawal by Subject|4
6042344|NCT00382018|9640603|FG002|Overall Study|Withdrawal by Subject|3
6042345|NCT00382018|9640604|FG003|Overall Study|Withdrawal by Subject|4
6042346|NCT00382018|9640601|FG000|Overall Study|Other, not protocol specified|0
6042347|NCT00382018|9640602|FG001|Overall Study|Other, not protocol specified|16
6042348|NCT00382018|9640603|FG002|Overall Study|Other, not protocol specified|3
6042349|NCT00382018|9640604|FG003|Overall Study|Other, not protocol specified|1
6042350|NCT00382070|9640628|FG000|Overall Study|No follow up data mapped to Other|17
6042351|NCT00382070|9640629|FG001|Overall Study|No follow up data mapped to Other|19
6042352|NCT00382070|9640628|FG000|Overall Study|Patient not at risk for primary endpoint mapped to Other|7
6042353|NCT00382070|9640629|FG001|Overall Study|Patient not at risk for primary endpoint mapped to Other|0
6042354|NCT00382070|9640628|FG000|Overall Study|No clinical assessment|9
6042355|NCT00382070|9640629|FG001|Overall Study|No clinical assessment|11
6042356|NCT00382109|9640637|FG000|Overall Study|Adverse Event|3
6042357|NCT00382109|9640638|FG001|Overall Study|Adverse Event|0
6042358|NCT00382109|9640637|FG000|Overall Study|Physician Decision|6
6042359|NCT00382109|9640638|FG001|Overall Study|Physician Decision|1
6042360|NCT00382109|9640637|FG000|Overall Study|Withdrawal by Subject|1
6042361|NCT00382109|9640638|FG001|Overall Study|Withdrawal by Subject|0
6042362|NCT00382109|9640637|FG000|Overall Study|ineligible|2
6042363|NCT00382109|9640638|FG001|Overall Study|ineligible|0
6042364|NCT00382109|9640637|FG000|Overall Study|Other|0
6042365|NCT00382109|9640638|FG001|Overall Study|Other|2
6042366|NCT00382109|9640637|FG000|Overall Study|consent withdrawal|0
6042367|NCT00382109|9640638|FG001|Overall Study|consent withdrawal|1
6042368|NCT00382174|9640658|FG000|Overall Study|Lost to Follow-up|1
6042369|NCT00382174|9640659|FG001|Overall Study|Lost to Follow-up|4
6042370|NCT00382174|9640660|FG002|Overall Study|Lost to Follow-up|5
6155628|NCT01144364|9794940|FG002|Induction Phase|Stable disease|0
6042371|NCT00382174|9640658|FG000|Overall Study|Adverse Event|1
6042372|NCT00382174|9640659|FG001|Overall Study|Adverse Event|4
6042373|NCT00382174|9640660|FG002|Overall Study|Adverse Event|5
6042374|NCT00382174|9640658|FG000|Overall Study|Withdrawal by Subject|1
6042375|NCT00382174|9640659|FG001|Overall Study|Withdrawal by Subject|4
6042376|NCT00382174|9640660|FG002|Overall Study|Withdrawal by Subject|5
6042377|NCT00382174|9640658|FG000|Overall Study|Non compliance|1
6042378|NCT00382174|9640659|FG001|Overall Study|Non compliance|0
6042379|NCT00382174|9640660|FG002|Overall Study|Non compliance|1
6042380|NCT00382174|9640658|FG000|Overall Study|Physician Decision|0
6042381|NCT00382174|9640659|FG001|Overall Study|Physician Decision|2
6042382|NCT00382174|9640660|FG002|Overall Study|Physician Decision|2
6042383|NCT00382174|9640658|FG000|Overall Study|Failed to meet criteria|0
6042384|NCT00382174|9640659|FG001|Overall Study|Failed to meet criteria|1
6042385|NCT00382174|9640660|FG002|Overall Study|Failed to meet criteria|1
6042386|NCT00382174|9640658|FG000|Overall Study|Wounds merged|0
6042387|NCT00382174|9640659|FG001|Overall Study|Wounds merged|2
6042388|NCT00382174|9640660|FG002|Overall Study|Wounds merged|2
6042389|NCT00382291|9640684|FG000|Overall Study|Adverse Event|1
6042390|NCT00382291|9640685|FG001|Overall Study|Adverse Event|2
6042391|NCT00382291|9640686|FG002|Overall Study|Adverse Event|2
6042392|NCT00382291|9640684|FG000|Overall Study|Protocol Violation|1
6042393|NCT00382291|9640685|FG001|Overall Study|Protocol Violation|0
6042394|NCT00382291|9640686|FG002|Overall Study|Protocol Violation|0
6042395|NCT00382291|9640684|FG000|Overall Study|Temporary study suspension|2
6042396|NCT00382291|9640685|FG001|Overall Study|Temporary study suspension|2
6042397|NCT00382291|9640686|FG002|Overall Study|Temporary study suspension|5
6042398|NCT00382291|9640684|FG000|Overall Study|Withdrawal by Subject|0
6042399|NCT00382291|9640685|FG001|Overall Study|Withdrawal by Subject|2
6042400|NCT00382291|9640686|FG002|Overall Study|Withdrawal by Subject|0
6042401|NCT00382291|9640684|FG000|Overall Study|Physician Decision|0
6042402|NCT00382291|9640685|FG001|Overall Study|Physician Decision|1
6042403|NCT00382291|9640686|FG002|Overall Study|Physician Decision|0
6042404|NCT00382291|9640684|FG000|Overall Study|Lack of Efficacy|0
6042405|NCT00382291|9640685|FG001|Overall Study|Lack of Efficacy|0
6042406|NCT00382291|9640686|FG002|Overall Study|Lack of Efficacy|1
6042407|NCT00382408|9640698|FG000|Overall Study|Did not meet protocol requirement|3
6324610|NCT02917941|10066321|FG000|Treatment Period|Progressive Disease|11
6324611|NCT02917941|10066321|FG000|Treatment Period|Reason not Specified|2
6324612|NCT02917941|10066321|FG000|Survival Follow-up Period|Lost to Follow-up|1
6324613|NCT02917941|10066321|FG000|Survival Follow-up Period|Withdrawal by Subject|4
6324614|NCT02918071|10066325|FG000|Overall Study|Withdrawal by Subject|2
6324615|NCT02918071|10066325|FG000|Overall Study|Lost to Follow-up|1
6324616|NCT02918266|10066344|FG000|Part 2: Intervention Period 1 (2 Days)|Study termination|0
6324617|NCT02918266|10066345|FG001|Part 2: Intervention Period 1 (2 Days)|Study termination|1
6324618|NCT02918266|10066346|FG002|Part 2: Intervention Period 1 (2 Days)|Study termination|1
6324619|NCT02918266|10066347|FG003|Part 2: Intervention Period 1 (2 Days)|Study termination|1
6324620|NCT02918266|10066348|FG004|Part 2: Intervention Period 1 (2 Days)|Study termination|1
6324621|NCT02918266|10066349|FG005|Part 2: Intervention Period 1 (2 Days)|Study termination|1
6324622|NCT02918266|10066350|FG006|Part 2: Intervention Period 1 (2 Days)|Study termination|2
6324623|NCT02918266|10066351|FG007|Part 2: Intervention Period 1 (2 Days)|Study termination|1
6324624|NCT02918266|10066352|FG008|Part 2: Intervention Period 1 (2 Days)|Study termination|2
6324625|NCT02918266|10066353|FG009|Part 2: Intervention Period 1 (2 Days)|Study termination|1
6324626|NCT02918266|10066354|FG010|Part 2: Intervention Period 1 (2 Days)|Study termination|1
6324627|NCT02918279|10066376|FG000|Overall Study|Lost to Follow-up|3
6324628|NCT02918279|10066377|FG001|Overall Study|Lost to Follow-up|6
6324629|NCT02918279|10066376|FG000|Overall Study|Withdrawal by Subject|5
6324630|NCT02918279|10066377|FG001|Overall Study|Withdrawal by Subject|15
6324631|NCT02918279|10066376|FG000|Overall Study|Withdrawal by parent/guardian|2
6324632|NCT02918279|10066377|FG001|Overall Study|Withdrawal by parent/guardian|1
6324633|NCT02918279|10066376|FG000|Overall Study|Other|3
6324634|NCT02918279|10066377|FG001|Overall Study|Other|1
6324635|NCT02918318|10066387|FG000|Double-blind Induction Phase: 4 Weeks|Adverse Event|1
6324636|NCT02918318|10066388|FG001|Double-blind Induction Phase: 4 Weeks|Adverse Event|4
6324637|NCT02918318|10066389|FG002|Double-blind Induction Phase: 4 Weeks|Adverse Event|2
6324638|NCT02918318|10066390|FG003|Double-blind Induction Phase: 4 Weeks|Adverse Event|3
6324639|NCT02918318|10066391|FG004|Double-blind Induction Phase: 4 Weeks|Adverse Event|0
6324640|NCT02918318|10066387|FG000|Double-blind Induction Phase: 4 Weeks|Lack of Efficacy|0
6324641|NCT02918318|10066388|FG001|Double-blind Induction Phase: 4 Weeks|Lack of Efficacy|0
6324642|NCT02918318|10066389|FG002|Double-blind Induction Phase: 4 Weeks|Lack of Efficacy|0
6324643|NCT02918318|10066390|FG003|Double-blind Induction Phase: 4 Weeks|Lack of Efficacy|2
6324644|NCT02918318|10066391|FG004|Double-blind Induction Phase: 4 Weeks|Lack of Efficacy|0
6324645|NCT02918318|10066387|FG000|Double-blind Induction Phase: 4 Weeks|Lost to Follow-up|0
6324646|NCT02918318|10066388|FG001|Double-blind Induction Phase: 4 Weeks|Lost to Follow-up|0
6324647|NCT02918318|10066389|FG002|Double-blind Induction Phase: 4 Weeks|Lost to Follow-up|0
6324648|NCT02918318|10066390|FG003|Double-blind Induction Phase: 4 Weeks|Lost to Follow-up|1
6324649|NCT02918318|10066391|FG004|Double-blind Induction Phase: 4 Weeks|Lost to Follow-up|0
6324650|NCT02918318|10066387|FG000|Double-blind Induction Phase: 4 Weeks|Withdrawal by Subject|1
6324651|NCT02918318|10066388|FG001|Double-blind Induction Phase: 4 Weeks|Withdrawal by Subject|1
6324652|NCT02918318|10066389|FG002|Double-blind Induction Phase: 4 Weeks|Withdrawal by Subject|0
6324653|NCT02918318|10066390|FG003|Double-blind Induction Phase: 4 Weeks|Withdrawal by Subject|0
6324654|NCT02918318|10066391|FG004|Double-blind Induction Phase: 4 Weeks|Withdrawal by Subject|0
6324655|NCT02918318|10066387|FG000|Double-blind Induction Phase: 4 Weeks|Non-compliance|0
6324656|NCT02918318|10066388|FG001|Double-blind Induction Phase: 4 Weeks|Non-compliance|0
6324657|NCT02918318|10066389|FG002|Double-blind Induction Phase: 4 Weeks|Non-compliance|0
6324658|NCT02918318|10066390|FG003|Double-blind Induction Phase: 4 Weeks|Non-compliance|1
6324659|NCT02918318|10066391|FG004|Double-blind Induction Phase: 4 Weeks|Non-compliance|0
6324660|NCT02918318|10066387|FG000|Double-blind Induction Phase: 4 Weeks|Other|0
6324661|NCT02918318|10066388|FG001|Double-blind Induction Phase: 4 Weeks|Other|2
6324662|NCT02918318|10066389|FG002|Double-blind Induction Phase: 4 Weeks|Other|0
6324663|NCT02918318|10066390|FG003|Double-blind Induction Phase: 4 Weeks|Other|1
6324664|NCT02918318|10066391|FG004|Double-blind Induction Phase: 4 Weeks|Other|0
6324665|NCT02918318|10066387|FG000|Double-blind Follow-up Phase: 4 Weeks|Withdrawal by Subject|0
6324666|NCT02918318|10066388|FG001|Double-blind Follow-up Phase: 4 Weeks|Withdrawal by Subject|0
6324667|NCT02918318|10066389|FG002|Double-blind Follow-up Phase: 4 Weeks|Withdrawal by Subject|0
6324668|NCT02918318|10066390|FG003|Double-blind Follow-up Phase: 4 Weeks|Withdrawal by Subject|2
6324669|NCT02918318|10066391|FG004|Double-blind Follow-up Phase: 4 Weeks|Withdrawal by Subject|0
6324670|NCT02918318|10066387|FG000|Double-blind Follow-up Phase: 4 Weeks|Adverse Event|1
6324671|NCT02918318|10066388|FG001|Double-blind Follow-up Phase: 4 Weeks|Adverse Event|0
6324672|NCT02918318|10066389|FG002|Double-blind Follow-up Phase: 4 Weeks|Adverse Event|1
6324673|NCT02918318|10066390|FG003|Double-blind Follow-up Phase: 4 Weeks|Adverse Event|1
6324674|NCT02918318|10066391|FG004|Double-blind Follow-up Phase: 4 Weeks|Adverse Event|0
6324675|NCT02918318|10066387|FG000|Posttreatment Phase: Up to 24 Weeks|Withdrawal by Subject|1
6324676|NCT02918318|10066388|FG001|Posttreatment Phase: Up to 24 Weeks|Withdrawal by Subject|0
6324677|NCT02918318|10066389|FG002|Posttreatment Phase: Up to 24 Weeks|Withdrawal by Subject|0
6324678|NCT02918318|10066390|FG003|Posttreatment Phase: Up to 24 Weeks|Withdrawal by Subject|1
6155629|NCT01144364|9794938|FG000|Induction Phase|Secondary neoplasia|1
6155630|NCT01144364|9794939|FG001|Induction Phase|Secondary neoplasia|0
6155631|NCT01144364|9794940|FG002|Induction Phase|Secondary neoplasia|0
6155632|NCT01144364|9794938|FG000|Induction Phase|Protocol Violation|1
6155633|NCT01144364|9794939|FG001|Induction Phase|Protocol Violation|0
6155634|NCT01144364|9794940|FG002|Induction Phase|Protocol Violation|0
6155635|NCT01144364|9794938|FG000|Follow-Up/Maintenance Phase|Disease progression|0
6155636|NCT01144364|9794939|FG001|Follow-Up/Maintenance Phase|Disease progression|23
6155637|NCT01144364|9794940|FG002|Follow-Up/Maintenance Phase|Disease progression|29
6155638|NCT01144364|9794938|FG000|Follow-Up/Maintenance Phase|Adverse Event|0
6155639|NCT01144364|9794939|FG001|Follow-Up/Maintenance Phase|Adverse Event|3
6155640|NCT01144364|9794940|FG002|Follow-Up/Maintenance Phase|Adverse Event|1
6155641|NCT01144364|9794938|FG000|Follow-Up/Maintenance Phase|Death|0
6155642|NCT01144364|9794939|FG001|Follow-Up/Maintenance Phase|Death|2
6155643|NCT01144364|9794940|FG002|Follow-Up/Maintenance Phase|Death|0
6155644|NCT01144364|9794938|FG000|Follow-Up/Maintenance Phase|Withdrawal by Subject|0
6155645|NCT01144364|9794939|FG001|Follow-Up/Maintenance Phase|Withdrawal by Subject|1
6155646|NCT01144364|9794940|FG002|Follow-Up/Maintenance Phase|Withdrawal by Subject|1
6155647|NCT01144364|9794938|FG000|Follow-Up/Maintenance Phase|Lost to Follow-up|0
6155648|NCT01144364|9794939|FG001|Follow-Up/Maintenance Phase|Lost to Follow-up|1
6155649|NCT01144364|9794940|FG002|Follow-Up/Maintenance Phase|Lost to Follow-up|4
6155650|NCT01144364|9794938|FG000|Follow-Up/Maintenance Phase|Relapse|0
6155651|NCT01144364|9794939|FG001|Follow-Up/Maintenance Phase|Relapse|5
6155652|NCT01144364|9794940|FG002|Follow-Up/Maintenance Phase|Relapse|5
6155653|NCT01144364|9794938|FG000|Follow-Up/Maintenance Phase|Physician Decision|0
6155654|NCT01144364|9794939|FG001|Follow-Up/Maintenance Phase|Physician Decision|0
6155655|NCT01144364|9794940|FG002|Follow-Up/Maintenance Phase|Physician Decision|1
6155656|NCT01144377|9794955|FG000|52 Week Treatment Period|Adverse Event|0
6155657|NCT01144377|9794956|FG001|52 Week Treatment Period|Adverse Event|0
6155658|NCT01144377|9794957|FG002|52 Week Treatment Period|Adverse Event|3
6155659|NCT01144377|9794958|FG003|52 Week Treatment Period|Adverse Event|2
6155660|NCT01144377|9794959|FG004|52 Week Treatment Period|Adverse Event|1
6155661|NCT01144377|9794955|FG000|52 Week Treatment Period|Entry Criteria Not Met|0
6155662|NCT01144377|9794956|FG001|52 Week Treatment Period|Entry Criteria Not Met|0
6155663|NCT01144377|9794957|FG002|52 Week Treatment Period|Entry Criteria Not Met|1
6155664|NCT01144377|9794958|FG003|52 Week Treatment Period|Entry Criteria Not Met|1
6155665|NCT01144377|9794959|FG004|52 Week Treatment Period|Entry Criteria Not Met|0
6155666|NCT01144377|9794955|FG000|52 Week Treatment Period|Protocol Violation|0
6155667|NCT01144377|9794956|FG001|52 Week Treatment Period|Protocol Violation|0
6155668|NCT01144377|9794957|FG002|52 Week Treatment Period|Protocol Violation|0
6155669|NCT01144377|9794958|FG003|52 Week Treatment Period|Protocol Violation|0
6155670|NCT01144377|9794959|FG004|52 Week Treatment Period|Protocol Violation|1
6155671|NCT01144377|9794955|FG000|52 Week Treatment Period|Lost to Follow-up|1
6155672|NCT01144377|9794956|FG001|52 Week Treatment Period|Lost to Follow-up|0
6155673|NCT01144377|9794957|FG002|52 Week Treatment Period|Lost to Follow-up|0
6155674|NCT01144377|9794958|FG003|52 Week Treatment Period|Lost to Follow-up|0
6155675|NCT01144377|9794959|FG004|52 Week Treatment Period|Lost to Follow-up|0
6155676|NCT01144377|9794955|FG000|52 Week Treatment Period|Withdrawal by Subject|4
6155677|NCT01144377|9794956|FG001|52 Week Treatment Period|Withdrawal by Subject|1
6155678|NCT01144377|9794957|FG002|52 Week Treatment Period|Withdrawal by Subject|1
6155679|NCT01144377|9794958|FG003|52 Week Treatment Period|Withdrawal by Subject|1
6155680|NCT01144377|9794959|FG004|52 Week Treatment Period|Withdrawal by Subject|0
6155681|NCT01144377|9794955|FG000|52 Week Treatment Period|Sponsor Decision|0
6155682|NCT01144377|9794956|FG001|52 Week Treatment Period|Sponsor Decision|0
6155683|NCT01144377|9794957|FG002|52 Week Treatment Period|Sponsor Decision|0
6155684|NCT01144377|9794958|FG003|52 Week Treatment Period|Sponsor Decision|0
6155685|NCT01144377|9794959|FG004|52 Week Treatment Period|Sponsor Decision|1
6155686|NCT01144377|9794955|FG000|Optional 40 Week Safety Follow-up Period|Adverse Event|0
6155687|NCT01144377|9794956|FG001|Optional 40 Week Safety Follow-up Period|Adverse Event|1
6155688|NCT01144377|9794957|FG002|Optional 40 Week Safety Follow-up Period|Adverse Event|0
6155689|NCT01144377|9794958|FG003|Optional 40 Week Safety Follow-up Period|Adverse Event|0
6155690|NCT01144377|9794959|FG004|Optional 40 Week Safety Follow-up Period|Adverse Event|1
6155691|NCT01144377|9794955|FG000|Optional 40 Week Safety Follow-up Period|Lost to Follow-up|0
6155692|NCT01144377|9794956|FG001|Optional 40 Week Safety Follow-up Period|Lost to Follow-up|0
6155693|NCT01144377|9794957|FG002|Optional 40 Week Safety Follow-up Period|Lost to Follow-up|0
6155694|NCT01144377|9794958|FG003|Optional 40 Week Safety Follow-up Period|Lost to Follow-up|0
6155695|NCT01144377|9794959|FG004|Optional 40 Week Safety Follow-up Period|Lost to Follow-up|1
6155696|NCT01144377|9794955|FG000|Optional 40 Week Safety Follow-up Period|Sponsor Decision|1
6155697|NCT01144377|9794956|FG001|Optional 40 Week Safety Follow-up Period|Sponsor Decision|0
6155698|NCT01144377|9794957|FG002|Optional 40 Week Safety Follow-up Period|Sponsor Decision|0
6155699|NCT01144377|9794958|FG003|Optional 40 Week Safety Follow-up Period|Sponsor Decision|0
6155700|NCT01144377|9794959|FG004|Optional 40 Week Safety Follow-up Period|Sponsor Decision|0
6155701|NCT01144403|9794973|FG000|Overall Study|Lost to Follow-up|3
6155702|NCT01144403|9794973|FG000|Overall Study|Death|1
6155703|NCT01144403|9794973|FG000|Overall Study|Adverse Event|1
6155704|NCT01144663|9795045|FG000|Primary Vaccination Phase|Serious adverse event, fatal|2
6155705|NCT01144663|9795046|FG001|Primary Vaccination Phase|Serious adverse event, fatal|0
6155706|NCT01144663|9795047|FG002|Primary Vaccination Phase|Serious adverse event, fatal|1
6155707|NCT01144663|9795048|FG003|Primary Vaccination Phase|Serious adverse event, fatal|0
6155708|NCT01144663|9795045|FG000|Primary Vaccination Phase|Adverse Event|1
6155709|NCT01144663|9795046|FG001|Primary Vaccination Phase|Adverse Event|0
6155710|NCT01144663|9795047|FG002|Primary Vaccination Phase|Adverse Event|0
6155711|NCT01144663|9795048|FG003|Primary Vaccination Phase|Adverse Event|1
6155712|NCT01144663|9795045|FG000|Primary Vaccination Phase|Protocol Violation|2
6042408|NCT00382408|9640699|FG001|Overall Study|Did not meet protocol requirement|3
6042409|NCT00382408|9640698|FG000|Overall Study|Protocol Violation|2
6042410|NCT00382408|9640699|FG001|Overall Study|Protocol Violation|2
6042411|NCT00382408|9640698|FG000|Overall Study|Physician Decision|1
6042412|NCT00382408|9640699|FG001|Overall Study|Physician Decision|0
6042413|NCT00382408|9640698|FG000|Overall Study|Withdrawal by Subject|17
6042414|NCT00382408|9640699|FG001|Overall Study|Withdrawal by Subject|6
6042415|NCT00382408|9640698|FG000|Overall Study|Pregnancy|2
6042416|NCT00382408|9640699|FG001|Overall Study|Pregnancy|0
6042417|NCT00382408|9640698|FG000|Overall Study|Lost to Follow-up|19
6155713|NCT01144663|9795046|FG001|Primary Vaccination Phase|Protocol Violation|0
6155714|NCT01144663|9795047|FG002|Primary Vaccination Phase|Protocol Violation|1
6155715|NCT01144663|9795048|FG003|Primary Vaccination Phase|Protocol Violation|0
6155716|NCT01144663|9795045|FG000|Primary Vaccination Phase|Withdrawal by Subject|9
6155717|NCT01144663|9795046|FG001|Primary Vaccination Phase|Withdrawal by Subject|5
6155718|NCT01144663|9795047|FG002|Primary Vaccination Phase|Withdrawal by Subject|3
6155719|NCT01144663|9795048|FG003|Primary Vaccination Phase|Withdrawal by Subject|10
6155720|NCT01144663|9795045|FG000|Primary Vaccination Phase|Migrated/moved from study area|4
6155721|NCT01144663|9795046|FG001|Primary Vaccination Phase|Migrated/moved from study area|1
6155722|NCT01144663|9795047|FG002|Primary Vaccination Phase|Migrated/moved from study area|2
6155723|NCT01144663|9795048|FG003|Primary Vaccination Phase|Migrated/moved from study area|3
6155724|NCT01144663|9795045|FG000|Primary Vaccination Phase|Lost to Follow-up|2
6155725|NCT01144663|9795046|FG001|Primary Vaccination Phase|Lost to Follow-up|0
6155726|NCT01144663|9795047|FG002|Primary Vaccination Phase|Lost to Follow-up|1
6155727|NCT01144663|9795048|FG003|Primary Vaccination Phase|Lost to Follow-up|2
6155728|NCT01144663|9795045|FG000|Primary Vaccination Phase|Other|0
6155729|NCT01144663|9795046|FG001|Primary Vaccination Phase|Other|1
6155730|NCT01144663|9795047|FG002|Primary Vaccination Phase|Other|0
6155731|NCT01144663|9795048|FG003|Primary Vaccination Phase|Other|2
6155732|NCT01144663|9795045|FG000|Booster Vaccination Phase|Withdrawal by Subject|0
6155733|NCT01144663|9795046|FG001|Booster Vaccination Phase|Withdrawal by Subject|0
6155734|NCT01144663|9795047|FG002|Booster Vaccination Phase|Withdrawal by Subject|1
6155735|NCT01144663|9795048|FG003|Booster Vaccination Phase|Withdrawal by Subject|1
6155736|NCT01144663|9795045|FG000|Booster Vaccination Phase|Migrated/moved from study area|1
6155737|NCT01144663|9795046|FG001|Booster Vaccination Phase|Migrated/moved from study area|1
6155738|NCT01144663|9795047|FG002|Booster Vaccination Phase|Migrated/moved from study area|1
6155739|NCT01144663|9795048|FG003|Booster Vaccination Phase|Migrated/moved from study area|0
6155740|NCT01144663|9795045|FG000|Booster Vaccination Phase|Lost to Follow-up|2
6155741|NCT01144663|9795046|FG001|Booster Vaccination Phase|Lost to Follow-up|1
6155742|NCT01144663|9795047|FG002|Booster Vaccination Phase|Lost to Follow-up|3
6155743|NCT01144663|9795048|FG003|Booster Vaccination Phase|Lost to Follow-up|0
6155744|NCT01144663|9795045|FG000|Extended Safety Follow-Up (ESFU)|Withdrawal by Subject|0
6155745|NCT01144663|9795046|FG001|Extended Safety Follow-Up (ESFU)|Withdrawal by Subject|0
6155746|NCT01144663|9795047|FG002|Extended Safety Follow-Up (ESFU)|Withdrawal by Subject|1
6155747|NCT01144663|9795048|FG003|Extended Safety Follow-Up (ESFU)|Withdrawal by Subject|1
6155748|NCT01144663|9795045|FG000|Extended Safety Follow-Up (ESFU)|Migrated/moved from study area|1
6155749|NCT01144663|9795046|FG001|Extended Safety Follow-Up (ESFU)|Migrated/moved from study area|3
6155750|NCT01144663|9795047|FG002|Extended Safety Follow-Up (ESFU)|Migrated/moved from study area|1
6155751|NCT01144663|9795048|FG003|Extended Safety Follow-Up (ESFU)|Migrated/moved from study area|0
6155752|NCT01144663|9795045|FG000|Extended Safety Follow-Up (ESFU)|Lost to Follow-up|4
6155753|NCT01144663|9795046|FG001|Extended Safety Follow-Up (ESFU)|Lost to Follow-up|6
6155754|NCT01144663|9795047|FG002|Extended Safety Follow-Up (ESFU)|Lost to Follow-up|5
6155755|NCT01144663|9795048|FG003|Extended Safety Follow-Up (ESFU)|Lost to Follow-up|0
6155756|NCT01144715|9795060|FG000|Overall Study|Lost to Follow-up|2
6155757|NCT01144715|9795061|FG001|Overall Study|Lost to Follow-up|1
6155758|NCT01144715|9795060|FG000|Overall Study|Withdrawal by Subject|2
6155759|NCT01144715|9795061|FG001|Overall Study|Withdrawal by Subject|1
6155760|NCT01144715|9795060|FG000|Overall Study|Adverse Event|0
6155761|NCT01144715|9795061|FG001|Overall Study|Adverse Event|1
6155762|NCT01145053|9795093|FG000|Overall Study|Adverse Event|22
6155763|NCT01145053|9795093|FG000|Overall Study|Lost to Follow-up|28
6155764|NCT01145053|9795093|FG000|Overall Study|Withdrawal by Subject|25
6042418|NCT00382408|9640699|FG001|Overall Study|Lost to Follow-up|8
6042419|NCT00382408|9640698|FG000|Overall Study|Other|100
6042420|NCT00382408|9640699|FG001|Overall Study|Other|35
6155765|NCT01145053|9795093|FG000|Overall Study|Other|18
6155766|NCT01145066|9795100|FG000|Overall Study|To resume NSAIDs|2
6155767|NCT01145066|9795101|FG001|Overall Study|To resume NSAIDs|2
6155768|NCT01145066|9795102|FG002|Overall Study|To resume NSAIDs|1
6155769|NCT01145066|9795100|FG000|Overall Study|Non-related surgery|0
6155770|NCT01145066|9795101|FG001|Overall Study|Non-related surgery|0
6155771|NCT01145066|9795102|FG002|Overall Study|Non-related surgery|1
6155772|NCT01145066|9795100|FG000|Overall Study|Withdrawal by Subject|0
6155773|NCT01145066|9795101|FG001|Overall Study|Withdrawal by Subject|0
6155774|NCT01145066|9795102|FG002|Overall Study|Withdrawal by Subject|2
6155775|NCT01145066|9795100|FG000|Overall Study|To start new med|1
6155776|NCT01145066|9795101|FG001|Overall Study|To start new med|0
6155777|NCT01145066|9795102|FG002|Overall Study|To start new med|0
6155778|NCT01145066|9795100|FG000|Overall Study|problems swallowing capsule|1
6155779|NCT01145066|9795101|FG001|Overall Study|problems swallowing capsule|0
6155780|NCT01145066|9795102|FG002|Overall Study|problems swallowing capsule|0
6155781|NCT01145066|9795100|FG000|Overall Study|Abdominal discomfort|0
6155782|NCT01145066|9795101|FG001|Overall Study|Abdominal discomfort|1
6155783|NCT01145066|9795102|FG002|Overall Study|Abdominal discomfort|0
6155784|NCT01145066|9795100|FG000|Overall Study|Low platelet count|0
6155785|NCT01145066|9795101|FG001|Overall Study|Low platelet count|1
6155786|NCT01145066|9795102|FG002|Overall Study|Low platelet count|0
6155787|NCT01145222|9795131|FG000|Overall Study|Procedure not done (no anesthesiologist)|0
6155788|NCT01145222|9795132|FG001|Overall Study|Procedure not done (no anesthesiologist)|0
6155789|NCT01145222|9795133|FG002|Overall Study|Procedure not done (no anesthesiologist)|1
6155790|NCT01145222|9795134|FG003|Overall Study|Procedure not done (no anesthesiologist)|0
6155791|NCT01145222|9795131|FG000|Overall Study|Poor bowel preparation|0
6155792|NCT01145222|9795132|FG001|Overall Study|Poor bowel preparation|0
6155793|NCT01145222|9795133|FG002|Overall Study|Poor bowel preparation|0
6155794|NCT01145222|9795134|FG003|Overall Study|Poor bowel preparation|1
6155795|NCT01145352|9795144|FG000|Overall Study|Found to have been registered twice|6
6155796|NCT01145352|9795144|FG000|Overall Study|Treated before marketing approval|4
6155797|NCT01145352|9795144|FG000|Overall Study|Syringe formulation was used|1
6155798|NCT01145417|9795161|FG000|Overall Study|Death|1
6155799|NCT01145417|9795162|FG001|Overall Study|Death|0
6155800|NCT01145417|9795161|FG000|Overall Study|Lost to Follow-up|2
6155801|NCT01145417|9795162|FG001|Overall Study|Lost to Follow-up|1
6155802|NCT01145417|9795161|FG000|Overall Study|Withdrawal by Subject|1
6155803|NCT01145417|9795162|FG001|Overall Study|Withdrawal by Subject|2
6155804|NCT01145417|9795161|FG000|Overall Study|Pregnancy|1
6155805|NCT01145417|9795162|FG001|Overall Study|Pregnancy|0
6155806|NCT01145417|9795161|FG000|Overall Study|Adverse Event|0
6155807|NCT01145417|9795162|FG001|Overall Study|Adverse Event|1
6155808|NCT01145417|9795161|FG000|Overall Study|Study terminated by sponsor|35
6155809|NCT01145417|9795162|FG001|Overall Study|Study terminated by sponsor|43
6155810|NCT01145417|9795161|FG000|Overall Study|Other|1
6155811|NCT01145417|9795162|FG001|Overall Study|Other|0
6155812|NCT01145482|9795170|FG000|First Intervention (1 Day)|Withdrawal by Subject|0
6155813|NCT01145482|9795171|FG001|First Intervention (1 Day)|Withdrawal by Subject|1
6155814|NCT01145508|9795179|FG000|Overall Study|Adverse Event|1
6155815|NCT01145508|9795180|FG001|Overall Study|Adverse Event|0
6155816|NCT01145508|9795179|FG000|Overall Study|Death|1
6155817|NCT01145508|9795180|FG001|Overall Study|Death|0
6155818|NCT01145508|9795179|FG000|Overall Study|Physician Decision|2
6155819|NCT01145508|9795180|FG001|Overall Study|Physician Decision|1
6155820|NCT01145508|9795179|FG000|Overall Study|Never started treatment|1
6155821|NCT01145508|9795180|FG001|Overall Study|Never started treatment|1
6155822|NCT01145560|9795196|FG000|Overall Study|Withdrawal by Subject|2
6155823|NCT01145560|9795197|FG001|Overall Study|Withdrawal by Subject|1
6155824|NCT01145560|9795198|FG002|Overall Study|Withdrawal by Subject|0
6155825|NCT01145560|9795196|FG000|Overall Study|Lost to Follow-up|1
6155826|NCT01145560|9795197|FG001|Overall Study|Lost to Follow-up|1
6155827|NCT01145560|9795198|FG002|Overall Study|Lost to Follow-up|1
6155828|NCT01145560|9795196|FG000|Overall Study|No study drug by 24h after organ failure|1
6155829|NCT01145560|9795197|FG001|Overall Study|No study drug by 24h after organ failure|0
6155830|NCT01145560|9795198|FG002|Overall Study|No study drug by 24h after organ failure|0
6155831|NCT01145560|9795196|FG000|Overall Study|Accidental unblinding of study treatment|0
6155832|NCT01145560|9795197|FG001|Overall Study|Accidental unblinding of study treatment|1
6155833|NCT01145560|9795198|FG002|Overall Study|Accidental unblinding of study treatment|0
6155834|NCT01145560|9795196|FG000|Overall Study|False insurance information|0
6155835|NCT01145560|9795197|FG001|Overall Study|False insurance information|1
6155836|NCT01145560|9795198|FG002|Overall Study|False insurance information|0
6155837|NCT01145560|9795196|FG000|Overall Study|Withdrawal of therapy|0
6155838|NCT01145560|9795197|FG001|Overall Study|Withdrawal of therapy|0
6155839|NCT01145560|9795198|FG002|Overall Study|Withdrawal of therapy|1
6155840|NCT01145625|9795208|FG000|Overall Study|Lost to Follow-up|8
6155841|NCT01145625|9795209|FG001|Overall Study|Lost to Follow-up|9
6155842|NCT01145625|9795208|FG000|Overall Study|Adverse Event|6
6155843|NCT01145625|9795209|FG001|Overall Study|Adverse Event|4
6155844|NCT01145625|9795208|FG000|Overall Study|Protocol Violation|3
6155845|NCT01145625|9795209|FG001|Overall Study|Protocol Violation|1
6155846|NCT01145625|9795208|FG000|Overall Study|Withdrawal by Subject|7
6155847|NCT01145625|9795209|FG001|Overall Study|Withdrawal by Subject|16
6155848|NCT01145625|9795208|FG000|Overall Study|Pregnancy|0
6155849|NCT01145625|9795209|FG001|Overall Study|Pregnancy|1
6155850|NCT01145755|9795227|FG000|Overall Study|Adverse Event|2
6155851|NCT01145755|9795228|FG001|Overall Study|Adverse Event|4
6155852|NCT01145755|9795229|FG002|Overall Study|Adverse Event|2
6155853|NCT01145755|9795227|FG000|Overall Study|Withdrawal by Subject|2
6155854|NCT01145755|9795228|FG001|Overall Study|Withdrawal by Subject|2
6155855|NCT01145755|9795229|FG002|Overall Study|Withdrawal by Subject|2
6155856|NCT01145755|9795227|FG000|Overall Study|Lost to Follow-up|2
6155857|NCT01145755|9795228|FG001|Overall Study|Lost to Follow-up|3
6155858|NCT01145755|9795229|FG002|Overall Study|Lost to Follow-up|1
6155859|NCT01145755|9795227|FG000|Overall Study|Protocol Violation|0
6155860|NCT01145755|9795228|FG001|Overall Study|Protocol Violation|3
6155861|NCT01145755|9795229|FG002|Overall Study|Protocol Violation|1
6155862|NCT01145755|9795227|FG000|Overall Study|Study Closure|14
6155863|NCT01145755|9795228|FG001|Overall Study|Study Closure|14
6155864|NCT01145755|9795229|FG002|Overall Study|Study Closure|17
6155865|NCT01145755|9795227|FG000|Overall Study|Lack of Efficacy|0
6155866|NCT01145755|9795228|FG001|Overall Study|Lack of Efficacy|1
6155867|NCT01145755|9795229|FG002|Overall Study|Lack of Efficacy|0
6155868|NCT01145755|9795227|FG000|Overall Study|Patient could not swollow medication|0
6155869|NCT01145755|9795228|FG001|Overall Study|Patient could not swollow medication|0
6155870|NCT01145755|9795229|FG002|Overall Study|Patient could not swollow medication|1
6155871|NCT01145755|9795227|FG000|Overall Study|Withdrawal by Subject|0
6155872|NCT01145755|9795228|FG001|Overall Study|Withdrawal by Subject|0
6155873|NCT01145755|9795229|FG002|Overall Study|Withdrawal by Subject|1
6155874|NCT01145755|9795227|FG000|Overall Study|Positive urine ethanol|0
6155875|NCT01145755|9795228|FG001|Overall Study|Positive urine ethanol|1
6155876|NCT01145755|9795229|FG002|Overall Study|Positive urine ethanol|0
6155877|NCT01145885|9795246|FG000|Overall Study|Progressive Disease|7
6155878|NCT01145898|9795258|FG000|3-year Treatment|medication change by treating physician|3
6155879|NCT01145898|9795259|FG001|3-year Treatment|medication change by treating physician|16
6155880|NCT01146054|9795264|FG000|Overall Study|Did not meet dose constraints for SBRT|5
6155881|NCT01146054|9795264|FG000|Overall Study|Rapid tumor progression|2
6155882|NCT01146054|9795264|FG000|Overall Study|Other illness precluded treatment|2
6155883|NCT01146054|9795264|FG000|Overall Study|Lost to Follow-up|1
6155884|NCT01146288|9795275|FG000|First Intervention(1 Day)|Adverse Event|0
6155885|NCT01146288|9795276|FG001|First Intervention(1 Day)|Adverse Event|1
6155886|NCT01146561|9795331|FG000|Overall Study|Withdrawal by Subject|1
6155887|NCT01146561|9795331|FG000|Overall Study|Lost to Follow-up|1
6155888|NCT01146613|9795347|FG000|Overall Study|Lost to Follow-up|3
6155889|NCT01146613|9795348|FG001|Overall Study|Lost to Follow-up|8
6155890|NCT01146613|9795347|FG000|Overall Study|Lack of Efficacy|0
6155891|NCT01146613|9795348|FG001|Overall Study|Lack of Efficacy|1
6155892|NCT01146613|9795347|FG000|Overall Study|Death|1
6155893|NCT01146613|9795348|FG001|Overall Study|Death|0
6155894|NCT01146613|9795347|FG000|Overall Study|Physician Decision|1
6155895|NCT01146613|9795348|FG001|Overall Study|Physician Decision|0
6155896|NCT01146613|9795347|FG000|Overall Study|Withdrawal by Subject|0
6155897|NCT01146613|9795348|FG001|Overall Study|Withdrawal by Subject|3
6155898|NCT01146613|9795347|FG000|Overall Study|schedule conflict|1
6155899|NCT01146613|9795348|FG001|Overall Study|schedule conflict|0
6155900|NCT01146613|9795347|FG000|Overall Study|Outpatient detox|1
6155901|NCT01146613|9795348|FG001|Overall Study|Outpatient detox|0
6191715|NCT01425281|9848677|FG000|At 30-day Clinical Follow-up|Withdrawal by Subject|1
6191716|NCT01425281|9848678|FG001|At 30-day Clinical Follow-up|Withdrawal by Subject|0
6191717|NCT01425281|9848677|FG000|At 180-day Clinical Follow-up|Withdrawal by Subject|3
6191718|NCT01425281|9848678|FG001|At 180-day Clinical Follow-up|Withdrawal by Subject|0
6191719|NCT01425281|9848677|FG000|At 180-day Clinical Follow-up|Death|0
6191720|NCT01425281|9848678|FG001|At 180-day Clinical Follow-up|Death|1
6191721|NCT01425281|9848677|FG000|At 1-year Clinical Follow-up|Withdrawal by Subject|1
6191722|NCT01425281|9848678|FG001|At 1-year Clinical Follow-up|Withdrawal by Subject|1
6191723|NCT01425281|9848677|FG000|At 1-year Clinical Follow-up|Withdrawal by Physician/Site|1
6191724|NCT01425281|9848678|FG001|At 1-year Clinical Follow-up|Withdrawal by Physician/Site|0
6191725|NCT01425281|9848677|FG000|At 2-year Clinical Follow-up|Withdrawal by Subject|2
6191726|NCT01425281|9848678|FG001|At 2-year Clinical Follow-up|Withdrawal by Subject|1
6191727|NCT01425281|9848677|FG000|At 2-year Clinical Follow-up|Death|2
6191728|NCT01425281|9848678|FG001|At 2-year Clinical Follow-up|Death|0
6191729|NCT01425281|9848677|FG000|At 2-year Clinical Follow-up|Lost to Follow-up|1
6191730|NCT01425281|9848678|FG001|At 2-year Clinical Follow-up|Lost to Follow-up|0
6191731|NCT01425281|9848677|FG000|At 2-year Clinical Follow-up|Patient did not want to participate in t|1
6191732|NCT01425281|9848678|FG001|At 2-year Clinical Follow-up|Patient did not want to participate in t|0
6191733|NCT01425281|9848677|FG000|At 3-year Clinical Follow-up|Withdrawal by Subject|3
6191734|NCT01425281|9848678|FG001|At 3-year Clinical Follow-up|Withdrawal by Subject|3
6191735|NCT01425281|9848677|FG000|At 3-year Clinical Follow-up|Death|2
6191736|NCT01425281|9848678|FG001|At 3-year Clinical Follow-up|Death|3
6191737|NCT01425281|9848677|FG000|At 4-year Clinical Follow-up|Death|7
6191738|NCT01425281|9848678|FG001|At 4-year Clinical Follow-up|Death|3
6191739|NCT01425281|9848677|FG000|At 4-year Clinical Follow-up|Withdrawal by Subject|3
6193360|NCT01437540|9851006|FG000|Overall Study|Protocol Violation|24
6155902|NCT01146665|9795356|FG000|Overall Study|Withdrawal by Subject|10
6155903|NCT01146665|9795357|FG001|Overall Study|Withdrawal by Subject|16
6155904|NCT01146782|9795381|FG000|Screening Cohort|Screen Failure|187
6155905|NCT01146782|9795381|FG000|Screening Cohort|Lost to Follow-up|4
6155906|NCT01146782|9795381|FG000|Screening Cohort|Physician Decision|1
6155907|NCT01146782|9795381|FG000|Screening Cohort|Withdrawal by Subject|29
6155908|NCT01146782|9795381|FG000|Safety Cohort|Screen Failure|61
6155909|NCT01146782|9795381|FG000|Safety Cohort|Withdrawal by Subject|4
6155910|NCT01146782|9795381|FG000|Safety Cohort|Control AHI <5|4
6155911|NCT01146782|9795381|FG000|Safety Cohort|TST <4 hrs|14
6155912|NCT01146782|9795381|FG000|Primary Endpoint Cohort|Withdrawal by Subject|5
6155913|NCT01146782|9795381|FG000|Primary Endpoint Cohort|Physician Decision|1
6155914|NCT01146795|9795386|FG000|Overall Study|Withdrawal by Subject|4
6155915|NCT01146795|9795386|FG000|Overall Study|Adverse Event|6
6155916|NCT01146795|9795386|FG000|Overall Study|Still in treatment at study closure|10
6155917|NCT01146860|9795417|FG000|Overall Study|Withdrawal by Subject|0
6155918|NCT01146860|9795418|FG001|Overall Study|Withdrawal by Subject|1
6155919|NCT01146873|9795426|FG000|Overall Study|Transfer out|0
6155920|NCT01146873|9795427|FG001|Overall Study|Transfer out|6
6155921|NCT01146912|9795440|FG000|Overall Study|Already received influenza vaccination|817
6155922|NCT01146912|9795441|FG001|Overall Study|Already received influenza vaccination|822
6155923|NCT01146912|9795442|FG002|Overall Study|Already received influenza vaccination|13
6155924|NCT01146912|9795443|FG003|Overall Study|Already received influenza vaccination|15
6155925|NCT01146912|9795444|FG004|Overall Study|Already received influenza vaccination|41
6155926|NCT01146912|9795445|FG005|Overall Study|Already received influenza vaccination|61
6155927|NCT01146912|9795446|FG006|Overall Study|Already received influenza vaccination|56
6155928|NCT01146912|9795447|FG007|Overall Study|Already received influenza vaccination|0
6155929|NCT01146912|9795440|FG000|Overall Study|< 14 weeks gestational age|0
6155930|NCT01146912|9795441|FG001|Overall Study|< 14 weeks gestational age|0
6155931|NCT01146912|9795442|FG002|Overall Study|< 14 weeks gestational age|3
6155932|NCT01146912|9795443|FG003|Overall Study|< 14 weeks gestational age|2
6155933|NCT01146912|9795444|FG004|Overall Study|< 14 weeks gestational age|0
6155934|NCT01146912|9795445|FG005|Overall Study|< 14 weeks gestational age|0
6155935|NCT01146912|9795446|FG006|Overall Study|< 14 weeks gestational age|0
6155936|NCT01146912|9795447|FG007|Overall Study|< 14 weeks gestational age|0
6155937|NCT01146912|9795440|FG000|Overall Study|Duplicate patient|0
6155938|NCT01146912|9795441|FG001|Overall Study|Duplicate patient|0
6155939|NCT01146912|9795442|FG002|Overall Study|Duplicate patient|1
6155940|NCT01146912|9795443|FG003|Overall Study|Duplicate patient|0
6155941|NCT01146912|9795444|FG004|Overall Study|Duplicate patient|0
6155942|NCT01146912|9795445|FG005|Overall Study|Duplicate patient|0
6155943|NCT01146912|9795446|FG006|Overall Study|Duplicate patient|0
6155944|NCT01146912|9795447|FG007|Overall Study|Duplicate patient|0
6155945|NCT01146951|9795468|FG000|Overall Study|Adverse Event|4
6155946|NCT01146951|9795469|FG001|Overall Study|Adverse Event|1
6155947|NCT01147055|9795475|FG000|First Intervention Period|Lost to Follow-up|1
6155948|NCT01147055|9795476|FG001|First Intervention Period|Lost to Follow-up|0
6155949|NCT01147068|9795489|FG000|Subjects That Received 2nd Dose|Lost to Follow-up|1
6155950|NCT01147068|9795490|FG001|Subjects That Received 2nd Dose|Lost to Follow-up|0
6080393|NCT00615836|9687575|FG001|Extension Study (FE992026 CS31)|Lost to Follow-up|14
6080394|NCT00615836|9687576|FG002|Extension Study (FE992026 CS31)|Lost to Follow-up|5
6080395|NCT00615836|9687577|FG003|Extension Study (FE992026 CS31)|Lost to Follow-up|10
6080396|NCT00615836|9687578|FG004|Extension Study (FE992026 CS31)|Lost to Follow-up|0
6080397|NCT00615836|9687574|FG000|Extension Study (FE992026 CS31)|Other|10
6080398|NCT00615836|9687575|FG001|Extension Study (FE992026 CS31)|Other|7
6080399|NCT00615836|9687576|FG002|Extension Study (FE992026 CS31)|Other|8
6080400|NCT00615836|9687577|FG003|Extension Study (FE992026 CS31)|Other|8
6080401|NCT00615836|9687578|FG004|Extension Study (FE992026 CS31)|Other|0
6042421|NCT00382720|9640717|FG000|Overall Study|Adverse Event|21
6155951|NCT01147068|9795491|FG002|Subjects That Received 2nd Dose|Lost to Follow-up|0
6155952|NCT01147068|9795492|FG003|Subjects That Received 2nd Dose|Lost to Follow-up|0
6155953|NCT01147068|9795493|FG004|Subjects That Received 2nd Dose|Lost to Follow-up|0
6042422|NCT00382720|9640718|FG001|Overall Study|Adverse Event|23
6042423|NCT00382720|9640719|FG002|Overall Study|Adverse Event|15
6042424|NCT00382720|9640717|FG000|Overall Study|Protocol Violation|2
6042425|NCT00382720|9640718|FG001|Overall Study|Protocol Violation|5
6042426|NCT00382720|9640719|FG002|Overall Study|Protocol Violation|1
6042427|NCT00382720|9640717|FG000|Overall Study|Death|0
6042428|NCT00382720|9640718|FG001|Overall Study|Death|1
6042429|NCT00382720|9640719|FG002|Overall Study|Death|2
6042430|NCT00382720|9640717|FG000|Overall Study|Progressive disease|37
6042431|NCT00382720|9640718|FG001|Overall Study|Progressive disease|28
6042432|NCT00382720|9640719|FG002|Overall Study|Progressive disease|38
6042433|NCT00382720|9640717|FG000|Overall Study|Withdrew consent|1
6042434|NCT00382720|9640718|FG001|Overall Study|Withdrew consent|1
6042435|NCT00382720|9640719|FG002|Overall Study|Withdrew consent|2
6042436|NCT00382720|9640717|FG000|Overall Study|Withdrawal by Subject|11
6042437|NCT00382720|9640718|FG001|Overall Study|Withdrawal by Subject|20
6155954|NCT01147068|9795494|FG005|Subjects That Received 2nd Dose|Lost to Follow-up|1
6042438|NCT00382720|9640719|FG002|Overall Study|Withdrawal by Subject|12
6042439|NCT00382720|9640717|FG000|Overall Study|Surgery|1
6042440|NCT00382720|9640718|FG001|Overall Study|Surgery|1
6155955|NCT01147068|9795495|FG006|Subjects That Received 2nd Dose|Lost to Follow-up|0
6042441|NCT00382720|9640719|FG002|Overall Study|Surgery|4
6042442|NCT00382720|9640717|FG000|Overall Study|Patient did not receive study medication|1
6155956|NCT01147068|9795489|FG000|Subjects That Received 2nd Dose|Ineligible|0
6155957|NCT01147068|9795490|FG001|Subjects That Received 2nd Dose|Ineligible|1
6155958|NCT01147068|9795491|FG002|Subjects That Received 2nd Dose|Ineligible|0
6155959|NCT01147068|9795492|FG003|Subjects That Received 2nd Dose|Ineligible|0
6155960|NCT01147068|9795493|FG004|Subjects That Received 2nd Dose|Ineligible|0
6155961|NCT01147068|9795494|FG005|Subjects That Received 2nd Dose|Ineligible|0
6155962|NCT01147068|9795495|FG006|Subjects That Received 2nd Dose|Ineligible|0
6155963|NCT01147068|9795489|FG000|Subjects That Received 2nd Dose|Did not complete the study|0
6155964|NCT01147068|9795490|FG001|Subjects That Received 2nd Dose|Did not complete the study|1
6155965|NCT01147068|9795491|FG002|Subjects That Received 2nd Dose|Did not complete the study|0
6155966|NCT01147068|9795492|FG003|Subjects That Received 2nd Dose|Did not complete the study|0
6155967|NCT01147068|9795493|FG004|Subjects That Received 2nd Dose|Did not complete the study|0
6155968|NCT01147068|9795494|FG005|Subjects That Received 2nd Dose|Did not complete the study|1
6155969|NCT01147068|9795495|FG006|Subjects That Received 2nd Dose|Did not complete the study|0
6155970|NCT01147068|9795489|FG000|Subjects That Received 2nd Dose|Other|0
6155971|NCT01147068|9795490|FG001|Subjects That Received 2nd Dose|Other|3
6155972|NCT01147068|9795491|FG002|Subjects That Received 2nd Dose|Other|3
6155973|NCT01147068|9795492|FG003|Subjects That Received 2nd Dose|Other|0
6155974|NCT01147068|9795493|FG004|Subjects That Received 2nd Dose|Other|1
6155975|NCT01147068|9795494|FG005|Subjects That Received 2nd Dose|Other|0
6155976|NCT01147068|9795495|FG006|Subjects That Received 2nd Dose|Other|0
6155977|NCT01147068|9795489|FG000|Subjects That Completed Safety Follow-up|Lost to Follow-up|1
6155978|NCT01147068|9795490|FG001|Subjects That Completed Safety Follow-up|Lost to Follow-up|0
6155979|NCT01147068|9795491|FG002|Subjects That Completed Safety Follow-up|Lost to Follow-up|0
6155980|NCT01147068|9795492|FG003|Subjects That Completed Safety Follow-up|Lost to Follow-up|0
6155981|NCT01147068|9795493|FG004|Subjects That Completed Safety Follow-up|Lost to Follow-up|0
6155982|NCT01147068|9795494|FG005|Subjects That Completed Safety Follow-up|Lost to Follow-up|1
6155983|NCT01147068|9795495|FG006|Subjects That Completed Safety Follow-up|Lost to Follow-up|1
6155984|NCT01147068|9795489|FG000|Subjects That Completed Safety Follow-up|Withdrawal by Subject|0
6155985|NCT01147068|9795490|FG001|Subjects That Completed Safety Follow-up|Withdrawal by Subject|0
6155986|NCT01147068|9795491|FG002|Subjects That Completed Safety Follow-up|Withdrawal by Subject|0
6155987|NCT01147068|9795492|FG003|Subjects That Completed Safety Follow-up|Withdrawal by Subject|2
6155988|NCT01147068|9795493|FG004|Subjects That Completed Safety Follow-up|Withdrawal by Subject|0
6193361|NCT01437540|9851007|FG001|Overall Study|Protocol Violation|12
6042443|NCT00382720|9640718|FG001|Overall Study|Patient did not receive study medication|1
6042444|NCT00382720|9640719|FG002|Overall Study|Patient did not receive study medication|4
6042445|NCT00382720|9640717|FG000|Overall Study|Clinically progressive disease|0
6042446|NCT00382720|9640718|FG001|Overall Study|Clinically progressive disease|1
6042447|NCT00382720|9640719|FG002|Overall Study|Clinically progressive disease|0
6042448|NCT00382720|9640717|FG000|Overall Study|Good prognosis|0
6042449|NCT00382720|9640718|FG001|Overall Study|Good prognosis|1
6042450|NCT00382720|9640719|FG002|Overall Study|Good prognosis|0
6042451|NCT00382720|9640717|FG000|Overall Study|Investigator/Clinical decision|5
6042452|NCT00382720|9640718|FG001|Overall Study|Investigator/Clinical decision|6
6042453|NCT00382720|9640719|FG002|Overall Study|Investigator/Clinical decision|6
6042454|NCT00382720|9640717|FG000|Overall Study|Discontinued at end of study|0
6042455|NCT00382720|9640718|FG001|Overall Study|Discontinued at end of study|1
6042456|NCT00382720|9640719|FG002|Overall Study|Discontinued at end of study|2
6042457|NCT00382733|9640727|FG000|Overall Study|Withdrawal by Subject|0
6042458|NCT00382733|9640728|FG001|Overall Study|Withdrawal by Subject|1
6042459|NCT00382733|9640729|FG002|Overall Study|Withdrawal by Subject|0
6042460|NCT00382733|9640730|FG003|Overall Study|Withdrawal by Subject|0
6042461|NCT00382733|9640731|FG004|Overall Study|Withdrawal by Subject|0
6042462|NCT00382863|9640764|FG000|Overall Study|Death|9
6042463|NCT00382863|9640765|FG001|Overall Study|Death|9
6042464|NCT00382863|9640764|FG000|Overall Study|Lost to Follow-up|1
6042465|NCT00382863|9640765|FG001|Overall Study|Lost to Follow-up|2
6042466|NCT00382863|9640764|FG000|Overall Study|Withdrawal by Subject|5
6042467|NCT00382863|9640765|FG001|Overall Study|Withdrawal by Subject|25
6049015|NCT00420927|9648199|FG000|Period 2|Noncompliant with study drug|0
6049016|NCT00420927|9648200|FG001|Period 2|Noncompliant with study drug|0
6049017|NCT00420927|9648201|FG002|Period 2|Noncompliant with study drug|0
6049018|NCT00420927|9648202|FG003|Period 2|Noncompliant with study drug|1
6049019|NCT00420927|9648203|FG004|Period 2|Noncompliant with study drug|0
6049020|NCT00420927|9648204|FG005|Period 2|Noncompliant with study drug|0
6049021|NCT00420927|9648205|FG006|Period 2|Noncompliant with study drug|2
6049022|NCT00420927|9648199|FG000|Period 2|Methotrexate intolerance|0
6042468|NCT00382967|9640787|FG000|Overall Study|Protocol Violation|1
6042469|NCT00382967|9640788|FG001|Overall Study|Protocol Violation|1
6042470|NCT00382993|9640794|FG000|Migraine Attack 1 (Period 1)|Lost to Follow-up|7
5972183|NCT03923738|9557864|FG000|Period 1|Withdrawal by Subject|1
5972184|NCT03887117|9557874|FG000|Overall Study|Discontinued prematurely|0
5972185|NCT03887117|9557875|FG001|Overall Study|Discontinued prematurely|1
5972186|NCT03887117|9557876|FG002|Overall Study|Discontinued prematurely|1
5972187|NCT03887117|9557877|FG003|Overall Study|Discontinued prematurely|2
5972188|NCT03858634|9557898|FG000|Overall Study|Withdrawal by Subject|1
5972189|NCT03858634|9557899|FG001|Overall Study|Withdrawal by Subject|0
5972190|NCT03858634|9557898|FG000|Overall Study|Adverse Event|1
5972191|NCT03858634|9557899|FG001|Overall Study|Adverse Event|0
5972192|NCT03858634|9557898|FG000|Overall Study|Lost to Follow-up|0
5972193|NCT03858634|9557899|FG001|Overall Study|Lost to Follow-up|1
5972194|NCT03858634|9557898|FG000|Overall Study|Other, Not Specified|1
5972195|NCT03858634|9557899|FG001|Overall Study|Other, Not Specified|1
5972196|NCT03819114|9557917|FG000|Overall Study|Protocol Violation|0
5972197|NCT03819114|9557918|FG001|Overall Study|Protocol Violation|1
5972198|NCT03819114|9557919|FG002|Overall Study|Protocol Violation|1
5972199|NCT03819114|9557920|FG003|Overall Study|Protocol Violation|0
5972200|NCT03819114|9557917|FG000|Overall Study|Lost to Follow-up|0
6042471|NCT00382993|9640795|FG001|Migraine Attack 1 (Period 1)|Lost to Follow-up|2
6042472|NCT00382993|9640794|FG000|Migraine Attack 1 (Period 1)|Withdrawal by Subject|1
6042473|NCT00382993|9640795|FG001|Migraine Attack 1 (Period 1)|Withdrawal by Subject|3
6042474|NCT00382993|9640794|FG000|Migraine Attack 1 (Period 1)|Lack of opportunity to treat migraine|0
6042475|NCT00382993|9640795|FG001|Migraine Attack 1 (Period 1)|Lack of opportunity to treat migraine|5
6042476|NCT00382993|9640794|FG000|Migraine Attack 1 (Period 1)|Did not meet Eligibility Criteria|3
6042477|NCT00382993|9640795|FG001|Migraine Attack 1 (Period 1)|Did not meet Eligibility Criteria|3
6042478|NCT00382993|9640794|FG000|Migraine Attack 1 (Period 1)|Other (no additional data present)|3
6042479|NCT00382993|9640795|FG001|Migraine Attack 1 (Period 1)|Other (no additional data present)|5
6042480|NCT00382993|9640794|FG000|Migraine Attack 2 (Period 2)|Lost to Follow-up|1
6042481|NCT00382993|9640795|FG001|Migraine Attack 2 (Period 2)|Lost to Follow-up|0
6042482|NCT00382993|9640794|FG000|Migraine Attack 2 (Period 2)|Lack of opportunity to treat migraine|0
6042483|NCT00382993|9640795|FG001|Migraine Attack 2 (Period 2)|Lack of opportunity to treat migraine|1
6042484|NCT00382993|9640794|FG000|Migraine Attack 2 (Period 2)|Did not meet Eligibility Criteria|0
6042485|NCT00382993|9640795|FG001|Migraine Attack 2 (Period 2)|Did not meet Eligibility Criteria|1
6042486|NCT00382993|9640794|FG000|Migraine Attack 2 (Period 2)|Protocol Violation|0
6042487|NCT00382993|9640795|FG001|Migraine Attack 2 (Period 2)|Protocol Violation|1
6042488|NCT00382993|9640794|FG000|Migraine Attack 2 (Period 2)|Other (no additional data present)|1
6042489|NCT00382993|9640795|FG001|Migraine Attack 2 (Period 2)|Other (no additional data present)|1
6042490|NCT00383019|9640803|FG000|Overall Study|Adverse Event|5
6042491|NCT00383019|9640804|FG001|Overall Study|Adverse Event|1
6042492|NCT00383019|9640803|FG000|Overall Study|Withdrawal by Subject|0
6042493|NCT00383019|9640804|FG001|Overall Study|Withdrawal by Subject|1
6042494|NCT00383084|9640829|FG000|Overall Study|Withdrawal by Subject|12
6042495|NCT00383084|9640830|FG001|Overall Study|Withdrawal by Subject|10
6042496|NCT00383123|9640848|FG000|Overall Study|Adverse Event|1
6042497|NCT00383123|9640849|FG001|Overall Study|Adverse Event|0
6042498|NCT00383123|9640848|FG000|Overall Study|Lost to Follow-up|68
6042499|NCT00383123|9640849|FG001|Overall Study|Lost to Follow-up|61
6042500|NCT00383123|9640848|FG000|Overall Study|Protocol Violation|5
6042501|NCT00383123|9640849|FG001|Overall Study|Protocol Violation|1
6042502|NCT00383123|9640848|FG000|Overall Study|Withdrawal by Subject|27
6042503|NCT00383123|9640849|FG001|Overall Study|Withdrawal by Subject|18
6042504|NCT00383123|9640848|FG000|Overall Study|Other reason|10
6042505|NCT00383123|9640849|FG001|Overall Study|Other reason|6
6042506|NCT00383149|9640855|FG000|Overall Study|Adverse Event not Related to Study Drug|3
6042507|NCT00383149|9640855|FG000|Overall Study|Death|2
6042508|NCT00383149|9640855|FG000|Overall Study|Disease Progression|38
6042509|NCT00383149|9640855|FG000|Overall Study|Lost to Follow-up|1
6042510|NCT00383149|9640855|FG000|Overall Study|Other|1
6042511|NCT00383149|9640855|FG000|Overall Study|Study Drug Toxicity|4
6042512|NCT00383149|9640855|FG000|Overall Study|Request to Discontinue Treatment|4
6042513|NCT00383149|9640855|FG000|Overall Study|Participant Withdrew Consent|1
6042514|NCT00383162|9640861|FG000|Migraine Attack 1 (Period 1)|No opportunity to treat migraine|3
6042515|NCT00383162|9640862|FG001|Migraine Attack 1 (Period 1)|No opportunity to treat migraine|4
6042516|NCT00383162|9640861|FG000|Migraine Attack 1 (Period 1)|Lost to Follow-up|8
6042517|NCT00383162|9640862|FG001|Migraine Attack 1 (Period 1)|Lost to Follow-up|7
6042518|NCT00383162|9640861|FG000|Migraine Attack 1 (Period 1)|Did not meet eligibility criteria|4
6042519|NCT00383162|9640862|FG001|Migraine Attack 1 (Period 1)|Did not meet eligibility criteria|2
6042520|NCT00383162|9640861|FG000|Migraine Attack 1 (Period 1)|Withdrawal by Subject|2
6042521|NCT00383162|9640862|FG001|Migraine Attack 1 (Period 1)|Withdrawal by Subject|0
6042522|NCT00383162|9640861|FG000|Migraine Attack 1 (Period 1)|Non-compliant|3
6042523|NCT00383162|9640862|FG001|Migraine Attack 1 (Period 1)|Non-compliant|0
6042524|NCT00383162|9640861|FG000|Migraine Attack 2 (Period 2)|No opportunity to treat migraine 2|1
6042525|NCT00383162|9640862|FG001|Migraine Attack 2 (Period 2)|No opportunity to treat migraine 2|3
6042526|NCT00383162|9640861|FG000|Migraine Attack 2 (Period 2)|Lost to Follow-up|0
6042527|NCT00383162|9640862|FG001|Migraine Attack 2 (Period 2)|Lost to Follow-up|1
6042528|NCT00383162|9640861|FG000|Migraine Attack 2 (Period 2)|Adverse Event|1
6042529|NCT00383162|9640862|FG001|Migraine Attack 2 (Period 2)|Adverse Event|0
6042530|NCT00383162|9640861|FG000|Migraine Attack 2 (Period 2)|Unknown reason|0
6042531|NCT00383162|9640862|FG001|Migraine Attack 2 (Period 2)|Unknown reason|3
6042532|NCT00383188|9640873|FG000|Overall Study|Adverse Event|4
6042533|NCT00383188|9640874|FG001|Overall Study|Adverse Event|7
6042534|NCT00383188|9640875|FG002|Overall Study|Adverse Event|9
6042535|NCT00383188|9640876|FG003|Overall Study|Adverse Event|8
6042536|NCT00383188|9640877|FG004|Overall Study|Adverse Event|8
6042537|NCT00383188|9640873|FG000|Overall Study|Lack of Efficacy|9
6042538|NCT00383188|9640874|FG001|Overall Study|Lack of Efficacy|3
6042539|NCT00383188|9640875|FG002|Overall Study|Lack of Efficacy|3
6042540|NCT00383188|9640876|FG003|Overall Study|Lack of Efficacy|2
6042541|NCT00383188|9640877|FG004|Overall Study|Lack of Efficacy|6
6042542|NCT00383188|9640873|FG000|Overall Study|Other|3
6042543|NCT00383188|9640874|FG001|Overall Study|Other|1
6042544|NCT00383188|9640875|FG002|Overall Study|Other|0
6042545|NCT00383188|9640876|FG003|Overall Study|Other|2
6042546|NCT00383188|9640877|FG004|Overall Study|Other|6
6042547|NCT00383188|9640873|FG000|Overall Study|No longer willing to participate|1
6042548|NCT00383188|9640874|FG001|Overall Study|No longer willing to participate|0
6042549|NCT00383188|9640875|FG002|Overall Study|No longer willing to participate|1
6042550|NCT00383188|9640876|FG003|Overall Study|No longer willing to participate|0
6042551|NCT00383188|9640877|FG004|Overall Study|No longer willing to participate|2
6042552|NCT00383188|9640873|FG000|Overall Study|Lost to Follow-up|0
6042553|NCT00383188|9640874|FG001|Overall Study|Lost to Follow-up|0
6042554|NCT00383188|9640875|FG002|Overall Study|Lost to Follow-up|0
6042555|NCT00383188|9640876|FG003|Overall Study|Lost to Follow-up|0
6042556|NCT00383188|9640877|FG004|Overall Study|Lost to Follow-up|1
6042557|NCT00383292|9640898|FG000|Overall Study|Adverse Event|4
6042558|NCT00383292|9640899|FG001|Overall Study|Adverse Event|1
6042559|NCT00383292|9640900|FG002|Overall Study|Adverse Event|2
6042560|NCT00383292|9640898|FG000|Overall Study|Death|3
6042561|NCT00383292|9640899|FG001|Overall Study|Death|3
6042562|NCT00383292|9640900|FG002|Overall Study|Death|3
6042563|NCT00383292|9640898|FG000|Overall Study|Physician Decision|4
6042564|NCT00383292|9640899|FG001|Overall Study|Physician Decision|0
6042565|NCT00383292|9640900|FG002|Overall Study|Physician Decision|1
6042566|NCT00383292|9640898|FG000|Overall Study|Withdrawal by Subject|3
6042567|NCT00383292|9640899|FG001|Overall Study|Withdrawal by Subject|2
6042568|NCT00383292|9640900|FG002|Overall Study|Withdrawal by Subject|2
6042569|NCT00383292|9640898|FG000|Overall Study|Other|1
6042570|NCT00383292|9640899|FG001|Overall Study|Other|0
6042571|NCT00383292|9640900|FG002|Overall Study|Other|0
6042572|NCT00383331|9640911|FG000|Overall Study|Protocol Violation|0
6042573|NCT00383331|9640912|FG001|Overall Study|Protocol Violation|1
6042574|NCT00383500|9640926|FG000|Overall Study|Withdrawal by Subject|8
6042575|NCT00383500|9640927|FG001|Overall Study|Withdrawal by Subject|3
6042576|NCT00383500|9640928|FG002|Overall Study|Withdrawal by Subject|0
6042577|NCT00383500|9640926|FG000|Overall Study|Lost to Follow-up|0
6042578|NCT00383500|9640927|FG001|Overall Study|Lost to Follow-up|0
6042579|NCT00383500|9640928|FG002|Overall Study|Lost to Follow-up|2
6042580|NCT00383786|9640979|FG000|Overall Study|Protocol Violation|2
6042581|NCT00383786|9640980|FG001|Overall Study|Protocol Violation|6
6042582|NCT00383786|9640979|FG000|Overall Study|Withdrawal by Subject|2
6042583|NCT00383786|9640980|FG001|Overall Study|Withdrawal by Subject|5
6042584|NCT00383786|9640979|FG000|Overall Study|Physician Decision|0
6042585|NCT00383786|9640980|FG001|Overall Study|Physician Decision|1
6042586|NCT00384033|9640999|FG000|Overall Study|Adverse Event|10
6042587|NCT00384033|9641000|FG001|Overall Study|Adverse Event|8
6042588|NCT00384033|9641001|FG002|Overall Study|Adverse Event|11
6042589|NCT00384033|9641002|FG003|Overall Study|Adverse Event|20
6042590|NCT00384033|9640999|FG000|Overall Study|Failed to return|1
6042591|NCT00384033|9641000|FG001|Overall Study|Failed to return|3
6042592|NCT00384033|9641001|FG002|Overall Study|Failed to return|2
6042593|NCT00384033|9641002|FG003|Overall Study|Failed to return|2
6042594|NCT00384033|9640999|FG000|Overall Study|Physician Decision|1
6042595|NCT00384033|9641000|FG001|Overall Study|Physician Decision|0
6042596|NCT00384033|9641001|FG002|Overall Study|Physician Decision|0
6042597|NCT00384033|9641002|FG003|Overall Study|Physician Decision|0
6042598|NCT00384033|9640999|FG000|Overall Study|Lost to Follow-up|6
6155989|NCT01147068|9795494|FG005|Subjects That Completed Safety Follow-up|Withdrawal by Subject|0
6155990|NCT01147068|9795495|FG006|Subjects That Completed Safety Follow-up|Withdrawal by Subject|0
6155991|NCT01147068|9795489|FG000|Subjects That Completed Safety Follow-up|Ineligible|0
6155992|NCT01147068|9795490|FG001|Subjects That Completed Safety Follow-up|Ineligible|1
6155993|NCT01147068|9795491|FG002|Subjects That Completed Safety Follow-up|Ineligible|0
6155994|NCT01147068|9795492|FG003|Subjects That Completed Safety Follow-up|Ineligible|0
6042599|NCT00384033|9641000|FG001|Overall Study|Lost to Follow-up|12
6042600|NCT00384033|9641001|FG002|Overall Study|Lost to Follow-up|7
6042601|NCT00384033|9641002|FG003|Overall Study|Lost to Follow-up|7
6042602|NCT00384033|9640999|FG000|Overall Study|Other|2
6155995|NCT01147068|9795493|FG004|Subjects That Completed Safety Follow-up|Ineligible|0
6155996|NCT01147068|9795494|FG005|Subjects That Completed Safety Follow-up|Ineligible|0
6155997|NCT01147068|9795495|FG006|Subjects That Completed Safety Follow-up|Ineligible|0
6155998|NCT01147107|9795513|FG000|Overall Study|Lack of Efficacy|5
6155999|NCT01147107|9795514|FG001|Overall Study|Lack of Efficacy|0
6156000|NCT01147107|9795513|FG000|Overall Study|Withdrawal by Subject|1
6156001|NCT01147107|9795514|FG001|Overall Study|Withdrawal by Subject|1
6156002|NCT01147172|9795520|FG000|Overall Study|Withdrawal by Subject|2
6042603|NCT00384033|9641000|FG001|Overall Study|Other|0
6042604|NCT00384033|9641001|FG002|Overall Study|Other|0
6042605|NCT00384033|9641002|FG003|Overall Study|Other|0
6042606|NCT00384033|9640999|FG000|Overall Study|Protocol Violation|5
6042607|NCT00384033|9641000|FG001|Overall Study|Protocol Violation|0
6042608|NCT00384033|9641001|FG002|Overall Study|Protocol Violation|5
6042609|NCT00384033|9641002|FG003|Overall Study|Protocol Violation|6
6042610|NCT00384033|9640999|FG000|Overall Study|Withdrawal by Subject|6
6042611|NCT00384033|9641000|FG001|Overall Study|Withdrawal by Subject|2
6042612|NCT00384033|9641001|FG002|Overall Study|Withdrawal by Subject|5
6042613|NCT00384033|9641002|FG003|Overall Study|Withdrawal by Subject|2
6042614|NCT00384033|9640999|FG000|Overall Study|Lack of Efficacy|7
6042615|NCT00384033|9641000|FG001|Overall Study|Lack of Efficacy|3
6042616|NCT00384033|9641001|FG002|Overall Study|Lack of Efficacy|3
6042617|NCT00384033|9641002|FG003|Overall Study|Lack of Efficacy|1
6042618|NCT00384033|9640999|FG000|Overall Study|Randomized but not treated|3
6042619|NCT00384033|9641000|FG001|Overall Study|Randomized but not treated|7
6042620|NCT00384033|9641001|FG002|Overall Study|Randomized but not treated|10
6042621|NCT00384033|9641002|FG003|Overall Study|Randomized but not treated|2
6042622|NCT00384059|9641014|FG000|Infant Series|Not consented|2
6042623|NCT00384059|9641015|FG001|Infant Series|Not consented|6
6042624|NCT00384059|9641014|FG000|Infant Series|Withdrawal by Subject|2
6042625|NCT00384059|9641015|FG001|Infant Series|Withdrawal by Subject|2
6042626|NCT00384059|9641014|FG000|Infant Series|Adverse Event|1
6042627|NCT00384059|9641015|FG001|Infant Series|Adverse Event|2
6156003|NCT01147172|9795520|FG000|Overall Study|Lost to Follow-up|2
6227407|NCT01716754|9900108|FG000|Overall Study|Lost to Follow-up|1
6227408|NCT01716754|9900109|FG001|Overall Study|Lost to Follow-up|0
6156004|NCT01147250|9795528|FG000|Overall Study|Lost to Follow-up|14
6156005|NCT01147250|9795529|FG001|Overall Study|Lost to Follow-up|11
6156006|NCT01147250|9795528|FG000|Overall Study|Withdrawal by Subject|83
6156007|NCT01147250|9795529|FG001|Overall Study|Withdrawal by Subject|88
6156008|NCT01147250|9795528|FG000|Overall Study|Site termination by sponsor|13
6156009|NCT01147250|9795529|FG001|Overall Study|Site termination by sponsor|5
6156010|NCT01147250|9795528|FG000|Overall Study|Other than specified|0
6156011|NCT01147250|9795529|FG001|Overall Study|Other than specified|1
6156012|NCT01147341|9795546|FG000|Double Blind Period|Lack of Efficacy|1
6156013|NCT01147341|9795547|FG001|Double Blind Period|Lack of Efficacy|1
6156014|NCT01147341|9795546|FG000|Double Blind Period|Withdrawal by Subject|0
6156015|NCT01147341|9795547|FG001|Double Blind Period|Withdrawal by Subject|1
6156016|NCT01147341|9795546|FG000|Open Label Period|Lack of Efficacy|3
6156017|NCT01147341|9795547|FG001|Open Label Period|Lack of Efficacy|0
6156018|NCT01147341|9795546|FG000|Open Label Period|Subject moved|1
6156019|NCT01147341|9795547|FG001|Open Label Period|Subject moved|0
6156020|NCT01147458|9795590|FG000|First Intervention|Study terminated by sponsor|8
6156021|NCT01147458|9795591|FG001|First Intervention|Study terminated by sponsor|8
6156022|NCT01147458|9795592|FG002|First Intervention|Study terminated by sponsor|7
6156023|NCT01147458|9795593|FG003|First Intervention|Study terminated by sponsor|8
6156024|NCT01147458|9795590|FG000|First Intervention|Protocol Violation|2
6227409|NCT01716754|9900110|FG002|Overall Study|Lost to Follow-up|0
6156025|NCT01147458|9795591|FG001|First Intervention|Protocol Violation|3
6156026|NCT01147458|9795592|FG002|First Intervention|Protocol Violation|2
6156027|NCT01147458|9795593|FG003|First Intervention|Protocol Violation|3
6156028|NCT01147458|9795590|FG000|First Intervention|Withdrawal by Subject|3
6156029|NCT01147458|9795591|FG001|First Intervention|Withdrawal by Subject|0
6156030|NCT01147458|9795592|FG002|First Intervention|Withdrawal by Subject|1
6156031|NCT01147458|9795593|FG003|First Intervention|Withdrawal by Subject|0
6156032|NCT01147458|9795590|FG000|First Intervention|Adverse Event|0
6156033|NCT01147458|9795591|FG001|First Intervention|Adverse Event|3
6156034|NCT01147458|9795592|FG002|First Intervention|Adverse Event|2
6156035|NCT01147458|9795593|FG003|First Intervention|Adverse Event|3
6156036|NCT01147458|9795590|FG000|First Intervention|Other|1
6156037|NCT01147458|9795591|FG001|First Intervention|Other|2
6156038|NCT01147458|9795592|FG002|First Intervention|Other|0
6156039|NCT01147458|9795593|FG003|First Intervention|Other|0
6156040|NCT01147458|9795590|FG000|Second Intervention|Study terminated by sponsor|7
6156041|NCT01147458|9795591|FG001|Second Intervention|Study terminated by sponsor|5
6156042|NCT01147458|9795592|FG002|Second Intervention|Study terminated by sponsor|5
6156043|NCT01147458|9795593|FG003|Second Intervention|Study terminated by sponsor|3
6156044|NCT01147458|9795590|FG000|Second Intervention|Protocol Violation|0
6156045|NCT01147458|9795591|FG001|Second Intervention|Protocol Violation|1
6156046|NCT01147458|9795592|FG002|Second Intervention|Protocol Violation|1
6156047|NCT01147458|9795593|FG003|Second Intervention|Protocol Violation|0
6156048|NCT01147458|9795590|FG000|Second Intervention|Withdrawal by Subject|0
6156049|NCT01147458|9795591|FG001|Second Intervention|Withdrawal by Subject|1
6156050|NCT01147458|9795592|FG002|Second Intervention|Withdrawal by Subject|0
6156051|NCT01147458|9795593|FG003|Second Intervention|Withdrawal by Subject|0
6156052|NCT01147458|9795590|FG000|Second Intervention|Adverse Event|2
6156053|NCT01147458|9795591|FG001|Second Intervention|Adverse Event|0
6156054|NCT01147458|9795592|FG002|Second Intervention|Adverse Event|1
6156055|NCT01147458|9795593|FG003|Second Intervention|Adverse Event|1
6156056|NCT01147458|9795590|FG000|Second Intervention|Other|0
6156057|NCT01147458|9795591|FG001|Second Intervention|Other|0
6156058|NCT01147458|9795592|FG002|Second Intervention|Other|1
6156059|NCT01147458|9795593|FG003|Second Intervention|Other|0
6156060|NCT01147471|9795607|FG000|Post-discharge Follow Up (Approx 2 Wks)|Lost to Follow-up|0
6156061|NCT01147471|9795608|FG001|Post-discharge Follow Up (Approx 2 Wks)|Lost to Follow-up|1
6156062|NCT01147471|9795607|FG000|Post-discharge Follow Up (Approx 2 Wks)|Withdrawal by Subject|0
6156063|NCT01147471|9795608|FG001|Post-discharge Follow Up (Approx 2 Wks)|Withdrawal by Subject|1
6156064|NCT01147471|9795607|FG000|Post-discharge Follow Up (Approx 2 Wks)|incarcerated|0
6156065|NCT01147471|9795608|FG001|Post-discharge Follow Up (Approx 2 Wks)|incarcerated|1
6156066|NCT01147471|9795607|FG000|3 Month Follow Up|Lost to Follow-up|1
6156067|NCT01147471|9795608|FG001|3 Month Follow Up|Lost to Follow-up|1
6156068|NCT01147471|9795607|FG000|3 Month Follow Up|Physician Decision|0
6156069|NCT01147471|9795608|FG001|3 Month Follow Up|Physician Decision|1
6156070|NCT01147471|9795607|FG000|6 Month Follow Up|Lost to Follow-up|4
6156071|NCT01147471|9795608|FG001|6 Month Follow Up|Lost to Follow-up|2
6156072|NCT01147497|9795616|FG000|Overall Study|failed insertion|2
6156073|NCT01147497|9795617|FG001|Overall Study|failed insertion|0
6156074|NCT01147640|9795647|FG000|Overall Study|Adverse Event|2
6156075|NCT01147640|9795648|FG001|Overall Study|Adverse Event|0
6156076|NCT01147640|9795647|FG000|Overall Study|Physician Decision|1
6156077|NCT01147640|9795648|FG001|Overall Study|Physician Decision|0
6156078|NCT01147640|9795647|FG000|Overall Study|Withdrawal by Subject|1
6156079|NCT01147640|9795648|FG001|Overall Study|Withdrawal by Subject|0
6156080|NCT01147640|9795647|FG000|Overall Study|Lost to Follow-up|0
6156081|NCT01147640|9795648|FG001|Overall Study|Lost to Follow-up|1
6156082|NCT01147640|9795647|FG000|Overall Study|Didn't meet eligibility criteria|1
6042628|NCT00384059|9641014|FG000|Infant Series|Protocol Violation|1
6042629|NCT00384059|9641015|FG001|Infant Series|Protocol Violation|2
6042630|NCT00384059|9641014|FG000|Infant Series|Lost to Follow-up|0
6042631|NCT00384059|9641015|FG001|Infant Series|Lost to Follow-up|1
6042632|NCT00384059|9641014|FG000|After Infant Series|Protocol Violation|2
6042633|NCT00384059|9641015|FG001|After Infant Series|Protocol Violation|3
6042634|NCT00384059|9641014|FG000|After Infant Series|Withdrawal by Subject|2
6042635|NCT00384059|9641015|FG001|After Infant Series|Withdrawal by Subject|2
6042636|NCT00384059|9641014|FG000|After Infant Series|Failed to Return|0
6042637|NCT00384059|9641015|FG001|After Infant Series|Failed to Return|2
6042638|NCT00384059|9641014|FG000|After Infant Series|Adverse Event|0
6042639|NCT00384059|9641015|FG001|After Infant Series|Adverse Event|1
6042640|NCT00384059|9641014|FG000|After Infant Series|Physician Decision|0
6042641|NCT00384059|9641015|FG001|After Infant Series|Physician Decision|1
6042642|NCT00384059|9641014|FG000|After Infant Series|Lost to Follow-up|0
6042643|NCT00384059|9641015|FG001|After Infant Series|Lost to Follow-up|1
6042644|NCT00384059|9641014|FG000|Toddler Dose|Lost to Follow-up|1
6042645|NCT00384059|9641015|FG001|Toddler Dose|Lost to Follow-up|1
6042646|NCT00384059|9641014|FG000|Toddler Dose|Failed to return|0
6042647|NCT00384059|9641015|FG001|Toddler Dose|Failed to return|1
6042648|NCT00384085|9641045|FG000|Overall Study|Adverse Event|5
6042649|NCT00384085|9641046|FG001|Overall Study|Adverse Event|5
6042650|NCT00384085|9641047|FG002|Overall Study|Adverse Event|4
6042651|NCT00384085|9641045|FG000|Overall Study|Lack of Efficacy|0
6042652|NCT00384085|9641046|FG001|Overall Study|Lack of Efficacy|3
6042653|NCT00384085|9641047|FG002|Overall Study|Lack of Efficacy|2
6042654|NCT00384085|9641045|FG000|Overall Study|No longer Requires Study Treatment|1
6042655|NCT00384085|9641046|FG001|Overall Study|No longer Requires Study Treatment|0
6042656|NCT00384085|9641047|FG002|Overall Study|No longer Requires Study Treatment|1
6042657|NCT00384085|9641045|FG000|Overall Study|Protocol Violation|2
6042658|NCT00384085|9641046|FG001|Overall Study|Protocol Violation|2
6042659|NCT00384085|9641047|FG002|Overall Study|Protocol Violation|2
6042660|NCT00384085|9641045|FG000|Overall Study|Lost to Follow-up|9
6042661|NCT00384085|9641046|FG001|Overall Study|Lost to Follow-up|9
6042662|NCT00384085|9641047|FG002|Overall Study|Lost to Follow-up|10
6042663|NCT00384085|9641045|FG000|Overall Study|Progressive Disease|0
6042664|NCT00384085|9641046|FG001|Overall Study|Progressive Disease|1
6042665|NCT00384085|9641047|FG002|Overall Study|Progressive Disease|0
6042666|NCT00384085|9641045|FG000|Overall Study|Withdrawal by Subject|14
6042667|NCT00384085|9641046|FG001|Overall Study|Withdrawal by Subject|19
6042668|NCT00384085|9641047|FG002|Overall Study|Withdrawal by Subject|29
6042669|NCT00384085|9641045|FG000|Overall Study|Patient non-compliant|4
6042670|NCT00384085|9641046|FG001|Overall Study|Patient non-compliant|4
6042671|NCT00384085|9641047|FG002|Overall Study|Patient non-compliant|5
6042672|NCT00384085|9641045|FG000|Overall Study|Physician Decision|1
6042673|NCT00384085|9641046|FG001|Overall Study|Physician Decision|0
6042674|NCT00384085|9641047|FG002|Overall Study|Physician Decision|0
6042675|NCT00384085|9641045|FG000|Overall Study|Loss of site personnel|1
6042676|NCT00384085|9641046|FG001|Overall Study|Loss of site personnel|0
6042677|NCT00384085|9641047|FG002|Overall Study|Loss of site personnel|1
6042678|NCT00384085|9641045|FG000|Overall Study|Sponsor decision|1
6042679|NCT00384085|9641046|FG001|Overall Study|Sponsor decision|2
6042680|NCT00384085|9641047|FG002|Overall Study|Sponsor decision|1
6042681|NCT00384085|9641045|FG000|Overall Study|Patient moved|1
6042682|NCT00384085|9641046|FG001|Overall Study|Patient moved|0
6042683|NCT00384085|9641047|FG002|Overall Study|Patient moved|1
6042684|NCT00384085|9641045|FG000|Overall Study|Patient required surgery|0
6042685|NCT00384085|9641046|FG001|Overall Study|Patient required surgery|1
6042686|NCT00384085|9641047|FG002|Overall Study|Patient required surgery|0
6080402|NCT00615836|9687574|FG000|Extension Study (FE992026 CS31)|Not reported|6
6042687|NCT00384176|9641060|FG000|Overall Study|Death|239
6080403|NCT00615836|9687575|FG001|Extension Study (FE992026 CS31)|Not reported|4
6080404|NCT00615836|9687576|FG002|Extension Study (FE992026 CS31)|Not reported|1
6080405|NCT00615836|9687577|FG003|Extension Study (FE992026 CS31)|Not reported|4
6080406|NCT00615836|9687578|FG004|Extension Study (FE992026 CS31)|Not reported|0
6080407|NCT00615836|9687574|FG000|Extension Study (FE992026 CS31)|Re-randomized to a higher dose|65
6087669|NCT00669942|9698118|FG002|Parts 2 and 3|Adverse Event|0
6156083|NCT01147640|9795648|FG001|Overall Study|Didn't meet eligibility criteria|0
6156084|NCT01147744|9795661|FG000|Overall Study|Protocol Violation|1
6156085|NCT01147744|9795662|FG001|Overall Study|Protocol Violation|0
6156086|NCT01147744|9795663|FG002|Overall Study|Protocol Violation|1
6156087|NCT01147744|9795664|FG003|Overall Study|Protocol Violation|0
6156088|NCT01147744|9795665|FG004|Overall Study|Protocol Violation|1
6156089|NCT01147744|9795666|FG005|Overall Study|Protocol Violation|3
6156090|NCT01147744|9795667|FG006|Overall Study|Protocol Violation|1
6156091|NCT01147744|9795661|FG000|Overall Study|Physician Decision|0
6156092|NCT01147744|9795662|FG001|Overall Study|Physician Decision|1
6156093|NCT01147744|9795663|FG002|Overall Study|Physician Decision|1
6156094|NCT01147744|9795664|FG003|Overall Study|Physician Decision|0
6156095|NCT01147744|9795665|FG004|Overall Study|Physician Decision|0
6156096|NCT01147744|9795666|FG005|Overall Study|Physician Decision|0
6156097|NCT01147744|9795667|FG006|Overall Study|Physician Decision|1
6156098|NCT01147744|9795661|FG000|Overall Study|Lack of Efficacy|11
6156099|NCT01147744|9795662|FG001|Overall Study|Lack of Efficacy|11
6156100|NCT01147744|9795663|FG002|Overall Study|Lack of Efficacy|9
6156101|NCT01147744|9795664|FG003|Overall Study|Lack of Efficacy|11
6156102|NCT01147744|9795665|FG004|Overall Study|Lack of Efficacy|13
6156103|NCT01147744|9795666|FG005|Overall Study|Lack of Efficacy|8
6156104|NCT01147744|9795667|FG006|Overall Study|Lack of Efficacy|7
6156105|NCT01147744|9795661|FG000|Overall Study|Adverse Event|1
6156106|NCT01147744|9795662|FG001|Overall Study|Adverse Event|2
6156107|NCT01147744|9795663|FG002|Overall Study|Adverse Event|3
6156108|NCT01147744|9795664|FG003|Overall Study|Adverse Event|0
6156109|NCT01147744|9795665|FG004|Overall Study|Adverse Event|2
6156110|NCT01147744|9795666|FG005|Overall Study|Adverse Event|1
6156111|NCT01147744|9795667|FG006|Overall Study|Adverse Event|2
6156112|NCT01147744|9795661|FG000|Overall Study|Withdrawal by Subject|8
6156113|NCT01147744|9795662|FG001|Overall Study|Withdrawal by Subject|4
6156114|NCT01147744|9795663|FG002|Overall Study|Withdrawal by Subject|2
6156115|NCT01147744|9795664|FG003|Overall Study|Withdrawal by Subject|2
6156116|NCT01147744|9795665|FG004|Overall Study|Withdrawal by Subject|2
6156117|NCT01147744|9795666|FG005|Overall Study|Withdrawal by Subject|5
6156118|NCT01147744|9795667|FG006|Overall Study|Withdrawal by Subject|2
6156119|NCT01147744|9795661|FG000|Overall Study|Lost to Follow-up|0
6156120|NCT01147744|9795662|FG001|Overall Study|Lost to Follow-up|1
6156121|NCT01147744|9795663|FG002|Overall Study|Lost to Follow-up|0
6156122|NCT01147744|9795664|FG003|Overall Study|Lost to Follow-up|0
6042688|NCT00384176|9641061|FG001|Overall Study|Death|247
6042689|NCT00384176|9641062|FG002|Overall Study|Death|105
6042690|NCT00384176|9641060|FG000|Overall Study|Withdrawal by Subject|52
6042691|NCT00384176|9641061|FG001|Overall Study|Withdrawal by Subject|48
6156123|NCT01147744|9795665|FG004|Overall Study|Lost to Follow-up|0
6156124|NCT01147744|9795666|FG005|Overall Study|Lost to Follow-up|0
6080408|NCT00615836|9687575|FG001|Extension Study (FE992026 CS31)|Re-randomized to a higher dose|0
6080409|NCT00615836|9687576|FG002|Extension Study (FE992026 CS31)|Re-randomized to a higher dose|0
6156125|NCT01147744|9795667|FG006|Overall Study|Lost to Follow-up|0
6080410|NCT00615836|9687577|FG003|Extension Study (FE992026 CS31)|Re-randomized to a higher dose|0
6080411|NCT00615836|9687578|FG004|Extension Study (FE992026 CS31)|Re-randomized to a higher dose|0
6156126|NCT01147744|9795661|FG000|Overall Study|Sponsor decision to amend protocol|7
6156127|NCT01147744|9795662|FG001|Overall Study|Sponsor decision to amend protocol|4
6156128|NCT01147744|9795663|FG002|Overall Study|Sponsor decision to amend protocol|2
6156129|NCT01147744|9795664|FG003|Overall Study|Sponsor decision to amend protocol|5
6156130|NCT01147744|9795665|FG004|Overall Study|Sponsor decision to amend protocol|7
6156131|NCT01147744|9795666|FG005|Overall Study|Sponsor decision to amend protocol|2
6080412|NCT00615901|9687594|FG000|Overall Study|Withdrawal by Subject|2
6080413|NCT00615901|9687594|FG000|Overall Study|Adverse Event|7
6080414|NCT00615914|9687598|FG000|Overall Study|Adverse Event|274
6080415|NCT00615914|9687598|FG000|Overall Study|Death|20
6080416|NCT00615914|9687598|FG000|Overall Study|Lack of Efficacy|59
6080417|NCT00615914|9687598|FG000|Overall Study|Lost to Follow-up|187
6080418|NCT00615914|9687598|FG000|Overall Study|Withdrawal by Subject|16
6080419|NCT00615914|9687598|FG000|Overall Study|Physician Decision|4
6324679|NCT02918318|10066391|FG004|Posttreatment Phase: Up to 24 Weeks|Withdrawal by Subject|0
6324680|NCT02918318|10066387|FG000|Posttreatment Phase: Up to 24 Weeks|Other|0
6324681|NCT02918318|10066388|FG001|Posttreatment Phase: Up to 24 Weeks|Other|3
6324682|NCT02918318|10066389|FG002|Posttreatment Phase: Up to 24 Weeks|Other|1
6324683|NCT02918318|10066390|FG003|Posttreatment Phase: Up to 24 Weeks|Other|1
6324684|NCT02918318|10066391|FG004|Posttreatment Phase: Up to 24 Weeks|Other|0
6324685|NCT02918318|10066387|FG000|Open Label Treatment Phase: 4 Weeks|Adverse Event|0
6324686|NCT02918318|10066388|FG001|Open Label Treatment Phase: 4 Weeks|Adverse Event|0
6324687|NCT02918318|10066389|FG002|Open Label Treatment Phase: 4 Weeks|Adverse Event|0
6324688|NCT02918318|10066390|FG003|Open Label Treatment Phase: 4 Weeks|Adverse Event|0
6324689|NCT02918318|10066391|FG004|Open Label Treatment Phase: 4 Weeks|Adverse Event|1
6324690|NCT02918318|10066387|FG000|Open Label Follow-up Phase: 4 Weeks|Adverse Event|0
6324691|NCT02918318|10066388|FG001|Open Label Follow-up Phase: 4 Weeks|Adverse Event|0
6324692|NCT02918318|10066389|FG002|Open Label Follow-up Phase: 4 Weeks|Adverse Event|0
6324693|NCT02918318|10066390|FG003|Open Label Follow-up Phase: 4 Weeks|Adverse Event|0
6324694|NCT02918318|10066391|FG004|Open Label Follow-up Phase: 4 Weeks|Adverse Event|1
6324695|NCT02918552|10066449|FG000|Overall Study|Failed Pharmacokinetics|1
6324696|NCT02918552|10066450|FG001|Overall Study|Failed Pharmacokinetics|0
6324697|NCT02918552|10066449|FG000|Overall Study|Withdrawal by Subject|0
6324698|NCT02918552|10066450|FG001|Overall Study|Withdrawal by Subject|1
6324699|NCT02918552|10066449|FG000|Overall Study|Lost to Follow-up|0
6324700|NCT02918552|10066450|FG001|Overall Study|Lost to Follow-up|1
6324701|NCT02918877|10066549|FG000|Overall Study|Withdrawal by Subject|2
6324702|NCT02918877|10066550|FG001|Overall Study|Withdrawal by Subject|2
6156132|NCT01147744|9795667|FG006|Overall Study|Sponsor decision to amend protocol|6
6156133|NCT01147744|9795661|FG000|Overall Study|Met Protocol-defined Stopping Criteria|1
6156134|NCT01147744|9795662|FG001|Overall Study|Met Protocol-defined Stopping Criteria|0
6156135|NCT01147744|9795663|FG002|Overall Study|Met Protocol-defined Stopping Criteria|0
6156136|NCT01147744|9795664|FG003|Overall Study|Met Protocol-defined Stopping Criteria|0
6156137|NCT01147744|9795665|FG004|Overall Study|Met Protocol-defined Stopping Criteria|0
6156138|NCT01147744|9795666|FG005|Overall Study|Met Protocol-defined Stopping Criteria|1
6156139|NCT01147744|9795667|FG006|Overall Study|Met Protocol-defined Stopping Criteria|0
6156140|NCT01147809|9795695|FG000|Phase I (168 Days)|Adverse Event|0
6156141|NCT01147809|9795696|FG001|Phase I (168 Days)|Adverse Event|0
6156142|NCT01147809|9795697|FG002|Phase I (168 Days)|Adverse Event|0
6156143|NCT01147809|9795698|FG003|Phase I (168 Days)|Adverse Event|1
6324703|NCT02918877|10066549|FG000|Overall Study|Surgery cancelled|1
6324704|NCT02918877|10066550|FG001|Overall Study|Surgery cancelled|0
6324705|NCT02918877|10066549|FG000|Overall Study|Physician Decision|1
6324706|NCT02918877|10066550|FG001|Overall Study|Physician Decision|0
6324707|NCT02918877|10066549|FG000|Overall Study|Received intraoperative steroids|1
6324708|NCT02918877|10066550|FG001|Overall Study|Received intraoperative steroids|0
6156144|NCT01147809|9795699|FG004|Phase I (168 Days)|Adverse Event|0
6156145|NCT01147809|9795700|FG005|Phase I (168 Days)|Adverse Event|0
6156146|NCT01147809|9795695|FG000|Phase I (168 Days)|Lost to Follow-up|1
6156147|NCT01147809|9795696|FG001|Phase I (168 Days)|Lost to Follow-up|0
6156148|NCT01147809|9795697|FG002|Phase I (168 Days)|Lost to Follow-up|0
6156149|NCT01147809|9795698|FG003|Phase I (168 Days)|Lost to Follow-up|1
6156150|NCT01147809|9795699|FG004|Phase I (168 Days)|Lost to Follow-up|0
6156151|NCT01147809|9795700|FG005|Phase I (168 Days)|Lost to Follow-up|0
6156152|NCT01147809|9795695|FG000|Phase I (168 Days)|Physician Decision|0
6156153|NCT01147809|9795696|FG001|Phase I (168 Days)|Physician Decision|1
6156154|NCT01147809|9795697|FG002|Phase I (168 Days)|Physician Decision|2
6156155|NCT01147809|9795698|FG003|Phase I (168 Days)|Physician Decision|0
6324709|NCT02918877|10066549|FG000|Overall Study|Unable to obtain lab samples|1
6324710|NCT02918877|10066550|FG001|Overall Study|Unable to obtain lab samples|0
6324711|NCT02918877|10066549|FG000|Overall Study|Unsafe to perform BAL|0
6156156|NCT01147809|9795699|FG004|Phase I (168 Days)|Physician Decision|0
6156157|NCT01147809|9795700|FG005|Phase I (168 Days)|Physician Decision|0
6156158|NCT01147809|9795695|FG000|Phase I (168 Days)|Withdrawal by Subject|0
6324712|NCT02918877|10066550|FG001|Overall Study|Unsafe to perform BAL|1
6080420|NCT00615914|9687598|FG000|Overall Study|No data was collected.|65
6080421|NCT00615914|9687598|FG000|Overall Study|No treatment|2
6080422|NCT00615914|9687598|FG000|Overall Study|Irregularly enrolled patients|10
6080423|NCT00615992|9687612|FG000|Overall Study|Protocol Violation|67
6080424|NCT00616018|9687616|FG000|Overall Study|Protocol Violation|3
6080425|NCT00616239|9687640|FG000|Overall Study|Withdrawal by Subject|2
6080426|NCT00616421|9687647|FG000|Overall Study|Withdrawal by Subject|9
6080427|NCT00616421|9687648|FG001|Overall Study|Withdrawal by Subject|11
6080428|NCT00616421|9687649|FG002|Overall Study|Withdrawal by Subject|8
6080429|NCT00616421|9687647|FG000|Overall Study|Lost to Follow-up|12
6080430|NCT00616421|9687648|FG001|Overall Study|Lost to Follow-up|26
6080431|NCT00616421|9687649|FG002|Overall Study|Lost to Follow-up|30
6080432|NCT00616421|9687647|FG000|Overall Study|Inappropriate enrollment|3
6080433|NCT00616421|9687648|FG001|Overall Study|Inappropriate enrollment|0
6080434|NCT00616421|9687649|FG002|Overall Study|Inappropriate enrollment|1
6080435|NCT00616421|9687647|FG000|Overall Study|Administrative reason|1
6080436|NCT00616421|9687648|FG001|Overall Study|Administrative reason|0
6080437|NCT00616421|9687649|FG002|Overall Study|Administrative reason|0
6080438|NCT00616421|9687647|FG000|Overall Study|Protocol Violation|0
6080439|NCT00616421|9687648|FG001|Overall Study|Protocol Violation|1
6080440|NCT00616421|9687649|FG002|Overall Study|Protocol Violation|2
6080441|NCT00616421|9687647|FG000|Overall Study|Unable to classify|1
6080442|NCT00616421|9687648|FG001|Overall Study|Unable to classify|0
6080443|NCT00616421|9687649|FG002|Overall Study|Unable to classify|0
6080444|NCT00616434|9687673|FG000|Overall Study|Adverse Event|5
6080445|NCT00616434|9687674|FG001|Overall Study|Adverse Event|2
6156159|NCT01147809|9795696|FG001|Phase I (168 Days)|Withdrawal by Subject|0
6156160|NCT01147809|9795697|FG002|Phase I (168 Days)|Withdrawal by Subject|0
6156161|NCT01147809|9795698|FG003|Phase I (168 Days)|Withdrawal by Subject|3
6156162|NCT01147809|9795699|FG004|Phase I (168 Days)|Withdrawal by Subject|0
6156163|NCT01147809|9795700|FG005|Phase I (168 Days)|Withdrawal by Subject|0
6156164|NCT01147809|9795695|FG000|Phase II (168 Days)|Adverse Event|0
6156165|NCT01147809|9795696|FG001|Phase II (168 Days)|Adverse Event|0
6156166|NCT01147809|9795697|FG002|Phase II (168 Days)|Adverse Event|0
6156167|NCT01147809|9795698|FG003|Phase II (168 Days)|Adverse Event|0
6156168|NCT01147809|9795699|FG004|Phase II (168 Days)|Adverse Event|3
6156169|NCT01147809|9795700|FG005|Phase II (168 Days)|Adverse Event|6
6156170|NCT01147809|9795695|FG000|Phase II (168 Days)|Protocol Violation|0
6156171|NCT01147809|9795696|FG001|Phase II (168 Days)|Protocol Violation|0
6156172|NCT01147809|9795697|FG002|Phase II (168 Days)|Protocol Violation|0
6156173|NCT01147809|9795698|FG003|Phase II (168 Days)|Protocol Violation|0
6156174|NCT01147809|9795699|FG004|Phase II (168 Days)|Protocol Violation|0
6080446|NCT00616434|9687673|FG000|Overall Study|Physician Decision|0
6080447|NCT00616434|9687674|FG001|Overall Study|Physician Decision|4
6080448|NCT00616434|9687673|FG000|Overall Study|Withdrawal by Subject|1
6080449|NCT00616434|9687674|FG001|Overall Study|Withdrawal by Subject|1
6156175|NCT01147809|9795700|FG005|Phase II (168 Days)|Protocol Violation|1
6156176|NCT01147809|9795695|FG000|Phase II (168 Days)|Physician Decision|0
6156177|NCT01147809|9795696|FG001|Phase II (168 Days)|Physician Decision|0
6156178|NCT01147809|9795697|FG002|Phase II (168 Days)|Physician Decision|0
6156179|NCT01147809|9795698|FG003|Phase II (168 Days)|Physician Decision|0
6156180|NCT01147809|9795699|FG004|Phase II (168 Days)|Physician Decision|5
6156181|NCT01147809|9795700|FG005|Phase II (168 Days)|Physician Decision|11
6156182|NCT01147809|9795695|FG000|Phase II (168 Days)|Withdrawal by Subject|0
6156183|NCT01147809|9795696|FG001|Phase II (168 Days)|Withdrawal by Subject|0
6156184|NCT01147809|9795697|FG002|Phase II (168 Days)|Withdrawal by Subject|0
6156185|NCT01147809|9795698|FG003|Phase II (168 Days)|Withdrawal by Subject|0
6156186|NCT01147809|9795699|FG004|Phase II (168 Days)|Withdrawal by Subject|7
6156187|NCT01147809|9795700|FG005|Phase II (168 Days)|Withdrawal by Subject|15
6156188|NCT01147809|9795695|FG000|Phase II (168 Days)|Ongoing|0
6156189|NCT01147809|9795696|FG001|Phase II (168 Days)|Ongoing|0
6156190|NCT01147809|9795697|FG002|Phase II (168 Days)|Ongoing|0
6156191|NCT01147809|9795698|FG003|Phase II (168 Days)|Ongoing|0
6156192|NCT01147809|9795699|FG004|Phase II (168 Days)|Ongoing|1
6156193|NCT01147809|9795700|FG005|Phase II (168 Days)|Ongoing|0
6156194|NCT01147848|9795717|FG000|Run-in Period|Screen Failure|623
6156195|NCT01147848|9795718|FG001|Run-in Period|Screen Failure|0
6156196|NCT01147848|9795719|FG002|Run-in Period|Screen Failure|0
6080450|NCT00616434|9687673|FG000|Overall Study|Protocol deviation|0
6080451|NCT00616434|9687674|FG001|Overall Study|Protocol deviation|1
6080452|NCT00616629|9687685|FG000|Overall Study|Protocol Violation|1
6080453|NCT00616629|9687686|FG001|Overall Study|Protocol Violation|2
6080454|NCT00616629|9687687|FG002|Overall Study|Protocol Violation|1
6080455|NCT00616629|9687688|FG003|Overall Study|Protocol Violation|0
6080456|NCT00616629|9687689|FG004|Overall Study|Protocol Violation|0
6080457|NCT00616629|9687685|FG000|Overall Study|AV-block|1
6080458|NCT00616629|9687686|FG001|Overall Study|AV-block|0
6080459|NCT00616629|9687687|FG002|Overall Study|AV-block|0
6080460|NCT00616629|9687688|FG003|Overall Study|AV-block|0
6080461|NCT00616629|9687689|FG004|Overall Study|AV-block|0
6080462|NCT00616655|9687704|FG000|Overall Study|Adverse Event|10
6080463|NCT00616655|9687705|FG001|Overall Study|Adverse Event|7
6080464|NCT00616655|9687706|FG002|Overall Study|Adverse Event|12
6080465|NCT00616655|9687704|FG000|Overall Study|Lack of Efficacy|5
6080466|NCT00616655|9687705|FG001|Overall Study|Lack of Efficacy|5
6080467|NCT00616655|9687706|FG002|Overall Study|Lack of Efficacy|5
6156197|NCT01147848|9795717|FG000|Run-in Period|Run-in Failure|135
6156198|NCT01147848|9795718|FG001|Run-in Period|Run-in Failure|0
6080468|NCT00616655|9687704|FG000|Overall Study|Lost to Follow-up|3
6080469|NCT00616655|9687705|FG001|Overall Study|Lost to Follow-up|12
6080470|NCT00616655|9687706|FG002|Overall Study|Lost to Follow-up|10
6080471|NCT00616655|9687704|FG000|Overall Study|Protocol Violation|2
6080472|NCT00616655|9687705|FG001|Overall Study|Protocol Violation|4
6080473|NCT00616655|9687706|FG002|Overall Study|Protocol Violation|3
6080474|NCT00616655|9687704|FG000|Overall Study|Withdrawal by Subject|9
6080475|NCT00616655|9687705|FG001|Overall Study|Withdrawal by Subject|7
6080476|NCT00616655|9687706|FG002|Overall Study|Withdrawal by Subject|11
6080477|NCT00616655|9687704|FG000|Overall Study|Does not meet in/ex criteria|0
6080478|NCT00616655|9687705|FG001|Overall Study|Does not meet in/ex criteria|0
6080479|NCT00616655|9687706|FG002|Overall Study|Does not meet in/ex criteria|2
6080480|NCT00616655|9687704|FG000|Overall Study|Other|6
6080481|NCT00616655|9687705|FG001|Overall Study|Other|6
6080482|NCT00616655|9687706|FG002|Overall Study|Other|5
6080483|NCT00616902|9687725|FG000|Overall Study|Termination of study|6
6080484|NCT00616902|9687726|FG001|Overall Study|Termination of study|6
6080485|NCT00616928|9687736|FG000|Overall Study|Adverse Event|6
6080486|NCT00616928|9687737|FG001|Overall Study|Adverse Event|3
6080487|NCT00616928|9687738|FG002|Overall Study|Adverse Event|2
6156199|NCT01147848|9795719|FG002|Run-in Period|Run-in Failure|0
6156200|NCT01147848|9795717|FG000|Randomized Phase|Adverse Event|0
6156201|NCT01147848|9795718|FG001|Randomized Phase|Adverse Event|6
6156202|NCT01147848|9795719|FG002|Randomized Phase|Adverse Event|8
6156203|NCT01147848|9795717|FG000|Randomized Phase|Lack of Efficacy|0
6156204|NCT01147848|9795718|FG001|Randomized Phase|Lack of Efficacy|20
6156205|NCT01147848|9795719|FG002|Randomized Phase|Lack of Efficacy|11
6156206|NCT01147848|9795717|FG000|Randomized Phase|Protocol Violation|0
6156207|NCT01147848|9795718|FG001|Randomized Phase|Protocol Violation|7
6156208|NCT01147848|9795719|FG002|Randomized Phase|Protocol Violation|10
6156209|NCT01147848|9795717|FG000|Randomized Phase|Lost to Follow-up|0
6156210|NCT01147848|9795718|FG001|Randomized Phase|Lost to Follow-up|5
6156211|NCT01147848|9795719|FG002|Randomized Phase|Lost to Follow-up|7
6156212|NCT01147848|9795717|FG000|Randomized Phase|Physician Decision|0
6156213|NCT01147848|9795718|FG001|Randomized Phase|Physician Decision|0
6156214|NCT01147848|9795719|FG002|Randomized Phase|Physician Decision|1
6156215|NCT01147848|9795717|FG000|Randomized Phase|Withdrawal by Subject|0
6156216|NCT01147848|9795718|FG001|Randomized Phase|Withdrawal by Subject|7
6156217|NCT01147848|9795719|FG002|Randomized Phase|Withdrawal by Subject|9
6156218|NCT01147874|9795726|FG000|Overall Study|Adverse Event|5
6156219|NCT01147874|9795726|FG000|Overall Study|Investigator's Request|1
6156220|NCT01147874|9795726|FG000|Overall Study|Lost to Follow-up|25
6156221|NCT01147874|9795726|FG000|Overall Study|Other|5
6156222|NCT01147874|9795726|FG000|Overall Study|Protocol Violation|5
6156223|NCT01147874|9795726|FG000|Overall Study|Sponsor's Decision|2
6156224|NCT01147874|9795726|FG000|Overall Study|Withdrawal by Subject|24
6156225|NCT01147900|9795733|FG000|At Year 10|Lost to Follow-up|0
6156226|NCT01147900|9795734|FG001|At Year 10|Lost to Follow-up|1
6156227|NCT01147900|9795735|FG002|At Year 10|Lost to Follow-up|0
6156228|NCT01147926|9795745|FG000|Overall Study|Subject Withdrew Consent|9
6156229|NCT01147926|9795746|FG001|Overall Study|Subject Withdrew Consent|10
6156230|NCT01147926|9795745|FG000|Overall Study|Adverse Event|7
6156231|NCT01147926|9795746|FG001|Overall Study|Adverse Event|6
6156232|NCT01147926|9795745|FG000|Overall Study|Subject Non-Compliant|5
6156233|NCT01147926|9795746|FG001|Overall Study|Subject Non-Compliant|4
6156234|NCT01147926|9795745|FG000|Overall Study|Principal investigator left hospital|1
6156235|NCT01147926|9795746|FG001|Overall Study|Principal investigator left hospital|3
6156236|NCT01147926|9795745|FG000|Overall Study|Selection criteria not met|3
6156237|NCT01147926|9795746|FG001|Overall Study|Selection criteria not met|1
6156238|NCT01147926|9795745|FG000|Overall Study|Lost to Follow-up|0
6156239|NCT01147926|9795746|FG001|Overall Study|Lost to Follow-up|2
6156240|NCT01147926|9795745|FG000|Overall Study|Sponsor's Decision|0
6156241|NCT01147926|9795746|FG001|Overall Study|Sponsor's Decision|1
6156242|NCT01147926|9795745|FG000|Overall Study|Lack of Efficacy|1
6156243|NCT01147926|9795746|FG001|Overall Study|Lack of Efficacy|0
6156244|NCT01147926|9795745|FG000|Overall Study|Too busy, no time for study|1
6156245|NCT01147926|9795746|FG001|Overall Study|Too busy, no time for study|0
6156246|NCT01147926|9795745|FG000|Overall Study|Went on holiday|0
6156247|NCT01147926|9795746|FG001|Overall Study|Went on holiday|1
6156248|NCT01147926|9795745|FG000|Overall Study|Colonoscopy result|0
6156249|NCT01147926|9795746|FG001|Overall Study|Colonoscopy result|1
6156250|NCT01148017|9795756|FG000|Overall Study|Withdrawal by Subject|31
6156251|NCT01148017|9795757|FG001|Overall Study|Withdrawal by Subject|14
6156252|NCT01148017|9795758|FG002|Overall Study|Withdrawal by Subject|0
6156253|NCT01148017|9795759|FG003|Overall Study|Withdrawal by Subject|0
6156254|NCT01148017|9795756|FG000|Overall Study|Lost to Follow-up|23
6156255|NCT01148017|9795757|FG001|Overall Study|Lost to Follow-up|10
6156256|NCT01148017|9795758|FG002|Overall Study|Lost to Follow-up|0
6156257|NCT01148017|9795759|FG003|Overall Study|Lost to Follow-up|0
6156258|NCT01148017|9795756|FG000|Overall Study|Inappropriate enrollment|1
6156259|NCT01148017|9795757|FG001|Overall Study|Inappropriate enrollment|0
6156260|NCT01148017|9795758|FG002|Overall Study|Inappropriate enrollment|0
6080488|NCT00616928|9687739|FG003|Overall Study|Adverse Event|2
6080489|NCT00616928|9687736|FG000|Overall Study|Other|51
6080490|NCT00616928|9687737|FG001|Overall Study|Other|8
6080491|NCT00616928|9687738|FG002|Overall Study|Other|15
6080492|NCT00616928|9687739|FG003|Overall Study|Other|5
6080493|NCT00616928|9687736|FG000|Overall Study|Lost to Follow-up|5
6080494|NCT00616928|9687737|FG001|Overall Study|Lost to Follow-up|7
6080495|NCT00616928|9687738|FG002|Overall Study|Lost to Follow-up|0
6080496|NCT00616928|9687739|FG003|Overall Study|Lost to Follow-up|0
6080497|NCT00616941|9687764|FG000|Overall Study|Progressive Disease|1
6080498|NCT00616941|9687765|FG001|Overall Study|Progressive Disease|2
6080499|NCT00616941|9687766|FG002|Overall Study|Progressive Disease|1
6080500|NCT00616941|9687764|FG000|Overall Study|Adverse Event|0
6080501|NCT00616941|9687765|FG001|Overall Study|Adverse Event|1
6080502|NCT00616941|9687766|FG002|Overall Study|Adverse Event|1
6080503|NCT00616941|9687764|FG000|Overall Study|Subject Non-compliance|0
6080504|NCT00616941|9687765|FG001|Overall Study|Subject Non-compliance|0
6080505|NCT00616941|9687766|FG002|Overall Study|Subject Non-compliance|1
6080506|NCT00616941|9687764|FG000|Overall Study|Unrelated Medical Illness/Complication|0
6080507|NCT00616941|9687765|FG001|Overall Study|Unrelated Medical Illness/Complication|2
6080508|NCT00616941|9687766|FG002|Overall Study|Unrelated Medical Illness/Complication|0
6080509|NCT00616941|9687764|FG000|Overall Study|Vaccination Suspended|0
6080510|NCT00616941|9687765|FG001|Overall Study|Vaccination Suspended|0
6080511|NCT00616941|9687766|FG002|Overall Study|Vaccination Suspended|3
6080512|NCT00617084|9687789|FG000|Overall Study|Withdrawal by Subject|5
6080513|NCT00617084|9687790|FG001|Overall Study|Withdrawal by Subject|7
6080514|NCT00617084|9687789|FG000|Overall Study|Missed 12 Months visit|16
6080515|NCT00617084|9687790|FG001|Overall Study|Missed 12 Months visit|19
6080516|NCT00617123|9687809|FG000|Referral Screening Period|Did Not Meet Protocol Eligibility|36
6080517|NCT00617123|9687810|FG001|Referral Screening Period|Did Not Meet Protocol Eligibility|24
6080518|NCT00617123|9687809|FG000|Referral Screening Period|Did Not Wish To Continue|3
6042692|NCT00384176|9641062|FG002|Overall Study|Withdrawal by Subject|22
6042693|NCT00384176|9641060|FG000|Overall Study|Lost to Follow-up|16
6042694|NCT00384176|9641061|FG001|Overall Study|Lost to Follow-up|18
6080519|NCT00617123|9687810|FG001|Referral Screening Period|Did Not Wish To Continue|1
6080520|NCT00617123|9687809|FG000|Referral Screening Period|Adverse Event|0
6080521|NCT00617123|9687810|FG001|Referral Screening Period|Adverse Event|1
6080522|NCT00617123|9687809|FG000|Study Treatment Period|Withdrawal by Subject|8
6080523|NCT00617123|9687810|FG001|Study Treatment Period|Withdrawal by Subject|12
6042695|NCT00384176|9641062|FG002|Overall Study|Lost to Follow-up|4
6156261|NCT01148017|9795759|FG003|Overall Study|Inappropriate enrollment|0
6156262|NCT01148017|9795756|FG000|Overall Study|Administrative reason|22
6156263|NCT01148017|9795757|FG001|Overall Study|Administrative reason|9
6156264|NCT01148017|9795758|FG002|Overall Study|Administrative reason|0
6156265|NCT01148017|9795759|FG003|Overall Study|Administrative reason|0
6080524|NCT00617123|9687809|FG000|Study Treatment Period|Adverse Event|7
6080525|NCT00617123|9687810|FG001|Study Treatment Period|Adverse Event|3
6080526|NCT00617123|9687809|FG000|Study Treatment Period|Did Not Meet Protocol Eligibility|2
6080527|NCT00617123|9687810|FG001|Study Treatment Period|Did Not Meet Protocol Eligibility|0
6080528|NCT00617123|9687809|FG000|Study Treatment Period|Noncompliance with Protocol|0
6080529|NCT00617123|9687810|FG001|Study Treatment Period|Noncompliance with Protocol|1
6080530|NCT00617201|9687831|FG000|Overall Study|Lost to Follow-up|9
6080531|NCT00617201|9687832|FG001|Overall Study|Lost to Follow-up|13
6080532|NCT00617240|9687842|FG000|Overall Study|Lack of Efficacy|1
6080533|NCT00617240|9687843|FG001|Overall Study|Lack of Efficacy|0
6080534|NCT00617279|9687851|FG000|Overall Study|Study terminated by Sponsor|10
6156266|NCT01148017|9795756|FG000|Overall Study|Unable to classify|3
6156267|NCT01148017|9795757|FG001|Overall Study|Unable to classify|1
6156268|NCT01148017|9795758|FG002|Overall Study|Unable to classify|0
6156269|NCT01148017|9795759|FG003|Overall Study|Unable to classify|0
6156270|NCT01148225|9795770|FG000|Overall Study|Other|185
6156271|NCT01148459|9795784|FG000|Overall Study|Serious Adverse Event|5
6156272|NCT01148459|9795785|FG001|Overall Study|Serious Adverse Event|4
6156273|NCT01148459|9795784|FG000|Overall Study|Withdrawal by Subject|1
6156274|NCT01148459|9795785|FG001|Overall Study|Withdrawal by Subject|0
6156275|NCT01148459|9795784|FG000|Overall Study|Migrated/moved from study area|3
6156276|NCT01148459|9795785|FG001|Overall Study|Migrated/moved from study area|6
6156277|NCT01148459|9795784|FG000|Overall Study|Lost to Follow-up|2
6156278|NCT01148459|9795785|FG001|Overall Study|Lost to Follow-up|0
6156279|NCT01148459|9795784|FG000|Overall Study|Refusal|1
6156280|NCT01148459|9795785|FG001|Overall Study|Refusal|0
6156281|NCT01148459|9795784|FG000|Overall Study|Failure to comply with study procedures|0
6156282|NCT01148459|9795785|FG001|Overall Study|Failure to comply with study procedures|1
6156283|NCT01148511|9795793|FG000|Exposed to Study Drug|Protocol Violation|2
6324713|NCT02918968|10066558|FG000|1st Line AAT|Progressive disease|9
6324714|NCT02918968|10066559|FG001|1st Line AAT|Progressive disease|4
6324715|NCT02918968|10066558|FG000|1st Line AAT|Adverse Event|12
6324716|NCT02918968|10066559|FG001|1st Line AAT|Adverse Event|3
6156284|NCT01148511|9795794|FG001|Exposed to Study Drug|Protocol Violation|0
6156285|NCT01148511|9795795|FG002|Exposed to Study Drug|Protocol Violation|0
6156286|NCT01148511|9795793|FG000|Exposed to Study Drug|Lost to Follow-up|4
6156287|NCT01148511|9795794|FG001|Exposed to Study Drug|Lost to Follow-up|0
6156288|NCT01148511|9795795|FG002|Exposed to Study Drug|Lost to Follow-up|0
6156289|NCT01148511|9795793|FG000|Randomized|Adverse Event|0
6156290|NCT01148511|9795794|FG001|Randomized|Adverse Event|1
6156291|NCT01148511|9795795|FG002|Randomized|Adverse Event|0
6156292|NCT01148511|9795793|FG000|Randomized|Protocol Violation|0
6156293|NCT01148511|9795794|FG001|Randomized|Protocol Violation|2
6156294|NCT01148511|9795795|FG002|Randomized|Protocol Violation|1
6156295|NCT01148511|9795793|FG000|Randomized|Lost to Follow-up|0
6156296|NCT01148511|9795794|FG001|Randomized|Lost to Follow-up|1
6156297|NCT01148511|9795795|FG002|Randomized|Lost to Follow-up|1
6156298|NCT01148511|9795793|FG000|Randomized|Consent withdrawal|0
6156299|NCT01148511|9795794|FG001|Randomized|Consent withdrawal|5
6156300|NCT01148511|9795795|FG002|Randomized|Consent withdrawal|3
6156301|NCT01148511|9795793|FG000|Randomized|Other|0
6156302|NCT01148511|9795794|FG001|Randomized|Other|1
6156303|NCT01148511|9795795|FG002|Randomized|Other|1
6156304|NCT01148537|9795842|FG000|Overall Study|Withdrawal by Subject|1
6156305|NCT01148537|9795843|FG001|Overall Study|Withdrawal by Subject|0
6156306|NCT01148537|9795844|FG002|Overall Study|Withdrawal by Subject|2
6324717|NCT02918968|10066558|FG000|1st Line AAT|Physician Decision|4
6324718|NCT02918968|10066559|FG001|1st Line AAT|Physician Decision|2
6156307|NCT01148537|9795842|FG000|Overall Study|Adverse Event|2
6156308|NCT01148537|9795843|FG001|Overall Study|Adverse Event|0
6156309|NCT01148537|9795844|FG002|Overall Study|Adverse Event|1
6156310|NCT01148693|9795865|FG000|Overall Study|Attempts for cannulation were failed|13
6156311|NCT01148693|9795866|FG001|Overall Study|Attempts for cannulation were failed|10
6156312|NCT01148771|9795880|FG000|Washout Period|Withdrawal by Subject|0
6156313|NCT01148771|9795881|FG001|Washout Period|Withdrawal by Subject|1
6156314|NCT01148810|9795893|FG000|Overall Study|Adverse Event|0
6080535|NCT00617279|9687852|FG001|Overall Study|Study terminated by Sponsor|15
6080536|NCT00617279|9687851|FG000|Overall Study|Graft abandonment|2
6080537|NCT00617279|9687852|FG001|Overall Study|Graft abandonment|0
6080538|NCT00617279|9687851|FG000|Overall Study|Lost to Follow-up|1
6080539|NCT00617279|9687852|FG001|Overall Study|Lost to Follow-up|0
6080540|NCT00617279|9687851|FG000|Overall Study|Death|1
6080541|NCT00617279|9687852|FG001|Overall Study|Death|2
6080542|NCT00617305|9687861|FG000|Overall Study|Adverse Event|4
6080543|NCT00617305|9687862|FG001|Overall Study|Adverse Event|0
6080544|NCT00617305|9687863|FG002|Overall Study|Adverse Event|0
6080545|NCT00617305|9687861|FG000|Overall Study|Death|1
6080546|NCT00617305|9687862|FG001|Overall Study|Death|0
6080547|NCT00617305|9687863|FG002|Overall Study|Death|0
6080548|NCT00617305|9687861|FG000|Overall Study|Physician Decision|1
6080549|NCT00617305|9687862|FG001|Overall Study|Physician Decision|0
6080550|NCT00617305|9687863|FG002|Overall Study|Physician Decision|0
6080551|NCT00617305|9687861|FG000|Overall Study|Protocol Violation|1
6080552|NCT00617305|9687862|FG001|Overall Study|Protocol Violation|0
6156315|NCT01148810|9795894|FG001|Overall Study|Adverse Event|2
6156316|NCT01148810|9795893|FG000|Overall Study|Lack of Efficacy|0
6156317|NCT01148810|9795894|FG001|Overall Study|Lack of Efficacy|1
6156318|NCT01148810|9795893|FG000|Overall Study|Withdrawal by Subject|0
6156319|NCT01148810|9795894|FG001|Overall Study|Withdrawal by Subject|2
6156320|NCT01148810|9795893|FG000|Overall Study|Protocol Violation|1
6156321|NCT01148810|9795894|FG001|Overall Study|Protocol Violation|0
6156322|NCT01148862|9795910|FG000|Second Intervention|Withdrawal by Subject|0
6156323|NCT01148862|9795911|FG001|Second Intervention|Withdrawal by Subject|2
6156324|NCT01148979|9795931|FG000|Overall Study|Lost to Follow-up|0
6156325|NCT01148979|9795932|FG001|Overall Study|Lost to Follow-up|1
6156326|NCT01149057|9795938|FG000|Overall Study|Lack of Efficacy|16
6156327|NCT01149057|9795938|FG000|Overall Study|Adverse Event|13
6156328|NCT01149057|9795938|FG000|Overall Study|Withdrawal by Subject|9
6156329|NCT01149057|9795938|FG000|Overall Study|Positive Hepatitis B Core Antibody|5
6156330|NCT01149057|9795938|FG000|Overall Study|B Cell Depletion|4
6156331|NCT01149057|9795938|FG000|Overall Study|Participant Non-Compliance|2
6156332|NCT01149057|9795938|FG000|Overall Study|Lost to Follow-up|1
6156333|NCT01149057|9795938|FG000|Overall Study|High Parathyroid Hormone Value|1
6156334|NCT01149057|9795938|FG000|Overall Study|Other|6
6156335|NCT01149096|9795944|FG000|Overall Study|Lost to Follow-up|0
6156336|NCT01149096|9795945|FG001|Overall Study|Lost to Follow-up|1
6156337|NCT01149148|9795954|FG000|Overall Study|Lost to Follow-up|1
6156338|NCT01149148|9795955|FG001|Overall Study|Lost to Follow-up|2
6156339|NCT01149148|9795954|FG000|Overall Study|Death|1
6156340|NCT01149148|9795955|FG001|Overall Study|Death|0
6156341|NCT01149343|9795966|FG000|Overall Study|Withdrawal by Subject|1
6156342|NCT01149343|9795967|FG001|Overall Study|Withdrawal by Subject|1
6156343|NCT01149343|9795968|FG002|Overall Study|Withdrawal by Subject|1
6156344|NCT01149343|9795969|FG003|Overall Study|Withdrawal by Subject|5
6156345|NCT01149343|9795966|FG000|Overall Study|Death|10
6156346|NCT01149343|9795967|FG001|Overall Study|Death|13
6156347|NCT01149343|9795968|FG002|Overall Study|Death|18
6156348|NCT01149343|9795969|FG003|Overall Study|Death|18
6156349|NCT01149343|9795966|FG000|Overall Study|Lost to Follow-up|1
6156350|NCT01149343|9795967|FG001|Overall Study|Lost to Follow-up|0
6156351|NCT01149343|9795968|FG002|Overall Study|Lost to Follow-up|0
6156352|NCT01149343|9795969|FG003|Overall Study|Lost to Follow-up|1
6156353|NCT01149343|9795966|FG000|Overall Study|Other|8
6156354|NCT01149343|9795967|FG001|Overall Study|Other|10
6156355|NCT01149343|9795968|FG002|Overall Study|Other|2
6156356|NCT01149343|9795969|FG003|Overall Study|Other|14
6156357|NCT01149343|9795966|FG000|Overall Study|Sponsor study termination|0
6156358|NCT01149343|9795967|FG001|Overall Study|Sponsor study termination|0
6156359|NCT01149343|9795968|FG002|Overall Study|Sponsor study termination|0
6156360|NCT01149343|9795969|FG003|Overall Study|Sponsor study termination|2
6156361|NCT01149343|9795966|FG000|Overall Study|Recurrence / Progressive disease|0
6156362|NCT01149343|9795967|FG001|Overall Study|Recurrence / Progressive disease|0
6156363|NCT01149343|9795968|FG002|Overall Study|Recurrence / Progressive disease|1
6156364|NCT01149343|9795969|FG003|Overall Study|Recurrence / Progressive disease|0
6156365|NCT01149369|9795985|FG000|Overall Study|Adverse Event|6
6156366|NCT01149369|9795986|FG001|Overall Study|Adverse Event|3
6156367|NCT01149421|9795995|FG000|Overall Study|Adverse Event|22
6156368|NCT01149421|9795996|FG001|Overall Study|Adverse Event|6
6080553|NCT00617305|9687863|FG002|Overall Study|Protocol Violation|1
6080554|NCT00617305|9687861|FG000|Overall Study|Withdrawal by Subject|1
6080555|NCT00617305|9687862|FG001|Overall Study|Withdrawal by Subject|0
6080556|NCT00617305|9687863|FG002|Overall Study|Withdrawal by Subject|0
6080557|NCT00617344|9687877|FG000|Overall Study|Serious adverse event|1
6080558|NCT00617344|9687878|FG001|Overall Study|Serious adverse event|0
6080559|NCT00617344|9687879|FG002|Overall Study|Serious adverse event|0
6080560|NCT00617344|9687877|FG000|Overall Study|Other Adverse Event|1
6080561|NCT00617344|9687878|FG001|Overall Study|Other Adverse Event|1
6156369|NCT01149421|9795997|FG002|Overall Study|Adverse Event|11
6156370|NCT01149421|9795995|FG000|Overall Study|Withdrawal by Subject|20
6156371|NCT01149421|9795996|FG001|Overall Study|Withdrawal by Subject|12
6156372|NCT01149421|9795997|FG002|Overall Study|Withdrawal by Subject|13
6156373|NCT01149421|9795995|FG000|Overall Study|Sponsor Decision|0
6156374|NCT01149421|9795996|FG001|Overall Study|Sponsor Decision|1
6156375|NCT01149421|9795997|FG002|Overall Study|Sponsor Decision|1
6156376|NCT01149421|9795995|FG000|Overall Study|Lost to Follow-up|2
6156377|NCT01149421|9795996|FG001|Overall Study|Lost to Follow-up|4
6156378|NCT01149421|9795997|FG002|Overall Study|Lost to Follow-up|5
6156379|NCT01149421|9795995|FG000|Overall Study|Physician Decision|5
6156380|NCT01149421|9795996|FG001|Overall Study|Physician Decision|3
6156381|NCT01149421|9795997|FG002|Overall Study|Physician Decision|6
6156382|NCT01149421|9795995|FG000|Overall Study|Entry Criteria Not Met|1
6156383|NCT01149421|9795996|FG001|Overall Study|Entry Criteria Not Met|1
6156384|NCT01149421|9795997|FG002|Overall Study|Entry Criteria Not Met|2
6156385|NCT01149421|9795995|FG000|Overall Study|Protocol Violation|2
6156386|NCT01149421|9795996|FG001|Overall Study|Protocol Violation|2
6156387|NCT01149421|9795997|FG002|Overall Study|Protocol Violation|6
6156388|NCT01149460|9796017|FG000|Overall Study|Withdrawal by Subject|0
6080562|NCT00617344|9687879|FG002|Overall Study|Other Adverse Event|0
6080563|NCT00617344|9687877|FG000|Overall Study|Protocol Violation|10
6156389|NCT01149460|9796018|FG001|Overall Study|Withdrawal by Subject|2
6156390|NCT01149473|9796026|FG000|First Intervention|Adverse Event|1
6156391|NCT01149473|9796027|FG001|First Intervention|Adverse Event|1
6156392|NCT01149473|9796026|FG000|Washout of 7 Days|Withdrawal by Subject|1
6156393|NCT01149473|9796027|FG001|Washout of 7 Days|Withdrawal by Subject|1
6042696|NCT00384176|9641060|FG000|Overall Study|Incorrect enrol/elig crit not fulfilled|2
6042697|NCT00384176|9641061|FG001|Overall Study|Incorrect enrol/elig crit not fulfilled|3
6042698|NCT00384176|9641062|FG002|Overall Study|Incorrect enrol/elig crit not fulfilled|0
6042699|NCT00384176|9641060|FG000|Overall Study|Longer QTC as Visit 1|1
6156394|NCT01149486|9796035|FG000|First Intervention|Adverse Event|0
6156395|NCT01149486|9796036|FG001|First Intervention|Adverse Event|1
6156396|NCT01149538|9796048|FG000|Overall Study|Lost to Follow-up|0
6156397|NCT01149538|9796049|FG001|Overall Study|Lost to Follow-up|1
6156398|NCT01149538|9796048|FG000|Overall Study|Withdrawal by Subject|5
6156399|NCT01149538|9796049|FG001|Overall Study|Withdrawal by Subject|3
6156400|NCT01149655|9796068|FG000|Period 1 - Conversion Phase|Lost to Follow-up|1
6156401|NCT01149655|9796069|FG001|Period 1 - Conversion Phase|Lost to Follow-up|0
6156402|NCT01149655|9796070|FG002|Period 1 - Conversion Phase|Lost to Follow-up|0
6156403|NCT01149655|9796071|FG003|Period 1 - Conversion Phase|Lost to Follow-up|0
6156404|NCT01149655|9796068|FG000|Period 1 - Conversion Phase|Sponsor Discontinued Trial|4
6156405|NCT01149655|9796069|FG001|Period 1 - Conversion Phase|Sponsor Discontinued Trial|0
6156406|NCT01149655|9796070|FG002|Period 1 - Conversion Phase|Sponsor Discontinued Trial|0
6156407|NCT01149655|9796071|FG003|Period 1 - Conversion Phase|Sponsor Discontinued Trial|0
6156408|NCT01149655|9796068|FG000|Period 1 - Conversion Phase|Met Withdrawal Criteria|1
6156409|NCT01149655|9796069|FG001|Period 1 - Conversion Phase|Met Withdrawal Criteria|0
6156410|NCT01149655|9796070|FG002|Period 1 - Conversion Phase|Met Withdrawal Criteria|0
6156411|NCT01149655|9796071|FG003|Period 1 - Conversion Phase|Met Withdrawal Criteria|0
6156412|NCT01149655|9796068|FG000|Period 1 - Conversion Phase|Physician Decision|2
6156413|NCT01149655|9796069|FG001|Period 1 - Conversion Phase|Physician Decision|0
6156414|NCT01149655|9796070|FG002|Period 1 - Conversion Phase|Physician Decision|0
6156415|NCT01149655|9796071|FG003|Period 1 - Conversion Phase|Physician Decision|0
6156416|NCT01149655|9796068|FG000|Period 1 - Conversion Phase|Withdrawal by Subject|7
6156417|NCT01149655|9796069|FG001|Period 1 - Conversion Phase|Withdrawal by Subject|0
6156418|NCT01149655|9796070|FG002|Period 1 - Conversion Phase|Withdrawal by Subject|0
6156419|NCT01149655|9796071|FG003|Period 1 - Conversion Phase|Withdrawal by Subject|0
6156420|NCT01149655|9796068|FG000|Period 1 - Conversion Phase|Adverse Event Without Relapse|3
6156421|NCT01149655|9796069|FG001|Period 1 - Conversion Phase|Adverse Event Without Relapse|0
6156422|NCT01149655|9796070|FG002|Period 1 - Conversion Phase|Adverse Event Without Relapse|0
6156423|NCT01149655|9796071|FG003|Period 1 - Conversion Phase|Adverse Event Without Relapse|0
6042700|NCT00384176|9641061|FG001|Overall Study|Longer QTC as Visit 1|0
6156424|NCT01149655|9796068|FG000|Period 2-Stabilization Phase|Sponsor Discontinued Trial|0
6156425|NCT01149655|9796069|FG001|Period 2-Stabilization Phase|Sponsor Discontinued Trial|16
6156426|NCT01149655|9796070|FG002|Period 2-Stabilization Phase|Sponsor Discontinued Trial|0
6156427|NCT01149655|9796071|FG003|Period 2-Stabilization Phase|Sponsor Discontinued Trial|0
6156428|NCT01149655|9796068|FG000|Period 2-Stabilization Phase|Met Withdrawal Criteria|0
6156429|NCT01149655|9796069|FG001|Period 2-Stabilization Phase|Met Withdrawal Criteria|7
6156430|NCT01149655|9796070|FG002|Period 2-Stabilization Phase|Met Withdrawal Criteria|0
6156431|NCT01149655|9796071|FG003|Period 2-Stabilization Phase|Met Withdrawal Criteria|0
6156432|NCT01149655|9796068|FG000|Period 2-Stabilization Phase|Physician Decision|0
6156433|NCT01149655|9796069|FG001|Period 2-Stabilization Phase|Physician Decision|3
6156434|NCT01149655|9796070|FG002|Period 2-Stabilization Phase|Physician Decision|0
6156435|NCT01149655|9796071|FG003|Period 2-Stabilization Phase|Physician Decision|0
6156436|NCT01149655|9796068|FG000|Period 2-Stabilization Phase|Withdrawal by Subject|0
6156437|NCT01149655|9796069|FG001|Period 2-Stabilization Phase|Withdrawal by Subject|5
6156438|NCT01149655|9796070|FG002|Period 2-Stabilization Phase|Withdrawal by Subject|0
6156439|NCT01149655|9796071|FG003|Period 2-Stabilization Phase|Withdrawal by Subject|0
6156440|NCT01149655|9796068|FG000|Period 2-Stabilization Phase|Adverse Event Without Relapse|0
6156441|NCT01149655|9796069|FG001|Period 2-Stabilization Phase|Adverse Event Without Relapse|6
6156442|NCT01149655|9796070|FG002|Period 2-Stabilization Phase|Adverse Event Without Relapse|0
6156443|NCT01149655|9796071|FG003|Period 2-Stabilization Phase|Adverse Event Without Relapse|0
6156444|NCT01149655|9796068|FG000|Period 3-DB Maintenance Phase|Sponsor Discontinued Trial|0
6156445|NCT01149655|9796069|FG001|Period 3-DB Maintenance Phase|Sponsor Discontinued Trial|0
6156446|NCT01149655|9796070|FG002|Period 3-DB Maintenance Phase|Sponsor Discontinued Trial|58
6156447|NCT01149655|9796071|FG003|Period 3-DB Maintenance Phase|Sponsor Discontinued Trial|19
6156448|NCT01149655|9796068|FG000|Period 3-DB Maintenance Phase|Physician Decision|0
6156449|NCT01149655|9796069|FG001|Period 3-DB Maintenance Phase|Physician Decision|0
6156450|NCT01149655|9796070|FG002|Period 3-DB Maintenance Phase|Physician Decision|1
6156451|NCT01149655|9796071|FG003|Period 3-DB Maintenance Phase|Physician Decision|0
6080564|NCT00617344|9687878|FG001|Overall Study|Protocol Violation|8
6080565|NCT00617344|9687879|FG002|Overall Study|Protocol Violation|5
6080566|NCT00617344|9687877|FG000|Overall Study|Lost to Follow-up|5
6080567|NCT00617344|9687878|FG001|Overall Study|Lost to Follow-up|4
6156452|NCT01149655|9796068|FG000|Period 3-DB Maintenance Phase|Withdrawal by Subject|0
6156453|NCT01149655|9796069|FG001|Period 3-DB Maintenance Phase|Withdrawal by Subject|0
6156454|NCT01149655|9796070|FG002|Period 3-DB Maintenance Phase|Withdrawal by Subject|4
6156455|NCT01149655|9796071|FG003|Period 3-DB Maintenance Phase|Withdrawal by Subject|4
6156456|NCT01149655|9796068|FG000|Period 3-DB Maintenance Phase|Adverse Event Without Relapse|0
6156457|NCT01149655|9796069|FG001|Period 3-DB Maintenance Phase|Adverse Event Without Relapse|0
6156458|NCT01149655|9796070|FG002|Period 3-DB Maintenance Phase|Adverse Event Without Relapse|1
6156459|NCT01149655|9796071|FG003|Period 3-DB Maintenance Phase|Adverse Event Without Relapse|1
6156460|NCT01149655|9796068|FG000|Period 3-DB Maintenance Phase|Relapse With AE|0
6156461|NCT01149655|9796069|FG001|Period 3-DB Maintenance Phase|Relapse With AE|0
6156462|NCT01149655|9796070|FG002|Period 3-DB Maintenance Phase|Relapse With AE|19
6156463|NCT01149655|9796071|FG003|Period 3-DB Maintenance Phase|Relapse With AE|18
6156464|NCT01149681|9796079|FG000|Overall Study|Withdrawal by Subject|7
6156465|NCT01149681|9796079|FG000|Overall Study|Progressive disease|1
6156466|NCT01149681|9796079|FG000|Overall Study|Physician Decision|2
6156467|NCT01149681|9796079|FG000|Overall Study|adverse events nonrelated study drug|2
6156468|NCT01149863|9796115|FG000|Overall Study|Missing data or Not receiveing studydrug|3
6080568|NCT00617344|9687879|FG002|Overall Study|Lost to Follow-up|1
6080569|NCT00617344|9687877|FG000|Overall Study|Withdrawal by Subject|8
6080570|NCT00617344|9687878|FG001|Overall Study|Withdrawal by Subject|9
6080571|NCT00617344|9687879|FG002|Overall Study|Withdrawal by Subject|2
6080572|NCT00617357|9687887|FG000|Overall Study|Lost to Follow-up|7
6080573|NCT00617357|9687887|FG000|Overall Study|Death|5
6080574|NCT00617357|9687887|FG000|Overall Study|insurance concerns|2
6080575|NCT00617357|9687887|FG000|Overall Study|Withdrawal by Subject|1
6080576|NCT00617357|9687887|FG000|Overall Study|Physician Decision|1
6080577|NCT00617409|9687899|FG000|Overall Study|Withdrawal by Subject|4
6080578|NCT00617409|9687900|FG001|Overall Study|Withdrawal by Subject|1
6080579|NCT00617409|9687901|FG002|Overall Study|Withdrawal by Subject|2
6080580|NCT00617409|9687899|FG000|Overall Study|Adverse Event|0
6080581|NCT00617409|9687900|FG001|Overall Study|Adverse Event|2
6080582|NCT00617409|9687901|FG002|Overall Study|Adverse Event|3
6080583|NCT00617409|9687899|FG000|Overall Study|Disease Progression|8
6080584|NCT00617409|9687900|FG001|Overall Study|Disease Progression|8
6080585|NCT00617409|9687901|FG002|Overall Study|Disease Progression|18
6080586|NCT00617409|9687899|FG000|Overall Study|Death|3
6080587|NCT00617409|9687900|FG001|Overall Study|Death|5
6080588|NCT00617409|9687901|FG002|Overall Study|Death|4
6156469|NCT01150097|9796140|FG000|Months 24 to 36 Post-transplantation|Death|2
6156470|NCT01150097|9796141|FG001|Months 24 to 36 Post-transplantation|Death|0
6156471|NCT01150097|9796142|FG002|Months 24 to 36 Post-transplantation|Death|0
6156472|NCT01150097|9796140|FG000|Months 24 to 36 Post-transplantation|Administrative problems|5
6156473|NCT01150097|9796141|FG001|Months 24 to 36 Post-transplantation|Administrative problems|2
6156474|NCT01150097|9796142|FG002|Months 24 to 36 Post-transplantation|Administrative problems|2
6156475|NCT01150097|9796140|FG000|Months 24 to 36 Post-transplantation|Lost to Follow-up|0
6156476|NCT01150097|9796141|FG001|Months 24 to 36 Post-transplantation|Lost to Follow-up|0
6156477|NCT01150097|9796142|FG002|Months 24 to 36 Post-transplantation|Lost to Follow-up|3
6156478|NCT01150097|9796140|FG000|Months 24 to 36 Post-transplantation|Withdrawal by Subject|3
6156479|NCT01150097|9796141|FG001|Months 24 to 36 Post-transplantation|Withdrawal by Subject|0
6156480|NCT01150097|9796142|FG002|Months 24 to 36 Post-transplantation|Withdrawal by Subject|3
6156481|NCT01150097|9796140|FG000|Months 24 to 48 Post-transplantation|Administrative problems|5
6156482|NCT01150097|9796141|FG001|Months 24 to 48 Post-transplantation|Administrative problems|4
6156483|NCT01150097|9796142|FG002|Months 24 to 48 Post-transplantation|Administrative problems|0
6156484|NCT01150097|9796140|FG000|Months 24 to 48 Post-transplantation|Withdrawal by Subject|4
6156485|NCT01150097|9796141|FG001|Months 24 to 48 Post-transplantation|Withdrawal by Subject|0
6156486|NCT01150097|9796142|FG002|Months 24 to 48 Post-transplantation|Withdrawal by Subject|0
6156487|NCT01150097|9796140|FG000|Months 24 to 48 Post-transplantation|Death|2
6156488|NCT01150097|9796141|FG001|Months 24 to 48 Post-transplantation|Death|0
6156489|NCT01150097|9796142|FG002|Months 24 to 48 Post-transplantation|Death|0
6156490|NCT01150123|9796170|FG000|Overall Study|Withdrawal by Subject|1
6156491|NCT01150123|9796171|FG001|Overall Study|Withdrawal by Subject|1
6156492|NCT01150123|9796172|FG002|Overall Study|Withdrawal by Subject|2
6156493|NCT01150123|9796173|FG003|Overall Study|Withdrawal by Subject|1
6156494|NCT01150123|9796174|FG004|Overall Study|Withdrawal by Subject|1
6156495|NCT01150123|9796175|FG005|Overall Study|Withdrawal by Subject|1
6156496|NCT01150123|9796176|FG006|Overall Study|Withdrawal by Subject|0
6156497|NCT01150123|9796177|FG007|Overall Study|Withdrawal by Subject|3
6156498|NCT01150123|9796178|FG008|Overall Study|Withdrawal by Subject|2
6156499|NCT01150123|9796179|FG009|Overall Study|Withdrawal by Subject|0
6156500|NCT01150123|9796180|FG010|Overall Study|Withdrawal by Subject|1
6156501|NCT01150123|9796181|FG011|Overall Study|Withdrawal by Subject|0
6156502|NCT01150123|9796182|FG012|Overall Study|Withdrawal by Subject|1
6156503|NCT01150123|9796183|FG013|Overall Study|Withdrawal by Subject|0
6156504|NCT01150123|9796184|FG014|Overall Study|Withdrawal by Subject|0
6156505|NCT01150123|9796185|FG015|Overall Study|Withdrawal by Subject|1
6156506|NCT01150123|9796186|FG016|Overall Study|Withdrawal by Subject|0
6156507|NCT01150123|9796187|FG017|Overall Study|Withdrawal by Subject|1
6156508|NCT01150123|9796170|FG000|Overall Study|Lost to Follow-up|2
6156509|NCT01150123|9796171|FG001|Overall Study|Lost to Follow-up|1
6156510|NCT01150123|9796172|FG002|Overall Study|Lost to Follow-up|2
6156511|NCT01150123|9796173|FG003|Overall Study|Lost to Follow-up|2
6156512|NCT01150123|9796174|FG004|Overall Study|Lost to Follow-up|2
6080589|NCT00617409|9687899|FG000|Overall Study|Alternative Therapy|1
6080590|NCT00617409|9687900|FG001|Overall Study|Alternative Therapy|2
6080591|NCT00617409|9687901|FG002|Overall Study|Alternative Therapy|0
6080592|NCT00617461|9687910|FG000|First Treatment Intervention Period|Adverse Event|2
6156513|NCT01150123|9796175|FG005|Overall Study|Lost to Follow-up|5
6156514|NCT01150123|9796176|FG006|Overall Study|Lost to Follow-up|0
6156515|NCT01150123|9796177|FG007|Overall Study|Lost to Follow-up|0
6156516|NCT01150123|9796178|FG008|Overall Study|Lost to Follow-up|3
6080593|NCT00617461|9687911|FG001|First Treatment Intervention Period|Adverse Event|0
6080594|NCT00617461|9687910|FG000|First Treatment Intervention Period|Lack of Efficacy|1
6080595|NCT00617461|9687911|FG001|First Treatment Intervention Period|Lack of Efficacy|0
6080596|NCT00617461|9687910|FG000|First Treatment Intervention Period|Protocol Violation|2
6080597|NCT00617461|9687911|FG001|First Treatment Intervention Period|Protocol Violation|1
6080598|NCT00617461|9687910|FG000|First Treatment Intervention Period|Lost to Follow-up|0
6080599|NCT00617461|9687911|FG001|First Treatment Intervention Period|Lost to Follow-up|1
6080600|NCT00617461|9687910|FG000|First Treatment Intervention Period|Investigator Discretion|1
6080601|NCT00617461|9687911|FG001|First Treatment Intervention Period|Investigator Discretion|1
6080602|NCT00617461|9687910|FG000|First Treatment Intervention Period|Withdrawal by Subject|4
6156517|NCT01150123|9796179|FG009|Overall Study|Lost to Follow-up|1
6156518|NCT01150123|9796180|FG010|Overall Study|Lost to Follow-up|1
6156519|NCT01150123|9796181|FG011|Overall Study|Lost to Follow-up|1
6156520|NCT01150123|9796182|FG012|Overall Study|Lost to Follow-up|2
6156521|NCT01150123|9796183|FG013|Overall Study|Lost to Follow-up|0
6156522|NCT01150123|9796184|FG014|Overall Study|Lost to Follow-up|0
6156523|NCT01150123|9796185|FG015|Overall Study|Lost to Follow-up|0
6156524|NCT01150123|9796186|FG016|Overall Study|Lost to Follow-up|0
6156525|NCT01150123|9796187|FG017|Overall Study|Lost to Follow-up|0
6156526|NCT01150357|9796247|FG000|Dose Response Phase (Phase 1)|Protocol Violation|0
6156527|NCT01150357|9796248|FG001|Dose Response Phase (Phase 1)|Protocol Violation|1
6156528|NCT01150357|9796249|FG002|Dose Response Phase (Phase 1)|Protocol Violation|1
6156529|NCT01150357|9796247|FG000|Dose Response Phase (Phase 1)|Unsatisfactory therapeutic effect|1
6156530|NCT01150357|9796248|FG001|Dose Response Phase (Phase 1)|Unsatisfactory therapeutic effect|0
6042701|NCT00384176|9641062|FG002|Overall Study|Longer QTC as Visit 1|0
6042702|NCT00384176|9641060|FG000|Overall Study|Toxicity of treatment|1
6042703|NCT00384176|9641061|FG001|Overall Study|Toxicity of treatment|0
6042704|NCT00384176|9641062|FG002|Overall Study|Toxicity of treatment|0
6042705|NCT00384176|9641060|FG000|Overall Study|Did not receive study treatment|0
6042706|NCT00384176|9641061|FG001|Overall Study|Did not receive study treatment|1
6042707|NCT00384176|9641062|FG002|Overall Study|Did not receive study treatment|1
6042708|NCT00384176|9641060|FG000|Overall Study|Physician Decision|0
6042709|NCT00384176|9641061|FG001|Overall Study|Physician Decision|2
6042710|NCT00384176|9641062|FG002|Overall Study|Physician Decision|0
6042711|NCT00384176|9641060|FG000|Overall Study|Liver metastases, colon resec. planned|1
6042712|NCT00384176|9641061|FG001|Overall Study|Liver metastases, colon resec. planned|0
6042713|NCT00384176|9641062|FG002|Overall Study|Liver metastases, colon resec. planned|0
6156531|NCT01150357|9796249|FG002|Dose Response Phase (Phase 1)|Unsatisfactory therapeutic effect|0
6156532|NCT01150357|9796247|FG000|Dose Response Phase (Phase 1)|Adverse Event|0
6156533|NCT01150357|9796248|FG001|Dose Response Phase (Phase 1)|Adverse Event|0
6156534|NCT01150357|9796249|FG002|Dose Response Phase (Phase 1)|Adverse Event|1
6156535|NCT01150357|9796247|FG000|Dose Response Phase (Phase 1)|Withdrawal by Participants|0
6156536|NCT01150357|9796248|FG001|Dose Response Phase (Phase 1)|Withdrawal by Participants|2
6156537|NCT01150357|9796249|FG002|Dose Response Phase (Phase 1)|Withdrawal by Participants|1
6156538|NCT01150357|9796247|FG000|Placebo-controlled Withdrawal (Phase 2)|Adverse Event|0
6156539|NCT01150357|9796248|FG001|Placebo-controlled Withdrawal (Phase 2)|Adverse Event|0
6156540|NCT01150357|9796249|FG002|Placebo-controlled Withdrawal (Phase 2)|Adverse Event|2
6156541|NCT01150357|9796247|FG000|Placebo-controlled Withdrawal (Phase 2)|Withdrawal by Subject|2
6156542|NCT01150357|9796248|FG001|Placebo-controlled Withdrawal (Phase 2)|Withdrawal by Subject|0
6156543|NCT01150357|9796249|FG002|Placebo-controlled Withdrawal (Phase 2)|Withdrawal by Subject|0
6156544|NCT01150357|9796247|FG000|Placebo-controlled Withdrawal (Phase 2)|Lost to Follow-up|1
6156545|NCT01150357|9796248|FG001|Placebo-controlled Withdrawal (Phase 2)|Lost to Follow-up|0
6156546|NCT01150357|9796249|FG002|Placebo-controlled Withdrawal (Phase 2)|Lost to Follow-up|0
6156547|NCT01150474|9796280|FG000|Overall Study|Withdrawal by Subject|5
6156548|NCT01150474|9796281|FG001|Overall Study|Withdrawal by Subject|2
6156549|NCT01150474|9796280|FG000|Overall Study|Cancer found|1
6156550|NCT01150474|9796281|FG001|Overall Study|Cancer found|0
6156551|NCT01150474|9796280|FG000|Overall Study|Multiple Studies|0
6156552|NCT01150474|9796281|FG001|Overall Study|Multiple Studies|1
6156553|NCT01150474|9796280|FG000|Overall Study|Rectotomy|1
6156554|NCT01150474|9796281|FG001|Overall Study|Rectotomy|0
6156555|NCT01150474|9796280|FG000|Overall Study|Drug did not arrive in time|1
6156556|NCT01150474|9796281|FG001|Overall Study|Drug did not arrive in time|0
6156557|NCT01150474|9796280|FG000|Overall Study|Drug not administered|1
6156558|NCT01150474|9796281|FG001|Overall Study|Drug not administered|0
6156559|NCT01150474|9796280|FG000|Overall Study|Surgery Changed|1
6156560|NCT01150474|9796281|FG001|Overall Study|Surgery Changed|0
6080603|NCT00617461|9687911|FG001|First Treatment Intervention Period|Withdrawal by Subject|0
6156561|NCT01151020|9796336|FG000|Overall Study|Death|25
6156562|NCT01151020|9796336|FG000|Overall Study|Conversion to open repair|1
6156563|NCT01151020|9796336|FG000|Overall Study|Lost to Follow-up|4
6156564|NCT01151020|9796336|FG000|Overall Study|Withdrawal by Subject|22
6156565|NCT01151020|9796336|FG000|Overall Study|Patients did not receive the device|2
6156566|NCT01151085|9796353|FG000|Overall Study|Lost to Follow-up|31
6156567|NCT01151085|9796353|FG000|Overall Study|Protocol Violation|25
6156568|NCT01151098|9796364|FG000|Overall Study|Adverse Event|82
6156569|NCT01151098|9796364|FG000|Overall Study|Lost to Follow-up|6
6156570|NCT01151098|9796364|FG000|Overall Study|Lack of Efficacy|15
6156571|NCT01151098|9796364|FG000|Overall Study|Protocol Violation|1
6156572|NCT01151098|9796364|FG000|Overall Study|Miscellaneous|13
6156573|NCT01151137|9796370|FG000|Overall Study|Death|15
6156574|NCT01151137|9796371|FG001|Overall Study|Death|27
6156575|NCT01151137|9796370|FG000|Overall Study|Lost to Follow-up|1
6156576|NCT01151137|9796371|FG001|Overall Study|Lost to Follow-up|1
6156577|NCT01151215|9796389|FG000|Overall Study|Worsening of condition under study|1
6156578|NCT01151215|9796390|FG001|Overall Study|Worsening of condition under study|1
6156579|NCT01151215|9796391|FG002|Overall Study|Worsening of condition under study|1
6156580|NCT01151215|9796389|FG000|Overall Study|Death|16
6156581|NCT01151215|9796390|FG001|Overall Study|Death|20
6156582|NCT01151215|9796391|FG002|Overall Study|Death|11
6080604|NCT00617461|9687910|FG000|4-Day Crossover Period|Withdrawal by Subject|1
6080605|NCT00617461|9687911|FG001|4-Day Crossover Period|Withdrawal by Subject|0
6080606|NCT00617461|9687910|FG000|Second Treatment Intervention Period|Adverse Event|0
6080607|NCT00617461|9687911|FG001|Second Treatment Intervention Period|Adverse Event|1
6080608|NCT00617461|9687910|FG000|Second Treatment Intervention Period|Lack of Efficacy|0
6080609|NCT00617461|9687911|FG001|Second Treatment Intervention Period|Lack of Efficacy|3
6080610|NCT00617461|9687910|FG000|6-Day Down-Titration Period|Withdrawal by Subject|1
6080611|NCT00617461|9687911|FG001|6-Day Down-Titration Period|Withdrawal by Subject|0
6080612|NCT00617461|9687910|FG000|6-Day Down-Titration Period|Did Not Attend Down-titration Visit|1
6080613|NCT00617461|9687911|FG001|6-Day Down-Titration Period|Did Not Attend Down-titration Visit|2
6080614|NCT00617591|9687938|FG000|Overall Study|Withdrew consent during Induction|4
6156583|NCT01151215|9796389|FG000|Overall Study|Lost to Follow-up|0
6156584|NCT01151215|9796390|FG001|Overall Study|Lost to Follow-up|0
6156585|NCT01151215|9796391|FG002|Overall Study|Lost to Follow-up|3
6156586|NCT01151215|9796389|FG000|Overall Study|Withdrawal by Subject|3
6156587|NCT01151215|9796390|FG001|Overall Study|Withdrawal by Subject|1
6156588|NCT01151215|9796391|FG002|Overall Study|Withdrawal by Subject|2
6156589|NCT01151215|9796389|FG000|Overall Study|Disease progression|0
6156590|NCT01151215|9796390|FG001|Overall Study|Disease progression|1
6156591|NCT01151215|9796391|FG002|Overall Study|Disease progression|1
6156592|NCT01151215|9796389|FG000|Overall Study|Safety as judged by the investigator|0
6156593|NCT01151215|9796390|FG001|Overall Study|Safety as judged by the investigator|0
6156594|NCT01151215|9796391|FG002|Overall Study|Safety as judged by the investigator|1
6156595|NCT01151280|9796399|FG000|Overall Study|Adverse Event|1
6156596|NCT01151280|9796399|FG000|Overall Study|Lack of Efficacy|3
6156597|NCT01151345|9796403|FG000|First Intervention Period|Protocol Violation|0
6156598|NCT01151345|9796404|FG001|First Intervention Period|Protocol Violation|1
6156599|NCT01151410|9796425|FG000|Overall Study|Withdrawal by Subject|3
6156600|NCT01151410|9796426|FG001|Overall Study|Withdrawal by Subject|5
6156601|NCT01151410|9796425|FG000|Overall Study|Lost to Follow-up|3
6156602|NCT01151410|9796426|FG001|Overall Study|Lost to Follow-up|4
6156603|NCT01151410|9796425|FG000|Overall Study|Adverse Event|1
6156604|NCT01151410|9796426|FG001|Overall Study|Adverse Event|2
6156605|NCT01151410|9796425|FG000|Overall Study|Protocol deviation|2
6156606|NCT01151410|9796426|FG001|Overall Study|Protocol deviation|1
6156607|NCT01151410|9796425|FG000|Overall Study|Administrative problems|1
6156608|NCT01151410|9796426|FG001|Overall Study|Administrative problems|1
6156609|NCT01151410|9796425|FG000|Overall Study|Unsatisfactory therapeutic effect|1
6156610|NCT01151410|9796426|FG001|Overall Study|Unsatisfactory therapeutic effect|1
6156611|NCT01151410|9796425|FG000|Overall Study|Abnormal laboratory value(s)|0
6156612|NCT01151410|9796426|FG001|Overall Study|Abnormal laboratory value(s)|1
6156613|NCT01151423|9796434|FG000|Overall Study|Study terminated by Sponsor|9
6156614|NCT01151423|9796435|FG001|Overall Study|Study terminated by Sponsor|10
6156615|NCT01151423|9796434|FG000|Overall Study|Protocol Violation|0
6156616|NCT01151423|9796435|FG001|Overall Study|Protocol Violation|1
6156617|NCT01151423|9796434|FG000|Overall Study|Physician Decision|1
6156618|NCT01151423|9796435|FG001|Overall Study|Physician Decision|1
6156619|NCT01151423|9796434|FG000|Overall Study|Pregnancy|0
6156620|NCT01151423|9796435|FG001|Overall Study|Pregnancy|1
6156621|NCT01151423|9796434|FG000|Overall Study|Death|0
6156622|NCT01151423|9796435|FG001|Overall Study|Death|1
6156623|NCT01151423|9796434|FG000|Overall Study|Adverse Event|3
6156624|NCT01151423|9796435|FG001|Overall Study|Adverse Event|0
6156625|NCT01151423|9796434|FG000|Overall Study|Withdrawal by Subject|1
6156626|NCT01151423|9796435|FG001|Overall Study|Withdrawal by Subject|3
6156627|NCT01151423|9796434|FG000|Overall Study|Lost to Follow-up|1
6156628|NCT01151423|9796435|FG001|Overall Study|Lost to Follow-up|0
6156629|NCT01151423|9796434|FG000|Overall Study|Diagnosed as non-TTP patient|0
6156630|NCT01151423|9796435|FG001|Overall Study|Diagnosed as non-TTP patient|1
6156631|NCT01151423|9796434|FG000|Overall Study|Participated in other clinical trial|1
6156632|NCT01151423|9796435|FG001|Overall Study|Participated in other clinical trial|0
6156633|NCT01151540|9796449|FG000|Overall Study|Other|2
6156634|NCT01151540|9796449|FG000|Overall Study|Adverse event, non-fatal|4
6156635|NCT01151540|9796449|FG000|Overall Study|Withdrawal by Subject|7
6156636|NCT01151579|9796455|FG000|Overall Study|Physician Decision|3
6156637|NCT01151579|9796456|FG001|Overall Study|Physician Decision|1
6156638|NCT01151579|9796455|FG000|Overall Study|Withdrawal by Subject|3
6156639|NCT01151579|9796456|FG001|Overall Study|Withdrawal by Subject|2
6156640|NCT01151579|9796455|FG000|Overall Study|Not meet inclusion criteria|6
6156641|NCT01151579|9796456|FG001|Overall Study|Not meet inclusion criteria|4
6156642|NCT01151618|9796462|FG000|Overall Study|Adverse Event|2
6156643|NCT01151618|9796462|FG000|Overall Study|Withdrawal by Subject|7
6156644|NCT01152021|9796489|FG000|Overall Study|Adverse Event|4
6156645|NCT01152021|9796490|FG001|Overall Study|Adverse Event|4
6156646|NCT01152021|9796489|FG000|Overall Study|Study drug had expired|1
6156647|NCT01152021|9796490|FG001|Overall Study|Study drug had expired|0
6156648|NCT01152021|9796489|FG000|Overall Study|Physician Decision|1
6156649|NCT01152021|9796490|FG001|Overall Study|Physician Decision|1
6156650|NCT01152021|9796489|FG000|Overall Study|No access to study drug in Pharmacy|0
6156651|NCT01152021|9796490|FG001|Overall Study|No access to study drug in Pharmacy|1
6191740|NCT01425281|9848678|FG001|At 4-year Clinical Follow-up|Withdrawal by Subject|2
6191741|NCT01425281|9848677|FG000|At 4-year Clinical Follow-up|Did not consent for follow-up after 3 ye|10
6191742|NCT01425281|9848678|FG001|At 4-year Clinical Follow-up|Did not consent for follow-up after 3 ye|10
6191743|NCT01425281|9848677|FG000|At 4-year Clinical Follow-up|Terminated by Polish Ethics Committee|6
6191744|NCT01425281|9848678|FG001|At 4-year Clinical Follow-up|Terminated by Polish Ethics Committee|5
6191745|NCT01425281|9848677|FG000|At 4-year Clinical Follow-up|Lost to Follow-up|4
6191746|NCT01425281|9848678|FG001|At 4-year Clinical Follow-up|Lost to Follow-up|1
6191747|NCT01425281|9848677|FG000|At 5-year Clinical Follow-up|Death|2
6191748|NCT01425281|9848678|FG001|At 5-year Clinical Follow-up|Death|0
6191749|NCT01425281|9848677|FG000|At 5-year Clinical Follow-up|Lost to Follow-up|2
6191750|NCT01425281|9848678|FG001|At 5-year Clinical Follow-up|Lost to Follow-up|1
6191751|NCT01425281|9848677|FG000|At 5-year Clinical Follow-up|Terminated by Polish Ethics Committee|19
6191752|NCT01425281|9848678|FG001|At 5-year Clinical Follow-up|Terminated by Polish Ethics Committee|7
6156652|NCT01152190|9796509|FG000|Overall Study|Adverse Event|2
6156653|NCT01152190|9796510|FG001|Overall Study|Adverse Event|4
6156654|NCT01152190|9796509|FG000|Overall Study|Death|1
6156655|NCT01152190|9796510|FG001|Overall Study|Death|0
6156656|NCT01152190|9796509|FG000|Overall Study|Protocol Violation|1
6156657|NCT01152190|9796510|FG001|Overall Study|Protocol Violation|1
6156658|NCT01152190|9796509|FG000|Overall Study|Withdrawal by Subject|1
6156659|NCT01152190|9796510|FG001|Overall Study|Withdrawal by Subject|3
6156660|NCT01152385|9796547|FG000|Overall Study|Withdrawal by Subject|3
6156661|NCT01152385|9796548|FG001|Overall Study|Withdrawal by Subject|1
6156662|NCT01152385|9796549|FG002|Overall Study|Withdrawal by Subject|1
6156663|NCT01152385|9796550|FG003|Overall Study|Withdrawal by Subject|1
6156664|NCT01152385|9796547|FG000|Overall Study|Protocol Violation|0
6156665|NCT01152385|9796548|FG001|Overall Study|Protocol Violation|0
6156666|NCT01152385|9796549|FG002|Overall Study|Protocol Violation|0
6156667|NCT01152385|9796550|FG003|Overall Study|Protocol Violation|1
6156668|NCT01152385|9796547|FG000|Overall Study|Adverse Event|1
6156669|NCT01152385|9796548|FG001|Overall Study|Adverse Event|1
6156670|NCT01152385|9796549|FG002|Overall Study|Adverse Event|0
6156671|NCT01152385|9796550|FG003|Overall Study|Adverse Event|0
6156672|NCT01152385|9796547|FG000|Overall Study|Study-specific withdrawal criteria|1
6156673|NCT01152385|9796548|FG001|Overall Study|Study-specific withdrawal criteria|1
6156674|NCT01152385|9796549|FG002|Overall Study|Study-specific withdrawal criteria|2
6156675|NCT01152385|9796550|FG003|Overall Study|Study-specific withdrawal criteria|0
6156676|NCT01152385|9796547|FG000|Overall Study|Other|4
6156677|NCT01152385|9796548|FG001|Overall Study|Other|3
6156678|NCT01152385|9796549|FG002|Overall Study|Other|2
6156679|NCT01152385|9796550|FG003|Overall Study|Other|3
6156680|NCT01152437|9796567|FG000|Overall Study|Other Adverse Event|8
6156681|NCT01152437|9796568|FG001|Overall Study|Other Adverse Event|1
6156682|NCT01152437|9796569|FG002|Overall Study|Other Adverse Event|7
6156683|NCT01152437|9796567|FG000|Overall Study|Not treated|0
6156684|NCT01152437|9796568|FG001|Overall Study|Not treated|1
6156685|NCT01152437|9796569|FG002|Overall Study|Not treated|2
6156686|NCT01152437|9796567|FG000|Overall Study|Progressive disease|27
6156687|NCT01152437|9796568|FG001|Overall Study|Progressive disease|13
6156688|NCT01152437|9796569|FG002|Overall Study|Progressive disease|32
6156689|NCT01152437|9796567|FG000|Overall Study|Refusal to continue taking trial medicat|1
6156690|NCT01152437|9796568|FG001|Overall Study|Refusal to continue taking trial medicat|0
6156691|NCT01152437|9796569|FG002|Overall Study|Refusal to continue taking trial medicat|2
6156692|NCT01152450|9796579|FG000|Period 1 (4 Weeks)|Adverse Event|0
6156693|NCT01152450|9796580|FG001|Period 1 (4 Weeks)|Adverse Event|0
6156694|NCT01152450|9796581|FG002|Period 1 (4 Weeks)|Adverse Event|0
6156695|NCT01152450|9796582|FG003|Period 1 (4 Weeks)|Adverse Event|0
6156696|NCT01152450|9796583|FG004|Period 1 (4 Weeks)|Adverse Event|1
6156697|NCT01152450|9796584|FG005|Period 1 (4 Weeks)|Adverse Event|1
6156698|NCT01152450|9796579|FG000|Period 1 (4 Weeks)|Protocol Violation|0
6156699|NCT01152450|9796580|FG001|Period 1 (4 Weeks)|Protocol Violation|0
6156700|NCT01152450|9796581|FG002|Period 1 (4 Weeks)|Protocol Violation|0
6156701|NCT01152450|9796582|FG003|Period 1 (4 Weeks)|Protocol Violation|0
6156702|NCT01152450|9796583|FG004|Period 1 (4 Weeks)|Protocol Violation|1
6156703|NCT01152450|9796584|FG005|Period 1 (4 Weeks)|Protocol Violation|0
6156704|NCT01152450|9796579|FG000|Period 1 (4 Weeks)|Lost to Follow-up|0
6156705|NCT01152450|9796580|FG001|Period 1 (4 Weeks)|Lost to Follow-up|1
6156706|NCT01152450|9796581|FG002|Period 1 (4 Weeks)|Lost to Follow-up|1
6156707|NCT01152450|9796582|FG003|Period 1 (4 Weeks)|Lost to Follow-up|0
6156708|NCT01152450|9796583|FG004|Period 1 (4 Weeks)|Lost to Follow-up|0
6156709|NCT01152450|9796584|FG005|Period 1 (4 Weeks)|Lost to Follow-up|0
6156710|NCT01152554|9796603|FG000|Overall Study|Withdrawal by Subject|73
6156711|NCT01152554|9796604|FG001|Overall Study|Withdrawal by Subject|28
6156712|NCT01152554|9796603|FG000|Overall Study|Eligiblity criteria not fulfilled|0
6156713|NCT01152554|9796604|FG001|Overall Study|Eligiblity criteria not fulfilled|1
6156714|NCT01152554|9796603|FG000|Overall Study|Adverse Event|67
6156715|NCT01152554|9796604|FG001|Overall Study|Adverse Event|14
6156716|NCT01152554|9796603|FG000|Overall Study|Severe non-compliance to protocol|36
6156717|NCT01152554|9796604|FG001|Overall Study|Severe non-compliance to protocol|14
6156718|NCT01152554|9796603|FG000|Overall Study|Condition under investigation worsened|5
6156719|NCT01152554|9796604|FG001|Overall Study|Condition under investigation worsened|2
6156720|NCT01152554|9796603|FG000|Overall Study|Lack of Efficacy|20
6156721|NCT01152554|9796604|FG001|Overall Study|Lack of Efficacy|3
6156722|NCT01152554|9796603|FG000|Overall Study|Study-specific withdrawal criteria|17
6156723|NCT01152554|9796604|FG001|Overall Study|Study-specific withdrawal criteria|8
6156724|NCT01152554|9796603|FG000|Overall Study|Lost to Follow-up|87
6156725|NCT01152554|9796604|FG001|Overall Study|Lost to Follow-up|32
6156726|NCT01152554|9796603|FG000|Overall Study|Other|28
6156727|NCT01152554|9796604|FG001|Overall Study|Other|8
6156728|NCT01152554|9796603|FG000|Overall Study|Death|1
6156729|NCT01152554|9796604|FG001|Overall Study|Death|1
6156730|NCT01152580|9796612|FG000|Overall Study|Withdrawal by Subject|0
6156731|NCT01152580|9796613|FG001|Overall Study|Withdrawal by Subject|1
6156732|NCT01152788|9796625|FG000|Overall Study|Withdrawal by Subject|0
6156733|NCT01152788|9796626|FG001|Overall Study|Withdrawal by Subject|3
6156734|NCT01152788|9796625|FG000|Overall Study|No treatment|0
6156735|NCT01152788|9796626|FG001|Overall Study|No treatment|1
6156736|NCT01152814|9796632|FG000|Overall Study|Lost to Follow-up|2
6156737|NCT01152996|9796636|FG000|Overall Study|Withdrawal by Subject|142
6156738|NCT01152996|9796636|FG000|Overall Study|Adverse Event|115
6156739|NCT01152996|9796636|FG000|Overall Study|Lost to Follow-up|112
6156740|NCT01152996|9796636|FG000|Overall Study|Lack of Efficacy|68
6156741|NCT01152996|9796636|FG000|Overall Study|Noncompliance|41
6156742|NCT01152996|9796636|FG000|Overall Study|Other|36
6156743|NCT01152996|9796636|FG000|Overall Study|Protocol Violation|22
6156744|NCT01152996|9796636|FG000|Overall Study|Elevated liver enzymes|1
6156745|NCT01153009|9796644|FG000|Overall Study|Adverse Event|4
6156746|NCT01153009|9796645|FG001|Overall Study|Adverse Event|14
6156747|NCT01153009|9796646|FG002|Overall Study|Adverse Event|14
6156748|NCT01153009|9796647|FG003|Overall Study|Adverse Event|10
6156749|NCT01153009|9796644|FG000|Overall Study|Lack of Efficacy|9
6156750|NCT01153009|9796645|FG001|Overall Study|Lack of Efficacy|0
6156751|NCT01153009|9796646|FG002|Overall Study|Lack of Efficacy|2
6156752|NCT01153009|9796647|FG003|Overall Study|Lack of Efficacy|1
6156753|NCT01153009|9796644|FG000|Overall Study|Noncompliance with Study Medication|1
6156754|NCT01153009|9796645|FG001|Overall Study|Noncompliance with Study Medication|3
6156755|NCT01153009|9796646|FG002|Overall Study|Noncompliance with Study Medication|4
6156756|NCT01153009|9796647|FG003|Overall Study|Noncompliance with Study Medication|1
6156757|NCT01153009|9796644|FG000|Overall Study|Protocol Deviations|4
6156758|NCT01153009|9796645|FG001|Overall Study|Protocol Deviations|3
6156759|NCT01153009|9796646|FG002|Overall Study|Protocol Deviations|3
6156760|NCT01153009|9796647|FG003|Overall Study|Protocol Deviations|2
6156761|NCT01153009|9796644|FG000|Overall Study|Withdrawal of Consent|5
6156762|NCT01153009|9796645|FG001|Overall Study|Withdrawal of Consent|5
6156763|NCT01153009|9796646|FG002|Overall Study|Withdrawal of Consent|4
6156764|NCT01153009|9796647|FG003|Overall Study|Withdrawal of Consent|6
6156765|NCT01153009|9796644|FG000|Overall Study|Lost to Follow-up|8
6156766|NCT01153009|9796645|FG001|Overall Study|Lost to Follow-up|8
6156767|NCT01153009|9796646|FG002|Overall Study|Lost to Follow-up|11
6156768|NCT01153009|9796647|FG003|Overall Study|Lost to Follow-up|15
6156769|NCT01153009|9796644|FG000|Overall Study|Other|1
6156770|NCT01153009|9796645|FG001|Overall Study|Other|1
6156771|NCT01153009|9796646|FG002|Overall Study|Other|3
6156772|NCT01153009|9796647|FG003|Overall Study|Other|2
6156773|NCT01153269|9796657|FG000|Overall Study|Withdrawal by Subject|1
6156774|NCT01153269|9796657|FG000|Overall Study|Antiretroviral therapy break|1
6156775|NCT01153321|9796666|FG000|Overall Study|Development of study withdrawal criteria|0
6156776|NCT01153321|9796667|FG001|Overall Study|Development of study withdrawal criteria|1
6156777|NCT01153321|9796666|FG000|Overall Study|Withdrawal by Subject|0
6156778|NCT01153321|9796667|FG001|Overall Study|Withdrawal by Subject|1
6156779|NCT01153321|9796666|FG000|Overall Study|Adverse Event|1
6156780|NCT01153321|9796667|FG001|Overall Study|Adverse Event|1
6156781|NCT01153347|9796677|FG000|Overall Study|Withdrawal by Subject|7
6156782|NCT01153347|9796678|FG001|Overall Study|Withdrawal by Subject|7
6156783|NCT01153347|9796679|FG002|Overall Study|Withdrawal by Subject|7
6156784|NCT01153347|9796680|FG003|Overall Study|Withdrawal by Subject|7
6156785|NCT01153347|9796677|FG000|Overall Study|Eligibility criteria not fulfilled|0
6156786|NCT01153347|9796678|FG001|Overall Study|Eligibility criteria not fulfilled|1
6156787|NCT01153347|9796679|FG002|Overall Study|Eligibility criteria not fulfilled|2
6156788|NCT01153347|9796680|FG003|Overall Study|Eligibility criteria not fulfilled|1
6156789|NCT01153347|9796677|FG000|Overall Study|Adverse Event|3
6156790|NCT01153347|9796678|FG001|Overall Study|Adverse Event|9
6156791|NCT01153347|9796679|FG002|Overall Study|Adverse Event|21
6156792|NCT01153347|9796680|FG003|Overall Study|Adverse Event|7
6156793|NCT01153347|9796677|FG000|Overall Study|Severe non-compliance to protocol|6
6156794|NCT01153347|9796678|FG001|Overall Study|Severe non-compliance to protocol|7
6156795|NCT01153347|9796679|FG002|Overall Study|Severe non-compliance to protocol|4
6156796|NCT01153347|9796680|FG003|Overall Study|Severe non-compliance to protocol|3
6156797|NCT01153347|9796677|FG000|Overall Study|Condition under investigation worsened|1
6156798|NCT01153347|9796678|FG001|Overall Study|Condition under investigation worsened|1
6156799|NCT01153347|9796679|FG002|Overall Study|Condition under investigation worsened|0
6156800|NCT01153347|9796680|FG003|Overall Study|Condition under investigation worsened|0
6156801|NCT01153347|9796677|FG000|Overall Study|Lack of Efficacy|2
6156802|NCT01153347|9796678|FG001|Overall Study|Lack of Efficacy|2
6156803|NCT01153347|9796679|FG002|Overall Study|Lack of Efficacy|0
6080615|NCT00617591|9687938|FG000|Overall Study|Withdrew consent during Maintenance|6
6080616|NCT00617604|9687945|FG000|Overall Study|Death|2
6080617|NCT00617604|9687946|FG001|Overall Study|Death|1
6080618|NCT00617604|9687945|FG000|Overall Study|Lost to Follow-up|1
6080619|NCT00617604|9687946|FG001|Overall Study|Lost to Follow-up|0
6080620|NCT00617604|9687945|FG000|Overall Study|Miscellaneous Reasons|8
6080621|NCT00617604|9687946|FG001|Overall Study|Miscellaneous Reasons|10
6080622|NCT00617604|9687945|FG000|Overall Study|Withdrawal by Subject|4
6080623|NCT00617604|9687946|FG001|Overall Study|Withdrawal by Subject|6
6080624|NCT00617604|9687945|FG000|Overall Study|Randomized but Never Received Study Drug|3
6080625|NCT00617604|9687946|FG001|Overall Study|Randomized but Never Received Study Drug|3
6080626|NCT00617669|9687954|FG000|Overall Study|Withdrawal by Subject|71
6080627|NCT00617669|9687955|FG001|Overall Study|Withdrawal by Subject|77
6080628|NCT00617669|9687954|FG000|Overall Study|Lost to Follow-up|3
6080629|NCT00617669|9687955|FG001|Overall Study|Lost to Follow-up|2
6080630|NCT00617669|9687954|FG000|Overall Study|Adverse Event|87
6156804|NCT01153347|9796680|FG003|Overall Study|Lack of Efficacy|4
6156805|NCT01153347|9796677|FG000|Overall Study|Study-specific withdrawal criteria|4
6156806|NCT01153347|9796678|FG001|Overall Study|Study-specific withdrawal criteria|3
6156807|NCT01153347|9796679|FG002|Overall Study|Study-specific withdrawal criteria|1
6080631|NCT00617669|9687955|FG001|Overall Study|Adverse Event|76
6080632|NCT00617669|9687954|FG000|Overall Study|Protocol Violation|2
6080633|NCT00617669|9687955|FG001|Overall Study|Protocol Violation|3
6080634|NCT00617669|9687954|FG000|Overall Study|Reason not otherwise captured, eg; death|265
6156808|NCT01153347|9796680|FG003|Overall Study|Study-specific withdrawal criteria|2
6156809|NCT01153347|9796677|FG000|Overall Study|Lost to Follow-up|4
6080635|NCT00617669|9687955|FG001|Overall Study|Reason not otherwise captured, eg; death|290
6080636|NCT00617669|9687954|FG000|Overall Study|Patients randomized but not treated|2
6080637|NCT00617669|9687955|FG001|Overall Study|Patients randomized but not treated|3
6080638|NCT00617734|9687963|FG000|Overall Study|Withdrew Consent|2
6080639|NCT00617734|9687964|FG001|Overall Study|Withdrew Consent|0
6080640|NCT00617734|9687963|FG000|Overall Study|Adverse Event|4
6080641|NCT00617734|9687964|FG001|Overall Study|Adverse Event|1
6080642|NCT00617734|9687963|FG000|Overall Study|Protocol Violation|1
6080643|NCT00617734|9687964|FG001|Overall Study|Protocol Violation|0
6080644|NCT00617734|9687963|FG000|Overall Study|Found Ineligible After Randomization|1
6080645|NCT00617734|9687964|FG001|Overall Study|Found Ineligible After Randomization|4
6080646|NCT00617734|9687963|FG000|Overall Study|Lost to Follow-up|0
6080647|NCT00617734|9687964|FG001|Overall Study|Lost to Follow-up|1
6080648|NCT00617773|9687970|FG000|Overall Study|Physician Decision|1
6080649|NCT00617773|9687970|FG000|Overall Study|Lack of compliance with the protocol|1
6080650|NCT00617773|9687970|FG000|Overall Study|Withdrawal by Subject|1
6080651|NCT00617773|9687970|FG000|Overall Study|Death|1
6080652|NCT00617773|9687970|FG000|Overall Study|Progressive disease|19
6080653|NCT00617773|9687970|FG000|Overall Study|Protocol Violation|1
6080654|NCT00617851|9687978|FG000|Overall Study|Death|0
6080655|NCT00617851|9687979|FG001|Overall Study|Death|0
6080656|NCT00617851|9687980|FG002|Overall Study|Death|0
6156810|NCT01153347|9796678|FG001|Overall Study|Lost to Follow-up|9
6156811|NCT01153347|9796679|FG002|Overall Study|Lost to Follow-up|11
6156812|NCT01153347|9796680|FG003|Overall Study|Lost to Follow-up|8
6156813|NCT01153347|9796677|FG000|Overall Study|Other|5
6156814|NCT01153347|9796678|FG001|Overall Study|Other|5
6156815|NCT01153347|9796679|FG002|Overall Study|Other|4
6156816|NCT01153347|9796680|FG003|Overall Study|Other|0
6156817|NCT01153347|9796677|FG000|Overall Study|Death|1
6156818|NCT01153347|9796678|FG001|Overall Study|Death|0
6156819|NCT01153347|9796679|FG002|Overall Study|Death|0
6156820|NCT01153347|9796680|FG003|Overall Study|Death|0
6156821|NCT01153425|9796692|FG000|Overall Study|Withdrawal by Subject|3
6156822|NCT01153425|9796693|FG001|Overall Study|Withdrawal by Subject|3
6156823|NCT01153516|9796715|FG000|Overall Study|Both subjects refused surgery|2
6156824|NCT01153516|9796716|FG001|Overall Study|Both subjects refused surgery|0
6156825|NCT01153633|9796743|FG000|Overall Study|Protocol Violation|1
6156826|NCT01153633|9796744|FG001|Overall Study|Protocol Violation|1
6156827|NCT01153633|9796743|FG000|Overall Study|Therapeutic failure|3
6156828|NCT01153633|9796744|FG001|Overall Study|Therapeutic failure|3
6156829|NCT01153698|9796765|FG000|Overall Study|Adverse Event|12
6156830|NCT01153698|9796765|FG000|Overall Study|Lost to Follow-up|4
6156831|NCT01153698|9796765|FG000|Overall Study|Withdrawal by Subject|2
6156832|NCT01153698|9796765|FG000|Overall Study|Switch to other anticoagulants|4
6156833|NCT01153698|9796765|FG000|Overall Study|Other|2
6156834|NCT01153698|9796765|FG000|Overall Study|Not treated with Pradaxa|5
6156835|NCT01153724|9796776|FG000|Treatment Period 1|Withdrawal by Subject|1
6156836|NCT01153724|9796776|FG000|Treatment Period 2|Adverse Event|1
6156837|NCT01153724|9796776|FG000|Treatment Period 2|Other reason not defined above|1
6156838|NCT01153763|9796782|FG000|Overall Study|Study Closed|16
6156839|NCT01153763|9796782|FG000|Overall Study|Lost to Follow-up|1
6156840|NCT01153763|9796782|FG000|Overall Study|Physician Decision|2
6324719|NCT02918968|10066558|FG000|1st Line AAT|Withdrawal by Subject|2
6324720|NCT02918968|10066559|FG001|1st Line AAT|Withdrawal by Subject|1
6324721|NCT02918968|10066558|FG000|1st Line AAT|Lost to Follow-up|0
6324722|NCT02918968|10066559|FG001|1st Line AAT|Lost to Follow-up|1
6324723|NCT02918968|10066558|FG000|1st Line AAT|Death|1
6156841|NCT01153763|9796782|FG000|Overall Study|Withdrawal by Subject|2
6156842|NCT01153815|9796788|FG000|Overall Study|Adverse Event|3
6156843|NCT01153815|9796789|FG001|Overall Study|Adverse Event|1
6156844|NCT01153815|9796788|FG000|Overall Study|Withdrawal by Subject|6
6324724|NCT02918968|10066559|FG001|1st Line AAT|Death|0
6324725|NCT02918968|10066558|FG000|1st Line AAT|Miscellaneous|1
6324726|NCT02918968|10066559|FG001|1st Line AAT|Miscellaneous|0
6324727|NCT02918968|10066558|FG000|2nd Line AAT|Progressive disease|21
6324728|NCT02918968|10066559|FG001|2nd Line AAT|Progressive disease|3
6324729|NCT02918968|10066558|FG000|2nd Line AAT|Adverse Event|2
6324730|NCT02918968|10066559|FG001|2nd Line AAT|Adverse Event|5
6324731|NCT02918968|10066558|FG000|2nd Line AAT|Physician Decision|0
6324732|NCT02918968|10066559|FG001|2nd Line AAT|Physician Decision|1
6324733|NCT02918968|10066558|FG000|2nd Line AAT|Withdrawal by Subject|2
6324734|NCT02918968|10066559|FG001|2nd Line AAT|Withdrawal by Subject|2
6324735|NCT02918968|10066558|FG000|2nd Line AAT|Death|0
6156845|NCT01153815|9796789|FG001|Overall Study|Withdrawal by Subject|4
6156846|NCT01153841|9796797|FG000|Overall Study|Adverse Event|1
6156847|NCT01153841|9796798|FG001|Overall Study|Adverse Event|0
6156848|NCT01153841|9796797|FG000|Overall Study|Withdrawal by Subject|1
6324736|NCT02918968|10066559|FG001|2nd Line AAT|Death|1
6324737|NCT02919267|10066579|FG000|Overall Study|Protocol Violation|0
6324738|NCT02919267|10066580|FG001|Overall Study|Protocol Violation|3
6324739|NCT02919267|10066581|FG002|Overall Study|Protocol Violation|3
6156849|NCT01153841|9796798|FG001|Overall Study|Withdrawal by Subject|0
6156850|NCT01153841|9796797|FG000|Overall Study|Protocol Violation|2
6156851|NCT01153841|9796798|FG001|Overall Study|Protocol Violation|0
6156852|NCT01153841|9796797|FG000|Overall Study|Lost to Follow-up|2
6156853|NCT01153841|9796798|FG001|Overall Study|Lost to Follow-up|0
6156854|NCT01153893|9796806|FG000|Overall Study|Adverse Event|1
6156855|NCT01153893|9796807|FG001|Overall Study|Adverse Event|0
6156856|NCT01153958|9796815|FG000|Overall Study|Study Terminated|36
6156857|NCT01153958|9796816|FG001|Overall Study|Study Terminated|32
6156858|NCT01153971|9796822|FG000|Induction Phase (Months 1 to 7 of Study)|Adverse Event|2
6156859|NCT01153971|9796822|FG000|Induction Phase (Months 1 to 7 of Study)|Withdrawal by Subject|1
6156860|NCT01153971|9796822|FG000|Maintenance Phase (Months 8-16 of Study)|Adverse Event|2
6156861|NCT01153971|9796822|FG000|Maintenance Phase (Months 8-16 of Study)|Clinical relapse|1
6156862|NCT01153971|9796822|FG000|Follow-up (Months 17-40 of Study)|Adverse Event|1
6156863|NCT01153971|9796822|FG000|Follow-up (Months 17-40 of Study)|Protocol Violation|1
6156864|NCT01153971|9796822|FG000|Follow-up (Months 17-40 of Study)|Disease progression|2
6156865|NCT01153984|9796826|FG000|Overall Study|Withdrawal by Subject|1
6156866|NCT01153984|9796826|FG000|Overall Study|Adverse Event|1
6156867|NCT01154010|9796832|FG000|Overall Study|Lost to Follow-up|0
6156868|NCT01154010|9796833|FG001|Overall Study|Lost to Follow-up|1
6156869|NCT01154088|9796842|FG000|Overall Study|Lost to Follow-up|4
6156870|NCT01154088|9796843|FG001|Overall Study|Lost to Follow-up|6
6156871|NCT01154088|9796844|FG002|Overall Study|Lost to Follow-up|7
6156872|NCT01154101|9796858|FG000|Overall Study|Adverse Event|0
6156873|NCT01154101|9796859|FG001|Overall Study|Adverse Event|2
6156874|NCT01154101|9796860|FG002|Overall Study|Adverse Event|1
6156875|NCT01154101|9796861|FG003|Overall Study|Adverse Event|1
6156876|NCT01154101|9796862|FG004|Overall Study|Adverse Event|0
6156877|NCT01154101|9796858|FG000|Overall Study|Lost to Follow-up|0
6156878|NCT01154101|9796859|FG001|Overall Study|Lost to Follow-up|1
6156879|NCT01154101|9796860|FG002|Overall Study|Lost to Follow-up|0
6156880|NCT01154101|9796861|FG003|Overall Study|Lost to Follow-up|1
6156881|NCT01154101|9796862|FG004|Overall Study|Lost to Follow-up|0
6156882|NCT01154101|9796858|FG000|Overall Study|Withdrawal by Subject|0
6156883|NCT01154101|9796859|FG001|Overall Study|Withdrawal by Subject|1
6156884|NCT01154101|9796860|FG002|Overall Study|Withdrawal by Subject|2
6156885|NCT01154101|9796861|FG003|Overall Study|Withdrawal by Subject|0
6156886|NCT01154101|9796862|FG004|Overall Study|Withdrawal by Subject|1
6156887|NCT01154127|9796881|FG000|Period 1 (21 Days)|Adverse Event|3
6156888|NCT01154127|9796882|FG001|Period 1 (21 Days)|Adverse Event|4
6156889|NCT01154127|9796881|FG000|Period 1 (21 Days)|Withdrawal by Subject|0
6156890|NCT01154127|9796882|FG001|Period 1 (21 Days)|Withdrawal by Subject|2
6156891|NCT01154127|9796881|FG000|Washout (14 - 28 Days)|Adverse Event|2
6156892|NCT01154127|9796882|FG001|Washout (14 - 28 Days)|Adverse Event|0
6156893|NCT01154127|9796881|FG000|Washout (14 - 28 Days)|Abnormal Test Procedure|1
6156894|NCT01154127|9796882|FG001|Washout (14 - 28 Days)|Abnormal Test Procedure|0
6156895|NCT01154127|9796881|FG000|Period 2 (21 Days)|Protocol Deviation|0
6156896|NCT01154127|9796882|FG001|Period 2 (21 Days)|Protocol Deviation|1
6156897|NCT01154140|9796890|FG000|Overall Study|Death|71
6156898|NCT01154140|9796891|FG001|Overall Study|Death|81
6156899|NCT01154140|9796890|FG000|Overall Study|Lost to Follow-up|4
6156900|NCT01154140|9796891|FG001|Overall Study|Lost to Follow-up|5
6156901|NCT01154140|9796890|FG000|Overall Study|Withdrawal by Subject|12
6156902|NCT01154140|9796891|FG001|Overall Study|Withdrawal by Subject|13
6156903|NCT01154140|9796890|FG000|Overall Study|Other|3
6156904|NCT01154140|9796891|FG001|Overall Study|Other|1
6156905|NCT01154140|9796890|FG000|Overall Study|Randomized but not treated|1
6156906|NCT01154140|9796891|FG001|Overall Study|Randomized but not treated|2
6156907|NCT01154153|9796899|FG000|Overall Study|Poor compliance to protocol|2
6156908|NCT01154153|9796900|FG001|Overall Study|Poor compliance to protocol|0
6156909|NCT01154153|9796899|FG000|Overall Study|Unable to use labs|2
6156910|NCT01154153|9796900|FG001|Overall Study|Unable to use labs|3
6156911|NCT01154153|9796899|FG000|Overall Study|Withdrew consent|1
6156912|NCT01154153|9796900|FG001|Overall Study|Withdrew consent|0
6156913|NCT01154166|9796908|FG000|Overall Study|Adverse Event|14
6156914|NCT01154166|9796909|FG001|Overall Study|Adverse Event|9
6156915|NCT01154166|9796908|FG000|Overall Study|Lost to Follow-up|1
6156916|NCT01154166|9796909|FG001|Overall Study|Lost to Follow-up|1
6156917|NCT01154166|9796908|FG000|Overall Study|Protocol Violation|4
6156918|NCT01154166|9796909|FG001|Overall Study|Protocol Violation|1
6156919|NCT01154166|9796908|FG000|Overall Study|Withdrawal by Subject|10
6156920|NCT01154166|9796909|FG001|Overall Study|Withdrawal by Subject|1
6156921|NCT01154166|9796908|FG000|Overall Study|Lack of Efficacy|3
6156922|NCT01154166|9796909|FG001|Overall Study|Lack of Efficacy|0
6156923|NCT01154166|9796908|FG000|Overall Study|Disease Progression|1
6156924|NCT01154166|9796909|FG001|Overall Study|Disease Progression|0
6156925|NCT01154166|9796908|FG000|Overall Study|Poor Compliance|1
6156926|NCT01154166|9796909|FG001|Overall Study|Poor Compliance|0
6156927|NCT01154218|9796929|FG000|Third Intervention Period|Adverse Event|0
6156928|NCT01154218|9796930|FG001|Third Intervention Period|Adverse Event|1
6156929|NCT01154218|9796931|FG002|Third Intervention Period|Adverse Event|0
6156930|NCT01154218|9796932|FG003|Third Intervention Period|Adverse Event|0
6156931|NCT01154218|9796929|FG000|Washout Period (at Least 14 Days)|Withdrawal by Subject|0
6156932|NCT01154218|9796930|FG001|Washout Period (at Least 14 Days)|Withdrawal by Subject|0
6156933|NCT01154218|9796931|FG002|Washout Period (at Least 14 Days)|Withdrawal by Subject|0
6156934|NCT01154218|9796932|FG003|Washout Period (at Least 14 Days)|Withdrawal by Subject|1
6156935|NCT01154218|9796929|FG000|Fourth Intervention Period|Withdrawal by Subject|1
6156936|NCT01154218|9796930|FG001|Fourth Intervention Period|Withdrawal by Subject|0
6156937|NCT01154218|9796931|FG002|Fourth Intervention Period|Withdrawal by Subject|0
6156938|NCT01154218|9796932|FG003|Fourth Intervention Period|Withdrawal by Subject|0
6156939|NCT01154231|9796942|FG000|Overall Study|Safety Unassessable, No Drug Admin.|1
6156940|NCT01154231|9796942|FG000|Overall Study|No Info. After 1st Day, No Drug Admin.|1
6156941|NCT01154283|9796948|FG000|0-6 Weeks|Withdrawal by Subject|7
6156942|NCT01154283|9796949|FG001|0-6 Weeks|Withdrawal by Subject|2
6156943|NCT01154283|9796948|FG000|0-6 Weeks|Death|0
6156944|NCT01154283|9796949|FG001|0-6 Weeks|Death|1
6156945|NCT01154283|9796948|FG000|7-12 Weeks|Death|1
6156946|NCT01154283|9796949|FG001|7-12 Weeks|Death|0
6156947|NCT01154283|9796948|FG000|7-12 Weeks|Withdrawal by Subject|0
6156948|NCT01154283|9796949|FG001|7-12 Weeks|Withdrawal by Subject|1
6156949|NCT01154296|9796957|FG000|Randomization and Intervention|Decided to decline|1
6156950|NCT01154296|9796958|FG001|Randomization and Intervention|Decided to decline|1
6156951|NCT01154296|9796957|FG000|Randomization and Intervention|Declined by staff|1
6156952|NCT01154296|9796958|FG001|Randomization and Intervention|Declined by staff|0
6156953|NCT01154296|9796957|FG000|Randomization and Intervention|Did not return|1
6156954|NCT01154296|9796958|FG001|Randomization and Intervention|Did not return|0
6156955|NCT01154296|9796957|FG000|Randomization and Intervention|Left before test|0
6156956|NCT01154296|9796958|FG001|Randomization and Intervention|Left before test|1
6156957|NCT01154296|9796957|FG000|Randomization and Intervention|Left clinic early|2
6156958|NCT01154296|9796958|FG001|Randomization and Intervention|Left clinic early|0
6156959|NCT01154296|9796957|FG000|6-month Follow-up|Lost contact|269
6156960|NCT01154296|9796958|FG001|6-month Follow-up|Lost contact|275
6156961|NCT01154296|9796957|FG000|6-month Follow-up|Incarcerated|37
6156962|NCT01154296|9796958|FG001|6-month Follow-up|Incarcerated|32
6156963|NCT01154296|9796957|FG000|6-month Follow-up|Withdrew consent|14
6156964|NCT01154296|9796958|FG001|6-month Follow-up|Withdrew consent|15
6156965|NCT01154296|9796957|FG000|6-month Follow-up|Death|3
6156966|NCT01154296|9796958|FG001|6-month Follow-up|Death|2
6156967|NCT01154296|9796957|FG000|6-month Follow-up|Declined by Study Coordinator|5
6156968|NCT01154296|9796958|FG001|6-month Follow-up|Declined by Study Coordinator|4
6156969|NCT01154452|9796973|FG000|Phase Ib|Not Treated|1
6156970|NCT01154452|9796974|FG001|Phase Ib|Not Treated|0
6156971|NCT01154452|9796975|FG002|Phase Ib|Not Treated|0
6156972|NCT01154452|9796976|FG003|Phase Ib|Not Treated|0
6156973|NCT01154452|9796973|FG000|Phase Ib|Adverse Event|2
6156974|NCT01154452|9796974|FG001|Phase Ib|Adverse Event|1
6156975|NCT01154452|9796975|FG002|Phase Ib|Adverse Event|0
6156976|NCT01154452|9796976|FG003|Phase Ib|Adverse Event|0
6156977|NCT01154452|9796973|FG000|Phase II|Withdrawal by Subject|0
6156978|NCT01154452|9796974|FG001|Phase II|Withdrawal by Subject|0
6156979|NCT01154452|9796975|FG002|Phase II|Withdrawal by Subject|1
6156980|NCT01154452|9796976|FG003|Phase II|Withdrawal by Subject|2
6156981|NCT01154452|9796973|FG000|Phase II|Adverse Event|0
6156982|NCT01154452|9796974|FG001|Phase II|Adverse Event|0
6156983|NCT01154452|9796975|FG002|Phase II|Adverse Event|4
6156984|NCT01154452|9796976|FG003|Phase II|Adverse Event|4
6156985|NCT01154673|9797008|FG000|Overall Study|Lost to Follow-up|1
6156986|NCT01154673|9797009|FG001|Overall Study|Lost to Follow-up|0
6156987|NCT01154673|9797008|FG000|Overall Study|moved out of province|1
6156988|NCT01154673|9797009|FG001|Overall Study|moved out of province|0
6156989|NCT01154816|9797042|FG000|Overall Study|Withdrawal by Subject|1
6156990|NCT01154816|9797043|FG001|Overall Study|Withdrawal by Subject|0
6156991|NCT01154816|9797044|FG002|Overall Study|Withdrawal by Subject|0
6156992|NCT01154816|9797045|FG003|Overall Study|Withdrawal by Subject|1
6156993|NCT01154816|9797046|FG004|Overall Study|Withdrawal by Subject|0
6156994|NCT01154816|9797047|FG005|Overall Study|Withdrawal by Subject|0
6156995|NCT01154816|9797048|FG006|Overall Study|Withdrawal by Subject|0
6156996|NCT01154816|9797049|FG007|Overall Study|Withdrawal by Subject|0
6156997|NCT01154816|9797050|FG008|Overall Study|Withdrawal by Subject|1
6156998|NCT01154816|9797051|FG009|Overall Study|Withdrawal by Subject|3
6156999|NCT01154816|9797052|FG010|Overall Study|Withdrawal by Subject|0
6157000|NCT01154816|9797053|FG011|Overall Study|Withdrawal by Subject|0
6157001|NCT01154816|9797042|FG000|Overall Study|Progressive Disease|13
6157002|NCT01154816|9797043|FG001|Overall Study|Progressive Disease|8
6157003|NCT01154816|9797044|FG002|Overall Study|Progressive Disease|9
6157004|NCT01154816|9797045|FG003|Overall Study|Progressive Disease|9
6157005|NCT01154816|9797046|FG004|Overall Study|Progressive Disease|8
6157006|NCT01154816|9797047|FG005|Overall Study|Progressive Disease|8
6157007|NCT01154816|9797048|FG006|Overall Study|Progressive Disease|5
6157008|NCT01154816|9797049|FG007|Overall Study|Progressive Disease|6
6157009|NCT01154816|9797050|FG008|Overall Study|Progressive Disease|8
6157010|NCT01154816|9797051|FG009|Overall Study|Progressive Disease|6
6157011|NCT01154816|9797052|FG010|Overall Study|Progressive Disease|10
6157012|NCT01154816|9797053|FG011|Overall Study|Progressive Disease|3
6157013|NCT01154816|9797042|FG000|Overall Study|Physician Decision|1
6157014|NCT01154816|9797043|FG001|Overall Study|Physician Decision|0
6157015|NCT01154816|9797044|FG002|Overall Study|Physician Decision|1
6157016|NCT01154816|9797045|FG003|Overall Study|Physician Decision|0
6157017|NCT01154816|9797046|FG004|Overall Study|Physician Decision|2
6157018|NCT01154816|9797047|FG005|Overall Study|Physician Decision|0
6157019|NCT01154816|9797048|FG006|Overall Study|Physician Decision|0
6157020|NCT01154816|9797049|FG007|Overall Study|Physician Decision|0
6157021|NCT01154816|9797050|FG008|Overall Study|Physician Decision|0
6157022|NCT01154816|9797051|FG009|Overall Study|Physician Decision|1
6157023|NCT01154816|9797052|FG010|Overall Study|Physician Decision|1
6157024|NCT01154816|9797053|FG011|Overall Study|Physician Decision|1
6157025|NCT01154816|9797042|FG000|Overall Study|Adverse Event|5
6157026|NCT01154816|9797043|FG001|Overall Study|Adverse Event|2
6157027|NCT01154816|9797044|FG002|Overall Study|Adverse Event|0
6157028|NCT01154816|9797045|FG003|Overall Study|Adverse Event|0
6157029|NCT01154816|9797046|FG004|Overall Study|Adverse Event|0
6157030|NCT01154816|9797047|FG005|Overall Study|Adverse Event|0
6157031|NCT01154816|9797048|FG006|Overall Study|Adverse Event|1
6157032|NCT01154816|9797049|FG007|Overall Study|Adverse Event|1
6157033|NCT01154816|9797050|FG008|Overall Study|Adverse Event|0
6157034|NCT01154816|9797051|FG009|Overall Study|Adverse Event|0
6157035|NCT01154816|9797052|FG010|Overall Study|Adverse Event|0
6157036|NCT01154816|9797053|FG011|Overall Study|Adverse Event|0
6157037|NCT01155011|9797096|FG000|Baseline to 6 Months|Withdrawal by Subject|18
6157038|NCT01155011|9797097|FG001|Baseline to 6 Months|Withdrawal by Subject|19
6157039|NCT01155011|9797096|FG000|Baseline to 6 Months|investigator decision, moved|4
6157040|NCT01155011|9797097|FG001|Baseline to 6 Months|investigator decision, moved|5
6157041|NCT01155011|9797096|FG000|Baseline to 6 Months|Death|0
6157042|NCT01155011|9797097|FG001|Baseline to 6 Months|Death|1
6157043|NCT01155011|9797096|FG000|6 to 12 Months|Withdrawal by Subject|8
6157044|NCT01155011|9797097|FG001|6 to 12 Months|Withdrawal by Subject|5
6157045|NCT01155011|9797096|FG000|6 to 12 Months|Death|1
6157046|NCT01155011|9797097|FG001|6 to 12 Months|Death|5
6157047|NCT01155024|9797107|FG000|Direct Manufactured Socket 3 Month Trial|Experienced inferior suspension system|0
6157048|NCT01155024|9797108|FG001|Direct Manufactured Socket 3 Month Trial|Experienced inferior suspension system|2
6157049|NCT01155024|9797107|FG000|Direct Manufactured Socket 3 Month Trial|Lost to Follow-up|0
6157050|NCT01155024|9797108|FG001|Direct Manufactured Socket 3 Month Trial|Lost to Follow-up|2
6157051|NCT01155024|9797107|FG000|Direct Manufactured Socket 3 Month Trial|Withdrawal by Subject|0
6157052|NCT01155024|9797108|FG001|Direct Manufactured Socket 3 Month Trial|Withdrawal by Subject|2
6157053|NCT01155050|9797119|FG000|Overall Study|Lost to Follow-up|15
6157054|NCT01155050|9797120|FG001|Overall Study|Lost to Follow-up|20
6157055|NCT01155050|9797121|FG002|Overall Study|Lost to Follow-up|19
6157056|NCT01155050|9797122|FG003|Overall Study|Lost to Follow-up|22
6157057|NCT01155063|9797132|FG000|Overall Study|Adverse Event|1
6157058|NCT01155063|9797132|FG000|Overall Study|Withdrawal by Subject|1
6157059|NCT01155063|9797132|FG000|Overall Study|Study terminated by sponsor|87
6157060|NCT01155141|9797136|FG000|Overall Study|Withdrawal by Subject|1
6157061|NCT01155141|9797136|FG000|Overall Study|Screen Failure|1
6157062|NCT01155167|9797155|FG000|Overall Study|Insufficient ultrasound data|2
6157063|NCT01155167|9797156|FG001|Overall Study|Insufficient ultrasound data|0
6157064|NCT01155167|9797155|FG000|Overall Study|Access site changed to femoral artery|1
6157065|NCT01155167|9797156|FG001|Overall Study|Access site changed to femoral artery|0
6157066|NCT01155219|9797195|FG000|Overall Study|Adverse Event|3
6157067|NCT01155219|9797196|FG001|Overall Study|Adverse Event|1
6157068|NCT01155219|9797195|FG000|Overall Study|non-medical reason|1
6157069|NCT01155219|9797196|FG001|Overall Study|non-medical reason|2
6157070|NCT01155284|9797204|FG000|Overall Study|Withdrawal by Subject|4
6157071|NCT01155284|9797205|FG001|Overall Study|Withdrawal by Subject|3
6157072|NCT01155284|9797204|FG000|Overall Study|Lost to Follow-up|1
6157073|NCT01155284|9797205|FG001|Overall Study|Lost to Follow-up|2
6157074|NCT01155284|9797204|FG000|Overall Study|Physician Decision|1
6157075|NCT01155284|9797205|FG001|Overall Study|Physician Decision|0
6157076|NCT01155284|9797204|FG000|Overall Study|Adverse Event|1
6157077|NCT01155284|9797205|FG001|Overall Study|Adverse Event|0
6157078|NCT01155323|9797213|FG000|First Intervention|exclusion criteria|1
6157079|NCT01155323|9797214|FG001|First Intervention|exclusion criteria|1
6157080|NCT01155323|9797213|FG000|Second Intervention|Lost to Follow-up|1
6157081|NCT01155323|9797214|FG001|Second Intervention|Lost to Follow-up|1
6157082|NCT01155466|9797234|FG000|Overall Study|Adverse Event|13
6157083|NCT01155466|9797235|FG001|Overall Study|Adverse Event|15
6157084|NCT01155466|9797236|FG002|Overall Study|Adverse Event|6
6157085|NCT01155466|9797237|FG003|Overall Study|Adverse Event|17
6157086|NCT01155466|9797238|FG004|Overall Study|Adverse Event|18
6157087|NCT01155466|9797234|FG000|Overall Study|Lost to Follow-up|0
6157088|NCT01155466|9797235|FG001|Overall Study|Lost to Follow-up|0
6157089|NCT01155466|9797236|FG002|Overall Study|Lost to Follow-up|0
6157090|NCT01155466|9797237|FG003|Overall Study|Lost to Follow-up|0
6157091|NCT01155466|9797238|FG004|Overall Study|Lost to Follow-up|2
6157092|NCT01155466|9797234|FG000|Overall Study|Withdrawal by Subject|7
6157093|NCT01155466|9797235|FG001|Overall Study|Withdrawal by Subject|5
6157094|NCT01155466|9797236|FG002|Overall Study|Withdrawal by Subject|9
6157095|NCT01155466|9797237|FG003|Overall Study|Withdrawal by Subject|4
6157096|NCT01155466|9797238|FG004|Overall Study|Withdrawal by Subject|4
6157097|NCT01155466|9797234|FG000|Overall Study|Protocol Violation|0
6157098|NCT01155466|9797235|FG001|Overall Study|Protocol Violation|0
6157099|NCT01155466|9797236|FG002|Overall Study|Protocol Violation|2
6157100|NCT01155466|9797237|FG003|Overall Study|Protocol Violation|0
6157101|NCT01155466|9797238|FG004|Overall Study|Protocol Violation|1
6157102|NCT01155466|9797234|FG000|Overall Study|Administrative|0
6157103|NCT01155466|9797235|FG001|Overall Study|Administrative|3
6157104|NCT01155466|9797236|FG002|Overall Study|Administrative|0
6157105|NCT01155466|9797237|FG003|Overall Study|Administrative|0
6157106|NCT01155466|9797238|FG004|Overall Study|Administrative|0
6157107|NCT01155466|9797234|FG000|Overall Study|Randomized not treated|2
6157108|NCT01155466|9797235|FG001|Overall Study|Randomized not treated|2
6157109|NCT01155466|9797236|FG002|Overall Study|Randomized not treated|3
6157110|NCT01155466|9797237|FG003|Overall Study|Randomized not treated|0
6157111|NCT01155466|9797238|FG004|Overall Study|Randomized not treated|2
6157112|NCT01155479|9797255|FG000|Part I|Adverse Event|13
6157113|NCT01155479|9797256|FG001|Part I|Adverse Event|8
6157114|NCT01155479|9797257|FG002|Part I|Adverse Event|18
6157115|NCT01155479|9797258|FG003|Part I|Adverse Event|7
6157116|NCT01155479|9797259|FG004|Part I|Adverse Event|6
6157117|NCT01155479|9797255|FG000|Part I|Administrative|2
6157118|NCT01155479|9797256|FG001|Part I|Administrative|2
6157119|NCT01155479|9797257|FG002|Part I|Administrative|2
6157120|NCT01155479|9797258|FG003|Part I|Administrative|0
6157121|NCT01155479|9797259|FG004|Part I|Administrative|0
6157122|NCT01155479|9797255|FG000|Part I|Did Not Meet Protocol Eligibility|3
6157123|NCT01155479|9797256|FG001|Part I|Did Not Meet Protocol Eligibility|1
6157124|NCT01155479|9797257|FG002|Part I|Did Not Meet Protocol Eligibility|2
6157125|NCT01155479|9797258|FG003|Part I|Did Not Meet Protocol Eligibility|1
6157126|NCT01155479|9797259|FG004|Part I|Did Not Meet Protocol Eligibility|3
6157127|NCT01155479|9797255|FG000|Part I|Withdrawal by Subject|11
6157128|NCT01155479|9797256|FG001|Part I|Withdrawal by Subject|13
6157129|NCT01155479|9797257|FG002|Part I|Withdrawal by Subject|8
6157130|NCT01155479|9797258|FG003|Part I|Withdrawal by Subject|8
6157131|NCT01155479|9797259|FG004|Part I|Withdrawal by Subject|9
6157132|NCT01155479|9797255|FG000|Part I|Lost to Follow-up|0
6157133|NCT01155479|9797256|FG001|Part I|Lost to Follow-up|0
6157134|NCT01155479|9797257|FG002|Part I|Lost to Follow-up|1
6157135|NCT01155479|9797258|FG003|Part I|Lost to Follow-up|1
6157136|NCT01155479|9797259|FG004|Part I|Lost to Follow-up|0
6157137|NCT01155479|9797255|FG000|Part I|Treatment Failure|3
6157138|NCT01155479|9797256|FG001|Part I|Treatment Failure|0
6157139|NCT01155479|9797257|FG002|Part I|Treatment Failure|3
6157140|NCT01155479|9797258|FG003|Part I|Treatment Failure|1
6157141|NCT01155479|9797259|FG004|Part I|Treatment Failure|2
6157142|NCT01155479|9797255|FG000|Part I|Did Not Receive Treatment|4
6157143|NCT01155479|9797256|FG001|Part I|Did Not Receive Treatment|2
6157144|NCT01155479|9797257|FG002|Part I|Did Not Receive Treatment|2
6157145|NCT01155479|9797258|FG003|Part I|Did Not Receive Treatment|6
6157146|NCT01155479|9797259|FG004|Part I|Did Not Receive Treatment|1
6157147|NCT01155479|9797255|FG000|Part I|Non-Compliance with Protocol|2
6157148|NCT01155479|9797256|FG001|Part I|Non-Compliance with Protocol|1
6157149|NCT01155479|9797257|FG002|Part I|Non-Compliance with Protocol|3
6157150|NCT01155479|9797258|FG003|Part I|Non-Compliance with Protocol|3
6157151|NCT01155479|9797259|FG004|Part I|Non-Compliance with Protocol|2
6157152|NCT01155479|9797255|FG000|Part II|Adverse Event|7
6157153|NCT01155479|9797256|FG001|Part II|Adverse Event|6
6157154|NCT01155479|9797257|FG002|Part II|Adverse Event|8
6157155|NCT01155479|9797258|FG003|Part II|Adverse Event|3
6157156|NCT01155479|9797259|FG004|Part II|Adverse Event|4
6157157|NCT01155479|9797255|FG000|Part II|Administrative|43
6157158|NCT01155479|9797256|FG001|Part II|Administrative|49
6157159|NCT01155479|9797257|FG002|Part II|Administrative|36
6157160|NCT01155479|9797258|FG003|Part II|Administrative|38
6157161|NCT01155479|9797259|FG004|Part II|Administrative|46
6157162|NCT01155479|9797255|FG000|Part II|Withdrawal by Subject|8
6157163|NCT01155479|9797256|FG001|Part II|Withdrawal by Subject|4
6157164|NCT01155479|9797257|FG002|Part II|Withdrawal by Subject|12
6157165|NCT01155479|9797258|FG003|Part II|Withdrawal by Subject|7
6157166|NCT01155479|9797259|FG004|Part II|Withdrawal by Subject|3
6157167|NCT01155479|9797255|FG000|Part II|Lost to Follow-up|1
6157168|NCT01155479|9797256|FG001|Part II|Lost to Follow-up|0
6157169|NCT01155479|9797257|FG002|Part II|Lost to Follow-up|0
6157170|NCT01155479|9797258|FG003|Part II|Lost to Follow-up|0
6157171|NCT01155479|9797259|FG004|Part II|Lost to Follow-up|1
6157172|NCT01155479|9797255|FG000|Part II|Treatment Failure|0
6157173|NCT01155479|9797256|FG001|Part II|Treatment Failure|1
6157174|NCT01155479|9797257|FG002|Part II|Treatment Failure|2
6157175|NCT01155479|9797258|FG003|Part II|Treatment Failure|0
6157176|NCT01155479|9797259|FG004|Part II|Treatment Failure|1
6157177|NCT01155479|9797255|FG000|Part II|Non-Compliance with Protocol|0
6157178|NCT01155479|9797256|FG001|Part II|Non-Compliance with Protocol|1
6157179|NCT01155479|9797257|FG002|Part II|Non-Compliance with Protocol|0
6157180|NCT01155479|9797258|FG003|Part II|Non-Compliance with Protocol|2
6157181|NCT01155479|9797259|FG004|Part II|Non-Compliance with Protocol|0
6157182|NCT01155531|9797291|FG000|Overall Study|Adverse Event|0
6157183|NCT01155531|9797292|FG001|Overall Study|Adverse Event|0
6157184|NCT01155531|9797293|FG002|Overall Study|Adverse Event|1
6157185|NCT01155531|9797294|FG003|Overall Study|Adverse Event|0
6157186|NCT01155531|9797291|FG000|Overall Study|Lost to Follow-up|0
6157187|NCT01155531|9797292|FG001|Overall Study|Lost to Follow-up|0
6157188|NCT01155531|9797293|FG002|Overall Study|Lost to Follow-up|0
6157189|NCT01155531|9797294|FG003|Overall Study|Lost to Follow-up|1
6157190|NCT01155531|9797291|FG000|Overall Study|Withdrawal by Subject|1
6157191|NCT01155531|9797292|FG001|Overall Study|Withdrawal by Subject|0
6157192|NCT01155531|9797293|FG002|Overall Study|Withdrawal by Subject|1
6157193|NCT01155531|9797294|FG003|Overall Study|Withdrawal by Subject|0
6157194|NCT01155570|9797304|FG000|Overall Study|Adverse Event|39
6157195|NCT01155570|9797304|FG000|Overall Study|Lack of Efficacy|46
6157196|NCT01155570|9797304|FG000|Overall Study|Participant's Economic Reasons|17
6157197|NCT01155570|9797304|FG000|Overall Study|No Hospital Visits|7
6157198|NCT01155570|9797304|FG000|Overall Study|Adverse Event + Lack of Efficacy|2
6157199|NCT01155570|9797304|FG000|Overall Study|Adverse Event + Other Reasons|7
6157200|NCT01155570|9797304|FG000|Overall Study|Participant's Economic Reasons + Other|1
6157201|NCT01155570|9797304|FG000|Overall Study|Other Reasons|23
6157202|NCT01155583|9797319|FG000|Phase I|Screen failure - did not start treatment|0
6157203|NCT01155583|9797320|FG001|Phase I|Screen failure - did not start treatment|0
6157204|NCT01155583|9797321|FG002|Phase I|Screen failure - did not start treatment|0
6157205|NCT01155583|9797322|FG003|Phase I|Screen failure - did not start treatment|0
6157206|NCT01155583|9797323|FG004|Phase I|Screen failure - did not start treatment|1
6157207|NCT01155583|9797324|FG005|Phase I|Screen failure - did not start treatment|0
6157208|NCT01155583|9797325|FG006|Phase I|Screen failure - did not start treatment|0
6157209|NCT01155583|9797326|FG007|Phase I|Screen failure - did not start treatment|2
6157210|NCT01155583|9797327|FG008|Phase I|Screen failure - did not start treatment|0
6157211|NCT01155583|9797319|FG000|Phase I|Withdrawal by Subject|0
6157212|NCT01155583|9797320|FG001|Phase I|Withdrawal by Subject|0
6157213|NCT01155583|9797321|FG002|Phase I|Withdrawal by Subject|0
6157214|NCT01155583|9797322|FG003|Phase I|Withdrawal by Subject|0
6157215|NCT01155583|9797323|FG004|Phase I|Withdrawal by Subject|0
6157216|NCT01155583|9797324|FG005|Phase I|Withdrawal by Subject|0
6157217|NCT01155583|9797325|FG006|Phase I|Withdrawal by Subject|0
6157218|NCT01155583|9797326|FG007|Phase I|Withdrawal by Subject|1
6157219|NCT01155583|9797327|FG008|Phase I|Withdrawal by Subject|0
6157220|NCT01155661|9797343|FG000|Overall Study|Adverse Event|101
6157221|NCT01155661|9797343|FG000|Overall Study|Death|1
6157222|NCT01155661|9797343|FG000|Overall Study|Lack of Efficacy|32
6157223|NCT01155661|9797343|FG000|Overall Study|Lost to Follow-up|22
6157224|NCT01155661|9797343|FG000|Overall Study|Physician Decision|3
6157225|NCT01155661|9797343|FG000|Overall Study|Protocol Violation|35
6157226|NCT01155661|9797343|FG000|Overall Study|Withdrawal by Subject|73
6157227|NCT01155661|9797343|FG000|Overall Study|Sponsor Decision|13
6157228|NCT01155726|9797349|FG000|Period 1, 3 Days (Masked)|Inconvenience|1
6157229|NCT01155726|9797350|FG001|Period 1, 3 Days (Masked)|Inconvenience|0
6157230|NCT01155726|9797351|FG002|Period 1, 3 Days (Masked)|Inconvenience|2
6157231|NCT01155726|9797352|FG003|Period 1, 3 Days (Masked)|Inconvenience|0
6157232|NCT01155869|9797402|FG000|Overall Study|Lost to Follow-up|3
6157233|NCT01155869|9797403|FG001|Overall Study|Lost to Follow-up|1
6157234|NCT01156012|9797420|FG000|Overall Study|Adverse Event|3
6157235|NCT01156012|9797421|FG001|Overall Study|Adverse Event|1
6157236|NCT01156012|9797420|FG000|Overall Study|Lost to Follow-up|1
6157237|NCT01156012|9797421|FG001|Overall Study|Lost to Follow-up|0
6157238|NCT01156012|9797420|FG000|Overall Study|Withdrawal by Subject|1
6157239|NCT01156012|9797421|FG001|Overall Study|Withdrawal by Subject|0
6157240|NCT01156012|9797420|FG000|Overall Study|use of commercial drug instead of study|0
6157241|NCT01156012|9797421|FG001|Overall Study|use of commercial drug instead of study|1
6157242|NCT01156012|9797420|FG000|Overall Study|Non respect of one of inclusion criteria|2
6157243|NCT01156012|9797421|FG001|Overall Study|Non respect of one of inclusion criteria|1
6157244|NCT01156051|9797429|FG000|Overall Study|Lost to Follow-up|1
6157245|NCT01156051|9797430|FG001|Overall Study|Lost to Follow-up|0
6157246|NCT01156051|9797429|FG000|Overall Study|patient not compliant with protocol|0
6157247|NCT01156051|9797430|FG001|Overall Study|patient not compliant with protocol|1
6157248|NCT01156116|9797438|FG000|Overall Study|Withdrawal by Subject|3
6157249|NCT01156116|9797439|FG001|Overall Study|Withdrawal by Subject|1
6157250|NCT01156116|9797438|FG000|Overall Study|CPAP intolerance|2
6157251|NCT01156116|9797439|FG001|Overall Study|CPAP intolerance|0
6157252|NCT01156142|9797447|FG000|Overall Study|Withdrawal by Subject|8
6157253|NCT01156142|9797448|FG001|Overall Study|Withdrawal by Subject|6
6157254|NCT01156142|9797447|FG000|Overall Study|Ineligible|0
6157255|NCT01156142|9797448|FG001|Overall Study|Ineligible|1
6157256|NCT01156311|9797456|FG000|2-Month Monotherapy Period|Withdrawal by Subject|1
6157257|NCT01156311|9797457|FG001|2-Month Monotherapy Period|Withdrawal by Subject|1
6157258|NCT01156311|9797458|FG002|2-Month Monotherapy Period|Withdrawal by Subject|0
6157259|NCT01156311|9797459|FG003|2-Month Monotherapy Period|Withdrawal by Subject|0
6157260|NCT01156311|9797456|FG000|2-Month Monotherapy Period|Physician Decision|0
6157261|NCT01156311|9797457|FG001|2-Month Monotherapy Period|Physician Decision|1
6157262|NCT01156311|9797458|FG002|2-Month Monotherapy Period|Physician Decision|0
6157263|NCT01156311|9797459|FG003|2-Month Monotherapy Period|Physician Decision|0
6157264|NCT01156311|9797456|FG000|2-Month Monotherapy Period|Other|1
6157265|NCT01156311|9797457|FG001|2-Month Monotherapy Period|Other|0
6157266|NCT01156311|9797458|FG002|2-Month Monotherapy Period|Other|0
6157267|NCT01156311|9797459|FG003|2-Month Monotherapy Period|Other|0
6157268|NCT01156311|9797456|FG000|6-month Add-on Therapy Period|Adverse Event|0
6157269|NCT01156311|9797457|FG001|6-month Add-on Therapy Period|Adverse Event|0
6157270|NCT01156311|9797458|FG002|6-month Add-on Therapy Period|Adverse Event|7
6157271|NCT01156311|9797459|FG003|6-month Add-on Therapy Period|Adverse Event|6
6157272|NCT01156311|9797456|FG000|6-month Add-on Therapy Period|Lost to Follow-up|0
6157273|NCT01156311|9797457|FG001|6-month Add-on Therapy Period|Lost to Follow-up|0
6157274|NCT01156311|9797458|FG002|6-month Add-on Therapy Period|Lost to Follow-up|2
6157275|NCT01156311|9797459|FG003|6-month Add-on Therapy Period|Lost to Follow-up|0
6157276|NCT01156311|9797456|FG000|6-month Add-on Therapy Period|Disease Activity|0
6157277|NCT01156311|9797457|FG001|6-month Add-on Therapy Period|Disease Activity|0
6157278|NCT01156311|9797458|FG002|6-month Add-on Therapy Period|Disease Activity|1
6157279|NCT01156311|9797459|FG003|6-month Add-on Therapy Period|Disease Activity|2
6157280|NCT01156311|9797456|FG000|6-month Add-on Therapy Period|Physician Decision|0
6157281|NCT01156311|9797457|FG001|6-month Add-on Therapy Period|Physician Decision|0
6157282|NCT01156311|9797458|FG002|6-month Add-on Therapy Period|Physician Decision|1
6157283|NCT01156311|9797459|FG003|6-month Add-on Therapy Period|Physician Decision|0
6157284|NCT01156311|9797456|FG000|6-month Add-on Therapy Period|Other|0
6157285|NCT01156311|9797457|FG001|6-month Add-on Therapy Period|Other|0
6157286|NCT01156311|9797458|FG002|6-month Add-on Therapy Period|Other|1
6157287|NCT01156311|9797459|FG003|6-month Add-on Therapy Period|Other|2
6157288|NCT01156363|9797470|FG000|Overall Study|Adverse Event|6
6157289|NCT01156363|9797470|FG000|Overall Study|Insufficient Therapeutic Response|5
6157290|NCT01156363|9797470|FG000|Overall Study|Failure to Return|1
6080657|NCT00617851|9687981|FG003|Overall Study|Death|1
6080658|NCT00617851|9687978|FG000|Overall Study|Withdrawal by Subject|14
6157291|NCT01156363|9797470|FG000|Overall Study|Refused Treatment|4
6157292|NCT01156363|9797470|FG000|Overall Study|Other|6
6157293|NCT01156376|9797484|FG000|Overall Study|Adverse Event|1
6157294|NCT01156376|9797485|FG001|Overall Study|Adverse Event|0
6157295|NCT01156376|9797486|FG002|Overall Study|Adverse Event|1
6157296|NCT01156376|9797484|FG000|Overall Study|Withdrawal by Subject|0
6157297|NCT01156376|9797485|FG001|Overall Study|Withdrawal by Subject|0
6157298|NCT01156376|9797486|FG002|Overall Study|Withdrawal by Subject|3
6157299|NCT01156480|9797496|FG000|Overall Study|change in diagnosis|0
6157300|NCT01156480|9797497|FG001|Overall Study|change in diagnosis|1
6157301|NCT01156532|9797505|FG000|Overall Study|Family Reasons|1
6157302|NCT01156532|9797505|FG000|Overall Study|Lost to Follow-up|1
6157303|NCT01156675|9797531|FG000|Overall Study|Death|5
6157304|NCT01156675|9797532|FG001|Overall Study|Death|3
6157305|NCT01156675|9797533|FG002|Overall Study|Death|0
6157306|NCT01156675|9797531|FG000|Overall Study|No data|29
6157307|NCT01156675|9797532|FG001|Overall Study|No data|22
6157308|NCT01156675|9797533|FG002|Overall Study|No data|2
6080659|NCT00617851|9687979|FG001|Overall Study|Withdrawal by Subject|7
6080660|NCT00617851|9687980|FG002|Overall Study|Withdrawal by Subject|12
6080661|NCT00617851|9687981|FG003|Overall Study|Withdrawal by Subject|4
6080662|NCT00617851|9687978|FG000|Overall Study|Lost to Follow-up|27
6080663|NCT00617851|9687979|FG001|Overall Study|Lost to Follow-up|29
6080664|NCT00617851|9687980|FG002|Overall Study|Lost to Follow-up|31
6157309|NCT01156714|9797558|FG000|Overall Study|Withdrawal by Subject|9
6157310|NCT01156714|9797559|FG001|Overall Study|Withdrawal by Subject|4
6157311|NCT01156714|9797560|FG002|Overall Study|Withdrawal by Subject|3
6157312|NCT01156792|9797571|FG000|Overall Study|Adverse Event|1
6157313|NCT01156792|9797571|FG000|Overall Study|Lack of Efficacy|36
6157314|NCT01156792|9797571|FG000|Overall Study|Protocol Violation|6
6157315|NCT01156792|9797571|FG000|Overall Study|Lost to Follow-up|3
6157316|NCT01156792|9797571|FG000|Overall Study|Physician Decision|3
6157317|NCT01156792|9797571|FG000|Overall Study|Withdrawal by Subject|9
6157318|NCT01156792|9797571|FG000|Overall Study|other Sponsor Decision (Protocol Amendme|11
6157319|NCT01156844|9797599|FG000|Overall Study|Adverse Event|0
6157320|NCT01156844|9797600|FG001|Overall Study|Adverse Event|0
6157321|NCT01156844|9797601|FG002|Overall Study|Adverse Event|1
6157322|NCT01156844|9797602|FG003|Overall Study|Adverse Event|1
6080665|NCT00617851|9687981|FG003|Overall Study|Lost to Follow-up|19
6080666|NCT00617851|9687978|FG000|Overall Study|Inappropriate Enrollment|5
6157323|NCT01156844|9797599|FG000|Overall Study|Abnormal test procedure result(s)|0
6157324|NCT01156844|9797600|FG001|Overall Study|Abnormal test procedure result(s)|1
6157325|NCT01156844|9797601|FG002|Overall Study|Abnormal test procedure result(s)|2
6157326|NCT01156844|9797602|FG003|Overall Study|Abnormal test procedure result(s)|2
6157327|NCT01156844|9797599|FG000|Overall Study|Withdrawal by Subject|0
6157328|NCT01156844|9797600|FG001|Overall Study|Withdrawal by Subject|0
6157329|NCT01156844|9797601|FG002|Overall Study|Withdrawal by Subject|2
6157330|NCT01156844|9797602|FG003|Overall Study|Withdrawal by Subject|2
6080667|NCT00617851|9687979|FG001|Overall Study|Inappropriate Enrollment|4
6080668|NCT00617851|9687980|FG002|Overall Study|Inappropriate Enrollment|1
6080669|NCT00617851|9687981|FG003|Overall Study|Inappropriate Enrollment|1
6080670|NCT00617851|9687978|FG000|Overall Study|Unable to classify|1
6080671|NCT00617851|9687979|FG001|Overall Study|Unable to classify|0
6080672|NCT00617851|9687980|FG002|Overall Study|Unable to classify|1
6080673|NCT00617851|9687981|FG003|Overall Study|Unable to classify|0
6080674|NCT00617890|9688005|FG000|Overall Study|Treatment ongoing at data cut-off|0
6080675|NCT00617890|9688006|FG001|Overall Study|Treatment ongoing at data cut-off|0
6080676|NCT00617890|9688007|FG002|Overall Study|Treatment ongoing at data cut-off|0
6080677|NCT00617890|9688008|FG003|Overall Study|Treatment ongoing at data cut-off|5
6080678|NCT00617890|9688005|FG000|Overall Study|Lack of Efficacy|23
6080679|NCT00617890|9688006|FG001|Overall Study|Lack of Efficacy|26
6080680|NCT00617890|9688007|FG002|Overall Study|Lack of Efficacy|30
6080681|NCT00617890|9688008|FG003|Overall Study|Lack of Efficacy|97
6080682|NCT00617890|9688005|FG000|Overall Study|Lost to Follow-up|0
6080683|NCT00617890|9688006|FG001|Overall Study|Lost to Follow-up|0
6080684|NCT00617890|9688007|FG002|Overall Study|Lost to Follow-up|1
6080685|NCT00617890|9688008|FG003|Overall Study|Lost to Follow-up|2
6080686|NCT00617890|9688005|FG000|Overall Study|Withdrawal by Subject|4
6080687|NCT00617890|9688006|FG001|Overall Study|Withdrawal by Subject|1
6080688|NCT00617890|9688007|FG002|Overall Study|Withdrawal by Subject|0
6080689|NCT00617890|9688008|FG003|Overall Study|Withdrawal by Subject|2
6080690|NCT00617890|9688005|FG000|Overall Study|Protocol Violation|2
6080691|NCT00617890|9688006|FG001|Overall Study|Protocol Violation|1
6080692|NCT00617890|9688007|FG002|Overall Study|Protocol Violation|0
6080693|NCT00617890|9688008|FG003|Overall Study|Protocol Violation|0
6080694|NCT00617890|9688005|FG000|Overall Study|Adverse Event|1
6157331|NCT01156844|9797599|FG000|Overall Study|Lost to Follow-up|0
6157332|NCT01156844|9797600|FG001|Overall Study|Lost to Follow-up|0
6157333|NCT01156844|9797601|FG002|Overall Study|Lost to Follow-up|1
6157334|NCT01156844|9797602|FG003|Overall Study|Lost to Follow-up|0
6157335|NCT01156844|9797599|FG000|Overall Study|Administrative problems|0
6157336|NCT01156844|9797600|FG001|Overall Study|Administrative problems|1
6157337|NCT01156844|9797601|FG002|Overall Study|Administrative problems|0
6157338|NCT01156844|9797602|FG003|Overall Study|Administrative problems|1
6157339|NCT01156844|9797599|FG000|Overall Study|Protocol deviation|2
6157340|NCT01156844|9797600|FG001|Overall Study|Protocol deviation|0
6157341|NCT01156844|9797601|FG002|Overall Study|Protocol deviation|0
6157342|NCT01156844|9797602|FG003|Overall Study|Protocol deviation|0
6157343|NCT01157065|9797626|FG000|Overall Study|Death|0
6157344|NCT01157065|9797627|FG001|Overall Study|Death|1
6157345|NCT01157078|9797635|FG000|Overall Study|Withdrawal by Subject|12
6157346|NCT01157078|9797636|FG001|Overall Study|Withdrawal by Subject|14
6157347|NCT01157078|9797635|FG000|Overall Study|Eligibility criteria not fulfilled|2
6157348|NCT01157078|9797636|FG001|Overall Study|Eligibility criteria not fulfilled|0
6157349|NCT01157078|9797635|FG000|Overall Study|Adverse Event|6
6157350|NCT01157078|9797636|FG001|Overall Study|Adverse Event|6
6157351|NCT01157078|9797635|FG000|Overall Study|Severe non-compliance to protocol|2
6157352|NCT01157078|9797636|FG001|Overall Study|Severe non-compliance to protocol|4
6157353|NCT01157078|9797635|FG000|Overall Study|Condition under investigation worsened|0
6157354|NCT01157078|9797636|FG001|Overall Study|Condition under investigation worsened|1
6157355|NCT01157078|9797635|FG000|Overall Study|Lack of Efficacy|2
6157356|NCT01157078|9797636|FG001|Overall Study|Lack of Efficacy|0
6157357|NCT01157078|9797635|FG000|Overall Study|Study-specific withdrawal criteria|2
6157358|NCT01157078|9797636|FG001|Overall Study|Study-specific withdrawal criteria|2
6157359|NCT01157078|9797635|FG000|Overall Study|Lost to Follow-up|7
6157360|NCT01157078|9797636|FG001|Overall Study|Lost to Follow-up|5
6157361|NCT01157078|9797635|FG000|Overall Study|Other|2
6157362|NCT01157078|9797636|FG001|Overall Study|Other|4
6191753|NCT01425281|9848677|FG000|At 5-year Clinical Follow-up|Refused/terminated|9
6191754|NCT01425281|9848678|FG001|At 5-year Clinical Follow-up|Refused/terminated|3
6191755|NCT01425632|9848688|FG000|Overall Study|Adverse Event|0
6191756|NCT01425632|9848689|FG001|Overall Study|Adverse Event|1
6191757|NCT01425632|9848690|FG002|Overall Study|Adverse Event|1
6191758|NCT01425632|9848688|FG000|Overall Study|Physician Decision|1
6191759|NCT01425632|9848689|FG001|Overall Study|Physician Decision|0
6191760|NCT01425632|9848690|FG002|Overall Study|Physician Decision|0
6080695|NCT00617890|9688006|FG001|Overall Study|Adverse Event|0
6080696|NCT00617890|9688007|FG002|Overall Study|Adverse Event|3
6080697|NCT00617890|9688008|FG003|Overall Study|Adverse Event|8
6080698|NCT00617890|9688005|FG000|Overall Study|Not treated|1
6080699|NCT00617890|9688006|FG001|Overall Study|Not treated|0
6080700|NCT00617890|9688007|FG002|Overall Study|Not treated|1
6080701|NCT00617890|9688008|FG003|Overall Study|Not treated|1
6080702|NCT00617903|9688023|FG000|Overall Study|Withdrawal by Subject|2
6080703|NCT00617903|9688024|FG001|Overall Study|Withdrawal by Subject|3
6191761|NCT01425632|9848688|FG000|Overall Study|Protocol Violation|0
6191762|NCT01425632|9848689|FG001|Overall Study|Protocol Violation|0
6191763|NCT01425632|9848690|FG002|Overall Study|Protocol Violation|2
6191764|NCT01425632|9848688|FG000|Overall Study|Withdrawal by Subject|0
6191765|NCT01425632|9848689|FG001|Overall Study|Withdrawal by Subject|0
6191766|NCT01425632|9848690|FG002|Overall Study|Withdrawal by Subject|1
6191767|NCT01425723|9848700|FG000|Overall Study|Lack of Efficacy|0
6191768|NCT01425723|9848701|FG001|Overall Study|Lack of Efficacy|1
6157363|NCT01157117|9797645|FG000|Overall Study|Dosing Symptoms|0
6157364|NCT01157117|9797646|FG001|Overall Study|Dosing Symptoms|4
6157365|NCT01157117|9797647|FG002|Overall Study|Dosing Symptoms|0
6157366|NCT01157117|9797645|FG000|Overall Study|Withdrawal by Subject|4
6157367|NCT01157117|9797646|FG001|Overall Study|Withdrawal by Subject|1
6157368|NCT01157117|9797647|FG002|Overall Study|Withdrawal by Subject|1
6157369|NCT01157117|9797645|FG000|Overall Study|Lack of Efficacy|1
6157370|NCT01157117|9797646|FG001|Overall Study|Lack of Efficacy|1
6157371|NCT01157117|9797647|FG002|Overall Study|Lack of Efficacy|0
6157372|NCT01157117|9797645|FG000|Overall Study|Lost to Follow-up|0
6157373|NCT01157117|9797646|FG001|Overall Study|Lost to Follow-up|0
6157374|NCT01157117|9797647|FG002|Overall Study|Lost to Follow-up|1
6157375|NCT01157117|9797645|FG000|Overall Study|Unknown (Pending Final Form Submission)|4
6157376|NCT01157117|9797646|FG001|Overall Study|Unknown (Pending Final Form Submission)|5
6157377|NCT01157117|9797647|FG002|Overall Study|Unknown (Pending Final Form Submission)|13
6042714|NCT00384189|9641074|FG000|Overall Study|Reason Not Specified|50
6042715|NCT00384189|9641075|FG001|Overall Study|Reason Not Specified|57
6042716|NCT00384189|9641076|FG002|Overall Study|Reason Not Specified|58
6042717|NCT00384189|9641077|FG003|Overall Study|Reason Not Specified|40
6042718|NCT00384332|9641097|FG000|Overall Study|Lost to Follow-up|4
6042719|NCT00384332|9641098|FG001|Overall Study|Lost to Follow-up|0
6042720|NCT00384397|9641109|FG000|Overall Study|Adverse Event|0
6042721|NCT00384397|9641110|FG001|Overall Study|Adverse Event|1
6042722|NCT00384397|9641111|FG002|Overall Study|Adverse Event|2
6042723|NCT00384397|9641109|FG000|Overall Study|Protocol Violation|7
6042724|NCT00384397|9641110|FG001|Overall Study|Protocol Violation|15
6042725|NCT00384397|9641111|FG002|Overall Study|Protocol Violation|13
6042726|NCT00384397|9641109|FG000|Overall Study|Lost to Follow-up|11
6042727|NCT00384397|9641110|FG001|Overall Study|Lost to Follow-up|13
6042728|NCT00384397|9641111|FG002|Overall Study|Lost to Follow-up|3
6042729|NCT00384397|9641109|FG000|Overall Study|Withdrawal by Subject|14
6042730|NCT00384397|9641110|FG001|Overall Study|Withdrawal by Subject|17
6042731|NCT00384397|9641111|FG002|Overall Study|Withdrawal by Subject|15
6042732|NCT00384839|9641174|FG000|Overall Study|Adverse Event|4
6042733|NCT00384839|9641174|FG000|Overall Study|Investigator Request|1
6042734|NCT00384839|9641174|FG000|Overall Study|Patient Request|1
6080704|NCT00617903|9688023|FG000|Overall Study|Lost to Follow-up|1
6042735|NCT00384839|9641174|FG000|Overall Study|Ineligible|2
6042736|NCT00384930|9641200|FG000|Overall Study|Adverse Event|5
6042737|NCT00384930|9641201|FG001|Overall Study|Adverse Event|4
6042738|NCT00384930|9641202|FG002|Overall Study|Adverse Event|12
6042739|NCT00384930|9641203|FG003|Overall Study|Adverse Event|11
6042740|NCT00384930|9641204|FG004|Overall Study|Adverse Event|14
6042741|NCT00384930|9641200|FG000|Overall Study|Entry Criteria Not Met|2
6042742|NCT00384930|9641201|FG001|Overall Study|Entry Criteria Not Met|6
6042743|NCT00384930|9641202|FG002|Overall Study|Entry Criteria Not Met|7
6042744|NCT00384930|9641203|FG003|Overall Study|Entry Criteria Not Met|8
6157378|NCT01157169|9797657|FG000|First Intervention|Emesis Within 4 hrs of Administration|4
6157379|NCT01157169|9797658|FG001|First Intervention|Emesis Within 4 hrs of Administration|2
6157380|NCT01157169|9797657|FG000|Second Intervention|Emesis Within 4 hrs of Administration|0
6157381|NCT01157169|9797658|FG001|Second Intervention|Emesis Within 4 hrs of Administration|1
6157382|NCT01157182|9797666|FG000|Washout of 28 Days|Adverse Event|2
6157383|NCT01157182|9797667|FG001|Washout of 28 Days|Adverse Event|0
6157384|NCT01157234|9797675|FG000|Overall Study|Withdrawal by Subject|1
6157385|NCT01157234|9797676|FG001|Overall Study|Withdrawal by Subject|0
6157386|NCT01157351|9797691|FG000|Overall Study|Adverse Event|5
6157387|NCT01157351|9797692|FG001|Overall Study|Adverse Event|4
6157388|NCT01157351|9797691|FG000|Overall Study|Death|1
6157389|NCT01157351|9797692|FG001|Overall Study|Death|0
6157390|NCT01157351|9797691|FG000|Overall Study|Lost to Follow-up|53
6157391|NCT01157351|9797692|FG001|Overall Study|Lost to Follow-up|55
6157392|NCT01157351|9797691|FG000|Overall Study|Withdrawal by Subject|37
6157393|NCT01157351|9797692|FG001|Overall Study|Withdrawal by Subject|27
6157394|NCT01157351|9797691|FG000|Overall Study|Physician Decision|5
6157395|NCT01157351|9797692|FG001|Overall Study|Physician Decision|4
6157396|NCT01157351|9797691|FG000|Overall Study|Protocol Violation|0
6157397|NCT01157351|9797692|FG001|Overall Study|Protocol Violation|1
6157398|NCT01157351|9797691|FG000|Overall Study|Other|32
6157399|NCT01157351|9797692|FG001|Overall Study|Other|36
6157400|NCT01157351|9797691|FG000|Overall Study|Noncompliance with Study Drug|0
6157401|NCT01157351|9797692|FG001|Overall Study|Noncompliance with Study Drug|3
6157402|NCT01157351|9797691|FG000|Overall Study|Randomized but not Treated|4
6157403|NCT01157351|9797692|FG001|Overall Study|Randomized but not Treated|2
6157404|NCT01157364|9797704|FG000|Overall Study|Other Reasons|1
6157405|NCT01157364|9797705|FG001|Overall Study|Other Reasons|1
6157406|NCT01157364|9797706|FG002|Overall Study|Other Reasons|2
6157407|NCT01157364|9797707|FG003|Overall Study|Other Reasons|1
6157408|NCT01157364|9797708|FG004|Overall Study|Other Reasons|0
6157409|NCT01157364|9797709|FG005|Overall Study|Other Reasons|0
6157410|NCT01157364|9797704|FG000|Overall Study|Personal Reasons|0
6157411|NCT01157364|9797705|FG001|Overall Study|Personal Reasons|2
6157412|NCT01157364|9797706|FG002|Overall Study|Personal Reasons|0
6157413|NCT01157364|9797707|FG003|Overall Study|Personal Reasons|0
6157414|NCT01157364|9797708|FG004|Overall Study|Personal Reasons|1
6157415|NCT01157364|9797709|FG005|Overall Study|Personal Reasons|1
6157416|NCT01157364|9797704|FG000|Overall Study|Lost to Follow-up|1
6157417|NCT01157364|9797705|FG001|Overall Study|Lost to Follow-up|0
6157418|NCT01157364|9797706|FG002|Overall Study|Lost to Follow-up|1
6157419|NCT01157364|9797707|FG003|Overall Study|Lost to Follow-up|0
6157420|NCT01157364|9797708|FG004|Overall Study|Lost to Follow-up|0
6157421|NCT01157364|9797709|FG005|Overall Study|Lost to Follow-up|0
6157422|NCT01157364|9797704|FG000|Overall Study|Lack of Efficacy|0
6157423|NCT01157364|9797705|FG001|Overall Study|Lack of Efficacy|0
6157424|NCT01157364|9797706|FG002|Overall Study|Lack of Efficacy|0
6157425|NCT01157364|9797707|FG003|Overall Study|Lack of Efficacy|1
6157426|NCT01157364|9797708|FG004|Overall Study|Lack of Efficacy|0
6157427|NCT01157364|9797709|FG005|Overall Study|Lack of Efficacy|0
6157428|NCT01157364|9797704|FG000|Overall Study|Adverse Event|0
6157429|NCT01157364|9797705|FG001|Overall Study|Adverse Event|1
6157430|NCT01157364|9797706|FG002|Overall Study|Adverse Event|1
6157431|NCT01157364|9797707|FG003|Overall Study|Adverse Event|0
6157432|NCT01157364|9797708|FG004|Overall Study|Adverse Event|1
6157433|NCT01157364|9797709|FG005|Overall Study|Adverse Event|0
6157434|NCT01157377|9797730|FG000|Overall Study|Lost to Follow-up|0
6157435|NCT01157377|9797731|FG001|Overall Study|Lost to Follow-up|0
6157436|NCT01157377|9797732|FG002|Overall Study|Lost to Follow-up|1
6157437|NCT01157377|9797733|FG003|Overall Study|Lost to Follow-up|0
6157438|NCT01157377|9797734|FG004|Overall Study|Lost to Follow-up|1
6157439|NCT01157377|9797735|FG005|Overall Study|Lost to Follow-up|1
6157440|NCT01157377|9797736|FG006|Overall Study|Lost to Follow-up|0
6157441|NCT01157377|9797730|FG000|Overall Study|Personal Reasons|2
6157442|NCT01157377|9797731|FG001|Overall Study|Personal Reasons|1
6157443|NCT01157377|9797732|FG002|Overall Study|Personal Reasons|0
6157444|NCT01157377|9797733|FG003|Overall Study|Personal Reasons|1
6157445|NCT01157377|9797734|FG004|Overall Study|Personal Reasons|0
6157446|NCT01157377|9797735|FG005|Overall Study|Personal Reasons|0
6157447|NCT01157377|9797736|FG006|Overall Study|Personal Reasons|0
6157448|NCT01157377|9797730|FG000|Overall Study|Protocol Violation|0
6157449|NCT01157377|9797731|FG001|Overall Study|Protocol Violation|0
6157450|NCT01157377|9797732|FG002|Overall Study|Protocol Violation|0
6157451|NCT01157377|9797733|FG003|Overall Study|Protocol Violation|0
6157452|NCT01157377|9797734|FG004|Overall Study|Protocol Violation|0
6157453|NCT01157377|9797735|FG005|Overall Study|Protocol Violation|1
6157454|NCT01157377|9797736|FG006|Overall Study|Protocol Violation|0
6157455|NCT01157377|9797730|FG000|Overall Study|Lack of Efficacy|0
6157456|NCT01157377|9797731|FG001|Overall Study|Lack of Efficacy|0
6157457|NCT01157377|9797732|FG002|Overall Study|Lack of Efficacy|0
6157458|NCT01157377|9797733|FG003|Overall Study|Lack of Efficacy|0
6157459|NCT01157377|9797734|FG004|Overall Study|Lack of Efficacy|0
6157460|NCT01157377|9797735|FG005|Overall Study|Lack of Efficacy|0
6157461|NCT01157377|9797736|FG006|Overall Study|Lack of Efficacy|1
6157462|NCT01157377|9797730|FG000|Overall Study|Other Miscellaneous Reasons|0
6157463|NCT01157377|9797731|FG001|Overall Study|Other Miscellaneous Reasons|2
6157464|NCT01157377|9797732|FG002|Overall Study|Other Miscellaneous Reasons|0
6157465|NCT01157377|9797733|FG003|Overall Study|Other Miscellaneous Reasons|0
6157466|NCT01157377|9797734|FG004|Overall Study|Other Miscellaneous Reasons|1
6157467|NCT01157377|9797735|FG005|Overall Study|Other Miscellaneous Reasons|1
6157468|NCT01157377|9797736|FG006|Overall Study|Other Miscellaneous Reasons|1
6157469|NCT01157676|9797772|FG000|Randomization|Death|1
6157470|NCT01157676|9797773|FG001|Randomization|Death|1
6157471|NCT01157676|9797772|FG000|Randomization|unresectable|2
6157472|NCT01157676|9797773|FG001|Randomization|unresectable|3
6157473|NCT01157676|9797772|FG000|Randomization|Withdrawal by Subject|17
6157474|NCT01157676|9797773|FG001|Randomization|Withdrawal by Subject|13
6157475|NCT01157676|9797772|FG000|Randomization|Physician Decision|1
6157476|NCT01157676|9797773|FG001|Randomization|Physician Decision|0
6157477|NCT01157676|9797772|FG000|Surgery|underwent open cystectomy|0
6157478|NCT01157676|9797773|FG001|Surgery|underwent open cystectomy|4
6157479|NCT01157676|9797772|FG000|Surgery|converted to open procedure|0
6157480|NCT01157676|9797773|FG001|Surgery|converted to open procedure|5
6157481|NCT01157676|9797772|FG000|Surgery|underwent robotic cystectomy|1
6157482|NCT01157676|9797773|FG001|Surgery|underwent robotic cystectomy|0
6157483|NCT01157845|9797785|FG000|Overall Study|Lost to Follow-up|5
6157484|NCT01157845|9797785|FG000|Overall Study|Withdrawal by Subject|12
6157485|NCT01157845|9797785|FG000|Overall Study|Physician Decision|3
6157486|NCT01157845|9797785|FG000|Overall Study|Protocol Violation|13
6157487|NCT01157845|9797785|FG000|Overall Study|Study was ended|1
6157488|NCT01157845|9797785|FG000|Overall Study|Device malfunction|1
6157489|NCT01157897|9797793|FG000|Overall Study|Lost to Follow-up|2
6157490|NCT01157897|9797794|FG001|Overall Study|Lost to Follow-up|0
6157491|NCT01157897|9797795|FG002|Overall Study|Lost to Follow-up|0
6157492|NCT01157897|9797796|FG003|Overall Study|Lost to Follow-up|1
6157493|NCT01157897|9797793|FG000|Overall Study|Relocated|0
6157494|NCT01157897|9797794|FG001|Overall Study|Relocated|2
6157495|NCT01157897|9797795|FG002|Overall Study|Relocated|0
6157496|NCT01157897|9797796|FG003|Overall Study|Relocated|0
6157497|NCT01158118|9797808|FG000|Overall Study|Screen failure|1
6157498|NCT01158118|9797809|FG001|Overall Study|Screen failure|0
6157499|NCT01158118|9797808|FG000|Overall Study|Donor match was a screen failure|0
6157500|NCT01158118|9797809|FG001|Overall Study|Donor match was a screen failure|1
6157501|NCT01158118|9797808|FG000|Overall Study|Suffered stroke prior to transplant|0
6157502|NCT01158118|9797809|FG001|Overall Study|Suffered stroke prior to transplant|1
6157503|NCT01158118|9797808|FG000|Overall Study|Death|0
6080705|NCT00617903|9688024|FG001|Overall Study|Lost to Follow-up|1
6157504|NCT01158118|9797809|FG001|Overall Study|Death|1
6157505|NCT01158222|9797819|FG000|Overall Study|Not eligible for intermediate phase|17
6157506|NCT01158261|9797823|FG000|Overall Study|Lost to Follow-up|9
6157507|NCT01158261|9797823|FG000|Overall Study|Death|7
6157508|NCT01158261|9797823|FG000|Overall Study|Withdrawal by Subject|1
6157509|NCT01158378|9797829|FG000|Overall Study|Death|4
6157510|NCT01158378|9797830|FG001|Overall Study|Death|5
6157511|NCT01158378|9797829|FG000|Overall Study|Lost to Follow-up|2
6157512|NCT01158378|9797830|FG001|Overall Study|Lost to Follow-up|4
6157513|NCT01158378|9797829|FG000|Overall Study|Withdrawal by Subject|4
6157514|NCT01158378|9797830|FG001|Overall Study|Withdrawal by Subject|0
6157515|NCT01158404|9797845|FG000|Overall Study|Withdrawal by Subject|0
6157516|NCT01158404|9797846|FG001|Overall Study|Withdrawal by Subject|1
6157517|NCT01158404|9797847|FG002|Overall Study|Withdrawal by Subject|0
6157518|NCT01158404|9797848|FG003|Overall Study|Withdrawal by Subject|0
6157519|NCT01158404|9797849|FG004|Overall Study|Withdrawal by Subject|3
6157520|NCT01158404|9797850|FG005|Overall Study|Withdrawal by Subject|1
6157521|NCT01158404|9797851|FG006|Overall Study|Withdrawal by Subject|0
6157522|NCT01158404|9797852|FG007|Overall Study|Withdrawal by Subject|1
6157523|NCT01158404|9797845|FG000|Overall Study|Physician Decision|0
6157524|NCT01158404|9797846|FG001|Overall Study|Physician Decision|0
6157525|NCT01158404|9797847|FG002|Overall Study|Physician Decision|0
6157526|NCT01158404|9797848|FG003|Overall Study|Physician Decision|0
6157527|NCT01158404|9797849|FG004|Overall Study|Physician Decision|0
6157528|NCT01158404|9797850|FG005|Overall Study|Physician Decision|0
6157529|NCT01158404|9797851|FG006|Overall Study|Physician Decision|0
6157530|NCT01158404|9797852|FG007|Overall Study|Physician Decision|1
6157531|NCT01158404|9797845|FG000|Overall Study|Progressive Disease|0
6157532|NCT01158404|9797846|FG001|Overall Study|Progressive Disease|0
6157533|NCT01158404|9797847|FG002|Overall Study|Progressive Disease|0
6157534|NCT01158404|9797848|FG003|Overall Study|Progressive Disease|0
6157535|NCT01158404|9797849|FG004|Overall Study|Progressive Disease|0
6157536|NCT01158404|9797850|FG005|Overall Study|Progressive Disease|0
6157537|NCT01158404|9797851|FG006|Overall Study|Progressive Disease|1
6157538|NCT01158404|9797852|FG007|Overall Study|Progressive Disease|0
6157539|NCT01158534|9797878|FG000|Overall Study|Withdrawal by Subject|1
6157540|NCT01158534|9797878|FG000|Overall Study|Death|1
6157541|NCT01158534|9797878|FG000|Overall Study|Other|1
6157542|NCT01158924|9797937|FG000|Overall Study|Withdrawal by Subject|1
6157543|NCT01158924|9797938|FG001|Overall Study|Withdrawal by Subject|2
6157544|NCT01158924|9797937|FG000|Overall Study|Lost to Follow-up|0
6157545|NCT01158924|9797938|FG001|Overall Study|Lost to Follow-up|1
6157546|NCT01158950|9797944|FG000|1st Intervention (1 Day)|Physician Decision|1
6157547|NCT01158950|9797945|FG001|1st Intervention (1 Day)|Physician Decision|2
6157548|NCT01159171|9797976|FG000|Overall Study|Adverse Event|11
6157549|NCT01159171|9797976|FG000|Overall Study|Progression of Disease|28
6157550|NCT01159171|9797976|FG000|Overall Study|Protocol Violation|1
6157551|NCT01159171|9797976|FG000|Overall Study|Need for Surgery|5
6157552|NCT01159171|9797976|FG000|Overall Study|Medical Decision|4
6157553|NCT01159171|9797976|FG000|Overall Study|Death|1
6157554|NCT01159431|9797996|FG000|Overall Study|Adverse Event|1
6157555|NCT01159431|9797997|FG001|Overall Study|Adverse Event|2
6157556|NCT01159431|9797996|FG000|Overall Study|non-compliance|1
6157557|NCT01159431|9797997|FG001|Overall Study|non-compliance|1
6157558|NCT01159431|9797996|FG000|Overall Study|Lack of Efficacy|0
6157559|NCT01159431|9797997|FG001|Overall Study|Lack of Efficacy|3
6157560|NCT01159574|9798023|FG000|Treatment Phase|non-evaluable/not included in analysis|1
6157561|NCT01159574|9798023|FG000|Treatment Phase|Adverse Event|3
6157562|NCT01159574|9798023|FG000|Treatment Phase|Death|6
6157563|NCT01159574|9798023|FG000|Treatment Phase|Physician Decision|2
6157564|NCT01159574|9798023|FG000|Treatment Phase|Withdrawal by Subject|7
6157565|NCT01159574|9798023|FG000|Treatment Phase|still on treatment|2
6157566|NCT01159574|9798023|FG000|Follow Up Phase|Lost to Follow-up|2
6157567|NCT01159574|9798023|FG000|Follow Up Phase|still being followed for overall surviva|18
6157568|NCT01159600|9798035|FG000|Overall Study|Not treated|0
6157569|NCT01159600|9798036|FG001|Overall Study|Not treated|0
6157570|NCT01159600|9798037|FG002|Overall Study|Not treated|1
6157571|NCT01159600|9798038|FG003|Overall Study|Not treated|0
6157572|NCT01159600|9798039|FG004|Overall Study|Not treated|0
6157573|NCT01159600|9798040|FG005|Overall Study|Not treated|1
6157574|NCT01159600|9798041|FG006|Overall Study|Not treated|2
6157575|NCT01159600|9798042|FG007|Overall Study|Not treated|2
6080706|NCT00617903|9688023|FG000|Overall Study|Lack of Efficacy|0
6080707|NCT00617903|9688024|FG001|Overall Study|Lack of Efficacy|1
6080708|NCT00617903|9688023|FG000|Overall Study|Adverse Event|0
6080709|NCT00617903|9688024|FG001|Overall Study|Adverse Event|1
6080710|NCT00617903|9688023|FG000|Overall Study|noncompliance|0
6080711|NCT00617903|9688024|FG001|Overall Study|noncompliance|1
6080712|NCT00617929|9688030|FG000|Overall Study|Physician Decision|1
6080713|NCT00618072|9688061|FG000|Overall Study|Lost to Follow-up|2
6157576|NCT01159600|9798035|FG000|Overall Study|Adverse Event|7
6157577|NCT01159600|9798036|FG001|Overall Study|Adverse Event|2
6080714|NCT00618072|9688062|FG001|Overall Study|Lost to Follow-up|0
6157578|NCT01159600|9798037|FG002|Overall Study|Adverse Event|5
6157579|NCT01159600|9798038|FG003|Overall Study|Adverse Event|1
6157580|NCT01159600|9798039|FG004|Overall Study|Adverse Event|8
6157581|NCT01159600|9798040|FG005|Overall Study|Adverse Event|6
6157582|NCT01159600|9798041|FG006|Overall Study|Adverse Event|7
6157583|NCT01159600|9798042|FG007|Overall Study|Adverse Event|5
6157584|NCT01159600|9798035|FG000|Overall Study|Lack of Efficacy|0
6157585|NCT01159600|9798036|FG001|Overall Study|Lack of Efficacy|0
6157586|NCT01159600|9798037|FG002|Overall Study|Lack of Efficacy|0
6157587|NCT01159600|9798038|FG003|Overall Study|Lack of Efficacy|0
6157588|NCT01159600|9798039|FG004|Overall Study|Lack of Efficacy|2
6157589|NCT01159600|9798040|FG005|Overall Study|Lack of Efficacy|0
6157590|NCT01159600|9798041|FG006|Overall Study|Lack of Efficacy|0
6157591|NCT01159600|9798042|FG007|Overall Study|Lack of Efficacy|1
6157592|NCT01159600|9798035|FG000|Overall Study|Non compliant with protocol|2
6157593|NCT01159600|9798036|FG001|Overall Study|Non compliant with protocol|1
6157594|NCT01159600|9798037|FG002|Overall Study|Non compliant with protocol|0
6157595|NCT01159600|9798038|FG003|Overall Study|Non compliant with protocol|0
6157596|NCT01159600|9798039|FG004|Overall Study|Non compliant with protocol|2
6157597|NCT01159600|9798040|FG005|Overall Study|Non compliant with protocol|0
6157598|NCT01159600|9798041|FG006|Overall Study|Non compliant with protocol|2
6157599|NCT01159600|9798042|FG007|Overall Study|Non compliant with protocol|0
6157600|NCT01159600|9798035|FG000|Overall Study|Lost to Follow-up|2
6157601|NCT01159600|9798036|FG001|Overall Study|Lost to Follow-up|3
6157602|NCT01159600|9798037|FG002|Overall Study|Lost to Follow-up|4
6157603|NCT01159600|9798038|FG003|Overall Study|Lost to Follow-up|3
6157604|NCT01159600|9798039|FG004|Overall Study|Lost to Follow-up|3
6157605|NCT01159600|9798040|FG005|Overall Study|Lost to Follow-up|0
6157606|NCT01159600|9798041|FG006|Overall Study|Lost to Follow-up|3
6157607|NCT01159600|9798042|FG007|Overall Study|Lost to Follow-up|2
6157608|NCT01159600|9798035|FG000|Overall Study|Patient refusal to continue,not due toAE|7
6157609|NCT01159600|9798036|FG001|Overall Study|Patient refusal to continue,not due toAE|2
6157610|NCT01159600|9798037|FG002|Overall Study|Patient refusal to continue,not due toAE|4
6157611|NCT01159600|9798038|FG003|Overall Study|Patient refusal to continue,not due toAE|5
6157612|NCT01159600|9798039|FG004|Overall Study|Patient refusal to continue,not due toAE|4
6157613|NCT01159600|9798040|FG005|Overall Study|Patient refusal to continue,not due toAE|4
6157614|NCT01159600|9798041|FG006|Overall Study|Patient refusal to continue,not due toAE|2
6157615|NCT01159600|9798042|FG007|Overall Study|Patient refusal to continue,not due toAE|5
6157616|NCT01159600|9798035|FG000|Overall Study|Other reason not defined above|3
6157617|NCT01159600|9798036|FG001|Overall Study|Other reason not defined above|0
6157618|NCT01159600|9798037|FG002|Overall Study|Other reason not defined above|4
6157619|NCT01159600|9798038|FG003|Overall Study|Other reason not defined above|2
6157620|NCT01159600|9798039|FG004|Overall Study|Other reason not defined above|5
6157621|NCT01159600|9798040|FG005|Overall Study|Other reason not defined above|7
6157622|NCT01159600|9798041|FG006|Overall Study|Other reason not defined above|3
6157623|NCT01159600|9798042|FG007|Overall Study|Other reason not defined above|3
6157624|NCT01159665|9798067|FG000|Overall Study|Withdrawal by Subject|0
6157625|NCT01159665|9798068|FG001|Overall Study|Withdrawal by Subject|1
6157626|NCT01159665|9798069|FG002|Overall Study|Withdrawal by Subject|0
6157627|NCT01159665|9798070|FG003|Overall Study|Withdrawal by Subject|0
6157628|NCT01159665|9798071|FG004|Overall Study|Withdrawal by Subject|0
6157629|NCT01159665|9798072|FG005|Overall Study|Withdrawal by Subject|0
6157630|NCT01159691|9798086|FG000|Overall Study|Lost to Follow-up|2
6157631|NCT01159691|9798086|FG000|Overall Study|Unknown reasons|1
6157632|NCT01159691|9798086|FG000|Overall Study|Discontinued Neupro due to Adverse Event|6
6157633|NCT01159691|9798086|FG000|Overall Study|Discontinued Neupro due to other reasons|1
6157634|NCT01159691|9798086|FG000|Overall Study|Disc. Neupro other & lost to follow-up|2
6157635|NCT01159691|9798086|FG000|Overall Study|Disc. Neupro other & unknown reasons|7
6157636|NCT01159691|9798086|FG000|Overall Study|Disc. Neupro due to AE & unknown reasons|2
6157637|NCT01159691|9798086|FG000|Overall Study|Disc. Neupro lack of efficacy & unknown|1
6157638|NCT01159769|9798099|FG000|Overall Study|Adverse Event|1
6157639|NCT01159912|9798106|FG000|Overall Study|Adverse Event|2
6157640|NCT01159912|9798107|FG001|Overall Study|Adverse Event|2
6157641|NCT01159912|9798108|FG002|Overall Study|Adverse Event|3
6157642|NCT01159912|9798106|FG000|Overall Study|Lack of Efficacy|23
6157643|NCT01159912|9798107|FG001|Overall Study|Lack of Efficacy|15
6157644|NCT01159912|9798108|FG002|Overall Study|Lack of Efficacy|14
6157645|NCT01159912|9798106|FG000|Overall Study|Protocol Violation|1
6157646|NCT01159912|9798107|FG001|Overall Study|Protocol Violation|2
6157647|NCT01159912|9798108|FG002|Overall Study|Protocol Violation|3
6157648|NCT01159912|9798106|FG000|Overall Study|Lost to Follow-up|4
6157649|NCT01159912|9798107|FG001|Overall Study|Lost to Follow-up|0
6157650|NCT01159912|9798108|FG002|Overall Study|Lost to Follow-up|0
6157651|NCT01159912|9798106|FG000|Overall Study|Physician Decision|0
6157652|NCT01159912|9798107|FG001|Overall Study|Physician Decision|0
6157653|NCT01159912|9798108|FG002|Overall Study|Physician Decision|3
6157654|NCT01159912|9798106|FG000|Overall Study|Withdrawal by Subject|10
6157655|NCT01159912|9798107|FG001|Overall Study|Withdrawal by Subject|3
6157656|NCT01159912|9798108|FG002|Overall Study|Withdrawal by Subject|3
6157657|NCT01159938|9798119|FG000|First Study Period|Protocol Violation (Microalbuminuria)|0
6157658|NCT01159938|9798120|FG001|First Study Period|Protocol Violation (Microalbuminuria)|0
6157659|NCT01159938|9798121|FG002|First Study Period|Protocol Violation (Microalbuminuria)|1
6157660|NCT01159938|9798122|FG003|First Study Period|Protocol Violation (Microalbuminuria)|0
6157661|NCT01159938|9798123|FG004|First Study Period|Protocol Violation (Microalbuminuria)|0
6157662|NCT01160198|9798147|FG000|Overall Study|Withdrawal by Subject|2
6157663|NCT01160198|9798148|FG001|Overall Study|Withdrawal by Subject|1
6157664|NCT01160198|9798149|FG002|Overall Study|Withdrawal by Subject|0
6157665|NCT01160198|9798147|FG000|Overall Study|Adverse Event|0
6157666|NCT01160198|9798148|FG001|Overall Study|Adverse Event|1
6157667|NCT01160198|9798149|FG002|Overall Study|Adverse Event|0
6157668|NCT01160198|9798147|FG000|Overall Study|Lost to Follow-up|0
6157669|NCT01160198|9798148|FG001|Overall Study|Lost to Follow-up|1
6157670|NCT01160198|9798149|FG002|Overall Study|Lost to Follow-up|0
6157671|NCT01160198|9798147|FG000|Overall Study|Participant lost drug; withdrew consent|0
6157672|NCT01160198|9798148|FG001|Overall Study|Participant lost drug; withdrew consent|0
6157673|NCT01160198|9798149|FG002|Overall Study|Participant lost drug; withdrew consent|1
6157674|NCT01160211|9798160|FG000|Overall Study|ongoing|90
6157675|NCT01160211|9798161|FG001|Overall Study|ongoing|75
6157676|NCT01160211|9798162|FG002|Overall Study|ongoing|79
6157677|NCT01160211|9798160|FG000|Overall Study|Withdrawal by Subject|3
6157678|NCT01160211|9798161|FG001|Overall Study|Withdrawal by Subject|5
6157679|NCT01160211|9798162|FG002|Overall Study|Withdrawal by Subject|3
6157680|NCT01160211|9798160|FG000|Overall Study|Physician Decision|2
6157681|NCT01160211|9798161|FG001|Overall Study|Physician Decision|0
6157682|NCT01160211|9798162|FG002|Overall Study|Physician Decision|0
6157683|NCT01160211|9798160|FG000|Overall Study|Lost to Follow-up|4
6157684|NCT01160211|9798161|FG001|Overall Study|Lost to Follow-up|7
6157685|NCT01160211|9798162|FG002|Overall Study|Lost to Follow-up|5
6157686|NCT01160289|9798189|FG000|Screening, Washout, and Lead-In Period|Adverse Event|8
6157687|NCT01160289|9798190|FG001|Screening, Washout, and Lead-In Period|Adverse Event|0
6157688|NCT01160289|9798191|FG002|Screening, Washout, and Lead-In Period|Adverse Event|0
6157689|NCT01160289|9798192|FG003|Screening, Washout, and Lead-In Period|Adverse Event|0
6157690|NCT01160289|9798193|FG004|Screening, Washout, and Lead-In Period|Adverse Event|0
6157691|NCT01160289|9798194|FG005|Screening, Washout, and Lead-In Period|Adverse Event|0
6157692|NCT01160289|9798189|FG000|Screening, Washout, and Lead-In Period|Entry Criteria Not Met|308
6157693|NCT01160289|9798190|FG001|Screening, Washout, and Lead-In Period|Entry Criteria Not Met|0
6157694|NCT01160289|9798191|FG002|Screening, Washout, and Lead-In Period|Entry Criteria Not Met|0
6157695|NCT01160289|9798192|FG003|Screening, Washout, and Lead-In Period|Entry Criteria Not Met|0
6157696|NCT01160289|9798193|FG004|Screening, Washout, and Lead-In Period|Entry Criteria Not Met|0
6157697|NCT01160289|9798194|FG005|Screening, Washout, and Lead-In Period|Entry Criteria Not Met|0
6157698|NCT01160289|9798189|FG000|Screening, Washout, and Lead-In Period|Lack of Efficacy|1
6157699|NCT01160289|9798190|FG001|Screening, Washout, and Lead-In Period|Lack of Efficacy|0
6157700|NCT01160289|9798191|FG002|Screening, Washout, and Lead-In Period|Lack of Efficacy|0
6157701|NCT01160289|9798192|FG003|Screening, Washout, and Lead-In Period|Lack of Efficacy|0
6157702|NCT01160289|9798193|FG004|Screening, Washout, and Lead-In Period|Lack of Efficacy|0
6157703|NCT01160289|9798194|FG005|Screening, Washout, and Lead-In Period|Lack of Efficacy|0
6157704|NCT01160289|9798189|FG000|Screening, Washout, and Lead-In Period|Lost to Follow-up|9
6157705|NCT01160289|9798190|FG001|Screening, Washout, and Lead-In Period|Lost to Follow-up|0
6157706|NCT01160289|9798191|FG002|Screening, Washout, and Lead-In Period|Lost to Follow-up|0
6157707|NCT01160289|9798192|FG003|Screening, Washout, and Lead-In Period|Lost to Follow-up|0
6157708|NCT01160289|9798193|FG004|Screening, Washout, and Lead-In Period|Lost to Follow-up|0
6157709|NCT01160289|9798194|FG005|Screening, Washout, and Lead-In Period|Lost to Follow-up|0
6157710|NCT01160289|9798189|FG000|Screening, Washout, and Lead-In Period|Physician Decision|26
6157711|NCT01160289|9798190|FG001|Screening, Washout, and Lead-In Period|Physician Decision|0
6157712|NCT01160289|9798191|FG002|Screening, Washout, and Lead-In Period|Physician Decision|0
6157713|NCT01160289|9798192|FG003|Screening, Washout, and Lead-In Period|Physician Decision|0
6157714|NCT01160289|9798193|FG004|Screening, Washout, and Lead-In Period|Physician Decision|0
6157715|NCT01160289|9798194|FG005|Screening, Washout, and Lead-In Period|Physician Decision|0
6157716|NCT01160289|9798189|FG000|Screening, Washout, and Lead-In Period|Protocol Violation|1
6157717|NCT01160289|9798190|FG001|Screening, Washout, and Lead-In Period|Protocol Violation|0
6157718|NCT01160289|9798191|FG002|Screening, Washout, and Lead-In Period|Protocol Violation|0
6157719|NCT01160289|9798192|FG003|Screening, Washout, and Lead-In Period|Protocol Violation|0
6157720|NCT01160289|9798193|FG004|Screening, Washout, and Lead-In Period|Protocol Violation|0
6157721|NCT01160289|9798194|FG005|Screening, Washout, and Lead-In Period|Protocol Violation|0
6157722|NCT01160289|9798189|FG000|Screening, Washout, and Lead-In Period|Randomization Criteria Not Met|67
6157723|NCT01160289|9798190|FG001|Screening, Washout, and Lead-In Period|Randomization Criteria Not Met|0
6157724|NCT01160289|9798191|FG002|Screening, Washout, and Lead-In Period|Randomization Criteria Not Met|0
6157725|NCT01160289|9798192|FG003|Screening, Washout, and Lead-In Period|Randomization Criteria Not Met|0
6157726|NCT01160289|9798193|FG004|Screening, Washout, and Lead-In Period|Randomization Criteria Not Met|0
6157727|NCT01160289|9798194|FG005|Screening, Washout, and Lead-In Period|Randomization Criteria Not Met|0
6157728|NCT01160289|9798189|FG000|Screening, Washout, and Lead-In Period|Withdrawal by Subject|64
6157729|NCT01160289|9798190|FG001|Screening, Washout, and Lead-In Period|Withdrawal by Subject|0
6157730|NCT01160289|9798191|FG002|Screening, Washout, and Lead-In Period|Withdrawal by Subject|0
6191769|NCT01425723|9848700|FG000|Overall Study|Withdrawal by Subject|1
6080715|NCT00618072|9688063|FG002|Overall Study|Lost to Follow-up|3
6080716|NCT00618072|9688061|FG000|Overall Study|Physician Decision|0
6080717|NCT00618072|9688062|FG001|Overall Study|Physician Decision|1
6080718|NCT00618072|9688063|FG002|Overall Study|Physician Decision|1
6080719|NCT00618371|9688080|FG000|Overall Study|Withdrawal by Subject|2
6080720|NCT00618410|9688085|FG000|Washout Period (2 Weeks)|Physician Decision|0
6080721|NCT00618410|9688086|FG001|Washout Period (2 Weeks)|Physician Decision|1
6080722|NCT00618449|9688103|FG000|Overall Study|Lost to Follow-up|98
6080723|NCT00618449|9688104|FG001|Overall Study|Lost to Follow-up|110
6080724|NCT00618514|9688112|FG000|Overall Study|Lost to Follow-up|11
6080725|NCT00618514|9688113|FG001|Overall Study|Lost to Follow-up|12
6080726|NCT00618514|9688114|FG002|Overall Study|Lost to Follow-up|4
6080727|NCT00618618|9688129|FG000|Overall Study|Patient Request|0
6080728|NCT00618618|9688130|FG001|Overall Study|Patient Request|0
6080729|NCT00618618|9688131|FG002|Overall Study|Patient Request|2
6080730|NCT00618618|9688132|FG003|Overall Study|Patient Request|0
6080731|NCT00618618|9688129|FG000|Overall Study|Inability to Complete Study Procedures|0
6080732|NCT00618618|9688130|FG001|Overall Study|Inability to Complete Study Procedures|1
6080733|NCT00618618|9688131|FG002|Overall Study|Inability to Complete Study Procedures|0
6080734|NCT00618618|9688132|FG003|Overall Study|Inability to Complete Study Procedures|0
6080735|NCT00618618|9688129|FG000|Overall Study|Lost to Follow-up|3
6080736|NCT00618618|9688130|FG001|Overall Study|Lost to Follow-up|0
6080737|NCT00618618|9688131|FG002|Overall Study|Lost to Follow-up|0
6080738|NCT00618618|9688132|FG003|Overall Study|Lost to Follow-up|1
6080739|NCT00618618|9688129|FG000|Overall Study|Non-compliance|1
6080740|NCT00618618|9688130|FG001|Overall Study|Non-compliance|1
6080741|NCT00618618|9688131|FG002|Overall Study|Non-compliance|0
6080742|NCT00618618|9688132|FG003|Overall Study|Non-compliance|0
6080743|NCT00618618|9688129|FG000|Overall Study|Did Not Meet Entry Criteria|0
6080744|NCT00618618|9688130|FG001|Overall Study|Did Not Meet Entry Criteria|0
6080745|NCT00618618|9688131|FG002|Overall Study|Did Not Meet Entry Criteria|1
6080746|NCT00618618|9688132|FG003|Overall Study|Did Not Meet Entry Criteria|0
6080747|NCT00618618|9688129|FG000|Overall Study|Death|0
6080748|NCT00618618|9688130|FG001|Overall Study|Death|1
6080749|NCT00618618|9688131|FG002|Overall Study|Death|0
6080750|NCT00618618|9688132|FG003|Overall Study|Death|0
6080751|NCT00618722|9688147|FG000|Overall Study|Refusal of Treatment|0
6080752|NCT00618722|9688148|FG001|Overall Study|Refusal of Treatment|0
6080753|NCT00618722|9688149|FG002|Overall Study|Refusal of Treatment|1
6080754|NCT00618722|9688150|FG003|Overall Study|Refusal of Treatment|0
6080755|NCT00618722|9688147|FG000|Overall Study|Patient Request|1
6080756|NCT00618722|9688148|FG001|Overall Study|Patient Request|1
6080757|NCT00618722|9688149|FG002|Overall Study|Patient Request|1
6080758|NCT00618722|9688150|FG003|Overall Study|Patient Request|1
6080759|NCT00618722|9688147|FG000|Overall Study|Inability to Complete Study Procedure|0
6080760|NCT00618722|9688148|FG001|Overall Study|Inability to Complete Study Procedure|1
6080761|NCT00618722|9688149|FG002|Overall Study|Inability to Complete Study Procedure|0
6157731|NCT01160289|9798192|FG003|Screening, Washout, and Lead-In Period|Withdrawal by Subject|0
6157732|NCT01160289|9798193|FG004|Screening, Washout, and Lead-In Period|Withdrawal by Subject|0
6157733|NCT01160289|9798194|FG005|Screening, Washout, and Lead-In Period|Withdrawal by Subject|0
6157734|NCT01160289|9798189|FG000|Post-Randomization Period|Adverse Event|0
6157735|NCT01160289|9798190|FG001|Post-Randomization Period|Adverse Event|4
6157736|NCT01160289|9798191|FG002|Post-Randomization Period|Adverse Event|4
6157737|NCT01160289|9798192|FG003|Post-Randomization Period|Adverse Event|2
6157738|NCT01160289|9798193|FG004|Post-Randomization Period|Adverse Event|0
6157739|NCT01160289|9798194|FG005|Post-Randomization Period|Adverse Event|0
6157740|NCT01160289|9798189|FG000|Post-Randomization Period|Death|0
6157741|NCT01160289|9798190|FG001|Post-Randomization Period|Death|0
6157742|NCT01160289|9798191|FG002|Post-Randomization Period|Death|0
6157743|NCT01160289|9798192|FG003|Post-Randomization Period|Death|1
6157744|NCT01160289|9798193|FG004|Post-Randomization Period|Death|0
6157745|NCT01160289|9798194|FG005|Post-Randomization Period|Death|0
6157746|NCT01160289|9798189|FG000|Post-Randomization Period|Lack of Efficacy|0
6157747|NCT01160289|9798190|FG001|Post-Randomization Period|Lack of Efficacy|1
6157748|NCT01160289|9798191|FG002|Post-Randomization Period|Lack of Efficacy|0
6157749|NCT01160289|9798192|FG003|Post-Randomization Period|Lack of Efficacy|3
6157750|NCT01160289|9798193|FG004|Post-Randomization Period|Lack of Efficacy|0
6080762|NCT00618722|9688150|FG003|Overall Study|Inability to Complete Study Procedure|0
6080763|NCT00618722|9688147|FG000|Overall Study|Lost to Follow-up|2
6080764|NCT00618722|9688148|FG001|Overall Study|Lost to Follow-up|0
6080765|NCT00618722|9688149|FG002|Overall Study|Lost to Follow-up|0
6080766|NCT00618722|9688150|FG003|Overall Study|Lost to Follow-up|2
6080767|NCT00618722|9688147|FG000|Overall Study|Miscellaneous Reasons|0
6080768|NCT00618722|9688148|FG001|Overall Study|Miscellaneous Reasons|0
6080769|NCT00618722|9688149|FG002|Overall Study|Miscellaneous Reasons|1
6080770|NCT00618722|9688150|FG003|Overall Study|Miscellaneous Reasons|1
6080771|NCT00618748|9688163|FG000|Overall Study|Adverse Event|4
6080772|NCT00618748|9688164|FG001|Overall Study|Adverse Event|3
6080773|NCT00618748|9688165|FG002|Overall Study|Adverse Event|8
6080774|NCT00618748|9688163|FG000|Overall Study|Physician Decision|3
6080775|NCT00618748|9688164|FG001|Overall Study|Physician Decision|1
6080776|NCT00618748|9688165|FG002|Overall Study|Physician Decision|1
6080777|NCT00618748|9688163|FG000|Overall Study|Withdrawal by Subject|4
6080778|NCT00618748|9688164|FG001|Overall Study|Withdrawal by Subject|1
6080779|NCT00618748|9688165|FG002|Overall Study|Withdrawal by Subject|5
6080780|NCT00618774|9688175|FG000|Overall Study|Adverse Event|5
6157751|NCT01160289|9798194|FG005|Post-Randomization Period|Lack of Efficacy|0
6157752|NCT01160289|9798189|FG000|Post-Randomization Period|Lost to Follow-up|0
6080781|NCT00618774|9688176|FG001|Overall Study|Adverse Event|3
6080782|NCT00618774|9688175|FG000|Overall Study|Withdrawal by Subject|1
6080783|NCT00618774|9688176|FG001|Overall Study|Withdrawal by Subject|0
6080784|NCT00618787|9688184|FG000|Overall Study|Adverse Event|0
6042745|NCT00384930|9641204|FG004|Overall Study|Entry Criteria Not Met|4
6157753|NCT01160289|9798190|FG001|Post-Randomization Period|Lost to Follow-up|3
6157754|NCT01160289|9798191|FG002|Post-Randomization Period|Lost to Follow-up|2
6157755|NCT01160289|9798192|FG003|Post-Randomization Period|Lost to Follow-up|5
6157756|NCT01160289|9798193|FG004|Post-Randomization Period|Lost to Follow-up|3
6157757|NCT01160289|9798194|FG005|Post-Randomization Period|Lost to Follow-up|4
6157758|NCT01160289|9798189|FG000|Post-Randomization Period|Physician Decision|0
6157759|NCT01160289|9798190|FG001|Post-Randomization Period|Physician Decision|0
6157760|NCT01160289|9798191|FG002|Post-Randomization Period|Physician Decision|1
6157761|NCT01160289|9798192|FG003|Post-Randomization Period|Physician Decision|0
6157762|NCT01160289|9798193|FG004|Post-Randomization Period|Physician Decision|0
6157763|NCT01160289|9798194|FG005|Post-Randomization Period|Physician Decision|0
6157764|NCT01160289|9798189|FG000|Post-Randomization Period|Protocol Violation|0
6157765|NCT01160289|9798190|FG001|Post-Randomization Period|Protocol Violation|4
6157766|NCT01160289|9798191|FG002|Post-Randomization Period|Protocol Violation|2
6157767|NCT01160289|9798192|FG003|Post-Randomization Period|Protocol Violation|0
6157768|NCT01160289|9798193|FG004|Post-Randomization Period|Protocol Violation|1
6042746|NCT00384930|9641200|FG000|Overall Study|Lack of Efficacy|1
6042747|NCT00384930|9641201|FG001|Overall Study|Lack of Efficacy|1
6157769|NCT01160289|9798194|FG005|Post-Randomization Period|Protocol Violation|3
6042748|NCT00384930|9641202|FG002|Overall Study|Lack of Efficacy|2
6042749|NCT00384930|9641203|FG003|Overall Study|Lack of Efficacy|1
6042750|NCT00384930|9641204|FG004|Overall Study|Lack of Efficacy|2
6042751|NCT00384930|9641200|FG000|Overall Study|Lost to Follow-up|5
6080785|NCT00618787|9688185|FG001|Overall Study|Adverse Event|1
6080786|NCT00618787|9688184|FG000|Overall Study|Withdrawal by Subject|2
6080787|NCT00618787|9688185|FG001|Overall Study|Withdrawal by Subject|1
6080788|NCT00618787|9688184|FG000|Overall Study|Lost to Follow-up|1
6080789|NCT00618787|9688185|FG001|Overall Study|Lost to Follow-up|0
6080790|NCT00618813|9688191|FG000|Overall Study|Lack of Efficacy|1
6080791|NCT00618813|9688191|FG000|Overall Study|Physician Decision|2
6080792|NCT00618813|9688191|FG000|Overall Study|Withdrawal by Subject|1
6080793|NCT00618826|9688195|FG000|Overall Study|Adverse Event|1
6080794|NCT00618956|9688222|FG000|Overall Study|Adverse Event|10
6080795|NCT00618956|9688223|FG001|Overall Study|Adverse Event|34
6080796|NCT00618956|9688222|FG000|Overall Study|Lack of Efficacy|2
6080797|NCT00618956|9688223|FG001|Overall Study|Lack of Efficacy|1
6080798|NCT00618956|9688222|FG000|Overall Study|Withdrawal by Subject|5
6080799|NCT00618956|9688223|FG001|Overall Study|Withdrawal by Subject|7
6080800|NCT00618956|9688222|FG000|Overall Study|Lost to Follow-up|4
6080801|NCT00618956|9688223|FG001|Overall Study|Lost to Follow-up|5
6080802|NCT00618956|9688222|FG000|Overall Study|Protocol Violation|2
6080803|NCT00618956|9688223|FG001|Overall Study|Protocol Violation|2
6080804|NCT00618956|9688222|FG000|Overall Study|did not meet criteria, non-compliance|2
6080805|NCT00618956|9688223|FG001|Overall Study|did not meet criteria, non-compliance|1
6080806|NCT00618982|9688235|FG000|Overall Study|Adverse Event|23
6080807|NCT00618982|9688235|FG000|Overall Study|Withdrawal by Subject|1
6080808|NCT00618982|9688235|FG000|Overall Study|Protocol Violation|1
6080809|NCT00618982|9688235|FG000|Overall Study|ongoing, still treated with study med.|25
6080810|NCT00618995|9688242|FG000|Period 1|Adverse Event|0
6080811|NCT00618995|9688243|FG001|Period 1|Adverse Event|0
6080812|NCT00618995|9688244|FG002|Period 1|Adverse Event|1
6080813|NCT00618995|9688245|FG003|Period 1|Adverse Event|0
6080814|NCT00618995|9688242|FG000|Period 1|Protocol Violation|0
6080815|NCT00618995|9688243|FG001|Period 1|Protocol Violation|1
6080816|NCT00618995|9688244|FG002|Period 1|Protocol Violation|1
6080817|NCT00618995|9688245|FG003|Period 1|Protocol Violation|0
6080818|NCT00618995|9688242|FG000|Period 2|Protocol Violation|0
6042752|NCT00384930|9641201|FG001|Overall Study|Lost to Follow-up|3
6042753|NCT00384930|9641202|FG002|Overall Study|Lost to Follow-up|0
6042754|NCT00384930|9641203|FG003|Overall Study|Lost to Follow-up|4
6042755|NCT00384930|9641204|FG004|Overall Study|Lost to Follow-up|6
6042756|NCT00384930|9641200|FG000|Overall Study|Physician Decision|0
6157770|NCT01160289|9798189|FG000|Post-Randomization Period|Withdrawal by Subject|0
6080819|NCT00618995|9688243|FG001|Period 2|Protocol Violation|0
6080820|NCT00618995|9688244|FG002|Period 2|Protocol Violation|1
6080821|NCT00618995|9688245|FG003|Period 2|Protocol Violation|0
6080822|NCT00618995|9688242|FG000|Period 4|Adverse Event|1
6080823|NCT00618995|9688243|FG001|Period 4|Adverse Event|0
6080824|NCT00618995|9688244|FG002|Period 4|Adverse Event|0
6080825|NCT00618995|9688245|FG003|Period 4|Adverse Event|0
6080826|NCT00619099|9688273|FG000|Overall Study|Progressive Disease|7
6080827|NCT00619099|9688274|FG001|Overall Study|Progressive Disease|5
6080828|NCT00619099|9688273|FG000|Overall Study|Allogeneic Bone Marrow Transplantation|2
6157771|NCT01160289|9798190|FG001|Post-Randomization Period|Withdrawal by Subject|5
6157772|NCT01160289|9798191|FG002|Post-Randomization Period|Withdrawal by Subject|13
6042757|NCT00384930|9641201|FG001|Overall Study|Physician Decision|1
6042758|NCT00384930|9641202|FG002|Overall Study|Physician Decision|1
6042759|NCT00384930|9641203|FG003|Overall Study|Physician Decision|0
6042760|NCT00384930|9641204|FG004|Overall Study|Physician Decision|1
6042761|NCT00384930|9641200|FG000|Overall Study|Protocol Violation|1
6042762|NCT00384930|9641201|FG001|Overall Study|Protocol Violation|0
6042763|NCT00384930|9641202|FG002|Overall Study|Protocol Violation|1
6042764|NCT00384930|9641203|FG003|Overall Study|Protocol Violation|6
6042765|NCT00384930|9641204|FG004|Overall Study|Protocol Violation|4
6042766|NCT00384930|9641200|FG000|Overall Study|Sponsor Decision|3
6042767|NCT00384930|9641201|FG001|Overall Study|Sponsor Decision|4
6042768|NCT00384930|9641202|FG002|Overall Study|Sponsor Decision|0
6042769|NCT00384930|9641203|FG003|Overall Study|Sponsor Decision|5
6042770|NCT00384930|9641204|FG004|Overall Study|Sponsor Decision|0
6042771|NCT00384930|9641200|FG000|Overall Study|Withdrawal by Subject|9
6042772|NCT00384930|9641201|FG001|Overall Study|Withdrawal by Subject|7
6042773|NCT00384930|9641202|FG002|Overall Study|Withdrawal by Subject|7
6042774|NCT00384930|9641203|FG003|Overall Study|Withdrawal by Subject|6
6042775|NCT00384930|9641204|FG004|Overall Study|Withdrawal by Subject|16
6042776|NCT00384930|9641200|FG000|Overall Study|Didn't Receive Double-Blind Study Drug|1
6042777|NCT00384930|9641201|FG001|Overall Study|Didn't Receive Double-Blind Study Drug|1
6042778|NCT00384930|9641202|FG002|Overall Study|Didn't Receive Double-Blind Study Drug|0
6080829|NCT00619099|9688274|FG001|Overall Study|Allogeneic Bone Marrow Transplantation|1
6080830|NCT00619099|9688273|FG000|Overall Study|Adverse Event|4
6080831|NCT00619099|9688274|FG001|Overall Study|Adverse Event|3
6080832|NCT00619099|9688273|FG000|Overall Study|Emergence of Clinically Significant Lab|1
6080833|NCT00619099|9688274|FG001|Overall Study|Emergence of Clinically Significant Lab|2
6042779|NCT00384930|9641203|FG003|Overall Study|Didn't Receive Double-Blind Study Drug|0
6042780|NCT00384930|9641204|FG004|Overall Study|Didn't Receive Double-Blind Study Drug|0
6042781|NCT00384956|9641219|FG000|Overall Study|Ineligible (acute myeloid leukemia)|3
6042782|NCT00385203|9641244|FG000|Overall Study|Adverse Event|5
6042783|NCT00385203|9641245|FG001|Overall Study|Adverse Event|4
6042784|NCT00385203|9641244|FG000|Overall Study|Death|1
6042785|NCT00385203|9641245|FG001|Overall Study|Death|0
6042786|NCT00385203|9641244|FG000|Overall Study|Condition under investigation worsened|18
6042787|NCT00385203|9641245|FG001|Overall Study|Condition under investigation worsened|3
6042788|NCT00385203|9641244|FG000|Overall Study|Incorrect enrollment|2
6042789|NCT00385203|9641245|FG001|Overall Study|Incorrect enrollment|0
6042790|NCT00385255|9641261|FG000|Overall Study|Serious Adverse Event|1
6042791|NCT00385255|9641262|FG001|Overall Study|Serious Adverse Event|2
6042792|NCT00385255|9641261|FG000|Overall Study|Protocol Violation|0
6042793|NCT00385255|9641262|FG001|Overall Study|Protocol Violation|4
6042794|NCT00385255|9641261|FG000|Overall Study|Withdrawal by Subject|0
6080834|NCT00619099|9688273|FG000|Overall Study|Withdrawal by Subject|10
6042795|NCT00385255|9641262|FG001|Overall Study|Withdrawal by Subject|8
6157773|NCT01160289|9798192|FG003|Post-Randomization Period|Withdrawal by Subject|8
6157774|NCT01160289|9798193|FG004|Post-Randomization Period|Withdrawal by Subject|5
6080835|NCT00619099|9688274|FG001|Overall Study|Withdrawal by Subject|2
6080836|NCT00619099|9688273|FG000|Overall Study|Physician Decision|9
6080837|NCT00619099|9688274|FG001|Overall Study|Physician Decision|6
6080838|NCT00619112|9688282|FG000|Overall Study|Adverse Event|1
6080839|NCT00619112|9688283|FG001|Overall Study|Adverse Event|2
6080840|NCT00619177|9688292|FG000|Overall Study|Adverse Event|18
6080841|NCT00619177|9688292|FG000|Overall Study|Lost to Follow-up|2
6080842|NCT00619177|9688292|FG000|Overall Study|Lack of Efficacy|1
6087670|NCT00669942|9698119|FG003|Parts 2 and 3|Adverse Event|0
6157775|NCT01160289|9798194|FG005|Post-Randomization Period|Withdrawal by Subject|7
6157776|NCT01160289|9798189|FG000|Post-Randomization Period|Entry Criteria Not Met|0
6157777|NCT01160289|9798190|FG001|Post-Randomization Period|Entry Criteria Not Met|2
6157778|NCT01160289|9798191|FG002|Post-Randomization Period|Entry Criteria Not Met|2
6042796|NCT00385255|9641261|FG000|Overall Study|Migrated/moved from study area|0
6157779|NCT01160289|9798192|FG003|Post-Randomization Period|Entry Criteria Not Met|2
6080843|NCT00619177|9688292|FG000|Overall Study|Missing termination information|481
6080844|NCT00619177|9688292|FG000|Overall Study|Not specified reasons|6
6087671|NCT00669942|9698120|FG004|Parts 2 and 3|Adverse Event|0
6087672|NCT00669942|9698121|FG005|Parts 2 and 3|Adverse Event|0
6087673|NCT00669942|9698122|FG006|Parts 2 and 3|Adverse Event|0
6087674|NCT00669942|9698123|FG007|Parts 2 and 3|Adverse Event|2
6087675|NCT00669942|9698124|FG008|Parts 2 and 3|Adverse Event|1
6087676|NCT00669942|9698125|FG009|Parts 2 and 3|Adverse Event|0
6087677|NCT00669942|9698126|FG010|Parts 2 and 3|Adverse Event|0
6087678|NCT00669942|9698127|FG011|Parts 2 and 3|Adverse Event|0
6087679|NCT00669942|9698116|FG000|Parts 2 and 3|Withdrawal by Subject|0
6087680|NCT00669942|9698117|FG001|Parts 2 and 3|Withdrawal by Subject|0
6087681|NCT00669942|9698118|FG002|Parts 2 and 3|Withdrawal by Subject|0
6087682|NCT00669942|9698119|FG003|Parts 2 and 3|Withdrawal by Subject|0
6087683|NCT00669942|9698120|FG004|Parts 2 and 3|Withdrawal by Subject|0
6087684|NCT00669942|9698121|FG005|Parts 2 and 3|Withdrawal by Subject|1
6087685|NCT00669942|9698122|FG006|Parts 2 and 3|Withdrawal by Subject|0
6087686|NCT00669942|9698123|FG007|Parts 2 and 3|Withdrawal by Subject|0
6087687|NCT00669942|9698124|FG008|Parts 2 and 3|Withdrawal by Subject|2
6087688|NCT00669942|9698125|FG009|Parts 2 and 3|Withdrawal by Subject|0
6087689|NCT00669942|9698126|FG010|Parts 2 and 3|Withdrawal by Subject|0
6087690|NCT00669942|9698127|FG011|Parts 2 and 3|Withdrawal by Subject|0
6087691|NCT00669942|9698116|FG000|Parts 2 and 3|Protocol Violation|0
6087692|NCT00669942|9698117|FG001|Parts 2 and 3|Protocol Violation|0
6087693|NCT00669942|9698118|FG002|Parts 2 and 3|Protocol Violation|0
6087694|NCT00669942|9698119|FG003|Parts 2 and 3|Protocol Violation|0
6087695|NCT00669942|9698120|FG004|Parts 2 and 3|Protocol Violation|0
6087696|NCT00669942|9698121|FG005|Parts 2 and 3|Protocol Violation|1
6087697|NCT00669942|9698122|FG006|Parts 2 and 3|Protocol Violation|0
6087698|NCT00669942|9698123|FG007|Parts 2 and 3|Protocol Violation|0
6087699|NCT00669942|9698124|FG008|Parts 2 and 3|Protocol Violation|0
6087700|NCT00669942|9698125|FG009|Parts 2 and 3|Protocol Violation|0
6087701|NCT00669942|9698126|FG010|Parts 2 and 3|Protocol Violation|0
6087702|NCT00669942|9698127|FG011|Parts 2 and 3|Protocol Violation|0
6087703|NCT00669955|9698152|FG000|Overall Study|Adverse Event|3
6087704|NCT00669955|9698153|FG001|Overall Study|Adverse Event|5
6087705|NCT00669955|9698152|FG000|Overall Study|Death|0
6087706|NCT00669955|9698153|FG001|Overall Study|Death|1
6087707|NCT00669955|9698152|FG000|Overall Study|Withdrawal by Subject|2
6157780|NCT01160289|9798193|FG004|Post-Randomization Period|Entry Criteria Not Met|0
6087708|NCT00669955|9698153|FG001|Overall Study|Withdrawal by Subject|3
6087709|NCT00669955|9698152|FG000|Overall Study|Lost to Follow-up|5
6087710|NCT00669955|9698153|FG001|Overall Study|Lost to Follow-up|7
6087711|NCT00669955|9698152|FG000|Overall Study|Protocol Violation|2
6087712|NCT00669955|9698153|FG001|Overall Study|Protocol Violation|7
6087713|NCT00669955|9698152|FG000|Overall Study|Investigator Sponsor Judgement|0
6087714|NCT00669955|9698153|FG001|Overall Study|Investigator Sponsor Judgement|1
6080845|NCT00619229|9688307|FG000|Overall Study|Withdrawal by Subject|1
6080846|NCT00619229|9688308|FG001|Overall Study|Withdrawal by Subject|1
6080847|NCT00619229|9688307|FG000|Overall Study|Lost to Follow-up|1
6080848|NCT00619229|9688308|FG001|Overall Study|Lost to Follow-up|0
6080849|NCT00619229|9688307|FG000|Overall Study|Termination of the Study by the Sponsor|1
6080850|NCT00619229|9688308|FG001|Overall Study|Termination of the Study by the Sponsor|1
6080851|NCT00619229|9688307|FG000|Overall Study|Investigator planned Cataract Operation|1
6080852|NCT00619229|9688308|FG001|Overall Study|Investigator planned Cataract Operation|0
6080853|NCT00619307|9688325|FG000|Overall Study|Adverse Event|0
6080854|NCT00619307|9688326|FG001|Overall Study|Adverse Event|1
6080855|NCT00619307|9688325|FG000|Overall Study|Lost to Follow-up|0
6080856|NCT00619307|9688326|FG001|Overall Study|Lost to Follow-up|1
6080857|NCT00619307|9688325|FG000|Overall Study|Protocol Violation|3
6080858|NCT00619307|9688326|FG001|Overall Study|Protocol Violation|0
6080859|NCT00619307|9688325|FG000|Overall Study|Withdrew consent|1
6080860|NCT00619307|9688326|FG001|Overall Study|Withdrew consent|0
6080861|NCT00619307|9688325|FG000|Overall Study|Severe migraine|0
6080862|NCT00619307|9688326|FG001|Overall Study|Severe migraine|1
6080863|NCT00619307|9688325|FG000|Overall Study|MS attack plus steroids|0
6080864|NCT00619307|9688326|FG001|Overall Study|MS attack plus steroids|1
6080865|NCT00619359|9688334|FG000|Overall Study|Adverse Event|32
6080866|NCT00619359|9688335|FG001|Overall Study|Adverse Event|36
6080867|NCT00619359|9688334|FG000|Overall Study|Lost to Follow-up|12
6080868|NCT00619359|9688335|FG001|Overall Study|Lost to Follow-up|16
6080869|NCT00619359|9688334|FG000|Overall Study|Physician Decision|0
6080870|NCT00619359|9688335|FG001|Overall Study|Physician Decision|7
6080871|NCT00619359|9688334|FG000|Overall Study|Protocol Violation|1
6157781|NCT01160289|9798194|FG005|Post-Randomization Period|Entry Criteria Not Met|0
6157782|NCT01160289|9798189|FG000|Post-Randomization Period|Sponsor Decision|0
6157783|NCT01160289|9798190|FG001|Post-Randomization Period|Sponsor Decision|1
6157784|NCT01160289|9798191|FG002|Post-Randomization Period|Sponsor Decision|0
6157785|NCT01160289|9798192|FG003|Post-Randomization Period|Sponsor Decision|0
6080872|NCT00619359|9688335|FG001|Overall Study|Protocol Violation|1
6080873|NCT00619359|9688334|FG000|Overall Study|Withdrawal by Subject|19
6080874|NCT00619359|9688335|FG001|Overall Study|Withdrawal by Subject|20
6080875|NCT00619359|9688334|FG000|Overall Study|Progressive Disease|3
6080876|NCT00619359|9688335|FG001|Overall Study|Progressive Disease|1
6080877|NCT00619385|9688344|FG000|Overall Study|Adverse Event|0
6080878|NCT00619385|9688345|FG001|Overall Study|Adverse Event|0
6080879|NCT00619385|9688346|FG002|Overall Study|Adverse Event|3
6080880|NCT00619385|9688344|FG000|Overall Study|Other|1
6080881|NCT00619385|9688345|FG001|Overall Study|Other|2
6080882|NCT00619385|9688346|FG002|Overall Study|Other|1
6080883|NCT00619476|9688361|FG000|Overall Study|Adverse Event|12
6157786|NCT01160289|9798193|FG004|Post-Randomization Period|Sponsor Decision|0
6157787|NCT01160289|9798194|FG005|Post-Randomization Period|Sponsor Decision|0
6157788|NCT01160354|9798210|FG000|Overall Study|Death|0
6157789|NCT01160354|9798211|FG001|Overall Study|Death|1
6157790|NCT01160354|9798212|FG002|Overall Study|Death|1
6157791|NCT01160484|9798242|FG000|Overall Study|Lack of Efficacy|9
6080884|NCT00619476|9688362|FG001|Overall Study|Adverse Event|6
6080885|NCT00619476|9688363|FG002|Overall Study|Adverse Event|12
6080886|NCT00619476|9688364|FG003|Overall Study|Adverse Event|16
6080887|NCT00619476|9688361|FG000|Overall Study|Lack of Efficacy|6
6080888|NCT00619476|9688362|FG001|Overall Study|Lack of Efficacy|1
6080889|NCT00619476|9688363|FG002|Overall Study|Lack of Efficacy|1
6080890|NCT00619476|9688364|FG003|Overall Study|Lack of Efficacy|4
6080891|NCT00619476|9688361|FG000|Overall Study|Protocol Violation|5
6080892|NCT00619476|9688362|FG001|Overall Study|Protocol Violation|4
6080893|NCT00619476|9688363|FG002|Overall Study|Protocol Violation|4
6080894|NCT00619476|9688364|FG003|Overall Study|Protocol Violation|9
6080895|NCT00619476|9688361|FG000|Overall Study|Lost to Follow-up|1
6080896|NCT00619476|9688362|FG001|Overall Study|Lost to Follow-up|2
6080897|NCT00619476|9688363|FG002|Overall Study|Lost to Follow-up|0
6157792|NCT01160484|9798242|FG000|Overall Study|Adverse Event|6
6157793|NCT01160484|9798242|FG000|Overall Study|Withdrawal by Subject|2
6157794|NCT01160484|9798242|FG000|Overall Study|inclusion/exclusion criteria failure|1
6157795|NCT01160614|9798248|FG000|Overall Study|Withdrawal by Subject|0
6157796|NCT01160614|9798249|FG001|Overall Study|Withdrawal by Subject|2
6157797|NCT01160640|9798275|FG000|Overall Study|Physician Decision|3
6157798|NCT01160640|9798276|FG001|Overall Study|Physician Decision|3
6157799|NCT01160640|9798275|FG000|Overall Study|Incarceration|1
6157800|NCT01160640|9798276|FG001|Overall Study|Incarceration|0
6157801|NCT01160640|9798275|FG000|Overall Study|Withdrawal by Subject|0
6157802|NCT01160640|9798276|FG001|Overall Study|Withdrawal by Subject|3
6157803|NCT01160744|9798288|FG000|Overall Study|Withdrawal by Subject|11
6157804|NCT01160744|9798289|FG001|Overall Study|Withdrawal by Subject|5
6157805|NCT01160744|9798290|FG002|Overall Study|Withdrawal by Subject|6
6157806|NCT01160744|9798291|FG003|Overall Study|Withdrawal by Subject|4
6157807|NCT01160744|9798288|FG000|Overall Study|Not meet inclusion/exclusion criteria|0
6157808|NCT01160744|9798289|FG001|Overall Study|Not meet inclusion/exclusion criteria|0
6157809|NCT01160744|9798290|FG002|Overall Study|Not meet inclusion/exclusion criteria|1
6157810|NCT01160744|9798291|FG003|Overall Study|Not meet inclusion/exclusion criteria|0
6080898|NCT00619476|9688364|FG003|Overall Study|Lost to Follow-up|1
6080899|NCT00619476|9688361|FG000|Overall Study|Investigator Discretion|2
6080900|NCT00619476|9688362|FG001|Overall Study|Investigator Discretion|2
6080901|NCT00619476|9688363|FG002|Overall Study|Investigator Discretion|2
6080902|NCT00619476|9688364|FG003|Overall Study|Investigator Discretion|0
6080903|NCT00619476|9688361|FG000|Overall Study|Withdrawal by Subject|5
6080904|NCT00619476|9688362|FG001|Overall Study|Withdrawal by Subject|7
6080905|NCT00619476|9688363|FG002|Overall Study|Withdrawal by Subject|5
6080906|NCT00619476|9688364|FG003|Overall Study|Withdrawal by Subject|4
6080907|NCT00619489|9688376|FG000|Overall Study|Adverse Event|0
6080908|NCT00619489|9688377|FG001|Overall Study|Adverse Event|7
6080909|NCT00619489|9688376|FG000|Overall Study|Withdrawal by Subject|1
6080910|NCT00619489|9688377|FG001|Overall Study|Withdrawal by Subject|1
6080911|NCT00619489|9688376|FG000|Overall Study|Lack of Efficacy|0
6157811|NCT01160770|9798303|FG000|Overall Study|Adverse Event|10
6157812|NCT01160770|9798303|FG000|Overall Study|Protocol Violation|2
6157813|NCT01160770|9798303|FG000|Overall Study|Subject/parent/caregiver request|33
6157814|NCT01160770|9798303|FG000|Overall Study|Physician Decision|1
6157815|NCT01160770|9798303|FG000|Overall Study|Lost to Follow-up|7
6157816|NCT01160770|9798303|FG000|Overall Study|Study termination or sponsor request|1
6157817|NCT01160770|9798303|FG000|Overall Study|Death|9
6157818|NCT01160770|9798303|FG000|Overall Study|Lack of Efficacy|15
6157819|NCT01160770|9798303|FG000|Overall Study|Other Reasons|1
6157820|NCT01160822|9798314|FG000|Overall Study|Adverse Event|0
6157821|NCT01160822|9798315|FG001|Overall Study|Adverse Event|0
6080912|NCT00619489|9688377|FG001|Overall Study|Lack of Efficacy|11
6080913|NCT00619489|9688376|FG000|Overall Study|Rolled over to Study C13008 (NCT00790933|22
6080914|NCT00619489|9688377|FG001|Overall Study|Rolled over to Study C13008 (NCT00790933|15
6080915|NCT00619502|9688385|FG000|Overall Study|Lost to Follow-up|8
6080916|NCT00619502|9688386|FG001|Overall Study|Lost to Follow-up|10
6080917|NCT00619619|9688402|FG000|Overall Study|Physician Decision|0
6080918|NCT00619619|9688403|FG001|Overall Study|Physician Decision|0
6080919|NCT00619619|9688404|FG002|Overall Study|Physician Decision|1
6080920|NCT00619619|9688405|FG003|Overall Study|Physician Decision|0
6157822|NCT01160822|9798316|FG002|Overall Study|Adverse Event|0
6157823|NCT01160822|9798317|FG003|Overall Study|Adverse Event|0
6157824|NCT01160822|9798318|FG004|Overall Study|Adverse Event|1
6157825|NCT01160822|9798319|FG005|Overall Study|Adverse Event|2
6157826|NCT01160822|9798320|FG006|Overall Study|Adverse Event|5
6157827|NCT01160822|9798314|FG000|Overall Study|Unsatisfactory therapeutic effect|0
6157828|NCT01160822|9798315|FG001|Overall Study|Unsatisfactory therapeutic effect|0
6157829|NCT01160822|9798316|FG002|Overall Study|Unsatisfactory therapeutic effect|0
6157830|NCT01160822|9798317|FG003|Overall Study|Unsatisfactory therapeutic effect|0
6157831|NCT01160822|9798318|FG004|Overall Study|Unsatisfactory therapeutic effect|4
6157832|NCT01160822|9798319|FG005|Overall Study|Unsatisfactory therapeutic effect|5
6157833|NCT01160822|9798320|FG006|Overall Study|Unsatisfactory therapeutic effect|3
6157834|NCT01160822|9798314|FG000|Overall Study|Withdrawal by Subject|0
6157835|NCT01160822|9798315|FG001|Overall Study|Withdrawal by Subject|0
6157836|NCT01160822|9798316|FG002|Overall Study|Withdrawal by Subject|0
6157837|NCT01160822|9798317|FG003|Overall Study|Withdrawal by Subject|0
6157838|NCT01160822|9798318|FG004|Overall Study|Withdrawal by Subject|0
6157839|NCT01160822|9798319|FG005|Overall Study|Withdrawal by Subject|0
6157840|NCT01160822|9798320|FG006|Overall Study|Withdrawal by Subject|1
6157841|NCT01160822|9798314|FG000|Overall Study|Lost to Follow-up|0
6157842|NCT01160822|9798315|FG001|Overall Study|Lost to Follow-up|0
6157843|NCT01160822|9798316|FG002|Overall Study|Lost to Follow-up|0
6157844|NCT01160822|9798317|FG003|Overall Study|Lost to Follow-up|0
6157845|NCT01160822|9798318|FG004|Overall Study|Lost to Follow-up|1
6157846|NCT01160822|9798319|FG005|Overall Study|Lost to Follow-up|0
6157847|NCT01160822|9798320|FG006|Overall Study|Lost to Follow-up|0
6157848|NCT01160822|9798314|FG000|Overall Study|Administrative problems|0
6157849|NCT01160822|9798315|FG001|Overall Study|Administrative problems|0
6157850|NCT01160822|9798316|FG002|Overall Study|Administrative problems|0
6157851|NCT01160822|9798317|FG003|Overall Study|Administrative problems|0
6157852|NCT01160822|9798318|FG004|Overall Study|Administrative problems|1
6157853|NCT01160822|9798319|FG005|Overall Study|Administrative problems|0
6157854|NCT01160822|9798320|FG006|Overall Study|Administrative problems|0
6157855|NCT01160822|9798314|FG000|Overall Study|Protocol deviation|0
6157856|NCT01160822|9798315|FG001|Overall Study|Protocol deviation|0
6157857|NCT01160822|9798316|FG002|Overall Study|Protocol deviation|0
6157858|NCT01160822|9798317|FG003|Overall Study|Protocol deviation|0
6157859|NCT01160822|9798318|FG004|Overall Study|Protocol deviation|2
6157860|NCT01160822|9798319|FG005|Overall Study|Protocol deviation|0
6157861|NCT01160822|9798320|FG006|Overall Study|Protocol deviation|0
6157862|NCT01161043|9798350|FG000|Overall Study|Withdrawal by Subject|3
6157863|NCT01161173|9798375|FG000|Overall Study|Protocol Violation|13
6157864|NCT01161173|9798375|FG000|Overall Study|Lost to Follow-up|7
6157865|NCT01161173|9798375|FG000|Overall Study|Progressive Disease|82
6157866|NCT01161173|9798375|FG000|Overall Study|Withdrawal of Consent|5
6157867|NCT01161173|9798375|FG000|Overall Study|Unacceptable Toxicity|21
6157868|NCT01161173|9798375|FG000|Overall Study|Death|194
6157869|NCT01161173|9798375|FG000|Overall Study|End of Study|2
6157870|NCT01161173|9798375|FG000|Overall Study|Reasons Not Specified|23
6157871|NCT01161407|9798408|FG000|Overall Study|Protocol Violation|3
6157872|NCT01161407|9798409|FG001|Overall Study|Protocol Violation|1
6157873|NCT01161446|9798427|FG000|Overall Study|Lost to Follow-up|18
6157874|NCT01161446|9798428|FG001|Overall Study|Lost to Follow-up|14
6157875|NCT01161446|9798427|FG000|Overall Study|Withdrawal by Subject|0
6157876|NCT01161446|9798428|FG001|Overall Study|Withdrawal by Subject|1
6157877|NCT01161472|9798434|FG000|Washout Period (At Least 3 to 6 Days)|Withdrawal by Subject|1
6157878|NCT01161472|9798435|FG001|Washout Period (At Least 3 to 6 Days)|Withdrawal by Subject|0
6157879|NCT01161472|9798436|FG002|Washout Period (At Least 3 to 6 Days)|Withdrawal by Subject|0
6157880|NCT01161472|9798437|FG003|Washout Period (At Least 3 to 6 Days)|Withdrawal by Subject|0
6157881|NCT01161498|9798449|FG000|Overall Study|Disease Progression|0
6157882|NCT01161498|9798450|FG001|Overall Study|Disease Progression|1
6157883|NCT01161524|9798458|FG000|Core Study (23 Weeks)|Adverse Event|3
6157884|NCT01161524|9798459|FG001|Core Study (23 Weeks)|Adverse Event|0
6157885|NCT01161524|9798460|FG002|Core Study (23 Weeks)|Adverse Event|0
6157886|NCT01161524|9798458|FG000|Core Study (23 Weeks)|Other|1
6157887|NCT01161524|9798459|FG001|Core Study (23 Weeks)|Other|0
6157888|NCT01161524|9798460|FG002|Core Study (23 Weeks)|Other|0
6157889|NCT01161524|9798458|FG000|Core Study (23 Weeks)|Withdrawal of Consent|1
6157890|NCT01161524|9798459|FG001|Core Study (23 Weeks)|Withdrawal of Consent|1
6157891|NCT01161524|9798460|FG002|Core Study (23 Weeks)|Withdrawal of Consent|0
6157892|NCT01161524|9798458|FG000|Core Study (23 Weeks)|Lost to Follow-up|1
6157893|NCT01161524|9798459|FG001|Core Study (23 Weeks)|Lost to Follow-up|2
6157894|NCT01161524|9798460|FG002|Core Study (23 Weeks)|Lost to Follow-up|0
6157895|NCT01161524|9798458|FG000|Core Study (23 Weeks)|Subject Choice|3
6157896|NCT01161524|9798459|FG001|Core Study (23 Weeks)|Subject Choice|2
6157897|NCT01161524|9798460|FG002|Core Study (23 Weeks)|Subject Choice|0
6157898|NCT01161524|9798458|FG000|Extension Phase (Approximately 83 Weeks)|Adverse Event|0
6157899|NCT01161524|9798459|FG001|Extension Phase (Approximately 83 Weeks)|Adverse Event|0
6157900|NCT01161524|9798460|FG002|Extension Phase (Approximately 83 Weeks)|Adverse Event|8
6157901|NCT01161524|9798458|FG000|Extension Phase (Approximately 83 Weeks)|Other|0
6157902|NCT01161524|9798459|FG001|Extension Phase (Approximately 83 Weeks)|Other|0
6157903|NCT01161524|9798460|FG002|Extension Phase (Approximately 83 Weeks)|Other|6
6157904|NCT01161524|9798458|FG000|Extension Phase (Approximately 83 Weeks)|Lost to Follow-up|0
6157905|NCT01161524|9798459|FG001|Extension Phase (Approximately 83 Weeks)|Lost to Follow-up|0
6157906|NCT01161524|9798460|FG002|Extension Phase (Approximately 83 Weeks)|Lost to Follow-up|1
6157907|NCT01161524|9798458|FG000|Extension Phase (Approximately 83 Weeks)|Subject Choice|0
6157908|NCT01161524|9798459|FG001|Extension Phase (Approximately 83 Weeks)|Subject Choice|0
6157909|NCT01161524|9798460|FG002|Extension Phase (Approximately 83 Weeks)|Subject Choice|5
6157910|NCT01161524|9798458|FG000|Extension Phase (Approximately 83 Weeks)|Inadequate Therapeutic Effect|0
6157911|NCT01161524|9798459|FG001|Extension Phase (Approximately 83 Weeks)|Inadequate Therapeutic Effect|0
6157912|NCT01161524|9798460|FG002|Extension Phase (Approximately 83 Weeks)|Inadequate Therapeutic Effect|4
6157913|NCT01161537|9798469|FG000|Part B|Withdrawal by Subject|2
6157914|NCT01161628|9798487|FG000|Overall Study|Death|6
6157915|NCT01161628|9798487|FG000|Overall Study|Lack of Efficacy|2
6157916|NCT01162122|9798525|FG000|Overall Study|Withdrawal by Subject|52
6157917|NCT01162122|9798526|FG001|Overall Study|Withdrawal by Subject|43
6157918|NCT01162122|9798525|FG000|Overall Study|Lost to Follow-up|73
6157919|NCT01162122|9798526|FG001|Overall Study|Lost to Follow-up|91
6157920|NCT01162122|9798525|FG000|Overall Study|Adverse Event|3
6157921|NCT01162122|9798526|FG001|Overall Study|Adverse Event|2
6157922|NCT01162122|9798525|FG000|Overall Study|Death|51
6157923|NCT01162122|9798526|FG001|Overall Study|Death|46
6157924|NCT01162122|9798525|FG000|Overall Study|Protocol Violation|2
6157925|NCT01162122|9798526|FG001|Overall Study|Protocol Violation|2
6157926|NCT01162122|9798525|FG000|Overall Study|Inappropriate enrollment|5
6157927|NCT01162122|9798526|FG001|Overall Study|Inappropriate enrollment|4
6157928|NCT01162122|9798525|FG000|Overall Study|Administrative reason|1
6157929|NCT01162122|9798526|FG001|Overall Study|Administrative reason|1
6157930|NCT01162122|9798525|FG000|Overall Study|Unable to classify|3
6157931|NCT01162122|9798526|FG001|Overall Study|Unable to classify|7
6157932|NCT01162122|9798525|FG000|Overall Study|Missing primary reason|1
6157933|NCT01162122|9798526|FG001|Overall Study|Missing primary reason|0
6157934|NCT01162135|9798535|FG000|Overall Study|Withdrawal by Subject|1
6157935|NCT01162135|9798535|FG000|Overall Study|Severe back pain|1
6157936|NCT01162135|9798535|FG000|Overall Study|Ineligible|1
6157937|NCT01162239|9798543|FG000|Treatment Phase|Withdrawal by Subject|1
6157938|NCT01162239|9798544|FG001|Treatment Phase|Withdrawal by Subject|3
6157939|NCT01162239|9798545|FG002|Treatment Phase|Withdrawal by Subject|2
6157940|NCT01162239|9798546|FG003|Treatment Phase|Withdrawal by Subject|3
6157941|NCT01162239|9798543|FG000|Treatment Phase|Death|0
6157942|NCT01162239|9798544|FG001|Treatment Phase|Death|0
6157943|NCT01162239|9798545|FG002|Treatment Phase|Death|0
6157944|NCT01162239|9798546|FG003|Treatment Phase|Death|1
6157945|NCT01162239|9798543|FG000|Treatment Phase|Lost to Follow-up|5
6157946|NCT01162239|9798544|FG001|Treatment Phase|Lost to Follow-up|4
6157947|NCT01162239|9798545|FG002|Treatment Phase|Lost to Follow-up|2
6157948|NCT01162239|9798546|FG003|Treatment Phase|Lost to Follow-up|1
6157949|NCT01162239|9798543|FG000|Extended Follow-up|Lost to Follow-up|8
6157950|NCT01162239|9798544|FG001|Extended Follow-up|Lost to Follow-up|13
6157951|NCT01162239|9798545|FG002|Extended Follow-up|Lost to Follow-up|8
6157952|NCT01162239|9798546|FG003|Extended Follow-up|Lost to Follow-up|6
6157953|NCT01162343|9798566|FG000|Overall Study|Left ED prior to psychiatrist assessment|80
6157954|NCT01162343|9798566|FG000|Overall Study|Refused psychiatrist assessment|12
6157955|NCT01162421|9798572|FG000|Overall Study|Did not receive study drug|2
6157956|NCT01162421|9798573|FG001|Overall Study|Did not receive study drug|1
6157957|NCT01162421|9798572|FG000|Overall Study|Adverse Event|2
6157958|NCT01162421|9798573|FG001|Overall Study|Adverse Event|5
6157959|NCT01162421|9798572|FG000|Overall Study|Lost to Follow-up|0
6157960|NCT01162421|9798573|FG001|Overall Study|Lost to Follow-up|2
6157961|NCT01162421|9798572|FG000|Overall Study|Lack of Efficacy|2
6157962|NCT01162421|9798573|FG001|Overall Study|Lack of Efficacy|2
6157963|NCT01162421|9798572|FG000|Overall Study|Other|2
6157964|NCT01162421|9798573|FG001|Overall Study|Other|3
6157965|NCT01162473|9798581|FG000|Overall Study|Adverse Event|2
6157966|NCT01162473|9798582|FG001|Overall Study|Adverse Event|1
6157967|NCT01162473|9798581|FG000|Overall Study|Withdrawal by Subject|0
6157968|NCT01162473|9798582|FG001|Overall Study|Withdrawal by Subject|4
6157969|NCT01162486|9798593|FG000|Overall Study|low ANC|1
6157970|NCT01162486|9798594|FG001|Overall Study|low ANC|0
6157971|NCT01162486|9798595|FG002|Overall Study|low ANC|0
6157972|NCT01162486|9798596|FG003|Overall Study|low ANC|0
6157973|NCT01162486|9798597|FG004|Overall Study|low ANC|0
6157974|NCT01162486|9798593|FG000|Overall Study|vomited Rifampin/ gagged with midazolam|1
6157975|NCT01162486|9798594|FG001|Overall Study|vomited Rifampin/ gagged with midazolam|0
6157976|NCT01162486|9798595|FG002|Overall Study|vomited Rifampin/ gagged with midazolam|0
6157977|NCT01162486|9798596|FG003|Overall Study|vomited Rifampin/ gagged with midazolam|0
6157978|NCT01162486|9798597|FG004|Overall Study|vomited Rifampin/ gagged with midazolam|0
6157979|NCT01162486|9798593|FG000|Overall Study|elevated LFTs|0
6157980|NCT01162486|9798594|FG001|Overall Study|elevated LFTs|0
6157981|NCT01162486|9798595|FG002|Overall Study|elevated LFTs|1
6157982|NCT01162486|9798596|FG003|Overall Study|elevated LFTs|0
6157983|NCT01162486|9798597|FG004|Overall Study|elevated LFTs|0
6157984|NCT01162486|9798593|FG000|Overall Study|Pregnancy|0
6157985|NCT01162486|9798594|FG001|Overall Study|Pregnancy|0
6157986|NCT01162486|9798595|FG002|Overall Study|Pregnancy|0
6157987|NCT01162486|9798596|FG003|Overall Study|Pregnancy|1
6157988|NCT01162486|9798597|FG004|Overall Study|Pregnancy|0
6157989|NCT01162499|9798613|FG000|Intervention 1 (4 Hours)|Unable to establish IV access|0
6157990|NCT01162499|9798614|FG001|Intervention 1 (4 Hours)|Unable to establish IV access|1
6157991|NCT01162863|9798638|FG000|Overall Study|Lack of Efficacy|1
6157992|NCT01162863|9798639|FG001|Overall Study|Lack of Efficacy|0
6157993|NCT01162863|9798640|FG002|Overall Study|Lack of Efficacy|0
6157994|NCT01162863|9798638|FG000|Overall Study|Adverse Event|0
6157995|NCT01162863|9798639|FG001|Overall Study|Adverse Event|1
6157996|NCT01162863|9798640|FG002|Overall Study|Adverse Event|0
6157997|NCT01163032|9798651|FG000|Randomization Phase|Withdrawal by Subject|2
6157998|NCT01163032|9798652|FG001|Randomization Phase|Withdrawal by Subject|3
6157999|NCT01163032|9798653|FG002|Randomization Phase|Withdrawal by Subject|0
6158000|NCT01163032|9798651|FG000|Randomization Phase|Adverse Event|3
6158001|NCT01163032|9798652|FG001|Randomization Phase|Adverse Event|3
6158002|NCT01163032|9798653|FG002|Randomization Phase|Adverse Event|0
6158003|NCT01163032|9798651|FG000|Randomization Phase|Protocol Violation|0
6158004|NCT01163032|9798652|FG001|Randomization Phase|Protocol Violation|1
6158005|NCT01163032|9798653|FG002|Randomization Phase|Protocol Violation|0
6158006|NCT01163032|9798651|FG000|Randomization Phase|Various*|5
6158007|NCT01163032|9798652|FG001|Randomization Phase|Various*|4
6080921|NCT00619619|9688406|FG004|Overall Study|Physician Decision|0
6080922|NCT00619619|9688407|FG005|Overall Study|Physician Decision|0
6080923|NCT00619619|9688408|FG006|Overall Study|Physician Decision|0
6080924|NCT00619619|9688409|FG007|Overall Study|Physician Decision|0
6080925|NCT00619619|9688402|FG000|Overall Study|Protocol Violation|0
6158008|NCT01163032|9798653|FG002|Randomization Phase|Various*|0
6158009|NCT01163032|9798651|FG000|Randomization Phase|Unsatisfactory Therapeutic Effect|0
6158010|NCT01163032|9798652|FG001|Randomization Phase|Unsatisfactory Therapeutic Effect|1
6158011|NCT01163032|9798653|FG002|Randomization Phase|Unsatisfactory Therapeutic Effect|0
6158012|NCT01163032|9798651|FG000|Open Label Extension Phase|Adverse Event|0
6158013|NCT01163032|9798652|FG001|Open Label Extension Phase|Adverse Event|0
6158014|NCT01163032|9798653|FG002|Open Label Extension Phase|Adverse Event|3
6158015|NCT01163032|9798651|FG000|Open Label Extension Phase|Withdrawal by Subject|0
6158016|NCT01163032|9798652|FG001|Open Label Extension Phase|Withdrawal by Subject|0
6158017|NCT01163032|9798653|FG002|Open Label Extension Phase|Withdrawal by Subject|3
6158018|NCT01163032|9798651|FG000|Open Label Extension Phase|Protocol Violation|0
6158019|NCT01163032|9798652|FG001|Open Label Extension Phase|Protocol Violation|0
6158020|NCT01163032|9798653|FG002|Open Label Extension Phase|Protocol Violation|1
6158021|NCT01163032|9798651|FG000|Open Label Extension Phase|Study Termination|0
6158022|NCT01163032|9798652|FG001|Open Label Extension Phase|Study Termination|0
6158023|NCT01163032|9798653|FG002|Open Label Extension Phase|Study Termination|7
6080926|NCT00619619|9688403|FG001|Overall Study|Protocol Violation|0
6080927|NCT00619619|9688404|FG002|Overall Study|Protocol Violation|0
6080928|NCT00619619|9688405|FG003|Overall Study|Protocol Violation|1
6080929|NCT00619619|9688406|FG004|Overall Study|Protocol Violation|0
6080930|NCT00619619|9688407|FG005|Overall Study|Protocol Violation|0
6080931|NCT00619619|9688408|FG006|Overall Study|Protocol Violation|1
6080932|NCT00619619|9688409|FG007|Overall Study|Protocol Violation|1
6080933|NCT00619619|9688402|FG000|Overall Study|Adverse Event|0
6080934|NCT00619619|9688403|FG001|Overall Study|Adverse Event|0
6080935|NCT00619619|9688404|FG002|Overall Study|Adverse Event|0
6080936|NCT00619619|9688405|FG003|Overall Study|Adverse Event|0
6080937|NCT00619619|9688406|FG004|Overall Study|Adverse Event|2
6080938|NCT00619619|9688407|FG005|Overall Study|Adverse Event|0
6080939|NCT00619619|9688408|FG006|Overall Study|Adverse Event|0
6080940|NCT00619619|9688409|FG007|Overall Study|Adverse Event|2
6158024|NCT01163032|9798651|FG000|Open Label Extension Phase|Unsatisfactory Therapeutic Effect|0
6158025|NCT01163032|9798652|FG001|Open Label Extension Phase|Unsatisfactory Therapeutic Effect|0
6158026|NCT01163032|9798653|FG002|Open Label Extension Phase|Unsatisfactory Therapeutic Effect|2
6158027|NCT01163149|9798679|FG000|Extension Treatment Period|Withdrawal by Subject|2
6158028|NCT01163149|9798680|FG001|Extension Treatment Period|Withdrawal by Subject|0
6158029|NCT01163149|9798681|FG002|Extension Treatment Period|Withdrawal by Subject|1
6158030|NCT01163149|9798679|FG000|Extension Treatment Period|Adverse Event|0
6158031|NCT01163149|9798680|FG001|Extension Treatment Period|Adverse Event|1
6158032|NCT01163149|9798681|FG002|Extension Treatment Period|Adverse Event|0
6158033|NCT01163149|9798679|FG000|Extension Treatment Period|Noncompliance|0
6158034|NCT01163149|9798680|FG001|Extension Treatment Period|Noncompliance|0
6158035|NCT01163149|9798681|FG002|Extension Treatment Period|Noncompliance|1
6158036|NCT01163253|9798718|FG000|Overall Study|Withdrawn Due to Pregnancy|12
6158037|NCT01163253|9798719|FG001|Overall Study|Withdrawn Due to Pregnancy|2
6158038|NCT01163253|9798718|FG000|Overall Study|Study Terminated by Sponsor|978
6158039|NCT01163253|9798719|FG001|Overall Study|Study Terminated by Sponsor|349
6158040|NCT01163253|9798718|FG000|Overall Study|Protocol Violation|43
6158041|NCT01163253|9798719|FG001|Overall Study|Protocol Violation|12
6158042|NCT01163253|9798718|FG000|Overall Study|Withdrawal by Subject|199
6158043|NCT01163253|9798719|FG001|Overall Study|Withdrawal by Subject|50
6158044|NCT01163253|9798718|FG000|Overall Study|Medication Error|1
6158045|NCT01163253|9798719|FG001|Overall Study|Medication Error|0
6158046|NCT01163253|9798718|FG000|Overall Study|Lost to Follow-up|125
6158047|NCT01163253|9798719|FG001|Overall Study|Lost to Follow-up|23
6158048|NCT01163253|9798718|FG000|Overall Study|Insufficient Clinical Response|423
6158049|NCT01163253|9798719|FG001|Overall Study|Insufficient Clinical Response|29
6158050|NCT01163253|9798718|FG000|Overall Study|Adverse Event|300
6158051|NCT01163253|9798719|FG001|Overall Study|Adverse Event|78
6158052|NCT01163253|9798718|FG000|Overall Study|Death|17
6158053|NCT01163253|9798719|FG001|Overall Study|Death|5
6158054|NCT01163253|9798718|FG000|Overall Study|Ongoing|13
6158055|NCT01163253|9798719|FG001|Overall Study|Ongoing|4
6158056|NCT01163253|9798718|FG000|Overall Study|Other Unspecified|170
6158057|NCT01163253|9798719|FG001|Overall Study|Other Unspecified|34
6158058|NCT01163266|9798728|FG000|Overall Study|Pretreatment Event or Adverse Event|2
6158059|NCT01163266|9798729|FG001|Overall Study|Pretreatment Event or Adverse Event|9
6158060|NCT01163266|9798730|FG002|Overall Study|Pretreatment Event or Adverse Event|7
6158061|NCT01163266|9798728|FG000|Overall Study|Lack of Efficacy|1
6158062|NCT01163266|9798729|FG001|Overall Study|Lack of Efficacy|3
6158063|NCT01163266|9798730|FG002|Overall Study|Lack of Efficacy|1
6158064|NCT01163266|9798728|FG000|Overall Study|Noncompliance with Study Drug|0
6158065|NCT01163266|9798729|FG001|Overall Study|Noncompliance with Study Drug|2
6158066|NCT01163266|9798730|FG002|Overall Study|Noncompliance with Study Drug|0
6158067|NCT01163266|9798728|FG000|Overall Study|Protocol Deviations|2
6158068|NCT01163266|9798729|FG001|Overall Study|Protocol Deviations|2
6158069|NCT01163266|9798730|FG002|Overall Study|Protocol Deviations|5
6158070|NCT01163266|9798728|FG000|Overall Study|Withdrawal of Consent|5
6158071|NCT01163266|9798729|FG001|Overall Study|Withdrawal of Consent|7
6158072|NCT01163266|9798730|FG002|Overall Study|Withdrawal of Consent|3
6158073|NCT01163266|9798728|FG000|Overall Study|Lost to Follow-up|7
6158074|NCT01163266|9798729|FG001|Overall Study|Lost to Follow-up|7
6158075|NCT01163266|9798730|FG002|Overall Study|Lost to Follow-up|10
6324740|NCT02919267|10066582|FG003|Overall Study|Protocol Violation|4
6324741|NCT02919475|10066606|FG000|Overall Study|Adverse Event|3
6158076|NCT01163266|9798728|FG000|Overall Study|Other|1
6158077|NCT01163266|9798729|FG001|Overall Study|Other|1
6158078|NCT01163266|9798730|FG002|Overall Study|Other|2
6158079|NCT01163279|9798740|FG000|Overall Study|Withdrawal by Subject|2
6158080|NCT01163279|9798741|FG001|Overall Study|Withdrawal by Subject|0
6158081|NCT01163292|9798750|FG000|Overall Study|Lack of Efficacy|9
6158082|NCT01163292|9798751|FG001|Overall Study|Lack of Efficacy|0
6158083|NCT01163292|9798750|FG000|Overall Study|Adverse Event|6
6158084|NCT01163292|9798751|FG001|Overall Study|Adverse Event|0
6158085|NCT01163292|9798750|FG000|Overall Study|Initiation of biological therapy|0
6158086|NCT01163292|9798751|FG001|Overall Study|Initiation of biological therapy|15
6158087|NCT01163292|9798750|FG000|Overall Study|Sufficient response to adalimumab|8
6158088|NCT01163292|9798751|FG001|Overall Study|Sufficient response to adalimumab|0
6158089|NCT01163292|9798750|FG000|Overall Study|Refusal to receive adalimumab|7
6158090|NCT01163292|9798751|FG001|Overall Study|Refusal to receive adalimumab|0
6158091|NCT01163292|9798750|FG000|Overall Study|Economic reasons|6
6158092|NCT01163292|9798751|FG001|Overall Study|Economic reasons|0
6158093|NCT01163292|9798750|FG000|Overall Study|No further visits|5
6324742|NCT02919475|10066607|FG001|Overall Study|Adverse Event|3
6158094|NCT01163292|9798751|FG001|Overall Study|No further visits|7
6158095|NCT01163318|9798757|FG000|Overall Study|Off-Label Use of Adalimumab|8
6158096|NCT01163318|9798757|FG000|Overall Study|Did Not Continue Use of Adalimumab|26
6158097|NCT01163318|9798757|FG000|Overall Study|History/comorbidity of malignant tumor|3
6324743|NCT02919475|10066608|FG002|Overall Study|Adverse Event|3
6158098|NCT01163318|9798757|FG000|Overall Study|Participants Without Case Report Form|7
6158099|NCT01163318|9798757|FG000|Overall Study|Multiple Reasons Per Participant|224
6191770|NCT01425723|9848701|FG001|Overall Study|Withdrawal by Subject|4
6191771|NCT01425723|9848700|FG000|Overall Study|Lost to Follow-up|0
6191772|NCT01425723|9848701|FG001|Overall Study|Lost to Follow-up|3
6191773|NCT01425723|9848700|FG000|Overall Study|Physician Decision|2
6191774|NCT01425723|9848701|FG001|Overall Study|Physician Decision|0
6191775|NCT01425723|9848700|FG000|Overall Study|Other|1
6191776|NCT01425723|9848701|FG001|Overall Study|Other|10
6191777|NCT01425749|9848718|FG000|Overall Study|progression of melanoma|0
6191778|NCT01425749|9848719|FG001|Overall Study|progression of melanoma|1
6191779|NCT01425801|9848728|FG000|Period 1|Withdrawal by Subject|0
6191780|NCT01425801|9848729|FG001|Period 1|Withdrawal by Subject|0
6191781|NCT01425801|9848730|FG002|Period 1|Withdrawal by Subject|0
6191782|NCT01425801|9848731|FG003|Period 1|Withdrawal by Subject|0
6191783|NCT01425801|9848732|FG004|Period 1|Withdrawal by Subject|1
6191784|NCT01425801|9848733|FG005|Period 1|Withdrawal by Subject|0
6191785|NCT01425801|9848728|FG000|Period 2|Withdrawal by Subject|0
6191786|NCT01425801|9848729|FG001|Period 2|Withdrawal by Subject|0
6191787|NCT01425801|9848730|FG002|Period 2|Withdrawal by Subject|0
6191788|NCT01425801|9848731|FG003|Period 2|Withdrawal by Subject|0
6191789|NCT01425801|9848732|FG004|Period 2|Withdrawal by Subject|1
6158100|NCT01163474|9798766|FG000|Overall Study|Withdrawal by Subject|1
6158101|NCT01163474|9798766|FG000|Overall Study|Tech barriers to videoteleconference vis|12
6158102|NCT01163474|9798766|FG000|Overall Study|Lost to Follow-up|3
6158103|NCT01163617|9798782|FG000|Phase A (User Experience), Weeks 0 and 2|Withdrew consent|0
6158104|NCT01163617|9798783|FG001|Phase A (User Experience), Weeks 0 and 2|Withdrew consent|1
6158105|NCT01163617|9798784|FG002|Phase A (User Experience), Weeks 0 and 2|Withdrew consent|0
6191790|NCT01425801|9848733|FG005|Period 2|Withdrawal by Subject|0
6158106|NCT01163617|9798785|FG003|Phase A (User Experience), Weeks 0 and 2|Withdrew consent|0
6158107|NCT01163617|9798786|FG004|Phase A (User Experience), Weeks 0 and 2|Withdrew consent|0
6158108|NCT01163617|9798787|FG005|Phase A (User Experience), Weeks 0 and 2|Withdrew consent|0
6158109|NCT01163617|9798788|FG006|Phase A (User Experience), Weeks 0 and 2|Withdrew consent|0
6158110|NCT01163617|9798789|FG007|Phase A (User Experience), Weeks 0 and 2|Withdrew consent|0
6158111|NCT01163617|9798782|FG000|Phase A (User Experience), Weeks 0 and 2|Failed to meet inclusion criteria|0
6158112|NCT01163617|9798783|FG001|Phase A (User Experience), Weeks 0 and 2|Failed to meet inclusion criteria|1
6158113|NCT01163617|9798784|FG002|Phase A (User Experience), Weeks 0 and 2|Failed to meet inclusion criteria|0
6158114|NCT01163617|9798785|FG003|Phase A (User Experience), Weeks 0 and 2|Failed to meet inclusion criteria|0
6158115|NCT01163617|9798786|FG004|Phase A (User Experience), Weeks 0 and 2|Failed to meet inclusion criteria|0
6158116|NCT01163617|9798787|FG005|Phase A (User Experience), Weeks 0 and 2|Failed to meet inclusion criteria|0
6158117|NCT01163617|9798788|FG006|Phase A (User Experience), Weeks 0 and 2|Failed to meet inclusion criteria|0
6158118|NCT01163617|9798789|FG007|Phase A (User Experience), Weeks 0 and 2|Failed to meet inclusion criteria|0
6158119|NCT01163617|9798782|FG000|Phase A (User Experience), Weeks 0 and 2|Didn't meet inclusion/exclusion criteria|0
6158120|NCT01163617|9798783|FG001|Phase A (User Experience), Weeks 0 and 2|Didn't meet inclusion/exclusion criteria|0
6158121|NCT01163617|9798784|FG002|Phase A (User Experience), Weeks 0 and 2|Didn't meet inclusion/exclusion criteria|1
6158122|NCT01163617|9798785|FG003|Phase A (User Experience), Weeks 0 and 2|Didn't meet inclusion/exclusion criteria|0
6158123|NCT01163617|9798786|FG004|Phase A (User Experience), Weeks 0 and 2|Didn't meet inclusion/exclusion criteria|0
6158124|NCT01163617|9798787|FG005|Phase A (User Experience), Weeks 0 and 2|Didn't meet inclusion/exclusion criteria|0
6158125|NCT01163617|9798788|FG006|Phase A (User Experience), Weeks 0 and 2|Didn't meet inclusion/exclusion criteria|0
6158126|NCT01163617|9798789|FG007|Phase A (User Experience), Weeks 0 and 2|Didn't meet inclusion/exclusion criteria|0
6158127|NCT01163721|9798845|FG000|Overall Study|Adverse Event|5
6158128|NCT01163721|9798846|FG001|Overall Study|Adverse Event|6
6158129|NCT01163721|9798845|FG000|Overall Study|Withdrawal by Subject|3
6158130|NCT01163721|9798846|FG001|Overall Study|Withdrawal by Subject|4
6158131|NCT01163721|9798845|FG000|Overall Study|Lost to Follow-up|0
6158132|NCT01163721|9798846|FG001|Overall Study|Lost to Follow-up|1
6158133|NCT01163721|9798845|FG000|Overall Study|Physician Decision|0
6158134|NCT01163721|9798846|FG001|Overall Study|Physician Decision|1
6158135|NCT01163747|9798854|FG000|Overall Study|Adverse Event|0
6158136|NCT01163747|9798855|FG001|Overall Study|Adverse Event|5
6158137|NCT01163747|9798854|FG000|Overall Study|Insufficient Therapeutic Response|0
6158138|NCT01163747|9798855|FG001|Overall Study|Insufficient Therapeutic Response|1
6158139|NCT01163747|9798854|FG000|Overall Study|Protocol Violation|0
6158140|NCT01163747|9798855|FG001|Overall Study|Protocol Violation|1
6158141|NCT01163747|9798854|FG000|Overall Study|Refused Treatment|6
6158142|NCT01163747|9798855|FG001|Overall Study|Refused Treatment|4
6158143|NCT01163786|9798872|FG000|Treatment With Bortezomib|Withdrawal by Subject|1
6158144|NCT01163786|9798872|FG000|Treatment With Bortezomib|Adverse Event|2
6158145|NCT01163786|9798872|FG000|Completed Follow up (Visit 9 and 10)|Other|1
6158146|NCT01163851|9798878|FG000|Overall Study|Site Closure|0
6158147|NCT01163851|9798879|FG001|Overall Study|Site Closure|1
6158148|NCT01163851|9798878|FG000|Overall Study|Enrolled but not treated|1
6158149|NCT01163851|9798879|FG001|Overall Study|Enrolled but not treated|0
6158150|NCT01163916|9798888|FG000|Overall Study|Withdrawal by Subject|2
6158151|NCT01163916|9798889|FG001|Overall Study|Withdrawal by Subject|0
6158152|NCT01163916|9798890|FG002|Overall Study|Withdrawal by Subject|2
6158153|NCT01163916|9798888|FG000|Overall Study|Adverse Event|2
6158154|NCT01163916|9798889|FG001|Overall Study|Adverse Event|0
6158155|NCT01163916|9798890|FG002|Overall Study|Adverse Event|1
6158156|NCT01163916|9798888|FG000|Overall Study|Lack of Efficacy|2
6158157|NCT01163916|9798889|FG001|Overall Study|Lack of Efficacy|0
6158158|NCT01163916|9798890|FG002|Overall Study|Lack of Efficacy|1
6158159|NCT01163916|9798888|FG000|Overall Study|Other|24
6158160|NCT01163916|9798889|FG001|Overall Study|Other|4
6158161|NCT01163916|9798890|FG002|Overall Study|Other|16
6158162|NCT01164007|9798912|FG000|Overall Study|Adverse Event|5
6158163|NCT01164007|9798912|FG000|Overall Study|Progression of Disease|30
6158164|NCT01164007|9798912|FG000|Overall Study|Protocol Violation|1
6158165|NCT01164007|9798912|FG000|Overall Study|Withdrawal by Subject|1
6158166|NCT01164007|9798912|FG000|Overall Study|Medical Decision|3
6158167|NCT01164475|9798936|FG000|Overall Study|Lack of Efficacy|1
6158168|NCT01164475|9798937|FG001|Overall Study|Lack of Efficacy|0
6158169|NCT01164475|9798936|FG000|Overall Study|Other|0
6158170|NCT01164475|9798937|FG001|Overall Study|Other|1
6042797|NCT00385255|9641262|FG001|Overall Study|Migrated/moved from study area|1
6042798|NCT00385255|9641261|FG000|Overall Study|Lost to Follow-up|20
6042799|NCT00385255|9641262|FG001|Overall Study|Lost to Follow-up|58
6042800|NCT00385541|9641283|FG000|Overall Study|severe pain, clinician requested unblind|0
6042801|NCT00385541|9641284|FG001|Overall Study|severe pain, clinician requested unblind|1
6042802|NCT00385593|9641311|FG000|Overall Study|Adverse Event|3
6042803|NCT00385593|9641312|FG001|Overall Study|Adverse Event|2
6042804|NCT00385593|9641311|FG000|Overall Study|Withdrawal by Subject|17
6080941|NCT00619645|9688430|FG000|Overall Study|Adverse Event|1
6080942|NCT00619801|9688454|FG000|Overall Study|Lack of Efficacy|0
6080943|NCT00619801|9688455|FG001|Overall Study|Lack of Efficacy|1
6080944|NCT00619801|9688454|FG000|Overall Study|Withdrawal by Subject|1
6080945|NCT00619801|9688455|FG001|Overall Study|Withdrawal by Subject|1
6080946|NCT00619801|9688454|FG000|Overall Study|Loss of efficacy|0
6080947|NCT00619801|9688455|FG001|Overall Study|Loss of efficacy|1
6080948|NCT00619827|9688463|FG000|Overall Study|Adverse Event|1
6080949|NCT00619827|9688464|FG001|Overall Study|Adverse Event|2
6080950|NCT00619827|9688463|FG000|Overall Study|Withdrawal by Subject|2
6080951|NCT00619827|9688464|FG001|Overall Study|Withdrawal by Subject|2
6080952|NCT00619866|9688473|FG000|Weeks 1 - 12|Adverse Event|0
6080953|NCT00619866|9688474|FG001|Weeks 1 - 12|Adverse Event|1
6080954|NCT00619866|9688475|FG002|Weeks 1 - 12|Adverse Event|2
6080955|NCT00619866|9688476|FG003|Weeks 1 - 12|Adverse Event|0
6080956|NCT00619866|9688477|FG004|Weeks 1 - 12|Adverse Event|0
6080957|NCT00619866|9688473|FG000|Weeks 1 - 12|Non-compliance|0
6080958|NCT00619866|9688474|FG001|Weeks 1 - 12|Non-compliance|0
6080959|NCT00619866|9688475|FG002|Weeks 1 - 12|Non-compliance|1
6080960|NCT00619866|9688476|FG003|Weeks 1 - 12|Non-compliance|0
6080961|NCT00619866|9688477|FG004|Weeks 1 - 12|Non-compliance|0
6080962|NCT00619866|9688473|FG000|Weeks 1 - 12|Withdrawal by Subject|7
6080963|NCT00619866|9688474|FG001|Weeks 1 - 12|Withdrawal by Subject|2
6080964|NCT00619866|9688475|FG002|Weeks 1 - 12|Withdrawal by Subject|4
6080965|NCT00619866|9688476|FG003|Weeks 1 - 12|Withdrawal by Subject|0
6080966|NCT00619866|9688477|FG004|Weeks 1 - 12|Withdrawal by Subject|0
6080967|NCT00619866|9688473|FG000|Weeks 1 - 12|Lack of Efficacy|3
6080968|NCT00619866|9688474|FG001|Weeks 1 - 12|Lack of Efficacy|2
6080969|NCT00619866|9688475|FG002|Weeks 1 - 12|Lack of Efficacy|1
6080970|NCT00619866|9688476|FG003|Weeks 1 - 12|Lack of Efficacy|0
6080971|NCT00619866|9688477|FG004|Weeks 1 - 12|Lack of Efficacy|0
6080972|NCT00619866|9688473|FG000|Weeks 1 - 12|Lost to Follow-up|4
6080973|NCT00619866|9688474|FG001|Weeks 1 - 12|Lost to Follow-up|0
6080974|NCT00619866|9688475|FG002|Weeks 1 - 12|Lost to Follow-up|2
6080975|NCT00619866|9688476|FG003|Weeks 1 - 12|Lost to Follow-up|0
6080976|NCT00619866|9688477|FG004|Weeks 1 - 12|Lost to Follow-up|0
6080977|NCT00619866|9688473|FG000|Weeks 1 - 12|Sponsor Decision|0
6080978|NCT00619866|9688474|FG001|Weeks 1 - 12|Sponsor Decision|1
6080979|NCT00619866|9688475|FG002|Weeks 1 - 12|Sponsor Decision|0
6080980|NCT00619866|9688476|FG003|Weeks 1 - 12|Sponsor Decision|0
6080981|NCT00619866|9688477|FG004|Weeks 1 - 12|Sponsor Decision|0
6080982|NCT00619866|9688473|FG000|Weeks 13 - 24|Adverse Event|0
6158171|NCT01164475|9798936|FG000|Overall Study|Progressive disease|0
6158172|NCT01164475|9798937|FG001|Overall Study|Progressive disease|1
6158173|NCT01164475|9798936|FG000|Overall Study|Protocol Violation|1
6158174|NCT01164475|9798937|FG001|Overall Study|Protocol Violation|0
6158175|NCT01164501|9798946|FG000|Overall Study|Not treated|2
6158176|NCT01164501|9798947|FG001|Overall Study|Not treated|0
6158177|NCT01164501|9798948|FG002|Overall Study|Not treated|1
6158178|NCT01164501|9798946|FG000|Overall Study|Adverse Event|18
6158179|NCT01164501|9798947|FG001|Overall Study|Adverse Event|4
6158180|NCT01164501|9798948|FG002|Overall Study|Adverse Event|21
6158181|NCT01164501|9798946|FG000|Overall Study|Lack of Efficacy|0
6158182|NCT01164501|9798947|FG001|Overall Study|Lack of Efficacy|0
6158183|NCT01164501|9798948|FG002|Overall Study|Lack of Efficacy|1
6158184|NCT01164501|9798946|FG000|Overall Study|Non compliant with protocol|1
6158185|NCT01164501|9798947|FG001|Overall Study|Non compliant with protocol|1
6158186|NCT01164501|9798948|FG002|Overall Study|Non compliant with protocol|4
6158187|NCT01164501|9798946|FG000|Overall Study|Lost to Follow-up|3
6080983|NCT00619866|9688474|FG001|Weeks 13 - 24|Adverse Event|0
6080984|NCT00619866|9688475|FG002|Weeks 13 - 24|Adverse Event|2
6080985|NCT00619866|9688476|FG003|Weeks 13 - 24|Adverse Event|1
6158188|NCT01164501|9798947|FG001|Overall Study|Lost to Follow-up|0
6080986|NCT00619866|9688477|FG004|Weeks 13 - 24|Adverse Event|0
6080987|NCT00619866|9688473|FG000|Weeks 13 - 24|Protocol Deviation|0
6080988|NCT00619866|9688474|FG001|Weeks 13 - 24|Protocol Deviation|0
6080989|NCT00619866|9688475|FG002|Weeks 13 - 24|Protocol Deviation|0
6080990|NCT00619866|9688476|FG003|Weeks 13 - 24|Protocol Deviation|1
6080991|NCT00619866|9688477|FG004|Weeks 13 - 24|Protocol Deviation|0
6080992|NCT00619866|9688473|FG000|Weeks 13 - 24|Withdrawal by Subject|0
6080993|NCT00619866|9688474|FG001|Weeks 13 - 24|Withdrawal by Subject|3
6158189|NCT01164501|9798948|FG002|Overall Study|Lost to Follow-up|3
6158190|NCT01164501|9798946|FG000|Overall Study|Patient refusal to continue,not due toAE|10
6158191|NCT01164501|9798947|FG001|Overall Study|Patient refusal to continue,not due toAE|4
6158192|NCT01164501|9798948|FG002|Overall Study|Patient refusal to continue,not due toAE|8
6158193|NCT01164501|9798946|FG000|Overall Study|Other reason not defined above|9
6158194|NCT01164501|9798947|FG001|Overall Study|Other reason not defined above|1
6080994|NCT00619866|9688475|FG002|Weeks 13 - 24|Withdrawal by Subject|2
6080995|NCT00619866|9688476|FG003|Weeks 13 - 24|Withdrawal by Subject|2
6080996|NCT00619866|9688477|FG004|Weeks 13 - 24|Withdrawal by Subject|2
6080997|NCT00619866|9688473|FG000|Weeks 13 - 24|Non-compliance|0
6080998|NCT00619866|9688474|FG001|Weeks 13 - 24|Non-compliance|1
6158195|NCT01164501|9798948|FG002|Overall Study|Other reason not defined above|4
6158196|NCT01164579|9798961|FG000|Overall Study|Lack of Efficacy|0
6158197|NCT01164579|9798962|FG001|Overall Study|Lack of Efficacy|0
6158198|NCT01164579|9798963|FG002|Overall Study|Lack of Efficacy|6
6158199|NCT01164579|9798961|FG000|Overall Study|Lost to Follow-up|1
6158200|NCT01164579|9798962|FG001|Overall Study|Lost to Follow-up|1
6158201|NCT01164579|9798963|FG002|Overall Study|Lost to Follow-up|0
6158202|NCT01164579|9798961|FG000|Overall Study|Withdrawal by Subject|2
6158203|NCT01164579|9798962|FG001|Overall Study|Withdrawal by Subject|5
6158204|NCT01164579|9798963|FG002|Overall Study|Withdrawal by Subject|3
6158205|NCT01164579|9798961|FG000|Overall Study|Protocol Violation|0
6158206|NCT01164579|9798962|FG001|Overall Study|Protocol Violation|1
6158207|NCT01164579|9798963|FG002|Overall Study|Protocol Violation|2
6158208|NCT01164579|9798961|FG000|Overall Study|Adverse Event|4
6158209|NCT01164579|9798962|FG001|Overall Study|Adverse Event|2
6158210|NCT01164579|9798963|FG002|Overall Study|Adverse Event|5
6158211|NCT01164579|9798961|FG000|Overall Study|Reason not specified|1
6158212|NCT01164579|9798962|FG001|Overall Study|Reason not specified|0
6158213|NCT01164579|9798963|FG002|Overall Study|Reason not specified|0
6158214|NCT01164722|9798983|FG000|Overall Study|Adverse Event|0
6158215|NCT01164722|9798984|FG001|Overall Study|Adverse Event|1
6158216|NCT01164722|9798983|FG000|Overall Study|Withdrawal by Subject|3
6158217|NCT01164722|9798984|FG001|Overall Study|Withdrawal by Subject|4
6158218|NCT01164722|9798983|FG000|Overall Study|Lost to Follow-up|3
6158219|NCT01164722|9798984|FG001|Overall Study|Lost to Follow-up|6
6158220|NCT01164722|9798983|FG000|Overall Study|met protocol criteria for non-treatment|11
6158221|NCT01164722|9798984|FG001|Overall Study|met protocol criteria for non-treatment|1
6158222|NCT01164722|9798983|FG000|Overall Study|enrolled on other study, concomitant med|1
6158223|NCT01164722|9798984|FG001|Overall Study|enrolled on other study, concomitant med|3
6158224|NCT01164865|9798992|FG000|Overall Study|Lost to Follow-up|2
6158225|NCT01164865|9798993|FG001|Overall Study|Lost to Follow-up|1
6158226|NCT01164891|9798999|FG000|Overall Study|Disease Progression|5
6158227|NCT01164891|9798999|FG000|Overall Study|Adverse Event|1
6158228|NCT01164956|9799004|FG000|Overall Study|Side Effects|1
6158229|NCT01164956|9799005|FG001|Overall Study|Side Effects|0
6158230|NCT01164956|9799006|FG002|Overall Study|Side Effects|1
6158231|NCT01165021|9799014|FG000|Overall Study|Death|1
6158232|NCT01165138|9799029|FG000|Overall Study|Adverse Event|0
6080999|NCT00619866|9688475|FG002|Weeks 13 - 24|Non-compliance|1
6081000|NCT00619866|9688476|FG003|Weeks 13 - 24|Non-compliance|0
6081001|NCT00619866|9688477|FG004|Weeks 13 - 24|Non-compliance|0
6081002|NCT00619866|9688473|FG000|Weeks 13 - 24|Lost to Follow-up|0
6081003|NCT00619866|9688474|FG001|Weeks 13 - 24|Lost to Follow-up|3
6081004|NCT00619866|9688475|FG002|Weeks 13 - 24|Lost to Follow-up|0
6081005|NCT00619866|9688476|FG003|Weeks 13 - 24|Lost to Follow-up|0
6081006|NCT00619866|9688477|FG004|Weeks 13 - 24|Lost to Follow-up|0
6081007|NCT00619892|9688491|FG000|Overall Study|Adverse Event|3
6158233|NCT01165138|9799030|FG001|Overall Study|Adverse Event|1
6158234|NCT01165138|9799031|FG002|Overall Study|Adverse Event|0
6081008|NCT00619892|9688492|FG001|Overall Study|Adverse Event|0
6081009|NCT00619892|9688491|FG000|Overall Study|Lost to Follow-up|0
6081010|NCT00619892|9688492|FG001|Overall Study|Lost to Follow-up|1
6081011|NCT00619892|9688491|FG000|Overall Study|Intercurrent illness|0
6081012|NCT00619892|9688492|FG001|Overall Study|Intercurrent illness|1
6158235|NCT01165138|9799032|FG003|Overall Study|Adverse Event|2
6158236|NCT01165138|9799029|FG000|Overall Study|Lack of Efficacy|0
6081013|NCT00619918|9688502|FG000|Overall Study|Withdrawal by Subject|4
6081014|NCT00619918|9688503|FG001|Overall Study|Withdrawal by Subject|3
6158237|NCT01165138|9799030|FG001|Overall Study|Lack of Efficacy|32
6158238|NCT01165138|9799031|FG002|Overall Study|Lack of Efficacy|6
6158239|NCT01165138|9799032|FG003|Overall Study|Lack of Efficacy|7
6158240|NCT01165138|9799029|FG000|Overall Study|Protocol Violation|0
6158241|NCT01165138|9799030|FG001|Overall Study|Protocol Violation|7
6158242|NCT01165138|9799031|FG002|Overall Study|Protocol Violation|0
6158243|NCT01165138|9799032|FG003|Overall Study|Protocol Violation|2
6158244|NCT01165138|9799029|FG000|Overall Study|Lost to Follow-up|0
6158245|NCT01165138|9799030|FG001|Overall Study|Lost to Follow-up|0
6158246|NCT01165138|9799031|FG002|Overall Study|Lost to Follow-up|1
6158247|NCT01165138|9799032|FG003|Overall Study|Lost to Follow-up|2
6158248|NCT01165138|9799029|FG000|Overall Study|Physician Decision|0
6158249|NCT01165138|9799030|FG001|Overall Study|Physician Decision|6
6158250|NCT01165138|9799031|FG002|Overall Study|Physician Decision|7
6158251|NCT01165138|9799032|FG003|Overall Study|Physician Decision|6
6158252|NCT01165138|9799029|FG000|Overall Study|Withdrawal by Subject|0
6158253|NCT01165138|9799030|FG001|Overall Study|Withdrawal by Subject|6
6158254|NCT01165138|9799031|FG002|Overall Study|Withdrawal by Subject|6
6158255|NCT01165138|9799032|FG003|Overall Study|Withdrawal by Subject|3
6158256|NCT01165177|9799042|FG000|Overall Study|Serious Adverse Event|227
6158257|NCT01165177|9799043|FG001|Overall Study|Serious Adverse Event|235
6158258|NCT01165177|9799042|FG000|Overall Study|Withdrawal by Subject|368
6158259|NCT01165177|9799043|FG001|Overall Study|Withdrawal by Subject|354
6081015|NCT00619918|9688502|FG000|Overall Study|Physician Decision|8
6081016|NCT00619918|9688503|FG001|Overall Study|Physician Decision|8
6081017|NCT00619918|9688502|FG000|Overall Study|Transfer to outside facility|3
6081018|NCT00619918|9688503|FG001|Overall Study|Transfer to outside facility|3
6081019|NCT00619918|9688502|FG000|Overall Study|Left before receiving first dose|5
6081020|NCT00619918|9688503|FG001|Overall Study|Left before receiving first dose|8
6081021|NCT00619957|9688511|FG000|Month 24 Double-Blind|Adverse Event|9
6081022|NCT00619957|9688512|FG001|Month 24 Double-Blind|Adverse Event|7
6081023|NCT00619957|9688511|FG000|Month 24 Double-Blind|Protocol Violation|1
6081024|NCT00619957|9688512|FG001|Month 24 Double-Blind|Protocol Violation|0
6081025|NCT00619957|9688511|FG000|Month 24 Double-Blind|Withdrawal by Subject|7
6081026|NCT00619957|9688512|FG001|Month 24 Double-Blind|Withdrawal by Subject|9
6081027|NCT00619957|9688511|FG000|Month 24 Double-Blind|Lost to Follow-up|1
6081028|NCT00619957|9688512|FG001|Month 24 Double-Blind|Lost to Follow-up|0
6081029|NCT00619957|9688511|FG000|Month 24 Double-Blind|Did not take any study medication|0
6081030|NCT00619957|9688512|FG001|Month 24 Double-Blind|Did not take any study medication|1
6081031|NCT00619957|9688511|FG000|Month 48 Open-Label|Adverse Event|4
6081032|NCT00619957|9688512|FG001|Month 48 Open-Label|Adverse Event|4
6081033|NCT00619957|9688511|FG000|Month 48 Open-Label|Lost to Follow-up|2
6081034|NCT00619957|9688512|FG001|Month 48 Open-Label|Lost to Follow-up|4
6081035|NCT00619957|9688511|FG000|Month 48 Open-Label|Withdrawal by Subject|6
6081036|NCT00619957|9688512|FG001|Month 48 Open-Label|Withdrawal by Subject|9
6081037|NCT00619983|9688539|FG000|Test Drug Alone|Withdrawal by Subject|1
6081038|NCT00619983|9688540|FG001|Test Drug Alone|Withdrawal by Subject|0
6158260|NCT01165177|9799042|FG000|Overall Study|Protocol Violation|19
6158261|NCT01165177|9799043|FG001|Overall Study|Protocol Violation|21
6158262|NCT01165177|9799042|FG000|Overall Study|Non-serious adverse event|30
6158263|NCT01165177|9799043|FG001|Overall Study|Non-serious adverse event|18
6158264|NCT01165177|9799042|FG000|Overall Study|Other unspecified reasons|47
6158265|NCT01165177|9799043|FG001|Overall Study|Other unspecified reasons|35
6158266|NCT01165177|9799042|FG000|Overall Study|Suspected HZ episode|0
6158267|NCT01165177|9799043|FG001|Overall Study|Suspected HZ episode|2
6158268|NCT01165177|9799042|FG000|Overall Study|Lost to Follow-up|183
6158269|NCT01165177|9799043|FG001|Overall Study|Lost to Follow-up|194
6158270|NCT01165177|9799042|FG000|Overall Study|Migrated/ moved from study area|48
6158271|NCT01165177|9799043|FG001|Overall Study|Migrated/ moved from study area|43
6158272|NCT01165203|9799059|FG000|Active Phase|Serious Adverse Event|1
6158273|NCT01165203|9799060|FG001|Active Phase|Serious Adverse Event|0
6158274|NCT01165203|9799059|FG000|Active Phase|Withdrawal by Subject|2
6158275|NCT01165203|9799060|FG001|Active Phase|Withdrawal by Subject|1
6158276|NCT01165203|9799059|FG000|Active Phase|Migrated/moved from study area|0
6158277|NCT01165203|9799060|FG001|Active Phase|Migrated/moved from study area|1
6158278|NCT01165203|9799059|FG000|Active Phase|Lost to Follow-up|2
6158279|NCT01165203|9799060|FG001|Active Phase|Lost to Follow-up|0
6158280|NCT01165203|9799059|FG000|Extended Safety Follow-up Phase|Serious Adverse Event|1
6158281|NCT01165203|9799060|FG001|Extended Safety Follow-up Phase|Serious Adverse Event|0
6158282|NCT01165203|9799059|FG000|Extended Safety Follow-up Phase|Withdrawal by Subject|2
6158283|NCT01165203|9799060|FG001|Extended Safety Follow-up Phase|Withdrawal by Subject|2
6158284|NCT01165203|9799059|FG000|Extended Safety Follow-up Phase|Migrated/moved from study area|2
6158285|NCT01165203|9799060|FG001|Extended Safety Follow-up Phase|Migrated/moved from study area|1
6158286|NCT01165203|9799059|FG000|Extended Safety Follow-up Phase|Lost to Follow-up|2
6158287|NCT01165203|9799060|FG001|Extended Safety Follow-up Phase|Lost to Follow-up|0
6158288|NCT01165203|9799059|FG000|Extended Safety Follow-up Phase|Other-subjects business reasons|0
6158289|NCT01165203|9799060|FG001|Extended Safety Follow-up Phase|Other-subjects business reasons|1
6158290|NCT01165216|9799075|FG000|Overall Study|Adverse Event|6
6158291|NCT01165216|9799076|FG001|Overall Study|Adverse Event|3
6158292|NCT01165216|9799075|FG000|Overall Study|Withdrawal by Subject|1
6158293|NCT01165216|9799076|FG001|Overall Study|Withdrawal by Subject|1
6158294|NCT01165216|9799075|FG000|Overall Study|Disease progression|1
6158295|NCT01165216|9799076|FG001|Overall Study|Disease progression|3
6158296|NCT01165229|9799086|FG000|Overall Study|Serious Adverse Event|456
6158297|NCT01165229|9799087|FG001|Overall Study|Serious Adverse Event|487
6158298|NCT01165229|9799086|FG000|Overall Study|Non-Serious Adverse Event|47
6158299|NCT01165229|9799087|FG001|Overall Study|Non-Serious Adverse Event|15
6158300|NCT01165229|9799086|FG000|Overall Study|Protocol Violation|6
6158301|NCT01165229|9799087|FG001|Overall Study|Protocol Violation|8
6158302|NCT01165229|9799086|FG000|Overall Study|Withdrawal by Subject|387
6158303|NCT01165229|9799087|FG001|Overall Study|Withdrawal by Subject|396
6158304|NCT01165229|9799086|FG000|Overall Study|Migrated/moved from study area|51
6158305|NCT01165229|9799087|FG001|Overall Study|Migrated/moved from study area|46
6158306|NCT01165229|9799086|FG000|Overall Study|Lost to Follow-up|123
6158307|NCT01165229|9799087|FG001|Overall Study|Lost to Follow-up|133
6158308|NCT01165229|9799086|FG000|Overall Study|Suspected HZ Episode|2
6158309|NCT01165229|9799087|FG001|Overall Study|Suspected HZ Episode|2
6158310|NCT01165229|9799086|FG000|Overall Study|No reason from the subject|108
6158311|NCT01165229|9799087|FG001|Overall Study|No reason from the subject|102
6158312|NCT01165229|9799086|FG000|Overall Study|Unknown completion status|0
6158313|NCT01165229|9799087|FG001|Overall Study|Unknown completion status|1
6158314|NCT01165242|9799126|FG000|Overall Study|Unreachable Subjects|1
6158315|NCT01165242|9799127|FG001|Overall Study|Unreachable Subjects|0
6158316|NCT01165242|9799128|FG002|Overall Study|Unreachable Subjects|0
6158317|NCT01165242|9799126|FG000|Overall Study|Incarcerated Subjects|0
6158318|NCT01165242|9799127|FG001|Overall Study|Incarcerated Subjects|1
6158319|NCT01165242|9799128|FG002|Overall Study|Incarcerated Subjects|0
6158320|NCT01165242|9799126|FG000|Overall Study|Visit 2 Declined by Subject|0
6158321|NCT01165242|9799127|FG001|Overall Study|Visit 2 Declined by Subject|0
6158322|NCT01165242|9799128|FG002|Overall Study|Visit 2 Declined by Subject|1
6158323|NCT01165242|9799126|FG000|Overall Study|Withdrawal by Subject|0
6158324|NCT01165242|9799127|FG001|Overall Study|Withdrawal by Subject|2
6158325|NCT01165242|9799128|FG002|Overall Study|Withdrawal by Subject|2
6158326|NCT01165242|9799126|FG000|Overall Study|Extended Holiday|0
6158327|NCT01165242|9799127|FG001|Overall Study|Extended Holiday|0
6158328|NCT01165242|9799128|FG002|Overall Study|Extended Holiday|1
6158329|NCT01165242|9799126|FG000|Overall Study|Lost to Follow-up|9
6158330|NCT01165242|9799127|FG001|Overall Study|Lost to Follow-up|7
6158331|NCT01165242|9799128|FG002|Overall Study|Lost to Follow-up|10
6158332|NCT01165281|9799140|FG000|Overall Study|Adverse Event|12
6158333|NCT01165281|9799141|FG001|Overall Study|Adverse Event|14
6158334|NCT01165281|9799140|FG000|Overall Study|Death|3
6158335|NCT01165281|9799141|FG001|Overall Study|Death|4
6158336|NCT01165281|9799140|FG000|Overall Study|Lack of Efficacy|4
6158337|NCT01165281|9799141|FG001|Overall Study|Lack of Efficacy|1
6158338|NCT01165281|9799140|FG000|Overall Study|Lost to Follow-up|0
6158339|NCT01165281|9799141|FG001|Overall Study|Lost to Follow-up|1
6158340|NCT01165281|9799140|FG000|Overall Study|Physician Decision|8
6158341|NCT01165281|9799141|FG001|Overall Study|Physician Decision|1
6158342|NCT01165281|9799140|FG000|Overall Study|Protocol Violation|6
6158343|NCT01165281|9799141|FG001|Overall Study|Protocol Violation|5
6158344|NCT01165281|9799140|FG000|Overall Study|Withdrawal by Subject|8
6158345|NCT01165281|9799141|FG001|Overall Study|Withdrawal by Subject|7
6158346|NCT01165281|9799140|FG000|Overall Study|Noncompliance with Study Drug|1
6158347|NCT01165281|9799141|FG001|Overall Study|Noncompliance with Study Drug|4
6158348|NCT01165281|9799140|FG000|Overall Study|Progressive Disease|10
6158349|NCT01165281|9799141|FG001|Overall Study|Progressive Disease|14
6158350|NCT01165281|9799140|FG000|Overall Study|Other|6
6081039|NCT00619983|9688541|FG002|Test Drug Alone|Withdrawal by Subject|0
6081040|NCT00619983|9688542|FG003|Test Drug Alone|Withdrawal by Subject|1
6081041|NCT00619983|9688539|FG000|Test Drug Alone|Failure of daily diary device|1
6081042|NCT00619983|9688540|FG001|Test Drug Alone|Failure of daily diary device|1
6081043|NCT00619983|9688541|FG002|Test Drug Alone|Failure of daily diary device|2
6081044|NCT00619983|9688542|FG003|Test Drug Alone|Failure of daily diary device|2
6081045|NCT00620022|9688552|FG000|Treatment Period 1|Adverse Event|4
6081046|NCT00620022|9688553|FG001|Treatment Period 1|Adverse Event|6
6081047|NCT00620022|9688552|FG000|Treatment Period 1|Subject withdrew consent|1
6081048|NCT00620022|9688553|FG001|Treatment Period 1|Subject withdrew consent|0
6081049|NCT00620022|9688552|FG000|Treatment Period 2|Adverse Event|2
6081050|NCT00620022|9688553|FG001|Treatment Period 2|Adverse Event|2
6081051|NCT00620074|9688564|FG000|Overall Study|Adverse Event|1
6081052|NCT00620113|9688572|FG000|Overall Study|Adverse Event|3
6081053|NCT00620113|9688573|FG001|Overall Study|Adverse Event|2
6081054|NCT00620113|9688574|FG002|Overall Study|Adverse Event|2
6081055|NCT00620113|9688575|FG003|Overall Study|Adverse Event|1
6081056|NCT00620113|9688572|FG000|Overall Study|Lack of Efficacy|2
6081057|NCT00620113|9688573|FG001|Overall Study|Lack of Efficacy|3
6158351|NCT01165281|9799141|FG001|Overall Study|Other|0
6158352|NCT01165307|9799149|FG000|Overall Study|Lost to Follow-up|11
6081058|NCT00620113|9688574|FG002|Overall Study|Lack of Efficacy|0
6081059|NCT00620113|9688575|FG003|Overall Study|Lack of Efficacy|2
6081060|NCT00620113|9688572|FG000|Overall Study|Physician Decision|1
6081061|NCT00620113|9688573|FG001|Overall Study|Physician Decision|0
6158353|NCT01165307|9799150|FG001|Overall Study|Lost to Follow-up|3
6158354|NCT01165307|9799149|FG000|Overall Study|Withdrawal by Subject|2
6081062|NCT00620113|9688574|FG002|Overall Study|Physician Decision|0
6081063|NCT00620113|9688575|FG003|Overall Study|Physician Decision|2
6081064|NCT00620113|9688572|FG000|Overall Study|Protocol Violation|2
6081065|NCT00620113|9688573|FG001|Overall Study|Protocol Violation|1
6081066|NCT00620113|9688574|FG002|Overall Study|Protocol Violation|0
6081067|NCT00620113|9688575|FG003|Overall Study|Protocol Violation|0
6081068|NCT00620113|9688572|FG000|Overall Study|Withdrawal by Subject|5
6158355|NCT01165307|9799150|FG001|Overall Study|Withdrawal by Subject|0
6158356|NCT01165307|9799149|FG000|Overall Study|Subject not available for contact|1
6158357|NCT01165307|9799150|FG001|Overall Study|Subject not available for contact|0
6158358|NCT01165320|9799158|FG000|Overall Study|Clinical adverse experience|2
6158359|NCT01165320|9799159|FG001|Overall Study|Clinical adverse experience|1
6158360|NCT01165320|9799160|FG002|Overall Study|Clinical adverse experience|0
6158361|NCT01165320|9799158|FG000|Overall Study|Laboratory adverse experience|1
6158362|NCT01165320|9799159|FG001|Overall Study|Laboratory adverse experience|0
6158363|NCT01165320|9799160|FG002|Overall Study|Laboratory adverse experience|0
6158364|NCT01165320|9799158|FG000|Overall Study|Lack of Efficacy|0
6158365|NCT01165320|9799159|FG001|Overall Study|Lack of Efficacy|2
6158366|NCT01165320|9799160|FG002|Overall Study|Lack of Efficacy|0
6158367|NCT01165320|9799158|FG000|Overall Study|Reason unknown|0
6158368|NCT01165320|9799159|FG001|Overall Study|Reason unknown|1
6158369|NCT01165320|9799160|FG002|Overall Study|Reason unknown|0
6158370|NCT01165554|9799172|FG000|Overall Study|Withdrawal by Subject|23
6158371|NCT01165684|9799181|FG000|Overall Study|Adverse Event|1
6158372|NCT01165684|9799182|FG001|Overall Study|Adverse Event|1
6158373|NCT01165684|9799181|FG000|Overall Study|Lack of Efficacy|2
6158374|NCT01165684|9799182|FG001|Overall Study|Lack of Efficacy|1
6158375|NCT01165684|9799181|FG000|Overall Study|Protocol Violation|7
5972201|NCT03819114|9557918|FG001|Overall Study|Lost to Follow-up|0
5972202|NCT03819114|9557919|FG002|Overall Study|Lost to Follow-up|1
5972203|NCT03819114|9557920|FG003|Overall Study|Lost to Follow-up|0
5972204|NCT03804268|9557934|FG000|Overall Study|Adverse Event|2
5972205|NCT03804268|9557935|FG001|Overall Study|Adverse Event|2
6081069|NCT00620113|9688573|FG001|Overall Study|Withdrawal by Subject|1
6042805|NCT00385593|9641312|FG001|Overall Study|Withdrawal by Subject|7
6042806|NCT00385593|9641311|FG000|Overall Study|Lost to Follow-up|12
6081070|NCT00620113|9688574|FG002|Overall Study|Withdrawal by Subject|3
6081071|NCT00620113|9688575|FG003|Overall Study|Withdrawal by Subject|5
6081072|NCT00620282|9688611|FG000|Overall Study|Adverse Event|0
6081073|NCT00620282|9688612|FG001|Overall Study|Adverse Event|1
6081074|NCT00620282|9688613|FG002|Overall Study|Adverse Event|0
5972206|NCT03804268|9557934|FG000|Overall Study|Withdrawal by Subject|2
5972207|NCT03804268|9557935|FG001|Overall Study|Withdrawal by Subject|0
5972208|NCT03804268|9557934|FG000|Overall Study|Lost to Follow-up|1
5972209|NCT03804268|9557935|FG001|Overall Study|Lost to Follow-up|0
5972210|NCT03804268|9557934|FG000|Overall Study|Physician Decision|2
5972211|NCT03804268|9557935|FG001|Overall Study|Physician Decision|0
5972281|NCT03730662|9558037|FG002|Treatment Period (52 Weeks)|Screen Failure|0
5972282|NCT03730662|9558038|FG003|Treatment Period (52 Weeks)|Screen Failure|0
5972283|NCT03730662|9558035|FG000|Treatment Period (52 Weeks)|Death|6
5972284|NCT03730662|9558036|FG001|Treatment Period (52 Weeks)|Death|2
5972285|NCT03730662|9558037|FG002|Treatment Period (52 Weeks)|Death|2
5972286|NCT03730662|9558038|FG003|Treatment Period (52 Weeks)|Death|9
6042807|NCT00385593|9641312|FG001|Overall Study|Lost to Follow-up|8
6081075|NCT00620282|9688611|FG000|Overall Study|Arterial line unable to be placed|0
6158376|NCT01165684|9799182|FG001|Overall Study|Protocol Violation|15
6158377|NCT01165684|9799181|FG000|Overall Study|Withdrawal Criteria|2
6158378|NCT01165684|9799182|FG001|Overall Study|Withdrawal Criteria|13
6158379|NCT01165684|9799181|FG000|Overall Study|Unclassified|16
6158380|NCT01165684|9799182|FG001|Overall Study|Unclassified|22
6158381|NCT01165996|9799211|FG000|Overall Study|Death|1
6158382|NCT01165996|9799211|FG000|Overall Study|Physician Decision|1
6158383|NCT01166282|9799235|FG000|Open-label Period|Adverse Event|0
6158384|NCT01166282|9799236|FG001|Open-label Period|Adverse Event|0
6158385|NCT01166282|9799237|FG002|Open-label Period|Adverse Event|6
6158386|NCT01166282|9799235|FG000|Open-label Period|Withdrawal by Subject|0
6158387|NCT01166282|9799236|FG001|Open-label Period|Withdrawal by Subject|0
6158388|NCT01166282|9799237|FG002|Open-label Period|Withdrawal by Subject|4
6158389|NCT01166282|9799235|FG000|Open-label Period|Lack of Efficacy|0
6158390|NCT01166282|9799236|FG001|Open-label Period|Lack of Efficacy|0
6158391|NCT01166282|9799237|FG002|Open-label Period|Lack of Efficacy|2
6081076|NCT00620282|9688612|FG001|Overall Study|Arterial line unable to be placed|0
6081077|NCT00620282|9688613|FG002|Overall Study|Arterial line unable to be placed|1
6081078|NCT00620282|9688611|FG000|Overall Study|Withdrawal by Subject|0
6081079|NCT00620282|9688612|FG001|Overall Study|Withdrawal by Subject|1
6081080|NCT00620282|9688613|FG002|Overall Study|Withdrawal by Subject|0
6081081|NCT00620321|9688623|FG000|Overall Study|Adverse Event|1
6081082|NCT00620321|9688624|FG001|Overall Study|Adverse Event|1
6081083|NCT00620321|9688623|FG000|Overall Study|Death|1
6081084|NCT00620321|9688624|FG001|Overall Study|Death|1
6081085|NCT00620321|9688623|FG000|Overall Study|Physician Decision|0
6158392|NCT01166282|9799235|FG000|Open-label Period|Remission|0
6158393|NCT01166282|9799236|FG001|Open-label Period|Remission|0
6042808|NCT00385593|9641311|FG000|Overall Study|Protocol Violation|7
6081086|NCT00620321|9688624|FG001|Overall Study|Physician Decision|7
6081087|NCT00620321|9688623|FG000|Overall Study|Progressive Disease|5
6081088|NCT00620321|9688624|FG001|Overall Study|Progressive Disease|5
6042809|NCT00385593|9641312|FG001|Overall Study|Protocol Violation|4
6081089|NCT00620321|9688623|FG000|Overall Study|Sponsor Decision|0
6081090|NCT00620321|9688624|FG001|Overall Study|Sponsor Decision|1
6081091|NCT00620321|9688623|FG000|Overall Study|Withdrawal by Subject|1
6081092|NCT00620321|9688624|FG001|Overall Study|Withdrawal by Subject|1
6081093|NCT00620373|9688630|FG000|Overall Study|Unverified cancer status|33
6081094|NCT00620542|9688663|FG000|Part A (Run-in - 2 Weeks)|Adverse Event|12
6081095|NCT00620542|9688664|FG001|Part A (Run-in - 2 Weeks)|Adverse Event|15
6081096|NCT00620542|9688665|FG002|Part A (Run-in - 2 Weeks)|Adverse Event|0
6081097|NCT00620542|9688666|FG003|Part A (Run-in - 2 Weeks)|Adverse Event|0
6081098|NCT00620542|9688663|FG000|Part A (Run-in - 2 Weeks)|Protocol Violation|406
6081099|NCT00620542|9688664|FG001|Part A (Run-in - 2 Weeks)|Protocol Violation|409
6081100|NCT00620542|9688665|FG002|Part A (Run-in - 2 Weeks)|Protocol Violation|0
6081101|NCT00620542|9688666|FG003|Part A (Run-in - 2 Weeks)|Protocol Violation|0
6081102|NCT00620542|9688663|FG000|Part A (Run-in - 2 Weeks)|Withdrawal by Subject|43
6081103|NCT00620542|9688664|FG001|Part A (Run-in - 2 Weeks)|Withdrawal by Subject|40
6081104|NCT00620542|9688665|FG002|Part A (Run-in - 2 Weeks)|Withdrawal by Subject|0
6042810|NCT00385593|9641311|FG000|Overall Study|Several reasons|17
6081105|NCT00620542|9688666|FG003|Part A (Run-in - 2 Weeks)|Withdrawal by Subject|0
6081106|NCT00620542|9688663|FG000|Part A (Run-in - 2 Weeks)|Lost to Follow-up|7
6081107|NCT00620542|9688664|FG001|Part A (Run-in - 2 Weeks)|Lost to Follow-up|6
6081108|NCT00620542|9688665|FG002|Part A (Run-in - 2 Weeks)|Lost to Follow-up|0
6081109|NCT00620542|9688666|FG003|Part A (Run-in - 2 Weeks)|Lost to Follow-up|0
6081110|NCT00620542|9688663|FG000|Part A (Run-in - 2 Weeks)|Protocol Violation|0
6081111|NCT00620542|9688664|FG001|Part A (Run-in - 2 Weeks)|Protocol Violation|1
6081112|NCT00620542|9688665|FG002|Part A (Run-in - 2 Weeks)|Protocol Violation|0
6081113|NCT00620542|9688666|FG003|Part A (Run-in - 2 Weeks)|Protocol Violation|0
6081114|NCT00620542|9688663|FG000|Part A (Run-in - 2 Weeks)|Safety reasons|0
6081115|NCT00620542|9688664|FG001|Part A (Run-in - 2 Weeks)|Safety reasons|1
6081116|NCT00620542|9688665|FG002|Part A (Run-in - 2 Weeks)|Safety reasons|0
6081117|NCT00620542|9688666|FG003|Part A (Run-in - 2 Weeks)|Safety reasons|0
6081118|NCT00620542|9688663|FG000|Part A (Run-in - 2 Weeks)|IVUS not available|4
6081119|NCT00620542|9688664|FG001|Part A (Run-in - 2 Weeks)|IVUS not available|4
6081120|NCT00620542|9688665|FG002|Part A (Run-in - 2 Weeks)|IVUS not available|0
6081121|NCT00620542|9688666|FG003|Part A (Run-in - 2 Weeks)|IVUS not available|0
6081122|NCT00620542|9688663|FG000|Part B (2 Year Core Study)|Adverse Event|0
6081123|NCT00620542|9688664|FG001|Part B (2 Year Core Study)|Adverse Event|0
6081124|NCT00620542|9688665|FG002|Part B (2 Year Core Study)|Adverse Event|46
6081125|NCT00620542|9688666|FG003|Part B (2 Year Core Study)|Adverse Event|49
6081126|NCT00620542|9688663|FG000|Part B (2 Year Core Study)|Protocol Violation|0
6081127|NCT00620542|9688664|FG001|Part B (2 Year Core Study)|Protocol Violation|0
6081128|NCT00620542|9688665|FG002|Part B (2 Year Core Study)|Protocol Violation|3
6081129|NCT00620542|9688666|FG003|Part B (2 Year Core Study)|Protocol Violation|5
6081130|NCT00620542|9688663|FG000|Part B (2 Year Core Study)|Withdrawal by Subject|0
6081131|NCT00620542|9688664|FG001|Part B (2 Year Core Study)|Withdrawal by Subject|0
6081132|NCT00620542|9688665|FG002|Part B (2 Year Core Study)|Withdrawal by Subject|55
6081133|NCT00620542|9688666|FG003|Part B (2 Year Core Study)|Withdrawal by Subject|54
6081134|NCT00620542|9688663|FG000|Part B (2 Year Core Study)|Lost to Follow-up|0
6081135|NCT00620542|9688664|FG001|Part B (2 Year Core Study)|Lost to Follow-up|0
6081136|NCT00620542|9688665|FG002|Part B (2 Year Core Study)|Lost to Follow-up|20
6081137|NCT00620542|9688666|FG003|Part B (2 Year Core Study)|Lost to Follow-up|9
6081138|NCT00620542|9688663|FG000|Part B (2 Year Core Study)|Protocol Violation|0
6081139|NCT00620542|9688664|FG001|Part B (2 Year Core Study)|Protocol Violation|0
6081140|NCT00620542|9688665|FG002|Part B (2 Year Core Study)|Protocol Violation|13
6081141|NCT00620542|9688666|FG003|Part B (2 Year Core Study)|Protocol Violation|16
6081142|NCT00620542|9688663|FG000|Part B (2 Year Core Study)|Safety reasons|0
6081143|NCT00620542|9688664|FG001|Part B (2 Year Core Study)|Safety reasons|0
6081144|NCT00620542|9688665|FG002|Part B (2 Year Core Study)|Safety reasons|2
6081145|NCT00620542|9688666|FG003|Part B (2 Year Core Study)|Safety reasons|3
6081146|NCT00620542|9688663|FG000|Part B (2 Year Core Study)|Study specific discontinuation criteris|0
6081147|NCT00620542|9688664|FG001|Part B (2 Year Core Study)|Study specific discontinuation criteris|0
6081148|NCT00620542|9688665|FG002|Part B (2 Year Core Study)|Study specific discontinuation criteris|6
6081149|NCT00620542|9688666|FG003|Part B (2 Year Core Study)|Study specific discontinuation criteris|6
6081150|NCT00620542|9688663|FG000|Part B (2 Year Core Study)|IVUS not available|0
6081151|NCT00620542|9688664|FG001|Part B (2 Year Core Study)|IVUS not available|0
6081152|NCT00620542|9688665|FG002|Part B (2 Year Core Study)|IVUS not available|3
6081153|NCT00620542|9688666|FG003|Part B (2 Year Core Study)|IVUS not available|2
6081154|NCT00620555|9688674|FG000|Overall Study|Adverse Event|4
6081155|NCT00620555|9688674|FG000|Overall Study|Protocol Violation|2
6081156|NCT00620555|9688674|FG000|Overall Study|Lack of Efficacy|12
6081157|NCT00620555|9688674|FG000|Overall Study|Withdrawal by Subject|1
6081158|NCT00620555|9688674|FG000|Overall Study|Choice of other treatment|1
6081159|NCT00620555|9688674|FG000|Overall Study|Visit failure against planned|1
6081160|NCT00620659|9688678|FG000|Treatment Period 1|Adverse Event|1
6081161|NCT00620659|9688679|FG001|Treatment Period 1|Adverse Event|0
6081162|NCT00620659|9688680|FG002|Treatment Period 1|Adverse Event|0
6081163|NCT00620659|9688681|FG003|Treatment Period 1|Adverse Event|3
6081164|NCT00620659|9688682|FG004|Treatment Period 1|Adverse Event|0
6081165|NCT00620659|9688683|FG005|Treatment Period 1|Adverse Event|0
6081166|NCT00620659|9688678|FG000|Treatment Period 1|Protocol Violation|1
6081167|NCT00620659|9688679|FG001|Treatment Period 1|Protocol Violation|0
6081168|NCT00620659|9688680|FG002|Treatment Period 1|Protocol Violation|0
6081169|NCT00620659|9688681|FG003|Treatment Period 1|Protocol Violation|0
6081170|NCT00620659|9688682|FG004|Treatment Period 1|Protocol Violation|0
6081171|NCT00620659|9688683|FG005|Treatment Period 1|Protocol Violation|0
6081172|NCT00620659|9688678|FG000|Treatment Period 1|Withdrawal by Subject|1
6081173|NCT00620659|9688679|FG001|Treatment Period 1|Withdrawal by Subject|0
6081174|NCT00620659|9688680|FG002|Treatment Period 1|Withdrawal by Subject|1
6081175|NCT00620659|9688681|FG003|Treatment Period 1|Withdrawal by Subject|0
6081176|NCT00620659|9688682|FG004|Treatment Period 1|Withdrawal by Subject|1
6081177|NCT00620659|9688683|FG005|Treatment Period 1|Withdrawal by Subject|0
6081178|NCT00620659|9688678|FG000|Placebo Washout Period 1|Withdrawal by Subject|0
6081179|NCT00620659|9688679|FG001|Placebo Washout Period 1|Withdrawal by Subject|0
6081180|NCT00620659|9688680|FG002|Placebo Washout Period 1|Withdrawal by Subject|0
6324744|NCT02919475|10066609|FG003|Overall Study|Adverse Event|9
6324745|NCT02919475|10066610|FG004|Overall Study|Adverse Event|2
6324746|NCT02919475|10066606|FG000|Overall Study|Death|0
6081181|NCT00620659|9688681|FG003|Placebo Washout Period 1|Withdrawal by Subject|1
6324747|NCT02919475|10066607|FG001|Overall Study|Death|1
6324748|NCT02919475|10066608|FG002|Overall Study|Death|0
6042811|NCT00385593|9641312|FG001|Overall Study|Several reasons|15
6042812|NCT00385593|9641311|FG000|Overall Study|Incorrect inclusion|2
6158394|NCT01166282|9799237|FG002|Open-label Period|Remission|4
6158395|NCT01166282|9799235|FG000|Open-label Period|Irregular Compliance|0
6158396|NCT01166282|9799236|FG001|Open-label Period|Irregular Compliance|0
6158397|NCT01166282|9799237|FG002|Open-label Period|Irregular Compliance|1
6158398|NCT01166373|9799258|FG000|Overall Study|Lost to Follow-up|3
6158399|NCT01166373|9799259|FG001|Overall Study|Lost to Follow-up|2
6158400|NCT01166373|9799260|FG002|Overall Study|Lost to Follow-up|2
6158401|NCT01166373|9799261|FG003|Overall Study|Lost to Follow-up|2
6158402|NCT01166373|9799258|FG000|Overall Study|Withdrawal by Subject|1
6158403|NCT01166373|9799259|FG001|Overall Study|Withdrawal by Subject|2
6158404|NCT01166373|9799260|FG002|Overall Study|Withdrawal by Subject|2
6158405|NCT01166373|9799261|FG003|Overall Study|Withdrawal by Subject|3
6158406|NCT01166373|9799258|FG000|Overall Study|Physician Decision|1
6158407|NCT01166373|9799259|FG001|Overall Study|Physician Decision|0
6158408|NCT01166373|9799260|FG002|Overall Study|Physician Decision|0
6158409|NCT01166373|9799261|FG003|Overall Study|Physician Decision|0
6158410|NCT01166438|9799275|FG000|Double-blind Phase: 1st 6 Months|Withdrawal by Subject|8
6158411|NCT01166438|9799276|FG001|Double-blind Phase: 1st 6 Months|Withdrawal by Subject|4
6158412|NCT01166438|9799275|FG000|Double-blind Phase: 1st 6 Months|Lost to Follow-up|0
6158413|NCT01166438|9799276|FG001|Double-blind Phase: 1st 6 Months|Lost to Follow-up|4
6158414|NCT01166438|9799275|FG000|Double-blind Phase: 1st 6 Months|Not treated|1
6158415|NCT01166438|9799276|FG001|Double-blind Phase: 1st 6 Months|Not treated|1
6158416|NCT01166438|9799275|FG000|Off Treatment Follow-up Phase|Withdrawal by Subject|1
6158417|NCT01166438|9799276|FG001|Off Treatment Follow-up Phase|Withdrawal by Subject|2
6158418|NCT01166438|9799275|FG000|Off Treatment Follow-up Phase|Lost to Follow-up|4
6158419|NCT01166438|9799276|FG001|Off Treatment Follow-up Phase|Lost to Follow-up|2
6158420|NCT01166438|9799275|FG000|Off Treatment Follow-up Phase|Lack of Efficacy|29
6158421|NCT01166438|9799276|FG001|Off Treatment Follow-up Phase|Lack of Efficacy|52
6158422|NCT01166568|9799286|FG000|Deferred Implantation- Randomized|Withdrawal by Subject|0
6158423|NCT01166568|9799287|FG001|Deferred Implantation- Randomized|Withdrawal by Subject|0
6158424|NCT01166568|9799288|FG002|Deferred Implantation- Randomized|Withdrawal by Subject|1
6158425|NCT01166568|9799286|FG000|Implantation- Nonrandomized & Randomized|Lost to Follow-up|7
6158426|NCT01166568|9799287|FG001|Implantation- Nonrandomized & Randomized|Lost to Follow-up|1
6158427|NCT01166568|9799288|FG002|Implantation- Nonrandomized & Randomized|Lost to Follow-up|0
6158428|NCT01166568|9799286|FG000|Implantation- Nonrandomized & Randomized|Withdrawal by Subject|7
6158429|NCT01166568|9799287|FG001|Implantation- Nonrandomized & Randomized|Withdrawal by Subject|0
6158430|NCT01166568|9799288|FG002|Implantation- Nonrandomized & Randomized|Withdrawal by Subject|1
6158431|NCT01166646|9799296|FG000|Overall Study|Protocol Violation|0
6158432|NCT01166646|9799297|FG001|Overall Study|Protocol Violation|1
6158433|NCT01166646|9799296|FG000|Overall Study|Adverse Event|1
6158434|NCT01166646|9799297|FG001|Overall Study|Adverse Event|0
6158435|NCT01166659|9799303|FG000|Overall Study|Subject Decision|8
6158436|NCT01166659|9799303|FG000|Overall Study|Investigator Decision|2
6158437|NCT01166659|9799303|FG000|Overall Study|Death|1
6158438|NCT01166659|9799303|FG000|Overall Study|Lost to Follow-up|1
6042813|NCT00385593|9641312|FG001|Overall Study|Incorrect inclusion|0
6042814|NCT00385593|9641311|FG000|Overall Study|Incorrect randomization|0
6042815|NCT00385593|9641312|FG001|Overall Study|Incorrect randomization|1
6042816|NCT00385671|9641321|FG000|Overall Study|Adverse Event|14
6042817|NCT00385671|9641322|FG001|Overall Study|Adverse Event|27
6042818|NCT00385671|9641323|FG002|Overall Study|Adverse Event|18
6042819|NCT00385671|9641321|FG000|Overall Study|Lack of Efficacy|5
6042820|NCT00385671|9641322|FG001|Overall Study|Lack of Efficacy|9
6042821|NCT00385671|9641323|FG002|Overall Study|Lack of Efficacy|5
6042822|NCT00385671|9641321|FG000|Overall Study|Lost to Follow-up|6
6042823|NCT00385671|9641322|FG001|Overall Study|Lost to Follow-up|6
6042824|NCT00385671|9641323|FG002|Overall Study|Lost to Follow-up|5
6042825|NCT00385671|9641321|FG000|Overall Study|Physician Decision|2
6324749|NCT02919475|10066609|FG003|Overall Study|Death|0
6324750|NCT02919475|10066610|FG004|Overall Study|Death|0
6324751|NCT02919475|10066606|FG000|Overall Study|Lost to Follow-up|0
6158439|NCT01166659|9799303|FG000|Overall Study|Study Closed at Site|1
6158440|NCT01166750|9799310|FG000|Overall Study|Lost to Follow-up|1
6158441|NCT01166750|9799311|FG001|Overall Study|Lost to Follow-up|0
6158442|NCT01166763|9799317|FG000|Overall Study|Withdrawal by Subject|3
6158443|NCT01166945|9799323|FG000|Randomized|diagnosed with Group A strep|4
6158444|NCT01166945|9799324|FG001|Randomized|diagnosed with Group A strep|4
6158445|NCT01166945|9799323|FG000|Day 10|NonCompliance/Lost to Follow Up|3
6158446|NCT01166945|9799324|FG001|Day 10|NonCompliance/Lost to Follow Up|2
6158447|NCT01166945|9799323|FG000|Day 15|NonCompliance/Lost to Follow Up|2
6324752|NCT02919475|10066607|FG001|Overall Study|Lost to Follow-up|0
6324753|NCT02919475|10066608|FG002|Overall Study|Lost to Follow-up|0
6158448|NCT01166945|9799324|FG001|Day 15|NonCompliance/Lost to Follow Up|1
6158449|NCT01166945|9799323|FG000|Day 30|Lost to Follow-up|4
6158450|NCT01166945|9799324|FG001|Day 30|Lost to Follow-up|3
6158451|NCT01166958|9799334|FG000|Overall Study|Withdrawal by Subject|1
6158452|NCT01166958|9799335|FG001|Overall Study|Withdrawal by Subject|0
6158453|NCT01167023|9799394|FG000|Overall Study|Lost to Follow-up|0
6158454|NCT01167023|9799395|FG001|Overall Study|Lost to Follow-up|1
6158455|NCT01167023|9799396|FG002|Overall Study|Lost to Follow-up|1
6158456|NCT01167023|9799394|FG000|Overall Study|Screen Failure|0
6158457|NCT01167023|9799395|FG001|Overall Study|Screen Failure|1
6158458|NCT01167023|9799396|FG002|Overall Study|Screen Failure|0
6158459|NCT01167023|9799394|FG000|Overall Study|Sponsor Decision|0
6158460|NCT01167023|9799395|FG001|Overall Study|Sponsor Decision|1
6158461|NCT01167023|9799396|FG002|Overall Study|Sponsor Decision|0
6158462|NCT01167023|9799394|FG000|Overall Study|Withdrawal by Subject|0
6158463|NCT01167023|9799395|FG001|Overall Study|Withdrawal by Subject|0
6158464|NCT01167023|9799396|FG002|Overall Study|Withdrawal by Subject|1
6158465|NCT01167140|9799402|FG000|Overall Study|Withdrawal by Subject|1
6158466|NCT01167153|9799408|FG000|Overall Study|Non-effective therapy|1
6158467|NCT01167153|9799409|FG001|Overall Study|Non-effective therapy|4
6158468|NCT01167153|9799408|FG000|Overall Study|AE including clinical laboratory AE|2
6158469|NCT01167153|9799409|FG001|Overall Study|AE including clinical laboratory AE|8
6158470|NCT01167153|9799408|FG000|Overall Study|Hypotension|1
6158471|NCT01167153|9799409|FG001|Overall Study|Hypotension|0
6158472|NCT01167153|9799408|FG000|Overall Study|Lost to Follow-up|7
6158473|NCT01167153|9799409|FG001|Overall Study|Lost to Follow-up|9
6158474|NCT01167153|9799408|FG000|Overall Study|Non-compliance to concomitant medication|0
6158475|NCT01167153|9799409|FG001|Overall Study|Non-compliance to concomitant medication|2
6158476|NCT01167153|9799408|FG000|Overall Study|Investigator initiation withdrawal,Other|1
6158477|NCT01167153|9799409|FG001|Overall Study|Investigator initiation withdrawal,Other|1
6158478|NCT01167153|9799408|FG000|Overall Study|Withdrawal consent|1
6158479|NCT01167153|9799409|FG001|Overall Study|Withdrawal consent|1
6158480|NCT01167153|9799408|FG000|Overall Study|Subject initiation withdrawal, Other|5
6158481|NCT01167153|9799409|FG001|Overall Study|Subject initiation withdrawal, Other|8
6158482|NCT01167179|9799417|FG000|Overall Study|disease recurrence|4
6158483|NCT01167179|9799418|FG001|Overall Study|disease recurrence|4
6158484|NCT01167179|9799417|FG000|Overall Study|Death|4
6158485|NCT01167179|9799418|FG001|Overall Study|Death|10
6158486|NCT01167179|9799417|FG000|Overall Study|Withdrawal by Subject|1
6158487|NCT01167179|9799418|FG001|Overall Study|Withdrawal by Subject|2
6158488|NCT01167179|9799417|FG000|Overall Study|diverse|6
6158489|NCT01167179|9799418|FG001|Overall Study|diverse|5
6158490|NCT01167192|9799424|FG000|Overall Study|Adverse Event|1
6158491|NCT01167192|9799424|FG000|Overall Study|Death|1
6158492|NCT01167192|9799424|FG000|Overall Study|Withdrawal by Subject|1
6158493|NCT01167192|9799424|FG000|Overall Study|Insurance denial|1
6158494|NCT01167257|9799430|FG000|Overall Study|Lost to Follow-up|2
6158495|NCT01167257|9799431|FG001|Overall Study|Lost to Follow-up|2
6158496|NCT01167257|9799430|FG000|Overall Study|Withdrew consent|1
6158497|NCT01167257|9799431|FG001|Overall Study|Withdrew consent|1
6158498|NCT01167426|9799441|FG000|Overall Study|Lost to Follow-up|6
6158499|NCT01167426|9799441|FG000|Overall Study|Protocol Violation|1
6158500|NCT01167426|9799441|FG000|Overall Study|Withdrawal by Subject|2
6158501|NCT01167426|9799441|FG000|Overall Study|Sponsor Decision|1
6158502|NCT01167582|9799468|FG000|Overall Study|Lost to Follow-up|0
6158503|NCT01167582|9799469|FG001|Overall Study|Lost to Follow-up|1
6158504|NCT01167634|9799493|FG000|Overall Study|Lost to Follow-up|1
6158505|NCT01167634|9799494|FG001|Overall Study|Lost to Follow-up|3
6158506|NCT01167634|9799495|FG002|Overall Study|Lost to Follow-up|3
6158507|NCT01167634|9799496|FG003|Overall Study|Lost to Follow-up|4
6158508|NCT01167634|9799493|FG000|Overall Study|Withdrawal by Subject|1
6158509|NCT01167634|9799494|FG001|Overall Study|Withdrawal by Subject|1
6158510|NCT01167634|9799495|FG002|Overall Study|Withdrawal by Subject|0
6158511|NCT01167634|9799496|FG003|Overall Study|Withdrawal by Subject|0
6158512|NCT01167881|9799523|FG000|Overall Study|Adverse Event|47
6158513|NCT01167881|9799524|FG001|Overall Study|Adverse Event|51
6158514|NCT01167881|9799523|FG000|Overall Study|Lack of Efficacy|4
6158515|NCT01167881|9799524|FG001|Overall Study|Lack of Efficacy|7
6158516|NCT01167881|9799523|FG000|Overall Study|Non compliant with protocol|9
6158517|NCT01167881|9799524|FG001|Overall Study|Non compliant with protocol|18
6158518|NCT01167881|9799523|FG000|Overall Study|Lost to Follow-up|19
6158519|NCT01167881|9799524|FG001|Overall Study|Lost to Follow-up|20
6158520|NCT01167881|9799523|FG000|Overall Study|Patient refusal to cont., not due to AE|45
6158521|NCT01167881|9799524|FG001|Overall Study|Patient refusal to cont., not due to AE|40
6158522|NCT01167881|9799523|FG000|Overall Study|Not treated|4
6158523|NCT01167881|9799524|FG001|Overall Study|Not treated|0
6158524|NCT01167881|9799523|FG000|Overall Study|Other not defined above|31
6158525|NCT01167881|9799524|FG001|Overall Study|Other not defined above|55
6324754|NCT02919475|10066609|FG003|Overall Study|Lost to Follow-up|1
6324755|NCT02919475|10066610|FG004|Overall Study|Lost to Follow-up|0
6324756|NCT02919475|10066606|FG000|Overall Study|Withdrawal by Subject|2
6081182|NCT00620659|9688682|FG004|Placebo Washout Period 1|Withdrawal by Subject|0
6081183|NCT00620659|9688683|FG005|Placebo Washout Period 1|Withdrawal by Subject|0
6158526|NCT01167907|9799532|FG000|Overall Study|Protocol Violation|1
6158527|NCT01167907|9799533|FG001|Overall Study|Protocol Violation|0
6158528|NCT01167907|9799532|FG000|Overall Study|saphenous catheter dislodged before comp|1
6158529|NCT01167907|9799533|FG001|Overall Study|saphenous catheter dislodged before comp|1
6158530|NCT01168232|9799548|FG000|Overall Study|Ineligible-Second primary cancer site|1
6158531|NCT01168232|9799548|FG000|Overall Study|Ineligible- Wrong cell type|6
6158532|NCT01168232|9799548|FG000|Overall Study|Ineligible-Inadequate pathology|1
6158533|NCT01168349|9799552|FG000|Overall Study|Death|157
6158534|NCT01168349|9799552|FG000|Overall Study|Lost to Follow-up|34
6158535|NCT01168349|9799552|FG000|Overall Study|Withdrawal by Subject|9
6158536|NCT01168349|9799552|FG000|Overall Study|Kidney transplantation|3
6158537|NCT01168349|9799552|FG000|Overall Study|Other|22
6158538|NCT01168349|9799552|FG000|Overall Study|Protocol Violation|76
6158539|NCT01168401|9799583|FG000|Overall Study|Lost to Follow-up|1
6158540|NCT01168401|9799584|FG001|Overall Study|Lost to Follow-up|1
6158541|NCT01168401|9799585|FG002|Overall Study|Lost to Follow-up|2
6158542|NCT01168401|9799586|FG003|Overall Study|Lost to Follow-up|1
6081184|NCT00620659|9688678|FG000|Treatment Period 2|Adverse Event|0
6081185|NCT00620659|9688679|FG001|Treatment Period 2|Adverse Event|3
6081186|NCT00620659|9688680|FG002|Treatment Period 2|Adverse Event|0
6081187|NCT00620659|9688681|FG003|Treatment Period 2|Adverse Event|0
6081188|NCT00620659|9688682|FG004|Treatment Period 2|Adverse Event|2
6081189|NCT00620659|9688683|FG005|Treatment Period 2|Adverse Event|0
6081190|NCT00620659|9688678|FG000|Treatment Period 2|Withdrawal by Subject|0
6081191|NCT00620659|9688679|FG001|Treatment Period 2|Withdrawal by Subject|0
6081192|NCT00620659|9688680|FG002|Treatment Period 2|Withdrawal by Subject|1
6081193|NCT00620659|9688681|FG003|Treatment Period 2|Withdrawal by Subject|0
6081194|NCT00620659|9688682|FG004|Treatment Period 2|Withdrawal by Subject|3
6081195|NCT00620659|9688683|FG005|Treatment Period 2|Withdrawal by Subject|0
6158543|NCT01168401|9799587|FG004|Overall Study|Lost to Follow-up|0
6158544|NCT01168401|9799588|FG005|Overall Study|Lost to Follow-up|0
6158545|NCT01168401|9799589|FG006|Overall Study|Lost to Follow-up|0
6158546|NCT01168401|9799590|FG007|Overall Study|Lost to Follow-up|0
6158547|NCT01168401|9799591|FG008|Overall Study|Lost to Follow-up|0
6158548|NCT01168401|9799592|FG009|Overall Study|Lost to Follow-up|0
6158549|NCT01168401|9799593|FG010|Overall Study|Lost to Follow-up|0
6158550|NCT01168401|9799583|FG000|Overall Study|Withdrawal by Subject|0
6158551|NCT01168401|9799584|FG001|Overall Study|Withdrawal by Subject|0
6158552|NCT01168401|9799585|FG002|Overall Study|Withdrawal by Subject|0
6158553|NCT01168401|9799586|FG003|Overall Study|Withdrawal by Subject|1
6158554|NCT01168401|9799587|FG004|Overall Study|Withdrawal by Subject|0
6158555|NCT01168401|9799588|FG005|Overall Study|Withdrawal by Subject|0
6158556|NCT01168401|9799589|FG006|Overall Study|Withdrawal by Subject|0
6158557|NCT01168401|9799590|FG007|Overall Study|Withdrawal by Subject|0
6158558|NCT01168401|9799591|FG008|Overall Study|Withdrawal by Subject|0
6158559|NCT01168401|9799592|FG009|Overall Study|Withdrawal by Subject|0
6158560|NCT01168401|9799593|FG010|Overall Study|Withdrawal by Subject|0
6158561|NCT01168427|9799617|FG000|Overall Study|Patient exited prior to implant|1
6158562|NCT01168596|9799623|FG000|Overall Study|Withdrawal by Subject|3
6158563|NCT01168596|9799624|FG001|Overall Study|Withdrawal by Subject|1
6158564|NCT01168856|9799662|FG000|Overall Study|Lost to Follow-up|4
6158565|NCT01168856|9799663|FG001|Overall Study|Lost to Follow-up|34
6158566|NCT01168856|9799662|FG000|Overall Study|Withdrawal by Subject|6
6158567|NCT01168856|9799663|FG001|Overall Study|Withdrawal by Subject|8
6158568|NCT01168856|9799662|FG000|Overall Study|Physician Decision|2
6158569|NCT01168856|9799663|FG001|Overall Study|Physician Decision|1
6158570|NCT01168856|9799662|FG000|Overall Study|Confirmed Quantifiable HCV RNA|0
6158571|NCT01168856|9799663|FG001|Overall Study|Confirmed Quantifiable HCV RNA|1
6158572|NCT01168856|9799662|FG000|Overall Study|Participant received anti-HCV treatment|1
6158573|NCT01168856|9799663|FG001|Overall Study|Participant received anti-HCV treatment|0
6158574|NCT01168856|9799662|FG000|Overall Study|Death|0
6158575|NCT01168856|9799663|FG001|Overall Study|Death|2
6158576|NCT01168856|9799662|FG000|Overall Study|Other|1
6158577|NCT01168856|9799663|FG001|Overall Study|Other|291
6158578|NCT01168856|9799662|FG000|Overall Study|Protocol Violation|4
6158579|NCT01168856|9799663|FG001|Overall Study|Protocol Violation|6
6158580|NCT01168973|9799693|FG000|Overall Study|Progressive Disease|341
6158581|NCT01168973|9799694|FG001|Overall Study|Progressive Disease|429
6158582|NCT01168973|9799693|FG000|Overall Study|Adverse Event|94
6158583|NCT01168973|9799694|FG001|Overall Study|Adverse Event|55
6158584|NCT01168973|9799693|FG000|Overall Study|Withdrawal by Subject|90
6158585|NCT01168973|9799694|FG001|Overall Study|Withdrawal by Subject|53
6158586|NCT01168973|9799693|FG000|Overall Study|Death|42
6158587|NCT01168973|9799694|FG001|Overall Study|Death|45
6158588|NCT01168973|9799693|FG000|Overall Study|Physician Decision|37
6158589|NCT01168973|9799694|FG001|Overall Study|Physician Decision|19
6158590|NCT01168973|9799693|FG000|Overall Study|Sponsor Decision|2
6158591|NCT01168973|9799694|FG001|Overall Study|Sponsor Decision|1
6158592|NCT01168973|9799693|FG000|Overall Study|Protocol Criterion Not Met and Deviation|7
6042826|NCT00385671|9641322|FG001|Overall Study|Physician Decision|1
6042827|NCT00385671|9641323|FG002|Overall Study|Physician Decision|2
6158593|NCT01168973|9799694|FG001|Overall Study|Protocol Criterion Not Met and Deviation|9
6158594|NCT01168999|9799717|FG000|Overall Study|Lost to Follow-up|2
6158595|NCT01168999|9799718|FG001|Overall Study|Lost to Follow-up|1
6158596|NCT01168999|9799719|FG002|Overall Study|Lost to Follow-up|0
6158597|NCT01168999|9799720|FG003|Overall Study|Lost to Follow-up|0
6158598|NCT01169038|9799730|FG000|Overall Study|Death|1
6158599|NCT01169038|9799730|FG000|Overall Study|Adverse Event|5
6158600|NCT01169038|9799730|FG000|Overall Study|Required antibiotic administration|1
6158601|NCT01169103|9799747|FG000|Overall Study|Lost to Follow-up|3
6158602|NCT01169103|9799748|FG001|Overall Study|Lost to Follow-up|3
6158603|NCT01169103|9799747|FG000|Overall Study|Withdrawal by Subject|3
6158604|NCT01169103|9799748|FG001|Overall Study|Withdrawal by Subject|1
6158605|NCT01169337|9799762|FG000|Overall Study|Lack of Efficacy|5
6158606|NCT01169337|9799763|FG001|Overall Study|Lack of Efficacy|7
6158607|NCT01169337|9799764|FG002|Overall Study|Lack of Efficacy|0
6158608|NCT01169337|9799762|FG000|Overall Study|Adverse Event|12
6158609|NCT01169337|9799763|FG001|Overall Study|Adverse Event|18
6158610|NCT01169337|9799764|FG002|Overall Study|Adverse Event|0
6158611|NCT01169337|9799762|FG000|Overall Study|Death|2
6158612|NCT01169337|9799763|FG001|Overall Study|Death|0
6158613|NCT01169337|9799764|FG002|Overall Study|Death|0
6158614|NCT01169337|9799762|FG000|Overall Study|Withdrawal by Subject|11
6158615|NCT01169337|9799763|FG001|Overall Study|Withdrawal by Subject|11
6158616|NCT01169337|9799764|FG002|Overall Study|Withdrawal by Subject|6
6158617|NCT01169337|9799762|FG000|Overall Study|Noncompliance|2
6158618|NCT01169337|9799763|FG001|Overall Study|Noncompliance|0
6158619|NCT01169337|9799764|FG002|Overall Study|Noncompliance|0
6158620|NCT01169337|9799762|FG000|Overall Study|Other complicating disease|1
6158621|NCT01169337|9799763|FG001|Overall Study|Other complicating disease|1
6158622|NCT01169337|9799764|FG002|Overall Study|Other complicating disease|0
6158623|NCT01169337|9799762|FG000|Overall Study|Physician Decision|1
6158624|NCT01169337|9799763|FG001|Overall Study|Physician Decision|5
6158625|NCT01169337|9799764|FG002|Overall Study|Physician Decision|0
6158626|NCT01169337|9799762|FG000|Overall Study|Alternative therapy|0
6158627|NCT01169337|9799763|FG001|Overall Study|Alternative therapy|2
6158628|NCT01169337|9799764|FG002|Overall Study|Alternative therapy|0
6158629|NCT01169337|9799762|FG000|Overall Study|Changed hospital|0
6158630|NCT01169337|9799763|FG001|Overall Study|Changed hospital|1
6158631|NCT01169337|9799764|FG002|Overall Study|Changed hospital|0
6158632|NCT01169337|9799762|FG000|Overall Study|Never started treatment|0
6158633|NCT01169337|9799763|FG001|Overall Study|Never started treatment|2
6158634|NCT01169337|9799764|FG002|Overall Study|Never started treatment|0
6158635|NCT01169337|9799762|FG000|Overall Study|Reason not reported|1
6158636|NCT01169337|9799763|FG001|Overall Study|Reason not reported|0
6158637|NCT01169337|9799764|FG002|Overall Study|Reason not reported|0
6158638|NCT01169337|9799762|FG000|Overall Study|Continuing lenalidomide|9
6158639|NCT01169337|9799763|FG001|Overall Study|Continuing lenalidomide|43
6158640|NCT01169337|9799764|FG002|Overall Study|Continuing lenalidomide|0
6158641|NCT01169350|9799772|FG000|Overall Study|Physician Decision|3
6158642|NCT01169350|9799772|FG000|Overall Study|Lost to Follow-up|2
6191791|NCT01425801|9848728|FG000|Period 3|Stability criteria not fullfilled|0
6191792|NCT01425801|9848729|FG001|Period 3|Stability criteria not fullfilled|0
6191793|NCT01425801|9848730|FG002|Period 3|Stability criteria not fullfilled|1
6191794|NCT01425801|9848731|FG003|Period 3|Stability criteria not fullfilled|0
6191795|NCT01425801|9848732|FG004|Period 3|Stability criteria not fullfilled|0
6191796|NCT01425801|9848733|FG005|Period 3|Stability criteria not fullfilled|0
6191797|NCT01425801|9848728|FG000|Period 4|Not able to maintain visit schedule|0
6191798|NCT01425801|9848729|FG001|Period 4|Not able to maintain visit schedule|0
6191799|NCT01425801|9848730|FG002|Period 4|Not able to maintain visit schedule|1
6191800|NCT01425801|9848731|FG003|Period 4|Not able to maintain visit schedule|0
6191801|NCT01425801|9848732|FG004|Period 4|Not able to maintain visit schedule|0
6191802|NCT01425801|9848733|FG005|Period 4|Not able to maintain visit schedule|0
6191803|NCT01425814|9848747|FG000|Period 1|Stability criteria not fulfilled|0
6191804|NCT01425814|9848748|FG001|Period 1|Stability criteria not fulfilled|1
6191805|NCT01425814|9848749|FG002|Period 1|Stability criteria not fulfilled|0
6191806|NCT01425814|9848750|FG003|Period 1|Stability criteria not fulfilled|0
6191807|NCT01425814|9848751|FG004|Period 1|Stability criteria not fulfilled|0
6158643|NCT01169493|9799791|FG000|Period 1 (6 Months)|Withdrawal by Subject|0
6158644|NCT01169493|9799792|FG001|Period 1 (6 Months)|Withdrawal by Subject|1
6158645|NCT01169493|9799793|FG002|Period 1 (6 Months)|Withdrawal by Subject|2
6158646|NCT01169493|9799794|FG003|Period 1 (6 Months)|Withdrawal by Subject|0
6158647|NCT01169493|9799795|FG004|Period 1 (6 Months)|Withdrawal by Subject|0
6158648|NCT01169493|9799796|FG005|Period 1 (6 Months)|Withdrawal by Subject|3
6158649|NCT01169493|9799791|FG000|Period 3 (6 Months)|Adverse Event|0
6158650|NCT01169493|9799792|FG001|Period 3 (6 Months)|Adverse Event|1
6158651|NCT01169493|9799793|FG002|Period 3 (6 Months)|Adverse Event|0
6158652|NCT01169493|9799794|FG003|Period 3 (6 Months)|Adverse Event|0
6158653|NCT01169493|9799795|FG004|Period 3 (6 Months)|Adverse Event|0
6158654|NCT01169493|9799796|FG005|Period 3 (6 Months)|Adverse Event|0
6158655|NCT01169493|9799791|FG000|Period 3 (6 Months)|Physician Decision|0
6158656|NCT01169493|9799792|FG001|Period 3 (6 Months)|Physician Decision|1
6158657|NCT01169493|9799793|FG002|Period 3 (6 Months)|Physician Decision|1
6158658|NCT01169493|9799794|FG003|Period 3 (6 Months)|Physician Decision|0
6158659|NCT01169493|9799795|FG004|Period 3 (6 Months)|Physician Decision|0
6158660|NCT01169493|9799796|FG005|Period 3 (6 Months)|Physician Decision|0
6158661|NCT01169532|9799816|FG000|Overall Study|Withdrawal by Subject|1
6158662|NCT01169558|9799820|FG000|Overall Study|Disease progression|98
6158663|NCT01169558|9799820|FG000|Overall Study|Adverse Event|25
6158664|NCT01169558|9799820|FG000|Overall Study|Withdrawal of Consent|8
6158665|NCT01169558|9799820|FG000|Overall Study|Medical Decision|7
6158666|NCT01169558|9799820|FG000|Overall Study|Stable Disease|4
6158667|NCT01169558|9799820|FG000|Overall Study|Lost to Follow-up|4
6158668|NCT01169558|9799820|FG000|Overall Study|Need for Surgery|4
6158669|NCT01169558|9799820|FG000|Overall Study|Non-compliance|2
6158670|NCT01169558|9799820|FG000|Overall Study|Protocol Violation|2
6158671|NCT01169558|9799820|FG000|Overall Study|Partial response|2
6158672|NCT01169636|9799829|FG000|Overall Study|Adverse Event|0
6158673|NCT01169636|9799830|FG001|Overall Study|Adverse Event|0
6158674|NCT01169636|9799831|FG002|Overall Study|Adverse Event|1
6227410|NCT01716754|9900111|FG003|Overall Study|Lost to Follow-up|1
6158675|NCT01169636|9799832|FG003|Overall Study|Adverse Event|1
6158676|NCT01169636|9799833|FG004|Overall Study|Adverse Event|0
6158677|NCT01169636|9799829|FG000|Overall Study|Screen failure|0
6158678|NCT01169636|9799830|FG001|Overall Study|Screen failure|0
6158679|NCT01169636|9799831|FG002|Overall Study|Screen failure|2
6227411|NCT01716754|9900108|FG000|Overall Study|Adverse Event|4
6042828|NCT00385671|9641321|FG000|Overall Study|Protocol Violation|5
6158680|NCT01169636|9799832|FG003|Overall Study|Screen failure|0
6158681|NCT01169636|9799833|FG004|Overall Study|Screen failure|0
6158682|NCT01169636|9799829|FG000|Overall Study|Withdrawal by Subject|0
6158683|NCT01169636|9799830|FG001|Overall Study|Withdrawal by Subject|0
6081196|NCT00620659|9688678|FG000|Placebo Washout Period 2|Adverse Event|2
6081197|NCT00620659|9688679|FG001|Placebo Washout Period 2|Adverse Event|0
6081198|NCT00620659|9688680|FG002|Placebo Washout Period 2|Adverse Event|0
6158684|NCT01169636|9799831|FG002|Overall Study|Withdrawal by Subject|0
6158685|NCT01169636|9799832|FG003|Overall Study|Withdrawal by Subject|0
6158686|NCT01169636|9799833|FG004|Overall Study|Withdrawal by Subject|3
6158687|NCT01169649|9799843|FG000|Overall Study|Patient Not Treated|3
6158688|NCT01169675|9799852|FG000|Overall Study|Progressive disease|13
6158689|NCT01169675|9799853|FG001|Overall Study|Progressive disease|2
6158690|NCT01169675|9799854|FG002|Overall Study|Progressive disease|5
6158691|NCT01169675|9799855|FG003|Overall Study|Progressive disease|15
6158692|NCT01169675|9799856|FG004|Overall Study|Progressive disease|1
6158693|NCT01169675|9799852|FG000|Overall Study|Dose Limiting Toxicity (DLT)|1
6158694|NCT01169675|9799853|FG001|Overall Study|Dose Limiting Toxicity (DLT)|0
6158695|NCT01169675|9799854|FG002|Overall Study|Dose Limiting Toxicity (DLT)|0
6158696|NCT01169675|9799855|FG003|Overall Study|Dose Limiting Toxicity (DLT)|0
6158697|NCT01169675|9799856|FG004|Overall Study|Dose Limiting Toxicity (DLT)|2
6158698|NCT01169675|9799852|FG000|Overall Study|Adverse Event|5
6158699|NCT01169675|9799853|FG001|Overall Study|Adverse Event|1
6158700|NCT01169675|9799854|FG002|Overall Study|Adverse Event|2
6158701|NCT01169675|9799855|FG003|Overall Study|Adverse Event|0
6158702|NCT01169675|9799856|FG004|Overall Study|Adverse Event|0
6158703|NCT01169675|9799852|FG000|Overall Study|Withdrawal by Subject|1
6158704|NCT01169675|9799853|FG001|Overall Study|Withdrawal by Subject|0
6158705|NCT01169675|9799854|FG002|Overall Study|Withdrawal by Subject|0
6081199|NCT00620659|9688681|FG003|Placebo Washout Period 2|Adverse Event|0
6081200|NCT00620659|9688682|FG004|Placebo Washout Period 2|Adverse Event|0
6081201|NCT00620659|9688683|FG005|Placebo Washout Period 2|Adverse Event|0
6081202|NCT00620659|9688678|FG000|Treatment Period 3|Adverse Event|0
6081203|NCT00620659|9688679|FG001|Treatment Period 3|Adverse Event|2
6081204|NCT00620659|9688680|FG002|Treatment Period 3|Adverse Event|0
6081205|NCT00620659|9688681|FG003|Treatment Period 3|Adverse Event|0
6081206|NCT00620659|9688682|FG004|Treatment Period 3|Adverse Event|0
6081207|NCT00620659|9688683|FG005|Treatment Period 3|Adverse Event|0
6081208|NCT00620659|9688678|FG000|Treatment Period 3|Withdrawal by Subject|0
6158706|NCT01169675|9799855|FG003|Overall Study|Withdrawal by Subject|1
6158707|NCT01169675|9799856|FG004|Overall Study|Withdrawal by Subject|2
6158708|NCT01169675|9799852|FG000|Overall Study|Other Reason Not Defined Above|0
6158709|NCT01169675|9799853|FG001|Overall Study|Other Reason Not Defined Above|0
6158710|NCT01169675|9799854|FG002|Overall Study|Other Reason Not Defined Above|0
6158711|NCT01169675|9799855|FG003|Overall Study|Other Reason Not Defined Above|1
6158712|NCT01169675|9799856|FG004|Overall Study|Other Reason Not Defined Above|1
6158713|NCT01169701|9799870|FG000|Overall Study|Lost to Follow-up|1
6158714|NCT01169701|9799871|FG001|Overall Study|Lost to Follow-up|1
6158715|NCT01169701|9799870|FG000|Overall Study|Withdrawal by Subject|1
6158716|NCT01169701|9799871|FG001|Overall Study|Withdrawal by Subject|3
6158717|NCT01169701|9799870|FG000|Overall Study|Adverse Event|1
6158718|NCT01169701|9799871|FG001|Overall Study|Adverse Event|2
6158719|NCT01169701|9799870|FG000|Overall Study|Exclusion criteria|2
6158720|NCT01169701|9799871|FG001|Overall Study|Exclusion criteria|0
6158721|NCT01169701|9799870|FG000|Overall Study|Death|0
6158722|NCT01169701|9799871|FG001|Overall Study|Death|1
6158723|NCT01169701|9799870|FG000|Overall Study|Administrative problems|0
6158724|NCT01169701|9799871|FG001|Overall Study|Administrative problems|1
6158725|NCT01169701|9799870|FG000|Overall Study|Serious adverse event|0
6158726|NCT01169701|9799871|FG001|Overall Study|Serious adverse event|1
6158727|NCT01169701|9799870|FG000|Overall Study|Sponsor decision|0
6158728|NCT01169701|9799871|FG001|Overall Study|Sponsor decision|1
6158729|NCT01169779|9799879|FG000|Overall Study|Adverse Event|3
6158730|NCT01169779|9799880|FG001|Overall Study|Adverse Event|11
6158731|NCT01169779|9799879|FG000|Overall Study|Lack of Efficacy|1
6158732|NCT01169779|9799880|FG001|Overall Study|Lack of Efficacy|0
6158733|NCT01169779|9799879|FG000|Overall Study|Protocol Violation|1
6158734|NCT01169779|9799880|FG001|Overall Study|Protocol Violation|1
6158735|NCT01169779|9799879|FG000|Overall Study|Withdrawal by Subject|3
6158736|NCT01169779|9799880|FG001|Overall Study|Withdrawal by Subject|2
6158737|NCT01169779|9799879|FG000|Overall Study|Familial and personal reasons|3
6158738|NCT01169779|9799880|FG001|Overall Study|Familial and personal reasons|3
6158739|NCT01169844|9799888|FG000|Overall Study|Adverse Event|0
6158740|NCT01169844|9799889|FG001|Overall Study|Adverse Event|1
6158741|NCT01169844|9799888|FG000|Overall Study|Patient withdrew consent|4
6158742|NCT01169844|9799889|FG001|Overall Study|Patient withdrew consent|0
6158743|NCT01169844|9799888|FG000|Overall Study|Unsatisfactory therapeutic effect|1
6158744|NCT01169844|9799889|FG001|Overall Study|Unsatisfactory therapeutic effect|0
6158745|NCT01169987|9799895|FG000|Overall Study|Withdrawal by Subject|3
6158746|NCT01169987|9799895|FG000|Overall Study|Lost to Follow-up|24
6158747|NCT01169987|9799895|FG000|Overall Study|Other|4
6158748|NCT01170039|9799907|FG000|Overall Study|Withdrawal by Subject|5
6158749|NCT01170039|9799908|FG001|Overall Study|Withdrawal by Subject|3
6158750|NCT01170039|9799907|FG000|Overall Study|Lack of funding, drug not available|3
6158751|NCT01170039|9799908|FG001|Overall Study|Lack of funding, drug not available|3
6158752|NCT01170065|9799917|FG000|Overall Study|Adverse Event|17
6158753|NCT01170065|9799918|FG001|Overall Study|Adverse Event|50
6158754|NCT01170065|9799919|FG002|Overall Study|Adverse Event|10
6158755|NCT01170065|9799917|FG000|Overall Study|Lost to Follow-up|1
6158756|NCT01170065|9799918|FG001|Overall Study|Lost to Follow-up|4
6158757|NCT01170065|9799919|FG002|Overall Study|Lost to Follow-up|1
6158758|NCT01170065|9799917|FG000|Overall Study|Consent withdrawn, not due to AE|2
6081209|NCT00620659|9688679|FG001|Treatment Period 3|Withdrawal by Subject|0
6081210|NCT00620659|9688680|FG002|Treatment Period 3|Withdrawal by Subject|0
6081211|NCT00620659|9688681|FG003|Treatment Period 3|Withdrawal by Subject|1
6081212|NCT00620659|9688682|FG004|Treatment Period 3|Withdrawal by Subject|0
6081213|NCT00620659|9688683|FG005|Treatment Period 3|Withdrawal by Subject|0
6081214|NCT00620750|9688704|FG000|Overall Study|Lost to Follow-up|25
6081215|NCT00620763|9688708|FG000|Period: First Intervention|Withdrawal by Subject|0
6081216|NCT00620763|9688709|FG001|Period: First Intervention|Withdrawal by Subject|2
6081217|NCT00620763|9688708|FG000|Period: First Intervention|Protocol Violation|0
6081218|NCT00620763|9688709|FG001|Period: First Intervention|Protocol Violation|3
6081219|NCT00620763|9688708|FG000|Period: Second Intervention|Withdrawal by Subject|1
6081220|NCT00620763|9688709|FG001|Period: Second Intervention|Withdrawal by Subject|0
6081221|NCT00620776|9688717|FG000|Overall Study|Did not receive treatment|3
6081222|NCT00620776|9688718|FG001|Overall Study|Did not receive treatment|5
6081223|NCT00620776|9688717|FG000|Overall Study|Adverse Event|2
6081224|NCT00620776|9688718|FG001|Overall Study|Adverse Event|3
6081225|NCT00620776|9688717|FG000|Overall Study|Lack of Efficacy|2
6081226|NCT00620776|9688718|FG001|Overall Study|Lack of Efficacy|1
6081227|NCT00620776|9688717|FG000|Overall Study|Lost to Follow-up|2
6081228|NCT00620776|9688718|FG001|Overall Study|Lost to Follow-up|5
6081229|NCT00620776|9688717|FG000|Overall Study|Withdrawal by Subject|3
6081230|NCT00620776|9688718|FG001|Overall Study|Withdrawal by Subject|2
6081231|NCT00620815|9688727|FG000|Overall Study|Adverse Event|1
6081232|NCT00620815|9688728|FG001|Overall Study|Adverse Event|1
6081233|NCT00620815|9688729|FG002|Overall Study|Adverse Event|2
6158759|NCT01170065|9799918|FG001|Overall Study|Consent withdrawn, not due to AE|4
6158760|NCT01170065|9799919|FG002|Overall Study|Consent withdrawn, not due to AE|2
6081234|NCT00620815|9688727|FG000|Overall Study|Withdrawal by Subject|1
6158761|NCT01170065|9799917|FG000|Overall Study|Reason other than specified|3
6158762|NCT01170065|9799918|FG001|Overall Study|Reason other than specified|8
6081235|NCT00620815|9688728|FG001|Overall Study|Withdrawal by Subject|2
6158763|NCT01170065|9799919|FG002|Overall Study|Reason other than specified|3
6158764|NCT01170065|9799917|FG000|Overall Study|Ongoing after planned observation time|5
6158765|NCT01170065|9799918|FG001|Overall Study|Ongoing after planned observation time|26
6081236|NCT00620815|9688729|FG002|Overall Study|Withdrawal by Subject|0
6081237|NCT00620815|9688727|FG000|Overall Study|Lost to Follow-up|1
6081238|NCT00620815|9688728|FG001|Overall Study|Lost to Follow-up|6
6081239|NCT00620815|9688729|FG002|Overall Study|Lost to Follow-up|3
6081240|NCT00620815|9688727|FG000|Overall Study|Inappropriate enrolment|0
6081241|NCT00620815|9688728|FG001|Overall Study|Inappropriate enrolment|0
6081242|NCT00620815|9688729|FG002|Overall Study|Inappropriate enrolment|1
6081243|NCT00620815|9688727|FG000|Overall Study|Protocol Violation|1
6081244|NCT00620815|9688728|FG001|Overall Study|Protocol Violation|2
6158766|NCT01170065|9799919|FG002|Overall Study|Ongoing after planned observation time|10
6158767|NCT01170091|9799927|FG000|Overall Study|Missing efficacy evaluation|3
6158768|NCT01170091|9799927|FG000|Overall Study|Treatment duration is less than 4 weeks|21
6158769|NCT01170208|9799943|FG000|Overall Study|Withdrawal by Subject|5
6158770|NCT01170208|9799944|FG001|Overall Study|Withdrawal by Subject|0
6158771|NCT01170208|9799945|FG002|Overall Study|Withdrawal by Subject|1
6158772|NCT01170208|9799943|FG000|Overall Study|Protocol Violation|1
6158773|NCT01170208|9799944|FG001|Overall Study|Protocol Violation|0
6158774|NCT01170208|9799945|FG002|Overall Study|Protocol Violation|1
6158775|NCT01170221|9799958|FG000|Overall Study|Lost to Follow-up|22
6158776|NCT01170221|9799959|FG001|Overall Study|Lost to Follow-up|21
6158777|NCT01170221|9799958|FG000|Overall Study|Withdrawal by Subject|9
6158778|NCT01170221|9799959|FG001|Overall Study|Withdrawal by Subject|7
6158779|NCT01170221|9799958|FG000|Overall Study|Subject completed only screening and LFU|1
6158780|NCT01170221|9799959|FG001|Overall Study|Subject completed only screening and LFU|0
6158781|NCT01170221|9799958|FG000|Overall Study|Randomized but not treated|1
6158782|NCT01170221|9799959|FG001|Overall Study|Randomized but not treated|0
6158783|NCT01170273|9799976|FG000|Overall Study|Lost to Follow-up|6
6158784|NCT01170273|9799977|FG001|Overall Study|Lost to Follow-up|8
6158785|NCT01170273|9799976|FG000|Overall Study|Protocol Violation|1
6158786|NCT01170273|9799977|FG001|Overall Study|Protocol Violation|0
6158787|NCT01170273|9799976|FG000|Overall Study|Death|1
6158788|NCT01170273|9799977|FG001|Overall Study|Death|0
6158789|NCT01170273|9799976|FG000|Overall Study|Adverse Event|0
6158790|NCT01170273|9799977|FG001|Overall Study|Adverse Event|1
6158791|NCT01170364|9799985|FG000|Overall Study|Protocol Violation|4
6158792|NCT01170364|9799986|FG001|Overall Study|Protocol Violation|1
6158793|NCT01170598|9800032|FG000|Overall Study|Withdrawal by Subject|1
6158794|NCT01170598|9800032|FG000|Overall Study|Death|3
6158795|NCT01170598|9800032|FG000|Overall Study|Lost to Follow-up|1
6158796|NCT01170598|9800032|FG000|Overall Study|Refused|1
6158797|NCT01170663|9800038|FG000|Overall Study|Lost to Follow-up|3
6158798|NCT01170663|9800039|FG001|Overall Study|Lost to Follow-up|9
6158799|NCT01170663|9800038|FG000|Overall Study|Withdrawal of consent without follow-up|11
6158800|NCT01170663|9800039|FG001|Overall Study|Withdrawal of consent without follow-up|11
6158801|NCT01170962|9800081|FG000|Treatment Period|Lack of Efficacy|96
6158802|NCT01170962|9800082|FG001|Treatment Period|Lack of Efficacy|91
6158803|NCT01170962|9800083|FG002|Treatment Period|Lack of Efficacy|7
6158804|NCT01170962|9800081|FG000|Treatment Period|Adverse Event|11
6158805|NCT01170962|9800082|FG001|Treatment Period|Adverse Event|12
6158806|NCT01170962|9800083|FG002|Treatment Period|Adverse Event|3
6158807|NCT01170962|9800081|FG000|Treatment Period|Withdrawal by Subject|2
6158808|NCT01170962|9800082|FG001|Treatment Period|Withdrawal by Subject|1
6158809|NCT01170962|9800083|FG002|Treatment Period|Withdrawal by Subject|0
6158810|NCT01170962|9800081|FG000|Treatment Period|Lost to Follow-up|1
6158811|NCT01170962|9800082|FG001|Treatment Period|Lost to Follow-up|1
6158812|NCT01170962|9800083|FG002|Treatment Period|Lost to Follow-up|1
6158813|NCT01170962|9800081|FG000|Treatment Period|Participant no longer meets criteria|0
6158814|NCT01170962|9800082|FG001|Treatment Period|Participant no longer meets criteria|1
6158815|NCT01170962|9800083|FG002|Treatment Period|Participant no longer meets criteria|0
6081245|NCT00620815|9688729|FG002|Overall Study|Protocol Violation|1
6081246|NCT00620854|9688768|FG000|Washout 1|Withdrawal by Subject|0
6081247|NCT00620854|9688769|FG001|Washout 1|Withdrawal by Subject|0
6081248|NCT00620854|9688770|FG002|Washout 1|Withdrawal by Subject|1
6081249|NCT00620854|9688771|FG003|Washout 1|Withdrawal by Subject|1
6081250|NCT00620854|9688772|FG004|Washout 1|Withdrawal by Subject|0
6081251|NCT00620854|9688773|FG005|Washout 1|Withdrawal by Subject|0
6081252|NCT00621023|9688788|FG000|Overall Study|Death|5
6081253|NCT00621023|9688788|FG000|Overall Study|Follow up discontinued|1
6081254|NCT00621140|9688803|FG000|Overall Study|Adverse Event|4
6081255|NCT00621140|9688804|FG001|Overall Study|Adverse Event|5
6081256|NCT00621140|9688803|FG000|Overall Study|Lost to Follow-up|1
6081257|NCT00621140|9688804|FG001|Overall Study|Lost to Follow-up|2
6081258|NCT00621140|9688803|FG000|Overall Study|Withdrawal by Subject|4
6081259|NCT00621140|9688804|FG001|Overall Study|Withdrawal by Subject|6
6158816|NCT01170962|9800081|FG000|Treatment Period|Request to discontinue treatment|7
6158817|NCT01170962|9800082|FG001|Treatment Period|Request to discontinue treatment|3
6158818|NCT01170962|9800083|FG002|Treatment Period|Request to discontinue treatment|1
6158819|NCT01170962|9800081|FG000|Treatment Period|Completed 24 Week treatment period only|10
6158820|NCT01170962|9800082|FG001|Treatment Period|Completed 24 Week treatment period only|2
6158821|NCT01170962|9800083|FG002|Treatment Period|Completed 24 Week treatment period only|0
6158822|NCT01170962|9800081|FG000|Follow up Period|Withdrawal by Subject|14
6158823|NCT01170962|9800082|FG001|Follow up Period|Withdrawal by Subject|10
6158824|NCT01170962|9800083|FG002|Follow up Period|Withdrawal by Subject|2
6158825|NCT01170962|9800081|FG000|Follow up Period|Lost to Follow-up|13
6158826|NCT01170962|9800082|FG001|Follow up Period|Lost to Follow-up|8
6158827|NCT01170962|9800083|FG002|Follow up Period|Lost to Follow-up|1
6158828|NCT01170962|9800081|FG000|Follow up Period|Death|2
6158829|NCT01170962|9800082|FG001|Follow up Period|Death|2
6158830|NCT01170962|9800083|FG002|Follow up Period|Death|0
6158831|NCT01170962|9800081|FG000|Follow up Period|Others|10
6158832|NCT01170962|9800082|FG001|Follow up Period|Others|7
6158833|NCT01170962|9800083|FG002|Follow up Period|Others|3
6158834|NCT01171183|9800112|FG000|Residential Facility (Weeks 1-2)|Withdrawal by Subject|2
6158835|NCT01171183|9800113|FG001|Residential Facility (Weeks 1-2)|Withdrawal by Subject|2
6158836|NCT01171183|9800112|FG000|Residential Facility (Weeks 1-2)|Protocol Violation|0
6158837|NCT01171183|9800113|FG001|Residential Facility (Weeks 1-2)|Protocol Violation|1
6158838|NCT01171183|9800112|FG000|Residential Facility (Weeks 1-2)|BP outside of study parameters|0
6158839|NCT01171183|9800113|FG001|Residential Facility (Weeks 1-2)|BP outside of study parameters|3
6158840|NCT01171183|9800112|FG000|Outpatient Participation (Weeks 3-10)|Withdrawal by Subject|2
6158841|NCT01171183|9800113|FG001|Outpatient Participation (Weeks 3-10)|Withdrawal by Subject|2
6158842|NCT01171183|9800112|FG000|Outpatient Participation (Weeks 3-10)|Lost to Follow-up|7
6158843|NCT01171183|9800113|FG001|Outpatient Participation (Weeks 3-10)|Lost to Follow-up|3
6158844|NCT01171183|9800112|FG000|Outpatient Participation (Weeks 3-10)|Use of contraindicated med: PI term|1
6158845|NCT01171183|9800113|FG001|Outpatient Participation (Weeks 3-10)|Use of contraindicated med: PI term|0
6158846|NCT01171521|9800119|FG000|Overall Study|Lost to Follow-up|5
6158847|NCT01171521|9800119|FG000|Overall Study|screen failure|1
6158848|NCT01171612|9800123|FG000|Overall Study|Lost to Follow-up|51
6158849|NCT01171625|9800130|FG000|Overall Study|On-Protocol|67
6158850|NCT01171625|9800130|FG000|Overall Study|Death|38
6158851|NCT01171625|9800130|FG000|Overall Study|Withdrawal by Subject|31
6158852|NCT01171625|9800130|FG000|Overall Study|Explanted|10
6158853|NCT01171625|9800130|FG000|Overall Study|Lost to Follow-up|5
6158854|NCT01171625|9800130|FG000|Overall Study|Patient received valve-in-valve|3
6158855|NCT01171625|9800130|FG000|Overall Study|Other|1
6158856|NCT01171625|9800130|FG000|Overall Study|Consented but did not receive device|25
6158857|NCT01171677|9800144|FG000|Overall Study|Withdrawal by Subject|0
6158858|NCT01171677|9800145|FG001|Overall Study|Withdrawal by Subject|3
6158859|NCT01171677|9800144|FG000|Overall Study|Adverse Event|1
6158860|NCT01171677|9800145|FG001|Overall Study|Adverse Event|0
6158861|NCT01171677|9800144|FG000|Overall Study|completed <70% IntenSati classes|5
6158862|NCT01171677|9800145|FG001|Overall Study|completed <70% IntenSati classes|0
6158863|NCT01171820|9800171|FG000|Overall Study|Death|3
6158864|NCT01171820|9800172|FG001|Overall Study|Death|3
6158865|NCT01171820|9800171|FG000|Overall Study|Lost to Follow-up|0
6158866|NCT01171820|9800172|FG001|Overall Study|Lost to Follow-up|1
6158867|NCT01171820|9800171|FG000|Overall Study|Withdrawal by Subject|2
6158868|NCT01171820|9800172|FG001|Overall Study|Withdrawal by Subject|0
6158869|NCT01171820|9800171|FG000|Overall Study|Physician Decision|0
6158870|NCT01171820|9800172|FG001|Overall Study|Physician Decision|1
6158871|NCT01171820|9800171|FG000|Overall Study|1-Year Missed Visit|1
6158872|NCT01171820|9800172|FG001|Overall Study|1-Year Missed Visit|1
6158873|NCT01171963|9800189|FG000|Overall Study|Adverse Event|10
6158874|NCT01171963|9800190|FG001|Overall Study|Adverse Event|15
6158875|NCT01171963|9800189|FG000|Overall Study|Lost to Follow-up|23
6158876|NCT01171963|9800190|FG001|Overall Study|Lost to Follow-up|24
6158877|NCT01171963|9800189|FG000|Overall Study|Other - diarrhoea|1
6158878|NCT01171963|9800190|FG001|Overall Study|Other - diarrhoea|0
6158879|NCT01171963|9800189|FG000|Overall Study|Withdrawal by Subject|114
6158880|NCT01171963|9800190|FG001|Overall Study|Withdrawal by Subject|129
6158881|NCT01171976|9800202|FG000|Overall Study|Protocol Violation|0
6158882|NCT01171976|9800203|FG001|Overall Study|Protocol Violation|0
6158883|NCT01171976|9800204|FG002|Overall Study|Protocol Violation|1
6158884|NCT01171976|9800202|FG000|Overall Study|Death|2
6158885|NCT01171976|9800203|FG001|Overall Study|Death|4
6158886|NCT01171976|9800204|FG002|Overall Study|Death|1
6158887|NCT01171976|9800202|FG000|Overall Study|Lost to Follow-up|4
6158888|NCT01171976|9800203|FG001|Overall Study|Lost to Follow-up|0
6158889|NCT01171976|9800204|FG002|Overall Study|Lost to Follow-up|2
6158890|NCT01171976|9800202|FG000|Overall Study|Withdrawal by Subject|1
6158891|NCT01171976|9800203|FG001|Overall Study|Withdrawal by Subject|5
6158892|NCT01171976|9800204|FG002|Overall Study|Withdrawal by Subject|6
6158893|NCT01171976|9800202|FG000|Overall Study|Abnormal test result|1
6158894|NCT01171976|9800203|FG001|Overall Study|Abnormal test result|0
6158895|NCT01171976|9800204|FG002|Overall Study|Abnormal test result|0
6158896|NCT01171976|9800202|FG000|Overall Study|Adverse Event|6
6158897|NCT01171976|9800203|FG001|Overall Study|Adverse Event|2
6158898|NCT01171976|9800204|FG002|Overall Study|Adverse Event|5
6158899|NCT01171989|9800215|FG000|Overall Study|Lost to Follow-up|0
6158900|NCT01171989|9800216|FG001|Overall Study|Lost to Follow-up|0
6158901|NCT01171989|9800217|FG002|Overall Study|Lost to Follow-up|1
6158902|NCT01172275|9800258|FG000|Overall Study|Lost to Follow-up|1
6158903|NCT01172275|9800259|FG001|Overall Study|Lost to Follow-up|0
6158904|NCT01172275|9800258|FG000|Overall Study|Protocol Violation|1
6158905|NCT01172275|9800259|FG001|Overall Study|Protocol Violation|0
6158906|NCT01172288|9800267|FG000|Overall Study|Adverse Event|1
6158907|NCT01172288|9800268|FG001|Overall Study|Adverse Event|0
6158908|NCT01172288|9800267|FG000|Overall Study|Protocol Violation|0
6158909|NCT01172288|9800268|FG001|Overall Study|Protocol Violation|1
6158910|NCT01172535|9800302|FG000|Overall Study|Death|3
6158911|NCT01172535|9800302|FG000|Overall Study|Withdrawal by Subject|2
6158912|NCT01172535|9800302|FG000|Overall Study|Lost to Follow-up|1
6158913|NCT01172535|9800302|FG000|Overall Study|Ineligible at study entry|1
6158914|NCT01172535|9800302|FG000|Overall Study|Unwilling to adhere to study requirement|1
6158915|NCT01172639|9800323|FG000|Overall Study|Death|1
6158916|NCT01172639|9800324|FG001|Overall Study|Death|1
6158917|NCT01172639|9800325|FG002|Overall Study|Death|0
6158918|NCT01172639|9800326|FG003|Overall Study|Death|0
6158919|NCT01172639|9800327|FG004|Overall Study|Death|0
6158920|NCT01172639|9800323|FG000|Overall Study|Lost to Follow-up|9
6158921|NCT01172639|9800324|FG001|Overall Study|Lost to Follow-up|7
6158922|NCT01172639|9800325|FG002|Overall Study|Lost to Follow-up|11
6158923|NCT01172639|9800326|FG003|Overall Study|Lost to Follow-up|6
6158924|NCT01172639|9800327|FG004|Overall Study|Lost to Follow-up|6
6158925|NCT01172639|9800323|FG000|Overall Study|Withdrawal by Subject|3
6158926|NCT01172639|9800324|FG001|Overall Study|Withdrawal by Subject|3
6158927|NCT01172639|9800325|FG002|Overall Study|Withdrawal by Subject|5
6158928|NCT01172639|9800326|FG003|Overall Study|Withdrawal by Subject|5
6158929|NCT01172639|9800327|FG004|Overall Study|Withdrawal by Subject|0
6158930|NCT01172808|9800343|FG000|Overall Study|Adverse Event|8
6158931|NCT01172808|9800344|FG001|Overall Study|Adverse Event|4
6158932|NCT01172808|9800345|FG002|Overall Study|Adverse Event|8
6158933|NCT01172808|9800346|FG003|Overall Study|Adverse Event|3
6158934|NCT01172808|9800343|FG000|Overall Study|Lack of Efficacy|1
6158935|NCT01172808|9800344|FG001|Overall Study|Lack of Efficacy|0
6158936|NCT01172808|9800345|FG002|Overall Study|Lack of Efficacy|0
6158937|NCT01172808|9800346|FG003|Overall Study|Lack of Efficacy|0
6158938|NCT01172808|9800343|FG000|Overall Study|Protocol Violation|2
6158939|NCT01172808|9800344|FG001|Overall Study|Protocol Violation|2
6158940|NCT01172808|9800345|FG002|Overall Study|Protocol Violation|2
6158941|NCT01172808|9800346|FG003|Overall Study|Protocol Violation|0
6158942|NCT01172808|9800343|FG000|Overall Study|Lost to Follow-up|0
6158943|NCT01172808|9800344|FG001|Overall Study|Lost to Follow-up|1
6158944|NCT01172808|9800345|FG002|Overall Study|Lost to Follow-up|1
6158945|NCT01172808|9800346|FG003|Overall Study|Lost to Follow-up|3
6158946|NCT01172808|9800343|FG000|Overall Study|Withdrawal by Subject|4
6158947|NCT01172808|9800344|FG001|Overall Study|Withdrawal by Subject|1
6158948|NCT01172808|9800345|FG002|Overall Study|Withdrawal by Subject|3
6158949|NCT01172808|9800346|FG003|Overall Study|Withdrawal by Subject|2
6158950|NCT01172808|9800343|FG000|Overall Study|Other|6
6158951|NCT01172808|9800344|FG001|Overall Study|Other|5
6158952|NCT01172808|9800345|FG002|Overall Study|Other|9
6158953|NCT01172808|9800346|FG003|Overall Study|Other|7
6158954|NCT01172821|9800360|FG000|Overall Study|Adverse Event|5
6158955|NCT01172821|9800361|FG001|Overall Study|Adverse Event|2
6158956|NCT01172821|9800362|FG002|Overall Study|Adverse Event|2
6158957|NCT01172821|9800363|FG003|Overall Study|Adverse Event|7
6158958|NCT01172821|9800360|FG000|Overall Study|Protocol Violation|0
6158959|NCT01172821|9800361|FG001|Overall Study|Protocol Violation|2
6158960|NCT01172821|9800362|FG002|Overall Study|Protocol Violation|1
6227412|NCT01716754|9900109|FG001|Overall Study|Adverse Event|2
6158961|NCT01172821|9800363|FG003|Overall Study|Protocol Violation|2
6158962|NCT01172821|9800360|FG000|Overall Study|Lost to Follow-up|4
6158963|NCT01172821|9800361|FG001|Overall Study|Lost to Follow-up|1
6158964|NCT01172821|9800362|FG002|Overall Study|Lost to Follow-up|2
6158965|NCT01172821|9800363|FG003|Overall Study|Lost to Follow-up|2
6158966|NCT01172821|9800360|FG000|Overall Study|Withdrawal by Subject|2
6158967|NCT01172821|9800361|FG001|Overall Study|Withdrawal by Subject|3
6158968|NCT01172821|9800362|FG002|Overall Study|Withdrawal by Subject|3
6158969|NCT01172821|9800363|FG003|Overall Study|Withdrawal by Subject|3
6158970|NCT01172821|9800360|FG000|Overall Study|Other|3
6158971|NCT01172821|9800361|FG001|Overall Study|Other|4
6158972|NCT01172821|9800362|FG002|Overall Study|Other|5
6158973|NCT01172821|9800363|FG003|Overall Study|Other|3
6158974|NCT01172847|9800373|FG000|Overall Study|Withdrawal by Subject|3
6158975|NCT01172873|9800385|FG000|Overall Study|Withdrawal by Subject|3
6158976|NCT01172873|9800386|FG001|Overall Study|Withdrawal by Subject|2
6191808|NCT01425814|9848752|FG005|Period 1|Stability criteria not fulfilled|0
6158977|NCT01172938|9800395|FG000|Placebo-controlled Phase (Week 0-24)|Adverse Event|11
6158978|NCT01172938|9800396|FG001|Placebo-controlled Phase (Week 0-24)|Adverse Event|8
6158979|NCT01172938|9800397|FG002|Placebo-controlled Phase (Week 0-24)|Adverse Event|10
6158980|NCT01172938|9800398|FG003|Placebo-controlled Phase (Week 0-24)|Adverse Event|0
6158981|NCT01172938|9800399|FG004|Placebo-controlled Phase (Week 0-24)|Adverse Event|0
6158982|NCT01172938|9800400|FG005|Placebo-controlled Phase (Week 0-24)|Adverse Event|0
6158983|NCT01172938|9800401|FG006|Placebo-controlled Phase (Week 0-24)|Adverse Event|0
6158984|NCT01172938|9800402|FG007|Placebo-controlled Phase (Week 0-24)|Adverse Event|0
6158985|NCT01172938|9800403|FG008|Placebo-controlled Phase (Week 0-24)|Adverse Event|0
6158986|NCT01172938|9800395|FG000|Placebo-controlled Phase (Week 0-24)|Lack of Efficacy|4
6158987|NCT01172938|9800396|FG001|Placebo-controlled Phase (Week 0-24)|Lack of Efficacy|5
6158988|NCT01172938|9800397|FG002|Placebo-controlled Phase (Week 0-24)|Lack of Efficacy|4
6158989|NCT01172938|9800398|FG003|Placebo-controlled Phase (Week 0-24)|Lack of Efficacy|0
6158990|NCT01172938|9800399|FG004|Placebo-controlled Phase (Week 0-24)|Lack of Efficacy|0
6158991|NCT01172938|9800400|FG005|Placebo-controlled Phase (Week 0-24)|Lack of Efficacy|0
6158992|NCT01172938|9800401|FG006|Placebo-controlled Phase (Week 0-24)|Lack of Efficacy|0
6158993|NCT01172938|9800402|FG007|Placebo-controlled Phase (Week 0-24)|Lack of Efficacy|0
6158994|NCT01172938|9800403|FG008|Placebo-controlled Phase (Week 0-24)|Lack of Efficacy|0
6158995|NCT01172938|9800395|FG000|Placebo-controlled Phase (Week 0-24)|Non-compliance with Study Drug|0
6158996|NCT01172938|9800396|FG001|Placebo-controlled Phase (Week 0-24)|Non-compliance with Study Drug|1
6158997|NCT01172938|9800397|FG002|Placebo-controlled Phase (Week 0-24)|Non-compliance with Study Drug|2
6158998|NCT01172938|9800398|FG003|Placebo-controlled Phase (Week 0-24)|Non-compliance with Study Drug|0
6158999|NCT01172938|9800399|FG004|Placebo-controlled Phase (Week 0-24)|Non-compliance with Study Drug|0
6159000|NCT01172938|9800400|FG005|Placebo-controlled Phase (Week 0-24)|Non-compliance with Study Drug|0
6159001|NCT01172938|9800401|FG006|Placebo-controlled Phase (Week 0-24)|Non-compliance with Study Drug|0
6159002|NCT01172938|9800402|FG007|Placebo-controlled Phase (Week 0-24)|Non-compliance with Study Drug|0
6159003|NCT01172938|9800403|FG008|Placebo-controlled Phase (Week 0-24)|Non-compliance with Study Drug|0
6159004|NCT01172938|9800395|FG000|Placebo-controlled Phase (Week 0-24)|Withdrawal by Subject|2
6159005|NCT01172938|9800396|FG001|Placebo-controlled Phase (Week 0-24)|Withdrawal by Subject|5
6159006|NCT01172938|9800397|FG002|Placebo-controlled Phase (Week 0-24)|Withdrawal by Subject|3
6159007|NCT01172938|9800398|FG003|Placebo-controlled Phase (Week 0-24)|Withdrawal by Subject|0
6159008|NCT01172938|9800399|FG004|Placebo-controlled Phase (Week 0-24)|Withdrawal by Subject|0
6159009|NCT01172938|9800400|FG005|Placebo-controlled Phase (Week 0-24)|Withdrawal by Subject|0
6159010|NCT01172938|9800401|FG006|Placebo-controlled Phase (Week 0-24)|Withdrawal by Subject|0
6159011|NCT01172938|9800402|FG007|Placebo-controlled Phase (Week 0-24)|Withdrawal by Subject|0
6159012|NCT01172938|9800403|FG008|Placebo-controlled Phase (Week 0-24)|Withdrawal by Subject|0
6159013|NCT01172938|9800395|FG000|Placebo-controlled Phase (Week 0-24)|Death|0
6159014|NCT01172938|9800396|FG001|Placebo-controlled Phase (Week 0-24)|Death|1
6159015|NCT01172938|9800397|FG002|Placebo-controlled Phase (Week 0-24)|Death|0
6159016|NCT01172938|9800398|FG003|Placebo-controlled Phase (Week 0-24)|Death|0
6159017|NCT01172938|9800399|FG004|Placebo-controlled Phase (Week 0-24)|Death|0
6159018|NCT01172938|9800400|FG005|Placebo-controlled Phase (Week 0-24)|Death|0
6159019|NCT01172938|9800401|FG006|Placebo-controlled Phase (Week 0-24)|Death|0
6159020|NCT01172938|9800402|FG007|Placebo-controlled Phase (Week 0-24)|Death|0
6159021|NCT01172938|9800403|FG008|Placebo-controlled Phase (Week 0-24)|Death|0
6159022|NCT01172938|9800395|FG000|Placebo-controlled Phase (Week 0-24)|Protocol Violation|1
6159023|NCT01172938|9800396|FG001|Placebo-controlled Phase (Week 0-24)|Protocol Violation|0
6159024|NCT01172938|9800397|FG002|Placebo-controlled Phase (Week 0-24)|Protocol Violation|0
6159025|NCT01172938|9800398|FG003|Placebo-controlled Phase (Week 0-24)|Protocol Violation|0
6159026|NCT01172938|9800399|FG004|Placebo-controlled Phase (Week 0-24)|Protocol Violation|0
6159027|NCT01172938|9800400|FG005|Placebo-controlled Phase (Week 0-24)|Protocol Violation|0
6159028|NCT01172938|9800401|FG006|Placebo-controlled Phase (Week 0-24)|Protocol Violation|0
6159029|NCT01172938|9800402|FG007|Placebo-controlled Phase (Week 0-24)|Protocol Violation|0
6159030|NCT01172938|9800403|FG008|Placebo-controlled Phase (Week 0-24)|Protocol Violation|0
6159031|NCT01172938|9800395|FG000|Placebo-controlled Phase (Week 0-24)|Other|0
6159032|NCT01172938|9800396|FG001|Placebo-controlled Phase (Week 0-24)|Other|2
6159033|NCT01172938|9800397|FG002|Placebo-controlled Phase (Week 0-24)|Other|1
6159034|NCT01172938|9800398|FG003|Placebo-controlled Phase (Week 0-24)|Other|0
6159035|NCT01172938|9800399|FG004|Placebo-controlled Phase (Week 0-24)|Other|0
6159036|NCT01172938|9800400|FG005|Placebo-controlled Phase (Week 0-24)|Other|0
6159037|NCT01172938|9800401|FG006|Placebo-controlled Phase (Week 0-24)|Other|0
6159038|NCT01172938|9800402|FG007|Placebo-controlled Phase (Week 0-24)|Other|0
6159039|NCT01172938|9800403|FG008|Placebo-controlled Phase (Week 0-24)|Other|0
6159040|NCT01172938|9800395|FG000|Active Treatment Phase (Weeks 25-52)|Adverse Event|0
6159041|NCT01172938|9800396|FG001|Active Treatment Phase (Weeks 25-52)|Adverse Event|2
6159042|NCT01172938|9800397|FG002|Active Treatment Phase (Weeks 25-52)|Adverse Event|5
6159043|NCT01172938|9800398|FG003|Active Treatment Phase (Weeks 25-52)|Adverse Event|1
6159044|NCT01172938|9800399|FG004|Active Treatment Phase (Weeks 25-52)|Adverse Event|1
6159045|NCT01172938|9800400|FG005|Active Treatment Phase (Weeks 25-52)|Adverse Event|2
6159046|NCT01172938|9800401|FG006|Active Treatment Phase (Weeks 25-52)|Adverse Event|0
6159047|NCT01172938|9800402|FG007|Active Treatment Phase (Weeks 25-52)|Adverse Event|0
6159048|NCT01172938|9800403|FG008|Active Treatment Phase (Weeks 25-52)|Adverse Event|0
6159049|NCT01172938|9800395|FG000|Active Treatment Phase (Weeks 25-52)|Lack of Efficacy|0
6159050|NCT01172938|9800396|FG001|Active Treatment Phase (Weeks 25-52)|Lack of Efficacy|4
6159051|NCT01172938|9800397|FG002|Active Treatment Phase (Weeks 25-52)|Lack of Efficacy|7
6159052|NCT01172938|9800398|FG003|Active Treatment Phase (Weeks 25-52)|Lack of Efficacy|3
6159053|NCT01172938|9800399|FG004|Active Treatment Phase (Weeks 25-52)|Lack of Efficacy|1
6159054|NCT01172938|9800400|FG005|Active Treatment Phase (Weeks 25-52)|Lack of Efficacy|3
6159055|NCT01172938|9800401|FG006|Active Treatment Phase (Weeks 25-52)|Lack of Efficacy|0
6159056|NCT01172938|9800402|FG007|Active Treatment Phase (Weeks 25-52)|Lack of Efficacy|0
6159057|NCT01172938|9800403|FG008|Active Treatment Phase (Weeks 25-52)|Lack of Efficacy|0
6159058|NCT01172938|9800395|FG000|Active Treatment Phase (Weeks 25-52)|Non-compliance with Study Drug|0
6159059|NCT01172938|9800396|FG001|Active Treatment Phase (Weeks 25-52)|Non-compliance with Study Drug|0
6159060|NCT01172938|9800397|FG002|Active Treatment Phase (Weeks 25-52)|Non-compliance with Study Drug|1
6159061|NCT01172938|9800398|FG003|Active Treatment Phase (Weeks 25-52)|Non-compliance with Study Drug|0
6159062|NCT01172938|9800399|FG004|Active Treatment Phase (Weeks 25-52)|Non-compliance with Study Drug|0
6159063|NCT01172938|9800400|FG005|Active Treatment Phase (Weeks 25-52)|Non-compliance with Study Drug|0
6159064|NCT01172938|9800401|FG006|Active Treatment Phase (Weeks 25-52)|Non-compliance with Study Drug|0
6159065|NCT01172938|9800402|FG007|Active Treatment Phase (Weeks 25-52)|Non-compliance with Study Drug|0
6159066|NCT01172938|9800403|FG008|Active Treatment Phase (Weeks 25-52)|Non-compliance with Study Drug|0
6159067|NCT01172938|9800395|FG000|Active Treatment Phase (Weeks 25-52)|Withdrawal by Subject|0
6159068|NCT01172938|9800396|FG001|Active Treatment Phase (Weeks 25-52)|Withdrawal by Subject|5
6159069|NCT01172938|9800397|FG002|Active Treatment Phase (Weeks 25-52)|Withdrawal by Subject|1
6159070|NCT01172938|9800398|FG003|Active Treatment Phase (Weeks 25-52)|Withdrawal by Subject|2
6159071|NCT01172938|9800399|FG004|Active Treatment Phase (Weeks 25-52)|Withdrawal by Subject|2
6159072|NCT01172938|9800400|FG005|Active Treatment Phase (Weeks 25-52)|Withdrawal by Subject|9
6159073|NCT01172938|9800401|FG006|Active Treatment Phase (Weeks 25-52)|Withdrawal by Subject|1
6159074|NCT01172938|9800402|FG007|Active Treatment Phase (Weeks 25-52)|Withdrawal by Subject|0
6159075|NCT01172938|9800403|FG008|Active Treatment Phase (Weeks 25-52)|Withdrawal by Subject|0
6159076|NCT01172938|9800395|FG000|Active Treatment Phase (Weeks 25-52)|Lost to Follow-up|0
6159077|NCT01172938|9800396|FG001|Active Treatment Phase (Weeks 25-52)|Lost to Follow-up|1
6159078|NCT01172938|9800397|FG002|Active Treatment Phase (Weeks 25-52)|Lost to Follow-up|1
6159079|NCT01172938|9800398|FG003|Active Treatment Phase (Weeks 25-52)|Lost to Follow-up|1
6159080|NCT01172938|9800399|FG004|Active Treatment Phase (Weeks 25-52)|Lost to Follow-up|0
6159081|NCT01172938|9800400|FG005|Active Treatment Phase (Weeks 25-52)|Lost to Follow-up|0
6159082|NCT01172938|9800401|FG006|Active Treatment Phase (Weeks 25-52)|Lost to Follow-up|0
6159083|NCT01172938|9800402|FG007|Active Treatment Phase (Weeks 25-52)|Lost to Follow-up|0
6159084|NCT01172938|9800403|FG008|Active Treatment Phase (Weeks 25-52)|Lost to Follow-up|0
6159085|NCT01172938|9800395|FG000|Active Treatment Phase (Weeks 25-52)|Other|0
6159086|NCT01172938|9800396|FG001|Active Treatment Phase (Weeks 25-52)|Other|0
6159087|NCT01172938|9800397|FG002|Active Treatment Phase (Weeks 25-52)|Other|0
6159088|NCT01172938|9800398|FG003|Active Treatment Phase (Weeks 25-52)|Other|0
6159089|NCT01172938|9800399|FG004|Active Treatment Phase (Weeks 25-52)|Other|0
6159090|NCT01172938|9800400|FG005|Active Treatment Phase (Weeks 25-52)|Other|1
6159091|NCT01172938|9800401|FG006|Active Treatment Phase (Weeks 25-52)|Other|1
6159092|NCT01172938|9800402|FG007|Active Treatment Phase (Weeks 25-52)|Other|0
6159093|NCT01172938|9800403|FG008|Active Treatment Phase (Weeks 25-52)|Other|0
6159094|NCT01172938|9800395|FG000|Active-Treatment Phase (Weeks 52-104)|Adverse Event|0
6159095|NCT01172938|9800396|FG001|Active-Treatment Phase (Weeks 52-104)|Adverse Event|2
6159096|NCT01172938|9800397|FG002|Active-Treatment Phase (Weeks 52-104)|Adverse Event|1
6159097|NCT01172938|9800398|FG003|Active-Treatment Phase (Weeks 52-104)|Adverse Event|0
6159098|NCT01172938|9800399|FG004|Active-Treatment Phase (Weeks 52-104)|Adverse Event|0
6159099|NCT01172938|9800400|FG005|Active-Treatment Phase (Weeks 52-104)|Adverse Event|0
6159100|NCT01172938|9800401|FG006|Active-Treatment Phase (Weeks 52-104)|Adverse Event|0
6159101|NCT01172938|9800402|FG007|Active-Treatment Phase (Weeks 52-104)|Adverse Event|3
6159102|NCT01172938|9800403|FG008|Active-Treatment Phase (Weeks 52-104)|Adverse Event|1
6159103|NCT01172938|9800395|FG000|Active-Treatment Phase (Weeks 52-104)|Lack of Efficacy|0
6159104|NCT01172938|9800396|FG001|Active-Treatment Phase (Weeks 52-104)|Lack of Efficacy|7
6159105|NCT01172938|9800397|FG002|Active-Treatment Phase (Weeks 52-104)|Lack of Efficacy|8
6159106|NCT01172938|9800398|FG003|Active-Treatment Phase (Weeks 52-104)|Lack of Efficacy|0
6159107|NCT01172938|9800399|FG004|Active-Treatment Phase (Weeks 52-104)|Lack of Efficacy|0
6159108|NCT01172938|9800400|FG005|Active-Treatment Phase (Weeks 52-104)|Lack of Efficacy|0
6159109|NCT01172938|9800401|FG006|Active-Treatment Phase (Weeks 52-104)|Lack of Efficacy|0
6159110|NCT01172938|9800402|FG007|Active-Treatment Phase (Weeks 52-104)|Lack of Efficacy|4
6159111|NCT01172938|9800403|FG008|Active-Treatment Phase (Weeks 52-104)|Lack of Efficacy|0
6159112|NCT01172938|9800395|FG000|Active-Treatment Phase (Weeks 52-104)|Non-compliance with Study Drug|0
6159113|NCT01172938|9800396|FG001|Active-Treatment Phase (Weeks 52-104)|Non-compliance with Study Drug|0
6159114|NCT01172938|9800397|FG002|Active-Treatment Phase (Weeks 52-104)|Non-compliance with Study Drug|2
6159115|NCT01172938|9800398|FG003|Active-Treatment Phase (Weeks 52-104)|Non-compliance with Study Drug|0
6159116|NCT01172938|9800399|FG004|Active-Treatment Phase (Weeks 52-104)|Non-compliance with Study Drug|0
6159117|NCT01172938|9800400|FG005|Active-Treatment Phase (Weeks 52-104)|Non-compliance with Study Drug|0
6159118|NCT01172938|9800401|FG006|Active-Treatment Phase (Weeks 52-104)|Non-compliance with Study Drug|0
6159119|NCT01172938|9800402|FG007|Active-Treatment Phase (Weeks 52-104)|Non-compliance with Study Drug|0
6159120|NCT01172938|9800403|FG008|Active-Treatment Phase (Weeks 52-104)|Non-compliance with Study Drug|0
6159121|NCT01172938|9800395|FG000|Active-Treatment Phase (Weeks 52-104)|Withdrawal by Subject|0
6159122|NCT01172938|9800396|FG001|Active-Treatment Phase (Weeks 52-104)|Withdrawal by Subject|10
6159123|NCT01172938|9800397|FG002|Active-Treatment Phase (Weeks 52-104)|Withdrawal by Subject|8
6159124|NCT01172938|9800398|FG003|Active-Treatment Phase (Weeks 52-104)|Withdrawal by Subject|0
6159125|NCT01172938|9800399|FG004|Active-Treatment Phase (Weeks 52-104)|Withdrawal by Subject|0
6159126|NCT01172938|9800400|FG005|Active-Treatment Phase (Weeks 52-104)|Withdrawal by Subject|0
6159127|NCT01172938|9800401|FG006|Active-Treatment Phase (Weeks 52-104)|Withdrawal by Subject|0
6159128|NCT01172938|9800402|FG007|Active-Treatment Phase (Weeks 52-104)|Withdrawal by Subject|5
6159129|NCT01172938|9800403|FG008|Active-Treatment Phase (Weeks 52-104)|Withdrawal by Subject|2
6159130|NCT01172938|9800395|FG000|Active-Treatment Phase (Weeks 52-104)|Death|0
6159131|NCT01172938|9800396|FG001|Active-Treatment Phase (Weeks 52-104)|Death|0
6159132|NCT01172938|9800397|FG002|Active-Treatment Phase (Weeks 52-104)|Death|1
6159133|NCT01172938|9800398|FG003|Active-Treatment Phase (Weeks 52-104)|Death|0
6159134|NCT01172938|9800399|FG004|Active-Treatment Phase (Weeks 52-104)|Death|0
6159135|NCT01172938|9800400|FG005|Active-Treatment Phase (Weeks 52-104)|Death|0
6159136|NCT01172938|9800401|FG006|Active-Treatment Phase (Weeks 52-104)|Death|0
6159137|NCT01172938|9800402|FG007|Active-Treatment Phase (Weeks 52-104)|Death|0
6159138|NCT01172938|9800403|FG008|Active-Treatment Phase (Weeks 52-104)|Death|0
6159139|NCT01172938|9800395|FG000|Active-Treatment Phase (Weeks 52-104)|Lost to Follow-up|0
6159140|NCT01172938|9800396|FG001|Active-Treatment Phase (Weeks 52-104)|Lost to Follow-up|1
6159141|NCT01172938|9800397|FG002|Active-Treatment Phase (Weeks 52-104)|Lost to Follow-up|1
6159142|NCT01172938|9800398|FG003|Active-Treatment Phase (Weeks 52-104)|Lost to Follow-up|0
6159143|NCT01172938|9800399|FG004|Active-Treatment Phase (Weeks 52-104)|Lost to Follow-up|0
6159144|NCT01172938|9800400|FG005|Active-Treatment Phase (Weeks 52-104)|Lost to Follow-up|0
6159145|NCT01172938|9800401|FG006|Active-Treatment Phase (Weeks 52-104)|Lost to Follow-up|0
6159146|NCT01172938|9800402|FG007|Active-Treatment Phase (Weeks 52-104)|Lost to Follow-up|3
6159147|NCT01172938|9800403|FG008|Active-Treatment Phase (Weeks 52-104)|Lost to Follow-up|0
6159148|NCT01172938|9800395|FG000|Active-Treatment Phase (Weeks 52-104)|Miscellaneous|0
6159149|NCT01172938|9800396|FG001|Active-Treatment Phase (Weeks 52-104)|Miscellaneous|2
6159150|NCT01172938|9800397|FG002|Active-Treatment Phase (Weeks 52-104)|Miscellaneous|0
6159151|NCT01172938|9800398|FG003|Active-Treatment Phase (Weeks 52-104)|Miscellaneous|0
6159152|NCT01172938|9800399|FG004|Active-Treatment Phase (Weeks 52-104)|Miscellaneous|0
6159153|NCT01172938|9800400|FG005|Active-Treatment Phase (Weeks 52-104)|Miscellaneous|0
6159154|NCT01172938|9800401|FG006|Active-Treatment Phase (Weeks 52-104)|Miscellaneous|0
6159155|NCT01172938|9800402|FG007|Active-Treatment Phase (Weeks 52-104)|Miscellaneous|0
6159156|NCT01172938|9800403|FG008|Active-Treatment Phase (Weeks 52-104)|Miscellaneous|1
6159157|NCT01172938|9800395|FG000|Active-Treatment Phase (Weeks 52-104)|Missing|0
6159158|NCT01172938|9800396|FG001|Active-Treatment Phase (Weeks 52-104)|Missing|1
6159159|NCT01172938|9800397|FG002|Active-Treatment Phase (Weeks 52-104)|Missing|0
6159160|NCT01172938|9800398|FG003|Active-Treatment Phase (Weeks 52-104)|Missing|0
6159161|NCT01172938|9800399|FG004|Active-Treatment Phase (Weeks 52-104)|Missing|0
6159162|NCT01172938|9800400|FG005|Active-Treatment Phase (Weeks 52-104)|Missing|0
6159163|NCT01172938|9800401|FG006|Active-Treatment Phase (Weeks 52-104)|Missing|0
6159164|NCT01172938|9800402|FG007|Active-Treatment Phase (Weeks 52-104)|Missing|0
6159165|NCT01172938|9800403|FG008|Active-Treatment Phase (Weeks 52-104)|Missing|0
6159166|NCT01172938|9800395|FG000|Active-Treatment Phase Weeks (104-156)|Adverse Event|0
6159167|NCT01172938|9800396|FG001|Active-Treatment Phase Weeks (104-156)|Adverse Event|0
6159168|NCT01172938|9800397|FG002|Active-Treatment Phase Weeks (104-156)|Adverse Event|0
6159169|NCT01172938|9800398|FG003|Active-Treatment Phase Weeks (104-156)|Adverse Event|0
6159170|NCT01172938|9800399|FG004|Active-Treatment Phase Weeks (104-156)|Adverse Event|0
6159171|NCT01172938|9800400|FG005|Active-Treatment Phase Weeks (104-156)|Adverse Event|0
6159172|NCT01172938|9800401|FG006|Active-Treatment Phase Weeks (104-156)|Adverse Event|0
6159173|NCT01172938|9800402|FG007|Active-Treatment Phase Weeks (104-156)|Adverse Event|0
6159174|NCT01172938|9800403|FG008|Active-Treatment Phase Weeks (104-156)|Adverse Event|1
6159175|NCT01172938|9800395|FG000|Active-Treatment Phase Weeks (104-156)|Lack of Efficacy|0
6159176|NCT01172938|9800396|FG001|Active-Treatment Phase Weeks (104-156)|Lack of Efficacy|4
6159177|NCT01172938|9800397|FG002|Active-Treatment Phase Weeks (104-156)|Lack of Efficacy|2
6159178|NCT01172938|9800398|FG003|Active-Treatment Phase Weeks (104-156)|Lack of Efficacy|0
6081260|NCT00621140|9688803|FG000|Overall Study|Other incl. lack of efficacy|6
6081261|NCT00621140|9688804|FG001|Overall Study|Other incl. lack of efficacy|5
6081262|NCT00621153|9688812|FG000|Overall Study|Safety Reason|8
6159179|NCT01172938|9800399|FG004|Active-Treatment Phase Weeks (104-156)|Lack of Efficacy|0
6159180|NCT01172938|9800400|FG005|Active-Treatment Phase Weeks (104-156)|Lack of Efficacy|0
6159181|NCT01172938|9800401|FG006|Active-Treatment Phase Weeks (104-156)|Lack of Efficacy|0
6159182|NCT01172938|9800402|FG007|Active-Treatment Phase Weeks (104-156)|Lack of Efficacy|2
6159183|NCT01172938|9800403|FG008|Active-Treatment Phase Weeks (104-156)|Lack of Efficacy|2
6159184|NCT01172938|9800395|FG000|Active-Treatment Phase Weeks (104-156)|Withdrawal by Subject|0
6159185|NCT01172938|9800396|FG001|Active-Treatment Phase Weeks (104-156)|Withdrawal by Subject|6
6159186|NCT01172938|9800397|FG002|Active-Treatment Phase Weeks (104-156)|Withdrawal by Subject|3
6191809|NCT01425814|9848747|FG000|Period 2|Stability criteria not fulfilled|0
6081263|NCT00621153|9688813|FG001|Overall Study|Safety Reason|7
6081264|NCT00621153|9688812|FG000|Overall Study|Adverse Event|3
6081265|NCT00621153|9688813|FG001|Overall Study|Adverse Event|2
6081266|NCT00621153|9688812|FG000|Overall Study|Lost to Follow-up|5
6081267|NCT00621153|9688813|FG001|Overall Study|Lost to Follow-up|1
6081268|NCT00621153|9688812|FG000|Overall Study|Withdrawal by Subject|4
6081269|NCT00621153|9688813|FG001|Overall Study|Withdrawal by Subject|5
6081270|NCT00621192|9688840|FG000|Overall Study|Withdrawal by Subject|0
6081271|NCT00621192|9688841|FG001|Overall Study|Withdrawal by Subject|0
6081272|NCT00621192|9688842|FG002|Overall Study|Withdrawal by Subject|2
6081273|NCT00621192|9688843|FG003|Overall Study|Withdrawal by Subject|0
6081274|NCT00621192|9688840|FG000|Overall Study|Physician Decision|1
6081275|NCT00621192|9688841|FG001|Overall Study|Physician Decision|3
6081276|NCT00621192|9688842|FG002|Overall Study|Physician Decision|0
6081277|NCT00621192|9688843|FG003|Overall Study|Physician Decision|0
6081278|NCT00621192|9688840|FG000|Overall Study|Protocol Violation|1
6081279|NCT00621192|9688841|FG001|Overall Study|Protocol Violation|0
6081280|NCT00621192|9688842|FG002|Overall Study|Protocol Violation|0
6081281|NCT00621192|9688843|FG003|Overall Study|Protocol Violation|1
6081282|NCT00621192|9688840|FG000|Overall Study|Adverse Event|0
6081283|NCT00621192|9688841|FG001|Overall Study|Adverse Event|1
6081284|NCT00621192|9688842|FG002|Overall Study|Adverse Event|0
6081285|NCT00621192|9688843|FG003|Overall Study|Adverse Event|1
6081286|NCT00621192|9688840|FG000|Overall Study|Death|2
6081287|NCT00621192|9688841|FG001|Overall Study|Death|5
6081288|NCT00621192|9688842|FG002|Overall Study|Death|0
6081289|NCT00621192|9688843|FG003|Overall Study|Death|0
6081290|NCT00621192|9688840|FG000|Overall Study|Final Assessments not Completed|0
6081291|NCT00621192|9688841|FG001|Overall Study|Final Assessments not Completed|0
6081292|NCT00621192|9688842|FG002|Overall Study|Final Assessments not Completed|3
6081293|NCT00621192|9688843|FG003|Overall Study|Final Assessments not Completed|1
6081294|NCT00621244|9688857|FG000|Overall Study|Withdrawal by Subject|7
6081295|NCT00621244|9688858|FG001|Overall Study|Withdrawal by Subject|3
6081296|NCT00621244|9688859|FG002|Overall Study|Withdrawal by Subject|3
6081297|NCT00621244|9688860|FG003|Overall Study|Withdrawal by Subject|3
6081298|NCT00621244|9688857|FG000|Overall Study|Disease progression|44
6081299|NCT00621244|9688858|FG001|Overall Study|Disease progression|20
6081300|NCT00621244|9688859|FG002|Overall Study|Disease progression|20
6081301|NCT00621244|9688860|FG003|Overall Study|Disease progression|15
6081302|NCT00621244|9688857|FG000|Overall Study|Death|3
6081303|NCT00621244|9688858|FG001|Overall Study|Death|3
6081304|NCT00621244|9688859|FG002|Overall Study|Death|1
6081305|NCT00621244|9688860|FG003|Overall Study|Death|1
6081306|NCT00621244|9688857|FG000|Overall Study|Adverse Event|27
6081307|NCT00621244|9688858|FG001|Overall Study|Adverse Event|7
6081308|NCT00621244|9688859|FG002|Overall Study|Adverse Event|9
6081309|NCT00621244|9688860|FG003|Overall Study|Adverse Event|2
6081310|NCT00621244|9688857|FG000|Overall Study|Administrative problems|5
6081311|NCT00621244|9688858|FG001|Overall Study|Administrative problems|1
6081312|NCT00621244|9688859|FG002|Overall Study|Administrative problems|0
6081313|NCT00621244|9688860|FG003|Overall Study|Administrative problems|2
6081314|NCT00621257|9688939|FG000|Overall Study|Lost to Follow-up|4
6081315|NCT00621257|9688940|FG001|Overall Study|Lost to Follow-up|0
6081316|NCT00621257|9688941|FG002|Overall Study|Lost to Follow-up|2
6081317|NCT00621257|9688942|FG003|Overall Study|Lost to Follow-up|4
6081318|NCT00621257|9688943|FG004|Overall Study|Lost to Follow-up|7
6081319|NCT00621257|9688939|FG000|Overall Study|Adverse Event|0
6081320|NCT00621257|9688940|FG001|Overall Study|Adverse Event|1
6081321|NCT00621257|9688941|FG002|Overall Study|Adverse Event|1
6081322|NCT00621257|9688942|FG003|Overall Study|Adverse Event|0
6081323|NCT00621257|9688943|FG004|Overall Study|Adverse Event|0
6081324|NCT00621257|9688939|FG000|Overall Study|Physician Decision|0
6159187|NCT01172938|9800398|FG003|Active-Treatment Phase Weeks (104-156)|Withdrawal by Subject|0
6159188|NCT01172938|9800399|FG004|Active-Treatment Phase Weeks (104-156)|Withdrawal by Subject|0
6159189|NCT01172938|9800400|FG005|Active-Treatment Phase Weeks (104-156)|Withdrawal by Subject|0
6159190|NCT01172938|9800401|FG006|Active-Treatment Phase Weeks (104-156)|Withdrawal by Subject|0
6159191|NCT01172938|9800402|FG007|Active-Treatment Phase Weeks (104-156)|Withdrawal by Subject|2
6159192|NCT01172938|9800403|FG008|Active-Treatment Phase Weeks (104-156)|Withdrawal by Subject|1
6159193|NCT01172938|9800395|FG000|Active-Treatment Phase Weeks (104-156)|Death|0
6159194|NCT01172938|9800396|FG001|Active-Treatment Phase Weeks (104-156)|Death|0
6159195|NCT01172938|9800397|FG002|Active-Treatment Phase Weeks (104-156)|Death|0
6159196|NCT01172938|9800398|FG003|Active-Treatment Phase Weeks (104-156)|Death|0
6159197|NCT01172938|9800399|FG004|Active-Treatment Phase Weeks (104-156)|Death|0
6159198|NCT01172938|9800400|FG005|Active-Treatment Phase Weeks (104-156)|Death|0
6159199|NCT01172938|9800401|FG006|Active-Treatment Phase Weeks (104-156)|Death|0
6159200|NCT01172938|9800402|FG007|Active-Treatment Phase Weeks (104-156)|Death|1
6159201|NCT01172938|9800403|FG008|Active-Treatment Phase Weeks (104-156)|Death|0
6159202|NCT01172938|9800395|FG000|Active-Treatment Phase Weeks (104-156)|Lost to Follow-up|0
6159203|NCT01172938|9800396|FG001|Active-Treatment Phase Weeks (104-156)|Lost to Follow-up|1
6159204|NCT01172938|9800397|FG002|Active-Treatment Phase Weeks (104-156)|Lost to Follow-up|0
6159205|NCT01172938|9800398|FG003|Active-Treatment Phase Weeks (104-156)|Lost to Follow-up|0
6159206|NCT01172938|9800399|FG004|Active-Treatment Phase Weeks (104-156)|Lost to Follow-up|0
6159207|NCT01172938|9800400|FG005|Active-Treatment Phase Weeks (104-156)|Lost to Follow-up|0
6159208|NCT01172938|9800401|FG006|Active-Treatment Phase Weeks (104-156)|Lost to Follow-up|0
6159209|NCT01172938|9800402|FG007|Active-Treatment Phase Weeks (104-156)|Lost to Follow-up|0
6159210|NCT01172938|9800403|FG008|Active-Treatment Phase Weeks (104-156)|Lost to Follow-up|0
6159211|NCT01172938|9800395|FG000|Active-Treatment Phase Weeks (104-156)|Miscellaneious|0
6159212|NCT01172938|9800396|FG001|Active-Treatment Phase Weeks (104-156)|Miscellaneious|0
6159213|NCT01172938|9800397|FG002|Active-Treatment Phase Weeks (104-156)|Miscellaneious|2
6159214|NCT01172938|9800398|FG003|Active-Treatment Phase Weeks (104-156)|Miscellaneious|0
6159215|NCT01172938|9800399|FG004|Active-Treatment Phase Weeks (104-156)|Miscellaneious|0
6159216|NCT01172938|9800400|FG005|Active-Treatment Phase Weeks (104-156)|Miscellaneious|0
6159217|NCT01172938|9800401|FG006|Active-Treatment Phase Weeks (104-156)|Miscellaneious|0
6159218|NCT01172938|9800402|FG007|Active-Treatment Phase Weeks (104-156)|Miscellaneious|0
6159219|NCT01172938|9800403|FG008|Active-Treatment Phase Weeks (104-156)|Miscellaneious|0
6159220|NCT01172938|9800395|FG000|Active-Treatment Phase (Weeks 156-208)|Adverse Event|0
6159221|NCT01172938|9800396|FG001|Active-Treatment Phase (Weeks 156-208)|Adverse Event|4
6042829|NCT00385671|9641322|FG001|Overall Study|Protocol Violation|2
6159222|NCT01172938|9800397|FG002|Active-Treatment Phase (Weeks 156-208)|Adverse Event|1
6159223|NCT01172938|9800398|FG003|Active-Treatment Phase (Weeks 156-208)|Adverse Event|0
6159224|NCT01172938|9800399|FG004|Active-Treatment Phase (Weeks 156-208)|Adverse Event|0
6159225|NCT01172938|9800400|FG005|Active-Treatment Phase (Weeks 156-208)|Adverse Event|0
6159226|NCT01172938|9800401|FG006|Active-Treatment Phase (Weeks 156-208)|Adverse Event|0
6159227|NCT01172938|9800402|FG007|Active-Treatment Phase (Weeks 156-208)|Adverse Event|3
6159228|NCT01172938|9800403|FG008|Active-Treatment Phase (Weeks 156-208)|Adverse Event|0
6159229|NCT01172938|9800395|FG000|Active-Treatment Phase (Weeks 156-208)|Lack of Efficacy|0
6159230|NCT01172938|9800396|FG001|Active-Treatment Phase (Weeks 156-208)|Lack of Efficacy|1
6159231|NCT01172938|9800397|FG002|Active-Treatment Phase (Weeks 156-208)|Lack of Efficacy|1
6159232|NCT01172938|9800398|FG003|Active-Treatment Phase (Weeks 156-208)|Lack of Efficacy|0
6159233|NCT01172938|9800399|FG004|Active-Treatment Phase (Weeks 156-208)|Lack of Efficacy|0
6159234|NCT01172938|9800400|FG005|Active-Treatment Phase (Weeks 156-208)|Lack of Efficacy|0
6159235|NCT01172938|9800401|FG006|Active-Treatment Phase (Weeks 156-208)|Lack of Efficacy|0
6159236|NCT01172938|9800402|FG007|Active-Treatment Phase (Weeks 156-208)|Lack of Efficacy|3
6159237|NCT01172938|9800403|FG008|Active-Treatment Phase (Weeks 156-208)|Lack of Efficacy|2
6159238|NCT01172938|9800395|FG000|Active-Treatment Phase (Weeks 156-208)|Withdrawal by Subject|0
6159239|NCT01172938|9800396|FG001|Active-Treatment Phase (Weeks 156-208)|Withdrawal by Subject|4
6159240|NCT01172938|9800397|FG002|Active-Treatment Phase (Weeks 156-208)|Withdrawal by Subject|2
6159241|NCT01172938|9800398|FG003|Active-Treatment Phase (Weeks 156-208)|Withdrawal by Subject|0
6159242|NCT01172938|9800399|FG004|Active-Treatment Phase (Weeks 156-208)|Withdrawal by Subject|0
6159243|NCT01172938|9800400|FG005|Active-Treatment Phase (Weeks 156-208)|Withdrawal by Subject|0
6159244|NCT01172938|9800401|FG006|Active-Treatment Phase (Weeks 156-208)|Withdrawal by Subject|0
6159245|NCT01172938|9800402|FG007|Active-Treatment Phase (Weeks 156-208)|Withdrawal by Subject|2
6159246|NCT01172938|9800403|FG008|Active-Treatment Phase (Weeks 156-208)|Withdrawal by Subject|4
6159247|NCT01172938|9800395|FG000|Active-Treatment Phase (Weeks 156-208)|Lost to Follow-up|0
6159248|NCT01172938|9800396|FG001|Active-Treatment Phase (Weeks 156-208)|Lost to Follow-up|0
6159249|NCT01172938|9800397|FG002|Active-Treatment Phase (Weeks 156-208)|Lost to Follow-up|1
6159250|NCT01172938|9800398|FG003|Active-Treatment Phase (Weeks 156-208)|Lost to Follow-up|0
6159251|NCT01172938|9800399|FG004|Active-Treatment Phase (Weeks 156-208)|Lost to Follow-up|0
6159252|NCT01172938|9800400|FG005|Active-Treatment Phase (Weeks 156-208)|Lost to Follow-up|0
6159253|NCT01172938|9800401|FG006|Active-Treatment Phase (Weeks 156-208)|Lost to Follow-up|0
6159254|NCT01172938|9800402|FG007|Active-Treatment Phase (Weeks 156-208)|Lost to Follow-up|0
6159255|NCT01172938|9800403|FG008|Active-Treatment Phase (Weeks 156-208)|Lost to Follow-up|1
6159256|NCT01172938|9800395|FG000|Active-Treatment Phase (Weeks 156-208)|Miscellaneous|0
6159257|NCT01172938|9800396|FG001|Active-Treatment Phase (Weeks 156-208)|Miscellaneous|0
6159258|NCT01172938|9800397|FG002|Active-Treatment Phase (Weeks 156-208)|Miscellaneous|0
6159259|NCT01172938|9800398|FG003|Active-Treatment Phase (Weeks 156-208)|Miscellaneous|0
6159260|NCT01172938|9800399|FG004|Active-Treatment Phase (Weeks 156-208)|Miscellaneous|0
6159261|NCT01172938|9800400|FG005|Active-Treatment Phase (Weeks 156-208)|Miscellaneous|0
6159262|NCT01172938|9800401|FG006|Active-Treatment Phase (Weeks 156-208)|Miscellaneous|0
6159263|NCT01172938|9800402|FG007|Active-Treatment Phase (Weeks 156-208)|Miscellaneous|1
6159264|NCT01172938|9800403|FG008|Active-Treatment Phase (Weeks 156-208)|Miscellaneous|0
6159265|NCT01172938|9800395|FG000|Active-Treatment Phase (Weeks 208-260)|Adverse Event|0
6159266|NCT01172938|9800396|FG001|Active-Treatment Phase (Weeks 208-260)|Adverse Event|0
6159267|NCT01172938|9800397|FG002|Active-Treatment Phase (Weeks 208-260)|Adverse Event|1
6159268|NCT01172938|9800398|FG003|Active-Treatment Phase (Weeks 208-260)|Adverse Event|0
6159269|NCT01172938|9800399|FG004|Active-Treatment Phase (Weeks 208-260)|Adverse Event|0
6159270|NCT01172938|9800400|FG005|Active-Treatment Phase (Weeks 208-260)|Adverse Event|0
6159271|NCT01172938|9800401|FG006|Active-Treatment Phase (Weeks 208-260)|Adverse Event|0
6159272|NCT01172938|9800402|FG007|Active-Treatment Phase (Weeks 208-260)|Adverse Event|1
6159273|NCT01172938|9800403|FG008|Active-Treatment Phase (Weeks 208-260)|Adverse Event|1
6159274|NCT01172938|9800395|FG000|Active-Treatment Phase (Weeks 208-260)|Lack of Efficacy|0
6159275|NCT01172938|9800396|FG001|Active-Treatment Phase (Weeks 208-260)|Lack of Efficacy|0
6159276|NCT01172938|9800397|FG002|Active-Treatment Phase (Weeks 208-260)|Lack of Efficacy|2
6159277|NCT01172938|9800398|FG003|Active-Treatment Phase (Weeks 208-260)|Lack of Efficacy|0
6159278|NCT01172938|9800399|FG004|Active-Treatment Phase (Weeks 208-260)|Lack of Efficacy|0
6159279|NCT01172938|9800400|FG005|Active-Treatment Phase (Weeks 208-260)|Lack of Efficacy|0
6159280|NCT01172938|9800401|FG006|Active-Treatment Phase (Weeks 208-260)|Lack of Efficacy|0
6159281|NCT01172938|9800402|FG007|Active-Treatment Phase (Weeks 208-260)|Lack of Efficacy|0
6159282|NCT01172938|9800403|FG008|Active-Treatment Phase (Weeks 208-260)|Lack of Efficacy|0
6159283|NCT01172938|9800395|FG000|Active-Treatment Phase (Weeks 208-260)|Non-compliance with study drug|0
6159284|NCT01172938|9800396|FG001|Active-Treatment Phase (Weeks 208-260)|Non-compliance with study drug|1
6159285|NCT01172938|9800397|FG002|Active-Treatment Phase (Weeks 208-260)|Non-compliance with study drug|0
6159286|NCT01172938|9800398|FG003|Active-Treatment Phase (Weeks 208-260)|Non-compliance with study drug|0
6159287|NCT01172938|9800399|FG004|Active-Treatment Phase (Weeks 208-260)|Non-compliance with study drug|0
6159288|NCT01172938|9800400|FG005|Active-Treatment Phase (Weeks 208-260)|Non-compliance with study drug|0
6159289|NCT01172938|9800401|FG006|Active-Treatment Phase (Weeks 208-260)|Non-compliance with study drug|0
6159290|NCT01172938|9800402|FG007|Active-Treatment Phase (Weeks 208-260)|Non-compliance with study drug|1
6159291|NCT01172938|9800403|FG008|Active-Treatment Phase (Weeks 208-260)|Non-compliance with study drug|0
6159292|NCT01172938|9800395|FG000|Active-Treatment Phase (Weeks 208-260)|Withdrawal by Subject|0
6159293|NCT01172938|9800396|FG001|Active-Treatment Phase (Weeks 208-260)|Withdrawal by Subject|2
6159294|NCT01172938|9800397|FG002|Active-Treatment Phase (Weeks 208-260)|Withdrawal by Subject|3
6159295|NCT01172938|9800398|FG003|Active-Treatment Phase (Weeks 208-260)|Withdrawal by Subject|0
6159296|NCT01172938|9800399|FG004|Active-Treatment Phase (Weeks 208-260)|Withdrawal by Subject|0
6159297|NCT01172938|9800400|FG005|Active-Treatment Phase (Weeks 208-260)|Withdrawal by Subject|0
6159298|NCT01172938|9800401|FG006|Active-Treatment Phase (Weeks 208-260)|Withdrawal by Subject|0
6159299|NCT01172938|9800402|FG007|Active-Treatment Phase (Weeks 208-260)|Withdrawal by Subject|1
6159300|NCT01172938|9800403|FG008|Active-Treatment Phase (Weeks 208-260)|Withdrawal by Subject|0
6159301|NCT01172938|9800395|FG000|Active-Treatment Phase (Weeks 208-260)|Death|0
6159302|NCT01172938|9800396|FG001|Active-Treatment Phase (Weeks 208-260)|Death|0
6159303|NCT01172938|9800397|FG002|Active-Treatment Phase (Weeks 208-260)|Death|1
6159304|NCT01172938|9800398|FG003|Active-Treatment Phase (Weeks 208-260)|Death|0
6159305|NCT01172938|9800399|FG004|Active-Treatment Phase (Weeks 208-260)|Death|0
6159306|NCT01172938|9800400|FG005|Active-Treatment Phase (Weeks 208-260)|Death|0
6159307|NCT01172938|9800401|FG006|Active-Treatment Phase (Weeks 208-260)|Death|0
6159308|NCT01172938|9800402|FG007|Active-Treatment Phase (Weeks 208-260)|Death|0
6159309|NCT01172938|9800403|FG008|Active-Treatment Phase (Weeks 208-260)|Death|0
6159310|NCT01172938|9800395|FG000|Active-Treatment Phase (Weeks 208-260)|Lost to Follow-up|0
6159311|NCT01172938|9800396|FG001|Active-Treatment Phase (Weeks 208-260)|Lost to Follow-up|0
6159312|NCT01172938|9800397|FG002|Active-Treatment Phase (Weeks 208-260)|Lost to Follow-up|1
6159313|NCT01172938|9800398|FG003|Active-Treatment Phase (Weeks 208-260)|Lost to Follow-up|0
6159314|NCT01172938|9800399|FG004|Active-Treatment Phase (Weeks 208-260)|Lost to Follow-up|0
6159315|NCT01172938|9800400|FG005|Active-Treatment Phase (Weeks 208-260)|Lost to Follow-up|0
6159316|NCT01172938|9800401|FG006|Active-Treatment Phase (Weeks 208-260)|Lost to Follow-up|0
6159317|NCT01172938|9800402|FG007|Active-Treatment Phase (Weeks 208-260)|Lost to Follow-up|0
6159318|NCT01172938|9800403|FG008|Active-Treatment Phase (Weeks 208-260)|Lost to Follow-up|0
6159319|NCT01172938|9800395|FG000|Active-Treatment Phase (Weeks 208-260)|Protocol Violation|0
6159320|NCT01172938|9800396|FG001|Active-Treatment Phase (Weeks 208-260)|Protocol Violation|0
6159321|NCT01172938|9800397|FG002|Active-Treatment Phase (Weeks 208-260)|Protocol Violation|0
6159322|NCT01172938|9800398|FG003|Active-Treatment Phase (Weeks 208-260)|Protocol Violation|0
6159323|NCT01172938|9800399|FG004|Active-Treatment Phase (Weeks 208-260)|Protocol Violation|0
6159324|NCT01172938|9800400|FG005|Active-Treatment Phase (Weeks 208-260)|Protocol Violation|0
6159325|NCT01172938|9800401|FG006|Active-Treatment Phase (Weeks 208-260)|Protocol Violation|0
6159326|NCT01172938|9800402|FG007|Active-Treatment Phase (Weeks 208-260)|Protocol Violation|0
6159327|NCT01172938|9800403|FG008|Active-Treatment Phase (Weeks 208-260)|Protocol Violation|1
6159328|NCT01173055|9800445|FG000|Period 1 - Day 1 to 49|Withdrawal by Subject|2
6159329|NCT01173055|9800446|FG001|Period 1 - Day 1 to 49|Withdrawal by Subject|2
6159330|NCT01173055|9800445|FG000|Period 2 - Day 64 to 112|Adverse Event|0
6159331|NCT01173055|9800446|FG001|Period 2 - Day 64 to 112|Adverse Event|1
6159332|NCT01173120|9800452|FG000|Overall Study|Lack of Efficacy|2
6159333|NCT01173120|9800452|FG000|Overall Study|Lost to Follow-up|1
6159334|NCT01173120|9800452|FG000|Overall Study|Participant Decision|2
6159335|NCT01173120|9800452|FG000|Overall Study|Switch-Administrative Reason By Sponsor|33
6159336|NCT01173120|9800452|FG000|Overall Study|Switch-Participant Decision|12
6159337|NCT01173120|9800452|FG000|Overall Study|Switch-Difficulty With Device|12
6159338|NCT01173471|9800491|FG000|Overall Study|Eligibility criteria not fulfilled|0
6159339|NCT01173471|9800492|FG001|Overall Study|Eligibility criteria not fulfilled|0
6159340|NCT01173471|9800493|FG002|Overall Study|Eligibility criteria not fulfilled|1
6159341|NCT01173471|9800494|FG003|Overall Study|Eligibility criteria not fulfilled|1
6159342|NCT01173471|9800491|FG000|Overall Study|Condition under investigation worsened|2
6159343|NCT01173471|9800492|FG001|Overall Study|Condition under investigation worsened|0
6159344|NCT01173471|9800493|FG002|Overall Study|Condition under investigation worsened|0
6159345|NCT01173471|9800494|FG003|Overall Study|Condition under investigation worsened|0
6159346|NCT01173471|9800491|FG000|Overall Study|Lost to Follow-up|0
6159347|NCT01173471|9800492|FG001|Overall Study|Lost to Follow-up|0
6159348|NCT01173471|9800493|FG002|Overall Study|Lost to Follow-up|1
6159349|NCT01173471|9800494|FG003|Overall Study|Lost to Follow-up|0
6159350|NCT01173471|9800491|FG000|Overall Study|Reason given as Other|0
6159351|NCT01173471|9800492|FG001|Overall Study|Reason given as Other|0
6159352|NCT01173471|9800493|FG002|Overall Study|Reason given as Other|1
6159353|NCT01173471|9800494|FG003|Overall Study|Reason given as Other|0
6159354|NCT01173523|9800506|FG000|Overall Study|Clinical Progression|1
6159355|NCT01173523|9800507|FG001|Overall Study|Clinical Progression|1
6159356|NCT01173523|9800506|FG000|Overall Study|Progressive Disease|10
6159357|NCT01173523|9800507|FG001|Overall Study|Progressive Disease|8
6159358|NCT01173523|9800506|FG000|Overall Study|Other|2
6159359|NCT01173523|9800507|FG001|Overall Study|Other|3
6159360|NCT01173601|9800517|FG000|Confirmation (CF) Phase, 3 Weeks|Adverse Event|23
6159361|NCT01173601|9800518|FG001|Confirmation (CF) Phase, 3 Weeks|Adverse Event|0
6159362|NCT01173601|9800519|FG002|Confirmation (CF) Phase, 3 Weeks|Adverse Event|0
6159363|NCT01173601|9800520|FG003|Confirmation (CF) Phase, 3 Weeks|Adverse Event|0
6159364|NCT01173601|9800521|FG004|Confirmation (CF) Phase, 3 Weeks|Adverse Event|0
6159365|NCT01173601|9800517|FG000|Confirmation (CF) Phase, 3 Weeks|Lack of Efficacy|9
6159366|NCT01173601|9800518|FG001|Confirmation (CF) Phase, 3 Weeks|Lack of Efficacy|0
6159367|NCT01173601|9800519|FG002|Confirmation (CF) Phase, 3 Weeks|Lack of Efficacy|0
6159368|NCT01173601|9800520|FG003|Confirmation (CF) Phase, 3 Weeks|Lack of Efficacy|0
6159369|NCT01173601|9800521|FG004|Confirmation (CF) Phase, 3 Weeks|Lack of Efficacy|0
6159370|NCT01173601|9800517|FG000|Confirmation (CF) Phase, 3 Weeks|Lost to Follow-up|7
6159371|NCT01173601|9800518|FG001|Confirmation (CF) Phase, 3 Weeks|Lost to Follow-up|0
6159372|NCT01173601|9800519|FG002|Confirmation (CF) Phase, 3 Weeks|Lost to Follow-up|0
6159373|NCT01173601|9800520|FG003|Confirmation (CF) Phase, 3 Weeks|Lost to Follow-up|0
6159374|NCT01173601|9800521|FG004|Confirmation (CF) Phase, 3 Weeks|Lost to Follow-up|0
6159375|NCT01173601|9800517|FG000|Confirmation (CF) Phase, 3 Weeks|Physician Decision|3
6159376|NCT01173601|9800518|FG001|Confirmation (CF) Phase, 3 Weeks|Physician Decision|0
6159377|NCT01173601|9800519|FG002|Confirmation (CF) Phase, 3 Weeks|Physician Decision|0
6159378|NCT01173601|9800520|FG003|Confirmation (CF) Phase, 3 Weeks|Physician Decision|0
6159379|NCT01173601|9800521|FG004|Confirmation (CF) Phase, 3 Weeks|Physician Decision|0
6159380|NCT01173601|9800517|FG000|Confirmation (CF) Phase, 3 Weeks|Protocol Violation|15
6159381|NCT01173601|9800518|FG001|Confirmation (CF) Phase, 3 Weeks|Protocol Violation|0
6159382|NCT01173601|9800519|FG002|Confirmation (CF) Phase, 3 Weeks|Protocol Violation|0
6159383|NCT01173601|9800520|FG003|Confirmation (CF) Phase, 3 Weeks|Protocol Violation|0
6159384|NCT01173601|9800521|FG004|Confirmation (CF) Phase, 3 Weeks|Protocol Violation|0
6159385|NCT01173601|9800517|FG000|Confirmation (CF) Phase, 3 Weeks|Withdrawal by Subject|25
6159386|NCT01173601|9800518|FG001|Confirmation (CF) Phase, 3 Weeks|Withdrawal by Subject|0
6159387|NCT01173601|9800519|FG002|Confirmation (CF) Phase, 3 Weeks|Withdrawal by Subject|0
6159388|NCT01173601|9800520|FG003|Confirmation (CF) Phase, 3 Weeks|Withdrawal by Subject|0
6159389|NCT01173601|9800521|FG004|Confirmation (CF) Phase, 3 Weeks|Withdrawal by Subject|0
6159390|NCT01173601|9800517|FG000|Confirmation (CF) Phase, 3 Weeks|Sponsor Decision|6
6159391|NCT01173601|9800518|FG001|Confirmation (CF) Phase, 3 Weeks|Sponsor Decision|0
6159392|NCT01173601|9800519|FG002|Confirmation (CF) Phase, 3 Weeks|Sponsor Decision|0
6159393|NCT01173601|9800520|FG003|Confirmation (CF) Phase, 3 Weeks|Sponsor Decision|0
6159394|NCT01173601|9800521|FG004|Confirmation (CF) Phase, 3 Weeks|Sponsor Decision|0
6159395|NCT01173601|9800517|FG000|Adjunctive Treatment (AT) Phase, 8 Weeks|Adverse Event|0
6159396|NCT01173601|9800518|FG001|Adjunctive Treatment (AT) Phase, 8 Weeks|Adverse Event|10
6159397|NCT01173601|9800519|FG002|Adjunctive Treatment (AT) Phase, 8 Weeks|Adverse Event|15
6159398|NCT01173601|9800520|FG003|Adjunctive Treatment (AT) Phase, 8 Weeks|Adverse Event|7
6159399|NCT01173601|9800521|FG004|Adjunctive Treatment (AT) Phase, 8 Weeks|Adverse Event|14
6159400|NCT01173601|9800517|FG000|Adjunctive Treatment (AT) Phase, 8 Weeks|Lack of Efficacy|0
6159401|NCT01173601|9800518|FG001|Adjunctive Treatment (AT) Phase, 8 Weeks|Lack of Efficacy|10
6159402|NCT01173601|9800519|FG002|Adjunctive Treatment (AT) Phase, 8 Weeks|Lack of Efficacy|6
6159403|NCT01173601|9800520|FG003|Adjunctive Treatment (AT) Phase, 8 Weeks|Lack of Efficacy|8
6159404|NCT01173601|9800521|FG004|Adjunctive Treatment (AT) Phase, 8 Weeks|Lack of Efficacy|9
6159405|NCT01173601|9800517|FG000|Adjunctive Treatment (AT) Phase, 8 Weeks|Lost to Follow-up|0
6159406|NCT01173601|9800518|FG001|Adjunctive Treatment (AT) Phase, 8 Weeks|Lost to Follow-up|3
6159407|NCT01173601|9800519|FG002|Adjunctive Treatment (AT) Phase, 8 Weeks|Lost to Follow-up|0
6159408|NCT01173601|9800520|FG003|Adjunctive Treatment (AT) Phase, 8 Weeks|Lost to Follow-up|2
6159409|NCT01173601|9800521|FG004|Adjunctive Treatment (AT) Phase, 8 Weeks|Lost to Follow-up|9
6159410|NCT01173601|9800517|FG000|Adjunctive Treatment (AT) Phase, 8 Weeks|Physician Decision|0
6159411|NCT01173601|9800518|FG001|Adjunctive Treatment (AT) Phase, 8 Weeks|Physician Decision|2
6159412|NCT01173601|9800519|FG002|Adjunctive Treatment (AT) Phase, 8 Weeks|Physician Decision|0
6159413|NCT01173601|9800520|FG003|Adjunctive Treatment (AT) Phase, 8 Weeks|Physician Decision|2
6159414|NCT01173601|9800521|FG004|Adjunctive Treatment (AT) Phase, 8 Weeks|Physician Decision|1
6159415|NCT01173601|9800517|FG000|Adjunctive Treatment (AT) Phase, 8 Weeks|Protocol Violation|0
6159416|NCT01173601|9800518|FG001|Adjunctive Treatment (AT) Phase, 8 Weeks|Protocol Violation|1
6159417|NCT01173601|9800519|FG002|Adjunctive Treatment (AT) Phase, 8 Weeks|Protocol Violation|5
6159418|NCT01173601|9800520|FG003|Adjunctive Treatment (AT) Phase, 8 Weeks|Protocol Violation|4
6159419|NCT01173601|9800521|FG004|Adjunctive Treatment (AT) Phase, 8 Weeks|Protocol Violation|5
6159420|NCT01173601|9800517|FG000|Adjunctive Treatment (AT) Phase, 8 Weeks|Withdrawal by Subject|0
6159421|NCT01173601|9800518|FG001|Adjunctive Treatment (AT) Phase, 8 Weeks|Withdrawal by Subject|9
6159422|NCT01173601|9800519|FG002|Adjunctive Treatment (AT) Phase, 8 Weeks|Withdrawal by Subject|7
6159423|NCT01173601|9800520|FG003|Adjunctive Treatment (AT) Phase, 8 Weeks|Withdrawal by Subject|5
6159424|NCT01173601|9800521|FG004|Adjunctive Treatment (AT) Phase, 8 Weeks|Withdrawal by Subject|24
6159425|NCT01173601|9800517|FG000|Adjunctive Treatment (AT) Phase, 8 Weeks|Sponsor Decision|0
6159426|NCT01173601|9800518|FG001|Adjunctive Treatment (AT) Phase, 8 Weeks|Sponsor Decision|0
6159427|NCT01173601|9800519|FG002|Adjunctive Treatment (AT) Phase, 8 Weeks|Sponsor Decision|0
6159428|NCT01173601|9800520|FG003|Adjunctive Treatment (AT) Phase, 8 Weeks|Sponsor Decision|2
6159429|NCT01173601|9800521|FG004|Adjunctive Treatment (AT) Phase, 8 Weeks|Sponsor Decision|6
6159430|NCT01173653|9800541|FG000|Overall Study|Pts unwilling to provide follow-up|53
6159431|NCT01173653|9800542|FG001|Overall Study|Pts unwilling to provide follow-up|41
6159432|NCT01173679|9800548|FG000|Overall Study|Death|1
6159433|NCT01173692|9800555|FG000|Overall Study|Adverse Event|1
6159434|NCT01173692|9800556|FG001|Overall Study|Adverse Event|2
6159435|NCT01173692|9800555|FG000|Overall Study|Withdrawal by Subject|1
6159436|NCT01173692|9800556|FG001|Overall Study|Withdrawal by Subject|3
6159437|NCT01173718|9800562|FG000|Overall Study|Death|17
6159438|NCT01173718|9800562|FG000|Overall Study|Abandonment of study graft|27
6159439|NCT01174004|9800585|FG000|Overall Study|Adverse Event|2
6159440|NCT01174004|9800586|FG001|Overall Study|Adverse Event|10
6159441|NCT01174004|9800585|FG000|Overall Study|Withdrawal by Subject|2
6159442|NCT01174004|9800586|FG001|Overall Study|Withdrawal by Subject|3
6159443|NCT01174004|9800585|FG000|Overall Study|At Discretion of Sponsor|2
6159444|NCT01174004|9800586|FG001|Overall Study|At Discretion of Sponsor|2
6159445|NCT01174004|9800585|FG000|Overall Study|Protocol Violation|0
6159446|NCT01174004|9800586|FG001|Overall Study|Protocol Violation|1
6159447|NCT01174004|9800585|FG000|Overall Study|Physician Decision|1
6159448|NCT01174004|9800586|FG001|Overall Study|Physician Decision|0
6159449|NCT01174043|9800613|FG000|Overall Study|Disease progression|5
6159450|NCT01174043|9800613|FG000|Overall Study|Adverse Event|3
6159451|NCT01174043|9800613|FG000|Overall Study|Death|1
6159452|NCT01174043|9800613|FG000|Overall Study|Withdrawal by Subject|2
6159453|NCT01174160|9800628|FG000|Overall Study|Adverse Event|1
6159454|NCT01174160|9800629|FG001|Overall Study|Adverse Event|0
6159455|NCT01174160|9800628|FG000|Overall Study|Lost to Follow-up|1
6159456|NCT01174160|9800629|FG001|Overall Study|Lost to Follow-up|0
6159457|NCT01174160|9800628|FG000|Overall Study|Physician Decision|1
6159458|NCT01174160|9800629|FG001|Overall Study|Physician Decision|0
6159459|NCT01174160|9800628|FG000|Overall Study|Protocol Violation|4
6159460|NCT01174160|9800629|FG001|Overall Study|Protocol Violation|6
6159461|NCT01174160|9800628|FG000|Overall Study|Withdrawal by Subject|1
6159462|NCT01174160|9800629|FG001|Overall Study|Withdrawal by Subject|0
6159463|NCT01174173|9800635|FG000|Overall Study|drug-drug interaction|1
6159464|NCT01174186|9800642|FG000|Overall Study|Lost to Follow-up|0
6159465|NCT01174186|9800643|FG001|Overall Study|Lost to Follow-up|1
6159466|NCT01174186|9800642|FG000|Overall Study|Withdrawal by Subject|0
6159467|NCT01174186|9800643|FG001|Overall Study|Withdrawal by Subject|2
6159468|NCT01174238|9800649|FG000|Overall Study|Lost to Follow-up|2
6159469|NCT01174264|9800659|FG000|Single Dose Pharmacokinetics|Early progressive disease|1
6159470|NCT01174264|9800660|FG001|Single Dose Pharmacokinetics|Early progressive disease|0
6159471|NCT01174264|9800661|FG002|Single Dose Pharmacokinetics|Early progressive disease|1
6159472|NCT01174264|9800659|FG000|Single Dose Pharmacokinetics|Patient entered hospice care|0
6159473|NCT01174264|9800660|FG001|Single Dose Pharmacokinetics|Patient entered hospice care|0
6159474|NCT01174264|9800661|FG002|Single Dose Pharmacokinetics|Patient entered hospice care|1
6159475|NCT01174264|9800659|FG000|Steady-state Pharmacokinetics|Not evaluable|6
6159476|NCT01174264|9800660|FG001|Steady-state Pharmacokinetics|Not evaluable|0
6159477|NCT01174264|9800661|FG002|Steady-state Pharmacokinetics|Not evaluable|2
6159478|NCT01174342|9800669|FG000|Overall Study|Conversion to cesarean section|4
6159479|NCT01174446|9800673|FG000|Part 2 -BAX326 Prophylaxis and On-demand|Withdrawal by Subject|0
6159480|NCT01174446|9800674|FG001|Part 2 -BAX326 Prophylaxis and On-demand|Withdrawal by Subject|0
6159481|NCT01174446|9800675|FG002|Part 2 -BAX326 Prophylaxis and On-demand|Withdrawal by Subject|1
6159482|NCT01174446|9800676|FG003|Part 2 -BAX326 Prophylaxis and On-demand|Withdrawal by Subject|0
6159483|NCT01174446|9800673|FG000|Part 2 -BAX326 Prophylaxis and On-demand|Physician Decision|0
6159484|NCT01174446|9800674|FG001|Part 2 -BAX326 Prophylaxis and On-demand|Physician Decision|0
6159485|NCT01174446|9800675|FG002|Part 2 -BAX326 Prophylaxis and On-demand|Physician Decision|1
6159486|NCT01174446|9800676|FG003|Part 2 -BAX326 Prophylaxis and On-demand|Physician Decision|0
6159487|NCT01174446|9800673|FG000|Part 3 -Pharmacokinetic BAX326 Only|Protocol Violation|1
6159488|NCT01174446|9800674|FG001|Part 3 -Pharmacokinetic BAX326 Only|Protocol Violation|0
6159489|NCT01174446|9800675|FG002|Part 3 -Pharmacokinetic BAX326 Only|Protocol Violation|0
6159490|NCT01174446|9800676|FG003|Part 3 -Pharmacokinetic BAX326 Only|Protocol Violation|0
6159491|NCT01174446|9800673|FG000|Part 3 -Pharmacokinetic BAX326 Only|Required Emergency Surgery|0
6159492|NCT01174446|9800674|FG001|Part 3 -Pharmacokinetic BAX326 Only|Required Emergency Surgery|1
6159493|NCT01174446|9800675|FG002|Part 3 -Pharmacokinetic BAX326 Only|Required Emergency Surgery|0
6159494|NCT01174446|9800676|FG003|Part 3 -Pharmacokinetic BAX326 Only|Required Emergency Surgery|0
6159495|NCT01174459|9800723|FG000|Overall Study|case report form (CRF) not collected|5
6159496|NCT01174550|9800729|FG000|Overall Study|Death|75
6159497|NCT01174550|9800730|FG001|Overall Study|Death|74
6159498|NCT01174550|9800729|FG000|Overall Study|Lost to Follow-up|652
6159499|NCT01174550|9800730|FG001|Overall Study|Lost to Follow-up|510
6159500|NCT01174550|9800729|FG000|Overall Study|Withdrawal by Subject|543
6159501|NCT01174550|9800730|FG001|Overall Study|Withdrawal by Subject|289
6159502|NCT01174784|9800749|FG000|Overall Study|Screen fails|4
6159503|NCT01175018|9800770|FG000|Overall Study|Adverse Event|3
6159504|NCT01175018|9800771|FG001|Overall Study|Adverse Event|1
6159505|NCT01175083|9800793|FG000|Primary Epoch|Withdrawal by Subject|0
6159506|NCT01175083|9800794|FG001|Primary Epoch|Withdrawal by Subject|0
6159507|NCT01175083|9800795|FG002|Primary Epoch|Withdrawal by Subject|0
6159508|NCT01175083|9800796|FG003|Primary Epoch|Withdrawal by Subject|0
6159509|NCT01175083|9800797|FG004|Primary Epoch|Withdrawal by Subject|0
6159510|NCT01175083|9800798|FG005|Primary Epoch|Withdrawal by Subject|2
6159511|NCT01175083|9800793|FG000|Primary Epoch|Lost to Follow-up|0
6159512|NCT01175083|9800794|FG001|Primary Epoch|Lost to Follow-up|0
6159513|NCT01175083|9800795|FG002|Primary Epoch|Lost to Follow-up|0
6159514|NCT01175083|9800796|FG003|Primary Epoch|Lost to Follow-up|0
6159515|NCT01175083|9800797|FG004|Primary Epoch|Lost to Follow-up|0
6159516|NCT01175083|9800798|FG005|Primary Epoch|Lost to Follow-up|1
6159517|NCT01175083|9800793|FG000|Booster Epoch|Death|0
6159518|NCT01175083|9800794|FG001|Booster Epoch|Death|0
6159519|NCT01175083|9800795|FG002|Booster Epoch|Death|1
6159520|NCT01175083|9800796|FG003|Booster Epoch|Death|0
6159521|NCT01175083|9800797|FG004|Booster Epoch|Death|0
6159522|NCT01175083|9800798|FG005|Booster Epoch|Death|0
6159523|NCT01175083|9800793|FG000|Booster Epoch|Withdrawal by Subject|0
6159524|NCT01175083|9800794|FG001|Booster Epoch|Withdrawal by Subject|0
6159525|NCT01175083|9800795|FG002|Booster Epoch|Withdrawal by Subject|0
6159526|NCT01175083|9800796|FG003|Booster Epoch|Withdrawal by Subject|1
6159527|NCT01175083|9800797|FG004|Booster Epoch|Withdrawal by Subject|0
6159528|NCT01175083|9800798|FG005|Booster Epoch|Withdrawal by Subject|0
6159529|NCT01175135|9800820|FG000|Overall Study|Adverse Event|2
6159530|NCT01175135|9800821|FG001|Overall Study|Adverse Event|5
6159531|NCT01175135|9800822|FG002|Overall Study|Adverse Event|3
6159532|NCT01175135|9800823|FG003|Overall Study|Adverse Event|4
6159533|NCT01175135|9800820|FG000|Overall Study|Death|1
6159534|NCT01175135|9800821|FG001|Overall Study|Death|0
6159535|NCT01175135|9800822|FG002|Overall Study|Death|0
6159536|NCT01175135|9800823|FG003|Overall Study|Death|0
6159537|NCT01175135|9800820|FG000|Overall Study|Lack of Efficacy|4
6159538|NCT01175135|9800821|FG001|Overall Study|Lack of Efficacy|5
6159539|NCT01175135|9800822|FG002|Overall Study|Lack of Efficacy|0
6159540|NCT01175135|9800823|FG003|Overall Study|Lack of Efficacy|5
6159541|NCT01175135|9800820|FG000|Overall Study|Lost to Follow-up|1
6159542|NCT01175135|9800821|FG001|Overall Study|Lost to Follow-up|2
6159543|NCT01175135|9800822|FG002|Overall Study|Lost to Follow-up|0
6159544|NCT01175135|9800823|FG003|Overall Study|Lost to Follow-up|0
6159545|NCT01175135|9800820|FG000|Overall Study|Protocol Violation|1
6159546|NCT01175135|9800821|FG001|Overall Study|Protocol Violation|1
6159547|NCT01175135|9800822|FG002|Overall Study|Protocol Violation|0
6159548|NCT01175135|9800823|FG003|Overall Study|Protocol Violation|0
6159549|NCT01175135|9800820|FG000|Overall Study|Withdrawal by Subject|4
6159550|NCT01175135|9800821|FG001|Overall Study|Withdrawal by Subject|8
6159551|NCT01175135|9800822|FG002|Overall Study|Withdrawal by Subject|5
5971912|NCT02983617|9557518|FG000|Overall Study|Adverse Event|0
5971913|NCT02983617|9557519|FG001|Overall Study|Adverse Event|7
5971914|NCT02983617|9557518|FG000|Overall Study|Death|0
5971915|NCT02983617|9557519|FG001|Overall Study|Death|1
5971916|NCT02983617|9557518|FG000|Overall Study|Investigator's Discretion|0
5971917|NCT02983617|9557519|FG001|Overall Study|Investigator's Discretion|1
5971918|NCT02649946|9557553|FG000|Overall Study|Withdrawal by Subject|1
5971919|NCT02649946|9557554|FG001|Overall Study|Withdrawal by Subject|1
5971920|NCT02649946|9557553|FG000|Overall Study|Death|7
5971921|NCT02649946|9557554|FG001|Overall Study|Death|9
5971922|NCT02649946|9557553|FG000|Overall Study|Physician Decision|1
5971923|NCT02649946|9557554|FG001|Overall Study|Physician Decision|0
5971924|NCT02649946|9557553|FG000|Overall Study|Lost to Follow-up|2
5971925|NCT02649946|9557554|FG001|Overall Study|Lost to Follow-up|1
5971926|NCT02649946|9557553|FG000|Overall Study|Erroneously enrolled|1
5971927|NCT02649946|9557554|FG001|Overall Study|Erroneously enrolled|0
5971928|NCT02649946|9557553|FG000|Overall Study|Missed 6-month follow-up visit|0
5971929|NCT02649946|9557554|FG001|Overall Study|Missed 6-month follow-up visit|4
6042830|NCT00385671|9641323|FG002|Overall Study|Protocol Violation|1
6159552|NCT01175135|9800823|FG003|Overall Study|Withdrawal by Subject|5
6159553|NCT01175135|9800820|FG000|Overall Study|Other|3
6081325|NCT00621257|9688940|FG001|Overall Study|Physician Decision|2
6081326|NCT00621257|9688941|FG002|Overall Study|Physician Decision|0
6081327|NCT00621257|9688942|FG003|Overall Study|Physician Decision|1
6081328|NCT00621257|9688943|FG004|Overall Study|Physician Decision|1
6081329|NCT00621257|9688939|FG000|Overall Study|Withdrawal by Subject|0
6081330|NCT00621257|9688940|FG001|Overall Study|Withdrawal by Subject|0
6081331|NCT00621257|9688941|FG002|Overall Study|Withdrawal by Subject|0
6081332|NCT00621257|9688942|FG003|Overall Study|Withdrawal by Subject|1
6081333|NCT00621257|9688943|FG004|Overall Study|Withdrawal by Subject|1
6081334|NCT00621296|9688955|FG000|Overall Study|Adverse Event|2
6081335|NCT00621296|9688955|FG000|Overall Study|Lack of Efficacy|1
6081336|NCT00621296|9688955|FG000|Overall Study|Physician Decision|7
6324757|NCT02919475|10066607|FG001|Overall Study|Withdrawal by Subject|3
6324758|NCT02919475|10066608|FG002|Overall Study|Withdrawal by Subject|1
6324759|NCT02919475|10066609|FG003|Overall Study|Withdrawal by Subject|2
6324760|NCT02919475|10066610|FG004|Overall Study|Withdrawal by Subject|2
6324761|NCT02919475|10066606|FG000|Overall Study|Inclusion/Exclusion Criteria Not Met|1
6324762|NCT02919475|10066607|FG001|Overall Study|Inclusion/Exclusion Criteria Not Met|1
6324763|NCT02919475|10066608|FG002|Overall Study|Inclusion/Exclusion Criteria Not Met|1
6324764|NCT02919475|10066609|FG003|Overall Study|Inclusion/Exclusion Criteria Not Met|1
6324765|NCT02919475|10066610|FG004|Overall Study|Inclusion/Exclusion Criteria Not Met|0
6324766|NCT02919696|10066631|FG000|Overall Study|Adverse Event|1
6324767|NCT02919696|10066632|FG001|Overall Study|Adverse Event|2
6324768|NCT02919696|10066631|FG000|Overall Study|Withdrawal by Subject|2
6324769|NCT02919696|10066632|FG001|Overall Study|Withdrawal by Subject|1
6324770|NCT02919696|10066631|FG000|Overall Study|Sponsor Decision|1
6324771|NCT02919696|10066632|FG001|Overall Study|Sponsor Decision|1
6081337|NCT00621296|9688955|FG000|Overall Study|Unmatch Criteria|1
6081338|NCT00621296|9688955|FG000|Overall Study|Stopping Criteria|3
6081339|NCT00621309|9688959|FG000|Overall Study|Withdrawal by Subject|2
6081340|NCT00621309|9688960|FG001|Overall Study|Withdrawal by Subject|0
6081341|NCT00621309|9688961|FG002|Overall Study|Withdrawal by Subject|1
6081342|NCT00621309|9688962|FG003|Overall Study|Withdrawal by Subject|1
6081343|NCT00621309|9688963|FG004|Overall Study|Withdrawal by Subject|1
6081344|NCT00621309|9688964|FG005|Overall Study|Withdrawal by Subject|1
6081345|NCT00621322|9688976|FG000|Overall Study|Lost to Follow-up|0
6081346|NCT00621322|9688977|FG001|Overall Study|Lost to Follow-up|0
6081347|NCT00621322|9688978|FG002|Overall Study|Lost to Follow-up|0
6081348|NCT00621322|9688979|FG003|Overall Study|Lost to Follow-up|0
6081349|NCT00621322|9688980|FG004|Overall Study|Lost to Follow-up|1
6081350|NCT00621322|9688981|FG005|Overall Study|Lost to Follow-up|0
6081351|NCT00621322|9688976|FG000|Overall Study|Physician Decision|0
6081352|NCT00621322|9688977|FG001|Overall Study|Physician Decision|0
6081353|NCT00621322|9688978|FG002|Overall Study|Physician Decision|1
6081354|NCT00621322|9688979|FG003|Overall Study|Physician Decision|1
6081355|NCT00621322|9688980|FG004|Overall Study|Physician Decision|0
6081356|NCT00621322|9688981|FG005|Overall Study|Physician Decision|0
6081357|NCT00621322|9688976|FG000|Overall Study|Withdrawal by Subject|0
6081358|NCT00621322|9688977|FG001|Overall Study|Withdrawal by Subject|0
6081359|NCT00621322|9688978|FG002|Overall Study|Withdrawal by Subject|0
6081360|NCT00621322|9688979|FG003|Overall Study|Withdrawal by Subject|1
6081361|NCT00621322|9688980|FG004|Overall Study|Withdrawal by Subject|0
6081362|NCT00621322|9688981|FG005|Overall Study|Withdrawal by Subject|2
6081363|NCT00621322|9688976|FG000|Overall Study|Migrated/moved from study area|1
6081364|NCT00621322|9688977|FG001|Overall Study|Migrated/moved from study area|0
6081365|NCT00621322|9688978|FG002|Overall Study|Migrated/moved from study area|1
6081366|NCT00621322|9688979|FG003|Overall Study|Migrated/moved from study area|1
6081367|NCT00621322|9688980|FG004|Overall Study|Migrated/moved from study area|0
6042831|NCT00385671|9641321|FG000|Overall Study|Sponsor Decision|2
6042832|NCT00385671|9641322|FG001|Overall Study|Sponsor Decision|2
6081368|NCT00621322|9688981|FG005|Overall Study|Migrated/moved from study area|2
6081369|NCT00621504|9689010|FG000|Overall Study|Adverse Event|1
6081370|NCT00621504|9689011|FG001|Overall Study|Adverse Event|3
6081371|NCT00621504|9689010|FG000|Overall Study|At the request of sponsor/investigator|1
6081372|NCT00621504|9689011|FG001|Overall Study|At the request of sponsor/investigator|0
6081373|NCT00621504|9689010|FG000|Overall Study|Withdrew consent|9
6081374|NCT00621504|9689011|FG001|Overall Study|Withdrew consent|6
6081375|NCT00621504|9689010|FG000|Overall Study|Lost to Follow-up|8
6081376|NCT00621504|9689011|FG001|Overall Study|Lost to Follow-up|10
6081377|NCT00621504|9689010|FG000|Overall Study|Other|1
6081378|NCT00621504|9689011|FG001|Overall Study|Other|0
6081379|NCT00621504|9689010|FG000|Overall Study|Death|6
6081380|NCT00621504|9689011|FG001|Overall Study|Death|6
6081381|NCT00621517|9689019|FG000|Overall Study|Lost to Follow-up|3
6081382|NCT00621517|9689020|FG001|Overall Study|Lost to Follow-up|3
6081383|NCT00621517|9689019|FG000|Overall Study|Withdrawal by Subject|3
6081384|NCT00621517|9689020|FG001|Overall Study|Withdrawal by Subject|4
6081385|NCT00621517|9689019|FG000|Overall Study|Adverse Event|1
6081386|NCT00621517|9689020|FG001|Overall Study|Adverse Event|0
6081387|NCT00621543|9689038|FG000|Overall Study|Lost to Follow-up|23
6081388|NCT00621582|9689042|FG000|Overall Study|Adverse Event|7
6081389|NCT00621582|9689042|FG000|Overall Study|Protocol Violation|57
5972212|NCT04435808|9557944|FG000|Overall Study|Study stopped by DSMB|0
6081390|NCT00621582|9689042|FG000|Overall Study|Lost to Follow-up|24
6081391|NCT00621582|9689042|FG000|Overall Study|issues not identified by investigators|18
6081392|NCT00621621|9689049|FG000|Overall Study|Subjects were exited at EP study|30
6081393|NCT00621621|9689050|FG001|Overall Study|Subjects were exited at EP study|0
6324772|NCT02919696|10066631|FG000|Overall Study|Never Treated|0
6081394|NCT00621764|9689072|FG000|Overall Study|Protocol Violation|0
6324773|NCT02919696|10066632|FG001|Overall Study|Never Treated|1
6324774|NCT02919761|10066644|FG000|Part 1: Open Label|Withdrawal by Subject|12
6324775|NCT02919761|10066645|FG001|Part 1: Open Label|Withdrawal by Subject|0
6324776|NCT02919761|10066646|FG002|Part 1: Open Label|Withdrawal by Subject|0
6324777|NCT02919761|10066644|FG000|Part 1: Open Label|Adverse Event|1
6324778|NCT02919761|10066645|FG001|Part 1: Open Label|Adverse Event|0
6324779|NCT02919761|10066646|FG002|Part 1: Open Label|Adverse Event|0
6324780|NCT02919761|10066644|FG000|Part 1: Open Label|Lost to Follow-up|1
6324781|NCT02919761|10066645|FG001|Part 1: Open Label|Lost to Follow-up|0
6324782|NCT02919761|10066646|FG002|Part 1: Open Label|Lost to Follow-up|0
6324783|NCT02919761|10066644|FG000|Part 1: Open Label|Met withdrawal criteria|5
6324784|NCT02919761|10066645|FG001|Part 1: Open Label|Met withdrawal criteria|0
6081395|NCT00621764|9689073|FG001|Overall Study|Protocol Violation|0
6081396|NCT00621764|9689074|FG002|Overall Study|Protocol Violation|0
6081397|NCT00621764|9689075|FG003|Overall Study|Protocol Violation|1
6081398|NCT00621777|9689088|FG000|Open Phase|Adverse Event|20
6081399|NCT00621777|9689089|FG001|Open Phase|Adverse Event|0
6081400|NCT00621777|9689088|FG000|Open Phase|Did not abstain during open phase|56
6081401|NCT00621777|9689089|FG001|Open Phase|Did not abstain during open phase|0
6081402|NCT00621777|9689088|FG000|Open Phase|Withdrawal by Subject|17
6081403|NCT00621777|9689089|FG001|Open Phase|Withdrawal by Subject|0
6081404|NCT00621777|9689088|FG000|Open Phase|administrative|13
6081405|NCT00621777|9689089|FG001|Open Phase|administrative|0
6081406|NCT00621777|9689088|FG000|Open Phase|Lost to Follow-up|10
6081407|NCT00621777|9689089|FG001|Open Phase|Lost to Follow-up|0
6081408|NCT00621777|9689088|FG000|Randomized Phase|Adverse Event|3
6081409|NCT00621777|9689089|FG001|Randomized Phase|Adverse Event|3
6081410|NCT00621777|9689088|FG000|Randomized Phase|Lost to Follow-up|3
6081411|NCT00621777|9689089|FG001|Randomized Phase|Lost to Follow-up|3
6081412|NCT00621777|9689088|FG000|Randomized Phase|Withdrawal by Subject|1
6081413|NCT00621777|9689089|FG001|Randomized Phase|Withdrawal by Subject|9
6081414|NCT00621777|9689088|FG000|Randomized Phase|administrative|0
6081415|NCT00621777|9689089|FG001|Randomized Phase|administrative|3
6081416|NCT00621777|9689088|FG000|Randomized Phase|Death|0
6081417|NCT00621777|9689089|FG001|Randomized Phase|Death|1
6081418|NCT00621842|9689097|FG000|Overall Study|Adverse Event|6
6081419|NCT00621842|9689097|FG000|Overall Study|Withdrawal by Subject|7
6081420|NCT00621842|9689097|FG000|Overall Study|Protocol Violation|4
6081421|NCT00621842|9689097|FG000|Overall Study|Lack of Efficacy|2
6081422|NCT00621855|9689106|FG000|Overall Study|Adverse Event|32
6081423|NCT00621855|9689107|FG001|Overall Study|Adverse Event|31
6081424|NCT00621855|9689108|FG002|Overall Study|Adverse Event|48
6081425|NCT00621855|9689109|FG003|Overall Study|Adverse Event|34
6081426|NCT00621855|9689110|FG004|Overall Study|Adverse Event|31
6081427|NCT00621855|9689106|FG000|Overall Study|Lost to Follow-up|0
6081428|NCT00621855|9689107|FG001|Overall Study|Lost to Follow-up|1
6081429|NCT00621855|9689108|FG002|Overall Study|Lost to Follow-up|3
6081430|NCT00621855|9689109|FG003|Overall Study|Lost to Follow-up|4
6081431|NCT00621855|9689110|FG004|Overall Study|Lost to Follow-up|1
6081432|NCT00621855|9689106|FG000|Overall Study|Protocol Violation|16
6081433|NCT00621855|9689107|FG001|Overall Study|Protocol Violation|8
6081434|NCT00621855|9689108|FG002|Overall Study|Protocol Violation|6
6081435|NCT00621855|9689109|FG003|Overall Study|Protocol Violation|7
6081436|NCT00621855|9689110|FG004|Overall Study|Protocol Violation|8
6081437|NCT00621855|9689106|FG000|Overall Study|Withdrawal by Subject|16
6081438|NCT00621855|9689107|FG001|Overall Study|Withdrawal by Subject|11
6081439|NCT00621855|9689108|FG002|Overall Study|Withdrawal by Subject|13
6081440|NCT00621855|9689109|FG003|Overall Study|Withdrawal by Subject|13
6081441|NCT00621855|9689110|FG004|Overall Study|Withdrawal by Subject|9
6081442|NCT00621855|9689106|FG000|Overall Study|Other|9
6081443|NCT00621855|9689107|FG001|Overall Study|Other|7
6081444|NCT00621855|9689108|FG002|Overall Study|Other|6
6081445|NCT00621855|9689109|FG003|Overall Study|Other|5
6081446|NCT00621855|9689110|FG004|Overall Study|Other|4
6081447|NCT00621855|9689106|FG000|Overall Study|Patients did not receive study drug|3
6081448|NCT00621855|9689107|FG001|Overall Study|Patients did not receive study drug|3
6081449|NCT00621855|9689108|FG002|Overall Study|Patients did not receive study drug|5
6081450|NCT00621855|9689109|FG003|Overall Study|Patients did not receive study drug|4
6081451|NCT00621855|9689110|FG004|Overall Study|Patients did not receive study drug|2
6081452|NCT00621959|9689138|FG000|Overall Study|Adverse Event|4
6081453|NCT00621959|9689139|FG001|Overall Study|Adverse Event|2
6081454|NCT00621959|9689138|FG000|Overall Study|Lack of Efficacy|1
6081455|NCT00621959|9689139|FG001|Overall Study|Lack of Efficacy|1
6081456|NCT00621959|9689138|FG000|Overall Study|Lost to Follow-up|0
6081457|NCT00621959|9689139|FG001|Overall Study|Lost to Follow-up|2
6081458|NCT00621959|9689138|FG000|Overall Study|Withdrawal by Subject|1
6081459|NCT00621959|9689139|FG001|Overall Study|Withdrawal by Subject|1
6081460|NCT00621959|9689138|FG000|Overall Study|Other|1
6081461|NCT00621959|9689139|FG001|Overall Study|Other|3
6081462|NCT00621985|9689145|FG000|Dexamethasone Admission|Adverse Event|1
6081463|NCT00622180|9689151|FG000|Overall Study|Lost to Follow-up|1
6081464|NCT00622180|9689152|FG001|Overall Study|Lost to Follow-up|2
6081465|NCT00622284|9689160|FG000|Overall Study|Lack of Efficacy|45
6081466|NCT00622284|9689161|FG001|Overall Study|Lack of Efficacy|15
6081467|NCT00622284|9689160|FG000|Overall Study|Adverse Event|61
6081468|NCT00622284|9689161|FG001|Overall Study|Adverse Event|90
6081469|NCT00622284|9689160|FG000|Overall Study|Protocol Violation|12
6081470|NCT00622284|9689161|FG001|Overall Study|Protocol Violation|5
6081471|NCT00622284|9689160|FG000|Overall Study|Lost to Follow-up|11
6081472|NCT00622284|9689161|FG001|Overall Study|Lost to Follow-up|13
6081473|NCT00622284|9689160|FG000|Overall Study|Withdrawal by Subject|27
6081474|NCT00622284|9689161|FG001|Overall Study|Withdrawal by Subject|24
6081475|NCT00622284|9689160|FG000|Overall Study|Other reason (not specified)|33
6081476|NCT00622284|9689161|FG001|Overall Study|Other reason (not specified)|24
6081477|NCT00622336|9689167|FG000|Treatment Phase|Progression of Disease|181
6081478|NCT00622336|9689167|FG000|Treatment Phase|Adverse Event|46
6081479|NCT00622336|9689167|FG000|Treatment Phase|Other|40
6081480|NCT00622336|9689167|FG000|Treatment Phase|Death|14
6081481|NCT00622336|9689167|FG000|Treatment Phase|Lack of therapeutic effect|13
6081482|NCT00622336|9689167|FG000|Treatment Phase|Withdrawal by Subject|13
6081483|NCT00622336|9689167|FG000|Treatment Phase|Lost to Follow-up|2
6081484|NCT00622336|9689167|FG000|Extension Phase|Adverse Event|2
6081485|NCT00622336|9689167|FG000|Extension Phase|Progressive Disease|6
6081486|NCT00622336|9689167|FG000|Extension Phase|Lack of therapeutic effect|2
6081487|NCT00622336|9689167|FG000|Extension Phase|Withdrawal by Subject|1
6081488|NCT00622336|9689167|FG000|Extension Phase|Lost to Follow-up|1
6081489|NCT00622336|9689167|FG000|Extension Phase|Other|9
6081490|NCT00622388|9689173|FG000|Overall Study|Disease Progression|47
6081491|NCT00622388|9689173|FG000|Overall Study|Adverse Event|6
6081492|NCT00622388|9689173|FG000|Overall Study|Protocol Violation|3
6081493|NCT00622388|9689173|FG000|Overall Study|Participant Refusal|1
6081494|NCT00622388|9689173|FG000|Overall Study|Death|3
6324785|NCT02919761|10066646|FG002|Part 1: Open Label|Met withdrawal criteria|0
6324786|NCT02919761|10066644|FG000|Part 1: Open Label|Did Not Achieve Lda At Week 12|2
6324787|NCT02919761|10066645|FG001|Part 1: Open Label|Did Not Achieve Lda At Week 12|0
6324788|NCT02919761|10066646|FG002|Part 1: Open Label|Did Not Achieve Lda At Week 12|0
6324789|NCT02919761|10066644|FG000|Part 1: Open Label|Dose Greater Than 20mg/Week|1
6324790|NCT02919761|10066645|FG001|Part 1: Open Label|Dose Greater Than 20mg/Week|0
6324791|NCT02919761|10066646|FG002|Part 1: Open Label|Dose Greater Than 20mg/Week|0
6324792|NCT02919761|10066644|FG000|Part 1: Open Label|did not meet inclusion criteria 8|1
6324793|NCT02919761|10066645|FG001|Part 1: Open Label|did not meet inclusion criteria 8|0
6324794|NCT02919761|10066646|FG002|Part 1: Open Label|did not meet inclusion criteria 8|0
6081495|NCT00622388|9689173|FG000|Overall Study|Received Alternate Anticancer Therapy|8
6081496|NCT00622388|9689173|FG000|Overall Study|Took Prohibited Medication|2
6081497|NCT00622388|9689173|FG000|Overall Study|Withdrew Consent|1
6081498|NCT00622388|9689173|FG000|Overall Study|Insurance Expired|1
6081499|NCT00622401|9689181|FG000|Overall Study|Disease progression prior to treatment|3
6081500|NCT00622401|9689182|FG001|Overall Study|Disease progression prior to treatment|2
6324795|NCT02919761|10066644|FG000|Part 1: Open Label|Termination by Sponsor|1
6081501|NCT00622401|9689183|FG002|Overall Study|Disease progression prior to treatment|0
6081502|NCT00622440|9689203|FG000|Baseline - Week 12 (Treatment)|Received cream but did not return|4
6081503|NCT00622440|9689204|FG001|Baseline - Week 12 (Treatment)|Received cream but did not return|1
6081504|NCT00622440|9689203|FG000|Week 12 - Week 48 (Treatment)|Lost to Follow-up|3
6081505|NCT00622440|9689204|FG001|Week 12 - Week 48 (Treatment)|Lost to Follow-up|5
6081506|NCT00622440|9689203|FG000|Week 12 - Week 48 (Treatment)|Not evaluable - censored from dataset|0
6081507|NCT00622440|9689204|FG001|Week 12 - Week 48 (Treatment)|Not evaluable - censored from dataset|1
6081508|NCT00622440|9689203|FG000|Week 60 (Post-treatment Follow-up Visit)|Lost to Follow-up|0
6081509|NCT00622440|9689204|FG001|Week 60 (Post-treatment Follow-up Visit)|Lost to Follow-up|1
6081510|NCT00622466|9689210|FG000|Overall Study|Death|1
6081511|NCT00622466|9689210|FG000|Overall Study|Adverse Event|1
6081512|NCT00622466|9689210|FG000|Overall Study|Withdrawal by Subject|2
6081513|NCT00622505|9689216|FG000|Overall Study|Adverse Event|9
6081514|NCT00622505|9689217|FG001|Overall Study|Adverse Event|7
6081515|NCT00622505|9689216|FG000|Overall Study|Abnormal Laboratory Value(s)|3
6081516|NCT00622505|9689217|FG001|Overall Study|Abnormal Laboratory Value(s)|5
6081517|NCT00622505|9689216|FG000|Overall Study|Abnormal Test Procedure Result(s)|1
6081518|NCT00622505|9689217|FG001|Overall Study|Abnormal Test Procedure Result(s)|0
6081519|NCT00622505|9689216|FG000|Overall Study|Withdrawal by Subject|12
6081520|NCT00622505|9689217|FG001|Overall Study|Withdrawal by Subject|5
6081521|NCT00622505|9689216|FG000|Overall Study|Administrative Problems|2
6081522|NCT00622505|9689217|FG001|Overall Study|Administrative Problems|4
6081523|NCT00622505|9689216|FG000|Overall Study|Death|2
6081524|NCT00622505|9689217|FG001|Overall Study|Death|2
6081525|NCT00622635|9689236|FG000|Treatment Period 1|Adverse Event|0
6159554|NCT01175135|9800821|FG001|Overall Study|Other|1
6081526|NCT00622635|9689237|FG001|Treatment Period 1|Adverse Event|0
6081527|NCT00622635|9689238|FG002|Treatment Period 1|Adverse Event|1
6081528|NCT00622635|9689239|FG003|Treatment Period 1|Adverse Event|0
6081529|NCT00622635|9689240|FG004|Treatment Period 1|Adverse Event|0
6081530|NCT00622635|9689241|FG005|Treatment Period 1|Adverse Event|0
6081531|NCT00622635|9689236|FG000|Treatment Period 1|Withdrawal by Subject|0
6081532|NCT00622635|9689237|FG001|Treatment Period 1|Withdrawal by Subject|1
5971930|NCT02431247|9557562|FG000|BL to EOE-Test and BL to Switch- Control|Other|11
5971931|NCT02431247|9557563|FG001|BL to EOE-Test and BL to Switch- Control|Other|2
5971932|NCT02431247|9557564|FG002|BL to EOE-Test and BL to Switch- Control|Other|0
5971933|NCT02431247|9557562|FG000|BL to EOE-Test and BL to Switch- Control|Lost to Follow-up|17
5971934|NCT02431247|9557563|FG001|BL to EOE-Test and BL to Switch- Control|Lost to Follow-up|8
5971935|NCT02431247|9557564|FG002|BL to EOE-Test and BL to Switch- Control|Lost to Follow-up|0
5971936|NCT02431247|9557562|FG000|BL to EOE-Test and BL to Switch- Control|Physician Decision|9
5971937|NCT02431247|9557563|FG001|BL to EOE-Test and BL to Switch- Control|Physician Decision|4
5971938|NCT02431247|9557564|FG002|BL to EOE-Test and BL to Switch- Control|Physician Decision|0
5971939|NCT02431247|9557562|FG000|BL to EOE-Test and BL to Switch- Control|Pregnancy|1
5972213|NCT04435808|9557945|FG001|Overall Study|Study stopped by DSMB|1
5971940|NCT02431247|9557563|FG001|BL to EOE-Test and BL to Switch- Control|Pregnancy|1
5971941|NCT02431247|9557564|FG002|BL to EOE-Test and BL to Switch- Control|Pregnancy|0
5971942|NCT02431247|9557562|FG000|BL to EOE-Test and BL to Switch- Control|Adverse Event|12
5971943|NCT02431247|9557563|FG001|BL to EOE-Test and BL to Switch- Control|Adverse Event|16
5971944|NCT02431247|9557564|FG002|BL to EOE-Test and BL to Switch- Control|Adverse Event|0
5971945|NCT02431247|9557562|FG000|BL to EOE-Test and BL to Switch- Control|Death|0
5971946|NCT02431247|9557563|FG001|BL to EOE-Test and BL to Switch- Control|Death|1
5971947|NCT02431247|9557564|FG002|BL to EOE-Test and BL to Switch- Control|Death|0
5971948|NCT02431247|9557562|FG000|BL to EOE-Test and BL to Switch- Control|Withdrawal by Subject|14
5971949|NCT02431247|9557563|FG001|BL to EOE-Test and BL to Switch- Control|Withdrawal by Subject|9
5971950|NCT02431247|9557564|FG002|BL to EOE-Test and BL to Switch- Control|Withdrawal by Subject|0
5971951|NCT02431247|9557562|FG000|BL to EOE-Test and BL to Switch- Control|Subject non-compliant|2
5971952|NCT02431247|9557563|FG001|BL to EOE-Test and BL to Switch- Control|Subject non-compliant|0
5971953|NCT02431247|9557564|FG002|BL to EOE-Test and BL to Switch- Control|Subject non-compliant|0
5971954|NCT02431247|9557562|FG000|Switch to D/C/F/TAF (Until EOE)|Other|0
5971955|NCT02431247|9557563|FG001|Switch to D/C/F/TAF (Until EOE)|Other|0
5971956|NCT02431247|9557564|FG002|Switch to D/C/F/TAF (Until EOE)|Other|4
5971957|NCT02431247|9557562|FG000|Switch to D/C/F/TAF (Until EOE)|Lost to Follow-up|0
5971958|NCT02431247|9557563|FG001|Switch to D/C/F/TAF (Until EOE)|Lost to Follow-up|0
5971959|NCT02431247|9557564|FG002|Switch to D/C/F/TAF (Until EOE)|Lost to Follow-up|12
5971960|NCT02431247|9557562|FG000|Switch to D/C/F/TAF (Until EOE)|Physician Decision|0
5971961|NCT02431247|9557563|FG001|Switch to D/C/F/TAF (Until EOE)|Physician Decision|0
5971962|NCT02431247|9557564|FG002|Switch to D/C/F/TAF (Until EOE)|Physician Decision|1
5971963|NCT02431247|9557562|FG000|Switch to D/C/F/TAF (Until EOE)|Adverse Event|0
5971964|NCT02431247|9557563|FG001|Switch to D/C/F/TAF (Until EOE)|Adverse Event|0
5971965|NCT02431247|9557564|FG002|Switch to D/C/F/TAF (Until EOE)|Adverse Event|5
5971966|NCT02431247|9557562|FG000|Switch to D/C/F/TAF (Until EOE)|Death|0
5971967|NCT02431247|9557563|FG001|Switch to D/C/F/TAF (Until EOE)|Death|0
5971968|NCT02431247|9557564|FG002|Switch to D/C/F/TAF (Until EOE)|Death|1
5971969|NCT02431247|9557562|FG000|Switch to D/C/F/TAF (Until EOE)|Withdrawal by Subject|0
5971970|NCT02431247|9557563|FG001|Switch to D/C/F/TAF (Until EOE)|Withdrawal by Subject|0
5971971|NCT02431247|9557564|FG002|Switch to D/C/F/TAF (Until EOE)|Withdrawal by Subject|10
5971972|NCT02345850|9557579|FG000|Overall Study|Not transplanted|10
5971973|NCT02345850|9557580|FG001|Overall Study|Not transplanted|5
5971974|NCT02345850|9557581|FG002|Overall Study|Not transplanted|4
5971975|NCT02345850|9557579|FG000|Overall Study|Lost to Follow-up|2
5971976|NCT02345850|9557580|FG001|Overall Study|Lost to Follow-up|3
5971977|NCT02345850|9557581|FG002|Overall Study|Lost to Follow-up|2
5971978|NCT02345850|9557579|FG000|Overall Study|Withdrawal by Subject|1
5971979|NCT02345850|9557580|FG001|Overall Study|Withdrawal by Subject|0
5971980|NCT02345850|9557581|FG002|Overall Study|Withdrawal by Subject|0
5971981|NCT02343302|9557591|FG000|Overall Study|Physician Decision|1
5971982|NCT02343302|9557592|FG001|Overall Study|Physician Decision|1
5971983|NCT02281084|9557602|FG000|Overall Study|Adverse Event|1
5971984|NCT02281084|9557603|FG001|Overall Study|Adverse Event|0
5971985|NCT02281084|9557604|FG002|Overall Study|Adverse Event|0
5971986|NCT02281084|9557605|FG003|Overall Study|Adverse Event|0
5971987|NCT02281084|9557602|FG000|Overall Study|Withdrawal by Subject|1
5971988|NCT02281084|9557603|FG001|Overall Study|Withdrawal by Subject|2
5971989|NCT02281084|9557604|FG002|Overall Study|Withdrawal by Subject|0
6159555|NCT01175135|9800822|FG002|Overall Study|Other|3
5971990|NCT02281084|9557605|FG003|Overall Study|Withdrawal by Subject|0
5971991|NCT02281084|9557602|FG000|Overall Study|Death|20
5971992|NCT02281084|9557603|FG001|Overall Study|Death|16
5971993|NCT02281084|9557604|FG002|Overall Study|Death|3
5971994|NCT02281084|9557605|FG003|Overall Study|Death|5
6159556|NCT01175135|9800823|FG003|Overall Study|Other|0
6159557|NCT01175135|9800820|FG000|Overall Study|Randomized But Not Treated|0
6159558|NCT01175135|9800821|FG001|Overall Study|Randomized But Not Treated|0
6159559|NCT01175135|9800822|FG002|Overall Study|Randomized But Not Treated|1
6159560|NCT01175135|9800823|FG003|Overall Study|Randomized But Not Treated|0
6159561|NCT01175213|9800845|FG000|IGSC, 10%/rHuPH20|Withdrawal by Subject|4
6159562|NCT01175213|9800846|FG001|IGSC, 10%/rHuPH20|Withdrawal by Subject|0
6159563|NCT01175213|9800845|FG000|IGSC, 10%/rHuPH20|Death|1
6159564|NCT01175213|9800846|FG001|IGSC, 10%/rHuPH20|Death|0
6159565|NCT01175213|9800845|FG000|IGSC, 10%/rHuPH20|bone marrow transplant|1
6159566|NCT01175213|9800846|FG001|IGSC, 10%/rHuPH20|bone marrow transplant|0
6159567|NCT01175213|9800845|FG000|IGSC, 10%/rHuPH20|clinical site closed by sponsor|6
6159568|NCT01175213|9800846|FG001|IGSC, 10%/rHuPH20|clinical site closed by sponsor|0
6159569|NCT01175213|9800845|FG000|IGSC, 10%/rHuPH20|site elected to exit study|3
6159570|NCT01175213|9800846|FG001|IGSC, 10%/rHuPH20|site elected to exit study|0
6042833|NCT00385671|9641323|FG002|Overall Study|Sponsor Decision|1
6042834|NCT00385671|9641321|FG000|Overall Study|Withdrawal by Subject|4
6042835|NCT00385671|9641322|FG001|Overall Study|Withdrawal by Subject|4
6081533|NCT00622635|9689238|FG002|Treatment Period 1|Withdrawal by Subject|0
6081534|NCT00622635|9689239|FG003|Treatment Period 1|Withdrawal by Subject|0
6081535|NCT00622635|9689240|FG004|Treatment Period 1|Withdrawal by Subject|0
6081536|NCT00622635|9689241|FG005|Treatment Period 1|Withdrawal by Subject|0
6081537|NCT00622635|9689236|FG000|Treatment Period 1|Abnormal test procedure result(s)|0
6159571|NCT01175213|9800845|FG000|Safety Follow-up|Adverse Event|1
6081538|NCT00622635|9689237|FG001|Treatment Period 1|Abnormal test procedure result(s)|0
6081539|NCT00622635|9689238|FG002|Treatment Period 1|Abnormal test procedure result(s)|0
6081540|NCT00622635|9689239|FG003|Treatment Period 1|Abnormal test procedure result(s)|0
6081541|NCT00622635|9689240|FG004|Treatment Period 1|Abnormal test procedure result(s)|1
6081542|NCT00622635|9689241|FG005|Treatment Period 1|Abnormal test procedure result(s)|0
6081543|NCT00622635|9689236|FG000|Treatment Period 2|Adverse Event|1
6081544|NCT00622635|9689237|FG001|Treatment Period 2|Adverse Event|0
6081545|NCT00622635|9689238|FG002|Treatment Period 2|Adverse Event|0
6081546|NCT00622635|9689239|FG003|Treatment Period 2|Adverse Event|0
6081547|NCT00622635|9689240|FG004|Treatment Period 2|Adverse Event|0
6081548|NCT00622635|9689241|FG005|Treatment Period 2|Adverse Event|0
6081549|NCT00622635|9689236|FG000|Treatment Period 3|Adverse Event|0
6081550|NCT00622635|9689237|FG001|Treatment Period 3|Adverse Event|0
6081551|NCT00622635|9689238|FG002|Treatment Period 3|Adverse Event|0
6081552|NCT00622635|9689239|FG003|Treatment Period 3|Adverse Event|2
6081553|NCT00622635|9689240|FG004|Treatment Period 3|Adverse Event|0
6081554|NCT00622635|9689241|FG005|Treatment Period 3|Adverse Event|0
6081555|NCT00622635|9689236|FG000|Treatment Period 3|Withdrawal by Subject|0
6081556|NCT00622635|9689237|FG001|Treatment Period 3|Withdrawal by Subject|0
6081557|NCT00622635|9689238|FG002|Treatment Period 3|Withdrawal by Subject|0
6081558|NCT00622635|9689239|FG003|Treatment Period 3|Withdrawal by Subject|1
6081559|NCT00622635|9689240|FG004|Treatment Period 3|Withdrawal by Subject|0
6081560|NCT00622635|9689241|FG005|Treatment Period 3|Withdrawal by Subject|0
6081561|NCT00622700|9689252|FG000|Core Treatment Period|Randomized but Not Treated|0
6081562|NCT00622700|9689253|FG001|Core Treatment Period|Randomized but Not Treated|2
6081563|NCT00622700|9689254|FG002|Core Treatment Period|Randomized but Not Treated|2
6081564|NCT00622700|9689255|FG003|Core Treatment Period|Randomized but Not Treated|0
6081565|NCT00622700|9689256|FG004|Core Treatment Period|Randomized but Not Treated|0
6081566|NCT00622700|9689257|FG005|Core Treatment Period|Randomized but Not Treated|0
6081567|NCT00622700|9689258|FG006|Core Treatment Period|Randomized but Not Treated|0
6081568|NCT00622700|9689252|FG000|Core Treatment Period|Adverse Event|18
6081569|NCT00622700|9689253|FG001|Core Treatment Period|Adverse Event|25
6081570|NCT00622700|9689254|FG002|Core Treatment Period|Adverse Event|18
6081571|NCT00622700|9689255|FG003|Core Treatment Period|Adverse Event|0
6081572|NCT00622700|9689256|FG004|Core Treatment Period|Adverse Event|0
6081573|NCT00622700|9689257|FG005|Core Treatment Period|Adverse Event|0
6081574|NCT00622700|9689258|FG006|Core Treatment Period|Adverse Event|0
6081575|NCT00622700|9689252|FG000|Core Treatment Period|Lack of Efficacy|19
6081576|NCT00622700|9689253|FG001|Core Treatment Period|Lack of Efficacy|6
6081577|NCT00622700|9689254|FG002|Core Treatment Period|Lack of Efficacy|12
6081578|NCT00622700|9689255|FG003|Core Treatment Period|Lack of Efficacy|0
6081579|NCT00622700|9689256|FG004|Core Treatment Period|Lack of Efficacy|0
6081580|NCT00622700|9689257|FG005|Core Treatment Period|Lack of Efficacy|0
6081581|NCT00622700|9689258|FG006|Core Treatment Period|Lack of Efficacy|0
6081582|NCT00622700|9689252|FG000|Core Treatment Period|Lost to Follow-up|1
6081583|NCT00622700|9689253|FG001|Core Treatment Period|Lost to Follow-up|1
6081584|NCT00622700|9689254|FG002|Core Treatment Period|Lost to Follow-up|1
6081585|NCT00622700|9689255|FG003|Core Treatment Period|Lost to Follow-up|0
6081586|NCT00622700|9689256|FG004|Core Treatment Period|Lost to Follow-up|0
6081587|NCT00622700|9689257|FG005|Core Treatment Period|Lost to Follow-up|0
6081588|NCT00622700|9689258|FG006|Core Treatment Period|Lost to Follow-up|0
6081589|NCT00622700|9689252|FG000|Core Treatment Period|Death|1
6081590|NCT00622700|9689253|FG001|Core Treatment Period|Death|0
6081591|NCT00622700|9689254|FG002|Core Treatment Period|Death|0
6081592|NCT00622700|9689255|FG003|Core Treatment Period|Death|0
6081593|NCT00622700|9689256|FG004|Core Treatment Period|Death|0
6081594|NCT00622700|9689257|FG005|Core Treatment Period|Death|0
6081595|NCT00622700|9689258|FG006|Core Treatment Period|Death|0
6081596|NCT00622700|9689252|FG000|Core Treatment Period|Progressive Disease|3
6081597|NCT00622700|9689253|FG001|Core Treatment Period|Progressive Disease|1
6081598|NCT00622700|9689254|FG002|Core Treatment Period|Progressive Disease|0
6081599|NCT00622700|9689255|FG003|Core Treatment Period|Progressive Disease|0
6081600|NCT00622700|9689256|FG004|Core Treatment Period|Progressive Disease|0
6081601|NCT00622700|9689257|FG005|Core Treatment Period|Progressive Disease|0
6081602|NCT00622700|9689258|FG006|Core Treatment Period|Progressive Disease|0
6081603|NCT00622700|9689252|FG000|Core Treatment Period|Withdrawal by Subject|12
6081604|NCT00622700|9689253|FG001|Core Treatment Period|Withdrawal by Subject|18
6081605|NCT00622700|9689254|FG002|Core Treatment Period|Withdrawal by Subject|15
6081606|NCT00622700|9689255|FG003|Core Treatment Period|Withdrawal by Subject|0
6081607|NCT00622700|9689256|FG004|Core Treatment Period|Withdrawal by Subject|0
6081608|NCT00622700|9689257|FG005|Core Treatment Period|Withdrawal by Subject|0
6081609|NCT00622700|9689258|FG006|Core Treatment Period|Withdrawal by Subject|0
6081610|NCT00622700|9689252|FG000|Core Treatment Period|Other than specified above|2
6081611|NCT00622700|9689253|FG001|Core Treatment Period|Other than specified above|2
6081612|NCT00622700|9689254|FG002|Core Treatment Period|Other than specified above|5
6081613|NCT00622700|9689255|FG003|Core Treatment Period|Other than specified above|0
6081614|NCT00622700|9689256|FG004|Core Treatment Period|Other than specified above|0
6081615|NCT00622700|9689257|FG005|Core Treatment Period|Other than specified above|0
6081616|NCT00622700|9689258|FG006|Core Treatment Period|Other than specified above|0
6081617|NCT00622700|9689252|FG000|Extension Treatment Period|Adverse Event|0
6081618|NCT00622700|9689253|FG001|Extension Treatment Period|Adverse Event|0
6081619|NCT00622700|9689254|FG002|Extension Treatment Period|Adverse Event|0
6081620|NCT00622700|9689255|FG003|Extension Treatment Period|Adverse Event|5
6081621|NCT00622700|9689256|FG004|Extension Treatment Period|Adverse Event|9
6081622|NCT00622700|9689257|FG005|Extension Treatment Period|Adverse Event|6
6081623|NCT00622700|9689258|FG006|Extension Treatment Period|Adverse Event|8
6081624|NCT00622700|9689252|FG000|Extension Treatment Period|Lack of Efficacy|0
6081625|NCT00622700|9689253|FG001|Extension Treatment Period|Lack of Efficacy|0
6081626|NCT00622700|9689254|FG002|Extension Treatment Period|Lack of Efficacy|0
6081627|NCT00622700|9689255|FG003|Extension Treatment Period|Lack of Efficacy|2
6081628|NCT00622700|9689256|FG004|Extension Treatment Period|Lack of Efficacy|8
6081629|NCT00622700|9689257|FG005|Extension Treatment Period|Lack of Efficacy|1
6081630|NCT00622700|9689258|FG006|Extension Treatment Period|Lack of Efficacy|9
6081631|NCT00622700|9689252|FG000|Extension Treatment Period|Protocol Violation|0
6081632|NCT00622700|9689253|FG001|Extension Treatment Period|Protocol Violation|0
6081633|NCT00622700|9689254|FG002|Extension Treatment Period|Protocol Violation|0
6081634|NCT00622700|9689255|FG003|Extension Treatment Period|Protocol Violation|0
6081635|NCT00622700|9689256|FG004|Extension Treatment Period|Protocol Violation|0
6081636|NCT00622700|9689257|FG005|Extension Treatment Period|Protocol Violation|2
6081637|NCT00622700|9689258|FG006|Extension Treatment Period|Protocol Violation|0
6081638|NCT00622700|9689252|FG000|Extension Treatment Period|Lost to Follow-up|0
6081639|NCT00622700|9689253|FG001|Extension Treatment Period|Lost to Follow-up|0
6081640|NCT00622700|9689254|FG002|Extension Treatment Period|Lost to Follow-up|0
6081641|NCT00622700|9689255|FG003|Extension Treatment Period|Lost to Follow-up|0
5971995|NCT02281084|9557602|FG000|Overall Study|Physician Decision|0
6081642|NCT00622700|9689256|FG004|Extension Treatment Period|Lost to Follow-up|1
6081643|NCT00622700|9689257|FG005|Extension Treatment Period|Lost to Follow-up|0
6081644|NCT00622700|9689258|FG006|Extension Treatment Period|Lost to Follow-up|0
6081645|NCT00622700|9689252|FG000|Extension Treatment Period|Progressive Disease|0
6081646|NCT00622700|9689253|FG001|Extension Treatment Period|Progressive Disease|0
6081647|NCT00622700|9689254|FG002|Extension Treatment Period|Progressive Disease|0
6081648|NCT00622700|9689255|FG003|Extension Treatment Period|Progressive Disease|1
6081649|NCT00622700|9689256|FG004|Extension Treatment Period|Progressive Disease|2
6081650|NCT00622700|9689257|FG005|Extension Treatment Period|Progressive Disease|0
6081651|NCT00622700|9689258|FG006|Extension Treatment Period|Progressive Disease|2
6081652|NCT00622700|9689252|FG000|Extension Treatment Period|Withdrawal by Subject|0
6081653|NCT00622700|9689253|FG001|Extension Treatment Period|Withdrawal by Subject|0
6081654|NCT00622700|9689254|FG002|Extension Treatment Period|Withdrawal by Subject|0
6081655|NCT00622700|9689255|FG003|Extension Treatment Period|Withdrawal by Subject|11
6081656|NCT00622700|9689256|FG004|Extension Treatment Period|Withdrawal by Subject|16
6081657|NCT00622700|9689257|FG005|Extension Treatment Period|Withdrawal by Subject|6
6081658|NCT00622700|9689258|FG006|Extension Treatment Period|Withdrawal by Subject|10
6081659|NCT00622700|9689252|FG000|Extension Treatment Period|Missing|0
6081660|NCT00622700|9689253|FG001|Extension Treatment Period|Missing|0
6081661|NCT00622700|9689254|FG002|Extension Treatment Period|Missing|0
6081662|NCT00622700|9689255|FG003|Extension Treatment Period|Missing|2
6081663|NCT00622700|9689256|FG004|Extension Treatment Period|Missing|3
6081664|NCT00622700|9689257|FG005|Extension Treatment Period|Missing|1
6081665|NCT00622700|9689258|FG006|Extension Treatment Period|Missing|0
6081666|NCT00622700|9689252|FG000|Extension Treatment Period|Other than specified above|0
6081667|NCT00622700|9689253|FG001|Extension Treatment Period|Other than specified above|0
6081668|NCT00622700|9689254|FG002|Extension Treatment Period|Other than specified above|0
6081669|NCT00622700|9689255|FG003|Extension Treatment Period|Other than specified above|0
6081670|NCT00622700|9689256|FG004|Extension Treatment Period|Other than specified above|0
6081671|NCT00622700|9689257|FG005|Extension Treatment Period|Other than specified above|1
6081672|NCT00622700|9689258|FG006|Extension Treatment Period|Other than specified above|1
6081673|NCT00622713|9689275|FG000|Overall Study|Adverse Event|35
6081674|NCT00622713|9689275|FG000|Overall Study|Administrative problems|4
6081675|NCT00622713|9689275|FG000|Overall Study|Withdrawal by Subject|11
6081676|NCT00622713|9689275|FG000|Overall Study|Lost to Follow-up|5
6081677|NCT00622713|9689275|FG000|Overall Study|Death|2
6081678|NCT00622713|9689275|FG000|Overall Study|Subject no longer required study drug|1
6081679|NCT00622713|9689275|FG000|Overall Study|Did not meet eligibility criteria|1
6081680|NCT00622726|9689281|FG000|March, 2008 to August, 2010|Death|5
6081681|NCT00622726|9689282|FG001|March, 2008 to August, 2010|Death|2
6081682|NCT00622726|9689281|FG000|August, 2010 to April, 2013|Death|1
6081683|NCT00622726|9689282|FG001|August, 2010 to April, 2013|Death|5
6081684|NCT00622739|9689294|FG000|Overall Study|Physician Decision|1
6081685|NCT00622739|9689295|FG001|Overall Study|Physician Decision|0
6081686|NCT00622739|9689294|FG000|Overall Study|Adverse Event|1
6081687|NCT00622739|9689295|FG001|Overall Study|Adverse Event|2
6081688|NCT00622739|9689294|FG000|Overall Study|Lack of Efficacy|0
6081689|NCT00622739|9689295|FG001|Overall Study|Lack of Efficacy|2
6081690|NCT00622739|9689294|FG000|Overall Study|Withdrawal by Subject|0
6081691|NCT00622739|9689295|FG001|Overall Study|Withdrawal by Subject|1
6081692|NCT00622739|9689294|FG000|Overall Study|Lost to Follow-up|0
6081693|NCT00622739|9689295|FG001|Overall Study|Lost to Follow-up|1
6081694|NCT00622869|9689306|FG000|Overall Study|Subject Withdrew Consent|13
6081695|NCT00622869|9689307|FG001|Overall Study|Subject Withdrew Consent|17
6081696|NCT00622869|9689308|FG002|Overall Study|Subject Withdrew Consent|11
6081697|NCT00622869|9689306|FG000|Overall Study|Administrative Problems|11
6081698|NCT00622869|9689307|FG001|Overall Study|Administrative Problems|17
6081699|NCT00622869|9689308|FG002|Overall Study|Administrative Problems|13
6081700|NCT00622869|9689306|FG000|Overall Study|Death|12
6081701|NCT00622869|9689307|FG001|Overall Study|Death|15
6081702|NCT00622869|9689308|FG002|Overall Study|Death|10
6081703|NCT00622869|9689306|FG000|Overall Study|Lost to Follow-up|2
6081704|NCT00622869|9689307|FG001|Overall Study|Lost to Follow-up|4
6081705|NCT00622869|9689308|FG002|Overall Study|Lost to Follow-up|2
6081706|NCT00622869|9689306|FG000|Overall Study|Graft Loss|5
6081707|NCT00622869|9689307|FG001|Overall Study|Graft Loss|3
6081708|NCT00622869|9689308|FG002|Overall Study|Graft Loss|2
6081709|NCT00622869|9689306|FG000|Overall Study|Missing|0
6081710|NCT00622869|9689307|FG001|Overall Study|Missing|1
6081711|NCT00622869|9689308|FG002|Overall Study|Missing|1
6081712|NCT00622908|9689325|FG000|Overall Study|Protocol Violation|1
6081713|NCT00622908|9689326|FG001|Overall Study|Protocol Violation|0
6081714|NCT00622908|9689325|FG000|Overall Study|Adverse Event|0
6081715|NCT00622908|9689326|FG001|Overall Study|Adverse Event|1
6081716|NCT00622908|9689325|FG000|Overall Study|Lack of Efficacy|1
6081717|NCT00622908|9689326|FG001|Overall Study|Lack of Efficacy|7
6081718|NCT00622908|9689325|FG000|Overall Study|Lost to Follow-up|1
6081719|NCT00622908|9689326|FG001|Overall Study|Lost to Follow-up|0
6081720|NCT00622908|9689325|FG000|Overall Study|Refusal|0
6081721|NCT00622908|9689326|FG001|Overall Study|Refusal|1
6081722|NCT00622908|9689325|FG000|Overall Study|Termination by study sponser|0
6081723|NCT00622908|9689326|FG001|Overall Study|Termination by study sponser|1
6081724|NCT00623103|9689338|FG000|Overall Study|Adverse Event|70
6081725|NCT00623103|9689339|FG001|Overall Study|Adverse Event|60
6081726|NCT00623103|9689338|FG000|Overall Study|Unsatisfactory therapeutic effect|4
6081727|NCT00623103|9689339|FG001|Overall Study|Unsatisfactory therapeutic effect|12
6081728|NCT00623103|9689338|FG000|Overall Study|Withdrawal by Subject|18
6081729|NCT00623103|9689339|FG001|Overall Study|Withdrawal by Subject|24
6081730|NCT00623103|9689338|FG000|Overall Study|Lost to Follow-up|4
6081731|NCT00623103|9689339|FG001|Overall Study|Lost to Follow-up|1
6081732|NCT00623103|9689338|FG000|Overall Study|Administrative problems|2
6081733|NCT00623103|9689339|FG001|Overall Study|Administrative problems|4
6081734|NCT00623103|9689338|FG000|Overall Study|Death|11
6081735|NCT00623103|9689339|FG001|Overall Study|Death|11
6081736|NCT00623103|9689338|FG000|Overall Study|Protocol deviation|2
6081737|NCT00623103|9689339|FG001|Overall Study|Protocol deviation|1
6081738|NCT00623194|9689358|FG000|Overall Study|Lack of Efficacy|1
6081739|NCT00623194|9689358|FG000|Overall Study|Protocol Violation|3
6081740|NCT00623194|9689358|FG000|Overall Study|Unclassified|1
6081741|NCT00623233|9689362|FG000|Overall Study|Adverse Event|10
6081742|NCT00623233|9689362|FG000|Overall Study|Physician Decision|10
6081743|NCT00623233|9689362|FG000|Overall Study|Lost to Follow-up|1
6081744|NCT00623233|9689362|FG000|Overall Study|Withdrawal by Subject|3
6081745|NCT00623363|9689368|FG000|Overall Study|Adverse Event|2
6081746|NCT00623363|9689369|FG001|Overall Study|Adverse Event|2
6081747|NCT00623428|9689378|FG000|Treatment Period|Adverse event/intercurrent illness|0
6081748|NCT00623428|9689379|FG001|Treatment Period|Adverse event/intercurrent illness|9
6081749|NCT00623428|9689378|FG000|Treatment Period|Death|0
6081750|NCT00623428|9689379|FG001|Treatment Period|Death|1
6081751|NCT00623428|9689378|FG000|Treatment Period|Did not cooperate / refused treatment|0
6081752|NCT00623428|9689379|FG001|Treatment Period|Did not cooperate / refused treatment|13
6081753|NCT00623428|9689378|FG000|Treatment Period|Insufficient therapeutic response|0
6081754|NCT00623428|9689379|FG001|Treatment Period|Insufficient therapeutic response|2
6081755|NCT00623428|9689378|FG000|Treatment Period|Other|0
6081756|NCT00623428|9689379|FG001|Treatment Period|Other|1
6081757|NCT00623428|9689378|FG000|Treatment Period|Withdrawal by Subject|0
6081758|NCT00623428|9689379|FG001|Treatment Period|Withdrawal by Subject|1
6081759|NCT00623428|9689378|FG000|Follow-up Period|Relapse post-treatment|11
6081760|NCT00623428|9689379|FG001|Follow-up Period|Relapse post-treatment|3
6081761|NCT00623428|9689378|FG000|Follow-up Period|Failure to return|10
6081762|NCT00623428|9689379|FG001|Follow-up Period|Failure to return|2
6081763|NCT00623428|9689378|FG000|Follow-up Period|Patient withdrew consent|5
6081764|NCT00623428|9689379|FG001|Follow-up Period|Patient withdrew consent|4
6081765|NCT00623428|9689378|FG000|Follow-up Period|HCV-RNA detectable at end of treatment|2
6081766|NCT00623428|9689379|FG001|Follow-up Period|HCV-RNA detectable at end of treatment|1
6081767|NCT00623428|9689378|FG000|Follow-up Period|Did not cooperate|0
6081768|NCT00623428|9689379|FG001|Follow-up Period|Did not cooperate|3
6081769|NCT00623428|9689378|FG000|Follow-up Period|Reason not specified|1
6081770|NCT00623428|9689379|FG001|Follow-up Period|Reason not specified|1
6081771|NCT00623428|9689378|FG000|Follow-up Period|Death|0
6081772|NCT00623428|9689379|FG001|Follow-up Period|Death|1
6081773|NCT00623467|9689389|FG000|Overall Study|Lost to Follow-up|1
6081774|NCT00623467|9689389|FG000|Overall Study|Protocol Violation|4
6081775|NCT00623467|9689389|FG000|Overall Study|Withdrawal by Subject|2
6087715|NCT00669955|9698152|FG000|Overall Study|not compliant with study drug/visit|2
6087716|NCT00669955|9698153|FG001|Overall Study|not compliant with study drug/visit|3
6087717|NCT00670007|9698159|FG000|Overall Study|Drug abuse|1
6087718|NCT00670007|9698159|FG000|Overall Study|Lung transplant|1
6087719|NCT00670007|9698159|FG000|Overall Study|Travel/Vacation|1
6087720|NCT00670007|9698159|FG000|Overall Study|Adverse event, serious fatal|1
5971996|NCT02281084|9557603|FG001|Overall Study|Physician Decision|0
6087721|NCT00670007|9698159|FG000|Overall Study|Adverse Event|1
6081776|NCT00623480|9689397|FG000|Overall Study|Lost to Follow-up|0
6081777|NCT00623480|9689398|FG001|Overall Study|Lost to Follow-up|1
6042836|NCT00385671|9641323|FG002|Overall Study|Withdrawal by Subject|4
6159572|NCT01175213|9800846|FG001|Safety Follow-up|Adverse Event|0
6191810|NCT01425814|9848748|FG001|Period 2|Stability criteria not fulfilled|1
6191811|NCT01425814|9848749|FG002|Period 2|Stability criteria not fulfilled|0
6191812|NCT01425814|9848750|FG003|Period 2|Stability criteria not fulfilled|0
6191813|NCT01425814|9848751|FG004|Period 2|Stability criteria not fulfilled|0
6191814|NCT01425814|9848752|FG005|Period 2|Stability criteria not fulfilled|0
6191815|NCT01425814|9848747|FG000|Period 3|Adverse Event|0
6159573|NCT01175382|9800889|FG000|Overall Study|Lost to Follow-up|4
6159574|NCT01175382|9800890|FG001|Overall Study|Lost to Follow-up|3
6159575|NCT01175382|9800891|FG002|Overall Study|Lost to Follow-up|1
6159576|NCT01175382|9800889|FG000|Overall Study|Physician Decision|0
6159577|NCT01175382|9800890|FG001|Overall Study|Physician Decision|1
6159578|NCT01175382|9800891|FG002|Overall Study|Physician Decision|0
6159579|NCT01175382|9800889|FG000|Overall Study|Withdrawal by Subject|0
6159580|NCT01175382|9800890|FG001|Overall Study|Withdrawal by Subject|0
6159581|NCT01175382|9800891|FG002|Overall Study|Withdrawal by Subject|1
6159582|NCT01175382|9800889|FG000|Overall Study|No longer having problem|1
6159583|NCT01175382|9800890|FG001|Overall Study|No longer having problem|0
6159584|NCT01175382|9800891|FG002|Overall Study|No longer having problem|1
6159585|NCT01175382|9800889|FG000|Overall Study|Unable/unwilling to attend visits|3
6159586|NCT01175382|9800890|FG001|Overall Study|Unable/unwilling to attend visits|1
6159587|NCT01175382|9800891|FG002|Overall Study|Unable/unwilling to attend visits|2
6159588|NCT01175382|9800889|FG000|Overall Study|Unwilling to follow protocol|0
6159589|NCT01175382|9800890|FG001|Overall Study|Unwilling to follow protocol|1
6159590|NCT01175382|9800891|FG002|Overall Study|Unwilling to follow protocol|0
6159591|NCT01175382|9800889|FG000|Overall Study|Unable to tolerate study meds|0
6159592|NCT01175382|9800890|FG001|Overall Study|Unable to tolerate study meds|1
6159593|NCT01175382|9800891|FG002|Overall Study|Unable to tolerate study meds|1
6159594|NCT01175473|9800914|FG000|Overall Study|Adverse Event|2
6159595|NCT01175473|9800915|FG001|Overall Study|Adverse Event|2
6159596|NCT01175590|9800923|FG000|Overall Study|Lost to Follow-up|1
6159597|NCT01175590|9800924|FG001|Overall Study|Lost to Follow-up|0
6159598|NCT01175590|9800923|FG000|Overall Study|Withdrawal by Subject|0
6159599|NCT01175590|9800924|FG001|Overall Study|Withdrawal by Subject|2
6081778|NCT00623480|9689397|FG000|Overall Study|Withdrawal by Subject|2
6081779|NCT00623480|9689398|FG001|Overall Study|Withdrawal by Subject|4
6081780|NCT00623480|9689397|FG000|Overall Study|Lack of Efficacy|1
6081781|NCT00623480|9689398|FG001|Overall Study|Lack of Efficacy|0
6081782|NCT00623480|9689397|FG000|Overall Study|Non-compliant with study medication|4
6081783|NCT00623480|9689398|FG001|Overall Study|Non-compliant with study medication|0
6081784|NCT00623480|9689397|FG000|Overall Study|Protocol Violation|0
6081785|NCT00623480|9689398|FG001|Overall Study|Protocol Violation|1
6081786|NCT00623480|9689397|FG000|Overall Study|Site closed by sponsor|0
6081787|NCT00623480|9689398|FG001|Overall Study|Site closed by sponsor|1
6081788|NCT00623545|9689413|FG000|Overall Study|Adverse Event|6
6159600|NCT01175590|9800923|FG000|Overall Study|Adverse Event|4
6159601|NCT01175590|9800924|FG001|Overall Study|Adverse Event|0
6159602|NCT01175590|9800923|FG000|Overall Study|Physician Decision|1
6159603|NCT01175590|9800924|FG001|Overall Study|Physician Decision|4
6081789|NCT00623545|9689413|FG000|Overall Study|Withdrawal by Subject|4
6081790|NCT00623597|9689420|FG000|Overall Study|Failed to return|1
6081791|NCT00623597|9689421|FG001|Overall Study|Failed to return|0
6081792|NCT00623623|9689431|FG000|Overall Study|Previous enrolment into this study|1
6081793|NCT00623623|9689432|FG001|Overall Study|Previous enrolment into this study|1
6081794|NCT00623727|9689457|FG000|Double Blind (DB)|Adverse Event|1
6081795|NCT00623727|9689458|FG001|Double Blind (DB)|Adverse Event|3
6081796|NCT00623727|9689457|FG000|Double Blind (DB)|Physician Decision|0
6081797|NCT00623727|9689458|FG001|Double Blind (DB)|Physician Decision|1
6081798|NCT00623727|9689457|FG000|Double Blind (DB)|Withdrawal by Subject|8
6081799|NCT00623727|9689458|FG001|Double Blind (DB)|Withdrawal by Subject|2
6081800|NCT00623727|9689457|FG000|Double Blind (DB)|Lack of Efficacy|2
6081801|NCT00623727|9689458|FG001|Double Blind (DB)|Lack of Efficacy|2
6081802|NCT00623727|9689457|FG000|Double Blind (DB)|Termination of the double-blind period|22
6081803|NCT00623727|9689458|FG001|Double Blind (DB)|Termination of the double-blind period|21
6081804|NCT00623727|9689457|FG000|Double Blind (DB)|Lost to Follow-up|1
6081805|NCT00623727|9689458|FG001|Double Blind (DB)|Lost to Follow-up|1
6081806|NCT00623727|9689457|FG000|Double Blind (DB)|Protocol Violation|2
6081807|NCT00623727|9689458|FG001|Double Blind (DB)|Protocol Violation|2
6081808|NCT00623727|9689457|FG000|Open Label Follow-up|Withdrawal by Subject|0
6081809|NCT00623727|9689458|FG001|Open Label Follow-up|Withdrawal by Subject|1
6081810|NCT00623727|9689457|FG000|Open Label Follow-up|Study termination|0
6081811|NCT00623727|9689458|FG001|Open Label Follow-up|Study termination|6
6081812|NCT00623727|9689457|FG000|Open Label Follow-up|Participant convenience|0
6081813|NCT00623727|9689458|FG001|Open Label Follow-up|Participant convenience|1
6081814|NCT00623766|9689468|FG000|Induction Phase (Day 1 to Week 24)|Off treatment|36
6081815|NCT00623766|9689469|FG001|Induction Phase (Day 1 to Week 24)|Off treatment|16
6081816|NCT00623766|9689468|FG000|Maintenance Phase (Week 24 to Year 2)|Disease progression|4
6081817|NCT00623766|9689469|FG001|Maintenance Phase (Week 24 to Year 2)|Disease progression|0
6081818|NCT00623766|9689468|FG000|Maintenance Phase (Week 24 to Year 2)|Administrative reason by sponsor|4
6081819|NCT00623766|9689469|FG001|Maintenance Phase (Week 24 to Year 2)|Administrative reason by sponsor|0
6081820|NCT00623766|9689468|FG000|Maintenance Phase (Week 24 to Year 2)|Withdrawal by Subject|1
6081821|NCT00623766|9689469|FG001|Maintenance Phase (Week 24 to Year 2)|Withdrawal by Subject|2
6081822|NCT00623766|9689468|FG000|Maintenance Phase (Week 24 to Year 2)|Patient required surgery|1
6081823|NCT00623766|9689469|FG001|Maintenance Phase (Week 24 to Year 2)|Patient required surgery|0
6081824|NCT00623779|9689482|FG000|Overall Study|Adverse Event|1
6081825|NCT00623779|9689483|FG001|Overall Study|Adverse Event|3
6081826|NCT00623779|9689484|FG002|Overall Study|Adverse Event|0
6081827|NCT00623779|9689482|FG000|Overall Study|Criteria from CSR|2
6081828|NCT00623779|9689483|FG001|Overall Study|Criteria from CSR|0
6081829|NCT00623779|9689484|FG002|Overall Study|Criteria from CSR|1
6081830|NCT00623805|9689494|FG000|Overall Study|Adverse Event|9
6081831|NCT00623805|9689495|FG001|Overall Study|Adverse Event|6
6081832|NCT00623805|9689494|FG000|Overall Study|Death|2
6081833|NCT00623805|9689495|FG001|Overall Study|Death|0
6081834|NCT00623805|9689494|FG000|Overall Study|Lack of Efficacy|3
6081835|NCT00623805|9689495|FG001|Overall Study|Lack of Efficacy|7
6081836|NCT00623805|9689494|FG000|Overall Study|Lost to Follow-up|2
6081837|NCT00623805|9689495|FG001|Overall Study|Lost to Follow-up|2
6081838|NCT00623805|9689494|FG000|Overall Study|Protocol Violation|1
6081839|NCT00623805|9689495|FG001|Overall Study|Protocol Violation|1
6081840|NCT00623805|9689494|FG000|Overall Study|Reason not Specified|3
6081841|NCT00623805|9689495|FG001|Overall Study|Reason not Specified|6
6081842|NCT00623831|9689503|FG000|Overall Study|Withdrawal by Subject|1
6081843|NCT00623831|9689504|FG001|Overall Study|Withdrawal by Subject|0
6081844|NCT00623831|9689503|FG000|Overall Study|Progressive Disease|0
5971997|NCT02281084|9557604|FG002|Overall Study|Physician Decision|1
6081845|NCT00623831|9689504|FG001|Overall Study|Progressive Disease|1
6081846|NCT00623935|9689513|FG000|Overall Study|Death|1
6081847|NCT00623935|9689513|FG000|Overall Study|Patient Declined Transplant|1
6081848|NCT00624052|9689532|FG000|Overall Study|Adverse Event|7
6081849|NCT00624052|9689533|FG001|Overall Study|Adverse Event|6
6081850|NCT00624052|9689534|FG002|Overall Study|Adverse Event|0
6081851|NCT00624052|9689535|FG003|Overall Study|Adverse Event|3
6081852|NCT00624052|9689532|FG000|Overall Study|Lack of Efficacy|1
6081853|NCT00624052|9689533|FG001|Overall Study|Lack of Efficacy|1
6081854|NCT00624052|9689534|FG002|Overall Study|Lack of Efficacy|0
6081855|NCT00624052|9689535|FG003|Overall Study|Lack of Efficacy|0
6081856|NCT00624052|9689532|FG000|Overall Study|Lost to Follow-up|2
6081857|NCT00624052|9689533|FG001|Overall Study|Lost to Follow-up|3
6081858|NCT00624052|9689534|FG002|Overall Study|Lost to Follow-up|1
6081859|NCT00624052|9689535|FG003|Overall Study|Lost to Follow-up|0
6081860|NCT00624052|9689532|FG000|Overall Study|Non compliant with the protocol|2
6081861|NCT00624052|9689533|FG001|Overall Study|Non compliant with the protocol|1
6081862|NCT00624052|9689534|FG002|Overall Study|Non compliant with the protocol|1
6081863|NCT00624052|9689535|FG003|Overall Study|Non compliant with the protocol|1
6081864|NCT00624052|9689532|FG000|Overall Study|Consent withdrawn|3
5971998|NCT02281084|9557605|FG003|Overall Study|Physician Decision|0
6081865|NCT00624052|9689533|FG001|Overall Study|Consent withdrawn|1
6081866|NCT00624052|9689534|FG002|Overall Study|Consent withdrawn|1
6081867|NCT00624052|9689535|FG003|Overall Study|Consent withdrawn|0
6081868|NCT00624052|9689532|FG000|Overall Study|Changed job/ran out if meds|0
6081869|NCT00624052|9689533|FG001|Overall Study|Changed job/ran out if meds|2
6081870|NCT00624052|9689534|FG002|Overall Study|Changed job/ran out if meds|0
6081871|NCT00624052|9689535|FG003|Overall Study|Changed job/ran out if meds|0
6042837|NCT00385684|9641333|FG000|FIRST INTERVENTION OF PHASE A|Death|1
6042838|NCT00385684|9641334|FG001|FIRST INTERVENTION OF PHASE A|Death|0
6042839|NCT00385684|9641333|FG000|SECOND INTERVENTION OF PHASE A|Adverse Event|0
6042840|NCT00385684|9641334|FG001|SECOND INTERVENTION OF PHASE A|Adverse Event|1
6042841|NCT00385684|9641333|FG000|SECOND INTERVENTION OF PHASE A|study drug recall|0
6042842|NCT00385684|9641334|FG001|SECOND INTERVENTION OF PHASE A|study drug recall|1
6042843|NCT00385723|9641343|FG000|Overall Study|Lost to Follow-up|1
6042844|NCT00385723|9641344|FG001|Overall Study|Lost to Follow-up|1
6042845|NCT00385723|9641345|FG002|Overall Study|Lost to Follow-up|0
6042846|NCT00385723|9641343|FG000|Overall Study|Withdrawal by Subject|1
6042847|NCT00385723|9641344|FG001|Overall Study|Withdrawal by Subject|0
6081872|NCT00624065|9689551|FG000|Overall Study|Adverse Event|5
6042848|NCT00385723|9641345|FG002|Overall Study|Withdrawal by Subject|2
6042849|NCT00385736|9641356|FG000|Efficacy Analysis Set - Induction|Adverse Event|5
6042850|NCT00385736|9641357|FG001|Efficacy Analysis Set - Induction|Adverse Event|6
6042851|NCT00385736|9641358|FG002|Efficacy Analysis Set - Induction|Adverse Event|4
6042852|NCT00385736|9641356|FG000|Efficacy Analysis Set - Induction|Withdrawal by Subject|0
6042853|NCT00385736|9641357|FG001|Efficacy Analysis Set - Induction|Withdrawal by Subject|2
6042854|NCT00385736|9641358|FG002|Efficacy Analysis Set - Induction|Withdrawal by Subject|1
6042855|NCT00385736|9641356|FG000|Efficacy Analysis Set - Induction|Lost to Follow-up|0
6042856|NCT00385736|9641357|FG001|Efficacy Analysis Set - Induction|Lost to Follow-up|2
6042857|NCT00385736|9641358|FG002|Efficacy Analysis Set - Induction|Lost to Follow-up|0
6042858|NCT00385736|9641356|FG000|Efficacy Analysis Set - Induction|Lack of Efficacy|4
6042859|NCT00385736|9641357|FG001|Efficacy Analysis Set - Induction|Lack of Efficacy|2
6042860|NCT00385736|9641358|FG002|Efficacy Analysis Set - Induction|Lack of Efficacy|1
6042861|NCT00385736|9641356|FG000|Efficacy Analysis Set - Induction|Protocol Violation|0
6042862|NCT00385736|9641357|FG001|Efficacy Analysis Set - Induction|Protocol Violation|0
6042863|NCT00385736|9641358|FG002|Efficacy Analysis Set - Induction|Protocol Violation|2
6042864|NCT00385736|9641356|FG000|Efficacy Analysis Set - Induction|Other|0
6042865|NCT00385736|9641357|FG001|Efficacy Analysis Set - Induction|Other|0
6042866|NCT00385736|9641358|FG002|Efficacy Analysis Set - Induction|Other|1
6042867|NCT00385736|9641356|FG000|Efficacy Analysis Set - Maintenance|Adverse Event|23
6042868|NCT00385736|9641357|FG001|Efficacy Analysis Set - Maintenance|Adverse Event|15
6042869|NCT00385736|9641358|FG002|Efficacy Analysis Set - Maintenance|Adverse Event|23
6081873|NCT00624065|9689552|FG001|Overall Study|Adverse Event|6
6081874|NCT00624065|9689551|FG000|Overall Study|Lost to Follow-up|4
6159604|NCT01175590|9800923|FG000|Overall Study|Lack of Efficacy|1
6081875|NCT00624065|9689552|FG001|Overall Study|Lost to Follow-up|1
6081876|NCT00624065|9689551|FG000|Overall Study|Consent withdrawn|6
6081877|NCT00624065|9689552|FG001|Overall Study|Consent withdrawn|5
6081878|NCT00624065|9689551|FG000|Overall Study|Lack of Efficacy|0
6081879|NCT00624065|9689552|FG001|Overall Study|Lack of Efficacy|3
6081880|NCT00624065|9689551|FG000|Overall Study|Met protocol-defined stopping criteria|4
6081881|NCT00624065|9689552|FG001|Overall Study|Met protocol-defined stopping criteria|9
6081882|NCT00624286|9689578|FG000|Overall Study|Protocol Deviation|7
6081883|NCT00624286|9689579|FG001|Overall Study|Protocol Deviation|9
6081884|NCT00624286|9689578|FG000|Overall Study|Adverse Event|6
6081885|NCT00624286|9689579|FG001|Overall Study|Adverse Event|3
6081886|NCT00624286|9689578|FG000|Overall Study|Withdrawal by Subject|5
6081887|NCT00624286|9689579|FG001|Overall Study|Withdrawal by Subject|4
6081888|NCT00624286|9689578|FG000|Overall Study|Lost to Follow-up|3
6081889|NCT00624286|9689579|FG001|Overall Study|Lost to Follow-up|2
6081890|NCT00624286|9689578|FG000|Overall Study|Administrative problems|3
6081891|NCT00624286|9689579|FG001|Overall Study|Administrative problems|0
6081892|NCT00624286|9689578|FG000|Overall Study|Lack of Efficacy|1
6081893|NCT00624286|9689579|FG001|Overall Study|Lack of Efficacy|6
6081894|NCT00624286|9689578|FG000|Overall Study|Not stated|0
6081895|NCT00624286|9689579|FG001|Overall Study|Not stated|1
6081896|NCT00624286|9689578|FG000|Overall Study|Abnormal test procedure result(s)|0
6081897|NCT00624286|9689579|FG001|Overall Study|Abnormal test procedure result(s)|1
6081898|NCT00624286|9689578|FG000|Overall Study|Death|0
6081899|NCT00624286|9689579|FG001|Overall Study|Death|1
6159605|NCT01175590|9800924|FG001|Overall Study|Lack of Efficacy|1
6159606|NCT01175590|9800923|FG000|Overall Study|Residual Bacterial Conjunctivitis|1
6159607|NCT01175590|9800924|FG001|Overall Study|Residual Bacterial Conjunctivitis|0
6159608|NCT01175590|9800923|FG000|Overall Study|Treated not as randomized|3
6159609|NCT01175590|9800924|FG001|Overall Study|Treated not as randomized|2
6159610|NCT01175590|9800923|FG000|Overall Study|Herpes Simplex Dermatitis|1
6159611|NCT01175590|9800924|FG001|Overall Study|Herpes Simplex Dermatitis|0
6159612|NCT01175590|9800923|FG000|Overall Study|Protocol Violation|0
5971999|NCT01464164|9557651|FG000|Overall Study|Screen failure|0
6159613|NCT01175590|9800924|FG001|Overall Study|Protocol Violation|1
5972000|NCT01464164|9557652|FG001|Overall Study|Screen failure|1
5972001|NCT01464164|9557653|FG002|Overall Study|Screen failure|2
5972002|NCT01464164|9557654|FG003|Overall Study|Screen failure|0
5972003|NCT01464164|9557655|FG004|Overall Study|Screen failure|0
5972004|NCT01464164|9557656|FG005|Overall Study|Screen failure|0
5972005|NCT01464164|9557657|FG006|Overall Study|Screen failure|0
5972006|NCT01464164|9557651|FG000|Overall Study|Physician Decision|0
6159614|NCT01175668|9800933|FG000|Overall Study|Withdrawal by Subject|2
6159615|NCT01175668|9800934|FG001|Overall Study|Withdrawal by Subject|0
6159616|NCT01175707|9800942|FG000|Overall Study|Adverse Event|4
6159617|NCT01175707|9800943|FG001|Overall Study|Adverse Event|6
6159618|NCT01175811|9800961|FG000|Overall Study|Adverse Event|1
6159619|NCT01175811|9800962|FG001|Overall Study|Adverse Event|1
6159620|NCT01175811|9800961|FG000|Overall Study|Entry criteria not met|3
6159621|NCT01175811|9800962|FG001|Overall Study|Entry criteria not met|1
6159622|NCT01175811|9800961|FG000|Overall Study|Lack of Efficacy|1
6159623|NCT01175811|9800962|FG001|Overall Study|Lack of Efficacy|0
6159624|NCT01175811|9800961|FG000|Overall Study|Lost to Follow-up|3
6159625|NCT01175811|9800962|FG001|Overall Study|Lost to Follow-up|2
6159626|NCT01175811|9800961|FG000|Overall Study|Physician Decision|1
6159627|NCT01175811|9800962|FG001|Overall Study|Physician Decision|1
6159628|NCT01175811|9800961|FG000|Overall Study|Protocol Violation|1
6159629|NCT01175811|9800962|FG001|Overall Study|Protocol Violation|2
6159630|NCT01175811|9800961|FG000|Overall Study|Withdrawal by Subject|6
6159631|NCT01175811|9800962|FG001|Overall Study|Withdrawal by Subject|7
6159632|NCT01175824|9800970|FG000|Overall Study|Adverse Event|2
6159633|NCT01175824|9800971|FG001|Overall Study|Adverse Event|1
6159634|NCT01175824|9800970|FG000|Overall Study|Lack of Efficacy|2
6159635|NCT01175824|9800971|FG001|Overall Study|Lack of Efficacy|0
6159636|NCT01175824|9800970|FG000|Overall Study|Lost to Follow-up|0
6159637|NCT01175824|9800971|FG001|Overall Study|Lost to Follow-up|1
6159638|NCT01175824|9800970|FG000|Overall Study|Physician Decision|0
6159639|NCT01175824|9800971|FG001|Overall Study|Physician Decision|4
6159640|NCT01175824|9800970|FG000|Overall Study|Protocol Violation|2
6159641|NCT01175824|9800971|FG001|Overall Study|Protocol Violation|5
6159642|NCT01175824|9800970|FG000|Overall Study|Withdrawal by Subject|3
6159643|NCT01175824|9800971|FG001|Overall Study|Withdrawal by Subject|7
6159644|NCT01175824|9800970|FG000|Overall Study|Sponsor Decision|1
6159645|NCT01175824|9800971|FG001|Overall Study|Sponsor Decision|0
6159646|NCT01175824|9800970|FG000|Overall Study|Entry Criteria Not Met|6
6159647|NCT01175824|9800971|FG001|Overall Study|Entry Criteria Not Met|4
6159648|NCT01176032|9801004|FG000|Overall Study|Adverse Event|1
6159649|NCT01176032|9801005|FG001|Overall Study|Adverse Event|0
6159650|NCT01176032|9801004|FG000|Overall Study|Unsatisfactory therapeutic effect|0
6324796|NCT02919761|10066645|FG001|Part 1: Open Label|Termination by Sponsor|0
6324797|NCT02919761|10066646|FG002|Part 1: Open Label|Termination by Sponsor|0
6324798|NCT02919761|10066644|FG000|Part 2: Double-blind|Withdrawal by Subject|0
6324799|NCT02919761|10066645|FG001|Part 2: Double-blind|Withdrawal by Subject|0
6324800|NCT02919761|10066646|FG002|Part 2: Double-blind|Withdrawal by Subject|2
6324801|NCT02919761|10066644|FG000|Part 2: Double-blind|Adverse Event|0
6324802|NCT02919761|10066645|FG001|Part 2: Double-blind|Adverse Event|1
6324803|NCT02919761|10066646|FG002|Part 2: Double-blind|Adverse Event|0
6324804|NCT02919761|10066644|FG000|Part 2: Double-blind|Lost to Follow-up|0
6324805|NCT02919761|10066645|FG001|Part 2: Double-blind|Lost to Follow-up|0
6324806|NCT02919761|10066646|FG002|Part 2: Double-blind|Lost to Follow-up|3
6324807|NCT02919761|10066644|FG000|Part 2: Double-blind|Met withdrawal criteria|0
6159651|NCT01176032|9801005|FG001|Overall Study|Unsatisfactory therapeutic effect|1
6324808|NCT02919761|10066645|FG001|Part 2: Double-blind|Met withdrawal criteria|1
6159652|NCT01176032|9801004|FG000|Overall Study|Protocol Violation|1
6081900|NCT00624338|9689588|FG000|Overall Study|Adverse Event|14
6081901|NCT00624338|9689589|FG001|Overall Study|Adverse Event|14
6081902|NCT00624338|9689590|FG002|Overall Study|Adverse Event|18
6159653|NCT01176032|9801005|FG001|Overall Study|Protocol Violation|0
6159654|NCT01176032|9801004|FG000|Overall Study|Informed consent withdrawn|3
6159655|NCT01176032|9801005|FG001|Overall Study|Informed consent withdrawn|0
6159656|NCT01176032|9801004|FG000|Overall Study|Other|1
6159657|NCT01176032|9801005|FG001|Overall Study|Other|0
6159658|NCT01176058|9801018|FG000|Overall Study|Adverse Event|1
6159659|NCT01176058|9801019|FG001|Overall Study|Adverse Event|0
6159660|NCT01176058|9801018|FG000|Overall Study|Insufficient clinical response|2
6159661|NCT01176058|9801019|FG001|Overall Study|Insufficient clinical response|2
6159662|NCT01176058|9801018|FG000|Overall Study|Insufficient mycological response|0
6159663|NCT01176058|9801019|FG001|Overall Study|Insufficient mycological response|1
6159664|NCT01176058|9801018|FG000|Overall Study|Withdrawal by Subject|1
6159665|NCT01176058|9801019|FG001|Overall Study|Withdrawal by Subject|0
6159666|NCT01176240|9801029|FG000|Study 306A|Lack of Efficacy|2
6159667|NCT01176240|9801030|FG001|Study 306A|Lack of Efficacy|1
6159668|NCT01176240|9801029|FG000|Study 306A|Protocol Violation|0
6324809|NCT02919761|10066646|FG002|Part 2: Double-blind|Met withdrawal criteria|2
6159669|NCT01176240|9801030|FG001|Study 306A|Protocol Violation|1
6159670|NCT01176240|9801029|FG000|Study 306A|Withdrawal by Subject|0
6159671|NCT01176240|9801030|FG001|Study 306A|Withdrawal by Subject|1
6159672|NCT01176240|9801029|FG000|Study 306A|Stop due to diverse problems|1
6159673|NCT01176240|9801030|FG001|Study 306A|Stop due to diverse problems|0
6159674|NCT01176240|9801029|FG000|Study 306B|Lack of Efficacy|5
6159675|NCT01176240|9801030|FG001|Study 306B|Lack of Efficacy|3
6324810|NCT02919761|10066644|FG000|Part 2: Double-blind|Worsening of disease activity|0
6324811|NCT02919761|10066645|FG001|Part 2: Double-blind|Worsening of disease activity|4
6324812|NCT02919761|10066646|FG002|Part 2: Double-blind|Worsening of disease activity|10
6324813|NCT02919761|10066644|FG000|Part 2: Double-blind|Did not meet LDA at Week 16|0
6324814|NCT02919761|10066645|FG001|Part 2: Double-blind|Did not meet LDA at Week 16|0
6324815|NCT02919761|10066646|FG002|Part 2: Double-blind|Did not meet LDA at Week 16|1
6324816|NCT02919761|10066644|FG000|Part 2: Double-blind|Did not meet LDA at Week 20|0
6324817|NCT02919761|10066645|FG001|Part 2: Double-blind|Did not meet LDA at Week 20|0
6324818|NCT02919761|10066646|FG002|Part 2: Double-blind|Did not meet LDA at Week 20|1
6324819|NCT02919761|10066644|FG000|Part 2: Double-blind|Discontinued exclusion 16|0
6324820|NCT02919761|10066645|FG001|Part 2: Double-blind|Discontinued exclusion 16|0
6324821|NCT02919761|10066646|FG002|Part 2: Double-blind|Discontinued exclusion 16|2
6324822|NCT02919995|10066683|FG000|Overall Study|Adverse Event|0
6324823|NCT02919995|10066684|FG001|Overall Study|Adverse Event|0
6324824|NCT02919995|10066685|FG002|Overall Study|Adverse Event|0
6324825|NCT02919995|10066686|FG003|Overall Study|Adverse Event|0
6324826|NCT02919995|10066687|FG004|Overall Study|Adverse Event|0
6324827|NCT02919995|10066688|FG005|Overall Study|Adverse Event|1
6324828|NCT02920528|10066703|FG000|Overall Study|Incomplete Data|1
6324829|NCT02920528|10066704|FG001|Overall Study|Incomplete Data|1
6324830|NCT02920528|10066705|FG002|Overall Study|Incomplete Data|1
6324831|NCT02920528|10066703|FG000|Overall Study|Adverse Event|0
6324832|NCT02920528|10066704|FG001|Overall Study|Adverse Event|0
6324833|NCT02920528|10066705|FG002|Overall Study|Adverse Event|3
6324834|NCT02920528|10066703|FG000|Overall Study|Did not meet inclusion criteria|2
6324835|NCT02920528|10066704|FG001|Overall Study|Did not meet inclusion criteria|0
6324836|NCT02920528|10066705|FG002|Overall Study|Did not meet inclusion criteria|1
6324837|NCT02920957|10066743|FG000|First Intervention : 1 Month|Withdrawal by Subject|2
6324838|NCT02920957|10066744|FG001|First Intervention : 1 Month|Withdrawal by Subject|0
6324839|NCT02920957|10066743|FG000|First Intervention : 1 Month|Lost to Follow-up|1
6324840|NCT02920957|10066744|FG001|First Intervention : 1 Month|Lost to Follow-up|0
6324841|NCT02920957|10066743|FG000|First Intervention : 1 Month|Adverse Event|1
6324842|NCT02920957|10066744|FG001|First Intervention : 1 Month|Adverse Event|0
6324843|NCT02920957|10066743|FG000|Second Intervention: 1 Month|Lost to Follow-up|0
6324844|NCT02920957|10066744|FG001|Second Intervention: 1 Month|Lost to Follow-up|1
6324845|NCT02920970|10066761|FG000|First Intervention|Protocol Violation|0
6324846|NCT02920970|10066762|FG001|First Intervention|Protocol Violation|1
6324847|NCT02920970|10066761|FG000|First Intervention|Adverse Event|0
6324848|NCT02920970|10066762|FG001|First Intervention|Adverse Event|1
6324849|NCT02920970|10066761|FG000|Second Intervention|Poor Lens Fit|1
6324850|NCT02920970|10066762|FG001|Second Intervention|Poor Lens Fit|0
6324851|NCT02920983|10066770|FG000|Dispense 1|Unacceptable Lens Fit|0
6324852|NCT02920983|10066771|FG001|Dispense 1|Unacceptable Lens Fit|0
6324853|NCT02920983|10066772|FG002|Dispense 1|Unacceptable Lens Fit|0
6159676|NCT01176240|9801029|FG000|Study 306B|Adverse Event|10
6159677|NCT01176240|9801030|FG001|Study 306B|Adverse Event|5
6159678|NCT01176240|9801029|FG000|Study 306B|Protocol Violation|2
6159679|NCT01176240|9801030|FG001|Study 306B|Protocol Violation|3
6159680|NCT01176240|9801029|FG000|Study 306B|Withdrawal by Subject|4
6159681|NCT01176240|9801030|FG001|Study 306B|Withdrawal by Subject|1
6159682|NCT01176240|9801029|FG000|Study 306B|Physician Decision|2
6042870|NCT00385736|9641356|FG000|Efficacy Analysis Set - Maintenance|Withdrawal by Subject|6
6081903|NCT00624338|9689588|FG000|Overall Study|Lost to Follow-up|1
6081904|NCT00624338|9689589|FG001|Overall Study|Lost to Follow-up|0
6081905|NCT00624338|9689590|FG002|Overall Study|Lost to Follow-up|0
6081906|NCT00624338|9689588|FG000|Overall Study|Lack of Efficacy|11
6081907|NCT00624338|9689589|FG001|Overall Study|Lack of Efficacy|3
6081908|NCT00624338|9689590|FG002|Overall Study|Lack of Efficacy|14
6081909|NCT00624338|9689588|FG000|Overall Study|Protocol Violation|3
6081910|NCT00624338|9689589|FG001|Overall Study|Protocol Violation|3
6081911|NCT00624338|9689590|FG002|Overall Study|Protocol Violation|2
6081912|NCT00624338|9689588|FG000|Overall Study|Death|0
6081913|NCT00624338|9689589|FG001|Overall Study|Death|2
6081914|NCT00624338|9689590|FG002|Overall Study|Death|0
6081915|NCT00624338|9689588|FG000|Overall Study|Immunoglobulin less than 3gram per liter|1
6081916|NCT00624338|9689589|FG001|Overall Study|Immunoglobulin less than 3gram per liter|0
6081917|NCT00624338|9689590|FG002|Overall Study|Immunoglobulin less than 3gram per liter|0
6081918|NCT00624338|9689588|FG000|Overall Study|Termination of 150 mg group by Sponsor|0
6081919|NCT00624338|9689589|FG001|Overall Study|Termination of 150 mg group by Sponsor|55
6081920|NCT00624338|9689590|FG002|Overall Study|Termination of 150 mg group by Sponsor|0
6081921|NCT00624338|9689588|FG000|Overall Study|Other|15
6081922|NCT00624338|9689589|FG001|Overall Study|Other|5
6081923|NCT00624338|9689590|FG002|Overall Study|Other|9
6081924|NCT00624338|9689588|FG000|Overall Study|Randomized but not treated|2
6081925|NCT00624338|9689589|FG001|Overall Study|Randomized but not treated|1
6081926|NCT00624338|9689590|FG002|Overall Study|Randomized but not treated|3
6081927|NCT00624377|9689598|FG000|Overall Study|Lost to Follow-up|355
6081928|NCT00624377|9689598|FG000|Overall Study|Withdrawal by Subject|100
6081929|NCT00624377|9689598|FG000|Overall Study|Adverse Event|14
6081930|NCT00624377|9689598|FG000|Overall Study|Other|91
6081931|NCT00624377|9689598|FG000|Overall Study|Non-evaluable population|84
6081932|NCT00624468|9689650|FG000|Double-blind Period|Early Termination Initiated by Sponsor|13
6081933|NCT00624468|9689651|FG001|Double-blind Period|Early Termination Initiated by Sponsor|12
6081934|NCT00624468|9689652|FG002|Double-blind Period|Early Termination Initiated by Sponsor|0
6081935|NCT00624468|9689653|FG003|Double-blind Period|Early Termination Initiated by Sponsor|0
6081936|NCT00624468|9689650|FG000|Double-blind Period|Withdrew Prematurely|1
6081937|NCT00624468|9689651|FG001|Double-blind Period|Withdrew Prematurely|1
6081938|NCT00624468|9689652|FG002|Double-blind Period|Withdrew Prematurely|0
6081939|NCT00624468|9689653|FG003|Double-blind Period|Withdrew Prematurely|0
6081940|NCT00624468|9689650|FG000|Safety Follow-up (SFU) Period|Lost to Follow-up|0
6081941|NCT00624468|9689651|FG001|Safety Follow-up (SFU) Period|Lost to Follow-up|0
6081942|NCT00624468|9689652|FG002|Safety Follow-up (SFU) Period|Lost to Follow-up|1
6081943|NCT00624468|9689653|FG003|Safety Follow-up (SFU) Period|Lost to Follow-up|2
6159683|NCT01176240|9801030|FG001|Study 306B|Physician Decision|1
6159684|NCT01176240|9801029|FG000|Study 306B|Supine Hypertension|1
6159685|NCT01176240|9801030|FG001|Study 306B|Supine Hypertension|2
6159686|NCT01176240|9801029|FG000|Study 306B|Lost to Follow-up|0
6159687|NCT01176240|9801030|FG001|Study 306B|Lost to Follow-up|1
6081944|NCT00624468|9689650|FG000|Safety Follow-up (SFU) Period|Other|0
6081945|NCT00624468|9689651|FG001|Safety Follow-up (SFU) Period|Other|0
6081946|NCT00624468|9689652|FG002|Safety Follow-up (SFU) Period|Other|1
6081947|NCT00624468|9689653|FG003|Safety Follow-up (SFU) Period|Other|1
6081948|NCT00624520|9689663|FG000|Overall Study|Withdrawal by Subject|12
6081949|NCT00624520|9689664|FG001|Overall Study|Withdrawal by Subject|7
6081950|NCT00624520|9689663|FG000|Overall Study|Death|0
6081951|NCT00624520|9689664|FG001|Overall Study|Death|1
6081952|NCT00624585|9689687|FG000|Overall Study|Death|3
6081953|NCT00624585|9689687|FG000|Overall Study|Disease Progression|6
6081954|NCT00624585|9689687|FG000|Overall Study|Adverse Event|3
6081955|NCT00624780|9689697|FG000|Treatment Optimization (Up to Week 12)|Adverse Event|7
6081956|NCT00624780|9689698|FG001|Treatment Optimization (Up to Week 12)|Adverse Event|5
6081957|NCT00624780|9689699|FG002|Treatment Optimization (Up to Week 12)|Adverse Event|15
6081958|NCT00624780|9689700|FG003|Treatment Optimization (Up to Week 12)|Adverse Event|3
6081959|NCT00624780|9689701|FG004|Treatment Optimization (Up to Week 12)|Adverse Event|9
6159688|NCT01176240|9801029|FG000|Study 306B|withdrew prior to dosing|2
6159689|NCT01176240|9801030|FG001|Study 306B|withdrew prior to dosing|1
6159690|NCT01176266|9801036|FG000|Overall Study|Death|6
6159691|NCT01176266|9801036|FG000|Overall Study|Withdrawal by Subject|3
6159692|NCT01176292|9801046|FG000|Overall Study|Lost to Follow-up|2
6159693|NCT01176292|9801047|FG001|Overall Study|Lost to Follow-up|4
6159694|NCT01176292|9801046|FG000|Overall Study|Adverse Event|1
6159695|NCT01176292|9801047|FG001|Overall Study|Adverse Event|1
6159696|NCT01176292|9801046|FG000|Overall Study|Physician Decision|0
6159697|NCT01176292|9801047|FG001|Overall Study|Physician Decision|2
6081960|NCT00624780|9689702|FG005|Treatment Optimization (Up to Week 12)|Adverse Event|5
6081961|NCT00624780|9689697|FG000|Treatment Optimization (Up to Week 12)|Lack of Efficacy|5
6081962|NCT00624780|9689698|FG001|Treatment Optimization (Up to Week 12)|Lack of Efficacy|2
6081963|NCT00624780|9689699|FG002|Treatment Optimization (Up to Week 12)|Lack of Efficacy|10
6081964|NCT00624780|9689700|FG003|Treatment Optimization (Up to Week 12)|Lack of Efficacy|5
6081965|NCT00624780|9689701|FG004|Treatment Optimization (Up to Week 12)|Lack of Efficacy|9
6081966|NCT00624780|9689702|FG005|Treatment Optimization (Up to Week 12)|Lack of Efficacy|1
6081967|NCT00624780|9689697|FG000|Treatment Optimization (Up to Week 12)|Lost to Follow-up|1
6081968|NCT00624780|9689698|FG001|Treatment Optimization (Up to Week 12)|Lost to Follow-up|0
6081969|NCT00624780|9689699|FG002|Treatment Optimization (Up to Week 12)|Lost to Follow-up|2
6081970|NCT00624780|9689700|FG003|Treatment Optimization (Up to Week 12)|Lost to Follow-up|0
6081971|NCT00624780|9689701|FG004|Treatment Optimization (Up to Week 12)|Lost to Follow-up|2
6081972|NCT00624780|9689702|FG005|Treatment Optimization (Up to Week 12)|Lost to Follow-up|1
6081973|NCT00624780|9689697|FG000|Treatment Optimization (Up to Week 12)|Withdrawal by Subject|10
6081974|NCT00624780|9689698|FG001|Treatment Optimization (Up to Week 12)|Withdrawal by Subject|2
6081975|NCT00624780|9689699|FG002|Treatment Optimization (Up to Week 12)|Withdrawal by Subject|7
6081976|NCT00624780|9689700|FG003|Treatment Optimization (Up to Week 12)|Withdrawal by Subject|4
6081977|NCT00624780|9689701|FG004|Treatment Optimization (Up to Week 12)|Withdrawal by Subject|10
6081978|NCT00624780|9689702|FG005|Treatment Optimization (Up to Week 12)|Withdrawal by Subject|4
6081979|NCT00624780|9689697|FG000|Treatment Optimization (Up to Week 12)|Other|10
6081980|NCT00624780|9689698|FG001|Treatment Optimization (Up to Week 12)|Other|4
6081981|NCT00624780|9689699|FG002|Treatment Optimization (Up to Week 12)|Other|8
6081982|NCT00624780|9689700|FG003|Treatment Optimization (Up to Week 12)|Other|2
6081983|NCT00624780|9689701|FG004|Treatment Optimization (Up to Week 12)|Other|9
6081984|NCT00624780|9689702|FG005|Treatment Optimization (Up to Week 12)|Other|0
6081985|NCT00624780|9689697|FG000|Fixed Dosing (Week 13 to Week 24)|Adverse Event|5
6081986|NCT00624780|9689698|FG001|Fixed Dosing (Week 13 to Week 24)|Adverse Event|4
6081987|NCT00624780|9689699|FG002|Fixed Dosing (Week 13 to Week 24)|Adverse Event|5
6081988|NCT00624780|9689700|FG003|Fixed Dosing (Week 13 to Week 24)|Adverse Event|2
6159698|NCT01176292|9801046|FG000|Overall Study|Has not scheduled one-year visit yet|2
6159699|NCT01176292|9801047|FG001|Overall Study|Has not scheduled one-year visit yet|2
6159700|NCT01176565|9801076|FG000|Overall Study|Lost to Follow-up|12
6159701|NCT01176565|9801077|FG001|Overall Study|Lost to Follow-up|16
6159702|NCT01176565|9801076|FG000|Overall Study|Withdrawal by Subject|7
6227413|NCT01716754|9900110|FG002|Overall Study|Adverse Event|2
6324854|NCT02920983|10066773|FG003|Dispense 1|Unacceptable Lens Fit|0
6324855|NCT02920983|10066774|FG004|Dispense 1|Unacceptable Lens Fit|1
6324856|NCT02920983|10066775|FG005|Dispense 1|Unacceptable Lens Fit|0
6324857|NCT02920983|10066770|FG000|Dispense 2|Unscceptable lens fit|1
6324858|NCT02920983|10066771|FG001|Dispense 2|Unscceptable lens fit|0
6324859|NCT02920983|10066772|FG002|Dispense 2|Unscceptable lens fit|0
6324860|NCT02920983|10066773|FG003|Dispense 2|Unscceptable lens fit|0
6324861|NCT02920983|10066774|FG004|Dispense 2|Unscceptable lens fit|1
6324862|NCT02920983|10066775|FG005|Dispense 2|Unscceptable lens fit|0
6324863|NCT02920983|10066770|FG000|Dispense 3|Unacceptable Lens Fit|1
6324864|NCT02920983|10066771|FG001|Dispense 3|Unacceptable Lens Fit|1
6324865|NCT02920983|10066772|FG002|Dispense 3|Unacceptable Lens Fit|0
6324866|NCT02920983|10066773|FG003|Dispense 3|Unacceptable Lens Fit|0
6324867|NCT02920983|10066774|FG004|Dispense 3|Unacceptable Lens Fit|1
6324868|NCT02920983|10066775|FG005|Dispense 3|Unacceptable Lens Fit|0
6324869|NCT02921087|10066789|FG000|Overall Study|Withdrawal by Subject|0
6324870|NCT02921087|10066790|FG001|Overall Study|Withdrawal by Subject|1
6324871|NCT02921425|10066834|FG000|Overall Study|Protocol Violation|9
6324872|NCT02921750|10066848|FG000|Overall Study|Adverse Event|1
6324873|NCT02921750|10066849|FG001|Overall Study|Adverse Event|2
6324874|NCT02921750|10066848|FG000|Overall Study|Withdrawal by Subject|1
6324875|NCT02921750|10066849|FG001|Overall Study|Withdrawal by Subject|1
6324876|NCT02921750|10066848|FG000|Overall Study|Lost to Follow-up|3
6324877|NCT02921750|10066849|FG001|Overall Study|Lost to Follow-up|3
6324878|NCT02921750|10066848|FG000|Overall Study|Wound healed|3
6324879|NCT02921750|10066849|FG001|Overall Study|Wound healed|3
6324880|NCT02921750|10066848|FG000|Overall Study|Serious Adverse Event|1
6324881|NCT02921750|10066849|FG001|Overall Study|Serious Adverse Event|2
6324882|NCT02922153|10066869|FG000|Overall Study|Death|8
6324883|NCT02922153|10066870|FG001|Overall Study|Death|1
6324884|NCT02922153|10066869|FG000|Overall Study|Lost to Follow-up|1
6324885|NCT02922153|10066870|FG001|Overall Study|Lost to Follow-up|0
6324886|NCT02922153|10066869|FG000|Overall Study|Physician Decision|1
6324887|NCT02922153|10066870|FG001|Overall Study|Physician Decision|1
6159703|NCT01176565|9801077|FG001|Overall Study|Withdrawal by Subject|1
6159704|NCT01176565|9801076|FG000|Overall Study|Not Analyzed (any other reason)|1
6324888|NCT02922634|10066893|FG000|Overall Study|Withdrawal by Subject|5
6324889|NCT02922634|10066893|FG000|Overall Study|Did not have their surgery|5
6324890|NCT02923115|10066939|FG000|Overall Study|Lost to Follow-up|0
6324891|NCT02923115|10066940|FG001|Overall Study|Lost to Follow-up|0
6324892|NCT02923115|10066941|FG002|Overall Study|Lost to Follow-up|0
6324893|NCT02923115|10066942|FG003|Overall Study|Lost to Follow-up|1
6191816|NCT01425814|9848748|FG001|Period 3|Adverse Event|0
6324894|NCT02923115|10066943|FG004|Overall Study|Lost to Follow-up|0
6324895|NCT02923115|10066944|FG005|Overall Study|Lost to Follow-up|0
6324896|NCT02923115|10066939|FG000|Overall Study|Withdrawal by Subject|0
6324897|NCT02923115|10066940|FG001|Overall Study|Withdrawal by Subject|1
6324898|NCT02923115|10066941|FG002|Overall Study|Withdrawal by Subject|0
6324899|NCT02923115|10066942|FG003|Overall Study|Withdrawal by Subject|0
6324900|NCT02923115|10066943|FG004|Overall Study|Withdrawal by Subject|0
6081989|NCT00624780|9689701|FG004|Fixed Dosing (Week 13 to Week 24)|Adverse Event|3
6081990|NCT00624780|9689702|FG005|Fixed Dosing (Week 13 to Week 24)|Adverse Event|1
6081991|NCT00624780|9689697|FG000|Fixed Dosing (Week 13 to Week 24)|Lack of Efficacy|2
6081992|NCT00624780|9689698|FG001|Fixed Dosing (Week 13 to Week 24)|Lack of Efficacy|1
6081993|NCT00624780|9689699|FG002|Fixed Dosing (Week 13 to Week 24)|Lack of Efficacy|2
5972007|NCT01464164|9557652|FG001|Overall Study|Physician Decision|0
5972008|NCT01464164|9557653|FG002|Overall Study|Physician Decision|0
5972009|NCT01464164|9557654|FG003|Overall Study|Physician Decision|0
5972010|NCT01464164|9557655|FG004|Overall Study|Physician Decision|0
5972011|NCT01464164|9557656|FG005|Overall Study|Physician Decision|0
5972012|NCT01464164|9557657|FG006|Overall Study|Physician Decision|2
5972013|NCT01111565|9557687|FG000|Phase B (Weeks 0 to 8)|Lost to Follow-up|3
5972014|NCT01111565|9557688|FG001|Phase B (Weeks 0 to 8)|Lost to Follow-up|0
5972015|NCT01111565|9557689|FG002|Phase B (Weeks 0 to 8)|Lost to Follow-up|0
5972016|NCT01111565|9557690|FG003|Phase B (Weeks 0 to 8)|Lost to Follow-up|0
5972017|NCT01111565|9557691|FG004|Phase B (Weeks 0 to 8)|Lost to Follow-up|0
5972018|NCT01111565|9557687|FG000|Phase B (Weeks 0 to 8)|Adverse Event|1
5972019|NCT01111565|9557688|FG001|Phase B (Weeks 0 to 8)|Adverse Event|0
5972020|NCT01111565|9557689|FG002|Phase B (Weeks 0 to 8)|Adverse Event|0
5972021|NCT01111565|9557690|FG003|Phase B (Weeks 0 to 8)|Adverse Event|0
5972022|NCT01111565|9557691|FG004|Phase B (Weeks 0 to 8)|Adverse Event|0
5972023|NCT01111565|9557687|FG000|Phase B (Weeks 0 to 8)|Sponsor Discontinued Study|58
5972024|NCT01111565|9557688|FG001|Phase B (Weeks 0 to 8)|Sponsor Discontinued Study|0
5972025|NCT01111565|9557689|FG002|Phase B (Weeks 0 to 8)|Sponsor Discontinued Study|0
5972026|NCT01111565|9557690|FG003|Phase B (Weeks 0 to 8)|Sponsor Discontinued Study|0
5972027|NCT01111565|9557691|FG004|Phase B (Weeks 0 to 8)|Sponsor Discontinued Study|0
5972028|NCT01111565|9557687|FG000|Phase B (Weeks 0 to 8)|Investigator Withdrew Subject|1
5972029|NCT01111565|9557688|FG001|Phase B (Weeks 0 to 8)|Investigator Withdrew Subject|0
5972030|NCT01111565|9557689|FG002|Phase B (Weeks 0 to 8)|Investigator Withdrew Subject|0
5972031|NCT01111565|9557690|FG003|Phase B (Weeks 0 to 8)|Investigator Withdrew Subject|0
5972032|NCT01111565|9557691|FG004|Phase B (Weeks 0 to 8)|Investigator Withdrew Subject|0
5972033|NCT01111565|9557687|FG000|Phase B (Weeks 0 to 8)|Subject Withdrew Consent|1
5972034|NCT01111565|9557688|FG001|Phase B (Weeks 0 to 8)|Subject Withdrew Consent|0
5972035|NCT01111565|9557689|FG002|Phase B (Weeks 0 to 8)|Subject Withdrew Consent|0
5972036|NCT01111565|9557690|FG003|Phase B (Weeks 0 to 8)|Subject Withdrew Consent|0
5972037|NCT01111565|9557691|FG004|Phase B (Weeks 0 to 8)|Subject Withdrew Consent|0
5972038|NCT01111565|9557687|FG000|Phase B (Weeks 0 to 8)|Protocol Deviation|1
5972039|NCT01111565|9557688|FG001|Phase B (Weeks 0 to 8)|Protocol Deviation|0
5972040|NCT01111565|9557689|FG002|Phase B (Weeks 0 to 8)|Protocol Deviation|0
5972041|NCT01111565|9557690|FG003|Phase B (Weeks 0 to 8)|Protocol Deviation|0
5972042|NCT01111565|9557691|FG004|Phase B (Weeks 0 to 8)|Protocol Deviation|0
6042871|NCT00385736|9641357|FG001|Efficacy Analysis Set - Maintenance|Withdrawal by Subject|6
6159705|NCT01176565|9801077|FG001|Overall Study|Not Analyzed (any other reason)|2
6159706|NCT01176773|9801106|FG000|Overall Study|Screen Failure|2
6159707|NCT01176773|9801106|FG000|Overall Study|Withdrew consent|1
6159708|NCT01176916|9801116|FG000|Overall Study|Adverse Event|61
6159709|NCT01176916|9801116|FG000|Overall Study|Death|1
6159710|NCT01176916|9801116|FG000|Overall Study|Lost to Follow-up|15
6159711|NCT01176916|9801116|FG000|Overall Study|Objective progression or relapse|17
6159712|NCT01176916|9801116|FG000|Overall Study|Protocol Violation|24
6324901|NCT02923115|10066944|FG005|Overall Study|Withdrawal by Subject|0
6159713|NCT01176916|9801116|FG000|Overall Study|Withdrawal by Subject|37
6159714|NCT01176916|9801116|FG000|Overall Study|Other|6
6159715|NCT01176916|9801116|FG000|Overall Study|Withdrawal prior to Treatment|6
6159716|NCT01176968|9801134|FG000|Overall Study|Adverse Event|10
6159717|NCT01176968|9801135|FG001|Overall Study|Adverse Event|11
6159718|NCT01176968|9801134|FG000|Overall Study|Death|2
6159719|NCT01176968|9801135|FG001|Overall Study|Death|3
6324902|NCT02923115|10066939|FG000|Overall Study|Randomized, but not dosed|0
6324903|NCT02923115|10066940|FG001|Overall Study|Randomized, but not dosed|0
6324904|NCT02923115|10066941|FG002|Overall Study|Randomized, but not dosed|3
6324905|NCT02923115|10066942|FG003|Overall Study|Randomized, but not dosed|1
6324906|NCT02923115|10066943|FG004|Overall Study|Randomized, but not dosed|5
6324907|NCT02923115|10066944|FG005|Overall Study|Randomized, but not dosed|0
6324908|NCT02923180|10066963|FG000|Overall Study|Off Study Due to Detectable PSA|13
6324909|NCT02923180|10066963|FG000|Overall Study|Remaining in Long Term Follow Up for PSA|13
6324910|NCT02923245|10066969|FG000|Overall Study|ultrasound order was cancelled|2
6324911|NCT02923245|10066970|FG001|Overall Study|ultrasound order was cancelled|1
6324912|NCT02923349|10066993|FG000|Overall Study|Other|1
6324913|NCT02923349|10066994|FG001|Overall Study|Other|2
6324914|NCT02923349|10066995|FG002|Overall Study|Other|4
6324915|NCT02923349|10066996|FG003|Overall Study|Other|1
6324916|NCT02923349|10066997|FG004|Overall Study|Other|3
6324917|NCT02923349|10066998|FG005|Overall Study|Other|0
6324918|NCT02923349|10066999|FG006|Overall Study|Other|1
6159720|NCT01176968|9801134|FG000|Overall Study|Lack of Efficacy|0
6159721|NCT01176968|9801135|FG001|Overall Study|Lack of Efficacy|1
6324919|NCT02923349|10066993|FG000|Overall Study|Withdrawal by Subject|2
6324920|NCT02923349|10066994|FG001|Overall Study|Withdrawal by Subject|2
6324921|NCT02923349|10066995|FG002|Overall Study|Withdrawal by Subject|8
6324922|NCT02923349|10066996|FG003|Overall Study|Withdrawal by Subject|10
6324923|NCT02923349|10066997|FG004|Overall Study|Withdrawal by Subject|12
6159722|NCT01176968|9801134|FG000|Overall Study|Lost to Follow-up|16
6159723|NCT01176968|9801135|FG001|Overall Study|Lost to Follow-up|14
6042872|NCT00385736|9641358|FG002|Efficacy Analysis Set - Maintenance|Withdrawal by Subject|14
6042873|NCT00385736|9641356|FG000|Efficacy Analysis Set - Maintenance|Lost to Follow-up|0
6042874|NCT00385736|9641357|FG001|Efficacy Analysis Set - Maintenance|Lost to Follow-up|2
6159724|NCT01176968|9801134|FG000|Overall Study|Withdrawal by Subject|48
6159725|NCT01176968|9801135|FG001|Overall Study|Withdrawal by Subject|48
6159726|NCT01176968|9801134|FG000|Overall Study|Protocol Violation|2
6159727|NCT01176968|9801135|FG001|Overall Study|Protocol Violation|1
6159728|NCT01176968|9801134|FG000|Overall Study|Did Not Meet Entrance Criteria|1
6159729|NCT01176968|9801135|FG001|Overall Study|Did Not Meet Entrance Criteria|0
6159730|NCT01176968|9801134|FG000|Overall Study|Study terminated by sponsor|0
6081994|NCT00624780|9689700|FG003|Fixed Dosing (Week 13 to Week 24)|Lack of Efficacy|5
6081995|NCT00624780|9689701|FG004|Fixed Dosing (Week 13 to Week 24)|Lack of Efficacy|5
6081996|NCT00624780|9689702|FG005|Fixed Dosing (Week 13 to Week 24)|Lack of Efficacy|2
6081997|NCT00624780|9689697|FG000|Fixed Dosing (Week 13 to Week 24)|Lost to Follow-up|1
6081998|NCT00624780|9689698|FG001|Fixed Dosing (Week 13 to Week 24)|Lost to Follow-up|0
6081999|NCT00624780|9689699|FG002|Fixed Dosing (Week 13 to Week 24)|Lost to Follow-up|1
6082000|NCT00624780|9689700|FG003|Fixed Dosing (Week 13 to Week 24)|Lost to Follow-up|0
6082001|NCT00624780|9689701|FG004|Fixed Dosing (Week 13 to Week 24)|Lost to Follow-up|1
6082002|NCT00624780|9689702|FG005|Fixed Dosing (Week 13 to Week 24)|Lost to Follow-up|1
6082003|NCT00624780|9689697|FG000|Fixed Dosing (Week 13 to Week 24)|Withdrawal by Subject|2
6082004|NCT00624780|9689698|FG001|Fixed Dosing (Week 13 to Week 24)|Withdrawal by Subject|3
6082005|NCT00624780|9689699|FG002|Fixed Dosing (Week 13 to Week 24)|Withdrawal by Subject|6
6082006|NCT00624780|9689700|FG003|Fixed Dosing (Week 13 to Week 24)|Withdrawal by Subject|3
6082007|NCT00624780|9689701|FG004|Fixed Dosing (Week 13 to Week 24)|Withdrawal by Subject|6
6082008|NCT00624780|9689702|FG005|Fixed Dosing (Week 13 to Week 24)|Withdrawal by Subject|2
6082009|NCT00624780|9689697|FG000|Fixed Dosing (Week 13 to Week 24)|Other|5
6082010|NCT00624780|9689698|FG001|Fixed Dosing (Week 13 to Week 24)|Other|3
6082011|NCT00624780|9689699|FG002|Fixed Dosing (Week 13 to Week 24)|Other|4
6082012|NCT00624780|9689700|FG003|Fixed Dosing (Week 13 to Week 24)|Other|1
6082013|NCT00624780|9689701|FG004|Fixed Dosing (Week 13 to Week 24)|Other|4
6082014|NCT00624780|9689702|FG005|Fixed Dosing (Week 13 to Week 24)|Other|3
6082015|NCT00624780|9689697|FG000|Treatment Discontinuation (Week 25)|Adverse Event|1
6082016|NCT00624780|9689698|FG001|Treatment Discontinuation (Week 25)|Adverse Event|0
6082017|NCT00624780|9689699|FG002|Treatment Discontinuation (Week 25)|Adverse Event|2
6082018|NCT00624780|9689700|FG003|Treatment Discontinuation (Week 25)|Adverse Event|1
6087722|NCT00670007|9698159|FG000|Overall Study|Withdrawal by Subject|4
6082019|NCT00624780|9689701|FG004|Treatment Discontinuation (Week 25)|Adverse Event|0
6082020|NCT00624780|9689702|FG005|Treatment Discontinuation (Week 25)|Adverse Event|1
6082021|NCT00624780|9689697|FG000|Treatment Discontinuation (Week 25)|Lack of Efficacy|1
6082022|NCT00624780|9689698|FG001|Treatment Discontinuation (Week 25)|Lack of Efficacy|0
6082023|NCT00624780|9689699|FG002|Treatment Discontinuation (Week 25)|Lack of Efficacy|0
6082024|NCT00624780|9689700|FG003|Treatment Discontinuation (Week 25)|Lack of Efficacy|0
6082025|NCT00624780|9689701|FG004|Treatment Discontinuation (Week 25)|Lack of Efficacy|0
6082026|NCT00624780|9689702|FG005|Treatment Discontinuation (Week 25)|Lack of Efficacy|0
6082027|NCT00624780|9689697|FG000|Treatment Discontinuation (Week 25)|Lost to Follow-up|0
5972214|NCT04409262|9557953|FG000|Overall Study|Adverse Event|0
5972215|NCT04409262|9557954|FG001|Overall Study|Adverse Event|2
6049023|NCT00420927|9648200|FG001|Period 2|Methotrexate intolerance|0
6042875|NCT00385736|9641358|FG002|Efficacy Analysis Set - Maintenance|Lost to Follow-up|2
6082028|NCT00624780|9689698|FG001|Treatment Discontinuation (Week 25)|Lost to Follow-up|0
6082029|NCT00624780|9689699|FG002|Treatment Discontinuation (Week 25)|Lost to Follow-up|1
6082030|NCT00624780|9689700|FG003|Treatment Discontinuation (Week 25)|Lost to Follow-up|0
6082031|NCT00624780|9689701|FG004|Treatment Discontinuation (Week 25)|Lost to Follow-up|0
6082032|NCT00624780|9689702|FG005|Treatment Discontinuation (Week 25)|Lost to Follow-up|0
6082033|NCT00624780|9689697|FG000|Follow-up (Week 26)|Death|0
6082034|NCT00624780|9689698|FG001|Follow-up (Week 26)|Death|0
6082035|NCT00624780|9689699|FG002|Follow-up (Week 26)|Death|1
6082036|NCT00624780|9689700|FG003|Follow-up (Week 26)|Death|0
6082037|NCT00624780|9689701|FG004|Follow-up (Week 26)|Death|0
6082038|NCT00624780|9689702|FG005|Follow-up (Week 26)|Death|0
6082039|NCT00624780|9689697|FG000|Follow-up (Week 26)|Adverse Event|0
6082040|NCT00624780|9689698|FG001|Follow-up (Week 26)|Adverse Event|0
6082041|NCT00624780|9689699|FG002|Follow-up (Week 26)|Adverse Event|0
6082042|NCT00624780|9689700|FG003|Follow-up (Week 26)|Adverse Event|0
6082043|NCT00624780|9689701|FG004|Follow-up (Week 26)|Adverse Event|1
6082044|NCT00624780|9689702|FG005|Follow-up (Week 26)|Adverse Event|0
6082045|NCT00624780|9689697|FG000|Follow-up (Week 26)|Lost to Follow-up|0
6082046|NCT00624780|9689698|FG001|Follow-up (Week 26)|Lost to Follow-up|0
6082047|NCT00624780|9689699|FG002|Follow-up (Week 26)|Lost to Follow-up|1
6082048|NCT00624780|9689700|FG003|Follow-up (Week 26)|Lost to Follow-up|0
6082049|NCT00624780|9689701|FG004|Follow-up (Week 26)|Lost to Follow-up|1
6082050|NCT00624780|9689702|FG005|Follow-up (Week 26)|Lost to Follow-up|0
6082051|NCT00624780|9689697|FG000|Follow-up (Week 26)|Withdrawal by Subject|1
6082052|NCT00624780|9689698|FG001|Follow-up (Week 26)|Withdrawal by Subject|0
6082053|NCT00624780|9689699|FG002|Follow-up (Week 26)|Withdrawal by Subject|0
6082054|NCT00624780|9689700|FG003|Follow-up (Week 26)|Withdrawal by Subject|0
6082055|NCT00624780|9689701|FG004|Follow-up (Week 26)|Withdrawal by Subject|0
6082056|NCT00624780|9689702|FG005|Follow-up (Week 26)|Withdrawal by Subject|0
6082057|NCT00624780|9689697|FG000|Follow-up (Week 26)|Other|1
6082058|NCT00624780|9689698|FG001|Follow-up (Week 26)|Other|1
6082059|NCT00624780|9689699|FG002|Follow-up (Week 26)|Other|0
6082060|NCT00624780|9689700|FG003|Follow-up (Week 26)|Other|0
6082061|NCT00624780|9689701|FG004|Follow-up (Week 26)|Other|0
6082062|NCT00624780|9689702|FG005|Follow-up (Week 26)|Other|0
6082063|NCT00624819|9689732|FG000|Follow-up Period: Year 4|Parents decision|0
6082064|NCT00624819|9689733|FG001|Follow-up Period: Year 4|Parents decision|0
6082065|NCT00624819|9689734|FG002|Follow-up Period: Year 4|Parents decision|1
6082066|NCT00624819|9689735|FG003|Follow-up Period: Year 4|Parents decision|0
6082067|NCT00624819|9689732|FG000|Follow-up Period: Year 4|Lost to Follow-up|1
6159731|NCT01176968|9801135|FG001|Overall Study|Study terminated by sponsor|1
6159732|NCT01176968|9801134|FG000|Overall Study|Reason not defined|5
6159733|NCT01176968|9801135|FG001|Overall Study|Reason not defined|3
6159734|NCT01177007|9801145|FG000|Overall Study|Lost to Follow-up|2
6159735|NCT01177007|9801145|FG000|Overall Study|Death|4
6159736|NCT01177007|9801145|FG000|Overall Study|Entered hospice care|5
6159737|NCT01177007|9801145|FG000|Overall Study|Required additional Y90 treatment|6
6159738|NCT01177007|9801145|FG000|Overall Study|Change in treatment modality|21
6159739|NCT01177059|9801151|FG000|Overall Study|Received placebo in OTH/OZ1-INT-1 study|30
6159740|NCT01177059|9801151|FG000|Overall Study|Withdrew consent|2
6082068|NCT00624819|9689733|FG001|Follow-up Period: Year 4|Lost to Follow-up|1
6082069|NCT00624819|9689734|FG002|Follow-up Period: Year 4|Lost to Follow-up|0
6082070|NCT00624819|9689735|FG003|Follow-up Period: Year 4|Lost to Follow-up|0
6159741|NCT01177059|9801151|FG000|Overall Study|Lost to Follow-up|18
6159742|NCT01177137|9801167|FG000|Overall Study|Withdrawal by Subject|10
6159743|NCT01177137|9801168|FG001|Overall Study|Withdrawal by Subject|10
6159744|NCT01177137|9801169|FG002|Overall Study|Withdrawal by Subject|2
6159745|NCT01177228|9801193|FG000|Overall Study|Positive tuberculosis test|0
6159746|NCT01177228|9801194|FG001|Overall Study|Positive tuberculosis test|1
6159747|NCT01177228|9801195|FG002|Overall Study|Positive tuberculosis test|0
6159748|NCT01177228|9801196|FG003|Overall Study|Positive tuberculosis test|0
6159749|NCT01177228|9801193|FG000|Overall Study|Worsening disease activity|1
6159750|NCT01177228|9801194|FG001|Overall Study|Worsening disease activity|0
6159751|NCT01177228|9801195|FG002|Overall Study|Worsening disease activity|0
6159752|NCT01177228|9801196|FG003|Overall Study|Worsening disease activity|0
6159753|NCT01177228|9801193|FG000|Overall Study|Withdrawal by Subject|0
6159754|NCT01177228|9801194|FG001|Overall Study|Withdrawal by Subject|1
6159755|NCT01177228|9801195|FG002|Overall Study|Withdrawal by Subject|0
6159756|NCT01177228|9801196|FG003|Overall Study|Withdrawal by Subject|0
6159757|NCT01177293|9801211|FG000|Washout Period (of 14 Days)|Lost to Follow-up|0
6159758|NCT01177293|9801212|FG001|Washout Period (of 14 Days)|Lost to Follow-up|1
6159759|NCT01177384|9801220|FG000|Overall Study|Adverse Event|6
6159760|NCT01177384|9801221|FG001|Overall Study|Adverse Event|4
6159761|NCT01177384|9801220|FG000|Overall Study|Lack of Efficacy|0
6159762|NCT01177384|9801221|FG001|Overall Study|Lack of Efficacy|1
6159763|NCT01177384|9801220|FG000|Overall Study|Lost to Follow-up|3
6159764|NCT01177384|9801221|FG001|Overall Study|Lost to Follow-up|4
6159765|NCT01177384|9801220|FG000|Overall Study|Physician Decision|0
6159766|NCT01177384|9801221|FG001|Overall Study|Physician Decision|3
6159767|NCT01177384|9801220|FG000|Overall Study|Protocol Violation|0
5972043|NCT01111565|9557687|FG000|Phase B (Weeks 0 to 8)|Lack of Efficacy as Determined by the Investigator|1
5972044|NCT01111565|9557688|FG001|Phase B (Weeks 0 to 8)|Lack of Efficacy as Determined by the Investigator|0
5972045|NCT01111565|9557689|FG002|Phase B (Weeks 0 to 8)|Lack of Efficacy as Determined by the Investigator|0
5972046|NCT01111565|9557690|FG003|Phase B (Weeks 0 to 8)|Lack of Efficacy as Determined by the Investigator|0
5972047|NCT01111565|9557691|FG004|Phase B (Weeks 0 to 8)|Lack of Efficacy as Determined by the Investigator|0
5972048|NCT01111565|9557687|FG000|Phase B + and Phase C (Weeks 9 to 14)|Lost to Follow-up|0
5972049|NCT01111565|9557688|FG001|Phase B + and Phase C (Weeks 9 to 14)|Lost to Follow-up|0
5972050|NCT01111565|9557689|FG002|Phase B + and Phase C (Weeks 9 to 14)|Lost to Follow-up|0
5972051|NCT01111565|9557690|FG003|Phase B + and Phase C (Weeks 9 to 14)|Lost to Follow-up|1
5972052|NCT01111565|9557691|FG004|Phase B + and Phase C (Weeks 9 to 14)|Lost to Follow-up|0
5972053|NCT01111565|9557687|FG000|Phase B + and Phase C (Weeks 9 to 14)|Adverse Event|0
5972054|NCT01111565|9557688|FG001|Phase B + and Phase C (Weeks 9 to 14)|Adverse Event|0
5972055|NCT01111565|9557689|FG002|Phase B + and Phase C (Weeks 9 to 14)|Adverse Event|2
5972056|NCT01111565|9557690|FG003|Phase B + and Phase C (Weeks 9 to 14)|Adverse Event|0
5972057|NCT01111565|9557691|FG004|Phase B + and Phase C (Weeks 9 to 14)|Adverse Event|0
5972058|NCT01111565|9557687|FG000|Phase B + and Phase C (Weeks 9 to 14)|Sponsor Discontinued Study|0
5972059|NCT01111565|9557688|FG001|Phase B + and Phase C (Weeks 9 to 14)|Sponsor Discontinued Study|7
5972060|NCT01111565|9557689|FG002|Phase B + and Phase C (Weeks 9 to 14)|Sponsor Discontinued Study|3
5972061|NCT01111565|9557690|FG003|Phase B + and Phase C (Weeks 9 to 14)|Sponsor Discontinued Study|2
5972062|NCT01111565|9557691|FG004|Phase B + and Phase C (Weeks 9 to 14)|Sponsor Discontinued Study|3
5972063|NCT01111565|9557687|FG000|Phase B + and Phase C (Weeks 9 to 14)|Investigator Withdrew Subjects|0
5972064|NCT01111565|9557688|FG001|Phase B + and Phase C (Weeks 9 to 14)|Investigator Withdrew Subjects|0
5972216|NCT04409262|9557953|FG000|Overall Study|Death|55
6159768|NCT01177384|9801221|FG001|Overall Study|Protocol Violation|2
6159769|NCT01177384|9801220|FG000|Overall Study|Withdrawal by Subject|5
6159770|NCT01177384|9801221|FG001|Overall Study|Withdrawal by Subject|12
6159771|NCT01177410|9801230|FG000|Overall Study|Adverse Event|0
6159772|NCT01177410|9801231|FG001|Overall Study|Adverse Event|2
6159773|NCT01177410|9801232|FG002|Overall Study|Adverse Event|2
6159774|NCT01177410|9801230|FG000|Overall Study|Withdrawal by Subject|1
6159775|NCT01177410|9801231|FG001|Overall Study|Withdrawal by Subject|4
6159776|NCT01177410|9801232|FG002|Overall Study|Withdrawal by Subject|3
6159777|NCT01177410|9801230|FG000|Overall Study|Lost to Follow-up|0
6159778|NCT01177410|9801231|FG001|Overall Study|Lost to Follow-up|1
6159779|NCT01177410|9801232|FG002|Overall Study|Lost to Follow-up|0
6159780|NCT01177553|9801242|FG000|Overall Study|babies not yet 6 months of age|1
6159781|NCT01177553|9801243|FG001|Overall Study|babies not yet 6 months of age|0
6324924|NCT02923349|10066998|FG005|Overall Study|Withdrawal by Subject|3
6324925|NCT02923349|10066999|FG006|Overall Study|Withdrawal by Subject|0
6324926|NCT02923349|10066993|FG000|Overall Study|Physician Decision|0
6324927|NCT02923349|10066994|FG001|Overall Study|Physician Decision|0
6324928|NCT02923349|10066995|FG002|Overall Study|Physician Decision|0
6324929|NCT02923349|10066996|FG003|Overall Study|Physician Decision|1
6324930|NCT02923349|10066997|FG004|Overall Study|Physician Decision|1
6324931|NCT02923349|10066998|FG005|Overall Study|Physician Decision|0
6324932|NCT02923349|10066999|FG006|Overall Study|Physician Decision|2
6324933|NCT02923349|10066993|FG000|Overall Study|Lost to Follow-up|0
6324934|NCT02923349|10066994|FG001|Overall Study|Lost to Follow-up|0
6324935|NCT02923349|10066995|FG002|Overall Study|Lost to Follow-up|3
6324936|NCT02923349|10066996|FG003|Overall Study|Lost to Follow-up|0
6324937|NCT02923349|10066997|FG004|Overall Study|Lost to Follow-up|1
6324938|NCT02923349|10066998|FG005|Overall Study|Lost to Follow-up|1
6082071|NCT00624832|9689749|FG000|Overall Study|Adverse Event|0
6082072|NCT00624832|9689750|FG001|Overall Study|Adverse Event|1
6082073|NCT00624832|9689751|FG002|Overall Study|Adverse Event|0
6082074|NCT00624832|9689752|FG003|Overall Study|Adverse Event|1
6082075|NCT00624832|9689749|FG000|Overall Study|Abnormal Laboratory Value|2
6082076|NCT00624832|9689750|FG001|Overall Study|Abnormal Laboratory Value|0
6082077|NCT00624832|9689751|FG002|Overall Study|Abnormal Laboratory Value|0
6082078|NCT00624832|9689752|FG003|Overall Study|Abnormal Laboratory Value|0
6159782|NCT01177670|9801249|FG000|Overall Study|Study Terminated|115
6159783|NCT01177670|9801249|FG000|Overall Study|Physician Decision|50
6159784|NCT01177670|9801249|FG000|Overall Study|Withdrawal by Subject|4
6159785|NCT01177722|9801261|FG000|Overall Study|Serious Adverse Event|0
6159786|NCT01177722|9801262|FG001|Overall Study|Serious Adverse Event|0
6159787|NCT01177722|9801263|FG002|Overall Study|Serious Adverse Event|1
6159788|NCT01177722|9801264|FG003|Overall Study|Serious Adverse Event|0
6042876|NCT00385736|9641356|FG000|Efficacy Analysis Set - Maintenance|Lack of Efficacy|38
6082079|NCT00625131|9689787|FG000|Overall Study|Lost to Follow-up|3
6082080|NCT00625131|9689788|FG001|Overall Study|Lost to Follow-up|2
6082081|NCT00625131|9689789|FG002|Overall Study|Lost to Follow-up|0
6082082|NCT00625131|9689787|FG000|Overall Study|Withdrawal by Subject|1
6082083|NCT00625131|9689788|FG001|Overall Study|Withdrawal by Subject|0
6082084|NCT00625131|9689789|FG002|Overall Study|Withdrawal by Subject|5
6082085|NCT00625183|9689795|FG000|Overall Study|Disease Progression|1
6082086|NCT00625365|9689801|FG000|Overall Study|Withdrawal by Subject|1
6082087|NCT00625365|9689801|FG000|Overall Study|No IV access|5
6082088|NCT00625365|9689801|FG000|Overall Study|VSD|1
6082089|NCT00625443|9689838|FG000|Overall Study|Adverse Event|1
6082090|NCT00625443|9689839|FG001|Overall Study|Adverse Event|4
6159789|NCT01177722|9801261|FG000|Overall Study|Protocol Violation|0
6159790|NCT01177722|9801262|FG001|Overall Study|Protocol Violation|0
6159791|NCT01177722|9801263|FG002|Overall Study|Protocol Violation|1
6159792|NCT01177722|9801264|FG003|Overall Study|Protocol Violation|0
6159793|NCT01177722|9801261|FG000|Overall Study|Lost to Follow-up|3
6159794|NCT01177722|9801262|FG001|Overall Study|Lost to Follow-up|4
6159795|NCT01177722|9801263|FG002|Overall Study|Lost to Follow-up|3
6159796|NCT01177722|9801264|FG003|Overall Study|Lost to Follow-up|1
6159797|NCT01177722|9801261|FG000|Overall Study|Withdrawal by Subject|10
6159798|NCT01177722|9801262|FG001|Overall Study|Withdrawal by Subject|6
6159799|NCT01177722|9801263|FG002|Overall Study|Withdrawal by Subject|4
6159800|NCT01177722|9801264|FG003|Overall Study|Withdrawal by Subject|6
6159801|NCT01177787|9801279|FG000|Cryolipolysis on Thigh|Protocol Violation|4
6159802|NCT01177787|9801279|FG000|Cryolipolysis on Thigh|Lack of Efficacy|9
6159803|NCT01177787|9801279|FG000|Cryolipolysis on Thigh|Lost to Follow-up|1
6159804|NCT01177800|9801293|FG000|Overall Study|Adverse Event|9
6159805|NCT01177800|9801294|FG001|Overall Study|Adverse Event|3
6159806|NCT01177800|9801293|FG000|Overall Study|Protocol Violation|0
6159807|NCT01177800|9801294|FG001|Overall Study|Protocol Violation|1
6159808|NCT01177800|9801293|FG000|Overall Study|Physician Decision|1
6159809|NCT01177800|9801294|FG001|Overall Study|Physician Decision|0
6159810|NCT01177800|9801293|FG000|Overall Study|Withdrawal of informed consent|0
6159811|NCT01177800|9801294|FG001|Overall Study|Withdrawal of informed consent|1
6159812|NCT01177813|9801305|FG000|Overall Study|Adverse Event|8
6159813|NCT01177813|9801306|FG001|Overall Study|Adverse Event|2
6159814|NCT01177813|9801307|FG002|Overall Study|Adverse Event|4
6159815|NCT01177813|9801308|FG003|Overall Study|Adverse Event|6
6159816|NCT01177813|9801309|FG004|Overall Study|Adverse Event|3
6159817|NCT01177813|9801305|FG000|Overall Study|Lack of Efficacy|1
6159818|NCT01177813|9801306|FG001|Overall Study|Lack of Efficacy|0
6159819|NCT01177813|9801307|FG002|Overall Study|Lack of Efficacy|0
6159820|NCT01177813|9801308|FG003|Overall Study|Lack of Efficacy|0
6159821|NCT01177813|9801309|FG004|Overall Study|Lack of Efficacy|0
6159822|NCT01177813|9801305|FG000|Overall Study|Protocol Violation|3
6159823|NCT01177813|9801306|FG001|Overall Study|Protocol Violation|2
6324939|NCT02923349|10066999|FG006|Overall Study|Lost to Follow-up|0
6324940|NCT02923349|10066993|FG000|Overall Study|Death|1
6324941|NCT02923349|10066994|FG001|Overall Study|Death|0
6324942|NCT02923349|10066995|FG002|Overall Study|Death|2
6324943|NCT02923349|10066996|FG003|Overall Study|Death|4
6324944|NCT02923349|10066997|FG004|Overall Study|Death|2
6324945|NCT02923349|10066998|FG005|Overall Study|Death|3
6324946|NCT02923349|10066999|FG006|Overall Study|Death|0
6324947|NCT02923427|10067017|FG000|Overall Study|convert to laparatomy|2
6324948|NCT02923427|10067018|FG001|Overall Study|convert to laparatomy|2
6324949|NCT02923427|10067017|FG000|Overall Study|destaturation|1
6324950|NCT02923427|10067018|FG001|Overall Study|destaturation|0
6324951|NCT02923427|10067017|FG000|Overall Study|can not replace LMA|1
6324952|NCT02923427|10067018|FG001|Overall Study|can not replace LMA|0
6324953|NCT02923921|10067035|FG000|Overall Study|Sponsor Decision|39
6324954|NCT02923921|10067036|FG001|Overall Study|Sponsor Decision|38
6324955|NCT02923921|10067035|FG000|Overall Study|Lost to Follow-up|1
6324956|NCT02923921|10067036|FG001|Overall Study|Lost to Follow-up|0
6324957|NCT02923921|10067035|FG000|Overall Study|Withdrawal by Subject|6
6324958|NCT02923921|10067036|FG001|Overall Study|Withdrawal by Subject|13
6324959|NCT02923921|10067035|FG000|Overall Study|Unknown, Not Collected|7
6324960|NCT02923921|10067036|FG001|Overall Study|Unknown, Not Collected|6
6324961|NCT02924051|10067044|FG000|Overall Study|Withdrawal by Subject|1
6324962|NCT02924051|10067045|FG001|Overall Study|Withdrawal by Subject|9
6324963|NCT02924428|10067064|FG000|Overall Study|Adverse Event|1
6324964|NCT02924428|10067065|FG001|Overall Study|Adverse Event|0
6324965|NCT02924428|10067064|FG000|Overall Study|Physician Decision|1
6324966|NCT02924428|10067065|FG001|Overall Study|Physician Decision|0
6324967|NCT02924428|10067064|FG000|Overall Study|Lost to Follow-up|2
6324968|NCT02924428|10067065|FG001|Overall Study|Lost to Follow-up|4
6324969|NCT02924428|10067064|FG000|Overall Study|Pregnancy|0
6324970|NCT02924428|10067065|FG001|Overall Study|Pregnancy|1
6324971|NCT02924688|10067077|FG000|Overall Study|Adverse Event|9
6324972|NCT02924688|10067078|FG001|Overall Study|Adverse Event|3
6082091|NCT00625443|9689840|FG002|Overall Study|Adverse Event|0
6082092|NCT00625443|9689838|FG000|Overall Study|Non-compliance with protocol|0
6082093|NCT00625443|9689839|FG001|Overall Study|Non-compliance with protocol|1
6082094|NCT00625443|9689840|FG002|Overall Study|Non-compliance with protocol|0
6082095|NCT00625443|9689838|FG000|Overall Study|Platelet count increase >=500,000/mm3|1
6082096|NCT00625443|9689839|FG001|Overall Study|Platelet count increase >=500,000/mm3|0
6082097|NCT00625443|9689840|FG002|Overall Study|Platelet count increase >=500,000/mm3|0
6082098|NCT00625443|9689838|FG000|Overall Study|Withdrawal by Subject|0
6082099|NCT00625443|9689839|FG001|Overall Study|Withdrawal by Subject|1
6082100|NCT00625443|9689840|FG002|Overall Study|Withdrawal by Subject|2
6082101|NCT00625443|9689838|FG000|Overall Study|Physician Decision|0
6082102|NCT00625443|9689839|FG001|Overall Study|Physician Decision|4
6082103|NCT00625443|9689840|FG002|Overall Study|Physician Decision|2
6082104|NCT00625443|9689838|FG000|Overall Study|Other|0
6159824|NCT01177813|9801307|FG002|Overall Study|Protocol Violation|2
6159825|NCT01177813|9801308|FG003|Overall Study|Protocol Violation|0
6159826|NCT01177813|9801309|FG004|Overall Study|Protocol Violation|1
6082105|NCT00625443|9689839|FG001|Overall Study|Other|1
6159827|NCT01177813|9801305|FG000|Overall Study|Lost to Follow-up|12
6159828|NCT01177813|9801306|FG001|Overall Study|Lost to Follow-up|5
6159829|NCT01177813|9801307|FG002|Overall Study|Lost to Follow-up|6
6159830|NCT01177813|9801308|FG003|Overall Study|Lost to Follow-up|3
6159831|NCT01177813|9801309|FG004|Overall Study|Lost to Follow-up|0
6159832|NCT01177813|9801305|FG000|Overall Study|Withdrawal by Subject|12
6159833|NCT01177813|9801306|FG001|Overall Study|Withdrawal by Subject|7
6082106|NCT00625443|9689840|FG002|Overall Study|Other|1
6082107|NCT00625807|9689858|FG000|Overall Study|schedule conflict|2
6159834|NCT01177813|9801307|FG002|Overall Study|Withdrawal by Subject|6
6159835|NCT01177813|9801308|FG003|Overall Study|Withdrawal by Subject|5
6082108|NCT00625807|9689859|FG001|Overall Study|schedule conflict|8
6082109|NCT00625820|9689867|FG000|Overall Study|Withdrawal by Subject|1
6082110|NCT00625846|9689876|FG000|Overall Study|Withdrawal by Subject|2
6082111|NCT00625846|9689877|FG001|Overall Study|Withdrawal by Subject|0
6082112|NCT00625846|9689878|FG002|Overall Study|Withdrawal by Subject|1
6082113|NCT00625846|9689879|FG003|Overall Study|Withdrawal by Subject|2
6082114|NCT00625872|9689895|FG000|Overall Study|Withdrawal by Subject|1
6082115|NCT00625872|9689896|FG001|Overall Study|Withdrawal by Subject|0
6082116|NCT00625872|9689895|FG000|Overall Study|Does not meet inclusion criteria|1
6082117|NCT00625872|9689896|FG001|Overall Study|Does not meet inclusion criteria|0
6082118|NCT00625872|9689895|FG000|Overall Study|Terminated by sponsor|2
6082119|NCT00625872|9689896|FG001|Overall Study|Terminated by sponsor|5
6082120|NCT00625872|9689895|FG000|Overall Study|Randomized but not treated|0
6082121|NCT00625872|9689896|FG001|Overall Study|Randomized but not treated|1
6159836|NCT01177813|9801309|FG004|Overall Study|Withdrawal by Subject|3
6159837|NCT01177813|9801305|FG000|Overall Study|Other reason not defined above|5
6159838|NCT01177813|9801306|FG001|Overall Study|Other reason not defined above|2
6159839|NCT01177813|9801307|FG002|Overall Study|Other reason not defined above|2
6159840|NCT01177813|9801308|FG003|Overall Study|Other reason not defined above|3
6159841|NCT01177813|9801309|FG004|Overall Study|Other reason not defined above|2
6159842|NCT01177943|9801323|FG000|First Intervention|Withdrawal by Subject|2
6159843|NCT01177943|9801324|FG001|First Intervention|Withdrawal by Subject|0
6159844|NCT01177969|9801337|FG000|Overall Study|Protocol Violation|2
6159845|NCT01177969|9801338|FG001|Overall Study|Protocol Violation|1
6159846|NCT01177969|9801337|FG000|Overall Study|Withdrawal by Subject|1
6159847|NCT01177969|9801338|FG001|Overall Study|Withdrawal by Subject|2
6159848|NCT01178073|9801347|FG000|Overall Study|Adverse Event|34
6159849|NCT01178073|9801348|FG001|Overall Study|Adverse Event|27
6159850|NCT01178073|9801349|FG002|Overall Study|Adverse Event|24
6159851|NCT01178073|9801347|FG000|Overall Study|Protocol Violation|1
6159852|NCT01178073|9801348|FG001|Overall Study|Protocol Violation|1
6159853|NCT01178073|9801349|FG002|Overall Study|Protocol Violation|1
6082122|NCT00626028|9689910|FG000|Overall Study|Adverse Event|1
6082123|NCT00626028|9689911|FG001|Overall Study|Adverse Event|1
6082124|NCT00626028|9689910|FG000|Overall Study|Device Failure|0
6082125|NCT00626028|9689911|FG001|Overall Study|Device Failure|1
6082126|NCT00626028|9689910|FG000|Overall Study|Physician Decision|2
6082127|NCT00626028|9689911|FG001|Overall Study|Physician Decision|1
5972065|NCT01111565|9557689|FG002|Phase B + and Phase C (Weeks 9 to 14)|Investigator Withdrew Subjects|0
5972066|NCT01111565|9557690|FG003|Phase B + and Phase C (Weeks 9 to 14)|Investigator Withdrew Subjects|1
5972067|NCT01111565|9557691|FG004|Phase B + and Phase C (Weeks 9 to 14)|Investigator Withdrew Subjects|0
5972068|NCT01111565|9557687|FG000|Phase B + and Phase C (Weeks 9 to 14)|Subjects Withdrew Consent|0
5972069|NCT01111565|9557688|FG001|Phase B + and Phase C (Weeks 9 to 14)|Subjects Withdrew Consent|0
5972070|NCT01111565|9557689|FG002|Phase B + and Phase C (Weeks 9 to 14)|Subjects Withdrew Consent|0
5972071|NCT01111565|9557690|FG003|Phase B + and Phase C (Weeks 9 to 14)|Subjects Withdrew Consent|0
5972072|NCT01111565|9557691|FG004|Phase B + and Phase C (Weeks 9 to 14)|Subjects Withdrew Consent|1
5972073|NCT01092117|9557701|FG000|Index Procedure to 1 Month|Death|1
5972074|NCT01092117|9557701|FG000|1 Month|Death|1
5972075|NCT01092117|9557701|FG000|1 Month|Withdrawal by Subject|1
5972076|NCT01092117|9557701|FG000|1 Month|Lost to Follow-up|1
5972077|NCT01092117|9557701|FG000|6 Months|Death|2
5972078|NCT01092117|9557701|FG000|6 Months|Withdrawal by Subject|3
5972079|NCT01092117|9557701|FG000|12 Month|Death|11
5972080|NCT01092117|9557701|FG000|12 Month|Withdrawal by Subject|2
5972081|NCT01092117|9557701|FG000|12 Month|Lost to Follow-up|1
5972082|NCT01092117|9557701|FG000|Year 2|Death|5
5972083|NCT01092117|9557701|FG000|Year 2|Withdrawal by Subject|4
5972084|NCT01092117|9557701|FG000|Year 2|Lost to Follow-up|1
5972085|NCT01092117|9557701|FG000|Year 3|Death|7
5972086|NCT01092117|9557701|FG000|Year 3|Withdrawal by Subject|9
5972087|NCT01092117|9557701|FG000|Year 3|Lost to Follow-up|3
5972088|NCT01092117|9557701|FG000|Year 4|Death|8
5972089|NCT01092117|9557701|FG000|Year 4|Withdrawal by Subject|4
5972090|NCT01092117|9557701|FG000|Year 4|Lost to Follow-up|4
5972091|NCT00950989|9557709|FG000|Overall Study|Death|0
6082128|NCT00626028|9689910|FG000|Overall Study|Inclusion/Exclusion Criteria|3
6087723|NCT00670046|9698166|FG000|Overall Study|Lost to Follow-up|1
5972092|NCT00950989|9557710|FG001|Overall Study|Death|0
5972093|NCT00950989|9557711|FG002|Overall Study|Death|1
5972094|NCT00950989|9557712|FG003|Overall Study|Death|0
5972095|NCT00950989|9557709|FG000|Overall Study|Administrative Decision|0
5972096|NCT00950989|9557710|FG001|Overall Study|Administrative Decision|1
5972097|NCT00950989|9557711|FG002|Overall Study|Administrative Decision|0
5972098|NCT00950989|9557712|FG003|Overall Study|Administrative Decision|0
5972099|NCT00950989|9557709|FG000|Overall Study|Disease Progression|0
5972100|NCT00950989|9557710|FG001|Overall Study|Disease Progression|0
5972101|NCT00950989|9557711|FG002|Overall Study|Disease Progression|1
5972102|NCT00950989|9557712|FG003|Overall Study|Disease Progression|0
5972103|NCT00950989|9557709|FG000|Overall Study|Withdrawal by Subject|2
6082129|NCT00626028|9689911|FG001|Overall Study|Inclusion/Exclusion Criteria|6
6082130|NCT00626093|9689917|FG000|Overall Study|Lost to Follow-up|5
6082131|NCT00626093|9689917|FG000|Overall Study|Death|1
6082132|NCT00626093|9689917|FG000|Overall Study|Physician Decision|4
6082133|NCT00626093|9689917|FG000|Overall Study|Withdrawal by Subject|6
6082134|NCT00626093|9689917|FG000|Overall Study|Protocol Violation|1
6082135|NCT00626093|9689917|FG000|Overall Study|One of the required devices not implante|6
6082136|NCT00626197|9689924|FG000|Overall Study|Did not cooperate|2
6082137|NCT00626197|9689925|FG001|Overall Study|Did not cooperate|6
6082138|NCT00626197|9689926|FG002|Overall Study|Did not cooperate|1
6082139|NCT00626197|9689924|FG000|Overall Study|Failure to return|6
6082140|NCT00626197|9689925|FG001|Overall Study|Failure to return|5
6082141|NCT00626197|9689926|FG002|Overall Study|Failure to return|6
6082142|NCT00626197|9689924|FG000|Overall Study|Adverse event, serious fatal|3
6082143|NCT00626197|9689925|FG001|Overall Study|Adverse event, serious fatal|6
6082144|NCT00626197|9689926|FG002|Overall Study|Adverse event, serious fatal|6
6082145|NCT00626197|9689924|FG000|Overall Study|Adverse Event|1
6082146|NCT00626197|9689925|FG001|Overall Study|Adverse Event|1
6082147|NCT00626197|9689926|FG002|Overall Study|Adverse Event|2
6082148|NCT00626197|9689924|FG000|Overall Study|Withdrawal by Subject|17
6082149|NCT00626197|9689925|FG001|Overall Study|Withdrawal by Subject|17
6082150|NCT00626197|9689926|FG002|Overall Study|Withdrawal by Subject|7
6159854|NCT01178073|9801347|FG000|Overall Study|Lost to Follow-up|2
6159855|NCT01178073|9801348|FG001|Overall Study|Lost to Follow-up|0
6159856|NCT01178073|9801349|FG002|Overall Study|Lost to Follow-up|3
6159857|NCT01178073|9801347|FG000|Overall Study|Physician Decision|14
6159858|NCT01178073|9801348|FG001|Overall Study|Physician Decision|10
6159859|NCT01178073|9801349|FG002|Overall Study|Physician Decision|10
6159860|NCT01178073|9801347|FG000|Overall Study|Withdrawal by Subject|10
6159861|NCT01178073|9801348|FG001|Overall Study|Withdrawal by Subject|6
6159862|NCT01178073|9801349|FG002|Overall Study|Withdrawal by Subject|8
6159863|NCT01178073|9801347|FG000|Overall Study|Missing Completion Status|1
6159864|NCT01178073|9801348|FG001|Overall Study|Missing Completion Status|0
6159865|NCT01178073|9801349|FG002|Overall Study|Missing Completion Status|0
6159866|NCT01178086|9801360|FG000|Overall Study|Participant refusal|7
6159867|NCT01178086|9801360|FG000|Overall Study|Physician Decision|44
6159868|NCT01178086|9801360|FG000|Overall Study|Switch to other CLL therapy|113
6159869|NCT01178086|9801360|FG000|Overall Study|Death|59
6159870|NCT01178086|9801360|FG000|Overall Study|Other unspecified|89
6159871|NCT01178086|9801360|FG000|Overall Study|Excluded from EAS|20
6159872|NCT01178099|9801370|FG000|Overall Study|Physician Decision|0
6159873|NCT01178099|9801371|FG001|Overall Study|Physician Decision|1
6159874|NCT01178125|9801381|FG000|Overall Study|Lost to Follow-up|397
6159875|NCT01178125|9801381|FG000|Overall Study|Adverse Event|244
6159876|NCT01178125|9801381|FG000|Overall Study|Withdrawal by Subject|209
6159877|NCT01178125|9801381|FG000|Overall Study|Noncompliance|184
6159878|NCT01178125|9801381|FG000|Overall Study|Pregnancy|55
6159879|NCT01178125|9801381|FG000|Overall Study|Other Reason|39
6159880|NCT01178125|9801381|FG000|Overall Study|Sponsor Decision|28
6159881|NCT01178125|9801381|FG000|Overall Study|Protocol Violation|17
6159882|NCT01178125|9801381|FG000|Overall Study|Investigator Decision|5
6159883|NCT01178138|9801390|FG000|Overall Study|Lost to Follow-up|8
6159884|NCT01178138|9801390|FG000|Overall Study|Withdrawal by Subject|7
6159885|NCT01178138|9801390|FG000|Overall Study|Physician Decision|8
6159886|NCT01178294|9801427|FG000|Overall Study|Adverse Event|4
6159887|NCT01178294|9801427|FG000|Overall Study|Lost to Follow-up|2
6159888|NCT01178294|9801427|FG000|Overall Study|Lack of Efficacy|1
6159889|NCT01178294|9801427|FG000|Overall Study|Death|1
6082151|NCT00626197|9689924|FG000|Overall Study|Administrative reasons|15
6082152|NCT00626197|9689925|FG001|Overall Study|Administrative reasons|19
6082153|NCT00626197|9689926|FG002|Overall Study|Administrative reasons|55
6082154|NCT00626275|9689944|FG000|Part A - Treatment Period 1|Adverse Event|1
6159890|NCT01178294|9801427|FG000|Overall Study|Development of inhibitors to OBI-1|1
6159891|NCT01178294|9801427|FG000|Overall Study|Subject status is terminal|1
6159892|NCT01178294|9801427|FG000|Overall Study|Completion status could not be verified|1
6159893|NCT01178385|9801448|FG000|Overall Study|Withdrawal by Subject|2
6159894|NCT01178385|9801449|FG001|Overall Study|Withdrawal by Subject|0
6159895|NCT01178411|9801455|FG000|Overall Study|Adverse Event|5
6159896|NCT01178411|9801455|FG000|Overall Study|Withdrawal by Subject|4
6159897|NCT01178411|9801455|FG000|Overall Study|Protocol Violation|1
6159898|NCT01178411|9801455|FG000|Overall Study|Progressive disease per RECIST|32
6159899|NCT01178411|9801455|FG000|Overall Study|Progressive disease per clinician|9
6159900|NCT01178411|9801455|FG000|Overall Study|Physician Decision|6
6159901|NCT01178411|9801455|FG000|Overall Study|Death|1
6159902|NCT01178411|9801455|FG000|Overall Study|No reason provided|1
6159903|NCT01178411|9801455|FG000|Overall Study|Drug manufacturing ended|1
6159904|NCT01178671|9801475|FG000|Overall Study|Adverse Event|4
6159905|NCT01178671|9801476|FG001|Overall Study|Adverse Event|6
6159906|NCT01178671|9801475|FG000|Overall Study|Protocol Violation|1
6082155|NCT00626275|9689945|FG001|Part A - Treatment Period 1|Adverse Event|0
6082156|NCT00626275|9689946|FG002|Part A - Treatment Period 1|Adverse Event|0
6082157|NCT00626275|9689947|FG003|Part A - Treatment Period 1|Adverse Event|0
6159907|NCT01178671|9801476|FG001|Overall Study|Protocol Violation|1
6159908|NCT01178671|9801475|FG000|Overall Study|Lack of Efficacy|0
6159909|NCT01178671|9801476|FG001|Overall Study|Lack of Efficacy|1
6159910|NCT01178671|9801475|FG000|Overall Study|Lost to Follow-up|3
6159911|NCT01178671|9801476|FG001|Overall Study|Lost to Follow-up|1
6159912|NCT01178671|9801475|FG000|Overall Study|Physician Decision|4
6082158|NCT00626275|9689948|FG004|Part A - Treatment Period 1|Adverse Event|0
6082159|NCT00626275|9689949|FG005|Part A - Treatment Period 1|Adverse Event|0
6082160|NCT00626275|9689950|FG006|Part A - Treatment Period 1|Adverse Event|0
6082161|NCT00626275|9689951|FG007|Part A - Treatment Period 1|Adverse Event|0
6082162|NCT00626275|9689944|FG000|Part A - Treatment Period 1|Withdrawal by Subject|0
6082163|NCT00626275|9689945|FG001|Part A - Treatment Period 1|Withdrawal by Subject|0
6082164|NCT00626275|9689946|FG002|Part A - Treatment Period 1|Withdrawal by Subject|1
6159913|NCT01178671|9801476|FG001|Overall Study|Physician Decision|6
6159914|NCT01178762|9801482|FG000|Overall Study|Lost to Follow-up|15
6159915|NCT01178853|9801501|FG000|Period 1 (Warfarin Titration)|INR Out of Range|1
6159916|NCT01178853|9801502|FG001|Period 1 (Warfarin Titration)|INR Out of Range|2
6159917|NCT01178853|9801501|FG000|Period 2 (Warfarin + Study Drug)|Withdrawal by Subject|1
6159918|NCT01178853|9801502|FG001|Period 2 (Warfarin + Study Drug)|Withdrawal by Subject|0
6159919|NCT01178853|9801501|FG000|Period 3 (Warfarin Titration)|Adverse Event|1
6159920|NCT01178853|9801502|FG001|Period 3 (Warfarin Titration)|Adverse Event|0
6159921|NCT01178853|9801501|FG000|Period 4 (Warfarin + Study Drug)|Adverse Event|0
6159922|NCT01178853|9801502|FG001|Period 4 (Warfarin + Study Drug)|Adverse Event|2
6159923|NCT01178853|9801501|FG000|Period 4 (Warfarin + Study Drug)|Withdrawal by Subject|0
6159924|NCT01178853|9801502|FG001|Period 4 (Warfarin + Study Drug)|Withdrawal by Subject|1
6159925|NCT01179048|9801514|FG000|Overall Study|Withdrawn - does not allow contact|4
6159926|NCT01179048|9801515|FG001|Overall Study|Withdrawn - does not allow contact|8
6159927|NCT01179048|9801514|FG000|Overall Study|Lost to Follow-up|8
6159928|NCT01179048|9801515|FG001|Overall Study|Lost to Follow-up|9
6159929|NCT01179048|9801514|FG000|Overall Study|Alive|127
6159930|NCT01179048|9801515|FG001|Overall Study|Alive|142
6159931|NCT01179191|9801530|FG000|Titration Phase (up to 6 Weeks)|Adverse Event|47
6159932|NCT01179191|9801530|FG000|Titration Phase (up to 6 Weeks)|Lost to Follow-up|19
6159933|NCT01179191|9801530|FG000|Titration Phase (up to 6 Weeks)|Physician Decision|30
6159934|NCT01179191|9801530|FG000|Titration Phase (up to 6 Weeks)|Withdrawal by Subject|162
6159935|NCT01179191|9801530|FG000|Titration Phase (up to 6 Weeks)|Participant did not reach stable dose|13
6159936|NCT01179191|9801530|FG000|Titration Phase (up to 6 Weeks)|Other|62
6159937|NCT01179191|9801530|FG000|Maintenance Phase (8 Weeks)|Adverse Event|10
6159938|NCT01179191|9801530|FG000|Maintenance Phase (8 Weeks)|Lost to Follow-up|9
6159939|NCT01179191|9801530|FG000|Maintenance Phase (8 Weeks)|Physician Decision|3
6159940|NCT01179191|9801530|FG000|Maintenance Phase (8 Weeks)|Withdrawal by Subject|29
6159941|NCT01179191|9801530|FG000|Maintenance Phase (8 Weeks)|Other|66
6159942|NCT01179334|9801547|FG000|Treatment Period|Adverse Event|1
6159943|NCT01179334|9801548|FG001|Treatment Period|Adverse Event|0
6159944|NCT01179334|9801547|FG000|Long-term Extension (LTE) Period|Study terminated by sponsor|6
6159945|NCT01179334|9801548|FG001|Long-term Extension (LTE) Period|Study terminated by sponsor|2
6159946|NCT01179334|9801547|FG000|Long-term Extension (LTE) Period|Death|3
6159947|NCT01179334|9801548|FG001|Long-term Extension (LTE) Period|Death|0
6159948|NCT01179334|9801547|FG000|Long-term Extension (LTE) Period|Adverse Event|2
6159949|NCT01179334|9801548|FG001|Long-term Extension (LTE) Period|Adverse Event|4
6159950|NCT01179347|9801556|FG000|Double-blind Period (12 Weeks)|Adverse Event|2
6159951|NCT01179347|9801557|FG001|Double-blind Period (12 Weeks)|Adverse Event|6
6159952|NCT01179347|9801556|FG000|Double-blind Period (12 Weeks)|Protocol Violation|2
6159953|NCT01179347|9801557|FG001|Double-blind Period (12 Weeks)|Protocol Violation|0
6159954|NCT01179347|9801556|FG000|Double-blind Period (12 Weeks)|Lost to Follow-up|1
6159955|NCT01179347|9801557|FG001|Double-blind Period (12 Weeks)|Lost to Follow-up|2
6159956|NCT01179347|9801556|FG000|Double-blind Period (12 Weeks)|Withdrawal by Subject|1
6159957|NCT01179347|9801557|FG001|Double-blind Period (12 Weeks)|Withdrawal by Subject|2
6159958|NCT01179347|9801556|FG000|Double-blind Period (12 Weeks)|Other|2
6159959|NCT01179347|9801557|FG001|Double-blind Period (12 Weeks)|Other|4
6159960|NCT01179347|9801556|FG000|Open-label Period (12 Weeks)|Adverse Event|5
6159961|NCT01179347|9801557|FG001|Open-label Period (12 Weeks)|Adverse Event|9
6159962|NCT01179347|9801556|FG000|Open-label Period (12 Weeks)|Lack of Efficacy|0
6159963|NCT01179347|9801557|FG001|Open-label Period (12 Weeks)|Lack of Efficacy|2
6159964|NCT01179347|9801556|FG000|Open-label Period (12 Weeks)|Lost to Follow-up|1
6159965|NCT01179347|9801557|FG001|Open-label Period (12 Weeks)|Lost to Follow-up|0
6159966|NCT01179347|9801556|FG000|Open-label Period (12 Weeks)|Withdrawal by Subject|1
6159967|NCT01179347|9801557|FG001|Open-label Period (12 Weeks)|Withdrawal by Subject|1
6159968|NCT01179347|9801556|FG000|Open-label Period (12 Weeks)|Protocol Violation|1
6159969|NCT01179347|9801557|FG001|Open-label Period (12 Weeks)|Protocol Violation|0
6159970|NCT01179347|9801556|FG000|Open-label Period (12 Weeks)|Other|7
6159971|NCT01179347|9801557|FG001|Open-label Period (12 Weeks)|Other|4
6159972|NCT01179477|9801565|FG000|Overall Study|Death|542
6159973|NCT01179477|9801565|FG000|Overall Study|Unsuccessful implant|80
6159974|NCT01179477|9801565|FG000|Overall Study|Non-death withdrawal|438
6159975|NCT01179477|9801565|FG000|Overall Study|Did not complete final visit|27
6324973|NCT02924688|10067079|FG002|Overall Study|Adverse Event|2
6324974|NCT02924688|10067080|FG003|Overall Study|Adverse Event|2
6324975|NCT02924688|10067081|FG004|Overall Study|Adverse Event|3
6324976|NCT02924688|10067082|FG005|Overall Study|Adverse Event|2
6324977|NCT02924688|10067077|FG000|Overall Study|Lack of Efficacy|2
6324978|NCT02924688|10067078|FG001|Overall Study|Lack of Efficacy|3
6324979|NCT02924688|10067079|FG002|Overall Study|Lack of Efficacy|4
6324980|NCT02924688|10067080|FG003|Overall Study|Lack of Efficacy|2
6324981|NCT02924688|10067081|FG004|Overall Study|Lack of Efficacy|1
6324982|NCT02924688|10067082|FG005|Overall Study|Lack of Efficacy|1
6324983|NCT02924688|10067077|FG000|Overall Study|Protocol Violation|3
6159976|NCT01179516|9801576|FG000|Overall Study|Pretreatment Event or Adverse Event|6
6159977|NCT01179516|9801577|FG001|Overall Study|Pretreatment Event or Adverse Event|8
6159978|NCT01179516|9801578|FG002|Overall Study|Pretreatment Event or Adverse Event|12
6159979|NCT01179516|9801576|FG000|Overall Study|Lack of Efficacy|4
6159980|NCT01179516|9801577|FG001|Overall Study|Lack of Efficacy|2
6159981|NCT01179516|9801578|FG002|Overall Study|Lack of Efficacy|0
6159982|NCT01179516|9801576|FG000|Overall Study|Noncompliance with Study Drug|2
6159983|NCT01179516|9801577|FG001|Overall Study|Noncompliance with Study Drug|0
6159984|NCT01179516|9801578|FG002|Overall Study|Noncompliance with Study Drug|1
6159985|NCT01179516|9801576|FG000|Overall Study|Protocol Deviations|4
6159986|NCT01179516|9801577|FG001|Overall Study|Protocol Deviations|3
6159987|NCT01179516|9801578|FG002|Overall Study|Protocol Deviations|3
6159988|NCT01179516|9801576|FG000|Overall Study|Withdrawal of Consent|2
6159989|NCT01179516|9801577|FG001|Overall Study|Withdrawal of Consent|6
6159990|NCT01179516|9801578|FG002|Overall Study|Withdrawal of Consent|10
6159991|NCT01179516|9801576|FG000|Overall Study|Lost to Follow-up|7
6159992|NCT01179516|9801577|FG001|Overall Study|Lost to Follow-up|7
6159993|NCT01179516|9801578|FG002|Overall Study|Lost to Follow-up|3
6159994|NCT01179516|9801576|FG000|Overall Study|Other|2
6159995|NCT01179516|9801577|FG001|Overall Study|Other|0
6159996|NCT01179516|9801578|FG002|Overall Study|Other|2
6159997|NCT01179672|9801608|FG000|Overall Study|Adverse Event|17
6159998|NCT01179672|9801609|FG001|Overall Study|Adverse Event|8
6159999|NCT01179672|9801608|FG000|Overall Study|Withdrawal by Subject|10
6160000|NCT01179672|9801609|FG001|Overall Study|Withdrawal by Subject|12
6160001|NCT01179672|9801608|FG000|Overall Study|Entry Criteria Not Met|0
6160002|NCT01179672|9801609|FG001|Overall Study|Entry Criteria Not Met|2
6160003|NCT01179672|9801608|FG000|Overall Study|Lost to Follow-up|0
6160004|NCT01179672|9801609|FG001|Overall Study|Lost to Follow-up|1
6160005|NCT01179672|9801608|FG000|Overall Study|Protocol Violation|2
6160006|NCT01179672|9801609|FG001|Overall Study|Protocol Violation|2
6324984|NCT02924688|10067078|FG001|Overall Study|Protocol Violation|7
6324985|NCT02924688|10067079|FG002|Overall Study|Protocol Violation|5
6324986|NCT02924688|10067080|FG003|Overall Study|Protocol Violation|6
6324987|NCT02924688|10067081|FG004|Overall Study|Protocol Violation|2
6324988|NCT02924688|10067082|FG005|Overall Study|Protocol Violation|2
6324989|NCT02924688|10067077|FG000|Overall Study|Protocol defined withdrawal criteria met|1
6324990|NCT02924688|10067078|FG001|Overall Study|Protocol defined withdrawal criteria met|0
6160007|NCT01179672|9801608|FG000|Overall Study|Physician Decision|1
6160008|NCT01179672|9801609|FG001|Overall Study|Physician Decision|1
6324991|NCT02924688|10067079|FG002|Overall Study|Protocol defined withdrawal criteria met|1
6160009|NCT01179919|9801619|FG000|Overall Study|Protocol Violation|1
6160010|NCT01179919|9801619|FG000|Overall Study|Adverse Event|1
6160011|NCT01180049|9801641|FG000|Overall Study|Other|9
6160012|NCT01180049|9801642|FG001|Overall Study|Other|7
6160013|NCT01180049|9801641|FG000|Overall Study|Lost to Follow-up|8
6160014|NCT01180049|9801642|FG001|Overall Study|Lost to Follow-up|6
6160015|NCT01180049|9801641|FG000|Overall Study|Death|36
6160016|NCT01180049|9801642|FG001|Overall Study|Death|35
6160017|NCT01180244|9801671|FG000|Overall Study|Lack of Efficacy|0
6160018|NCT01180244|9801672|FG001|Overall Study|Lack of Efficacy|7
6160019|NCT01180244|9801671|FG000|Overall Study|Physician Decision|3
6160020|NCT01180244|9801672|FG001|Overall Study|Physician Decision|0
6160021|NCT01180244|9801671|FG000|Overall Study|Adverse Event|1
6160022|NCT01180244|9801672|FG001|Overall Study|Adverse Event|0
6160023|NCT01180244|9801671|FG000|Overall Study|Withdrawal by Subject|0
6160024|NCT01180244|9801672|FG001|Overall Study|Withdrawal by Subject|1
6160025|NCT01180244|9801671|FG000|Overall Study|Protocol Violation|1
6160026|NCT01180244|9801672|FG001|Overall Study|Protocol Violation|0
6160027|NCT01180244|9801671|FG000|Overall Study|Lost to Follow-up|1
6160028|NCT01180244|9801672|FG001|Overall Study|Lost to Follow-up|0
6160029|NCT01180296|9801680|FG000|Overall Study|Protocol Violation|1
6160030|NCT01180296|9801681|FG001|Overall Study|Protocol Violation|2
6160031|NCT01180400|9801691|FG000|Overall Study|Withdrawal by Subject|5
6160032|NCT01180400|9801692|FG001|Overall Study|Withdrawal by Subject|6
6160033|NCT01180400|9801691|FG000|Overall Study|Eligibility criteria not fulfilled|0
6160034|NCT01180400|9801692|FG001|Overall Study|Eligibility criteria not fulfilled|2
6227414|NCT01716754|9900111|FG003|Overall Study|Adverse Event|1
6324992|NCT02924688|10067080|FG003|Overall Study|Protocol defined withdrawal criteria met|1
6324993|NCT02924688|10067081|FG004|Overall Study|Protocol defined withdrawal criteria met|1
6324994|NCT02924688|10067082|FG005|Overall Study|Protocol defined withdrawal criteria met|0
6324995|NCT02924688|10067077|FG000|Overall Study|Lost to Follow-up|2
6324996|NCT02924688|10067078|FG001|Overall Study|Lost to Follow-up|4
6324997|NCT02924688|10067079|FG002|Overall Study|Lost to Follow-up|2
6324998|NCT02924688|10067080|FG003|Overall Study|Lost to Follow-up|4
6324999|NCT02924688|10067081|FG004|Overall Study|Lost to Follow-up|2
6325000|NCT02924688|10067082|FG005|Overall Study|Lost to Follow-up|4
6325001|NCT02924688|10067077|FG000|Overall Study|Physician Decision|2
6325002|NCT02924688|10067078|FG001|Overall Study|Physician Decision|1
6325003|NCT02924688|10067079|FG002|Overall Study|Physician Decision|0
6325004|NCT02924688|10067080|FG003|Overall Study|Physician Decision|1
6325005|NCT02924688|10067081|FG004|Overall Study|Physician Decision|1
6325006|NCT02924688|10067082|FG005|Overall Study|Physician Decision|1
6325007|NCT02924688|10067077|FG000|Overall Study|Withdrawal by Subject|14
6325008|NCT02924688|10067078|FG001|Overall Study|Withdrawal by Subject|13
6325009|NCT02924688|10067079|FG002|Overall Study|Withdrawal by Subject|9
6325010|NCT02924688|10067080|FG003|Overall Study|Withdrawal by Subject|12
6325011|NCT02924688|10067081|FG004|Overall Study|Withdrawal by Subject|13
6325012|NCT02924688|10067082|FG005|Overall Study|Withdrawal by Subject|14
6325013|NCT02924883|10067101|FG000|Overall Study|Death|39
6325014|NCT02924883|10067102|FG001|Overall Study|Death|20
6325015|NCT02924883|10067101|FG000|Overall Study|Lost to Follow-up|1
6325016|NCT02924883|10067102|FG001|Overall Study|Lost to Follow-up|0
6325017|NCT02924883|10067101|FG000|Overall Study|Symptomatic Deterioration/ Clinical Progression|0
6325018|NCT02924883|10067102|FG001|Overall Study|Symptomatic Deterioration/ Clinical Progression|1
6325019|NCT02924883|10067101|FG000|Overall Study|Protocol Violation|1
6325020|NCT02924883|10067102|FG001|Overall Study|Protocol Violation|0
6325021|NCT02924883|10067101|FG000|Overall Study|Withdrawal by Subject|22
6325022|NCT02924883|10067102|FG001|Overall Study|Withdrawal by Subject|16
6082165|NCT00626275|9689947|FG003|Part A - Treatment Period 1|Withdrawal by Subject|0
6082166|NCT00626275|9689948|FG004|Part A - Treatment Period 1|Withdrawal by Subject|0
6082167|NCT00626275|9689949|FG005|Part A - Treatment Period 1|Withdrawal by Subject|0
6082168|NCT00626275|9689950|FG006|Part A - Treatment Period 1|Withdrawal by Subject|0
6082169|NCT00626275|9689951|FG007|Part A - Treatment Period 1|Withdrawal by Subject|0
6160035|NCT01180400|9801691|FG000|Overall Study|Adverse Event|12
6082170|NCT00626275|9689944|FG000|Part B|Lost to Follow-up|0
6082171|NCT00626275|9689945|FG001|Part B|Lost to Follow-up|0
6160036|NCT01180400|9801692|FG001|Overall Study|Adverse Event|10
6160037|NCT01180400|9801691|FG000|Overall Study|Severe non-compliance to protocol|1
6160038|NCT01180400|9801692|FG001|Overall Study|Severe non-compliance to protocol|2
6160039|NCT01180400|9801691|FG000|Overall Study|Condition under investigation worsened|2
6160040|NCT01180400|9801692|FG001|Overall Study|Condition under investigation worsened|1
6160041|NCT01180400|9801691|FG000|Overall Study|Lack of Efficacy|2
6082172|NCT00626275|9689946|FG002|Part B|Lost to Follow-up|0
6082173|NCT00626275|9689947|FG003|Part B|Lost to Follow-up|0
6160042|NCT01180400|9801692|FG001|Overall Study|Lack of Efficacy|0
6160043|NCT01180400|9801691|FG000|Overall Study|Study-specific withdrawal criteria|1
6160044|NCT01180400|9801692|FG001|Overall Study|Study-specific withdrawal criteria|2
6160045|NCT01180400|9801691|FG000|Overall Study|Lost to Follow-up|2
6160046|NCT01180400|9801692|FG001|Overall Study|Lost to Follow-up|3
6160047|NCT01180400|9801691|FG000|Overall Study|Other|0
6160048|NCT01180400|9801692|FG001|Overall Study|Other|1
6160049|NCT01180647|9801711|FG000|Overall Study|Lost to Follow-up|5
6160050|NCT01180647|9801712|FG001|Overall Study|Lost to Follow-up|6
6160051|NCT01180660|9801720|FG000|Overall Study|Changed to open surgery|1
6160052|NCT01180660|9801721|FG001|Overall Study|Changed to open surgery|0
6160053|NCT01180777|9801727|FG000|Overall Study|Protocol Violation|6
6160054|NCT01180777|9801727|FG000|Overall Study|Poor lens fit|4
6160055|NCT01180777|9801727|FG000|Overall Study|Lost to Follow-up|1
6160056|NCT01180777|9801727|FG000|Overall Study|Adverse Event|1
6160057|NCT01180790|9801740|FG000|Overall Study|Adverse Event|1
6160058|NCT01180790|9801741|FG001|Overall Study|Adverse Event|1
6160059|NCT01180790|9801742|FG002|Overall Study|Adverse Event|2
6160060|NCT01180790|9801743|FG003|Overall Study|Adverse Event|0
6160061|NCT01180790|9801744|FG004|Overall Study|Adverse Event|1
6160062|NCT01180790|9801745|FG005|Overall Study|Adverse Event|3
6160063|NCT01180790|9801746|FG006|Overall Study|Adverse Event|0
6160064|NCT01180790|9801740|FG000|Overall Study|Withdrawal by Subject|3
6160065|NCT01180790|9801741|FG001|Overall Study|Withdrawal by Subject|0
6160066|NCT01180790|9801742|FG002|Overall Study|Withdrawal by Subject|5
6160067|NCT01180790|9801743|FG003|Overall Study|Withdrawal by Subject|0
6160068|NCT01180790|9801744|FG004|Overall Study|Withdrawal by Subject|2
6325023|NCT02924883|10067101|FG000|Overall Study|Progressive Disease|1
6325024|NCT02924883|10067102|FG001|Overall Study|Progressive Disease|0
6325025|NCT02924883|10067101|FG000|Overall Study|Study Terminated by Sponsor|69
6325026|NCT02924883|10067102|FG001|Overall Study|Study Terminated by Sponsor|32
6160069|NCT01180790|9801745|FG005|Overall Study|Withdrawal by Subject|1
6325027|NCT02925117|10067123|FG000|Period 1 (Weeks 0 - 16)|Adverse Event|1
6325028|NCT02925117|10067124|FG001|Period 1 (Weeks 0 - 16)|Adverse Event|3
6325029|NCT02925117|10067125|FG002|Period 1 (Weeks 0 - 16)|Adverse Event|1
6325030|NCT02925117|10067126|FG003|Period 1 (Weeks 0 - 16)|Adverse Event|2
6325031|NCT02925117|10067127|FG004|Period 1 (Weeks 0 - 16)|Adverse Event|0
6325032|NCT02925117|10067128|FG005|Period 1 (Weeks 0 - 16)|Adverse Event|0
6325033|NCT02925117|10067129|FG006|Period 1 (Weeks 0 - 16)|Adverse Event|0
6325034|NCT02925117|10067130|FG007|Period 1 (Weeks 0 - 16)|Adverse Event|0
6325035|NCT02925117|10067131|FG008|Period 1 (Weeks 0 - 16)|Adverse Event|0
6325036|NCT02925117|10067132|FG009|Period 1 (Weeks 0 - 16)|Adverse Event|0
6325037|NCT02925117|10067133|FG010|Period 1 (Weeks 0 - 16)|Adverse Event|0
6325038|NCT02925117|10067134|FG011|Period 1 (Weeks 0 - 16)|Adverse Event|0
6325039|NCT02925117|10067123|FG000|Period 1 (Weeks 0 - 16)|Withdrawal by Subject|10
6325040|NCT02925117|10067124|FG001|Period 1 (Weeks 0 - 16)|Withdrawal by Subject|3
6325041|NCT02925117|10067125|FG002|Period 1 (Weeks 0 - 16)|Withdrawal by Subject|3
6325042|NCT02925117|10067126|FG003|Period 1 (Weeks 0 - 16)|Withdrawal by Subject|0
6325043|NCT02925117|10067127|FG004|Period 1 (Weeks 0 - 16)|Withdrawal by Subject|0
6325044|NCT02925117|10067128|FG005|Period 1 (Weeks 0 - 16)|Withdrawal by Subject|0
6325045|NCT02925117|10067129|FG006|Period 1 (Weeks 0 - 16)|Withdrawal by Subject|0
6325046|NCT02925117|10067130|FG007|Period 1 (Weeks 0 - 16)|Withdrawal by Subject|0
6325047|NCT02925117|10067131|FG008|Period 1 (Weeks 0 - 16)|Withdrawal by Subject|0
6325048|NCT02925117|10067132|FG009|Period 1 (Weeks 0 - 16)|Withdrawal by Subject|0
6160070|NCT01180790|9801746|FG006|Overall Study|Withdrawal by Subject|0
6160071|NCT01180790|9801740|FG000|Overall Study|Lost to Follow-up|3
6160072|NCT01180790|9801741|FG001|Overall Study|Lost to Follow-up|1
6160073|NCT01180790|9801742|FG002|Overall Study|Lost to Follow-up|0
6160074|NCT01180790|9801743|FG003|Overall Study|Lost to Follow-up|2
6160075|NCT01180790|9801744|FG004|Overall Study|Lost to Follow-up|1
6325049|NCT02925117|10067133|FG010|Period 1 (Weeks 0 - 16)|Withdrawal by Subject|0
6325050|NCT02925117|10067134|FG011|Period 1 (Weeks 0 - 16)|Withdrawal by Subject|0
6325051|NCT02925117|10067123|FG000|Period 1 (Weeks 0 - 16)|Lost to Follow-up|2
6325052|NCT02925117|10067124|FG001|Period 1 (Weeks 0 - 16)|Lost to Follow-up|1
6325053|NCT02925117|10067125|FG002|Period 1 (Weeks 0 - 16)|Lost to Follow-up|0
6325054|NCT02925117|10067126|FG003|Period 1 (Weeks 0 - 16)|Lost to Follow-up|0
6325055|NCT02925117|10067127|FG004|Period 1 (Weeks 0 - 16)|Lost to Follow-up|0
6325056|NCT02925117|10067128|FG005|Period 1 (Weeks 0 - 16)|Lost to Follow-up|0
6160076|NCT01180790|9801745|FG005|Overall Study|Lost to Follow-up|0
6160077|NCT01180790|9801746|FG006|Overall Study|Lost to Follow-up|1
6160078|NCT01180790|9801740|FG000|Overall Study|Physician Decision|1
6160079|NCT01180790|9801741|FG001|Overall Study|Physician Decision|0
6160080|NCT01180790|9801742|FG002|Overall Study|Physician Decision|0
6160081|NCT01180790|9801743|FG003|Overall Study|Physician Decision|1
6160082|NCT01180790|9801744|FG004|Overall Study|Physician Decision|0
6160083|NCT01180790|9801745|FG005|Overall Study|Physician Decision|0
6160084|NCT01180790|9801746|FG006|Overall Study|Physician Decision|0
6227415|NCT01716754|9900108|FG000|Overall Study|Withdrawal by Subject|5
6325057|NCT02925117|10067129|FG006|Period 1 (Weeks 0 - 16)|Lost to Follow-up|0
6160085|NCT01180790|9801740|FG000|Overall Study|Lack of Efficacy|1
6082174|NCT00626275|9689948|FG004|Part B|Lost to Follow-up|0
6082175|NCT00626275|9689949|FG005|Part B|Lost to Follow-up|0
6082176|NCT00626275|9689950|FG006|Part B|Lost to Follow-up|1
6160086|NCT01180790|9801741|FG001|Overall Study|Lack of Efficacy|2
6160087|NCT01180790|9801742|FG002|Overall Study|Lack of Efficacy|5
6160088|NCT01180790|9801743|FG003|Overall Study|Lack of Efficacy|6
6160089|NCT01180790|9801744|FG004|Overall Study|Lack of Efficacy|1
6160090|NCT01180790|9801745|FG005|Overall Study|Lack of Efficacy|3
6160091|NCT01180790|9801746|FG006|Overall Study|Lack of Efficacy|0
6160092|NCT01180790|9801740|FG000|Overall Study|compliance|0
6160093|NCT01180790|9801741|FG001|Overall Study|compliance|1
6160094|NCT01180790|9801742|FG002|Overall Study|compliance|0
6160095|NCT01180790|9801743|FG003|Overall Study|compliance|0
6160096|NCT01180790|9801744|FG004|Overall Study|compliance|0
6160097|NCT01180790|9801745|FG005|Overall Study|compliance|0
6160098|NCT01180790|9801746|FG006|Overall Study|compliance|0
6160099|NCT01180790|9801740|FG000|Overall Study|Severe coronary atherosclerosis (death)|0
6082177|NCT00626275|9689951|FG007|Part B|Lost to Follow-up|0
6082178|NCT00626275|9689944|FG000|Part B|Withdrawal by Subject|0
6082179|NCT00626275|9689945|FG001|Part B|Withdrawal by Subject|0
6082180|NCT00626275|9689946|FG002|Part B|Withdrawal by Subject|0
6082181|NCT00626275|9689947|FG003|Part B|Withdrawal by Subject|0
6160100|NCT01180790|9801741|FG001|Overall Study|Severe coronary atherosclerosis (death)|0
6160101|NCT01180790|9801742|FG002|Overall Study|Severe coronary atherosclerosis (death)|1
6160102|NCT01180790|9801743|FG003|Overall Study|Severe coronary atherosclerosis (death)|0
6160103|NCT01180790|9801744|FG004|Overall Study|Severe coronary atherosclerosis (death)|0
6160104|NCT01180790|9801745|FG005|Overall Study|Severe coronary atherosclerosis (death)|0
6160105|NCT01180790|9801746|FG006|Overall Study|Severe coronary atherosclerosis (death)|0
6160106|NCT01180985|9801801|FG000|Period 2 (7 +/- 1 Days)|Lost to Follow-up|1
6160107|NCT01180985|9801802|FG001|Period 2 (7 +/- 1 Days)|Lost to Follow-up|0
6160108|NCT01180998|9801812|FG000|Overall Study|Poor Vision|0
6160109|NCT01180998|9801813|FG001|Overall Study|Poor Vision|2
6160110|NCT01180998|9801814|FG002|Overall Study|Poor Vision|2
6160111|NCT01180998|9801812|FG000|Overall Study|Lost to Follow-up|0
6160112|NCT01180998|9801813|FG001|Overall Study|Lost to Follow-up|0
6160113|NCT01180998|9801814|FG002|Overall Study|Lost to Follow-up|1
6160114|NCT01180998|9801812|FG000|Overall Study|Protocol Violation|1
6160115|NCT01180998|9801813|FG001|Overall Study|Protocol Violation|2
6160116|NCT01180998|9801814|FG002|Overall Study|Protocol Violation|0
6160117|NCT01180998|9801812|FG000|Overall Study|Withdrawal by Subject|0
6160118|NCT01180998|9801813|FG001|Overall Study|Withdrawal by Subject|0
6160119|NCT01180998|9801814|FG002|Overall Study|Withdrawal by Subject|1
6160120|NCT01180998|9801812|FG000|Overall Study|Poor comfort|3
6160121|NCT01180998|9801813|FG001|Overall Study|Poor comfort|0
6160122|NCT01180998|9801814|FG002|Overall Study|Poor comfort|4
6160123|NCT01180998|9801812|FG000|Overall Study|Poor lens handling|0
6160124|NCT01180998|9801813|FG001|Overall Study|Poor lens handling|0
6160125|NCT01180998|9801814|FG002|Overall Study|Poor lens handling|2
6160126|NCT01181011|9801823|FG000|Overall Study|Adverse Event|2
6160127|NCT01181011|9801823|FG000|Overall Study|Lost to Follow-up|1
6160128|NCT01181102|9801852|FG000|Overall Study|Adverse Event|28
6160129|NCT01181102|9801853|FG001|Overall Study|Adverse Event|26
6160130|NCT01181102|9801852|FG000|Overall Study|Lack of Efficacy|3
6160131|NCT01181102|9801853|FG001|Overall Study|Lack of Efficacy|1
6160132|NCT01181102|9801852|FG000|Overall Study|Lost to Follow-up|2
6160133|NCT01181102|9801853|FG001|Overall Study|Lost to Follow-up|0
6160134|NCT01181102|9801852|FG000|Overall Study|Physician Decision|3
6160135|NCT01181102|9801853|FG001|Overall Study|Physician Decision|1
6160136|NCT01181102|9801852|FG000|Overall Study|Protocol Violation|5
6160137|NCT01181102|9801853|FG001|Overall Study|Protocol Violation|6
6160138|NCT01181102|9801852|FG000|Overall Study|Withdrawal by Subject|10
6160139|NCT01181102|9801853|FG001|Overall Study|Withdrawal by Subject|12
6191817|NCT01425814|9848749|FG002|Period 3|Adverse Event|0
6191818|NCT01425814|9848750|FG003|Period 3|Adverse Event|0
6191819|NCT01425814|9848751|FG004|Period 3|Adverse Event|0
6191820|NCT01425814|9848752|FG005|Period 3|Adverse Event|1
6191821|NCT01425814|9848747|FG000|Period 4|Adverse Event|1
6191822|NCT01425814|9848748|FG001|Period 4|Adverse Event|0
6191823|NCT01425814|9848749|FG002|Period 4|Adverse Event|1
6082182|NCT00626275|9689948|FG004|Part B|Withdrawal by Subject|0
6082183|NCT00626275|9689949|FG005|Part B|Withdrawal by Subject|0
6082184|NCT00626275|9689950|FG006|Part B|Withdrawal by Subject|0
6082185|NCT00626275|9689951|FG007|Part B|Withdrawal by Subject|1
6082186|NCT00626327|9689968|FG000|Overall Study|Withdrawal by Subject|21
6191824|NCT01425814|9848750|FG003|Period 4|Adverse Event|0
6191825|NCT01425814|9848751|FG004|Period 4|Adverse Event|0
6082187|NCT00626327|9689969|FG001|Overall Study|Withdrawal by Subject|29
6082188|NCT00626327|9689970|FG002|Overall Study|Withdrawal by Subject|30
6082189|NCT00626327|9689968|FG000|Overall Study|Adverse Event|1
6082190|NCT00626327|9689969|FG001|Overall Study|Adverse Event|0
6082191|NCT00626327|9689970|FG002|Overall Study|Adverse Event|0
6082192|NCT00626327|9689968|FG000|Overall Study|Lost to Follow-up|24
6082193|NCT00626327|9689969|FG001|Overall Study|Lost to Follow-up|21
6160140|NCT01181128|9801862|FG000|Overall Study|Withdrawal by Subject|2
6160141|NCT01181128|9801863|FG001|Overall Study|Withdrawal by Subject|2
6160142|NCT01181128|9801864|FG002|Overall Study|Withdrawal by Subject|0
6160143|NCT01181128|9801862|FG000|Overall Study|Death|1
6160144|NCT01181128|9801863|FG001|Overall Study|Death|0
6160145|NCT01181128|9801864|FG002|Overall Study|Death|0
6160146|NCT01181128|9801862|FG000|Overall Study|Physician Decision|2
6160147|NCT01181128|9801863|FG001|Overall Study|Physician Decision|0
6160148|NCT01181128|9801864|FG002|Overall Study|Physician Decision|0
6160149|NCT01181128|9801862|FG000|Overall Study|Adverse Event|0
6160150|NCT01181128|9801863|FG001|Overall Study|Adverse Event|2
6160151|NCT01181128|9801864|FG002|Overall Study|Adverse Event|0
6160152|NCT01181128|9801862|FG000|Overall Study|Other|1
6160153|NCT01181128|9801863|FG001|Overall Study|Other|1
6160154|NCT01181128|9801864|FG002|Overall Study|Other|1
6160155|NCT01181141|9801886|FG000|Overall Study|Adverse Event|2
6160156|NCT01181141|9801887|FG001|Overall Study|Adverse Event|1
6160157|NCT01181141|9801886|FG000|Overall Study|Lack of Efficacy|1
6160158|NCT01181141|9801887|FG001|Overall Study|Lack of Efficacy|0
6160159|NCT01181141|9801886|FG000|Overall Study|Lost to Follow-up|1
6160160|NCT01181141|9801887|FG001|Overall Study|Lost to Follow-up|1
6160161|NCT01181141|9801886|FG000|Overall Study|Physician Decision|2
6160162|NCT01181141|9801887|FG001|Overall Study|Physician Decision|0
6325058|NCT02925117|10067130|FG007|Period 1 (Weeks 0 - 16)|Lost to Follow-up|0
6325059|NCT02925117|10067131|FG008|Period 1 (Weeks 0 - 16)|Lost to Follow-up|0
6325060|NCT02925117|10067132|FG009|Period 1 (Weeks 0 - 16)|Lost to Follow-up|0
6325061|NCT02925117|10067133|FG010|Period 1 (Weeks 0 - 16)|Lost to Follow-up|0
6325062|NCT02925117|10067134|FG011|Period 1 (Weeks 0 - 16)|Lost to Follow-up|0
6325063|NCT02925117|10067123|FG000|Period 1 (Weeks 0 - 16)|Other|5
6325064|NCT02925117|10067124|FG001|Period 1 (Weeks 0 - 16)|Other|4
6325065|NCT02925117|10067125|FG002|Period 1 (Weeks 0 - 16)|Other|1
6325066|NCT02925117|10067126|FG003|Period 1 (Weeks 0 - 16)|Other|1
6325067|NCT02925117|10067127|FG004|Period 1 (Weeks 0 - 16)|Other|0
6325068|NCT02925117|10067128|FG005|Period 1 (Weeks 0 - 16)|Other|0
6325069|NCT02925117|10067129|FG006|Period 1 (Weeks 0 - 16)|Other|0
6325070|NCT02925117|10067130|FG007|Period 1 (Weeks 0 - 16)|Other|0
6325071|NCT02925117|10067131|FG008|Period 1 (Weeks 0 - 16)|Other|0
6325072|NCT02925117|10067132|FG009|Period 1 (Weeks 0 - 16)|Other|0
6325073|NCT02925117|10067133|FG010|Period 1 (Weeks 0 - 16)|Other|0
6325074|NCT02925117|10067134|FG011|Period 1 (Weeks 0 - 16)|Other|0
6325075|NCT02925117|10067123|FG000|Period 2 (Weeks 16 - 88)|Adverse Event|0
6325076|NCT02925117|10067124|FG001|Period 2 (Weeks 16 - 88)|Adverse Event|0
6325077|NCT02925117|10067125|FG002|Period 2 (Weeks 16 - 88)|Adverse Event|0
6325078|NCT02925117|10067126|FG003|Period 2 (Weeks 16 - 88)|Adverse Event|0
6325079|NCT02925117|10067127|FG004|Period 2 (Weeks 16 - 88)|Adverse Event|0
6325080|NCT02925117|10067128|FG005|Period 2 (Weeks 16 - 88)|Adverse Event|1
6325081|NCT02925117|10067129|FG006|Period 2 (Weeks 16 - 88)|Adverse Event|0
6325082|NCT02925117|10067130|FG007|Period 2 (Weeks 16 - 88)|Adverse Event|0
6325083|NCT02925117|10067131|FG008|Period 2 (Weeks 16 - 88)|Adverse Event|0
6325084|NCT02925117|10067132|FG009|Period 2 (Weeks 16 - 88)|Adverse Event|0
6325085|NCT02925117|10067133|FG010|Period 2 (Weeks 16 - 88)|Adverse Event|3
6325086|NCT02925117|10067134|FG011|Period 2 (Weeks 16 - 88)|Adverse Event|2
6325087|NCT02925117|10067123|FG000|Period 2 (Weeks 16 - 88)|Withdrawal by Subject|0
6325088|NCT02925117|10067124|FG001|Period 2 (Weeks 16 - 88)|Withdrawal by Subject|0
6325089|NCT02925117|10067125|FG002|Period 2 (Weeks 16 - 88)|Withdrawal by Subject|0
6325090|NCT02925117|10067126|FG003|Period 2 (Weeks 16 - 88)|Withdrawal by Subject|0
6325091|NCT02925117|10067127|FG004|Period 2 (Weeks 16 - 88)|Withdrawal by Subject|0
6325092|NCT02925117|10067128|FG005|Period 2 (Weeks 16 - 88)|Withdrawal by Subject|1
6325093|NCT02925117|10067129|FG006|Period 2 (Weeks 16 - 88)|Withdrawal by Subject|4
6325094|NCT02925117|10067130|FG007|Period 2 (Weeks 16 - 88)|Withdrawal by Subject|3
6325095|NCT02925117|10067131|FG008|Period 2 (Weeks 16 - 88)|Withdrawal by Subject|2
6325096|NCT02925117|10067132|FG009|Period 2 (Weeks 16 - 88)|Withdrawal by Subject|2
6160163|NCT01181141|9801886|FG000|Overall Study|Protocol Violation|3
6160164|NCT01181141|9801887|FG001|Overall Study|Protocol Violation|1
6160165|NCT01181141|9801886|FG000|Overall Study|Withdrawal by Subject|3
6160166|NCT01181141|9801887|FG001|Overall Study|Withdrawal by Subject|1
6160167|NCT01181167|9801895|FG000|Overall Study|Adverse Event|11
6160168|NCT01181167|9801896|FG001|Overall Study|Adverse Event|21
6325097|NCT02925117|10067133|FG010|Period 2 (Weeks 16 - 88)|Withdrawal by Subject|2
6325098|NCT02925117|10067134|FG011|Period 2 (Weeks 16 - 88)|Withdrawal by Subject|2
6325099|NCT02925117|10067123|FG000|Period 2 (Weeks 16 - 88)|Lost to Follow-up|0
6325100|NCT02925117|10067124|FG001|Period 2 (Weeks 16 - 88)|Lost to Follow-up|0
6325101|NCT02925117|10067125|FG002|Period 2 (Weeks 16 - 88)|Lost to Follow-up|0
6325102|NCT02925117|10067126|FG003|Period 2 (Weeks 16 - 88)|Lost to Follow-up|0
6325103|NCT02925117|10067127|FG004|Period 2 (Weeks 16 - 88)|Lost to Follow-up|1
6160169|NCT01181167|9801895|FG000|Overall Study|Lost to Follow-up|1
6160170|NCT01181167|9801896|FG001|Overall Study|Lost to Follow-up|0
6160171|NCT01181167|9801895|FG000|Overall Study|Physician Decision|2
6160172|NCT01181167|9801896|FG001|Overall Study|Physician Decision|3
6160173|NCT01181167|9801895|FG000|Overall Study|Protocol Violation|3
6160174|NCT01181167|9801896|FG001|Overall Study|Protocol Violation|0
6160175|NCT01181167|9801895|FG000|Overall Study|Withdrawal by Subject|6
6160176|NCT01181167|9801896|FG001|Overall Study|Withdrawal by Subject|8
6160177|NCT01181271|9801906|FG000|Evaluation for Allogeneic Transplant|Lack of Efficacy|6
6160178|NCT01181271|9801906|FG000|Evaluation for Allogeneic Transplant|Withdrawal by Subject|4
6160179|NCT01181271|9801906|FG000|Evaluation for Allogeneic Transplant|No suitable donor|2
6160180|NCT01181271|9801906|FG000|Evaluation for Allogeneic Transplant|therapy-related AML diagnosed|1
6160181|NCT01181531|9801976|FG000|Overall Study|Other|17
6160182|NCT01181531|9801977|FG001|Overall Study|Other|12
6160183|NCT01181531|9801976|FG000|Overall Study|Partial consent by subject withdrawn|0
6160184|NCT01181531|9801977|FG001|Overall Study|Partial consent by subject withdrawn|1
6160185|NCT01181531|9801976|FG000|Overall Study|Physician Decision|3
6160186|NCT01181531|9801977|FG001|Overall Study|Physician Decision|1
6160187|NCT01181531|9801976|FG000|Overall Study|Noncompliance|2
6160188|NCT01181531|9801977|FG001|Overall Study|Noncompliance|2
6160189|NCT01181531|9801976|FG000|Overall Study|Ineligibility determined|1
6160190|NCT01181531|9801977|FG001|Overall Study|Ineligibility determined|2
6160191|NCT01181531|9801976|FG000|Overall Study|Protocol Specified Criteria|15
6160192|NCT01181531|9801977|FG001|Overall Study|Protocol Specified Criteria|8
6160193|NCT01181531|9801976|FG000|Overall Study|Pregnancy|0
6160194|NCT01181531|9801977|FG001|Overall Study|Pregnancy|1
6160195|NCT01181531|9801976|FG000|Overall Study|Withdrawal by Subject|8
6160196|NCT01181531|9801977|FG001|Overall Study|Withdrawal by Subject|7
6160197|NCT01181531|9801976|FG000|Overall Study|Protocol Violation|6
6160198|NCT01181531|9801977|FG001|Overall Study|Protocol Violation|6
6160199|NCT01181531|9801976|FG000|Overall Study|Death|9
6160200|NCT01181531|9801977|FG001|Overall Study|Death|12
6160201|NCT01181531|9801976|FG000|Overall Study|Adverse Event|0
6160202|NCT01181531|9801977|FG001|Overall Study|Adverse Event|1
6160203|NCT01181609|9801988|FG000|Overall Study|Adverse Event|1
6160204|NCT01181609|9801988|FG000|Overall Study|Withdrawal by Subject|1
6160205|NCT01181609|9801988|FG000|Overall Study|Lost to Follow-up|1
6160206|NCT01181609|9801988|FG000|Overall Study|Death|50
6325104|NCT02925117|10067128|FG005|Period 2 (Weeks 16 - 88)|Lost to Follow-up|2
6325105|NCT02925117|10067129|FG006|Period 2 (Weeks 16 - 88)|Lost to Follow-up|1
6160207|NCT01181726|9802007|FG000|First Intervention|Adverse Event|1
6160208|NCT01181726|9802008|FG001|First Intervention|Adverse Event|0
6160209|NCT01181895|9802034|FG000|Overall Study|Adverse Event|3
6160210|NCT01181895|9802035|FG001|Overall Study|Adverse Event|1
6160211|NCT01181895|9802036|FG002|Overall Study|Adverse Event|1
6160212|NCT01181895|9802034|FG000|Overall Study|Lack of Efficacy|8
6160213|NCT01181895|9802035|FG001|Overall Study|Lack of Efficacy|9
6160214|NCT01181895|9802036|FG002|Overall Study|Lack of Efficacy|9
6160215|NCT01181895|9802034|FG000|Overall Study|Protocol Violation|2
6160216|NCT01181895|9802035|FG001|Overall Study|Protocol Violation|1
6160217|NCT01181895|9802036|FG002|Overall Study|Protocol Violation|0
6160218|NCT01181895|9802034|FG000|Overall Study|Lost to Follow-up|0
6160219|NCT01181895|9802035|FG001|Overall Study|Lost to Follow-up|1
6160220|NCT01181895|9802036|FG002|Overall Study|Lost to Follow-up|2
6160221|NCT01181895|9802034|FG000|Overall Study|Investigator Discretion|1
6160222|NCT01181895|9802035|FG001|Overall Study|Investigator Discretion|2
6160223|NCT01181895|9802036|FG002|Overall Study|Investigator Discretion|1
6160224|NCT01181895|9802034|FG000|Overall Study|Withdrawal by Subject|3
6160225|NCT01181895|9802035|FG001|Overall Study|Withdrawal by Subject|0
6160226|NCT01181895|9802036|FG002|Overall Study|Withdrawal by Subject|5
6160227|NCT01181986|9802051|FG000|Phase 1|Lost to Follow-up|0
6160228|NCT01181986|9802052|FG001|Phase 1|Lost to Follow-up|1
6160229|NCT01181986|9802053|FG002|Phase 1|Lost to Follow-up|1
6160230|NCT01181986|9802051|FG000|Phase 1|Adverse Event|0
6160231|NCT01181986|9802052|FG001|Phase 1|Adverse Event|0
6160232|NCT01181986|9802053|FG002|Phase 1|Adverse Event|1
6160233|NCT01181986|9802051|FG000|Phase 1|Protocol Violation|1
6325106|NCT02925117|10067130|FG007|Period 2 (Weeks 16 - 88)|Lost to Follow-up|1
6325107|NCT02925117|10067131|FG008|Period 2 (Weeks 16 - 88)|Lost to Follow-up|1
6325108|NCT02925117|10067132|FG009|Period 2 (Weeks 16 - 88)|Lost to Follow-up|0
6325109|NCT02925117|10067133|FG010|Period 2 (Weeks 16 - 88)|Lost to Follow-up|0
6325110|NCT02925117|10067134|FG011|Period 2 (Weeks 16 - 88)|Lost to Follow-up|1
6325111|NCT02925117|10067123|FG000|Period 2 (Weeks 16 - 88)|Other|0
6325112|NCT02925117|10067124|FG001|Period 2 (Weeks 16 - 88)|Other|0
6325113|NCT02925117|10067125|FG002|Period 2 (Weeks 16 - 88)|Other|0
6325114|NCT02925117|10067126|FG003|Period 2 (Weeks 16 - 88)|Other|0
6325115|NCT02925117|10067127|FG004|Period 2 (Weeks 16 - 88)|Other|1
6325116|NCT02925117|10067128|FG005|Period 2 (Weeks 16 - 88)|Other|1
6325117|NCT02925117|10067129|FG006|Period 2 (Weeks 16 - 88)|Other|1
6325118|NCT02925117|10067130|FG007|Period 2 (Weeks 16 - 88)|Other|1
6325119|NCT02925117|10067131|FG008|Period 2 (Weeks 16 - 88)|Other|3
6325120|NCT02925117|10067132|FG009|Period 2 (Weeks 16 - 88)|Other|4
6325121|NCT02925117|10067133|FG010|Period 2 (Weeks 16 - 88)|Other|3
6325122|NCT02925117|10067134|FG011|Period 2 (Weeks 16 - 88)|Other|0
6082194|NCT00626327|9689970|FG002|Overall Study|Lost to Follow-up|23
6082195|NCT00626327|9689968|FG000|Overall Study|Inappropriate enrollment|4
6082196|NCT00626327|9689969|FG001|Overall Study|Inappropriate enrollment|5
6082197|NCT00626327|9689970|FG002|Overall Study|Inappropriate enrollment|3
6082198|NCT00626327|9689968|FG000|Overall Study|Administrative Reason|2
6082199|NCT00626327|9689969|FG001|Overall Study|Administrative Reason|0
6082200|NCT00626327|9689970|FG002|Overall Study|Administrative Reason|6
6082201|NCT00626327|9689968|FG000|Overall Study|Protocol Violation|26
6082202|NCT00626327|9689969|FG001|Overall Study|Protocol Violation|4
6160234|NCT01181986|9802052|FG001|Phase 1|Protocol Violation|0
6082203|NCT00626327|9689970|FG002|Overall Study|Protocol Violation|26
6082204|NCT00626392|9690005|FG000|Run-in Period|Adverse Event|0
6082205|NCT00626392|9690006|FG001|Run-in Period|Adverse Event|0
6160235|NCT01181986|9802053|FG002|Phase 1|Protocol Violation|0
6160236|NCT01181986|9802051|FG000|Phase 2|Adverse Event|0
6160237|NCT01181986|9802052|FG001|Phase 2|Adverse Event|3
6160238|NCT01181986|9802053|FG002|Phase 2|Adverse Event|0
6160239|NCT01181986|9802051|FG000|Phase 2|Medical condition|0
6160240|NCT01181986|9802052|FG001|Phase 2|Medical condition|1
6160241|NCT01181986|9802053|FG002|Phase 2|Medical condition|0
6160242|NCT01182181|9802081|FG000|First Intervention|Adverse Event|1
6160243|NCT01182181|9802082|FG001|First Intervention|Adverse Event|0
6160244|NCT01182181|9802081|FG000|Washout of 21 Days|Withdrawal by Subject|0
6160245|NCT01182181|9802082|FG001|Washout of 21 Days|Withdrawal by Subject|1
6160246|NCT01182194|9802090|FG000|Washout of 28 Days|Withdrawal by Subject|1
6160247|NCT01182194|9802091|FG001|Washout of 28 Days|Withdrawal by Subject|0
6160248|NCT01182207|9802099|FG000|First Intervention|Positive Hepatitis Results|0
6160249|NCT01182207|9802100|FG001|First Intervention|Positive Hepatitis Results|1
6160250|NCT01182207|9802099|FG000|Second Intervention|Emeses within 1 hour of dosing|1
6160251|NCT01182207|9802100|FG001|Second Intervention|Emeses within 1 hour of dosing|0
6160252|NCT01182285|9802106|FG000|First Intervention Week 1-10|Disease progression|1
6160253|NCT01182285|9802107|FG001|First Intervention Week 1-10|Disease progression|0
6160254|NCT01182285|9802108|FG002|First Intervention Week 1-10|Disease progression|0
6160255|NCT01182285|9802106|FG000|First Intervention Week 1-10|Adverse Event|1
6160256|NCT01182285|9802107|FG001|First Intervention Week 1-10|Adverse Event|0
6160257|NCT01182285|9802108|FG002|First Intervention Week 1-10|Adverse Event|0
6160258|NCT01182285|9802106|FG000|First Intervention Week 1-10|Non-compliance|1
6160259|NCT01182285|9802107|FG001|First Intervention Week 1-10|Non-compliance|0
6160260|NCT01182285|9802108|FG002|First Intervention Week 1-10|Non-compliance|0
6160261|NCT01182285|9802106|FG000|Third Intervention Week 11-52|Disease Progression|0
6160262|NCT01182285|9802107|FG001|Third Intervention Week 11-52|Disease Progression|0
6160263|NCT01182285|9802108|FG002|Third Intervention Week 11-52|Disease Progression|6
6160264|NCT01182285|9802106|FG000|Third Intervention Week 11-52|Other|0
6160265|NCT01182285|9802107|FG001|Third Intervention Week 11-52|Other|0
6160266|NCT01182285|9802108|FG002|Third Intervention Week 11-52|Other|2
6160267|NCT01182298|9802115|FG000|Overall Study|Lack of Efficacy|4
6160268|NCT01182298|9802115|FG000|Overall Study|Withdrawal by Subject|2
6160269|NCT01182337|9802121|FG000|Overall Study|Withdrawal by Subject|3
6325123|NCT02925312|10067162|FG000|Overall Study|Lost to Follow-up|25
6325124|NCT02925312|10067163|FG001|Overall Study|Lost to Follow-up|0
6325125|NCT02925312|10067162|FG000|Overall Study|Adverse Event|2
6325126|NCT02925312|10067163|FG001|Overall Study|Adverse Event|0
6325127|NCT02925403|10067171|FG000|Overall Study|Lost to Follow-up|0
6325128|NCT02925403|10067172|FG001|Overall Study|Lost to Follow-up|1
6325129|NCT02925455|10067180|FG000|Overall Study|Withdrawal by Subject|2
6325130|NCT02925455|10067181|FG001|Overall Study|Withdrawal by Subject|0
6325131|NCT02925494|10067191|FG000|Post-Treatment Follow-Up Period|Withdrawal by Subject|8
6325132|NCT02925494|10067192|FG001|Post-Treatment Follow-Up Period|Withdrawal by Subject|2
6160270|NCT01182337|9802122|FG001|Overall Study|Withdrawal by Subject|1
6325133|NCT02925494|10067193|FG002|Post-Treatment Follow-Up Period|Withdrawal by Subject|8
6325134|NCT02925494|10067194|FG003|Post-Treatment Follow-Up Period|Withdrawal by Subject|23
6325135|NCT02925494|10067191|FG000|Post-Treatment Follow-Up Period|Lost to Follow-up|3
6160271|NCT01182337|9802121|FG000|Overall Study|Lost to Follow-up|0
6160272|NCT01182337|9802122|FG001|Overall Study|Lost to Follow-up|1
6160273|NCT01182350|9802129|FG000|Overall Study|Adverse Event|5
6160274|NCT01182350|9802130|FG001|Overall Study|Adverse Event|0
6160275|NCT01182350|9802131|FG002|Overall Study|Adverse Event|0
6160276|NCT01182350|9802132|FG003|Overall Study|Adverse Event|0
6160277|NCT01182350|9802133|FG004|Overall Study|Adverse Event|0
6160278|NCT01182350|9802129|FG000|Overall Study|Disease Progression|15
6160279|NCT01182350|9802130|FG001|Overall Study|Disease Progression|12
6160280|NCT01182350|9802131|FG002|Overall Study|Disease Progression|0
6160281|NCT01182350|9802132|FG003|Overall Study|Disease Progression|1
6160282|NCT01182350|9802133|FG004|Overall Study|Disease Progression|0
6160283|NCT01182350|9802129|FG000|Overall Study|Death|0
6160284|NCT01182350|9802130|FG001|Overall Study|Death|1
6160285|NCT01182350|9802131|FG002|Overall Study|Death|1
6160286|NCT01182350|9802132|FG003|Overall Study|Death|0
6160287|NCT01182350|9802133|FG004|Overall Study|Death|0
6325136|NCT02925494|10067192|FG001|Post-Treatment Follow-Up Period|Lost to Follow-up|2
6325137|NCT02925494|10067193|FG002|Post-Treatment Follow-Up Period|Lost to Follow-up|9
6082206|NCT00626392|9690007|FG002|Run-in Period|Adverse Event|1
6082207|NCT00626392|9690008|FG003|Run-in Period|Adverse Event|0
6082208|NCT00626392|9690009|FG004|Run-in Period|Adverse Event|1
6082209|NCT00626392|9690010|FG005|Run-in Period|Adverse Event|0
6082210|NCT00626392|9690005|FG000|Run-in Period|Withdrawal by Subject|0
6082211|NCT00626392|9690006|FG001|Run-in Period|Withdrawal by Subject|1
6082212|NCT00626392|9690007|FG002|Run-in Period|Withdrawal by Subject|1
6160288|NCT01182350|9802129|FG000|Overall Study|Withdrawal by Subject|3
6160289|NCT01182350|9802130|FG001|Overall Study|Withdrawal by Subject|1
6160290|NCT01182350|9802131|FG002|Overall Study|Withdrawal by Subject|0
6160291|NCT01182350|9802132|FG003|Overall Study|Withdrawal by Subject|1
6160292|NCT01182350|9802133|FG004|Overall Study|Withdrawal by Subject|0
6160293|NCT01182350|9802129|FG000|Overall Study|Alternative Therapy|2
6160294|NCT01182350|9802130|FG001|Overall Study|Alternative Therapy|0
6160295|NCT01182350|9802131|FG002|Overall Study|Alternative Therapy|1
6160296|NCT01182350|9802132|FG003|Overall Study|Alternative Therapy|0
6160297|NCT01182350|9802133|FG004|Overall Study|Alternative Therapy|0
6160298|NCT01182350|9802129|FG000|Overall Study|Travel Issue/Prefer Treatment at Home|2
6160299|NCT01182350|9802130|FG001|Overall Study|Travel Issue/Prefer Treatment at Home|0
6160300|NCT01182350|9802131|FG002|Overall Study|Travel Issue/Prefer Treatment at Home|1
6160301|NCT01182350|9802132|FG003|Overall Study|Travel Issue/Prefer Treatment at Home|1
6160302|NCT01182350|9802133|FG004|Overall Study|Travel Issue/Prefer Treatment at Home|0
6160303|NCT01182350|9802129|FG000|Overall Study|Unevaluable for Biopsy|0
6160304|NCT01182350|9802130|FG001|Overall Study|Unevaluable for Biopsy|0
6160305|NCT01182350|9802131|FG002|Overall Study|Unevaluable for Biopsy|0
6160306|NCT01182350|9802132|FG003|Overall Study|Unevaluable for Biopsy|0
6160307|NCT01182350|9802133|FG004|Overall Study|Unevaluable for Biopsy|3
6160308|NCT01182415|9802158|FG000|Overall Study|Lost to Follow-up|1
6160309|NCT01182428|9802164|FG000|Overall Study|Physician Decision|1
6160310|NCT01182428|9802165|FG001|Overall Study|Physician Decision|0
6325138|NCT02925494|10067194|FG003|Post-Treatment Follow-Up Period|Lost to Follow-up|10
6325139|NCT02925494|10067191|FG000|Post-Treatment Follow-Up Period|Other|1
6325140|NCT02925494|10067192|FG001|Post-Treatment Follow-Up Period|Other|4
6325141|NCT02925494|10067193|FG002|Post-Treatment Follow-Up Period|Other|3
6325142|NCT02925494|10067194|FG003|Post-Treatment Follow-Up Period|Other|6
6325143|NCT02925494|10067191|FG000|Post-Treatment Follow-Up Period|Required Surgery/ Invasive Intervention|1
6325144|NCT02925494|10067192|FG001|Post-Treatment Follow-Up Period|Required Surgery/ Invasive Intervention|2
6325145|NCT02925494|10067193|FG002|Post-Treatment Follow-Up Period|Required Surgery/ Invasive Intervention|2
6325146|NCT02925494|10067194|FG003|Post-Treatment Follow-Up Period|Required Surgery/ Invasive Intervention|6
6325147|NCT02925494|10067191|FG000|Post-Treatment Follow-Up Period|Pregnancy|1
6325148|NCT02925494|10067192|FG001|Post-Treatment Follow-Up Period|Pregnancy|0
6325149|NCT02925494|10067193|FG002|Post-Treatment Follow-Up Period|Pregnancy|1
6325150|NCT02925494|10067194|FG003|Post-Treatment Follow-Up Period|Pregnancy|2
6325151|NCT02925494|10067191|FG000|Post-Treatment Follow-Up Period|Non-Compliance|0
6325152|NCT02925494|10067192|FG001|Post-Treatment Follow-Up Period|Non-Compliance|0
6325153|NCT02925494|10067193|FG002|Post-Treatment Follow-Up Period|Non-Compliance|1
6325154|NCT02925494|10067194|FG003|Post-Treatment Follow-Up Period|Non-Compliance|2
6325155|NCT02925494|10067191|FG000|Post-Treatment Follow-Up Period|Adverse Event|0
6325156|NCT02925494|10067192|FG001|Post-Treatment Follow-Up Period|Adverse Event|0
6325157|NCT02925494|10067193|FG002|Post-Treatment Follow-Up Period|Adverse Event|0
6325158|NCT02925494|10067194|FG003|Post-Treatment Follow-Up Period|Adverse Event|1
6325159|NCT02925741|10067216|FG000|Overall Study|Withdrawal by Subject|11
6325160|NCT02925741|10067217|FG001|Overall Study|Withdrawal by Subject|0
6325161|NCT02925923|10067237|FG000|Overall Study|blood samples hemolyzed|0
6325162|NCT02925923|10067238|FG001|Overall Study|blood samples hemolyzed|2
6325163|NCT02926209|10067253|FG000|Study Cohort|Poor Bowel Preparation|1
6325164|NCT02926209|10067254|FG001|Study Cohort|Poor Bowel Preparation|0
6325165|NCT02926573|10067263|FG000|Overall Study|Nausea|1
6325166|NCT02926573|10067264|FG001|Overall Study|Nausea|0
6160311|NCT01182428|9802164|FG000|Overall Study|Lost to Follow-up|9
6325167|NCT02926573|10067263|FG000|Overall Study|Remain intubated|2
6325168|NCT02926573|10067264|FG001|Overall Study|Remain intubated|2
6325169|NCT02926573|10067263|FG000|Overall Study|Change in surgery plan|3
6325170|NCT02926573|10067264|FG001|Overall Study|Change in surgery plan|1
6325171|NCT02926573|10067263|FG000|Overall Study|Change to outpatient status|5
6160312|NCT01182428|9802165|FG001|Overall Study|Lost to Follow-up|1
6160313|NCT01182428|9802164|FG000|Overall Study|Withdrawal by Subject|1
6160314|NCT01182428|9802165|FG001|Overall Study|Withdrawal by Subject|0
6160315|NCT01182441|9802173|FG000|Overall Study|Patient Still in Follow-up|152
6160316|NCT01182441|9802174|FG001|Overall Study|Patient Still in Follow-up|72
6160317|NCT01182441|9802173|FG000|Overall Study|Death|37
6160318|NCT01182441|9802174|FG001|Overall Study|Death|25
6160319|NCT01182441|9802173|FG000|Overall Study|Implant Attempt Unsuccessful|13
6160320|NCT01182441|9802174|FG001|Overall Study|Implant Attempt Unsuccessful|0
6160321|NCT01182441|9802173|FG000|Overall Study|Lost to Follow-up|5
6160322|NCT01182441|9802174|FG001|Overall Study|Lost to Follow-up|8
6160323|NCT01182441|9802173|FG000|Overall Study|Withdrawal by Subject|6
6160324|NCT01182441|9802174|FG001|Overall Study|Withdrawal by Subject|13
6160325|NCT01182441|9802173|FG000|Overall Study|Implant Not Attempted|4
6160326|NCT01182441|9802174|FG001|Overall Study|Implant Not Attempted|0
6160327|NCT01182441|9802173|FG000|Overall Study|Adverse Event|2
6160328|NCT01182441|9802174|FG001|Overall Study|Adverse Event|0
6160329|NCT01182441|9802173|FG000|Overall Study|Physician Decision|1
6160330|NCT01182441|9802174|FG001|Overall Study|Physician Decision|1
6082213|NCT00626392|9690008|FG003|Run-in Period|Withdrawal by Subject|1
6082214|NCT00626392|9690009|FG004|Run-in Period|Withdrawal by Subject|3
6160331|NCT01182844|9802212|FG000|Overall Study|Withdrawal by Subject|0
6160332|NCT01182844|9802213|FG001|Overall Study|Withdrawal by Subject|2
6160333|NCT01183013|9802226|FG000|Overall Study|Adverse Event|6
6160334|NCT01183013|9802227|FG001|Overall Study|Adverse Event|8
6160335|NCT01183013|9802228|FG002|Overall Study|Adverse Event|5
6160336|NCT01183013|9802229|FG003|Overall Study|Adverse Event|5
6160337|NCT01183013|9802230|FG004|Overall Study|Adverse Event|10
6160338|NCT01183013|9802231|FG005|Overall Study|Adverse Event|10
6160339|NCT01183013|9802232|FG006|Overall Study|Adverse Event|6
6160340|NCT01183013|9802226|FG000|Overall Study|Lack of Efficacy|3
6160341|NCT01183013|9802227|FG001|Overall Study|Lack of Efficacy|2
6160342|NCT01183013|9802228|FG002|Overall Study|Lack of Efficacy|1
6160343|NCT01183013|9802229|FG003|Overall Study|Lack of Efficacy|2
6160344|NCT01183013|9802230|FG004|Overall Study|Lack of Efficacy|1
6160345|NCT01183013|9802231|FG005|Overall Study|Lack of Efficacy|2
6160346|NCT01183013|9802232|FG006|Overall Study|Lack of Efficacy|0
6160347|NCT01183013|9802226|FG000|Overall Study|Protocol Violation|5
6160348|NCT01183013|9802227|FG001|Overall Study|Protocol Violation|2
6160349|NCT01183013|9802228|FG002|Overall Study|Protocol Violation|4
6160350|NCT01183013|9802229|FG003|Overall Study|Protocol Violation|0
6160351|NCT01183013|9802230|FG004|Overall Study|Protocol Violation|4
6160352|NCT01183013|9802231|FG005|Overall Study|Protocol Violation|3
6160353|NCT01183013|9802232|FG006|Overall Study|Protocol Violation|3
6160354|NCT01183013|9802226|FG000|Overall Study|Lost to Follow-up|7
6160355|NCT01183013|9802227|FG001|Overall Study|Lost to Follow-up|3
6160356|NCT01183013|9802228|FG002|Overall Study|Lost to Follow-up|4
6160357|NCT01183013|9802229|FG003|Overall Study|Lost to Follow-up|3
6160358|NCT01183013|9802230|FG004|Overall Study|Lost to Follow-up|2
6325172|NCT02926573|10067264|FG001|Overall Study|Change to outpatient status|1
6325173|NCT02926573|10067263|FG000|Overall Study|Withdrawal by Subject|0
6160359|NCT01183013|9802231|FG005|Overall Study|Lost to Follow-up|6
6160360|NCT01183013|9802232|FG006|Overall Study|Lost to Follow-up|5
6160361|NCT01183013|9802226|FG000|Overall Study|Withdrawal by Subject|9
6160362|NCT01183013|9802227|FG001|Overall Study|Withdrawal by Subject|13
6160363|NCT01183013|9802228|FG002|Overall Study|Withdrawal by Subject|10
6160364|NCT01183013|9802229|FG003|Overall Study|Withdrawal by Subject|8
6160365|NCT01183013|9802230|FG004|Overall Study|Withdrawal by Subject|7
6160366|NCT01183013|9802231|FG005|Overall Study|Withdrawal by Subject|9
6160367|NCT01183013|9802232|FG006|Overall Study|Withdrawal by Subject|10
6160368|NCT01183013|9802226|FG000|Overall Study|Reasons other than stated above|15
6325174|NCT02926573|10067264|FG001|Overall Study|Withdrawal by Subject|2
6325175|NCT02926573|10067263|FG000|Overall Study|Return to operating room|0
6325176|NCT02926573|10067264|FG001|Overall Study|Return to operating room|2
6325177|NCT02926573|10067263|FG000|Overall Study|Delirium|0
6325178|NCT02926573|10067264|FG001|Overall Study|Delirium|1
6325179|NCT02926937|10067287|FG000|Overall Study|Adverse Event|0
6325180|NCT02926937|10067288|FG001|Overall Study|Adverse Event|1
6325181|NCT02926937|10067289|FG002|Overall Study|Adverse Event|1
6325182|NCT02926937|10067287|FG000|Overall Study|Poor Compliance to Protocol|1
6325183|NCT02926937|10067288|FG001|Overall Study|Poor Compliance to Protocol|0
6325184|NCT02926937|10067289|FG002|Overall Study|Poor Compliance to Protocol|0
6325185|NCT02926937|10067287|FG000|Overall Study|Lost to Follow-up|4
6325186|NCT02926937|10067288|FG001|Overall Study|Lost to Follow-up|5
6325187|NCT02926937|10067289|FG002|Overall Study|Lost to Follow-up|0
6082215|NCT00626392|9690010|FG005|Run-in Period|Withdrawal by Subject|1
6082216|NCT00626392|9690005|FG000|Run-in Period|Noncompliance|1
6325188|NCT02926937|10067287|FG000|Overall Study|At the Participant's own Request|11
6082217|NCT00626392|9690006|FG001|Run-in Period|Noncompliance|0
6082218|NCT00626392|9690007|FG002|Run-in Period|Noncompliance|1
6082219|NCT00626392|9690008|FG003|Run-in Period|Noncompliance|0
6082220|NCT00626392|9690009|FG004|Run-in Period|Noncompliance|0
6082221|NCT00626392|9690010|FG005|Run-in Period|Noncompliance|0
6082222|NCT00626392|9690005|FG000|Coadministration Period|Adverse Event|3
6082223|NCT00626392|9690006|FG001|Coadministration Period|Adverse Event|1
6082224|NCT00626392|9690007|FG002|Coadministration Period|Adverse Event|7
6082225|NCT00626392|9690008|FG003|Coadministration Period|Adverse Event|4
6082226|NCT00626392|9690009|FG004|Coadministration Period|Adverse Event|3
6082227|NCT00626392|9690010|FG005|Coadministration Period|Adverse Event|4
6082228|NCT00626392|9690005|FG000|Coadministration Period|Withdrawal by Subject|1
6082229|NCT00626392|9690006|FG001|Coadministration Period|Withdrawal by Subject|1
6082230|NCT00626392|9690007|FG002|Coadministration Period|Withdrawal by Subject|0
6082231|NCT00626392|9690008|FG003|Coadministration Period|Withdrawal by Subject|1
6082232|NCT00626392|9690009|FG004|Coadministration Period|Withdrawal by Subject|0
6082233|NCT00626392|9690010|FG005|Coadministration Period|Withdrawal by Subject|1
6191826|NCT01425814|9848752|FG005|Period 4|Adverse Event|0
6325189|NCT02926937|10067288|FG001|Overall Study|At the Participant's own Request|5
6325190|NCT02926937|10067289|FG002|Overall Study|At the Participant's own Request|8
6325191|NCT02926937|10067287|FG000|Overall Study|Reason not Specified|3
6325192|NCT02926937|10067288|FG001|Overall Study|Reason not Specified|4
6160369|NCT01183013|9802227|FG001|Overall Study|Reasons other than stated above|11
6160370|NCT01183013|9802228|FG002|Overall Study|Reasons other than stated above|17
6160371|NCT01183013|9802229|FG003|Overall Study|Reasons other than stated above|12
6160372|NCT01183013|9802230|FG004|Overall Study|Reasons other than stated above|12
6160373|NCT01183013|9802231|FG005|Overall Study|Reasons other than stated above|15
6160374|NCT01183013|9802232|FG006|Overall Study|Reasons other than stated above|13
6160375|NCT01183065|9802249|FG000|Overall Study|Patient no longer fits eligibility crite|1
6160376|NCT01183104|9802255|FG000|Overall Study|Adverse Event|8
6160377|NCT01183104|9802256|FG001|Overall Study|Adverse Event|6
6160378|NCT01183104|9802255|FG000|Overall Study|Death|0
6160379|NCT01183104|9802256|FG001|Overall Study|Death|1
6160380|NCT01183104|9802255|FG000|Overall Study|Lost to Follow-up|14
6160381|NCT01183104|9802256|FG001|Overall Study|Lost to Follow-up|7
6325193|NCT02926937|10067289|FG002|Overall Study|Reason not Specified|2
6325194|NCT02926950|10067300|FG000|Overall Study|Adverse Event|4
6325195|NCT02926950|10067301|FG001|Overall Study|Adverse Event|6
6325196|NCT02926950|10067300|FG000|Overall Study|At the participant's own request|21
6325197|NCT02926950|10067301|FG001|Overall Study|At the participant's own request|25
6325198|NCT02926950|10067300|FG000|Overall Study|Reason not Specified|17
6325199|NCT02926950|10067301|FG001|Overall Study|Reason not Specified|9
6325200|NCT02926950|10067300|FG000|Overall Study|Lost to Follow-up|7
6325201|NCT02926950|10067301|FG001|Overall Study|Lost to Follow-up|8
6325202|NCT02927080|10067318|FG000|Overall Study|Withdrawal by Subject|0
6325203|NCT02927080|10067319|FG001|Overall Study|Withdrawal by Subject|0
6325204|NCT02927080|10067320|FG002|Overall Study|Withdrawal by Subject|0
6325205|NCT02927080|10067321|FG003|Overall Study|Withdrawal by Subject|0
6325206|NCT02927080|10067322|FG004|Overall Study|Withdrawal by Subject|1
6325207|NCT02927080|10067323|FG005|Overall Study|Withdrawal by Subject|0
6325208|NCT02927080|10067324|FG006|Overall Study|Withdrawal by Subject|1
6325209|NCT02927080|10067325|FG007|Overall Study|Withdrawal by Subject|1
6325210|NCT02927080|10067326|FG008|Overall Study|Withdrawal by Subject|0
6325211|NCT02927080|10067327|FG009|Overall Study|Withdrawal by Subject|2
6325212|NCT02927080|10067318|FG000|Overall Study|Willingness to comply with protocol|0
6325213|NCT02927080|10067319|FG001|Overall Study|Willingness to comply with protocol|0
6325214|NCT02927080|10067320|FG002|Overall Study|Willingness to comply with protocol|0
6325215|NCT02927080|10067321|FG003|Overall Study|Willingness to comply with protocol|0
6325216|NCT02927080|10067322|FG004|Overall Study|Willingness to comply with protocol|0
6325217|NCT02927080|10067323|FG005|Overall Study|Willingness to comply with protocol|0
6325218|NCT02927080|10067324|FG006|Overall Study|Willingness to comply with protocol|0
6325219|NCT02927080|10067325|FG007|Overall Study|Willingness to comply with protocol|0
6325220|NCT02927080|10067326|FG008|Overall Study|Willingness to comply with protocol|0
6325221|NCT02927080|10067327|FG009|Overall Study|Willingness to comply with protocol|1
6325222|NCT02927080|10067318|FG000|Overall Study|Study terminated by Sponsor|0
6325223|NCT02927080|10067319|FG001|Overall Study|Study terminated by Sponsor|0
6325224|NCT02927080|10067320|FG002|Overall Study|Study terminated by Sponsor|0
6325225|NCT02927080|10067321|FG003|Overall Study|Study terminated by Sponsor|0
6325226|NCT02927080|10067322|FG004|Overall Study|Study terminated by Sponsor|0
6325227|NCT02927080|10067323|FG005|Overall Study|Study terminated by Sponsor|0
6325228|NCT02927080|10067324|FG006|Overall Study|Study terminated by Sponsor|6
6325229|NCT02927080|10067325|FG007|Overall Study|Study terminated by Sponsor|7
6325230|NCT02927080|10067326|FG008|Overall Study|Study terminated by Sponsor|2
6325231|NCT02927080|10067327|FG009|Overall Study|Study terminated by Sponsor|3
6325232|NCT02927080|10067318|FG000|Overall Study|Adverse Event|0
6325233|NCT02927080|10067319|FG001|Overall Study|Adverse Event|1
6325234|NCT02927080|10067320|FG002|Overall Study|Adverse Event|0
6325235|NCT02927080|10067321|FG003|Overall Study|Adverse Event|0
6325236|NCT02927080|10067322|FG004|Overall Study|Adverse Event|0
6325237|NCT02927080|10067323|FG005|Overall Study|Adverse Event|0
6325238|NCT02927080|10067324|FG006|Overall Study|Adverse Event|0
6325239|NCT02927080|10067325|FG007|Overall Study|Adverse Event|1
6325240|NCT02927080|10067326|FG008|Overall Study|Adverse Event|0
6325241|NCT02927080|10067327|FG009|Overall Study|Adverse Event|1
6325242|NCT02927080|10067318|FG000|Overall Study|Other|0
6160382|NCT01183104|9802255|FG000|Overall Study|Physician Decision|5
6160383|NCT01183104|9802256|FG001|Overall Study|Physician Decision|8
6325243|NCT02927080|10067319|FG001|Overall Study|Other|0
6325244|NCT02927080|10067320|FG002|Overall Study|Other|0
6325245|NCT02927080|10067321|FG003|Overall Study|Other|0
6160384|NCT01183104|9802255|FG000|Overall Study|Withdrawal by Subject|6
6160385|NCT01183104|9802256|FG001|Overall Study|Withdrawal by Subject|11
6160386|NCT01183104|9802255|FG000|Overall Study|Nonparticipation in Extension Study|39
6160387|NCT01183104|9802256|FG001|Overall Study|Nonparticipation in Extension Study|50
6160388|NCT01183104|9802255|FG000|Overall Study|Did not receive study drug|5
6160389|NCT01183104|9802256|FG001|Overall Study|Did not receive study drug|9
6160390|NCT01183143|9802262|FG000|Overall Study|Protocol Violation|115
6160391|NCT01183143|9802262|FG000|Overall Study|Withdrawal by Subject|19
6160392|NCT01183143|9802262|FG000|Overall Study|Subject Questionnaires not returned|5
6160393|NCT01183143|9802262|FG000|Overall Study|Subjects enrolled, but not treated|11
6160394|NCT01183234|9802296|FG000|First Intervention|Adverse Event|1
6160395|NCT01183234|9802297|FG001|First Intervention|Adverse Event|0
6160396|NCT01183260|9802305|FG000|Overall Study|Intraop screen failure|2
6160397|NCT01183260|9802306|FG001|Overall Study|Intraop screen failure|0
6160398|NCT01183260|9802305|FG000|Overall Study|Withdrawal by Subject|1
6160399|NCT01183260|9802306|FG001|Overall Study|Withdrawal by Subject|1
6160400|NCT01183260|9802305|FG000|Overall Study|Revised within 30 days|0
6160401|NCT01183260|9802306|FG001|Overall Study|Revised within 30 days|1
6160402|NCT01183260|9802305|FG000|Overall Study|Death|1
6160403|NCT01183260|9802306|FG001|Overall Study|Death|0
6160404|NCT01183390|9802323|FG000|First Intervention|Adverse Event|0
6160405|NCT01183390|9802324|FG001|First Intervention|Adverse Event|1
6160406|NCT01183780|9802379|FG000|Overall Study|Withdrawal by Subject|25
6160407|NCT01183780|9802380|FG001|Overall Study|Withdrawal by Subject|14
6160408|NCT01183780|9802379|FG000|Overall Study|Lost to Follow-up|6
6160409|NCT01183780|9802380|FG001|Overall Study|Lost to Follow-up|11
6160410|NCT01183858|9802388|FG000|Overall Study|Death not related to Progressive Disease|5
6160411|NCT01183858|9802389|FG001|Overall Study|Death not related to Progressive Disease|6
6160412|NCT01183858|9802388|FG000|Overall Study|Adverse Event|14
6160413|NCT01183858|9802389|FG001|Overall Study|Adverse Event|11
6160414|NCT01183858|9802388|FG000|Overall Study|Investigator's Decision|0
6160415|NCT01183858|9802389|FG001|Overall Study|Investigator's Decision|3
6160416|NCT01183858|9802388|FG000|Overall Study|Insufficient Therapeutic Response|2
6160417|NCT01183858|9802389|FG001|Overall Study|Insufficient Therapeutic Response|0
6160418|NCT01183858|9802388|FG000|Overall Study|Refused Treatment|1
6160419|NCT01183858|9802389|FG001|Overall Study|Refused Treatment|4
6160420|NCT01183858|9802388|FG000|Overall Study|Withdrew Consent|4
6160421|NCT01183858|9802389|FG001|Overall Study|Withdrew Consent|4
6160422|NCT01183858|9802388|FG000|Overall Study|Discontinued Smoking|3
6160423|NCT01183858|9802389|FG001|Overall Study|Discontinued Smoking|1
6160424|NCT01183858|9802388|FG000|Overall Study|Protocol Violation|1
6160425|NCT01183858|9802389|FG001|Overall Study|Protocol Violation|0
6160426|NCT01183858|9802388|FG000|Overall Study|Administrative/Other|6
6160427|NCT01183858|9802389|FG001|Overall Study|Administrative/Other|6
6160428|NCT01183858|9802388|FG000|Overall Study|Progressive Disease|112
6160429|NCT01183858|9802389|FG001|Overall Study|Progressive Disease|115
6160430|NCT01183858|9802388|FG000|Overall Study|Death related to Progressive Disease|4
6160431|NCT01183858|9802389|FG001|Overall Study|Death related to Progressive Disease|5
6160432|NCT01183858|9802388|FG000|Overall Study|Lost to Follow-up|1
6160433|NCT01183858|9802389|FG001|Overall Study|Lost to Follow-up|1
6160434|NCT01183975|9802401|FG000|Overall Study|Lost to Follow-up|73
6160435|NCT01184053|9802414|FG000|Overall Study|progression while on treatment|3
6160436|NCT01184079|9802421|FG000|Overall Study|Lost to Follow-up|14
6160437|NCT01184079|9802422|FG001|Overall Study|Lost to Follow-up|2
6160438|NCT01184118|9802430|FG000|Overall Study|Only asthma step 1 - screen fail|1
6160439|NCT01184118|9802430|FG000|Overall Study|No physiologic confirmation of asthma|8
6160440|NCT01184118|9802430|FG000|Overall Study|FEV1 <60% predicted|2
6160441|NCT01184118|9802430|FG000|Overall Study|Exclusionary medical condition|2
6160442|NCT01184118|9802430|FG000|Overall Study|Withdrawal by Subject|5
6160443|NCT01184326|9802437|FG000|Overall Study|Adverse Event|1
6160444|NCT01184326|9802438|FG001|Overall Study|Adverse Event|2
6160445|NCT01184326|9802439|FG002|Overall Study|Adverse Event|0
6160446|NCT01184326|9802437|FG000|Overall Study|Death|0
6160447|NCT01184326|9802438|FG001|Overall Study|Death|0
6160448|NCT01184326|9802439|FG002|Overall Study|Death|1
6160449|NCT01184326|9802437|FG000|Overall Study|Withdrawal by Subject|0
6160450|NCT01184326|9802438|FG001|Overall Study|Withdrawal by Subject|0
6160451|NCT01184326|9802439|FG002|Overall Study|Withdrawal by Subject|1
6160452|NCT01184326|9802437|FG000|Overall Study|Physician Decision|1
6160453|NCT01184326|9802438|FG001|Overall Study|Physician Decision|1
6160454|NCT01184326|9802439|FG002|Overall Study|Physician Decision|0
6160455|NCT01184326|9802437|FG000|Overall Study|Disease Progression|1
6160456|NCT01184326|9802438|FG001|Overall Study|Disease Progression|3
6160457|NCT01184326|9802439|FG002|Overall Study|Disease Progression|12
6160458|NCT01184508|9802461|FG000|Overall Study|Adverse Event|4
6160459|NCT01184508|9802462|FG001|Overall Study|Adverse Event|6
6160460|NCT01184508|9802461|FG000|Overall Study|Lack of Efficacy|1
6160461|NCT01184508|9802462|FG001|Overall Study|Lack of Efficacy|1
6160462|NCT01184508|9802461|FG000|Overall Study|Lost to Follow-up|1
6160463|NCT01184508|9802462|FG001|Overall Study|Lost to Follow-up|1
6160464|NCT01184508|9802461|FG000|Overall Study|Physician Decision|1
6160465|NCT01184508|9802462|FG001|Overall Study|Physician Decision|0
6160466|NCT01184508|9802461|FG000|Overall Study|Protocol Violation|3
6160467|NCT01184508|9802462|FG001|Overall Study|Protocol Violation|1
6160468|NCT01184508|9802461|FG000|Overall Study|Sponsor Decision|5
6160469|NCT01184508|9802462|FG001|Overall Study|Sponsor Decision|2
6160470|NCT01184508|9802461|FG000|Overall Study|Withdrawal by Subject|1
6160471|NCT01184508|9802462|FG001|Overall Study|Withdrawal by Subject|3
6160472|NCT01184508|9802461|FG000|Overall Study|Randomized, Not Treated|0
6160473|NCT01184508|9802462|FG001|Overall Study|Randomized, Not Treated|1
6160474|NCT01184846|9802482|FG000|Overall Study|Adverse Event|2
6160475|NCT01184846|9802482|FG000|Overall Study|Insufficient response|1
6160476|NCT01184859|9802493|FG000|Period 1: Single Dose|Insufficient urine production|0
6160477|NCT01184859|9802494|FG001|Period 1: Single Dose|Insufficient urine production|1
6160478|NCT01184859|9802495|FG002|Period 1: Single Dose|Insufficient urine production|0
6160479|NCT01184859|9802496|FG003|Period 1: Single Dose|Insufficient urine production|0
6160480|NCT01184859|9802497|FG004|Period 1: Single Dose|Insufficient urine production|0
6160481|NCT01184859|9802493|FG000|Period 1: Single Dose|Protocol Violation|0
6160482|NCT01184859|9802494|FG001|Period 1: Single Dose|Protocol Violation|1
6160483|NCT01184859|9802495|FG002|Period 1: Single Dose|Protocol Violation|0
6160484|NCT01184859|9802496|FG003|Period 1: Single Dose|Protocol Violation|0
6160485|NCT01184859|9802497|FG004|Period 1: Single Dose|Protocol Violation|0
6160486|NCT01184859|9802493|FG000|Period 1: Single Dose|Adverse Event|0
6160487|NCT01184859|9802494|FG001|Period 1: Single Dose|Adverse Event|0
6160488|NCT01184859|9802495|FG002|Period 1: Single Dose|Adverse Event|0
6160489|NCT01184859|9802496|FG003|Period 1: Single Dose|Adverse Event|0
6160490|NCT01184859|9802497|FG004|Period 1: Single Dose|Adverse Event|1
6160491|NCT01184859|9802493|FG000|Period 2: Daily Dose for 28 Days|Withdrawal by Subject|0
6160492|NCT01184859|9802494|FG001|Period 2: Daily Dose for 28 Days|Withdrawal by Subject|0
6160493|NCT01184859|9802495|FG002|Period 2: Daily Dose for 28 Days|Withdrawal by Subject|0
6160494|NCT01184859|9802496|FG003|Period 2: Daily Dose for 28 Days|Withdrawal by Subject|0
6160495|NCT01184859|9802497|FG004|Period 2: Daily Dose for 28 Days|Withdrawal by Subject|1
6160496|NCT01184859|9802493|FG000|Period 2: Daily Dose for 28 Days|Adverse Event|1
6160497|NCT01184859|9802494|FG001|Period 2: Daily Dose for 28 Days|Adverse Event|0
6160498|NCT01184859|9802495|FG002|Period 2: Daily Dose for 28 Days|Adverse Event|0
6160499|NCT01184859|9802496|FG003|Period 2: Daily Dose for 28 Days|Adverse Event|0
6160500|NCT01184859|9802497|FG004|Period 2: Daily Dose for 28 Days|Adverse Event|0
6160501|NCT01184872|9802516|FG000|Overall Study|Adverse Event|3
6160502|NCT01184872|9802517|FG001|Overall Study|Adverse Event|4
6160503|NCT01184872|9802516|FG000|Overall Study|Unsatisfactory therapeutic effect|3
6160504|NCT01184872|9802517|FG001|Overall Study|Unsatisfactory therapeutic effect|2
6160505|NCT01184872|9802516|FG000|Overall Study|Withdrawal by Subject|2
6160506|NCT01184872|9802517|FG001|Overall Study|Withdrawal by Subject|0
6160507|NCT01184872|9802516|FG000|Overall Study|Lost to Follow-up|0
6160508|NCT01184872|9802517|FG001|Overall Study|Lost to Follow-up|1
6160509|NCT01184872|9802516|FG000|Overall Study|Administrative problems|1
6160510|NCT01184872|9802517|FG001|Overall Study|Administrative problems|1
6160511|NCT01184872|9802516|FG000|Overall Study|Protocol deviation|1
6160512|NCT01184872|9802517|FG001|Overall Study|Protocol deviation|0
6160513|NCT01184989|9802532|FG000|Overall Study|Adverse Event|11
6160514|NCT01184989|9802532|FG000|Overall Study|Withdrawal by Subject|1
6160515|NCT01185080|9802543|FG000|Overall Study|Adverse Event|1
6160516|NCT01185080|9802544|FG001|Overall Study|Adverse Event|1
6160517|NCT01185080|9802545|FG002|Overall Study|Adverse Event|0
6160518|NCT01185080|9802543|FG000|Overall Study|Personal reasons|0
6160519|NCT01185080|9802544|FG001|Overall Study|Personal reasons|0
6160520|NCT01185080|9802545|FG002|Overall Study|Personal reasons|1
6160521|NCT01185171|9802553|FG000|Induction Chemotherapy|Withdrawal by Subject|1
6160522|NCT01185171|9802553|FG000|Induction Chemotherapy|Duodenal Ulcer|1
6160523|NCT01185171|9802553|FG000|Concurrent Chemo and Radiation Treatment|Death|3
6160524|NCT01185171|9802553|FG000|Maintenance|Elevated liver transaminases|3
6160525|NCT01185171|9802553|FG000|Maintenance|Rush|2
6160526|NCT01185171|9802553|FG000|Maintenance|Diarrhea|1
6160527|NCT01185171|9802553|FG000|Maintenance|Xerostomia|1
6160528|NCT01185171|9802553|FG000|Maintenance|Nausea|1
6160529|NCT01185171|9802553|FG000|Maintenance|Comorbid Illness|2
6160530|NCT01185171|9802553|FG000|Maintenance|Withdrawal by Subject|1
6160531|NCT01185171|9802553|FG000|Maintenance|Disease Recurrence|1
6160532|NCT01185249|9802557|FG000|Overall Study|Patients discharged or change in status|42
6160533|NCT01185288|9802564|FG000|Overall Study|Adverse Event|7
6160534|NCT01185288|9802565|FG001|Overall Study|Adverse Event|6
6160535|NCT01185288|9802564|FG000|Overall Study|Withdrawal by Subject|6
6160536|NCT01185288|9802565|FG001|Overall Study|Withdrawal by Subject|4
6160537|NCT01185288|9802564|FG000|Overall Study|Lost to Follow-up|2
6160538|NCT01185288|9802565|FG001|Overall Study|Lost to Follow-up|5
6160539|NCT01185288|9802564|FG000|Overall Study|Lack of Efficacy|2
6160540|NCT01185288|9802565|FG001|Overall Study|Lack of Efficacy|0
6160541|NCT01185288|9802564|FG000|Overall Study|Investigator discretion|1
6160542|NCT01185288|9802565|FG001|Overall Study|Investigator discretion|0
6160543|NCT01185288|9802564|FG000|Overall Study|Did not meet inclusion criteria|1
6160544|NCT01185288|9802565|FG001|Overall Study|Did not meet inclusion criteria|0
6160545|NCT01185288|9802564|FG000|Overall Study|Noncompliance|0
6160546|NCT01185288|9802565|FG001|Overall Study|Noncompliance|1
6160547|NCT01185301|9802575|FG000|Overall Study|Adverse Event|3
6160548|NCT01185301|9802576|FG001|Overall Study|Adverse Event|0
6160549|NCT01185301|9802577|FG002|Overall Study|Adverse Event|2
6160550|NCT01185301|9802578|FG003|Overall Study|Adverse Event|3
6160551|NCT01185301|9802575|FG000|Overall Study|Withdrawal by Subject|7
6160552|NCT01185301|9802576|FG001|Overall Study|Withdrawal by Subject|5
6160553|NCT01185301|9802577|FG002|Overall Study|Withdrawal by Subject|2
6160554|NCT01185301|9802578|FG003|Overall Study|Withdrawal by Subject|3
6160555|NCT01185301|9802575|FG000|Overall Study|Lost to Follow-up|2
6160556|NCT01185301|9802576|FG001|Overall Study|Lost to Follow-up|0
6160557|NCT01185301|9802577|FG002|Overall Study|Lost to Follow-up|0
6160558|NCT01185301|9802578|FG003|Overall Study|Lost to Follow-up|1
6160559|NCT01185301|9802575|FG000|Overall Study|Other Reason|3
6160560|NCT01185301|9802576|FG001|Overall Study|Other Reason|2
6160561|NCT01185301|9802577|FG002|Overall Study|Other Reason|2
6160562|NCT01185301|9802578|FG003|Overall Study|Other Reason|2
6160563|NCT01185340|9802591|FG000|Confirmation (CF) Phase, 3 Weeks|Adverse Event|24
6160564|NCT01185340|9802592|FG001|Confirmation (CF) Phase, 3 Weeks|Adverse Event|0
6160565|NCT01185340|9802593|FG002|Confirmation (CF) Phase, 3 Weeks|Adverse Event|0
6160566|NCT01185340|9802594|FG003|Confirmation (CF) Phase, 3 Weeks|Adverse Event|0
6160567|NCT01185340|9802591|FG000|Confirmation (CF) Phase, 3 Weeks|Lack of Efficacy|6
6160568|NCT01185340|9802592|FG001|Confirmation (CF) Phase, 3 Weeks|Lack of Efficacy|0
6160569|NCT01185340|9802593|FG002|Confirmation (CF) Phase, 3 Weeks|Lack of Efficacy|0
6160570|NCT01185340|9802594|FG003|Confirmation (CF) Phase, 3 Weeks|Lack of Efficacy|0
6160571|NCT01185340|9802591|FG000|Confirmation (CF) Phase, 3 Weeks|Lost to Follow-up|5
6160572|NCT01185340|9802592|FG001|Confirmation (CF) Phase, 3 Weeks|Lost to Follow-up|0
6160573|NCT01185340|9802593|FG002|Confirmation (CF) Phase, 3 Weeks|Lost to Follow-up|0
6160574|NCT01185340|9802594|FG003|Confirmation (CF) Phase, 3 Weeks|Lost to Follow-up|0
6160575|NCT01185340|9802591|FG000|Confirmation (CF) Phase, 3 Weeks|Physician Decision|2
6160576|NCT01185340|9802592|FG001|Confirmation (CF) Phase, 3 Weeks|Physician Decision|0
6160577|NCT01185340|9802593|FG002|Confirmation (CF) Phase, 3 Weeks|Physician Decision|0
6160578|NCT01185340|9802594|FG003|Confirmation (CF) Phase, 3 Weeks|Physician Decision|0
6160579|NCT01185340|9802591|FG000|Confirmation (CF) Phase, 3 Weeks|Protocol Violation|16
6160580|NCT01185340|9802592|FG001|Confirmation (CF) Phase, 3 Weeks|Protocol Violation|0
6160581|NCT01185340|9802593|FG002|Confirmation (CF) Phase, 3 Weeks|Protocol Violation|0
6160582|NCT01185340|9802594|FG003|Confirmation (CF) Phase, 3 Weeks|Protocol Violation|0
6160583|NCT01185340|9802591|FG000|Confirmation (CF) Phase, 3 Weeks|Withdrawal by Subject|32
6160584|NCT01185340|9802592|FG001|Confirmation (CF) Phase, 3 Weeks|Withdrawal by Subject|0
6160585|NCT01185340|9802593|FG002|Confirmation (CF) Phase, 3 Weeks|Withdrawal by Subject|0
6160586|NCT01185340|9802594|FG003|Confirmation (CF) Phase, 3 Weeks|Withdrawal by Subject|0
6160587|NCT01185340|9802591|FG000|Confirmation (CF) Phase, 3 Weeks|Sponsor Decision|3
6160588|NCT01185340|9802592|FG001|Confirmation (CF) Phase, 3 Weeks|Sponsor Decision|0
6160589|NCT01185340|9802593|FG002|Confirmation (CF) Phase, 3 Weeks|Sponsor Decision|0
6160590|NCT01185340|9802594|FG003|Confirmation (CF) Phase, 3 Weeks|Sponsor Decision|0
6160591|NCT01185340|9802591|FG000|Adjunctive Treatment (AT) Phase, 8 Weeks|Adverse Event|0
6160592|NCT01185340|9802592|FG001|Adjunctive Treatment (AT) Phase, 8 Weeks|Adverse Event|13
6160593|NCT01185340|9802593|FG002|Adjunctive Treatment (AT) Phase, 8 Weeks|Adverse Event|8
6160594|NCT01185340|9802594|FG003|Adjunctive Treatment (AT) Phase, 8 Weeks|Adverse Event|13
6160595|NCT01185340|9802591|FG000|Adjunctive Treatment (AT) Phase, 8 Weeks|Lack of Efficacy|0
6160596|NCT01185340|9802592|FG001|Adjunctive Treatment (AT) Phase, 8 Weeks|Lack of Efficacy|4
6160597|NCT01185340|9802593|FG002|Adjunctive Treatment (AT) Phase, 8 Weeks|Lack of Efficacy|7
6160598|NCT01185340|9802594|FG003|Adjunctive Treatment (AT) Phase, 8 Weeks|Lack of Efficacy|4
6160599|NCT01185340|9802591|FG000|Adjunctive Treatment (AT) Phase, 8 Weeks|Lost to Follow-up|0
6160600|NCT01185340|9802592|FG001|Adjunctive Treatment (AT) Phase, 8 Weeks|Lost to Follow-up|4
6160601|NCT01185340|9802593|FG002|Adjunctive Treatment (AT) Phase, 8 Weeks|Lost to Follow-up|5
6160602|NCT01185340|9802594|FG003|Adjunctive Treatment (AT) Phase, 8 Weeks|Lost to Follow-up|7
6160603|NCT01185340|9802591|FG000|Adjunctive Treatment (AT) Phase, 8 Weeks|Physician Decision|0
6160604|NCT01185340|9802592|FG001|Adjunctive Treatment (AT) Phase, 8 Weeks|Physician Decision|1
6160605|NCT01185340|9802593|FG002|Adjunctive Treatment (AT) Phase, 8 Weeks|Physician Decision|0
6160606|NCT01185340|9802594|FG003|Adjunctive Treatment (AT) Phase, 8 Weeks|Physician Decision|1
6160607|NCT01185340|9802591|FG000|Adjunctive Treatment (AT) Phase, 8 Weeks|Protocol Violation|0
6160608|NCT01185340|9802592|FG001|Adjunctive Treatment (AT) Phase, 8 Weeks|Protocol Violation|5
6160609|NCT01185340|9802593|FG002|Adjunctive Treatment (AT) Phase, 8 Weeks|Protocol Violation|2
6160610|NCT01185340|9802594|FG003|Adjunctive Treatment (AT) Phase, 8 Weeks|Protocol Violation|5
6160611|NCT01185340|9802591|FG000|Adjunctive Treatment (AT) Phase, 8 Weeks|Withdrawal by Subject|0
6160612|NCT01185340|9802592|FG001|Adjunctive Treatment (AT) Phase, 8 Weeks|Withdrawal by Subject|8
6160613|NCT01185340|9802593|FG002|Adjunctive Treatment (AT) Phase, 8 Weeks|Withdrawal by Subject|8
6160614|NCT01185340|9802594|FG003|Adjunctive Treatment (AT) Phase, 8 Weeks|Withdrawal by Subject|24
6160615|NCT01185340|9802591|FG000|Adjunctive Treatment (AT) Phase, 8 Weeks|Sponsor Decision|0
6160616|NCT01185340|9802592|FG001|Adjunctive Treatment (AT) Phase, 8 Weeks|Sponsor Decision|0
6160617|NCT01185340|9802593|FG002|Adjunctive Treatment (AT) Phase, 8 Weeks|Sponsor Decision|3
6160618|NCT01185340|9802594|FG003|Adjunctive Treatment (AT) Phase, 8 Weeks|Sponsor Decision|7
6160619|NCT01185353|9802611|FG000|Part A (Weeks 0 Through 12)|Adverse Event|1
6160620|NCT01185353|9802612|FG001|Part A (Weeks 0 Through 12)|Adverse Event|1
6160621|NCT01185353|9802613|FG002|Part A (Weeks 0 Through 12)|Adverse Event|1
6160622|NCT01185353|9802614|FG003|Part A (Weeks 0 Through 12)|Adverse Event|1
6160623|NCT01185353|9802615|FG004|Part A (Weeks 0 Through 12)|Adverse Event|5
6160624|NCT01185353|9802616|FG005|Part A (Weeks 0 Through 12)|Adverse Event|0
6160625|NCT01185353|9802617|FG006|Part A (Weeks 0 Through 12)|Adverse Event|0
6160626|NCT01185353|9802618|FG007|Part A (Weeks 0 Through 12)|Adverse Event|0
6160627|NCT01185353|9802619|FG008|Part A (Weeks 0 Through 12)|Adverse Event|0
6160628|NCT01185353|9802620|FG009|Part A (Weeks 0 Through 12)|Adverse Event|0
6160629|NCT01185353|9802611|FG000|Part A (Weeks 0 Through 12)|Entry Criteria Not Met|0
6160630|NCT01185353|9802612|FG001|Part A (Weeks 0 Through 12)|Entry Criteria Not Met|0
6160631|NCT01185353|9802613|FG002|Part A (Weeks 0 Through 12)|Entry Criteria Not Met|0
6160632|NCT01185353|9802614|FG003|Part A (Weeks 0 Through 12)|Entry Criteria Not Met|0
6160633|NCT01185353|9802615|FG004|Part A (Weeks 0 Through 12)|Entry Criteria Not Met|4
6160634|NCT01185353|9802616|FG005|Part A (Weeks 0 Through 12)|Entry Criteria Not Met|0
6160635|NCT01185353|9802617|FG006|Part A (Weeks 0 Through 12)|Entry Criteria Not Met|0
6160636|NCT01185353|9802618|FG007|Part A (Weeks 0 Through 12)|Entry Criteria Not Met|0
6160637|NCT01185353|9802619|FG008|Part A (Weeks 0 Through 12)|Entry Criteria Not Met|0
6160638|NCT01185353|9802620|FG009|Part A (Weeks 0 Through 12)|Entry Criteria Not Met|0
6160639|NCT01185353|9802611|FG000|Part A (Weeks 0 Through 12)|Lack of Efficacy|2
6160640|NCT01185353|9802612|FG001|Part A (Weeks 0 Through 12)|Lack of Efficacy|0
6160641|NCT01185353|9802613|FG002|Part A (Weeks 0 Through 12)|Lack of Efficacy|0
6160642|NCT01185353|9802614|FG003|Part A (Weeks 0 Through 12)|Lack of Efficacy|0
6160643|NCT01185353|9802615|FG004|Part A (Weeks 0 Through 12)|Lack of Efficacy|1
6160644|NCT01185353|9802616|FG005|Part A (Weeks 0 Through 12)|Lack of Efficacy|0
6160645|NCT01185353|9802617|FG006|Part A (Weeks 0 Through 12)|Lack of Efficacy|0
6160646|NCT01185353|9802618|FG007|Part A (Weeks 0 Through 12)|Lack of Efficacy|0
6160647|NCT01185353|9802619|FG008|Part A (Weeks 0 Through 12)|Lack of Efficacy|0
6160648|NCT01185353|9802620|FG009|Part A (Weeks 0 Through 12)|Lack of Efficacy|0
6160649|NCT01185353|9802611|FG000|Part A (Weeks 0 Through 12)|Physician Decision|0
6160650|NCT01185353|9802612|FG001|Part A (Weeks 0 Through 12)|Physician Decision|0
6160651|NCT01185353|9802613|FG002|Part A (Weeks 0 Through 12)|Physician Decision|1
6160652|NCT01185353|9802614|FG003|Part A (Weeks 0 Through 12)|Physician Decision|0
6160653|NCT01185353|9802615|FG004|Part A (Weeks 0 Through 12)|Physician Decision|2
6160654|NCT01185353|9802616|FG005|Part A (Weeks 0 Through 12)|Physician Decision|0
6160655|NCT01185353|9802617|FG006|Part A (Weeks 0 Through 12)|Physician Decision|0
6160656|NCT01185353|9802618|FG007|Part A (Weeks 0 Through 12)|Physician Decision|0
6160657|NCT01185353|9802619|FG008|Part A (Weeks 0 Through 12)|Physician Decision|0
6160658|NCT01185353|9802620|FG009|Part A (Weeks 0 Through 12)|Physician Decision|0
6160659|NCT01185353|9802611|FG000|Part A (Weeks 0 Through 12)|Protocol Violation|0
6160660|NCT01185353|9802612|FG001|Part A (Weeks 0 Through 12)|Protocol Violation|0
6160661|NCT01185353|9802613|FG002|Part A (Weeks 0 Through 12)|Protocol Violation|0
6160662|NCT01185353|9802614|FG003|Part A (Weeks 0 Through 12)|Protocol Violation|0
6160663|NCT01185353|9802615|FG004|Part A (Weeks 0 Through 12)|Protocol Violation|1
6160664|NCT01185353|9802616|FG005|Part A (Weeks 0 Through 12)|Protocol Violation|0
6325246|NCT02927080|10067322|FG004|Overall Study|Other|0
6325247|NCT02927080|10067323|FG005|Overall Study|Other|0
6325248|NCT02927080|10067324|FG006|Overall Study|Other|1
6325249|NCT02927080|10067325|FG007|Overall Study|Other|0
6325250|NCT02927080|10067326|FG008|Overall Study|Other|1
6325251|NCT02927080|10067327|FG009|Overall Study|Other|0
6325252|NCT02927171|10067374|FG000|Overall Study|Lost to Follow-up|0
6325253|NCT02927171|10067375|FG001|Overall Study|Lost to Follow-up|1
6325254|NCT02927301|10067387|FG000|Overall Study|Adverse Event|7
6325255|NCT02927301|10067387|FG000|Overall Study|Withdrawal by Subject|1
6325256|NCT02927301|10067387|FG000|Overall Study|Physician Decision|2
6325257|NCT02927366|10067402|FG000|Overall Study|Adverse Event|1
6325258|NCT02927366|10067403|FG001|Overall Study|Adverse Event|0
6325259|NCT02927366|10067402|FG000|Overall Study|Patient schedule|1
6325260|NCT02927366|10067403|FG001|Overall Study|Patient schedule|0
6325261|NCT02927431|10067412|FG000|Overall Study|Withdrawal by Subject|0
6325262|NCT02927431|10067413|FG001|Overall Study|Withdrawal by Subject|0
6325263|NCT02927431|10067414|FG002|Overall Study|Withdrawal by Subject|1
6325264|NCT02927795|10067446|FG000|Overall Study|Non-evaluable PF10 quest. at visit 2|19
6325265|NCT02927795|10067446|FG000|Overall Study|Not Treated|4
6325266|NCT02927834|10067453|FG000|Overall Study|Lost to Follow-up|1
6325267|NCT02927834|10067454|FG001|Overall Study|Lost to Follow-up|2
6325268|NCT02927834|10067455|FG002|Overall Study|Lost to Follow-up|2
6325269|NCT02927873|10067469|FG000|Overall Study|Lost to Follow-up|0
6325270|NCT02927873|10067470|FG001|Overall Study|Lost to Follow-up|1
6325271|NCT02927873|10067471|FG002|Overall Study|Lost to Follow-up|0
6160665|NCT01185353|9802617|FG006|Part A (Weeks 0 Through 12)|Protocol Violation|0
6160666|NCT01185353|9802618|FG007|Part A (Weeks 0 Through 12)|Protocol Violation|0
6160667|NCT01185353|9802619|FG008|Part A (Weeks 0 Through 12)|Protocol Violation|0
6160668|NCT01185353|9802620|FG009|Part A (Weeks 0 Through 12)|Protocol Violation|0
6160669|NCT01185353|9802611|FG000|Part A (Weeks 0 Through 12)|Withdrawal by Subject|2
6160670|NCT01185353|9802612|FG001|Part A (Weeks 0 Through 12)|Withdrawal by Subject|0
6160671|NCT01185353|9802613|FG002|Part A (Weeks 0 Through 12)|Withdrawal by Subject|0
6160672|NCT01185353|9802614|FG003|Part A (Weeks 0 Through 12)|Withdrawal by Subject|0
6160673|NCT01185353|9802615|FG004|Part A (Weeks 0 Through 12)|Withdrawal by Subject|3
6160674|NCT01185353|9802616|FG005|Part A (Weeks 0 Through 12)|Withdrawal by Subject|0
6160675|NCT01185353|9802617|FG006|Part A (Weeks 0 Through 12)|Withdrawal by Subject|0
6160676|NCT01185353|9802618|FG007|Part A (Weeks 0 Through 12)|Withdrawal by Subject|0
6160677|NCT01185353|9802619|FG008|Part A (Weeks 0 Through 12)|Withdrawal by Subject|0
6160678|NCT01185353|9802620|FG009|Part A (Weeks 0 Through 12)|Withdrawal by Subject|0
6160679|NCT01185353|9802611|FG000|Part B (Weeks 12 Through 24)|Adverse Event|0
6160680|NCT01185353|9802612|FG001|Part B (Weeks 12 Through 24)|Adverse Event|0
6160681|NCT01185353|9802613|FG002|Part B (Weeks 12 Through 24)|Adverse Event|1
6160682|NCT01185353|9802614|FG003|Part B (Weeks 12 Through 24)|Adverse Event|0
6160683|NCT01185353|9802615|FG004|Part B (Weeks 12 Through 24)|Adverse Event|0
6160684|NCT01185353|9802616|FG005|Part B (Weeks 12 Through 24)|Adverse Event|1
6160685|NCT01185353|9802617|FG006|Part B (Weeks 12 Through 24)|Adverse Event|0
6160686|NCT01185353|9802618|FG007|Part B (Weeks 12 Through 24)|Adverse Event|0
6160687|NCT01185353|9802619|FG008|Part B (Weeks 12 Through 24)|Adverse Event|0
6160688|NCT01185353|9802620|FG009|Part B (Weeks 12 Through 24)|Adverse Event|0
6160689|NCT01185353|9802611|FG000|Part B (Weeks 12 Through 24)|Lack of Efficacy|0
6160690|NCT01185353|9802612|FG001|Part B (Weeks 12 Through 24)|Lack of Efficacy|1
6325272|NCT02927873|10067472|FG003|Overall Study|Lost to Follow-up|0
6325273|NCT02927873|10067473|FG004|Overall Study|Lost to Follow-up|0
6325274|NCT02927873|10067474|FG005|Overall Study|Lost to Follow-up|0
6325275|NCT02927873|10067469|FG000|Overall Study|CONSENT WITHDRAWAL NOT DUE TO ADV. EVENT|0
6325276|NCT02927873|10067470|FG001|Overall Study|CONSENT WITHDRAWAL NOT DUE TO ADV. EVENT|1
6325277|NCT02927873|10067471|FG002|Overall Study|CONSENT WITHDRAWAL NOT DUE TO ADV. EVENT|0
6325278|NCT02927873|10067472|FG003|Overall Study|CONSENT WITHDRAWAL NOT DUE TO ADV. EVENT|0
6325279|NCT02927873|10067473|FG004|Overall Study|CONSENT WITHDRAWAL NOT DUE TO ADV. EVENT|0
6325280|NCT02927873|10067474|FG005|Overall Study|CONSENT WITHDRAWAL NOT DUE TO ADV. EVENT|0
6325281|NCT02927873|10067469|FG000|Overall Study|MIGRATED / MOVED FROM THE STUDY AREA|0
6325282|NCT02927873|10067470|FG001|Overall Study|MIGRATED / MOVED FROM THE STUDY AREA|0
6325283|NCT02927873|10067471|FG002|Overall Study|MIGRATED / MOVED FROM THE STUDY AREA|0
6325284|NCT02927873|10067472|FG003|Overall Study|MIGRATED / MOVED FROM THE STUDY AREA|0
6325285|NCT02927873|10067473|FG004|Overall Study|MIGRATED / MOVED FROM THE STUDY AREA|0
6325286|NCT02927873|10067474|FG005|Overall Study|MIGRATED / MOVED FROM THE STUDY AREA|1
6325287|NCT02927873|10067469|FG000|Overall Study|PARENTS NOT ABLE TO COME TO SITE|0
6325288|NCT02927873|10067470|FG001|Overall Study|PARENTS NOT ABLE TO COME TO SITE|1
6325289|NCT02927873|10067471|FG002|Overall Study|PARENTS NOT ABLE TO COME TO SITE|0
6325290|NCT02927873|10067472|FG003|Overall Study|PARENTS NOT ABLE TO COME TO SITE|0
6325291|NCT02927873|10067473|FG004|Overall Study|PARENTS NOT ABLE TO COME TO SITE|0
6325292|NCT02927873|10067474|FG005|Overall Study|PARENTS NOT ABLE TO COME TO SITE|0
6325293|NCT02927873|10067469|FG000|Overall Study|SUBJECT WITHDRAWN AT AN INTERIM TIMEPOINT, BUT ACCEPTED CALLS FOR SAFETY SURVEILLANCE|1
6325294|NCT02927873|10067470|FG001|Overall Study|SUBJECT WITHDRAWN AT AN INTERIM TIMEPOINT, BUT ACCEPTED CALLS FOR SAFETY SURVEILLANCE|0
6325295|NCT02927873|10067471|FG002|Overall Study|SUBJECT WITHDRAWN AT AN INTERIM TIMEPOINT, BUT ACCEPTED CALLS FOR SAFETY SURVEILLANCE|0
6325296|NCT02927873|10067472|FG003|Overall Study|SUBJECT WITHDRAWN AT AN INTERIM TIMEPOINT, BUT ACCEPTED CALLS FOR SAFETY SURVEILLANCE|0
6325297|NCT02927873|10067473|FG004|Overall Study|SUBJECT WITHDRAWN AT AN INTERIM TIMEPOINT, BUT ACCEPTED CALLS FOR SAFETY SURVEILLANCE|0
6325298|NCT02927873|10067474|FG005|Overall Study|SUBJECT WITHDRAWN AT AN INTERIM TIMEPOINT, BUT ACCEPTED CALLS FOR SAFETY SURVEILLANCE|0
6325299|NCT02927873|10067469|FG000|Overall Study|PARENTS REFUSED SAFETY FOLLOW-UP|1
6325300|NCT02927873|10067470|FG001|Overall Study|PARENTS REFUSED SAFETY FOLLOW-UP|0
6325301|NCT02927873|10067471|FG002|Overall Study|PARENTS REFUSED SAFETY FOLLOW-UP|0
6325302|NCT02927873|10067472|FG003|Overall Study|PARENTS REFUSED SAFETY FOLLOW-UP|0
6325303|NCT02927873|10067473|FG004|Overall Study|PARENTS REFUSED SAFETY FOLLOW-UP|0
6325304|NCT02927873|10067474|FG005|Overall Study|PARENTS REFUSED SAFETY FOLLOW-UP|0
6325305|NCT02927925|10067488|FG000|Overall Study|Death|16
6325306|NCT02927925|10067488|FG000|Overall Study|Physician Decision|1
6325307|NCT02927925|10067488|FG000|Overall Study|Withdrawal by Subject|11
6325308|NCT02927925|10067488|FG000|Overall Study|Other|3
6325309|NCT02927925|10067488|FG000|Overall Study|Disease progression at clinical cutoff|1
6325310|NCT02928029|10067494|FG000|Overall Study|Withdrawal by Subject|0
6325311|NCT02928029|10067495|FG001|Overall Study|Withdrawal by Subject|1
6325312|NCT02928029|10067494|FG000|Overall Study|Radiological progression|1
6325313|NCT02928029|10067495|FG001|Overall Study|Radiological progression|0
6325314|NCT02928029|10067494|FG000|Overall Study|Clinical progression|1
6325315|NCT02928029|10067495|FG001|Overall Study|Clinical progression|2
6325316|NCT02928029|10067494|FG000|Overall Study|AE not related to clinical progression|1
6325317|NCT02928029|10067495|FG001|Overall Study|AE not related to clinical progression|1
6160691|NCT01185353|9802613|FG002|Part B (Weeks 12 Through 24)|Lack of Efficacy|0
6160692|NCT01185353|9802614|FG003|Part B (Weeks 12 Through 24)|Lack of Efficacy|1
6160693|NCT01185353|9802615|FG004|Part B (Weeks 12 Through 24)|Lack of Efficacy|0
6160694|NCT01185353|9802616|FG005|Part B (Weeks 12 Through 24)|Lack of Efficacy|0
6160695|NCT01185353|9802617|FG006|Part B (Weeks 12 Through 24)|Lack of Efficacy|0
6160696|NCT01185353|9802618|FG007|Part B (Weeks 12 Through 24)|Lack of Efficacy|0
6160697|NCT01185353|9802619|FG008|Part B (Weeks 12 Through 24)|Lack of Efficacy|0
6160698|NCT01185353|9802620|FG009|Part B (Weeks 12 Through 24)|Lack of Efficacy|0
6160699|NCT01185353|9802611|FG000|Part B (Weeks 12 Through 24)|Lost to Follow-up|0
6160700|NCT01185353|9802612|FG001|Part B (Weeks 12 Through 24)|Lost to Follow-up|0
6160701|NCT01185353|9802613|FG002|Part B (Weeks 12 Through 24)|Lost to Follow-up|0
6160702|NCT01185353|9802614|FG003|Part B (Weeks 12 Through 24)|Lost to Follow-up|1
6160703|NCT01185353|9802615|FG004|Part B (Weeks 12 Through 24)|Lost to Follow-up|0
6160704|NCT01185353|9802616|FG005|Part B (Weeks 12 Through 24)|Lost to Follow-up|0
6160705|NCT01185353|9802617|FG006|Part B (Weeks 12 Through 24)|Lost to Follow-up|1
6160706|NCT01185353|9802618|FG007|Part B (Weeks 12 Through 24)|Lost to Follow-up|0
6160707|NCT01185353|9802619|FG008|Part B (Weeks 12 Through 24)|Lost to Follow-up|0
6160708|NCT01185353|9802620|FG009|Part B (Weeks 12 Through 24)|Lost to Follow-up|0
6160709|NCT01185353|9802611|FG000|Part B (Weeks 12 Through 24)|Withdrawal by Subject|0
6160710|NCT01185353|9802612|FG001|Part B (Weeks 12 Through 24)|Withdrawal by Subject|0
6160711|NCT01185353|9802613|FG002|Part B (Weeks 12 Through 24)|Withdrawal by Subject|1
6160712|NCT01185353|9802614|FG003|Part B (Weeks 12 Through 24)|Withdrawal by Subject|2
6160713|NCT01185353|9802615|FG004|Part B (Weeks 12 Through 24)|Withdrawal by Subject|0
6160714|NCT01185353|9802616|FG005|Part B (Weeks 12 Through 24)|Withdrawal by Subject|3
6160715|NCT01185353|9802617|FG006|Part B (Weeks 12 Through 24)|Withdrawal by Subject|4
6160716|NCT01185353|9802618|FG007|Part B (Weeks 12 Through 24)|Withdrawal by Subject|0
6160717|NCT01185353|9802619|FG008|Part B (Weeks 12 Through 24)|Withdrawal by Subject|0
6160718|NCT01185353|9802620|FG009|Part B (Weeks 12 Through 24)|Withdrawal by Subject|0
6160719|NCT01185353|9802611|FG000|Part B (Weeks 12 Through 24)|Entry Criteria Not Met|0
6160720|NCT01185353|9802612|FG001|Part B (Weeks 12 Through 24)|Entry Criteria Not Met|0
6160721|NCT01185353|9802613|FG002|Part B (Weeks 12 Through 24)|Entry Criteria Not Met|0
6160722|NCT01185353|9802614|FG003|Part B (Weeks 12 Through 24)|Entry Criteria Not Met|0
6160723|NCT01185353|9802615|FG004|Part B (Weeks 12 Through 24)|Entry Criteria Not Met|0
6160724|NCT01185353|9802616|FG005|Part B (Weeks 12 Through 24)|Entry Criteria Not Met|0
6160725|NCT01185353|9802617|FG006|Part B (Weeks 12 Through 24)|Entry Criteria Not Met|1
6160726|NCT01185353|9802618|FG007|Part B (Weeks 12 Through 24)|Entry Criteria Not Met|0
6325318|NCT02928770|10067534|FG000|Overall Study|Withdrawal by Subject|2
6325319|NCT02928848|10067540|FG000|Arm 2|Withdrawal by Subject|1
6325320|NCT02928848|10067541|FG001|Arm 2|Withdrawal by Subject|0
6325321|NCT02928952|10067551|FG000|Overall Study|Lost to Follow-up|5
6325322|NCT02928952|10067552|FG001|Overall Study|Lost to Follow-up|5
6325323|NCT02928952|10067551|FG000|Overall Study|Withdrawal by Subject|5
6325324|NCT02928952|10067552|FG001|Overall Study|Withdrawal by Subject|1
6325325|NCT02928952|10067551|FG000|Overall Study|Physician Decision|0
6325326|NCT02928952|10067552|FG001|Overall Study|Physician Decision|1
6325327|NCT02929329|10067560|FG000|Overall Study|Withdrawal by Subject|24
6325328|NCT02929329|10067561|FG001|Overall Study|Withdrawal by Subject|21
6325329|NCT02929329|10067560|FG000|Overall Study|Lost to Follow-up|26
6325330|NCT02929329|10067561|FG001|Overall Study|Lost to Follow-up|20
6325331|NCT02929329|10067560|FG000|Overall Study|Death|1054
6325332|NCT02929329|10067561|FG001|Overall Study|Death|1051
6325333|NCT02929407|10067571|FG000|Overall Study|Adverse Event|1
6325334|NCT02929498|10067578|FG000|Part 1: Dose Confirmation (Upto 2 Years)|Study terminated by sponsor|3
6325335|NCT02929498|10067579|FG001|Part 1: Dose Confirmation (Upto 2 Years)|Study terminated by sponsor|0
6325336|NCT02929498|10067580|FG002|Part 1: Dose Confirmation (Upto 2 Years)|Study terminated by sponsor|0
6325337|NCT02929498|10067578|FG000|Part 1: Dose Confirmation (Upto 2 Years)|Death|2
6325338|NCT02929498|10067579|FG001|Part 1: Dose Confirmation (Upto 2 Years)|Death|0
6325339|NCT02929498|10067580|FG002|Part 1: Dose Confirmation (Upto 2 Years)|Death|0
6325340|NCT02930005|10067622|FG000|Overall Study|Lost to Follow-up|1
6325341|NCT02930005|10067623|FG001|Overall Study|Lost to Follow-up|5
6325342|NCT02930018|10067631|FG000|Overall Study|Lost to Follow-up|1
6325343|NCT02930018|10067632|FG001|Overall Study|Lost to Follow-up|1
6325344|NCT02930018|10067631|FG000|Overall Study|Withdrawal by Subject|5
6325345|NCT02930018|10067632|FG001|Overall Study|Withdrawal by Subject|2
6325346|NCT02930226|10067655|FG000|Overall Study|Technical Problems: Leak in plasma bag|0
6325347|NCT02930226|10067656|FG001|Overall Study|Technical Problems: Leak in plasma bag|0
6325348|NCT02930226|10067657|FG002|Overall Study|Technical Problems: Leak in plasma bag|0
6325349|NCT02930226|10067658|FG003|Overall Study|Technical Problems: Leak in plasma bag|0
6160727|NCT01185353|9802619|FG008|Part B (Weeks 12 Through 24)|Entry Criteria Not Met|0
6160728|NCT01185353|9802620|FG009|Part B (Weeks 12 Through 24)|Entry Criteria Not Met|0
6160729|NCT01185353|9802611|FG000|Part C (Weeks 24 Through 76)|Adverse Event|0
6160730|NCT01185353|9802612|FG001|Part C (Weeks 24 Through 76)|Adverse Event|0
6160731|NCT01185353|9802613|FG002|Part C (Weeks 24 Through 76)|Adverse Event|0
6325350|NCT02930226|10067659|FG004|Overall Study|Technical Problems: Leak in plasma bag|1
6325351|NCT02930226|10067660|FG005|Overall Study|Technical Problems: Leak in plasma bag|0
6160732|NCT01185353|9802614|FG003|Part C (Weeks 24 Through 76)|Adverse Event|0
6160733|NCT01185353|9802615|FG004|Part C (Weeks 24 Through 76)|Adverse Event|0
6160734|NCT01185353|9802616|FG005|Part C (Weeks 24 Through 76)|Adverse Event|0
6160735|NCT01185353|9802617|FG006|Part C (Weeks 24 Through 76)|Adverse Event|0
6160736|NCT01185353|9802618|FG007|Part C (Weeks 24 Through 76)|Adverse Event|8
6160737|NCT01185353|9802619|FG008|Part C (Weeks 24 Through 76)|Adverse Event|2
6160738|NCT01185353|9802620|FG009|Part C (Weeks 24 Through 76)|Adverse Event|2
6160739|NCT01185353|9802611|FG000|Part C (Weeks 24 Through 76)|Withdrawal by Subject|0
6160740|NCT01185353|9802612|FG001|Part C (Weeks 24 Through 76)|Withdrawal by Subject|0
6160741|NCT01185353|9802613|FG002|Part C (Weeks 24 Through 76)|Withdrawal by Subject|0
6160742|NCT01185353|9802614|FG003|Part C (Weeks 24 Through 76)|Withdrawal by Subject|0
6160743|NCT01185353|9802615|FG004|Part C (Weeks 24 Through 76)|Withdrawal by Subject|0
6160744|NCT01185353|9802616|FG005|Part C (Weeks 24 Through 76)|Withdrawal by Subject|0
6160745|NCT01185353|9802617|FG006|Part C (Weeks 24 Through 76)|Withdrawal by Subject|0
6160746|NCT01185353|9802618|FG007|Part C (Weeks 24 Through 76)|Withdrawal by Subject|6
6160747|NCT01185353|9802619|FG008|Part C (Weeks 24 Through 76)|Withdrawal by Subject|2
6160748|NCT01185353|9802620|FG009|Part C (Weeks 24 Through 76)|Withdrawal by Subject|2
6160749|NCT01185353|9802611|FG000|Part C (Weeks 24 Through 76)|Lost to Follow-up|0
6160750|NCT01185353|9802612|FG001|Part C (Weeks 24 Through 76)|Lost to Follow-up|0
6160751|NCT01185353|9802613|FG002|Part C (Weeks 24 Through 76)|Lost to Follow-up|0
6160752|NCT01185353|9802614|FG003|Part C (Weeks 24 Through 76)|Lost to Follow-up|0
6160753|NCT01185353|9802615|FG004|Part C (Weeks 24 Through 76)|Lost to Follow-up|0
6160754|NCT01185353|9802616|FG005|Part C (Weeks 24 Through 76)|Lost to Follow-up|0
6160755|NCT01185353|9802617|FG006|Part C (Weeks 24 Through 76)|Lost to Follow-up|0
6160756|NCT01185353|9802618|FG007|Part C (Weeks 24 Through 76)|Lost to Follow-up|2
6160757|NCT01185353|9802619|FG008|Part C (Weeks 24 Through 76)|Lost to Follow-up|1
6160758|NCT01185353|9802620|FG009|Part C (Weeks 24 Through 76)|Lost to Follow-up|1
6160759|NCT01185353|9802611|FG000|Part C (Weeks 24 Through 76)|Lack of Efficacy|0
6160760|NCT01185353|9802612|FG001|Part C (Weeks 24 Through 76)|Lack of Efficacy|0
6160761|NCT01185353|9802613|FG002|Part C (Weeks 24 Through 76)|Lack of Efficacy|0
6160762|NCT01185353|9802614|FG003|Part C (Weeks 24 Through 76)|Lack of Efficacy|0
6160763|NCT01185353|9802615|FG004|Part C (Weeks 24 Through 76)|Lack of Efficacy|0
6160764|NCT01185353|9802616|FG005|Part C (Weeks 24 Through 76)|Lack of Efficacy|0
6160765|NCT01185353|9802617|FG006|Part C (Weeks 24 Through 76)|Lack of Efficacy|0
6160766|NCT01185353|9802618|FG007|Part C (Weeks 24 Through 76)|Lack of Efficacy|0
6160767|NCT01185353|9802619|FG008|Part C (Weeks 24 Through 76)|Lack of Efficacy|2
6160768|NCT01185353|9802620|FG009|Part C (Weeks 24 Through 76)|Lack of Efficacy|0
6160769|NCT01185353|9802611|FG000|Part C (Weeks 24 Through 76)|Death|0
6160770|NCT01185353|9802612|FG001|Part C (Weeks 24 Through 76)|Death|0
6160771|NCT01185353|9802613|FG002|Part C (Weeks 24 Through 76)|Death|0
6160772|NCT01185353|9802614|FG003|Part C (Weeks 24 Through 76)|Death|0
6160773|NCT01185353|9802615|FG004|Part C (Weeks 24 Through 76)|Death|0
6160774|NCT01185353|9802616|FG005|Part C (Weeks 24 Through 76)|Death|0
6160775|NCT01185353|9802617|FG006|Part C (Weeks 24 Through 76)|Death|0
6160776|NCT01185353|9802618|FG007|Part C (Weeks 24 Through 76)|Death|0
6160777|NCT01185353|9802619|FG008|Part C (Weeks 24 Through 76)|Death|0
6160778|NCT01185353|9802620|FG009|Part C (Weeks 24 Through 76)|Death|1
6160779|NCT01185353|9802611|FG000|Part C (Weeks 24 Through 76)|Entry Criteria Not Met|0
6160780|NCT01185353|9802612|FG001|Part C (Weeks 24 Through 76)|Entry Criteria Not Met|0
6160781|NCT01185353|9802613|FG002|Part C (Weeks 24 Through 76)|Entry Criteria Not Met|0
6160782|NCT01185353|9802614|FG003|Part C (Weeks 24 Through 76)|Entry Criteria Not Met|0
6160783|NCT01185353|9802615|FG004|Part C (Weeks 24 Through 76)|Entry Criteria Not Met|0
6160784|NCT01185353|9802616|FG005|Part C (Weeks 24 Through 76)|Entry Criteria Not Met|0
6160785|NCT01185353|9802617|FG006|Part C (Weeks 24 Through 76)|Entry Criteria Not Met|0
6160786|NCT01185353|9802618|FG007|Part C (Weeks 24 Through 76)|Entry Criteria Not Met|0
6160787|NCT01185353|9802619|FG008|Part C (Weeks 24 Through 76)|Entry Criteria Not Met|0
6160788|NCT01185353|9802620|FG009|Part C (Weeks 24 Through 76)|Entry Criteria Not Met|1
6160789|NCT01185353|9802611|FG000|Part C (Weeks 24 Through 76)|Physician Decision|0
6160790|NCT01185353|9802612|FG001|Part C (Weeks 24 Through 76)|Physician Decision|0
6160791|NCT01185353|9802613|FG002|Part C (Weeks 24 Through 76)|Physician Decision|0
6160792|NCT01185353|9802614|FG003|Part C (Weeks 24 Through 76)|Physician Decision|0
6160793|NCT01185353|9802615|FG004|Part C (Weeks 24 Through 76)|Physician Decision|0
6160794|NCT01185353|9802616|FG005|Part C (Weeks 24 Through 76)|Physician Decision|0
6160795|NCT01185353|9802617|FG006|Part C (Weeks 24 Through 76)|Physician Decision|0
6160796|NCT01185353|9802618|FG007|Part C (Weeks 24 Through 76)|Physician Decision|0
6160797|NCT01185353|9802619|FG008|Part C (Weeks 24 Through 76)|Physician Decision|0
6160798|NCT01185353|9802620|FG009|Part C (Weeks 24 Through 76)|Physician Decision|1
6160799|NCT01185353|9802611|FG000|Part C (Weeks 24 Through 76)|Reason missing|0
6160800|NCT01185353|9802612|FG001|Part C (Weeks 24 Through 76)|Reason missing|0
6160801|NCT01185353|9802613|FG002|Part C (Weeks 24 Through 76)|Reason missing|0
6160802|NCT01185353|9802614|FG003|Part C (Weeks 24 Through 76)|Reason missing|0
6160803|NCT01185353|9802615|FG004|Part C (Weeks 24 Through 76)|Reason missing|0
6160804|NCT01185353|9802616|FG005|Part C (Weeks 24 Through 76)|Reason missing|0
6160805|NCT01185353|9802617|FG006|Part C (Weeks 24 Through 76)|Reason missing|0
6160806|NCT01185353|9802618|FG007|Part C (Weeks 24 Through 76)|Reason missing|0
6160807|NCT01185353|9802619|FG008|Part C (Weeks 24 Through 76)|Reason missing|1
6160808|NCT01185353|9802620|FG009|Part C (Weeks 24 Through 76)|Reason missing|0
6160809|NCT01185353|9802611|FG000|Part D (Weeks 76 Through 128)|Lost to Follow-up|0
6160810|NCT01185353|9802612|FG001|Part D (Weeks 76 Through 128)|Lost to Follow-up|0
6160811|NCT01185353|9802613|FG002|Part D (Weeks 76 Through 128)|Lost to Follow-up|0
6160812|NCT01185353|9802614|FG003|Part D (Weeks 76 Through 128)|Lost to Follow-up|0
6160813|NCT01185353|9802615|FG004|Part D (Weeks 76 Through 128)|Lost to Follow-up|0
6160814|NCT01185353|9802616|FG005|Part D (Weeks 76 Through 128)|Lost to Follow-up|0
6160815|NCT01185353|9802617|FG006|Part D (Weeks 76 Through 128)|Lost to Follow-up|0
6160816|NCT01185353|9802618|FG007|Part D (Weeks 76 Through 128)|Lost to Follow-up|1
6160817|NCT01185353|9802619|FG008|Part D (Weeks 76 Through 128)|Lost to Follow-up|3
6160818|NCT01185353|9802620|FG009|Part D (Weeks 76 Through 128)|Lost to Follow-up|0
6160819|NCT01185353|9802611|FG000|Part D (Weeks 76 Through 128)|Withdrawal by Subject|0
6160820|NCT01185353|9802612|FG001|Part D (Weeks 76 Through 128)|Withdrawal by Subject|0
6160821|NCT01185353|9802613|FG002|Part D (Weeks 76 Through 128)|Withdrawal by Subject|0
6160822|NCT01185353|9802614|FG003|Part D (Weeks 76 Through 128)|Withdrawal by Subject|0
6160823|NCT01185353|9802615|FG004|Part D (Weeks 76 Through 128)|Withdrawal by Subject|0
6160824|NCT01185353|9802616|FG005|Part D (Weeks 76 Through 128)|Withdrawal by Subject|0
6160825|NCT01185353|9802617|FG006|Part D (Weeks 76 Through 128)|Withdrawal by Subject|0
6160826|NCT01185353|9802618|FG007|Part D (Weeks 76 Through 128)|Withdrawal by Subject|1
6160827|NCT01185353|9802619|FG008|Part D (Weeks 76 Through 128)|Withdrawal by Subject|2
6325352|NCT02930343|10067678|FG000|Overall Study|Lost to Follow-up|9
6325353|NCT02930343|10067679|FG001|Overall Study|Lost to Follow-up|7
6325354|NCT02930837|10067723|FG000|Overall Study|Adverse Event|6
6325355|NCT02930837|10067723|FG000|Overall Study|Lost to Follow-up|5
6325356|NCT02930837|10067723|FG000|Overall Study|Withdrawal by Subject|1
6325357|NCT02930941|10067729|FG000|Overall Study|Lost to Follow-up|1
6325358|NCT02930941|10067730|FG001|Overall Study|Lost to Follow-up|2
6325359|NCT02931396|10067764|FG000|Overall Study|Lost to Follow-up|3
6325360|NCT02931396|10067765|FG001|Overall Study|Lost to Follow-up|0
6325361|NCT02931396|10067764|FG000|Overall Study|Withdrawal by Subject|2
6325362|NCT02931396|10067765|FG001|Overall Study|Withdrawal by Subject|0
6325363|NCT02931539|10067773|FG000|Period 1: Treatment Phase|Investigator discretion|1
6325364|NCT02931539|10067774|FG001|Period 1: Treatment Phase|Investigator discretion|1
6325365|NCT02931539|10067775|FG002|Period 1: Treatment Phase|Investigator discretion|0
6325366|NCT02931539|10067773|FG000|Period 1: Treatment Phase|Adverse Event|5
6325367|NCT02931539|10067774|FG001|Period 1: Treatment Phase|Adverse Event|1
6325368|NCT02931539|10067775|FG002|Period 1: Treatment Phase|Adverse Event|0
6082234|NCT00626392|9690005|FG000|Coadministration Period|Protocol Violation|0
6082235|NCT00626392|9690006|FG001|Coadministration Period|Protocol Violation|1
6082236|NCT00626392|9690007|FG002|Coadministration Period|Protocol Violation|0
6160828|NCT01185353|9802620|FG009|Part D (Weeks 76 Through 128)|Withdrawal by Subject|1
6325369|NCT02931539|10067773|FG000|Period 1: Treatment Phase|Lost to Follow-up|1
6325370|NCT02931539|10067774|FG001|Period 1: Treatment Phase|Lost to Follow-up|2
6325371|NCT02931539|10067775|FG002|Period 1: Treatment Phase|Lost to Follow-up|0
6325372|NCT02931539|10067773|FG000|Period 1: Treatment Phase|Death|8
6325373|NCT02931539|10067774|FG001|Period 1: Treatment Phase|Death|24
6325374|NCT02931539|10067775|FG002|Period 1: Treatment Phase|Death|0
6325375|NCT02931539|10067773|FG000|Period 1: Treatment Phase|Withdrawal by Subject|16
6325376|NCT02931539|10067774|FG001|Period 1: Treatment Phase|Withdrawal by Subject|8
6325377|NCT02931539|10067775|FG002|Period 1: Treatment Phase|Withdrawal by Subject|0
6325378|NCT02931539|10067773|FG000|Period 1: Treatment Phase|Protocol Violation|6
6325379|NCT02931539|10067774|FG001|Period 1: Treatment Phase|Protocol Violation|0
6325380|NCT02931539|10067775|FG002|Period 1: Treatment Phase|Protocol Violation|0
6325381|NCT02931539|10067773|FG000|Period 1: Treatment Phase|Participants transitioned into maribavir rescue arm|22
6325382|NCT02931539|10067774|FG001|Period 1: Treatment Phase|Participants transitioned into maribavir rescue arm|0
6325383|NCT02931539|10067775|FG002|Period 1: Treatment Phase|Participants transitioned into maribavir rescue arm|0
6325384|NCT02931539|10067773|FG000|Period 2: Maribavir Rescue Therapy|Sponsor decision|0
6325385|NCT02931539|10067774|FG001|Period 2: Maribavir Rescue Therapy|Sponsor decision|0
6325386|NCT02931539|10067775|FG002|Period 2: Maribavir Rescue Therapy|Sponsor decision|2
6325387|NCT02931838|10067804|FG000|Overall Study|Reason not provided by investigator|1
6325388|NCT02931838|10067805|FG001|Overall Study|Reason not provided by investigator|0
6325389|NCT02931838|10067806|FG002|Overall Study|Reason not provided by investigator|1
6325390|NCT02931838|10067807|FG003|Overall Study|Reason not provided by investigator|0
6325391|NCT02931838|10067808|FG004|Overall Study|Reason not provided by investigator|0
6325392|NCT02931838|10067809|FG005|Overall Study|Reason not provided by investigator|0
6325393|NCT02931838|10067804|FG000|Overall Study|Poor/non-compliance|0
6325394|NCT02931838|10067805|FG001|Overall Study|Poor/non-compliance|0
6325395|NCT02931838|10067806|FG002|Overall Study|Poor/non-compliance|1
6325396|NCT02931838|10067807|FG003|Overall Study|Poor/non-compliance|0
6325397|NCT02931838|10067808|FG004|Overall Study|Poor/non-compliance|0
6325398|NCT02931838|10067809|FG005|Overall Study|Poor/non-compliance|0
6325399|NCT02931838|10067804|FG000|Overall Study|Lack of Efficacy|5
6325400|NCT02931838|10067805|FG001|Overall Study|Lack of Efficacy|4
6160829|NCT01185353|9802611|FG000|Part D (Weeks 76 Through 128)|Adverse Event|0
6160830|NCT01185353|9802612|FG001|Part D (Weeks 76 Through 128)|Adverse Event|0
6160831|NCT01185353|9802613|FG002|Part D (Weeks 76 Through 128)|Adverse Event|0
6160832|NCT01185353|9802614|FG003|Part D (Weeks 76 Through 128)|Adverse Event|0
6160833|NCT01185353|9802615|FG004|Part D (Weeks 76 Through 128)|Adverse Event|0
6160834|NCT01185353|9802616|FG005|Part D (Weeks 76 Through 128)|Adverse Event|0
6160835|NCT01185353|9802617|FG006|Part D (Weeks 76 Through 128)|Adverse Event|0
6160836|NCT01185353|9802618|FG007|Part D (Weeks 76 Through 128)|Adverse Event|1
6160837|NCT01185353|9802619|FG008|Part D (Weeks 76 Through 128)|Adverse Event|2
6160838|NCT01185353|9802620|FG009|Part D (Weeks 76 Through 128)|Adverse Event|0
6160839|NCT01185366|9802661|FG000|First Line Therapy|Insurance Coverage Denied|1
6160840|NCT01185366|9802662|FG001|First Line Therapy|Insurance Coverage Denied|1
6160841|NCT01185366|9802661|FG000|First Line Therapy|Withdrawal by Subject|1
6160842|NCT01185366|9802662|FG001|First Line Therapy|Withdrawal by Subject|0
6160843|NCT01185366|9802661|FG000|First Line Therapy|Lack of Metastatic Site|1
6160844|NCT01185366|9802662|FG001|First Line Therapy|Lack of Metastatic Site|0
6160845|NCT01185366|9802661|FG000|Crossover to Second Line Therapy|Adverse Event|3
6160846|NCT01185366|9802662|FG001|Crossover to Second Line Therapy|Adverse Event|6
6160847|NCT01185366|9802661|FG000|Crossover to Second Line Therapy|Physician Decision|5
6160848|NCT01185366|9802662|FG001|Crossover to Second Line Therapy|Physician Decision|1
6160849|NCT01185366|9802661|FG000|Crossover to Second Line Therapy|Withdrawal by Subject|1
6160850|NCT01185366|9802662|FG001|Crossover to Second Line Therapy|Withdrawal by Subject|0
6160851|NCT01185366|9802661|FG000|Crossover to Second Line Therapy|Continued with 1st drug|5
6325401|NCT02931838|10067806|FG002|Overall Study|Lack of Efficacy|0
6325402|NCT02931838|10067807|FG003|Overall Study|Lack of Efficacy|0
6325403|NCT02931838|10067808|FG004|Overall Study|Lack of Efficacy|0
6325404|NCT02931838|10067809|FG005|Overall Study|Lack of Efficacy|1
6325405|NCT02931838|10067804|FG000|Overall Study|Lost to Follow-up|1
6325406|NCT02931838|10067805|FG001|Overall Study|Lost to Follow-up|0
6325407|NCT02931838|10067806|FG002|Overall Study|Lost to Follow-up|1
6325408|NCT02931838|10067807|FG003|Overall Study|Lost to Follow-up|1
6325409|NCT02931838|10067808|FG004|Overall Study|Lost to Follow-up|2
6325410|NCT02931838|10067809|FG005|Overall Study|Lost to Follow-up|0
6325411|NCT02931838|10067804|FG000|Overall Study|Subject request to discontinue treatment|4
6325412|NCT02931838|10067805|FG001|Overall Study|Subject request to discontinue treatment|3
6325413|NCT02931838|10067806|FG002|Overall Study|Subject request to discontinue treatment|3
6325414|NCT02931838|10067807|FG003|Overall Study|Subject request to discontinue treatment|0
6325415|NCT02931838|10067808|FG004|Overall Study|Subject request to discontinue treatment|1
6325416|NCT02931838|10067809|FG005|Overall Study|Subject request to discontinue treatment|0
6325417|NCT02931838|10067804|FG000|Overall Study|Withdrawal by Subject|1
6325418|NCT02931838|10067805|FG001|Overall Study|Withdrawal by Subject|2
6325419|NCT02931838|10067806|FG002|Overall Study|Withdrawal by Subject|0
6325420|NCT02931838|10067807|FG003|Overall Study|Withdrawal by Subject|1
6325421|NCT02931838|10067808|FG004|Overall Study|Withdrawal by Subject|0
6325422|NCT02931838|10067809|FG005|Overall Study|Withdrawal by Subject|0
6325423|NCT02931838|10067804|FG000|Overall Study|Adverse Event|2
6325424|NCT02931838|10067805|FG001|Overall Study|Adverse Event|1
6325425|NCT02931838|10067806|FG002|Overall Study|Adverse Event|2
6325426|NCT02931838|10067807|FG003|Overall Study|Adverse Event|1
6325427|NCT02931838|10067808|FG004|Overall Study|Adverse Event|3
6325428|NCT02931838|10067809|FG005|Overall Study|Adverse Event|1
6325429|NCT02932228|10067830|FG000|Overall Study|Death|8
6325430|NCT02932228|10067831|FG001|Overall Study|Death|23
6325431|NCT02932228|10067830|FG000|Overall Study|not eligible upon chart review|2
6325432|NCT02932228|10067831|FG001|Overall Study|not eligible upon chart review|5
6160852|NCT01185366|9802662|FG001|Crossover to Second Line Therapy|Continued with 1st drug|3
6160853|NCT01185509|9802672|FG000|Overall Study|Progression/Relapse|9
6160854|NCT01185509|9802673|FG001|Overall Study|Progression/Relapse|15
6160855|NCT01185509|9802672|FG000|Overall Study|Physician Decision|2
6160856|NCT01185509|9802673|FG001|Overall Study|Physician Decision|2
6160857|NCT01185509|9802672|FG000|Overall Study|Withdrawal by Subject|0
6160858|NCT01185509|9802673|FG001|Overall Study|Withdrawal by Subject|1
6160859|NCT01185509|9802672|FG000|Overall Study|Death|0
6160860|NCT01185509|9802673|FG001|Overall Study|Death|1
6160861|NCT01185509|9802672|FG000|Overall Study|Intercurrent Illness|0
6160862|NCT01185509|9802673|FG001|Overall Study|Intercurrent Illness|1
6160863|NCT01185522|9802680|FG000|Overall Study|Lack of Efficacy|28
6160864|NCT01185522|9802680|FG000|Overall Study|Lost to Follow-up|19
6160865|NCT01185522|9802680|FG000|Overall Study|Withdrawal by Subject|10
6160866|NCT01185522|9802680|FG000|Overall Study|Poor tolerance|39
6160867|NCT01185522|9802680|FG000|Overall Study|Other reasons|12
6325433|NCT02932267|10067839|FG000|Overall Study|Withdrawal by Subject|3
6325434|NCT02932267|10067839|FG000|Overall Study|Lost to Follow-up|4
6325435|NCT02932267|10067839|FG000|Overall Study|Pregnancy|1
6325436|NCT02932306|10067845|FG000|Overall Study|Withdrawal by Subject|16
6325437|NCT02932306|10067846|FG001|Overall Study|Withdrawal by Subject|25
6325438|NCT02932306|10067845|FG000|Overall Study|Adverse Event|3
6325439|NCT02932306|10067846|FG001|Overall Study|Adverse Event|0
6325440|NCT02932306|10067845|FG000|Overall Study|Pregnancy|2
6325441|NCT02932306|10067846|FG001|Overall Study|Pregnancy|0
6325442|NCT02932306|10067845|FG000|Overall Study|Protocol Violation|1
6160868|NCT01185548|9802685|FG000|Period 2: Tasisulam and Tolbutamide|Sponsor Decision|2
6160869|NCT01185561|9802700|FG000|Overall Study|Lost to Follow-up|0
6160870|NCT01185561|9802701|FG001|Overall Study|Lost to Follow-up|4
6160871|NCT01185561|9802700|FG000|Overall Study|Withdrawal by Subject|2
6160872|NCT01185561|9802701|FG001|Overall Study|Withdrawal by Subject|8
6160873|NCT01185600|9802709|FG000|Overall Study|Adverse Event|1
6160874|NCT01185600|9802710|FG001|Overall Study|Adverse Event|1
6160875|NCT01185600|9802709|FG000|Overall Study|Death|0
6160876|NCT01185600|9802710|FG001|Overall Study|Death|1
6160877|NCT01185600|9802709|FG000|Overall Study|Lost to Follow-up|0
6160878|NCT01185600|9802710|FG001|Overall Study|Lost to Follow-up|5
6160879|NCT01185600|9802709|FG000|Overall Study|Physician Decision|29
6160880|NCT01185600|9802710|FG001|Overall Study|Physician Decision|35
6160881|NCT01185600|9802709|FG000|Overall Study|Withdrawal by Subject|1
6160882|NCT01185600|9802710|FG001|Overall Study|Withdrawal by Subject|1
6160883|NCT01185600|9802709|FG000|Overall Study|Hold by DSMB|1
6160884|NCT01185600|9802710|FG001|Overall Study|Hold by DSMB|2
6160885|NCT01185639|9802719|FG000|Overall Study|Progressed and didn't receive therapy|2
6160886|NCT01185704|9802725|FG000|Overall Study|Randomized but not treated|3
6160887|NCT01185704|9802726|FG001|Overall Study|Randomized but not treated|3
6160888|NCT01185704|9802725|FG000|Overall Study|Lack of ovarian response|5
6160889|NCT01185704|9802726|FG001|Overall Study|Lack of ovarian response|1
6160890|NCT01185704|9802725|FG000|Overall Study|Ovarian hyperstimulation syndrome risk|5
6160891|NCT01185704|9802726|FG001|Overall Study|Ovarian hyperstimulation syndrome risk|3
6160892|NCT01185704|9802725|FG000|Overall Study|Ectopic pregnancy|0
6160893|NCT01185704|9802726|FG001|Overall Study|Ectopic pregnancy|1
6160894|NCT01185782|9802734|FG000|Overall Study|Adverse Event|0
6160895|NCT01185782|9802735|FG001|Overall Study|Adverse Event|1
6160896|NCT01185782|9802734|FG000|Overall Study|Protocol Violation|1
6160897|NCT01185782|9802735|FG001|Overall Study|Protocol Violation|0
6160898|NCT01185782|9802734|FG000|Overall Study|Poor Response to Treatment|3
6160899|NCT01185782|9802735|FG001|Overall Study|Poor Response to Treatment|1
6160900|NCT01185782|9802734|FG000|Overall Study|Other|2
6160901|NCT01185782|9802735|FG001|Overall Study|Other|5
6160902|NCT01185782|9802734|FG000|Overall Study|Randomized but not treated|0
6160903|NCT01185782|9802735|FG001|Overall Study|Randomized but not treated|4
6160904|NCT01185821|9802746|FG000|Overall Study|Abnormal laboratory value(s)|1
6160905|NCT01185821|9802747|FG001|Overall Study|Abnormal laboratory value(s)|2
6160906|NCT01185821|9802748|FG002|Overall Study|Abnormal laboratory value(s)|1
6160907|NCT01185821|9802749|FG003|Overall Study|Abnormal laboratory value(s)|0
6160908|NCT01185821|9802750|FG004|Overall Study|Abnormal laboratory value(s)|0
6160909|NCT01185821|9802746|FG000|Overall Study|Protocol Violation|0
6160910|NCT01185821|9802747|FG001|Overall Study|Protocol Violation|0
6160911|NCT01185821|9802748|FG002|Overall Study|Protocol Violation|0
6160912|NCT01185821|9802749|FG003|Overall Study|Protocol Violation|1
6160913|NCT01185821|9802750|FG004|Overall Study|Protocol Violation|1
6160914|NCT01185821|9802746|FG000|Overall Study|Abnormal test procedure result|0
6160915|NCT01185821|9802747|FG001|Overall Study|Abnormal test procedure result|0
6160916|NCT01185821|9802748|FG002|Overall Study|Abnormal test procedure result|0
6160917|NCT01185821|9802749|FG003|Overall Study|Abnormal test procedure result|0
6160918|NCT01185821|9802750|FG004|Overall Study|Abnormal test procedure result|1
6160919|NCT01185821|9802746|FG000|Overall Study|Death|0
6160920|NCT01185821|9802747|FG001|Overall Study|Death|1
6160921|NCT01185821|9802748|FG002|Overall Study|Death|0
6160922|NCT01185821|9802749|FG003|Overall Study|Death|0
6160923|NCT01185821|9802750|FG004|Overall Study|Death|0
6160924|NCT01185821|9802746|FG000|Overall Study|Condition no longer required study drug|0
6160925|NCT01185821|9802747|FG001|Overall Study|Condition no longer required study drug|0
6160926|NCT01185821|9802748|FG002|Overall Study|Condition no longer required study drug|0
6160927|NCT01185821|9802749|FG003|Overall Study|Condition no longer required study drug|0
6160928|NCT01185821|9802750|FG004|Overall Study|Condition no longer required study drug|1
6160929|NCT01185821|9802746|FG000|Overall Study|Adverse Event|2
6160930|NCT01185821|9802747|FG001|Overall Study|Adverse Event|3
6160931|NCT01185821|9802748|FG002|Overall Study|Adverse Event|1
6160932|NCT01185821|9802749|FG003|Overall Study|Adverse Event|2
6160933|NCT01185821|9802750|FG004|Overall Study|Adverse Event|5
6160934|NCT01185821|9802746|FG000|Overall Study|Lack of Efficacy|0
6160935|NCT01185821|9802747|FG001|Overall Study|Lack of Efficacy|0
6160936|NCT01185821|9802748|FG002|Overall Study|Lack of Efficacy|3
6160937|NCT01185821|9802749|FG003|Overall Study|Lack of Efficacy|0
6160938|NCT01185821|9802750|FG004|Overall Study|Lack of Efficacy|9
6160939|NCT01185821|9802746|FG000|Overall Study|Withdrawal by Subject|3
6160940|NCT01185821|9802747|FG001|Overall Study|Withdrawal by Subject|2
6160941|NCT01185821|9802748|FG002|Overall Study|Withdrawal by Subject|2
6160942|NCT01185821|9802749|FG003|Overall Study|Withdrawal by Subject|1
6160943|NCT01185821|9802750|FG004|Overall Study|Withdrawal by Subject|3
6160944|NCT01185821|9802746|FG000|Overall Study|Lost to Follow-up|1
6160945|NCT01185821|9802747|FG001|Overall Study|Lost to Follow-up|1
6160946|NCT01185821|9802748|FG002|Overall Study|Lost to Follow-up|2
6160947|NCT01185821|9802749|FG003|Overall Study|Lost to Follow-up|1
6160948|NCT01185821|9802750|FG004|Overall Study|Lost to Follow-up|2
6160949|NCT01185821|9802746|FG000|Overall Study|Administrative problems|0
6160950|NCT01185821|9802747|FG001|Overall Study|Administrative problems|0
6160951|NCT01185821|9802748|FG002|Overall Study|Administrative problems|1
6160952|NCT01185821|9802749|FG003|Overall Study|Administrative problems|1
6160953|NCT01185821|9802750|FG004|Overall Study|Administrative problems|2
6160954|NCT01185834|9802764|FG000|Overall Study|Lost to Follow-up|2
6160955|NCT01185834|9802764|FG000|Overall Study|Discomfort|4
6160956|NCT01185834|9802764|FG000|Overall Study|Biomicroscopy|4
6160957|NCT01185834|9802764|FG000|Overall Study|Time/Job Conflict|2
6160958|NCT01185834|9802764|FG000|Overall Study|Early exit - Site error|2
6160959|NCT01185964|9802771|FG000|Phase 1b and Phase 2|Withdrawal by Subject|1
6160960|NCT01185964|9802772|FG001|Phase 1b and Phase 2|Withdrawal by Subject|6
6160961|NCT01185964|9802773|FG002|Phase 1b and Phase 2|Withdrawal by Subject|2
6160962|NCT01185964|9802774|FG003|Phase 1b and Phase 2|Withdrawal by Subject|0
6160963|NCT01185964|9802771|FG000|Phase 1b and Phase 2|Other Therapy Started|0
6160964|NCT01185964|9802772|FG001|Phase 1b and Phase 2|Other Therapy Started|3
6160965|NCT01185964|9802773|FG002|Phase 1b and Phase 2|Other Therapy Started|3
6160966|NCT01185964|9802774|FG003|Phase 1b and Phase 2|Other Therapy Started|0
6160967|NCT01185964|9802771|FG000|Phase 1b and Phase 2|Participant was beyond maximum weight|0
6160968|NCT01185964|9802772|FG001|Phase 1b and Phase 2|Participant was beyond maximum weight|0
6160969|NCT01185964|9802773|FG002|Phase 1b and Phase 2|Participant was beyond maximum weight|1
6160970|NCT01185964|9802774|FG003|Phase 1b and Phase 2|Participant was beyond maximum weight|0
6160971|NCT01185964|9802771|FG000|Phase 1b and Phase 2|Adverse Event|1
6160972|NCT01185964|9802772|FG001|Phase 1b and Phase 2|Adverse Event|0
6160973|NCT01185964|9802773|FG002|Phase 1b and Phase 2|Adverse Event|2
6160974|NCT01185964|9802774|FG003|Phase 1b and Phase 2|Adverse Event|0
6160975|NCT01185964|9802771|FG000|Phase 1b and Phase 2|Off Treatment but alive and on study|0
6160976|NCT01185964|9802772|FG001|Phase 1b and Phase 2|Off Treatment but alive and on study|1
6160977|NCT01185964|9802773|FG002|Phase 1b and Phase 2|Off Treatment but alive and on study|1
6160978|NCT01185964|9802774|FG003|Phase 1b and Phase 2|Off Treatment but alive and on study|0
6160979|NCT01185964|9802771|FG000|Optional Olaratumab Monotherapy on Dox|Withdrawal by Subject|0
6160980|NCT01185964|9802772|FG001|Optional Olaratumab Monotherapy on Dox|Withdrawal by Subject|0
6160981|NCT01185964|9802773|FG002|Optional Olaratumab Monotherapy on Dox|Withdrawal by Subject|0
6160982|NCT01185964|9802774|FG003|Optional Olaratumab Monotherapy on Dox|Withdrawal by Subject|2
6160983|NCT01185964|9802771|FG000|Optional Olaratumab Monotherapy on Dox|Adverse Event|0
6160984|NCT01185964|9802772|FG001|Optional Olaratumab Monotherapy on Dox|Adverse Event|0
6160985|NCT01185964|9802773|FG002|Optional Olaratumab Monotherapy on Dox|Adverse Event|0
6160986|NCT01185964|9802774|FG003|Optional Olaratumab Monotherapy on Dox|Adverse Event|1
6160987|NCT01185964|9802771|FG000|Optional Olaratumab Monotherapy on Dox|On Study Treatment|0
6160988|NCT01185964|9802772|FG001|Optional Olaratumab Monotherapy on Dox|On Study Treatment|0
6160989|NCT01185964|9802773|FG002|Optional Olaratumab Monotherapy on Dox|On Study Treatment|0
6160990|NCT01185964|9802774|FG003|Optional Olaratumab Monotherapy on Dox|On Study Treatment|2
6160991|NCT01186328|9802799|FG000|Overall Study|Death|1
6160992|NCT01186328|9802800|FG001|Overall Study|Death|0
6082237|NCT00626392|9690008|FG003|Coadministration Period|Protocol Violation|1
6082238|NCT00626392|9690009|FG004|Coadministration Period|Protocol Violation|1
6082239|NCT00626392|9690010|FG005|Coadministration Period|Protocol Violation|0
6160993|NCT01186328|9802801|FG002|Overall Study|Death|0
6160994|NCT01186419|9802812|FG000|Overall Study|Withdrawal by Subject|5
6160995|NCT01186419|9802813|FG001|Overall Study|Withdrawal by Subject|3
6160996|NCT01186419|9802812|FG000|Overall Study|Adverse Event|1
6160997|NCT01186419|9802813|FG001|Overall Study|Adverse Event|2
6160998|NCT01186419|9802812|FG000|Overall Study|Physician Decision|0
6160999|NCT01186419|9802813|FG001|Overall Study|Physician Decision|3
6161000|NCT01186419|9802812|FG000|Overall Study|Other|1
6161001|NCT01186419|9802813|FG001|Overall Study|Other|1
6161002|NCT01186458|9802818|FG000|Overall Study|Adverse Event|1
6161003|NCT01186692|9802831|FG000|Overall Study|Not Catheterized|11
6161004|NCT01186692|9802831|FG000|Overall Study|Futher testing contraindicated implant|19
6161005|NCT01186692|9802831|FG000|Overall Study|Adverse Event|2
6161006|NCT01186744|9802849|FG000|Overall Study|Lack of Efficacy|156
6161007|NCT01186744|9802850|FG001|Overall Study|Lack of Efficacy|99
6161008|NCT01186744|9802851|FG002|Overall Study|Lack of Efficacy|0
6161009|NCT01186744|9802852|FG003|Overall Study|Lack of Efficacy|2
6082240|NCT00626392|9690005|FG000|Coadministration Period|Other|0
6082241|NCT00626392|9690006|FG001|Coadministration Period|Other|2
6082242|NCT00626392|9690007|FG002|Coadministration Period|Other|3
6082243|NCT00626392|9690008|FG003|Coadministration Period|Other|1
6082244|NCT00626392|9690009|FG004|Coadministration Period|Other|1
6082245|NCT00626392|9690010|FG005|Coadministration Period|Other|1
6082246|NCT00626405|9690018|FG000|Overall Study|Deemed Ineligible|1
6082247|NCT00626405|9690019|FG001|Overall Study|Deemed Ineligible|0
6082248|NCT00626405|9690018|FG000|Overall Study|Withdrawal by Subject|0
6082249|NCT00626405|9690019|FG001|Overall Study|Withdrawal by Subject|1
6082250|NCT00626522|9690040|FG000|Overall Study|Protocol Violation|0
6082251|NCT00626522|9690041|FG001|Overall Study|Protocol Violation|0
6082252|NCT00626522|9690042|FG002|Overall Study|Protocol Violation|0
6082253|NCT00626522|9690043|FG003|Overall Study|Protocol Violation|0
6082254|NCT00626522|9690044|FG004|Overall Study|Protocol Violation|1
6082255|NCT00626522|9690045|FG005|Overall Study|Protocol Violation|0
6082256|NCT00626522|9690040|FG000|Overall Study|Adverse Event|2
6082257|NCT00626522|9690041|FG001|Overall Study|Adverse Event|1
6161010|NCT01186744|9802853|FG004|Overall Study|Lack of Efficacy|2
6161011|NCT01186744|9802854|FG005|Overall Study|Lack of Efficacy|5
6161012|NCT01186744|9802849|FG000|Overall Study|Protocol Violation|1
6161013|NCT01186744|9802850|FG001|Overall Study|Protocol Violation|2
6161014|NCT01186744|9802851|FG002|Overall Study|Protocol Violation|0
6161015|NCT01186744|9802852|FG003|Overall Study|Protocol Violation|1
6161016|NCT01186744|9802853|FG004|Overall Study|Protocol Violation|1
6161017|NCT01186744|9802854|FG005|Overall Study|Protocol Violation|2
6161018|NCT01186744|9802849|FG000|Overall Study|Lost to Follow-up|15
6161019|NCT01186744|9802850|FG001|Overall Study|Lost to Follow-up|16
6161020|NCT01186744|9802851|FG002|Overall Study|Lost to Follow-up|2
6161021|NCT01186744|9802852|FG003|Overall Study|Lost to Follow-up|1
6161022|NCT01186744|9802853|FG004|Overall Study|Lost to Follow-up|1
6161023|NCT01186744|9802854|FG005|Overall Study|Lost to Follow-up|4
6161024|NCT01186744|9802849|FG000|Overall Study|Screen failure|1
6161025|NCT01186744|9802850|FG001|Overall Study|Screen failure|1
6161026|NCT01186744|9802851|FG002|Overall Study|Screen failure|0
6161027|NCT01186744|9802852|FG003|Overall Study|Screen failure|1
6161028|NCT01186744|9802853|FG004|Overall Study|Screen failure|0
6161029|NCT01186744|9802854|FG005|Overall Study|Screen failure|0
6161030|NCT01186744|9802849|FG000|Overall Study|Withdrawal by Subject|14
6161031|NCT01186744|9802850|FG001|Overall Study|Withdrawal by Subject|10
6161032|NCT01186744|9802851|FG002|Overall Study|Withdrawal by Subject|2
6161033|NCT01186744|9802852|FG003|Overall Study|Withdrawal by Subject|5
6161034|NCT01186744|9802853|FG004|Overall Study|Withdrawal by Subject|0
6161035|NCT01186744|9802854|FG005|Overall Study|Withdrawal by Subject|6
6161036|NCT01186744|9802849|FG000|Overall Study|Study terminated by Sponsor|1
6161037|NCT01186744|9802850|FG001|Overall Study|Study terminated by Sponsor|0
6161038|NCT01186744|9802851|FG002|Overall Study|Study terminated by Sponsor|0
6161039|NCT01186744|9802852|FG003|Overall Study|Study terminated by Sponsor|0
6325443|NCT02932306|10067846|FG001|Overall Study|Protocol Violation|1
6325444|NCT02932306|10067845|FG000|Overall Study|Noncompliance with Study Drug|1
6325445|NCT02932306|10067846|FG001|Overall Study|Noncompliance with Study Drug|1
6325446|NCT02932306|10067845|FG000|Overall Study|Lost to Follow-up|36
6161040|NCT01186744|9802853|FG004|Overall Study|Study terminated by Sponsor|0
6161041|NCT01186744|9802854|FG005|Overall Study|Study terminated by Sponsor|0
6161042|NCT01186744|9802849|FG000|Overall Study|Other|9
6161043|NCT01186744|9802850|FG001|Overall Study|Other|10
6161044|NCT01186744|9802851|FG002|Overall Study|Other|1
6161045|NCT01186744|9802852|FG003|Overall Study|Other|2
6161046|NCT01186744|9802853|FG004|Overall Study|Other|1
6161047|NCT01186744|9802854|FG005|Overall Study|Other|5
6161048|NCT01186744|9802849|FG000|Overall Study|Adverse Event|10
6161049|NCT01186744|9802850|FG001|Overall Study|Adverse Event|14
6161050|NCT01186744|9802851|FG002|Overall Study|Adverse Event|1
6161051|NCT01186744|9802852|FG003|Overall Study|Adverse Event|0
6325447|NCT02932306|10067846|FG001|Overall Study|Lost to Follow-up|40
6325448|NCT02932306|10067845|FG000|Overall Study|Withdrawal by Parent or Guardian|6
6325449|NCT02932306|10067846|FG001|Overall Study|Withdrawal by Parent or Guardian|8
6325450|NCT02932306|10067845|FG000|Overall Study|Lack of Efficacy|0
6325451|NCT02932306|10067846|FG001|Overall Study|Lack of Efficacy|2
6325452|NCT02932306|10067845|FG000|Overall Study|Worsening condition|2
6325453|NCT02932306|10067846|FG001|Overall Study|Worsening condition|0
6161052|NCT01186744|9802853|FG004|Overall Study|Adverse Event|1
6161053|NCT01186744|9802854|FG005|Overall Study|Adverse Event|4
6161054|NCT01186744|9802849|FG000|Overall Study|Death|1
6161055|NCT01186744|9802850|FG001|Overall Study|Death|0
6161056|NCT01186744|9802851|FG002|Overall Study|Death|0
6161057|NCT01186744|9802852|FG003|Overall Study|Death|0
6161058|NCT01186744|9802853|FG004|Overall Study|Death|0
6161059|NCT01186744|9802854|FG005|Overall Study|Death|0
6161060|NCT01186770|9802893|FG000|Overall Study|Ineligibility|0
6161061|NCT01186770|9802894|FG001|Overall Study|Ineligibility|0
6161062|NCT01186770|9802895|FG002|Overall Study|Ineligibility|2
6161063|NCT01186770|9802896|FG003|Overall Study|Ineligibility|0
6161064|NCT01186770|9802893|FG000|Overall Study|Protocol Violation|7
6161065|NCT01186770|9802894|FG001|Overall Study|Protocol Violation|9
6161066|NCT01186770|9802895|FG002|Overall Study|Protocol Violation|12
6161067|NCT01186770|9802896|FG003|Overall Study|Protocol Violation|14
6161068|NCT01186770|9802893|FG000|Overall Study|Adverse Event|2
6161069|NCT01186770|9802894|FG001|Overall Study|Adverse Event|9
6161070|NCT01186770|9802895|FG002|Overall Study|Adverse Event|7
6161071|NCT01186770|9802896|FG003|Overall Study|Adverse Event|9
6161072|NCT01186770|9802893|FG000|Overall Study|Withdrawal by Subject|15
6161073|NCT01186770|9802894|FG001|Overall Study|Withdrawal by Subject|13
6161074|NCT01186770|9802895|FG002|Overall Study|Withdrawal by Subject|11
6161075|NCT01186770|9802896|FG003|Overall Study|Withdrawal by Subject|17
6161076|NCT01186770|9802893|FG000|Overall Study|Lost to Follow-up|10
6161077|NCT01186770|9802894|FG001|Overall Study|Lost to Follow-up|6
6161078|NCT01186770|9802895|FG002|Overall Study|Lost to Follow-up|14
6161079|NCT01186770|9802896|FG003|Overall Study|Lost to Follow-up|9
6161080|NCT01186770|9802893|FG000|Overall Study|Insufficient response to treatment|7
6161081|NCT01186770|9802894|FG001|Overall Study|Insufficient response to treatment|8
6161082|NCT01186770|9802895|FG002|Overall Study|Insufficient response to treatment|5
6161083|NCT01186770|9802896|FG003|Overall Study|Insufficient response to treatment|7
6161084|NCT01186770|9802893|FG000|Overall Study|Other than specified|0
6161085|NCT01186770|9802894|FG001|Overall Study|Other than specified|1
6161086|NCT01186770|9802895|FG002|Overall Study|Other than specified|1
6161087|NCT01186770|9802896|FG003|Overall Study|Other than specified|2
6161088|NCT01186796|9802908|FG000|Overall Study|Adverse Event|3
6161089|NCT01186796|9802909|FG001|Overall Study|Adverse Event|0
6161090|NCT01186796|9802908|FG000|Overall Study|Withdrawal by Subject|1
6161091|NCT01186796|9802909|FG001|Overall Study|Withdrawal by Subject|1
6161092|NCT01186796|9802908|FG000|Overall Study|Protocol Violation|0
6161093|NCT01186796|9802909|FG001|Overall Study|Protocol Violation|1
6191827|NCT01425814|9848747|FG000|Period 5|Stability criteria not fulfilled|0
6191828|NCT01425814|9848748|FG001|Period 5|Stability criteria not fulfilled|0
6191829|NCT01425814|9848749|FG002|Period 5|Stability criteria not fulfilled|1
6191830|NCT01425814|9848750|FG003|Period 5|Stability criteria not fulfilled|0
6191831|NCT01425814|9848751|FG004|Period 5|Stability criteria not fulfilled|0
6191832|NCT01425814|9848752|FG005|Period 5|Stability criteria not fulfilled|1
6191833|NCT01426009|9848780|FG000|Period 1-First Intervention (7 Days)|Adverse Event|1
6191834|NCT01426009|9848780|FG000|Period 1-First Intervention (7 Days)|Personal Reasons|1
6191835|NCT01426009|9848780|FG000|Washout 1|Withdrawal by Subject|1
6191836|NCT01426009|9848780|FG000|Washout 1|Personal Reasons|1
6325454|NCT02932306|10067845|FG000|Overall Study|Withdrew due to burning,itching,stinging|1
6325455|NCT02932306|10067846|FG001|Overall Study|Withdrew due to burning,itching,stinging|0
6325456|NCT02932462|10067854|FG000|Overall Study|Adverse Event|1
6325457|NCT02932462|10067855|FG001|Overall Study|Adverse Event|2
6325458|NCT02932462|10067854|FG000|Overall Study|Lost to Follow-up|4
6325459|NCT02932462|10067855|FG001|Overall Study|Lost to Follow-up|1
6325460|NCT02932462|10067854|FG000|Overall Study|Protocol Violation|0
6325461|NCT02932462|10067855|FG001|Overall Study|Protocol Violation|5
6325462|NCT02932462|10067854|FG000|Overall Study|Withdrawal by Subject|1
6325463|NCT02932462|10067855|FG001|Overall Study|Withdrawal by Subject|4
6325464|NCT02932462|10067854|FG000|Overall Study|Non-Compliance With Study Drug|0
6325465|NCT02932462|10067855|FG001|Overall Study|Non-Compliance With Study Drug|1
6325466|NCT02932462|10067854|FG000|Overall Study|Progressive Disease|1
6325467|NCT02932462|10067855|FG001|Overall Study|Progressive Disease|0
6325468|NCT02932878|10067875|FG000|Overall Study|Due to Lab Results|2
6325469|NCT02932878|10067876|FG001|Overall Study|Due to Lab Results|1
6325470|NCT02932891|10067882|FG000|Overall Study|Lost to Follow-up|2
6325471|NCT02932891|10067882|FG000|Overall Study|HPA Suppress|2
6325472|NCT02932904|10067890|FG000|Overall Study|Reason not Specified|1
6325473|NCT02932904|10067891|FG001|Overall Study|Reason not Specified|0
6191837|NCT01426009|9848780|FG000|Period 2-Second Intervention (7 Days)|Adverse Event|4
6191838|NCT01426009|9848780|FG000|Period 2-Second Intervention (7 Days)|personal reasons|1
6191839|NCT01426009|9848780|FG000|Washout 2|electrive surgery|1
6191840|NCT01426009|9848780|FG000|Washout 3|personal reasons|1
6191841|NCT01426009|9848780|FG000|Period 4-Fourth Intervention (7 Days)|personal reasons|1
6191842|NCT01426009|9848780|FG000|Washout 4|Lost to Follow-up|1
6191843|NCT01426217|9848802|FG000|Overall Study|lost sample|8
6191844|NCT01426217|9848803|FG001|Overall Study|lost sample|14
6191845|NCT01426269|9848817|FG000|Period 1: 12 Weeks|Adverse Event|5
6191846|NCT01426269|9848818|FG001|Period 1: 12 Weeks|Adverse Event|0
6191847|NCT01426269|9848819|FG002|Period 1: 12 Weeks|Adverse Event|0
6191848|NCT01426269|9848817|FG000|Period 1: 12 Weeks|Withdrawal by Subject|22
6191849|NCT01426269|9848818|FG001|Period 1: 12 Weeks|Withdrawal by Subject|0
6191850|NCT01426269|9848819|FG002|Period 1: 12 Weeks|Withdrawal by Subject|0
6191851|NCT01426269|9848817|FG000|Period 1: 12 Weeks|Protocol Violation|5
6191852|NCT01426269|9848818|FG001|Period 1: 12 Weeks|Protocol Violation|0
6191853|NCT01426269|9848819|FG002|Period 1: 12 Weeks|Protocol Violation|0
6191854|NCT01426269|9848817|FG000|Period 1: 12 Weeks|Lost to Follow-up|22
6191855|NCT01426269|9848818|FG001|Period 1: 12 Weeks|Lost to Follow-up|0
6191856|NCT01426269|9848819|FG002|Period 1: 12 Weeks|Lost to Follow-up|0
6325474|NCT02932904|10067892|FG002|Overall Study|Reason not Specified|2
6191857|NCT01426269|9848817|FG000|Period 1: 12 Weeks|Pregnancy|1
6191858|NCT01426269|9848818|FG001|Period 1: 12 Weeks|Pregnancy|0
6191859|NCT01426269|9848819|FG002|Period 1: 12 Weeks|Pregnancy|0
6191860|NCT01426269|9848817|FG000|Eligibility for Period 2, Randomization|Did not qualify|42
6191861|NCT01426269|9848818|FG001|Eligibility for Period 2, Randomization|Did not qualify|0
6325475|NCT02932904|10067893|FG003|Overall Study|Reason not Specified|2
6191862|NCT01426269|9848819|FG002|Eligibility for Period 2, Randomization|Did not qualify|0
6161094|NCT01186809|9802915|FG000|Overall Study|Death|30
6161095|NCT01186939|9802919|FG000|Overall Study|Death|7
6161096|NCT01186939|9802919|FG000|Overall Study|Withdrawal by Subject|2
6161097|NCT01186939|9802919|FG000|Overall Study|No longer receiving clinical benefit|17
6161098|NCT01186939|9802919|FG000|Overall Study|Program closed|5
6161099|NCT01186939|9802919|FG000|Overall Study|Sponsor decision|4
6161100|NCT01186939|9802919|FG000|Overall Study|Started additional treatment|1
6161101|NCT01186939|9802919|FG000|Overall Study|NCI CTC Grade 3 or 4 toxicity|1
6161102|NCT01186939|9802919|FG000|Overall Study|Myocardial infarction|1
6161103|NCT01186939|9802919|FG000|Overall Study|Bone marrow transplant|1
6161104|NCT01186939|9802919|FG000|Overall Study|Transformation to AML|1
6161105|NCT01186978|9802923|FG000|Overall Study|Withdrawal by Subject|1
6161106|NCT01187043|9802948|FG000|Overall Study|Adverse Event|0
6161107|NCT01187043|9802949|FG001|Overall Study|Adverse Event|0
6161108|NCT01187043|9802950|FG002|Overall Study|Adverse Event|0
6161109|NCT01187043|9802951|FG003|Overall Study|Adverse Event|0
6161110|NCT01187043|9802952|FG004|Overall Study|Adverse Event|1
6161111|NCT01187043|9802948|FG000|Overall Study|Unable to make scheduled visits|1
6325476|NCT02932904|10067890|FG000|Overall Study|Noncompliance with Study Drug|2
6325477|NCT02932904|10067891|FG001|Overall Study|Noncompliance with Study Drug|3
6325478|NCT02932904|10067892|FG002|Overall Study|Noncompliance with Study Drug|3
6325479|NCT02932904|10067893|FG003|Overall Study|Noncompliance with Study Drug|4
6325480|NCT02932904|10067890|FG000|Overall Study|Pregnancy|0
6325481|NCT02932904|10067891|FG001|Overall Study|Pregnancy|1
6325482|NCT02932904|10067892|FG002|Overall Study|Pregnancy|1
6325483|NCT02932904|10067893|FG003|Overall Study|Pregnancy|0
6325484|NCT02932904|10067890|FG000|Overall Study|Study Termination|0
6325485|NCT02932904|10067891|FG001|Overall Study|Study Termination|1
6325486|NCT02932904|10067892|FG002|Overall Study|Study Termination|0
6325487|NCT02932904|10067893|FG003|Overall Study|Study Termination|0
6325488|NCT02932904|10067890|FG000|Overall Study|Voluntary Withdrawal|2
6325489|NCT02932904|10067891|FG001|Overall Study|Voluntary Withdrawal|1
6325490|NCT02932904|10067892|FG002|Overall Study|Voluntary Withdrawal|4
6325491|NCT02932904|10067893|FG003|Overall Study|Voluntary Withdrawal|2
6325492|NCT02932904|10067890|FG000|Overall Study|Lost to Follow-up|5
6325493|NCT02932904|10067891|FG001|Overall Study|Lost to Follow-up|3
6325494|NCT02932904|10067892|FG002|Overall Study|Lost to Follow-up|6
6325495|NCT02932904|10067893|FG003|Overall Study|Lost to Follow-up|0
6325496|NCT02932904|10067890|FG000|Overall Study|Significant Protocol Deviation|2
6325497|NCT02932904|10067891|FG001|Overall Study|Significant Protocol Deviation|3
6325498|NCT02932904|10067892|FG002|Overall Study|Significant Protocol Deviation|6
6325499|NCT02932904|10067893|FG003|Overall Study|Significant Protocol Deviation|1
6325500|NCT02932904|10067890|FG000|Overall Study|Pretreatment Event/Adverse Event|3
6325501|NCT02932904|10067891|FG001|Overall Study|Pretreatment Event/Adverse Event|5
6325502|NCT02932904|10067892|FG002|Overall Study|Pretreatment Event/Adverse Event|1
6325503|NCT02932904|10067893|FG003|Overall Study|Pretreatment Event/Adverse Event|3
6325504|NCT02932904|10067890|FG000|Overall Study|Randomized But Not Treated|1
6325505|NCT02932904|10067891|FG001|Overall Study|Randomized But Not Treated|1
6325506|NCT02932904|10067892|FG002|Overall Study|Randomized But Not Treated|0
6325507|NCT02932904|10067893|FG003|Overall Study|Randomized But Not Treated|2
6325508|NCT02932943|10067908|FG000|Overall Study|Lost to Follow-up|0
6325509|NCT02932943|10067909|FG001|Overall Study|Lost to Follow-up|2
6325510|NCT02932943|10067908|FG000|Overall Study|Adverse Event|2
6325511|NCT02932943|10067909|FG001|Overall Study|Adverse Event|2
6325512|NCT02932943|10067908|FG000|Overall Study|Withdrawal by Subject|3
6325513|NCT02932943|10067909|FG001|Overall Study|Withdrawal by Subject|3
6325514|NCT02933060|10067921|FG000|Overall Study|Withdrawal by Subject|0
6325515|NCT02933060|10067922|FG001|Overall Study|Withdrawal by Subject|1
6325516|NCT02933489|10067969|FG000|Overall Study|Ineligible|3
6325517|NCT02933489|10067970|FG001|Overall Study|Ineligible|3
6325518|NCT02933489|10067969|FG000|Overall Study|Withdrawal by Subject|27
6325519|NCT02933489|10067970|FG001|Overall Study|Withdrawal by Subject|18
6325520|NCT02933489|10067969|FG000|Overall Study|Unable to complete exams (other)|14
6325521|NCT02933489|10067970|FG001|Overall Study|Unable to complete exams (other)|7
6325522|NCT02933528|10067985|FG000|Overall Study|Lost to Follow-up|2
6325523|NCT02934178|10068015|FG000|Received Vaccination 2|Death|0
6325524|NCT02934178|10068016|FG001|Received Vaccination 2|Death|1
6325525|NCT02934178|10068015|FG000|Received Vaccination 3|Withdrawal by Subject|1
6325526|NCT02934178|10068016|FG001|Received Vaccination 3|Withdrawal by Subject|0
6325527|NCT02935192|10068098|FG000|Overall Study|Withdrawal by Subject|8
6325528|NCT02935192|10068099|FG001|Overall Study|Withdrawal by Subject|4
6325529|NCT02935452|10068107|FG000|Overall Study|work and life commintment|3
6325530|NCT02935452|10068108|FG001|Overall Study|work and life commintment|1
6325531|NCT02935673|10068121|FG000|Overall Study|Adverse Event|0
6325532|NCT02935673|10068122|FG001|Overall Study|Adverse Event|1
6161112|NCT01187043|9802949|FG001|Overall Study|Unable to make scheduled visits|0
6161113|NCT01187043|9802950|FG002|Overall Study|Unable to make scheduled visits|4
6161114|NCT01187043|9802951|FG003|Overall Study|Unable to make scheduled visits|0
6325533|NCT02935673|10068123|FG002|Overall Study|Adverse Event|0
6325534|NCT02935673|10068121|FG000|Overall Study|Withdrawal by Subject|1
6325535|NCT02935673|10068122|FG001|Overall Study|Withdrawal by Subject|2
6325536|NCT02935673|10068123|FG002|Overall Study|Withdrawal by Subject|0
6161115|NCT01187043|9802952|FG004|Overall Study|Unable to make scheduled visits|1
6161116|NCT01187407|9802999|FG000|Confirmation (CF) Phase, 3 Weeks|Adverse Event|29
6161117|NCT01187407|9803000|FG001|Confirmation (CF) Phase, 3 Weeks|Adverse Event|0
6161118|NCT01187407|9803001|FG002|Confirmation (CF) Phase, 3 Weeks|Adverse Event|0
6161119|NCT01187407|9803002|FG003|Confirmation (CF) Phase, 3 Weeks|Adverse Event|0
6161120|NCT01187407|9803003|FG004|Confirmation (CF) Phase, 3 Weeks|Adverse Event|0
6161121|NCT01187407|9802999|FG000|Confirmation (CF) Phase, 3 Weeks|Lack of Efficacy|4
6161122|NCT01187407|9803000|FG001|Confirmation (CF) Phase, 3 Weeks|Lack of Efficacy|0
6161123|NCT01187407|9803001|FG002|Confirmation (CF) Phase, 3 Weeks|Lack of Efficacy|0
6161124|NCT01187407|9803002|FG003|Confirmation (CF) Phase, 3 Weeks|Lack of Efficacy|0
6161125|NCT01187407|9803003|FG004|Confirmation (CF) Phase, 3 Weeks|Lack of Efficacy|0
6161126|NCT01187407|9802999|FG000|Confirmation (CF) Phase, 3 Weeks|Lost to Follow-up|9
6161127|NCT01187407|9803000|FG001|Confirmation (CF) Phase, 3 Weeks|Lost to Follow-up|0
6161128|NCT01187407|9803001|FG002|Confirmation (CF) Phase, 3 Weeks|Lost to Follow-up|0
6161129|NCT01187407|9803002|FG003|Confirmation (CF) Phase, 3 Weeks|Lost to Follow-up|0
6161130|NCT01187407|9803003|FG004|Confirmation (CF) Phase, 3 Weeks|Lost to Follow-up|0
6161131|NCT01187407|9802999|FG000|Confirmation (CF) Phase, 3 Weeks|Physician Decision|2
6161132|NCT01187407|9803000|FG001|Confirmation (CF) Phase, 3 Weeks|Physician Decision|0
6161133|NCT01187407|9803001|FG002|Confirmation (CF) Phase, 3 Weeks|Physician Decision|0
6161134|NCT01187407|9803002|FG003|Confirmation (CF) Phase, 3 Weeks|Physician Decision|0
6161135|NCT01187407|9803003|FG004|Confirmation (CF) Phase, 3 Weeks|Physician Decision|0
6161136|NCT01187407|9802999|FG000|Confirmation (CF) Phase, 3 Weeks|Protocol Violation|13
6161137|NCT01187407|9803000|FG001|Confirmation (CF) Phase, 3 Weeks|Protocol Violation|0
6161138|NCT01187407|9803001|FG002|Confirmation (CF) Phase, 3 Weeks|Protocol Violation|0
6161139|NCT01187407|9803002|FG003|Confirmation (CF) Phase, 3 Weeks|Protocol Violation|0
6161140|NCT01187407|9803003|FG004|Confirmation (CF) Phase, 3 Weeks|Protocol Violation|0
6161141|NCT01187407|9802999|FG000|Confirmation (CF) Phase, 3 Weeks|Withdrawal by Subject|29
6161142|NCT01187407|9803000|FG001|Confirmation (CF) Phase, 3 Weeks|Withdrawal by Subject|0
6161143|NCT01187407|9803001|FG002|Confirmation (CF) Phase, 3 Weeks|Withdrawal by Subject|0
6325537|NCT02935842|10068163|FG000|Testing and Therapy Period 2|Withdrawal by Subject|2
6325538|NCT02935842|10068164|FG001|Testing and Therapy Period 2|Withdrawal by Subject|0
6325539|NCT02935842|10068165|FG002|Testing and Therapy Period 2|Withdrawal by Subject|0
6325540|NCT02935842|10068166|FG003|Testing and Therapy Period 2|Withdrawal by Subject|0
6325541|NCT02935842|10068163|FG000|Testing and Therapy Period 3|Required other therapy (dysphagia)|1
6325542|NCT02935842|10068164|FG001|Testing and Therapy Period 3|Required other therapy (dysphagia)|2
6325543|NCT02935842|10068165|FG002|Testing and Therapy Period 3|Required other therapy (dysphagia)|2
6325544|NCT02935842|10068166|FG003|Testing and Therapy Period 3|Required other therapy (dysphagia)|0
6325545|NCT02935842|10068163|FG000|Testing and Therapy Period 3|Accident prior to treatment|2
6325546|NCT02935842|10068164|FG001|Testing and Therapy Period 3|Accident prior to treatment|2
6325547|NCT02935842|10068165|FG002|Testing and Therapy Period 3|Accident prior to treatment|0
6325548|NCT02935842|10068166|FG003|Testing and Therapy Period 3|Accident prior to treatment|0
6325549|NCT02935842|10068163|FG000|Testing and Therapy Period 3|Lost to Follow-up|0
6325550|NCT02935842|10068164|FG001|Testing and Therapy Period 3|Lost to Follow-up|0
6325551|NCT02935842|10068165|FG002|Testing and Therapy Period 3|Lost to Follow-up|0
6325552|NCT02935842|10068166|FG003|Testing and Therapy Period 3|Lost to Follow-up|1
6325553|NCT02935842|10068163|FG000|Testing and Therapy Period 3|Withdrawal by Subject|0
6325554|NCT02935842|10068164|FG001|Testing and Therapy Period 3|Withdrawal by Subject|0
6325555|NCT02935842|10068165|FG002|Testing and Therapy Period 3|Withdrawal by Subject|3
6325556|NCT02935842|10068166|FG003|Testing and Therapy Period 3|Withdrawal by Subject|0
6325557|NCT02935894|10068183|FG000|Overall Study|Subject dismissed|1
6325558|NCT02936037|10068189|FG000|Double-Blind Treatment Period|Protocol Violation|1
6325559|NCT02936037|10068190|FG001|Double-Blind Treatment Period|Protocol Violation|4
6325560|NCT02936037|10068189|FG000|Double-Blind Treatment Period|Suicidal risk, etc.|2
6325561|NCT02936037|10068190|FG001|Double-Blind Treatment Period|Suicidal risk, etc.|8
6325562|NCT02936037|10068189|FG000|Double-Blind Treatment Period|Lack of Efficacy|4
6325563|NCT02936037|10068190|FG001|Double-Blind Treatment Period|Lack of Efficacy|12
6325564|NCT02936037|10068189|FG000|Double-Blind Treatment Period|Death|0
6325565|NCT02936037|10068190|FG001|Double-Blind Treatment Period|Death|1
6325566|NCT02936037|10068189|FG000|Double-Blind Treatment Period|Adverse Event|11
6325567|NCT02936037|10068190|FG001|Double-Blind Treatment Period|Adverse Event|11
6325568|NCT02936037|10068189|FG000|Double-Blind Treatment Period|Withdrawal by Subject|31
6325569|NCT02936037|10068190|FG001|Double-Blind Treatment Period|Withdrawal by Subject|28
6325570|NCT02936037|10068189|FG000|Double-Blind Treatment Period|Lost to Follow-up|0
6325571|NCT02936037|10068190|FG001|Double-Blind Treatment Period|Lost to Follow-up|1
6325572|NCT02936037|10068189|FG000|Open Label Extension|Adverse Event|0
6325573|NCT02936037|10068190|FG001|Open Label Extension|Adverse Event|3
6325574|NCT02936037|10068189|FG000|Open Label Extension|Other|0
6325575|NCT02936037|10068190|FG001|Open Label Extension|Other|3
6325576|NCT02936037|10068189|FG000|Open Label Extension|Withdrawal by Subject|0
6161144|NCT01187407|9803002|FG003|Confirmation (CF) Phase, 3 Weeks|Withdrawal by Subject|0
6161145|NCT01187407|9803003|FG004|Confirmation (CF) Phase, 3 Weeks|Withdrawal by Subject|0
6161146|NCT01187407|9802999|FG000|Confirmation (CF) Phase, 3 Weeks|Sponsor Decision|4
6161147|NCT01187407|9803000|FG001|Confirmation (CF) Phase, 3 Weeks|Sponsor Decision|0
6161148|NCT01187407|9803001|FG002|Confirmation (CF) Phase, 3 Weeks|Sponsor Decision|0
6161149|NCT01187407|9803002|FG003|Confirmation (CF) Phase, 3 Weeks|Sponsor Decision|0
6161150|NCT01187407|9803003|FG004|Confirmation (CF) Phase, 3 Weeks|Sponsor Decision|0
6161151|NCT01187407|9802999|FG000|Adjunctive Treatment (AT) Phase, 8 Weeks|Adverse Event|0
6161152|NCT01187407|9803000|FG001|Adjunctive Treatment (AT) Phase, 8 Weeks|Adverse Event|13
6161153|NCT01187407|9803001|FG002|Adjunctive Treatment (AT) Phase, 8 Weeks|Adverse Event|6
6161154|NCT01187407|9803002|FG003|Adjunctive Treatment (AT) Phase, 8 Weeks|Adverse Event|5
6161155|NCT01187407|9803003|FG004|Adjunctive Treatment (AT) Phase, 8 Weeks|Adverse Event|12
6161156|NCT01187407|9802999|FG000|Adjunctive Treatment (AT) Phase, 8 Weeks|Lack of Efficacy|0
6161157|NCT01187407|9803000|FG001|Adjunctive Treatment (AT) Phase, 8 Weeks|Lack of Efficacy|3
6161158|NCT01187407|9803001|FG002|Adjunctive Treatment (AT) Phase, 8 Weeks|Lack of Efficacy|8
6161159|NCT01187407|9803002|FG003|Adjunctive Treatment (AT) Phase, 8 Weeks|Lack of Efficacy|5
6161160|NCT01187407|9803003|FG004|Adjunctive Treatment (AT) Phase, 8 Weeks|Lack of Efficacy|13
6161161|NCT01187407|9802999|FG000|Adjunctive Treatment (AT) Phase, 8 Weeks|Lost to Follow-up|0
6161162|NCT01187407|9803000|FG001|Adjunctive Treatment (AT) Phase, 8 Weeks|Lost to Follow-up|3
6161163|NCT01187407|9803001|FG002|Adjunctive Treatment (AT) Phase, 8 Weeks|Lost to Follow-up|5
6161164|NCT01187407|9803002|FG003|Adjunctive Treatment (AT) Phase, 8 Weeks|Lost to Follow-up|2
6161165|NCT01187407|9803003|FG004|Adjunctive Treatment (AT) Phase, 8 Weeks|Lost to Follow-up|9
6161166|NCT01187407|9802999|FG000|Adjunctive Treatment (AT) Phase, 8 Weeks|Physician Decision|0
6325577|NCT02936037|10068190|FG001|Open Label Extension|Withdrawal by Subject|4
6325578|NCT02936635|10068211|FG000|Overall Study|Adverse Event|43
6325579|NCT02936635|10068212|FG001|Overall Study|Adverse Event|25
6325580|NCT02936635|10068211|FG000|Overall Study|Progressive Disease|10
6325581|NCT02936635|10068212|FG001|Overall Study|Progressive Disease|18
6325582|NCT02936635|10068211|FG000|Overall Study|Sponsor Discretion|10
6325583|NCT02936635|10068212|FG001|Overall Study|Sponsor Discretion|16
6325584|NCT02936635|10068211|FG000|Overall Study|Death|9
6325585|NCT02936635|10068212|FG001|Overall Study|Death|15
6325586|NCT02936635|10068211|FG000|Overall Study|Withdrawal by Subject|8
6325587|NCT02936635|10068212|FG001|Overall Study|Withdrawal by Subject|15
6325588|NCT02936635|10068211|FG000|Overall Study|Physician Decision|2
6325589|NCT02936635|10068212|FG001|Overall Study|Physician Decision|9
6325590|NCT02936635|10068211|FG000|Overall Study|Lost to Follow-up|1
6325591|NCT02936635|10068212|FG001|Overall Study|Lost to Follow-up|2
6325592|NCT02936635|10068211|FG000|Overall Study|Protocol Violation|1
6325593|NCT02936635|10068212|FG001|Overall Study|Protocol Violation|0
6325594|NCT02936635|10068211|FG000|Overall Study|Lack of effect/Entry into other study|31
6325595|NCT02936635|10068212|FG001|Overall Study|Lack of effect/Entry into other study|65
6325596|NCT02936869|10068224|FG000|Overall Study|Lost to Follow-up|1
6161167|NCT01187407|9803000|FG001|Adjunctive Treatment (AT) Phase, 8 Weeks|Physician Decision|0
6161168|NCT01187407|9803001|FG002|Adjunctive Treatment (AT) Phase, 8 Weeks|Physician Decision|0
6161169|NCT01187407|9803002|FG003|Adjunctive Treatment (AT) Phase, 8 Weeks|Physician Decision|1
6161170|NCT01187407|9803003|FG004|Adjunctive Treatment (AT) Phase, 8 Weeks|Physician Decision|2
6161171|NCT01187407|9802999|FG000|Adjunctive Treatment (AT) Phase, 8 Weeks|Protocol Violation|0
6161172|NCT01187407|9803000|FG001|Adjunctive Treatment (AT) Phase, 8 Weeks|Protocol Violation|6
6161173|NCT01187407|9803001|FG002|Adjunctive Treatment (AT) Phase, 8 Weeks|Protocol Violation|5
6161174|NCT01187407|9803002|FG003|Adjunctive Treatment (AT) Phase, 8 Weeks|Protocol Violation|3
6161175|NCT01187407|9803003|FG004|Adjunctive Treatment (AT) Phase, 8 Weeks|Protocol Violation|10
6161176|NCT01187407|9802999|FG000|Adjunctive Treatment (AT) Phase, 8 Weeks|Withdrawal by Subject|0
6161177|NCT01187407|9803000|FG001|Adjunctive Treatment (AT) Phase, 8 Weeks|Withdrawal by Subject|9
6161178|NCT01187407|9803001|FG002|Adjunctive Treatment (AT) Phase, 8 Weeks|Withdrawal by Subject|9
6161179|NCT01187407|9803002|FG003|Adjunctive Treatment (AT) Phase, 8 Weeks|Withdrawal by Subject|11
6161180|NCT01187407|9803003|FG004|Adjunctive Treatment (AT) Phase, 8 Weeks|Withdrawal by Subject|22
6161181|NCT01187407|9802999|FG000|Adjunctive Treatment (AT) Phase, 8 Weeks|Sponsor Decision|0
6161182|NCT01187407|9803000|FG001|Adjunctive Treatment (AT) Phase, 8 Weeks|Sponsor Decision|2
6161183|NCT01187407|9803001|FG002|Adjunctive Treatment (AT) Phase, 8 Weeks|Sponsor Decision|2
6161184|NCT01187407|9803002|FG003|Adjunctive Treatment (AT) Phase, 8 Weeks|Sponsor Decision|2
6161185|NCT01187407|9803003|FG004|Adjunctive Treatment (AT) Phase, 8 Weeks|Sponsor Decision|7
6161186|NCT01187446|9803022|FG000|Overall Study|Patient started non-protocol therapy|0
6161187|NCT01187446|9803023|FG001|Overall Study|Patient started non-protocol therapy|1
6161188|NCT01187550|9803049|FG000|Overall Study|Protocol Violation|3
6161189|NCT01187550|9803050|FG001|Overall Study|Protocol Violation|1
6161190|NCT01187550|9803049|FG000|Overall Study|Other|3
6161191|NCT01187550|9803050|FG001|Overall Study|Other|0
6161192|NCT01187550|9803049|FG000|Overall Study|Randomized but not treated|8
6161193|NCT01187550|9803050|FG001|Overall Study|Randomized but not treated|0
6161194|NCT01187901|9803069|FG000|Overall Study|Protocol Violation|1
6161195|NCT01187901|9803070|FG001|Overall Study|Protocol Violation|0
6161196|NCT01187901|9803069|FG000|Overall Study|Lost to Follow-up|1
6161197|NCT01187901|9803070|FG001|Overall Study|Lost to Follow-up|2
6161198|NCT01187901|9803069|FG000|Overall Study|Unrelated Health Reasons|1
6325597|NCT02936869|10068225|FG001|Overall Study|Lost to Follow-up|3
6325598|NCT02936869|10068224|FG000|Overall Study|Death|0
6161199|NCT01187901|9803070|FG001|Overall Study|Unrelated Health Reasons|2
6161200|NCT01187901|9803069|FG000|Overall Study|Suspected Allergic Reaction|1
6161201|NCT01187901|9803070|FG001|Overall Study|Suspected Allergic Reaction|1
6161202|NCT01187901|9803069|FG000|Overall Study|Adverse Event|3
6161203|NCT01187901|9803070|FG001|Overall Study|Adverse Event|0
6161204|NCT01187901|9803069|FG000|Overall Study|No Endpoint due to Early Study Halt|2
6161205|NCT01187901|9803070|FG001|Overall Study|No Endpoint due to Early Study Halt|3
6161206|NCT01187901|9803069|FG000|Overall Study|Pregnancy|0
6161207|NCT01187901|9803070|FG001|Overall Study|Pregnancy|2
6161208|NCT01187953|9803082|FG000|Overall Study|Death|11
6161209|NCT01187953|9803083|FG001|Overall Study|Death|13
6161210|NCT01187953|9803082|FG000|Overall Study|Adverse Event|1
6161211|NCT01187953|9803083|FG001|Overall Study|Adverse Event|2
6161212|NCT01187953|9803082|FG000|Overall Study|Lost to Follow-up|0
6161213|NCT01187953|9803083|FG001|Overall Study|Lost to Follow-up|3
6161214|NCT01187953|9803082|FG000|Overall Study|Withdrawal by Subject|3
6161215|NCT01187953|9803083|FG001|Overall Study|Withdrawal by Subject|3
6161216|NCT01188226|9803093|FG000|Overall Study|Withdrawal by Subject|4
6161217|NCT01188343|9803110|FG000|Overall Study|Not vaccinated|0
6161218|NCT01188343|9803111|FG001|Overall Study|Not vaccinated|2
6161219|NCT01188343|9803112|FG002|Overall Study|Not vaccinated|1
6161220|NCT01188343|9803110|FG000|Overall Study|Withdrawal by Subject|1
6161221|NCT01188343|9803111|FG001|Overall Study|Withdrawal by Subject|24
6161222|NCT01188343|9803112|FG002|Overall Study|Withdrawal by Subject|0
6161223|NCT01188538|9803182|FG000|Overall Study|Lost to Follow-up|0
6161224|NCT01188538|9803183|FG001|Overall Study|Lost to Follow-up|1
6161225|NCT01188551|9803195|FG000|Overall Study|Pharmacy issues|1
6161226|NCT01188551|9803196|FG001|Overall Study|Pharmacy issues|0
6161227|NCT01188551|9803197|FG002|Overall Study|Pharmacy issues|0
6161228|NCT01188551|9803198|FG003|Overall Study|Pharmacy issues|0
6161229|NCT01188564|9803210|FG000|Double-blind Phase|randomized not treated|1
6161230|NCT01188564|9803211|FG001|Double-blind Phase|randomized not treated|0
6161231|NCT01188655|9803230|FG000|Overall Study|Lack of Efficacy|1
6161232|NCT01188655|9803230|FG000|Overall Study|Lost to Follow-up|1
6161233|NCT01188655|9803230|FG000|Overall Study|Other|11
6161234|NCT01188668|9803234|FG000|Period 1: ARIP Alone|Protocol Violation|2
6161235|NCT01188668|9803234|FG000|Period 2: Coadministration ARIP + DVS SR|Lost to Follow-up|2
6161236|NCT01188668|9803234|FG000|Period 2: Coadministration ARIP + DVS SR|Withdrawal by Subject|1
6161237|NCT01188681|9803245|FG000|Overall Study|bladder cancer|0
6161238|NCT01188681|9803246|FG001|Overall Study|bladder cancer|0
6161239|NCT01188681|9803247|FG002|Overall Study|bladder cancer|1
6161240|NCT01188681|9803248|FG003|Overall Study|bladder cancer|0
6325599|NCT02936869|10068225|FG001|Overall Study|Death|1
6325600|NCT02936869|10068224|FG000|Overall Study|Legal Case|0
6325601|NCT02936869|10068225|FG001|Overall Study|Legal Case|1
6325602|NCT02936869|10068224|FG000|Overall Study|Protocol Violation|1
6325603|NCT02936869|10068225|FG001|Overall Study|Protocol Violation|0
6161241|NCT01188681|9803245|FG000|Overall Study|Withdrawal by Subject|0
6161242|NCT01188681|9803246|FG001|Overall Study|Withdrawal by Subject|0
6161243|NCT01188681|9803247|FG002|Overall Study|Withdrawal by Subject|0
6161244|NCT01188681|9803248|FG003|Overall Study|Withdrawal by Subject|1
6161245|NCT01188772|9803279|FG000|Overall Study|Randomized but Not Treated|0
6161246|NCT01188772|9803280|FG001|Overall Study|Randomized but Not Treated|1
6161247|NCT01188772|9803281|FG002|Overall Study|Randomized but Not Treated|0
6161248|NCT01188772|9803282|FG003|Overall Study|Randomized but Not Treated|0
6161249|NCT01188772|9803279|FG000|Overall Study|Adverse Event|0
6161250|NCT01188772|9803280|FG001|Overall Study|Adverse Event|1
6161251|NCT01188772|9803281|FG002|Overall Study|Adverse Event|2
6161252|NCT01188772|9803282|FG003|Overall Study|Adverse Event|0
6161253|NCT01188772|9803279|FG000|Overall Study|Lost to Follow-up|4
6161254|NCT01188772|9803280|FG001|Overall Study|Lost to Follow-up|1
6161255|NCT01188772|9803281|FG002|Overall Study|Lost to Follow-up|1
6161256|NCT01188772|9803282|FG003|Overall Study|Lost to Follow-up|1
6161257|NCT01188772|9803279|FG000|Overall Study|Non-responder|0
6161258|NCT01188772|9803280|FG001|Overall Study|Non-responder|0
6161259|NCT01188772|9803281|FG002|Overall Study|Non-responder|3
6161260|NCT01188772|9803282|FG003|Overall Study|Non-responder|0
6161261|NCT01188772|9803279|FG000|Overall Study|Physician Decision|0
6161262|NCT01188772|9803280|FG001|Overall Study|Physician Decision|0
6161263|NCT01188772|9803281|FG002|Overall Study|Physician Decision|1
6161264|NCT01188772|9803282|FG003|Overall Study|Physician Decision|0
6161265|NCT01188772|9803279|FG000|Overall Study|Terminated by Sponsor|0
6161266|NCT01188772|9803280|FG001|Overall Study|Terminated by Sponsor|0
6161267|NCT01188772|9803281|FG002|Overall Study|Terminated by Sponsor|1
6161268|NCT01188772|9803282|FG003|Overall Study|Terminated by Sponsor|0
6161269|NCT01188772|9803279|FG000|Overall Study|Treatment Failure|0
6161270|NCT01188772|9803280|FG001|Overall Study|Treatment Failure|0
6161271|NCT01188772|9803281|FG002|Overall Study|Treatment Failure|1
6161272|NCT01188772|9803282|FG003|Overall Study|Treatment Failure|0
6161273|NCT01188772|9803279|FG000|Overall Study|Virologic Failure|1
6161274|NCT01188772|9803280|FG001|Overall Study|Virologic Failure|0
6161275|NCT01188772|9803281|FG002|Overall Study|Virologic Failure|0
6325604|NCT02937350|10068301|FG000|Overall Study|Withdrawal by Subject|0
6325605|NCT02937350|10068302|FG001|Overall Study|Withdrawal by Subject|1
6325606|NCT02937350|10068303|FG002|Overall Study|Withdrawal by Subject|0
6325607|NCT02937454|10068311|FG000|Overall Study|Adverse Event|0
6325608|NCT02937454|10068312|FG001|Overall Study|Adverse Event|1
6325609|NCT02937454|10068311|FG000|Overall Study|Death|98
6325610|NCT02937454|10068312|FG001|Overall Study|Death|95
6325611|NCT02937454|10068311|FG000|Overall Study|Lost to Follow-up|1
6325612|NCT02937454|10068312|FG001|Overall Study|Lost to Follow-up|1
6325613|NCT02937454|10068311|FG000|Overall Study|Physician Decision|0
6325614|NCT02937454|10068312|FG001|Overall Study|Physician Decision|1
6325615|NCT02937454|10068311|FG000|Overall Study|Protocol Violation|6
6325616|NCT02937454|10068312|FG001|Overall Study|Protocol Violation|10
6325617|NCT02937454|10068311|FG000|Overall Study|Withdrawal by Subject|27
6325618|NCT02937454|10068312|FG001|Overall Study|Withdrawal by Subject|15
6325619|NCT02937454|10068311|FG000|Overall Study|Other|8
6325620|NCT02937454|10068312|FG001|Overall Study|Other|5
6325621|NCT02937545|10068330|FG000|Overall Study|Withdrawal by Subject|1
6325622|NCT02937545|10068331|FG001|Overall Study|Withdrawal by Subject|2
6325623|NCT02937545|10068332|FG002|Overall Study|Withdrawal by Subject|6
6325624|NCT02937545|10068333|FG003|Overall Study|Withdrawal by Subject|7
6325625|NCT02937545|10068330|FG000|Overall Study|Lost to Follow-up|1
6325626|NCT02937545|10068331|FG001|Overall Study|Lost to Follow-up|0
6325627|NCT02937545|10068332|FG002|Overall Study|Lost to Follow-up|0
6325628|NCT02937545|10068333|FG003|Overall Study|Lost to Follow-up|0
6325629|NCT02937584|10068354|FG000|Period 1|Adverse Event|1
6325630|NCT02937584|10068355|FG001|Period 1|Adverse Event|2
6325631|NCT02937584|10068354|FG000|Washout|Adverse Event|0
6325632|NCT02937584|10068355|FG001|Washout|Adverse Event|1
6325633|NCT02937636|10068372|FG000|Overall Study|Other (Not specified)|3
6325634|NCT02937636|10068373|FG001|Overall Study|Other (Not specified)|2
6325635|NCT02937701|10068382|FG000|Day 1 to Week 22|Adverse Event|11
6325636|NCT02937701|10068383|FG001|Day 1 to Week 22|Adverse Event|14
6325637|NCT02937701|10068384|FG002|Day 1 to Week 22|Adverse Event|0
6325638|NCT02937701|10068385|FG003|Day 1 to Week 22|Adverse Event|0
6325639|NCT02937701|10068386|FG004|Day 1 to Week 22|Adverse Event|0
6325640|NCT02937701|10068382|FG000|Day 1 to Week 22|Protocol Specified Criteria|7
6325641|NCT02937701|10068383|FG001|Day 1 to Week 22|Protocol Specified Criteria|7
6325642|NCT02937701|10068384|FG002|Day 1 to Week 22|Protocol Specified Criteria|0
6325643|NCT02937701|10068385|FG003|Day 1 to Week 22|Protocol Specified Criteria|0
6325644|NCT02937701|10068386|FG004|Day 1 to Week 22|Protocol Specified Criteria|0
6325645|NCT02937701|10068382|FG000|Day 1 to Week 22|Dissatisfied With Treatment Efficacy|5
6325646|NCT02937701|10068383|FG001|Day 1 to Week 22|Dissatisfied With Treatment Efficacy|9
6325647|NCT02937701|10068384|FG002|Day 1 to Week 22|Dissatisfied With Treatment Efficacy|0
6325648|NCT02937701|10068385|FG003|Day 1 to Week 22|Dissatisfied With Treatment Efficacy|0
6325649|NCT02937701|10068386|FG004|Day 1 to Week 22|Dissatisfied With Treatment Efficacy|0
6325650|NCT02937701|10068382|FG000|Day 1 to Week 22|Withdrawal by Subject|6
6325651|NCT02937701|10068383|FG001|Day 1 to Week 22|Withdrawal by Subject|6
6325652|NCT02937701|10068384|FG002|Day 1 to Week 22|Withdrawal by Subject|0
6325653|NCT02937701|10068385|FG003|Day 1 to Week 22|Withdrawal by Subject|0
6325654|NCT02937701|10068386|FG004|Day 1 to Week 22|Withdrawal by Subject|0
6325655|NCT02937701|10068382|FG000|Day 1 to Week 22|Death|1
6325656|NCT02937701|10068383|FG001|Day 1 to Week 22|Death|1
6325657|NCT02937701|10068384|FG002|Day 1 to Week 22|Death|0
6325658|NCT02937701|10068385|FG003|Day 1 to Week 22|Death|0
6325659|NCT02937701|10068386|FG004|Day 1 to Week 22|Death|0
6325660|NCT02937701|10068382|FG000|Day 1 to Week 22|Protocol Violation|1
6161276|NCT01188772|9803282|FG003|Overall Study|Virologic Failure|0
6161277|NCT01188772|9803279|FG000|Overall Study|Withdrawal by Subject|0
6161278|NCT01188772|9803280|FG001|Overall Study|Withdrawal by Subject|0
6161279|NCT01188772|9803281|FG002|Overall Study|Withdrawal by Subject|2
6325661|NCT02937701|10068383|FG001|Day 1 to Week 22|Protocol Violation|1
6325662|NCT02937701|10068384|FG002|Day 1 to Week 22|Protocol Violation|0
6325663|NCT02937701|10068385|FG003|Day 1 to Week 22|Protocol Violation|0
6325664|NCT02937701|10068386|FG004|Day 1 to Week 22|Protocol Violation|0
6325665|NCT02937701|10068382|FG000|Day 1 to Week 22|Lost to Follow-up|1
6325666|NCT02937701|10068383|FG001|Day 1 to Week 22|Lost to Follow-up|1
6325667|NCT02937701|10068384|FG002|Day 1 to Week 22|Lost to Follow-up|0
6325668|NCT02937701|10068385|FG003|Day 1 to Week 22|Lost to Follow-up|0
6161280|NCT01188772|9803282|FG003|Overall Study|Withdrawal by Subject|0
6161281|NCT01188811|9803297|FG000|Overall Study|Withdrawal by Subject|0
6161282|NCT01188811|9803298|FG001|Overall Study|Withdrawal by Subject|2
6161283|NCT01188811|9803297|FG000|Overall Study|Adverse Event|6
6161284|NCT01188811|9803298|FG001|Overall Study|Adverse Event|0
6161285|NCT01188967|9803327|FG000|Overall Study|Withdrawal by Subject|1
6161286|NCT01188967|9803328|FG001|Overall Study|Withdrawal by Subject|1
6161287|NCT01188967|9803327|FG000|Overall Study|Physician Decision|1
6161288|NCT01188967|9803328|FG001|Overall Study|Physician Decision|1
6161289|NCT01188967|9803327|FG000|Overall Study|Lost to Follow-up|3
6161290|NCT01188967|9803328|FG001|Overall Study|Lost to Follow-up|2
6161291|NCT01189032|9803339|FG000|Overall Study|Adverse Event|1
6161292|NCT01189032|9803340|FG001|Overall Study|Adverse Event|3
6161293|NCT01189032|9803341|FG002|Overall Study|Adverse Event|4
6161294|NCT01189032|9803339|FG000|Overall Study|Lack of Efficacy|2
6161295|NCT01189032|9803340|FG001|Overall Study|Lack of Efficacy|3
6161296|NCT01189032|9803341|FG002|Overall Study|Lack of Efficacy|0
6161297|NCT01189032|9803339|FG000|Overall Study|Withdrawal by Subject|1
6161298|NCT01189032|9803340|FG001|Overall Study|Withdrawal by Subject|0
6161299|NCT01189032|9803341|FG002|Overall Study|Withdrawal by Subject|1
6161300|NCT01189032|9803339|FG000|Overall Study|Protocol Violation|1
6161301|NCT01189032|9803340|FG001|Overall Study|Protocol Violation|1
6161302|NCT01189032|9803341|FG002|Overall Study|Protocol Violation|1
6161303|NCT01189201|9803376|FG000|Overall Study|Adverse Event|1
6161304|NCT01189266|9803406|FG000|Overall Study|Adverse Event|1
6161305|NCT01189266|9803407|FG001|Overall Study|Adverse Event|0
6161306|NCT01189266|9803408|FG002|Overall Study|Adverse Event|5
6161307|NCT01189266|9803406|FG000|Overall Study|Death|0
6161308|NCT01189266|9803407|FG001|Overall Study|Death|0
6161309|NCT01189266|9803408|FG002|Overall Study|Death|5
6161310|NCT01189266|9803406|FG000|Overall Study|Lack of Efficacy|4
6161311|NCT01189266|9803407|FG001|Overall Study|Lack of Efficacy|5
6161312|NCT01189266|9803408|FG002|Overall Study|Lack of Efficacy|44
6161313|NCT01189266|9803406|FG000|Overall Study|Physician Decision|0
6161314|NCT01189266|9803407|FG001|Overall Study|Physician Decision|0
6161315|NCT01189266|9803408|FG002|Overall Study|Physician Decision|1
6161316|NCT01189266|9803406|FG000|Overall Study|Protocol Violation|0
6161317|NCT01189266|9803407|FG001|Overall Study|Protocol Violation|1
6161318|NCT01189266|9803408|FG002|Overall Study|Protocol Violation|1
6161319|NCT01189266|9803406|FG000|Overall Study|Withdrawal by Subject|0
6161320|NCT01189266|9803407|FG001|Overall Study|Withdrawal by Subject|0
6161321|NCT01189266|9803408|FG002|Overall Study|Withdrawal by Subject|1
6161322|NCT01189266|9803406|FG000|Overall Study|Patient refuses further therapy|1
6161323|NCT01189266|9803407|FG001|Overall Study|Patient refuses further therapy|0
6161324|NCT01189266|9803408|FG002|Overall Study|Patient refuses further therapy|7
6161325|NCT01189266|9803406|FG000|Overall Study|No treatment|0
6161326|NCT01189266|9803407|FG001|Overall Study|No treatment|0
6161327|NCT01189266|9803408|FG002|Overall Study|No treatment|1
6161328|NCT01189461|9803464|FG000|Overall Study|Lack of Efficacy|13
6161329|NCT01189461|9803464|FG000|Overall Study|Lost to Follow-up|1
6161330|NCT01189461|9803464|FG000|Overall Study|Withdrawal by Subject|6
6161331|NCT01189461|9803464|FG000|Overall Study|Protocol Violation|1
6161332|NCT01189461|9803464|FG000|Overall Study|Adverse Event|2
6161333|NCT01189461|9803464|FG000|Overall Study|Did not meet entrance criteria|3
6161334|NCT01189461|9803464|FG000|Overall Study|Other|8
6161335|NCT01189487|9803468|FG000|Overall Study|Lack of Efficacy|2
6161336|NCT01189487|9803468|FG000|Overall Study|Adverse Event|1
6161337|NCT01189500|9803472|FG000|Period 1: TAMOX Alone|Adverse Event|1
6161338|NCT01189500|9803472|FG000|Period 2: Coadministration TAMOX+DVS SR|Withdrawal by Subject|1
6161339|NCT01189604|9803486|FG000|Overall Study|Impossible to visit|0
6161340|NCT01189604|9803487|FG001|Overall Study|Impossible to visit|0
6161341|NCT01189604|9803488|FG002|Overall Study|Impossible to visit|0
6161342|NCT01189604|9803489|FG003|Overall Study|Impossible to visit|0
6161343|NCT01189604|9803490|FG004|Overall Study|Impossible to visit|0
6161344|NCT01189604|9803491|FG005|Overall Study|Impossible to visit|1
6161345|NCT01189604|9803492|FG006|Overall Study|Impossible to visit|0
6161346|NCT01189604|9803486|FG000|Overall Study|Adverse Event|0
6161347|NCT01189604|9803487|FG001|Overall Study|Adverse Event|1
6161348|NCT01189604|9803488|FG002|Overall Study|Adverse Event|0
6161349|NCT01189604|9803489|FG003|Overall Study|Adverse Event|0
6161350|NCT01189604|9803490|FG004|Overall Study|Adverse Event|2
6161351|NCT01189604|9803491|FG005|Overall Study|Adverse Event|0
6161352|NCT01189604|9803492|FG006|Overall Study|Adverse Event|1
6161353|NCT01189604|9803486|FG000|Overall Study|Withdrawal by Subject|1
6161354|NCT01189604|9803487|FG001|Overall Study|Withdrawal by Subject|0
6161355|NCT01189604|9803488|FG002|Overall Study|Withdrawal by Subject|0
6161356|NCT01189604|9803489|FG003|Overall Study|Withdrawal by Subject|0
6161357|NCT01189604|9803490|FG004|Overall Study|Withdrawal by Subject|0
6161358|NCT01189604|9803491|FG005|Overall Study|Withdrawal by Subject|0
6161359|NCT01189604|9803492|FG006|Overall Study|Withdrawal by Subject|0
6161360|NCT01189812|9803541|FG000|Overall Study|Withdrawal by Subject|2
6161361|NCT01189812|9803542|FG001|Overall Study|Withdrawal by Subject|3
6161362|NCT01189812|9803541|FG000|Overall Study|Adverse Event|1
6161363|NCT01189812|9803542|FG001|Overall Study|Adverse Event|0
6161364|NCT01189812|9803541|FG000|Overall Study|Out of Window|4
6161365|NCT01189812|9803542|FG001|Overall Study|Out of Window|3
6161366|NCT01189812|9803541|FG000|Overall Study|Moved out of State|1
6161367|NCT01189812|9803542|FG001|Overall Study|Moved out of State|2
6161368|NCT01189890|9803550|FG000|Overall Study|Adverse Event|3
6161369|NCT01189890|9803551|FG001|Overall Study|Adverse Event|4
6161370|NCT01189890|9803550|FG000|Overall Study|Lack of Efficacy|7
6161371|NCT01189890|9803551|FG001|Overall Study|Lack of Efficacy|2
6161372|NCT01189890|9803550|FG000|Overall Study|Lost to Follow-up|1
6161373|NCT01189890|9803551|FG001|Overall Study|Lost to Follow-up|7
6161374|NCT01189890|9803550|FG000|Overall Study|Protocol Violation|1
6161375|NCT01189890|9803551|FG001|Overall Study|Protocol Violation|5
6161376|NCT01189890|9803550|FG000|Overall Study|Withdrawal by Subject|15
6161377|NCT01189890|9803551|FG001|Overall Study|Withdrawal by Subject|11
6161378|NCT01189890|9803550|FG000|Overall Study|Non Compliance|0
6161379|NCT01189890|9803551|FG001|Overall Study|Non Compliance|1
6161380|NCT01189890|9803550|FG000|Overall Study|Physician Decision|5
6161381|NCT01189890|9803551|FG001|Overall Study|Physician Decision|4
6161382|NCT01189890|9803550|FG000|Overall Study|Hyperglycemia Discontinuation Criteria|5
6161383|NCT01189890|9803551|FG001|Overall Study|Hyperglycemia Discontinuation Criteria|5
6161384|NCT01190007|9803557|FG000|Overall Study|Withdrawal by Subject|4
6161385|NCT01190007|9803557|FG000|Overall Study|Adverse Event|8
6161386|NCT01190007|9803557|FG000|Overall Study|Difficulty of visit for complications|1
6161387|NCT01190007|9803557|FG000|Overall Study|Participant was arrested|1
6161388|NCT01190020|9803563|FG000|Overall Study|Adverse Event|2
6161389|NCT01190020|9803564|FG001|Overall Study|Adverse Event|0
6325669|NCT02937701|10068386|FG004|Day 1 to Week 22|Lost to Follow-up|0
6325670|NCT02937701|10068382|FG000|Day 1 to Week 22|Physician Decision|2
6325671|NCT02937701|10068383|FG001|Day 1 to Week 22|Physician Decision|0
6325672|NCT02937701|10068384|FG002|Day 1 to Week 22|Physician Decision|0
6325673|NCT02937701|10068385|FG003|Day 1 to Week 22|Physician Decision|0
6325674|NCT02937701|10068386|FG004|Day 1 to Week 22|Physician Decision|0
6325675|NCT02937701|10068382|FG000|Day 1 to Week 22|Other|1
6325676|NCT02937701|10068383|FG001|Day 1 to Week 22|Other|0
6325677|NCT02937701|10068384|FG002|Day 1 to Week 22|Other|0
6325678|NCT02937701|10068385|FG003|Day 1 to Week 22|Other|0
6325679|NCT02937701|10068386|FG004|Day 1 to Week 22|Other|0
6325680|NCT02937701|10068382|FG000|Week 22 to Week 50|Adverse Event|0
6325681|NCT02937701|10068383|FG001|Week 22 to Week 50|Adverse Event|0
6325682|NCT02937701|10068384|FG002|Week 22 to Week 50|Adverse Event|10
6325683|NCT02937701|10068385|FG003|Week 22 to Week 50|Adverse Event|3
6325684|NCT02937701|10068386|FG004|Week 22 to Week 50|Adverse Event|3
6325685|NCT02937701|10068382|FG000|Week 22 to Week 50|Dissatisfied with Treatment Efficacy|0
6325686|NCT02937701|10068383|FG001|Week 22 to Week 50|Dissatisfied with Treatment Efficacy|0
6325687|NCT02937701|10068384|FG002|Week 22 to Week 50|Dissatisfied with Treatment Efficacy|10
6325688|NCT02937701|10068385|FG003|Week 22 to Week 50|Dissatisfied with Treatment Efficacy|3
6325689|NCT02937701|10068386|FG004|Week 22 to Week 50|Dissatisfied with Treatment Efficacy|2
6325690|NCT02937701|10068382|FG000|Week 22 to Week 50|Withdrawal by Subject|0
6325691|NCT02937701|10068383|FG001|Week 22 to Week 50|Withdrawal by Subject|0
6325692|NCT02937701|10068384|FG002|Week 22 to Week 50|Withdrawal by Subject|8
6325693|NCT02937701|10068385|FG003|Week 22 to Week 50|Withdrawal by Subject|2
6325694|NCT02937701|10068386|FG004|Week 22 to Week 50|Withdrawal by Subject|1
6325695|NCT02937701|10068382|FG000|Week 22 to Week 50|Lost to Follow-up|0
6325696|NCT02937701|10068383|FG001|Week 22 to Week 50|Lost to Follow-up|0
6325697|NCT02937701|10068384|FG002|Week 22 to Week 50|Lost to Follow-up|2
6325698|NCT02937701|10068385|FG003|Week 22 to Week 50|Lost to Follow-up|0
6325699|NCT02937701|10068386|FG004|Week 22 to Week 50|Lost to Follow-up|1
6325700|NCT02937701|10068382|FG000|Week 22 to Week 50|Physician Decision|0
6325701|NCT02937701|10068383|FG001|Week 22 to Week 50|Physician Decision|0
6325702|NCT02937701|10068384|FG002|Week 22 to Week 50|Physician Decision|2
6325703|NCT02937701|10068385|FG003|Week 22 to Week 50|Physician Decision|0
6325704|NCT02937701|10068386|FG004|Week 22 to Week 50|Physician Decision|1
6325705|NCT02937701|10068382|FG000|Week 22 to Week 50|Other|0
6325706|NCT02937701|10068383|FG001|Week 22 to Week 50|Other|0
6325707|NCT02937701|10068384|FG002|Week 22 to Week 50|Other|0
6325708|NCT02937701|10068385|FG003|Week 22 to Week 50|Other|0
6325709|NCT02937701|10068386|FG004|Week 22 to Week 50|Other|1
6325710|NCT02937740|10068400|FG000|BID for 90 Days, 22 mg/Day|Withdrawal by Subject|3
6325711|NCT02937740|10068401|FG001|BID for 90 Days, 22 mg/Day|Withdrawal by Subject|14
6325712|NCT02937740|10068400|FG000|BID for 90 Days, 22 mg/Day|Adverse Event|0
6325713|NCT02937740|10068401|FG001|BID for 90 Days, 22 mg/Day|Adverse Event|10
6325714|NCT02937740|10068400|FG000|BID for 90 Days, 22 mg/Day|Lost to Follow-up|2
6325715|NCT02937740|10068401|FG001|BID for 90 Days, 22 mg/Day|Lost to Follow-up|7
6325716|NCT02937740|10068400|FG000|Uptitrated to TID on Day 90 for 30 Days|Withdrawal by Subject|1
6161390|NCT01190020|9803563|FG000|Overall Study|Lost to Follow-up|2
6161391|NCT01190020|9803564|FG001|Overall Study|Lost to Follow-up|0
6161392|NCT01190020|9803563|FG000|Overall Study|Withdrawal by Subject|3
6161393|NCT01190020|9803564|FG001|Overall Study|Withdrawal by Subject|0
6325717|NCT02937740|10068401|FG001|Uptitrated to TID on Day 90 for 30 Days|Withdrawal by Subject|0
6325718|NCT02937740|10068400|FG000|Uptitrated to TID on Day 90 for 30 Days|Lost to Follow-up|0
6325719|NCT02937740|10068401|FG001|Uptitrated to TID on Day 90 for 30 Days|Lost to Follow-up|1
6325720|NCT02937740|10068400|FG000|Uptitrated to TID on Day 90 for 30 Days|Missed visits|0
6325721|NCT02937740|10068401|FG001|Uptitrated to TID on Day 90 for 30 Days|Missed visits|1
6325722|NCT02937870|10068413|FG000|Overall Study|Adverse Event|1
6161394|NCT01190098|9803585|FG000|Overall Study|Adverse Event|2
6161395|NCT01190098|9803586|FG001|Overall Study|Adverse Event|0
6161396|NCT01190098|9803585|FG000|Overall Study|Patient coomorbidity|0
6161397|NCT01190098|9803586|FG001|Overall Study|Patient coomorbidity|1
6161398|NCT01190098|9803585|FG000|Overall Study|Lack of transportation|1
6161399|NCT01190098|9803586|FG001|Overall Study|Lack of transportation|0
6161400|NCT01190098|9803585|FG000|Overall Study|Other|0
6161401|NCT01190098|9803586|FG001|Overall Study|Other|1
6161402|NCT01190124|9803595|FG000|Overall Study|Death|3
6161403|NCT01190124|9803596|FG001|Overall Study|Death|0
6161404|NCT01190124|9803597|FG002|Overall Study|Death|0
6161405|NCT01190124|9803595|FG000|Overall Study|Therapeutic Failure|12
6161406|NCT01190124|9803596|FG001|Overall Study|Therapeutic Failure|0
6161407|NCT01190124|9803597|FG002|Overall Study|Therapeutic Failure|1
6161408|NCT01190124|9803595|FG000|Overall Study|Lost to Follow-up|2
6161409|NCT01190124|9803596|FG001|Overall Study|Lost to Follow-up|0
6161410|NCT01190124|9803597|FG002|Overall Study|Lost to Follow-up|0
6161411|NCT01190150|9803610|FG000|First Treatment|Withdrawal by Subject|1
6161412|NCT01190150|9803611|FG001|First Treatment|Withdrawal by Subject|0
6161413|NCT01190150|9803610|FG000|Washout|Withdrawal by Subject|0
6161414|NCT01190150|9803611|FG001|Washout|Withdrawal by Subject|1
6161415|NCT01190150|9803610|FG000|Washout|Difficulty in adherence|0
6161416|NCT01190150|9803611|FG001|Washout|Difficulty in adherence|1
6161417|NCT01190176|9803617|FG000|Overall Study|Withdrawal by Subject|1
6161418|NCT01190176|9803617|FG000|Overall Study|Lost to Follow-up|1
6161419|NCT01190189|9803621|FG000|Overall Study|Lost to Follow-up|4
6161420|NCT01190189|9803621|FG000|Overall Study|Withdrawal by Subject|1
6161421|NCT01190189|9803621|FG000|Overall Study|Migrated/moved from study area|1
6161422|NCT01190215|9803627|FG000|Up to Month 6|Lost to Follow-up|2
6161423|NCT01190215|9803628|FG001|Up to Month 6|Lost to Follow-up|0
6161424|NCT01190410|9803636|FG000|Overall Study|Adverse Event|0
6161425|NCT01190410|9803637|FG001|Overall Study|Adverse Event|3
6161426|NCT01190410|9803636|FG000|Overall Study|Lack of Efficacy|0
6161427|NCT01190410|9803637|FG001|Overall Study|Lack of Efficacy|2
6161428|NCT01190410|9803636|FG000|Overall Study|Withdrawal by Subject|0
6161429|NCT01190410|9803637|FG001|Overall Study|Withdrawal by Subject|2
6161430|NCT01190410|9803636|FG000|Overall Study|Administrative decision|1
6161431|NCT01190410|9803637|FG001|Overall Study|Administrative decision|0
6161432|NCT01190410|9803636|FG000|Overall Study|PI discretion|0
6161433|NCT01190410|9803637|FG001|Overall Study|PI discretion|2
6161434|NCT01190436|9803649|FG000|Overall Study|Lost to Follow-up|35
6161435|NCT01190436|9803649|FG000|Overall Study|Other|4
6161436|NCT01190449|9803656|FG000|Overall Study|Ineligible|0
6161437|NCT01190449|9803657|FG001|Overall Study|Ineligible|4
6161438|NCT01190475|9803666|FG000|Overall Study|Withdrawal by Subject|0
6161439|NCT01190475|9803667|FG001|Overall Study|Withdrawal by Subject|0
6161440|NCT01190475|9803668|FG002|Overall Study|Withdrawal by Subject|1
6161441|NCT01190514|9803678|FG000|First Intervention (Period 1)|Adverse Event|1
6161442|NCT01190514|9803679|FG001|First Intervention (Period 1)|Adverse Event|0
6161443|NCT01190514|9803680|FG002|First Intervention (Period 1)|Adverse Event|0
6161444|NCT01190514|9803681|FG003|First Intervention (Period 1)|Adverse Event|0
6161445|NCT01190514|9803678|FG000|Third Intervention (Period 3)|Adverse Event|1
6161446|NCT01190514|9803679|FG001|Third Intervention (Period 3)|Adverse Event|0
6161447|NCT01190514|9803680|FG002|Third Intervention (Period 3)|Adverse Event|0
6161448|NCT01190514|9803681|FG003|Third Intervention (Period 3)|Adverse Event|0
6161449|NCT01190813|9803707|FG000|Overall Study|Lost to Follow-up|1
6161450|NCT01190813|9803708|FG001|Overall Study|Lost to Follow-up|2
6161451|NCT01190813|9803707|FG000|Overall Study|Withdrawal by Subject|2
6161452|NCT01190813|9803708|FG001|Overall Study|Withdrawal by Subject|1
6161453|NCT01190813|9803707|FG000|Overall Study|Refused study treatment after randomized|1
6161454|NCT01190813|9803708|FG001|Overall Study|Refused study treatment after randomized|0
6161455|NCT01190813|9803707|FG000|Overall Study|Adverse Event|0
6161456|NCT01190813|9803708|FG001|Overall Study|Adverse Event|1
6161457|NCT01190839|9803716|FG000|Overall Study|Adverse Event|32
6161458|NCT01190839|9803717|FG001|Overall Study|Adverse Event|41
6161459|NCT01190839|9803716|FG000|Overall Study|Protocol Violation|2
6161460|NCT01190839|9803717|FG001|Overall Study|Protocol Violation|2
6161461|NCT01190839|9803716|FG000|Overall Study|Lost to Follow-up|7
6161462|NCT01190839|9803717|FG001|Overall Study|Lost to Follow-up|1
6161463|NCT01190839|9803716|FG000|Overall Study|Death|1
6161464|NCT01190839|9803717|FG001|Overall Study|Death|0
6161465|NCT01190839|9803716|FG000|Overall Study|Trial stopped by Sponsor|71
6161466|NCT01190839|9803717|FG001|Overall Study|Trial stopped by Sponsor|68
6161467|NCT01190839|9803716|FG000|Overall Study|Undefined|35
6161468|NCT01190839|9803717|FG001|Overall Study|Undefined|31
6161469|NCT01190839|9803716|FG000|Overall Study|Randomized but not treated|2
6161470|NCT01190839|9803717|FG001|Overall Study|Randomized but not treated|4
6161471|NCT01190865|9803725|FG000|Overall Study|Withdrawal by Subject|1
6161472|NCT01190865|9803725|FG000|Overall Study|Non-compliance|2
6161473|NCT01190891|9803748|FG000|Overall Study|Protocol Violation|1
6161474|NCT01190891|9803749|FG001|Overall Study|Protocol Violation|0
6161475|NCT01190891|9803748|FG000|Overall Study|Withdrawal by Subject|5
6161476|NCT01190891|9803749|FG001|Overall Study|Withdrawal by Subject|0
6161477|NCT01190930|9803757|FG000|Induction|Adverse Event|17
6161478|NCT01190930|9803758|FG001|Induction|Adverse Event|0
6161479|NCT01190930|9803759|FG002|Induction|Adverse Event|0
6161480|NCT01190930|9803760|FG003|Induction|Adverse Event|0
6161481|NCT01190930|9803761|FG004|Induction|Adverse Event|0
6161482|NCT01190930|9803762|FG005|Induction|Adverse Event|0
6161483|NCT01190930|9803763|FG006|Induction|Adverse Event|0
6161484|NCT01190930|9803764|FG007|Induction|Adverse Event|0
6161485|NCT01190930|9803765|FG008|Induction|Adverse Event|0
6161486|NCT01190930|9803766|FG009|Induction|Adverse Event|0
6161487|NCT01190930|9803757|FG000|Induction|Death|34
6161488|NCT01190930|9803758|FG001|Induction|Death|0
6161489|NCT01190930|9803759|FG002|Induction|Death|0
6161490|NCT01190930|9803760|FG003|Induction|Death|0
6161491|NCT01190930|9803761|FG004|Induction|Death|0
6161492|NCT01190930|9803762|FG005|Induction|Death|0
6161493|NCT01190930|9803763|FG006|Induction|Death|0
6161494|NCT01190930|9803764|FG007|Induction|Death|0
6161495|NCT01190930|9803765|FG008|Induction|Death|0
6161496|NCT01190930|9803766|FG009|Induction|Death|0
6161497|NCT01190930|9803757|FG000|Induction|Lost to Follow-up|1
6161498|NCT01190930|9803758|FG001|Induction|Lost to Follow-up|0
6161499|NCT01190930|9803759|FG002|Induction|Lost to Follow-up|0
6161500|NCT01190930|9803760|FG003|Induction|Lost to Follow-up|0
6161501|NCT01190930|9803761|FG004|Induction|Lost to Follow-up|0
6161502|NCT01190930|9803762|FG005|Induction|Lost to Follow-up|0
6161503|NCT01190930|9803763|FG006|Induction|Lost to Follow-up|0
6161504|NCT01190930|9803764|FG007|Induction|Lost to Follow-up|0
6161505|NCT01190930|9803765|FG008|Induction|Lost to Follow-up|0
6161506|NCT01190930|9803766|FG009|Induction|Lost to Follow-up|0
6161507|NCT01190930|9803757|FG000|Induction|Physician Decision|125
6161508|NCT01190930|9803758|FG001|Induction|Physician Decision|3
6161509|NCT01190930|9803759|FG002|Induction|Physician Decision|0
6161510|NCT01190930|9803760|FG003|Induction|Physician Decision|0
6161511|NCT01190930|9803761|FG004|Induction|Physician Decision|0
6161512|NCT01190930|9803762|FG005|Induction|Physician Decision|0
6161513|NCT01190930|9803763|FG006|Induction|Physician Decision|0
6161514|NCT01190930|9803764|FG007|Induction|Physician Decision|0
6161515|NCT01190930|9803765|FG008|Induction|Physician Decision|0
6161516|NCT01190930|9803766|FG009|Induction|Physician Decision|0
6161517|NCT01190930|9803757|FG000|Induction|Withdrawal by Subject|9
6161518|NCT01190930|9803758|FG001|Induction|Withdrawal by Subject|0
6161519|NCT01190930|9803759|FG002|Induction|Withdrawal by Subject|0
6161520|NCT01190930|9803760|FG003|Induction|Withdrawal by Subject|0
6161521|NCT01190930|9803761|FG004|Induction|Withdrawal by Subject|0
6161522|NCT01190930|9803762|FG005|Induction|Withdrawal by Subject|0
6161523|NCT01190930|9803763|FG006|Induction|Withdrawal by Subject|0
6161524|NCT01190930|9803764|FG007|Induction|Withdrawal by Subject|0
6161525|NCT01190930|9803765|FG008|Induction|Withdrawal by Subject|0
6161526|NCT01190930|9803766|FG009|Induction|Withdrawal by Subject|0
6161527|NCT01190930|9803757|FG000|Induction|Refusal|235
6161528|NCT01190930|9803758|FG001|Induction|Refusal|0
6161529|NCT01190930|9803759|FG002|Induction|Refusal|0
6161530|NCT01190930|9803760|FG003|Induction|Refusal|0
6161531|NCT01190930|9803761|FG004|Induction|Refusal|0
6161532|NCT01190930|9803762|FG005|Induction|Refusal|0
6161533|NCT01190930|9803763|FG006|Induction|Refusal|0
6161534|NCT01190930|9803764|FG007|Induction|Refusal|0
6161535|NCT01190930|9803765|FG008|Induction|Refusal|0
6161536|NCT01190930|9803766|FG009|Induction|Refusal|0
6161537|NCT01190930|9803757|FG000|Induction|Inevaluable|23
6161538|NCT01190930|9803758|FG001|Induction|Inevaluable|1
6161539|NCT01190930|9803759|FG002|Induction|Inevaluable|0
6161540|NCT01190930|9803760|FG003|Induction|Inevaluable|0
6161541|NCT01190930|9803761|FG004|Induction|Inevaluable|0
6161542|NCT01190930|9803762|FG005|Induction|Inevaluable|0
6161543|NCT01190930|9803763|FG006|Induction|Inevaluable|0
6161544|NCT01190930|9803764|FG007|Induction|Inevaluable|0
6161545|NCT01190930|9803765|FG008|Induction|Inevaluable|0
6161546|NCT01190930|9803766|FG009|Induction|Inevaluable|0
6161547|NCT01190930|9803757|FG000|Induction|BM MRD >= 0.01% on Day 29 of Induction|61
6161548|NCT01190930|9803758|FG001|Induction|BM MRD >= 0.01% on Day 29 of Induction|0
6161549|NCT01190930|9803759|FG002|Induction|BM MRD >= 0.01% on Day 29 of Induction|0
6161550|NCT01190930|9803760|FG003|Induction|BM MRD >= 0.01% on Day 29 of Induction|0
6161551|NCT01190930|9803761|FG004|Induction|BM MRD >= 0.01% on Day 29 of Induction|0
6161552|NCT01190930|9803762|FG005|Induction|BM MRD >= 0.01% on Day 29 of Induction|0
6161553|NCT01190930|9803763|FG006|Induction|BM MRD >= 0.01% on Day 29 of Induction|0
6161554|NCT01190930|9803764|FG007|Induction|BM MRD >= 0.01% on Day 29 of Induction|0
6161555|NCT01190930|9803765|FG008|Induction|BM MRD >= 0.01% on Day 29 of Induction|0
6161556|NCT01190930|9803766|FG009|Induction|BM MRD >= 0.01% on Day 29 of Induction|0
6161557|NCT01190930|9803757|FG000|Induction|High Risk Downs|80
6161558|NCT01190930|9803758|FG001|Induction|High Risk Downs|0
6161559|NCT01190930|9803759|FG002|Induction|High Risk Downs|0
6161560|NCT01190930|9803760|FG003|Induction|High Risk Downs|0
6161561|NCT01190930|9803761|FG004|Induction|High Risk Downs|0
6161562|NCT01190930|9803762|FG005|Induction|High Risk Downs|0
6161563|NCT01190930|9803763|FG006|Induction|High Risk Downs|0
6161564|NCT01190930|9803764|FG007|Induction|High Risk Downs|0
6161565|NCT01190930|9803765|FG008|Induction|High Risk Downs|0
6161566|NCT01190930|9803766|FG009|Induction|High Risk Downs|0
6161567|NCT01190930|9803757|FG000|Induction|Enrollment onto another COG Protocol|1
6161568|NCT01190930|9803758|FG001|Induction|Enrollment onto another COG Protocol|0
6161569|NCT01190930|9803759|FG002|Induction|Enrollment onto another COG Protocol|0
6161570|NCT01190930|9803760|FG003|Induction|Enrollment onto another COG Protocol|0
6161571|NCT01190930|9803761|FG004|Induction|Enrollment onto another COG Protocol|0
6161572|NCT01190930|9803762|FG005|Induction|Enrollment onto another COG Protocol|0
6161573|NCT01190930|9803763|FG006|Induction|Enrollment onto another COG Protocol|0
6161574|NCT01190930|9803764|FG007|Induction|Enrollment onto another COG Protocol|0
6161575|NCT01190930|9803765|FG008|Induction|Enrollment onto another COG Protocol|0
6161576|NCT01190930|9803766|FG009|Induction|Enrollment onto another COG Protocol|0
6161577|NCT01190930|9803757|FG000|Induction|Average Risk|1847
6161578|NCT01190930|9803758|FG001|Induction|Average Risk|0
6161579|NCT01190930|9803759|FG002|Induction|Average Risk|0
6161580|NCT01190930|9803760|FG003|Induction|Average Risk|0
6161581|NCT01190930|9803761|FG004|Induction|Average Risk|0
6161582|NCT01190930|9803762|FG005|Induction|Average Risk|0
6161583|NCT01190930|9803763|FG006|Induction|Average Risk|0
6161584|NCT01190930|9803764|FG007|Induction|Average Risk|0
6161585|NCT01190930|9803765|FG008|Induction|Average Risk|0
6161586|NCT01190930|9803766|FG009|Induction|Average Risk|0
6161587|NCT01190930|9803757|FG000|Induction|High Risk|1227
6161588|NCT01190930|9803758|FG001|Induction|High Risk|0
6161589|NCT01190930|9803759|FG002|Induction|High Risk|0
6161590|NCT01190930|9803760|FG003|Induction|High Risk|0
6161591|NCT01190930|9803761|FG004|Induction|High Risk|0
6161592|NCT01190930|9803762|FG005|Induction|High Risk|0
6161593|NCT01190930|9803763|FG006|Induction|High Risk|0
6161594|NCT01190930|9803764|FG007|Induction|High Risk|0
6325723|NCT02937870|10068413|FG000|Overall Study|Protocol Deviation|2
6325724|NCT02938520|10068474|FG000|Overall Study|On-going at the time of analysis|258
6325725|NCT02938520|10068475|FG001|Overall Study|On-going at the time of analysis|261
6325726|NCT02938520|10068474|FG000|Overall Study|Physician Decision|2
6325727|NCT02938520|10068475|FG001|Overall Study|Physician Decision|5
6325728|NCT02938520|10068474|FG000|Overall Study|Lost to Follow-up|2
6325729|NCT02938520|10068475|FG001|Overall Study|Lost to Follow-up|2
6325730|NCT02938520|10068474|FG000|Overall Study|Withdrawal by Subject|7
6325731|NCT02938520|10068475|FG001|Overall Study|Withdrawal by Subject|7
6325732|NCT02938520|10068474|FG000|Overall Study|Protocol Violation|0
6325733|NCT02938520|10068475|FG001|Overall Study|Protocol Violation|1
6325734|NCT02938520|10068474|FG000|Overall Study|Lack of Efficacy|5
6325735|NCT02938520|10068475|FG001|Overall Study|Lack of Efficacy|3
6161595|NCT01190930|9803765|FG008|Induction|High Risk|0
6161596|NCT01190930|9803766|FG009|Induction|High Risk|0
6161597|NCT01190930|9803757|FG000|Induction|Low Risk|443
6161598|NCT01190930|9803758|FG001|Induction|Low Risk|0
6161599|NCT01190930|9803759|FG002|Induction|Low Risk|0
6161600|NCT01190930|9803760|FG003|Induction|Low Risk|0
6161601|NCT01190930|9803761|FG004|Induction|Low Risk|0
6161602|NCT01190930|9803762|FG005|Induction|Low Risk|0
6161603|NCT01190930|9803763|FG006|Induction|Low Risk|0
6161604|NCT01190930|9803764|FG007|Induction|Low Risk|0
6161605|NCT01190930|9803765|FG008|Induction|Low Risk|0
6161606|NCT01190930|9803766|FG009|Induction|Low Risk|0
6161607|NCT01190930|9803757|FG000|Induction|Very High Risk|1012
6161608|NCT01190930|9803758|FG001|Induction|Very High Risk|0
6161609|NCT01190930|9803759|FG002|Induction|Very High Risk|0
6161610|NCT01190930|9803760|FG003|Induction|Very High Risk|0
6161611|NCT01190930|9803761|FG004|Induction|Very High Risk|0
6161612|NCT01190930|9803762|FG005|Induction|Very High Risk|0
6161613|NCT01190930|9803763|FG006|Induction|Very High Risk|0
6161614|NCT01190930|9803764|FG007|Induction|Very High Risk|0
6161615|NCT01190930|9803765|FG008|Induction|Very High Risk|0
6161616|NCT01190930|9803766|FG009|Induction|Very High Risk|0
6161617|NCT01190930|9803757|FG000|Induction|Philadelphia chromosome-positive|99
6161618|NCT01190930|9803758|FG001|Induction|Philadelphia chromosome-positive|0
6161619|NCT01190930|9803759|FG002|Induction|Philadelphia chromosome-positive|0
6161620|NCT01190930|9803760|FG003|Induction|Philadelphia chromosome-positive|0
6161621|NCT01190930|9803761|FG004|Induction|Philadelphia chromosome-positive|0
6161622|NCT01190930|9803762|FG005|Induction|Philadelphia chromosome-positive|0
6161623|NCT01190930|9803763|FG006|Induction|Philadelphia chromosome-positive|0
6161624|NCT01190930|9803764|FG007|Induction|Philadelphia chromosome-positive|0
6161625|NCT01190930|9803765|FG008|Induction|Philadelphia chromosome-positive|0
6161626|NCT01190930|9803766|FG009|Induction|Philadelphia chromosome-positive|0
6161627|NCT01190930|9803757|FG000|Induction|Incomplete Induction data|63
6161628|NCT01190930|9803758|FG001|Induction|Incomplete Induction data|0
6161629|NCT01190930|9803759|FG002|Induction|Incomplete Induction data|0
6161630|NCT01190930|9803760|FG003|Induction|Incomplete Induction data|0
6161631|NCT01190930|9803761|FG004|Induction|Incomplete Induction data|0
6161632|NCT01190930|9803762|FG005|Induction|Incomplete Induction data|0
6161633|NCT01190930|9803763|FG006|Induction|Incomplete Induction data|0
6161634|NCT01190930|9803764|FG007|Induction|Incomplete Induction data|0
6161635|NCT01190930|9803765|FG008|Induction|Incomplete Induction data|0
6161636|NCT01190930|9803766|FG009|Induction|Incomplete Induction data|0
6161637|NCT01190930|9803757|FG000|Induction|Progressive disease|0
6325736|NCT02938520|10068474|FG000|Overall Study|Adverse Event|9
6325737|NCT02938520|10068475|FG001|Overall Study|Adverse Event|4
6161638|NCT01190930|9803758|FG001|Induction|Progressive disease|1
6161639|NCT01190930|9803759|FG002|Induction|Progressive disease|0
6161640|NCT01190930|9803760|FG003|Induction|Progressive disease|0
6161641|NCT01190930|9803761|FG004|Induction|Progressive disease|0
6161642|NCT01190930|9803762|FG005|Induction|Progressive disease|0
6161643|NCT01190930|9803763|FG006|Induction|Progressive disease|0
6161644|NCT01190930|9803764|FG007|Induction|Progressive disease|0
6161645|NCT01190930|9803765|FG008|Induction|Progressive disease|0
6161646|NCT01190930|9803766|FG009|Induction|Progressive disease|0
6161647|NCT01190930|9803757|FG000|Induction|No treatment|3
6161648|NCT01190930|9803758|FG001|Induction|No treatment|0
6161649|NCT01190930|9803759|FG002|Induction|No treatment|0
6161650|NCT01190930|9803760|FG003|Induction|No treatment|0
6161651|NCT01190930|9803761|FG004|Induction|No treatment|0
6161652|NCT01190930|9803762|FG005|Induction|No treatment|0
6161653|NCT01190930|9803763|FG006|Induction|No treatment|0
6161654|NCT01190930|9803764|FG007|Induction|No treatment|0
6161655|NCT01190930|9803765|FG008|Induction|No treatment|0
6161656|NCT01190930|9803766|FG009|Induction|No treatment|0
6161657|NCT01190930|9803757|FG000|Induction|Ineligible|69
6161658|NCT01190930|9803758|FG001|Induction|Ineligible|4
6161659|NCT01190930|9803759|FG002|Induction|Ineligible|0
6161660|NCT01190930|9803760|FG003|Induction|Ineligible|0
6161661|NCT01190930|9803761|FG004|Induction|Ineligible|0
6161662|NCT01190930|9803762|FG005|Induction|Ineligible|0
6161663|NCT01190930|9803763|FG006|Induction|Ineligible|0
6161664|NCT01190930|9803764|FG007|Induction|Ineligible|0
6161665|NCT01190930|9803765|FG008|Induction|Ineligible|0
6161666|NCT01190930|9803766|FG009|Induction|Ineligible|0
6161667|NCT01190930|9803757|FG000|Post Induction Pre-Maintenance|Adverse Event|0
6161668|NCT01190930|9803758|FG001|Post Induction Pre-Maintenance|Adverse Event|0
6161669|NCT01190930|9803759|FG002|Post Induction Pre-Maintenance|Adverse Event|8
6161670|NCT01190930|9803760|FG003|Post Induction Pre-Maintenance|Adverse Event|0
6161671|NCT01190930|9803761|FG004|Post Induction Pre-Maintenance|Adverse Event|0
6161672|NCT01190930|9803762|FG005|Post Induction Pre-Maintenance|Adverse Event|0
6161673|NCT01190930|9803763|FG006|Post Induction Pre-Maintenance|Adverse Event|0
6161674|NCT01190930|9803764|FG007|Post Induction Pre-Maintenance|Adverse Event|0
6161675|NCT01190930|9803765|FG008|Post Induction Pre-Maintenance|Adverse Event|0
6161676|NCT01190930|9803766|FG009|Post Induction Pre-Maintenance|Adverse Event|0
6161677|NCT01190930|9803757|FG000|Post Induction Pre-Maintenance|Death|0
6161678|NCT01190930|9803758|FG001|Post Induction Pre-Maintenance|Death|0
6161679|NCT01190930|9803759|FG002|Post Induction Pre-Maintenance|Death|8
6161680|NCT01190930|9803760|FG003|Post Induction Pre-Maintenance|Death|4
6161681|NCT01190930|9803761|FG004|Post Induction Pre-Maintenance|Death|0
6161682|NCT01190930|9803762|FG005|Post Induction Pre-Maintenance|Death|0
6161683|NCT01190930|9803763|FG006|Post Induction Pre-Maintenance|Death|0
6161684|NCT01190930|9803764|FG007|Post Induction Pre-Maintenance|Death|0
6161685|NCT01190930|9803765|FG008|Post Induction Pre-Maintenance|Death|0
6161686|NCT01190930|9803766|FG009|Post Induction Pre-Maintenance|Death|0
6161687|NCT01190930|9803757|FG000|Post Induction Pre-Maintenance|Physician Decision|0
6161688|NCT01190930|9803758|FG001|Post Induction Pre-Maintenance|Physician Decision|2
6161689|NCT01190930|9803759|FG002|Post Induction Pre-Maintenance|Physician Decision|35
6161690|NCT01190930|9803760|FG003|Post Induction Pre-Maintenance|Physician Decision|7
6161691|NCT01190930|9803761|FG004|Post Induction Pre-Maintenance|Physician Decision|5
6161692|NCT01190930|9803762|FG005|Post Induction Pre-Maintenance|Physician Decision|3
6161693|NCT01190930|9803763|FG006|Post Induction Pre-Maintenance|Physician Decision|0
6161694|NCT01190930|9803764|FG007|Post Induction Pre-Maintenance|Physician Decision|0
6161695|NCT01190930|9803765|FG008|Post Induction Pre-Maintenance|Physician Decision|0
6161696|NCT01190930|9803766|FG009|Post Induction Pre-Maintenance|Physician Decision|0
6161697|NCT01190930|9803757|FG000|Post Induction Pre-Maintenance|Withdrawal by Subject|0
6161698|NCT01190930|9803758|FG001|Post Induction Pre-Maintenance|Withdrawal by Subject|1
6161699|NCT01190930|9803759|FG002|Post Induction Pre-Maintenance|Withdrawal by Subject|5
6161700|NCT01190930|9803760|FG003|Post Induction Pre-Maintenance|Withdrawal by Subject|2
6161701|NCT01190930|9803761|FG004|Post Induction Pre-Maintenance|Withdrawal by Subject|0
6161702|NCT01190930|9803762|FG005|Post Induction Pre-Maintenance|Withdrawal by Subject|0
6161703|NCT01190930|9803763|FG006|Post Induction Pre-Maintenance|Withdrawal by Subject|0
6161704|NCT01190930|9803764|FG007|Post Induction Pre-Maintenance|Withdrawal by Subject|0
6161705|NCT01190930|9803765|FG008|Post Induction Pre-Maintenance|Withdrawal by Subject|0
6161706|NCT01190930|9803766|FG009|Post Induction Pre-Maintenance|Withdrawal by Subject|0
6161707|NCT01190930|9803757|FG000|Post Induction Pre-Maintenance|Refusal|0
6161708|NCT01190930|9803758|FG001|Post Induction Pre-Maintenance|Refusal|2
6161709|NCT01190930|9803759|FG002|Post Induction Pre-Maintenance|Refusal|694
6161710|NCT01190930|9803760|FG003|Post Induction Pre-Maintenance|Refusal|4
6161711|NCT01190930|9803761|FG004|Post Induction Pre-Maintenance|Refusal|0
6161712|NCT01190930|9803762|FG005|Post Induction Pre-Maintenance|Refusal|3
6161713|NCT01190930|9803763|FG006|Post Induction Pre-Maintenance|Refusal|0
6161714|NCT01190930|9803764|FG007|Post Induction Pre-Maintenance|Refusal|0
6161715|NCT01190930|9803765|FG008|Post Induction Pre-Maintenance|Refusal|0
6161716|NCT01190930|9803766|FG009|Post Induction Pre-Maintenance|Refusal|0
6161717|NCT01190930|9803757|FG000|Post Induction Pre-Maintenance|Inevaluable|0
6161718|NCT01190930|9803758|FG001|Post Induction Pre-Maintenance|Inevaluable|0
6161719|NCT01190930|9803759|FG002|Post Induction Pre-Maintenance|Inevaluable|6
6161720|NCT01190930|9803760|FG003|Post Induction Pre-Maintenance|Inevaluable|0
6161721|NCT01190930|9803761|FG004|Post Induction Pre-Maintenance|Inevaluable|0
6161722|NCT01190930|9803762|FG005|Post Induction Pre-Maintenance|Inevaluable|0
6161723|NCT01190930|9803763|FG006|Post Induction Pre-Maintenance|Inevaluable|0
6161724|NCT01190930|9803764|FG007|Post Induction Pre-Maintenance|Inevaluable|0
6161725|NCT01190930|9803765|FG008|Post Induction Pre-Maintenance|Inevaluable|0
6161726|NCT01190930|9803766|FG009|Post Induction Pre-Maintenance|Inevaluable|0
6161727|NCT01190930|9803757|FG000|Post Induction Pre-Maintenance|CR failure at the end of consolidation|0
6161728|NCT01190930|9803758|FG001|Post Induction Pre-Maintenance|CR failure at the end of consolidation|1
6161729|NCT01190930|9803759|FG002|Post Induction Pre-Maintenance|CR failure at the end of consolidation|0
6161730|NCT01190930|9803760|FG003|Post Induction Pre-Maintenance|CR failure at the end of consolidation|0
6161731|NCT01190930|9803761|FG004|Post Induction Pre-Maintenance|CR failure at the end of consolidation|0
6161732|NCT01190930|9803762|FG005|Post Induction Pre-Maintenance|CR failure at the end of consolidation|0
6161733|NCT01190930|9803763|FG006|Post Induction Pre-Maintenance|CR failure at the end of consolidation|0
6161734|NCT01190930|9803764|FG007|Post Induction Pre-Maintenance|CR failure at the end of consolidation|0
6161735|NCT01190930|9803765|FG008|Post Induction Pre-Maintenance|CR failure at the end of consolidation|0
6161736|NCT01190930|9803766|FG009|Post Induction Pre-Maintenance|CR failure at the end of consolidation|0
6161737|NCT01190930|9803757|FG000|Post Induction Pre-Maintenance|Progressive disease|0
6161738|NCT01190930|9803758|FG001|Post Induction Pre-Maintenance|Progressive disease|0
6161739|NCT01190930|9803759|FG002|Post Induction Pre-Maintenance|Progressive disease|1
6161740|NCT01190930|9803760|FG003|Post Induction Pre-Maintenance|Progressive disease|0
6161741|NCT01190930|9803761|FG004|Post Induction Pre-Maintenance|Progressive disease|0
6161742|NCT01190930|9803762|FG005|Post Induction Pre-Maintenance|Progressive disease|0
6161743|NCT01190930|9803763|FG006|Post Induction Pre-Maintenance|Progressive disease|0
6161744|NCT01190930|9803764|FG007|Post Induction Pre-Maintenance|Progressive disease|0
6161745|NCT01190930|9803765|FG008|Post Induction Pre-Maintenance|Progressive disease|0
6161746|NCT01190930|9803766|FG009|Post Induction Pre-Maintenance|Progressive disease|0
6161747|NCT01190930|9803757|FG000|Post Induction Pre-Maintenance|Relapse|0
6161748|NCT01190930|9803758|FG001|Post Induction Pre-Maintenance|Relapse|0
6161749|NCT01190930|9803759|FG002|Post Induction Pre-Maintenance|Relapse|1
6161750|NCT01190930|9803760|FG003|Post Induction Pre-Maintenance|Relapse|0
6161751|NCT01190930|9803761|FG004|Post Induction Pre-Maintenance|Relapse|0
6161752|NCT01190930|9803762|FG005|Post Induction Pre-Maintenance|Relapse|0
6161753|NCT01190930|9803763|FG006|Post Induction Pre-Maintenance|Relapse|0
6161754|NCT01190930|9803764|FG007|Post Induction Pre-Maintenance|Relapse|0
6161755|NCT01190930|9803765|FG008|Post Induction Pre-Maintenance|Relapse|0
6161756|NCT01190930|9803766|FG009|Post Induction Pre-Maintenance|Relapse|0
6161757|NCT01190930|9803757|FG000|Maintenance|Adverse Event|0
6161758|NCT01190930|9803758|FG001|Maintenance|Adverse Event|0
6161759|NCT01190930|9803759|FG002|Maintenance|Adverse Event|0
6161760|NCT01190930|9803760|FG003|Maintenance|Adverse Event|0
6161761|NCT01190930|9803761|FG004|Maintenance|Adverse Event|0
6161762|NCT01190930|9803762|FG005|Maintenance|Adverse Event|1
6161763|NCT01190930|9803763|FG006|Maintenance|Adverse Event|1
6161764|NCT01190930|9803764|FG007|Maintenance|Adverse Event|3
6161765|NCT01190930|9803765|FG008|Maintenance|Adverse Event|3
6161766|NCT01190930|9803766|FG009|Maintenance|Adverse Event|0
6161767|NCT01190930|9803757|FG000|Maintenance|Death|0
6161768|NCT01190930|9803758|FG001|Maintenance|Death|0
6161769|NCT01190930|9803759|FG002|Maintenance|Death|0
6161770|NCT01190930|9803760|FG003|Maintenance|Death|1
6161771|NCT01190930|9803761|FG004|Maintenance|Death|0
6325738|NCT02938585|10068488|FG000|Overall Study|Withdrawal by parent or guardian|0
6325739|NCT02938585|10068489|FG001|Overall Study|Withdrawal by parent or guardian|1
6325740|NCT02938585|10068490|FG002|Overall Study|Withdrawal by parent or guardian|0
6325741|NCT02938585|10068491|FG003|Overall Study|Withdrawal by parent or guardian|0
6325742|NCT02938585|10068488|FG000|Overall Study|Withdrawal by Subject|0
6161772|NCT01190930|9803762|FG005|Maintenance|Death|0
6161773|NCT01190930|9803763|FG006|Maintenance|Death|2
6161774|NCT01190930|9803764|FG007|Maintenance|Death|2
6161775|NCT01190930|9803765|FG008|Maintenance|Death|2
6161776|NCT01190930|9803766|FG009|Maintenance|Death|2
6161777|NCT01190930|9803757|FG000|Maintenance|Lost to Follow-up|0
6161778|NCT01190930|9803758|FG001|Maintenance|Lost to Follow-up|0
6161779|NCT01190930|9803759|FG002|Maintenance|Lost to Follow-up|0
6161780|NCT01190930|9803760|FG003|Maintenance|Lost to Follow-up|0
6161781|NCT01190930|9803761|FG004|Maintenance|Lost to Follow-up|0
6161782|NCT01190930|9803762|FG005|Maintenance|Lost to Follow-up|0
6161783|NCT01190930|9803763|FG006|Maintenance|Lost to Follow-up|1
6161784|NCT01190930|9803764|FG007|Maintenance|Lost to Follow-up|1
6161785|NCT01190930|9803765|FG008|Maintenance|Lost to Follow-up|1
6161786|NCT01190930|9803766|FG009|Maintenance|Lost to Follow-up|0
6161787|NCT01190930|9803757|FG000|Maintenance|Physician Decision|0
6161788|NCT01190930|9803758|FG001|Maintenance|Physician Decision|1
6161789|NCT01190930|9803759|FG002|Maintenance|Physician Decision|0
6161790|NCT01190930|9803760|FG003|Maintenance|Physician Decision|5
6161791|NCT01190930|9803761|FG004|Maintenance|Physician Decision|9
6161792|NCT01190930|9803762|FG005|Maintenance|Physician Decision|4
6325743|NCT02938585|10068489|FG001|Overall Study|Withdrawal by Subject|0
6161793|NCT01190930|9803763|FG006|Maintenance|Physician Decision|8
6161794|NCT01190930|9803764|FG007|Maintenance|Physician Decision|8
6161795|NCT01190930|9803765|FG008|Maintenance|Physician Decision|10
6161796|NCT01190930|9803766|FG009|Maintenance|Physician Decision|17
6325744|NCT02938585|10068490|FG002|Overall Study|Withdrawal by Subject|0
6161797|NCT01190930|9803757|FG000|Maintenance|Withdrawal by Subject|0
6161798|NCT01190930|9803758|FG001|Maintenance|Withdrawal by Subject|0
6161799|NCT01190930|9803759|FG002|Maintenance|Withdrawal by Subject|0
6161800|NCT01190930|9803760|FG003|Maintenance|Withdrawal by Subject|0
6161801|NCT01190930|9803761|FG004|Maintenance|Withdrawal by Subject|0
6161802|NCT01190930|9803762|FG005|Maintenance|Withdrawal by Subject|0
6161803|NCT01190930|9803763|FG006|Maintenance|Withdrawal by Subject|2
6161804|NCT01190930|9803764|FG007|Maintenance|Withdrawal by Subject|1
6161805|NCT01190930|9803765|FG008|Maintenance|Withdrawal by Subject|4
6161806|NCT01190930|9803766|FG009|Maintenance|Withdrawal by Subject|1
6161807|NCT01190930|9803757|FG000|Maintenance|Refusal|0
6161808|NCT01190930|9803758|FG001|Maintenance|Refusal|1
6161809|NCT01190930|9803759|FG002|Maintenance|Refusal|0
6161810|NCT01190930|9803760|FG003|Maintenance|Refusal|2
6161811|NCT01190930|9803761|FG004|Maintenance|Refusal|0
6325745|NCT02938585|10068491|FG003|Overall Study|Withdrawal by Subject|5
6161812|NCT01190930|9803762|FG005|Maintenance|Refusal|4
6161813|NCT01190930|9803763|FG006|Maintenance|Refusal|5
6161814|NCT01190930|9803764|FG007|Maintenance|Refusal|17
6325746|NCT02939014|10068526|FG000|Overall Study|Lost to Follow-up|1
6325747|NCT02939014|10068527|FG001|Overall Study|Lost to Follow-up|0
6325748|NCT02939014|10068526|FG000|Overall Study|Death|4
6325749|NCT02939014|10068527|FG001|Overall Study|Death|3
6325750|NCT02939079|10068536|FG000|Overall Study|Adverse Event|2
6325751|NCT02939079|10068537|FG001|Overall Study|Adverse Event|1
6325752|NCT02939079|10068536|FG000|Overall Study|Lost to Follow-up|0
6325753|NCT02939079|10068537|FG001|Overall Study|Lost to Follow-up|2
6325754|NCT02939079|10068536|FG000|Overall Study|Protocol Violation|1
6325755|NCT02939079|10068537|FG001|Overall Study|Protocol Violation|0
6325756|NCT02939079|10068536|FG000|Overall Study|Withdrawal by Subject|0
6325757|NCT02939079|10068537|FG001|Overall Study|Withdrawal by Subject|1
6325758|NCT02939079|10068536|FG000|Overall Study|relapse during the study|1
6325759|NCT02939079|10068537|FG001|Overall Study|relapse during the study|1
6325760|NCT02939131|10068550|FG000|Overall Study|Unable to get to clinic|6
6325761|NCT02939131|10068551|FG001|Overall Study|Unable to get to clinic|4
6325762|NCT02939131|10068550|FG000|Overall Study|Lost to Follow-up|2
6325763|NCT02939131|10068551|FG001|Overall Study|Lost to Follow-up|4
6325764|NCT02939131|10068550|FG000|Overall Study|severe debilitation|1
6325765|NCT02939131|10068551|FG001|Overall Study|severe debilitation|0
6325766|NCT02939131|10068550|FG000|Overall Study|Other|0
6325767|NCT02939131|10068551|FG001|Overall Study|Other|1
6325768|NCT02939131|10068550|FG000|Overall Study|not willing to adhere to protocol|2
6325769|NCT02939131|10068551|FG001|Overall Study|not willing to adhere to protocol|0
6325770|NCT02939560|10068601|FG000|Overall Study|Withdrawal by Subject|2
6325771|NCT02939560|10068601|FG000|Overall Study|Protocol Violation|1
6161815|NCT01190930|9803765|FG008|Maintenance|Refusal|13
6325772|NCT02939599|10068607|FG000|Overall Study|Adverse Event|1
6082258|NCT00626522|9690042|FG002|Overall Study|Adverse Event|2
6082259|NCT00626522|9690043|FG003|Overall Study|Adverse Event|0
6161816|NCT01190930|9803766|FG009|Maintenance|Refusal|6
6161817|NCT01190930|9803757|FG000|Maintenance|second malignant neoplasm|0
6161818|NCT01190930|9803758|FG001|Maintenance|second malignant neoplasm|0
6161819|NCT01190930|9803759|FG002|Maintenance|second malignant neoplasm|0
6161820|NCT01190930|9803760|FG003|Maintenance|second malignant neoplasm|1
6161821|NCT01190930|9803761|FG004|Maintenance|second malignant neoplasm|0
6161822|NCT01190930|9803762|FG005|Maintenance|second malignant neoplasm|1
6161823|NCT01190930|9803763|FG006|Maintenance|second malignant neoplasm|0
6161824|NCT01190930|9803764|FG007|Maintenance|second malignant neoplasm|0
6161825|NCT01190930|9803765|FG008|Maintenance|second malignant neoplasm|1
6161826|NCT01190930|9803766|FG009|Maintenance|second malignant neoplasm|0
6161827|NCT01190930|9803757|FG000|Maintenance|Inevaluable|0
6161828|NCT01190930|9803758|FG001|Maintenance|Inevaluable|0
6161829|NCT01190930|9803759|FG002|Maintenance|Inevaluable|0
6161830|NCT01190930|9803760|FG003|Maintenance|Inevaluable|0
6161831|NCT01190930|9803761|FG004|Maintenance|Inevaluable|0
6161832|NCT01190930|9803762|FG005|Maintenance|Inevaluable|1
6161833|NCT01190930|9803763|FG006|Maintenance|Inevaluable|1
6161834|NCT01190930|9803764|FG007|Maintenance|Inevaluable|1
6161835|NCT01190930|9803765|FG008|Maintenance|Inevaluable|0
6161836|NCT01190930|9803766|FG009|Maintenance|Inevaluable|0
6161837|NCT01190930|9803757|FG000|Maintenance|Enrollment onto another COG Protocol|0
6161838|NCT01190930|9803758|FG001|Maintenance|Enrollment onto another COG Protocol|0
6161839|NCT01190930|9803759|FG002|Maintenance|Enrollment onto another COG Protocol|0
6161840|NCT01190930|9803760|FG003|Maintenance|Enrollment onto another COG Protocol|0
6161841|NCT01190930|9803761|FG004|Maintenance|Enrollment onto another COG Protocol|0
6161842|NCT01190930|9803762|FG005|Maintenance|Enrollment onto another COG Protocol|0
6161843|NCT01190930|9803763|FG006|Maintenance|Enrollment onto another COG Protocol|0
6161844|NCT01190930|9803764|FG007|Maintenance|Enrollment onto another COG Protocol|0
6161845|NCT01190930|9803765|FG008|Maintenance|Enrollment onto another COG Protocol|1
6161846|NCT01190930|9803766|FG009|Maintenance|Enrollment onto another COG Protocol|0
6161847|NCT01190930|9803757|FG000|Maintenance|Relapse|0
6161848|NCT01190930|9803758|FG001|Maintenance|Relapse|0
6161849|NCT01190930|9803759|FG002|Maintenance|Relapse|0
6161850|NCT01190930|9803760|FG003|Maintenance|Relapse|2
6161851|NCT01190930|9803761|FG004|Maintenance|Relapse|0
6161852|NCT01190930|9803762|FG005|Maintenance|Relapse|1
6161853|NCT01190930|9803763|FG006|Maintenance|Relapse|6
6161854|NCT01190930|9803764|FG007|Maintenance|Relapse|13
6161855|NCT01190930|9803765|FG008|Maintenance|Relapse|11
6161856|NCT01190930|9803766|FG009|Maintenance|Relapse|11
6161857|NCT01190930|9803757|FG000|Maintenance|Still on therapy|0
6161858|NCT01190930|9803758|FG001|Maintenance|Still on therapy|8
6161859|NCT01190930|9803759|FG002|Maintenance|Still on therapy|0
6161860|NCT01190930|9803760|FG003|Maintenance|Still on therapy|29
6161861|NCT01190930|9803761|FG004|Maintenance|Still on therapy|0
6161862|NCT01190930|9803762|FG005|Maintenance|Still on therapy|0
6161863|NCT01190930|9803763|FG006|Maintenance|Still on therapy|0
6161864|NCT01190930|9803764|FG007|Maintenance|Still on therapy|0
6161865|NCT01190930|9803765|FG008|Maintenance|Still on therapy|0
6161866|NCT01190930|9803766|FG009|Maintenance|Still on therapy|0
6161867|NCT01191008|9803790|FG000|Overall Study|Protocol Violation|7
6161868|NCT01191008|9803790|FG000|Overall Study|Lost to Follow-up|8
6161869|NCT01191086|9803794|FG000|Overall Study|Adverse Event|20
6082260|NCT00626522|9690044|FG004|Overall Study|Adverse Event|1
6082261|NCT00626522|9690045|FG005|Overall Study|Adverse Event|1
6082262|NCT00626522|9690040|FG000|Overall Study|Withdrawal by Subject|2
6082263|NCT00626522|9690041|FG001|Overall Study|Withdrawal by Subject|5
6082264|NCT00626522|9690042|FG002|Overall Study|Withdrawal by Subject|5
6082265|NCT00626522|9690043|FG003|Overall Study|Withdrawal by Subject|0
6082266|NCT00626522|9690044|FG004|Overall Study|Withdrawal by Subject|4
6082267|NCT00626522|9690045|FG005|Overall Study|Withdrawal by Subject|1
6082268|NCT00626522|9690040|FG000|Overall Study|COPD exacerbation|0
6082269|NCT00626522|9690041|FG001|Overall Study|COPD exacerbation|0
6082270|NCT00626522|9690042|FG002|Overall Study|COPD exacerbation|0
6082271|NCT00626522|9690043|FG003|Overall Study|COPD exacerbation|1
6082272|NCT00626522|9690044|FG004|Overall Study|COPD exacerbation|1
6082273|NCT00626522|9690045|FG005|Overall Study|COPD exacerbation|0
6082274|NCT00626522|9690040|FG000|Overall Study|Lost to Follow-up|0
6082275|NCT00626522|9690041|FG001|Overall Study|Lost to Follow-up|1
6082276|NCT00626522|9690042|FG002|Overall Study|Lost to Follow-up|0
6082277|NCT00626522|9690043|FG003|Overall Study|Lost to Follow-up|0
6082278|NCT00626522|9690044|FG004|Overall Study|Lost to Follow-up|0
6161870|NCT01191086|9803794|FG000|Overall Study|Lack of Efficacy|10
6161871|NCT01191086|9803794|FG000|Overall Study|Lost to Follow-up|4
6161872|NCT01191086|9803794|FG000|Overall Study|Physician Decision|2
6161873|NCT01191086|9803794|FG000|Overall Study|Withdrawal by Subject|24
6161874|NCT01191086|9803794|FG000|Overall Study|Discontinuation criterion met|1
6161875|NCT01191086|9803794|FG000|Overall Study|Other|1
6161876|NCT01191190|9803798|FG000|Overall Study|Withdrawal by Subject|1
6082279|NCT00626522|9690045|FG005|Overall Study|Lost to Follow-up|0
6087724|NCT00670046|9698167|FG001|Overall Study|Lost to Follow-up|1
6161877|NCT01191268|9803826|FG000|Overall Study|Withdrawal by Subject|19
6161878|NCT01191268|9803827|FG001|Overall Study|Withdrawal by Subject|25
6161879|NCT01191268|9803828|FG002|Overall Study|Withdrawal by Subject|21
6161880|NCT01191268|9803826|FG000|Overall Study|Adverse Event|21
6161881|NCT01191268|9803827|FG001|Overall Study|Adverse Event|13
6161882|NCT01191268|9803828|FG002|Overall Study|Adverse Event|8
6161883|NCT01191268|9803826|FG000|Overall Study|Physician Decision|6
6161884|NCT01191268|9803827|FG001|Overall Study|Physician Decision|8
6161885|NCT01191268|9803828|FG002|Overall Study|Physician Decision|9
6161886|NCT01191268|9803826|FG000|Overall Study|Lost to Follow-up|8
6161887|NCT01191268|9803827|FG001|Overall Study|Lost to Follow-up|5
6161888|NCT01191268|9803828|FG002|Overall Study|Lost to Follow-up|9
6161889|NCT01191268|9803826|FG000|Overall Study|Entry Criteria Not Met|3
6161890|NCT01191268|9803827|FG001|Overall Study|Entry Criteria Not Met|1
6161891|NCT01191268|9803828|FG002|Overall Study|Entry Criteria Not Met|1
6161892|NCT01191268|9803826|FG000|Overall Study|Death|0
6161893|NCT01191268|9803827|FG001|Overall Study|Death|1
6161894|NCT01191268|9803828|FG002|Overall Study|Death|3
6161895|NCT01191268|9803826|FG000|Overall Study|Protocol Violation|1
6161896|NCT01191268|9803827|FG001|Overall Study|Protocol Violation|0
6161897|NCT01191268|9803828|FG002|Overall Study|Protocol Violation|1
6161898|NCT01191268|9803826|FG000|Overall Study|Sponsor Decision|0
6161899|NCT01191268|9803827|FG001|Overall Study|Sponsor Decision|2
6161900|NCT01191268|9803828|FG002|Overall Study|Sponsor Decision|0
6161901|NCT01191762|9803968|FG000|Overall Study|Adverse Event|1
6161902|NCT01191762|9803969|FG001|Overall Study|Adverse Event|0
6161903|NCT01191788|9803977|FG000|Overall Study|Lost to Follow-up|21
6161904|NCT01191788|9803978|FG001|Overall Study|Lost to Follow-up|22
6191863|NCT01426269|9848817|FG000|Eligibility for Period 2, Randomization|Qualified, opted out|8
6191864|NCT01426269|9848818|FG001|Eligibility for Period 2, Randomization|Qualified, opted out|0
6191865|NCT01426269|9848819|FG002|Eligibility for Period 2, Randomization|Qualified, opted out|0
6191866|NCT01426269|9848817|FG000|Period 2: 40 Weeks|Adverse Event|0
6191867|NCT01426269|9848818|FG001|Period 2: 40 Weeks|Adverse Event|1
6191868|NCT01426269|9848819|FG002|Period 2: 40 Weeks|Adverse Event|2
6191869|NCT01426269|9848817|FG000|Period 2: 40 Weeks|Withdrawal by Subject|0
6191870|NCT01426269|9848818|FG001|Period 2: 40 Weeks|Withdrawal by Subject|9
6191871|NCT01426269|9848819|FG002|Period 2: 40 Weeks|Withdrawal by Subject|11
6191872|NCT01426269|9848817|FG000|Period 2: 40 Weeks|Protocol Violation|0
6191873|NCT01426269|9848818|FG001|Period 2: 40 Weeks|Protocol Violation|5
6191874|NCT01426269|9848819|FG002|Period 2: 40 Weeks|Protocol Violation|5
6191875|NCT01426269|9848817|FG000|Period 2: 40 Weeks|Lost to Follow-up|0
6191876|NCT01426269|9848818|FG001|Period 2: 40 Weeks|Lost to Follow-up|8
6191877|NCT01426269|9848819|FG002|Period 2: 40 Weeks|Lost to Follow-up|6
6191878|NCT01426269|9848817|FG000|Period 2: 40 Weeks|Site closed|0
6191879|NCT01426269|9848818|FG001|Period 2: 40 Weeks|Site closed|6
6191880|NCT01426269|9848819|FG002|Period 2: 40 Weeks|Site closed|5
6191881|NCT01426269|9848817|FG000|Period 2: 40 Weeks|Relapsed|0
6191882|NCT01426269|9848818|FG001|Period 2: 40 Weeks|Relapsed|9
6191883|NCT01426269|9848819|FG002|Period 2: 40 Weeks|Relapsed|18
6191884|NCT01426347|9848832|FG000|Overall Study|Lost to Follow-up|0
6191885|NCT01426347|9848833|FG001|Overall Study|Lost to Follow-up|3
6191886|NCT01426347|9848832|FG000|Overall Study|Protocol Violation|2
6191887|NCT01426347|9848833|FG001|Overall Study|Protocol Violation|0
6191888|NCT01426347|9848832|FG000|Overall Study|Withdrawal by Subject|5
6191889|NCT01426347|9848833|FG001|Overall Study|Withdrawal by Subject|0
6191890|NCT01426373|9848848|FG000|Overall Study|Adverse Event|6
6191891|NCT01426373|9848848|FG000|Overall Study|Lost to Follow-up|14
6191892|NCT01426373|9848848|FG000|Overall Study|Participant Convenience|10
6191893|NCT01426373|9848848|FG000|Overall Study|Miscellaneous Reasons|4
6191894|NCT01426386|9848860|FG000|Overall Study|Adverse Event|0
6191895|NCT01426386|9848861|FG001|Overall Study|Adverse Event|1
6191896|NCT01426386|9848862|FG002|Overall Study|Adverse Event|0
6191897|NCT01426386|9848863|FG003|Overall Study|Adverse Event|0
6191898|NCT01426386|9848864|FG004|Overall Study|Adverse Event|0
6191899|NCT01426386|9848865|FG005|Overall Study|Adverse Event|0
6191900|NCT01426386|9848860|FG000|Overall Study|Did not attend scheduled visit|1
6191901|NCT01426386|9848861|FG001|Overall Study|Did not attend scheduled visit|4
6191902|NCT01426386|9848862|FG002|Overall Study|Did not attend scheduled visit|0
6191903|NCT01426386|9848863|FG003|Overall Study|Did not attend scheduled visit|0
6191904|NCT01426386|9848864|FG004|Overall Study|Did not attend scheduled visit|2
6191905|NCT01426386|9848865|FG005|Overall Study|Did not attend scheduled visit|1
6191906|NCT01426386|9848860|FG000|Overall Study|Poor response|2
6191907|NCT01426386|9848861|FG001|Overall Study|Poor response|1
6191908|NCT01426386|9848862|FG002|Overall Study|Poor response|2
6191909|NCT01426386|9848863|FG003|Overall Study|Poor response|0
6191910|NCT01426386|9848864|FG004|Overall Study|Poor response|1
6191911|NCT01426386|9848865|FG005|Overall Study|Poor response|0
6191912|NCT01426386|9848860|FG000|Overall Study|Personal reasons|0
6191913|NCT01426386|9848861|FG001|Overall Study|Personal reasons|0
6191914|NCT01426386|9848862|FG002|Overall Study|Personal reasons|0
6191915|NCT01426386|9848863|FG003|Overall Study|Personal reasons|0
6191916|NCT01426386|9848864|FG004|Overall Study|Personal reasons|1
6191917|NCT01426386|9848865|FG005|Overall Study|Personal reasons|0
6191918|NCT01426412|9848888|FG000|Overall Study|Withdrawal by Subject|1
6191919|NCT01426412|9848889|FG001|Overall Study|Withdrawal by Subject|0
6191920|NCT01426412|9848890|FG002|Overall Study|Withdrawal by Subject|0
6161905|NCT01191801|9803987|FG000|Overall Study|Death|36
6161906|NCT01191801|9803988|FG001|Overall Study|Death|12
6161907|NCT01191801|9803987|FG000|Overall Study|Lack of Efficacy|176
6161908|NCT01191801|9803988|FG001|Overall Study|Lack of Efficacy|258
6161909|NCT01191801|9803987|FG000|Overall Study|Adverse Event|9
6161910|NCT01191801|9803988|FG001|Overall Study|Adverse Event|8
6161911|NCT01191801|9803987|FG000|Overall Study|Protocol Violation|2
6161912|NCT01191801|9803988|FG001|Overall Study|Protocol Violation|4
6161913|NCT01191801|9803987|FG000|Overall Study|Physician Decision|47
6161914|NCT01191801|9803988|FG001|Overall Study|Physician Decision|24
6161915|NCT01191801|9803987|FG000|Overall Study|Withdrawal by Subject|1
6161916|NCT01191801|9803988|FG001|Overall Study|Withdrawal by Subject|4
6161917|NCT01191801|9803987|FG000|Overall Study|Not Provided|45
6161918|NCT01191801|9803988|FG001|Overall Study|Not Provided|27
6161919|NCT01191840|9804005|FG000|Overall Study|withdrew consent|2
6161920|NCT01191840|9804006|FG001|Overall Study|withdrew consent|1
6161921|NCT01191840|9804005|FG000|Overall Study|Subject discontinued treatment|1
6161922|NCT01191840|9804006|FG001|Overall Study|Subject discontinued treatment|2
6161923|NCT01191840|9804005|FG000|Overall Study|Lost to Follow-up|4
6161924|NCT01191840|9804006|FG001|Overall Study|Lost to Follow-up|6
6161925|NCT01191840|9804005|FG000|Overall Study|Non Staph Infection|4
6161926|NCT01191840|9804006|FG001|Overall Study|Non Staph Infection|3
6161927|NCT01191840|9804005|FG000|Overall Study|ineligible at enrollment|1
6161928|NCT01191840|9804006|FG001|Overall Study|ineligible at enrollment|0
6161929|NCT01191840|9804005|FG000|Overall Study|IRB approval lapse|0
6161930|NCT01191840|9804006|FG001|Overall Study|IRB approval lapse|2
6161931|NCT01191840|9804005|FG000|Overall Study|lab error speciation - non Staph infecti|0
6161932|NCT01191840|9804006|FG001|Overall Study|lab error speciation - non Staph infecti|1
6161933|NCT01191840|9804005|FG000|Overall Study|Withdrawal by Subject|2
6161934|NCT01191840|9804006|FG001|Overall Study|Withdrawal by Subject|0
6161935|NCT01191944|9804014|FG000|Overall Study|Adverse Event|11
6161936|NCT01191944|9804015|FG001|Overall Study|Adverse Event|12
6161937|NCT01191944|9804014|FG000|Overall Study|Protocol Violation|1
6082280|NCT00626522|9690040|FG000|Overall Study|Inconsistent reason reported|1
6161938|NCT01191944|9804015|FG001|Overall Study|Protocol Violation|2
6082281|NCT00626522|9690041|FG001|Overall Study|Inconsistent reason reported|0
6082282|NCT00626522|9690042|FG002|Overall Study|Inconsistent reason reported|0
6082283|NCT00626522|9690043|FG003|Overall Study|Inconsistent reason reported|0
6082284|NCT00626522|9690044|FG004|Overall Study|Inconsistent reason reported|0
6082285|NCT00626522|9690045|FG005|Overall Study|Inconsistent reason reported|0
6082286|NCT00626522|9690040|FG000|Overall Study|Non-fulfilment of in/exclusion criteria|1
6082287|NCT00626522|9690041|FG001|Overall Study|Non-fulfilment of in/exclusion criteria|0
6082288|NCT00626522|9690042|FG002|Overall Study|Non-fulfilment of in/exclusion criteria|1
6082289|NCT00626522|9690043|FG003|Overall Study|Non-fulfilment of in/exclusion criteria|1
6082290|NCT00626522|9690044|FG004|Overall Study|Non-fulfilment of in/exclusion criteria|0
6082291|NCT00626522|9690045|FG005|Overall Study|Non-fulfilment of in/exclusion criteria|0
6082292|NCT00626548|9690061|FG000|Overall Study|Adverse Event|164
6082293|NCT00626548|9690062|FG001|Overall Study|Adverse Event|44
6082294|NCT00626548|9690061|FG000|Overall Study|Withdrawal by Subject|42
6082295|NCT00626548|9690062|FG001|Overall Study|Withdrawal by Subject|46
6082296|NCT00626548|9690061|FG000|Overall Study|Protocol Violation|4
6082297|NCT00626548|9690062|FG001|Overall Study|Protocol Violation|11
6082298|NCT00626548|9690061|FG000|Overall Study|Lost to Follow-up|2
6082299|NCT00626548|9690062|FG001|Overall Study|Lost to Follow-up|2
6082300|NCT00626548|9690061|FG000|Overall Study|Other termination reason|493
6082301|NCT00626548|9690062|FG001|Overall Study|Other termination reason|613
6082302|NCT00626639|9690091|FG000|Overall Study|Occurrence of grade 3 oral mucositis|2
6082303|NCT00626639|9690092|FG001|Overall Study|Occurrence of grade 3 oral mucositis|2
6082304|NCT00626795|9690123|FG000|Open-label TD1414 Cream TID Treatment|Adverse Event|0
6082305|NCT00626795|9690124|FG001|Open-label TD1414 Cream TID Treatment|Adverse Event|1
6082306|NCT00626795|9690125|FG002|Open-label TD1414 Cream TID Treatment|Adverse Event|0
6082307|NCT00626795|9690123|FG000|Blinded Treatment|Lack of Efficacy|2
6082308|NCT00626795|9690124|FG001|Blinded Treatment|Lack of Efficacy|0
6082309|NCT00626795|9690125|FG002|Blinded Treatment|Lack of Efficacy|0
6082310|NCT00626795|9690123|FG000|Blinded Treatment|Unacceptable adverse event|0
6082311|NCT00626795|9690124|FG001|Blinded Treatment|Unacceptable adverse event|0
6082312|NCT00626795|9690125|FG002|Blinded Treatment|Unacceptable adverse event|1
6082313|NCT00626795|9690123|FG000|Blinded Treatment|Protocol Violation|0
6082314|NCT00626795|9690124|FG001|Blinded Treatment|Protocol Violation|1
6082315|NCT00626795|9690125|FG002|Blinded Treatment|Protocol Violation|1
6082316|NCT00626795|9690123|FG000|Blinded Treatment|Withdrawal by Subject|1
6082317|NCT00626795|9690124|FG001|Blinded Treatment|Withdrawal by Subject|1
6082318|NCT00626795|9690125|FG002|Blinded Treatment|Withdrawal by Subject|0
6082319|NCT00626795|9690123|FG000|Blinded Treatment|Other reasons|2
6082320|NCT00626795|9690124|FG001|Blinded Treatment|Other reasons|0
6082321|NCT00626795|9690125|FG002|Blinded Treatment|Other reasons|2
6161939|NCT01191944|9804014|FG000|Overall Study|Withdrawal by Subject|4
6161940|NCT01191944|9804015|FG001|Overall Study|Withdrawal by Subject|2
6161941|NCT01191944|9804014|FG000|Overall Study|Other|1
6161942|NCT01191944|9804015|FG001|Overall Study|Other|3
6161943|NCT01192022|9804025|FG000|Overall Study|Withdrawal of Consent|3
6161944|NCT01192022|9804026|FG001|Overall Study|Withdrawal of Consent|1
6161945|NCT01192022|9804027|FG002|Overall Study|Withdrawal of Consent|0
6161946|NCT01192022|9804028|FG003|Overall Study|Withdrawal of Consent|0
6161947|NCT01192022|9804029|FG004|Overall Study|Withdrawal of Consent|0
6161948|NCT01192022|9804025|FG000|Overall Study|Lost to Follow-up|4
6161949|NCT01192022|9804026|FG001|Overall Study|Lost to Follow-up|2
6161950|NCT01192022|9804027|FG002|Overall Study|Lost to Follow-up|1
6161951|NCT01192022|9804028|FG003|Overall Study|Lost to Follow-up|1
6161952|NCT01192022|9804029|FG004|Overall Study|Lost to Follow-up|0
6161953|NCT01192022|9804025|FG000|Overall Study|Adverse Event|1
6161954|NCT01192022|9804026|FG001|Overall Study|Adverse Event|0
6161955|NCT01192022|9804027|FG002|Overall Study|Adverse Event|0
6161956|NCT01192022|9804028|FG003|Overall Study|Adverse Event|0
6161957|NCT01192022|9804029|FG004|Overall Study|Adverse Event|0
6161958|NCT01192022|9804025|FG000|Overall Study|Fatal Adverse Event|4
6161959|NCT01192022|9804026|FG001|Overall Study|Fatal Adverse Event|6
6161960|NCT01192022|9804027|FG002|Overall Study|Fatal Adverse Event|0
6161961|NCT01192022|9804028|FG003|Overall Study|Fatal Adverse Event|0
6325773|NCT02939599|10068608|FG001|Overall Study|Adverse Event|0
6325774|NCT02939599|10068607|FG000|Overall Study|Study Terminated By Sponsor|2
6325775|NCT02939599|10068608|FG001|Overall Study|Study Terminated By Sponsor|2
6325776|NCT02939716|10068619|FG000|Overall Study|scanner failure|0
6325777|NCT02939716|10068620|FG001|Overall Study|scanner failure|0
6325778|NCT02939716|10068621|FG002|Overall Study|scanner failure|0
6325779|NCT02939716|10068622|FG003|Overall Study|scanner failure|1
6325780|NCT02939716|10068623|FG004|Overall Study|scanner failure|1
6325781|NCT02939716|10068624|FG005|Overall Study|scanner failure|1
6325782|NCT02939781|10068641|FG000|Overall Study|Protocol Violation|8
6325783|NCT02939781|10068641|FG000|Overall Study|Withdrawal by Subject|1
6325784|NCT02939937|10068648|FG000|Overall Study|Adverse Event|5
6325785|NCT02939937|10068649|FG001|Overall Study|Adverse Event|0
6325786|NCT02939937|10068648|FG000|Overall Study|Lost to Follow-up|1
6325787|NCT02939937|10068649|FG001|Overall Study|Lost to Follow-up|3
6325788|NCT02939950|10068657|FG000|Overall Study|Lost to Follow-up|13
6325789|NCT02939950|10068658|FG001|Overall Study|Lost to Follow-up|16
6325790|NCT02939950|10068657|FG000|Overall Study|Positive slit lamp findings|0
6325791|NCT02939950|10068658|FG001|Overall Study|Positive slit lamp findings|1
6325792|NCT02939950|10068657|FG000|Overall Study|Chalazion upper lid|0
6325793|NCT02939950|10068658|FG001|Overall Study|Chalazion upper lid|1
6325794|NCT02939950|10068657|FG000|Overall Study|Lack of motivation|0
6325795|NCT02939950|10068658|FG001|Overall Study|Lack of motivation|2
6325796|NCT02939950|10068657|FG000|Overall Study|Unacceptable distance lens visual acuity|1
6325797|NCT02939950|10068658|FG001|Overall Study|Unacceptable distance lens visual acuity|1
6325798|NCT02939950|10068657|FG000|Overall Study|Military orders|1
6325799|NCT02939950|10068658|FG001|Overall Study|Military orders|0
6325800|NCT02939950|10068657|FG000|Overall Study|Participant Relocated|5
6325801|NCT02939950|10068658|FG001|Overall Study|Participant Relocated|3
6325802|NCT02939950|10068657|FG000|Overall Study|Study related symptoms|8
6325803|NCT02939950|10068658|FG001|Overall Study|Study related symptoms|8
6325804|NCT02939950|10068657|FG000|Overall Study|Unacceptable lens movement|2
6325805|NCT02939950|10068658|FG001|Overall Study|Unacceptable lens movement|0
6161962|NCT01192022|9804029|FG004|Overall Study|Fatal Adverse Event|1
6161963|NCT01192022|9804025|FG000|Overall Study|Physician withdrew-patient hardship|1
6161964|NCT01192022|9804026|FG001|Overall Study|Physician withdrew-patient hardship|0
6161965|NCT01192022|9804027|FG002|Overall Study|Physician withdrew-patient hardship|0
6161966|NCT01192022|9804028|FG003|Overall Study|Physician withdrew-patient hardship|0
6161967|NCT01192022|9804029|FG004|Overall Study|Physician withdrew-patient hardship|0
6161968|NCT01192022|9804025|FG000|Overall Study|Patient too sick from chemotherapy|0
6161969|NCT01192022|9804026|FG001|Overall Study|Patient too sick from chemotherapy|1
6161970|NCT01192022|9804027|FG002|Overall Study|Patient too sick from chemotherapy|0
6161971|NCT01192022|9804028|FG003|Overall Study|Patient too sick from chemotherapy|0
6161972|NCT01192022|9804029|FG004|Overall Study|Patient too sick from chemotherapy|0
6161973|NCT01192022|9804025|FG000|Overall Study|Patient needed surgery|0
6161974|NCT01192022|9804026|FG001|Overall Study|Patient needed surgery|1
6161975|NCT01192022|9804027|FG002|Overall Study|Patient needed surgery|0
6161976|NCT01192022|9804028|FG003|Overall Study|Patient needed surgery|0
6161977|NCT01192022|9804029|FG004|Overall Study|Patient needed surgery|0
6161978|NCT01192022|9804025|FG000|Overall Study|Parents did not allow all follow up|0
6161979|NCT01192022|9804026|FG001|Overall Study|Parents did not allow all follow up|0
6161980|NCT01192022|9804027|FG002|Overall Study|Parents did not allow all follow up|0
6161981|NCT01192022|9804028|FG003|Overall Study|Parents did not allow all follow up|1
6161982|NCT01192022|9804029|FG004|Overall Study|Parents did not allow all follow up|0
6161983|NCT01192100|9804040|FG000|Overall Study|Withdrawal by Subject|0
6161984|NCT01192100|9804041|FG001|Overall Study|Withdrawal by Subject|0
6161985|NCT01192100|9804042|FG002|Overall Study|Withdrawal by Subject|0
6161986|NCT01192100|9804043|FG003|Overall Study|Withdrawal by Subject|0
6161987|NCT01192100|9804044|FG004|Overall Study|Withdrawal by Subject|1
6161988|NCT01192100|9804045|FG005|Overall Study|Withdrawal by Subject|0
6325806|NCT02939950|10068657|FG000|Overall Study|Protocol Violation|6
6325807|NCT02939950|10068658|FG001|Overall Study|Protocol Violation|3
6325808|NCT02939950|10068657|FG000|Overall Study|Physician Decision|2
6325809|NCT02939950|10068658|FG001|Overall Study|Physician Decision|0
6325810|NCT02939950|10068657|FG000|Overall Study|Pregnancy|6
6161989|NCT01192100|9804040|FG000|Overall Study|Protocol Violation|0
6161990|NCT01192100|9804041|FG001|Overall Study|Protocol Violation|0
6161991|NCT01192100|9804042|FG002|Overall Study|Protocol Violation|0
6161992|NCT01192100|9804043|FG003|Overall Study|Protocol Violation|1
6161993|NCT01192100|9804044|FG004|Overall Study|Protocol Violation|0
6161994|NCT01192100|9804045|FG005|Overall Study|Protocol Violation|0
6161995|NCT01192126|9804055|FG000|First Intervention (1 Week)|Unacceptable Distance Visual Acuity|1
6161996|NCT01192126|9804056|FG001|First Intervention (1 Week)|Unacceptable Distance Visual Acuity|0
6161997|NCT01192126|9804055|FG000|First Intervention (1 Week)|Lost to Follow-up|1
6161998|NCT01192126|9804056|FG001|First Intervention (1 Week)|Lost to Follow-up|1
6161999|NCT01192152|9804075|FG000|Period 1|left prematurely (while on treatment B)|0
6162000|NCT01192152|9804076|FG001|Period 1|left prematurely (while on treatment B)|1
6162001|NCT01192152|9804075|FG000|Period 3|family emergency|1
6162002|NCT01192152|9804076|FG001|Period 3|family emergency|0
6162003|NCT01192178|9804086|FG000|Overall Study|Withdrawal by Subject|6
6162004|NCT01192178|9804087|FG001|Overall Study|Withdrawal by Subject|10
6162005|NCT01192178|9804086|FG000|Overall Study|Protocol Violation|10
6162006|NCT01192178|9804087|FG001|Overall Study|Protocol Violation|3
6162007|NCT01192178|9804086|FG000|Overall Study|Physician Decision|2
6162008|NCT01192178|9804087|FG001|Overall Study|Physician Decision|4
6162009|NCT01192178|9804086|FG000|Overall Study|Lost to Follow-up|3
6162010|NCT01192178|9804087|FG001|Overall Study|Lost to Follow-up|3
6162011|NCT01192178|9804086|FG000|Overall Study|Adverse Event|2
6162012|NCT01192178|9804087|FG001|Overall Study|Adverse Event|1
6162013|NCT01192178|9804086|FG000|Overall Study|Lack of Efficacy|1
6082322|NCT00626795|9690123|FG000|Blinded Treatment|Missing reason for withdrawal|5
6082323|NCT00626795|9690124|FG001|Blinded Treatment|Missing reason for withdrawal|3
6082324|NCT00626795|9690125|FG002|Blinded Treatment|Missing reason for withdrawal|5
6082325|NCT00626821|9690154|FG000|Overall Study|Adverse Event|44
6162014|NCT01192178|9804087|FG001|Overall Study|Lack of Efficacy|2
6162015|NCT01192191|9804097|FG000|Overall Study|Adverse Event|7
6162016|NCT01192191|9804098|FG001|Overall Study|Adverse Event|12
6162017|NCT01192191|9804097|FG000|Overall Study|Participants Reached Stopping Criteria|3
6162018|NCT01192191|9804098|FG001|Overall Study|Participants Reached Stopping Criteria|2
6162019|NCT01192191|9804097|FG000|Overall Study|Lost to Follow-up|0
6162020|NCT01192191|9804098|FG001|Overall Study|Lost to Follow-up|1
6162021|NCT01192191|9804097|FG000|Overall Study|Withdrawal by Subject|1
6162022|NCT01192191|9804098|FG001|Overall Study|Withdrawal by Subject|6
6162023|NCT01192204|9804106|FG000|Overall Study|could not keep recall appointments|1
6162024|NCT01192204|9804107|FG001|Overall Study|could not keep recall appointments|0
6162025|NCT01192295|9804132|FG000|Overall Study|Adverse Event|3
6162026|NCT01192295|9804133|FG001|Overall Study|Adverse Event|7
6162027|NCT01192295|9804132|FG000|Overall Study|Withdrawal by Subject|3
6162028|NCT01192295|9804133|FG001|Overall Study|Withdrawal by Subject|4
6162029|NCT01192295|9804132|FG000|Overall Study|Lost to Follow-up|0
6162030|NCT01192295|9804133|FG001|Overall Study|Lost to Follow-up|1
6162031|NCT01192295|9804132|FG000|Overall Study|Lack of Efficacy|0
6162032|NCT01192295|9804133|FG001|Overall Study|Lack of Efficacy|5
6162033|NCT01192295|9804132|FG000|Overall Study|Administrative|4
6162034|NCT01192295|9804133|FG001|Overall Study|Administrative|6
6162035|NCT01192347|9804141|FG000|Overall Study|Death|3
6162036|NCT01192347|9804141|FG000|Overall Study|Lost to Follow-up|3
6162037|NCT01192347|9804141|FG000|Overall Study|Withdrawal by Subject|1
6162038|NCT01192347|9804141|FG000|Overall Study|Adverse Event|1
6162039|NCT01192347|9804141|FG000|Overall Study|Suspected serious adverse drug reaction|1
6162040|NCT01192347|9804141|FG000|Overall Study|Patient seen in different hospital|1
6162041|NCT01192347|9804141|FG000|Overall Study|Patient not visiting hospital regularly|1
6162042|NCT01192347|9804141|FG000|Overall Study|Patient did not show up for visits|1
6162043|NCT01192399|9804145|FG000|Overall Study|Lack of Efficacy|2
6162044|NCT01192412|9804151|FG000|Overall Study|Lost to Follow-up|2
6162045|NCT01192412|9804152|FG001|Overall Study|Lost to Follow-up|1
6162046|NCT01192412|9804151|FG000|Overall Study|Withdrawal by Subject|2
6162047|NCT01192412|9804152|FG001|Overall Study|Withdrawal by Subject|1
6162048|NCT01192516|9804161|FG000|Overall Study|Lost to Follow-up|7
6082326|NCT00626821|9690154|FG000|Overall Study|Protocol Violation|33
6082327|NCT00626821|9690154|FG000|Overall Study|Withdrawal by Subject|10
6082328|NCT00626821|9690154|FG000|Overall Study|Physician Decision|9
6082329|NCT00626821|9690154|FG000|Overall Study|Product dysfunction|21
6082330|NCT00626821|9690154|FG000|Overall Study|other/unknown reason|104
6082331|NCT00626925|9690178|FG000|Overall Study|Lost to Follow-up|1
6162049|NCT01192516|9804162|FG001|Overall Study|Lost to Follow-up|10
6162050|NCT01192516|9804163|FG002|Overall Study|Lost to Follow-up|7
6162051|NCT01192516|9804161|FG000|Overall Study|Withdrawal by Subject|4
6162052|NCT01192516|9804162|FG001|Overall Study|Withdrawal by Subject|4
6162053|NCT01192516|9804163|FG002|Overall Study|Withdrawal by Subject|1
6162054|NCT01192516|9804161|FG000|Overall Study|started new treatment|5
6162055|NCT01192516|9804162|FG001|Overall Study|started new treatment|1
6162056|NCT01192516|9804163|FG002|Overall Study|started new treatment|0
6162057|NCT01192516|9804161|FG000|Overall Study|Unable to follow Actiwatch instructions|4
6162058|NCT01192516|9804162|FG001|Overall Study|Unable to follow Actiwatch instructions|2
6162059|NCT01192516|9804163|FG002|Overall Study|Unable to follow Actiwatch instructions|0
6162060|NCT01192815|9804184|FG000|Overall Study|Withdrawal by Subject|1
6162061|NCT01192815|9804184|FG000|Overall Study|Lack of Efficacy|1
6162062|NCT01193101|9804214|FG000|Overall Study|Adverse Event|0
6162063|NCT01193101|9804215|FG001|Overall Study|Adverse Event|1
6162064|NCT01193101|9804216|FG002|Overall Study|Adverse Event|1
6162065|NCT01193101|9804217|FG003|Overall Study|Adverse Event|3
6162066|NCT01193101|9804214|FG000|Overall Study|Lack of Efficacy|3
6162067|NCT01193101|9804215|FG001|Overall Study|Lack of Efficacy|1
6162068|NCT01193101|9804216|FG002|Overall Study|Lack of Efficacy|0
6162069|NCT01193101|9804217|FG003|Overall Study|Lack of Efficacy|8
6162070|NCT01193101|9804214|FG000|Overall Study|Withdrawal by Subject|2
6162071|NCT01193101|9804215|FG001|Overall Study|Withdrawal by Subject|4
6162072|NCT01193101|9804216|FG002|Overall Study|Withdrawal by Subject|1
6162073|NCT01193101|9804217|FG003|Overall Study|Withdrawal by Subject|1
6162074|NCT01193101|9804214|FG000|Overall Study|Administrative problems|0
6162075|NCT01193101|9804215|FG001|Overall Study|Administrative problems|0
6162076|NCT01193101|9804216|FG002|Overall Study|Administrative problems|1
6162077|NCT01193101|9804217|FG003|Overall Study|Administrative problems|0
6162078|NCT01193101|9804214|FG000|Overall Study|Abnormal test procedure results|0
6162079|NCT01193101|9804215|FG001|Overall Study|Abnormal test procedure results|1
6162080|NCT01193101|9804216|FG002|Overall Study|Abnormal test procedure results|0
6162081|NCT01193101|9804217|FG003|Overall Study|Abnormal test procedure results|0
6162082|NCT01193127|9804240|FG000|Randomized|Surgery Cancelled|0
6162083|NCT01193127|9804241|FG001|Randomized|Surgery Cancelled|0
6162084|NCT01193127|9804242|FG002|Randomized|Surgery Cancelled|0
6162085|NCT01193127|9804243|FG003|Randomized|Surgery Cancelled|1
6162086|NCT01193127|9804240|FG000|Treated|Withdrawal by Subject|0
6162087|NCT01193127|9804241|FG001|Treated|Withdrawal by Subject|0
6162088|NCT01193127|9804242|FG002|Treated|Withdrawal by Subject|0
6162089|NCT01193127|9804243|FG003|Treated|Withdrawal by Subject|1
6162090|NCT01193153|9804255|FG000|Open-label Lead in Period|Lost to Follow-up|32
6162091|NCT01193153|9804256|FG001|Open-label Lead in Period|Lost to Follow-up|0
6162092|NCT01193153|9804255|FG000|Open-label Lead in Period|Pregnancy|1
6162093|NCT01193153|9804256|FG001|Open-label Lead in Period|Pregnancy|0
6162094|NCT01193153|9804255|FG000|Open-label Lead in Period|Withdrawal by Subject|69
6162095|NCT01193153|9804256|FG001|Open-label Lead in Period|Withdrawal by Subject|0
6162096|NCT01193153|9804255|FG000|Open-label Lead in Period|> 6 Weeks Between 2 Study Drug|4
6162097|NCT01193153|9804256|FG001|Open-label Lead in Period|> 6 Weeks Between 2 Study Drug|0
6162098|NCT01193153|9804255|FG000|Open-label Lead in Period|Other|14
6162099|NCT01193153|9804256|FG001|Open-label Lead in Period|Other|0
6162100|NCT01193153|9804255|FG000|Open-label Lead in Period|Subject Failed Stabilization Criteria|47
6162101|NCT01193153|9804256|FG001|Open-label Lead in Period|Subject Failed Stabilization Criteria|0
6162102|NCT01193153|9804255|FG000|Open-label Lead in Period|Adverse Event|41
6162103|NCT01193153|9804256|FG001|Open-label Lead in Period|Adverse Event|0
6162104|NCT01193153|9804255|FG000|Open-label Lead in Period|Death|1
6162105|NCT01193153|9804256|FG001|Open-label Lead in Period|Death|0
6162106|NCT01193153|9804255|FG000|Open-label Lead in Period|Lack of Efficacy|26
6162107|NCT01193153|9804256|FG001|Open-label Lead in Period|Lack of Efficacy|0
6162108|NCT01193153|9804255|FG000|Open-label Stabilization Period|Adverse Event|9
6162109|NCT01193153|9804256|FG001|Open-label Stabilization Period|Adverse Event|0
6162110|NCT01193153|9804255|FG000|Open-label Stabilization Period|Death|2
6162111|NCT01193153|9804256|FG001|Open-label Stabilization Period|Death|0
6162112|NCT01193153|9804255|FG000|Open-label Stabilization Period|Lost to Follow-up|10
6162113|NCT01193153|9804256|FG001|Open-label Stabilization Period|Lost to Follow-up|0
6162114|NCT01193153|9804255|FG000|Open-label Stabilization Period|Lack of Efficacy|5
6162115|NCT01193153|9804256|FG001|Open-label Stabilization Period|Lack of Efficacy|0
6162116|NCT01193153|9804255|FG000|Open-label Stabilization Period|Withdrawal by Subject|29
6162117|NCT01193153|9804256|FG001|Open-label Stabilization Period|Withdrawal by Subject|0
6162118|NCT01193153|9804255|FG000|Open-label Stabilization Period|Subject Failed Stabilization Criteria|35
6162119|NCT01193153|9804256|FG001|Open-label Stabilization Period|Subject Failed Stabilization Criteria|0
6162120|NCT01193153|9804255|FG000|Open-label Stabilization Period|Other|8
6162121|NCT01193153|9804256|FG001|Open-label Stabilization Period|Other|0
6162122|NCT01193153|9804255|FG000|Double Blind Relapse Prevention Period|Other|2
6162123|NCT01193153|9804256|FG001|Double Blind Relapse Prevention Period|Other|3
6162124|NCT01193153|9804255|FG000|Double Blind Relapse Prevention Period|Adverse Event|12
6162125|NCT01193153|9804256|FG001|Double Blind Relapse Prevention Period|Adverse Event|3
6162126|NCT01193153|9804255|FG000|Double Blind Relapse Prevention Period|Death|2
6162127|NCT01193153|9804256|FG001|Double Blind Relapse Prevention Period|Death|0
6162128|NCT01193153|9804255|FG000|Double Blind Relapse Prevention Period|Lost to Follow-up|2
6162129|NCT01193153|9804256|FG001|Double Blind Relapse Prevention Period|Lost to Follow-up|9
6162130|NCT01193153|9804255|FG000|Double Blind Relapse Prevention Period|Pregnancy|1
6162131|NCT01193153|9804256|FG001|Double Blind Relapse Prevention Period|Pregnancy|0
6162132|NCT01193153|9804255|FG000|Double Blind Relapse Prevention Period|Withdrawal by Subject|19
6162133|NCT01193153|9804256|FG001|Double Blind Relapse Prevention Period|Withdrawal by Subject|30
6162134|NCT01193153|9804255|FG000|Double Blind Relapse Prevention Period|Experienced Relapse|25
6162135|NCT01193153|9804256|FG001|Double Blind Relapse Prevention Period|Experienced Relapse|57
6162136|NCT01193153|9804255|FG000|Double Blind Relapse Prevention Period|> 6 Weeks Between 2 Study Drug|1
6162137|NCT01193153|9804256|FG001|Double Blind Relapse Prevention Period|> 6 Weeks Between 2 Study Drug|3
6162138|NCT01193218|9804270|FG000|0-12 Weeks|Adverse Event|6
6162139|NCT01193218|9804271|FG001|0-12 Weeks|Adverse Event|0
6162140|NCT01193218|9804272|FG002|0-12 Weeks|Adverse Event|1
6162141|NCT01193218|9804273|FG003|0-12 Weeks|Adverse Event|0
6162142|NCT01193218|9804274|FG004|0-12 Weeks|Adverse Event|0
6162143|NCT01193218|9804275|FG005|0-12 Weeks|Adverse Event|2
6162144|NCT01193218|9804276|FG006|0-12 Weeks|Adverse Event|2
6162145|NCT01193218|9804277|FG007|0-12 Weeks|Adverse Event|0
6162146|NCT01193218|9804270|FG000|0-12 Weeks|Protocol Violation|0
6162147|NCT01193218|9804271|FG001|0-12 Weeks|Protocol Violation|0
6162148|NCT01193218|9804272|FG002|0-12 Weeks|Protocol Violation|0
6162149|NCT01193218|9804273|FG003|0-12 Weeks|Protocol Violation|0
6162150|NCT01193218|9804274|FG004|0-12 Weeks|Protocol Violation|1
6162151|NCT01193218|9804275|FG005|0-12 Weeks|Protocol Violation|1
6162152|NCT01193218|9804276|FG006|0-12 Weeks|Protocol Violation|0
6162153|NCT01193218|9804277|FG007|0-12 Weeks|Protocol Violation|0
6162154|NCT01193218|9804270|FG000|0-12 Weeks|Withdrawal by Subject|3
6162155|NCT01193218|9804271|FG001|0-12 Weeks|Withdrawal by Subject|0
6162156|NCT01193218|9804272|FG002|0-12 Weeks|Withdrawal by Subject|2
6162157|NCT01193218|9804273|FG003|0-12 Weeks|Withdrawal by Subject|0
6162158|NCT01193218|9804274|FG004|0-12 Weeks|Withdrawal by Subject|0
6162159|NCT01193218|9804275|FG005|0-12 Weeks|Withdrawal by Subject|0
6162160|NCT01193218|9804276|FG006|0-12 Weeks|Withdrawal by Subject|1
6162161|NCT01193218|9804277|FG007|0-12 Weeks|Withdrawal by Subject|0
6162162|NCT01193218|9804270|FG000|12-52 Weeks|Adverse Event|1
6162163|NCT01193218|9804271|FG001|12-52 Weeks|Adverse Event|0
6162164|NCT01193218|9804272|FG002|12-52 Weeks|Adverse Event|1
6162165|NCT01193218|9804273|FG003|12-52 Weeks|Adverse Event|2
6162166|NCT01193218|9804274|FG004|12-52 Weeks|Adverse Event|3
6162167|NCT01193218|9804275|FG005|12-52 Weeks|Adverse Event|3
6162168|NCT01193218|9804276|FG006|12-52 Weeks|Adverse Event|1
6162169|NCT01193218|9804277|FG007|12-52 Weeks|Adverse Event|2
6162170|NCT01193218|9804270|FG000|12-52 Weeks|Lack of Efficacy|0
6162171|NCT01193218|9804271|FG001|12-52 Weeks|Lack of Efficacy|0
6162172|NCT01193218|9804272|FG002|12-52 Weeks|Lack of Efficacy|0
6162173|NCT01193218|9804273|FG003|12-52 Weeks|Lack of Efficacy|0
6162174|NCT01193218|9804274|FG004|12-52 Weeks|Lack of Efficacy|0
6162175|NCT01193218|9804275|FG005|12-52 Weeks|Lack of Efficacy|0
6162176|NCT01193218|9804276|FG006|12-52 Weeks|Lack of Efficacy|1
6162177|NCT01193218|9804277|FG007|12-52 Weeks|Lack of Efficacy|0
6162178|NCT01193218|9804270|FG000|12-52 Weeks|Withdrawal by Subject|3
6162179|NCT01193218|9804271|FG001|12-52 Weeks|Withdrawal by Subject|0
6162180|NCT01193218|9804272|FG002|12-52 Weeks|Withdrawal by Subject|3
6162181|NCT01193218|9804273|FG003|12-52 Weeks|Withdrawal by Subject|0
6162182|NCT01193218|9804274|FG004|12-52 Weeks|Withdrawal by Subject|0
6162183|NCT01193218|9804275|FG005|12-52 Weeks|Withdrawal by Subject|2
6162184|NCT01193218|9804276|FG006|12-52 Weeks|Withdrawal by Subject|1
6162185|NCT01193218|9804277|FG007|12-52 Weeks|Withdrawal by Subject|2
6162186|NCT01193218|9804270|FG000|12-52 Weeks|Other reason than above|1
6162187|NCT01193218|9804271|FG001|12-52 Weeks|Other reason than above|0
6162188|NCT01193218|9804272|FG002|12-52 Weeks|Other reason than above|0
6162189|NCT01193218|9804273|FG003|12-52 Weeks|Other reason than above|1
6162190|NCT01193218|9804274|FG004|12-52 Weeks|Other reason than above|1
6162191|NCT01193218|9804275|FG005|12-52 Weeks|Other reason than above|0
6162192|NCT01193218|9804276|FG006|12-52 Weeks|Other reason than above|0
6162193|NCT01193218|9804277|FG007|12-52 Weeks|Other reason than above|0
6162194|NCT01193244|9804295|FG000|Overall Study|Withdrawal by Subject|79
6162195|NCT01193244|9804296|FG001|Overall Study|Withdrawal by Subject|97
6162196|NCT01193244|9804295|FG000|Overall Study|Other|303
6162197|NCT01193244|9804296|FG001|Overall Study|Other|278
6162198|NCT01193244|9804295|FG000|Overall Study|Lost to Follow-up|6
6162199|NCT01193244|9804296|FG001|Overall Study|Lost to Follow-up|15
6162200|NCT01193257|9804304|FG000|Overall Study|Death|202
6162201|NCT01193257|9804305|FG001|Overall Study|Death|391
6162202|NCT01193257|9804304|FG000|Overall Study|Study termination by sponsor|0
6162203|NCT01193257|9804305|FG001|Overall Study|Study termination by sponsor|3
6162204|NCT01193257|9804304|FG000|Overall Study|Withdrawal by Subject|26
6162205|NCT01193257|9804305|FG001|Overall Study|Withdrawal by Subject|86
6162206|NCT01193257|9804304|FG000|Overall Study|Lost to Follow-up|2
6162207|NCT01193257|9804305|FG001|Overall Study|Lost to Follow-up|3
6162208|NCT01193257|9804304|FG000|Overall Study|Unblinded due to futility|135
6162209|NCT01193257|9804305|FG001|Overall Study|Unblinded due to futility|251
6162210|NCT01193283|9804311|FG000|Overall Study|Death|1
6162211|NCT01193335|9804317|FG000|After Infant Series|Lost to Follow-up|1
6162212|NCT01193335|9804318|FG001|After Infant Series|Lost to Follow-up|2
6162213|NCT01193335|9804317|FG000|After Infant Series|No Longer Met Eligibility Criteria|0
6162214|NCT01193335|9804318|FG001|After Infant Series|No Longer Met Eligibility Criteria|1
6162215|NCT01193335|9804317|FG000|1-Year Follow-up|No Longer Willing to Participate|7
6162216|NCT01193335|9804318|FG001|1-Year Follow-up|No Longer Willing to Participate|9
6162217|NCT01193335|9804317|FG000|1-Year Follow-up|Lost to Follow-up|4
6162218|NCT01193335|9804318|FG001|1-Year Follow-up|Lost to Follow-up|0
6162219|NCT01193335|9804317|FG000|2-Year Follow-up|No Longer Willing to Participate|5
6162220|NCT01193335|9804318|FG001|2-Year Follow-up|No Longer Willing to Participate|6
6162221|NCT01193335|9804317|FG000|2-Year Follow-up|No Longer Met Eligibility Criteria|2
6162222|NCT01193335|9804318|FG001|2-Year Follow-up|No Longer Met Eligibility Criteria|2
6162223|NCT01193348|9804340|FG000|Screening Period|Screen Failure|5
6162224|NCT01193348|9804340|FG000|Treatment Period (26 Weeks)|Positive Shiga-Toxin Result vial Local|1
6162225|NCT01193348|9804340|FG000|Treatment Period (26 Weeks)|Serious Adverse Event|1
6162226|NCT01193348|9804340|FG000|Treatment Period (26 Weeks)|Patient Requested to Withdraw|1
6162227|NCT01193348|9804340|FG000|Extension Treatment Period|Physician Decision|1
6162228|NCT01193348|9804340|FG000|Post Treatment Period (Patients Who Disc|Patient did not return for visit|2
6162229|NCT01193517|9804352|FG000|Overall Study|Early Progression|1
6162230|NCT01193517|9804353|FG001|Overall Study|Early Progression|0
6162231|NCT01193517|9804354|FG002|Overall Study|Early Progression|0
6162232|NCT01193582|9804367|FG000|Vaccination Series|Withdrawal by Subject|11
6162233|NCT01193582|9804368|FG001|Vaccination Series|Withdrawal by Subject|13
6162234|NCT01193582|9804369|FG002|Vaccination Series|Withdrawal by Subject|8
6162235|NCT01193582|9804370|FG003|Vaccination Series|Withdrawal by Subject|3
6162236|NCT01193582|9804367|FG000|12 Month Follow-up|Death|0
6162237|NCT01193582|9804368|FG001|12 Month Follow-up|Death|0
6162238|NCT01193582|9804369|FG002|12 Month Follow-up|Death|1
6162239|NCT01193582|9804370|FG003|12 Month Follow-up|Death|0
6162240|NCT01193582|9804367|FG000|12 Month Follow-up|Withdrawal by Subject|6
6162241|NCT01193582|9804368|FG001|12 Month Follow-up|Withdrawal by Subject|0
6162242|NCT01193582|9804369|FG002|12 Month Follow-up|Withdrawal by Subject|3
6162243|NCT01193582|9804370|FG003|12 Month Follow-up|Withdrawal by Subject|11
6162244|NCT01193608|9804388|FG000|Overall Study|Other|0
6162245|NCT01193608|9804389|FG001|Overall Study|Other|1
6162246|NCT01193608|9804390|FG002|Overall Study|Other|0
6162247|NCT01193608|9804391|FG003|Overall Study|Other|0
6162248|NCT01193608|9804392|FG004|Overall Study|Other|0
6162249|NCT01193608|9804393|FG005|Overall Study|Other|0
6162250|NCT01193608|9804388|FG000|Overall Study|Withdrawal by Subject|0
6162251|NCT01193608|9804389|FG001|Overall Study|Withdrawal by Subject|1
6162252|NCT01193608|9804390|FG002|Overall Study|Withdrawal by Subject|2
6162253|NCT01193608|9804391|FG003|Overall Study|Withdrawal by Subject|3
6162254|NCT01193608|9804392|FG004|Overall Study|Withdrawal by Subject|3
6162255|NCT01193608|9804393|FG005|Overall Study|Withdrawal by Subject|0
6162256|NCT01193608|9804388|FG000|Overall Study|Lost to Follow-up|0
6162257|NCT01193608|9804389|FG001|Overall Study|Lost to Follow-up|0
6162258|NCT01193608|9804390|FG002|Overall Study|Lost to Follow-up|0
6162259|NCT01193608|9804391|FG003|Overall Study|Lost to Follow-up|0
6162260|NCT01193608|9804392|FG004|Overall Study|Lost to Follow-up|1
6162261|NCT01193608|9804393|FG005|Overall Study|Lost to Follow-up|2
6162262|NCT01193608|9804388|FG000|Overall Study|Adverse Event|0
6162263|NCT01193608|9804389|FG001|Overall Study|Adverse Event|0
6162264|NCT01193608|9804390|FG002|Overall Study|Adverse Event|0
6162265|NCT01193608|9804391|FG003|Overall Study|Adverse Event|0
6162266|NCT01193608|9804392|FG004|Overall Study|Adverse Event|1
6162267|NCT01193608|9804393|FG005|Overall Study|Adverse Event|0
6162268|NCT01193660|9804415|FG000|Overall Study|Withdrawal by Subject|2
6162269|NCT01193660|9804416|FG001|Overall Study|Withdrawal by Subject|3
6162270|NCT01193660|9804417|FG002|Overall Study|Withdrawal by Subject|1
6162271|NCT01193660|9804415|FG000|Overall Study|Death|1
6162272|NCT01193660|9804416|FG001|Overall Study|Death|0
6162273|NCT01193660|9804417|FG002|Overall Study|Death|0
6162274|NCT01193660|9804415|FG000|Overall Study|Physician Decision|1
6162275|NCT01193660|9804416|FG001|Overall Study|Physician Decision|0
6162276|NCT01193660|9804417|FG002|Overall Study|Physician Decision|1
6162277|NCT01193686|9804427|FG000|Overall Study|Withdrawal by Subject|4
6162278|NCT01193686|9804428|FG001|Overall Study|Withdrawal by Subject|1
6162279|NCT01193686|9804427|FG000|Overall Study|Removed by Investigators; unable to matc|3
6162280|NCT01193686|9804428|FG001|Overall Study|Removed by Investigators; unable to matc|0
6162281|NCT01193920|9804466|FG000|Overall Study|Withdrawal by Subject|1
6162282|NCT01193920|9804467|FG001|Overall Study|Withdrawal by Subject|0
6162283|NCT01193920|9804468|FG002|Overall Study|Withdrawal by Subject|5
6162284|NCT01193920|9804469|FG003|Overall Study|Withdrawal by Subject|1
6162285|NCT01193920|9804470|FG004|Overall Study|Withdrawal by Subject|3
6162286|NCT01193920|9804471|FG005|Overall Study|Withdrawal by Subject|1
6162287|NCT01193920|9804472|FG006|Overall Study|Withdrawal by Subject|3
6162288|NCT01193920|9804473|FG007|Overall Study|Withdrawal by Subject|0
6162289|NCT01193920|9804474|FG008|Overall Study|Withdrawal by Subject|1
6162290|NCT01193920|9804475|FG009|Overall Study|Withdrawal by Subject|0
6162291|NCT01193920|9804466|FG000|Overall Study|Lost to Follow-up|1
6162292|NCT01193920|9804467|FG001|Overall Study|Lost to Follow-up|0
6162293|NCT01193920|9804468|FG002|Overall Study|Lost to Follow-up|1
6162294|NCT01193920|9804469|FG003|Overall Study|Lost to Follow-up|1
6162295|NCT01193920|9804470|FG004|Overall Study|Lost to Follow-up|3
6162296|NCT01193920|9804471|FG005|Overall Study|Lost to Follow-up|3
6162297|NCT01193920|9804472|FG006|Overall Study|Lost to Follow-up|1
6162298|NCT01193920|9804473|FG007|Overall Study|Lost to Follow-up|0
6162299|NCT01193920|9804474|FG008|Overall Study|Lost to Follow-up|2
6162300|NCT01193920|9804475|FG009|Overall Study|Lost to Follow-up|3
6162301|NCT01193920|9804466|FG000|Overall Study|Protocol Violation|1
6162302|NCT01193920|9804467|FG001|Overall Study|Protocol Violation|0
6162303|NCT01193920|9804468|FG002|Overall Study|Protocol Violation|0
6162304|NCT01193920|9804469|FG003|Overall Study|Protocol Violation|0
6162305|NCT01193920|9804470|FG004|Overall Study|Protocol Violation|0
6162306|NCT01193920|9804471|FG005|Overall Study|Protocol Violation|0
6162307|NCT01193920|9804472|FG006|Overall Study|Protocol Violation|0
6162308|NCT01193920|9804473|FG007|Overall Study|Protocol Violation|0
6162309|NCT01193920|9804474|FG008|Overall Study|Protocol Violation|0
6162310|NCT01193920|9804475|FG009|Overall Study|Protocol Violation|0
6162311|NCT01193920|9804466|FG000|Overall Study|Death|0
6162312|NCT01193920|9804467|FG001|Overall Study|Death|0
6162313|NCT01193920|9804468|FG002|Overall Study|Death|0
6162314|NCT01193920|9804469|FG003|Overall Study|Death|1
6162315|NCT01193920|9804470|FG004|Overall Study|Death|0
6162316|NCT01193920|9804471|FG005|Overall Study|Death|0
6162317|NCT01193920|9804472|FG006|Overall Study|Death|2
6162318|NCT01193920|9804473|FG007|Overall Study|Death|3
6162319|NCT01193920|9804474|FG008|Overall Study|Death|2
6162320|NCT01193920|9804475|FG009|Overall Study|Death|4
6162321|NCT01193920|9804466|FG000|Overall Study|Unable to classify|0
6162322|NCT01193920|9804467|FG001|Overall Study|Unable to classify|0
6162323|NCT01193920|9804468|FG002|Overall Study|Unable to classify|0
6162324|NCT01193920|9804469|FG003|Overall Study|Unable to classify|1
6162325|NCT01193920|9804470|FG004|Overall Study|Unable to classify|0
6162326|NCT01193920|9804471|FG005|Overall Study|Unable to classify|0
6162327|NCT01193920|9804472|FG006|Overall Study|Unable to classify|0
6162328|NCT01193920|9804473|FG007|Overall Study|Unable to classify|1
6162329|NCT01193920|9804474|FG008|Overall Study|Unable to classify|0
6162330|NCT01193920|9804475|FG009|Overall Study|Unable to classify|0
6162331|NCT01194154|9804509|FG000|Overall Study|Adverse Event|12
6162332|NCT01194154|9804510|FG001|Overall Study|Adverse Event|7
6162333|NCT01194154|9804509|FG000|Overall Study|Lost to Follow-up|2
6162334|NCT01194154|9804510|FG001|Overall Study|Lost to Follow-up|3
6162335|NCT01194154|9804509|FG000|Overall Study|Protocol Violation|0
6162336|NCT01194154|9804510|FG001|Overall Study|Protocol Violation|1
6162337|NCT01194154|9804509|FG000|Overall Study|Withdrawal by Subject|5
6162338|NCT01194154|9804510|FG001|Overall Study|Withdrawal by Subject|6
6162339|NCT01194154|9804509|FG000|Overall Study|Blood pressure increase|5
6162340|NCT01194154|9804510|FG001|Overall Study|Blood pressure increase|3
6162341|NCT01194154|9804509|FG000|Overall Study|Hemoglobin decrease|0
6162342|NCT01194154|9804510|FG001|Overall Study|Hemoglobin decrease|1
6162343|NCT01194154|9804509|FG000|Overall Study|Hemoglobin increase|12
6162344|NCT01194154|9804510|FG001|Overall Study|Hemoglobin increase|3
6162345|NCT01194154|9804509|FG000|Overall Study|Skipping of CERA treatment at two visits|3
6162346|NCT01194154|9804510|FG001|Overall Study|Skipping of CERA treatment at two visits|0
6162347|NCT01194154|9804509|FG000|Overall Study|Treatment with prohibited medication|4
6162348|NCT01194154|9804510|FG001|Overall Study|Treatment with prohibited medication|5
6162349|NCT01194154|9804509|FG000|Overall Study|Other|4
6162350|NCT01194154|9804510|FG001|Overall Study|Other|0
6162351|NCT01194154|9804509|FG000|Overall Study|Did not receive study medication|2
6162352|NCT01194154|9804510|FG001|Overall Study|Did not receive study medication|4
6162353|NCT01194245|9804523|FG000|Titration Period (4 to 6 Weeks)|Withdrawal by Subject|5
6162354|NCT01194245|9804524|FG001|Titration Period (4 to 6 Weeks)|Withdrawal by Subject|0
6162355|NCT01194245|9804525|FG002|Titration Period (4 to 6 Weeks)|Withdrawal by Subject|0
6162356|NCT01194245|9804526|FG003|Titration Period (4 to 6 Weeks)|Withdrawal by Subject|0
6162357|NCT01194245|9804527|FG004|Titration Period (4 to 6 Weeks)|Withdrawal by Subject|0
6162358|NCT01194245|9804523|FG000|Titration Period (4 to 6 Weeks)|Physician Decision|3
6162359|NCT01194245|9804524|FG001|Titration Period (4 to 6 Weeks)|Physician Decision|0
6162360|NCT01194245|9804525|FG002|Titration Period (4 to 6 Weeks)|Physician Decision|0
6162361|NCT01194245|9804526|FG003|Titration Period (4 to 6 Weeks)|Physician Decision|0
6162362|NCT01194245|9804527|FG004|Titration Period (4 to 6 Weeks)|Physician Decision|0
6162363|NCT01194245|9804523|FG000|Titration Period (4 to 6 Weeks)|Titration Failure|3
6162364|NCT01194245|9804524|FG001|Titration Period (4 to 6 Weeks)|Titration Failure|0
6162365|NCT01194245|9804525|FG002|Titration Period (4 to 6 Weeks)|Titration Failure|0
6162366|NCT01194245|9804526|FG003|Titration Period (4 to 6 Weeks)|Titration Failure|0
6162367|NCT01194245|9804527|FG004|Titration Period (4 to 6 Weeks)|Titration Failure|0
6162368|NCT01194245|9804523|FG000|Titration Period (4 to 6 Weeks)|Did Not Meet Randomization Criteria|7
6162369|NCT01194245|9804524|FG001|Titration Period (4 to 6 Weeks)|Did Not Meet Randomization Criteria|0
6162370|NCT01194245|9804525|FG002|Titration Period (4 to 6 Weeks)|Did Not Meet Randomization Criteria|0
6162371|NCT01194245|9804526|FG003|Titration Period (4 to 6 Weeks)|Did Not Meet Randomization Criteria|0
6162372|NCT01194245|9804527|FG004|Titration Period (4 to 6 Weeks)|Did Not Meet Randomization Criteria|0
6162373|NCT01194245|9804523|FG000|Treatment Period 1 (Weeks 0 to 12)|Lost to Follow-up|0
6162374|NCT01194245|9804524|FG001|Treatment Period 1 (Weeks 0 to 12)|Lost to Follow-up|0
6162375|NCT01194245|9804525|FG002|Treatment Period 1 (Weeks 0 to 12)|Lost to Follow-up|0
6162376|NCT01194245|9804526|FG003|Treatment Period 1 (Weeks 0 to 12)|Lost to Follow-up|0
6162377|NCT01194245|9804527|FG004|Treatment Period 1 (Weeks 0 to 12)|Lost to Follow-up|1
6162378|NCT01194245|9804523|FG000|Treatment Period 1 (Weeks 0 to 12)|Withdrawal by Subject|0
6162379|NCT01194245|9804524|FG001|Treatment Period 1 (Weeks 0 to 12)|Withdrawal by Subject|0
6162380|NCT01194245|9804525|FG002|Treatment Period 1 (Weeks 0 to 12)|Withdrawal by Subject|1
6162381|NCT01194245|9804526|FG003|Treatment Period 1 (Weeks 0 to 12)|Withdrawal by Subject|1
6162382|NCT01194245|9804527|FG004|Treatment Period 1 (Weeks 0 to 12)|Withdrawal by Subject|1
6162383|NCT01194258|9804536|FG000|Titration Period|Withdrawal by Subject|6
6162384|NCT01194258|9804537|FG001|Titration Period|Withdrawal by Subject|0
6162385|NCT01194258|9804538|FG002|Titration Period|Withdrawal by Subject|0
6162386|NCT01194258|9804539|FG003|Titration Period|Withdrawal by Subject|0
6162387|NCT01194258|9804540|FG004|Titration Period|Withdrawal by Subject|0
6162388|NCT01194258|9804536|FG000|Titration Period|Lost to Follow-up|2
6162389|NCT01194258|9804537|FG001|Titration Period|Lost to Follow-up|0
6162390|NCT01194258|9804538|FG002|Titration Period|Lost to Follow-up|0
6162391|NCT01194258|9804539|FG003|Titration Period|Lost to Follow-up|0
6162392|NCT01194258|9804540|FG004|Titration Period|Lost to Follow-up|0
6162393|NCT01194258|9804536|FG000|Titration Period|Titration failure|3
6162394|NCT01194258|9804537|FG001|Titration Period|Titration failure|0
6162395|NCT01194258|9804538|FG002|Titration Period|Titration failure|0
6162396|NCT01194258|9804539|FG003|Titration Period|Titration failure|0
6162397|NCT01194258|9804540|FG004|Titration Period|Titration failure|0
6162398|NCT01194258|9804536|FG000|Period 1 (12 Weeks)|Death|0
6162399|NCT01194258|9804537|FG001|Period 1 (12 Weeks)|Death|0
6162400|NCT01194258|9804538|FG002|Period 1 (12 Weeks)|Death|0
6162401|NCT01194258|9804539|FG003|Period 1 (12 Weeks)|Death|0
6162402|NCT01194258|9804540|FG004|Period 1 (12 Weeks)|Death|1
6162403|NCT01194258|9804536|FG000|Period 2 (12 Weeks)|Lost to Follow-up|0
6162404|NCT01194258|9804537|FG001|Period 2 (12 Weeks)|Lost to Follow-up|0
6162405|NCT01194258|9804538|FG002|Period 2 (12 Weeks)|Lost to Follow-up|0
6162406|NCT01194258|9804539|FG003|Period 2 (12 Weeks)|Lost to Follow-up|0
6162407|NCT01194258|9804540|FG004|Period 2 (12 Weeks)|Lost to Follow-up|2
6162408|NCT01194258|9804536|FG000|Period 2 (12 Weeks)|Adverse Event|0
6162409|NCT01194258|9804537|FG001|Period 2 (12 Weeks)|Adverse Event|1
6162410|NCT01194258|9804538|FG002|Period 2 (12 Weeks)|Adverse Event|0
6162411|NCT01194258|9804539|FG003|Period 2 (12 Weeks)|Adverse Event|0
6162412|NCT01194258|9804540|FG004|Period 2 (12 Weeks)|Adverse Event|0
6162413|NCT01194258|9804536|FG000|Period 2 (12 Weeks)|Withdrawal by Subject|0
6162414|NCT01194258|9804537|FG001|Period 2 (12 Weeks)|Withdrawal by Subject|1
6162415|NCT01194258|9804538|FG002|Period 2 (12 Weeks)|Withdrawal by Subject|1
6162416|NCT01194258|9804539|FG003|Period 2 (12 Weeks)|Withdrawal by Subject|0
6162417|NCT01194258|9804540|FG004|Period 2 (12 Weeks)|Withdrawal by Subject|0
6162418|NCT01194271|9804551|FG000|Overall Study|Withdrawal by Subject|1
6162419|NCT01194271|9804551|FG000|Overall Study|Ineligible, Screen Failure|1
6162420|NCT01194271|9804551|FG000|Overall Study|Death|1
6162421|NCT01194414|9804566|FG000|24 Weeks Double Blind Period|Insufficient Therapeutic Response|11
6162422|NCT01194414|9804567|FG001|24 Weeks Double Blind Period|Insufficient Therapeutic Response|8
6162423|NCT01194414|9804568|FG002|24 Weeks Double Blind Period|Insufficient Therapeutic Response|0
6162424|NCT01194414|9804569|FG003|24 Weeks Double Blind Period|Insufficient Therapeutic Response|0
6162425|NCT01194414|9804566|FG000|24 Weeks Double Blind Period|Subject/legal Guardian Decision|9
6162426|NCT01194414|9804567|FG001|24 Weeks Double Blind Period|Subject/legal Guardian Decision|5
6162427|NCT01194414|9804568|FG002|24 Weeks Double Blind Period|Subject/legal Guardian Decision|0
6162428|NCT01194414|9804569|FG003|24 Weeks Double Blind Period|Subject/legal Guardian Decision|0
6162429|NCT01194414|9804566|FG000|24 Weeks Double Blind Period|Protocol Violation|5
6162430|NCT01194414|9804567|FG001|24 Weeks Double Blind Period|Protocol Violation|3
6162431|NCT01194414|9804568|FG002|24 Weeks Double Blind Period|Protocol Violation|0
6162432|NCT01194414|9804569|FG003|24 Weeks Double Blind Period|Protocol Violation|0
6162433|NCT01194414|9804566|FG000|24 Weeks Double Blind Period|Physician Decision to Withdraw Subject|0
6162434|NCT01194414|9804567|FG001|24 Weeks Double Blind Period|Physician Decision to Withdraw Subject|5
6162435|NCT01194414|9804568|FG002|24 Weeks Double Blind Period|Physician Decision to Withdraw Subject|0
6162436|NCT01194414|9804569|FG003|24 Weeks Double Blind Period|Physician Decision to Withdraw Subject|0
6162437|NCT01194414|9804566|FG000|24 Weeks Double Blind Period|Pregnancy|2
6162438|NCT01194414|9804567|FG001|24 Weeks Double Blind Period|Pregnancy|2
6162439|NCT01194414|9804568|FG002|24 Weeks Double Blind Period|Pregnancy|0
6162440|NCT01194414|9804569|FG003|24 Weeks Double Blind Period|Pregnancy|0
6162441|NCT01194414|9804566|FG000|24 Weeks Double Blind Period|Lost to Follow-up|2
6162442|NCT01194414|9804567|FG001|24 Weeks Double Blind Period|Lost to Follow-up|1
6162443|NCT01194414|9804568|FG002|24 Weeks Double Blind Period|Lost to Follow-up|0
6162444|NCT01194414|9804569|FG003|24 Weeks Double Blind Period|Lost to Follow-up|0
6162445|NCT01194414|9804566|FG000|24 Weeks Double Blind Period|Other|0
6162446|NCT01194414|9804567|FG001|24 Weeks Double Blind Period|Other|1
6162447|NCT01194414|9804568|FG002|24 Weeks Double Blind Period|Other|0
6162448|NCT01194414|9804569|FG003|24 Weeks Double Blind Period|Other|0
6162449|NCT01194414|9804566|FG000|24 Weeks Double Blind Period|Adverse Event|28
6162450|NCT01194414|9804567|FG001|24 Weeks Double Blind Period|Adverse Event|40
6162451|NCT01194414|9804568|FG002|24 Weeks Double Blind Period|Adverse Event|0
6162452|NCT01194414|9804569|FG003|24 Weeks Double Blind Period|Adverse Event|0
6162453|NCT01194414|9804566|FG000|24 Weeks Double Blind Period|Anaphylaxis or Hypersensitivity Reaction|2
6162454|NCT01194414|9804567|FG001|24 Weeks Double Blind Period|Anaphylaxis or Hypersensitivity Reaction|1
6162455|NCT01194414|9804568|FG002|24 Weeks Double Blind Period|Anaphylaxis or Hypersensitivity Reaction|0
6162456|NCT01194414|9804569|FG003|24 Weeks Double Blind Period|Anaphylaxis or Hypersensitivity Reaction|0
6162457|NCT01194414|9804566|FG000|24 Weeks Double Blind Period|Death|0
6162458|NCT01194414|9804567|FG001|24 Weeks Double Blind Period|Death|1
6162459|NCT01194414|9804568|FG002|24 Weeks Double Blind Period|Death|0
6162460|NCT01194414|9804569|FG003|24 Weeks Double Blind Period|Death|0
6162461|NCT01194414|9804566|FG000|72 Weeks Open Label Extension|Randomized but not Treated|3
6162462|NCT01194414|9804567|FG001|72 Weeks Open Label Extension|Randomized but not Treated|5
6162463|NCT01194414|9804568|FG002|72 Weeks Open Label Extension|Randomized but not Treated|0
6162464|NCT01194414|9804569|FG003|72 Weeks Open Label Extension|Randomized but not Treated|0
6162465|NCT01194414|9804566|FG000|72 Weeks Open Label Extension|Subject/legal Guardian Decision|20
6162466|NCT01194414|9804567|FG001|72 Weeks Open Label Extension|Subject/legal Guardian Decision|14
6162467|NCT01194414|9804568|FG002|72 Weeks Open Label Extension|Subject/legal Guardian Decision|1
6162468|NCT01194414|9804569|FG003|72 Weeks Open Label Extension|Subject/legal Guardian Decision|6
6162469|NCT01194414|9804566|FG000|72 Weeks Open Label Extension|Insufficient Therapeutic Response|9
6162470|NCT01194414|9804567|FG001|72 Weeks Open Label Extension|Insufficient Therapeutic Response|11
6162471|NCT01194414|9804568|FG002|72 Weeks Open Label Extension|Insufficient Therapeutic Response|2
6162472|NCT01194414|9804569|FG003|72 Weeks Open Label Extension|Insufficient Therapeutic Response|3
6162473|NCT01194414|9804566|FG000|72 Weeks Open Label Extension|Lost to Follow-up|4
6162474|NCT01194414|9804567|FG001|72 Weeks Open Label Extension|Lost to Follow-up|3
6162475|NCT01194414|9804568|FG002|72 Weeks Open Label Extension|Lost to Follow-up|2
6162476|NCT01194414|9804569|FG003|72 Weeks Open Label Extension|Lost to Follow-up|1
6162477|NCT01194414|9804566|FG000|72 Weeks Open Label Extension|Physician Decision to Withdraw Subject|3
6162478|NCT01194414|9804567|FG001|72 Weeks Open Label Extension|Physician Decision to Withdraw Subject|5
6162479|NCT01194414|9804568|FG002|72 Weeks Open Label Extension|Physician Decision to Withdraw Subject|0
6162480|NCT01194414|9804569|FG003|72 Weeks Open Label Extension|Physician Decision to Withdraw Subject|0
6162481|NCT01194414|9804566|FG000|72 Weeks Open Label Extension|Pregnancy|1
6162482|NCT01194414|9804567|FG001|72 Weeks Open Label Extension|Pregnancy|3
6162483|NCT01194414|9804568|FG002|72 Weeks Open Label Extension|Pregnancy|1
6162484|NCT01194414|9804569|FG003|72 Weeks Open Label Extension|Pregnancy|1
6162485|NCT01194414|9804566|FG000|72 Weeks Open Label Extension|Other|2
6162486|NCT01194414|9804567|FG001|72 Weeks Open Label Extension|Other|1
6162487|NCT01194414|9804568|FG002|72 Weeks Open Label Extension|Other|0
6162488|NCT01194414|9804569|FG003|72 Weeks Open Label Extension|Other|0
6162489|NCT01194414|9804566|FG000|72 Weeks Open Label Extension|Protocol Violation|0
6162490|NCT01194414|9804567|FG001|72 Weeks Open Label Extension|Protocol Violation|0
6162491|NCT01194414|9804568|FG002|72 Weeks Open Label Extension|Protocol Violation|0
6162492|NCT01194414|9804569|FG003|72 Weeks Open Label Extension|Protocol Violation|1
6162493|NCT01194414|9804566|FG000|72 Weeks Open Label Extension|Adverse Event|35
6162494|NCT01194414|9804567|FG001|72 Weeks Open Label Extension|Adverse Event|21
6162495|NCT01194414|9804568|FG002|72 Weeks Open Label Extension|Adverse Event|2
6162496|NCT01194414|9804569|FG003|72 Weeks Open Label Extension|Adverse Event|12
6162497|NCT01194414|9804566|FG000|72 Weeks Open Label Extension|Anaphylaxis or Hypersensitivity Reaction|1
6162498|NCT01194414|9804567|FG001|72 Weeks Open Label Extension|Anaphylaxis or Hypersensitivity Reaction|1
6162499|NCT01194414|9804568|FG002|72 Weeks Open Label Extension|Anaphylaxis or Hypersensitivity Reaction|0
6162500|NCT01194414|9804569|FG003|72 Weeks Open Label Extension|Anaphylaxis or Hypersensitivity Reaction|0
6162501|NCT01194414|9804566|FG000|72 Weeks Open Label Extension|Death|1
6162502|NCT01194414|9804567|FG001|72 Weeks Open Label Extension|Death|2
6162503|NCT01194414|9804568|FG002|72 Weeks Open Label Extension|Death|0
6162504|NCT01194414|9804569|FG003|72 Weeks Open Label Extension|Death|2
6162505|NCT01194440|9804581|FG000|Baseline (First Dose)|Reason not specified|4
6162506|NCT01194440|9804581|FG000|Baseline (First Dose)|Lack of Efficacy|1
6162507|NCT01194440|9804581|FG000|Baseline (First Dose)|Change in therapy|1
6162508|NCT01194440|9804581|FG000|Baseline (First Dose)|Adverse Event|1
6162509|NCT01194440|9804581|FG000|6-months (2nd Dose)|Change in therapy|4
6162510|NCT01194531|9804622|FG000|Overall Study|Withdrawal by Subject|1
6162511|NCT01194531|9804623|FG001|Overall Study|Withdrawal by Subject|0
6162512|NCT01194531|9804622|FG000|Overall Study|Protocol Violation|4
6162513|NCT01194531|9804623|FG001|Overall Study|Protocol Violation|1
6162514|NCT01194531|9804622|FG000|Overall Study|Physician Decision|0
6162515|NCT01194531|9804623|FG001|Overall Study|Physician Decision|2
6162516|NCT01194804|9804634|FG000|Overall Study|Withdrawal by Subject|1
6162517|NCT01194830|9804640|FG000|Overall Study|Adverse Event|3
6162518|NCT01194830|9804641|FG001|Overall Study|Adverse Event|2
6162519|NCT01194830|9804640|FG000|Overall Study|Protocol Violation|5
6162520|NCT01194830|9804641|FG001|Overall Study|Protocol Violation|4
6162521|NCT01194830|9804640|FG000|Overall Study|Lost to Follow-up|9
6162522|NCT01194830|9804641|FG001|Overall Study|Lost to Follow-up|7
6162523|NCT01194830|9804640|FG000|Overall Study|Withdrawal by Subject|2
6162524|NCT01194830|9804641|FG001|Overall Study|Withdrawal by Subject|1
6162525|NCT01194830|9804640|FG000|Overall Study|Lack of Efficacy|1
6162526|NCT01194830|9804641|FG001|Overall Study|Lack of Efficacy|1
6162527|NCT01194830|9804640|FG000|Overall Study|Non-compliance issues|4
6162528|NCT01194830|9804641|FG001|Overall Study|Non-compliance issues|4
6162529|NCT01194830|9804640|FG000|Overall Study|Other Reason|12
6162530|NCT01194830|9804641|FG001|Overall Study|Other Reason|8
6162531|NCT01194869|9804647|FG000|Overall Study|Disease Progression|2
6162532|NCT01194869|9804647|FG000|Overall Study|Toxicity|2
6162533|NCT01194973|9804651|FG000|Screening Period|Screen Failure|3
6162534|NCT01194973|9804651|FG000|26 Week Treatment Period|Adverse Event|1
6162535|NCT01194973|9804651|FG000|26 Week Treatment Period|Lack of Efficacy|1
6162536|NCT01194973|9804651|FG000|26 Week Treatment Period|Pregnancy|1
6162537|NCT01194999|9804655|FG000|Overall Study|Lost to Follow-up|17
6162538|NCT01195090|9804671|FG000|Overall Study|Adverse Event|1
6162539|NCT01195090|9804672|FG001|Overall Study|Adverse Event|2
6162540|NCT01195090|9804671|FG000|Overall Study|Lost to Follow-up|2
6162541|NCT01195090|9804672|FG001|Overall Study|Lost to Follow-up|2
6162542|NCT01195090|9804671|FG000|Overall Study|Protocol Violation|3
6162543|NCT01195090|9804672|FG001|Overall Study|Protocol Violation|4
6162544|NCT01195103|9804681|FG000|Overall Study|Withdrawal by Subject|1
6162545|NCT01195103|9804682|FG001|Overall Study|Withdrawal by Subject|0
6162546|NCT01195103|9804683|FG002|Overall Study|Withdrawal by Subject|0
6162547|NCT01195272|9804700|FG000|Overall Study|Adverse Event|1
6162548|NCT01195272|9804700|FG000|Overall Study|Lack of Efficacy|3
6162549|NCT01195363|9804706|FG000|Overall Study|Lost to Follow-up|7
6162550|NCT01195363|9804707|FG001|Overall Study|Lost to Follow-up|4
6162551|NCT01195363|9804706|FG000|Overall Study|Adverse Event|3
6162552|NCT01195363|9804707|FG001|Overall Study|Adverse Event|1
6162553|NCT01195363|9804706|FG000|Overall Study|Lack of Efficacy|0
6162554|NCT01195363|9804707|FG001|Overall Study|Lack of Efficacy|4
6162555|NCT01195363|9804706|FG000|Overall Study|incarceration|1
6162556|NCT01195363|9804707|FG001|Overall Study|incarceration|0
6162557|NCT01195415|9804713|FG000|Overall Study|No repeat biopsy due to progression|2
6162558|NCT01195545|9804721|FG000|Overall Study|Protocol Violation|4
6162559|NCT01195623|9804746|FG000|Overall Study|Lost to Follow-up|35
6162560|NCT01195623|9804747|FG001|Overall Study|Lost to Follow-up|37
6162561|NCT01195636|9804755|FG000|First Intervention (3 Weeks)|Adverse Event|2
6162562|NCT01195636|9804756|FG001|First Intervention (3 Weeks)|Adverse Event|3
6162563|NCT01195636|9804755|FG000|First Intervention (3 Weeks)|Protocol Violation|1
6162564|NCT01195636|9804756|FG001|First Intervention (3 Weeks)|Protocol Violation|0
6162565|NCT01195636|9804755|FG000|First Intervention (3 Weeks)|Withdrawal by Subject|1
6162566|NCT01195636|9804756|FG001|First Intervention (3 Weeks)|Withdrawal by Subject|0
6162567|NCT01195636|9804755|FG000|First Intervention (3 Weeks)|Lost to Follow-up|1
6162568|NCT01195636|9804756|FG001|First Intervention (3 Weeks)|Lost to Follow-up|0
6162569|NCT01195636|9804755|FG000|Washout Period (2 Weeks)|Adverse Event|1
6162570|NCT01195636|9804756|FG001|Washout Period (2 Weeks)|Adverse Event|1
6162571|NCT01195636|9804755|FG000|Washout Period (2 Weeks)|Withdrawal by Subject|1
6162572|NCT01195636|9804756|FG001|Washout Period (2 Weeks)|Withdrawal by Subject|2
6162573|NCT01195636|9804755|FG000|Second Intervention (3 Weeks)|Adverse Event|1
6162574|NCT01195636|9804756|FG001|Second Intervention (3 Weeks)|Adverse Event|1
6162575|NCT01195636|9804755|FG000|Second Intervention (3 Weeks)|Withdrawal by Subject|0
6162576|NCT01195636|9804756|FG001|Second Intervention (3 Weeks)|Withdrawal by Subject|1
6162577|NCT01195662|9804765|FG000|Double Blind Treatment Period|Adverse Event|4
6162578|NCT01195662|9804766|FG001|Double Blind Treatment Period|Adverse Event|1
6162579|NCT01195662|9804767|FG002|Double Blind Treatment Period|Adverse Event|2
6162580|NCT01195662|9804765|FG000|Double Blind Treatment Period|Withdrawal by Subject|6
6325811|NCT02939950|10068658|FG001|Overall Study|Pregnancy|7
6325812|NCT02939950|10068657|FG000|Overall Study|Withdrawal by Subject|12
6325813|NCT02939950|10068658|FG001|Overall Study|Withdrawal by Subject|28
6325814|NCT02939950|10068657|FG000|Overall Study|Adverse Event|7
6325815|NCT02939950|10068658|FG001|Overall Study|Adverse Event|3
6325816|NCT02939950|10068657|FG000|Overall Study|Randomized, not dispensed|1
6325817|NCT02939950|10068658|FG001|Overall Study|Randomized, not dispensed|0
6325818|NCT02939950|10068657|FG000|Overall Study|Ineligible at Baseline|2
6325819|NCT02939950|10068658|FG001|Overall Study|Ineligible at Baseline|8
6325820|NCT02940392|10068679|FG000|Overall Study|Lost to Follow-up|3
6325821|NCT02940392|10068679|FG000|Overall Study|Retreatment|3
6325822|NCT02940392|10068679|FG000|Overall Study|Death|2
6325823|NCT02940574|10068685|FG000|From Study Start to 1-month Follow-up|Withdrawal by Subject|1
6325824|NCT02940574|10068686|FG001|From Study Start to 1-month Follow-up|Withdrawal by Subject|0
6325825|NCT02940574|10068685|FG000|1-year Follow-up|Lost to Follow-up|3
6325826|NCT02940574|10068686|FG001|1-year Follow-up|Lost to Follow-up|4
6325827|NCT02940626|10068698|FG000|Overall Study|Death|40
6325828|NCT02940626|10068699|FG001|Overall Study|Death|32
6325829|NCT02940626|10068698|FG000|Overall Study|Lost to Follow-up|5
6325830|NCT02940626|10068699|FG001|Overall Study|Lost to Follow-up|2
6325831|NCT02940626|10068698|FG000|Overall Study|Withdrawal by Subject|1
6325832|NCT02940626|10068699|FG001|Overall Study|Withdrawal by Subject|0
6325833|NCT02940626|10068698|FG000|Overall Study|Transfer to Hospice Care|1
6325834|NCT02940626|10068699|FG001|Overall Study|Transfer to Hospice Care|0
6325835|NCT02940626|10068698|FG000|Overall Study|Prohibited Concomitant Medication|0
6325836|NCT02940626|10068699|FG001|Overall Study|Prohibited Concomitant Medication|1
6325837|NCT02940691|10068707|FG000|Overall Study|Lost to Follow-up|5
6325838|NCT02940691|10068707|FG000|Overall Study|Incarceration|1
6325839|NCT02940730|10068714|FG000|Intervention 2|Physician Decision|7
6325840|NCT02940730|10068715|FG001|Intervention 2|Physician Decision|0
6325841|NCT02940860|10068723|FG000|Overall Study|Non-serious AE|1
6325842|NCT02940860|10068724|FG001|Overall Study|Non-serious AE|2
6162581|NCT01195662|9804766|FG001|Double Blind Treatment Period|Withdrawal by Subject|4
6162582|NCT01195662|9804767|FG002|Double Blind Treatment Period|Withdrawal by Subject|4
6162583|NCT01195662|9804765|FG000|Double Blind Treatment Period|Lost to Follow-up|3
6162584|NCT01195662|9804766|FG001|Double Blind Treatment Period|Lost to Follow-up|2
6325843|NCT02940860|10068723|FG000|Overall Study|Serious AE|7
6325844|NCT02940860|10068724|FG001|Overall Study|Serious AE|3
6325845|NCT02940860|10068723|FG000|Overall Study|Withdrawal by Subject|19
6325846|NCT02940860|10068724|FG001|Overall Study|Withdrawal by Subject|9
6162585|NCT01195662|9804767|FG002|Double Blind Treatment Period|Lost to Follow-up|3
6162586|NCT01195662|9804765|FG000|Double Blind Treatment Period|Administrative reason|2
6162587|NCT01195662|9804766|FG001|Double Blind Treatment Period|Administrative reason|1
6162588|NCT01195662|9804767|FG002|Double Blind Treatment Period|Administrative reason|1
6162589|NCT01195662|9804765|FG000|Double Blind Treatment Period|Requested discontinue treatment|1
6162590|NCT01195662|9804766|FG001|Double Blind Treatment Period|Requested discontinue treatment|0
6162591|NCT01195662|9804767|FG002|Double Blind Treatment Period|Requested discontinue treatment|1
6162592|NCT01195662|9804765|FG000|Double Blind Treatment Period|No Longer Meets Criteria|1
6162593|NCT01195662|9804766|FG001|Double Blind Treatment Period|No Longer Meets Criteria|5
6162594|NCT01195662|9804767|FG002|Double Blind Treatment Period|No Longer Meets Criteria|2
6325847|NCT02940860|10068723|FG000|Overall Study|Lost to Follow-up|13
6325848|NCT02940860|10068724|FG001|Overall Study|Lost to Follow-up|7
6325849|NCT02940860|10068723|FG000|Overall Study|Physician Decision|5
6325850|NCT02940860|10068724|FG001|Overall Study|Physician Decision|3
6082332|NCT00626925|9690179|FG001|Overall Study|Lost to Follow-up|2
6082333|NCT00626925|9690178|FG000|Overall Study|relapse|1
6082334|NCT00626925|9690179|FG001|Overall Study|relapse|0
6082335|NCT00626925|9690178|FG000|Overall Study|Adverse effect|6
6082336|NCT00626925|9690179|FG001|Overall Study|Adverse effect|2
6082337|NCT00626925|9690178|FG000|Overall Study|Lack of Efficacy|1
6082338|NCT00626925|9690179|FG001|Overall Study|Lack of Efficacy|4
6082339|NCT00626925|9690178|FG000|Overall Study|Time constraints|3
6082340|NCT00626925|9690179|FG001|Overall Study|Time constraints|1
6082341|NCT00627016|9690201|FG000|Overall Study|Adverse Event|1
6082342|NCT00627016|9690202|FG001|Overall Study|Adverse Event|1
6082343|NCT00627016|9690201|FG000|Overall Study|Protocol Violation|0
6082344|NCT00627016|9690202|FG001|Overall Study|Protocol Violation|2
6082345|NCT00627016|9690201|FG000|Overall Study|Lost to Follow-up|0
6082346|NCT00627016|9690202|FG001|Overall Study|Lost to Follow-up|1
6082347|NCT00627016|9690201|FG000|Overall Study|Withdrawal by Subject|2
6082348|NCT00627016|9690202|FG001|Overall Study|Withdrawal by Subject|1
6082349|NCT00627016|9690201|FG000|Overall Study|Failed Inclusion/Exclusion Criteria|0
6082350|NCT00627016|9690202|FG001|Overall Study|Failed Inclusion/Exclusion Criteria|1
6082351|NCT00627016|9690201|FG000|Overall Study|Lack of Efficacy|1
6082352|NCT00627016|9690202|FG001|Overall Study|Lack of Efficacy|0
6082353|NCT00627016|9690201|FG000|Overall Study|Placed on Excluded Drugs|1
6082354|NCT00627016|9690202|FG001|Overall Study|Placed on Excluded Drugs|0
6082355|NCT00627016|9690201|FG000|Overall Study|Pregnancy|1
6082356|NCT00627016|9690202|FG001|Overall Study|Pregnancy|0
6082357|NCT00627042|9690208|FG000|Overall Study|Withdrawal by Subject|2
6082358|NCT00627094|9690214|FG000|Overall Study|Adverse Event|8
6082359|NCT00627094|9690215|FG001|Overall Study|Adverse Event|7
6082360|NCT00627094|9690214|FG000|Overall Study|Lost to Follow-up|1
6082361|NCT00627094|9690215|FG001|Overall Study|Lost to Follow-up|0
6082362|NCT00627094|9690214|FG000|Overall Study|Withdrawal by Subject|1
6082363|NCT00627094|9690215|FG001|Overall Study|Withdrawal by Subject|1
6082364|NCT00627094|9690214|FG000|Overall Study|ulcer healed|1
6082365|NCT00627094|9690215|FG001|Overall Study|ulcer healed|7
6082366|NCT00627094|9690214|FG000|Overall Study|Other reason|1
6082367|NCT00627094|9690215|FG001|Overall Study|Other reason|0
6082368|NCT00627393|9690235|FG000|Intention-To-Treat Analysis|Adjudication indeterminate|5
6082369|NCT00627393|9690236|FG001|Intention-To-Treat Analysis|Adjudication indeterminate|3
6082370|NCT00627393|9690235|FG000|Intention-To-Treat Analysis|Withdrawal by patient/family/physician|4
6082371|NCT00627393|9690236|FG001|Intention-To-Treat Analysis|Withdrawal by patient/family/physician|5
6082372|NCT00627393|9690235|FG000|Per-Protocol Analysis|Received unstimulated/no granulocytes|6
6082373|NCT00627393|9690236|FG001|Per-Protocol Analysis|Received unstimulated/no granulocytes|3
6082374|NCT00627393|9690235|FG000|Per-Protocol Analysis|Withdrawal by patient/family/physician|4
6162595|NCT01195662|9804765|FG000|Double Blind Treatment Period|Lack of Efficacy|2
6162596|NCT01195662|9804766|FG001|Double Blind Treatment Period|Lack of Efficacy|0
6082375|NCT00627393|9690236|FG001|Per-Protocol Analysis|Withdrawal by patient/family/physician|10
6162597|NCT01195662|9804767|FG002|Double Blind Treatment Period|Lack of Efficacy|0
6162598|NCT01195662|9804765|FG000|Double Blind Treatment Period|Non-specified|3
6162599|NCT01195662|9804766|FG001|Double Blind Treatment Period|Non-specified|0
6162600|NCT01195662|9804767|FG002|Double Blind Treatment Period|Non-specified|0
6162601|NCT01195662|9804765|FG000|Double Blind Treatment Period|Missing disposition information|0
6162602|NCT01195662|9804766|FG001|Double Blind Treatment Period|Missing disposition information|1
6162603|NCT01195662|9804767|FG002|Double Blind Treatment Period|Missing disposition information|1
6162604|NCT01195662|9804765|FG000|Follow-Up(Week 13/1 Week Post Last Dose)|Withdrawal by Subject|2
6162605|NCT01195662|9804766|FG001|Follow-Up(Week 13/1 Week Post Last Dose)|Withdrawal by Subject|0
6162606|NCT01195662|9804767|FG002|Follow-Up(Week 13/1 Week Post Last Dose)|Withdrawal by Subject|1
6162607|NCT01195662|9804765|FG000|Follow-Up(Week 13/1 Week Post Last Dose)|non-specified|1
6162608|NCT01195662|9804766|FG001|Follow-Up(Week 13/1 Week Post Last Dose)|non-specified|0
6162609|NCT01195662|9804767|FG002|Follow-Up(Week 13/1 Week Post Last Dose)|non-specified|0
6162610|NCT01195675|9804776|FG000|Overall Study|Adverse Event|1
6162611|NCT01195675|9804776|FG000|Overall Study|Withdrawal by Subject|2
6325851|NCT02940860|10068723|FG000|Overall Study|Sponsor Decision|0
6325852|NCT02940860|10068724|FG001|Overall Study|Sponsor Decision|1
6325853|NCT02940860|10068723|FG000|Overall Study|Protocol Violation|0
6082376|NCT00627445|9690263|FG000|Overall Study|Adverse Event|3
6082377|NCT00627445|9690264|FG001|Overall Study|Adverse Event|3
6082378|NCT00627445|9690263|FG000|Overall Study|Lack of Efficacy|0
6082379|NCT00627445|9690264|FG001|Overall Study|Lack of Efficacy|1
6082380|NCT00627445|9690263|FG000|Overall Study|Other|6
6082381|NCT00627445|9690264|FG001|Overall Study|Other|8
6082382|NCT00627458|9690275|FG000|Overall Study|Migrated from study area|1
6162612|NCT01195831|9804859|FG000|Overall Study|Lost to Follow-up|2
6162613|NCT01195831|9804860|FG001|Overall Study|Lost to Follow-up|4
6162614|NCT01195831|9804859|FG000|Overall Study|Withdrawal by Subject|2
6162615|NCT01195831|9804860|FG001|Overall Study|Withdrawal by Subject|2
6162616|NCT01195831|9804859|FG000|Overall Study|Adverse Event|4
6162617|NCT01195831|9804860|FG001|Overall Study|Adverse Event|2
6162618|NCT01195831|9804859|FG000|Overall Study|Protocol Violation|0
6162619|NCT01195831|9804860|FG001|Overall Study|Protocol Violation|2
6162620|NCT01195844|9804866|FG000|Overall Study|Fecal sample not collected|40
6162621|NCT01195948|9804896|FG000|Overall Study|Lost to Follow-up|0
6162622|NCT01195948|9804897|FG001|Overall Study|Lost to Follow-up|1
6162623|NCT01195948|9804898|FG002|Overall Study|Lost to Follow-up|2
6162624|NCT01196026|9804915|FG000|Overall Study|Withdrawal by Subject|1
6162625|NCT01196026|9804916|FG001|Overall Study|Withdrawal by Subject|4
6162626|NCT01196026|9804917|FG002|Overall Study|Withdrawal by Subject|0
6162627|NCT01196026|9804918|FG003|Overall Study|Withdrawal by Subject|0
6162628|NCT01196026|9804919|FG004|Overall Study|Withdrawal by Subject|0
6162629|NCT01196026|9804920|FG005|Overall Study|Withdrawal by Subject|0
6162630|NCT01196026|9804915|FG000|Overall Study|Lost to Follow-up|0
6162631|NCT01196026|9804916|FG001|Overall Study|Lost to Follow-up|3
6162632|NCT01196026|9804917|FG002|Overall Study|Lost to Follow-up|0
6162633|NCT01196026|9804918|FG003|Overall Study|Lost to Follow-up|0
6162634|NCT01196026|9804919|FG004|Overall Study|Lost to Follow-up|1
6162635|NCT01196026|9804920|FG005|Overall Study|Lost to Follow-up|0
6162636|NCT01196026|9804915|FG000|Overall Study|Other|0
6162637|NCT01196026|9804916|FG001|Overall Study|Other|1
6162638|NCT01196026|9804917|FG002|Overall Study|Other|0
6162639|NCT01196026|9804918|FG003|Overall Study|Other|0
6162640|NCT01196026|9804919|FG004|Overall Study|Other|0
6162641|NCT01196026|9804920|FG005|Overall Study|Other|0
6162642|NCT01196052|9804936|FG000|Overall Study|Adverse Event|9
6162643|NCT01196052|9804936|FG000|Overall Study|Lost to Follow-up|1
6162644|NCT01196052|9804936|FG000|Overall Study|Noncompliance to Protocol Requirements|2
6162645|NCT01196052|9804936|FG000|Overall Study|Reason not Specified|5
6162646|NCT01196052|9804936|FG000|Overall Study|Withdrawal by Subject|6
6162647|NCT01196078|9804942|FG000|Overall Study|Withdrawal by Subject|3
6162648|NCT01196078|9804943|FG001|Overall Study|Withdrawal by Subject|5
6162649|NCT01196078|9804942|FG000|Overall Study|Adverse Event|4
6162650|NCT01196078|9804943|FG001|Overall Study|Adverse Event|4
6162651|NCT01196078|9804942|FG000|Overall Study|Protocol Violation|2
6162652|NCT01196078|9804943|FG001|Overall Study|Protocol Violation|1
6162653|NCT01196078|9804942|FG000|Overall Study|Lack of Efficacy|17
6162654|NCT01196078|9804943|FG001|Overall Study|Lack of Efficacy|23
6162655|NCT01196078|9804942|FG000|Overall Study|Lost to Follow-up|1
6162656|NCT01196078|9804943|FG001|Overall Study|Lost to Follow-up|0
6162657|NCT01196078|9804942|FG000|Overall Study|Death|6
6162658|NCT01196078|9804943|FG001|Overall Study|Death|4
6162659|NCT01196091|9804952|FG000|Overall Study|Adverse Event|22
6325854|NCT02940860|10068724|FG001|Overall Study|Protocol Violation|2
6325855|NCT02940860|10068723|FG000|Overall Study|Death|3
6325856|NCT02940860|10068724|FG001|Overall Study|Death|2
6325857|NCT02940860|10068723|FG000|Overall Study|Moved, poor venous access, transport|6
6325858|NCT02940860|10068724|FG001|Overall Study|Moved, poor venous access, transport|4
6325859|NCT02940860|10068723|FG000|Overall Study|Not treated|2
6325860|NCT02940860|10068724|FG001|Overall Study|Not treated|2
6325861|NCT02940886|10068734|FG000|Overall Study|Adverse Event|7
6325862|NCT02940886|10068735|FG001|Overall Study|Adverse Event|3
6082383|NCT00627458|9690276|FG001|Overall Study|Migrated from study area|0
6325863|NCT02940886|10068734|FG000|Overall Study|Protocol Violation|0
6325864|NCT02940886|10068735|FG001|Overall Study|Protocol Violation|2
6325865|NCT02940886|10068734|FG000|Overall Study|Withdrawal by Subject|28
6325866|NCT02940886|10068735|FG001|Overall Study|Withdrawal by Subject|20
6325867|NCT02940886|10068734|FG000|Overall Study|Death|1
6325868|NCT02940886|10068735|FG001|Overall Study|Death|0
6325869|NCT02940886|10068734|FG000|Overall Study|Lack of Efficacy|1
6325870|NCT02940886|10068735|FG001|Overall Study|Lack of Efficacy|0
6325871|NCT02940886|10068734|FG000|Overall Study|Lost to Follow-up|49
6325872|NCT02940886|10068735|FG001|Overall Study|Lost to Follow-up|21
6082384|NCT00627458|9690277|FG002|Overall Study|Migrated from study area|1
6082385|NCT00627458|9690275|FG000|Overall Study|Withdrawal by Subject|2
6162660|NCT01196091|9804953|FG001|Overall Study|Adverse Event|27
6162661|NCT01196091|9804954|FG002|Overall Study|Adverse Event|26
6162662|NCT01196091|9804952|FG000|Overall Study|Death|3
6162663|NCT01196091|9804953|FG001|Overall Study|Death|2
6162664|NCT01196091|9804954|FG002|Overall Study|Death|2
6162665|NCT01196091|9804952|FG000|Overall Study|Entry Criteria Not Met|11
6162666|NCT01196091|9804953|FG001|Overall Study|Entry Criteria Not Met|11
6162667|NCT01196091|9804954|FG002|Overall Study|Entry Criteria Not Met|10
6325873|NCT02940886|10068734|FG000|Overall Study|Physician Decision|9
6325874|NCT02940886|10068735|FG001|Overall Study|Physician Decision|4
6162668|NCT01196091|9804952|FG000|Overall Study|Lack of Efficacy|15
6162669|NCT01196091|9804953|FG001|Overall Study|Lack of Efficacy|12
6162670|NCT01196091|9804954|FG002|Overall Study|Lack of Efficacy|17
6162671|NCT01196091|9804952|FG000|Overall Study|Lost to Follow-up|5
6162672|NCT01196091|9804953|FG001|Overall Study|Lost to Follow-up|5
6162673|NCT01196091|9804954|FG002|Overall Study|Lost to Follow-up|6
6162674|NCT01196091|9804952|FG000|Overall Study|Parent/Caregiver Decision|0
6162675|NCT01196091|9804953|FG001|Overall Study|Parent/Caregiver Decision|0
6162676|NCT01196091|9804954|FG002|Overall Study|Parent/Caregiver Decision|1
6162677|NCT01196091|9804952|FG000|Overall Study|Withdrawal by Subject|16
6162678|NCT01196091|9804953|FG001|Overall Study|Withdrawal by Subject|19
6162679|NCT01196091|9804954|FG002|Overall Study|Withdrawal by Subject|22
6162680|NCT01196091|9804952|FG000|Overall Study|Physician Decision|3
6162681|NCT01196091|9804953|FG001|Overall Study|Physician Decision|3
6162682|NCT01196091|9804954|FG002|Overall Study|Physician Decision|4
6162683|NCT01196091|9804952|FG000|Overall Study|Protocol Violation|1
6162684|NCT01196091|9804953|FG001|Overall Study|Protocol Violation|3
6162685|NCT01196091|9804954|FG002|Overall Study|Protocol Violation|3
6162686|NCT01196091|9804952|FG000|Overall Study|Sponsor Decision|6
6162687|NCT01196091|9804953|FG001|Overall Study|Sponsor Decision|5
6162688|NCT01196091|9804954|FG002|Overall Study|Sponsor Decision|4
6162689|NCT01196091|9804952|FG000|Overall Study|Excluded Site|5
6162690|NCT01196091|9804953|FG001|Overall Study|Excluded Site|11
6162691|NCT01196091|9804954|FG002|Overall Study|Excluded Site|8
6162692|NCT01196091|9804952|FG000|Overall Study|Randomized, No Study Drug Received|1
6162693|NCT01196091|9804953|FG001|Overall Study|Randomized, No Study Drug Received|0
6162694|NCT01196091|9804954|FG002|Overall Study|Randomized, No Study Drug Received|1
6162695|NCT01196104|9804969|FG000|Overall Study|Lost to Follow-up|1
6162696|NCT01196104|9804970|FG001|Overall Study|Lost to Follow-up|0
6162697|NCT01196104|9804969|FG000|Overall Study|Physician Decision|0
6162698|NCT01196104|9804970|FG001|Overall Study|Physician Decision|1
6162699|NCT01196104|9804969|FG000|Overall Study|Withdrawal by Subject|3
6162700|NCT01196104|9804970|FG001|Overall Study|Withdrawal by Subject|3
6162701|NCT01196104|9804969|FG000|Overall Study|Various|0
6325875|NCT02940886|10068734|FG000|Overall Study|Sponsor decision|0
6325876|NCT02940886|10068735|FG001|Overall Study|Sponsor decision|1
6325877|NCT02940886|10068734|FG000|Overall Study|No treatment|7
6325878|NCT02940886|10068735|FG001|Overall Study|No treatment|2
6325879|NCT02940886|10068734|FG000|Overall Study|Enrolment error|0
6325880|NCT02940886|10068735|FG001|Overall Study|Enrolment error|1
6325881|NCT02941523|10068745|FG000|Monotherapy|Withdrawal by Subject|0
6325882|NCT02941523|10068746|FG001|Monotherapy|Withdrawal by Subject|1
6325883|NCT02941523|10068745|FG000|Carboplatin Combination Therapy|Adverse Event|0
6325884|NCT02941523|10068746|FG001|Carboplatin Combination Therapy|Adverse Event|1
6082386|NCT00627458|9690276|FG001|Overall Study|Withdrawal by Subject|6
6325885|NCT02941523|10068745|FG000|Carboplatin Combination Therapy|Death|1
6325886|NCT02941523|10068746|FG001|Carboplatin Combination Therapy|Death|2
6325887|NCT02941523|10068745|FG000|Carboplatin Combination Therapy|Disease progression|2
6325888|NCT02941523|10068746|FG001|Carboplatin Combination Therapy|Disease progression|0
6325889|NCT02941523|10068745|FG000|Carboplatin Combination Therapy|Withdrawal by Subject|2
6325890|NCT02941523|10068746|FG001|Carboplatin Combination Therapy|Withdrawal by Subject|1
6082387|NCT00627458|9690277|FG002|Overall Study|Withdrawal by Subject|5
6082388|NCT00627458|9690275|FG000|Overall Study|Lost to Follow-up|1
6082389|NCT00627458|9690276|FG001|Overall Study|Lost to Follow-up|1
6082390|NCT00627458|9690277|FG002|Overall Study|Lost to Follow-up|0
6082391|NCT00627497|9690290|FG000|Overall Study|Lost to Follow-up|1
6082392|NCT00627497|9690291|FG001|Overall Study|Lost to Follow-up|1
6082393|NCT00627497|9690292|FG002|Overall Study|Lost to Follow-up|0
6082394|NCT00627497|9690293|FG003|Overall Study|Lost to Follow-up|0
6082395|NCT00627523|9690305|FG000|Overall Study|Lack of Efficacy|1
6082396|NCT00627523|9690306|FG001|Overall Study|Lack of Efficacy|0
6082397|NCT00627523|9690305|FG000|Overall Study|Withdrawal by Subject|0
6082398|NCT00627523|9690306|FG001|Overall Study|Withdrawal by Subject|2
6082399|NCT00627523|9690305|FG000|Overall Study|Other|1
6082400|NCT00627523|9690306|FG001|Overall Study|Other|0
6082401|NCT00627705|9690327|FG000|Overall Study|Unwilling to take the compound (taste)|1
6082402|NCT00627705|9690328|FG001|Overall Study|Unwilling to take the compound (taste)|3
6082403|NCT00627705|9690327|FG000|Overall Study|Adverse Event|1
6082404|NCT00627705|9690328|FG001|Overall Study|Adverse Event|0
6162702|NCT01196104|9804970|FG001|Overall Study|Various|1
6162703|NCT01196416|9805006|FG000|Overall Study|Withdrawal by Subject|2
6162704|NCT01196429|9805012|FG000|Overall Study|Ineligible - inadequate pathology|1
6162705|NCT01196429|9805013|FG001|Overall Study|Ineligible - inadequate pathology|0
6162706|NCT01196429|9805012|FG000|Overall Study|Ineligible - wrong cell type|1
6162707|NCT01196429|9805013|FG001|Overall Study|Ineligible - wrong cell type|0
6162708|NCT01196429|9805012|FG000|Overall Study|Refused - Never Treated|1
6162709|NCT01196429|9805013|FG001|Overall Study|Refused - Never Treated|0
6162710|NCT01196741|9805032|FG000|Overall Study|Disease progression|34
6162711|NCT01196741|9805033|FG001|Overall Study|Disease progression|14
6162712|NCT01196741|9805032|FG000|Overall Study|Adverse Event|10
6162713|NCT01196741|9805033|FG001|Overall Study|Adverse Event|6
6162714|NCT01196741|9805032|FG000|Overall Study|Serious Adverse Event|3
6162715|NCT01196741|9805033|FG001|Overall Study|Serious Adverse Event|1
6162716|NCT01196741|9805032|FG000|Overall Study|Dose limiting Adverse Event|2
6162717|NCT01196741|9805033|FG001|Overall Study|Dose limiting Adverse Event|1
6162718|NCT01196741|9805032|FG000|Overall Study|Withdrawal by Subject|3
6162719|NCT01196741|9805033|FG001|Overall Study|Withdrawal by Subject|0
6162720|NCT01196741|9805032|FG000|Overall Study|Other reason|3
6162721|NCT01196741|9805033|FG001|Overall Study|Other reason|3
6162722|NCT01196741|9805032|FG000|Overall Study|Other|3
6162723|NCT01196741|9805033|FG001|Overall Study|Other|2
6162724|NCT01196741|9805032|FG000|Overall Study|Protocol Violation|2
6162725|NCT01196741|9805033|FG001|Overall Study|Protocol Violation|1
6162726|NCT01196975|9805095|FG000|Overall Study|Adverse Event|2
6162727|NCT01196975|9805096|FG001|Overall Study|Adverse Event|2
6162728|NCT01196975|9805097|FG002|Overall Study|Adverse Event|0
6162729|NCT01196975|9805098|FG003|Overall Study|Adverse Event|0
6162730|NCT01196975|9805099|FG004|Overall Study|Adverse Event|2
6162731|NCT01196975|9805095|FG000|Overall Study|Withdrawal by Subject|2
6162732|NCT01196975|9805096|FG001|Overall Study|Withdrawal by Subject|1
6162733|NCT01196975|9805097|FG002|Overall Study|Withdrawal by Subject|0
6162734|NCT01196975|9805098|FG003|Overall Study|Withdrawal by Subject|1
6162735|NCT01196975|9805099|FG004|Overall Study|Withdrawal by Subject|0
6162736|NCT01196975|9805095|FG000|Overall Study|Lost to Follow-up|11
6162737|NCT01196975|9805096|FG001|Overall Study|Lost to Follow-up|6
6162738|NCT01196975|9805097|FG002|Overall Study|Lost to Follow-up|5
6162739|NCT01196975|9805098|FG003|Overall Study|Lost to Follow-up|5
6162740|NCT01196975|9805099|FG004|Overall Study|Lost to Follow-up|11
6162741|NCT01196988|9805138|FG000|Overall Study|Adverse Event|1
6162742|NCT01196988|9805139|FG001|Overall Study|Adverse Event|2
6162743|NCT01196988|9805140|FG002|Overall Study|Adverse Event|0
6162744|NCT01196988|9805141|FG003|Overall Study|Adverse Event|0
6162745|NCT01196988|9805138|FG000|Overall Study|Withdrawal by Subject|5
6162746|NCT01196988|9805139|FG001|Overall Study|Withdrawal by Subject|1
6162747|NCT01196988|9805140|FG002|Overall Study|Withdrawal by Subject|4
6162748|NCT01196988|9805141|FG003|Overall Study|Withdrawal by Subject|0
6162749|NCT01196988|9805138|FG000|Overall Study|Lost to Follow-up|16
6162750|NCT01196988|9805139|FG001|Overall Study|Lost to Follow-up|29
6162751|NCT01196988|9805140|FG002|Overall Study|Lost to Follow-up|21
6162752|NCT01196988|9805141|FG003|Overall Study|Lost to Follow-up|1
6162753|NCT01196988|9805138|FG000|Overall Study|Other|2
6162754|NCT01196988|9805139|FG001|Overall Study|Other|0
6162755|NCT01196988|9805140|FG002|Overall Study|Other|0
6162756|NCT01196988|9805141|FG003|Overall Study|Other|0
6162757|NCT01197300|9805154|FG000|Overall Study|Lost to Follow-up|0
6162758|NCT01197300|9805155|FG001|Overall Study|Lost to Follow-up|1
6162759|NCT01197300|9805154|FG000|Overall Study|Protocol Violation|0
6162760|NCT01197300|9805155|FG001|Overall Study|Protocol Violation|1
6191921|NCT01426412|9848891|FG003|Overall Study|Withdrawal by Subject|0
6191922|NCT01426412|9848892|FG004|Overall Study|Withdrawal by Subject|1
6191923|NCT01426412|9848893|FG005|Overall Study|Withdrawal by Subject|0
6191924|NCT01426412|9848894|FG006|Overall Study|Withdrawal by Subject|0
6191925|NCT01426412|9848895|FG007|Overall Study|Withdrawal by Subject|3
6191926|NCT01426412|9848896|FG008|Overall Study|Withdrawal by Subject|1
6191927|NCT01426425|9848927|FG000|Overall Study|Exited prior to EP study|22
6191928|NCT01426425|9848927|FG000|Overall Study|Inclusion/exclusion criteria not met|151
6325891|NCT02941627|10068771|FG000|Overall Study|Death|1
6325892|NCT02941627|10068771|FG000|Overall Study|Surgical failure|1
6325893|NCT02941627|10068771|FG000|Overall Study|cholesteatoma prevented implantation|1
6325894|NCT02942264|10068824|FG000|Phase 1 MTD Finding Stage|Withdrawal of consent|0
6325895|NCT02942264|10068825|FG001|Phase 1 MTD Finding Stage|Withdrawal of consent|1
6325896|NCT02942264|10068826|FG002|Phase 1 MTD Finding Stage|Withdrawal of consent|0
6325897|NCT02942264|10068827|FG003|Phase 1 MTD Finding Stage|Withdrawal of consent|0
6325898|NCT02942264|10068828|FG004|Phase 1 MTD Finding Stage|Withdrawal of consent|0
6325899|NCT02942264|10068829|FG005|Phase 1 MTD Finding Stage|Withdrawal of consent|0
6325900|NCT02942264|10068830|FG006|Phase 1 MTD Finding Stage|Withdrawal of consent|1
6325901|NCT02942264|10068831|FG007|Phase 1 MTD Finding Stage|Withdrawal of consent|0
6325902|NCT02942264|10068832|FG008|Phase 1 MTD Finding Stage|Withdrawal of consent|0
6325903|NCT02942264|10068824|FG000|Phase 1 Cohort Expansion Stage|Withdrawal of consent|0
6325904|NCT02942264|10068825|FG001|Phase 1 Cohort Expansion Stage|Withdrawal of consent|0
6325905|NCT02942264|10068826|FG002|Phase 1 Cohort Expansion Stage|Withdrawal of consent|0
6325906|NCT02942264|10068827|FG003|Phase 1 Cohort Expansion Stage|Withdrawal of consent|0
6325907|NCT02942264|10068828|FG004|Phase 1 Cohort Expansion Stage|Withdrawal of consent|0
6325908|NCT02942264|10068829|FG005|Phase 1 Cohort Expansion Stage|Withdrawal of consent|0
6325909|NCT02942264|10068830|FG006|Phase 1 Cohort Expansion Stage|Withdrawal of consent|0
6325910|NCT02942264|10068831|FG007|Phase 1 Cohort Expansion Stage|Withdrawal of consent|0
6191929|NCT01426425|9848927|FG000|Overall Study|Met inclusion/exclusion, not treated|2
6191930|NCT01426438|9848934|FG000|Overall Study|Lost to Follow-up|1
6191931|NCT01426438|9848935|FG001|Overall Study|Lost to Follow-up|3
6191932|NCT01426438|9848934|FG000|Overall Study|Off study Treatment|9
6191933|NCT01426438|9848935|FG001|Overall Study|Off study Treatment|3
6191934|NCT01426438|9848934|FG000|Overall Study|Poor scan quality|3
6191935|NCT01426438|9848935|FG001|Overall Study|Poor scan quality|2
6191936|NCT01426438|9848934|FG000|Overall Study|Missed Scan|2
6191937|NCT01426438|9848935|FG001|Overall Study|Missed Scan|2
6191938|NCT01426789|9848965|FG000|Part 1|Protocol deviation|0
6162761|NCT01197378|9805172|FG000|Overall Study|Adverse Event|3
6162762|NCT01197378|9805172|FG000|Overall Study|Withdrawal by Subject|1
6162763|NCT01197378|9805172|FG000|Overall Study|Physician Decision|1
6162764|NCT01197378|9805172|FG000|Overall Study|Other|2
6162765|NCT01197417|9805178|FG000|Overall Study|Physician Decision|3
6162766|NCT01197417|9805179|FG001|Overall Study|Physician Decision|2
6162767|NCT01197417|9805178|FG000|Overall Study|Withdrawal by Subject|2
6162768|NCT01197417|9805179|FG001|Overall Study|Withdrawal by Subject|4
6162769|NCT01197417|9805178|FG000|Overall Study|Site miscommunication|0
6162770|NCT01197417|9805179|FG001|Overall Study|Site miscommunication|1
6162771|NCT01197417|9805178|FG000|Overall Study|Subject transferred to intensive care|0
6162772|NCT01197417|9805179|FG001|Overall Study|Subject transferred to intensive care|1
6162773|NCT01197417|9805178|FG000|Overall Study|Not consented in time to receive drug|0
6162774|NCT01197417|9805179|FG001|Overall Study|Not consented in time to receive drug|1
6162775|NCT01197417|9805178|FG000|Overall Study|Hypotension|1
6162776|NCT01197417|9805179|FG001|Overall Study|Hypotension|2
6162777|NCT01197417|9805178|FG000|Overall Study|Found to be ineligible|2
6162778|NCT01197417|9805179|FG001|Overall Study|Found to be ineligible|5
6162779|NCT01197417|9805178|FG000|Overall Study|No 25-hour magnesium level|0
6162780|NCT01197417|9805179|FG001|Overall Study|No 25-hour magnesium level|2
6162781|NCT01197508|9805207|FG000|Overall Study|Withdrawal by Subject|8
6162782|NCT01197508|9805208|FG001|Overall Study|Withdrawal by Subject|7
6162783|NCT01197508|9805209|FG002|Overall Study|Withdrawal by Subject|15
6162784|NCT01197508|9805210|FG003|Overall Study|Withdrawal by Subject|4
6162785|NCT01197508|9805207|FG000|Overall Study|Eligiblity criteria not fulfilled|0
6162786|NCT01197508|9805208|FG001|Overall Study|Eligiblity criteria not fulfilled|0
6162787|NCT01197508|9805209|FG002|Overall Study|Eligiblity criteria not fulfilled|2
6162788|NCT01197508|9805210|FG003|Overall Study|Eligiblity criteria not fulfilled|0
6162789|NCT01197508|9805207|FG000|Overall Study|Adverse Event|10
6162790|NCT01197508|9805208|FG001|Overall Study|Adverse Event|13
6162791|NCT01197508|9805209|FG002|Overall Study|Adverse Event|23
6162792|NCT01197508|9805210|FG003|Overall Study|Adverse Event|3
6162793|NCT01197508|9805207|FG000|Overall Study|Severe non-compliance to protocol|0
6162794|NCT01197508|9805208|FG001|Overall Study|Severe non-compliance to protocol|3
6162795|NCT01197508|9805209|FG002|Overall Study|Severe non-compliance to protocol|1
6162796|NCT01197508|9805210|FG003|Overall Study|Severe non-compliance to protocol|3
6162797|NCT01197508|9805207|FG000|Overall Study|Condition under investigation worsened|1
6162798|NCT01197508|9805208|FG001|Overall Study|Condition under investigation worsened|1
6162799|NCT01197508|9805209|FG002|Overall Study|Condition under investigation worsened|1
6162800|NCT01197508|9805210|FG003|Overall Study|Condition under investigation worsened|1
6162801|NCT01197508|9805207|FG000|Overall Study|Lack of Efficacy|1
6162802|NCT01197508|9805208|FG001|Overall Study|Lack of Efficacy|2
6162803|NCT01197508|9805209|FG002|Overall Study|Lack of Efficacy|2
6162804|NCT01197508|9805210|FG003|Overall Study|Lack of Efficacy|1
6162805|NCT01197508|9805207|FG000|Overall Study|Study-specific withdrawal criteria|0
6162806|NCT01197508|9805208|FG001|Overall Study|Study-specific withdrawal criteria|0
6162807|NCT01197508|9805209|FG002|Overall Study|Study-specific withdrawal criteria|1
6162808|NCT01197508|9805210|FG003|Overall Study|Study-specific withdrawal criteria|2
6162809|NCT01197508|9805207|FG000|Overall Study|Lost to Follow-up|1
6325911|NCT02942264|10068832|FG008|Phase 1 Cohort Expansion Stage|Withdrawal of consent|1
6325912|NCT02942407|10068859|FG000|Overall Study|Lost to Follow-up|3
6325913|NCT02942407|10068860|FG001|Overall Study|Lost to Follow-up|2
6325914|NCT02942407|10068859|FG000|Overall Study|Withdrawal by Subject|7
6325915|NCT02942407|10068860|FG001|Overall Study|Withdrawal by Subject|9
6325916|NCT02942407|10068859|FG000|Overall Study|Death|16
6325917|NCT02942407|10068860|FG001|Overall Study|Death|13
6325918|NCT02942485|10068876|FG000|Overall Study|Lost to Follow-up|1
6325919|NCT02942485|10068877|FG001|Overall Study|Lost to Follow-up|0
6325920|NCT02942576|10068885|FG000|Overall Study|Adverse Event|28
6325921|NCT02942576|10068886|FG001|Overall Study|Adverse Event|6
6325922|NCT02942576|10068885|FG000|Overall Study|Withdrawal by Subject|7
6325923|NCT02942576|10068886|FG001|Overall Study|Withdrawal by Subject|5
6325924|NCT02942576|10068885|FG000|Overall Study|Physician Decision|1
6325925|NCT02942576|10068886|FG001|Overall Study|Physician Decision|4
6325926|NCT02942576|10068885|FG000|Overall Study|Other|10
6325927|NCT02942576|10068886|FG001|Overall Study|Other|8
6325928|NCT02942771|10068904|FG000|Overall Study|Adverse Event|1
6325929|NCT02942771|10068905|FG001|Overall Study|Adverse Event|0
6325930|NCT02942771|10068906|FG002|Overall Study|Adverse Event|0
6325931|NCT02942771|10068907|FG003|Overall Study|Adverse Event|0
6325932|NCT02942771|10068908|FG004|Overall Study|Adverse Event|2
6162810|NCT01197508|9805208|FG001|Overall Study|Lost to Follow-up|1
6162811|NCT01197508|9805209|FG002|Overall Study|Lost to Follow-up|2
6162812|NCT01197508|9805210|FG003|Overall Study|Lost to Follow-up|0
6162813|NCT01197508|9805207|FG000|Overall Study|Other|2
6162814|NCT01197508|9805208|FG001|Overall Study|Other|3
6162815|NCT01197508|9805209|FG002|Overall Study|Other|2
6162816|NCT01197508|9805210|FG003|Overall Study|Other|2
6162817|NCT01197521|9805223|FG000|Overall Study|Not reported|24
6162818|NCT01197521|9805224|FG001|Overall Study|Not reported|25
6325933|NCT02942771|10068904|FG000|Overall Study|Lost to Follow-up|1
6325934|NCT02942771|10068905|FG001|Overall Study|Lost to Follow-up|0
6162819|NCT01197521|9805225|FG002|Overall Study|Not reported|21
6162820|NCT01197521|9805223|FG000|Overall Study|Enrolment in long term extension|42
6162821|NCT01197521|9805224|FG001|Overall Study|Enrolment in long term extension|36
6162822|NCT01197521|9805225|FG002|Overall Study|Enrolment in long term extension|87
6162823|NCT01197521|9805223|FG000|Overall Study|Severe non-compliance to protocol|1
6162824|NCT01197521|9805224|FG001|Overall Study|Severe non-compliance to protocol|3
6162825|NCT01197521|9805225|FG002|Overall Study|Severe non-compliance to protocol|3
6162826|NCT01197521|9805223|FG000|Overall Study|Lack of therapeutic response|2
6162827|NCT01197521|9805224|FG001|Overall Study|Lack of therapeutic response|3
6162828|NCT01197521|9805225|FG002|Overall Study|Lack of therapeutic response|4
6162829|NCT01197521|9805223|FG000|Overall Study|Dev. of study specific discont. criteria|6
6162830|NCT01197521|9805224|FG001|Overall Study|Dev. of study specific discont. criteria|16
6162831|NCT01197521|9805225|FG002|Overall Study|Dev. of study specific discont. criteria|2
6162832|NCT01197521|9805223|FG000|Overall Study|Lost to Follow-up|3
6162833|NCT01197521|9805224|FG001|Overall Study|Lost to Follow-up|2
6162834|NCT01197521|9805225|FG002|Overall Study|Lost to Follow-up|2
6162835|NCT01197521|9805223|FG000|Overall Study|Adverse Event|25
6162836|NCT01197521|9805224|FG001|Overall Study|Adverse Event|28
6162837|NCT01197521|9805225|FG002|Overall Study|Adverse Event|24
6162838|NCT01197534|9805239|FG000|Overall Study|Not reported|16
6162839|NCT01197534|9805240|FG001|Overall Study|Not reported|10
6162840|NCT01197534|9805241|FG002|Overall Study|Not reported|16
6162841|NCT01197534|9805239|FG000|Overall Study|Enrolment in long term extension|57
6162842|NCT01197534|9805240|FG001|Overall Study|Enrolment in long term extension|66
6162843|NCT01197534|9805241|FG002|Overall Study|Enrolment in long term extension|119
6162844|NCT01197534|9805239|FG000|Overall Study|Severe non-compliance to protocol|3
6162845|NCT01197534|9805240|FG001|Overall Study|Severe non-compliance to protocol|4
6162846|NCT01197534|9805241|FG002|Overall Study|Severe non-compliance to protocol|1
6162847|NCT01197534|9805239|FG000|Overall Study|Lack of therapeutic response|9
6162848|NCT01197534|9805240|FG001|Overall Study|Lack of therapeutic response|4
6162849|NCT01197534|9805241|FG002|Overall Study|Lack of therapeutic response|9
6162850|NCT01197534|9805239|FG000|Overall Study|Dev. of study specific discont. criteria|13
6162851|NCT01197534|9805240|FG001|Overall Study|Dev. of study specific discont. criteria|6
6162852|NCT01197534|9805241|FG002|Overall Study|Dev. of study specific discont. criteria|2
6162853|NCT01197534|9805239|FG000|Overall Study|Lost to Follow-up|1
6162854|NCT01197534|9805240|FG001|Overall Study|Lost to Follow-up|4
6162855|NCT01197534|9805241|FG002|Overall Study|Lost to Follow-up|2
6162856|NCT01197534|9805239|FG000|Overall Study|Adverse Event|35
6162857|NCT01197534|9805240|FG001|Overall Study|Adverse Event|36
6162858|NCT01197534|9805241|FG002|Overall Study|Adverse Event|24
6162859|NCT01197560|9805258|FG000|Overall Study|Adverse Event|6
6162860|NCT01197560|9805259|FG001|Overall Study|Adverse Event|8
6162861|NCT01197560|9805258|FG000|Overall Study|Death|3
6162862|NCT01197560|9805259|FG001|Overall Study|Death|5
6162863|NCT01197560|9805258|FG000|Overall Study|Withdrawal by Subject|1
6162864|NCT01197560|9805259|FG001|Overall Study|Withdrawal by Subject|1
6162865|NCT01197560|9805258|FG000|Overall Study|Disease progression|40
6162866|NCT01197560|9805259|FG001|Overall Study|Disease progression|35
6162867|NCT01197560|9805258|FG000|Overall Study|Miscellaneous|4
6162868|NCT01197560|9805259|FG001|Overall Study|Miscellaneous|3
6162869|NCT01197560|9805258|FG000|Overall Study|Missing|0
6162870|NCT01197560|9805259|FG001|Overall Study|Missing|1
6162871|NCT01197755|9805293|FG000|Overall Study|Adverse Event|8
6162872|NCT01197755|9805294|FG001|Overall Study|Adverse Event|10
6162873|NCT01197755|9805295|FG002|Overall Study|Adverse Event|10
6162874|NCT01197755|9805293|FG000|Overall Study|Study-specific discontinuation criteria|2
6162875|NCT01197755|9805294|FG001|Overall Study|Study-specific discontinuation criteria|1
6162876|NCT01197755|9805295|FG002|Overall Study|Study-specific discontinuation criteria|0
6162877|NCT01197755|9805293|FG000|Overall Study|Entered the long-term extension study|18
6162878|NCT01197755|9805294|FG001|Overall Study|Entered the long-term extension study|21
6162879|NCT01197755|9805295|FG002|Overall Study|Entered the long-term extension study|35
6162880|NCT01197755|9805293|FG000|Overall Study|Lack of therapeutic response|0
6162881|NCT01197755|9805294|FG001|Overall Study|Lack of therapeutic response|7
6162882|NCT01197755|9805295|FG002|Overall Study|Lack of therapeutic response|4
6325935|NCT02942771|10068906|FG002|Overall Study|Lost to Follow-up|0
6325936|NCT02942771|10068907|FG003|Overall Study|Lost to Follow-up|0
6325937|NCT02942771|10068908|FG004|Overall Study|Lost to Follow-up|0
6325938|NCT02942771|10068904|FG000|Overall Study|Withdrawal by Subject|1
6325939|NCT02942771|10068905|FG001|Overall Study|Withdrawal by Subject|0
6325940|NCT02942771|10068906|FG002|Overall Study|Withdrawal by Subject|0
6325941|NCT02942771|10068907|FG003|Overall Study|Withdrawal by Subject|0
6325942|NCT02942771|10068908|FG004|Overall Study|Withdrawal by Subject|2
6325943|NCT02943070|10068929|FG000|Overall Study|Physician Decision|1
6325944|NCT02943070|10068929|FG000|Overall Study|Adverse Event|2
6325945|NCT02943070|10068929|FG000|Overall Study|Death|2
6325946|NCT02943070|10068929|FG000|Overall Study|Withdrawal by Subject|3
6325947|NCT02943070|10068929|FG000|Overall Study|Lost to Follow-up|4
6325948|NCT02943070|10068929|FG000|Overall Study|Retreatment or TURP|13
6162883|NCT01197755|9805293|FG000|Overall Study|Severe non-compliance to the protocol|2
6162884|NCT01197755|9805294|FG001|Overall Study|Severe non-compliance to the protocol|1
6162885|NCT01197755|9805295|FG002|Overall Study|Severe non-compliance to the protocol|2
6162886|NCT01197755|9805293|FG000|Overall Study|Withdrawal by Subject|1
6162887|NCT01197755|9805294|FG001|Overall Study|Withdrawal by Subject|0
6162888|NCT01197755|9805295|FG002|Overall Study|Withdrawal by Subject|0
6162889|NCT01197755|9805293|FG000|Overall Study|Lost to Follow-up|0
6162890|NCT01197755|9805294|FG001|Overall Study|Lost to Follow-up|0
6162891|NCT01197755|9805295|FG002|Overall Study|Lost to Follow-up|1
6162892|NCT01197755|9805293|FG000|Overall Study|eg, change in circumstances|7
6162893|NCT01197755|9805294|FG001|Overall Study|eg, change in circumstances|3
6162894|NCT01197755|9805295|FG002|Overall Study|eg, change in circumstances|2
6162895|NCT01197794|9805312|FG000|Overall Study|Adverse Event|3
6162896|NCT01197794|9805313|FG001|Overall Study|Adverse Event|2
6162897|NCT01197794|9805314|FG002|Overall Study|Adverse Event|4
6162898|NCT01197794|9805315|FG003|Overall Study|Adverse Event|4
6162899|NCT01197794|9805316|FG004|Overall Study|Adverse Event|4
6162900|NCT01197794|9805317|FG005|Overall Study|Adverse Event|2
6162901|NCT01197794|9805318|FG006|Overall Study|Adverse Event|3
6162902|NCT01197794|9805312|FG000|Overall Study|Protocol Violation|0
6162903|NCT01197794|9805313|FG001|Overall Study|Protocol Violation|0
6162904|NCT01197794|9805314|FG002|Overall Study|Protocol Violation|0
6162905|NCT01197794|9805315|FG003|Overall Study|Protocol Violation|0
6162906|NCT01197794|9805316|FG004|Overall Study|Protocol Violation|2
6162907|NCT01197794|9805317|FG005|Overall Study|Protocol Violation|0
6162908|NCT01197794|9805318|FG006|Overall Study|Protocol Violation|1
6162909|NCT01197794|9805312|FG000|Overall Study|Development of study withdrawal criteria|3
6162910|NCT01197794|9805313|FG001|Overall Study|Development of study withdrawal criteria|0
6162911|NCT01197794|9805314|FG002|Overall Study|Development of study withdrawal criteria|0
6162912|NCT01197794|9805315|FG003|Overall Study|Development of study withdrawal criteria|1
6162913|NCT01197794|9805316|FG004|Overall Study|Development of study withdrawal criteria|0
6162914|NCT01197794|9805317|FG005|Overall Study|Development of study withdrawal criteria|0
6162915|NCT01197794|9805318|FG006|Overall Study|Development of study withdrawal criteria|1
6162916|NCT01197794|9805312|FG000|Overall Study|Eligibility criteria not fulfilled|5
6162917|NCT01197794|9805313|FG001|Overall Study|Eligibility criteria not fulfilled|8
6162918|NCT01197794|9805314|FG002|Overall Study|Eligibility criteria not fulfilled|2
6162919|NCT01197794|9805315|FG003|Overall Study|Eligibility criteria not fulfilled|5
6162920|NCT01197794|9805316|FG004|Overall Study|Eligibility criteria not fulfilled|5
6162921|NCT01197794|9805317|FG005|Overall Study|Eligibility criteria not fulfilled|9
6162922|NCT01197794|9805318|FG006|Overall Study|Eligibility criteria not fulfilled|6
6162923|NCT01197794|9805312|FG000|Overall Study|Withdrawal by Subject|3
6162924|NCT01197794|9805313|FG001|Overall Study|Withdrawal by Subject|3
6162925|NCT01197794|9805314|FG002|Overall Study|Withdrawal by Subject|4
6162926|NCT01197794|9805315|FG003|Overall Study|Withdrawal by Subject|1
6162927|NCT01197794|9805316|FG004|Overall Study|Withdrawal by Subject|1
6162928|NCT01197794|9805317|FG005|Overall Study|Withdrawal by Subject|5
6162929|NCT01197794|9805318|FG006|Overall Study|Withdrawal by Subject|6
6162930|NCT01197794|9805312|FG000|Overall Study|Lost to Follow-up|1
6162931|NCT01197794|9805313|FG001|Overall Study|Lost to Follow-up|1
6162932|NCT01197794|9805314|FG002|Overall Study|Lost to Follow-up|0
6162933|NCT01197794|9805315|FG003|Overall Study|Lost to Follow-up|1
6162934|NCT01197794|9805316|FG004|Overall Study|Lost to Follow-up|0
6162935|NCT01197794|9805317|FG005|Overall Study|Lost to Follow-up|1
6162936|NCT01197794|9805318|FG006|Overall Study|Lost to Follow-up|0
6162937|NCT01197794|9805312|FG000|Overall Study|Other|1
6162938|NCT01197794|9805313|FG001|Overall Study|Other|1
6162939|NCT01197794|9805314|FG002|Overall Study|Other|3
6162940|NCT01197794|9805315|FG003|Overall Study|Other|0
6162941|NCT01197794|9805316|FG004|Overall Study|Other|2
6162942|NCT01197794|9805317|FG005|Overall Study|Other|2
6162943|NCT01197794|9805318|FG006|Overall Study|Other|4
6162944|NCT01197911|9805360|FG000|Overall Study|Adverse Event|0
6162945|NCT01197911|9805361|FG001|Overall Study|Adverse Event|0
6162946|NCT01197911|9805362|FG002|Overall Study|Adverse Event|1
6162947|NCT01198002|9805374|FG000|Treatment Period 1 (Weeks 0-52)|Adverse Event|18
6162948|NCT01198002|9805375|FG001|Treatment Period 1 (Weeks 0-52)|Adverse Event|11
6162949|NCT01198002|9805376|FG002|Treatment Period 1 (Weeks 0-52)|Adverse Event|11
6162950|NCT01198002|9805374|FG000|Treatment Period 1 (Weeks 0-52)|Death|2
6162951|NCT01198002|9805375|FG001|Treatment Period 1 (Weeks 0-52)|Death|0
6162952|NCT01198002|9805376|FG002|Treatment Period 1 (Weeks 0-52)|Death|1
6162953|NCT01198002|9805374|FG000|Treatment Period 1 (Weeks 0-52)|Lack of Efficacy|10
6162954|NCT01198002|9805375|FG001|Treatment Period 1 (Weeks 0-52)|Lack of Efficacy|9
6162955|NCT01198002|9805376|FG002|Treatment Period 1 (Weeks 0-52)|Lack of Efficacy|6
6162956|NCT01198002|9805374|FG000|Treatment Period 1 (Weeks 0-52)|Entry Criteria Not Met|1
6162957|NCT01198002|9805375|FG001|Treatment Period 1 (Weeks 0-52)|Entry Criteria Not Met|3
6162958|NCT01198002|9805376|FG002|Treatment Period 1 (Weeks 0-52)|Entry Criteria Not Met|3
6162959|NCT01198002|9805374|FG000|Treatment Period 1 (Weeks 0-52)|Lost to Follow-up|0
6162960|NCT01198002|9805375|FG001|Treatment Period 1 (Weeks 0-52)|Lost to Follow-up|2
6162961|NCT01198002|9805376|FG002|Treatment Period 1 (Weeks 0-52)|Lost to Follow-up|0
6162962|NCT01198002|9805374|FG000|Treatment Period 1 (Weeks 0-52)|Withdrawal by Subject|16
6162963|NCT01198002|9805375|FG001|Treatment Period 1 (Weeks 0-52)|Withdrawal by Subject|21
6191939|NCT01426789|9848966|FG001|Part 1|Protocol deviation|1
6325949|NCT02943070|10068929|FG000|Overall Study|Subjects exited after their 48 month visit per the Sponsor's decision to close the study.|18
6325950|NCT02943096|10068942|FG000|Overall Study|Lack of Efficacy|0
6325951|NCT02943096|10068943|FG001|Overall Study|Lack of Efficacy|1
6325952|NCT02943447|10068967|FG000|Blinded Study Phase|Withdrew Consent|1
6325953|NCT02943447|10068968|FG001|Blinded Study Phase|Withdrew Consent|2
6325954|NCT02943447|10068969|FG002|Blinded Study Phase|Withdrew Consent|1
6325955|NCT02943447|10068967|FG000|Blinded Study Phase|Adverse Event|3
6325956|NCT02943447|10068968|FG001|Blinded Study Phase|Adverse Event|0
6325957|NCT02943447|10068969|FG002|Blinded Study Phase|Adverse Event|0
6325958|NCT02943447|10068967|FG000|Blinded Study Phase|Investigator's discretion|1
6325959|NCT02943447|10068968|FG001|Blinded Study Phase|Investigator's discretion|0
6325960|NCT02943447|10068969|FG002|Blinded Study Phase|Investigator's discretion|0
6325961|NCT02943447|10068967|FG000|Open-Label Extension Phase|Study terminated by sponsor|10
6325962|NCT02943447|10068968|FG001|Open-Label Extension Phase|Study terminated by sponsor|12
6325963|NCT02943447|10068969|FG002|Open-Label Extension Phase|Study terminated by sponsor|6
6325964|NCT02943447|10068967|FG000|Open-Label Extension Phase|Adverse Event|4
6325965|NCT02943447|10068968|FG001|Open-Label Extension Phase|Adverse Event|7
6325966|NCT02943447|10068969|FG002|Open-Label Extension Phase|Adverse Event|3
6325967|NCT02943447|10068967|FG000|Open-Label Extension Phase|Lack of Efficacy|3
6325968|NCT02943447|10068968|FG001|Open-Label Extension Phase|Lack of Efficacy|4
6325969|NCT02943447|10068969|FG002|Open-Label Extension Phase|Lack of Efficacy|0
6325970|NCT02943447|10068967|FG000|Open-Label Extension Phase|Withdrew consent|1
6325971|NCT02943447|10068968|FG001|Open-Label Extension Phase|Withdrew consent|1
6325972|NCT02943447|10068969|FG002|Open-Label Extension Phase|Withdrew consent|1
6325973|NCT02943447|10068967|FG000|Open-Label Extension Phase|Lost to Follow-up|0
6325974|NCT02943447|10068968|FG001|Open-Label Extension Phase|Lost to Follow-up|1
6325975|NCT02943447|10068969|FG002|Open-Label Extension Phase|Lost to Follow-up|0
6325976|NCT02943460|10068989|FG000|Blinded Study Phase|Adverse Event|3
6325977|NCT02943460|10068990|FG001|Blinded Study Phase|Adverse Event|0
6325978|NCT02943460|10068991|FG002|Blinded Study Phase|Adverse Event|0
6325979|NCT02943460|10068989|FG000|Blinded Study Phase|Withdrew Consent|0
6325980|NCT02943460|10068990|FG001|Blinded Study Phase|Withdrew Consent|1
6325981|NCT02943460|10068991|FG002|Blinded Study Phase|Withdrew Consent|0
6082405|NCT00627705|9690327|FG000|Overall Study|Withdrawal by Subject|0
6082406|NCT00627705|9690328|FG001|Overall Study|Withdrawal by Subject|2
6082407|NCT00627705|9690327|FG000|Overall Study|Lost to Follow-up|0
6162964|NCT01198002|9805376|FG002|Treatment Period 1 (Weeks 0-52)|Withdrawal by Subject|12
6325982|NCT02943460|10068989|FG000|Open Label Extension (OLE) Phase|Adverse Event|2
6325983|NCT02943460|10068990|FG001|Open Label Extension (OLE) Phase|Adverse Event|5
6325984|NCT02943460|10068991|FG002|Open Label Extension (OLE) Phase|Adverse Event|2
6325985|NCT02943460|10068989|FG000|Open Label Extension (OLE) Phase|Withdrew Consent|2
6325986|NCT02943460|10068990|FG001|Open Label Extension (OLE) Phase|Withdrew Consent|1
6325987|NCT02943460|10068991|FG002|Open Label Extension (OLE) Phase|Withdrew Consent|0
6325988|NCT02943460|10068989|FG000|Open Label Extension (OLE) Phase|Investigator's Discretion|1
6325989|NCT02943460|10068990|FG001|Open Label Extension (OLE) Phase|Investigator's Discretion|1
6325990|NCT02943460|10068991|FG002|Open Label Extension (OLE) Phase|Investigator's Discretion|0
6325991|NCT02943473|10069000|FG000|Overall Study|enrolled but not dosed|1
6082408|NCT00627705|9690328|FG001|Overall Study|Lost to Follow-up|1
6162965|NCT01198002|9805374|FG000|Treatment Period 1 (Weeks 0-52)|Physician Decision|1
6162966|NCT01198002|9805375|FG001|Treatment Period 1 (Weeks 0-52)|Physician Decision|2
6162967|NCT01198002|9805376|FG002|Treatment Period 1 (Weeks 0-52)|Physician Decision|2
6162968|NCT01198002|9805374|FG000|Treatment Period 1 (Weeks 0-52)|Protocol Violation|14
6162969|NCT01198002|9805375|FG001|Treatment Period 1 (Weeks 0-52)|Protocol Violation|10
6082409|NCT00627926|9690343|FG000|Overall Study|Adverse Event|26
6082410|NCT00627926|9690344|FG001|Overall Study|Adverse Event|37
6082411|NCT00627926|9690345|FG002|Overall Study|Adverse Event|36
6082412|NCT00627926|9690343|FG000|Overall Study|Death|1
6082413|NCT00627926|9690344|FG001|Overall Study|Death|0
6082414|NCT00627926|9690345|FG002|Overall Study|Death|0
6082415|NCT00627926|9690343|FG000|Overall Study|Lost to Follow-up|4
6082416|NCT00627926|9690344|FG001|Overall Study|Lost to Follow-up|3
6082417|NCT00627926|9690345|FG002|Overall Study|Lost to Follow-up|4
6082418|NCT00627926|9690343|FG000|Overall Study|Withdrawal by Subject|2
6082419|NCT00627926|9690344|FG001|Overall Study|Withdrawal by Subject|1
6082420|NCT00627926|9690345|FG002|Overall Study|Withdrawal by Subject|0
6082421|NCT00627926|9690343|FG000|Overall Study|Lack of Efficacy|118
6082422|NCT00627926|9690344|FG001|Overall Study|Lack of Efficacy|40
6082423|NCT00627926|9690345|FG002|Overall Study|Lack of Efficacy|38
6082424|NCT00627926|9690343|FG000|Overall Study|Noncompliance/unspecified|8
6082425|NCT00627926|9690344|FG001|Overall Study|Noncompliance/unspecified|23
6082426|NCT00627926|9690345|FG002|Overall Study|Noncompliance/unspecified|17
6082427|NCT00628030|9690364|FG000|Baseline to Post-Assessment|Lost to Follow-up|28
6082428|NCT00628030|9690365|FG001|Baseline to Post-Assessment|Lost to Follow-up|29
6082429|NCT00628030|9690364|FG000|Baseline to Post-Assessment|Withdrawal by Subject|5
6325992|NCT02943473|10069000|FG000|Overall Study|screen failure|1
6325993|NCT02943473|10069000|FG000|Overall Study|Physician Decision|4
6325994|NCT02943564|10069016|FG000|Overall Study|Miscellaneous Reasons|0
6325995|NCT02943564|10069017|FG001|Overall Study|Miscellaneous Reasons|0
6325996|NCT02943564|10069018|FG002|Overall Study|Miscellaneous Reasons|3
6325997|NCT02943564|10069016|FG000|Overall Study|Site terminated by sponsor|0
6325998|NCT02943564|10069017|FG001|Overall Study|Site terminated by sponsor|1
6325999|NCT02943564|10069018|FG002|Overall Study|Site terminated by sponsor|0
6326000|NCT02943564|10069016|FG000|Overall Study|Non-compliance with study drug|0
6326001|NCT02943564|10069017|FG001|Overall Study|Non-compliance with study drug|1
6326002|NCT02943564|10069018|FG002|Overall Study|Non-compliance with study drug|0
6326003|NCT02943564|10069016|FG000|Overall Study|Pregnancy|0
6326004|NCT02943564|10069017|FG001|Overall Study|Pregnancy|1
6326005|NCT02943564|10069018|FG002|Overall Study|Pregnancy|1
6326006|NCT02943564|10069016|FG000|Overall Study|Protocol Violation|2
6326007|NCT02943564|10069017|FG001|Overall Study|Protocol Violation|2
6326008|NCT02943564|10069018|FG002|Overall Study|Protocol Violation|2
6326009|NCT02943564|10069016|FG000|Overall Study|Lost to Follow-up|1
6326010|NCT02943564|10069017|FG001|Overall Study|Lost to Follow-up|0
6326011|NCT02943564|10069018|FG002|Overall Study|Lost to Follow-up|0
6326012|NCT02943564|10069016|FG000|Overall Study|Withdrawal by Subject|6
6326013|NCT02943564|10069017|FG001|Overall Study|Withdrawal by Subject|5
6326014|NCT02943564|10069018|FG002|Overall Study|Withdrawal by Subject|2
6326015|NCT02943564|10069016|FG000|Overall Study|Adverse Event|1
6326016|NCT02943564|10069017|FG001|Overall Study|Adverse Event|2
6326017|NCT02943564|10069018|FG002|Overall Study|Adverse Event|1
6326018|NCT02943564|10069016|FG000|Overall Study|Lack of Efficacy|0
6326019|NCT02943564|10069017|FG001|Overall Study|Lack of Efficacy|1
6326020|NCT02943564|10069018|FG002|Overall Study|Lack of Efficacy|0
6326021|NCT02943577|10069028|FG000|Overall Study|Protocol Violation|0
6326022|NCT02943577|10069029|FG001|Overall Study|Protocol Violation|1
6326023|NCT02943577|10069028|FG000|Overall Study|Adverse Event|3
6326024|NCT02943577|10069029|FG001|Overall Study|Adverse Event|2
6326025|NCT02943577|10069028|FG000|Overall Study|Lost to Follow-up|0
6326026|NCT02943577|10069029|FG001|Overall Study|Lost to Follow-up|1
6326027|NCT02943577|10069028|FG000|Overall Study|Withdrawal by Subject|1
6326028|NCT02943577|10069029|FG001|Overall Study|Withdrawal by Subject|1
6326029|NCT02943577|10069028|FG000|Overall Study|Pregnancy|1
6326030|NCT02943577|10069029|FG001|Overall Study|Pregnancy|0
6326031|NCT02943668|10069035|FG000|Overall Study|Disease Progression|1
6326032|NCT02944383|10069050|FG000|Overall Study|Lost to Follow-up|0
6326033|NCT02944383|10069051|FG001|Overall Study|Lost to Follow-up|0
6326034|NCT02944383|10069052|FG002|Overall Study|Lost to Follow-up|1
6326035|NCT02944383|10069050|FG000|Overall Study|Withdrawal by Subject|1
6326036|NCT02944383|10069051|FG001|Overall Study|Withdrawal by Subject|0
6326037|NCT02944383|10069052|FG002|Overall Study|Withdrawal by Subject|0
6326038|NCT02944448|10069064|FG000|Overall Study|Adverse Event|37
6326039|NCT02944448|10069065|FG001|Overall Study|Adverse Event|6
6326040|NCT02944448|10069064|FG000|Overall Study|Lack of Efficacy|8
6162970|NCT01198002|9805376|FG002|Treatment Period 1 (Weeks 0-52)|Protocol Violation|10
6162971|NCT01198002|9805374|FG000|Treatment Period 1 (Weeks 0-52)|Sponsor Decision|213
6162972|NCT01198002|9805375|FG001|Treatment Period 1 (Weeks 0-52)|Sponsor Decision|216
6162973|NCT01198002|9805376|FG002|Treatment Period 1 (Weeks 0-52)|Sponsor Decision|224
6162974|NCT01198002|9805374|FG000|Treatment Period 2 (Weeks 52-100)|Adverse Event|2
6162975|NCT01198002|9805375|FG001|Treatment Period 2 (Weeks 52-100)|Adverse Event|0
6162976|NCT01198002|9805376|FG002|Treatment Period 2 (Weeks 52-100)|Adverse Event|1
6162977|NCT01198002|9805374|FG000|Treatment Period 2 (Weeks 52-100)|Lack of Efficacy|3
6162978|NCT01198002|9805375|FG001|Treatment Period 2 (Weeks 52-100)|Lack of Efficacy|1
6162979|NCT01198002|9805376|FG002|Treatment Period 2 (Weeks 52-100)|Lack of Efficacy|1
6162980|NCT01198002|9805374|FG000|Treatment Period 2 (Weeks 52-100)|Entry Criteria Not Met|1
6162981|NCT01198002|9805375|FG001|Treatment Period 2 (Weeks 52-100)|Entry Criteria Not Met|0
6162982|NCT01198002|9805376|FG002|Treatment Period 2 (Weeks 52-100)|Entry Criteria Not Met|0
6162983|NCT01198002|9805374|FG000|Treatment Period 2 (Weeks 52-100)|Lost to Follow-up|0
6162984|NCT01198002|9805375|FG001|Treatment Period 2 (Weeks 52-100)|Lost to Follow-up|2
6162985|NCT01198002|9805376|FG002|Treatment Period 2 (Weeks 52-100)|Lost to Follow-up|0
6162986|NCT01198002|9805374|FG000|Treatment Period 2 (Weeks 52-100)|Physician Decision|1
6162987|NCT01198002|9805375|FG001|Treatment Period 2 (Weeks 52-100)|Physician Decision|0
6162988|NCT01198002|9805376|FG002|Treatment Period 2 (Weeks 52-100)|Physician Decision|1
6162989|NCT01198002|9805374|FG000|Treatment Period 2 (Weeks 52-100)|Sponsor Decision|62
6162990|NCT01198002|9805375|FG001|Treatment Period 2 (Weeks 52-100)|Sponsor Decision|70
6162991|NCT01198002|9805376|FG002|Treatment Period 2 (Weeks 52-100)|Sponsor Decision|75
6326041|NCT02944448|10069065|FG001|Overall Study|Lack of Efficacy|5
6326042|NCT02944448|10069064|FG000|Overall Study|Lost to Follow-up|3
6326043|NCT02944448|10069065|FG001|Overall Study|Lost to Follow-up|1
6326044|NCT02944448|10069064|FG000|Overall Study|Protocol Violation|25
6326045|NCT02944448|10069065|FG001|Overall Study|Protocol Violation|7
6326046|NCT02944448|10069064|FG000|Overall Study|Withdrawal by Subject|14
6326047|NCT02944448|10069065|FG001|Overall Study|Withdrawal by Subject|4
6326048|NCT02944448|10069064|FG000|Overall Study|Sponsor did not supply drug in time|0
6326049|NCT02944448|10069065|FG001|Overall Study|Sponsor did not supply drug in time|1
6162992|NCT01198028|9805406|FG000|Overall Study|Adverse Event|5
6162993|NCT01198028|9805406|FG000|Overall Study|Death|3
6162994|NCT01198028|9805406|FG000|Overall Study|Physician Decision|2
6162995|NCT01198132|9805412|FG000|Overall Study|Withdrawal by Subject|4
6162996|NCT01198132|9805413|FG001|Overall Study|Withdrawal by Subject|5
6162997|NCT01198132|9805412|FG000|Overall Study|Physician Decision|5
6162998|NCT01198132|9805413|FG001|Overall Study|Physician Decision|4
6162999|NCT01198132|9805412|FG000|Overall Study|Other Unspecified|3
6163000|NCT01198132|9805413|FG001|Overall Study|Other Unspecified|6
6163001|NCT01198132|9805412|FG000|Overall Study|Lack of Efficacy|2
6163002|NCT01198132|9805413|FG001|Overall Study|Lack of Efficacy|3
6163003|NCT01198132|9805412|FG000|Overall Study|Sign/symptoms of underlying disease|2
6163004|NCT01198132|9805413|FG001|Overall Study|Sign/symptoms of underlying disease|1
6163005|NCT01198132|9805412|FG000|Overall Study|Abnormal/clinically significant biologic|1
6163006|NCT01198132|9805413|FG001|Overall Study|Abnormal/clinically significant biologic|1
6163007|NCT01198132|9805412|FG000|Overall Study|Adverse Event|0
6163008|NCT01198132|9805413|FG001|Overall Study|Adverse Event|1
6163009|NCT01198132|9805412|FG000|Overall Study|Protocol Violation|1
6163010|NCT01198132|9805413|FG001|Overall Study|Protocol Violation|0
6163011|NCT01198145|9805423|FG000|Overall Study|Withdrawal by Subject|1
6163012|NCT01198145|9805424|FG001|Overall Study|Withdrawal by Subject|1
6163013|NCT01198275|9805442|FG000|Overall Study|Adverse Event|2
6163014|NCT01198275|9805443|FG001|Overall Study|Adverse Event|3
6163015|NCT01198275|9805442|FG000|Overall Study|spontaneous return to sinus rhythm|4
6163016|NCT01198275|9805443|FG001|Overall Study|spontaneous return to sinus rhythm|2
6163017|NCT01198470|9805481|FG000|Overall Study|Adverse Event|2
6163018|NCT01198509|9805491|FG000|Overall Study|Withdrawal by Subject|1
6163019|NCT01198509|9805492|FG001|Overall Study|Withdrawal by Subject|0
6163020|NCT01198509|9805493|FG002|Overall Study|Withdrawal by Subject|0
6163021|NCT01198509|9805494|FG003|Overall Study|Withdrawal by Subject|0
6163022|NCT01198509|9805495|FG004|Overall Study|Withdrawal by Subject|0
6163023|NCT01198509|9805496|FG005|Overall Study|Withdrawal by Subject|0
6163024|NCT01198574|9805512|FG000|Overall Study|Resigned from schools|4
6163025|NCT01198574|9805513|FG001|Overall Study|Resigned from schools|1
6163026|NCT01198574|9805514|FG002|Overall Study|Resigned from schools|1
6163027|NCT01198574|9805515|FG003|Overall Study|Resigned from schools|4
6163028|NCT01198587|9805529|FG000|Overall Study|Lost to Follow-up|8
6163029|NCT01198587|9805530|FG001|Overall Study|Lost to Follow-up|0
6163030|NCT01198587|9805531|FG002|Overall Study|Lost to Follow-up|9
6163031|NCT01198587|9805532|FG003|Overall Study|Lost to Follow-up|0
6163032|NCT01198600|9805547|FG000|Phase 1: Period One, 30 Days of Wear|Inconvenience|1
6163033|NCT01198600|9805548|FG001|Phase 1: Period One, 30 Days of Wear|Inconvenience|0
6163034|NCT01198600|9805549|FG002|Phase 1: Period One, 30 Days of Wear|Inconvenience|0
6163035|NCT01198600|9805550|FG003|Phase 1: Period One, 30 Days of Wear|Inconvenience|0
6163036|NCT01198600|9805547|FG000|Phase 1: Period One, 30 Days of Wear|Asymptomatic infiltrates|1
6163037|NCT01198600|9805548|FG001|Phase 1: Period One, 30 Days of Wear|Asymptomatic infiltrates|0
6163038|NCT01198600|9805549|FG002|Phase 1: Period One, 30 Days of Wear|Asymptomatic infiltrates|0
6163039|NCT01198600|9805550|FG003|Phase 1: Period One, 30 Days of Wear|Asymptomatic infiltrates|0
6163040|NCT01198600|9805547|FG000|Phase 1: Period One, 30 Days of Wear|Unable to achieve acceptable comfort|0
6163041|NCT01198600|9805548|FG001|Phase 1: Period One, 30 Days of Wear|Unable to achieve acceptable comfort|1
6163042|NCT01198600|9805549|FG002|Phase 1: Period One, 30 Days of Wear|Unable to achieve acceptable comfort|0
6163043|NCT01198600|9805550|FG003|Phase 1: Period One, 30 Days of Wear|Unable to achieve acceptable comfort|0
6163044|NCT01198600|9805547|FG000|Phase 1: Period Two, 30 Days of Wear|Inconvenience|0
6163045|NCT01198600|9805548|FG001|Phase 1: Period Two, 30 Days of Wear|Inconvenience|1
6163046|NCT01198600|9805549|FG002|Phase 1: Period Two, 30 Days of Wear|Inconvenience|0
6326050|NCT02944448|10069064|FG000|Overall Study|Noncompliant with dosing|1
6326051|NCT02944448|10069065|FG001|Overall Study|Noncompliant with dosing|0
6326052|NCT02944448|10069064|FG000|Overall Study|Abnormal laboratory values|1
6326053|NCT02944448|10069065|FG001|Overall Study|Abnormal laboratory values|0
6326054|NCT02944656|10069083|FG000|Overall Study|No longer eligible|3
6326055|NCT02944656|10069084|FG001|Overall Study|No longer eligible|0
6326056|NCT02944656|10069083|FG000|Overall Study|Lost to Follow-up|7
6326057|NCT02944656|10069084|FG001|Overall Study|Lost to Follow-up|10
6326058|NCT02944968|10069090|FG000|Overall Study|Subject excluded before study procedure|1
6326059|NCT02944968|10069090|FG000|Overall Study|Subject didn't meet eligibility criteria|2
6326060|NCT02945046|10069097|FG000|Overall Study|Adverse Event|1
6326061|NCT02945046|10069098|FG001|Overall Study|Adverse Event|0
6326062|NCT02945046|10069099|FG002|Overall Study|Adverse Event|2
6326063|NCT02945046|10069097|FG000|Overall Study|Withdrawal by Subject|3
6163047|NCT01198600|9805550|FG003|Phase 1: Period Two, 30 Days of Wear|Inconvenience|0
6163048|NCT01198600|9805547|FG000|Phase 2: 56 Days of Wear|Inconvenience|0
6163049|NCT01198600|9805548|FG001|Phase 2: 56 Days of Wear|Inconvenience|0
6163050|NCT01198600|9805549|FG002|Phase 2: 56 Days of Wear|Inconvenience|2
6163051|NCT01198600|9805550|FG003|Phase 2: 56 Days of Wear|Inconvenience|0
6163052|NCT01198600|9805547|FG000|Phase 2: 56 Days of Wear|Relocation|0
6326064|NCT02945046|10069098|FG001|Overall Study|Withdrawal by Subject|3
6326065|NCT02945046|10069099|FG002|Overall Study|Withdrawal by Subject|3
6326066|NCT02945046|10069097|FG000|Overall Study|Protocol Violation|2
6326067|NCT02945046|10069098|FG001|Overall Study|Protocol Violation|3
6163053|NCT01198600|9805548|FG001|Phase 2: 56 Days of Wear|Relocation|0
6163054|NCT01198600|9805549|FG002|Phase 2: 56 Days of Wear|Relocation|2
6163055|NCT01198600|9805550|FG003|Phase 2: 56 Days of Wear|Relocation|0
6163056|NCT01198600|9805547|FG000|Phase 2: 56 Days of Wear|Unable to achieve satisfactory comfort|0
6163057|NCT01198600|9805548|FG001|Phase 2: 56 Days of Wear|Unable to achieve satisfactory comfort|0
6163058|NCT01198600|9805549|FG002|Phase 2: 56 Days of Wear|Unable to achieve satisfactory comfort|1
6163059|NCT01198600|9805550|FG003|Phase 2: 56 Days of Wear|Unable to achieve satisfactory comfort|0
6163060|NCT01198756|9805571|FG000|Overall Study|Adverse Event|0
6163061|NCT01198756|9805572|FG001|Overall Study|Adverse Event|0
6163062|NCT01198756|9805573|FG002|Overall Study|Adverse Event|0
6163063|NCT01198756|9805574|FG003|Overall Study|Adverse Event|1
6163064|NCT01198756|9805571|FG000|Overall Study|Protocol Violation|0
6163065|NCT01198756|9805572|FG001|Overall Study|Protocol Violation|0
6163066|NCT01198756|9805573|FG002|Overall Study|Protocol Violation|0
6163067|NCT01198756|9805574|FG003|Overall Study|Protocol Violation|2
6163068|NCT01198756|9805571|FG000|Overall Study|Withdrawal by Subject|9
6163069|NCT01198756|9805572|FG001|Overall Study|Withdrawal by Subject|4
6163070|NCT01198756|9805573|FG002|Overall Study|Withdrawal by Subject|7
6163071|NCT01198756|9805574|FG003|Overall Study|Withdrawal by Subject|5
6163072|NCT01198756|9805571|FG000|Overall Study|Lost to Follow-up|29
6163073|NCT01198756|9805572|FG001|Overall Study|Lost to Follow-up|36
6326068|NCT02945046|10069099|FG002|Overall Study|Protocol Violation|2
6326069|NCT02945046|10069097|FG000|Overall Study|Lost to Follow-up|1
6326070|NCT02945046|10069098|FG001|Overall Study|Lost to Follow-up|1
6326071|NCT02945046|10069099|FG002|Overall Study|Lost to Follow-up|0
6326072|NCT02945046|10069097|FG000|Overall Study|Lack of Efficacy|1
6326073|NCT02945046|10069098|FG001|Overall Study|Lack of Efficacy|2
6326074|NCT02945046|10069099|FG002|Overall Study|Lack of Efficacy|1
6326075|NCT02945046|10069097|FG000|Overall Study|Other than specified|5
6326076|NCT02945046|10069098|FG001|Overall Study|Other than specified|4
6326077|NCT02945046|10069099|FG002|Overall Study|Other than specified|7
6326078|NCT02945254|10069113|FG000|Overall Study|Lost to Follow-up|1
6326079|NCT02945254|10069114|FG001|Overall Study|Lost to Follow-up|0
6326080|NCT02945254|10069113|FG000|Overall Study|Withdrawal by Subject|1
6326081|NCT02945254|10069114|FG001|Overall Study|Withdrawal by Subject|0
6326082|NCT02945410|10069126|FG000|Intervention 1 (5 Days)|Withdrawal by Subject|0
6326083|NCT02945410|10069127|FG001|Intervention 1 (5 Days)|Withdrawal by Subject|3
6326084|NCT02945410|10069128|FG002|Intervention 1 (5 Days)|Withdrawal by Subject|0
6326085|NCT02945410|10069129|FG003|Intervention 1 (5 Days)|Withdrawal by Subject|0
6326086|NCT02945410|10069130|FG004|Intervention 1 (5 Days)|Withdrawal by Subject|0
6326087|NCT02945410|10069131|FG005|Intervention 1 (5 Days)|Withdrawal by Subject|0
6326088|NCT02945410|10069126|FG000|Intervention 1 (5 Days)|Adverse Event|1
6326089|NCT02945410|10069127|FG001|Intervention 1 (5 Days)|Adverse Event|0
6326090|NCT02945410|10069128|FG002|Intervention 1 (5 Days)|Adverse Event|0
6326091|NCT02945410|10069129|FG003|Intervention 1 (5 Days)|Adverse Event|0
6326092|NCT02945410|10069130|FG004|Intervention 1 (5 Days)|Adverse Event|0
6326093|NCT02945410|10069131|FG005|Intervention 1 (5 Days)|Adverse Event|1
6326094|NCT02945410|10069126|FG000|Washout 1 (14 Days)|Withdrawal by Subject|0
6326095|NCT02945410|10069127|FG001|Washout 1 (14 Days)|Withdrawal by Subject|0
6326096|NCT02945410|10069128|FG002|Washout 1 (14 Days)|Withdrawal by Subject|2
6326097|NCT02945410|10069129|FG003|Washout 1 (14 Days)|Withdrawal by Subject|0
6326098|NCT02945410|10069130|FG004|Washout 1 (14 Days)|Withdrawal by Subject|1
6326099|NCT02945410|10069131|FG005|Washout 1 (14 Days)|Withdrawal by Subject|0
6326100|NCT02945657|10069152|FG000|Overall Study|Adverse Event|1
6326101|NCT02945657|10069152|FG000|Overall Study|Withdrawal by Parent/Guardian|3
6326102|NCT02946385|10069208|FG000|Overall Study|Lost to Follow-up|0
6326103|NCT02946385|10069209|FG001|Overall Study|Lost to Follow-up|0
6326104|NCT02946385|10069210|FG002|Overall Study|Lost to Follow-up|3
6326105|NCT02946385|10069211|FG003|Overall Study|Lost to Follow-up|0
6326106|NCT02946385|10069212|FG004|Overall Study|Lost to Follow-up|2
6326107|NCT02946385|10069213|FG005|Overall Study|Lost to Follow-up|1
6326108|NCT02946463|10069235|FG000|Primary Evaluation Period|Physician Decision|0
6326109|NCT02946463|10069236|FG001|Primary Evaluation Period|Physician Decision|1
6326110|NCT02946463|10069235|FG000|Primary Evaluation Period|Withdrawal by Subject|0
6326111|NCT02946463|10069236|FG001|Primary Evaluation Period|Withdrawal by Subject|1
6326112|NCT02946515|10069248|FG000|Overall Study|Lost to Follow-up|2
6326113|NCT02946515|10069249|FG001|Overall Study|Lost to Follow-up|1
6326114|NCT02946580|10069257|FG000|Overall Study|Withdrawal by Subject|1
6326115|NCT02946580|10069258|FG001|Overall Study|Withdrawal by Subject|2
6326116|NCT02946580|10069257|FG000|Overall Study|Adverse Event|0
6326117|NCT02946580|10069258|FG001|Overall Study|Adverse Event|2
6326118|NCT02946580|10069257|FG000|Overall Study|Did not undergo posterior spinal fusion|0
6326119|NCT02946580|10069258|FG001|Overall Study|Did not undergo posterior spinal fusion|1
6326120|NCT02946918|10069273|FG000|Overall Study|Patient unblinded himself|1
6326121|NCT02946918|10069274|FG001|Overall Study|Patient unblinded himself|0
6326122|NCT02946918|10069273|FG000|Overall Study|Physician Decision|0
6163074|NCT01198756|9805573|FG002|Overall Study|Lost to Follow-up|23
6163075|NCT01198756|9805574|FG003|Overall Study|Lost to Follow-up|18
6163076|NCT01198795|9805595|FG000|Overall Study|Did not meet InclusionExclusion criteria|30
6326123|NCT02946918|10069274|FG001|Overall Study|Physician Decision|2
6326124|NCT02946918|10069273|FG000|Overall Study|Ran out of study medication|0
6163077|NCT01198795|9805595|FG000|Overall Study|Withdrawal by Subject|17
6163078|NCT01198795|9805595|FG000|Overall Study|Lost to Follow-up|15
6163079|NCT01198795|9805595|FG000|Overall Study|Adverse Event|9
6163080|NCT01198795|9805595|FG000|Overall Study|Lack of Efficacy|5
6163081|NCT01198795|9805595|FG000|Overall Study|Protocol Violation|2
6163082|NCT01198795|9805595|FG000|Overall Study|Other Reason|4
6163083|NCT01198873|9805601|FG000|Overall Study|Adverse Event|4
6163084|NCT01198873|9805602|FG001|Overall Study|Adverse Event|7
6163085|NCT01198873|9805601|FG000|Overall Study|Study closure|29
6163086|NCT01198873|9805602|FG001|Overall Study|Study closure|23
6163087|NCT01198873|9805601|FG000|Overall Study|Other than above|4
6163088|NCT01198873|9805602|FG001|Overall Study|Other than above|2
6163089|NCT01198977|9805610|FG000|Overall Study|Lost to Follow-up|1
6163090|NCT01198977|9805611|FG001|Overall Study|Lost to Follow-up|0
6163091|NCT01199016|9805619|FG000|Overall Study|No longer meets eligibility criteria|4
6163092|NCT01199016|9805619|FG000|Overall Study|Entrance criteria|5
6163093|NCT01199016|9805619|FG000|Overall Study|Protocol Violation|9
6163094|NCT01199016|9805619|FG000|Overall Study|Other|13
6163095|NCT01199016|9805619|FG000|Overall Study|Withdrawal by Subject|21
6163096|NCT01199016|9805619|FG000|Overall Study|Lost to Follow-up|25
6163097|NCT01199042|9805623|FG000|Sleep Laboratory (3 Nights)|Didn't meet inclusion/exclusion criteria|2
6163098|NCT01199042|9805623|FG000|At Home (3 Months)|Lost to Follow-up|1
6163099|NCT01199055|9805635|FG000|Overall Study|Death|0
6163100|NCT01199055|9805636|FG001|Overall Study|Death|1
6163101|NCT01199055|9805637|FG002|Overall Study|Death|0
6163102|NCT01199055|9805635|FG000|Overall Study|Physician Decision|0
6163103|NCT01199055|9805636|FG001|Overall Study|Physician Decision|1
6163104|NCT01199055|9805637|FG002|Overall Study|Physician Decision|1
6163105|NCT01199055|9805635|FG000|Overall Study|Progressive disease|2
6163106|NCT01199055|9805636|FG001|Overall Study|Progressive disease|1
6163107|NCT01199055|9805637|FG002|Overall Study|Progressive disease|2
6163108|NCT01199055|9805635|FG000|Overall Study|Withdrawal by Subject|0
6163109|NCT01199055|9805636|FG001|Overall Study|Withdrawal by Subject|0
6163110|NCT01199055|9805637|FG002|Overall Study|Withdrawal by Subject|1
6163111|NCT01199068|9805650|FG000|Overall Study|Unacceptable toxicity|0
6163112|NCT01199068|9805651|FG001|Overall Study|Unacceptable toxicity|0
6163113|NCT01199068|9805652|FG002|Overall Study|Unacceptable toxicity|2
6163114|NCT01199068|9805650|FG000|Overall Study|Progressive disease|3
6163115|NCT01199068|9805651|FG001|Overall Study|Progressive disease|3
6163116|NCT01199068|9805652|FG002|Overall Study|Progressive disease|6
6326125|NCT02946918|10069274|FG001|Overall Study|Ran out of study medication|1
6326126|NCT02948582|10069316|FG000|Washout Period 1|Adverse Event|0
6326127|NCT02948582|10069317|FG001|Washout Period 1|Adverse Event|2
6326128|NCT02948582|10069318|FG002|Washout Period 1|Adverse Event|0
6326129|NCT02948582|10069319|FG003|Washout Period 1|Adverse Event|0
6326130|NCT02948582|10069320|FG004|Washout Period 1|Adverse Event|0
6326131|NCT02948582|10069321|FG005|Washout Period 1|Adverse Event|0
6326132|NCT02948582|10069316|FG000|Washout Period 1|Protocol Violation|0
6326133|NCT02948582|10069317|FG001|Washout Period 1|Protocol Violation|0
6326134|NCT02948582|10069318|FG002|Washout Period 1|Protocol Violation|0
6326135|NCT02948582|10069319|FG003|Washout Period 1|Protocol Violation|0
6326136|NCT02948582|10069320|FG004|Washout Period 1|Protocol Violation|0
6326137|NCT02948582|10069321|FG005|Washout Period 1|Protocol Violation|1
6326138|NCT02948582|10069316|FG000|Washout Period 2|Adverse Event|0
6326139|NCT02948582|10069317|FG001|Washout Period 2|Adverse Event|1
6326140|NCT02948582|10069318|FG002|Washout Period 2|Adverse Event|0
6326141|NCT02948582|10069319|FG003|Washout Period 2|Adverse Event|0
6326142|NCT02948582|10069320|FG004|Washout Period 2|Adverse Event|0
6326143|NCT02948582|10069321|FG005|Washout Period 2|Adverse Event|0
6326144|NCT02948582|10069316|FG000|Washout Period 2|personal reasons|0
6326145|NCT02948582|10069317|FG001|Washout Period 2|personal reasons|0
6326146|NCT02948582|10069318|FG002|Washout Period 2|personal reasons|0
6326147|NCT02948582|10069319|FG003|Washout Period 2|personal reasons|1
6326148|NCT02948582|10069320|FG004|Washout Period 2|personal reasons|0
6326149|NCT02948582|10069321|FG005|Washout Period 2|personal reasons|0
6326150|NCT02948582|10069316|FG000|Washout Period 4|Adverse Event|1
6326151|NCT02948582|10069317|FG001|Washout Period 4|Adverse Event|0
6326152|NCT02948582|10069318|FG002|Washout Period 4|Adverse Event|1
6326153|NCT02948582|10069319|FG003|Washout Period 4|Adverse Event|0
6326154|NCT02948582|10069320|FG004|Washout Period 4|Adverse Event|0
6326155|NCT02948582|10069321|FG005|Washout Period 4|Adverse Event|0
6326156|NCT02948634|10069337|FG000|Overall Study|Lack of efficacy and study suspended|10
6326157|NCT02948634|10069338|FG001|Overall Study|Lack of efficacy and study suspended|2
6326158|NCT02948777|10069344|FG000|Overall Study|worsening of asthma symptoms resulting in oral prednisolone use.|1
6326159|NCT02948829|10069349|FG000|Overall Study|Withdrawal by Subject|4
6326160|NCT02948829|10069349|FG000|Overall Study|Ongoing (at data cut-off date: 29 May 2018)|195
6326161|NCT02948829|10069349|FG000|Overall Study|Non-Compliance with Study Procedures|1
6326162|NCT02949011|10069371|FG000|Overall Study|Adverse Event|6
6326163|NCT02949011|10069372|FG001|Overall Study|Adverse Event|7
6326164|NCT02949011|10069373|FG002|Overall Study|Adverse Event|3
6326165|NCT02949011|10069371|FG000|Overall Study|Failed Inclusion/Exclusion Criteria|0
6163117|NCT01199068|9805650|FG000|Overall Study|Withdrawal by Subject|0
6163118|NCT01199068|9805651|FG001|Overall Study|Withdrawal by Subject|0
6163119|NCT01199068|9805652|FG002|Overall Study|Withdrawal by Subject|1
6163120|NCT01199198|9805673|FG000|Overall Study|Adverse Event|3
6163121|NCT01199198|9805674|FG001|Overall Study|Adverse Event|0
6163122|NCT01199198|9805673|FG000|Overall Study|Lost to Follow-up|1
6163123|NCT01199198|9805674|FG001|Overall Study|Lost to Follow-up|5
6326166|NCT02949011|10069372|FG001|Overall Study|Failed Inclusion/Exclusion Criteria|0
6326167|NCT02949011|10069373|FG002|Overall Study|Failed Inclusion/Exclusion Criteria|3
6326168|NCT02949011|10069371|FG000|Overall Study|Protocol Deviation|5
6326169|NCT02949011|10069372|FG001|Overall Study|Protocol Deviation|3
6082430|NCT00628030|9690365|FG001|Baseline to Post-Assessment|Withdrawal by Subject|0
6082431|NCT00628030|9690364|FG000|Post to 6 Month Follow-up|Lost to Follow-up|32
6326170|NCT02949011|10069373|FG002|Overall Study|Protocol Deviation|3
6326171|NCT02949011|10069371|FG000|Overall Study|Lack of Efficacy|0
6326172|NCT02949011|10069372|FG001|Overall Study|Lack of Efficacy|2
6326173|NCT02949011|10069373|FG002|Overall Study|Lack of Efficacy|0
6326174|NCT02949011|10069371|FG000|Overall Study|Withdrawal by Subject|13
6326175|NCT02949011|10069372|FG001|Overall Study|Withdrawal by Subject|13
6326176|NCT02949011|10069373|FG002|Overall Study|Withdrawal by Subject|21
6326177|NCT02949011|10069371|FG000|Overall Study|Lost to Follow-up|7
6326178|NCT02949011|10069372|FG001|Overall Study|Lost to Follow-up|5
6326179|NCT02949011|10069373|FG002|Overall Study|Lost to Follow-up|5
6326180|NCT02949011|10069371|FG000|Overall Study|Death|0
6326181|NCT02949011|10069372|FG001|Overall Study|Death|0
6326182|NCT02949011|10069373|FG002|Overall Study|Death|1
6326183|NCT02949011|10069371|FG000|Overall Study|Miscellaneous|2
6326184|NCT02949011|10069372|FG001|Overall Study|Miscellaneous|4
6326185|NCT02949011|10069373|FG002|Overall Study|Miscellaneous|6
6326186|NCT02949024|10069383|FG000|Overall Study|Withdrawal by Subject|0
6326187|NCT02949024|10069384|FG001|Overall Study|Withdrawal by Subject|1
6082432|NCT00628030|9690365|FG001|Post to 6 Month Follow-up|Lost to Follow-up|30
6082433|NCT00628108|9690373|FG000|Overall Study|Adverse Event|0
6082434|NCT00628108|9690374|FG001|Overall Study|Adverse Event|3
6082435|NCT00628108|9690373|FG000|Overall Study|Withdrawal by Subject|1
6082436|NCT00628108|9690374|FG001|Overall Study|Withdrawal by Subject|0
6082437|NCT00628212|9690400|FG000|Overall Study|Adverse Event|2
6082438|NCT00628212|9690401|FG001|Overall Study|Adverse Event|0
6082439|NCT00628212|9690402|FG002|Overall Study|Adverse Event|1
6082440|NCT00628212|9690403|FG003|Overall Study|Adverse Event|2
6082441|NCT00628212|9690400|FG000|Overall Study|Physician Decision|1
6082442|NCT00628212|9690401|FG001|Overall Study|Physician Decision|1
6082443|NCT00628212|9690402|FG002|Overall Study|Physician Decision|2
6082444|NCT00628212|9690403|FG003|Overall Study|Physician Decision|3
6082445|NCT00628251|9690416|FG000|Randomised Part|Withdrawal by Subject|0
6163124|NCT01199198|9805673|FG000|Overall Study|Withdrawal by Subject|1
6163125|NCT01199198|9805674|FG001|Overall Study|Withdrawal by Subject|2
6163126|NCT01199198|9805673|FG000|Overall Study|ICU Transfer|1
6163127|NCT01199198|9805674|FG001|Overall Study|ICU Transfer|2
6163128|NCT01199198|9805673|FG000|Overall Study|Hospice-care transfer|1
6163129|NCT01199198|9805674|FG001|Overall Study|Hospice-care transfer|2
6163130|NCT01199263|9805693|FG000|Overall Study|Ineligible|0
6163131|NCT01199263|9805694|FG001|Overall Study|Ineligible|2
6163132|NCT01199263|9805693|FG000|Overall Study|Never Treated|6
6163133|NCT01199263|9805694|FG001|Overall Study|Never Treated|0
6163134|NCT01199289|9805706|FG000|Overall Study|Ineligibility determined|2
6163135|NCT01199289|9805707|FG001|Overall Study|Ineligibility determined|1
6163136|NCT01199289|9805708|FG002|Overall Study|Ineligibility determined|0
6163137|NCT01199289|9805709|FG003|Overall Study|Ineligibility determined|0
6163138|NCT01199289|9805706|FG000|Overall Study|Protocol Violation|1
6163139|NCT01199289|9805707|FG001|Overall Study|Protocol Violation|0
6163140|NCT01199289|9805708|FG002|Overall Study|Protocol Violation|0
6163141|NCT01199289|9805709|FG003|Overall Study|Protocol Violation|1
6163142|NCT01199289|9805706|FG000|Overall Study|Noncompliance|1
6163143|NCT01199289|9805707|FG001|Overall Study|Noncompliance|0
6163144|NCT01199289|9805708|FG002|Overall Study|Noncompliance|2
6163145|NCT01199289|9805709|FG003|Overall Study|Noncompliance|0
6163146|NCT01199289|9805706|FG000|Overall Study|Adverse Event|0
6163147|NCT01199289|9805707|FG001|Overall Study|Adverse Event|3
6163148|NCT01199289|9805708|FG002|Overall Study|Adverse Event|1
6163149|NCT01199289|9805709|FG003|Overall Study|Adverse Event|4
6163150|NCT01199289|9805706|FG000|Overall Study|Full consent withdrawn|2
6163151|NCT01199289|9805707|FG001|Overall Study|Full consent withdrawn|2
6163152|NCT01199289|9805708|FG002|Overall Study|Full consent withdrawn|2
6163153|NCT01199289|9805709|FG003|Overall Study|Full consent withdrawn|3
6163154|NCT01199289|9805706|FG000|Overall Study|Administrative decision|0
6163155|NCT01199289|9805707|FG001|Overall Study|Administrative decision|0
6163156|NCT01199289|9805708|FG002|Overall Study|Administrative decision|0
6163157|NCT01199289|9805709|FG003|Overall Study|Administrative decision|1
6326188|NCT02949271|10069401|FG000|Overall Study|Lack of Efficacy|5
6326189|NCT02949271|10069402|FG001|Overall Study|Lack of Efficacy|4
6326190|NCT02949271|10069401|FG000|Overall Study|Lost to Follow-up|3
6326191|NCT02949271|10069402|FG001|Overall Study|Lost to Follow-up|6
6326192|NCT02949271|10069401|FG000|Overall Study|Physician Decision|5
6326193|NCT02949271|10069402|FG001|Overall Study|Physician Decision|5
6326194|NCT02949271|10069401|FG000|Overall Study|Protocol Violation|6
6326195|NCT02949271|10069402|FG001|Overall Study|Protocol Violation|3
6326196|NCT02949271|10069401|FG000|Overall Study|Withdrawal by Subject|1
6326197|NCT02949271|10069402|FG001|Overall Study|Withdrawal by Subject|0
6326198|NCT02949271|10069401|FG000|Overall Study|Delivered prior to intervention|7
6326199|NCT02949271|10069402|FG001|Overall Study|Delivered prior to intervention|9
6326200|NCT02949271|10069401|FG000|Overall Study|Outside the window for cervical dilation|2
6326201|NCT02949271|10069402|FG001|Overall Study|Outside the window for cervical dilation|3
6326202|NCT02949362|10069410|FG000|Retrospective Period|Inform consent not signed by participant|4
6326203|NCT02949362|10069411|FG001|Retrospective Period|Inform consent not signed by participant|1
6326204|NCT02949362|10069412|FG002|Retrospective Period|Inform consent not signed by participant|0
6326205|NCT02949362|10069413|FG003|Retrospective Period|Inform consent not signed by participant|0
6326206|NCT02949362|10069410|FG000|Prospective Period|Discontinued the study early but didn't complete an ET Visit.|0
6326207|NCT02949362|10069411|FG001|Prospective Period|Discontinued the study early but didn't complete an ET Visit.|0
6326208|NCT02949362|10069412|FG002|Prospective Period|Discontinued the study early but didn't complete an ET Visit.|1
6326209|NCT02949362|10069413|FG003|Prospective Period|Discontinued the study early but didn't complete an ET Visit.|0
6326210|NCT02949362|10069410|FG000|Prospective Period|Other|0
6326211|NCT02949362|10069411|FG001|Prospective Period|Other|0
6326212|NCT02949362|10069412|FG002|Prospective Period|Other|0
6326213|NCT02949362|10069413|FG003|Prospective Period|Other|4
6326214|NCT02949908|10069449|FG000|Overall Study|Study termination|2
6326215|NCT02949973|10069462|FG000|Overall Study|Physician Decision|1
6326216|NCT02950545|10069485|FG000|Session 1 (70 Minutes)|Withdrawal by Subject|0
6326217|NCT02950545|10069486|FG001|Session 1 (70 Minutes)|Withdrawal by Subject|0
6326218|NCT02950545|10069487|FG002|Session 1 (70 Minutes)|Withdrawal by Subject|0
6326219|NCT02950545|10069488|FG003|Session 1 (70 Minutes)|Withdrawal by Subject|0
6326220|NCT02950545|10069489|FG004|Session 1 (70 Minutes)|Withdrawal by Subject|0
6326221|NCT02950545|10069490|FG005|Session 1 (70 Minutes)|Withdrawal by Subject|1
6326222|NCT02950545|10069485|FG000|Washout 1 (5 Minutes)|Withdrawal by Subject|1
6326223|NCT02950545|10069486|FG001|Washout 1 (5 Minutes)|Withdrawal by Subject|0
6326224|NCT02950545|10069487|FG002|Washout 1 (5 Minutes)|Withdrawal by Subject|0
6326225|NCT02950545|10069488|FG003|Washout 1 (5 Minutes)|Withdrawal by Subject|1
6163158|NCT01199289|9805706|FG000|Overall Study|Lost to Follow-up|0
6163159|NCT01199289|9805707|FG001|Overall Study|Lost to Follow-up|0
6163160|NCT01199289|9805708|FG002|Overall Study|Lost to Follow-up|0
6163161|NCT01199289|9805709|FG003|Overall Study|Lost to Follow-up|1
6163162|NCT01199289|9805706|FG000|Overall Study|Protocol-specified criteria|3
6163163|NCT01199289|9805707|FG001|Overall Study|Protocol-specified criteria|0
6163164|NCT01199289|9805708|FG002|Overall Study|Protocol-specified criteria|0
6163165|NCT01199289|9805709|FG003|Overall Study|Protocol-specified criteria|1
6163166|NCT01199289|9805706|FG000|Overall Study|Pregnancy|0
6163167|NCT01199289|9805707|FG001|Overall Study|Pregnancy|1
6163168|NCT01199289|9805708|FG002|Overall Study|Pregnancy|0
6163169|NCT01199289|9805709|FG003|Overall Study|Pregnancy|1
6163170|NCT01199471|9805722|FG000|Overall Study|Protocol Violation|4
6163171|NCT01199471|9805722|FG000|Overall Study|Withdrawal by Subject|1
6163172|NCT01199471|9805722|FG000|Overall Study|Physician Decision|1
6163173|NCT01199575|9805727|FG000|Overall Study|Withdrawal by Subject|5
6163174|NCT01199601|9805734|FG000|Overall Study|Lost to Follow-up|47
6163175|NCT01199601|9805735|FG001|Overall Study|Lost to Follow-up|66
6163176|NCT01199601|9805734|FG000|Overall Study|Withdrawal by Subject|15
6163177|NCT01199601|9805735|FG001|Overall Study|Withdrawal by Subject|3
6163178|NCT01199601|9805734|FG000|Overall Study|Insecurity prevented staff interviewing.|7
6163179|NCT01199601|9805735|FG001|Overall Study|Insecurity prevented staff interviewing.|9
6163180|NCT01199705|9805741|FG000|SCIG Treatment (Wash-in/Wash-out)|Transfer of Residence|1
6163181|NCT01199731|9805759|FG000|Overall Study|Adverse Event|0
6163182|NCT01199731|9805760|FG001|Overall Study|Adverse Event|1
6163183|NCT01199731|9805761|FG002|Overall Study|Adverse Event|0
6163184|NCT01199731|9805759|FG000|Overall Study|Study closed/terminated|7
6163185|NCT01199731|9805760|FG001|Overall Study|Study closed/terminated|9
6163186|NCT01199731|9805761|FG002|Overall Study|Study closed/terminated|7
6163187|NCT01199731|9805759|FG000|Overall Study|Lost to Follow-up|0
6163188|NCT01199731|9805760|FG001|Overall Study|Lost to Follow-up|0
6163189|NCT01199731|9805761|FG002|Overall Study|Lost to Follow-up|2
6163190|NCT01199731|9805759|FG000|Overall Study|Physician Decision|0
6163191|NCT01199731|9805760|FG001|Overall Study|Physician Decision|1
6163192|NCT01199731|9805761|FG002|Overall Study|Physician Decision|1
6163193|NCT01199731|9805759|FG000|Overall Study|Withdrawal by Subject|2
6163194|NCT01199731|9805760|FG001|Overall Study|Withdrawal by Subject|0
6163195|NCT01199731|9805761|FG002|Overall Study|Withdrawal by Subject|0
6163196|NCT01199822|9805776|FG000|Overall Study|Investigator discontinued therapy|0
6163197|NCT01199822|9805777|FG001|Overall Study|Investigator discontinued therapy|1
6163198|NCT01199822|9805778|FG002|Overall Study|Investigator discontinued therapy|0
6163199|NCT01199861|9805805|FG000|Overall Study|Administrative problems|1
6163200|NCT01199861|9805806|FG001|Overall Study|Administrative problems|0
6163201|NCT01199861|9805805|FG000|Overall Study|Adverse Event|1
6163202|NCT01199861|9805806|FG001|Overall Study|Adverse Event|0
6163203|NCT01199939|9805821|FG000|Overall Study|Adverse Event|4
6163204|NCT01199939|9805821|FG000|Overall Study|Protocol Violation|3
6163205|NCT01199939|9805821|FG000|Overall Study|Lost to Follow-up|2
6163206|NCT01199939|9805821|FG000|Overall Study|Reached a virologic endpoint|4
6163207|NCT01200069|9805867|FG000|Overall Study|Withdrawal by Subject|0
6163208|NCT01200069|9805868|FG001|Overall Study|Withdrawal by Subject|1
6163209|NCT01200238|9805923|FG000|Overall Study|Adverse Event|2
6163210|NCT01200238|9805924|FG001|Overall Study|Adverse Event|1
6163211|NCT01200238|9805923|FG000|Overall Study|Progressive Disease|5
6163212|NCT01200238|9805924|FG001|Overall Study|Progressive Disease|8
6163213|NCT01200238|9805923|FG000|Overall Study|Withdrawal by Subject|0
6163214|NCT01200238|9805924|FG001|Overall Study|Withdrawal by Subject|1
6163215|NCT01200290|9805930|FG000|Treatment Period|Adverse Event|1
6163216|NCT01200290|9805930|FG000|Post-Treatment Follow-Up Period|Death|2
6326226|NCT02950545|10069489|FG004|Washout 1 (5 Minutes)|Withdrawal by Subject|0
6326227|NCT02950545|10069490|FG005|Washout 1 (5 Minutes)|Withdrawal by Subject|1
6326228|NCT02950545|10069485|FG000|Session 2 (70 Minutes)|Withdrawal by Subject|0
6326229|NCT02950545|10069486|FG001|Session 2 (70 Minutes)|Withdrawal by Subject|0
6326230|NCT02950545|10069487|FG002|Session 2 (70 Minutes)|Withdrawal by Subject|0
6326231|NCT02950545|10069488|FG003|Session 2 (70 Minutes)|Withdrawal by Subject|0
6326232|NCT02950545|10069489|FG004|Session 2 (70 Minutes)|Withdrawal by Subject|1
6326233|NCT02950545|10069490|FG005|Session 2 (70 Minutes)|Withdrawal by Subject|0
6326234|NCT02950545|10069485|FG000|Washout 2 (5 Minutes)|Withdrawal by Subject|1
6326235|NCT02950545|10069486|FG001|Washout 2 (5 Minutes)|Withdrawal by Subject|0
6326236|NCT02950545|10069487|FG002|Washout 2 (5 Minutes)|Withdrawal by Subject|0
6326237|NCT02950545|10069488|FG003|Washout 2 (5 Minutes)|Withdrawal by Subject|0
6326238|NCT02950545|10069489|FG004|Washout 2 (5 Minutes)|Withdrawal by Subject|0
6326239|NCT02950545|10069490|FG005|Washout 2 (5 Minutes)|Withdrawal by Subject|0
6326240|NCT02950545|10069485|FG000|Session 3 (70 Minutes)|Withdrawal by Subject|0
6163217|NCT01200329|9805934|FG000|Overall Study|Lack of financial coverage|2
6163218|NCT01200329|9805934|FG000|Overall Study|Progressive disease|1
6163219|NCT01200342|9805938|FG000|Overall Study|Disease Progression|1
6163220|NCT01200355|9805944|FG000|Overall Study|Death|7
6163221|NCT01200355|9805945|FG001|Overall Study|Death|2
6163222|NCT01200368|9805954|FG000|Infant Series|Adverse Event|2
6326241|NCT02950545|10069486|FG001|Session 3 (70 Minutes)|Withdrawal by Subject|0
6326242|NCT02950545|10069487|FG002|Session 3 (70 Minutes)|Withdrawal by Subject|0
6163223|NCT01200368|9805955|FG001|Infant Series|Adverse Event|2
6163224|NCT01200368|9805956|FG002|Infant Series|Adverse Event|3
6163225|NCT01200368|9805954|FG000|Infant Series|Withdrawal by Subject|0
6163226|NCT01200368|9805955|FG001|Infant Series|Withdrawal by Subject|2
6163227|NCT01200368|9805956|FG002|Infant Series|Withdrawal by Subject|2
6163228|NCT01200368|9805954|FG000|Infant Series|Did not meet entrance criteria|0
6163229|NCT01200368|9805955|FG001|Infant Series|Did not meet entrance criteria|1
6163230|NCT01200368|9805956|FG002|Infant Series|Did not meet entrance criteria|0
6163231|NCT01200368|9805954|FG000|Infant Series|Randomized, not vaccinated|0
6163232|NCT01200368|9805955|FG001|Infant Series|Randomized, not vaccinated|1
6163233|NCT01200368|9805956|FG002|Infant Series|Randomized, not vaccinated|1
6163234|NCT01200368|9805954|FG000|Infant Series|Other|1
6163235|NCT01200368|9805955|FG001|Infant Series|Other|0
6163236|NCT01200368|9805956|FG002|Infant Series|Other|0
6163237|NCT01200368|9805954|FG000|After Infant Series|Adverse Event|6
6163238|NCT01200368|9805955|FG001|After Infant Series|Adverse Event|6
6163239|NCT01200368|9805956|FG002|After Infant Series|Adverse Event|3
6163240|NCT01200368|9805954|FG000|After Infant Series|Withdrawal by Subject|10
6163241|NCT01200368|9805955|FG001|After Infant Series|Withdrawal by Subject|8
6163242|NCT01200368|9805956|FG002|After Infant Series|Withdrawal by Subject|4
6163243|NCT01200368|9805954|FG000|After Infant Series|Lost to Follow-up|1
6163244|NCT01200368|9805955|FG001|After Infant Series|Lost to Follow-up|0
6163245|NCT01200368|9805956|FG002|After Infant Series|Lost to Follow-up|0
6163246|NCT01200368|9805954|FG000|After Infant Series|Other|1
6163247|NCT01200368|9805955|FG001|After Infant Series|Other|2
6163248|NCT01200368|9805956|FG002|After Infant Series|Other|2
6163249|NCT01200368|9805954|FG000|Toddler Dose|Adverse Event|0
6163250|NCT01200368|9805955|FG001|Toddler Dose|Adverse Event|3
6163251|NCT01200368|9805956|FG002|Toddler Dose|Adverse Event|1
6163252|NCT01200394|9805973|FG000|Overall Study|Adverse Event|0
6163253|NCT01200394|9805974|FG001|Overall Study|Adverse Event|14
6163254|NCT01200394|9805973|FG000|Overall Study|Death|1
6163255|NCT01200394|9805974|FG001|Overall Study|Death|0
6163256|NCT01200394|9805973|FG000|Overall Study|Lost to Follow-up|0
6326243|NCT02950545|10069488|FG003|Session 3 (70 Minutes)|Withdrawal by Subject|0
6326244|NCT02950545|10069489|FG004|Session 3 (70 Minutes)|Withdrawal by Subject|0
6326245|NCT02950545|10069490|FG005|Session 3 (70 Minutes)|Withdrawal by Subject|1
6326246|NCT02950558|10069498|FG000|Overall Study|Lost to Follow-up|2
6326247|NCT02950558|10069499|FG001|Overall Study|Lost to Follow-up|0
6326248|NCT02950831|10069515|FG000|Overall Study|Lost to Follow-up|1
6326249|NCT02950831|10069515|FG000|Overall Study|Withdrawal by Subject|3
6326250|NCT02950831|10069515|FG000|Overall Study|stimulation trail failure|5
6326251|NCT02951156|10069547|FG000|Overall Study|Death|3
6326252|NCT02951156|10069548|FG001|Overall Study|Death|8
6326253|NCT02951156|10069549|FG002|Overall Study|Death|5
6326254|NCT02951156|10069547|FG000|Overall Study|Progressive disease|1
6326255|NCT02951156|10069548|FG001|Overall Study|Progressive disease|0
6326256|NCT02951156|10069549|FG002|Overall Study|Progressive disease|1
6326257|NCT02951156|10069547|FG000|Overall Study|Withdrawal by Subject|0
6326258|NCT02951156|10069548|FG001|Overall Study|Withdrawal by Subject|0
6326259|NCT02951156|10069549|FG002|Overall Study|Withdrawal by Subject|1
6326260|NCT02951156|10069547|FG000|Overall Study|Study terminated by sponsor|0
6326261|NCT02951156|10069548|FG001|Overall Study|Study terminated by sponsor|0
6326262|NCT02951156|10069549|FG002|Overall Study|Study terminated by sponsor|1
6326263|NCT02951156|10069547|FG000|Overall Study|Other|5
6326264|NCT02951156|10069548|FG001|Overall Study|Other|1
6326265|NCT02951156|10069549|FG002|Overall Study|Other|2
6326266|NCT02951429|10069674|FG000|Overall Study|Adverse Event|3
6326267|NCT02951429|10069675|FG001|Overall Study|Adverse Event|7
6326268|NCT02951429|10069674|FG000|Overall Study|Death|28
6326269|NCT02951429|10069675|FG001|Overall Study|Death|36
6326270|NCT02951429|10069674|FG000|Overall Study|Lack of Efficacy|0
6326271|NCT02951429|10069675|FG001|Overall Study|Lack of Efficacy|1
6326272|NCT02951429|10069674|FG000|Overall Study|Lost to Follow-up|0
6326273|NCT02951429|10069675|FG001|Overall Study|Lost to Follow-up|1
6326274|NCT02951429|10069674|FG000|Overall Study|Lung Transplantation|9
6326275|NCT02951429|10069675|FG001|Overall Study|Lung Transplantation|6
6326276|NCT02951429|10069674|FG000|Overall Study|Other|1
6326277|NCT02951429|10069675|FG001|Overall Study|Other|3
6326278|NCT02951429|10069674|FG000|Overall Study|Progressive Disease|1
6163257|NCT01200394|9805974|FG001|Overall Study|Lost to Follow-up|1
6163258|NCT01200394|9805973|FG000|Overall Study|Did Not Meet Entrance Criteria|1
6163259|NCT01200394|9805974|FG001|Overall Study|Did Not Meet Entrance Criteria|4
6326279|NCT02951429|10069675|FG001|Overall Study|Progressive Disease|1
6326280|NCT02951429|10069674|FG000|Overall Study|Withdrawal by Subject|7
6326281|NCT02951429|10069675|FG001|Overall Study|Withdrawal by Subject|11
6326282|NCT02951429|10069674|FG000|Overall Study|Participant ongoing in the study|23
6163260|NCT01200394|9805973|FG000|Overall Study|Protocol Violation|0
6163261|NCT01200394|9805974|FG001|Overall Study|Protocol Violation|3
6163262|NCT01200394|9805973|FG000|Overall Study|Withdrawal by Subject|0
6163263|NCT01200394|9805974|FG001|Overall Study|Withdrawal by Subject|5
6163264|NCT01200394|9805973|FG000|Overall Study|Other|0
6326283|NCT02951429|10069675|FG001|Overall Study|Participant ongoing in the study|17
6326284|NCT02951533|10069683|FG000|Part I (Week 0 Through Week 24)|Adverse Event|0
6326285|NCT02951533|10069684|FG001|Part I (Week 0 Through Week 24)|Adverse Event|16
6326286|NCT02951533|10069685|FG002|Part I (Week 0 Through Week 24)|Adverse Event|0
6326287|NCT02951533|10069683|FG000|Part I (Week 0 Through Week 24)|Lost to Follow-up|2
6163265|NCT01200394|9805974|FG001|Overall Study|Other|1
6163266|NCT01200407|9805981|FG000|Overall Study|Lost to Follow-up|56
6163267|NCT01200407|9805981|FG000|Overall Study|Adverse Event|3
6163268|NCT01200407|9805981|FG000|Overall Study|Withdrawal by Subject|4
6163269|NCT01200407|9805981|FG000|Overall Study|Other|19
6326288|NCT02951533|10069684|FG001|Part I (Week 0 Through Week 24)|Lost to Follow-up|2
6163270|NCT01200485|9805994|FG000|Cycle 1: Rasburicase Alone Delivery|Withdrawal by Subject|1
6163271|NCT01200485|9805995|FG001|Cycle 1: Rasburicase Alone Delivery|Withdrawal by Subject|0
6163272|NCT01200485|9805996|FG002|Cycle 1: Rasburicase Alone Delivery|Withdrawal by Subject|0
6163273|NCT01200485|9805994|FG000|Cycle 1: Rasburicase Alone Delivery|Insurance Coverage Denied|2
6163274|NCT01200485|9805995|FG001|Cycle 1: Rasburicase Alone Delivery|Insurance Coverage Denied|0
6163275|NCT01200485|9805996|FG002|Cycle 1: Rasburicase Alone Delivery|Insurance Coverage Denied|0
6163276|NCT01200511|9806007|FG000|Overall Study|Lost to Follow-up|3
6163277|NCT01200511|9806007|FG000|Overall Study|Withdrawal by Subject|1
6163278|NCT01200511|9806007|FG000|Overall Study|Adverse Event|1
6163279|NCT01200524|9806016|FG000|Overall Study|Withdrawal by Subject|1
6163280|NCT01200524|9806017|FG001|Overall Study|Withdrawal by Subject|1
6163281|NCT01200524|9806018|FG002|Overall Study|Withdrawal by Subject|3
6163282|NCT01200524|9806016|FG000|Overall Study|Adverse Event|1
6163283|NCT01200524|9806017|FG001|Overall Study|Adverse Event|0
6163284|NCT01200524|9806018|FG002|Overall Study|Adverse Event|0
6163285|NCT01200524|9806016|FG000|Overall Study|Non availability of study nurse|0
6163286|NCT01200524|9806017|FG001|Overall Study|Non availability of study nurse|0
6163287|NCT01200524|9806018|FG002|Overall Study|Non availability of study nurse|1
6163288|NCT01200589|9806028|FG000|Overall Study|Withdrawal by Subject|13
6163289|NCT01200589|9806029|FG001|Overall Study|Withdrawal by Subject|11
6163290|NCT01200589|9806028|FG000|Overall Study|Physician Decision|2
6163291|NCT01200589|9806029|FG001|Overall Study|Physician Decision|2
6163292|NCT01200589|9806028|FG000|Overall Study|Lost to Follow-up|5
6163293|NCT01200589|9806029|FG001|Overall Study|Lost to Follow-up|4
6163294|NCT01200589|9806028|FG000|Overall Study|Study terminated|170
6163295|NCT01200589|9806029|FG001|Overall Study|Study terminated|172
6163296|NCT01200758|9806037|FG000|Stage I|Death|0
6163297|NCT01200758|9806038|FG001|Stage I|Death|1
6163298|NCT01200758|9806039|FG002|Stage I|Death|0
6163299|NCT01200758|9806040|FG003|Stage I|Death|0
6163300|NCT01200758|9806037|FG000|Stage I|Physician Decision|1
6163301|NCT01200758|9806038|FG001|Stage I|Physician Decision|1
6163302|NCT01200758|9806039|FG002|Stage I|Physician Decision|0
6163303|NCT01200758|9806040|FG003|Stage I|Physician Decision|0
6163304|NCT01200758|9806037|FG000|Stage I|Lack of Efficacy|2
6163305|NCT01200758|9806038|FG001|Stage I|Lack of Efficacy|1
6163306|NCT01200758|9806039|FG002|Stage I|Lack of Efficacy|0
6163307|NCT01200758|9806040|FG003|Stage I|Lack of Efficacy|0
6163308|NCT01200758|9806037|FG000|Stage I|Adverse Event|5
6163309|NCT01200758|9806038|FG001|Stage I|Adverse Event|5
6163310|NCT01200758|9806039|FG002|Stage I|Adverse Event|0
6163311|NCT01200758|9806040|FG003|Stage I|Adverse Event|0
6163312|NCT01200758|9806037|FG000|Stage I|Withdrawal by Subject|1
6163313|NCT01200758|9806038|FG001|Stage I|Withdrawal by Subject|2
6163314|NCT01200758|9806039|FG002|Stage I|Withdrawal by Subject|0
6163315|NCT01200758|9806040|FG003|Stage I|Withdrawal by Subject|0
6163316|NCT01200758|9806037|FG000|Stage I|Disease Progression|9
6163317|NCT01200758|9806038|FG001|Stage I|Disease Progression|7
6163318|NCT01200758|9806039|FG002|Stage I|Disease Progression|0
6163319|NCT01200758|9806040|FG003|Stage I|Disease Progression|0
6163320|NCT01200758|9806037|FG000|Stage 2|Disease Progression|0
6163321|NCT01200758|9806038|FG001|Stage 2|Disease Progression|0
6163322|NCT01200758|9806039|FG002|Stage 2|Disease Progression|16
6163323|NCT01200758|9806040|FG003|Stage 2|Disease Progression|21
6163324|NCT01200758|9806037|FG000|Stage 2|Lack of Efficacy|0
6163325|NCT01200758|9806038|FG001|Stage 2|Lack of Efficacy|0
6163326|NCT01200758|9806039|FG002|Stage 2|Lack of Efficacy|4
6163327|NCT01200758|9806040|FG003|Stage 2|Lack of Efficacy|2
6163328|NCT01200758|9806037|FG000|Stage 2|Physician Decision|0
6163329|NCT01200758|9806038|FG001|Stage 2|Physician Decision|0
6163330|NCT01200758|9806039|FG002|Stage 2|Physician Decision|5
6163331|NCT01200758|9806040|FG003|Stage 2|Physician Decision|7
6163332|NCT01200758|9806037|FG000|Stage 2|Adverse Event|0
6163333|NCT01200758|9806038|FG001|Stage 2|Adverse Event|0
6163334|NCT01200758|9806039|FG002|Stage 2|Adverse Event|5
6163335|NCT01200758|9806040|FG003|Stage 2|Adverse Event|9
6163336|NCT01200758|9806037|FG000|Stage 2|Withdrawal by Subject|0
6163337|NCT01200758|9806038|FG001|Stage 2|Withdrawal by Subject|0
6163338|NCT01200758|9806039|FG002|Stage 2|Withdrawal by Subject|4
6163339|NCT01200758|9806040|FG003|Stage 2|Withdrawal by Subject|1
6163340|NCT01200758|9806037|FG000|Stage 2|Lost to Follow-up|0
6163341|NCT01200758|9806038|FG001|Stage 2|Lost to Follow-up|0
6163342|NCT01200758|9806039|FG002|Stage 2|Lost to Follow-up|3
6163343|NCT01200758|9806040|FG003|Stage 2|Lost to Follow-up|1
6163344|NCT01200758|9806037|FG000|Stage 2|Protocol Violation|0
6163345|NCT01200758|9806038|FG001|Stage 2|Protocol Violation|0
6163346|NCT01200758|9806039|FG002|Stage 2|Protocol Violation|1
6163347|NCT01200758|9806040|FG003|Stage 2|Protocol Violation|4
6163348|NCT01200758|9806037|FG000|Stage 2|Death|0
6163349|NCT01200758|9806038|FG001|Stage 2|Death|0
6163350|NCT01200758|9806039|FG002|Stage 2|Death|3
6163351|NCT01200758|9806040|FG003|Stage 2|Death|5
6163352|NCT01200797|9806052|FG000|Overall Study|symptomatic deterioration|2
6163353|NCT01200797|9806052|FG000|Overall Study|Adverse Event|4
6163354|NCT01200797|9806052|FG000|Overall Study|Disease Progression|13
6163355|NCT01200810|9806059|FG000|Overall Study|Physician Decision|1
6163356|NCT01200810|9806060|FG001|Overall Study|Physician Decision|0
6163357|NCT01200810|9806059|FG000|Overall Study|Withdrawal by Subject|1
6163358|NCT01200810|9806060|FG001|Overall Study|Withdrawal by Subject|2
6163359|NCT01200810|9806059|FG000|Overall Study|Sponsor stopped making study drug|3
6163360|NCT01200810|9806060|FG001|Overall Study|Sponsor stopped making study drug|3
6163361|NCT01200992|9806072|FG000|Overall Study|Study terminated early|35
6163362|NCT01200992|9806073|FG001|Overall Study|Study terminated early|41
6163363|NCT01200992|9806072|FG000|Overall Study|Randomized but not treated|2
6163364|NCT01200992|9806073|FG001|Overall Study|Randomized but not treated|0
6163365|NCT01201265|9806098|FG000|Overall Study|Death|14
6163366|NCT01201265|9806098|FG000|Overall Study|Insufficient Therapeutic Response|3
6163367|NCT01201265|9806098|FG000|Overall Study|Lost to Follow-up|10
6163368|NCT01201265|9806098|FG000|Overall Study|Withdrawal by Subject|7
6163369|NCT01201265|9806098|FG000|Overall Study|Disease Progression|4
6163370|NCT01201317|9806105|FG000|Overall Study|Withdrawal by Subject|5
6163371|NCT01201317|9806106|FG001|Overall Study|Withdrawal by Subject|0
6163372|NCT01201317|9806107|FG002|Overall Study|Withdrawal by Subject|3
6163373|NCT01201317|9806105|FG000|Overall Study|Adverse Event|2
6163374|NCT01201317|9806106|FG001|Overall Study|Adverse Event|2
6163375|NCT01201317|9806107|FG002|Overall Study|Adverse Event|2
6163376|NCT01201317|9806105|FG000|Overall Study|Screen failure|1
6326289|NCT02951533|10069685|FG002|Part I (Week 0 Through Week 24)|Lost to Follow-up|0
6326290|NCT02951533|10069683|FG000|Part I (Week 0 Through Week 24)|Withdrawal by Subject|2
6326291|NCT02951533|10069684|FG001|Part I (Week 0 Through Week 24)|Withdrawal by Subject|4
6326292|NCT02951533|10069685|FG002|Part I (Week 0 Through Week 24)|Withdrawal by Subject|0
6326293|NCT02951533|10069683|FG000|Part I (Week 0 Through Week 24)|Noncompliance with Study Drug|0
6326294|NCT02951533|10069684|FG001|Part I (Week 0 Through Week 24)|Noncompliance with Study Drug|1
6326295|NCT02951533|10069685|FG002|Part I (Week 0 Through Week 24)|Noncompliance with Study Drug|0
6326296|NCT02951533|10069683|FG000|Part IIa (Week 24 Through Week 32)|Adverse Event|0
6326297|NCT02951533|10069684|FG001|Part IIa (Week 24 Through Week 32)|Adverse Event|1
6326298|NCT02951533|10069685|FG002|Part IIa (Week 24 Through Week 32)|Adverse Event|0
6326299|NCT02951533|10069683|FG000|Part IIa (Week 24 Through Week 32)|Withdrawal by Subject|1
6326300|NCT02951533|10069684|FG001|Part IIa (Week 24 Through Week 32)|Withdrawal by Subject|0
6326301|NCT02951533|10069685|FG002|Part IIa (Week 24 Through Week 32)|Withdrawal by Subject|0
6326302|NCT02951533|10069683|FG000|Part IIb (Week 32 Through Week 56)|Adverse Event|0
6326303|NCT02951533|10069684|FG001|Part IIb (Week 32 Through Week 56)|Adverse Event|2
6326304|NCT02951533|10069685|FG002|Part IIb (Week 32 Through Week 56)|Adverse Event|0
6326305|NCT02951533|10069683|FG000|Part IIb (Week 32 Through Week 56)|Lost to Follow-up|1
6326306|NCT02951533|10069684|FG001|Part IIb (Week 32 Through Week 56)|Lost to Follow-up|2
6326307|NCT02951533|10069685|FG002|Part IIb (Week 32 Through Week 56)|Lost to Follow-up|0
6326308|NCT02951533|10069683|FG000|Part III (Week 64 Through Week 100)|Prohibited Medication Therapy|1
6326309|NCT02951533|10069684|FG001|Part III (Week 64 Through Week 100)|Prohibited Medication Therapy|0
6326310|NCT02951533|10069685|FG002|Part III (Week 64 Through Week 100)|Prohibited Medication Therapy|0
6326311|NCT02951533|10069683|FG000|Part III (Week 64 Through Week 100)|Lost to Follow-up|1
6326312|NCT02951533|10069684|FG001|Part III (Week 64 Through Week 100)|Lost to Follow-up|0
6326313|NCT02951533|10069685|FG002|Part III (Week 64 Through Week 100)|Lost to Follow-up|0
6326314|NCT02951533|10069683|FG000|Part III (Week 64 Through Week 100)|Withdrawal by Subject|2
6326315|NCT02951533|10069684|FG001|Part III (Week 64 Through Week 100)|Withdrawal by Subject|0
6326316|NCT02951533|10069685|FG002|Part III (Week 64 Through Week 100)|Withdrawal by Subject|2
6326317|NCT02951780|10069720|FG000|Period 1|Adverse Event|0
6326318|NCT02951780|10069721|FG001|Period 1|Adverse Event|0
6326319|NCT02951780|10069722|FG002|Period 1|Adverse Event|0
6326320|NCT02951780|10069723|FG003|Period 1|Adverse Event|1
6326321|NCT02951780|10069724|FG004|Period 1|Adverse Event|0
6326322|NCT02951780|10069725|FG005|Period 1|Adverse Event|0
6326323|NCT02951780|10069726|FG006|Period 1|Adverse Event|0
6326324|NCT02951780|10069727|FG007|Period 1|Adverse Event|0
6326325|NCT02951780|10069728|FG008|Period 1|Adverse Event|0
6326326|NCT02951780|10069720|FG000|Period 1|Scheduling Conflicts|0
6326327|NCT02951780|10069721|FG001|Period 1|Scheduling Conflicts|0
6326328|NCT02951780|10069722|FG002|Period 1|Scheduling Conflicts|0
6326329|NCT02951780|10069723|FG003|Period 1|Scheduling Conflicts|0
6326330|NCT02951780|10069724|FG004|Period 1|Scheduling Conflicts|0
6326331|NCT02951780|10069725|FG005|Period 1|Scheduling Conflicts|0
6326332|NCT02951780|10069726|FG006|Period 1|Scheduling Conflicts|0
6326333|NCT02951780|10069727|FG007|Period 1|Scheduling Conflicts|1
6326334|NCT02951780|10069728|FG008|Period 1|Scheduling Conflicts|0
6326335|NCT02951780|10069720|FG000|Period 2|Scheduling Conflicts|0
6326336|NCT02951780|10069721|FG001|Period 2|Scheduling Conflicts|0
6326337|NCT02951780|10069722|FG002|Period 2|Scheduling Conflicts|0
6326338|NCT02951780|10069723|FG003|Period 2|Scheduling Conflicts|0
6326339|NCT02951780|10069724|FG004|Period 2|Scheduling Conflicts|0
6326340|NCT02951780|10069725|FG005|Period 2|Scheduling Conflicts|0
6163377|NCT01201317|9806106|FG001|Overall Study|Screen failure|1
6163378|NCT01201317|9806107|FG002|Overall Study|Screen failure|0
6163379|NCT01201317|9806105|FG000|Overall Study|Protocol Violation|0
6163380|NCT01201317|9806106|FG001|Overall Study|Protocol Violation|1
6163381|NCT01201317|9806107|FG002|Overall Study|Protocol Violation|1
6326341|NCT02951780|10069726|FG006|Period 2|Scheduling Conflicts|0
6326342|NCT02951780|10069727|FG007|Period 2|Scheduling Conflicts|1
6163382|NCT01201317|9806105|FG000|Overall Study|Death|0
6163383|NCT01201317|9806106|FG001|Overall Study|Death|1
6163384|NCT01201317|9806107|FG002|Overall Study|Death|0
6163385|NCT01201317|9806105|FG000|Overall Study|Study-specific withdrawal criteria|0
6163386|NCT01201317|9806106|FG001|Overall Study|Study-specific withdrawal criteria|0
6163387|NCT01201317|9806107|FG002|Overall Study|Study-specific withdrawal criteria|1
6163388|NCT01201317|9806105|FG000|Overall Study|Painful Diabetic Neuropathy worsening|0
6163389|NCT01201317|9806106|FG001|Overall Study|Painful Diabetic Neuropathy worsening|1
6163390|NCT01201317|9806107|FG002|Overall Study|Painful Diabetic Neuropathy worsening|0
6163391|NCT01201317|9806105|FG000|Overall Study|Decrease in renal function|0
6163392|NCT01201317|9806106|FG001|Overall Study|Decrease in renal function|1
6163393|NCT01201317|9806107|FG002|Overall Study|Decrease in renal function|0
6163394|NCT01201317|9806105|FG000|Overall Study|Lack of Efficacy|1
6163395|NCT01201317|9806106|FG001|Overall Study|Lack of Efficacy|0
6163396|NCT01201317|9806107|FG002|Overall Study|Lack of Efficacy|0
6163397|NCT01201317|9806105|FG000|Overall Study|Safety, possible history of tuberculosis|0
6163398|NCT01201317|9806106|FG001|Overall Study|Safety, possible history of tuberculosis|0
6163399|NCT01201317|9806107|FG002|Overall Study|Safety, possible history of tuberculosis|1
6163400|NCT01201343|9806115|FG000|Overall Study|Adverse Event|6
6163401|NCT01201343|9806115|FG000|Overall Study|Withdrawal by Subject|5
6163402|NCT01201343|9806115|FG000|Overall Study|Lost to Follow-up|2
6163403|NCT01201343|9806115|FG000|Overall Study|Lack of Efficacy|2
6163404|NCT01201343|9806115|FG000|Overall Study|Participant wrongly included in trial|1
6163405|NCT01201343|9806115|FG000|Overall Study|Randomized, not treated|3
6163406|NCT01201356|9806119|FG000|Overall Study|Adverse Event|170
6163407|NCT01201356|9806119|FG000|Overall Study|Abnormal laboratory value(s)|51
6163408|NCT01201356|9806119|FG000|Overall Study|Abnormal test procedure result(s)|3
6163409|NCT01201356|9806119|FG000|Overall Study|Unsatisfactory therapeutic effect|112
6163410|NCT01201356|9806119|FG000|Overall Study|Condition no longer requires study drug|12
6163411|NCT01201356|9806119|FG000|Overall Study|Withdrawal by Subject|144
6163412|NCT01201356|9806119|FG000|Overall Study|Lost to Follow-up|50
6163413|NCT01201356|9806119|FG000|Overall Study|administrative problems|74
6163414|NCT01201356|9806119|FG000|Overall Study|Death|16
6163415|NCT01201356|9806119|FG000|Overall Study|Protocol Violation|12
6163416|NCT01201759|9806138|FG000|Visit 1 Wash-in ( Untreated)|Lost to Follow-up|2
6326343|NCT02951780|10069728|FG008|Period 2|Scheduling Conflicts|0
6326344|NCT02951819|10069750|FG000|Overall Study|Death|9
6326345|NCT02951819|10069751|FG001|Overall Study|Death|7
6326346|NCT02951819|10069750|FG000|Overall Study|Withdrawal by Subject|3
6326347|NCT02951819|10069751|FG001|Overall Study|Withdrawal by Subject|0
6326348|NCT02951819|10069750|FG000|Overall Study|Adverse Event|1
6326349|NCT02951819|10069751|FG001|Overall Study|Adverse Event|0
6326350|NCT02951819|10069750|FG000|Overall Study|Lack of Efficacy|4
6326351|NCT02951819|10069751|FG001|Overall Study|Lack of Efficacy|0
6326352|NCT02951819|10069750|FG000|Overall Study|Lost to Follow-up|1
6163417|NCT01201759|9806139|FG001|Visit 1 Wash-in ( Untreated)|Lost to Follow-up|1
6163418|NCT01201759|9806138|FG000|Visit 3 - Washout|Adverse Event|0
6163419|NCT01201759|9806139|FG001|Visit 3 - Washout|Adverse Event|3
6163420|NCT01201759|9806138|FG000|Visit 3 - Washout|Lost to Follow-up|1
6163421|NCT01201759|9806139|FG001|Visit 3 - Washout|Lost to Follow-up|0
6163422|NCT01201759|9806138|FG000|Visit 4 Crossover|Lost to Follow-up|0
6163423|NCT01201759|9806139|FG001|Visit 4 Crossover|Lost to Follow-up|1
6163424|NCT01201785|9806158|FG000|Overall Study|Lost to Follow-up|16
6163425|NCT01201798|9806164|FG000|Overall Study|Adverse Event|2
6163426|NCT01201798|9806165|FG001|Overall Study|Adverse Event|0
6163427|NCT01201798|9806164|FG000|Overall Study|Lost to Follow-up|3
6163428|NCT01201798|9806165|FG001|Overall Study|Lost to Follow-up|5
6163429|NCT01201798|9806164|FG000|Overall Study|Decision Unrelated to an Adverse Event|1
6163430|NCT01201798|9806165|FG001|Overall Study|Decision Unrelated to an Adverse Event|1
6163431|NCT01201798|9806164|FG000|Overall Study|Noncompliance|1
6163432|NCT01201798|9806165|FG001|Overall Study|Noncompliance|0
6163433|NCT01201798|9806164|FG000|Overall Study|Protocol Violation|1
6163434|NCT01201798|9806165|FG001|Overall Study|Protocol Violation|1
6163435|NCT01201798|9806164|FG000|Overall Study|Treatment Failure|1
6163436|NCT01201798|9806165|FG001|Overall Study|Treatment Failure|8
6163437|NCT01201811|9806171|FG000|Overall Study|Adverse Event|6
6163438|NCT01201811|9806171|FG000|Overall Study|Disease progression|3
6163439|NCT01201811|9806171|FG000|Overall Study|Withdrawal by Subject|3
6163440|NCT01201811|9806171|FG000|Overall Study|Death|4
6163441|NCT01201811|9806171|FG000|Overall Study|Treatment Failure|2
6163442|NCT01201811|9806171|FG000|Overall Study|Physician Decision|1
6163443|NCT01201850|9806175|FG000|Overall Study|Tumor progression|4
6163444|NCT01201915|9806195|FG000|Overall Study|Adverse Event|2
6163445|NCT01201915|9806196|FG001|Overall Study|Adverse Event|1
6163446|NCT01201915|9806197|FG002|Overall Study|Adverse Event|1
6163447|NCT01201915|9806195|FG000|Overall Study|Lost to Follow-up|0
6163448|NCT01201915|9806196|FG001|Overall Study|Lost to Follow-up|4
6163449|NCT01201915|9806197|FG002|Overall Study|Lost to Follow-up|0
6163450|NCT01201915|9806195|FG000|Overall Study|Physician Decision|3
6163451|NCT01201915|9806196|FG001|Overall Study|Physician Decision|0
6163452|NCT01201915|9806197|FG002|Overall Study|Physician Decision|0
6163453|NCT01201915|9806195|FG000|Overall Study|Subject Decision|3
6163454|NCT01201915|9806196|FG001|Overall Study|Subject Decision|3
6163455|NCT01201915|9806197|FG002|Overall Study|Subject Decision|5
6163456|NCT01201915|9806195|FG000|Overall Study|Target Lesion Progression|0
6163457|NCT01201915|9806196|FG001|Overall Study|Target Lesion Progression|3
6163458|NCT01201915|9806197|FG002|Overall Study|Target Lesion Progression|0
6163459|NCT01201967|9806207|FG000|Overall Study|Lost to Follow-up|6
6163460|NCT01201967|9806208|FG001|Overall Study|Lost to Follow-up|5
6163461|NCT01202175|9806239|FG000|Overall Study|Lost to Follow-up|2
6163462|NCT01202175|9806239|FG000|Overall Study|Withdrawal by Subject|1
6163463|NCT01202175|9806239|FG000|Overall Study|Adverse Event|2
6163464|NCT01202188|9806249|FG000|Overall Study|Protocol deviation|14
6163465|NCT01202188|9806250|FG001|Overall Study|Protocol deviation|8
6326353|NCT02951819|10069751|FG001|Overall Study|Lost to Follow-up|0
6326354|NCT02951819|10069750|FG000|Overall Study|Progressive Disease|1
6326355|NCT02951819|10069751|FG001|Overall Study|Progressive Disease|0
6326356|NCT02951819|10069750|FG000|Overall Study|Other|9
6326357|NCT02951819|10069751|FG001|Overall Study|Other|0
6326358|NCT02951988|10069773|FG000|Open-Label Treatment Period|Miscellaneous Reasons|8
6326359|NCT02951988|10069774|FG001|Open-Label Treatment Period|Miscellaneous Reasons|0
6326360|NCT02951988|10069775|FG002|Open-Label Treatment Period|Miscellaneous Reasons|0
6326361|NCT02951988|10069776|FG003|Open-Label Treatment Period|Miscellaneous Reasons|0
6326362|NCT02951988|10069773|FG000|Open-Label Treatment Period|Study terminated by sponsor|9
6326363|NCT02951988|10069774|FG001|Open-Label Treatment Period|Study terminated by sponsor|0
6326364|NCT02951988|10069775|FG002|Open-Label Treatment Period|Study terminated by sponsor|0
6326365|NCT02951988|10069776|FG003|Open-Label Treatment Period|Study terminated by sponsor|0
6326366|NCT02951988|10069773|FG000|Open-Label Treatment Period|Non-compliance with background ADT|2
6326367|NCT02951988|10069774|FG001|Open-Label Treatment Period|Non-compliance with background ADT|0
6326368|NCT02951988|10069775|FG002|Open-Label Treatment Period|Non-compliance with background ADT|0
6326369|NCT02951988|10069776|FG003|Open-Label Treatment Period|Non-compliance with background ADT|0
6326370|NCT02951988|10069773|FG000|Open-Label Treatment Period|Non-compliance with study drug|5
6326371|NCT02951988|10069774|FG001|Open-Label Treatment Period|Non-compliance with study drug|0
6326372|NCT02951988|10069775|FG002|Open-Label Treatment Period|Non-compliance with study drug|0
6326373|NCT02951988|10069776|FG003|Open-Label Treatment Period|Non-compliance with study drug|0
6326374|NCT02951988|10069773|FG000|Open-Label Treatment Period|Protocol Violation|22
6326375|NCT02951988|10069774|FG001|Open-Label Treatment Period|Protocol Violation|0
6326376|NCT02951988|10069775|FG002|Open-Label Treatment Period|Protocol Violation|0
6326377|NCT02951988|10069776|FG003|Open-Label Treatment Period|Protocol Violation|0
6326378|NCT02951988|10069773|FG000|Open-Label Treatment Period|Pregnancy|2
6082446|NCT00628251|9690417|FG001|Randomised Part|Withdrawal by Subject|0
6082447|NCT00628251|9690418|FG002|Randomised Part|Withdrawal by Subject|1
6082448|NCT00628251|9690416|FG000|Ongoing Initial Study Treatment at DCO|Adverse Event|1
6082449|NCT00628251|9690417|FG001|Ongoing Initial Study Treatment at DCO|Adverse Event|2
6163466|NCT01202188|9806251|FG002|Overall Study|Protocol deviation|12
6163467|NCT01202188|9806252|FG003|Overall Study|Protocol deviation|10
6163468|NCT01202188|9806253|FG004|Overall Study|Protocol deviation|11
6163469|NCT01202188|9806249|FG000|Overall Study|Subject withdrew consent|12
6163470|NCT01202188|9806250|FG001|Overall Study|Subject withdrew consent|13
6163471|NCT01202188|9806251|FG002|Overall Study|Subject withdrew consent|22
6163472|NCT01202188|9806252|FG003|Overall Study|Subject withdrew consent|11
6326379|NCT02951988|10069774|FG001|Open-Label Treatment Period|Pregnancy|0
6082450|NCT00628251|9690418|FG002|Ongoing Initial Study Treatment at DCO|Adverse Event|3
6082451|NCT00628251|9690416|FG000|Ongoing Initial Study Treatment at DCO|Condition under investigation worsened|19
6082452|NCT00628251|9690417|FG001|Ongoing Initial Study Treatment at DCO|Condition under investigation worsened|15
6082453|NCT00628251|9690418|FG002|Ongoing Initial Study Treatment at DCO|Condition under investigation worsened|13
6082454|NCT00628251|9690416|FG000|Ongoing Initial Study Treatment at DCO|Withdrawal by Subject|1
6082455|NCT00628251|9690417|FG001|Ongoing Initial Study Treatment at DCO|Withdrawal by Subject|2
6082456|NCT00628251|9690418|FG002|Ongoing Initial Study Treatment at DCO|Withdrawal by Subject|1
6082457|NCT00628251|9690416|FG000|Ongoing Initial Study Treatment at DCO|Other reason|0
6082458|NCT00628251|9690417|FG001|Ongoing Initial Study Treatment at DCO|Other reason|1
6082459|NCT00628251|9690418|FG002|Ongoing Initial Study Treatment at DCO|Other reason|6
6082460|NCT00628251|9690416|FG000|Ongoing Initial Study Treatment at DCO|Other|1
6082461|NCT00628251|9690417|FG001|Ongoing Initial Study Treatment at DCO|Other|0
6082462|NCT00628251|9690418|FG002|Ongoing Initial Study Treatment at DCO|Other|2
6082463|NCT00628355|9690430|FG000|Overall Study|Withdrawal by Subject|1
6082464|NCT00628355|9690431|FG001|Overall Study|Withdrawal by Subject|1
6082465|NCT00628758|9690487|FG000|Overall Study|Adverse Event|2
6082466|NCT00628758|9690488|FG001|Overall Study|Adverse Event|3
6082467|NCT00628758|9690487|FG000|Overall Study|Withdrawal by Subject|6
6082468|NCT00628758|9690488|FG001|Overall Study|Withdrawal by Subject|3
6082469|NCT00628758|9690487|FG000|Overall Study|Death|1
6082470|NCT00628758|9690488|FG001|Overall Study|Death|0
6082471|NCT00628758|9690487|FG000|Overall Study|Protocol Violation|5
6082472|NCT00628758|9690488|FG001|Overall Study|Protocol Violation|1
6082473|NCT00628758|9690487|FG000|Overall Study|Lost to Follow-up|25
6082474|NCT00628758|9690488|FG001|Overall Study|Lost to Follow-up|31
6082475|NCT00628758|9690487|FG000|Overall Study|Pregnancy|2
6082476|NCT00628758|9690488|FG001|Overall Study|Pregnancy|2
6082477|NCT00628758|9690487|FG000|Overall Study|Investigator Moved|3
6163473|NCT01202188|9806253|FG004|Overall Study|Subject withdrew consent|13
6163474|NCT01202188|9806249|FG000|Overall Study|Adverse Event|5
6163475|NCT01202188|9806250|FG001|Overall Study|Adverse Event|23
6163476|NCT01202188|9806251|FG002|Overall Study|Adverse Event|13
6163477|NCT01202188|9806252|FG003|Overall Study|Adverse Event|10
6163478|NCT01202188|9806253|FG004|Overall Study|Adverse Event|10
6163479|NCT01202188|9806249|FG000|Overall Study|Administrative problems|3
6163480|NCT01202188|9806250|FG001|Overall Study|Administrative problems|2
6163481|NCT01202188|9806251|FG002|Overall Study|Administrative problems|1
6163482|NCT01202188|9806252|FG003|Overall Study|Administrative problems|1
6163483|NCT01202188|9806253|FG004|Overall Study|Administrative problems|2
6163484|NCT01202188|9806249|FG000|Overall Study|Unsatisfactory therapeutic effect|2
6163485|NCT01202188|9806250|FG001|Overall Study|Unsatisfactory therapeutic effect|8
6163486|NCT01202188|9806251|FG002|Overall Study|Unsatisfactory therapeutic effect|2
6163487|NCT01202188|9806252|FG003|Overall Study|Unsatisfactory therapeutic effect|5
6163488|NCT01202188|9806253|FG004|Overall Study|Unsatisfactory therapeutic effect|8
6163489|NCT01202188|9806249|FG000|Overall Study|Lost to Follow-up|1
6163490|NCT01202188|9806250|FG001|Overall Study|Lost to Follow-up|1
6163491|NCT01202188|9806251|FG002|Overall Study|Lost to Follow-up|0
6163492|NCT01202188|9806252|FG003|Overall Study|Lost to Follow-up|4
6163493|NCT01202188|9806253|FG004|Overall Study|Lost to Follow-up|1
6163494|NCT01202188|9806249|FG000|Overall Study|Death|1
6163495|NCT01202188|9806250|FG001|Overall Study|Death|1
6163496|NCT01202188|9806251|FG002|Overall Study|Death|1
6163497|NCT01202188|9806252|FG003|Overall Study|Death|1
6163498|NCT01202188|9806253|FG004|Overall Study|Death|0
6163499|NCT01202188|9806249|FG000|Overall Study|Abnormal test procedure result (s)|0
6163500|NCT01202188|9806250|FG001|Overall Study|Abnormal test procedure result (s)|0
6163501|NCT01202188|9806251|FG002|Overall Study|Abnormal test procedure result (s)|2
6163502|NCT01202188|9806252|FG003|Overall Study|Abnormal test procedure result (s)|0
6163503|NCT01202188|9806253|FG004|Overall Study|Abnormal test procedure result (s)|0
6191940|NCT01426789|9848967|FG002|Part 1|Protocol deviation|0
6191941|NCT01426789|9848968|FG003|Part 1|Protocol deviation|0
6191942|NCT01426789|9848969|FG004|Part 1|Protocol deviation|0
6191943|NCT01426789|9848970|FG005|Part 1|Protocol deviation|0
6191944|NCT01426789|9848965|FG000|Part 1|Lost to Follow-up|1
6191945|NCT01426789|9848966|FG001|Part 1|Lost to Follow-up|2
6191946|NCT01426789|9848967|FG002|Part 1|Lost to Follow-up|0
6191947|NCT01426789|9848968|FG003|Part 1|Lost to Follow-up|0
6191948|NCT01426789|9848969|FG004|Part 1|Lost to Follow-up|0
6191949|NCT01426789|9848970|FG005|Part 1|Lost to Follow-up|0
6191950|NCT01426789|9848965|FG000|Part 1|Lack of Efficacy|2
6191951|NCT01426789|9848966|FG001|Part 1|Lack of Efficacy|1
6191952|NCT01426789|9848967|FG002|Part 1|Lack of Efficacy|0
6191953|NCT01426789|9848968|FG003|Part 1|Lack of Efficacy|0
6191954|NCT01426789|9848969|FG004|Part 1|Lack of Efficacy|0
6191955|NCT01426789|9848970|FG005|Part 1|Lack of Efficacy|0
6191956|NCT01426789|9848965|FG000|Part 1|Adverse Event|3
6191957|NCT01426789|9848966|FG001|Part 1|Adverse Event|0
6191958|NCT01426789|9848967|FG002|Part 1|Adverse Event|0
6191959|NCT01426789|9848968|FG003|Part 1|Adverse Event|0
6191960|NCT01426789|9848969|FG004|Part 1|Adverse Event|0
6191961|NCT01426789|9848970|FG005|Part 1|Adverse Event|0
6191962|NCT01426789|9848965|FG000|Part 2|Protocol deviation|0
6191963|NCT01426789|9848966|FG001|Part 2|Protocol deviation|0
6191964|NCT01426789|9848967|FG002|Part 2|Protocol deviation|1
6191965|NCT01426789|9848968|FG003|Part 2|Protocol deviation|0
6191966|NCT01426789|9848969|FG004|Part 2|Protocol deviation|0
6191967|NCT01426789|9848970|FG005|Part 2|Protocol deviation|0
6191968|NCT01426789|9848965|FG000|Part 2|Death|0
6191969|NCT01426789|9848966|FG001|Part 2|Death|0
6191970|NCT01426789|9848967|FG002|Part 2|Death|1
6191971|NCT01426789|9848968|FG003|Part 2|Death|0
6191972|NCT01426789|9848969|FG004|Part 2|Death|1
6191973|NCT01426789|9848970|FG005|Part 2|Death|0
6191974|NCT01426789|9848965|FG000|Part 2|Administrative problems|0
6191975|NCT01426789|9848966|FG001|Part 2|Administrative problems|0
6191976|NCT01426789|9848967|FG002|Part 2|Administrative problems|2
6191977|NCT01426789|9848968|FG003|Part 2|Administrative problems|0
6191978|NCT01426789|9848969|FG004|Part 2|Administrative problems|1
6191979|NCT01426789|9848970|FG005|Part 2|Administrative problems|0
6191980|NCT01426789|9848965|FG000|Part 2|Lost to Follow-up|0
6191981|NCT01426789|9848966|FG001|Part 2|Lost to Follow-up|0
6191982|NCT01426789|9848967|FG002|Part 2|Lost to Follow-up|4
6191983|NCT01426789|9848968|FG003|Part 2|Lost to Follow-up|0
6191984|NCT01426789|9848969|FG004|Part 2|Lost to Follow-up|1
6191985|NCT01426789|9848970|FG005|Part 2|Lost to Follow-up|0
6191986|NCT01426789|9848965|FG000|Part 2|Withdrawal by Subject|0
6191987|NCT01426789|9848966|FG001|Part 2|Withdrawal by Subject|0
6191988|NCT01426789|9848967|FG002|Part 2|Withdrawal by Subject|0
6191989|NCT01426789|9848968|FG003|Part 2|Withdrawal by Subject|1
6191990|NCT01426789|9848969|FG004|Part 2|Withdrawal by Subject|2
6191991|NCT01426789|9848970|FG005|Part 2|Withdrawal by Subject|0
6191992|NCT01426789|9848965|FG000|Part 2|Lack of Efficacy|0
6191993|NCT01426789|9848966|FG001|Part 2|Lack of Efficacy|0
6191994|NCT01426789|9848967|FG002|Part 2|Lack of Efficacy|5
6191995|NCT01426789|9848968|FG003|Part 2|Lack of Efficacy|0
6191996|NCT01426789|9848969|FG004|Part 2|Lack of Efficacy|2
6163504|NCT01202227|9806271|FG000|Overall Study|Adverse Event|16
6163505|NCT01202227|9806271|FG000|Overall Study|Withdrawal by Subject|2
6163506|NCT01202227|9806271|FG000|Overall Study|Lack of Efficacy|1
6163507|NCT01202279|9806281|FG000|Overall Study|Adverse Event|8
6163508|NCT01202279|9806282|FG001|Overall Study|Adverse Event|6
6163509|NCT01202279|9806281|FG000|Overall Study|Withdrawal by Subject|13
6163510|NCT01202279|9806282|FG001|Overall Study|Withdrawal by Subject|10
6163511|NCT01202279|9806281|FG000|Overall Study|Physician Decision|0
6163512|NCT01202279|9806282|FG001|Overall Study|Physician Decision|1
6163513|NCT01202279|9806281|FG000|Overall Study|Lost to Follow-up|10
6163514|NCT01202279|9806282|FG001|Overall Study|Lost to Follow-up|7
6163515|NCT01202279|9806281|FG000|Overall Study|Protocol Violation|1
6163516|NCT01202279|9806282|FG001|Overall Study|Protocol Violation|1
6163517|NCT01202279|9806281|FG000|Overall Study|study compliance|5
6163518|NCT01202279|9806282|FG001|Overall Study|study compliance|2
6163519|NCT01202409|9806288|FG000|Overall Study|Adverse Event|1
6163520|NCT01202409|9806288|FG000|Overall Study|Ineligible - KRAS mutants|7
6163521|NCT01202591|9806306|FG000|Overall Study|Adverse Event|2
6163522|NCT01202591|9806307|FG001|Overall Study|Adverse Event|1
6163523|NCT01202591|9806308|FG002|Overall Study|Adverse Event|4
6163524|NCT01202591|9806309|FG003|Overall Study|Adverse Event|4
6163525|NCT01202591|9806310|FG004|Overall Study|Adverse Event|0
6163526|NCT01202591|9806311|FG005|Overall Study|Adverse Event|0
6163527|NCT01202591|9806306|FG000|Overall Study|Other reason as per investigator|3
6163528|NCT01202591|9806307|FG001|Overall Study|Other reason as per investigator|4
6163529|NCT01202591|9806308|FG002|Overall Study|Other reason as per investigator|7
6163530|NCT01202591|9806309|FG003|Overall Study|Other reason as per investigator|3
6163531|NCT01202591|9806310|FG004|Overall Study|Other reason as per investigator|1
6163532|NCT01202591|9806311|FG005|Overall Study|Other reason as per investigator|3
6163533|NCT01202591|9806306|FG000|Overall Study|Withdrawal by Subject|0
6163534|NCT01202591|9806307|FG001|Overall Study|Withdrawal by Subject|0
6163535|NCT01202591|9806308|FG002|Overall Study|Withdrawal by Subject|0
6163536|NCT01202591|9806309|FG003|Overall Study|Withdrawal by Subject|0
6163537|NCT01202591|9806310|FG004|Overall Study|Withdrawal by Subject|2
6163538|NCT01202591|9806311|FG005|Overall Study|Withdrawal by Subject|1
6163539|NCT01202591|9806306|FG000|Overall Study|Objective Disease Progression|0
6163540|NCT01202591|9806307|FG001|Overall Study|Objective Disease Progression|0
6163541|NCT01202591|9806308|FG002|Overall Study|Objective Disease Progression|0
6163542|NCT01202591|9806309|FG003|Overall Study|Objective Disease Progression|0
6163543|NCT01202591|9806310|FG004|Overall Study|Objective Disease Progression|2
6163544|NCT01202591|9806311|FG005|Overall Study|Objective Disease Progression|0
6163545|NCT01202747|9806362|FG000|Overall Study|Withdrawal by Subject|1
6163546|NCT01202760|9806369|FG000|Overall Study|Entry Criteria Not Met|0
6163547|NCT01202760|9806370|FG001|Overall Study|Entry Criteria Not Met|3
6163548|NCT01202760|9806371|FG002|Overall Study|Entry Criteria Not Met|1
6163549|NCT01202760|9806369|FG000|Overall Study|Adverse Event|11
6163550|NCT01202760|9806370|FG001|Overall Study|Adverse Event|9
6163551|NCT01202760|9806371|FG002|Overall Study|Adverse Event|10
6163552|NCT01202760|9806369|FG000|Overall Study|Death|2
6163553|NCT01202760|9806370|FG001|Overall Study|Death|1
6163554|NCT01202760|9806371|FG002|Overall Study|Death|0
6163555|NCT01202760|9806369|FG000|Overall Study|Lack of Efficacy|6
6163556|NCT01202760|9806370|FG001|Overall Study|Lack of Efficacy|8
6163557|NCT01202760|9806371|FG002|Overall Study|Lack of Efficacy|7
6163558|NCT01202760|9806369|FG000|Overall Study|Lost to Follow-up|0
6163559|NCT01202760|9806370|FG001|Overall Study|Lost to Follow-up|2
6163560|NCT01202760|9806371|FG002|Overall Study|Lost to Follow-up|1
6163561|NCT01202760|9806369|FG000|Overall Study|Parent / Caregiver Decision|0
6163562|NCT01202760|9806370|FG001|Overall Study|Parent / Caregiver Decision|1
6163563|NCT01202760|9806371|FG002|Overall Study|Parent / Caregiver Decision|0
6163564|NCT01202760|9806369|FG000|Overall Study|Withdrawal by Subject|17
6163565|NCT01202760|9806370|FG001|Overall Study|Withdrawal by Subject|18
6163566|NCT01202760|9806371|FG002|Overall Study|Withdrawal by Subject|14
6163567|NCT01202760|9806369|FG000|Overall Study|Physician Decision|0
6163568|NCT01202760|9806370|FG001|Overall Study|Physician Decision|1
6163569|NCT01202760|9806371|FG002|Overall Study|Physician Decision|0
6163570|NCT01202760|9806369|FG000|Overall Study|Protocol Violation|7
6163571|NCT01202760|9806370|FG001|Overall Study|Protocol Violation|5
6163572|NCT01202760|9806371|FG002|Overall Study|Protocol Violation|2
6163573|NCT01202760|9806369|FG000|Overall Study|Sponsor Decision|4
6163574|NCT01202760|9806370|FG001|Overall Study|Sponsor Decision|4
6163575|NCT01202760|9806371|FG002|Overall Study|Sponsor Decision|0
6163576|NCT01202773|9806394|FG000|Overall Study|Adverse Event|4
6163577|NCT01202773|9806395|FG001|Overall Study|Adverse Event|5
6163578|NCT01202773|9806396|FG002|Overall Study|Adverse Event|5
6163579|NCT01202773|9806394|FG000|Overall Study|Lack of Efficacy|5
6163580|NCT01202773|9806395|FG001|Overall Study|Lack of Efficacy|4
6163581|NCT01202773|9806396|FG002|Overall Study|Lack of Efficacy|9
6163582|NCT01202773|9806394|FG000|Overall Study|Entry Criteria Not Met|2
6163583|NCT01202773|9806395|FG001|Overall Study|Entry Criteria Not Met|0
6163584|NCT01202773|9806396|FG002|Overall Study|Entry Criteria Not Met|1
6163585|NCT01202773|9806394|FG000|Overall Study|Lost to Follow-up|1
6163586|NCT01202773|9806395|FG001|Overall Study|Lost to Follow-up|2
6163587|NCT01202773|9806396|FG002|Overall Study|Lost to Follow-up|2
6326380|NCT02951988|10069775|FG002|Open-Label Treatment Period|Pregnancy|0
6326381|NCT02951988|10069776|FG003|Open-Label Treatment Period|Pregnancy|0
6326382|NCT02951988|10069773|FG000|Open-Label Treatment Period|Lost to Follow-up|28
6326383|NCT02951988|10069774|FG001|Open-Label Treatment Period|Lost to Follow-up|0
6326384|NCT02951988|10069775|FG002|Open-Label Treatment Period|Lost to Follow-up|0
6326385|NCT02951988|10069776|FG003|Open-Label Treatment Period|Lost to Follow-up|0
6326386|NCT02951988|10069773|FG000|Open-Label Treatment Period|Withdrawal by Subject|78
6326387|NCT02951988|10069774|FG001|Open-Label Treatment Period|Withdrawal by Subject|0
6326388|NCT02951988|10069775|FG002|Open-Label Treatment Period|Withdrawal by Subject|0
6326389|NCT02951988|10069776|FG003|Open-Label Treatment Period|Withdrawal by Subject|0
6326390|NCT02951988|10069773|FG000|Open-Label Treatment Period|Lack of Efficacy|49
6326391|NCT02951988|10069774|FG001|Open-Label Treatment Period|Lack of Efficacy|0
6326392|NCT02951988|10069775|FG002|Open-Label Treatment Period|Lack of Efficacy|0
6326393|NCT02951988|10069776|FG003|Open-Label Treatment Period|Lack of Efficacy|0
6326394|NCT02951988|10069773|FG000|Open-Label Treatment Period|Adverse Event|45
6326395|NCT02951988|10069774|FG001|Open-Label Treatment Period|Adverse Event|0
6326396|NCT02951988|10069775|FG002|Open-Label Treatment Period|Adverse Event|0
6326397|NCT02951988|10069776|FG003|Open-Label Treatment Period|Adverse Event|0
6326398|NCT02951988|10069773|FG000|Double-Blind Treatment Period|Site terminated by sponsor|0
6326399|NCT02951988|10069774|FG001|Double-Blind Treatment Period|Site terminated by sponsor|0
6326400|NCT02951988|10069775|FG002|Double-Blind Treatment Period|Site terminated by sponsor|1
6326401|NCT02951988|10069776|FG003|Double-Blind Treatment Period|Site terminated by sponsor|1
6326402|NCT02951988|10069773|FG000|Double-Blind Treatment Period|Study terminated by sponsor|0
6326403|NCT02951988|10069774|FG001|Double-Blind Treatment Period|Study terminated by sponsor|58
6326404|NCT02951988|10069775|FG002|Double-Blind Treatment Period|Study terminated by sponsor|54
6326405|NCT02951988|10069776|FG003|Double-Blind Treatment Period|Study terminated by sponsor|69
6326406|NCT02951988|10069773|FG000|Double-Blind Treatment Period|Non-compliance with study drug|0
6326407|NCT02951988|10069774|FG001|Double-Blind Treatment Period|Non-compliance with study drug|1
6326408|NCT02951988|10069775|FG002|Double-Blind Treatment Period|Non-compliance with study drug|3
6326409|NCT02951988|10069776|FG003|Double-Blind Treatment Period|Non-compliance with study drug|0
6326410|NCT02951988|10069773|FG000|Double-Blind Treatment Period|Protocol Violation|0
6326411|NCT02951988|10069774|FG001|Double-Blind Treatment Period|Protocol Violation|4
6326412|NCT02951988|10069775|FG002|Double-Blind Treatment Period|Protocol Violation|4
6326413|NCT02951988|10069776|FG003|Double-Blind Treatment Period|Protocol Violation|8
6326414|NCT02951988|10069773|FG000|Double-Blind Treatment Period|Pregnancy|0
6326415|NCT02951988|10069774|FG001|Double-Blind Treatment Period|Pregnancy|1
6326416|NCT02951988|10069775|FG002|Double-Blind Treatment Period|Pregnancy|1
6326417|NCT02951988|10069776|FG003|Double-Blind Treatment Period|Pregnancy|0
6326418|NCT02951988|10069773|FG000|Double-Blind Treatment Period|Lost to Follow-up|0
6326419|NCT02951988|10069774|FG001|Double-Blind Treatment Period|Lost to Follow-up|4
6326420|NCT02951988|10069775|FG002|Double-Blind Treatment Period|Lost to Follow-up|12
6326421|NCT02951988|10069776|FG003|Double-Blind Treatment Period|Lost to Follow-up|3
6326422|NCT02951988|10069773|FG000|Double-Blind Treatment Period|Withdrawal by Subject|0
6326423|NCT02951988|10069774|FG001|Double-Blind Treatment Period|Withdrawal by Subject|23
6326424|NCT02951988|10069775|FG002|Double-Blind Treatment Period|Withdrawal by Subject|22
6326425|NCT02951988|10069776|FG003|Double-Blind Treatment Period|Withdrawal by Subject|28
6326426|NCT02951988|10069773|FG000|Double-Blind Treatment Period|Adverse Event|0
6163588|NCT01202773|9806394|FG000|Overall Study|Withdrawal by Subject|13
6163589|NCT01202773|9806395|FG001|Overall Study|Withdrawal by Subject|6
6163590|NCT01202773|9806396|FG002|Overall Study|Withdrawal by Subject|5
6163591|NCT01202773|9806394|FG000|Overall Study|Physician Decision|2
6163592|NCT01202773|9806395|FG001|Overall Study|Physician Decision|0
6163593|NCT01202773|9806396|FG002|Overall Study|Physician Decision|0
6163594|NCT01202773|9806394|FG000|Overall Study|Protocol Violation|11
6163595|NCT01202773|9806395|FG001|Overall Study|Protocol Violation|6
6163596|NCT01202773|9806396|FG002|Overall Study|Protocol Violation|10
6163597|NCT01202773|9806394|FG000|Overall Study|Sponsor Decision|19
6163598|NCT01202773|9806395|FG001|Overall Study|Sponsor Decision|20
6163599|NCT01202773|9806396|FG002|Overall Study|Sponsor Decision|23
6163600|NCT01202877|9806417|FG000|Overall Study|Disease Progression|0
6163601|NCT01202877|9806418|FG001|Overall Study|Disease Progression|1
6163602|NCT01202877|9806419|FG002|Overall Study|Disease Progression|2
6163603|NCT01202877|9806417|FG000|Overall Study|Adverse Event|0
6163604|NCT01202877|9806418|FG001|Overall Study|Adverse Event|0
6163605|NCT01202877|9806419|FG002|Overall Study|Adverse Event|2
6163606|NCT01202877|9806417|FG000|Overall Study|Withdrawal by Subject|0
6163607|NCT01202877|9806418|FG001|Overall Study|Withdrawal by Subject|0
6163608|NCT01202877|9806419|FG002|Overall Study|Withdrawal by Subject|1
6163609|NCT01202877|9806417|FG000|Overall Study|Death|0
6326427|NCT02951988|10069774|FG001|Double-Blind Treatment Period|Adverse Event|8
6326428|NCT02951988|10069775|FG002|Double-Blind Treatment Period|Adverse Event|3
6326429|NCT02951988|10069776|FG003|Double-Blind Treatment Period|Adverse Event|6
6326430|NCT02951988|10069773|FG000|Double-Blind Treatment Period|Miscellaneous Reasons|0
6163610|NCT01202877|9806418|FG001|Overall Study|Death|0
6163611|NCT01202877|9806419|FG002|Overall Study|Death|1
6163612|NCT01202903|9806429|FG000|Overall Study|Administrative Probelms|1
6163613|NCT01202903|9806430|FG001|Overall Study|Administrative Probelms|4
6163614|NCT01202903|9806429|FG000|Overall Study|Protocol Violation|0
6163615|NCT01202903|9806430|FG001|Overall Study|Protocol Violation|1
6163616|NCT01202903|9806429|FG000|Overall Study|Death|1
6163617|NCT01202903|9806430|FG001|Overall Study|Death|0
6163618|NCT01202903|9806429|FG000|Overall Study|Lost to Follow-up|1
6163619|NCT01202903|9806430|FG001|Overall Study|Lost to Follow-up|1
6163620|NCT01202903|9806429|FG000|Overall Study|Lack of Efficacy|1
6163621|NCT01202903|9806430|FG001|Overall Study|Lack of Efficacy|3
6163622|NCT01202903|9806429|FG000|Overall Study|Adverse Event|3
6163623|NCT01202903|9806430|FG001|Overall Study|Adverse Event|3
6163624|NCT01202903|9806429|FG000|Overall Study|Withdrawal by Subject|4
6082478|NCT00628758|9690488|FG001|Overall Study|Investigator Moved|0
6082479|NCT00628758|9690487|FG000|Overall Study|Treatment Failure|0
6082480|NCT00628758|9690488|FG001|Overall Study|Treatment Failure|2
6082481|NCT00628862|9690499|FG000|Overall Study|Adverse Event|6
6082482|NCT00628862|9690500|FG001|Overall Study|Adverse Event|8
6082483|NCT00628862|9690501|FG002|Overall Study|Adverse Event|10
6082484|NCT00628862|9690499|FG000|Overall Study|Withdrawal by Subject|4
6082485|NCT00628862|9690500|FG001|Overall Study|Withdrawal by Subject|6
6082486|NCT00628862|9690501|FG002|Overall Study|Withdrawal by Subject|11
6082487|NCT00628862|9690499|FG000|Overall Study|Lost to Follow-up|0
6082488|NCT00628862|9690500|FG001|Overall Study|Lost to Follow-up|2
6082489|NCT00628862|9690501|FG002|Overall Study|Lost to Follow-up|1
6082490|NCT00628862|9690499|FG000|Overall Study|Protocol Violation|1
6082491|NCT00628862|9690500|FG001|Overall Study|Protocol Violation|0
6082492|NCT00628862|9690501|FG002|Overall Study|Protocol Violation|0
6082493|NCT00628862|9690499|FG000|Overall Study|COPD Exacerbation|0
6082494|NCT00628862|9690500|FG001|Overall Study|COPD Exacerbation|1
6082495|NCT00628862|9690501|FG002|Overall Study|COPD Exacerbation|0
6082496|NCT00628927|9690520|FG000|Overall Study|Problems performing blood draw|6
6082497|NCT00628927|9690521|FG001|Overall Study|Problems performing blood draw|0
6082498|NCT00628927|9690520|FG000|Overall Study|Lost to Follow-up|1
6082499|NCT00628927|9690521|FG001|Overall Study|Lost to Follow-up|0
6163625|NCT01202903|9806430|FG001|Overall Study|Withdrawal by Subject|4
6163626|NCT01202955|9806438|FG000|Period 1: 10 Days|Withdrawal by Subject|0
6163627|NCT01202955|9806439|FG001|Period 1: 10 Days|Withdrawal by Subject|2
6163628|NCT01203072|9806466|FG000|Overall Study|Adverse Event|5
6163629|NCT01203072|9806467|FG001|Overall Study|Adverse Event|3
6163630|NCT01203072|9806468|FG002|Overall Study|Adverse Event|2
6163631|NCT01203072|9806469|FG003|Overall Study|Adverse Event|4
6163632|NCT01203072|9806470|FG004|Overall Study|Adverse Event|2
6163633|NCT01203072|9806466|FG000|Overall Study|Lack of Efficacy|1
6163634|NCT01203072|9806467|FG001|Overall Study|Lack of Efficacy|0
6163635|NCT01203072|9806468|FG002|Overall Study|Lack of Efficacy|0
6163636|NCT01203072|9806469|FG003|Overall Study|Lack of Efficacy|0
6163637|NCT01203072|9806470|FG004|Overall Study|Lack of Efficacy|0
6163638|NCT01203072|9806466|FG000|Overall Study|Lost to Follow-up|0
6163639|NCT01203072|9806467|FG001|Overall Study|Lost to Follow-up|1
6163640|NCT01203072|9806468|FG002|Overall Study|Lost to Follow-up|0
6163641|NCT01203072|9806469|FG003|Overall Study|Lost to Follow-up|0
6163642|NCT01203072|9806470|FG004|Overall Study|Lost to Follow-up|0
6163643|NCT01203072|9806466|FG000|Overall Study|Protocol Violation|2
6163644|NCT01203072|9806467|FG001|Overall Study|Protocol Violation|0
6163645|NCT01203072|9806468|FG002|Overall Study|Protocol Violation|0
6163646|NCT01203072|9806469|FG003|Overall Study|Protocol Violation|0
6163647|NCT01203072|9806470|FG004|Overall Study|Protocol Violation|1
6163648|NCT01203072|9806466|FG000|Overall Study|Withdrawal by Subject|2
6163649|NCT01203072|9806467|FG001|Overall Study|Withdrawal by Subject|2
6163650|NCT01203072|9806468|FG002|Overall Study|Withdrawal by Subject|1
6163651|NCT01203072|9806469|FG003|Overall Study|Withdrawal by Subject|2
6163652|NCT01203072|9806470|FG004|Overall Study|Withdrawal by Subject|3
6326431|NCT02951988|10069774|FG001|Double-Blind Treatment Period|Miscellaneous Reasons|2
6326432|NCT02951988|10069775|FG002|Double-Blind Treatment Period|Miscellaneous Reasons|1
6326433|NCT02951988|10069776|FG003|Double-Blind Treatment Period|Miscellaneous Reasons|0
6326434|NCT02952001|10069788|FG000|Overall Study|Adverse Event|3
6326435|NCT02952001|10069789|FG001|Overall Study|Adverse Event|0
6326436|NCT02952001|10069788|FG000|Overall Study|Prohibited therapy|10
6082500|NCT00628927|9690520|FG000|Overall Study|Equipment failure|1
6082501|NCT00628927|9690521|FG001|Overall Study|Equipment failure|0
6087725|NCT00670046|9698166|FG000|Overall Study|Withdrawal by Subject|0
6163653|NCT01203098|9806485|FG000|Overall Study|Adverse Event|3
6163654|NCT01203098|9806486|FG001|Overall Study|Adverse Event|1
6163655|NCT01203098|9806487|FG002|Overall Study|Adverse Event|7
6163656|NCT01203098|9806485|FG000|Overall Study|Lost to Follow-up|0
6163657|NCT01203098|9806486|FG001|Overall Study|Lost to Follow-up|0
6163658|NCT01203098|9806487|FG002|Overall Study|Lost to Follow-up|1
6163659|NCT01203098|9806485|FG000|Overall Study|Physician Decision|2
6326437|NCT02952001|10069789|FG001|Overall Study|Prohibited therapy|3
6087726|NCT00670046|9698167|FG001|Overall Study|Withdrawal by Subject|1
6163660|NCT01203098|9806486|FG001|Overall Study|Physician Decision|2
6087727|NCT00670111|9698176|FG000|Enrollment to One Month|Testing Failure|0
6087728|NCT00670111|9698177|FG001|Enrollment to One Month|Testing Failure|0
6087729|NCT00670111|9698178|FG002|Enrollment to One Month|Testing Failure|13
6163661|NCT01203098|9806487|FG002|Overall Study|Physician Decision|0
6163662|NCT01203098|9806485|FG000|Overall Study|Withdrawal by Subject|1
6163663|NCT01203098|9806486|FG001|Overall Study|Withdrawal by Subject|1
6163664|NCT01203098|9806487|FG002|Overall Study|Withdrawal by Subject|3
6163665|NCT01203787|9806542|FG000|Overall Study|Death|12
6163666|NCT01203787|9806543|FG001|Overall Study|Death|10
6163667|NCT01203787|9806542|FG000|Overall Study|Withdrawal by Subject|6
6163668|NCT01203787|9806543|FG001|Overall Study|Withdrawal by Subject|2
6163669|NCT01203787|9806542|FG000|Overall Study|Lost to Follow-up|2
6163670|NCT01203787|9806543|FG001|Overall Study|Lost to Follow-up|0
6163671|NCT01203787|9806542|FG000|Overall Study|Adverse Event|11
6163672|NCT01203787|9806543|FG001|Overall Study|Adverse Event|15
6163673|NCT01203852|9806560|FG000|Metoprolol 8 Weeks|Physician Decision|470
6163674|NCT01203852|9806560|FG000|Washout 2 Weeks|Physician Decision|46
6163675|NCT01203878|9806570|FG000|Overall Study|Withdrawal by Subject|0
6163676|NCT01203878|9806571|FG001|Overall Study|Withdrawal by Subject|0
6163677|NCT01203878|9806572|FG002|Overall Study|Withdrawal by Subject|1
6163678|NCT01203878|9806570|FG000|Overall Study|Adverse Event|0
6163679|NCT01203878|9806571|FG001|Overall Study|Adverse Event|0
6163680|NCT01203878|9806572|FG002|Overall Study|Adverse Event|2
6163681|NCT01203917|9806579|FG000|Overall Study|Death|29
6163682|NCT01203917|9806579|FG000|Overall Study|Lost to Follow-up|2
6163683|NCT01203917|9806579|FG000|Overall Study|Withdrawal by Subject|3
6163684|NCT01203917|9806579|FG000|Overall Study|Due to objective disease progression|1
6163685|NCT01203917|9806579|FG000|Overall Study|Due to EGFR M+I patient|1
6163686|NCT01203930|9806585|FG000|Overall Study|Disease Progression|0
6163687|NCT01203930|9806586|FG001|Overall Study|Disease Progression|4
6163688|NCT01203930|9806585|FG000|Overall Study|Death|3
6163689|NCT01203930|9806586|FG001|Overall Study|Death|1
6163690|NCT01203930|9806585|FG000|Overall Study|Withdrew Consent|1
6163691|NCT01203930|9806586|FG001|Overall Study|Withdrew Consent|10
6163692|NCT01203930|9806585|FG000|Overall Study|Investigator Request|0
6163693|NCT01203930|9806586|FG001|Overall Study|Investigator Request|8
6163694|NCT01203930|9806585|FG000|Overall Study|Study Terminated by Sponsor|0
6163695|NCT01203930|9806586|FG001|Overall Study|Study Terminated by Sponsor|12
6163696|NCT01203930|9806585|FG000|Overall Study|Poor tolerance of study drug|0
6163697|NCT01203930|9806586|FG001|Overall Study|Poor tolerance of study drug|1
6163698|NCT01203930|9806585|FG000|Overall Study|Adverse Event|17
6163699|NCT01203930|9806586|FG001|Overall Study|Adverse Event|5
6163700|NCT01203956|9806594|FG000|Second Two-week Period|Non-compliant: no evaluable results|5
6163701|NCT01203956|9806595|FG001|Second Two-week Period|Non-compliant: no evaluable results|6
6163702|NCT01204294|9806617|FG000|Overall Study|Adverse Event|2
6163703|NCT01204294|9806618|FG001|Overall Study|Adverse Event|6
6163704|NCT01204294|9806619|FG002|Overall Study|Adverse Event|0
6163705|NCT01204294|9806620|FG003|Overall Study|Adverse Event|7
6163706|NCT01204294|9806621|FG004|Overall Study|Adverse Event|1
6163707|NCT01204294|9806622|FG005|Overall Study|Adverse Event|4
6163708|NCT01204294|9806623|FG006|Overall Study|Adverse Event|0
6163709|NCT01204294|9806617|FG000|Overall Study|Protocol Violation|1
6163710|NCT01204294|9806618|FG001|Overall Study|Protocol Violation|0
6163711|NCT01204294|9806619|FG002|Overall Study|Protocol Violation|2
6163712|NCT01204294|9806620|FG003|Overall Study|Protocol Violation|1
6163713|NCT01204294|9806621|FG004|Overall Study|Protocol Violation|0
6163714|NCT01204294|9806622|FG005|Overall Study|Protocol Violation|0
6163715|NCT01204294|9806623|FG006|Overall Study|Protocol Violation|0
6163716|NCT01204294|9806617|FG000|Overall Study|Withdrawal by Subject|0
6163717|NCT01204294|9806618|FG001|Overall Study|Withdrawal by Subject|2
6163718|NCT01204294|9806619|FG002|Overall Study|Withdrawal by Subject|2
6163719|NCT01204294|9806620|FG003|Overall Study|Withdrawal by Subject|1
6163720|NCT01204294|9806621|FG004|Overall Study|Withdrawal by Subject|1
6163721|NCT01204294|9806622|FG005|Overall Study|Withdrawal by Subject|1
6163722|NCT01204294|9806623|FG006|Overall Study|Withdrawal by Subject|2
6163723|NCT01204294|9806617|FG000|Overall Study|Lack of Efficacy|0
6163724|NCT01204294|9806618|FG001|Overall Study|Lack of Efficacy|0
6163725|NCT01204294|9806619|FG002|Overall Study|Lack of Efficacy|0
6163726|NCT01204294|9806620|FG003|Overall Study|Lack of Efficacy|2
6163727|NCT01204294|9806621|FG004|Overall Study|Lack of Efficacy|0
6163728|NCT01204294|9806622|FG005|Overall Study|Lack of Efficacy|0
6163729|NCT01204294|9806623|FG006|Overall Study|Lack of Efficacy|0
6163730|NCT01204294|9806617|FG000|Overall Study|Other (house moving)|0
6163731|NCT01204294|9806618|FG001|Overall Study|Other (house moving)|0
6163732|NCT01204294|9806619|FG002|Overall Study|Other (house moving)|1
6163733|NCT01204294|9806620|FG003|Overall Study|Other (house moving)|0
6163734|NCT01204294|9806621|FG004|Overall Study|Other (house moving)|0
6163735|NCT01204294|9806622|FG005|Overall Study|Other (house moving)|0
6163736|NCT01204294|9806623|FG006|Overall Study|Other (house moving)|0
6163737|NCT01204398|9806639|FG000|Overall Study|Adverse Event|1
6163738|NCT01204658|9806647|FG000|Primary Phase|Adverse Event|0
6163739|NCT01204658|9806648|FG001|Primary Phase|Adverse Event|0
6163740|NCT01204658|9806649|FG002|Primary Phase|Adverse Event|1
6163741|NCT01204658|9806650|FG003|Primary Phase|Adverse Event|0
6163742|NCT01204671|9806668|FG000|Overall Study|Adverse Event|4
6163743|NCT01204671|9806669|FG001|Overall Study|Adverse Event|3
6163744|NCT01204671|9806670|FG002|Overall Study|Adverse Event|3
6163745|NCT01204671|9806671|FG003|Overall Study|Adverse Event|3
6163746|NCT01204671|9806672|FG004|Overall Study|Adverse Event|1
6163747|NCT01204671|9806668|FG000|Overall Study|Withdrawal by Subject|2
6163748|NCT01204671|9806669|FG001|Overall Study|Withdrawal by Subject|3
6163749|NCT01204671|9806670|FG002|Overall Study|Withdrawal by Subject|4
6163750|NCT01204671|9806671|FG003|Overall Study|Withdrawal by Subject|5
6163751|NCT01204671|9806672|FG004|Overall Study|Withdrawal by Subject|3
6163752|NCT01204671|9806668|FG000|Overall Study|Lost to Follow-up|7
6163753|NCT01204671|9806669|FG001|Overall Study|Lost to Follow-up|8
6163754|NCT01204671|9806670|FG002|Overall Study|Lost to Follow-up|6
6163755|NCT01204671|9806671|FG003|Overall Study|Lost to Follow-up|4
6163756|NCT01204671|9806672|FG004|Overall Study|Lost to Follow-up|0
6163757|NCT01204671|9806668|FG000|Overall Study|Unknown Completion Status|1
6163758|NCT01204671|9806669|FG001|Overall Study|Unknown Completion Status|1
6163759|NCT01204671|9806670|FG002|Overall Study|Unknown Completion Status|0
6163760|NCT01204671|9806671|FG003|Overall Study|Unknown Completion Status|0
6163761|NCT01204671|9806672|FG004|Overall Study|Unknown Completion Status|0
6163762|NCT01204671|9806668|FG000|Overall Study|Physician Decision|0
6163763|NCT01204671|9806669|FG001|Overall Study|Physician Decision|0
6163764|NCT01204671|9806670|FG002|Overall Study|Physician Decision|0
6163765|NCT01204671|9806671|FG003|Overall Study|Physician Decision|1
6163766|NCT01204671|9806672|FG004|Overall Study|Physician Decision|0
6163767|NCT01204697|9806690|FG000|Overall Study|Death|26
6163768|NCT01204697|9806691|FG001|Overall Study|Death|27
6163769|NCT01204697|9806690|FG000|Overall Study|Lost to Follow-up|3
6163770|NCT01204697|9806691|FG001|Overall Study|Lost to Follow-up|4
6163771|NCT01204697|9806690|FG000|Overall Study|Withdrawal by Subject|2
6163772|NCT01204697|9806691|FG001|Overall Study|Withdrawal by Subject|4
6163773|NCT01204697|9806690|FG000|Overall Study|Randomized, but not treated|0
6163774|NCT01204697|9806691|FG001|Overall Study|Randomized, but not treated|1
6163775|NCT01204710|9806699|FG000|Randomization Treatment|Lost to Follow-up|1
6163776|NCT01204710|9806700|FG001|Randomization Treatment|Lost to Follow-up|0
6163777|NCT01204710|9806699|FG000|Randomization Treatment|Withdrawal by Subject|6
6163778|NCT01204710|9806700|FG001|Randomization Treatment|Withdrawal by Subject|5
6163779|NCT01204710|9806699|FG000|Randomization Treatment|Physician Decision|3
6163780|NCT01204710|9806700|FG001|Randomization Treatment|Physician Decision|2
6163781|NCT01204710|9806699|FG000|Randomization Treatment|Entry criteria not met|0
6163782|NCT01204710|9806700|FG001|Randomization Treatment|Entry criteria not met|1
6163783|NCT01204710|9806699|FG000|Randomization Treatment|Adverse Event|4
6163784|NCT01204710|9806700|FG001|Randomization Treatment|Adverse Event|2
6163785|NCT01204710|9806699|FG000|Randomization Treatment|Sponsor Decision|0
6326438|NCT02952001|10069788|FG000|Overall Study|Due to Posterior Capsular Opacity|1
6326439|NCT02952001|10069789|FG001|Overall Study|Due to Posterior Capsular Opacity|0
6326440|NCT02952261|10069798|FG000|Overall Study|Withdrawal by Subject|4
6326441|NCT02952261|10069799|FG001|Overall Study|Withdrawal by Subject|5
6326442|NCT02952261|10069798|FG000|Overall Study|Protocol Violation|1
6326443|NCT02952261|10069799|FG001|Overall Study|Protocol Violation|0
6326444|NCT02952313|10069805|FG000|Primary Endpoint|Lost to Follow-up|4
6326445|NCT02952313|10069805|FG000|Primary Endpoint|Withdrawal by Subject|1
6326446|NCT02952313|10069805|FG000|Primary Endpoint|Lack of Efficacy|1
6326447|NCT02952313|10069805|FG000|Primary Endpoint|Missed visit|1
6326448|NCT02952313|10069805|FG000|Long-term Follow-up|Lost to Follow-up|12
6326449|NCT02952313|10069805|FG000|Long-term Follow-up|Did not reconsent for long-term FU|7
6326450|NCT02952313|10069805|FG000|Long-term Follow-up|Lack of Efficacy|6
6163786|NCT01204710|9806700|FG001|Randomization Treatment|Sponsor Decision|1
6163787|NCT01204710|9806699|FG000|Randomization Treatment|Worsening of General condition|0
6163788|NCT01204710|9806700|FG001|Randomization Treatment|Worsening of General condition|1
6163789|NCT01204710|9806699|FG000|Randomization Treatment|Moved and Followed for Survival|0
6163790|NCT01204710|9806700|FG001|Randomization Treatment|Moved and Followed for Survival|1
6163791|NCT01204710|9806699|FG000|Optional Olaratumab Monotherapy|Olaratumab Intolerance|0
6163792|NCT01204710|9806700|FG001|Optional Olaratumab Monotherapy|Olaratumab Intolerance|1
6163793|NCT01204710|9806699|FG000|Optional Olaratumab Monotherapy|Physician Decision|0
6163794|NCT01204710|9806700|FG001|Optional Olaratumab Monotherapy|Physician Decision|1
6163795|NCT01204710|9806699|FG000|Optional Olaratumab Monotherapy|Withdrawal by Subject|0
6163796|NCT01204710|9806700|FG001|Optional Olaratumab Monotherapy|Withdrawal by Subject|1
6163797|NCT01204775|9806732|FG000|Overall Study|Poor/non-compliance|0
6163798|NCT01204775|9806733|FG001|Overall Study|Poor/non-compliance|1
6163799|NCT01204775|9806732|FG000|Overall Study|Withdrawal by Subject|1
6163800|NCT01204775|9806733|FG001|Overall Study|Withdrawal by Subject|0
6163801|NCT01204918|9806750|FG000|Overall Study|Withdrawal by Subject|4
6163802|NCT01204918|9806751|FG001|Overall Study|Withdrawal by Subject|10
6163803|NCT01204918|9806752|FG002|Overall Study|Withdrawal by Subject|5
6163804|NCT01205035|9806762|FG000|Overall Study|Withdrawal by Subject|1
6163805|NCT01205035|9806763|FG001|Overall Study|Withdrawal by Subject|0
6163806|NCT01205035|9806762|FG000|Overall Study|Physician Decision|1
6163807|NCT01205035|9806763|FG001|Overall Study|Physician Decision|0
6163808|NCT01205126|9806771|FG000|Titration Phase|Adverse Event|5
6163809|NCT01205126|9806772|FG001|Titration Phase|Adverse Event|3
6163810|NCT01205126|9806771|FG000|Titration Phase|Withdrawal by Subject|5
6163811|NCT01205126|9806772|FG001|Titration Phase|Withdrawal by Subject|5
6326451|NCT02952313|10069805|FG000|Long-term Follow-up|Withdrawal by Subject|5
6326452|NCT02952313|10069805|FG000|Long-term Follow-up|Physician Decision|1
6326453|NCT02952313|10069805|FG000|Long-term Follow-up|Death|1
6326454|NCT02952586|10069812|FG000|Lead-In Phase (7 Days)|Death|0
6326455|NCT02952586|10069813|FG001|Lead-In Phase (7 Days)|Death|1
6326456|NCT02952586|10069812|FG000|Lead-In Phase (7 Days)|Adverse Event|3
6326457|NCT02952586|10069813|FG001|Lead-In Phase (7 Days)|Adverse Event|0
6326458|NCT02952586|10069812|FG000|Lead-In Phase (7 Days)|No Longer Met Eligibility Criteria|0
6326459|NCT02952586|10069813|FG001|Lead-In Phase (7 Days)|No Longer Met Eligibility Criteria|1
6326460|NCT02952586|10069812|FG000|Lead-In Phase (7 Days)|Withdrawal by Subject|2
6326461|NCT02952586|10069813|FG001|Lead-In Phase (7 Days)|Withdrawal by Subject|2
6326462|NCT02952586|10069812|FG000|CRT for Avelumab or Placebo (63 Days)|Death|5
6326463|NCT02952586|10069813|FG001|CRT for Avelumab or Placebo (63 Days)|Death|8
6326464|NCT02952586|10069812|FG000|CRT for Avelumab or Placebo (63 Days)|Adverse Event|12
6326465|NCT02952586|10069813|FG001|CRT for Avelumab or Placebo (63 Days)|Adverse Event|12
6326466|NCT02952586|10069812|FG000|CRT for Avelumab or Placebo (63 Days)|Physician Decision|2
6326467|NCT02952586|10069813|FG001|CRT for Avelumab or Placebo (63 Days)|Physician Decision|1
6326468|NCT02952586|10069812|FG000|CRT for Avelumab or Placebo (63 Days)|Global Deterioration of Health Status|1
6326469|NCT02952586|10069813|FG001|CRT for Avelumab or Placebo (63 Days)|Global Deterioration of Health Status|0
6326470|NCT02952586|10069812|FG000|CRT for Avelumab or Placebo (63 Days)|Withdrawal by Subject|10
6326471|NCT02952586|10069813|FG001|CRT for Avelumab or Placebo (63 Days)|Withdrawal by Subject|4
6326472|NCT02952586|10069812|FG000|CRT for Avelumab or Placebo (63 Days)|Lost to Follow-up|1
6326473|NCT02952586|10069813|FG001|CRT for Avelumab or Placebo (63 Days)|Lost to Follow-up|1
6326474|NCT02952586|10069812|FG000|CRT for Avelumab or Placebo (63 Days)|Other|2
6326475|NCT02952586|10069813|FG001|CRT for Avelumab or Placebo (63 Days)|Other|1
6326476|NCT02952586|10069812|FG000|CRT for Cisplatin (63 Days)|Death|3
6326477|NCT02952586|10069813|FG001|CRT for Cisplatin (63 Days)|Death|8
6326478|NCT02952586|10069812|FG000|CRT for Cisplatin (63 Days)|Adverse Event|82
6326479|NCT02952586|10069813|FG001|CRT for Cisplatin (63 Days)|Adverse Event|81
6326480|NCT02952586|10069812|FG000|CRT for Cisplatin (63 Days)|Physician Decision|12
6326481|NCT02952586|10069813|FG001|CRT for Cisplatin (63 Days)|Physician Decision|10
6326482|NCT02952586|10069812|FG000|CRT for Cisplatin (63 Days)|Global Deterioration of Health Status|1
6326483|NCT02952586|10069813|FG001|CRT for Cisplatin (63 Days)|Global Deterioration of Health Status|0
6326484|NCT02952586|10069812|FG000|CRT for Cisplatin (63 Days)|Withdrawal by Subject|11
6326485|NCT02952586|10069813|FG001|CRT for Cisplatin (63 Days)|Withdrawal by Subject|3
6326486|NCT02952586|10069812|FG000|CRT for Cisplatin (63 Days)|Lost to Follow-up|1
6326487|NCT02952586|10069813|FG001|CRT for Cisplatin (63 Days)|Lost to Follow-up|1
6326488|NCT02952586|10069812|FG000|CRT for Cisplatin (63 Days)|Other|1
6326489|NCT02952586|10069813|FG001|CRT for Cisplatin (63 Days)|Other|1
6326490|NCT02952586|10069812|FG000|CRT for IMRT (63 Days)|Death|5
6326491|NCT02952586|10069813|FG001|CRT for IMRT (63 Days)|Death|8
6326492|NCT02952586|10069812|FG000|CRT for IMRT (63 Days)|Adverse Event|5
6326493|NCT02952586|10069813|FG001|CRT for IMRT (63 Days)|Adverse Event|5
6326494|NCT02952586|10069812|FG000|CRT for IMRT (63 Days)|Global Deterioration of Health Status|1
6326495|NCT02952586|10069813|FG001|CRT for IMRT (63 Days)|Global Deterioration of Health Status|0
6326496|NCT02952586|10069812|FG000|CRT for IMRT (63 Days)|Withdrawal by Subject|10
6326497|NCT02952586|10069813|FG001|CRT for IMRT (63 Days)|Withdrawal by Subject|6
6326498|NCT02952586|10069812|FG000|CRT for IMRT (63 Days)|Lost to Follow-up|1
6326499|NCT02952586|10069813|FG001|CRT for IMRT (63 Days)|Lost to Follow-up|1
6326500|NCT02952586|10069812|FG000|CRT for IMRT (63 Days)|Other|1
6326501|NCT02952586|10069813|FG001|CRT for IMRT (63 Days)|Other|0
6163812|NCT01205126|9806771|FG000|Titration Phase|Lost to Follow-up|2
6163813|NCT01205126|9806772|FG001|Titration Phase|Lost to Follow-up|2
6163814|NCT01205126|9806771|FG000|Titration Phase|No stable titration dose|1
6163815|NCT01205126|9806772|FG001|Titration Phase|No stable titration dose|0
6163816|NCT01205126|9806771|FG000|Titration Phase|More than maximum dosage required|2
6163817|NCT01205126|9806772|FG001|Titration Phase|More than maximum dosage required|3
6163818|NCT01205126|9806771|FG000|Titration Phase|Other|8
6163819|NCT01205126|9806772|FG001|Titration Phase|Other|6
6163820|NCT01205126|9806771|FG000|Between Titration & Maintenance Phase|Other|0
6163821|NCT01205126|9806772|FG001|Between Titration & Maintenance Phase|Other|4
6163822|NCT01205126|9806771|FG000|Maintenance Phase|Adverse Event|3
6163823|NCT01205126|9806772|FG001|Maintenance Phase|Adverse Event|7
6163824|NCT01205126|9806771|FG000|Maintenance Phase|Death|4
6163825|NCT01205126|9806772|FG001|Maintenance Phase|Death|4
6163826|NCT01205126|9806771|FG000|Maintenance Phase|More than the maximum dosage required|5
6163827|NCT01205126|9806772|FG001|Maintenance Phase|More than the maximum dosage required|5
6163828|NCT01205126|9806771|FG000|Maintenance Phase|Prohibited drugs used|1
6163829|NCT01205126|9806772|FG001|Maintenance Phase|Prohibited drugs used|0
6163830|NCT01205126|9806771|FG000|Maintenance Phase|Other|11
6163831|NCT01205126|9806772|FG001|Maintenance Phase|Other|8
6326502|NCT02952586|10069812|FG000|Maintenance Phase (12 Months)|Death|17
6326503|NCT02952586|10069813|FG001|Maintenance Phase (12 Months)|Death|11
6326504|NCT02952586|10069812|FG000|Maintenance Phase (12 Months)|Progressive disease|60
6326505|NCT02952586|10069813|FG001|Maintenance Phase (12 Months)|Progressive disease|54
6326506|NCT02952586|10069812|FG000|Maintenance Phase (12 Months)|Adverse Event|24
6326507|NCT02952586|10069813|FG001|Maintenance Phase (12 Months)|Adverse Event|21
6163832|NCT01205126|9806771|FG000|Maintenance Phase|Lost to Follow-up|5
6163833|NCT01205126|9806772|FG001|Maintenance Phase|Lost to Follow-up|5
6163834|NCT01205126|9806771|FG000|Maintenance Phase|Withdrawal by Subject|8
6163835|NCT01205126|9806772|FG001|Maintenance Phase|Withdrawal by Subject|11
6163836|NCT01205152|9806778|FG000|Overall Study|Death|1
6163837|NCT01205165|9806784|FG000|Overall Study|Lost to Follow-up|2
6163838|NCT01205230|9806791|FG000|Overall Study|Adverse Event|4
6163839|NCT01205230|9806792|FG001|Overall Study|Adverse Event|0
6163840|NCT01205230|9806791|FG000|Overall Study|Physician Decision|1
6163841|NCT01205230|9806792|FG001|Overall Study|Physician Decision|0
6163842|NCT01205269|9806803|FG000|Period 4 - Washout|Eligibility criteria not fulfilled|0
6163843|NCT01205269|9806804|FG001|Period 4 - Washout|Eligibility criteria not fulfilled|0
6163844|NCT01205269|9806805|FG002|Period 4 - Washout|Eligibility criteria not fulfilled|0
6163845|NCT01205269|9806806|FG003|Period 4 - Washout|Eligibility criteria not fulfilled|1
6163846|NCT01205269|9806807|FG004|Period 4 - Washout|Eligibility criteria not fulfilled|0
6163847|NCT01205269|9806808|FG005|Period 4 - Washout|Eligibility criteria not fulfilled|0
6163848|NCT01205438|9806823|FG000|Overall Study|Adverse Event|19
6163849|NCT01205438|9806824|FG001|Overall Study|Adverse Event|17
6163850|NCT01205438|9806825|FG002|Overall Study|Adverse Event|24
6163851|NCT01205438|9806823|FG000|Overall Study|Death|1
6163852|NCT01205438|9806824|FG001|Overall Study|Death|1
6163853|NCT01205438|9806825|FG002|Overall Study|Death|3
6163854|NCT01205438|9806823|FG000|Overall Study|Entry Criteria Not Met|16
6163855|NCT01205438|9806824|FG001|Overall Study|Entry Criteria Not Met|15
6163856|NCT01205438|9806825|FG002|Overall Study|Entry Criteria Not Met|13
6163857|NCT01205438|9806823|FG000|Overall Study|Lack of Efficacy|14
6163858|NCT01205438|9806824|FG001|Overall Study|Lack of Efficacy|11
6163859|NCT01205438|9806825|FG002|Overall Study|Lack of Efficacy|14
6163860|NCT01205438|9806823|FG000|Overall Study|Lost to Follow-up|6
6163861|NCT01205438|9806824|FG001|Overall Study|Lost to Follow-up|7
6163862|NCT01205438|9806825|FG002|Overall Study|Lost to Follow-up|8
6163863|NCT01205438|9806823|FG000|Overall Study|Withdrawal by Subject|19
6163864|NCT01205438|9806824|FG001|Overall Study|Withdrawal by Subject|25
6163865|NCT01205438|9806825|FG002|Overall Study|Withdrawal by Subject|19
6326508|NCT02952586|10069812|FG000|Maintenance Phase (12 Months)|Non-compliance With Study Drug|1
6326509|NCT02952586|10069813|FG001|Maintenance Phase (12 Months)|Non-compliance With Study Drug|1
6326510|NCT02952586|10069812|FG000|Maintenance Phase (12 Months)|Physician Decision|1
6326511|NCT02952586|10069813|FG001|Maintenance Phase (12 Months)|Physician Decision|1
6326512|NCT02952586|10069812|FG000|Maintenance Phase (12 Months)|Global Deterioration of Health Status|14
6326513|NCT02952586|10069813|FG001|Maintenance Phase (12 Months)|Global Deterioration of Health Status|5
6326514|NCT02952586|10069812|FG000|Maintenance Phase (12 Months)|Withdrawal by Subject|31
6326515|NCT02952586|10069813|FG001|Maintenance Phase (12 Months)|Withdrawal by Subject|25
6326516|NCT02952586|10069812|FG000|Maintenance Phase (12 Months)|Lost to Follow-up|1
6326517|NCT02952586|10069813|FG001|Maintenance Phase (12 Months)|Lost to Follow-up|2
6326518|NCT02952586|10069812|FG000|Maintenance Phase (12 Months)|Other|2
6326519|NCT02952586|10069813|FG001|Maintenance Phase (12 Months)|Other|1
6326520|NCT02952586|10069812|FG000|Maintenance Phase (12 Months)|Study Terminated by Sponsor|1
6326521|NCT02952586|10069813|FG001|Maintenance Phase (12 Months)|Study Terminated by Sponsor|6
6326522|NCT02952586|10069812|FG000|Follow-Up Phase (90 Days)|Death|12
6326523|NCT02952586|10069813|FG001|Follow-Up Phase (90 Days)|Death|10
6326524|NCT02952586|10069812|FG000|Follow-Up Phase (90 Days)|Withdrawal by Subject|6
6326525|NCT02952586|10069813|FG001|Follow-Up Phase (90 Days)|Withdrawal by Subject|2
6326526|NCT02952586|10069812|FG000|Follow-Up Phase (90 Days)|Lost to Follow-up|1
6326527|NCT02952586|10069813|FG001|Follow-Up Phase (90 Days)|Lost to Follow-up|1
6326528|NCT02952586|10069812|FG000|Follow-Up Phase (90 Days)|Other|7
6326529|NCT02952586|10069813|FG001|Follow-Up Phase (90 Days)|Other|5
6326530|NCT02952586|10069812|FG000|Follow-Up Phase (90 Days)|Study Terminated by Sponsor|32
6326531|NCT02952586|10069813|FG001|Follow-Up Phase (90 Days)|Study Terminated by Sponsor|50
6326532|NCT02952586|10069812|FG000|LT Follow-up (up to 45 Months)|Death|51
6326533|NCT02952586|10069813|FG001|LT Follow-up (up to 45 Months)|Death|31
6326534|NCT02952586|10069812|FG000|LT Follow-up (up to 45 Months)|Withdrawal by Subject|7
6326535|NCT02952586|10069813|FG001|LT Follow-up (up to 45 Months)|Withdrawal by Subject|1
6163866|NCT01205438|9806823|FG000|Overall Study|Physician Decision|0
6163867|NCT01205438|9806824|FG001|Overall Study|Physician Decision|3
6163868|NCT01205438|9806825|FG002|Overall Study|Physician Decision|2
6163869|NCT01205438|9806823|FG000|Overall Study|Protocol Violation|2
6163870|NCT01205438|9806824|FG001|Overall Study|Protocol Violation|7
6163871|NCT01205438|9806825|FG002|Overall Study|Protocol Violation|4
6163872|NCT01205438|9806823|FG000|Overall Study|Sponsor Decision|0
6163873|NCT01205438|9806824|FG001|Overall Study|Sponsor Decision|1
6163874|NCT01205438|9806825|FG002|Overall Study|Sponsor Decision|1
6163875|NCT01205451|9806838|FG000|Overall Study|Lost to Follow-up|1
6163876|NCT01205451|9806839|FG001|Overall Study|Lost to Follow-up|1
6163877|NCT01205451|9806838|FG000|Overall Study|Withdrawal by Subject|5
6163878|NCT01205451|9806839|FG001|Overall Study|Withdrawal by Subject|9
6163879|NCT01205529|9806854|FG000|Overall Study|Procedure Cancelled|4
6163880|NCT01205529|9806854|FG000|Overall Study|Withdrawal by Subject|2
6163881|NCT01205529|9806854|FG000|Overall Study|Physician Decision|4
6163882|NCT01205529|9806854|FG000|Overall Study|Unstable post op|15
6163883|NCT01205529|9806854|FG000|Overall Study|No longer met criteria|30
6163884|NCT01205581|9806869|FG000|Overall Study|Withdrawal by Subject|1
6163885|NCT01205581|9806870|FG001|Overall Study|Withdrawal by Subject|0
6163886|NCT01205581|9806871|FG002|Overall Study|Withdrawal by Subject|0
6163887|NCT01205581|9806872|FG003|Overall Study|Withdrawal by Subject|0
6163888|NCT01205581|9806873|FG004|Overall Study|Withdrawal by Subject|0
6163889|NCT01205581|9806874|FG005|Overall Study|Withdrawal by Subject|0
6163890|NCT01205685|9806909|FG000|Overall Study|Disease Progression|10
6163891|NCT01205685|9806909|FG000|Overall Study|Withdrawal by Subject|1
6163892|NCT01205776|9806915|FG000|Overall Study|Lost to Follow-up|53
6163893|NCT01205776|9806916|FG001|Overall Study|Lost to Follow-up|61
6163894|NCT01205776|9806915|FG000|Overall Study|Withdrawal by Subject|11
6163895|NCT01205776|9806916|FG001|Overall Study|Withdrawal by Subject|34
6163896|NCT01206140|9806940|FG000|Overall Study|Deemed ineligible due to incorrect diag.|1
6163897|NCT01206140|9806941|FG001|Overall Study|Deemed ineligible due to incorrect diag.|0
6163898|NCT01206166|9806949|FG000|Overall Study|No evaluable data|2
6163899|NCT01206166|9806950|FG001|Overall Study|No evaluable data|3
6163900|NCT01206322|9806961|FG000|Overall Study|Adverse Event|0
6163901|NCT01206322|9806962|FG001|Overall Study|Adverse Event|0
6163902|NCT01206322|9806963|FG002|Overall Study|Adverse Event|0
6163903|NCT01206322|9806964|FG003|Overall Study|Adverse Event|1
6163904|NCT01206582|9807023|FG000|Overall Study|Withdrew prior to study|1
6163905|NCT01206582|9807024|FG001|Overall Study|Withdrew prior to study|0
6163906|NCT01206582|9807023|FG000|Overall Study|Discontinued intervention before week 8|1
6163907|NCT01206582|9807024|FG001|Overall Study|Discontinued intervention before week 8|2
6163908|NCT01206764|9807074|FG000|Overall Study|Adverse Event|20
6163909|NCT01206764|9807074|FG000|Overall Study|Abnormal laboratory value|2
6163910|NCT01206764|9807074|FG000|Overall Study|Abnormal test procedure result|1
6163911|NCT01206764|9807074|FG000|Overall Study|Patient withdrew consent|5
6163912|NCT01206764|9807074|FG000|Overall Study|Lost to Follow-up|6
6163913|NCT01206764|9807074|FG000|Overall Study|Death|11
6163914|NCT01206764|9807074|FG000|Overall Study|New cancer therapy|2
6326536|NCT02952586|10069812|FG000|LT Follow-up (up to 45 Months)|Lost to Follow-up|2
6326537|NCT02952586|10069813|FG001|LT Follow-up (up to 45 Months)|Lost to Follow-up|4
6326538|NCT02952586|10069812|FG000|LT Follow-up (up to 45 Months)|Study Terminated by Sponsor|187
6326539|NCT02952586|10069813|FG001|LT Follow-up (up to 45 Months)|Study Terminated by Sponsor|201
6326540|NCT02952820|10069823|FG000|Placebo-Controlled Treatment (6 Months)|Adverse Event|8
6326541|NCT02952820|10069824|FG001|Placebo-Controlled Treatment (6 Months)|Adverse Event|9
6326542|NCT02952820|10069825|FG002|Placebo-Controlled Treatment (6 Months)|Adverse Event|16
6326543|NCT02952820|10069823|FG000|Placebo-Controlled Treatment (6 Months)|Lost to Follow-up|7
6326544|NCT02952820|10069824|FG001|Placebo-Controlled Treatment (6 Months)|Lost to Follow-up|7
6326545|NCT02952820|10069825|FG002|Placebo-Controlled Treatment (6 Months)|Lost to Follow-up|6
6326546|NCT02952820|10069823|FG000|Placebo-Controlled Treatment (6 Months)|Subject choice|15
6326547|NCT02952820|10069824|FG001|Placebo-Controlled Treatment (6 Months)|Subject choice|12
6326548|NCT02952820|10069825|FG002|Placebo-Controlled Treatment (6 Months)|Subject choice|17
6326549|NCT02952820|10069823|FG000|Placebo-Controlled Treatment (6 Months)|Inadequate therapeutic effect|17
6326550|NCT02952820|10069824|FG001|Placebo-Controlled Treatment (6 Months)|Inadequate therapeutic effect|12
6326551|NCT02952820|10069825|FG002|Placebo-Controlled Treatment (6 Months)|Inadequate therapeutic effect|11
6326552|NCT02952820|10069823|FG000|Placebo-Controlled Treatment (6 Months)|Other than specified|0
6326553|NCT02952820|10069824|FG001|Placebo-Controlled Treatment (6 Months)|Other than specified|14
6326554|NCT02952820|10069825|FG002|Placebo-Controlled Treatment (6 Months)|Other than specified|13
6326555|NCT02952820|10069823|FG000|Placebo-Controlled Treatment (6 Months)|Withdrawal of consent|13
6326556|NCT02952820|10069824|FG001|Placebo-Controlled Treatment (6 Months)|Withdrawal of consent|11
6326557|NCT02952820|10069825|FG002|Placebo-Controlled Treatment (6 Months)|Withdrawal of consent|21
6326558|NCT02952820|10069823|FG000|Placebo-Controlled Treatment (6 Months)|Not treated|4
6326559|NCT02952820|10069824|FG001|Placebo-Controlled Treatment (6 Months)|Not treated|4
6326560|NCT02952820|10069825|FG002|Placebo-Controlled Treatment (6 Months)|Not treated|4
6326561|NCT02952820|10069823|FG000|Active Treatment Period (6 Months)|Adverse Event|0
6326562|NCT02952820|10069824|FG001|Active Treatment Period (6 Months)|Adverse Event|6
6326563|NCT02952820|10069825|FG002|Active Treatment Period (6 Months)|Adverse Event|5
6326564|NCT02952820|10069823|FG000|Active Treatment Period (6 Months)|Lost to Follow-up|0
6326565|NCT02952820|10069824|FG001|Active Treatment Period (6 Months)|Lost to Follow-up|4
6163915|NCT01206764|9807074|FG000|Overall Study|Disease progression|88
6163916|NCT01206764|9807074|FG000|Overall Study|Protocol deviation|3
6163917|NCT01206777|9807078|FG000|Overall Study|Death|1
6163918|NCT01206777|9807078|FG000|Overall Study|Adverse Event|1
6163919|NCT01206816|9807089|FG000|Overall Study|Protocol Violation|0
6163920|NCT01206816|9807090|FG001|Overall Study|Protocol Violation|0
6163921|NCT01206816|9807091|FG002|Overall Study|Protocol Violation|1
6163922|NCT01206816|9807092|FG003|Overall Study|Protocol Violation|0
6163923|NCT01206816|9807093|FG004|Overall Study|Protocol Violation|0
6163924|NCT01206816|9807094|FG005|Overall Study|Protocol Violation|0
6163925|NCT01206816|9807095|FG006|Overall Study|Protocol Violation|0
6163926|NCT01206816|9807089|FG000|Overall Study|Withdrawal by Subject|0
6163927|NCT01206816|9807090|FG001|Overall Study|Withdrawal by Subject|0
6163928|NCT01206816|9807091|FG002|Overall Study|Withdrawal by Subject|1
6326566|NCT02952820|10069825|FG002|Active Treatment Period (6 Months)|Lost to Follow-up|6
6227416|NCT01716754|9900109|FG001|Overall Study|Withdrawal by Subject|0
6163929|NCT01206816|9807092|FG003|Overall Study|Withdrawal by Subject|0
6163930|NCT01206816|9807093|FG004|Overall Study|Withdrawal by Subject|0
6163931|NCT01206816|9807094|FG005|Overall Study|Withdrawal by Subject|0
6163932|NCT01206816|9807095|FG006|Overall Study|Withdrawal by Subject|0
6163933|NCT01206816|9807089|FG000|Overall Study|Progressive disease|3
6163934|NCT01206816|9807090|FG001|Overall Study|Progressive disease|3
6163935|NCT01206816|9807091|FG002|Overall Study|Progressive disease|13
6163936|NCT01206816|9807092|FG003|Overall Study|Progressive disease|3
6163937|NCT01206816|9807093|FG004|Overall Study|Progressive disease|3
6163938|NCT01206816|9807094|FG005|Overall Study|Progressive disease|16
6163939|NCT01206816|9807095|FG006|Overall Study|Progressive disease|3
6163940|NCT01206816|9807089|FG000|Overall Study|Other AE|0
6163941|NCT01206816|9807090|FG001|Overall Study|Other AE|0
6163942|NCT01206816|9807091|FG002|Overall Study|Other AE|4
6163943|NCT01206816|9807092|FG003|Overall Study|Other AE|0
6163944|NCT01206816|9807093|FG004|Overall Study|Other AE|0
6163945|NCT01206816|9807094|FG005|Overall Study|Other AE|3
6163946|NCT01206816|9807095|FG006|Overall Study|Other AE|2
6163947|NCT01206816|9807089|FG000|Overall Study|other than stated above|0
6163948|NCT01206816|9807090|FG001|Overall Study|other than stated above|0
6163949|NCT01206816|9807091|FG002|Overall Study|other than stated above|1
6163950|NCT01206816|9807092|FG003|Overall Study|other than stated above|0
6163951|NCT01206816|9807093|FG004|Overall Study|other than stated above|0
6163952|NCT01206816|9807094|FG005|Overall Study|other than stated above|0
6163953|NCT01206816|9807095|FG006|Overall Study|other than stated above|1
6163954|NCT01207219|9807118|FG000|Overall Study|changed diagnosis during study period|5
6163955|NCT01207219|9807119|FG001|Overall Study|changed diagnosis during study period|3
6163956|NCT01207219|9807120|FG002|Overall Study|changed diagnosis during study period|1
6163957|NCT01207219|9807118|FG000|Overall Study|Lost to Follow-up|6
6163958|NCT01207219|9807119|FG001|Overall Study|Lost to Follow-up|8
6163959|NCT01207219|9807120|FG002|Overall Study|Lost to Follow-up|6
6163960|NCT01207388|9807128|FG000|Overall Study|Death|67
6163961|NCT01207388|9807128|FG000|Overall Study|Withdrawal by Subject|1
6163962|NCT01207414|9807151|FG000|Overall Study|Adverse Event|25
6163963|NCT01207414|9807152|FG001|Overall Study|Adverse Event|39
6163964|NCT01207414|9807151|FG000|Overall Study|Abnormal test procedure results|0
6163965|NCT01207414|9807152|FG001|Overall Study|Abnormal test procedure results|1
6163966|NCT01207414|9807151|FG000|Overall Study|Unsatisfactory therapeutic effect|5
6163967|NCT01207414|9807152|FG001|Overall Study|Unsatisfactory therapeutic effect|4
6163968|NCT01207414|9807151|FG000|Overall Study|Patient withdrew consent|14
6163969|NCT01207414|9807152|FG001|Overall Study|Patient withdrew consent|11
6163970|NCT01207414|9807151|FG000|Overall Study|Lost to Follow-up|15
6163971|NCT01207414|9807152|FG001|Overall Study|Lost to Follow-up|17
6163972|NCT01207414|9807151|FG000|Overall Study|Administrative problems|1
6163973|NCT01207414|9807152|FG001|Overall Study|Administrative problems|1
6163974|NCT01207414|9807151|FG000|Overall Study|Protocol deviation|12
6163975|NCT01207414|9807152|FG001|Overall Study|Protocol deviation|9
6163976|NCT01207414|9807151|FG000|Overall Study|Randomized in error|1
6163977|NCT01207414|9807152|FG001|Overall Study|Randomized in error|0
6163978|NCT01207427|9807161|FG000|Double-blind Treatment Period|Adverse Event|0
6163979|NCT01207427|9807162|FG001|Double-blind Treatment Period|Adverse Event|1
6163980|NCT01207427|9807163|FG002|Double-blind Treatment Period|Adverse Event|0
6163981|NCT01207427|9807161|FG000|Double-blind Treatment Period|Lost to Follow-up|0
6163982|NCT01207427|9807162|FG001|Double-blind Treatment Period|Lost to Follow-up|0
6163983|NCT01207427|9807163|FG002|Double-blind Treatment Period|Lost to Follow-up|1
6163984|NCT01207427|9807161|FG000|Double-blind Treatment Period|Protocol Violation|2
6163985|NCT01207427|9807162|FG001|Double-blind Treatment Period|Protocol Violation|1
6163986|NCT01207427|9807163|FG002|Double-blind Treatment Period|Protocol Violation|1
6163987|NCT01207427|9807161|FG000|Double-blind Treatment Period|Withdrawal by Subject|1
6163988|NCT01207427|9807162|FG001|Double-blind Treatment Period|Withdrawal by Subject|0
6163989|NCT01207427|9807163|FG002|Double-blind Treatment Period|Withdrawal by Subject|0
6163990|NCT01207440|9807178|FG000|Overall Study|Adverse Event|46
6163991|NCT01207440|9807179|FG001|Overall Study|Adverse Event|11
6163992|NCT01207440|9807180|FG002|Overall Study|Adverse Event|7
6163993|NCT01207440|9807181|FG003|Overall Study|Adverse Event|2
6163994|NCT01207440|9807182|FG004|Overall Study|Adverse Event|6
6163995|NCT01207440|9807183|FG005|Overall Study|Adverse Event|6
6163996|NCT01207440|9807184|FG006|Overall Study|Adverse Event|2
6163997|NCT01207440|9807178|FG000|Overall Study|Death|6
6163998|NCT01207440|9807179|FG001|Overall Study|Death|3
6163999|NCT01207440|9807180|FG002|Overall Study|Death|2
6164000|NCT01207440|9807181|FG003|Overall Study|Death|2
6164001|NCT01207440|9807182|FG004|Overall Study|Death|7
6164002|NCT01207440|9807183|FG005|Overall Study|Death|5
6164003|NCT01207440|9807184|FG006|Overall Study|Death|1
6164004|NCT01207440|9807178|FG000|Overall Study|Lack of Efficacy|13
6164005|NCT01207440|9807179|FG001|Overall Study|Lack of Efficacy|2
6164006|NCT01207440|9807180|FG002|Overall Study|Lack of Efficacy|5
6164007|NCT01207440|9807181|FG003|Overall Study|Lack of Efficacy|1
6164008|NCT01207440|9807182|FG004|Overall Study|Lack of Efficacy|2
6164009|NCT01207440|9807183|FG005|Overall Study|Lack of Efficacy|3
6164010|NCT01207440|9807184|FG006|Overall Study|Lack of Efficacy|0
6164011|NCT01207440|9807178|FG000|Overall Study|Lost to Follow-up|0
6164012|NCT01207440|9807179|FG001|Overall Study|Lost to Follow-up|0
6164013|NCT01207440|9807180|FG002|Overall Study|Lost to Follow-up|2
6164014|NCT01207440|9807181|FG003|Overall Study|Lost to Follow-up|1
6164015|NCT01207440|9807182|FG004|Overall Study|Lost to Follow-up|0
6164016|NCT01207440|9807183|FG005|Overall Study|Lost to Follow-up|0
6164017|NCT01207440|9807184|FG006|Overall Study|Lost to Follow-up|0
6164018|NCT01207440|9807178|FG000|Overall Study|Non-compliance with Study Drug|3
6164019|NCT01207440|9807179|FG001|Overall Study|Non-compliance with Study Drug|0
6164020|NCT01207440|9807180|FG002|Overall Study|Non-compliance with Study Drug|1
6164021|NCT01207440|9807181|FG003|Overall Study|Non-compliance with Study Drug|0
6164022|NCT01207440|9807182|FG004|Overall Study|Non-compliance with Study Drug|0
6164023|NCT01207440|9807183|FG005|Overall Study|Non-compliance with Study Drug|0
6164024|NCT01207440|9807184|FG006|Overall Study|Non-compliance with Study Drug|0
6164025|NCT01207440|9807178|FG000|Overall Study|Physician Decision|6
6164026|NCT01207440|9807179|FG001|Overall Study|Physician Decision|5
6164027|NCT01207440|9807180|FG002|Overall Study|Physician Decision|5
6164028|NCT01207440|9807181|FG003|Overall Study|Physician Decision|0
6164029|NCT01207440|9807182|FG004|Overall Study|Physician Decision|1
6164030|NCT01207440|9807183|FG005|Overall Study|Physician Decision|0
6164031|NCT01207440|9807184|FG006|Overall Study|Physician Decision|0
6164032|NCT01207440|9807178|FG000|Overall Study|Progressive Disease|19
6164033|NCT01207440|9807179|FG001|Overall Study|Progressive Disease|10
6164034|NCT01207440|9807180|FG002|Overall Study|Progressive Disease|19
6164035|NCT01207440|9807181|FG003|Overall Study|Progressive Disease|7
6164036|NCT01207440|9807182|FG004|Overall Study|Progressive Disease|23
6164037|NCT01207440|9807183|FG005|Overall Study|Progressive Disease|27
6164038|NCT01207440|9807184|FG006|Overall Study|Progressive Disease|0
6164039|NCT01207440|9807178|FG000|Overall Study|Protocol Violation|2
6164040|NCT01207440|9807179|FG001|Overall Study|Protocol Violation|0
6164041|NCT01207440|9807180|FG002|Overall Study|Protocol Violation|0
6164042|NCT01207440|9807181|FG003|Overall Study|Protocol Violation|0
6164043|NCT01207440|9807182|FG004|Overall Study|Protocol Violation|0
6164044|NCT01207440|9807183|FG005|Overall Study|Protocol Violation|0
6164045|NCT01207440|9807184|FG006|Overall Study|Protocol Violation|0
6164046|NCT01207440|9807178|FG000|Overall Study|Site Terminated by Sponsor|69
6164047|NCT01207440|9807179|FG001|Overall Study|Site Terminated by Sponsor|19
6164048|NCT01207440|9807180|FG002|Overall Study|Site Terminated by Sponsor|12
6164049|NCT01207440|9807181|FG003|Overall Study|Site Terminated by Sponsor|2
6164050|NCT01207440|9807182|FG004|Overall Study|Site Terminated by Sponsor|3
6164051|NCT01207440|9807183|FG005|Overall Study|Site Terminated by Sponsor|0
6164052|NCT01207440|9807184|FG006|Overall Study|Site Terminated by Sponsor|2
6164053|NCT01207440|9807178|FG000|Overall Study|Withdrawal by Subject|29
6164054|NCT01207440|9807179|FG001|Overall Study|Withdrawal by Subject|4
6164055|NCT01207440|9807180|FG002|Overall Study|Withdrawal by Subject|5
6164056|NCT01207440|9807181|FG003|Overall Study|Withdrawal by Subject|3
6164057|NCT01207440|9807182|FG004|Overall Study|Withdrawal by Subject|2
6164058|NCT01207440|9807183|FG005|Overall Study|Withdrawal by Subject|2
6164059|NCT01207440|9807184|FG006|Overall Study|Withdrawal by Subject|0
6164060|NCT01207440|9807178|FG000|Overall Study|Reason Not Specified|10
6164061|NCT01207440|9807179|FG001|Overall Study|Reason Not Specified|10
6164062|NCT01207440|9807180|FG002|Overall Study|Reason Not Specified|7
6164063|NCT01207440|9807181|FG003|Overall Study|Reason Not Specified|0
6164064|NCT01207440|9807182|FG004|Overall Study|Reason Not Specified|4
6164065|NCT01207440|9807183|FG005|Overall Study|Reason Not Specified|3
6164066|NCT01207440|9807184|FG006|Overall Study|Reason Not Specified|0
6164067|NCT01207453|9807208|FG000|First Intervention|Adverse Event|2
6164068|NCT01207453|9807209|FG001|First Intervention|Adverse Event|1
6164069|NCT01207453|9807208|FG000|Washout|Adverse Event|1
6164070|NCT01207453|9807209|FG001|Washout|Adverse Event|0
6164071|NCT01207453|9807208|FG000|Washout|Lost to Follow-up|1
6164072|NCT01207453|9807209|FG001|Washout|Lost to Follow-up|0
6164073|NCT01207453|9807208|FG000|2nd Intervention|Adverse Event|1
6164074|NCT01207453|9807209|FG001|2nd Intervention|Adverse Event|2
6164075|NCT01207453|9807208|FG000|2nd Intervention|Lost to Follow-up|1
6164076|NCT01207453|9807209|FG001|2nd Intervention|Lost to Follow-up|0
6164077|NCT01207583|9807239|FG000|Overall Study|Withdrawal by Subject|0
6164078|NCT01207583|9807240|FG001|Overall Study|Withdrawal by Subject|3
6164079|NCT01207583|9807241|FG002|Overall Study|Withdrawal by Subject|1
6164080|NCT01207583|9807239|FG000|Overall Study|Participant failed to return|1
6164081|NCT01207583|9807240|FG001|Overall Study|Participant failed to return|0
6164082|NCT01207583|9807241|FG002|Overall Study|Participant failed to return|0
6164083|NCT01207583|9807239|FG000|Overall Study|Lost to Follow-up|0
6164084|NCT01207583|9807240|FG001|Overall Study|Lost to Follow-up|2
6164085|NCT01207583|9807241|FG002|Overall Study|Lost to Follow-up|0
6164086|NCT01207596|9807262|FG000|Overall Study|Physician Decision|4
6164087|NCT01207596|9807262|FG000|Overall Study|Lack of Efficacy|1
6164088|NCT01207596|9807262|FG000|Overall Study|Adverse Event|3
6164089|NCT01207596|9807262|FG000|Overall Study|Withdrawal by Subject|1
6164090|NCT01207687|9807270|FG000|Overall Study|Adverse Event|1
6164091|NCT01207687|9807270|FG000|Overall Study|Withdrawal by Subject|1
6164092|NCT01208038|9807315|FG000|Overall Study|Withdrawal by Subject|1
6164093|NCT01208051|9807324|FG000|Total Enrollment|Withdrawal by Subject|0
6164094|NCT01208051|9807325|FG001|Total Enrollment|Withdrawal by Subject|1
6164095|NCT01208051|9807326|FG002|Total Enrollment|Withdrawal by Subject|0
6164096|NCT01208051|9807327|FG003|Total Enrollment|Withdrawal by Subject|0
6164097|NCT01208051|9807328|FG004|Total Enrollment|Withdrawal by Subject|2
6164098|NCT01208051|9807324|FG000|Total Enrollment|Brain metastases|0
6164099|NCT01208051|9807325|FG001|Total Enrollment|Brain metastases|0
6164100|NCT01208051|9807326|FG002|Total Enrollment|Brain metastases|1
6164101|NCT01208051|9807327|FG003|Total Enrollment|Brain metastases|0
6164102|NCT01208051|9807328|FG004|Total Enrollment|Brain metastases|0
6164103|NCT01208103|9807344|FG000|Overall Study|Adverse Event|1
6164104|NCT01208103|9807344|FG000|Overall Study|Withdrawal by Subject|1
6164105|NCT01208233|9807364|FG000|Overall Study|Adverse Event|0
6164106|NCT01208233|9807365|FG001|Overall Study|Adverse Event|1
6164107|NCT01208233|9807366|FG002|Overall Study|Adverse Event|2
6164108|NCT01208233|9807367|FG003|Overall Study|Adverse Event|0
6164109|NCT01208233|9807368|FG004|Overall Study|Adverse Event|3
6164110|NCT01208233|9807369|FG005|Overall Study|Adverse Event|5
6164111|NCT01208233|9807364|FG000|Overall Study|Death|0
6164112|NCT01208233|9807365|FG001|Overall Study|Death|0
6164113|NCT01208233|9807366|FG002|Overall Study|Death|0
6164114|NCT01208233|9807367|FG003|Overall Study|Death|0
6164115|NCT01208233|9807368|FG004|Overall Study|Death|3
6164116|NCT01208233|9807369|FG005|Overall Study|Death|5
6164117|NCT01208233|9807364|FG000|Overall Study|Did not meet entrance criteria|2
6164118|NCT01208233|9807365|FG001|Overall Study|Did not meet entrance criteria|1
6164119|NCT01208233|9807366|FG002|Overall Study|Did not meet entrance criteria|1
6082502|NCT00629083|9690543|FG000|Overall Study|Adverse Event|0
6082503|NCT00629083|9690544|FG001|Overall Study|Adverse Event|2
6082504|NCT00629083|9690543|FG000|Overall Study|Lack of Efficacy|3
6082505|NCT00629083|9690544|FG001|Overall Study|Lack of Efficacy|1
6082506|NCT00629083|9690543|FG000|Overall Study|Withdrawal by Subject|10
6082507|NCT00629083|9690544|FG001|Overall Study|Withdrawal by Subject|2
6082508|NCT00629083|9690543|FG000|Overall Study|Lost to Follow-up|12
6082509|NCT00629083|9690544|FG001|Overall Study|Lost to Follow-up|8
6082510|NCT00629083|9690543|FG000|Overall Study|Moved out of country/state|2
6082511|NCT00629083|9690544|FG001|Overall Study|Moved out of country/state|1
6082512|NCT00629083|9690543|FG000|Overall Study|Refused to return for 12 month visit|1
6082513|NCT00629083|9690544|FG001|Overall Study|Refused to return for 12 month visit|0
6082514|NCT00629239|9690563|FG000|Overall Study|Adverse Event|7
6082515|NCT00629239|9690564|FG001|Overall Study|Adverse Event|4
6082516|NCT00629239|9690563|FG000|Overall Study|Physician Decision|1
6082517|NCT00629239|9690564|FG001|Overall Study|Physician Decision|0
6082518|NCT00629265|9690572|FG000|Overall Study|Lost to Follow-up|4
6082519|NCT00629265|9690573|FG001|Overall Study|Lost to Follow-up|5
6082520|NCT00629265|9690572|FG000|Overall Study|Withdrawal by Subject|11
6082521|NCT00629265|9690573|FG001|Overall Study|Withdrawal by Subject|8
6164120|NCT01208233|9807367|FG003|Overall Study|Did not meet entrance criteria|0
6164121|NCT01208233|9807368|FG004|Overall Study|Did not meet entrance criteria|1
6164122|NCT01208233|9807369|FG005|Overall Study|Did not meet entrance criteria|0
6164123|NCT01208233|9807364|FG000|Overall Study|Medication error without adverse event|0
6164124|NCT01208233|9807365|FG001|Overall Study|Medication error without adverse event|0
6164125|NCT01208233|9807366|FG002|Overall Study|Medication error without adverse event|0
6164126|NCT01208233|9807367|FG003|Overall Study|Medication error without adverse event|0
6164127|NCT01208233|9807368|FG004|Overall Study|Medication error without adverse event|0
6164128|NCT01208233|9807369|FG005|Overall Study|Medication error without adverse event|1
6164129|NCT01208233|9807364|FG000|Overall Study|Study terminated by sponsor|0
6164130|NCT01208233|9807365|FG001|Overall Study|Study terminated by sponsor|0
6164131|NCT01208233|9807366|FG002|Overall Study|Study terminated by sponsor|0
6164132|NCT01208233|9807367|FG003|Overall Study|Study terminated by sponsor|0
6164133|NCT01208233|9807368|FG004|Overall Study|Study terminated by sponsor|10
6164134|NCT01208233|9807369|FG005|Overall Study|Study terminated by sponsor|7
6164135|NCT01208233|9807364|FG000|Overall Study|Protocol Violation|0
6164136|NCT01208233|9807365|FG001|Overall Study|Protocol Violation|0
6164137|NCT01208233|9807366|FG002|Overall Study|Protocol Violation|0
6164138|NCT01208233|9807367|FG003|Overall Study|Protocol Violation|0
6164139|NCT01208233|9807368|FG004|Overall Study|Protocol Violation|3
6164140|NCT01208233|9807369|FG005|Overall Study|Protocol Violation|0
6164141|NCT01208233|9807364|FG000|Overall Study|Other|2
6164142|NCT01208233|9807365|FG001|Overall Study|Other|1
6164143|NCT01208233|9807366|FG002|Overall Study|Other|0
6164144|NCT01208233|9807367|FG003|Overall Study|Other|0
6164145|NCT01208233|9807368|FG004|Overall Study|Other|0
6164146|NCT01208233|9807369|FG005|Overall Study|Other|1
6164147|NCT01208233|9807364|FG000|Overall Study|Withdrawal by Subject|1
6164148|NCT01208233|9807365|FG001|Overall Study|Withdrawal by Subject|0
6164149|NCT01208233|9807366|FG002|Overall Study|Withdrawal by Subject|1
6164150|NCT01208233|9807367|FG003|Overall Study|Withdrawal by Subject|1
6164151|NCT01208233|9807368|FG004|Overall Study|Withdrawal by Subject|4
6164152|NCT01208233|9807369|FG005|Overall Study|Withdrawal by Subject|2
6164153|NCT01208324|9807393|FG000|Post-randomization of Patch|Withdrawal by Subject|1
6164154|NCT01208324|9807394|FG001|Post-randomization of Patch|Withdrawal by Subject|0
6082522|NCT00629265|9690572|FG000|Overall Study|Death|1
6082523|NCT00629265|9690573|FG001|Overall Study|Death|0
6082524|NCT00629265|9690572|FG000|Overall Study|Adverse Event|2
6082525|NCT00629265|9690573|FG001|Overall Study|Adverse Event|0
6082526|NCT00629265|9690572|FG000|Overall Study|HNC Recurrence|4
6082527|NCT00629265|9690573|FG001|Overall Study|HNC Recurrence|0
6082528|NCT00629265|9690572|FG000|Overall Study|Other CA Requiring Treatment|1
6164155|NCT01208324|9807395|FG002|Post-randomization of Patch|Withdrawal by Subject|0
6164156|NCT01208324|9807396|FG003|Post-randomization of Patch|Withdrawal by Subject|0
6191997|NCT01426789|9848970|FG005|Part 2|Lack of Efficacy|0
6191998|NCT01426789|9848965|FG000|Part 2|Adverse Event|0
6191999|NCT01426789|9848966|FG001|Part 2|Adverse Event|0
6192000|NCT01426789|9848967|FG002|Part 2|Adverse Event|2
6192001|NCT01426789|9848968|FG003|Part 2|Adverse Event|0
6192002|NCT01426789|9848969|FG004|Part 2|Adverse Event|1
6192003|NCT01426789|9848970|FG005|Part 2|Adverse Event|0
6192004|NCT01426854|9848989|FG000|Overall Study|Adverse Event|1
6192005|NCT01426854|9848990|FG001|Overall Study|Adverse Event|5
6192006|NCT01426854|9848989|FG000|Overall Study|Subject Decision Unrelated to AE|5
6192007|NCT01426854|9848990|FG001|Overall Study|Subject Decision Unrelated to AE|6
6192008|NCT01426854|9848989|FG000|Overall Study|Lost to Follow-up|3
6192009|NCT01426854|9848990|FG001|Overall Study|Lost to Follow-up|0
6192010|NCT01426854|9848989|FG000|Overall Study|Noncompliance|0
6192011|NCT01426854|9848990|FG001|Overall Study|Noncompliance|1
6192012|NCT01426854|9848989|FG000|Overall Study|Treatment Failure|0
6192013|NCT01426854|9848990|FG001|Overall Study|Treatment Failure|16
6192014|NCT01426854|9848989|FG000|Overall Study|Protocol Deviation|0
6192015|NCT01426854|9848990|FG001|Overall Study|Protocol Deviation|1
6192016|NCT01426854|9848989|FG000|Overall Study|Other|3
6192017|NCT01426854|9848990|FG001|Overall Study|Other|2
6082529|NCT00629265|9690573|FG001|Overall Study|Other CA Requiring Treatment|3
6192018|NCT01426958|9849009|FG000|Overall Study|Adverse Event|2
6192019|NCT01427309|9849030|FG000|Overall Study|Lost to Follow-up|130
6192020|NCT01427309|9849031|FG001|Overall Study|Lost to Follow-up|145
6192021|NCT01427309|9849032|FG002|Overall Study|Lost to Follow-up|122
6192022|NCT01427309|9849033|FG003|Overall Study|Lost to Follow-up|135
6192023|NCT01427309|9849030|FG000|Overall Study|Protocol Violation|42
6192024|NCT01427309|9849031|FG001|Overall Study|Protocol Violation|69
6192025|NCT01427309|9849032|FG002|Overall Study|Protocol Violation|125
6192026|NCT01427309|9849033|FG003|Overall Study|Protocol Violation|124
6192027|NCT01427309|9849030|FG000|Overall Study|Adverse Event|0
6192028|NCT01427309|9849031|FG001|Overall Study|Adverse Event|0
6192029|NCT01427309|9849032|FG002|Overall Study|Adverse Event|3
6192030|NCT01427309|9849033|FG003|Overall Study|Adverse Event|1
6192031|NCT01427309|9849030|FG000|Overall Study|Serious adverse event|52
6192032|NCT01427309|9849031|FG001|Overall Study|Serious adverse event|45
6192033|NCT01427309|9849032|FG002|Overall Study|Serious adverse event|50
6192034|NCT01427309|9849033|FG003|Overall Study|Serious adverse event|61
6192035|NCT01427309|9849030|FG000|Overall Study|Withdrawal by Subject|148
6192036|NCT01427309|9849031|FG001|Overall Study|Withdrawal by Subject|148
6192037|NCT01427309|9849032|FG002|Overall Study|Withdrawal by Subject|61
6192038|NCT01427309|9849033|FG003|Overall Study|Withdrawal by Subject|55
6192039|NCT01427608|9849090|FG000|Overall Study|Death|1
6192040|NCT01427608|9849091|FG001|Overall Study|Death|0
6192041|NCT01427608|9849090|FG000|Overall Study|Withdrawal by Subject|7
6192042|NCT01427608|9849091|FG001|Overall Study|Withdrawal by Subject|3
6192043|NCT01427608|9849090|FG000|Overall Study|Relapsed-all cause|13
6192044|NCT01427608|9849091|FG001|Overall Study|Relapsed-all cause|34
6192045|NCT01427608|9849090|FG000|Overall Study|Events not attributed to study meds|0
6192046|NCT01427608|9849091|FG001|Overall Study|Events not attributed to study meds|1
6192047|NCT01427738|9849101|FG000|Overall Study|Death|12
6192048|NCT01427738|9849102|FG001|Overall Study|Death|9
6192049|NCT01427738|9849101|FG000|Overall Study|Severe debilitation, unable to continue|0
6192050|NCT01427738|9849102|FG001|Overall Study|Severe debilitation, unable to continue|1
6192051|NCT01427738|9849101|FG000|Overall Study|Subject unable to get to clinic|5
6192052|NCT01427738|9849102|FG001|Overall Study|Subject unable to get to clinic|2
6192053|NCT01427738|9849101|FG000|Overall Study|Withdrawal by Subject|0
6192054|NCT01427738|9849102|FG001|Overall Study|Withdrawal by Subject|2
6192055|NCT01427738|9849101|FG000|Overall Study|Subject not willing to adhere to reqs|1
6192056|NCT01427738|9849102|FG001|Overall Study|Subject not willing to adhere to reqs|2
6192057|NCT01427738|9849101|FG000|Overall Study|Lost to Follow-up|1
6192058|NCT01427738|9849102|FG001|Overall Study|Lost to Follow-up|5
6192059|NCT01427751|9849110|FG000|Overall Study|Adverse Event|18
6192060|NCT01427751|9849111|FG001|Overall Study|Adverse Event|2
6192061|NCT01427751|9849110|FG000|Overall Study|No further treatment benefit expected|5
6192062|NCT01427751|9849111|FG001|Overall Study|No further treatment benefit expected|1
6082530|NCT00629265|9690572|FG000|Overall Study|Needed Esophageal Dilation|4
6082531|NCT00629265|9690573|FG001|Overall Study|Needed Esophageal Dilation|1
6082532|NCT00629265|9690572|FG000|Overall Study|Unrelated Medical Complications|3
6082533|NCT00629265|9690573|FG001|Overall Study|Unrelated Medical Complications|1
6082534|NCT00629265|9690572|FG000|Overall Study|Unknown Reason|2
6082535|NCT00629265|9690573|FG001|Overall Study|Unknown Reason|2
6082536|NCT00629707|9690589|FG000|Overall Study|Withdrawal by Subject|0
6082537|NCT00629707|9690590|FG001|Overall Study|Withdrawal by Subject|1
6082538|NCT00629707|9690589|FG000|Overall Study|Physician Decision|0
6082539|NCT00629707|9690590|FG001|Overall Study|Physician Decision|1
6082540|NCT00629772|9690598|FG000|Second Intervention Week 14 - Week 26|Adverse Event|1
6192063|NCT01427751|9849110|FG000|Overall Study|Lost to Follow-up|3
6192064|NCT01427751|9849111|FG001|Overall Study|Lost to Follow-up|1
6164157|NCT01208337|9807406|FG000|Overall Study|Death|3
6164158|NCT01208402|9807412|FG000|Overall Study|Withdrawal by Subject|1
6164159|NCT01208402|9807413|FG001|Overall Study|Withdrawal by Subject|0
6164160|NCT01208415|9807419|FG000|Overall Study|Death|1
6164161|NCT01208415|9807419|FG000|Overall Study|Lost to Follow-up|2
6164162|NCT01208415|9807419|FG000|Overall Study|Withdrawal by Subject|3
6164163|NCT01208415|9807419|FG000|Overall Study|Device not placed|1
6164164|NCT01208415|9807419|FG000|Overall Study|Still be eligible for follow-up|33
6164165|NCT01208870|9807425|FG000|Overall Study|Lost to Follow-up|2
6164166|NCT01208870|9807426|FG001|Overall Study|Lost to Follow-up|8
6164167|NCT01208961|9807443|FG000|High-Fat Period III|Protocol Violation|1
6164168|NCT01208961|9807444|FG001|High-Fat Period III|Protocol Violation|0
6164169|NCT01209078|9807451|FG000|Overall Study|Adverse Event|5
6164170|NCT01209078|9807452|FG001|Overall Study|Adverse Event|0
6164171|NCT01209078|9807451|FG000|Overall Study|Lost to Follow-up|4
6164172|NCT01209078|9807452|FG001|Overall Study|Lost to Follow-up|0
6164173|NCT01209078|9807451|FG000|Overall Study|Physician Decision|5
6164174|NCT01209078|9807452|FG001|Overall Study|Physician Decision|2
6164175|NCT01209078|9807451|FG000|Overall Study|Withdrawal by Subject|2
6164176|NCT01209078|9807452|FG001|Overall Study|Withdrawal by Subject|1
6164177|NCT01209143|9807462|FG000|Overall Study|Adverse Event|2
6164178|NCT01209143|9807463|FG001|Overall Study|Adverse Event|1
6164179|NCT01209143|9807462|FG000|Overall Study|Death|0
6164180|NCT01209143|9807463|FG001|Overall Study|Death|1
6164181|NCT01209143|9807462|FG000|Overall Study|Physician Decision|3
6164182|NCT01209143|9807463|FG001|Overall Study|Physician Decision|1
6164183|NCT01209143|9807462|FG000|Overall Study|Lost to Follow-up|1
6164184|NCT01209143|9807463|FG001|Overall Study|Lost to Follow-up|0
6164185|NCT01209143|9807462|FG000|Overall Study|Withdrawal by Subject|2
6164186|NCT01209143|9807463|FG001|Overall Study|Withdrawal by Subject|1
6164187|NCT01209143|9807462|FG000|Overall Study|Disease progression|11
6164188|NCT01209143|9807463|FG001|Overall Study|Disease progression|16
6164189|NCT01209286|9807515|FG000|Overall Study|Adverse Event|4
6164190|NCT01209286|9807516|FG001|Overall Study|Adverse Event|3
6164191|NCT01209286|9807517|FG002|Overall Study|Adverse Event|1
6164192|NCT01209286|9807515|FG000|Overall Study|Hematological Relapse After Remission|0
6326567|NCT02952820|10069823|FG000|Active Treatment Period (6 Months)|Subject choice|0
6326568|NCT02952820|10069824|FG001|Active Treatment Period (6 Months)|Subject choice|10
6326569|NCT02952820|10069825|FG002|Active Treatment Period (6 Months)|Subject choice|7
6326570|NCT02952820|10069823|FG000|Active Treatment Period (6 Months)|Inadequate therapeutic effect|0
6326571|NCT02952820|10069824|FG001|Active Treatment Period (6 Months)|Inadequate therapeutic effect|6
6326572|NCT02952820|10069825|FG002|Active Treatment Period (6 Months)|Inadequate therapeutic effect|2
6326573|NCT02952820|10069823|FG000|Active Treatment Period (6 Months)|Withdrawal of consent|0
6326574|NCT02952820|10069824|FG001|Active Treatment Period (6 Months)|Withdrawal of consent|6
6326575|NCT02952820|10069825|FG002|Active Treatment Period (6 Months)|Withdrawal of consent|8
6326576|NCT02952820|10069823|FG000|Active Treatment Period (6 Months)|Other than specified|0
6326577|NCT02952820|10069824|FG001|Active Treatment Period (6 Months)|Other than specified|6
6326578|NCT02952820|10069825|FG002|Active Treatment Period (6 Months)|Other than specified|2
6326579|NCT02952820|10069823|FG000|Active Treatment Period (6 Months)|Not treated|0
6326580|NCT02952820|10069824|FG001|Active Treatment Period (6 Months)|Not treated|0
6326581|NCT02952820|10069825|FG002|Active Treatment Period (6 Months)|Not treated|1
6326582|NCT02952898|10069904|FG000|Overall Study|Withdrawal by Subject|10
6326583|NCT02952898|10069905|FG001|Overall Study|Withdrawal by Subject|8
6326584|NCT02952898|10069906|FG002|Overall Study|Withdrawal by Subject|8
6326585|NCT02952898|10069904|FG000|Overall Study|Adverse Event|8
6326586|NCT02952898|10069905|FG001|Overall Study|Adverse Event|8
6326587|NCT02952898|10069906|FG002|Overall Study|Adverse Event|3
6326588|NCT02952898|10069904|FG000|Overall Study|Lost to Follow-up|3
6326589|NCT02952898|10069905|FG001|Overall Study|Lost to Follow-up|2
6326590|NCT02952898|10069906|FG002|Overall Study|Lost to Follow-up|2
6326591|NCT02952898|10069904|FG000|Overall Study|Non-compliance with study drug|1
6326592|NCT02952898|10069905|FG001|Overall Study|Non-compliance with study drug|1
6326593|NCT02952898|10069906|FG002|Overall Study|Non-compliance with study drug|2
6326594|NCT02953262|10069918|FG000|Overall Study|Used portal during 6 months prior to randomization|3
6326595|NCT02953262|10069919|FG001|Overall Study|Used portal during 6 months prior to randomization|6
6326596|NCT02953262|10069920|FG002|Overall Study|Used portal during 6 months prior to randomization|3
6326597|NCT02953262|10069921|FG003|Overall Study|Used portal during 6 months prior to randomization|3
6326598|NCT02953314|10069937|FG000|Overall Study|Adverse Event|0
6326599|NCT02953314|10069938|FG001|Overall Study|Adverse Event|1
6326600|NCT02953314|10069937|FG000|Overall Study|Withdrawal of consent (not due to AE)|0
6326601|NCT02953314|10069938|FG001|Overall Study|Withdrawal of consent (not due to AE)|2
6326602|NCT02953639|10069963|FG000|Overall Study|Adverse Event|2
6326603|NCT02953639|10069964|FG001|Overall Study|Adverse Event|0
6326604|NCT02953639|10069965|FG002|Overall Study|Adverse Event|1
6326605|NCT02953639|10069963|FG000|Overall Study|Lost to Follow-up|8
6326606|NCT02953639|10069964|FG001|Overall Study|Lost to Follow-up|4
6164193|NCT01209286|9807516|FG001|Overall Study|Hematological Relapse After Remission|1
6164194|NCT01209286|9807517|FG002|Overall Study|Hematological Relapse After Remission|1
6164195|NCT01209286|9807515|FG000|Overall Study|Remission Not Achieved in 2 Cycles|1
6164196|NCT01209286|9807516|FG001|Overall Study|Remission Not Achieved in 2 Cycles|3
6326607|NCT02953639|10069965|FG002|Overall Study|Lost to Follow-up|3
6326608|NCT02953639|10069963|FG000|Overall Study|Non-Compliance With Study Drug|0
6326609|NCT02953639|10069964|FG001|Overall Study|Non-Compliance With Study Drug|2
6326610|NCT02953639|10069965|FG002|Overall Study|Non-Compliance With Study Drug|1
6326611|NCT02953639|10069963|FG000|Overall Study|Multiple Reasons|1
6326612|NCT02953639|10069964|FG001|Overall Study|Multiple Reasons|0
6326613|NCT02953639|10069965|FG002|Overall Study|Multiple Reasons|1
6164197|NCT01209286|9807517|FG002|Overall Study|Remission Not Achieved in 2 Cycles|1
6164198|NCT01209286|9807515|FG000|Overall Study|Physician Decision|0
6164199|NCT01209286|9807516|FG001|Overall Study|Physician Decision|2
6164200|NCT01209286|9807517|FG002|Overall Study|Physician Decision|0
6164201|NCT01209286|9807515|FG000|Overall Study|Other|0
6164202|NCT01209286|9807516|FG001|Overall Study|Other|1
6164203|NCT01209286|9807517|FG002|Overall Study|Other|0
6164204|NCT01209325|9807534|FG000|Overall Study|Lost to Follow-up|24
6164205|NCT01209325|9807534|FG000|Overall Study|Adverse Event|1
6164206|NCT01209325|9807534|FG000|Overall Study|Relocated|3
6164207|NCT01209325|9807534|FG000|Overall Study|Refusal after starting therapy|8
6164208|NCT01209325|9807534|FG000|Overall Study|Protocol Violation|4
6164209|NCT01209325|9807534|FG000|Overall Study|Refusal prior to therapy|1
6164210|NCT01209325|9807534|FG000|Overall Study|Incarceration|2
6164211|NCT01209598|9807566|FG000|Overall Study|Withdrawal by Subject|1
6164212|NCT01209598|9807567|FG001|Overall Study|Withdrawal by Subject|0
6164213|NCT01209624|9807574|FG000|Overall Study|Death|2
6164214|NCT01209624|9807574|FG000|Overall Study|Adverse Event|13
6164215|NCT01209624|9807574|FG000|Overall Study|Lack of Efficacy|17
6164216|NCT01209624|9807574|FG000|Overall Study|Lost to Follow-up|290
6164217|NCT01209624|9807574|FG000|Overall Study|Other|4
6164218|NCT01209689|9807580|FG000|Overall Study|Insufficient Therapeutic Response|7
6164219|NCT01209689|9807581|FG001|Overall Study|Insufficient Therapeutic Response|2
6164220|NCT01209689|9807580|FG000|Overall Study|Refused Treatment|8
6164221|NCT01209689|9807581|FG001|Overall Study|Refused Treatment|3
6164222|NCT01209689|9807580|FG000|Overall Study|Adverse Event|4
6164223|NCT01209689|9807581|FG001|Overall Study|Adverse Event|0
6164224|NCT01209689|9807580|FG000|Overall Study|Violation of Selection Criteria at Entry|1
6164225|NCT01209689|9807581|FG001|Overall Study|Violation of Selection Criteria at Entry|0
6164226|NCT01209689|9807580|FG000|Overall Study|Failure to Return|3
6164227|NCT01209689|9807581|FG001|Overall Study|Failure to Return|0
6164228|NCT01209689|9807580|FG000|Overall Study|Sponsor's Decision to Stop the Study|68
6164229|NCT01209689|9807581|FG001|Overall Study|Sponsor's Decision to Stop the Study|17
6164230|NCT01209780|9807615|FG000|Overall Study|Adverse Event|0
6164231|NCT01209780|9807616|FG001|Overall Study|Adverse Event|1
6164232|NCT01209780|9807617|FG002|Overall Study|Adverse Event|0
6164233|NCT01209780|9807618|FG003|Overall Study|Adverse Event|0
6164234|NCT01209780|9807619|FG004|Overall Study|Adverse Event|0
6164235|NCT01209780|9807615|FG000|Overall Study|Withdrawal by Subject|9
6164236|NCT01209780|9807616|FG001|Overall Study|Withdrawal by Subject|2
6164237|NCT01209780|9807617|FG002|Overall Study|Withdrawal by Subject|1
6164238|NCT01209780|9807618|FG003|Overall Study|Withdrawal by Subject|1
6164239|NCT01209780|9807619|FG004|Overall Study|Withdrawal by Subject|0
6164240|NCT01209780|9807615|FG000|Overall Study|Lost to Follow-up|17
6164241|NCT01209780|9807616|FG001|Overall Study|Lost to Follow-up|12
6164242|NCT01209780|9807617|FG002|Overall Study|Lost to Follow-up|3
6164243|NCT01209780|9807618|FG003|Overall Study|Lost to Follow-up|9
6164244|NCT01209780|9807619|FG004|Overall Study|Lost to Follow-up|4
6164245|NCT01209780|9807615|FG000|Overall Study|Protocol Violation|0
6164246|NCT01209780|9807616|FG001|Overall Study|Protocol Violation|1
6164247|NCT01209780|9807617|FG002|Overall Study|Protocol Violation|0
6164248|NCT01209780|9807618|FG003|Overall Study|Protocol Violation|0
6164249|NCT01209780|9807619|FG004|Overall Study|Protocol Violation|0
6164250|NCT01209780|9807615|FG000|Overall Study|Inappropriate enrollment|0
6164251|NCT01209780|9807616|FG001|Overall Study|Inappropriate enrollment|2
6164252|NCT01209780|9807617|FG002|Overall Study|Inappropriate enrollment|0
6164253|NCT01209780|9807618|FG003|Overall Study|Inappropriate enrollment|0
6164254|NCT01209780|9807619|FG004|Overall Study|Inappropriate enrollment|1
6164255|NCT01209832|9807632|FG000|Period 1|Sponsor Decision and was not dosed|1
6164256|NCT01209832|9807632|FG000|Period 2|Sponsor Decision|1
6164257|NCT01209949|9807643|FG000|Overall Study|Lost to Follow-up|3
6164258|NCT01210001|9807650|FG000|Overall Study|Not treated|1
6164259|NCT01210001|9807651|FG001|Overall Study|Not treated|0
6326614|NCT02953639|10069963|FG000|Overall Study|Physician Decision|1
6164260|NCT01210001|9807652|FG002|Overall Study|Not treated|0
6164261|NCT01210001|9807650|FG000|Overall Study|Adverse Event|4
6164262|NCT01210001|9807651|FG001|Overall Study|Adverse Event|2
6164263|NCT01210001|9807652|FG002|Overall Study|Adverse Event|5
6164264|NCT01210001|9807650|FG000|Overall Study|Non compliant with protocol|2
6164265|NCT01210001|9807651|FG001|Overall Study|Non compliant with protocol|2
6164266|NCT01210001|9807652|FG002|Overall Study|Non compliant with protocol|3
6164267|NCT01210001|9807650|FG000|Overall Study|Lost to Follow-up|4
6164268|NCT01210001|9807651|FG001|Overall Study|Lost to Follow-up|3
6164269|NCT01210001|9807652|FG002|Overall Study|Lost to Follow-up|2
6164270|NCT01210001|9807650|FG000|Overall Study|Patient refusal to continue,not due toAE|6
6164271|NCT01210001|9807651|FG001|Overall Study|Patient refusal to continue,not due toAE|2
6326615|NCT02953639|10069964|FG001|Overall Study|Physician Decision|0
6326616|NCT02953639|10069965|FG002|Overall Study|Physician Decision|0
6326617|NCT02953639|10069963|FG000|Overall Study|Withdrawal by Subject|7
6326618|NCT02953639|10069964|FG001|Overall Study|Withdrawal by Subject|8
6326619|NCT02953639|10069965|FG002|Overall Study|Withdrawal by Subject|10
6326620|NCT02953639|10069963|FG000|Overall Study|Completed or Discontinued information is missing|1
6326621|NCT02953639|10069964|FG001|Overall Study|Completed or Discontinued information is missing|0
6326622|NCT02953639|10069965|FG002|Overall Study|Completed or Discontinued information is missing|0
6326623|NCT02953678|10069975|FG000|Overall Study|Adverse Event|20
6326624|NCT02953678|10069975|FG000|Overall Study|Death|7
6326625|NCT02953678|10069975|FG000|Overall Study|Physician Decision|23
6326626|NCT02953678|10069975|FG000|Overall Study|Progressive Disease of GVHD|7
6326627|NCT02953678|10069975|FG000|Overall Study|Relapse of Underlying Malignancy|3
6326628|NCT02953678|10069975|FG000|Overall Study|Withdrawal by participant|3
6326629|NCT02953678|10069975|FG000|Overall Study|Includes 2 participants who discontinued ruxolitinib treatment because of clinical improvement|5
6326630|NCT02953678|10069975|FG000|Overall Study|Participants were transferred to commercial product.|3
6326631|NCT02953782|10069988|FG000|Phase 1b (Maximum Duration: 14.3 Months)|Death|5
6326632|NCT02953782|10069989|FG001|Phase 1b (Maximum Duration: 14.3 Months)|Death|2
6326633|NCT02953782|10069990|FG002|Phase 1b (Maximum Duration: 14.3 Months)|Death|6
6326634|NCT02953782|10069991|FG003|Phase 1b (Maximum Duration: 14.3 Months)|Death|6
6326635|NCT02953782|10069992|FG004|Phase 1b (Maximum Duration: 14.3 Months)|Death|4
6326636|NCT02953782|10069993|FG005|Phase 1b (Maximum Duration: 14.3 Months)|Death|0
6326637|NCT02953782|10069994|FG006|Phase 1b (Maximum Duration: 14.3 Months)|Death|0
6326638|NCT02953782|10069995|FG007|Phase 1b (Maximum Duration: 14.3 Months)|Death|0
6326639|NCT02953782|10069988|FG000|Phase 1b (Maximum Duration: 14.3 Months)|Withdrawal by Subject|1
6326640|NCT02953782|10069989|FG001|Phase 1b (Maximum Duration: 14.3 Months)|Withdrawal by Subject|0
6164272|NCT01210001|9807652|FG002|Overall Study|Patient refusal to continue,not due toAE|1
6164273|NCT01210001|9807650|FG000|Overall Study|Other reason not defined above|2
6326641|NCT02953782|10069990|FG002|Phase 1b (Maximum Duration: 14.3 Months)|Withdrawal by Subject|2
6326642|NCT02953782|10069991|FG003|Phase 1b (Maximum Duration: 14.3 Months)|Withdrawal by Subject|0
6326643|NCT02953782|10069992|FG004|Phase 1b (Maximum Duration: 14.3 Months)|Withdrawal by Subject|1
6326644|NCT02953782|10069993|FG005|Phase 1b (Maximum Duration: 14.3 Months)|Withdrawal by Subject|0
6326645|NCT02953782|10069994|FG006|Phase 1b (Maximum Duration: 14.3 Months)|Withdrawal by Subject|0
6326646|NCT02953782|10069995|FG007|Phase 1b (Maximum Duration: 14.3 Months)|Withdrawal by Subject|0
6326647|NCT02953782|10069988|FG000|Phase 1b (Maximum Duration: 14.3 Months)|Discontinued by Sponsor|0
6326648|NCT02953782|10069989|FG001|Phase 1b (Maximum Duration: 14.3 Months)|Discontinued by Sponsor|1
6326649|NCT02953782|10069990|FG002|Phase 1b (Maximum Duration: 14.3 Months)|Discontinued by Sponsor|0
6326650|NCT02953782|10069991|FG003|Phase 1b (Maximum Duration: 14.3 Months)|Discontinued by Sponsor|1
6326651|NCT02953782|10069992|FG004|Phase 1b (Maximum Duration: 14.3 Months)|Discontinued by Sponsor|1
6326652|NCT02953782|10069993|FG005|Phase 1b (Maximum Duration: 14.3 Months)|Discontinued by Sponsor|0
6326653|NCT02953782|10069994|FG006|Phase 1b (Maximum Duration: 14.3 Months)|Discontinued by Sponsor|0
6326654|NCT02953782|10069995|FG007|Phase 1b (Maximum Duration: 14.3 Months)|Discontinued by Sponsor|0
6326655|NCT02953782|10069988|FG000|Phase 1b (Maximum Duration: 14.3 Months)|Participant placed in hospice care|0
6326656|NCT02953782|10069989|FG001|Phase 1b (Maximum Duration: 14.3 Months)|Participant placed in hospice care|0
6326657|NCT02953782|10069990|FG002|Phase 1b (Maximum Duration: 14.3 Months)|Participant placed in hospice care|1
6326658|NCT02953782|10069991|FG003|Phase 1b (Maximum Duration: 14.3 Months)|Participant placed in hospice care|1
6326659|NCT02953782|10069992|FG004|Phase 1b (Maximum Duration: 14.3 Months)|Participant placed in hospice care|0
6326660|NCT02953782|10069993|FG005|Phase 1b (Maximum Duration: 14.3 Months)|Participant placed in hospice care|0
6326661|NCT02953782|10069994|FG006|Phase 1b (Maximum Duration: 14.3 Months)|Participant placed in hospice care|0
6326662|NCT02953782|10069995|FG007|Phase 1b (Maximum Duration: 14.3 Months)|Participant placed in hospice care|0
6326663|NCT02953782|10069988|FG000|Phase 2 (Maximum Duration: 11.1 Months)|Death|0
6326664|NCT02953782|10069989|FG001|Phase 2 (Maximum Duration: 11.1 Months)|Death|0
6326665|NCT02953782|10069990|FG002|Phase 2 (Maximum Duration: 11.1 Months)|Death|0
6164274|NCT01210001|9807651|FG001|Overall Study|Other reason not defined above|2
6164275|NCT01210001|9807652|FG002|Overall Study|Other reason not defined above|1
6164276|NCT01210118|9807671|FG000|Overall Study|Lost to Follow-up|1
6164277|NCT01210118|9807672|FG001|Overall Study|Lost to Follow-up|1
6164278|NCT01210118|9807671|FG000|Overall Study|Protocol Violation|1
6164279|NCT01210118|9807672|FG001|Overall Study|Protocol Violation|1
6164280|NCT01210118|9807671|FG000|Overall Study|Spontaneous abortion|1
6164281|NCT01210118|9807672|FG001|Overall Study|Spontaneous abortion|3
6164282|NCT01210144|9807683|FG000|Overall Study|Lack of ovarian response|1
6164283|NCT01210144|9807684|FG001|Overall Study|Lack of ovarian response|0
6164284|NCT01210144|9807683|FG000|Overall Study|No fertilization|1
6164285|NCT01210144|9807684|FG001|Overall Study|No fertilization|0
6164286|NCT01210144|9807683|FG000|Overall Study|No transfer|1
6164287|NCT01210144|9807684|FG001|Overall Study|No transfer|0
6326666|NCT02953782|10069991|FG003|Phase 2 (Maximum Duration: 11.1 Months)|Death|0
6164288|NCT01210222|9807712|FG000|Overall Study|Ineligible|2
6164289|NCT01210222|9807712|FG000|Overall Study|Never treated|1
6326667|NCT02953782|10069992|FG004|Phase 2 (Maximum Duration: 11.1 Months)|Death|0
6326668|NCT02953782|10069993|FG005|Phase 2 (Maximum Duration: 11.1 Months)|Death|14
6326669|NCT02953782|10069994|FG006|Phase 2 (Maximum Duration: 11.1 Months)|Death|11
6326670|NCT02953782|10069995|FG007|Phase 2 (Maximum Duration: 11.1 Months)|Death|8
6326671|NCT02953782|10069988|FG000|Phase 2 (Maximum Duration: 11.1 Months)|Withdrawal by Subject|0
6326672|NCT02953782|10069989|FG001|Phase 2 (Maximum Duration: 11.1 Months)|Withdrawal by Subject|0
6326673|NCT02953782|10069990|FG002|Phase 2 (Maximum Duration: 11.1 Months)|Withdrawal by Subject|0
6326674|NCT02953782|10069991|FG003|Phase 2 (Maximum Duration: 11.1 Months)|Withdrawal by Subject|0
6326675|NCT02953782|10069992|FG004|Phase 2 (Maximum Duration: 11.1 Months)|Withdrawal by Subject|0
6326676|NCT02953782|10069993|FG005|Phase 2 (Maximum Duration: 11.1 Months)|Withdrawal by Subject|1
6326677|NCT02953782|10069994|FG006|Phase 2 (Maximum Duration: 11.1 Months)|Withdrawal by Subject|2
6326678|NCT02953782|10069995|FG007|Phase 2 (Maximum Duration: 11.1 Months)|Withdrawal by Subject|3
6326679|NCT02953782|10069988|FG000|Phase 2 (Maximum Duration: 11.1 Months)|Discontinued by Sponsor|0
6326680|NCT02953782|10069989|FG001|Phase 2 (Maximum Duration: 11.1 Months)|Discontinued by Sponsor|0
6082541|NCT00629772|9690599|FG001|Second Intervention Week 14 - Week 26|Adverse Event|1
6082542|NCT00629772|9690598|FG000|Second Intervention Week 14 - Week 26|Lack of Efficacy|0
6082543|NCT00629772|9690599|FG001|Second Intervention Week 14 - Week 26|Lack of Efficacy|1
6326681|NCT02953782|10069990|FG002|Phase 2 (Maximum Duration: 11.1 Months)|Discontinued by Sponsor|0
6326682|NCT02953782|10069991|FG003|Phase 2 (Maximum Duration: 11.1 Months)|Discontinued by Sponsor|0
6326683|NCT02953782|10069992|FG004|Phase 2 (Maximum Duration: 11.1 Months)|Discontinued by Sponsor|0
6326684|NCT02953782|10069993|FG005|Phase 2 (Maximum Duration: 11.1 Months)|Discontinued by Sponsor|1
6326685|NCT02953782|10069994|FG006|Phase 2 (Maximum Duration: 11.1 Months)|Discontinued by Sponsor|1
6326686|NCT02953782|10069995|FG007|Phase 2 (Maximum Duration: 11.1 Months)|Discontinued by Sponsor|4
6326687|NCT02953782|10069988|FG000|Phase 2 (Maximum Duration: 11.1 Months)|Lost to Follow-up|0
6326688|NCT02953782|10069989|FG001|Phase 2 (Maximum Duration: 11.1 Months)|Lost to Follow-up|0
6326689|NCT02953782|10069990|FG002|Phase 2 (Maximum Duration: 11.1 Months)|Lost to Follow-up|0
6326690|NCT02953782|10069991|FG003|Phase 2 (Maximum Duration: 11.1 Months)|Lost to Follow-up|0
6326691|NCT02953782|10069992|FG004|Phase 2 (Maximum Duration: 11.1 Months)|Lost to Follow-up|0
6082544|NCT00630032|9690608|FG000|Overall Study|Death|55
6082545|NCT00630032|9690609|FG001|Overall Study|Death|49
6082546|NCT00630032|9690608|FG000|Overall Study|Withdrawal by Subject|3
6164290|NCT01210352|9807731|FG000|Overall Study|Adverse Event|0
6164291|NCT01210352|9807732|FG001|Overall Study|Adverse Event|0
6164292|NCT01210352|9807733|FG002|Overall Study|Adverse Event|0
6164293|NCT01210352|9807734|FG003|Overall Study|Adverse Event|0
6164294|NCT01210352|9807735|FG004|Overall Study|Adverse Event|0
6164295|NCT01210352|9807736|FG005|Overall Study|Adverse Event|0
6164296|NCT01210352|9807737|FG006|Overall Study|Adverse Event|0
6164297|NCT01210352|9807738|FG007|Overall Study|Adverse Event|2
6164298|NCT01210352|9807739|FG008|Overall Study|Adverse Event|1
6164299|NCT01210352|9807731|FG000|Overall Study|Lack of Efficacy|0
6164300|NCT01210352|9807732|FG001|Overall Study|Lack of Efficacy|0
6164301|NCT01210352|9807733|FG002|Overall Study|Lack of Efficacy|0
6164302|NCT01210352|9807734|FG003|Overall Study|Lack of Efficacy|0
6164303|NCT01210352|9807735|FG004|Overall Study|Lack of Efficacy|0
6164304|NCT01210352|9807736|FG005|Overall Study|Lack of Efficacy|0
6164305|NCT01210352|9807737|FG006|Overall Study|Lack of Efficacy|1
6164306|NCT01210352|9807738|FG007|Overall Study|Lack of Efficacy|0
6164307|NCT01210352|9807739|FG008|Overall Study|Lack of Efficacy|0
6164308|NCT01210352|9807731|FG000|Overall Study|Physician Decision|0
6164309|NCT01210352|9807732|FG001|Overall Study|Physician Decision|0
6164310|NCT01210352|9807733|FG002|Overall Study|Physician Decision|0
6164311|NCT01210352|9807734|FG003|Overall Study|Physician Decision|0
6164312|NCT01210352|9807735|FG004|Overall Study|Physician Decision|0
6164313|NCT01210352|9807736|FG005|Overall Study|Physician Decision|0
6164314|NCT01210352|9807737|FG006|Overall Study|Physician Decision|0
6164315|NCT01210352|9807738|FG007|Overall Study|Physician Decision|1
6164316|NCT01210352|9807739|FG008|Overall Study|Physician Decision|2
6164317|NCT01210352|9807731|FG000|Overall Study|Withdrawal by Subject|0
6164318|NCT01210352|9807732|FG001|Overall Study|Withdrawal by Subject|0
6164319|NCT01210352|9807733|FG002|Overall Study|Withdrawal by Subject|1
6164320|NCT01210352|9807734|FG003|Overall Study|Withdrawal by Subject|0
6164321|NCT01210352|9807735|FG004|Overall Study|Withdrawal by Subject|0
6164322|NCT01210352|9807736|FG005|Overall Study|Withdrawal by Subject|0
6164323|NCT01210352|9807737|FG006|Overall Study|Withdrawal by Subject|1
6164324|NCT01210352|9807738|FG007|Overall Study|Withdrawal by Subject|0
6164325|NCT01210352|9807739|FG008|Overall Study|Withdrawal by Subject|1
6082547|NCT00630032|9690609|FG001|Overall Study|Withdrawal by Subject|2
6082548|NCT00630032|9690608|FG000|Overall Study|Lost to Follow-up|18
6082549|NCT00630032|9690609|FG001|Overall Study|Lost to Follow-up|31
6082550|NCT00630032|9690608|FG000|Overall Study|Protocol Violation|1
6082551|NCT00630032|9690609|FG001|Overall Study|Protocol Violation|0
6082552|NCT00630032|9690608|FG000|Overall Study|Patient has moved|1
6082553|NCT00630032|9690609|FG001|Overall Study|Patient has moved|1
6082554|NCT00630032|9690608|FG000|Overall Study|Disease progression|1
6082555|NCT00630032|9690609|FG001|Overall Study|Disease progression|1
6326692|NCT02953782|10069993|FG005|Phase 2 (Maximum Duration: 11.1 Months)|Lost to Follow-up|0
6164326|NCT01210352|9807731|FG000|Overall Study|Patient Discharged Early|0
6164327|NCT01210352|9807732|FG001|Overall Study|Patient Discharged Early|0
6164328|NCT01210352|9807733|FG002|Overall Study|Patient Discharged Early|1
6164329|NCT01210352|9807734|FG003|Overall Study|Patient Discharged Early|0
6164330|NCT01210352|9807735|FG004|Overall Study|Patient Discharged Early|0
6164331|NCT01210352|9807736|FG005|Overall Study|Patient Discharged Early|0
6164332|NCT01210352|9807737|FG006|Overall Study|Patient Discharged Early|0
6164333|NCT01210352|9807738|FG007|Overall Study|Patient Discharged Early|0
6164334|NCT01210352|9807739|FG008|Overall Study|Patient Discharged Early|0
6164335|NCT01210443|9807844|FG000|Overall Study|Study terminated by sponsor|2
6164336|NCT01210495|9807852|FG000|Overall Study|Participant Refused Further Follow-Up|1
6164337|NCT01210495|9807853|FG001|Overall Study|Participant Refused Further Follow-Up|0
6164338|NCT01210495|9807854|FG002|Overall Study|Participant Refused Further Follow-Up|11
6164339|NCT01210495|9807855|FG003|Overall Study|Participant Refused Further Follow-Up|2
6164340|NCT01210495|9807852|FG000|Overall Study|Death|14
6164341|NCT01210495|9807853|FG001|Overall Study|Death|7
6164342|NCT01210495|9807854|FG002|Overall Study|Death|112
6164343|NCT01210495|9807855|FG003|Overall Study|Death|54
6164344|NCT01210495|9807852|FG000|Overall Study|Study Terminated by Sponsor|0
6164345|NCT01210495|9807853|FG001|Overall Study|Study Terminated by Sponsor|0
6164346|NCT01210495|9807854|FG002|Overall Study|Study Terminated by Sponsor|4
6164347|NCT01210495|9807855|FG003|Overall Study|Study Terminated by Sponsor|11
6164348|NCT01210495|9807852|FG000|Overall Study|Lost to Follow-up|0
6164349|NCT01210495|9807853|FG001|Overall Study|Lost to Follow-up|0
6164350|NCT01210495|9807854|FG002|Overall Study|Lost to Follow-up|1
6164351|NCT01210495|9807855|FG003|Overall Study|Lost to Follow-up|1
6164352|NCT01210495|9807852|FG000|Overall Study|Other unspecified|0
6164353|NCT01210495|9807853|FG001|Overall Study|Other unspecified|0
6164354|NCT01210495|9807854|FG002|Overall Study|Other unspecified|6
6164355|NCT01210495|9807855|FG003|Overall Study|Other unspecified|0
6164356|NCT01210651|9807890|FG000|Overall Study|Lost to Follow-up|1
6164357|NCT01210651|9807891|FG001|Overall Study|Lost to Follow-up|1
6164358|NCT01210651|9807890|FG000|Overall Study|schedule conflicts|1
6164359|NCT01210651|9807891|FG001|Overall Study|schedule conflicts|5
6164360|NCT01210651|9807890|FG000|Overall Study|Withdrawn by PI for disruptive behavior|0
6164361|NCT01210651|9807891|FG001|Overall Study|Withdrawn by PI for disruptive behavior|1
6164362|NCT01210651|9807890|FG000|Overall Study|Withdrawal by Subject|1
6164363|NCT01210651|9807891|FG001|Overall Study|Withdrawal by Subject|1
6164364|NCT01210651|9807890|FG000|Overall Study|Injury outside study|2
6164365|NCT01210651|9807891|FG001|Overall Study|Injury outside study|0
6164366|NCT01210664|9807901|FG000|Cohort 3: PolyTregs 3.2 x 10^8 Cells|Lost to Follow-up|0
6164367|NCT01210664|9807902|FG001|Cohort 3: PolyTregs 3.2 x 10^8 Cells|Lost to Follow-up|0
6164368|NCT01210664|9807903|FG002|Cohort 3: PolyTregs 3.2 x 10^8 Cells|Lost to Follow-up|1
6164369|NCT01210664|9807904|FG003|Cohort 3: PolyTregs 3.2 x 10^8 Cells|Lost to Follow-up|0
6164370|NCT01210664|9807901|FG000|Cohort 3: PolyTregs 3.2 x 10^8 Cells|Treg Manufacturing Failure|0
6164371|NCT01210664|9807902|FG001|Cohort 3: PolyTregs 3.2 x 10^8 Cells|Treg Manufacturing Failure|0
6164372|NCT01210664|9807903|FG002|Cohort 3: PolyTregs 3.2 x 10^8 Cells|Treg Manufacturing Failure|1
6164373|NCT01210664|9807904|FG003|Cohort 3: PolyTregs 3.2 x 10^8 Cells|Treg Manufacturing Failure|0
6164374|NCT01210664|9807901|FG000|Cohort 4: PolyTregs 26 x 10^8 Cells|Treg Manufacturing Failure|0
6164375|NCT01210664|9807902|FG001|Cohort 4: PolyTregs 26 x 10^8 Cells|Treg Manufacturing Failure|0
6164376|NCT01210664|9807903|FG002|Cohort 4: PolyTregs 26 x 10^8 Cells|Treg Manufacturing Failure|0
6164377|NCT01210664|9807904|FG003|Cohort 4: PolyTregs 26 x 10^8 Cells|Treg Manufacturing Failure|1
6164378|NCT01210690|9807914|FG000|Overall Study|Adverse Event|7
6164379|NCT01210690|9807914|FG000|Overall Study|Lack of Efficacy|12
6164380|NCT01210690|9807914|FG000|Overall Study|Lost to Follow-up|3
6164381|NCT01210690|9807914|FG000|Overall Study|Disease Remission|1
6164382|NCT01210690|9807914|FG000|Overall Study|Withdrawal by Subject|1
6164383|NCT01210690|9807914|FG000|Overall Study|Patient refused to swallow|1
6164384|NCT01210690|9807914|FG000|Overall Study|Patient could not take glucose|1
6164385|NCT01210807|9807928|FG000|Overall Study|Lost to Follow-up|1
6164386|NCT01210807|9807929|FG001|Overall Study|Lost to Follow-up|2
6164387|NCT01210807|9807928|FG000|Overall Study|Not implanted bilaterally|2
6164388|NCT01210807|9807929|FG001|Overall Study|Not implanted bilaterally|1
6164389|NCT01211145|9807959|FG000|Overall Study|Reason not specified|3
6164390|NCT01211145|9807960|FG001|Overall Study|Reason not specified|2
6164391|NCT01211145|9807961|FG002|Overall Study|Reason not specified|2
6164392|NCT01211145|9807962|FG003|Overall Study|Reason not specified|1
6164393|NCT01211145|9807959|FG000|Overall Study|Lost to Follow-up|3
6164394|NCT01211145|9807960|FG001|Overall Study|Lost to Follow-up|2
6164395|NCT01211145|9807961|FG002|Overall Study|Lost to Follow-up|1
6164396|NCT01211145|9807962|FG003|Overall Study|Lost to Follow-up|2
6164397|NCT01211145|9807959|FG000|Overall Study|Study-specific withdrawal criteria|1
6164398|NCT01211145|9807960|FG001|Overall Study|Study-specific withdrawal criteria|0
6164399|NCT01211145|9807961|FG002|Overall Study|Study-specific withdrawal criteria|0
6164400|NCT01211145|9807962|FG003|Overall Study|Study-specific withdrawal criteria|0
6164401|NCT01211145|9807959|FG000|Overall Study|Severe noncompliance to protocol|1
6164402|NCT01211145|9807960|FG001|Overall Study|Severe noncompliance to protocol|0
6164403|NCT01211145|9807961|FG002|Overall Study|Severe noncompliance to protocol|0
6164404|NCT01211145|9807962|FG003|Overall Study|Severe noncompliance to protocol|0
6164405|NCT01211145|9807959|FG000|Overall Study|Eligibility criteria not fulfilled|16
6164406|NCT01211145|9807960|FG001|Overall Study|Eligibility criteria not fulfilled|12
6164407|NCT01211145|9807961|FG002|Overall Study|Eligibility criteria not fulfilled|10
6164408|NCT01211145|9807962|FG003|Overall Study|Eligibility criteria not fulfilled|15
6164409|NCT01211145|9807959|FG000|Overall Study|Patient decision|2
6164410|NCT01211145|9807960|FG001|Overall Study|Patient decision|1
6164411|NCT01211145|9807961|FG002|Overall Study|Patient decision|0
6164412|NCT01211145|9807962|FG003|Overall Study|Patient decision|2
6164413|NCT01211184|9807975|FG000|Overall Study|Withdrawal by Subject|0
6164414|NCT01211184|9807976|FG001|Overall Study|Withdrawal by Subject|2
6164415|NCT01211184|9807977|FG002|Overall Study|Withdrawal by Subject|1
6164416|NCT01211197|9807988|FG000|Washout Period 1 (7 Days)|Withdrawal by Subject|0
6164417|NCT01211197|9807989|FG001|Washout Period 1 (7 Days)|Withdrawal by Subject|0
6164418|NCT01211197|9807990|FG002|Washout Period 1 (7 Days)|Withdrawal by Subject|1
6164419|NCT01211197|9807991|FG003|Washout Period 1 (7 Days)|Withdrawal by Subject|0
6164420|NCT01211197|9807992|FG004|Washout Period 1 (7 Days)|Withdrawal by Subject|0
6164421|NCT01211197|9807993|FG005|Washout Period 1 (7 Days)|Withdrawal by Subject|0
6164422|NCT01211197|9807988|FG000|Washout Period 2 (7 Days)|Adverse Event|1
6164423|NCT01211197|9807989|FG001|Washout Period 2 (7 Days)|Adverse Event|0
6164424|NCT01211197|9807990|FG002|Washout Period 2 (7 Days)|Adverse Event|0
6164425|NCT01211197|9807991|FG003|Washout Period 2 (7 Days)|Adverse Event|0
6164426|NCT01211197|9807992|FG004|Washout Period 2 (7 Days)|Adverse Event|0
6164427|NCT01211197|9807993|FG005|Washout Period 2 (7 Days)|Adverse Event|0
6164428|NCT01211262|9808003|FG000|Overall Study|Progressive Disease|18
6164429|NCT01211262|9808004|FG001|Overall Study|Progressive Disease|9
6164430|NCT01211262|9808003|FG000|Overall Study|Adverse Event|4
6164431|NCT01211262|9808004|FG001|Overall Study|Adverse Event|0
6164432|NCT01211262|9808003|FG000|Overall Study|Withdrawal of Consent|1
6164433|NCT01211262|9808004|FG001|Overall Study|Withdrawal of Consent|0
6164434|NCT01211262|9808003|FG000|Overall Study|Other|0
6164435|NCT01211262|9808004|FG001|Overall Study|Other|1
6164436|NCT01211288|9808015|FG000|Overall Study|Lost to Follow-up|1
6164437|NCT01211288|9808016|FG001|Overall Study|Lost to Follow-up|1
6164438|NCT01211483|9808037|FG000|Phase 1b|Death|6
6164439|NCT01211483|9808038|FG001|Phase 1b|Death|0
6164440|NCT01211483|9808039|FG002|Phase 1b|Death|0
6164441|NCT01211483|9808040|FG003|Phase 1b|Death|0
6326693|NCT02953782|10069994|FG006|Phase 2 (Maximum Duration: 11.1 Months)|Lost to Follow-up|1
6326694|NCT02953782|10069995|FG007|Phase 2 (Maximum Duration: 11.1 Months)|Lost to Follow-up|0
6326695|NCT02953821|10070018|FG000|Overall Study|Adverse Event|0
6326696|NCT02953821|10070019|FG001|Overall Study|Adverse Event|4
6326697|NCT02953821|10070018|FG000|Overall Study|Death|1
6326698|NCT02953821|10070019|FG001|Overall Study|Death|0
6326699|NCT02953821|10070018|FG000|Overall Study|Progressive Disease|5
6326700|NCT02953821|10070019|FG001|Overall Study|Progressive Disease|1
6326701|NCT02953821|10070018|FG000|Overall Study|Lost to Follow-up|2
6326702|NCT02953821|10070019|FG001|Overall Study|Lost to Follow-up|0
6326703|NCT02953821|10070018|FG000|Overall Study|Physician Decision|1
6326704|NCT02953821|10070019|FG001|Overall Study|Physician Decision|1
6326705|NCT02953821|10070018|FG000|Overall Study|Withdrawal by Subject|3
6326706|NCT02953821|10070019|FG001|Overall Study|Withdrawal by Subject|3
6326707|NCT02953821|10070018|FG000|Overall Study|Change of address|0
6326708|NCT02953821|10070019|FG001|Overall Study|Change of address|1
6326709|NCT02953821|10070018|FG000|Overall Study|Lack of Efficacy|1
6326710|NCT02953821|10070019|FG001|Overall Study|Lack of Efficacy|0
6326711|NCT02953821|10070018|FG000|Overall Study|Out of state for indeterminate time|0
6326712|NCT02953821|10070019|FG001|Overall Study|Out of state for indeterminate time|1
6326713|NCT02953821|10070018|FG000|Overall Study|No improvement|0
6326714|NCT02953821|10070019|FG001|Overall Study|No improvement|1
6326715|NCT02953821|10070018|FG000|Overall Study|Refused follow-up visit|2
6326716|NCT02953821|10070019|FG001|Overall Study|Refused follow-up visit|1
6326717|NCT02953938|10070041|FG000|Overall Study|Adverse Event|0
6326718|NCT02953938|10070042|FG001|Overall Study|Adverse Event|1
6326719|NCT02953938|10070041|FG000|Overall Study|Withdrawal by Subject|1
6164442|NCT01211483|9808037|FG000|Phase 1b|Withdrawal by Subject|1
6164443|NCT01211483|9808038|FG001|Phase 1b|Withdrawal by Subject|0
6164444|NCT01211483|9808039|FG002|Phase 1b|Withdrawal by Subject|0
6164445|NCT01211483|9808040|FG003|Phase 1b|Withdrawal by Subject|0
6164446|NCT01211483|9808037|FG000|Phase 2|Lost to Follow-up|0
6164447|NCT01211483|9808038|FG001|Phase 2|Lost to Follow-up|1
6164448|NCT01211483|9808039|FG002|Phase 2|Lost to Follow-up|1
6164449|NCT01211483|9808040|FG003|Phase 2|Lost to Follow-up|2
6164450|NCT01211483|9808037|FG000|Phase 2|Death|0
6164451|NCT01211483|9808038|FG001|Phase 2|Death|64
6326720|NCT02953938|10070042|FG001|Overall Study|Withdrawal by Subject|1
6164452|NCT01211483|9808039|FG002|Phase 2|Death|53
6164453|NCT01211483|9808040|FG003|Phase 2|Death|53
6164454|NCT01211483|9808037|FG000|Phase 2|Withdrawal by Subject|0
6326721|NCT02954172|10070051|FG000|Overall Study|Protocol Violation|3
6326722|NCT02954172|10070052|FG001|Overall Study|Protocol Violation|0
6164455|NCT01211483|9808038|FG001|Phase 2|Withdrawal by Subject|1
6326723|NCT02954172|10070051|FG000|Overall Study|allergic reaction|2
6326724|NCT02954172|10070052|FG001|Overall Study|allergic reaction|1
6326725|NCT02954172|10070051|FG000|Overall Study|non-measurable lesions at baseline|1
6326726|NCT02954172|10070052|FG001|Overall Study|non-measurable lesions at baseline|2
6164456|NCT01211483|9808039|FG002|Phase 2|Withdrawal by Subject|10
6164457|NCT01211483|9808040|FG003|Phase 2|Withdrawal by Subject|5
6164458|NCT01211483|9808037|FG000|Phase 2|Study terminated by Sponsor|0
6164459|NCT01211483|9808038|FG001|Phase 2|Study terminated by Sponsor|6
6164460|NCT01211483|9808039|FG002|Phase 2|Study terminated by Sponsor|8
6164461|NCT01211483|9808040|FG003|Phase 2|Study terminated by Sponsor|11
6164462|NCT01211522|9808057|FG000|Overall Study|Withdrawal by Subject|3
6164463|NCT01211522|9808058|FG001|Overall Study|Withdrawal by Subject|7
6164464|NCT01211522|9808059|FG002|Overall Study|Withdrawal by Subject|5
6164465|NCT01211535|9808069|FG000|Overall Study|Adverse Event|0
6164466|NCT01211535|9808070|FG001|Overall Study|Adverse Event|1
6164467|NCT01211613|9808090|FG000|Overall Study|Lost to Follow-up|2
6164468|NCT01211613|9808091|FG001|Overall Study|Lost to Follow-up|2
6164469|NCT01211613|9808092|FG002|Overall Study|Lost to Follow-up|2
6164470|NCT01211613|9808090|FG000|Overall Study|Withdrawal by Subject|1
6164471|NCT01211613|9808091|FG001|Overall Study|Withdrawal by Subject|0
6164472|NCT01211613|9808092|FG002|Overall Study|Withdrawal by Subject|0
6164473|NCT01211665|9808102|FG000|Overall Study|Withdrawal by Subject|1
6164474|NCT01211665|9808103|FG001|Overall Study|Withdrawal by Subject|0
6164475|NCT01211665|9808102|FG000|Overall Study|Death|1
6164476|NCT01211665|9808103|FG001|Overall Study|Death|0
6164477|NCT01211769|9808122|FG000|Overall Study|Lost to Follow-up|7
6326727|NCT02954354|10070071|FG000|Overall Study|Adverse Event|2
6326728|NCT02954354|10070072|FG001|Overall Study|Adverse Event|2
6326729|NCT02954354|10070073|FG002|Overall Study|Adverse Event|4
6326730|NCT02954354|10070071|FG000|Overall Study|Failure to Meet Eligibility Criteria|1
6326731|NCT02954354|10070072|FG001|Overall Study|Failure to Meet Eligibility Criteria|0
6326732|NCT02954354|10070073|FG002|Overall Study|Failure to Meet Eligibility Criteria|0
6326733|NCT02954354|10070071|FG000|Overall Study|Lack of Efficacy|0
6326734|NCT02954354|10070072|FG001|Overall Study|Lack of Efficacy|2
6326735|NCT02954354|10070073|FG002|Overall Study|Lack of Efficacy|0
6326736|NCT02954354|10070071|FG000|Overall Study|Withdrawal by Subject|17
6326737|NCT02954354|10070072|FG001|Overall Study|Withdrawal by Subject|9
6326738|NCT02954354|10070073|FG002|Overall Study|Withdrawal by Subject|11
6326739|NCT02954354|10070071|FG000|Overall Study|Lost to Follow-up|12
6326740|NCT02954354|10070072|FG001|Overall Study|Lost to Follow-up|5
6326741|NCT02954354|10070073|FG002|Overall Study|Lost to Follow-up|0
6326742|NCT02954354|10070071|FG000|Overall Study|Miscellaneous|2
6326743|NCT02954354|10070072|FG001|Overall Study|Miscellaneous|2
6326744|NCT02954354|10070073|FG002|Overall Study|Miscellaneous|1
6326745|NCT02954458|10070087|FG000|Overall Study|Adverse Event|0
6326746|NCT02954458|10070088|FG001|Overall Study|Adverse Event|0
6326747|NCT02954458|10070089|FG002|Overall Study|Adverse Event|0
6326748|NCT02954458|10070090|FG003|Overall Study|Adverse Event|1
6326749|NCT02954458|10070087|FG000|Overall Study|Withdrawal by Subject|0
6326750|NCT02954458|10070088|FG001|Overall Study|Withdrawal by Subject|0
6326751|NCT02954458|10070089|FG002|Overall Study|Withdrawal by Subject|0
6326752|NCT02954458|10070090|FG003|Overall Study|Withdrawal by Subject|1
6326753|NCT02954458|10070087|FG000|Overall Study|Physician Decision|0
6326754|NCT02954458|10070088|FG001|Overall Study|Physician Decision|0
6326755|NCT02954458|10070089|FG002|Overall Study|Physician Decision|1
6326756|NCT02954458|10070090|FG003|Overall Study|Physician Decision|1
6326757|NCT02954458|10070087|FG000|Overall Study|Lost to Follow-up|1
6326758|NCT02954458|10070088|FG001|Overall Study|Lost to Follow-up|0
6326759|NCT02954458|10070089|FG002|Overall Study|Lost to Follow-up|0
6326760|NCT02954458|10070090|FG003|Overall Study|Lost to Follow-up|1
6326761|NCT02954458|10070087|FG000|Overall Study|Death|0
6326762|NCT02954458|10070088|FG001|Overall Study|Death|0
6164478|NCT01211769|9808123|FG001|Overall Study|Lost to Follow-up|9
6164479|NCT01211769|9808124|FG002|Overall Study|Lost to Follow-up|5
6164480|NCT01211769|9808125|FG003|Overall Study|Lost to Follow-up|9
6164481|NCT01211769|9808122|FG000|Overall Study|Physician Decision|2
6164482|NCT01211769|9808123|FG001|Overall Study|Physician Decision|0
6164483|NCT01211769|9808124|FG002|Overall Study|Physician Decision|2
6164484|NCT01211769|9808125|FG003|Overall Study|Physician Decision|1
6164485|NCT01211769|9808122|FG000|Overall Study|Adverse Event|0
6164486|NCT01211769|9808123|FG001|Overall Study|Adverse Event|1
6164487|NCT01211769|9808124|FG002|Overall Study|Adverse Event|1
6164488|NCT01211769|9808125|FG003|Overall Study|Adverse Event|1
6164489|NCT01212094|9808152|FG000|Year 1: Baseline Monitoring|Study terminated|7
6164490|NCT01212094|9808153|FG001|Year 1: Baseline Monitoring|Study terminated|0
6164491|NCT01212094|9808154|FG002|Year 1: Baseline Monitoring|Study terminated|0
6164492|NCT01212094|9808152|FG000|Year 1: Baseline Monitoring|Withdrawal by Subject|7
6164493|NCT01212094|9808153|FG001|Year 1: Baseline Monitoring|Withdrawal by Subject|0
6326763|NCT02954458|10070089|FG002|Overall Study|Death|0
6326764|NCT02954458|10070090|FG003|Overall Study|Death|1
6326765|NCT02954458|10070087|FG000|Overall Study|Other|0
6326766|NCT02954458|10070088|FG001|Overall Study|Other|0
6326767|NCT02954458|10070089|FG002|Overall Study|Other|0
6326768|NCT02954458|10070090|FG003|Overall Study|Other|7
6326769|NCT02954575|10070104|FG000|Overall Study|Withdrawal by Subject|2
6326770|NCT02954575|10070104|FG000|Overall Study|Adverse Event|1
6326771|NCT02954601|10070116|FG000|First Intervention (Five Days)|Withdrawal by Subject|0
6326772|NCT02954601|10070117|FG001|First Intervention (Five Days)|Withdrawal by Subject|0
6326773|NCT02954601|10070118|FG002|First Intervention (Five Days)|Withdrawal by Subject|1
6164494|NCT01212094|9808154|FG002|Year 1: Baseline Monitoring|Withdrawal by Subject|0
6164495|NCT01212094|9808152|FG000|Year 1: Baseline Monitoring|Started on DMT|2
6164496|NCT01212094|9808153|FG001|Year 1: Baseline Monitoring|Started on DMT|0
6164497|NCT01212094|9808154|FG002|Year 1: Baseline Monitoring|Started on DMT|0
6164498|NCT01212094|9808152|FG000|Years 2 & 3: Treatment Randomization|Study terminated|0
6164499|NCT01212094|9808153|FG001|Years 2 & 3: Treatment Randomization|Study terminated|4
6164500|NCT01212094|9808154|FG002|Years 2 & 3: Treatment Randomization|Study terminated|7
6164501|NCT01212094|9808152|FG000|Years 2 & 3: Treatment Randomization|Withdrawal by Subject|0
6164502|NCT01212094|9808153|FG001|Years 2 & 3: Treatment Randomization|Withdrawal by Subject|0
6164503|NCT01212094|9808154|FG002|Years 2 & 3: Treatment Randomization|Withdrawal by Subject|3
6164504|NCT01212094|9808152|FG000|Years 2 & 3: Treatment Randomization|Adverse Event|0
6164505|NCT01212094|9808153|FG001|Years 2 & 3: Treatment Randomization|Adverse Event|0
6164506|NCT01212094|9808154|FG002|Years 2 & 3: Treatment Randomization|Adverse Event|1
6164507|NCT01212159|9808228|FG000|Overall Study|Withdrawal by Subject|12
6164508|NCT01212159|9808229|FG001|Overall Study|Withdrawal by Subject|12
6164509|NCT01212185|9808246|FG000|Overall Study|Protocol Violation|2
6164510|NCT01212185|9808247|FG001|Overall Study|Protocol Violation|1
6164511|NCT01212588|9808293|FG000|Overall Study|Physician Decision|0
6164512|NCT01212588|9808294|FG001|Overall Study|Physician Decision|1
6164513|NCT01212588|9808293|FG000|Overall Study|Protocol Violation|1
6164514|NCT01212588|9808294|FG001|Overall Study|Protocol Violation|1
6164515|NCT01212744|9808304|FG000|Overall Study|Withdrawal by Subject|1
6164516|NCT01212757|9808313|FG000|Placebo-controlled Phase (Week 0 - 24)|Adverse Event|4
6164517|NCT01212757|9808314|FG001|Placebo-controlled Phase (Week 0 - 24)|Adverse Event|5
6164518|NCT01212757|9808315|FG002|Placebo-controlled Phase (Week 0 - 24)|Adverse Event|12
6164519|NCT01212757|9808316|FG003|Placebo-controlled Phase (Week 0 - 24)|Adverse Event|0
6164520|NCT01212757|9808317|FG004|Placebo-controlled Phase (Week 0 - 24)|Adverse Event|0
6164521|NCT01212757|9808318|FG005|Placebo-controlled Phase (Week 0 - 24)|Adverse Event|0
6164522|NCT01212757|9808319|FG006|Placebo-controlled Phase (Week 0 - 24)|Adverse Event|0
6164523|NCT01212757|9808320|FG007|Placebo-controlled Phase (Week 0 - 24)|Adverse Event|0
6164524|NCT01212757|9808321|FG008|Placebo-controlled Phase (Week 0 - 24)|Adverse Event|0
6164525|NCT01212757|9808313|FG000|Placebo-controlled Phase (Week 0 - 24)|Lack of Efficacy|3
6164526|NCT01212757|9808314|FG001|Placebo-controlled Phase (Week 0 - 24)|Lack of Efficacy|2
6164527|NCT01212757|9808315|FG002|Placebo-controlled Phase (Week 0 - 24)|Lack of Efficacy|2
6164528|NCT01212757|9808316|FG003|Placebo-controlled Phase (Week 0 - 24)|Lack of Efficacy|0
6164529|NCT01212757|9808317|FG004|Placebo-controlled Phase (Week 0 - 24)|Lack of Efficacy|0
6164530|NCT01212757|9808318|FG005|Placebo-controlled Phase (Week 0 - 24)|Lack of Efficacy|0
6164531|NCT01212757|9808319|FG006|Placebo-controlled Phase (Week 0 - 24)|Lack of Efficacy|0
6164532|NCT01212757|9808320|FG007|Placebo-controlled Phase (Week 0 - 24)|Lack of Efficacy|0
6164533|NCT01212757|9808321|FG008|Placebo-controlled Phase (Week 0 - 24)|Lack of Efficacy|0
6164534|NCT01212757|9808313|FG000|Placebo-controlled Phase (Week 0 - 24)|Withdrawal by Subject|7
6164535|NCT01212757|9808314|FG001|Placebo-controlled Phase (Week 0 - 24)|Withdrawal by Subject|9
6164536|NCT01212757|9808315|FG002|Placebo-controlled Phase (Week 0 - 24)|Withdrawal by Subject|3
6164537|NCT01212757|9808316|FG003|Placebo-controlled Phase (Week 0 - 24)|Withdrawal by Subject|0
6164538|NCT01212757|9808317|FG004|Placebo-controlled Phase (Week 0 - 24)|Withdrawal by Subject|0
6164539|NCT01212757|9808318|FG005|Placebo-controlled Phase (Week 0 - 24)|Withdrawal by Subject|0
6164540|NCT01212757|9808319|FG006|Placebo-controlled Phase (Week 0 - 24)|Withdrawal by Subject|0
6164541|NCT01212757|9808320|FG007|Placebo-controlled Phase (Week 0 - 24)|Withdrawal by Subject|0
6326774|NCT02954601|10070119|FG003|First Intervention (Five Days)|Withdrawal by Subject|0
6326775|NCT02954653|10070131|FG000|Overall Study|Death|3
6326776|NCT02954653|10070132|FG001|Overall Study|Death|1
6326777|NCT02954653|10070133|FG002|Overall Study|Death|0
6326778|NCT02954653|10070134|FG003|Overall Study|Death|0
6326779|NCT02954653|10070135|FG004|Overall Study|Death|0
6326780|NCT02954653|10070136|FG005|Overall Study|Death|0
6326781|NCT02954653|10070137|FG006|Overall Study|Death|0
6326782|NCT02954653|10070138|FG007|Overall Study|Death|0
6326783|NCT02954653|10070139|FG008|Overall Study|Death|0
6326784|NCT02954653|10070131|FG000|Overall Study|Randomized but did not receive treatment|1
6326785|NCT02954653|10070132|FG001|Overall Study|Randomized but did not receive treatment|0
6326786|NCT02954653|10070133|FG002|Overall Study|Randomized but did not receive treatment|0
6326787|NCT02954653|10070134|FG003|Overall Study|Randomized but did not receive treatment|0
6326788|NCT02954653|10070135|FG004|Overall Study|Randomized but did not receive treatment|0
6326789|NCT02954653|10070136|FG005|Overall Study|Randomized but did not receive treatment|0
6326790|NCT02954653|10070137|FG006|Overall Study|Randomized but did not receive treatment|0
6326791|NCT02954653|10070138|FG007|Overall Study|Randomized but did not receive treatment|0
6326792|NCT02954653|10070139|FG008|Overall Study|Randomized but did not receive treatment|0
6326793|NCT02954653|10070131|FG000|Overall Study|Started another anti-cancer therapy|0
6326794|NCT02954653|10070132|FG001|Overall Study|Started another anti-cancer therapy|1
6326795|NCT02954653|10070133|FG002|Overall Study|Started another anti-cancer therapy|0
6326796|NCT02954653|10070134|FG003|Overall Study|Started another anti-cancer therapy|0
6326797|NCT02954653|10070135|FG004|Overall Study|Started another anti-cancer therapy|0
6326798|NCT02954653|10070136|FG005|Overall Study|Started another anti-cancer therapy|0
6326799|NCT02954653|10070137|FG006|Overall Study|Started another anti-cancer therapy|0
6326800|NCT02954653|10070138|FG007|Overall Study|Started another anti-cancer therapy|0
6326801|NCT02954653|10070139|FG008|Overall Study|Started another anti-cancer therapy|0
6164542|NCT01212757|9808321|FG008|Placebo-controlled Phase (Week 0 - 24)|Withdrawal by Subject|0
6164543|NCT01212757|9808313|FG000|Placebo-controlled Phase (Week 0 - 24)|Randomization Error|3
6164544|NCT01212757|9808314|FG001|Placebo-controlled Phase (Week 0 - 24)|Randomization Error|0
6164545|NCT01212757|9808315|FG002|Placebo-controlled Phase (Week 0 - 24)|Randomization Error|1
6164546|NCT01212757|9808316|FG003|Placebo-controlled Phase (Week 0 - 24)|Randomization Error|0
6164547|NCT01212757|9808317|FG004|Placebo-controlled Phase (Week 0 - 24)|Randomization Error|0
6164548|NCT01212757|9808318|FG005|Placebo-controlled Phase (Week 0 - 24)|Randomization Error|0
6164549|NCT01212757|9808319|FG006|Placebo-controlled Phase (Week 0 - 24)|Randomization Error|0
6164550|NCT01212757|9808320|FG007|Placebo-controlled Phase (Week 0 - 24)|Randomization Error|0
6164551|NCT01212757|9808321|FG008|Placebo-controlled Phase (Week 0 - 24)|Randomization Error|0
6164552|NCT01212757|9808313|FG000|Placebo-controlled Phase (Week 0 - 24)|Lost to Follow-up|1
6164553|NCT01212757|9808314|FG001|Placebo-controlled Phase (Week 0 - 24)|Lost to Follow-up|1
6164554|NCT01212757|9808315|FG002|Placebo-controlled Phase (Week 0 - 24)|Lost to Follow-up|2
6164555|NCT01212757|9808316|FG003|Placebo-controlled Phase (Week 0 - 24)|Lost to Follow-up|0
6164556|NCT01212757|9808317|FG004|Placebo-controlled Phase (Week 0 - 24)|Lost to Follow-up|0
6164557|NCT01212757|9808318|FG005|Placebo-controlled Phase (Week 0 - 24)|Lost to Follow-up|0
6164558|NCT01212757|9808319|FG006|Placebo-controlled Phase (Week 0 - 24)|Lost to Follow-up|0
6164559|NCT01212757|9808320|FG007|Placebo-controlled Phase (Week 0 - 24)|Lost to Follow-up|0
6164560|NCT01212757|9808321|FG008|Placebo-controlled Phase (Week 0 - 24)|Lost to Follow-up|0
6164561|NCT01212757|9808313|FG000|Placebo-controlled Phase (Week 0 - 24)|Protocol Violation|0
6164562|NCT01212757|9808314|FG001|Placebo-controlled Phase (Week 0 - 24)|Protocol Violation|1
6164563|NCT01212757|9808315|FG002|Placebo-controlled Phase (Week 0 - 24)|Protocol Violation|1
6164564|NCT01212757|9808316|FG003|Placebo-controlled Phase (Week 0 - 24)|Protocol Violation|0
6164565|NCT01212757|9808317|FG004|Placebo-controlled Phase (Week 0 - 24)|Protocol Violation|0
6164566|NCT01212757|9808318|FG005|Placebo-controlled Phase (Week 0 - 24)|Protocol Violation|0
6164567|NCT01212757|9808319|FG006|Placebo-controlled Phase (Week 0 - 24)|Protocol Violation|0
6164568|NCT01212757|9808320|FG007|Placebo-controlled Phase (Week 0 - 24)|Protocol Violation|0
6164569|NCT01212757|9808321|FG008|Placebo-controlled Phase (Week 0 - 24)|Protocol Violation|0
6164570|NCT01212757|9808313|FG000|Placebo-controlled Phase (Week 0 - 24)|Other|1
6164571|NCT01212757|9808314|FG001|Placebo-controlled Phase (Week 0 - 24)|Other|2
6164572|NCT01212757|9808315|FG002|Placebo-controlled Phase (Week 0 - 24)|Other|0
6164573|NCT01212757|9808316|FG003|Placebo-controlled Phase (Week 0 - 24)|Other|0
6164574|NCT01212757|9808317|FG004|Placebo-controlled Phase (Week 0 - 24)|Other|0
6164575|NCT01212757|9808318|FG005|Placebo-controlled Phase (Week 0 - 24)|Other|0
6164576|NCT01212757|9808319|FG006|Placebo-controlled Phase (Week 0 - 24)|Other|0
6164577|NCT01212757|9808320|FG007|Placebo-controlled Phase (Week 0 - 24)|Other|0
6164578|NCT01212757|9808321|FG008|Placebo-controlled Phase (Week 0 - 24)|Other|0
6164579|NCT01212757|9808313|FG000|Active Treatment Phase (Weeks 24 - 52)|Adverse Event|0
6164580|NCT01212757|9808314|FG001|Active Treatment Phase (Weeks 24 - 52)|Adverse Event|2
6164581|NCT01212757|9808315|FG002|Active Treatment Phase (Weeks 24 - 52)|Adverse Event|3
6164582|NCT01212757|9808316|FG003|Active Treatment Phase (Weeks 24 - 52)|Adverse Event|1
6164583|NCT01212757|9808317|FG004|Active Treatment Phase (Weeks 24 - 52)|Adverse Event|0
6164584|NCT01212757|9808318|FG005|Active Treatment Phase (Weeks 24 - 52)|Adverse Event|2
6164585|NCT01212757|9808319|FG006|Active Treatment Phase (Weeks 24 - 52)|Adverse Event|0
6164586|NCT01212757|9808320|FG007|Active Treatment Phase (Weeks 24 - 52)|Adverse Event|0
6164587|NCT01212757|9808321|FG008|Active Treatment Phase (Weeks 24 - 52)|Adverse Event|0
6164588|NCT01212757|9808313|FG000|Active Treatment Phase (Weeks 24 - 52)|Lack of Efficacy|0
6164589|NCT01212757|9808314|FG001|Active Treatment Phase (Weeks 24 - 52)|Lack of Efficacy|5
6164590|NCT01212757|9808315|FG002|Active Treatment Phase (Weeks 24 - 52)|Lack of Efficacy|7
6164591|NCT01212757|9808316|FG003|Active Treatment Phase (Weeks 24 - 52)|Lack of Efficacy|4
6164592|NCT01212757|9808317|FG004|Active Treatment Phase (Weeks 24 - 52)|Lack of Efficacy|0
6164593|NCT01212757|9808318|FG005|Active Treatment Phase (Weeks 24 - 52)|Lack of Efficacy|2
6164594|NCT01212757|9808319|FG006|Active Treatment Phase (Weeks 24 - 52)|Lack of Efficacy|0
6164595|NCT01212757|9808320|FG007|Active Treatment Phase (Weeks 24 - 52)|Lack of Efficacy|0
6164596|NCT01212757|9808321|FG008|Active Treatment Phase (Weeks 24 - 52)|Lack of Efficacy|0
6164597|NCT01212757|9808313|FG000|Active Treatment Phase (Weeks 24 - 52)|Non-compliance with Study Drug|0
6164598|NCT01212757|9808314|FG001|Active Treatment Phase (Weeks 24 - 52)|Non-compliance with Study Drug|0
6164599|NCT01212757|9808315|FG002|Active Treatment Phase (Weeks 24 - 52)|Non-compliance with Study Drug|2
6164600|NCT01212757|9808316|FG003|Active Treatment Phase (Weeks 24 - 52)|Non-compliance with Study Drug|0
6164601|NCT01212757|9808317|FG004|Active Treatment Phase (Weeks 24 - 52)|Non-compliance with Study Drug|0
6164602|NCT01212757|9808318|FG005|Active Treatment Phase (Weeks 24 - 52)|Non-compliance with Study Drug|0
6164603|NCT01212757|9808319|FG006|Active Treatment Phase (Weeks 24 - 52)|Non-compliance with Study Drug|0
6164604|NCT01212757|9808320|FG007|Active Treatment Phase (Weeks 24 - 52)|Non-compliance with Study Drug|0
6164605|NCT01212757|9808321|FG008|Active Treatment Phase (Weeks 24 - 52)|Non-compliance with Study Drug|0
6164606|NCT01212757|9808313|FG000|Active Treatment Phase (Weeks 24 - 52)|Withdrawal by Subject|0
6082556|NCT00630032|9690608|FG000|Overall Study|End of monitoring in US centers|11
6082557|NCT00630032|9690609|FG001|Overall Study|End of monitoring in US centers|11
6082558|NCT00630058|9690617|FG000|Overall Study|Adverse Event|1
6082559|NCT00630058|9690618|FG001|Overall Study|Adverse Event|1
6082560|NCT00630058|9690617|FG000|Overall Study|Withdrawal by Subject|0
6164607|NCT01212757|9808314|FG001|Active Treatment Phase (Weeks 24 - 52)|Withdrawal by Subject|3
6164608|NCT01212757|9808315|FG002|Active Treatment Phase (Weeks 24 - 52)|Withdrawal by Subject|7
6164609|NCT01212757|9808316|FG003|Active Treatment Phase (Weeks 24 - 52)|Withdrawal by Subject|3
6164610|NCT01212757|9808317|FG004|Active Treatment Phase (Weeks 24 - 52)|Withdrawal by Subject|1
6164611|NCT01212757|9808318|FG005|Active Treatment Phase (Weeks 24 - 52)|Withdrawal by Subject|3
6164612|NCT01212757|9808319|FG006|Active Treatment Phase (Weeks 24 - 52)|Withdrawal by Subject|0
6164613|NCT01212757|9808320|FG007|Active Treatment Phase (Weeks 24 - 52)|Withdrawal by Subject|0
6164614|NCT01212757|9808321|FG008|Active Treatment Phase (Weeks 24 - 52)|Withdrawal by Subject|0
6164615|NCT01212757|9808313|FG000|Active Treatment Phase (Weeks 24 - 52)|Lost to Follow-up|0
6164616|NCT01212757|9808314|FG001|Active Treatment Phase (Weeks 24 - 52)|Lost to Follow-up|1
6164617|NCT01212757|9808315|FG002|Active Treatment Phase (Weeks 24 - 52)|Lost to Follow-up|0
6164618|NCT01212757|9808316|FG003|Active Treatment Phase (Weeks 24 - 52)|Lost to Follow-up|0
6164619|NCT01212757|9808317|FG004|Active Treatment Phase (Weeks 24 - 52)|Lost to Follow-up|1
6164620|NCT01212757|9808318|FG005|Active Treatment Phase (Weeks 24 - 52)|Lost to Follow-up|0
6164621|NCT01212757|9808319|FG006|Active Treatment Phase (Weeks 24 - 52)|Lost to Follow-up|0
6164622|NCT01212757|9808320|FG007|Active Treatment Phase (Weeks 24 - 52)|Lost to Follow-up|0
6164623|NCT01212757|9808321|FG008|Active Treatment Phase (Weeks 24 - 52)|Lost to Follow-up|0
6164624|NCT01212757|9808313|FG000|Active Treatment Phase (Weeks 24 - 52)|Other|0
6164625|NCT01212757|9808314|FG001|Active Treatment Phase (Weeks 24 - 52)|Other|1
6164626|NCT01212757|9808315|FG002|Active Treatment Phase (Weeks 24 - 52)|Other|1
6164627|NCT01212757|9808316|FG003|Active Treatment Phase (Weeks 24 - 52)|Other|0
6164628|NCT01212757|9808317|FG004|Active Treatment Phase (Weeks 24 - 52)|Other|0
6164629|NCT01212757|9808318|FG005|Active Treatment Phase (Weeks 24 - 52)|Other|0
6164630|NCT01212757|9808319|FG006|Active Treatment Phase (Weeks 24 - 52)|Other|0
6164631|NCT01212757|9808320|FG007|Active Treatment Phase (Weeks 24 - 52)|Other|0
6164632|NCT01212757|9808321|FG008|Active Treatment Phase (Weeks 24 - 52)|Other|0
6164633|NCT01212757|9808313|FG000|Long-Term Safety Phase (Year 2)|Miscellaneous|0
6164634|NCT01212757|9808314|FG001|Long-Term Safety Phase (Year 2)|Miscellaneous|0
6164635|NCT01212757|9808315|FG002|Long-Term Safety Phase (Year 2)|Miscellaneous|0
6164636|NCT01212757|9808316|FG003|Long-Term Safety Phase (Year 2)|Miscellaneous|0
6164637|NCT01212757|9808317|FG004|Long-Term Safety Phase (Year 2)|Miscellaneous|0
6164638|NCT01212757|9808318|FG005|Long-Term Safety Phase (Year 2)|Miscellaneous|0
6164639|NCT01212757|9808319|FG006|Long-Term Safety Phase (Year 2)|Miscellaneous|0
6164640|NCT01212757|9808320|FG007|Long-Term Safety Phase (Year 2)|Miscellaneous|0
6164641|NCT01212757|9808321|FG008|Long-Term Safety Phase (Year 2)|Miscellaneous|1
6164642|NCT01212757|9808313|FG000|Long-Term Safety Phase (Year 2)|Adverse Event|0
6164643|NCT01212757|9808314|FG001|Long-Term Safety Phase (Year 2)|Adverse Event|1
6164644|NCT01212757|9808315|FG002|Long-Term Safety Phase (Year 2)|Adverse Event|1
6164645|NCT01212757|9808316|FG003|Long-Term Safety Phase (Year 2)|Adverse Event|0
6164646|NCT01212757|9808317|FG004|Long-Term Safety Phase (Year 2)|Adverse Event|0
6164647|NCT01212757|9808318|FG005|Long-Term Safety Phase (Year 2)|Adverse Event|0
6164648|NCT01212757|9808319|FG006|Long-Term Safety Phase (Year 2)|Adverse Event|0
6164649|NCT01212757|9808320|FG007|Long-Term Safety Phase (Year 2)|Adverse Event|2
6164650|NCT01212757|9808321|FG008|Long-Term Safety Phase (Year 2)|Adverse Event|2
6164651|NCT01212757|9808313|FG000|Long-Term Safety Phase (Year 2)|Lack of Efficacy|0
6164652|NCT01212757|9808314|FG001|Long-Term Safety Phase (Year 2)|Lack of Efficacy|4
6164653|NCT01212757|9808315|FG002|Long-Term Safety Phase (Year 2)|Lack of Efficacy|2
6164654|NCT01212757|9808316|FG003|Long-Term Safety Phase (Year 2)|Lack of Efficacy|0
6164655|NCT01212757|9808317|FG004|Long-Term Safety Phase (Year 2)|Lack of Efficacy|0
6326802|NCT02954653|10070131|FG000|Overall Study|Treatment failure and consent withdrawal|0
6326803|NCT02954653|10070132|FG001|Overall Study|Treatment failure and consent withdrawal|1
6326804|NCT02954653|10070133|FG002|Overall Study|Treatment failure and consent withdrawal|0
6082561|NCT00630058|9690618|FG001|Overall Study|Withdrawal by Subject|1
6164656|NCT01212757|9808318|FG005|Long-Term Safety Phase (Year 2)|Lack of Efficacy|0
6164657|NCT01212757|9808319|FG006|Long-Term Safety Phase (Year 2)|Lack of Efficacy|0
6164658|NCT01212757|9808320|FG007|Long-Term Safety Phase (Year 2)|Lack of Efficacy|4
6164659|NCT01212757|9808321|FG008|Long-Term Safety Phase (Year 2)|Lack of Efficacy|0
6164660|NCT01212757|9808313|FG000|Long-Term Safety Phase (Year 2)|Withdrawal by Subject|0
6164661|NCT01212757|9808314|FG001|Long-Term Safety Phase (Year 2)|Withdrawal by Subject|7
6164662|NCT01212757|9808315|FG002|Long-Term Safety Phase (Year 2)|Withdrawal by Subject|9
6164663|NCT01212757|9808316|FG003|Long-Term Safety Phase (Year 2)|Withdrawal by Subject|0
6164664|NCT01212757|9808317|FG004|Long-Term Safety Phase (Year 2)|Withdrawal by Subject|0
6164665|NCT01212757|9808318|FG005|Long-Term Safety Phase (Year 2)|Withdrawal by Subject|0
6164666|NCT01212757|9808319|FG006|Long-Term Safety Phase (Year 2)|Withdrawal by Subject|0
6164667|NCT01212757|9808320|FG007|Long-Term Safety Phase (Year 2)|Withdrawal by Subject|4
6164668|NCT01212757|9808321|FG008|Long-Term Safety Phase (Year 2)|Withdrawal by Subject|6
6082562|NCT00630058|9690617|FG000|Overall Study|stopping criteria|3
6082563|NCT00630058|9690618|FG001|Overall Study|stopping criteria|2
6082564|NCT00630305|9690637|FG000|Overall Study|Withdrawal by Subject|1
6082565|NCT00630305|9690637|FG000|Overall Study|Inability to insert contact lens|1
6082566|NCT00630331|9690653|FG000|Overall Study|Death|2
6082567|NCT00630331|9690654|FG001|Overall Study|Death|1
6082568|NCT00630331|9690655|FG002|Overall Study|Death|1
6082569|NCT00630331|9690653|FG000|Overall Study|Adverse Event|1
6082570|NCT00630331|9690654|FG001|Overall Study|Adverse Event|0
6082571|NCT00630331|9690655|FG002|Overall Study|Adverse Event|0
6082572|NCT00630331|9690653|FG000|Overall Study|Withdrawal by Subject|12
6082573|NCT00630331|9690654|FG001|Overall Study|Withdrawal by Subject|7
6082574|NCT00630331|9690655|FG002|Overall Study|Withdrawal by Subject|5
6082575|NCT00630331|9690653|FG000|Overall Study|Lost to Follow-up|175
6082576|NCT00630331|9690654|FG001|Overall Study|Lost to Follow-up|143
6082577|NCT00630331|9690655|FG002|Overall Study|Lost to Follow-up|170
6082578|NCT00630331|9690653|FG000|Overall Study|Inappropriate enrollment|3
6082579|NCT00630331|9690654|FG001|Overall Study|Inappropriate enrollment|6
6082580|NCT00630331|9690655|FG002|Overall Study|Inappropriate enrollment|3
6082581|NCT00630331|9690653|FG000|Overall Study|Unable to classify|9
6082582|NCT00630331|9690654|FG001|Overall Study|Unable to classify|4
6082583|NCT00630331|9690655|FG002|Overall Study|Unable to classify|3
6082584|NCT00630331|9690653|FG000|Overall Study|Protocol Violation|4
6082585|NCT00630331|9690654|FG001|Overall Study|Protocol Violation|5
6082586|NCT00630331|9690655|FG002|Overall Study|Protocol Violation|6
6164669|NCT01212757|9808313|FG000|Long-Term Safety Phase (Year 2)|Lost to Follow-up|0
6164670|NCT01212757|9808314|FG001|Long-Term Safety Phase (Year 2)|Lost to Follow-up|0
6164671|NCT01212757|9808315|FG002|Long-Term Safety Phase (Year 2)|Lost to Follow-up|2
6164672|NCT01212757|9808316|FG003|Long-Term Safety Phase (Year 2)|Lost to Follow-up|0
6164673|NCT01212757|9808317|FG004|Long-Term Safety Phase (Year 2)|Lost to Follow-up|0
6164674|NCT01212757|9808318|FG005|Long-Term Safety Phase (Year 2)|Lost to Follow-up|0
6164675|NCT01212757|9808319|FG006|Long-Term Safety Phase (Year 2)|Lost to Follow-up|0
6164676|NCT01212757|9808320|FG007|Long-Term Safety Phase (Year 2)|Lost to Follow-up|0
6164677|NCT01212757|9808321|FG008|Long-Term Safety Phase (Year 2)|Lost to Follow-up|0
6164678|NCT01212757|9808313|FG000|Long-Term Safety Phase (Year 3)|Adverse Event|0
6164679|NCT01212757|9808314|FG001|Long-Term Safety Phase (Year 3)|Adverse Event|4
6164680|NCT01212757|9808315|FG002|Long-Term Safety Phase (Year 3)|Adverse Event|1
6164681|NCT01212757|9808316|FG003|Long-Term Safety Phase (Year 3)|Adverse Event|0
6164682|NCT01212757|9808317|FG004|Long-Term Safety Phase (Year 3)|Adverse Event|0
6164683|NCT01212757|9808318|FG005|Long-Term Safety Phase (Year 3)|Adverse Event|0
6164684|NCT01212757|9808319|FG006|Long-Term Safety Phase (Year 3)|Adverse Event|0
6164685|NCT01212757|9808320|FG007|Long-Term Safety Phase (Year 3)|Adverse Event|2
6164686|NCT01212757|9808321|FG008|Long-Term Safety Phase (Year 3)|Adverse Event|0
6164687|NCT01212757|9808313|FG000|Long-Term Safety Phase (Year 3)|Lack of Efficacy|0
6164688|NCT01212757|9808314|FG001|Long-Term Safety Phase (Year 3)|Lack of Efficacy|8
6164689|NCT01212757|9808315|FG002|Long-Term Safety Phase (Year 3)|Lack of Efficacy|5
6164690|NCT01212757|9808316|FG003|Long-Term Safety Phase (Year 3)|Lack of Efficacy|0
6164691|NCT01212757|9808317|FG004|Long-Term Safety Phase (Year 3)|Lack of Efficacy|0
6164692|NCT01212757|9808318|FG005|Long-Term Safety Phase (Year 3)|Lack of Efficacy|0
6164693|NCT01212757|9808319|FG006|Long-Term Safety Phase (Year 3)|Lack of Efficacy|0
6164694|NCT01212757|9808320|FG007|Long-Term Safety Phase (Year 3)|Lack of Efficacy|3
6164695|NCT01212757|9808321|FG008|Long-Term Safety Phase (Year 3)|Lack of Efficacy|1
6164696|NCT01212757|9808313|FG000|Long-Term Safety Phase (Year 3)|Non-compliance with study drug|0
6164697|NCT01212757|9808314|FG001|Long-Term Safety Phase (Year 3)|Non-compliance with study drug|0
6164698|NCT01212757|9808315|FG002|Long-Term Safety Phase (Year 3)|Non-compliance with study drug|1
6164699|NCT01212757|9808316|FG003|Long-Term Safety Phase (Year 3)|Non-compliance with study drug|0
6164700|NCT01212757|9808317|FG004|Long-Term Safety Phase (Year 3)|Non-compliance with study drug|0
6164701|NCT01212757|9808318|FG005|Long-Term Safety Phase (Year 3)|Non-compliance with study drug|0
6164702|NCT01212757|9808319|FG006|Long-Term Safety Phase (Year 3)|Non-compliance with study drug|0
6164703|NCT01212757|9808320|FG007|Long-Term Safety Phase (Year 3)|Non-compliance with study drug|0
6164704|NCT01212757|9808321|FG008|Long-Term Safety Phase (Year 3)|Non-compliance with study drug|0
6164705|NCT01212757|9808313|FG000|Long-Term Safety Phase (Year 3)|Withdrawal by Subject|0
6164706|NCT01212757|9808314|FG001|Long-Term Safety Phase (Year 3)|Withdrawal by Subject|5
6164707|NCT01212757|9808315|FG002|Long-Term Safety Phase (Year 3)|Withdrawal by Subject|1
6164708|NCT01212757|9808316|FG003|Long-Term Safety Phase (Year 3)|Withdrawal by Subject|0
6164709|NCT01212757|9808317|FG004|Long-Term Safety Phase (Year 3)|Withdrawal by Subject|0
6164710|NCT01212757|9808318|FG005|Long-Term Safety Phase (Year 3)|Withdrawal by Subject|0
6164711|NCT01212757|9808319|FG006|Long-Term Safety Phase (Year 3)|Withdrawal by Subject|0
6164712|NCT01212757|9808320|FG007|Long-Term Safety Phase (Year 3)|Withdrawal by Subject|1
6082587|NCT00630344|9690663|FG000|Overall Study|Adverse Event|5
6082588|NCT00630344|9690663|FG000|Overall Study|Progressive Disease|19
6082589|NCT00630344|9690663|FG000|Overall Study|Physician Decision|9
6082590|NCT00630344|9690663|FG000|Overall Study|Withdrawal by Subject|1
6082591|NCT00630344|9690663|FG000|Overall Study|Intercurrent Illness|1
6082592|NCT00630344|9690663|FG000|Overall Study|Other|1
6082593|NCT00630396|9690668|FG000|Overall Study|Death|4
6326805|NCT02954653|10070134|FG003|Overall Study|Treatment failure and consent withdrawal|0
6326806|NCT02954653|10070135|FG004|Overall Study|Treatment failure and consent withdrawal|0
6326807|NCT02954653|10070136|FG005|Overall Study|Treatment failure and consent withdrawal|0
6326808|NCT02954653|10070137|FG006|Overall Study|Treatment failure and consent withdrawal|0
6326809|NCT02954653|10070138|FG007|Overall Study|Treatment failure and consent withdrawal|0
6326810|NCT02954653|10070139|FG008|Overall Study|Treatment failure and consent withdrawal|0
6326811|NCT02954848|10070153|FG000|Overall Study|Randomized but Not Treated|0
6326812|NCT02954848|10070154|FG001|Overall Study|Randomized but Not Treated|1
6326813|NCT02954848|10070153|FG000|Overall Study|Adverse Event|2
6326814|NCT02954848|10070154|FG001|Overall Study|Adverse Event|3
6326815|NCT02954848|10070153|FG000|Overall Study|Withdrawal by Participant|0
6326816|NCT02954848|10070154|FG001|Overall Study|Withdrawal by Participant|1
6326817|NCT02954887|10070160|FG000|Overall Study|Withdrawal by Subject|3
6326818|NCT02954887|10070160|FG000|Overall Study|Lack of Efficacy|3
6326819|NCT02954887|10070160|FG000|Overall Study|Other|1
6326820|NCT02955069|10070166|FG000|Overall Study|Adverse Event|7
6326821|NCT02955069|10070167|FG001|Overall Study|Adverse Event|2
6326822|NCT02955069|10070166|FG000|Overall Study|Death|7
6326823|NCT02955069|10070167|FG001|Overall Study|Death|3
6326824|NCT02955069|10070166|FG000|Overall Study|Physician Decision|10
6326825|NCT02955069|10070167|FG001|Overall Study|Physician Decision|2
6326826|NCT02955069|10070166|FG000|Overall Study|Progressive disease|64
6326827|NCT02955069|10070167|FG001|Overall Study|Progressive disease|13
6326828|NCT02955069|10070166|FG000|Overall Study|Study terminated by sponsor|4
6326829|NCT02955069|10070167|FG001|Overall Study|Study terminated by sponsor|0
6326830|NCT02955069|10070166|FG000|Overall Study|Subject/Guardian decision|3
6326831|NCT02955069|10070167|FG001|Overall Study|Subject/Guardian decision|1
6326832|NCT02955186|10070181|FG000|Overall Study|Withdrawal by Subject|6
6326833|NCT02955186|10070182|FG001|Overall Study|Withdrawal by Subject|2
6326834|NCT02955186|10070181|FG000|Overall Study|Protocol Violation|1
6326835|NCT02955186|10070182|FG001|Overall Study|Protocol Violation|0
6326836|NCT02955212|10070190|FG000|Period 1: Double-blind Treatment Period|Adverse Event|4
6326837|NCT02955212|10070191|FG001|Period 1: Double-blind Treatment Period|Adverse Event|7
6326838|NCT02955212|10070190|FG000|Period 1: Double-blind Treatment Period|Withdrawal by Subject|8
6326839|NCT02955212|10070191|FG001|Period 1: Double-blind Treatment Period|Withdrawal by Subject|3
6326840|NCT02955212|10070190|FG000|Period 1: Double-blind Treatment Period|Lost to Follow-up|1
6326841|NCT02955212|10070191|FG001|Period 1: Double-blind Treatment Period|Lost to Follow-up|0
6326842|NCT02955212|10070190|FG000|Period 1: Double-blind Treatment Period|Other|3
6326843|NCT02955212|10070191|FG001|Period 1: Double-blind Treatment Period|Other|2
6326844|NCT02955212|10070190|FG000|Period 2: Open-label Extension|Adverse Event|11
6326845|NCT02955212|10070191|FG001|Period 2: Open-label Extension|Adverse Event|7
6326846|NCT02955212|10070190|FG000|Period 2: Open-label Extension|Withdrawal by Subject|1
6326847|NCT02955212|10070191|FG001|Period 2: Open-label Extension|Withdrawal by Subject|4
6326848|NCT02955212|10070190|FG000|Period 2: Open-label Extension|Lack of Efficacy|3
6326849|NCT02955212|10070191|FG001|Period 2: Open-label Extension|Lack of Efficacy|2
6326850|NCT02955212|10070190|FG000|Period 2: Open-label Extension|COVID-19 Logistical Restrictions|0
6326851|NCT02955212|10070191|FG001|Period 2: Open-label Extension|COVID-19 Logistical Restrictions|1
6326852|NCT02955212|10070190|FG000|Period 2: Open-label Extension|Other|2
6326853|NCT02955212|10070191|FG001|Period 2: Open-label Extension|Other|4
6326854|NCT02956057|10070239|FG000|Overall Study|Discontinued intervention|14
6326855|NCT02956057|10070240|FG001|Overall Study|Discontinued intervention|10
6326856|NCT02956057|10070241|FG002|Overall Study|Discontinued intervention|7
6326857|NCT02956057|10070242|FG003|Overall Study|Discontinued intervention|14
6326858|NCT02956057|10070243|FG004|Overall Study|Discontinued intervention|4
6082594|NCT00630396|9690668|FG000|Overall Study|Lost to Follow-up|3
6082595|NCT00630539|9690681|FG000|Overall Study|Adverse Event|1
6082596|NCT00630539|9690682|FG001|Overall Study|Adverse Event|3
6082597|NCT00630539|9690683|FG002|Overall Study|Adverse Event|1
6082598|NCT00630539|9690684|FG003|Overall Study|Adverse Event|2
6082599|NCT00630539|9690681|FG000|Overall Study|Withdrawal by Subject|0
6082600|NCT00630539|9690682|FG001|Overall Study|Withdrawal by Subject|1
6082601|NCT00630539|9690683|FG002|Overall Study|Withdrawal by Subject|0
6082602|NCT00630539|9690684|FG003|Overall Study|Withdrawal by Subject|1
6082603|NCT00630747|9690716|FG000|Overall Study|Death|1
6164713|NCT01212757|9808321|FG008|Long-Term Safety Phase (Year 3)|Withdrawal by Subject|1
6164714|NCT01212757|9808313|FG000|Long-Term Safety Phase (Year 3)|Lost to Follow-up|0
6326859|NCT02956057|10070244|FG005|Overall Study|Discontinued intervention|17
6326860|NCT02956057|10070239|FG000|Overall Study|Lost to Follow-up|0
6326861|NCT02956057|10070240|FG001|Overall Study|Lost to Follow-up|2
6326862|NCT02956057|10070241|FG002|Overall Study|Lost to Follow-up|1
6326863|NCT02956057|10070242|FG003|Overall Study|Lost to Follow-up|1
6326864|NCT02956057|10070243|FG004|Overall Study|Lost to Follow-up|1
6082604|NCT00630747|9690716|FG000|Overall Study|Transferred to Study TKT031NPU|7
6082605|NCT00630747|9690716|FG000|Overall Study|Returned to country of origin|1
6326865|NCT02956057|10070244|FG005|Overall Study|Lost to Follow-up|0
6326866|NCT02956278|10070281|FG000|Overall Study|Withdrawal by Subject|6
6326867|NCT02956278|10070282|FG001|Overall Study|Withdrawal by Subject|2
6326868|NCT02956278|10070283|FG002|Overall Study|Withdrawal by Subject|0
6326869|NCT02956460|10070293|FG000|Lens 1|Lost to Follow-up|1
6326870|NCT02956460|10070294|FG001|Lens 1|Lost to Follow-up|0
6082606|NCT00630786|9690723|FG000|Overall Study|Physician Decision|0
6082607|NCT00630786|9690724|FG001|Overall Study|Physician Decision|0
6082608|NCT00630786|9690725|FG002|Overall Study|Physician Decision|1
6082609|NCT00630786|9690723|FG000|Overall Study|Withdrawal by Subject|0
6082610|NCT00630786|9690724|FG001|Overall Study|Withdrawal by Subject|1
6082611|NCT00630786|9690725|FG002|Overall Study|Withdrawal by Subject|1
6082612|NCT00630786|9690723|FG000|Overall Study|Lost to Follow-up|0
6082613|NCT00630786|9690724|FG001|Overall Study|Lost to Follow-up|1
6082614|NCT00630786|9690725|FG002|Overall Study|Lost to Follow-up|0
6082615|NCT00630786|9690723|FG000|Overall Study|Other|1
6082616|NCT00630786|9690724|FG001|Overall Study|Other|0
6082617|NCT00630786|9690725|FG002|Overall Study|Other|0
6082618|NCT00630812|9690733|FG000|Randomisation to First Dose|Adverse Event|1
6082619|NCT00630812|9690734|FG001|Randomisation to First Dose|Adverse Event|1
6082620|NCT00630812|9690733|FG000|Randomisation to First Dose|Withdrawal by Subject|2
6082621|NCT00630812|9690734|FG001|Randomisation to First Dose|Withdrawal by Subject|3
6082622|NCT00630812|9690733|FG000|Randomisation to First Dose|Lost to Follow-up|1
6082623|NCT00630812|9690734|FG001|Randomisation to First Dose|Lost to Follow-up|0
6082624|NCT00630812|9690733|FG000|Randomisation to First Dose|Protocol Violation|4
6082625|NCT00630812|9690734|FG001|Randomisation to First Dose|Protocol Violation|1
6082626|NCT00630812|9690733|FG000|Double Blind Treatment Period|Adverse Event|13
6082627|NCT00630812|9690734|FG001|Double Blind Treatment Period|Adverse Event|5
6164715|NCT01212757|9808314|FG001|Long-Term Safety Phase (Year 3)|Lost to Follow-up|0
6164716|NCT01212757|9808315|FG002|Long-Term Safety Phase (Year 3)|Lost to Follow-up|0
6164717|NCT01212757|9808316|FG003|Long-Term Safety Phase (Year 3)|Lost to Follow-up|0
6164718|NCT01212757|9808317|FG004|Long-Term Safety Phase (Year 3)|Lost to Follow-up|0
6164719|NCT01212757|9808318|FG005|Long-Term Safety Phase (Year 3)|Lost to Follow-up|0
6164720|NCT01212757|9808319|FG006|Long-Term Safety Phase (Year 3)|Lost to Follow-up|0
6164721|NCT01212757|9808320|FG007|Long-Term Safety Phase (Year 3)|Lost to Follow-up|0
6164722|NCT01212757|9808321|FG008|Long-Term Safety Phase (Year 3)|Lost to Follow-up|1
6164723|NCT01212757|9808313|FG000|Long-Term Safety Phase (Year 3)|Protocol Violation|0
6164724|NCT01212757|9808314|FG001|Long-Term Safety Phase (Year 3)|Protocol Violation|1
6164725|NCT01212757|9808315|FG002|Long-Term Safety Phase (Year 3)|Protocol Violation|0
6164726|NCT01212757|9808316|FG003|Long-Term Safety Phase (Year 3)|Protocol Violation|0
6164727|NCT01212757|9808317|FG004|Long-Term Safety Phase (Year 3)|Protocol Violation|0
6164728|NCT01212757|9808318|FG005|Long-Term Safety Phase (Year 3)|Protocol Violation|0
6164729|NCT01212757|9808319|FG006|Long-Term Safety Phase (Year 3)|Protocol Violation|0
6164730|NCT01212757|9808320|FG007|Long-Term Safety Phase (Year 3)|Protocol Violation|0
6164731|NCT01212757|9808321|FG008|Long-Term Safety Phase (Year 3)|Protocol Violation|0
6164732|NCT01212757|9808313|FG000|Long-Term Safety Phase (Year 3)|Miscellaneous|0
6164733|NCT01212757|9808314|FG001|Long-Term Safety Phase (Year 3)|Miscellaneous|0
6164734|NCT01212757|9808315|FG002|Long-Term Safety Phase (Year 3)|Miscellaneous|3
6164735|NCT01212757|9808316|FG003|Long-Term Safety Phase (Year 3)|Miscellaneous|0
6164736|NCT01212757|9808317|FG004|Long-Term Safety Phase (Year 3)|Miscellaneous|0
6164737|NCT01212757|9808318|FG005|Long-Term Safety Phase (Year 3)|Miscellaneous|0
6164738|NCT01212757|9808319|FG006|Long-Term Safety Phase (Year 3)|Miscellaneous|0
6164739|NCT01212757|9808320|FG007|Long-Term Safety Phase (Year 3)|Miscellaneous|0
6164740|NCT01212757|9808321|FG008|Long-Term Safety Phase (Year 3)|Miscellaneous|2
6164741|NCT01212757|9808313|FG000|Long-Term Safety Phase (Year 4)|Miscellaneous|0
6164742|NCT01212757|9808314|FG001|Long-Term Safety Phase (Year 4)|Miscellaneous|2
6164743|NCT01212757|9808315|FG002|Long-Term Safety Phase (Year 4)|Miscellaneous|0
6164744|NCT01212757|9808316|FG003|Long-Term Safety Phase (Year 4)|Miscellaneous|0
6164745|NCT01212757|9808317|FG004|Long-Term Safety Phase (Year 4)|Miscellaneous|0
6164746|NCT01212757|9808318|FG005|Long-Term Safety Phase (Year 4)|Miscellaneous|0
6164747|NCT01212757|9808319|FG006|Long-Term Safety Phase (Year 4)|Miscellaneous|0
6164748|NCT01212757|9808320|FG007|Long-Term Safety Phase (Year 4)|Miscellaneous|0
6164749|NCT01212757|9808321|FG008|Long-Term Safety Phase (Year 4)|Miscellaneous|1
6164750|NCT01212757|9808313|FG000|Long-Term Safety Phase (Year 4)|Adverse Event|0
6164751|NCT01212757|9808314|FG001|Long-Term Safety Phase (Year 4)|Adverse Event|1
6164752|NCT01212757|9808315|FG002|Long-Term Safety Phase (Year 4)|Adverse Event|2
6164753|NCT01212757|9808316|FG003|Long-Term Safety Phase (Year 4)|Adverse Event|0
6164754|NCT01212757|9808317|FG004|Long-Term Safety Phase (Year 4)|Adverse Event|0
6164755|NCT01212757|9808318|FG005|Long-Term Safety Phase (Year 4)|Adverse Event|0
6164756|NCT01212757|9808319|FG006|Long-Term Safety Phase (Year 4)|Adverse Event|0
6164757|NCT01212757|9808320|FG007|Long-Term Safety Phase (Year 4)|Adverse Event|1
6164758|NCT01212757|9808321|FG008|Long-Term Safety Phase (Year 4)|Adverse Event|1
6164759|NCT01212757|9808313|FG000|Long-Term Safety Phase (Year 4)|Lack of Efficacy|0
6164760|NCT01212757|9808314|FG001|Long-Term Safety Phase (Year 4)|Lack of Efficacy|2
6164761|NCT01212757|9808315|FG002|Long-Term Safety Phase (Year 4)|Lack of Efficacy|2
6164762|NCT01212757|9808316|FG003|Long-Term Safety Phase (Year 4)|Lack of Efficacy|0
6164763|NCT01212757|9808317|FG004|Long-Term Safety Phase (Year 4)|Lack of Efficacy|0
6164764|NCT01212757|9808318|FG005|Long-Term Safety Phase (Year 4)|Lack of Efficacy|0
6164765|NCT01212757|9808319|FG006|Long-Term Safety Phase (Year 4)|Lack of Efficacy|0
6164766|NCT01212757|9808320|FG007|Long-Term Safety Phase (Year 4)|Lack of Efficacy|1
6326871|NCT02956486|10070302|FG000|Core Phase|Adverse Event|51
6326872|NCT02956486|10070303|FG001|Core Phase|Adverse Event|88
6326873|NCT02956486|10070304|FG002|Core Phase|Adverse Event|0
6326874|NCT02956486|10070302|FG000|Core Phase|Lost to Follow-up|8
6326875|NCT02956486|10070303|FG001|Core Phase|Lost to Follow-up|6
6326876|NCT02956486|10070304|FG002|Core Phase|Lost to Follow-up|0
6326877|NCT02956486|10070302|FG000|Core Phase|Inadequate therapeutic effect|4
6326878|NCT02956486|10070303|FG001|Core Phase|Inadequate therapeutic effect|5
6326879|NCT02956486|10070304|FG002|Core Phase|Inadequate therapeutic effect|0
6326880|NCT02956486|10070302|FG000|Core Phase|Withdrawal by Subject|101
6326881|NCT02956486|10070303|FG001|Core Phase|Withdrawal by Subject|104
6326882|NCT02956486|10070304|FG002|Core Phase|Withdrawal by Subject|0
6326883|NCT02956486|10070302|FG000|Core Phase|Study terminated by sponsor|888
6326884|NCT02956486|10070303|FG001|Core Phase|Study terminated by sponsor|848
6326885|NCT02956486|10070304|FG002|Core Phase|Study terminated by sponsor|0
6326886|NCT02956486|10070302|FG000|Core Phase|Other|27
6326887|NCT02956486|10070303|FG001|Core Phase|Other|18
6326888|NCT02956486|10070304|FG002|Core Phase|Other|0
6326889|NCT02956486|10070302|FG000|Core Phase|Not treated|0
6326890|NCT02956486|10070303|FG001|Core Phase|Not treated|3
6326891|NCT02956486|10070304|FG002|Core Phase|Not treated|0
6326892|NCT02956486|10070302|FG000|Extension Phase|Adverse Event|0
6326893|NCT02956486|10070303|FG001|Extension Phase|Adverse Event|0
6326894|NCT02956486|10070304|FG002|Extension Phase|Adverse Event|2
6326895|NCT02956486|10070302|FG000|Extension Phase|Study terminated by sponsor|0
6326896|NCT02956486|10070303|FG001|Extension Phase|Study terminated by sponsor|0
6326897|NCT02956486|10070304|FG002|Extension Phase|Study terminated by sponsor|16
6326898|NCT02956486|10070302|FG000|Extension Phase|Not Treated|0
6326899|NCT02956486|10070303|FG001|Extension Phase|Not Treated|0
6326900|NCT02956486|10070304|FG002|Extension Phase|Not Treated|1
6326901|NCT02956629|10070328|FG000|Overall Study|Adverse Event|0
6326902|NCT02956629|10070329|FG001|Overall Study|Adverse Event|0
6326903|NCT02956629|10070330|FG002|Overall Study|Adverse Event|1
6326904|NCT02956629|10070331|FG003|Overall Study|Adverse Event|0
6326905|NCT02956629|10070332|FG004|Overall Study|Adverse Event|0
6326906|NCT02956629|10070333|FG005|Overall Study|Adverse Event|0
6326907|NCT02956629|10070328|FG000|Overall Study|Lost to Follow-up|2
6326908|NCT02956629|10070329|FG001|Overall Study|Lost to Follow-up|5
6326909|NCT02956629|10070330|FG002|Overall Study|Lost to Follow-up|3
6164767|NCT01212757|9808321|FG008|Long-Term Safety Phase (Year 4)|Lack of Efficacy|1
6164768|NCT01212757|9808313|FG000|Long-Term Safety Phase (Year 4)|Withdrawal by Subject|0
6164769|NCT01212757|9808314|FG001|Long-Term Safety Phase (Year 4)|Withdrawal by Subject|4
6164770|NCT01212757|9808315|FG002|Long-Term Safety Phase (Year 4)|Withdrawal by Subject|2
6164771|NCT01212757|9808316|FG003|Long-Term Safety Phase (Year 4)|Withdrawal by Subject|0
6164772|NCT01212757|9808317|FG004|Long-Term Safety Phase (Year 4)|Withdrawal by Subject|0
6164773|NCT01212757|9808318|FG005|Long-Term Safety Phase (Year 4)|Withdrawal by Subject|0
6164774|NCT01212757|9808319|FG006|Long-Term Safety Phase (Year 4)|Withdrawal by Subject|0
6164775|NCT01212757|9808320|FG007|Long-Term Safety Phase (Year 4)|Withdrawal by Subject|1
6164776|NCT01212757|9808321|FG008|Long-Term Safety Phase (Year 4)|Withdrawal by Subject|3
6164777|NCT01212757|9808313|FG000|Long-Term Safety Phase (Year 4)|Death|0
6164778|NCT01212757|9808314|FG001|Long-Term Safety Phase (Year 4)|Death|0
6164779|NCT01212757|9808315|FG002|Long-Term Safety Phase (Year 4)|Death|1
6164780|NCT01212757|9808316|FG003|Long-Term Safety Phase (Year 4)|Death|0
6164781|NCT01212757|9808317|FG004|Long-Term Safety Phase (Year 4)|Death|0
6164782|NCT01212757|9808318|FG005|Long-Term Safety Phase (Year 4)|Death|0
6164783|NCT01212757|9808319|FG006|Long-Term Safety Phase (Year 4)|Death|0
6164784|NCT01212757|9808320|FG007|Long-Term Safety Phase (Year 4)|Death|0
6164785|NCT01212757|9808321|FG008|Long-Term Safety Phase (Year 4)|Death|1
6164786|NCT01212757|9808313|FG000|Long-Term Safety Phase (Year 4)|Lost to Follow-up|0
6164787|NCT01212757|9808314|FG001|Long-Term Safety Phase (Year 4)|Lost to Follow-up|0
6164788|NCT01212757|9808315|FG002|Long-Term Safety Phase (Year 4)|Lost to Follow-up|0
6164789|NCT01212757|9808316|FG003|Long-Term Safety Phase (Year 4)|Lost to Follow-up|0
6164790|NCT01212757|9808317|FG004|Long-Term Safety Phase (Year 4)|Lost to Follow-up|0
6164791|NCT01212757|9808318|FG005|Long-Term Safety Phase (Year 4)|Lost to Follow-up|0
6164792|NCT01212757|9808319|FG006|Long-Term Safety Phase (Year 4)|Lost to Follow-up|0
6164793|NCT01212757|9808320|FG007|Long-Term Safety Phase (Year 4)|Lost to Follow-up|1
6164794|NCT01212757|9808321|FG008|Long-Term Safety Phase (Year 4)|Lost to Follow-up|0
6164795|NCT01212757|9808313|FG000|Long-Term Safety Phase (Year 5)|Withdrawal by Subject|0
6164796|NCT01212757|9808314|FG001|Long-Term Safety Phase (Year 5)|Withdrawal by Subject|3
6164797|NCT01212757|9808315|FG002|Long-Term Safety Phase (Year 5)|Withdrawal by Subject|3
6164798|NCT01212757|9808316|FG003|Long-Term Safety Phase (Year 5)|Withdrawal by Subject|0
6164799|NCT01212757|9808317|FG004|Long-Term Safety Phase (Year 5)|Withdrawal by Subject|0
6326910|NCT02956629|10070331|FG003|Overall Study|Lost to Follow-up|1
6326911|NCT02956629|10070332|FG004|Overall Study|Lost to Follow-up|0
6326912|NCT02956629|10070333|FG005|Overall Study|Lost to Follow-up|1
6326913|NCT02956629|10070328|FG000|Overall Study|Withdrawal by Subject|3
6326914|NCT02956629|10070329|FG001|Overall Study|Withdrawal by Subject|1
6326915|NCT02956629|10070330|FG002|Overall Study|Withdrawal by Subject|0
6326916|NCT02956629|10070331|FG003|Overall Study|Withdrawal by Subject|0
6326917|NCT02956629|10070332|FG004|Overall Study|Withdrawal by Subject|0
6164800|NCT01212757|9808318|FG005|Long-Term Safety Phase (Year 5)|Withdrawal by Subject|0
6164801|NCT01212757|9808319|FG006|Long-Term Safety Phase (Year 5)|Withdrawal by Subject|0
6164802|NCT01212757|9808320|FG007|Long-Term Safety Phase (Year 5)|Withdrawal by Subject|1
6164803|NCT01212757|9808321|FG008|Long-Term Safety Phase (Year 5)|Withdrawal by Subject|1
6164804|NCT01212757|9808313|FG000|Long-Term Safety Phase (Year 5)|Adverse Event|0
6164805|NCT01212757|9808314|FG001|Long-Term Safety Phase (Year 5)|Adverse Event|2
6164806|NCT01212757|9808315|FG002|Long-Term Safety Phase (Year 5)|Adverse Event|2
6164807|NCT01212757|9808316|FG003|Long-Term Safety Phase (Year 5)|Adverse Event|0
6164808|NCT01212757|9808317|FG004|Long-Term Safety Phase (Year 5)|Adverse Event|0
6164809|NCT01212757|9808318|FG005|Long-Term Safety Phase (Year 5)|Adverse Event|0
6164810|NCT01212757|9808319|FG006|Long-Term Safety Phase (Year 5)|Adverse Event|0
6164811|NCT01212757|9808320|FG007|Long-Term Safety Phase (Year 5)|Adverse Event|2
6164812|NCT01212757|9808321|FG008|Long-Term Safety Phase (Year 5)|Adverse Event|0
6164813|NCT01212757|9808313|FG000|Long-Term Safety Phase (Year 5)|Lack of Efficacy|0
6164814|NCT01212757|9808314|FG001|Long-Term Safety Phase (Year 5)|Lack of Efficacy|1
6164815|NCT01212757|9808315|FG002|Long-Term Safety Phase (Year 5)|Lack of Efficacy|2
6164816|NCT01212757|9808316|FG003|Long-Term Safety Phase (Year 5)|Lack of Efficacy|0
6164817|NCT01212757|9808317|FG004|Long-Term Safety Phase (Year 5)|Lack of Efficacy|0
6164818|NCT01212757|9808318|FG005|Long-Term Safety Phase (Year 5)|Lack of Efficacy|0
6164819|NCT01212757|9808319|FG006|Long-Term Safety Phase (Year 5)|Lack of Efficacy|0
6164820|NCT01212757|9808320|FG007|Long-Term Safety Phase (Year 5)|Lack of Efficacy|2
6164821|NCT01212757|9808321|FG008|Long-Term Safety Phase (Year 5)|Lack of Efficacy|1
6164822|NCT01212757|9808313|FG000|Long-Term Safety Phase (Year 5)|Non-compliance with study drug|0
6164823|NCT01212757|9808314|FG001|Long-Term Safety Phase (Year 5)|Non-compliance with study drug|1
6164824|NCT01212757|9808315|FG002|Long-Term Safety Phase (Year 5)|Non-compliance with study drug|0
6164825|NCT01212757|9808316|FG003|Long-Term Safety Phase (Year 5)|Non-compliance with study drug|0
6164826|NCT01212757|9808317|FG004|Long-Term Safety Phase (Year 5)|Non-compliance with study drug|0
6164827|NCT01212757|9808318|FG005|Long-Term Safety Phase (Year 5)|Non-compliance with study drug|0
6164828|NCT01212757|9808319|FG006|Long-Term Safety Phase (Year 5)|Non-compliance with study drug|0
6164829|NCT01212757|9808320|FG007|Long-Term Safety Phase (Year 5)|Non-compliance with study drug|0
6164830|NCT01212757|9808321|FG008|Long-Term Safety Phase (Year 5)|Non-compliance with study drug|0
6164831|NCT01212757|9808313|FG000|Long-Term Safety Phase (Year 5)|Miscellaneous|0
6164832|NCT01212757|9808314|FG001|Long-Term Safety Phase (Year 5)|Miscellaneous|1
6164833|NCT01212757|9808315|FG002|Long-Term Safety Phase (Year 5)|Miscellaneous|1
6164834|NCT01212757|9808316|FG003|Long-Term Safety Phase (Year 5)|Miscellaneous|0
6164835|NCT01212757|9808317|FG004|Long-Term Safety Phase (Year 5)|Miscellaneous|0
6164836|NCT01212757|9808318|FG005|Long-Term Safety Phase (Year 5)|Miscellaneous|0
6164837|NCT01212757|9808319|FG006|Long-Term Safety Phase (Year 5)|Miscellaneous|0
6164838|NCT01212757|9808320|FG007|Long-Term Safety Phase (Year 5)|Miscellaneous|0
6164839|NCT01212757|9808321|FG008|Long-Term Safety Phase (Year 5)|Miscellaneous|0
6164840|NCT01212770|9808342|FG000|Placebo-controlled Phase (Week 0 - 24)|Adverse Event|10
6164841|NCT01212770|9808343|FG001|Placebo-controlled Phase (Week 0 - 24)|Adverse Event|12
6164842|NCT01212770|9808344|FG002|Placebo-controlled Phase (Week 0 - 24)|Adverse Event|8
6164843|NCT01212770|9808345|FG003|Placebo-controlled Phase (Week 0 - 24)|Adverse Event|0
6164844|NCT01212770|9808346|FG004|Placebo-controlled Phase (Week 0 - 24)|Adverse Event|0
6164845|NCT01212770|9808347|FG005|Placebo-controlled Phase (Week 0 - 24)|Adverse Event|0
6164846|NCT01212770|9808348|FG006|Placebo-controlled Phase (Week 0 - 24)|Adverse Event|0
6164847|NCT01212770|9808349|FG007|Placebo-controlled Phase (Week 0 - 24)|Adverse Event|0
6164848|NCT01212770|9808350|FG008|Placebo-controlled Phase (Week 0 - 24)|Adverse Event|0
6164849|NCT01212770|9808342|FG000|Placebo-controlled Phase (Week 0 - 24)|Lack of Efficacy|6
6326918|NCT02956629|10070333|FG005|Overall Study|Withdrawal by Subject|0
6164850|NCT01212770|9808343|FG001|Placebo-controlled Phase (Week 0 - 24)|Lack of Efficacy|5
6164851|NCT01212770|9808344|FG002|Placebo-controlled Phase (Week 0 - 24)|Lack of Efficacy|7
6164852|NCT01212770|9808345|FG003|Placebo-controlled Phase (Week 0 - 24)|Lack of Efficacy|0
6164853|NCT01212770|9808346|FG004|Placebo-controlled Phase (Week 0 - 24)|Lack of Efficacy|0
6164854|NCT01212770|9808347|FG005|Placebo-controlled Phase (Week 0 - 24)|Lack of Efficacy|0
6164855|NCT01212770|9808348|FG006|Placebo-controlled Phase (Week 0 - 24)|Lack of Efficacy|0
6164856|NCT01212770|9808349|FG007|Placebo-controlled Phase (Week 0 - 24)|Lack of Efficacy|0
6164857|NCT01212770|9808350|FG008|Placebo-controlled Phase (Week 0 - 24)|Lack of Efficacy|0
6164858|NCT01212770|9808342|FG000|Placebo-controlled Phase (Week 0 - 24)|Withdrawal by Subject|3
6164859|NCT01212770|9808343|FG001|Placebo-controlled Phase (Week 0 - 24)|Withdrawal by Subject|4
6164860|NCT01212770|9808344|FG002|Placebo-controlled Phase (Week 0 - 24)|Withdrawal by Subject|1
6164861|NCT01212770|9808345|FG003|Placebo-controlled Phase (Week 0 - 24)|Withdrawal by Subject|0
6164862|NCT01212770|9808346|FG004|Placebo-controlled Phase (Week 0 - 24)|Withdrawal by Subject|0
6164863|NCT01212770|9808347|FG005|Placebo-controlled Phase (Week 0 - 24)|Withdrawal by Subject|0
6164864|NCT01212770|9808348|FG006|Placebo-controlled Phase (Week 0 - 24)|Withdrawal by Subject|0
6164865|NCT01212770|9808349|FG007|Placebo-controlled Phase (Week 0 - 24)|Withdrawal by Subject|0
6164866|NCT01212770|9808350|FG008|Placebo-controlled Phase (Week 0 - 24)|Withdrawal by Subject|0
6164867|NCT01212770|9808342|FG000|Placebo-controlled Phase (Week 0 - 24)|Lost to Follow-up|1
6164868|NCT01212770|9808343|FG001|Placebo-controlled Phase (Week 0 - 24)|Lost to Follow-up|0
6164869|NCT01212770|9808344|FG002|Placebo-controlled Phase (Week 0 - 24)|Lost to Follow-up|3
6164870|NCT01212770|9808345|FG003|Placebo-controlled Phase (Week 0 - 24)|Lost to Follow-up|0
6164871|NCT01212770|9808346|FG004|Placebo-controlled Phase (Week 0 - 24)|Lost to Follow-up|0
6164872|NCT01212770|9808347|FG005|Placebo-controlled Phase (Week 0 - 24)|Lost to Follow-up|0
6164873|NCT01212770|9808348|FG006|Placebo-controlled Phase (Week 0 - 24)|Lost to Follow-up|0
6164874|NCT01212770|9808349|FG007|Placebo-controlled Phase (Week 0 - 24)|Lost to Follow-up|0
6164875|NCT01212770|9808350|FG008|Placebo-controlled Phase (Week 0 - 24)|Lost to Follow-up|0
6164876|NCT01212770|9808342|FG000|Placebo-controlled Phase (Week 0 - 24)|Protocol Violation|0
6164877|NCT01212770|9808343|FG001|Placebo-controlled Phase (Week 0 - 24)|Protocol Violation|0
6164878|NCT01212770|9808344|FG002|Placebo-controlled Phase (Week 0 - 24)|Protocol Violation|1
6164879|NCT01212770|9808345|FG003|Placebo-controlled Phase (Week 0 - 24)|Protocol Violation|0
6164880|NCT01212770|9808346|FG004|Placebo-controlled Phase (Week 0 - 24)|Protocol Violation|0
6164881|NCT01212770|9808347|FG005|Placebo-controlled Phase (Week 0 - 24)|Protocol Violation|0
6164882|NCT01212770|9808348|FG006|Placebo-controlled Phase (Week 0 - 24)|Protocol Violation|0
6164883|NCT01212770|9808349|FG007|Placebo-controlled Phase (Week 0 - 24)|Protocol Violation|0
6164884|NCT01212770|9808350|FG008|Placebo-controlled Phase (Week 0 - 24)|Protocol Violation|0
6164885|NCT01212770|9808342|FG000|Placebo-controlled Phase (Week 0 - 24)|Miscellaneous|3
6164886|NCT01212770|9808343|FG001|Placebo-controlled Phase (Week 0 - 24)|Miscellaneous|1
6164887|NCT01212770|9808344|FG002|Placebo-controlled Phase (Week 0 - 24)|Miscellaneous|2
6164888|NCT01212770|9808345|FG003|Placebo-controlled Phase (Week 0 - 24)|Miscellaneous|0
6164889|NCT01212770|9808346|FG004|Placebo-controlled Phase (Week 0 - 24)|Miscellaneous|0
6164890|NCT01212770|9808347|FG005|Placebo-controlled Phase (Week 0 - 24)|Miscellaneous|0
6164891|NCT01212770|9808348|FG006|Placebo-controlled Phase (Week 0 - 24)|Miscellaneous|0
6164892|NCT01212770|9808349|FG007|Placebo-controlled Phase (Week 0 - 24)|Miscellaneous|0
6164893|NCT01212770|9808350|FG008|Placebo-controlled Phase (Week 0 - 24)|Miscellaneous|0
6164894|NCT01212770|9808342|FG000|Active Treatment Phase (Weeks 25 - 52)|Adverse Event|0
6164895|NCT01212770|9808343|FG001|Active Treatment Phase (Weeks 25 - 52)|Adverse Event|6
6164896|NCT01212770|9808344|FG002|Active Treatment Phase (Weeks 25 - 52)|Adverse Event|2
6164897|NCT01212770|9808345|FG003|Active Treatment Phase (Weeks 25 - 52)|Adverse Event|2
6164898|NCT01212770|9808346|FG004|Active Treatment Phase (Weeks 25 - 52)|Adverse Event|0
6164899|NCT01212770|9808347|FG005|Active Treatment Phase (Weeks 25 - 52)|Adverse Event|0
6164900|NCT01212770|9808348|FG006|Active Treatment Phase (Weeks 25 - 52)|Adverse Event|1
6164901|NCT01212770|9808349|FG007|Active Treatment Phase (Weeks 25 - 52)|Adverse Event|0
6164902|NCT01212770|9808350|FG008|Active Treatment Phase (Weeks 25 - 52)|Adverse Event|0
6164903|NCT01212770|9808342|FG000|Active Treatment Phase (Weeks 25 - 52)|Lack of Efficacy|0
6164904|NCT01212770|9808343|FG001|Active Treatment Phase (Weeks 25 - 52)|Lack of Efficacy|7
6164905|NCT01212770|9808344|FG002|Active Treatment Phase (Weeks 25 - 52)|Lack of Efficacy|5
6164906|NCT01212770|9808345|FG003|Active Treatment Phase (Weeks 25 - 52)|Lack of Efficacy|4
6164907|NCT01212770|9808346|FG004|Active Treatment Phase (Weeks 25 - 52)|Lack of Efficacy|1
6164908|NCT01212770|9808347|FG005|Active Treatment Phase (Weeks 25 - 52)|Lack of Efficacy|2
6164909|NCT01212770|9808348|FG006|Active Treatment Phase (Weeks 25 - 52)|Lack of Efficacy|0
6164910|NCT01212770|9808349|FG007|Active Treatment Phase (Weeks 25 - 52)|Lack of Efficacy|0
6164911|NCT01212770|9808350|FG008|Active Treatment Phase (Weeks 25 - 52)|Lack of Efficacy|0
6164912|NCT01212770|9808342|FG000|Active Treatment Phase (Weeks 25 - 52)|Withdrawal by Subject|0
6164913|NCT01212770|9808343|FG001|Active Treatment Phase (Weeks 25 - 52)|Withdrawal by Subject|6
6164914|NCT01212770|9808344|FG002|Active Treatment Phase (Weeks 25 - 52)|Withdrawal by Subject|3
6164915|NCT01212770|9808345|FG003|Active Treatment Phase (Weeks 25 - 52)|Withdrawal by Subject|3
6164916|NCT01212770|9808346|FG004|Active Treatment Phase (Weeks 25 - 52)|Withdrawal by Subject|1
6164917|NCT01212770|9808347|FG005|Active Treatment Phase (Weeks 25 - 52)|Withdrawal by Subject|1
6164918|NCT01212770|9808348|FG006|Active Treatment Phase (Weeks 25 - 52)|Withdrawal by Subject|1
6164919|NCT01212770|9808349|FG007|Active Treatment Phase (Weeks 25 - 52)|Withdrawal by Subject|0
6164920|NCT01212770|9808350|FG008|Active Treatment Phase (Weeks 25 - 52)|Withdrawal by Subject|0
6164921|NCT01212770|9808342|FG000|Active Treatment Phase (Weeks 25 - 52)|Lost to Follow-up|0
6164922|NCT01212770|9808343|FG001|Active Treatment Phase (Weeks 25 - 52)|Lost to Follow-up|0
6164923|NCT01212770|9808344|FG002|Active Treatment Phase (Weeks 25 - 52)|Lost to Follow-up|1
6164924|NCT01212770|9808345|FG003|Active Treatment Phase (Weeks 25 - 52)|Lost to Follow-up|0
6164925|NCT01212770|9808346|FG004|Active Treatment Phase (Weeks 25 - 52)|Lost to Follow-up|0
6164926|NCT01212770|9808347|FG005|Active Treatment Phase (Weeks 25 - 52)|Lost to Follow-up|0
6164927|NCT01212770|9808348|FG006|Active Treatment Phase (Weeks 25 - 52)|Lost to Follow-up|0
6164928|NCT01212770|9808349|FG007|Active Treatment Phase (Weeks 25 - 52)|Lost to Follow-up|0
6164929|NCT01212770|9808350|FG008|Active Treatment Phase (Weeks 25 - 52)|Lost to Follow-up|0
6164930|NCT01212770|9808342|FG000|Active Treatment Phase (Weeks 25 - 52)|Protocol Violation|0
6164931|NCT01212770|9808343|FG001|Active Treatment Phase (Weeks 25 - 52)|Protocol Violation|0
6164932|NCT01212770|9808344|FG002|Active Treatment Phase (Weeks 25 - 52)|Protocol Violation|0
6164933|NCT01212770|9808345|FG003|Active Treatment Phase (Weeks 25 - 52)|Protocol Violation|1
6326919|NCT02956837|10070369|FG000|Overall Study|Serious Adverse Events|0
6164934|NCT01212770|9808346|FG004|Active Treatment Phase (Weeks 25 - 52)|Protocol Violation|0
6164935|NCT01212770|9808347|FG005|Active Treatment Phase (Weeks 25 - 52)|Protocol Violation|0
6164936|NCT01212770|9808348|FG006|Active Treatment Phase (Weeks 25 - 52)|Protocol Violation|0
6164937|NCT01212770|9808349|FG007|Active Treatment Phase (Weeks 25 - 52)|Protocol Violation|0
6164938|NCT01212770|9808350|FG008|Active Treatment Phase (Weeks 25 - 52)|Protocol Violation|0
6164939|NCT01212770|9808342|FG000|Active Treatment Phase (Weeks 25 - 52)|Miscellaneous|0
6164940|NCT01212770|9808343|FG001|Active Treatment Phase (Weeks 25 - 52)|Miscellaneous|0
6164941|NCT01212770|9808344|FG002|Active Treatment Phase (Weeks 25 - 52)|Miscellaneous|1
6164942|NCT01212770|9808345|FG003|Active Treatment Phase (Weeks 25 - 52)|Miscellaneous|1
6164943|NCT01212770|9808346|FG004|Active Treatment Phase (Weeks 25 - 52)|Miscellaneous|0
6164944|NCT01212770|9808347|FG005|Active Treatment Phase (Weeks 25 - 52)|Miscellaneous|0
6164945|NCT01212770|9808348|FG006|Active Treatment Phase (Weeks 25 - 52)|Miscellaneous|0
6164946|NCT01212770|9808349|FG007|Active Treatment Phase (Weeks 25 - 52)|Miscellaneous|0
6326920|NCT02956837|10070370|FG001|Overall Study|Serious Adverse Events|1
6326921|NCT02956837|10070371|FG002|Overall Study|Serious Adverse Events|0
6326922|NCT02956837|10070372|FG003|Overall Study|Serious Adverse Events|0
6326923|NCT02956837|10070369|FG000|Overall Study|Withdrawal by Subject|0
6326924|NCT02956837|10070370|FG001|Overall Study|Withdrawal by Subject|1
6164947|NCT01212770|9808350|FG008|Active Treatment Phase (Weeks 25 - 52)|Miscellaneous|0
6164948|NCT01212770|9808342|FG000|Long-term Safety Phase (Year 2)|Adverse Event|0
6164949|NCT01212770|9808343|FG001|Long-term Safety Phase (Year 2)|Adverse Event|3
6164950|NCT01212770|9808344|FG002|Long-term Safety Phase (Year 2)|Adverse Event|3
6164951|NCT01212770|9808345|FG003|Long-term Safety Phase (Year 2)|Adverse Event|0
6164952|NCT01212770|9808346|FG004|Long-term Safety Phase (Year 2)|Adverse Event|0
6164953|NCT01212770|9808347|FG005|Long-term Safety Phase (Year 2)|Adverse Event|0
6164954|NCT01212770|9808348|FG006|Long-term Safety Phase (Year 2)|Adverse Event|0
6164955|NCT01212770|9808349|FG007|Long-term Safety Phase (Year 2)|Adverse Event|0
6164956|NCT01212770|9808350|FG008|Long-term Safety Phase (Year 2)|Adverse Event|2
6164957|NCT01212770|9808342|FG000|Long-term Safety Phase (Year 2)|Lack of Efficacy|0
6164958|NCT01212770|9808343|FG001|Long-term Safety Phase (Year 2)|Lack of Efficacy|6
6164959|NCT01212770|9808344|FG002|Long-term Safety Phase (Year 2)|Lack of Efficacy|7
6164960|NCT01212770|9808345|FG003|Long-term Safety Phase (Year 2)|Lack of Efficacy|0
6164961|NCT01212770|9808346|FG004|Long-term Safety Phase (Year 2)|Lack of Efficacy|0
6164962|NCT01212770|9808347|FG005|Long-term Safety Phase (Year 2)|Lack of Efficacy|0
6164963|NCT01212770|9808348|FG006|Long-term Safety Phase (Year 2)|Lack of Efficacy|0
6164964|NCT01212770|9808349|FG007|Long-term Safety Phase (Year 2)|Lack of Efficacy|4
6164965|NCT01212770|9808350|FG008|Long-term Safety Phase (Year 2)|Lack of Efficacy|6
6164966|NCT01212770|9808342|FG000|Long-term Safety Phase (Year 2)|Non-compliance to study drug|0
6164967|NCT01212770|9808343|FG001|Long-term Safety Phase (Year 2)|Non-compliance to study drug|1
6164968|NCT01212770|9808344|FG002|Long-term Safety Phase (Year 2)|Non-compliance to study drug|0
6164969|NCT01212770|9808345|FG003|Long-term Safety Phase (Year 2)|Non-compliance to study drug|0
6164970|NCT01212770|9808346|FG004|Long-term Safety Phase (Year 2)|Non-compliance to study drug|0
6164971|NCT01212770|9808347|FG005|Long-term Safety Phase (Year 2)|Non-compliance to study drug|0
6164972|NCT01212770|9808348|FG006|Long-term Safety Phase (Year 2)|Non-compliance to study drug|0
6164973|NCT01212770|9808349|FG007|Long-term Safety Phase (Year 2)|Non-compliance to study drug|0
6164974|NCT01212770|9808350|FG008|Long-term Safety Phase (Year 2)|Non-compliance to study drug|0
6164975|NCT01212770|9808342|FG000|Long-term Safety Phase (Year 2)|Withdrawal by Subject|0
6164976|NCT01212770|9808343|FG001|Long-term Safety Phase (Year 2)|Withdrawal by Subject|9
6164977|NCT01212770|9808344|FG002|Long-term Safety Phase (Year 2)|Withdrawal by Subject|3
6164978|NCT01212770|9808345|FG003|Long-term Safety Phase (Year 2)|Withdrawal by Subject|0
6164979|NCT01212770|9808346|FG004|Long-term Safety Phase (Year 2)|Withdrawal by Subject|0
6164980|NCT01212770|9808347|FG005|Long-term Safety Phase (Year 2)|Withdrawal by Subject|0
6164981|NCT01212770|9808348|FG006|Long-term Safety Phase (Year 2)|Withdrawal by Subject|0
6164982|NCT01212770|9808349|FG007|Long-term Safety Phase (Year 2)|Withdrawal by Subject|4
6164983|NCT01212770|9808350|FG008|Long-term Safety Phase (Year 2)|Withdrawal by Subject|4
6164984|NCT01212770|9808342|FG000|Long-term Safety Phase (Year 2)|Lost to Follow-up|0
6164985|NCT01212770|9808343|FG001|Long-term Safety Phase (Year 2)|Lost to Follow-up|2
6164986|NCT01212770|9808344|FG002|Long-term Safety Phase (Year 2)|Lost to Follow-up|1
6164987|NCT01212770|9808345|FG003|Long-term Safety Phase (Year 2)|Lost to Follow-up|0
6164988|NCT01212770|9808346|FG004|Long-term Safety Phase (Year 2)|Lost to Follow-up|0
6164989|NCT01212770|9808347|FG005|Long-term Safety Phase (Year 2)|Lost to Follow-up|0
6164990|NCT01212770|9808348|FG006|Long-term Safety Phase (Year 2)|Lost to Follow-up|0
6164991|NCT01212770|9808349|FG007|Long-term Safety Phase (Year 2)|Lost to Follow-up|1
6164992|NCT01212770|9808350|FG008|Long-term Safety Phase (Year 2)|Lost to Follow-up|1
6164993|NCT01212770|9808342|FG000|Long-term Safety Phase (Year 2)|Miscellaneous|0
6164994|NCT01212770|9808343|FG001|Long-term Safety Phase (Year 2)|Miscellaneous|2
6164995|NCT01212770|9808344|FG002|Long-term Safety Phase (Year 2)|Miscellaneous|1
6164996|NCT01212770|9808345|FG003|Long-term Safety Phase (Year 2)|Miscellaneous|0
6164997|NCT01212770|9808346|FG004|Long-term Safety Phase (Year 2)|Miscellaneous|0
6164998|NCT01212770|9808347|FG005|Long-term Safety Phase (Year 2)|Miscellaneous|0
6164999|NCT01212770|9808348|FG006|Long-term Safety Phase (Year 2)|Miscellaneous|0
6165000|NCT01212770|9808349|FG007|Long-term Safety Phase (Year 2)|Miscellaneous|0
6165001|NCT01212770|9808350|FG008|Long-term Safety Phase (Year 2)|Miscellaneous|1
6165002|NCT01212770|9808342|FG000|Long-term Safety Phase (Year 3)|Adverse Event|0
6165003|NCT01212770|9808343|FG001|Long-term Safety Phase (Year 3)|Adverse Event|2
6165004|NCT01212770|9808344|FG002|Long-term Safety Phase (Year 3)|Adverse Event|2
6165005|NCT01212770|9808345|FG003|Long-term Safety Phase (Year 3)|Adverse Event|0
6165006|NCT01212770|9808346|FG004|Long-term Safety Phase (Year 3)|Adverse Event|0
6165007|NCT01212770|9808347|FG005|Long-term Safety Phase (Year 3)|Adverse Event|0
6165008|NCT01212770|9808348|FG006|Long-term Safety Phase (Year 3)|Adverse Event|0
6165009|NCT01212770|9808349|FG007|Long-term Safety Phase (Year 3)|Adverse Event|2
6165010|NCT01212770|9808350|FG008|Long-term Safety Phase (Year 3)|Adverse Event|1
6165011|NCT01212770|9808342|FG000|Long-term Safety Phase (Year 3)|Lack of Efficacy|0
6165012|NCT01212770|9808343|FG001|Long-term Safety Phase (Year 3)|Lack of Efficacy|3
6165013|NCT01212770|9808344|FG002|Long-term Safety Phase (Year 3)|Lack of Efficacy|4
6165014|NCT01212770|9808345|FG003|Long-term Safety Phase (Year 3)|Lack of Efficacy|0
6165015|NCT01212770|9808346|FG004|Long-term Safety Phase (Year 3)|Lack of Efficacy|0
6165016|NCT01212770|9808347|FG005|Long-term Safety Phase (Year 3)|Lack of Efficacy|0
6165017|NCT01212770|9808348|FG006|Long-term Safety Phase (Year 3)|Lack of Efficacy|0
6165018|NCT01212770|9808349|FG007|Long-term Safety Phase (Year 3)|Lack of Efficacy|2
6165019|NCT01212770|9808350|FG008|Long-term Safety Phase (Year 3)|Lack of Efficacy|2
6165020|NCT01212770|9808342|FG000|Long-term Safety Phase (Year 3)|Withdrawal by Subject|0
6165021|NCT01212770|9808343|FG001|Long-term Safety Phase (Year 3)|Withdrawal by Subject|3
6165022|NCT01212770|9808344|FG002|Long-term Safety Phase (Year 3)|Withdrawal by Subject|4
6165023|NCT01212770|9808345|FG003|Long-term Safety Phase (Year 3)|Withdrawal by Subject|0
6165024|NCT01212770|9808346|FG004|Long-term Safety Phase (Year 3)|Withdrawal by Subject|0
6165025|NCT01212770|9808347|FG005|Long-term Safety Phase (Year 3)|Withdrawal by Subject|0
6165026|NCT01212770|9808348|FG006|Long-term Safety Phase (Year 3)|Withdrawal by Subject|0
6165027|NCT01212770|9808349|FG007|Long-term Safety Phase (Year 3)|Withdrawal by Subject|1
6165028|NCT01212770|9808350|FG008|Long-term Safety Phase (Year 3)|Withdrawal by Subject|1
6165029|NCT01212770|9808342|FG000|Long-term Safety Phase (Year 3)|Lost to Follow-up|0
6165030|NCT01212770|9808343|FG001|Long-term Safety Phase (Year 3)|Lost to Follow-up|1
6165031|NCT01212770|9808344|FG002|Long-term Safety Phase (Year 3)|Lost to Follow-up|0
6165032|NCT01212770|9808345|FG003|Long-term Safety Phase (Year 3)|Lost to Follow-up|0
6165033|NCT01212770|9808346|FG004|Long-term Safety Phase (Year 3)|Lost to Follow-up|0
6165034|NCT01212770|9808347|FG005|Long-term Safety Phase (Year 3)|Lost to Follow-up|0
6165035|NCT01212770|9808348|FG006|Long-term Safety Phase (Year 3)|Lost to Follow-up|0
6165036|NCT01212770|9808349|FG007|Long-term Safety Phase (Year 3)|Lost to Follow-up|0
6165037|NCT01212770|9808350|FG008|Long-term Safety Phase (Year 3)|Lost to Follow-up|0
6165038|NCT01212770|9808342|FG000|Long-term Safety Phase (Year 3)|Protocol Violation|0
6165039|NCT01212770|9808343|FG001|Long-term Safety Phase (Year 3)|Protocol Violation|0
6165040|NCT01212770|9808344|FG002|Long-term Safety Phase (Year 3)|Protocol Violation|0
6165041|NCT01212770|9808345|FG003|Long-term Safety Phase (Year 3)|Protocol Violation|0
6165042|NCT01212770|9808346|FG004|Long-term Safety Phase (Year 3)|Protocol Violation|0
6165043|NCT01212770|9808347|FG005|Long-term Safety Phase (Year 3)|Protocol Violation|0
6165044|NCT01212770|9808348|FG006|Long-term Safety Phase (Year 3)|Protocol Violation|0
6165045|NCT01212770|9808349|FG007|Long-term Safety Phase (Year 3)|Protocol Violation|1
6165046|NCT01212770|9808350|FG008|Long-term Safety Phase (Year 3)|Protocol Violation|0
6165047|NCT01212770|9808342|FG000|Long-term Safety Phase (Year 3)|Miscellaneous|0
6165048|NCT01212770|9808343|FG001|Long-term Safety Phase (Year 3)|Miscellaneous|2
6165049|NCT01212770|9808344|FG002|Long-term Safety Phase (Year 3)|Miscellaneous|1
6165050|NCT01212770|9808345|FG003|Long-term Safety Phase (Year 3)|Miscellaneous|0
6165051|NCT01212770|9808346|FG004|Long-term Safety Phase (Year 3)|Miscellaneous|0
6165052|NCT01212770|9808347|FG005|Long-term Safety Phase (Year 3)|Miscellaneous|0
6165053|NCT01212770|9808348|FG006|Long-term Safety Phase (Year 3)|Miscellaneous|0
6165054|NCT01212770|9808349|FG007|Long-term Safety Phase (Year 3)|Miscellaneous|1
6165055|NCT01212770|9808350|FG008|Long-term Safety Phase (Year 3)|Miscellaneous|1
6165056|NCT01212770|9808342|FG000|Long-term Safety Phase (Year 4)|Adverse Event|0
6165057|NCT01212770|9808343|FG001|Long-term Safety Phase (Year 4)|Adverse Event|1
6326925|NCT02956837|10070371|FG002|Overall Study|Withdrawal by Subject|0
6326926|NCT02956837|10070372|FG003|Overall Study|Withdrawal by Subject|3
6165058|NCT01212770|9808344|FG002|Long-term Safety Phase (Year 4)|Adverse Event|1
6165059|NCT01212770|9808345|FG003|Long-term Safety Phase (Year 4)|Adverse Event|0
6165060|NCT01212770|9808346|FG004|Long-term Safety Phase (Year 4)|Adverse Event|0
6165061|NCT01212770|9808347|FG005|Long-term Safety Phase (Year 4)|Adverse Event|0
6165062|NCT01212770|9808348|FG006|Long-term Safety Phase (Year 4)|Adverse Event|0
6165063|NCT01212770|9808349|FG007|Long-term Safety Phase (Year 4)|Adverse Event|0
6165064|NCT01212770|9808350|FG008|Long-term Safety Phase (Year 4)|Adverse Event|1
6165065|NCT01212770|9808342|FG000|Long-term Safety Phase (Year 4)|Lack of Efficacy|0
6165066|NCT01212770|9808343|FG001|Long-term Safety Phase (Year 4)|Lack of Efficacy|1
6165067|NCT01212770|9808344|FG002|Long-term Safety Phase (Year 4)|Lack of Efficacy|5
6165068|NCT01212770|9808345|FG003|Long-term Safety Phase (Year 4)|Lack of Efficacy|0
6165069|NCT01212770|9808346|FG004|Long-term Safety Phase (Year 4)|Lack of Efficacy|0
6165070|NCT01212770|9808347|FG005|Long-term Safety Phase (Year 4)|Lack of Efficacy|0
6165071|NCT01212770|9808348|FG006|Long-term Safety Phase (Year 4)|Lack of Efficacy|0
6165072|NCT01212770|9808349|FG007|Long-term Safety Phase (Year 4)|Lack of Efficacy|2
6165073|NCT01212770|9808350|FG008|Long-term Safety Phase (Year 4)|Lack of Efficacy|0
6165074|NCT01212770|9808342|FG000|Long-term Safety Phase (Year 4)|Non-compliance with study drug|0
6165075|NCT01212770|9808343|FG001|Long-term Safety Phase (Year 4)|Non-compliance with study drug|1
6165076|NCT01212770|9808344|FG002|Long-term Safety Phase (Year 4)|Non-compliance with study drug|1
6165077|NCT01212770|9808345|FG003|Long-term Safety Phase (Year 4)|Non-compliance with study drug|0
6165078|NCT01212770|9808346|FG004|Long-term Safety Phase (Year 4)|Non-compliance with study drug|0
6165079|NCT01212770|9808347|FG005|Long-term Safety Phase (Year 4)|Non-compliance with study drug|0
6165080|NCT01212770|9808348|FG006|Long-term Safety Phase (Year 4)|Non-compliance with study drug|0
6165081|NCT01212770|9808349|FG007|Long-term Safety Phase (Year 4)|Non-compliance with study drug|1
6165082|NCT01212770|9808350|FG008|Long-term Safety Phase (Year 4)|Non-compliance with study drug|0
6165083|NCT01212770|9808342|FG000|Long-term Safety Phase (Year 4)|Withdrawal by Subject|0
6165084|NCT01212770|9808343|FG001|Long-term Safety Phase (Year 4)|Withdrawal by Subject|2
6165085|NCT01212770|9808344|FG002|Long-term Safety Phase (Year 4)|Withdrawal by Subject|3
6165086|NCT01212770|9808345|FG003|Long-term Safety Phase (Year 4)|Withdrawal by Subject|0
6165087|NCT01212770|9808346|FG004|Long-term Safety Phase (Year 4)|Withdrawal by Subject|0
6326927|NCT02956837|10070369|FG000|Overall Study|Lost to Follow-up|0
6326928|NCT02956837|10070370|FG001|Overall Study|Lost to Follow-up|1
6326929|NCT02956837|10070371|FG002|Overall Study|Lost to Follow-up|2
6326930|NCT02956837|10070372|FG003|Overall Study|Lost to Follow-up|0
6326931|NCT02956967|10070385|FG000|Overall Study|Adverse Event|3
6326932|NCT02956967|10070385|FG000|Overall Study|Reason non-related to neutropenia|10
6326933|NCT02956967|10070385|FG000|Overall Study|Lost to Follow-up|5
6326934|NCT02956967|10070385|FG000|Overall Study|Missing|1
6326935|NCT02956967|10070385|FG000|Overall Study|Termination of Nivestim administration|29
6326936|NCT02957136|10070395|FG000|Overall Study|Withdrawal by Subject|2
6326937|NCT02957136|10070396|FG001|Overall Study|Withdrawal by Subject|1
6326938|NCT02957331|10070413|FG000|Overall Study|Protocol Violation|1
6326939|NCT02957331|10070414|FG001|Overall Study|Protocol Violation|0
6326940|NCT02957682|10070438|FG000|Overall Study|Adverse Event|64
6326941|NCT02957682|10070439|FG001|Overall Study|Adverse Event|67
6326942|NCT02957682|10070438|FG000|Overall Study|Poor Compliance to Protocol|30
6326943|NCT02957682|10070439|FG001|Overall Study|Poor Compliance to Protocol|26
6326944|NCT02957682|10070438|FG000|Overall Study|Physician Decision|4
6326945|NCT02957682|10070439|FG001|Overall Study|Physician Decision|4
6326946|NCT02957682|10070438|FG000|Overall Study|Study Terminated by Sponsor|4
6326947|NCT02957682|10070439|FG001|Overall Study|Study Terminated by Sponsor|3
6326948|NCT02957682|10070438|FG000|Overall Study|Subject Moved|10
6326949|NCT02957682|10070439|FG001|Overall Study|Subject Moved|16
6326950|NCT02957682|10070438|FG000|Overall Study|Withdrawal by Subject|64
6326951|NCT02957682|10070439|FG001|Overall Study|Withdrawal by Subject|33
6326952|NCT02957682|10070438|FG000|Overall Study|Related to IMP Administration|3
6326953|NCT02957682|10070439|FG001|Overall Study|Related to IMP Administration|6
6326954|NCT02957682|10070438|FG000|Overall Study|Non-disclosed|16
6326955|NCT02957682|10070439|FG001|Overall Study|Non-disclosed|12
6326956|NCT02957682|10070438|FG000|Overall Study|Discontinued After Randomization and Prior to Any Treatment|3
6326957|NCT02957682|10070439|FG001|Overall Study|Discontinued After Randomization and Prior to Any Treatment|2
6326958|NCT02957747|10070447|FG000|Overall Study|Withdrawal by Subject|0
6326959|NCT02957747|10070448|FG001|Overall Study|Withdrawal by Subject|3
6326960|NCT02957747|10070447|FG000|Overall Study|Lost to Follow-up|10
6326961|NCT02957747|10070448|FG001|Overall Study|Lost to Follow-up|5
6326962|NCT02957942|10070457|FG000|Overall Study|Withdrawal by Subject|0
6326963|NCT02957942|10070458|FG001|Overall Study|Withdrawal by Subject|1
6326964|NCT02957942|10070457|FG000|Overall Study|Practicing experiment protocol|0
6326965|NCT02957942|10070458|FG001|Overall Study|Practicing experiment protocol|6
6326966|NCT02958267|10070466|FG000|Enrollment to Actual Treatment Complete|Withdrawal by Subject|1
6326967|NCT02958267|10070467|FG001|Enrollment to Actual Treatment Complete|Withdrawal by Subject|0
6326968|NCT02958267|10070466|FG000|Enrollment to Actual Treatment Complete|Physician Decision|1
6326969|NCT02958267|10070467|FG001|Enrollment to Actual Treatment Complete|Physician Decision|0
6326970|NCT02958267|10070466|FG000|Follow-up Visits|Additional treatment pursued|2
6326971|NCT02958267|10070467|FG001|Follow-up Visits|Additional treatment pursued|1
6326972|NCT02958527|10070482|FG000|Overall Study|Not collected CRFs|12
6326973|NCT02958553|10070495|FG000|Phase I, 3rd Visit -2 Week emPOWER FU|Withdrawal by Subject|1
6326974|NCT02958553|10070495|FG000|Phase II, 6th Visit -6 Month emPOWER FU|Adverse Event|2
6326975|NCT02959138|10070595|FG000|Overall Study|Enrolled but Never Treated|0
6326976|NCT02959138|10070596|FG001|Overall Study|Enrolled but Never Treated|1
6326977|NCT02959138|10070597|FG002|Overall Study|Enrolled but Never Treated|0
6326978|NCT02959177|10070612|FG000|Double-Blind Treatment Phase|Adverse Event|5
6326979|NCT02959177|10070613|FG001|Double-Blind Treatment Phase|Adverse Event|2
6326980|NCT02959177|10070614|FG002|Double-Blind Treatment Phase|Adverse Event|0
6326981|NCT02959177|10070612|FG000|Double-Blind Treatment Phase|Physician Decision|1
6326982|NCT02959177|10070613|FG001|Double-Blind Treatment Phase|Physician Decision|0
6326983|NCT02959177|10070614|FG002|Double-Blind Treatment Phase|Physician Decision|0
6326984|NCT02959177|10070612|FG000|Double-Blind Treatment Phase|Protocol Violation|0
6326985|NCT02959177|10070613|FG001|Double-Blind Treatment Phase|Protocol Violation|1
6165088|NCT01212770|9808347|FG005|Long-term Safety Phase (Year 4)|Withdrawal by Subject|0
6165089|NCT01212770|9808348|FG006|Long-term Safety Phase (Year 4)|Withdrawal by Subject|0
6165090|NCT01212770|9808349|FG007|Long-term Safety Phase (Year 4)|Withdrawal by Subject|0
6165091|NCT01212770|9808350|FG008|Long-term Safety Phase (Year 4)|Withdrawal by Subject|0
6165092|NCT01212770|9808342|FG000|Long-term Safety Phase (Year 4)|Lost to Follow-up|0
6165093|NCT01212770|9808343|FG001|Long-term Safety Phase (Year 4)|Lost to Follow-up|0
6165094|NCT01212770|9808344|FG002|Long-term Safety Phase (Year 4)|Lost to Follow-up|1
6165095|NCT01212770|9808345|FG003|Long-term Safety Phase (Year 4)|Lost to Follow-up|0
6165096|NCT01212770|9808346|FG004|Long-term Safety Phase (Year 4)|Lost to Follow-up|0
6165097|NCT01212770|9808347|FG005|Long-term Safety Phase (Year 4)|Lost to Follow-up|0
6165098|NCT01212770|9808348|FG006|Long-term Safety Phase (Year 4)|Lost to Follow-up|0
6165099|NCT01212770|9808349|FG007|Long-term Safety Phase (Year 4)|Lost to Follow-up|0
6165100|NCT01212770|9808350|FG008|Long-term Safety Phase (Year 4)|Lost to Follow-up|0
6165101|NCT01212770|9808342|FG000|Long-term Safety Phase (Year 4)|Miscellaneous|0
6165102|NCT01212770|9808343|FG001|Long-term Safety Phase (Year 4)|Miscellaneous|1
6165103|NCT01212770|9808344|FG002|Long-term Safety Phase (Year 4)|Miscellaneous|0
6165104|NCT01212770|9808345|FG003|Long-term Safety Phase (Year 4)|Miscellaneous|0
6165105|NCT01212770|9808346|FG004|Long-term Safety Phase (Year 4)|Miscellaneous|0
6165106|NCT01212770|9808347|FG005|Long-term Safety Phase (Year 4)|Miscellaneous|0
6165107|NCT01212770|9808348|FG006|Long-term Safety Phase (Year 4)|Miscellaneous|0
6165108|NCT01212770|9808349|FG007|Long-term Safety Phase (Year 4)|Miscellaneous|0
6326986|NCT02959177|10070614|FG002|Double-Blind Treatment Phase|Protocol Violation|0
6326987|NCT02959177|10070612|FG000|Double-Blind Treatment Phase|Withdrawal by Subject|5
6326988|NCT02959177|10070613|FG001|Double-Blind Treatment Phase|Withdrawal by Subject|0
6326989|NCT02959177|10070614|FG002|Double-Blind Treatment Phase|Withdrawal by Subject|5
6326990|NCT02959177|10070612|FG000|Follow-up Post Treatment Phase|Lost to Follow-up|1
6326991|NCT02959177|10070613|FG001|Follow-up Post Treatment Phase|Lost to Follow-up|0
6326992|NCT02959177|10070614|FG002|Follow-up Post Treatment Phase|Lost to Follow-up|0
6326993|NCT02959177|10070612|FG000|Follow-up Post Treatment Phase|Adverse Event|0
6326994|NCT02959177|10070613|FG001|Follow-up Post Treatment Phase|Adverse Event|1
6326995|NCT02959177|10070614|FG002|Follow-up Post Treatment Phase|Adverse Event|0
6326996|NCT02959177|10070612|FG000|Follow-up Post Treatment Phase|Withdrawal by Subject|0
6326997|NCT02959177|10070613|FG001|Follow-up Post Treatment Phase|Withdrawal by Subject|0
6326998|NCT02959177|10070614|FG002|Follow-up Post Treatment Phase|Withdrawal by Subject|2
6326999|NCT02959190|10070632|FG000|Open Label|Adverse Event|5
6327000|NCT02959190|10070633|FG001|Open Label|Adverse Event|7
6327001|NCT02959190|10070634|FG002|Open Label|Adverse Event|3
6327002|NCT02959190|10070635|FG003|Open Label|Adverse Event|4
6165109|NCT01212770|9808350|FG008|Long-term Safety Phase (Year 4)|Miscellaneous|1
6165110|NCT01212770|9808342|FG000|Long-term Safety Phase (Year 5)|Missing|0
6165111|NCT01212770|9808343|FG001|Long-term Safety Phase (Year 5)|Missing|0
6165112|NCT01212770|9808344|FG002|Long-term Safety Phase (Year 5)|Missing|1
6165113|NCT01212770|9808345|FG003|Long-term Safety Phase (Year 5)|Missing|0
6165114|NCT01212770|9808346|FG004|Long-term Safety Phase (Year 5)|Missing|0
6165115|NCT01212770|9808347|FG005|Long-term Safety Phase (Year 5)|Missing|0
6165116|NCT01212770|9808348|FG006|Long-term Safety Phase (Year 5)|Missing|0
6165117|NCT01212770|9808349|FG007|Long-term Safety Phase (Year 5)|Missing|0
6165118|NCT01212770|9808350|FG008|Long-term Safety Phase (Year 5)|Missing|0
6165119|NCT01212770|9808342|FG000|Long-term Safety Phase (Year 5)|Miscellaneous|0
6165120|NCT01212770|9808343|FG001|Long-term Safety Phase (Year 5)|Miscellaneous|0
6165121|NCT01212770|9808344|FG002|Long-term Safety Phase (Year 5)|Miscellaneous|3
6165122|NCT01212770|9808345|FG003|Long-term Safety Phase (Year 5)|Miscellaneous|0
6165123|NCT01212770|9808346|FG004|Long-term Safety Phase (Year 5)|Miscellaneous|0
6165124|NCT01212770|9808347|FG005|Long-term Safety Phase (Year 5)|Miscellaneous|0
6165125|NCT01212770|9808348|FG006|Long-term Safety Phase (Year 5)|Miscellaneous|0
6165126|NCT01212770|9808349|FG007|Long-term Safety Phase (Year 5)|Miscellaneous|0
6165127|NCT01212770|9808350|FG008|Long-term Safety Phase (Year 5)|Miscellaneous|0
6165128|NCT01212770|9808342|FG000|Long-term Safety Phase (Year 5)|Adverse Event|0
6165129|NCT01212770|9808343|FG001|Long-term Safety Phase (Year 5)|Adverse Event|0
6165130|NCT01212770|9808344|FG002|Long-term Safety Phase (Year 5)|Adverse Event|2
6165131|NCT01212770|9808345|FG003|Long-term Safety Phase (Year 5)|Adverse Event|0
6165132|NCT01212770|9808346|FG004|Long-term Safety Phase (Year 5)|Adverse Event|0
6165133|NCT01212770|9808347|FG005|Long-term Safety Phase (Year 5)|Adverse Event|0
6165134|NCT01212770|9808348|FG006|Long-term Safety Phase (Year 5)|Adverse Event|0
6165135|NCT01212770|9808349|FG007|Long-term Safety Phase (Year 5)|Adverse Event|0
6165136|NCT01212770|9808350|FG008|Long-term Safety Phase (Year 5)|Adverse Event|1
6165137|NCT01212770|9808342|FG000|Long-term Safety Phase (Year 5)|Lack of Efficacy|0
6165138|NCT01212770|9808343|FG001|Long-term Safety Phase (Year 5)|Lack of Efficacy|0
6165139|NCT01212770|9808344|FG002|Long-term Safety Phase (Year 5)|Lack of Efficacy|4
6165140|NCT01212770|9808345|FG003|Long-term Safety Phase (Year 5)|Lack of Efficacy|0
6165141|NCT01212770|9808346|FG004|Long-term Safety Phase (Year 5)|Lack of Efficacy|0
6165142|NCT01212770|9808347|FG005|Long-term Safety Phase (Year 5)|Lack of Efficacy|0
6165143|NCT01212770|9808348|FG006|Long-term Safety Phase (Year 5)|Lack of Efficacy|0
6165144|NCT01212770|9808349|FG007|Long-term Safety Phase (Year 5)|Lack of Efficacy|0
6327003|NCT02959190|10070632|FG000|Open Label|Pregnancy|0
6165145|NCT01212770|9808350|FG008|Long-term Safety Phase (Year 5)|Lack of Efficacy|0
6165146|NCT01212770|9808342|FG000|Long-term Safety Phase (Year 5)|Withdrawal by Subject|0
6165147|NCT01212770|9808343|FG001|Long-term Safety Phase (Year 5)|Withdrawal by Subject|2
6165148|NCT01212770|9808344|FG002|Long-term Safety Phase (Year 5)|Withdrawal by Subject|1
6165149|NCT01212770|9808345|FG003|Long-term Safety Phase (Year 5)|Withdrawal by Subject|0
6165150|NCT01212770|9808346|FG004|Long-term Safety Phase (Year 5)|Withdrawal by Subject|0
6165151|NCT01212770|9808347|FG005|Long-term Safety Phase (Year 5)|Withdrawal by Subject|0
6165152|NCT01212770|9808348|FG006|Long-term Safety Phase (Year 5)|Withdrawal by Subject|0
6165153|NCT01212770|9808349|FG007|Long-term Safety Phase (Year 5)|Withdrawal by Subject|1
6165154|NCT01212770|9808350|FG008|Long-term Safety Phase (Year 5)|Withdrawal by Subject|0
6165155|NCT01212770|9808342|FG000|Long-term Safety Phase (Year 5)|Death|0
6165156|NCT01212770|9808343|FG001|Long-term Safety Phase (Year 5)|Death|0
6165157|NCT01212770|9808344|FG002|Long-term Safety Phase (Year 5)|Death|0
6165158|NCT01212770|9808345|FG003|Long-term Safety Phase (Year 5)|Death|0
6165159|NCT01212770|9808346|FG004|Long-term Safety Phase (Year 5)|Death|0
6165160|NCT01212770|9808347|FG005|Long-term Safety Phase (Year 5)|Death|0
6165161|NCT01212770|9808348|FG006|Long-term Safety Phase (Year 5)|Death|0
6165162|NCT01212770|9808349|FG007|Long-term Safety Phase (Year 5)|Death|1
6165163|NCT01212770|9808350|FG008|Long-term Safety Phase (Year 5)|Death|0
6165164|NCT01212991|9808407|FG000|Double-blind|Lost to Follow-up|8
6165165|NCT01212991|9808408|FG001|Double-blind|Lost to Follow-up|4
6165166|NCT01212991|9808409|FG002|Double-blind|Lost to Follow-up|0
6165167|NCT01212991|9808407|FG000|Double-blind|Death|699
6165168|NCT01212991|9808408|FG001|Double-blind|Death|550
6165169|NCT01212991|9808409|FG002|Double-blind|Death|0
6165170|NCT01212991|9808407|FG000|Double-blind|Withdrawal by Subject|16
6165171|NCT01212991|9808408|FG001|Double-blind|Withdrawal by Subject|19
6165172|NCT01212991|9808409|FG002|Double-blind|Withdrawal by Subject|0
6165173|NCT01212991|9808407|FG000|Double-blind|Other|7
6165174|NCT01212991|9808408|FG001|Double-blind|Other|0
6165175|NCT01212991|9808409|FG002|Double-blind|Other|0
6165176|NCT01212991|9808407|FG000|Double-blind|Sponsor decision|142
6165177|NCT01212991|9808408|FG001|Double-blind|Sponsor decision|38
6165178|NCT01212991|9808409|FG002|Double-blind|Sponsor decision|0
6165179|NCT01212991|9808407|FG000|Open-label|Death|0
6165180|NCT01212991|9808408|FG001|Open-label|Death|0
6165181|NCT01212991|9808409|FG002|Open-label|Death|166
6165182|NCT01212991|9808407|FG000|Open-label|Lost to Follow-up|0
6165183|NCT01212991|9808408|FG001|Open-label|Lost to Follow-up|0
6165184|NCT01212991|9808409|FG002|Open-label|Lost to Follow-up|5
6327004|NCT02959190|10070633|FG001|Open Label|Pregnancy|1
6327005|NCT02959190|10070634|FG002|Open Label|Pregnancy|0
6327006|NCT02959190|10070635|FG003|Open Label|Pregnancy|0
6327007|NCT02959190|10070632|FG000|Open Label|Withdrawal by Subject|2
6327008|NCT02959190|10070633|FG001|Open Label|Withdrawal by Subject|8
6327009|NCT02959190|10070634|FG002|Open Label|Withdrawal by Subject|0
6327010|NCT02959190|10070635|FG003|Open Label|Withdrawal by Subject|0
6327011|NCT02959190|10070632|FG000|Open Label|Physician Decision|0
6327012|NCT02959190|10070633|FG001|Open Label|Physician Decision|0
6327013|NCT02959190|10070634|FG002|Open Label|Physician Decision|1
6327014|NCT02959190|10070635|FG003|Open Label|Physician Decision|0
6165185|NCT01212991|9808407|FG000|Open-label|Withdrawal by Subject|0
6165186|NCT01212991|9808408|FG001|Open-label|Withdrawal by Subject|0
6165187|NCT01212991|9808409|FG002|Open-label|Withdrawal by Subject|7
6165188|NCT01212991|9808407|FG000|Open-label|Sponsor decision|0
6165189|NCT01212991|9808408|FG001|Open-label|Sponsor decision|0
6165190|NCT01212991|9808409|FG002|Open-label|Sponsor decision|53
6327015|NCT02959190|10070632|FG000|Open Label|Protocol Violation|0
6327016|NCT02959190|10070633|FG001|Open Label|Protocol Violation|0
6327017|NCT02959190|10070634|FG002|Open Label|Protocol Violation|0
6165191|NCT01212991|9808407|FG000|Open-label|Other|0
6165192|NCT01212991|9808408|FG001|Open-label|Other|0
6165193|NCT01212991|9808409|FG002|Open-label|Other|3
6165194|NCT01213082|9808429|FG000|Overall Study|Lost to Follow-up|6
6165195|NCT01213082|9808430|FG001|Overall Study|Lost to Follow-up|7
6165196|NCT01213082|9808431|FG002|Overall Study|Lost to Follow-up|4
6165197|NCT01213082|9808429|FG000|Overall Study|Physician Decision|0
6165198|NCT01213082|9808430|FG001|Overall Study|Physician Decision|0
6165199|NCT01213082|9808431|FG002|Overall Study|Physician Decision|1
6165200|NCT01213173|9808441|FG000|Overall Study|Protocol Violation|2
6165201|NCT01213173|9808442|FG001|Overall Study|Protocol Violation|0
6165202|NCT01213173|9808441|FG000|Overall Study|Adverse Event|4
6165203|NCT01213173|9808442|FG001|Overall Study|Adverse Event|8
6165204|NCT01213173|9808441|FG000|Overall Study|Withdrawal by Subject|5
6165205|NCT01213173|9808442|FG001|Overall Study|Withdrawal by Subject|5
6165206|NCT01213173|9808441|FG000|Overall Study|Incorrect Enrollment|1
6165207|NCT01213173|9808442|FG001|Overall Study|Incorrect Enrollment|3
6165208|NCT01213251|9808455|FG000|Overall Study|Death|2
6165209|NCT01213251|9808456|FG001|Overall Study|Death|1
6165210|NCT01213251|9808457|FG002|Overall Study|Death|2
6165211|NCT01213251|9808455|FG000|Overall Study|Exit|3
6327018|NCT02959190|10070635|FG003|Open Label|Protocol Violation|2
6327019|NCT02959190|10070632|FG000|Post Treatment Follow Up|Adverse Event|1
6327020|NCT02959190|10070633|FG001|Post Treatment Follow Up|Adverse Event|1
6327021|NCT02959190|10070634|FG002|Post Treatment Follow Up|Adverse Event|0
6327022|NCT02959190|10070635|FG003|Post Treatment Follow Up|Adverse Event|0
6082628|NCT00630812|9690733|FG000|Double Blind Treatment Period|Lost to Follow-up|1
6327023|NCT02959190|10070632|FG000|Post Treatment Follow Up|Withdrawal by Subject|2
6327024|NCT02959190|10070633|FG001|Post Treatment Follow Up|Withdrawal by Subject|0
6327025|NCT02959190|10070634|FG002|Post Treatment Follow Up|Withdrawal by Subject|1
6327026|NCT02959190|10070635|FG003|Post Treatment Follow Up|Withdrawal by Subject|0
6327027|NCT02959437|10070667|FG000|Overall Study|Death|33
6327028|NCT02959437|10070668|FG001|Overall Study|Death|3
6327029|NCT02959437|10070669|FG002|Overall Study|Death|0
6327030|NCT02959437|10070670|FG003|Overall Study|Death|0
6327031|NCT02959437|10070667|FG000|Overall Study|Lost to Follow-up|3
6327032|NCT02959437|10070668|FG001|Overall Study|Lost to Follow-up|1
6327033|NCT02959437|10070669|FG002|Overall Study|Lost to Follow-up|0
6327034|NCT02959437|10070670|FG003|Overall Study|Lost to Follow-up|0
6327035|NCT02959437|10070667|FG000|Overall Study|Withdrawal by Subject|11
6327036|NCT02959437|10070668|FG001|Overall Study|Withdrawal by Subject|3
6327037|NCT02959437|10070669|FG002|Overall Study|Withdrawal by Subject|0
6327038|NCT02959437|10070670|FG003|Overall Study|Withdrawal by Subject|0
6327039|NCT02959437|10070667|FG000|Overall Study|Progressive Disease|9
6327040|NCT02959437|10070668|FG001|Overall Study|Progressive Disease|1
6327041|NCT02959437|10070669|FG002|Overall Study|Progressive Disease|0
6327042|NCT02959437|10070670|FG003|Overall Study|Progressive Disease|0
6327043|NCT02959437|10070667|FG000|Overall Study|Study Terminated by Sponsor|4
6327044|NCT02959437|10070668|FG001|Overall Study|Study Terminated by Sponsor|0
6327045|NCT02959437|10070669|FG002|Overall Study|Study Terminated by Sponsor|0
6327046|NCT02959437|10070670|FG003|Overall Study|Study Terminated by Sponsor|0
6327047|NCT02959437|10070667|FG000|Overall Study|Other Unspecified|2
6327048|NCT02959437|10070668|FG001|Overall Study|Other Unspecified|0
6327049|NCT02959437|10070669|FG002|Overall Study|Other Unspecified|0
6327050|NCT02959437|10070670|FG003|Overall Study|Other Unspecified|0
6327051|NCT02959671|10070681|FG000|Overall Study|Adverse Event|2
6327052|NCT02959671|10070681|FG000|Overall Study|Participants signed a consent; however enrollment was complete before they started study activity.|3
6327053|NCT02959814|10070685|FG000|Overall Study|Excluded based on diagnostic angiography|16
6327054|NCT02959814|10070685|FG000|Overall Study|Excluded based on anatomical criteria|2
6082629|NCT00630812|9690734|FG001|Double Blind Treatment Period|Lost to Follow-up|0
6082630|NCT00630812|9690733|FG000|Double Blind Treatment Period|Physician Decision|2
6165212|NCT01213251|9808456|FG001|Overall Study|Exit|2
6165213|NCT01213251|9808457|FG002|Overall Study|Exit|8
6165214|NCT01213251|9808455|FG000|Overall Study|Protocol Violation|1
6165215|NCT01213251|9808456|FG001|Overall Study|Protocol Violation|1
6165216|NCT01213251|9808457|FG002|Overall Study|Protocol Violation|0
6165217|NCT01213251|9808455|FG000|Overall Study|Missed 18-Month Follow-up|0
6165218|NCT01213251|9808456|FG001|Overall Study|Missed 18-Month Follow-up|0
6165219|NCT01213251|9808457|FG002|Overall Study|Missed 18-Month Follow-up|1
6165220|NCT01213264|9808473|FG000|Overall Study|Adverse Event|1
6165221|NCT01213264|9808474|FG001|Overall Study|Adverse Event|0
6165222|NCT01213264|9808475|FG002|Overall Study|Adverse Event|0
6165223|NCT01213264|9808473|FG000|Overall Study|Lost to Follow-up|1
6165224|NCT01213264|9808474|FG001|Overall Study|Lost to Follow-up|2
6165225|NCT01213264|9808475|FG002|Overall Study|Lost to Follow-up|6
6165226|NCT01213472|9808494|FG000|Overall Study|Recurrence/Progressive disease|25
6165227|NCT01213472|9808494|FG000|Overall Study|Withdrawal by Subject|1
6327055|NCT02959814|10070685|FG000|Overall Study|Protocol Violation|7
6327056|NCT02959814|10070685|FG000|Overall Study|FFR not measured|2
6327057|NCT02959814|10070685|FG000|Overall Study|In-procedure QFR not computed|6
6327058|NCT02959814|10070685|FG000|Overall Study|Excluded by FFR core-lab|24
6165228|NCT01213472|9808494|FG000|Overall Study|Physician Decision|1
6165229|NCT01213524|9808500|FG000|Baseline|Withdrawal by Subject|5
6165230|NCT01213524|9808500|FG000|Baseline|high breath alcohol levels|1
6165231|NCT01213524|9808500|FG000|Baseline|Physician Decision|1
6165232|NCT01213524|9808500|FG000|Session 2|Withdrawal by Subject|5
6165233|NCT01213524|9808500|FG000|Session 3|Withdrawal by Subject|4
6165234|NCT01213524|9808500|FG000|Session 4|Physician Decision|1
6165235|NCT01213524|9808500|FG000|Session 4|Withdrawal by Subject|2
6165236|NCT01213836|9808558|FG000|Period 1, First Intervention|Adverse Event|2
6165237|NCT01213836|9808559|FG001|Period 1, First Intervention|Adverse Event|1
6165238|NCT01213836|9808558|FG000|Period 1, First Intervention|Protocol Violation|0
6165239|NCT01213836|9808559|FG001|Period 1, First Intervention|Protocol Violation|1
6165240|NCT01213836|9808558|FG000|Period 1, First Intervention|Withdrawal by Subject|1
6165241|NCT01213836|9808559|FG001|Period 1, First Intervention|Withdrawal by Subject|1
6165242|NCT01213966|9808581|FG000|Overall Study|Protocol Violation|1
6165243|NCT01213966|9808582|FG001|Overall Study|Protocol Violation|0
6165244|NCT01213966|9808583|FG002|Overall Study|Protocol Violation|3
6165245|NCT01213966|9808584|FG003|Overall Study|Protocol Violation|1
6165246|NCT01214044|9808594|FG000|Visit 1: Screening and Consent, Washout|Withdrawal by Subject|5
6165247|NCT01214044|9808594|FG000|Visit 1: Screening and Consent, Washout|Ineligible|3
6165248|NCT01214044|9808594|FG000|Visit 1: Screening and Consent, Washout|Lost to Follow-up|4
6165249|NCT01214044|9808594|FG000|Visits 3-5: Escitalopram 10 mg Daily|Withdrawal by Subject|3
6165250|NCT01214044|9808594|FG000|Visits 6-11: Escitalopram 20 mg Daily|Withdrawal by Subject|3
6165251|NCT01214044|9808594|FG000|Visits 6-11: Escitalopram 20 mg Daily|Adverse Event|1
6165252|NCT01214174|9808654|FG000|Overall Study|Withdrawal by Subject|0
6165253|NCT01214174|9808655|FG001|Overall Study|Withdrawal by Subject|0
6165254|NCT01214174|9808656|FG002|Overall Study|Withdrawal by Subject|1
6165255|NCT01214187|9808666|FG000|Overall Study|Adverse Event|6
6165256|NCT01214187|9808667|FG001|Overall Study|Adverse Event|2
6165257|NCT01214187|9808666|FG000|Overall Study|Death|1
6165258|NCT01214187|9808667|FG001|Overall Study|Death|1
6165259|NCT01214187|9808666|FG000|Overall Study|Withdrawal by Subject|0
6165260|NCT01214187|9808667|FG001|Overall Study|Withdrawal by Subject|3
6165261|NCT01214200|9808673|FG000|Overall Study|Did not meet inclusion/exclusion|9
6165262|NCT01214200|9808673|FG000|Overall Study|Withdrawal by Subject|2
6165263|NCT01214239|9808681|FG000|Overall Study|Adverse Event|3
6165264|NCT01214239|9808682|FG001|Overall Study|Adverse Event|4
6165265|NCT01214239|9808681|FG000|Overall Study|Protocol Violation|2
6165266|NCT01214239|9808682|FG001|Overall Study|Protocol Violation|1
6165267|NCT01214239|9808681|FG000|Overall Study|Lost to Follow-up|1
6165268|NCT01214239|9808682|FG001|Overall Study|Lost to Follow-up|1
6165269|NCT01214239|9808681|FG000|Overall Study|Withdrawal by Subject|4
6165270|NCT01214239|9808682|FG001|Overall Study|Withdrawal by Subject|9
6165271|NCT01214239|9808681|FG000|Overall Study|Lack of Efficacy|1
6165272|NCT01214239|9808682|FG001|Overall Study|Lack of Efficacy|2
6165273|NCT01214239|9808681|FG000|Overall Study|patient's private reason|1
6165274|NCT01214239|9808682|FG001|Overall Study|patient's private reason|1
6165275|NCT01214252|9808688|FG000|Overall Study|Not eligible per protocol|82
6192065|NCT01427751|9849110|FG000|Overall Study|Withdrawal of consent|2
6192066|NCT01427751|9849111|FG001|Overall Study|Withdrawal of consent|2
6192067|NCT01427751|9849110|FG000|Overall Study|Protocol Violation|6
6192068|NCT01427751|9849111|FG001|Overall Study|Protocol Violation|4
6192069|NCT01427751|9849110|FG000|Overall Study|Death|2
6192070|NCT01427751|9849111|FG001|Overall Study|Death|0
6192071|NCT01427751|9849110|FG000|Overall Study|Other miscellaneous reasons|6
6192072|NCT01427751|9849111|FG001|Overall Study|Other miscellaneous reasons|4
6192073|NCT01427803|9849119|FG000|Overall Study|Lost to Follow-up|32
6192074|NCT01427803|9849120|FG001|Overall Study|Lost to Follow-up|26
6192075|NCT01427803|9849119|FG000|Overall Study|Withdrawal by Subject|20
6192076|NCT01427803|9849120|FG001|Overall Study|Withdrawal by Subject|0
6192077|NCT01427803|9849119|FG000|Overall Study|Unable to complete full treatment period|6
6192078|NCT01427803|9849120|FG001|Overall Study|Unable to complete full treatment period|0
6192079|NCT01427803|9849119|FG000|Overall Study|Protocol Violation|1
6192080|NCT01427803|9849120|FG001|Overall Study|Protocol Violation|0
6192081|NCT01427803|9849119|FG000|Overall Study|Physician Decision|3
6192082|NCT01427803|9849120|FG001|Overall Study|Physician Decision|0
6192083|NCT01427803|9849119|FG000|Overall Study|did not take product|1
6192084|NCT01427803|9849120|FG001|Overall Study|did not take product|0
6192085|NCT01427907|9849130|FG000|Overall Study|Withdrawal by Subject|3
6192086|NCT01427907|9849131|FG001|Overall Study|Withdrawal by Subject|4
6192087|NCT01427920|9849139|FG000|Overall Study|Adverse Event|1
6192088|NCT01427920|9849140|FG001|Overall Study|Adverse Event|2
6192089|NCT01427920|9849139|FG000|Overall Study|Lack of Efficacy|1
6192090|NCT01427920|9849140|FG001|Overall Study|Lack of Efficacy|0
6192091|NCT01427920|9849139|FG000|Overall Study|Protocol Violation|1
6192092|NCT01427920|9849140|FG001|Overall Study|Protocol Violation|3
6192093|NCT01427920|9849139|FG000|Overall Study|Withdrawal Criteria|4
6192094|NCT01427920|9849140|FG001|Overall Study|Withdrawal Criteria|4
6192095|NCT01427920|9849139|FG000|Overall Study|Unclassified|2
6192096|NCT01427920|9849140|FG001|Overall Study|Unclassified|8
6192097|NCT01427933|9849148|FG000|Overall Study|Withdrawal by Subject|5
6192098|NCT01427933|9849149|FG001|Overall Study|Withdrawal by Subject|8
6327059|NCT02959866|10070721|FG000|Overall Study|Withdrawal by Subject|1
6327060|NCT02959892|10070728|FG000|Overall Study|PET tracer synthesis failure|1
6327061|NCT02959892|10070729|FG001|Overall Study|PET tracer synthesis failure|0
6327062|NCT02959892|10070728|FG000|Overall Study|Study termination|0
6327063|NCT02959892|10070729|FG001|Overall Study|Study termination|1
6327064|NCT02959970|10070737|FG000|Overall Study|Adverse Event|1
6327065|NCT02959970|10070738|FG001|Overall Study|Adverse Event|0
6327066|NCT02959970|10070737|FG000|Overall Study|Withdrawal by Subject|0
6327067|NCT02959970|10070738|FG001|Overall Study|Withdrawal by Subject|2
6327068|NCT02959970|10070737|FG000|Overall Study|Lost to Follow-up|1
6327069|NCT02959970|10070738|FG001|Overall Study|Lost to Follow-up|5
6327070|NCT02959983|10070748|FG000|Overall Study|Protocol Violation|0
6327071|NCT02959983|10070749|FG001|Overall Study|Protocol Violation|1
6327072|NCT02959983|10070748|FG000|Overall Study|Lack of Efficacy|0
6327073|NCT02959983|10070749|FG001|Overall Study|Lack of Efficacy|1
6327074|NCT02959983|10070748|FG000|Overall Study|Lost to Follow-up|12
6327075|NCT02959983|10070749|FG001|Overall Study|Lost to Follow-up|9
6327076|NCT02959983|10070748|FG000|Overall Study|Other|1
6327077|NCT02959983|10070749|FG001|Overall Study|Other|1
6327078|NCT02959983|10070748|FG000|Overall Study|Physician Decision|1
6327079|NCT02959983|10070749|FG001|Overall Study|Physician Decision|0
6327080|NCT02959983|10070748|FG000|Overall Study|Adverse Event|5
6327081|NCT02959983|10070749|FG001|Overall Study|Adverse Event|1
6327082|NCT02959983|10070748|FG000|Overall Study|Withdrawal by Subject|7
6327083|NCT02959983|10070749|FG001|Overall Study|Withdrawal by Subject|12
6327084|NCT02960217|10070766|FG000|Maintenance Phase: Treatment Period 1|Adverse Event|1
6327085|NCT02960217|10070767|FG001|Maintenance Phase: Treatment Period 1|Adverse Event|0
6327086|NCT02960217|10070766|FG000|Maintenance Phase: Treatment Period 2|Adverse Event|0
6327087|NCT02960217|10070767|FG001|Maintenance Phase: Treatment Period 2|Adverse Event|1
6327088|NCT02960217|10070766|FG000|Maintenance Phase: Treatment Period 2|Withdrawal by Subject|0
6082631|NCT00630812|9690734|FG001|Double Blind Treatment Period|Physician Decision|1
6082632|NCT00630812|9690733|FG000|Double Blind Treatment Period|Protocol Violation|1
6082633|NCT00630812|9690734|FG001|Double Blind Treatment Period|Protocol Violation|0
6082634|NCT00630812|9690733|FG000|Double Blind Treatment Period|Withdrawal by Subject|13
6082635|NCT00630812|9690734|FG001|Double Blind Treatment Period|Withdrawal by Subject|7
6165276|NCT01214395|9808717|FG000|Overall Study|All patients had infection|5
6327089|NCT02960217|10070767|FG001|Maintenance Phase: Treatment Period 2|Withdrawal by Subject|1
6327090|NCT02960217|10070766|FG000|Maintenance Phase: Treatment Period 2|Lack of Efficacy|1
6327091|NCT02960217|10070767|FG001|Maintenance Phase: Treatment Period 2|Lack of Efficacy|0
6327092|NCT02960217|10070766|FG000|Maintenance Phase: Treatment Period 2|Other, Not Specified|0
6327093|NCT02960217|10070767|FG001|Maintenance Phase: Treatment Period 2|Other, Not Specified|1
6327094|NCT02960217|10070766|FG000|Open-Label Extension Phase|Adverse Event|1
6327095|NCT02960217|10070767|FG001|Open-Label Extension Phase|Adverse Event|0
6327096|NCT02960217|10070766|FG000|Open-Label Extension Phase|Sponsor Decision|18
6327097|NCT02960217|10070767|FG001|Open-Label Extension Phase|Sponsor Decision|11
6327098|NCT02960217|10070766|FG000|Open-Label Extension Phase|Lack of Efficacy|1
6327099|NCT02960217|10070767|FG001|Open-Label Extension Phase|Lack of Efficacy|1
6327100|NCT02960217|10070766|FG000|Open-Label Extension Phase|Other, Not Specified|0
6327101|NCT02960217|10070767|FG001|Open-Label Extension Phase|Other, Not Specified|1
6327102|NCT02960438|10070786|FG000|Treatment Phase (Double-blind): 24 Weeks|Inadequate Therapeutic Effect|2
6327103|NCT02960438|10070787|FG001|Treatment Phase (Double-blind): 24 Weeks|Inadequate Therapeutic Effect|1
6327104|NCT02960438|10070788|FG002|Treatment Phase (Double-blind): 24 Weeks|Inadequate Therapeutic Effect|2
6327105|NCT02960438|10070789|FG003|Treatment Phase (Double-blind): 24 Weeks|Inadequate Therapeutic Effect|5
6327106|NCT02960438|10070786|FG000|Treatment Phase (Double-blind): 24 Weeks|Adverse Event|2
6327107|NCT02960438|10070787|FG001|Treatment Phase (Double-blind): 24 Weeks|Adverse Event|1
6327108|NCT02960438|10070788|FG002|Treatment Phase (Double-blind): 24 Weeks|Adverse Event|0
6327109|NCT02960438|10070789|FG003|Treatment Phase (Double-blind): 24 Weeks|Adverse Event|3
6327110|NCT02960438|10070786|FG000|Treatment Phase (Double-blind): 24 Weeks|Progression of Disease|2
6327111|NCT02960438|10070787|FG001|Treatment Phase (Double-blind): 24 Weeks|Progression of Disease|0
6327112|NCT02960438|10070788|FG002|Treatment Phase (Double-blind): 24 Weeks|Progression of Disease|0
6327113|NCT02960438|10070789|FG003|Treatment Phase (Double-blind): 24 Weeks|Progression of Disease|0
6327114|NCT02960438|10070786|FG000|Treatment Phase (Double-blind): 24 Weeks|Withdrawal by Subject|1
6327115|NCT02960438|10070787|FG001|Treatment Phase (Double-blind): 24 Weeks|Withdrawal by Subject|0
6327116|NCT02960438|10070788|FG002|Treatment Phase (Double-blind): 24 Weeks|Withdrawal by Subject|1
6327117|NCT02960438|10070789|FG003|Treatment Phase (Double-blind): 24 Weeks|Withdrawal by Subject|0
6327118|NCT02960438|10070786|FG000|Treatment Phase (Double-blind): 24 Weeks|Other|0
6327119|NCT02960438|10070787|FG001|Treatment Phase (Double-blind): 24 Weeks|Other|0
6165277|NCT01214421|9808726|FG000|Overall Study|Lost to Follow-up|7
6165278|NCT01214421|9808727|FG001|Overall Study|Lost to Follow-up|3
6327120|NCT02960438|10070788|FG002|Treatment Phase (Double-blind): 24 Weeks|Other|1
6327121|NCT02960438|10070789|FG003|Treatment Phase (Double-blind): 24 Weeks|Other|0
6327122|NCT02960438|10070786|FG000|Treatment Phase (Double-blind): 24 Weeks|Not Treated|2
6327123|NCT02960438|10070787|FG001|Treatment Phase (Double-blind): 24 Weeks|Not Treated|1
6327124|NCT02960438|10070788|FG002|Treatment Phase (Double-blind): 24 Weeks|Not Treated|0
6165279|NCT01214421|9808728|FG002|Overall Study|Lost to Follow-up|7
6165280|NCT01214421|9808729|FG003|Overall Study|Lost to Follow-up|3
6165281|NCT01214421|9808726|FG000|Overall Study|Adverse Event|16
6165282|NCT01214421|9808727|FG001|Overall Study|Adverse Event|35
6165283|NCT01214421|9808728|FG002|Overall Study|Adverse Event|14
6165284|NCT01214421|9808729|FG003|Overall Study|Adverse Event|3
6165285|NCT01214421|9808726|FG000|Overall Study|Sponsor Discontinued Site|1
6165286|NCT01214421|9808727|FG001|Overall Study|Sponsor Discontinued Site|2
6165287|NCT01214421|9808728|FG002|Overall Study|Sponsor Discontinued Site|0
6165288|NCT01214421|9808729|FG003|Overall Study|Sponsor Discontinued Site|0
6165289|NCT01214421|9808726|FG000|Overall Study|Withdrawal Criteria Met|3
6165290|NCT01214421|9808727|FG001|Overall Study|Withdrawal Criteria Met|0
6165291|NCT01214421|9808728|FG002|Overall Study|Withdrawal Criteria Met|2
6165292|NCT01214421|9808729|FG003|Overall Study|Withdrawal Criteria Met|1
6165293|NCT01214421|9808726|FG000|Overall Study|Physician Decision|2
6165294|NCT01214421|9808727|FG001|Overall Study|Physician Decision|0
6165295|NCT01214421|9808728|FG002|Overall Study|Physician Decision|4
6165296|NCT01214421|9808729|FG003|Overall Study|Physician Decision|0
6165297|NCT01214421|9808726|FG000|Overall Study|Withdrawal by Subject|21
6165298|NCT01214421|9808727|FG001|Overall Study|Withdrawal by Subject|18
6165299|NCT01214421|9808728|FG002|Overall Study|Withdrawal by Subject|11
6165300|NCT01214421|9808729|FG003|Overall Study|Withdrawal by Subject|2
6165301|NCT01214434|9808741|FG000|Overall Study|Withdrawal by Subject|1
6165302|NCT01214434|9808742|FG001|Overall Study|Withdrawal by Subject|0
6165303|NCT01214434|9808741|FG000|Overall Study|Lost to Follow-up|2
6165304|NCT01214434|9808742|FG001|Overall Study|Lost to Follow-up|2
6165305|NCT01214434|9808741|FG000|Overall Study|Site error|1
6165306|NCT01214434|9808742|FG001|Overall Study|Site error|0
6165307|NCT01214603|9808751|FG000|Overall Study|Adverse Event|0
6165308|NCT01214603|9808752|FG001|Overall Study|Adverse Event|0
6165309|NCT01214603|9808753|FG002|Overall Study|Adverse Event|1
6165310|NCT01214603|9808751|FG000|Overall Study|Death|1
6165311|NCT01214603|9808752|FG001|Overall Study|Death|0
6165312|NCT01214603|9808753|FG002|Overall Study|Death|0
6165313|NCT01214603|9808751|FG000|Overall Study|Progressive Disease|4
6165314|NCT01214603|9808752|FG001|Overall Study|Progressive Disease|1
6165315|NCT01214603|9808753|FG002|Overall Study|Progressive Disease|3
6165316|NCT01214616|9808766|FG000|Overall Study|Progressive disease|2
6165317|NCT01214616|9808767|FG001|Overall Study|Progressive disease|2
6165318|NCT01214616|9808768|FG002|Overall Study|Progressive disease|2
6165319|NCT01214616|9808769|FG003|Overall Study|Progressive disease|4
6165320|NCT01214616|9808766|FG000|Overall Study|Dose limiting toxicity|0
6165321|NCT01214616|9808767|FG001|Overall Study|Dose limiting toxicity|2
6165322|NCT01214616|9808768|FG002|Overall Study|Dose limiting toxicity|0
6165323|NCT01214616|9808769|FG003|Overall Study|Dose limiting toxicity|0
6165324|NCT01214616|9808766|FG000|Overall Study|Other adverse events|0
6165325|NCT01214616|9808767|FG001|Overall Study|Other adverse events|1
6165326|NCT01214616|9808768|FG002|Overall Study|Other adverse events|1
6165327|NCT01214616|9808769|FG003|Overall Study|Other adverse events|1
6165328|NCT01214616|9808766|FG000|Overall Study|Withdrawal by Subject|1
6165329|NCT01214616|9808767|FG001|Overall Study|Withdrawal by Subject|0
6165330|NCT01214616|9808768|FG002|Overall Study|Withdrawal by Subject|0
6165331|NCT01214616|9808769|FG003|Overall Study|Withdrawal by Subject|1
6165332|NCT01214629|9808798|FG000|Overall Study|Progressive Disease|1
6165333|NCT01214629|9808799|FG001|Overall Study|Progressive Disease|1
6165334|NCT01214629|9808800|FG002|Overall Study|Progressive Disease|0
6165335|NCT01214629|9808801|FG003|Overall Study|Progressive Disease|1
6165336|NCT01214629|9808802|FG004|Overall Study|Progressive Disease|2
6165337|NCT01214629|9808803|FG005|Overall Study|Progressive Disease|3
6165338|NCT01214629|9808804|FG006|Overall Study|Progressive Disease|1
6165339|NCT01214629|9808805|FG007|Overall Study|Progressive Disease|1
6165340|NCT01214629|9808806|FG008|Overall Study|Progressive Disease|1
6165341|NCT01214629|9808807|FG009|Overall Study|Progressive Disease|5
6165342|NCT01214629|9808808|FG010|Overall Study|Progressive Disease|1
6165343|NCT01214629|9808798|FG000|Overall Study|Adverse Event|0
6165344|NCT01214629|9808799|FG001|Overall Study|Adverse Event|0
6165345|NCT01214629|9808800|FG002|Overall Study|Adverse Event|0
6165346|NCT01214629|9808801|FG003|Overall Study|Adverse Event|1
6165347|NCT01214629|9808802|FG004|Overall Study|Adverse Event|0
6165348|NCT01214629|9808803|FG005|Overall Study|Adverse Event|1
6165349|NCT01214629|9808804|FG006|Overall Study|Adverse Event|0
6165350|NCT01214629|9808805|FG007|Overall Study|Adverse Event|0
6165351|NCT01214629|9808806|FG008|Overall Study|Adverse Event|0
6165352|NCT01214629|9808807|FG009|Overall Study|Adverse Event|1
6165353|NCT01214629|9808808|FG010|Overall Study|Adverse Event|0
6165354|NCT01214629|9808798|FG000|Overall Study|Physician Decision|0
6165355|NCT01214629|9808799|FG001|Overall Study|Physician Decision|0
6165356|NCT01214629|9808800|FG002|Overall Study|Physician Decision|0
6165357|NCT01214629|9808801|FG003|Overall Study|Physician Decision|0
6165358|NCT01214629|9808802|FG004|Overall Study|Physician Decision|0
6165359|NCT01214629|9808803|FG005|Overall Study|Physician Decision|0
6165360|NCT01214629|9808804|FG006|Overall Study|Physician Decision|0
6165361|NCT01214629|9808805|FG007|Overall Study|Physician Decision|0
6165362|NCT01214629|9808806|FG008|Overall Study|Physician Decision|0
6165363|NCT01214629|9808807|FG009|Overall Study|Physician Decision|0
6165364|NCT01214629|9808808|FG010|Overall Study|Physician Decision|1
6165365|NCT01214629|9808798|FG000|Overall Study|Withdrawal by Subject|0
6165366|NCT01214629|9808799|FG001|Overall Study|Withdrawal by Subject|0
6165367|NCT01214629|9808800|FG002|Overall Study|Withdrawal by Subject|0
6165368|NCT01214629|9808801|FG003|Overall Study|Withdrawal by Subject|0
6165369|NCT01214629|9808802|FG004|Overall Study|Withdrawal by Subject|0
6165370|NCT01214629|9808803|FG005|Overall Study|Withdrawal by Subject|0
6165371|NCT01214629|9808804|FG006|Overall Study|Withdrawal by Subject|0
6165372|NCT01214629|9808805|FG007|Overall Study|Withdrawal by Subject|0
6165373|NCT01214629|9808806|FG008|Overall Study|Withdrawal by Subject|0
6165374|NCT01214629|9808807|FG009|Overall Study|Withdrawal by Subject|1
6165375|NCT01214629|9808808|FG010|Overall Study|Withdrawal by Subject|0
6165376|NCT01214642|9808858|FG000|Overall Study|Progressive Disease|3
6165377|NCT01214642|9808859|FG001|Overall Study|Progressive Disease|2
6165378|NCT01214642|9808860|FG002|Overall Study|Progressive Disease|3
6165379|NCT01214642|9808861|FG003|Overall Study|Progressive Disease|5
6165380|NCT01214642|9808862|FG004|Overall Study|Progressive Disease|5
6165381|NCT01214642|9808863|FG005|Overall Study|Progressive Disease|3
6165382|NCT01214642|9808864|FG006|Overall Study|Progressive Disease|5
6165383|NCT01214642|9808865|FG007|Overall Study|Progressive Disease|3
6165384|NCT01214642|9808866|FG008|Overall Study|Progressive Disease|10
6165385|NCT01214642|9808867|FG009|Overall Study|Progressive Disease|2
6165386|NCT01214642|9808868|FG010|Overall Study|Progressive Disease|1
6165387|NCT01214642|9808869|FG011|Overall Study|Progressive Disease|4
6327125|NCT02960438|10070789|FG003|Treatment Phase (Double-blind): 24 Weeks|Not Treated|1
6327126|NCT02960438|10070786|FG000|Extension Phase (Open-label): 80 Weeks|Adverse Event|1
6327127|NCT02960438|10070787|FG001|Extension Phase (Open-label): 80 Weeks|Adverse Event|2
6327128|NCT02960438|10070788|FG002|Extension Phase (Open-label): 80 Weeks|Adverse Event|4
6327129|NCT02960438|10070789|FG003|Extension Phase (Open-label): 80 Weeks|Adverse Event|1
6327130|NCT02960438|10070786|FG000|Extension Phase (Open-label): 80 Weeks|Lost to Follow-up|0
6327131|NCT02960438|10070787|FG001|Extension Phase (Open-label): 80 Weeks|Lost to Follow-up|0
6327132|NCT02960438|10070788|FG002|Extension Phase (Open-label): 80 Weeks|Lost to Follow-up|1
6327133|NCT02960438|10070789|FG003|Extension Phase (Open-label): 80 Weeks|Lost to Follow-up|0
6327134|NCT02960438|10070786|FG000|Extension Phase (Open-label): 80 Weeks|Withdrawal by Subject|1
6327135|NCT02960438|10070787|FG001|Extension Phase (Open-label): 80 Weeks|Withdrawal by Subject|1
6327136|NCT02960438|10070788|FG002|Extension Phase (Open-label): 80 Weeks|Withdrawal by Subject|0
6327137|NCT02960438|10070789|FG003|Extension Phase (Open-label): 80 Weeks|Withdrawal by Subject|1
6327138|NCT02960438|10070786|FG000|Extension Phase (Open-label): 80 Weeks|Inadequate Therapeutic Effect|7
6327139|NCT02960438|10070787|FG001|Extension Phase (Open-label): 80 Weeks|Inadequate Therapeutic Effect|5
6327140|NCT02960438|10070788|FG002|Extension Phase (Open-label): 80 Weeks|Inadequate Therapeutic Effect|7
6327141|NCT02960438|10070789|FG003|Extension Phase (Open-label): 80 Weeks|Inadequate Therapeutic Effect|6
6327142|NCT02960438|10070786|FG000|Extension Phase (Open-label): 80 Weeks|Progression of Disease|2
6327143|NCT02960438|10070787|FG001|Extension Phase (Open-label): 80 Weeks|Progression of Disease|1
6327144|NCT02960438|10070788|FG002|Extension Phase (Open-label): 80 Weeks|Progression of Disease|1
6327145|NCT02960438|10070789|FG003|Extension Phase (Open-label): 80 Weeks|Progression of Disease|2
6327146|NCT02960438|10070786|FG000|Extension Phase (Open-label): 80 Weeks|Other|0
6327147|NCT02960438|10070787|FG001|Extension Phase (Open-label): 80 Weeks|Other|0
6327148|NCT02960438|10070788|FG002|Extension Phase (Open-label): 80 Weeks|Other|1
6327149|NCT02960438|10070789|FG003|Extension Phase (Open-label): 80 Weeks|Other|1
6327150|NCT02960490|10070809|FG000|Treatment Phase(Double-blind): 12 Weeks|Lack of Efficacy|3
6327151|NCT02960490|10070810|FG001|Treatment Phase(Double-blind): 12 Weeks|Lack of Efficacy|2
6327152|NCT02960490|10070811|FG002|Treatment Phase(Double-blind): 12 Weeks|Lack of Efficacy|0
6327153|NCT02960490|10070812|FG003|Treatment Phase(Double-blind): 12 Weeks|Lack of Efficacy|0
6327154|NCT02960490|10070813|FG004|Treatment Phase(Double-blind): 12 Weeks|Lack of Efficacy|0
6327155|NCT02960490|10070814|FG005|Treatment Phase(Double-blind): 12 Weeks|Lack of Efficacy|0
6327156|NCT02960490|10070815|FG006|Treatment Phase(Double-blind): 12 Weeks|Lack of Efficacy|0
6327157|NCT02960490|10070816|FG007|Treatment Phase(Double-blind): 12 Weeks|Lack of Efficacy|0
6327158|NCT02960490|10070817|FG008|Treatment Phase(Double-blind): 12 Weeks|Lack of Efficacy|0
6327159|NCT02960490|10070818|FG009|Treatment Phase(Double-blind): 12 Weeks|Lack of Efficacy|0
6327160|NCT02960490|10070809|FG000|Treatment Phase(Double-blind): 12 Weeks|Adverse Event|0
6327161|NCT02960490|10070810|FG001|Treatment Phase(Double-blind): 12 Weeks|Adverse Event|1
6327162|NCT02960490|10070811|FG002|Treatment Phase(Double-blind): 12 Weeks|Adverse Event|0
6327163|NCT02960490|10070812|FG003|Treatment Phase(Double-blind): 12 Weeks|Adverse Event|0
6327164|NCT02960490|10070813|FG004|Treatment Phase(Double-blind): 12 Weeks|Adverse Event|0
6327165|NCT02960490|10070814|FG005|Treatment Phase(Double-blind): 12 Weeks|Adverse Event|0
6327166|NCT02960490|10070815|FG006|Treatment Phase(Double-blind): 12 Weeks|Adverse Event|0
6327167|NCT02960490|10070816|FG007|Treatment Phase(Double-blind): 12 Weeks|Adverse Event|0
6327168|NCT02960490|10070817|FG008|Treatment Phase(Double-blind): 12 Weeks|Adverse Event|0
6165388|NCT01214642|9808858|FG000|Overall Study|Adverse Event|0
6165389|NCT01214642|9808859|FG001|Overall Study|Adverse Event|1
6165390|NCT01214642|9808860|FG002|Overall Study|Adverse Event|0
6165391|NCT01214642|9808861|FG003|Overall Study|Adverse Event|0
6165392|NCT01214642|9808862|FG004|Overall Study|Adverse Event|0
6165393|NCT01214642|9808863|FG005|Overall Study|Adverse Event|0
6165394|NCT01214642|9808864|FG006|Overall Study|Adverse Event|1
6165395|NCT01214642|9808865|FG007|Overall Study|Adverse Event|0
6165396|NCT01214642|9808866|FG008|Overall Study|Adverse Event|0
6165397|NCT01214642|9808867|FG009|Overall Study|Adverse Event|1
6165398|NCT01214642|9808868|FG010|Overall Study|Adverse Event|1
6165399|NCT01214642|9808869|FG011|Overall Study|Adverse Event|0
6165400|NCT01214642|9808858|FG000|Overall Study|Death|0
6165401|NCT01214642|9808859|FG001|Overall Study|Death|0
6165402|NCT01214642|9808860|FG002|Overall Study|Death|1
6165403|NCT01214642|9808861|FG003|Overall Study|Death|0
6165404|NCT01214642|9808862|FG004|Overall Study|Death|0
6165405|NCT01214642|9808863|FG005|Overall Study|Death|0
6165406|NCT01214642|9808864|FG006|Overall Study|Death|0
6165407|NCT01214642|9808865|FG007|Overall Study|Death|0
6165408|NCT01214642|9808866|FG008|Overall Study|Death|0
6165409|NCT01214642|9808867|FG009|Overall Study|Death|0
6165410|NCT01214642|9808868|FG010|Overall Study|Death|1
6165411|NCT01214642|9808869|FG011|Overall Study|Death|0
6165412|NCT01214642|9808858|FG000|Overall Study|Withdrawal by Subject|0
6165413|NCT01214642|9808859|FG001|Overall Study|Withdrawal by Subject|0
6165414|NCT01214642|9808860|FG002|Overall Study|Withdrawal by Subject|1
6165415|NCT01214642|9808861|FG003|Overall Study|Withdrawal by Subject|0
6165416|NCT01214642|9808862|FG004|Overall Study|Withdrawal by Subject|0
6165417|NCT01214642|9808863|FG005|Overall Study|Withdrawal by Subject|0
6165418|NCT01214642|9808864|FG006|Overall Study|Withdrawal by Subject|0
6165419|NCT01214642|9808865|FG007|Overall Study|Withdrawal by Subject|0
6165420|NCT01214642|9808866|FG008|Overall Study|Withdrawal by Subject|3
6165421|NCT01214642|9808867|FG009|Overall Study|Withdrawal by Subject|1
6327169|NCT02960490|10070818|FG009|Treatment Phase(Double-blind): 12 Weeks|Adverse Event|0
6327170|NCT02960490|10070809|FG000|Treatment Phase(Double-blind): 12 Weeks|Disease Progression|1
6327171|NCT02960490|10070810|FG001|Treatment Phase(Double-blind): 12 Weeks|Disease Progression|2
6327172|NCT02960490|10070811|FG002|Treatment Phase(Double-blind): 12 Weeks|Disease Progression|0
6327173|NCT02960490|10070812|FG003|Treatment Phase(Double-blind): 12 Weeks|Disease Progression|0
6327174|NCT02960490|10070813|FG004|Treatment Phase(Double-blind): 12 Weeks|Disease Progression|0
6327175|NCT02960490|10070814|FG005|Treatment Phase(Double-blind): 12 Weeks|Disease Progression|0
6327176|NCT02960490|10070815|FG006|Treatment Phase(Double-blind): 12 Weeks|Disease Progression|0
6327177|NCT02960490|10070816|FG007|Treatment Phase(Double-blind): 12 Weeks|Disease Progression|0
6327178|NCT02960490|10070817|FG008|Treatment Phase(Double-blind): 12 Weeks|Disease Progression|0
6327179|NCT02960490|10070818|FG009|Treatment Phase(Double-blind): 12 Weeks|Disease Progression|0
6327180|NCT02960490|10070809|FG000|Treatment Phase(Double-blind): 12 Weeks|Not treated|1
6327181|NCT02960490|10070810|FG001|Treatment Phase(Double-blind): 12 Weeks|Not treated|1
6327182|NCT02960490|10070811|FG002|Treatment Phase(Double-blind): 12 Weeks|Not treated|0
6327183|NCT02960490|10070812|FG003|Treatment Phase(Double-blind): 12 Weeks|Not treated|0
6327184|NCT02960490|10070813|FG004|Treatment Phase(Double-blind): 12 Weeks|Not treated|0
6327185|NCT02960490|10070814|FG005|Treatment Phase(Double-blind): 12 Weeks|Not treated|0
6327186|NCT02960490|10070815|FG006|Treatment Phase(Double-blind): 12 Weeks|Not treated|0
6327187|NCT02960490|10070816|FG007|Treatment Phase(Double-blind): 12 Weeks|Not treated|0
6327188|NCT02960490|10070817|FG008|Treatment Phase(Double-blind): 12 Weeks|Not treated|0
6327189|NCT02960490|10070818|FG009|Treatment Phase(Double-blind): 12 Weeks|Not treated|0
6327190|NCT02960490|10070809|FG000|Re-randomized Participants: 12 Weeks|Lack of Efficacy|0
6327191|NCT02960490|10070810|FG001|Re-randomized Participants: 12 Weeks|Lack of Efficacy|0
6327192|NCT02960490|10070811|FG002|Re-randomized Participants: 12 Weeks|Lack of Efficacy|1
6327193|NCT02960490|10070812|FG003|Re-randomized Participants: 12 Weeks|Lack of Efficacy|1
6327194|NCT02960490|10070813|FG004|Re-randomized Participants: 12 Weeks|Lack of Efficacy|0
6327195|NCT02960490|10070814|FG005|Re-randomized Participants: 12 Weeks|Lack of Efficacy|2
6327196|NCT02960490|10070815|FG006|Re-randomized Participants: 12 Weeks|Lack of Efficacy|0
6327197|NCT02960490|10070816|FG007|Re-randomized Participants: 12 Weeks|Lack of Efficacy|0
6327198|NCT02960490|10070817|FG008|Re-randomized Participants: 12 Weeks|Lack of Efficacy|0
6327199|NCT02960490|10070818|FG009|Re-randomized Participants: 12 Weeks|Lack of Efficacy|0
6327200|NCT02960490|10070809|FG000|Re-randomized Participants: 12 Weeks|Adverse Event|0
6327201|NCT02960490|10070810|FG001|Re-randomized Participants: 12 Weeks|Adverse Event|0
6327202|NCT02960490|10070811|FG002|Re-randomized Participants: 12 Weeks|Adverse Event|1
6327203|NCT02960490|10070812|FG003|Re-randomized Participants: 12 Weeks|Adverse Event|0
6165422|NCT01214642|9808868|FG010|Overall Study|Withdrawal by Subject|1
6165423|NCT01214642|9808869|FG011|Overall Study|Withdrawal by Subject|0
6165424|NCT01214642|9808858|FG000|Overall Study|Physician Decision|0
6165425|NCT01214642|9808859|FG001|Overall Study|Physician Decision|0
6165426|NCT01214642|9808860|FG002|Overall Study|Physician Decision|1
6165427|NCT01214642|9808861|FG003|Overall Study|Physician Decision|1
6165428|NCT01214642|9808862|FG004|Overall Study|Physician Decision|1
6165429|NCT01214642|9808863|FG005|Overall Study|Physician Decision|0
6165430|NCT01214642|9808864|FG006|Overall Study|Physician Decision|0
6165431|NCT01214642|9808865|FG007|Overall Study|Physician Decision|0
6165432|NCT01214642|9808866|FG008|Overall Study|Physician Decision|0
6165433|NCT01214642|9808867|FG009|Overall Study|Physician Decision|0
6165434|NCT01214642|9808868|FG010|Overall Study|Physician Decision|0
6165435|NCT01214642|9808869|FG011|Overall Study|Physician Decision|2
6165436|NCT01214655|9808915|FG000|Part A|Progressive Disease|7
6165437|NCT01214655|9808916|FG001|Part A|Progressive Disease|0
6165438|NCT01214655|9808917|FG002|Part A|Progressive Disease|0
6165439|NCT01214655|9808915|FG000|Part A|Physician Decision|1
6165440|NCT01214655|9808916|FG001|Part A|Physician Decision|0
6165441|NCT01214655|9808917|FG002|Part A|Physician Decision|0
6165442|NCT01214655|9808915|FG000|Part B|Progressive disease|0
6165443|NCT01214655|9808916|FG001|Part B|Progressive disease|10
6165444|NCT01214655|9808917|FG002|Part B|Progressive disease|0
6165445|NCT01214655|9808915|FG000|Part B|Death|0
6165446|NCT01214655|9808916|FG001|Part B|Death|1
6165447|NCT01214655|9808917|FG002|Part B|Death|0
6165448|NCT01214655|9808915|FG000|Part B|Withdrawal by Subject|0
6165449|NCT01214655|9808916|FG001|Part B|Withdrawal by Subject|2
6165450|NCT01214655|9808917|FG002|Part B|Withdrawal by Subject|0
6165451|NCT01214655|9808915|FG000|Part C|Progressive Disease|0
6165452|NCT01214655|9808916|FG001|Part C|Progressive Disease|0
6165453|NCT01214655|9808917|FG002|Part C|Progressive Disease|5
6165454|NCT01214655|9808915|FG000|Part C|Death|0
6165455|NCT01214655|9808916|FG001|Part C|Death|0
6165456|NCT01214655|9808917|FG002|Part C|Death|1
6165457|NCT01214655|9808915|FG000|Part C|Physician Decision|0
6165458|NCT01214655|9808916|FG001|Part C|Physician Decision|0
6165459|NCT01214655|9808917|FG002|Part C|Physician Decision|1
6165460|NCT01214668|9808969|FG000|Overall Study|Adverse Event|0
6165461|NCT01214668|9808970|FG001|Overall Study|Adverse Event|1
6165462|NCT01214668|9808971|FG002|Overall Study|Adverse Event|0
6165463|NCT01214668|9808972|FG003|Overall Study|Adverse Event|2
6165464|NCT01214668|9808973|FG004|Overall Study|Adverse Event|1
6165465|NCT01214668|9808974|FG005|Overall Study|Adverse Event|1
6165466|NCT01214668|9808969|FG000|Overall Study|Death|0
6165467|NCT01214668|9808970|FG001|Overall Study|Death|0
6165468|NCT01214668|9808971|FG002|Overall Study|Death|1
6165469|NCT01214668|9808972|FG003|Overall Study|Death|0
6327204|NCT02960490|10070813|FG004|Re-randomized Participants: 12 Weeks|Adverse Event|1
6327205|NCT02960490|10070814|FG005|Re-randomized Participants: 12 Weeks|Adverse Event|0
6327206|NCT02960490|10070815|FG006|Re-randomized Participants: 12 Weeks|Adverse Event|0
6327207|NCT02960490|10070816|FG007|Re-randomized Participants: 12 Weeks|Adverse Event|0
6327208|NCT02960490|10070817|FG008|Re-randomized Participants: 12 Weeks|Adverse Event|0
6327209|NCT02960490|10070818|FG009|Re-randomized Participants: 12 Weeks|Adverse Event|0
6327210|NCT02960490|10070809|FG000|Re-randomized Participants: 12 Weeks|Other|0
6327211|NCT02960490|10070810|FG001|Re-randomized Participants: 12 Weeks|Other|0
6327212|NCT02960490|10070811|FG002|Re-randomized Participants: 12 Weeks|Other|0
6327213|NCT02960490|10070812|FG003|Re-randomized Participants: 12 Weeks|Other|1
6327214|NCT02960490|10070813|FG004|Re-randomized Participants: 12 Weeks|Other|0
6327215|NCT02960490|10070814|FG005|Re-randomized Participants: 12 Weeks|Other|0
6327216|NCT02960490|10070815|FG006|Re-randomized Participants: 12 Weeks|Other|0
6327217|NCT02960490|10070816|FG007|Re-randomized Participants: 12 Weeks|Other|0
6327218|NCT02960490|10070817|FG008|Re-randomized Participants: 12 Weeks|Other|0
6327219|NCT02960490|10070818|FG009|Re-randomized Participants: 12 Weeks|Other|0
6327220|NCT02960490|10070809|FG000|Extension Phase(Open-label): 80 Weeks|Adverse Event|0
6327221|NCT02960490|10070810|FG001|Extension Phase(Open-label): 80 Weeks|Adverse Event|0
6327222|NCT02960490|10070811|FG002|Extension Phase(Open-label): 80 Weeks|Adverse Event|0
6327223|NCT02960490|10070812|FG003|Extension Phase(Open-label): 80 Weeks|Adverse Event|0
6327224|NCT02960490|10070813|FG004|Extension Phase(Open-label): 80 Weeks|Adverse Event|0
6327225|NCT02960490|10070814|FG005|Extension Phase(Open-label): 80 Weeks|Adverse Event|0
6327226|NCT02960490|10070815|FG006|Extension Phase(Open-label): 80 Weeks|Adverse Event|3
6327227|NCT02960490|10070816|FG007|Extension Phase(Open-label): 80 Weeks|Adverse Event|1
6327228|NCT02960490|10070817|FG008|Extension Phase(Open-label): 80 Weeks|Adverse Event|1
6327229|NCT02960490|10070818|FG009|Extension Phase(Open-label): 80 Weeks|Adverse Event|0
6327230|NCT02960490|10070809|FG000|Extension Phase(Open-label): 80 Weeks|Withdrawal by Subject|0
6327231|NCT02960490|10070810|FG001|Extension Phase(Open-label): 80 Weeks|Withdrawal by Subject|0
6327232|NCT02960490|10070811|FG002|Extension Phase(Open-label): 80 Weeks|Withdrawal by Subject|0
6327233|NCT02960490|10070812|FG003|Extension Phase(Open-label): 80 Weeks|Withdrawal by Subject|0
6327234|NCT02960490|10070813|FG004|Extension Phase(Open-label): 80 Weeks|Withdrawal by Subject|0
6327235|NCT02960490|10070814|FG005|Extension Phase(Open-label): 80 Weeks|Withdrawal by Subject|0
6327236|NCT02960490|10070815|FG006|Extension Phase(Open-label): 80 Weeks|Withdrawal by Subject|0
6327237|NCT02960490|10070816|FG007|Extension Phase(Open-label): 80 Weeks|Withdrawal by Subject|1
6327238|NCT02960490|10070817|FG008|Extension Phase(Open-label): 80 Weeks|Withdrawal by Subject|0
6165470|NCT01214668|9808973|FG004|Overall Study|Death|0
6165471|NCT01214668|9808974|FG005|Overall Study|Death|0
6165472|NCT01214668|9808969|FG000|Overall Study|Progressive Disease|4
6165473|NCT01214668|9808970|FG001|Overall Study|Progressive Disease|2
6165474|NCT01214668|9808971|FG002|Overall Study|Progressive Disease|5
6165475|NCT01214668|9808972|FG003|Overall Study|Progressive Disease|4
6165476|NCT01214668|9808973|FG004|Overall Study|Progressive Disease|4
6165477|NCT01214668|9808974|FG005|Overall Study|Progressive Disease|5
6165478|NCT01214668|9808969|FG000|Overall Study|Withdrawal by Subject|0
6165479|NCT01214668|9808970|FG001|Overall Study|Withdrawal by Subject|0
6165480|NCT01214668|9808971|FG002|Overall Study|Withdrawal by Subject|0
6165481|NCT01214668|9808972|FG003|Overall Study|Withdrawal by Subject|0
6165482|NCT01214668|9808973|FG004|Overall Study|Withdrawal by Subject|1
6165483|NCT01214668|9808974|FG005|Overall Study|Withdrawal by Subject|0
6165484|NCT01214720|9808991|FG000|Overall Study|Alive and still on treatment|34
6165485|NCT01214720|9808992|FG001|Overall Study|Alive and still on treatment|18
6165486|NCT01214720|9808991|FG000|Overall Study|Alive and in follow-up|45
6165487|NCT01214720|9808992|FG001|Overall Study|Alive and in follow-up|48
6165488|NCT01214720|9808991|FG000|Overall Study|Lost to Follow-up|6
6165489|NCT01214720|9808992|FG001|Overall Study|Lost to Follow-up|2
6165490|NCT01214837|9809014|FG000|Overall Study|Death|0
6165491|NCT01214837|9809015|FG001|Overall Study|Death|0
6165492|NCT01214837|9809016|FG002|Overall Study|Death|1
6165493|NCT01214837|9809014|FG000|Overall Study|Adverse Event|1
6165494|NCT01214837|9809015|FG001|Overall Study|Adverse Event|2
6165495|NCT01214837|9809016|FG002|Overall Study|Adverse Event|1
6165496|NCT01214837|9809014|FG000|Overall Study|Withdrawal by Subject|27
6165497|NCT01214837|9809015|FG001|Overall Study|Withdrawal by Subject|36
6165498|NCT01214837|9809016|FG002|Overall Study|Withdrawal by Subject|28
6165499|NCT01214837|9809014|FG000|Overall Study|Lost to Follow-up|20
6165500|NCT01214837|9809015|FG001|Overall Study|Lost to Follow-up|15
6165501|NCT01214837|9809016|FG002|Overall Study|Lost to Follow-up|21
6165502|NCT01214837|9809014|FG000|Overall Study|Inappropriate Enrolment|0
6165503|NCT01214837|9809015|FG001|Overall Study|Inappropriate Enrolment|1
6165504|NCT01214837|9809016|FG002|Overall Study|Inappropriate Enrolment|2
6165505|NCT01214837|9809014|FG000|Overall Study|Administrative Reason|2
6165506|NCT01214837|9809015|FG001|Overall Study|Administrative Reason|6
6165507|NCT01214837|9809016|FG002|Overall Study|Administrative Reason|4
6165508|NCT01214837|9809014|FG000|Overall Study|Protocol Violation|3
6165509|NCT01214837|9809015|FG001|Overall Study|Protocol Violation|1
6165510|NCT01214837|9809016|FG002|Overall Study|Protocol Violation|5
6165511|NCT01214837|9809014|FG000|Overall Study|Unable to Classify|1
6165512|NCT01214837|9809015|FG001|Overall Study|Unable to Classify|3
6165513|NCT01214837|9809016|FG002|Overall Study|Unable to Classify|0
6165514|NCT01214850|9809028|FG000|Overall Study|Withdrawal by Subject|38
6165515|NCT01214850|9809029|FG001|Overall Study|Withdrawal by Subject|31
6165516|NCT01214850|9809030|FG002|Overall Study|Withdrawal by Subject|28
6165517|NCT01214850|9809028|FG000|Overall Study|Lost to Follow-up|124
6165518|NCT01214850|9809029|FG001|Overall Study|Lost to Follow-up|98
6165519|NCT01214850|9809030|FG002|Overall Study|Lost to Follow-up|123
6165520|NCT01214850|9809028|FG000|Overall Study|Protocol Violation|5
6165521|NCT01214850|9809029|FG001|Overall Study|Protocol Violation|5
6165522|NCT01214850|9809030|FG002|Overall Study|Protocol Violation|6
6327239|NCT02960490|10070818|FG009|Extension Phase(Open-label): 80 Weeks|Withdrawal by Subject|0
6327240|NCT02960490|10070809|FG000|Extension Phase(Open-label): 80 Weeks|Lack of Efficacy|0
6327241|NCT02960490|10070810|FG001|Extension Phase(Open-label): 80 Weeks|Lack of Efficacy|0
6327242|NCT02960490|10070811|FG002|Extension Phase(Open-label): 80 Weeks|Lack of Efficacy|0
6327243|NCT02960490|10070812|FG003|Extension Phase(Open-label): 80 Weeks|Lack of Efficacy|0
6327244|NCT02960490|10070813|FG004|Extension Phase(Open-label): 80 Weeks|Lack of Efficacy|0
6327245|NCT02960490|10070814|FG005|Extension Phase(Open-label): 80 Weeks|Lack of Efficacy|0
6327246|NCT02960490|10070815|FG006|Extension Phase(Open-label): 80 Weeks|Lack of Efficacy|4
6327247|NCT02960490|10070816|FG007|Extension Phase(Open-label): 80 Weeks|Lack of Efficacy|3
6327248|NCT02960490|10070817|FG008|Extension Phase(Open-label): 80 Weeks|Lack of Efficacy|3
6327249|NCT02960490|10070818|FG009|Extension Phase(Open-label): 80 Weeks|Lack of Efficacy|7
6327250|NCT02960490|10070809|FG000|Extension Phase(Open-label): 80 Weeks|Disease Progression|0
6327251|NCT02960490|10070810|FG001|Extension Phase(Open-label): 80 Weeks|Disease Progression|0
6327252|NCT02960490|10070811|FG002|Extension Phase(Open-label): 80 Weeks|Disease Progression|0
6327253|NCT02960490|10070812|FG003|Extension Phase(Open-label): 80 Weeks|Disease Progression|0
6327254|NCT02960490|10070813|FG004|Extension Phase(Open-label): 80 Weeks|Disease Progression|0
6327255|NCT02960490|10070814|FG005|Extension Phase(Open-label): 80 Weeks|Disease Progression|0
6327256|NCT02960490|10070815|FG006|Extension Phase(Open-label): 80 Weeks|Disease Progression|2
6327257|NCT02960490|10070816|FG007|Extension Phase(Open-label): 80 Weeks|Disease Progression|0
6327258|NCT02960490|10070817|FG008|Extension Phase(Open-label): 80 Weeks|Disease Progression|0
6327259|NCT02960490|10070818|FG009|Extension Phase(Open-label): 80 Weeks|Disease Progression|0
6327260|NCT02960490|10070809|FG000|Extension Phase(Open-label): 80 Weeks|Other|0
6327261|NCT02960490|10070810|FG001|Extension Phase(Open-label): 80 Weeks|Other|0
6327262|NCT02960490|10070811|FG002|Extension Phase(Open-label): 80 Weeks|Other|0
6327263|NCT02960490|10070812|FG003|Extension Phase(Open-label): 80 Weeks|Other|0
6327264|NCT02960490|10070813|FG004|Extension Phase(Open-label): 80 Weeks|Other|0
6327265|NCT02960490|10070814|FG005|Extension Phase(Open-label): 80 Weeks|Other|0
6327266|NCT02960490|10070815|FG006|Extension Phase(Open-label): 80 Weeks|Other|0
6327267|NCT02960490|10070816|FG007|Extension Phase(Open-label): 80 Weeks|Other|1
6327268|NCT02960490|10070817|FG008|Extension Phase(Open-label): 80 Weeks|Other|0
6327269|NCT02960490|10070818|FG009|Extension Phase(Open-label): 80 Weeks|Other|0
6327270|NCT02960854|10070842|FG000|Overall Study|Not Disclosed|2
6165523|NCT01214850|9809028|FG000|Overall Study|Adverse event or death|11
6165524|NCT01214850|9809029|FG001|Overall Study|Adverse event or death|8
6165525|NCT01214850|9809030|FG002|Overall Study|Adverse event or death|3
6327271|NCT02960854|10070843|FG001|Overall Study|Not Disclosed|2
6165526|NCT01214850|9809028|FG000|Overall Study|Inappropriate enrollment|2
6165527|NCT01214850|9809029|FG001|Overall Study|Inappropriate enrollment|1
6165528|NCT01214850|9809030|FG002|Overall Study|Inappropriate enrollment|0
6165529|NCT01214850|9809028|FG000|Overall Study|Administrative reason|1
6165530|NCT01214850|9809029|FG001|Overall Study|Administrative reason|0
6165531|NCT01214850|9809030|FG002|Overall Study|Administrative reason|0
6165532|NCT01214850|9809028|FG000|Overall Study|Unable to classify|2
6165533|NCT01214850|9809029|FG001|Overall Study|Unable to classify|1
6165534|NCT01214850|9809030|FG002|Overall Study|Unable to classify|1
6165535|NCT01214915|9809041|FG000|Overall Study|Adverse Event|8
6165536|NCT01214915|9809041|FG000|Overall Study|Lack of Efficacy|3
6165537|NCT01215032|9809054|FG000|Overall Study|Adverse Event|3
6165538|NCT01215032|9809054|FG000|Overall Study|Lack of Efficacy|17
6165539|NCT01215097|9809062|FG000|Overall Study|Adverse Event|1
6165540|NCT01215097|9809063|FG001|Overall Study|Adverse Event|3
6165541|NCT01215097|9809062|FG000|Overall Study|Protocol Violation|0
6165542|NCT01215097|9809063|FG001|Overall Study|Protocol Violation|2
6165543|NCT01215097|9809062|FG000|Overall Study|Lost to Follow-up|2
6165544|NCT01215097|9809063|FG001|Overall Study|Lost to Follow-up|0
6165545|NCT01215097|9809062|FG000|Overall Study|Withdrawal by Subject|6
6165546|NCT01215097|9809063|FG001|Overall Study|Withdrawal by Subject|3
6165547|NCT01215097|9809062|FG000|Overall Study|Lack of Efficacy|0
6165548|NCT01215097|9809063|FG001|Overall Study|Lack of Efficacy|3
6327272|NCT02960854|10070842|FG000|Overall Study|Subject No Longer Meets Study Criteria|1
6327273|NCT02960854|10070843|FG001|Overall Study|Subject No Longer Meets Study Criteria|0
6327274|NCT02960854|10070842|FG000|Overall Study|Subject Withdrew Consent|0
6327275|NCT02960854|10070843|FG001|Overall Study|Subject Withdrew Consent|1
6327276|NCT02960854|10070842|FG000|Overall Study|Death|4
6327277|NCT02960854|10070843|FG001|Overall Study|Death|6
6327278|NCT02961218|10070860|FG000|Overall Study|Lost to Follow-up|0
6327279|NCT02961218|10070861|FG001|Overall Study|Lost to Follow-up|2
6327280|NCT02961218|10070860|FG000|Overall Study|Physician Decision|0
6327281|NCT02961218|10070861|FG001|Overall Study|Physician Decision|2
6327282|NCT02961218|10070860|FG000|Overall Study|Subject/Guardian Decision|3
6327283|NCT02961218|10070861|FG001|Overall Study|Subject/Guardian Decision|1
6327284|NCT02961244|10070871|FG000|Overall Study|Protocol Violation|0
6327285|NCT02961244|10070872|FG001|Overall Study|Protocol Violation|1
6327286|NCT02961244|10070871|FG000|Overall Study|Withdrawal by Subject|1
6327287|NCT02961244|10070872|FG001|Overall Study|Withdrawal by Subject|2
6327288|NCT02961244|10070871|FG000|Overall Study|Surgery plan change after study approval|0
6327289|NCT02961244|10070872|FG001|Overall Study|Surgery plan change after study approval|2
6327290|NCT02961244|10070871|FG000|Overall Study|Lost to Follow-up|0
6327291|NCT02961244|10070872|FG001|Overall Study|Lost to Follow-up|2
6327292|NCT02961244|10070871|FG000|Overall Study|İnadequate data|0
6327293|NCT02961244|10070872|FG001|Overall Study|İnadequate data|2
6327294|NCT02961751|10070878|FG000|Overall Study|Lost to Follow-up|11
6327295|NCT02961751|10070878|FG000|Overall Study|Physician Decision|2
6327296|NCT02961751|10070878|FG000|Overall Study|Not Eligible at Enrollment|1
6327297|NCT02961751|10070878|FG000|Overall Study|Protocol Violation|1
6327298|NCT02961764|10070884|FG000|Overall Study|Protocol Violation|0
6327299|NCT02961764|10070885|FG001|Overall Study|Protocol Violation|1
6327300|NCT02961764|10070884|FG000|Overall Study|Death|2
6327301|NCT02961764|10070885|FG001|Overall Study|Death|0
6327302|NCT02961764|10070884|FG000|Overall Study|Lost to Follow-up|35
6327303|NCT02961764|10070885|FG001|Overall Study|Lost to Follow-up|24
6327304|NCT02961764|10070884|FG000|Overall Study|Withdrawal by Subject|2
6327305|NCT02961764|10070885|FG001|Overall Study|Withdrawal by Subject|0
6327306|NCT02961790|10070895|FG000|Overall Study|Canceled|4
6327307|NCT02961790|10070896|FG001|Overall Study|Canceled|5
6327308|NCT02961790|10070897|FG002|Overall Study|Canceled|1
6327309|NCT02961790|10070898|FG003|Overall Study|Canceled|4
6327310|NCT02961790|10070895|FG000|Overall Study|without baseline data|4
6327311|NCT02961790|10070896|FG001|Overall Study|without baseline data|0
6327312|NCT02961790|10070897|FG002|Overall Study|without baseline data|1
6327313|NCT02961790|10070898|FG003|Overall Study|without baseline data|0
6327314|NCT02961790|10070895|FG000|Overall Study|without post baseline data|7
6327315|NCT02961790|10070896|FG001|Overall Study|without post baseline data|6
6327316|NCT02961790|10070897|FG002|Overall Study|without post baseline data|4
6327317|NCT02961790|10070898|FG003|Overall Study|without post baseline data|1
6327318|NCT02961920|10070915|FG000|Overall Study|did not achive stydy protocol schedule|1
6327319|NCT02961920|10070916|FG001|Overall Study|did not achive stydy protocol schedule|1
6327320|NCT02962284|10070937|FG000|Overall Study|Death|2
6327321|NCT02962284|10070938|FG001|Overall Study|Death|0
6327322|NCT02962284|10070937|FG000|Overall Study|Progressive disease|2
6327323|NCT02962284|10070938|FG001|Overall Study|Progressive disease|3
6327324|NCT02962284|10070937|FG000|Overall Study|Withdrawal by Subject|1
6165549|NCT01215097|9809062|FG000|Overall Study|patient's refusal to come|2
6165550|NCT01215097|9809063|FG001|Overall Study|patient's refusal to come|2
6327325|NCT02962284|10070938|FG001|Overall Study|Withdrawal by Subject|0
6327326|NCT02962648|10070966|FG000|Overall Study|Withdrawal by Subject|3
6327327|NCT02962648|10070966|FG000|Overall Study|Lost to Follow-up|3
6327328|NCT02962648|10070966|FG000|Overall Study|Physician Decision|1
6327329|NCT02962648|10070966|FG000|Overall Study|Subject had problems with transportation|2
6327330|NCT02962674|10070970|FG000|Overall Study|Study terminated by sponsor prior to completion of all study protocol visits by enrolled subjects.|49
6165551|NCT01215097|9809062|FG000|Overall Study|patient's private reason|1
6165552|NCT01215097|9809063|FG001|Overall Study|patient's private reason|1
6165553|NCT01215175|9809103|FG000|Overall Study|Lost to Follow-up|0
6165554|NCT01215175|9809104|FG001|Overall Study|Lost to Follow-up|1
6165555|NCT01215175|9809105|FG002|Overall Study|Lost to Follow-up|0
6165556|NCT01215175|9809106|FG003|Overall Study|Lost to Follow-up|1
6165557|NCT01215175|9809107|FG004|Overall Study|Lost to Follow-up|0
6165558|NCT01215188|9809122|FG000|Overall Study|Lost to Follow-up|22
6165559|NCT01215188|9809123|FG001|Overall Study|Lost to Follow-up|22
6165560|NCT01215188|9809124|FG002|Overall Study|Lost to Follow-up|16
6165561|NCT01215188|9809122|FG000|Overall Study|Adverse Event|1
6165562|NCT01215188|9809123|FG001|Overall Study|Adverse Event|1
6165563|NCT01215188|9809124|FG002|Overall Study|Adverse Event|3
6165564|NCT01215188|9809122|FG000|Overall Study|Physician Decision|2
6165565|NCT01215188|9809123|FG001|Overall Study|Physician Decision|1
6165566|NCT01215188|9809124|FG002|Overall Study|Physician Decision|0
6165567|NCT01215188|9809122|FG000|Overall Study|Lack of Efficacy|0
6165568|NCT01215188|9809123|FG001|Overall Study|Lack of Efficacy|0
6165569|NCT01215188|9809124|FG002|Overall Study|Lack of Efficacy|1
6165570|NCT01215188|9809122|FG000|Overall Study|Protocol Violation|1
6165571|NCT01215188|9809123|FG001|Overall Study|Protocol Violation|1
6165572|NCT01215188|9809124|FG002|Overall Study|Protocol Violation|1
6165573|NCT01215188|9809122|FG000|Overall Study|Withdrawal by Subject|32
6165574|NCT01215188|9809123|FG001|Overall Study|Withdrawal by Subject|34
6165575|NCT01215188|9809124|FG002|Overall Study|Withdrawal by Subject|31
6165576|NCT01215227|9809138|FG000|Overall Study|Adverse Event|11
6165577|NCT01215227|9809139|FG001|Overall Study|Adverse Event|11
6165578|NCT01215227|9809140|FG002|Overall Study|Adverse Event|4
6165579|NCT01215227|9809141|FG003|Overall Study|Adverse Event|8
6165580|NCT01215227|9809142|FG004|Overall Study|Adverse Event|7
6165581|NCT01215227|9809143|FG005|Overall Study|Adverse Event|6
6165582|NCT01215227|9809138|FG000|Overall Study|Treatment Failure|8
6165583|NCT01215227|9809139|FG001|Overall Study|Treatment Failure|4
6165584|NCT01215227|9809140|FG002|Overall Study|Treatment Failure|1
6165585|NCT01215227|9809141|FG003|Overall Study|Treatment Failure|5
6165586|NCT01215227|9809142|FG004|Overall Study|Treatment Failure|1
6165587|NCT01215227|9809143|FG005|Overall Study|Treatment Failure|1
6165588|NCT01215227|9809138|FG000|Overall Study|Lost to Follow-up|1
6165589|NCT01215227|9809139|FG001|Overall Study|Lost to Follow-up|4
6165590|NCT01215227|9809140|FG002|Overall Study|Lost to Follow-up|1
6165591|NCT01215227|9809141|FG003|Overall Study|Lost to Follow-up|1
6165592|NCT01215227|9809142|FG004|Overall Study|Lost to Follow-up|1
6165593|NCT01215227|9809143|FG005|Overall Study|Lost to Follow-up|2
6165594|NCT01215227|9809138|FG000|Overall Study|Subject Withdrew Consent|16
6165595|NCT01215227|9809139|FG001|Overall Study|Subject Withdrew Consent|20
6165596|NCT01215227|9809140|FG002|Overall Study|Subject Withdrew Consent|7
6165597|NCT01215227|9809141|FG003|Overall Study|Subject Withdrew Consent|10
6165598|NCT01215227|9809142|FG004|Overall Study|Subject Withdrew Consent|11
6165599|NCT01215227|9809143|FG005|Overall Study|Subject Withdrew Consent|8
6165600|NCT01215227|9809138|FG000|Overall Study|Non-Compliance With Protocol|2
6165601|NCT01215227|9809139|FG001|Overall Study|Non-Compliance With Protocol|6
6165602|NCT01215227|9809140|FG002|Overall Study|Non-Compliance With Protocol|1
6165603|NCT01215227|9809141|FG003|Overall Study|Non-Compliance With Protocol|0
6165604|NCT01215227|9809142|FG004|Overall Study|Non-Compliance With Protocol|0
6165605|NCT01215227|9809143|FG005|Overall Study|Non-Compliance With Protocol|0
6165606|NCT01215227|9809138|FG000|Overall Study|Administrative|83
6165607|NCT01215227|9809139|FG001|Overall Study|Administrative|73
6165608|NCT01215227|9809140|FG002|Overall Study|Administrative|42
6165609|NCT01215227|9809141|FG003|Overall Study|Administrative|24
6165610|NCT01215227|9809142|FG004|Overall Study|Administrative|28
6165611|NCT01215227|9809143|FG005|Overall Study|Administrative|40
6165612|NCT01215227|9809138|FG000|Overall Study|Missing Status|0
6165613|NCT01215227|9809139|FG001|Overall Study|Missing Status|1
6165614|NCT01215227|9809140|FG002|Overall Study|Missing Status|0
6165615|NCT01215227|9809141|FG003|Overall Study|Missing Status|0
6165616|NCT01215227|9809142|FG004|Overall Study|Missing Status|0
6165617|NCT01215227|9809143|FG005|Overall Study|Missing Status|0
6165618|NCT01215227|9809138|FG000|Overall Study|Randomized but not treated|0
6165619|NCT01215227|9809139|FG001|Overall Study|Randomized but not treated|0
6165620|NCT01215227|9809140|FG002|Overall Study|Randomized but not treated|1
6327331|NCT02962739|10070987|FG000|Overall Study|Withdrawal by Subject|0
6165621|NCT01215227|9809141|FG003|Overall Study|Randomized but not treated|1
6165622|NCT01215227|9809142|FG004|Overall Study|Randomized but not treated|0
6165623|NCT01215227|9809143|FG005|Overall Study|Randomized but not treated|1
6165624|NCT01215253|9809168|FG000|Overall Study|Withdrawal by Subject|57
6165625|NCT01215253|9809169|FG001|Overall Study|Withdrawal by Subject|35
6165626|NCT01215253|9809168|FG000|Overall Study|Physician Decision|9
6165627|NCT01215253|9809169|FG001|Overall Study|Physician Decision|12
6165628|NCT01215253|9809168|FG000|Overall Study|Lost to Follow-up|6
6165629|NCT01215253|9809169|FG001|Overall Study|Lost to Follow-up|4
6165630|NCT01215253|9809168|FG000|Overall Study|Other|14
6165631|NCT01215253|9809169|FG001|Overall Study|Other|12
6165632|NCT01215357|9809236|FG000|Overall Study|Withdrawal by Subject|3
6327332|NCT02962739|10070988|FG001|Overall Study|Withdrawal by Subject|1
6165633|NCT01215357|9809236|FG000|Overall Study|Protocol Violation|9
6165634|NCT01215422|9809244|FG000|Overall Study|Relocation|1
6165635|NCT01215422|9809245|FG001|Overall Study|Relocation|0
6165636|NCT01215422|9809246|FG002|Overall Study|Relocation|0
6165637|NCT01215422|9809247|FG003|Overall Study|Relocation|0
6165638|NCT01215422|9809244|FG000|Overall Study|Failed intubations|0
6165639|NCT01215422|9809245|FG001|Overall Study|Failed intubations|0
6165640|NCT01215422|9809246|FG002|Overall Study|Failed intubations|3
6165641|NCT01215422|9809247|FG003|Overall Study|Failed intubations|8
6165642|NCT01215422|9809244|FG000|Overall Study|Did not complete all intubations|7
6165643|NCT01215422|9809245|FG001|Overall Study|Did not complete all intubations|0
6165644|NCT01215422|9809246|FG002|Overall Study|Did not complete all intubations|0
6165645|NCT01215422|9809247|FG003|Overall Study|Did not complete all intubations|0
6165646|NCT01215435|9809271|FG000|Overall Study|Adverse Event|1
6165647|NCT01215435|9809272|FG001|Overall Study|Adverse Event|0
6165648|NCT01215435|9809271|FG000|Overall Study|Protocol Violation|2
6165649|NCT01215435|9809272|FG001|Overall Study|Protocol Violation|0
6165650|NCT01215435|9809271|FG000|Overall Study|Withdrawal Criteria|8
6165651|NCT01215435|9809272|FG001|Overall Study|Withdrawal Criteria|11
6165652|NCT01215435|9809271|FG000|Overall Study|Lost to Follow-up|3
6165653|NCT01215435|9809272|FG001|Overall Study|Lost to Follow-up|0
6165654|NCT01215435|9809271|FG000|Overall Study|Unclassified|5
6165655|NCT01215435|9809272|FG001|Overall Study|Unclassified|5
6165656|NCT01215513|9809278|FG000|Overall Study|Not completed CS42|9
6165657|NCT01215513|9809278|FG000|Overall Study|Not enrolled from CS42 to CS42A|21
6165658|NCT01215513|9809278|FG000|Overall Study|Adverse event (CS42A)|2
6165659|NCT01215513|9809278|FG000|Overall Study|Physician decision (CS42A)|6
6165660|NCT01215513|9809278|FG000|Overall Study|Withdrawal by subject (CS42A)|5
6165661|NCT01215513|9809278|FG000|Overall Study|Miscellaneous reasons (CS42A)|2
6165662|NCT01215721|9809318|FG000|Overall Study|Adverse Event|2
6165663|NCT01215734|9809324|FG000|Overall Study|Death|0
6165664|NCT01215734|9809325|FG001|Overall Study|Death|1
6165665|NCT01215851|9809350|FG000|Treatment Period|Adverse Event|1
6165666|NCT01215851|9809351|FG001|Treatment Period|Adverse Event|1
6165667|NCT01215851|9809352|FG002|Treatment Period|Adverse Event|1
6165668|NCT01215851|9809353|FG003|Treatment Period|Adverse Event|3
6165669|NCT01215851|9809354|FG004|Treatment Period|Adverse Event|0
6165670|NCT01215851|9809355|FG005|Treatment Period|Adverse Event|1
6165671|NCT01215851|9809350|FG000|Follow up Period|Lost to Follow-up|0
6165672|NCT01215851|9809351|FG001|Follow up Period|Lost to Follow-up|0
6165673|NCT01215851|9809352|FG002|Follow up Period|Lost to Follow-up|0
6082636|NCT00630812|9690733|FG000|Double Blind Treatment Period|Wanted to take drug in non-protocol way|1
6082637|NCT00630812|9690734|FG001|Double Blind Treatment Period|Wanted to take drug in non-protocol way|0
6082638|NCT00630812|9690733|FG000|Double Blind Treatment Period|Non-compliance|0
6165674|NCT01215851|9809353|FG003|Follow up Period|Lost to Follow-up|0
6165675|NCT01215851|9809354|FG004|Follow up Period|Lost to Follow-up|0
6165676|NCT01215851|9809355|FG005|Follow up Period|Lost to Follow-up|1
6165677|NCT01215916|9809379|FG000|Overall Study|Progressive Disease|0
6165678|NCT01215916|9809380|FG001|Overall Study|Progressive Disease|2
6165679|NCT01215916|9809381|FG002|Overall Study|Progressive Disease|1
6327333|NCT02962739|10070989|FG002|Overall Study|Withdrawal by Subject|0
6327334|NCT02962739|10070990|FG003|Overall Study|Withdrawal by Subject|0
6327335|NCT02962739|10070991|FG004|Overall Study|Withdrawal by Subject|0
6327336|NCT02962739|10070992|FG005|Overall Study|Withdrawal by Subject|0
6327337|NCT02962739|10070987|FG000|Overall Study|Protocol Violation|0
6327338|NCT02962739|10070988|FG001|Overall Study|Protocol Violation|0
6327339|NCT02962739|10070989|FG002|Overall Study|Protocol Violation|1
6327340|NCT02962739|10070990|FG003|Overall Study|Protocol Violation|0
6327341|NCT02962739|10070991|FG004|Overall Study|Protocol Violation|1
6327342|NCT02962739|10070992|FG005|Overall Study|Protocol Violation|0
6327343|NCT02962765|10070998|FG000|Overall Study|Protocol Violation|9
6327344|NCT02962765|10070998|FG000|Overall Study|Withdrawal by Subject|3
6327345|NCT02962765|10070998|FG000|Overall Study|Lost to Follow-up|1
6327346|NCT02962765|10070998|FG000|Overall Study|Death|1
6327347|NCT02962765|10070998|FG000|Overall Study|Limited access to study medication|3
6327348|NCT02962882|10071009|FG000|Overall Study|Adverse Event|2
6327349|NCT02962882|10071009|FG000|Overall Study|Withdrawal by Subject|2
6327350|NCT02962882|10071009|FG000|Overall Study|Transfer from ICU|32
6327351|NCT02962908|10071018|FG000|Overall Study|Lost to Follow-up|0
6327352|NCT02962908|10071019|FG001|Overall Study|Lost to Follow-up|3
6327353|NCT02962908|10071020|FG002|Overall Study|Lost to Follow-up|0
6327354|NCT02962908|10071021|FG003|Overall Study|Lost to Follow-up|1
6327355|NCT02962908|10071018|FG000|Overall Study|Withdrawal by Subject|0
6327356|NCT02962908|10071019|FG001|Overall Study|Withdrawal by Subject|3
6165680|NCT01215916|9809382|FG003|Overall Study|Progressive Disease|2
6165681|NCT01215916|9809383|FG004|Overall Study|Progressive Disease|5
6165682|NCT01215916|9809384|FG005|Overall Study|Progressive Disease|4
6165683|NCT01215916|9809385|FG006|Overall Study|Progressive Disease|5
6165684|NCT01215916|9809386|FG007|Overall Study|Progressive Disease|3
6165685|NCT01215916|9809387|FG008|Overall Study|Progressive Disease|1
6165686|NCT01215916|9809379|FG000|Overall Study|Adverse Event|1
6165687|NCT01215916|9809380|FG001|Overall Study|Adverse Event|1
6327357|NCT02962908|10071020|FG002|Overall Study|Withdrawal by Subject|0
6327358|NCT02962908|10071021|FG003|Overall Study|Withdrawal by Subject|2
6327359|NCT02962908|10071018|FG000|Overall Study|Protocol Violation|0
6165688|NCT01215916|9809381|FG002|Overall Study|Adverse Event|0
6165689|NCT01215916|9809382|FG003|Overall Study|Adverse Event|1
6165690|NCT01215916|9809383|FG004|Overall Study|Adverse Event|0
6165691|NCT01215916|9809384|FG005|Overall Study|Adverse Event|0
6165692|NCT01215916|9809385|FG006|Overall Study|Adverse Event|3
6165693|NCT01215916|9809386|FG007|Overall Study|Adverse Event|0
6165694|NCT01215916|9809387|FG008|Overall Study|Adverse Event|0
6165695|NCT01215916|9809379|FG000|Overall Study|Withdrawal by Subject|0
6165696|NCT01215916|9809380|FG001|Overall Study|Withdrawal by Subject|1
6165697|NCT01215916|9809381|FG002|Overall Study|Withdrawal by Subject|1
6165698|NCT01215916|9809382|FG003|Overall Study|Withdrawal by Subject|2
6165699|NCT01215916|9809383|FG004|Overall Study|Withdrawal by Subject|0
6165700|NCT01215916|9809384|FG005|Overall Study|Withdrawal by Subject|0
6165701|NCT01215916|9809385|FG006|Overall Study|Withdrawal by Subject|1
6165702|NCT01215916|9809386|FG007|Overall Study|Withdrawal by Subject|0
6165703|NCT01215916|9809387|FG008|Overall Study|Withdrawal by Subject|0
6165704|NCT01215916|9809379|FG000|Overall Study|Death|0
6165705|NCT01215916|9809380|FG001|Overall Study|Death|1
6165706|NCT01215916|9809381|FG002|Overall Study|Death|0
6165707|NCT01215916|9809382|FG003|Overall Study|Death|0
6165708|NCT01215916|9809383|FG004|Overall Study|Death|1
6165709|NCT01215916|9809384|FG005|Overall Study|Death|0
6165710|NCT01215916|9809385|FG006|Overall Study|Death|0
6165711|NCT01215916|9809386|FG007|Overall Study|Death|0
6165712|NCT01215916|9809387|FG008|Overall Study|Death|1
6165713|NCT01215916|9809379|FG000|Overall Study|Physician Decision|0
6165714|NCT01215916|9809380|FG001|Overall Study|Physician Decision|0
6165715|NCT01215916|9809381|FG002|Overall Study|Physician Decision|1
6165716|NCT01215916|9809382|FG003|Overall Study|Physician Decision|1
6165717|NCT01215916|9809383|FG004|Overall Study|Physician Decision|0
6165718|NCT01215916|9809384|FG005|Overall Study|Physician Decision|0
6165719|NCT01215916|9809385|FG006|Overall Study|Physician Decision|0
6165720|NCT01215916|9809386|FG007|Overall Study|Physician Decision|0
6165721|NCT01215916|9809387|FG008|Overall Study|Physician Decision|0
6165722|NCT01215942|9809422|FG000|Treatment Period|Adverse Event|15
6165723|NCT01215942|9809423|FG001|Treatment Period|Adverse Event|26
6165724|NCT01215942|9809422|FG000|Treatment Period|Death|2
6165725|NCT01215942|9809423|FG001|Treatment Period|Death|4
6165726|NCT01215942|9809422|FG000|Treatment Period|Lack of Efficacy|23
6165727|NCT01215942|9809423|FG001|Treatment Period|Lack of Efficacy|62
6165728|NCT01215942|9809422|FG000|Treatment Period|Lost to Follow-up|3
6165729|NCT01215942|9809423|FG001|Treatment Period|Lost to Follow-up|4
6165730|NCT01215942|9809422|FG000|Treatment Period|Withdrawal by Subject|17
6165731|NCT01215942|9809423|FG001|Treatment Period|Withdrawal by Subject|40
6165732|NCT01215942|9809422|FG000|Treatment Period|Physician Decision|5
6165733|NCT01215942|9809423|FG001|Treatment Period|Physician Decision|5
6165734|NCT01215942|9809422|FG000|Treatment Period|Protocol Violation|0
6165735|NCT01215942|9809423|FG001|Treatment Period|Protocol Violation|1
6165736|NCT01215942|9809422|FG000|Treatment Period|Sponsor Decision|349
6165737|NCT01215942|9809423|FG001|Treatment Period|Sponsor Decision|530
6165738|NCT01215942|9809422|FG000|Post-Treatment Follow-Up Period|Death|0
6165739|NCT01215942|9809423|FG001|Post-Treatment Follow-Up Period|Death|1
6165740|NCT01215942|9809422|FG000|Post-Treatment Follow-Up Period|Lost to Follow-up|13
6165741|NCT01215942|9809423|FG001|Post-Treatment Follow-Up Period|Lost to Follow-up|13
6165742|NCT01215942|9809422|FG000|Post-Treatment Follow-Up Period|Withdrawal by Subject|43
6165743|NCT01215942|9809423|FG001|Post-Treatment Follow-Up Period|Withdrawal by Subject|69
6165744|NCT01215942|9809422|FG000|Post-Treatment Follow-Up Period|Physician Decision|1
6165745|NCT01215942|9809423|FG001|Post-Treatment Follow-Up Period|Physician Decision|2
6165746|NCT01215942|9809422|FG000|Post-Treatment Follow-Up Period|Sponsor Decision|28
6165747|NCT01215942|9809423|FG001|Post-Treatment Follow-Up Period|Sponsor Decision|61
6165748|NCT01215955|9809444|FG000|Overall Study|Adverse Event|1
6165749|NCT01215955|9809445|FG001|Overall Study|Adverse Event|4
6165750|NCT01215955|9809446|FG002|Overall Study|Adverse Event|2
6165751|NCT01215955|9809447|FG003|Overall Study|Adverse Event|3
6165752|NCT01215955|9809444|FG000|Overall Study|Death|2
6165753|NCT01215955|9809445|FG001|Overall Study|Death|0
6165754|NCT01215955|9809446|FG002|Overall Study|Death|1
6165755|NCT01215955|9809447|FG003|Overall Study|Death|3
6165756|NCT01215955|9809444|FG000|Overall Study|Entry Criteria Not Met|1
6165757|NCT01215955|9809445|FG001|Overall Study|Entry Criteria Not Met|3
6165758|NCT01215955|9809446|FG002|Overall Study|Entry Criteria Not Met|4
6165759|NCT01215955|9809447|FG003|Overall Study|Entry Criteria Not Met|7
6165760|NCT01215955|9809444|FG000|Overall Study|Lack of Efficacy|1
6165761|NCT01215955|9809445|FG001|Overall Study|Lack of Efficacy|2
6165762|NCT01215955|9809446|FG002|Overall Study|Lack of Efficacy|1
6165763|NCT01215955|9809447|FG003|Overall Study|Lack of Efficacy|0
6165764|NCT01215955|9809444|FG000|Overall Study|Lost to Follow-up|4
6165765|NCT01215955|9809445|FG001|Overall Study|Lost to Follow-up|4
6165766|NCT01215955|9809446|FG002|Overall Study|Lost to Follow-up|8
6165767|NCT01215955|9809447|FG003|Overall Study|Lost to Follow-up|9
6165768|NCT01215955|9809444|FG000|Overall Study|Physician Decision|4
6165769|NCT01215955|9809445|FG001|Overall Study|Physician Decision|10
6165770|NCT01215955|9809446|FG002|Overall Study|Physician Decision|8
6165771|NCT01215955|9809447|FG003|Overall Study|Physician Decision|11
6165772|NCT01215955|9809444|FG000|Overall Study|Protocol Violation|17
6165773|NCT01215955|9809445|FG001|Overall Study|Protocol Violation|13
6165774|NCT01215955|9809446|FG002|Overall Study|Protocol Violation|8
6165775|NCT01215955|9809447|FG003|Overall Study|Protocol Violation|8
6165776|NCT01215955|9809444|FG000|Overall Study|Sponsor Decision|1
6165777|NCT01215955|9809445|FG001|Overall Study|Sponsor Decision|2
6165778|NCT01215955|9809446|FG002|Overall Study|Sponsor Decision|0
6165779|NCT01215955|9809447|FG003|Overall Study|Sponsor Decision|1
6165780|NCT01215955|9809444|FG000|Overall Study|Withdrawal by Subject|14
6165781|NCT01215955|9809445|FG001|Overall Study|Withdrawal by Subject|15
6165782|NCT01215955|9809446|FG002|Overall Study|Withdrawal by Subject|13
6165783|NCT01215955|9809447|FG003|Overall Study|Withdrawal by Subject|9
6165784|NCT01215955|9809444|FG000|Overall Study|Quality Issues|0
6165785|NCT01215955|9809445|FG001|Overall Study|Quality Issues|0
6327360|NCT02962908|10071019|FG001|Overall Study|Protocol Violation|1
6327361|NCT02962908|10071020|FG002|Overall Study|Protocol Violation|0
6327362|NCT02962908|10071021|FG003|Overall Study|Protocol Violation|0
6327363|NCT02962908|10071018|FG000|Overall Study|Physician Decision|0
6327364|NCT02962908|10071019|FG001|Overall Study|Physician Decision|1
6327365|NCT02962908|10071020|FG002|Overall Study|Physician Decision|0
6327366|NCT02962908|10071021|FG003|Overall Study|Physician Decision|0
6327367|NCT02962960|10071049|FG000|Overall Study|Withdrawal by Subject|1
6327368|NCT02962960|10071050|FG001|Overall Study|Withdrawal by Subject|1
6327369|NCT02962960|10071051|FG002|Overall Study|Withdrawal by Subject|0
6327370|NCT02962960|10071049|FG000|Overall Study|Adverse Event|1
6327371|NCT02962960|10071050|FG001|Overall Study|Adverse Event|1
6327372|NCT02962960|10071051|FG002|Overall Study|Adverse Event|0
6327373|NCT02962960|10071049|FG000|Overall Study|Protocol Violation|1
6327374|NCT02962960|10071050|FG001|Overall Study|Protocol Violation|0
6327375|NCT02962960|10071051|FG002|Overall Study|Protocol Violation|0
6327376|NCT02963311|10071061|FG000|Overall Study|Withdrawal by Subject|1
6327377|NCT02963311|10071061|FG000|Overall Study|Screen Failure|4
6327378|NCT02963441|10071096|FG000|Overall Study|Protocol violation or withdrawn|8
6327379|NCT02963441|10071096|FG000|Overall Study|Ungradeable by FPRC or IDx|40
6327380|NCT02963441|10071096|FG000|Overall Study|IDx-DR insufficient quality|33
6327381|NCT02963506|10071106|FG000|Double-Blind Period|Adverse Event|0
6327382|NCT02963506|10071107|FG001|Double-Blind Period|Adverse Event|0
6327383|NCT02963506|10071108|FG002|Double-Blind Period|Adverse Event|1
6327384|NCT02963506|10071109|FG003|Double-Blind Period|Adverse Event|0
6327385|NCT02963506|10071110|FG004|Double-Blind Period|Adverse Event|0
6327386|NCT02963506|10071111|FG005|Double-Blind Period|Adverse Event|0
6327387|NCT02963506|10071112|FG006|Double-Blind Period|Adverse Event|0
6327388|NCT02963506|10071113|FG007|Double-Blind Period|Adverse Event|0
6327389|NCT02963506|10071114|FG008|Double-Blind Period|Adverse Event|0
6327390|NCT02963506|10071115|FG009|Double-Blind Period|Adverse Event|0
6327391|NCT02963506|10071116|FG010|Double-Blind Period|Adverse Event|0
6327392|NCT02963506|10071117|FG011|Double-Blind Period|Adverse Event|0
6327393|NCT02963506|10071118|FG012|Double-Blind Period|Adverse Event|0
6327394|NCT02963506|10071106|FG000|Double-Blind Period|Death|0
6327395|NCT02963506|10071107|FG001|Double-Blind Period|Death|0
6327396|NCT02963506|10071108|FG002|Double-Blind Period|Death|0
6327397|NCT02963506|10071109|FG003|Double-Blind Period|Death|1
6327398|NCT02963506|10071110|FG004|Double-Blind Period|Death|0
6327399|NCT02963506|10071111|FG005|Double-Blind Period|Death|0
6327400|NCT02963506|10071112|FG006|Double-Blind Period|Death|0
6327401|NCT02963506|10071113|FG007|Double-Blind Period|Death|0
6327402|NCT02963506|10071114|FG008|Double-Blind Period|Death|0
6327403|NCT02963506|10071115|FG009|Double-Blind Period|Death|0
6327404|NCT02963506|10071116|FG010|Double-Blind Period|Death|0
6327405|NCT02963506|10071117|FG011|Double-Blind Period|Death|0
6327406|NCT02963506|10071118|FG012|Double-Blind Period|Death|0
6327407|NCT02963506|10071106|FG000|Double-Blind Period|Lost to Follow-up|0
6327408|NCT02963506|10071107|FG001|Double-Blind Period|Lost to Follow-up|1
6327409|NCT02963506|10071108|FG002|Double-Blind Period|Lost to Follow-up|0
6327410|NCT02963506|10071109|FG003|Double-Blind Period|Lost to Follow-up|0
6327411|NCT02963506|10071110|FG004|Double-Blind Period|Lost to Follow-up|0
6327412|NCT02963506|10071111|FG005|Double-Blind Period|Lost to Follow-up|0
6327413|NCT02963506|10071112|FG006|Double-Blind Period|Lost to Follow-up|0
6327414|NCT02963506|10071113|FG007|Double-Blind Period|Lost to Follow-up|0
6327415|NCT02963506|10071114|FG008|Double-Blind Period|Lost to Follow-up|0
6327416|NCT02963506|10071115|FG009|Double-Blind Period|Lost to Follow-up|0
6165786|NCT01215955|9809446|FG002|Overall Study|Quality Issues|3
6165787|NCT01215955|9809447|FG003|Overall Study|Quality Issues|2
6165788|NCT01215968|9809462|FG000|Overall Study|Adverse Event|0
6165789|NCT01215968|9809463|FG001|Overall Study|Adverse Event|2
6165790|NCT01215968|9809462|FG000|Overall Study|Protocol Violation|2
6165791|NCT01215968|9809463|FG001|Overall Study|Protocol Violation|4
6165792|NCT01215968|9809462|FG000|Overall Study|Not received study drug|0
6327417|NCT02963506|10071116|FG010|Double-Blind Period|Lost to Follow-up|0
6327418|NCT02963506|10071117|FG011|Double-Blind Period|Lost to Follow-up|0
6327419|NCT02963506|10071118|FG012|Double-Blind Period|Lost to Follow-up|0
6327420|NCT02963506|10071106|FG000|Double-Blind Period|Withdrawal by Subject|0
6327421|NCT02963506|10071107|FG001|Double-Blind Period|Withdrawal by Subject|0
6165793|NCT01215968|9809463|FG001|Overall Study|Not received study drug|1
6165794|NCT01215981|9809474|FG000|Overall Study|Physician Decision|0
6165795|NCT01215981|9809475|FG001|Overall Study|Physician Decision|1
6165796|NCT01215981|9809474|FG000|Overall Study|Protocol Violation|1
6165797|NCT01215981|9809475|FG001|Overall Study|Protocol Violation|0
6165798|NCT01215981|9809474|FG000|Overall Study|Withdrawal by Subject|1
6165799|NCT01215981|9809475|FG001|Overall Study|Withdrawal by Subject|0
6165800|NCT01216072|9809483|FG000|Open-Label Core Period ( 6 Months)|Adverse Event|40
6165801|NCT01216072|9809484|FG001|Open-Label Core Period ( 6 Months)|Adverse Event|4
6165802|NCT01216072|9809483|FG000|Open-Label Core Period ( 6 Months)|Abnormal laboratory value(s)|2
6165803|NCT01216072|9809484|FG001|Open-Label Core Period ( 6 Months)|Abnormal laboratory value(s)|0
6165804|NCT01216072|9809483|FG000|Open-Label Core Period ( 6 Months)|Abnormal test procedure result(s)|3
6165805|NCT01216072|9809484|FG001|Open-Label Core Period ( 6 Months)|Abnormal test procedure result(s)|0
6165806|NCT01216072|9809483|FG000|Open-Label Core Period ( 6 Months)|Lack of Efficacy|3
6165807|NCT01216072|9809484|FG001|Open-Label Core Period ( 6 Months)|Lack of Efficacy|4
6165808|NCT01216072|9809483|FG000|Open-Label Core Period ( 6 Months)|Withdrawal by Subject|12
6165809|NCT01216072|9809484|FG001|Open-Label Core Period ( 6 Months)|Withdrawal by Subject|22
6165810|NCT01216072|9809483|FG000|Open-Label Core Period ( 6 Months)|Lost to Follow-up|5
6165811|NCT01216072|9809484|FG001|Open-Label Core Period ( 6 Months)|Lost to Follow-up|0
6165812|NCT01216072|9809483|FG000|Open-Label Core Period ( 6 Months)|Protocol Deviation|11
6165813|NCT01216072|9809484|FG001|Open-Label Core Period ( 6 Months)|Protocol Deviation|4
6165814|NCT01216072|9809483|FG000|Open-Label Extension Period (3 Months)|Adverse Event|0
6165815|NCT01216072|9809484|FG001|Open-Label Extension Period (3 Months)|Adverse Event|10
6165816|NCT01216072|9809483|FG000|Open-Label Extension Period (3 Months)|Abnormal test procedure results|0
6165817|NCT01216072|9809484|FG001|Open-Label Extension Period (3 Months)|Abnormal test procedure results|1
6165818|NCT01216072|9809483|FG000|Open-Label Extension Period (3 Months)|Withdrawal by Subject|0
6165819|NCT01216072|9809484|FG001|Open-Label Extension Period (3 Months)|Withdrawal by Subject|3
6165820|NCT01216163|9809496|FG000|Overall Study|Withdrawal by Subject|1
6165821|NCT01216163|9809497|FG001|Overall Study|Withdrawal by Subject|1
6165822|NCT01216163|9809498|FG002|Overall Study|Withdrawal by Subject|0
6165823|NCT01216176|9809509|FG000|Overall Study|Adverse Event|0
6165824|NCT01216176|9809510|FG001|Overall Study|Adverse Event|8
6165825|NCT01216176|9809511|FG002|Overall Study|Adverse Event|0
6165826|NCT01216176|9809509|FG000|Overall Study|Physician Decision|0
6165827|NCT01216176|9809510|FG001|Overall Study|Physician Decision|0
6165828|NCT01216176|9809511|FG002|Overall Study|Physician Decision|1
6165829|NCT01216189|9809522|FG000|Overall Study|Lost to Follow-up|21
6165830|NCT01216189|9809523|FG001|Overall Study|Lost to Follow-up|3
6165831|NCT01216189|9809522|FG000|Overall Study|Death|4
6165832|NCT01216189|9809523|FG001|Overall Study|Death|2
6165833|NCT01216202|9809531|FG000|Overall Study|Withdrawal by Subject|8
6165834|NCT01216202|9809532|FG001|Overall Study|Withdrawal by Subject|0
6165835|NCT01216202|9809531|FG000|Overall Study|Death|0
6165836|NCT01216202|9809532|FG001|Overall Study|Death|2
6165837|NCT01216202|9809531|FG000|Overall Study|Lost to Follow-up|14
6165838|NCT01216202|9809532|FG001|Overall Study|Lost to Follow-up|0
6165839|NCT01216319|9809549|FG000|Overall Study|Lost to Follow-up|2
6165840|NCT01216319|9809549|FG000|Overall Study|Unanticipated chemo for breast cancer|2
6165841|NCT01216332|9809555|FG000|Overall Study|Withdrawal by Subject|4
6165842|NCT01216332|9809556|FG001|Overall Study|Withdrawal by Subject|0
6165843|NCT01217073|9809615|FG000|Base Period|Adverse Event|1
6165844|NCT01217073|9809616|FG001|Base Period|Adverse Event|0
6165845|NCT01217073|9809617|FG002|Base Period|Adverse Event|1
6165846|NCT01217073|9809618|FG003|Base Period|Adverse Event|0
6165847|NCT01217073|9809619|FG004|Base Period|Adverse Event|4
6165848|NCT01217073|9809620|FG005|Base Period|Adverse Event|1
6165849|NCT01217073|9809621|FG006|Base Period|Adverse Event|0
6165850|NCT01217073|9809622|FG007|Base Period|Adverse Event|0
6165851|NCT01217073|9809615|FG000|Base Period|Alanine aminotransferase (ALT)/AST|1
6165852|NCT01217073|9809616|FG001|Base Period|Alanine aminotransferase (ALT)/AST|0
6165853|NCT01217073|9809617|FG002|Base Period|Alanine aminotransferase (ALT)/AST|0
6165854|NCT01217073|9809618|FG003|Base Period|Alanine aminotransferase (ALT)/AST|0
6165855|NCT01217073|9809619|FG004|Base Period|Alanine aminotransferase (ALT)/AST|0
6165856|NCT01217073|9809620|FG005|Base Period|Alanine aminotransferase (ALT)/AST|0
6165857|NCT01217073|9809621|FG006|Base Period|Alanine aminotransferase (ALT)/AST|0
6165858|NCT01217073|9809622|FG007|Base Period|Alanine aminotransferase (ALT)/AST|0
6165859|NCT01217073|9809615|FG000|Base Period|Excluded medication|0
6165860|NCT01217073|9809616|FG001|Base Period|Excluded medication|0
6165861|NCT01217073|9809617|FG002|Base Period|Excluded medication|0
6165862|NCT01217073|9809618|FG003|Base Period|Excluded medication|0
6165863|NCT01217073|9809619|FG004|Base Period|Excluded medication|1
6165864|NCT01217073|9809620|FG005|Base Period|Excluded medication|0
6165865|NCT01217073|9809621|FG006|Base Period|Excluded medication|0
6165866|NCT01217073|9809622|FG007|Base Period|Excluded medication|0
6165867|NCT01217073|9809615|FG000|Base Period|Lack of Efficacy|0
6165868|NCT01217073|9809616|FG001|Base Period|Lack of Efficacy|0
6165869|NCT01217073|9809617|FG002|Base Period|Lack of Efficacy|0
6165870|NCT01217073|9809618|FG003|Base Period|Lack of Efficacy|0
6165871|NCT01217073|9809619|FG004|Base Period|Lack of Efficacy|0
6165872|NCT01217073|9809620|FG005|Base Period|Lack of Efficacy|1
6165873|NCT01217073|9809621|FG006|Base Period|Lack of Efficacy|0
6165874|NCT01217073|9809622|FG007|Base Period|Lack of Efficacy|0
6165875|NCT01217073|9809615|FG000|Base Period|Lost to Follow-up|0
6165876|NCT01217073|9809616|FG001|Base Period|Lost to Follow-up|0
6165877|NCT01217073|9809617|FG002|Base Period|Lost to Follow-up|1
6165878|NCT01217073|9809618|FG003|Base Period|Lost to Follow-up|1
6165879|NCT01217073|9809619|FG004|Base Period|Lost to Follow-up|3
6165880|NCT01217073|9809620|FG005|Base Period|Lost to Follow-up|0
6165881|NCT01217073|9809621|FG006|Base Period|Lost to Follow-up|0
6165882|NCT01217073|9809622|FG007|Base Period|Lost to Follow-up|0
6165883|NCT01217073|9809615|FG000|Base Period|Physician Decision|0
6165884|NCT01217073|9809616|FG001|Base Period|Physician Decision|0
6165885|NCT01217073|9809617|FG002|Base Period|Physician Decision|0
6165886|NCT01217073|9809618|FG003|Base Period|Physician Decision|0
6165887|NCT01217073|9809619|FG004|Base Period|Physician Decision|1
6165888|NCT01217073|9809620|FG005|Base Period|Physician Decision|0
6165889|NCT01217073|9809621|FG006|Base Period|Physician Decision|0
6165890|NCT01217073|9809622|FG007|Base Period|Physician Decision|0
6327422|NCT02963506|10071108|FG002|Double-Blind Period|Withdrawal by Subject|1
6327423|NCT02963506|10071109|FG003|Double-Blind Period|Withdrawal by Subject|1
6327424|NCT02963506|10071110|FG004|Double-Blind Period|Withdrawal by Subject|0
6327425|NCT02963506|10071111|FG005|Double-Blind Period|Withdrawal by Subject|0
6327426|NCT02963506|10071112|FG006|Double-Blind Period|Withdrawal by Subject|0
6327427|NCT02963506|10071113|FG007|Double-Blind Period|Withdrawal by Subject|0
6327428|NCT02963506|10071114|FG008|Double-Blind Period|Withdrawal by Subject|0
6327429|NCT02963506|10071115|FG009|Double-Blind Period|Withdrawal by Subject|0
6327430|NCT02963506|10071116|FG010|Double-Blind Period|Withdrawal by Subject|0
6327431|NCT02963506|10071117|FG011|Double-Blind Period|Withdrawal by Subject|0
6327432|NCT02963506|10071118|FG012|Double-Blind Period|Withdrawal by Subject|0
6327433|NCT02963506|10071106|FG000|Double-Blind Period|No compliance|0
6327434|NCT02963506|10071107|FG001|Double-Blind Period|No compliance|1
6327435|NCT02963506|10071108|FG002|Double-Blind Period|No compliance|0
6327436|NCT02963506|10071109|FG003|Double-Blind Period|No compliance|0
6327437|NCT02963506|10071110|FG004|Double-Blind Period|No compliance|0
6327438|NCT02963506|10071111|FG005|Double-Blind Period|No compliance|0
6327439|NCT02963506|10071112|FG006|Double-Blind Period|No compliance|0
6327440|NCT02963506|10071113|FG007|Double-Blind Period|No compliance|0
6327441|NCT02963506|10071114|FG008|Double-Blind Period|No compliance|0
6327442|NCT02963506|10071115|FG009|Double-Blind Period|No compliance|0
6327443|NCT02963506|10071116|FG010|Double-Blind Period|No compliance|0
6327444|NCT02963506|10071117|FG011|Double-Blind Period|No compliance|0
6327445|NCT02963506|10071118|FG012|Double-Blind Period|No compliance|0
6327446|NCT02963506|10071106|FG000|Double-Blind Period|Adverse event, non fatal after Wk12|0
6327447|NCT02963506|10071107|FG001|Double-Blind Period|Adverse event, non fatal after Wk12|1
6327448|NCT02963506|10071108|FG002|Double-Blind Period|Adverse event, non fatal after Wk12|0
6327449|NCT02963506|10071109|FG003|Double-Blind Period|Adverse event, non fatal after Wk12|0
6327450|NCT02963506|10071110|FG004|Double-Blind Period|Adverse event, non fatal after Wk12|0
6327451|NCT02963506|10071111|FG005|Double-Blind Period|Adverse event, non fatal after Wk12|0
6327452|NCT02963506|10071112|FG006|Double-Blind Period|Adverse event, non fatal after Wk12|0
6327453|NCT02963506|10071113|FG007|Double-Blind Period|Adverse event, non fatal after Wk12|0
6327454|NCT02963506|10071114|FG008|Double-Blind Period|Adverse event, non fatal after Wk12|0
6327455|NCT02963506|10071115|FG009|Double-Blind Period|Adverse event, non fatal after Wk12|0
6327456|NCT02963506|10071116|FG010|Double-Blind Period|Adverse event, non fatal after Wk12|0
6327457|NCT02963506|10071117|FG011|Double-Blind Period|Adverse event, non fatal after Wk12|0
6327458|NCT02963506|10071118|FG012|Double-Blind Period|Adverse event, non fatal after Wk12|0
6327459|NCT02963506|10071106|FG000|Dose-Blind Period|Adverse Event|0
6327460|NCT02963506|10071107|FG001|Dose-Blind Period|Adverse Event|0
6327461|NCT02963506|10071108|FG002|Dose-Blind Period|Adverse Event|0
6327462|NCT02963506|10071109|FG003|Dose-Blind Period|Adverse Event|0
6327463|NCT02963506|10071110|FG004|Dose-Blind Period|Adverse Event|0
6327464|NCT02963506|10071111|FG005|Dose-Blind Period|Adverse Event|1
6327465|NCT02963506|10071112|FG006|Dose-Blind Period|Adverse Event|3
6327466|NCT02963506|10071113|FG007|Dose-Blind Period|Adverse Event|2
6327467|NCT02963506|10071114|FG008|Dose-Blind Period|Adverse Event|2
6327468|NCT02963506|10071115|FG009|Dose-Blind Period|Adverse Event|2
6327469|NCT02963506|10071116|FG010|Dose-Blind Period|Adverse Event|1
6327470|NCT02963506|10071117|FG011|Dose-Blind Period|Adverse Event|1
6327471|NCT02963506|10071118|FG012|Dose-Blind Period|Adverse Event|6
6327472|NCT02963506|10071106|FG000|Dose-Blind Period|Lack of Efficacy|0
6327473|NCT02963506|10071107|FG001|Dose-Blind Period|Lack of Efficacy|0
6327474|NCT02963506|10071108|FG002|Dose-Blind Period|Lack of Efficacy|0
6327475|NCT02963506|10071109|FG003|Dose-Blind Period|Lack of Efficacy|0
6327476|NCT02963506|10071110|FG004|Dose-Blind Period|Lack of Efficacy|0
6327477|NCT02963506|10071111|FG005|Dose-Blind Period|Lack of Efficacy|0
6327478|NCT02963506|10071112|FG006|Dose-Blind Period|Lack of Efficacy|0
6327479|NCT02963506|10071113|FG007|Dose-Blind Period|Lack of Efficacy|1
6327480|NCT02963506|10071114|FG008|Dose-Blind Period|Lack of Efficacy|0
6327481|NCT02963506|10071115|FG009|Dose-Blind Period|Lack of Efficacy|1
6327482|NCT02963506|10071116|FG010|Dose-Blind Period|Lack of Efficacy|0
6327483|NCT02963506|10071117|FG011|Dose-Blind Period|Lack of Efficacy|0
6165891|NCT01217073|9809615|FG000|Base Period|Protocol Violation|1
6165892|NCT01217073|9809616|FG001|Base Period|Protocol Violation|0
6165893|NCT01217073|9809617|FG002|Base Period|Protocol Violation|0
6165894|NCT01217073|9809618|FG003|Base Period|Protocol Violation|0
6165895|NCT01217073|9809619|FG004|Base Period|Protocol Violation|1
6165896|NCT01217073|9809620|FG005|Base Period|Protocol Violation|2
6165897|NCT01217073|9809621|FG006|Base Period|Protocol Violation|0
6165898|NCT01217073|9809622|FG007|Base Period|Protocol Violation|0
6165899|NCT01217073|9809615|FG000|Base Period|Withdrawal by Subject|4
6165900|NCT01217073|9809616|FG001|Base Period|Withdrawal by Subject|5
6165901|NCT01217073|9809617|FG002|Base Period|Withdrawal by Subject|5
6165902|NCT01217073|9809618|FG003|Base Period|Withdrawal by Subject|1
6165903|NCT01217073|9809619|FG004|Base Period|Withdrawal by Subject|5
6165904|NCT01217073|9809620|FG005|Base Period|Withdrawal by Subject|5
6165905|NCT01217073|9809621|FG006|Base Period|Withdrawal by Subject|0
6165906|NCT01217073|9809622|FG007|Base Period|Withdrawal by Subject|0
6165907|NCT01217073|9809615|FG000|Extension Period|Adverse Event|0
6165908|NCT01217073|9809616|FG001|Extension Period|Adverse Event|0
6165909|NCT01217073|9809617|FG002|Extension Period|Adverse Event|0
6165910|NCT01217073|9809618|FG003|Extension Period|Adverse Event|0
6165911|NCT01217073|9809619|FG004|Extension Period|Adverse Event|0
6165912|NCT01217073|9809620|FG005|Extension Period|Adverse Event|0
6165913|NCT01217073|9809621|FG006|Extension Period|Adverse Event|19
6165914|NCT01217073|9809622|FG007|Extension Period|Adverse Event|5
6165915|NCT01217073|9809615|FG000|Extension Period|ALT/AST|0
6165916|NCT01217073|9809616|FG001|Extension Period|ALT/AST|0
6165917|NCT01217073|9809617|FG002|Extension Period|ALT/AST|0
6165918|NCT01217073|9809618|FG003|Extension Period|ALT/AST|0
6165919|NCT01217073|9809619|FG004|Extension Period|ALT/AST|0
6165920|NCT01217073|9809620|FG005|Extension Period|ALT/AST|0
6165921|NCT01217073|9809621|FG006|Extension Period|ALT/AST|2
6165922|NCT01217073|9809622|FG007|Extension Period|ALT/AST|0
6165923|NCT01217073|9809615|FG000|Extension Period|Contraindication to study medication|0
6165924|NCT01217073|9809616|FG001|Extension Period|Contraindication to study medication|0
6165925|NCT01217073|9809617|FG002|Extension Period|Contraindication to study medication|0
6165926|NCT01217073|9809618|FG003|Extension Period|Contraindication to study medication|0
6165927|NCT01217073|9809619|FG004|Extension Period|Contraindication to study medication|0
6165928|NCT01217073|9809620|FG005|Extension Period|Contraindication to study medication|0
6165929|NCT01217073|9809621|FG006|Extension Period|Contraindication to study medication|1
6165930|NCT01217073|9809622|FG007|Extension Period|Contraindication to study medication|0
6165931|NCT01217073|9809615|FG000|Extension Period|Creatinine/eGFR|0
6165932|NCT01217073|9809616|FG001|Extension Period|Creatinine/eGFR|0
6165933|NCT01217073|9809617|FG002|Extension Period|Creatinine/eGFR|0
6165934|NCT01217073|9809618|FG003|Extension Period|Creatinine/eGFR|0
6165935|NCT01217073|9809619|FG004|Extension Period|Creatinine/eGFR|0
6165936|NCT01217073|9809620|FG005|Extension Period|Creatinine/eGFR|0
6165937|NCT01217073|9809621|FG006|Extension Period|Creatinine/eGFR|11
6165938|NCT01217073|9809622|FG007|Extension Period|Creatinine/eGFR|1
6165939|NCT01217073|9809615|FG000|Extension Period|Death|0
6165940|NCT01217073|9809616|FG001|Extension Period|Death|0
6165941|NCT01217073|9809617|FG002|Extension Period|Death|0
6165942|NCT01217073|9809618|FG003|Extension Period|Death|0
6165943|NCT01217073|9809619|FG004|Extension Period|Death|0
6165944|NCT01217073|9809620|FG005|Extension Period|Death|0
6165945|NCT01217073|9809621|FG006|Extension Period|Death|1
6165946|NCT01217073|9809622|FG007|Extension Period|Death|0
6165947|NCT01217073|9809615|FG000|Extension Period|Excluded medication|0
6165948|NCT01217073|9809616|FG001|Extension Period|Excluded medication|0
6165949|NCT01217073|9809617|FG002|Extension Period|Excluded medication|0
6165950|NCT01217073|9809618|FG003|Extension Period|Excluded medication|0
6165951|NCT01217073|9809619|FG004|Extension Period|Excluded medication|0
6165952|NCT01217073|9809620|FG005|Extension Period|Excluded medication|0
6165953|NCT01217073|9809621|FG006|Extension Period|Excluded medication|2
6165954|NCT01217073|9809622|FG007|Extension Period|Excluded medication|0
6165955|NCT01217073|9809615|FG000|Extension Period|Lack of Efficacy|0
6165956|NCT01217073|9809616|FG001|Extension Period|Lack of Efficacy|0
6165957|NCT01217073|9809617|FG002|Extension Period|Lack of Efficacy|0
6165958|NCT01217073|9809618|FG003|Extension Period|Lack of Efficacy|0
6165959|NCT01217073|9809619|FG004|Extension Period|Lack of Efficacy|0
6165960|NCT01217073|9809620|FG005|Extension Period|Lack of Efficacy|0
6165961|NCT01217073|9809621|FG006|Extension Period|Lack of Efficacy|3
6165962|NCT01217073|9809622|FG007|Extension Period|Lack of Efficacy|0
6165963|NCT01217073|9809615|FG000|Extension Period|Lost to Follow-up|0
6165964|NCT01217073|9809616|FG001|Extension Period|Lost to Follow-up|0
6165965|NCT01217073|9809617|FG002|Extension Period|Lost to Follow-up|0
6165966|NCT01217073|9809618|FG003|Extension Period|Lost to Follow-up|0
6165967|NCT01217073|9809619|FG004|Extension Period|Lost to Follow-up|0
6165968|NCT01217073|9809620|FG005|Extension Period|Lost to Follow-up|0
6165969|NCT01217073|9809621|FG006|Extension Period|Lost to Follow-up|9
6165970|NCT01217073|9809622|FG007|Extension Period|Lost to Follow-up|1
6165971|NCT01217073|9809615|FG000|Extension Period|Non-compliance with study drug|0
6165972|NCT01217073|9809616|FG001|Extension Period|Non-compliance with study drug|0
6165973|NCT01217073|9809617|FG002|Extension Period|Non-compliance with study drug|0
6165974|NCT01217073|9809618|FG003|Extension Period|Non-compliance with study drug|0
6165975|NCT01217073|9809619|FG004|Extension Period|Non-compliance with study drug|0
6165976|NCT01217073|9809620|FG005|Extension Period|Non-compliance with study drug|0
6165977|NCT01217073|9809621|FG006|Extension Period|Non-compliance with study drug|0
6165978|NCT01217073|9809622|FG007|Extension Period|Non-compliance with study drug|1
6165979|NCT01217073|9809615|FG000|Extension Period|Physician Decision|0
6165980|NCT01217073|9809616|FG001|Extension Period|Physician Decision|0
6165981|NCT01217073|9809617|FG002|Extension Period|Physician Decision|0
6165982|NCT01217073|9809618|FG003|Extension Period|Physician Decision|0
6165983|NCT01217073|9809619|FG004|Extension Period|Physician Decision|0
6165984|NCT01217073|9809620|FG005|Extension Period|Physician Decision|0
6165985|NCT01217073|9809621|FG006|Extension Period|Physician Decision|4
6165986|NCT01217073|9809622|FG007|Extension Period|Physician Decision|1
6165987|NCT01217073|9809615|FG000|Extension Period|Protocol Violation|0
6165988|NCT01217073|9809616|FG001|Extension Period|Protocol Violation|0
6165989|NCT01217073|9809617|FG002|Extension Period|Protocol Violation|0
6165990|NCT01217073|9809618|FG003|Extension Period|Protocol Violation|0
6165991|NCT01217073|9809619|FG004|Extension Period|Protocol Violation|0
6165992|NCT01217073|9809620|FG005|Extension Period|Protocol Violation|0
6165993|NCT01217073|9809621|FG006|Extension Period|Protocol Violation|2
6165994|NCT01217073|9809622|FG007|Extension Period|Protocol Violation|1
6165995|NCT01217073|9809615|FG000|Extension Period|Site discontinued study participation|0
6165996|NCT01217073|9809616|FG001|Extension Period|Site discontinued study participation|0
6165997|NCT01217073|9809617|FG002|Extension Period|Site discontinued study participation|0
6165998|NCT01217073|9809618|FG003|Extension Period|Site discontinued study participation|0
6165999|NCT01217073|9809619|FG004|Extension Period|Site discontinued study participation|0
6166000|NCT01217073|9809620|FG005|Extension Period|Site discontinued study participation|0
6166001|NCT01217073|9809621|FG006|Extension Period|Site discontinued study participation|7
6166002|NCT01217073|9809622|FG007|Extension Period|Site discontinued study participation|2
6327484|NCT02963506|10071118|FG012|Dose-Blind Period|Lack of Efficacy|0
6327485|NCT02963506|10071106|FG000|Dose-Blind Period|Lost to Follow-up|0
6327486|NCT02963506|10071107|FG001|Dose-Blind Period|Lost to Follow-up|0
6327487|NCT02963506|10071108|FG002|Dose-Blind Period|Lost to Follow-up|0
6327488|NCT02963506|10071109|FG003|Dose-Blind Period|Lost to Follow-up|0
6327489|NCT02963506|10071110|FG004|Dose-Blind Period|Lost to Follow-up|0
6327490|NCT02963506|10071111|FG005|Dose-Blind Period|Lost to Follow-up|1
6327491|NCT02963506|10071112|FG006|Dose-Blind Period|Lost to Follow-up|0
6327492|NCT02963506|10071113|FG007|Dose-Blind Period|Lost to Follow-up|0
6327493|NCT02963506|10071114|FG008|Dose-Blind Period|Lost to Follow-up|1
6327494|NCT02963506|10071115|FG009|Dose-Blind Period|Lost to Follow-up|0
6327495|NCT02963506|10071116|FG010|Dose-Blind Period|Lost to Follow-up|0
6327496|NCT02963506|10071117|FG011|Dose-Blind Period|Lost to Follow-up|1
6327497|NCT02963506|10071118|FG012|Dose-Blind Period|Lost to Follow-up|0
6327498|NCT02963506|10071106|FG000|Dose-Blind Period|Withdrawal by Subject|0
6327499|NCT02963506|10071107|FG001|Dose-Blind Period|Withdrawal by Subject|0
6327500|NCT02963506|10071108|FG002|Dose-Blind Period|Withdrawal by Subject|0
6327501|NCT02963506|10071109|FG003|Dose-Blind Period|Withdrawal by Subject|0
6327502|NCT02963506|10071110|FG004|Dose-Blind Period|Withdrawal by Subject|0
6327503|NCT02963506|10071111|FG005|Dose-Blind Period|Withdrawal by Subject|1
6327504|NCT02963506|10071112|FG006|Dose-Blind Period|Withdrawal by Subject|2
6327505|NCT02963506|10071113|FG007|Dose-Blind Period|Withdrawal by Subject|2
6327506|NCT02963506|10071114|FG008|Dose-Blind Period|Withdrawal by Subject|0
6327507|NCT02963506|10071115|FG009|Dose-Blind Period|Withdrawal by Subject|1
6327508|NCT02963506|10071116|FG010|Dose-Blind Period|Withdrawal by Subject|0
6327509|NCT02963506|10071117|FG011|Dose-Blind Period|Withdrawal by Subject|0
6327510|NCT02963506|10071118|FG012|Dose-Blind Period|Withdrawal by Subject|0
6327511|NCT02963506|10071106|FG000|Dose-Blind Period|Sponsor decision|0
6327512|NCT02963506|10071107|FG001|Dose-Blind Period|Sponsor decision|0
6327513|NCT02963506|10071108|FG002|Dose-Blind Period|Sponsor decision|0
6327514|NCT02963506|10071109|FG003|Dose-Blind Period|Sponsor decision|0
6327515|NCT02963506|10071110|FG004|Dose-Blind Period|Sponsor decision|0
6327516|NCT02963506|10071111|FG005|Dose-Blind Period|Sponsor decision|1
6327517|NCT02963506|10071112|FG006|Dose-Blind Period|Sponsor decision|0
6327518|NCT02963506|10071113|FG007|Dose-Blind Period|Sponsor decision|0
6327519|NCT02963506|10071114|FG008|Dose-Blind Period|Sponsor decision|0
6327520|NCT02963506|10071115|FG009|Dose-Blind Period|Sponsor decision|0
6327521|NCT02963506|10071116|FG010|Dose-Blind Period|Sponsor decision|0
6327522|NCT02963506|10071117|FG011|Dose-Blind Period|Sponsor decision|0
6327523|NCT02963506|10071118|FG012|Dose-Blind Period|Sponsor decision|0
6327524|NCT02963506|10071106|FG000|Dose-Blind Period|Meeting exclusion criteria 9|0
6327525|NCT02963506|10071107|FG001|Dose-Blind Period|Meeting exclusion criteria 9|0
6327526|NCT02963506|10071108|FG002|Dose-Blind Period|Meeting exclusion criteria 9|0
6327527|NCT02963506|10071109|FG003|Dose-Blind Period|Meeting exclusion criteria 9|0
6327528|NCT02963506|10071110|FG004|Dose-Blind Period|Meeting exclusion criteria 9|0
6327529|NCT02963506|10071111|FG005|Dose-Blind Period|Meeting exclusion criteria 9|0
6327530|NCT02963506|10071112|FG006|Dose-Blind Period|Meeting exclusion criteria 9|0
6327531|NCT02963506|10071113|FG007|Dose-Blind Period|Meeting exclusion criteria 9|0
6327532|NCT02963506|10071114|FG008|Dose-Blind Period|Meeting exclusion criteria 9|0
6327533|NCT02963506|10071115|FG009|Dose-Blind Period|Meeting exclusion criteria 9|0
6327534|NCT02963506|10071116|FG010|Dose-Blind Period|Meeting exclusion criteria 9|0
6327535|NCT02963506|10071117|FG011|Dose-Blind Period|Meeting exclusion criteria 9|0
6327536|NCT02963506|10071118|FG012|Dose-Blind Period|Meeting exclusion criteria 9|1
6327537|NCT02963701|10071146|FG000|Period 1 (Including Washout) (2 Days)|Withdrawal by Subject|1
6166003|NCT01217073|9809615|FG000|Extension Period|Withdrawal by Subject|0
6166004|NCT01217073|9809616|FG001|Extension Period|Withdrawal by Subject|0
6166005|NCT01217073|9809617|FG002|Extension Period|Withdrawal by Subject|0
6166006|NCT01217073|9809618|FG003|Extension Period|Withdrawal by Subject|0
6166007|NCT01217073|9809619|FG004|Extension Period|Withdrawal by Subject|0
6166008|NCT01217073|9809620|FG005|Extension Period|Withdrawal by Subject|0
6166009|NCT01217073|9809621|FG006|Extension Period|Withdrawal by Subject|30
6166010|NCT01217073|9809622|FG007|Extension Period|Withdrawal by Subject|8
6166011|NCT01217112|9809651|FG000|Overall Study|Adverse Event|0
6166012|NCT01217112|9809652|FG001|Overall Study|Adverse Event|2
6166013|NCT01217112|9809653|FG002|Overall Study|Adverse Event|0
6166014|NCT01217112|9809654|FG003|Overall Study|Adverse Event|2
6166015|NCT01217112|9809655|FG004|Overall Study|Adverse Event|0
6166016|NCT01217112|9809651|FG000|Overall Study|Withdrawal by Subject|0
6166017|NCT01217112|9809652|FG001|Overall Study|Withdrawal by Subject|0
6166018|NCT01217112|9809653|FG002|Overall Study|Withdrawal by Subject|1
6166019|NCT01217112|9809654|FG003|Overall Study|Withdrawal by Subject|0
6166020|NCT01217112|9809655|FG004|Overall Study|Withdrawal by Subject|0
6166021|NCT01217112|9809651|FG000|Overall Study|Physician Decision|0
6166022|NCT01217112|9809652|FG001|Overall Study|Physician Decision|0
6166023|NCT01217112|9809653|FG002|Overall Study|Physician Decision|0
6166024|NCT01217112|9809654|FG003|Overall Study|Physician Decision|0
6166025|NCT01217112|9809655|FG004|Overall Study|Physician Decision|1
6166026|NCT01217190|9809669|FG000|Second Dosing|Withdrawal by Subject|0
6166027|NCT01217190|9809670|FG001|Second Dosing|Withdrawal by Subject|2
6166028|NCT01217229|9809679|FG000|Overall Study|Adverse Event|1
6166029|NCT01217229|9809679|FG000|Overall Study|Disease progression, deterioration|2
6166030|NCT01217229|9809679|FG000|Overall Study|Disease progression, Cheson criteria|14
6166031|NCT01217229|9809679|FG000|Overall Study|Protocol Violation|1
6166032|NCT01217229|9809679|FG000|Overall Study|Disease progression not confirmed|2
6166033|NCT01217307|9809685|FG000|Overall Study|Withdrawal by Subject|0
6166034|NCT01217307|9809686|FG001|Overall Study|Withdrawal by Subject|1
6166035|NCT01217385|9809692|FG000|Overall Study|Withdrawal by Subject|3
6166036|NCT01217385|9809692|FG000|Overall Study|DOSI not performed/not eval|12
6166037|NCT01217385|9809692|FG000|Overall Study|Central Path not Available|1
6166038|NCT01217385|9809692|FG000|Overall Study|Normal Breast TOI not available|10
6166039|NCT01217437|9809715|FG000|Overall Study|Adverse Event|0
6166040|NCT01217437|9809716|FG001|Overall Study|Adverse Event|8
6166041|NCT01217437|9809715|FG000|Overall Study|Death|5
6166042|NCT01217437|9809716|FG001|Overall Study|Death|0
6166043|NCT01217437|9809715|FG000|Overall Study|Lack of Efficacy|29
6166044|NCT01217437|9809716|FG001|Overall Study|Lack of Efficacy|25
6166045|NCT01217437|9809715|FG000|Overall Study|Physician Decision|8
6166046|NCT01217437|9809716|FG001|Overall Study|Physician Decision|5
6166047|NCT01217437|9809715|FG000|Overall Study|Withdrawal by Subject|0
6166048|NCT01217437|9809716|FG001|Overall Study|Withdrawal by Subject|2
6166049|NCT01217437|9809715|FG000|Overall Study|Ineligible|1
6166050|NCT01217437|9809716|FG001|Overall Study|Ineligible|1
6166051|NCT01217463|9809724|FG000|Overall Study|Adverse Event|8
6166052|NCT01217463|9809725|FG001|Overall Study|Adverse Event|5
6166053|NCT01217463|9809724|FG000|Overall Study|Physician Decision|0
6166054|NCT01217463|9809725|FG001|Overall Study|Physician Decision|1
6166055|NCT01217463|9809724|FG000|Overall Study|Withdrawal by Subject|3
6166056|NCT01217463|9809725|FG001|Overall Study|Withdrawal by Subject|0
6166057|NCT01217463|9809724|FG000|Overall Study|Surgery on the Target Limb|0
6166058|NCT01217463|9809725|FG001|Overall Study|Surgery on the Target Limb|1
6166059|NCT01217463|9809724|FG000|Overall Study|Patient Non-compliant|1
6166060|NCT01217463|9809725|FG001|Overall Study|Patient Non-compliant|0
6166061|NCT01217463|9809724|FG000|Overall Study|Other|1
6166062|NCT01217463|9809725|FG001|Overall Study|Other|1
6166063|NCT01217476|9809735|FG000|Overall Study|Adverse Event|6
6166064|NCT01217476|9809736|FG001|Overall Study|Adverse Event|1
6166065|NCT01217476|9809735|FG000|Overall Study|Physician Decision|0
6166066|NCT01217476|9809736|FG001|Overall Study|Physician Decision|1
6166067|NCT01217476|9809735|FG000|Overall Study|Withdrawal by Subject|3
6166068|NCT01217476|9809736|FG001|Overall Study|Withdrawal by Subject|3
6166069|NCT01217476|9809735|FG000|Overall Study|Surgery on the Target Limb|0
6166070|NCT01217476|9809736|FG001|Overall Study|Surgery on the Target Limb|2
6166071|NCT01217476|9809735|FG000|Overall Study|Protocol Deviation|1
6166072|NCT01217476|9809736|FG001|Overall Study|Protocol Deviation|0
6166073|NCT01217476|9809735|FG000|Overall Study|Other|2
6166074|NCT01217476|9809736|FG001|Overall Study|Other|0
6166075|NCT01217606|9809757|FG000|Initial Treatment Phase|Other Reasons|0
6166076|NCT01217606|9809758|FG001|Initial Treatment Phase|Other Reasons|2
6166077|NCT01217606|9809757|FG000|Initial Treatment Phase|Protocol Violation|3
6166078|NCT01217606|9809758|FG001|Initial Treatment Phase|Protocol Violation|2
6166079|NCT01217606|9809757|FG000|Initial Treatment Phase|Personal Reasons|0
6166080|NCT01217606|9809758|FG001|Initial Treatment Phase|Personal Reasons|2
6166081|NCT01217606|9809757|FG000|Initial Treatment Phase|Lack of Efficacy|1
6166082|NCT01217606|9809758|FG001|Initial Treatment Phase|Lack of Efficacy|0
6166083|NCT01217606|9809757|FG000|Initial Treatment Phase|Adverse Event|10
6166084|NCT01217606|9809758|FG001|Initial Treatment Phase|Adverse Event|6
6166085|NCT01217606|9809757|FG000|9-Month Masked Extension|Adverse Event|3
6166086|NCT01217606|9809758|FG001|9-Month Masked Extension|Adverse Event|6
6166087|NCT01217606|9809757|FG000|9-Month Masked Extension|Other Reasons|4
6166088|NCT01217606|9809758|FG001|9-Month Masked Extension|Other Reasons|4
6166089|NCT01217606|9809757|FG000|9-Month Masked Extension|Personal Reasons|2
6166090|NCT01217606|9809758|FG001|9-Month Masked Extension|Personal Reasons|1
6166091|NCT01217606|9809757|FG000|9-Month Masked Extension|Lost to Follow-up|1
6166092|NCT01217606|9809758|FG001|9-Month Masked Extension|Lost to Follow-up|0
6166093|NCT01217606|9809757|FG000|9-Month Masked Extension|Pregnancy|1
6166094|NCT01217606|9809758|FG001|9-Month Masked Extension|Pregnancy|0
6166095|NCT01217606|9809757|FG000|9-Month Masked Extension|Lack of Efficacy|2
6166096|NCT01217606|9809758|FG001|9-Month Masked Extension|Lack of Efficacy|0
6166097|NCT01217801|9809781|FG000|Period 1|Protocol Violation|1
6166098|NCT01217801|9809782|FG001|Period 1|Protocol Violation|1
6166099|NCT01217801|9809781|FG000|Period 1|Withdrawal by Subject|0
6166100|NCT01217801|9809782|FG001|Period 1|Withdrawal by Subject|1
6166101|NCT01217814|9809791|FG000|Overall Study|Adverse Event|1
6166102|NCT01217814|9809792|FG001|Overall Study|Adverse Event|1
6166103|NCT01217814|9809793|FG002|Overall Study|Adverse Event|0
6166104|NCT01217814|9809791|FG000|Overall Study|Lack of Efficacy|0
6166105|NCT01217814|9809792|FG001|Overall Study|Lack of Efficacy|0
6166106|NCT01217814|9809793|FG002|Overall Study|Lack of Efficacy|1
6166107|NCT01217892|9809825|FG000|Overall Study|Adverse Event|1
6166108|NCT01217892|9809826|FG001|Overall Study|Adverse Event|1
6166109|NCT01217892|9809827|FG002|Overall Study|Adverse Event|1
6166110|NCT01217892|9809828|FG003|Overall Study|Adverse Event|0
6166111|NCT01217892|9809825|FG000|Overall Study|Withdrawal by Subject|0
6166112|NCT01217892|9809826|FG001|Overall Study|Withdrawal by Subject|2
6166113|NCT01217892|9809827|FG002|Overall Study|Withdrawal by Subject|1
6166114|NCT01217892|9809828|FG003|Overall Study|Withdrawal by Subject|0
6166115|NCT01217892|9809825|FG000|Overall Study|Lab value|1
6166116|NCT01217892|9809826|FG001|Overall Study|Lab value|0
6166117|NCT01217892|9809827|FG002|Overall Study|Lab value|1
6166118|NCT01217892|9809828|FG003|Overall Study|Lab value|0
6166119|NCT01217892|9809825|FG000|Overall Study|Subject no longer meets study criteria|5
6166120|NCT01217892|9809826|FG001|Overall Study|Subject no longer meets study criteria|2
6166121|NCT01217892|9809827|FG002|Overall Study|Subject no longer meets study criteria|4
6166122|NCT01217892|9809828|FG003|Overall Study|Subject no longer meets study criteria|8
6166123|NCT01217892|9809825|FG000|Overall Study|Incorrect enrollment|0
6166124|NCT01217892|9809826|FG001|Overall Study|Incorrect enrollment|1
6166125|NCT01217892|9809827|FG002|Overall Study|Incorrect enrollment|1
6166126|NCT01217892|9809828|FG003|Overall Study|Incorrect enrollment|0
6166127|NCT01217892|9809825|FG000|Overall Study|Poor/Non-Compliance|0
6166128|NCT01217892|9809826|FG001|Overall Study|Poor/Non-Compliance|0
6166129|NCT01217892|9809827|FG002|Overall Study|Poor/Non-Compliance|1
6166130|NCT01217892|9809828|FG003|Overall Study|Poor/Non-Compliance|0
6166131|NCT01217944|9809841|FG000|Overall Study|Protocol Violation|1
6166132|NCT01217944|9809842|FG001|Overall Study|Protocol Violation|1
6166133|NCT01217944|9809843|FG002|Overall Study|Protocol Violation|0
6166134|NCT01217944|9809841|FG000|Overall Study|Lost to Follow-up|3
6166135|NCT01217944|9809842|FG001|Overall Study|Lost to Follow-up|1
6166136|NCT01217944|9809843|FG002|Overall Study|Lost to Follow-up|0
6166137|NCT01217944|9809841|FG000|Overall Study|Withdrawal by Subject|1
6166138|NCT01217944|9809842|FG001|Overall Study|Withdrawal by Subject|2
6166139|NCT01217944|9809843|FG002|Overall Study|Withdrawal by Subject|0
6166140|NCT01217944|9809841|FG000|Overall Study|Lack of Efficacy|1
6166141|NCT01217944|9809842|FG001|Overall Study|Lack of Efficacy|0
6166142|NCT01217944|9809843|FG002|Overall Study|Lack of Efficacy|0
6166143|NCT01217957|9809858|FG000|Phase 1|Withdrawal by Patient|1
6166144|NCT01217957|9809859|FG001|Phase 1|Withdrawal by Patient|0
6166145|NCT01217957|9809860|FG002|Phase 1|Withdrawal by Patient|1
6166146|NCT01217957|9809861|FG003|Phase 1|Withdrawal by Patient|1
6166147|NCT01217957|9809862|FG004|Phase 1|Withdrawal by Patient|0
6166148|NCT01217957|9809858|FG000|Phase 2|Withdrawal by Patient|0
6166149|NCT01217957|9809859|FG001|Phase 2|Withdrawal by Patient|0
6166150|NCT01217957|9809860|FG002|Phase 2|Withdrawal by Patient|0
6166151|NCT01217957|9809861|FG003|Phase 2|Withdrawal by Patient|0
6166152|NCT01217957|9809862|FG004|Phase 2|Withdrawal by Patient|1
6166153|NCT01218009|9809885|FG000|Overall Study|Protocol Violation|2
6166154|NCT01218009|9809886|FG001|Overall Study|Protocol Violation|1
6166155|NCT01218009|9809885|FG000|Overall Study|Withdrawal by Subject|3
6166156|NCT01218009|9809886|FG001|Overall Study|Withdrawal by Subject|1
6166157|NCT01218009|9809885|FG000|Overall Study|Sponsor terminated study|161
6166158|NCT01218009|9809886|FG001|Overall Study|Sponsor terminated study|163
6166159|NCT01218087|9809899|FG000|Overall Study|Death|2
6166160|NCT01218087|9809900|FG001|Overall Study|Death|1
6166161|NCT01218087|9809899|FG000|Overall Study|Withdrawal by Subject|5
6166162|NCT01218087|9809900|FG001|Overall Study|Withdrawal by Subject|0
6166163|NCT01218087|9809899|FG000|Overall Study|Transferred|8
6166164|NCT01218087|9809900|FG001|Overall Study|Transferred|5
6166165|NCT01218100|9809910|FG000|Overall Study|Did not meet InclusionExclusion criteria|1
6166166|NCT01218100|9809911|FG001|Overall Study|Did not meet InclusionExclusion criteria|1
6166167|NCT01218100|9809912|FG002|Overall Study|Did not meet InclusionExclusion criteria|1
6166168|NCT01218100|9809913|FG003|Overall Study|Did not meet InclusionExclusion criteria|2
6166169|NCT01218100|9809910|FG000|Overall Study|Adverse Event|4
6166170|NCT01218100|9809911|FG001|Overall Study|Adverse Event|6
6166171|NCT01218100|9809912|FG002|Overall Study|Adverse Event|6
6166172|NCT01218100|9809913|FG003|Overall Study|Adverse Event|7
6166173|NCT01218100|9809910|FG000|Overall Study|Lack of Efficacy|9
6166174|NCT01218100|9809911|FG001|Overall Study|Lack of Efficacy|6
6166175|NCT01218100|9809912|FG002|Overall Study|Lack of Efficacy|5
6166176|NCT01218100|9809913|FG003|Overall Study|Lack of Efficacy|12
6166177|NCT01218100|9809910|FG000|Overall Study|Protocol Violation|0
6166178|NCT01218100|9809911|FG001|Overall Study|Protocol Violation|0
6166179|NCT01218100|9809912|FG002|Overall Study|Protocol Violation|1
6166180|NCT01218100|9809913|FG003|Overall Study|Protocol Violation|1
6166181|NCT01218100|9809910|FG000|Overall Study|Withdrawal by Subject|5
6166182|NCT01218100|9809911|FG001|Overall Study|Withdrawal by Subject|2
6166183|NCT01218100|9809912|FG002|Overall Study|Withdrawal by Subject|6
6166184|NCT01218100|9809913|FG003|Overall Study|Withdrawal by Subject|7
6166185|NCT01218100|9809910|FG000|Overall Study|Lost to Follow-up|3
6166186|NCT01218100|9809911|FG001|Overall Study|Lost to Follow-up|8
6166187|NCT01218100|9809912|FG002|Overall Study|Lost to Follow-up|2
6166188|NCT01218100|9809913|FG003|Overall Study|Lost to Follow-up|1
6166189|NCT01218100|9809910|FG000|Overall Study|Other Reason|2
6166190|NCT01218100|9809911|FG001|Overall Study|Other Reason|2
6166191|NCT01218100|9809912|FG002|Overall Study|Other Reason|6
6166192|NCT01218100|9809913|FG003|Overall Study|Other Reason|4
6166193|NCT01218113|9809926|FG000|Overall Study|Withdrawal by Subject|1
6166194|NCT01218113|9809927|FG001|Overall Study|Withdrawal by Subject|0
6166195|NCT01218113|9809928|FG002|Overall Study|Withdrawal by Subject|1
6166196|NCT01218113|9809926|FG000|Overall Study|Lost to Follow-up|4
6166197|NCT01218113|9809927|FG001|Overall Study|Lost to Follow-up|1
6166198|NCT01218113|9809928|FG002|Overall Study|Lost to Follow-up|4
6166199|NCT01218113|9809926|FG000|Overall Study|Protocol Deviation Eligibility Criteria|0
6166200|NCT01218113|9809927|FG001|Overall Study|Protocol Deviation Eligibility Criteria|0
6166201|NCT01218113|9809928|FG002|Overall Study|Protocol Deviation Eligibility Criteria|1
6166202|NCT01218126|9809947|FG000|Overall Study|Adverse Event|8
6166203|NCT01218126|9809948|FG001|Overall Study|Adverse Event|10
6166204|NCT01218126|9809949|FG002|Overall Study|Adverse Event|12
6166205|NCT01218126|9809950|FG003|Overall Study|Adverse Event|16
6166206|NCT01218126|9809947|FG000|Overall Study|Lack of Efficacy|7
6166207|NCT01218126|9809948|FG001|Overall Study|Lack of Efficacy|2
6166208|NCT01218126|9809949|FG002|Overall Study|Lack of Efficacy|2
6166209|NCT01218126|9809950|FG003|Overall Study|Lack of Efficacy|6
6166210|NCT01218126|9809947|FG000|Overall Study|Protocol Violation|5
6166211|NCT01218126|9809948|FG001|Overall Study|Protocol Violation|2
6166212|NCT01218126|9809949|FG002|Overall Study|Protocol Violation|2
6166213|NCT01218126|9809950|FG003|Overall Study|Protocol Violation|3
6166214|NCT01218126|9809947|FG000|Overall Study|Protocol-defined stopping criteria|1
6166215|NCT01218126|9809948|FG001|Overall Study|Protocol-defined stopping criteria|1
6166216|NCT01218126|9809949|FG002|Overall Study|Protocol-defined stopping criteria|0
6166217|NCT01218126|9809950|FG003|Overall Study|Protocol-defined stopping criteria|0
6166218|NCT01218126|9809947|FG000|Overall Study|Lost to Follow-up|0
6166219|NCT01218126|9809948|FG001|Overall Study|Lost to Follow-up|0
6166220|NCT01218126|9809949|FG002|Overall Study|Lost to Follow-up|0
6166221|NCT01218126|9809950|FG003|Overall Study|Lost to Follow-up|2
6166222|NCT01218126|9809947|FG000|Overall Study|Physician Decision|1
6166223|NCT01218126|9809948|FG001|Overall Study|Physician Decision|2
6327538|NCT02963701|10071147|FG001|Period 1 (Including Washout) (2 Days)|Withdrawal by Subject|0
6327539|NCT02963922|10071155|FG000|Overall Study|Adverse Event|15
6327540|NCT02963922|10071156|FG001|Overall Study|Adverse Event|6
6327541|NCT02963922|10071155|FG000|Overall Study|Protocol deviation|6
6327542|NCT02963922|10071156|FG001|Overall Study|Protocol deviation|6
6327543|NCT02963922|10071155|FG000|Overall Study|Lack of Efficacy|1
6327544|NCT02963922|10071156|FG001|Overall Study|Lack of Efficacy|1
6166224|NCT01218126|9809949|FG002|Overall Study|Physician Decision|4
6166225|NCT01218126|9809950|FG003|Overall Study|Physician Decision|2
6166226|NCT01218126|9809947|FG000|Overall Study|Withdrawal by Subject|2
6166227|NCT01218126|9809948|FG001|Overall Study|Withdrawal by Subject|5
6166228|NCT01218126|9809949|FG002|Overall Study|Withdrawal by Subject|4
6166229|NCT01218126|9809950|FG003|Overall Study|Withdrawal by Subject|6
6166230|NCT01218204|9809962|FG000|Part B Washout|Adverse Event|0
6166231|NCT01218204|9809963|FG001|Part B Washout|Adverse Event|1
6166232|NCT01218204|9809964|FG002|Part B Washout|Adverse Event|0
6166233|NCT01218204|9809965|FG003|Part B Washout|Adverse Event|0
6166234|NCT01218204|9809962|FG000|Part B Washout|Lost to Follow-up|0
6166235|NCT01218204|9809963|FG001|Part B Washout|Lost to Follow-up|2
6166236|NCT01218204|9809964|FG002|Part B Washout|Lost to Follow-up|0
6166237|NCT01218204|9809965|FG003|Part B Washout|Lost to Follow-up|0
6166238|NCT01218204|9809962|FG000|Part B Washout|Physician Decision|0
6166239|NCT01218204|9809963|FG001|Part B Washout|Physician Decision|14
6166240|NCT01218204|9809964|FG002|Part B Washout|Physician Decision|0
6327545|NCT02963922|10071155|FG000|Overall Study|Lost to Follow-up|2
6327546|NCT02963922|10071156|FG001|Overall Study|Lost to Follow-up|3
6166241|NCT01218204|9809965|FG003|Part B Washout|Physician Decision|0
6166242|NCT01218204|9809962|FG000|Part B Washout|Withdrawal by Subject|0
6166243|NCT01218204|9809963|FG001|Part B Washout|Withdrawal by Subject|14
6166244|NCT01218204|9809964|FG002|Part B Washout|Withdrawal by Subject|0
6166245|NCT01218204|9809965|FG003|Part B Washout|Withdrawal by Subject|0
6166246|NCT01218204|9809962|FG000|Part B Washout|Reached defined stopping criteria|0
6166247|NCT01218204|9809963|FG001|Part B Washout|Reached defined stopping criteria|2
6166248|NCT01218204|9809964|FG002|Part B Washout|Reached defined stopping criteria|0
6166249|NCT01218204|9809965|FG003|Part B Washout|Reached defined stopping criteria|0
6166250|NCT01218204|9809962|FG000|Part B Washout|Did not meet continuation criteria|0
6166251|NCT01218204|9809963|FG001|Part B Washout|Did not meet continuation criteria|112
6166252|NCT01218204|9809964|FG002|Part B Washout|Did not meet continuation criteria|0
6166253|NCT01218204|9809965|FG003|Part B Washout|Did not meet continuation criteria|0
6166254|NCT01218204|9809962|FG000|Part B Run-in|Adverse Event|0
6166255|NCT01218204|9809963|FG001|Part B Run-in|Adverse Event|0
6166256|NCT01218204|9809964|FG002|Part B Run-in|Adverse Event|1
6166257|NCT01218204|9809965|FG003|Part B Run-in|Adverse Event|0
6166258|NCT01218204|9809962|FG000|Part B Run-in|Protocol Violation|0
6166259|NCT01218204|9809963|FG001|Part B Run-in|Protocol Violation|0
6166260|NCT01218204|9809964|FG002|Part B Run-in|Protocol Violation|2
6166261|NCT01218204|9809965|FG003|Part B Run-in|Protocol Violation|0
6166262|NCT01218204|9809962|FG000|Part B Run-in|Withdrawal by Subject|0
6166263|NCT01218204|9809963|FG001|Part B Run-in|Withdrawal by Subject|0
6166264|NCT01218204|9809964|FG002|Part B Run-in|Withdrawal by Subject|3
6166265|NCT01218204|9809965|FG003|Part B Run-in|Withdrawal by Subject|0
6166266|NCT01218204|9809962|FG000|Part B Pooled Treatment Arm|Adverse Event|0
6166267|NCT01218204|9809963|FG001|Part B Pooled Treatment Arm|Adverse Event|0
6166268|NCT01218204|9809964|FG002|Part B Pooled Treatment Arm|Adverse Event|0
6166269|NCT01218204|9809965|FG003|Part B Pooled Treatment Arm|Adverse Event|2
6166270|NCT01218204|9809962|FG000|Part B Pooled Treatment Arm|Protocol Violation|0
6166271|NCT01218204|9809963|FG001|Part B Pooled Treatment Arm|Protocol Violation|0
6166272|NCT01218204|9809964|FG002|Part B Pooled Treatment Arm|Protocol Violation|0
6166273|NCT01218204|9809965|FG003|Part B Pooled Treatment Arm|Protocol Violation|1
6166274|NCT01218243|9810014|FG000|Overall Study|Lack of Efficacy|1
6166275|NCT01218243|9810015|FG001|Overall Study|Lack of Efficacy|1
6166276|NCT01218243|9810014|FG000|Overall Study|Lost to Follow-up|3
6166277|NCT01218243|9810015|FG001|Overall Study|Lost to Follow-up|3
6166278|NCT01218243|9810014|FG000|Overall Study|Protocol Violation|5
6166279|NCT01218243|9810015|FG001|Overall Study|Protocol Violation|10
6166280|NCT01218308|9810023|FG000|Overall Study|Adverse Event|1
6166281|NCT01218308|9810024|FG001|Overall Study|Adverse Event|2
6166282|NCT01218308|9810023|FG000|Overall Study|Protocol Violation|0
6166283|NCT01218308|9810024|FG001|Overall Study|Protocol Violation|2
6166284|NCT01218308|9810023|FG000|Overall Study|Withdrawal by Subject|61
6166285|NCT01218308|9810024|FG001|Overall Study|Withdrawal by Subject|64
6166286|NCT01218308|9810023|FG000|Overall Study|Lost to Follow-up|27
6166287|NCT01218308|9810024|FG001|Overall Study|Lost to Follow-up|31
6166288|NCT01218308|9810023|FG000|Overall Study|Other|14
6166289|NCT01218308|9810024|FG001|Overall Study|Other|21
6166290|NCT01218438|9810039|FG000|Epoch 1|Physician Decision|2
6166291|NCT01218438|9810039|FG000|Epoch 1|Adverse Event|1
6166292|NCT01218438|9810039|FG000|Epoch 3|Withdrawal by Subject|3
6166293|NCT01218438|9810039|FG000|Epoch 3|Adverse Event|1
6166294|NCT01218438|9810039|FG000|Epoch 4|Physician Decision|1
6166295|NCT01218438|9810039|FG000|Epoch 4|Withdrawal by Subject|2
6166296|NCT01218477|9810117|FG000|Overall Study|Disease progression|2
6166297|NCT01218477|9810118|FG001|Overall Study|Disease progression|3
6166298|NCT01218477|9810119|FG002|Overall Study|Disease progression|6
6166299|NCT01218477|9810120|FG003|Overall Study|Disease progression|2
6166300|NCT01218477|9810117|FG000|Overall Study|Study drug toxicity|0
6166301|NCT01218477|9810118|FG001|Overall Study|Study drug toxicity|2
6166302|NCT01218477|9810119|FG002|Overall Study|Study drug toxicity|5
6166303|NCT01218477|9810120|FG003|Overall Study|Study drug toxicity|0
6166304|NCT01218477|9810117|FG000|Overall Study|No longer meets study criteria|1
6166305|NCT01218477|9810118|FG001|Overall Study|No longer meets study criteria|0
6166306|NCT01218477|9810119|FG002|Overall Study|No longer meets study criteria|0
6166307|NCT01218477|9810120|FG003|Overall Study|No longer meets study criteria|0
6166308|NCT01218477|9810117|FG000|Overall Study|Withdrawal by Subject|0
6166309|NCT01218477|9810118|FG001|Overall Study|Withdrawal by Subject|0
6166310|NCT01218477|9810119|FG002|Overall Study|Withdrawal by Subject|1
6166311|NCT01218477|9810120|FG003|Overall Study|Withdrawal by Subject|0
6166312|NCT01218477|9810117|FG000|Overall Study|Prepared for cell transplantation|0
6166313|NCT01218477|9810118|FG001|Overall Study|Prepared for cell transplantation|1
6166314|NCT01218477|9810119|FG002|Overall Study|Prepared for cell transplantation|1
6166315|NCT01218477|9810120|FG003|Overall Study|Prepared for cell transplantation|0
6166316|NCT01218477|9810117|FG000|Overall Study|Administrative reason by sponsor|0
6166317|NCT01218477|9810118|FG001|Overall Study|Administrative reason by sponsor|0
6166318|NCT01218477|9810119|FG002|Overall Study|Administrative reason by sponsor|1
6166319|NCT01218477|9810120|FG003|Overall Study|Administrative reason by sponsor|0
6166320|NCT01218477|9810117|FG000|Overall Study|Maximum clinical benefit|0
6166321|NCT01218477|9810118|FG001|Overall Study|Maximum clinical benefit|2
6166322|NCT01218477|9810119|FG002|Overall Study|Maximum clinical benefit|0
6166323|NCT01218477|9810120|FG003|Overall Study|Maximum clinical benefit|0
6166324|NCT01218516|9810136|FG000|Combination Therapy (up to 4.5 Months)|Death|2
6166325|NCT01218516|9810137|FG001|Combination Therapy (up to 4.5 Months)|Death|1
6166326|NCT01218516|9810138|FG002|Combination Therapy (up to 4.5 Months)|Death|0
6166327|NCT01218516|9810139|FG003|Combination Therapy (up to 4.5 Months)|Death|0
6166328|NCT01218516|9810136|FG000|Combination Therapy (up to 4.5 Months)|Delay in TA Administration of >=28 days|0
6192099|NCT01427933|9849148|FG000|Overall Study|Lost to Follow-up|1
6166329|NCT01218516|9810137|FG001|Combination Therapy (up to 4.5 Months)|Delay in TA Administration of >=28 days|3
6166330|NCT01218516|9810138|FG002|Combination Therapy (up to 4.5 Months)|Delay in TA Administration of >=28 days|0
6166331|NCT01218516|9810139|FG003|Combination Therapy (up to 4.5 Months)|Delay in TA Administration of >=28 days|0
6166332|NCT01218516|9810136|FG000|Combination Therapy (up to 4.5 Months)|Physician Decision|2
6166333|NCT01218516|9810137|FG001|Combination Therapy (up to 4.5 Months)|Physician Decision|2
6166334|NCT01218516|9810138|FG002|Combination Therapy (up to 4.5 Months)|Physician Decision|0
6166335|NCT01218516|9810139|FG003|Combination Therapy (up to 4.5 Months)|Physician Decision|0
6166336|NCT01218516|9810136|FG000|Combination Therapy (up to 4.5 Months)|Chemotherapy Discontinued|2
6166337|NCT01218516|9810137|FG001|Combination Therapy (up to 4.5 Months)|Chemotherapy Discontinued|0
6166338|NCT01218516|9810138|FG002|Combination Therapy (up to 4.5 Months)|Chemotherapy Discontinued|0
6166339|NCT01218516|9810139|FG003|Combination Therapy (up to 4.5 Months)|Chemotherapy Discontinued|0
6166340|NCT01218516|9810136|FG000|Combination Therapy (up to 4.5 Months)|Progressive Disease (PD) by RECIST v 1.1|17
6166341|NCT01218516|9810137|FG001|Combination Therapy (up to 4.5 Months)|Progressive Disease (PD) by RECIST v 1.1|15
6166342|NCT01218516|9810138|FG002|Combination Therapy (up to 4.5 Months)|Progressive Disease (PD) by RECIST v 1.1|0
6166343|NCT01218516|9810139|FG003|Combination Therapy (up to 4.5 Months)|Progressive Disease (PD) by RECIST v 1.1|0
6166344|NCT01218516|9810136|FG000|Combination Therapy (up to 4.5 Months)|Randomized but Not Treated|0
6166345|NCT01218516|9810137|FG001|Combination Therapy (up to 4.5 Months)|Randomized but Not Treated|1
6166346|NCT01218516|9810138|FG002|Combination Therapy (up to 4.5 Months)|Randomized but Not Treated|0
6166347|NCT01218516|9810139|FG003|Combination Therapy (up to 4.5 Months)|Randomized but Not Treated|0
6166348|NCT01218516|9810136|FG000|Combination Therapy (up to 4.5 Months)|Withdrew Consent|0
6166349|NCT01218516|9810137|FG001|Combination Therapy (up to 4.5 Months)|Withdrew Consent|1
6166350|NCT01218516|9810138|FG002|Combination Therapy (up to 4.5 Months)|Withdrew Consent|0
6166351|NCT01218516|9810139|FG003|Combination Therapy (up to 4.5 Months)|Withdrew Consent|0
6166352|NCT01218516|9810136|FG000|Combination Therapy (up to 4.5 Months)|Deterioration of Performance Status|0
6166353|NCT01218516|9810137|FG001|Combination Therapy (up to 4.5 Months)|Deterioration of Performance Status|3
6166354|NCT01218516|9810138|FG002|Combination Therapy (up to 4.5 Months)|Deterioration of Performance Status|0
6166355|NCT01218516|9810139|FG003|Combination Therapy (up to 4.5 Months)|Deterioration of Performance Status|0
6166356|NCT01218516|9810136|FG000|Combination Therapy (up to 4.5 Months)|Other|3
6166357|NCT01218516|9810137|FG001|Combination Therapy (up to 4.5 Months)|Other|4
6166358|NCT01218516|9810138|FG002|Combination Therapy (up to 4.5 Months)|Other|0
6166359|NCT01218516|9810139|FG003|Combination Therapy (up to 4.5 Months)|Other|0
6166360|NCT01218516|9810136|FG000|Combination Therapy (up to 4.5 Months)|Toxicity to TA|0
6166361|NCT01218516|9810137|FG001|Combination Therapy (up to 4.5 Months)|Toxicity to TA|1
6166362|NCT01218516|9810138|FG002|Combination Therapy (up to 4.5 Months)|Toxicity to TA|0
6166363|NCT01218516|9810139|FG003|Combination Therapy (up to 4.5 Months)|Toxicity to TA|0
6166364|NCT01218516|9810136|FG000|Combination Therapy (up to 4.5 Months)|Participant Discontinued Treatment|2
6327547|NCT02963922|10071155|FG000|Overall Study|Other|8
6327548|NCT02963922|10071156|FG001|Overall Study|Other|14
6327549|NCT02963935|10071164|FG000|Overall Study|Adverse Event|12
6327550|NCT02963935|10071165|FG001|Overall Study|Adverse Event|6
6327551|NCT02963935|10071164|FG000|Overall Study|Protocol Violation|2
6327552|NCT02963935|10071165|FG001|Overall Study|Protocol Violation|1
6327553|NCT02963935|10071164|FG000|Overall Study|Lack of Efficacy|0
6327554|NCT02963935|10071165|FG001|Overall Study|Lack of Efficacy|2
6327555|NCT02963935|10071164|FG000|Overall Study|Lost to Follow-up|1
6327556|NCT02963935|10071165|FG001|Overall Study|Lost to Follow-up|6
6327557|NCT02963935|10071164|FG000|Overall Study|Unclassified|13
6327558|NCT02963935|10071165|FG001|Overall Study|Unclassified|22
6327559|NCT02964234|10071186|FG000|Overall Study|Lost to Follow-up|22
6327560|NCT02964234|10071187|FG001|Overall Study|Lost to Follow-up|13
6327561|NCT02964247|10071195|FG000|Overall Study|Lost to Follow-up|2
6327562|NCT02964247|10071196|FG001|Overall Study|Lost to Follow-up|0
6327563|NCT02964247|10071195|FG000|Overall Study|Withdrawal by Subject|1
6327564|NCT02964247|10071196|FG001|Overall Study|Withdrawal by Subject|2
6327565|NCT02964312|10071202|FG000|Overall Study|Lost to Follow-up|28
6327566|NCT02964312|10071202|FG000|Overall Study|Withdrawal by Subject|11
6327567|NCT02964312|10071202|FG000|Overall Study|Lack of Efficacy|10
6327568|NCT02964312|10071202|FG000|Overall Study|Did not consent to long-term FU|14
6327569|NCT02964312|10071202|FG000|Overall Study|Death|1
6327570|NCT02964325|10071211|FG000|Overall Study|Lost to Follow-up|3
6327571|NCT02964325|10071212|FG001|Overall Study|Lost to Follow-up|3
6327572|NCT02964325|10071211|FG000|Overall Study|Physician Decision|5
6327573|NCT02964325|10071212|FG001|Overall Study|Physician Decision|4
6166365|NCT01218516|9810137|FG001|Combination Therapy (up to 4.5 Months)|Participant Discontinued Treatment|3
6166366|NCT01218516|9810138|FG002|Combination Therapy (up to 4.5 Months)|Participant Discontinued Treatment|0
6166367|NCT01218516|9810139|FG003|Combination Therapy (up to 4.5 Months)|Participant Discontinued Treatment|0
6166368|NCT01218516|9810136|FG000|Combination Therapy (up to 4.5 Months)|Treatment With Items Outside Protocol|1
6166369|NCT01218516|9810137|FG001|Combination Therapy (up to 4.5 Months)|Treatment With Items Outside Protocol|1
6327574|NCT02964325|10071211|FG000|Overall Study|Death|1
6327575|NCT02964325|10071212|FG001|Overall Study|Death|3
6327576|NCT02964325|10071211|FG000|Overall Study|Withdrawal by Subject|2
6327577|NCT02964325|10071212|FG001|Overall Study|Withdrawal by Subject|1
6166370|NCT01218516|9810138|FG002|Combination Therapy (up to 4.5 Months)|Treatment With Items Outside Protocol|0
6166371|NCT01218516|9810139|FG003|Combination Therapy (up to 4.5 Months)|Treatment With Items Outside Protocol|0
6166372|NCT01218594|9810154|FG000|Overall Study|Death|1
6166373|NCT01218594|9810154|FG000|Overall Study|Withdrawal by Subject|3
6166374|NCT01218594|9810154|FG000|Overall Study|Adverse Event|2
6166375|NCT01218594|9810154|FG000|Overall Study|Physician Decision|6
6166376|NCT01218646|9810162|FG000|Overall Study|Adverse Event|0
6166377|NCT01218646|9810163|FG001|Overall Study|Adverse Event|0
6166378|NCT01218646|9810164|FG002|Overall Study|Adverse Event|1
6166379|NCT01218646|9810165|FG003|Overall Study|Adverse Event|0
6166380|NCT01218646|9810162|FG000|Overall Study|Lost to Follow-up|1
6166381|NCT01218646|9810163|FG001|Overall Study|Lost to Follow-up|0
6166382|NCT01218646|9810164|FG002|Overall Study|Lost to Follow-up|0
6166383|NCT01218646|9810165|FG003|Overall Study|Lost to Follow-up|0
6166384|NCT01218646|9810162|FG000|Overall Study|Protocol Violation|0
6166385|NCT01218646|9810163|FG001|Overall Study|Protocol Violation|0
6166386|NCT01218646|9810164|FG002|Overall Study|Protocol Violation|1
6166387|NCT01218646|9810165|FG003|Overall Study|Protocol Violation|1
6166388|NCT01218659|9810177|FG000|18-Month Randomized Period|Withdrawal by Subject|2
6166389|NCT01218659|9810178|FG001|18-Month Randomized Period|Withdrawal by Subject|3
6166390|NCT01218659|9810179|FG002|18-Month Randomized Period|Withdrawal by Subject|0
6166391|NCT01218659|9810177|FG000|18-Month Randomized Period|Did not receive study drug|0
6166392|NCT01218659|9810178|FG001|18-Month Randomized Period|Did not receive study drug|3
6166393|NCT01218659|9810179|FG002|18-Month Randomized Period|Did not receive study drug|0
6166394|NCT01218659|9810177|FG000|12-Month OLE|Withdrawal by Subject|0
6166395|NCT01218659|9810178|FG001|12-Month OLE|Withdrawal by Subject|0
6166396|NCT01218659|9810179|FG002|12-Month OLE|Withdrawal by Subject|2
6166397|NCT01218659|9810177|FG000|12-Month OLE|Physician Decision|0
6166398|NCT01218659|9810178|FG001|12-Month OLE|Physician Decision|0
6166399|NCT01218659|9810179|FG002|12-Month OLE|Physician Decision|1
6166400|NCT01218659|9810177|FG000|12-Month OLE|Lost to Follow-up|0
6166401|NCT01218659|9810178|FG001|12-Month OLE|Lost to Follow-up|0
6166402|NCT01218659|9810179|FG002|12-Month OLE|Lost to Follow-up|1
6166403|NCT01218659|9810177|FG000|12-Month OLE|Pregnancy|0
6082639|NCT00630812|9690734|FG001|Double Blind Treatment Period|Non-compliance|1
6082640|NCT00630825|9690744|FG000|Overall Study|Adverse Event|4
6082641|NCT00630825|9690745|FG001|Overall Study|Adverse Event|4
6082642|NCT00630825|9690746|FG002|Overall Study|Adverse Event|3
6166404|NCT01218659|9810178|FG001|12-Month OLE|Pregnancy|0
6166405|NCT01218659|9810179|FG002|12-Month OLE|Pregnancy|1
6166406|NCT01218659|9810177|FG000|12-Month OLE|Lack of Efficacy|0
6166407|NCT01218659|9810178|FG001|12-Month OLE|Lack of Efficacy|0
6166408|NCT01218659|9810179|FG002|12-Month OLE|Lack of Efficacy|1
6166409|NCT01218659|9810177|FG000|12-Month OLE|Declined to participate in the OLE|0
6166410|NCT01218659|9810178|FG001|12-Month OLE|Declined to participate in the OLE|0
6166411|NCT01218659|9810179|FG002|12-Month OLE|Declined to participate in the OLE|4
6166412|NCT01218802|9810199|FG000|Overall Study|Lost to Follow-up|5
6166413|NCT01218802|9810200|FG001|Overall Study|Lost to Follow-up|6
6166414|NCT01218802|9810199|FG000|Overall Study|Withdrawal by Subject|3
6166415|NCT01218802|9810200|FG001|Overall Study|Withdrawal by Subject|10
6166416|NCT01218802|9810199|FG000|Overall Study|Adverse Event|0
6166417|NCT01218802|9810200|FG001|Overall Study|Adverse Event|2
6166418|NCT01218802|9810199|FG000|Overall Study|Incarcerated|2
6166419|NCT01218802|9810200|FG001|Overall Study|Incarcerated|0
6166420|NCT01218867|9810217|FG000|Overall Study|Death during treatment|0
6166421|NCT01218867|9810218|FG001|Overall Study|Death during treatment|0
6166422|NCT01218867|9810219|FG002|Overall Study|Death during treatment|0
6166423|NCT01218867|9810220|FG003|Overall Study|Death during treatment|0
6166424|NCT01218867|9810221|FG004|Overall Study|Death during treatment|0
6166425|NCT01218867|9810222|FG005|Overall Study|Death during treatment|0
6166426|NCT01218867|9810223|FG006|Overall Study|Death during treatment|1
6166427|NCT01218867|9810224|FG007|Overall Study|Death during treatment|0
6166428|NCT01218867|9810225|FG008|Overall Study|Death during treatment|0
6166429|NCT01218867|9810226|FG009|Overall Study|Death during treatment|0
6166430|NCT01218867|9810227|FG010|Overall Study|Death during treatment|0
6192100|NCT01427933|9849149|FG001|Overall Study|Lost to Follow-up|5
6192101|NCT01427933|9849148|FG000|Overall Study|Other|1
6192102|NCT01427933|9849149|FG001|Overall Study|Other|0
6192103|NCT01427933|9849148|FG000|Overall Study|Investigator's Decision|1
6192104|NCT01427933|9849149|FG001|Overall Study|Investigator's Decision|0
6192105|NCT01427972|9849168|FG000|Treatment Period 1 (21 Days)|Protocol Violation|0
6192106|NCT01427972|9849169|FG001|Treatment Period 1 (21 Days)|Protocol Violation|0
6192107|NCT01427972|9849170|FG002|Treatment Period 1 (21 Days)|Protocol Violation|0
6192108|NCT01427972|9849171|FG003|Treatment Period 1 (21 Days)|Protocol Violation|0
6192109|NCT01427972|9849172|FG004|Treatment Period 1 (21 Days)|Protocol Violation|0
6192110|NCT01427972|9849173|FG005|Treatment Period 1 (21 Days)|Protocol Violation|0
6192111|NCT01427972|9849174|FG006|Treatment Period 1 (21 Days)|Protocol Violation|0
6192112|NCT01427972|9849175|FG007|Treatment Period 1 (21 Days)|Protocol Violation|1
6192113|NCT01427972|9849176|FG008|Treatment Period 1 (21 Days)|Protocol Violation|0
6082643|NCT00630825|9690747|FG003|Overall Study|Adverse Event|1
6192114|NCT01427972|9849177|FG009|Treatment Period 1 (21 Days)|Protocol Violation|0
6192115|NCT01427972|9849178|FG010|Treatment Period 1 (21 Days)|Protocol Violation|0
6166431|NCT01219933|9810357|FG000|Overall Study|Adverse Event|8
6166432|NCT01219933|9810357|FG000|Overall Study|No LDA reached|5
6166433|NCT01219933|9810357|FG000|Overall Study|No LDA maintained|7
6166434|NCT01219933|9810357|FG000|Overall Study|Lost to Follow-up|3
6166435|NCT01219933|9810357|FG000|Overall Study|GC free|1
6166436|NCT01219933|9810357|FG000|Overall Study|Withdrawal by Subject|5
6166437|NCT01219933|9810357|FG000|Overall Study|Protocol Violation|8
6327578|NCT02964325|10071211|FG000|Overall Study|Did not require PLT transfusion, had HLA positive|10
6327579|NCT02964325|10071212|FG001|Overall Study|Did not require PLT transfusion, had HLA positive|12
6327580|NCT02964338|10071221|FG000|Overall Study|Sponsor terminated study for futility|12
6327581|NCT02964338|10071222|FG001|Overall Study|Sponsor terminated study for futility|15
6327582|NCT02964338|10071223|FG002|Overall Study|Sponsor terminated study for futility|14
6327583|NCT02964338|10071221|FG000|Overall Study|Lack of Efficacy|0
6327584|NCT02964338|10071222|FG001|Overall Study|Lack of Efficacy|3
6327585|NCT02964338|10071223|FG002|Overall Study|Lack of Efficacy|0
6327586|NCT02964338|10071221|FG000|Overall Study|Lost to Follow-up|1
6327587|NCT02964338|10071222|FG001|Overall Study|Lost to Follow-up|0
6327588|NCT02964338|10071223|FG002|Overall Study|Lost to Follow-up|3
6327589|NCT02964338|10071221|FG000|Overall Study|Protocol Violation|0
6327590|NCT02964338|10071222|FG001|Overall Study|Protocol Violation|1
6327591|NCT02964338|10071223|FG002|Overall Study|Protocol Violation|0
6327592|NCT02964338|10071221|FG000|Overall Study|Withdrawal by Subject|1
6327593|NCT02964338|10071222|FG001|Overall Study|Withdrawal by Subject|3
6327594|NCT02964338|10071223|FG002|Overall Study|Withdrawal by Subject|1
6327595|NCT02964338|10071221|FG000|Overall Study|Adverse Event|2
6327596|NCT02964338|10071222|FG001|Overall Study|Adverse Event|1
6327597|NCT02964338|10071223|FG002|Overall Study|Adverse Event|1
6327598|NCT02964338|10071221|FG000|Overall Study|Non-compliant with e-diary|0
6327599|NCT02964338|10071222|FG001|Overall Study|Non-compliant with e-diary|1
6327600|NCT02964338|10071223|FG002|Overall Study|Non-compliant with e-diary|0
6327601|NCT02964338|10071221|FG000|Overall Study|Did not meet criteria|1
6327602|NCT02964338|10071222|FG001|Overall Study|Did not meet criteria|0
6327603|NCT02964338|10071223|FG002|Overall Study|Did not meet criteria|0
6327604|NCT02965378|10071271|FG000|Overall Study|Progression|16
6327605|NCT02965378|10071272|FG001|Overall Study|Progression|4
6327606|NCT02965378|10071271|FG000|Overall Study|Adverse Event|5
6327607|NCT02965378|10071272|FG001|Overall Study|Adverse Event|2
6327608|NCT02965378|10071271|FG000|Overall Study|Death|2
6327609|NCT02965378|10071272|FG001|Overall Study|Death|0
6327610|NCT02965378|10071271|FG000|Overall Study|Refusal|2
6327611|NCT02965378|10071272|FG001|Overall Study|Refusal|1
6327612|NCT02965378|10071271|FG000|Overall Study|Not protocol specified|0
6327613|NCT02965378|10071272|FG001|Overall Study|Not protocol specified|2
6327614|NCT02965456|10071280|FG000|Overall Study|Lost to Follow-up|40
6327615|NCT02965456|10071281|FG001|Overall Study|Lost to Follow-up|18
6327616|NCT02965456|10071280|FG000|Overall Study|Subject Request|22
6327617|NCT02965456|10071281|FG001|Overall Study|Subject Request|13
6327618|NCT02965456|10071280|FG000|Overall Study|Withdrawal by Parent or Guardian|3
6327619|NCT02965456|10071281|FG001|Overall Study|Withdrawal by Parent or Guardian|6
6327620|NCT02965456|10071280|FG000|Overall Study|Adverse Event|3
6327621|NCT02965456|10071281|FG001|Overall Study|Adverse Event|0
6166438|NCT01219933|9810357|FG000|Overall Study|Lack of Efficacy|1
6166439|NCT01219959|9810364|FG000|Overall Study|Adverse Event|6
6166440|NCT01219959|9810365|FG001|Overall Study|Adverse Event|14
6166441|NCT01219959|9810364|FG000|Overall Study|Physician Decision|0
6166442|NCT01219959|9810365|FG001|Overall Study|Physician Decision|4
6166443|NCT01219959|9810364|FG000|Overall Study|Withdrawal by Subject|0
6166444|NCT01219959|9810365|FG001|Overall Study|Withdrawal by Subject|2
6166445|NCT01219959|9810364|FG000|Overall Study|Renal Transplantation|0
6166446|NCT01219959|9810365|FG001|Overall Study|Renal Transplantation|3
6166447|NCT01219959|9810364|FG000|Overall Study|Other|1
6166448|NCT01219959|9810365|FG001|Overall Study|Other|0
6166449|NCT01219985|9810371|FG000|Overall Study|Physician Decision|20
6166450|NCT01220024|9810379|FG000|Overall Study|Lost to Follow-up|1
6166451|NCT01220024|9810380|FG001|Overall Study|Lost to Follow-up|1
6166452|NCT01220128|9810393|FG000|Overall Study|Progressive disease|0
6166453|NCT01220128|9810394|FG001|Overall Study|Progressive disease|0
6166454|NCT01220128|9810395|FG002|Overall Study|Progressive disease|2
6166455|NCT01220128|9810396|FG003|Overall Study|Progressive disease|0
6166456|NCT01220128|9810397|FG004|Overall Study|Progressive disease|0
6166457|NCT01220128|9810398|FG005|Overall Study|Progressive disease|0
6166458|NCT01220128|9810399|FG006|Overall Study|Progressive disease|0
6166459|NCT01220128|9810393|FG000|Overall Study|Sponsor study termination|0
6166460|NCT01220128|9810394|FG001|Overall Study|Sponsor study termination|1
6166461|NCT01220128|9810395|FG002|Overall Study|Sponsor study termination|0
6166462|NCT01220128|9810396|FG003|Overall Study|Sponsor study termination|0
6166463|NCT01220128|9810397|FG004|Overall Study|Sponsor study termination|0
6166464|NCT01220128|9810398|FG005|Overall Study|Sponsor study termination|0
6327622|NCT02965456|10071280|FG000|Overall Study|Noncompliance with Study Drug|1
6327623|NCT02965456|10071281|FG001|Overall Study|Noncompliance with Study Drug|1
6327624|NCT02965456|10071280|FG000|Overall Study|Worsening Condition|0
6327625|NCT02965456|10071281|FG001|Overall Study|Worsening Condition|2
6327626|NCT02965456|10071280|FG000|Overall Study|Lack of Efficacy|1
6327627|NCT02965456|10071281|FG001|Overall Study|Lack of Efficacy|0
6166465|NCT01220128|9810399|FG006|Overall Study|Sponsor study termination|1
6166466|NCT01220128|9810393|FG000|Overall Study|Adverse event, serious fatal|2
6166467|NCT01220128|9810394|FG001|Overall Study|Adverse event, serious fatal|0
6166468|NCT01220128|9810395|FG002|Overall Study|Adverse event, serious fatal|0
6166469|NCT01220128|9810396|FG003|Overall Study|Adverse event, serious fatal|0
6166470|NCT01220128|9810397|FG004|Overall Study|Adverse event, serious fatal|0
6166471|NCT01220128|9810398|FG005|Overall Study|Adverse event, serious fatal|0
6166472|NCT01220128|9810399|FG006|Overall Study|Adverse event, serious fatal|1
6166473|NCT01220128|9810393|FG000|Overall Study|Adverse event, non-fatal|1
6166474|NCT01220128|9810394|FG001|Overall Study|Adverse event, non-fatal|0
6166475|NCT01220128|9810395|FG002|Overall Study|Adverse event, non-fatal|0
6166476|NCT01220128|9810396|FG003|Overall Study|Adverse event, non-fatal|0
6166477|NCT01220128|9810397|FG004|Overall Study|Adverse event, non-fatal|0
6166478|NCT01220128|9810398|FG005|Overall Study|Adverse event, non-fatal|0
6166479|NCT01220128|9810399|FG006|Overall Study|Adverse event, non-fatal|3
6166480|NCT01220128|9810393|FG000|Overall Study|Other|0
6166481|NCT01220128|9810394|FG001|Overall Study|Other|0
6166482|NCT01220128|9810395|FG002|Overall Study|Other|1
6166483|NCT01220128|9810396|FG003|Overall Study|Other|0
6166484|NCT01220128|9810397|FG004|Overall Study|Other|0
6166485|NCT01220128|9810398|FG005|Overall Study|Other|0
6166486|NCT01220128|9810399|FG006|Overall Study|Other|0
6166487|NCT01220128|9810393|FG000|Overall Study|Consent withdrawn by subject|1
6166488|NCT01220128|9810394|FG001|Overall Study|Consent withdrawn by subject|0
6166489|NCT01220128|9810395|FG002|Overall Study|Consent withdrawn by subject|0
6166490|NCT01220128|9810396|FG003|Overall Study|Consent withdrawn by subject|0
6166491|NCT01220128|9810397|FG004|Overall Study|Consent withdrawn by subject|0
6166492|NCT01220128|9810398|FG005|Overall Study|Consent withdrawn by subject|0
6166493|NCT01220128|9810399|FG006|Overall Study|Consent withdrawn by subject|0
6166494|NCT01220167|9810419|FG000|Period 3|Urine positive for substance abuse|0
6166495|NCT01220167|9810420|FG001|Period 3|Urine positive for substance abuse|1
6166496|NCT01220167|9810421|FG002|Period 3|Urine positive for substance abuse|0
6166497|NCT01220180|9810430|FG000|Overall Study|Lost to Follow-up|76
6166498|NCT01220180|9810430|FG000|Overall Study|Other|72
6166499|NCT01220180|9810430|FG000|Overall Study|Adverse Event|35
6166500|NCT01220180|9810430|FG000|Overall Study|Lack of Efficacy|22
6166501|NCT01220180|9810430|FG000|Overall Study|Death|1
6166502|NCT01220180|9810430|FG000|Overall Study|Randomized but not treated|1
6166503|NCT01220297|9810436|FG000|Overall Study|Death|2
6166504|NCT01220297|9810436|FG000|Overall Study|Lost to Follow-up|1
6166505|NCT01220401|9810442|FG000|Overall Study|Withdrawal by Subject|2
6166506|NCT01220401|9810442|FG000|Overall Study|Protocol Violation|1
6166507|NCT01220414|9810448|FG000|Overall Study|Withdrawal by Subject|1
6166508|NCT01220414|9810449|FG001|Overall Study|Withdrawal by Subject|0
6166509|NCT01220414|9810450|FG002|Overall Study|Withdrawal by Subject|0
6166510|NCT01220414|9810451|FG003|Overall Study|Withdrawal by Subject|1
6166511|NCT01220557|9810473|FG000|Overall Study|Lost to Follow-up|5
6166512|NCT01220557|9810474|FG001|Overall Study|Lost to Follow-up|3
6166513|NCT01220557|9810473|FG000|Overall Study|attended less than 6 lessons|1
6166514|NCT01220557|9810474|FG001|Overall Study|attended less than 6 lessons|2
6166515|NCT01220609|9810480|FG000|Overall Study|Ineligible-Wrong primary cancer site|1
6166516|NCT01220609|9810480|FG000|Overall Study|Ineligible- Wrong cell type|1
6166517|NCT01220609|9810480|FG000|Overall Study|Ineligible-Never treated|1
6166518|NCT01220856|9810519|FG000|Overall Study|graft loss|3
6166519|NCT01220856|9810520|FG001|Overall Study|graft loss|3
6166520|NCT01220856|9810519|FG000|Overall Study|Lost to Follow-up|1
6166521|NCT01220856|9810520|FG001|Overall Study|Lost to Follow-up|0
6166522|NCT01220999|9810542|FG000|Overall Study|Progressive disease|0
6166523|NCT01220999|9810543|FG001|Overall Study|Progressive disease|0
6166524|NCT01220999|9810544|FG002|Overall Study|Progressive disease|1
6166525|NCT01220999|9810545|FG003|Overall Study|Progressive disease|0
6166526|NCT01220999|9810546|FG004|Overall Study|Progressive disease|0
6166527|NCT01221090|9810562|FG000|Overall Study|Non-Compliant or Unable to Contact|15
6166528|NCT01221090|9810563|FG001|Overall Study|Non-Compliant or Unable to Contact|12
6166529|NCT01221090|9810564|FG002|Overall Study|Non-Compliant or Unable to Contact|15
6082644|NCT00630825|9690744|FG000|Overall Study|Entry Criteria Not Met|1
6166530|NCT01221090|9810565|FG003|Overall Study|Non-Compliant or Unable to Contact|20
6166531|NCT01221090|9810562|FG000|Overall Study|Withdrawal by Subject|0
6166532|NCT01221090|9810563|FG001|Overall Study|Withdrawal by Subject|22
6166533|NCT01221090|9810564|FG002|Overall Study|Withdrawal by Subject|27
6227417|NCT01716754|9900110|FG002|Overall Study|Withdrawal by Subject|4
6166534|NCT01221090|9810565|FG003|Overall Study|Withdrawal by Subject|2
6166535|NCT01221181|9810575|FG000|Overall Study|Lost to Follow-up|1
6166536|NCT01221233|9810603|FG000|Overall Study|Withdrawal by Subject|3
6166537|NCT01221233|9810604|FG001|Overall Study|Withdrawal by Subject|1
6166538|NCT01221272|9810610|FG000|Period 1|Adverse Event|2
6166539|NCT01221272|9810611|FG001|Period 1|Adverse Event|0
6166540|NCT01221272|9810610|FG000|Period 1|Consent Withdrawal|0
6166541|NCT01221272|9810611|FG001|Period 1|Consent Withdrawal|1
6166542|NCT01221272|9810610|FG000|Period 1|Significant Dosing Noncompliance|0
6166543|NCT01221272|9810611|FG001|Period 1|Significant Dosing Noncompliance|1
6166544|NCT01221272|9810610|FG000|Period 2|Adverse Event|0
6166545|NCT01221272|9810611|FG001|Period 2|Adverse Event|2
6166546|NCT01221285|9810620|FG000|Overall Study|Withdrawal by Subject|1
6166547|NCT01221350|9810639|FG000|Overall Study|Discontinued intervention (GERD)|1
6166548|NCT01221350|9810640|FG001|Overall Study|Discontinued intervention (GERD)|0
6166549|NCT01221350|9810639|FG000|Overall Study|Exclusion criteria, asthma exacerbation|0
6166550|NCT01221350|9810640|FG001|Overall Study|Exclusion criteria, asthma exacerbation|1
6166551|NCT01221350|9810639|FG000|Overall Study|Withdrawal by Subject|4
6166552|NCT01221350|9810640|FG001|Overall Study|Withdrawal by Subject|2
6166553|NCT01221363|9810650|FG000|Overall Study|Pregnancy|1
6166554|NCT01221363|9810651|FG001|Overall Study|Pregnancy|0
6166555|NCT01221363|9810650|FG000|Overall Study|Withdrawal by Subject|11
6166556|NCT01221363|9810651|FG001|Overall Study|Withdrawal by Subject|5
6166557|NCT01221597|9810668|FG000|Overall Study|Adverse Event|4
6166558|NCT01221597|9810669|FG001|Overall Study|Adverse Event|1
6166559|NCT01221597|9810668|FG000|Overall Study|Withdrawal by Subject|20
6166560|NCT01221597|9810669|FG001|Overall Study|Withdrawal by Subject|6
6166561|NCT01221597|9810668|FG000|Overall Study|Lost to Follow-up|6
6166562|NCT01221597|9810669|FG001|Overall Study|Lost to Follow-up|5
6166563|NCT01221597|9810668|FG000|Overall Study|Protocol Violation|1
6166564|NCT01221597|9810669|FG001|Overall Study|Protocol Violation|0
6166565|NCT01221597|9810668|FG000|Overall Study|Other|3
6166566|NCT01221597|9810669|FG001|Overall Study|Other|4
6166567|NCT01221597|9810668|FG000|Overall Study|Death|2
6166568|NCT01221597|9810669|FG001|Overall Study|Death|0
6166569|NCT01221623|9810678|FG000|Overall Study|Withdrawal by Subject|19
6166570|NCT01221623|9810679|FG001|Overall Study|Withdrawal by Subject|8
6166571|NCT01221623|9810678|FG000|Overall Study|Lost to Follow-up|7
6166572|NCT01221623|9810679|FG001|Overall Study|Lost to Follow-up|1
6166573|NCT01221623|9810678|FG000|Overall Study|Adverse Event|6
6166574|NCT01221623|9810679|FG001|Overall Study|Adverse Event|3
6166575|NCT01221623|9810678|FG000|Overall Study|Death|1
6166576|NCT01221623|9810679|FG001|Overall Study|Death|0
6166577|NCT01221623|9810678|FG000|Overall Study|Other|5
6166578|NCT01221623|9810679|FG001|Overall Study|Other|2
6166579|NCT01221727|9810687|FG000|Overall Study|Physician Decision|2
6166580|NCT01221727|9810688|FG001|Overall Study|Physician Decision|0
6166581|NCT01221727|9810687|FG000|Overall Study|Withdrawal by Subject|1
6166582|NCT01221727|9810688|FG001|Overall Study|Withdrawal by Subject|1
6166583|NCT01221753|9810700|FG000|Overall Study|Adverse Event|1
6166584|NCT01221948|9810712|FG000|Overall Study|Physician Decision|5
6166585|NCT01221948|9810712|FG000|Overall Study|Withdrawal by Subject|2
6166586|NCT01221948|9810712|FG000|Overall Study|not disclosed|2
6166587|NCT01221948|9810712|FG000|Overall Study|Death|1
6166588|NCT01221948|9810712|FG000|Overall Study|Protocol Violation|4
6166589|NCT01222078|9810716|FG000|Overall Study|Early termination of the study|1
6166590|NCT01222104|9810728|FG000|Overall Study|Lost to Follow-up|37
6166591|NCT01222104|9810728|FG000|Overall Study|Death|10
6166592|NCT01222403|9810841|FG000|Overall Study|Inappropriate enrollment|0
6166593|NCT01222403|9810842|FG001|Overall Study|Inappropriate enrollment|2
6166594|NCT01222416|9810850|FG000|Overall Study|ineligible;metastasis|3
6166595|NCT01222416|9810851|FG001|Overall Study|ineligible;metastasis|0
6166596|NCT01222416|9810850|FG000|Overall Study|Adverse Event|4
6166597|NCT01222416|9810851|FG001|Overall Study|Adverse Event|0
6166598|NCT01222416|9810850|FG000|Overall Study|Withdrawal by Subject|5
6166599|NCT01222416|9810851|FG001|Overall Study|Withdrawal by Subject|0
6166600|NCT01222416|9810850|FG000|Overall Study|scheduling|6
6166601|NCT01222416|9810851|FG001|Overall Study|scheduling|0
6166602|NCT01222416|9810850|FG000|Overall Study|missed view/scan|1
6166603|NCT01222416|9810851|FG001|Overall Study|missed view/scan|0
6166604|NCT01222416|9810850|FG000|Overall Study|Death|1
6166605|NCT01222416|9810851|FG001|Overall Study|Death|0
6166606|NCT01222507|9810870|FG000|Overall Study|Physician Decision|1
6166607|NCT01222507|9810870|FG000|Overall Study|Withdrawal by Subject|1
6166608|NCT01222520|9810876|FG000|Open-label run-in Period|Withdrawal by Subject|0
6166609|NCT01222520|9810877|FG001|Open-label run-in Period|Withdrawal by Subject|2
6166610|NCT01222520|9810876|FG000|Open-label run-in Period|Blood pressure criteria not met|0
6166611|NCT01222520|9810877|FG001|Open-label run-in Period|Blood pressure criteria not met|18
6166612|NCT01222520|9810876|FG000|Open-label run-in Period|Number of patients fulfilled|0
6166613|NCT01222520|9810877|FG001|Open-label run-in Period|Number of patients fulfilled|3
6166614|NCT01222520|9810876|FG000|Double-blind Period|Adverse Event|0
6166615|NCT01222520|9810877|FG001|Double-blind Period|Adverse Event|1
6166616|NCT01222520|9810876|FG000|Double-blind Period|Lack of Efficacy|0
6166617|NCT01222520|9810877|FG001|Double-blind Period|Lack of Efficacy|1
6166618|NCT01222520|9810876|FG000|Double-blind Period|Study medication stolen|1
6166619|NCT01222520|9810877|FG001|Double-blind Period|Study medication stolen|0
6166620|NCT01222533|9810883|FG000|Overall Study|Adverse Event|5
6166621|NCT01222533|9810883|FG000|Overall Study|Withdrawal by Subject|5
6166622|NCT01222533|9810883|FG000|Overall Study|Other|4
6166623|NCT01222715|9810911|FG000|Overall Study|Adverse Event|0
6166624|NCT01222715|9810912|FG001|Overall Study|Adverse Event|4
6166625|NCT01222715|9810911|FG000|Overall Study|Death|0
6166626|NCT01222715|9810912|FG001|Overall Study|Death|1
6166627|NCT01222715|9810911|FG000|Overall Study|Lack of Efficacy|22
6166628|NCT01222715|9810912|FG001|Overall Study|Lack of Efficacy|14
6166629|NCT01222715|9810911|FG000|Overall Study|Physician Decision|12
6166630|NCT01222715|9810912|FG001|Overall Study|Physician Decision|2
6166631|NCT01222715|9810911|FG000|Overall Study|Refusal of further protocol therapy|0
6166632|NCT01222715|9810912|FG001|Overall Study|Refusal of further protocol therapy|4
6166633|NCT01222715|9810911|FG000|Overall Study|Pt cannot receive treatment for >9 wks|1
6166634|NCT01222715|9810912|FG001|Overall Study|Pt cannot receive treatment for >9 wks|1
6166635|NCT01222715|9810911|FG000|Overall Study|Ineligible|0
6166636|NCT01222715|9810912|FG001|Overall Study|Ineligible|1
6166637|NCT01222715|9810911|FG000|Overall Study|Surgery or radiation therapy in 1st 6 wk|1
6166638|NCT01222715|9810912|FG001|Overall Study|Surgery or radiation therapy in 1st 6 wk|0
6166639|NCT01222767|9810918|FG000|Overall Study|Progressive disease|13
6166640|NCT01222767|9810918|FG000|Overall Study|Adverse Event|2
6166641|NCT01222767|9810918|FG000|Overall Study|Surgical resection|1
6166642|NCT01222767|9810918|FG000|Overall Study|Never treated|1
6166643|NCT01223027|9810942|FG000|Overall Study|Adverse Event|20
6166644|NCT01223027|9810943|FG001|Overall Study|Adverse Event|10
6166645|NCT01223027|9810942|FG000|Overall Study|Death|42
6166646|NCT01223027|9810943|FG001|Overall Study|Death|42
6327628|NCT02965456|10071280|FG000|Overall Study|Physician Decision|0
6327629|NCT02965456|10071281|FG001|Overall Study|Physician Decision|1
6327630|NCT02965456|10071280|FG000|Overall Study|Pregnancy|1
6327631|NCT02965456|10071281|FG001|Overall Study|Pregnancy|0
6327632|NCT02965456|10071280|FG000|Overall Study|Protocol Violation|0
6327633|NCT02965456|10071281|FG001|Overall Study|Protocol Violation|1
6327634|NCT02965456|10071280|FG000|Overall Study|Participant ran out of study drug|0
6327635|NCT02965456|10071281|FG001|Overall Study|Participant ran out of study drug|1
6327636|NCT02965573|10071297|FG000|Overall Study|Lack of Efficacy|1
6327637|NCT02965573|10071298|FG001|Overall Study|Lack of Efficacy|0
6327638|NCT02965599|10071306|FG000|Overall Study|Protocol-defined stop criteria reached|1
6327639|NCT02965599|10071307|FG001|Overall Study|Protocol-defined stop criteria reached|0
6327640|NCT02965820|10071327|FG000|Period 2, Second 30 Days|Adverse Event|1
6327641|NCT02965820|10071328|FG001|Period 2, Second 30 Days|Adverse Event|1
6327642|NCT02965833|10071334|FG000|Period 1, First 30 Days of Wear|Adverse Event|0
6327643|NCT02965833|10071335|FG001|Period 1, First 30 Days of Wear|Adverse Event|1
6327644|NCT02965833|10071334|FG000|Period 1, First 30 Days of Wear|Lost to Follow-up|1
6327645|NCT02965833|10071335|FG001|Period 1, First 30 Days of Wear|Lost to Follow-up|1
6327646|NCT02965833|10071334|FG000|Period 1, First 30 Days of Wear|Protocol Violation|1
6327647|NCT02965833|10071335|FG001|Period 1, First 30 Days of Wear|Protocol Violation|0
6327648|NCT02965833|10071334|FG000|Period 1, First 30 Days of Wear|Withdrawal by Subject|1
6327649|NCT02965833|10071335|FG001|Period 1, First 30 Days of Wear|Withdrawal by Subject|0
6327650|NCT02965833|10071334|FG000|Period 2, Second 30 Days of Wear|Protocol Violation|2
6327651|NCT02965833|10071335|FG001|Period 2, Second 30 Days of Wear|Protocol Violation|0
6327652|NCT02966002|10071360|FG000|Overall Study|Withdrawal by Subject|2
6327653|NCT02966002|10071360|FG000|Overall Study|Adverse Event|1
6327654|NCT02966002|10071360|FG000|Overall Study|Lost to Follow-up|1
6327655|NCT02966015|10071366|FG000|Inclusion Visit|did not answer questionnaire|8
6327656|NCT02966015|10071367|FG001|Inclusion Visit|did not answer questionnaire|3
6327657|NCT02966028|10071376|FG000|Overall Study|Adverse Event|7
6327658|NCT02966028|10071377|FG001|Overall Study|Adverse Event|13
6327659|NCT02966028|10071378|FG002|Overall Study|Adverse Event|10
6327660|NCT02966028|10071376|FG000|Overall Study|Physician Decision|1
6327661|NCT02966028|10071377|FG001|Overall Study|Physician Decision|0
6327662|NCT02966028|10071378|FG002|Overall Study|Physician Decision|2
6327663|NCT02966028|10071376|FG000|Overall Study|Withdrawal by Subject|7
6166647|NCT01223027|9810942|FG000|Overall Study|Lost to Follow-up|2
6166648|NCT01223027|9810943|FG001|Overall Study|Lost to Follow-up|1
6166649|NCT01223027|9810942|FG000|Overall Study|Physician Decision|4
6166650|NCT01223027|9810943|FG001|Overall Study|Physician Decision|8
6166651|NCT01223027|9810942|FG000|Overall Study|Progressive Disease|167
6166652|NCT01223027|9810943|FG001|Overall Study|Progressive Disease|183
6166653|NCT01223027|9810942|FG000|Overall Study|Protocol Violation|2
6166654|NCT01223027|9810943|FG001|Overall Study|Protocol Violation|1
6166655|NCT01223027|9810942|FG000|Overall Study|Subject/guardian decicion|18
6166656|NCT01223027|9810943|FG001|Overall Study|Subject/guardian decicion|16
6166657|NCT01223027|9810942|FG000|Overall Study|New therapy for study indication|17
6166658|NCT01223027|9810943|FG001|Overall Study|New therapy for study indication|8
6166659|NCT01223027|9810942|FG000|Overall Study|Study terminated by sponsor|2
6166660|NCT01223027|9810943|FG001|Overall Study|Study terminated by sponsor|8
6166661|NCT01223183|9810951|FG000|Imaging Day 1|Physician Decision|0
6166662|NCT01223183|9810952|FG001|Imaging Day 1|Physician Decision|1
6166663|NCT01223183|9810951|FG000|Washout Period (5-24 Days)|Lost to Follow-up|1
6166664|NCT01223183|9810952|FG001|Washout Period (5-24 Days)|Lost to Follow-up|0
6166665|NCT01223183|9810951|FG000|Washout Period (5-24 Days)|Physician Decision|1
6166666|NCT01223183|9810952|FG001|Washout Period (5-24 Days)|Physician Decision|0
6166667|NCT01223196|9810961|FG000|Overall Study|Lost to Follow-up|2
6166668|NCT01223196|9810962|FG001|Overall Study|Lost to Follow-up|0
6166669|NCT01223196|9810961|FG000|Overall Study|Physician Decision|1
6166670|NCT01223196|9810962|FG001|Overall Study|Physician Decision|0
6327664|NCT02966028|10071377|FG001|Overall Study|Withdrawal by Subject|5
6166671|NCT01223196|9810961|FG000|Overall Study|Withdrawal by Subject|1
6166672|NCT01223196|9810962|FG001|Overall Study|Withdrawal by Subject|0
6166673|NCT01223235|9810970|FG000|Overall Study|Withdrawal by Subject|1
6193362|NCT01437540|9851006|FG000|Overall Study|Adverse Event|26
6166674|NCT01223365|9810989|FG000|Open-label Titration Period|Enrolled but not treated|1
6166675|NCT01223365|9810989|FG000|Open-label Titration Period|Adverse Event|23
6166676|NCT01223365|9810989|FG000|Open-label Titration Period|Lack of Efficacy|3
6166677|NCT01223365|9810989|FG000|Open-label Titration Period|Withdrawal by Subject|5
6166678|NCT01223365|9810989|FG000|Open-label Titration Period|Protocol Violation|1
6166679|NCT01223365|9810989|FG000|Open-label Titration Period|Lost to Follow-up|2
6166680|NCT01223365|9810989|FG000|Open-label Titration Period|Noncompliance with study drug admin|1
6166681|NCT01223365|9810989|FG000|Open-label Titration Period|Noncompliance with study procedures|2
6166682|NCT01223365|9810989|FG000|Open-label Titration Period|Starting physical therapy|1
6166683|NCT01223365|9810989|FG000|Open-label Treatment Period|Adverse Event|39
6166684|NCT01223365|9810989|FG000|Open-label Treatment Period|Lack of Efficacy|2
6166685|NCT01223365|9810989|FG000|Open-label Treatment Period|Withdrawal by Subject|19
6166686|NCT01223365|9810989|FG000|Open-label Treatment Period|Protocol Violation|15
6166687|NCT01223365|9810989|FG000|Open-label Treatment Period|Lost to Follow-up|7
6166688|NCT01223365|9810989|FG000|Open-label Treatment Period|Noncompliance with study drug admin|7
6166689|NCT01223365|9810989|FG000|Open-label Treatment Period|Noncompliance with study procedures|6
6166690|NCT01223365|9810989|FG000|Open-label Treatment Period|Moved out of area|2
6166691|NCT01223365|9810989|FG000|Open-label Treatment Period|Negative urine drug screen when on treat|1
6166692|NCT01223365|9810989|FG000|Open-label Treatment Period|"Out of window"|1
6166693|NCT01223365|9810989|FG000|Open-label Treatment Period|Starting physical therapy|1
6166694|NCT01223365|9810989|FG000|Open-label Treatment Period|Physician Decision|2
6166695|NCT01223404|9811019|FG000|First Intervention (1 Day)|Adverse Event|0
6166696|NCT01223404|9811020|FG001|First Intervention (1 Day)|Adverse Event|0
6166697|NCT01223404|9811021|FG002|First Intervention (1 Day)|Adverse Event|0
6166698|NCT01223404|9811022|FG003|First Intervention (1 Day)|Adverse Event|1
6166699|NCT01223404|9811023|FG004|First Intervention (1 Day)|Adverse Event|0
6166700|NCT01223404|9811024|FG005|First Intervention (1 Day)|Adverse Event|0
6166701|NCT01223404|9811019|FG000|Second Intervention (1 Day)|Adverse Event|1
6166702|NCT01223404|9811020|FG001|Second Intervention (1 Day)|Adverse Event|0
6166703|NCT01223404|9811021|FG002|Second Intervention (1 Day)|Adverse Event|0
6166704|NCT01223404|9811022|FG003|Second Intervention (1 Day)|Adverse Event|0
6166705|NCT01223404|9811023|FG004|Second Intervention (1 Day)|Adverse Event|0
6166706|NCT01223404|9811024|FG005|Second Intervention (1 Day)|Adverse Event|0
6166707|NCT01223404|9811019|FG000|Third Intervention (1 Day)|Non-compliance (slept)|0
6166708|NCT01223404|9811020|FG001|Third Intervention (1 Day)|Non-compliance (slept)|0
6166709|NCT01223404|9811021|FG002|Third Intervention (1 Day)|Non-compliance (slept)|0
6166710|NCT01223404|9811022|FG003|Third Intervention (1 Day)|Non-compliance (slept)|1
6166711|NCT01223404|9811023|FG004|Third Intervention (1 Day)|Non-compliance (slept)|0
6166712|NCT01223404|9811024|FG005|Third Intervention (1 Day)|Non-compliance (slept)|0
6166713|NCT01223937|9811060|FG000|Overall Study|Withdrawal by Subject|3
6166714|NCT01223937|9811061|FG001|Overall Study|Withdrawal by Subject|2
6166715|NCT01223937|9811060|FG000|Overall Study|Lost to Follow-up|1
6166716|NCT01223937|9811061|FG001|Overall Study|Lost to Follow-up|4
6166717|NCT01223937|9811060|FG000|Overall Study|Adverse Event|1
6166718|NCT01223937|9811061|FG001|Overall Study|Adverse Event|4
6166719|NCT01223937|9811060|FG000|Overall Study|Protocol Violation|8
6166720|NCT01223937|9811061|FG001|Overall Study|Protocol Violation|7
6166721|NCT01223937|9811060|FG000|Overall Study|Other|4
6166722|NCT01223937|9811061|FG001|Overall Study|Other|1
6166723|NCT01224158|9811092|FG000|Overall Study|Withdrawal by Subject|1
6166724|NCT01224158|9811093|FG001|Overall Study|Withdrawal by Subject|0
6166725|NCT01224171|9811101|FG000|Overall Study|Adverse Event|8
6166726|NCT01224171|9811102|FG001|Overall Study|Adverse Event|4
6166727|NCT01224171|9811101|FG000|Overall Study|Protocol Violation|0
6166728|NCT01224171|9811102|FG001|Overall Study|Protocol Violation|1
6166729|NCT01224171|9811101|FG000|Overall Study|Lack of Efficacy|5
6166730|NCT01224171|9811102|FG001|Overall Study|Lack of Efficacy|1
6166731|NCT01224171|9811101|FG000|Overall Study|Withdrawal of Consent|2
6166732|NCT01224171|9811102|FG001|Overall Study|Withdrawal of Consent|4
6166733|NCT01224171|9811101|FG000|Overall Study|Lost to Follow-up|0
6166734|NCT01224171|9811102|FG001|Overall Study|Lost to Follow-up|3
6166735|NCT01224431|9811124|FG000|Overall Study|not randomized|0
6166736|NCT01224431|9811125|FG001|Overall Study|not randomized|4
6166737|NCT01224431|9811124|FG000|Overall Study|no video record|0
6082645|NCT00630825|9690745|FG001|Overall Study|Entry Criteria Not Met|0
6082646|NCT00630825|9690746|FG002|Overall Study|Entry Criteria Not Met|2
6082647|NCT00630825|9690747|FG003|Overall Study|Entry Criteria Not Met|1
6082648|NCT00630825|9690744|FG000|Overall Study|Lost to Follow-up|1
6082649|NCT00630825|9690745|FG001|Overall Study|Lost to Follow-up|1
6082650|NCT00630825|9690746|FG002|Overall Study|Lost to Follow-up|1
6082651|NCT00630825|9690747|FG003|Overall Study|Lost to Follow-up|1
6082652|NCT00630825|9690744|FG000|Overall Study|Physician Decision|1
6166738|NCT01224431|9811125|FG001|Overall Study|no video record|1
6166739|NCT01224639|9811149|FG000|Overall Study|Withdrawal by Subject|0
6166740|NCT01224639|9811150|FG001|Overall Study|Withdrawal by Subject|0
6166741|NCT01224639|9811151|FG002|Overall Study|Withdrawal by Subject|0
6166742|NCT01224639|9811152|FG003|Overall Study|Withdrawal by Subject|0
6166743|NCT01224639|9811153|FG004|Overall Study|Withdrawal by Subject|2
6166744|NCT01224639|9811154|FG005|Overall Study|Withdrawal by Subject|0
6166745|NCT01224639|9811155|FG006|Overall Study|Withdrawal by Subject|1
6166746|NCT01224639|9811156|FG007|Overall Study|Withdrawal by Subject|1
6166747|NCT01224639|9811149|FG000|Overall Study|Adverse Event|0
6166748|NCT01224639|9811150|FG001|Overall Study|Adverse Event|0
6166749|NCT01224639|9811151|FG002|Overall Study|Adverse Event|0
6166750|NCT01224639|9811152|FG003|Overall Study|Adverse Event|0
6166751|NCT01224639|9811153|FG004|Overall Study|Adverse Event|0
6166752|NCT01224639|9811154|FG005|Overall Study|Adverse Event|0
6166753|NCT01224639|9811155|FG006|Overall Study|Adverse Event|0
6166754|NCT01224639|9811156|FG007|Overall Study|Adverse Event|1
6166755|NCT01224782|9811183|FG000|Overall Study|Lost to Follow-up|177
6166756|NCT01224782|9811183|FG000|Overall Study|Withdrawal by Subject|16
6166757|NCT01224782|9811183|FG000|Overall Study|Death|14
6166758|NCT01224782|9811183|FG000|Overall Study|Improvement|13
6166759|NCT01224782|9811183|FG000|Overall Study|Adverse Event|12
6166760|NCT01224782|9811183|FG000|Overall Study|Adverse Reaction|11
6166761|NCT01224782|9811183|FG000|Overall Study|Noncompliance|10
6166762|NCT01224782|9811183|FG000|Overall Study|Other|4
6166763|NCT01224782|9811183|FG000|Overall Study|Start of Dialysis|3
6166764|NCT01224782|9811183|FG000|Overall Study|Change of Treatment|1
6166765|NCT01224782|9811183|FG000|Overall Study|Financial Reasons|1
6166766|NCT01224782|9811183|FG000|Overall Study|Deterioration|1
6166767|NCT01224782|9811183|FG000|Overall Study|Transplantation|1
6166768|NCT01224821|9811187|FG000|Dosimetric and Therapeutic Treatment|Adverse Event|1
6166769|NCT01224821|9811187|FG000|Dosimetric and Therapeutic Treatment|Progressive Disease|38
6166770|NCT01224821|9811187|FG000|Dosimetric and Therapeutic Treatment|Continued Follow-up in Study BEX104526|3
6166771|NCT01224821|9811187|FG000|Dosimetric and Therapeutic Treatment|Lost to Follow-up|2
6166772|NCT01224821|9811187|FG000|Dosimetric and Therapeutic Treatment|Withdrawal by Subject|1
6166773|NCT01224821|9811187|FG000|Dosimetric and Therapeutic Treatment|Started Other Treatment|1
6166774|NCT01224821|9811187|FG000|Long-Term Follow-Up|Death|2
6166775|NCT01224821|9811187|FG000|Long-Term Follow-Up|Completion of 10 Year Follow-up|9
6166776|NCT01224925|9811193|FG000|Overall Study|Lost to Follow-up|3
6166777|NCT01224925|9811194|FG001|Overall Study|Lost to Follow-up|2
6166778|NCT01225146|9811235|FG000|Overall Study|Sponsor discontinued making 2mg drug|0
6166779|NCT01225146|9811236|FG001|Overall Study|Sponsor discontinued making 2mg drug|2
6192116|NCT01427972|9849179|FG011|Treatment Period 1 (21 Days)|Protocol Violation|0
6192117|NCT01427972|9849168|FG000|Washout (at Least 28 Days)|Withdrawal by Subject|0
6192118|NCT01427972|9849169|FG001|Washout (at Least 28 Days)|Withdrawal by Subject|0
6192119|NCT01427972|9849170|FG002|Washout (at Least 28 Days)|Withdrawal by Subject|0
6192120|NCT01427972|9849171|FG003|Washout (at Least 28 Days)|Withdrawal by Subject|0
6192121|NCT01427972|9849172|FG004|Washout (at Least 28 Days)|Withdrawal by Subject|0
6192122|NCT01427972|9849173|FG005|Washout (at Least 28 Days)|Withdrawal by Subject|2
6192123|NCT01427972|9849174|FG006|Washout (at Least 28 Days)|Withdrawal by Subject|0
6192124|NCT01427972|9849175|FG007|Washout (at Least 28 Days)|Withdrawal by Subject|0
6192125|NCT01427972|9849176|FG008|Washout (at Least 28 Days)|Withdrawal by Subject|0
6192126|NCT01427972|9849177|FG009|Washout (at Least 28 Days)|Withdrawal by Subject|0
6192127|NCT01427972|9849178|FG010|Washout (at Least 28 Days)|Withdrawal by Subject|0
6192128|NCT01427972|9849179|FG011|Washout (at Least 28 Days)|Withdrawal by Subject|0
6192129|NCT01427972|9849168|FG000|Treatment Period 2 (21 Days)|Withdrawal by Subject|0
6192130|NCT01427972|9849169|FG001|Treatment Period 2 (21 Days)|Withdrawal by Subject|1
6192131|NCT01427972|9849170|FG002|Treatment Period 2 (21 Days)|Withdrawal by Subject|0
6192132|NCT01427972|9849171|FG003|Treatment Period 2 (21 Days)|Withdrawal by Subject|0
6192133|NCT01427972|9849172|FG004|Treatment Period 2 (21 Days)|Withdrawal by Subject|0
6192134|NCT01427972|9849173|FG005|Treatment Period 2 (21 Days)|Withdrawal by Subject|0
6192135|NCT01427972|9849174|FG006|Treatment Period 2 (21 Days)|Withdrawal by Subject|0
6192136|NCT01427972|9849175|FG007|Treatment Period 2 (21 Days)|Withdrawal by Subject|0
6192137|NCT01427972|9849176|FG008|Treatment Period 2 (21 Days)|Withdrawal by Subject|0
6192138|NCT01427972|9849177|FG009|Treatment Period 2 (21 Days)|Withdrawal by Subject|0
6192139|NCT01427972|9849178|FG010|Treatment Period 2 (21 Days)|Withdrawal by Subject|0
6192140|NCT01427972|9849179|FG011|Treatment Period 2 (21 Days)|Withdrawal by Subject|0
6192141|NCT01428063|9849212|FG000|Overall Study|Lack of Efficacy|8
6192142|NCT01428063|9849213|FG001|Overall Study|Lack of Efficacy|4
6192143|NCT01428063|9849214|FG002|Overall Study|Lack of Efficacy|1
6192144|NCT01428063|9849212|FG000|Overall Study|Adverse Event|2
6192145|NCT01428063|9849213|FG001|Overall Study|Adverse Event|3
6192146|NCT01428063|9849214|FG002|Overall Study|Adverse Event|0
6192147|NCT01428063|9849212|FG000|Overall Study|Lost to Follow-up|0
6192148|NCT01428063|9849213|FG001|Overall Study|Lost to Follow-up|2
6192149|NCT01428063|9849214|FG002|Overall Study|Lost to Follow-up|0
6192150|NCT01428063|9849212|FG000|Overall Study|No longer meets study criteria|0
6192151|NCT01428063|9849213|FG001|Overall Study|No longer meets study criteria|1
6192152|NCT01428063|9849214|FG002|Overall Study|No longer meets study criteria|0
6192153|NCT01428076|9849235|FG000|Overall Study|Adverse Event|0
6192154|NCT01428076|9849236|FG001|Overall Study|Adverse Event|1
6192155|NCT01428115|9849244|FG000|Overall Study|Lack of Efficacy|3
6192156|NCT01428115|9849244|FG000|Overall Study|Lost to Follow-up|10
6192157|NCT01428115|9849244|FG000|Overall Study|Pregnancy|1
6192158|NCT01428115|9849244|FG000|Overall Study|Protocol Violation|3
6166780|NCT01225159|9811246|FG000|Overall Study|Change operation|1
6166781|NCT01225159|9811247|FG001|Overall Study|Change operation|0
6166782|NCT01225172|9811255|FG000|Overall Study|Subject decision to stop|1
6166783|NCT01225172|9811256|FG001|Overall Study|Subject decision to stop|0
6166784|NCT01225172|9811255|FG000|Overall Study|Subject request to discontinue treatment|3
6166785|NCT01225172|9811256|FG001|Overall Study|Subject request to discontinue treatment|1
6166786|NCT01225172|9811255|FG000|Overall Study|Subject no longer meets study criteria|1
6166787|NCT01225172|9811256|FG001|Overall Study|Subject no longer meets study criteria|0
6166788|NCT01225172|9811255|FG000|Overall Study|Withdrawal by Subject|1
6166789|NCT01225172|9811256|FG001|Overall Study|Withdrawal by Subject|0
6166790|NCT01225211|9811272|FG000|Overall Study|Adverse Event|0
6166791|NCT01225211|9811273|FG001|Overall Study|Adverse Event|0
6166792|NCT01225211|9811274|FG002|Overall Study|Adverse Event|1
6166793|NCT01225211|9811275|FG003|Overall Study|Adverse Event|0
6166794|NCT01225211|9811276|FG004|Overall Study|Adverse Event|0
6166795|NCT01225211|9811277|FG005|Overall Study|Adverse Event|0
6166796|NCT01225211|9811278|FG006|Overall Study|Adverse Event|0
6166797|NCT01225211|9811279|FG007|Overall Study|Adverse Event|0
6166798|NCT01225211|9811280|FG008|Overall Study|Adverse Event|0
6166799|NCT01225211|9811281|FG009|Overall Study|Adverse Event|1
6166800|NCT01225211|9811272|FG000|Overall Study|Withdrawal by Subject|0
6166801|NCT01225211|9811273|FG001|Overall Study|Withdrawal by Subject|0
6166802|NCT01225211|9811274|FG002|Overall Study|Withdrawal by Subject|0
6166803|NCT01225211|9811275|FG003|Overall Study|Withdrawal by Subject|0
6166804|NCT01225211|9811276|FG004|Overall Study|Withdrawal by Subject|0
6166805|NCT01225211|9811277|FG005|Overall Study|Withdrawal by Subject|0
6166806|NCT01225211|9811278|FG006|Overall Study|Withdrawal by Subject|1
6166807|NCT01225211|9811279|FG007|Overall Study|Withdrawal by Subject|0
6166808|NCT01225211|9811280|FG008|Overall Study|Withdrawal by Subject|1
6166809|NCT01225211|9811281|FG009|Overall Study|Withdrawal by Subject|3
6166810|NCT01225211|9811272|FG000|Overall Study|Other|0
6166811|NCT01225211|9811273|FG001|Overall Study|Other|0
6166812|NCT01225211|9811274|FG002|Overall Study|Other|0
6166813|NCT01225211|9811275|FG003|Overall Study|Other|0
6166814|NCT01225211|9811276|FG004|Overall Study|Other|0
6166815|NCT01225211|9811277|FG005|Overall Study|Other|0
6166816|NCT01225211|9811278|FG006|Overall Study|Other|0
6166817|NCT01225211|9811279|FG007|Overall Study|Other|0
6166818|NCT01225211|9811280|FG008|Overall Study|Other|0
6166819|NCT01225211|9811281|FG009|Overall Study|Other|1
6166820|NCT01225549|9811371|FG000|Period 4 - Washout|Disallowed medication|0
6166821|NCT01225549|9811372|FG001|Period 4 - Washout|Disallowed medication|1
6166822|NCT01225549|9811373|FG002|Period 4 - Washout|Disallowed medication|0
6166823|NCT01225549|9811374|FG003|Period 4 - Washout|Disallowed medication|0
6166824|NCT01225549|9811375|FG004|Period 4 - Washout|Disallowed medication|0
6166825|NCT01225549|9811376|FG005|Period 4 - Washout|Disallowed medication|0
6166826|NCT01225549|9811377|FG006|Period 4 - Washout|Disallowed medication|0
6166827|NCT01225549|9811378|FG007|Period 4 - Washout|Disallowed medication|0
6166828|NCT01225549|9811379|FG008|Period 4 - Washout|Disallowed medication|0
6166829|NCT01225549|9811380|FG009|Period 4 - Washout|Disallowed medication|0
6166830|NCT01225549|9811371|FG000|Period 6 - Washout|Disallowed medication|0
6166831|NCT01225549|9811372|FG001|Period 6 - Washout|Disallowed medication|0
6166832|NCT01225549|9811373|FG002|Period 6 - Washout|Disallowed medication|0
6166833|NCT01225549|9811374|FG003|Period 6 - Washout|Disallowed medication|1
6166834|NCT01225549|9811375|FG004|Period 6 - Washout|Disallowed medication|0
6166835|NCT01225549|9811376|FG005|Period 6 - Washout|Disallowed medication|0
6166836|NCT01225549|9811377|FG006|Period 6 - Washout|Disallowed medication|0
6166837|NCT01225549|9811378|FG007|Period 6 - Washout|Disallowed medication|0
6166838|NCT01225549|9811379|FG008|Period 6 - Washout|Disallowed medication|0
6166839|NCT01225549|9811380|FG009|Period 6 - Washout|Disallowed medication|0
6166840|NCT01225562|9811393|FG000|Overall Study|Withdrawal by Subject|52
6166841|NCT01225562|9811394|FG001|Overall Study|Withdrawal by Subject|50
6166842|NCT01225562|9811395|FG002|Overall Study|Withdrawal by Subject|52
6166843|NCT01225562|9811393|FG000|Overall Study|Lost to Follow-up|3
6166844|NCT01225562|9811394|FG001|Overall Study|Lost to Follow-up|6
6166845|NCT01225562|9811395|FG002|Overall Study|Lost to Follow-up|1
6166846|NCT01225731|9811408|FG000|Part 1|Did not meet eligibility criteria|1
6166847|NCT01225731|9811409|FG001|Part 1|Did not meet eligibility criteria|0
6166848|NCT01225731|9811410|FG002|Part 1|Did not meet eligibility criteria|0
6166849|NCT01225731|9811411|FG003|Part 1|Did not meet eligibility criteria|0
6166850|NCT01225731|9811412|FG004|Part 1|Did not meet eligibility criteria|1
6166851|NCT01225731|9811413|FG005|Part 1|Did not meet eligibility criteria|0
6166852|NCT01225731|9811414|FG006|Part 1|Did not meet eligibility criteria|0
6166853|NCT01225731|9811415|FG007|Part 1|Did not meet eligibility criteria|0
6166854|NCT01225731|9811416|FG008|Part 1|Did not meet eligibility criteria|0
6166855|NCT01225731|9811417|FG009|Part 1|Did not meet eligibility criteria|0
6166856|NCT01225731|9811418|FG010|Part 1|Did not meet eligibility criteria|0
6166857|NCT01225731|9811419|FG011|Part 1|Did not meet eligibility criteria|0
6166858|NCT01225731|9811420|FG012|Part 1|Did not meet eligibility criteria|0
6166859|NCT01225731|9811408|FG000|Part 1|Adverse Event|1
6166860|NCT01225731|9811409|FG001|Part 1|Adverse Event|2
6166861|NCT01225731|9811410|FG002|Part 1|Adverse Event|1
6166862|NCT01225731|9811411|FG003|Part 1|Adverse Event|1
6166863|NCT01225731|9811412|FG004|Part 1|Adverse Event|1
6166864|NCT01225731|9811413|FG005|Part 1|Adverse Event|0
6166865|NCT01225731|9811414|FG006|Part 1|Adverse Event|0
6166866|NCT01225731|9811415|FG007|Part 1|Adverse Event|0
6166867|NCT01225731|9811416|FG008|Part 1|Adverse Event|0
6166868|NCT01225731|9811417|FG009|Part 1|Adverse Event|0
6166869|NCT01225731|9811418|FG010|Part 1|Adverse Event|0
6166870|NCT01225731|9811419|FG011|Part 1|Adverse Event|0
6166871|NCT01225731|9811420|FG012|Part 1|Adverse Event|0
6166872|NCT01225731|9811408|FG000|Part 1|Withdrawal by Subject|0
6166873|NCT01225731|9811409|FG001|Part 1|Withdrawal by Subject|3
6166874|NCT01225731|9811410|FG002|Part 1|Withdrawal by Subject|0
6166875|NCT01225731|9811411|FG003|Part 1|Withdrawal by Subject|0
6166876|NCT01225731|9811412|FG004|Part 1|Withdrawal by Subject|4
6166877|NCT01225731|9811413|FG005|Part 1|Withdrawal by Subject|0
6166878|NCT01225731|9811414|FG006|Part 1|Withdrawal by Subject|0
6166879|NCT01225731|9811415|FG007|Part 1|Withdrawal by Subject|0
6166880|NCT01225731|9811416|FG008|Part 1|Withdrawal by Subject|0
6166881|NCT01225731|9811417|FG009|Part 1|Withdrawal by Subject|0
6166882|NCT01225731|9811418|FG010|Part 1|Withdrawal by Subject|0
6166883|NCT01225731|9811419|FG011|Part 1|Withdrawal by Subject|0
6166884|NCT01225731|9811420|FG012|Part 1|Withdrawal by Subject|0
6166885|NCT01225731|9811408|FG000|Part 1|Protocol Violation|0
6166886|NCT01225731|9811409|FG001|Part 1|Protocol Violation|0
6166887|NCT01225731|9811410|FG002|Part 1|Protocol Violation|0
6166888|NCT01225731|9811411|FG003|Part 1|Protocol Violation|1
6166889|NCT01225731|9811412|FG004|Part 1|Protocol Violation|0
6166890|NCT01225731|9811413|FG005|Part 1|Protocol Violation|0
6166891|NCT01225731|9811414|FG006|Part 1|Protocol Violation|0
6166892|NCT01225731|9811415|FG007|Part 1|Protocol Violation|0
6166893|NCT01225731|9811416|FG008|Part 1|Protocol Violation|0
6166894|NCT01225731|9811417|FG009|Part 1|Protocol Violation|0
6166895|NCT01225731|9811418|FG010|Part 1|Protocol Violation|0
6227418|NCT01716754|9900111|FG003|Overall Study|Withdrawal by Subject|3
6269560|NCT02141854|9969904|FG005|Run-In Period (Pre-assignment)|Randomization criteria not met|0
6269561|NCT02141854|9969899|FG000|Run-In Period (Pre-assignment)|Exclusion criteria met|14
6269562|NCT02141854|9969900|FG001|Run-In Period (Pre-assignment)|Exclusion criteria met|0
6269563|NCT02141854|9969901|FG002|Run-In Period (Pre-assignment)|Exclusion criteria met|0
6269564|NCT02141854|9969902|FG003|Run-In Period (Pre-assignment)|Exclusion criteria met|0
6269565|NCT02141854|9969903|FG004|Run-In Period (Pre-assignment)|Exclusion criteria met|0
6269566|NCT02141854|9969904|FG005|Run-In Period (Pre-assignment)|Exclusion criteria met|0
6269567|NCT02141854|9969899|FG000|Run-In Period (Pre-assignment)|Other|14
6269568|NCT02141854|9969900|FG001|Run-In Period (Pre-assignment)|Other|0
6269569|NCT02141854|9969901|FG002|Run-In Period (Pre-assignment)|Other|0
6269570|NCT02141854|9969902|FG003|Run-In Period (Pre-assignment)|Other|0
6327665|NCT02966028|10071378|FG002|Overall Study|Withdrawal by Subject|5
6327666|NCT02966028|10071376|FG000|Overall Study|Kidney transplant Changed dialysis units|9
6327667|NCT02966028|10071377|FG001|Overall Study|Kidney transplant Changed dialysis units|16
6327668|NCT02966028|10071378|FG002|Overall Study|Kidney transplant Changed dialysis units|14
6327669|NCT02966314|10071399|FG000|Overall Study|Lost to Follow-up|1
6327670|NCT02966314|10071400|FG001|Overall Study|Lost to Follow-up|0
6082653|NCT00630825|9690745|FG001|Overall Study|Physician Decision|0
6082654|NCT00630825|9690746|FG002|Overall Study|Physician Decision|0
6082655|NCT00630825|9690747|FG003|Overall Study|Physician Decision|0
6082656|NCT00630825|9690744|FG000|Overall Study|Withdrawal by Subject|2
6082657|NCT00630825|9690745|FG001|Overall Study|Withdrawal by Subject|2
6082658|NCT00630825|9690746|FG002|Overall Study|Withdrawal by Subject|2
6082659|NCT00630825|9690747|FG003|Overall Study|Withdrawal by Subject|3
6082660|NCT00630838|9690759|FG000|Overall Study|Death|0
6082661|NCT00630838|9690760|FG001|Overall Study|Death|1
6082662|NCT00630838|9690759|FG000|Overall Study|Lost to Follow-up|0
6082663|NCT00630838|9690760|FG001|Overall Study|Lost to Follow-up|1
6082664|NCT00630864|9690768|FG000|Part 1 (up to Week 6)|Adverse Event|1
6082665|NCT00630864|9690768|FG000|Part 2 (After Week 6 up to Month 12)|Liver transplant|2
6082666|NCT00630877|9690775|FG000|Overall Study|Adverse Event|11
6269571|NCT02141854|9969903|FG004|Run-In Period (Pre-assignment)|Other|0
6269572|NCT02141854|9969904|FG005|Run-In Period (Pre-assignment)|Other|0
6269573|NCT02141854|9969899|FG000|Run-In Period (Pre-assignment)|Adverse Event|10
6269574|NCT02141854|9969900|FG001|Run-In Period (Pre-assignment)|Adverse Event|0
6269575|NCT02141854|9969901|FG002|Run-In Period (Pre-assignment)|Adverse Event|0
6269576|NCT02141854|9969902|FG003|Run-In Period (Pre-assignment)|Adverse Event|0
6269577|NCT02141854|9969903|FG004|Run-In Period (Pre-assignment)|Adverse Event|0
6269578|NCT02141854|9969904|FG005|Run-In Period (Pre-assignment)|Adverse Event|0
6269579|NCT02141854|9969899|FG000|Run-In Period (Pre-assignment)|Withdrawal by Subject|9
6269580|NCT02141854|9969900|FG001|Run-In Period (Pre-assignment)|Withdrawal by Subject|0
6271923|NCT02169336|9974035|FG001|Overall Study|Physician Decision|0
6166896|NCT01225731|9811419|FG011|Part 1|Protocol Violation|0
6166897|NCT01225731|9811420|FG012|Part 1|Protocol Violation|0
6166898|NCT01225731|9811408|FG000|Part 2|Protocol Violation|0
6166899|NCT01225731|9811409|FG001|Part 2|Protocol Violation|0
6166900|NCT01225731|9811410|FG002|Part 2|Protocol Violation|0
6166901|NCT01225731|9811411|FG003|Part 2|Protocol Violation|0
6166902|NCT01225731|9811412|FG004|Part 2|Protocol Violation|0
6166903|NCT01225731|9811413|FG005|Part 2|Protocol Violation|1
6082667|NCT00630877|9690776|FG001|Overall Study|Adverse Event|8
6082668|NCT00630877|9690777|FG002|Overall Study|Adverse Event|7
6082669|NCT00630877|9690775|FG000|Overall Study|Withdrawal by Subject|3
6082670|NCT00630877|9690776|FG001|Overall Study|Withdrawal by Subject|4
6082671|NCT00630877|9690777|FG002|Overall Study|Withdrawal by Subject|0
6082672|NCT00630877|9690775|FG000|Overall Study|Lost to Follow-up|2
6082673|NCT00630877|9690776|FG001|Overall Study|Lost to Follow-up|0
6082674|NCT00630877|9690777|FG002|Overall Study|Lost to Follow-up|0
6082675|NCT00630877|9690775|FG000|Overall Study|Noncompliance|2
6082676|NCT00630877|9690776|FG001|Overall Study|Noncompliance|3
6166904|NCT01225731|9811414|FG006|Part 2|Protocol Violation|0
6166905|NCT01225731|9811415|FG007|Part 2|Protocol Violation|0
6166906|NCT01225731|9811416|FG008|Part 2|Protocol Violation|1
6166907|NCT01225731|9811417|FG009|Part 2|Protocol Violation|0
6166908|NCT01225731|9811418|FG010|Part 2|Protocol Violation|0
6166909|NCT01225731|9811419|FG011|Part 2|Protocol Violation|0
6166910|NCT01225731|9811420|FG012|Part 2|Protocol Violation|0
6166911|NCT01225731|9811408|FG000|Part 2|Adverse Event|0
6166912|NCT01225731|9811409|FG001|Part 2|Adverse Event|0
6166913|NCT01225731|9811410|FG002|Part 2|Adverse Event|0
6166914|NCT01225731|9811411|FG003|Part 2|Adverse Event|0
6166915|NCT01225731|9811412|FG004|Part 2|Adverse Event|0
6166916|NCT01225731|9811413|FG005|Part 2|Adverse Event|0
6166917|NCT01225731|9811414|FG006|Part 2|Adverse Event|4
6166918|NCT01225731|9811415|FG007|Part 2|Adverse Event|4
6166919|NCT01225731|9811416|FG008|Part 2|Adverse Event|2
6166920|NCT01225731|9811417|FG009|Part 2|Adverse Event|0
6166921|NCT01225731|9811418|FG010|Part 2|Adverse Event|0
6166922|NCT01225731|9811419|FG011|Part 2|Adverse Event|0
6166923|NCT01225731|9811420|FG012|Part 2|Adverse Event|0
6166924|NCT01225731|9811408|FG000|Part 2|Lack of Efficacy|0
6166925|NCT01225731|9811409|FG001|Part 2|Lack of Efficacy|0
6166926|NCT01225731|9811410|FG002|Part 2|Lack of Efficacy|0
6166927|NCT01225731|9811411|FG003|Part 2|Lack of Efficacy|0
6166928|NCT01225731|9811412|FG004|Part 2|Lack of Efficacy|0
6166929|NCT01225731|9811413|FG005|Part 2|Lack of Efficacy|1
6166930|NCT01225731|9811414|FG006|Part 2|Lack of Efficacy|0
6166931|NCT01225731|9811415|FG007|Part 2|Lack of Efficacy|12
6166932|NCT01225731|9811416|FG008|Part 2|Lack of Efficacy|3
6166933|NCT01225731|9811417|FG009|Part 2|Lack of Efficacy|0
6166934|NCT01225731|9811418|FG010|Part 2|Lack of Efficacy|0
6166935|NCT01225731|9811419|FG011|Part 2|Lack of Efficacy|0
6166936|NCT01225731|9811420|FG012|Part 2|Lack of Efficacy|0
6166937|NCT01225731|9811408|FG000|Part 2|Pregnancy|0
6166938|NCT01225731|9811409|FG001|Part 2|Pregnancy|0
6166939|NCT01225731|9811410|FG002|Part 2|Pregnancy|0
6166940|NCT01225731|9811411|FG003|Part 2|Pregnancy|0
6166941|NCT01225731|9811412|FG004|Part 2|Pregnancy|0
6166942|NCT01225731|9811413|FG005|Part 2|Pregnancy|0
6166943|NCT01225731|9811414|FG006|Part 2|Pregnancy|1
6166944|NCT01225731|9811415|FG007|Part 2|Pregnancy|0
6166945|NCT01225731|9811416|FG008|Part 2|Pregnancy|1
6166946|NCT01225731|9811417|FG009|Part 2|Pregnancy|0
6166947|NCT01225731|9811418|FG010|Part 2|Pregnancy|0
6166948|NCT01225731|9811419|FG011|Part 2|Pregnancy|0
6166949|NCT01225731|9811420|FG012|Part 2|Pregnancy|0
6166950|NCT01225731|9811408|FG000|Part 2|Lost to Follow-up|0
6166951|NCT01225731|9811409|FG001|Part 2|Lost to Follow-up|0
6166952|NCT01225731|9811410|FG002|Part 2|Lost to Follow-up|0
6166953|NCT01225731|9811411|FG003|Part 2|Lost to Follow-up|0
6166954|NCT01225731|9811412|FG004|Part 2|Lost to Follow-up|0
6166955|NCT01225731|9811413|FG005|Part 2|Lost to Follow-up|0
6166956|NCT01225731|9811414|FG006|Part 2|Lost to Follow-up|0
6166957|NCT01225731|9811415|FG007|Part 2|Lost to Follow-up|3
6166958|NCT01225731|9811416|FG008|Part 2|Lost to Follow-up|1
6166959|NCT01225731|9811417|FG009|Part 2|Lost to Follow-up|0
6166960|NCT01225731|9811418|FG010|Part 2|Lost to Follow-up|0
6166961|NCT01225731|9811419|FG011|Part 2|Lost to Follow-up|0
6166962|NCT01225731|9811420|FG012|Part 2|Lost to Follow-up|0
6166963|NCT01225731|9811408|FG000|Part 2|Physician Decision|0
6166964|NCT01225731|9811409|FG001|Part 2|Physician Decision|0
6166965|NCT01225731|9811410|FG002|Part 2|Physician Decision|0
6082677|NCT00630877|9690777|FG002|Overall Study|Noncompliance|1
6166966|NCT01225731|9811411|FG003|Part 2|Physician Decision|0
6166967|NCT01225731|9811412|FG004|Part 2|Physician Decision|0
6166968|NCT01225731|9811413|FG005|Part 2|Physician Decision|0
6166969|NCT01225731|9811414|FG006|Part 2|Physician Decision|0
6166970|NCT01225731|9811415|FG007|Part 2|Physician Decision|2
6166971|NCT01225731|9811416|FG008|Part 2|Physician Decision|2
6166972|NCT01225731|9811417|FG009|Part 2|Physician Decision|0
6166973|NCT01225731|9811418|FG010|Part 2|Physician Decision|0
6166974|NCT01225731|9811419|FG011|Part 2|Physician Decision|0
6082678|NCT00630877|9690775|FG000|Overall Study|Protocol violation|1
6166975|NCT01225731|9811420|FG012|Part 2|Physician Decision|0
6166976|NCT01225731|9811408|FG000|Part 2|Withdrawal by Subject|0
6166977|NCT01225731|9811409|FG001|Part 2|Withdrawal by Subject|0
6166978|NCT01225731|9811410|FG002|Part 2|Withdrawal by Subject|0
6166979|NCT01225731|9811411|FG003|Part 2|Withdrawal by Subject|0
6166980|NCT01225731|9811412|FG004|Part 2|Withdrawal by Subject|0
6166981|NCT01225731|9811413|FG005|Part 2|Withdrawal by Subject|1
6166982|NCT01225731|9811414|FG006|Part 2|Withdrawal by Subject|3
6166983|NCT01225731|9811415|FG007|Part 2|Withdrawal by Subject|4
6166984|NCT01225731|9811416|FG008|Part 2|Withdrawal by Subject|1
6166985|NCT01225731|9811417|FG009|Part 2|Withdrawal by Subject|0
6166986|NCT01225731|9811418|FG010|Part 2|Withdrawal by Subject|0
6166987|NCT01225731|9811419|FG011|Part 2|Withdrawal by Subject|0
6166988|NCT01225731|9811420|FG012|Part 2|Withdrawal by Subject|0
6166989|NCT01225731|9811408|FG000|Part 3|Adverse Event|0
6166990|NCT01225731|9811409|FG001|Part 3|Adverse Event|0
6166991|NCT01225731|9811410|FG002|Part 3|Adverse Event|0
6166992|NCT01225731|9811411|FG003|Part 3|Adverse Event|0
6166993|NCT01225731|9811412|FG004|Part 3|Adverse Event|0
6166994|NCT01225731|9811413|FG005|Part 3|Adverse Event|0
6166995|NCT01225731|9811414|FG006|Part 3|Adverse Event|0
6166996|NCT01225731|9811415|FG007|Part 3|Adverse Event|0
6166997|NCT01225731|9811416|FG008|Part 3|Adverse Event|0
6166998|NCT01225731|9811417|FG009|Part 3|Adverse Event|0
6166999|NCT01225731|9811418|FG010|Part 3|Adverse Event|1
6167000|NCT01225731|9811419|FG011|Part 3|Adverse Event|1
6167001|NCT01225731|9811420|FG012|Part 3|Adverse Event|0
6167002|NCT01225731|9811408|FG000|Part 3|Lost to Follow-up|0
6167003|NCT01225731|9811409|FG001|Part 3|Lost to Follow-up|0
6167004|NCT01225731|9811410|FG002|Part 3|Lost to Follow-up|0
6167005|NCT01225731|9811411|FG003|Part 3|Lost to Follow-up|0
6167006|NCT01225731|9811412|FG004|Part 3|Lost to Follow-up|0
6167007|NCT01225731|9811413|FG005|Part 3|Lost to Follow-up|0
6167008|NCT01225731|9811414|FG006|Part 3|Lost to Follow-up|0
6167009|NCT01225731|9811415|FG007|Part 3|Lost to Follow-up|0
6167010|NCT01225731|9811416|FG008|Part 3|Lost to Follow-up|0
6167011|NCT01225731|9811417|FG009|Part 3|Lost to Follow-up|0
6167012|NCT01225731|9811418|FG010|Part 3|Lost to Follow-up|1
6167013|NCT01225731|9811419|FG011|Part 3|Lost to Follow-up|2
6167014|NCT01225731|9811420|FG012|Part 3|Lost to Follow-up|1
6167015|NCT01225731|9811408|FG000|Part 3|Physician Decision|0
6167016|NCT01225731|9811409|FG001|Part 3|Physician Decision|0
6167017|NCT01225731|9811410|FG002|Part 3|Physician Decision|0
6167018|NCT01225731|9811411|FG003|Part 3|Physician Decision|0
6167019|NCT01225731|9811412|FG004|Part 3|Physician Decision|0
6167020|NCT01225731|9811413|FG005|Part 3|Physician Decision|0
6167021|NCT01225731|9811414|FG006|Part 3|Physician Decision|0
6167022|NCT01225731|9811415|FG007|Part 3|Physician Decision|0
6167023|NCT01225731|9811416|FG008|Part 3|Physician Decision|0
6167024|NCT01225731|9811417|FG009|Part 3|Physician Decision|0
6167025|NCT01225731|9811418|FG010|Part 3|Physician Decision|0
6167026|NCT01225731|9811419|FG011|Part 3|Physician Decision|1
6167027|NCT01225731|9811420|FG012|Part 3|Physician Decision|2
6167028|NCT01225731|9811408|FG000|Part 3|Withdrawal by Subject|0
6167029|NCT01225731|9811409|FG001|Part 3|Withdrawal by Subject|0
6167030|NCT01225731|9811410|FG002|Part 3|Withdrawal by Subject|0
6167031|NCT01225731|9811411|FG003|Part 3|Withdrawal by Subject|0
6167032|NCT01225731|9811412|FG004|Part 3|Withdrawal by Subject|0
6167033|NCT01225731|9811413|FG005|Part 3|Withdrawal by Subject|0
6167034|NCT01225731|9811414|FG006|Part 3|Withdrawal by Subject|0
6167035|NCT01225731|9811415|FG007|Part 3|Withdrawal by Subject|0
6167036|NCT01225731|9811416|FG008|Part 3|Withdrawal by Subject|0
6167037|NCT01225731|9811417|FG009|Part 3|Withdrawal by Subject|0
6167038|NCT01225731|9811418|FG010|Part 3|Withdrawal by Subject|4
6167039|NCT01225731|9811419|FG011|Part 3|Withdrawal by Subject|6
6167040|NCT01225731|9811420|FG012|Part 3|Withdrawal by Subject|4
6167041|NCT01225822|9811454|FG000|Overall Study|Adverse Event|13
6167042|NCT01225822|9811455|FG001|Overall Study|Adverse Event|31
6167043|NCT01225822|9811456|FG002|Overall Study|Adverse Event|18
6167044|NCT01225822|9811457|FG003|Overall Study|Adverse Event|23
6167045|NCT01225822|9811458|FG004|Overall Study|Adverse Event|14
6167046|NCT01225822|9811454|FG000|Overall Study|Protocol Violation|6
6167047|NCT01225822|9811455|FG001|Overall Study|Protocol Violation|8
6167048|NCT01225822|9811456|FG002|Overall Study|Protocol Violation|6
6167049|NCT01225822|9811457|FG003|Overall Study|Protocol Violation|7
6167050|NCT01225822|9811458|FG004|Overall Study|Protocol Violation|4
6167051|NCT01225822|9811454|FG000|Overall Study|Lost to Follow-up|0
6167052|NCT01225822|9811455|FG001|Overall Study|Lost to Follow-up|0
6167053|NCT01225822|9811456|FG002|Overall Study|Lost to Follow-up|0
6167054|NCT01225822|9811457|FG003|Overall Study|Lost to Follow-up|1
6167055|NCT01225822|9811458|FG004|Overall Study|Lost to Follow-up|0
6167056|NCT01225822|9811454|FG000|Overall Study|Withdrawal by Subject|6
6167057|NCT01225822|9811455|FG001|Overall Study|Withdrawal by Subject|7
6167058|NCT01225822|9811456|FG002|Overall Study|Withdrawal by Subject|7
6167059|NCT01225822|9811457|FG003|Overall Study|Withdrawal by Subject|11
6167060|NCT01225822|9811458|FG004|Overall Study|Withdrawal by Subject|6
6167061|NCT01225822|9811454|FG000|Overall Study|Other|13
6167062|NCT01225822|9811455|FG001|Overall Study|Other|10
6167063|NCT01225822|9811456|FG002|Overall Study|Other|7
6167064|NCT01225822|9811457|FG003|Overall Study|Other|10
6167065|NCT01225822|9811458|FG004|Overall Study|Other|7
6167066|NCT01225835|9811475|FG000|Overall Study|Completed protocol|2
6167067|NCT01225835|9811476|FG001|Overall Study|Completed protocol|1
6167068|NCT01225835|9811475|FG000|Overall Study|Did not meet hCG criterion|2
6167069|NCT01225835|9811476|FG001|Overall Study|Did not meet hCG criterion|0
6167070|NCT01225835|9811475|FG000|Overall Study|Adverse Event|2
6167071|NCT01225835|9811476|FG001|Overall Study|Adverse Event|1
6167072|NCT01225835|9811475|FG000|Overall Study|Other|1
6167073|NCT01225835|9811476|FG001|Overall Study|Other|1
6167074|NCT01225887|9811488|FG000|Overall Study|Ineligible:required test not done|2
6167075|NCT01225887|9811488|FG000|Overall Study|Ineligible;improper pre-protocol therapy|1
6167076|NCT01225887|9811488|FG000|Overall Study|Ineligible:inadequate pathology|2
6167077|NCT01225952|9811504|FG000|Overall Study|Lost to Follow-up|1
6167078|NCT01225952|9811505|FG001|Overall Study|Lost to Follow-up|0
6327671|NCT02966340|10071406|FG000|Overall Study|Adverse Event|0
6327672|NCT02966340|10071407|FG001|Overall Study|Adverse Event|1
6327673|NCT02966340|10071406|FG000|Overall Study|Lost to Follow-up|0
6327674|NCT02966340|10071407|FG001|Overall Study|Lost to Follow-up|1
6327675|NCT02966340|10071406|FG000|Overall Study|Withdrawal by Subject|1
6327676|NCT02966340|10071407|FG001|Overall Study|Withdrawal by Subject|0
6327677|NCT02966340|10071406|FG000|Overall Study|data acquisition error|1
6327678|NCT02966340|10071407|FG001|Overall Study|data acquisition error|0
6327679|NCT02966340|10071406|FG000|Overall Study|startle non-responder|1
6327680|NCT02966340|10071407|FG001|Overall Study|startle non-responder|1
6327681|NCT02966353|10071413|FG000|Overall Study|Withdrawal by Subject|7
6327682|NCT02966353|10071413|FG000|Overall Study|Adverse Event|4
6327683|NCT02966353|10071413|FG000|Overall Study|Death|4
6327684|NCT02966353|10071413|FG000|Overall Study|Physician Decision|3
6327685|NCT02966353|10071413|FG000|Overall Study|Progressive disease|2
6327686|NCT02966353|10071413|FG000|Overall Study|Protocol deviation|2
6327687|NCT02966509|10071419|FG000|Baseline Satisfaction Survey|Withdrawal by Subject|2
6327688|NCT02966509|10071420|FG001|Baseline Satisfaction Survey|Withdrawal by Subject|3
6327689|NCT02966509|10071419|FG000|Baseline Satisfaction Survey|Death|0
6327690|NCT02966509|10071420|FG001|Baseline Satisfaction Survey|Death|1
6327691|NCT02966509|10071419|FG000|Baseline Satisfaction Survey|Lost to Follow-up|1
6327692|NCT02966509|10071420|FG001|Baseline Satisfaction Survey|Lost to Follow-up|1
6327693|NCT02966509|10071419|FG000|Baseline Satisfaction Survey|Refused to Answer|1
6327694|NCT02966509|10071420|FG001|Baseline Satisfaction Survey|Refused to Answer|2
6327695|NCT02966509|10071419|FG000|6 Month Satisfaction Decision Survey|Death|22
6327696|NCT02966509|10071420|FG001|6 Month Satisfaction Decision Survey|Death|25
6327697|NCT02966509|10071419|FG000|6 Month Satisfaction Decision Survey|Withdrawal by Subject|2
6327698|NCT02966509|10071420|FG001|6 Month Satisfaction Decision Survey|Withdrawal by Subject|3
6327699|NCT02966509|10071419|FG000|6 Month Satisfaction Decision Survey|Lost to Follow-up|1
6327700|NCT02966509|10071420|FG001|6 Month Satisfaction Decision Survey|Lost to Follow-up|1
6327701|NCT02966509|10071419|FG000|6 Month Satisfaction Decision Survey|Refused to Answer|0
6327702|NCT02966509|10071420|FG001|6 Month Satisfaction Decision Survey|Refused to Answer|2
6327703|NCT02966509|10071419|FG000|6 Month Satisfaction Survey|Death|36
6327704|NCT02966509|10071420|FG001|6 Month Satisfaction Survey|Death|33
6327705|NCT02966509|10071419|FG000|6 Month Satisfaction Survey|Withdrawal by Subject|2
6327706|NCT02966509|10071420|FG001|6 Month Satisfaction Survey|Withdrawal by Subject|3
6327707|NCT02966509|10071419|FG000|6 Month Satisfaction Survey|Lost to Follow-up|1
6327708|NCT02966509|10071420|FG001|6 Month Satisfaction Survey|Lost to Follow-up|1
6327709|NCT02966509|10071419|FG000|6 Month Satisfaction Survey|Refused to Answer|8
6327710|NCT02966509|10071420|FG001|6 Month Satisfaction Survey|Refused to Answer|11
6327711|NCT02966509|10071419|FG000|End of Life Utilization and Cost 6 Month|Patient Still Alive|69
6327712|NCT02966509|10071420|FG001|End of Life Utilization and Cost 6 Month|Patient Still Alive|75
6327713|NCT02966509|10071419|FG000|End of Life Utilization and Cost 15month|Patient Still Alive|45
6327714|NCT02966509|10071420|FG001|End of Life Utilization and Cost 15month|Patient Still Alive|48
6327715|NCT02966795|10071428|FG000|Overall Study|Patient Left the Country|0
6327716|NCT02966795|10071429|FG001|Overall Study|Patient Left the Country|1
6327717|NCT02966834|10071440|FG000|Main Study Period (Up to 12 Weeks)|Adverse Event|0
6327718|NCT02966834|10071441|FG001|Main Study Period (Up to 12 Weeks)|Adverse Event|0
6327719|NCT02966834|10071442|FG002|Main Study Period (Up to 12 Weeks)|Adverse Event|0
6327720|NCT02966834|10071443|FG003|Main Study Period (Up to 12 Weeks)|Adverse Event|0
6327721|NCT02966834|10071444|FG004|Main Study Period (Up to 12 Weeks)|Adverse Event|1
6327722|NCT02966834|10071445|FG005|Main Study Period (Up to 12 Weeks)|Adverse Event|0
6327723|NCT02966834|10071440|FG000|Main Study Period (Up to 12 Weeks)|Lack of Efficacy|1
6327724|NCT02966834|10071441|FG001|Main Study Period (Up to 12 Weeks)|Lack of Efficacy|0
6327725|NCT02966834|10071442|FG002|Main Study Period (Up to 12 Weeks)|Lack of Efficacy|0
6327726|NCT02966834|10071443|FG003|Main Study Period (Up to 12 Weeks)|Lack of Efficacy|0
6327727|NCT02966834|10071444|FG004|Main Study Period (Up to 12 Weeks)|Lack of Efficacy|0
6327728|NCT02966834|10071445|FG005|Main Study Period (Up to 12 Weeks)|Lack of Efficacy|0
6327729|NCT02966834|10071440|FG000|Main Study Period (Up to 12 Weeks)|Discontinued study treatment and entered follow-up|0
6327730|NCT02966834|10071441|FG001|Main Study Period (Up to 12 Weeks)|Discontinued study treatment and entered follow-up|0
6327731|NCT02966834|10071442|FG002|Main Study Period (Up to 12 Weeks)|Discontinued study treatment and entered follow-up|4
6327732|NCT02966834|10071443|FG003|Main Study Period (Up to 12 Weeks)|Discontinued study treatment and entered follow-up|8
6167079|NCT01225952|9811506|FG002|Overall Study|Lost to Follow-up|0
6167080|NCT01225952|9811504|FG000|Overall Study|Study Eye Explanted|0
6167081|NCT01225952|9811505|FG001|Overall Study|Study Eye Explanted|0
6167082|NCT01225952|9811506|FG002|Overall Study|Study Eye Explanted|1
6167083|NCT01225952|9811504|FG000|Overall Study|Withdrawal by Subject|4
6167084|NCT01225952|9811505|FG001|Overall Study|Withdrawal by Subject|4
6167085|NCT01225952|9811506|FG002|Overall Study|Withdrawal by Subject|5
6167086|NCT01225952|9811504|FG000|Overall Study|Surgical complications|1
6167087|NCT01225952|9811505|FG001|Overall Study|Surgical complications|0
6167088|NCT01225952|9811506|FG002|Overall Study|Surgical complications|0
6167089|NCT01225991|9811514|FG000|Overall Study|Withdrawal by Subject|6
6167090|NCT01226043|9811520|FG000|4-week Crossover Phase - Period 1|Protocol Violation|1
6167091|NCT01226043|9811521|FG001|4-week Crossover Phase - Period 1|Protocol Violation|2
6167092|NCT01226043|9811522|FG002|4-week Crossover Phase - Period 1|Protocol Violation|0
6167093|NCT01226043|9811523|FG003|4-week Crossover Phase - Period 1|Protocol Violation|0
6167094|NCT01226043|9811520|FG000|4-week Crossover Phase - Period 1|Lost to Follow-up|0
6167095|NCT01226043|9811521|FG001|4-week Crossover Phase - Period 1|Lost to Follow-up|1
6167096|NCT01226043|9811522|FG002|4-week Crossover Phase - Period 1|Lost to Follow-up|0
6167097|NCT01226043|9811523|FG003|4-week Crossover Phase - Period 1|Lost to Follow-up|0
6167098|NCT01226043|9811520|FG000|4-week Crossover Phase - Period 1|Withdrawal by Subject|2
6167099|NCT01226043|9811521|FG001|4-week Crossover Phase - Period 1|Withdrawal by Subject|0
6167100|NCT01226043|9811522|FG002|4-week Crossover Phase - Period 1|Withdrawal by Subject|0
6167101|NCT01226043|9811523|FG003|4-week Crossover Phase - Period 1|Withdrawal by Subject|0
6167102|NCT01226043|9811520|FG000|4-week Crossover Phase - Period 1|Physician Decision|0
6167103|NCT01226043|9811521|FG001|4-week Crossover Phase - Period 1|Physician Decision|6
6167104|NCT01226043|9811522|FG002|4-week Crossover Phase - Period 1|Physician Decision|0
6167105|NCT01226043|9811523|FG003|4-week Crossover Phase - Period 1|Physician Decision|0
6167106|NCT01226043|9811520|FG000|4-week Crossover Phase - Period 2|Withdrawal by Subject|0
6167107|NCT01226043|9811521|FG001|4-week Crossover Phase - Period 2|Withdrawal by Subject|1
6167108|NCT01226043|9811522|FG002|4-week Crossover Phase - Period 2|Withdrawal by Subject|0
6167109|NCT01226043|9811523|FG003|4-week Crossover Phase - Period 2|Withdrawal by Subject|0
6167110|NCT01226043|9811520|FG000|4-week Crossover Phase - Period 2|Physician Decision|4
6167111|NCT01226043|9811521|FG001|4-week Crossover Phase - Period 2|Physician Decision|5
6167112|NCT01226043|9811522|FG002|4-week Crossover Phase - Period 2|Physician Decision|0
6167113|NCT01226043|9811523|FG003|4-week Crossover Phase - Period 2|Physician Decision|0
6167114|NCT01226043|9811520|FG000|6-week Re-randomization Phase|Adverse Event|0
6167115|NCT01226043|9811521|FG001|6-week Re-randomization Phase|Adverse Event|0
6167116|NCT01226043|9811522|FG002|6-week Re-randomization Phase|Adverse Event|1
6167117|NCT01226043|9811523|FG003|6-week Re-randomization Phase|Adverse Event|1
6167118|NCT01226043|9811520|FG000|6-week Re-randomization Phase|Protocol Violation|0
6167119|NCT01226043|9811521|FG001|6-week Re-randomization Phase|Protocol Violation|0
6167120|NCT01226043|9811522|FG002|6-week Re-randomization Phase|Protocol Violation|1
6167121|NCT01226043|9811523|FG003|6-week Re-randomization Phase|Protocol Violation|1
6167122|NCT01226043|9811520|FG000|6-week Re-randomization Phase|Lost to Follow-up|0
6167123|NCT01226043|9811521|FG001|6-week Re-randomization Phase|Lost to Follow-up|0
6167124|NCT01226043|9811522|FG002|6-week Re-randomization Phase|Lost to Follow-up|1
6167125|NCT01226043|9811523|FG003|6-week Re-randomization Phase|Lost to Follow-up|3
6167126|NCT01226043|9811520|FG000|6-week Re-randomization Phase|Withdrawal by Subject|0
6167127|NCT01226043|9811521|FG001|6-week Re-randomization Phase|Withdrawal by Subject|0
6167128|NCT01226043|9811522|FG002|6-week Re-randomization Phase|Withdrawal by Subject|1
6167129|NCT01226043|9811523|FG003|6-week Re-randomization Phase|Withdrawal by Subject|3
6167130|NCT01226043|9811520|FG000|6-week Re-randomization Phase|Physician Decision|0
6167131|NCT01226043|9811521|FG001|6-week Re-randomization Phase|Physician Decision|0
6167132|NCT01226043|9811522|FG002|6-week Re-randomization Phase|Physician Decision|3
6167133|NCT01226043|9811523|FG003|6-week Re-randomization Phase|Physician Decision|2
6167134|NCT01226043|9811520|FG000|6-week Re-randomization Phase|completed in error|0
6167135|NCT01226043|9811521|FG001|6-week Re-randomization Phase|completed in error|0
6167136|NCT01226043|9811522|FG002|6-week Re-randomization Phase|completed in error|0
6167137|NCT01226043|9811523|FG003|6-week Re-randomization Phase|completed in error|1
6167138|NCT01226043|9811520|FG000|30-week Observational Phase|Adverse Event|0
6167139|NCT01226043|9811521|FG001|30-week Observational Phase|Adverse Event|0
6167140|NCT01226043|9811522|FG002|30-week Observational Phase|Adverse Event|1
6327733|NCT02966834|10071444|FG004|Main Study Period (Up to 12 Weeks)|Discontinued study treatment and entered follow-up|0
6327734|NCT02966834|10071445|FG005|Main Study Period (Up to 12 Weeks)|Discontinued study treatment and entered follow-up|5
6327735|NCT02966834|10071440|FG000|Follow-up (Up to 4 Weeks)|Adverse Event|0
6327736|NCT02966834|10071441|FG001|Follow-up (Up to 4 Weeks)|Adverse Event|0
6327737|NCT02966834|10071442|FG002|Follow-up (Up to 4 Weeks)|Adverse Event|1
6327738|NCT02966834|10071443|FG003|Follow-up (Up to 4 Weeks)|Adverse Event|2
6327739|NCT02966834|10071444|FG004|Follow-up (Up to 4 Weeks)|Adverse Event|0
6327740|NCT02966834|10071445|FG005|Follow-up (Up to 4 Weeks)|Adverse Event|1
6327741|NCT02966834|10071440|FG000|Follow-up (Up to 4 Weeks)|Withdrawal by Subject|0
6327742|NCT02966834|10071441|FG001|Follow-up (Up to 4 Weeks)|Withdrawal by Subject|0
6327743|NCT02966834|10071442|FG002|Follow-up (Up to 4 Weeks)|Withdrawal by Subject|0
6327744|NCT02966834|10071443|FG003|Follow-up (Up to 4 Weeks)|Withdrawal by Subject|2
6167141|NCT01226043|9811523|FG003|30-week Observational Phase|Adverse Event|1
6167142|NCT01226043|9811520|FG000|30-week Observational Phase|Protocol Violation|0
6167143|NCT01226043|9811521|FG001|30-week Observational Phase|Protocol Violation|0
6167144|NCT01226043|9811522|FG002|30-week Observational Phase|Protocol Violation|0
6167145|NCT01226043|9811523|FG003|30-week Observational Phase|Protocol Violation|1
6167146|NCT01226043|9811520|FG000|30-week Observational Phase|Lost to Follow-up|0
6167147|NCT01226043|9811521|FG001|30-week Observational Phase|Lost to Follow-up|0
6167148|NCT01226043|9811522|FG002|30-week Observational Phase|Lost to Follow-up|2
6167149|NCT01226043|9811523|FG003|30-week Observational Phase|Lost to Follow-up|2
6167150|NCT01226043|9811520|FG000|30-week Observational Phase|Withdrawal by Subject|0
6167151|NCT01226043|9811521|FG001|30-week Observational Phase|Withdrawal by Subject|0
6327745|NCT02966834|10071444|FG004|Follow-up (Up to 4 Weeks)|Withdrawal by Subject|0
6327746|NCT02966834|10071445|FG005|Follow-up (Up to 4 Weeks)|Withdrawal by Subject|0
6327747|NCT02966834|10071440|FG000|Follow-up (Up to 4 Weeks)|Protocol Violation|0
6327748|NCT02966834|10071441|FG001|Follow-up (Up to 4 Weeks)|Protocol Violation|0
6327749|NCT02966834|10071442|FG002|Follow-up (Up to 4 Weeks)|Protocol Violation|0
6327750|NCT02966834|10071443|FG003|Follow-up (Up to 4 Weeks)|Protocol Violation|1
6327751|NCT02966834|10071444|FG004|Follow-up (Up to 4 Weeks)|Protocol Violation|0
6327752|NCT02966834|10071445|FG005|Follow-up (Up to 4 Weeks)|Protocol Violation|0
6327753|NCT02967055|10071503|FG000|Overall Study|Excluded|40
6327754|NCT02967055|10071503|FG000|Overall Study|Screen fail|3
6327755|NCT02967055|10071503|FG000|Overall Study|Lost to Follow-up|2
6327756|NCT02967055|10071503|FG000|Overall Study|Stopped due to side effects|3
6327757|NCT02967055|10071503|FG000|Overall Study|Stopped due to drug cost|1
6327758|NCT02967562|10071572|FG000|Overall Study|Consent not obtained|1
6327759|NCT02967562|10071573|FG001|Overall Study|Consent not obtained|0
6327760|NCT02967562|10071572|FG000|Overall Study|High leak precluding analysis|1
6327761|NCT02967562|10071573|FG001|Overall Study|High leak precluding analysis|1
6327762|NCT02967679|10071579|FG000|Overall Study|Adverse Event|1
6327763|NCT02968004|10071596|FG000|Overall Study|Adverse Event|1
6327764|NCT02968004|10071597|FG001|Overall Study|Adverse Event|0
6327765|NCT02968004|10071596|FG000|Overall Study|Withdrawal by Subject|0
6327766|NCT02968004|10071597|FG001|Overall Study|Withdrawal by Subject|1
6327767|NCT02968173|10071607|FG000|Overall Study|Withdrawal by Subject|1
6327768|NCT02968433|10071653|FG000|Overall Study|Withdrawal by Subject|1
6327769|NCT02968576|10071663|FG000|Overall Study|Pregnancy|0
6327770|NCT02968576|10071664|FG001|Overall Study|Pregnancy|1
6327771|NCT02968979|10071685|FG000|Overall Study|Protocol Violation|7
6327772|NCT02968979|10071685|FG000|Overall Study|Withdrawal by Subject|1
6327773|NCT02969018|10071752|FG000|Overall Study|Adverse Event|2
6327774|NCT02969018|10071753|FG001|Overall Study|Adverse Event|4
6327775|NCT02969018|10071754|FG002|Overall Study|Adverse Event|1
6327776|NCT02969018|10071755|FG003|Overall Study|Adverse Event|2
6327777|NCT02969018|10071756|FG004|Overall Study|Adverse Event|0
6327778|NCT02969018|10071757|FG005|Overall Study|Adverse Event|1
6327779|NCT02969018|10071758|FG006|Overall Study|Adverse Event|2
6327780|NCT02969018|10071759|FG007|Overall Study|Adverse Event|0
6327781|NCT02969018|10071752|FG000|Overall Study|Lack of Efficacy|0
6327782|NCT02969018|10071753|FG001|Overall Study|Lack of Efficacy|1
6327783|NCT02969018|10071754|FG002|Overall Study|Lack of Efficacy|0
6327784|NCT02969018|10071755|FG003|Overall Study|Lack of Efficacy|0
6327785|NCT02969018|10071756|FG004|Overall Study|Lack of Efficacy|1
6327786|NCT02969018|10071757|FG005|Overall Study|Lack of Efficacy|1
6327787|NCT02969018|10071758|FG006|Overall Study|Lack of Efficacy|1
6327788|NCT02969018|10071759|FG007|Overall Study|Lack of Efficacy|1
6327789|NCT02969018|10071752|FG000|Overall Study|Lost to Follow-up|1
6327790|NCT02969018|10071753|FG001|Overall Study|Lost to Follow-up|2
6327791|NCT02969018|10071754|FG002|Overall Study|Lost to Follow-up|2
6327792|NCT02969018|10071755|FG003|Overall Study|Lost to Follow-up|0
6327793|NCT02969018|10071756|FG004|Overall Study|Lost to Follow-up|1
6327794|NCT02969018|10071757|FG005|Overall Study|Lost to Follow-up|1
6327795|NCT02969018|10071758|FG006|Overall Study|Lost to Follow-up|0
6327796|NCT02969018|10071759|FG007|Overall Study|Lost to Follow-up|1
6327797|NCT02969018|10071752|FG000|Overall Study|No Longer Meets Eligibility Criteria|0
6327798|NCT02969018|10071753|FG001|Overall Study|No Longer Meets Eligibility Criteria|0
6327799|NCT02969018|10071754|FG002|Overall Study|No Longer Meets Eligibility Criteria|0
6327800|NCT02969018|10071755|FG003|Overall Study|No Longer Meets Eligibility Criteria|0
6327801|NCT02969018|10071756|FG004|Overall Study|No Longer Meets Eligibility Criteria|0
6327802|NCT02969018|10071757|FG005|Overall Study|No Longer Meets Eligibility Criteria|0
6327803|NCT02969018|10071758|FG006|Overall Study|No Longer Meets Eligibility Criteria|1
6327804|NCT02969018|10071759|FG007|Overall Study|No Longer Meets Eligibility Criteria|0
6327805|NCT02969018|10071752|FG000|Overall Study|Non-Compliance With Study Drug|1
6327806|NCT02969018|10071753|FG001|Overall Study|Non-Compliance With Study Drug|0
6327807|NCT02969018|10071754|FG002|Overall Study|Non-Compliance With Study Drug|0
6327808|NCT02969018|10071755|FG003|Overall Study|Non-Compliance With Study Drug|0
6327809|NCT02969018|10071756|FG004|Overall Study|Non-Compliance With Study Drug|0
6327810|NCT02969018|10071757|FG005|Overall Study|Non-Compliance With Study Drug|0
6327811|NCT02969018|10071758|FG006|Overall Study|Non-Compliance With Study Drug|0
6327812|NCT02969018|10071759|FG007|Overall Study|Non-Compliance With Study Drug|0
6327813|NCT02969018|10071752|FG000|Overall Study|Other|0
6327814|NCT02969018|10071753|FG001|Overall Study|Other|0
6327815|NCT02969018|10071754|FG002|Overall Study|Other|0
6327816|NCT02969018|10071755|FG003|Overall Study|Other|1
6327817|NCT02969018|10071756|FG004|Overall Study|Other|0
6327818|NCT02969018|10071757|FG005|Overall Study|Other|0
6327819|NCT02969018|10071758|FG006|Overall Study|Other|0
6327820|NCT02969018|10071759|FG007|Overall Study|Other|2
6327821|NCT02969018|10071752|FG000|Overall Study|Pregnancy|0
6327822|NCT02969018|10071753|FG001|Overall Study|Pregnancy|0
6327823|NCT02969018|10071754|FG002|Overall Study|Pregnancy|0
6327824|NCT02969018|10071755|FG003|Overall Study|Pregnancy|0
6327825|NCT02969018|10071756|FG004|Overall Study|Pregnancy|0
6327826|NCT02969018|10071757|FG005|Overall Study|Pregnancy|1
6327827|NCT02969018|10071758|FG006|Overall Study|Pregnancy|0
6327828|NCT02969018|10071759|FG007|Overall Study|Pregnancy|0
6327829|NCT02969018|10071752|FG000|Overall Study|Protocol Violation|0
6327830|NCT02969018|10071753|FG001|Overall Study|Protocol Violation|0
6327831|NCT02969018|10071754|FG002|Overall Study|Protocol Violation|1
6327832|NCT02969018|10071755|FG003|Overall Study|Protocol Violation|1
6327833|NCT02969018|10071756|FG004|Overall Study|Protocol Violation|0
6327834|NCT02969018|10071757|FG005|Overall Study|Protocol Violation|0
6327835|NCT02969018|10071758|FG006|Overall Study|Protocol Violation|0
6327836|NCT02969018|10071759|FG007|Overall Study|Protocol Violation|0
6327837|NCT02969018|10071752|FG000|Overall Study|Withdrawal by Subject|0
6327838|NCT02969018|10071753|FG001|Overall Study|Withdrawal by Subject|1
6327839|NCT02969018|10071754|FG002|Overall Study|Withdrawal by Subject|2
6327840|NCT02969018|10071755|FG003|Overall Study|Withdrawal by Subject|1
6327841|NCT02969018|10071756|FG004|Overall Study|Withdrawal by Subject|0
6327842|NCT02969018|10071757|FG005|Overall Study|Withdrawal by Subject|4
6327843|NCT02969018|10071758|FG006|Overall Study|Withdrawal by Subject|4
6327844|NCT02969018|10071759|FG007|Overall Study|Withdrawal by Subject|3
6327845|NCT02969044|10071791|FG000|Overall Study|Withdrawal by Subject|2
6327846|NCT02969044|10071792|FG001|Overall Study|Withdrawal by Subject|6
6327847|NCT02969044|10071791|FG000|Overall Study|Adverse Event|3
6327848|NCT02969044|10071792|FG001|Overall Study|Adverse Event|0
6327849|NCT02969187|10071800|FG000|Overall Study|Physician Decision|12
6327850|NCT02969187|10071801|FG001|Overall Study|Physician Decision|13
6327851|NCT02969356|10071814|FG000|Overall Study|Adverse Event|7
6327852|NCT02969356|10071814|FG000|Overall Study|Consent withdrawn|2
6327853|NCT02969356|10071814|FG000|Overall Study|Lost to Follow-up|3
6327854|NCT02969356|10071814|FG000|Overall Study|Did not need to be reinjected|6
6327855|NCT02969356|10071814|FG000|Overall Study|Personal reasons|5
6327856|NCT02969382|10071820|FG000|Overall Study|Adverse Event|8
6327857|NCT02969382|10071821|FG001|Overall Study|Adverse Event|10
6327858|NCT02969382|10071820|FG000|Overall Study|Lack of Efficacy|4
6327859|NCT02969382|10071821|FG001|Overall Study|Lack of Efficacy|5
6327860|NCT02969382|10071820|FG000|Overall Study|Death|0
6327861|NCT02969382|10071821|FG001|Overall Study|Death|1
6327862|NCT02969382|10071820|FG000|Overall Study|PROTOCOL DEVIATION|0
6327863|NCT02969382|10071821|FG001|Overall Study|PROTOCOL DEVIATION|1
6327864|NCT02969382|10071820|FG000|Overall Study|Withdrawal by Subject|14
6327865|NCT02969382|10071821|FG001|Overall Study|Withdrawal by Subject|9
6327866|NCT02969408|10071827|FG000|Overall Study|Adverse Event|2
6327867|NCT02969408|10071827|FG000|Overall Study|Withdrawal by Subject|8
6327868|NCT02969408|10071827|FG000|Overall Study|Lost to Follow-up|4
6327869|NCT02969408|10071827|FG000|Overall Study|Protocol Violation|1
6327870|NCT02969408|10071827|FG000|Overall Study|Other than specified|1
6327871|NCT02969525|10071849|FG000|Double-Blind Period|Adverse Event|0
6327872|NCT02969525|10071850|FG001|Double-Blind Period|Adverse Event|0
6327873|NCT02969525|10071851|FG002|Double-Blind Period|Adverse Event|1
6327874|NCT02969525|10071852|FG003|Double-Blind Period|Adverse Event|1
6327875|NCT02969525|10071853|FG004|Double-Blind Period|Adverse Event|0
6327876|NCT02969525|10071854|FG005|Double-Blind Period|Adverse Event|0
6327877|NCT02969525|10071855|FG006|Double-Blind Period|Adverse Event|0
6327878|NCT02969525|10071856|FG007|Double-Blind Period|Adverse Event|0
6327879|NCT02969525|10071857|FG008|Double-Blind Period|Adverse Event|0
6327880|NCT02969525|10071858|FG009|Double-Blind Period|Adverse Event|0
6327881|NCT02969525|10071859|FG010|Double-Blind Period|Adverse Event|0
6327882|NCT02969525|10071860|FG011|Double-Blind Period|Adverse Event|0
6327883|NCT02969525|10071849|FG000|Double-Blind Period|LOW EGFR|0
6327884|NCT02969525|10071850|FG001|Double-Blind Period|LOW EGFR|0
6327885|NCT02969525|10071851|FG002|Double-Blind Period|LOW EGFR|0
6327886|NCT02969525|10071852|FG003|Double-Blind Period|LOW EGFR|1
6327887|NCT02969525|10071853|FG004|Double-Blind Period|LOW EGFR|0
6327888|NCT02969525|10071854|FG005|Double-Blind Period|LOW EGFR|0
6327889|NCT02969525|10071855|FG006|Double-Blind Period|LOW EGFR|0
6327890|NCT02969525|10071856|FG007|Double-Blind Period|LOW EGFR|0
6327891|NCT02969525|10071857|FG008|Double-Blind Period|LOW EGFR|0
6327892|NCT02969525|10071858|FG009|Double-Blind Period|LOW EGFR|0
6327893|NCT02969525|10071859|FG010|Double-Blind Period|LOW EGFR|0
6327894|NCT02969525|10071860|FG011|Double-Blind Period|LOW EGFR|0
6327895|NCT02969525|10071849|FG000|Double-Blind Period|Study medication discontinued prior Wk12|2
6327896|NCT02969525|10071850|FG001|Double-Blind Period|Study medication discontinued prior Wk12|0
6327897|NCT02969525|10071851|FG002|Double-Blind Period|Study medication discontinued prior Wk12|0
6327898|NCT02969525|10071852|FG003|Double-Blind Period|Study medication discontinued prior Wk12|2
6327899|NCT02969525|10071853|FG004|Double-Blind Period|Study medication discontinued prior Wk12|0
6327900|NCT02969525|10071854|FG005|Double-Blind Period|Study medication discontinued prior Wk12|0
6327901|NCT02969525|10071855|FG006|Double-Blind Period|Study medication discontinued prior Wk12|0
6327902|NCT02969525|10071856|FG007|Double-Blind Period|Study medication discontinued prior Wk12|0
6327903|NCT02969525|10071857|FG008|Double-Blind Period|Study medication discontinued prior Wk12|0
6327904|NCT02969525|10071858|FG009|Double-Blind Period|Study medication discontinued prior Wk12|0
6327905|NCT02969525|10071859|FG010|Double-Blind Period|Study medication discontinued prior Wk12|0
6327906|NCT02969525|10071860|FG011|Double-Blind Period|Study medication discontinued prior Wk12|0
6327907|NCT02969525|10071849|FG000|Dose-Blind Period|Adverse Event|0
6327908|NCT02969525|10071850|FG001|Dose-Blind Period|Adverse Event|0
6327909|NCT02969525|10071851|FG002|Dose-Blind Period|Adverse Event|0
6327910|NCT02969525|10071852|FG003|Dose-Blind Period|Adverse Event|0
6327911|NCT02969525|10071853|FG004|Dose-Blind Period|Adverse Event|0
6327912|NCT02969525|10071854|FG005|Dose-Blind Period|Adverse Event|0
6327913|NCT02969525|10071855|FG006|Dose-Blind Period|Adverse Event|0
6327914|NCT02969525|10071856|FG007|Dose-Blind Period|Adverse Event|0
6327915|NCT02969525|10071857|FG008|Dose-Blind Period|Adverse Event|0
6327916|NCT02969525|10071858|FG009|Dose-Blind Period|Adverse Event|1
6327917|NCT02969525|10071859|FG010|Dose-Blind Period|Adverse Event|1
6327918|NCT02969525|10071860|FG011|Dose-Blind Period|Adverse Event|1
6327919|NCT02969525|10071849|FG000|Dose-Blind Period|Withdrawal by Subject|0
6327920|NCT02969525|10071850|FG001|Dose-Blind Period|Withdrawal by Subject|0
6327921|NCT02969525|10071851|FG002|Dose-Blind Period|Withdrawal by Subject|0
6327922|NCT02969525|10071852|FG003|Dose-Blind Period|Withdrawal by Subject|0
6327923|NCT02969525|10071853|FG004|Dose-Blind Period|Withdrawal by Subject|0
6327924|NCT02969525|10071854|FG005|Dose-Blind Period|Withdrawal by Subject|0
6327925|NCT02969525|10071855|FG006|Dose-Blind Period|Withdrawal by Subject|2
6327926|NCT02969525|10071856|FG007|Dose-Blind Period|Withdrawal by Subject|0
6327927|NCT02969525|10071857|FG008|Dose-Blind Period|Withdrawal by Subject|1
6327928|NCT02969525|10071858|FG009|Dose-Blind Period|Withdrawal by Subject|2
6327929|NCT02969525|10071859|FG010|Dose-Blind Period|Withdrawal by Subject|0
6327930|NCT02969525|10071860|FG011|Dose-Blind Period|Withdrawal by Subject|0
6327931|NCT02969525|10071849|FG000|Dose-Blind Period|Non-cooperating patient|0
6327932|NCT02969525|10071850|FG001|Dose-Blind Period|Non-cooperating patient|0
6327933|NCT02969525|10071851|FG002|Dose-Blind Period|Non-cooperating patient|0
6327934|NCT02969525|10071852|FG003|Dose-Blind Period|Non-cooperating patient|0
6327935|NCT02969525|10071853|FG004|Dose-Blind Period|Non-cooperating patient|0
6327936|NCT02969525|10071854|FG005|Dose-Blind Period|Non-cooperating patient|0
6327937|NCT02969525|10071855|FG006|Dose-Blind Period|Non-cooperating patient|0
6327938|NCT02969525|10071856|FG007|Dose-Blind Period|Non-cooperating patient|0
6327939|NCT02969525|10071857|FG008|Dose-Blind Period|Non-cooperating patient|0
6327940|NCT02969525|10071858|FG009|Dose-Blind Period|Non-cooperating patient|0
6327941|NCT02969525|10071859|FG010|Dose-Blind Period|Non-cooperating patient|0
6327942|NCT02969525|10071860|FG011|Dose-Blind Period|Non-cooperating patient|1
6327943|NCT02969525|10071849|FG000|Dose-Blind Period|Withdrew before Safety Follow-up visit|0
6327944|NCT02969525|10071850|FG001|Dose-Blind Period|Withdrew before Safety Follow-up visit|0
6327945|NCT02969525|10071851|FG002|Dose-Blind Period|Withdrew before Safety Follow-up visit|0
6327946|NCT02969525|10071852|FG003|Dose-Blind Period|Withdrew before Safety Follow-up visit|0
6327947|NCT02969525|10071853|FG004|Dose-Blind Period|Withdrew before Safety Follow-up visit|0
6327948|NCT02969525|10071854|FG005|Dose-Blind Period|Withdrew before Safety Follow-up visit|0
6327949|NCT02969525|10071855|FG006|Dose-Blind Period|Withdrew before Safety Follow-up visit|0
6327950|NCT02969525|10071856|FG007|Dose-Blind Period|Withdrew before Safety Follow-up visit|0
6327951|NCT02969525|10071857|FG008|Dose-Blind Period|Withdrew before Safety Follow-up visit|0
6327952|NCT02969525|10071858|FG009|Dose-Blind Period|Withdrew before Safety Follow-up visit|0
6327953|NCT02969525|10071859|FG010|Dose-Blind Period|Withdrew before Safety Follow-up visit|1
6327954|NCT02969525|10071860|FG011|Dose-Blind Period|Withdrew before Safety Follow-up visit|0
6327955|NCT02969590|10071882|FG000|Screening Period|Hormones not suppressed post Lupron|1
6327956|NCT02969590|10071883|FG001|Screening Period|Hormones not suppressed post Lupron|0
6327957|NCT02969590|10071884|FG002|Screening Period|Hormones not suppressed post Lupron|0
6327958|NCT02969655|10071896|FG000|Overall Study|Withdrawal by Subject|3
6327959|NCT02969655|10071897|FG001|Overall Study|Withdrawal by Subject|2
6327960|NCT02969655|10071896|FG000|Overall Study|Physician Decision|4
6327961|NCT02969655|10071897|FG001|Overall Study|Physician Decision|3
6327962|NCT02969655|10071896|FG000|Overall Study|Protocol-specified withdrawal criteria|4
6327963|NCT02969655|10071897|FG001|Overall Study|Protocol-specified withdrawal criteria|2
6327964|NCT02969655|10071896|FG000|Overall Study|Adverse Event|10
6327965|NCT02969655|10071897|FG001|Overall Study|Adverse Event|8
6327966|NCT02969707|10071906|FG000|Overall Study|Adverse Event|1
6327967|NCT02969707|10071907|FG001|Overall Study|Adverse Event|2
6327968|NCT02969707|10071906|FG000|Overall Study|Lost to Follow-up|3
6327969|NCT02969707|10071907|FG001|Overall Study|Lost to Follow-up|0
6327970|NCT02969707|10071906|FG000|Overall Study|Physician Decision|0
6327971|NCT02969707|10071907|FG001|Overall Study|Physician Decision|1
6327972|NCT02969707|10071906|FG000|Overall Study|Protocol Violation|1
6327973|NCT02969707|10071907|FG001|Overall Study|Protocol Violation|1
6327974|NCT02969707|10071906|FG000|Overall Study|Withdrawal by Subject|3
6327975|NCT02969707|10071907|FG001|Overall Study|Withdrawal by Subject|4
6327976|NCT02969863|10071918|FG000|Overall Study|Physician Decision|1
6327977|NCT02969863|10071919|FG001|Overall Study|Physician Decision|0
6327978|NCT02969863|10071920|FG002|Overall Study|Physician Decision|0
6327979|NCT02969863|10071921|FG003|Overall Study|Physician Decision|0
6327980|NCT02969863|10071922|FG004|Overall Study|Physician Decision|0
6327981|NCT02969863|10071923|FG005|Overall Study|Physician Decision|0
6327982|NCT02970292|10071962|FG000|Overall Study|Physician Decision|1
6327983|NCT02970292|10071963|FG001|Overall Study|Physician Decision|1
6327984|NCT02970292|10071962|FG000|Overall Study|Withdrawal by Subject|11
6327985|NCT02970292|10071963|FG001|Overall Study|Withdrawal by Subject|5
6327986|NCT02970292|10071962|FG000|Overall Study|Noncompliance with study drug|2
6327987|NCT02970292|10071963|FG001|Overall Study|Noncompliance with study drug|2
6327988|NCT02970292|10071962|FG000|Overall Study|Adverse Event|5
6327989|NCT02970292|10071963|FG001|Overall Study|Adverse Event|0
6327990|NCT02970292|10071962|FG000|Overall Study|Lack of Efficacy|1
6327991|NCT02970292|10071963|FG001|Overall Study|Lack of Efficacy|0
6327992|NCT02970292|10071962|FG000|Overall Study|Lost to Follow-up|1
6327993|NCT02970292|10071963|FG001|Overall Study|Lost to Follow-up|0
6327994|NCT02970292|10071962|FG000|Overall Study|Protocol Violation|2
6327995|NCT02970292|10071963|FG001|Overall Study|Protocol Violation|0
6327996|NCT02970292|10071962|FG000|Overall Study|Other|1
6327997|NCT02970292|10071963|FG001|Overall Study|Other|0
6327998|NCT02970305|10071971|FG000|Overall Study|Adverse Event|10
6327999|NCT02970305|10071972|FG001|Overall Study|Adverse Event|6
6328000|NCT02970305|10071971|FG000|Overall Study|Lack of Efficacy|1
6328001|NCT02970305|10071972|FG001|Overall Study|Lack of Efficacy|1
6328002|NCT02970305|10071971|FG000|Overall Study|Noncompliance with study drug|2
6328003|NCT02970305|10071972|FG001|Overall Study|Noncompliance with study drug|4
6328004|NCT02970305|10071971|FG000|Overall Study|Protocol Violation|2
6328005|NCT02970305|10071972|FG001|Overall Study|Protocol Violation|2
6328006|NCT02970305|10071971|FG000|Overall Study|Withdrawal by Subject|12
6328007|NCT02970305|10071972|FG001|Overall Study|Withdrawal by Subject|11
6328008|NCT02970305|10071971|FG000|Overall Study|Not further specified|1
6328009|NCT02970305|10071972|FG001|Overall Study|Not further specified|2
6328010|NCT02970305|10071971|FG000|Overall Study|Lost to Follow-up|1
6328011|NCT02970305|10071972|FG001|Overall Study|Lost to Follow-up|2
6328012|NCT02970669|10072016|FG000|Double-blind Period|Adverse Event|4
6328013|NCT02970669|10072017|FG001|Double-blind Period|Adverse Event|0
6328014|NCT02970669|10072016|FG000|Double-blind Period|Death|1
6328015|NCT02970669|10072017|FG001|Double-blind Period|Death|0
6328016|NCT02970669|10072016|FG000|Double-blind Period|Study terminated by sponsor|1
6328017|NCT02970669|10072017|FG001|Double-blind Period|Study terminated by sponsor|2
6328018|NCT02970669|10072016|FG000|Double-blind Period|Physician Decision|0
6328019|NCT02970669|10072017|FG001|Double-blind Period|Physician Decision|2
6328020|NCT02970669|10072016|FG000|Double-blind Period|Withdrawal by Subject|2
6328021|NCT02970669|10072017|FG001|Double-blind Period|Withdrawal by Subject|2
6328022|NCT02970669|10072016|FG000|Open-label Period|Withdrawal by Subject|2
6328023|NCT02970669|10072017|FG001|Open-label Period|Withdrawal by Subject|2
6328024|NCT02970669|10072016|FG000|Open-label Period|Adverse Event|1
6328025|NCT02970669|10072017|FG001|Open-label Period|Adverse Event|0
6328026|NCT02970669|10072016|FG000|Open-label Period|Physician Decision|1
6328027|NCT02970669|10072017|FG001|Open-label Period|Physician Decision|0
6328028|NCT02970942|10072038|FG000|Overall Study|Death|0
6328029|NCT02970942|10072039|FG001|Overall Study|Death|1
6328030|NCT02970942|10072040|FG002|Overall Study|Death|0
6328031|NCT02970942|10072041|FG003|Overall Study|Death|0
6328032|NCT02970942|10072038|FG000|Overall Study|Lost to Follow-up|1
6328033|NCT02970942|10072039|FG001|Overall Study|Lost to Follow-up|0
6328034|NCT02970942|10072040|FG002|Overall Study|Lost to Follow-up|2
6328035|NCT02970942|10072041|FG003|Overall Study|Lost to Follow-up|1
6328036|NCT02970942|10072038|FG000|Overall Study|Withdrawal by Subject|3
6328037|NCT02970942|10072039|FG001|Overall Study|Withdrawal by Subject|5
6328038|NCT02970942|10072040|FG002|Overall Study|Withdrawal by Subject|3
6328039|NCT02970942|10072041|FG003|Overall Study|Withdrawal by Subject|2
6328040|NCT02971007|10072054|FG000|Overall Study|Adverse Event|1
6328041|NCT02971007|10072055|FG001|Overall Study|Adverse Event|0
6328042|NCT02971007|10072056|FG002|Overall Study|Adverse Event|0
6328043|NCT02971007|10072054|FG000|Overall Study|Lost to Follow-up|0
6328044|NCT02971007|10072055|FG001|Overall Study|Lost to Follow-up|1
6328045|NCT02971007|10072056|FG002|Overall Study|Lost to Follow-up|1
6328046|NCT02971007|10072054|FG000|Overall Study|Withdrawal by Subject|0
6328047|NCT02971007|10072055|FG001|Overall Study|Withdrawal by Subject|1
6328048|NCT02971007|10072056|FG002|Overall Study|Withdrawal by Subject|0
6328049|NCT02971007|10072054|FG000|Overall Study|Patient had yeast at Day 5 visit|1
6328050|NCT02971007|10072055|FG001|Overall Study|Patient had yeast at Day 5 visit|0
6328051|NCT02971007|10072056|FG002|Overall Study|Patient had yeast at Day 5 visit|0
6328052|NCT02971007|10072054|FG000|Overall Study|Patient discontinued study drug|0
6328053|NCT02971007|10072055|FG001|Overall Study|Patient discontinued study drug|1
6328054|NCT02971007|10072056|FG002|Overall Study|Patient discontinued study drug|0
6328055|NCT02971163|10072066|FG000|Overall Study|Lost to Follow-up|4
6328056|NCT02971163|10072067|FG001|Overall Study|Lost to Follow-up|2
6328057|NCT02971202|10072076|FG000|Overall Study|Pregnancy|1
6328058|NCT02971202|10072077|FG001|Overall Study|Pregnancy|0
6328059|NCT02971202|10072078|FG002|Overall Study|Pregnancy|0
6328060|NCT02971202|10072076|FG000|Overall Study|screen fail after consent|1
6328061|NCT02971202|10072077|FG001|Overall Study|screen fail after consent|0
6328062|NCT02971202|10072078|FG002|Overall Study|screen fail after consent|1
6328063|NCT02971228|10072086|FG000|Overall Study|Withdrawal by Subject|1
6328064|NCT02971228|10072087|FG001|Overall Study|Withdrawal by Subject|1
6328065|NCT02971228|10072088|FG002|Overall Study|Withdrawal by Subject|0
6328066|NCT02971228|10072089|FG003|Overall Study|Withdrawal by Subject|0
6328067|NCT02971228|10072090|FG004|Overall Study|Withdrawal by Subject|0
6328068|NCT02971228|10072086|FG000|Overall Study|Logistical challenges|0
6328069|NCT02971228|10072087|FG001|Overall Study|Logistical challenges|1
6328070|NCT02971228|10072088|FG002|Overall Study|Logistical challenges|0
6328071|NCT02971228|10072089|FG003|Overall Study|Logistical challenges|0
6328072|NCT02971228|10072090|FG004|Overall Study|Logistical challenges|0
6328073|NCT02971605|10072116|FG000|Overall Study|Withdrawal by Subject|1
6328074|NCT02971670|10072134|FG000|Overall Study|Withdrawal by Subject|4
6328075|NCT02971670|10072135|FG001|Overall Study|Withdrawal by Subject|1
6328076|NCT02971670|10072136|FG002|Overall Study|Withdrawal by Subject|1
6328077|NCT02971670|10072137|FG003|Overall Study|Withdrawal by Subject|2
6328078|NCT02971800|10072156|FG000|Overall Study|Protocol Violation|1
6328079|NCT02971800|10072156|FG000|Overall Study|Withdrawal by Subject|1
6328080|NCT02971800|10072156|FG000|Overall Study|Exclusion criteria prior intervention|1
6328081|NCT02971800|10072156|FG000|Overall Study|Number evaluable participant already reached|4
6328082|NCT02972242|10072162|FG000|Overall Study|Withdrawal by Subject|1
6328083|NCT02972242|10072163|FG001|Overall Study|Withdrawal by Subject|0
6328084|NCT02972359|10072169|FG000|Overall Study|Incl. criteria not met/Exclusion met|2
6328085|NCT02972359|10072169|FG000|Overall Study|Lack of Efficacy|1
6328086|NCT02972359|10072169|FG000|Overall Study|Adverse Event|4
6328087|NCT02972359|10072169|FG000|Overall Study|Death|1
6328088|NCT02972359|10072169|FG000|Overall Study|Withdrawal by Subject|30
6328089|NCT02972359|10072169|FG000|Overall Study|Protocol Violation|1
6328090|NCT02972359|10072169|FG000|Overall Study|Lost to Follow-up|26
6328091|NCT02972359|10072169|FG000|Overall Study|Other reasons|5
6328092|NCT02972359|10072169|FG000|Overall Study|Missing|1
6328093|NCT02972502|10072175|FG000|Overall Study|Lost to Follow-up|3
6328094|NCT02972502|10072176|FG001|Overall Study|Lost to Follow-up|1
6328095|NCT02972502|10072175|FG000|Overall Study|Withdrawal by Subject|1
6328096|NCT02972502|10072176|FG001|Overall Study|Withdrawal by Subject|1
6328097|NCT02972515|10072182|FG000|Overall Study|Lost to Follow-up|78
6328098|NCT02972632|10072195|FG000|Overall Study|Pretreatment Event/Adverse Event|3
6328099|NCT02972632|10072195|FG000|Overall Study|Lost to Follow-up|4
6328100|NCT02972632|10072195|FG000|Overall Study|Voluntary Withdrawal|10
6328101|NCT02972658|10072203|FG000|Overall Study|Adverse Event|0
6328102|NCT02972658|10072204|FG001|Overall Study|Adverse Event|3
6328103|NCT02972658|10072205|FG002|Overall Study|Adverse Event|0
6328104|NCT02972658|10072206|FG003|Overall Study|Adverse Event|2
6328105|NCT02972658|10072203|FG000|Overall Study|Other-determined by Investigator|1
6328106|NCT02972658|10072204|FG001|Overall Study|Other-determined by Investigator|1
6328107|NCT02972658|10072205|FG002|Overall Study|Other-determined by Investigator|0
6328108|NCT02972658|10072206|FG003|Overall Study|Other-determined by Investigator|0
6328109|NCT02972658|10072203|FG000|Overall Study|Death|0
6328110|NCT02972658|10072204|FG001|Overall Study|Death|0
6328111|NCT02972658|10072205|FG002|Overall Study|Death|0
6328112|NCT02972658|10072206|FG003|Overall Study|Death|1
6328113|NCT02972658|10072203|FG000|Overall Study|Lost to Follow-up|0
6328114|NCT02972658|10072204|FG001|Overall Study|Lost to Follow-up|1
6328115|NCT02972658|10072205|FG002|Overall Study|Lost to Follow-up|1
6328116|NCT02972658|10072206|FG003|Overall Study|Lost to Follow-up|2
6328117|NCT02972658|10072203|FG000|Overall Study|Progressive Disease|0
6328118|NCT02972658|10072204|FG001|Overall Study|Progressive Disease|1
6328119|NCT02972658|10072205|FG002|Overall Study|Progressive Disease|0
6328120|NCT02972658|10072206|FG003|Overall Study|Progressive Disease|1
6328121|NCT02972658|10072203|FG000|Overall Study|Withdrawal by Subject|4
6328122|NCT02972658|10072204|FG001|Overall Study|Withdrawal by Subject|4
6328123|NCT02972658|10072205|FG002|Overall Study|Withdrawal by Subject|1
6328124|NCT02972658|10072206|FG003|Overall Study|Withdrawal by Subject|6
6328125|NCT02972658|10072203|FG000|Overall Study|Withdrawal due to Caregiver Circumstance|1
6328126|NCT02972658|10072204|FG001|Overall Study|Withdrawal due to Caregiver Circumstance|1
6328127|NCT02972658|10072205|FG002|Overall Study|Withdrawal due to Caregiver Circumstance|1
6328128|NCT02972658|10072206|FG003|Overall Study|Withdrawal due to Caregiver Circumstance|0
6328129|NCT02972658|10072203|FG000|Overall Study|Sponsor Decision|70
6328130|NCT02972658|10072204|FG001|Overall Study|Sponsor Decision|127
6328131|NCT02972658|10072205|FG002|Overall Study|Sponsor Decision|72
6328132|NCT02972658|10072206|FG003|Overall Study|Sponsor Decision|119
6328133|NCT02973048|10072218|FG000|Overall Study|Epidural catheter insertion failure|1
6328134|NCT02973048|10072219|FG001|Overall Study|Epidural catheter insertion failure|0
6328135|NCT02973048|10072218|FG000|Overall Study|Withdrawal by Subject|0
6328136|NCT02973048|10072219|FG001|Overall Study|Withdrawal by Subject|3
6328137|NCT02973087|10072227|FG000|Overall Study|Withdrawal by Subject|2
6328138|NCT02973087|10072228|FG001|Overall Study|Withdrawal by Subject|1
6328139|NCT02973087|10072227|FG000|Overall Study|Adverse Event|1
6328140|NCT02973087|10072228|FG001|Overall Study|Adverse Event|0
6328141|NCT02973087|10072227|FG000|Overall Study|other|1
6328142|NCT02973087|10072228|FG001|Overall Study|other|1
6328143|NCT02973100|10072239|FG000|Overall Study|Adverse Event|1
6328144|NCT02973100|10072240|FG001|Overall Study|Adverse Event|2
6328145|NCT02973100|10072241|FG002|Overall Study|Adverse Event|1
6328146|NCT02973100|10072242|FG003|Overall Study|Adverse Event|2
6328147|NCT02973100|10072239|FG000|Overall Study|Lost to Follow-up|3
6328148|NCT02973100|10072240|FG001|Overall Study|Lost to Follow-up|1
6328149|NCT02973100|10072241|FG002|Overall Study|Lost to Follow-up|1
6328150|NCT02973100|10072242|FG003|Overall Study|Lost to Follow-up|0
6328151|NCT02973100|10072239|FG000|Overall Study|Withdrawal by Subject|3
6328152|NCT02973100|10072240|FG001|Overall Study|Withdrawal by Subject|5
6328153|NCT02973100|10072241|FG002|Overall Study|Withdrawal by Subject|1
6328154|NCT02973100|10072242|FG003|Overall Study|Withdrawal by Subject|4
6328155|NCT02973100|10072239|FG000|Overall Study|Notification of change in address|0
6328156|NCT02973100|10072240|FG001|Overall Study|Notification of change in address|0
6328157|NCT02973100|10072241|FG002|Overall Study|Notification of change in address|0
6328158|NCT02973100|10072242|FG003|Overall Study|Notification of change in address|1
6328159|NCT02973100|10072239|FG000|Overall Study|Failed to attend Safety followup period|0
6328160|NCT02973100|10072240|FG001|Overall Study|Failed to attend Safety followup period|0
6328161|NCT02973100|10072241|FG002|Overall Study|Failed to attend Safety followup period|1
6328162|NCT02973100|10072242|FG003|Overall Study|Failed to attend Safety followup period|0
6328163|NCT02973477|10072275|FG000|First Intervention|Lost to Follow-up|0
6328164|NCT02973477|10072276|FG001|First Intervention|Lost to Follow-up|2
6328165|NCT02973477|10072275|FG000|Washout|Withdrawal by Subject|1
6328166|NCT02973477|10072276|FG001|Washout|Withdrawal by Subject|0
6328167|NCT02973477|10072275|FG000|Second Intervention|Lost to Follow-up|1
6328168|NCT02973477|10072276|FG001|Second Intervention|Lost to Follow-up|0
6328169|NCT02973802|10072306|FG000|Overall Study|Lost to Follow-up|1
6328170|NCT02973802|10072306|FG000|Overall Study|Withdrawal by Subject|1
6328171|NCT02974010|10072315|FG000|Overall Study|Lost to Follow-up|3
6328172|NCT02974010|10072316|FG001|Overall Study|Lost to Follow-up|1
6328173|NCT02974010|10072317|FG002|Overall Study|Lost to Follow-up|0
6328174|NCT02974010|10072318|FG003|Overall Study|Lost to Follow-up|0
6328175|NCT02974010|10072315|FG000|Overall Study|Withdrawal by Subject|2
6328176|NCT02974010|10072316|FG001|Overall Study|Withdrawal by Subject|1
6328177|NCT02974010|10072317|FG002|Overall Study|Withdrawal by Subject|0
6328178|NCT02974010|10072318|FG003|Overall Study|Withdrawal by Subject|0
6328179|NCT02974010|10072315|FG000|Overall Study|Adverse Event|0
6328180|NCT02974010|10072316|FG001|Overall Study|Adverse Event|1
6328181|NCT02974010|10072317|FG002|Overall Study|Adverse Event|0
6328182|NCT02974010|10072318|FG003|Overall Study|Adverse Event|0
6328183|NCT02974010|10072315|FG000|Overall Study|Completed day 42 but did not return for day 70|1
6328184|NCT02974010|10072316|FG001|Overall Study|Completed day 42 but did not return for day 70|0
6328185|NCT02974010|10072317|FG002|Overall Study|Completed day 42 but did not return for day 70|1
6328186|NCT02974010|10072318|FG003|Overall Study|Completed day 42 but did not return for day 70|0
6328187|NCT02974010|10072315|FG000|Overall Study|Lack of Efficacy|0
6328188|NCT02974010|10072316|FG001|Overall Study|Lack of Efficacy|0
6328189|NCT02974010|10072317|FG002|Overall Study|Lack of Efficacy|1
6328190|NCT02974010|10072318|FG003|Overall Study|Lack of Efficacy|0
6328191|NCT02974088|10072330|FG000|Overall Study|Lost to Follow-up|0
6328192|NCT02974088|10072331|FG001|Overall Study|Lost to Follow-up|2
6328193|NCT02974088|10072330|FG000|Overall Study|Adverse Event|0
6328194|NCT02974088|10072331|FG001|Overall Study|Adverse Event|1
6328195|NCT02974114|10072340|FG000|Overall Study|Other (Not specified)|0
6328196|NCT02974114|10072341|FG001|Overall Study|Other (Not specified)|1
6328197|NCT02974114|10072342|FG002|Overall Study|Other (Not specified)|2
6328198|NCT02974140|10072352|FG000|Overall Study|Adverse Event|2
6328199|NCT02974140|10072352|FG000|Overall Study|Lost to Follow-up|1
6328200|NCT02974140|10072352|FG000|Overall Study|Study Terminated by Sponsor|36
6328201|NCT02974153|10072362|FG000|Overall Study|Adverse Event|6
6328202|NCT02974153|10072363|FG001|Overall Study|Adverse Event|0
6328203|NCT02974153|10072364|FG002|Overall Study|Adverse Event|1
6328204|NCT02974153|10072362|FG000|Overall Study|Lack of Efficacy|6
6167152|NCT01226043|9811522|FG002|30-week Observational Phase|Withdrawal by Subject|1
6167153|NCT01226043|9811523|FG003|30-week Observational Phase|Withdrawal by Subject|7
6328205|NCT02974153|10072363|FG001|Overall Study|Lack of Efficacy|5
6328206|NCT02974153|10072364|FG002|Overall Study|Lack of Efficacy|10
6328207|NCT02974153|10072362|FG000|Overall Study|Lost to Follow-up|9
6328208|NCT02974153|10072363|FG001|Overall Study|Lost to Follow-up|10
6328209|NCT02974153|10072364|FG002|Overall Study|Lost to Follow-up|17
6328210|NCT02974153|10072362|FG000|Overall Study|Physician Decision|0
6328211|NCT02974153|10072363|FG001|Overall Study|Physician Decision|2
6328212|NCT02974153|10072364|FG002|Overall Study|Physician Decision|1
6328213|NCT02974153|10072362|FG000|Overall Study|Withdrawal by Subject|9
6328214|NCT02974153|10072363|FG001|Overall Study|Withdrawal by Subject|16
6328215|NCT02974153|10072364|FG002|Overall Study|Withdrawal by Subject|11
6328216|NCT02974153|10072362|FG000|Overall Study|Study Burden|8
6328217|NCT02974153|10072363|FG001|Overall Study|Study Burden|7
6328218|NCT02974153|10072364|FG002|Overall Study|Study Burden|3
6328219|NCT02974153|10072362|FG000|Overall Study|Other|14
6328220|NCT02974153|10072363|FG001|Overall Study|Other|8
6328221|NCT02974153|10072364|FG002|Overall Study|Other|7
6328222|NCT02974543|10072383|FG000|Overall Study|Withdrawal by Subject|1
6328223|NCT02974543|10072384|FG001|Overall Study|Withdrawal by Subject|0
6328224|NCT02974634|10072400|FG000|Overall Study|Advanced disease|12
6328225|NCT02974634|10072401|FG001|Overall Study|Advanced disease|3
6328226|NCT02974634|10072400|FG000|Overall Study|Noncompliance|3
6328227|NCT02974634|10072401|FG001|Overall Study|Noncompliance|7
6328228|NCT02974634|10072400|FG000|Overall Study|intervention technology related issues|5
6328229|NCT02974634|10072401|FG001|Overall Study|intervention technology related issues|0
6328230|NCT02974634|10072400|FG000|Overall Study|Death|8
6328231|NCT02974634|10072401|FG001|Overall Study|Death|11
6167154|NCT01226043|9811520|FG000|30-week Observational Phase|Physician Decision|0
6167155|NCT01226043|9811521|FG001|30-week Observational Phase|Physician Decision|0
6167156|NCT01226043|9811522|FG002|30-week Observational Phase|Physician Decision|2
6167157|NCT01226043|9811523|FG003|30-week Observational Phase|Physician Decision|2
6167158|NCT01226095|9811553|FG000|Overall Study|Poor compliance|1
6167159|NCT01226121|9811567|FG000|Overall Study|Lost to Follow-up|2
6167160|NCT01226121|9811568|FG001|Overall Study|Lost to Follow-up|0
6167161|NCT01226121|9811569|FG002|Overall Study|Lost to Follow-up|1
6328232|NCT02974842|10072408|FG000|Overall Study|Withdrawal by Subject|4
6328233|NCT02974842|10072408|FG000|Overall Study|Screen failures|4
6328234|NCT02974855|10072416|FG000|Overall Study|Adverse Event|0
6328235|NCT02974855|10072417|FG001|Overall Study|Adverse Event|1
6328236|NCT02974855|10072418|FG002|Overall Study|Adverse Event|0
6328237|NCT02974855|10072419|FG003|Overall Study|Adverse Event|1
6328238|NCT02974868|10072436|FG000|Initial 24-Week Treatment Period (TP)|Adverse Event|1
6328239|NCT02974868|10072437|FG001|Initial 24-Week Treatment Period (TP)|Adverse Event|1
6328240|NCT02974868|10072438|FG002|Initial 24-Week Treatment Period (TP)|Adverse Event|2
6328241|NCT02974868|10072439|FG003|Initial 24-Week Treatment Period (TP)|Adverse Event|4
6328242|NCT02974868|10072436|FG000|Initial 24-Week Treatment Period (TP)|others|3
6328243|NCT02974868|10072437|FG001|Initial 24-Week Treatment Period (TP)|others|8
6328244|NCT02974868|10072438|FG002|Initial 24-Week Treatment Period (TP)|others|1
6328245|NCT02974868|10072439|FG003|Initial 24-Week Treatment Period (TP)|others|8
6328246|NCT02974868|10072436|FG000|Single-Blind Extension (SBE) Period|AE & Withdraw by participants|2
6328247|NCT02974868|10072437|FG001|Single-Blind Extension (SBE) Period|AE & Withdraw by participants|1
6328248|NCT02974868|10072438|FG002|Single-Blind Extension (SBE) Period|AE & Withdraw by participants|11
6328249|NCT02974868|10072439|FG003|Single-Blind Extension (SBE) Period|AE & Withdraw by participants|6
6328250|NCT02974868|10072436|FG000|Cross-Over Extension (COE) Period|Withdrawal by Subject|2
6328251|NCT02974868|10072437|FG001|Cross-Over Extension (COE) Period|Withdrawal by Subject|1
6328252|NCT02974868|10072438|FG002|Cross-Over Extension (COE) Period|Withdrawal by Subject|3
6328253|NCT02974868|10072439|FG003|Cross-Over Extension (COE) Period|Withdrawal by Subject|0
6328254|NCT02975206|10072483|FG000|Overall Study|Withdrawal by Subject|14
6328255|NCT02975206|10072484|FG001|Overall Study|Withdrawal by Subject|11
6328256|NCT02975206|10072485|FG002|Overall Study|Withdrawal by Subject|11
6328257|NCT02975206|10072483|FG000|Overall Study|Other (e.g., lost to follow up)|13
6328258|NCT02975206|10072484|FG001|Overall Study|Other (e.g., lost to follow up)|6
6328259|NCT02975206|10072485|FG002|Overall Study|Other (e.g., lost to follow up)|6
6328260|NCT02975336|10072506|FG000|DBPC (52 Weeks)|Adverse Event|16
6328261|NCT02975336|10072507|FG001|DBPC (52 Weeks)|Adverse Event|17
6328262|NCT02975336|10072508|FG002|DBPC (52 Weeks)|Adverse Event|13
6328263|NCT02975336|10072509|FG003|DBPC (52 Weeks)|Adverse Event|18
6328264|NCT02975336|10072510|FG004|DBPC (52 Weeks)|Adverse Event|0
6328265|NCT02975336|10072511|FG005|DBPC (52 Weeks)|Adverse Event|0
6328266|NCT02975336|10072512|FG006|DBPC (52 Weeks)|Adverse Event|0
6328267|NCT02975336|10072513|FG007|DBPC (52 Weeks)|Adverse Event|0
6328268|NCT02975336|10072506|FG000|DBPC (52 Weeks)|Lost to Follow-up|2
6328269|NCT02975336|10072507|FG001|DBPC (52 Weeks)|Lost to Follow-up|1
6328270|NCT02975336|10072508|FG002|DBPC (52 Weeks)|Lost to Follow-up|2
6328271|NCT02975336|10072509|FG003|DBPC (52 Weeks)|Lost to Follow-up|4
6328272|NCT02975336|10072510|FG004|DBPC (52 Weeks)|Lost to Follow-up|0
6328273|NCT02975336|10072511|FG005|DBPC (52 Weeks)|Lost to Follow-up|0
6328274|NCT02975336|10072512|FG006|DBPC (52 Weeks)|Lost to Follow-up|0
6328275|NCT02975336|10072513|FG007|DBPC (52 Weeks)|Lost to Follow-up|0
6328276|NCT02975336|10072506|FG000|DBPC (52 Weeks)|Protocol Violation|4
6328277|NCT02975336|10072507|FG001|DBPC (52 Weeks)|Protocol Violation|1
6328278|NCT02975336|10072508|FG002|DBPC (52 Weeks)|Protocol Violation|3
6328279|NCT02975336|10072509|FG003|DBPC (52 Weeks)|Protocol Violation|1
6328280|NCT02975336|10072510|FG004|DBPC (52 Weeks)|Protocol Violation|0
6328281|NCT02975336|10072511|FG005|DBPC (52 Weeks)|Protocol Violation|0
6328282|NCT02975336|10072512|FG006|DBPC (52 Weeks)|Protocol Violation|0
6328283|NCT02975336|10072513|FG007|DBPC (52 Weeks)|Protocol Violation|0
6328284|NCT02975336|10072506|FG000|DBPC (52 Weeks)|Lack of Efficacy|4
6328285|NCT02975336|10072507|FG001|DBPC (52 Weeks)|Lack of Efficacy|4
6328286|NCT02975336|10072508|FG002|DBPC (52 Weeks)|Lack of Efficacy|2
6328287|NCT02975336|10072509|FG003|DBPC (52 Weeks)|Lack of Efficacy|3
6328288|NCT02975336|10072510|FG004|DBPC (52 Weeks)|Lack of Efficacy|0
6328289|NCT02975336|10072511|FG005|DBPC (52 Weeks)|Lack of Efficacy|0
6328290|NCT02975336|10072512|FG006|DBPC (52 Weeks)|Lack of Efficacy|0
6328291|NCT02975336|10072513|FG007|DBPC (52 Weeks)|Lack of Efficacy|0
6328292|NCT02975336|10072506|FG000|DBPC (52 Weeks)|Withdrawal by Subject|1
6328293|NCT02975336|10072507|FG001|DBPC (52 Weeks)|Withdrawal by Subject|0
6328294|NCT02975336|10072508|FG002|DBPC (52 Weeks)|Withdrawal by Subject|1
6328295|NCT02975336|10072509|FG003|DBPC (52 Weeks)|Withdrawal by Subject|3
6328296|NCT02975336|10072510|FG004|DBPC (52 Weeks)|Withdrawal by Subject|0
6328297|NCT02975336|10072511|FG005|DBPC (52 Weeks)|Withdrawal by Subject|0
6328298|NCT02975336|10072512|FG006|DBPC (52 Weeks)|Withdrawal by Subject|0
6328299|NCT02975336|10072513|FG007|DBPC (52 Weeks)|Withdrawal by Subject|0
6328300|NCT02975336|10072506|FG000|DBPC (52 Weeks)|Premature termination of the study|5
6328301|NCT02975336|10072507|FG001|DBPC (52 Weeks)|Premature termination of the study|6
6328302|NCT02975336|10072508|FG002|DBPC (52 Weeks)|Premature termination of the study|6
6328303|NCT02975336|10072509|FG003|DBPC (52 Weeks)|Premature termination of the study|4
6328304|NCT02975336|10072510|FG004|DBPC (52 Weeks)|Premature termination of the study|0
6328305|NCT02975336|10072511|FG005|DBPC (52 Weeks)|Premature termination of the study|0
6328306|NCT02975336|10072512|FG006|DBPC (52 Weeks)|Premature termination of the study|0
6328307|NCT02975336|10072513|FG007|DBPC (52 Weeks)|Premature termination of the study|0
6328308|NCT02975336|10072506|FG000|LTE (104 Weeks)|Adverse Event|0
6328309|NCT02975336|10072507|FG001|LTE (104 Weeks)|Adverse Event|0
6328310|NCT02975336|10072508|FG002|LTE (104 Weeks)|Adverse Event|0
6328311|NCT02975336|10072509|FG003|LTE (104 Weeks)|Adverse Event|0
6328312|NCT02975336|10072510|FG004|LTE (104 Weeks)|Adverse Event|7
6328313|NCT02975336|10072511|FG005|LTE (104 Weeks)|Adverse Event|4
6328314|NCT02975336|10072512|FG006|LTE (104 Weeks)|Adverse Event|2
6328315|NCT02975336|10072513|FG007|LTE (104 Weeks)|Adverse Event|0
6328316|NCT02975336|10072506|FG000|LTE (104 Weeks)|Lost to Follow-up|0
6328317|NCT02975336|10072507|FG001|LTE (104 Weeks)|Lost to Follow-up|0
6328318|NCT02975336|10072508|FG002|LTE (104 Weeks)|Lost to Follow-up|0
6328319|NCT02975336|10072509|FG003|LTE (104 Weeks)|Lost to Follow-up|0
6328320|NCT02975336|10072510|FG004|LTE (104 Weeks)|Lost to Follow-up|0
6328321|NCT02975336|10072511|FG005|LTE (104 Weeks)|Lost to Follow-up|1
6328322|NCT02975336|10072512|FG006|LTE (104 Weeks)|Lost to Follow-up|0
6328323|NCT02975336|10072513|FG007|LTE (104 Weeks)|Lost to Follow-up|0
6328324|NCT02975336|10072506|FG000|LTE (104 Weeks)|Lack of Efficacy|0
6328325|NCT02975336|10072507|FG001|LTE (104 Weeks)|Lack of Efficacy|0
6328326|NCT02975336|10072508|FG002|LTE (104 Weeks)|Lack of Efficacy|0
6328327|NCT02975336|10072509|FG003|LTE (104 Weeks)|Lack of Efficacy|0
6328328|NCT02975336|10072510|FG004|LTE (104 Weeks)|Lack of Efficacy|0
6328329|NCT02975336|10072511|FG005|LTE (104 Weeks)|Lack of Efficacy|1
6328330|NCT02975336|10072512|FG006|LTE (104 Weeks)|Lack of Efficacy|2
6328331|NCT02975336|10072513|FG007|LTE (104 Weeks)|Lack of Efficacy|0
6328332|NCT02975336|10072506|FG000|LTE (104 Weeks)|Other|0
6328333|NCT02975336|10072507|FG001|LTE (104 Weeks)|Other|0
6328334|NCT02975336|10072508|FG002|LTE (104 Weeks)|Other|0
6167162|NCT01226459|9811583|FG000|Overall Study|Adverse Event|2
6167163|NCT01226459|9811584|FG001|Overall Study|Adverse Event|8
6167164|NCT01226459|9811583|FG000|Overall Study|Protocol Violation|4
6167165|NCT01226459|9811584|FG001|Overall Study|Protocol Violation|3
6167166|NCT01226459|9811583|FG000|Overall Study|Withdrawal by Subject|10
6167167|NCT01226459|9811584|FG001|Overall Study|Withdrawal by Subject|13
6167168|NCT01226459|9811583|FG000|Overall Study|Lost to Follow-up|4
6167169|NCT01226459|9811584|FG001|Overall Study|Lost to Follow-up|8
6328335|NCT02975336|10072509|FG003|LTE (104 Weeks)|Other|0
6328336|NCT02975336|10072510|FG004|LTE (104 Weeks)|Other|55
6328337|NCT02975336|10072511|FG005|LTE (104 Weeks)|Other|63
6328338|NCT02975336|10072512|FG006|LTE (104 Weeks)|Other|76
6328339|NCT02975336|10072513|FG007|LTE (104 Weeks)|Other|72
6328340|NCT02975349|10072532|FG000|Active Treatment Period (24 Weeks)|Withdrawal by Subject|0
6328341|NCT02975349|10072533|FG001|Active Treatment Period (24 Weeks)|Withdrawal by Subject|0
6328342|NCT02975349|10072534|FG002|Active Treatment Period (24 Weeks)|Withdrawal by Subject|3
6328343|NCT02975349|10072535|FG003|Active Treatment Period (24 Weeks)|Withdrawal by Subject|3
6328344|NCT02975349|10072536|FG004|Active Treatment Period (24 Weeks)|Withdrawal by Subject|0
6328345|NCT02975349|10072537|FG005|Active Treatment Period (24 Weeks)|Withdrawal by Subject|0
6167170|NCT01226459|9811583|FG000|Overall Study|Pregnancy|1
6328346|NCT02975349|10072532|FG000|Active Treatment Period (24 Weeks)|Lost to Follow-up|1
6328347|NCT02975349|10072533|FG001|Active Treatment Period (24 Weeks)|Lost to Follow-up|0
6328348|NCT02975349|10072534|FG002|Active Treatment Period (24 Weeks)|Lost to Follow-up|0
6328349|NCT02975349|10072535|FG003|Active Treatment Period (24 Weeks)|Lost to Follow-up|0
6328350|NCT02975349|10072536|FG004|Active Treatment Period (24 Weeks)|Lost to Follow-up|0
6328351|NCT02975349|10072537|FG005|Active Treatment Period (24 Weeks)|Lost to Follow-up|0
6328352|NCT02975349|10072532|FG000|Active Treatment Period (24 Weeks)|Adverse Event|4
6328353|NCT02975349|10072533|FG001|Active Treatment Period (24 Weeks)|Adverse Event|0
6328354|NCT02975349|10072534|FG002|Active Treatment Period (24 Weeks)|Adverse Event|1
6328355|NCT02975349|10072535|FG003|Active Treatment Period (24 Weeks)|Adverse Event|2
6328356|NCT02975349|10072536|FG004|Active Treatment Period (24 Weeks)|Adverse Event|6
6328357|NCT02975349|10072537|FG005|Active Treatment Period (24 Weeks)|Adverse Event|2
6328358|NCT02975349|10072532|FG000|Active Treatment Period (24 Weeks)|Un-specified|0
6328359|NCT02975349|10072533|FG001|Active Treatment Period (24 Weeks)|Un-specified|0
6328360|NCT02975349|10072534|FG002|Active Treatment Period (24 Weeks)|Un-specified|1
6328361|NCT02975349|10072535|FG003|Active Treatment Period (24 Weeks)|Un-specified|0
6328362|NCT02975349|10072536|FG004|Active Treatment Period (24 Weeks)|Un-specified|0
6328363|NCT02975349|10072537|FG005|Active Treatment Period (24 Weeks)|Un-specified|0
6328364|NCT02975349|10072532|FG000|Blinded Extension Period (24 Weeks)|Adverse Event|0
6328365|NCT02975349|10072533|FG001|Blinded Extension Period (24 Weeks)|Adverse Event|1
6328366|NCT02975349|10072534|FG002|Blinded Extension Period (24 Weeks)|Adverse Event|1
6328367|NCT02975349|10072535|FG003|Blinded Extension Period (24 Weeks)|Adverse Event|2
6328368|NCT02975349|10072536|FG004|Blinded Extension Period (24 Weeks)|Adverse Event|1
6328369|NCT02975349|10072537|FG005|Blinded Extension Period (24 Weeks)|Adverse Event|0
6328370|NCT02975349|10072532|FG000|Blinded Extension Period (24 Weeks)|Withdrawal by Subject|0
6328371|NCT02975349|10072533|FG001|Blinded Extension Period (24 Weeks)|Withdrawal by Subject|5
6328372|NCT02975349|10072534|FG002|Blinded Extension Period (24 Weeks)|Withdrawal by Subject|2
6328373|NCT02975349|10072535|FG003|Blinded Extension Period (24 Weeks)|Withdrawal by Subject|1
6328374|NCT02975349|10072536|FG004|Blinded Extension Period (24 Weeks)|Withdrawal by Subject|1
6328375|NCT02975349|10072537|FG005|Blinded Extension Period (24 Weeks)|Withdrawal by Subject|0
6328376|NCT02975349|10072532|FG000|Blinded Extension Period (24 Weeks)|Lack of Efficacy|0
6328377|NCT02975349|10072533|FG001|Blinded Extension Period (24 Weeks)|Lack of Efficacy|0
6328378|NCT02975349|10072534|FG002|Blinded Extension Period (24 Weeks)|Lack of Efficacy|1
6328379|NCT02975349|10072535|FG003|Blinded Extension Period (24 Weeks)|Lack of Efficacy|0
6328380|NCT02975349|10072536|FG004|Blinded Extension Period (24 Weeks)|Lack of Efficacy|0
6328381|NCT02975349|10072537|FG005|Blinded Extension Period (24 Weeks)|Lack of Efficacy|0
6328382|NCT02975349|10072532|FG000|Blinded Extension Period (24 Weeks)|Progressive Disease|0
6328383|NCT02975349|10072533|FG001|Blinded Extension Period (24 Weeks)|Progressive Disease|1
6328384|NCT02975349|10072534|FG002|Blinded Extension Period (24 Weeks)|Progressive Disease|0
6328385|NCT02975349|10072535|FG003|Blinded Extension Period (24 Weeks)|Progressive Disease|0
6328386|NCT02975349|10072536|FG004|Blinded Extension Period (24 Weeks)|Progressive Disease|0
6328387|NCT02975349|10072537|FG005|Blinded Extension Period (24 Weeks)|Progressive Disease|0
6328388|NCT02975349|10072532|FG000|Blinded Extension Period (24 Weeks)|Un-specified|0
6328389|NCT02975349|10072533|FG001|Blinded Extension Period (24 Weeks)|Un-specified|0
6328390|NCT02975349|10072534|FG002|Blinded Extension Period (24 Weeks)|Un-specified|0
6328391|NCT02975349|10072535|FG003|Blinded Extension Period (24 Weeks)|Un-specified|1
6328392|NCT02975349|10072536|FG004|Blinded Extension Period (24 Weeks)|Un-specified|0
6328393|NCT02975349|10072537|FG005|Blinded Extension Period (24 Weeks)|Un-specified|0
6328394|NCT02975973|10072582|FG000|Overall Study|Adverse Event|1
6328395|NCT02975973|10072583|FG001|Overall Study|Adverse Event|1
6328396|NCT02975973|10072584|FG002|Overall Study|Adverse Event|1
6328397|NCT02975973|10072585|FG003|Overall Study|Adverse Event|0
6328398|NCT02976103|10072597|FG000|Overall Study|Withdrawal by Subject|1
6328399|NCT02976103|10072598|FG001|Overall Study|Withdrawal by Subject|0
6328400|NCT02976103|10072597|FG000|Overall Study|Lost to Follow-up|12
6328401|NCT02976103|10072598|FG001|Overall Study|Lost to Follow-up|8
6328402|NCT02976519|10072617|FG000|Treatment Period 1 (Part 1 and Part 2)|Adverse Event|0
6328403|NCT02976519|10072618|FG001|Treatment Period 1 (Part 1 and Part 2)|Adverse Event|1
6328404|NCT02976519|10072619|FG002|Treatment Period 1 (Part 1 and Part 2)|Adverse Event|0
6328405|NCT02976519|10072620|FG003|Treatment Period 1 (Part 1 and Part 2)|Adverse Event|0
6328406|NCT02976519|10072621|FG004|Treatment Period 1 (Part 1 and Part 2)|Adverse Event|0
6328407|NCT02976519|10072622|FG005|Treatment Period 1 (Part 1 and Part 2)|Adverse Event|0
6328408|NCT02976519|10072623|FG006|Treatment Period 1 (Part 1 and Part 2)|Adverse Event|0
6328409|NCT02976519|10072617|FG000|Treatment Period 1 (Part 1 and Part 2)|Withdrawal by Subject|0
6328410|NCT02976519|10072618|FG001|Treatment Period 1 (Part 1 and Part 2)|Withdrawal by Subject|0
6328411|NCT02976519|10072619|FG002|Treatment Period 1 (Part 1 and Part 2)|Withdrawal by Subject|0
6328412|NCT02976519|10072620|FG003|Treatment Period 1 (Part 1 and Part 2)|Withdrawal by Subject|1
6328413|NCT02976519|10072621|FG004|Treatment Period 1 (Part 1 and Part 2)|Withdrawal by Subject|0
6328414|NCT02976519|10072622|FG005|Treatment Period 1 (Part 1 and Part 2)|Withdrawal by Subject|0
6328415|NCT02976519|10072623|FG006|Treatment Period 1 (Part 1 and Part 2)|Withdrawal by Subject|0
6328416|NCT02976519|10072617|FG000|Wash-out Period (Part 2 Only)|Reason not listed|0
6328417|NCT02976519|10072618|FG001|Wash-out Period (Part 2 Only)|Reason not listed|0
6328418|NCT02976519|10072619|FG002|Wash-out Period (Part 2 Only)|Reason not listed|0
6328419|NCT02976519|10072620|FG003|Wash-out Period (Part 2 Only)|Reason not listed|0
6328420|NCT02976519|10072621|FG004|Wash-out Period (Part 2 Only)|Reason not listed|0
6328421|NCT02976519|10072622|FG005|Wash-out Period (Part 2 Only)|Reason not listed|0
6328422|NCT02976519|10072623|FG006|Wash-out Period (Part 2 Only)|Reason not listed|1
6328423|NCT02976519|10072617|FG000|Wash-out Period (Part 2 Only)|Withdrawal by Subject|0
6328424|NCT02976519|10072618|FG001|Wash-out Period (Part 2 Only)|Withdrawal by Subject|0
6328425|NCT02976519|10072619|FG002|Wash-out Period (Part 2 Only)|Withdrawal by Subject|0
6328426|NCT02976519|10072620|FG003|Wash-out Period (Part 2 Only)|Withdrawal by Subject|0
6328427|NCT02976519|10072621|FG004|Wash-out Period (Part 2 Only)|Withdrawal by Subject|0
6328428|NCT02976519|10072622|FG005|Wash-out Period (Part 2 Only)|Withdrawal by Subject|0
6328429|NCT02976519|10072623|FG006|Wash-out Period (Part 2 Only)|Withdrawal by Subject|1
6328430|NCT02976519|10072617|FG000|Treatment Period 2 (Part 2 Only)|Adverse Event|0
6328431|NCT02976519|10072618|FG001|Treatment Period 2 (Part 2 Only)|Adverse Event|0
6328432|NCT02976519|10072619|FG002|Treatment Period 2 (Part 2 Only)|Adverse Event|0
6328433|NCT02976519|10072620|FG003|Treatment Period 2 (Part 2 Only)|Adverse Event|0
6328434|NCT02976519|10072621|FG004|Treatment Period 2 (Part 2 Only)|Adverse Event|0
6328435|NCT02976519|10072622|FG005|Treatment Period 2 (Part 2 Only)|Adverse Event|0
6328436|NCT02976519|10072623|FG006|Treatment Period 2 (Part 2 Only)|Adverse Event|1
6328437|NCT02977507|10072643|FG000|Overall Study|Protocol Deviation|1
6328438|NCT02977507|10072644|FG001|Overall Study|Protocol Deviation|0
6328439|NCT02977507|10072643|FG000|Overall Study|Lost to Follow-up|1
6328440|NCT02977507|10072644|FG001|Overall Study|Lost to Follow-up|0
6328441|NCT02977572|10072653|FG000|Overall Study|Exclusion criterion|2
6328442|NCT02977572|10072654|FG001|Overall Study|Exclusion criterion|2
6328443|NCT02978417|10072688|FG000|Overall Study|Lost to Follow-up|2
6328444|NCT02978417|10072689|FG001|Overall Study|Lost to Follow-up|2
6328445|NCT02979197|10072716|FG000|Overall Study|Adverse Event|4
6328446|NCT02979197|10072717|FG001|Overall Study|Adverse Event|2
6328447|NCT02979197|10072718|FG002|Overall Study|Adverse Event|0
6328448|NCT02979197|10072716|FG000|Overall Study|Protocol Violation|0
6328449|NCT02979197|10072717|FG001|Overall Study|Protocol Violation|1
6328450|NCT02979197|10072718|FG002|Overall Study|Protocol Violation|0
6328451|NCT02979197|10072716|FG000|Overall Study|Subject unable to commit to study dates|0
6328452|NCT02979197|10072717|FG001|Overall Study|Subject unable to commit to study dates|1
6328453|NCT02979197|10072718|FG002|Overall Study|Subject unable to commit to study dates|0
6328454|NCT02979249|10072726|FG000|Overall Study|Lost to Follow-up|2
6328455|NCT02979249|10072726|FG000|Overall Study|Withdrawal by Subject|4
6328456|NCT02979431|10072752|FG000|Overall Study|Parent/guardian withdrew consent|2
6328457|NCT02979431|10072753|FG001|Overall Study|Parent/guardian withdrew consent|1
6328458|NCT02979431|10072754|FG002|Overall Study|Parent/guardian withdrew consent|1
6328459|NCT02979431|10072755|FG003|Overall Study|Parent/guardian withdrew consent|1
6328460|NCT02979431|10072752|FG000|Overall Study|Randomized but received no study drug|1
6328461|NCT02979431|10072753|FG001|Overall Study|Randomized but received no study drug|1
6328462|NCT02979431|10072754|FG002|Overall Study|Randomized but received no study drug|0
6328463|NCT02979431|10072755|FG003|Overall Study|Randomized but received no study drug|0
6328464|NCT02979431|10072752|FG000|Overall Study|Adverse Event|0
6328465|NCT02979431|10072753|FG001|Overall Study|Adverse Event|0
6328466|NCT02979431|10072754|FG002|Overall Study|Adverse Event|1
6328467|NCT02979431|10072755|FG003|Overall Study|Adverse Event|0
6328468|NCT02979431|10072752|FG000|Overall Study|Subject left country after Day14|1
6328469|NCT02979431|10072753|FG001|Overall Study|Subject left country after Day14|0
6328470|NCT02979431|10072754|FG002|Overall Study|Subject left country after Day14|0
6328471|NCT02979431|10072755|FG003|Overall Study|Subject left country after Day14|0
6328472|NCT02979613|10072789|FG000|Double-Blind Phase|Withdrew Consent|2
6328473|NCT02979613|10072790|FG001|Double-Blind Phase|Withdrew Consent|4
6328474|NCT02979613|10072789|FG000|Double-Blind Phase|Pregnancy|2
6328475|NCT02979613|10072790|FG001|Double-Blind Phase|Pregnancy|2
6328476|NCT02979613|10072789|FG000|Double-Blind Phase|Adverse Event|2
6328477|NCT02979613|10072790|FG001|Double-Blind Phase|Adverse Event|0
6328478|NCT02979613|10072789|FG000|Double-Blind Phase|Lost to Follow-up|1
6328479|NCT02979613|10072790|FG001|Double-Blind Phase|Lost to Follow-up|1
6328480|NCT02979613|10072789|FG000|Double-Blind Phase|Protocol Violation|1
6328481|NCT02979613|10072790|FG001|Double-Blind Phase|Protocol Violation|1
6328482|NCT02979613|10072789|FG000|Double-Blind Phase|Randomized but Never Treated|2
6328483|NCT02979613|10072790|FG001|Double-Blind Phase|Randomized but Never Treated|0
6328484|NCT02979613|10072789|FG000|Open-Label Extension (OLE) Phase|Withdrew Consent|2
6328485|NCT02979613|10072790|FG001|Open-Label Extension (OLE) Phase|Withdrew Consent|4
6328486|NCT02979613|10072789|FG000|Open-Label Extension (OLE) Phase|Adverse Event|1
6328487|NCT02979613|10072790|FG001|Open-Label Extension (OLE) Phase|Adverse Event|0
6328488|NCT02979613|10072789|FG000|Open-Label Extension (OLE) Phase|Death|0
6328489|NCT02979613|10072790|FG001|Open-Label Extension (OLE) Phase|Death|1
6328490|NCT02979613|10072789|FG000|Open-Label Extension (OLE) Phase|Investigator's Discretion|0
6328491|NCT02979613|10072790|FG001|Open-Label Extension (OLE) Phase|Investigator's Discretion|1
6328492|NCT02979639|10072807|FG000|Overall Study|Withdrawal based on medical judgement|1
6328493|NCT02979639|10072807|FG000|Overall Study|Lost to Follow-up|8
6328494|NCT02979639|10072807|FG000|Overall Study|Withdrawal by Subject|3
6328495|NCT02979639|10072807|FG000|Overall Study|Adverse Event|2
6328496|NCT02980042|10072831|FG000|Overall Study|Lost to Follow-up|5
6328497|NCT02980042|10072832|FG001|Overall Study|Lost to Follow-up|0
6328498|NCT02980042|10072831|FG000|Overall Study|Insurance issues/treatment plan changes|2
6328499|NCT02980042|10072832|FG001|Overall Study|Insurance issues/treatment plan changes|0
6328500|NCT02980107|10072852|FG000|Overall Study|Withdrawal by Subject|51
6328501|NCT02980107|10072853|FG001|Overall Study|Withdrawal by Subject|62
6328502|NCT02980133|10072863|FG000|Overall Study|Other than specified|1
6328503|NCT02980133|10072864|FG001|Overall Study|Other than specified|1
6328504|NCT02980133|10072865|FG002|Overall Study|Other than specified|2
6328505|NCT02980133|10072866|FG003|Overall Study|Other than specified|2
6328506|NCT02980133|10072863|FG000|Overall Study|Lost to Follow-up|0
6328507|NCT02980133|10072864|FG001|Overall Study|Lost to Follow-up|0
6328508|NCT02980133|10072865|FG002|Overall Study|Lost to Follow-up|1
6328509|NCT02980133|10072866|FG003|Overall Study|Lost to Follow-up|3
6328510|NCT02980133|10072863|FG000|Overall Study|Protocol Violation|0
6328511|NCT02980133|10072864|FG001|Overall Study|Protocol Violation|1
6328512|NCT02980133|10072865|FG002|Overall Study|Protocol Violation|0
6328513|NCT02980133|10072866|FG003|Overall Study|Protocol Violation|0
6328514|NCT02980133|10072863|FG000|Overall Study|Withdrawal by parent/guardian|6
6328515|NCT02980133|10072864|FG001|Overall Study|Withdrawal by parent/guardian|3
6328516|NCT02980133|10072865|FG002|Overall Study|Withdrawal by parent/guardian|3
6328517|NCT02980133|10072866|FG003|Overall Study|Withdrawal by parent/guardian|1
6328518|NCT02980133|10072863|FG000|Overall Study|Withdrawal by Subject|0
6328519|NCT02980133|10072864|FG001|Overall Study|Withdrawal by Subject|0
6328520|NCT02980133|10072865|FG002|Overall Study|Withdrawal by Subject|1
6328521|NCT02980133|10072866|FG003|Overall Study|Withdrawal by Subject|0
6328522|NCT02980224|10072885|FG000|Overall Study|Adverse Event|4
6328523|NCT02980224|10072886|FG001|Overall Study|Adverse Event|1
6328524|NCT02980224|10072885|FG000|Overall Study|Withdrawal by Subject|0
6328525|NCT02980224|10072886|FG001|Overall Study|Withdrawal by Subject|2
6328526|NCT02980523|10072897|FG000|Overall Study|Lost to Follow-up|1
6328527|NCT02980523|10072898|FG001|Overall Study|Lost to Follow-up|4
6328528|NCT02980523|10072899|FG002|Overall Study|Lost to Follow-up|1
6328529|NCT02980523|10072900|FG003|Overall Study|Lost to Follow-up|2
6328530|NCT02980523|10072901|FG004|Overall Study|Lost to Follow-up|1
6328531|NCT02980523|10072897|FG000|Overall Study|Excluded from analysis|1
6328532|NCT02980523|10072898|FG001|Overall Study|Excluded from analysis|3
6328533|NCT02980523|10072899|FG002|Overall Study|Excluded from analysis|1
6328534|NCT02980523|10072900|FG003|Overall Study|Excluded from analysis|1
6328535|NCT02980523|10072901|FG004|Overall Study|Excluded from analysis|1
6328536|NCT02980523|10072897|FG000|Overall Study|Lack of Efficacy|1
6328537|NCT02980523|10072898|FG001|Overall Study|Lack of Efficacy|4
6328538|NCT02980523|10072899|FG002|Overall Study|Lack of Efficacy|4
6328539|NCT02980523|10072900|FG003|Overall Study|Lack of Efficacy|5
6328540|NCT02980523|10072901|FG004|Overall Study|Lack of Efficacy|8
6328541|NCT02980523|10072897|FG000|Overall Study|Did not receive intervention|0
6328542|NCT02980523|10072898|FG001|Overall Study|Did not receive intervention|0
6328543|NCT02980523|10072899|FG002|Overall Study|Did not receive intervention|0
6328544|NCT02980523|10072900|FG003|Overall Study|Did not receive intervention|1
6328545|NCT02980523|10072901|FG004|Overall Study|Did not receive intervention|0
6328546|NCT02980601|10072918|FG000|Overall Study|Lost to Follow-up|2
6328547|NCT02980601|10072919|FG001|Overall Study|Lost to Follow-up|2
6328548|NCT02980601|10072918|FG000|Overall Study|Death|0
6328549|NCT02980601|10072919|FG001|Overall Study|Death|1
6328550|NCT02980601|10072918|FG000|Overall Study|Graft loss|1
6328551|NCT02980601|10072919|FG001|Overall Study|Graft loss|0
6328552|NCT02980601|10072918|FG000|Overall Study|Failed to sign consent|2
6328553|NCT02980601|10072919|FG001|Overall Study|Failed to sign consent|0
6328554|NCT02980692|10072930|FG000|Overall Study|Adverse Event|0
6328555|NCT02980692|10072931|FG001|Overall Study|Adverse Event|2
6328556|NCT02980692|10072932|FG002|Overall Study|Adverse Event|0
6328557|NCT02980692|10072933|FG003|Overall Study|Adverse Event|0
6328558|NCT02980692|10072934|FG004|Overall Study|Adverse Event|1
6328559|NCT02980692|10072930|FG000|Overall Study|Withdrawal by Subject|4
6328560|NCT02980692|10072931|FG001|Overall Study|Withdrawal by Subject|3
6328561|NCT02980692|10072932|FG002|Overall Study|Withdrawal by Subject|6
6328562|NCT02980692|10072933|FG003|Overall Study|Withdrawal by Subject|6
6328563|NCT02980692|10072934|FG004|Overall Study|Withdrawal by Subject|7
6328564|NCT02980692|10072930|FG000|Overall Study|Lost to Follow-up|3
6328565|NCT02980692|10072931|FG001|Overall Study|Lost to Follow-up|0
6328566|NCT02980692|10072932|FG002|Overall Study|Lost to Follow-up|4
6328567|NCT02980692|10072933|FG003|Overall Study|Lost to Follow-up|1
6328568|NCT02980692|10072934|FG004|Overall Study|Lost to Follow-up|1
6328569|NCT02980692|10072930|FG000|Overall Study|Death|1
6328570|NCT02980692|10072931|FG001|Overall Study|Death|0
6328571|NCT02980692|10072932|FG002|Overall Study|Death|0
6328572|NCT02980692|10072933|FG003|Overall Study|Death|0
6328573|NCT02980692|10072934|FG004|Overall Study|Death|0
6328574|NCT02980692|10072930|FG000|Overall Study|Physician Decision|0
6328575|NCT02980692|10072931|FG001|Overall Study|Physician Decision|0
6328576|NCT02980692|10072932|FG002|Overall Study|Physician Decision|1
6328577|NCT02980692|10072933|FG003|Overall Study|Physician Decision|1
6328578|NCT02980692|10072934|FG004|Overall Study|Physician Decision|0
6328579|NCT02980692|10072930|FG000|Overall Study|NON COMPLIANCE|1
6328580|NCT02980692|10072931|FG001|Overall Study|NON COMPLIANCE|0
6328581|NCT02980692|10072932|FG002|Overall Study|NON COMPLIANCE|0
6328582|NCT02980692|10072933|FG003|Overall Study|NON COMPLIANCE|0
6328583|NCT02980692|10072934|FG004|Overall Study|NON COMPLIANCE|0
6328584|NCT02980692|10072930|FG000|Overall Study|DOES NOT WANT TO RETURN FOR FOLLOW UP VISITS|0
6328585|NCT02980692|10072931|FG001|Overall Study|DOES NOT WANT TO RETURN FOR FOLLOW UP VISITS|1
6328586|NCT02980692|10072932|FG002|Overall Study|DOES NOT WANT TO RETURN FOR FOLLOW UP VISITS|0
6328587|NCT02980692|10072933|FG003|Overall Study|DOES NOT WANT TO RETURN FOR FOLLOW UP VISITS|0
6328588|NCT02980692|10072934|FG004|Overall Study|DOES NOT WANT TO RETURN FOR FOLLOW UP VISITS|0
6328589|NCT02980692|10072930|FG000|Overall Study|LACK OF EFFICACY OF THE STUDY TREATMENT|0
6328590|NCT02980692|10072931|FG001|Overall Study|LACK OF EFFICACY OF THE STUDY TREATMENT|0
6328591|NCT02980692|10072932|FG002|Overall Study|LACK OF EFFICACY OF THE STUDY TREATMENT|1
6328592|NCT02980692|10072933|FG003|Overall Study|LACK OF EFFICACY OF THE STUDY TREATMENT|0
6328593|NCT02980692|10072934|FG004|Overall Study|LACK OF EFFICACY OF THE STUDY TREATMENT|0
6328594|NCT02980692|10072930|FG000|Overall Study|Lack of Efficacy|0
6328595|NCT02980692|10072931|FG001|Overall Study|Lack of Efficacy|0
6328596|NCT02980692|10072932|FG002|Overall Study|Lack of Efficacy|0
6328597|NCT02980692|10072933|FG003|Overall Study|Lack of Efficacy|1
6328598|NCT02980692|10072934|FG004|Overall Study|Lack of Efficacy|0
6328599|NCT02980692|10072930|FG000|Overall Study|RELOCATION|0
6328600|NCT02980692|10072931|FG001|Overall Study|RELOCATION|0
6328601|NCT02980692|10072932|FG002|Overall Study|RELOCATION|0
6328602|NCT02980692|10072933|FG003|Overall Study|RELOCATION|0
6328603|NCT02980692|10072934|FG004|Overall Study|RELOCATION|1
6328604|NCT02980692|10072930|FG000|Overall Study|SUBJECT ENROLLED IN STUDY WITH POSITIVE QUANT & DISCHARGED FROM STUDY BY SPONSOR|0
6328605|NCT02980692|10072931|FG001|Overall Study|SUBJECT ENROLLED IN STUDY WITH POSITIVE QUANT & DISCHARGED FROM STUDY BY SPONSOR|0
6328606|NCT02980692|10072932|FG002|Overall Study|SUBJECT ENROLLED IN STUDY WITH POSITIVE QUANT & DISCHARGED FROM STUDY BY SPONSOR|0
6328607|NCT02980692|10072933|FG003|Overall Study|SUBJECT ENROLLED IN STUDY WITH POSITIVE QUANT & DISCHARGED FROM STUDY BY SPONSOR|0
6328608|NCT02980692|10072934|FG004|Overall Study|SUBJECT ENROLLED IN STUDY WITH POSITIVE QUANT & DISCHARGED FROM STUDY BY SPONSOR|1
6328609|NCT02980705|10072949|FG000|Overall Study|Adverse Event|0
6328610|NCT02980705|10072950|FG001|Overall Study|Adverse Event|1
6328611|NCT02980705|10072949|FG000|Overall Study|Withdrawal by Subject|6
6328612|NCT02980705|10072950|FG001|Overall Study|Withdrawal by Subject|9
6328613|NCT02980705|10072949|FG000|Overall Study|withdrew participation|0
6328614|NCT02980705|10072950|FG001|Overall Study|withdrew participation|1
6328615|NCT02980705|10072949|FG000|Overall Study|Lost to Follow-up|2
6328616|NCT02980705|10072950|FG001|Overall Study|Lost to Follow-up|0
6328617|NCT02980783|10072957|FG000|Overall Study|Lost to Follow-up|1
6328618|NCT02980874|10072963|FG000|Overall Study|Adverse Event|2
6328619|NCT02980874|10072964|FG001|Overall Study|Adverse Event|7
6328620|NCT02980874|10072963|FG000|Overall Study|Withdrawal by Subject|7
6328621|NCT02980874|10072964|FG001|Overall Study|Withdrawal by Subject|2
6328622|NCT02980874|10072963|FG000|Overall Study|Lost to Follow-up|5
6328623|NCT02980874|10072964|FG001|Overall Study|Lost to Follow-up|5
6328624|NCT02980874|10072963|FG000|Overall Study|Includes premature discontinuation due to study termination.|88
6328625|NCT02980874|10072964|FG001|Overall Study|Includes premature discontinuation due to study termination.|88
6328626|NCT02980874|10072963|FG000|Overall Study|Unknown study completion status|1
6328627|NCT02980874|10072964|FG001|Overall Study|Unknown study completion status|0
6328628|NCT02981342|10072983|FG000|Overall Study|Adverse Event|0
6328629|NCT02981342|10072984|FG001|Overall Study|Adverse Event|0
6328630|NCT02981342|10072985|FG002|Overall Study|Adverse Event|0
6328631|NCT02981342|10072986|FG003|Overall Study|Adverse Event|1
6328632|NCT02981342|10072983|FG000|Overall Study|Death|0
6328633|NCT02981342|10072984|FG001|Overall Study|Death|9
6328634|NCT02981342|10072985|FG002|Overall Study|Death|9
6328635|NCT02981342|10072986|FG003|Overall Study|Death|4
6328636|NCT02981342|10072983|FG000|Overall Study|Withdrawal by Subject|0
6328637|NCT02981342|10072984|FG001|Overall Study|Withdrawal by Subject|0
6328638|NCT02981342|10072985|FG002|Overall Study|Withdrawal by Subject|3
6328639|NCT02981342|10072986|FG003|Overall Study|Withdrawal by Subject|1
6328640|NCT02981342|10072983|FG000|Overall Study|Study closed by sponsor|0
6328641|NCT02981342|10072984|FG001|Overall Study|Study closed by sponsor|0
6328642|NCT02981342|10072985|FG002|Overall Study|Study closed by sponsor|1
6328643|NCT02981342|10072986|FG003|Overall Study|Study closed by sponsor|1
6328644|NCT02981342|10072983|FG000|Overall Study|Randomized, Never Treated|0
6328645|NCT02981342|10072984|FG001|Overall Study|Randomized, Never Treated|1
6328646|NCT02981342|10072985|FG002|Overall Study|Randomized, Never Treated|0
6328647|NCT02981342|10072986|FG003|Overall Study|Randomized, Never Treated|7
6328648|NCT02981342|10072983|FG000|Overall Study|Lost to Follow-up|0
6328649|NCT02981342|10072984|FG001|Overall Study|Lost to Follow-up|1
6328650|NCT02981342|10072985|FG002|Overall Study|Lost to Follow-up|0
6328651|NCT02981342|10072986|FG003|Overall Study|Lost to Follow-up|0
6328652|NCT02981524|10073034|FG000|Overall Study|Progressive Disease|14
6328653|NCT02981524|10073034|FG000|Overall Study|Death (unrelated)|1
6328654|NCT02981524|10073034|FG000|Overall Study|Treatment Related Toxicity|1
6328655|NCT02981524|10073034|FG000|Overall Study|Withdrawal by Subject|1
6328656|NCT02981602|10073043|FG000|Overall Study|Adverse Event|0
6328657|NCT02981602|10073044|FG001|Overall Study|Adverse Event|0
6328658|NCT02981602|10073045|FG002|Overall Study|Adverse Event|0
6328659|NCT02981602|10073046|FG003|Overall Study|Adverse Event|1
6328660|NCT02981602|10073047|FG004|Overall Study|Adverse Event|0
6328661|NCT02981953|10073060|FG000|Overall Study|Death|9
6328662|NCT02981953|10073060|FG000|Overall Study|Withdrawal by Subject|1
6328663|NCT02981953|10073060|FG000|Overall Study|Withdrawal to non-compliance|1
6328664|NCT02982018|10073066|FG000|Overall Study|Incorrect Lens Dispensed|1
6328665|NCT02982018|10073067|FG001|Overall Study|Incorrect Lens Dispensed|0
6328666|NCT02982018|10073066|FG000|Overall Study|Protocol Violation|1
6328667|NCT02982018|10073067|FG001|Overall Study|Protocol Violation|1
6328668|NCT02982018|10073066|FG000|Overall Study|Adverse Event|1
6328669|NCT02982018|10073067|FG001|Overall Study|Adverse Event|1
6328670|NCT02982018|10073066|FG000|Overall Study|Lens Discomfort|2
6328671|NCT02982018|10073067|FG001|Overall Study|Lens Discomfort|0
6328672|NCT02982018|10073066|FG000|Overall Study|Withdrawal by Subject|0
6328673|NCT02982018|10073067|FG001|Overall Study|Withdrawal by Subject|1
6328674|NCT02982187|10073075|FG000|Overall Study|Withdrawal by Subject|0
6328675|NCT02982187|10073076|FG001|Overall Study|Withdrawal by Subject|0
6328676|NCT02982187|10073077|FG002|Overall Study|Withdrawal by Subject|0
6328677|NCT02982187|10073078|FG003|Overall Study|Withdrawal by Subject|0
6328678|NCT02982187|10073079|FG004|Overall Study|Withdrawal by Subject|0
6328679|NCT02982187|10073080|FG005|Overall Study|Withdrawal by Subject|0
6328680|NCT02982187|10073081|FG006|Overall Study|Withdrawal by Subject|1
6328681|NCT02982187|10073082|FG007|Overall Study|Withdrawal by Subject|0
6328682|NCT02982213|10073094|FG000|Overall Study|Did not complete follow up questionnaire|5
6328683|NCT02982213|10073095|FG001|Overall Study|Did not complete follow up questionnaire|1
6328684|NCT02982239|10073103|FG000|Overall Study|Lost to Follow-up|3
6328685|NCT02982239|10073104|FG001|Overall Study|Lost to Follow-up|2
6328686|NCT02982590|10073113|FG000|Overall Study|Lost to Follow-up|0
6328687|NCT02982590|10073114|FG001|Overall Study|Lost to Follow-up|1
6328688|NCT02982590|10073113|FG000|Overall Study|Death|4
6328689|NCT02982590|10073114|FG001|Overall Study|Death|0
6328690|NCT02982772|10073122|FG000|Intervention|Lost to Follow-up|19
6328691|NCT02982772|10073123|FG001|Intervention|Lost to Follow-up|13
6328692|NCT02982772|10073122|FG000|1M Follow-Up|Lost to Follow-up|21
6328693|NCT02982772|10073123|FG001|1M Follow-Up|Lost to Follow-up|18
6328694|NCT02982772|10073122|FG000|3M Follow-Up|Lost to Follow-up|17
6328695|NCT02982772|10073123|FG001|3M Follow-Up|Lost to Follow-up|11
6328696|NCT02982772|10073122|FG000|6M Follow-Up|Lost to Follow-up|11
6328697|NCT02982772|10073123|FG001|6M Follow-Up|Lost to Follow-up|9
6328698|NCT02982772|10073122|FG000|12M Follow-Up|Lost to Follow-up|11
6328699|NCT02982772|10073123|FG001|12M Follow-Up|Lost to Follow-up|5
6328700|NCT02982863|10073136|FG000|Overall Study|Not eligible patients|809
6328701|NCT02982863|10073137|FG001|Overall Study|Not eligible patients|4261
6328702|NCT02982863|10073138|FG002|Overall Study|Not eligible patients|1852
6328703|NCT02982863|10073139|FG003|Overall Study|Not eligible patients|1400
6328704|NCT02982863|10073140|FG004|Overall Study|Not eligible patients|492
6328705|NCT02983227|10073171|FG000|Overall Study|Adverse Event|21
6328706|NCT02983227|10073172|FG001|Overall Study|Adverse Event|3
6328707|NCT02983227|10073171|FG000|Overall Study|Death|3
6328708|NCT02983227|10073172|FG001|Overall Study|Death|0
6328709|NCT02983227|10073171|FG000|Overall Study|Lack of Efficacy|8
6328710|NCT02983227|10073172|FG001|Overall Study|Lack of Efficacy|1
6328711|NCT02983227|10073171|FG000|Overall Study|Lost to Follow-up|3
6328712|NCT02983227|10073172|FG001|Overall Study|Lost to Follow-up|0
6328713|NCT02983227|10073171|FG000|Overall Study|Multiple Reasons|2
6328714|NCT02983227|10073172|FG001|Overall Study|Multiple Reasons|1
6328715|NCT02983227|10073171|FG000|Overall Study|Physician Decision|3
6328716|NCT02983227|10073172|FG001|Overall Study|Physician Decision|1
6328717|NCT02983227|10073171|FG000|Overall Study|Withdrawal by Subject|19
6328718|NCT02983227|10073172|FG001|Overall Study|Withdrawal by Subject|8
6328719|NCT02983305|10073180|FG000|Overall Study|incomplete data|2
6328720|NCT02983305|10073181|FG001|Overall Study|incomplete data|0
6328721|NCT02983604|10073221|FG000|Overall Study|Enrolled but not Treated|0
6328722|NCT02983604|10073222|FG001|Overall Study|Enrolled but not Treated|0
6328723|NCT02983604|10073223|FG002|Overall Study|Enrolled but not Treated|1
6328724|NCT02983604|10073224|FG003|Overall Study|Enrolled but not Treated|0
6328725|NCT02984267|10073249|FG000|Overall Study|Protocol Violation|1
6328726|NCT02984267|10073250|FG001|Overall Study|Protocol Violation|0
6328727|NCT02984267|10073249|FG000|Overall Study|Withdrawal by Subject|0
6328728|NCT02984267|10073250|FG001|Overall Study|Withdrawal by Subject|1
6328729|NCT02984683|10073288|FG000|Overall Study|Adverse Event|3
6328730|NCT02984683|10073289|FG001|Overall Study|Adverse Event|3
6328731|NCT02984683|10073288|FG000|Overall Study|Withdrawal by Subject|1
6328732|NCT02984683|10073289|FG001|Overall Study|Withdrawal by Subject|0
6328733|NCT02984683|10073288|FG000|Overall Study|Disease progression|7
6328734|NCT02984683|10073289|FG001|Overall Study|Disease progression|9
6328735|NCT02984943|10073318|FG000|Overall Study|Withdrawal by Subject|3
6328736|NCT02984943|10073318|FG000|Overall Study|Physician Decision|1
6328737|NCT02984982|10073324|FG000|Overall Study|Adverse Event|2
6328738|NCT02984982|10073325|FG001|Overall Study|Adverse Event|5
6328739|NCT02984982|10073324|FG000|Overall Study|Poor Compliance to Protocol|4
6328740|NCT02984982|10073325|FG001|Overall Study|Poor Compliance to Protocol|4
6328741|NCT02984982|10073324|FG000|Overall Study|Withdrawal by Subject|2
6328742|NCT02984982|10073325|FG001|Overall Study|Withdrawal by Subject|0
6328743|NCT02984982|10073324|FG000|Overall Study|Randomized but not treated|0
6328744|NCT02984982|10073325|FG001|Overall Study|Randomized but not treated|1
6328745|NCT02984995|10073334|FG000|Overall Study|Required stem cell transplant|13
6328746|NCT02984995|10073335|FG001|Overall Study|Required stem cell transplant|2
6328747|NCT02984995|10073334|FG000|Overall Study|Progressive disease|11
6328748|NCT02984995|10073335|FG001|Overall Study|Progressive disease|1
6328749|NCT02984995|10073334|FG000|Overall Study|Adverse Event|1
6328750|NCT02984995|10073335|FG001|Overall Study|Adverse Event|0
6328751|NCT02985021|10073347|FG000|Overall Study|Inability to comply with study procedures|1
6328752|NCT02985398|10073351|FG000|Overall Study|Adverse Event|1
6328753|NCT02985398|10073351|FG000|Overall Study|Lost to Follow-up|4
6328754|NCT02985398|10073351|FG000|Overall Study|Withdrawal by Subject|8
6328755|NCT02985398|10073351|FG000|Overall Study|Study Burden|9
6328756|NCT02985450|10073355|FG000|Overall Study|Lost to Follow-up|7
6328757|NCT02985879|10073383|FG000|Overall Study|Adverse Event|7
6328758|NCT02985879|10073384|FG001|Overall Study|Adverse Event|9
6328759|NCT02985879|10073385|FG002|Overall Study|Adverse Event|7
6328760|NCT02985879|10073383|FG000|Overall Study|Withdrew consent|6
6328761|NCT02985879|10073384|FG001|Overall Study|Withdrew consent|8
6328762|NCT02985879|10073385|FG002|Overall Study|Withdrew consent|10
6328763|NCT02985879|10073383|FG000|Overall Study|Lost to Follow-up|1
6328764|NCT02985879|10073384|FG001|Overall Study|Lost to Follow-up|0
6328765|NCT02985879|10073385|FG002|Overall Study|Lost to Follow-up|2
6328766|NCT02985879|10073383|FG000|Overall Study|Other, not specified|62
6328767|NCT02985879|10073384|FG001|Overall Study|Other, not specified|58
6328768|NCT02985879|10073385|FG002|Overall Study|Other, not specified|58
6328769|NCT02985996|10073404|FG000|Overall Study|Withdrawal by Subject|0
6328770|NCT02985996|10073405|FG001|Overall Study|Withdrawal by Subject|0
6328771|NCT02985996|10073406|FG002|Overall Study|Withdrawal by Subject|1
6328772|NCT02985996|10073407|FG003|Overall Study|Withdrawal by Subject|0
6328773|NCT02985996|10073408|FG004|Overall Study|Withdrawal by Subject|0
6328774|NCT02985996|10073404|FG000|Overall Study|Protocol Violation|0
6328775|NCT02985996|10073405|FG001|Overall Study|Protocol Violation|1
6328776|NCT02985996|10073406|FG002|Overall Study|Protocol Violation|0
6328777|NCT02985996|10073407|FG003|Overall Study|Protocol Violation|0
6328778|NCT02985996|10073408|FG004|Overall Study|Protocol Violation|0
6328779|NCT02986074|10073424|FG000|First Trial Period|Adverse Event|1
6328780|NCT02986074|10073425|FG001|First Trial Period|Adverse Event|0
6328781|NCT02986074|10073426|FG002|First Trial Period|Adverse Event|0
6328782|NCT02986074|10073427|FG003|First Trial Period|Adverse Event|0
6328783|NCT02986074|10073424|FG000|Follow up Period|system explant|0
6328784|NCT02986074|10073425|FG001|Follow up Period|system explant|0
6328785|NCT02986074|10073426|FG002|Follow up Period|system explant|1
6328786|NCT02986074|10073427|FG003|Follow up Period|system explant|2
6328787|NCT02986074|10073424|FG000|Follow up Period|Physician Decision|0
6328788|NCT02986074|10073425|FG001|Follow up Period|Physician Decision|0
6328789|NCT02986074|10073426|FG002|Follow up Period|Physician Decision|0
6328790|NCT02986074|10073427|FG003|Follow up Period|Physician Decision|1
6328791|NCT02986139|10073434|FG000|Overall Study|Sponsor Decision|1
6328792|NCT02986139|10073435|FG001|Overall Study|Sponsor Decision|2
6328793|NCT02986139|10073434|FG000|Overall Study|Withdrawal by Subject|0
6328794|NCT02986139|10073435|FG001|Overall Study|Withdrawal by Subject|1
6328795|NCT02986139|10073434|FG000|Overall Study|Lost to Follow-up|0
6328796|NCT02986139|10073435|FG001|Overall Study|Lost to Follow-up|1
6328797|NCT02986373|10073449|FG000|Overall Study|Adverse Event|4
6328798|NCT02986373|10073449|FG000|Overall Study|Lost to Follow-up|1
6328799|NCT02986373|10073449|FG000|Overall Study|Withdrawal by Subject|10
6328800|NCT02986373|10073449|FG000|Overall Study|Other|24
6328801|NCT02986854|10073482|FG000|Overall Study|Withdrawal by Subject|0
6328802|NCT02986854|10073483|FG001|Overall Study|Withdrawal by Subject|1
6328803|NCT02986854|10073484|FG002|Overall Study|Withdrawal by Subject|1
6082679|NCT00630877|9690776|FG001|Overall Study|Protocol violation|0
6082680|NCT00630877|9690777|FG002|Overall Study|Protocol violation|1
6082681|NCT00630877|9690775|FG000|Overall Study|Personal reasons|0
6082682|NCT00630877|9690776|FG001|Overall Study|Personal reasons|0
6082683|NCT00630877|9690777|FG002|Overall Study|Personal reasons|1
6082684|NCT00630916|9690789|FG000|Overall Study|Death|110
6082685|NCT00630916|9690789|FG000|Overall Study|Explant|8
6082686|NCT00630916|9690789|FG000|Overall Study|Lost to Follow-up|5
6082687|NCT00630916|9690789|FG000|Overall Study|Withdrawal by Subject|30
6082688|NCT00630916|9690789|FG000|Overall Study|Protocol Violation|7
6082689|NCT00630916|9690789|FG000|Overall Study|Physician Decision|47
6082690|NCT00630916|9690789|FG000|Overall Study|Lack of Efficacy|3
6328804|NCT02986854|10073482|FG000|Overall Study|Lost to Follow-up|3
6328805|NCT02986854|10073483|FG001|Overall Study|Lost to Follow-up|11
6328806|NCT02986854|10073484|FG002|Overall Study|Lost to Follow-up|2
6328807|NCT02987205|10073503|FG000|Overall Study|Adverse Event|1
6082691|NCT00630994|9690806|FG000|Overall Study|Adverse Event|1
6082692|NCT00630994|9690806|FG000|Overall Study|Disease Progression|1
6167171|NCT01226459|9811584|FG001|Overall Study|Pregnancy|0
6167172|NCT01226472|9811590|FG000|Overall Study|Progressive Disease|1
6167173|NCT01226511|9811633|FG000|Acute Treatment Period|Adverse Event|7
6328808|NCT02987205|10073503|FG000|Overall Study|Withdrawal by Subject|3
6328809|NCT02987660|10073533|FG000|Overall Study|Study terminated by sponsor|10
6328810|NCT02987660|10073534|FG001|Overall Study|Study terminated by sponsor|10
6328811|NCT02987972|10073578|FG000|Overall Study|Adverse Event|1
6328812|NCT02987972|10073579|FG001|Overall Study|Adverse Event|1
6328813|NCT02987972|10073580|FG002|Overall Study|Adverse Event|0
6328814|NCT02987972|10073578|FG000|Overall Study|Death|1
6082693|NCT00630994|9690806|FG000|Overall Study|Lack of Efficacy|1
6328815|NCT02987972|10073579|FG001|Overall Study|Death|0
6328816|NCT02987972|10073580|FG002|Overall Study|Death|0
6328817|NCT02987972|10073578|FG000|Overall Study|Lack of Efficacy|9
6328818|NCT02987972|10073579|FG001|Overall Study|Lack of Efficacy|12
6328819|NCT02987972|10073580|FG002|Overall Study|Lack of Efficacy|12
6328820|NCT02987972|10073578|FG000|Overall Study|Lost to Follow-up|7
6328821|NCT02987972|10073579|FG001|Overall Study|Lost to Follow-up|8
6328822|NCT02987972|10073580|FG002|Overall Study|Lost to Follow-up|4
6328823|NCT02987972|10073578|FG000|Overall Study|Physician Decision|1
6328824|NCT02987972|10073579|FG001|Overall Study|Physician Decision|6
6328825|NCT02987972|10073580|FG002|Overall Study|Physician Decision|0
6328826|NCT02987972|10073578|FG000|Overall Study|Protocol Violation|2
6328827|NCT02987972|10073579|FG001|Overall Study|Protocol Violation|1
6328828|NCT02987972|10073580|FG002|Overall Study|Protocol Violation|5
6328829|NCT02987972|10073578|FG000|Overall Study|Withdrawal by Subject|22
6328830|NCT02987972|10073579|FG001|Overall Study|Withdrawal by Subject|17
6328831|NCT02987972|10073580|FG002|Overall Study|Withdrawal by Subject|21
6328832|NCT02988115|10073599|FG000|Overall Study|Adverse Event|6
6328833|NCT02988115|10073600|FG001|Overall Study|Adverse Event|1
6328834|NCT02988115|10073599|FG000|Overall Study|Sponsor Decision|5
6328835|NCT02988115|10073600|FG001|Overall Study|Sponsor Decision|2
6328836|NCT02988115|10073599|FG000|Overall Study|Withdrawal by Subject|1
6328837|NCT02988115|10073600|FG001|Overall Study|Withdrawal by Subject|1
6328838|NCT02988115|10073599|FG000|Overall Study|Withdrawn by Mistake|1
6328839|NCT02988115|10073600|FG001|Overall Study|Withdrawn by Mistake|0
6328840|NCT02988115|10073599|FG000|Overall Study|Lost to Follow-up|1
6328841|NCT02988115|10073600|FG001|Overall Study|Lost to Follow-up|0
6328842|NCT02988219|10073617|FG000|Overall Study|Lack of Efficacy|1
6328843|NCT02988219|10073618|FG001|Overall Study|Lack of Efficacy|1
6328844|NCT02988219|10073617|FG000|Overall Study|Withdrawal by Subject|0
6328845|NCT02988219|10073618|FG001|Overall Study|Withdrawal by Subject|2
6328846|NCT02988622|10073633|FG000|Overall Study|Lost to Follow-up|17
6328847|NCT02989168|10073663|FG000|Overall Study|Withdrawal by Subject|2
6328848|NCT02989168|10073664|FG001|Overall Study|Withdrawal by Subject|0
6328849|NCT02989168|10073663|FG000|Overall Study|Physician Decision|0
6328850|NCT02989168|10073664|FG001|Overall Study|Physician Decision|1
6328851|NCT02989168|10073663|FG000|Overall Study|Adverse Event|1
6328852|NCT02989168|10073664|FG001|Overall Study|Adverse Event|2
6328853|NCT02989168|10073663|FG000|Overall Study|Sponsor stopped study.|1
6328854|NCT02989168|10073664|FG001|Overall Study|Sponsor stopped study.|0
6328855|NCT02989389|10073686|FG000|Period 1|Lost to Follow-up|0
6328856|NCT02989389|10073687|FG001|Period 1|Lost to Follow-up|1
6328857|NCT02989389|10073688|FG002|Period 1|Lost to Follow-up|0
6328858|NCT02989389|10073689|FG003|Period 1|Lost to Follow-up|0
6328859|NCT02989389|10073690|FG004|Period 1|Lost to Follow-up|0
6328860|NCT02989389|10073691|FG005|Period 1|Lost to Follow-up|0
6328861|NCT02989389|10073692|FG006|Period 1|Lost to Follow-up|0
6328862|NCT02989389|10073693|FG007|Period 1|Lost to Follow-up|0
6328863|NCT02989389|10073694|FG008|Period 1|Lost to Follow-up|0
6328864|NCT02989389|10073695|FG009|Period 1|Lost to Follow-up|0
6328865|NCT02989389|10073686|FG000|Period 1|Physician Decision|0
6328866|NCT02989389|10073687|FG001|Period 1|Physician Decision|0
6328867|NCT02989389|10073688|FG002|Period 1|Physician Decision|0
6328868|NCT02989389|10073689|FG003|Period 1|Physician Decision|0
6328869|NCT02989389|10073690|FG004|Period 1|Physician Decision|0
6328870|NCT02989389|10073691|FG005|Period 1|Physician Decision|0
6328871|NCT02989389|10073692|FG006|Period 1|Physician Decision|0
6328872|NCT02989389|10073693|FG007|Period 1|Physician Decision|0
6328873|NCT02989389|10073694|FG008|Period 1|Physician Decision|1
6082694|NCT00630994|9690806|FG000|Overall Study|Other|1
6082695|NCT00631007|9690816|FG000|Overall Study|Adverse Event|0
6082696|NCT00631007|9690817|FG001|Overall Study|Adverse Event|2
6082697|NCT00631007|9690818|FG002|Overall Study|Adverse Event|0
6082698|NCT00631007|9690819|FG003|Overall Study|Adverse Event|2
6082699|NCT00631007|9690820|FG004|Overall Study|Adverse Event|3
6082700|NCT00631007|9690821|FG005|Overall Study|Adverse Event|2
6167174|NCT01226511|9811634|FG001|Acute Treatment Period|Adverse Event|6
6328874|NCT02989389|10073695|FG009|Period 1|Physician Decision|0
6328875|NCT02989610|10073752|FG000|Overall Study|Withdrawal/Other reasons|39
6328876|NCT02989649|10073756|FG000|Overall Study|Patient/Investigator's Decision to Stop|403
6082701|NCT00631007|9690816|FG000|Overall Study|Lost to Follow-up|2
6082702|NCT00631007|9690817|FG001|Overall Study|Lost to Follow-up|1
6082703|NCT00631007|9690818|FG002|Overall Study|Lost to Follow-up|2
6328877|NCT02989649|10073756|FG000|Overall Study|Adverse Event/Adverse Drug Reaction|1
6328878|NCT02989649|10073756|FG000|Overall Study|Lost For Observation During Study|3
6328879|NCT02989649|10073756|FG000|Overall Study|Reason Not Specified|13
6328880|NCT02989805|10073782|FG000|Overall Study|invalid consent|6
6328881|NCT02989805|10073783|FG001|Overall Study|invalid consent|4
6328882|NCT02990000|10073791|FG000|Overall Study|Failed to provide data beyond baseline|36
6328883|NCT02990000|10073792|FG001|Overall Study|Failed to provide data beyond baseline|34
6328884|NCT02990910|10073800|FG000|Overall Study|Lack of Efficacy|6
6328885|NCT02990910|10073801|FG001|Overall Study|Lack of Efficacy|10
6328886|NCT02991040|10073807|FG000|Overall Study|Withdrawal by Subject|2
6328887|NCT02991040|10073807|FG000|Overall Study|Lost to Follow-up|2
6328888|NCT02991118|10073815|FG000|Overall Study|Death|3
6328889|NCT02991118|10073816|FG001|Overall Study|Death|8
6328890|NCT02991118|10073815|FG000|Overall Study|Protocol Violation|0
6328891|NCT02991118|10073816|FG001|Overall Study|Protocol Violation|3
6328892|NCT02991118|10073815|FG000|Overall Study|Physician Decision|0
6328893|NCT02991118|10073816|FG001|Overall Study|Physician Decision|1
6328894|NCT02991118|10073815|FG000|Overall Study|Moved out of the country|0
6328895|NCT02991118|10073816|FG001|Overall Study|Moved out of the country|1
6328896|NCT02991118|10073815|FG000|Overall Study|Adverse Event|2
6328897|NCT02991118|10073816|FG001|Overall Study|Adverse Event|2
6328898|NCT02991118|10073815|FG000|Overall Study|Withdrawal by Subject|1
6328899|NCT02991118|10073816|FG001|Overall Study|Withdrawal by Subject|7
6328900|NCT02991118|10073815|FG000|Overall Study|Could not attend study visits|0
6328901|NCT02991118|10073816|FG001|Overall Study|Could not attend study visits|1
6328902|NCT02991118|10073815|FG000|Overall Study|Lost to Follow-up|1
6328903|NCT02991118|10073816|FG001|Overall Study|Lost to Follow-up|9
6328904|NCT02991859|10073861|FG000|Period 1,Escalation Phase 1,Upto Day 7|Withdrawal by Subject|0
6328905|NCT02991859|10073862|FG001|Period 1,Escalation Phase 1,Upto Day 7|Withdrawal by Subject|1
6328906|NCT02991859|10073863|FG002|Period 1,Escalation Phase 1,Upto Day 7|Withdrawal by Subject|0
6328907|NCT02991859|10073864|FG003|Period 1,Escalation Phase 1,Upto Day 7|Withdrawal by Subject|0
6328908|NCT02991859|10073865|FG004|Period 1,Escalation Phase 1,Upto Day 7|Withdrawal by Subject|1
6328909|NCT02991859|10073866|FG005|Period 1,Escalation Phase 1,Upto Day 7|Withdrawal by Subject|0
6328910|NCT02991859|10073867|FG006|Period 1,Escalation Phase 1,Upto Day 7|Withdrawal by Subject|0
6328911|NCT02991859|10073868|FG007|Period 1,Escalation Phase 1,Upto Day 7|Withdrawal by Subject|0
6328912|NCT02991859|10073869|FG008|Period 1,Escalation Phase 1,Upto Day 7|Withdrawal by Subject|0
6328913|NCT02991859|10073870|FG009|Period 1,Escalation Phase 1,Upto Day 7|Withdrawal by Subject|0
6328914|NCT02991859|10073871|FG010|Period 1,Escalation Phase 1,Upto Day 7|Withdrawal by Subject|0
6328915|NCT02991859|10073872|FG011|Period 1,Escalation Phase 1,Upto Day 7|Withdrawal by Subject|0
6328916|NCT02991859|10073873|FG012|Period 1,Escalation Phase 1,Upto Day 7|Withdrawal by Subject|0
6328917|NCT02991859|10073874|FG013|Period 1,Escalation Phase 1,Upto Day 7|Withdrawal by Subject|0
6328918|NCT02991859|10073875|FG014|Period 1,Escalation Phase 1,Upto Day 7|Withdrawal by Subject|0
6328919|NCT02991859|10073876|FG015|Period 1,Escalation Phase 1,Upto Day 7|Withdrawal by Subject|0
6328920|NCT02991859|10073877|FG016|Period 1,Escalation Phase 1,Upto Day 7|Withdrawal by Subject|0
6328921|NCT02991859|10073861|FG000|Period1, Escalation Phase3, Upto Day21|Withdrawal by Subject|0
6328922|NCT02991859|10073862|FG001|Period1, Escalation Phase3, Upto Day21|Withdrawal by Subject|0
6328923|NCT02991859|10073863|FG002|Period1, Escalation Phase3, Upto Day21|Withdrawal by Subject|0
6328924|NCT02991859|10073864|FG003|Period1, Escalation Phase3, Upto Day21|Withdrawal by Subject|0
6328925|NCT02991859|10073865|FG004|Period1, Escalation Phase3, Upto Day21|Withdrawal by Subject|0
6328926|NCT02991859|10073866|FG005|Period1, Escalation Phase3, Upto Day21|Withdrawal by Subject|0
6328927|NCT02991859|10073867|FG006|Period1, Escalation Phase3, Upto Day21|Withdrawal by Subject|0
6328928|NCT02991859|10073868|FG007|Period1, Escalation Phase3, Upto Day21|Withdrawal by Subject|0
6328929|NCT02991859|10073869|FG008|Period1, Escalation Phase3, Upto Day21|Withdrawal by Subject|0
6328930|NCT02991859|10073870|FG009|Period1, Escalation Phase3, Upto Day21|Withdrawal by Subject|0
6328931|NCT02991859|10073871|FG010|Period1, Escalation Phase3, Upto Day21|Withdrawal by Subject|0
6328932|NCT02991859|10073872|FG011|Period1, Escalation Phase3, Upto Day21|Withdrawal by Subject|0
6328933|NCT02991859|10073873|FG012|Period1, Escalation Phase3, Upto Day21|Withdrawal by Subject|1
6328934|NCT02991859|10073874|FG013|Period1, Escalation Phase3, Upto Day21|Withdrawal by Subject|1
6328935|NCT02991859|10073875|FG014|Period1, Escalation Phase3, Upto Day21|Withdrawal by Subject|0
6328936|NCT02991859|10073876|FG015|Period1, Escalation Phase3, Upto Day21|Withdrawal by Subject|0
6328937|NCT02991859|10073877|FG016|Period1, Escalation Phase3, Upto Day21|Withdrawal by Subject|0
6328938|NCT02991859|10073861|FG000|Wash Out, Up to Day 77|Withdrawal by Subject|0
6328939|NCT02991859|10073862|FG001|Wash Out, Up to Day 77|Withdrawal by Subject|0
6328940|NCT02991859|10073863|FG002|Wash Out, Up to Day 77|Withdrawal by Subject|0
6328941|NCT02991859|10073864|FG003|Wash Out, Up to Day 77|Withdrawal by Subject|0
6328942|NCT02991859|10073865|FG004|Wash Out, Up to Day 77|Withdrawal by Subject|0
6328943|NCT02991859|10073866|FG005|Wash Out, Up to Day 77|Withdrawal by Subject|1
6328944|NCT02991859|10073867|FG006|Wash Out, Up to Day 77|Withdrawal by Subject|0
6328945|NCT02991859|10073868|FG007|Wash Out, Up to Day 77|Withdrawal by Subject|0
6328946|NCT02991859|10073869|FG008|Wash Out, Up to Day 77|Withdrawal by Subject|0
6328947|NCT02991859|10073870|FG009|Wash Out, Up to Day 77|Withdrawal by Subject|0
6328948|NCT02991859|10073871|FG010|Wash Out, Up to Day 77|Withdrawal by Subject|0
6328949|NCT02991859|10073872|FG011|Wash Out, Up to Day 77|Withdrawal by Subject|0
6328950|NCT02991859|10073873|FG012|Wash Out, Up to Day 77|Withdrawal by Subject|0
6328951|NCT02991859|10073874|FG013|Wash Out, Up to Day 77|Withdrawal by Subject|0
6328952|NCT02991859|10073875|FG014|Wash Out, Up to Day 77|Withdrawal by Subject|0
6328953|NCT02991859|10073876|FG015|Wash Out, Up to Day 77|Withdrawal by Subject|0
6328954|NCT02991859|10073877|FG016|Wash Out, Up to Day 77|Withdrawal by Subject|0
6328955|NCT02991859|10073861|FG000|Wash Out, Up to Day 77|Lost to Follow-up|0
6328956|NCT02991859|10073862|FG001|Wash Out, Up to Day 77|Lost to Follow-up|0
6328957|NCT02991859|10073863|FG002|Wash Out, Up to Day 77|Lost to Follow-up|0
6328958|NCT02991859|10073864|FG003|Wash Out, Up to Day 77|Lost to Follow-up|0
6328959|NCT02991859|10073865|FG004|Wash Out, Up to Day 77|Lost to Follow-up|0
6328960|NCT02991859|10073866|FG005|Wash Out, Up to Day 77|Lost to Follow-up|0
6328961|NCT02991859|10073867|FG006|Wash Out, Up to Day 77|Lost to Follow-up|0
6328962|NCT02991859|10073868|FG007|Wash Out, Up to Day 77|Lost to Follow-up|0
6328963|NCT02991859|10073869|FG008|Wash Out, Up to Day 77|Lost to Follow-up|0
6328964|NCT02991859|10073870|FG009|Wash Out, Up to Day 77|Lost to Follow-up|1
6328965|NCT02991859|10073871|FG010|Wash Out, Up to Day 77|Lost to Follow-up|0
6328966|NCT02991859|10073872|FG011|Wash Out, Up to Day 77|Lost to Follow-up|0
6328967|NCT02991859|10073873|FG012|Wash Out, Up to Day 77|Lost to Follow-up|0
6328968|NCT02991859|10073874|FG013|Wash Out, Up to Day 77|Lost to Follow-up|0
6328969|NCT02991859|10073875|FG014|Wash Out, Up to Day 77|Lost to Follow-up|0
6328970|NCT02991859|10073876|FG015|Wash Out, Up to Day 77|Lost to Follow-up|0
6328971|NCT02991859|10073877|FG016|Wash Out, Up to Day 77|Lost to Follow-up|0
6328972|NCT02991859|10073861|FG000|Period2, Escalation Phase4, Upto Day 105|Withdrawal by Subject|0
6328973|NCT02991859|10073862|FG001|Period2, Escalation Phase4, Upto Day 105|Withdrawal by Subject|0
6328974|NCT02991859|10073863|FG002|Period2, Escalation Phase4, Upto Day 105|Withdrawal by Subject|0
6328975|NCT02991859|10073864|FG003|Period2, Escalation Phase4, Upto Day 105|Withdrawal by Subject|0
6328976|NCT02991859|10073865|FG004|Period2, Escalation Phase4, Upto Day 105|Withdrawal by Subject|0
6328977|NCT02991859|10073866|FG005|Period2, Escalation Phase4, Upto Day 105|Withdrawal by Subject|0
6328978|NCT02991859|10073867|FG006|Period2, Escalation Phase4, Upto Day 105|Withdrawal by Subject|0
6328979|NCT02991859|10073868|FG007|Period2, Escalation Phase4, Upto Day 105|Withdrawal by Subject|0
6328980|NCT02991859|10073869|FG008|Period2, Escalation Phase4, Upto Day 105|Withdrawal by Subject|1
6328981|NCT02991859|10073870|FG009|Period2, Escalation Phase4, Upto Day 105|Withdrawal by Subject|0
6328982|NCT02991859|10073871|FG010|Period2, Escalation Phase4, Upto Day 105|Withdrawal by Subject|0
6328983|NCT02991859|10073872|FG011|Period2, Escalation Phase4, Upto Day 105|Withdrawal by Subject|0
6328984|NCT02991859|10073873|FG012|Period2, Escalation Phase4, Upto Day 105|Withdrawal by Subject|0
6328985|NCT02991859|10073874|FG013|Period2, Escalation Phase4, Upto Day 105|Withdrawal by Subject|0
6328986|NCT02991859|10073875|FG014|Period2, Escalation Phase4, Upto Day 105|Withdrawal by Subject|0
6328987|NCT02991859|10073876|FG015|Period2, Escalation Phase4, Upto Day 105|Withdrawal by Subject|0
6328988|NCT02991859|10073877|FG016|Period2, Escalation Phase4, Upto Day 105|Withdrawal by Subject|0
6328989|NCT02992132|10073963|FG000|Overall Study|Adverse Event|4
6328990|NCT02992132|10073964|FG001|Overall Study|Adverse Event|1
6328991|NCT02992132|10073965|FG002|Overall Study|Adverse Event|3
6328992|NCT02992132|10073963|FG000|Overall Study|Lack of Efficacy|2
6328993|NCT02992132|10073964|FG001|Overall Study|Lack of Efficacy|0
6328994|NCT02992132|10073965|FG002|Overall Study|Lack of Efficacy|0
6328995|NCT02992132|10073963|FG000|Overall Study|Non-compliance with study drug|2
6328996|NCT02992132|10073964|FG001|Overall Study|Non-compliance with study drug|0
6328997|NCT02992132|10073965|FG002|Overall Study|Non-compliance with study drug|0
6328998|NCT02992132|10073963|FG000|Overall Study|Progressive disease|1
6328999|NCT02992132|10073964|FG001|Overall Study|Progressive disease|0
6329000|NCT02992132|10073965|FG002|Overall Study|Progressive disease|0
6329001|NCT02992132|10073963|FG000|Overall Study|Protocol Violation|2
6329002|NCT02992132|10073964|FG001|Overall Study|Protocol Violation|2
6329003|NCT02992132|10073965|FG002|Overall Study|Protocol Violation|0
6329004|NCT02992132|10073963|FG000|Overall Study|Caregiver withdrew consent|2
6329005|NCT02992132|10073964|FG001|Overall Study|Caregiver withdrew consent|3
6329006|NCT02992132|10073965|FG002|Overall Study|Caregiver withdrew consent|2
6329007|NCT02992132|10073963|FG000|Overall Study|Withdrawal by Subject|0
6329008|NCT02992132|10073964|FG001|Overall Study|Withdrawal by Subject|2
6329009|NCT02992132|10073965|FG002|Overall Study|Withdrawal by Subject|1
6329010|NCT02992132|10073963|FG000|Overall Study|Physician Decision|0
6329011|NCT02992132|10073964|FG001|Overall Study|Physician Decision|0
6329012|NCT02992132|10073965|FG002|Overall Study|Physician Decision|1
6329013|NCT02992288|10073999|FG000|Overall Study|Adverse Event|8
6329014|NCT02992288|10074000|FG001|Overall Study|Adverse Event|2
6329015|NCT02992288|10074001|FG002|Overall Study|Adverse Event|2
6329016|NCT02992288|10074002|FG003|Overall Study|Adverse Event|2
6329017|NCT02992288|10074003|FG004|Overall Study|Adverse Event|2
6329018|NCT02992288|10074004|FG005|Overall Study|Adverse Event|7
6329019|NCT02992288|10073999|FG000|Overall Study|Non-compliance with study drug|0
6329020|NCT02992288|10074000|FG001|Overall Study|Non-compliance with study drug|1
6329021|NCT02992288|10074001|FG002|Overall Study|Non-compliance with study drug|1
6329022|NCT02992288|10074002|FG003|Overall Study|Non-compliance with study drug|0
6329023|NCT02992288|10074003|FG004|Overall Study|Non-compliance with study drug|1
6329024|NCT02992288|10074004|FG005|Overall Study|Non-compliance with study drug|0
6329025|NCT02992288|10073999|FG000|Overall Study|Physician Decision|3
5972104|NCT00950989|9557710|FG001|Overall Study|Withdrawal by Subject|1
6329026|NCT02992288|10074000|FG001|Overall Study|Physician Decision|0
6329027|NCT02992288|10074001|FG002|Overall Study|Physician Decision|1
6329028|NCT02992288|10074002|FG003|Overall Study|Physician Decision|0
6329029|NCT02992288|10074003|FG004|Overall Study|Physician Decision|0
6329030|NCT02992288|10074004|FG005|Overall Study|Physician Decision|1
6329031|NCT02992288|10073999|FG000|Overall Study|Death|2
6329032|NCT02992288|10074000|FG001|Overall Study|Death|0
6329033|NCT02992288|10074001|FG002|Overall Study|Death|2
6329034|NCT02992288|10074002|FG003|Overall Study|Death|1
6329035|NCT02992288|10074003|FG004|Overall Study|Death|2
6329036|NCT02992288|10074004|FG005|Overall Study|Death|0
6329037|NCT02992288|10073999|FG000|Overall Study|Lost to Follow-up|0
6329038|NCT02992288|10074000|FG001|Overall Study|Lost to Follow-up|0
6329039|NCT02992288|10074001|FG002|Overall Study|Lost to Follow-up|0
6329040|NCT02992288|10074002|FG003|Overall Study|Lost to Follow-up|1
6329041|NCT02992288|10074003|FG004|Overall Study|Lost to Follow-up|0
6329042|NCT02992288|10074004|FG005|Overall Study|Lost to Follow-up|0
6329043|NCT02992288|10073999|FG000|Overall Study|Protocol Violation|0
6329044|NCT02992288|10074000|FG001|Overall Study|Protocol Violation|0
6329045|NCT02992288|10074001|FG002|Overall Study|Protocol Violation|0
6329046|NCT02992288|10074002|FG003|Overall Study|Protocol Violation|0
6329047|NCT02992288|10074003|FG004|Overall Study|Protocol Violation|0
6329048|NCT02992288|10074004|FG005|Overall Study|Protocol Violation|1
6329049|NCT02992288|10073999|FG000|Overall Study|Withdrawal by Subject|4
6329050|NCT02992288|10074000|FG001|Overall Study|Withdrawal by Subject|2
6329051|NCT02992288|10074001|FG002|Overall Study|Withdrawal by Subject|1
6329052|NCT02992288|10074002|FG003|Overall Study|Withdrawal by Subject|5
6329053|NCT02992288|10074003|FG004|Overall Study|Withdrawal by Subject|3
6329054|NCT02992288|10074004|FG005|Overall Study|Withdrawal by Subject|4
6329055|NCT02992691|10074018|FG000|Overall Study|Adverse Event|2
6329056|NCT02992691|10074018|FG000|Overall Study|Withdrawal by Subject|1
6329057|NCT02992899|10074035|FG000|Overall Study|Withdrawal by Subject|1
6329058|NCT02992899|10074036|FG001|Overall Study|Withdrawal by Subject|0
6329059|NCT02992899|10074035|FG000|Overall Study|Lost to Follow-up|1
6329060|NCT02992899|10074036|FG001|Overall Study|Lost to Follow-up|3
6329061|NCT02993224|10074042|FG000|Core Phase - Period 1|Adverse Event|4
6329062|NCT02993224|10074042|FG000|Core Phase - Period 1|Withdrawal by Subject|1
6329063|NCT02993224|10074042|FG000|Core Phase - Period 1|Lost to Follow-up|3
6329064|NCT02993224|10074042|FG000|Core Phase- Period 2|Adverse Event|1
6329065|NCT02993224|10074042|FG000|Core Phase- Period 2|Unwillingness To Comply With Protocol Procedures And Prescribed Study Treatment|2
6329066|NCT02993224|10074042|FG000|Core Phase- Period 2|Allogenic stem cell transplantation|1
6329067|NCT02993224|10074042|FG000|Extension Phase|Unwillingness To Comply With Protocol Procedures And Prescribed Study Treatment|1
6329068|NCT02993224|10074042|FG000|Extension Phase|Adverse Event|3
6329069|NCT02993224|10074042|FG000|Extension Phase|Withdrawal by Subject|3
6329070|NCT02993224|10074042|FG000|Extension Phase|Lost to Follow-up|2
6329071|NCT02993224|10074042|FG000|Extension Phase|Deferasirox FCT locally reimbursed|27
6329072|NCT02993250|10074050|FG000|Overall Study|Lost to Follow-up|0
6329073|NCT02993250|10074051|FG001|Overall Study|Lost to Follow-up|1
6329074|NCT02993471|10074075|FG000|Period 2 (Drug Cocktail + Ixekizumab)|Protocol Violation|1
6329075|NCT02993471|10074075|FG000|Period 2 (Drug Cocktail + Ixekizumab)|Withdrawal by Subject|1
6329076|NCT02993783|10074099|FG000|Overall Study|Reason not Specified|6
6329077|NCT02993783|10074100|FG001|Overall Study|Reason not Specified|9
6329078|NCT02994056|10074106|FG000|Overall Study|Death|8
6329079|NCT02994056|10074106|FG000|Overall Study|Withdrew Consent|1
6329080|NCT02994108|10074121|FG000|Intervention Messages|Withdrawal by Subject|2
6329081|NCT02994108|10074122|FG001|Intervention Messages|Withdrawal by Subject|0
6329082|NCT02994108|10074121|FG000|Phase 1 Assessment|Lost to Follow-up|5
6329083|NCT02994108|10074122|FG001|Phase 1 Assessment|Lost to Follow-up|3
6329084|NCT02994108|10074121|FG000|Phase 2 Assessment|Lost to Follow-up|8
6329085|NCT02994108|10074122|FG001|Phase 2 Assessment|Lost to Follow-up|7
6329086|NCT02994108|10074121|FG000|Phase 2 Assessment|Withdrawal by Subject|1
6329087|NCT02994108|10074122|FG001|Phase 2 Assessment|Withdrawal by Subject|0
6329088|NCT02994394|10074140|FG000|Period 1 (Days 1 to 3)|Adverse Event|0
6329089|NCT02994394|10074141|FG001|Period 1 (Days 1 to 3)|Adverse Event|0
6329090|NCT02994394|10074142|FG002|Period 1 (Days 1 to 3)|Adverse Event|1
6329091|NCT02994394|10074143|FG003|Period 1 (Days 1 to 3)|Adverse Event|0
6329092|NCT02994394|10074144|FG004|Period 1 (Days 1 to 3)|Adverse Event|0
6329093|NCT02994394|10074145|FG005|Period 1 (Days 1 to 3)|Adverse Event|0
6329094|NCT02994394|10074140|FG000|Period 2 (Days 4 to 6)|Adverse Event|0
6329095|NCT02994394|10074141|FG001|Period 2 (Days 4 to 6)|Adverse Event|1
6329096|NCT02994394|10074142|FG002|Period 2 (Days 4 to 6)|Adverse Event|0
6329097|NCT02994394|10074143|FG003|Period 2 (Days 4 to 6)|Adverse Event|0
6329098|NCT02994394|10074144|FG004|Period 2 (Days 4 to 6)|Adverse Event|1
6167175|NCT01226511|9811633|FG000|Acute Treatment Period|Lack of Efficacy|2
6167176|NCT01226511|9811634|FG001|Acute Treatment Period|Lack of Efficacy|1
6167177|NCT01226511|9811633|FG000|Acute Treatment Period|Lost to Follow-up|3
6329099|NCT02994394|10074145|FG005|Period 2 (Days 4 to 6)|Adverse Event|0
6329100|NCT02994654|10074159|FG000|Overall Study|Lost to Follow-up|1
6329101|NCT02994940|10074171|FG000|Overall Study|Did not receive study medications: Study drug not available prior to anesthesia induction|6
6329102|NCT02994940|10074172|FG001|Overall Study|Did not receive study medications: Study drug not available prior to anesthesia induction|0
6329103|NCT02994940|10074171|FG000|Overall Study|Did not receive study medications: vomited after ingestion|1
6329104|NCT02994940|10074172|FG001|Overall Study|Did not receive study medications: vomited after ingestion|0
6329105|NCT02994940|10074171|FG000|Overall Study|Did not receive study medications: red dye allergy|0
6329106|NCT02994940|10074172|FG001|Overall Study|Did not receive study medications: red dye allergy|1
6329107|NCT02995980|10074196|FG000|Overall Study|Lost to Follow-up|14
6329108|NCT02996097|10074201|FG000|Overall Study|Lost to Follow-up|11
6329109|NCT02996097|10074202|FG001|Overall Study|Lost to Follow-up|11
6329110|NCT02996448|10074207|FG000|Overall Study|Study terminated due to adverse effects|3
6329111|NCT02996474|10074212|FG000|Overall Study|Physician Decision|5
6329112|NCT02996500|10074222|FG000|Overall Study|Adverse Event|1
6329113|NCT02996500|10074223|FG001|Overall Study|Adverse Event|1
6329114|NCT02996500|10074224|FG002|Overall Study|Adverse Event|4
6329115|NCT02996500|10074225|FG003|Overall Study|Adverse Event|3
6329116|NCT02996500|10074226|FG004|Overall Study|Adverse Event|1
6329117|NCT02996500|10074227|FG005|Overall Study|Adverse Event|2
6329118|NCT02996500|10074222|FG000|Overall Study|Lack of Efficacy|0
6329119|NCT02996500|10074223|FG001|Overall Study|Lack of Efficacy|0
6329120|NCT02996500|10074224|FG002|Overall Study|Lack of Efficacy|0
6329121|NCT02996500|10074225|FG003|Overall Study|Lack of Efficacy|0
6329122|NCT02996500|10074226|FG004|Overall Study|Lack of Efficacy|2
6329123|NCT02996500|10074227|FG005|Overall Study|Lack of Efficacy|0
6329124|NCT02996500|10074222|FG000|Overall Study|Lost to Follow-up|1
6329125|NCT02996500|10074223|FG001|Overall Study|Lost to Follow-up|0
6329126|NCT02996500|10074224|FG002|Overall Study|Lost to Follow-up|0
6329127|NCT02996500|10074225|FG003|Overall Study|Lost to Follow-up|0
6329128|NCT02996500|10074226|FG004|Overall Study|Lost to Follow-up|0
6329129|NCT02996500|10074227|FG005|Overall Study|Lost to Follow-up|1
6329130|NCT02996500|10074222|FG000|Overall Study|No Longer Meets Eligibility Criteria|0
6329131|NCT02996500|10074223|FG001|Overall Study|No Longer Meets Eligibility Criteria|0
6329132|NCT02996500|10074224|FG002|Overall Study|No Longer Meets Eligibility Criteria|1
6329133|NCT02996500|10074225|FG003|Overall Study|No Longer Meets Eligibility Criteria|0
6329134|NCT02996500|10074226|FG004|Overall Study|No Longer Meets Eligibility Criteria|0
6082704|NCT00631007|9690819|FG003|Overall Study|Lost to Follow-up|4
6329135|NCT02996500|10074227|FG005|Overall Study|No Longer Meets Eligibility Criteria|0
6329136|NCT02996500|10074222|FG000|Overall Study|Non-Compliance With Study Drug|0
6329137|NCT02996500|10074223|FG001|Overall Study|Non-Compliance With Study Drug|0
6329138|NCT02996500|10074224|FG002|Overall Study|Non-Compliance With Study Drug|0
6329139|NCT02996500|10074225|FG003|Overall Study|Non-Compliance With Study Drug|0
6329140|NCT02996500|10074226|FG004|Overall Study|Non-Compliance With Study Drug|0
6329141|NCT02996500|10074227|FG005|Overall Study|Non-Compliance With Study Drug|1
6329142|NCT02996500|10074222|FG000|Overall Study|Progressive Disease|1
6329143|NCT02996500|10074223|FG001|Overall Study|Progressive Disease|0
6329144|NCT02996500|10074224|FG002|Overall Study|Progressive Disease|0
6329145|NCT02996500|10074225|FG003|Overall Study|Progressive Disease|0
6329146|NCT02996500|10074226|FG004|Overall Study|Progressive Disease|0
6329147|NCT02996500|10074227|FG005|Overall Study|Progressive Disease|0
6329148|NCT02996500|10074222|FG000|Overall Study|Other|2
6329149|NCT02996500|10074223|FG001|Overall Study|Other|0
6329150|NCT02996500|10074224|FG002|Overall Study|Other|2
6329151|NCT02996500|10074225|FG003|Overall Study|Other|0
6329152|NCT02996500|10074226|FG004|Overall Study|Other|0
6329153|NCT02996500|10074227|FG005|Overall Study|Other|0
6329154|NCT02996500|10074222|FG000|Overall Study|Protocol Violation|0
6329155|NCT02996500|10074223|FG001|Overall Study|Protocol Violation|0
6329156|NCT02996500|10074224|FG002|Overall Study|Protocol Violation|0
6329157|NCT02996500|10074225|FG003|Overall Study|Protocol Violation|1
6329158|NCT02996500|10074226|FG004|Overall Study|Protocol Violation|0
6329159|NCT02996500|10074227|FG005|Overall Study|Protocol Violation|0
6329160|NCT02996500|10074222|FG000|Overall Study|Withdrawal by Subject|3
6329161|NCT02996500|10074223|FG001|Overall Study|Withdrawal by Subject|0
6329162|NCT02996500|10074224|FG002|Overall Study|Withdrawal by Subject|3
6082705|NCT00631007|9690820|FG004|Overall Study|Lost to Follow-up|5
6082706|NCT00631007|9690821|FG005|Overall Study|Lost to Follow-up|3
6082707|NCT00631007|9690816|FG000|Overall Study|Physician Decision|1
6082708|NCT00631007|9690817|FG001|Overall Study|Physician Decision|0
6082709|NCT00631007|9690818|FG002|Overall Study|Physician Decision|1
6082710|NCT00631007|9690819|FG003|Overall Study|Physician Decision|0
6082711|NCT00631007|9690820|FG004|Overall Study|Physician Decision|0
6082712|NCT00631007|9690821|FG005|Overall Study|Physician Decision|2
6082713|NCT00631007|9690816|FG000|Overall Study|Persistent Hyperglycemia|2
6082714|NCT00631007|9690817|FG001|Overall Study|Persistent Hyperglycemia|2
6082715|NCT00631007|9690818|FG002|Overall Study|Persistent Hyperglycemia|5
6082716|NCT00631007|9690819|FG003|Overall Study|Persistent Hyperglycemia|1
6082717|NCT00631007|9690820|FG004|Overall Study|Persistent Hyperglycemia|2
6082718|NCT00631007|9690821|FG005|Overall Study|Persistent Hyperglycemia|5
6082719|NCT00631007|9690816|FG000|Overall Study|Withdrawal by Subject|4
6329163|NCT02996500|10074225|FG003|Overall Study|Withdrawal by Subject|0
6329164|NCT02996500|10074226|FG004|Overall Study|Withdrawal by Subject|2
6329165|NCT02996500|10074227|FG005|Overall Study|Withdrawal by Subject|0
6329166|NCT02996682|10074256|FG000|Overall Study|Death|0
6082720|NCT00631007|9690817|FG001|Overall Study|Withdrawal by Subject|5
6082721|NCT00631007|9690818|FG002|Overall Study|Withdrawal by Subject|2
6082722|NCT00631007|9690819|FG003|Overall Study|Withdrawal by Subject|2
6329167|NCT02996682|10074257|FG001|Overall Study|Death|3
6329168|NCT02996968|10074274|FG000|Overall Study|Withdrawal by Subject|1
6329169|NCT02996968|10074275|FG001|Overall Study|Withdrawal by Subject|0
6329170|NCT02997163|10074297|FG000|Overall Study|Adverse Event|1
6329171|NCT02997163|10074298|FG001|Overall Study|Adverse Event|0
6082723|NCT00631007|9690820|FG004|Overall Study|Withdrawal by Subject|1
6082724|NCT00631007|9690821|FG005|Overall Study|Withdrawal by Subject|3
6082725|NCT00631007|9690816|FG000|Overall Study|Other|2
6082726|NCT00631007|9690817|FG001|Overall Study|Other|1
6082727|NCT00631007|9690818|FG002|Overall Study|Other|0
6082728|NCT00631007|9690819|FG003|Overall Study|Other|0
6082729|NCT00631007|9690820|FG004|Overall Study|Other|1
6082730|NCT00631007|9690821|FG005|Overall Study|Other|0
6082731|NCT00631020|9690835|FG000|Overall Study|Lost to Follow-up|7
6082732|NCT00631020|9690835|FG000|Overall Study|Incarcerated|1
6082733|NCT00631163|9690839|FG000|Number of Participants in Year 1|Adverse Event|12
6082734|NCT00631163|9690839|FG000|Number of Participants in Year 1|Withdrawal by Subject|8
6082735|NCT00631163|9690839|FG000|Number of Participants in Year 1|Death|6
6082736|NCT00631163|9690839|FG000|Number of Participants in Year 1|Lost to Follow-up|1
6082737|NCT00631163|9690839|FG000|Number of Participants in Year 1|Patient's condition no longer requires study drug|1
6329172|NCT02997163|10074299|FG002|Overall Study|Adverse Event|0
6329173|NCT02997163|10074300|FG003|Overall Study|Adverse Event|1
6329174|NCT02997176|10074314|FG000|Overall Study|Adverse Event|0
6329175|NCT02997176|10074315|FG001|Overall Study|Adverse Event|0
6329176|NCT02997176|10074316|FG002|Overall Study|Adverse Event|0
6329177|NCT02997176|10074317|FG003|Overall Study|Adverse Event|8
6329178|NCT02997176|10074314|FG000|Overall Study|Progressive Disease|1
6329179|NCT02997176|10074315|FG001|Overall Study|Progressive Disease|0
6329180|NCT02997176|10074316|FG002|Overall Study|Progressive Disease|1
6329181|NCT02997176|10074317|FG003|Overall Study|Progressive Disease|1
6329182|NCT02997176|10074314|FG000|Overall Study|Death|0
6329183|NCT02997176|10074315|FG001|Overall Study|Death|0
6329184|NCT02997176|10074316|FG002|Overall Study|Death|1
6329185|NCT02997176|10074317|FG003|Overall Study|Death|1
6329186|NCT02997176|10074314|FG000|Overall Study|Withdrawal by Subject|0
6329187|NCT02997176|10074315|FG001|Overall Study|Withdrawal by Subject|2
6329188|NCT02997176|10074316|FG002|Overall Study|Withdrawal by Subject|0
6329189|NCT02997176|10074317|FG003|Overall Study|Withdrawal by Subject|1
6329190|NCT02998021|10074360|FG000|Overall Study|Withdrawal by Subject|3
6329191|NCT02998021|10074361|FG001|Overall Study|Withdrawal by Subject|1
6329192|NCT02998021|10074360|FG000|Overall Study|unsafe home|0
6329193|NCT02998021|10074361|FG001|Overall Study|unsafe home|1
6329194|NCT02998151|10074367|FG000|Overall Study|Withdrawal by Subject|3
6329195|NCT02998151|10074367|FG000|Overall Study|Participant declined to re-enroll for baclofen|8
6329196|NCT02998151|10074367|FG000|Overall Study|Participant was not offered acamprosate; acamprosate was discontinued and replaced with baclofen|13
6329197|NCT02998541|10074382|FG000|Overall Study|Adverse Event|4
6329198|NCT02998541|10074383|FG001|Overall Study|Adverse Event|5
6329199|NCT02998541|10074384|FG002|Overall Study|Adverse Event|1
6329200|NCT02998541|10074382|FG000|Overall Study|Protocol Violation|1
6329201|NCT02998541|10074383|FG001|Overall Study|Protocol Violation|0
6329202|NCT02998541|10074384|FG002|Overall Study|Protocol Violation|0
6329203|NCT02998541|10074382|FG000|Overall Study|Withdrawal by Subject|3
6329204|NCT02998541|10074383|FG001|Overall Study|Withdrawal by Subject|1
6329205|NCT02998541|10074384|FG002|Overall Study|Withdrawal by Subject|0
6329206|NCT02998541|10074382|FG000|Overall Study|Lost to Follow-up|0
6329207|NCT02998541|10074383|FG001|Overall Study|Lost to Follow-up|3
6329208|NCT02998541|10074384|FG002|Overall Study|Lost to Follow-up|1
6329209|NCT02998541|10074382|FG000|Overall Study|Physician Decision|0
6329210|NCT02998541|10074383|FG001|Overall Study|Physician Decision|0
6329211|NCT02998541|10074384|FG002|Overall Study|Physician Decision|3
6329212|NCT02998541|10074382|FG000|Overall Study|Withdrawal by Parent/Guardian|0
6329213|NCT02998541|10074383|FG001|Overall Study|Withdrawal by Parent/Guardian|0
6329214|NCT02998541|10074384|FG002|Overall Study|Withdrawal by Parent/Guardian|1
6329215|NCT02998554|10074394|FG000|Overall Study|Adverse Event|8
6329216|NCT02998554|10074395|FG001|Overall Study|Adverse Event|3
6329217|NCT02998554|10074394|FG000|Overall Study|Protocol deviation|1
6329218|NCT02998554|10074395|FG001|Overall Study|Protocol deviation|0
6329219|NCT02998554|10074394|FG000|Overall Study|Withdrawal by Subject|2
6329220|NCT02998554|10074395|FG001|Overall Study|Withdrawal by Subject|6
6329221|NCT02998554|10074394|FG000|Overall Study|Lost to Follow-up|0
6329222|NCT02998554|10074395|FG001|Overall Study|Lost to Follow-up|1
6329223|NCT02998554|10074394|FG000|Overall Study|Lack of Efficacy|0
6329224|NCT02998554|10074395|FG001|Overall Study|Lack of Efficacy|1
6329225|NCT02998671|10074408|FG000|Period 1|Study Terminated By Sponsor|2
6329226|NCT02998671|10074409|FG001|Period 1|Study Terminated By Sponsor|1
6329227|NCT02998671|10074410|FG002|Period 1|Study Terminated By Sponsor|0
6329228|NCT02998671|10074411|FG003|Period 1|Study Terminated By Sponsor|0
6082738|NCT00631163|9690839|FG000|Number of Participants in Year 1|Administrative problems|6
6329229|NCT02998671|10074412|FG004|Period 1|Study Terminated By Sponsor|1
6329230|NCT02998671|10074408|FG000|Period 1|Withdrawal by Subject|1
6329231|NCT02998671|10074409|FG001|Period 1|Withdrawal by Subject|2
6329232|NCT02998671|10074410|FG002|Period 1|Withdrawal by Subject|0
6329233|NCT02998671|10074411|FG003|Period 1|Withdrawal by Subject|0
6329234|NCT02998671|10074412|FG004|Period 1|Withdrawal by Subject|2
6082739|NCT00631163|9690839|FG000|Number of Participants in Year 2|Withdrawal by Subject|2
6082740|NCT00631163|9690839|FG000|Number of Participants in Year 2|Adverse Event|1
6329235|NCT02998671|10074408|FG000|Period 1|Pregnancy|1
6329236|NCT02998671|10074409|FG001|Period 1|Pregnancy|0
6329237|NCT02998671|10074410|FG002|Period 1|Pregnancy|0
6329238|NCT02998671|10074411|FG003|Period 1|Pregnancy|0
6329239|NCT02998671|10074412|FG004|Period 1|Pregnancy|0
6329240|NCT02998671|10074408|FG000|Period 1|Adverse Event|0
6329241|NCT02998671|10074409|FG001|Period 1|Adverse Event|0
6329242|NCT02998671|10074410|FG002|Period 1|Adverse Event|0
6329243|NCT02998671|10074411|FG003|Period 1|Adverse Event|0
6329244|NCT02998671|10074412|FG004|Period 1|Adverse Event|1
6329245|NCT02998671|10074408|FG000|Period 2|Adverse Event|0
6329246|NCT02998671|10074409|FG001|Period 2|Adverse Event|1
6329247|NCT02998671|10074410|FG002|Period 2|Adverse Event|0
6329248|NCT02998671|10074411|FG003|Period 2|Adverse Event|0
6329249|NCT02998671|10074412|FG004|Period 2|Adverse Event|0
6329250|NCT02998671|10074408|FG000|Period 2|Study Terminated By Sponsor|3
6329251|NCT02998671|10074409|FG001|Period 2|Study Terminated By Sponsor|5
6329252|NCT02998671|10074410|FG002|Period 2|Study Terminated By Sponsor|1
6329253|NCT02998671|10074411|FG003|Period 2|Study Terminated By Sponsor|3
6329254|NCT02998671|10074412|FG004|Period 2|Study Terminated By Sponsor|0
6329255|NCT02998671|10074408|FG000|Period 2|Withdrawal by Subject|0
6329256|NCT02998671|10074409|FG001|Period 2|Withdrawal by Subject|1
6329257|NCT02998671|10074410|FG002|Period 2|Withdrawal by Subject|0
6329258|NCT02998671|10074411|FG003|Period 2|Withdrawal by Subject|0
6329259|NCT02998671|10074412|FG004|Period 2|Withdrawal by Subject|0
6329260|NCT02998671|10074408|FG000|Period 2|Lost to Follow-up|0
6329261|NCT02998671|10074409|FG001|Period 2|Lost to Follow-up|0
6329262|NCT02998671|10074410|FG002|Period 2|Lost to Follow-up|0
6329263|NCT02998671|10074411|FG003|Period 2|Lost to Follow-up|1
6329264|NCT02998671|10074412|FG004|Period 2|Lost to Follow-up|0
6329265|NCT02998996|10074447|FG000|Overall Study|Lost to Follow-up|0
6329266|NCT02998996|10074448|FG001|Overall Study|Lost to Follow-up|0
6329267|NCT02998996|10074449|FG002|Overall Study|Lost to Follow-up|1
6329268|NCT02998996|10074450|FG003|Overall Study|Lost to Follow-up|0
6329269|NCT02998996|10074451|FG004|Overall Study|Lost to Follow-up|0
6329270|NCT02998996|10074452|FG005|Overall Study|Lost to Follow-up|0
6329271|NCT02998996|10074447|FG000|Overall Study|Pregnancy|0
6329272|NCT02998996|10074448|FG001|Overall Study|Pregnancy|1
6329273|NCT02998996|10074449|FG002|Overall Study|Pregnancy|0
6329274|NCT02998996|10074450|FG003|Overall Study|Pregnancy|0
6329275|NCT02998996|10074451|FG004|Overall Study|Pregnancy|0
6329276|NCT02998996|10074452|FG005|Overall Study|Pregnancy|0
6329277|NCT02998996|10074447|FG000|Overall Study|Family reasons|0
6329278|NCT02998996|10074448|FG001|Overall Study|Family reasons|0
6329279|NCT02998996|10074449|FG002|Overall Study|Family reasons|0
6329280|NCT02998996|10074450|FG003|Overall Study|Family reasons|0
6329281|NCT02998996|10074451|FG004|Overall Study|Family reasons|1
6329282|NCT02998996|10074452|FG005|Overall Study|Family reasons|0
6329283|NCT02999100|10074472|FG000|Part 1 (up to 15 Days)|Adverse Event|0
6329284|NCT02999100|10074473|FG001|Part 1 (up to 15 Days)|Adverse Event|1
6329285|NCT02999100|10074474|FG002|Part 1 (up to 15 Days)|Adverse Event|0
6329286|NCT02999100|10074475|FG003|Part 1 (up to 15 Days)|Adverse Event|0
6329287|NCT02999100|10074476|FG004|Part 1 (up to 15 Days)|Adverse Event|0
6329288|NCT02999100|10074477|FG005|Part 1 (up to 15 Days)|Adverse Event|0
6329289|NCT02999100|10074472|FG000|Part 2 (Day 1): Dosing Session 1|Withdrawal by Subject|0
6329290|NCT02999100|10074473|FG001|Part 2 (Day 1): Dosing Session 1|Withdrawal by Subject|0
6329291|NCT02999100|10074474|FG002|Part 2 (Day 1): Dosing Session 1|Withdrawal by Subject|0
6329292|NCT02999100|10074475|FG003|Part 2 (Day 1): Dosing Session 1|Withdrawal by Subject|0
6329293|NCT02999100|10074476|FG004|Part 2 (Day 1): Dosing Session 1|Withdrawal by Subject|0
6329294|NCT02999100|10074477|FG005|Part 2 (Day 1): Dosing Session 1|Withdrawal by Subject|1
6329295|NCT02999100|10074472|FG000|Part 2 (Day 1): Dosing Session 1|Protocol Violation|0
6329296|NCT02999100|10074473|FG001|Part 2 (Day 1): Dosing Session 1|Protocol Violation|0
6329297|NCT02999100|10074474|FG002|Part 2 (Day 1): Dosing Session 1|Protocol Violation|1
6329298|NCT02999100|10074475|FG003|Part 2 (Day 1): Dosing Session 1|Protocol Violation|0
6329299|NCT02999100|10074476|FG004|Part 2 (Day 1): Dosing Session 1|Protocol Violation|0
6329300|NCT02999100|10074477|FG005|Part 2 (Day 1): Dosing Session 1|Protocol Violation|0
6329301|NCT02999178|10074501|FG000|Overall Study|Adverse Event|85
6329302|NCT02999178|10074502|FG001|Overall Study|Adverse Event|62
6329303|NCT02999178|10074501|FG000|Overall Study|Protocol Violation|1
6329304|NCT02999178|10074502|FG001|Overall Study|Protocol Violation|2
6329305|NCT02999178|10074501|FG000|Overall Study|Lost to Follow-up|0
6329306|NCT02999178|10074502|FG001|Overall Study|Lost to Follow-up|2
6329307|NCT02999178|10074501|FG000|Overall Study|Withdrawal by Subject|21
6329308|NCT02999178|10074502|FG001|Overall Study|Withdrawal by Subject|21
6329309|NCT02999178|10074501|FG000|Overall Study|Other reason not defined above|7
6329310|NCT02999178|10074502|FG001|Overall Study|Other reason not defined above|13
6329311|NCT02999191|10074511|FG000|Wash-out Period 1 [21 Days]|Adverse Event|0
6329312|NCT02999191|10074512|FG001|Wash-out Period 1 [21 Days]|Adverse Event|1
6329313|NCT02999191|10074513|FG002|Wash-out Period 1 [21 Days]|Adverse Event|0
6329314|NCT02999672|10074523|FG000|Overall Study|Death|0
6329315|NCT02999672|10074524|FG001|Overall Study|Death|1
6329316|NCT02999672|10074523|FG000|Overall Study|Study Terminated by Sponsor|0
6329317|NCT02999672|10074524|FG001|Overall Study|Study Terminated by Sponsor|1
6329318|NCT02999672|10074523|FG000|Overall Study|Progressive Disease|9
6329319|NCT02999672|10074524|FG001|Overall Study|Progressive Disease|5
6329320|NCT02999672|10074523|FG000|Overall Study|Adverse Event|4
6329321|NCT02999672|10074524|FG001|Overall Study|Adverse Event|0
6329322|NCT03000075|10074546|FG000|Part A|Adverse Event|4
6329323|NCT03000075|10074547|FG001|Part A|Adverse Event|0
6329324|NCT03000075|10074548|FG002|Part A|Adverse Event|0
6329325|NCT03000075|10074549|FG003|Part A|Adverse Event|0
6329326|NCT03000075|10074550|FG004|Part A|Adverse Event|0
6329327|NCT03000075|10074551|FG005|Part A|Adverse Event|0
6329328|NCT03000075|10074552|FG006|Part A|Adverse Event|0
6329329|NCT03000075|10074546|FG000|Part B|Not dosed due to AE|0
6329330|NCT03000075|10074547|FG001|Part B|Not dosed due to AE|0
6329331|NCT03000075|10074548|FG002|Part B|Not dosed due to AE|0
6329332|NCT03000075|10074549|FG003|Part B|Not dosed due to AE|0
6329333|NCT03000075|10074550|FG004|Part B|Not dosed due to AE|0
6329334|NCT03000075|10074551|FG005|Part B|Not dosed due to AE|2
6329335|NCT03000075|10074552|FG006|Part B|Not dosed due to AE|1
6329336|NCT03000075|10074546|FG000|Part B|Adverse Event|0
6329337|NCT03000075|10074547|FG001|Part B|Adverse Event|0
6329338|NCT03000075|10074548|FG002|Part B|Adverse Event|0
6329339|NCT03000075|10074549|FG003|Part B|Adverse Event|0
6329340|NCT03000075|10074550|FG004|Part B|Adverse Event|1
6329341|NCT03000075|10074551|FG005|Part B|Adverse Event|0
6329342|NCT03000075|10074552|FG006|Part B|Adverse Event|0
6329343|NCT03000348|10074601|FG000|Overall Study|Adverse Event|1
6329344|NCT03000348|10074602|FG001|Overall Study|Adverse Event|1
6329345|NCT03000348|10074603|FG002|Overall Study|Adverse Event|1
6329346|NCT03000348|10074604|FG003|Overall Study|Adverse Event|1
6329347|NCT03000348|10074605|FG004|Overall Study|Adverse Event|1
6329348|NCT03000348|10074606|FG005|Overall Study|Adverse Event|1
6329349|NCT03000348|10074601|FG000|Overall Study|Lost to Follow-up|0
6329350|NCT03000348|10074602|FG001|Overall Study|Lost to Follow-up|0
6329351|NCT03000348|10074603|FG002|Overall Study|Lost to Follow-up|1
6329352|NCT03000348|10074604|FG003|Overall Study|Lost to Follow-up|0
6329353|NCT03000348|10074605|FG004|Overall Study|Lost to Follow-up|0
6329354|NCT03000348|10074606|FG005|Overall Study|Lost to Follow-up|0
6329355|NCT03000348|10074601|FG000|Overall Study|Withdrawal by Subject|0
6329356|NCT03000348|10074602|FG001|Overall Study|Withdrawal by Subject|1
6329357|NCT03000348|10074603|FG002|Overall Study|Withdrawal by Subject|0
6329358|NCT03000348|10074604|FG003|Overall Study|Withdrawal by Subject|0
6329359|NCT03000348|10074605|FG004|Overall Study|Withdrawal by Subject|0
6329360|NCT03000348|10074606|FG005|Overall Study|Withdrawal by Subject|0
6329361|NCT03000348|10074601|FG000|Overall Study|Consent|0
6329362|NCT03000348|10074602|FG001|Overall Study|Consent|0
6329363|NCT03000348|10074603|FG002|Overall Study|Consent|0
6329364|NCT03000348|10074604|FG003|Overall Study|Consent|0
6329365|NCT03000348|10074605|FG004|Overall Study|Consent|1
6329366|NCT03000348|10074606|FG005|Overall Study|Consent|0
6329367|NCT03000348|10074601|FG000|Overall Study|Failure to expectorate sputum|1
6329368|NCT03000348|10074602|FG001|Overall Study|Failure to expectorate sputum|0
6329369|NCT03000348|10074603|FG002|Overall Study|Failure to expectorate sputum|1
6329370|NCT03000348|10074604|FG003|Overall Study|Failure to expectorate sputum|0
6329371|NCT03000348|10074605|FG004|Overall Study|Failure to expectorate sputum|1
6329372|NCT03000348|10074606|FG005|Overall Study|Failure to expectorate sputum|0
6329373|NCT03000348|10074601|FG000|Overall Study|No gram negative|1
6329374|NCT03000348|10074602|FG001|Overall Study|No gram negative|2
6329375|NCT03000348|10074603|FG002|Overall Study|No gram negative|1
6329376|NCT03000348|10074604|FG003|Overall Study|No gram negative|1
6329377|NCT03000348|10074605|FG004|Overall Study|No gram negative|1
6329378|NCT03000348|10074606|FG005|Overall Study|No gram negative|1
6329379|NCT03000348|10074601|FG000|Overall Study|Patient had no transport|0
6329380|NCT03000348|10074602|FG001|Overall Study|Patient had no transport|0
6329381|NCT03000348|10074603|FG002|Overall Study|Patient had no transport|0
6329382|NCT03000348|10074604|FG003|Overall Study|Patient had no transport|1
6329383|NCT03000348|10074605|FG004|Overall Study|Patient had no transport|0
6329384|NCT03000348|10074606|FG005|Overall Study|Patient had no transport|0
6329385|NCT03000348|10074601|FG000|Overall Study|Dosing|0
6329386|NCT03000348|10074602|FG001|Overall Study|Dosing|0
6329387|NCT03000348|10074603|FG002|Overall Study|Dosing|0
6329388|NCT03000348|10074604|FG003|Overall Study|Dosing|0
6329389|NCT03000348|10074605|FG004|Overall Study|Dosing|1
6329390|NCT03000348|10074606|FG005|Overall Study|Dosing|0
6329391|NCT03000452|10074623|FG000|Treatment Period|Death|1
6329392|NCT03000452|10074623|FG000|Treatment Period|Progressive Disease (PD)|14
6329393|NCT03000452|10074623|FG000|Treatment Period|Physician Decision|1
6329394|NCT03000452|10074623|FG000|Treatment Period|Miscellaneous|2
6329395|NCT03000452|10074623|FG000|Follow-Up Period|Study Terminated by Sponsor|1
6329396|NCT03000452|10074623|FG000|Follow-Up Period|Death|3
6329397|NCT03000452|10074623|FG000|Follow-Up Period|Withdrawal by Subject|3
6329398|NCT03000673|10074640|FG000|Overall Study|Withdrawal by Subject|1
6329399|NCT03000673|10074641|FG001|Overall Study|Withdrawal by Subject|0
6329400|NCT03000673|10074642|FG002|Overall Study|Withdrawal by Subject|0
6329401|NCT03000673|10074643|FG003|Overall Study|Withdrawal by Subject|0
6329402|NCT03000686|10074656|FG000|Part 1, Period 1 (1 Day)|Adverse Event|0
6329403|NCT03000686|10074657|FG001|Part 1, Period 1 (1 Day)|Adverse Event|1
6329404|NCT03000686|10074658|FG002|Part 1, Period 1 (1 Day)|Adverse Event|0
6329405|NCT03000686|10074659|FG003|Part 1, Period 1 (1 Day)|Adverse Event|0
6329406|NCT03001076|10074673|FG000|Overall Study|Withdrawal by patient|2
6329407|NCT03001076|10074674|FG001|Overall Study|Withdrawal by patient|0
6329408|NCT03001076|10074673|FG000|Overall Study|Other|1
6329409|NCT03001076|10074674|FG001|Overall Study|Other|0
6167178|NCT01226511|9811634|FG001|Acute Treatment Period|Lost to Follow-up|6
6329410|NCT03001076|10074673|FG000|Overall Study|Adverse Event|3
6329411|NCT03001076|10074674|FG001|Overall Study|Adverse Event|3
6329412|NCT03001076|10074673|FG000|Overall Study|Sponsor decision|1
6329413|NCT03001076|10074674|FG001|Overall Study|Sponsor decision|0
6329414|NCT03001076|10074673|FG000|Overall Study|Lost to Follow-up|0
6329415|NCT03001076|10074674|FG001|Overall Study|Lost to Follow-up|2
6329416|NCT03001219|10074682|FG000|Proof of Concept|Study Termination by Sponsor|0
6329417|NCT03001219|10074683|FG001|Proof of Concept|Study Termination by Sponsor|1
6329418|NCT03001219|10074682|FG000|Proof of Concept|Withdrawal by Subject|0
6329419|NCT03001219|10074683|FG001|Proof of Concept|Withdrawal by Subject|4
6329420|NCT03001219|10074682|FG000|Proof of Concept|Protocol Deviation|0
6329421|NCT03001219|10074683|FG001|Proof of Concept|Protocol Deviation|1
6329422|NCT03001219|10074682|FG000|Proof of Concept|Adverse Event|1
6329423|NCT03001219|10074683|FG001|Proof of Concept|Adverse Event|1
6329424|NCT03001219|10074682|FG000|Proof of Concept|Physician Decision|1
6329425|NCT03001219|10074683|FG001|Proof of Concept|Physician Decision|0
6329426|NCT03001219|10074682|FG000|Extension Period Analysis|Study Termination by Sponsor|0
6329427|NCT03001219|10074683|FG001|Extension Period Analysis|Study Termination by Sponsor|36
6329428|NCT03001219|10074682|FG000|Extension Period Analysis|Participant Non-Compliance|0
6329429|NCT03001219|10074683|FG001|Extension Period Analysis|Participant Non-Compliance|1
6329430|NCT03001219|10074682|FG000|Extension Period Analysis|Physician Decision|0
6329431|NCT03001219|10074683|FG001|Extension Period Analysis|Physician Decision|1
6329432|NCT03001219|10074682|FG000|Extension Period Analysis|Adverse Event|1
6329433|NCT03001219|10074683|FG001|Extension Period Analysis|Adverse Event|1
6329434|NCT03001219|10074682|FG000|Extension Period Analysis|Protocol Deviation|0
6329435|NCT03001219|10074683|FG001|Extension Period Analysis|Protocol Deviation|1
6329436|NCT03001219|10074682|FG000|Extension Period Analysis|Withdrawal by Subject|4
6329437|NCT03001219|10074683|FG001|Extension Period Analysis|Withdrawal by Subject|5
6329438|NCT03001557|10074721|FG000|Core Phase|Randomized but not treated|0
6329439|NCT03001557|10074722|FG001|Core Phase|Randomized but not treated|0
6329440|NCT03001557|10074723|FG002|Core Phase|Randomized but not treated|1
6329441|NCT03001557|10074724|FG003|Core Phase|Randomized but not treated|0
6329442|NCT03001557|10074725|FG004|Core Phase|Randomized but not treated|0
6329443|NCT03001557|10074726|FG005|Core Phase|Randomized but not treated|0
6329444|NCT03001557|10074727|FG006|Core Phase|Randomized but not treated|0
6329445|NCT03001557|10074728|FG007|Core Phase|Randomized but not treated|0
6329446|NCT03001557|10074721|FG000|Extension Phase|Adverse Event|0
6329447|NCT03001557|10074722|FG001|Extension Phase|Adverse Event|0
6329448|NCT03001557|10074723|FG002|Extension Phase|Adverse Event|0
6329449|NCT03001557|10074724|FG003|Extension Phase|Adverse Event|0
6329450|NCT03001557|10074725|FG004|Extension Phase|Adverse Event|0
6329451|NCT03001557|10074726|FG005|Extension Phase|Adverse Event|2
6329452|NCT03001557|10074727|FG006|Extension Phase|Adverse Event|0
6329453|NCT03001557|10074728|FG007|Extension Phase|Adverse Event|0
6329454|NCT03001557|10074721|FG000|Extension Phase|Withdrawal by Subject|0
6329455|NCT03001557|10074722|FG001|Extension Phase|Withdrawal by Subject|0
6329456|NCT03001557|10074723|FG002|Extension Phase|Withdrawal by Subject|0
6329457|NCT03001557|10074724|FG003|Extension Phase|Withdrawal by Subject|0
6329458|NCT03001557|10074725|FG004|Extension Phase|Withdrawal by Subject|0
6329459|NCT03001557|10074726|FG005|Extension Phase|Withdrawal by Subject|1
6329460|NCT03001557|10074727|FG006|Extension Phase|Withdrawal by Subject|5
6329461|NCT03001557|10074728|FG007|Extension Phase|Withdrawal by Subject|2
6329462|NCT03001557|10074721|FG000|Extension Phase|Lost to Follow-up|0
6329463|NCT03001557|10074722|FG001|Extension Phase|Lost to Follow-up|0
6329464|NCT03001557|10074723|FG002|Extension Phase|Lost to Follow-up|0
6329465|NCT03001557|10074724|FG003|Extension Phase|Lost to Follow-up|0
6329466|NCT03001557|10074725|FG004|Extension Phase|Lost to Follow-up|0
6329467|NCT03001557|10074726|FG005|Extension Phase|Lost to Follow-up|0
6329468|NCT03001557|10074727|FG006|Extension Phase|Lost to Follow-up|2
6329469|NCT03001557|10074728|FG007|Extension Phase|Lost to Follow-up|1
6329470|NCT03001557|10074721|FG000|Extension Phase|Administrative Reason|0
6329471|NCT03001557|10074722|FG001|Extension Phase|Administrative Reason|0
6329472|NCT03001557|10074723|FG002|Extension Phase|Administrative Reason|0
6329473|NCT03001557|10074724|FG003|Extension Phase|Administrative Reason|0
6329474|NCT03001557|10074725|FG004|Extension Phase|Administrative Reason|0
6329475|NCT03001557|10074726|FG005|Extension Phase|Administrative Reason|1
6329476|NCT03001557|10074727|FG006|Extension Phase|Administrative Reason|3
6329477|NCT03001557|10074728|FG007|Extension Phase|Administrative Reason|3
6329478|NCT03001557|10074721|FG000|Extension Phase|Loss of caregiver|0
6329479|NCT03001557|10074722|FG001|Extension Phase|Loss of caregiver|0
6329480|NCT03001557|10074723|FG002|Extension Phase|Loss of caregiver|0
6329481|NCT03001557|10074724|FG003|Extension Phase|Loss of caregiver|0
6329482|NCT03001557|10074725|FG004|Extension Phase|Loss of caregiver|0
6329483|NCT03001557|10074726|FG005|Extension Phase|Loss of caregiver|0
6329484|NCT03001557|10074727|FG006|Extension Phase|Loss of caregiver|1
6329485|NCT03001557|10074728|FG007|Extension Phase|Loss of caregiver|0
6329486|NCT03001557|10074721|FG000|Extension Phase|Others|0
6329487|NCT03001557|10074722|FG001|Extension Phase|Others|0
6329488|NCT03001557|10074723|FG002|Extension Phase|Others|0
6329489|NCT03001557|10074724|FG003|Extension Phase|Others|0
6329490|NCT03001557|10074725|FG004|Extension Phase|Others|0
6329491|NCT03001557|10074726|FG005|Extension Phase|Others|1
6329492|NCT03001557|10074727|FG006|Extension Phase|Others|3
6329493|NCT03001557|10074728|FG007|Extension Phase|Others|0
6329494|NCT03002038|10074788|FG000|Overall Study|Adverse Event|3
6329495|NCT03002038|10074789|FG001|Overall Study|Adverse Event|1
6329496|NCT03002038|10074788|FG000|Overall Study|Withdrawal by Subject|8
6329497|NCT03002038|10074789|FG001|Overall Study|Withdrawal by Subject|4
6329498|NCT03002038|10074788|FG000|Overall Study|Immigration to another region|0
6329499|NCT03002038|10074789|FG001|Overall Study|Immigration to another region|2
6329500|NCT03002077|10074795|FG000|Overall Study|Non-compliance with Study Drug|4
6329501|NCT03002077|10074795|FG000|Overall Study|Non-compliance w/Background ADT|1
6329502|NCT03002077|10074795|FG000|Overall Study|Study Terminated by Sponsor|257
6329503|NCT03002077|10074795|FG000|Overall Study|Site Terminated by Sponsor|5
6329504|NCT03002077|10074795|FG000|Overall Study|Miscellaneous Reasons|10
6329505|NCT03002077|10074795|FG000|Overall Study|Adverse Event|23
6329506|NCT03002077|10074795|FG000|Overall Study|Lack of Efficacy|20
6329507|NCT03002077|10074795|FG000|Overall Study|Withdrawal by Subject|72
6329508|NCT03002077|10074795|FG000|Overall Study|Lost to Follow-up|21
6329509|NCT03002077|10074795|FG000|Overall Study|Pregnancy|4
6329510|NCT03002077|10074795|FG000|Overall Study|Protocol Violation|21
6329511|NCT03002194|10074799|FG000|Overall Study|Lost to Follow-up|6
6329512|NCT03002194|10074799|FG000|Overall Study|Adverse Event|1
6329513|NCT03002194|10074799|FG000|Overall Study|Lack of Efficacy|1
6329514|NCT03002194|10074799|FG000|Overall Study|Withdrawal by Subject|2
6329515|NCT03002311|10074805|FG000|Overall Study|Lost to Follow-up|13
6329516|NCT03002311|10074806|FG001|Overall Study|Lost to Follow-up|26
6329517|NCT03002311|10074805|FG000|Overall Study|Referral provider called to schedule app|3
6329518|NCT03002311|10074806|FG001|Overall Study|Referral provider called to schedule app|3
6329519|NCT03002311|10074805|FG000|Overall Study|Physician Decision|3
6329520|NCT03002311|10074806|FG001|Overall Study|Physician Decision|1
6329521|NCT03002610|10074824|FG000|Overall Study|Withdrawal by Subject|6
6329522|NCT03002610|10074825|FG001|Overall Study|Withdrawal by Subject|25
6329523|NCT03002610|10074826|FG002|Overall Study|Withdrawal by Subject|13
6329524|NCT03002623|10074836|FG000|Overall Study|Lost to Follow-up|1
6329525|NCT03002623|10074837|FG001|Overall Study|Lost to Follow-up|0
6329526|NCT03002623|10074836|FG000|Overall Study|Physician Decision|1
6329527|NCT03002623|10074837|FG001|Overall Study|Physician Decision|1
6329528|NCT03002818|10074857|FG000|Overall Study|Decision of the investigator|1
6329529|NCT03003000|10074877|FG000|Overall Study|Adverse Event|1
6329530|NCT03003000|10074878|FG001|Overall Study|Adverse Event|2
6329531|NCT03003000|10074879|FG002|Overall Study|Adverse Event|3
6329532|NCT03003000|10074877|FG000|Overall Study|Lack of Efficacy|1
6329533|NCT03003000|10074878|FG001|Overall Study|Lack of Efficacy|0
6329534|NCT03003000|10074879|FG002|Overall Study|Lack of Efficacy|0
6329535|NCT03003000|10074877|FG000|Overall Study|Non-compliant with protocol|0
6329536|NCT03003000|10074878|FG001|Overall Study|Non-compliant with protocol|1
6329537|NCT03003000|10074879|FG002|Overall Study|Non-compliant with protocol|1
6329538|NCT03003000|10074877|FG000|Overall Study|Refused to continue medication|2
6329539|NCT03003000|10074878|FG001|Overall Study|Refused to continue medication|0
6329540|NCT03003000|10074879|FG002|Overall Study|Refused to continue medication|0
6329541|NCT03003000|10074877|FG000|Overall Study|Other than listed|1
6329542|NCT03003000|10074878|FG001|Overall Study|Other than listed|1
6329543|NCT03003000|10074879|FG002|Overall Study|Other than listed|1
6329544|NCT03003390|10074898|FG000|Overall Study|Physician Decision|2
6329545|NCT03003390|10074899|FG001|Overall Study|Physician Decision|0
6329546|NCT03003390|10074898|FG000|Overall Study|Parent refused intervention|2
6329547|NCT03003390|10074899|FG001|Overall Study|Parent refused intervention|0
6329548|NCT03003494|10074910|FG000|Overall Study|Evaluable PF10 questionnaire at visit1|28
6329549|NCT03003676|10074916|FG000|Overall Study|Lack of Efficacy|5
6329550|NCT03003676|10074917|FG001|Overall Study|Lack of Efficacy|7
6329551|NCT03003676|10074916|FG000|Overall Study|Withdrawal by Subject|0
6329552|NCT03003676|10074917|FG001|Overall Study|Withdrawal by Subject|1
6329553|NCT03003676|10074916|FG000|Overall Study|Hepatitis B infection|1
6329554|NCT03003676|10074917|FG001|Overall Study|Hepatitis B infection|0
6329555|NCT03004469|10074946|FG000|Overall Study|Adverse Event|6
6329556|NCT03004469|10074947|FG001|Overall Study|Adverse Event|4
6329557|NCT03004469|10074948|FG002|Overall Study|Adverse Event|6
6329558|NCT03004469|10074946|FG000|Overall Study|Lack of Efficacy|1
6329559|NCT03004469|10074947|FG001|Overall Study|Lack of Efficacy|0
6329560|NCT03004469|10074948|FG002|Overall Study|Lack of Efficacy|1
6329561|NCT03004469|10074946|FG000|Overall Study|Lost to Follow-up|23
6329562|NCT03004469|10074947|FG001|Overall Study|Lost to Follow-up|14
6329563|NCT03004469|10074948|FG002|Overall Study|Lost to Follow-up|6
6329564|NCT03004469|10074946|FG000|Overall Study|Non-Compliance with Study Drug|2
6329565|NCT03004469|10074947|FG001|Overall Study|Non-Compliance with Study Drug|0
6329566|NCT03004469|10074948|FG002|Overall Study|Non-Compliance with Study Drug|0
6329567|NCT03004469|10074946|FG000|Overall Study|Protocol Violation|0
6329568|NCT03004469|10074947|FG001|Overall Study|Protocol Violation|0
6329569|NCT03004469|10074948|FG002|Overall Study|Protocol Violation|1
6329570|NCT03004469|10074946|FG000|Overall Study|Withdrawal by Subject|29
6329571|NCT03004469|10074947|FG001|Overall Study|Withdrawal by Subject|27
6329572|NCT03004469|10074948|FG002|Overall Study|Withdrawal by Subject|10
6329573|NCT03004469|10074946|FG000|Overall Study|Other unspecified reason|0
6329574|NCT03004469|10074947|FG001|Overall Study|Other unspecified reason|4
6329575|NCT03004469|10074948|FG002|Overall Study|Other unspecified reason|1
6329576|NCT03004924|10075016|FG000|Overall Study|Adverse Event|6
6329577|NCT03004924|10075017|FG001|Overall Study|Adverse Event|5
6329578|NCT03004924|10075018|FG002|Overall Study|Adverse Event|10
6329579|NCT03004924|10075016|FG000|Overall Study|Protocol Violation|4
6329580|NCT03004924|10075017|FG001|Overall Study|Protocol Violation|0
6329581|NCT03004924|10075018|FG002|Overall Study|Protocol Violation|1
6329582|NCT03004924|10075016|FG000|Overall Study|Withdrawal by Subject|5
6329583|NCT03004924|10075017|FG001|Overall Study|Withdrawal by Subject|3
6329584|NCT03004924|10075018|FG002|Overall Study|Withdrawal by Subject|5
6329585|NCT03004924|10075016|FG000|Overall Study|Lost to Follow-up|6
6329586|NCT03004924|10075017|FG001|Overall Study|Lost to Follow-up|1
6329587|NCT03004924|10075018|FG002|Overall Study|Lost to Follow-up|4
6329588|NCT03004924|10075016|FG000|Overall Study|Lack of Efficacy|2
6329589|NCT03004924|10075017|FG001|Overall Study|Lack of Efficacy|4
6329590|NCT03004924|10075018|FG002|Overall Study|Lack of Efficacy|2
6329591|NCT03004924|10075016|FG000|Overall Study|Physician Decision|1
6329592|NCT03004924|10075017|FG001|Overall Study|Physician Decision|0
6329593|NCT03004924|10075018|FG002|Overall Study|Physician Decision|1
6329594|NCT03004924|10075016|FG000|Overall Study|Withdrawal by parent/guardian|1
6329595|NCT03004924|10075017|FG001|Overall Study|Withdrawal by parent/guardian|0
6329596|NCT03004924|10075018|FG002|Overall Study|Withdrawal by parent/guardian|2
6329597|NCT03004924|10075016|FG000|Overall Study|Screen Failure|1
6329598|NCT03004924|10075017|FG001|Overall Study|Screen Failure|0
6329599|NCT03004924|10075018|FG002|Overall Study|Screen Failure|0
6329600|NCT03004924|10075016|FG000|Overall Study|Pregnancy|0
6329601|NCT03004924|10075017|FG001|Overall Study|Pregnancy|1
6329602|NCT03004924|10075018|FG002|Overall Study|Pregnancy|0
6329603|NCT03004924|10075016|FG000|Overall Study|Terminated by Sponsor|0
6329604|NCT03004924|10075017|FG001|Overall Study|Terminated by Sponsor|0
6329605|NCT03004924|10075018|FG002|Overall Study|Terminated by Sponsor|1
6329606|NCT03004924|10075016|FG000|Overall Study|Missed Study Visit|0
6329607|NCT03004924|10075017|FG001|Overall Study|Missed Study Visit|0
6329608|NCT03004924|10075018|FG002|Overall Study|Missed Study Visit|2
6329609|NCT03004924|10075016|FG000|Overall Study|HSV1 Positive|1
6329610|NCT03004924|10075017|FG001|Overall Study|HSV1 Positive|0
6329611|NCT03004924|10075018|FG002|Overall Study|HSV1 Positive|0
6329612|NCT03005067|10075040|FG000|Overall Study|Withdrawal by Subject|3
6329613|NCT03005067|10075041|FG001|Overall Study|Withdrawal by Subject|2
6329614|NCT03005067|10075040|FG000|Overall Study|Adverse Event|4
6329615|NCT03005067|10075041|FG001|Overall Study|Adverse Event|3
6329616|NCT03005067|10075040|FG000|Overall Study|Other (reason not specified)|3
6329617|NCT03005067|10075041|FG001|Overall Study|Other (reason not specified)|1
6329618|NCT03005067|10075040|FG000|Overall Study|Protocol Violation|0
6329619|NCT03005067|10075041|FG001|Overall Study|Protocol Violation|1
6329620|NCT03005106|10075047|FG000|Overall Study|Lost to Follow-up|16
6329621|NCT03005106|10075047|FG000|Overall Study|Adverse Event|1
6329622|NCT03005106|10075047|FG000|Overall Study|Physician Decision|1
6082741|NCT00631163|9690839|FG000|Number of Participants in Year 2|Protocol Violation|1
6082742|NCT00631163|9690839|FG000|Number of Participants in Year 2|Abnormal laboratory value|1
6082743|NCT00631189|9690854|FG000|Initial Phase|Protocol Violation|347
6082744|NCT00631189|9690855|FG001|Initial Phase|Protocol Violation|0
6082745|NCT00631189|9690856|FG002|Initial Phase|Protocol Violation|0
6082746|NCT00631189|9690857|FG003|Initial Phase|Protocol Violation|0
6082747|NCT00631189|9690854|FG000|Initial Phase|Withdrawal by Subject|4
6082748|NCT00631189|9690855|FG001|Initial Phase|Withdrawal by Subject|0
6082749|NCT00631189|9690856|FG002|Initial Phase|Withdrawal by Subject|0
6082750|NCT00631189|9690857|FG003|Initial Phase|Withdrawal by Subject|0
6082751|NCT00631189|9690854|FG000|Treatment Phase|Withdrawal by Subject|0
6082752|NCT00631189|9690855|FG001|Treatment Phase|Withdrawal by Subject|2
6082753|NCT00631189|9690856|FG002|Treatment Phase|Withdrawal by Subject|1
6082754|NCT00631189|9690857|FG003|Treatment Phase|Withdrawal by Subject|1
6082755|NCT00631189|9690854|FG000|Treatment Phase|Protocol Violation|0
6082756|NCT00631189|9690855|FG001|Treatment Phase|Protocol Violation|1
6082757|NCT00631189|9690856|FG002|Treatment Phase|Protocol Violation|6
6082758|NCT00631189|9690857|FG003|Treatment Phase|Protocol Violation|2
6082759|NCT00631189|9690854|FG000|Treatment Phase|Adverse Event|0
6082760|NCT00631189|9690855|FG001|Treatment Phase|Adverse Event|3
6329623|NCT03005106|10075047|FG000|Overall Study|Death|2
6329624|NCT03005288|10075053|FG000|Overall Study|Withdrawal by Subject|7
6329625|NCT03005288|10075054|FG001|Overall Study|Withdrawal by Subject|5
6329626|NCT03005288|10075053|FG000|Overall Study|Lost to Follow-up|0
6329627|NCT03005288|10075054|FG001|Overall Study|Lost to Follow-up|1
6329628|NCT03005288|10075053|FG000|Overall Study|Adverse Event|5
6329629|NCT03005288|10075054|FG001|Overall Study|Adverse Event|0
6329630|NCT03005288|10075053|FG000|Overall Study|Protocol deviation|0
6329631|NCT03005288|10075054|FG001|Overall Study|Protocol deviation|1
6082761|NCT00631189|9690856|FG002|Treatment Phase|Adverse Event|2
6082762|NCT00631189|9690857|FG003|Treatment Phase|Adverse Event|4
6082763|NCT00631189|9690854|FG000|Treatment Phase|Lost to Follow-up|0
6329632|NCT03005288|10075053|FG000|Overall Study|Physician Decision|0
6329633|NCT03005288|10075054|FG001|Overall Study|Physician Decision|1
6329634|NCT03006341|10075064|FG000|Overall Study|Not linked in the EMR|25069
6329635|NCT03006341|10075065|FG001|Overall Study|Not linked in the EMR|67505
6329636|NCT03006341|10075066|FG002|Overall Study|Not linked in the EMR|30993
6329637|NCT03006341|10075067|FG003|Overall Study|Not linked in the EMR|10685
6329638|NCT03006393|10075077|FG000|Overall Study|Withdrawal by Subject|1
6329639|NCT03006393|10075078|FG001|Overall Study|Withdrawal by Subject|1
6329640|NCT03006393|10075077|FG000|Overall Study|Pregnancy|0
6329641|NCT03006393|10075078|FG001|Overall Study|Pregnancy|1
6329642|NCT03006393|10075077|FG000|Overall Study|Lost to Follow-up|0
6329643|NCT03006393|10075078|FG001|Overall Study|Lost to Follow-up|1
6329644|NCT03006458|10075084|FG000|First Intervention|Unsatisfied Vision|0
6329645|NCT03006458|10075085|FG001|First Intervention|Unsatisfied Vision|3
6329646|NCT03006562|10075102|FG000|Overall Study|Lost to Follow-up|0
6329647|NCT03006562|10075103|FG001|Overall Study|Lost to Follow-up|1
6329648|NCT03006848|10075109|FG000|Overall Study|Adverse Event|1
6329649|NCT03006848|10075109|FG000|Overall Study|Physician Decision|1
6329650|NCT03006848|10075109|FG000|Overall Study|Lack of Efficacy|16
6329651|NCT03006887|10075120|FG000|Overall Study|Adverse Event|1
6329652|NCT03007472|10075142|FG000|Overall Study|Did not have aidable contralateral thresholds at the time|2
6329653|NCT03007472|10075142|FG000|Overall Study|Death|2
6329654|NCT03007472|10075142|FG000|Overall Study|Loss to Follow Up|1
6329655|NCT03007953|10075148|FG000|Overall Study|Withdrawal by Subject|5
6329656|NCT03007953|10075149|FG001|Overall Study|Withdrawal by Subject|2
6329657|NCT03007953|10075148|FG000|Overall Study|Death|5
6329658|NCT03007953|10075149|FG001|Overall Study|Death|7
6329659|NCT03007953|10075148|FG000|Overall Study|Lost to Follow-up|3
6329660|NCT03007953|10075149|FG001|Overall Study|Lost to Follow-up|2
6329661|NCT03007953|10075148|FG000|Overall Study|Enrolled in Hospice|3
6329662|NCT03007953|10075149|FG001|Overall Study|Enrolled in Hospice|2
6329663|NCT03007966|10075157|FG000|Overall Study|Did not meeting inclusion/exclusion|1
6329664|NCT03007966|10075158|FG001|Overall Study|Did not meeting inclusion/exclusion|0
6329665|NCT03008070|10075168|FG000|Overall Study|Adverse Event|3
6329666|NCT03008070|10075169|FG001|Overall Study|Adverse Event|3
6329667|NCT03008070|10075170|FG002|Overall Study|Adverse Event|3
6329668|NCT03008070|10075168|FG000|Overall Study|Lost to Follow-up|1
6329669|NCT03008070|10075169|FG001|Overall Study|Lost to Follow-up|1
6329670|NCT03008070|10075170|FG002|Overall Study|Lost to Follow-up|0
6329671|NCT03008070|10075168|FG000|Overall Study|Non compliance|0
6329672|NCT03008070|10075169|FG001|Overall Study|Non compliance|1
6329673|NCT03008070|10075170|FG002|Overall Study|Non compliance|1
6329674|NCT03008070|10075168|FG000|Overall Study|Withdrawal by patient and adverse event non fatal|0
6329675|NCT03008070|10075169|FG001|Overall Study|Withdrawal by patient and adverse event non fatal|1
6329676|NCT03008070|10075170|FG002|Overall Study|Withdrawal by patient and adverse event non fatal|0
6329677|NCT03008070|10075168|FG000|Overall Study|Withdrawal by Subject|2
6329678|NCT03008070|10075169|FG001|Overall Study|Withdrawal by Subject|0
6329679|NCT03008070|10075170|FG002|Overall Study|Withdrawal by Subject|1
6329680|NCT03008070|10075168|FG000|Overall Study|Use of prohibited drug|0
6329681|NCT03008070|10075169|FG001|Overall Study|Use of prohibited drug|0
6329682|NCT03008070|10075170|FG002|Overall Study|Use of prohibited drug|2
6329683|NCT03008460|10075195|FG000|Overall Study|Protocol deviation|0
6329684|NCT03008460|10075196|FG001|Overall Study|Protocol deviation|2
6329685|NCT03008460|10075195|FG000|Overall Study|Study drug not dispensed|0
6329686|NCT03008460|10075196|FG001|Overall Study|Study drug not dispensed|1
6329687|NCT03008460|10075195|FG000|Overall Study|Adverse Event|0
6329688|NCT03008460|10075196|FG001|Overall Study|Adverse Event|1
6329689|NCT03008460|10075195|FG000|Overall Study|Withdrawal by Subject|5
6329690|NCT03008460|10075196|FG001|Overall Study|Withdrawal by Subject|6
6329691|NCT03008460|10075195|FG000|Overall Study|COVID-19 pandemic - consent withdrawn|1
6329692|NCT03008460|10075196|FG001|Overall Study|COVID-19 pandemic - consent withdrawn|0
6329693|NCT03008460|10075195|FG000|Overall Study|End of study visit outside permitted time window|0
6329694|NCT03008460|10075196|FG001|Overall Study|End of study visit outside permitted time window|1
6329695|NCT03008460|10075195|FG000|Overall Study|Lost to Follow-up|1
6329696|NCT03008460|10075196|FG001|Overall Study|Lost to Follow-up|3
6329697|NCT03008915|10075242|FG000|Treatment 1|Withdrawal by Subject|0
6329698|NCT03008915|10075243|FG001|Treatment 1|Withdrawal by Subject|1
6329699|NCT03010254|10075278|FG000|Overall Study|Adverse Event|0
6329700|NCT03010254|10075279|FG001|Overall Study|Adverse Event|1
6329701|NCT03010254|10075278|FG000|Overall Study|Lost to Follow-up|4
6329702|NCT03010254|10075279|FG001|Overall Study|Lost to Follow-up|0
6329703|NCT03010254|10075278|FG000|Overall Study|Withdrawal by Subject|1
6329704|NCT03010254|10075279|FG001|Overall Study|Withdrawal by Subject|1
6329705|NCT03010254|10075278|FG000|Overall Study|Other|2
6329706|NCT03010254|10075279|FG001|Overall Study|Other|3
6329707|NCT03010462|10075294|FG000|Overall Study|Withdrawal by Subject|3
6329708|NCT03010462|10075295|FG001|Overall Study|Withdrawal by Subject|1
6329709|NCT03010501|10075310|FG000|Study Week 1|Withdrawal by Subject|2
6082764|NCT00631189|9690855|FG001|Treatment Phase|Lost to Follow-up|1
6329710|NCT03010501|10075311|FG001|Study Week 1|Withdrawal by Subject|1
6329711|NCT03010501|10075312|FG002|Study Week 1|Withdrawal by Subject|0
6329712|NCT03010501|10075313|FG003|Study Week 1|Withdrawal by Subject|2
6329713|NCT03010501|10075314|FG004|Study Week 1|Withdrawal by Subject|0
6329714|NCT03010501|10075315|FG005|Study Week 1|Withdrawal by Subject|0
6329715|NCT03010501|10075310|FG000|Study Week 3|Withdrawal by Subject|0
6329716|NCT03010501|10075311|FG001|Study Week 3|Withdrawal by Subject|0
6329717|NCT03010501|10075312|FG002|Study Week 3|Withdrawal by Subject|0
6329718|NCT03010501|10075313|FG003|Study Week 3|Withdrawal by Subject|1
6329719|NCT03010501|10075314|FG004|Study Week 3|Withdrawal by Subject|0
6329720|NCT03010501|10075315|FG005|Study Week 3|Withdrawal by Subject|0
6329721|NCT03010527|10075326|FG000|Overall Study|Death|0
6329722|NCT03010527|10075327|FG001|Overall Study|Death|0
6329723|NCT03010527|10075328|FG002|Overall Study|Death|1
6329724|NCT03010527|10075326|FG000|Overall Study|Adverse Event|0
6329725|NCT03010527|10075327|FG001|Overall Study|Adverse Event|4
6329726|NCT03010527|10075328|FG002|Overall Study|Adverse Event|2
6329727|NCT03010527|10075326|FG000|Overall Study|Protocol Violation|0
6329728|NCT03010527|10075327|FG001|Overall Study|Protocol Violation|1
6329729|NCT03010527|10075328|FG002|Overall Study|Protocol Violation|0
6329730|NCT03010527|10075326|FG000|Overall Study|Lost to Follow-up|0
6329731|NCT03010527|10075327|FG001|Overall Study|Lost to Follow-up|2
6329732|NCT03010527|10075328|FG002|Overall Study|Lost to Follow-up|1
6329733|NCT03010527|10075326|FG000|Overall Study|Withdrawal by Subject|0
6329734|NCT03010527|10075327|FG001|Overall Study|Withdrawal by Subject|3
6329735|NCT03010527|10075328|FG002|Overall Study|Withdrawal by Subject|4
6329736|NCT03010527|10075326|FG000|Overall Study|WITHDRAWAL CRITERIA #9|0
6329737|NCT03010527|10075327|FG001|Overall Study|WITHDRAWAL CRITERIA #9|4
6329738|NCT03010527|10075328|FG002|Overall Study|WITHDRAWAL CRITERIA #9|6
6329739|NCT03010527|10075326|FG000|Overall Study|WITHDRAWAL CRITERIA #12|0
6329740|NCT03010527|10075327|FG001|Overall Study|WITHDRAWAL CRITERIA #12|4
6329741|NCT03010527|10075328|FG002|Overall Study|WITHDRAWAL CRITERIA #12|2
6329742|NCT03010527|10075326|FG000|Overall Study|PDILI and WITHDRAWAL CRITERIA #9|0
6329743|NCT03010527|10075327|FG001|Overall Study|PDILI and WITHDRAWAL CRITERIA #9|1
6329744|NCT03010527|10075328|FG002|Overall Study|PDILI and WITHDRAWAL CRITERIA #9|0
6329745|NCT03011099|10075386|FG000|Overall Study|Withdrawal by Subject|0
6329746|NCT03011099|10075387|FG001|Overall Study|Withdrawal by Subject|2
6329747|NCT03011333|10075402|FG000|Overall Study|Lost to Follow-up|0
6329748|NCT03011333|10075403|FG001|Overall Study|Lost to Follow-up|1
6329749|NCT03011333|10075404|FG002|Overall Study|Lost to Follow-up|0
6329750|NCT03011333|10075405|FG003|Overall Study|Lost to Follow-up|1
6329751|NCT03011333|10075406|FG004|Overall Study|Lost to Follow-up|4
6329752|NCT03011333|10075407|FG005|Overall Study|Lost to Follow-up|4
6329753|NCT03011333|10075408|FG006|Overall Study|Lost to Follow-up|5
6329754|NCT03011840|10075426|FG000|Overall Study|Not received PIL in post PIL phase|0
6329755|NCT03011840|10075427|FG001|Overall Study|Not received PIL in post PIL phase|21
6329756|NCT03011892|10075439|FG000|Double Blind (DB) Period|Adverse Event|0
6329757|NCT03011892|10075440|FG001|Double Blind (DB) Period|Adverse Event|1
6329758|NCT03011892|10075441|FG002|Double Blind (DB) Period|Adverse Event|1
6329759|NCT03011892|10075442|FG003|Double Blind (DB) Period|Adverse Event|0
6329760|NCT03011892|10075443|FG004|Double Blind (DB) Period|Adverse Event|0
6329761|NCT03011892|10075444|FG005|Double Blind (DB) Period|Adverse Event|0
6329762|NCT03011892|10075445|FG006|Double Blind (DB) Period|Adverse Event|0
6329763|NCT03011892|10075446|FG007|Double Blind (DB) Period|Adverse Event|0
6329764|NCT03011892|10075447|FG008|Double Blind (DB) Period|Adverse Event|0
6329765|NCT03011892|10075448|FG009|Double Blind (DB) Period|Adverse Event|0
6329766|NCT03011892|10075449|FG010|Double Blind (DB) Period|Adverse Event|0
6329767|NCT03011892|10075450|FG011|Double Blind (DB) Period|Adverse Event|0
6329768|NCT03011892|10075439|FG000|Double Blind (DB) Period|Lack of Efficacy|1
6329769|NCT03011892|10075440|FG001|Double Blind (DB) Period|Lack of Efficacy|0
6329770|NCT03011892|10075441|FG002|Double Blind (DB) Period|Lack of Efficacy|0
6329771|NCT03011892|10075442|FG003|Double Blind (DB) Period|Lack of Efficacy|0
6329772|NCT03011892|10075443|FG004|Double Blind (DB) Period|Lack of Efficacy|0
6329773|NCT03011892|10075444|FG005|Double Blind (DB) Period|Lack of Efficacy|0
6329774|NCT03011892|10075445|FG006|Double Blind (DB) Period|Lack of Efficacy|0
6329775|NCT03011892|10075446|FG007|Double Blind (DB) Period|Lack of Efficacy|0
6329776|NCT03011892|10075447|FG008|Double Blind (DB) Period|Lack of Efficacy|0
6329777|NCT03011892|10075448|FG009|Double Blind (DB) Period|Lack of Efficacy|0
6329778|NCT03011892|10075449|FG010|Double Blind (DB) Period|Lack of Efficacy|0
6329779|NCT03011892|10075450|FG011|Double Blind (DB) Period|Lack of Efficacy|0
6329780|NCT03011892|10075439|FG000|Double Blind (DB) Period|Lost to Follow-up|0
6329781|NCT03011892|10075440|FG001|Double Blind (DB) Period|Lost to Follow-up|3
6329782|NCT03011892|10075441|FG002|Double Blind (DB) Period|Lost to Follow-up|2
6329783|NCT03011892|10075442|FG003|Double Blind (DB) Period|Lost to Follow-up|5
6329784|NCT03011892|10075443|FG004|Double Blind (DB) Period|Lost to Follow-up|0
6329785|NCT03011892|10075444|FG005|Double Blind (DB) Period|Lost to Follow-up|2
6329786|NCT03011892|10075445|FG006|Double Blind (DB) Period|Lost to Follow-up|0
6329787|NCT03011892|10075446|FG007|Double Blind (DB) Period|Lost to Follow-up|0
6329788|NCT03011892|10075447|FG008|Double Blind (DB) Period|Lost to Follow-up|0
6329789|NCT03011892|10075448|FG009|Double Blind (DB) Period|Lost to Follow-up|0
6329790|NCT03011892|10075449|FG010|Double Blind (DB) Period|Lost to Follow-up|0
6329791|NCT03011892|10075450|FG011|Double Blind (DB) Period|Lost to Follow-up|0
6329792|NCT03011892|10075439|FG000|Double Blind (DB) Period|Other|1
6329793|NCT03011892|10075440|FG001|Double Blind (DB) Period|Other|1
6329794|NCT03011892|10075441|FG002|Double Blind (DB) Period|Other|1
6329795|NCT03011892|10075442|FG003|Double Blind (DB) Period|Other|0
6329796|NCT03011892|10075443|FG004|Double Blind (DB) Period|Other|1
6329797|NCT03011892|10075444|FG005|Double Blind (DB) Period|Other|0
6329798|NCT03011892|10075445|FG006|Double Blind (DB) Period|Other|0
6329799|NCT03011892|10075446|FG007|Double Blind (DB) Period|Other|0
6329800|NCT03011892|10075447|FG008|Double Blind (DB) Period|Other|0
6329801|NCT03011892|10075448|FG009|Double Blind (DB) Period|Other|0
6329802|NCT03011892|10075449|FG010|Double Blind (DB) Period|Other|0
6329803|NCT03011892|10075450|FG011|Double Blind (DB) Period|Other|0
6329804|NCT03011892|10075439|FG000|Double Blind (DB) Period|Physician Decision|1
6329805|NCT03011892|10075440|FG001|Double Blind (DB) Period|Physician Decision|0
6329806|NCT03011892|10075441|FG002|Double Blind (DB) Period|Physician Decision|1
6329807|NCT03011892|10075442|FG003|Double Blind (DB) Period|Physician Decision|0
6329808|NCT03011892|10075443|FG004|Double Blind (DB) Period|Physician Decision|0
6329809|NCT03011892|10075444|FG005|Double Blind (DB) Period|Physician Decision|0
6329810|NCT03011892|10075445|FG006|Double Blind (DB) Period|Physician Decision|0
6329811|NCT03011892|10075446|FG007|Double Blind (DB) Period|Physician Decision|0
6329812|NCT03011892|10075447|FG008|Double Blind (DB) Period|Physician Decision|0
6329813|NCT03011892|10075448|FG009|Double Blind (DB) Period|Physician Decision|0
6329814|NCT03011892|10075449|FG010|Double Blind (DB) Period|Physician Decision|0
6329815|NCT03011892|10075450|FG011|Double Blind (DB) Period|Physician Decision|0
6329816|NCT03011892|10075439|FG000|Double Blind (DB) Period|Pregnancy|0
6329817|NCT03011892|10075440|FG001|Double Blind (DB) Period|Pregnancy|0
6329818|NCT03011892|10075441|FG002|Double Blind (DB) Period|Pregnancy|0
6329819|NCT03011892|10075442|FG003|Double Blind (DB) Period|Pregnancy|0
6329820|NCT03011892|10075443|FG004|Double Blind (DB) Period|Pregnancy|1
6329821|NCT03011892|10075444|FG005|Double Blind (DB) Period|Pregnancy|0
6329822|NCT03011892|10075445|FG006|Double Blind (DB) Period|Pregnancy|0
6329823|NCT03011892|10075446|FG007|Double Blind (DB) Period|Pregnancy|0
6329824|NCT03011892|10075447|FG008|Double Blind (DB) Period|Pregnancy|0
6329825|NCT03011892|10075448|FG009|Double Blind (DB) Period|Pregnancy|0
6329826|NCT03011892|10075449|FG010|Double Blind (DB) Period|Pregnancy|0
6329827|NCT03011892|10075450|FG011|Double Blind (DB) Period|Pregnancy|0
6329828|NCT03011892|10075439|FG000|Double Blind (DB) Period|Protocol Violation|1
6329829|NCT03011892|10075440|FG001|Double Blind (DB) Period|Protocol Violation|0
6329830|NCT03011892|10075441|FG002|Double Blind (DB) Period|Protocol Violation|0
6329831|NCT03011892|10075442|FG003|Double Blind (DB) Period|Protocol Violation|0
6329832|NCT03011892|10075443|FG004|Double Blind (DB) Period|Protocol Violation|0
6329833|NCT03011892|10075444|FG005|Double Blind (DB) Period|Protocol Violation|0
6329834|NCT03011892|10075445|FG006|Double Blind (DB) Period|Protocol Violation|0
6329835|NCT03011892|10075446|FG007|Double Blind (DB) Period|Protocol Violation|0
6329836|NCT03011892|10075447|FG008|Double Blind (DB) Period|Protocol Violation|0
6329837|NCT03011892|10075448|FG009|Double Blind (DB) Period|Protocol Violation|0
6329838|NCT03011892|10075449|FG010|Double Blind (DB) Period|Protocol Violation|0
6329839|NCT03011892|10075450|FG011|Double Blind (DB) Period|Protocol Violation|0
6329840|NCT03011892|10075439|FG000|Double Blind (DB) Period|Withdrawal by Subject|7
6329841|NCT03011892|10075440|FG001|Double Blind (DB) Period|Withdrawal by Subject|5
6329842|NCT03011892|10075441|FG002|Double Blind (DB) Period|Withdrawal by Subject|1
6329843|NCT03011892|10075442|FG003|Double Blind (DB) Period|Withdrawal by Subject|2
6329844|NCT03011892|10075443|FG004|Double Blind (DB) Period|Withdrawal by Subject|4
6329845|NCT03011892|10075444|FG005|Double Blind (DB) Period|Withdrawal by Subject|3
6329846|NCT03011892|10075445|FG006|Double Blind (DB) Period|Withdrawal by Subject|0
6329847|NCT03011892|10075446|FG007|Double Blind (DB) Period|Withdrawal by Subject|0
6329848|NCT03011892|10075447|FG008|Double Blind (DB) Period|Withdrawal by Subject|0
6329849|NCT03011892|10075448|FG009|Double Blind (DB) Period|Withdrawal by Subject|0
6329850|NCT03011892|10075449|FG010|Double Blind (DB) Period|Withdrawal by Subject|0
6329851|NCT03011892|10075450|FG011|Double Blind (DB) Period|Withdrawal by Subject|0
6329852|NCT03011892|10075439|FG000|Double Blind (DB) Period|Randomized but not treated|0
6329853|NCT03011892|10075440|FG001|Double Blind (DB) Period|Randomized but not treated|0
6329854|NCT03011892|10075441|FG002|Double Blind (DB) Period|Randomized but not treated|0
6329855|NCT03011892|10075442|FG003|Double Blind (DB) Period|Randomized but not treated|0
6329856|NCT03011892|10075443|FG004|Double Blind (DB) Period|Randomized but not treated|1
6329857|NCT03011892|10075444|FG005|Double Blind (DB) Period|Randomized but not treated|0
6329858|NCT03011892|10075445|FG006|Double Blind (DB) Period|Randomized but not treated|0
6329859|NCT03011892|10075446|FG007|Double Blind (DB) Period|Randomized but not treated|0
6329860|NCT03011892|10075447|FG008|Double Blind (DB) Period|Randomized but not treated|0
6329861|NCT03011892|10075448|FG009|Double Blind (DB) Period|Randomized but not treated|0
6329862|NCT03011892|10075449|FG010|Double Blind (DB) Period|Randomized but not treated|0
6329863|NCT03011892|10075450|FG011|Double Blind (DB) Period|Randomized but not treated|0
6329864|NCT03011892|10075439|FG000|Open Label (OL) Period|Lost to Follow-up|0
6329865|NCT03011892|10075440|FG001|Open Label (OL) Period|Lost to Follow-up|0
6329866|NCT03011892|10075441|FG002|Open Label (OL) Period|Lost to Follow-up|0
6329867|NCT03011892|10075442|FG003|Open Label (OL) Period|Lost to Follow-up|0
6329868|NCT03011892|10075443|FG004|Open Label (OL) Period|Lost to Follow-up|0
6329869|NCT03011892|10075444|FG005|Open Label (OL) Period|Lost to Follow-up|0
6329870|NCT03011892|10075445|FG006|Open Label (OL) Period|Lost to Follow-up|4
6329871|NCT03011892|10075446|FG007|Open Label (OL) Period|Lost to Follow-up|2
6329872|NCT03011892|10075447|FG008|Open Label (OL) Period|Lost to Follow-up|1
6329873|NCT03011892|10075448|FG009|Open Label (OL) Period|Lost to Follow-up|0
6329874|NCT03011892|10075449|FG010|Open Label (OL) Period|Lost to Follow-up|1
6329875|NCT03011892|10075450|FG011|Open Label (OL) Period|Lost to Follow-up|1
6329876|NCT03011892|10075439|FG000|Open Label (OL) Period|Withdrawal by Subject|0
6329877|NCT03011892|10075440|FG001|Open Label (OL) Period|Withdrawal by Subject|0
6329878|NCT03011892|10075441|FG002|Open Label (OL) Period|Withdrawal by Subject|0
6329879|NCT03011892|10075442|FG003|Open Label (OL) Period|Withdrawal by Subject|0
6329880|NCT03011892|10075443|FG004|Open Label (OL) Period|Withdrawal by Subject|0
6329881|NCT03011892|10075444|FG005|Open Label (OL) Period|Withdrawal by Subject|0
6329882|NCT03011892|10075445|FG006|Open Label (OL) Period|Withdrawal by Subject|3
6329883|NCT03011892|10075446|FG007|Open Label (OL) Period|Withdrawal by Subject|0
6329884|NCT03011892|10075447|FG008|Open Label (OL) Period|Withdrawal by Subject|1
6329885|NCT03011892|10075448|FG009|Open Label (OL) Period|Withdrawal by Subject|0
6329886|NCT03011892|10075449|FG010|Open Label (OL) Period|Withdrawal by Subject|1
6329887|NCT03011892|10075450|FG011|Open Label (OL) Period|Withdrawal by Subject|2
6329888|NCT03011892|10075439|FG000|Open Label (OL) Period|Reason not specified|0
6329889|NCT03011892|10075440|FG001|Open Label (OL) Period|Reason not specified|0
6329890|NCT03011892|10075441|FG002|Open Label (OL) Period|Reason not specified|0
6329891|NCT03011892|10075442|FG003|Open Label (OL) Period|Reason not specified|0
6329892|NCT03011892|10075443|FG004|Open Label (OL) Period|Reason not specified|0
6329893|NCT03011892|10075444|FG005|Open Label (OL) Period|Reason not specified|0
6329894|NCT03011892|10075445|FG006|Open Label (OL) Period|Reason not specified|0
6329895|NCT03011892|10075446|FG007|Open Label (OL) Period|Reason not specified|1
6329896|NCT03011892|10075447|FG008|Open Label (OL) Period|Reason not specified|0
6329897|NCT03011892|10075448|FG009|Open Label (OL) Period|Reason not specified|0
6329898|NCT03011892|10075449|FG010|Open Label (OL) Period|Reason not specified|0
6329899|NCT03011892|10075450|FG011|Open Label (OL) Period|Reason not specified|0
6329900|NCT03012061|10075480|FG000|Overall Study|Withdrawal by Subject|1
6329901|NCT03012061|10075481|FG001|Overall Study|Withdrawal by Subject|5
6329902|NCT03012061|10075482|FG002|Overall Study|Withdrawal by Subject|4
6329903|NCT03012061|10075480|FG000|Overall Study|Investigator Site Closed|1
6329904|NCT03012061|10075481|FG001|Overall Study|Investigator Site Closed|2
6329905|NCT03012061|10075482|FG002|Overall Study|Investigator Site Closed|0
6329906|NCT03012061|10075480|FG000|Overall Study|Lost to Follow-up|2
6329907|NCT03012061|10075481|FG001|Overall Study|Lost to Follow-up|1
6329908|NCT03012061|10075482|FG002|Overall Study|Lost to Follow-up|0
6329909|NCT03012061|10075480|FG000|Overall Study|Study closed/ Terminated|0
6329910|NCT03012061|10075481|FG001|Overall Study|Study closed/ Terminated|0
6329911|NCT03012061|10075482|FG002|Overall Study|Study closed/ Terminated|1
6329912|NCT03012061|10075480|FG000|Overall Study|Met Protocol Withdrawal Criterion|0
6329913|NCT03012061|10075481|FG001|Overall Study|Met Protocol Withdrawal Criterion|0
6329914|NCT03012061|10075482|FG002|Overall Study|Met Protocol Withdrawal Criterion|1
6329915|NCT03012061|10075480|FG000|Overall Study|Protocol Violation|0
6329916|NCT03012061|10075481|FG001|Overall Study|Protocol Violation|0
6329917|NCT03012061|10075482|FG002|Overall Study|Protocol Violation|2
6329918|NCT03012061|10075480|FG000|Overall Study|Lack of Efficacy|0
6329919|NCT03012061|10075481|FG001|Overall Study|Lack of Efficacy|1
6329920|NCT03012061|10075482|FG002|Overall Study|Lack of Efficacy|0
6329921|NCT03012061|10075480|FG000|Overall Study|Adverse Event|2
6329922|NCT03012061|10075481|FG001|Overall Study|Adverse Event|0
6329923|NCT03012061|10075482|FG002|Overall Study|Adverse Event|0
6329924|NCT03012334|10075514|FG000|Period 1|Withdrawal by Subject|0
6329925|NCT03012334|10075515|FG001|Period 1|Withdrawal by Subject|0
6329926|NCT03012334|10075516|FG002|Period 1|Withdrawal by Subject|0
6329927|NCT03012334|10075517|FG003|Period 1|Withdrawal by Subject|0
6329928|NCT03012334|10075518|FG004|Period 1|Withdrawal by Subject|0
6329929|NCT03012334|10075519|FG005|Period 1|Withdrawal by Subject|0
6329930|NCT03012334|10075520|FG006|Period 1|Withdrawal by Subject|0
6329931|NCT03012334|10075521|FG007|Period 1|Withdrawal by Subject|0
6329932|NCT03012334|10075522|FG008|Period 1|Withdrawal by Subject|0
6329933|NCT03012334|10075523|FG009|Period 1|Withdrawal by Subject|1
6329934|NCT03012334|10075514|FG000|Period 2|Withdrawal by Subject|0
6329935|NCT03012334|10075515|FG001|Period 2|Withdrawal by Subject|1
6329936|NCT03012334|10075516|FG002|Period 2|Withdrawal by Subject|0
6329937|NCT03012334|10075517|FG003|Period 2|Withdrawal by Subject|0
6329938|NCT03012334|10075518|FG004|Period 2|Withdrawal by Subject|0
6329939|NCT03012334|10075519|FG005|Period 2|Withdrawal by Subject|0
6329940|NCT03012334|10075520|FG006|Period 2|Withdrawal by Subject|0
6329941|NCT03012334|10075521|FG007|Period 2|Withdrawal by Subject|0
6329942|NCT03012334|10075522|FG008|Period 2|Withdrawal by Subject|0
6329943|NCT03012334|10075523|FG009|Period 2|Withdrawal by Subject|0
6329944|NCT03012334|10075514|FG000|Period 2|Protocol Violation|0
6329945|NCT03012334|10075515|FG001|Period 2|Protocol Violation|0
6329946|NCT03012334|10075516|FG002|Period 2|Protocol Violation|1
6329947|NCT03012334|10075517|FG003|Period 2|Protocol Violation|0
6329948|NCT03012334|10075518|FG004|Period 2|Protocol Violation|0
6329949|NCT03012334|10075519|FG005|Period 2|Protocol Violation|0
6329950|NCT03012334|10075520|FG006|Period 2|Protocol Violation|0
6329951|NCT03012334|10075521|FG007|Period 2|Protocol Violation|1
6329952|NCT03012334|10075522|FG008|Period 2|Protocol Violation|0
6329953|NCT03012334|10075523|FG009|Period 2|Protocol Violation|0
6329954|NCT03012334|10075514|FG000|Period 4|Non-Compliance|0
6329955|NCT03012334|10075515|FG001|Period 4|Non-Compliance|0
6329956|NCT03012334|10075516|FG002|Period 4|Non-Compliance|0
6329957|NCT03012334|10075517|FG003|Period 4|Non-Compliance|0
6329958|NCT03012334|10075518|FG004|Period 4|Non-Compliance|0
6329959|NCT03012334|10075519|FG005|Period 4|Non-Compliance|0
6329960|NCT03012334|10075520|FG006|Period 4|Non-Compliance|1
6329961|NCT03012334|10075521|FG007|Period 4|Non-Compliance|0
6329962|NCT03012334|10075522|FG008|Period 4|Non-Compliance|0
6329963|NCT03012334|10075523|FG009|Period 4|Non-Compliance|0
6329964|NCT03012334|10075514|FG000|Period 4|Adverse Event|0
6329965|NCT03012334|10075515|FG001|Period 4|Adverse Event|0
6329966|NCT03012334|10075516|FG002|Period 4|Adverse Event|0
6329967|NCT03012334|10075517|FG003|Period 4|Adverse Event|0
6329968|NCT03012334|10075518|FG004|Period 4|Adverse Event|0
6329969|NCT03012334|10075519|FG005|Period 4|Adverse Event|0
6329970|NCT03012334|10075520|FG006|Period 4|Adverse Event|0
6329971|NCT03012334|10075521|FG007|Period 4|Adverse Event|0
6329972|NCT03012334|10075522|FG008|Period 4|Adverse Event|1
6329973|NCT03012334|10075523|FG009|Period 4|Adverse Event|0
6329974|NCT03012828|10075550|FG000|Overall Study|Lost to Follow-up|1
6329975|NCT03012828|10075551|FG001|Overall Study|Lost to Follow-up|0
6329976|NCT03012828|10075552|FG002|Overall Study|Lost to Follow-up|1
6329977|NCT03012828|10075553|FG003|Overall Study|Lost to Follow-up|0
6329978|NCT03012828|10075554|FG004|Overall Study|Lost to Follow-up|1
6329979|NCT03012828|10075555|FG005|Overall Study|Lost to Follow-up|0
6329980|NCT03012828|10075550|FG000|Overall Study|Withdrawal by Subject|0
6329981|NCT03012828|10075551|FG001|Overall Study|Withdrawal by Subject|0
6329982|NCT03012828|10075552|FG002|Overall Study|Withdrawal by Subject|1
6329983|NCT03012828|10075553|FG003|Overall Study|Withdrawal by Subject|0
6329984|NCT03012828|10075554|FG004|Overall Study|Withdrawal by Subject|0
6329985|NCT03012828|10075555|FG005|Overall Study|Withdrawal by Subject|1
6329986|NCT03012828|10075550|FG000|Overall Study|Non-compliance with protocol|0
6329987|NCT03012828|10075551|FG001|Overall Study|Non-compliance with protocol|0
6329988|NCT03012828|10075552|FG002|Overall Study|Non-compliance with protocol|0
6329989|NCT03012828|10075553|FG003|Overall Study|Non-compliance with protocol|0
6329990|NCT03012828|10075554|FG004|Overall Study|Non-compliance with protocol|1
6329991|NCT03012828|10075555|FG005|Overall Study|Non-compliance with protocol|0
6329992|NCT03012828|10075550|FG000|Overall Study|Delay to last visit would delay DBL|0
6329993|NCT03012828|10075551|FG001|Overall Study|Delay to last visit would delay DBL|0
6329994|NCT03012828|10075552|FG002|Overall Study|Delay to last visit would delay DBL|0
6329995|NCT03012828|10075553|FG003|Overall Study|Delay to last visit would delay DBL|0
6082765|NCT00631189|9690856|FG002|Treatment Phase|Lost to Follow-up|0
6329996|NCT03012828|10075554|FG004|Overall Study|Delay to last visit would delay DBL|0
6329997|NCT03012828|10075555|FG005|Overall Study|Delay to last visit would delay DBL|1
6329998|NCT03012841|10075571|FG000|Overall Study|Protocol Violation|0
6329999|NCT03012841|10075572|FG001|Overall Study|Protocol Violation|10
6330000|NCT03012841|10075571|FG000|Overall Study|Lost to Follow-up|6
6330001|NCT03012841|10075572|FG001|Overall Study|Lost to Follow-up|1
6330002|NCT03012841|10075571|FG000|Overall Study|Withdrawal by Subject|6
6330003|NCT03012841|10075572|FG001|Overall Study|Withdrawal by Subject|0
6330004|NCT03012841|10075571|FG000|Overall Study|Unable to complete 12 month visit|6
6330005|NCT03012841|10075572|FG001|Overall Study|Unable to complete 12 month visit|0
6330006|NCT03012841|10075571|FG000|Overall Study|Subject relocation|1
6330007|NCT03012841|10075572|FG001|Overall Study|Subject relocation|0
6330008|NCT03012841|10075571|FG000|Overall Study|Seasonal winter travel|1
6330009|NCT03012841|10075572|FG001|Overall Study|Seasonal winter travel|0
6330010|NCT03012841|10075571|FG000|Overall Study|Physician Decision|0
6330011|NCT03012841|10075572|FG001|Overall Study|Physician Decision|2
6330012|NCT03012841|10075571|FG000|Overall Study|No ablation performed|0
6330013|NCT03012841|10075572|FG001|Overall Study|No ablation performed|2
6330014|NCT03012841|10075571|FG000|Overall Study|Study reached n=165 treated subject cap|0
6330015|NCT03012841|10075572|FG001|Overall Study|Study reached n=165 treated subject cap|5
6330016|NCT03012841|10075571|FG000|Overall Study|Insurance change|0
6082766|NCT00631189|9690857|FG003|Treatment Phase|Lost to Follow-up|0
6330017|NCT03012841|10075572|FG001|Overall Study|Insurance change|1
6330018|NCT03013985|10075579|FG000|Overall Study|Protocol Violation|2
6330019|NCT03013985|10075580|FG001|Overall Study|Protocol Violation|2
6330020|NCT03013985|10075579|FG000|Overall Study|Withdrawal by Subject|14
6330021|NCT03013985|10075580|FG001|Overall Study|Withdrawal by Subject|17
6330022|NCT03014011|10075586|FG000|First Intervention|Withdrawal by Subject|1
6330023|NCT03014011|10075587|FG001|First Intervention|Withdrawal by Subject|0
6330024|NCT03014011|10075586|FG000|Washout|Withdrawal by Subject|1
6330025|NCT03014011|10075587|FG001|Washout|Withdrawal by Subject|0
6330026|NCT03014180|10075593|FG000|Overall Study|Protocol Violation|2
6330027|NCT03014206|10075601|FG000|Overall Study|Registration Violation|12
6330028|NCT03014453|10075605|FG000|Overall Study|Lost to Follow-up|12
6330029|NCT03014453|10075605|FG000|Overall Study|Discontinued GER|3
6330030|NCT03014453|10075605|FG000|Overall Study|Excluded|19
6330031|NCT03014453|10075605|FG000|Overall Study|Refused to take part in|37
6330032|NCT03014479|10075611|FG000|Overall Study|Adverse Event|0
6330033|NCT03014479|10075612|FG001|Overall Study|Adverse Event|1
6330034|NCT03014479|10075611|FG000|Overall Study|Voluntary Withdrawal|0
6330035|NCT03014479|10075612|FG001|Overall Study|Voluntary Withdrawal|2
6330036|NCT03014479|10075611|FG000|Overall Study|Unacceptable Inability of Site Visit|0
6330037|NCT03014479|10075612|FG001|Overall Study|Unacceptable Inability of Site Visit|1
6330038|NCT03014674|10075630|FG000|Overall Study|Withdrawal by Subject|1
6330039|NCT03014674|10075631|FG001|Overall Study|Withdrawal by Subject|0
6330040|NCT03014674|10075632|FG002|Overall Study|Withdrawal by Subject|0
6330041|NCT03015116|10075652|FG000|Overall Study|Lost to Follow-up|3
6330042|NCT03015116|10075653|FG001|Overall Study|Lost to Follow-up|0
6330043|NCT03015116|10075654|FG002|Overall Study|Lost to Follow-up|2
6330044|NCT03015116|10075652|FG000|Overall Study|Withdrawal by Subject|3
6330045|NCT03015116|10075653|FG001|Overall Study|Withdrawal by Subject|1
6330046|NCT03015116|10075654|FG002|Overall Study|Withdrawal by Subject|0
6330047|NCT03015116|10075652|FG000|Overall Study|Subject has New Medical Status|1
6330048|NCT03015116|10075653|FG001|Overall Study|Subject has New Medical Status|0
6330049|NCT03015116|10075654|FG002|Overall Study|Subject has New Medical Status|0
6330050|NCT03015116|10075652|FG000|Overall Study|Physician Decision|0
6330051|NCT03015116|10075653|FG001|Overall Study|Physician Decision|1
6330052|NCT03015116|10075654|FG002|Overall Study|Physician Decision|0
6330053|NCT03015181|10075671|FG000|Overall Study|Enrolled, but product never administered|1
6330054|NCT03015181|10075672|FG001|Overall Study|Enrolled, but product never administered|0
6330055|NCT03015181|10075673|FG002|Overall Study|Enrolled, but product never administered|0
6330056|NCT03015181|10075674|FG003|Overall Study|Enrolled, but product never administered|0
6330057|NCT03015181|10075675|FG004|Overall Study|Enrolled, but product never administered|0
6330058|NCT03015181|10075676|FG005|Overall Study|Enrolled, but product never administered|0
6330059|NCT03015181|10075677|FG006|Overall Study|Enrolled, but product never administered|0
6330060|NCT03015181|10075671|FG000|Overall Study|Withdrawal by Subject|0
6330061|NCT03015181|10075672|FG001|Overall Study|Withdrawal by Subject|0
6330062|NCT03015181|10075673|FG002|Overall Study|Withdrawal by Subject|0
6330063|NCT03015181|10075674|FG003|Overall Study|Withdrawal by Subject|0
6330064|NCT03015181|10075675|FG004|Overall Study|Withdrawal by Subject|0
6330065|NCT03015181|10075676|FG005|Overall Study|Withdrawal by Subject|1
6330066|NCT03015181|10075677|FG006|Overall Study|Withdrawal by Subject|0
6330067|NCT03015181|10075671|FG000|Overall Study|Physician Decision|0
6330068|NCT03015181|10075672|FG001|Overall Study|Physician Decision|0
6330069|NCT03015181|10075673|FG002|Overall Study|Physician Decision|0
6330070|NCT03015181|10075674|FG003|Overall Study|Physician Decision|0
6330071|NCT03015181|10075675|FG004|Overall Study|Physician Decision|0
6330072|NCT03015181|10075676|FG005|Overall Study|Physician Decision|0
6330073|NCT03015181|10075677|FG006|Overall Study|Physician Decision|1
6330074|NCT03015220|10075717|FG000|Overall Study|Withdrawal by Subject|3
6330075|NCT03015220|10075718|FG001|Overall Study|Withdrawal by Subject|2
6330076|NCT03015220|10075719|FG002|Overall Study|Withdrawal by Subject|2
6330077|NCT03015220|10075720|FG003|Overall Study|Withdrawal by Subject|2
6330078|NCT03015220|10075717|FG000|Overall Study|Lost to Follow-up|0
6330079|NCT03015220|10075718|FG001|Overall Study|Lost to Follow-up|0
6330080|NCT03015220|10075719|FG002|Overall Study|Lost to Follow-up|1
6330081|NCT03015220|10075720|FG003|Overall Study|Lost to Follow-up|0
6330082|NCT03015363|10075730|FG000|Overall Study|Physician Decision|14
6330083|NCT03015363|10075730|FG000|Overall Study|Withdrawal by Subject|3
6330084|NCT03015532|10075742|FG000|Overall Study|Adverse Event|0
6330085|NCT03015532|10075743|FG001|Overall Study|Adverse Event|0
6330086|NCT03015532|10075744|FG002|Overall Study|Adverse Event|0
6330087|NCT03015532|10075745|FG003|Overall Study|Adverse Event|0
6330088|NCT03015532|10075746|FG004|Overall Study|Adverse Event|0
6330089|NCT03015532|10075747|FG005|Overall Study|Adverse Event|2
6330090|NCT03015532|10075748|FG006|Overall Study|Adverse Event|1
6330091|NCT03015532|10075749|FG007|Overall Study|Adverse Event|0
6330092|NCT03015532|10075742|FG000|Overall Study|Withdrawal by Subject|0
6330093|NCT03015532|10075743|FG001|Overall Study|Withdrawal by Subject|0
6330094|NCT03015532|10075744|FG002|Overall Study|Withdrawal by Subject|0
6330095|NCT03015532|10075745|FG003|Overall Study|Withdrawal by Subject|0
6330096|NCT03015532|10075746|FG004|Overall Study|Withdrawal by Subject|0
6330097|NCT03015532|10075747|FG005|Overall Study|Withdrawal by Subject|0
6330098|NCT03015532|10075748|FG006|Overall Study|Withdrawal by Subject|1
6330099|NCT03015532|10075749|FG007|Overall Study|Withdrawal by Subject|0
6330100|NCT03016078|10075782|FG000|Overall Study|Protocol Violation|1
6330101|NCT03016078|10075782|FG000|Overall Study|Protocol Violation|1
6330102|NCT03016325|10075794|FG000|Treatment Period|Participant withdrew consent|0
6330103|NCT03016325|10075795|FG001|Treatment Period|Participant withdrew consent|1
6330104|NCT03016325|10075796|FG002|Treatment Period|Participant withdrew consent|0
6330105|NCT03016325|10075797|FG003|Treatment Period|Participant withdrew consent|0
6330106|NCT03016325|10075798|FG004|Treatment Period|Participant withdrew consent|0
6330107|NCT03016325|10075799|FG005|Treatment Period|Participant withdrew consent|0
6082767|NCT00631189|9690854|FG000|Treatment Phase|Pregnancy|0
6082768|NCT00631189|9690855|FG001|Treatment Phase|Pregnancy|0
6082769|NCT00631189|9690856|FG002|Treatment Phase|Pregnancy|1
6082770|NCT00631189|9690857|FG003|Treatment Phase|Pregnancy|0
6082771|NCT00631189|9690854|FG000|Treatment Phase|patient did not take pravastatin|0
6082772|NCT00631189|9690855|FG001|Treatment Phase|patient did not take pravastatin|0
6082773|NCT00631189|9690856|FG002|Treatment Phase|patient did not take pravastatin|1
6082774|NCT00631189|9690857|FG003|Treatment Phase|patient did not take pravastatin|0
6082775|NCT00631371|9690888|FG000|Overall Study|Lost to Follow-up|24
6082776|NCT00631371|9690889|FG001|Overall Study|Lost to Follow-up|19
6082777|NCT00631371|9690888|FG000|Overall Study|Other reason|5
6082778|NCT00631371|9690889|FG001|Overall Study|Other reason|12
6082779|NCT00631371|9690888|FG000|Overall Study|subject request|38
6082780|NCT00631371|9690889|FG001|Overall Study|subject request|45
6082781|NCT00631371|9690888|FG000|Overall Study|Discontinuation of study by Sponsor|70
6082782|NCT00631371|9690889|FG001|Overall Study|Discontinuation of study by Sponsor|76
6082783|NCT00631371|9690888|FG000|Overall Study|Death|263
6082784|NCT00631371|9690889|FG001|Overall Study|Death|239
6082785|NCT00631410|9690897|FG000|Overall Study|Adverse Event|1
6330108|NCT03016325|10075800|FG006|Treatment Period|Participant withdrew consent|0
6330109|NCT03016325|10075801|FG007|Treatment Period|Participant withdrew consent|0
6330110|NCT03016325|10075794|FG000|Treatment Period|Death|0
6330111|NCT03016325|10075795|FG001|Treatment Period|Death|0
6330112|NCT03016325|10075796|FG002|Treatment Period|Death|0
6330113|NCT03016325|10075797|FG003|Treatment Period|Death|0
6330114|NCT03016325|10075798|FG004|Treatment Period|Death|2
6330115|NCT03016325|10075799|FG005|Treatment Period|Death|0
6330116|NCT03016325|10075800|FG006|Treatment Period|Death|0
6330117|NCT03016325|10075801|FG007|Treatment Period|Death|0
6330118|NCT03016325|10075794|FG000|Treatment Period|Participant refuses assessments|0
6330119|NCT03016325|10075795|FG001|Treatment Period|Participant refuses assessments|0
6330120|NCT03016325|10075796|FG002|Treatment Period|Participant refuses assessments|1
6330121|NCT03016325|10075797|FG003|Treatment Period|Participant refuses assessments|0
6330122|NCT03016325|10075798|FG004|Treatment Period|Participant refuses assessments|0
6330123|NCT03016325|10075799|FG005|Treatment Period|Participant refuses assessments|0
6330124|NCT03016325|10075800|FG006|Treatment Period|Participant refuses assessments|0
6330125|NCT03016325|10075801|FG007|Treatment Period|Participant refuses assessments|0
6330126|NCT03016325|10075794|FG000|32-Day Follow-Up Period|Death|2
6330127|NCT03016325|10075795|FG001|32-Day Follow-Up Period|Death|0
6330128|NCT03016325|10075796|FG002|32-Day Follow-Up Period|Death|5
6330129|NCT03016325|10075797|FG003|32-Day Follow-Up Period|Death|6
6330130|NCT03016325|10075798|FG004|32-Day Follow-Up Period|Death|3
6330131|NCT03016325|10075799|FG005|32-Day Follow-Up Period|Death|0
6330132|NCT03016325|10075800|FG006|32-Day Follow-Up Period|Death|0
6330133|NCT03016325|10075801|FG007|32-Day Follow-Up Period|Death|0
6330134|NCT03016325|10075794|FG000|32-Day Follow-Up Period|Lost to Follow-up|1
6330135|NCT03016325|10075795|FG001|32-Day Follow-Up Period|Lost to Follow-up|0
6330136|NCT03016325|10075796|FG002|32-Day Follow-Up Period|Lost to Follow-up|1
6330137|NCT03016325|10075797|FG003|32-Day Follow-Up Period|Lost to Follow-up|1
6330138|NCT03016325|10075798|FG004|32-Day Follow-Up Period|Lost to Follow-up|0
6330139|NCT03016325|10075799|FG005|32-Day Follow-Up Period|Lost to Follow-up|0
6330140|NCT03016325|10075800|FG006|32-Day Follow-Up Period|Lost to Follow-up|0
6330141|NCT03016325|10075801|FG007|32-Day Follow-Up Period|Lost to Follow-up|0
6330142|NCT03016325|10075794|FG000|32-Day Follow-Up Period|Poor/non-compliance|1
6330143|NCT03016325|10075795|FG001|32-Day Follow-Up Period|Poor/non-compliance|0
6330144|NCT03016325|10075796|FG002|32-Day Follow-Up Period|Poor/non-compliance|0
6330145|NCT03016325|10075797|FG003|32-Day Follow-Up Period|Poor/non-compliance|1
6330146|NCT03016325|10075798|FG004|32-Day Follow-Up Period|Poor/non-compliance|1
6330147|NCT03016325|10075799|FG005|32-Day Follow-Up Period|Poor/non-compliance|0
6330148|NCT03016325|10075800|FG006|32-Day Follow-Up Period|Poor/non-compliance|0
6330149|NCT03016325|10075801|FG007|32-Day Follow-Up Period|Poor/non-compliance|0
6330150|NCT03016325|10075794|FG000|32-Day Follow-Up Period|Participant refused to visit|0
6330151|NCT03016325|10075795|FG001|32-Day Follow-Up Period|Participant refused to visit|1
6330152|NCT03016325|10075796|FG002|32-Day Follow-Up Period|Participant refused to visit|2
6330153|NCT03016325|10075797|FG003|32-Day Follow-Up Period|Participant refused to visit|0
6330154|NCT03016325|10075798|FG004|32-Day Follow-Up Period|Participant refused to visit|2
6082786|NCT00631410|9690898|FG001|Overall Study|Adverse Event|3
6330155|NCT03016325|10075799|FG005|32-Day Follow-Up Period|Participant refused to visit|0
6330156|NCT03016325|10075800|FG006|32-Day Follow-Up Period|Participant refused to visit|0
6330157|NCT03016325|10075801|FG007|32-Day Follow-Up Period|Participant refused to visit|0
6330158|NCT03016325|10075794|FG000|32-Day Follow-Up Period|Participant withdrew consent|0
6330159|NCT03016325|10075795|FG001|32-Day Follow-Up Period|Participant withdrew consent|0
6330160|NCT03016325|10075796|FG002|32-Day Follow-Up Period|Participant withdrew consent|0
6330161|NCT03016325|10075797|FG003|32-Day Follow-Up Period|Participant withdrew consent|0
6082787|NCT00631410|9690897|FG000|Overall Study|Objective Progression or Relapse|4
6082788|NCT00631410|9690898|FG001|Overall Study|Objective Progression or Relapse|3
6330162|NCT03016325|10075798|FG004|32-Day Follow-Up Period|Participant withdrew consent|2
6330163|NCT03016325|10075799|FG005|32-Day Follow-Up Period|Participant withdrew consent|0
6330164|NCT03016325|10075800|FG006|32-Day Follow-Up Period|Participant withdrew consent|1
6330165|NCT03016325|10075801|FG007|32-Day Follow-Up Period|Participant withdrew consent|0
6330166|NCT03016325|10075794|FG000|32-Day Follow-Up Period|Family doctor OK'd participant, per call|0
6330167|NCT03016325|10075795|FG001|32-Day Follow-Up Period|Family doctor OK'd participant, per call|0
6330168|NCT03016325|10075796|FG002|32-Day Follow-Up Period|Family doctor OK'd participant, per call|1
6330169|NCT03016325|10075797|FG003|32-Day Follow-Up Period|Family doctor OK'd participant, per call|0
6330170|NCT03016325|10075798|FG004|32-Day Follow-Up Period|Family doctor OK'd participant, per call|0
6330171|NCT03016325|10075799|FG005|32-Day Follow-Up Period|Family doctor OK'd participant, per call|0
6330172|NCT03016325|10075800|FG006|32-Day Follow-Up Period|Family doctor OK'd participant, per call|0
6330173|NCT03016325|10075801|FG007|32-Day Follow-Up Period|Family doctor OK'd participant, per call|0
6330174|NCT03016325|10075794|FG000|32-Day Follow-Up Period|withdrew from Day 5, D32 form not done|0
6330175|NCT03016325|10075795|FG001|32-Day Follow-Up Period|withdrew from Day 5, D32 form not done|1
6330176|NCT03016325|10075796|FG002|32-Day Follow-Up Period|withdrew from Day 5, D32 form not done|0
6330177|NCT03016325|10075797|FG003|32-Day Follow-Up Period|withdrew from Day 5, D32 form not done|0
6330178|NCT03016325|10075798|FG004|32-Day Follow-Up Period|withdrew from Day 5, D32 form not done|0
6330179|NCT03016325|10075799|FG005|32-Day Follow-Up Period|withdrew from Day 5, D32 form not done|0
6330180|NCT03016325|10075800|FG006|32-Day Follow-Up Period|withdrew from Day 5, D32 form not done|0
6330181|NCT03016325|10075801|FG007|32-Day Follow-Up Period|withdrew from Day 5, D32 form not done|0
6330182|NCT03016325|10075794|FG000|182-Day Follow-Up Period|Death|3
6330183|NCT03016325|10075795|FG001|182-Day Follow-Up Period|Death|3
6330184|NCT03016325|10075796|FG002|182-Day Follow-Up Period|Death|11
6330185|NCT03016325|10075797|FG003|182-Day Follow-Up Period|Death|12
6330186|NCT03016325|10075798|FG004|182-Day Follow-Up Period|Death|9
6330187|NCT03016325|10075799|FG005|182-Day Follow-Up Period|Death|0
6330188|NCT03016325|10075800|FG006|182-Day Follow-Up Period|Death|0
6330189|NCT03016325|10075801|FG007|182-Day Follow-Up Period|Death|1
6330190|NCT03016325|10075794|FG000|182-Day Follow-Up Period|Alive, per national insurance system|1
6330191|NCT03016325|10075795|FG001|182-Day Follow-Up Period|Alive, per national insurance system|0
6330192|NCT03016325|10075796|FG002|182-Day Follow-Up Period|Alive, per national insurance system|0
6330193|NCT03016325|10075797|FG003|182-Day Follow-Up Period|Alive, per national insurance system|0
6330194|NCT03016325|10075798|FG004|182-Day Follow-Up Period|Alive, per national insurance system|0
6330195|NCT03016325|10075799|FG005|182-Day Follow-Up Period|Alive, per national insurance system|0
6330196|NCT03016325|10075800|FG006|182-Day Follow-Up Period|Alive, per national insurance system|0
6330197|NCT03016325|10075801|FG007|182-Day Follow-Up Period|Alive, per national insurance system|0
6330198|NCT03016325|10075794|FG000|182-Day Follow-Up Period|Participant withdrew consent|0
6330199|NCT03016325|10075795|FG001|182-Day Follow-Up Period|Participant withdrew consent|0
6330200|NCT03016325|10075796|FG002|182-Day Follow-Up Period|Participant withdrew consent|0
6330201|NCT03016325|10075797|FG003|182-Day Follow-Up Period|Participant withdrew consent|0
6330202|NCT03016325|10075798|FG004|182-Day Follow-Up Period|Participant withdrew consent|1
6330203|NCT03016325|10075799|FG005|182-Day Follow-Up Period|Participant withdrew consent|0
6330204|NCT03016325|10075800|FG006|182-Day Follow-Up Period|Participant withdrew consent|1
6330205|NCT03016325|10075801|FG007|182-Day Follow-Up Period|Participant withdrew consent|0
6330206|NCT03016325|10075794|FG000|182-Day Follow-Up Period|Alive, per Family doctor|0
6330207|NCT03016325|10075795|FG001|182-Day Follow-Up Period|Alive, per Family doctor|0
6330208|NCT03016325|10075796|FG002|182-Day Follow-Up Period|Alive, per Family doctor|0
6330209|NCT03016325|10075797|FG003|182-Day Follow-Up Period|Alive, per Family doctor|0
6330210|NCT03016325|10075798|FG004|182-Day Follow-Up Period|Alive, per Family doctor|1
6330211|NCT03016325|10075799|FG005|182-Day Follow-Up Period|Alive, per Family doctor|0
6330212|NCT03016325|10075800|FG006|182-Day Follow-Up Period|Alive, per Family doctor|0
6330213|NCT03016325|10075801|FG007|182-Day Follow-Up Period|Alive, per Family doctor|0
6330214|NCT03016325|10075794|FG000|182-Day Follow-Up Period|Alive, per civil unit|0
6330215|NCT03016325|10075795|FG001|182-Day Follow-Up Period|Alive, per civil unit|0
6330216|NCT03016325|10075796|FG002|182-Day Follow-Up Period|Alive, per civil unit|0
6330217|NCT03016325|10075797|FG003|182-Day Follow-Up Period|Alive, per civil unit|0
6330218|NCT03016325|10075798|FG004|182-Day Follow-Up Period|Alive, per civil unit|1
6330219|NCT03016325|10075799|FG005|182-Day Follow-Up Period|Alive, per civil unit|0
6330220|NCT03016325|10075800|FG006|182-Day Follow-Up Period|Alive, per civil unit|0
6330221|NCT03016325|10075801|FG007|182-Day Follow-Up Period|Alive, per civil unit|0
6330222|NCT03016325|10075794|FG000|182-Day Follow-Up Period|Vital status collected via EMR|0
6330223|NCT03016325|10075795|FG001|182-Day Follow-Up Period|Vital status collected via EMR|0
6330224|NCT03016325|10075796|FG002|182-Day Follow-Up Period|Vital status collected via EMR|0
6330225|NCT03016325|10075797|FG003|182-Day Follow-Up Period|Vital status collected via EMR|1
6330226|NCT03016325|10075798|FG004|182-Day Follow-Up Period|Vital status collected via EMR|0
6330227|NCT03016325|10075799|FG005|182-Day Follow-Up Period|Vital status collected via EMR|0
6330228|NCT03016325|10075800|FG006|182-Day Follow-Up Period|Vital status collected via EMR|0
6330229|NCT03016325|10075801|FG007|182-Day Follow-Up Period|Vital status collected via EMR|0
6330230|NCT03016325|10075794|FG000|182-Day Follow-Up Period|withdrew from D5, D32/182 forms not done|0
6330231|NCT03016325|10075795|FG001|182-Day Follow-Up Period|withdrew from D5, D32/182 forms not done|1
6330232|NCT03016325|10075796|FG002|182-Day Follow-Up Period|withdrew from D5, D32/182 forms not done|0
6330233|NCT03016325|10075797|FG003|182-Day Follow-Up Period|withdrew from D5, D32/182 forms not done|0
6330234|NCT03016325|10075798|FG004|182-Day Follow-Up Period|withdrew from D5, D32/182 forms not done|0
6330235|NCT03016325|10075799|FG005|182-Day Follow-Up Period|withdrew from D5, D32/182 forms not done|0
6330236|NCT03016325|10075800|FG006|182-Day Follow-Up Period|withdrew from D5, D32/182 forms not done|0
6330237|NCT03016325|10075801|FG007|182-Day Follow-Up Period|withdrew from D5, D32/182 forms not done|0
6330238|NCT03016325|10075794|FG000|182-Day Follow-Up Period|No cont D182 FU, Sponsor admin reason|0
6330239|NCT03016325|10075795|FG001|182-Day Follow-Up Period|No cont D182 FU, Sponsor admin reason|0
6330240|NCT03016325|10075796|FG002|182-Day Follow-Up Period|No cont D182 FU, Sponsor admin reason|0
6330241|NCT03016325|10075797|FG003|182-Day Follow-Up Period|No cont D182 FU, Sponsor admin reason|0
6330242|NCT03016325|10075798|FG004|182-Day Follow-Up Period|No cont D182 FU, Sponsor admin reason|0
6330243|NCT03016325|10075799|FG005|182-Day Follow-Up Period|No cont D182 FU, Sponsor admin reason|5
6330244|NCT03016325|10075800|FG006|182-Day Follow-Up Period|No cont D182 FU, Sponsor admin reason|3
6330245|NCT03016325|10075801|FG007|182-Day Follow-Up Period|No cont D182 FU, Sponsor admin reason|4
6330246|NCT03016403|10075826|FG000|Baseline|Death|5
6330247|NCT03016403|10075827|FG001|Baseline|Death|8
6330248|NCT03016403|10075828|FG002|Baseline|Death|1
6330249|NCT03016403|10075829|FG003|Baseline|Death|0
6330250|NCT03016403|10075826|FG000|Baseline|Withdrawal by Subject|2
6330251|NCT03016403|10075827|FG001|Baseline|Withdrawal by Subject|8
6330252|NCT03016403|10075828|FG002|Baseline|Withdrawal by Subject|4
6330253|NCT03016403|10075829|FG003|Baseline|Withdrawal by Subject|10
6330254|NCT03016403|10075826|FG000|Baseline|Lost to Follow-up|9
6330255|NCT03016403|10075827|FG001|Baseline|Lost to Follow-up|11
6330256|NCT03016403|10075828|FG002|Baseline|Lost to Follow-up|6
6330257|NCT03016403|10075829|FG003|Baseline|Lost to Follow-up|24
6330258|NCT03016403|10075826|FG000|6-week Follow-up|Death|1
6330259|NCT03016403|10075827|FG001|6-week Follow-up|Death|4
6330260|NCT03016403|10075828|FG002|6-week Follow-up|Death|0
6330261|NCT03016403|10075829|FG003|6-week Follow-up|Death|0
6330262|NCT03016403|10075826|FG000|6-week Follow-up|Lost to Follow-up|2
6330263|NCT03016403|10075827|FG001|6-week Follow-up|Lost to Follow-up|7
6330264|NCT03016403|10075828|FG002|6-week Follow-up|Lost to Follow-up|4
6330265|NCT03016403|10075829|FG003|6-week Follow-up|Lost to Follow-up|8
6330266|NCT03016403|10075826|FG000|6-week Follow-up|Withdrawal by Subject|0
6330267|NCT03016403|10075827|FG001|6-week Follow-up|Withdrawal by Subject|2
6330268|NCT03016403|10075828|FG002|6-week Follow-up|Withdrawal by Subject|0
6330269|NCT03016403|10075829|FG003|6-week Follow-up|Withdrawal by Subject|1
6330270|NCT03016403|10075826|FG000|3-month Follow-up and 6-month Follow-up|Death|6
6330271|NCT03016403|10075827|FG001|3-month Follow-up and 6-month Follow-up|Death|4
6330272|NCT03016403|10075828|FG002|3-month Follow-up and 6-month Follow-up|Death|0
6330273|NCT03016403|10075829|FG003|3-month Follow-up and 6-month Follow-up|Death|0
6330274|NCT03016403|10075826|FG000|3-month Follow-up and 6-month Follow-up|Lost to Follow-up|6
6330275|NCT03016403|10075827|FG001|3-month Follow-up and 6-month Follow-up|Lost to Follow-up|7
6330276|NCT03016403|10075828|FG002|3-month Follow-up and 6-month Follow-up|Lost to Follow-up|8
6330277|NCT03016403|10075829|FG003|3-month Follow-up and 6-month Follow-up|Lost to Follow-up|6
6330278|NCT03016403|10075826|FG000|3-month Follow-up and 6-month Follow-up|Withdrawal by Subject|0
6330279|NCT03016403|10075827|FG001|3-month Follow-up and 6-month Follow-up|Withdrawal by Subject|0
6330280|NCT03016403|10075828|FG002|3-month Follow-up and 6-month Follow-up|Withdrawal by Subject|0
6330281|NCT03016403|10075829|FG003|3-month Follow-up and 6-month Follow-up|Withdrawal by Subject|1
6330282|NCT03016598|10075843|FG000|Overall Study|Lost to Follow-up|0
6330283|NCT03016598|10075844|FG001|Overall Study|Lost to Follow-up|2
6330284|NCT03017079|10075852|FG000|Overall Study|Physician Decision|1
6330285|NCT03017079|10075853|FG001|Overall Study|Physician Decision|1
6330286|NCT03017079|10075852|FG000|Overall Study|Death|3
6330287|NCT03017079|10075853|FG001|Overall Study|Death|2
6330288|NCT03017079|10075852|FG000|Overall Study|Lack of Efficacy|2
6330289|NCT03017079|10075853|FG001|Overall Study|Lack of Efficacy|2
6330290|NCT03017079|10075852|FG000|Overall Study|Protocol Violation|0
6330291|NCT03017079|10075853|FG001|Overall Study|Protocol Violation|1
6330292|NCT03017235|10075868|FG000|Overall Study|Withdrawal by Subject|4
6330293|NCT03017235|10075869|FG001|Overall Study|Withdrawal by Subject|3
6330294|NCT03017235|10075868|FG000|Overall Study|Lost to Follow-up|2
6330295|NCT03017235|10075869|FG001|Overall Study|Lost to Follow-up|7
6330296|NCT03017235|10075868|FG000|Overall Study|Adverse Event|0
6330297|NCT03017235|10075869|FG001|Overall Study|Adverse Event|1
6330298|NCT03017235|10075868|FG000|Overall Study|Protocol Violation|2
6330299|NCT03017235|10075869|FG001|Overall Study|Protocol Violation|1
6330300|NCT03017235|10075868|FG000|Overall Study|Cancer, emergency, allergy, active UTI|4
6330301|NCT03017235|10075869|FG001|Overall Study|Cancer, emergency, allergy, active UTI|2
6330302|NCT03017612|10075888|FG000|Overall Study|Adverse Event|2
6330303|NCT03017846|10075892|FG000|Overall Study|Lost to Follow-up|3
6330304|NCT03017846|10075892|FG000|Overall Study|Adverse Event|2
6330305|NCT03018028|10075919|FG000|Overall Study|Withdrawal by Subject|3
6330306|NCT03018028|10075920|FG001|Overall Study|Withdrawal by Subject|0
6330307|NCT03018028|10075921|FG002|Overall Study|Withdrawal by Subject|1
6330308|NCT03018028|10075922|FG003|Overall Study|Withdrawal by Subject|2
6330309|NCT03018028|10075923|FG004|Overall Study|Withdrawal by Subject|0
6330310|NCT03018106|10075937|FG000|Overall Study|Lost to Follow-up|0
6330311|NCT03018106|10075938|FG001|Overall Study|Lost to Follow-up|1
6330312|NCT03018249|10075948|FG000|Overall Study|Withdrawal by Subject|2
6330313|NCT03018249|10075949|FG001|Overall Study|Withdrawal by Subject|2
6330314|NCT03018340|10075957|FG000|Overall Study|Adverse Event|1
6330315|NCT03018340|10075958|FG001|Overall Study|Adverse Event|2
6330316|NCT03018340|10075957|FG000|Overall Study|Withdrawal by Subject|0
6330317|NCT03018340|10075958|FG001|Overall Study|Withdrawal by Subject|8
6330318|NCT03018340|10075957|FG000|Overall Study|Lack of Efficacy|0
6330319|NCT03018340|10075958|FG001|Overall Study|Lack of Efficacy|1
6330320|NCT03018340|10075957|FG000|Overall Study|Non-compliance with study drug/procedure|3
6330321|NCT03018340|10075958|FG001|Overall Study|Non-compliance with study drug/procedure|4
6330322|NCT03018340|10075957|FG000|Overall Study|Lost to Follow-up|1
6330323|NCT03018340|10075958|FG001|Overall Study|Lost to Follow-up|7
6330324|NCT03018340|10075957|FG000|Overall Study|Protocol Violation|3
6330325|NCT03018340|10075958|FG001|Overall Study|Protocol Violation|7
6330326|NCT03018340|10075957|FG000|Overall Study|Not further specified|0
6330327|NCT03018340|10075958|FG001|Overall Study|Not further specified|1
6330328|NCT03018691|10075971|FG000|Overall Study|Adverse Event|1
6330329|NCT03018691|10075972|FG001|Overall Study|Adverse Event|1
6330330|NCT03018691|10075973|FG002|Overall Study|Adverse Event|4
6330331|NCT03018691|10075971|FG000|Overall Study|Lack of Efficacy|0
6330332|NCT03018691|10075972|FG001|Overall Study|Lack of Efficacy|0
6330333|NCT03018691|10075973|FG002|Overall Study|Lack of Efficacy|1
6330334|NCT03018691|10075971|FG000|Overall Study|Withdrawal by Subject|0
6330335|NCT03018691|10075972|FG001|Overall Study|Withdrawal by Subject|0
6330336|NCT03018691|10075973|FG002|Overall Study|Withdrawal by Subject|1
6330337|NCT03018691|10075971|FG000|Overall Study|Withdrawal by parent/guardian|1
6330338|NCT03018691|10075972|FG001|Overall Study|Withdrawal by parent/guardian|0
6330339|NCT03018691|10075973|FG002|Overall Study|Withdrawal by parent/guardian|1
6330340|NCT03018938|10076010|FG000|Overall Study|Death|0
6330341|NCT03018938|10076011|FG001|Overall Study|Death|1
6330342|NCT03018938|10076010|FG000|Overall Study|Lost to Follow-up|21
6330343|NCT03018938|10076011|FG001|Overall Study|Lost to Follow-up|32
6330344|NCT03018938|10076010|FG000|Overall Study|Withdrawal by Subject|38
6330345|NCT03018938|10076011|FG001|Overall Study|Withdrawal by Subject|45
6330346|NCT03018938|10076010|FG000|Overall Study|Physician Decision|3
6330347|NCT03018938|10076011|FG001|Overall Study|Physician Decision|2
6330348|NCT03018938|10076010|FG000|Overall Study|Sponsor Decision|0
6330349|NCT03018938|10076011|FG001|Overall Study|Sponsor Decision|1
6330350|NCT03018938|10076010|FG000|Overall Study|Screen failure-After randomization|4
6330351|NCT03018938|10076011|FG001|Overall Study|Screen failure-After randomization|2
6330352|NCT03018938|10076010|FG000|Overall Study|Not recorded|0
6330353|NCT03018938|10076011|FG001|Overall Study|Not recorded|2
6330354|NCT03019289|10076052|FG000|Overall Study|Adverse Event|1
6330355|NCT03019289|10076053|FG001|Overall Study|Adverse Event|0
6330356|NCT03019289|10076054|FG002|Overall Study|Adverse Event|0
6330357|NCT03019289|10076055|FG003|Overall Study|Adverse Event|0
6330358|NCT03019289|10076056|FG004|Overall Study|Adverse Event|0
6330359|NCT03019289|10076057|FG005|Overall Study|Adverse Event|0
6330360|NCT03019289|10076058|FG006|Overall Study|Adverse Event|0
6167179|NCT01226511|9811633|FG000|Acute Treatment Period|Parent/caregiver decision|5
6167180|NCT01226511|9811634|FG001|Acute Treatment Period|Parent/caregiver decision|7
6167181|NCT01226511|9811633|FG000|Acute Treatment Period|Protocol Violation|5
6167182|NCT01226511|9811634|FG001|Acute Treatment Period|Protocol Violation|5
6330361|NCT03019289|10076059|FG007|Overall Study|Adverse Event|0
6330362|NCT03019289|10076060|FG008|Overall Study|Adverse Event|1
6330363|NCT03019289|10076052|FG000|Overall Study|Other|1
6330364|NCT03019289|10076053|FG001|Overall Study|Other|0
6330365|NCT03019289|10076054|FG002|Overall Study|Other|0
6330366|NCT03019289|10076055|FG003|Overall Study|Other|0
6330367|NCT03019289|10076056|FG004|Overall Study|Other|0
6330368|NCT03019289|10076057|FG005|Overall Study|Other|0
6330369|NCT03019289|10076058|FG006|Overall Study|Other|0
6330370|NCT03019289|10076059|FG007|Overall Study|Other|0
6330371|NCT03019289|10076060|FG008|Overall Study|Other|0
6330372|NCT03019458|10076083|FG000|Overall Study|Death|0
6330373|NCT03019458|10076084|FG001|Overall Study|Death|1
6330374|NCT03019549|10076092|FG000|Washout|DId not meet genotype criteria|11
6330375|NCT03019549|10076092|FG000|Period 2|Adverse Event|2
6330376|NCT03019549|10076092|FG000|Period 2|Physician Decision|2
6330377|NCT03019549|10076092|FG000|Period 2|Withdrawal by Subject|1
6330378|NCT03019627|10076103|FG000|Overall Study|Adverse Event|8
6330379|NCT03019627|10076104|FG001|Overall Study|Adverse Event|0
6330380|NCT03019627|10076103|FG000|Overall Study|Unrelated to adverse event|1
6330381|NCT03019627|10076104|FG001|Overall Study|Unrelated to adverse event|3
6330382|NCT03019627|10076103|FG000|Overall Study|Lost to Follow-up|2
6330383|NCT03019627|10076104|FG001|Overall Study|Lost to Follow-up|1
6330384|NCT03019627|10076103|FG000|Overall Study|not compliance|2
6330385|NCT03019627|10076104|FG001|Overall Study|not compliance|2
6330386|NCT03019627|10076103|FG000|Overall Study|Other|2
6330387|NCT03019627|10076104|FG001|Overall Study|Other|2
6330388|NCT03019965|10076146|FG000|Overall Study|Withdrawal by Subject|1
6330389|NCT03019965|10076147|FG001|Overall Study|Withdrawal by Subject|0
6330390|NCT03019965|10076146|FG000|Overall Study|Protocol Violation|1
6330391|NCT03019965|10076147|FG001|Overall Study|Protocol Violation|3
6330392|NCT03019965|10076146|FG000|Overall Study|viral or fungal infection|3
6330393|NCT03019965|10076147|FG001|Overall Study|viral or fungal infection|4
6330394|NCT03019965|10076146|FG000|Overall Study|acute liver failure in the first 24 hours of randomization|4
6330395|NCT03019965|10076147|FG001|Overall Study|acute liver failure in the first 24 hours of randomization|5
6330396|NCT03019965|10076146|FG000|Overall Study|Physician Decision|1
6330397|NCT03019965|10076147|FG001|Overall Study|Physician Decision|1
6330398|NCT03020069|10076159|FG000|Overall Study|Lost to Follow-up|0
6330399|NCT03020069|10076160|FG001|Overall Study|Lost to Follow-up|1
6330400|NCT03020407|10076176|FG000|Overall Study|Withdrawal by Subject|2
6330401|NCT03020407|10076177|FG001|Overall Study|Withdrawal by Subject|1
6330402|NCT03020407|10076176|FG000|Overall Study|Lost to Follow-up|2
6330403|NCT03020407|10076177|FG001|Overall Study|Lost to Follow-up|3
6330404|NCT03020407|10076176|FG000|Overall Study|Protocol Violation|0
6330405|NCT03020407|10076177|FG001|Overall Study|Protocol Violation|1
6330406|NCT03020576|10076233|FG000|Overall Study|Withdrawal by Subject|1
6330407|NCT03020576|10076234|FG001|Overall Study|Withdrawal by Subject|2
6330408|NCT03020615|10076243|FG000|Overall Study|Physician Decision|3
6330409|NCT03020615|10076244|FG001|Overall Study|Physician Decision|1
6330410|NCT03020615|10076245|FG002|Overall Study|Physician Decision|2
6330411|NCT03020615|10076243|FG000|Overall Study|Parent/guardian/patient choice|3
6330412|NCT03020615|10076244|FG001|Overall Study|Parent/guardian/patient choice|0
6330413|NCT03020615|10076245|FG002|Overall Study|Parent/guardian/patient choice|4
6330414|NCT03020615|10076243|FG000|Overall Study|Screen failure|0
6330415|NCT03020615|10076244|FG001|Overall Study|Screen failure|0
6330416|NCT03020615|10076245|FG002|Overall Study|Screen failure|1
6330417|NCT03020615|10076243|FG000|Overall Study|Death|1
6330418|NCT03020615|10076244|FG001|Overall Study|Death|0
6330419|NCT03020615|10076245|FG002|Overall Study|Death|0
6330420|NCT03020615|10076243|FG000|Overall Study|Lost to Follow-up|0
6330421|NCT03020615|10076244|FG001|Overall Study|Lost to Follow-up|1
6330422|NCT03020615|10076245|FG002|Overall Study|Lost to Follow-up|0
6330423|NCT03020641|10076258|FG000|Overall Study|Lost to Follow-up|0
6330424|NCT03020641|10076259|FG001|Overall Study|Lost to Follow-up|1
6330425|NCT03020641|10076258|FG000|Overall Study|Converted to open surgery|2
6330426|NCT03020641|10076259|FG001|Overall Study|Converted to open surgery|1
6330427|NCT03020641|10076258|FG000|Overall Study|for surgery not performed|0
6330428|NCT03020641|10076259|FG001|Overall Study|for surgery not performed|1
6330429|NCT03020745|10076285|FG000|Part 2 (Up to 169 Days)|Adverse Event|0
6330430|NCT03020745|10076286|FG001|Part 2 (Up to 169 Days)|Adverse Event|0
6330431|NCT03020745|10076287|FG002|Part 2 (Up to 169 Days)|Adverse Event|0
6330432|NCT03020745|10076288|FG003|Part 2 (Up to 169 Days)|Adverse Event|0
6330433|NCT03020745|10076289|FG004|Part 2 (Up to 169 Days)|Adverse Event|0
6330434|NCT03020745|10076290|FG005|Part 2 (Up to 169 Days)|Adverse Event|0
6330435|NCT03020745|10076291|FG006|Part 2 (Up to 169 Days)|Adverse Event|0
6330436|NCT03020745|10076292|FG007|Part 2 (Up to 169 Days)|Adverse Event|0
6330437|NCT03020745|10076293|FG008|Part 2 (Up to 169 Days)|Adverse Event|1
6330438|NCT03020745|10076294|FG009|Part 2 (Up to 169 Days)|Adverse Event|0
6330439|NCT03020745|10076285|FG000|Part 2 (Up to 169 Days)|Withdrawal by Subject|0
6330440|NCT03020745|10076286|FG001|Part 2 (Up to 169 Days)|Withdrawal by Subject|0
6330441|NCT03020745|10076287|FG002|Part 2 (Up to 169 Days)|Withdrawal by Subject|0
6330442|NCT03020745|10076288|FG003|Part 2 (Up to 169 Days)|Withdrawal by Subject|0
6330443|NCT03020745|10076289|FG004|Part 2 (Up to 169 Days)|Withdrawal by Subject|0
6330444|NCT03020745|10076290|FG005|Part 2 (Up to 169 Days)|Withdrawal by Subject|0
6330445|NCT03020745|10076291|FG006|Part 2 (Up to 169 Days)|Withdrawal by Subject|0
6330446|NCT03020745|10076292|FG007|Part 2 (Up to 169 Days)|Withdrawal by Subject|1
6330447|NCT03020745|10076293|FG008|Part 2 (Up to 169 Days)|Withdrawal by Subject|0
6330448|NCT03020745|10076294|FG009|Part 2 (Up to 169 Days)|Withdrawal by Subject|0
6330449|NCT03020745|10076285|FG000|Part 2:Optional FU (Up to 450 Days)|Lost to Follow-up|0
6330450|NCT03020745|10076286|FG001|Part 2:Optional FU (Up to 450 Days)|Lost to Follow-up|0
6330451|NCT03020745|10076287|FG002|Part 2:Optional FU (Up to 450 Days)|Lost to Follow-up|0
6330452|NCT03020745|10076288|FG003|Part 2:Optional FU (Up to 450 Days)|Lost to Follow-up|0
6330453|NCT03020745|10076289|FG004|Part 2:Optional FU (Up to 450 Days)|Lost to Follow-up|0
6330454|NCT03020745|10076290|FG005|Part 2:Optional FU (Up to 450 Days)|Lost to Follow-up|1
6330455|NCT03020745|10076291|FG006|Part 2:Optional FU (Up to 450 Days)|Lost to Follow-up|0
6330456|NCT03020745|10076292|FG007|Part 2:Optional FU (Up to 450 Days)|Lost to Follow-up|0
6330457|NCT03020745|10076293|FG008|Part 2:Optional FU (Up to 450 Days)|Lost to Follow-up|1
6330458|NCT03020745|10076294|FG009|Part 2:Optional FU (Up to 450 Days)|Lost to Follow-up|0
6330459|NCT03020745|10076285|FG000|Part 2:Optional FU (Up to 450 Days)|Withdrawal by Subject|0
6330460|NCT03020745|10076286|FG001|Part 2:Optional FU (Up to 450 Days)|Withdrawal by Subject|0
6330461|NCT03020745|10076287|FG002|Part 2:Optional FU (Up to 450 Days)|Withdrawal by Subject|0
6330462|NCT03020745|10076288|FG003|Part 2:Optional FU (Up to 450 Days)|Withdrawal by Subject|0
6330463|NCT03020745|10076289|FG004|Part 2:Optional FU (Up to 450 Days)|Withdrawal by Subject|0
6330464|NCT03020745|10076290|FG005|Part 2:Optional FU (Up to 450 Days)|Withdrawal by Subject|0
6330465|NCT03020745|10076291|FG006|Part 2:Optional FU (Up to 450 Days)|Withdrawal by Subject|0
6330466|NCT03020745|10076292|FG007|Part 2:Optional FU (Up to 450 Days)|Withdrawal by Subject|0
6330467|NCT03020745|10076293|FG008|Part 2:Optional FU (Up to 450 Days)|Withdrawal by Subject|2
6330468|NCT03020745|10076294|FG009|Part 2:Optional FU (Up to 450 Days)|Withdrawal by Subject|0
6330469|NCT03020888|10076318|FG000|Overall Study|Physician Decision|4
6330470|NCT03020888|10076318|FG000|Overall Study|Withdrawal by Subject|6
6330471|NCT03020888|10076318|FG000|Overall Study|Insurance coverage|2
6330472|NCT03020888|10076318|FG000|Overall Study|Lost to Follow-up|1
6330473|NCT03020966|10076324|FG000|Overall Study|Withdrawal by Subject|2
6330474|NCT03020966|10076325|FG001|Overall Study|Withdrawal by Subject|0
6330475|NCT03020992|10076331|FG000|Overall Study|Adverse Event|5
6330476|NCT03020992|10076331|FG000|Overall Study|Withdrawal by Subject|1
6330477|NCT03021005|10076338|FG000|Overall Study|Lost to Follow-up|39
6330478|NCT03021005|10076339|FG001|Overall Study|Lost to Follow-up|26
6330479|NCT03021018|10076348|FG000|Overall Study|Adverse Event|1
6330480|NCT03021018|10076349|FG001|Overall Study|Adverse Event|0
6330481|NCT03021018|10076350|FG002|Overall Study|Adverse Event|0
6330482|NCT03021018|10076348|FG000|Overall Study|Fall with subsequent nasal fracture|1
6330483|NCT03021018|10076349|FG001|Overall Study|Fall with subsequent nasal fracture|0
6330484|NCT03021018|10076350|FG002|Overall Study|Fall with subsequent nasal fracture|0
6330485|NCT03021187|10076362|FG000|Overall Study|Death|0
6330486|NCT03021187|10076363|FG001|Overall Study|Death|0
6330487|NCT03021187|10076364|FG002|Overall Study|Death|3
6330488|NCT03021187|10076365|FG003|Overall Study|Death|0
6330489|NCT03021187|10076362|FG000|Overall Study|Withdrawal by Subject|0
6330490|NCT03021187|10076363|FG001|Overall Study|Withdrawal by Subject|6
6330491|NCT03021187|10076364|FG002|Overall Study|Withdrawal by Subject|2
6330492|NCT03021187|10076365|FG003|Overall Study|Withdrawal by Subject|5
6330493|NCT03021187|10076362|FG000|Overall Study|Lost to Follow-up|10
6330494|NCT03021187|10076363|FG001|Overall Study|Lost to Follow-up|3
6330495|NCT03021187|10076364|FG002|Overall Study|Lost to Follow-up|1
6330496|NCT03021187|10076365|FG003|Overall Study|Lost to Follow-up|4
6330497|NCT03021265|10076375|FG000|Overall Study|Adverse Event|29
6330498|NCT03021265|10076375|FG000|Overall Study|Lack of Efficacy|3
6330499|NCT03021265|10076375|FG000|Overall Study|Improved|17
6330500|NCT03021265|10076375|FG000|Overall Study|Lost to Follow-up|67
6330501|NCT03021265|10076375|FG000|Overall Study|No reason given|2
6330502|NCT03021265|10076375|FG000|Overall Study|No visit since the first visit|4
6330503|NCT03021304|10076379|FG000|Overall Study|Lack of Efficacy|1
6330504|NCT03021499|10076394|FG000|Overall Study|Adverse Event|1
6330505|NCT03021499|10076395|FG001|Overall Study|Adverse Event|0
6330506|NCT03021499|10076394|FG000|Overall Study|Death|1
6330507|NCT03021499|10076395|FG001|Overall Study|Death|5
6330508|NCT03021499|10076394|FG000|Overall Study|Lack of Efficacy|0
6330509|NCT03021499|10076395|FG001|Overall Study|Lack of Efficacy|1
6330510|NCT03021499|10076394|FG000|Overall Study|Lost to Follow-up|1
6330511|NCT03021499|10076395|FG001|Overall Study|Lost to Follow-up|3
6330512|NCT03021499|10076394|FG000|Overall Study|Physician Decision|2
6330513|NCT03021499|10076395|FG001|Overall Study|Physician Decision|3
6330514|NCT03021499|10076394|FG000|Overall Study|Pregnancy|1
6330515|NCT03021499|10076395|FG001|Overall Study|Pregnancy|0
6330516|NCT03021499|10076394|FG000|Overall Study|Withdrawal by Subject|7
6330517|NCT03021499|10076395|FG001|Overall Study|Withdrawal by Subject|14
6330518|NCT03021499|10076394|FG000|Overall Study|Prohibited medication required|1
6330519|NCT03021499|10076395|FG001|Overall Study|Prohibited medication required|0
6330520|NCT03021499|10076394|FG000|Overall Study|Protocol non-compliance|1
6330521|NCT03021499|10076395|FG001|Overall Study|Protocol non-compliance|1
6330522|NCT03021499|10076394|FG000|Overall Study|None of the above|0
6330523|NCT03021499|10076395|FG001|Overall Study|None of the above|4
6330524|NCT03021499|10076394|FG000|Overall Study|Adverse Event (AE) Prior to First Dose|1
6330525|NCT03021499|10076395|FG001|Overall Study|Adverse Event (AE) Prior to First Dose|0
6330526|NCT03021564|10076414|FG000|Overall Study|Death|84
6330527|NCT03021564|10076415|FG001|Overall Study|Death|466
6330528|NCT03021564|10076414|FG000|Overall Study|Lost to Follow-up|0
6330529|NCT03021564|10076415|FG001|Overall Study|Lost to Follow-up|2
6330530|NCT03021642|10076425|FG000|Washout Period (21 Days)|Adverse Event|1
6330531|NCT03021642|10076426|FG001|Washout Period (21 Days)|Adverse Event|1
6330532|NCT03021668|10076434|FG000|Overall Study|Physician Decision|0
6330533|NCT03021668|10076435|FG001|Overall Study|Physician Decision|1
6330534|NCT03022045|10076456|FG000|Overall Study|Adverse Event|0
6330535|NCT03022045|10076457|FG001|Overall Study|Adverse Event|1
6330536|NCT03022045|10076456|FG000|Overall Study|Withdrawal by Subject|1
6330537|NCT03022045|10076457|FG001|Overall Study|Withdrawal by Subject|1
6330538|NCT03022084|10076469|FG000|Overall Study|Lost to Follow-up|2
6330539|NCT03022084|10076470|FG001|Overall Study|Lost to Follow-up|3
6330540|NCT03022370|10076480|FG000|Overall Study|Death|6
6330541|NCT03022370|10076481|FG001|Overall Study|Death|12
6330542|NCT03022370|10076480|FG000|Overall Study|Lost to Follow-up|174
6330543|NCT03022370|10076481|FG001|Overall Study|Lost to Follow-up|109
6330544|NCT03022422|10076522|FG000|Overall Study|3 subjects consented but not vaccinated|0
6330545|NCT03022422|10076523|FG001|Overall Study|3 subjects consented but not vaccinated|0
6330546|NCT03022422|10076524|FG002|Overall Study|3 subjects consented but not vaccinated|3
6330547|NCT03022422|10076525|FG003|Overall Study|3 subjects consented but not vaccinated|0
6330548|NCT03022422|10076526|FG004|Overall Study|3 subjects consented but not vaccinated|0
6330549|NCT03022422|10076527|FG005|Overall Study|3 subjects consented but not vaccinated|0
6330550|NCT03022630|10076582|FG000|Overall Study|Death|9
6330551|NCT03022630|10076583|FG001|Overall Study|Death|7
6330552|NCT03022630|10076582|FG000|Overall Study|Withdrawal by Subject|0
6330553|NCT03022630|10076583|FG001|Overall Study|Withdrawal by Subject|5
6330554|NCT03022799|10076607|FG000|Overall Study|Adverse Event|0
6330555|NCT03022799|10076608|FG001|Overall Study|Adverse Event|0
6330556|NCT03022799|10076609|FG002|Overall Study|Adverse Event|0
6330557|NCT03022799|10076610|FG003|Overall Study|Adverse Event|0
6330558|NCT03022799|10076611|FG004|Overall Study|Adverse Event|0
6330559|NCT03022799|10076612|FG005|Overall Study|Adverse Event|0
6330560|NCT03022799|10076613|FG006|Overall Study|Adverse Event|0
6330561|NCT03022799|10076614|FG007|Overall Study|Adverse Event|0
6330562|NCT03022799|10076615|FG008|Overall Study|Adverse Event|0
6330563|NCT03022799|10076616|FG009|Overall Study|Adverse Event|1
6330564|NCT03022799|10076617|FG010|Overall Study|Adverse Event|1
6330565|NCT03022799|10076618|FG011|Overall Study|Adverse Event|0
6330566|NCT03022799|10076619|FG012|Overall Study|Adverse Event|0
6330567|NCT03022981|10076677|FG000|Overall Study|Adverse Event|0
6330568|NCT03022981|10076678|FG001|Overall Study|Adverse Event|1
6330569|NCT03022981|10076679|FG002|Overall Study|Adverse Event|0
6330570|NCT03022981|10076677|FG000|Overall Study|Investigator's Discretion|0
6330571|NCT03022981|10076678|FG001|Overall Study|Investigator's Discretion|1
6330572|NCT03022981|10076679|FG002|Overall Study|Investigator's Discretion|2
6330573|NCT03022981|10076677|FG000|Overall Study|Lost to Follow-up|6
6330574|NCT03022981|10076678|FG001|Overall Study|Lost to Follow-up|2
6330575|NCT03022981|10076679|FG002|Overall Study|Lost to Follow-up|1
6330576|NCT03022981|10076677|FG000|Overall Study|Non-Compliance With Study Drug|0
6330577|NCT03022981|10076678|FG001|Overall Study|Non-Compliance With Study Drug|0
6330578|NCT03022981|10076679|FG002|Overall Study|Non-Compliance With Study Drug|2
6330579|NCT03022981|10076677|FG000|Overall Study|Withdrew Assent By Parent/Guardian|0
6330580|NCT03022981|10076678|FG001|Overall Study|Withdrew Assent By Parent/Guardian|0
6330581|NCT03022981|10076679|FG002|Overall Study|Withdrew Assent By Parent/Guardian|1
6330582|NCT03023137|10076699|FG000|Overall Study|Multiple pregnancy|2
6330583|NCT03023137|10076700|FG001|Overall Study|Multiple pregnancy|4
6330584|NCT03023137|10076699|FG000|Overall Study|Lost to Follow-up|1
6330585|NCT03023137|10076700|FG001|Overall Study|Lost to Follow-up|1
6330586|NCT03023137|10076699|FG000|Overall Study|Protocol Violation|0
6330587|NCT03023137|10076700|FG001|Overall Study|Protocol Violation|4
6330588|NCT03023137|10076699|FG000|Overall Study|Lost the baby in a car accident|1
6330589|NCT03023137|10076700|FG001|Overall Study|Lost the baby in a car accident|0
6330590|NCT03023397|10076714|FG000|Run-In|Failed screening allergen challenge|1
6330591|NCT03023397|10076715|FG001|Run-In|Failed screening allergen challenge|0
6330592|NCT03023397|10076716|FG002|Run-In|Failed screening allergen challenge|0
6330593|NCT03023397|10076714|FG000|Run-In|Loss of funding after informed consent but before screening allergen challenge|1
6330594|NCT03023397|10076715|FG001|Run-In|Loss of funding after informed consent but before screening allergen challenge|0
6330595|NCT03023397|10076716|FG002|Run-In|Loss of funding after informed consent but before screening allergen challenge|0
6330596|NCT03023423|10076728|FG000|Overall Study|Death|5
6330597|NCT03023423|10076729|FG001|Overall Study|Death|12
6330598|NCT03023423|10076730|FG002|Overall Study|Death|20
6330599|NCT03023423|10076728|FG000|Overall Study|Other|0
6330600|NCT03023423|10076729|FG001|Overall Study|Other|2
6330601|NCT03023423|10076730|FG002|Overall Study|Other|2
6330602|NCT03023423|10076728|FG000|Overall Study|Ongoing|2
6330603|NCT03023423|10076729|FG001|Overall Study|Ongoing|32
6330604|NCT03023423|10076730|FG002|Overall Study|Ongoing|24
6330605|NCT03023722|10076781|FG000|Overall Study|No follow-up assessment|4
6330606|NCT03023826|10076785|FG000|Period 1|Withdrawal by Subject|0
6330607|NCT03023826|10076786|FG001|Period 1|Withdrawal by Subject|0
6330608|NCT03023826|10076787|FG002|Period 1|Withdrawal by Subject|0
6330609|NCT03023826|10076788|FG003|Period 1|Withdrawal by Subject|0
6330610|NCT03023826|10076789|FG004|Period 1|Withdrawal by Subject|1
6330611|NCT03023826|10076790|FG005|Period 1|Withdrawal by Subject|0
6330612|NCT03023878|10076798|FG000|Pre-Study Run-In Period|Protocol-specified criteria|11
6330613|NCT03023878|10076798|FG000|Pre-Study Run-In Period|Death|1
6330614|NCT03023878|10076798|FG000|Pre-Study Run-In Period|Withdrawal by Subject|5
6330615|NCT03023878|10076798|FG000|Between Run-In and Treatment Periods|Protocol-specified criteria|2
6330616|NCT03023878|10076798|FG000|Treatment Period|Disease Progression|1
6330617|NCT03023878|10076798|FG000|Treatment Period|Withdrawal by Subject|1
6330618|NCT03023878|10076798|FG000|Treatment Period|Adverse Event|1
6330619|NCT03023878|10076798|FG000|Long Term Follow-Up Period|Death|2
6330620|NCT03024606|10076817|FG000|Overall Study|Withdrawal by Subject|9
6330621|NCT03024606|10076818|FG001|Overall Study|Withdrawal by Subject|10
6330622|NCT03024970|10076824|FG000|First Intervention|Adverse Event|1
6330623|NCT03024970|10076825|FG001|First Intervention|Adverse Event|0
6330624|NCT03024970|10076824|FG000|Second Intervention|Lost to Follow-up|1
6330625|NCT03024970|10076825|FG001|Second Intervention|Lost to Follow-up|0
6330626|NCT03025217|10076831|FG000|Overall Study|Pregnancy|1
6330627|NCT03025217|10076831|FG000|Overall Study|Lost to Follow-up|1
6330628|NCT03025217|10076831|FG000|Overall Study|Not eligible, poor English|2
6330629|NCT03026075|10076844|FG000|Overall Study|Physician Decision|1
6330630|NCT03026088|10076848|FG000|Overall Study|Study termination|20
6330631|NCT03026166|10076854|FG000|Overall Study|Death|22
6330632|NCT03026166|10076855|FG001|Overall Study|Death|7
6330633|NCT03026166|10076854|FG000|Overall Study|Physician Decision|2
6330634|NCT03026166|10076855|FG001|Overall Study|Physician Decision|0
6330635|NCT03026166|10076854|FG000|Overall Study|Withdrawal by Subject|1
6082789|NCT00631410|9690897|FG000|Overall Study|Surgery|1
6082790|NCT00631410|9690898|FG001|Overall Study|Surgery|0
6082791|NCT00631475|9690918|FG000|Overall Study|Death|18
6082792|NCT00631475|9690918|FG000|Overall Study|Adverse Event|14
6082793|NCT00631475|9690918|FG000|Overall Study|Withdrew consent|5
6082794|NCT00631475|9690918|FG000|Overall Study|Preparation for lung transplant|8
6082795|NCT00631488|9690925|FG000|Overall Study|Adverse Event|1
6082796|NCT00631488|9690926|FG001|Overall Study|Adverse Event|0
6082797|NCT00631488|9690927|FG002|Overall Study|Adverse Event|0
6082798|NCT00631488|9690925|FG000|Overall Study|Lost to Follow-up|2
6082799|NCT00631488|9690926|FG001|Overall Study|Lost to Follow-up|2
6082800|NCT00631488|9690927|FG002|Overall Study|Lost to Follow-up|0
6082801|NCT00631488|9690925|FG000|Overall Study|Physician Decision|1
6082802|NCT00631488|9690926|FG001|Overall Study|Physician Decision|0
6082803|NCT00631488|9690927|FG002|Overall Study|Physician Decision|1
6082804|NCT00631488|9690925|FG000|Overall Study|Protocol Violation|0
6082805|NCT00631488|9690926|FG001|Overall Study|Protocol Violation|0
6082806|NCT00631488|9690927|FG002|Overall Study|Protocol Violation|1
6082807|NCT00631540|9690935|FG000|Overall Study|Withdrawal by Subject|5
6082808|NCT00631540|9690935|FG000|Overall Study|Death|4
6082809|NCT00631540|9690935|FG000|Overall Study|Lost to Follow-up|2
6082810|NCT00631540|9690935|FG000|Overall Study|Core Lab Data Unavailable|3
6082811|NCT00631657|9690954|FG000|6-Month Treatment Period|Adverse Event|47
6082812|NCT00631657|9690955|FG001|6-Month Treatment Period|Adverse Event|0
6082813|NCT00631657|9690956|FG002|6-Month Treatment Period|Adverse Event|7
6082814|NCT00631657|9690954|FG000|6-Month Treatment Period|Withdrawal by Subject|14
6082815|NCT00631657|9690955|FG001|6-Month Treatment Period|Withdrawal by Subject|0
6082816|NCT00631657|9690956|FG002|6-Month Treatment Period|Withdrawal by Subject|5
6082817|NCT00631657|9690954|FG000|6-Month Treatment Period|Lack of Efficacy|34
6082818|NCT00631657|9690955|FG001|6-Month Treatment Period|Lack of Efficacy|0
6082819|NCT00631657|9690956|FG002|6-Month Treatment Period|Lack of Efficacy|25
6082820|NCT00631657|9690954|FG000|6-Month Treatment Period|Lost to Follow-up|7
6082821|NCT00631657|9690955|FG001|6-Month Treatment Period|Lost to Follow-up|0
6082822|NCT00631657|9690956|FG002|6-Month Treatment Period|Lost to Follow-up|2
6330636|NCT03026166|10076855|FG001|Overall Study|Withdrawal by Subject|2
6330637|NCT03026166|10076854|FG000|Overall Study|Lost to Follow-up|1
6330638|NCT03026166|10076855|FG001|Overall Study|Lost to Follow-up|0
6330639|NCT03026166|10076854|FG000|Overall Study|Study Terminated by Sponsor|3
6330640|NCT03026166|10076855|FG001|Overall Study|Study Terminated by Sponsor|3
6330641|NCT03026166|10076854|FG000|Overall Study|Other|1
6330642|NCT03026166|10076855|FG001|Overall Study|Other|0
6330643|NCT03026257|10076867|FG000|Overall Study|Adverse Event|3
6330644|NCT03026257|10076868|FG001|Overall Study|Adverse Event|0
6330645|NCT03026257|10076869|FG002|Overall Study|Adverse Event|0
6330646|NCT03026257|10076870|FG003|Overall Study|Adverse Event|0
6330647|NCT03026257|10076871|FG004|Overall Study|Adverse Event|0
6330648|NCT03026257|10076872|FG005|Overall Study|Adverse Event|0
6330649|NCT03026257|10076867|FG000|Overall Study|Lost to Follow-up|1
6330650|NCT03026257|10076868|FG001|Overall Study|Lost to Follow-up|0
6330651|NCT03026257|10076869|FG002|Overall Study|Lost to Follow-up|0
6330652|NCT03026257|10076870|FG003|Overall Study|Lost to Follow-up|0
6330653|NCT03026257|10076871|FG004|Overall Study|Lost to Follow-up|0
6330654|NCT03026257|10076872|FG005|Overall Study|Lost to Follow-up|0
6330655|NCT03026257|10076867|FG000|Overall Study|Protocol Violation|1
6330656|NCT03026257|10076868|FG001|Overall Study|Protocol Violation|0
6330657|NCT03026257|10076869|FG002|Overall Study|Protocol Violation|0
6330658|NCT03026257|10076870|FG003|Overall Study|Protocol Violation|1
6330659|NCT03026257|10076871|FG004|Overall Study|Protocol Violation|1
6330660|NCT03026257|10076872|FG005|Overall Study|Protocol Violation|0
6330661|NCT03026257|10076867|FG000|Overall Study|Withdrawal by Subject|1
6330662|NCT03026257|10076868|FG001|Overall Study|Withdrawal by Subject|1
6330663|NCT03026257|10076869|FG002|Overall Study|Withdrawal by Subject|0
6330664|NCT03026257|10076870|FG003|Overall Study|Withdrawal by Subject|0
6330665|NCT03026257|10076871|FG004|Overall Study|Withdrawal by Subject|0
6082823|NCT00631657|9690954|FG000|6-Month Treatment Period|Uncooperative Reasons Unrelated to Trial|21
6082824|NCT00631657|9690955|FG001|6-Month Treatment Period|Uncooperative Reasons Unrelated to Trial|0
6082825|NCT00631657|9690956|FG002|6-Month Treatment Period|Uncooperative Reasons Unrelated to Trial|6
6330666|NCT03026257|10076872|FG005|Overall Study|Withdrawal by Subject|0
6330667|NCT03026283|10076886|FG000|CCTA Diagnosis|CCTA not performed as planned|9
6330668|NCT03026283|10076887|FG001|CCTA Diagnosis|CCTA not performed as planned|0
6330669|NCT03026283|10076888|FG002|CCTA Diagnosis|CCTA not performed as planned|0
6330670|NCT03026283|10076889|FG003|CCTA Diagnosis|CCTA not performed as planned|0
6330671|NCT03026283|10076890|FG004|CCTA Diagnosis|CCTA not performed as planned|0
6330672|NCT03026283|10076891|FG005|CCTA Diagnosis|CCTA not performed as planned|0
6330673|NCT03026283|10076892|FG006|CCTA Diagnosis|CCTA not performed as planned|0
6330674|NCT03026283|10076893|FG007|CCTA Diagnosis|CCTA not performed as planned|0
6330675|NCT03026283|10076886|FG000|CCTA Diagnosis|Withdrawal by Subject|5
6330676|NCT03026283|10076887|FG001|CCTA Diagnosis|Withdrawal by Subject|0
6330677|NCT03026283|10076888|FG002|CCTA Diagnosis|Withdrawal by Subject|0
6330678|NCT03026283|10076889|FG003|CCTA Diagnosis|Withdrawal by Subject|0
6330679|NCT03026283|10076890|FG004|CCTA Diagnosis|Withdrawal by Subject|0
6330680|NCT03026283|10076891|FG005|CCTA Diagnosis|Withdrawal by Subject|0
6330681|NCT03026283|10076892|FG006|CCTA Diagnosis|Withdrawal by Subject|0
6330682|NCT03026283|10076893|FG007|CCTA Diagnosis|Withdrawal by Subject|0
6330683|NCT03026283|10076886|FG000|Optimal Medical Care/FFR-CT Diagnosis|Screen Failure: Enrollment Criteria|0
6330684|NCT03026283|10076887|FG001|Optimal Medical Care/FFR-CT Diagnosis|Screen Failure: Enrollment Criteria|3
6330685|NCT03026283|10076888|FG002|Optimal Medical Care/FFR-CT Diagnosis|Screen Failure: Enrollment Criteria|0
6330686|NCT03026283|10076889|FG003|Optimal Medical Care/FFR-CT Diagnosis|Screen Failure: Enrollment Criteria|0
6330687|NCT03026283|10076890|FG004|Optimal Medical Care/FFR-CT Diagnosis|Screen Failure: Enrollment Criteria|0
6330688|NCT03026283|10076891|FG005|Optimal Medical Care/FFR-CT Diagnosis|Screen Failure: Enrollment Criteria|0
6330689|NCT03026283|10076892|FG006|Optimal Medical Care/FFR-CT Diagnosis|Screen Failure: Enrollment Criteria|0
6330690|NCT03026283|10076893|FG007|Optimal Medical Care/FFR-CT Diagnosis|Screen Failure: Enrollment Criteria|0
6330691|NCT03026283|10076886|FG000|Optimal Medical Care/FFR-CT Diagnosis|FFRCT Nondiagnostic|0
6330692|NCT03026283|10076887|FG001|Optimal Medical Care/FFR-CT Diagnosis|FFRCT Nondiagnostic|0
6330693|NCT03026283|10076888|FG002|Optimal Medical Care/FFR-CT Diagnosis|FFRCT Nondiagnostic|15
6330694|NCT03026283|10076889|FG003|Optimal Medical Care/FFR-CT Diagnosis|FFRCT Nondiagnostic|0
6330695|NCT03026283|10076890|FG004|Optimal Medical Care/FFR-CT Diagnosis|FFRCT Nondiagnostic|0
6330696|NCT03026283|10076891|FG005|Optimal Medical Care/FFR-CT Diagnosis|FFRCT Nondiagnostic|0
6330697|NCT03026283|10076892|FG006|Optimal Medical Care/FFR-CT Diagnosis|FFRCT Nondiagnostic|0
6330698|NCT03026283|10076893|FG007|Optimal Medical Care/FFR-CT Diagnosis|FFRCT Nondiagnostic|0
6330699|NCT03026283|10076886|FG000|Optimal Care/Stress Test/ICA|Referring MD ordered diagnostic cath|0
6330700|NCT03026283|10076887|FG001|Optimal Care/Stress Test/ICA|Referring MD ordered diagnostic cath|0
6330701|NCT03026283|10076888|FG002|Optimal Care/Stress Test/ICA|Referring MD ordered diagnostic cath|0
6330702|NCT03026283|10076889|FG003|Optimal Care/Stress Test/ICA|Referring MD ordered diagnostic cath|8
6330703|NCT03026283|10076890|FG004|Optimal Care/Stress Test/ICA|Referring MD ordered diagnostic cath|11
6330704|NCT03026283|10076891|FG005|Optimal Care/Stress Test/ICA|Referring MD ordered diagnostic cath|0
6330705|NCT03026283|10076892|FG006|Optimal Care/Stress Test/ICA|Referring MD ordered diagnostic cath|0
6330706|NCT03026283|10076893|FG007|Optimal Care/Stress Test/ICA|Referring MD ordered diagnostic cath|0
6330707|NCT03026283|10076886|FG000|Optimal Care/Stress Test/ICA|Lost to Follow-up|0
6330708|NCT03026283|10076887|FG001|Optimal Care/Stress Test/ICA|Lost to Follow-up|0
6330709|NCT03026283|10076888|FG002|Optimal Care/Stress Test/ICA|Lost to Follow-up|0
6330710|NCT03026283|10076889|FG003|Optimal Care/Stress Test/ICA|Lost to Follow-up|9
6330711|NCT03026283|10076890|FG004|Optimal Care/Stress Test/ICA|Lost to Follow-up|2
6330712|NCT03026283|10076891|FG005|Optimal Care/Stress Test/ICA|Lost to Follow-up|2
6330713|NCT03026283|10076892|FG006|Optimal Care/Stress Test/ICA|Lost to Follow-up|0
6330714|NCT03026283|10076893|FG007|Optimal Care/Stress Test/ICA|Lost to Follow-up|0
6330715|NCT03026283|10076886|FG000|Optimal Care/Stress Test/ICA|Referring MD ordered stress test|0
6330716|NCT03026283|10076887|FG001|Optimal Care/Stress Test/ICA|Referring MD ordered stress test|0
6330717|NCT03026283|10076888|FG002|Optimal Care/Stress Test/ICA|Referring MD ordered stress test|0
6330718|NCT03026283|10076889|FG003|Optimal Care/Stress Test/ICA|Referring MD ordered stress test|2
6330719|NCT03026283|10076890|FG004|Optimal Care/Stress Test/ICA|Referring MD ordered stress test|0
6330720|NCT03026283|10076891|FG005|Optimal Care/Stress Test/ICA|Referring MD ordered stress test|7
6330721|NCT03026283|10076892|FG006|Optimal Care/Stress Test/ICA|Referring MD ordered stress test|0
6330722|NCT03026283|10076893|FG007|Optimal Care/Stress Test/ICA|Referring MD ordered stress test|0
6330723|NCT03026283|10076886|FG000|Optimal Care/Stress Test/ICA|Withdrawal by Subject|0
6330724|NCT03026283|10076887|FG001|Optimal Care/Stress Test/ICA|Withdrawal by Subject|0
6330725|NCT03026283|10076888|FG002|Optimal Care/Stress Test/ICA|Withdrawal by Subject|0
6330726|NCT03026283|10076889|FG003|Optimal Care/Stress Test/ICA|Withdrawal by Subject|1
6330727|NCT03026283|10076890|FG004|Optimal Care/Stress Test/ICA|Withdrawal by Subject|0
6330728|NCT03026283|10076891|FG005|Optimal Care/Stress Test/ICA|Withdrawal by Subject|0
6330729|NCT03026283|10076892|FG006|Optimal Care/Stress Test/ICA|Withdrawal by Subject|0
6330730|NCT03026283|10076893|FG007|Optimal Care/Stress Test/ICA|Withdrawal by Subject|0
6330731|NCT03026283|10076886|FG000|Optimal Care/Stress Test/ICA|Referring MD used only optimal med care|0
6330732|NCT03026283|10076887|FG001|Optimal Care/Stress Test/ICA|Referring MD used only optimal med care|0
6330733|NCT03026283|10076888|FG002|Optimal Care/Stress Test/ICA|Referring MD used only optimal med care|0
6330734|NCT03026283|10076889|FG003|Optimal Care/Stress Test/ICA|Referring MD used only optimal med care|0
6330735|NCT03026283|10076890|FG004|Optimal Care/Stress Test/ICA|Referring MD used only optimal med care|25
6330736|NCT03026283|10076891|FG005|Optimal Care/Stress Test/ICA|Referring MD used only optimal med care|19
6330737|NCT03026283|10076892|FG006|Optimal Care/Stress Test/ICA|Referring MD used only optimal med care|0
6330738|NCT03026283|10076893|FG007|Optimal Care/Stress Test/ICA|Referring MD used only optimal med care|0
6330739|NCT03026530|10076908|FG000|Overall Study|Lost to Follow-up|19
6330740|NCT03026530|10076909|FG001|Overall Study|Lost to Follow-up|24
6330741|NCT03026530|10076908|FG000|Overall Study|Protocol Violation|2
6330742|NCT03026530|10076909|FG001|Overall Study|Protocol Violation|5
6330743|NCT03027466|10076946|FG000|Overall Study|Opting out of the app|1869
6330744|NCT03027466|10076947|FG001|Overall Study|Opting out of the app|1819
6330745|NCT03027466|10076948|FG002|Overall Study|Opting out of the app|1743
6330746|NCT03027466|10076949|FG003|Overall Study|Opting out of the app|1821
6330747|NCT03027557|10076962|FG000|Overall Study|Adverse Event|1
6330748|NCT03027557|10076963|FG001|Overall Study|Adverse Event|0
6330749|NCT03027557|10076964|FG002|Overall Study|Adverse Event|0
6330750|NCT03028012|10076984|FG000|Overall Study|Lost to Follow-up|2
6330751|NCT03028012|10076985|FG001|Overall Study|Lost to Follow-up|3
6330752|NCT03028012|10076986|FG002|Overall Study|Lost to Follow-up|3
6330753|NCT03028129|10077019|FG000|Overall Study|Adverse Event|13
6330754|NCT03028129|10077020|FG001|Overall Study|Adverse Event|2
6330755|NCT03028129|10077019|FG000|Overall Study|Lost to Follow-up|50
6330756|NCT03028129|10077020|FG001|Overall Study|Lost to Follow-up|38
6330757|NCT03028129|10077019|FG000|Overall Study|Physician Decision|0
6330758|NCT03028129|10077020|FG001|Overall Study|Physician Decision|1
6330759|NCT03028129|10077019|FG000|Overall Study|Protocol Violation|1
6330760|NCT03028129|10077020|FG001|Overall Study|Protocol Violation|1
6330761|NCT03028129|10077019|FG000|Overall Study|Withdrawal by Subject|62
6330762|NCT03028129|10077020|FG001|Overall Study|Withdrawal by Subject|45
6330763|NCT03028142|10077026|FG000|Overall Study|Adverse Event|1
6330764|NCT03028142|10077027|FG001|Overall Study|Adverse Event|1
6330765|NCT03028142|10077028|FG002|Overall Study|Adverse Event|0
6330766|NCT03028142|10077029|FG003|Overall Study|Adverse Event|0
6330767|NCT03028142|10077030|FG004|Overall Study|Adverse Event|0
6330768|NCT03028142|10077031|FG005|Overall Study|Adverse Event|1
6330769|NCT03028142|10077026|FG000|Overall Study|Withdrawal by Subject|0
6330770|NCT03028142|10077027|FG001|Overall Study|Withdrawal by Subject|0
6330771|NCT03028142|10077028|FG002|Overall Study|Withdrawal by Subject|0
6330772|NCT03028142|10077029|FG003|Overall Study|Withdrawal by Subject|0
6330773|NCT03028142|10077030|FG004|Overall Study|Withdrawal by Subject|1
6330774|NCT03028142|10077031|FG005|Overall Study|Withdrawal by Subject|0
6330775|NCT03028415|10077064|FG000|Overall Study|Lost to Follow-up|6
6330776|NCT03028415|10077065|FG001|Overall Study|Lost to Follow-up|3
6330777|NCT03028415|10077064|FG000|Overall Study|Withdrawal by Subject|1
6330778|NCT03028415|10077065|FG001|Overall Study|Withdrawal by Subject|0
6330779|NCT03028415|10077064|FG000|Overall Study|Discontinued due to COVID-19|1
6330780|NCT03028415|10077065|FG001|Overall Study|Discontinued due to COVID-19|0
6330781|NCT03028870|10077105|FG000|Overall Study|Adverse Event|7
6330782|NCT03028870|10077106|FG001|Overall Study|Adverse Event|4
6330783|NCT03028870|10077107|FG002|Overall Study|Adverse Event|3
6330784|NCT03028870|10077108|FG003|Overall Study|Adverse Event|3
6330785|NCT03028870|10077105|FG000|Overall Study|Withdrawal by Subject|1
6330786|NCT03028870|10077106|FG001|Overall Study|Withdrawal by Subject|1
6330787|NCT03028870|10077107|FG002|Overall Study|Withdrawal by Subject|1
6330788|NCT03028870|10077108|FG003|Overall Study|Withdrawal by Subject|2
6330789|NCT03028870|10077105|FG000|Overall Study|Lost to Follow-up|1
6330790|NCT03028870|10077106|FG001|Overall Study|Lost to Follow-up|0
6330791|NCT03028870|10077107|FG002|Overall Study|Lost to Follow-up|0
6330792|NCT03028870|10077108|FG003|Overall Study|Lost to Follow-up|0
6330793|NCT03028870|10077105|FG000|Overall Study|Lack of Efficacy|3
6330794|NCT03028870|10077106|FG001|Overall Study|Lack of Efficacy|0
6330795|NCT03028870|10077107|FG002|Overall Study|Lack of Efficacy|0
6330796|NCT03028870|10077108|FG003|Overall Study|Lack of Efficacy|0
6330797|NCT03028870|10077105|FG000|Overall Study|Administrative|5
6330798|NCT03028870|10077106|FG001|Overall Study|Administrative|5
6330799|NCT03028870|10077107|FG002|Overall Study|Administrative|12
6330800|NCT03028870|10077108|FG003|Overall Study|Administrative|4
6330801|NCT03029143|10077162|FG000|Lead-in Period (6 Weeks)|Pretreatment Event/Adverse Event|8
6330802|NCT03029143|10077163|FG001|Lead-in Period (6 Weeks)|Pretreatment Event/Adverse Event|0
6330803|NCT03029143|10077164|FG002|Lead-in Period (6 Weeks)|Pretreatment Event/Adverse Event|0
6330804|NCT03029143|10077162|FG000|Lead-in Period (6 Weeks)|Significant Protocol Deviation|12
6330805|NCT03029143|10077163|FG001|Lead-in Period (6 Weeks)|Significant Protocol Deviation|0
6330806|NCT03029143|10077164|FG002|Lead-in Period (6 Weeks)|Significant Protocol Deviation|0
6330807|NCT03029143|10077162|FG000|Lead-in Period (6 Weeks)|Lost to Follow-up|1
6330808|NCT03029143|10077163|FG001|Lead-in Period (6 Weeks)|Lost to Follow-up|0
6330809|NCT03029143|10077164|FG002|Lead-in Period (6 Weeks)|Lost to Follow-up|0
6330810|NCT03029143|10077162|FG000|Lead-in Period (6 Weeks)|Voluntary Withdrawal|6
6330811|NCT03029143|10077163|FG001|Lead-in Period (6 Weeks)|Voluntary Withdrawal|0
6330812|NCT03029143|10077164|FG002|Lead-in Period (6 Weeks)|Voluntary Withdrawal|0
6330813|NCT03029143|10077162|FG000|Lead-in Period (6 Weeks)|Randomized but not Treated|142
6330814|NCT03029143|10077163|FG001|Lead-in Period (6 Weeks)|Randomized but not Treated|0
6330815|NCT03029143|10077164|FG002|Lead-in Period (6 Weeks)|Randomized but not Treated|0
6330816|NCT03029143|10077162|FG000|Randomized Treatment Period (24 Weeks)|Pretreatment Event/Adverse Event|0
6330817|NCT03029143|10077163|FG001|Randomized Treatment Period (24 Weeks)|Pretreatment Event/Adverse Event|3
6330818|NCT03029143|10077164|FG002|Randomized Treatment Period (24 Weeks)|Pretreatment Event/Adverse Event|9
6330819|NCT03029143|10077162|FG000|Randomized Treatment Period (24 Weeks)|Significant Protocol Deviation|0
6330820|NCT03029143|10077163|FG001|Randomized Treatment Period (24 Weeks)|Significant Protocol Deviation|1
6330821|NCT03029143|10077164|FG002|Randomized Treatment Period (24 Weeks)|Significant Protocol Deviation|3
6330822|NCT03029143|10077162|FG000|Randomized Treatment Period (24 Weeks)|Lost to Follow-up|0
6330823|NCT03029143|10077163|FG001|Randomized Treatment Period (24 Weeks)|Lost to Follow-up|1
6330824|NCT03029143|10077164|FG002|Randomized Treatment Period (24 Weeks)|Lost to Follow-up|3
6330825|NCT03029143|10077162|FG000|Randomized Treatment Period (24 Weeks)|Voluntary Withdrawal|0
6330826|NCT03029143|10077163|FG001|Randomized Treatment Period (24 Weeks)|Voluntary Withdrawal|10
6330827|NCT03029143|10077164|FG002|Randomized Treatment Period (24 Weeks)|Voluntary Withdrawal|1
6330828|NCT03029143|10077162|FG000|Randomized Treatment Period (24 Weeks)|Lack of Efficacy|0
6330829|NCT03029143|10077163|FG001|Randomized Treatment Period (24 Weeks)|Lack of Efficacy|6
6330830|NCT03029143|10077164|FG002|Randomized Treatment Period (24 Weeks)|Lack of Efficacy|7
6330831|NCT03029143|10077162|FG000|Randomized Treatment Period (24 Weeks)|Reason not Specified|0
6330832|NCT03029143|10077163|FG001|Randomized Treatment Period (24 Weeks)|Reason not Specified|2
6330833|NCT03029143|10077164|FG002|Randomized Treatment Period (24 Weeks)|Reason not Specified|1
6330834|NCT03029208|10077175|FG000|Overall Study|Withdrawal by Subject|2
6330835|NCT03029208|10077176|FG001|Overall Study|Withdrawal by Subject|3
6330836|NCT03029208|10077175|FG000|Overall Study|Lost to Follow-up|0
6330837|NCT03029208|10077176|FG001|Overall Study|Lost to Follow-up|1
6330838|NCT03029247|10077193|FG000|Hgb Maintenance Phase (8 Weeks)|Withdrawal by Subject|3
6330839|NCT03029247|10077194|FG001|Hgb Maintenance Phase (8 Weeks)|Withdrawal by Subject|0
6330840|NCT03029247|10077193|FG000|Hgb Maintenance Phase (8 Weeks)|Physician Decision|1
6330841|NCT03029247|10077194|FG001|Hgb Maintenance Phase (8 Weeks)|Physician Decision|1
6330842|NCT03029247|10077193|FG000|Hgb Maintenance Phase (8 Weeks)|Protocol-specified withdrawal criterion|7
6330843|NCT03029247|10077194|FG001|Hgb Maintenance Phase (8 Weeks)|Protocol-specified withdrawal criterion|4
6330844|NCT03029247|10077193|FG000|Hgb Maintenance Phase (8 Weeks)|Adverse Event|2
6330845|NCT03029247|10077194|FG001|Hgb Maintenance Phase (8 Weeks)|Adverse Event|2
6330846|NCT03029585|10077202|FG000|Overall Study|Death|1
6330847|NCT03029585|10077203|FG001|Overall Study|Death|1
6330848|NCT03029585|10077202|FG000|Overall Study|Withdrawal by Subject|1
6330849|NCT03029585|10077203|FG001|Overall Study|Withdrawal by Subject|0
6330850|NCT03029624|10077209|FG000|Overall Study|Adverse Event|1
6330851|NCT03029624|10077209|FG000|Overall Study|Withdrawal by Subject|1
6330852|NCT03029624|10077209|FG000|Overall Study|Lack of Efficacy|1
6330853|NCT03029624|10077209|FG000|Overall Study|MRI need|2
6330854|NCT03029650|10077215|FG000|Washout (1 Week)|Withdrawal by Subject|1
6330855|NCT03029650|10077216|FG001|Washout (1 Week)|Withdrawal by Subject|1
6330856|NCT03029650|10077215|FG000|Washout (1 Week)|Physician Decision|0
6330857|NCT03029650|10077216|FG001|Washout (1 Week)|Physician Decision|1
6330858|NCT03029780|10077237|FG000|Overall Study|Disease Progression|1
6330859|NCT03029780|10077238|FG001|Overall Study|Disease Progression|3
6330860|NCT03029780|10077237|FG000|Overall Study|Study Drug Toxicity|5
6330861|NCT03029780|10077238|FG001|Overall Study|Study Drug Toxicity|5
6330862|NCT03029780|10077237|FG000|Overall Study|Adverse Event Unrelated to Study Drug|0
6330863|NCT03029780|10077238|FG001|Overall Study|Adverse Event Unrelated to Study Drug|3
6330864|NCT03029819|10077246|FG000|Overall Study|Lost to Follow-up|3
6330865|NCT03029819|10077247|FG001|Overall Study|Lost to Follow-up|5
6330866|NCT03029819|10077246|FG000|Overall Study|Removed due to disruptive behavior|0
6330867|NCT03029819|10077247|FG001|Overall Study|Removed due to disruptive behavior|1
6330868|NCT03030599|10077265|FG000|Open Label Treatment and Titration|Protocol deviation|8
6330869|NCT03030599|10077266|FG001|Open Label Treatment and Titration|Protocol deviation|0
6330870|NCT03030599|10077267|FG002|Open Label Treatment and Titration|Protocol deviation|0
6330871|NCT03030599|10077265|FG000|Open Label Treatment and Titration|Other|1
6330872|NCT03030599|10077266|FG001|Open Label Treatment and Titration|Other|0
6330873|NCT03030599|10077267|FG002|Open Label Treatment and Titration|Other|0
6330874|NCT03030599|10077265|FG000|Open Label Treatment and Titration|Physician Decision|3
6330875|NCT03030599|10077266|FG001|Open Label Treatment and Titration|Physician Decision|0
6330876|NCT03030599|10077267|FG002|Open Label Treatment and Titration|Physician Decision|0
6330877|NCT03030599|10077265|FG000|Open Label Treatment and Titration|Lack of Efficacy|1
6330878|NCT03030599|10077266|FG001|Open Label Treatment and Titration|Lack of Efficacy|0
6330879|NCT03030599|10077267|FG002|Open Label Treatment and Titration|Lack of Efficacy|0
6330880|NCT03030599|10077265|FG000|Open Label Treatment and Titration|Non-Compliance with Study Drug|4
6330881|NCT03030599|10077266|FG001|Open Label Treatment and Titration|Non-Compliance with Study Drug|0
6330882|NCT03030599|10077267|FG002|Open Label Treatment and Titration|Non-Compliance with Study Drug|0
6330883|NCT03030599|10077265|FG000|Open Label Treatment and Titration|Adverse Event|18
6330884|NCT03030599|10077266|FG001|Open Label Treatment and Titration|Adverse Event|0
6330885|NCT03030599|10077267|FG002|Open Label Treatment and Titration|Adverse Event|0
6330886|NCT03030599|10077265|FG000|Open Label Treatment and Titration|Withdrawal by Subject|6
6330887|NCT03030599|10077266|FG001|Open Label Treatment and Titration|Withdrawal by Subject|0
6330888|NCT03030599|10077267|FG002|Open Label Treatment and Titration|Withdrawal by Subject|0
6082826|NCT00631657|9690954|FG000|6-Month Treatment Period|Other|16
6167183|NCT01226511|9811633|FG000|Acute Treatment Period|Withdrawal by Subject|10
6330889|NCT03030599|10077265|FG000|Open Label Treatment and Titration|Sponsor decision|2
6330890|NCT03030599|10077266|FG001|Open Label Treatment and Titration|Sponsor decision|0
6330891|NCT03030599|10077267|FG002|Open Label Treatment and Titration|Sponsor decision|0
6330892|NCT03030599|10077265|FG000|Open Label Treatment and Titration|Lost to Follow-up|3
6330893|NCT03030599|10077266|FG001|Open Label Treatment and Titration|Lost to Follow-up|0
6330894|NCT03030599|10077267|FG002|Open Label Treatment and Titration|Lost to Follow-up|0
6330895|NCT03030599|10077265|FG000|Stable Dose|Protocol deviation|3
6330896|NCT03030599|10077266|FG001|Stable Dose|Protocol deviation|0
6330897|NCT03030599|10077267|FG002|Stable Dose|Protocol deviation|0
6330898|NCT03030599|10077265|FG000|Stable Dose|Adverse Event|1
6330899|NCT03030599|10077266|FG001|Stable Dose|Adverse Event|0
6330900|NCT03030599|10077267|FG002|Stable Dose|Adverse Event|0
6330901|NCT03030599|10077265|FG000|Stable Dose|Lost to Follow-up|1
6330902|NCT03030599|10077266|FG001|Stable Dose|Lost to Follow-up|0
6330903|NCT03030599|10077267|FG002|Stable Dose|Lost to Follow-up|0
6330904|NCT03030599|10077265|FG000|Double Blind Randomized Withdrawal|Lack of Efficacy|0
6330905|NCT03030599|10077266|FG001|Double Blind Randomized Withdrawal|Lack of Efficacy|0
6330906|NCT03030599|10077267|FG002|Double Blind Randomized Withdrawal|Lack of Efficacy|2
6330907|NCT03030599|10077265|FG000|Double Blind Randomized Withdrawal|Adverse Event|0
6330908|NCT03030599|10077266|FG001|Double Blind Randomized Withdrawal|Adverse Event|0
6330909|NCT03030599|10077267|FG002|Double Blind Randomized Withdrawal|Adverse Event|3
6330910|NCT03030599|10077265|FG000|Double Blind Randomized Withdrawal|Randomized in error|0
6330911|NCT03030599|10077266|FG001|Double Blind Randomized Withdrawal|Randomized in error|0
6330912|NCT03030599|10077267|FG002|Double Blind Randomized Withdrawal|Randomized in error|2
6330913|NCT03030599|10077265|FG000|Double Blind Randomized Withdrawal|Withdrawal by Subject|0
6330914|NCT03030599|10077266|FG001|Double Blind Randomized Withdrawal|Withdrawal by Subject|0
6330915|NCT03030599|10077267|FG002|Double Blind Randomized Withdrawal|Withdrawal by Subject|1
6330916|NCT03030599|10077265|FG000|Open-label Extension|Adverse Event|3
6330917|NCT03030599|10077266|FG001|Open-label Extension|Adverse Event|0
6330918|NCT03030599|10077267|FG002|Open-label Extension|Adverse Event|0
6330919|NCT03030599|10077265|FG000|Open-label Extension|Lost to Follow-up|2
6330920|NCT03030599|10077266|FG001|Open-label Extension|Lost to Follow-up|0
6330921|NCT03030599|10077267|FG002|Open-label Extension|Lost to Follow-up|0
6330922|NCT03030599|10077265|FG000|Open-label Extension|Lack of Efficacy|1
6330923|NCT03030599|10077266|FG001|Open-label Extension|Lack of Efficacy|0
6330924|NCT03030599|10077267|FG002|Open-label Extension|Lack of Efficacy|0
6330925|NCT03030599|10077265|FG000|Open-label Extension|Other Reason|1
6330926|NCT03030599|10077266|FG001|Open-label Extension|Other Reason|0
6330927|NCT03030599|10077267|FG002|Open-label Extension|Other Reason|0
6330928|NCT03030989|10077310|FG000|Overall Study|Fever|2
6330929|NCT03030989|10077311|FG001|Overall Study|Fever|2
6330930|NCT03030989|10077310|FG000|Overall Study|Rash|2
6330931|NCT03030989|10077311|FG001|Overall Study|Rash|1
6330932|NCT03030989|10077310|FG000|Overall Study|Fatigue/Overwhelmed|1
6330933|NCT03030989|10077311|FG001|Overall Study|Fatigue/Overwhelmed|5
6330934|NCT03030989|10077310|FG000|Overall Study|Positive Blood Cultures|2
6330935|NCT03030989|10077311|FG001|Overall Study|Positive Blood Cultures|1
6330936|NCT03030989|10077310|FG000|Overall Study|Line Removed|0
6330937|NCT03030989|10077311|FG001|Overall Study|Line Removed|2
6330938|NCT03030989|10077310|FG000|Overall Study|No longer interested|5
6330939|NCT03030989|10077311|FG001|Overall Study|No longer interested|3
6330940|NCT03031431|10077317|FG000|Overall Study|Infant removed by maternal request|1
6330941|NCT03031496|10077321|FG000|Period 1|Adverse Event|2
6330942|NCT03031496|10077322|FG001|Period 1|Adverse Event|0
6330943|NCT03031496|10077321|FG000|Period 1|Withdrawal by Subject|0
6330944|NCT03031496|10077322|FG001|Period 1|Withdrawal by Subject|2
6330945|NCT03031678|10077328|FG000|Overall Study|Study closed prior to completion|1
6330946|NCT03031899|10077345|FG000|Overall Study|Protocol Violation|1
6330947|NCT03031899|10077345|FG000|Overall Study|lesion disappeared after stopping habit|1
6330948|NCT03031938|10077355|FG000|Overall Study|Death|1
6330949|NCT03031938|10077356|FG001|Overall Study|Death|0
6330950|NCT03032380|10077373|FG000|Overall Study|Adverse Event|0
6330951|NCT03032380|10077374|FG001|Overall Study|Adverse Event|1
6330952|NCT03032380|10077373|FG000|Overall Study|Lack of Efficacy|1
6330953|NCT03032380|10077374|FG001|Overall Study|Lack of Efficacy|0
6330954|NCT03032380|10077373|FG000|Overall Study|Withdrawal by Subject|2
6330955|NCT03032380|10077374|FG001|Overall Study|Withdrawal by Subject|3
6330956|NCT03032380|10077373|FG000|Overall Study|Recovery|0
6330957|NCT03032380|10077374|FG001|Overall Study|Recovery|1
6330958|NCT03032380|10077373|FG000|Overall Study|Death|39
6330959|NCT03032380|10077374|FG001|Overall Study|Death|34
6330960|NCT03032380|10077373|FG000|Overall Study|Other - Miscellaneous|0
6330961|NCT03032380|10077374|FG001|Overall Study|Other - Miscellaneous|1
6330962|NCT03032523|10077391|FG000|Overall Study|Withdrawal by Subject|2
6330963|NCT03032523|10077392|FG001|Overall Study|Withdrawal by Subject|2
6330964|NCT03032523|10077391|FG000|Overall Study|Physician Decision|1
6330965|NCT03032523|10077392|FG001|Overall Study|Physician Decision|0
6330966|NCT03033394|10077432|FG000|Completed Pharmacokinetic Analysis|Missing data|1
6330967|NCT03033394|10077432|FG000|Completed Pharmacokinetic Analysis|Oral dosing not incorporated into pharmacokinetic model|3
6330968|NCT03033394|10077432|FG000|Completed Pharmacokinetic Analysis|Level taken at incorrect time|1
6330969|NCT03033394|10077432|FG000|Completed Pharmacokinetic Analysis|Pharmacokinetic soffware unable to generate predicted values|1
6330970|NCT03033394|10077432|FG000|Completed Final Analysis|1 participant excluded from final analysis as an outlier (>1.5 x interquartile range)|1
6330971|NCT03033745|10077453|FG000|Overall Study|Protocol Violation|0
6330972|NCT03033745|10077454|FG001|Overall Study|Protocol Violation|0
6330973|NCT03033745|10077455|FG002|Overall Study|Protocol Violation|1
6330974|NCT03033745|10077453|FG000|Overall Study|Adverse Event|1
6330975|NCT03033745|10077454|FG001|Overall Study|Adverse Event|0
6330976|NCT03033745|10077455|FG002|Overall Study|Adverse Event|1
6330977|NCT03033745|10077453|FG000|Overall Study|Withdrawal by Subject|0
6330978|NCT03033745|10077454|FG001|Overall Study|Withdrawal by Subject|1
6330979|NCT03033745|10077455|FG002|Overall Study|Withdrawal by Subject|0
6330980|NCT03033784|10077472|FG000|Overall Study|Anxiety related to MRI scanner|0
6330981|NCT03033784|10077473|FG001|Overall Study|Anxiety related to MRI scanner|1
6330982|NCT03033784|10077474|FG002|Overall Study|Anxiety related to MRI scanner|0
6330983|NCT03033784|10077475|FG003|Overall Study|Anxiety related to MRI scanner|0
6330984|NCT03033784|10077476|FG004|Overall Study|Anxiety related to MRI scanner|0
6330985|NCT03033784|10077477|FG005|Overall Study|Anxiety related to MRI scanner|0
6330986|NCT03033784|10077478|FG006|Overall Study|Anxiety related to MRI scanner|0
6330987|NCT03033784|10077479|FG007|Overall Study|Anxiety related to MRI scanner|0
6330988|NCT03033784|10077480|FG008|Overall Study|Anxiety related to MRI scanner|0
6330989|NCT03033784|10077481|FG009|Overall Study|Anxiety related to MRI scanner|0
6330990|NCT03033784|10077482|FG010|Overall Study|Anxiety related to MRI scanner|0
6330991|NCT03033784|10077483|FG011|Overall Study|Anxiety related to MRI scanner|0
6330992|NCT03033784|10077484|FG012|Overall Study|Anxiety related to MRI scanner|0
6330993|NCT03033784|10077472|FG000|Overall Study|Withdrawal by Subject|0
6330994|NCT03033784|10077473|FG001|Overall Study|Withdrawal by Subject|0
6330995|NCT03033784|10077474|FG002|Overall Study|Withdrawal by Subject|0
6330996|NCT03033784|10077475|FG003|Overall Study|Withdrawal by Subject|0
6330997|NCT03033784|10077476|FG004|Overall Study|Withdrawal by Subject|0
6330998|NCT03033784|10077477|FG005|Overall Study|Withdrawal by Subject|0
6330999|NCT03033784|10077478|FG006|Overall Study|Withdrawal by Subject|0
6331000|NCT03033784|10077479|FG007|Overall Study|Withdrawal by Subject|0
6331001|NCT03033784|10077480|FG008|Overall Study|Withdrawal by Subject|0
6331002|NCT03033784|10077481|FG009|Overall Study|Withdrawal by Subject|0
6331003|NCT03033784|10077482|FG010|Overall Study|Withdrawal by Subject|0
6331004|NCT03033784|10077483|FG011|Overall Study|Withdrawal by Subject|0
6331005|NCT03033784|10077484|FG012|Overall Study|Withdrawal by Subject|2
6331006|NCT03034044|10077495|FG000|Overall Study|Enrolled, but not received Xyntha|1
6331007|NCT03034057|10077499|FG000|Overall Study|Withdrawal by Subject|10
6331008|NCT03034057|10077499|FG000|Overall Study|Protocol Violation|1
6331009|NCT03034057|10077499|FG000|Overall Study|Not defined|2
6331010|NCT03034057|10077499|FG000|Overall Study|Lost to Follow-up|19
6331011|NCT03034057|10077499|FG000|Overall Study|Adverse Event|22
6331012|NCT03034057|10077499|FG000|Overall Study|Medication error without associated AE|1
6331013|NCT03034135|10077503|FG000|Overall Study|Withdrawal by Subject|2
6331014|NCT03034460|10077509|FG000|Overall Study|Adverse Event|0
6331015|NCT03034460|10077510|FG001|Overall Study|Adverse Event|1
6331016|NCT03034460|10077509|FG000|Overall Study|Withdrawal by Subject|2
6331017|NCT03034460|10077510|FG001|Overall Study|Withdrawal by Subject|2
6331018|NCT03034460|10077509|FG000|Overall Study|Personal Reasons|1
6331019|NCT03034460|10077510|FG001|Overall Study|Personal Reasons|0
6331020|NCT03034577|10077522|FG000|Overall Study|Withdrawal by Subject|6
6331021|NCT03034577|10077523|FG001|Overall Study|Withdrawal by Subject|9
6331022|NCT03034577|10077522|FG000|Overall Study|Lost to Follow-up|25
6331023|NCT03034577|10077523|FG001|Overall Study|Lost to Follow-up|26
6331024|NCT03034772|10077533|FG000|Overall Study|Adverse Event|0
6331025|NCT03034772|10077534|FG001|Overall Study|Adverse Event|1
6331026|NCT03034772|10077533|FG000|Overall Study|Withdrawal by Subject|0
6331027|NCT03034772|10077534|FG001|Overall Study|Withdrawal by Subject|1
6331028|NCT03034915|10077543|FG000|Overall Study|Adverse Event|29
6331029|NCT03034915|10077544|FG001|Overall Study|Adverse Event|32
6331030|NCT03034915|10077545|FG002|Overall Study|Adverse Event|22
6331031|NCT03034915|10077543|FG000|Overall Study|Lost to Follow-up|5
6331032|NCT03034915|10077544|FG001|Overall Study|Lost to Follow-up|13
6331033|NCT03034915|10077545|FG002|Overall Study|Lost to Follow-up|3
6331034|NCT03034915|10077543|FG000|Overall Study|Withdrawal by Subject|29
6331035|NCT03034915|10077544|FG001|Overall Study|Withdrawal by Subject|46
6331036|NCT03034915|10077545|FG002|Overall Study|Withdrawal by Subject|41
6331037|NCT03034915|10077543|FG000|Overall Study|Protocol Deviation|2
6331038|NCT03034915|10077544|FG001|Overall Study|Protocol Deviation|14
6331039|NCT03034915|10077545|FG002|Overall Study|Protocol Deviation|7
6331040|NCT03034915|10077543|FG000|Overall Study|Lack of Efficacy|8
6331041|NCT03034915|10077544|FG001|Overall Study|Lack of Efficacy|16
6331042|NCT03034915|10077545|FG002|Overall Study|Lack of Efficacy|18
6331043|NCT03034915|10077543|FG000|Overall Study|Site closed|2
6331044|NCT03034915|10077544|FG001|Overall Study|Site closed|2
6331045|NCT03034915|10077545|FG002|Overall Study|Site closed|4
6331046|NCT03034915|10077543|FG000|Overall Study|Protocol-defined withdrawal criteria met|19
6331047|NCT03034915|10077544|FG001|Overall Study|Protocol-defined withdrawal criteria met|26
6331048|NCT03034915|10077545|FG002|Overall Study|Protocol-defined withdrawal criteria met|29
6331049|NCT03034915|10077543|FG000|Overall Study|Physician Decision|1
6331050|NCT03034915|10077544|FG001|Overall Study|Physician Decision|5
6331051|NCT03034915|10077545|FG002|Overall Study|Physician Decision|2
6331052|NCT03034954|10077567|FG000|Overall Study|Machine malfunction; did not reach 3 mA|1
6331053|NCT03034954|10077568|FG001|Overall Study|Machine malfunction; did not reach 3 mA|0
6331054|NCT03034967|10077580|FG000|Overall Study|Withdrawal by Subject|9
6331055|NCT03034967|10077581|FG001|Overall Study|Withdrawal by Subject|2
6331056|NCT03034967|10077582|FG002|Overall Study|Withdrawal by Subject|6
6331057|NCT03034967|10077583|FG003|Overall Study|Withdrawal by Subject|6
6331058|NCT03034967|10077584|FG004|Overall Study|Withdrawal by Subject|9
6331059|NCT03034967|10077585|FG005|Overall Study|Withdrawal by Subject|2
6331060|NCT03034967|10077580|FG000|Overall Study|Physician Decision|1
6331061|NCT03034967|10077581|FG001|Overall Study|Physician Decision|0
6331062|NCT03034967|10077582|FG002|Overall Study|Physician Decision|1
6331063|NCT03034967|10077583|FG003|Overall Study|Physician Decision|1
6331064|NCT03034967|10077584|FG004|Overall Study|Physician Decision|1
6331065|NCT03034967|10077585|FG005|Overall Study|Physician Decision|0
6331066|NCT03034967|10077580|FG000|Overall Study|Lost to Follow-up|0
6331067|NCT03034967|10077581|FG001|Overall Study|Lost to Follow-up|0
6331068|NCT03034967|10077582|FG002|Overall Study|Lost to Follow-up|0
6331069|NCT03034967|10077583|FG003|Overall Study|Lost to Follow-up|1
6331070|NCT03034967|10077584|FG004|Overall Study|Lost to Follow-up|0
6331071|NCT03034967|10077585|FG005|Overall Study|Lost to Follow-up|2
6331072|NCT03034967|10077580|FG000|Overall Study|Liver function test abnormality|0
6331073|NCT03034967|10077581|FG001|Overall Study|Liver function test abnormality|0
6331074|NCT03034967|10077582|FG002|Overall Study|Liver function test abnormality|1
6331075|NCT03034967|10077583|FG003|Overall Study|Liver function test abnormality|0
6331076|NCT03034967|10077584|FG004|Overall Study|Liver function test abnormality|0
6331077|NCT03034967|10077585|FG005|Overall Study|Liver function test abnormality|0
6331078|NCT03034967|10077580|FG000|Overall Study|Protocol Violation|1
6331079|NCT03034967|10077581|FG001|Overall Study|Protocol Violation|0
6331080|NCT03034967|10077582|FG002|Overall Study|Protocol Violation|0
6331081|NCT03034967|10077583|FG003|Overall Study|Protocol Violation|0
6331082|NCT03034967|10077584|FG004|Overall Study|Protocol Violation|0
6331083|NCT03034967|10077585|FG005|Overall Study|Protocol Violation|2
6331084|NCT03034967|10077580|FG000|Overall Study|Lack of Efficacy|0
6331085|NCT03034967|10077581|FG001|Overall Study|Lack of Efficacy|1
6331086|NCT03034967|10077582|FG002|Overall Study|Lack of Efficacy|2
6331087|NCT03034967|10077583|FG003|Overall Study|Lack of Efficacy|1
6331088|NCT03034967|10077584|FG004|Overall Study|Lack of Efficacy|1
6331089|NCT03034967|10077585|FG005|Overall Study|Lack of Efficacy|0
6331090|NCT03034967|10077580|FG000|Overall Study|Adverse Event, non-fatal|3
6331091|NCT03034967|10077581|FG001|Overall Study|Adverse Event, non-fatal|1
6331092|NCT03034967|10077582|FG002|Overall Study|Adverse Event, non-fatal|2
6331093|NCT03034967|10077583|FG003|Overall Study|Adverse Event, non-fatal|0
6331094|NCT03034967|10077584|FG004|Overall Study|Adverse Event, non-fatal|2
6331095|NCT03034967|10077585|FG005|Overall Study|Adverse Event, non-fatal|8
6331096|NCT03034967|10077580|FG000|Overall Study|Adverse Event, Serious Fatal|0
6331097|NCT03034967|10077581|FG001|Overall Study|Adverse Event, Serious Fatal|1
6331098|NCT03034967|10077582|FG002|Overall Study|Adverse Event, Serious Fatal|1
6331099|NCT03034967|10077583|FG003|Overall Study|Adverse Event, Serious Fatal|2
6331100|NCT03034967|10077584|FG004|Overall Study|Adverse Event, Serious Fatal|1
6331101|NCT03034967|10077585|FG005|Overall Study|Adverse Event, Serious Fatal|1
6331102|NCT03035032|10077604|FG000|Overall Study|Adverse Event|2
6331103|NCT03035032|10077604|FG000|Overall Study|Death|9
6331104|NCT03035032|10077604|FG000|Overall Study|Lost to Follow-up|1
6331105|NCT03035032|10077604|FG000|Overall Study|Progressive Disease|22
6331106|NCT03035032|10077604|FG000|Overall Study|Protocol Violation|2
6331107|NCT03035032|10077604|FG000|Overall Study|Withdrawal by Subject|2
6331108|NCT03035032|10077604|FG000|Overall Study|Physician Decision|5
6331109|NCT03035864|10077668|FG000|Treatment Period|Adverse Event|1
6331110|NCT03035864|10077669|FG001|Treatment Period|Adverse Event|0
6331111|NCT03035864|10077668|FG000|Treatment Period|Other|3
6331112|NCT03035864|10077669|FG001|Treatment Period|Other|1
6331113|NCT03035864|10077668|FG000|Follow-up Period|Adverse Event|1
6331114|NCT03035864|10077669|FG001|Follow-up Period|Adverse Event|0
6331115|NCT03035864|10077668|FG000|Follow-up Period|Lost to Follow-up|6
6331116|NCT03035864|10077669|FG001|Follow-up Period|Lost to Follow-up|2
6331117|NCT03035864|10077668|FG000|Follow-up Period|Physician Decision|1
6331118|NCT03035864|10077669|FG001|Follow-up Period|Physician Decision|0
6331119|NCT03035864|10077668|FG000|Follow-up Period|Other|3
6331120|NCT03035864|10077669|FG001|Follow-up Period|Other|2
6331121|NCT03035916|10077678|FG000|Overall Study|Puncture failed|0
6331122|NCT03035916|10077679|FG001|Overall Study|Puncture failed|2
6331123|NCT03035916|10077680|FG002|Overall Study|Puncture failed|0
6331124|NCT03035942|10077696|FG000|Overall Study|Adverse Event|8
6331125|NCT03035942|10077697|FG001|Overall Study|Adverse Event|4
6331126|NCT03035942|10077698|FG002|Overall Study|Adverse Event|5
6331127|NCT03036072|10077719|FG000|Overall Study|Death|0
6331128|NCT03036072|10077720|FG001|Overall Study|Death|1
6331129|NCT03036072|10077719|FG000|Overall Study|Withdrawal by Subject|0
6331130|NCT03036072|10077720|FG001|Overall Study|Withdrawal by Subject|1
6331131|NCT03036072|10077719|FG000|Overall Study|Physician Decision|0
6331132|NCT03036072|10077720|FG001|Overall Study|Physician Decision|1
6331133|NCT03036124|10077728|FG000|Overall Study|Lost to Follow-up|0
6331134|NCT03036124|10077729|FG001|Overall Study|Lost to Follow-up|2
6331135|NCT03036124|10077728|FG000|Overall Study|Withdrawal by Subject|5
6331136|NCT03036124|10077729|FG001|Overall Study|Withdrawal by Subject|4
6331137|NCT03036150|10077737|FG000|Overall Study|Withdrawal by Subject|8
6331138|NCT03036150|10077738|FG001|Overall Study|Withdrawal by Subject|3
6331139|NCT03036150|10077737|FG000|Overall Study|Lost to Follow-up|2
6331140|NCT03036150|10077738|FG001|Overall Study|Lost to Follow-up|2
6331141|NCT03036813|10077834|FG000|Overall Study|Adverse Event|6
6331142|NCT03036813|10077835|FG001|Overall Study|Adverse Event|11
6331143|NCT03036813|10077836|FG002|Overall Study|Adverse Event|6
6331144|NCT03036813|10077834|FG000|Overall Study|Withdrawal by Subject|12
6331145|NCT03036813|10077835|FG001|Overall Study|Withdrawal by Subject|6
6331146|NCT03036813|10077836|FG002|Overall Study|Withdrawal by Subject|10
6331147|NCT03036813|10077834|FG000|Overall Study|Lost to Follow-up|1
6331148|NCT03036813|10077835|FG001|Overall Study|Lost to Follow-up|1
6331149|NCT03036813|10077836|FG002|Overall Study|Lost to Follow-up|0
6331150|NCT03036813|10077834|FG000|Overall Study|Physician Decision|2
6331151|NCT03036813|10077835|FG001|Overall Study|Physician Decision|1
6331152|NCT03036813|10077836|FG002|Overall Study|Physician Decision|1
6331153|NCT03036813|10077834|FG000|Overall Study|Non-Compliance|1
6331154|NCT03036813|10077835|FG001|Overall Study|Non-Compliance|5
6331155|NCT03036813|10077836|FG002|Overall Study|Non-Compliance|3
6082827|NCT00631657|9690955|FG001|6-Month Treatment Period|Other|0
6082828|NCT00631657|9690956|FG002|6-Month Treatment Period|Other|4
6331156|NCT03036813|10077834|FG000|Overall Study|Pregnancy|0
6331157|NCT03036813|10077835|FG001|Overall Study|Pregnancy|0
6331158|NCT03036813|10077836|FG002|Overall Study|Pregnancy|1
6331159|NCT03036813|10077834|FG000|Overall Study|Other|0
6331160|NCT03036813|10077835|FG001|Overall Study|Other|3
6331161|NCT03036813|10077836|FG002|Overall Study|Other|5
6331162|NCT03036839|10077850|FG000|Overall Study|Adverse Event|0
6331163|NCT03036839|10077851|FG001|Overall Study|Adverse Event|0
6331164|NCT03036839|10077852|FG002|Overall Study|Adverse Event|1
6331165|NCT03036839|10077850|FG000|Overall Study|Death|3
6331166|NCT03036839|10077851|FG001|Overall Study|Death|0
6331167|NCT03036839|10077852|FG002|Overall Study|Death|3
6331168|NCT03036839|10077850|FG000|Overall Study|Withdrew Consent|0
6331169|NCT03036839|10077851|FG001|Overall Study|Withdrew Consent|0
6331170|NCT03036839|10077852|FG002|Overall Study|Withdrew Consent|1
6331171|NCT03036852|10077866|FG000|Overall Study|Death|2
6331172|NCT03036852|10077866|FG000|Overall Study|Lack of Efficacy|2
6331173|NCT03036852|10077866|FG000|Overall Study|Adverse Event|1
6331174|NCT03036852|10077866|FG000|Overall Study|Lost to Follow-up|1
6331175|NCT03037307|10077914|FG000|Period 1|Did Not Meet Study Criteria|0
6331176|NCT03037307|10077915|FG001|Period 1|Did Not Meet Study Criteria|0
6331177|NCT03037307|10077916|FG002|Period 1|Did Not Meet Study Criteria|0
6331178|NCT03037307|10077917|FG003|Period 1|Did Not Meet Study Criteria|1
6331179|NCT03037307|10077918|FG004|Period 1|Did Not Meet Study Criteria|0
6331180|NCT03037307|10077919|FG005|Period 1|Did Not Meet Study Criteria|0
6331181|NCT03037489|10077930|FG000|Overall Study|Adverse Event|4
6331182|NCT03037489|10077931|FG001|Overall Study|Adverse Event|0
6331183|NCT03037489|10077930|FG000|Overall Study|Withdrawal by Subject|3
6331184|NCT03037489|10077931|FG001|Overall Study|Withdrawal by Subject|0
6331185|NCT03037580|10077948|FG000|Overall Study|Withdrawal by Subject|3
6331186|NCT03037580|10077949|FG001|Overall Study|Withdrawal by Subject|0
6331187|NCT03037580|10077948|FG000|Overall Study|Adverse Event|1
6331188|NCT03037580|10077949|FG001|Overall Study|Adverse Event|0
6331189|NCT03037580|10077948|FG000|Overall Study|Study Terminated by Sponsor|12
6331190|NCT03037580|10077949|FG001|Overall Study|Study Terminated by Sponsor|15
6331191|NCT03037580|10077948|FG000|Overall Study|Death|0
6082829|NCT00631657|9690954|FG000|6-Month Treatment Period|Not Treated|2
6331192|NCT03037580|10077949|FG001|Overall Study|Death|1
6331193|NCT03037619|10077957|FG000|Overall Study|Lost to Follow-up|0
6331194|NCT03037619|10077958|FG001|Overall Study|Lost to Follow-up|1
6331195|NCT03038113|10077998|FG000|Overall Study|Withdrawal by Subject|0
6331196|NCT03038113|10077999|FG001|Overall Study|Withdrawal by Subject|0
6331197|NCT03038113|10078000|FG002|Overall Study|Withdrawal by Subject|1
6331198|NCT03038113|10078001|FG003|Overall Study|Withdrawal by Subject|0
6331199|NCT03038113|10078002|FG004|Overall Study|Withdrawal by Subject|0
6331200|NCT03038113|10078003|FG005|Overall Study|Withdrawal by Subject|0
6331201|NCT03038113|10078004|FG006|Overall Study|Withdrawal by Subject|0
6331202|NCT03038113|10078005|FG007|Overall Study|Withdrawal by Subject|0
6331203|NCT03038113|10078006|FG008|Overall Study|Withdrawal by Subject|0
6331204|NCT03038113|10078007|FG009|Overall Study|Withdrawal by Subject|0
6331205|NCT03038113|10078008|FG010|Overall Study|Withdrawal by Subject|0
6331206|NCT03038113|10078009|FG011|Overall Study|Withdrawal by Subject|0
6331207|NCT03038113|10078010|FG012|Overall Study|Withdrawal by Subject|0
6331208|NCT03038113|10078011|FG013|Overall Study|Withdrawal by Subject|1
6331209|NCT03038113|10077998|FG000|Overall Study|Lost to Follow-up|0
6331210|NCT03038113|10077999|FG001|Overall Study|Lost to Follow-up|0
6331211|NCT03038113|10078000|FG002|Overall Study|Lost to Follow-up|0
6331212|NCT03038113|10078001|FG003|Overall Study|Lost to Follow-up|0
6331213|NCT03038113|10078002|FG004|Overall Study|Lost to Follow-up|0
6331214|NCT03038113|10078003|FG005|Overall Study|Lost to Follow-up|0
6331215|NCT03038113|10078004|FG006|Overall Study|Lost to Follow-up|1
6331216|NCT03038113|10078005|FG007|Overall Study|Lost to Follow-up|0
6331217|NCT03038113|10078006|FG008|Overall Study|Lost to Follow-up|0
6331218|NCT03038113|10078007|FG009|Overall Study|Lost to Follow-up|0
6331219|NCT03038113|10078008|FG010|Overall Study|Lost to Follow-up|0
6331220|NCT03038113|10078009|FG011|Overall Study|Lost to Follow-up|0
6331221|NCT03038113|10078010|FG012|Overall Study|Lost to Follow-up|0
6331222|NCT03038113|10078011|FG013|Overall Study|Lost to Follow-up|0
6331223|NCT03038126|10078060|FG000|Overall Study|Death|1
6331224|NCT03038126|10078061|FG001|Overall Study|Death|1
6331225|NCT03038126|10078060|FG000|Overall Study|Withdrawal by Subject|5
6331226|NCT03038126|10078061|FG001|Overall Study|Withdrawal by Subject|0
6331227|NCT03038126|10078060|FG000|Overall Study|Lost to Follow-up|0
6331228|NCT03038126|10078061|FG001|Overall Study|Lost to Follow-up|1
6331229|NCT03038126|10078060|FG000|Overall Study|Long Term Hospitalization|2
6331230|NCT03038126|10078061|FG001|Overall Study|Long Term Hospitalization|0
6331231|NCT03038126|10078060|FG000|Overall Study|Too Ill to Participate|1
6331232|NCT03038126|10078061|FG001|Overall Study|Too Ill to Participate|2
6331233|NCT03038620|10078092|FG000|Overall Study|Lost to Follow-up|18
6331234|NCT03038620|10078093|FG001|Overall Study|Lost to Follow-up|23
6331235|NCT03038620|10078092|FG000|Overall Study|Withdrawal by Subject|0
6331236|NCT03038620|10078093|FG001|Overall Study|Withdrawal by Subject|15
6331237|NCT03038620|10078092|FG000|Overall Study|Uninterpretable Outcome (Imaging)|1
6331238|NCT03038620|10078093|FG001|Overall Study|Uninterpretable Outcome (Imaging)|0
6331239|NCT03038880|10078121|FG000|Overall Study|Death|1
6331240|NCT03038880|10078122|FG001|Overall Study|Death|2
6331241|NCT03038880|10078123|FG002|Overall Study|Death|0
6331242|NCT03038880|10078121|FG000|Overall Study|Physician Decision|2
6331243|NCT03038880|10078122|FG001|Overall Study|Physician Decision|1
6331244|NCT03038880|10078123|FG002|Overall Study|Physician Decision|0
6331245|NCT03039023|10078136|FG000|Overall Study|Withdrawal by Subject|1
6331246|NCT03039023|10078137|FG001|Overall Study|Withdrawal by Subject|0
6331247|NCT03039023|10078138|FG002|Overall Study|Withdrawal by Subject|1
6331248|NCT03039023|10078139|FG003|Overall Study|Withdrawal by Subject|1
6331249|NCT03039023|10078140|FG004|Overall Study|Withdrawal by Subject|0
6331250|NCT03039023|10078136|FG000|Overall Study|Physician Decision|0
6331251|NCT03039023|10078137|FG001|Overall Study|Physician Decision|0
6331252|NCT03039023|10078138|FG002|Overall Study|Physician Decision|0
6331253|NCT03039023|10078139|FG003|Overall Study|Physician Decision|1
6331254|NCT03039023|10078140|FG004|Overall Study|Physician Decision|0
6331255|NCT03039192|10078172|FG000|Overall Study|Lost to Follow-up|4
6331256|NCT03039192|10078173|FG001|Overall Study|Lost to Follow-up|4
6331257|NCT03039192|10078172|FG000|Overall Study|Adverse event, serious fatal|0
6331258|NCT03039192|10078173|FG001|Overall Study|Adverse event, serious fatal|1
6331259|NCT03039192|10078172|FG000|Overall Study|Adverse event, non-fatal|0
6331260|NCT03039192|10078173|FG001|Overall Study|Adverse event, non-fatal|2
6331261|NCT03039192|10078172|FG000|Overall Study|Withdrawal by Subject|6
6331262|NCT03039192|10078173|FG001|Overall Study|Withdrawal by Subject|9
6331263|NCT03039192|10078172|FG000|Overall Study|Discontinued from treatment phase|19
6331264|NCT03039192|10078173|FG001|Overall Study|Discontinued from treatment phase|12
6331265|NCT03039192|10078172|FG000|Overall Study|Other|3
6331266|NCT03039192|10078173|FG001|Overall Study|Other|2
6331267|NCT03039283|10078179|FG000|Overall Study|Protocol Violation|2
6331268|NCT03039569|10078194|FG000|Overall Study|Lost to Follow-up|5
6331269|NCT03039569|10078195|FG001|Overall Study|Lost to Follow-up|4
6331270|NCT03039621|10078204|FG000|Overall Study|Violation of inclusion criteria|3
6331271|NCT03039621|10078205|FG001|Overall Study|Violation of inclusion criteria|2
6331272|NCT03039621|10078204|FG000|Overall Study|Non-compliance with protocol requirement|4
6331273|NCT03039621|10078205|FG001|Overall Study|Non-compliance with protocol requirement|5
6331274|NCT03039621|10078204|FG000|Overall Study|Necessity to use drugs forbidden by pro|4
6331275|NCT03039621|10078205|FG001|Overall Study|Necessity to use drugs forbidden by pro|7
6331276|NCT03039621|10078204|FG000|Overall Study|Violation of non-inclusion criteria|1
6331277|NCT03039621|10078205|FG001|Overall Study|Violation of non-inclusion criteria|2
6331278|NCT03039686|10078214|FG000|Double-blind Period|Administrative Reason by Sponsor|24
6331279|NCT03039686|10078215|FG001|Double-blind Period|Administrative Reason by Sponsor|25
6331280|NCT03039686|10078216|FG002|Double-blind Period|Administrative Reason by Sponsor|21
6331281|NCT03039686|10078214|FG000|Double-blind Period|Subject Request to Discontinue Study Treatment|1
6331282|NCT03039686|10078215|FG001|Double-blind Period|Subject Request to Discontinue Study Treatment|2
6167184|NCT01226511|9811634|FG001|Acute Treatment Period|Withdrawal by Subject|6
6167185|NCT01226511|9811633|FG000|Extension Treatment Period|Adverse Event|8
6167186|NCT01226511|9811634|FG001|Extension Treatment Period|Adverse Event|8
6167187|NCT01226511|9811633|FG000|Extension Treatment Period|Lack of Efficacy|3
6167188|NCT01226511|9811634|FG001|Extension Treatment Period|Lack of Efficacy|2
6167189|NCT01226511|9811633|FG000|Extension Treatment Period|Lost to Follow-up|4
6167190|NCT01226511|9811634|FG001|Extension Treatment Period|Lost to Follow-up|3
6167191|NCT01226511|9811633|FG000|Extension Treatment Period|Protocol Violation|2
6167192|NCT01226511|9811634|FG001|Extension Treatment Period|Protocol Violation|2
6331283|NCT03039686|10078216|FG002|Double-blind Period|Subject Request to Discontinue Study Treatment|0
6331284|NCT03039686|10078214|FG000|Double-blind Period|Withdrawal by Subject|2
6331285|NCT03039686|10078215|FG001|Double-blind Period|Withdrawal by Subject|2
6331286|NCT03039686|10078216|FG002|Double-blind Period|Withdrawal by Subject|1
6331287|NCT03039686|10078214|FG000|Double-blind Period|Death|0
6331288|NCT03039686|10078215|FG001|Double-blind Period|Death|0
6331289|NCT03039686|10078216|FG002|Double-blind Period|Death|1
6331290|NCT03039686|10078214|FG000|Open Label Period|Administrative Reason by Sponsor|0
6331291|NCT03039686|10078215|FG001|Open Label Period|Administrative Reason by Sponsor|34
6331292|NCT03039686|10078216|FG002|Open Label Period|Administrative Reason by Sponsor|41
6331293|NCT03039686|10078214|FG000|Open Label Period|Subject Request to Discontinue Study Treatment|0
6331294|NCT03039686|10078215|FG001|Open Label Period|Subject Request to Discontinue Study Treatment|1
6331295|NCT03039686|10078216|FG002|Open Label Period|Subject Request to Discontinue Study Treatment|0
6331296|NCT03039686|10078214|FG000|Open Label Period|Withdrawal by Subject|0
6331297|NCT03039686|10078215|FG001|Open Label Period|Withdrawal by Subject|3
6331298|NCT03039686|10078216|FG002|Open Label Period|Withdrawal by Subject|1
6331299|NCT03039699|10078236|FG000|Overall Study|Incorrect inclusion|5
6331300|NCT03039699|10078237|FG001|Overall Study|Incorrect inclusion|4
6331301|NCT03039699|10078236|FG000|Overall Study|Lack of data to assess study endpoint|5
6331302|NCT03039699|10078237|FG001|Overall Study|Lack of data to assess study endpoint|3
6331303|NCT03039699|10078236|FG000|Overall Study|Bacterial infection|12
6331304|NCT03039699|10078237|FG001|Overall Study|Bacterial infection|28
6331305|NCT03039738|10078245|FG000|Overall Study|Incomplete data sets|54
6331306|NCT03039738|10078246|FG001|Overall Study|Incomplete data sets|0
6331307|NCT03040024|10078268|FG000|Overall Study|Adverse Event|0
6331308|NCT03040024|10078269|FG001|Overall Study|Adverse Event|1
6331309|NCT03040024|10078270|FG002|Overall Study|Adverse Event|0
6331310|NCT03040024|10078268|FG000|Overall Study|Death|0
6331311|NCT03040024|10078269|FG001|Overall Study|Death|1
6331312|NCT03040024|10078270|FG002|Overall Study|Death|0
6331313|NCT03040024|10078268|FG000|Overall Study|Physician Decision|0
6331314|NCT03040024|10078269|FG001|Overall Study|Physician Decision|0
6331315|NCT03040024|10078270|FG002|Overall Study|Physician Decision|1
6331316|NCT03040336|10078289|FG000|Overall Study|Death|1
6331317|NCT03040336|10078290|FG001|Overall Study|Death|0
6331318|NCT03040336|10078289|FG000|Overall Study|Withdrawal by Subject|2
6331319|NCT03040336|10078290|FG001|Overall Study|Withdrawal by Subject|3
6331320|NCT03040674|10078347|FG000|Overall Study|Lost to Follow-up|225
6331321|NCT03040674|10078347|FG000|Overall Study|Death|23
6331322|NCT03040687|10078355|FG000|Overall Study|Withdrawal by Subject|1
6331323|NCT03040687|10078356|FG001|Overall Study|Withdrawal by Subject|0
6331324|NCT03040687|10078357|FG002|Overall Study|Withdrawal by Subject|0
6331325|NCT03040713|10078365|FG000|Overall Study|Positive amyloid scan|3
6331326|NCT03040986|10078375|FG000|Overall Study|Hospice|1
6331327|NCT03040986|10078376|FG001|Overall Study|Hospice|0
6331328|NCT03040986|10078375|FG000|Overall Study|Adverse Event|2
6331329|NCT03040986|10078376|FG001|Overall Study|Adverse Event|1
6331330|NCT03040986|10078375|FG000|Overall Study|Disease progression on study|3
6331331|NCT03040986|10078376|FG001|Overall Study|Disease progression on study|1
6331332|NCT03041025|10078387|FG000|Overall Study|Adverse Event|0
6331333|NCT03041025|10078388|FG001|Overall Study|Adverse Event|0
6331334|NCT03041025|10078389|FG002|Overall Study|Adverse Event|1
6331335|NCT03041025|10078387|FG000|Overall Study|Lost to Follow-up|1
6331336|NCT03041025|10078388|FG001|Overall Study|Lost to Follow-up|0
6331337|NCT03041025|10078389|FG002|Overall Study|Lost to Follow-up|0
6331338|NCT03041025|10078387|FG000|Overall Study|Withdrawal by Subject|0
6331339|NCT03041025|10078388|FG001|Overall Study|Withdrawal by Subject|0
6331340|NCT03041025|10078389|FG002|Overall Study|Withdrawal by Subject|1
6331341|NCT03041038|10078402|FG000|Overall Study|Withdrawal by Subject|4
6331342|NCT03041038|10078403|FG001|Overall Study|Withdrawal by Subject|0
6331343|NCT03041038|10078402|FG000|Overall Study|Lost to Follow-up|1
6331344|NCT03041038|10078403|FG001|Overall Study|Lost to Follow-up|1
6331345|NCT03041038|10078402|FG000|Overall Study|Protocol Violation|1
6167193|NCT01226511|9811633|FG000|Extension Treatment Period|Withdrawal by Subject|1
6331346|NCT03041038|10078403|FG001|Overall Study|Protocol Violation|1
6331347|NCT03041090|10078413|FG000|Overall Study|technical error|0
6331348|NCT03041090|10078414|FG001|Overall Study|technical error|3
6331349|NCT03041116|10078422|FG000|Double-blind|Death|0
6331350|NCT03041116|10078423|FG001|Double-blind|Death|2
6331351|NCT03041116|10078422|FG000|Double-blind|Withdrawal by Subject|0
6331352|NCT03041116|10078423|FG001|Double-blind|Withdrawal by Subject|4
6331353|NCT03041116|10078422|FG000|Open-label|Death|1
6331354|NCT03041116|10078423|FG001|Open-label|Death|0
6331355|NCT03041116|10078422|FG000|Open-label|Termination of the study by Sponsor|39
6331356|NCT03041116|10078423|FG001|Open-label|Termination of the study by Sponsor|37
6331357|NCT03041116|10078422|FG000|Open-label|Withdrawal by Subject|1
6331358|NCT03041116|10078423|FG001|Open-label|Withdrawal by Subject|0
6331359|NCT03041181|10078435|FG000|Overall Study|Disease Progression|1
6331360|NCT03041181|10078436|FG001|Overall Study|Disease Progression|2
6331361|NCT03041792|10078468|FG000|Overall Study|Adverse Event|4
6331362|NCT03041792|10078469|FG001|Overall Study|Adverse Event|0
6331363|NCT03041792|10078468|FG000|Overall Study|Death in the family|0
6331364|NCT03041792|10078469|FG001|Overall Study|Death in the family|2
6331365|NCT03041792|10078468|FG000|Overall Study|Randomized but not treated|0
6331366|NCT03041792|10078469|FG001|Overall Study|Randomized but not treated|1
6331367|NCT03042312|10078520|FG000|Overall Study|Administrative Reason|1
6331368|NCT03042312|10078521|FG001|Overall Study|Administrative Reason|1
6331369|NCT03042312|10078520|FG000|Overall Study|Adverse Event|0
6331370|NCT03042312|10078521|FG001|Overall Study|Adverse Event|1
6331371|NCT03042312|10078520|FG000|Overall Study|Lost to Follow-up|1
6331372|NCT03042312|10078521|FG001|Overall Study|Lost to Follow-up|3
6331373|NCT03042312|10078520|FG000|Overall Study|Any occurrence of conditions which prevented the patient's participation in the study.|4
6331374|NCT03042312|10078521|FG001|Overall Study|Any occurrence of conditions which prevented the patient's participation in the study.|2
6331375|NCT03042312|10078520|FG000|Overall Study|Withdrawal by Subject|4
6331376|NCT03042312|10078521|FG001|Overall Study|Withdrawal by Subject|5
6331377|NCT03042559|10078529|FG000|Overall Study|drop out|1
6331378|NCT03042559|10078530|FG001|Overall Study|drop out|1
6331379|NCT03042767|10078547|FG000|Overall Study|Lost to Follow-up|1
6331380|NCT03042767|10078548|FG001|Overall Study|Lost to Follow-up|2
6331381|NCT03042910|10078554|FG000|Overall Study|Adverse Event|1
6331382|NCT03042910|10078554|FG000|Overall Study|Disease Progression|2
6331383|NCT03042910|10078554|FG000|Overall Study|Withdrawal by Subject|3
6331384|NCT03042910|10078554|FG000|Overall Study|Enrolled but not treated|1
6331385|NCT03043365|10078587|FG000|Weeks 0 to Week 8|Adverse Event|1
6331386|NCT03043365|10078588|FG001|Weeks 0 to Week 8|Adverse Event|3
6331387|NCT03043365|10078587|FG000|Weeks 0 to Week 8|Lost to Follow-up|2
6331388|NCT03043365|10078588|FG001|Weeks 0 to Week 8|Lost to Follow-up|0
6331389|NCT03043365|10078587|FG000|Week 8 to Week 16 - Washout Period|Lost to Follow-up|1
6331390|NCT03043365|10078588|FG001|Week 8 to Week 16 - Washout Period|Lost to Follow-up|0
6331391|NCT03043560|10078607|FG000|Overall Study|Discontinued Intervention|1
6331392|NCT03043560|10078608|FG001|Overall Study|Discontinued Intervention|2
6331393|NCT03043560|10078607|FG000|Overall Study|Lost to Follow-up|0
6331394|NCT03043560|10078608|FG001|Overall Study|Lost to Follow-up|1
6331395|NCT03043651|10078614|FG000|Overall Study|Death|1
6331396|NCT03043651|10078614|FG000|Overall Study|Progressive Disease|2
6331397|NCT03043651|10078614|FG000|Overall Study|Adverse Event|2
6331398|NCT03043651|10078614|FG000|Overall Study|Withdrawal by Subject|4
6331399|NCT03043651|10078614|FG000|Overall Study|Study Terminated by Sponsor|39
6331400|NCT03044106|10078649|FG000|Washout (1 Week)|Withdrawal by Subject|0
6331401|NCT03044106|10078650|FG001|Washout (1 Week)|Withdrawal by Subject|2
6331402|NCT03044197|10078665|FG000|Overall Study|Withdrawal by Subject|3
6331403|NCT03044197|10078666|FG001|Overall Study|Withdrawal by Subject|1
6331404|NCT03044249|10078674|FG000|Overall Study|Adverse Event|4
6331405|NCT03044249|10078675|FG001|Overall Study|Adverse Event|9
6331406|NCT03044249|10078674|FG000|Overall Study|Lost to Follow-up|1
6331407|NCT03044249|10078675|FG001|Overall Study|Lost to Follow-up|0
6331408|NCT03044249|10078674|FG000|Overall Study|Non-compliance with Study Drug|1
6331409|NCT03044249|10078675|FG001|Overall Study|Non-compliance with Study Drug|0
6331410|NCT03044249|10078674|FG000|Overall Study|Study Terminated by Sponsor|2
6331411|NCT03044249|10078675|FG001|Overall Study|Study Terminated by Sponsor|0
6331412|NCT03044249|10078674|FG000|Overall Study|Withdrawal by Subject|2
6331413|NCT03044249|10078675|FG001|Overall Study|Withdrawal by Subject|5
6331414|NCT03044353|10078689|FG000|Overall Study|Adverse Event|0
6331415|NCT03044353|10078690|FG001|Overall Study|Adverse Event|1
6331416|NCT03044353|10078691|FG002|Overall Study|Adverse Event|0
6331417|NCT03044431|10078702|FG000|Overall Study|Lost to Follow-up|59
6331418|NCT03044574|10078708|FG000|Overall Study|Lost to Follow-up|37
6331419|NCT03044574|10078709|FG001|Overall Study|Lost to Follow-up|45
6331420|NCT03044730|10078724|FG000|3 Cycles of Pembro + Capecitab|Progressive Disease|1
6331421|NCT03044730|10078724|FG000|3 Cycles of Pembro + Capecitab|Patient non-compliant with capecitabine|1
6331422|NCT03044730|10078724|FG000|3 Cycles of Pembro + Capecitab|Death|1
6331423|NCT03044730|10078724|FG000|3 Cycles of Pembro + Capecitab|Adverse Event|1
6331424|NCT03044730|10078724|FG000|Cycles 4 and Beyond|Progressive Disease|9
6331425|NCT03044730|10078724|FG000|Cycles 4 and Beyond|Adverse Event|1
6331426|NCT03044730|10078724|FG000|On Follow-up for 2 Years|Still in follow-up|7
6331427|NCT03044730|10078724|FG000|On Follow-up for 2 Years|Lost to Follow-up|1
6331428|NCT03044730|10078724|FG000|On Follow-up for 2 Years|Death|17
6331429|NCT03044886|10078732|FG000|Overall Study|Lost to Follow-up|15
6331430|NCT03044886|10078733|FG001|Overall Study|Lost to Follow-up|10
6331431|NCT03044886|10078734|FG002|Overall Study|Lost to Follow-up|12
6331432|NCT03045081|10078744|FG000|Overall Study|Withdrawal by Subject|6
6331433|NCT03045081|10078745|FG001|Overall Study|Withdrawal by Subject|11
6331434|NCT03045302|10078751|FG000|Overall Study|Pre-treatment adverse event|1
6331435|NCT03045328|10078755|FG000|Overall Study|Withdrawal by Subject|2
6082830|NCT00631657|9690955|FG001|6-Month Treatment Period|Not Treated|0
6331436|NCT03045887|10078793|FG000|Part A,Washout Period 1(4 Weeks)|Physician Decision|3
6331437|NCT03045887|10078794|FG001|Part A,Washout Period 1(4 Weeks)|Physician Decision|0
6331438|NCT03045887|10078795|FG002|Part A,Washout Period 1(4 Weeks)|Physician Decision|0
6331439|NCT03045887|10078796|FG003|Part A,Washout Period 1(4 Weeks)|Physician Decision|0
6331440|NCT03045887|10078797|FG004|Part A,Washout Period 1(4 Weeks)|Physician Decision|0
6331441|NCT03045887|10078798|FG005|Part A,Washout Period 1(4 Weeks)|Physician Decision|0
6331442|NCT03045887|10078799|FG006|Part A,Washout Period 1(4 Weeks)|Physician Decision|0
6331443|NCT03045887|10078800|FG007|Part A,Washout Period 1(4 Weeks)|Physician Decision|0
6331444|NCT03045887|10078801|FG008|Part A,Washout Period 1(4 Weeks)|Physician Decision|0
6331445|NCT03045887|10078802|FG009|Part A,Washout Period 1(4 Weeks)|Physician Decision|0
6331446|NCT03045887|10078793|FG000|Part A,Washout Period 1(4 Weeks)|Withdrawal by Subject|0
6331447|NCT03045887|10078794|FG001|Part A,Washout Period 1(4 Weeks)|Withdrawal by Subject|0
6331448|NCT03045887|10078795|FG002|Part A,Washout Period 1(4 Weeks)|Withdrawal by Subject|0
6331449|NCT03045887|10078796|FG003|Part A,Washout Period 1(4 Weeks)|Withdrawal by Subject|1
6331450|NCT03045887|10078797|FG004|Part A,Washout Period 1(4 Weeks)|Withdrawal by Subject|0
6331451|NCT03045887|10078798|FG005|Part A,Washout Period 1(4 Weeks)|Withdrawal by Subject|0
6331452|NCT03045887|10078799|FG006|Part A,Washout Period 1(4 Weeks)|Withdrawal by Subject|0
6331453|NCT03045887|10078800|FG007|Part A,Washout Period 1(4 Weeks)|Withdrawal by Subject|0
6331454|NCT03045887|10078801|FG008|Part A,Washout Period 1(4 Weeks)|Withdrawal by Subject|0
6331455|NCT03045887|10078802|FG009|Part A,Washout Period 1(4 Weeks)|Withdrawal by Subject|0
6331456|NCT03045887|10078793|FG000|Part A, Period 2 (1 Day)|Adverse Event|1
6331457|NCT03045887|10078794|FG001|Part A, Period 2 (1 Day)|Adverse Event|0
6331458|NCT03045887|10078795|FG002|Part A, Period 2 (1 Day)|Adverse Event|0
6331459|NCT03045887|10078796|FG003|Part A, Period 2 (1 Day)|Adverse Event|0
6331460|NCT03045887|10078797|FG004|Part A, Period 2 (1 Day)|Adverse Event|0
6331461|NCT03045887|10078798|FG005|Part A, Period 2 (1 Day)|Adverse Event|0
6331462|NCT03045887|10078799|FG006|Part A, Period 2 (1 Day)|Adverse Event|0
6331463|NCT03045887|10078800|FG007|Part A, Period 2 (1 Day)|Adverse Event|0
6331464|NCT03045887|10078801|FG008|Part A, Period 2 (1 Day)|Adverse Event|0
6331465|NCT03045887|10078802|FG009|Part A, Period 2 (1 Day)|Adverse Event|0
6331466|NCT03045887|10078793|FG000|Part A,Washout Period 2 (4 Weeks)|Physician Decision|0
6331467|NCT03045887|10078794|FG001|Part A,Washout Period 2 (4 Weeks)|Physician Decision|0
6331468|NCT03045887|10078795|FG002|Part A,Washout Period 2 (4 Weeks)|Physician Decision|1
6331469|NCT03045887|10078796|FG003|Part A,Washout Period 2 (4 Weeks)|Physician Decision|1
6331470|NCT03045887|10078797|FG004|Part A,Washout Period 2 (4 Weeks)|Physician Decision|0
6331471|NCT03045887|10078798|FG005|Part A,Washout Period 2 (4 Weeks)|Physician Decision|0
6331472|NCT03045887|10078799|FG006|Part A,Washout Period 2 (4 Weeks)|Physician Decision|0
6331473|NCT03045887|10078800|FG007|Part A,Washout Period 2 (4 Weeks)|Physician Decision|0
6331474|NCT03045887|10078801|FG008|Part A,Washout Period 2 (4 Weeks)|Physician Decision|0
6331475|NCT03045887|10078802|FG009|Part A,Washout Period 2 (4 Weeks)|Physician Decision|0
6331476|NCT03045887|10078793|FG000|Part A,Washout Period 2 (4 Weeks)|Withdrawal by Subject|0
6331477|NCT03045887|10078794|FG001|Part A,Washout Period 2 (4 Weeks)|Withdrawal by Subject|0
6331478|NCT03045887|10078795|FG002|Part A,Washout Period 2 (4 Weeks)|Withdrawal by Subject|0
6331479|NCT03045887|10078796|FG003|Part A,Washout Period 2 (4 Weeks)|Withdrawal by Subject|1
6331480|NCT03045887|10078797|FG004|Part A,Washout Period 2 (4 Weeks)|Withdrawal by Subject|0
6331481|NCT03045887|10078798|FG005|Part A,Washout Period 2 (4 Weeks)|Withdrawal by Subject|0
6331482|NCT03045887|10078799|FG006|Part A,Washout Period 2 (4 Weeks)|Withdrawal by Subject|0
6331483|NCT03045887|10078800|FG007|Part A,Washout Period 2 (4 Weeks)|Withdrawal by Subject|0
6331484|NCT03045887|10078801|FG008|Part A,Washout Period 2 (4 Weeks)|Withdrawal by Subject|0
6331485|NCT03045887|10078802|FG009|Part A,Washout Period 2 (4 Weeks)|Withdrawal by Subject|0
6331486|NCT03046056|10078836|FG000|Overall Study|Non-responder at Week 10|6
6331487|NCT03046056|10078837|FG001|Overall Study|Non-responder at Week 10|6
6331488|NCT03046056|10078838|FG002|Overall Study|Non-responder at Week 10|4
6331489|NCT03046056|10078836|FG000|Overall Study|Protocol-specified Disease Worsening|3
6331490|NCT03046056|10078837|FG001|Overall Study|Protocol-specified Disease Worsening|3
6331491|NCT03046056|10078838|FG002|Overall Study|Protocol-specified Disease Worsening|1
6331492|NCT03046056|10078836|FG000|Overall Study|Adverse Event|1
6331493|NCT03046056|10078837|FG001|Overall Study|Adverse Event|5
6331494|NCT03046056|10078838|FG002|Overall Study|Adverse Event|0
6331495|NCT03046056|10078836|FG000|Overall Study|Non-compliance With Study Drug|0
6331496|NCT03046056|10078837|FG001|Overall Study|Non-compliance With Study Drug|0
6331497|NCT03046056|10078838|FG002|Overall Study|Non-compliance With Study Drug|2
6331498|NCT03046056|10078836|FG000|Overall Study|Protocol Violation|1
6331499|NCT03046056|10078837|FG001|Overall Study|Protocol Violation|1
6331500|NCT03046056|10078838|FG002|Overall Study|Protocol Violation|0
6331501|NCT03046056|10078836|FG000|Overall Study|Investigator's Discretion|0
6331502|NCT03046056|10078837|FG001|Overall Study|Investigator's Discretion|1
6331503|NCT03046056|10078838|FG002|Overall Study|Investigator's Discretion|0
6331504|NCT03046056|10078836|FG000|Overall Study|Withdrew Consent|1
6331505|NCT03046056|10078837|FG001|Overall Study|Withdrew Consent|0
6331506|NCT03046056|10078838|FG002|Overall Study|Withdrew Consent|0
6331507|NCT03046446|10078864|FG000|Overall Study|Lack of Efficacy|7
6331508|NCT03046446|10078864|FG000|Overall Study|Adverse Event|6
6331509|NCT03046446|10078864|FG000|Overall Study|Lost to Follow-up|3
6331510|NCT03046446|10078864|FG000|Overall Study|Withdrawal by Subject|14
6331511|NCT03046446|10078864|FG000|Overall Study|Withdrawn by Investigator/Sponsor|3
6331512|NCT03046446|10078864|FG000|Overall Study|Disease Progression (see caveats)|25
6331513|NCT03046446|10078864|FG000|Overall Study|Non OA related knee surgery|1
6331514|NCT03047551|10078927|FG000|Overall Study|Did not receive TAS|1
6331515|NCT03047551|10078928|FG001|Overall Study|Did not receive TAS|0
6331516|NCT03047551|10078927|FG000|Overall Study|Physician Decision|1
6331517|NCT03047551|10078928|FG001|Overall Study|Physician Decision|0
6331518|NCT03047551|10078927|FG000|Overall Study|Withdrawal by Subject|0
6331519|NCT03047551|10078928|FG001|Overall Study|Withdrawal by Subject|1
6331520|NCT03047551|10078927|FG000|Overall Study|Probe malfunction|0
6331521|NCT03047551|10078928|FG001|Overall Study|Probe malfunction|1
6331522|NCT03047551|10078927|FG000|Overall Study|Ineligible|0
6331523|NCT03047551|10078928|FG001|Overall Study|Ineligible|1
6331524|NCT03047720|10078936|FG000|First Intervention (6weeks)|Participant data entry insufficient|7
6331525|NCT03047720|10078937|FG001|First Intervention (6weeks)|Participant data entry insufficient|0
6331526|NCT03047980|10078943|FG000|Overall Study|Adverse Event|1
6331527|NCT03048058|10078953|FG000|Overall Study|Lost to Follow-up|4
6331528|NCT03048058|10078954|FG001|Overall Study|Lost to Follow-up|0
6331529|NCT03048058|10078953|FG000|Overall Study|Withdrawal by Subject|0
6331530|NCT03048058|10078954|FG001|Overall Study|Withdrawal by Subject|4
6331531|NCT03048500|10078973|FG000|2 Cycles of Treatment|Withdrawal by Subject|1
6331532|NCT03048500|10078973|FG000|Reached 1st Response/Continued Treatment|Progressive Disease|4
6331533|NCT03048500|10078973|FG000|Reached 1st Response/Continued Treatment|Death|1
6331534|NCT03048500|10078973|FG000|Reached 1st Response/Continued Treatment|Withdrawal by Subject|1
6331535|NCT03048500|10078973|FG000|Reached 1st Response/Continued Treatment|Physician decision, Patient PS declining|1
6331536|NCT03048500|10078973|FG000|Follow up for 3 Years|Currently in Follow-up|4
6331537|NCT03048500|10078973|FG000|Follow up for 3 Years|Death|12
6331538|NCT03048747|10078977|FG000|Overall Study|Adverse Event|2
6331539|NCT03048747|10078977|FG000|Overall Study|Participant Met Withdrawal Criteria|2
6331540|NCT03048747|10078977|FG000|Overall Study|Physician Decision|1
6331541|NCT03049280|10078991|FG000|Overall Study|Physician Decision|1
6331542|NCT03049488|10079003|FG000|Overall Study|Lost to Follow-up|1
6331543|NCT03049488|10079004|FG001|Overall Study|Lost to Follow-up|1
6331544|NCT03049488|10079005|FG002|Overall Study|Lost to Follow-up|0
6331545|NCT03049488|10079006|FG003|Overall Study|Lost to Follow-up|0
6331546|NCT03049488|10079007|FG004|Overall Study|Lost to Follow-up|0
6331547|NCT03049488|10079008|FG005|Overall Study|Lost to Follow-up|0
6331548|NCT03049488|10079003|FG000|Overall Study|Moved from Area|1
6331549|NCT03049488|10079004|FG001|Overall Study|Moved from Area|0
6331550|NCT03049488|10079005|FG002|Overall Study|Moved from Area|0
6331551|NCT03049488|10079006|FG003|Overall Study|Moved from Area|1
6331552|NCT03049488|10079007|FG004|Overall Study|Moved from Area|1
6331553|NCT03049488|10079008|FG005|Overall Study|Moved from Area|0
6331554|NCT03049488|10079003|FG000|Overall Study|Physician Decision|0
6331555|NCT03049488|10079004|FG001|Overall Study|Physician Decision|1
6331556|NCT03049488|10079005|FG002|Overall Study|Physician Decision|0
6331557|NCT03049488|10079006|FG003|Overall Study|Physician Decision|0
6331558|NCT03049488|10079007|FG004|Overall Study|Physician Decision|0
6331559|NCT03049488|10079008|FG005|Overall Study|Physician Decision|0
6331560|NCT03049488|10079003|FG000|Overall Study|Withdrawal by Subject|0
6331561|NCT03049488|10079004|FG001|Overall Study|Withdrawal by Subject|0
6331562|NCT03049488|10079005|FG002|Overall Study|Withdrawal by Subject|0
6331563|NCT03049488|10079006|FG003|Overall Study|Withdrawal by Subject|1
6331564|NCT03049488|10079007|FG004|Overall Study|Withdrawal by Subject|1
6331565|NCT03049488|10079008|FG005|Overall Study|Withdrawal by Subject|0
6331566|NCT03049748|10079034|FG000|Overall Study|Lost to Follow-up|1
6331567|NCT03049748|10079035|FG001|Overall Study|Lost to Follow-up|0
6331568|NCT03049748|10079034|FG000|Overall Study|Death|3
6331569|NCT03049748|10079035|FG001|Overall Study|Death|0
6331570|NCT03049748|10079034|FG000|Overall Study|Withdrawal by Subject|0
6331571|NCT03049748|10079035|FG001|Overall Study|Withdrawal by Subject|3
6331572|NCT03049748|10079034|FG000|Overall Study|Protocol Violation|0
6331573|NCT03049748|10079035|FG001|Overall Study|Protocol Violation|2
6331574|NCT03049748|10079034|FG000|Overall Study|Moved out of state (relocation)|0
6331575|NCT03049748|10079035|FG001|Overall Study|Moved out of state (relocation)|1
6331576|NCT03049852|10079044|FG000|Overall Study|Lost to Follow-up|0
6331577|NCT03049852|10079045|FG001|Overall Study|Lost to Follow-up|1
6331578|NCT03049852|10079046|FG002|Overall Study|Lost to Follow-up|0
6331579|NCT03050307|10079131|FG000|Overall Study|Adverse Event|4
6331580|NCT03050307|10079132|FG001|Overall Study|Adverse Event|2
6331581|NCT03050307|10079131|FG000|Overall Study|Significant Protocol Deviation|0
6331582|NCT03050307|10079132|FG001|Overall Study|Significant Protocol Deviation|1
6331583|NCT03050307|10079131|FG000|Overall Study|Lost to Follow-up|0
6331584|NCT03050307|10079132|FG001|Overall Study|Lost to Follow-up|1
6331585|NCT03050307|10079131|FG000|Overall Study|Voluntary Withdrawal|3
6331586|NCT03050307|10079132|FG001|Overall Study|Voluntary Withdrawal|4
6331587|NCT03050307|10079131|FG000|Overall Study|Reason not Specified|1
6331588|NCT03050307|10079132|FG001|Overall Study|Reason not Specified|1
6331589|NCT03050359|10079151|FG000|Overall Study|Randomized But Not Treated|2
6331590|NCT03050359|10079152|FG001|Overall Study|Randomized But Not Treated|0
6331591|NCT03050359|10079151|FG000|Overall Study|Pretreatment Event/Adverse Event|5
6331592|NCT03050359|10079152|FG001|Overall Study|Pretreatment Event/Adverse Event|10
6331593|NCT03050359|10079151|FG000|Overall Study|Significant Protocol Deviation|2
6331594|NCT03050359|10079152|FG001|Overall Study|Significant Protocol Deviation|3
6331595|NCT03050359|10079151|FG000|Overall Study|Lost to Follow-up|2
6331596|NCT03050359|10079152|FG001|Overall Study|Lost to Follow-up|1
6331597|NCT03050359|10079151|FG000|Overall Study|Voluntary Withdrawal|4
6331598|NCT03050359|10079152|FG001|Overall Study|Voluntary Withdrawal|6
6331599|NCT03050359|10079151|FG000|Overall Study|Pregnancy|1
6331600|NCT03050359|10079152|FG001|Overall Study|Pregnancy|0
6331601|NCT03050359|10079151|FG000|Overall Study|Reason Not Specified|1
6331602|NCT03050359|10079152|FG001|Overall Study|Reason Not Specified|0
6331603|NCT03050372|10079160|FG000|Adaptation Night (Night #1 PSG)|Adverse Event|1
6331604|NCT03050372|10079161|FG001|Adaptation Night (Night #1 PSG)|Adverse Event|0
6331605|NCT03050372|10079160|FG000|Second Intervention (Nights #4 and #5)|Lost to Follow-up|0
6331606|NCT03050372|10079161|FG001|Second Intervention (Nights #4 and #5)|Lost to Follow-up|1
6331607|NCT03050450|10079171|FG000|Overall Study|Physician Decision|1
6331608|NCT03050450|10079172|FG001|Overall Study|Physician Decision|0
6331609|NCT03050450|10079173|FG002|Overall Study|Physician Decision|0
6331610|NCT03050450|10079174|FG003|Overall Study|Physician Decision|0
6331611|NCT03050450|10079175|FG004|Overall Study|Physician Decision|0
6331612|NCT03050801|10079256|FG000|Experiment 1|Lost to Follow-up|0
6331613|NCT03050801|10079257|FG001|Experiment 1|Lost to Follow-up|1
6331614|NCT03050801|10079258|FG002|Experiment 1|Lost to Follow-up|0
6331615|NCT03050801|10079259|FG003|Experiment 1|Lost to Follow-up|0
6331616|NCT03050801|10079260|FG004|Experiment 1|Lost to Follow-up|0
6331617|NCT03050801|10079261|FG005|Experiment 1|Lost to Follow-up|0
6331618|NCT03050801|10079256|FG000|Experiment 1|Physician Decision|0
6331619|NCT03050801|10079257|FG001|Experiment 1|Physician Decision|3
6331620|NCT03050801|10079258|FG002|Experiment 1|Physician Decision|0
6331621|NCT03050801|10079259|FG003|Experiment 1|Physician Decision|0
6331622|NCT03050801|10079260|FG004|Experiment 1|Physician Decision|0
6331623|NCT03050801|10079261|FG005|Experiment 1|Physician Decision|0
6331624|NCT03050801|10079256|FG000|Experiment 1|Change of experimental design|0
6331625|NCT03050801|10079257|FG001|Experiment 1|Change of experimental design|3
6331626|NCT03050801|10079258|FG002|Experiment 1|Change of experimental design|0
6331627|NCT03050801|10079259|FG003|Experiment 1|Change of experimental design|0
6331628|NCT03050801|10079260|FG004|Experiment 1|Change of experimental design|0
6331629|NCT03050801|10079261|FG005|Experiment 1|Change of experimental design|0
6331630|NCT03050801|10079256|FG000|Experiment 1|Unable to obtain critical rTMS measure|0
6331631|NCT03050801|10079257|FG001|Experiment 1|Unable to obtain critical rTMS measure|0
6331632|NCT03050801|10079258|FG002|Experiment 1|Unable to obtain critical rTMS measure|2
6331633|NCT03050801|10079259|FG003|Experiment 1|Unable to obtain critical rTMS measure|0
6331634|NCT03050801|10079260|FG004|Experiment 1|Unable to obtain critical rTMS measure|0
6331635|NCT03050801|10079261|FG005|Experiment 1|Unable to obtain critical rTMS measure|0
6331636|NCT03050801|10079256|FG000|Experiment 2|Lost to Follow-up|0
6331637|NCT03050801|10079257|FG001|Experiment 2|Lost to Follow-up|0
6331638|NCT03050801|10079258|FG002|Experiment 2|Lost to Follow-up|0
6331639|NCT03050801|10079259|FG003|Experiment 2|Lost to Follow-up|1
6331640|NCT03050801|10079260|FG004|Experiment 2|Lost to Follow-up|1
6331641|NCT03050801|10079261|FG005|Experiment 2|Lost to Follow-up|0
6331642|NCT03050801|10079256|FG000|Experiment 2|Physician Decision|0
6331643|NCT03050801|10079257|FG001|Experiment 2|Physician Decision|0
6331644|NCT03050801|10079258|FG002|Experiment 2|Physician Decision|0
6331645|NCT03050801|10079259|FG003|Experiment 2|Physician Decision|0
6331646|NCT03050801|10079260|FG004|Experiment 2|Physician Decision|1
6331647|NCT03050801|10079261|FG005|Experiment 2|Physician Decision|0
6331648|NCT03050801|10079256|FG000|Experiment 2|Pregnancy|0
6331649|NCT03050801|10079257|FG001|Experiment 2|Pregnancy|0
6331650|NCT03050801|10079258|FG002|Experiment 2|Pregnancy|0
6331651|NCT03050801|10079259|FG003|Experiment 2|Pregnancy|0
6331652|NCT03050801|10079260|FG004|Experiment 2|Pregnancy|1
6331653|NCT03050801|10079261|FG005|Experiment 2|Pregnancy|0
6331654|NCT03050801|10079256|FG000|Experiment 2|Withdrawal by Subject|0
6331655|NCT03050801|10079257|FG001|Experiment 2|Withdrawal by Subject|0
6331656|NCT03050801|10079258|FG002|Experiment 2|Withdrawal by Subject|0
6331657|NCT03050801|10079259|FG003|Experiment 2|Withdrawal by Subject|1
6331658|NCT03050801|10079260|FG004|Experiment 2|Withdrawal by Subject|0
6331659|NCT03050801|10079261|FG005|Experiment 2|Withdrawal by Subject|0
6331660|NCT03050801|10079256|FG000|Experiment 2|Poor data quality|0
6331661|NCT03050801|10079257|FG001|Experiment 2|Poor data quality|0
6331662|NCT03050801|10079258|FG002|Experiment 2|Poor data quality|0
6331663|NCT03050801|10079259|FG003|Experiment 2|Poor data quality|4
6331664|NCT03050801|10079260|FG004|Experiment 2|Poor data quality|1
6331665|NCT03050801|10079261|FG005|Experiment 2|Poor data quality|0
6331666|NCT03050801|10079256|FG000|Experiment 2|Discomfort during stimulation|0
6331667|NCT03050801|10079257|FG001|Experiment 2|Discomfort during stimulation|0
6331668|NCT03050801|10079258|FG002|Experiment 2|Discomfort during stimulation|0
6331669|NCT03050801|10079259|FG003|Experiment 2|Discomfort during stimulation|0
6331670|NCT03050801|10079260|FG004|Experiment 2|Discomfort during stimulation|0
6331671|NCT03050801|10079261|FG005|Experiment 2|Discomfort during stimulation|2
6331672|NCT03051100|10079289|FG000|Overall Study|Withdrawal by Subject|1
6331673|NCT03051100|10079290|FG001|Overall Study|Withdrawal by Subject|0
6331674|NCT03051165|10079296|FG000|Overall Study|Withdrawal by Subject|1
6331675|NCT03051165|10079296|FG000|Overall Study|Early termination of study|12
6331676|NCT03051607|10079314|FG000|Overall Study|Adverse Event|66
6331677|NCT03051620|10079318|FG000|Overall Study|Lost to Follow-up|6
6331678|NCT03051620|10079318|FG000|Overall Study|n=124 enrolled in extension (all completed)|12
6331679|NCT03052322|10079358|FG000|Overall Study|Other un-specified|1
6331680|NCT03052322|10079359|FG001|Overall Study|Other un-specified|2
6331681|NCT03052322|10079358|FG000|Overall Study|Withdrawal by Subject|10
6331682|NCT03052322|10079359|FG001|Overall Study|Withdrawal by Subject|9
6331683|NCT03052322|10079358|FG000|Overall Study|Death|0
6331684|NCT03052322|10079359|FG001|Overall Study|Death|2
6331685|NCT03052322|10079358|FG000|Overall Study|Lack of Efficacy|1
6331686|NCT03052322|10079359|FG001|Overall Study|Lack of Efficacy|2
6331687|NCT03052322|10079358|FG000|Overall Study|Protocol Violation|1
6331688|NCT03052322|10079359|FG001|Overall Study|Protocol Violation|0
6331689|NCT03052322|10079358|FG000|Overall Study|Lost to Follow-up|2
6331690|NCT03052322|10079359|FG001|Overall Study|Lost to Follow-up|4
6331691|NCT03052322|10079358|FG000|Overall Study|Adverse Event|6
6331692|NCT03052322|10079359|FG001|Overall Study|Adverse Event|13
6331693|NCT03052426|10079368|FG000|Overall Study|Withdrawal by Subject|0
6331694|NCT03052426|10079369|FG001|Overall Study|Withdrawal by Subject|1
6331695|NCT03052426|10079370|FG002|Overall Study|Withdrawal by Subject|0
6331696|NCT03052426|10079368|FG000|Overall Study|Lost to Follow-up|2
6331697|NCT03052426|10079369|FG001|Overall Study|Lost to Follow-up|0
6331698|NCT03052426|10079370|FG002|Overall Study|Lost to Follow-up|1
6331699|NCT03052517|10079386|FG000|Overall Study|Study Terminated By Sponsor|928
6331700|NCT03052517|10079387|FG001|Overall Study|Study Terminated By Sponsor|938
6331701|NCT03052517|10079388|FG002|Overall Study|Study Terminated By Sponsor|296
6331702|NCT03052517|10079386|FG000|Overall Study|Subject/Guardian Decision|50
6331703|NCT03052517|10079387|FG001|Overall Study|Subject/Guardian Decision|45
6331704|NCT03052517|10079388|FG002|Overall Study|Subject/Guardian Decision|22
6331705|NCT03052517|10079386|FG000|Overall Study|Lack of Efficacy|23
6331706|NCT03052517|10079387|FG001|Overall Study|Lack of Efficacy|14
6331707|NCT03052517|10079388|FG002|Overall Study|Lack of Efficacy|7
6331708|NCT03052517|10079386|FG000|Overall Study|Adverse Event|6
6331709|NCT03052517|10079387|FG001|Overall Study|Adverse Event|5
6331710|NCT03052517|10079388|FG002|Overall Study|Adverse Event|0
6331711|NCT03052517|10079386|FG000|Overall Study|Physician Decision|4
6331712|NCT03052517|10079387|FG001|Overall Study|Physician Decision|5
6331713|NCT03052517|10079388|FG002|Overall Study|Physician Decision|1
6331714|NCT03052517|10079386|FG000|Overall Study|Death|3
6331715|NCT03052517|10079387|FG001|Overall Study|Death|0
6331716|NCT03052517|10079388|FG002|Overall Study|Death|1
6331717|NCT03052517|10079386|FG000|Overall Study|Lost to Follow-up|2
6331718|NCT03052517|10079387|FG001|Overall Study|Lost to Follow-up|4
6331719|NCT03052517|10079388|FG002|Overall Study|Lost to Follow-up|0
6331720|NCT03052517|10079386|FG000|Overall Study|Pregnancy|1
6331721|NCT03052517|10079387|FG001|Overall Study|Pregnancy|0
6331722|NCT03052517|10079388|FG002|Overall Study|Pregnancy|1
6331723|NCT03052517|10079386|FG000|Overall Study|Non-Compliance With Study Treatment|0
6331724|NCT03052517|10079387|FG001|Overall Study|Non-Compliance With Study Treatment|2
6331725|NCT03052517|10079388|FG002|Overall Study|Non-Compliance With Study Treatment|0
6331726|NCT03052517|10079386|FG000|Overall Study|Technical Problems|0
6331727|NCT03052517|10079387|FG001|Overall Study|Technical Problems|1
6331728|NCT03052517|10079388|FG002|Overall Study|Technical Problems|0
6331729|NCT03052725|10079402|FG000|Overall Study|Adverse Event|2
6331730|NCT03052725|10079403|FG001|Overall Study|Adverse Event|0
6331731|NCT03052725|10079402|FG000|Overall Study|Withdrawal by Subject|3
6331732|NCT03052725|10079403|FG001|Overall Study|Withdrawal by Subject|4
6331733|NCT03052725|10079402|FG000|Overall Study|Pregnancy|0
6331734|NCT03052725|10079403|FG001|Overall Study|Pregnancy|1
6331735|NCT03052725|10079402|FG000|Overall Study|Site closure|0
6331736|NCT03052725|10079403|FG001|Overall Study|Site closure|1
6331737|NCT03052725|10079402|FG000|Overall Study|Study terminated by sponsor|143
6331738|NCT03052725|10079403|FG001|Overall Study|Study terminated by sponsor|144
6331739|NCT03052751|10079410|FG000|Dosing Period 1|Adverse Event|0
6331740|NCT03052751|10079411|FG001|Dosing Period 1|Adverse Event|1
6331741|NCT03052751|10079412|FG002|Dosing Period 1|Adverse Event|0
6331742|NCT03052751|10079413|FG003|Dosing Period 1|Adverse Event|0
6331743|NCT03052751|10079414|FG004|Dosing Period 1|Adverse Event|0
6331744|NCT03052751|10079415|FG005|Dosing Period 1|Adverse Event|0
6331745|NCT03052751|10079410|FG000|Dosing Period 2|Adverse Event|0
6331746|NCT03052751|10079411|FG001|Dosing Period 2|Adverse Event|0
6331747|NCT03052751|10079412|FG002|Dosing Period 2|Adverse Event|3
6331748|NCT03052751|10079413|FG003|Dosing Period 2|Adverse Event|0
6331749|NCT03052751|10079414|FG004|Dosing Period 2|Adverse Event|0
6331750|NCT03052751|10079415|FG005|Dosing Period 2|Adverse Event|0
6331751|NCT03052751|10079410|FG000|Observation Period|Adverse Event|0
6331752|NCT03052751|10079411|FG001|Observation Period|Adverse Event|0
6331753|NCT03052751|10079412|FG002|Observation Period|Adverse Event|0
6331754|NCT03052751|10079413|FG003|Observation Period|Adverse Event|0
6331755|NCT03052751|10079414|FG004|Observation Period|Adverse Event|1
6331756|NCT03052751|10079415|FG005|Observation Period|Adverse Event|0
6331757|NCT03052764|10079427|FG000|Double-Blind Treatment Period|Adverse Event|2
6331758|NCT03052764|10079428|FG001|Double-Blind Treatment Period|Adverse Event|0
6331759|NCT03052764|10079427|FG000|Double-Blind Treatment Period|Lack of Efficacy|1
6331760|NCT03052764|10079428|FG001|Double-Blind Treatment Period|Lack of Efficacy|0
6331761|NCT03052764|10079427|FG000|Double-Blind Treatment Period|Protocol Violation|2
6331762|NCT03052764|10079428|FG001|Double-Blind Treatment Period|Protocol Violation|1
6331763|NCT03052764|10079427|FG000|Double-Blind Treatment Period|Withdrawal by Subject|3
6331764|NCT03052764|10079428|FG001|Double-Blind Treatment Period|Withdrawal by Subject|1
6331765|NCT03052764|10079427|FG000|Double-Blind Treatment Period|Reason not Specified|2
6331766|NCT03052764|10079428|FG001|Double-Blind Treatment Period|Reason not Specified|1
6331767|NCT03052816|10079438|FG000|Overall Study|Withdrawal by Subject|1
6331768|NCT03052816|10079439|FG001|Overall Study|Withdrawal by Subject|0
6331769|NCT03052816|10079438|FG000|Overall Study|Desired opioids|2
6331770|NCT03052816|10079439|FG001|Overall Study|Desired opioids|0
6331771|NCT03052959|10079449|FG000|Overall Study|Lost to Follow-up|4
6331772|NCT03052959|10079450|FG001|Overall Study|Lost to Follow-up|5
6331773|NCT03053050|10079470|FG000|Randomized Phase|Study Terminated by Sponsor|259
6331774|NCT03053050|10079471|FG001|Randomized Phase|Study Terminated by Sponsor|260
6331775|NCT03053050|10079472|FG002|Randomized Phase|Study Terminated by Sponsor|128
6331776|NCT03053050|10079473|FG003|Randomized Phase|Study Terminated by Sponsor|0
6331777|NCT03053050|10079470|FG000|Randomized Phase|Withdrew Consent|16
6331778|NCT03053050|10079471|FG001|Randomized Phase|Withdrew Consent|8
6331779|NCT03053050|10079472|FG002|Randomized Phase|Withdrew Consent|9
6331780|NCT03053050|10079473|FG003|Randomized Phase|Withdrew Consent|0
6331781|NCT03053050|10079470|FG000|Randomized Phase|Investigator's Discretion|6
6331782|NCT03053050|10079471|FG001|Randomized Phase|Investigator's Discretion|6
6331783|NCT03053050|10079472|FG002|Randomized Phase|Investigator's Discretion|3
6331784|NCT03053050|10079473|FG003|Randomized Phase|Investigator's Discretion|0
6331785|NCT03053050|10079470|FG000|Randomized Phase|Lost to Follow-up|5
6331786|NCT03053050|10079471|FG001|Randomized Phase|Lost to Follow-up|1
6331787|NCT03053050|10079472|FG002|Randomized Phase|Lost to Follow-up|1
6331788|NCT03053050|10079473|FG003|Randomized Phase|Lost to Follow-up|0
6331789|NCT03053050|10079470|FG000|Randomized Phase|Adverse Event|0
6331790|NCT03053050|10079471|FG001|Randomized Phase|Adverse Event|1
6331791|NCT03053050|10079472|FG002|Randomized Phase|Adverse Event|0
6331792|NCT03053050|10079473|FG003|Randomized Phase|Adverse Event|0
6331793|NCT03053050|10079470|FG000|Randomized Phase|Randomized but Never Treated|2
6331794|NCT03053050|10079471|FG001|Randomized Phase|Randomized but Never Treated|2
6331795|NCT03053050|10079472|FG002|Randomized Phase|Randomized but Never Treated|2
6331796|NCT03053050|10079473|FG003|Randomized Phase|Randomized but Never Treated|0
6331797|NCT03053050|10079470|FG000|Randomized Phase|Entered the Open-Label Phase|36
6331798|NCT03053050|10079471|FG001|Randomized Phase|Entered the Open-Label Phase|45
6331799|NCT03053050|10079472|FG002|Randomized Phase|Entered the Open-Label Phase|18
6331800|NCT03053050|10079473|FG003|Randomized Phase|Entered the Open-Label Phase|0
6331801|NCT03053050|10079470|FG000|Open-label Phase|Study Terminated by Sponsor|0
6331802|NCT03053050|10079471|FG001|Open-label Phase|Study Terminated by Sponsor|0
6331803|NCT03053050|10079472|FG002|Open-label Phase|Study Terminated by Sponsor|0
6331804|NCT03053050|10079473|FG003|Open-label Phase|Study Terminated by Sponsor|89
6331805|NCT03053050|10079470|FG000|Open-label Phase|Withdrew Consent|0
6331806|NCT03053050|10079471|FG001|Open-label Phase|Withdrew Consent|0
6331807|NCT03053050|10079472|FG002|Open-label Phase|Withdrew Consent|0
6331808|NCT03053050|10079473|FG003|Open-label Phase|Withdrew Consent|6
6331809|NCT03053050|10079470|FG000|Open-label Phase|Investigator's Discretion|0
6331810|NCT03053050|10079471|FG001|Open-label Phase|Investigator's Discretion|0
6331811|NCT03053050|10079472|FG002|Open-label Phase|Investigator's Discretion|0
6331812|NCT03053050|10079473|FG003|Open-label Phase|Investigator's Discretion|4
6331813|NCT03053063|10079485|FG000|Randomized Phase|Study Terminated by Sponsor|326
6331814|NCT03053063|10079486|FG001|Randomized Phase|Study Terminated by Sponsor|317
6331815|NCT03053063|10079487|FG002|Randomized Phase|Study Terminated by Sponsor|161
6331816|NCT03053063|10079488|FG003|Randomized Phase|Study Terminated by Sponsor|0
6331817|NCT03053063|10079485|FG000|Randomized Phase|Withdrew consent|8
6331818|NCT03053063|10079486|FG001|Randomized Phase|Withdrew consent|11
6331819|NCT03053063|10079487|FG002|Randomized Phase|Withdrew consent|5
6331820|NCT03053063|10079488|FG003|Randomized Phase|Withdrew consent|0
6331821|NCT03053063|10079485|FG000|Randomized Phase|Investigator's Discretion|8
6331822|NCT03053063|10079486|FG001|Randomized Phase|Investigator's Discretion|6
6331823|NCT03053063|10079487|FG002|Randomized Phase|Investigator's Discretion|2
6331824|NCT03053063|10079488|FG003|Randomized Phase|Investigator's Discretion|0
6331825|NCT03053063|10079485|FG000|Randomized Phase|Lost to Follow-up|3
6331826|NCT03053063|10079486|FG001|Randomized Phase|Lost to Follow-up|5
6331827|NCT03053063|10079487|FG002|Randomized Phase|Lost to Follow-up|1
6331828|NCT03053063|10079488|FG003|Randomized Phase|Lost to Follow-up|0
6331829|NCT03053063|10079485|FG000|Randomized Phase|Adverse Event|0
6331830|NCT03053063|10079486|FG001|Randomized Phase|Adverse Event|1
6331831|NCT03053063|10079487|FG002|Randomized Phase|Adverse Event|0
6331832|NCT03053063|10079488|FG003|Randomized Phase|Adverse Event|0
6331833|NCT03053063|10079485|FG000|Randomized Phase|Randomized but Never Treated|1
6331834|NCT03053063|10079486|FG001|Randomized Phase|Randomized but Never Treated|3
6331835|NCT03053063|10079487|FG002|Randomized Phase|Randomized but Never Treated|2
6331836|NCT03053063|10079488|FG003|Randomized Phase|Randomized but Never Treated|0
6331837|NCT03053063|10079485|FG000|Randomized Phase|Entered the Open-Label Phase|9
6331838|NCT03053063|10079486|FG001|Randomized Phase|Entered the Open-Label Phase|11
6331839|NCT03053063|10079487|FG002|Randomized Phase|Entered the Open-Label Phase|3
6331840|NCT03053063|10079488|FG003|Randomized Phase|Entered the Open-Label Phase|0
6331841|NCT03053063|10079485|FG000|Open-Label Phase|Study Terminated by Sponsor|0
6331842|NCT03053063|10079486|FG001|Open-Label Phase|Study Terminated by Sponsor|0
6331843|NCT03053063|10079487|FG002|Open-Label Phase|Study Terminated by Sponsor|0
6331844|NCT03053063|10079488|FG003|Open-Label Phase|Study Terminated by Sponsor|19
6331845|NCT03053063|10079485|FG000|Open-Label Phase|Death|0
6331846|NCT03053063|10079486|FG001|Open-Label Phase|Death|0
6167194|NCT01226511|9811634|FG001|Extension Treatment Period|Withdrawal by Subject|3
6167195|NCT01226511|9811633|FG000|Extension Treatment Period|Parent/Caregiver Decision|8
6167196|NCT01226511|9811634|FG001|Extension Treatment Period|Parent/Caregiver Decision|8
6167197|NCT01226511|9811633|FG000|Extension Treatment Period|Sponsor Decision|1
6167198|NCT01226511|9811634|FG001|Extension Treatment Period|Sponsor Decision|1
6167199|NCT01226511|9811633|FG000|Taper Period|Adverse Event|1
6167200|NCT01226511|9811634|FG001|Taper Period|Adverse Event|0
6167201|NCT01226511|9811633|FG000|Taper Period|Lost to Follow-up|2
6167202|NCT01226511|9811634|FG001|Taper Period|Lost to Follow-up|2
6167203|NCT01226511|9811633|FG000|Taper Period|Protocol Violation|1
6167204|NCT01226511|9811634|FG001|Taper Period|Protocol Violation|0
6167205|NCT01226511|9811633|FG000|Taper Period|Parent/Caregiver Decision|1
6167206|NCT01226511|9811634|FG001|Taper Period|Parent/Caregiver Decision|1
6167207|NCT01226745|9811667|FG000|Overall Study|Did not complete schedule of assessments|8
6167208|NCT01226745|9811668|FG001|Overall Study|Did not complete schedule of assessments|3
6167209|NCT01226745|9811669|FG002|Overall Study|Did not complete schedule of assessments|6
6167210|NCT01226745|9811670|FG003|Overall Study|Did not complete schedule of assessments|0
6167211|NCT01226745|9811671|FG004|Overall Study|Did not complete schedule of assessments|0
6167212|NCT01226745|9811672|FG005|Overall Study|Did not complete schedule of assessments|1
6167213|NCT01226745|9811667|FG000|Overall Study|Lost to Follow-up|2
6167214|NCT01226745|9811668|FG001|Overall Study|Lost to Follow-up|6
6167215|NCT01226745|9811669|FG002|Overall Study|Lost to Follow-up|6
6167216|NCT01226745|9811670|FG003|Overall Study|Lost to Follow-up|1
6167217|NCT01226745|9811671|FG004|Overall Study|Lost to Follow-up|1
6167218|NCT01226745|9811672|FG005|Overall Study|Lost to Follow-up|2
6167219|NCT01226745|9811667|FG000|Overall Study|Death|1
6167220|NCT01226745|9811668|FG001|Overall Study|Death|0
6167221|NCT01226745|9811669|FG002|Overall Study|Death|0
6167222|NCT01226745|9811670|FG003|Overall Study|Death|0
6167223|NCT01226745|9811671|FG004|Overall Study|Death|0
6167224|NCT01226745|9811672|FG005|Overall Study|Death|1
6167225|NCT01226745|9811667|FG000|Overall Study|Other|6
6167226|NCT01226745|9811668|FG001|Overall Study|Other|7
6167227|NCT01226745|9811669|FG002|Overall Study|Other|8
6167228|NCT01226745|9811670|FG003|Overall Study|Other|4
6167229|NCT01226745|9811671|FG004|Overall Study|Other|3
6167230|NCT01226745|9811672|FG005|Overall Study|Other|1
6167231|NCT01227018|9811710|FG000|Overall Study|Disease progression|9
6167232|NCT01227018|9811710|FG000|Overall Study|Toxicity|2
6167233|NCT01227018|9811710|FG000|Overall Study|Withdrew after beginning treatment|4
6167234|NCT01227044|9811716|FG000|Overall Study|Lost to Follow-up|5
6167235|NCT01227044|9811717|FG001|Overall Study|Lost to Follow-up|7
6167236|NCT01227044|9811716|FG000|Overall Study|Discontinued Intervention|1
6167237|NCT01227044|9811717|FG001|Overall Study|Discontinued Intervention|2
6167238|NCT01227252|9811737|FG000|Overall Study|Sponsor Decision|0
6167239|NCT01227252|9811738|FG001|Overall Study|Sponsor Decision|1
6167240|NCT01227252|9811739|FG002|Overall Study|Sponsor Decision|0
6167241|NCT01227252|9811740|FG003|Overall Study|Sponsor Decision|0
6167242|NCT01227252|9811737|FG000|Overall Study|Lost to Follow-up|0
6167243|NCT01227252|9811738|FG001|Overall Study|Lost to Follow-up|1
6167244|NCT01227252|9811739|FG002|Overall Study|Lost to Follow-up|0
6167245|NCT01227252|9811740|FG003|Overall Study|Lost to Follow-up|0
6167246|NCT01227252|9811737|FG000|Overall Study|Withdrawal by Subject|0
6167247|NCT01227252|9811738|FG001|Overall Study|Withdrawal by Subject|1
6167248|NCT01227252|9811739|FG002|Overall Study|Withdrawal by Subject|0
6167249|NCT01227252|9811740|FG003|Overall Study|Withdrawal by Subject|0
6167250|NCT01227265|9811756|FG000|Overall Study|Did Not Receive Treatment|1
6167251|NCT01227265|9811757|FG001|Overall Study|Did Not Receive Treatment|2
6167252|NCT01227265|9811758|FG002|Overall Study|Did Not Receive Treatment|0
6167253|NCT01227265|9811756|FG000|Overall Study|Administrative|1
6167254|NCT01227265|9811757|FG001|Overall Study|Administrative|0
6167255|NCT01227265|9811758|FG002|Overall Study|Administrative|2
6167256|NCT01227265|9811756|FG000|Overall Study|Did Not Meet Protocol Eligibility|0
6167257|NCT01227265|9811757|FG001|Overall Study|Did Not Meet Protocol Eligibility|0
6167258|NCT01227265|9811758|FG002|Overall Study|Did Not Meet Protocol Eligibility|1
6167259|NCT01227265|9811756|FG000|Overall Study|Protocol Violation|2
6167260|NCT01227265|9811757|FG001|Overall Study|Protocol Violation|1
6167261|NCT01227265|9811758|FG002|Overall Study|Protocol Violation|0
6167262|NCT01227265|9811756|FG000|Overall Study|Withdrawal by Subject|7
6167263|NCT01227265|9811757|FG001|Overall Study|Withdrawal by Subject|7
6167264|NCT01227265|9811758|FG002|Overall Study|Withdrawal by Subject|3
6167265|NCT01227265|9811756|FG000|Overall Study|Lost to Follow-up|2
6167266|NCT01227265|9811757|FG001|Overall Study|Lost to Follow-up|0
6167267|NCT01227265|9811758|FG002|Overall Study|Lost to Follow-up|3
6167268|NCT01227265|9811756|FG000|Overall Study|Adverse Event|6
6167269|NCT01227265|9811757|FG001|Overall Study|Adverse Event|10
6167270|NCT01227265|9811758|FG002|Overall Study|Adverse Event|5
6167271|NCT01227278|9811768|FG000|Overall Study|Withdrawal by Subject|4
6167272|NCT01227278|9811769|FG001|Overall Study|Withdrawal by Subject|4
6167273|NCT01227278|9811768|FG000|Overall Study|Death|0
6167274|NCT01227278|9811769|FG001|Overall Study|Death|2
6167275|NCT01227278|9811768|FG000|Overall Study|Other|1
6167276|NCT01227278|9811769|FG001|Overall Study|Other|2
6167277|NCT01227395|9811783|FG000|Overall Study|Protocol Violation|0
6167278|NCT01227395|9811784|FG001|Overall Study|Protocol Violation|1
6167279|NCT01227421|9811812|FG000|Overall Study|Lost to Follow-up|6
6167280|NCT01227421|9811813|FG001|Overall Study|Lost to Follow-up|7
6167281|NCT01227421|9811814|FG002|Overall Study|Lost to Follow-up|5
6167282|NCT01227421|9811812|FG000|Overall Study|Adverse Event|2
6167283|NCT01227421|9811813|FG001|Overall Study|Adverse Event|7
6167284|NCT01227421|9811814|FG002|Overall Study|Adverse Event|2
6167285|NCT01227421|9811812|FG000|Overall Study|Withdrawal by Subject|1
6167286|NCT01227421|9811813|FG001|Overall Study|Withdrawal by Subject|2
6167287|NCT01227421|9811814|FG002|Overall Study|Withdrawal by Subject|1
6167288|NCT01227421|9811812|FG000|Overall Study|Protocol Violation|1
6167289|NCT01227421|9811813|FG001|Overall Study|Protocol Violation|1
6167290|NCT01227421|9811814|FG002|Overall Study|Protocol Violation|2
6167291|NCT01227421|9811812|FG000|Overall Study|Randomized in error|1
6167292|NCT01227421|9811813|FG001|Overall Study|Randomized in error|1
6167293|NCT01227421|9811814|FG002|Overall Study|Randomized in error|0
6167294|NCT01227512|9811834|FG000|Overall Study|Physician Decision|6
6167295|NCT01227512|9811835|FG001|Overall Study|Physician Decision|6
6167296|NCT01227512|9811834|FG000|Overall Study|Adverse Event|4
6167297|NCT01227512|9811835|FG001|Overall Study|Adverse Event|3
6167298|NCT01227512|9811834|FG000|Overall Study|Withdrawal by Subject|3
6167299|NCT01227512|9811835|FG001|Overall Study|Withdrawal by Subject|0
6331847|NCT03053063|10079487|FG002|Open-Label Phase|Death|0
6331848|NCT03053063|10079488|FG003|Open-Label Phase|Death|2
6331849|NCT03053063|10079485|FG000|Open-Label Phase|Investigator's discretion|0
6331850|NCT03053063|10079486|FG001|Open-Label Phase|Investigator's discretion|0
6331851|NCT03053063|10079487|FG002|Open-Label Phase|Investigator's discretion|0
6331852|NCT03053063|10079488|FG003|Open-Label Phase|Investigator's discretion|2
6331853|NCT03053102|10079497|FG000|Study Part 2: 84-Day Treatment|Adverse Event|1
6331854|NCT03053102|10079497|FG000|Study Part 2: 84-Day Treatment|Withdrawal by Subject|1
6331855|NCT03053180|10079502|FG000|Overall Study|Failure to Return|1
6331856|NCT03053271|10079506|FG000|Overall Study|Did not meet randomization criteria|3
6331857|NCT03053271|10079506|FG000|Overall Study|Withdrawal by Subject|1
6331858|NCT03053427|10079522|FG000|Overall Study|Adverse Event|4
6331859|NCT03053427|10079523|FG001|Overall Study|Adverse Event|4
6331860|NCT03053427|10079522|FG000|Overall Study|Lack of Efficacy|1
6331861|NCT03053427|10079523|FG001|Overall Study|Lack of Efficacy|3
6331862|NCT03053427|10079522|FG000|Overall Study|Lost to Follow-up|2
6331863|NCT03053427|10079523|FG001|Overall Study|Lost to Follow-up|2
6331864|NCT03053427|10079522|FG000|Overall Study|Worsening of the target disease|0
6331865|NCT03053427|10079523|FG001|Overall Study|Worsening of the target disease|1
6331866|NCT03053427|10079522|FG000|Overall Study|Protocol Deviation|3
6331867|NCT03053427|10079523|FG001|Overall Study|Protocol Deviation|3
6331868|NCT03053427|10079522|FG000|Overall Study|Withdrawal by Subject|3
6331869|NCT03053427|10079523|FG001|Overall Study|Withdrawal by Subject|2
6331870|NCT03053427|10079522|FG000|Overall Study|Miscellaneous|0
6331871|NCT03053427|10079523|FG001|Overall Study|Miscellaneous|1
6331872|NCT03053492|10079531|FG000|Overall Study|Adverse Event|1
6331873|NCT03053492|10079532|FG001|Overall Study|Adverse Event|1
6331874|NCT03053492|10079531|FG000|Overall Study|Withdrawal by Subject|7
6331875|NCT03053492|10079532|FG001|Overall Study|Withdrawal by Subject|5
6331876|NCT03054064|10079549|FG000|Overall Study|Lower Extremity Deep Vein Thrombosis|1
6331877|NCT03054064|10079549|FG000|Overall Study|Investigator Decision|2
6331878|NCT03054064|10079549|FG000|Overall Study|Bladder Issue|1
6331879|NCT03054064|10079549|FG000|Overall Study|High Blood Pressure|1
6331880|NCT03054064|10079549|FG000|Overall Study|Change in Status|1
6331881|NCT03054337|10079581|FG000|Dose Adjustment and Maintenance Period|Investigator discretion|1
6331882|NCT03054337|10079582|FG001|Dose Adjustment and Maintenance Period|Investigator discretion|2
6331883|NCT03054337|10079583|FG002|Dose Adjustment and Maintenance Period|Investigator discretion|1
6331884|NCT03054337|10079584|FG003|Dose Adjustment and Maintenance Period|Investigator discretion|0
6167300|NCT01227512|9811834|FG000|Overall Study|Participant met withdrawal criteria|0
6167301|NCT01227512|9811835|FG001|Overall Study|Participant met withdrawal criteria|1
6167302|NCT01227564|9811850|FG000|Overall Study|No Longer Willing to Participate|4
6167303|NCT01227564|9811851|FG001|Overall Study|No Longer Willing to Participate|2
6192159|NCT01428115|9849244|FG000|Overall Study|Withdrawal by Subject|4
6331885|NCT03054337|10079585|FG004|Dose Adjustment and Maintenance Period|Investigator discretion|0
6331886|NCT03054337|10079586|FG005|Dose Adjustment and Maintenance Period|Investigator discretion|1
6331887|NCT03054350|10079619|FG000|Primary Efficacy Period (6 Weeks)|ESA Rescue/Blood Transfusion for Anemia|4
6331888|NCT03054350|10079620|FG001|Primary Efficacy Period (6 Weeks)|ESA Rescue/Blood Transfusion for Anemia|2
6331889|NCT03054350|10079621|FG002|Primary Efficacy Period (6 Weeks)|ESA Rescue/Blood Transfusion for Anemia|1
6331890|NCT03054350|10079622|FG003|Primary Efficacy Period (6 Weeks)|ESA Rescue/Blood Transfusion for Anemia|2
6331891|NCT03054350|10079623|FG004|Primary Efficacy Period (6 Weeks)|ESA Rescue/Blood Transfusion for Anemia|4
6331892|NCT03054350|10079624|FG005|Primary Efficacy Period (6 Weeks)|ESA Rescue/Blood Transfusion for Anemia|3
6331893|NCT03054350|10079619|FG000|Primary Efficacy Period (6 Weeks)|Withdrawal by Subject|0
6331894|NCT03054350|10079620|FG001|Primary Efficacy Period (6 Weeks)|Withdrawal by Subject|0
6331895|NCT03054350|10079621|FG002|Primary Efficacy Period (6 Weeks)|Withdrawal by Subject|1
6331896|NCT03054350|10079622|FG003|Primary Efficacy Period (6 Weeks)|Withdrawal by Subject|0
6331897|NCT03054350|10079623|FG004|Primary Efficacy Period (6 Weeks)|Withdrawal by Subject|0
6331898|NCT03054350|10079624|FG005|Primary Efficacy Period (6 Weeks)|Withdrawal by Subject|0
6331899|NCT03054350|10079619|FG000|Dose Adjustment and Maintenance Period|ESA Rescue/Blood Transfusion for Anemia|1
6331900|NCT03054350|10079620|FG001|Dose Adjustment and Maintenance Period|ESA Rescue/Blood Transfusion for Anemia|0
6331901|NCT03054350|10079621|FG002|Dose Adjustment and Maintenance Period|ESA Rescue/Blood Transfusion for Anemia|0
6331902|NCT03054350|10079622|FG003|Dose Adjustment and Maintenance Period|ESA Rescue/Blood Transfusion for Anemia|1
6331903|NCT03054350|10079623|FG004|Dose Adjustment and Maintenance Period|ESA Rescue/Blood Transfusion for Anemia|0
6331904|NCT03054350|10079624|FG005|Dose Adjustment and Maintenance Period|ESA Rescue/Blood Transfusion for Anemia|0
6331905|NCT03054350|10079619|FG000|Dose Adjustment and Maintenance Period|Captured as Other|0
6331906|NCT03054350|10079620|FG001|Dose Adjustment and Maintenance Period|Captured as Other|0
6331907|NCT03054350|10079621|FG002|Dose Adjustment and Maintenance Period|Captured as Other|1
6331908|NCT03054350|10079622|FG003|Dose Adjustment and Maintenance Period|Captured as Other|0
6331909|NCT03054350|10079623|FG004|Dose Adjustment and Maintenance Period|Captured as Other|0
6331910|NCT03054350|10079624|FG005|Dose Adjustment and Maintenance Period|Captured as Other|0
6331911|NCT03054428|10079658|FG000|Overall Study|Physician Decision|0
6331912|NCT03054428|10079659|FG001|Overall Study|Physician Decision|1
6331913|NCT03054428|10079660|FG002|Overall Study|Physician Decision|1
6331914|NCT03054428|10079658|FG000|Overall Study|Lack of Efficacy|3
6331915|NCT03054428|10079659|FG001|Overall Study|Lack of Efficacy|1
6331916|NCT03054428|10079660|FG002|Overall Study|Lack of Efficacy|0
6331917|NCT03054428|10079658|FG000|Overall Study|Discontinued to enroll in OLE: enrolled|0
6331918|NCT03054428|10079659|FG001|Overall Study|Discontinued to enroll in OLE: enrolled|0
6331919|NCT03054428|10079660|FG002|Overall Study|Discontinued to enroll in OLE: enrolled|1
6331920|NCT03054428|10079658|FG000|Overall Study|Discont'd to enroll in OLE: not enrolled|1
6331921|NCT03054428|10079659|FG001|Overall Study|Discont'd to enroll in OLE: not enrolled|0
6331922|NCT03054428|10079660|FG002|Overall Study|Discont'd to enroll in OLE: not enrolled|0
6331923|NCT03054428|10079658|FG000|Overall Study|Transitioned to OLE study|76
6331924|NCT03054428|10079659|FG001|Overall Study|Transitioned to OLE study|76
6331925|NCT03054428|10079660|FG002|Overall Study|Transitioned to OLE study|73
6331926|NCT03054428|10079658|FG000|Overall Study|Withdrawal by Subject|3
6331927|NCT03054428|10079659|FG001|Overall Study|Withdrawal by Subject|2
6331928|NCT03054428|10079660|FG002|Overall Study|Withdrawal by Subject|3
6331929|NCT03054428|10079658|FG000|Overall Study|Lost to Follow-up|0
6331930|NCT03054428|10079659|FG001|Overall Study|Lost to Follow-up|0
6331931|NCT03054428|10079660|FG002|Overall Study|Lost to Follow-up|1
6331932|NCT03054870|10079755|FG000|Day of Ventilation Imaging|Protocol Violation|4
6331933|NCT03054870|10079755|FG000|Day of Ventilation Imaging|Lost to Follow-up|1
6331934|NCT03055195|10079807|FG000|Overall Study|Lack of Efficacy|1
6331935|NCT03055195|10079808|FG001|Overall Study|Lack of Efficacy|0
6331936|NCT03055195|10079807|FG000|Overall Study|Withdrawal by Subject|6
6331937|NCT03055195|10079808|FG001|Overall Study|Withdrawal by Subject|7
6331938|NCT03055195|10079807|FG000|Overall Study|Study Terminated by Sponsor|2
6331939|NCT03055195|10079808|FG001|Overall Study|Study Terminated by Sponsor|6
6331940|NCT03055195|10079807|FG000|Overall Study|Protocol Violation|2
6331941|NCT03055195|10079808|FG001|Overall Study|Protocol Violation|1
6331942|NCT03055195|10079807|FG000|Overall Study|Physician Decision|1
6331943|NCT03055195|10079808|FG001|Overall Study|Physician Decision|0
6331944|NCT03055221|10079814|FG000|Overall Study|Adverse Event|2
6331945|NCT03055221|10079814|FG000|Overall Study|Withdrawal by Subject|4
6331946|NCT03055221|10079814|FG000|Overall Study|Death|6
6331947|NCT03055221|10079814|FG000|Overall Study|Physician Decision|1
6331948|NCT03055221|10079814|FG000|Overall Study|Study terminated by Sponsor|3
6331949|NCT03055260|10079820|FG000|Overall Study|Withdrawal by Subject|1
6331950|NCT03055260|10079821|FG001|Overall Study|Withdrawal by Subject|0
6331951|NCT03055338|10079830|FG000|Overall Study|Lost to Follow-up|9
6331952|NCT03055338|10079831|FG001|Overall Study|Lost to Follow-up|2
6331953|NCT03055338|10079832|FG002|Overall Study|Lost to Follow-up|3
6331954|NCT03055338|10079830|FG000|Overall Study|No Post-treatment Protocol Contact|0
6331955|NCT03055338|10079831|FG001|Overall Study|No Post-treatment Protocol Contact|1
6331956|NCT03055338|10079832|FG002|Overall Study|No Post-treatment Protocol Contact|0
6331957|NCT03055338|10079830|FG000|Overall Study|Physician Decision|0
6331958|NCT03055338|10079831|FG001|Overall Study|Physician Decision|0
6331959|NCT03055338|10079832|FG002|Overall Study|Physician Decision|2
6331960|NCT03055338|10079830|FG000|Overall Study|Withdrawal by Subject|9
6331961|NCT03055338|10079831|FG001|Overall Study|Withdrawal by Subject|8
6331962|NCT03055338|10079832|FG002|Overall Study|Withdrawal by Subject|7
6331963|NCT03055494|10079842|FG000|Overall Study|Lost to Follow-up|6
6331964|NCT03055494|10079843|FG001|Overall Study|Lost to Follow-up|0
6331965|NCT03055494|10079842|FG000|Overall Study|Physician Decision|2
6331966|NCT03055494|10079843|FG001|Overall Study|Physician Decision|0
6331967|NCT03055494|10079842|FG000|Overall Study|Withdrawal by Subject|1
6331968|NCT03055494|10079843|FG001|Overall Study|Withdrawal by Subject|0
6331969|NCT03055494|10079842|FG000|Overall Study|Adverse Event|0
6331970|NCT03055494|10079843|FG001|Overall Study|Adverse Event|1
6331971|NCT03055494|10079842|FG000|Overall Study|Non-compliance with study treatment|1
6331972|NCT03055494|10079843|FG001|Overall Study|Non-compliance with study treatment|0
6331973|NCT03055624|10079850|FG000|Overall Study|Study closed|9
6331974|NCT03055806|10079862|FG000|Overall Study|Adverse Event|0
6331975|NCT03055806|10079863|FG001|Overall Study|Adverse Event|0
6331976|NCT03055806|10079864|FG002|Overall Study|Adverse Event|1
6331977|NCT03055806|10079865|FG003|Overall Study|Adverse Event|1
6331978|NCT03055806|10079862|FG000|Overall Study|Lost to Follow-up|0
6331979|NCT03055806|10079863|FG001|Overall Study|Lost to Follow-up|3
6331980|NCT03055806|10079864|FG002|Overall Study|Lost to Follow-up|6
6331981|NCT03055806|10079865|FG003|Overall Study|Lost to Follow-up|7
6331982|NCT03055806|10079862|FG000|Overall Study|Physician Decision|1
6331983|NCT03055806|10079863|FG001|Overall Study|Physician Decision|0
6331984|NCT03055806|10079864|FG002|Overall Study|Physician Decision|0
6331985|NCT03055806|10079865|FG003|Overall Study|Physician Decision|1
6331986|NCT03055806|10079862|FG000|Overall Study|Protocol Violation|1
6331987|NCT03055806|10079863|FG001|Overall Study|Protocol Violation|0
6331988|NCT03055806|10079864|FG002|Overall Study|Protocol Violation|0
6331989|NCT03055806|10079865|FG003|Overall Study|Protocol Violation|0
6331990|NCT03055806|10079862|FG000|Overall Study|Withdrawal of consent to continue drug|1
6331991|NCT03055806|10079863|FG001|Overall Study|Withdrawal of consent to continue drug|1
6331992|NCT03055806|10079864|FG002|Overall Study|Withdrawal of consent to continue drug|2
6331993|NCT03055806|10079865|FG003|Overall Study|Withdrawal of consent to continue drug|0
6331994|NCT03055806|10079862|FG000|Overall Study|Withdrawal of consent to continue study|2
6331995|NCT03055806|10079863|FG001|Overall Study|Withdrawal of consent to continue study|3
6331996|NCT03055806|10079864|FG002|Overall Study|Withdrawal of consent to continue study|4
6331997|NCT03055806|10079865|FG003|Overall Study|Withdrawal of consent to continue study|6
6331998|NCT03055806|10079862|FG000|Overall Study|Partner not willing to try intercourse|1
6331999|NCT03055806|10079863|FG001|Overall Study|Partner not willing to try intercourse|0
6332000|NCT03055806|10079864|FG002|Overall Study|Partner not willing to try intercourse|0
6332001|NCT03055806|10079865|FG003|Overall Study|Partner not willing to try intercourse|0
6332002|NCT03055832|10079877|FG000|Week 2|Withdrawal by Subject|1
6332003|NCT03055832|10079878|FG001|Week 2|Withdrawal by Subject|0
6332004|NCT03055858|10079898|FG000|Overall Study|Death|5
6332005|NCT03055858|10079898|FG000|Overall Study|Adverse Event|1
6332006|NCT03055936|10079910|FG000|Overall Study|Adverse Event|0
6332007|NCT03055936|10079911|FG001|Overall Study|Adverse Event|1
6332008|NCT03055936|10079912|FG002|Overall Study|Adverse Event|1
6332009|NCT03055936|10079913|FG003|Overall Study|Adverse Event|1
6332010|NCT03055936|10079910|FG000|Overall Study|Personal reason|2
6332011|NCT03055936|10079911|FG001|Overall Study|Personal reason|0
6332012|NCT03055936|10079912|FG002|Overall Study|Personal reason|1
6332013|NCT03055936|10079913|FG003|Overall Study|Personal reason|0
6332014|NCT03055988|10079947|FG000|Period 1|Adverse Event|0
6332015|NCT03055988|10079948|FG001|Period 1|Adverse Event|1
6332016|NCT03055988|10079947|FG000|Period 1|Lost to Follow-up|1
6332017|NCT03055988|10079948|FG001|Period 1|Lost to Follow-up|0
6332018|NCT03055988|10079947|FG000|Period 1|Withdrawal by Subject|0
6332019|NCT03055988|10079948|FG001|Period 1|Withdrawal by Subject|4
6332020|NCT03055988|10079947|FG000|Period 2|Adverse Event|0
6332021|NCT03055988|10079948|FG001|Period 2|Adverse Event|1
6332022|NCT03055988|10079947|FG000|Period 2|Other than listed|1
6332023|NCT03055988|10079948|FG001|Period 2|Other than listed|1
6332024|NCT03056040|10079956|FG000|Primary Evaluation Period|Withdrawal by Subject|1
6332025|NCT03056040|10079957|FG001|Primary Evaluation Period|Withdrawal by Subject|1
6332026|NCT03056040|10079956|FG000|Primary Evaluation Period|Lack of Efficacy|0
6332027|NCT03056040|10079957|FG001|Primary Evaluation Period|Lack of Efficacy|1
6332028|NCT03056040|10079956|FG000|Primary Evaluation Period|Pregnancy|0
6332029|NCT03056040|10079957|FG001|Primary Evaluation Period|Pregnancy|1
6332030|NCT03056300|10079967|FG000|Overall Study|Surgical reason per study protocol|3
6332031|NCT03056352|10079971|FG000|Overall Study|Lost to Follow-up|1
6332032|NCT03056573|10079993|FG000|Overall Study|Death|2
6332033|NCT03056573|10079994|FG001|Overall Study|Death|4
6332034|NCT03056573|10079993|FG000|Overall Study|Withdrawal by Subject|2
6332035|NCT03056573|10079994|FG001|Overall Study|Withdrawal by Subject|0
6332036|NCT03056573|10079993|FG000|Overall Study|Lost to Follow-up|1
6332037|NCT03056573|10079994|FG001|Overall Study|Lost to Follow-up|1
6332038|NCT03056690|10080002|FG000|Overall Study|Adverse Event|3
6332039|NCT03056690|10080003|FG001|Overall Study|Adverse Event|2
6332040|NCT03056690|10080002|FG000|Overall Study|Lack of Efficacy|1
6332041|NCT03056690|10080003|FG001|Overall Study|Lack of Efficacy|2
6332042|NCT03056690|10080002|FG000|Overall Study|Lost to Follow-up|3
6332043|NCT03056690|10080003|FG001|Overall Study|Lost to Follow-up|2
6332044|NCT03056690|10080002|FG000|Overall Study|Protocol Violation|2
6332045|NCT03056690|10080003|FG001|Overall Study|Protocol Violation|2
6332046|NCT03056690|10080002|FG000|Overall Study|Withdrawal by Subject|3
6332047|NCT03056690|10080003|FG001|Overall Study|Withdrawal by Subject|6
6332048|NCT03056690|10080002|FG000|Overall Study|Non-compliance with Study Drug|1
6332049|NCT03056690|10080003|FG001|Overall Study|Non-compliance with Study Drug|0
6332050|NCT03056690|10080002|FG000|Overall Study|Miscellaneous|1
6332051|NCT03056690|10080003|FG001|Overall Study|Miscellaneous|2
6332052|NCT03057496|10080026|FG000|Overall Study|Withdrawal by Subject|8
6332053|NCT03057496|10080026|FG000|Overall Study|Lost to Follow-up|5
6332054|NCT03057496|10080026|FG000|Overall Study|Did not use device during home trial|3
6332055|NCT03057496|10080026|FG000|Overall Study|Device failure|2
6332056|NCT03057977|10080047|FG000|Discontinuation From Treatment|Withdrawal by Subject|124
6332057|NCT03057977|10080048|FG001|Discontinuation From Treatment|Withdrawal by Subject|92
6332058|NCT03057977|10080047|FG000|Discontinuation From Treatment|Lost to Follow-up|11
6332059|NCT03057977|10080048|FG001|Discontinuation From Treatment|Lost to Follow-up|17
6332060|NCT03057977|10080047|FG000|Discontinuation From Treatment|Protocol Violation|6
6332061|NCT03057977|10080048|FG001|Discontinuation From Treatment|Protocol Violation|5
6332062|NCT03057977|10080047|FG000|Discontinuation From Treatment|Not treated|4
6332063|NCT03057977|10080048|FG001|Discontinuation From Treatment|Not treated|0
6332064|NCT03057977|10080047|FG000|Discontinuation From Treatment|Adverse Event|343
6332065|NCT03057977|10080048|FG001|Discontinuation From Treatment|Adverse Event|337
6082831|NCT00631657|9690956|FG002|6-Month Treatment Period|Not Treated|1
6082832|NCT00631657|9690954|FG000|7-Day Discontinuation Period|Not Treated|1
6167304|NCT01227564|9811852|FG002|Overall Study|No Longer Willing to Participate|5
6332066|NCT03057977|10080047|FG000|Discontinuation From Treatment|Reason Unknown|0
6332067|NCT03057977|10080048|FG001|Discontinuation From Treatment|Reason Unknown|1
6332068|NCT03057977|10080047|FG000|Discontinuation From Treatment|Personal Reasons|1
6332069|NCT03057977|10080048|FG001|Discontinuation From Treatment|Personal Reasons|1
6332070|NCT03057977|10080047|FG000|Discontinuation From Treatment|Unblinded medication|1
6332071|NCT03057977|10080048|FG001|Discontinuation From Treatment|Unblinded medication|0
6332072|NCT03057977|10080047|FG000|Discontinuation From Treatment|Patient received Empagliflozin for Diabetes|1
6332073|NCT03057977|10080048|FG001|Discontinuation From Treatment|Patient received Empagliflozin for Diabetes|1
6332074|NCT03057977|10080047|FG000|Discontinuation From Treatment|Principle Investigator Decision|2
6332075|NCT03057977|10080048|FG001|Discontinuation From Treatment|Principle Investigator Decision|0
6332076|NCT03057977|10080047|FG000|Discontinuation From Treatment|Other medical condition (no Adverse Event)|2
6332077|NCT03057977|10080048|FG001|Discontinuation From Treatment|Other medical condition (no Adverse Event)|4
6332078|NCT03057977|10080047|FG000|Discontinuation From Treatment|Patient moved away/being abroad|4
6332079|NCT03057977|10080048|FG001|Discontinuation From Treatment|Patient moved away/being abroad|3
6332080|NCT03057977|10080047|FG000|Discontinuation From Treatment|Unable to continue treatment|4
6332081|NCT03057977|10080048|FG001|Discontinuation From Treatment|Unable to continue treatment|1
6332082|NCT03057977|10080047|FG000|Discontinuation From Treatment|Not attending study visit|3
6332083|NCT03057977|10080048|FG001|Discontinuation From Treatment|Not attending study visit|10
6332084|NCT03057977|10080047|FG000|Discontinuation From Treatment|Due to Covid-19 Pandemic|1
6332085|NCT03057977|10080048|FG001|Discontinuation From Treatment|Due to Covid-19 Pandemic|4
6332086|NCT03057977|10080047|FG000|Discontinuation From Treatment|Patient decision to stop/interrupt medication|8
6167305|NCT01227564|9811850|FG000|Overall Study|Participant moved to another town|0
6167306|NCT01227564|9811851|FG001|Overall Study|Participant moved to another town|0
6167307|NCT01227564|9811852|FG002|Overall Study|Participant moved to another town|1
6167308|NCT01227577|9811862|FG000|Overall Study|Protocol deviation|3
6167309|NCT01227577|9811862|FG000|Overall Study|Death|3
6167310|NCT01227577|9811862|FG000|Overall Study|Administrative problems|2
6167311|NCT01227577|9811862|FG000|Overall Study|Lost to Follow-up|1
6167312|NCT01227577|9811862|FG000|Overall Study|Withdrawal by Subject|4
6167313|NCT01227577|9811862|FG000|Overall Study|Lack of Efficacy|5
6332087|NCT03057977|10080048|FG001|Discontinuation From Treatment|Patient decision to stop/interrupt medication|6
6332088|NCT03057977|10080047|FG000|Discontinuation From Trial|Lost to follow-up to primary endpoint|9
6332089|NCT03057977|10080048|FG001|Discontinuation From Trial|Lost to follow-up to primary endpoint|9
6332090|NCT03057977|10080047|FG000|Discontinuation From Trial|Limited follow-up agreed|2
6082833|NCT00631657|9690955|FG001|7-Day Discontinuation Period|Not Treated|1
6167314|NCT01227577|9811862|FG000|Overall Study|Adverse Event|17
6167315|NCT01227629|9811876|FG000|Overall Study|Adverse Event|2
6332091|NCT03057977|10080048|FG001|Discontinuation From Trial|Limited follow-up agreed|2
6332092|NCT03057977|10080047|FG000|Discontinuation From Trial|Withdrawal by Subject|9
6332093|NCT03057977|10080048|FG001|Discontinuation From Trial|Withdrawal by Subject|11
6332094|NCT03058679|10080056|FG000|Baseline to Week 6|Lost to Follow-up|3
6332095|NCT03058679|10080057|FG001|Baseline to Week 6|Lost to Follow-up|2
6332096|NCT03058679|10080056|FG000|Baseline to Week 6|Change in Crohn's disease medication|4
6332097|NCT03058679|10080057|FG001|Baseline to Week 6|Change in Crohn's disease medication|2
6332098|NCT03058679|10080056|FG000|Baseline to Week 6|Adverse Event|6
6082834|NCT00631657|9690956|FG002|7-Day Discontinuation Period|Not Treated|1
6082835|NCT00631657|9690954|FG000|7-Day Discontinuation Period|Other|1
6082836|NCT00631657|9690955|FG001|7-Day Discontinuation Period|Other|0
6082837|NCT00631657|9690956|FG002|7-Day Discontinuation Period|Other|0
6167316|NCT01227629|9811877|FG001|Overall Study|Adverse Event|2
6332099|NCT03058679|10080057|FG001|Baseline to Week 6|Adverse Event|6
6332100|NCT03058679|10080056|FG000|Baseline to Week 6|Withdrawal by Subject|4
6332101|NCT03058679|10080057|FG001|Baseline to Week 6|Withdrawal by Subject|3
6332102|NCT03058679|10080056|FG000|Baseline to Week 6|Difficulty following the diet|0
6332103|NCT03058679|10080057|FG001|Baseline to Week 6|Difficulty following the diet|2
6332104|NCT03058679|10080056|FG000|Baseline to Week 6|Physician Decision|1
6332105|NCT03058679|10080057|FG001|Baseline to Week 6|Physician Decision|0
6332106|NCT03058679|10080056|FG000|Week 6 to Week 12|Change in medication|5
6332107|NCT03058679|10080057|FG001|Week 6 to Week 12|Change in medication|7
6332108|NCT03058679|10080056|FG000|Week 6 to Week 12|Adverse Event|4
6332109|NCT03058679|10080057|FG001|Week 6 to Week 12|Adverse Event|3
6332110|NCT03058679|10080056|FG000|Week 6 to Week 12|Withdrawal by Subject|9
6332111|NCT03058679|10080057|FG001|Week 6 to Week 12|Withdrawal by Subject|4
6332112|NCT03058679|10080056|FG000|Week 6 to Week 12|Difficulty following the assigned diet|2
6332113|NCT03058679|10080057|FG001|Week 6 to Week 12|Difficulty following the assigned diet|3
6332114|NCT03058692|10080065|FG000|Overall Study|Lost to Follow-up|2
6332115|NCT03058692|10080066|FG001|Overall Study|Lost to Follow-up|1
6332116|NCT03058692|10080065|FG000|Overall Study|Withdrawal by Subject|1
6332117|NCT03058692|10080066|FG001|Overall Study|Withdrawal by Subject|1
6332118|NCT03058991|10080076|FG000|Overall Study|Lost to Follow-up|17
6332119|NCT03058991|10080077|FG001|Overall Study|Lost to Follow-up|12
6332120|NCT03058991|10080078|FG002|Overall Study|Lost to Follow-up|12
6332121|NCT03058991|10080076|FG000|Overall Study|Withdrawal by Subject|1
6332122|NCT03058991|10080077|FG001|Overall Study|Withdrawal by Subject|0
6332123|NCT03058991|10080078|FG002|Overall Study|Withdrawal by Subject|0
6332124|NCT03060447|10080101|FG000|Overall Study|Withdrawal by Subject|2
6332125|NCT03060447|10080102|FG001|Overall Study|Withdrawal by Subject|0
6332126|NCT03060512|10080120|FG000|Overall Study|Adverse Event|4
6332127|NCT03060512|10080121|FG001|Overall Study|Adverse Event|6
6332128|NCT03060512|10080120|FG000|Overall Study|Lost to Follow-up|1
6332129|NCT03060512|10080121|FG001|Overall Study|Lost to Follow-up|1
6332130|NCT03060512|10080120|FG000|Overall Study|Withdrawal by Subject|1
6332131|NCT03060512|10080121|FG001|Overall Study|Withdrawal by Subject|0
6332132|NCT03060512|10080120|FG000|Overall Study|Non-compliance with study medication|1
6332133|NCT03060512|10080121|FG001|Overall Study|Non-compliance with study medication|2
6332134|NCT03060551|10080132|FG000|Overall Study|Withdrawal by Subject|1
6332135|NCT03060551|10080132|FG000|Overall Study|Adverse Event|1
6332136|NCT03061097|10080147|FG000|Overall Study|Withdrawal by Subject|0
6332137|NCT03061097|10080148|FG001|Overall Study|Withdrawal by Subject|3
6332138|NCT03061175|10080156|FG000|Baseline|Participant was deemed ineligible|1
6332139|NCT03061175|10080157|FG001|Baseline|Participant was deemed ineligible|0
6332140|NCT03061175|10080156|FG000|Followup 1 at 2-4 Weeks Post-surgery|Skipped assessment|6
6332141|NCT03061175|10080157|FG001|Followup 1 at 2-4 Weeks Post-surgery|Skipped assessment|2
6332142|NCT03061175|10080156|FG000|Followup 1 at 2-4 Weeks Post-surgery|Withdrawal by Subject|0
6332143|NCT03061175|10080157|FG001|Followup 1 at 2-4 Weeks Post-surgery|Withdrawal by Subject|1
6332144|NCT03061175|10080156|FG000|Followup 2 at 6 Months|Lost to Follow-up|4
6332145|NCT03061175|10080157|FG001|Followup 2 at 6 Months|Lost to Follow-up|7
6332146|NCT03061188|10080167|FG000|Went on to Cycle 2 and Beyond|Adverse Event|0
6332147|NCT03061188|10080168|FG001|Went on to Cycle 2 and Beyond|Adverse Event|0
6332148|NCT03061188|10080169|FG002|Went on to Cycle 2 and Beyond|Adverse Event|1
6332149|NCT03061188|10080170|FG003|Went on to Cycle 2 and Beyond|Adverse Event|1
6332150|NCT03061188|10080167|FG000|On Follow-up for 3 Years|Death|0
6332151|NCT03061188|10080168|FG001|On Follow-up for 3 Years|Death|3
6332152|NCT03061188|10080169|FG002|On Follow-up for 3 Years|Death|5
6332153|NCT03061188|10080170|FG003|On Follow-up for 3 Years|Death|2
6332154|NCT03061188|10080167|FG000|On Follow-up for 3 Years|Still in follow-up|0
6082838|NCT00631696|9690982|FG000|Overall Study|Entered, not randomized to treatment|1
6167317|NCT01227629|9811878|FG002|Overall Study|Adverse Event|1
6332155|NCT03061188|10080168|FG001|On Follow-up for 3 Years|Still in follow-up|0
6332156|NCT03061188|10080169|FG002|On Follow-up for 3 Years|Still in follow-up|0
6167318|NCT01227629|9811879|FG003|Overall Study|Adverse Event|6
6167319|NCT01227629|9811880|FG004|Overall Study|Adverse Event|1
6167320|NCT01227629|9811881|FG005|Overall Study|Adverse Event|1
6167321|NCT01227629|9811882|FG006|Overall Study|Adverse Event|6
6167322|NCT01227629|9811883|FG007|Overall Study|Adverse Event|6
6167323|NCT01227629|9811884|FG008|Overall Study|Adverse Event|4
6167324|NCT01227629|9811885|FG009|Overall Study|Adverse Event|0
6167325|NCT01227629|9811876|FG000|Overall Study|Protocol Violation|0
6167326|NCT01227629|9811877|FG001|Overall Study|Protocol Violation|0
6332157|NCT03061188|10080170|FG003|On Follow-up for 3 Years|Still in follow-up|3
6082839|NCT00631696|9690983|FG001|Overall Study|Entered, not randomized to treatment|1
6082840|NCT00631696|9690982|FG000|Overall Study|Discontinued after database release date|1
6082841|NCT00631696|9690983|FG001|Overall Study|Discontinued after database release date|0
6082842|NCT00631696|9690982|FG000|Overall Study|Follow up after database release date|1
6082843|NCT00631696|9690983|FG001|Overall Study|Follow up after database release date|0
6167327|NCT01227629|9811878|FG002|Overall Study|Protocol Violation|0
6332158|NCT03061214|10080188|FG000|Overall Study|Withdrawal by Subject|21
6332159|NCT03061214|10080189|FG001|Overall Study|Withdrawal by Subject|26
6332160|NCT03061214|10080190|FG002|Overall Study|Withdrawal by Subject|9
6332161|NCT03061214|10080188|FG000|Overall Study|Lost to Follow-up|3
6332162|NCT03061214|10080189|FG001|Overall Study|Lost to Follow-up|1
6332163|NCT03061214|10080190|FG002|Overall Study|Lost to Follow-up|1
6332164|NCT03061214|10080188|FG000|Overall Study|Death|1
6332165|NCT03061214|10080189|FG001|Overall Study|Death|1
6332166|NCT03061214|10080190|FG002|Overall Study|Death|0
6332167|NCT03061331|10080200|FG000|Washout Period (8 Weeks)|Adverse Event|2
6332168|NCT03061331|10080201|FG001|Washout Period (8 Weeks)|Adverse Event|1
6332169|NCT03062891|10080262|FG000|Overall Study|Withdrawal by Subject|2
6332170|NCT03062891|10080263|FG001|Overall Study|Withdrawal by Subject|0
6332171|NCT03062891|10080262|FG000|Overall Study|Lost to Follow-up|50
6332172|NCT03062891|10080263|FG001|Overall Study|Lost to Follow-up|38
6332173|NCT03063086|10080290|FG000|Overall Study|technical problems|1
6332174|NCT03063086|10080291|FG001|Overall Study|technical problems|0
6332175|NCT03063086|10080292|FG002|Overall Study|technical problems|0
6332176|NCT03063086|10080293|FG003|Overall Study|technical problems|0
6332177|NCT03063086|10080294|FG004|Overall Study|technical problems|0
6332178|NCT03063086|10080295|FG005|Overall Study|technical problems|0
6332179|NCT03063086|10080290|FG000|Overall Study|Adverse Event|1
6332180|NCT03063086|10080291|FG001|Overall Study|Adverse Event|1
6332181|NCT03063086|10080292|FG002|Overall Study|Adverse Event|1
6332182|NCT03063086|10080293|FG003|Overall Study|Adverse Event|1
6332183|NCT03063086|10080294|FG004|Overall Study|Adverse Event|0
6332184|NCT03063086|10080295|FG005|Overall Study|Adverse Event|0
6332185|NCT03063086|10080290|FG000|Overall Study|subject/guardian decision|1
6332186|NCT03063086|10080291|FG001|Overall Study|subject/guardian decision|0
6332187|NCT03063086|10080292|FG002|Overall Study|subject/guardian decision|0
6332188|NCT03063086|10080293|FG003|Overall Study|subject/guardian decision|0
6332189|NCT03063086|10080294|FG004|Overall Study|subject/guardian decision|0
6332190|NCT03063086|10080295|FG005|Overall Study|subject/guardian decision|0
6332191|NCT03063086|10080290|FG000|Overall Study|Non-compliance with study treatment|0
6332192|NCT03063086|10080291|FG001|Overall Study|Non-compliance with study treatment|0
6332193|NCT03063086|10080292|FG002|Overall Study|Non-compliance with study treatment|0
6332194|NCT03063086|10080293|FG003|Overall Study|Non-compliance with study treatment|1
6332195|NCT03063086|10080294|FG004|Overall Study|Non-compliance with study treatment|0
6332196|NCT03063086|10080295|FG005|Overall Study|Non-compliance with study treatment|1
6332197|NCT03063086|10080290|FG000|Overall Study|Physician Decision|0
6332198|NCT03063086|10080291|FG001|Overall Study|Physician Decision|0
6332199|NCT03063086|10080292|FG002|Overall Study|Physician Decision|0
6332200|NCT03063086|10080293|FG003|Overall Study|Physician Decision|1
6332201|NCT03063086|10080294|FG004|Overall Study|Physician Decision|0
6332202|NCT03063086|10080295|FG005|Overall Study|Physician Decision|0
6332203|NCT03064438|10080359|FG000|Overall Study|Lost to Follow-up|1
6332204|NCT03064438|10080360|FG001|Overall Study|Lost to Follow-up|0
6332205|NCT03064438|10080359|FG000|Overall Study|Withdrawal by Subject|0
6332206|NCT03064438|10080360|FG001|Overall Study|Withdrawal by Subject|1
6332207|NCT03064451|10080366|FG000|Overall Study|Lost to Follow-up|1
6332208|NCT03064451|10080366|FG000|Overall Study|Mapping Failure|4
6332209|NCT03064451|10080366|FG000|Overall Study|Exited prior to procedure|8
6332210|NCT03064451|10080366|FG000|Overall Study|Withdrew consent: 3-month FU visit|1
6332211|NCT03064841|10080370|FG000|Overall Study|Inclusion/exclusion criteria violation|4
6332212|NCT03064841|10080370|FG000|Overall Study|No glycated haemoglobinA1c measurement|11
6332213|NCT03064841|10080370|FG000|Overall Study|Screen failure|2
6332214|NCT03065023|10080378|FG000|Overall Study|Progressive Disease|0
6332215|NCT03065023|10080379|FG001|Overall Study|Progressive Disease|1
6332216|NCT03065023|10080380|FG002|Overall Study|Progressive Disease|0
6332217|NCT03065023|10080381|FG003|Overall Study|Progressive Disease|0
6332218|NCT03065023|10080382|FG004|Overall Study|Progressive Disease|0
6332219|NCT03065023|10080378|FG000|Overall Study|Death|2
6332220|NCT03065023|10080379|FG001|Overall Study|Death|0
6332221|NCT03065023|10080380|FG002|Overall Study|Death|1
6332222|NCT03065023|10080381|FG003|Overall Study|Death|1
6332223|NCT03065023|10080382|FG004|Overall Study|Death|0
6332224|NCT03065023|10080378|FG000|Overall Study|Lost to Follow-up|0
6332225|NCT03065023|10080379|FG001|Overall Study|Lost to Follow-up|1
6332226|NCT03065023|10080380|FG002|Overall Study|Lost to Follow-up|0
6332227|NCT03065023|10080381|FG003|Overall Study|Lost to Follow-up|0
6332228|NCT03065023|10080382|FG004|Overall Study|Lost to Follow-up|0
6332229|NCT03065023|10080378|FG000|Overall Study|Participant Decision|0
6332230|NCT03065023|10080379|FG001|Overall Study|Participant Decision|0
6332231|NCT03065023|10080380|FG002|Overall Study|Participant Decision|0
6332232|NCT03065023|10080381|FG003|Overall Study|Participant Decision|1
6332233|NCT03065023|10080382|FG004|Overall Study|Participant Decision|0
6332234|NCT03065023|10080378|FG000|Overall Study|Withdrawal by Subject|0
6332235|NCT03065023|10080379|FG001|Overall Study|Withdrawal by Subject|0
6332236|NCT03065023|10080380|FG002|Overall Study|Withdrawal by Subject|0
6332237|NCT03065023|10080381|FG003|Overall Study|Withdrawal by Subject|1
6332238|NCT03065023|10080382|FG004|Overall Study|Withdrawal by Subject|0
6332239|NCT03065400|10080419|FG000|Overall Study|Adverse Event|1
6332240|NCT03065400|10080419|FG000|Overall Study|Physician Decision|3
6332241|NCT03065400|10080419|FG000|Overall Study|Withdrawal by Subject|1
6332242|NCT03065400|10080419|FG000|Overall Study|Completed 6 cycles but did not meet criteria to continue past cycle 6|5
6332243|NCT03065530|10080427|FG000|Overall Study|Lack of Efficacy|1
6332244|NCT03065530|10080428|FG001|Overall Study|Lack of Efficacy|1
6332245|NCT03065530|10080429|FG002|Overall Study|Lack of Efficacy|0
6332246|NCT03065530|10080430|FG003|Overall Study|Lack of Efficacy|1
6332247|NCT03065530|10080427|FG000|Overall Study|Protocol Violation|1
6332248|NCT03065530|10080428|FG001|Overall Study|Protocol Violation|0
6332249|NCT03065530|10080429|FG002|Overall Study|Protocol Violation|1
6332250|NCT03065530|10080430|FG003|Overall Study|Protocol Violation|1
6332251|NCT03066193|10080461|FG000|Overall Study|Withdrawal by Subject|1
6332252|NCT03066609|10080468|FG000|INDUCTION|Pregnancy|0
6332253|NCT03066609|10080469|FG001|INDUCTION|Pregnancy|0
6332254|NCT03066609|10080470|FG002|INDUCTION|Pregnancy|1
6332255|NCT03066609|10080471|FG003|INDUCTION|Pregnancy|0
6332256|NCT03066609|10080468|FG000|INDUCTION|Lack of Efficacy|0
6332257|NCT03066609|10080469|FG001|INDUCTION|Lack of Efficacy|0
6332258|NCT03066609|10080470|FG002|INDUCTION|Lack of Efficacy|1
6332259|NCT03066609|10080471|FG003|INDUCTION|Lack of Efficacy|0
6332260|NCT03066609|10080468|FG000|INDUCTION|Adverse Event|2
6332261|NCT03066609|10080469|FG001|INDUCTION|Adverse Event|2
6332262|NCT03066609|10080470|FG002|INDUCTION|Adverse Event|0
6332263|NCT03066609|10080471|FG003|INDUCTION|Adverse Event|0
6332264|NCT03066609|10080468|FG000|MAINTENANCE|Adverse Event|0
6332265|NCT03066609|10080469|FG001|MAINTENANCE|Adverse Event|0
6332266|NCT03066609|10080470|FG002|MAINTENANCE|Adverse Event|0
6332267|NCT03066609|10080471|FG003|MAINTENANCE|Adverse Event|1
6332268|NCT03066609|10080468|FG000|MAINTENANCE|Withdrawal by Subject|4
6332269|NCT03066609|10080469|FG001|MAINTENANCE|Withdrawal by Subject|2
6332270|NCT03066609|10080470|FG002|MAINTENANCE|Withdrawal by Subject|1
6332271|NCT03066609|10080471|FG003|MAINTENANCE|Withdrawal by Subject|1
6332272|NCT03066609|10080468|FG000|MAINTENANCE|Lost to Follow-up|0
6332273|NCT03066609|10080469|FG001|MAINTENANCE|Lost to Follow-up|1
6332274|NCT03066609|10080470|FG002|MAINTENANCE|Lost to Follow-up|1
6332275|NCT03066609|10080471|FG003|MAINTENANCE|Lost to Follow-up|0
6332276|NCT03066609|10080468|FG000|MAINTENANCE|Pregnancy|1
6332277|NCT03066609|10080469|FG001|MAINTENANCE|Pregnancy|0
6332278|NCT03066609|10080470|FG002|MAINTENANCE|Pregnancy|0
6332279|NCT03066609|10080471|FG003|MAINTENANCE|Pregnancy|0
6332280|NCT03066609|10080468|FG000|MAINTENANCE|Lack of Efficacy|2
6332281|NCT03066609|10080469|FG001|MAINTENANCE|Lack of Efficacy|1
6332282|NCT03066609|10080470|FG002|MAINTENANCE|Lack of Efficacy|0
6332283|NCT03066609|10080471|FG003|MAINTENANCE|Lack of Efficacy|1
6332284|NCT03066609|10080468|FG000|OVERALL STUDY|Adverse Event|2
6332285|NCT03066609|10080469|FG001|OVERALL STUDY|Adverse Event|2
6332286|NCT03066609|10080470|FG002|OVERALL STUDY|Adverse Event|0
6332287|NCT03066609|10080471|FG003|OVERALL STUDY|Adverse Event|1
6332288|NCT03066609|10080468|FG000|OVERALL STUDY|Withdrawal by Subject|4
6332289|NCT03066609|10080469|FG001|OVERALL STUDY|Withdrawal by Subject|2
6332290|NCT03066609|10080470|FG002|OVERALL STUDY|Withdrawal by Subject|1
6332291|NCT03066609|10080471|FG003|OVERALL STUDY|Withdrawal by Subject|2
6332292|NCT03066609|10080468|FG000|OVERALL STUDY|Lost to Follow-up|1
6332293|NCT03066609|10080469|FG001|OVERALL STUDY|Lost to Follow-up|1
6332294|NCT03066609|10080470|FG002|OVERALL STUDY|Lost to Follow-up|1
6332295|NCT03066609|10080471|FG003|OVERALL STUDY|Lost to Follow-up|1
6332296|NCT03066609|10080468|FG000|OVERALL STUDY|Pregnancy|1
6332297|NCT03066609|10080469|FG001|OVERALL STUDY|Pregnancy|0
6332298|NCT03066609|10080470|FG002|OVERALL STUDY|Pregnancy|1
6332299|NCT03066609|10080471|FG003|OVERALL STUDY|Pregnancy|0
6332300|NCT03066609|10080468|FG000|OVERALL STUDY|Lack of Efficacy|2
6332301|NCT03066609|10080469|FG001|OVERALL STUDY|Lack of Efficacy|1
6332302|NCT03066609|10080470|FG002|OVERALL STUDY|Lack of Efficacy|1
6332303|NCT03066609|10080471|FG003|OVERALL STUDY|Lack of Efficacy|1
6332304|NCT03066609|10080468|FG000|OVERALL STUDY|discontinued follow up|0
6332305|NCT03066609|10080469|FG001|OVERALL STUDY|discontinued follow up|2
6332306|NCT03066609|10080470|FG002|OVERALL STUDY|discontinued follow up|0
6332307|NCT03066609|10080471|FG003|OVERALL STUDY|discontinued follow up|0
6332308|NCT03066778|10080484|FG000|Overall Study|Death|167
6332309|NCT03066778|10080485|FG001|Overall Study|Death|183
6332310|NCT03066778|10080484|FG000|Overall Study|Withdrawal by Subject|4
6332311|NCT03066778|10080485|FG001|Overall Study|Withdrawal by Subject|5
6332312|NCT03066778|10080484|FG000|Overall Study|Ongoing in Study|57
6332313|NCT03066778|10080485|FG001|Overall Study|Ongoing in Study|37
6332314|NCT03066804|10080493|FG000|Overall Study|Physician Decision|0
6332315|NCT03066804|10080494|FG001|Overall Study|Physician Decision|4
6332316|NCT03066804|10080493|FG000|Overall Study|Death|23
6332317|NCT03066804|10080494|FG001|Overall Study|Death|17
6332318|NCT03066804|10080493|FG000|Overall Study|Withdrawal by Subject|19
6332319|NCT03066804|10080494|FG001|Overall Study|Withdrawal by Subject|25
6332320|NCT03066804|10080493|FG000|Overall Study|Lost to Follow-up|2
6332321|NCT03066804|10080494|FG001|Overall Study|Lost to Follow-up|0
6332322|NCT03066804|10080493|FG000|Overall Study|Adverse Event|2
6332323|NCT03066804|10080494|FG001|Overall Study|Adverse Event|3
6332324|NCT03066804|10080493|FG000|Overall Study|Technical problems|5
6332325|NCT03066804|10080494|FG001|Overall Study|Technical problems|1
6332326|NCT03066830|10080503|FG000|Overall Study|At the Participant's own Request|16
6332327|NCT03066830|10080504|FG001|Overall Study|At the Participant's own Request|17
6332328|NCT03066830|10080503|FG000|Overall Study|Other|3
6332329|NCT03066830|10080504|FG001|Overall Study|Other|0
6332330|NCT03066830|10080503|FG000|Overall Study|Poor Compliance to Protocol|1
6332331|NCT03066830|10080504|FG001|Overall Study|Poor Compliance to Protocol|0
6332332|NCT03066830|10080503|FG000|Overall Study|Adverse Event|2
6332333|NCT03066830|10080504|FG001|Overall Study|Adverse Event|2
6332334|NCT03066830|10080503|FG000|Overall Study|Lost to Follow-up|11
6332335|NCT03066830|10080504|FG001|Overall Study|Lost to Follow-up|3
6332336|NCT03066999|10080518|FG000|Overall Study|abnormal urethraBladder neck contracture|0
6332337|NCT03066999|10080519|FG001|Overall Study|abnormal urethraBladder neck contracture|2
6332338|NCT03067129|10080530|FG000|Overall Study|Ongoing|45
6332339|NCT03067129|10080531|FG001|Overall Study|Ongoing|28
6332340|NCT03067129|10080532|FG002|Overall Study|Ongoing|27
6332341|NCT03067129|10080533|FG003|Overall Study|Ongoing|23
6332342|NCT03067129|10080530|FG000|Overall Study|Partially dosed; refused to swallow entire dose|0
6332343|NCT03067129|10080531|FG001|Overall Study|Partially dosed; refused to swallow entire dose|0
6332344|NCT03067129|10080532|FG002|Overall Study|Partially dosed; refused to swallow entire dose|0
6332345|NCT03067129|10080533|FG003|Overall Study|Partially dosed; refused to swallow entire dose|1
6332346|NCT03067311|10080553|FG000|Overall Study|Lost to Follow-up|1
6332347|NCT03067311|10080554|FG001|Overall Study|Lost to Follow-up|1
6332348|NCT03067311|10080553|FG000|Overall Study|Moved away|1
6332349|NCT03067311|10080554|FG001|Overall Study|Moved away|1
6332350|NCT03067441|10080562|FG000|Overall Study|Withdrawal by Subject|16
6332351|NCT03067441|10080563|FG001|Overall Study|Withdrawal by Subject|34
6332352|NCT03067441|10080562|FG000|Overall Study|Lost to Follow-up|7
6332353|NCT03067441|10080563|FG001|Overall Study|Lost to Follow-up|5
6332354|NCT03067441|10080562|FG000|Overall Study|Adverse Event|7
6332355|NCT03067441|10080563|FG001|Overall Study|Adverse Event|14
6332356|NCT03067441|10080562|FG000|Overall Study|Study Terminated by Sponsor or Investigator|1
6332357|NCT03067441|10080563|FG001|Overall Study|Study Terminated by Sponsor or Investigator|0
6332358|NCT03067441|10080562|FG000|Overall Study|Physician Decision|1
6332359|NCT03067441|10080563|FG001|Overall Study|Physician Decision|3
6332360|NCT03067441|10080562|FG000|Overall Study|Other|1
6332361|NCT03067441|10080563|FG001|Overall Study|Other|1
6332362|NCT03067987|10080582|FG000|Overall Study|Lost to Follow-up|7
6332363|NCT03067987|10080583|FG001|Overall Study|Lost to Follow-up|10
6332364|NCT03067987|10080582|FG000|Overall Study|Protocol Violation|1
6332365|NCT03067987|10080583|FG001|Overall Study|Protocol Violation|2
6332366|NCT03067987|10080582|FG000|Overall Study|Withdrawal by Subject|2
6332367|NCT03067987|10080583|FG001|Overall Study|Withdrawal by Subject|1
6332368|NCT03068455|10080605|FG000|Pre-treatment Period|Disease progression|0
6332369|NCT03068455|10080606|FG001|Pre-treatment Period|Disease progression|1
6332370|NCT03068455|10080605|FG000|Pre-treatment Period|Participant withdrew consent|1
6332371|NCT03068455|10080606|FG001|Pre-treatment Period|Participant withdrew consent|1
6332372|NCT03068455|10080605|FG000|Pre-treatment Period|Poor/non-compliance|0
6332373|NCT03068455|10080606|FG001|Pre-treatment Period|Poor/non-compliance|1
6332374|NCT03068455|10080605|FG000|Pre-treatment Period|Participant no longer meets study criteria|1
6332375|NCT03068455|10080606|FG001|Pre-treatment Period|Participant no longer meets study criteria|3
6332376|NCT03068455|10080605|FG000|Pre-treatment Period|Not reported|2
6332377|NCT03068455|10080606|FG001|Pre-treatment Period|Not reported|1
6332378|NCT03068455|10080605|FG000|Treatment Period|Disease progression|166
6332379|NCT03068455|10080606|FG001|Treatment Period|Disease progression|208
6332380|NCT03068455|10080605|FG000|Treatment Period|Study drug toxicity|317
6332381|NCT03068455|10080606|FG001|Treatment Period|Study drug toxicity|104
6332382|NCT03068455|10080605|FG000|Treatment Period|Adverse Event unrelated to study drug|15
6332383|NCT03068455|10080606|FG001|Treatment Period|Adverse Event unrelated to study drug|7
6332384|NCT03068455|10080605|FG000|Treatment Period|Participant request to stop therapy|33
6332385|NCT03068455|10080606|FG001|Treatment Period|Participant request to stop therapy|20
6332386|NCT03068455|10080605|FG000|Treatment Period|Participant withdrew consent|5
6332387|NCT03068455|10080606|FG001|Treatment Period|Participant withdrew consent|10
6332388|NCT03068455|10080605|FG000|Treatment Period|Poor/non-compliance|3
6332389|NCT03068455|10080606|FG001|Treatment Period|Poor/non-compliance|0
6332390|NCT03068455|10080605|FG000|Treatment Period|Participant no longer meets study criteria|1
6332391|NCT03068455|10080606|FG001|Treatment Period|Participant no longer meets study criteria|3
6332392|NCT03068455|10080605|FG000|Treatment Period|Other reasons|12
6332393|NCT03068455|10080606|FG001|Treatment Period|Other reasons|4
6332394|NCT03068468|10080614|FG000|Placebo-Controlled Period|Randomized but not Treated|1
6332395|NCT03068468|10080615|FG001|Placebo-Controlled Period|Randomized but not Treated|3
6332396|NCT03068468|10080616|FG002|Placebo-Controlled Period|Randomized but not Treated|0
6332397|NCT03068468|10080617|FG003|Placebo-Controlled Period|Randomized but not Treated|0
6332398|NCT03068468|10080614|FG000|Placebo-Controlled Period|Lack of Efficacy|0
6332399|NCT03068468|10080615|FG001|Placebo-Controlled Period|Lack of Efficacy|1
6332400|NCT03068468|10080616|FG002|Placebo-Controlled Period|Lack of Efficacy|0
6332401|NCT03068468|10080617|FG003|Placebo-Controlled Period|Lack of Efficacy|0
6332402|NCT03068468|10080614|FG000|Placebo-Controlled Period|Adverse Event|16
6332403|NCT03068468|10080615|FG001|Placebo-Controlled Period|Adverse Event|21
6332404|NCT03068468|10080616|FG002|Placebo-Controlled Period|Adverse Event|0
6332405|NCT03068468|10080617|FG003|Placebo-Controlled Period|Adverse Event|0
6332406|NCT03068468|10080614|FG000|Placebo-Controlled Period|Withdrawal by Subject|3
6332407|NCT03068468|10080615|FG001|Placebo-Controlled Period|Withdrawal by Subject|11
6332408|NCT03068468|10080616|FG002|Placebo-Controlled Period|Withdrawal by Subject|0
6332409|NCT03068468|10080617|FG003|Placebo-Controlled Period|Withdrawal by Subject|0
6332410|NCT03068468|10080614|FG000|Placebo-Controlled Period|Withdrawal by Parent/Guardian|1
6332411|NCT03068468|10080615|FG001|Placebo-Controlled Period|Withdrawal by Parent/Guardian|2
6332412|NCT03068468|10080616|FG002|Placebo-Controlled Period|Withdrawal by Parent/Guardian|0
6332413|NCT03068468|10080617|FG003|Placebo-Controlled Period|Withdrawal by Parent/Guardian|0
6332414|NCT03068468|10080614|FG000|Placebo-Controlled Period|Reason Not Specified|1
6332415|NCT03068468|10080615|FG001|Placebo-Controlled Period|Reason Not Specified|6
6332416|NCT03068468|10080616|FG002|Placebo-Controlled Period|Reason Not Specified|0
6332417|NCT03068468|10080617|FG003|Placebo-Controlled Period|Reason Not Specified|0
6332418|NCT03068468|10080614|FG000|Placebo-Controlled Period|Death|0
6332419|NCT03068468|10080615|FG001|Placebo-Controlled Period|Death|1
6332420|NCT03068468|10080616|FG002|Placebo-Controlled Period|Death|0
6332421|NCT03068468|10080617|FG003|Placebo-Controlled Period|Death|0
6332422|NCT03068468|10080614|FG000|Open-Label Extension Period|Lack of Efficacy|0
6332423|NCT03068468|10080615|FG001|Open-Label Extension Period|Lack of Efficacy|0
6332424|NCT03068468|10080616|FG002|Open-Label Extension Period|Lack of Efficacy|1
6332425|NCT03068468|10080617|FG003|Open-Label Extension Period|Lack of Efficacy|2
6332426|NCT03068468|10080614|FG000|Open-Label Extension Period|Adverse Event|0
6332427|NCT03068468|10080615|FG001|Open-Label Extension Period|Adverse Event|0
6332428|NCT03068468|10080616|FG002|Open-Label Extension Period|Adverse Event|13
6332429|NCT03068468|10080617|FG003|Open-Label Extension Period|Adverse Event|17
6332430|NCT03068468|10080614|FG000|Open-Label Extension Period|Withdrawal by Subject|0
6332431|NCT03068468|10080615|FG001|Open-Label Extension Period|Withdrawal by Subject|0
6332432|NCT03068468|10080616|FG002|Open-Label Extension Period|Withdrawal by Subject|7
6332433|NCT03068468|10080617|FG003|Open-Label Extension Period|Withdrawal by Subject|20
6332434|NCT03068468|10080614|FG000|Open-Label Extension Period|Death|0
6332435|NCT03068468|10080615|FG001|Open-Label Extension Period|Death|0
6332436|NCT03068468|10080616|FG002|Open-Label Extension Period|Death|0
6332437|NCT03068468|10080617|FG003|Open-Label Extension Period|Death|1
6332438|NCT03068468|10080614|FG000|Open-Label Extension Period|Lost to Follow-up|0
6332439|NCT03068468|10080615|FG001|Open-Label Extension Period|Lost to Follow-up|0
6332440|NCT03068468|10080616|FG002|Open-Label Extension Period|Lost to Follow-up|1
6332441|NCT03068468|10080617|FG003|Open-Label Extension Period|Lost to Follow-up|0
6332442|NCT03068468|10080614|FG000|Open-Label Extension Period|Failure to Meet Randomization Criteria|0
6332443|NCT03068468|10080615|FG001|Open-Label Extension Period|Failure to Meet Randomization Criteria|0
6332444|NCT03068468|10080616|FG002|Open-Label Extension Period|Failure to Meet Randomization Criteria|2
6332445|NCT03068468|10080617|FG003|Open-Label Extension Period|Failure to Meet Randomization Criteria|0
6332446|NCT03068468|10080614|FG000|Open-Label Extension Period|Withdrawal by Sponsor|0
6332447|NCT03068468|10080615|FG001|Open-Label Extension Period|Withdrawal by Sponsor|0
6332448|NCT03068468|10080616|FG002|Open-Label Extension Period|Withdrawal by Sponsor|115
6332449|NCT03068468|10080617|FG003|Open-Label Extension Period|Withdrawal by Sponsor|228
6332450|NCT03068468|10080614|FG000|Open-Label Extension Period|Withdrawal by Parent/Guardian|0
6332451|NCT03068468|10080615|FG001|Open-Label Extension Period|Withdrawal by Parent/Guardian|0
6332452|NCT03068468|10080616|FG002|Open-Label Extension Period|Withdrawal by Parent/Guardian|0
6332453|NCT03068468|10080617|FG003|Open-Label Extension Period|Withdrawal by Parent/Guardian|4
6332454|NCT03068468|10080614|FG000|Open-Label Extension Period|Reason not Specified|0
6332455|NCT03068468|10080615|FG001|Open-Label Extension Period|Reason not Specified|0
6332456|NCT03068468|10080616|FG002|Open-Label Extension Period|Reason not Specified|1
6332457|NCT03068468|10080617|FG003|Open-Label Extension Period|Reason not Specified|4
6332458|NCT03068754|10080636|FG000|Randomized Treatment Period (RTP)|Adverse Event|1
6332459|NCT03068754|10080637|FG001|Randomized Treatment Period (RTP)|Adverse Event|3
6332460|NCT03068754|10080638|FG002|Randomized Treatment Period (RTP)|Adverse Event|0
6332461|NCT03068754|10080639|FG003|Randomized Treatment Period (RTP)|Adverse Event|0
6332462|NCT03068754|10080636|FG000|Randomized Treatment Period (RTP)|Death|2
6332463|NCT03068754|10080637|FG001|Randomized Treatment Period (RTP)|Death|2
6332464|NCT03068754|10080638|FG002|Randomized Treatment Period (RTP)|Death|0
6332465|NCT03068754|10080639|FG003|Randomized Treatment Period (RTP)|Death|0
6332466|NCT03068754|10080636|FG000|Randomized Treatment Period (RTP)|Disease progression|1
6332467|NCT03068754|10080637|FG001|Randomized Treatment Period (RTP)|Disease progression|2
6332468|NCT03068754|10080638|FG002|Randomized Treatment Period (RTP)|Disease progression|0
6332469|NCT03068754|10080639|FG003|Randomized Treatment Period (RTP)|Disease progression|0
6332470|NCT03068754|10080636|FG000|Randomized Treatment Period (RTP)|Lost to Follow-up|1
6332471|NCT03068754|10080637|FG001|Randomized Treatment Period (RTP)|Lost to Follow-up|0
6332472|NCT03068754|10080638|FG002|Randomized Treatment Period (RTP)|Lost to Follow-up|0
6332473|NCT03068754|10080639|FG003|Randomized Treatment Period (RTP)|Lost to Follow-up|0
6332474|NCT03068754|10080636|FG000|Randomized Treatment Period (RTP)|Withdrawal by Subject|6
6332475|NCT03068754|10080637|FG001|Randomized Treatment Period (RTP)|Withdrawal by Subject|2
6332476|NCT03068754|10080638|FG002|Randomized Treatment Period (RTP)|Withdrawal by Subject|0
6332477|NCT03068754|10080639|FG003|Randomized Treatment Period (RTP)|Withdrawal by Subject|0
6332478|NCT03068754|10080636|FG000|Randomized Treatment Period (RTP)|Discontinued by Physician|1
6332479|NCT03068754|10080637|FG001|Randomized Treatment Period (RTP)|Discontinued by Physician|0
6332480|NCT03068754|10080638|FG002|Randomized Treatment Period (RTP)|Discontinued by Physician|0
6332481|NCT03068754|10080639|FG003|Randomized Treatment Period (RTP)|Discontinued by Physician|0
6332482|NCT03068754|10080636|FG000|Randomized Treatment Period (RTP)|Subject Decision based on Compensation|0
6332483|NCT03068754|10080637|FG001|Randomized Treatment Period (RTP)|Subject Decision based on Compensation|1
6332484|NCT03068754|10080638|FG002|Randomized Treatment Period (RTP)|Subject Decision based on Compensation|0
6332485|NCT03068754|10080639|FG003|Randomized Treatment Period (RTP)|Subject Decision based on Compensation|0
6332486|NCT03068754|10080636|FG000|Randomized Treatment Period (RTP)|Trial Terminated by Sponsor|55
6332487|NCT03068754|10080637|FG001|Randomized Treatment Period (RTP)|Trial Terminated by Sponsor|29
6332488|NCT03068754|10080638|FG002|Randomized Treatment Period (RTP)|Trial Terminated by Sponsor|0
6332489|NCT03068754|10080639|FG003|Randomized Treatment Period (RTP)|Trial Terminated by Sponsor|0
6332490|NCT03068754|10080636|FG000|Open Label Extension Period (OLE)|Adverse Event|0
6332491|NCT03068754|10080637|FG001|Open Label Extension Period (OLE)|Adverse Event|0
6332492|NCT03068754|10080638|FG002|Open Label Extension Period (OLE)|Adverse Event|0
6332493|NCT03068754|10080639|FG003|Open Label Extension Period (OLE)|Adverse Event|1
6332494|NCT03068754|10080636|FG000|Open Label Extension Period (OLE)|Death|0
6332495|NCT03068754|10080637|FG001|Open Label Extension Period (OLE)|Death|0
6332496|NCT03068754|10080638|FG002|Open Label Extension Period (OLE)|Death|0
6332497|NCT03068754|10080639|FG003|Open Label Extension Period (OLE)|Death|1
6332498|NCT03068754|10080636|FG000|Open Label Extension Period (OLE)|Disease progression|0
6332499|NCT03068754|10080637|FG001|Open Label Extension Period (OLE)|Disease progression|0
6332500|NCT03068754|10080638|FG002|Open Label Extension Period (OLE)|Disease progression|3
6332501|NCT03068754|10080639|FG003|Open Label Extension Period (OLE)|Disease progression|1
6332502|NCT03068754|10080636|FG000|Open Label Extension Period (OLE)|Withdrawal by Subject|0
6332503|NCT03068754|10080637|FG001|Open Label Extension Period (OLE)|Withdrawal by Subject|0
6332504|NCT03068754|10080638|FG002|Open Label Extension Period (OLE)|Withdrawal by Subject|5
6332505|NCT03068754|10080639|FG003|Open Label Extension Period (OLE)|Withdrawal by Subject|0
6332506|NCT03068754|10080636|FG000|Open Label Extension Period (OLE)|Subject Discontinued for Non-efficacy|0
6332507|NCT03068754|10080637|FG001|Open Label Extension Period (OLE)|Subject Discontinued for Non-efficacy|0
6332508|NCT03068754|10080638|FG002|Open Label Extension Period (OLE)|Subject Discontinued for Non-efficacy|1
6332509|NCT03068754|10080639|FG003|Open Label Extension Period (OLE)|Subject Discontinued for Non-efficacy|0
6332510|NCT03068754|10080636|FG000|Open Label Extension Period (OLE)|Trial Terminated by Sponsor|0
6332511|NCT03068754|10080637|FG001|Open Label Extension Period (OLE)|Trial Terminated by Sponsor|0
6332512|NCT03068754|10080638|FG002|Open Label Extension Period (OLE)|Trial Terminated by Sponsor|12
6332513|NCT03068754|10080639|FG003|Open Label Extension Period (OLE)|Trial Terminated by Sponsor|3
6332514|NCT03068767|10080651|FG000|Overall Study|Lost to Follow-up|7
6332515|NCT03068767|10080652|FG001|Overall Study|Lost to Follow-up|3
6332516|NCT03068767|10080651|FG000|Overall Study|Protocol Violation|3
6332517|NCT03068767|10080652|FG001|Overall Study|Protocol Violation|0
6332518|NCT03069313|10080692|FG000|Overall Study|Adverse Event|5
6332519|NCT03069352|10080698|FG000|Overall Study|Ongoing|12
6332520|NCT03069352|10080699|FG001|Overall Study|Ongoing|40
6332521|NCT03069365|10080705|FG000|Overall Study|Adverse Event|1
6332522|NCT03069482|10080711|FG000|Overall Study|Lost to Follow-up|0
6332523|NCT03069482|10080712|FG001|Overall Study|Lost to Follow-up|1
6332524|NCT03069482|10080711|FG000|Overall Study|Physician Decision|1
6332525|NCT03069482|10080712|FG001|Overall Study|Physician Decision|0
6332526|NCT03069716|10080732|FG000|Run-in Period (2 Weeks)|Adverse Event|1
6332527|NCT03069716|10080733|FG001|Run-in Period (2 Weeks)|Adverse Event|0
6332528|NCT03069716|10080734|FG002|Run-in Period (2 Weeks)|Adverse Event|0
6332529|NCT03069716|10080732|FG000|Run-in Period (2 Weeks)|Protocol Violation|1
6332530|NCT03069716|10080733|FG001|Run-in Period (2 Weeks)|Protocol Violation|0
6332531|NCT03069716|10080734|FG002|Run-in Period (2 Weeks)|Protocol Violation|0
6332532|NCT03069716|10080732|FG000|Run-in Period (2 Weeks)|Withdrawal by Subject|5
6332533|NCT03069716|10080733|FG001|Run-in Period (2 Weeks)|Withdrawal by Subject|0
6332534|NCT03069716|10080734|FG002|Run-in Period (2 Weeks)|Withdrawal by Subject|0
6332535|NCT03069716|10080732|FG000|Randomized Treatment|Withdrawal by Subject|0
6332536|NCT03069716|10080733|FG001|Randomized Treatment|Withdrawal by Subject|2
6332537|NCT03069716|10080734|FG002|Randomized Treatment|Withdrawal by Subject|0
6332538|NCT03069989|10080743|FG000|Dosing Period 2 (Up to 16 Days)|Protocol-defined stop criteria reached|1
6332539|NCT03069989|10080744|FG001|Dosing Period 2 (Up to 16 Days)|Protocol-defined stop criteria reached|0
6332540|NCT03070171|10080753|FG000|Treatment Period 2 + Washout|Other Adverse Event|0
6332541|NCT03070171|10080754|FG001|Treatment Period 2 + Washout|Other Adverse Event|1
6332542|NCT03070171|10080753|FG000|Treatment Period 4 + Washout|Withdrawal by Subject|0
6332543|NCT03070171|10080754|FG001|Treatment Period 4 + Washout|Withdrawal by Subject|1
6332544|NCT03070431|10080760|FG000|Overall Study|Withdrawal by Subject|2
6332545|NCT03070431|10080760|FG000|Overall Study|Lost to Follow-up|2
6332546|NCT03070483|10080796|FG000|Overall Study|Lost to Follow-up|2
6332547|NCT03070782|10080824|FG000|Overall Study|Adverse Event|3
6332548|NCT03070782|10080825|FG001|Overall Study|Adverse Event|0
6332549|NCT03070782|10080826|FG002|Overall Study|Adverse Event|3
6332550|NCT03070782|10080827|FG003|Overall Study|Adverse Event|1
6332551|NCT03070782|10080828|FG004|Overall Study|Adverse Event|6
6332552|NCT03070782|10080829|FG005|Overall Study|Adverse Event|2
6332553|NCT03070782|10080824|FG000|Overall Study|Withdrawal by Subject|2
6332554|NCT03070782|10080825|FG001|Overall Study|Withdrawal by Subject|1
6332555|NCT03070782|10080826|FG002|Overall Study|Withdrawal by Subject|1
6332556|NCT03070782|10080827|FG003|Overall Study|Withdrawal by Subject|0
6332557|NCT03070782|10080828|FG004|Overall Study|Withdrawal by Subject|4
6332558|NCT03070782|10080829|FG005|Overall Study|Withdrawal by Subject|3
6332559|NCT03070782|10080824|FG000|Overall Study|Reason Not Specified|2
6332560|NCT03070782|10080825|FG001|Overall Study|Reason Not Specified|0
6332561|NCT03070782|10080826|FG002|Overall Study|Reason Not Specified|0
6332562|NCT03070782|10080827|FG003|Overall Study|Reason Not Specified|1
6332563|NCT03070782|10080828|FG004|Overall Study|Reason Not Specified|2
6332564|NCT03070782|10080829|FG005|Overall Study|Reason Not Specified|1
6332565|NCT03070782|10080824|FG000|Overall Study|Ineligibility|0
6332566|NCT03070782|10080825|FG001|Overall Study|Ineligibility|0
6332567|NCT03070782|10080826|FG002|Overall Study|Ineligibility|0
6332568|NCT03070782|10080827|FG003|Overall Study|Ineligibility|1
6332569|NCT03070782|10080828|FG004|Overall Study|Ineligibility|0
6332570|NCT03070782|10080829|FG005|Overall Study|Ineligibility|1
6332571|NCT03070782|10080824|FG000|Overall Study|Pregnancy|0
6332572|NCT03070782|10080825|FG001|Overall Study|Pregnancy|0
6332573|NCT03070782|10080826|FG002|Overall Study|Pregnancy|0
6332574|NCT03070782|10080827|FG003|Overall Study|Pregnancy|1
6332575|NCT03070782|10080828|FG004|Overall Study|Pregnancy|0
6332576|NCT03070782|10080829|FG005|Overall Study|Pregnancy|0
6332577|NCT03070782|10080824|FG000|Overall Study|Investigator Judgement|0
6332578|NCT03070782|10080825|FG001|Overall Study|Investigator Judgement|0
6332579|NCT03070782|10080826|FG002|Overall Study|Investigator Judgement|0
6332580|NCT03070782|10080827|FG003|Overall Study|Investigator Judgement|1
6332581|NCT03070782|10080828|FG004|Overall Study|Investigator Judgement|0
6332582|NCT03070782|10080829|FG005|Overall Study|Investigator Judgement|0
6332583|NCT03070964|10080843|FG000|Overall Study|Progressive disease|8
6332584|NCT03070964|10080843|FG000|Overall Study|Treatment-unrelated adverse event|2
6332585|NCT03070964|10080843|FG000|Overall Study|Never treated|1
6332586|NCT03070964|10080843|FG000|Overall Study|Physician Decision|1
6332587|NCT03070964|10080843|FG000|Overall Study|Withdrawal by Subject|1
6332588|NCT03070964|10080843|FG000|Overall Study|Adverse Event|1
6332589|NCT03071094|10080849|FG000|Overall Study|Death|1
6332590|NCT03071094|10080850|FG001|Overall Study|Death|1
6332591|NCT03071094|10080849|FG000|Overall Study|Adverse Event|1
6332592|NCT03071094|10080850|FG001|Overall Study|Adverse Event|0
6167328|NCT01227629|9811879|FG003|Overall Study|Protocol Violation|1
6167329|NCT01227629|9811880|FG004|Overall Study|Protocol Violation|0
6167330|NCT01227629|9811881|FG005|Overall Study|Protocol Violation|0
6167331|NCT01227629|9811882|FG006|Overall Study|Protocol Violation|0
6167332|NCT01227629|9811883|FG007|Overall Study|Protocol Violation|0
6167333|NCT01227629|9811884|FG008|Overall Study|Protocol Violation|0
6332593|NCT03071263|10080858|FG000|Overall Study|Adverse Event|1
6332594|NCT03071263|10080859|FG001|Overall Study|Adverse Event|3
6332595|NCT03071263|10080858|FG000|Overall Study|Withdrawal by Subject|1
6332596|NCT03071263|10080859|FG001|Overall Study|Withdrawal by Subject|3
6332597|NCT03071263|10080858|FG000|Overall Study|Physician Decision|1
6332598|NCT03071263|10080859|FG001|Overall Study|Physician Decision|0
6332599|NCT03071263|10080858|FG000|Overall Study|Participant moved to another city|0
6332600|NCT03071263|10080859|FG001|Overall Study|Participant moved to another city|1
6332601|NCT03071276|10080865|FG000|Overall Study|Adverse Event|1
6332602|NCT03071276|10080865|FG000|Overall Study|Lack of Efficacy|14
6332603|NCT03072160|10080879|FG000|Overall Study|Adverse Event|3
6332604|NCT03072160|10080880|FG001|Overall Study|Adverse Event|1
6332605|NCT03072160|10080879|FG000|Overall Study|Refused further treatment|6
6332606|NCT03072160|10080880|FG001|Overall Study|Refused further treatment|1
6332607|NCT03072160|10080879|FG000|Overall Study|Physician Decision|1
6332608|NCT03072160|10080880|FG001|Overall Study|Physician Decision|0
6332609|NCT03072160|10080879|FG000|Overall Study|Disease progression on study|1
6332610|NCT03072160|10080880|FG001|Overall Study|Disease progression on study|1
6332611|NCT03072160|10080879|FG000|Overall Study|No contact|0
6332612|NCT03072160|10080880|FG001|Overall Study|No contact|1
6332613|NCT03072719|10080937|FG000|Overall Study|Adverse Event|1
6332614|NCT03072719|10080938|FG001|Overall Study|Adverse Event|1
6167334|NCT01227629|9811885|FG009|Overall Study|Protocol Violation|0
6167335|NCT01227629|9811876|FG000|Overall Study|Lost to Follow-up|0
6332615|NCT03072875|10080953|FG000|Overall Study|Lost to Follow-up|1
6332616|NCT03073005|10080966|FG000|Overall Study|Death|6
6332617|NCT03073005|10080967|FG001|Overall Study|Death|0
6332618|NCT03073005|10080968|FG002|Overall Study|Death|7
6332619|NCT03073005|10080969|FG003|Overall Study|Death|0
6332620|NCT03073005|10080966|FG000|Overall Study|caregiver withdrew bc of pt death|0
6332621|NCT03073005|10080967|FG001|Overall Study|caregiver withdrew bc of pt death|6
6332622|NCT03073005|10080968|FG002|Overall Study|caregiver withdrew bc of pt death|0
6332623|NCT03073005|10080969|FG003|Overall Study|caregiver withdrew bc of pt death|7
6332624|NCT03073005|10080966|FG000|Overall Study|Lost to Follow-up|2
6332625|NCT03073005|10080967|FG001|Overall Study|Lost to Follow-up|2
6332626|NCT03073005|10080968|FG002|Overall Study|Lost to Follow-up|1
6332627|NCT03073005|10080969|FG003|Overall Study|Lost to Follow-up|2
6332628|NCT03073005|10080966|FG000|Overall Study|Withdrawal by Subject|0
6332629|NCT03073005|10080967|FG001|Overall Study|Withdrawal by Subject|4
6332630|NCT03073005|10080968|FG002|Overall Study|Withdrawal by Subject|4
6332631|NCT03073005|10080969|FG003|Overall Study|Withdrawal by Subject|4
6332632|NCT03073109|10080984|FG000|Overall Study|Adverse Event|0
6332633|NCT03073109|10080985|FG001|Overall Study|Adverse Event|1
6332634|NCT03073109|10080984|FG000|Overall Study|Other|2
6332635|NCT03073109|10080985|FG001|Overall Study|Other|0
6332636|NCT03073109|10080984|FG000|Overall Study|Lost to Follow-up|8
6332637|NCT03073109|10080985|FG001|Overall Study|Lost to Follow-up|1
6332638|NCT03073200|10081020|FG000|Double Blind Treatment Period|Protocol Violation|1
6332639|NCT03073200|10081021|FG001|Double Blind Treatment Period|Protocol Violation|0
6332640|NCT03073200|10081022|FG002|Double Blind Treatment Period|Protocol Violation|0
6332641|NCT03073200|10081023|FG003|Double Blind Treatment Period|Protocol Violation|0
6332642|NCT03073200|10081024|FG004|Double Blind Treatment Period|Protocol Violation|0
6332643|NCT03073200|10081025|FG005|Double Blind Treatment Period|Protocol Violation|0
6332644|NCT03073200|10081026|FG006|Double Blind Treatment Period|Protocol Violation|0
6332645|NCT03073200|10081027|FG007|Double Blind Treatment Period|Protocol Violation|0
6332646|NCT03073200|10081028|FG008|Double Blind Treatment Period|Protocol Violation|0
6332647|NCT03073200|10081029|FG009|Double Blind Treatment Period|Protocol Violation|0
6332648|NCT03073200|10081030|FG010|Double Blind Treatment Period|Protocol Violation|0
6332649|NCT03073200|10081031|FG011|Double Blind Treatment Period|Protocol Violation|0
6332650|NCT03073200|10081032|FG012|Double Blind Treatment Period|Protocol Violation|0
6332651|NCT03073200|10081033|FG013|Double Blind Treatment Period|Protocol Violation|0
6332652|NCT03073200|10081034|FG014|Double Blind Treatment Period|Protocol Violation|0
6332653|NCT03073200|10081020|FG000|Double Blind Treatment Period|Withdrawal by Parent/Guardian|0
6332654|NCT03073200|10081021|FG001|Double Blind Treatment Period|Withdrawal by Parent/Guardian|1
6332655|NCT03073200|10081022|FG002|Double Blind Treatment Period|Withdrawal by Parent/Guardian|0
6332656|NCT03073200|10081023|FG003|Double Blind Treatment Period|Withdrawal by Parent/Guardian|0
6332657|NCT03073200|10081024|FG004|Double Blind Treatment Period|Withdrawal by Parent/Guardian|0
6332658|NCT03073200|10081025|FG005|Double Blind Treatment Period|Withdrawal by Parent/Guardian|0
6332659|NCT03073200|10081026|FG006|Double Blind Treatment Period|Withdrawal by Parent/Guardian|0
6332660|NCT03073200|10081027|FG007|Double Blind Treatment Period|Withdrawal by Parent/Guardian|0
6332661|NCT03073200|10081028|FG008|Double Blind Treatment Period|Withdrawal by Parent/Guardian|0
6332662|NCT03073200|10081029|FG009|Double Blind Treatment Period|Withdrawal by Parent/Guardian|0
6332663|NCT03073200|10081030|FG010|Double Blind Treatment Period|Withdrawal by Parent/Guardian|0
6332664|NCT03073200|10081031|FG011|Double Blind Treatment Period|Withdrawal by Parent/Guardian|0
6332665|NCT03073200|10081032|FG012|Double Blind Treatment Period|Withdrawal by Parent/Guardian|0
6332666|NCT03073200|10081033|FG013|Double Blind Treatment Period|Withdrawal by Parent/Guardian|0
6332667|NCT03073200|10081034|FG014|Double Blind Treatment Period|Withdrawal by Parent/Guardian|0
6332668|NCT03073200|10081020|FG000|Double Blind Treatment Period|Withdrawal by Subject|1
6332669|NCT03073200|10081021|FG001|Double Blind Treatment Period|Withdrawal by Subject|0
6332670|NCT03073200|10081022|FG002|Double Blind Treatment Period|Withdrawal by Subject|0
6332671|NCT03073200|10081023|FG003|Double Blind Treatment Period|Withdrawal by Subject|0
6332672|NCT03073200|10081024|FG004|Double Blind Treatment Period|Withdrawal by Subject|0
6332673|NCT03073200|10081025|FG005|Double Blind Treatment Period|Withdrawal by Subject|0
6332674|NCT03073200|10081026|FG006|Double Blind Treatment Period|Withdrawal by Subject|0
6332675|NCT03073200|10081027|FG007|Double Blind Treatment Period|Withdrawal by Subject|0
6332676|NCT03073200|10081028|FG008|Double Blind Treatment Period|Withdrawal by Subject|0
6332677|NCT03073200|10081029|FG009|Double Blind Treatment Period|Withdrawal by Subject|0
6332678|NCT03073200|10081030|FG010|Double Blind Treatment Period|Withdrawal by Subject|0
6332679|NCT03073200|10081031|FG011|Double Blind Treatment Period|Withdrawal by Subject|0
6332680|NCT03073200|10081032|FG012|Double Blind Treatment Period|Withdrawal by Subject|0
6332681|NCT03073200|10081033|FG013|Double Blind Treatment Period|Withdrawal by Subject|0
6332682|NCT03073200|10081034|FG014|Double Blind Treatment Period|Withdrawal by Subject|0
6332683|NCT03073200|10081020|FG000|Open-Label Maintenance Period|Lost to Follow-up|0
6332684|NCT03073200|10081021|FG001|Open-Label Maintenance Period|Lost to Follow-up|0
6332685|NCT03073200|10081022|FG002|Open-Label Maintenance Period|Lost to Follow-up|0
6332686|NCT03073200|10081023|FG003|Open-Label Maintenance Period|Lost to Follow-up|1
6332687|NCT03073200|10081024|FG004|Open-Label Maintenance Period|Lost to Follow-up|2
6332688|NCT03073200|10081025|FG005|Open-Label Maintenance Period|Lost to Follow-up|0
6332689|NCT03073200|10081026|FG006|Open-Label Maintenance Period|Lost to Follow-up|0
6332690|NCT03073200|10081027|FG007|Open-Label Maintenance Period|Lost to Follow-up|0
6332691|NCT03073200|10081028|FG008|Open-Label Maintenance Period|Lost to Follow-up|0
6332692|NCT03073200|10081029|FG009|Open-Label Maintenance Period|Lost to Follow-up|0
6332693|NCT03073200|10081030|FG010|Open-Label Maintenance Period|Lost to Follow-up|0
6332694|NCT03073200|10081031|FG011|Open-Label Maintenance Period|Lost to Follow-up|0
6332695|NCT03073200|10081032|FG012|Open-Label Maintenance Period|Lost to Follow-up|0
6332696|NCT03073200|10081033|FG013|Open-Label Maintenance Period|Lost to Follow-up|0
6332697|NCT03073200|10081034|FG014|Open-Label Maintenance Period|Lost to Follow-up|0
6332698|NCT03073200|10081020|FG000|Open-Label Maintenance Period|Participant moved to another city|0
6332699|NCT03073200|10081021|FG001|Open-Label Maintenance Period|Participant moved to another city|0
6332700|NCT03073200|10081022|FG002|Open-Label Maintenance Period|Participant moved to another city|0
6332701|NCT03073200|10081023|FG003|Open-Label Maintenance Period|Participant moved to another city|1
6332702|NCT03073200|10081024|FG004|Open-Label Maintenance Period|Participant moved to another city|0
6332703|NCT03073200|10081025|FG005|Open-Label Maintenance Period|Participant moved to another city|0
6332704|NCT03073200|10081026|FG006|Open-Label Maintenance Period|Participant moved to another city|0
6332705|NCT03073200|10081027|FG007|Open-Label Maintenance Period|Participant moved to another city|0
6332706|NCT03073200|10081028|FG008|Open-Label Maintenance Period|Participant moved to another city|0
6332707|NCT03073200|10081029|FG009|Open-Label Maintenance Period|Participant moved to another city|0
6332708|NCT03073200|10081030|FG010|Open-Label Maintenance Period|Participant moved to another city|0
6332709|NCT03073200|10081031|FG011|Open-Label Maintenance Period|Participant moved to another city|0
6332710|NCT03073200|10081032|FG012|Open-Label Maintenance Period|Participant moved to another city|0
6332711|NCT03073200|10081033|FG013|Open-Label Maintenance Period|Participant moved to another city|0
6332712|NCT03073200|10081034|FG014|Open-Label Maintenance Period|Participant moved to another city|0
6332713|NCT03073200|10081020|FG000|Open-Label Maintenance Period|Lack of Efficacy|0
6332714|NCT03073200|10081021|FG001|Open-Label Maintenance Period|Lack of Efficacy|0
6332715|NCT03073200|10081022|FG002|Open-Label Maintenance Period|Lack of Efficacy|0
6332716|NCT03073200|10081023|FG003|Open-Label Maintenance Period|Lack of Efficacy|0
6332717|NCT03073200|10081024|FG004|Open-Label Maintenance Period|Lack of Efficacy|1
6332718|NCT03073200|10081025|FG005|Open-Label Maintenance Period|Lack of Efficacy|0
6332719|NCT03073200|10081026|FG006|Open-Label Maintenance Period|Lack of Efficacy|0
6332720|NCT03073200|10081027|FG007|Open-Label Maintenance Period|Lack of Efficacy|0
6332721|NCT03073200|10081028|FG008|Open-Label Maintenance Period|Lack of Efficacy|0
6332722|NCT03073200|10081029|FG009|Open-Label Maintenance Period|Lack of Efficacy|0
6332723|NCT03073200|10081030|FG010|Open-Label Maintenance Period|Lack of Efficacy|0
6332724|NCT03073200|10081031|FG011|Open-Label Maintenance Period|Lack of Efficacy|0
6332725|NCT03073200|10081032|FG012|Open-Label Maintenance Period|Lack of Efficacy|0
6332726|NCT03073200|10081033|FG013|Open-Label Maintenance Period|Lack of Efficacy|0
6332727|NCT03073200|10081034|FG014|Open-Label Maintenance Period|Lack of Efficacy|0
6332728|NCT03073200|10081020|FG000|Open-Label Maintenance Period|Withdrawal by Subject|0
6332729|NCT03073200|10081021|FG001|Open-Label Maintenance Period|Withdrawal by Subject|0
6332730|NCT03073200|10081022|FG002|Open-Label Maintenance Period|Withdrawal by Subject|0
6332731|NCT03073200|10081023|FG003|Open-Label Maintenance Period|Withdrawal by Subject|2
6332732|NCT03073200|10081024|FG004|Open-Label Maintenance Period|Withdrawal by Subject|1
6332733|NCT03073200|10081025|FG005|Open-Label Maintenance Period|Withdrawal by Subject|0
6332734|NCT03073200|10081026|FG006|Open-Label Maintenance Period|Withdrawal by Subject|0
6332735|NCT03073200|10081027|FG007|Open-Label Maintenance Period|Withdrawal by Subject|0
6332736|NCT03073200|10081028|FG008|Open-Label Maintenance Period|Withdrawal by Subject|0
6332737|NCT03073200|10081029|FG009|Open-Label Maintenance Period|Withdrawal by Subject|0
6332738|NCT03073200|10081030|FG010|Open-Label Maintenance Period|Withdrawal by Subject|0
6332739|NCT03073200|10081031|FG011|Open-Label Maintenance Period|Withdrawal by Subject|0
6332740|NCT03073200|10081032|FG012|Open-Label Maintenance Period|Withdrawal by Subject|0
6332741|NCT03073200|10081033|FG013|Open-Label Maintenance Period|Withdrawal by Subject|0
6332742|NCT03073200|10081034|FG014|Open-Label Maintenance Period|Withdrawal by Subject|0
6332743|NCT03073200|10081020|FG000|Extension Period|Lost to Follow-up|0
6332744|NCT03073200|10081021|FG001|Extension Period|Lost to Follow-up|0
6332745|NCT03073200|10081022|FG002|Extension Period|Lost to Follow-up|0
6332746|NCT03073200|10081023|FG003|Extension Period|Lost to Follow-up|0
6332747|NCT03073200|10081024|FG004|Extension Period|Lost to Follow-up|0
6332748|NCT03073200|10081025|FG005|Extension Period|Lost to Follow-up|0
6332749|NCT03073200|10081026|FG006|Extension Period|Lost to Follow-up|1
6332750|NCT03073200|10081027|FG007|Extension Period|Lost to Follow-up|1
6332751|NCT03073200|10081028|FG008|Extension Period|Lost to Follow-up|0
6332752|NCT03073200|10081029|FG009|Extension Period|Lost to Follow-up|0
6332753|NCT03073200|10081030|FG010|Extension Period|Lost to Follow-up|0
6332754|NCT03073200|10081031|FG011|Extension Period|Lost to Follow-up|0
6332755|NCT03073200|10081032|FG012|Extension Period|Lost to Follow-up|0
6332756|NCT03073200|10081033|FG013|Extension Period|Lost to Follow-up|0
6332757|NCT03073200|10081034|FG014|Extension Period|Lost to Follow-up|0
6332758|NCT03073200|10081020|FG000|Extension Period|Sponsor Decision|0
6332759|NCT03073200|10081021|FG001|Extension Period|Sponsor Decision|0
6332760|NCT03073200|10081022|FG002|Extension Period|Sponsor Decision|0
6332761|NCT03073200|10081023|FG003|Extension Period|Sponsor Decision|0
6332762|NCT03073200|10081024|FG004|Extension Period|Sponsor Decision|0
6332763|NCT03073200|10081025|FG005|Extension Period|Sponsor Decision|0
6332764|NCT03073200|10081026|FG006|Extension Period|Sponsor Decision|0
6332765|NCT03073200|10081027|FG007|Extension Period|Sponsor Decision|0
6167336|NCT01227629|9811877|FG001|Overall Study|Lost to Follow-up|0
6167337|NCT01227629|9811878|FG002|Overall Study|Lost to Follow-up|0
6167338|NCT01227629|9811879|FG003|Overall Study|Lost to Follow-up|0
6167339|NCT01227629|9811880|FG004|Overall Study|Lost to Follow-up|1
6167340|NCT01227629|9811881|FG005|Overall Study|Lost to Follow-up|0
6167341|NCT01227629|9811882|FG006|Overall Study|Lost to Follow-up|0
6167342|NCT01227629|9811883|FG007|Overall Study|Lost to Follow-up|0
6167343|NCT01227629|9811884|FG008|Overall Study|Lost to Follow-up|0
6167344|NCT01227629|9811885|FG009|Overall Study|Lost to Follow-up|0
6167345|NCT01227629|9811876|FG000|Overall Study|Withdrawal by Subject|0
6167346|NCT01227629|9811877|FG001|Overall Study|Withdrawal by Subject|0
6167347|NCT01227629|9811878|FG002|Overall Study|Withdrawal by Subject|0
6167348|NCT01227629|9811879|FG003|Overall Study|Withdrawal by Subject|0
6167349|NCT01227629|9811880|FG004|Overall Study|Withdrawal by Subject|0
6167350|NCT01227629|9811881|FG005|Overall Study|Withdrawal by Subject|0
6167351|NCT01227629|9811882|FG006|Overall Study|Withdrawal by Subject|2
6167352|NCT01227629|9811883|FG007|Overall Study|Withdrawal by Subject|0
6167353|NCT01227629|9811884|FG008|Overall Study|Withdrawal by Subject|0
6167354|NCT01227629|9811885|FG009|Overall Study|Withdrawal by Subject|1
6167355|NCT01227629|9811876|FG000|Overall Study|Other|0
6167356|NCT01227629|9811877|FG001|Overall Study|Other|0
6167357|NCT01227629|9811878|FG002|Overall Study|Other|0
6332766|NCT03073200|10081028|FG008|Extension Period|Sponsor Decision|1
6332767|NCT03073200|10081029|FG009|Extension Period|Sponsor Decision|0
6332768|NCT03073200|10081030|FG010|Extension Period|Sponsor Decision|0
6332769|NCT03073200|10081031|FG011|Extension Period|Sponsor Decision|0
6332770|NCT03073200|10081032|FG012|Extension Period|Sponsor Decision|0
6332771|NCT03073200|10081033|FG013|Extension Period|Sponsor Decision|0
6332772|NCT03073200|10081034|FG014|Extension Period|Sponsor Decision|0
6332773|NCT03073200|10081020|FG000|Extension Period|Withdrawal by Parent/Guardian|0
6332774|NCT03073200|10081021|FG001|Extension Period|Withdrawal by Parent/Guardian|0
6332775|NCT03073200|10081022|FG002|Extension Period|Withdrawal by Parent/Guardian|0
6332776|NCT03073200|10081023|FG003|Extension Period|Withdrawal by Parent/Guardian|0
6332777|NCT03073200|10081024|FG004|Extension Period|Withdrawal by Parent/Guardian|0
6332778|NCT03073200|10081025|FG005|Extension Period|Withdrawal by Parent/Guardian|0
6332779|NCT03073200|10081026|FG006|Extension Period|Withdrawal by Parent/Guardian|1
6332780|NCT03073200|10081027|FG007|Extension Period|Withdrawal by Parent/Guardian|3
6332781|NCT03073200|10081028|FG008|Extension Period|Withdrawal by Parent/Guardian|1
6332782|NCT03073200|10081029|FG009|Extension Period|Withdrawal by Parent/Guardian|0
6332783|NCT03073200|10081030|FG010|Extension Period|Withdrawal by Parent/Guardian|0
6332784|NCT03073200|10081031|FG011|Extension Period|Withdrawal by Parent/Guardian|0
6332785|NCT03073200|10081032|FG012|Extension Period|Withdrawal by Parent/Guardian|0
6332786|NCT03073200|10081033|FG013|Extension Period|Withdrawal by Parent/Guardian|0
6332787|NCT03073200|10081034|FG014|Extension Period|Withdrawal by Parent/Guardian|0
6332788|NCT03073200|10081020|FG000|Extension Period|Withdrawal by Subject|0
6332789|NCT03073200|10081021|FG001|Extension Period|Withdrawal by Subject|0
6332790|NCT03073200|10081022|FG002|Extension Period|Withdrawal by Subject|0
6332791|NCT03073200|10081023|FG003|Extension Period|Withdrawal by Subject|0
6332792|NCT03073200|10081024|FG004|Extension Period|Withdrawal by Subject|0
6332793|NCT03073200|10081025|FG005|Extension Period|Withdrawal by Subject|0
6332794|NCT03073200|10081026|FG006|Extension Period|Withdrawal by Subject|1
6332795|NCT03073200|10081027|FG007|Extension Period|Withdrawal by Subject|2
6332796|NCT03073200|10081028|FG008|Extension Period|Withdrawal by Subject|0
6332797|NCT03073200|10081029|FG009|Extension Period|Withdrawal by Subject|0
6332798|NCT03073200|10081030|FG010|Extension Period|Withdrawal by Subject|0
6332799|NCT03073200|10081031|FG011|Extension Period|Withdrawal by Subject|0
6332800|NCT03073200|10081032|FG012|Extension Period|Withdrawal by Subject|0
6332801|NCT03073200|10081033|FG013|Extension Period|Withdrawal by Subject|0
6332802|NCT03073200|10081034|FG014|Extension Period|Withdrawal by Subject|0
6332803|NCT03073200|10081020|FG000|Randomized Withdrawal Period|Lost to Follow-up|0
6332804|NCT03073200|10081021|FG001|Randomized Withdrawal Period|Lost to Follow-up|0
6332805|NCT03073200|10081022|FG002|Randomized Withdrawal Period|Lost to Follow-up|0
6167358|NCT01227629|9811879|FG003|Overall Study|Other|1
6167359|NCT01227629|9811880|FG004|Overall Study|Other|0
6167360|NCT01227629|9811881|FG005|Overall Study|Other|0
6167361|NCT01227629|9811882|FG006|Overall Study|Other|0
6167362|NCT01227629|9811883|FG007|Overall Study|Other|0
6332806|NCT03073200|10081023|FG003|Randomized Withdrawal Period|Lost to Follow-up|0
6332807|NCT03073200|10081024|FG004|Randomized Withdrawal Period|Lost to Follow-up|0
6332808|NCT03073200|10081025|FG005|Randomized Withdrawal Period|Lost to Follow-up|0
6332809|NCT03073200|10081026|FG006|Randomized Withdrawal Period|Lost to Follow-up|0
6332810|NCT03073200|10081027|FG007|Randomized Withdrawal Period|Lost to Follow-up|0
6332811|NCT03073200|10081028|FG008|Randomized Withdrawal Period|Lost to Follow-up|0
6332812|NCT03073200|10081029|FG009|Randomized Withdrawal Period|Lost to Follow-up|0
6332813|NCT03073200|10081030|FG010|Randomized Withdrawal Period|Lost to Follow-up|0
6167363|NCT01227629|9811884|FG008|Overall Study|Other|2
6167364|NCT01227629|9811885|FG009|Overall Study|Other|1
6167365|NCT01227668|9811946|FG000|Phase 1 (Stabilization Phase)|Adverse Event|12
6332814|NCT03073200|10081031|FG011|Randomized Withdrawal Period|Lost to Follow-up|1
6332815|NCT03073200|10081032|FG012|Randomized Withdrawal Period|Lost to Follow-up|0
6332816|NCT03073200|10081033|FG013|Randomized Withdrawal Period|Lost to Follow-up|0
6332817|NCT03073200|10081034|FG014|Randomized Withdrawal Period|Lost to Follow-up|0
6332818|NCT03073200|10081020|FG000|Randomized Withdrawal Period|Withdrawal by Parent/Guardian|0
6332819|NCT03073200|10081021|FG001|Randomized Withdrawal Period|Withdrawal by Parent/Guardian|0
6332820|NCT03073200|10081022|FG002|Randomized Withdrawal Period|Withdrawal by Parent/Guardian|0
6332821|NCT03073200|10081023|FG003|Randomized Withdrawal Period|Withdrawal by Parent/Guardian|0
6332822|NCT03073200|10081024|FG004|Randomized Withdrawal Period|Withdrawal by Parent/Guardian|0
6332823|NCT03073200|10081025|FG005|Randomized Withdrawal Period|Withdrawal by Parent/Guardian|0
6332824|NCT03073200|10081026|FG006|Randomized Withdrawal Period|Withdrawal by Parent/Guardian|0
6332825|NCT03073200|10081027|FG007|Randomized Withdrawal Period|Withdrawal by Parent/Guardian|0
6332826|NCT03073200|10081028|FG008|Randomized Withdrawal Period|Withdrawal by Parent/Guardian|0
6332827|NCT03073200|10081029|FG009|Randomized Withdrawal Period|Withdrawal by Parent/Guardian|0
6332828|NCT03073200|10081030|FG010|Randomized Withdrawal Period|Withdrawal by Parent/Guardian|0
6332829|NCT03073200|10081031|FG011|Randomized Withdrawal Period|Withdrawal by Parent/Guardian|1
6332830|NCT03073200|10081032|FG012|Randomized Withdrawal Period|Withdrawal by Parent/Guardian|0
6332831|NCT03073200|10081033|FG013|Randomized Withdrawal Period|Withdrawal by Parent/Guardian|0
6332832|NCT03073200|10081034|FG014|Randomized Withdrawal Period|Withdrawal by Parent/Guardian|0
6332833|NCT03073200|10081020|FG000|Randomized Withdrawal Period|Withdrawal by Subject|0
6332834|NCT03073200|10081021|FG001|Randomized Withdrawal Period|Withdrawal by Subject|0
6332835|NCT03073200|10081022|FG002|Randomized Withdrawal Period|Withdrawal by Subject|0
6332836|NCT03073200|10081023|FG003|Randomized Withdrawal Period|Withdrawal by Subject|0
6332837|NCT03073200|10081024|FG004|Randomized Withdrawal Period|Withdrawal by Subject|0
6332838|NCT03073200|10081025|FG005|Randomized Withdrawal Period|Withdrawal by Subject|0
6332839|NCT03073200|10081026|FG006|Randomized Withdrawal Period|Withdrawal by Subject|0
6332840|NCT03073200|10081027|FG007|Randomized Withdrawal Period|Withdrawal by Subject|0
6332841|NCT03073200|10081028|FG008|Randomized Withdrawal Period|Withdrawal by Subject|0
6332842|NCT03073200|10081029|FG009|Randomized Withdrawal Period|Withdrawal by Subject|0
6332843|NCT03073200|10081030|FG010|Randomized Withdrawal Period|Withdrawal by Subject|1
6332844|NCT03073200|10081031|FG011|Randomized Withdrawal Period|Withdrawal by Subject|1
6332845|NCT03073200|10081032|FG012|Randomized Withdrawal Period|Withdrawal by Subject|0
6332846|NCT03073200|10081033|FG013|Randomized Withdrawal Period|Withdrawal by Subject|0
6332847|NCT03073200|10081034|FG014|Randomized Withdrawal Period|Withdrawal by Subject|0
6332848|NCT03073200|10081020|FG000|Randomized Withdrawal Period|Adverse Event|0
6332849|NCT03073200|10081021|FG001|Randomized Withdrawal Period|Adverse Event|0
6332850|NCT03073200|10081022|FG002|Randomized Withdrawal Period|Adverse Event|0
6332851|NCT03073200|10081023|FG003|Randomized Withdrawal Period|Adverse Event|0
6332852|NCT03073200|10081024|FG004|Randomized Withdrawal Period|Adverse Event|0
6332853|NCT03073200|10081025|FG005|Randomized Withdrawal Period|Adverse Event|0
6332854|NCT03073200|10081026|FG006|Randomized Withdrawal Period|Adverse Event|0
6332855|NCT03073200|10081027|FG007|Randomized Withdrawal Period|Adverse Event|0
6332856|NCT03073200|10081028|FG008|Randomized Withdrawal Period|Adverse Event|0
6332857|NCT03073200|10081029|FG009|Randomized Withdrawal Period|Adverse Event|0
6332858|NCT03073200|10081030|FG010|Randomized Withdrawal Period|Adverse Event|1
6332859|NCT03073200|10081031|FG011|Randomized Withdrawal Period|Adverse Event|0
6332860|NCT03073200|10081032|FG012|Randomized Withdrawal Period|Adverse Event|0
6332861|NCT03073200|10081033|FG013|Randomized Withdrawal Period|Adverse Event|0
6332862|NCT03073200|10081034|FG014|Randomized Withdrawal Period|Adverse Event|0
6332863|NCT03073200|10081020|FG000|Post-Treatment Follow-Up Period|Adverse Event|0
6332864|NCT03073200|10081021|FG001|Post-Treatment Follow-Up Period|Adverse Event|0
6332865|NCT03073200|10081022|FG002|Post-Treatment Follow-Up Period|Adverse Event|0
6332866|NCT03073200|10081023|FG003|Post-Treatment Follow-Up Period|Adverse Event|0
6332867|NCT03073200|10081024|FG004|Post-Treatment Follow-Up Period|Adverse Event|0
6332868|NCT03073200|10081025|FG005|Post-Treatment Follow-Up Period|Adverse Event|0
6332869|NCT03073200|10081026|FG006|Post-Treatment Follow-Up Period|Adverse Event|0
6332870|NCT03073200|10081027|FG007|Post-Treatment Follow-Up Period|Adverse Event|0
6332871|NCT03073200|10081028|FG008|Post-Treatment Follow-Up Period|Adverse Event|0
6332872|NCT03073200|10081029|FG009|Post-Treatment Follow-Up Period|Adverse Event|0
6332873|NCT03073200|10081030|FG010|Post-Treatment Follow-Up Period|Adverse Event|0
6332874|NCT03073200|10081031|FG011|Post-Treatment Follow-Up Period|Adverse Event|0
6332875|NCT03073200|10081032|FG012|Post-Treatment Follow-Up Period|Adverse Event|0
6332876|NCT03073200|10081033|FG013|Post-Treatment Follow-Up Period|Adverse Event|2
6332877|NCT03073200|10081034|FG014|Post-Treatment Follow-Up Period|Adverse Event|0
6167366|NCT01227668|9811947|FG001|Phase 1 (Stabilization Phase)|Adverse Event|0
6167367|NCT01227668|9811946|FG000|Phase 1 (Stabilization Phase)|Withdrawal by Subject|7
6167368|NCT01227668|9811947|FG001|Phase 1 (Stabilization Phase)|Withdrawal by Subject|0
6167369|NCT01227668|9811946|FG000|Phase 1 (Stabilization Phase)|Lost to Follow-up|8
6167370|NCT01227668|9811947|FG001|Phase 1 (Stabilization Phase)|Lost to Follow-up|0
6167371|NCT01227668|9811946|FG000|Phase 1 (Stabilization Phase)|Sponsor's administrative reason|11
6167372|NCT01227668|9811947|FG001|Phase 1 (Stabilization Phase)|Sponsor's administrative reason|0
6332878|NCT03073200|10081020|FG000|Post-Treatment Follow-Up Period|Lost to Follow-up|0
6332879|NCT03073200|10081021|FG001|Post-Treatment Follow-Up Period|Lost to Follow-up|0
6332880|NCT03073200|10081022|FG002|Post-Treatment Follow-Up Period|Lost to Follow-up|0
6332881|NCT03073200|10081023|FG003|Post-Treatment Follow-Up Period|Lost to Follow-up|0
6332882|NCT03073200|10081024|FG004|Post-Treatment Follow-Up Period|Lost to Follow-up|0
6332883|NCT03073200|10081025|FG005|Post-Treatment Follow-Up Period|Lost to Follow-up|0
6332884|NCT03073200|10081026|FG006|Post-Treatment Follow-Up Period|Lost to Follow-up|0
6332885|NCT03073200|10081027|FG007|Post-Treatment Follow-Up Period|Lost to Follow-up|0
6332886|NCT03073200|10081028|FG008|Post-Treatment Follow-Up Period|Lost to Follow-up|0
6332887|NCT03073200|10081029|FG009|Post-Treatment Follow-Up Period|Lost to Follow-up|0
6332888|NCT03073200|10081030|FG010|Post-Treatment Follow-Up Period|Lost to Follow-up|0
6332889|NCT03073200|10081031|FG011|Post-Treatment Follow-Up Period|Lost to Follow-up|0
6332890|NCT03073200|10081032|FG012|Post-Treatment Follow-Up Period|Lost to Follow-up|0
6332891|NCT03073200|10081033|FG013|Post-Treatment Follow-Up Period|Lost to Follow-up|1
6332892|NCT03073200|10081034|FG014|Post-Treatment Follow-Up Period|Lost to Follow-up|0
6332893|NCT03073200|10081020|FG000|Post-Treatment Follow-Up Period|Participant moved to another city|0
6332894|NCT03073200|10081021|FG001|Post-Treatment Follow-Up Period|Participant moved to another city|0
6332895|NCT03073200|10081022|FG002|Post-Treatment Follow-Up Period|Participant moved to another city|0
6332896|NCT03073200|10081023|FG003|Post-Treatment Follow-Up Period|Participant moved to another city|0
6332897|NCT03073200|10081024|FG004|Post-Treatment Follow-Up Period|Participant moved to another city|0
6332898|NCT03073200|10081025|FG005|Post-Treatment Follow-Up Period|Participant moved to another city|0
6332899|NCT03073200|10081026|FG006|Post-Treatment Follow-Up Period|Participant moved to another city|0
6332900|NCT03073200|10081027|FG007|Post-Treatment Follow-Up Period|Participant moved to another city|0
6332901|NCT03073200|10081028|FG008|Post-Treatment Follow-Up Period|Participant moved to another city|0
6332902|NCT03073200|10081029|FG009|Post-Treatment Follow-Up Period|Participant moved to another city|0
6332903|NCT03073200|10081030|FG010|Post-Treatment Follow-Up Period|Participant moved to another city|0
6332904|NCT03073200|10081031|FG011|Post-Treatment Follow-Up Period|Participant moved to another city|0
6332905|NCT03073200|10081032|FG012|Post-Treatment Follow-Up Period|Participant moved to another city|0
6332906|NCT03073200|10081033|FG013|Post-Treatment Follow-Up Period|Participant moved to another city|1
6332907|NCT03073200|10081034|FG014|Post-Treatment Follow-Up Period|Participant moved to another city|0
6332908|NCT03073200|10081020|FG000|Post-Treatment Follow-Up Period|Protocol Violation|0
6332909|NCT03073200|10081021|FG001|Post-Treatment Follow-Up Period|Protocol Violation|0
6332910|NCT03073200|10081022|FG002|Post-Treatment Follow-Up Period|Protocol Violation|0
6332911|NCT03073200|10081023|FG003|Post-Treatment Follow-Up Period|Protocol Violation|0
6332912|NCT03073200|10081024|FG004|Post-Treatment Follow-Up Period|Protocol Violation|0
6332913|NCT03073200|10081025|FG005|Post-Treatment Follow-Up Period|Protocol Violation|0
6332914|NCT03073200|10081026|FG006|Post-Treatment Follow-Up Period|Protocol Violation|0
6332915|NCT03073200|10081027|FG007|Post-Treatment Follow-Up Period|Protocol Violation|0
6332916|NCT03073200|10081028|FG008|Post-Treatment Follow-Up Period|Protocol Violation|0
6332917|NCT03073200|10081029|FG009|Post-Treatment Follow-Up Period|Protocol Violation|0
6332918|NCT03073200|10081030|FG010|Post-Treatment Follow-Up Period|Protocol Violation|0
6332919|NCT03073200|10081031|FG011|Post-Treatment Follow-Up Period|Protocol Violation|0
6332920|NCT03073200|10081032|FG012|Post-Treatment Follow-Up Period|Protocol Violation|0
6332921|NCT03073200|10081033|FG013|Post-Treatment Follow-Up Period|Protocol Violation|1
6332922|NCT03073200|10081034|FG014|Post-Treatment Follow-Up Period|Protocol Violation|0
6332923|NCT03073200|10081020|FG000|Post-Treatment Follow-Up Period|Site terminated by sponsor|0
6332924|NCT03073200|10081021|FG001|Post-Treatment Follow-Up Period|Site terminated by sponsor|0
6332925|NCT03073200|10081022|FG002|Post-Treatment Follow-Up Period|Site terminated by sponsor|0
6332926|NCT03073200|10081023|FG003|Post-Treatment Follow-Up Period|Site terminated by sponsor|0
6332927|NCT03073200|10081024|FG004|Post-Treatment Follow-Up Period|Site terminated by sponsor|0
6332928|NCT03073200|10081025|FG005|Post-Treatment Follow-Up Period|Site terminated by sponsor|0
6332929|NCT03073200|10081026|FG006|Post-Treatment Follow-Up Period|Site terminated by sponsor|0
6332930|NCT03073200|10081027|FG007|Post-Treatment Follow-Up Period|Site terminated by sponsor|0
6332931|NCT03073200|10081028|FG008|Post-Treatment Follow-Up Period|Site terminated by sponsor|0
6332932|NCT03073200|10081029|FG009|Post-Treatment Follow-Up Period|Site terminated by sponsor|0
6332933|NCT03073200|10081030|FG010|Post-Treatment Follow-Up Period|Site terminated by sponsor|0
6332934|NCT03073200|10081031|FG011|Post-Treatment Follow-Up Period|Site terminated by sponsor|0
6332935|NCT03073200|10081032|FG012|Post-Treatment Follow-Up Period|Site terminated by sponsor|0
6332936|NCT03073200|10081033|FG013|Post-Treatment Follow-Up Period|Site terminated by sponsor|0
6332937|NCT03073200|10081034|FG014|Post-Treatment Follow-Up Period|Site terminated by sponsor|1
6332938|NCT03073200|10081020|FG000|Post-Treatment Follow-Up Period|Withdrawal by Parent/Guardian|0
6332939|NCT03073200|10081021|FG001|Post-Treatment Follow-Up Period|Withdrawal by Parent/Guardian|0
6332940|NCT03073200|10081022|FG002|Post-Treatment Follow-Up Period|Withdrawal by Parent/Guardian|0
6332941|NCT03073200|10081023|FG003|Post-Treatment Follow-Up Period|Withdrawal by Parent/Guardian|0
6332942|NCT03073200|10081024|FG004|Post-Treatment Follow-Up Period|Withdrawal by Parent/Guardian|0
6332943|NCT03073200|10081025|FG005|Post-Treatment Follow-Up Period|Withdrawal by Parent/Guardian|0
6332944|NCT03073200|10081026|FG006|Post-Treatment Follow-Up Period|Withdrawal by Parent/Guardian|0
6332945|NCT03073200|10081027|FG007|Post-Treatment Follow-Up Period|Withdrawal by Parent/Guardian|0
6332946|NCT03073200|10081028|FG008|Post-Treatment Follow-Up Period|Withdrawal by Parent/Guardian|0
6332947|NCT03073200|10081029|FG009|Post-Treatment Follow-Up Period|Withdrawal by Parent/Guardian|0
6332948|NCT03073200|10081030|FG010|Post-Treatment Follow-Up Period|Withdrawal by Parent/Guardian|0
6332949|NCT03073200|10081031|FG011|Post-Treatment Follow-Up Period|Withdrawal by Parent/Guardian|0
6332950|NCT03073200|10081032|FG012|Post-Treatment Follow-Up Period|Withdrawal by Parent/Guardian|0
6332951|NCT03073200|10081033|FG013|Post-Treatment Follow-Up Period|Withdrawal by Parent/Guardian|11
6332952|NCT03073200|10081034|FG014|Post-Treatment Follow-Up Period|Withdrawal by Parent/Guardian|0
6332953|NCT03073200|10081020|FG000|Post-Treatment Follow-Up Period|Withdrawal by Subject|0
6332954|NCT03073200|10081021|FG001|Post-Treatment Follow-Up Period|Withdrawal by Subject|0
6332955|NCT03073200|10081022|FG002|Post-Treatment Follow-Up Period|Withdrawal by Subject|0
6332956|NCT03073200|10081023|FG003|Post-Treatment Follow-Up Period|Withdrawal by Subject|0
6332957|NCT03073200|10081024|FG004|Post-Treatment Follow-Up Period|Withdrawal by Subject|0
6332958|NCT03073200|10081025|FG005|Post-Treatment Follow-Up Period|Withdrawal by Subject|0
6332959|NCT03073200|10081026|FG006|Post-Treatment Follow-Up Period|Withdrawal by Subject|0
6332960|NCT03073200|10081027|FG007|Post-Treatment Follow-Up Period|Withdrawal by Subject|0
6332961|NCT03073200|10081028|FG008|Post-Treatment Follow-Up Period|Withdrawal by Subject|0
6332962|NCT03073200|10081029|FG009|Post-Treatment Follow-Up Period|Withdrawal by Subject|0
6332963|NCT03073200|10081030|FG010|Post-Treatment Follow-Up Period|Withdrawal by Subject|0
6332964|NCT03073200|10081031|FG011|Post-Treatment Follow-Up Period|Withdrawal by Subject|0
6332965|NCT03073200|10081032|FG012|Post-Treatment Follow-Up Period|Withdrawal by Subject|0
6332966|NCT03073200|10081033|FG013|Post-Treatment Follow-Up Period|Withdrawal by Subject|9
6332967|NCT03073200|10081034|FG014|Post-Treatment Follow-Up Period|Withdrawal by Subject|0
6332968|NCT03073200|10081020|FG000|Post-Treatment Follow-Up Period|Other-determined by Investigator|0
6332969|NCT03073200|10081021|FG001|Post-Treatment Follow-Up Period|Other-determined by Investigator|0
6332970|NCT03073200|10081022|FG002|Post-Treatment Follow-Up Period|Other-determined by Investigator|0
6332971|NCT03073200|10081023|FG003|Post-Treatment Follow-Up Period|Other-determined by Investigator|0
6332972|NCT03073200|10081024|FG004|Post-Treatment Follow-Up Period|Other-determined by Investigator|0
6332973|NCT03073200|10081025|FG005|Post-Treatment Follow-Up Period|Other-determined by Investigator|0
6332974|NCT03073200|10081026|FG006|Post-Treatment Follow-Up Period|Other-determined by Investigator|0
6332975|NCT03073200|10081027|FG007|Post-Treatment Follow-Up Period|Other-determined by Investigator|0
6332976|NCT03073200|10081028|FG008|Post-Treatment Follow-Up Period|Other-determined by Investigator|0
6332977|NCT03073200|10081029|FG009|Post-Treatment Follow-Up Period|Other-determined by Investigator|0
6332978|NCT03073200|10081030|FG010|Post-Treatment Follow-Up Period|Other-determined by Investigator|0
6332979|NCT03073200|10081031|FG011|Post-Treatment Follow-Up Period|Other-determined by Investigator|0
6332980|NCT03073200|10081032|FG012|Post-Treatment Follow-Up Period|Other-determined by Investigator|0
6332981|NCT03073200|10081033|FG013|Post-Treatment Follow-Up Period|Other-determined by Investigator|2
6332982|NCT03073200|10081034|FG014|Post-Treatment Follow-Up Period|Other-determined by Investigator|0
6332983|NCT03073213|10081059|FG000|Multiple Dose Period|Protocol Violation|0
6332984|NCT03073213|10081060|FG001|Multiple Dose Period|Protocol Violation|0
6332985|NCT03073213|10081061|FG002|Multiple Dose Period|Protocol Violation|1
6332986|NCT03073798|10081089|FG000|Overall Study|Adverse Event|1
6332987|NCT03073798|10081089|FG000|Overall Study|Withdrawal by Subject|1
6332988|NCT03074162|10081114|FG000|Period 1 Including Washout 1|Withdrawal by Subject|0
6332989|NCT03074162|10081115|FG001|Period 1 Including Washout 1|Withdrawal by Subject|0
6332990|NCT03074162|10081116|FG002|Period 1 Including Washout 1|Withdrawal by Subject|1
6332991|NCT03074162|10081117|FG003|Period 1 Including Washout 1|Withdrawal by Subject|0
6332992|NCT03074162|10081118|FG004|Period 1 Including Washout 1|Withdrawal by Subject|0
6332993|NCT03074162|10081119|FG005|Period 1 Including Washout 1|Withdrawal by Subject|0
6332994|NCT03074162|10081114|FG000|Period 2 Including Washout 2|Withdrawal by Subject|0
6332995|NCT03074162|10081115|FG001|Period 2 Including Washout 2|Withdrawal by Subject|0
6332996|NCT03074162|10081116|FG002|Period 2 Including Washout 2|Withdrawal by Subject|1
6332997|NCT03074162|10081117|FG003|Period 2 Including Washout 2|Withdrawal by Subject|0
6332998|NCT03074162|10081118|FG004|Period 2 Including Washout 2|Withdrawal by Subject|0
6332999|NCT03074162|10081119|FG005|Period 2 Including Washout 2|Withdrawal by Subject|1
6333000|NCT03074162|10081114|FG000|Period 3|Withdrawal by Subject|1
6333001|NCT03074162|10081115|FG001|Period 3|Withdrawal by Subject|0
6333002|NCT03074162|10081116|FG002|Period 3|Withdrawal by Subject|0
6333003|NCT03074162|10081117|FG003|Period 3|Withdrawal by Subject|0
6333004|NCT03074162|10081118|FG004|Period 3|Withdrawal by Subject|1
6333005|NCT03074162|10081119|FG005|Period 3|Withdrawal by Subject|0
6333006|NCT03074331|10081127|FG000|Overall Study|Enrolled but Not Treated|1
6333007|NCT03074331|10081127|FG000|Overall Study|Lost to Follow-up|5
6333008|NCT03074331|10081127|FG000|Overall Study|Withdrew Consent|1
6333009|NCT03074500|10081143|FG000|Overall Study|Lost to Follow-up|1
6333010|NCT03074500|10081144|FG001|Overall Study|Lost to Follow-up|0
6333011|NCT03074500|10081145|FG002|Overall Study|Lost to Follow-up|0
6333012|NCT03074500|10081143|FG000|Overall Study|Lack of Efficacy|0
6333013|NCT03074500|10081144|FG001|Overall Study|Lack of Efficacy|1
6333014|NCT03074500|10081145|FG002|Overall Study|Lack of Efficacy|0
6333015|NCT03074500|10081143|FG000|Overall Study|Adverse Event|0
6333016|NCT03074500|10081144|FG001|Overall Study|Adverse Event|0
6333017|NCT03074500|10081145|FG002|Overall Study|Adverse Event|1
6333018|NCT03075163|10081184|FG000|Overall Study|not eligible for treatment limb|138
6333019|NCT03075163|10081185|FG001|Overall Study|not eligible for treatment limb|138
6333020|NCT03075267|10081194|FG000|Overall Study|Protocol Violation|1
6333021|NCT03075267|10081195|FG001|Overall Study|Protocol Violation|0
6333022|NCT03075267|10081196|FG002|Overall Study|Protocol Violation|0
6333023|NCT03075410|10081213|FG000|Part A-Period 2 (14 Days)|Personal reasons|1
6333024|NCT03075410|10081214|FG001|Part A-Period 2 (14 Days)|Personal reasons|0
6333025|NCT03075410|10081215|FG002|Part A-Period 2 (14 Days)|Personal reasons|1
6333026|NCT03075410|10081216|FG003|Part A-Period 2 (14 Days)|Personal reasons|0
6333027|NCT03075410|10081217|FG004|Part A-Period 2 (14 Days)|Personal reasons|0
6333028|NCT03075410|10081218|FG005|Part A-Period 2 (14 Days)|Personal reasons|0
6333029|NCT03075410|10081219|FG006|Part A-Period 2 (14 Days)|Personal reasons|0
6333030|NCT03075410|10081220|FG007|Part A-Period 2 (14 Days)|Personal reasons|0
6333031|NCT03075410|10081221|FG008|Part A-Period 2 (14 Days)|Personal reasons|0
6333032|NCT03075410|10081213|FG000|Part A-Period 3 (14 Days)|Reaction to ECG tabs causing a rash|1
6333033|NCT03075410|10081214|FG001|Part A-Period 3 (14 Days)|Reaction to ECG tabs causing a rash|0
6333034|NCT03075410|10081215|FG002|Part A-Period 3 (14 Days)|Reaction to ECG tabs causing a rash|0
6333035|NCT03075410|10081216|FG003|Part A-Period 3 (14 Days)|Reaction to ECG tabs causing a rash|0
6333036|NCT03075410|10081217|FG004|Part A-Period 3 (14 Days)|Reaction to ECG tabs causing a rash|0
6333037|NCT03075410|10081218|FG005|Part A-Period 3 (14 Days)|Reaction to ECG tabs causing a rash|0
6333038|NCT03075410|10081219|FG006|Part A-Period 3 (14 Days)|Reaction to ECG tabs causing a rash|0
6333039|NCT03075410|10081220|FG007|Part A-Period 3 (14 Days)|Reaction to ECG tabs causing a rash|0
6333040|NCT03075410|10081221|FG008|Part A-Period 3 (14 Days)|Reaction to ECG tabs causing a rash|0
6333041|NCT03075501|10081251|FG000|Overall Study|Scheduling difficulties|15
6333042|NCT03075501|10081252|FG001|Overall Study|Scheduling difficulties|9
6333043|NCT03075644|10081265|FG000|Overall Study|Withdrawal by Subject|1
6333044|NCT03075644|10081266|FG001|Overall Study|Withdrawal by Subject|1
6333045|NCT03075761|10081275|FG000|Overall Study|Lost to Follow-up|1
6333046|NCT03075761|10081276|FG001|Overall Study|Lost to Follow-up|6
6333047|NCT03075839|10081287|FG000|Overall Study|Lost to Follow-up|4
6333048|NCT03075878|10081291|FG000|Overall Study|Physician Decision|1
6333049|NCT03075891|10081297|FG000|Overall Study|Withdrawal by Subject|3
6333050|NCT03075891|10081298|FG001|Overall Study|Withdrawal by Subject|6
6333051|NCT03075891|10081297|FG000|Overall Study|Lost to Follow-up|1
6333052|NCT03075891|10081298|FG001|Overall Study|Lost to Follow-up|0
6333053|NCT03075891|10081297|FG000|Overall Study|Pregnancy|3
6333054|NCT03075891|10081298|FG001|Overall Study|Pregnancy|1
6333055|NCT03075891|10081297|FG000|Overall Study|visits not performed (no time)|1
6333056|NCT03075891|10081298|FG001|Overall Study|visits not performed (no time)|0
6333057|NCT03075891|10081297|FG000|Overall Study|Drug abuse relapse issue|0
6333058|NCT03075891|10081298|FG001|Overall Study|Drug abuse relapse issue|1
6333059|NCT03075891|10081297|FG000|Overall Study|Participant requiring study withdrawal|0
6333060|NCT03075891|10081298|FG001|Overall Study|Participant requiring study withdrawal|1
6333061|NCT03075891|10081297|FG000|Overall Study|Adverse event, non-fatal|1
6333062|NCT03075891|10081298|FG001|Overall Study|Adverse event, non-fatal|4
6333063|NCT03075904|10081306|FG000|Overall Study|Physician Decision|3
6333064|NCT03075904|10081306|FG000|Overall Study|Need for Medication not Permitted|1
6333065|NCT03076190|10081312|FG000|Overall Study|Lost to Follow-up|9
6333066|NCT03076190|10081313|FG001|Overall Study|Lost to Follow-up|34
6333067|NCT03076190|10081312|FG000|Overall Study|Excluded from Analysis (zero duration ev|9
6333068|NCT03076190|10081313|FG001|Overall Study|Excluded from Analysis (zero duration ev|7
6333069|NCT03076515|10081339|FG000|Overall Study|DMC decision based on interim analysis|25
6333070|NCT03076515|10081340|FG001|Overall Study|DMC decision based on interim analysis|29
6333071|NCT03076970|10081346|FG000|Washout Period 2|Adverse Event|0
6333072|NCT03076970|10081347|FG001|Washout Period 2|Adverse Event|0
6333073|NCT03076970|10081348|FG002|Washout Period 2|Adverse Event|0
6333074|NCT03076970|10081349|FG003|Washout Period 2|Adverse Event|0
6333075|NCT03076970|10081350|FG004|Washout Period 2|Adverse Event|1
6333076|NCT03076970|10081351|FG005|Washout Period 2|Adverse Event|0
6333077|NCT03076970|10081346|FG000|Period 3|Withdrawal by Subject|0
6333078|NCT03076970|10081347|FG001|Period 3|Withdrawal by Subject|0
6333079|NCT03076970|10081348|FG002|Period 3|Withdrawal by Subject|0
6333080|NCT03076970|10081349|FG003|Period 3|Withdrawal by Subject|0
6333081|NCT03076970|10081350|FG004|Period 3|Withdrawal by Subject|0
6333082|NCT03076970|10081351|FG005|Period 3|Withdrawal by Subject|1
6333083|NCT03076970|10081346|FG000|Period 3|Failure to meet I/E criteria|0
6333084|NCT03076970|10081347|FG001|Period 3|Failure to meet I/E criteria|0
6333085|NCT03076970|10081348|FG002|Period 3|Failure to meet I/E criteria|0
6333086|NCT03076970|10081349|FG003|Period 3|Failure to meet I/E criteria|0
6333087|NCT03076970|10081350|FG004|Period 3|Failure to meet I/E criteria|1
6333088|NCT03076970|10081351|FG005|Period 3|Failure to meet I/E criteria|0
6333089|NCT03076996|10081371|FG000|Overall Study|Withdrawal by Subject|2
6333090|NCT03076996|10081371|FG000|Overall Study|Lost to Follow-up|3
6333091|NCT03076996|10081371|FG000|Overall Study|Literacy precluded participation|1
6333092|NCT03077607|10081402|FG000|Period 1 (15 Days)|Adverse Event|1
6333093|NCT03077607|10081403|FG001|Period 1 (15 Days)|Adverse Event|0
6333094|NCT03077607|10081402|FG000|Period 1 (15 Days)|Death|1
6333095|NCT03077607|10081403|FG001|Period 1 (15 Days)|Death|0
6333096|NCT03077607|10081402|FG000|Period 2 (Arm A:21 Days; Arm B:23 Days)|Death|1
6333097|NCT03077607|10081403|FG001|Period 2 (Arm A:21 Days; Arm B:23 Days)|Death|0
6333098|NCT03077607|10081402|FG000|Period 2 (Arm A:21 Days; Arm B:23 Days)|Adverse Event|2
6333099|NCT03077607|10081403|FG001|Period 2 (Arm A:21 Days; Arm B:23 Days)|Adverse Event|2
6333100|NCT03077646|10081423|FG000|Overall Study|Lost to Follow-up|29
6333101|NCT03077646|10081424|FG001|Overall Study|Lost to Follow-up|30
6333102|NCT03077646|10081425|FG002|Overall Study|Lost to Follow-up|31
6333103|NCT03077659|10081436|FG000|Overall Study|Withdrawal by Subject|0
6333104|NCT03077659|10081437|FG001|Overall Study|Withdrawal by Subject|0
6333105|NCT03077659|10081438|FG002|Overall Study|Withdrawal by Subject|1
6333106|NCT03077711|10081451|FG000|Overall Study|Lost to Follow-up|2
6333107|NCT03077711|10081452|FG001|Overall Study|Lost to Follow-up|2
6333108|NCT03077711|10081451|FG000|Overall Study|noncompliant taking medication|2
6333109|NCT03077711|10081452|FG001|Overall Study|noncompliant taking medication|0
6333110|NCT03077724|10081462|FG000|Overall Study|Lost to Follow-up|5
6333111|NCT03077724|10081463|FG001|Overall Study|Lost to Follow-up|1
6333112|NCT03077724|10081462|FG000|Overall Study|Withdrawal by Subject|3
6333113|NCT03077724|10081463|FG001|Overall Study|Withdrawal by Subject|1
6333114|NCT03077919|10081481|FG000|Overall Study|Lost to Follow-up|4
6333115|NCT03077919|10081482|FG001|Overall Study|Lost to Follow-up|1
6333116|NCT03078556|10081539|FG000|Treatment Period 1 (4 Days)|Adverse Event|0
6333117|NCT03078556|10081540|FG001|Treatment Period 1 (4 Days)|Adverse Event|1
6333118|NCT03078556|10081541|FG002|Treatment Period 1 (4 Days)|Adverse Event|0
6333119|NCT03078556|10081542|FG003|Treatment Period 1 (4 Days)|Adverse Event|0
6333120|NCT03078556|10081539|FG000|Washout Period 1 (7 Days)|Lost to Follow-up|2
6333121|NCT03078556|10081540|FG001|Washout Period 1 (7 Days)|Lost to Follow-up|0
6333122|NCT03078556|10081541|FG002|Washout Period 1 (7 Days)|Lost to Follow-up|1
6333123|NCT03078556|10081542|FG003|Washout Period 1 (7 Days)|Lost to Follow-up|0
6333124|NCT03078556|10081539|FG000|Washout Period 1 (7 Days)|Adverse Event|0
6333125|NCT03078556|10081540|FG001|Washout Period 1 (7 Days)|Adverse Event|1
6333126|NCT03078556|10081541|FG002|Washout Period 1 (7 Days)|Adverse Event|0
6333127|NCT03078556|10081542|FG003|Washout Period 1 (7 Days)|Adverse Event|1
6333128|NCT03078556|10081539|FG000|Washout Period 1 (7 Days)|Physician Decision|0
6333129|NCT03078556|10081540|FG001|Washout Period 1 (7 Days)|Physician Decision|1
6333130|NCT03078556|10081541|FG002|Washout Period 1 (7 Days)|Physician Decision|0
6333131|NCT03078556|10081542|FG003|Washout Period 1 (7 Days)|Physician Decision|0
6333132|NCT03078582|10081569|FG000|Overall Study|Adverse Event|0
6333133|NCT03078582|10081570|FG001|Overall Study|Adverse Event|8
6333134|NCT03078751|10081600|FG000|Overall Study|Adverse Event|4
6333135|NCT03078751|10081601|FG001|Overall Study|Adverse Event|0
6333136|NCT03078751|10081600|FG000|Overall Study|Physician Decision|1
6333137|NCT03078751|10081601|FG001|Overall Study|Physician Decision|0
6333138|NCT03078751|10081600|FG000|Overall Study|Terminated by Sponsor = early terminated recruitment|0
6333139|NCT03078751|10081601|FG001|Overall Study|Terminated by Sponsor = early terminated recruitment|23
6333140|NCT03078751|10081600|FG000|Overall Study|Subject/guardian decision|8
6333141|NCT03078751|10081601|FG001|Overall Study|Subject/guardian decision|1
6333142|NCT03078751|10081600|FG000|Overall Study|Untreated|0
6333143|NCT03078751|10081601|FG001|Overall Study|Untreated|4
6333144|NCT03078816|10081607|FG000|Overall Study|Withdrawal by Subject|1
6333145|NCT03078907|10081613|FG000|Overall Study|Adverse Event|2
6333146|NCT03078907|10081614|FG001|Overall Study|Adverse Event|0
6333147|NCT03078907|10081613|FG000|Overall Study|Other|1
6333148|NCT03078907|10081614|FG001|Overall Study|Other|0
6333149|NCT03078907|10081613|FG000|Overall Study|Protocol Violation|0
6333150|NCT03078907|10081614|FG001|Overall Study|Protocol Violation|1
6333151|NCT03080454|10081659|FG000|Baseline|Adverse Event|2
6333152|NCT03080454|10081659|FG000|Anodal Doublestim (5 Days)|Adverse Event|1
6333153|NCT03080454|10081659|FG000|Anodal FU (7 Days)|Lost to Follow-up|4
6333154|NCT03080493|10081668|FG000|Overall Study|Did not provide NRS pain results|1
6333155|NCT03080493|10081669|FG001|Overall Study|Did not provide NRS pain results|0
6333156|NCT03080493|10081668|FG000|Overall Study|Adverse Event|0
6333157|NCT03080493|10081669|FG001|Overall Study|Adverse Event|1
6333158|NCT03080493|10081668|FG000|Overall Study|Randomization error (parity group)|0
6333159|NCT03080493|10081669|FG001|Overall Study|Randomization error (parity group)|1
6333160|NCT03080961|10081675|FG000|Overall Study|Withdrawal by Subject|3
6333161|NCT03081884|10081693|FG000|Overall Study|deferred prostate cancer treatment|1
6333162|NCT03081884|10081693|FG000|Overall Study|metastasis managed with systemic therapy|3
6333163|NCT03082261|10081707|FG000|Overall Study|Death|4
6333164|NCT03082261|10081707|FG000|Overall Study|Implant of dorsal root ganglion stimulation (DRG) device|1
6333165|NCT03082261|10081707|FG000|Overall Study|Insurance denial|1
6333166|NCT03082261|10081707|FG000|Overall Study|Peripheral lead added|1
6333167|NCT03082261|10081707|FG000|Overall Study|Withdrawal by Subject|40
6333168|NCT03082261|10081707|FG000|Overall Study|Subject did not meet screening inclusion/exclusion criteria|2
6333169|NCT03082261|10081707|FG000|Overall Study|Subject implanted with device other than study device|1
6333170|NCT03082261|10081707|FG000|Overall Study|Lost to Follow-up|14
6333171|NCT03082261|10081707|FG000|Overall Study|Subject moved to a different state|1
6333172|NCT03082261|10081707|FG000|Overall Study|Subject non-compliance|2
6333173|NCT03082261|10081707|FG000|Overall Study|Subject participation terminated by investigator|9
6333174|NCT03082261|10081707|FG000|Overall Study|Subject participation terminated by sponsor|4
6333175|NCT03082261|10081707|FG000|Overall Study|System explant|19
6333176|NCT03082261|10081707|FG000|Overall Study|Unable to place lead(s)|2
6333177|NCT03082261|10081707|FG000|Overall Study|Unsuccessful trial evaluation period|19
6333178|NCT03082599|10081744|FG000|Overall Study|Lost to Follow-up|1
6333179|NCT03082599|10081745|FG001|Overall Study|Lost to Follow-up|0
6333180|NCT03083132|10081762|FG000|First 12 Weeks (Placebo vs Modafinil)|Withdrawal by Subject|0
6333181|NCT03083132|10081763|FG001|First 12 Weeks (Placebo vs Modafinil)|Withdrawal by Subject|2
6333182|NCT03083132|10081762|FG000|Last 12 Weeks (Drug for All Subjects)|Physician Decision|1
6333183|NCT03083132|10081763|FG001|Last 12 Weeks (Drug for All Subjects)|Physician Decision|0
6333184|NCT03083132|10081762|FG000|Last 12 Weeks (Drug for All Subjects)|Withdrawal by Subject|0
6333185|NCT03083132|10081763|FG001|Last 12 Weeks (Drug for All Subjects)|Withdrawal by Subject|1
6333186|NCT03083470|10081783|FG000|Overall Study|Lost to Follow-up|0
6333187|NCT03083470|10081784|FG001|Overall Study|Lost to Follow-up|0
6333188|NCT03083470|10081785|FG002|Overall Study|Lost to Follow-up|0
6333189|NCT03083470|10081786|FG003|Overall Study|Lost to Follow-up|0
6333190|NCT03083470|10081787|FG004|Overall Study|Lost to Follow-up|1
6333191|NCT03083470|10081783|FG000|Overall Study|Withdrawal by Subject|0
6333192|NCT03083470|10081784|FG001|Overall Study|Withdrawal by Subject|0
6333193|NCT03083470|10081785|FG002|Overall Study|Withdrawal by Subject|0
6082844|NCT00631696|9690982|FG000|Overall Study|Lost to Follow-up|7
6082845|NCT00631696|9690983|FG001|Overall Study|Lost to Follow-up|10
6333194|NCT03083470|10081786|FG003|Overall Study|Withdrawal by Subject|0
6333195|NCT03083470|10081787|FG004|Overall Study|Withdrawal by Subject|1
6333196|NCT03083483|10081802|FG000|Overall Study|Adverse Event|1
6333197|NCT03083483|10081803|FG001|Overall Study|Adverse Event|1
6333198|NCT03083483|10081804|FG002|Overall Study|Adverse Event|1
6333199|NCT03083483|10081802|FG000|Overall Study|Lost to Follow-up|2
6333200|NCT03083483|10081803|FG001|Overall Study|Lost to Follow-up|1
6333201|NCT03083483|10081804|FG002|Overall Study|Lost to Follow-up|1
6333202|NCT03083483|10081802|FG000|Overall Study|technological issues|1
6333203|NCT03083483|10081803|FG001|Overall Study|technological issues|0
6333204|NCT03083483|10081804|FG002|Overall Study|technological issues|1
6333205|NCT03083639|10081814|FG000|Washout Period (at Least 6 Days)|Pregnancy|0
6333206|NCT03083639|10081815|FG001|Washout Period (at Least 6 Days)|Pregnancy|1
6333207|NCT03083639|10081814|FG000|Washout Period (at Least 6 Days)|Lost to Follow-up|1
6333208|NCT03083639|10081815|FG001|Washout Period (at Least 6 Days)|Lost to Follow-up|0
6333209|NCT03083847|10081840|FG000|Main|Physician Decision|0
6333210|NCT03083847|10081841|FG001|Main|Physician Decision|0
6333211|NCT03083847|10081842|FG002|Main|Physician Decision|0
6333212|NCT03083847|10081843|FG003|Main|Physician Decision|0
6333213|NCT03083847|10081844|FG004|Main|Physician Decision|0
6333214|NCT03083847|10081845|FG005|Main|Physician Decision|1
6333215|NCT03083847|10081846|FG006|Main|Physician Decision|0
6333216|NCT03083847|10081847|FG007|Main|Physician Decision|0
6333217|NCT03083847|10081848|FG008|Main|Physician Decision|0
6333218|NCT03083847|10081849|FG009|Main|Physician Decision|0
6333219|NCT03083847|10081840|FG000|Main|Pregnancy|0
6333220|NCT03083847|10081841|FG001|Main|Pregnancy|0
6333221|NCT03083847|10081842|FG002|Main|Pregnancy|0
6333222|NCT03083847|10081843|FG003|Main|Pregnancy|0
6333223|NCT03083847|10081844|FG004|Main|Pregnancy|0
6333224|NCT03083847|10081845|FG005|Main|Pregnancy|0
6333225|NCT03083847|10081846|FG006|Main|Pregnancy|0
6333226|NCT03083847|10081847|FG007|Main|Pregnancy|1
6082846|NCT00631696|9690982|FG000|Overall Study|Withdrawal by Subject|2
6167373|NCT01227668|9811946|FG000|Phase 1 (Stabilization Phase)|No longer meets study criteria|7
6167374|NCT01227668|9811947|FG001|Phase 1 (Stabilization Phase)|No longer meets study criteria|0
6167375|NCT01227668|9811946|FG000|Phase 1 (Stabilization Phase)|Lack of Efficacy|25
6167376|NCT01227668|9811947|FG001|Phase 1 (Stabilization Phase)|Lack of Efficacy|0
6167377|NCT01227668|9811946|FG000|Phase 1 (Stabilization Phase)|Poor compliance/noncompliance|2
6167378|NCT01227668|9811947|FG001|Phase 1 (Stabilization Phase)|Poor compliance/noncompliance|0
6167379|NCT01227668|9811946|FG000|Phase 2 (Randomization Phase)|Adverse Event|0
6167380|NCT01227668|9811947|FG001|Phase 2 (Randomization Phase)|Adverse Event|1
6167381|NCT01227668|9811946|FG000|Phase 2 (Randomization Phase)|Withdrawal by Subject|5
6167382|NCT01227668|9811947|FG001|Phase 2 (Randomization Phase)|Withdrawal by Subject|0
6167383|NCT01227668|9811946|FG000|Phase 2 (Randomization Phase)|Lost to Follow-up|1
6167384|NCT01227668|9811947|FG001|Phase 2 (Randomization Phase)|Lost to Follow-up|0
6167385|NCT01227668|9811946|FG000|Phase 2 (Randomization Phase)|Lack of Efficacy|13
6167386|NCT01227668|9811947|FG001|Phase 2 (Randomization Phase)|Lack of Efficacy|23
6167387|NCT01227668|9811946|FG000|Phase 2 (Randomization Phase)|Poor compliance/noncompliance|0
6167388|NCT01227668|9811947|FG001|Phase 2 (Randomization Phase)|Poor compliance/noncompliance|1
6167389|NCT01227707|9811966|FG000|Overall Study|Adverse Event|10
6333227|NCT03083847|10081848|FG008|Main|Pregnancy|0
6333228|NCT03083847|10081849|FG009|Main|Pregnancy|0
6333229|NCT03083847|10081840|FG000|Main|Adverse Event|0
6333230|NCT03083847|10081841|FG001|Main|Adverse Event|0
6167390|NCT01227707|9811966|FG000|Overall Study|Progression of disease|3
6167391|NCT01227707|9811966|FG000|Overall Study|Withdrawal by Subject|1
6333231|NCT03083847|10081842|FG002|Main|Adverse Event|0
6333232|NCT03083847|10081843|FG003|Main|Adverse Event|0
6333233|NCT03083847|10081844|FG004|Main|Adverse Event|0
6333234|NCT03083847|10081845|FG005|Main|Adverse Event|0
6333235|NCT03083847|10081846|FG006|Main|Adverse Event|0
6333236|NCT03083847|10081847|FG007|Main|Adverse Event|2
6333237|NCT03083847|10081848|FG008|Main|Adverse Event|0
6333238|NCT03083847|10081849|FG009|Main|Adverse Event|0
6333239|NCT03083847|10081840|FG000|Main|Withdrawal by Subject|0
6333240|NCT03083847|10081841|FG001|Main|Withdrawal by Subject|0
6333241|NCT03083847|10081842|FG002|Main|Withdrawal by Subject|0
6333242|NCT03083847|10081843|FG003|Main|Withdrawal by Subject|0
6333243|NCT03083847|10081844|FG004|Main|Withdrawal by Subject|0
6333244|NCT03083847|10081845|FG005|Main|Withdrawal by Subject|0
6333245|NCT03083847|10081846|FG006|Main|Withdrawal by Subject|1
6333246|NCT03083847|10081847|FG007|Main|Withdrawal by Subject|1
6333247|NCT03083847|10081848|FG008|Main|Withdrawal by Subject|0
6333248|NCT03083847|10081849|FG009|Main|Withdrawal by Subject|0
6333249|NCT03083990|10081879|FG000|Overall Study|Adverse Event|1
6333250|NCT03083990|10081880|FG001|Overall Study|Adverse Event|0
6333251|NCT03084302|10081886|FG000|Overall Study|Miscarriage, twin pregnancy, congenital abnormality|9
6333252|NCT03084302|10081886|FG000|Overall Study|No valid objective monitor data|6
6333253|NCT03084315|10081893|FG000|Overall Study|Lost to Follow-up|8
6333254|NCT03084315|10081894|FG001|Overall Study|Lost to Follow-up|7
6333255|NCT03084315|10081893|FG000|Overall Study|Withdrawal by Subject|2
6333256|NCT03084315|10081894|FG001|Overall Study|Withdrawal by Subject|2
6333257|NCT03084796|10081906|FG000|Overall Study|Adverse Event|4
6333258|NCT03084796|10081907|FG001|Overall Study|Adverse Event|5
6333259|NCT03084796|10081908|FG002|Overall Study|Adverse Event|6
6333260|NCT03084796|10081909|FG003|Overall Study|Adverse Event|2
6333261|NCT03084796|10081910|FG004|Overall Study|Adverse Event|3
6333262|NCT03084796|10081911|FG005|Overall Study|Adverse Event|5
6333263|NCT03084796|10081906|FG000|Overall Study|Withdrawal by Subject|3
6333264|NCT03084796|10081907|FG001|Overall Study|Withdrawal by Subject|5
6333265|NCT03084796|10081908|FG002|Overall Study|Withdrawal by Subject|2
6333266|NCT03084796|10081909|FG003|Overall Study|Withdrawal by Subject|1
6333267|NCT03084796|10081910|FG004|Overall Study|Withdrawal by Subject|3
6333268|NCT03084796|10081911|FG005|Overall Study|Withdrawal by Subject|0
6333269|NCT03084796|10081906|FG000|Overall Study|Protocol Violation|0
6333270|NCT03084796|10081907|FG001|Overall Study|Protocol Violation|0
6333271|NCT03084796|10081908|FG002|Overall Study|Protocol Violation|1
6333272|NCT03084796|10081909|FG003|Overall Study|Protocol Violation|0
6333273|NCT03084796|10081910|FG004|Overall Study|Protocol Violation|1
6333274|NCT03084796|10081911|FG005|Overall Study|Protocol Violation|1
6333275|NCT03084796|10081906|FG000|Overall Study|Lack of Efficacy|0
6333276|NCT03084796|10081907|FG001|Overall Study|Lack of Efficacy|0
6333277|NCT03084796|10081908|FG002|Overall Study|Lack of Efficacy|1
6333278|NCT03084796|10081909|FG003|Overall Study|Lack of Efficacy|0
6333279|NCT03084796|10081910|FG004|Overall Study|Lack of Efficacy|1
6333280|NCT03084796|10081911|FG005|Overall Study|Lack of Efficacy|0
6333281|NCT03084796|10081906|FG000|Overall Study|Lost to Follow-up|0
6333282|NCT03084796|10081907|FG001|Overall Study|Lost to Follow-up|0
6333283|NCT03084796|10081908|FG002|Overall Study|Lost to Follow-up|1
6333284|NCT03084796|10081909|FG003|Overall Study|Lost to Follow-up|1
6333285|NCT03084796|10081910|FG004|Overall Study|Lost to Follow-up|3
6333286|NCT03084796|10081911|FG005|Overall Study|Lost to Follow-up|1
6333287|NCT03084796|10081906|FG000|Overall Study|Randomization error|0
6333288|NCT03084796|10081907|FG001|Overall Study|Randomization error|0
6333289|NCT03084796|10081908|FG002|Overall Study|Randomization error|1
6333290|NCT03084796|10081909|FG003|Overall Study|Randomization error|0
6333291|NCT03084796|10081910|FG004|Overall Study|Randomization error|0
6333292|NCT03084796|10081911|FG005|Overall Study|Randomization error|0
6333293|NCT03085017|10081927|FG000|Overall Study|Death|0
6333294|NCT03085017|10081928|FG001|Overall Study|Death|3
6333295|NCT03085238|10081934|FG000|Overall Study|Adverse Event|2
6333296|NCT03085238|10081934|FG000|Overall Study|Death|2
6333297|NCT03085758|10081950|FG000|Overall Study|Death|26
6333298|NCT03085758|10081951|FG001|Overall Study|Death|24
6333299|NCT03085758|10081952|FG002|Overall Study|Death|53
6333300|NCT03085758|10081950|FG000|Overall Study|Lost to Follow-up|1
6333301|NCT03085758|10081951|FG001|Overall Study|Lost to Follow-up|1
6333302|NCT03085758|10081952|FG002|Overall Study|Lost to Follow-up|1
6333303|NCT03085758|10081950|FG000|Overall Study|Withdrawal by Subject|2
6333304|NCT03085758|10081951|FG001|Overall Study|Withdrawal by Subject|2
6333305|NCT03085758|10081952|FG002|Overall Study|Withdrawal by Subject|1
6333306|NCT03085758|10081950|FG000|Overall Study|Refusal to recall it up to day 90|0
6333307|NCT03085758|10081951|FG001|Overall Study|Refusal to recall it up to day 90|0
6333308|NCT03085758|10081952|FG002|Overall Study|Refusal to recall it up to day 90|1
6333309|NCT03085758|10081950|FG000|Overall Study|Pt seen by doctor in digestive surgery|0
6333310|NCT03085758|10081951|FG001|Overall Study|Pt seen by doctor in digestive surgery|1
6333311|NCT03085758|10081952|FG002|Overall Study|Pt seen by doctor in digestive surgery|0
6333312|NCT03085797|10081966|FG000|Treatment Period (TP) (52 Weeks)|Lost to Follow-up|1
6333313|NCT03085797|10081967|FG001|Treatment Period (TP) (52 Weeks)|Lost to Follow-up|0
6333314|NCT03085797|10081966|FG000|Treatment Period (TP) (52 Weeks)|Withdrawal by Subject|16
6333315|NCT03085797|10081967|FG001|Treatment Period (TP) (52 Weeks)|Withdrawal by Subject|17
6333316|NCT03085797|10081966|FG000|No-treatment Follow-up Period (6 Months)|Withdrawal by Subject|0
6333317|NCT03085797|10081967|FG001|No-treatment Follow-up Period (6 Months)|Withdrawal by Subject|1
6333318|NCT03085914|10081995|FG000|Overall Study|Death|6
6333319|NCT03085914|10081996|FG001|Overall Study|Death|6
6333320|NCT03085914|10081997|FG002|Overall Study|Death|4
6333321|NCT03085914|10081998|FG003|Overall Study|Death|1
6333322|NCT03085914|10081999|FG004|Overall Study|Death|5
6333323|NCT03085914|10082000|FG005|Overall Study|Death|2
6333324|NCT03085914|10082001|FG006|Overall Study|Death|2
6333325|NCT03085914|10081995|FG000|Overall Study|Withdrawal by Subject|1
6333326|NCT03085914|10081996|FG001|Overall Study|Withdrawal by Subject|1
6333327|NCT03085914|10081997|FG002|Overall Study|Withdrawal by Subject|2
6333328|NCT03085914|10081998|FG003|Overall Study|Withdrawal by Subject|2
6333329|NCT03085914|10081999|FG004|Overall Study|Withdrawal by Subject|2
6333330|NCT03085914|10082000|FG005|Overall Study|Withdrawal by Subject|0
6333331|NCT03085914|10082001|FG006|Overall Study|Withdrawal by Subject|1
6333332|NCT03085914|10081995|FG000|Overall Study|Lost to Follow-up|0
6333333|NCT03085914|10081996|FG001|Overall Study|Lost to Follow-up|0
6333334|NCT03085914|10081997|FG002|Overall Study|Lost to Follow-up|1
6333335|NCT03085914|10081998|FG003|Overall Study|Lost to Follow-up|0
6333336|NCT03085914|10081999|FG004|Overall Study|Lost to Follow-up|0
6333337|NCT03085914|10082000|FG005|Overall Study|Lost to Follow-up|1
6333338|NCT03085914|10082001|FG006|Overall Study|Lost to Follow-up|1
6333339|NCT03085914|10081995|FG000|Overall Study|Reason was not specified,|2
6333340|NCT03085914|10081996|FG001|Overall Study|Reason was not specified,|2
6333341|NCT03085914|10081997|FG002|Overall Study|Reason was not specified,|2
6333342|NCT03085914|10081998|FG003|Overall Study|Reason was not specified,|3
6333343|NCT03085914|10081999|FG004|Overall Study|Reason was not specified,|3
6333344|NCT03085914|10082000|FG005|Overall Study|Reason was not specified,|3
6333345|NCT03085914|10082001|FG006|Overall Study|Reason was not specified,|6
6333346|NCT03085914|10081995|FG000|Overall Study|Progressive Disease|0
6333347|NCT03085914|10081996|FG001|Overall Study|Progressive Disease|0
6333348|NCT03085914|10081997|FG002|Overall Study|Progressive Disease|2
6333349|NCT03085914|10081998|FG003|Overall Study|Progressive Disease|2
6333350|NCT03085914|10081999|FG004|Overall Study|Progressive Disease|1
6333351|NCT03085914|10082000|FG005|Overall Study|Progressive Disease|1
6333352|NCT03085914|10082001|FG006|Overall Study|Progressive Disease|1
6333353|NCT03085914|10081995|FG000|Overall Study|Study Terminated by the Sponsor|0
6333354|NCT03085914|10081996|FG001|Overall Study|Study Terminated by the Sponsor|0
6333355|NCT03085914|10081997|FG002|Overall Study|Study Terminated by the Sponsor|0
6333356|NCT03085914|10081998|FG003|Overall Study|Study Terminated by the Sponsor|1
6333357|NCT03085914|10081999|FG004|Overall Study|Study Terminated by the Sponsor|2
6333358|NCT03085914|10082000|FG005|Overall Study|Study Terminated by the Sponsor|1
6333359|NCT03085914|10082001|FG006|Overall Study|Study Terminated by the Sponsor|0
6082847|NCT00631696|9690983|FG001|Overall Study|Withdrawal by Subject|9
6082848|NCT00631696|9690982|FG000|Overall Study|Other|8
6167392|NCT01227707|9811966|FG000|Overall Study|Patient non-compliance|3
6167393|NCT01227707|9811966|FG000|Overall Study|Medical decision|6
6333360|NCT03085927|10082022|FG000|Overall Study|Withdrawal by Subject|1
6333361|NCT03085927|10082023|FG001|Overall Study|Withdrawal by Subject|4
6333362|NCT03085927|10082022|FG000|Overall Study|Lost to Follow-up|3
6333363|NCT03085927|10082023|FG001|Overall Study|Lost to Follow-up|1
6333364|NCT03085927|10082022|FG000|Overall Study|Death|1
6333365|NCT03085927|10082023|FG001|Overall Study|Death|0
6333366|NCT03085927|10082022|FG000|Overall Study|Child Toxicity/Side Effects of Treatment|1
6333367|NCT03085927|10082023|FG001|Overall Study|Child Toxicity/Side Effects of Treatment|0
6333368|NCT03085927|10082022|FG000|Overall Study|Dyad Became Ineligible|0
6333369|NCT03085927|10082023|FG001|Overall Study|Dyad Became Ineligible|1
6167394|NCT01227707|9811966|FG000|Overall Study|Death|1
6167395|NCT01227824|9811983|FG000|Double-blind Phase: 96 Weeks Duration|Adverse Event|12
6167396|NCT01227824|9811984|FG001|Double-blind Phase: 96 Weeks Duration|Adverse Event|7
6167397|NCT01227824|9811985|FG002|Double-blind Phase: 96 Weeks Duration|Adverse Event|0
6167398|NCT01227824|9811983|FG000|Double-blind Phase: 96 Weeks Duration|Lack of Efficacy|22
6167399|NCT01227824|9811984|FG001|Double-blind Phase: 96 Weeks Duration|Lack of Efficacy|25
6167400|NCT01227824|9811985|FG002|Double-blind Phase: 96 Weeks Duration|Lack of Efficacy|0
6192160|NCT01428128|9849249|FG000|Overall Study|Withdrawal by Subject|4
6333370|NCT03086018|10082031|FG000|Final Testing for End of Trial|Adverse Event|1
6333371|NCT03086018|10082031|FG000|Final Testing for End of Trial|Withdrawal by Subject|1
6333372|NCT03086057|10082041|FG000|Stage 1: PrEP Uptake|Incarcerated|3
6333373|NCT03086057|10082042|FG001|Stage 1: PrEP Uptake|Incarcerated|1
6333374|NCT03086057|10082043|FG002|Stage 1: PrEP Uptake|Incarcerated|0
6333375|NCT03086057|10082044|FG003|Stage 1: PrEP Uptake|Incarcerated|0
6333376|NCT03086057|10082041|FG000|Stage 1: PrEP Uptake|Withdrawal by Subject|1
6333377|NCT03086057|10082042|FG001|Stage 1: PrEP Uptake|Withdrawal by Subject|4
6333378|NCT03086057|10082043|FG002|Stage 1: PrEP Uptake|Withdrawal by Subject|0
6333379|NCT03086057|10082044|FG003|Stage 1: PrEP Uptake|Withdrawal by Subject|0
6082849|NCT00631696|9690983|FG001|Overall Study|Other|8
6082850|NCT00631696|9690982|FG000|Overall Study|Protocol Violation|9
6082851|NCT00631696|9690983|FG001|Overall Study|Protocol Violation|9
6082852|NCT00631696|9690982|FG000|Overall Study|Study terminated by sponsor|3
6082853|NCT00631696|9690983|FG001|Overall Study|Study terminated by sponsor|3
6082854|NCT00631696|9690982|FG000|Overall Study|Adverse Event|5
6082855|NCT00631696|9690983|FG001|Overall Study|Adverse Event|0
6082856|NCT00631917|9691005|FG000|Overall Study|Adverse Event|34
6082857|NCT00631917|9691006|FG001|Overall Study|Adverse Event|45
6082858|NCT00631917|9691005|FG000|Overall Study|Abnormal laboratory value(s)|2
6082859|NCT00631917|9691006|FG001|Overall Study|Abnormal laboratory value(s)|1
6082860|NCT00631917|9691005|FG000|Overall Study|Abnormal test procedure result(s)|3
6082861|NCT00631917|9691006|FG001|Overall Study|Abnormal test procedure result(s)|2
6333380|NCT03086057|10082041|FG000|Stage 1: PrEP Uptake|Lost to Follow-up|6
6333381|NCT03086057|10082042|FG001|Stage 1: PrEP Uptake|Lost to Follow-up|5
6333382|NCT03086057|10082043|FG002|Stage 1: PrEP Uptake|Lost to Follow-up|0
6333383|NCT03086057|10082044|FG003|Stage 1: PrEP Uptake|Lost to Follow-up|0
6333384|NCT03086057|10082041|FG000|Stage 1: PrEP Uptake|Death|1
6333385|NCT03086057|10082042|FG001|Stage 1: PrEP Uptake|Death|0
6333386|NCT03086057|10082043|FG002|Stage 1: PrEP Uptake|Death|0
6333387|NCT03086057|10082044|FG003|Stage 1: PrEP Uptake|Death|0
6333388|NCT03086057|10082041|FG000|Stage 2: PrEP Adherence|Incarcerated|0
6333389|NCT03086057|10082042|FG001|Stage 2: PrEP Adherence|Incarcerated|0
6333390|NCT03086057|10082043|FG002|Stage 2: PrEP Adherence|Incarcerated|2
6333391|NCT03086057|10082044|FG003|Stage 2: PrEP Adherence|Incarcerated|0
6333392|NCT03086057|10082041|FG000|Stage 2: PrEP Adherence|Withdrawal by Subject|0
6333393|NCT03086057|10082042|FG001|Stage 2: PrEP Adherence|Withdrawal by Subject|0
6333394|NCT03086057|10082043|FG002|Stage 2: PrEP Adherence|Withdrawal by Subject|1
6333395|NCT03086057|10082044|FG003|Stage 2: PrEP Adherence|Withdrawal by Subject|0
6333396|NCT03086057|10082041|FG000|Stage 2: PrEP Adherence|Lost to Follow-up|0
6333397|NCT03086057|10082042|FG001|Stage 2: PrEP Adherence|Lost to Follow-up|0
6333398|NCT03086057|10082043|FG002|Stage 2: PrEP Adherence|Lost to Follow-up|3
6333399|NCT03086057|10082044|FG003|Stage 2: PrEP Adherence|Lost to Follow-up|2
6333400|NCT03086135|10082054|FG000|Overall Study|Adverse Event|1
6333401|NCT03086135|10082054|FG000|Overall Study|Lost to Follow-up|2
6333402|NCT03086330|10082076|FG000|Overall Study|Withdrawal by Subject|3
6333403|NCT03086330|10082077|FG001|Overall Study|Withdrawal by Subject|2
6333404|NCT03086330|10082076|FG000|Overall Study|Lost to Follow-up|1
6333405|NCT03086330|10082077|FG001|Overall Study|Lost to Follow-up|2
6333406|NCT03086343|10082085|FG000|Overall Study|Adverse Event|7
6333407|NCT03086343|10082086|FG001|Overall Study|Adverse Event|7
6333408|NCT03086343|10082085|FG000|Overall Study|Withdrawal by Subject|10
6333409|NCT03086343|10082086|FG001|Overall Study|Withdrawal by Subject|6
6333410|NCT03086343|10082085|FG000|Overall Study|Lost to Follow-up|3
6333411|NCT03086343|10082086|FG001|Overall Study|Lost to Follow-up|1
6333412|NCT03086343|10082085|FG000|Overall Study|Lack of Efficacy|4
6333413|NCT03086343|10082086|FG001|Overall Study|Lack of Efficacy|6
6333414|NCT03086343|10082085|FG000|Overall Study|Other, not specified|8
6333415|NCT03086343|10082086|FG001|Overall Study|Other, not specified|4
6333416|NCT03086343|10082085|FG000|Overall Study|Missing|0
6333417|NCT03086343|10082086|FG001|Overall Study|Missing|1
6333418|NCT03086447|10082107|FG000|Overall Study|No Longer Meets Eligibility Criteria|0
6333419|NCT03086447|10082108|FG001|Overall Study|No Longer Meets Eligibility Criteria|1
6333420|NCT03086447|10082107|FG000|Overall Study|Lost Lens|2
6333421|NCT03086447|10082108|FG001|Overall Study|Lost Lens|5
6333422|NCT03086447|10082107|FG000|Overall Study|Product quality complaint|0
6167401|NCT01227824|9811983|FG000|Double-blind Phase: 96 Weeks Duration|Protocol Violation|18
6167402|NCT01227824|9811984|FG001|Double-blind Phase: 96 Weeks Duration|Protocol Violation|16
6167403|NCT01227824|9811985|FG002|Double-blind Phase: 96 Weeks Duration|Protocol Violation|0
6167404|NCT01227824|9811983|FG000|Double-blind Phase: 96 Weeks Duration|Met Protocol-defined Stopping Criteria|6
6167405|NCT01227824|9811984|FG001|Double-blind Phase: 96 Weeks Duration|Met Protocol-defined Stopping Criteria|3
6167406|NCT01227824|9811985|FG002|Double-blind Phase: 96 Weeks Duration|Met Protocol-defined Stopping Criteria|0
6167407|NCT01227824|9811983|FG000|Double-blind Phase: 96 Weeks Duration|Study Closed/Terminated|6
6167408|NCT01227824|9811984|FG001|Double-blind Phase: 96 Weeks Duration|Study Closed/Terminated|4
6167409|NCT01227824|9811985|FG002|Double-blind Phase: 96 Weeks Duration|Study Closed/Terminated|0
6167410|NCT01227824|9811983|FG000|Double-blind Phase: 96 Weeks Duration|Lost to Follow-up|22
6167411|NCT01227824|9811984|FG001|Double-blind Phase: 96 Weeks Duration|Lost to Follow-up|10
6167412|NCT01227824|9811985|FG002|Double-blind Phase: 96 Weeks Duration|Lost to Follow-up|0
6167413|NCT01227824|9811983|FG000|Double-blind Phase: 96 Weeks Duration|Withdrawal by Subject|18
6167414|NCT01227824|9811984|FG001|Double-blind Phase: 96 Weeks Duration|Withdrawal by Subject|14
6167415|NCT01227824|9811985|FG002|Double-blind Phase: 96 Weeks Duration|Withdrawal by Subject|0
6167416|NCT01227824|9811983|FG000|Double-blind Phase: 96 Weeks Duration|Physician Decision|3
6167417|NCT01227824|9811984|FG001|Double-blind Phase: 96 Weeks Duration|Physician Decision|0
6167418|NCT01227824|9811985|FG002|Double-blind Phase: 96 Weeks Duration|Physician Decision|0
6167419|NCT01227824|9811983|FG000|Open-label Phase: Median of 1267 Days|Adverse Event|0
6167420|NCT01227824|9811984|FG001|Open-label Phase: Median of 1267 Days|Adverse Event|0
6167421|NCT01227824|9811985|FG002|Open-label Phase: Median of 1267 Days|Adverse Event|4
6167422|NCT01227824|9811983|FG000|Open-label Phase: Median of 1267 Days|Lack of Efficacy|0
6167423|NCT01227824|9811984|FG001|Open-label Phase: Median of 1267 Days|Lack of Efficacy|0
6167424|NCT01227824|9811985|FG002|Open-label Phase: Median of 1267 Days|Lack of Efficacy|5
6167425|NCT01227824|9811983|FG000|Open-label Phase: Median of 1267 Days|Protocol Violation|0
6192161|NCT01428128|9849249|FG000|Overall Study|Screen failure by p53|10
6333423|NCT03086447|10082108|FG001|Overall Study|Product quality complaint|1
6333424|NCT03086447|10082107|FG000|Overall Study|Lens Damage|1
6333425|NCT03086447|10082108|FG001|Overall Study|Lens Damage|6
6333426|NCT03086447|10082107|FG000|Overall Study|Unsatisfactory Lens Fitting|0
6333427|NCT03086447|10082108|FG001|Overall Study|Unsatisfactory Lens Fitting|1
6333428|NCT03086447|10082107|FG000|Overall Study|Test Article No Longer Available|1
6333429|NCT03086447|10082108|FG001|Overall Study|Test Article No Longer Available|0
6333430|NCT03086447|10082107|FG000|Overall Study|Protocol Violation|2
6333431|NCT03086447|10082108|FG001|Overall Study|Protocol Violation|4
6333432|NCT03086447|10082107|FG000|Overall Study|Lost to Follow-up|0
6333433|NCT03086447|10082108|FG001|Overall Study|Lost to Follow-up|1
6333434|NCT03086447|10082107|FG000|Overall Study|Adverse Event|3
6333435|NCT03086447|10082108|FG001|Overall Study|Adverse Event|0
6333436|NCT03086447|10082107|FG000|Overall Study|Lens Discomfort|2
6333437|NCT03086447|10082108|FG001|Overall Study|Lens Discomfort|1
6333438|NCT03086460|10082114|FG000|Study Participants|Lost to Follow-up|2
6333439|NCT03086460|10082114|FG000|Study Participants|Protocol Violation|1
6333440|NCT03086460|10082114|FG000|Study Participants|Withdrawal by Subject|6
6333441|NCT03086460|10082114|FG000|Treatment A|Lost to Follow-up|1
6333442|NCT03086460|10082114|FG000|Treatment A|Protocol Violation|1
6333443|NCT03086460|10082114|FG000|Treatment A|Withdrawal by Subject|2
6333444|NCT03086460|10082114|FG000|Treatment C|Withdrawal by Subject|2
6333445|NCT03086460|10082114|FG000|Treatment E|Lost to Follow-up|1
6333446|NCT03086460|10082114|FG000|Treatment E|Withdrawal by Subject|3
6333447|NCT03086551|10082131|FG000|First Intervention|Failure to meet inclusion criterion|1
6333448|NCT03086551|10082132|FG001|First Intervention|Failure to meet inclusion criterion|0
6333449|NCT03086551|10082131|FG000|First Intervention|Lost to Follow-up|0
6333450|NCT03086551|10082132|FG001|First Intervention|Lost to Follow-up|1
6333451|NCT03086551|10082131|FG000|Washout|Lost to Follow-up|1
6333452|NCT03086551|10082132|FG001|Washout|Lost to Follow-up|2
6333453|NCT03086551|10082131|FG000|Washout|Withdrawal by Subject|2
6333454|NCT03086551|10082132|FG001|Washout|Withdrawal by Subject|1
6082862|NCT00631917|9691005|FG000|Overall Study|Unsatisfactory therapeutic effect|8
6082863|NCT00631917|9691006|FG001|Overall Study|Unsatisfactory therapeutic effect|14
6082864|NCT00631917|9691005|FG000|Overall Study|No longer required study drug|0
6167426|NCT01227824|9811984|FG001|Open-label Phase: Median of 1267 Days|Protocol Violation|0
6167427|NCT01227824|9811985|FG002|Open-label Phase: Median of 1267 Days|Protocol Violation|5
6167428|NCT01227824|9811983|FG000|Open-label Phase: Median of 1267 Days|Met Protocol-defined Stopping Criteria|0
6167429|NCT01227824|9811984|FG001|Open-label Phase: Median of 1267 Days|Met Protocol-defined Stopping Criteria|0
6167430|NCT01227824|9811985|FG002|Open-label Phase: Median of 1267 Days|Met Protocol-defined Stopping Criteria|4
6167431|NCT01227824|9811983|FG000|Open-label Phase: Median of 1267 Days|Lost to Follow-up|0
6167432|NCT01227824|9811984|FG001|Open-label Phase: Median of 1267 Days|Lost to Follow-up|0
6167433|NCT01227824|9811985|FG002|Open-label Phase: Median of 1267 Days|Lost to Follow-up|15
6082865|NCT00631917|9691006|FG001|Overall Study|No longer required study drug|1
6082866|NCT00631917|9691005|FG000|Overall Study|Protocol deviation|6
6082867|NCT00631917|9691006|FG001|Overall Study|Protocol deviation|5
6082868|NCT00631917|9691005|FG000|Overall Study|Subject withdrew consent|25
6082869|NCT00631917|9691006|FG001|Overall Study|Subject withdrew consent|33
6333455|NCT03087513|10082158|FG000|Second Intervention After 3 hr Washout|Equipment malfunction|2
6333456|NCT03087643|10082182|FG000|Overall Study|Withdrawal by Subject|2
6333457|NCT03087643|10082183|FG001|Overall Study|Withdrawal by Subject|4
6333458|NCT03087643|10082182|FG000|Overall Study|Death|2
6333459|NCT03087643|10082183|FG001|Overall Study|Death|2
6333460|NCT03087786|10082191|FG000|Overall Study|Withdrawal by Subject|2
6333461|NCT03087786|10082192|FG001|Overall Study|Withdrawal by Subject|0
6333462|NCT03087851|10082201|FG000|Overall Study|Withdraw on medical grounds|0
6333463|NCT03087851|10082202|FG001|Overall Study|Withdraw on medical grounds|1
6333464|NCT03087851|10082203|FG002|Overall Study|Withdraw on medical grounds|2
6333465|NCT03088917|10082250|FG000|Overall Study|In care/cured elsewhere|15
6333466|NCT03088917|10082250|FG000|Overall Study|Refuse re-evaluation|13
6333467|NCT03088917|10082250|FG000|Overall Study|Contact not established|13
6333468|NCT03088917|10082250|FG000|Overall Study|Severe comorbidity/short life expectancy|5
6333469|NCT03088917|10082250|FG000|Overall Study|Moved outside study region|50
6333470|NCT03089047|10082258|FG000|Overall Study|Lost to Follow-up|1
6333471|NCT03089047|10082259|FG001|Overall Study|Lost to Follow-up|0
6333472|NCT03089216|10082269|FG000|Overall Study|Adverse Event|0
6333473|NCT03089216|10082270|FG001|Overall Study|Adverse Event|0
6333474|NCT03089216|10082271|FG002|Overall Study|Adverse Event|0
6333475|NCT03089216|10082272|FG003|Overall Study|Adverse Event|1
6333476|NCT03089580|10082286|FG000|Overall Study|Lost to Follow-up|2
6333477|NCT03089697|10082294|FG000|Overall Study|Adverse Event|1
6333478|NCT03089697|10082295|FG001|Overall Study|Adverse Event|2
6333479|NCT03089697|10082294|FG000|Overall Study|Withdrawal by Subject|1
6333480|NCT03089697|10082295|FG001|Overall Study|Withdrawal by Subject|0
6333481|NCT03089944|10082315|FG000|Overall Study|Lost to Follow-up|8
6333482|NCT03089944|10082315|FG000|Overall Study|Withdrew Consent|2
6333483|NCT03089944|10082315|FG000|Overall Study|Adverse Event|1
6333484|NCT03089944|10082315|FG000|Overall Study|Other|1
6333485|NCT03090100|10082321|FG000|Overall Study|Adverse Event|9
6333486|NCT03090100|10082322|FG001|Overall Study|Adverse Event|11
6333487|NCT03090100|10082321|FG000|Overall Study|Pregnancy|1
6333488|NCT03090100|10082322|FG001|Overall Study|Pregnancy|1
6333489|NCT03090100|10082321|FG000|Overall Study|Lack of Efficacy|2
6333490|NCT03090100|10082322|FG001|Overall Study|Lack of Efficacy|7
6333491|NCT03090100|10082321|FG000|Overall Study|Lost to Follow-up|2
6333492|NCT03090100|10082322|FG001|Overall Study|Lost to Follow-up|2
6333493|NCT03090100|10082321|FG000|Overall Study|Withdrawal by Subject|7
6333494|NCT03090100|10082322|FG001|Overall Study|Withdrawal by Subject|19
6333495|NCT03090100|10082321|FG000|Overall Study|Protocol Violation|2
6333496|NCT03090100|10082322|FG001|Overall Study|Protocol Violation|6
6333497|NCT03090100|10082321|FG000|Overall Study|Non-compliance|2
6333498|NCT03090100|10082322|FG001|Overall Study|Non-compliance|0
6333499|NCT03090100|10082321|FG000|Overall Study|Other|2
6333500|NCT03090100|10082322|FG001|Overall Study|Other|2
6333501|NCT03091348|10082357|FG000|Overall Study|Lost to Follow-up|2
6333502|NCT03091348|10082358|FG001|Overall Study|Lost to Follow-up|1
6082870|NCT00631917|9691005|FG000|Overall Study|Lost to Follow-up|7
6082871|NCT00631917|9691006|FG001|Overall Study|Lost to Follow-up|7
6333503|NCT03091400|10082371|FG000|Washout - 2 Weeks|Withdrawal by Subject|1
6333504|NCT03091400|10082372|FG001|Washout - 2 Weeks|Withdrawal by Subject|0
6333505|NCT03091439|10082380|FG000|Overall Study|Study Terminated by the Sponsor|1
6333506|NCT03091439|10082381|FG001|Overall Study|Study Terminated by the Sponsor|0
6333507|NCT03091738|10082406|FG000|Overall Study|Adverse Event|1
6333508|NCT03091738|10082406|FG000|Overall Study|Lost to Follow-up|1
6333509|NCT03091777|10082417|FG000|Overall Study|Pregnancy|2
6333510|NCT03091777|10082418|FG001|Overall Study|Pregnancy|1
6333511|NCT03091777|10082419|FG002|Overall Study|Pregnancy|0
6333512|NCT03091777|10082417|FG000|Overall Study|Adverse Event|2
6333513|NCT03091777|10082418|FG001|Overall Study|Adverse Event|1
6333514|NCT03091777|10082419|FG002|Overall Study|Adverse Event|4
6333515|NCT03091777|10082417|FG000|Overall Study|Withdrawal by Subject|4
6333516|NCT03091777|10082418|FG001|Overall Study|Withdrawal by Subject|2
6333517|NCT03091777|10082419|FG002|Overall Study|Withdrawal by Subject|6
6333518|NCT03091777|10082417|FG000|Overall Study|Protocol Violation|2
6333519|NCT03091777|10082418|FG001|Overall Study|Protocol Violation|1
6333520|NCT03091777|10082419|FG002|Overall Study|Protocol Violation|1
6333521|NCT03091777|10082417|FG000|Overall Study|Lost to Follow-up|12
6333522|NCT03091777|10082418|FG001|Overall Study|Lost to Follow-up|14
6333523|NCT03091777|10082419|FG002|Overall Study|Lost to Follow-up|7
6333524|NCT03091777|10082417|FG000|Overall Study|Lack of Efficacy|0
6333525|NCT03091777|10082418|FG001|Overall Study|Lack of Efficacy|0
6333526|NCT03091777|10082419|FG002|Overall Study|Lack of Efficacy|5
6333527|NCT03091777|10082417|FG000|Overall Study|Noncompliance with study drug|2
6333528|NCT03091777|10082418|FG001|Overall Study|Noncompliance with study drug|3
6333529|NCT03091777|10082419|FG002|Overall Study|Noncompliance with study drug|1
6333530|NCT03091777|10082417|FG000|Overall Study|Physician Decision|1
6333531|NCT03091777|10082418|FG001|Overall Study|Physician Decision|0
6333532|NCT03091777|10082419|FG002|Overall Study|Physician Decision|1
6333533|NCT03091777|10082417|FG000|Overall Study|Abnormal Laboratory Value|7
6333534|NCT03091777|10082418|FG001|Overall Study|Abnormal Laboratory Value|11
6333535|NCT03091777|10082419|FG002|Overall Study|Abnormal Laboratory Value|12
6333536|NCT03091920|10082430|FG000|Overall Study|Adverse Event|0
6333537|NCT03091920|10082431|FG001|Overall Study|Adverse Event|1
6333538|NCT03091920|10082432|FG002|Overall Study|Adverse Event|0
6333539|NCT03092375|10082463|FG000|Overall Study|Lack of Efficacy|0
6333540|NCT03092375|10082464|FG001|Overall Study|Lack of Efficacy|1
6333541|NCT03092375|10082465|FG002|Overall Study|Lack of Efficacy|1
6333542|NCT03092375|10082466|FG003|Overall Study|Lack of Efficacy|0
6333543|NCT03092479|10082485|FG000|Overall Study|Lost to Follow-up|3
6333544|NCT03092479|10082486|FG001|Overall Study|Lost to Follow-up|2
6333545|NCT03092479|10082485|FG000|Overall Study|Withdrawal by Subject|4
6333546|NCT03092479|10082486|FG001|Overall Study|Withdrawal by Subject|0
6333547|NCT03092726|10082494|FG000|Overall Study|Adverse Event|3
6333548|NCT03092726|10082495|FG001|Overall Study|Adverse Event|10
6333549|NCT03092726|10082494|FG000|Overall Study|Lack of Efficacy|0
6333550|NCT03092726|10082495|FG001|Overall Study|Lack of Efficacy|1
6333551|NCT03092726|10082494|FG000|Overall Study|Lost to Follow-up|1
6333552|NCT03092726|10082495|FG001|Overall Study|Lost to Follow-up|0
6333553|NCT03092726|10082494|FG000|Overall Study|Withdrawal by Subject|5
6333554|NCT03092726|10082495|FG001|Overall Study|Withdrawal by Subject|3
6333555|NCT03092752|10082501|FG000|Overall Study|Aged <40 years|14209
6333556|NCT03092752|10082501|FG000|Overall Study|At least one claim with T2DM|61299
6333557|NCT03092752|10082501|FG000|Overall Study|Having no claim of study drugs|29282
6333558|NCT03092752|10082501|FG000|Overall Study|Average hospital visit interval >92 days|10779
6333559|NCT03092752|10082501|FG000|Overall Study|<6 month history|245900
6333560|NCT03092791|10082530|FG000|Overall Study|Lost to Follow-up|0
6333561|NCT03092791|10082531|FG001|Overall Study|Lost to Follow-up|0
6333562|NCT03092791|10082532|FG002|Overall Study|Lost to Follow-up|0
6333563|NCT03092791|10082533|FG003|Overall Study|Lost to Follow-up|0
6333564|NCT03092791|10082534|FG004|Overall Study|Lost to Follow-up|0
6333565|NCT03092791|10082535|FG005|Overall Study|Lost to Follow-up|0
6333566|NCT03092791|10082536|FG006|Overall Study|Lost to Follow-up|1
6333567|NCT03092791|10082537|FG007|Overall Study|Lost to Follow-up|0
6333568|NCT03092791|10082530|FG000|Overall Study|Withdrawal of Consent|0
6333569|NCT03092791|10082531|FG001|Overall Study|Withdrawal of Consent|0
6333570|NCT03092791|10082532|FG002|Overall Study|Withdrawal of Consent|0
6333571|NCT03092791|10082533|FG003|Overall Study|Withdrawal of Consent|0
6333572|NCT03092791|10082534|FG004|Overall Study|Withdrawal of Consent|4
6333573|NCT03092791|10082535|FG005|Overall Study|Withdrawal of Consent|12
6333574|NCT03092791|10082536|FG006|Overall Study|Withdrawal of Consent|6
6333575|NCT03092791|10082537|FG007|Overall Study|Withdrawal of Consent|4
6333576|NCT03092791|10082530|FG000|Overall Study|Study Termination|0
6333577|NCT03092791|10082531|FG001|Overall Study|Study Termination|0
6333578|NCT03092791|10082532|FG002|Overall Study|Study Termination|0
6333579|NCT03092791|10082533|FG003|Overall Study|Study Termination|0
6333580|NCT03092791|10082534|FG004|Overall Study|Study Termination|55
6333581|NCT03092791|10082535|FG005|Overall Study|Study Termination|46
6333582|NCT03092791|10082536|FG006|Overall Study|Study Termination|53
6333583|NCT03092791|10082537|FG007|Overall Study|Study Termination|55
6333584|NCT03092791|10082530|FG000|Overall Study|Death|0
6333585|NCT03092791|10082531|FG001|Overall Study|Death|0
6333586|NCT03092791|10082532|FG002|Overall Study|Death|0
6333587|NCT03092791|10082533|FG003|Overall Study|Death|0
6333588|NCT03092791|10082534|FG004|Overall Study|Death|0
6333589|NCT03092791|10082535|FG005|Overall Study|Death|1
6333590|NCT03092791|10082536|FG006|Overall Study|Death|0
6333591|NCT03092791|10082537|FG007|Overall Study|Death|1
6333592|NCT03092791|10082530|FG000|Overall Study|Reason Not Specified|0
6333593|NCT03092791|10082531|FG001|Overall Study|Reason Not Specified|0
6333594|NCT03092791|10082532|FG002|Overall Study|Reason Not Specified|0
6333595|NCT03092791|10082533|FG003|Overall Study|Reason Not Specified|0
6333596|NCT03092791|10082534|FG004|Overall Study|Reason Not Specified|1
6333597|NCT03092791|10082535|FG005|Overall Study|Reason Not Specified|1
6333598|NCT03092791|10082536|FG006|Overall Study|Reason Not Specified|0
6333599|NCT03092791|10082537|FG007|Overall Study|Reason Not Specified|0
6333600|NCT03093181|10082597|FG000|Overall Study|Withdrawal by Subject|2
6333601|NCT03093181|10082598|FG001|Overall Study|Withdrawal by Subject|1
6333602|NCT03093181|10082599|FG002|Overall Study|Withdrawal by Subject|2
6333603|NCT03093181|10082597|FG000|Overall Study|Other (Not specified)|1
6333604|NCT03093181|10082598|FG001|Overall Study|Other (Not specified)|0
6333605|NCT03093181|10082599|FG002|Overall Study|Other (Not specified)|0
6333606|NCT03093181|10082597|FG000|Overall Study|Adverse Event|0
6333607|NCT03093181|10082598|FG001|Overall Study|Adverse Event|1
6333608|NCT03093181|10082599|FG002|Overall Study|Adverse Event|0
6333609|NCT03093181|10082597|FG000|Overall Study|Other (Protocol violation)|0
6333610|NCT03093181|10082598|FG001|Overall Study|Other (Protocol violation)|0
6333611|NCT03093181|10082599|FG002|Overall Study|Other (Protocol violation)|1
6333612|NCT03093324|10082622|FG000|Overall Study|Adverse Event|4
6333613|NCT03093324|10082623|FG001|Overall Study|Adverse Event|15
6333614|NCT03093324|10082622|FG000|Overall Study|Lost to Follow-up|1
6333615|NCT03093324|10082623|FG001|Overall Study|Lost to Follow-up|0
6333616|NCT03093324|10082622|FG000|Overall Study|Protocol Deviation|2
6333617|NCT03093324|10082623|FG001|Overall Study|Protocol Deviation|2
6333618|NCT03093324|10082622|FG000|Overall Study|Withdrawal by Subject|2
6333619|NCT03093324|10082623|FG001|Overall Study|Withdrawal by Subject|2
6333620|NCT03093415|10082632|FG000|Assessed for Eligibility --> Enrollment|Lost to Follow-up|17
6333621|NCT03093415|10082633|FG001|Assessed for Eligibility --> Enrollment|Lost to Follow-up|36
6333622|NCT03093415|10082634|FG002|Assessed for Eligibility --> Enrollment|Lost to Follow-up|0
6333623|NCT03093415|10082632|FG000|Assessed for Eligibility --> Enrollment|Inclusion Criteria: No MAT|40
6333624|NCT03093415|10082633|FG001|Assessed for Eligibility --> Enrollment|Inclusion Criteria: No MAT|0
6333625|NCT03093415|10082634|FG002|Assessed for Eligibility --> Enrollment|Inclusion Criteria: No MAT|0
6333626|NCT03093415|10082632|FG000|Assessed for Eligibility --> Enrollment|Inclusion Criteria: neg HCV|28
6333627|NCT03093415|10082633|FG001|Assessed for Eligibility --> Enrollment|Inclusion Criteria: neg HCV|6
6333628|NCT03093415|10082634|FG002|Assessed for Eligibility --> Enrollment|Inclusion Criteria: neg HCV|0
6333629|NCT03093415|10082632|FG000|Assessed for Eligibility --> Enrollment|Inclusion Criteria: No active use|0
6333630|NCT03093415|10082633|FG001|Assessed for Eligibility --> Enrollment|Inclusion Criteria: No active use|12
6333631|NCT03093415|10082634|FG002|Assessed for Eligibility --> Enrollment|Inclusion Criteria: No active use|0
6333632|NCT03093415|10082632|FG000|Assessed for Eligibility --> Enrollment|Inclusion Criteria: Fibrosis > F2|18
6333633|NCT03093415|10082633|FG001|Assessed for Eligibility --> Enrollment|Inclusion Criteria: Fibrosis > F2|12
6333634|NCT03093415|10082634|FG002|Assessed for Eligibility --> Enrollment|Inclusion Criteria: Fibrosis > F2|0
6333635|NCT03093415|10082632|FG000|Assessed for Eligibility --> Enrollment|Exclusion Criteria: HIV|4
6333636|NCT03093415|10082633|FG001|Assessed for Eligibility --> Enrollment|Exclusion Criteria: HIV|4
6333637|NCT03093415|10082634|FG002|Assessed for Eligibility --> Enrollment|Exclusion Criteria: HIV|0
6333638|NCT03093415|10082632|FG000|Assessed for Eligibility --> Enrollment|Inclusion Criteria: Wrong Genotype|15
6333639|NCT03093415|10082633|FG001|Assessed for Eligibility --> Enrollment|Inclusion Criteria: Wrong Genotype|32
6333640|NCT03093415|10082634|FG002|Assessed for Eligibility --> Enrollment|Inclusion Criteria: Wrong Genotype|0
6333641|NCT03093415|10082632|FG000|Assessed for Eligibility --> Enrollment|Exclusion Criteria: NS5a Resistance|5
6333642|NCT03093415|10082633|FG001|Assessed for Eligibility --> Enrollment|Exclusion Criteria: NS5a Resistance|3
6333643|NCT03093415|10082634|FG002|Assessed for Eligibility --> Enrollment|Exclusion Criteria: NS5a Resistance|0
6333644|NCT03093415|10082632|FG000|Assessed for Eligibility --> Enrollment|Exclusion Criteria: Treatment Readiness|4
6333645|NCT03093415|10082633|FG001|Assessed for Eligibility --> Enrollment|Exclusion Criteria: Treatment Readiness|2
6333646|NCT03093415|10082634|FG002|Assessed for Eligibility --> Enrollment|Exclusion Criteria: Treatment Readiness|0
6333647|NCT03093415|10082632|FG000|Assessed for Eligibility --> Enrollment|Other Lab exclusion Criteria|9
6333648|NCT03093415|10082633|FG001|Assessed for Eligibility --> Enrollment|Other Lab exclusion Criteria|3
6333649|NCT03093415|10082634|FG002|Assessed for Eligibility --> Enrollment|Other Lab exclusion Criteria|0
6333650|NCT03093415|10082632|FG000|Enrollment to SVR12 Results|Lost to Follow-up|1
6333651|NCT03093415|10082633|FG001|Enrollment to SVR12 Results|Lost to Follow-up|8
6333652|NCT03093415|10082634|FG002|Enrollment to SVR12 Results|Lost to Follow-up|3
6333653|NCT03093454|10082644|FG000|Overall Study|Withdrawal by Subject|1
6333654|NCT03093454|10082645|FG001|Overall Study|Withdrawal by Subject|1
6333655|NCT03093454|10082644|FG000|Overall Study|Scheduling conflict|3
6333656|NCT03093454|10082645|FG001|Overall Study|Scheduling conflict|1
6333657|NCT03093454|10082644|FG000|Overall Study|Physician Decision|2
6333658|NCT03093454|10082645|FG001|Overall Study|Physician Decision|1
6167434|NCT01227824|9811983|FG000|Open-label Phase: Median of 1267 Days|Withdrawal by Subject|0
6167435|NCT01227824|9811984|FG001|Open-label Phase: Median of 1267 Days|Withdrawal by Subject|0
6167436|NCT01227824|9811985|FG002|Open-label Phase: Median of 1267 Days|Withdrawal by Subject|8
6333659|NCT03093870|10082663|FG000|Overall Study|Withdrawal by Subject|2
6333660|NCT03093870|10082664|FG001|Overall Study|Withdrawal by Subject|6
6333661|NCT03093870|10082665|FG002|Overall Study|Withdrawal by Subject|5
6333662|NCT03093870|10082663|FG000|Overall Study|Death|1
6333663|NCT03093870|10082664|FG001|Overall Study|Death|35
6333664|NCT03093870|10082665|FG002|Overall Study|Death|35
6333665|NCT03093870|10082663|FG000|Overall Study|Radiographic disease progression|10
6333666|NCT03093870|10082664|FG001|Overall Study|Radiographic disease progression|0
6333667|NCT03093870|10082665|FG002|Overall Study|Radiographic disease progression|0
6333668|NCT03093870|10082663|FG000|Overall Study|Clinical disease progression|1
6333669|NCT03093870|10082664|FG001|Overall Study|Clinical disease progression|0
6333670|NCT03093870|10082665|FG002|Overall Study|Clinical disease progression|0
6333671|NCT03093870|10082663|FG000|Overall Study|Physician Decision|2
6333672|NCT03093870|10082664|FG001|Overall Study|Physician Decision|0
6333673|NCT03093870|10082665|FG002|Overall Study|Physician Decision|0
6333674|NCT03093870|10082663|FG000|Overall Study|Adverse Event|7
6333675|NCT03093870|10082664|FG001|Overall Study|Adverse Event|0
6333676|NCT03093870|10082665|FG002|Overall Study|Adverse Event|0
6333677|NCT03093870|10082663|FG000|Overall Study|Patient withdrew from treatment voluntarily due to intermittent constipation and anorexia|1
6333678|NCT03093870|10082664|FG001|Overall Study|Patient withdrew from treatment voluntarily due to intermittent constipation and anorexia|0
6333679|NCT03093870|10082665|FG002|Overall Study|Patient withdrew from treatment voluntarily due to intermittent constipation and anorexia|0
6333680|NCT03093870|10082663|FG000|Overall Study|Lost to Follow-up|0
6333681|NCT03093870|10082664|FG001|Overall Study|Lost to Follow-up|0
6333682|NCT03093870|10082665|FG002|Overall Study|Lost to Follow-up|1
6333683|NCT03094195|10082676|FG000|Double-Blind Treatment Period (DB)|Study terminated by sponsor|12
6333684|NCT03094195|10082677|FG001|Double-Blind Treatment Period (DB)|Study terminated by sponsor|10
6333685|NCT03094195|10082678|FG002|Double-Blind Treatment Period (DB)|Study terminated by sponsor|11
6333686|NCT03094195|10082679|FG003|Double-Blind Treatment Period (DB)|Study terminated by sponsor|0
6333687|NCT03094195|10082680|FG004|Double-Blind Treatment Period (DB)|Study terminated by sponsor|0
6333688|NCT03094195|10082681|FG005|Double-Blind Treatment Period (DB)|Study terminated by sponsor|0
6333689|NCT03094195|10082682|FG006|Double-Blind Treatment Period (DB)|Study terminated by sponsor|0
6333690|NCT03094195|10082683|FG007|Double-Blind Treatment Period (DB)|Study terminated by sponsor|0
6333691|NCT03094195|10082676|FG000|Double-Blind Treatment Period (DB)|Adverse Event|3
6333692|NCT03094195|10082677|FG001|Double-Blind Treatment Period (DB)|Adverse Event|2
6333693|NCT03094195|10082678|FG002|Double-Blind Treatment Period (DB)|Adverse Event|1
6333694|NCT03094195|10082679|FG003|Double-Blind Treatment Period (DB)|Adverse Event|0
6333695|NCT03094195|10082680|FG004|Double-Blind Treatment Period (DB)|Adverse Event|0
6333696|NCT03094195|10082681|FG005|Double-Blind Treatment Period (DB)|Adverse Event|0
6333697|NCT03094195|10082682|FG006|Double-Blind Treatment Period (DB)|Adverse Event|0
6333698|NCT03094195|10082683|FG007|Double-Blind Treatment Period (DB)|Adverse Event|0
6333699|NCT03094195|10082676|FG000|Double-Blind Treatment Period (DB)|Physician Decision|0
6333700|NCT03094195|10082677|FG001|Double-Blind Treatment Period (DB)|Physician Decision|0
6333701|NCT03094195|10082678|FG002|Double-Blind Treatment Period (DB)|Physician Decision|1
6333702|NCT03094195|10082679|FG003|Double-Blind Treatment Period (DB)|Physician Decision|0
6333703|NCT03094195|10082680|FG004|Double-Blind Treatment Period (DB)|Physician Decision|0
6333704|NCT03094195|10082681|FG005|Double-Blind Treatment Period (DB)|Physician Decision|0
6333705|NCT03094195|10082682|FG006|Double-Blind Treatment Period (DB)|Physician Decision|0
6333706|NCT03094195|10082683|FG007|Double-Blind Treatment Period (DB)|Physician Decision|0
6333707|NCT03094195|10082676|FG000|Double-Blind Treatment Period (DB)|Withdrawal by Subject|0
6333708|NCT03094195|10082677|FG001|Double-Blind Treatment Period (DB)|Withdrawal by Subject|1
6333709|NCT03094195|10082678|FG002|Double-Blind Treatment Period (DB)|Withdrawal by Subject|1
6333710|NCT03094195|10082679|FG003|Double-Blind Treatment Period (DB)|Withdrawal by Subject|0
6333711|NCT03094195|10082680|FG004|Double-Blind Treatment Period (DB)|Withdrawal by Subject|0
6333712|NCT03094195|10082681|FG005|Double-Blind Treatment Period (DB)|Withdrawal by Subject|0
6333713|NCT03094195|10082682|FG006|Double-Blind Treatment Period (DB)|Withdrawal by Subject|0
6333714|NCT03094195|10082683|FG007|Double-Blind Treatment Period (DB)|Withdrawal by Subject|0
6333715|NCT03094611|10082707|FG000|Overall Study|Lack of Efficacy|1
6333716|NCT03094611|10082707|FG000|Overall Study|Stem Cell Transplant|1
6333717|NCT03095027|10082730|FG000|Period 2, Second Week of Wear|Adverse Event|1
6333718|NCT03095027|10082731|FG001|Period 2, Second Week of Wear|Adverse Event|0
6333719|NCT03095118|10082746|FG000|Overall Study|Adverse Event|1
6333720|NCT03095118|10082746|FG000|Overall Study|Diagnosis not associated with monoclonal gammopathy|1
6333721|NCT03095508|10082752|FG000|Overall Study|Adverse Event|0
6333722|NCT03095508|10082753|FG001|Overall Study|Adverse Event|1
6333723|NCT03095521|10082761|FG000|Overall Study|Withdrawal by Subject|0
6333724|NCT03095521|10082762|FG001|Overall Study|Withdrawal by Subject|1
6333725|NCT03095521|10082761|FG000|Overall Study|Lost to Follow-up|0
6333726|NCT03095521|10082762|FG001|Overall Study|Lost to Follow-up|1
6333727|NCT03095599|10082770|FG000|Overall Study|Withdrawal by Subject|1
6333728|NCT03095599|10082771|FG001|Overall Study|Withdrawal by Subject|0
6333729|NCT03095599|10082770|FG000|Overall Study|Lost to Follow-up|1
6333730|NCT03095599|10082771|FG001|Overall Study|Lost to Follow-up|0
6333731|NCT03095599|10082770|FG000|Overall Study|Withdrawal prior to vaccination|1
6333732|NCT03095599|10082771|FG001|Overall Study|Withdrawal prior to vaccination|0
6333733|NCT03095651|10082816|FG000|Overall Study|Lost to Follow-up|1
6333734|NCT03095651|10082817|FG001|Overall Study|Lost to Follow-up|1
6333735|NCT03095651|10082818|FG002|Overall Study|Lost to Follow-up|0
6333736|NCT03095651|10082819|FG003|Overall Study|Lost to Follow-up|1
6333737|NCT03095651|10082820|FG004|Overall Study|Lost to Follow-up|0
6333738|NCT03095651|10082821|FG005|Overall Study|Lost to Follow-up|0
6333739|NCT03095651|10082822|FG006|Overall Study|Lost to Follow-up|0
6333740|NCT03095651|10082823|FG007|Overall Study|Lost to Follow-up|0
6333741|NCT03095651|10082816|FG000|Overall Study|Withdrawal by Subject|0
6333742|NCT03095651|10082817|FG001|Overall Study|Withdrawal by Subject|0
6333743|NCT03095651|10082818|FG002|Overall Study|Withdrawal by Subject|0
6333744|NCT03095651|10082819|FG003|Overall Study|Withdrawal by Subject|0
6333745|NCT03095651|10082820|FG004|Overall Study|Withdrawal by Subject|0
6333746|NCT03095651|10082821|FG005|Overall Study|Withdrawal by Subject|1
6333747|NCT03095651|10082822|FG006|Overall Study|Withdrawal by Subject|0
6333748|NCT03095651|10082823|FG007|Overall Study|Withdrawal by Subject|0
6333749|NCT03096314|10082851|FG000|Screened Vitamin D Deficient|Lost to Follow-up|9
6333750|NCT03096314|10082852|FG001|Screened Vitamin D Deficient|Lost to Follow-up|12
6333751|NCT03096483|10082879|FG000|Overall Study|Withdrawal by site|1
6333752|NCT03096847|10082907|FG000|Overall Study|Other|2
6333753|NCT03096847|10082908|FG001|Overall Study|Other|1
6333754|NCT03096847|10082909|FG002|Overall Study|Other|2
6333755|NCT03096847|10082907|FG000|Overall Study|Lost to Follow-up|1
6333756|NCT03096847|10082908|FG001|Overall Study|Lost to Follow-up|0
6333757|NCT03096847|10082909|FG002|Overall Study|Lost to Follow-up|1
6333758|NCT03096847|10082907|FG000|Overall Study|Death|6
6333759|NCT03096847|10082908|FG001|Overall Study|Death|0
6333760|NCT03096847|10082909|FG002|Overall Study|Death|2
6333761|NCT03096847|10082907|FG000|Overall Study|Protocol Violation|3
6333762|NCT03096847|10082908|FG001|Overall Study|Protocol Violation|0
6333763|NCT03096847|10082909|FG002|Overall Study|Protocol Violation|6
6333764|NCT03096847|10082907|FG000|Overall Study|Physician Decision|12
6333765|NCT03096847|10082908|FG001|Overall Study|Physician Decision|2
6333766|NCT03096847|10082909|FG002|Overall Study|Physician Decision|8
6167437|NCT01227824|9811983|FG000|Open-label Phase: Median of 1267 Days|Physician Decision|0
6167438|NCT01227824|9811984|FG001|Open-label Phase: Median of 1267 Days|Physician Decision|0
6167439|NCT01227824|9811985|FG002|Open-label Phase: Median of 1267 Days|Physician Decision|3
6167440|NCT01227889|9811994|FG000|Randomized Phase (RP)|Adverse Event|13
6167441|NCT01227889|9811995|FG001|Randomized Phase (RP)|Adverse Event|0
6167442|NCT01227889|9811994|FG000|Randomized Phase (RP)|Physician Decision|13
6167443|NCT01227889|9811995|FG001|Randomized Phase (RP)|Physician Decision|5
6167444|NCT01227889|9811994|FG000|Randomized Phase (RP)|Progressive Disease|135
6167445|NCT01227889|9811995|FG001|Randomized Phase (RP)|Progressive Disease|52
6167446|NCT01227889|9811994|FG000|Randomized Phase (RP)|Study terminated by sponsor|10
6167447|NCT01227889|9811995|FG001|Randomized Phase (RP)|Study terminated by sponsor|0
6167448|NCT01227889|9811994|FG000|Randomized Phase (RP)|Missing|1
6167449|NCT01227889|9811995|FG001|Randomized Phase (RP)|Missing|3
6167450|NCT01227889|9811994|FG000|Randomized Phase (RP)|Withdrawal by Subject|15
6167451|NCT01227889|9811995|FG001|Randomized Phase (RP)|Withdrawal by Subject|3
6167452|NCT01227889|9811994|FG000|Crossover Phase|Adverse Event|0
6167453|NCT01227889|9811995|FG001|Crossover Phase|Adverse Event|1
6167454|NCT01227889|9811994|FG000|Crossover Phase|Physician Decision|0
6167455|NCT01227889|9811995|FG001|Crossover Phase|Physician Decision|3
6167456|NCT01227889|9811994|FG000|Crossover Phase|Progressive Disease|0
6167457|NCT01227889|9811995|FG001|Crossover Phase|Progressive Disease|31
6167458|NCT01227889|9811994|FG000|Crossover Phase|Study Terminated By Sponsor|0
6167459|NCT01227889|9811995|FG001|Crossover Phase|Study Terminated By Sponsor|1
6167460|NCT01227889|9811994|FG000|Crossover Phase|Withdrawal by Subject|0
6167461|NCT01227889|9811995|FG001|Crossover Phase|Withdrawal by Subject|1
6167462|NCT01227902|9812013|FG000|Overall Study|Adverse Event|12
6167463|NCT01227902|9812014|FG001|Overall Study|Adverse Event|8
6167464|NCT01227902|9812015|FG002|Overall Study|Adverse Event|11
6167465|NCT01227902|9812016|FG003|Overall Study|Adverse Event|4
6167466|NCT01227902|9812013|FG000|Overall Study|Lack of Efficacy|1
6167467|NCT01227902|9812014|FG001|Overall Study|Lack of Efficacy|2
6167468|NCT01227902|9812015|FG002|Overall Study|Lack of Efficacy|2
6167469|NCT01227902|9812016|FG003|Overall Study|Lack of Efficacy|1
6333767|NCT03096847|10082907|FG000|Overall Study|Withdrawal by Subject|24
6333768|NCT03096847|10082908|FG001|Overall Study|Withdrawal by Subject|1
6333769|NCT03096847|10082909|FG002|Overall Study|Withdrawal by Subject|12
6333770|NCT03096847|10082907|FG000|Overall Study|Adverse Event|72
6333771|NCT03096847|10082908|FG001|Overall Study|Adverse Event|6
6333772|NCT03096847|10082909|FG002|Overall Study|Adverse Event|28
6167470|NCT01227902|9812013|FG000|Overall Study|Protocol Violation|1
6167471|NCT01227902|9812014|FG001|Overall Study|Protocol Violation|0
6167472|NCT01227902|9812015|FG002|Overall Study|Protocol Violation|0
6167473|NCT01227902|9812016|FG003|Overall Study|Protocol Violation|0
6167474|NCT01227902|9812013|FG000|Overall Study|Lost to Follow-up|0
6167475|NCT01227902|9812014|FG001|Overall Study|Lost to Follow-up|0
6333773|NCT03096847|10082907|FG000|Overall Study|Progressive disease|97
6333774|NCT03096847|10082908|FG001|Overall Study|Progressive disease|10
6333775|NCT03096847|10082909|FG002|Overall Study|Progressive disease|78
6333776|NCT03096847|10082907|FG000|Overall Study|Non-compliance with study medication|1
6333777|NCT03096847|10082908|FG001|Overall Study|Non-compliance with study medication|0
6333778|NCT03096847|10082909|FG002|Overall Study|Non-compliance with study medication|0
6333779|NCT03096847|10082907|FG000|Overall Study|New therapy for study indication|1
6333780|NCT03096847|10082908|FG001|Overall Study|New therapy for study indication|0
6333781|NCT03096847|10082909|FG002|Overall Study|New therapy for study indication|1
6333782|NCT03097029|10082936|FG000|Overall Study|Withdrawal by Subject|1
6333783|NCT03097133|10082942|FG000|Overall Study|Lost to Follow-up|3
6333784|NCT03097133|10082943|FG001|Overall Study|Lost to Follow-up|2
6333785|NCT03097133|10082942|FG000|Overall Study|Withdrawal by Subject|2
6333786|NCT03097133|10082943|FG001|Overall Study|Withdrawal by Subject|5
6333787|NCT03097133|10082942|FG000|Overall Study|Discontinued DB, not entered FU Phase|21
6333788|NCT03097133|10082943|FG001|Overall Study|Discontinued DB, not entered FU Phase|25
6333789|NCT03097133|10082942|FG000|Overall Study|Other|3
6333790|NCT03097133|10082943|FG001|Overall Study|Other|2
6333791|NCT03097133|10082942|FG000|Overall Study|Adverse Event|1
6333792|NCT03097133|10082943|FG001|Overall Study|Adverse Event|0
6333793|NCT03097289|10082949|FG000|Overall Study|Adverse Event|1
6333794|NCT03097289|10082949|FG000|Overall Study|Equipment failure|2
6333795|NCT03097289|10082949|FG000|Overall Study|Collected platelet product unusable|3
6333796|NCT03097315|10082954|FG000|Overall Study|Withdrawal by Subject|1
6333797|NCT03097588|10082988|FG000|Overall Study|Adverse Event|1
6333798|NCT03097614|10082992|FG000|Overall Study|Adverse Event|3
6333799|NCT03097861|10083017|FG000|Overall Study|Adverse Event|3
6333800|NCT03097861|10083018|FG001|Overall Study|Adverse Event|8
6333801|NCT03097861|10083019|FG002|Overall Study|Adverse Event|4
6333802|NCT03097861|10083017|FG000|Overall Study|Investigator Decision|0
6333803|NCT03097861|10083018|FG001|Overall Study|Investigator Decision|1
6333804|NCT03097861|10083019|FG002|Overall Study|Investigator Decision|0
6333805|NCT03097861|10083017|FG000|Overall Study|Lost to Follow-up|0
6333806|NCT03097861|10083018|FG001|Overall Study|Lost to Follow-up|7
6333807|NCT03097861|10083019|FG002|Overall Study|Lost to Follow-up|1
6082872|NCT00631917|9691005|FG000|Overall Study|Administrative problems|2
6082873|NCT00631917|9691006|FG001|Overall Study|Administrative problems|0
6082874|NCT00631917|9691005|FG000|Overall Study|Death|1
6082875|NCT00631917|9691006|FG001|Overall Study|Death|0
6082876|NCT00631969|9691014|FG000|Overall Study|Adverse Event|3
6082877|NCT00631969|9691015|FG001|Overall Study|Adverse Event|1
6333808|NCT03097861|10083017|FG000|Overall Study|Withdrawal by Subject|1
6333809|NCT03097861|10083018|FG001|Overall Study|Withdrawal by Subject|5
6333810|NCT03097861|10083019|FG002|Overall Study|Withdrawal by Subject|3
6333811|NCT03097861|10083017|FG000|Overall Study|Reason not provided|3
6333812|NCT03097861|10083018|FG001|Overall Study|Reason not provided|1
6333813|NCT03097861|10083019|FG002|Overall Study|Reason not provided|1
6333814|NCT03098030|10083033|FG000|Overall Study|Death|10
6333815|NCT03098030|10083034|FG001|Overall Study|Death|156
6333816|NCT03098030|10083035|FG002|Overall Study|Death|156
6333817|NCT03098030|10083036|FG003|Overall Study|Death|82
6333818|NCT03098030|10083033|FG000|Overall Study|Withdrawal by Subject|0
6333819|NCT03098030|10083034|FG001|Overall Study|Withdrawal by Subject|7
6333820|NCT03098030|10083035|FG002|Overall Study|Withdrawal by Subject|8
6333821|NCT03098030|10083036|FG003|Overall Study|Withdrawal by Subject|2
6333822|NCT03098030|10083033|FG000|Overall Study|Lost to Follow-up|0
6333823|NCT03098030|10083034|FG001|Overall Study|Lost to Follow-up|0
6333824|NCT03098030|10083035|FG002|Overall Study|Lost to Follow-up|2
6333825|NCT03098030|10083036|FG003|Overall Study|Lost to Follow-up|1
6333826|NCT03098433|10083069|FG000|Overall Study|Withdrawal by Subject|10
6333827|NCT03098550|10083077|FG000|Overall Study|Disease Progression|30
6333828|NCT03098550|10083078|FG001|Overall Study|Disease Progression|19
6333829|NCT03098550|10083079|FG002|Overall Study|Disease Progression|41
6333830|NCT03098550|10083077|FG000|Overall Study|Study Drug Toxicity|2
6333831|NCT03098550|10083078|FG001|Overall Study|Study Drug Toxicity|1
6333832|NCT03098550|10083079|FG002|Overall Study|Study Drug Toxicity|0
6333833|NCT03098550|10083077|FG000|Overall Study|Death|1
6333834|NCT03098550|10083078|FG001|Overall Study|Death|0
6333835|NCT03098550|10083079|FG002|Overall Study|Death|0
6333836|NCT03098550|10083077|FG000|Overall Study|Adverse Event unrelated to Study Drug|6
6333837|NCT03098550|10083078|FG001|Overall Study|Adverse Event unrelated to Study Drug|0
6333838|NCT03098550|10083079|FG002|Overall Study|Adverse Event unrelated to Study Drug|1
6333839|NCT03098550|10083077|FG000|Overall Study|Administrative reason by sponsor|0
6333840|NCT03098550|10083078|FG001|Overall Study|Administrative reason by sponsor|0
6333841|NCT03098550|10083079|FG002|Overall Study|Administrative reason by sponsor|1
6333842|NCT03098550|10083077|FG000|Overall Study|Other reasons|2
6333843|NCT03098550|10083078|FG001|Overall Study|Other reasons|0
6333844|NCT03098550|10083079|FG002|Overall Study|Other reasons|0
6333845|NCT03098979|10083124|FG000|Overall Study|Adverse Event|1
6333846|NCT03098979|10083125|FG001|Overall Study|Adverse Event|0
6333847|NCT03098979|10083126|FG002|Overall Study|Adverse Event|1
6333848|NCT03098979|10083127|FG003|Overall Study|Adverse Event|4
6333849|NCT03098979|10083128|FG004|Overall Study|Adverse Event|6
6333850|NCT03098979|10083129|FG005|Overall Study|Adverse Event|1
6333851|NCT03098979|10083124|FG000|Overall Study|Withdrawal by Subject|2
6333852|NCT03098979|10083125|FG001|Overall Study|Withdrawal by Subject|1
6333853|NCT03098979|10083126|FG002|Overall Study|Withdrawal by Subject|1
6333854|NCT03098979|10083127|FG003|Overall Study|Withdrawal by Subject|1
6082878|NCT00631969|9691014|FG000|Overall Study|Lack of Efficacy|2
6333855|NCT03098979|10083128|FG004|Overall Study|Withdrawal by Subject|2
6333856|NCT03098979|10083129|FG005|Overall Study|Withdrawal by Subject|1
6333857|NCT03098979|10083124|FG000|Overall Study|Death|1
6333858|NCT03098979|10083125|FG001|Overall Study|Death|0
6167476|NCT01227902|9812015|FG002|Overall Study|Lost to Follow-up|1
6167477|NCT01227902|9812016|FG003|Overall Study|Lost to Follow-up|2
6167478|NCT01227902|9812013|FG000|Overall Study|Physician Decision|0
6167479|NCT01227902|9812014|FG001|Overall Study|Physician Decision|1
6167480|NCT01227902|9812015|FG002|Overall Study|Physician Decision|1
6167481|NCT01227902|9812016|FG003|Overall Study|Physician Decision|0
6167482|NCT01227902|9812013|FG000|Overall Study|Withdrawal by Subject|4
6167483|NCT01227902|9812014|FG001|Overall Study|Withdrawal by Subject|2
6167484|NCT01227902|9812015|FG002|Overall Study|Withdrawal by Subject|4
6333859|NCT03098979|10083126|FG002|Overall Study|Death|2
6333860|NCT03098979|10083127|FG003|Overall Study|Death|0
6333861|NCT03098979|10083128|FG004|Overall Study|Death|1
6333862|NCT03098979|10083129|FG005|Overall Study|Death|0
6333863|NCT03098979|10083124|FG000|Overall Study|Physician Decision|2
6333864|NCT03098979|10083125|FG001|Overall Study|Physician Decision|1
6333865|NCT03098979|10083126|FG002|Overall Study|Physician Decision|0
6333866|NCT03098979|10083127|FG003|Overall Study|Physician Decision|0
6333867|NCT03098979|10083128|FG004|Overall Study|Physician Decision|0
6333868|NCT03098979|10083129|FG005|Overall Study|Physician Decision|0
6333869|NCT03098979|10083124|FG000|Overall Study|Non-compliance|0
6333870|NCT03098979|10083125|FG001|Overall Study|Non-compliance|0
6333871|NCT03098979|10083126|FG002|Overall Study|Non-compliance|0
6333872|NCT03098979|10083127|FG003|Overall Study|Non-compliance|0
6333873|NCT03098979|10083128|FG004|Overall Study|Non-compliance|0
6333874|NCT03098979|10083129|FG005|Overall Study|Non-compliance|1
6333875|NCT03098979|10083124|FG000|Overall Study|Protocol Violation|0
6333876|NCT03098979|10083125|FG001|Overall Study|Protocol Violation|0
6333877|NCT03098979|10083126|FG002|Overall Study|Protocol Violation|0
6333878|NCT03098979|10083127|FG003|Overall Study|Protocol Violation|0
6333879|NCT03098979|10083128|FG004|Overall Study|Protocol Violation|0
6333880|NCT03098979|10083129|FG005|Overall Study|Protocol Violation|1
6333881|NCT03099096|10083143|FG000|Overall Study|Adverse Event|1
6333882|NCT03099096|10083143|FG000|Overall Study|Physician Decision|1
6333883|NCT03099161|10083150|FG000|Overall Study|Adverse Event|0
6333884|NCT03099161|10083151|FG001|Overall Study|Adverse Event|0
6333885|NCT03099161|10083152|FG002|Overall Study|Adverse Event|2
6333886|NCT03099161|10083150|FG000|Overall Study|Physician Decision|2
6333887|NCT03099161|10083151|FG001|Overall Study|Physician Decision|0
6333888|NCT03099161|10083152|FG002|Overall Study|Physician Decision|0
6333889|NCT03099161|10083150|FG000|Overall Study|Progressive Disease|1
6333890|NCT03099161|10083151|FG001|Overall Study|Progressive Disease|4
6333891|NCT03099161|10083152|FG002|Overall Study|Progressive Disease|1
6333892|NCT03099187|10083162|FG000|Double-blind Treatment|Adverse Event|19
6333893|NCT03099187|10083163|FG001|Double-blind Treatment|Adverse Event|1
6333894|NCT03099187|10083164|FG002|Double-blind Treatment|Adverse Event|0
6333895|NCT03099187|10083165|FG003|Double-blind Treatment|Adverse Event|0
6333896|NCT03099187|10083162|FG000|Double-blind Treatment|Death|1
6333897|NCT03099187|10083163|FG001|Double-blind Treatment|Death|3
6333898|NCT03099187|10083164|FG002|Double-blind Treatment|Death|0
6333899|NCT03099187|10083165|FG003|Double-blind Treatment|Death|0
6333900|NCT03099187|10083162|FG000|Double-blind Treatment|Lack of Efficacy|1
6333901|NCT03099187|10083163|FG001|Double-blind Treatment|Lack of Efficacy|0
6333902|NCT03099187|10083164|FG002|Double-blind Treatment|Lack of Efficacy|0
6333903|NCT03099187|10083165|FG003|Double-blind Treatment|Lack of Efficacy|0
6333904|NCT03099187|10083162|FG000|Double-blind Treatment|Physician Decision|2
6333905|NCT03099187|10083163|FG001|Double-blind Treatment|Physician Decision|1
6333906|NCT03099187|10083164|FG002|Double-blind Treatment|Physician Decision|0
6333907|NCT03099187|10083165|FG003|Double-blind Treatment|Physician Decision|0
6333908|NCT03099187|10083162|FG000|Double-blind Treatment|Withdrawal by Subject|9
6333909|NCT03099187|10083163|FG001|Double-blind Treatment|Withdrawal by Subject|4
6333910|NCT03099187|10083164|FG002|Double-blind Treatment|Withdrawal by Subject|0
6333911|NCT03099187|10083165|FG003|Double-blind Treatment|Withdrawal by Subject|0
6333912|NCT03099187|10083162|FG000|Double-blind Treatment|Lung transplantation|0
6333913|NCT03099187|10083163|FG001|Double-blind Treatment|Lung transplantation|1
6333914|NCT03099187|10083164|FG002|Double-blind Treatment|Lung transplantation|0
6333915|NCT03099187|10083165|FG003|Double-blind Treatment|Lung transplantation|0
6333916|NCT03099187|10083162|FG000|Double-blind Treatment|Non-compliance with study drug|0
6333917|NCT03099187|10083163|FG001|Double-blind Treatment|Non-compliance with study drug|2
6333918|NCT03099187|10083164|FG002|Double-blind Treatment|Non-compliance with study drug|0
6333919|NCT03099187|10083165|FG003|Double-blind Treatment|Non-compliance with study drug|0
6333920|NCT03099187|10083162|FG000|Double-blind Treatment|Disease progression|0
6333921|NCT03099187|10083163|FG001|Double-blind Treatment|Disease progression|1
6333922|NCT03099187|10083164|FG002|Double-blind Treatment|Disease progression|0
6333923|NCT03099187|10083165|FG003|Double-blind Treatment|Disease progression|0
6333924|NCT03099187|10083162|FG000|Double-blind Treatment|Randomization error|0
6333925|NCT03099187|10083163|FG001|Double-blind Treatment|Randomization error|2
6167485|NCT01227902|9812016|FG003|Overall Study|Withdrawal by Subject|3
6167486|NCT01227928|9812029|FG000|Overall Study|Lost to Follow-up|4
6333926|NCT03099187|10083164|FG002|Double-blind Treatment|Randomization error|0
6167487|NCT01227928|9812030|FG001|Overall Study|Lost to Follow-up|2
6333927|NCT03099187|10083165|FG003|Double-blind Treatment|Randomization error|0
6333928|NCT03099187|10083162|FG000|Double-blind Treatment|Non-compliance with Protocol procedure|1
6333929|NCT03099187|10083163|FG001|Double-blind Treatment|Non-compliance with Protocol procedure|1
6333930|NCT03099187|10083164|FG002|Double-blind Treatment|Non-compliance with Protocol procedure|0
6082879|NCT00631969|9691015|FG001|Overall Study|Lack of Efficacy|8
6082880|NCT00631969|9691014|FG000|Overall Study|Lost to Follow-up|2
6167488|NCT01227928|9812029|FG000|Overall Study|Withdrawal by Subject|4
6167489|NCT01227928|9812030|FG001|Overall Study|Withdrawal by Subject|3
6167490|NCT01227928|9812029|FG000|Overall Study|Death|14
6167491|NCT01227928|9812030|FG001|Overall Study|Death|12
6167492|NCT01227954|9812036|FG000|Overall Study|Protocol Violation|6
6167493|NCT01227954|9812036|FG000|Overall Study|No protocol treatment|7
6167494|NCT01227967|9812042|FG000|Overall Study|Protocol Violation|3
6167495|NCT01227967|9812043|FG001|Overall Study|Protocol Violation|1
6167496|NCT01227967|9812042|FG000|Overall Study|Death|0
6167497|NCT01227967|9812043|FG001|Overall Study|Death|1
6167498|NCT01227967|9812042|FG000|Overall Study|Lost to Follow-up|8
6167499|NCT01227967|9812043|FG001|Overall Study|Lost to Follow-up|3
6167500|NCT01227967|9812042|FG000|Overall Study|Withdrawal by Subject|4
6167501|NCT01227967|9812043|FG001|Overall Study|Withdrawal by Subject|3
6167502|NCT01227967|9812042|FG000|Overall Study|Physician Decision|0
6333931|NCT03099187|10083165|FG003|Double-blind Treatment|Non-compliance with Protocol procedure|0
6333932|NCT03099187|10083162|FG000|12-month Safety Follow-up|Adverse Event|0
6333933|NCT03099187|10083163|FG001|12-month Safety Follow-up|Adverse Event|0
6333934|NCT03099187|10083164|FG002|12-month Safety Follow-up|Adverse Event|5
6333935|NCT03099187|10083165|FG003|12-month Safety Follow-up|Adverse Event|12
6333936|NCT03099187|10083162|FG000|12-month Safety Follow-up|Death|0
6333937|NCT03099187|10083163|FG001|12-month Safety Follow-up|Death|0
6333938|NCT03099187|10083164|FG002|12-month Safety Follow-up|Death|7
6333939|NCT03099187|10083165|FG003|12-month Safety Follow-up|Death|9
6082881|NCT00631969|9691015|FG001|Overall Study|Lost to Follow-up|1
6082882|NCT00631969|9691014|FG000|Overall Study|Protocol Violation|1
6167503|NCT01227967|9812043|FG001|Overall Study|Physician Decision|1
6167504|NCT01227967|9812042|FG000|Overall Study|Never Started Treatment|0
6167505|NCT01227967|9812043|FG001|Overall Study|Never Started Treatment|4
6167506|NCT01227967|9812042|FG000|Overall Study|Taking Additional Antiviral Drug|1
6167507|NCT01227967|9812043|FG001|Overall Study|Taking Additional Antiviral Drug|0
6167508|NCT01228019|9812062|FG000|Overall Study|Dose Violation|70
6167509|NCT01228019|9812062|FG000|Overall Study|Duplicate enrollment|1
6167510|NCT01228019|9812062|FG000|Overall Study|Missing pre-treatment data|72
6167511|NCT01228019|9812062|FG000|Overall Study|Triglyceride Entry Criteria Not Met|152
6167512|NCT01228019|9812062|FG000|Overall Study|Violation of Entry Criterion|9
6167513|NCT01228071|9812066|FG000|Overall Study|Protocol Violation|1
6167514|NCT01228071|9812066|FG000|Overall Study|Withdrawal by Subject|1
6167515|NCT01228175|9812088|FG000|Overall Study|Lost to Follow-up|64
6167516|NCT01228175|9812089|FG001|Overall Study|Lost to Follow-up|50
6167517|NCT01228175|9812088|FG000|Overall Study|Withdrawal by Subject|1
6167518|NCT01228175|9812089|FG001|Overall Study|Withdrawal by Subject|2
6167519|NCT01228175|9812088|FG000|Overall Study|Physician Decision|1
6167520|NCT01228175|9812089|FG001|Overall Study|Physician Decision|1
6167521|NCT01228318|9812097|FG000|Overall Study|Clinic no show to receive intervention|1
6167522|NCT01228318|9812098|FG001|Overall Study|Clinic no show to receive intervention|0
6167523|NCT01228318|9812097|FG000|Overall Study|Unable to contact|2
6167524|NCT01228318|9812098|FG001|Overall Study|Unable to contact|5
6167525|NCT01228318|9812097|FG000|Overall Study|Moved|0
6167526|NCT01228318|9812098|FG001|Overall Study|Moved|2
6167527|NCT01228318|9812097|FG000|Overall Study|Incarcerated|1
6167528|NCT01228318|9812098|FG001|Overall Study|Incarcerated|0
6167529|NCT01228591|9812113|FG000|Baseline|Lack of Efficacy|1
6167530|NCT01228591|9812114|FG001|Baseline|Lack of Efficacy|2
6167531|NCT01228734|9812126|FG000|Overall Study|Randomized, but not treated|0
6167532|NCT01228734|9812127|FG001|Overall Study|Randomized, but not treated|4
6167533|NCT01228747|9812135|FG000|Overall Study|Adverse Event|8
6167534|NCT01228747|9812136|FG001|Overall Study|Adverse Event|4
6167535|NCT01228747|9812135|FG000|Overall Study|Lack of Efficacy|40
6167536|NCT01228747|9812136|FG001|Overall Study|Lack of Efficacy|27
6167537|NCT01228747|9812135|FG000|Overall Study|Protocol Violation|6
6167538|NCT01228747|9812136|FG001|Overall Study|Protocol Violation|5
6167539|NCT01228747|9812135|FG000|Overall Study|Lost to Follow-up|4
6167540|NCT01228747|9812136|FG001|Overall Study|Lost to Follow-up|3
6167541|NCT01228747|9812135|FG000|Overall Study|Withdrawal by Subject|5
6167542|NCT01228747|9812136|FG001|Overall Study|Withdrawal by Subject|1
6167543|NCT01228747|9812135|FG000|Overall Study|Other Reason|2
6167544|NCT01228747|9812136|FG001|Overall Study|Other Reason|5
6167545|NCT01229111|9812168|FG000|Overall Study|Death|1
6333940|NCT03099187|10083162|FG000|12-month Safety Follow-up|Lung transplantation|0
6333941|NCT03099187|10083163|FG001|12-month Safety Follow-up|Lung transplantation|0
6167546|NCT01229150|9812176|FG000|Overall Study|Toxicity|2
6167547|NCT01229150|9812177|FG001|Overall Study|Toxicity|2
6167548|NCT01229150|9812178|FG002|Overall Study|Toxicity|0
6167549|NCT01229150|9812179|FG003|Overall Study|Toxicity|0
6167550|NCT01229176|9812201|FG000|Overall Study|Withdrawal by Subject|0
6167551|NCT01229176|9812202|FG001|Overall Study|Withdrawal by Subject|0
6167552|NCT01229176|9812203|FG002|Overall Study|Withdrawal by Subject|0
6333942|NCT03099187|10083164|FG002|12-month Safety Follow-up|Lung transplantation|2
6333943|NCT03099187|10083165|FG003|12-month Safety Follow-up|Lung transplantation|1
6333944|NCT03099187|10083162|FG000|12-month Safety Follow-up|Lost to Follow-up|0
6333945|NCT03099187|10083163|FG001|12-month Safety Follow-up|Lost to Follow-up|0
6333946|NCT03099187|10083164|FG002|12-month Safety Follow-up|Lost to Follow-up|1
6333947|NCT03099187|10083165|FG003|12-month Safety Follow-up|Lost to Follow-up|0
6333948|NCT03099187|10083162|FG000|12-month Safety Follow-up|Symptomatic deterioration|0
6333949|NCT03099187|10083163|FG001|12-month Safety Follow-up|Symptomatic deterioration|0
6333950|NCT03099187|10083164|FG002|12-month Safety Follow-up|Symptomatic deterioration|1
6333951|NCT03099187|10083165|FG003|12-month Safety Follow-up|Symptomatic deterioration|1
6333952|NCT03099187|10083162|FG000|12-month Safety Follow-up|Withdrawal by Subject|0
6333953|NCT03099187|10083163|FG001|12-month Safety Follow-up|Withdrawal by Subject|0
6333954|NCT03099187|10083164|FG002|12-month Safety Follow-up|Withdrawal by Subject|3
6333955|NCT03099187|10083165|FG003|12-month Safety Follow-up|Withdrawal by Subject|2
6333956|NCT03099187|10083162|FG000|12-month Safety Follow-up|Due to hospitalization|0
6333957|NCT03099187|10083163|FG001|12-month Safety Follow-up|Due to hospitalization|0
6333958|NCT03099187|10083164|FG002|12-month Safety Follow-up|Due to hospitalization|0
6333959|NCT03099187|10083165|FG003|12-month Safety Follow-up|Due to hospitalization|1
6333960|NCT03099538|10083185|FG000|Overall Study|Lack of Efficacy|3
6082883|NCT00631969|9691015|FG001|Overall Study|Protocol Violation|1
6167553|NCT01229176|9812204|FG003|Overall Study|Withdrawal by Subject|1
6167554|NCT01229176|9812205|FG004|Overall Study|Withdrawal by Subject|1
6167555|NCT01229176|9812206|FG005|Overall Study|Withdrawal by Subject|1
6167556|NCT01229176|9812207|FG006|Overall Study|Withdrawal by Subject|0
6167557|NCT01229176|9812208|FG007|Overall Study|Withdrawal by Subject|1
6167558|NCT01229176|9812201|FG000|Overall Study|Lost to Follow-up|0
6167559|NCT01229176|9812202|FG001|Overall Study|Lost to Follow-up|3
6167560|NCT01229176|9812203|FG002|Overall Study|Lost to Follow-up|0
6167561|NCT01229176|9812204|FG003|Overall Study|Lost to Follow-up|0
6167562|NCT01229176|9812205|FG004|Overall Study|Lost to Follow-up|1
6333961|NCT03099694|10083198|FG000|Overall Study|Withdrawal by Subject|11
6333962|NCT03099694|10083199|FG001|Overall Study|Withdrawal by Subject|13
6333963|NCT03099694|10083198|FG000|Overall Study|Lost to Follow-up|9
6333964|NCT03099694|10083199|FG001|Overall Study|Lost to Follow-up|5
6333965|NCT03100058|10083215|FG000|Epoch 3 (24 Weeks of Treatment)|Adverse Event|0
6333966|NCT03100058|10083216|FG001|Epoch 3 (24 Weeks of Treatment)|Adverse Event|0
6333967|NCT03100058|10083217|FG002|Epoch 3 (24 Weeks of Treatment)|Adverse Event|4
6333968|NCT03100058|10083218|FG003|Epoch 3 (24 Weeks of Treatment)|Adverse Event|8
6333969|NCT03100058|10083219|FG004|Epoch 3 (24 Weeks of Treatment)|Adverse Event|1
6333970|NCT03100058|10083220|FG005|Epoch 3 (24 Weeks of Treatment)|Adverse Event|0
6333971|NCT03100058|10083221|FG006|Epoch 3 (24 Weeks of Treatment)|Adverse Event|3
6333972|NCT03100058|10083222|FG007|Epoch 3 (24 Weeks of Treatment)|Adverse Event|11
6333973|NCT03100058|10083223|FG008|Epoch 3 (24 Weeks of Treatment)|Adverse Event|2
6333974|NCT03100058|10083224|FG009|Epoch 3 (24 Weeks of Treatment)|Adverse Event|0
6333975|NCT03100058|10083225|FG010|Epoch 3 (24 Weeks of Treatment)|Adverse Event|0
6333976|NCT03100058|10083226|FG011|Epoch 3 (24 Weeks of Treatment)|Adverse Event|0
6333977|NCT03100058|10083227|FG012|Epoch 3 (24 Weeks of Treatment)|Adverse Event|0
6333978|NCT03100058|10083215|FG000|Epoch 3 (24 Weeks of Treatment)|Withdrawal by Subject|2
6333979|NCT03100058|10083216|FG001|Epoch 3 (24 Weeks of Treatment)|Withdrawal by Subject|4
6333980|NCT03100058|10083217|FG002|Epoch 3 (24 Weeks of Treatment)|Withdrawal by Subject|3
6333981|NCT03100058|10083218|FG003|Epoch 3 (24 Weeks of Treatment)|Withdrawal by Subject|4
6333982|NCT03100058|10083219|FG004|Epoch 3 (24 Weeks of Treatment)|Withdrawal by Subject|1
6333983|NCT03100058|10083220|FG005|Epoch 3 (24 Weeks of Treatment)|Withdrawal by Subject|1
6333984|NCT03100058|10083221|FG006|Epoch 3 (24 Weeks of Treatment)|Withdrawal by Subject|1
6042877|NCT00385736|9641357|FG001|Efficacy Analysis Set - Maintenance|Lack of Efficacy|16
6042878|NCT00385736|9641358|FG002|Efficacy Analysis Set - Maintenance|Lack of Efficacy|31
6049024|NCT00420927|9648201|FG002|Period 2|Methotrexate intolerance|0
6167563|NCT01229176|9812206|FG005|Overall Study|Lost to Follow-up|1
6167564|NCT01229176|9812207|FG006|Overall Study|Lost to Follow-up|0
6167565|NCT01229176|9812208|FG007|Overall Study|Lost to Follow-up|2
6167566|NCT01229254|9812250|FG000|Overall Study|Not Continuing Into Safety Extension|3
6167567|NCT01229254|9812251|FG001|Overall Study|Not Continuing Into Safety Extension|1
6167568|NCT01229254|9812252|FG002|Overall Study|Not Continuing Into Safety Extension|1
6167569|NCT01229254|9812250|FG000|Overall Study|Adverse Event|4
6167570|NCT01229254|9812251|FG001|Overall Study|Adverse Event|5
6167571|NCT01229254|9812252|FG002|Overall Study|Adverse Event|3
6167572|NCT01229254|9812250|FG000|Overall Study|Lost to Follow-up|3
6167573|NCT01229254|9812251|FG001|Overall Study|Lost to Follow-up|0
6167574|NCT01229254|9812252|FG002|Overall Study|Lost to Follow-up|1
6167575|NCT01229254|9812250|FG000|Overall Study|Physician Decision|0
6167576|NCT01229254|9812251|FG001|Overall Study|Physician Decision|3
6167577|NCT01229254|9812252|FG002|Overall Study|Physician Decision|0
6167578|NCT01229254|9812250|FG000|Overall Study|Protocol Violation|4
6167579|NCT01229254|9812251|FG001|Overall Study|Protocol Violation|6
6167580|NCT01229254|9812252|FG002|Overall Study|Protocol Violation|5
6167581|NCT01229254|9812250|FG000|Overall Study|Withdrawal by Subject|1
6167582|NCT01229254|9812251|FG001|Overall Study|Withdrawal by Subject|0
6167583|NCT01229254|9812252|FG002|Overall Study|Withdrawal by Subject|1
6167584|NCT01229254|9812250|FG000|Overall Study|Non-compliance with Study Drug|0
6167585|NCT01229254|9812251|FG001|Overall Study|Non-compliance with Study Drug|1
6167586|NCT01229254|9812252|FG002|Overall Study|Non-compliance with Study Drug|1
6167587|NCT01229267|9812266|FG000|Overall Study|Adverse Event|4
6167588|NCT01229267|9812267|FG001|Overall Study|Adverse Event|6
6167589|NCT01229267|9812268|FG002|Overall Study|Adverse Event|3
6167590|NCT01229267|9812269|FG003|Overall Study|Adverse Event|2
6167591|NCT01229267|9812270|FG004|Overall Study|Adverse Event|10
6167592|NCT01229267|9812266|FG000|Overall Study|Death|40
6167593|NCT01229267|9812267|FG001|Overall Study|Death|37
6167594|NCT01229267|9812268|FG002|Overall Study|Death|35
6167595|NCT01229267|9812269|FG003|Overall Study|Death|13
6167596|NCT01229267|9812270|FG004|Overall Study|Death|103
6167597|NCT01229267|9812266|FG000|Overall Study|Withdrawal by Subject|23
6167598|NCT01229267|9812267|FG001|Overall Study|Withdrawal by Subject|22
6167599|NCT01229267|9812268|FG002|Overall Study|Withdrawal by Subject|32
6167600|NCT01229267|9812269|FG003|Overall Study|Withdrawal by Subject|14
6167601|NCT01229267|9812270|FG004|Overall Study|Withdrawal by Subject|59
6167602|NCT01229267|9812266|FG000|Overall Study|Protocol Violation|0
6167603|NCT01229267|9812267|FG001|Overall Study|Protocol Violation|1
6167604|NCT01229267|9812268|FG002|Overall Study|Protocol Violation|0
6333985|NCT03100058|10083222|FG007|Epoch 3 (24 Weeks of Treatment)|Withdrawal by Subject|4
6333986|NCT03100058|10083223|FG008|Epoch 3 (24 Weeks of Treatment)|Withdrawal by Subject|2
6167605|NCT01229267|9812269|FG003|Overall Study|Protocol Violation|0
6167606|NCT01229267|9812270|FG004|Overall Study|Protocol Violation|0
6167607|NCT01229267|9812266|FG000|Overall Study|Progressive disease|0
6167608|NCT01229267|9812267|FG001|Overall Study|Progressive disease|0
6167609|NCT01229267|9812268|FG002|Overall Study|Progressive disease|0
6167610|NCT01229267|9812269|FG003|Overall Study|Progressive disease|0
6167611|NCT01229267|9812270|FG004|Overall Study|Progressive disease|1
6333987|NCT03100058|10083224|FG009|Epoch 3 (24 Weeks of Treatment)|Withdrawal by Subject|0
6333988|NCT03100058|10083225|FG010|Epoch 3 (24 Weeks of Treatment)|Withdrawal by Subject|0
6333989|NCT03100058|10083226|FG011|Epoch 3 (24 Weeks of Treatment)|Withdrawal by Subject|0
6333990|NCT03100058|10083227|FG012|Epoch 3 (24 Weeks of Treatment)|Withdrawal by Subject|0
6333991|NCT03100058|10083215|FG000|Epoch 3 (24 Weeks of Treatment)|Non-compliance with study treatment|0
6333992|NCT03100058|10083216|FG001|Epoch 3 (24 Weeks of Treatment)|Non-compliance with study treatment|1
6333993|NCT03100058|10083217|FG002|Epoch 3 (24 Weeks of Treatment)|Non-compliance with study treatment|1
6333994|NCT03100058|10083218|FG003|Epoch 3 (24 Weeks of Treatment)|Non-compliance with study treatment|0
6333995|NCT03100058|10083219|FG004|Epoch 3 (24 Weeks of Treatment)|Non-compliance with study treatment|0
6333996|NCT03100058|10083220|FG005|Epoch 3 (24 Weeks of Treatment)|Non-compliance with study treatment|1
6333997|NCT03100058|10083221|FG006|Epoch 3 (24 Weeks of Treatment)|Non-compliance with study treatment|1
6333998|NCT03100058|10083222|FG007|Epoch 3 (24 Weeks of Treatment)|Non-compliance with study treatment|0
6333999|NCT03100058|10083223|FG008|Epoch 3 (24 Weeks of Treatment)|Non-compliance with study treatment|0
6334000|NCT03100058|10083224|FG009|Epoch 3 (24 Weeks of Treatment)|Non-compliance with study treatment|0
6334001|NCT03100058|10083225|FG010|Epoch 3 (24 Weeks of Treatment)|Non-compliance with study treatment|0
6334002|NCT03100058|10083226|FG011|Epoch 3 (24 Weeks of Treatment)|Non-compliance with study treatment|0
6334003|NCT03100058|10083227|FG012|Epoch 3 (24 Weeks of Treatment)|Non-compliance with study treatment|0
6334004|NCT03100058|10083215|FG000|Epoch 3 (24 Weeks of Treatment)|Lost to Follow-up|0
6334005|NCT03100058|10083216|FG001|Epoch 3 (24 Weeks of Treatment)|Lost to Follow-up|1
6334006|NCT03100058|10083217|FG002|Epoch 3 (24 Weeks of Treatment)|Lost to Follow-up|1
6334007|NCT03100058|10083218|FG003|Epoch 3 (24 Weeks of Treatment)|Lost to Follow-up|0
6334008|NCT03100058|10083219|FG004|Epoch 3 (24 Weeks of Treatment)|Lost to Follow-up|0
6334009|NCT03100058|10083220|FG005|Epoch 3 (24 Weeks of Treatment)|Lost to Follow-up|0
6334010|NCT03100058|10083221|FG006|Epoch 3 (24 Weeks of Treatment)|Lost to Follow-up|1
6334011|NCT03100058|10083222|FG007|Epoch 3 (24 Weeks of Treatment)|Lost to Follow-up|0
6334012|NCT03100058|10083223|FG008|Epoch 3 (24 Weeks of Treatment)|Lost to Follow-up|1
6334013|NCT03100058|10083224|FG009|Epoch 3 (24 Weeks of Treatment)|Lost to Follow-up|0
6334014|NCT03100058|10083225|FG010|Epoch 3 (24 Weeks of Treatment)|Lost to Follow-up|0
6334015|NCT03100058|10083226|FG011|Epoch 3 (24 Weeks of Treatment)|Lost to Follow-up|0
6334016|NCT03100058|10083227|FG012|Epoch 3 (24 Weeks of Treatment)|Lost to Follow-up|0
6334017|NCT03100058|10083215|FG000|Epoch 3 (24 Weeks of Treatment)|Physician Decision|0
6334018|NCT03100058|10083216|FG001|Epoch 3 (24 Weeks of Treatment)|Physician Decision|0
6334019|NCT03100058|10083217|FG002|Epoch 3 (24 Weeks of Treatment)|Physician Decision|0
6334020|NCT03100058|10083218|FG003|Epoch 3 (24 Weeks of Treatment)|Physician Decision|1
6334021|NCT03100058|10083219|FG004|Epoch 3 (24 Weeks of Treatment)|Physician Decision|0
6334022|NCT03100058|10083220|FG005|Epoch 3 (24 Weeks of Treatment)|Physician Decision|0
6334023|NCT03100058|10083221|FG006|Epoch 3 (24 Weeks of Treatment)|Physician Decision|0
6334024|NCT03100058|10083222|FG007|Epoch 3 (24 Weeks of Treatment)|Physician Decision|1
6334025|NCT03100058|10083223|FG008|Epoch 3 (24 Weeks of Treatment)|Physician Decision|0
6334026|NCT03100058|10083224|FG009|Epoch 3 (24 Weeks of Treatment)|Physician Decision|0
6334027|NCT03100058|10083225|FG010|Epoch 3 (24 Weeks of Treatment)|Physician Decision|0
6334028|NCT03100058|10083226|FG011|Epoch 3 (24 Weeks of Treatment)|Physician Decision|0
6334029|NCT03100058|10083227|FG012|Epoch 3 (24 Weeks of Treatment)|Physician Decision|0
6334030|NCT03100058|10083215|FG000|Epoch 3 (24 Weeks of Treatment)|Protocol Violation|0
6334031|NCT03100058|10083216|FG001|Epoch 3 (24 Weeks of Treatment)|Protocol Violation|0
6334032|NCT03100058|10083217|FG002|Epoch 3 (24 Weeks of Treatment)|Protocol Violation|0
6334033|NCT03100058|10083218|FG003|Epoch 3 (24 Weeks of Treatment)|Protocol Violation|1
6334034|NCT03100058|10083219|FG004|Epoch 3 (24 Weeks of Treatment)|Protocol Violation|0
6334035|NCT03100058|10083220|FG005|Epoch 3 (24 Weeks of Treatment)|Protocol Violation|0
6334036|NCT03100058|10083221|FG006|Epoch 3 (24 Weeks of Treatment)|Protocol Violation|1
6334037|NCT03100058|10083222|FG007|Epoch 3 (24 Weeks of Treatment)|Protocol Violation|0
6334038|NCT03100058|10083223|FG008|Epoch 3 (24 Weeks of Treatment)|Protocol Violation|0
6334039|NCT03100058|10083224|FG009|Epoch 3 (24 Weeks of Treatment)|Protocol Violation|0
6334040|NCT03100058|10083225|FG010|Epoch 3 (24 Weeks of Treatment)|Protocol Violation|0
6334041|NCT03100058|10083226|FG011|Epoch 3 (24 Weeks of Treatment)|Protocol Violation|0
6334042|NCT03100058|10083227|FG012|Epoch 3 (24 Weeks of Treatment)|Protocol Violation|0
6334043|NCT03100058|10083215|FG000|Epoch 3 (24 Weeks of Treatment)|Death|0
6334044|NCT03100058|10083216|FG001|Epoch 3 (24 Weeks of Treatment)|Death|1
6334045|NCT03100058|10083217|FG002|Epoch 3 (24 Weeks of Treatment)|Death|0
6334046|NCT03100058|10083218|FG003|Epoch 3 (24 Weeks of Treatment)|Death|0
6334047|NCT03100058|10083219|FG004|Epoch 3 (24 Weeks of Treatment)|Death|0
6334048|NCT03100058|10083220|FG005|Epoch 3 (24 Weeks of Treatment)|Death|0
6334049|NCT03100058|10083221|FG006|Epoch 3 (24 Weeks of Treatment)|Death|0
6334050|NCT03100058|10083222|FG007|Epoch 3 (24 Weeks of Treatment)|Death|0
6334051|NCT03100058|10083223|FG008|Epoch 3 (24 Weeks of Treatment)|Death|0
6334052|NCT03100058|10083224|FG009|Epoch 3 (24 Weeks of Treatment)|Death|0
6334053|NCT03100058|10083225|FG010|Epoch 3 (24 Weeks of Treatment)|Death|0
6334054|NCT03100058|10083226|FG011|Epoch 3 (24 Weeks of Treatment)|Death|0
6334055|NCT03100058|10083227|FG012|Epoch 3 (24 Weeks of Treatment)|Death|0
6334056|NCT03100058|10083215|FG000|Epoch 3 (24 Weeks of Treatment)|Pregnancy|1
6334057|NCT03100058|10083216|FG001|Epoch 3 (24 Weeks of Treatment)|Pregnancy|0
6334058|NCT03100058|10083217|FG002|Epoch 3 (24 Weeks of Treatment)|Pregnancy|0
6334059|NCT03100058|10083218|FG003|Epoch 3 (24 Weeks of Treatment)|Pregnancy|0
6334060|NCT03100058|10083219|FG004|Epoch 3 (24 Weeks of Treatment)|Pregnancy|0
6334061|NCT03100058|10083220|FG005|Epoch 3 (24 Weeks of Treatment)|Pregnancy|0
6334062|NCT03100058|10083221|FG006|Epoch 3 (24 Weeks of Treatment)|Pregnancy|0
6334063|NCT03100058|10083222|FG007|Epoch 3 (24 Weeks of Treatment)|Pregnancy|0
6334064|NCT03100058|10083223|FG008|Epoch 3 (24 Weeks of Treatment)|Pregnancy|0
6334065|NCT03100058|10083224|FG009|Epoch 3 (24 Weeks of Treatment)|Pregnancy|0
6334066|NCT03100058|10083225|FG010|Epoch 3 (24 Weeks of Treatment)|Pregnancy|0
6334067|NCT03100058|10083226|FG011|Epoch 3 (24 Weeks of Treatment)|Pregnancy|0
6334068|NCT03100058|10083227|FG012|Epoch 3 (24 Weeks of Treatment)|Pregnancy|0
6334069|NCT03100058|10083215|FG000|Epoch 3 (24 Weeks of Treatment)|Lack of Efficacy|0
6334070|NCT03100058|10083216|FG001|Epoch 3 (24 Weeks of Treatment)|Lack of Efficacy|0
6334071|NCT03100058|10083217|FG002|Epoch 3 (24 Weeks of Treatment)|Lack of Efficacy|0
6334072|NCT03100058|10083218|FG003|Epoch 3 (24 Weeks of Treatment)|Lack of Efficacy|0
6334073|NCT03100058|10083219|FG004|Epoch 3 (24 Weeks of Treatment)|Lack of Efficacy|0
6334074|NCT03100058|10083220|FG005|Epoch 3 (24 Weeks of Treatment)|Lack of Efficacy|0
6334075|NCT03100058|10083221|FG006|Epoch 3 (24 Weeks of Treatment)|Lack of Efficacy|1
6334076|NCT03100058|10083222|FG007|Epoch 3 (24 Weeks of Treatment)|Lack of Efficacy|0
6334077|NCT03100058|10083223|FG008|Epoch 3 (24 Weeks of Treatment)|Lack of Efficacy|0
6334078|NCT03100058|10083224|FG009|Epoch 3 (24 Weeks of Treatment)|Lack of Efficacy|0
6334079|NCT03100058|10083225|FG010|Epoch 3 (24 Weeks of Treatment)|Lack of Efficacy|0
6334080|NCT03100058|10083226|FG011|Epoch 3 (24 Weeks of Treatment)|Lack of Efficacy|0
6334081|NCT03100058|10083227|FG012|Epoch 3 (24 Weeks of Treatment)|Lack of Efficacy|0
6334082|NCT03100058|10083215|FG000|Epoch 4 (Last 24 Weeks of the Study)|Withdrawal by Subject|0
6334083|NCT03100058|10083216|FG001|Epoch 4 (Last 24 Weeks of the Study)|Withdrawal by Subject|0
6334084|NCT03100058|10083217|FG002|Epoch 4 (Last 24 Weeks of the Study)|Withdrawal by Subject|0
6334085|NCT03100058|10083218|FG003|Epoch 4 (Last 24 Weeks of the Study)|Withdrawal by Subject|0
6334086|NCT03100058|10083219|FG004|Epoch 4 (Last 24 Weeks of the Study)|Withdrawal by Subject|0
6334087|NCT03100058|10083220|FG005|Epoch 4 (Last 24 Weeks of the Study)|Withdrawal by Subject|0
6334088|NCT03100058|10083221|FG006|Epoch 4 (Last 24 Weeks of the Study)|Withdrawal by Subject|0
6334089|NCT03100058|10083222|FG007|Epoch 4 (Last 24 Weeks of the Study)|Withdrawal by Subject|0
6334090|NCT03100058|10083223|FG008|Epoch 4 (Last 24 Weeks of the Study)|Withdrawal by Subject|0
6334091|NCT03100058|10083224|FG009|Epoch 4 (Last 24 Weeks of the Study)|Withdrawal by Subject|0
6334092|NCT03100058|10083225|FG010|Epoch 4 (Last 24 Weeks of the Study)|Withdrawal by Subject|4
6334093|NCT03100058|10083226|FG011|Epoch 4 (Last 24 Weeks of the Study)|Withdrawal by Subject|2
6334094|NCT03100058|10083227|FG012|Epoch 4 (Last 24 Weeks of the Study)|Withdrawal by Subject|1
6334095|NCT03100058|10083215|FG000|Epoch 4 (Last 24 Weeks of the Study)|Lost to Follow-up|0
6334096|NCT03100058|10083216|FG001|Epoch 4 (Last 24 Weeks of the Study)|Lost to Follow-up|0
6334097|NCT03100058|10083217|FG002|Epoch 4 (Last 24 Weeks of the Study)|Lost to Follow-up|0
6334098|NCT03100058|10083218|FG003|Epoch 4 (Last 24 Weeks of the Study)|Lost to Follow-up|0
6334099|NCT03100058|10083219|FG004|Epoch 4 (Last 24 Weeks of the Study)|Lost to Follow-up|0
6334100|NCT03100058|10083220|FG005|Epoch 4 (Last 24 Weeks of the Study)|Lost to Follow-up|0
6334101|NCT03100058|10083221|FG006|Epoch 4 (Last 24 Weeks of the Study)|Lost to Follow-up|0
6334102|NCT03100058|10083222|FG007|Epoch 4 (Last 24 Weeks of the Study)|Lost to Follow-up|0
6334103|NCT03100058|10083223|FG008|Epoch 4 (Last 24 Weeks of the Study)|Lost to Follow-up|0
6334104|NCT03100058|10083224|FG009|Epoch 4 (Last 24 Weeks of the Study)|Lost to Follow-up|0
6334105|NCT03100058|10083225|FG010|Epoch 4 (Last 24 Weeks of the Study)|Lost to Follow-up|3
6334106|NCT03100058|10083226|FG011|Epoch 4 (Last 24 Weeks of the Study)|Lost to Follow-up|1
6334107|NCT03100058|10083227|FG012|Epoch 4 (Last 24 Weeks of the Study)|Lost to Follow-up|0
6334108|NCT03100058|10083215|FG000|Epoch 4 (Last 24 Weeks of the Study)|Adverse Event|0
6334109|NCT03100058|10083216|FG001|Epoch 4 (Last 24 Weeks of the Study)|Adverse Event|0
6334110|NCT03100058|10083217|FG002|Epoch 4 (Last 24 Weeks of the Study)|Adverse Event|0
6334111|NCT03100058|10083218|FG003|Epoch 4 (Last 24 Weeks of the Study)|Adverse Event|0
6334112|NCT03100058|10083219|FG004|Epoch 4 (Last 24 Weeks of the Study)|Adverse Event|0
6334113|NCT03100058|10083220|FG005|Epoch 4 (Last 24 Weeks of the Study)|Adverse Event|0
6334114|NCT03100058|10083221|FG006|Epoch 4 (Last 24 Weeks of the Study)|Adverse Event|0
6334115|NCT03100058|10083222|FG007|Epoch 4 (Last 24 Weeks of the Study)|Adverse Event|0
6334116|NCT03100058|10083223|FG008|Epoch 4 (Last 24 Weeks of the Study)|Adverse Event|0
6334117|NCT03100058|10083224|FG009|Epoch 4 (Last 24 Weeks of the Study)|Adverse Event|4
6334118|NCT03100058|10083225|FG010|Epoch 4 (Last 24 Weeks of the Study)|Adverse Event|7
6334119|NCT03100058|10083226|FG011|Epoch 4 (Last 24 Weeks of the Study)|Adverse Event|0
6334120|NCT03100058|10083227|FG012|Epoch 4 (Last 24 Weeks of the Study)|Adverse Event|2
6334121|NCT03100058|10083215|FG000|Epoch 4 (Last 24 Weeks of the Study)|Death|0
6334122|NCT03100058|10083216|FG001|Epoch 4 (Last 24 Weeks of the Study)|Death|0
6334123|NCT03100058|10083217|FG002|Epoch 4 (Last 24 Weeks of the Study)|Death|0
6334124|NCT03100058|10083218|FG003|Epoch 4 (Last 24 Weeks of the Study)|Death|0
6334125|NCT03100058|10083219|FG004|Epoch 4 (Last 24 Weeks of the Study)|Death|0
6334126|NCT03100058|10083220|FG005|Epoch 4 (Last 24 Weeks of the Study)|Death|0
6334127|NCT03100058|10083221|FG006|Epoch 4 (Last 24 Weeks of the Study)|Death|0
6334128|NCT03100058|10083222|FG007|Epoch 4 (Last 24 Weeks of the Study)|Death|0
6334129|NCT03100058|10083223|FG008|Epoch 4 (Last 24 Weeks of the Study)|Death|0
6334130|NCT03100058|10083224|FG009|Epoch 4 (Last 24 Weeks of the Study)|Death|0
6334131|NCT03100058|10083225|FG010|Epoch 4 (Last 24 Weeks of the Study)|Death|1
6334132|NCT03100058|10083226|FG011|Epoch 4 (Last 24 Weeks of the Study)|Death|0
6334133|NCT03100058|10083227|FG012|Epoch 4 (Last 24 Weeks of the Study)|Death|0
6334134|NCT03100058|10083215|FG000|Epoch 4 (Last 24 Weeks of the Study)|Pregnancy|0
6334135|NCT03100058|10083216|FG001|Epoch 4 (Last 24 Weeks of the Study)|Pregnancy|0
6334136|NCT03100058|10083217|FG002|Epoch 4 (Last 24 Weeks of the Study)|Pregnancy|0
6334137|NCT03100058|10083218|FG003|Epoch 4 (Last 24 Weeks of the Study)|Pregnancy|0
6334138|NCT03100058|10083219|FG004|Epoch 4 (Last 24 Weeks of the Study)|Pregnancy|0
6334139|NCT03100058|10083220|FG005|Epoch 4 (Last 24 Weeks of the Study)|Pregnancy|0
6334140|NCT03100058|10083221|FG006|Epoch 4 (Last 24 Weeks of the Study)|Pregnancy|0
6334141|NCT03100058|10083222|FG007|Epoch 4 (Last 24 Weeks of the Study)|Pregnancy|0
6334142|NCT03100058|10083223|FG008|Epoch 4 (Last 24 Weeks of the Study)|Pregnancy|0
6334143|NCT03100058|10083224|FG009|Epoch 4 (Last 24 Weeks of the Study)|Pregnancy|0
6334144|NCT03100058|10083225|FG010|Epoch 4 (Last 24 Weeks of the Study)|Pregnancy|0
6334145|NCT03100058|10083226|FG011|Epoch 4 (Last 24 Weeks of the Study)|Pregnancy|0
6334146|NCT03100058|10083227|FG012|Epoch 4 (Last 24 Weeks of the Study)|Pregnancy|1
6334147|NCT03100058|10083215|FG000|Epoch 4 (Last 24 Weeks of the Study)|non-compliance with study treatment|0
6334148|NCT03100058|10083216|FG001|Epoch 4 (Last 24 Weeks of the Study)|non-compliance with study treatment|0
6334149|NCT03100058|10083217|FG002|Epoch 4 (Last 24 Weeks of the Study)|non-compliance with study treatment|0
6334150|NCT03100058|10083218|FG003|Epoch 4 (Last 24 Weeks of the Study)|non-compliance with study treatment|0
6334151|NCT03100058|10083219|FG004|Epoch 4 (Last 24 Weeks of the Study)|non-compliance with study treatment|0
6334152|NCT03100058|10083220|FG005|Epoch 4 (Last 24 Weeks of the Study)|non-compliance with study treatment|0
6334153|NCT03100058|10083221|FG006|Epoch 4 (Last 24 Weeks of the Study)|non-compliance with study treatment|0
6334154|NCT03100058|10083222|FG007|Epoch 4 (Last 24 Weeks of the Study)|non-compliance with study treatment|0
6334155|NCT03100058|10083223|FG008|Epoch 4 (Last 24 Weeks of the Study)|non-compliance with study treatment|0
6334156|NCT03100058|10083224|FG009|Epoch 4 (Last 24 Weeks of the Study)|non-compliance with study treatment|1
6334157|NCT03100058|10083225|FG010|Epoch 4 (Last 24 Weeks of the Study)|non-compliance with study treatment|0
6334158|NCT03100058|10083226|FG011|Epoch 4 (Last 24 Weeks of the Study)|non-compliance with study treatment|0
6334159|NCT03100058|10083227|FG012|Epoch 4 (Last 24 Weeks of the Study)|non-compliance with study treatment|0
6334160|NCT03100344|10083274|FG000|Overall Study|Adverse Event|0
6334161|NCT03100344|10083275|FG001|Overall Study|Adverse Event|3
6334162|NCT03100344|10083276|FG002|Overall Study|Adverse Event|2
6334163|NCT03100344|10083277|FG003|Overall Study|Adverse Event|3
6334164|NCT03100344|10083274|FG000|Overall Study|Lack of Efficacy|2
6334165|NCT03100344|10083275|FG001|Overall Study|Lack of Efficacy|0
6334166|NCT03100344|10083276|FG002|Overall Study|Lack of Efficacy|0
6334167|NCT03100344|10083277|FG003|Overall Study|Lack of Efficacy|0
6334168|NCT03100344|10083274|FG000|Overall Study|Protocol Violation|1
6334169|NCT03100344|10083275|FG001|Overall Study|Protocol Violation|0
6334170|NCT03100344|10083276|FG002|Overall Study|Protocol Violation|0
6334171|NCT03100344|10083277|FG003|Overall Study|Protocol Violation|0
6334172|NCT03100344|10083274|FG000|Overall Study|Withdrawal by Subject|10
6334173|NCT03100344|10083275|FG001|Overall Study|Withdrawal by Subject|7
6334174|NCT03100344|10083276|FG002|Overall Study|Withdrawal by Subject|4
6334175|NCT03100344|10083277|FG003|Overall Study|Withdrawal by Subject|8
6334176|NCT03100344|10083274|FG000|Overall Study|Lost to Follow-up|1
6334177|NCT03100344|10083275|FG001|Overall Study|Lost to Follow-up|1
6167612|NCT01229267|9812266|FG000|Overall Study|Physician Decision|8
6167613|NCT01229267|9812267|FG001|Overall Study|Physician Decision|11
6167614|NCT01229267|9812268|FG002|Overall Study|Physician Decision|8
6167615|NCT01229267|9812269|FG003|Overall Study|Physician Decision|3
6334178|NCT03100344|10083276|FG002|Overall Study|Lost to Follow-up|1
6334179|NCT03100344|10083277|FG003|Overall Study|Lost to Follow-up|1
6334180|NCT03100825|10083292|FG000|Overall Study|Participant/Guardian Decision|7
6334181|NCT03100825|10083292|FG000|Overall Study|Physician Decision|1
6334182|NCT03100838|10083296|FG000|Overall Study|Adverse Event|1
6334183|NCT03100838|10083297|FG001|Overall Study|Adverse Event|0
6334184|NCT03100838|10083298|FG002|Overall Study|Adverse Event|0
6334185|NCT03100838|10083299|FG003|Overall Study|Adverse Event|0
6334186|NCT03100838|10083296|FG000|Overall Study|Physician Decision|1
6334187|NCT03100838|10083297|FG001|Overall Study|Physician Decision|1
6334188|NCT03100838|10083298|FG002|Overall Study|Physician Decision|1
6334189|NCT03100838|10083299|FG003|Overall Study|Physician Decision|1
6334190|NCT03100838|10083296|FG000|Overall Study|Pregnancy|0
6334191|NCT03100838|10083297|FG001|Overall Study|Pregnancy|1
6334192|NCT03100838|10083298|FG002|Overall Study|Pregnancy|0
6334193|NCT03100838|10083299|FG003|Overall Study|Pregnancy|0
6334194|NCT03100838|10083296|FG000|Overall Study|Lost to Follow-up|0
6334195|NCT03100838|10083297|FG001|Overall Study|Lost to Follow-up|0
6334196|NCT03100838|10083298|FG002|Overall Study|Lost to Follow-up|1
6334197|NCT03100838|10083299|FG003|Overall Study|Lost to Follow-up|0
6334198|NCT03100942|10083317|FG000|Randomized Treatment Period|Withdrew Consent|4
6334199|NCT03100942|10083318|FG001|Randomized Treatment Period|Withdrew Consent|5
6334200|NCT03100942|10083319|FG002|Randomized Treatment Period|Withdrew Consent|3
6334201|NCT03100942|10083320|FG003|Randomized Treatment Period|Withdrew Consent|3
6167616|NCT01229267|9812270|FG004|Overall Study|Physician Decision|25
6334202|NCT03100942|10083321|FG004|Randomized Treatment Period|Withdrew Consent|0
6334203|NCT03100942|10083322|FG005|Randomized Treatment Period|Withdrew Consent|0
6334204|NCT03100942|10083323|FG006|Randomized Treatment Period|Withdrew Consent|0
6334205|NCT03100942|10083317|FG000|Randomized Treatment Period|Adverse Event|5
6334206|NCT03100942|10083318|FG001|Randomized Treatment Period|Adverse Event|2
6334207|NCT03100942|10083319|FG002|Randomized Treatment Period|Adverse Event|1
6334208|NCT03100942|10083320|FG003|Randomized Treatment Period|Adverse Event|0
6334209|NCT03100942|10083321|FG004|Randomized Treatment Period|Adverse Event|0
6334210|NCT03100942|10083322|FG005|Randomized Treatment Period|Adverse Event|0
6334211|NCT03100942|10083323|FG006|Randomized Treatment Period|Adverse Event|0
6334212|NCT03100942|10083317|FG000|Randomized Treatment Period|Investigator's Discretion|2
6334213|NCT03100942|10083318|FG001|Randomized Treatment Period|Investigator's Discretion|1
6334214|NCT03100942|10083319|FG002|Randomized Treatment Period|Investigator's Discretion|0
6334215|NCT03100942|10083320|FG003|Randomized Treatment Period|Investigator's Discretion|0
6334216|NCT03100942|10083321|FG004|Randomized Treatment Period|Investigator's Discretion|0
6334217|NCT03100942|10083322|FG005|Randomized Treatment Period|Investigator's Discretion|0
6334218|NCT03100942|10083323|FG006|Randomized Treatment Period|Investigator's Discretion|0
6334219|NCT03100942|10083317|FG000|Randomized Treatment Period|Protocol Violation|0
6334220|NCT03100942|10083318|FG001|Randomized Treatment Period|Protocol Violation|1
6334221|NCT03100942|10083319|FG002|Randomized Treatment Period|Protocol Violation|1
6334222|NCT03100942|10083320|FG003|Randomized Treatment Period|Protocol Violation|1
6334223|NCT03100942|10083321|FG004|Randomized Treatment Period|Protocol Violation|0
6334224|NCT03100942|10083322|FG005|Randomized Treatment Period|Protocol Violation|0
6334225|NCT03100942|10083323|FG006|Randomized Treatment Period|Protocol Violation|0
6334226|NCT03100942|10083317|FG000|Randomized Treatment Period|Lost to Follow-up|0
6334227|NCT03100942|10083318|FG001|Randomized Treatment Period|Lost to Follow-up|0
6334228|NCT03100942|10083319|FG002|Randomized Treatment Period|Lost to Follow-up|1
6334229|NCT03100942|10083320|FG003|Randomized Treatment Period|Lost to Follow-up|0
6334230|NCT03100942|10083321|FG004|Randomized Treatment Period|Lost to Follow-up|0
6334231|NCT03100942|10083322|FG005|Randomized Treatment Period|Lost to Follow-up|0
6334232|NCT03100942|10083323|FG006|Randomized Treatment Period|Lost to Follow-up|0
6334233|NCT03100942|10083317|FG000|Randomized Treatment Period|Randomized but Didn't Receive Study Drug|1
6334234|NCT03100942|10083318|FG001|Randomized Treatment Period|Randomized but Didn't Receive Study Drug|0
6334235|NCT03100942|10083319|FG002|Randomized Treatment Period|Randomized but Didn't Receive Study Drug|0
6167617|NCT01229267|9812266|FG000|Overall Study|Lost to Follow-up|6
6167618|NCT01229267|9812267|FG001|Overall Study|Lost to Follow-up|5
6167619|NCT01229267|9812268|FG002|Overall Study|Lost to Follow-up|8
6167620|NCT01229267|9812269|FG003|Overall Study|Lost to Follow-up|3
6167621|NCT01229267|9812270|FG004|Overall Study|Lost to Follow-up|22
6167622|NCT01229371|9812281|FG000|Overall Study|Withdrawal by Subject|0
6167623|NCT01229371|9812282|FG001|Overall Study|Withdrawal by Subject|1
6167624|NCT01229371|9812283|FG002|Overall Study|Withdrawal by Subject|0
6167625|NCT01229371|9812284|FG003|Overall Study|Withdrawal by Subject|0
6167626|NCT01229397|9812296|FG000|Overall Study|Withdrawal by Subject|3
6167627|NCT01229397|9812297|FG001|Overall Study|Withdrawal by Subject|3
6167628|NCT01229397|9812296|FG000|Overall Study|Lost to Follow-up|7
6167629|NCT01229397|9812297|FG001|Overall Study|Lost to Follow-up|6
6167630|NCT01229397|9812296|FG000|Overall Study|Migrated/moved from study area|1
6167631|NCT01229397|9812297|FG001|Overall Study|Migrated/moved from study area|0
6167632|NCT01229436|9812320|FG000|Overall Study|Withdrawal by Subject|2
6167633|NCT01229436|9812320|FG000|Overall Study|Lost to Follow-up|3
6167634|NCT01229449|9812329|FG000|Overall Study|Withdrawal by Subject|0
6167635|NCT01229449|9812330|FG001|Overall Study|Withdrawal by Subject|3
6167636|NCT01229449|9812331|FG002|Overall Study|Withdrawal by Subject|0
6167637|NCT01229449|9812332|FG003|Overall Study|Withdrawal by Subject|1
6167638|NCT01229449|9812333|FG004|Overall Study|Withdrawal by Subject|1
6167639|NCT01229449|9812329|FG000|Overall Study|Lost to Follow-up|1
6167640|NCT01229449|9812330|FG001|Overall Study|Lost to Follow-up|1
6167641|NCT01229449|9812331|FG002|Overall Study|Lost to Follow-up|1
6167642|NCT01229449|9812332|FG003|Overall Study|Lost to Follow-up|0
6167643|NCT01229449|9812333|FG004|Overall Study|Lost to Follow-up|0
6167644|NCT01229449|9812329|FG000|Overall Study|Physician Decision|0
6167645|NCT01229449|9812330|FG001|Overall Study|Physician Decision|0
6167646|NCT01229449|9812331|FG002|Overall Study|Physician Decision|1
6167647|NCT01229449|9812332|FG003|Overall Study|Physician Decision|0
6167648|NCT01229449|9812333|FG004|Overall Study|Physician Decision|0
6167649|NCT01229735|9812382|FG000|Overall Study|Lack of Efficacy|8
6167650|NCT01229735|9812383|FG001|Overall Study|Lack of Efficacy|8
6167651|NCT01229735|9812382|FG000|Overall Study|Protocol Violation|13
6167652|NCT01229735|9812383|FG001|Overall Study|Protocol Violation|8
6334236|NCT03100942|10083320|FG003|Randomized Treatment Period|Randomized but Didn't Receive Study Drug|1
6334237|NCT03100942|10083321|FG004|Randomized Treatment Period|Randomized but Didn't Receive Study Drug|0
6334238|NCT03100942|10083322|FG005|Randomized Treatment Period|Randomized but Didn't Receive Study Drug|0
6167653|NCT01229735|9812382|FG000|Overall Study|Lost to Follow-up|0
6167654|NCT01229735|9812383|FG001|Overall Study|Lost to Follow-up|2
6167655|NCT01229735|9812382|FG000|Overall Study|Withdrawal by Subject|18
6167656|NCT01229735|9812383|FG001|Overall Study|Withdrawal by Subject|17
6334239|NCT03100942|10083323|FG006|Randomized Treatment Period|Randomized but Didn't Receive Study Drug|0
6334240|NCT03100942|10083317|FG000|Placebo Arm Re-Randomized|Withdrew Consent|0
6334241|NCT03100942|10083318|FG001|Placebo Arm Re-Randomized|Withdrew Consent|0
6334242|NCT03100942|10083319|FG002|Placebo Arm Re-Randomized|Withdrew Consent|0
6334243|NCT03100942|10083320|FG003|Placebo Arm Re-Randomized|Withdrew Consent|0
6334244|NCT03100942|10083321|FG004|Placebo Arm Re-Randomized|Withdrew Consent|0
6334245|NCT03100942|10083322|FG005|Placebo Arm Re-Randomized|Withdrew Consent|0
6334246|NCT03100942|10083323|FG006|Placebo Arm Re-Randomized|Withdrew Consent|1
6334247|NCT03101020|10083347|FG000|Overall Study|Lack of time to participate|1
6334248|NCT03101020|10083348|FG001|Overall Study|Lack of time to participate|0
6334249|NCT03101020|10083347|FG000|Overall Study|Ran over by a car|0
6334250|NCT03101020|10083348|FG001|Overall Study|Ran over by a car|1
6334251|NCT03101020|10083347|FG000|Overall Study|Withdrawal by Subject|0
6334252|NCT03101020|10083348|FG001|Overall Study|Withdrawal by Subject|2
6334253|NCT03101150|10083378|FG000|Overall Study|Lost to Follow-up|2
6334254|NCT03101150|10083379|FG001|Overall Study|Lost to Follow-up|4
6334255|NCT03101150|10083378|FG000|Overall Study|Miscarriage|3
6334256|NCT03101150|10083379|FG001|Overall Study|Miscarriage|6
6334257|NCT03101241|10083387|FG000|Overall Study|Intercurrent condition necessitating discontinuation|4
6167657|NCT01229735|9812382|FG000|Overall Study|Other Reason|13
6167658|NCT01229735|9812383|FG001|Overall Study|Other Reason|10
6167659|NCT01229735|9812382|FG000|Overall Study|SAE, non-fatal|0
6167660|NCT01229735|9812383|FG001|Overall Study|SAE, non-fatal|4
6167661|NCT01229735|9812382|FG000|Overall Study|AE, non-serious non-fatal|13
6167662|NCT01229735|9812383|FG001|Overall Study|AE, non-serious non-fatal|17
6167663|NCT01229735|9812382|FG000|Overall Study|SAE, non-fatal+AE, non-serious non-fatal|1
6167664|NCT01229735|9812383|FG001|Overall Study|SAE, non-fatal+AE, non-serious non-fatal|0
6167665|NCT01230060|9812408|FG000|Overall Study|Withdrawal by Subject|1
6167666|NCT01230554|9812453|FG000|Overall Study|Lost to Follow-up|2
6167667|NCT01230554|9812453|FG000|Overall Study|Inability to maintain visit schedule|1
6167668|NCT01230710|9812470|FG000|Overall Study|Disease Progression|41
6167669|NCT01230710|9812470|FG000|Overall Study|Lost to Follow-up|3
6167670|NCT01230710|9812470|FG000|Overall Study|Death|4
6167671|NCT01230710|9812470|FG000|Overall Study|Withdrawal of Consent|1
6167672|NCT01230749|9812478|FG000|Overall Study|Adverse Event|0
6167673|NCT01230749|9812479|FG001|Overall Study|Adverse Event|0
6167674|NCT01230749|9812480|FG002|Overall Study|Adverse Event|0
6167675|NCT01230749|9812481|FG003|Overall Study|Adverse Event|1
6167676|NCT01230749|9812478|FG000|Overall Study|Physician Decision|0
6167677|NCT01230749|9812479|FG001|Overall Study|Physician Decision|0
6167678|NCT01230749|9812480|FG002|Overall Study|Physician Decision|1
6167679|NCT01230749|9812481|FG003|Overall Study|Physician Decision|0
6167680|NCT01230749|9812478|FG000|Overall Study|Withdrawal by Subject|0
6167681|NCT01230749|9812479|FG001|Overall Study|Withdrawal by Subject|1
6167682|NCT01230749|9812480|FG002|Overall Study|Withdrawal by Subject|0
6167683|NCT01230749|9812481|FG003|Overall Study|Withdrawal by Subject|0
6167684|NCT01230749|9812478|FG000|Overall Study|Fasting glucose more than 270 mg/dL|0
6167685|NCT01230749|9812479|FG001|Overall Study|Fasting glucose more than 270 mg/dL|1
6167686|NCT01230749|9812480|FG002|Overall Study|Fasting glucose more than 270 mg/dL|1
6167687|NCT01230749|9812481|FG003|Overall Study|Fasting glucose more than 270 mg/dL|1
6167688|NCT01230814|9812512|FG000|Overall Study|Lost to Follow-up|11
6167689|NCT01230814|9812513|FG001|Overall Study|Lost to Follow-up|3
6167690|NCT01230814|9812512|FG000|Overall Study|Discontinued (not due to adverse event)|2
6167691|NCT01230814|9812513|FG001|Overall Study|Discontinued (not due to adverse event)|1
6192162|NCT01428128|9849249|FG000|Overall Study|Received Neulasta in one cycle|2
6192163|NCT01428128|9849249|FG000|Overall Study|Adverse Event|1
6192164|NCT01428193|9849254|FG000|Overall Study|Physician Decision|1
6192165|NCT01428193|9849254|FG000|Overall Study|Elevated screening liver enzymes|1
6192166|NCT01428219|9849258|FG000|Overall Study|25 patients enrolled, 3 were not treated|3
6192167|NCT01428258|9849268|FG000|Intervention 1|Withdrawal by Subject|2
6192168|NCT01428258|9849269|FG001|Intervention 1|Withdrawal by Subject|0
6192169|NCT01428453|9849297|FG000|Overall Study|Adverse Event|2
6192170|NCT01428453|9849298|FG001|Overall Study|Adverse Event|7
6192171|NCT01428453|9849297|FG000|Overall Study|Protocol Violation|1
6192172|NCT01428453|9849298|FG001|Overall Study|Protocol Violation|0
6192173|NCT01428453|9849297|FG000|Overall Study|Lost to Follow-up|0
6192174|NCT01428453|9849298|FG001|Overall Study|Lost to Follow-up|1
6192175|NCT01428453|9849297|FG000|Overall Study|Withdrawal by Subject|3
6192176|NCT01428453|9849298|FG001|Overall Study|Withdrawal by Subject|1
6334258|NCT03101241|10083388|FG001|Overall Study|Intercurrent condition necessitating discontinuation|2
6334259|NCT03101241|10083387|FG000|Overall Study|Participant withdrew consent|3
6334260|NCT03101241|10083388|FG001|Overall Study|Participant withdrew consent|1
6334261|NCT03101241|10083387|FG000|Overall Study|Investigator decision that withdrawal was in best interest of participant|2
6192177|NCT01428583|9849306|FG000|Overall Study|Adverse Event|75
6192178|NCT01428583|9849306|FG000|Overall Study|Withdrawal by Subject|51
6192179|NCT01428583|9849306|FG000|Overall Study|Lack of Efficacy|37
6192180|NCT01428583|9849306|FG000|Overall Study|Lost to Follow-up|17
6192181|NCT01428583|9849306|FG000|Overall Study|Death|1
6192182|NCT01428583|9849306|FG000|Overall Study|Pregnancy|1
6192183|NCT01428583|9849306|FG000|Overall Study|Protocol Violation|1
6334262|NCT03101241|10083388|FG001|Overall Study|Investigator decision that withdrawal was in best interest of participant|0
6334263|NCT03101241|10083387|FG000|Overall Study|Lost to Follow-up|2
6334264|NCT03101241|10083388|FG001|Overall Study|Lost to Follow-up|0
6334265|NCT03101241|10083387|FG000|Overall Study|Lack of Efficacy|0
6334266|NCT03101241|10083388|FG001|Overall Study|Lack of Efficacy|1
6334267|NCT03101241|10083387|FG000|Overall Study|Lack of efficacy/subject withdrew consent|0
6334268|NCT03101241|10083388|FG001|Overall Study|Lack of efficacy/subject withdrew consent|1
6334269|NCT03101267|10083397|FG000|Primary Study Period|Withdrawal by Subject|1
6334270|NCT03101267|10083398|FG001|Primary Study Period|Withdrawal by Subject|2
6334271|NCT03101267|10083399|FG002|Primary Study Period|Withdrawal by Subject|3
6334272|NCT03101267|10083397|FG000|Primary Study Period|Miscellaneous|2
6334273|NCT03101267|10083398|FG001|Primary Study Period|Miscellaneous|0
6334274|NCT03101267|10083399|FG002|Primary Study Period|Miscellaneous|0
6334275|NCT03101293|10083409|FG000|Washout Period (at Least 7 Days)|Positive drug urine screen|1
6334276|NCT03101293|10083410|FG001|Washout Period (at Least 7 Days)|Positive drug urine screen|0
6334277|NCT03101358|10083420|FG000|Overall Study|Non-compliance with study schedule|1
6334278|NCT03101358|10083421|FG001|Overall Study|Non-compliance with study schedule|0
6334279|NCT03101358|10083422|FG002|Overall Study|Non-compliance with study schedule|0
6334280|NCT03101358|10083423|FG003|Overall Study|Non-compliance with study schedule|1
6334281|NCT03101358|10083420|FG000|Overall Study|Decision to start another clinical trial. Not related to AE.|0
6334282|NCT03101358|10083421|FG001|Overall Study|Decision to start another clinical trial. Not related to AE.|0
6334283|NCT03101358|10083422|FG002|Overall Study|Decision to start another clinical trial. Not related to AE.|1
6334284|NCT03101358|10083423|FG003|Overall Study|Decision to start another clinical trial. Not related to AE.|0
6334285|NCT03101358|10083420|FG000|Overall Study|Physician Decision|1
6334286|NCT03101358|10083421|FG001|Overall Study|Physician Decision|0
6334287|NCT03101358|10083422|FG002|Overall Study|Physician Decision|0
6334288|NCT03101358|10083423|FG003|Overall Study|Physician Decision|3
6334289|NCT03101358|10083420|FG000|Overall Study|Adverse Event|0
6334290|NCT03101358|10083421|FG001|Overall Study|Adverse Event|0
6334291|NCT03101358|10083422|FG002|Overall Study|Adverse Event|1
6334292|NCT03101358|10083423|FG003|Overall Study|Adverse Event|0
6167692|NCT01230827|9812523|FG000|Overall Study|Lost to Follow-up|0
6167693|NCT01230827|9812524|FG001|Overall Study|Lost to Follow-up|0
6167694|NCT01230827|9812525|FG002|Overall Study|Lost to Follow-up|1
6167695|NCT01230827|9812526|FG003|Overall Study|Lost to Follow-up|3
6167696|NCT01230827|9812523|FG000|Overall Study|Withdrawal by Subject|1
6167697|NCT01230827|9812524|FG001|Overall Study|Withdrawal by Subject|0
6167698|NCT01230827|9812525|FG002|Overall Study|Withdrawal by Subject|3
6167699|NCT01230827|9812526|FG003|Overall Study|Withdrawal by Subject|2
6167700|NCT01230827|9812523|FG000|Overall Study|Lack of Efficacy|14
6167701|NCT01230827|9812524|FG001|Overall Study|Lack of Efficacy|1
6167702|NCT01230827|9812525|FG002|Overall Study|Lack of Efficacy|2
6167703|NCT01230827|9812526|FG003|Overall Study|Lack of Efficacy|3
6167704|NCT01230827|9812523|FG000|Overall Study|Adverse Event|4
6167705|NCT01230827|9812524|FG001|Overall Study|Adverse Event|2
6167706|NCT01230827|9812525|FG002|Overall Study|Adverse Event|3
6167707|NCT01230827|9812526|FG003|Overall Study|Adverse Event|7
6167708|NCT01230827|9812523|FG000|Overall Study|Recovery|0
6167709|NCT01230827|9812524|FG001|Overall Study|Recovery|6
6167710|NCT01230827|9812525|FG002|Overall Study|Recovery|0
6167711|NCT01230827|9812526|FG003|Overall Study|Recovery|0
6167712|NCT01230827|9812523|FG000|Overall Study|Study terminated by Sponsor|0
6167713|NCT01230827|9812524|FG001|Overall Study|Study terminated by Sponsor|2
6167714|NCT01230827|9812525|FG002|Overall Study|Study terminated by Sponsor|56
6167715|NCT01230827|9812526|FG003|Overall Study|Study terminated by Sponsor|63
6167716|NCT01230892|9812536|FG000|Overall Study|Withdrawal by Subject|1
6167717|NCT01230892|9812537|FG001|Overall Study|Withdrawal by Subject|1
6167718|NCT01230892|9812536|FG000|Overall Study|Lost to Follow-up|2
6167719|NCT01230892|9812537|FG001|Overall Study|Lost to Follow-up|0
6167720|NCT01231321|9812563|FG000|Overall Study|Adverse Event|3
6167721|NCT01231321|9812563|FG000|Overall Study|Lack of Efficacy|2
6167722|NCT01231373|9812586|FG000|Overall Study|Withdrew consent prior to randomization|2
6167723|NCT01231373|9812587|FG001|Overall Study|Withdrew consent prior to randomization|1
6167724|NCT01231373|9812588|FG002|Overall Study|Withdrew consent prior to randomization|0
6167725|NCT01231373|9812589|FG003|Overall Study|Withdrew consent prior to randomization|0
6167726|NCT01231373|9812586|FG000|Overall Study|Lost to Follow-up|0
6167727|NCT01231373|9812587|FG001|Overall Study|Lost to Follow-up|0
6167728|NCT01231373|9812588|FG002|Overall Study|Lost to Follow-up|0
6167729|NCT01231373|9812589|FG003|Overall Study|Lost to Follow-up|1
6167730|NCT01231373|9812586|FG000|Overall Study|Withdrew Consent|1
6167731|NCT01231373|9812587|FG001|Overall Study|Withdrew Consent|0
6334293|NCT03101358|10083420|FG000|Overall Study|Oncologist decision to start subject on IV chemotherapy prohibited under protocol.|0
6167732|NCT01231373|9812588|FG002|Overall Study|Withdrew Consent|0
6167733|NCT01231373|9812589|FG003|Overall Study|Withdrew Consent|0
6167734|NCT01231464|9812621|FG000|Overall Study|Adverse Event|0
6167735|NCT01231464|9812622|FG001|Overall Study|Adverse Event|1
6167736|NCT01231464|9812621|FG000|Overall Study|Protocol Violation|1
6167737|NCT01231464|9812622|FG001|Overall Study|Protocol Violation|2
6334294|NCT03101358|10083421|FG001|Overall Study|Oncologist decision to start subject on IV chemotherapy prohibited under protocol.|0
6167738|NCT01231464|9812621|FG000|Overall Study|Lost to Follow-up|1
6334295|NCT03101358|10083422|FG002|Overall Study|Oncologist decision to start subject on IV chemotherapy prohibited under protocol.|0
6334296|NCT03101358|10083423|FG003|Overall Study|Oncologist decision to start subject on IV chemotherapy prohibited under protocol.|1
6334297|NCT03101358|10083420|FG000|Overall Study|Lost to Follow-up|1
6334298|NCT03101358|10083421|FG001|Overall Study|Lost to Follow-up|0
6334299|NCT03101358|10083422|FG002|Overall Study|Lost to Follow-up|0
6334300|NCT03101358|10083423|FG003|Overall Study|Lost to Follow-up|1
6334301|NCT03101371|10083436|FG000|Overall Study|Physician Decision|0
6334302|NCT03101371|10083437|FG001|Overall Study|Physician Decision|1
6334303|NCT03101371|10083436|FG000|Overall Study|Lost to Follow-up|1
6334304|NCT03101371|10083437|FG001|Overall Study|Lost to Follow-up|4
6334305|NCT03101371|10083436|FG000|Overall Study|Did not meet eligibility criteria|2
6334306|NCT03101371|10083437|FG001|Overall Study|Did not meet eligibility criteria|1
6334307|NCT03101462|10083445|FG000|Overall Study|Missed Visit 02 and/or Visit 03|1
6334308|NCT03101462|10083446|FG001|Overall Study|Missed Visit 02 and/or Visit 03|1
6334309|NCT03101514|10083452|FG000|Overall Study|Withdrawal by Subject|4
6334310|NCT03101514|10083452|FG000|Overall Study|Protocol Violation|2
6334311|NCT03101514|10083452|FG000|Overall Study|patient's information was incomplete|1
6334312|NCT03101592|10083459|FG000|Overall Study|participant files could not be located|111
6334313|NCT03101592|10083460|FG001|Overall Study|participant files could not be located|170
6334314|NCT03101592|10083461|FG002|Overall Study|participant files could not be located|118
6334315|NCT03102710|10083506|FG000|Overall Study|Dental metal affected MRI scan quality|1
6334316|NCT03102710|10083507|FG001|Overall Study|Dental metal affected MRI scan quality|0
6334317|NCT03102710|10083508|FG002|Overall Study|Dental metal affected MRI scan quality|0
6334318|NCT03102710|10083506|FG000|Overall Study|Technical issues during final MRI scan|0
6334319|NCT03102710|10083507|FG001|Overall Study|Technical issues during final MRI scan|1
6334320|NCT03102710|10083508|FG002|Overall Study|Technical issues during final MRI scan|0
6334321|NCT03102710|10083506|FG000|Overall Study|Nausea during MRI scan|0
6334322|NCT03102710|10083507|FG001|Overall Study|Nausea during MRI scan|1
6334323|NCT03102710|10083508|FG002|Overall Study|Nausea during MRI scan|0
6334324|NCT03102710|10083506|FG000|Overall Study|Subject unable to attend final session|0
6334325|NCT03102710|10083507|FG001|Overall Study|Subject unable to attend final session|1
6334326|NCT03102710|10083508|FG002|Overall Study|Subject unable to attend final session|0
6334327|NCT03102762|10083527|FG000|Overall Study|Lost to Follow-up|1
6334328|NCT03102762|10083528|FG001|Overall Study|Lost to Follow-up|0
6334329|NCT03102918|10083550|FG000|Overall Study|Protocol Violation|1
6334330|NCT03102918|10083551|FG001|Overall Study|Protocol Violation|0
6334331|NCT03103100|10083564|FG000|Overall Study|Adverse Event|1
6334332|NCT03103100|10083565|FG001|Overall Study|Adverse Event|0
6334333|NCT03103100|10083566|FG002|Overall Study|Adverse Event|0
6334334|NCT03103100|10083564|FG000|Overall Study|Physician Decision|1
6334335|NCT03103100|10083565|FG001|Overall Study|Physician Decision|0
6334336|NCT03103100|10083566|FG002|Overall Study|Physician Decision|2
6334337|NCT03103503|10083607|FG000|Overall Study|Death|64
6334338|NCT03103503|10083607|FG000|Overall Study|Physician Decision|57
6334339|NCT03103503|10083607|FG000|Overall Study|Withdrawal by Subject|10
6334340|NCT03103503|10083607|FG000|Overall Study|Plexa Lead or Pulse Generator Extraction|10
6334341|NCT03103503|10083607|FG000|Overall Study|Lost to Follow-up|3
6334342|NCT03103503|10083607|FG000|Overall Study|Study Closure|757
6334343|NCT03103763|10083614|FG000|Overall Study|Death|15
6334344|NCT03103763|10083615|FG001|Overall Study|Death|5
6334345|NCT03103763|10083616|FG002|Overall Study|Death|5
6334346|NCT03103763|10083614|FG000|Overall Study|Withdrawal by Subject|0
6082884|NCT00631969|9691014|FG000|Overall Study|Consent Withdrawn|5
6082885|NCT00631969|9691015|FG001|Overall Study|Consent Withdrawn|7
6082886|NCT00631969|9691014|FG000|Overall Study|Noncompliant With Study Medication|0
6082887|NCT00631969|9691015|FG001|Overall Study|Noncompliant With Study Medication|1
6082888|NCT00631969|9691014|FG000|Overall Study|No Drug Exposure|2
6082889|NCT00631969|9691015|FG001|Overall Study|No Drug Exposure|2
6082890|NCT00632021|9691025|FG000|Overall Study|Withdrawal/death|4
6082891|NCT00632021|9691026|FG001|Overall Study|Withdrawal/death|7
6082892|NCT00632099|9691035|FG000|Overall Study|Lost to Follow-up|3
6082893|NCT00632099|9691036|FG001|Overall Study|Lost to Follow-up|3
6082894|NCT00632125|9691042|FG000|Overall Study|Death|82
6167739|NCT01231464|9812622|FG001|Overall Study|Lost to Follow-up|2
6167740|NCT01231464|9812621|FG000|Overall Study|Withdrawal by Subject|3
6167741|NCT01231464|9812622|FG001|Overall Study|Withdrawal by Subject|2
6167742|NCT01231503|9812638|FG000|Overall Study|Adverse Event|0
6167743|NCT01231503|9812639|FG001|Overall Study|Adverse Event|0
6334347|NCT03103763|10083615|FG001|Overall Study|Withdrawal by Subject|3
6082895|NCT00632125|9691042|FG000|Overall Study|Withdrawal by Subject|44
6082896|NCT00632125|9691042|FG000|Overall Study|Adverse Event|36
6167744|NCT01231503|9812640|FG002|Overall Study|Adverse Event|0
6334348|NCT03103763|10083616|FG002|Overall Study|Withdrawal by Subject|2
6334349|NCT03103906|10083626|FG000|Overall Study|Adverse Event|2
6334350|NCT03103906|10083627|FG001|Overall Study|Adverse Event|3
6334351|NCT03103906|10083626|FG000|Overall Study|Other|2
6334352|NCT03103906|10083627|FG001|Overall Study|Other|0
6334353|NCT03103919|10083635|FG000|Overall Study|Adverse Event|2
6334354|NCT03103919|10083636|FG001|Overall Study|Adverse Event|2
6334355|NCT03104816|10083696|FG000|Overall Study|Lack of Efficacy|0
6334356|NCT03104816|10083697|FG001|Overall Study|Lack of Efficacy|2
6334357|NCT03104816|10083698|FG002|Overall Study|Lack of Efficacy|0
6334358|NCT03104816|10083696|FG000|Overall Study|Protocol Violation|2
6334359|NCT03104816|10083697|FG001|Overall Study|Protocol Violation|0
6334360|NCT03104816|10083698|FG002|Overall Study|Protocol Violation|2
6334361|NCT03105297|10083715|FG000|Baseline Phase (Day 1)|Other|21
6334362|NCT03105297|10083715|FG000|Nasal Resistance Phase (Day 30, 31)|Adverse Event|1
6334363|NCT03105297|10083715|FG000|Nasal Resistance Phase (Day 30, 31)|Withdrawal by Subject|7
6334364|NCT03105362|10083726|FG000|Overall Study|Withdrawal by Subject|1
6334365|NCT03105362|10083726|FG000|Overall Study|Lost to Follow-up|1
6334366|NCT03106077|10083750|FG000|Overall Study|Screen Failure|94
6334367|NCT03106077|10083751|FG001|Overall Study|Screen Failure|0
6334368|NCT03106753|10083772|FG000|Overall Study|Withdrawal by Subject|0
6334369|NCT03106753|10083773|FG001|Overall Study|Withdrawal by Subject|1
6334370|NCT03107026|10083797|FG000|Overall Study|Adverse Event|2
6334371|NCT03107026|10083798|FG001|Overall Study|Adverse Event|14
6334372|NCT03107026|10083799|FG002|Overall Study|Adverse Event|23
6334373|NCT03107026|10083797|FG000|Overall Study|Lost to Follow-up|12
6334374|NCT03107026|10083798|FG001|Overall Study|Lost to Follow-up|12
6334375|NCT03107026|10083799|FG002|Overall Study|Lost to Follow-up|13
6334376|NCT03107026|10083797|FG000|Overall Study|Protocol Violation|1
6334377|NCT03107026|10083798|FG001|Overall Study|Protocol Violation|2
6334378|NCT03107026|10083799|FG002|Overall Study|Protocol Violation|0
6334379|NCT03107026|10083797|FG000|Overall Study|Pregnancy|1
6334380|NCT03107026|10083798|FG001|Overall Study|Pregnancy|0
6334381|NCT03107026|10083799|FG002|Overall Study|Pregnancy|0
6334382|NCT03107026|10083797|FG000|Overall Study|Withdrawal by Subject|13
6334383|NCT03107026|10083798|FG001|Overall Study|Withdrawal by Subject|5
6334384|NCT03107026|10083799|FG002|Overall Study|Withdrawal by Subject|17
6334385|NCT03107026|10083797|FG000|Overall Study|non compliance with study visits|1
6334386|NCT03107026|10083798|FG001|Overall Study|non compliance with study visits|2
6334387|NCT03107026|10083799|FG002|Overall Study|non compliance with study visits|0
6334388|NCT03107026|10083797|FG000|Overall Study|non-compliance with study drug|2
6334389|NCT03107026|10083798|FG001|Overall Study|non-compliance with study drug|2
6334390|NCT03107026|10083799|FG002|Overall Study|non-compliance with study drug|3
6334391|NCT03107026|10083797|FG000|Overall Study|Physician Decision|0
6334392|NCT03107026|10083798|FG001|Overall Study|Physician Decision|1
6334393|NCT03107026|10083799|FG002|Overall Study|Physician Decision|0
6334394|NCT03107052|10083810|FG000|Overall Study|Adverse Event|6
6334395|NCT03107052|10083811|FG001|Overall Study|Adverse Event|1
6334396|NCT03107052|10083812|FG002|Overall Study|Adverse Event|2
6334397|NCT03107052|10083810|FG000|Overall Study|Withdrawal by Subject|9
6334398|NCT03107052|10083811|FG001|Overall Study|Withdrawal by Subject|5
6334399|NCT03107052|10083812|FG002|Overall Study|Withdrawal by Subject|8
6334400|NCT03107052|10083810|FG000|Overall Study|Protocol Violation|6
6334401|NCT03107052|10083811|FG001|Overall Study|Protocol Violation|0
6334402|NCT03107052|10083812|FG002|Overall Study|Protocol Violation|3
6334403|NCT03107052|10083810|FG000|Overall Study|Lost to Follow-up|4
6334404|NCT03107052|10083811|FG001|Overall Study|Lost to Follow-up|0
6167745|NCT01231503|9812641|FG003|Overall Study|Adverse Event|0
6167746|NCT01231503|9812642|FG004|Overall Study|Adverse Event|0
6167747|NCT01231503|9812643|FG005|Overall Study|Adverse Event|1
6167748|NCT01231503|9812644|FG006|Overall Study|Adverse Event|0
6167749|NCT01231503|9812645|FG007|Overall Study|Adverse Event|0
6167750|NCT01231503|9812638|FG000|Overall Study|Adverse event, serious fatal|0
6167751|NCT01231503|9812639|FG001|Overall Study|Adverse event, serious fatal|0
6167752|NCT01231503|9812640|FG002|Overall Study|Adverse event, serious fatal|1
6167753|NCT01231503|9812641|FG003|Overall Study|Adverse event, serious fatal|1
6167754|NCT01231503|9812642|FG004|Overall Study|Adverse event, serious fatal|0
6167755|NCT01231503|9812643|FG005|Overall Study|Adverse event, serious fatal|1
6167756|NCT01231503|9812644|FG006|Overall Study|Adverse event, serious fatal|0
6167757|NCT01231503|9812645|FG007|Overall Study|Adverse event, serious fatal|0
6167758|NCT01231503|9812638|FG000|Overall Study|Withdrawal by Subject|6
6167759|NCT01231503|9812639|FG001|Overall Study|Withdrawal by Subject|3
6167760|NCT01231503|9812640|FG002|Overall Study|Withdrawal by Subject|3
6334405|NCT03107052|10083812|FG002|Overall Study|Lost to Follow-up|1
6334406|NCT03107052|10083810|FG000|Overall Study|Lack of Efficacy|23
6334407|NCT03107052|10083811|FG001|Overall Study|Lack of Efficacy|7
6334408|NCT03107052|10083812|FG002|Overall Study|Lack of Efficacy|4
6334409|NCT03107052|10083810|FG000|Overall Study|Other than specified|4
6334410|NCT03107052|10083811|FG001|Overall Study|Other than specified|2
6334411|NCT03107052|10083812|FG002|Overall Study|Other than specified|0
6334412|NCT03107052|10083810|FG000|Overall Study|Study terminated due to futility|67
6334413|NCT03107052|10083811|FG001|Overall Study|Study terminated due to futility|31
6334414|NCT03107052|10083812|FG002|Overall Study|Study terminated due to futility|23
6334415|NCT03107091|10083820|FG000|Overall Study|Physician Decision|1
6334416|NCT03107377|10083827|FG000|Overall Study|Adverse Event|3
6334417|NCT03107377|10083828|FG001|Overall Study|Adverse Event|3
6334418|NCT03107377|10083827|FG000|Overall Study|Protocol Violation|9
6334419|NCT03107377|10083828|FG001|Overall Study|Protocol Violation|12
6334420|NCT03107377|10083827|FG000|Overall Study|Physician Decision|3
6334421|NCT03107377|10083828|FG001|Overall Study|Physician Decision|6
6334422|NCT03107377|10083827|FG000|Overall Study|Pregnancy|7
6334423|NCT03107377|10083828|FG001|Overall Study|Pregnancy|7
6334424|NCT03107377|10083827|FG000|Overall Study|Withdrawal by Subject|16
6334425|NCT03107377|10083828|FG001|Overall Study|Withdrawal by Subject|22
6334426|NCT03107377|10083827|FG000|Overall Study|Lost to Follow-up|37
6334427|NCT03107377|10083828|FG001|Overall Study|Lost to Follow-up|34
6334428|NCT03107377|10083827|FG000|Overall Study|Other reason not specified|16
6334429|NCT03107377|10083828|FG001|Overall Study|Other reason not specified|15
6334430|NCT03107715|10083836|FG000|Overall Study|did not deliver at the home hospital|4
6334431|NCT03107715|10083837|FG001|Overall Study|did not deliver at the home hospital|6
6334432|NCT03107715|10083836|FG000|Overall Study|infant stillborn|0
6334433|NCT03107715|10083837|FG001|Overall Study|infant stillborn|1
6334434|NCT03107793|10083852|FG000|Induction Period (16 Weeks)|Adverse Event|5
6334435|NCT03107793|10083853|FG001|Induction Period (16 Weeks)|Adverse Event|0
6334436|NCT03107793|10083854|FG002|Induction Period (16 Weeks)|Adverse Event|0
6334437|NCT03107793|10083852|FG000|Induction Period (16 Weeks)|Withdrawal by Subject|3
6334438|NCT03107793|10083853|FG001|Induction Period (16 Weeks)|Withdrawal by Subject|0
6334439|NCT03107793|10083854|FG002|Induction Period (16 Weeks)|Withdrawal by Subject|0
6167761|NCT01231503|9812641|FG003|Overall Study|Withdrawal by Subject|1
6167762|NCT01231503|9812642|FG004|Overall Study|Withdrawal by Subject|3
6167763|NCT01231503|9812643|FG005|Overall Study|Withdrawal by Subject|5
6167764|NCT01231503|9812644|FG006|Overall Study|Withdrawal by Subject|1
6167765|NCT01231503|9812645|FG007|Overall Study|Withdrawal by Subject|2
6167766|NCT01231503|9812638|FG000|Overall Study|Lost to Follow-up|8
6167767|NCT01231503|9812639|FG001|Overall Study|Lost to Follow-up|10
6167768|NCT01231503|9812640|FG002|Overall Study|Lost to Follow-up|8
6167769|NCT01231503|9812641|FG003|Overall Study|Lost to Follow-up|5
6167770|NCT01231503|9812642|FG004|Overall Study|Lost to Follow-up|7
6167771|NCT01231503|9812643|FG005|Overall Study|Lost to Follow-up|9
6167772|NCT01231503|9812644|FG006|Overall Study|Lost to Follow-up|6
6167773|NCT01231503|9812645|FG007|Overall Study|Lost to Follow-up|6
6167774|NCT01231503|9812638|FG000|Overall Study|Protocol Violation|0
6167775|NCT01231503|9812639|FG001|Overall Study|Protocol Violation|0
6167776|NCT01231503|9812640|FG002|Overall Study|Protocol Violation|0
6167777|NCT01231503|9812641|FG003|Overall Study|Protocol Violation|1
6167778|NCT01231503|9812642|FG004|Overall Study|Protocol Violation|0
6167779|NCT01231503|9812643|FG005|Overall Study|Protocol Violation|0
6167780|NCT01231503|9812644|FG006|Overall Study|Protocol Violation|0
6167781|NCT01231503|9812645|FG007|Overall Study|Protocol Violation|0
6167782|NCT01231555|9812676|FG000|Overall Study|Study terminated|8
6167783|NCT01231555|9812677|FG001|Overall Study|Study terminated|5
6167784|NCT01231555|9812678|FG002|Overall Study|Study terminated|8
6167785|NCT01231555|9812676|FG000|Overall Study|Withdrawal by Subject|0
6167786|NCT01231555|9812677|FG001|Overall Study|Withdrawal by Subject|2
6167787|NCT01231555|9812678|FG002|Overall Study|Withdrawal by Subject|0
6167788|NCT01231581|9812688|FG000|Overall Study|Lost to Follow-up|2
6167789|NCT01231581|9812689|FG001|Overall Study|Lost to Follow-up|2
6167790|NCT01231581|9812688|FG000|Overall Study|Withdrawal by Subject|6
6167791|NCT01231581|9812689|FG001|Overall Study|Withdrawal by Subject|9
6167792|NCT01231581|9812688|FG000|Overall Study|Study Closed/Terminated|6
6167793|NCT01231581|9812689|FG001|Overall Study|Study Closed/Terminated|5
6167794|NCT01231581|9812688|FG000|Overall Study|Death|65
6167795|NCT01231581|9812689|FG001|Overall Study|Death|64
6167796|NCT01231581|9812688|FG000|Overall Study|Ongoing|1
6167797|NCT01231581|9812689|FG001|Overall Study|Ongoing|0
6167798|NCT01231607|9812700|FG000|Overall Study|Adverse Event|0
6167799|NCT01231607|9812701|FG001|Overall Study|Adverse Event|8
6167800|NCT01231607|9812702|FG002|Overall Study|Adverse Event|4
6167801|NCT01231607|9812703|FG003|Overall Study|Adverse Event|4
6167802|NCT01231607|9812704|FG004|Overall Study|Adverse Event|5
6167803|NCT01231607|9812700|FG000|Overall Study|Lost to Follow-up|13
6167804|NCT01231607|9812701|FG001|Overall Study|Lost to Follow-up|11
6167805|NCT01231607|9812702|FG002|Overall Study|Lost to Follow-up|10
6167806|NCT01231607|9812703|FG003|Overall Study|Lost to Follow-up|10
6167807|NCT01231607|9812704|FG004|Overall Study|Lost to Follow-up|4
6334440|NCT03107793|10083852|FG000|Induction Period (16 Weeks)|Physician Decision|1
6334441|NCT03107793|10083853|FG001|Induction Period (16 Weeks)|Physician Decision|0
6334442|NCT03107793|10083854|FG002|Induction Period (16 Weeks)|Physician Decision|0
6334443|NCT03107793|10083852|FG000|Induction Period (16 Weeks)|Progressive Disease|1
6334444|NCT03107793|10083853|FG001|Induction Period (16 Weeks)|Progressive Disease|0
6167808|NCT01231607|9812700|FG000|Overall Study|Physician Decision|4
6167809|NCT01231607|9812701|FG001|Overall Study|Physician Decision|4
6167810|NCT01231607|9812702|FG002|Overall Study|Physician Decision|3
6167811|NCT01231607|9812703|FG003|Overall Study|Physician Decision|5
6167812|NCT01231607|9812704|FG004|Overall Study|Physician Decision|4
6167813|NCT01231607|9812700|FG000|Overall Study|Protocol Violation|3
6167814|NCT01231607|9812701|FG001|Overall Study|Protocol Violation|2
6167815|NCT01231607|9812702|FG002|Overall Study|Protocol Violation|0
6167816|NCT01231607|9812703|FG003|Overall Study|Protocol Violation|2
6167817|NCT01231607|9812704|FG004|Overall Study|Protocol Violation|2
6167818|NCT01231607|9812700|FG000|Overall Study|Withdrawal by Subject|9
6167819|NCT01231607|9812701|FG001|Overall Study|Withdrawal by Subject|9
6167820|NCT01231607|9812702|FG002|Overall Study|Withdrawal by Subject|14
6167821|NCT01231607|9812703|FG003|Overall Study|Withdrawal by Subject|17
6167822|NCT01231607|9812704|FG004|Overall Study|Withdrawal by Subject|9
6167823|NCT01231620|9812722|FG000|Overall Study|Physician Decision|3
6334445|NCT03107793|10083854|FG002|Induction Period (16 Weeks)|Progressive Disease|0
6334446|NCT03107793|10083852|FG000|Maintenance Period (16-48 Week)|Adverse Event|0
6334447|NCT03107793|10083853|FG001|Maintenance Period (16-48 Week)|Adverse Event|6
6334448|NCT03107793|10083854|FG002|Maintenance Period (16-48 Week)|Adverse Event|10
6334449|NCT03107793|10083852|FG000|Maintenance Period (16-48 Week)|Death|0
6334450|NCT03107793|10083853|FG001|Maintenance Period (16-48 Week)|Death|2
6334451|NCT03107793|10083854|FG002|Maintenance Period (16-48 Week)|Death|0
6334452|NCT03107793|10083852|FG000|Maintenance Period (16-48 Week)|Lack of Efficacy|0
6334453|NCT03107793|10083853|FG001|Maintenance Period (16-48 Week)|Lack of Efficacy|21
6334454|NCT03107793|10083854|FG002|Maintenance Period (16-48 Week)|Lack of Efficacy|8
6334455|NCT03107793|10083852|FG000|Maintenance Period (16-48 Week)|Lost to Follow-up|0
6334456|NCT03107793|10083853|FG001|Maintenance Period (16-48 Week)|Lost to Follow-up|1
6334457|NCT03107793|10083854|FG002|Maintenance Period (16-48 Week)|Lost to Follow-up|0
6334458|NCT03107793|10083852|FG000|Maintenance Period (16-48 Week)|Withdrawal by Subject|0
6334459|NCT03107793|10083853|FG001|Maintenance Period (16-48 Week)|Withdrawal by Subject|12
6334460|NCT03107793|10083854|FG002|Maintenance Period (16-48 Week)|Withdrawal by Subject|4
6334461|NCT03107793|10083852|FG000|Maintenance Period (16-48 Week)|Physician Decision|0
6334462|NCT03107793|10083853|FG001|Maintenance Period (16-48 Week)|Physician Decision|1
6334463|NCT03107793|10083854|FG002|Maintenance Period (16-48 Week)|Physician Decision|2
6334464|NCT03107793|10083852|FG000|Maintenance Period (16-48 Week)|Pregnancy|0
6334465|NCT03107793|10083853|FG001|Maintenance Period (16-48 Week)|Pregnancy|1
6334466|NCT03107793|10083854|FG002|Maintenance Period (16-48 Week)|Pregnancy|1
6334467|NCT03107793|10083852|FG000|Maintenance Period (16-48 Week)|Disease Relapse|0
6334468|NCT03107793|10083853|FG001|Maintenance Period (16-48 Week)|Disease Relapse|2
6334469|NCT03107793|10083854|FG002|Maintenance Period (16-48 Week)|Disease Relapse|1
6334470|NCT03107793|10083852|FG000|Maintenance Period (16-48 Week)|Progressive Disease|0
6334471|NCT03107793|10083853|FG001|Maintenance Period (16-48 Week)|Progressive Disease|0
6334472|NCT03107793|10083854|FG002|Maintenance Period (16-48 Week)|Progressive Disease|1
6334473|NCT03107793|10083852|FG000|Maintenance Period (16-48 Week)|Received A Disallowed Concomitant Treatment|0
6334474|NCT03107793|10083853|FG001|Maintenance Period (16-48 Week)|Received A Disallowed Concomitant Treatment|0
6334475|NCT03107793|10083854|FG002|Maintenance Period (16-48 Week)|Received A Disallowed Concomitant Treatment|1
6334476|NCT03108027|10083861|FG000|Period 1|Subject/Guardian Decision|0
6334477|NCT03108027|10083862|FG001|Period 1|Subject/Guardian Decision|0
6334478|NCT03108027|10083863|FG002|Period 1|Subject/Guardian Decision|0
6334479|NCT03108027|10083864|FG003|Period 1|Subject/Guardian Decision|2
6334480|NCT03108027|10083865|FG004|Period 1|Subject/Guardian Decision|0
6334481|NCT03108027|10083866|FG005|Period 1|Subject/Guardian Decision|0
6334482|NCT03108027|10083861|FG000|Period 3|Adverse Event|0
6334483|NCT03108027|10083862|FG001|Period 3|Adverse Event|1
6167824|NCT01231620|9812723|FG001|Overall Study|Physician Decision|5
6167825|NCT01231620|9812724|FG002|Overall Study|Physician Decision|10
6167826|NCT01231620|9812722|FG000|Overall Study|Death|12
6167827|NCT01231620|9812723|FG001|Overall Study|Death|14
6167828|NCT01231620|9812724|FG002|Overall Study|Death|11
6167829|NCT01231620|9812722|FG000|Overall Study|Adverse Event|2
6167830|NCT01231620|9812723|FG001|Overall Study|Adverse Event|2
6167831|NCT01231620|9812724|FG002|Overall Study|Adverse Event|1
6167832|NCT01231620|9812722|FG000|Overall Study|Withdrawal by Subject|6
6167833|NCT01231620|9812723|FG001|Overall Study|Withdrawal by Subject|6
6167834|NCT01231620|9812724|FG002|Overall Study|Withdrawal by Subject|8
6167835|NCT01231620|9812722|FG000|Overall Study|Lost to Follow-up|3
6167836|NCT01231620|9812723|FG001|Overall Study|Lost to Follow-up|4
6167837|NCT01231620|9812724|FG002|Overall Study|Lost to Follow-up|9
6167838|NCT01231659|9812752|FG000|Overall Study|Adverse Event|9
6167839|NCT01231659|9812752|FG000|Overall Study|Disease Progression|48
6167840|NCT01231659|9812752|FG000|Overall Study|Death|2
6167841|NCT01231659|9812752|FG000|Overall Study|Patient refused to complete study visit|1
6167842|NCT01231659|9812752|FG000|Overall Study|Other protocol defined criteria|12
6167843|NCT01231984|9812762|FG000|Study Period 1|Withdrawal by Subject|0
6334484|NCT03108027|10083863|FG002|Period 3|Adverse Event|0
6334485|NCT03108027|10083864|FG003|Period 3|Adverse Event|0
6334486|NCT03108027|10083865|FG004|Period 3|Adverse Event|0
6334487|NCT03108027|10083866|FG005|Period 3|Adverse Event|0
6167844|NCT01231984|9812763|FG001|Study Period 1|Withdrawal by Subject|0
6167845|NCT01231984|9812764|FG002|Study Period 1|Withdrawal by Subject|0
6334488|NCT03108157|10083876|FG000|Overall Study|Protocol Violation|15
6334489|NCT03108157|10083877|FG001|Overall Study|Protocol Violation|4
6334490|NCT03108521|10083912|FG000|Overall Study|Lost to Follow-up|3
6334491|NCT03108521|10083913|FG001|Overall Study|Lost to Follow-up|0
6334492|NCT03108521|10083912|FG000|Overall Study|Lack of Efficacy|2
6334493|NCT03108521|10083913|FG001|Overall Study|Lack of Efficacy|0
6334494|NCT03108521|10083912|FG000|Overall Study|Physician Decision|4
6334495|NCT03108521|10083913|FG001|Overall Study|Physician Decision|0
6334496|NCT03108521|10083912|FG000|Overall Study|Adverse Event|3
6334497|NCT03108521|10083913|FG001|Overall Study|Adverse Event|0
6167846|NCT01231984|9812765|FG003|Study Period 1|Withdrawal by Subject|1
6167847|NCT01231984|9812762|FG000|Study Period 1|Lost to Follow-up|1
6167848|NCT01231984|9812763|FG001|Study Period 1|Lost to Follow-up|1
6167849|NCT01231984|9812764|FG002|Study Period 1|Lost to Follow-up|1
6167850|NCT01231984|9812765|FG003|Study Period 1|Lost to Follow-up|0
6192184|NCT01428583|9849306|FG000|Overall Study|Physician Decision|12
6334498|NCT03109184|10083960|FG000|Overall Study|Lost to Follow-up|6
6334499|NCT03109184|10083961|FG001|Overall Study|Lost to Follow-up|6
6334500|NCT03109184|10083960|FG000|Overall Study|Withdrawal by Subject|1
6334501|NCT03109184|10083961|FG001|Overall Study|Withdrawal by Subject|1
6334502|NCT03110029|10083991|FG000|Overall Study|Withdrawal by Subject|1
6334503|NCT03110029|10083992|FG001|Overall Study|Withdrawal by Subject|1
6334504|NCT03110185|10084000|FG000|Overall Study|Death|0
6334505|NCT03110185|10084001|FG001|Overall Study|Death|1
6334506|NCT03110185|10084000|FG000|Overall Study|Withdrawal by Subject|2
6334507|NCT03110185|10084001|FG001|Overall Study|Withdrawal by Subject|7
6334508|NCT03110185|10084000|FG000|Overall Study|Time Constraints|0
6334509|NCT03110185|10084001|FG001|Overall Study|Time Constraints|6
6334510|NCT03110185|10084000|FG000|Overall Study|Conflict with care|5
6334511|NCT03110185|10084001|FG001|Overall Study|Conflict with care|12
6334512|NCT03110185|10084000|FG000|Overall Study|Protocol Violation|1
6334513|NCT03110185|10084001|FG001|Overall Study|Protocol Violation|4
6334514|NCT03110185|10084000|FG000|Overall Study|MRI Incompatible|2
6334515|NCT03110185|10084001|FG001|Overall Study|MRI Incompatible|0
6334516|NCT03110185|10084000|FG000|Overall Study|Patient Refusal|0
6167851|NCT01231984|9812762|FG000|Study Period 1|Did not continue to meet I/E Criteria|2
6167852|NCT01231984|9812763|FG001|Study Period 1|Did not continue to meet I/E Criteria|2
6167853|NCT01231984|9812764|FG002|Study Period 1|Did not continue to meet I/E Criteria|2
6167854|NCT01231984|9812765|FG003|Study Period 1|Did not continue to meet I/E Criteria|2
6167855|NCT01231984|9812762|FG000|Study Period 1|Screen Failure|0
6167856|NCT01231984|9812763|FG001|Study Period 1|Screen Failure|0
6167857|NCT01231984|9812764|FG002|Study Period 1|Screen Failure|0
6167858|NCT01231984|9812765|FG003|Study Period 1|Screen Failure|1
6167859|NCT01231984|9812762|FG000|Study Period 1|Non-compliance with study requirements|5
6167860|NCT01231984|9812763|FG001|Study Period 1|Non-compliance with study requirements|0
6167861|NCT01231984|9812764|FG002|Study Period 1|Non-compliance with study requirements|2
6167862|NCT01231984|9812765|FG003|Study Period 1|Non-compliance with study requirements|1
6167863|NCT01231984|9812762|FG000|Study Period 1|Protocol Violation|3
6167864|NCT01231984|9812763|FG001|Study Period 1|Protocol Violation|4
6167865|NCT01231984|9812764|FG002|Study Period 1|Protocol Violation|2
6167866|NCT01231984|9812765|FG003|Study Period 1|Protocol Violation|3
6167867|NCT01231984|9812762|FG000|Study Period 1|Adverse Event|1
6167868|NCT01231984|9812763|FG001|Study Period 1|Adverse Event|0
6167869|NCT01231984|9812764|FG002|Study Period 1|Adverse Event|0
6167870|NCT01231984|9812765|FG003|Study Period 1|Adverse Event|0
6167871|NCT01231984|9812762|FG000|Study Period 1|Other|0
6167872|NCT01231984|9812763|FG001|Study Period 1|Other|0
6167873|NCT01231984|9812764|FG002|Study Period 1|Other|0
6167874|NCT01231984|9812765|FG003|Study Period 1|Other|1
6042879|NCT00385736|9641356|FG000|Efficacy Analysis Set - Maintenance|Protocol Violation|2
6042880|NCT00385736|9641357|FG001|Efficacy Analysis Set - Maintenance|Protocol Violation|1
6042881|NCT00385736|9641358|FG002|Efficacy Analysis Set - Maintenance|Protocol Violation|6
6042882|NCT00385736|9641356|FG000|Efficacy Analysis Set - Maintenance|Other|0
6042883|NCT00385736|9641357|FG001|Efficacy Analysis Set - Maintenance|Other|4
6042884|NCT00385736|9641358|FG002|Efficacy Analysis Set - Maintenance|Other|4
6167875|NCT01231984|9812762|FG000|Study Period 2|Withdrawal by Subject|1
6167876|NCT01231984|9812763|FG001|Study Period 2|Withdrawal by Subject|1
6167877|NCT01231984|9812764|FG002|Study Period 2|Withdrawal by Subject|0
6167878|NCT01231984|9812765|FG003|Study Period 2|Withdrawal by Subject|0
6167879|NCT01231984|9812762|FG000|Study Period 2|Lost to Follow-up|1
6167880|NCT01231984|9812763|FG001|Study Period 2|Lost to Follow-up|0
6167881|NCT01231984|9812764|FG002|Study Period 2|Lost to Follow-up|0
6167882|NCT01231984|9812765|FG003|Study Period 2|Lost to Follow-up|3
6167883|NCT01231984|9812762|FG000|Study Period 2|Did not continue to meet I/E Criteria|1
6167884|NCT01231984|9812763|FG001|Study Period 2|Did not continue to meet I/E Criteria|1
6167885|NCT01231984|9812764|FG002|Study Period 2|Did not continue to meet I/E Criteria|0
6167886|NCT01231984|9812765|FG003|Study Period 2|Did not continue to meet I/E Criteria|1
6167887|NCT01232127|9812783|FG000|Period 1: Days 1-10|Discontinued due to dosing error|1
6167888|NCT01232127|9812784|FG001|Period 1: Days 1-10|Discontinued due to dosing error|0
6167889|NCT01232127|9812785|FG002|Period 1: Days 1-10|Discontinued due to dosing error|0
6167890|NCT01232296|9812808|FG000|Overall Study|Adverse Event|24
6167891|NCT01232296|9812809|FG001|Overall Study|Adverse Event|12
6167892|NCT01232296|9812808|FG000|Overall Study|Physician Decision|1
6167893|NCT01232296|9812809|FG001|Overall Study|Physician Decision|1
6167894|NCT01232296|9812808|FG000|Overall Study|Progressive disease|43
6334517|NCT03110185|10084001|FG001|Overall Study|Patient Refusal|1
6334518|NCT03110562|10084032|FG000|Overall Study|Withdrawal by Subject|37
6167895|NCT01232296|9812809|FG001|Overall Study|Progressive disease|61
6167896|NCT01232296|9812808|FG000|Overall Study|Study terminated by sponsor|0
6167897|NCT01232296|9812809|FG001|Overall Study|Study terminated by sponsor|1
6167898|NCT01232296|9812808|FG000|Overall Study|Technical problems|3
6167899|NCT01232296|9812809|FG001|Overall Study|Technical problems|0
6334519|NCT03110562|10084033|FG001|Overall Study|Withdrawal by Subject|35
6334520|NCT03110562|10084032|FG000|Overall Study|Death|47
6334521|NCT03110562|10084033|FG001|Overall Study|Death|61
6167900|NCT01232296|9812808|FG000|Overall Study|Subject/guardian decision|10
6167901|NCT01232296|9812809|FG001|Overall Study|Subject/guardian decision|2
6334522|NCT03110562|10084032|FG000|Overall Study|Lost to Follow-up|7
6334523|NCT03110562|10084033|FG001|Overall Study|Lost to Follow-up|6
6334524|NCT03110562|10084032|FG000|Overall Study|Other|2
6334525|NCT03110562|10084033|FG001|Overall Study|Other|1
6334526|NCT03110562|10084032|FG000|Overall Study|Randomized but never treated|0
6334527|NCT03110562|10084033|FG001|Overall Study|Randomized but never treated|3
6334528|NCT03110562|10084032|FG000|Overall Study|Ongoing|102
6334529|NCT03110562|10084033|FG001|Overall Study|Ongoing|101
6334530|NCT03110770|10084060|FG000|Overall Study|Death|1
6334531|NCT03110770|10084061|FG001|Overall Study|Death|0
6334532|NCT03110770|10084062|FG002|Overall Study|Death|0
6334533|NCT03110770|10084063|FG003|Overall Study|Death|1
6334534|NCT03110770|10084064|FG004|Overall Study|Death|0
6334535|NCT03110770|10084060|FG000|Overall Study|Enrolled but did not receive product|0
6334536|NCT03110770|10084061|FG001|Overall Study|Enrolled but did not receive product|0
6334537|NCT03110770|10084062|FG002|Overall Study|Enrolled but did not receive product|0
6334538|NCT03110770|10084063|FG003|Overall Study|Enrolled but did not receive product|8
6334539|NCT03110770|10084064|FG004|Overall Study|Enrolled but did not receive product|7
6334540|NCT03110770|10084060|FG000|Overall Study|Lost to Follow-up|0
6334541|NCT03110770|10084061|FG001|Overall Study|Lost to Follow-up|0
6334542|NCT03110770|10084062|FG002|Overall Study|Lost to Follow-up|0
6334543|NCT03110770|10084063|FG003|Overall Study|Lost to Follow-up|53
6334544|NCT03110770|10084064|FG004|Overall Study|Lost to Follow-up|45
6167902|NCT01232296|9812808|FG000|Overall Study|Death|1
6167903|NCT01232296|9812809|FG001|Overall Study|Death|6
6167904|NCT01232452|9812817|FG000|Overall Study|Adverse Event|17
6167905|NCT01232452|9812818|FG001|Overall Study|Adverse Event|15
6167906|NCT01232452|9812817|FG000|Overall Study|Withdrawal by Subject|11
6167907|NCT01232452|9812818|FG001|Overall Study|Withdrawal by Subject|8
6167908|NCT01232452|9812817|FG000|Overall Study|Physician Decision|8
6167909|NCT01232452|9812818|FG001|Overall Study|Physician Decision|12
6167910|NCT01232452|9812817|FG000|Overall Study|Protocol entry criterion not met|0
6167911|NCT01232452|9812818|FG001|Overall Study|Protocol entry criterion not met|2
6167912|NCT01232452|9812817|FG000|Overall Study|Sponsor Decision|3
6167913|NCT01232452|9812818|FG001|Overall Study|Sponsor Decision|1
6167914|NCT01232452|9812817|FG000|Overall Study|Protocol Violation|0
6167915|NCT01232452|9812818|FG001|Overall Study|Protocol Violation|1
6167916|NCT01232491|9812835|FG000|Overall Study|Adverse Event|13
6167917|NCT01232491|9812836|FG001|Overall Study|Adverse Event|8
6167918|NCT01232491|9812835|FG000|Overall Study|Lack of Efficacy|1
6167919|NCT01232491|9812836|FG001|Overall Study|Lack of Efficacy|5
6167920|NCT01232491|9812835|FG000|Overall Study|Protocol Violation|13
6167921|NCT01232491|9812836|FG001|Overall Study|Protocol Violation|11
6167922|NCT01232491|9812835|FG000|Overall Study|Withdrawal Criteria|12
6167923|NCT01232491|9812836|FG001|Overall Study|Withdrawal Criteria|21
6167924|NCT01232491|9812835|FG000|Overall Study|Other|21
6167925|NCT01232491|9812836|FG001|Overall Study|Other|18
6167926|NCT01232556|9812865|FG000|Overall Study|Withdrawal by Subject|21
6167927|NCT01232556|9812866|FG001|Overall Study|Withdrawal by Subject|17
6167928|NCT01232556|9812865|FG000|Overall Study|Death|97
6167929|NCT01232556|9812866|FG001|Overall Study|Death|97
6167930|NCT01232556|9812865|FG000|Overall Study|Lost to Follow-up|0
6167931|NCT01232556|9812866|FG001|Overall Study|Lost to Follow-up|2
6167932|NCT01232556|9812865|FG000|Overall Study|Terminated by Sponsor|35
6167933|NCT01232556|9812866|FG001|Overall Study|Terminated by Sponsor|51
6167934|NCT01232556|9812865|FG000|Overall Study|Other|6
6167935|NCT01232556|9812866|FG001|Overall Study|Other|4
6167936|NCT01232569|9812874|FG000|Double-blind Treatment Period|Withdrawal by Subject|9
6167937|NCT01232569|9812875|FG001|Double-blind Treatment Period|Withdrawal by Subject|2
6167938|NCT01232569|9812876|FG002|Double-blind Treatment Period|Withdrawal by Subject|0
6167939|NCT01232569|9812877|FG003|Double-blind Treatment Period|Withdrawal by Subject|0
6167940|NCT01232569|9812874|FG000|Double-blind Treatment Period|Escape|2
6167941|NCT01232569|9812875|FG001|Double-blind Treatment Period|Escape|2
6167942|NCT01232569|9812876|FG002|Double-blind Treatment Period|Escape|0
6167943|NCT01232569|9812877|FG003|Double-blind Treatment Period|Escape|0
6167944|NCT01232569|9812874|FG000|Double-blind Treatment Period|Lost to Follow-up|4
6167945|NCT01232569|9812875|FG001|Double-blind Treatment Period|Lost to Follow-up|0
6167946|NCT01232569|9812876|FG002|Double-blind Treatment Period|Lost to Follow-up|0
6167947|NCT01232569|9812877|FG003|Double-blind Treatment Period|Lost to Follow-up|0
6167948|NCT01232569|9812874|FG000|Double-blind Treatment Period|Lack of Efficacy|1
6167949|NCT01232569|9812875|FG001|Double-blind Treatment Period|Lack of Efficacy|2
6334545|NCT03110770|10084060|FG000|Overall Study|Investigator Decision|0
6334546|NCT03110770|10084061|FG001|Overall Study|Investigator Decision|0
6334547|NCT03110770|10084062|FG002|Overall Study|Investigator Decision|0
6334548|NCT03110770|10084063|FG003|Overall Study|Investigator Decision|5
6334549|NCT03110770|10084064|FG004|Overall Study|Investigator Decision|3
6334550|NCT03110770|10084060|FG000|Overall Study|Withdrawal by Subject|0
6167950|NCT01232569|9812876|FG002|Double-blind Treatment Period|Lack of Efficacy|0
6167951|NCT01232569|9812877|FG003|Double-blind Treatment Period|Lack of Efficacy|0
6167952|NCT01232569|9812874|FG000|Double-blind Treatment Period|Physician Decision|1
6167953|NCT01232569|9812875|FG001|Double-blind Treatment Period|Physician Decision|0
6334551|NCT03110770|10084061|FG001|Overall Study|Withdrawal by Subject|0
6334552|NCT03110770|10084062|FG002|Overall Study|Withdrawal by Subject|0
6334553|NCT03110770|10084063|FG003|Overall Study|Withdrawal by Subject|24
6334554|NCT03110770|10084064|FG004|Overall Study|Withdrawal by Subject|24
6334555|NCT03110770|10084060|FG000|Overall Study|Moved from area|5
6334556|NCT03110770|10084061|FG001|Overall Study|Moved from area|0
6334557|NCT03110770|10084062|FG002|Overall Study|Moved from area|2
6334558|NCT03110770|10084063|FG003|Overall Study|Moved from area|42
6334559|NCT03110770|10084064|FG004|Overall Study|Moved from area|43
6334560|NCT03110770|10084060|FG000|Overall Study|Illness/Injury unrelated to product|0
6334561|NCT03110770|10084061|FG001|Overall Study|Illness/Injury unrelated to product|0
6334562|NCT03110770|10084062|FG002|Overall Study|Illness/Injury unrelated to product|0
6334563|NCT03110770|10084063|FG003|Overall Study|Illness/Injury unrelated to product|0
6334564|NCT03110770|10084064|FG004|Overall Study|Illness/Injury unrelated to product|1
6334565|NCT03111108|10084080|FG000|Overall Study|Death|0
6334566|NCT03111108|10084081|FG001|Overall Study|Death|1
6334567|NCT03111108|10084080|FG000|Overall Study|Withdrawal by Subject|1
6334568|NCT03111108|10084081|FG001|Overall Study|Withdrawal by Subject|0
6334569|NCT03113916|10084192|FG000|Overall Study|Withdrawal by Subject|9
6334570|NCT03113916|10084193|FG001|Overall Study|Withdrawal by Subject|7
6334571|NCT03113916|10084192|FG000|Overall Study|Pregnancy|1
6334572|NCT03113916|10084193|FG001|Overall Study|Pregnancy|3
6334573|NCT03113916|10084192|FG000|Overall Study|Lost to Follow-up|1
6334574|NCT03113916|10084193|FG001|Overall Study|Lost to Follow-up|2
6334575|NCT03114488|10084213|FG000|Time Period 2|Withdrawal by Subject|1
6334576|NCT03114488|10084214|FG001|Time Period 2|Withdrawal by Subject|3
6334577|NCT03114657|10084226|FG000|Overall Study|Adverse Event|9
6334578|NCT03114657|10084227|FG001|Overall Study|Adverse Event|6
6334579|NCT03114657|10084226|FG000|Overall Study|Death|4
6334580|NCT03114657|10084227|FG001|Overall Study|Death|0
6334581|NCT03114657|10084226|FG000|Overall Study|Multiple Reasons|1
6334582|NCT03114657|10084227|FG001|Overall Study|Multiple Reasons|2
6334583|NCT03114657|10084226|FG000|Overall Study|Physician Decision|2
6334584|NCT03114657|10084227|FG001|Overall Study|Physician Decision|2
6334585|NCT03114657|10084226|FG000|Overall Study|Study Terminated By Sponsor|355
6334586|NCT03114657|10084227|FG001|Overall Study|Study Terminated By Sponsor|374
6334587|NCT03114657|10084226|FG000|Overall Study|Symptomatic Deterioration|0
6334588|NCT03114657|10084227|FG001|Overall Study|Symptomatic Deterioration|1
6334589|NCT03114657|10084226|FG000|Overall Study|Withdrawal by Subject|28
6334590|NCT03114657|10084227|FG001|Overall Study|Withdrawal by Subject|22
6334591|NCT03114969|10084247|FG000|Overall Study|Lost to Follow-up|0
6334592|NCT03114969|10084248|FG001|Overall Study|Lost to Follow-up|0
6334593|NCT03114969|10084249|FG002|Overall Study|Lost to Follow-up|3
6334594|NCT03114969|10084250|FG003|Overall Study|Lost to Follow-up|2
6334595|NCT03114969|10084251|FG004|Overall Study|Lost to Follow-up|0
6334596|NCT03114969|10084252|FG005|Overall Study|Lost to Follow-up|0
6334597|NCT03114969|10084253|FG006|Overall Study|Lost to Follow-up|0
6334598|NCT03114969|10084254|FG007|Overall Study|Lost to Follow-up|0
6334599|NCT03114969|10084255|FG008|Overall Study|Lost to Follow-up|0
6334600|NCT03114969|10084247|FG000|Overall Study|Adverse Event|0
6334601|NCT03114969|10084248|FG001|Overall Study|Adverse Event|0
6334602|NCT03114969|10084249|FG002|Overall Study|Adverse Event|1
6334603|NCT03114969|10084250|FG003|Overall Study|Adverse Event|0
6334604|NCT03114969|10084251|FG004|Overall Study|Adverse Event|0
6334605|NCT03114969|10084252|FG005|Overall Study|Adverse Event|1
6334606|NCT03114969|10084253|FG006|Overall Study|Adverse Event|1
6334607|NCT03114969|10084254|FG007|Overall Study|Adverse Event|0
6334608|NCT03114969|10084255|FG008|Overall Study|Adverse Event|2
6334609|NCT03115112|10084297|FG000|Overall Study|Adverse Event|5
6334610|NCT03115112|10084298|FG001|Overall Study|Adverse Event|1
6334611|NCT03115112|10084297|FG000|Overall Study|Withdrawal by Subject|4
6334612|NCT03115112|10084298|FG001|Overall Study|Withdrawal by Subject|2
6334613|NCT03115112|10084297|FG000|Overall Study|Lost to Follow-up|0
6334614|NCT03115112|10084298|FG001|Overall Study|Lost to Follow-up|1
6334615|NCT03115112|10084297|FG000|Overall Study|Death|1
6334616|NCT03115112|10084298|FG001|Overall Study|Death|0
6334617|NCT03115112|10084297|FG000|Overall Study|Pregnancy|1
6334618|NCT03115112|10084298|FG001|Overall Study|Pregnancy|0
6334619|NCT03115112|10084297|FG000|Overall Study|Site closure|1
6334620|NCT03115112|10084298|FG001|Overall Study|Site closure|1
6334621|NCT03115476|10084322|FG000|LP0084-1369|Death|1
6334622|NCT03115476|10084323|FG001|LP0084-1369|Death|0
6334623|NCT03115476|10084324|FG002|LP0084-1369|Death|2
6334624|NCT03115476|10084322|FG000|LP0084-1369|Trial terminated by Sponsor|190
6334625|NCT03115476|10084323|FG001|LP0084-1369|Trial terminated by Sponsor|210
6334626|NCT03115476|10084324|FG002|LP0084-1369|Trial terminated by Sponsor|160
6334627|NCT03116152|10084356|FG000|Overall Study|Disease Progression|49
6334628|NCT03116152|10084357|FG001|Overall Study|Disease Progression|47
6334629|NCT03116152|10084356|FG000|Overall Study|Death|5
6334630|NCT03116152|10084357|FG001|Overall Study|Death|2
6334631|NCT03116152|10084356|FG000|Overall Study|Adverse Event|21
6334632|NCT03116152|10084357|FG001|Overall Study|Adverse Event|7
6334633|NCT03116152|10084356|FG000|Overall Study|Protocol Violation|2
6334634|NCT03116152|10084357|FG001|Overall Study|Protocol Violation|2
6334635|NCT03116152|10084356|FG000|Overall Study|Withdrawal by Subject|0
6334636|NCT03116152|10084357|FG001|Overall Study|Withdrawal by Subject|1
6334637|NCT03116152|10084356|FG000|Overall Study|Physician Decision|3
6334638|NCT03116152|10084357|FG001|Overall Study|Physician Decision|2
6334639|NCT03116152|10084356|FG000|Overall Study|other|11
6334640|NCT03116152|10084357|FG001|Overall Study|other|34
6334641|NCT03116698|10084376|FG000|Overall Study|Adverse Event|1
6334642|NCT03116698|10084377|FG001|Overall Study|Adverse Event|1
6334643|NCT03116698|10084378|FG002|Overall Study|Adverse Event|1
6334644|NCT03116698|10084379|FG003|Overall Study|Adverse Event|0
6334645|NCT03116698|10084376|FG000|Overall Study|Withdrawal by Subject|1
6334646|NCT03116698|10084377|FG001|Overall Study|Withdrawal by Subject|4
6334647|NCT03116698|10084378|FG002|Overall Study|Withdrawal by Subject|5
6334648|NCT03116698|10084379|FG003|Overall Study|Withdrawal by Subject|2
6334649|NCT03116698|10084376|FG000|Overall Study|Lost to Follow-up|2
6334650|NCT03116698|10084377|FG001|Overall Study|Lost to Follow-up|0
6334651|NCT03116698|10084378|FG002|Overall Study|Lost to Follow-up|0
6334652|NCT03116698|10084379|FG003|Overall Study|Lost to Follow-up|0
6334653|NCT03116698|10084376|FG000|Overall Study|Physician Decision|1
6334654|NCT03116698|10084377|FG001|Overall Study|Physician Decision|1
6334655|NCT03116698|10084378|FG002|Overall Study|Physician Decision|0
6334656|NCT03116698|10084379|FG003|Overall Study|Physician Decision|0
6334657|NCT03116698|10084376|FG000|Overall Study|Protocol Violation|1
6334658|NCT03116698|10084377|FG001|Overall Study|Protocol Violation|0
6334659|NCT03116698|10084378|FG002|Overall Study|Protocol Violation|0
6334660|NCT03116698|10084379|FG003|Overall Study|Protocol Violation|0
6334661|NCT03116698|10084376|FG000|Overall Study|Death|0
6334662|NCT03116698|10084377|FG001|Overall Study|Death|0
6334663|NCT03116698|10084378|FG002|Overall Study|Death|2
6334664|NCT03116698|10084379|FG003|Overall Study|Death|0
6334665|NCT03116828|10084391|FG000|Overall Study|Adverse Event|1
6334666|NCT03116828|10084392|FG001|Overall Study|Adverse Event|10
6334667|NCT03116828|10084391|FG000|Overall Study|Withdrawal by Subject|4
6334668|NCT03116828|10084392|FG001|Overall Study|Withdrawal by Subject|8
6334669|NCT03116828|10084391|FG000|Overall Study|OTHER|3
6334670|NCT03116828|10084392|FG001|Overall Study|OTHER|3
6334671|NCT03117361|10084422|FG000|Overall Study|Progressive disease|5
6334672|NCT03117361|10084422|FG000|Overall Study|Death|1
6334673|NCT03117361|10084422|FG000|Overall Study|Physician Decision|2
6334674|NCT03117361|10084422|FG000|Overall Study|On study treatment at the end of study|1
6334675|NCT03117361|10084422|FG000|Overall Study|Treatment-related adverse event|1
6334676|NCT03117738|10084463|FG000|Overall Study|Withdrawal by Subject|3
6334677|NCT03117738|10084464|FG001|Overall Study|Withdrawal by Subject|1
6334678|NCT03117738|10084463|FG000|Overall Study|Lost to Follow-up|1
6334679|NCT03117738|10084464|FG001|Overall Study|Lost to Follow-up|4
6334680|NCT03118297|10084472|FG000|Overall Study|Lost to Follow-up|0
6334681|NCT03118297|10084473|FG001|Overall Study|Lost to Follow-up|2
6334682|NCT03118518|10084485|FG000|Overall Study|Early Exit after treatment|2
6334683|NCT03118518|10084486|FG001|Overall Study|Early Exit after treatment|8
6334684|NCT03118518|10084485|FG000|Overall Study|Early Exit after randomization but prior to treatment|4
6334685|NCT03118518|10084486|FG001|Overall Study|Early Exit after randomization but prior to treatment|3
6334686|NCT03118739|10084503|FG000|Overall Study|Physician Decision|0
6334687|NCT03118739|10084504|FG001|Overall Study|Physician Decision|1
6334688|NCT03118739|10084503|FG000|Overall Study|Withdrawal by Subject|5
6334689|NCT03118739|10084504|FG001|Overall Study|Withdrawal by Subject|3
6334690|NCT03118739|10084503|FG000|Overall Study|Lost to Follow-up|2
6334691|NCT03118739|10084504|FG001|Overall Study|Lost to Follow-up|0
6334692|NCT03118765|10084515|FG000|Overall Study|Withdrawal by Subject|0
6334693|NCT03118765|10084516|FG001|Overall Study|Withdrawal by Subject|0
6334694|NCT03118765|10084517|FG002|Overall Study|Withdrawal by Subject|1
6334695|NCT03118765|10084518|FG003|Overall Study|Withdrawal by Subject|0
6334696|NCT03118765|10084519|FG004|Overall Study|Withdrawal by Subject|0
6334697|NCT03118765|10084515|FG000|Overall Study|Adverse Event|1
6334698|NCT03118765|10084516|FG001|Overall Study|Adverse Event|1
6334699|NCT03118765|10084517|FG002|Overall Study|Adverse Event|1
6334700|NCT03118765|10084518|FG003|Overall Study|Adverse Event|1
6334701|NCT03118765|10084519|FG004|Overall Study|Adverse Event|1
6334702|NCT03118765|10084515|FG000|Overall Study|Non compliance with Study Procedures|0
6334703|NCT03118765|10084516|FG001|Overall Study|Non compliance with Study Procedures|0
6334704|NCT03118765|10084517|FG002|Overall Study|Non compliance with Study Procedures|0
6334705|NCT03118765|10084518|FG003|Overall Study|Non compliance with Study Procedures|1
6334706|NCT03118765|10084519|FG004|Overall Study|Non compliance with Study Procedures|0
6334707|NCT03118765|10084515|FG000|Overall Study|Violation of Inclusion/ExclusionCriteria|0
6334708|NCT03118765|10084516|FG001|Overall Study|Violation of Inclusion/ExclusionCriteria|1
6334709|NCT03118765|10084517|FG002|Overall Study|Violation of Inclusion/ExclusionCriteria|1
6334710|NCT03118765|10084518|FG003|Overall Study|Violation of Inclusion/ExclusionCriteria|0
6334711|NCT03118765|10084519|FG004|Overall Study|Violation of Inclusion/ExclusionCriteria|0
6334712|NCT03118765|10084515|FG000|Overall Study|COPD Exacerbation|1
6334713|NCT03118765|10084516|FG001|Overall Study|COPD Exacerbation|0
6334714|NCT03118765|10084517|FG002|Overall Study|COPD Exacerbation|0
6334715|NCT03118765|10084518|FG003|Overall Study|COPD Exacerbation|1
6334716|NCT03118765|10084519|FG004|Overall Study|COPD Exacerbation|0
6334717|NCT03118765|10084515|FG000|Overall Study|Lost to Follow-up|1
6334718|NCT03118765|10084516|FG001|Overall Study|Lost to Follow-up|0
6334719|NCT03118765|10084517|FG002|Overall Study|Lost to Follow-up|1
6334720|NCT03118765|10084518|FG003|Overall Study|Lost to Follow-up|0
6334721|NCT03118765|10084519|FG004|Overall Study|Lost to Follow-up|0
6334722|NCT03118765|10084515|FG000|Overall Study|Sponsor Decision|1
6334723|NCT03118765|10084516|FG001|Overall Study|Sponsor Decision|0
6334724|NCT03118765|10084517|FG002|Overall Study|Sponsor Decision|1
6334725|NCT03118765|10084518|FG003|Overall Study|Sponsor Decision|0
6334726|NCT03118765|10084519|FG004|Overall Study|Sponsor Decision|1
6334727|NCT03118934|10084539|FG000|Overall Study|Adverse Event|0
6334728|NCT03118934|10084540|FG001|Overall Study|Adverse Event|0
6334729|NCT03118934|10084541|FG002|Overall Study|Adverse Event|0
6334730|NCT03118934|10084542|FG003|Overall Study|Adverse Event|0
6334731|NCT03118934|10084543|FG004|Overall Study|Adverse Event|0
6334732|NCT03118934|10084544|FG005|Overall Study|Adverse Event|1
6334733|NCT03118934|10084539|FG000|Overall Study|Physician Decision|0
6334734|NCT03118934|10084540|FG001|Overall Study|Physician Decision|0
6334735|NCT03118934|10084541|FG002|Overall Study|Physician Decision|0
6334736|NCT03118934|10084542|FG003|Overall Study|Physician Decision|0
6334737|NCT03118934|10084543|FG004|Overall Study|Physician Decision|0
6334738|NCT03118934|10084544|FG005|Overall Study|Physician Decision|1
6334739|NCT03118934|10084539|FG000|Overall Study|Discontinued prior to exposure|0
6334740|NCT03118934|10084540|FG001|Overall Study|Discontinued prior to exposure|1
6334741|NCT03118934|10084541|FG002|Overall Study|Discontinued prior to exposure|1
6334742|NCT03118934|10084542|FG003|Overall Study|Discontinued prior to exposure|1
6334743|NCT03118934|10084543|FG004|Overall Study|Discontinued prior to exposure|2
6334744|NCT03118934|10084544|FG005|Overall Study|Discontinued prior to exposure|0
6334745|NCT03118947|10084554|FG000|Overall Study|Adverse Event|7
6334746|NCT03118947|10084554|FG000|Overall Study|Death|3
6334747|NCT03118947|10084554|FG000|Overall Study|Lack of Efficacy|4
6334748|NCT03118947|10084554|FG000|Overall Study|Non-compliance with study drug|1
6334749|NCT03118947|10084554|FG000|Overall Study|Protocol Violation|2
6334750|NCT03118947|10084554|FG000|Overall Study|Withdrawal by Subject|3
6334751|NCT03118947|10084554|FG000|Overall Study|Withdrawal by caregiver|3
6334752|NCT03118947|10084554|FG000|Overall Study|Change in patient's living situation|4
6334753|NCT03118947|10084554|FG000|Overall Study|Lost to Follow-up|2
6334754|NCT03119610|10084604|FG000|Overall Study|Adverse Event|1
6334755|NCT03119610|10084605|FG001|Overall Study|Adverse Event|0
6334756|NCT03119610|10084604|FG000|Overall Study|Lost to Follow-up|0
6334757|NCT03119610|10084605|FG001|Overall Study|Lost to Follow-up|1
6334758|NCT03119688|10084636|FG000|Overall Study|Adverse Event|4
6334759|NCT03119701|10084655|FG000|6-day Dosing|Death|4
6334760|NCT03119701|10084656|FG001|6-day Dosing|Death|1
6334761|NCT03119701|10084655|FG000|6-day Dosing|Adverse Event|3
6334762|NCT03119701|10084656|FG001|6-day Dosing|Adverse Event|0
6334763|NCT03119701|10084655|FG000|6-day Dosing|Physician Decision|0
6334764|NCT03119701|10084656|FG001|6-day Dosing|Physician Decision|1
6334765|NCT03119701|10084655|FG000|6-day Dosing|Withdrawal by Subject|0
6334766|NCT03119701|10084656|FG001|6-day Dosing|Withdrawal by Subject|1
6334767|NCT03119701|10084655|FG000|Mid-term (Final) Follow-up at D90|Death|3
6334768|NCT03119701|10084656|FG001|Mid-term (Final) Follow-up at D90|Death|1
6334769|NCT03120013|10084678|FG000|First Intervention (2 Weeks)|Withdrawal by Subject|0
6334770|NCT03120013|10084679|FG001|First Intervention (2 Weeks)|Withdrawal by Subject|1
6334771|NCT03120351|10084687|FG000|Overall Study|Physician Decision|1
6334772|NCT03120351|10084688|FG001|Overall Study|Physician Decision|1
6334773|NCT03120520|10084698|FG000|Overall Study|Lost to Follow-up|1
6334774|NCT03120520|10084699|FG001|Overall Study|Lost to Follow-up|1
6334775|NCT03120520|10084700|FG002|Overall Study|Lost to Follow-up|1
6334776|NCT03120520|10084701|FG003|Overall Study|Lost to Follow-up|1
6334777|NCT03120520|10084698|FG000|Overall Study|Withdrawal by Subject|3
6334778|NCT03120520|10084699|FG001|Overall Study|Withdrawal by Subject|2
6334779|NCT03120520|10084700|FG002|Overall Study|Withdrawal by Subject|3
6334780|NCT03120520|10084701|FG003|Overall Study|Withdrawal by Subject|2
6334781|NCT03120520|10084698|FG000|Overall Study|Other|0
6334782|NCT03120520|10084699|FG001|Overall Study|Other|1
6334783|NCT03120520|10084700|FG002|Overall Study|Other|0
6334784|NCT03120520|10084701|FG003|Overall Study|Other|0
6334785|NCT03121950|10084761|FG000|Overall Study|Withdrawal by Subject|11
6334786|NCT03121950|10084762|FG001|Overall Study|Withdrawal by Subject|2
6334787|NCT03122145|10084772|FG000|Overall Study|Concurrent respiratory disease|3
6334788|NCT03122145|10084773|FG001|Overall Study|Concurrent respiratory disease|0
6334789|NCT03122171|10084779|FG000|Overall Study|Withdrawal by Subject|1
6334790|NCT03122184|10084785|FG000|Overall Study|Lost to Follow-up|4
6334791|NCT03122184|10084786|FG001|Overall Study|Lost to Follow-up|6
6334792|NCT03122184|10084785|FG000|Overall Study|Withdrawal by Subject|3
6334793|NCT03122184|10084786|FG001|Overall Study|Withdrawal by Subject|0
6334794|NCT03122184|10084785|FG000|Overall Study|Terminated due to cognitive problem|1
6334795|NCT03122184|10084786|FG001|Overall Study|Terminated due to cognitive problem|0
6334796|NCT03122223|10084796|FG000|Overall Study|Withdrawal by Subject|2
6334797|NCT03122223|10084797|FG001|Overall Study|Withdrawal by Subject|2
6334798|NCT03122223|10084798|FG002|Overall Study|Withdrawal by Subject|1
6334799|NCT03122223|10084799|FG003|Overall Study|Withdrawal by Subject|0
6334800|NCT03122223|10084796|FG000|Overall Study|Lost to Follow-up|0
6334801|NCT03122223|10084797|FG001|Overall Study|Lost to Follow-up|2
6334802|NCT03122223|10084798|FG002|Overall Study|Lost to Follow-up|2
6334803|NCT03122223|10084799|FG003|Overall Study|Lost to Follow-up|0
6334804|NCT03122223|10084796|FG000|Overall Study|Participant unable to adhere|1
6334805|NCT03122223|10084797|FG001|Overall Study|Participant unable to adhere|1
6334806|NCT03122223|10084798|FG002|Overall Study|Participant unable to adhere|1
6334807|NCT03122223|10084799|FG003|Overall Study|Participant unable to adhere|0
6334808|NCT03122457|10084809|FG000|Overall Study|Withdrawal by Subject|6
6334809|NCT03122535|10084813|FG000|Overall Study|Lost to Follow-up|68
6334810|NCT03122535|10084814|FG001|Overall Study|Lost to Follow-up|68
6334811|NCT03122535|10084813|FG000|Overall Study|Physician Decision|3
6334812|NCT03122535|10084814|FG001|Overall Study|Physician Decision|3
6334813|NCT03122535|10084813|FG000|Overall Study|Withdrawal by Subject|2
6334814|NCT03122535|10084814|FG001|Overall Study|Withdrawal by Subject|2
6334815|NCT03122548|10084820|FG000|Overall Study|Death|2
6334816|NCT03122548|10084820|FG000|Overall Study|Progression - subject went into hospice|1
6334817|NCT03122548|10084820|FG000|Overall Study|Study Terminated by Sponsor|2
6334818|NCT03122860|10084843|FG000|Overall Study|Discontinued Before Treatment|1
6334819|NCT03122860|10084844|FG001|Overall Study|Discontinued Before Treatment|1
6334820|NCT03122860|10084845|FG002|Overall Study|Discontinued Before Treatment|2
6334821|NCT03122860|10084846|FG003|Overall Study|Discontinued Before Treatment|0
6334822|NCT03122860|10084847|FG004|Overall Study|Discontinued Before Treatment|1
6334823|NCT03122860|10084848|FG005|Overall Study|Discontinued Before Treatment|0
6334824|NCT03122860|10084843|FG000|Overall Study|Adverse Event|1
6334825|NCT03122860|10084844|FG001|Overall Study|Adverse Event|0
6334826|NCT03122860|10084845|FG002|Overall Study|Adverse Event|1
6334827|NCT03122860|10084846|FG003|Overall Study|Adverse Event|1
6334828|NCT03122860|10084847|FG004|Overall Study|Adverse Event|0
6167954|NCT01232569|9812876|FG002|Double-blind Treatment Period|Physician Decision|0
6167955|NCT01232569|9812877|FG003|Double-blind Treatment Period|Physician Decision|0
6167956|NCT01232569|9812874|FG000|Double-blind Treatment Period|Adverse Event (Except Anaphylaxis)|9
6167957|NCT01232569|9812875|FG001|Double-blind Treatment Period|Adverse Event (Except Anaphylaxis)|3
6167958|NCT01232569|9812876|FG002|Double-blind Treatment Period|Adverse Event (Except Anaphylaxis)|0
6167959|NCT01232569|9812877|FG003|Double-blind Treatment Period|Adverse Event (Except Anaphylaxis)|0
6167960|NCT01232569|9812874|FG000|Double-blind Treatment Period|Death|2
6167961|NCT01232569|9812875|FG001|Double-blind Treatment Period|Death|0
6167962|NCT01232569|9812876|FG002|Double-blind Treatment Period|Death|0
6167963|NCT01232569|9812877|FG003|Double-blind Treatment Period|Death|0
6167964|NCT01232738|9812886|FG000|Overall Study|Death|3
6167965|NCT01232738|9812886|FG000|Overall Study|Physician Decision|2
6167966|NCT01232738|9812886|FG000|Overall Study|Lost to Follow-up|1
6167967|NCT01232738|9812886|FG000|Overall Study|Withdrawal by Subject|2
6167968|NCT01232738|9812886|FG000|Overall Study|Adverse Event|5
6167969|NCT01232790|9812894|FG000|Randomization|Withdrawal by Subject|2
6167970|NCT01232790|9812895|FG001|Randomization|Withdrawal by Subject|0
6167971|NCT01232790|9812894|FG000|Randomization|Protocol Violation|0
6167972|NCT01232790|9812895|FG001|Randomization|Protocol Violation|1
6167973|NCT01232790|9812894|FG000|Randomization|Physician Decision|0
6167974|NCT01232790|9812895|FG001|Randomization|Physician Decision|1
6167975|NCT01232790|9812894|FG000|Initial Assessment|Withdrawal by Subject|0
6167976|NCT01232790|9812895|FG001|Initial Assessment|Withdrawal by Subject|1
6167977|NCT01232790|9812894|FG000|First Crossover|Withdrawal by Subject|1
6167978|NCT01232790|9812895|FG001|First Crossover|Withdrawal by Subject|0
6167979|NCT01232790|9812894|FG000|Second Crossover|Withdrawal by Subject|1
6167980|NCT01232790|9812895|FG001|Second Crossover|Withdrawal by Subject|2
6167981|NCT01232868|9812917|FG000|Overall Study|Lost to Follow-up|2
6167982|NCT01232868|9812918|FG001|Overall Study|Lost to Follow-up|4
6167983|NCT01232894|9812926|FG000|Overall Study|Lost to Follow-up|0
6334829|NCT03122860|10084848|FG005|Overall Study|Adverse Event|0
6334830|NCT03122860|10084843|FG000|Overall Study|Lost to Follow-up|5
6334831|NCT03122860|10084844|FG001|Overall Study|Lost to Follow-up|2
6334832|NCT03122860|10084845|FG002|Overall Study|Lost to Follow-up|3
6334833|NCT03122860|10084846|FG003|Overall Study|Lost to Follow-up|3
6334834|NCT03122860|10084847|FG004|Overall Study|Lost to Follow-up|5
6334835|NCT03122860|10084848|FG005|Overall Study|Lost to Follow-up|4
6334836|NCT03122860|10084843|FG000|Overall Study|Subject Non-Compliance|0
6334837|NCT03122860|10084844|FG001|Overall Study|Subject Non-Compliance|0
6334838|NCT03122860|10084845|FG002|Overall Study|Subject Non-Compliance|1
6334839|NCT03122860|10084846|FG003|Overall Study|Subject Non-Compliance|0
6334840|NCT03122860|10084847|FG004|Overall Study|Subject Non-Compliance|0
6334841|NCT03122860|10084848|FG005|Overall Study|Subject Non-Compliance|0
6334842|NCT03122860|10084843|FG000|Overall Study|Withdrawal by Subject|3
6334843|NCT03122860|10084844|FG001|Overall Study|Withdrawal by Subject|2
6334844|NCT03122860|10084845|FG002|Overall Study|Withdrawal by Subject|5
6334845|NCT03122860|10084846|FG003|Overall Study|Withdrawal by Subject|7
6334846|NCT03122860|10084847|FG004|Overall Study|Withdrawal by Subject|9
6334847|NCT03122860|10084848|FG005|Overall Study|Withdrawal by Subject|8
6334848|NCT03122886|10084865|FG000|Overall Study|Withdrawal by Subject|1
6334849|NCT03122886|10084866|FG001|Overall Study|Withdrawal by Subject|2
6334850|NCT03123120|10084888|FG000|Overall Study|Lost to Follow-up|0
6334851|NCT03123120|10084889|FG001|Overall Study|Lost to Follow-up|1
6334852|NCT03123120|10084888|FG000|Overall Study|Withdrawal by Subject|0
6334853|NCT03123120|10084889|FG001|Overall Study|Withdrawal by Subject|1
6334854|NCT03123354|10084904|FG000|Overall Study|Physician Decision|6
6334855|NCT03123471|10084910|FG000|Placebo-controlled Phase|Adverse Event|3
6334856|NCT03123471|10084911|FG001|Placebo-controlled Phase|Adverse Event|8
6334857|NCT03123471|10084910|FG000|Placebo-controlled Phase|Lack of Efficacy|3
6334858|NCT03123471|10084911|FG001|Placebo-controlled Phase|Lack of Efficacy|4
6334859|NCT03123471|10084910|FG000|Placebo-controlled Phase|Withdrawal by Subject|6
6334860|NCT03123471|10084911|FG001|Placebo-controlled Phase|Withdrawal by Subject|16
6334861|NCT03123471|10084910|FG000|Placebo-controlled Phase|Non-compliance with Study Drug|3
6334862|NCT03123471|10084911|FG001|Placebo-controlled Phase|Non-compliance with Study Drug|0
6334863|NCT03123471|10084910|FG000|Placebo-controlled Phase|Lost to Follow-up|1
6334864|NCT03123471|10084911|FG001|Placebo-controlled Phase|Lost to Follow-up|3
6334865|NCT03123471|10084910|FG000|Placebo-controlled Phase|Protocol Deviation|2
6334866|NCT03123471|10084911|FG001|Placebo-controlled Phase|Protocol Deviation|1
6334867|NCT03123471|10084910|FG000|Placebo-controlled Phase|Miscellaneous|0
6334868|NCT03123471|10084911|FG001|Placebo-controlled Phase|Miscellaneous|1
6334869|NCT03123471|10084910|FG000|Apremilast Extension Phase|Lost to Follow-up|2
6334870|NCT03123471|10084911|FG001|Apremilast Extension Phase|Lost to Follow-up|5
6334871|NCT03123471|10084910|FG000|Apremilast Extension Phase|Adverse Event|1
6334872|NCT03123471|10084911|FG001|Apremilast Extension Phase|Adverse Event|5
6082897|NCT00632125|9691042|FG000|Overall Study|Renal transplantation|17
6082898|NCT00632125|9691042|FG000|Overall Study|Need for systemic immunosuppressive medi|8
6082899|NCT00632125|9691042|FG000|Overall Study|Non-compliance|8
6082900|NCT00632125|9691042|FG000|Overall Study|Development of uncontrolled hypertension|5
6082901|NCT00632125|9691042|FG000|Overall Study|Moved to other dialysis unit, etc.|102
6082902|NCT00632203|9691048|FG000|Overall Study|Did not start study treatment|1
6082903|NCT00632203|9691049|FG001|Overall Study|Did not start study treatment|0
6082904|NCT00632229|9691057|FG000|Overall Study|Adverse Event|6
6167984|NCT01232894|9812927|FG001|Overall Study|Lost to Follow-up|1
6167985|NCT01232894|9812926|FG000|Overall Study|Death|1
6167986|NCT01232894|9812927|FG001|Overall Study|Death|0
6167987|NCT01232894|9812926|FG000|Overall Study|Protocol Violation|1
6167988|NCT01232894|9812927|FG001|Overall Study|Protocol Violation|1
6167989|NCT01232894|9812926|FG000|Overall Study|Withdrawal by Subject|8
6167990|NCT01232894|9812927|FG001|Overall Study|Withdrawal by Subject|5
6167991|NCT01232894|9812926|FG000|Overall Study|Physician Decision|2
6167992|NCT01232894|9812927|FG001|Overall Study|Physician Decision|1
6167993|NCT01233050|9812957|FG000|Overall Study|protocol deviation (inclusion/exclusion)|8
6167994|NCT01233050|9812958|FG001|Overall Study|protocol deviation (inclusion/exclusion)|6
6167995|NCT01233076|9812964|FG000|Period 2, One Week|Lost to Follow-up|1
6167996|NCT01233076|9812965|FG001|Period 2, One Week|Lost to Follow-up|0
6167997|NCT01233232|9812974|FG000|Overall Study|Voluntary Discontinuation by Subject|1
6167998|NCT01233232|9812975|FG001|Overall Study|Voluntary Discontinuation by Subject|0
6167999|NCT01233232|9812976|FG002|Overall Study|Voluntary Discontinuation by Subject|0
6168000|NCT01233258|9812989|FG000|First Intervention (6 Months)|Withdrawal by Subject|0
6168001|NCT01233258|9812990|FG001|First Intervention (6 Months)|Withdrawal by Subject|0
6168002|NCT01233258|9812991|FG002|First Intervention (6 Months)|Withdrawal by Subject|0
6168003|NCT01233258|9812992|FG003|First Intervention (6 Months)|Withdrawal by Subject|1
6168004|NCT01233258|9812993|FG004|First Intervention (6 Months)|Withdrawal by Subject|0
6168005|NCT01233258|9812994|FG005|First Intervention (6 Months)|Withdrawal by Subject|1
6082905|NCT00632229|9691058|FG001|Overall Study|Adverse Event|0
6082906|NCT00632229|9691057|FG000|Overall Study|Lost to Follow-up|0
6168006|NCT01233258|9812989|FG000|First Intervention (6 Months)|Protocol Violation|0
6168007|NCT01233258|9812990|FG001|First Intervention (6 Months)|Protocol Violation|0
6168008|NCT01233258|9812991|FG002|First Intervention (6 Months)|Protocol Violation|1
6168009|NCT01233258|9812992|FG003|First Intervention (6 Months)|Protocol Violation|0
6168010|NCT01233258|9812993|FG004|First Intervention (6 Months)|Protocol Violation|0
6334873|NCT03123471|10084910|FG000|Apremilast Extension Phase|Lack of Efficacy|2
6334874|NCT03123471|10084911|FG001|Apremilast Extension Phase|Lack of Efficacy|8
6334875|NCT03123471|10084910|FG000|Apremilast Extension Phase|Withdrawal by Subject|3
6334876|NCT03123471|10084911|FG001|Apremilast Extension Phase|Withdrawal by Subject|7
6168011|NCT01233258|9812994|FG005|First Intervention (6 Months)|Protocol Violation|0
6334877|NCT03123588|10084925|FG000|Overall Study|Study Terminated by Sponsor|2
6334878|NCT03123588|10084926|FG001|Overall Study|Study Terminated by Sponsor|5
6334879|NCT03123588|10084925|FG000|Overall Study|Withdrawal by Subject|1
6334880|NCT03123588|10084926|FG001|Overall Study|Withdrawal by Subject|0
6168012|NCT01233258|9812989|FG000|First Intervention (6 Months)|Non-compliance with study medication|1
6334881|NCT03123588|10084925|FG000|Overall Study|Adverse Event|1
6334882|NCT03123588|10084926|FG001|Overall Study|Adverse Event|0
6334883|NCT03123588|10084925|FG000|Overall Study|Physician Decision|2
6334884|NCT03123588|10084926|FG001|Overall Study|Physician Decision|1
6334885|NCT03123861|10084950|FG000|Overall Study|Protocol Violation|1
6334886|NCT03123861|10084951|FG001|Overall Study|Protocol Violation|1
6334887|NCT03123861|10084950|FG000|Overall Study|Withdrawal by Subject|2
6334888|NCT03123861|10084951|FG001|Overall Study|Withdrawal by Subject|2
6334889|NCT03123939|10084970|FG000|Overall Study|Lack of Efficacy|6
6334890|NCT03123939|10084970|FG000|Overall Study|Death|5
6334891|NCT03123939|10084970|FG000|Overall Study|Physician Decision|2
6334892|NCT03123939|10084970|FG000|Overall Study|Subject/guardian decision|2
6334893|NCT03123939|10084970|FG000|Overall Study|Lost to Follow-up|1
6334894|NCT03123939|10084970|FG000|Overall Study|New therapy for study indication|1
6334895|NCT03123939|10084970|FG000|Overall Study|Protocol deviation|1
6334896|NCT03123939|10084970|FG000|Overall Study|Progressive disease|18
6334897|NCT03123939|10084970|FG000|Overall Study|Discontinued prior to CTL019 infusion due to death|4
6334898|NCT03123939|10084970|FG000|Overall Study|Discontinued prior to CTL019 infusion due to technical problems|1
6168013|NCT01233258|9812990|FG001|First Intervention (6 Months)|Non-compliance with study medication|0
6168014|NCT01233258|9812991|FG002|First Intervention (6 Months)|Non-compliance with study medication|0
6168015|NCT01233258|9812992|FG003|First Intervention (6 Months)|Non-compliance with study medication|0
6168016|NCT01233258|9812993|FG004|First Intervention (6 Months)|Non-compliance with study medication|0
6168017|NCT01233258|9812994|FG005|First Intervention (6 Months)|Non-compliance with study medication|0
6168018|NCT01233284|9813009|FG000|Period 1 (4 Weeks)|Lost to Follow-up|1
6168019|NCT01233284|9813010|FG001|Period 1 (4 Weeks)|Lost to Follow-up|0
6168020|NCT01233284|9813011|FG002|Period 1 (4 Weeks)|Lost to Follow-up|0
6168021|NCT01233284|9813012|FG003|Period 1 (4 Weeks)|Lost to Follow-up|0
6168022|NCT01233284|9813013|FG004|Period 1 (4 Weeks)|Lost to Follow-up|0
6168023|NCT01233284|9813009|FG000|Period 1 (4 Weeks)|Withdrawal by Subject|0
6168024|NCT01233284|9813010|FG001|Period 1 (4 Weeks)|Withdrawal by Subject|1
6168025|NCT01233284|9813011|FG002|Period 1 (4 Weeks)|Withdrawal by Subject|0
6168026|NCT01233284|9813012|FG003|Period 1 (4 Weeks)|Withdrawal by Subject|0
6168027|NCT01233284|9813013|FG004|Period 1 (4 Weeks)|Withdrawal by Subject|0
6168028|NCT01233284|9813009|FG000|Period 1 (4 Weeks)|Other|0
6168029|NCT01233284|9813010|FG001|Period 1 (4 Weeks)|Other|0
6168030|NCT01233284|9813011|FG002|Period 1 (4 Weeks)|Other|1
6168031|NCT01233284|9813012|FG003|Period 1 (4 Weeks)|Other|0
6168032|NCT01233284|9813013|FG004|Period 1 (4 Weeks)|Other|0
6168033|NCT01233284|9813009|FG000|Period 2 (4 Weeks)|Withdrawal by Subject|0
6168034|NCT01233284|9813010|FG001|Period 2 (4 Weeks)|Withdrawal by Subject|0
6168035|NCT01233284|9813011|FG002|Period 2 (4 Weeks)|Withdrawal by Subject|1
6168036|NCT01233284|9813012|FG003|Period 2 (4 Weeks)|Withdrawal by Subject|0
6168037|NCT01233284|9813013|FG004|Period 2 (4 Weeks)|Withdrawal by Subject|0
6168038|NCT01233284|9813009|FG000|Period 3 (4 Weeks)|Withdrawal by Subject|0
6168039|NCT01233284|9813010|FG001|Period 3 (4 Weeks)|Withdrawal by Subject|0
6168040|NCT01233284|9813011|FG002|Period 3 (4 Weeks)|Withdrawal by Subject|1
6168041|NCT01233284|9813012|FG003|Period 3 (4 Weeks)|Withdrawal by Subject|0
6168042|NCT01233284|9813013|FG004|Period 3 (4 Weeks)|Withdrawal by Subject|0
6168043|NCT01233284|9813009|FG000|Period 3 (4 Weeks)|Other|0
6168044|NCT01233284|9813010|FG001|Period 3 (4 Weeks)|Other|0
6168045|NCT01233284|9813011|FG002|Period 3 (4 Weeks)|Other|0
6168046|NCT01233284|9813012|FG003|Period 3 (4 Weeks)|Other|1
6168047|NCT01233284|9813013|FG004|Period 3 (4 Weeks)|Other|0
6168048|NCT01233284|9813009|FG000|Period 4 (4 Weeks)|Adverse Event|0
6168049|NCT01233284|9813010|FG001|Period 4 (4 Weeks)|Adverse Event|1
6168050|NCT01233284|9813011|FG002|Period 4 (4 Weeks)|Adverse Event|0
6168051|NCT01233284|9813012|FG003|Period 4 (4 Weeks)|Adverse Event|0
6168052|NCT01233284|9813013|FG004|Period 4 (4 Weeks)|Adverse Event|0
6168053|NCT01233284|9813009|FG000|Period 4 (4 Weeks)|Lost to Follow-up|0
6168054|NCT01233284|9813010|FG001|Period 4 (4 Weeks)|Lost to Follow-up|0
6168055|NCT01233284|9813011|FG002|Period 4 (4 Weeks)|Lost to Follow-up|0
6168056|NCT01233284|9813012|FG003|Period 4 (4 Weeks)|Lost to Follow-up|1
6168057|NCT01233284|9813013|FG004|Period 4 (4 Weeks)|Lost to Follow-up|0
6168058|NCT01233609|9813030|FG000|Overall Study|Death|1
6168059|NCT01233609|9813031|FG001|Overall Study|Death|0
6168060|NCT01233609|9813030|FG000|Overall Study|Lost to Follow-up|3
6168061|NCT01233609|9813031|FG001|Overall Study|Lost to Follow-up|1
6168062|NCT01233609|9813030|FG000|Overall Study|Adverse Event|2
6168063|NCT01233609|9813031|FG001|Overall Study|Adverse Event|1
6168064|NCT01233609|9813030|FG000|Overall Study|Withdrawal by Subject|3
6168065|NCT01233609|9813031|FG001|Overall Study|Withdrawal by Subject|0
6168066|NCT01233687|9813045|FG000|Phase II AMG 102 + Erlotinib|Death|1
6334899|NCT03124108|10084983|FG000|Overall Study|Adverse Event|0
6334900|NCT03124108|10084984|FG001|Overall Study|Adverse Event|1
6334901|NCT03124108|10084985|FG002|Overall Study|Adverse Event|0
6334902|NCT03124199|10085006|FG000|Overall Study|Lost to Follow-up|4
6334903|NCT03124381|10085036|FG000|Overall Study|Lost to Follow-up|1
5972105|NCT00950989|9557711|FG002|Overall Study|Withdrawal by Subject|0
6168067|NCT01233687|9813045|FG000|Phase II AMG 102 + Erlotinib|Physician Decision|2
6168068|NCT01233687|9813045|FG000|Phase II AMG 102 + Erlotinib|Withdrawal by Subject|1
6334904|NCT03124381|10085037|FG001|Overall Study|Lost to Follow-up|1
6334905|NCT03124381|10085036|FG000|Overall Study|Withdrawal by Subject|6
6334906|NCT03124381|10085037|FG001|Overall Study|Withdrawal by Subject|3
6334907|NCT03124381|10085036|FG000|Overall Study|Protocol Violation|0
6334908|NCT03124381|10085037|FG001|Overall Study|Protocol Violation|1
6334909|NCT03124381|10085036|FG000|Overall Study|Adverse Event|1
6334910|NCT03124381|10085037|FG001|Overall Study|Adverse Event|1
6334911|NCT03124381|10085036|FG000|Overall Study|Non-Compliance with Study Treatment|1
6334912|NCT03124381|10085037|FG001|Overall Study|Non-Compliance with Study Treatment|0
6334913|NCT03124407|10085047|FG000|Overall Study|Lost to Follow-up|1
6334914|NCT03124407|10085048|FG001|Overall Study|Lost to Follow-up|0
6334915|NCT03124407|10085049|FG002|Overall Study|Lost to Follow-up|0
6334916|NCT03124407|10085050|FG003|Overall Study|Lost to Follow-up|0
6334917|NCT03124407|10085047|FG000|Overall Study|Adverse Event|0
6334918|NCT03124407|10085048|FG001|Overall Study|Adverse Event|0
6334919|NCT03124407|10085049|FG002|Overall Study|Adverse Event|1
6334920|NCT03124407|10085050|FG003|Overall Study|Adverse Event|0
6334921|NCT03124459|10085070|FG000|Phase 2- Randomized Doubled-blind|Adverse Event|0
6334922|NCT03124459|10085071|FG001|Phase 2- Randomized Doubled-blind|Adverse Event|0
6334923|NCT03124459|10085072|FG002|Phase 2- Randomized Doubled-blind|Adverse Event|0
6334924|NCT03124459|10085073|FG003|Phase 2- Randomized Doubled-blind|Adverse Event|0
6334925|NCT03124459|10085074|FG004|Phase 2- Randomized Doubled-blind|Adverse Event|2
6334926|NCT03124459|10085075|FG005|Phase 2- Randomized Doubled-blind|Adverse Event|0
6334927|NCT03124459|10085070|FG000|Phase 2- Randomized Doubled-blind|Lost to Follow-up|0
6334928|NCT03124459|10085071|FG001|Phase 2- Randomized Doubled-blind|Lost to Follow-up|0
6334929|NCT03124459|10085072|FG002|Phase 2- Randomized Doubled-blind|Lost to Follow-up|0
6168069|NCT01233817|9813065|FG000|Overall Study|Lost to Follow-up|1
6168070|NCT01233817|9813065|FG000|Overall Study|Withdrawal by Subject|2
6168071|NCT01233869|9813073|FG000|Initial Treatment Period (24 Months)|Death|1
6168072|NCT01233869|9813074|FG001|Initial Treatment Period (24 Months)|Death|0
6168073|NCT01233869|9813075|FG002|Initial Treatment Period (24 Months)|Death|0
6168074|NCT01233869|9813076|FG003|Initial Treatment Period (24 Months)|Death|0
6168075|NCT01233869|9813073|FG000|Initial Treatment Period (24 Months)|Adverse Event|9
6168076|NCT01233869|9813074|FG001|Initial Treatment Period (24 Months)|Adverse Event|17
6168077|NCT01233869|9813075|FG002|Initial Treatment Period (24 Months)|Adverse Event|0
6168078|NCT01233869|9813076|FG003|Initial Treatment Period (24 Months)|Adverse Event|3
6168079|NCT01233869|9813073|FG000|Initial Treatment Period (24 Months)|Not Related to Study Drug|14
6168080|NCT01233869|9813074|FG001|Initial Treatment Period (24 Months)|Not Related to Study Drug|11
6168081|NCT01233869|9813075|FG002|Initial Treatment Period (24 Months)|Not Related to Study Drug|2
6168082|NCT01233869|9813076|FG003|Initial Treatment Period (24 Months)|Not Related to Study Drug|19
6168083|NCT01233869|9813073|FG000|Extended Treatment Period (46 Months)|Lost to Follow-up|0
6168084|NCT01233869|9813074|FG001|Extended Treatment Period (46 Months)|Lost to Follow-up|0
6168085|NCT01233869|9813075|FG002|Extended Treatment Period (46 Months)|Lost to Follow-up|0
6168086|NCT01233869|9813076|FG003|Extended Treatment Period (46 Months)|Lost to Follow-up|1
6168087|NCT01233869|9813073|FG000|Extended Treatment Period (46 Months)|Withdrawal by Subject|10
6168088|NCT01233869|9813074|FG001|Extended Treatment Period (46 Months)|Withdrawal by Subject|3
6168089|NCT01233869|9813075|FG002|Extended Treatment Period (46 Months)|Withdrawal by Subject|5
6168090|NCT01233869|9813076|FG003|Extended Treatment Period (46 Months)|Withdrawal by Subject|11
6168091|NCT01233869|9813073|FG000|Extended Treatment Period (46 Months)|Other|3
6168092|NCT01233869|9813074|FG001|Extended Treatment Period (46 Months)|Other|0
6168093|NCT01233869|9813075|FG002|Extended Treatment Period (46 Months)|Other|0
6168094|NCT01233869|9813076|FG003|Extended Treatment Period (46 Months)|Other|3
6168095|NCT01233869|9813073|FG000|Extended Treatment Period (46 Months)|Adverse Event|1
6168096|NCT01233869|9813074|FG001|Extended Treatment Period (46 Months)|Adverse Event|0
6168097|NCT01233869|9813075|FG002|Extended Treatment Period (46 Months)|Adverse Event|0
6168098|NCT01233869|9813076|FG003|Extended Treatment Period (46 Months)|Adverse Event|1
6168099|NCT01233999|9813095|FG000|Overall Study|Withdrawal by Subject|1
6168100|NCT01233999|9813095|FG000|Overall Study|Lost to Follow-up|1
6168101|NCT01234337|9813110|FG000|Overall Study|Adverse Event|58
6168102|NCT01234337|9813111|FG001|Overall Study|Adverse Event|21
6168103|NCT01234337|9813110|FG000|Overall Study|Disease progression/recurrence/relapse|181
6168104|NCT01234337|9813111|FG001|Overall Study|Disease progression/recurrence/relapse|223
6168105|NCT01234337|9813110|FG000|Overall Study|Investi. decision not protocol driven|5
6168106|NCT01234337|9813111|FG001|Overall Study|Investi. decision not protocol driven|6
6168107|NCT01234337|9813110|FG000|Overall Study|Non-compliant with study medication|3
6168108|NCT01234337|9813111|FG001|Overall Study|Non-compliant with study medication|2
6168109|NCT01234337|9813110|FG000|Overall Study|Randomized but not treated|6
6168110|NCT01234337|9813111|FG001|Overall Study|Randomized but not treated|4
6168111|NCT01234337|9813110|FG000|Overall Study|Lost to Follow-up|0
6168112|NCT01234337|9813111|FG001|Overall Study|Lost to Follow-up|1
6168113|NCT01234337|9813110|FG000|Overall Study|Protocol Violation|2
6168114|NCT01234337|9813111|FG001|Overall Study|Protocol Violation|3
6168115|NCT01234337|9813110|FG000|Overall Study|Withdrawal by Subject|11
6334930|NCT03124459|10085073|FG003|Phase 2- Randomized Doubled-blind|Lost to Follow-up|0
6334931|NCT03124459|10085074|FG004|Phase 2- Randomized Doubled-blind|Lost to Follow-up|1
6334932|NCT03124459|10085075|FG005|Phase 2- Randomized Doubled-blind|Lost to Follow-up|0
6334933|NCT03124459|10085070|FG000|Phase 2- Randomized Doubled-blind|Study terminated by Sponsor|0
6334934|NCT03124459|10085071|FG001|Phase 2- Randomized Doubled-blind|Study terminated by Sponsor|0
6334935|NCT03124459|10085072|FG002|Phase 2- Randomized Doubled-blind|Study terminated by Sponsor|0
6334936|NCT03124459|10085073|FG003|Phase 2- Randomized Doubled-blind|Study terminated by Sponsor|11
6334937|NCT03124459|10085074|FG004|Phase 2- Randomized Doubled-blind|Study terminated by Sponsor|12
6334938|NCT03124459|10085075|FG005|Phase 2- Randomized Doubled-blind|Study terminated by Sponsor|0
6334939|NCT03124459|10085070|FG000|Phase 2- Randomized Doubled-blind|Withdrawal by Subject|0
6334940|NCT03124459|10085071|FG001|Phase 2- Randomized Doubled-blind|Withdrawal by Subject|0
6334941|NCT03124459|10085072|FG002|Phase 2- Randomized Doubled-blind|Withdrawal by Subject|0
6334942|NCT03124459|10085073|FG003|Phase 2- Randomized Doubled-blind|Withdrawal by Subject|1
6334943|NCT03124459|10085074|FG004|Phase 2- Randomized Doubled-blind|Withdrawal by Subject|4
6334944|NCT03124459|10085075|FG005|Phase 2- Randomized Doubled-blind|Withdrawal by Subject|0
6334945|NCT03124459|10085070|FG000|Part 2- Open Label ACE-083|Study terminated by Sponsor|0
6334946|NCT03124459|10085071|FG001|Part 2- Open Label ACE-083|Study terminated by Sponsor|0
6334947|NCT03124459|10085072|FG002|Part 2- Open Label ACE-083|Study terminated by Sponsor|0
6334948|NCT03124459|10085073|FG003|Part 2- Open Label ACE-083|Study terminated by Sponsor|0
6334949|NCT03124459|10085074|FG004|Part 2- Open Label ACE-083|Study terminated by Sponsor|0
6334950|NCT03124459|10085075|FG005|Part 2- Open Label ACE-083|Study terminated by Sponsor|22
6334951|NCT03124459|10085070|FG000|Part 2- Open Label ACE-083|Withdrawal by Subject|0
6334952|NCT03124459|10085071|FG001|Part 2- Open Label ACE-083|Withdrawal by Subject|0
6334953|NCT03124459|10085072|FG002|Part 2- Open Label ACE-083|Withdrawal by Subject|0
6334954|NCT03124459|10085073|FG003|Part 2- Open Label ACE-083|Withdrawal by Subject|0
6334955|NCT03124459|10085074|FG004|Part 2- Open Label ACE-083|Withdrawal by Subject|0
6334956|NCT03124459|10085075|FG005|Part 2- Open Label ACE-083|Withdrawal by Subject|1
6334957|NCT03124537|10085090|FG000|Overall Study|Lost to Follow-up|3
6334958|NCT03124537|10085091|FG001|Overall Study|Lost to Follow-up|5
6334959|NCT03124537|10085090|FG000|Overall Study|App Crash, Incomplete Data|7
6334960|NCT03124537|10085091|FG001|Overall Study|App Crash, Incomplete Data|8
6168116|NCT01234337|9813111|FG001|Overall Study|Withdrawal by Subject|9
6168117|NCT01234337|9813110|FG000|Overall Study|Death|0
6168118|NCT01234337|9813111|FG001|Overall Study|Death|1
6168119|NCT01234337|9813110|FG000|Overall Study|Switch to commercial drug|0
6168120|NCT01234337|9813111|FG001|Overall Study|Switch to commercial drug|1
6168121|NCT01234350|9813119|FG000|Overall Study|Adverse Event|277
6168122|NCT01234350|9813120|FG001|Overall Study|Adverse Event|92
6168123|NCT01234350|9813119|FG000|Overall Study|Withdrawal by Subject|61
6168124|NCT01234350|9813120|FG001|Overall Study|Withdrawal by Subject|36
6168125|NCT01234350|9813119|FG000|Overall Study|Lost to Follow-up|115
6168126|NCT01234350|9813120|FG001|Overall Study|Lost to Follow-up|47
6168127|NCT01234350|9813119|FG000|Overall Study|Covers a diverse set of reasons|234
6168128|NCT01234350|9813120|FG001|Overall Study|Covers a diverse set of reasons|92
6168129|NCT01234402|9813131|FG000|Overall Study|Lost to Follow-up|0
6168130|NCT01234402|9813132|FG001|Overall Study|Lost to Follow-up|1
6168131|NCT01234402|9813133|FG002|Overall Study|Lost to Follow-up|3
6168132|NCT01234402|9813131|FG000|Overall Study|Withdrawal by Subject|1
6168133|NCT01234402|9813132|FG001|Overall Study|Withdrawal by Subject|3
6168134|NCT01234402|9813133|FG002|Overall Study|Withdrawal by Subject|4
6168135|NCT01234402|9813131|FG000|Overall Study|Never treated: Death|0
6168136|NCT01234402|9813132|FG001|Overall Study|Never treated: Death|0
6168137|NCT01234402|9813133|FG002|Overall Study|Never treated: Death|1
6168138|NCT01234402|9813131|FG000|Overall Study|Never treated: Withdrawal By Subject|0
6168139|NCT01234402|9813132|FG001|Overall Study|Never treated: Withdrawal By Subject|1
6168140|NCT01234402|9813133|FG002|Overall Study|Never treated: Withdrawal By Subject|0
6168141|NCT01234402|9813131|FG000|Overall Study|Never treated: Insurance Denied Xeloda|0
6168142|NCT01234402|9813132|FG001|Overall Study|Never treated: Insurance Denied Xeloda|1
6168143|NCT01234402|9813133|FG002|Overall Study|Never treated: Insurance Denied Xeloda|0
6168144|NCT01234467|9813143|FG000|Overall Study|Adverse Event|3
6168145|NCT01234467|9813143|FG000|Overall Study|Death|2
6168146|NCT01234467|9813143|FG000|Overall Study|Withdrawal by Subject|2
6168147|NCT01234467|9813143|FG000|Overall Study|Disease Progression|2
6168148|NCT01234467|9813143|FG000|Overall Study|Clinical deterioration|1
6168149|NCT01234467|9813143|FG000|Overall Study|Physician Decision|1
6168150|NCT01234467|9813143|FG000|Overall Study|Other complicating disease (stroke)|1
6168151|NCT01234480|9813147|FG000|Overall Study|Pregnancy|88
6168152|NCT01234480|9813147|FG000|Overall Study|>36/Normal History|50
6168153|NCT01234480|9813147|FG000|Overall Study|Age|3
6168154|NCT01234480|9813147|FG000|Overall Study|HPV Vaccine History|28
6168155|NCT01234480|9813147|FG000|Overall Study|HPV Vaccine after Enrollment|17
6168156|NCT01234480|9813147|FG000|Overall Study|Hysterectomy|2
6168157|NCT01234480|9813147|FG000|Overall Study|Hysterectomy post enrollment|1
6168158|NCT01234480|9813147|FG000|Overall Study|Inclusion/Exclusion Violation|3
6168159|NCT01234480|9813147|FG000|Overall Study|Informed Consent Form Violation|30
6168160|NCT01234480|9813147|FG000|Overall Study|Incorrect Visit|3
6168161|NCT01234480|9813147|FG000|Overall Study|No Florida Lab License|20
6168162|NCT01234480|9813147|FG000|Overall Study|Out of Window|42
6334961|NCT03124563|10085103|FG000|Overall Study|Lost to Follow-up|1
6334962|NCT03124563|10085104|FG001|Overall Study|Lost to Follow-up|1
6334963|NCT03124563|10085103|FG000|Overall Study|Withdrawal by Subject|1
6334964|NCT03124563|10085104|FG001|Overall Study|Withdrawal by Subject|1
6334965|NCT03124784|10085126|FG000|Overall Study|Adverse Event|1
6334966|NCT03124784|10085126|FG000|Overall Study|Computer/Equip Malfunction|1
6334967|NCT03125200|10085179|FG000|Overall Study|Study Termination|0
6334968|NCT03125200|10085180|FG001|Overall Study|Study Termination|0
6334969|NCT03125200|10085181|FG002|Overall Study|Study Termination|0
6168163|NCT01234480|9813147|FG000|Overall Study|Sample Processing/Storage|92
6168164|NCT01234480|9813147|FG000|Overall Study|Site Amendment prohibited colposcopy|11
6168165|NCT01234480|9813147|FG000|Overall Study|Site/Subject non-compliance|44
6168166|NCT01234480|9813147|FG000|Overall Study|Missing Sample|9
6168167|NCT01234649|9813156|FG000|Overall Study|Withdrawal by Subject|32
6168168|NCT01234649|9813157|FG001|Overall Study|Withdrawal by Subject|26
6168169|NCT01234649|9813156|FG000|Overall Study|Pregnancy|6
6168170|NCT01234649|9813157|FG001|Overall Study|Pregnancy|6
6168171|NCT01234649|9813156|FG000|Overall Study|intolerant to side effects|4
6168172|NCT01234649|9813157|FG001|Overall Study|intolerant to side effects|3
6168173|NCT01234649|9813156|FG000|Overall Study|Allergic reaction|1
6168174|NCT01234649|9813157|FG001|Overall Study|Allergic reaction|0
6168175|NCT01234649|9813156|FG000|Overall Study|Lack of Efficacy|0
6168176|NCT01234649|9813157|FG001|Overall Study|Lack of Efficacy|3
6168177|NCT01234675|9813163|FG000|First Intervention (6 Weeks)|Adverse Event|0
6168178|NCT01234675|9813164|FG001|First Intervention (6 Weeks)|Adverse Event|1
6168179|NCT01234675|9813163|FG000|First Intervention (6 Weeks)|Withdrawal by Subject|1
6168180|NCT01234675|9813164|FG001|First Intervention (6 Weeks)|Withdrawal by Subject|0
6168181|NCT01234883|9813198|FG000|Overall Study|Early treatment release|8
6168182|NCT01234883|9813199|FG001|Overall Study|Early treatment release|10
6168183|NCT01234883|9813198|FG000|Overall Study|Parent/guardian withdrew consent|1
6168184|NCT01234883|9813199|FG001|Overall Study|Parent/guardian withdrew consent|2
6168185|NCT01234883|9813198|FG000|Overall Study|Technical difficulties with IV infusion|0
6168186|NCT01234883|9813199|FG001|Overall Study|Technical difficulties with IV infusion|1
6168187|NCT01234883|9813198|FG000|Overall Study|Inclusion/exclusion failure|1
6168188|NCT01234883|9813199|FG001|Overall Study|Inclusion/exclusion failure|0
6168189|NCT01235234|9813232|FG000|Overall Study|Adverse Event|2
6168190|NCT01235234|9813233|FG001|Overall Study|Adverse Event|2
6168191|NCT01235234|9813234|FG002|Overall Study|Adverse Event|1
6168192|NCT01235338|9813244|FG000|Overall Study|Adverse Event|3
6168193|NCT01235338|9813245|FG001|Overall Study|Adverse Event|2
6168194|NCT01235338|9813244|FG000|Overall Study|Protocol Violation|1
6168195|NCT01235338|9813245|FG001|Overall Study|Protocol Violation|1
6168196|NCT01235338|9813244|FG000|Overall Study|Withdrawal by Subject|5
6168197|NCT01235338|9813245|FG001|Overall Study|Withdrawal by Subject|0
6168198|NCT01235338|9813244|FG000|Overall Study|Exclusion criteria violations|1
6168199|NCT01235338|9813245|FG001|Overall Study|Exclusion criteria violations|1
6168200|NCT01235338|9813244|FG000|Overall Study|Positive drug screen|0
6168201|NCT01235338|9813245|FG001|Overall Study|Positive drug screen|1
6168202|NCT01235338|9813244|FG000|Overall Study|Prohibited meds|1
6168203|NCT01235338|9813245|FG001|Overall Study|Prohibited meds|0
6168204|NCT01235351|9813255|FG000|Initial Treatment With 75 mg and 150 mg|No follow-up sample|10
6168205|NCT01235351|9813256|FG001|Initial Treatment With 75 mg and 150 mg|No follow-up sample|4
6168206|NCT01235403|9813275|FG000|Overall Study|Adverse Event|14
6168207|NCT01235403|9813275|FG000|Overall Study|Lost to Follow-up|2
6168208|NCT01235403|9813275|FG000|Overall Study|Withdrawal by Subject|4
6168209|NCT01235403|9813275|FG000|Overall Study|Lack of Efficacy|2
6168210|NCT01235403|9813275|FG000|Overall Study|Other reasons for premature termination|4
6168211|NCT01235442|9813281|FG000|Overall Study|Lost to Follow-up|12
6168212|NCT01235442|9813282|FG001|Overall Study|Lost to Follow-up|10
6168213|NCT01235442|9813281|FG000|Overall Study|Death|0
6168214|NCT01235442|9813282|FG001|Overall Study|Death|2
6168215|NCT01235442|9813281|FG000|Overall Study|Pregnancy|1
6168216|NCT01235442|9813282|FG001|Overall Study|Pregnancy|1
6168217|NCT01235442|9813281|FG000|Overall Study|Ineligibility determined|5
6168218|NCT01235442|9813282|FG001|Overall Study|Ineligibility determined|4
6168219|NCT01235442|9813281|FG000|Overall Study|Protocol Violation|3
6168220|NCT01235442|9813282|FG001|Overall Study|Protocol Violation|3
6168221|NCT01235442|9813281|FG000|Overall Study|Adverse Event|4
6168222|NCT01235442|9813282|FG001|Overall Study|Adverse Event|6
6168223|NCT01235442|9813281|FG000|Overall Study|Withdrawal by Subject|15
6334970|NCT03125200|10085182|FG003|Overall Study|Study Termination|1
6334971|NCT03125200|10085183|FG004|Overall Study|Study Termination|1
6168224|NCT01235442|9813282|FG001|Overall Study|Withdrawal by Subject|9
6168225|NCT01235442|9813281|FG000|Overall Study|Lack of Efficacy|1
6168226|NCT01235442|9813282|FG001|Overall Study|Lack of Efficacy|3
6168227|NCT01235442|9813281|FG000|Overall Study|Noncompliance|1
6168228|NCT01235442|9813282|FG001|Overall Study|Noncompliance|2
6168229|NCT01235442|9813281|FG000|Overall Study|Administrative decision|1
6168230|NCT01235442|9813282|FG001|Overall Study|Administrative decision|2
6168231|NCT01235442|9813281|FG000|Overall Study|Other unspecified|1
6168232|NCT01235442|9813282|FG001|Overall Study|Other unspecified|2
6168233|NCT01235507|9813288|FG000|Overall Study|Adverse Event|1
6168234|NCT01235507|9813288|FG000|Overall Study|Withdrawal by Subject|1
6168235|NCT01235546|9813294|FG000|Overall Study|Staff error, medication not administered|1
6168236|NCT01235546|9813295|FG001|Overall Study|Staff error, medication not administered|0
6168237|NCT01235546|9813294|FG000|Overall Study|Protocol Violation|1
6334972|NCT03125200|10085184|FG005|Overall Study|Study Termination|2
6334973|NCT03125200|10085185|FG006|Overall Study|Study Termination|1
6334974|NCT03125200|10085179|FG000|Overall Study|Clinical Progression|0
6334975|NCT03125200|10085180|FG001|Overall Study|Clinical Progression|0
6334976|NCT03125200|10085181|FG002|Overall Study|Clinical Progression|0
6334977|NCT03125200|10085182|FG003|Overall Study|Clinical Progression|1
6334978|NCT03125200|10085183|FG004|Overall Study|Clinical Progression|0
6334979|NCT03125200|10085184|FG005|Overall Study|Clinical Progression|1
6334980|NCT03125200|10085185|FG006|Overall Study|Clinical Progression|0
6334981|NCT03125200|10085179|FG000|Overall Study|Progressive Disease|2
6334982|NCT03125200|10085180|FG001|Overall Study|Progressive Disease|1
6334983|NCT03125200|10085181|FG002|Overall Study|Progressive Disease|2
6334984|NCT03125200|10085182|FG003|Overall Study|Progressive Disease|1
6334985|NCT03125200|10085183|FG004|Overall Study|Progressive Disease|2
6334986|NCT03125200|10085184|FG005|Overall Study|Progressive Disease|0
6334987|NCT03125200|10085185|FG006|Overall Study|Progressive Disease|1
6334988|NCT03125200|10085179|FG000|Overall Study|Lack of Efficacy|0
6334989|NCT03125200|10085180|FG001|Overall Study|Lack of Efficacy|0
6334990|NCT03125200|10085181|FG002|Overall Study|Lack of Efficacy|0
6082907|NCT00632229|9691058|FG001|Overall Study|Lost to Follow-up|3
6168238|NCT01235546|9813295|FG001|Overall Study|Protocol Violation|1
6168239|NCT01235598|9813312|FG000|Overall Study|Adverse Event|0
6168240|NCT01235598|9813313|FG001|Overall Study|Adverse Event|3
6168241|NCT01235598|9813312|FG000|Overall Study|Lack of Efficacy|0
6168242|NCT01235598|9813313|FG001|Overall Study|Lack of Efficacy|1
6168243|NCT01235598|9813312|FG000|Overall Study|Withdrawal by Subject|1
6168244|NCT01235598|9813313|FG001|Overall Study|Withdrawal by Subject|0
6168245|NCT01235689|9813322|FG000|Overall Study|Adverse Event|12
6168246|NCT01235689|9813323|FG001|Overall Study|Adverse Event|16
6168247|NCT01235689|9813322|FG000|Overall Study|Lack of Efficacy|12
6168248|NCT01235689|9813323|FG001|Overall Study|Lack of Efficacy|5
6168249|NCT01235689|9813322|FG000|Overall Study|Withdrawal by Subject|3
6168250|NCT01235689|9813323|FG001|Overall Study|Withdrawal by Subject|4
6168251|NCT01235689|9813322|FG000|Overall Study|Lost to Follow-up|1
6168252|NCT01235689|9813323|FG001|Overall Study|Lost to Follow-up|2
6168253|NCT01235689|9813322|FG000|Overall Study|Miscellaneous|1
6168254|NCT01235689|9813323|FG001|Overall Study|Miscellaneous|5
6168255|NCT01235715|9813331|FG000|Overall Study|Physician Decision|0
6168256|NCT01235715|9813332|FG001|Overall Study|Physician Decision|2
6168257|NCT01235728|9813339|FG000|Overall Study|Protocol Violation|0
6168258|NCT01235728|9813340|FG001|Overall Study|Protocol Violation|0
6168259|NCT01235728|9813341|FG002|Overall Study|Protocol Violation|0
6168260|NCT01235728|9813342|FG003|Overall Study|Protocol Violation|1
6168261|NCT01235728|9813343|FG004|Overall Study|Protocol Violation|0
6334991|NCT03125200|10085182|FG003|Overall Study|Lack of Efficacy|1
6334992|NCT03125200|10085183|FG004|Overall Study|Lack of Efficacy|0
6334993|NCT03125200|10085184|FG005|Overall Study|Lack of Efficacy|0
6334994|NCT03125200|10085185|FG006|Overall Study|Lack of Efficacy|0
6082908|NCT00632229|9691057|FG000|Overall Study|Lack of Efficacy|0
6082909|NCT00632229|9691058|FG001|Overall Study|Lack of Efficacy|2
6082910|NCT00632229|9691057|FG000|Overall Study|Undisclosed reasons within the first wee|0
6082911|NCT00632229|9691058|FG001|Overall Study|Undisclosed reasons within the first wee|1
6082912|NCT00632359|9691068|FG000|Overall Study|Withdrawal by Subject|2
6082913|NCT00632424|9691085|FG000|Overall Study|Disease Progression|17
6082914|NCT00632424|9691085|FG000|Overall Study|Study Drug Toxicity|1
6082915|NCT00632463|9691102|FG000|Overall Study|Adverse Event|0
6082916|NCT00632463|9691103|FG001|Overall Study|Adverse Event|1
6082917|NCT00632463|9691104|FG002|Overall Study|Adverse Event|0
6082918|NCT00632502|9691127|FG000|Overall Study|Adverse Event|0
6082919|NCT00632502|9691128|FG001|Overall Study|Adverse Event|1
6082920|NCT00632502|9691127|FG000|Overall Study|Randomized not treated|3
6082921|NCT00632502|9691128|FG001|Overall Study|Randomized not treated|0
6082922|NCT00632541|9691135|FG000|Overall Study|Adverse Event|7
6082923|NCT00632736|9691157|FG000|Overall Study|Adverse Event|104
6082924|NCT00632736|9691157|FG000|Overall Study|Lost to Follow-up|15
6082925|NCT00632736|9691157|FG000|Overall Study|Protocol Violation|14
6082926|NCT00632736|9691157|FG000|Overall Study|Withdrawal by Subject|99
6082927|NCT00632736|9691157|FG000|Overall Study|Lack of Efficacy|5
6082928|NCT00632736|9691157|FG000|Overall Study|Sponsor terminated study|5
6082929|NCT00632736|9691157|FG000|Overall Study|Non-compliance|10
6082930|NCT00632736|9691157|FG000|Overall Study|Other|16
6082931|NCT00632749|9691175|FG000|Overall Study|Progressive disease|3
6082932|NCT00632749|9691176|FG001|Overall Study|Progressive disease|2
6082933|NCT00632749|9691177|FG002|Overall Study|Progressive disease|2
6082934|NCT00632749|9691178|FG003|Overall Study|Progressive disease|2
6082935|NCT00632749|9691179|FG004|Overall Study|Progressive disease|4
6082936|NCT00632749|9691180|FG005|Overall Study|Progressive disease|4
6334995|NCT03125200|10085179|FG000|Overall Study|Toxicity|0
6334996|NCT03125200|10085180|FG001|Overall Study|Toxicity|0
6168262|NCT01235728|9813344|FG005|Overall Study|Protocol Violation|0
6168263|NCT01235728|9813345|FG006|Overall Study|Protocol Violation|0
6168264|NCT01235728|9813346|FG007|Overall Study|Protocol Violation|0
6168265|NCT01235741|9813357|FG000|Non-Randomized Low Calorie Diet Lead-In|Withdrawal by Subject|9
6168266|NCT01235741|9813358|FG001|Non-Randomized Low Calorie Diet Lead-In|Withdrawal by Subject|0
6192185|NCT01428583|9849306|FG000|Overall Study|Non-compliant|25
6334997|NCT03125200|10085181|FG002|Overall Study|Toxicity|0
6334998|NCT03125200|10085182|FG003|Overall Study|Toxicity|1
6334999|NCT03125200|10085183|FG004|Overall Study|Toxicity|0
6335000|NCT03125200|10085184|FG005|Overall Study|Toxicity|0
6335001|NCT03125200|10085185|FG006|Overall Study|Toxicity|0
6335002|NCT03125200|10085179|FG000|Overall Study|Consent Withdrawn by Subject|0
6335003|NCT03125200|10085180|FG001|Overall Study|Consent Withdrawn by Subject|1
6335004|NCT03125200|10085181|FG002|Overall Study|Consent Withdrawn by Subject|0
6335005|NCT03125200|10085182|FG003|Overall Study|Consent Withdrawn by Subject|0
6335006|NCT03125200|10085183|FG004|Overall Study|Consent Withdrawn by Subject|1
6335007|NCT03125200|10085184|FG005|Overall Study|Consent Withdrawn by Subject|0
6335008|NCT03125200|10085185|FG006|Overall Study|Consent Withdrawn by Subject|1
6335009|NCT03125395|10085208|FG000|Overall Study|Adverse Event|2
6335010|NCT03125395|10085208|FG000|Overall Study|Withdrawal of consent (not due to AE)|1
6335011|NCT03125395|10085208|FG000|Overall Study|Physician Decision|2
6335012|NCT03125395|10085208|FG000|Overall Study|Commercial drug is available|5
6335013|NCT03125629|10085212|FG000|Overall Study|Withdrawal by Subject|2
6335014|NCT03125629|10085212|FG000|Overall Study|Equipment malfunction|1
6168267|NCT01235741|9813359|FG002|Non-Randomized Low Calorie Diet Lead-In|Withdrawal by Subject|0
6168268|NCT01235741|9813357|FG000|Non-Randomized Low Calorie Diet Lead-In|Sponsor terminated study|121
6168269|NCT01235741|9813358|FG001|Non-Randomized Low Calorie Diet Lead-In|Sponsor terminated study|0
6168270|NCT01235741|9813359|FG002|Non-Randomized Low Calorie Diet Lead-In|Sponsor terminated study|0
6168271|NCT01235741|9813357|FG000|Non-Randomized Low Calorie Diet Lead-In|Physician Decision|1
6168272|NCT01235741|9813358|FG001|Non-Randomized Low Calorie Diet Lead-In|Physician Decision|0
6168273|NCT01235741|9813359|FG002|Non-Randomized Low Calorie Diet Lead-In|Physician Decision|0
6168274|NCT01235741|9813357|FG000|Non-Randomized Low Calorie Diet Lead-In|Protocol Violation|1
6168275|NCT01235741|9813358|FG001|Non-Randomized Low Calorie Diet Lead-In|Protocol Violation|0
6168276|NCT01235741|9813359|FG002|Non-Randomized Low Calorie Diet Lead-In|Protocol Violation|0
6168277|NCT01235741|9813357|FG000|Non-Randomized Low Calorie Diet Lead-In|Lost to Follow-up|5
6168278|NCT01235741|9813358|FG001|Non-Randomized Low Calorie Diet Lead-In|Lost to Follow-up|0
6168279|NCT01235741|9813359|FG002|Non-Randomized Low Calorie Diet Lead-In|Lost to Follow-up|0
6168280|NCT01235741|9813357|FG000|Non-Randomized Low Calorie Diet Lead-In|Failed to meet weight loss in Period 1|4
6168281|NCT01235741|9813358|FG001|Non-Randomized Low Calorie Diet Lead-In|Failed to meet weight loss in Period 1|0
6168282|NCT01235741|9813359|FG002|Non-Randomized Low Calorie Diet Lead-In|Failed to meet weight loss in Period 1|0
6168283|NCT01235741|9813357|FG000|Randomized to Treatment|Withdrawal by Subject|0
6168284|NCT01235741|9813358|FG001|Randomized to Treatment|Withdrawal by Subject|0
6168285|NCT01235741|9813359|FG002|Randomized to Treatment|Withdrawal by Subject|1
6168286|NCT01235741|9813357|FG000|Randomized to Treatment|Adverse Event|0
6168287|NCT01235741|9813358|FG001|Randomized to Treatment|Adverse Event|1
6168288|NCT01235741|9813359|FG002|Randomized to Treatment|Adverse Event|1
6168289|NCT01235741|9813357|FG000|Randomized to Treatment|Sponsor terminated study|0
6168290|NCT01235741|9813358|FG001|Randomized to Treatment|Sponsor terminated study|35
6168291|NCT01235741|9813359|FG002|Randomized to Treatment|Sponsor terminated study|34
6168292|NCT01235741|9813357|FG000|Follow-Up Post Treatment up to Month 6|Withdrawal by Subject|0
6168293|NCT01235741|9813358|FG001|Follow-Up Post Treatment up to Month 6|Withdrawal by Subject|3
6168294|NCT01235741|9813359|FG002|Follow-Up Post Treatment up to Month 6|Withdrawal by Subject|6
6168295|NCT01235741|9813357|FG000|Follow-Up Post Treatment up to Month 6|Lost to Follow-up|0
6168296|NCT01235741|9813358|FG001|Follow-Up Post Treatment up to Month 6|Lost to Follow-up|5
6168297|NCT01235741|9813359|FG002|Follow-Up Post Treatment up to Month 6|Lost to Follow-up|1
6168298|NCT01235741|9813357|FG000|Follow-Up Post Treatment up to Month 6|Other|0
6168299|NCT01235741|9813358|FG001|Follow-Up Post Treatment up to Month 6|Other|1
6168300|NCT01235741|9813359|FG002|Follow-Up Post Treatment up to Month 6|Other|0
6168301|NCT01235793|9813371|FG000|Overall Study|Death|6
6168302|NCT01235949|9813412|FG000|Primary Phase|Migrated/moved from study area|1
6168303|NCT01235949|9813413|FG001|Primary Phase|Migrated/moved from study area|1
6168304|NCT01235949|9813414|FG002|Primary Phase|Migrated/moved from study area|0
6168305|NCT01235949|9813415|FG003|Primary Phase|Migrated/moved from study area|0
6168306|NCT01235949|9813416|FG004|Primary Phase|Migrated/moved from study area|1
6168307|NCT01235949|9813417|FG005|Primary Phase|Migrated/moved from study area|2
6168308|NCT01235949|9813418|FG006|Primary Phase|Migrated/moved from study area|0
6168309|NCT01235949|9813419|FG007|Primary Phase|Migrated/moved from study area|0
6168310|NCT01235949|9813420|FG008|Primary Phase|Migrated/moved from study area|0
6168311|NCT01235949|9813421|FG009|Primary Phase|Migrated/moved from study area|0
6168312|NCT01235949|9813422|FG010|Primary Phase|Migrated/moved from study area|0
6168313|NCT01235949|9813423|FG011|Primary Phase|Migrated/moved from study area|0
6168314|NCT01235949|9813424|FG012|Primary Phase|Migrated/moved from study area|0
6168315|NCT01235949|9813425|FG013|Primary Phase|Migrated/moved from study area|0
6168316|NCT01235949|9813426|FG014|Primary Phase|Migrated/moved from study area|0
6168317|NCT01235949|9813427|FG015|Primary Phase|Migrated/moved from study area|0
6335015|NCT03125915|10085228|FG000|1 Month Follow up|Lost to Follow-up|3
6335016|NCT03125915|10085229|FG001|1 Month Follow up|Lost to Follow-up|3
6335017|NCT03125915|10085230|FG002|1 Month Follow up|Lost to Follow-up|2
6335018|NCT03125915|10085231|FG003|1 Month Follow up|Lost to Follow-up|3
6335019|NCT03125915|10085228|FG000|3 Month Follow-up|Lost to Follow-up|6
6335020|NCT03125915|10085229|FG001|3 Month Follow-up|Lost to Follow-up|4
6335021|NCT03125915|10085230|FG002|3 Month Follow-up|Lost to Follow-up|4
6335022|NCT03125915|10085231|FG003|3 Month Follow-up|Lost to Follow-up|2
6335023|NCT03125915|10085228|FG000|6 Month Follow-up|Lost to Follow-up|7
6335024|NCT03125915|10085229|FG001|6 Month Follow-up|Lost to Follow-up|3
6335025|NCT03125915|10085230|FG002|6 Month Follow-up|Lost to Follow-up|6
6335026|NCT03125915|10085231|FG003|6 Month Follow-up|Lost to Follow-up|3
6335027|NCT03125941|10085243|FG000|Overall Study|did not receive intervention|1
6335028|NCT03125941|10085244|FG001|Overall Study|did not receive intervention|2
6335029|NCT03126227|10085252|FG000|Overall Study|Adverse Event|43
6335030|NCT03126227|10085253|FG001|Overall Study|Adverse Event|4
6335031|NCT03126227|10085252|FG000|Overall Study|Death|0
6335032|NCT03126227|10085253|FG001|Overall Study|Death|1
6168318|NCT01235949|9813428|FG016|Primary Phase|Migrated/moved from study area|0
6168319|NCT01235949|9813429|FG017|Primary Phase|Migrated/moved from study area|0
6168320|NCT01235949|9813412|FG000|Primary Phase|Adverse Event|0
6168321|NCT01235949|9813413|FG001|Primary Phase|Adverse Event|0
6168322|NCT01235949|9813414|FG002|Primary Phase|Adverse Event|0
6168323|NCT01235949|9813415|FG003|Primary Phase|Adverse Event|1
6168324|NCT01235949|9813416|FG004|Primary Phase|Adverse Event|0
6168325|NCT01235949|9813417|FG005|Primary Phase|Adverse Event|0
6168326|NCT01235949|9813418|FG006|Primary Phase|Adverse Event|0
6168327|NCT01235949|9813419|FG007|Primary Phase|Adverse Event|0
6168328|NCT01235949|9813420|FG008|Primary Phase|Adverse Event|0
6168329|NCT01235949|9813421|FG009|Primary Phase|Adverse Event|0
6168330|NCT01235949|9813422|FG010|Primary Phase|Adverse Event|0
6168331|NCT01235949|9813423|FG011|Primary Phase|Adverse Event|0
6168332|NCT01235949|9813424|FG012|Primary Phase|Adverse Event|0
6168333|NCT01235949|9813425|FG013|Primary Phase|Adverse Event|0
6168334|NCT01235949|9813426|FG014|Primary Phase|Adverse Event|0
6168335|NCT01235949|9813427|FG015|Primary Phase|Adverse Event|0
6168336|NCT01235949|9813428|FG016|Primary Phase|Adverse Event|0
6168337|NCT01235949|9813429|FG017|Primary Phase|Adverse Event|0
6168338|NCT01235949|9813412|FG000|Primary Phase|Withdrawal by Subject|3
6168339|NCT01235949|9813413|FG001|Primary Phase|Withdrawal by Subject|2
6168340|NCT01235949|9813414|FG002|Primary Phase|Withdrawal by Subject|2
6168341|NCT01235949|9813415|FG003|Primary Phase|Withdrawal by Subject|0
6168342|NCT01235949|9813416|FG004|Primary Phase|Withdrawal by Subject|0
6168343|NCT01235949|9813417|FG005|Primary Phase|Withdrawal by Subject|3
6168344|NCT01235949|9813418|FG006|Primary Phase|Withdrawal by Subject|0
6168345|NCT01235949|9813419|FG007|Primary Phase|Withdrawal by Subject|0
6168346|NCT01235949|9813420|FG008|Primary Phase|Withdrawal by Subject|0
6168347|NCT01235949|9813421|FG009|Primary Phase|Withdrawal by Subject|0
6168348|NCT01235949|9813422|FG010|Primary Phase|Withdrawal by Subject|0
6168349|NCT01235949|9813423|FG011|Primary Phase|Withdrawal by Subject|0
6168350|NCT01235949|9813424|FG012|Primary Phase|Withdrawal by Subject|0
6168351|NCT01235949|9813425|FG013|Primary Phase|Withdrawal by Subject|0
6335033|NCT03126227|10085252|FG000|Overall Study|Lost to Follow-up|0
6168352|NCT01235949|9813426|FG014|Primary Phase|Withdrawal by Subject|0
6168353|NCT01235949|9813427|FG015|Primary Phase|Withdrawal by Subject|0
6168354|NCT01235949|9813428|FG016|Primary Phase|Withdrawal by Subject|0
6168355|NCT01235949|9813429|FG017|Primary Phase|Withdrawal by Subject|0
6168356|NCT01235949|9813412|FG000|Primary Phase|Lost to Follow-up|0
6168357|NCT01235949|9813413|FG001|Primary Phase|Lost to Follow-up|0
6168358|NCT01235949|9813414|FG002|Primary Phase|Lost to Follow-up|1
6168359|NCT01235949|9813415|FG003|Primary Phase|Lost to Follow-up|1
6168360|NCT01235949|9813416|FG004|Primary Phase|Lost to Follow-up|0
6168361|NCT01235949|9813417|FG005|Primary Phase|Lost to Follow-up|2
6168362|NCT01235949|9813418|FG006|Primary Phase|Lost to Follow-up|0
6168363|NCT01235949|9813419|FG007|Primary Phase|Lost to Follow-up|0
6168364|NCT01235949|9813420|FG008|Primary Phase|Lost to Follow-up|0
6168365|NCT01235949|9813421|FG009|Primary Phase|Lost to Follow-up|0
6168366|NCT01235949|9813422|FG010|Primary Phase|Lost to Follow-up|0
6168367|NCT01235949|9813423|FG011|Primary Phase|Lost to Follow-up|0
6168368|NCT01235949|9813424|FG012|Primary Phase|Lost to Follow-up|0
6168369|NCT01235949|9813425|FG013|Primary Phase|Lost to Follow-up|0
6168370|NCT01235949|9813426|FG014|Primary Phase|Lost to Follow-up|0
6168371|NCT01235949|9813427|FG015|Primary Phase|Lost to Follow-up|0
6168372|NCT01235949|9813428|FG016|Primary Phase|Lost to Follow-up|0
6168373|NCT01235949|9813429|FG017|Primary Phase|Lost to Follow-up|0
6168374|NCT01235949|9813412|FG000|Booster Phase|Migrated/moved from study area|0
6168375|NCT01235949|9813413|FG001|Booster Phase|Migrated/moved from study area|0
6168376|NCT01235949|9813414|FG002|Booster Phase|Migrated/moved from study area|0
6168377|NCT01235949|9813415|FG003|Booster Phase|Migrated/moved from study area|0
6168378|NCT01235949|9813416|FG004|Booster Phase|Migrated/moved from study area|0
6168379|NCT01235949|9813417|FG005|Booster Phase|Migrated/moved from study area|0
6168380|NCT01235949|9813418|FG006|Booster Phase|Migrated/moved from study area|0
6168381|NCT01235949|9813419|FG007|Booster Phase|Migrated/moved from study area|0
6168382|NCT01235949|9813420|FG008|Booster Phase|Migrated/moved from study area|0
6168383|NCT01235949|9813421|FG009|Booster Phase|Migrated/moved from study area|0
6168384|NCT01235949|9813422|FG010|Booster Phase|Migrated/moved from study area|0
6168385|NCT01235949|9813423|FG011|Booster Phase|Migrated/moved from study area|1
6168386|NCT01235949|9813424|FG012|Booster Phase|Migrated/moved from study area|1
6168387|NCT01235949|9813425|FG013|Booster Phase|Migrated/moved from study area|0
6335034|NCT03126227|10085253|FG001|Overall Study|Lost to Follow-up|1
6168388|NCT01235949|9813426|FG014|Booster Phase|Migrated/moved from study area|0
6168389|NCT01235949|9813427|FG015|Booster Phase|Migrated/moved from study area|0
6168390|NCT01235949|9813428|FG016|Booster Phase|Migrated/moved from study area|0
6168391|NCT01235949|9813429|FG017|Booster Phase|Migrated/moved from study area|1
6168392|NCT01235949|9813412|FG000|Booster Phase|Adverse Event|0
6335035|NCT03126227|10085252|FG000|Overall Study|Physician Decision|2
6335036|NCT03126227|10085253|FG001|Overall Study|Physician Decision|0
6335037|NCT03126227|10085252|FG000|Overall Study|Protocol Violation|1
6335038|NCT03126227|10085253|FG001|Overall Study|Protocol Violation|0
6335039|NCT03126227|10085252|FG000|Overall Study|Withdrawal by Subject|19
6335040|NCT03126227|10085253|FG001|Overall Study|Withdrawal by Subject|3
6335041|NCT03126227|10085252|FG000|Overall Study|Discontinued due to early termination and continuation in follow-on study due to study closure|8
6335042|NCT03126227|10085253|FG001|Overall Study|Discontinued due to early termination and continuation in follow-on study due to study closure|1
6335043|NCT03126227|10085252|FG000|Overall Study|Lack of dosing compliance|2
6335044|NCT03126227|10085253|FG001|Overall Study|Lack of dosing compliance|0
6168393|NCT01235949|9813413|FG001|Booster Phase|Adverse Event|0
6168394|NCT01235949|9813414|FG002|Booster Phase|Adverse Event|0
6168395|NCT01235949|9813415|FG003|Booster Phase|Adverse Event|0
6168396|NCT01235949|9813416|FG004|Booster Phase|Adverse Event|0
6168397|NCT01235949|9813417|FG005|Booster Phase|Adverse Event|0
6168398|NCT01235949|9813418|FG006|Booster Phase|Adverse Event|0
6168399|NCT01235949|9813419|FG007|Booster Phase|Adverse Event|0
6168400|NCT01235949|9813420|FG008|Booster Phase|Adverse Event|0
6168401|NCT01235949|9813421|FG009|Booster Phase|Adverse Event|0
6168402|NCT01235949|9813422|FG010|Booster Phase|Adverse Event|0
6168403|NCT01235949|9813423|FG011|Booster Phase|Adverse Event|0
6168404|NCT01235949|9813424|FG012|Booster Phase|Adverse Event|0
6168405|NCT01235949|9813425|FG013|Booster Phase|Adverse Event|0
6168406|NCT01235949|9813426|FG014|Booster Phase|Adverse Event|0
6168407|NCT01235949|9813427|FG015|Booster Phase|Adverse Event|1
6168408|NCT01235949|9813428|FG016|Booster Phase|Adverse Event|0
6168409|NCT01235949|9813429|FG017|Booster Phase|Adverse Event|0
6168410|NCT01235949|9813412|FG000|Booster Phase|Withdrawal by Subject|0
6168411|NCT01235949|9813413|FG001|Booster Phase|Withdrawal by Subject|0
6168412|NCT01235949|9813414|FG002|Booster Phase|Withdrawal by Subject|0
6168413|NCT01235949|9813415|FG003|Booster Phase|Withdrawal by Subject|0
6168414|NCT01235949|9813416|FG004|Booster Phase|Withdrawal by Subject|0
6168415|NCT01235949|9813417|FG005|Booster Phase|Withdrawal by Subject|0
6168416|NCT01235949|9813418|FG006|Booster Phase|Withdrawal by Subject|0
6168417|NCT01235949|9813419|FG007|Booster Phase|Withdrawal by Subject|1
6168418|NCT01235949|9813420|FG008|Booster Phase|Withdrawal by Subject|1
6168419|NCT01235949|9813421|FG009|Booster Phase|Withdrawal by Subject|0
6168420|NCT01235949|9813422|FG010|Booster Phase|Withdrawal by Subject|1
6168421|NCT01235949|9813423|FG011|Booster Phase|Withdrawal by Subject|1
6168422|NCT01235949|9813424|FG012|Booster Phase|Withdrawal by Subject|2
6168423|NCT01235949|9813425|FG013|Booster Phase|Withdrawal by Subject|0
6168424|NCT01235949|9813426|FG014|Booster Phase|Withdrawal by Subject|2
6168425|NCT01235949|9813427|FG015|Booster Phase|Withdrawal by Subject|0
6168426|NCT01235949|9813428|FG016|Booster Phase|Withdrawal by Subject|0
6168427|NCT01235949|9813429|FG017|Booster Phase|Withdrawal by Subject|0
6168428|NCT01235949|9813412|FG000|Booster Phase|Lost to Follow-up|0
6168429|NCT01235949|9813413|FG001|Booster Phase|Lost to Follow-up|0
6168430|NCT01235949|9813414|FG002|Booster Phase|Lost to Follow-up|0
6168431|NCT01235949|9813415|FG003|Booster Phase|Lost to Follow-up|0
6168432|NCT01235949|9813416|FG004|Booster Phase|Lost to Follow-up|0
6168433|NCT01235949|9813417|FG005|Booster Phase|Lost to Follow-up|0
6168434|NCT01235949|9813418|FG006|Booster Phase|Lost to Follow-up|0
6168435|NCT01235949|9813419|FG007|Booster Phase|Lost to Follow-up|0
6168436|NCT01235949|9813420|FG008|Booster Phase|Lost to Follow-up|1
6168437|NCT01235949|9813421|FG009|Booster Phase|Lost to Follow-up|1
6168438|NCT01235949|9813422|FG010|Booster Phase|Lost to Follow-up|1
6168439|NCT01235949|9813423|FG011|Booster Phase|Lost to Follow-up|1
6168440|NCT01235949|9813424|FG012|Booster Phase|Lost to Follow-up|0
6168441|NCT01235949|9813425|FG013|Booster Phase|Lost to Follow-up|0
6168442|NCT01235949|9813426|FG014|Booster Phase|Lost to Follow-up|0
6168443|NCT01235949|9813427|FG015|Booster Phase|Lost to Follow-up|0
6168444|NCT01235949|9813428|FG016|Booster Phase|Lost to Follow-up|0
6168445|NCT01235949|9813429|FG017|Booster Phase|Lost to Follow-up|1
6168446|NCT01235975|9813469|FG000|Overall Study|Serious Adverse Event|0
6168447|NCT01235975|9813470|FG001|Overall Study|Serious Adverse Event|1
6168448|NCT01235975|9813469|FG000|Overall Study|Withdrawal by Subject|8
6168449|NCT01235975|9813470|FG001|Overall Study|Withdrawal by Subject|2
6168450|NCT01235975|9813469|FG000|Overall Study|Migrated/moved from study area|2
6168451|NCT01235975|9813470|FG001|Overall Study|Migrated/moved from study area|1
6168452|NCT01235975|9813469|FG000|Overall Study|Lost to Follow-up|7
6168453|NCT01235975|9813470|FG001|Overall Study|Lost to Follow-up|3
6168454|NCT01236001|9813478|FG000|Overall Study|Adverse Event|5
6168455|NCT01236001|9813479|FG001|Overall Study|Adverse Event|14
6168456|NCT01236001|9813478|FG000|Overall Study|Lack of Efficacy|6
6168457|NCT01236001|9813479|FG001|Overall Study|Lack of Efficacy|6
6168458|NCT01236001|9813478|FG000|Overall Study|Lost to Follow-up|6
6168459|NCT01236001|9813479|FG001|Overall Study|Lost to Follow-up|1
6168460|NCT01236001|9813478|FG000|Overall Study|Incompliance|1
6168461|NCT01236001|9813479|FG001|Overall Study|Incompliance|0
6168462|NCT01236001|9813478|FG000|Overall Study|Planned Visit After End of Study|0
6168463|NCT01236001|9813479|FG001|Overall Study|Planned Visit After End of Study|1
6168464|NCT01236118|9813589|FG000|Overall Study|Adverse Event|2
6168465|NCT01236118|9813590|FG001|Overall Study|Adverse Event|0
6168466|NCT01236118|9813591|FG002|Overall Study|Adverse Event|2
6168467|NCT01236118|9813589|FG000|Overall Study|Physician Decision|0
6168468|NCT01236118|9813590|FG001|Overall Study|Physician Decision|1
6335045|NCT03126227|10085252|FG000|Overall Study|Did not meet eligibility criteria subsequent to enrollment|2
6335046|NCT03126227|10085253|FG001|Overall Study|Did not meet eligibility criteria subsequent to enrollment|0
6335047|NCT03126227|10085252|FG000|Overall Study|Scheduling conflict|1
6335048|NCT03126227|10085253|FG001|Overall Study|Scheduling conflict|0
6335049|NCT03126344|10085262|FG000|Overall Study|Lost to Follow-up|0
6335050|NCT03126344|10085263|FG001|Overall Study|Lost to Follow-up|0
6335051|NCT03126344|10085264|FG002|Overall Study|Lost to Follow-up|5
6335052|NCT03126539|10085295|FG000|Overall Study|Lost to Follow-up|1
6335053|NCT03126539|10085296|FG001|Overall Study|Lost to Follow-up|1
6335054|NCT03126539|10085297|FG002|Overall Study|Lost to Follow-up|1
6335055|NCT03126539|10085298|FG003|Overall Study|Lost to Follow-up|0
6335056|NCT03126539|10085299|FG004|Overall Study|Lost to Follow-up|0
6335057|NCT03126786|10085332|FG000|Overall Study|Adverse Event|3
6335058|NCT03126786|10085333|FG001|Overall Study|Adverse Event|0
6335059|NCT03126786|10085332|FG000|Overall Study|Lost to Follow-up|0
6335060|NCT03126786|10085333|FG001|Overall Study|Lost to Follow-up|1
6335061|NCT03126786|10085332|FG000|Overall Study|Withdrawal by Subject|3
6335062|NCT03126786|10085333|FG001|Overall Study|Withdrawal by Subject|1
6335063|NCT03127384|10085367|FG000|Overall Study|Lost to Follow-up|4
6335064|NCT03127384|10085367|FG000|Overall Study|Subject request|2
6335065|NCT03127644|10085385|FG000|Overall Study|Study-specific withdrawal criteria|0
6335066|NCT03127644|10085386|FG001|Overall Study|Study-specific withdrawal criteria|0
6335067|NCT03127644|10085387|FG002|Overall Study|Study-specific withdrawal criteria|2
6335068|NCT03128099|10085425|FG000|Overall Study|High dose task was too long|0
6335069|NCT03128099|10085426|FG001|Overall Study|High dose task was too long|4
6335070|NCT03128099|10085427|FG002|Overall Study|High dose task was too long|0
6335071|NCT03128099|10085425|FG000|Overall Study|Participant got a full time job.|1
6335072|NCT03128099|10085426|FG001|Overall Study|Participant got a full time job.|0
6335073|NCT03128099|10085427|FG002|Overall Study|Participant got a full time job.|0
6335074|NCT03128099|10085425|FG000|Overall Study|Became homeless and lost contact|1
6335075|NCT03128099|10085426|FG001|Overall Study|Became homeless and lost contact|0
6335076|NCT03128099|10085427|FG002|Overall Study|Became homeless and lost contact|0
6335077|NCT03128099|10085425|FG000|Overall Study|Did not complete all the assessments|0
6335078|NCT03128099|10085426|FG001|Overall Study|Did not complete all the assessments|0
6335079|NCT03128099|10085427|FG002|Overall Study|Did not complete all the assessments|1
6335080|NCT03128307|10085433|FG000|Overall Study|Lost to Follow-up|29
6335081|NCT03128307|10085433|FG000|Overall Study|Withdrawal by Subject|5
6335082|NCT03128723|10085441|FG000|Overall Study|Withdrawal by Subject|2
6335083|NCT03128892|10085445|FG000|Overall Study|Withdrawal by Subject|2
6335084|NCT03128892|10085445|FG000|Overall Study|Physician Decision|1
6335085|NCT03129100|10085454|FG000|Lead-In Period (Period 1)|Adverse Event|2
6335086|NCT03129100|10085455|FG001|Lead-In Period (Period 1)|Adverse Event|6
6335087|NCT03129100|10085456|FG002|Lead-In Period (Period 1)|Adverse Event|0
6335088|NCT03129100|10085457|FG003|Lead-In Period (Period 1)|Adverse Event|0
6335089|NCT03129100|10085458|FG004|Lead-In Period (Period 1)|Adverse Event|0
6335090|NCT03129100|10085459|FG005|Lead-In Period (Period 1)|Adverse Event|0
6335091|NCT03129100|10085460|FG006|Lead-In Period (Period 1)|Adverse Event|0
6335092|NCT03129100|10085461|FG007|Lead-In Period (Period 1)|Adverse Event|0
6335093|NCT03129100|10085462|FG008|Lead-In Period (Period 1)|Adverse Event|0
6335094|NCT03129100|10085463|FG009|Lead-In Period (Period 1)|Adverse Event|0
6335095|NCT03129100|10085464|FG010|Lead-In Period (Period 1)|Adverse Event|0
6335096|NCT03129100|10085454|FG000|Lead-In Period (Period 1)|Lost to Follow-up|2
6335097|NCT03129100|10085455|FG001|Lead-In Period (Period 1)|Lost to Follow-up|0
6335098|NCT03129100|10085456|FG002|Lead-In Period (Period 1)|Lost to Follow-up|0
6335099|NCT03129100|10085457|FG003|Lead-In Period (Period 1)|Lost to Follow-up|0
6335100|NCT03129100|10085458|FG004|Lead-In Period (Period 1)|Lost to Follow-up|0
6335101|NCT03129100|10085459|FG005|Lead-In Period (Period 1)|Lost to Follow-up|0
6335102|NCT03129100|10085460|FG006|Lead-In Period (Period 1)|Lost to Follow-up|0
6335103|NCT03129100|10085461|FG007|Lead-In Period (Period 1)|Lost to Follow-up|0
6335104|NCT03129100|10085462|FG008|Lead-In Period (Period 1)|Lost to Follow-up|0
6335105|NCT03129100|10085463|FG009|Lead-In Period (Period 1)|Lost to Follow-up|0
6335106|NCT03129100|10085464|FG010|Lead-In Period (Period 1)|Lost to Follow-up|0
6335107|NCT03129100|10085454|FG000|Lead-In Period (Period 1)|Withdrawal by Subject|8
6335108|NCT03129100|10085455|FG001|Lead-In Period (Period 1)|Withdrawal by Subject|8
6335109|NCT03129100|10085456|FG002|Lead-In Period (Period 1)|Withdrawal by Subject|0
6335110|NCT03129100|10085457|FG003|Lead-In Period (Period 1)|Withdrawal by Subject|0
6335111|NCT03129100|10085458|FG004|Lead-In Period (Period 1)|Withdrawal by Subject|0
6335112|NCT03129100|10085459|FG005|Lead-In Period (Period 1)|Withdrawal by Subject|0
6335113|NCT03129100|10085460|FG006|Lead-In Period (Period 1)|Withdrawal by Subject|0
6335114|NCT03129100|10085461|FG007|Lead-In Period (Period 1)|Withdrawal by Subject|0
6335115|NCT03129100|10085462|FG008|Lead-In Period (Period 1)|Withdrawal by Subject|0
6335116|NCT03129100|10085463|FG009|Lead-In Period (Period 1)|Withdrawal by Subject|0
6335117|NCT03129100|10085464|FG010|Lead-In Period (Period 1)|Withdrawal by Subject|0
6335118|NCT03129100|10085454|FG000|Lead-In Period (Period 1)|Lack of Efficacy|3
6335119|NCT03129100|10085455|FG001|Lead-In Period (Period 1)|Lack of Efficacy|2
6335120|NCT03129100|10085456|FG002|Lead-In Period (Period 1)|Lack of Efficacy|0
6335121|NCT03129100|10085457|FG003|Lead-In Period (Period 1)|Lack of Efficacy|0
6335122|NCT03129100|10085458|FG004|Lead-In Period (Period 1)|Lack of Efficacy|0
6335123|NCT03129100|10085459|FG005|Lead-In Period (Period 1)|Lack of Efficacy|0
6335124|NCT03129100|10085460|FG006|Lead-In Period (Period 1)|Lack of Efficacy|0
6335125|NCT03129100|10085461|FG007|Lead-In Period (Period 1)|Lack of Efficacy|0
6335126|NCT03129100|10085462|FG008|Lead-In Period (Period 1)|Lack of Efficacy|0
6335127|NCT03129100|10085463|FG009|Lead-In Period (Period 1)|Lack of Efficacy|0
6335128|NCT03129100|10085464|FG010|Lead-In Period (Period 1)|Lack of Efficacy|0
6335129|NCT03129100|10085454|FG000|Lead-In Period (Period 1)|Surgery Programmed|0
6335130|NCT03129100|10085455|FG001|Lead-In Period (Period 1)|Surgery Programmed|1
6335131|NCT03129100|10085456|FG002|Lead-In Period (Period 1)|Surgery Programmed|0
6335132|NCT03129100|10085457|FG003|Lead-In Period (Period 1)|Surgery Programmed|0
6335133|NCT03129100|10085458|FG004|Lead-In Period (Period 1)|Surgery Programmed|0
6335134|NCT03129100|10085459|FG005|Lead-In Period (Period 1)|Surgery Programmed|0
6335135|NCT03129100|10085460|FG006|Lead-In Period (Period 1)|Surgery Programmed|0
6335136|NCT03129100|10085461|FG007|Lead-In Period (Period 1)|Surgery Programmed|0
6335137|NCT03129100|10085462|FG008|Lead-In Period (Period 1)|Surgery Programmed|0
6335138|NCT03129100|10085463|FG009|Lead-In Period (Period 1)|Surgery Programmed|0
6335139|NCT03129100|10085464|FG010|Lead-In Period (Period 1)|Surgery Programmed|0
6335140|NCT03129100|10085454|FG000|Period2 Extension Period (Group A and B)|Adverse Event|0
6335141|NCT03129100|10085455|FG001|Period2 Extension Period (Group A and B)|Adverse Event|0
6335142|NCT03129100|10085456|FG002|Period2 Extension Period (Group A and B)|Adverse Event|2
6335143|NCT03129100|10085457|FG003|Period2 Extension Period (Group A and B)|Adverse Event|1
6335144|NCT03129100|10085458|FG004|Period2 Extension Period (Group A and B)|Adverse Event|0
6335145|NCT03129100|10085459|FG005|Period2 Extension Period (Group A and B)|Adverse Event|2
6335146|NCT03129100|10085460|FG006|Period2 Extension Period (Group A and B)|Adverse Event|0
6335147|NCT03129100|10085461|FG007|Period2 Extension Period (Group A and B)|Adverse Event|0
6335148|NCT03129100|10085462|FG008|Period2 Extension Period (Group A and B)|Adverse Event|0
6335149|NCT03129100|10085463|FG009|Period2 Extension Period (Group A and B)|Adverse Event|0
6335150|NCT03129100|10085464|FG010|Period2 Extension Period (Group A and B)|Adverse Event|0
6335151|NCT03129100|10085454|FG000|Period2 Extension Period (Group A and B)|Death|0
6335152|NCT03129100|10085455|FG001|Period2 Extension Period (Group A and B)|Death|0
6335153|NCT03129100|10085456|FG002|Period2 Extension Period (Group A and B)|Death|1
6335154|NCT03129100|10085457|FG003|Period2 Extension Period (Group A and B)|Death|0
6335155|NCT03129100|10085458|FG004|Period2 Extension Period (Group A and B)|Death|0
6335156|NCT03129100|10085459|FG005|Period2 Extension Period (Group A and B)|Death|0
6335157|NCT03129100|10085460|FG006|Period2 Extension Period (Group A and B)|Death|0
6335158|NCT03129100|10085461|FG007|Period2 Extension Period (Group A and B)|Death|0
6335159|NCT03129100|10085462|FG008|Period2 Extension Period (Group A and B)|Death|0
6335160|NCT03129100|10085463|FG009|Period2 Extension Period (Group A and B)|Death|0
6335161|NCT03129100|10085464|FG010|Period2 Extension Period (Group A and B)|Death|0
6335162|NCT03129100|10085454|FG000|Period2 Extension Period (Group A and B)|Withdrawal by Subject|0
6335163|NCT03129100|10085455|FG001|Period2 Extension Period (Group A and B)|Withdrawal by Subject|0
6335164|NCT03129100|10085456|FG002|Period2 Extension Period (Group A and B)|Withdrawal by Subject|13
6335165|NCT03129100|10085457|FG003|Period2 Extension Period (Group A and B)|Withdrawal by Subject|5
6335166|NCT03129100|10085458|FG004|Period2 Extension Period (Group A and B)|Withdrawal by Subject|1
6335167|NCT03129100|10085459|FG005|Period2 Extension Period (Group A and B)|Withdrawal by Subject|1
6335168|NCT03129100|10085460|FG006|Period2 Extension Period (Group A and B)|Withdrawal by Subject|2
6335169|NCT03129100|10085461|FG007|Period2 Extension Period (Group A and B)|Withdrawal by Subject|0
6335170|NCT03129100|10085462|FG008|Period2 Extension Period (Group A and B)|Withdrawal by Subject|0
6335171|NCT03129100|10085463|FG009|Period2 Extension Period (Group A and B)|Withdrawal by Subject|0
6335172|NCT03129100|10085464|FG010|Period2 Extension Period (Group A and B)|Withdrawal by Subject|0
6335173|NCT03129100|10085454|FG000|Period2 Extension Period (Group A and B)|Physician Decision|0
6335174|NCT03129100|10085455|FG001|Period2 Extension Period (Group A and B)|Physician Decision|0
6335175|NCT03129100|10085456|FG002|Period2 Extension Period (Group A and B)|Physician Decision|1
6335176|NCT03129100|10085457|FG003|Period2 Extension Period (Group A and B)|Physician Decision|0
6335177|NCT03129100|10085458|FG004|Period2 Extension Period (Group A and B)|Physician Decision|0
6335178|NCT03129100|10085459|FG005|Period2 Extension Period (Group A and B)|Physician Decision|0
6335179|NCT03129100|10085460|FG006|Period2 Extension Period (Group A and B)|Physician Decision|0
6335180|NCT03129100|10085461|FG007|Period2 Extension Period (Group A and B)|Physician Decision|0
6082937|NCT00632749|9691181|FG006|Overall Study|Progressive disease|3
6082938|NCT00632749|9691182|FG007|Overall Study|Progressive disease|2
6082939|NCT00632749|9691183|FG008|Overall Study|Progressive disease|3
6082940|NCT00632749|9691184|FG009|Overall Study|Progressive disease|2
6082941|NCT00632749|9691185|FG010|Overall Study|Progressive disease|4
6082942|NCT00632749|9691186|FG011|Overall Study|Progressive disease|3
6082943|NCT00632749|9691187|FG012|Overall Study|Progressive disease|2
6082944|NCT00632749|9691188|FG013|Overall Study|Progressive disease|4
6082945|NCT00632749|9691175|FG000|Overall Study|Other Adverse event|1
6082946|NCT00632749|9691176|FG001|Overall Study|Other Adverse event|1
6082947|NCT00632749|9691177|FG002|Overall Study|Other Adverse event|1
6082948|NCT00632749|9691178|FG003|Overall Study|Other Adverse event|1
6082949|NCT00632749|9691179|FG004|Overall Study|Other Adverse event|2
6082950|NCT00632749|9691180|FG005|Overall Study|Other Adverse event|4
6082951|NCT00632749|9691181|FG006|Overall Study|Other Adverse event|1
6082952|NCT00632749|9691182|FG007|Overall Study|Other Adverse event|2
6082953|NCT00632749|9691183|FG008|Overall Study|Other Adverse event|2
6082954|NCT00632749|9691184|FG009|Overall Study|Other Adverse event|0
6082955|NCT00632749|9691185|FG010|Overall Study|Other Adverse event|1
6082956|NCT00632749|9691186|FG011|Overall Study|Other Adverse event|0
6082957|NCT00632749|9691187|FG012|Overall Study|Other Adverse event|1
6082958|NCT00632749|9691188|FG013|Overall Study|Other Adverse event|0
6082959|NCT00632749|9691175|FG000|Overall Study|Refuse to continue medication|0
6082960|NCT00632749|9691176|FG001|Overall Study|Refuse to continue medication|0
6082961|NCT00632749|9691177|FG002|Overall Study|Refuse to continue medication|0
6082962|NCT00632749|9691178|FG003|Overall Study|Refuse to continue medication|1
6082963|NCT00632749|9691179|FG004|Overall Study|Refuse to continue medication|0
6082964|NCT00632749|9691180|FG005|Overall Study|Refuse to continue medication|0
6082965|NCT00632749|9691181|FG006|Overall Study|Refuse to continue medication|0
6082966|NCT00632749|9691182|FG007|Overall Study|Refuse to continue medication|0
6082967|NCT00632749|9691183|FG008|Overall Study|Refuse to continue medication|0
6082968|NCT00632749|9691184|FG009|Overall Study|Refuse to continue medication|1
6082969|NCT00632749|9691185|FG010|Overall Study|Refuse to continue medication|0
6082970|NCT00632749|9691186|FG011|Overall Study|Refuse to continue medication|0
6082971|NCT00632749|9691187|FG012|Overall Study|Refuse to continue medication|0
6082972|NCT00632749|9691188|FG013|Overall Study|Refuse to continue medication|0
6082973|NCT00632749|9691175|FG000|Overall Study|Reason other than those specified above|0
6082974|NCT00632749|9691176|FG001|Overall Study|Reason other than those specified above|2
6082975|NCT00632749|9691177|FG002|Overall Study|Reason other than those specified above|0
6082976|NCT00632749|9691178|FG003|Overall Study|Reason other than those specified above|0
6082977|NCT00632749|9691179|FG004|Overall Study|Reason other than those specified above|1
6082978|NCT00632749|9691180|FG005|Overall Study|Reason other than those specified above|0
6082979|NCT00632749|9691181|FG006|Overall Study|Reason other than those specified above|1
6082980|NCT00632749|9691182|FG007|Overall Study|Reason other than those specified above|0
6082981|NCT00632749|9691183|FG008|Overall Study|Reason other than those specified above|0
6082982|NCT00632749|9691184|FG009|Overall Study|Reason other than those specified above|0
6082983|NCT00632749|9691185|FG010|Overall Study|Reason other than those specified above|2
6082984|NCT00632749|9691186|FG011|Overall Study|Reason other than those specified above|1
6082985|NCT00632749|9691187|FG012|Overall Study|Reason other than those specified above|0
6082986|NCT00632749|9691188|FG013|Overall Study|Reason other than those specified above|2
6082987|NCT00632827|9691237|FG000|Overall Study|Excluded after GVD (Not evaluable)|2
6082988|NCT00632827|9691237|FG000|Overall Study|Death|2
6082989|NCT00632827|9691237|FG000|Overall Study|Adverse Event|5
6082990|NCT00632827|9691237|FG000|Overall Study|Lost to Follow-up|1
6082991|NCT00632931|9691242|FG000|Part 1, Period 1|Protocol Violation|1
6335181|NCT03129100|10085462|FG008|Period2 Extension Period (Group A and B)|Physician Decision|0
6335182|NCT03129100|10085463|FG009|Period2 Extension Period (Group A and B)|Physician Decision|0
6335183|NCT03129100|10085464|FG010|Period2 Extension Period (Group A and B)|Physician Decision|0
6335184|NCT03129100|10085454|FG000|Period2 Extension Period (Group A and B)|Lack of Efficacy|0
6335185|NCT03129100|10085455|FG001|Period2 Extension Period (Group A and B)|Lack of Efficacy|0
6335186|NCT03129100|10085456|FG002|Period2 Extension Period (Group A and B)|Lack of Efficacy|2
6335187|NCT03129100|10085457|FG003|Period2 Extension Period (Group A and B)|Lack of Efficacy|0
6335188|NCT03129100|10085458|FG004|Period2 Extension Period (Group A and B)|Lack of Efficacy|0
6335189|NCT03129100|10085459|FG005|Period2 Extension Period (Group A and B)|Lack of Efficacy|0
6335190|NCT03129100|10085460|FG006|Period2 Extension Period (Group A and B)|Lack of Efficacy|0
6335191|NCT03129100|10085461|FG007|Period2 Extension Period (Group A and B)|Lack of Efficacy|0
6335192|NCT03129100|10085462|FG008|Period2 Extension Period (Group A and B)|Lack of Efficacy|0
6335193|NCT03129100|10085463|FG009|Period2 Extension Period (Group A and B)|Lack of Efficacy|0
6335194|NCT03129100|10085464|FG010|Period2 Extension Period (Group A and B)|Lack of Efficacy|0
6335195|NCT03129100|10085454|FG000|Period2 Extension Period (Group A and B)|Lost to Follow-up|0
6335196|NCT03129100|10085455|FG001|Period2 Extension Period (Group A and B)|Lost to Follow-up|0
6335197|NCT03129100|10085456|FG002|Period2 Extension Period (Group A and B)|Lost to Follow-up|2
6335198|NCT03129100|10085457|FG003|Period2 Extension Period (Group A and B)|Lost to Follow-up|0
6335199|NCT03129100|10085458|FG004|Period2 Extension Period (Group A and B)|Lost to Follow-up|0
6335200|NCT03129100|10085459|FG005|Period2 Extension Period (Group A and B)|Lost to Follow-up|0
6335201|NCT03129100|10085460|FG006|Period2 Extension Period (Group A and B)|Lost to Follow-up|0
6335202|NCT03129100|10085461|FG007|Period2 Extension Period (Group A and B)|Lost to Follow-up|0
6335203|NCT03129100|10085462|FG008|Period2 Extension Period (Group A and B)|Lost to Follow-up|0
6335204|NCT03129100|10085463|FG009|Period2 Extension Period (Group A and B)|Lost to Follow-up|0
6335205|NCT03129100|10085464|FG010|Period2 Extension Period (Group A and B)|Lost to Follow-up|0
6335206|NCT03129100|10085454|FG000|Period2 Extension Period (Group A and B)|Experienced Flare|0
6082992|NCT00632931|9691243|FG001|Part 1, Period 1|Protocol Violation|0
6082993|NCT00632931|9691244|FG002|Part 1, Period 1|Protocol Violation|0
6082994|NCT00632931|9691242|FG000|Part 1, Period 1|Withdrawal by Subject|1
6082995|NCT00632931|9691243|FG001|Part 1, Period 1|Withdrawal by Subject|0
6082996|NCT00632931|9691244|FG002|Part 1, Period 1|Withdrawal by Subject|0
6082997|NCT00632931|9691242|FG000|Part 2|Adverse Event|0
6335207|NCT03129100|10085455|FG001|Period2 Extension Period (Group A and B)|Experienced Flare|0
6335208|NCT03129100|10085456|FG002|Period2 Extension Period (Group A and B)|Experienced Flare|0
6335209|NCT03129100|10085457|FG003|Period2 Extension Period (Group A and B)|Experienced Flare|0
6335210|NCT03129100|10085458|FG004|Period2 Extension Period (Group A and B)|Experienced Flare|5
6335211|NCT03129100|10085459|FG005|Period2 Extension Period (Group A and B)|Experienced Flare|6
6335212|NCT03129100|10085460|FG006|Period2 Extension Period (Group A and B)|Experienced Flare|19
6335213|NCT03129100|10085461|FG007|Period2 Extension Period (Group A and B)|Experienced Flare|0
6335214|NCT03129100|10085462|FG008|Period2 Extension Period (Group A and B)|Experienced Flare|0
6335215|NCT03129100|10085463|FG009|Period2 Extension Period (Group A and B)|Experienced Flare|0
6335216|NCT03129100|10085464|FG010|Period2 Extension Period (Group A and B)|Experienced Flare|0
6335217|NCT03129100|10085454|FG000|Period 2 (Retreatment Extension Period)|Withdrawal by Subject|0
6335218|NCT03129100|10085455|FG001|Period 2 (Retreatment Extension Period)|Withdrawal by Subject|0
6335219|NCT03129100|10085456|FG002|Period 2 (Retreatment Extension Period)|Withdrawal by Subject|0
6335220|NCT03129100|10085457|FG003|Period 2 (Retreatment Extension Period)|Withdrawal by Subject|0
6335221|NCT03129100|10085458|FG004|Period 2 (Retreatment Extension Period)|Withdrawal by Subject|0
6335222|NCT03129100|10085459|FG005|Period 2 (Retreatment Extension Period)|Withdrawal by Subject|0
6335223|NCT03129100|10085460|FG006|Period 2 (Retreatment Extension Period)|Withdrawal by Subject|0
6335224|NCT03129100|10085461|FG007|Period 2 (Retreatment Extension Period)|Withdrawal by Subject|0
6335225|NCT03129100|10085462|FG008|Period 2 (Retreatment Extension Period)|Withdrawal by Subject|0
6335226|NCT03129100|10085463|FG009|Period 2 (Retreatment Extension Period)|Withdrawal by Subject|1
6335227|NCT03129100|10085464|FG010|Period 2 (Retreatment Extension Period)|Withdrawal by Subject|0
6335228|NCT03130257|10085512|FG000|Overall Study|Withdrawal by Subject|1
6335229|NCT03130257|10085513|FG001|Overall Study|Withdrawal by Subject|0
6335230|NCT03130257|10085514|FG002|Overall Study|Withdrawal by Subject|2
6335231|NCT03131167|10085548|FG000|Overall Study|Other (Unspecified)|0
6335232|NCT03131167|10085549|FG001|Overall Study|Other (Unspecified)|0
6335233|NCT03131167|10085550|FG002|Overall Study|Other (Unspecified)|0
6335234|NCT03131167|10085551|FG003|Overall Study|Other (Unspecified)|0
6335235|NCT03131167|10085552|FG004|Overall Study|Other (Unspecified)|0
6335236|NCT03131167|10085553|FG005|Overall Study|Other (Unspecified)|1
6335237|NCT03131167|10085554|FG006|Overall Study|Other (Unspecified)|0
6335238|NCT03131167|10085555|FG007|Overall Study|Other (Unspecified)|0
6335239|NCT03131167|10085556|FG008|Overall Study|Other (Unspecified)|0
6335240|NCT03131167|10085557|FG009|Overall Study|Other (Unspecified)|0
6335241|NCT03131167|10085558|FG010|Overall Study|Other (Unspecified)|0
6335242|NCT03131167|10085559|FG011|Overall Study|Other (Unspecified)|0
6335243|NCT03131167|10085560|FG012|Overall Study|Other (Unspecified)|0
6335244|NCT03131453|10085613|FG000|Overall Study|Study terminated by Sponsor|424
6335245|NCT03131453|10085614|FG001|Overall Study|Study terminated by Sponsor|222
6335246|NCT03131453|10085615|FG002|Overall Study|Study terminated by Sponsor|438
6335247|NCT03131453|10085613|FG000|Overall Study|Withdrawal by Subject|18
6335248|NCT03131453|10085614|FG001|Overall Study|Withdrawal by Subject|7
6335249|NCT03131453|10085615|FG002|Overall Study|Withdrawal by Subject|13
6335250|NCT03131453|10085613|FG000|Overall Study|Adverse Event|10
6335251|NCT03131453|10085614|FG001|Overall Study|Adverse Event|3
6335252|NCT03131453|10085615|FG002|Overall Study|Adverse Event|3
6335253|NCT03131453|10085613|FG000|Overall Study|Lost to Follow-up|1
6335254|NCT03131453|10085614|FG001|Overall Study|Lost to Follow-up|0
6335255|NCT03131453|10085615|FG002|Overall Study|Lost to Follow-up|1
6335256|NCT03131453|10085613|FG000|Overall Study|Physician Decision|1
6335257|NCT03131453|10085614|FG001|Overall Study|Physician Decision|0
6335258|NCT03131453|10085615|FG002|Overall Study|Physician Decision|1
6335259|NCT03131453|10085613|FG000|Overall Study|Non-compliance with study treatment|1
6335260|NCT03131453|10085614|FG001|Overall Study|Non-compliance with study treatment|0
6335261|NCT03131453|10085615|FG002|Overall Study|Non-compliance with study treatment|0
6335262|NCT03131453|10085613|FG000|Overall Study|Technical problems|1
6335263|NCT03131453|10085614|FG001|Overall Study|Technical problems|0
6335264|NCT03131453|10085615|FG002|Overall Study|Technical problems|0
6335265|NCT03131453|10085613|FG000|Overall Study|Protocol deviation|0
6335266|NCT03131453|10085614|FG001|Overall Study|Protocol deviation|1
6335267|NCT03131453|10085615|FG002|Overall Study|Protocol deviation|0
6335268|NCT03131479|10085628|FG000|Overall Study|Adverse Event|0
6335269|NCT03131479|10085629|FG001|Overall Study|Adverse Event|0
6335270|NCT03131479|10085630|FG002|Overall Study|Adverse Event|1
6335271|NCT03131479|10085631|FG003|Overall Study|Adverse Event|1
6335272|NCT03131479|10085632|FG004|Overall Study|Adverse Event|0
6335273|NCT03131479|10085628|FG000|Overall Study|Subject/Guardian Decision|0
6335274|NCT03131479|10085629|FG001|Overall Study|Subject/Guardian Decision|0
6335275|NCT03131479|10085630|FG002|Overall Study|Subject/Guardian Decision|0
6335276|NCT03131479|10085631|FG003|Overall Study|Subject/Guardian Decision|1
6335277|NCT03131479|10085632|FG004|Overall Study|Subject/Guardian Decision|0
6335278|NCT03131570|10085646|FG000|Overall Study|Adverse Event|1
6335279|NCT03131570|10085647|FG001|Overall Study|Adverse Event|0
6335280|NCT03131596|10085655|FG000|Overall Study|Protocol Violation|3
6335281|NCT03131596|10085656|FG001|Overall Study|Protocol Violation|3
6335282|NCT03131596|10085655|FG000|Overall Study|Lost to Follow-up|3
6335283|NCT03131596|10085656|FG001|Overall Study|Lost to Follow-up|0
6335284|NCT03131648|10085664|FG000|Initial Treatment Period|Not dosed|2
6335285|NCT03131648|10085665|FG001|Initial Treatment Period|Not dosed|2
6335286|NCT03131648|10085666|FG002|Initial Treatment Period|Not dosed|0
6335287|NCT03131648|10085667|FG003|Initial Treatment Period|Not dosed|0
6168469|NCT01236118|9813591|FG002|Overall Study|Physician Decision|0
6168470|NCT01236118|9813589|FG000|Overall Study|Withdrawal by Subject|0
6335288|NCT03131648|10085668|FG004|Initial Treatment Period|Not dosed|0
6335289|NCT03131648|10085669|FG005|Initial Treatment Period|Not dosed|0
6335290|NCT03131648|10085670|FG006|Initial Treatment Period|Not dosed|0
6335291|NCT03131648|10085671|FG007|Initial Treatment Period|Not dosed|0
6335292|NCT03131648|10085664|FG000|Initial Treatment Period|Discontinued IMP before Week 16|51
6335293|NCT03131648|10085665|FG001|Initial Treatment Period|Discontinued IMP before Week 16|18
6335294|NCT03131648|10085666|FG002|Initial Treatment Period|Discontinued IMP before Week 16|0
6335295|NCT03131648|10085667|FG003|Initial Treatment Period|Discontinued IMP before Week 16|0
6168471|NCT01236118|9813590|FG001|Overall Study|Withdrawal by Subject|0
6168472|NCT01236118|9813591|FG002|Overall Study|Withdrawal by Subject|1
6335296|NCT03131648|10085668|FG004|Initial Treatment Period|Discontinued IMP before Week 16|0
6335297|NCT03131648|10085669|FG005|Initial Treatment Period|Discontinued IMP before Week 16|0
6335298|NCT03131648|10085670|FG006|Initial Treatment Period|Discontinued IMP before Week 16|0
6335299|NCT03131648|10085671|FG007|Initial Treatment Period|Discontinued IMP before Week 16|0
6335300|NCT03131648|10085664|FG000|Open-label Treatment|Discontinued IMP|0
6335301|NCT03131648|10085665|FG001|Open-label Treatment|Discontinued IMP|0
6335302|NCT03131648|10085666|FG002|Open-label Treatment|Discontinued IMP|0
6335303|NCT03131648|10085667|FG003|Open-label Treatment|Discontinued IMP|0
6335304|NCT03131648|10085668|FG004|Open-label Treatment|Discontinued IMP|0
6335305|NCT03131648|10085669|FG005|Open-label Treatment|Discontinued IMP|0
6335306|NCT03131648|10085670|FG006|Open-label Treatment|Discontinued IMP|112
6335307|NCT03131648|10085671|FG007|Open-label Treatment|Discontinued IMP|0
6335308|NCT03131648|10085664|FG000|Open-label Treatment|Completed Week 50|0
6335309|NCT03131648|10085665|FG001|Open-label Treatment|Completed Week 50|0
6335310|NCT03131648|10085666|FG002|Open-label Treatment|Completed Week 50|0
6335311|NCT03131648|10085667|FG003|Open-label Treatment|Completed Week 50|0
6335312|NCT03131648|10085668|FG004|Open-label Treatment|Completed Week 50|0
6335313|NCT03131648|10085669|FG005|Open-label Treatment|Completed Week 50|0
6335314|NCT03131648|10085670|FG006|Open-label Treatment|Completed Week 50|6
6335315|NCT03131648|10085671|FG007|Open-label Treatment|Completed Week 50|0
6335316|NCT03131648|10085664|FG000|Maintenance Treatment Period|Not dosed|0
6335317|NCT03131648|10085665|FG001|Maintenance Treatment Period|Not dosed|0
6335318|NCT03131648|10085666|FG002|Maintenance Treatment Period|Not dosed|3
6335319|NCT03131648|10085667|FG003|Maintenance Treatment Period|Not dosed|2
6335320|NCT03131648|10085668|FG004|Maintenance Treatment Period|Not dosed|1
6335321|NCT03131648|10085669|FG005|Maintenance Treatment Period|Not dosed|0
6335322|NCT03131648|10085670|FG006|Maintenance Treatment Period|Not dosed|0
6335323|NCT03131648|10085671|FG007|Maintenance Treatment Period|Not dosed|0
6335324|NCT03131648|10085664|FG000|Maintenance Treatment Period|Discontinued IMP|0
6335325|NCT03131648|10085665|FG001|Maintenance Treatment Period|Discontinued IMP|0
6335326|NCT03131648|10085666|FG002|Maintenance Treatment Period|Discontinued IMP|3
6335327|NCT03131648|10085667|FG003|Maintenance Treatment Period|Discontinued IMP|5
6335328|NCT03131648|10085668|FG004|Maintenance Treatment Period|Discontinued IMP|4
6335329|NCT03131648|10085669|FG005|Maintenance Treatment Period|Discontinued IMP|4
6335330|NCT03131648|10085670|FG006|Maintenance Treatment Period|Discontinued IMP|0
6335331|NCT03131648|10085671|FG007|Maintenance Treatment Period|Discontinued IMP|0
6335332|NCT03131648|10085664|FG000|Maintenance Treatment Period|Transfer to open-label treatment|0
6335333|NCT03131648|10085665|FG001|Maintenance Treatment Period|Transfer to open-label treatment|0
6335334|NCT03131648|10085666|FG002|Maintenance Treatment Period|Transfer to open-label treatment|21
6335335|NCT03131648|10085667|FG003|Maintenance Treatment Period|Transfer to open-label treatment|18
6335336|NCT03131648|10085668|FG004|Maintenance Treatment Period|Transfer to open-label treatment|9
6335337|NCT03131648|10085669|FG005|Maintenance Treatment Period|Transfer to open-label treatment|10
6335338|NCT03131648|10085670|FG006|Maintenance Treatment Period|Transfer to open-label treatment|0
6335339|NCT03131648|10085671|FG007|Maintenance Treatment Period|Transfer to open-label treatment|0
6335340|NCT03131648|10085664|FG000|Maintenance Treatment Period|Completed Week 50|0
6335341|NCT03131648|10085665|FG001|Maintenance Treatment Period|Completed Week 50|0
6335342|NCT03131648|10085666|FG002|Maintenance Treatment Period|Completed Week 50|0
6335343|NCT03131648|10085667|FG003|Maintenance Treatment Period|Completed Week 50|0
6335344|NCT03131648|10085668|FG004|Maintenance Treatment Period|Completed Week 50|1
6335345|NCT03131648|10085669|FG005|Maintenance Treatment Period|Completed Week 50|0
6335346|NCT03131648|10085670|FG006|Maintenance Treatment Period|Completed Week 50|0
6335347|NCT03131648|10085671|FG007|Maintenance Treatment Period|Completed Week 50|0
6335348|NCT03131648|10085664|FG000|Open-label (Short Term Extension)|Discontinued IMP|0
6335349|NCT03131648|10085665|FG001|Open-label (Short Term Extension)|Discontinued IMP|0
6335350|NCT03131648|10085666|FG002|Open-label (Short Term Extension)|Discontinued IMP|0
6335351|NCT03131648|10085667|FG003|Open-label (Short Term Extension)|Discontinued IMP|0
6335352|NCT03131648|10085668|FG004|Open-label (Short Term Extension)|Discontinued IMP|0
6335353|NCT03131648|10085669|FG005|Open-label (Short Term Extension)|Discontinued IMP|0
6335354|NCT03131648|10085670|FG006|Open-label (Short Term Extension)|Discontinued IMP|0
6335355|NCT03131648|10085671|FG007|Open-label (Short Term Extension)|Discontinued IMP|3
6335356|NCT03131687|10085694|FG000|Overall Study|Adverse Event|0
6335357|NCT03131687|10085695|FG001|Overall Study|Adverse Event|1
6335358|NCT03131687|10085696|FG002|Overall Study|Adverse Event|0
6335359|NCT03131687|10085697|FG003|Overall Study|Adverse Event|1
6335360|NCT03131687|10085698|FG004|Overall Study|Adverse Event|2
6335361|NCT03131687|10085699|FG005|Overall Study|Adverse Event|2
6335362|NCT03131687|10085694|FG000|Overall Study|Death|1
6335363|NCT03131687|10085695|FG001|Overall Study|Death|0
6335364|NCT03131687|10085696|FG002|Overall Study|Death|0
6335365|NCT03131687|10085697|FG003|Overall Study|Death|0
6335366|NCT03131687|10085698|FG004|Overall Study|Death|0
6335367|NCT03131687|10085699|FG005|Overall Study|Death|0
6335368|NCT03131687|10085694|FG000|Overall Study|Withdrawal by Subject|3
6335369|NCT03131687|10085695|FG001|Overall Study|Withdrawal by Subject|3
6335370|NCT03131687|10085696|FG002|Overall Study|Withdrawal by Subject|3
6335371|NCT03131687|10085697|FG003|Overall Study|Withdrawal by Subject|1
6335372|NCT03131687|10085698|FG004|Overall Study|Withdrawal by Subject|2
6082998|NCT00632931|9691243|FG001|Part 2|Adverse Event|0
6082999|NCT00632931|9691244|FG002|Part 2|Adverse Event|3
6083000|NCT00632931|9691242|FG000|Part 2|Death|0
6083001|NCT00632931|9691243|FG001|Part 2|Death|0
6083002|NCT00632931|9691244|FG002|Part 2|Death|1
6335373|NCT03131687|10085699|FG005|Overall Study|Withdrawal by Subject|1
6335374|NCT03131687|10085694|FG000|Overall Study|Lost to Follow-up|1
6335375|NCT03131687|10085695|FG001|Overall Study|Lost to Follow-up|4
6335376|NCT03131687|10085696|FG002|Overall Study|Lost to Follow-up|0
6335377|NCT03131687|10085697|FG003|Overall Study|Lost to Follow-up|1
6335378|NCT03131687|10085698|FG004|Overall Study|Lost to Follow-up|4
6335379|NCT03131687|10085699|FG005|Overall Study|Lost to Follow-up|2
6335380|NCT03131687|10085694|FG000|Overall Study|Participant Started New Diabetic Drug|1
6335381|NCT03131687|10085695|FG001|Overall Study|Participant Started New Diabetic Drug|0
6335382|NCT03131687|10085696|FG002|Overall Study|Participant Started New Diabetic Drug|0
6335383|NCT03131687|10085697|FG003|Overall Study|Participant Started New Diabetic Drug|0
6335384|NCT03131687|10085698|FG004|Overall Study|Participant Started New Diabetic Drug|0
6335385|NCT03131687|10085699|FG005|Overall Study|Participant Started New Diabetic Drug|0
6335386|NCT03131687|10085694|FG000|Overall Study|Principle Investigator Decision|0
6335387|NCT03131687|10085695|FG001|Overall Study|Principle Investigator Decision|1
6335388|NCT03131687|10085696|FG002|Overall Study|Principle Investigator Decision|0
6335389|NCT03131687|10085697|FG003|Overall Study|Principle Investigator Decision|0
6335390|NCT03131687|10085698|FG004|Overall Study|Principle Investigator Decision|0
6335391|NCT03131687|10085699|FG005|Overall Study|Principle Investigator Decision|0
6335392|NCT03131687|10085694|FG000|Overall Study|Inadvertent Enrollment|0
6335393|NCT03131687|10085695|FG001|Overall Study|Inadvertent Enrollment|0
6335394|NCT03131687|10085696|FG002|Overall Study|Inadvertent Enrollment|0
6335395|NCT03131687|10085697|FG003|Overall Study|Inadvertent Enrollment|1
6335396|NCT03131687|10085698|FG004|Overall Study|Inadvertent Enrollment|0
6335397|NCT03131687|10085699|FG005|Overall Study|Inadvertent Enrollment|0
6335398|NCT03131713|10085728|FG000|Overall Study|Lost to Follow-up|5
6335399|NCT03131713|10085729|FG001|Overall Study|Lost to Follow-up|0
6335400|NCT03131895|10085739|FG000|Washout Period (at Least 5 Days)|Adverse Event|1
6335401|NCT03131895|10085740|FG001|Washout Period (at Least 5 Days)|Adverse Event|0
6335402|NCT03131895|10085741|FG002|Washout Period (at Least 5 Days)|Adverse Event|0
6335403|NCT03131895|10085742|FG003|Washout Period (at Least 5 Days)|Adverse Event|1
6335404|NCT03131895|10085739|FG000|Washout Period (at Least 5 Days)|Lost to Follow-up|0
6335405|NCT03131895|10085740|FG001|Washout Period (at Least 5 Days)|Lost to Follow-up|3
6335406|NCT03131895|10085741|FG002|Washout Period (at Least 5 Days)|Lost to Follow-up|2
6335407|NCT03131895|10085742|FG003|Washout Period (at Least 5 Days)|Lost to Follow-up|3
6335408|NCT03131895|10085739|FG000|Washout Period (at Least 5 Days)|Withdrawal by Subject|0
6335409|NCT03131895|10085740|FG001|Washout Period (at Least 5 Days)|Withdrawal by Subject|2
6335410|NCT03131895|10085741|FG002|Washout Period (at Least 5 Days)|Withdrawal by Subject|0
6335411|NCT03131895|10085742|FG003|Washout Period (at Least 5 Days)|Withdrawal by Subject|1
6335412|NCT03131895|10085739|FG000|Washout Period (at Least 5 Days)|Other|0
6335413|NCT03131895|10085740|FG001|Washout Period (at Least 5 Days)|Other|0
6335414|NCT03131895|10085741|FG002|Washout Period (at Least 5 Days)|Other|2
6335415|NCT03131895|10085742|FG003|Washout Period (at Least 5 Days)|Other|0
6335416|NCT03131895|10085739|FG000|Intervention Period 2 (2 Days)|Lost to Follow-up|0
6335417|NCT03131895|10085740|FG001|Intervention Period 2 (2 Days)|Lost to Follow-up|1
6335418|NCT03131895|10085741|FG002|Intervention Period 2 (2 Days)|Lost to Follow-up|0
6335419|NCT03131895|10085742|FG003|Intervention Period 2 (2 Days)|Lost to Follow-up|0
6335420|NCT03131895|10085739|FG000|Intervention Period 2 (2 Days)|Withdrawal by Subject|1
6335421|NCT03131895|10085740|FG001|Intervention Period 2 (2 Days)|Withdrawal by Subject|0
6335422|NCT03131895|10085741|FG002|Intervention Period 2 (2 Days)|Withdrawal by Subject|0
6335423|NCT03131895|10085742|FG003|Intervention Period 2 (2 Days)|Withdrawal by Subject|0
6335424|NCT03131999|10085754|FG000|Overall Study|Withdrawal by Subject|0
6335425|NCT03131999|10085755|FG001|Overall Study|Withdrawal by Subject|1
6335426|NCT03132220|10085763|FG000|Overall Study|Lost to Follow-up|17
6335427|NCT03132220|10085764|FG001|Overall Study|Lost to Follow-up|8
6335428|NCT03132220|10085763|FG000|Overall Study|Withdrawal by Subject|1
6335429|NCT03132220|10085764|FG001|Overall Study|Withdrawal by Subject|4
6335430|NCT03133481|10085799|FG000|Overall Study|FC Catheter fell out post operative day1|0
6335431|NCT03133481|10085800|FG001|Overall Study|FC Catheter fell out post operative day1|4
6335432|NCT03133767|10085852|FG000|Overall Study|Lost to Follow-up|38
6335433|NCT03133767|10085853|FG001|Overall Study|Lost to Follow-up|24
6335434|NCT03133767|10085852|FG000|Overall Study|Protocol Violation|0
6083003|NCT00632931|9691242|FG000|Part 2|Lack of Efficacy|0
6083004|NCT00632931|9691243|FG001|Part 2|Lack of Efficacy|0
6335435|NCT03133767|10085853|FG001|Overall Study|Protocol Violation|1
6335436|NCT03134183|10085892|FG000|Overall Study|Withdrawal by Subject|1
6335437|NCT03134183|10085893|FG001|Overall Study|Withdrawal by Subject|1
6335438|NCT03134222|10085915|FG000|Treatment Period (Up to Week 12)|Adverse Event|4
6335439|NCT03134222|10085916|FG001|Treatment Period (Up to Week 12)|Adverse Event|1
6335440|NCT03134222|10085917|FG002|Treatment Period (Up to Week 12)|Adverse Event|0
6335441|NCT03134222|10085918|FG003|Treatment Period (Up to Week 12)|Adverse Event|0
6335442|NCT03134222|10085919|FG004|Treatment Period (Up to Week 12)|Adverse Event|0
6083005|NCT00632931|9691244|FG002|Part 2|Lack of Efficacy|17
6083006|NCT00632931|9691242|FG000|Part 2|Withdrawal by Subject|0
6335443|NCT03134222|10085915|FG000|Treatment Period (Up to Week 12)|Lost to Follow-up|1
6335444|NCT03134222|10085916|FG001|Treatment Period (Up to Week 12)|Lost to Follow-up|1
6335445|NCT03134222|10085917|FG002|Treatment Period (Up to Week 12)|Lost to Follow-up|1
6335446|NCT03134222|10085918|FG003|Treatment Period (Up to Week 12)|Lost to Follow-up|0
6335447|NCT03134222|10085919|FG004|Treatment Period (Up to Week 12)|Lost to Follow-up|0
6335448|NCT03134222|10085915|FG000|Treatment Period (Up to Week 12)|Withdrew Consent|0
6335449|NCT03134222|10085916|FG001|Treatment Period (Up to Week 12)|Withdrew Consent|1
6335450|NCT03134222|10085917|FG002|Treatment Period (Up to Week 12)|Withdrew Consent|0
6335451|NCT03134222|10085918|FG003|Treatment Period (Up to Week 12)|Withdrew Consent|0
6335452|NCT03134222|10085919|FG004|Treatment Period (Up to Week 12)|Withdrew Consent|0
6335453|NCT03134222|10085915|FG000|Treatment Period (Up to Week 12)|Randomized but not treated|0
6335454|NCT03134222|10085916|FG001|Treatment Period (Up to Week 12)|Randomized but not treated|1
6335455|NCT03134222|10085917|FG002|Treatment Period (Up to Week 12)|Randomized but not treated|1
6335456|NCT03134222|10085918|FG003|Treatment Period (Up to Week 12)|Randomized but not treated|0
6335457|NCT03134222|10085919|FG004|Treatment Period (Up to Week 12)|Randomized but not treated|0
6335458|NCT03134222|10085915|FG000|Treatment Period (Week 12 to 48)|Withdrew Consent|0
6335459|NCT03134222|10085916|FG001|Treatment Period (Week 12 to 48)|Withdrew Consent|2
6335460|NCT03134222|10085917|FG002|Treatment Period (Week 12 to 48)|Withdrew Consent|0
6335461|NCT03134222|10085918|FG003|Treatment Period (Week 12 to 48)|Withdrew Consent|0
6335462|NCT03134222|10085919|FG004|Treatment Period (Week 12 to 48)|Withdrew Consent|1
6335463|NCT03134222|10085915|FG000|Treatment Period (Week 12 to 48)|Lack of Efficacy|2
6335464|NCT03134222|10085916|FG001|Treatment Period (Week 12 to 48)|Lack of Efficacy|0
6335465|NCT03134222|10085917|FG002|Treatment Period (Week 12 to 48)|Lack of Efficacy|0
6335466|NCT03134222|10085918|FG003|Treatment Period (Week 12 to 48)|Lack of Efficacy|0
6335467|NCT03134222|10085919|FG004|Treatment Period (Week 12 to 48)|Lack of Efficacy|0
6335468|NCT03134222|10085915|FG000|Treatment Period (Week 12 to 48)|Investigator's Discretion|0
6335469|NCT03134222|10085916|FG001|Treatment Period (Week 12 to 48)|Investigator's Discretion|0
6335470|NCT03134222|10085917|FG002|Treatment Period (Week 12 to 48)|Investigator's Discretion|0
6335471|NCT03134222|10085918|FG003|Treatment Period (Week 12 to 48)|Investigator's Discretion|1
6335472|NCT03134222|10085919|FG004|Treatment Period (Week 12 to 48)|Investigator's Discretion|0
6335473|NCT03134222|10085915|FG000|Treatment Period (Week 12 to 48)|Lost to Follow-up|0
6335474|NCT03134222|10085916|FG001|Treatment Period (Week 12 to 48)|Lost to Follow-up|1
6335475|NCT03134222|10085917|FG002|Treatment Period (Week 12 to 48)|Lost to Follow-up|0
6335476|NCT03134222|10085918|FG003|Treatment Period (Week 12 to 48)|Lost to Follow-up|0
6335477|NCT03134222|10085919|FG004|Treatment Period (Week 12 to 48)|Lost to Follow-up|0
6335478|NCT03134599|10085952|FG000|Week 1|Lost to Follow-up|0
6335479|NCT03134599|10085953|FG001|Week 1|Lost to Follow-up|0
6335480|NCT03134599|10085954|FG002|Week 1|Lost to Follow-up|0
6335481|NCT03134599|10085955|FG003|Week 1|Lost to Follow-up|0
6335482|NCT03134599|10085956|FG004|Week 1|Lost to Follow-up|1
6335483|NCT03134599|10085957|FG005|Week 1|Lost to Follow-up|0
6335484|NCT03134599|10085952|FG000|Week 2|Lost to Follow-up|1
6335485|NCT03134599|10085953|FG001|Week 2|Lost to Follow-up|0
6335486|NCT03134599|10085954|FG002|Week 2|Lost to Follow-up|0
6335487|NCT03134599|10085955|FG003|Week 2|Lost to Follow-up|1
6335488|NCT03134599|10085956|FG004|Week 2|Lost to Follow-up|1
6168473|NCT01236339|9813628|FG000|Overall Study|Termination of study by sponsor|11
6168474|NCT01236339|9813629|FG001|Overall Study|Termination of study by sponsor|13
6168475|NCT01236352|9813647|FG000|Overall Study|Death|0
6168476|NCT01236352|9813648|FG001|Overall Study|Death|0
6168477|NCT01236352|9813649|FG002|Overall Study|Death|0
6168478|NCT01236352|9813650|FG003|Overall Study|Death|0
6168479|NCT01236352|9813651|FG004|Overall Study|Death|0
6335489|NCT03134599|10085957|FG005|Week 2|Lost to Follow-up|0
6335490|NCT03134599|10085952|FG000|Week 3|Lost to Follow-up|0
6335491|NCT03134599|10085953|FG001|Week 3|Lost to Follow-up|0
6335492|NCT03134599|10085954|FG002|Week 3|Lost to Follow-up|0
6335493|NCT03134599|10085955|FG003|Week 3|Lost to Follow-up|1
6335494|NCT03134599|10085956|FG004|Week 3|Lost to Follow-up|0
6335495|NCT03134599|10085957|FG005|Week 3|Lost to Follow-up|1
6335496|NCT03134911|10085980|FG000|Overall Study|Screen failure|31
6335497|NCT03134911|10085980|FG000|Overall Study|Not meeting inclusion/exclusion criteria|3
6335498|NCT03135028|10086063|FG000|Overall Study|Death|6
6335499|NCT03135028|10086063|FG000|Overall Study|Study Terminated by Sponsor|2
6335500|NCT03135028|10086063|FG000|Overall Study|Withdrew Consent|1
6335501|NCT03135210|10086069|FG000|Overall Study|Death|0
6335502|NCT03135210|10086070|FG001|Overall Study|Death|1
6335503|NCT03135431|10086087|FG000|Overall Study|Study Surgeon not available|2
6335504|NCT03135431|10086088|FG001|Overall Study|Study Surgeon not available|0
6168480|NCT01236352|9813652|FG005|Overall Study|Death|0
6168481|NCT01236352|9813653|FG006|Overall Study|Death|0
6168482|NCT01236352|9813654|FG007|Overall Study|Death|1
6335505|NCT03135522|10086096|FG000|Overall Study|Adverse Event|1
6335506|NCT03135522|10086097|FG001|Overall Study|Adverse Event|0
6335507|NCT03135548|10086110|FG000|Overall Study|Lost to Follow-up|3
6335508|NCT03135548|10086111|FG001|Overall Study|Lost to Follow-up|0
6335509|NCT03135548|10086112|FG002|Overall Study|Lost to Follow-up|0
6335510|NCT03135548|10086110|FG000|Overall Study|Withdrawal by Subject|2
6335511|NCT03135548|10086111|FG001|Overall Study|Withdrawal by Subject|2
6335512|NCT03135548|10086112|FG002|Overall Study|Withdrawal by Subject|1
6335513|NCT03135548|10086110|FG000|Overall Study|Other than listed|0
6335514|NCT03135548|10086111|FG001|Overall Study|Other than listed|2
6335515|NCT03135548|10086112|FG002|Overall Study|Other than listed|2
6335516|NCT03135899|10086128|FG000|Overall Study|Failed spirometry,unable to repeat visit|0
6335517|NCT03135899|10086129|FG001|Overall Study|Failed spirometry,unable to repeat visit|0
6335518|NCT03135899|10086130|FG002|Overall Study|Failed spirometry,unable to repeat visit|0
6335519|NCT03135899|10086131|FG003|Overall Study|Failed spirometry,unable to repeat visit|0
6335520|NCT03135899|10086132|FG004|Overall Study|Failed spirometry,unable to repeat visit|0
6335521|NCT03135899|10086133|FG005|Overall Study|Failed spirometry,unable to repeat visit|0
6335522|NCT03135899|10086134|FG006|Overall Study|Failed spirometry,unable to repeat visit|1
6335523|NCT03135899|10086135|FG007|Overall Study|Failed spirometry,unable to repeat visit|0
6335524|NCT03135899|10086128|FG000|Overall Study|Withdrawal by Subject|0
6335525|NCT03135899|10086129|FG001|Overall Study|Withdrawal by Subject|0
6335526|NCT03135899|10086130|FG002|Overall Study|Withdrawal by Subject|0
6335527|NCT03135899|10086131|FG003|Overall Study|Withdrawal by Subject|0
6335528|NCT03135899|10086132|FG004|Overall Study|Withdrawal by Subject|0
6335529|NCT03135899|10086133|FG005|Overall Study|Withdrawal by Subject|2
6335530|NCT03135899|10086134|FG006|Overall Study|Withdrawal by Subject|0
6335531|NCT03135899|10086135|FG007|Overall Study|Withdrawal by Subject|0
6335532|NCT03136068|10086151|FG000|Overall Study|Lost to Follow-up|1
6335533|NCT03136068|10086152|FG001|Overall Study|Lost to Follow-up|1
6335534|NCT03136068|10086151|FG000|Overall Study|Protocol Violation|1
6335535|NCT03136068|10086152|FG001|Overall Study|Protocol Violation|0
6335536|NCT03136107|10086158|FG000|Overall Study|Other (Not specified)|1
6335537|NCT03136159|10086168|FG000|Overall Study|chorioamnionitis|2
6335538|NCT03136159|10086169|FG001|Overall Study|chorioamnionitis|0
6335539|NCT03136159|10086168|FG000|Overall Study|vertical skin incision|1
6335540|NCT03136159|10086169|FG001|Overall Study|vertical skin incision|0
6335541|NCT03136159|10086168|FG000|Overall Study|additional dressing|1
6335542|NCT03136159|10086169|FG001|Overall Study|additional dressing|0
6335543|NCT03136159|10086168|FG000|Overall Study|never got dressing placed|1
6335544|NCT03136159|10086169|FG001|Overall Study|never got dressing placed|0
6335545|NCT03136198|10086177|FG000|Overall Study|Withdrawal by Subject|0
6335546|NCT03136198|10086178|FG001|Overall Study|Withdrawal by Subject|1
6335547|NCT03136367|10086192|FG000|T1 Consultation|discontinued mistakenly included|2
6335548|NCT03136367|10086193|FG001|T1 Consultation|discontinued mistakenly included|6
6335549|NCT03136367|10086194|FG002|T1 Consultation|discontinued mistakenly included|1
6335550|NCT03136367|10086192|FG000|T1 Consultation|Discontinued other|0
6335551|NCT03136367|10086193|FG001|T1 Consultation|Discontinued other|1
6335552|NCT03136367|10086194|FG002|T1 Consultation|Discontinued other|0
6335553|NCT03136367|10086192|FG000|T2 Post-consultation|Withdrawal by Subject|1
6335554|NCT03136367|10086193|FG001|T2 Post-consultation|Withdrawal by Subject|1
6335555|NCT03136367|10086194|FG002|T2 Post-consultation|Withdrawal by Subject|5
6335556|NCT03136367|10086192|FG000|T2 Post-consultation|discontinued mistakenly included|2
6335557|NCT03136367|10086193|FG001|T2 Post-consultation|discontinued mistakenly included|2
6335558|NCT03136367|10086194|FG002|T2 Post-consultation|discontinued mistakenly included|17
6335559|NCT03136367|10086192|FG000|T2 Post-consultation|Discontinued other|0
6335560|NCT03136367|10086193|FG001|T2 Post-consultation|Discontinued other|2
6335561|NCT03136367|10086194|FG002|T2 Post-consultation|Discontinued other|6
6335562|NCT03136367|10086192|FG000|T2 Post-consultation|Discontinued transferred care|0
6335563|NCT03136367|10086193|FG001|T2 Post-consultation|Discontinued transferred care|0
6335564|NCT03136367|10086194|FG002|T2 Post-consultation|Discontinued transferred care|3
6335565|NCT03136367|10086192|FG000|T2 Post-consultation|Discontinued lost contact|0
6335566|NCT03136367|10086193|FG001|T2 Post-consultation|Discontinued lost contact|1
6335567|NCT03136367|10086194|FG002|T2 Post-consultation|Discontinued lost contact|0
6335568|NCT03136367|10086192|FG000|T3 1 Week After Surgery|Discontinued mistakenly included|5
6335569|NCT03136367|10086193|FG001|T3 1 Week After Surgery|Discontinued mistakenly included|9
6335570|NCT03136367|10086194|FG002|T3 1 Week After Surgery|Discontinued mistakenly included|8
6335571|NCT03136367|10086192|FG000|T3 1 Week After Surgery|Discontinued transferred care|2
6335572|NCT03136367|10086193|FG001|T3 1 Week After Surgery|Discontinued transferred care|11
6335573|NCT03136367|10086194|FG002|T3 1 Week After Surgery|Discontinued transferred care|14
6335574|NCT03136367|10086192|FG000|T3 1 Week After Surgery|other discontinued|2
6335575|NCT03136367|10086193|FG001|T3 1 Week After Surgery|other discontinued|4
6335576|NCT03136367|10086194|FG002|T3 1 Week After Surgery|other discontinued|3
6335577|NCT03136367|10086192|FG000|T3 1 Week After Surgery|Withdrawal by Subject|0
6335578|NCT03136367|10086193|FG001|T3 1 Week After Surgery|Withdrawal by Subject|6
6335579|NCT03136367|10086194|FG002|T3 1 Week After Surgery|Withdrawal by Subject|2
6335580|NCT03136367|10086192|FG000|T3 1 Week After Surgery|Discontinued lost contact|1
6335581|NCT03136367|10086193|FG001|T3 1 Week After Surgery|Discontinued lost contact|2
6335582|NCT03136367|10086194|FG002|T3 1 Week After Surgery|Discontinued lost contact|4
6335583|NCT03136367|10086192|FG000|T4 12 Weeks After Surgery|Withdrawal by Subject|1
6335584|NCT03136367|10086193|FG001|T4 12 Weeks After Surgery|Withdrawal by Subject|3
6335585|NCT03136367|10086194|FG002|T4 12 Weeks After Surgery|Withdrawal by Subject|0
6335586|NCT03136367|10086192|FG000|T4 12 Weeks After Surgery|Death|0
6335587|NCT03136367|10086193|FG001|T4 12 Weeks After Surgery|Death|1
6335588|NCT03136367|10086194|FG002|T4 12 Weeks After Surgery|Death|3
6335589|NCT03136367|10086192|FG000|T4 12 Weeks After Surgery|discontinued lost contact|1
6335590|NCT03136367|10086193|FG001|T4 12 Weeks After Surgery|discontinued lost contact|0
6335591|NCT03136367|10086194|FG002|T4 12 Weeks After Surgery|discontinued lost contact|0
6335592|NCT03136367|10086192|FG000|T4 12 Weeks After Surgery|discontinued transferred care|0
6335593|NCT03136367|10086193|FG001|T4 12 Weeks After Surgery|discontinued transferred care|1
6335594|NCT03136367|10086194|FG002|T4 12 Weeks After Surgery|discontinued transferred care|5
6335595|NCT03136367|10086192|FG000|T4 12 Weeks After Surgery|discontinued mistakenly included|0
6083007|NCT00632931|9691243|FG001|Part 2|Withdrawal by Subject|0
6083008|NCT00632931|9691244|FG002|Part 2|Withdrawal by Subject|3
6335596|NCT03136367|10086193|FG001|T4 12 Weeks After Surgery|discontinued mistakenly included|0
6335597|NCT03136367|10086194|FG002|T4 12 Weeks After Surgery|discontinued mistakenly included|1
6335598|NCT03136367|10086192|FG000|T5 1 Year After Surgery|discontinued mistakenly included|1
6335599|NCT03136367|10086193|FG001|T5 1 Year After Surgery|discontinued mistakenly included|1
6335600|NCT03136367|10086194|FG002|T5 1 Year After Surgery|discontinued mistakenly included|1
6335601|NCT03136367|10086192|FG000|T5 1 Year After Surgery|Withdrawal by Subject|1
6335602|NCT03136367|10086193|FG001|T5 1 Year After Surgery|Withdrawal by Subject|0
6335603|NCT03136367|10086194|FG002|T5 1 Year After Surgery|Withdrawal by Subject|0
6335604|NCT03136367|10086192|FG000|T5 1 Year After Surgery|Death|0
6335605|NCT03136367|10086193|FG001|T5 1 Year After Surgery|Death|0
6335606|NCT03136367|10086194|FG002|T5 1 Year After Surgery|Death|1
6335607|NCT03136367|10086192|FG000|T5 1 Year After Surgery|Discontinued lost contact|1
6335608|NCT03136367|10086193|FG001|T5 1 Year After Surgery|Discontinued lost contact|6
6335609|NCT03136367|10086194|FG002|T5 1 Year After Surgery|Discontinued lost contact|0
6335610|NCT03136367|10086192|FG000|T5 1 Year After Surgery|Lost to Follow-up|2
6335611|NCT03136367|10086193|FG001|T5 1 Year After Surgery|Lost to Follow-up|22
6335612|NCT03136367|10086194|FG002|T5 1 Year After Surgery|Lost to Follow-up|15
6335613|NCT03136367|10086192|FG000|T5 1 Year After Surgery|study ended before due|31
6335614|NCT03136367|10086193|FG001|T5 1 Year After Surgery|study ended before due|103
6335615|NCT03136367|10086194|FG002|T5 1 Year After Surgery|study ended before due|110
6335616|NCT03136367|10086192|FG000|T5 1 Year After Surgery|logistical issues prevented contact|0
6335617|NCT03136367|10086193|FG001|T5 1 Year After Surgery|logistical issues prevented contact|4
6335618|NCT03136367|10086194|FG002|T5 1 Year After Surgery|logistical issues prevented contact|2
6335619|NCT03136380|10086207|FG000|Part 1, Washout Period 2 (7 Days)|Withdrawal by Subject|0
6335620|NCT03136380|10086208|FG001|Part 1, Washout Period 2 (7 Days)|Withdrawal by Subject|1
6335621|NCT03136380|10086209|FG002|Part 1, Washout Period 2 (7 Days)|Withdrawal by Subject|0
6335622|NCT03136380|10086210|FG003|Part 1, Washout Period 2 (7 Days)|Withdrawal by Subject|0
6335623|NCT03136380|10086211|FG004|Part 1, Washout Period 2 (7 Days)|Withdrawal by Subject|0
6335624|NCT03136484|10086231|FG000|Overall Study|Withdrawal by Subject|19
6335625|NCT03136484|10086232|FG001|Overall Study|Withdrawal by Subject|14
6335626|NCT03136484|10086231|FG000|Overall Study|Lost to Follow-up|7
6335627|NCT03136484|10086232|FG001|Overall Study|Lost to Follow-up|8
6335628|NCT03136484|10086231|FG000|Overall Study|Death|1
6335629|NCT03136484|10086232|FG001|Overall Study|Death|0
6335630|NCT03136861|10086245|FG000|Treatment Period 1 (TP1)(Baseline-Wk 8)|Adverse Event|3
6335631|NCT03136861|10086246|FG001|Treatment Period 1 (TP1)(Baseline-Wk 8)|Adverse Event|2
6335632|NCT03136861|10086247|FG002|Treatment Period 1 (TP1)(Baseline-Wk 8)|Adverse Event|0
6335633|NCT03136861|10086248|FG003|Treatment Period 1 (TP1)(Baseline-Wk 8)|Adverse Event|0
6335634|NCT03136861|10086249|FG004|Treatment Period 1 (TP1)(Baseline-Wk 8)|Adverse Event|0
6335635|NCT03136861|10086250|FG005|Treatment Period 1 (TP1)(Baseline-Wk 8)|Adverse Event|0
6335636|NCT03136861|10086251|FG006|Treatment Period 1 (TP1)(Baseline-Wk 8)|Adverse Event|0
6335637|NCT03136861|10086245|FG000|Treatment Period 1 (TP1)(Baseline-Wk 8)|Lost to Follow-up|1
6335638|NCT03136861|10086246|FG001|Treatment Period 1 (TP1)(Baseline-Wk 8)|Lost to Follow-up|1
6335639|NCT03136861|10086247|FG002|Treatment Period 1 (TP1)(Baseline-Wk 8)|Lost to Follow-up|0
6335640|NCT03136861|10086248|FG003|Treatment Period 1 (TP1)(Baseline-Wk 8)|Lost to Follow-up|0
6335641|NCT03136861|10086249|FG004|Treatment Period 1 (TP1)(Baseline-Wk 8)|Lost to Follow-up|0
6335642|NCT03136861|10086250|FG005|Treatment Period 1 (TP1)(Baseline-Wk 8)|Lost to Follow-up|0
6335643|NCT03136861|10086251|FG006|Treatment Period 1 (TP1)(Baseline-Wk 8)|Lost to Follow-up|0
6335644|NCT03136861|10086245|FG000|Treatment Period 1 (TP1)(Baseline-Wk 8)|Protocol Deviation|2
6335645|NCT03136861|10086246|FG001|Treatment Period 1 (TP1)(Baseline-Wk 8)|Protocol Deviation|1
6335646|NCT03136861|10086247|FG002|Treatment Period 1 (TP1)(Baseline-Wk 8)|Protocol Deviation|0
6335647|NCT03136861|10086248|FG003|Treatment Period 1 (TP1)(Baseline-Wk 8)|Protocol Deviation|0
6335648|NCT03136861|10086249|FG004|Treatment Period 1 (TP1)(Baseline-Wk 8)|Protocol Deviation|0
6335649|NCT03136861|10086250|FG005|Treatment Period 1 (TP1)(Baseline-Wk 8)|Protocol Deviation|0
6335650|NCT03136861|10086251|FG006|Treatment Period 1 (TP1)(Baseline-Wk 8)|Protocol Deviation|0
6335651|NCT03136861|10086245|FG000|Treatment Period 1 (TP1)(Baseline-Wk 8)|Subject/Guardian Decision|0
6335652|NCT03136861|10086246|FG001|Treatment Period 1 (TP1)(Baseline-Wk 8)|Subject/Guardian Decision|1
6335653|NCT03136861|10086247|FG002|Treatment Period 1 (TP1)(Baseline-Wk 8)|Subject/Guardian Decision|0
6335654|NCT03136861|10086248|FG003|Treatment Period 1 (TP1)(Baseline-Wk 8)|Subject/Guardian Decision|0
6335655|NCT03136861|10086249|FG004|Treatment Period 1 (TP1)(Baseline-Wk 8)|Subject/Guardian Decision|0
6335656|NCT03136861|10086250|FG005|Treatment Period 1 (TP1)(Baseline-Wk 8)|Subject/Guardian Decision|0
6335657|NCT03136861|10086251|FG006|Treatment Period 1 (TP1)(Baseline-Wk 8)|Subject/Guardian Decision|0
6335658|NCT03136861|10086245|FG000|Treatment Period 1 (TP1)(Baseline-Wk 8)|Withdrawal of Informed Consent|1
6335659|NCT03136861|10086246|FG001|Treatment Period 1 (TP1)(Baseline-Wk 8)|Withdrawal of Informed Consent|1
6335660|NCT03136861|10086247|FG002|Treatment Period 1 (TP1)(Baseline-Wk 8)|Withdrawal of Informed Consent|0
6335661|NCT03136861|10086248|FG003|Treatment Period 1 (TP1)(Baseline-Wk 8)|Withdrawal of Informed Consent|0
6335662|NCT03136861|10086249|FG004|Treatment Period 1 (TP1)(Baseline-Wk 8)|Withdrawal of Informed Consent|0
6335663|NCT03136861|10086250|FG005|Treatment Period 1 (TP1)(Baseline-Wk 8)|Withdrawal of Informed Consent|0
6335664|NCT03136861|10086251|FG006|Treatment Period 1 (TP1)(Baseline-Wk 8)|Withdrawal of Informed Consent|0
6335665|NCT03136861|10086245|FG000|Treatment Period 2 (TP2) (Wk 8-Wk 24)|Adverse Event|0
6335666|NCT03136861|10086246|FG001|Treatment Period 2 (TP2) (Wk 8-Wk 24)|Adverse Event|0
6335667|NCT03136861|10086247|FG002|Treatment Period 2 (TP2) (Wk 8-Wk 24)|Adverse Event|0
6335668|NCT03136861|10086248|FG003|Treatment Period 2 (TP2) (Wk 8-Wk 24)|Adverse Event|1
6335669|NCT03136861|10086249|FG004|Treatment Period 2 (TP2) (Wk 8-Wk 24)|Adverse Event|2
6335670|NCT03136861|10086250|FG005|Treatment Period 2 (TP2) (Wk 8-Wk 24)|Adverse Event|0
6335671|NCT03136861|10086251|FG006|Treatment Period 2 (TP2) (Wk 8-Wk 24)|Adverse Event|1
6335672|NCT03136861|10086245|FG000|Treatment Period 2 (TP2) (Wk 8-Wk 24)|Lost to Follow-up|0
6335673|NCT03136861|10086246|FG001|Treatment Period 2 (TP2) (Wk 8-Wk 24)|Lost to Follow-up|0
6335674|NCT03136861|10086247|FG002|Treatment Period 2 (TP2) (Wk 8-Wk 24)|Lost to Follow-up|1
6335675|NCT03136861|10086248|FG003|Treatment Period 2 (TP2) (Wk 8-Wk 24)|Lost to Follow-up|0
6335676|NCT03136861|10086249|FG004|Treatment Period 2 (TP2) (Wk 8-Wk 24)|Lost to Follow-up|0
6335677|NCT03136861|10086250|FG005|Treatment Period 2 (TP2) (Wk 8-Wk 24)|Lost to Follow-up|0
6335678|NCT03136861|10086251|FG006|Treatment Period 2 (TP2) (Wk 8-Wk 24)|Lost to Follow-up|0
6335679|NCT03136861|10086245|FG000|Treatment Period 2 (TP2) (Wk 8-Wk 24)|Withdrawal of Informed Consent|0
6335680|NCT03136861|10086246|FG001|Treatment Period 2 (TP2) (Wk 8-Wk 24)|Withdrawal of Informed Consent|0
6335681|NCT03136861|10086247|FG002|Treatment Period 2 (TP2) (Wk 8-Wk 24)|Withdrawal of Informed Consent|1
6335682|NCT03136861|10086248|FG003|Treatment Period 2 (TP2) (Wk 8-Wk 24)|Withdrawal of Informed Consent|0
6335683|NCT03136861|10086249|FG004|Treatment Period 2 (TP2) (Wk 8-Wk 24)|Withdrawal of Informed Consent|0
6335684|NCT03136861|10086250|FG005|Treatment Period 2 (TP2) (Wk 8-Wk 24)|Withdrawal of Informed Consent|0
6335685|NCT03136861|10086251|FG006|Treatment Period 2 (TP2) (Wk 8-Wk 24)|Withdrawal of Informed Consent|0
6335686|NCT03137069|10086275|FG000|Overall Study|Withdrawal by Subject|1
6335687|NCT03137069|10086276|FG001|Overall Study|Withdrawal by Subject|2
6335688|NCT03137069|10086277|FG002|Overall Study|Withdrawal by Subject|2
6335689|NCT03137069|10086278|FG003|Overall Study|Withdrawal by Subject|2
6335690|NCT03137069|10086279|FG004|Overall Study|Withdrawal by Subject|0
6335691|NCT03137069|10086280|FG005|Overall Study|Withdrawal by Subject|0
6335692|NCT03137069|10086275|FG000|Overall Study|Adverse Event|0
6335693|NCT03137069|10086276|FG001|Overall Study|Adverse Event|3
6335694|NCT03137069|10086277|FG002|Overall Study|Adverse Event|1
6335695|NCT03137069|10086278|FG003|Overall Study|Adverse Event|1
6335696|NCT03137069|10086279|FG004|Overall Study|Adverse Event|0
6335697|NCT03137069|10086280|FG005|Overall Study|Adverse Event|1
6335698|NCT03137069|10086275|FG000|Overall Study|Protocol Violation|0
6335699|NCT03137069|10086276|FG001|Overall Study|Protocol Violation|1
6335700|NCT03137069|10086277|FG002|Overall Study|Protocol Violation|0
6335701|NCT03137069|10086278|FG003|Overall Study|Protocol Violation|1
6335702|NCT03137069|10086279|FG004|Overall Study|Protocol Violation|1
6335703|NCT03137069|10086280|FG005|Overall Study|Protocol Violation|1
6335704|NCT03137069|10086275|FG000|Overall Study|Physician Decision|0
6335705|NCT03137069|10086276|FG001|Overall Study|Physician Decision|0
6335706|NCT03137069|10086277|FG002|Overall Study|Physician Decision|0
6335707|NCT03137069|10086278|FG003|Overall Study|Physician Decision|1
6335708|NCT03137069|10086279|FG004|Overall Study|Physician Decision|0
6335709|NCT03137069|10086280|FG005|Overall Study|Physician Decision|0
6335710|NCT03137069|10086275|FG000|Overall Study|Study Terminated by Sponsor|0
6335711|NCT03137069|10086276|FG001|Overall Study|Study Terminated by Sponsor|0
6335712|NCT03137069|10086277|FG002|Overall Study|Study Terminated by Sponsor|0
6335713|NCT03137069|10086278|FG003|Overall Study|Study Terminated by Sponsor|0
6335714|NCT03137069|10086279|FG004|Overall Study|Study Terminated by Sponsor|1
6335715|NCT03137069|10086280|FG005|Overall Study|Study Terminated by Sponsor|0
6335716|NCT03137069|10086275|FG000|Overall Study|Data Entry Error|0
6335717|NCT03137069|10086276|FG001|Overall Study|Data Entry Error|0
6335718|NCT03137069|10086277|FG002|Overall Study|Data Entry Error|0
6335719|NCT03137069|10086278|FG003|Overall Study|Data Entry Error|1
6335720|NCT03137069|10086279|FG004|Overall Study|Data Entry Error|0
6335721|NCT03137069|10086280|FG005|Overall Study|Data Entry Error|0
6335722|NCT03137121|10086300|FG000|Overall Study|Withdrawal by Subject|0
6335723|NCT03137121|10086301|FG001|Overall Study|Withdrawal by Subject|1
6335724|NCT03137303|10086309|FG000|T1: 3-month Follow-up|Withdrawal by Subject|1
6335725|NCT03137303|10086310|FG001|T1: 3-month Follow-up|Withdrawal by Subject|4
6335726|NCT03137303|10086309|FG000|T1: 3-month Follow-up|Lost to Follow-up|5
6335727|NCT03137303|10086310|FG001|T1: 3-month Follow-up|Lost to Follow-up|6
6335728|NCT03137303|10086309|FG000|T2: 6-month Follow-up|Lost to Follow-up|5
6335729|NCT03137303|10086310|FG001|T2: 6-month Follow-up|Lost to Follow-up|5
6335730|NCT03137303|10086309|FG000|T3: 9-month Follow-up|Death|1
6335731|NCT03137303|10086310|FG001|T3: 9-month Follow-up|Death|0
6335732|NCT03137303|10086309|FG000|T3: 9-month Follow-up|Lost to Follow-up|4
6335733|NCT03137303|10086310|FG001|T3: 9-month Follow-up|Lost to Follow-up|4
6335734|NCT03137303|10086309|FG000|T4: 12-month Follow-up|Withdrawal by Subject|0
6335735|NCT03137303|10086310|FG001|T4: 12-month Follow-up|Withdrawal by Subject|1
6335736|NCT03137303|10086309|FG000|T4: 12-month Follow-up|Lost to Follow-up|7
6335737|NCT03137303|10086310|FG001|T4: 12-month Follow-up|Lost to Follow-up|4
6335738|NCT03137459|10086318|FG000|2-month Assessment|Withdrawal by Subject|13
6335739|NCT03137459|10086319|FG001|2-month Assessment|Withdrawal by Subject|3
6335740|NCT03137459|10086318|FG000|2-month Assessment|Unable to reach|42
6335741|NCT03137459|10086319|FG001|2-month Assessment|Unable to reach|32
6335742|NCT03137459|10086318|FG000|2-month Assessment|Refused assessment|7
6335743|NCT03137459|10086319|FG001|2-month Assessment|Refused assessment|5
6335744|NCT03137459|10086318|FG000|2-month Assessment|Acutely ill|6
6335745|NCT03137459|10086319|FG001|2-month Assessment|Acutely ill|2
6335746|NCT03137459|10086318|FG000|4-month Assessment|Death|4
6335747|NCT03137459|10086319|FG001|4-month Assessment|Death|2
6335748|NCT03137459|10086318|FG000|4-month Assessment|Withdrawal by Subject|4
6335749|NCT03137459|10086319|FG001|4-month Assessment|Withdrawal by Subject|2
6335750|NCT03137459|10086318|FG000|4-month Assessment|Unable to reach|44
6335751|NCT03137459|10086319|FG001|4-month Assessment|Unable to reach|29
6335752|NCT03137459|10086318|FG000|4-month Assessment|Refused assessment|24
6335753|NCT03137459|10086319|FG001|4-month Assessment|Refused assessment|10
6335754|NCT03137459|10086318|FG000|4-month Assessment|Acutely ill|2
6335755|NCT03137459|10086319|FG001|4-month Assessment|Acutely ill|3
6335756|NCT03137459|10086318|FG000|6-months|Lost to Follow-up|14
6335757|NCT03137459|10086319|FG001|6-months|Lost to Follow-up|11
6335758|NCT03137459|10086318|FG000|6-months|Death|0
6335759|NCT03137459|10086319|FG001|6-months|Death|2
6335760|NCT03137459|10086318|FG000|6-months|Refused assessment|6
6335761|NCT03137459|10086319|FG001|6-months|Refused assessment|3
6335762|NCT03137459|10086318|FG000|6-months|Acutely ill|1
6335763|NCT03137459|10086319|FG001|6-months|Acutely ill|1
6335764|NCT03137784|10086326|FG000|Overall Study|Adverse Event|1
6335765|NCT03137784|10086327|FG001|Overall Study|Adverse Event|1
6335766|NCT03137784|10086328|FG002|Overall Study|Adverse Event|0
6335767|NCT03137784|10086329|FG003|Overall Study|Adverse Event|0
6335768|NCT03137784|10086330|FG004|Overall Study|Adverse Event|0
6335769|NCT03137784|10086331|FG005|Overall Study|Adverse Event|0
6335770|NCT03137784|10086326|FG000|Overall Study|Subject/guardian decision|1
6335771|NCT03137784|10086327|FG001|Overall Study|Subject/guardian decision|0
6335772|NCT03137784|10086328|FG002|Overall Study|Subject/guardian decision|0
6335773|NCT03137784|10086329|FG003|Overall Study|Subject/guardian decision|0
6335774|NCT03137784|10086330|FG004|Overall Study|Subject/guardian decision|0
6335775|NCT03137784|10086331|FG005|Overall Study|Subject/guardian decision|0
6335776|NCT03137784|10086326|FG000|Overall Study|Non-compliance with study treatment|0
6335777|NCT03137784|10086327|FG001|Overall Study|Non-compliance with study treatment|0
6335778|NCT03137784|10086328|FG002|Overall Study|Non-compliance with study treatment|0
6335779|NCT03137784|10086329|FG003|Overall Study|Non-compliance with study treatment|0
6335780|NCT03137784|10086330|FG004|Overall Study|Non-compliance with study treatment|1
6335781|NCT03137784|10086331|FG005|Overall Study|Non-compliance with study treatment|0
6335782|NCT03137992|10086339|FG000|Washout Period 1|Adverse Event|1
6335783|NCT03137992|10086340|FG001|Washout Period 1|Adverse Event|1
6335784|NCT03137992|10086341|FG002|Washout Period 1|Adverse Event|0
6335785|NCT03137992|10086342|FG003|Washout Period 1|Adverse Event|0
6335786|NCT03137992|10086343|FG004|Washout Period 1|Adverse Event|0
6335787|NCT03137992|10086344|FG005|Washout Period 1|Adverse Event|1
6335788|NCT03137992|10086339|FG000|Washout Period 1|Withdrawal by Subject|0
6335789|NCT03137992|10086340|FG001|Washout Period 1|Withdrawal by Subject|1
6335790|NCT03137992|10086341|FG002|Washout Period 1|Withdrawal by Subject|1
6335791|NCT03137992|10086342|FG003|Washout Period 1|Withdrawal by Subject|0
6335792|NCT03137992|10086343|FG004|Washout Period 1|Withdrawal by Subject|0
6335793|NCT03137992|10086344|FG005|Washout Period 1|Withdrawal by Subject|0
6335794|NCT03137992|10086339|FG000|Washout Period 1|Principal Investigator Discretion|0
6335795|NCT03137992|10086340|FG001|Washout Period 1|Principal Investigator Discretion|1
6335796|NCT03137992|10086341|FG002|Washout Period 1|Principal Investigator Discretion|0
6335797|NCT03137992|10086342|FG003|Washout Period 1|Principal Investigator Discretion|0
6335798|NCT03137992|10086343|FG004|Washout Period 1|Principal Investigator Discretion|0
6335799|NCT03137992|10086344|FG005|Washout Period 1|Principal Investigator Discretion|0
6335800|NCT03137992|10086339|FG000|Washout Period 1|COPD Exacerbation|1
6335801|NCT03137992|10086340|FG001|Washout Period 1|COPD Exacerbation|1
6335802|NCT03137992|10086341|FG002|Washout Period 1|COPD Exacerbation|1
6335803|NCT03137992|10086342|FG003|Washout Period 1|COPD Exacerbation|0
6335804|NCT03137992|10086343|FG004|Washout Period 1|COPD Exacerbation|1
6335805|NCT03137992|10086344|FG005|Washout Period 1|COPD Exacerbation|1
6335806|NCT03137992|10086339|FG000|Washout Period 1|Subject Noncompliance|1
6335807|NCT03137992|10086340|FG001|Washout Period 1|Subject Noncompliance|0
6335808|NCT03137992|10086341|FG002|Washout Period 1|Subject Noncompliance|0
6335809|NCT03137992|10086342|FG003|Washout Period 1|Subject Noncompliance|0
6335810|NCT03137992|10086343|FG004|Washout Period 1|Subject Noncompliance|1
6335811|NCT03137992|10086344|FG005|Washout Period 1|Subject Noncompliance|0
6335812|NCT03137992|10086339|FG000|Period 2 (Visit 3)|COPD Exacerbation|1
6335813|NCT03137992|10086340|FG001|Period 2 (Visit 3)|COPD Exacerbation|1
6335814|NCT03137992|10086341|FG002|Period 2 (Visit 3)|COPD Exacerbation|0
6335815|NCT03137992|10086342|FG003|Period 2 (Visit 3)|COPD Exacerbation|0
6335816|NCT03137992|10086343|FG004|Period 2 (Visit 3)|COPD Exacerbation|0
6335817|NCT03137992|10086344|FG005|Period 2 (Visit 3)|COPD Exacerbation|1
6335818|NCT03137992|10086339|FG000|Period 2 (Visit 3)|Did not meet continuation criteria|2
6335819|NCT03137992|10086340|FG001|Period 2 (Visit 3)|Did not meet continuation criteria|3
6335820|NCT03137992|10086341|FG002|Period 2 (Visit 3)|Did not meet continuation criteria|3
6335821|NCT03137992|10086342|FG003|Period 2 (Visit 3)|Did not meet continuation criteria|4
6083009|NCT00633022|9691277|FG000|Overall Study|Adverse Event|1
6083010|NCT00633022|9691278|FG001|Overall Study|Adverse Event|0
6083011|NCT00633022|9691279|FG002|Overall Study|Adverse Event|5
6083012|NCT00633022|9691277|FG000|Overall Study|Physician Decision|0
6083013|NCT00633022|9691278|FG001|Overall Study|Physician Decision|1
6083014|NCT00633022|9691279|FG002|Overall Study|Physician Decision|0
6083015|NCT00633074|9691289|FG000|Overall Study|Adverse Event|1
6083016|NCT00633074|9691290|FG001|Overall Study|Adverse Event|0
6083017|NCT00633126|9691296|FG000|Overall Study|Did not receive full dose|1
6083018|NCT00633139|9691303|FG000|Overall Study|Non compliance|0
6083019|NCT00633139|9691304|FG001|Overall Study|Non compliance|0
6083020|NCT00633139|9691305|FG002|Overall Study|Non compliance|1
6083021|NCT00633139|9691303|FG000|Overall Study|Withdrawal by Subject|0
6083022|NCT00633139|9691304|FG001|Overall Study|Withdrawal by Subject|1
6083023|NCT00633139|9691305|FG002|Overall Study|Withdrawal by Subject|0
6083024|NCT00633152|9691315|FG000|Overall Study|Adverse Event|1
6168483|NCT01236352|9813655|FG008|Overall Study|Death|0
6168484|NCT01236352|9813656|FG009|Overall Study|Death|0
6168485|NCT01236352|9813657|FG010|Overall Study|Death|0
6168486|NCT01236352|9813647|FG000|Overall Study|Withdrawal by Subject|0
6168487|NCT01236352|9813648|FG001|Overall Study|Withdrawal by Subject|0
6168488|NCT01236352|9813649|FG002|Overall Study|Withdrawal by Subject|0
6168489|NCT01236352|9813650|FG003|Overall Study|Withdrawal by Subject|0
6168490|NCT01236352|9813651|FG004|Overall Study|Withdrawal by Subject|0
6168491|NCT01236352|9813652|FG005|Overall Study|Withdrawal by Subject|0
6168492|NCT01236352|9813653|FG006|Overall Study|Withdrawal by Subject|0
6335822|NCT03137992|10086343|FG004|Period 2 (Visit 3)|Did not meet continuation criteria|3
6335823|NCT03137992|10086344|FG005|Period 2 (Visit 3)|Did not meet continuation criteria|7
6335824|NCT03137992|10086339|FG000|Period 2 (Visit 3)|Adverse Event|0
6335825|NCT03137992|10086340|FG001|Period 2 (Visit 3)|Adverse Event|1
6335826|NCT03137992|10086341|FG002|Period 2 (Visit 3)|Adverse Event|0
6335827|NCT03137992|10086342|FG003|Period 2 (Visit 3)|Adverse Event|0
6335828|NCT03137992|10086343|FG004|Period 2 (Visit 3)|Adverse Event|0
6335829|NCT03137992|10086344|FG005|Period 2 (Visit 3)|Adverse Event|0
6335830|NCT03137992|10086339|FG000|Period 2 (Visit 3)|Lost to Follow-up|0
6335831|NCT03137992|10086340|FG001|Period 2 (Visit 3)|Lost to Follow-up|0
6335832|NCT03137992|10086341|FG002|Period 2 (Visit 3)|Lost to Follow-up|0
6335833|NCT03137992|10086342|FG003|Period 2 (Visit 3)|Lost to Follow-up|1
6335834|NCT03137992|10086343|FG004|Period 2 (Visit 3)|Lost to Follow-up|0
6335835|NCT03137992|10086344|FG005|Period 2 (Visit 3)|Lost to Follow-up|0
6335836|NCT03137992|10086339|FG000|Period 2 (Visit 3)|Withdrawal by Subject|0
6335837|NCT03137992|10086340|FG001|Period 2 (Visit 3)|Withdrawal by Subject|2
6335838|NCT03137992|10086341|FG002|Period 2 (Visit 3)|Withdrawal by Subject|0
6335839|NCT03137992|10086342|FG003|Period 2 (Visit 3)|Withdrawal by Subject|0
6335840|NCT03137992|10086343|FG004|Period 2 (Visit 3)|Withdrawal by Subject|1
6335841|NCT03137992|10086344|FG005|Period 2 (Visit 3)|Withdrawal by Subject|0
6335842|NCT03137992|10086339|FG000|Washout Period 2|COPD Exacerbation|1
6335843|NCT03137992|10086340|FG001|Washout Period 2|COPD Exacerbation|1
6335844|NCT03137992|10086341|FG002|Washout Period 2|COPD Exacerbation|0
6335845|NCT03137992|10086342|FG003|Washout Period 2|COPD Exacerbation|0
6335846|NCT03137992|10086343|FG004|Washout Period 2|COPD Exacerbation|1
6335847|NCT03137992|10086344|FG005|Washout Period 2|COPD Exacerbation|0
6335848|NCT03137992|10086339|FG000|Washout Period 2|Subject Non-compliance|0
6335849|NCT03137992|10086340|FG001|Washout Period 2|Subject Non-compliance|1
6335850|NCT03137992|10086341|FG002|Washout Period 2|Subject Non-compliance|0
6335851|NCT03137992|10086342|FG003|Washout Period 2|Subject Non-compliance|0
6335852|NCT03137992|10086343|FG004|Washout Period 2|Subject Non-compliance|0
6335853|NCT03137992|10086344|FG005|Washout Period 2|Subject Non-compliance|0
6335854|NCT03137992|10086339|FG000|Washout Period 2|Adverse Event|0
6335855|NCT03137992|10086340|FG001|Washout Period 2|Adverse Event|0
6168493|NCT01236352|9813654|FG007|Overall Study|Withdrawal by Subject|0
6168494|NCT01236352|9813655|FG008|Overall Study|Withdrawal by Subject|0
6168495|NCT01236352|9813656|FG009|Overall Study|Withdrawal by Subject|2
6335856|NCT03137992|10086341|FG002|Washout Period 2|Adverse Event|0
6335857|NCT03137992|10086342|FG003|Washout Period 2|Adverse Event|1
6335858|NCT03137992|10086343|FG004|Washout Period 2|Adverse Event|1
6335859|NCT03137992|10086344|FG005|Washout Period 2|Adverse Event|0
6335860|NCT03137992|10086339|FG000|Washout Period 2|Withdrawal by Subject|1
6335861|NCT03137992|10086340|FG001|Washout Period 2|Withdrawal by Subject|0
6335862|NCT03137992|10086341|FG002|Washout Period 2|Withdrawal by Subject|0
6335863|NCT03137992|10086342|FG003|Washout Period 2|Withdrawal by Subject|0
6335864|NCT03137992|10086343|FG004|Washout Period 2|Withdrawal by Subject|1
6335865|NCT03137992|10086344|FG005|Washout Period 2|Withdrawal by Subject|0
6083025|NCT00633152|9691316|FG001|Overall Study|Adverse Event|0
6083026|NCT00633152|9691315|FG000|Overall Study|Randomized, did not receive study drug|5
6335866|NCT03137992|10086339|FG000|Washout Period 2|Sponsor Decision|0
6335867|NCT03137992|10086340|FG001|Washout Period 2|Sponsor Decision|0
6335868|NCT03137992|10086341|FG002|Washout Period 2|Sponsor Decision|0
6335869|NCT03137992|10086342|FG003|Washout Period 2|Sponsor Decision|0
6335870|NCT03137992|10086343|FG004|Washout Period 2|Sponsor Decision|0
6335871|NCT03137992|10086344|FG005|Washout Period 2|Sponsor Decision|1
6335872|NCT03137992|10086339|FG000|Period 3 (Visit 04)|Did not meet continuation criteria|6
6335873|NCT03137992|10086340|FG001|Period 3 (Visit 04)|Did not meet continuation criteria|0
6335874|NCT03137992|10086341|FG002|Period 3 (Visit 04)|Did not meet continuation criteria|2
6335875|NCT03137992|10086342|FG003|Period 3 (Visit 04)|Did not meet continuation criteria|0
6335876|NCT03137992|10086343|FG004|Period 3 (Visit 04)|Did not meet continuation criteria|2
6335877|NCT03137992|10086344|FG005|Period 3 (Visit 04)|Did not meet continuation criteria|3
6335878|NCT03137992|10086339|FG000|Period 3 (Visit 04)|Withdrawal by Subject|0
6335879|NCT03137992|10086340|FG001|Period 3 (Visit 04)|Withdrawal by Subject|2
6335880|NCT03137992|10086341|FG002|Period 3 (Visit 04)|Withdrawal by Subject|1
6335881|NCT03137992|10086342|FG003|Period 3 (Visit 04)|Withdrawal by Subject|0
6335882|NCT03137992|10086343|FG004|Period 3 (Visit 04)|Withdrawal by Subject|1
6335883|NCT03137992|10086344|FG005|Period 3 (Visit 04)|Withdrawal by Subject|0
6335884|NCT03137992|10086339|FG000|Part 2 (Open-label Extension)|Withdrawal by Subject|1
6335885|NCT03137992|10086340|FG001|Part 2 (Open-label Extension)|Withdrawal by Subject|0
6335886|NCT03137992|10086341|FG002|Part 2 (Open-label Extension)|Withdrawal by Subject|1
6335887|NCT03137992|10086342|FG003|Part 2 (Open-label Extension)|Withdrawal by Subject|0
6335888|NCT03137992|10086343|FG004|Part 2 (Open-label Extension)|Withdrawal by Subject|0
6335889|NCT03137992|10086344|FG005|Part 2 (Open-label Extension)|Withdrawal by Subject|0
6335890|NCT03137992|10086339|FG000|Part 2 (Open-label Extension)|COPD exacerbation|0
6335891|NCT03137992|10086340|FG001|Part 2 (Open-label Extension)|COPD exacerbation|0
6335892|NCT03137992|10086341|FG002|Part 2 (Open-label Extension)|COPD exacerbation|0
6335893|NCT03137992|10086342|FG003|Part 2 (Open-label Extension)|COPD exacerbation|1
6335894|NCT03137992|10086343|FG004|Part 2 (Open-label Extension)|COPD exacerbation|0
6335895|NCT03137992|10086344|FG005|Part 2 (Open-label Extension)|COPD exacerbation|0
6335896|NCT03137992|10086339|FG000|Part 2 (Open-label Extension)|Per study team|1
6335897|NCT03137992|10086340|FG001|Part 2 (Open-label Extension)|Per study team|0
6335898|NCT03137992|10086341|FG002|Part 2 (Open-label Extension)|Per study team|0
6335899|NCT03137992|10086342|FG003|Part 2 (Open-label Extension)|Per study team|0
6335900|NCT03137992|10086343|FG004|Part 2 (Open-label Extension)|Per study team|0
6335901|NCT03137992|10086344|FG005|Part 2 (Open-label Extension)|Per study team|0
6335902|NCT03137992|10086339|FG000|Part 2 (Open-label Extension)|Prohibited Medication|0
6335903|NCT03137992|10086340|FG001|Part 2 (Open-label Extension)|Prohibited Medication|0
6335904|NCT03137992|10086341|FG002|Part 2 (Open-label Extension)|Prohibited Medication|0
6335905|NCT03137992|10086342|FG003|Part 2 (Open-label Extension)|Prohibited Medication|0
6335906|NCT03137992|10086343|FG004|Part 2 (Open-label Extension)|Prohibited Medication|0
6335907|NCT03137992|10086344|FG005|Part 2 (Open-label Extension)|Prohibited Medication|1
6335908|NCT03138655|10086404|FG000|Overall Study|Adverse Event|2
6335909|NCT03138655|10086405|FG001|Overall Study|Adverse Event|1
6335910|NCT03138655|10086406|FG002|Overall Study|Adverse Event|2
6335911|NCT03138655|10086407|FG003|Overall Study|Adverse Event|1
6335912|NCT03138655|10086408|FG004|Overall Study|Adverse Event|1
6335913|NCT03138655|10086409|FG005|Overall Study|Adverse Event|4
6335914|NCT03138655|10086410|FG006|Overall Study|Adverse Event|2
6335915|NCT03138655|10086411|FG007|Overall Study|Adverse Event|2
6335916|NCT03138655|10086404|FG000|Overall Study|Withdrawal by Subject|0
6335917|NCT03138655|10086405|FG001|Overall Study|Withdrawal by Subject|1
6335918|NCT03138655|10086406|FG002|Overall Study|Withdrawal by Subject|0
6335919|NCT03138655|10086407|FG003|Overall Study|Withdrawal by Subject|0
6335920|NCT03138655|10086408|FG004|Overall Study|Withdrawal by Subject|0
6335921|NCT03138655|10086409|FG005|Overall Study|Withdrawal by Subject|0
6335922|NCT03138655|10086410|FG006|Overall Study|Withdrawal by Subject|1
6335923|NCT03138655|10086411|FG007|Overall Study|Withdrawal by Subject|0
6335924|NCT03138655|10086404|FG000|Overall Study|Reason not Specified|1
6335925|NCT03138655|10086405|FG001|Overall Study|Reason not Specified|0
6335926|NCT03138655|10086406|FG002|Overall Study|Reason not Specified|0
6335927|NCT03138655|10086407|FG003|Overall Study|Reason not Specified|2
6335928|NCT03138655|10086408|FG004|Overall Study|Reason not Specified|1
6335929|NCT03138655|10086409|FG005|Overall Study|Reason not Specified|1
6335930|NCT03138655|10086410|FG006|Overall Study|Reason not Specified|0
6335931|NCT03138655|10086411|FG007|Overall Study|Reason not Specified|0
6335932|NCT03138967|10086449|FG000|Overall Study|Death|0
6335933|NCT03138967|10086450|FG001|Overall Study|Death|1
6335934|NCT03138967|10086449|FG000|Overall Study|Physician Decision|1
6335935|NCT03138967|10086450|FG001|Overall Study|Physician Decision|3
6335936|NCT03139240|10086465|FG000|Overall Study|Lost to Follow-up|0
6335937|NCT03139240|10086466|FG001|Overall Study|Lost to Follow-up|1
6335938|NCT03139240|10086467|FG002|Overall Study|Lost to Follow-up|1
6335939|NCT03139240|10086468|FG003|Overall Study|Lost to Follow-up|0
6335940|NCT03139279|10086478|FG000|Overall Study|Physician Decision|2
6335941|NCT03139279|10086479|FG001|Overall Study|Physician Decision|0
6335942|NCT03139279|10086478|FG000|Overall Study|Protocol Violation|5
6335943|NCT03139279|10086479|FG001|Overall Study|Protocol Violation|4
6335944|NCT03139279|10086478|FG000|Overall Study|Withdrawal by Subject|0
6335945|NCT03139279|10086479|FG001|Overall Study|Withdrawal by Subject|2
6335946|NCT03139448|10086487|FG000|Overall Study|Lack of Efficacy|6
6335947|NCT03139448|10086488|FG001|Overall Study|Lack of Efficacy|7
6335948|NCT03139448|10086487|FG000|Overall Study|Location of procedure changed|2
6335949|NCT03139448|10086488|FG001|Overall Study|Location of procedure changed|8
6335950|NCT03139448|10086487|FG000|Overall Study|Withdrawal by Subject|3
6335951|NCT03139448|10086488|FG001|Overall Study|Withdrawal by Subject|6
6335952|NCT03139448|10086487|FG000|Overall Study|Screen fail|1
6335953|NCT03139448|10086488|FG001|Overall Study|Screen fail|3
6335954|NCT03139448|10086487|FG000|Overall Study|Physician Decision|0
6335955|NCT03139448|10086488|FG001|Overall Study|Physician Decision|2
6335956|NCT03139552|10086494|FG000|Overall Study|unable to attend tasting due to schedule|3
6335957|NCT03139604|10086520|FG000|Overall Study|Other|7
6335958|NCT03139604|10086521|FG001|Overall Study|Other|3
6335959|NCT03139604|10086520|FG000|Overall Study|Withdrawal by Subject|16
6335960|NCT03139604|10086521|FG001|Overall Study|Withdrawal by Subject|17
6335961|NCT03139604|10086520|FG000|Overall Study|Physician Decision|1
6335962|NCT03139604|10086521|FG001|Overall Study|Physician Decision|2
6335963|NCT03139604|10086520|FG000|Overall Study|Lost to Follow-up|3
6335964|NCT03139604|10086521|FG001|Overall Study|Lost to Follow-up|1
6335965|NCT03139604|10086520|FG000|Overall Study|Death|65
6335966|NCT03139604|10086521|FG001|Overall Study|Death|67
6335967|NCT03139604|10086520|FG000|Overall Study|Study Terminated by Sponsor|122
6335968|NCT03139604|10086521|FG001|Overall Study|Study Terminated by Sponsor|127
6335969|NCT03139604|10086520|FG000|Overall Study|Final EOS data missing due to COVID-19 restrictions that affected on-site monitoring|5
6335970|NCT03139604|10086521|FG001|Overall Study|Final EOS data missing due to COVID-19 restrictions that affected on-site monitoring|3
6335971|NCT03141086|10086555|FG000|Overall Study|Study Terminated By Sponsor|1
6335972|NCT03141086|10086556|FG001|Overall Study|Study Terminated By Sponsor|1
6335973|NCT03141086|10086555|FG000|Overall Study|Withdrawal by Subject|0
6335974|NCT03141086|10086556|FG001|Overall Study|Withdrawal by Subject|1
6335975|NCT03141086|10086555|FG000|Overall Study|Protocol Violation|0
6335976|NCT03141086|10086556|FG001|Overall Study|Protocol Violation|1
6335977|NCT03141086|10086555|FG000|Overall Study|Adverse Event|0
6335978|NCT03141086|10086556|FG001|Overall Study|Adverse Event|2
6335979|NCT03141151|10086564|FG000|Overall Study|Lost to Follow-up|3
6335980|NCT03141151|10086565|FG001|Overall Study|Lost to Follow-up|2
6335981|NCT03141151|10086564|FG000|Overall Study|Withdrawal by Subject|3
6335982|NCT03141151|10086565|FG001|Overall Study|Withdrawal by Subject|2
6335983|NCT03141307|10086600|FG000|In-Hospital|Withdrawal by Subject|0
6335984|NCT03141307|10086601|FG001|In-Hospital|Withdrawal by Subject|2
6335985|NCT03141307|10086600|FG000|In-Hospital|Protocol Violation|4
6335986|NCT03141307|10086601|FG001|In-Hospital|Protocol Violation|0
6335987|NCT03141307|10086600|FG000|Follow-Up|Lost to Follow-up|97
6335988|NCT03141307|10086601|FG001|Follow-Up|Lost to Follow-up|54
6335989|NCT03141788|10086627|FG000|Overall Study|Lost to Follow-up|1
6335990|NCT03141788|10086627|FG000|Overall Study|Protocol Violation|3
6335991|NCT03141788|10086627|FG000|Overall Study|Withdrawal by Subject|4
6335992|NCT03141905|10086636|FG000|Overall Study|Death|3
6335993|NCT03141905|10086637|FG001|Overall Study|Death|2
6335994|NCT03141905|10086636|FG000|Overall Study|Withdrawal by Subject|1
6335995|NCT03141905|10086637|FG001|Overall Study|Withdrawal by Subject|0
6335996|NCT03141905|10086636|FG000|Overall Study|Lost to Follow-up|3
6335997|NCT03141905|10086637|FG001|Overall Study|Lost to Follow-up|7
6335998|NCT03141905|10086636|FG000|Overall Study|Randomized, but did not receive intervention. Withdrew prior to baseline visit.|17
6335999|NCT03141905|10086637|FG001|Overall Study|Randomized, but did not receive intervention. Withdrew prior to baseline visit.|10
6336000|NCT03142451|10086659|FG000|Overall Study|Adverse Event|5
6336001|NCT03142451|10086660|FG001|Overall Study|Adverse Event|2
6336002|NCT03142451|10086659|FG000|Overall Study|Lost to Follow-up|25
6336003|NCT03142451|10086660|FG001|Overall Study|Lost to Follow-up|8
6336004|NCT03142451|10086659|FG000|Overall Study|Participant request|24
6336005|NCT03142451|10086660|FG001|Overall Study|Participant request|12
6336006|NCT03142451|10086659|FG000|Overall Study|Protocol Violation|3
6336007|NCT03142451|10086660|FG001|Overall Study|Protocol Violation|1
6336008|NCT03142451|10086659|FG000|Overall Study|Other|1
6336009|NCT03142451|10086660|FG001|Overall Study|Other|1
6336010|NCT03142750|10086668|FG000|Overall Study|Lost to Follow-up|4
6336011|NCT03142750|10086669|FG001|Overall Study|Lost to Follow-up|1
6336012|NCT03142932|10086681|FG000|Overall Study|Lost to Follow-up|2
6336013|NCT03142932|10086682|FG001|Overall Study|Lost to Follow-up|11
6336014|NCT03143101|10086691|FG000|Overall Study|Withdrawal by Subject|0
6336015|NCT03143101|10086692|FG001|Overall Study|Withdrawal by Subject|1
6336016|NCT03143101|10086693|FG002|Overall Study|Withdrawal by Subject|0
6336017|NCT03143101|10086691|FG000|Overall Study|Lost to Follow-up|2
6336018|NCT03143101|10086692|FG001|Overall Study|Lost to Follow-up|2
6336019|NCT03143101|10086693|FG002|Overall Study|Lost to Follow-up|0
6336020|NCT03143166|10086701|FG000|Period 2 (Washout of at Least 4 Days)|Withdrawal by Subject|1
6336021|NCT03143855|10086720|FG000|Overall Study|Withdrawal by Subject|4
6336022|NCT03143855|10086721|FG001|Overall Study|Withdrawal by Subject|3
6336023|NCT03143855|10086720|FG000|Overall Study|Protocol Violation|1
6336024|NCT03143855|10086721|FG001|Overall Study|Protocol Violation|0
6336025|NCT03143855|10086720|FG000|Overall Study|Participant experienced withdrawal|0
6336026|NCT03143855|10086721|FG001|Overall Study|Participant experienced withdrawal|1
6336027|NCT03144180|10086751|FG000|Overall Study|STAT Delivery|1
6336028|NCT03144180|10086752|FG001|Overall Study|STAT Delivery|1
6336029|NCT03144180|10086751|FG000|Overall Study|Provider forgot to fill out forms|1
6336030|NCT03144180|10086752|FG001|Overall Study|Provider forgot to fill out forms|3
6336031|NCT03144180|10086751|FG000|Overall Study|Provider forgot to use the Q-cup|0
6336032|NCT03144180|10086752|FG001|Overall Study|Provider forgot to use the Q-cup|1
6336033|NCT03144180|10086751|FG000|Overall Study|Scrub tech removed tube cap|0
6336034|NCT03144180|10086752|FG001|Overall Study|Scrub tech removed tube cap|1
6336035|NCT03144687|10086778|FG000|Overall Study|Adverse Event|1
6336036|NCT03144687|10086779|FG001|Overall Study|Adverse Event|0
6336037|NCT03144687|10086778|FG000|Overall Study|Progressive disease|3
6336038|NCT03144687|10086779|FG001|Overall Study|Progressive disease|0
6336039|NCT03144687|10086778|FG000|Overall Study|Death|0
6336040|NCT03144687|10086779|FG001|Overall Study|Death|2
6336041|NCT03144687|10086778|FG000|Overall Study|Lost to Follow-up|0
6336042|NCT03144687|10086779|FG001|Overall Study|Lost to Follow-up|1
6336043|NCT03144687|10086778|FG000|Overall Study|Physician Decision|5
6336044|NCT03144687|10086779|FG001|Overall Study|Physician Decision|2
6336045|NCT03144687|10086778|FG000|Overall Study|Withdrawal by Subject|1
6336046|NCT03144687|10086779|FG001|Overall Study|Withdrawal by Subject|3
6336047|NCT03144687|10086778|FG000|Overall Study|Participants With Ongoing Treatment|3
6336048|NCT03144687|10086779|FG001|Overall Study|Participants With Ongoing Treatment|2
6336049|NCT03144804|10086789|FG000|Overall Study|4 participants had disease progression within 1 month of study treatment and were deemed unevaluable|4
6336050|NCT03145064|10086793|FG000|Overall Study|Death|24
6336051|NCT03145064|10086793|FG000|Overall Study|Lost to Follow-up|3
6336052|NCT03145064|10086793|FG000|Overall Study|Withdrawal by Subject|6
6336053|NCT03145064|10086793|FG000|Overall Study|Study ended by sponsor once primary/ secondary analysis was complete and participants discontinued|4
6336054|NCT03145064|10086793|FG000|Overall Study|Other: Transferred to Long term Extension (LTE) study BGB-3111-LTE1 (NCT04170283)|4
6336055|NCT03145207|10086798|FG000|Overall Study|volunteer started taking allergy shots|1
6336056|NCT03145207|10086798|FG000|Overall Study|baseline blood pressure high|1
6336057|NCT03146403|10086837|FG000|Overall Study|Withdrawal by Subject|0
6336058|NCT03146403|10086838|FG001|Overall Study|Withdrawal by Subject|3
6336059|NCT03146403|10086837|FG000|Overall Study|Lost to Follow-up|2
6336060|NCT03146403|10086838|FG001|Overall Study|Lost to Follow-up|0
6336061|NCT03146663|10086859|FG000|Overall Study|Did not receive study treatment|1
6336062|NCT03146663|10086860|FG001|Overall Study|Did not receive study treatment|1
6336063|NCT03146741|10086867|FG000|Overall Study|Txp with non-HCV+ heart|4
6336064|NCT03146741|10086867|FG000|Overall Study|Listeted for MOT|2
6336065|NCT03146741|10086867|FG000|Overall Study|Physician Decision|2
6336066|NCT03146741|10086867|FG000|Overall Study|Awaiting txp|2
6336067|NCT03147248|10086893|FG000|Overall Study|Adverse Event|0
6336068|NCT03147248|10086894|FG001|Overall Study|Adverse Event|2
6336069|NCT03147248|10086895|FG002|Overall Study|Adverse Event|2
6336070|NCT03147248|10086896|FG003|Overall Study|Adverse Event|2
6336071|NCT03147248|10086897|FG004|Overall Study|Adverse Event|6
6336072|NCT03147248|10086898|FG005|Overall Study|Adverse Event|11
6336073|NCT03147248|10086893|FG000|Overall Study|Disease progression|1
6336074|NCT03147248|10086894|FG001|Overall Study|Disease progression|0
6336075|NCT03147248|10086895|FG002|Overall Study|Disease progression|0
6336076|NCT03147248|10086896|FG003|Overall Study|Disease progression|0
6336077|NCT03147248|10086897|FG004|Overall Study|Disease progression|0
6336078|NCT03147248|10086898|FG005|Overall Study|Disease progression|2
6336079|NCT03147248|10086893|FG000|Overall Study|Withdrawal by Subject|0
6336080|NCT03147248|10086894|FG001|Overall Study|Withdrawal by Subject|0
6336081|NCT03147248|10086895|FG002|Overall Study|Withdrawal by Subject|0
6336082|NCT03147248|10086896|FG003|Overall Study|Withdrawal by Subject|0
6336083|NCT03147248|10086897|FG004|Overall Study|Withdrawal by Subject|12
6336084|NCT03147248|10086898|FG005|Overall Study|Withdrawal by Subject|9
6336085|NCT03147248|10086893|FG000|Overall Study|Protocol Violation|0
6336086|NCT03147248|10086894|FG001|Overall Study|Protocol Violation|0
6336087|NCT03147248|10086895|FG002|Overall Study|Protocol Violation|0
6336088|NCT03147248|10086896|FG003|Overall Study|Protocol Violation|0
6336089|NCT03147248|10086897|FG004|Overall Study|Protocol Violation|2
6336090|NCT03147248|10086898|FG005|Overall Study|Protocol Violation|0
6336091|NCT03147248|10086893|FG000|Overall Study|Lost to Follow-up|0
6336092|NCT03147248|10086894|FG001|Overall Study|Lost to Follow-up|0
6336093|NCT03147248|10086895|FG002|Overall Study|Lost to Follow-up|0
6336094|NCT03147248|10086896|FG003|Overall Study|Lost to Follow-up|0
6336095|NCT03147248|10086897|FG004|Overall Study|Lost to Follow-up|2
6336096|NCT03147248|10086898|FG005|Overall Study|Lost to Follow-up|0
6336097|NCT03147248|10086893|FG000|Overall Study|Pregnancy|0
6336098|NCT03147248|10086894|FG001|Overall Study|Pregnancy|0
6336099|NCT03147248|10086895|FG002|Overall Study|Pregnancy|0
6336100|NCT03147248|10086896|FG003|Overall Study|Pregnancy|0
6336101|NCT03147248|10086897|FG004|Overall Study|Pregnancy|1
6336102|NCT03147248|10086898|FG005|Overall Study|Pregnancy|0
6336103|NCT03147248|10086893|FG000|Overall Study|Death|0
6336104|NCT03147248|10086894|FG001|Overall Study|Death|0
6336105|NCT03147248|10086895|FG002|Overall Study|Death|0
6336106|NCT03147248|10086896|FG003|Overall Study|Death|0
6336107|NCT03147248|10086897|FG004|Overall Study|Death|0
6336108|NCT03147248|10086898|FG005|Overall Study|Death|4
6336109|NCT03147248|10086893|FG000|Overall Study|Physician Decision|0
6336110|NCT03147248|10086894|FG001|Overall Study|Physician Decision|0
6336111|NCT03147248|10086895|FG002|Overall Study|Physician Decision|0
6336112|NCT03147248|10086896|FG003|Overall Study|Physician Decision|0
6336113|NCT03147248|10086897|FG004|Overall Study|Physician Decision|2
6336114|NCT03147248|10086898|FG005|Overall Study|Physician Decision|4
6336115|NCT03147248|10086893|FG000|Overall Study|Prolonged Dosing Interval|0
6336116|NCT03147248|10086894|FG001|Overall Study|Prolonged Dosing Interval|0
6336117|NCT03147248|10086895|FG002|Overall Study|Prolonged Dosing Interval|0
6336118|NCT03147248|10086896|FG003|Overall Study|Prolonged Dosing Interval|0
6336119|NCT03147248|10086897|FG004|Overall Study|Prolonged Dosing Interval|1
6336120|NCT03147248|10086898|FG005|Overall Study|Prolonged Dosing Interval|1
6336121|NCT03147495|10086914|FG000|Overall Study|Physician Decision|0
6336122|NCT03147495|10086915|FG001|Overall Study|Physician Decision|6
6336123|NCT03148067|10086938|FG000|Overall Study|Lost to Follow-up|3
6336124|NCT03148067|10086938|FG000|Overall Study|Death|1
6336125|NCT03148691|10086981|FG000|Overall Study|Protocol Violation|1
6336126|NCT03148691|10086982|FG001|Overall Study|Protocol Violation|2
6336127|NCT03148691|10086983|FG002|Overall Study|Protocol Violation|7
6336128|NCT03148691|10086981|FG000|Overall Study|Lost to Follow-up|0
6336129|NCT03148691|10086982|FG001|Overall Study|Lost to Follow-up|0
6336130|NCT03148691|10086983|FG002|Overall Study|Lost to Follow-up|1
6336131|NCT03148691|10086981|FG000|Overall Study|Other|1
6336132|NCT03148691|10086982|FG001|Overall Study|Other|0
6336133|NCT03148691|10086983|FG002|Overall Study|Other|0
6336134|NCT03148691|10086981|FG000|Overall Study|Withdrawal by Subject|1
6336135|NCT03148691|10086982|FG001|Overall Study|Withdrawal by Subject|0
6336136|NCT03148691|10086983|FG002|Overall Study|Withdrawal by Subject|0
6336137|NCT03149042|10086991|FG000|Overall Study|Invasive FFR not performed|21
6336138|NCT03149042|10086991|FG000|Overall Study|Poor CT Image Quality|1
6336139|NCT03149042|10086991|FG000|Overall Study|Invasive FFR Measurement cancelled|1
6336140|NCT03149055|10086996|FG000|Overall Study|Not treated|4
6336141|NCT03149328|10087015|FG000|Overall Study|Withdrawal by Subject|30
6336142|NCT03149328|10087016|FG001|Overall Study|Withdrawal by Subject|26
6336143|NCT03149328|10087015|FG000|Overall Study|Changed Dialysis Modality|18
6336144|NCT03149328|10087016|FG001|Overall Study|Changed Dialysis Modality|1
6336145|NCT03149328|10087015|FG000|Overall Study|Transplant|9
6336146|NCT03149328|10087016|FG001|Overall Study|Transplant|1
6336147|NCT03149328|10087015|FG000|Overall Study|Lost to Follow-up|25
6336148|NCT03149328|10087016|FG001|Overall Study|Lost to Follow-up|16
6336149|NCT03149328|10087015|FG000|Overall Study|Left Study Site|1
6336150|NCT03149328|10087016|FG001|Overall Study|Left Study Site|2
6336151|NCT03149328|10087015|FG000|Overall Study|Language Barrier|1
6336152|NCT03149328|10087016|FG001|Overall Study|Language Barrier|0
6336153|NCT03149848|10087022|FG000|Period 1 (Day 1 to Day 14)|Protocol-Defined Stopping criteria|1
6336154|NCT03149848|10087022|FG000|Period 2 (Day 15 to Day 28)|Adverse Event|2
6336155|NCT03150056|10087058|FG000|Overall Study|Withdrawal by Subject|0
6336156|NCT03150056|10087059|FG001|Overall Study|Withdrawal by Subject|0
6336157|NCT03150056|10087060|FG002|Overall Study|Withdrawal by Subject|0
6336158|NCT03150056|10087061|FG003|Overall Study|Withdrawal by Subject|0
6336159|NCT03150056|10087062|FG004|Overall Study|Withdrawal by Subject|0
6336160|NCT03150056|10087063|FG005|Overall Study|Withdrawal by Subject|2
6336161|NCT03150056|10087058|FG000|Overall Study|Study terminated by Sponsor|1
6336162|NCT03150056|10087059|FG001|Overall Study|Study terminated by Sponsor|3
6336163|NCT03150056|10087060|FG002|Overall Study|Study terminated by Sponsor|1
6336164|NCT03150056|10087061|FG003|Overall Study|Study terminated by Sponsor|1
6336165|NCT03150056|10087062|FG004|Overall Study|Study terminated by Sponsor|5
6336166|NCT03150056|10087063|FG005|Overall Study|Study terminated by Sponsor|6
6336167|NCT03150056|10087058|FG000|Overall Study|Death|9
6336168|NCT03150056|10087059|FG001|Overall Study|Death|2
6336169|NCT03150056|10087060|FG002|Overall Study|Death|2
6336170|NCT03150056|10087061|FG003|Overall Study|Death|7
6336171|NCT03150056|10087062|FG004|Overall Study|Death|8
6336172|NCT03150056|10087063|FG005|Overall Study|Death|10
6336173|NCT03150056|10087058|FG000|Overall Study|Ongoing in the study|0
6336174|NCT03150056|10087059|FG001|Overall Study|Ongoing in the study|0
6336175|NCT03150056|10087060|FG002|Overall Study|Ongoing in the study|1
6336176|NCT03150056|10087061|FG003|Overall Study|Ongoing in the study|1
6336177|NCT03150056|10087062|FG004|Overall Study|Ongoing in the study|3
6336178|NCT03150056|10087063|FG005|Overall Study|Ongoing in the study|0
6336179|NCT03150082|10087080|FG000|Treatment Period 1 (Up to 4 Weeks)|Adverse Event|1
6336180|NCT03150082|10087081|FG001|Treatment Period 1 (Up to 4 Weeks)|Adverse Event|0
6336181|NCT03150485|10087117|FG000|Overall Study|Unsatisfactory Lens Fitting|0
6336182|NCT03150485|10087118|FG001|Overall Study|Unsatisfactory Lens Fitting|1
6336183|NCT03150485|10087119|FG002|Overall Study|Unsatisfactory Lens Fitting|0
6336184|NCT03150485|10087120|FG003|Overall Study|Unsatisfactory Lens Fitting|0
6336185|NCT03150485|10087121|FG004|Overall Study|Unsatisfactory Lens Fitting|0
6336186|NCT03150485|10087122|FG005|Overall Study|Unsatisfactory Lens Fitting|0
6336187|NCT03150589|10087129|FG000|Overall Study|Withdrawal by Subject|16
6336188|NCT03150589|10087130|FG001|Overall Study|Withdrawal by Subject|9
6336189|NCT03150589|10087129|FG000|Overall Study|Adverse Event|7
6336190|NCT03150589|10087130|FG001|Overall Study|Adverse Event|6
6336191|NCT03150589|10087129|FG000|Overall Study|Protocol Violation|4
6336192|NCT03150589|10087130|FG001|Overall Study|Protocol Violation|3
6336193|NCT03150589|10087129|FG000|Overall Study|Lost to Follow-up|3
6336194|NCT03150589|10087130|FG001|Overall Study|Lost to Follow-up|3
6336195|NCT03150589|10087129|FG000|Overall Study|Death|2
6336196|NCT03150589|10087130|FG001|Overall Study|Death|3
6336197|NCT03150589|10087129|FG000|Overall Study|IP non-compliance and other reasons|12
6336198|NCT03150589|10087130|FG001|Overall Study|IP non-compliance and other reasons|3
6336199|NCT03150719|10087138|FG000|Overall Study|Adverse Event|0
6336200|NCT03150719|10087139|FG001|Overall Study|Adverse Event|1
6336201|NCT03150719|10087138|FG000|Overall Study|Death|0
6336202|NCT03150719|10087139|FG001|Overall Study|Death|1
6336203|NCT03150719|10087138|FG000|Overall Study|Other|1
6336204|NCT03150719|10087139|FG001|Overall Study|Other|0
6336205|NCT03151148|10087160|FG000|Overall Study|Lost to Follow-up|1
6336206|NCT03151148|10087161|FG001|Overall Study|Lost to Follow-up|0
6336207|NCT03151148|10087160|FG000|Overall Study|Withdrawal by Subject|1
6336208|NCT03151148|10087161|FG001|Overall Study|Withdrawal by Subject|0
6336209|NCT03151395|10087177|FG000|Overall Study|Adverse Event|2
6336210|NCT03151395|10087177|FG000|Overall Study|CONSENT WITHDRAWAL NOT DUE TO ADV. EVENT|6
6336211|NCT03151395|10087177|FG000|Overall Study|Subjects could not perform last visit before study completion date due to local COVID19 restrictions|3
6336212|NCT03151395|10087177|FG000|Overall Study|Unspecified reason|4
6336213|NCT03151551|10087199|FG000|Open-Label Treatment Period|Adverse Event|0
6336214|NCT03151551|10087200|FG001|Open-Label Treatment Period|Adverse Event|2
6336215|NCT03151551|10087199|FG000|Open-Label Treatment Period|Lost to Follow-up|1
6336216|NCT03151551|10087200|FG001|Open-Label Treatment Period|Lost to Follow-up|1
6336217|NCT03151551|10087199|FG000|Open-Label Treatment Period|Withdrawal by Subject|12
6336218|NCT03151551|10087200|FG001|Open-Label Treatment Period|Withdrawal by Subject|18
6336219|NCT03151551|10087199|FG000|Open-Label Treatment Period|Lack of Efficacy|1
6336220|NCT03151551|10087200|FG001|Open-Label Treatment Period|Lack of Efficacy|1
6336221|NCT03151551|10087199|FG000|Open-Label Treatment Period|Physician Decision|3
6336222|NCT03151551|10087200|FG001|Open-Label Treatment Period|Physician Decision|0
6336223|NCT03151551|10087199|FG000|Open-Label Treatment Period|Protocol Deviation|1
6336224|NCT03151551|10087200|FG001|Open-Label Treatment Period|Protocol Deviation|2
6336225|NCT03151551|10087199|FG000|Post-Treatment Follow-Up Period|Adverse Event|1
6336226|NCT03151551|10087200|FG001|Post-Treatment Follow-Up Period|Adverse Event|3
6336227|NCT03151551|10087199|FG000|Post-Treatment Follow-Up Period|Lost to Follow-up|4
6336228|NCT03151551|10087200|FG001|Post-Treatment Follow-Up Period|Lost to Follow-up|2
6336229|NCT03151551|10087199|FG000|Post-Treatment Follow-Up Period|Withdrawal by Subject|20
6336230|NCT03151551|10087200|FG001|Post-Treatment Follow-Up Period|Withdrawal by Subject|22
6336231|NCT03151551|10087199|FG000|Post-Treatment Follow-Up Period|Physician Decision|0
6336232|NCT03151551|10087200|FG001|Post-Treatment Follow-Up Period|Physician Decision|1
6336233|NCT03152019|10087210|FG000|Overall Study|Adverse Event|0
6336234|NCT03152019|10087211|FG001|Overall Study|Adverse Event|1
6336235|NCT03152110|10087226|FG000|Overall Study|Withdrawal by Subject|3
6336236|NCT03152552|10087248|FG000|Treatment Period 1 (12 Weeks)|Death|0
6336237|NCT03152552|10087249|FG001|Treatment Period 1 (12 Weeks)|Death|1
6336238|NCT03152552|10087250|FG002|Treatment Period 1 (12 Weeks)|Death|0
6336239|NCT03152552|10087251|FG003|Treatment Period 1 (12 Weeks)|Death|0
6336240|NCT03152552|10087252|FG004|Treatment Period 1 (12 Weeks)|Death|1
6336241|NCT03152552|10087248|FG000|Treatment Period 1 (12 Weeks)|Protocol deviation|0
6336242|NCT03152552|10087249|FG001|Treatment Period 1 (12 Weeks)|Protocol deviation|1
6336243|NCT03152552|10087250|FG002|Treatment Period 1 (12 Weeks)|Protocol deviation|0
6336244|NCT03152552|10087251|FG003|Treatment Period 1 (12 Weeks)|Protocol deviation|0
6336245|NCT03152552|10087252|FG004|Treatment Period 1 (12 Weeks)|Protocol deviation|0
6336246|NCT03152552|10087248|FG000|Treatment Period 1 (12 Weeks)|Study terminated by sponsor|8
6336247|NCT03152552|10087249|FG001|Treatment Period 1 (12 Weeks)|Study terminated by sponsor|9
6336248|NCT03152552|10087250|FG002|Treatment Period 1 (12 Weeks)|Study terminated by sponsor|19
6336249|NCT03152552|10087251|FG003|Treatment Period 1 (12 Weeks)|Study terminated by sponsor|19
6336250|NCT03152552|10087252|FG004|Treatment Period 1 (12 Weeks)|Study terminated by sponsor|20
6336251|NCT03152552|10087248|FG000|Treatment Period 1 (12 Weeks)|Lost to Follow-up|0
6336252|NCT03152552|10087249|FG001|Treatment Period 1 (12 Weeks)|Lost to Follow-up|0
6336253|NCT03152552|10087250|FG002|Treatment Period 1 (12 Weeks)|Lost to Follow-up|1
6336254|NCT03152552|10087251|FG003|Treatment Period 1 (12 Weeks)|Lost to Follow-up|0
6336255|NCT03152552|10087252|FG004|Treatment Period 1 (12 Weeks)|Lost to Follow-up|0
6336256|NCT03152552|10087248|FG000|Treatment Period 1 (12 Weeks)|Technical problems|0
6336257|NCT03152552|10087249|FG001|Treatment Period 1 (12 Weeks)|Technical problems|0
6336258|NCT03152552|10087250|FG002|Treatment Period 1 (12 Weeks)|Technical problems|1
6336259|NCT03152552|10087251|FG003|Treatment Period 1 (12 Weeks)|Technical problems|0
6336260|NCT03152552|10087252|FG004|Treatment Period 1 (12 Weeks)|Technical problems|0
6336261|NCT03152552|10087248|FG000|Treatment Period 1 (12 Weeks)|Subject/guardian decision|0
6336262|NCT03152552|10087249|FG001|Treatment Period 1 (12 Weeks)|Subject/guardian decision|0
6336263|NCT03152552|10087250|FG002|Treatment Period 1 (12 Weeks)|Subject/guardian decision|0
6336264|NCT03152552|10087251|FG003|Treatment Period 1 (12 Weeks)|Subject/guardian decision|1
6336265|NCT03152552|10087252|FG004|Treatment Period 1 (12 Weeks)|Subject/guardian decision|0
6336266|NCT03152552|10087248|FG000|Treatment Period 2 (24 Weeks)|Study terminated by sponsor|6
6336267|NCT03152552|10087249|FG001|Treatment Period 2 (24 Weeks)|Study terminated by sponsor|5
6336268|NCT03152552|10087250|FG002|Treatment Period 2 (24 Weeks)|Study terminated by sponsor|9
6336269|NCT03152552|10087251|FG003|Treatment Period 2 (24 Weeks)|Study terminated by sponsor|9
6336270|NCT03152552|10087252|FG004|Treatment Period 2 (24 Weeks)|Study terminated by sponsor|11
6336271|NCT03154047|10087283|FG000|Overall Study|Death|1
6336272|NCT03154047|10087283|FG000|Overall Study|Study terminated by sponsor|76
6336273|NCT03154047|10087283|FG000|Overall Study|Withdrawal by Subject|3
6336274|NCT03154086|10087302|FG000|Part A: Cohort1 Washout1 (Up to 14 Days)|Protocol Violation|0
6336275|NCT03154086|10087303|FG001|Part A: Cohort1 Washout1 (Up to 14 Days)|Protocol Violation|0
6336276|NCT03154086|10087304|FG002|Part A: Cohort1 Washout1 (Up to 14 Days)|Protocol Violation|0
6336277|NCT03154086|10087305|FG003|Part A: Cohort1 Washout1 (Up to 14 Days)|Protocol Violation|1
6336278|NCT03154086|10087306|FG004|Part A: Cohort1 Washout1 (Up to 14 Days)|Protocol Violation|0
6336279|NCT03154086|10087307|FG005|Part A: Cohort1 Washout1 (Up to 14 Days)|Protocol Violation|0
6168496|NCT01236352|9813657|FG010|Overall Study|Withdrawal by Subject|1
6336280|NCT03154086|10087308|FG006|Part A: Cohort1 Washout1 (Up to 14 Days)|Protocol Violation|0
6336281|NCT03154086|10087309|FG007|Part A: Cohort1 Washout1 (Up to 14 Days)|Protocol Violation|0
6336282|NCT03154086|10087310|FG008|Part A: Cohort1 Washout1 (Up to 14 Days)|Protocol Violation|0
6336283|NCT03154086|10087311|FG009|Part A: Cohort1 Washout1 (Up to 14 Days)|Protocol Violation|0
6336284|NCT03154086|10087312|FG010|Part A: Cohort1 Washout1 (Up to 14 Days)|Protocol Violation|0
6336285|NCT03154086|10087313|FG011|Part A: Cohort1 Washout1 (Up to 14 Days)|Protocol Violation|0
6336286|NCT03154086|10087314|FG012|Part A: Cohort1 Washout1 (Up to 14 Days)|Protocol Violation|0
6336287|NCT03154086|10087315|FG013|Part A: Cohort1 Washout1 (Up to 14 Days)|Protocol Violation|0
6336288|NCT03154086|10087316|FG014|Part A: Cohort1 Washout1 (Up to 14 Days)|Protocol Violation|0
6336289|NCT03154086|10087302|FG000|PartA: Cohort1 Washout2 (Up to 14 Days)|Adverse Event|0
6336290|NCT03154086|10087303|FG001|PartA: Cohort1 Washout2 (Up to 14 Days)|Adverse Event|1
6336291|NCT03154086|10087304|FG002|PartA: Cohort1 Washout2 (Up to 14 Days)|Adverse Event|0
6336292|NCT03154086|10087305|FG003|PartA: Cohort1 Washout2 (Up to 14 Days)|Adverse Event|0
6336293|NCT03154086|10087306|FG004|PartA: Cohort1 Washout2 (Up to 14 Days)|Adverse Event|0
6336294|NCT03154086|10087307|FG005|PartA: Cohort1 Washout2 (Up to 14 Days)|Adverse Event|0
6336295|NCT03154086|10087308|FG006|PartA: Cohort1 Washout2 (Up to 14 Days)|Adverse Event|0
6336296|NCT03154086|10087309|FG007|PartA: Cohort1 Washout2 (Up to 14 Days)|Adverse Event|0
6336297|NCT03154086|10087310|FG008|PartA: Cohort1 Washout2 (Up to 14 Days)|Adverse Event|0
6336298|NCT03154086|10087311|FG009|PartA: Cohort1 Washout2 (Up to 14 Days)|Adverse Event|0
6336299|NCT03154086|10087312|FG010|PartA: Cohort1 Washout2 (Up to 14 Days)|Adverse Event|0
6336300|NCT03154086|10087313|FG011|PartA: Cohort1 Washout2 (Up to 14 Days)|Adverse Event|0
6336301|NCT03154086|10087314|FG012|PartA: Cohort1 Washout2 (Up to 14 Days)|Adverse Event|0
6336302|NCT03154086|10087315|FG013|PartA: Cohort1 Washout2 (Up to 14 Days)|Adverse Event|0
6336303|NCT03154086|10087316|FG014|PartA: Cohort1 Washout2 (Up to 14 Days)|Adverse Event|0
6336304|NCT03154086|10087302|FG000|Part A: Cohort1 Washout3 (Up to 14 Days)|Adverse Event|0
6336305|NCT03154086|10087303|FG001|Part A: Cohort1 Washout3 (Up to 14 Days)|Adverse Event|0
6336306|NCT03154086|10087304|FG002|Part A: Cohort1 Washout3 (Up to 14 Days)|Adverse Event|1
6336307|NCT03154086|10087305|FG003|Part A: Cohort1 Washout3 (Up to 14 Days)|Adverse Event|0
6336308|NCT03154086|10087306|FG004|Part A: Cohort1 Washout3 (Up to 14 Days)|Adverse Event|0
6336309|NCT03154086|10087307|FG005|Part A: Cohort1 Washout3 (Up to 14 Days)|Adverse Event|0
6336310|NCT03154086|10087308|FG006|Part A: Cohort1 Washout3 (Up to 14 Days)|Adverse Event|0
6336311|NCT03154086|10087309|FG007|Part A: Cohort1 Washout3 (Up to 14 Days)|Adverse Event|0
6336312|NCT03154086|10087310|FG008|Part A: Cohort1 Washout3 (Up to 14 Days)|Adverse Event|0
6336313|NCT03154086|10087311|FG009|Part A: Cohort1 Washout3 (Up to 14 Days)|Adverse Event|0
6336314|NCT03154086|10087312|FG010|Part A: Cohort1 Washout3 (Up to 14 Days)|Adverse Event|0
6336315|NCT03154086|10087313|FG011|Part A: Cohort1 Washout3 (Up to 14 Days)|Adverse Event|0
6336316|NCT03154086|10087314|FG012|Part A: Cohort1 Washout3 (Up to 14 Days)|Adverse Event|0
6336317|NCT03154086|10087315|FG013|Part A: Cohort1 Washout3 (Up to 14 Days)|Adverse Event|0
6336318|NCT03154086|10087316|FG014|Part A: Cohort1 Washout3 (Up to 14 Days)|Adverse Event|0
6336319|NCT03154086|10087302|FG000|Part A: Cohort1 Period4 (Up to 3 Days)|Protocol Violation|1
6336320|NCT03154086|10087303|FG001|Part A: Cohort1 Period4 (Up to 3 Days)|Protocol Violation|0
6336321|NCT03154086|10087304|FG002|Part A: Cohort1 Period4 (Up to 3 Days)|Protocol Violation|0
6336322|NCT03154086|10087305|FG003|Part A: Cohort1 Period4 (Up to 3 Days)|Protocol Violation|0
6336323|NCT03154086|10087306|FG004|Part A: Cohort1 Period4 (Up to 3 Days)|Protocol Violation|0
6336324|NCT03154086|10087307|FG005|Part A: Cohort1 Period4 (Up to 3 Days)|Protocol Violation|0
6336325|NCT03154086|10087308|FG006|Part A: Cohort1 Period4 (Up to 3 Days)|Protocol Violation|0
6336326|NCT03154086|10087309|FG007|Part A: Cohort1 Period4 (Up to 3 Days)|Protocol Violation|0
6336327|NCT03154086|10087310|FG008|Part A: Cohort1 Period4 (Up to 3 Days)|Protocol Violation|0
6336328|NCT03154086|10087311|FG009|Part A: Cohort1 Period4 (Up to 3 Days)|Protocol Violation|0
6336329|NCT03154086|10087312|FG010|Part A: Cohort1 Period4 (Up to 3 Days)|Protocol Violation|0
6168497|NCT01236352|9813647|FG000|Overall Study|Adverse Event|0
6168498|NCT01236352|9813648|FG001|Overall Study|Adverse Event|0
6168499|NCT01236352|9813649|FG002|Overall Study|Adverse Event|0
6336330|NCT03154086|10087313|FG011|Part A: Cohort1 Period4 (Up to 3 Days)|Protocol Violation|0
6336331|NCT03154086|10087314|FG012|Part A: Cohort1 Period4 (Up to 3 Days)|Protocol Violation|0
6336332|NCT03154086|10087315|FG013|Part A: Cohort1 Period4 (Up to 3 Days)|Protocol Violation|0
6336333|NCT03154086|10087316|FG014|Part A: Cohort1 Period4 (Up to 3 Days)|Protocol Violation|0
6336334|NCT03154086|10087302|FG000|Part A: Cohort3 Period2 (Up to 3 Days)|Withdrawal by Subject|0
6336335|NCT03154086|10087303|FG001|Part A: Cohort3 Period2 (Up to 3 Days)|Withdrawal by Subject|0
6336336|NCT03154086|10087304|FG002|Part A: Cohort3 Period2 (Up to 3 Days)|Withdrawal by Subject|0
6336337|NCT03154086|10087305|FG003|Part A: Cohort3 Period2 (Up to 3 Days)|Withdrawal by Subject|0
6336338|NCT03154086|10087306|FG004|Part A: Cohort3 Period2 (Up to 3 Days)|Withdrawal by Subject|0
6336339|NCT03154086|10087307|FG005|Part A: Cohort3 Period2 (Up to 3 Days)|Withdrawal by Subject|0
6336340|NCT03154086|10087308|FG006|Part A: Cohort3 Period2 (Up to 3 Days)|Withdrawal by Subject|0
6336341|NCT03154086|10087309|FG007|Part A: Cohort3 Period2 (Up to 3 Days)|Withdrawal by Subject|0
6336342|NCT03154086|10087310|FG008|Part A: Cohort3 Period2 (Up to 3 Days)|Withdrawal by Subject|1
6336343|NCT03154086|10087311|FG009|Part A: Cohort3 Period2 (Up to 3 Days)|Withdrawal by Subject|0
6336344|NCT03154086|10087312|FG010|Part A: Cohort3 Period2 (Up to 3 Days)|Withdrawal by Subject|0
6336345|NCT03154086|10087313|FG011|Part A: Cohort3 Period2 (Up to 3 Days)|Withdrawal by Subject|0
6336346|NCT03154086|10087314|FG012|Part A: Cohort3 Period2 (Up to 3 Days)|Withdrawal by Subject|0
6336347|NCT03154086|10087315|FG013|Part A: Cohort3 Period2 (Up to 3 Days)|Withdrawal by Subject|0
6336348|NCT03154086|10087316|FG014|Part A: Cohort3 Period2 (Up to 3 Days)|Withdrawal by Subject|0
6336349|NCT03154086|10087302|FG000|Part A: Cohort3 Period2 (Up to 3 Days)|Protocol Violation|0
6336350|NCT03154086|10087303|FG001|Part A: Cohort3 Period2 (Up to 3 Days)|Protocol Violation|0
6336351|NCT03154086|10087304|FG002|Part A: Cohort3 Period2 (Up to 3 Days)|Protocol Violation|0
6336352|NCT03154086|10087305|FG003|Part A: Cohort3 Period2 (Up to 3 Days)|Protocol Violation|0
6336353|NCT03154086|10087306|FG004|Part A: Cohort3 Period2 (Up to 3 Days)|Protocol Violation|0
6336354|NCT03154086|10087307|FG005|Part A: Cohort3 Period2 (Up to 3 Days)|Protocol Violation|0
6336355|NCT03154086|10087308|FG006|Part A: Cohort3 Period2 (Up to 3 Days)|Protocol Violation|0
6336356|NCT03154086|10087309|FG007|Part A: Cohort3 Period2 (Up to 3 Days)|Protocol Violation|1
6336357|NCT03154086|10087310|FG008|Part A: Cohort3 Period2 (Up to 3 Days)|Protocol Violation|0
6336358|NCT03154086|10087311|FG009|Part A: Cohort3 Period2 (Up to 3 Days)|Protocol Violation|0
6336359|NCT03154086|10087312|FG010|Part A: Cohort3 Period2 (Up to 3 Days)|Protocol Violation|0
6336360|NCT03154086|10087313|FG011|Part A: Cohort3 Period2 (Up to 3 Days)|Protocol Violation|0
6336361|NCT03154086|10087314|FG012|Part A: Cohort3 Period2 (Up to 3 Days)|Protocol Violation|0
6336362|NCT03154086|10087315|FG013|Part A: Cohort3 Period2 (Up to 3 Days)|Protocol Violation|0
6336363|NCT03154086|10087316|FG014|Part A: Cohort3 Period2 (Up to 3 Days)|Protocol Violation|0
6336364|NCT03154086|10087302|FG000|Part B (Up to 25 Days)|Adverse Event|0
6336365|NCT03154086|10087303|FG001|Part B (Up to 25 Days)|Adverse Event|0
6336366|NCT03154086|10087304|FG002|Part B (Up to 25 Days)|Adverse Event|0
6336367|NCT03154086|10087305|FG003|Part B (Up to 25 Days)|Adverse Event|0
6336368|NCT03154086|10087306|FG004|Part B (Up to 25 Days)|Adverse Event|0
6336369|NCT03154086|10087307|FG005|Part B (Up to 25 Days)|Adverse Event|0
6336370|NCT03154086|10087308|FG006|Part B (Up to 25 Days)|Adverse Event|0
6336371|NCT03154086|10087309|FG007|Part B (Up to 25 Days)|Adverse Event|0
6336372|NCT03154086|10087310|FG008|Part B (Up to 25 Days)|Adverse Event|0
6336373|NCT03154086|10087311|FG009|Part B (Up to 25 Days)|Adverse Event|0
6336374|NCT03154086|10087312|FG010|Part B (Up to 25 Days)|Adverse Event|1
6336375|NCT03154086|10087313|FG011|Part B (Up to 25 Days)|Adverse Event|0
6336376|NCT03154086|10087314|FG012|Part B (Up to 25 Days)|Adverse Event|0
6336377|NCT03154086|10087315|FG013|Part B (Up to 25 Days)|Adverse Event|0
6336378|NCT03154086|10087316|FG014|Part B (Up to 25 Days)|Adverse Event|0
6336379|NCT03154476|10087384|FG000|Overall Study|Lost to Follow-up|4
6336380|NCT03154476|10087385|FG001|Overall Study|Lost to Follow-up|4
6336381|NCT03155178|10087413|FG000|Overall Study|Did not meet treatment day baseline|7
6336382|NCT03155178|10087414|FG001|Overall Study|Did not meet treatment day baseline|7
6336383|NCT03155178|10087415|FG002|Overall Study|Did not meet treatment day baseline|7
6336384|NCT03155178|10087416|FG003|Overall Study|Did not meet treatment day baseline|7
6336385|NCT03155269|10087432|FG000|Overall Study|Withdrawal by Subject|4
6336386|NCT03155269|10087433|FG001|Overall Study|Withdrawal by Subject|5
6336387|NCT03155269|10087432|FG000|Overall Study|Lost to Follow-up|1
6336388|NCT03155269|10087433|FG001|Overall Study|Lost to Follow-up|2
6336389|NCT03155724|10087439|FG000|Overall Study|Death|3
6336390|NCT03155724|10087439|FG000|Overall Study|Physician Decision|1
6336391|NCT03155724|10087439|FG000|Overall Study|Study closure|7
6336392|NCT03155945|10087445|FG000|Overall Study|Lost to Follow-up|0
6336393|NCT03155945|10087446|FG001|Overall Study|Lost to Follow-up|1
6336394|NCT03155945|10087445|FG000|Overall Study|Withdrawal by Subject|0
6336395|NCT03155945|10087446|FG001|Overall Study|Withdrawal by Subject|1
6336396|NCT03155945|10087445|FG000|Overall Study|Other Reason|0
6336397|NCT03155945|10087446|FG001|Overall Study|Other Reason|1
6336398|NCT03156270|10087452|FG000|Overall Study|Failed pre-treatment screening|1
6336399|NCT03156270|10087452|FG000|Overall Study|Lost to Follow-up|1
6168500|NCT01236352|9813650|FG003|Overall Study|Adverse Event|0
6168501|NCT01236352|9813651|FG004|Overall Study|Adverse Event|0
6336400|NCT03156543|10087460|FG000|Overall Study|Withdrawal by Subject|1
6336401|NCT03156543|10087461|FG001|Overall Study|Withdrawal by Subject|0
6336402|NCT03156621|10087469|FG000|Open-Label Treatment Period (OLTP)|Adverse Event|0
6336403|NCT03156621|10087470|FG001|Open-Label Treatment Period (OLTP)|Adverse Event|2
6336404|NCT03156621|10087469|FG000|Open-Label Treatment Period (OLTP)|Withdrawal by Subject|0
6336405|NCT03156621|10087470|FG001|Open-Label Treatment Period (OLTP)|Withdrawal by Subject|1
6336406|NCT03157089|10087481|FG000|Overall Study|Treated only with pembrolizumab|1
6336407|NCT03157089|10087482|FG001|Overall Study|Treated only with pembrolizumab|0
6336408|NCT03157089|10087481|FG000|Overall Study|Adverse Event|5
6336409|NCT03157089|10087482|FG001|Overall Study|Adverse Event|4
6336410|NCT03157089|10087481|FG000|Overall Study|Progressive disease|6
6336411|NCT03157089|10087482|FG001|Overall Study|Progressive disease|8
6336412|NCT03157531|10087493|FG000|Overall Study|Death|2
6336413|NCT03157531|10087493|FG000|Overall Study|Lost to Follow-up|4
6336414|NCT03157583|10087497|FG000|Overall Study|Other (did not meet study criteria)|1
6336415|NCT03158012|10087517|FG000|Overall Study|Withdrawal by Subject|0
6336416|NCT03158012|10087518|FG001|Overall Study|Withdrawal by Subject|1
6336417|NCT03158220|10087539|FG000|Overall Study|Screen Failure|0
6336418|NCT03158220|10087540|FG001|Overall Study|Screen Failure|1
6336419|NCT03158220|10087539|FG000|Overall Study|Withdrawal by Subject|8
6336420|NCT03158220|10087540|FG001|Overall Study|Withdrawal by Subject|9
6336421|NCT03158220|10087539|FG000|Overall Study|Status unknown|0
6336422|NCT03158220|10087540|FG001|Overall Study|Status unknown|1
6336423|NCT03158220|10087539|FG000|Overall Study|Lost to Follow-up|8
6336424|NCT03158220|10087540|FG001|Overall Study|Lost to Follow-up|5
6336425|NCT03158220|10087539|FG000|Overall Study|Physician Decision|1
6336426|NCT03158220|10087540|FG001|Overall Study|Physician Decision|0
6336427|NCT03158272|10087550|FG000|Overall Study|Disease progression|3
6336428|NCT03158272|10087551|FG001|Overall Study|Disease progression|3
6336429|NCT03158272|10087552|FG002|Overall Study|Disease progression|4
6336430|NCT03158272|10087553|FG003|Overall Study|Disease progression|6
6336431|NCT03158272|10087550|FG000|Overall Study|Death|0
6336432|NCT03158272|10087551|FG001|Overall Study|Death|0
6336433|NCT03158272|10087552|FG002|Overall Study|Death|1
6336434|NCT03158272|10087553|FG003|Overall Study|Death|0
6336435|NCT03158272|10087550|FG000|Overall Study|Other reasons|0
6336436|NCT03158272|10087551|FG001|Overall Study|Other reasons|0
6336437|NCT03158272|10087552|FG002|Overall Study|Other reasons|1
6336438|NCT03158272|10087553|FG003|Overall Study|Other reasons|0
6336439|NCT03158272|10087550|FG000|Overall Study|Adverse event unrelated to the drug|0
6336440|NCT03158272|10087551|FG001|Overall Study|Adverse event unrelated to the drug|1
6336441|NCT03158272|10087552|FG002|Overall Study|Adverse event unrelated to the drug|0
6336442|NCT03158272|10087553|FG003|Overall Study|Adverse event unrelated to the drug|0
6336443|NCT03158311|10087568|FG000|Overall Study|Subject/Guardian Decision|10
6336444|NCT03158311|10087569|FG001|Overall Study|Subject/Guardian Decision|6
6336445|NCT03158311|10087570|FG002|Overall Study|Subject/Guardian Decision|11
6336446|NCT03158311|10087568|FG000|Overall Study|Adverse Event|5
6336447|NCT03158311|10087569|FG001|Overall Study|Adverse Event|3
6336448|NCT03158311|10087570|FG002|Overall Study|Adverse Event|3
6336449|NCT03158311|10087568|FG000|Overall Study|Techinical Problems|3
6336450|NCT03158311|10087569|FG001|Overall Study|Techinical Problems|1
6336451|NCT03158311|10087570|FG002|Overall Study|Techinical Problems|5
6336452|NCT03158311|10087568|FG000|Overall Study|Physician Decision|2
6336453|NCT03158311|10087569|FG001|Overall Study|Physician Decision|3
6336454|NCT03158311|10087570|FG002|Overall Study|Physician Decision|7
6336455|NCT03158311|10087568|FG000|Overall Study|Lost to Follow-up|1
6336456|NCT03158311|10087569|FG001|Overall Study|Lost to Follow-up|1
6336457|NCT03158311|10087570|FG002|Overall Study|Lost to Follow-up|1
6336458|NCT03158311|10087568|FG000|Overall Study|Sponsor decision|1
6336459|NCT03158311|10087569|FG001|Overall Study|Sponsor decision|0
6336460|NCT03158311|10087570|FG002|Overall Study|Sponsor decision|0
6336461|NCT03158311|10087568|FG000|Overall Study|Pregnancy|0
6336462|NCT03158311|10087569|FG001|Overall Study|Pregnancy|2
6336463|NCT03158311|10087570|FG002|Overall Study|Pregnancy|0
6336464|NCT03158311|10087568|FG000|Overall Study|Randomized in error|0
6336465|NCT03158311|10087569|FG001|Overall Study|Randomized in error|0
6336466|NCT03158311|10087570|FG002|Overall Study|Randomized in error|1
6336467|NCT03159091|10087593|FG000|Overall Study|Incorrect inclusion ineligible patient|5
6336468|NCT03159091|10087594|FG001|Overall Study|Incorrect inclusion ineligible patient|3
6336469|NCT03159091|10087593|FG000|Overall Study|Patient has taken no dose of study drug|0
6336470|NCT03159091|10087594|FG001|Overall Study|Patient has taken no dose of study drug|1
6336471|NCT03159455|10087637|FG000|Overall Study|Adverse Event|0
6336472|NCT03159455|10087638|FG001|Overall Study|Adverse Event|0
6336473|NCT03159455|10087639|FG002|Overall Study|Adverse Event|0
6336474|NCT03159455|10087640|FG003|Overall Study|Adverse Event|0
6336475|NCT03159455|10087641|FG004|Overall Study|Adverse Event|0
6336476|NCT03159455|10087642|FG005|Overall Study|Adverse Event|1
6336477|NCT03159468|10087666|FG000|Overall Study|Withdrawal by Subject|0
6336478|NCT03159468|10087667|FG001|Overall Study|Withdrawal by Subject|0
6336479|NCT03159468|10087668|FG002|Overall Study|Withdrawal by Subject|3
6336480|NCT03159468|10087669|FG003|Overall Study|Withdrawal by Subject|0
6336481|NCT03159468|10087670|FG004|Overall Study|Withdrawal by Subject|0
6336482|NCT03159468|10087671|FG005|Overall Study|Withdrawal by Subject|0
6336483|NCT03159611|10087687|FG000|Overall Study|Did Not Meet Inclusion Criteria|9
6336484|NCT03159611|10087688|FG001|Overall Study|Did Not Meet Inclusion Criteria|5
6336485|NCT03159611|10087687|FG000|Overall Study|Did Not Meet Exclusion Criteria|1
6336486|NCT03159611|10087688|FG001|Overall Study|Did Not Meet Exclusion Criteria|3
6336487|NCT03159611|10087687|FG000|Overall Study|Protocol Violation|7
6336488|NCT03159611|10087688|FG001|Overall Study|Protocol Violation|4
6336489|NCT03159611|10087687|FG000|Overall Study|Adverse Event|1
6336490|NCT03159611|10087688|FG001|Overall Study|Adverse Event|0
6336491|NCT03159611|10087687|FG000|Overall Study|Withdrawal by Subject|1
6336492|NCT03159611|10087688|FG001|Overall Study|Withdrawal by Subject|1
6336493|NCT03159611|10087687|FG000|Overall Study|Non-compliance with protocol requirement|3
6336494|NCT03159611|10087688|FG001|Overall Study|Non-compliance with protocol requirement|2
6336495|NCT03159611|10087687|FG000|Overall Study|Inability to perform procedures|1
6336496|NCT03159611|10087688|FG001|Overall Study|Inability to perform procedures|0
6336497|NCT03160560|10087738|FG000|First Intervention (3 Weeks)|Withdrawal by Subject|2
6336498|NCT03160560|10087739|FG001|First Intervention (3 Weeks)|Withdrawal by Subject|1
6336499|NCT03160560|10087740|FG002|First Intervention (3 Weeks)|Withdrawal by Subject|1
6336500|NCT03160560|10087741|FG003|First Intervention (3 Weeks)|Withdrawal by Subject|0
6336501|NCT03160560|10087738|FG000|Second Intervention (3 Weeks)|Withdrawal by Subject|1
6336502|NCT03160560|10087739|FG001|Second Intervention (3 Weeks)|Withdrawal by Subject|0
6336503|NCT03160560|10087740|FG002|Second Intervention (3 Weeks)|Withdrawal by Subject|0
6336504|NCT03160560|10087741|FG003|Second Intervention (3 Weeks)|Withdrawal by Subject|0
6336505|NCT03160573|10087755|FG000|First Sequence (3 Weeks)|Withdrawal by Subject|1
6336506|NCT03160573|10087756|FG001|First Sequence (3 Weeks)|Withdrawal by Subject|3
6336507|NCT03160573|10087757|FG002|First Sequence (3 Weeks)|Withdrawal by Subject|2
6336508|NCT03160573|10087758|FG003|First Sequence (3 Weeks)|Withdrawal by Subject|2
6336509|NCT03160703|10087772|FG000|Overall Study|Withdrawal by Subject|0
6336510|NCT03160703|10087773|FG001|Overall Study|Withdrawal by Subject|0
6336511|NCT03160703|10087774|FG002|Overall Study|Withdrawal by Subject|0
6336512|NCT03160703|10087775|FG003|Overall Study|Withdrawal by Subject|1
6336513|NCT03160716|10087785|FG000|Overall Study|Lost to Follow-up|1
6336514|NCT03160885|10087791|FG000|Initial Treatment Period|Not dosed|2
6336515|NCT03160885|10087792|FG001|Initial Treatment Period|Not dosed|0
6336516|NCT03160885|10087793|FG002|Initial Treatment Period|Not dosed|0
6336517|NCT03160885|10087794|FG003|Initial Treatment Period|Not dosed|0
6336518|NCT03160885|10087795|FG004|Initial Treatment Period|Not dosed|0
6336519|NCT03160885|10087796|FG005|Initial Treatment Period|Not dosed|0
6336520|NCT03160885|10087797|FG006|Initial Treatment Period|Not dosed|0
6336521|NCT03160885|10087791|FG000|Initial Treatment Period|Discontinued IMP before Week 16|33
6336522|NCT03160885|10087792|FG001|Initial Treatment Period|Discontinued IMP before Week 16|22
6336523|NCT03160885|10087793|FG002|Initial Treatment Period|Discontinued IMP before Week 16|0
6336524|NCT03160885|10087794|FG003|Initial Treatment Period|Discontinued IMP before Week 16|0
6336525|NCT03160885|10087795|FG004|Initial Treatment Period|Discontinued IMP before Week 16|0
6336526|NCT03160885|10087796|FG005|Initial Treatment Period|Discontinued IMP before Week 16|0
6336527|NCT03160885|10087797|FG006|Initial Treatment Period|Discontinued IMP before Week 16|0
6336528|NCT03160885|10087791|FG000|Open-label Treatment|Not dosed|0
6336529|NCT03160885|10087792|FG001|Open-label Treatment|Not dosed|0
6336530|NCT03160885|10087793|FG002|Open-label Treatment|Not dosed|0
6336531|NCT03160885|10087794|FG003|Open-label Treatment|Not dosed|0
6336532|NCT03160885|10087795|FG004|Open-label Treatment|Not dosed|0
6336533|NCT03160885|10087796|FG005|Open-label Treatment|Not dosed|0
6336534|NCT03160885|10087797|FG006|Open-label Treatment|Not dosed|2
6336535|NCT03160885|10087791|FG000|Open-label Treatment|Discontinued IMP|0
6336536|NCT03160885|10087792|FG001|Open-label Treatment|Discontinued IMP|0
6336537|NCT03160885|10087793|FG002|Open-label Treatment|Discontinued IMP|0
6336538|NCT03160885|10087794|FG003|Open-label Treatment|Discontinued IMP|0
6336539|NCT03160885|10087795|FG004|Open-label Treatment|Discontinued IMP|0
6336540|NCT03160885|10087796|FG005|Open-label Treatment|Discontinued IMP|0
6336541|NCT03160885|10087797|FG006|Open-label Treatment|Discontinued IMP|131
6336542|NCT03160885|10087791|FG000|Open-label Treatment|Completed Week 50|0
6336543|NCT03160885|10087792|FG001|Open-label Treatment|Completed Week 50|0
6336544|NCT03160885|10087793|FG002|Open-label Treatment|Completed Week 50|0
6336545|NCT03160885|10087794|FG003|Open-label Treatment|Completed Week 50|0
6336546|NCT03160885|10087795|FG004|Open-label Treatment|Completed Week 50|0
6336547|NCT03160885|10087796|FG005|Open-label Treatment|Completed Week 50|0
6336548|NCT03160885|10087797|FG006|Open-label Treatment|Completed Week 50|4
6336549|NCT03160885|10087791|FG000|Maintenance Treatment Period|Not dosed - transfer to open-label|0
6336550|NCT03160885|10087792|FG001|Maintenance Treatment Period|Not dosed - transfer to open-label|0
6336551|NCT03160885|10087793|FG002|Maintenance Treatment Period|Not dosed - transfer to open-label|0
6336552|NCT03160885|10087794|FG003|Maintenance Treatment Period|Not dosed - transfer to open-label|1
6336553|NCT03160885|10087795|FG004|Maintenance Treatment Period|Not dosed - transfer to open-label|0
6336554|NCT03160885|10087796|FG005|Maintenance Treatment Period|Not dosed - transfer to open-label|0
6336555|NCT03160885|10087797|FG006|Maintenance Treatment Period|Not dosed - transfer to open-label|0
6336556|NCT03160885|10087791|FG000|Maintenance Treatment Period|Discontinued IMP|0
6168502|NCT01236352|9813652|FG005|Overall Study|Adverse Event|0
6168503|NCT01236352|9813653|FG006|Overall Study|Adverse Event|2
6168504|NCT01236352|9813654|FG007|Overall Study|Adverse Event|0
6336557|NCT03160885|10087792|FG001|Maintenance Treatment Period|Discontinued IMP|0
6336558|NCT03160885|10087793|FG002|Maintenance Treatment Period|Discontinued IMP|9
6336559|NCT03160885|10087794|FG003|Maintenance Treatment Period|Discontinued IMP|13
6336560|NCT03160885|10087795|FG004|Maintenance Treatment Period|Discontinued IMP|5
6336561|NCT03160885|10087796|FG005|Maintenance Treatment Period|Discontinued IMP|7
6336562|NCT03160885|10087797|FG006|Maintenance Treatment Period|Discontinued IMP|0
6336563|NCT03160885|10087791|FG000|Maintenance Treatment Period|Transfer to open-label treatment|0
6336564|NCT03160885|10087792|FG001|Maintenance Treatment Period|Transfer to open-label treatment|0
6336565|NCT03160885|10087793|FG002|Maintenance Treatment Period|Transfer to open-label treatment|29
6336566|NCT03160885|10087794|FG003|Maintenance Treatment Period|Transfer to open-label treatment|26
6336567|NCT03160885|10087795|FG004|Maintenance Treatment Period|Transfer to open-label treatment|26
6336568|NCT03160885|10087796|FG005|Maintenance Treatment Period|Transfer to open-label treatment|8
6336569|NCT03160885|10087797|FG006|Maintenance Treatment Period|Transfer to open-label treatment|0
6336570|NCT03160885|10087791|FG000|Maintenance Treatment Period|Completed Week 50|0
6336571|NCT03160885|10087792|FG001|Maintenance Treatment Period|Completed Week 50|0
6336572|NCT03160885|10087793|FG002|Maintenance Treatment Period|Completed Week 50|1
6336573|NCT03160885|10087794|FG003|Maintenance Treatment Period|Completed Week 50|0
6336574|NCT03160885|10087795|FG004|Maintenance Treatment Period|Completed Week 50|0
6336575|NCT03160885|10087796|FG005|Maintenance Treatment Period|Completed Week 50|0
6336576|NCT03160885|10087797|FG006|Maintenance Treatment Period|Completed Week 50|0
6336577|NCT03160898|10087818|FG000|Overall Study|Adverse Event|4
6336578|NCT03160898|10087819|FG001|Overall Study|Adverse Event|8
6336579|NCT03160898|10087820|FG002|Overall Study|Adverse Event|7
6336580|NCT03160898|10087821|FG003|Overall Study|Adverse Event|10
6336581|NCT03160898|10087818|FG000|Overall Study|Death|1
6336582|NCT03160898|10087819|FG001|Overall Study|Death|0
6336583|NCT03160898|10087820|FG002|Overall Study|Death|0
6336584|NCT03160898|10087821|FG003|Overall Study|Death|1
6336585|NCT03160898|10087818|FG000|Overall Study|Difficulty Traveling to Clinic Visits|3
6336586|NCT03160898|10087819|FG001|Overall Study|Difficulty Traveling to Clinic Visits|0
6336587|NCT03160898|10087820|FG002|Overall Study|Difficulty Traveling to Clinic Visits|0
6336588|NCT03160898|10087821|FG003|Overall Study|Difficulty Traveling to Clinic Visits|1
6336589|NCT03160898|10087818|FG000|Overall Study|Lost to Follow-up|1
6336590|NCT03160898|10087819|FG001|Overall Study|Lost to Follow-up|1
6336591|NCT03160898|10087820|FG002|Overall Study|Lost to Follow-up|1
6336592|NCT03160898|10087821|FG003|Overall Study|Lost to Follow-up|2
6336593|NCT03160898|10087818|FG000|Overall Study|Physician Decision|1
6336594|NCT03160898|10087819|FG001|Overall Study|Physician Decision|0
6336595|NCT03160898|10087820|FG002|Overall Study|Physician Decision|0
6336596|NCT03160898|10087821|FG003|Overall Study|Physician Decision|1
6336597|NCT03160898|10087818|FG000|Overall Study|Progressive Disease|4
6336598|NCT03160898|10087819|FG001|Overall Study|Progressive Disease|1
6336599|NCT03160898|10087820|FG002|Overall Study|Progressive Disease|2
6336600|NCT03160898|10087821|FG003|Overall Study|Progressive Disease|1
6336601|NCT03160898|10087818|FG000|Overall Study|Protocol Violation|1
6336602|NCT03160898|10087819|FG001|Overall Study|Protocol Violation|0
6336603|NCT03160898|10087820|FG002|Overall Study|Protocol Violation|2
6336604|NCT03160898|10087821|FG003|Overall Study|Protocol Violation|0
6336605|NCT03160898|10087818|FG000|Overall Study|Sponsor Discretion|2
6336606|NCT03160898|10087819|FG001|Overall Study|Sponsor Discretion|0
6336607|NCT03160898|10087820|FG002|Overall Study|Sponsor Discretion|0
6336608|NCT03160898|10087821|FG003|Overall Study|Sponsor Discretion|0
6336609|NCT03160898|10087818|FG000|Overall Study|Withdrawal by Subject|1
6336610|NCT03160898|10087819|FG001|Overall Study|Withdrawal by Subject|3
6336611|NCT03160898|10087820|FG002|Overall Study|Withdrawal by Subject|2
6336612|NCT03160898|10087821|FG003|Overall Study|Withdrawal by Subject|1
6336613|NCT03160898|10087818|FG000|Overall Study|Other|2
6336614|NCT03160898|10087819|FG001|Overall Study|Other|0
6336615|NCT03160898|10087820|FG002|Overall Study|Other|2
6336616|NCT03160898|10087821|FG003|Overall Study|Other|2
6336617|NCT03161405|10087846|FG000|Second Intervention Period (6 Days)|Positive urine drug screen|1
6336618|NCT03161483|10087857|FG000|Overall Study|Death|1
6336619|NCT03161483|10087858|FG001|Overall Study|Death|0
6168505|NCT01236352|9813655|FG008|Overall Study|Adverse Event|0
6168506|NCT01236352|9813656|FG009|Overall Study|Adverse Event|4
6336620|NCT03161483|10087859|FG002|Overall Study|Death|0
6336621|NCT03161483|10087860|FG003|Overall Study|Death|0
6336622|NCT03161483|10087857|FG000|Overall Study|Adverse Event|5
6336623|NCT03161483|10087858|FG001|Overall Study|Adverse Event|1
6168507|NCT01236352|9813657|FG010|Overall Study|Adverse Event|1
6336624|NCT03161483|10087859|FG002|Overall Study|Adverse Event|11
6336625|NCT03161483|10087860|FG003|Overall Study|Adverse Event|2
6336626|NCT03161483|10087857|FG000|Overall Study|Pregnancy|1
6336627|NCT03161483|10087858|FG001|Overall Study|Pregnancy|0
6336628|NCT03161483|10087859|FG002|Overall Study|Pregnancy|0
6336629|NCT03161483|10087860|FG003|Overall Study|Pregnancy|0
6336630|NCT03161483|10087857|FG000|Overall Study|Lack of Efficacy|0
6336631|NCT03161483|10087858|FG001|Overall Study|Lack of Efficacy|0
6336632|NCT03161483|10087859|FG002|Overall Study|Lack of Efficacy|1
6336633|NCT03161483|10087860|FG003|Overall Study|Lack of Efficacy|0
6336634|NCT03161483|10087857|FG000|Overall Study|Withdrawal by Subject|2
6336635|NCT03161483|10087858|FG001|Overall Study|Withdrawal by Subject|2
6336636|NCT03161483|10087859|FG002|Overall Study|Withdrawal by Subject|6
6336637|NCT03161483|10087860|FG003|Overall Study|Withdrawal by Subject|5
6336638|NCT03161483|10087857|FG000|Overall Study|Lost to Follow-up|0
6336639|NCT03161483|10087858|FG001|Overall Study|Lost to Follow-up|0
6336640|NCT03161483|10087859|FG002|Overall Study|Lost to Follow-up|1
6336641|NCT03161483|10087860|FG003|Overall Study|Lost to Follow-up|0
6336642|NCT03161483|10087857|FG000|Overall Study|Protocol Violation|0
6336643|NCT03161483|10087858|FG001|Overall Study|Protocol Violation|0
6336644|NCT03161483|10087859|FG002|Overall Study|Protocol Violation|1
6336645|NCT03161483|10087860|FG003|Overall Study|Protocol Violation|0
6336646|NCT03161483|10087857|FG000|Overall Study|Other reasons|1
6336647|NCT03161483|10087858|FG001|Overall Study|Other reasons|0
6336648|NCT03161483|10087859|FG002|Overall Study|Other reasons|0
6336649|NCT03161483|10087860|FG003|Overall Study|Other reasons|1
6336650|NCT03162055|10087881|FG000|Overall Study|Adverse Event|6
6336651|NCT03162055|10087882|FG001|Overall Study|Adverse Event|5
6336652|NCT03162055|10087881|FG000|Overall Study|Death|3
6336653|NCT03162055|10087882|FG001|Overall Study|Death|3
6336654|NCT03162055|10087881|FG000|Overall Study|Lost to Follow-up|0
6336655|NCT03162055|10087882|FG001|Overall Study|Lost to Follow-up|1
6336656|NCT03162055|10087881|FG000|Overall Study|Study-specific withdrawal criteria|22
6336657|NCT03162055|10087882|FG001|Overall Study|Study-specific withdrawal criteria|14
6336658|NCT03162055|10087881|FG000|Overall Study|Withdrawal by Subject|17
6336659|NCT03162055|10087882|FG001|Overall Study|Withdrawal by Subject|2
6336660|NCT03162055|10087881|FG000|Overall Study|Did not receive treatment|2
6336661|NCT03162055|10087882|FG001|Overall Study|Did not receive treatment|0
6336662|NCT03162055|10087881|FG000|Overall Study|Incorrect randomization|4
6336663|NCT03162055|10087882|FG001|Overall Study|Incorrect randomization|3
6336664|NCT03162055|10087881|FG000|Overall Study|Other|8
6336665|NCT03162055|10087882|FG001|Overall Study|Other|15
6336666|NCT03162328|10087888|FG000|Screening Period|Did not meet inclusion/exclusion|21
6336667|NCT03162328|10087889|FG001|Screening Period|Did not meet inclusion/exclusion|0
6336668|NCT03162328|10087890|FG002|Screening Period|Did not meet inclusion/exclusion|0
6336669|NCT03162328|10087888|FG000|Screening Period|Withdrawal by Subject|1
6336670|NCT03162328|10087889|FG001|Screening Period|Withdrawal by Subject|0
6336671|NCT03162328|10087890|FG002|Screening Period|Withdrawal by Subject|0
6336672|NCT03162328|10087888|FG000|Study Period|Withdrawal by Subject|0
6336673|NCT03162328|10087889|FG001|Study Period|Withdrawal by Subject|0
6336674|NCT03162328|10087890|FG002|Study Period|Withdrawal by Subject|1
6336675|NCT03162614|10087930|FG000|Overall Study|Lost to Follow-up|2
6336676|NCT03162614|10087931|FG001|Overall Study|Lost to Follow-up|1
6336677|NCT03162614|10087932|FG002|Overall Study|Lost to Follow-up|1
6336678|NCT03162614|10087933|FG003|Overall Study|Lost to Follow-up|1
6336679|NCT03162614|10087934|FG004|Overall Study|Lost to Follow-up|2
6336680|NCT03162614|10087935|FG005|Overall Study|Lost to Follow-up|0
6336681|NCT03162614|10087930|FG000|Overall Study|Protocol Violation|0
6336682|NCT03162614|10087931|FG001|Overall Study|Protocol Violation|1
6336683|NCT03162614|10087932|FG002|Overall Study|Protocol Violation|0
6336684|NCT03162614|10087933|FG003|Overall Study|Protocol Violation|1
6336685|NCT03162614|10087934|FG004|Overall Study|Protocol Violation|0
6336686|NCT03162614|10087935|FG005|Overall Study|Protocol Violation|0
6336687|NCT03162614|10087930|FG000|Overall Study|Withdrawal by Subject|2
6336688|NCT03162614|10087931|FG001|Overall Study|Withdrawal by Subject|1
6336689|NCT03162614|10087932|FG002|Overall Study|Withdrawal by Subject|1
6336690|NCT03162614|10087933|FG003|Overall Study|Withdrawal by Subject|1
6336691|NCT03162614|10087934|FG004|Overall Study|Withdrawal by Subject|0
6042885|NCT00385736|9641356|FG000|Safety Analysis Set|Adverse Event|23
6336692|NCT03162614|10087935|FG005|Overall Study|Withdrawal by Subject|0
6336693|NCT03162614|10087930|FG000|Overall Study|Missed vaccination, exclusion criteria|2
6336694|NCT03162614|10087931|FG001|Overall Study|Missed vaccination, exclusion criteria|2
6336695|NCT03162614|10087932|FG002|Overall Study|Missed vaccination, exclusion criteria|2
6336696|NCT03162614|10087933|FG003|Overall Study|Missed vaccination, exclusion criteria|4
6336697|NCT03162614|10087934|FG004|Overall Study|Missed vaccination, exclusion criteria|3
6336698|NCT03162614|10087935|FG005|Overall Study|Missed vaccination, exclusion criteria|0
6336699|NCT03162796|10087952|FG000|Placebo Controlled Period: Week 0 - 24|Other|0
6336700|NCT03162796|10087953|FG001|Placebo Controlled Period: Week 0 - 24|Other|1
6336701|NCT03162796|10087954|FG002|Placebo Controlled Period: Week 0 - 24|Other|1
6336702|NCT03162796|10087952|FG000|Placebo Controlled Period: Week 0 - 24|Initiated prohibited medication|1
6336703|NCT03162796|10087953|FG001|Placebo Controlled Period: Week 0 - 24|Initiated prohibited medication|0
6336704|NCT03162796|10087954|FG002|Placebo Controlled Period: Week 0 - 24|Initiated prohibited medication|0
6336705|NCT03162796|10087952|FG000|Placebo Controlled Period: Week 0 - 24|Death|1
6336706|NCT03162796|10087953|FG001|Placebo Controlled Period: Week 0 - 24|Death|0
6336707|NCT03162796|10087954|FG002|Placebo Controlled Period: Week 0 - 24|Death|0
6336708|NCT03162796|10087952|FG000|Placebo Controlled Period: Week 0 - 24|Lost to Follow-up|1
6336709|NCT03162796|10087953|FG001|Placebo Controlled Period: Week 0 - 24|Lost to Follow-up|0
6336710|NCT03162796|10087954|FG002|Placebo Controlled Period: Week 0 - 24|Lost to Follow-up|0
6336711|NCT03162796|10087952|FG000|Placebo Controlled Period: Week 0 - 24|Withdrawal by Subject|3
6336712|NCT03162796|10087953|FG001|Placebo Controlled Period: Week 0 - 24|Withdrawal by Subject|0
6336713|NCT03162796|10087954|FG002|Placebo Controlled Period: Week 0 - 24|Withdrawal by Subject|1
6336714|NCT03162796|10087952|FG000|Placebo Controlled Period: Week 0 - 24|Lack of Efficacy|4
6336715|NCT03162796|10087953|FG001|Placebo Controlled Period: Week 0 - 24|Lack of Efficacy|0
6336716|NCT03162796|10087954|FG002|Placebo Controlled Period: Week 0 - 24|Lack of Efficacy|0
6336717|NCT03162796|10087952|FG000|Placebo Controlled Period: Week 0 - 24|Adverse Event|2
6336718|NCT03162796|10087953|FG001|Placebo Controlled Period: Week 0 - 24|Adverse Event|3
6336719|NCT03162796|10087954|FG002|Placebo Controlled Period: Week 0 - 24|Adverse Event|1
6336720|NCT03162796|10087952|FG000|Active Treatment Period: Week 24 - 52|Withdrawal by Subject|0
6336721|NCT03162796|10087953|FG001|Active Treatment Period: Week 24 - 52|Withdrawal by Subject|2
6336722|NCT03162796|10087954|FG002|Active Treatment Period: Week 24 - 52|Withdrawal by Subject|0
6336723|NCT03162796|10087952|FG000|Active Treatment Period: Week 24 - 52|Lack of Efficacy|4
6336724|NCT03162796|10087953|FG001|Active Treatment Period: Week 24 - 52|Lack of Efficacy|3
6336725|NCT03162796|10087954|FG002|Active Treatment Period: Week 24 - 52|Lack of Efficacy|1
6336726|NCT03162796|10087952|FG000|Active Treatment Period: Week 24 - 52|Adverse Event|3
6336727|NCT03162796|10087953|FG001|Active Treatment Period: Week 24 - 52|Adverse Event|2
6336728|NCT03162796|10087954|FG002|Active Treatment Period: Week 24 - 52|Adverse Event|0
6336729|NCT03162796|10087952|FG000|Safety Follow-up: Week 52 - 60|Withdrawal by Subject|1
6336730|NCT03162796|10087953|FG001|Safety Follow-up: Week 52 - 60|Withdrawal by Subject|2
6336731|NCT03162796|10087954|FG002|Safety Follow-up: Week 52 - 60|Withdrawal by Subject|1
6336732|NCT03163446|10087995|FG000|Overall Study|Unable to return for Day 180 visit|2
6336733|NCT03163446|10087996|FG001|Overall Study|Unable to return for Day 180 visit|0
6336734|NCT03163446|10087995|FG000|Overall Study|Withdrawal by Subject|2
6336735|NCT03163446|10087996|FG001|Overall Study|Withdrawal by Subject|6
6336736|NCT03163446|10087995|FG000|Overall Study|Death|16
6336737|NCT03163446|10087996|FG001|Overall Study|Death|5
6336738|NCT03163446|10087995|FG000|Overall Study|Lost to Follow-up|6
6336739|NCT03163446|10087996|FG001|Overall Study|Lost to Follow-up|5
6336740|NCT03163446|10087995|FG000|Overall Study|Physician Decision|1
6336741|NCT03163446|10087996|FG001|Overall Study|Physician Decision|1
6336742|NCT03163446|10087995|FG000|Overall Study|Patient randomized but went to surgery and was unable to be dosed.|1
6336743|NCT03163446|10087996|FG001|Overall Study|Patient randomized but went to surgery and was unable to be dosed.|0
6336744|NCT03164551|10088039|FG000|Overall Study|Imaging discontinued prior completion|8
6336745|NCT03164551|10088040|FG001|Overall Study|Imaging discontinued prior completion|0
6336746|NCT03164551|10088039|FG000|Overall Study|Participant was non-compliant|1
6336747|NCT03164551|10088040|FG001|Overall Study|Participant was non-compliant|0
6336748|NCT03164551|10088039|FG000|Overall Study|Cancellation of Fresh Embryo Transfer|12
6336749|NCT03164551|10088040|FG001|Overall Study|Cancellation of Fresh Embryo Transfer|14
6336750|NCT03164551|10088039|FG000|Overall Study|Other|8
6336751|NCT03164551|10088040|FG001|Overall Study|Other|2
6336752|NCT03165045|10088055|FG000|Visit 1|No registration after visit 1|9
6336753|NCT03165045|10088055|FG000|Visit 1|No treatment documented|10
6336754|NCT03165045|10088055|FG000|Visit 1|No visit 1|10
6336755|NCT03165045|10088055|FG000|Visit 2|Available CCQ score at visit 1 only|109
6336756|NCT03165045|10088055|FG000|Visit 2|No available total CCQ score at all|29
6336757|NCT03165045|10088055|FG000|Visit 2|Available total CCQ score at vist 2 only|44
6336758|NCT03165110|10088070|FG000|Overall Study|Anroid phone software incompatibility|1
6336759|NCT03166124|10088121|FG000|Treatment Period 1|Adverse Event|0
6336760|NCT03166124|10088122|FG001|Treatment Period 1|Adverse Event|0
6336761|NCT03166124|10088123|FG002|Treatment Period 1|Adverse Event|1
6168508|NCT01236352|9813647|FG000|Overall Study|Study drug toxicity|0
6168509|NCT01236352|9813648|FG001|Overall Study|Study drug toxicity|0
6336762|NCT03166124|10088124|FG003|Treatment Period 1|Adverse Event|0
6336763|NCT03166124|10088121|FG000|Wash-out Period|Withdrawal by Subject|0
6336764|NCT03166124|10088122|FG001|Wash-out Period|Withdrawal by Subject|1
6336765|NCT03166124|10088123|FG002|Wash-out Period|Withdrawal by Subject|0
6336766|NCT03166124|10088124|FG003|Wash-out Period|Withdrawal by Subject|1
6336767|NCT03166124|10088121|FG000|Wash-out Period|Adverse Event|0
6336768|NCT03166124|10088122|FG001|Wash-out Period|Adverse Event|1
6336769|NCT03166124|10088123|FG002|Wash-out Period|Adverse Event|1
6336770|NCT03166124|10088124|FG003|Wash-out Period|Adverse Event|0
6336771|NCT03166215|10088137|FG000|Part 1 (Double-blind TP: Days 1 - 30)|Adverse Event|0
6336772|NCT03166215|10088138|FG001|Part 1 (Double-blind TP: Days 1 - 30)|Adverse Event|2
6336773|NCT03166215|10088139|FG002|Part 1 (Double-blind TP: Days 1 - 30)|Adverse Event|0
6336774|NCT03166215|10088137|FG000|Part 2 (Open-Label TP: Days 31 - 85)|Adverse Event|0
6336775|NCT03166215|10088138|FG001|Part 2 (Open-Label TP: Days 31 - 85)|Adverse Event|0
6336776|NCT03166215|10088139|FG002|Part 2 (Open-Label TP: Days 31 - 85)|Adverse Event|2
6336777|NCT03166735|10088155|FG000|Overall Study|Not Treated|1
6336778|NCT03166735|10088156|FG001|Overall Study|Not Treated|0
6336779|NCT03166735|10088157|FG002|Overall Study|Not Treated|0
6336780|NCT03166735|10088158|FG003|Overall Study|Not Treated|0
6336781|NCT03166735|10088159|FG004|Overall Study|Not Treated|0
6336782|NCT03166735|10088155|FG000|Overall Study|follow-up not completed as planned|0
6336783|NCT03166735|10088156|FG001|Overall Study|follow-up not completed as planned|1
6336784|NCT03166735|10088157|FG002|Overall Study|follow-up not completed as planned|1
6336785|NCT03166735|10088158|FG003|Overall Study|follow-up not completed as planned|0
6336786|NCT03166735|10088159|FG004|Overall Study|follow-up not completed as planned|1
6336787|NCT03166735|10088155|FG000|Overall Study|Withdrawal by Subject|0
6336788|NCT03166735|10088156|FG001|Overall Study|Withdrawal by Subject|0
6336789|NCT03166735|10088157|FG002|Overall Study|Withdrawal by Subject|1
6336790|NCT03166735|10088158|FG003|Overall Study|Withdrawal by Subject|1
6336791|NCT03166735|10088159|FG004|Overall Study|Withdrawal by Subject|2
6336792|NCT03166735|10088155|FG000|Overall Study|Lost to Follow-up|0
6336793|NCT03166735|10088156|FG001|Overall Study|Lost to Follow-up|2
6336794|NCT03166735|10088157|FG002|Overall Study|Lost to Follow-up|1
6336795|NCT03166735|10088158|FG003|Overall Study|Lost to Follow-up|0
6336796|NCT03166735|10088159|FG004|Overall Study|Lost to Follow-up|1
6336797|NCT03167073|10088174|FG000|Overall Study|Stillbirth|1
6336798|NCT03167073|10088175|FG001|Overall Study|Stillbirth|0
6336799|NCT03167151|10088184|FG000|Overall Study|Withdrawal by Subject|1
6336800|NCT03167151|10088185|FG001|Overall Study|Withdrawal by Subject|0
6336801|NCT03167151|10088186|FG002|Overall Study|Withdrawal by Subject|0
6336802|NCT03167151|10088184|FG000|Overall Study|No evidence of tumour at surgery|0
6336803|NCT03167151|10088185|FG001|Overall Study|No evidence of tumour at surgery|1
6336804|NCT03167151|10088186|FG002|Overall Study|No evidence of tumour at surgery|1
6336805|NCT03167359|10088194|FG000|Overall Study|Physician Decision|1
6336806|NCT03167359|10088194|FG000|Overall Study|Lost to Follow-up|1
6336807|NCT03167411|10088200|FG000|Overall Study|Adverse Event|0
6336808|NCT03167411|10088201|FG001|Overall Study|Adverse Event|1
6336809|NCT03168425|10088271|FG000|Overall Study|Lost to Follow-up|5
6336810|NCT03168425|10088272|FG001|Overall Study|Lost to Follow-up|8
6336811|NCT03168425|10088271|FG000|Overall Study|unable to confirm post op opioids|2
6336812|NCT03168425|10088272|FG001|Overall Study|unable to confirm post op opioids|3
6336813|NCT03168711|10088288|FG000|Overall Study|Adverse Event|2
6336814|NCT03168711|10088289|FG001|Overall Study|Adverse Event|0
6336815|NCT03168711|10088288|FG000|Overall Study|Withdrawal by Subject|0
6336816|NCT03168711|10088289|FG001|Overall Study|Withdrawal by Subject|1
6336817|NCT03168711|10088288|FG000|Overall Study|Death|0
6336818|NCT03168711|10088289|FG001|Overall Study|Death|1
6336819|NCT03168919|10088299|FG000|Overall Study|Withdrawal by Subject|2
6336820|NCT03169153|10088311|FG000|Period 1, First 30 Days of Wear|Lost to Follow-up|1
6336821|NCT03169153|10088312|FG001|Period 1, First 30 Days of Wear|Lost to Follow-up|1
6336822|NCT03169153|10088311|FG000|Period 1, First 30 Days of Wear|Withdrawal by Subject|2
6336823|NCT03169153|10088312|FG001|Period 1, First 30 Days of Wear|Withdrawal by Subject|3
6336824|NCT03169153|10088311|FG000|Period 2, Second 30 Days of Wear|Adverse Event|1
6336825|NCT03169153|10088312|FG001|Period 2, Second 30 Days of Wear|Adverse Event|2
6336826|NCT03169153|10088311|FG000|Period 2, Second 30 Days of Wear|Could not attend visit|1
6336827|NCT03169153|10088312|FG001|Period 2, Second 30 Days of Wear|Could not attend visit|0
6336828|NCT03169244|10088320|FG000|Overall Study|Lost to Follow-up|1
6336829|NCT03169244|10088321|FG001|Overall Study|Lost to Follow-up|2
6336830|NCT03169244|10088320|FG000|Overall Study|Adverse Event|1
6336831|NCT03169244|10088321|FG001|Overall Study|Adverse Event|0
6168510|NCT01236352|9813649|FG002|Overall Study|Study drug toxicity|0
6168511|NCT01236352|9813650|FG003|Overall Study|Study drug toxicity|0
6168512|NCT01236352|9813651|FG004|Overall Study|Study drug toxicity|0
6168513|NCT01236352|9813652|FG005|Overall Study|Study drug toxicity|1
6168514|NCT01236352|9813653|FG006|Overall Study|Study drug toxicity|1
6168515|NCT01236352|9813654|FG007|Overall Study|Study drug toxicity|0
6336832|NCT03169244|10088320|FG000|Overall Study|Withdrawal by Subject|2
6336833|NCT03169244|10088321|FG001|Overall Study|Withdrawal by Subject|2
6336834|NCT03169244|10088320|FG000|Overall Study|Physician Decision|1
6336835|NCT03169244|10088321|FG001|Overall Study|Physician Decision|0
6336836|NCT03170154|10088336|FG000|Overall Study|Lost to Follow-up|4
6336837|NCT03170154|10088336|FG000|Overall Study|Death|2
6336838|NCT03170154|10088336|FG000|Overall Study|Withdrawal by Subject|2
6336839|NCT03170193|10088352|FG000|Overall Study|Withdrawal by Subject|0
6336840|NCT03170193|10088353|FG001|Overall Study|Withdrawal by Subject|0
6336841|NCT03170193|10088354|FG002|Overall Study|Withdrawal by Subject|0
6336842|NCT03170193|10088355|FG003|Overall Study|Withdrawal by Subject|1
6336843|NCT03170193|10088356|FG004|Overall Study|Withdrawal by Subject|0
6336844|NCT03170193|10088357|FG005|Overall Study|Withdrawal by Subject|0
6336845|NCT03170193|10088358|FG006|Overall Study|Withdrawal by Subject|0
6336846|NCT03170193|10088352|FG000|Overall Study|Lost to Follow-up|1
6336847|NCT03170193|10088353|FG001|Overall Study|Lost to Follow-up|1
6336848|NCT03170193|10088354|FG002|Overall Study|Lost to Follow-up|0
6336849|NCT03170193|10088355|FG003|Overall Study|Lost to Follow-up|0
6336850|NCT03170193|10088356|FG004|Overall Study|Lost to Follow-up|0
6336851|NCT03170193|10088357|FG005|Overall Study|Lost to Follow-up|0
6336852|NCT03170193|10088358|FG006|Overall Study|Lost to Follow-up|0
6336853|NCT03170232|10088391|FG000|Overall Study|Adverse Event|0
6336854|NCT03170232|10088392|FG001|Overall Study|Adverse Event|1
6336855|NCT03170232|10088391|FG000|Overall Study|Protocol Violation|0
6336856|NCT03170232|10088392|FG001|Overall Study|Protocol Violation|1
6336857|NCT03170232|10088391|FG000|Overall Study|Lack of Efficacy|0
6336858|NCT03170232|10088392|FG001|Overall Study|Lack of Efficacy|1
6336859|NCT03170232|10088391|FG000|Overall Study|Study closed/terminated|26
6336860|NCT03170232|10088392|FG001|Overall Study|Study closed/terminated|23
6336861|NCT03170232|10088391|FG000|Overall Study|Lost to Follow-up|1
6336862|NCT03170232|10088392|FG001|Overall Study|Lost to Follow-up|0
6336863|NCT03170232|10088391|FG000|Overall Study|Withdrawal by Subject|0
6336864|NCT03170232|10088392|FG001|Overall Study|Withdrawal by Subject|1
6336865|NCT03170271|10088400|FG000|Overall Study|Adverse Event|7
6336866|NCT03170271|10088401|FG001|Overall Study|Adverse Event|2
6336867|NCT03170271|10088400|FG000|Overall Study|Lost to Follow-up|0
6336868|NCT03170271|10088401|FG001|Overall Study|Lost to Follow-up|1
6336869|NCT03170271|10088400|FG000|Overall Study|Physician Decision|1
6336870|NCT03170271|10088401|FG001|Overall Study|Physician Decision|0
6336871|NCT03170271|10088400|FG000|Overall Study|Protocol-specified withdrawal criterion|2
6336872|NCT03170271|10088401|FG001|Overall Study|Protocol-specified withdrawal criterion|1
6336873|NCT03170271|10088400|FG000|Overall Study|Withdrawal by Subject|17
6336874|NCT03170271|10088401|FG001|Overall Study|Withdrawal by Subject|5
6336875|NCT03170271|10088400|FG000|Overall Study|Other|2
6336876|NCT03170271|10088401|FG001|Overall Study|Other|2
6336877|NCT03170271|10088400|FG000|Overall Study|Randomized in error|4
6336878|NCT03170271|10088401|FG001|Overall Study|Randomized in error|0
6336879|NCT03170544|10088440|FG000|Part 1|Lost to Follow-up|1
6336880|NCT03170544|10088441|FG001|Part 1|Lost to Follow-up|0
6336881|NCT03170544|10088442|FG002|Part 1|Lost to Follow-up|0
6336882|NCT03170544|10088443|FG003|Part 1|Lost to Follow-up|0
6336883|NCT03170544|10088444|FG004|Part 1|Lost to Follow-up|0
6336884|NCT03170544|10088445|FG005|Part 1|Lost to Follow-up|0
6336885|NCT03170544|10088446|FG006|Part 1|Lost to Follow-up|0
6336886|NCT03170544|10088447|FG007|Part 1|Lost to Follow-up|0
6336887|NCT03170544|10088448|FG008|Part 1|Lost to Follow-up|0
6336888|NCT03170544|10088449|FG009|Part 1|Lost to Follow-up|0
6336889|NCT03170544|10088450|FG010|Part 1|Lost to Follow-up|0
6336890|NCT03170544|10088451|FG011|Part 1|Lost to Follow-up|0
6336891|NCT03170544|10088440|FG000|Part 1|Not treated|0
6336892|NCT03170544|10088441|FG001|Part 1|Not treated|0
6336893|NCT03170544|10088442|FG002|Part 1|Not treated|0
6336894|NCT03170544|10088443|FG003|Part 1|Not treated|1
6336895|NCT03170544|10088444|FG004|Part 1|Not treated|0
6336896|NCT03170544|10088445|FG005|Part 1|Not treated|0
6336897|NCT03170544|10088446|FG006|Part 1|Not treated|0
6336898|NCT03170544|10088447|FG007|Part 1|Not treated|0
6336899|NCT03170544|10088448|FG008|Part 1|Not treated|0
6336900|NCT03170544|10088449|FG009|Part 1|Not treated|0
6336901|NCT03170544|10088450|FG010|Part 1|Not treated|0
6336902|NCT03170544|10088451|FG011|Part 1|Not treated|0
6336903|NCT03170609|10088541|FG000|Overall Study|Death|0
6336904|NCT03170609|10088542|FG001|Overall Study|Death|0
6336905|NCT03170609|10088543|FG002|Overall Study|Death|1
6336906|NCT03170609|10088544|FG003|Overall Study|Death|0
6336907|NCT03170609|10088545|FG004|Overall Study|Death|0
6336908|NCT03170609|10088546|FG005|Overall Study|Death|0
6336909|NCT03170609|10088547|FG006|Overall Study|Death|0
6336910|NCT03170609|10088541|FG000|Overall Study|Withdrawal by Subject|1
6336911|NCT03170609|10088542|FG001|Overall Study|Withdrawal by Subject|2
6336912|NCT03170609|10088543|FG002|Overall Study|Withdrawal by Subject|0
6336913|NCT03170609|10088544|FG003|Overall Study|Withdrawal by Subject|0
6336914|NCT03170609|10088545|FG004|Overall Study|Withdrawal by Subject|0
6336915|NCT03170609|10088546|FG005|Overall Study|Withdrawal by Subject|0
6336916|NCT03170609|10088547|FG006|Overall Study|Withdrawal by Subject|1
6336917|NCT03170609|10088541|FG000|Overall Study|Lost to Follow-up|1
6336918|NCT03170609|10088542|FG001|Overall Study|Lost to Follow-up|0
6336919|NCT03170609|10088543|FG002|Overall Study|Lost to Follow-up|5
6336920|NCT03170609|10088544|FG003|Overall Study|Lost to Follow-up|2
6336921|NCT03170609|10088545|FG004|Overall Study|Lost to Follow-up|1
6336922|NCT03170609|10088546|FG005|Overall Study|Lost to Follow-up|1
6336923|NCT03170609|10088547|FG006|Overall Study|Lost to Follow-up|0
6336924|NCT03170609|10088541|FG000|Overall Study|Other|1
6336925|NCT03170609|10088542|FG001|Overall Study|Other|0
6336926|NCT03170609|10088543|FG002|Overall Study|Other|0
6336927|NCT03170609|10088544|FG003|Overall Study|Other|0
6336928|NCT03170609|10088545|FG004|Overall Study|Other|0
6336929|NCT03170609|10088546|FG005|Overall Study|Other|1
6336930|NCT03170609|10088547|FG006|Overall Study|Other|0
6336931|NCT03171415|10088584|FG000|Overall Study|Lost to Follow-up|0
6336932|NCT03171415|10088585|FG001|Overall Study|Lost to Follow-up|0
6336933|NCT03171415|10088586|FG002|Overall Study|Lost to Follow-up|0
6336934|NCT03171415|10088587|FG003|Overall Study|Lost to Follow-up|0
6336935|NCT03171415|10088588|FG004|Overall Study|Lost to Follow-up|2
6336936|NCT03172130|10088613|FG000|Overall Study|Failure to tolerate CPAP/Sham CPAP|3
6336937|NCT03172130|10088614|FG001|Overall Study|Failure to tolerate CPAP/Sham CPAP|1
6336938|NCT03172325|10088622|FG000|Overall Study|Adverse Event|2
6336939|NCT03172325|10088623|FG001|Overall Study|Adverse Event|3
6336940|NCT03172325|10088622|FG000|Overall Study|Positive PPD|1
6336941|NCT03172325|10088623|FG001|Overall Study|Positive PPD|0
6336942|NCT03172325|10088622|FG000|Overall Study|Poor Compliance|1
6336943|NCT03172325|10088623|FG001|Overall Study|Poor Compliance|1
6336944|NCT03172364|10088631|FG000|Overall Study|Adverse Event|1
6336945|NCT03172364|10088632|FG001|Overall Study|Adverse Event|1
6336946|NCT03172364|10088631|FG000|Overall Study|Protocol Violation|1
6336947|NCT03172364|10088632|FG001|Overall Study|Protocol Violation|0
6336948|NCT03172481|10088640|FG000|Double-blind|Withdrawal by Subject|1
6336949|NCT03172481|10088641|FG001|Double-blind|Withdrawal by Subject|0
6336950|NCT03172494|10088650|FG000|Overall Study|Adverse Event|5
6336951|NCT03172494|10088651|FG001|Overall Study|Adverse Event|1
6336952|NCT03172494|10088652|FG002|Overall Study|Adverse Event|15
6336953|NCT03172494|10088650|FG000|Overall Study|Protocol Violation|3
6336954|NCT03172494|10088651|FG001|Overall Study|Protocol Violation|2
6336955|NCT03172494|10088652|FG002|Overall Study|Protocol Violation|1
6336956|NCT03172494|10088650|FG000|Overall Study|Lack of Efficacy|0
6336957|NCT03172494|10088651|FG001|Overall Study|Lack of Efficacy|0
6336958|NCT03172494|10088652|FG002|Overall Study|Lack of Efficacy|4
6336959|NCT03172494|10088650|FG000|Overall Study|Pregnancy|0
6336960|NCT03172494|10088651|FG001|Overall Study|Pregnancy|1
6336961|NCT03172494|10088652|FG002|Overall Study|Pregnancy|0
6336962|NCT03172494|10088650|FG000|Overall Study|Withdrawal by Subject|10
6336963|NCT03172494|10088651|FG001|Overall Study|Withdrawal by Subject|8
6336964|NCT03172494|10088652|FG002|Overall Study|Withdrawal by Subject|8
6336965|NCT03172494|10088650|FG000|Overall Study|Severe hypoglycaemic episode|0
6336966|NCT03172494|10088651|FG001|Overall Study|Severe hypoglycaemic episode|0
6336967|NCT03172494|10088652|FG002|Overall Study|Severe hypoglycaemic episode|1
6336968|NCT03172494|10088650|FG000|Overall Study|Non-compliance towards treatment|2
6336969|NCT03172494|10088651|FG001|Overall Study|Non-compliance towards treatment|0
6336970|NCT03172494|10088652|FG002|Overall Study|Non-compliance towards treatment|0
6336971|NCT03172702|10088661|FG000|Overall Study|Adverse Event|9
6336972|NCT03172702|10088661|FG000|Overall Study|Death|2
6336973|NCT03172702|10088661|FG000|Overall Study|Study-specific Withdrawal Criteria|10
6336974|NCT03172702|10088661|FG000|Overall Study|Withdrawal by Subject|5
6336975|NCT03172702|10088661|FG000|Overall Study|Other|2
6336976|NCT03173313|10088693|FG000|Overall Study|Lost to Follow-up|2
6336977|NCT03173313|10088694|FG001|Overall Study|Lost to Follow-up|3
6336978|NCT03173313|10088693|FG000|Overall Study|Withdrawal by Subject|0
6336979|NCT03173313|10088694|FG001|Overall Study|Withdrawal by Subject|1
6336980|NCT03173313|10088693|FG000|Overall Study|Death|5
6336981|NCT03173313|10088694|FG001|Overall Study|Death|0
6336982|NCT03173313|10088693|FG000|Overall Study|Physician Decision|1
6336983|NCT03173313|10088694|FG001|Overall Study|Physician Decision|0
6336984|NCT03173313|10088693|FG000|Overall Study|Diagnosis of Takotsubo Cardiomyopathy|0
6336985|NCT03173313|10088694|FG001|Overall Study|Diagnosis of Takotsubo Cardiomyopathy|1
6336986|NCT03173313|10088693|FG000|Overall Study|Bone Fracture|1
6336987|NCT03173313|10088694|FG001|Overall Study|Bone Fracture|0
6336988|NCT03173547|10088702|FG000|Overall Study|Adverse Event|2
6336989|NCT03173547|10088703|FG001|Overall Study|Adverse Event|0
6336990|NCT03173547|10088702|FG000|Overall Study|Withdrawal by Subject|2
6336991|NCT03173547|10088703|FG001|Overall Study|Withdrawal by Subject|2
6168516|NCT01236352|9813655|FG008|Overall Study|Study drug toxicity|0
6168517|NCT01236352|9813656|FG009|Overall Study|Study drug toxicity|2
6168518|NCT01236352|9813657|FG010|Overall Study|Study drug toxicity|2
6168519|NCT01236352|9813647|FG000|Overall Study|Disease progression|1
6336992|NCT03173560|10088711|FG000|Overall Study|Ongoing on Treatment|38
6336993|NCT03173560|10088712|FG001|Overall Study|Ongoing on Treatment|50
6336994|NCT03173560|10088711|FG000|Overall Study|Ongoing Survival Follow-up|56
6336995|NCT03173560|10088712|FG001|Overall Study|Ongoing Survival Follow-up|57
6336996|NCT03173560|10088711|FG000|Overall Study|Lost to Follow-up|1
6336997|NCT03173560|10088712|FG001|Overall Study|Lost to Follow-up|4
6336998|NCT03173560|10088711|FG000|Overall Study|Withdrawal by Subject|10
6336999|NCT03173560|10088712|FG001|Overall Study|Withdrawal by Subject|5
6337000|NCT03173560|10088711|FG000|Overall Study|Other|0
6337001|NCT03173560|10088712|FG001|Overall Study|Other|1
6337002|NCT03174925|10088751|FG000|Overall Study|Elastographic images not retrievable|2
6337003|NCT03174925|10088751|FG000|Overall Study|Elastography image not interpretable|1
6337004|NCT03175120|10088757|FG000|Overall Study|Adverse Event|2
6337005|NCT03175120|10088758|FG001|Overall Study|Adverse Event|2
6337006|NCT03175120|10088757|FG000|Overall Study|Protocol Violation|5
6337007|NCT03175120|10088758|FG001|Overall Study|Protocol Violation|2
6337008|NCT03175120|10088757|FG000|Overall Study|Lost to Follow-up|1
6337009|NCT03175120|10088758|FG001|Overall Study|Lost to Follow-up|0
6337010|NCT03175120|10088757|FG000|Overall Study|Withdrawal by Subject|2
6337011|NCT03175120|10088758|FG001|Overall Study|Withdrawal by Subject|5
6337012|NCT03175120|10088757|FG000|Overall Study|Other|2
6337013|NCT03175120|10088758|FG001|Overall Study|Other|3
6337014|NCT03175172|10088764|FG000|Overall Study|Death|3
6337015|NCT03175172|10088764|FG000|Overall Study|Withdrawal by Subject|3
6337016|NCT03175172|10088764|FG000|Overall Study|Lost to Follow-up|1
6337017|NCT03175172|10088764|FG000|Overall Study|Study Terminated by Sponsor|3
6337018|NCT03175562|10088768|FG000|Overall Study|Adverse Event|1
6337019|NCT03175562|10088768|FG000|Overall Study|Lost to Follow-up|3
6337020|NCT03175562|10088768|FG000|Overall Study|Withdrawal by Subject|7
6337021|NCT03175562|10088768|FG000|Overall Study|Other (Not Specified)|5
6337022|NCT03176238|10088786|FG000|Overall Study|Unacceptable AEs|15
6337023|NCT03176238|10088787|FG001|Overall Study|Unacceptable AEs|8
6337024|NCT03176238|10088786|FG000|Overall Study|Abnormal lab value(s)|2
6337025|NCT03176238|10088787|FG001|Overall Study|Abnormal lab value(s)|0
6337026|NCT03176238|10088786|FG000|Overall Study|Inter-current illness|0
6337027|NCT03176238|10088787|FG001|Overall Study|Inter-current illness|1
6337028|NCT03176238|10088786|FG000|Overall Study|Consent withdrawal|14
6337029|NCT03176238|10088787|FG001|Overall Study|Consent withdrawal|2
6337030|NCT03176238|10088786|FG000|Overall Study|Lost to Follow-up|3
6337031|NCT03176238|10088787|FG001|Overall Study|Lost to Follow-up|0
6337032|NCT03176238|10088786|FG000|Overall Study|Administrative problems|1
6337033|NCT03176238|10088787|FG001|Overall Study|Administrative problems|0
6337034|NCT03176238|10088786|FG000|Overall Study|Death|3
6337035|NCT03176238|10088787|FG001|Overall Study|Death|0
6337036|NCT03176238|10088786|FG000|Overall Study|Disease Progression|133
6337037|NCT03176238|10088787|FG001|Overall Study|Disease Progression|22
6337038|NCT03176238|10088786|FG000|Overall Study|Tx duration completed per EAP|0
6337039|NCT03176238|10088787|FG001|Overall Study|Tx duration completed per EAP|1
6337040|NCT03176238|10088786|FG000|Overall Study|Patient is switched to commercial drug|16
6337041|NCT03176238|10088787|FG001|Overall Study|Patient is switched to commercial drug|1
6337042|NCT03176238|10088786|FG000|Overall Study|Protocol Violation|1
6337043|NCT03176238|10088787|FG001|Overall Study|Protocol Violation|0
6337044|NCT03176238|10088786|FG000|Overall Study|Changes in the patient's condition|2
6337045|NCT03176238|10088787|FG001|Overall Study|Changes in the patient's condition|1
6337046|NCT03176238|10088786|FG000|Overall Study|Everolimus dose interrupt > 4 wks|9
6337047|NCT03176238|10088787|FG001|Overall Study|Everolimus dose interrupt > 4 wks|0
6337048|NCT03176407|10088797|FG000|Overall Study|Protocol Violation|1
6337049|NCT03176407|10088797|FG000|Overall Study|human failure|1
6337050|NCT03176407|10088797|FG000|Overall Study|EGD showed esophageal varices=excl. crit|1
6337051|NCT03176459|10088805|FG000|Overall Study|Lost to Follow-up|5
6337052|NCT03176459|10088806|FG001|Overall Study|Lost to Follow-up|7
6337053|NCT03176784|10088825|FG000|Overall Study|Lost to Follow-up|77
6337054|NCT03176784|10088826|FG001|Overall Study|Lost to Follow-up|79
6337055|NCT03176784|10088827|FG002|Overall Study|Lost to Follow-up|79
6337056|NCT03176784|10088828|FG003|Overall Study|Lost to Follow-up|49
6337057|NCT03176784|10088825|FG000|Overall Study|Withdrawal by Subject|28
6337058|NCT03176784|10088826|FG001|Overall Study|Withdrawal by Subject|34
6337059|NCT03176784|10088827|FG002|Overall Study|Withdrawal by Subject|34
6337060|NCT03176784|10088828|FG003|Overall Study|Withdrawal by Subject|21
6337061|NCT03178266|10088896|FG000|Overall Study|Death|0
6337062|NCT03178266|10088897|FG001|Overall Study|Death|1
6337063|NCT03178266|10088896|FG000|Overall Study|Disont. Early|0
6337064|NCT03178266|10088897|FG001|Overall Study|Disont. Early|1
6337065|NCT03178266|10088896|FG000|Overall Study|Withdrawal by Subject|0
6337066|NCT03178266|10088897|FG001|Overall Study|Withdrawal by Subject|2
6337067|NCT03178669|10088915|FG000|Overall Study|Adverse Event|4
6337068|NCT03178669|10088916|FG001|Overall Study|Adverse Event|1
6337069|NCT03178669|10088917|FG002|Overall Study|Adverse Event|4
6337070|NCT03178669|10088918|FG003|Overall Study|Adverse Event|2
6337071|NCT03178669|10088919|FG004|Overall Study|Adverse Event|2
6337072|NCT03178669|10088915|FG000|Overall Study|Lack of Efficacy|0
6337073|NCT03178669|10088916|FG001|Overall Study|Lack of Efficacy|0
6337074|NCT03178669|10088917|FG002|Overall Study|Lack of Efficacy|2
6337075|NCT03178669|10088918|FG003|Overall Study|Lack of Efficacy|0
6337076|NCT03178669|10088919|FG004|Overall Study|Lack of Efficacy|1
6337077|NCT03178669|10088915|FG000|Overall Study|Physician Decision|0
6337078|NCT03178669|10088916|FG001|Overall Study|Physician Decision|0
6337079|NCT03178669|10088917|FG002|Overall Study|Physician Decision|0
6337080|NCT03178669|10088918|FG003|Overall Study|Physician Decision|0
6337081|NCT03178669|10088919|FG004|Overall Study|Physician Decision|1
6337082|NCT03178669|10088915|FG000|Overall Study|Withdrawal by Subject|1
6337083|NCT03178669|10088916|FG001|Overall Study|Withdrawal by Subject|0
6337084|NCT03178669|10088917|FG002|Overall Study|Withdrawal by Subject|1
6337085|NCT03178669|10088918|FG003|Overall Study|Withdrawal by Subject|1
6337086|NCT03178669|10088919|FG004|Overall Study|Withdrawal by Subject|0
6337087|NCT03178669|10088915|FG000|Overall Study|Lost to Follow-up|0
6337088|NCT03178669|10088916|FG001|Overall Study|Lost to Follow-up|0
6337089|NCT03178669|10088917|FG002|Overall Study|Lost to Follow-up|0
6337090|NCT03178669|10088918|FG003|Overall Study|Lost to Follow-up|1
6337091|NCT03178669|10088919|FG004|Overall Study|Lost to Follow-up|0
6337092|NCT03178773|10088933|FG000|Overall Study|Death|0
6337093|NCT03178773|10088934|FG001|Overall Study|Death|1
6337094|NCT03178773|10088933|FG000|Overall Study|Lost to Follow-up|29
6337095|NCT03178773|10088934|FG001|Overall Study|Lost to Follow-up|25
6337096|NCT03178773|10088933|FG000|Overall Study|Withdrawal by Subject|10
6337097|NCT03178773|10088934|FG001|Overall Study|Withdrawal by Subject|14
6337098|NCT03178851|10088944|FG000|Overall Study|Death|48
6337099|NCT03178851|10088945|FG001|Overall Study|Death|2
6337100|NCT03178851|10088946|FG002|Overall Study|Death|25
6337101|NCT03178851|10088944|FG000|Overall Study|Withdrawal by Subject|8
6337102|NCT03178851|10088945|FG001|Overall Study|Withdrawal by Subject|0
6337103|NCT03178851|10088946|FG002|Overall Study|Withdrawal by Subject|0
6337104|NCT03178851|10088944|FG000|Overall Study|Lost to Follow-up|5
6337105|NCT03178851|10088945|FG001|Overall Study|Lost to Follow-up|2
6337106|NCT03178851|10088946|FG002|Overall Study|Lost to Follow-up|0
6337107|NCT03178851|10088944|FG000|Overall Study|Adverse Event|0
6337108|NCT03178851|10088945|FG001|Overall Study|Adverse Event|0
6337109|NCT03178851|10088946|FG002|Overall Study|Adverse Event|1
6337110|NCT03178851|10088944|FG000|Overall Study|Study Termination by Sponsor|31
6337111|NCT03178851|10088945|FG001|Overall Study|Study Termination by Sponsor|7
6337112|NCT03178851|10088946|FG002|Overall Study|Study Termination by Sponsor|26
6337113|NCT03178942|10088957|FG000|Overall Study|Withdrawal by Subject|2
6337114|NCT03178942|10088958|FG001|Overall Study|Withdrawal by Subject|0
6337115|NCT03178942|10088957|FG000|Overall Study|Lost to Follow-up|1
6337116|NCT03178942|10088958|FG001|Overall Study|Lost to Follow-up|2
6337117|NCT03179319|10088966|FG000|Overall Study|Lost to Follow-up|6
6337118|NCT03179319|10088967|FG001|Overall Study|Lost to Follow-up|0
6337119|NCT03179787|10089000|FG000|Overall Study|Lost to Follow-up|15
6337120|NCT03179787|10089000|FG000|Overall Study|Case report failures|2
6337121|NCT03179787|10089000|FG000|Overall Study|Treatment not administered|1
6337122|NCT03179891|10089004|FG000|First Intervention|Withdrawal by Subject|1
6337123|NCT03179891|10089005|FG001|First Intervention|Withdrawal by Subject|1
6337124|NCT03179891|10089004|FG000|First Intervention|Unspecified reason|1
6337125|NCT03179891|10089005|FG001|First Intervention|Unspecified reason|0
6337126|NCT03179891|10089004|FG000|First Intervention|Protocol Violation|0
6337127|NCT03179891|10089005|FG001|First Intervention|Protocol Violation|1
6337128|NCT03180138|10089017|FG000|Overall Study|Mobile-phone could not be verified|2
6337129|NCT03180138|10089018|FG001|Overall Study|Mobile-phone could not be verified|13
6337130|NCT03180138|10089019|FG002|Overall Study|Mobile-phone could not be verified|15
6337131|NCT03180138|10089017|FG000|Overall Study|No prior immunization records|17
6337132|NCT03180138|10089018|FG001|Overall Study|No prior immunization records|0
6337133|NCT03180138|10089019|FG002|Overall Study|No prior immunization records|6
6337134|NCT03180138|10089017|FG000|Overall Study|Found to be >24 mon after randomization|3
6337135|NCT03180138|10089018|FG001|Overall Study|Found to be >24 mon after randomization|0
6337136|NCT03180138|10089019|FG002|Overall Study|Found to be >24 mon after randomization|3
6337137|NCT03180528|10089061|FG000|Overall Study|Adverse Event|1
6337138|NCT03180528|10089061|FG000|Overall Study|Withdrawal by Subject|1
6337139|NCT03180528|10089061|FG000|Overall Study|Eligible and enrolled, but withdrawn due to abnormal baseline laboratory values.|1
6337140|NCT03180619|10089068|FG000|Overall Study|Withdrew Consent|5
6337141|NCT03180619|10089069|FG001|Overall Study|Withdrew Consent|0
6337142|NCT03180619|10089070|FG002|Overall Study|Withdrew Consent|2
6337143|NCT03180619|10089068|FG000|Overall Study|Death|2
6337144|NCT03180619|10089069|FG001|Overall Study|Death|1
6337145|NCT03180619|10089070|FG002|Overall Study|Death|2
6337146|NCT03180619|10089068|FG000|Overall Study|Adverse Event|2
6337147|NCT03180619|10089069|FG001|Overall Study|Adverse Event|0
6337148|NCT03180619|10089070|FG002|Overall Study|Adverse Event|1
6337149|NCT03180619|10089068|FG000|Overall Study|Investigator's discretion|2
6337150|NCT03180619|10089069|FG001|Overall Study|Investigator's discretion|0
6337151|NCT03180619|10089070|FG002|Overall Study|Investigator's discretion|1
6337152|NCT04042103|10089098|FG000|Overall Study|Lost to Follow-up|1
6337153|NCT04042103|10089098|FG000|Overall Study|Withdrawal by Subject|1
6337154|NCT04004208|10089104|FG000|Overall Study|Withdrawal by parent/guardian|1
6337155|NCT04004208|10089105|FG001|Overall Study|Withdrawal by parent/guardian|1
6337156|NCT04004208|10089104|FG000|Overall Study|Death|3
6337157|NCT04004208|10089105|FG001|Overall Study|Death|0
6337158|NCT04004208|10089104|FG000|Overall Study|COVID-19 pandemic|1
6337159|NCT04004208|10089105|FG001|Overall Study|COVID-19 pandemic|0
6337160|NCT04004208|10089104|FG000|Overall Study|Physician Decision|1
6337161|NCT04004208|10089105|FG001|Overall Study|Physician Decision|0
6337162|NCT04004208|10089104|FG000|Overall Study|Adverse Event|1
6337163|NCT04004208|10089105|FG001|Overall Study|Adverse Event|1
6337178|NCT03041311|10089126|FG000|Overall Study|Death|39
6337179|NCT03041311|10089127|FG001|Overall Study|Death|42
6337180|NCT03041311|10089126|FG000|Overall Study|Lost to Follow-up|0
6337181|NCT03041311|10089127|FG001|Overall Study|Lost to Follow-up|1
6337182|NCT03041311|10089126|FG000|Overall Study|Withdrawal by Subject|8
6337183|NCT03041311|10089127|FG001|Overall Study|Withdrawal by Subject|5
6337184|NCT03041311|10089126|FG000|Overall Study|Sponsor Terminated Study|2
6337185|NCT03041311|10089127|FG001|Overall Study|Sponsor Terminated Study|4
6337186|NCT03041311|10089126|FG000|Overall Study|Disease Progression|3
6337187|NCT03041311|10089127|FG001|Overall Study|Disease Progression|1
6337188|NCT03041311|10089126|FG000|Overall Study|Randomized in error, did not receive drug|2
6337189|NCT03041311|10089127|FG001|Overall Study|Randomized in error, did not receive drug|0
6337190|NCT03020914|10089143|FG000|Overall Study|Surgery Cancelled|1
6337191|NCT03020914|10089144|FG001|Overall Study|Surgery Cancelled|0
6337192|NCT02698891|10089159|FG000|Overall Study|Withdrawal by Subject|2
6337193|NCT02698891|10089159|FG000|Overall Study|deemed ineligible|1
6337194|NCT02698891|10089159|FG000|Overall Study|Adverse Event|9
6337195|NCT02537678|10089165|FG000|Baseline to Post-treatment|Parent/Guardian- child dyads: Never started|4
6337196|NCT02537678|10089166|FG001|Baseline to Post-treatment|Parent/Guardian- child dyads: Never started|3
6337197|NCT02537678|10089165|FG000|Baseline to Post-treatment|Parent/Guardian-child dyads: Withdrew|4
6337198|NCT02537678|10089166|FG001|Baseline to Post-treatment|Parent/Guardian-child dyads: Withdrew|4
6337199|NCT02537678|10089165|FG000|Baseline to Post-treatment|Parent/Guardian-child dyads: Unknown|6
6337200|NCT02537678|10089166|FG001|Baseline to Post-treatment|Parent/Guardian-child dyads: Unknown|5
6337201|NCT02537678|10089165|FG000|Baseline to Post-treatment|Parent/Guardian-child: Dislike therapy|2
6337202|NCT02537678|10089166|FG001|Baseline to Post-treatment|Parent/Guardian-child: Dislike therapy|3
6337203|NCT02537678|10089165|FG000|Baseline to Post-treatment|Parent/Guardian barriers: work, moved, homeless, illness, transportation, perpetrator in home|14
6337204|NCT02537678|10089166|FG001|Baseline to Post-treatment|Parent/Guardian barriers: work, moved, homeless, illness, transportation, perpetrator in home|6
6337205|NCT02537678|10089165|FG000|Post-treatment to 6 Month Assessment|Lost to Follow-up|8
6337206|NCT02537678|10089166|FG001|Post-treatment to 6 Month Assessment|Lost to Follow-up|7
6337207|NCT02537678|10089165|FG000|6 Month to 12 Month Assessment|Lost to Follow-up|0
6337208|NCT02537678|10089166|FG001|6 Month to 12 Month Assessment|Lost to Follow-up|1
6337209|NCT02400476|10089182|FG000|Overall Study|Adverse Event|57
6337210|NCT02400476|10089183|FG001|Overall Study|Adverse Event|10
6337211|NCT02400476|10089184|FG002|Overall Study|Adverse Event|22
6337212|NCT02400476|10089185|FG003|Overall Study|Adverse Event|19
6337213|NCT02400476|10089186|FG004|Overall Study|Adverse Event|5
6337214|NCT02400476|10089187|FG005|Overall Study|Adverse Event|8
6337215|NCT02400476|10089182|FG000|Overall Study|Withdrawal by Subject|4
6337216|NCT02400476|10089183|FG001|Overall Study|Withdrawal by Subject|1
6337217|NCT02400476|10089184|FG002|Overall Study|Withdrawal by Subject|12
6337218|NCT02400476|10089185|FG003|Overall Study|Withdrawal by Subject|7
6337219|NCT02400476|10089186|FG004|Overall Study|Withdrawal by Subject|5
6337220|NCT02400476|10089187|FG005|Overall Study|Withdrawal by Subject|5
6337221|NCT02400476|10089182|FG000|Overall Study|Lost to Follow-up|0
6337222|NCT02400476|10089183|FG001|Overall Study|Lost to Follow-up|0
6337223|NCT02400476|10089184|FG002|Overall Study|Lost to Follow-up|0
6337224|NCT02400476|10089185|FG003|Overall Study|Lost to Follow-up|1
6337225|NCT02400476|10089186|FG004|Overall Study|Lost to Follow-up|3
6337226|NCT02400476|10089187|FG005|Overall Study|Lost to Follow-up|1
6337227|NCT02400476|10089182|FG000|Overall Study|Physician Decision|0
6337228|NCT02400476|10089183|FG001|Overall Study|Physician Decision|0
6337229|NCT02400476|10089184|FG002|Overall Study|Physician Decision|1
6337230|NCT02400476|10089185|FG003|Overall Study|Physician Decision|1
6337231|NCT02400476|10089186|FG004|Overall Study|Physician Decision|0
6337232|NCT02400476|10089187|FG005|Overall Study|Physician Decision|1
6337233|NCT02400476|10089182|FG000|Overall Study|Other, Disease Progression|0
6337234|NCT02400476|10089183|FG001|Overall Study|Other, Disease Progression|1
6337235|NCT02400476|10089184|FG002|Overall Study|Other, Disease Progression|2
6337236|NCT02400476|10089185|FG003|Overall Study|Other, Disease Progression|1
6337237|NCT02400476|10089186|FG004|Overall Study|Other, Disease Progression|2
6337238|NCT02400476|10089187|FG005|Overall Study|Other, Disease Progression|1
6337239|NCT02400476|10089182|FG000|Overall Study|Other, Decreased Quality of Life|0
6337240|NCT02400476|10089183|FG001|Overall Study|Other, Decreased Quality of Life|0
6337241|NCT02400476|10089184|FG002|Overall Study|Other, Decreased Quality of Life|2
6337242|NCT02400476|10089185|FG003|Overall Study|Other, Decreased Quality of Life|0
6337243|NCT02400476|10089186|FG004|Overall Study|Other, Decreased Quality of Life|0
6337244|NCT02400476|10089187|FG005|Overall Study|Other, Decreased Quality of Life|0
6337164|NCT03817190|10089113|FG000|Overall Study|Early Termination|13
6337165|NCT03817190|10089114|FG001|Overall Study|Early Termination|20
6337166|NCT03817190|10089113|FG000|Overall Study|Adverse Event|10
6337167|NCT03817190|10089114|FG001|Overall Study|Adverse Event|17
6168520|NCT01236352|9813648|FG001|Overall Study|Disease progression|2
6168521|NCT01236352|9813649|FG002|Overall Study|Disease progression|1
6168522|NCT01236352|9813650|FG003|Overall Study|Disease progression|2
6168523|NCT01236352|9813651|FG004|Overall Study|Disease progression|2
6168524|NCT01236352|9813652|FG005|Overall Study|Disease progression|2
6337168|NCT03817190|10089113|FG000|Overall Study|Withdrawal by Subject|12
6337169|NCT03817190|10089114|FG001|Overall Study|Withdrawal by Subject|8
6337170|NCT03817190|10089113|FG000|Overall Study|Lost to Follow-up|11
6337171|NCT03817190|10089114|FG001|Overall Study|Lost to Follow-up|7
6337172|NCT03817190|10089113|FG000|Overall Study|Lack of Efficacy|7
6337173|NCT03817190|10089114|FG001|Overall Study|Lack of Efficacy|5
6337174|NCT03817190|10089113|FG000|Overall Study|Investigator Decision|5
6337175|NCT03817190|10089114|FG001|Overall Study|Investigator Decision|1
6337176|NCT03817190|10089113|FG000|Overall Study|Missing Effect|2
6337177|NCT03817190|10089114|FG001|Overall Study|Missing Effect|1
6337245|NCT02400476|10089182|FG000|Overall Study|Other, Noncompliance to Protocol Requirements|0
6337246|NCT02400476|10089183|FG001|Overall Study|Other, Noncompliance to Protocol Requirements|0
6337247|NCT02400476|10089184|FG002|Overall Study|Other, Noncompliance to Protocol Requirements|2
6337248|NCT02400476|10089185|FG003|Overall Study|Other, Noncompliance to Protocol Requirements|1
6337249|NCT02400476|10089186|FG004|Overall Study|Other, Noncompliance to Protocol Requirements|0
6337250|NCT02400476|10089187|FG005|Overall Study|Other, Noncompliance to Protocol Requirements|0
6337251|NCT02362035|10089201|FG000|Overall Study|Death|67
6337252|NCT02362035|10089201|FG000|Overall Study|Lost to Follow-up|3
6337253|NCT02362035|10089201|FG000|Overall Study|Adverse Event|1
6337254|NCT02362035|10089201|FG000|Overall Study|Physician Decision|1
6337255|NCT02362035|10089201|FG000|Overall Study|Subject started another cancer therapy|10
6337256|NCT02362035|10089201|FG000|Overall Study|Study terminated by sponsor|45
6337257|NCT02362035|10089201|FG000|Overall Study|Decision by subject not related to AE/SAE|2
6337258|NCT02362035|10089201|FG000|Overall Study|Decision by PI not related to AE/SAE|1
6337259|NCT02362035|10089201|FG000|Overall Study|Disease progression|11
6337260|NCT02362035|10089201|FG000|Overall Study|Withdrawal by Subject|20
6337261|NCT02231749|10089207|FG000|Overall Study|Disease progression|229
6337262|NCT02231749|10089208|FG001|Overall Study|Disease progression|297
6337263|NCT02231749|10089207|FG000|Overall Study|Study Drug Toxicity|134
6337264|NCT02231749|10089208|FG001|Overall Study|Study Drug Toxicity|63
6337265|NCT02231749|10089207|FG000|Overall Study|Death|1
6337266|NCT02231749|10089208|FG001|Overall Study|Death|1
6337267|NCT02231749|10089207|FG000|Overall Study|AE unrelated to Study drug|32
6337268|NCT02231749|10089208|FG001|Overall Study|AE unrelated to Study drug|31
6337269|NCT02231749|10089207|FG000|Overall Study|Participant's request to discontinue|10
6337270|NCT02231749|10089208|FG001|Overall Study|Participant's request to discontinue|21
6337271|NCT02231749|10089207|FG000|Overall Study|Participant withdrew Consent|8
6337272|NCT02231749|10089208|FG001|Overall Study|Participant withdrew Consent|15
6337273|NCT02231749|10089207|FG000|Overall Study|Lost to Follow-up|1
6337274|NCT02231749|10089208|FG001|Overall Study|Lost to Follow-up|2
6337275|NCT02231749|10089207|FG000|Overall Study|Maximum Clinical Benefit|5
6337276|NCT02231749|10089208|FG001|Overall Study|Maximum Clinical Benefit|8
6337277|NCT02231749|10089207|FG000|Overall Study|Poor/Non-Compliance|0
6337278|NCT02231749|10089208|FG001|Overall Study|Poor/Non-Compliance|3
6337279|NCT02231749|10089207|FG000|Overall Study|Pregnancy|1
6337280|NCT02231749|10089208|FG001|Overall Study|Pregnancy|0
6337281|NCT02231749|10089207|FG000|Overall Study|other|0
6337282|NCT02231749|10089208|FG001|Overall Study|other|8
6337283|NCT02231749|10089207|FG000|Overall Study|No longer meets Study Criteria|1
6337284|NCT02231749|10089208|FG001|Overall Study|No longer meets Study Criteria|0
6337285|NCT01660451|10089221|FG000|Overall Study|Protocol Violation|0
6337286|NCT01660451|10089222|FG001|Overall Study|Protocol Violation|1
6337287|NCT01660451|10089223|FG002|Overall Study|Protocol Violation|1
6337288|NCT01660451|10089221|FG000|Overall Study|Adverse Event (AE) without Clinical PD|11
6337289|NCT01660451|10089222|FG001|Overall Study|Adverse Event (AE) without Clinical PD|8
6337290|NCT01660451|10089223|FG002|Overall Study|Adverse Event (AE) without Clinical PD|26
6337291|NCT01660451|10089221|FG000|Overall Study|AE with Clinical PD|1
6337292|NCT01660451|10089222|FG001|Overall Study|AE with Clinical PD|3
6337293|NCT01660451|10089223|FG002|Overall Study|AE with Clinical PD|9
6337294|NCT01660451|10089221|FG000|Overall Study|Sponsor Decision|0
6337295|NCT01660451|10089222|FG001|Overall Study|Sponsor Decision|0
6337296|NCT01660451|10089223|FG002|Overall Study|Sponsor Decision|1
6337297|NCT01660451|10089221|FG000|Overall Study|Protocol Deviation|0
6337298|NCT01660451|10089222|FG001|Overall Study|Protocol Deviation|0
6337299|NCT01660451|10089223|FG002|Overall Study|Protocol Deviation|1
6337300|NCT01660451|10089221|FG000|Overall Study|Physician Decision|1
6337301|NCT01660451|10089222|FG001|Overall Study|Physician Decision|2
6337302|NCT01660451|10089223|FG002|Overall Study|Physician Decision|5
6168525|NCT01236352|9813653|FG006|Overall Study|Disease progression|1
6337303|NCT01660451|10089221|FG000|Overall Study|Withdrawal by Subject|1
6337304|NCT01660451|10089222|FG001|Overall Study|Withdrawal by Subject|0
6337305|NCT01660451|10089223|FG002|Overall Study|Withdrawal by Subject|16
6337306|NCT01660451|10089221|FG000|Overall Study|Ongoing with treatment|3
6168526|NCT01236352|9813654|FG007|Overall Study|Disease progression|3
6337307|NCT01660451|10089222|FG001|Overall Study|Ongoing with treatment|3
6337308|NCT01660451|10089223|FG002|Overall Study|Ongoing with treatment|46
6337309|NCT01507545|10089234|FG000|Overall Study|Withdrawal by Subject|6
6337310|NCT01507545|10089235|FG001|Overall Study|Withdrawal by Subject|2
6337311|NCT01507545|10089234|FG000|Overall Study|Lost to Follow-up|1
6337312|NCT01507545|10089235|FG001|Overall Study|Lost to Follow-up|0
6337313|NCT01507545|10089234|FG000|Overall Study|Discontinuation of the study by sponsor|11
6337314|NCT01507545|10089235|FG001|Overall Study|Discontinuation of the study by sponsor|9
6337315|NCT01507545|10089234|FG000|Overall Study|Progressive disease|60
6337316|NCT01507545|10089235|FG001|Overall Study|Progressive disease|27
6337317|NCT01507545|10089234|FG000|Overall Study|Other|6
6337318|NCT01507545|10089235|FG001|Overall Study|Other|4
6337319|NCT00920816|10089249|FG000|Overall Study|Death|116
6337320|NCT00920816|10089250|FG001|Overall Study|Death|63
6337321|NCT00920816|10089251|FG002|Overall Study|Death|8
6337322|NCT00920816|10089252|FG003|Overall Study|Death|3
6337323|NCT00920816|10089249|FG000|Overall Study|Participant refused continued treatment for reason other than adverse events|11
6337324|NCT00920816|10089250|FG001|Overall Study|Participant refused continued treatment for reason other than adverse events|5
6337325|NCT00920816|10089251|FG002|Overall Study|Participant refused continued treatment for reason other than adverse events|1
6337326|NCT00920816|10089252|FG003|Overall Study|Participant refused continued treatment for reason other than adverse events|0
6337327|NCT00920816|10089249|FG000|Overall Study|Global deterioration of health status|2
6337328|NCT00920816|10089250|FG001|Overall Study|Global deterioration of health status|0
6337329|NCT00920816|10089251|FG002|Overall Study|Global deterioration of health status|0
6337330|NCT00920816|10089252|FG003|Overall Study|Global deterioration of health status|0
6337331|NCT00920816|10089249|FG000|Overall Study|Objective progression or relapse|6
6337332|NCT00920816|10089250|FG001|Overall Study|Objective progression or relapse|2
6337333|NCT00920816|10089251|FG002|Overall Study|Objective progression or relapse|0
6337334|NCT00920816|10089252|FG003|Overall Study|Objective progression or relapse|0
6337335|NCT00920816|10089249|FG000|Overall Study|Other|26
6337336|NCT00920816|10089250|FG001|Overall Study|Other|15
6337337|NCT00920816|10089251|FG002|Overall Study|Other|1
6337338|NCT00920816|10089252|FG003|Overall Study|Other|2
6337339|NCT00920816|10089249|FG000|Overall Study|Lost to Follow-up|11
6337340|NCT00920816|10089250|FG001|Overall Study|Lost to Follow-up|2
6337341|NCT00920816|10089251|FG002|Overall Study|Lost to Follow-up|0
6083027|NCT00633152|9691316|FG001|Overall Study|Randomized, did not receive study drug|2
6083028|NCT00633152|9691315|FG000|Overall Study|Withdrawal by Subject|1
6083029|NCT00633152|9691316|FG001|Overall Study|Withdrawal by Subject|1
6168527|NCT01236352|9813655|FG008|Overall Study|Disease progression|2
6168528|NCT01236352|9813656|FG009|Overall Study|Disease progression|2
6168529|NCT01236352|9813657|FG010|Overall Study|Disease progression|2
6168530|NCT01236352|9813647|FG000|Overall Study|Poor/Non-compliance|1
6168531|NCT01236352|9813648|FG001|Overall Study|Poor/Non-compliance|0
6168532|NCT01236352|9813649|FG002|Overall Study|Poor/Non-compliance|0
6168533|NCT01236352|9813650|FG003|Overall Study|Poor/Non-compliance|0
6168534|NCT01236352|9813651|FG004|Overall Study|Poor/Non-compliance|0
6168535|NCT01236352|9813652|FG005|Overall Study|Poor/Non-compliance|0
6168536|NCT01236352|9813653|FG006|Overall Study|Poor/Non-compliance|0
6168537|NCT01236352|9813654|FG007|Overall Study|Poor/Non-compliance|0
6168538|NCT01236352|9813655|FG008|Overall Study|Poor/Non-compliance|0
6168539|NCT01236352|9813656|FG009|Overall Study|Poor/Non-compliance|0
6083030|NCT00633152|9691315|FG000|Overall Study|Lost to Follow-up|4
6083031|NCT00633152|9691316|FG001|Overall Study|Lost to Follow-up|1
6083032|NCT00633152|9691315|FG000|Overall Study|Miscellaneous Other|3
6083033|NCT00633152|9691316|FG001|Overall Study|Miscellaneous Other|2
6083034|NCT00633217|9691326|FG000|Overall Study|Adverse Event|5
6083035|NCT00633217|9691327|FG001|Overall Study|Adverse Event|9
6083036|NCT00633217|9691326|FG000|Overall Study|Lack of Efficacy|0
6083037|NCT00633217|9691327|FG001|Overall Study|Lack of Efficacy|2
6083038|NCT00633217|9691326|FG000|Overall Study|Protocol Violation|3
6083039|NCT00633217|9691327|FG001|Overall Study|Protocol Violation|7
6083040|NCT00633217|9691326|FG000|Overall Study|Lost to Follow-up|2
6083041|NCT00633217|9691327|FG001|Overall Study|Lost to Follow-up|2
6083042|NCT00633217|9691326|FG000|Overall Study|Investigator Discretion|2
6083043|NCT00633217|9691327|FG001|Overall Study|Investigator Discretion|0
6083044|NCT00633217|9691326|FG000|Overall Study|Withdrew Consent|3
6083045|NCT00633217|9691327|FG001|Overall Study|Withdrew Consent|3
6083046|NCT00633243|9691335|FG000|Overall Study|Withdrawal by Subject|0
6083047|NCT00633243|9691336|FG001|Overall Study|Withdrawal by Subject|1
6083048|NCT00633243|9691335|FG000|Overall Study|incarceration|0
6083049|NCT00633243|9691336|FG001|Overall Study|incarceration|2
6168540|NCT01236352|9813657|FG010|Overall Study|Poor/Non-compliance|0
6337342|NCT00920816|10089252|FG003|Overall Study|Lost to Follow-up|0
6337343|NCT00920816|10089249|FG000|Overall Study|Adverse Event|1
6337344|NCT00920816|10089250|FG001|Overall Study|Adverse Event|1
6337345|NCT00920816|10089251|FG002|Overall Study|Adverse Event|1
6337346|NCT00920816|10089252|FG003|Overall Study|Adverse Event|0
6337347|NCT00920816|10089249|FG000|Overall Study|Data not disclosed due to lack of HGRAC filings|16
6083050|NCT00633243|9691335|FG000|Overall Study|Homeless--no refrigeration for meds|0
6083051|NCT00633243|9691336|FG001|Overall Study|Homeless--no refrigeration for meds|1
6083052|NCT00633243|9691335|FG000|Overall Study|Not comfortable with self-injecting|0
6168541|NCT01236352|9813647|FG000|Overall Study|Maximum clinical benefit|1
6083053|NCT00633243|9691336|FG001|Overall Study|Not comfortable with self-injecting|1
6083054|NCT00633243|9691335|FG000|Overall Study|Mental Health--Depression|0
6083055|NCT00633243|9691336|FG001|Overall Study|Mental Health--Depression|1
6083056|NCT00633243|9691335|FG000|Overall Study|Couldn't tolerate side-effects|1
6083057|NCT00633243|9691336|FG001|Overall Study|Couldn't tolerate side-effects|1
6083058|NCT00633360|9691353|FG000|Overall Study|Lost to Follow-up|1
6083059|NCT00633360|9691354|FG001|Overall Study|Lost to Follow-up|1
6083060|NCT00633360|9691353|FG000|Overall Study|Adverse Event|3
6083061|NCT00633360|9691354|FG001|Overall Study|Adverse Event|1
6083062|NCT00633360|9691353|FG000|Overall Study|Protocol Violation|0
6083063|NCT00633360|9691354|FG001|Overall Study|Protocol Violation|1
6083064|NCT00633464|9691373|FG000|Overall Study|Never Treated (Not met study criteria)|0
6083065|NCT00633464|9691374|FG001|Overall Study|Never Treated (Not met study criteria)|1
6083066|NCT00633464|9691373|FG000|Overall Study|Never Treated (Randomized in error)|0
6083067|NCT00633464|9691374|FG001|Overall Study|Never Treated (Randomized in error)|1
6083068|NCT00633477|9691382|FG000|Overall Study|Death|1
6083069|NCT00633477|9691383|FG001|Overall Study|Death|0
6083070|NCT00633477|9691382|FG000|Overall Study|Randomized but not treated|1
6083071|NCT00633477|9691383|FG001|Overall Study|Randomized but not treated|0
6083072|NCT00633594|9691392|FG000|Overall Study|Adverse Event|0
6083073|NCT00633594|9691393|FG001|Overall Study|Adverse Event|4
6083074|NCT00633594|9691394|FG002|Overall Study|Adverse Event|7
6083075|NCT00633594|9691392|FG000|Overall Study|Death|0
6083076|NCT00633594|9691393|FG001|Overall Study|Death|1
6083077|NCT00633594|9691394|FG002|Overall Study|Death|2
6083078|NCT00633594|9691392|FG000|Overall Study|Disease Progression|0
6083079|NCT00633594|9691393|FG001|Overall Study|Disease Progression|0
6083080|NCT00633594|9691394|FG002|Overall Study|Disease Progression|1
6083081|NCT00633750|9691405|FG000|Overall Study|Adverse Event|2
6083082|NCT00633750|9691405|FG000|Overall Study|Withdrawal by Subject|3
6083083|NCT00633880|9691423|FG000|Open Label Titration|Lack of Efficacy|1
6083084|NCT00633880|9691424|FG001|Open Label Titration|Lack of Efficacy|0
6083085|NCT00633880|9691425|FG002|Open Label Titration|Lack of Efficacy|0
6083086|NCT00633880|9691423|FG000|Open Label Titration|Adverse Event|13
6083087|NCT00633880|9691424|FG001|Open Label Titration|Adverse Event|0
6083088|NCT00633880|9691425|FG002|Open Label Titration|Adverse Event|0
6083089|NCT00633880|9691423|FG000|Open Label Titration|Treatment Failure|55
6083090|NCT00633880|9691424|FG001|Open Label Titration|Treatment Failure|0
6083091|NCT00633880|9691425|FG002|Open Label Titration|Treatment Failure|0
6083092|NCT00633880|9691423|FG000|Open Label Titration|Protocol Violation|6
6083093|NCT00633880|9691424|FG001|Open Label Titration|Protocol Violation|0
6083094|NCT00633880|9691425|FG002|Open Label Titration|Protocol Violation|0
6083095|NCT00633880|9691423|FG000|Open Label Titration|Physician Decision|1
6042886|NCT00385736|9641357|FG001|Safety Analysis Set|Adverse Event|15
6042887|NCT00385736|9641358|FG002|Safety Analysis Set|Adverse Event|23
6042888|NCT00385736|9641356|FG000|Safety Analysis Set|Withdrawal by Subject|6
6042889|NCT00385736|9641357|FG001|Safety Analysis Set|Withdrawal by Subject|6
6042890|NCT00385736|9641358|FG002|Safety Analysis Set|Withdrawal by Subject|14
6083096|NCT00633880|9691424|FG001|Open Label Titration|Physician Decision|0
6083097|NCT00633880|9691425|FG002|Open Label Titration|Physician Decision|0
6083098|NCT00633880|9691423|FG000|Open Label Titration|Withdrawal by Subject|4
6083099|NCT00633880|9691424|FG001|Open Label Titration|Withdrawal by Subject|0
6083100|NCT00633880|9691425|FG002|Open Label Titration|Withdrawal by Subject|0
6083101|NCT00633893|9691435|FG000|Overall Study|Death|1
6042891|NCT00385736|9641356|FG000|Safety Analysis Set|Lost to Follow-up|0
6042892|NCT00385736|9641357|FG001|Safety Analysis Set|Lost to Follow-up|2
6042893|NCT00385736|9641358|FG002|Safety Analysis Set|Lost to Follow-up|2
6042894|NCT00385736|9641356|FG000|Safety Analysis Set|Lack of Efficacy|38
6042895|NCT00385736|9641357|FG001|Safety Analysis Set|Lack of Efficacy|16
6042896|NCT00385736|9641358|FG002|Safety Analysis Set|Lack of Efficacy|31
6083102|NCT00633893|9691436|FG001|Overall Study|Death|3
6083103|NCT00633893|9691437|FG002|Overall Study|Death|9
6083104|NCT00633893|9691435|FG000|Overall Study|Adverse Event|65
6083105|NCT00633893|9691436|FG001|Overall Study|Adverse Event|58
6083106|NCT00633893|9691437|FG002|Overall Study|Adverse Event|126
6083107|NCT00633893|9691435|FG000|Overall Study|Withdrawal by Subject|7
6083108|NCT00633893|9691436|FG001|Overall Study|Withdrawal by Subject|12
6083109|NCT00633893|9691437|FG002|Overall Study|Withdrawal by Subject|6
6083110|NCT00633893|9691435|FG000|Overall Study|Lost to Follow-up|2
6083111|NCT00633893|9691436|FG001|Overall Study|Lost to Follow-up|4
6083112|NCT00633893|9691437|FG002|Overall Study|Lost to Follow-up|8
6083113|NCT00633893|9691435|FG000|Overall Study|Poor/non-compliance|5
6083114|NCT00633893|9691436|FG001|Overall Study|Poor/non-compliance|12
6083115|NCT00633893|9691437|FG002|Overall Study|Poor/non-compliance|3
6083116|NCT00633893|9691435|FG000|Overall Study|Pregnancy|2
6042897|NCT00385736|9641356|FG000|Safety Analysis Set|Protocol Violation|2
6083117|NCT00633893|9691436|FG001|Overall Study|Pregnancy|1
6083118|NCT00633893|9691437|FG002|Overall Study|Pregnancy|1
6083119|NCT00633893|9691435|FG000|Overall Study|Not meet/no longer meets criteria|4
6083120|NCT00633893|9691436|FG001|Overall Study|Not meet/no longer meets criteria|6
6083121|NCT00633893|9691437|FG002|Overall Study|Not meet/no longer meets criteria|4
6083122|NCT00633893|9691435|FG000|Overall Study|Other|28
6083123|NCT00633893|9691436|FG001|Overall Study|Other|33
6083124|NCT00633893|9691437|FG002|Overall Study|Other|31
6083125|NCT00633932|9691457|FG000|Overall Study|Adverse Event|1
6083126|NCT00633932|9691458|FG001|Overall Study|Adverse Event|3
6083127|NCT00633932|9691459|FG002|Overall Study|Adverse Event|4
6083128|NCT00633932|9691457|FG000|Overall Study|Withdrawal by Subject|3
6083129|NCT00633932|9691458|FG001|Overall Study|Withdrawal by Subject|9
6083130|NCT00633932|9691459|FG002|Overall Study|Withdrawal by Subject|1
6083131|NCT00633932|9691457|FG000|Overall Study|Lost to Follow-up|1
6083132|NCT00633932|9691458|FG001|Overall Study|Lost to Follow-up|0
6083133|NCT00633932|9691459|FG002|Overall Study|Lost to Follow-up|2
6083134|NCT00633932|9691457|FG000|Overall Study|Protocol Violation|5
6083135|NCT00633932|9691458|FG001|Overall Study|Protocol Violation|2
6083136|NCT00633932|9691459|FG002|Overall Study|Protocol Violation|3
6083137|NCT00633932|9691457|FG000|Overall Study|Physician Decision|0
6083138|NCT00633932|9691458|FG001|Overall Study|Physician Decision|0
6083139|NCT00633932|9691459|FG002|Overall Study|Physician Decision|1
6083140|NCT00633932|9691457|FG000|Overall Study|Doctor's judgement|1
6083141|NCT00633932|9691458|FG001|Overall Study|Doctor's judgement|0
6083142|NCT00633932|9691459|FG002|Overall Study|Doctor's judgement|0
6083143|NCT00633932|9691457|FG000|Overall Study|Moved Away|1
6083144|NCT00633932|9691458|FG001|Overall Study|Moved Away|0
6083145|NCT00633932|9691459|FG002|Overall Study|Moved Away|0
6083146|NCT00633945|9691467|FG000|Overall Study|Physician Decision|2
6083147|NCT00633984|9691475|FG000|Overall Study|Lost to Follow-up|0
6083148|NCT00633984|9691476|FG001|Overall Study|Lost to Follow-up|6
6083149|NCT00633984|9691475|FG000|Overall Study|Withdrawal by Subject|8
6083150|NCT00633984|9691476|FG001|Overall Study|Withdrawal by Subject|7
6083151|NCT00633984|9691475|FG000|Overall Study|Hospitalized|1
6083152|NCT00633984|9691476|FG001|Overall Study|Hospitalized|0
6083153|NCT00634036|9691484|FG000|Overall Study|Lost to Follow-up|1
6083154|NCT00634036|9691485|FG001|Overall Study|Lost to Follow-up|1
6083155|NCT00634036|9691484|FG000|Overall Study|Withdrawal by Subject|1
6083156|NCT00634036|9691485|FG001|Overall Study|Withdrawal by Subject|1
6083157|NCT00634049|9691491|FG000|Overall Study|Never received study drug|1
6083158|NCT00634049|9691491|FG000|Overall Study|Died prior to receiving study drug|1
6083159|NCT00634049|9691491|FG000|Overall Study|Screening failure|1
6083160|NCT00634088|9691528|FG000|Time Period 1: Dose Level 1|Disease progression|2
6083161|NCT00634088|9691529|FG001|Time Period 1: Dose Level 1|Disease progression|0
6083162|NCT00634088|9691530|FG002|Time Period 1: Dose Level 1|Disease progression|0
6083163|NCT00634088|9691531|FG003|Time Period 1: Dose Level 1|Disease progression|0
6083164|NCT00634088|9691528|FG000|Time Period 1: Dose Level 1|Physician Decision|1
6083165|NCT00634088|9691529|FG001|Time Period 1: Dose Level 1|Physician Decision|0
6083166|NCT00634088|9691530|FG002|Time Period 1: Dose Level 1|Physician Decision|0
6083167|NCT00634088|9691531|FG003|Time Period 1: Dose Level 1|Physician Decision|0
6083168|NCT00634088|9691528|FG000|Time Period 1: Dose Level 1|Adverse Event|3
6083169|NCT00634088|9691529|FG001|Time Period 1: Dose Level 1|Adverse Event|0
6083170|NCT00634088|9691530|FG002|Time Period 1: Dose Level 1|Adverse Event|0
6083171|NCT00634088|9691531|FG003|Time Period 1: Dose Level 1|Adverse Event|0
6083172|NCT00634088|9691528|FG000|Time Period 2: Dose Level 2|Adverse Event|0
6083173|NCT00634088|9691529|FG001|Time Period 2: Dose Level 2|Adverse Event|2
6083174|NCT00634088|9691530|FG002|Time Period 2: Dose Level 2|Adverse Event|0
6083175|NCT00634088|9691531|FG003|Time Period 2: Dose Level 2|Adverse Event|0
6083176|NCT00634088|9691528|FG000|Time Period 2: Dose Level 2|Progressive disease|0
6083177|NCT00634088|9691529|FG001|Time Period 2: Dose Level 2|Progressive disease|1
6083178|NCT00634088|9691530|FG002|Time Period 2: Dose Level 2|Progressive disease|0
6083179|NCT00634088|9691531|FG003|Time Period 2: Dose Level 2|Progressive disease|0
6083180|NCT00634088|9691528|FG000|Time Period 3: Dose Level 3|Progressive disease|0
6083181|NCT00634088|9691529|FG001|Time Period 3: Dose Level 3|Progressive disease|0
6083182|NCT00634088|9691530|FG002|Time Period 3: Dose Level 3|Progressive disease|1
6083183|NCT00634088|9691531|FG003|Time Period 3: Dose Level 3|Progressive disease|0
6168542|NCT01236352|9813648|FG001|Overall Study|Maximum clinical benefit|1
6083184|NCT00634101|9691543|FG000|Overall Study|Study Terminated|3
6083185|NCT00634101|9691544|FG001|Overall Study|Study Terminated|3
6083186|NCT00634101|9691543|FG000|Overall Study|Lost to Follow-up|2
6083187|NCT00634101|9691544|FG001|Overall Study|Lost to Follow-up|0
6083188|NCT00634114|9691553|FG000|Overall Study|Adverse Event|6
6083189|NCT00634114|9691554|FG001|Overall Study|Adverse Event|8
6083190|NCT00634114|9691555|FG002|Overall Study|Adverse Event|3
6083191|NCT00634114|9691553|FG000|Overall Study|Withdrawal by Subject|9
6083192|NCT00634114|9691554|FG001|Overall Study|Withdrawal by Subject|6
6083193|NCT00634114|9691555|FG002|Overall Study|Withdrawal by Subject|11
6083194|NCT00634114|9691553|FG000|Overall Study|Lost to Follow-up|0
6083195|NCT00634114|9691554|FG001|Overall Study|Lost to Follow-up|0
6083196|NCT00634114|9691555|FG002|Overall Study|Lost to Follow-up|1
6083197|NCT00634114|9691553|FG000|Overall Study|Protocol Violation|3
6083198|NCT00634114|9691554|FG001|Overall Study|Protocol Violation|3
6083199|NCT00634114|9691555|FG002|Overall Study|Protocol Violation|1
6083200|NCT00634114|9691553|FG000|Overall Study|Pregnancy|1
6083201|NCT00634114|9691554|FG001|Overall Study|Pregnancy|0
6168543|NCT01236352|9813649|FG002|Overall Study|Maximum clinical benefit|1
6083202|NCT00634114|9691555|FG002|Overall Study|Pregnancy|0
6083203|NCT00634114|9691553|FG000|Overall Study|Incorrect enrolment|0
6083204|NCT00634114|9691554|FG001|Overall Study|Incorrect enrolment|1
6083205|NCT00634114|9691555|FG002|Overall Study|Incorrect enrolment|0
6083206|NCT00634114|9691553|FG000|Overall Study|Recurrence of reflux esophagitis|5
6083207|NCT00634114|9691554|FG001|Overall Study|Recurrence of reflux esophagitis|15
6083208|NCT00634114|9691555|FG002|Overall Study|Recurrence of reflux esophagitis|21
6083209|NCT00634114|9691553|FG000|Overall Study|Difficult to continue|3
6083210|NCT00634114|9691554|FG001|Overall Study|Difficult to continue|1
6083211|NCT00634114|9691555|FG002|Overall Study|Difficult to continue|1
6083212|NCT00634114|9691553|FG000|Overall Study|Other reason|1
6337348|NCT00920816|10089250|FG001|Overall Study|Data not disclosed due to lack of HGRAC filings|8
6337349|NCT00920816|10089251|FG002|Overall Study|Data not disclosed due to lack of HGRAC filings|124
6337350|NCT00920816|10089252|FG003|Overall Study|Data not disclosed due to lack of HGRAC filings|64
6337351|NCT00920816|10089249|FG000|Overall Study|Randomized but not treated|3
6337352|NCT00920816|10089250|FG001|Overall Study|Randomized but not treated|0
6337353|NCT00920816|10089251|FG002|Overall Study|Randomized but not treated|0
6337354|NCT00920816|10089252|FG003|Overall Study|Randomized but not treated|0
6083213|NCT00634114|9691554|FG001|Overall Study|Other reason|1
6083214|NCT00634114|9691555|FG002|Overall Study|Other reason|1
6083215|NCT00634179|9691572|FG000|Phase II: Maintenance|Diagnosis changed after re-review|1
6337355|NCT00565851|10089270|FG000|Chemotherapy Assignment|Never Initiated Chemotherapy|9
6337356|NCT00565851|10089271|FG001|Chemotherapy Assignment|Never Initiated Chemotherapy|9
6337357|NCT00565851|10089272|FG002|Chemotherapy Assignment|Never Initiated Chemotherapy|3
6337358|NCT00565851|10089273|FG003|Chemotherapy Assignment|Never Initiated Chemotherapy|18
6337359|NCT00565851|10089274|FG004|Chemotherapy Assignment|Never Initiated Chemotherapy|0
6337360|NCT00565851|10089275|FG005|Chemotherapy Assignment|Never Initiated Chemotherapy|2
6337361|NCT00565851|10089276|FG006|Chemotherapy Assignment|Never Initiated Chemotherapy|0
6337362|NCT00565851|10089277|FG007|Chemotherapy Assignment|Never Initiated Chemotherapy|2
6337363|NCT00565851|10089270|FG000|Chemotherapy Assignment|Still On Chemotherapy|0
6337364|NCT00565851|10089271|FG001|Chemotherapy Assignment|Still On Chemotherapy|14
6337365|NCT00565851|10089272|FG002|Chemotherapy Assignment|Still On Chemotherapy|0
6337366|NCT00565851|10089273|FG003|Chemotherapy Assignment|Still On Chemotherapy|18
6337367|NCT00565851|10089274|FG004|Chemotherapy Assignment|Still On Chemotherapy|0
6337368|NCT00565851|10089275|FG005|Chemotherapy Assignment|Still On Chemotherapy|1
6337369|NCT00565851|10089276|FG006|Chemotherapy Assignment|Still On Chemotherapy|0
6337370|NCT00565851|10089277|FG007|Chemotherapy Assignment|Still On Chemotherapy|1
6337371|NCT00376623|10089302|FG000|Overall Study|Progressive disease|35
6337372|NCT00376623|10089303|FG001|Overall Study|Progressive disease|22
6337373|NCT00376623|10089304|FG002|Overall Study|Progressive disease|17
6337374|NCT00376623|10089302|FG000|Overall Study|Lost to Follow-up|0
6337375|NCT00376623|10089303|FG001|Overall Study|Lost to Follow-up|1
6337376|NCT00376623|10089304|FG002|Overall Study|Lost to Follow-up|0
6337377|NCT00376623|10089302|FG000|Overall Study|Adverse Event other than Dose Limiting Toxicity|6
6337378|NCT00376623|10089303|FG001|Overall Study|Adverse Event other than Dose Limiting Toxicity|1
6337379|NCT00376623|10089304|FG002|Overall Study|Adverse Event other than Dose Limiting Toxicity|2
6337380|NCT00376623|10089302|FG000|Overall Study|Not treated with BI 2536|1
6337381|NCT00376623|10089303|FG001|Overall Study|Not treated with BI 2536|0
6337382|NCT00376623|10089304|FG002|Overall Study|Not treated with BI 2536|0
6337383|NCT00376623|10089302|FG000|Overall Study|Investigator's and participant's decision to stop treatment with BI 2536 after 6 cycles|1
6337384|NCT00376623|10089303|FG001|Overall Study|Investigator's and participant's decision to stop treatment with BI 2536 after 6 cycles|0
6337385|NCT00376623|10089304|FG002|Overall Study|Investigator's and participant's decision to stop treatment with BI 2536 after 6 cycles|0
6337386|NCT00376623|10089302|FG000|Overall Study|Investigator's and participant's decision to stop treatment with BI 2536|1
6337387|NCT00376623|10089303|FG001|Overall Study|Investigator's and participant's decision to stop treatment with BI 2536|0
6337388|NCT00376623|10089304|FG002|Overall Study|Investigator's and participant's decision to stop treatment with BI 2536|0
6337389|NCT00376623|10089302|FG000|Overall Study|Investigator's decision to stop treatment with BI 2536 after 6 cycles|2
6337390|NCT00376623|10089303|FG001|Overall Study|Investigator's decision to stop treatment with BI 2536 after 6 cycles|0
6337391|NCT00376623|10089304|FG002|Overall Study|Investigator's decision to stop treatment with BI 2536 after 6 cycles|0
6337392|NCT00376623|10089302|FG000|Overall Study|Investigator's decision to stop treatment with BI 2536|0
6337393|NCT00376623|10089303|FG001|Overall Study|Investigator's decision to stop treatment with BI 2536|1
6337394|NCT00376623|10089304|FG002|Overall Study|Investigator's decision to stop treatment with BI 2536|0
6337395|NCT00376623|10089302|FG000|Overall Study|Participant's decision to stop treatment with BI 2536 after 6 cycles|0
6337396|NCT00376623|10089303|FG001|Overall Study|Participant's decision to stop treatment with BI 2536 after 6 cycles|0
6337397|NCT00376623|10089304|FG002|Overall Study|Participant's decision to stop treatment with BI 2536 after 6 cycles|1
6337398|NCT00376623|10089302|FG000|Overall Study|Participant's decision to stop treatment with BI 2536|2
6337399|NCT00376623|10089303|FG001|Overall Study|Participant's decision to stop treatment with BI 2536|0
6337400|NCT00376623|10089304|FG002|Overall Study|Participant's decision to stop treatment with BI 2536|1
6337401|NCT00376623|10089302|FG000|Overall Study|Increase of tumour markers|0
6337402|NCT00376623|10089303|FG001|Overall Study|Increase of tumour markers|1
6337403|NCT00376623|10089304|FG002|Overall Study|Increase of tumour markers|0
6337404|NCT00376623|10089302|FG000|Overall Study|Bone metastasis|1
6337405|NCT00376623|10089303|FG001|Overall Study|Bone metastasis|0
6337406|NCT00376623|10089304|FG002|Overall Study|Bone metastasis|0
6337407|NCT03180645|10089321|FG000|Overall Study|Adverse Event|0
6337408|NCT03180645|10089322|FG001|Overall Study|Adverse Event|1
6337409|NCT03180645|10089323|FG002|Overall Study|Adverse Event|2
6337410|NCT03180801|10089338|FG000|Overall Study|Physician Decision|3
6337411|NCT03180801|10089339|FG001|Overall Study|Physician Decision|3
6337412|NCT03180801|10089340|FG002|Overall Study|Physician Decision|1
6337413|NCT03180801|10089338|FG000|Overall Study|Non-compliance|1
6337414|NCT03180801|10089339|FG001|Overall Study|Non-compliance|4
6337415|NCT03180801|10089340|FG002|Overall Study|Non-compliance|0
6337416|NCT03180801|10089338|FG000|Overall Study|Inoculation Target Reached|1
6337417|NCT03180801|10089339|FG001|Overall Study|Inoculation Target Reached|1
6337418|NCT03180801|10089340|FG002|Overall Study|Inoculation Target Reached|3
6337419|NCT03180801|10089338|FG000|Overall Study|Adverse Event|1
6337420|NCT03180801|10089339|FG001|Overall Study|Adverse Event|0
6337421|NCT03180801|10089340|FG002|Overall Study|Adverse Event|2
6337422|NCT03180801|10089338|FG000|Overall Study|Withdrawal by Subject|2
6168544|NCT01236352|9813650|FG003|Overall Study|Maximum clinical benefit|0
6337423|NCT03180801|10089339|FG001|Overall Study|Withdrawal by Subject|2
6168545|NCT01236352|9813651|FG004|Overall Study|Maximum clinical benefit|2
6337424|NCT03180801|10089340|FG002|Overall Study|Withdrawal by Subject|1
6337425|NCT03180801|10089338|FG000|Overall Study|Lost to Follow-up|0
6337426|NCT03180801|10089339|FG001|Overall Study|Lost to Follow-up|2
6337427|NCT03180801|10089340|FG002|Overall Study|Lost to Follow-up|3
6337428|NCT03181451|10089372|FG000|Overall Study|Adverse Event|0
6337429|NCT03181451|10089373|FG001|Overall Study|Adverse Event|1
6337430|NCT03181451|10089374|FG002|Overall Study|Adverse Event|0
6337431|NCT03181451|10089372|FG000|Overall Study|Withdrawal by Subject|0
6337432|NCT03181451|10089373|FG001|Overall Study|Withdrawal by Subject|1
6337433|NCT03181451|10089374|FG002|Overall Study|Withdrawal by Subject|0
6337434|NCT03181503|10089386|FG000|Overall Study|Adverse Event|2
6337435|NCT03181503|10089387|FG001|Overall Study|Adverse Event|2
6337436|NCT03181503|10089386|FG000|Overall Study|Protocol Violation|1
6337437|NCT03181503|10089387|FG001|Overall Study|Protocol Violation|0
6337438|NCT03181503|10089386|FG000|Overall Study|Withdrawal by Subject|3
6337439|NCT03181503|10089387|FG001|Overall Study|Withdrawal by Subject|0
6337440|NCT03181503|10089386|FG000|Overall Study|Lost to Follow-up|1
6337441|NCT03181503|10089387|FG001|Overall Study|Lost to Follow-up|1
6337442|NCT03181594|10089396|FG000|Initial Study Protocol (12-month FU)|Lost to Follow-up|4
6337443|NCT03181594|10089396|FG000|Initial Study Protocol (12-month FU)|Withdrawal by Subject|3
6337444|NCT03181594|10089396|FG000|Initial Study Protocol (12-month FU)|Physician Decision|1
6337445|NCT03181594|10089396|FG000|Initial Study Protocol (12-month FU)|Death|1
6337446|NCT03181594|10089396|FG000|Long-term Extension (15-24 Month FU)|Lost to Follow-up|3
6337447|NCT03181594|10089396|FG000|Long-term Extension (15-24 Month FU)|Death|2
6337448|NCT03181932|10089411|FG000|Period 1 (Double-blind Period)|Adverse Event|5
6337449|NCT03181932|10089412|FG001|Period 1 (Double-blind Period)|Adverse Event|1
6337450|NCT03181932|10089411|FG000|Period 1 (Double-blind Period)|Lost to Follow-up|0
6337451|NCT03181932|10089412|FG001|Period 1 (Double-blind Period)|Lost to Follow-up|1
6337452|NCT03181932|10089411|FG000|Period 1 (Double-blind Period)|Protocol Violation|1
6337453|NCT03181932|10089412|FG001|Period 1 (Double-blind Period)|Protocol Violation|2
6337454|NCT03181932|10089411|FG000|Period 1 (Double-blind Period)|Withdrawal by Subject|5
6337455|NCT03181932|10089412|FG001|Period 1 (Double-blind Period)|Withdrawal by Subject|9
6337456|NCT03181932|10089411|FG000|Period 2 (Open-label Period)|Adverse Event|1
6337457|NCT03181932|10089412|FG001|Period 2 (Open-label Period)|Adverse Event|6
6337458|NCT03181932|10089411|FG000|Period 2 (Open-label Period)|Lost to Follow-up|0
6337459|NCT03181932|10089412|FG001|Period 2 (Open-label Period)|Lost to Follow-up|1
6337460|NCT03181932|10089411|FG000|Period 2 (Open-label Period)|Protocol Violation|3
6337461|NCT03181932|10089412|FG001|Period 2 (Open-label Period)|Protocol Violation|1
6337462|NCT03181932|10089411|FG000|Period 2 (Open-label Period)|Withdrawal by Subject|2
6337463|NCT03181932|10089412|FG001|Period 2 (Open-label Period)|Withdrawal by Subject|5
6337464|NCT03181932|10089411|FG000|Period 2 (Open-label Period)|Reason missing|2
6337465|NCT03181932|10089412|FG001|Period 2 (Open-label Period)|Reason missing|0
6337466|NCT03181958|10089422|FG000|Overall Study|Lost to Follow-up|17
6337467|NCT03181958|10089423|FG001|Overall Study|Lost to Follow-up|21
6337468|NCT03181958|10089424|FG002|Overall Study|Lost to Follow-up|15
6337469|NCT03182738|10089455|FG000|Overall Study|Lost to Follow-up|9
6337470|NCT03182738|10089456|FG001|Overall Study|Lost to Follow-up|3
6337471|NCT03182738|10089455|FG000|Overall Study|Pregnancy|0
6337472|NCT03182738|10089456|FG001|Overall Study|Pregnancy|1
6337473|NCT03182738|10089455|FG000|Overall Study|Withdrawal by Subject|0
6337474|NCT03182738|10089456|FG001|Overall Study|Withdrawal by Subject|1
6337475|NCT03183063|10089485|FG000|Overall Study|Withdrawal by Subject|2
6337476|NCT03183063|10089486|FG001|Overall Study|Withdrawal by Subject|0
6337477|NCT03183063|10089487|FG002|Overall Study|Withdrawal by Subject|0
6337478|NCT03183063|10089485|FG000|Overall Study|Physician Decision|3
6337479|NCT03183063|10089486|FG001|Overall Study|Physician Decision|4
6337480|NCT03183063|10089487|FG002|Overall Study|Physician Decision|4
6337481|NCT03183518|10089501|FG000|Overall Study|Other (Not specified)|2
6337482|NCT03183518|10089501|FG000|Overall Study|Other (Withdrawal of consent)|1
6337483|NCT03183908|10089517|FG000|Overall Study|Missing Symptom Diary Data|0
6337484|NCT03183908|10089518|FG001|Overall Study|Missing Symptom Diary Data|2
6337485|NCT03184077|10089530|FG000|Overall Study|Lost to Follow-up|21
6337486|NCT03184077|10089531|FG001|Overall Study|Lost to Follow-up|21
6337487|NCT03184441|10089553|FG000|Overall Study|Withdrawal by Subject|1
6337488|NCT03184519|10089560|FG000|Overall Study|Lost to Follow-up|6
6337489|NCT03184519|10089560|FG000|Overall Study|Physician Decision|21
6337490|NCT03184558|10089564|FG000|Overall Study|Withdrawal by Subject|2
6337491|NCT03184558|10089564|FG000|Overall Study|Death|16
6337492|NCT03184558|10089564|FG000|Overall Study|Lost to Follow-up|2
5972106|NCT00950989|9557712|FG003|Overall Study|Withdrawal by Subject|0
6337493|NCT03184558|10089564|FG000|Overall Study|Other|9
6337494|NCT03184701|10089568|FG000|Overall Study|Death|3
6337495|NCT03184701|10089568|FG000|Overall Study|Physician Decision|3
6337496|NCT03184701|10089568|FG000|Overall Study|Withdrawal by Subject|6
6337497|NCT03184701|10089568|FG000|Overall Study|Lost to Follow-up|5
6337498|NCT03184987|10089575|FG000|Overall Study|Withdrawal by Subject|0
6337499|NCT03184987|10089576|FG001|Overall Study|Withdrawal by Subject|1
6337500|NCT03184987|10089577|FG002|Overall Study|Withdrawal by Subject|2
6337501|NCT03184987|10089575|FG000|Overall Study|Physician Decision|0
6337502|NCT03184987|10089576|FG001|Overall Study|Physician Decision|0
6337503|NCT03184987|10089577|FG002|Overall Study|Physician Decision|1
6337504|NCT03184987|10089575|FG000|Overall Study|Adverse Event|1
6337505|NCT03184987|10089576|FG001|Overall Study|Adverse Event|0
6337506|NCT03184987|10089577|FG002|Overall Study|Adverse Event|1
6337507|NCT03185481|10089617|FG000|Overall Study|Adverse Event|1
6337508|NCT03185481|10089617|FG000|Overall Study|Study Terminated by Sponsor|4
6337509|NCT03186378|10089666|FG000|Overall Study|Lost to Follow-up|1
6337510|NCT03186378|10089667|FG001|Overall Study|Lost to Follow-up|0
6337511|NCT03186781|10089700|FG000|Overall Study|Lost to Follow-up|0
6337512|NCT03186781|10089701|FG001|Overall Study|Lost to Follow-up|0
6337513|NCT03186781|10089702|FG002|Overall Study|Lost to Follow-up|1
6337514|NCT03186781|10089703|FG003|Overall Study|Lost to Follow-up|0
6337515|NCT03186781|10089704|FG004|Overall Study|Lost to Follow-up|1
6337516|NCT03186781|10089705|FG005|Overall Study|Lost to Follow-up|0
6337517|NCT03186781|10089700|FG000|Overall Study|Moved from Area|0
6337518|NCT03186781|10089701|FG001|Overall Study|Moved from Area|0
6337519|NCT03186781|10089702|FG002|Overall Study|Moved from Area|0
6337520|NCT03186781|10089703|FG003|Overall Study|Moved from Area|0
6337521|NCT03186781|10089704|FG004|Overall Study|Moved from Area|1
6337522|NCT03186781|10089705|FG005|Overall Study|Moved from Area|0
6337523|NCT03186781|10089700|FG000|Overall Study|Withdrawal by Subject|0
6337524|NCT03186781|10089701|FG001|Overall Study|Withdrawal by Subject|0
6337525|NCT03186781|10089702|FG002|Overall Study|Withdrawal by Subject|0
6337526|NCT03186781|10089703|FG003|Overall Study|Withdrawal by Subject|0
6337527|NCT03186781|10089704|FG004|Overall Study|Withdrawal by Subject|1
6337528|NCT03186781|10089705|FG005|Overall Study|Withdrawal by Subject|0
6337529|NCT03187132|10089743|FG000|Inpatient Trauma Only|Lost to Follow-up|3
6337530|NCT03187132|10089744|FG001|Inpatient Trauma Only|Lost to Follow-up|12
6337531|NCT03187132|10089743|FG000|Inpatient Trauma Only|socioeconomic burden|1
6337532|NCT03187132|10089744|FG001|Inpatient Trauma Only|socioeconomic burden|0
6337533|NCT03187132|10089743|FG000|Inpatient Trauma+Pain Clinic, no Opioid|Lost to Follow-up|0
6337534|NCT03187132|10089744|FG001|Inpatient Trauma+Pain Clinic, no Opioid|Lost to Follow-up|5
6337535|NCT03187132|10089743|FG000|Inpatient Trauma+Pain Clinic, no Opioid|Disease burden|1
6337536|NCT03187132|10089744|FG001|Inpatient Trauma+Pain Clinic, no Opioid|Disease burden|0
6337537|NCT03187132|10089743|FG000|Inpatient Trauma+Pain Clinic|Lost to Follow-up|2
6337538|NCT03187132|10089744|FG001|Inpatient Trauma+Pain Clinic|Lost to Follow-up|5
6337539|NCT03187132|10089743|FG000|Inpatient Trauma+Pain Clinic|Disease burden|1
6337540|NCT03187132|10089744|FG001|Inpatient Trauma+Pain Clinic|Disease burden|0
6337541|NCT03187132|10089743|FG000|Inpatient Trauma+Pain Clinic|Unhappy with allocation|0
6337542|NCT03187132|10089744|FG001|Inpatient Trauma+Pain Clinic|Unhappy with allocation|2
6337543|NCT03187132|10089743|FG000|Pain Clinic Only, Fully Remote|Lost to Follow-up|27
6337544|NCT03187132|10089744|FG001|Pain Clinic Only, Fully Remote|Lost to Follow-up|47
6337545|NCT03187132|10089743|FG000|Pain Clinic Only, Fully Remote|Disease burden|6
6337546|NCT03187132|10089744|FG001|Pain Clinic Only, Fully Remote|Disease burden|5
6337547|NCT03187132|10089743|FG000|Pain Clinic Only, Fully Remote|Language barrier|0
6337548|NCT03187132|10089744|FG001|Pain Clinic Only, Fully Remote|Language barrier|1
6337549|NCT03187132|10089743|FG000|Pain Clinic Only, Fully Remote|EMR|0
6337550|NCT03187132|10089744|FG001|Pain Clinic Only, Fully Remote|EMR|1
6337551|NCT03187197|10089753|FG000|Overall Study|Stopped Pradaxa®/VKA|11
6337552|NCT03187197|10089754|FG001|Overall Study|Stopped Pradaxa®/VKA|65
6337553|NCT03187197|10089755|FG002|Overall Study|Stopped Pradaxa®/VKA|4
6337554|NCT03187197|10089753|FG000|Overall Study|Withdrawal by Subject|8
6337555|NCT03187197|10089754|FG001|Overall Study|Withdrawal by Subject|63
6337556|NCT03187197|10089755|FG002|Overall Study|Withdrawal by Subject|4
6337557|NCT03187197|10089753|FG000|Overall Study|Lost to Follow-up|1
6337558|NCT03187197|10089754|FG001|Overall Study|Lost to Follow-up|60
6337559|NCT03187197|10089755|FG002|Overall Study|Lost to Follow-up|7
6337560|NCT03187197|10089753|FG000|Overall Study|Adverse Event|6
6337561|NCT03187197|10089754|FG001|Overall Study|Adverse Event|29
6337562|NCT03187197|10089755|FG002|Overall Study|Adverse Event|0
6337563|NCT03187197|10089753|FG000|Overall Study|Death|0
6337564|NCT03187197|10089754|FG001|Overall Study|Death|11
6337565|NCT03187197|10089755|FG002|Overall Study|Death|0
6337566|NCT03187197|10089753|FG000|Overall Study|Administrative problem|1
6337567|NCT03187197|10089754|FG001|Overall Study|Administrative problem|1
6337568|NCT03187197|10089755|FG002|Overall Study|Administrative problem|0
6337569|NCT03187197|10089753|FG000|Overall Study|Reason not listed|2
6337570|NCT03187197|10089754|FG001|Overall Study|Reason not listed|54
6337571|NCT03187197|10089755|FG002|Overall Study|Reason not listed|1
6337572|NCT03187197|10089753|FG000|Overall Study|Missing|1
6337573|NCT03187197|10089754|FG001|Overall Study|Missing|32
6337574|NCT03187197|10089755|FG002|Overall Study|Missing|3
6337575|NCT03187197|10089753|FG000|Overall Study|Status missing|2
6337576|NCT03187197|10089754|FG001|Overall Study|Status missing|33
6337577|NCT03187197|10089755|FG002|Overall Study|Status missing|3
6337578|NCT03187197|10089753|FG000|Overall Study|NA in incl/excl criteria, not analyzed.|14
6337579|NCT03187197|10089754|FG001|Overall Study|NA in incl/excl criteria, not analyzed.|45
6337580|NCT03187197|10089755|FG002|Overall Study|NA in incl/excl criteria, not analyzed.|1
6337581|NCT03187301|10089763|FG000|Titration Period|Adverse Event|0
6337582|NCT03187301|10089764|FG001|Titration Period|Adverse Event|0
6337583|NCT03187301|10089765|FG002|Titration Period|Adverse Event|0
6337584|NCT03187301|10089766|FG003|Titration Period|Adverse Event|0
6337585|NCT03187301|10089767|FG004|Titration Period|Adverse Event|0
6337586|NCT03187301|10089768|FG005|Titration Period|Adverse Event|0
6337587|NCT03187301|10089769|FG006|Titration Period|Adverse Event|5
6337588|NCT03187301|10089763|FG000|Titration Period|Withdrawal by Subject|0
6337589|NCT03187301|10089764|FG001|Titration Period|Withdrawal by Subject|0
6337590|NCT03187301|10089765|FG002|Titration Period|Withdrawal by Subject|0
6337591|NCT03187301|10089766|FG003|Titration Period|Withdrawal by Subject|0
6337592|NCT03187301|10089767|FG004|Titration Period|Withdrawal by Subject|0
6337593|NCT03187301|10089768|FG005|Titration Period|Withdrawal by Subject|0
6337594|NCT03187301|10089769|FG006|Titration Period|Withdrawal by Subject|1
6337595|NCT03187301|10089763|FG000|Titration Period|Exclusion Criteria Met|0
6337596|NCT03187301|10089764|FG001|Titration Period|Exclusion Criteria Met|0
6337597|NCT03187301|10089765|FG002|Titration Period|Exclusion Criteria Met|0
6337598|NCT03187301|10089766|FG003|Titration Period|Exclusion Criteria Met|0
6337599|NCT03187301|10089767|FG004|Titration Period|Exclusion Criteria Met|0
6337600|NCT03187301|10089768|FG005|Titration Period|Exclusion Criteria Met|0
6337601|NCT03187301|10089769|FG006|Titration Period|Exclusion Criteria Met|1
6337602|NCT03187301|10089763|FG000|Pre-Intervention|Withdrawal by Subject|1
6337603|NCT03187301|10089764|FG001|Pre-Intervention|Withdrawal by Subject|0
6337604|NCT03187301|10089765|FG002|Pre-Intervention|Withdrawal by Subject|0
6337605|NCT03187301|10089766|FG003|Pre-Intervention|Withdrawal by Subject|0
6337606|NCT03187301|10089767|FG004|Pre-Intervention|Withdrawal by Subject|0
6337607|NCT03187301|10089768|FG005|Pre-Intervention|Withdrawal by Subject|0
6337608|NCT03187301|10089769|FG006|Pre-Intervention|Withdrawal by Subject|0
6337609|NCT03187756|10089807|FG000|Overall Study|Termination of study|4
6337610|NCT03188055|10089813|FG000|Overall Study|Unavailable for training|0
6337611|NCT03188055|10089814|FG001|Overall Study|Unavailable for training|0
6337612|NCT03188055|10089815|FG002|Overall Study|Unavailable for training|19
6337613|NCT03188055|10089816|FG003|Overall Study|Unavailable for training|0
6337614|NCT03188055|10089817|FG004|Overall Study|Unavailable for training|0
6337615|NCT03188055|10089818|FG005|Overall Study|Unavailable for training|
6337616|NCT03188055|10089813|FG000|Overall Study|Lost to Follow-up|0
6337617|NCT03188055|10089814|FG001|Overall Study|Lost to Follow-up|18
6337618|NCT03188055|10089815|FG002|Overall Study|Lost to Follow-up|0
6337619|NCT03188055|10089816|FG003|Overall Study|Lost to Follow-up|11
6337620|NCT03188055|10089817|FG004|Overall Study|Lost to Follow-up|0
6337621|NCT03188055|10089818|FG005|Overall Study|Lost to Follow-up|
6337622|NCT03188055|10089813|FG000|Overall Study|Withdrawal by Subject|0
6337623|NCT03188055|10089814|FG001|Overall Study|Withdrawal by Subject|1
6337624|NCT03188055|10089815|FG002|Overall Study|Withdrawal by Subject|0
6337625|NCT03188055|10089816|FG003|Overall Study|Withdrawal by Subject|1
6337626|NCT03188055|10089817|FG004|Overall Study|Withdrawal by Subject|0
6337627|NCT03188055|10089818|FG005|Overall Study|Withdrawal by Subject|
6337628|NCT03188120|10089829|FG000|Overall Study|Adverse Event|4
6337629|NCT03188120|10089829|FG000|Overall Study|Insufficient Effectiveness|8
6337630|NCT03188120|10089829|FG000|Overall Study|Improved|12
6337631|NCT03188120|10089829|FG000|Overall Study|Lost to Follow-up|7
6337632|NCT03188120|10089829|FG000|Overall Study|Other than specified|3
6337633|NCT03188120|10089829|FG000|Overall Study|No visit after the first visit|13
6337634|NCT03188185|10089835|FG000|Stage 1|Adverse Event|4
6337635|NCT03188185|10089836|FG001|Stage 1|Adverse Event|12
6337636|NCT03188185|10089837|FG002|Stage 1|Adverse Event|0
6337637|NCT03188185|10089838|FG003|Stage 1|Adverse Event|0
6337638|NCT03188185|10089835|FG000|Stage 1|Lack of Efficacy|0
6337639|NCT03188185|10089836|FG001|Stage 1|Lack of Efficacy|2
6337640|NCT03188185|10089837|FG002|Stage 1|Lack of Efficacy|0
6337641|NCT03188185|10089838|FG003|Stage 1|Lack of Efficacy|0
6337642|NCT03188185|10089835|FG000|Stage 1|Lost to Follow-up|6
6337643|NCT03188185|10089836|FG001|Stage 1|Lost to Follow-up|1
6337644|NCT03188185|10089837|FG002|Stage 1|Lost to Follow-up|0
6337645|NCT03188185|10089838|FG003|Stage 1|Lost to Follow-up|0
6337646|NCT03188185|10089835|FG000|Stage 1|Withdrawal by Subject|9
6337647|NCT03188185|10089836|FG001|Stage 1|Withdrawal by Subject|0
6337648|NCT03188185|10089837|FG002|Stage 1|Withdrawal by Subject|0
6337649|NCT03188185|10089838|FG003|Stage 1|Withdrawal by Subject|0
6337650|NCT03188185|10089835|FG000|Stage 1|Identified as a professional patient|0
6337651|NCT03188185|10089836|FG001|Stage 1|Identified as a professional patient|1
6337652|NCT03188185|10089837|FG002|Stage 1|Identified as a professional patient|0
6337653|NCT03188185|10089838|FG003|Stage 1|Identified as a professional patient|0
6337654|NCT03188185|10089835|FG000|Stage 2|Adverse Event|0
6337655|NCT03188185|10089836|FG001|Stage 2|Adverse Event|0
6337656|NCT03188185|10089837|FG002|Stage 2|Adverse Event|2
6337657|NCT03188185|10089838|FG003|Stage 2|Adverse Event|4
6337658|NCT03188185|10089835|FG000|Stage 2|Lack of Efficacy|0
6337659|NCT03188185|10089836|FG001|Stage 2|Lack of Efficacy|0
6337660|NCT03188185|10089837|FG002|Stage 2|Lack of Efficacy|3
6337661|NCT03188185|10089838|FG003|Stage 2|Lack of Efficacy|0
6337662|NCT03188185|10089835|FG000|Stage 2|Lost to Follow-up|0
6337663|NCT03188185|10089836|FG001|Stage 2|Lost to Follow-up|0
6337664|NCT03188185|10089837|FG002|Stage 2|Lost to Follow-up|1
6337665|NCT03188185|10089838|FG003|Stage 2|Lost to Follow-up|0
6337666|NCT03188185|10089835|FG000|Stage 2|Physician Decision|0
6337667|NCT03188185|10089836|FG001|Stage 2|Physician Decision|0
6337668|NCT03188185|10089837|FG002|Stage 2|Physician Decision|0
6337669|NCT03188185|10089838|FG003|Stage 2|Physician Decision|1
6337670|NCT03188185|10089835|FG000|Stage 2|Withdrawal by Subject|0
6337671|NCT03188185|10089836|FG001|Stage 2|Withdrawal by Subject|0
6337672|NCT03188185|10089837|FG002|Stage 2|Withdrawal by Subject|3
6337673|NCT03188185|10089838|FG003|Stage 2|Withdrawal by Subject|1
6337674|NCT03188263|10089850|FG000|Overall Study|Withdrawal by Subject|3
6337675|NCT03188263|10089851|FG001|Overall Study|Withdrawal by Subject|0
6337676|NCT03188263|10089850|FG000|Overall Study|Physician Decision|1
6337677|NCT03188263|10089851|FG001|Overall Study|Physician Decision|0
6337678|NCT03188536|10089868|FG000|Overall Study|No relapse/refractoriness(last 6 months)|5
6337679|NCT03188536|10089868|FG000|Overall Study|Not participated/met inclusion criteria|1
6337680|NCT03188718|10089872|FG000|Overall Study|Participant noncompliance|4
6337681|NCT03188718|10089872|FG000|Overall Study|Withdrawal by Subject|1
6337682|NCT03188718|10089872|FG000|Overall Study|Device failure|3
6337683|NCT03188991|10089880|FG000|Overall Study|Withdrawal by Subject|0
6337684|NCT03188991|10089881|FG001|Overall Study|Withdrawal by Subject|0
6337685|NCT03188991|10089882|FG002|Overall Study|Withdrawal by Subject|0
6337686|NCT03188991|10089883|FG003|Overall Study|Withdrawal by Subject|1
6337687|NCT03189446|10089897|FG000|Overall Study|Adverse Event|2
6337688|NCT03189446|10089897|FG000|Overall Study|Withdrawal by Subject|2
6337689|NCT03189446|10089897|FG000|Overall Study|Physician Decision|1
6337690|NCT03189524|10089904|FG000|Overall Study|Study terminated by Sponsor after final analysis and all remaining participants transferred to LTE|7
6337691|NCT03189524|10089905|FG001|Overall Study|Study terminated by Sponsor after final analysis and all remaining participants transferred to LTE|5
6337692|NCT03189524|10089906|FG002|Overall Study|Study terminated by Sponsor after final analysis and all remaining participants transferred to LTE|11
6337693|NCT03189524|10089904|FG000|Overall Study|Death|2
6337694|NCT03189524|10089905|FG001|Overall Study|Death|2
6337695|NCT03189524|10089906|FG002|Overall Study|Death|1
6337696|NCT03189524|10089904|FG000|Overall Study|Lost to Follow-up|1
6337697|NCT03189524|10089905|FG001|Overall Study|Lost to Follow-up|0
6337698|NCT03189524|10089906|FG002|Overall Study|Lost to Follow-up|8
6337699|NCT03189524|10089904|FG000|Overall Study|Withdrawal by Subject|1
6337700|NCT03189524|10089905|FG001|Overall Study|Withdrawal by Subject|1
6337701|NCT03189524|10089906|FG002|Overall Study|Withdrawal by Subject|3
6337702|NCT03189524|10089904|FG000|Overall Study|Progressive Disease|0
6337703|NCT03189524|10089905|FG001|Overall Study|Progressive Disease|2
6337704|NCT03189524|10089906|FG002|Overall Study|Progressive Disease|0
6337705|NCT03189745|10089929|FG000|Overall Study|Conflict in work schedule of participant|1
6337706|NCT03189745|10089930|FG001|Overall Study|Conflict in work schedule of participant|1
6337707|NCT03191396|10089993|FG000|Overall Study|Lost to Follow-up|0
6337708|NCT03191396|10089994|FG001|Overall Study|Lost to Follow-up|3
6337709|NCT03191396|10089993|FG000|Overall Study|Withdrawal by Subject|3
6337710|NCT03191396|10089994|FG001|Overall Study|Withdrawal by Subject|2
6337711|NCT03191552|10090003|FG000|Overall Study|Lost to Follow-up|1
6337712|NCT03191552|10090004|FG001|Overall Study|Lost to Follow-up|0
6337713|NCT03191552|10090005|FG002|Overall Study|Lost to Follow-up|0
6337714|NCT03191552|10090003|FG000|Overall Study|Undergone surgery (Progressive hip dyspl|0
6337715|NCT03191552|10090004|FG001|Overall Study|Undergone surgery (Progressive hip dyspl|1
6337716|NCT03191552|10090005|FG002|Overall Study|Undergone surgery (Progressive hip dyspl|0
6337717|NCT03191630|10090019|FG000|Overall Study|Lost to Follow-up|7
6337718|NCT03191630|10090020|FG001|Overall Study|Lost to Follow-up|7
6337719|NCT03191799|10090028|FG000|Overall Study|Withdrawal by Subject|4
6337720|NCT03191799|10090028|FG000|Overall Study|Physician Decision|2
6337721|NCT03191799|10090028|FG000|Overall Study|Lost to Follow-up|1
6337722|NCT03191799|10090028|FG000|Overall Study|Death|2
6337723|NCT03192137|10090034|FG000|Overall Study|Adverse Event|10
6337724|NCT03192137|10090035|FG001|Overall Study|Adverse Event|11
6337725|NCT03192137|10090034|FG000|Overall Study|Physician Decision|1
6337726|NCT03192137|10090035|FG001|Overall Study|Physician Decision|0
6337727|NCT03192137|10090034|FG000|Overall Study|Lack of Efficacy|20
6337728|NCT03192137|10090035|FG001|Overall Study|Lack of Efficacy|37
6337729|NCT03192137|10090034|FG000|Overall Study|Withdrawal by Subject|3
6337730|NCT03192137|10090035|FG001|Overall Study|Withdrawal by Subject|3
6337731|NCT03192137|10090034|FG000|Overall Study|Protocol Violation|4
6337732|NCT03192137|10090035|FG001|Overall Study|Protocol Violation|3
6337733|NCT03192137|10090034|FG000|Overall Study|Surgery Cancelled|4
6337734|NCT03192137|10090035|FG001|Overall Study|Surgery Cancelled|1
6337735|NCT03192137|10090034|FG000|Overall Study|Other - Various Administrative Reasons|8
6337736|NCT03192137|10090035|FG001|Overall Study|Other - Various Administrative Reasons|3
6337737|NCT03192150|10090043|FG000|Overall Study|Adverse Event|14
6337738|NCT03192150|10090044|FG001|Overall Study|Adverse Event|12
6337739|NCT03192150|10090043|FG000|Overall Study|Lack of Efficacy|23
6337740|NCT03192150|10090044|FG001|Overall Study|Lack of Efficacy|30
6337741|NCT03192150|10090043|FG000|Overall Study|Lost to Follow-up|1
6337742|NCT03192150|10090044|FG001|Overall Study|Lost to Follow-up|1
6337743|NCT03192150|10090043|FG000|Overall Study|Withdrawal by Subject|4
6337744|NCT03192150|10090044|FG001|Overall Study|Withdrawal by Subject|2
6337745|NCT03192150|10090043|FG000|Overall Study|Protocol Violation|5
6337746|NCT03192150|10090044|FG001|Overall Study|Protocol Violation|2
6337747|NCT03192150|10090043|FG000|Overall Study|Surgery Canceled|6
6337748|NCT03192150|10090044|FG001|Overall Study|Surgery Canceled|2
6337749|NCT03192150|10090043|FG000|Overall Study|Other-Various Administrative Reasons|2
6337750|NCT03192150|10090044|FG001|Overall Study|Other-Various Administrative Reasons|5
6337751|NCT03192176|10090058|FG000|Overall Study|Adverse Event|1
6337752|NCT03192176|10090059|FG001|Overall Study|Adverse Event|0
6337753|NCT03192176|10090060|FG002|Overall Study|Adverse Event|4
6337754|NCT03192176|10090061|FG003|Overall Study|Adverse Event|5
6337755|NCT03192176|10090062|FG004|Overall Study|Adverse Event|3
6337756|NCT03192176|10090063|FG005|Overall Study|Adverse Event|2
6337757|NCT03192176|10090064|FG006|Overall Study|Adverse Event|3
6337758|NCT03192176|10090065|FG007|Overall Study|Adverse Event|3
6337759|NCT03192176|10090058|FG000|Overall Study|Lost to Follow-up|0
6337760|NCT03192176|10090059|FG001|Overall Study|Lost to Follow-up|0
6337761|NCT03192176|10090060|FG002|Overall Study|Lost to Follow-up|1
6337762|NCT03192176|10090061|FG003|Overall Study|Lost to Follow-up|2
6337763|NCT03192176|10090062|FG004|Overall Study|Lost to Follow-up|3
6337764|NCT03192176|10090063|FG005|Overall Study|Lost to Follow-up|1
6337765|NCT03192176|10090064|FG006|Overall Study|Lost to Follow-up|1
6337766|NCT03192176|10090065|FG007|Overall Study|Lost to Follow-up|1
6337767|NCT03192176|10090058|FG000|Overall Study|Physician Decision|1
6337768|NCT03192176|10090059|FG001|Overall Study|Physician Decision|0
6337769|NCT03192176|10090060|FG002|Overall Study|Physician Decision|0
6337770|NCT03192176|10090061|FG003|Overall Study|Physician Decision|0
6337771|NCT03192176|10090062|FG004|Overall Study|Physician Decision|0
6337772|NCT03192176|10090063|FG005|Overall Study|Physician Decision|2
6337773|NCT03192176|10090064|FG006|Overall Study|Physician Decision|1
6337774|NCT03192176|10090065|FG007|Overall Study|Physician Decision|0
6337775|NCT03192176|10090058|FG000|Overall Study|Protocol Deviation|1
6337776|NCT03192176|10090059|FG001|Overall Study|Protocol Deviation|1
6337777|NCT03192176|10090060|FG002|Overall Study|Protocol Deviation|0
6337778|NCT03192176|10090061|FG003|Overall Study|Protocol Deviation|0
6337779|NCT03192176|10090062|FG004|Overall Study|Protocol Deviation|2
6337780|NCT03192176|10090063|FG005|Overall Study|Protocol Deviation|0
6337781|NCT03192176|10090064|FG006|Overall Study|Protocol Deviation|0
6337782|NCT03192176|10090065|FG007|Overall Study|Protocol Deviation|0
6337783|NCT03192176|10090058|FG000|Overall Study|Withdrawal by Subject|3
6337784|NCT03192176|10090059|FG001|Overall Study|Withdrawal by Subject|4
6337785|NCT03192176|10090060|FG002|Overall Study|Withdrawal by Subject|0
6337786|NCT03192176|10090061|FG003|Overall Study|Withdrawal by Subject|4
6337787|NCT03192176|10090062|FG004|Overall Study|Withdrawal by Subject|3
6337788|NCT03192176|10090063|FG005|Overall Study|Withdrawal by Subject|4
6337789|NCT03192176|10090064|FG006|Overall Study|Withdrawal by Subject|4
6337790|NCT03192176|10090065|FG007|Overall Study|Withdrawal by Subject|2
6337791|NCT03192176|10090058|FG000|Overall Study|Miscellaneous|1
6337792|NCT03192176|10090059|FG001|Overall Study|Miscellaneous|0
6337793|NCT03192176|10090060|FG002|Overall Study|Miscellaneous|1
6337794|NCT03192176|10090061|FG003|Overall Study|Miscellaneous|1
6337795|NCT03192176|10090062|FG004|Overall Study|Miscellaneous|1
6337796|NCT03192176|10090063|FG005|Overall Study|Miscellaneous|2
6337797|NCT03192176|10090064|FG006|Overall Study|Miscellaneous|0
6337798|NCT03192176|10090065|FG007|Overall Study|Miscellaneous|1
6337799|NCT03192306|10090086|FG000|Overall Study|Did not treat cold sore during study|149
6337800|NCT03192306|10090087|FG001|Overall Study|Did not treat cold sore during study|143
6337801|NCT03192306|10090086|FG000|Overall Study|Withdrawal by Subject|1
6337802|NCT03192306|10090087|FG001|Overall Study|Withdrawal by Subject|1
6337803|NCT03192306|10090086|FG000|Overall Study|Lost to Follow-up|1
6337804|NCT03192306|10090087|FG001|Overall Study|Lost to Follow-up|0
6337805|NCT03192306|10090086|FG000|Overall Study|Protocol Violation|1
6337806|NCT03192306|10090087|FG001|Overall Study|Protocol Violation|1
6337807|NCT03192475|10090095|FG000|Overall Study|Death|0
6337808|NCT03192475|10090096|FG001|Overall Study|Death|1
6337809|NCT03192475|10090095|FG000|Overall Study|Lost to Follow-up|13
6337810|NCT03192475|10090096|FG001|Overall Study|Lost to Follow-up|8
6337811|NCT03192488|10090103|FG000|First Washout (>6d)|Withdrawal by Subject|0
6337812|NCT03192488|10090104|FG001|First Washout (>6d)|Withdrawal by Subject|0
6337813|NCT03192488|10090105|FG002|First Washout (>6d)|Withdrawal by Subject|1
6337814|NCT03192488|10090106|FG003|First Washout (>6d)|Withdrawal by Subject|0
6337815|NCT03192488|10090107|FG004|First Washout (>6d)|Withdrawal by Subject|0
6337816|NCT03192488|10090108|FG005|First Washout (>6d)|Withdrawal by Subject|1
6337817|NCT03192488|10090103|FG000|Third Intervention (d1)|Adverse Event|0
6337818|NCT03192488|10090104|FG001|Third Intervention (d1)|Adverse Event|0
6337819|NCT03192488|10090105|FG002|Third Intervention (d1)|Adverse Event|0
6337820|NCT03192488|10090106|FG003|Third Intervention (d1)|Adverse Event|0
6337821|NCT03192488|10090107|FG004|Third Intervention (d1)|Adverse Event|1
6337822|NCT03192488|10090108|FG005|Third Intervention (d1)|Adverse Event|0
6337823|NCT03192904|10090137|FG000|Overall Study|Physician Decision|3
6337824|NCT03192904|10090138|FG001|Overall Study|Physician Decision|1
6337825|NCT03192904|10090137|FG000|Overall Study|Lost to Follow-up|0
6337826|NCT03192904|10090138|FG001|Overall Study|Lost to Follow-up|1
6337827|NCT03193021|10090146|FG000|Overall Study|Lost to Follow-up|1
6337828|NCT03193021|10090147|FG001|Overall Study|Lost to Follow-up|1
6337829|NCT03193047|10090155|FG000|Overall Study|Physician Decision|1
6337830|NCT03193047|10090156|FG001|Overall Study|Physician Decision|0
6337831|NCT03193047|10090155|FG000|Overall Study|Participant Left State|1
6337832|NCT03193047|10090156|FG001|Overall Study|Participant Left State|0
6337833|NCT03193736|10090202|FG000|Overall Study|Death|2
6337834|NCT03193736|10090202|FG000|Overall Study|Withdrawal by Subject|1
6337835|NCT03193736|10090202|FG000|Overall Study|Lost to Follow-up|1
6337836|NCT03193736|10090202|FG000|Overall Study|implant not received|1
6337837|NCT03194217|10090210|FG000|Overall Study|Adverse Event|0
6337838|NCT03194217|10090211|FG001|Overall Study|Adverse Event|2
6337839|NCT03194217|10090212|FG002|Overall Study|Adverse Event|3
6337840|NCT03194217|10090213|FG003|Overall Study|Adverse Event|3
6337841|NCT03194217|10090210|FG000|Overall Study|Failure to meet randomisation criteria|0
6337842|NCT03194217|10090211|FG001|Overall Study|Failure to meet randomisation criteria|0
6337843|NCT03194217|10090212|FG002|Overall Study|Failure to meet randomisation criteria|0
6337844|NCT03194217|10090213|FG003|Overall Study|Failure to meet randomisation criteria|1
6337845|NCT03194217|10090210|FG000|Overall Study|Other|0
6337846|NCT03194217|10090211|FG001|Overall Study|Other|1
6337847|NCT03194217|10090212|FG002|Overall Study|Other|1
6337848|NCT03194217|10090213|FG003|Overall Study|Other|0
6337849|NCT03194464|10090241|FG000|Overall Study|data not usable|2
6337850|NCT03194490|10090249|FG000|Overall Study|Lost to Follow-up|1
6337851|NCT03194490|10090250|FG001|Overall Study|Lost to Follow-up|3
6337852|NCT03194490|10090249|FG000|Overall Study|participant developed specific neck pain|1
6337853|NCT03194490|10090250|FG001|Overall Study|participant developed specific neck pain|0
6337854|NCT03196193|10090330|FG000|Overall Study|Adverse Event|1
6337855|NCT03196193|10090331|FG001|Overall Study|Adverse Event|0
6337856|NCT03196193|10090330|FG000|Overall Study|Computed Tomography (CT) data missing|2
6337857|NCT03196193|10090331|FG001|Overall Study|Computed Tomography (CT) data missing|0
6337858|NCT03196284|10090343|FG000|Main Part|Withdrawal by Subject|0
6337859|NCT03196284|10090344|FG001|Main Part|Withdrawal by Subject|1
6337860|NCT03196284|10090345|FG002|Main Part|Withdrawal by Subject|0
6337861|NCT03196284|10090343|FG000|Extension Part|Lack of Efficacy|0
6337862|NCT03196284|10090344|FG001|Extension Part|Lack of Efficacy|0
6337863|NCT03196284|10090345|FG002|Extension Part|Lack of Efficacy|1
6337864|NCT03196284|10090343|FG000|Extension Part|Withdrawal by Subject|0
6337865|NCT03196284|10090344|FG001|Extension Part|Withdrawal by Subject|0
6337866|NCT03196284|10090345|FG002|Extension Part|Withdrawal by Subject|1
6337867|NCT03196284|10090343|FG000|Extension Part|Physician Decision|0
6337868|NCT03196284|10090344|FG001|Extension Part|Physician Decision|0
6337869|NCT03196284|10090345|FG002|Extension Part|Physician Decision|1
6337870|NCT03196297|10090365|FG000|Main Period|Withdrawal by Subject|4
6337871|NCT03196297|10090365|FG000|Extension Period|Withdrawal by Subject|1
6337872|NCT03196297|10090365|FG000|Extension Period|Lack of Efficacy|2
6337873|NCT03196349|10090384|FG000|Overall Study|Did not receive study drug|0
6337874|NCT03196349|10090385|FG001|Overall Study|Did not receive study drug|1
6337875|NCT03196349|10090386|FG002|Overall Study|Did not receive study drug|2
6337876|NCT03196349|10090384|FG000|Overall Study|No data entered|2
6337877|NCT03196349|10090385|FG001|Overall Study|No data entered|4
6337878|NCT03196349|10090386|FG002|Overall Study|No data entered|0
6337879|NCT03196349|10090384|FG000|Overall Study|Study Terminated early|15
6337880|NCT03196349|10090385|FG001|Overall Study|Study Terminated early|9
6337881|NCT03196349|10090386|FG002|Overall Study|Study Terminated early|11
6337882|NCT03196505|10090396|FG000|Overall Study|Physician Decision|26
6337883|NCT03196505|10090397|FG001|Overall Study|Physician Decision|26
6337884|NCT03196635|10090403|FG000|Overall Study|Withdrawal by Subject|1
6337885|NCT03196791|10090423|FG000|Overall Study|Protocol Violation|7
6337886|NCT03196791|10090424|FG001|Overall Study|Protocol Violation|3
6337887|NCT03196791|10090423|FG000|Overall Study|Withdrawal by Subject|3
6337888|NCT03196791|10090424|FG001|Overall Study|Withdrawal by Subject|2
6337889|NCT03196973|10090433|FG000|Overall Study|Adverse Event|1
6337890|NCT03196973|10090434|FG001|Overall Study|Adverse Event|1
6337891|NCT03196973|10090435|FG002|Overall Study|Adverse Event|2
6337892|NCT03196973|10090433|FG000|Overall Study|Lack of Efficacy|2
6337893|NCT03196973|10090434|FG001|Overall Study|Lack of Efficacy|6
6337894|NCT03196973|10090435|FG002|Overall Study|Lack of Efficacy|1
6337895|NCT03196973|10090433|FG000|Overall Study|Lost to Follow-up|4
6337896|NCT03196973|10090434|FG001|Overall Study|Lost to Follow-up|3
6337897|NCT03196973|10090435|FG002|Overall Study|Lost to Follow-up|2
6337898|NCT03196973|10090433|FG000|Overall Study|Consent withdrawn|2
6337899|NCT03196973|10090434|FG001|Overall Study|Consent withdrawn|1
6337900|NCT03196973|10090435|FG002|Overall Study|Consent withdrawn|0
6337901|NCT03196973|10090433|FG000|Overall Study|Administration of a wrong kit of study medication|0
6337902|NCT03196973|10090434|FG001|Overall Study|Administration of a wrong kit of study medication|1
6337903|NCT03196973|10090435|FG002|Overall Study|Administration of a wrong kit of study medication|0
6337904|NCT03197129|10090458|FG000|Overall Study|did not answer the VPT: shyness|4
6337905|NCT03197129|10090459|FG001|Overall Study|did not answer the VPT: shyness|5
6337906|NCT03197324|10090467|FG000|Overall Study|Adverse Event|0
6337907|NCT03197324|10090468|FG001|Overall Study|Adverse Event|1
6337908|NCT03197376|10090478|FG000|Primary and Booster Phase|Adverse Event|0
6337909|NCT03197376|10090479|FG001|Primary and Booster Phase|Adverse Event|0
6337910|NCT03197376|10090480|FG002|Primary and Booster Phase|Adverse Event|0
6337911|NCT03197376|10090481|FG003|Primary and Booster Phase|Adverse Event|1
6337912|NCT03197376|10090478|FG000|Primary and Booster Phase|Death|1
6337913|NCT03197376|10090479|FG001|Primary and Booster Phase|Death|0
6337914|NCT03197376|10090480|FG002|Primary and Booster Phase|Death|0
6337915|NCT03197376|10090481|FG003|Primary and Booster Phase|Death|2
6337916|NCT03197376|10090478|FG000|Primary and Booster Phase|Lost to Follow-up|0
6337917|NCT03197376|10090479|FG001|Primary and Booster Phase|Lost to Follow-up|0
6337918|NCT03197376|10090480|FG002|Primary and Booster Phase|Lost to Follow-up|1
6337919|NCT03197376|10090481|FG003|Primary and Booster Phase|Lost to Follow-up|0
6337920|NCT03197376|10090478|FG000|Primary and Booster Phase|Physician Decision|1
6337921|NCT03197376|10090479|FG001|Primary and Booster Phase|Physician Decision|0
6337922|NCT03197376|10090480|FG002|Primary and Booster Phase|Physician Decision|1
6337923|NCT03197376|10090481|FG003|Primary and Booster Phase|Physician Decision|3
6337924|NCT03197376|10090478|FG000|Primary and Booster Phase|Withdrawal by subject's parents|11
6337925|NCT03197376|10090479|FG001|Primary and Booster Phase|Withdrawal by subject's parents|10
6337926|NCT03197376|10090480|FG002|Primary and Booster Phase|Withdrawal by subject's parents|14
6337927|NCT03197376|10090481|FG003|Primary and Booster Phase|Withdrawal by subject's parents|11
6337928|NCT03197376|10090478|FG000|Primary and Booster Phase|Ineligibility criteria|1
6337929|NCT03197376|10090479|FG001|Primary and Booster Phase|Ineligibility criteria|1
6337930|NCT03197376|10090480|FG002|Primary and Booster Phase|Ineligibility criteria|4
6337931|NCT03197376|10090481|FG003|Primary and Booster Phase|Ineligibility criteria|2
6337932|NCT03197376|10090478|FG000|Primary and Booster Phase|Not vaccine related|1
6337933|NCT03197376|10090479|FG001|Primary and Booster Phase|Not vaccine related|2
6337934|NCT03197376|10090480|FG002|Primary and Booster Phase|Not vaccine related|0
6337935|NCT03197376|10090481|FG003|Primary and Booster Phase|Not vaccine related|6
6337936|NCT03197376|10090478|FG000|Immune Persistence Phase|Lost to Follow-up|0
6337937|NCT03197376|10090479|FG001|Immune Persistence Phase|Lost to Follow-up|0
6337938|NCT03197376|10090480|FG002|Immune Persistence Phase|Lost to Follow-up|2
6337939|NCT03197376|10090481|FG003|Immune Persistence Phase|Lost to Follow-up|1
6337940|NCT03197376|10090478|FG000|Immune Persistence Phase|Withdrawal by subject's parents|4
6337941|NCT03197376|10090479|FG001|Immune Persistence Phase|Withdrawal by subject's parents|4
6337942|NCT03197376|10090480|FG002|Immune Persistence Phase|Withdrawal by subject's parents|2
6337943|NCT03197376|10090481|FG003|Immune Persistence Phase|Withdrawal by subject's parents|3
6337944|NCT03197376|10090478|FG000|Immune Persistence Phase|Not vaccine related|1
6337945|NCT03197376|10090479|FG001|Immune Persistence Phase|Not vaccine related|0
6337946|NCT03197376|10090480|FG002|Immune Persistence Phase|Not vaccine related|1
6337947|NCT03197376|10090481|FG003|Immune Persistence Phase|Not vaccine related|1
6337948|NCT03197558|10090539|FG000|Overall Study|Tubes not placed|1
6337949|NCT03197883|10090545|FG000|Overall Study|Adverse Event|1
6337950|NCT03197883|10090546|FG001|Overall Study|Adverse Event|1
6337951|NCT03197883|10090545|FG000|Overall Study|Lost to Follow-up|1
6337952|NCT03197883|10090546|FG001|Overall Study|Lost to Follow-up|0
6337953|NCT03197883|10090545|FG000|Overall Study|Protocol Violation|1
6337954|NCT03197883|10090546|FG001|Overall Study|Protocol Violation|0
6337955|NCT03197883|10090545|FG000|Overall Study|Other (Not Specified)|0
6337956|NCT03197883|10090546|FG001|Overall Study|Other (Not Specified)|5
6337957|NCT03198507|10090584|FG000|Overall Study|Withdrawal by Subject|1
6337958|NCT03198507|10090585|FG001|Overall Study|Withdrawal by Subject|0
6337959|NCT03198520|10090591|FG000|Overall Study|Physician Decision|2
6337960|NCT03198520|10090591|FG000|Overall Study|Protocol Violation|2
6337961|NCT03198520|10090591|FG000|Overall Study|Withdrawal by Subject|1
6337962|NCT03198520|10090591|FG000|Overall Study|Study Ended|1
6337963|NCT03198715|10090608|FG000|Overall Study|Death|0
6337964|NCT03198715|10090609|FG001|Overall Study|Death|0
6337965|NCT03198715|10090610|FG002|Overall Study|Death|1
6337966|NCT03198715|10090611|FG003|Overall Study|Death|0
6337967|NCT03198715|10090612|FG004|Overall Study|Death|2
6337968|NCT03198715|10090608|FG000|Overall Study|Other|0
6337969|NCT03198715|10090609|FG001|Overall Study|Other|1
6337970|NCT03198715|10090610|FG002|Overall Study|Other|1
6337971|NCT03198715|10090611|FG003|Overall Study|Other|0
6337972|NCT03198715|10090612|FG004|Overall Study|Other|0
6337973|NCT03198754|10090626|FG000|Overall Study|Withdrawal by Subject|5
6337974|NCT03198754|10090627|FG001|Overall Study|Withdrawal by Subject|4
6337975|NCT03198754|10090626|FG000|Overall Study|Lost to Follow-up|4
6337976|NCT03198754|10090627|FG001|Overall Study|Lost to Follow-up|3
6337977|NCT03198754|10090626|FG000|Overall Study|Ineligible|2
6337978|NCT03198754|10090627|FG001|Overall Study|Ineligible|1
6337979|NCT03198767|10090640|FG000|Overall Study|Protocol Violation|0
6337980|NCT03198767|10090641|FG001|Overall Study|Protocol Violation|0
6337981|NCT03198767|10090642|FG002|Overall Study|Protocol Violation|0
6337982|NCT03198767|10090643|FG003|Overall Study|Protocol Violation|6
6337983|NCT03198767|10090644|FG004|Overall Study|Protocol Violation|0
6337984|NCT03198767|10090645|FG005|Overall Study|Protocol Violation|0
6337985|NCT03198767|10090646|FG006|Overall Study|Protocol Violation|0
6337986|NCT03199911|10090713|FG000|Overall Study|Lost to Follow-up|5
6337987|NCT03199911|10090714|FG001|Overall Study|Lost to Follow-up|5
6337988|NCT03199911|10090713|FG000|Overall Study|Did not proceed with surgery|2
6337989|NCT03199911|10090714|FG001|Overall Study|Did not proceed with surgery|1
6337990|NCT03199963|10090722|FG000|Blinded Phase - Overall Study|Withdrawal by Subject|5
6337991|NCT03199963|10090723|FG001|Blinded Phase - Overall Study|Withdrawal by Subject|5
6337992|NCT03199963|10090722|FG000|Blinded Phase - Overall Study|Lost to Follow-up|9
6337993|NCT03199963|10090723|FG001|Blinded Phase - Overall Study|Lost to Follow-up|2
6337994|NCT03199963|10090722|FG000|Blinded Phase - Overall Study|Adverse Event|10
6337995|NCT03199963|10090723|FG001|Blinded Phase - Overall Study|Adverse Event|5
6337996|NCT03199963|10090722|FG000|Blinded Phase - Overall Study|Study was terminated early by the Sponsor for administrative reasons.|109
6337997|NCT03199963|10090723|FG001|Blinded Phase - Overall Study|Study was terminated early by the Sponsor for administrative reasons.|54
6337998|NCT03199963|10090722|FG000|Optional Open-Label Phase - BHR-700|Study terminated early by Sponsor for administrative reasons; data contribution was negligible.|7
6337999|NCT03199963|10090723|FG001|Optional Open-Label Phase - BHR-700|Study terminated early by Sponsor for administrative reasons; data contribution was negligible.|5
6338000|NCT03199963|10090722|FG000|Optional Open-Label Phase - BHR-700|Adverse Event|0
6338001|NCT03199963|10090723|FG001|Optional Open-Label Phase - BHR-700|Adverse Event|1
6338002|NCT03200366|10090734|FG000|Patient Navigation Intervention Given|Death|0
6338003|NCT03200366|10090735|FG001|Patient Navigation Intervention Given|Death|2
6338004|NCT03200366|10090736|FG002|Patient Navigation Intervention Given|Death|0
6338005|NCT03200366|10090734|FG000|Patient Navigation Intervention Given|Lost to Follow-up|0
6338006|NCT03200366|10090735|FG001|Patient Navigation Intervention Given|Lost to Follow-up|25
6338007|NCT03200366|10090736|FG002|Patient Navigation Intervention Given|Lost to Follow-up|0
6338008|NCT03200366|10090734|FG000|Patient Navigation Intervention Given|Not attempted/missed by nurse|0
6338009|NCT03200366|10090735|FG001|Patient Navigation Intervention Given|Not attempted/missed by nurse|1
6338010|NCT03200366|10090736|FG002|Patient Navigation Intervention Given|Not attempted/missed by nurse|0
6338011|NCT03200366|10090734|FG000|Patient Navigation Intervention Given|Colonoscopy already re-scheduled and completed|0
6338012|NCT03200366|10090735|FG001|Patient Navigation Intervention Given|Colonoscopy already re-scheduled and completed|2
6338013|NCT03200366|10090736|FG002|Patient Navigation Intervention Given|Colonoscopy already re-scheduled and completed|0
6338014|NCT03200366|10090734|FG000|Patient Navigation Intervention Given|Declined navigation intervention|0
6338015|NCT03200366|10090735|FG001|Patient Navigation Intervention Given|Declined navigation intervention|1
6338016|NCT03200366|10090736|FG002|Patient Navigation Intervention Given|Declined navigation intervention|0
6338017|NCT03200366|10090734|FG000|6 Month Post-Baseline Interview|Death|1
6338018|NCT03200366|10090735|FG001|6 Month Post-Baseline Interview|Death|1
6338019|NCT03200366|10090736|FG002|6 Month Post-Baseline Interview|Death|1
6338020|NCT03200366|10090734|FG000|6 Month Post-Baseline Interview|Lost to Follow-up|27
6338021|NCT03200366|10090735|FG001|6 Month Post-Baseline Interview|Lost to Follow-up|21
6338022|NCT03200366|10090736|FG002|6 Month Post-Baseline Interview|Lost to Follow-up|17
6338023|NCT03200366|10090734|FG000|6 Month Post-Baseline Interview|Withdrawal by Subject|1
6338024|NCT03200366|10090735|FG001|6 Month Post-Baseline Interview|Withdrawal by Subject|1
6338025|NCT03200366|10090736|FG002|6 Month Post-Baseline Interview|Withdrawal by Subject|0
6338026|NCT03200366|10090734|FG000|6 Month Post-Baseline Interview|Refused 6 month interview but continued in study|1
6338027|NCT03200366|10090735|FG001|6 Month Post-Baseline Interview|Refused 6 month interview but continued in study|0
6338028|NCT03200366|10090736|FG002|6 Month Post-Baseline Interview|Refused 6 month interview but continued in study|0
6338029|NCT03200366|10090734|FG000|6 Month Post-Baseline Interview|Not attempted/missed by data collectors|0
6338030|NCT03200366|10090735|FG001|6 Month Post-Baseline Interview|Not attempted/missed by data collectors|0
6338031|NCT03200366|10090736|FG002|6 Month Post-Baseline Interview|Not attempted/missed by data collectors|1
6338032|NCT03200366|10090734|FG000|9 Month Post-Baseline Interview|Death|1
6338033|NCT03200366|10090735|FG001|9 Month Post-Baseline Interview|Death|1
6338034|NCT03200366|10090736|FG002|9 Month Post-Baseline Interview|Death|1
6338035|NCT03200366|10090734|FG000|9 Month Post-Baseline Interview|Lost to Follow-up|23
6338036|NCT03200366|10090735|FG001|9 Month Post-Baseline Interview|Lost to Follow-up|18
6338037|NCT03200366|10090736|FG002|9 Month Post-Baseline Interview|Lost to Follow-up|9
6338038|NCT03200366|10090734|FG000|9 Month Post-Baseline Interview|Withdrawal by PI|0
6338039|NCT03200366|10090735|FG001|9 Month Post-Baseline Interview|Withdrawal by PI|0
6338040|NCT03200366|10090736|FG002|9 Month Post-Baseline Interview|Withdrawal by PI|1
6338041|NCT03200366|10090734|FG000|9 Month Post-Baseline Interview|Refused interview|0
6338042|NCT03200366|10090735|FG001|9 Month Post-Baseline Interview|Refused interview|2
6338043|NCT03200366|10090736|FG002|9 Month Post-Baseline Interview|Refused interview|0
6338044|NCT03200860|10090765|FG000|Overall Study|Withdrawal by Subject|1
6338045|NCT03200860|10090766|FG001|Overall Study|Withdrawal by Subject|0
6338046|NCT03200912|10090775|FG000|Overall Study|Adverse Event|3
6338047|NCT03200912|10090776|FG001|Overall Study|Adverse Event|0
6338048|NCT03200912|10090777|FG002|Overall Study|Adverse Event|0
6338049|NCT03200912|10090775|FG000|Overall Study|Withdrawal by Subject|1
6338050|NCT03200912|10090776|FG001|Overall Study|Withdrawal by Subject|2
6338051|NCT03200912|10090777|FG002|Overall Study|Withdrawal by Subject|4
6338052|NCT03200912|10090775|FG000|Overall Study|Non-compliance with study drug|0
6338053|NCT03200912|10090776|FG001|Overall Study|Non-compliance with study drug|1
6338054|NCT03200912|10090777|FG002|Overall Study|Non-compliance with study drug|0
6338055|NCT03201003|10090796|FG000|Overall Study|Adverse Event|14
6338056|NCT03201003|10090797|FG001|Overall Study|Adverse Event|1
6338057|NCT03201003|10090796|FG000|Overall Study|Other reasons|5
6338058|NCT03201003|10090797|FG001|Overall Study|Other reasons|1
6338059|NCT03201003|10090796|FG000|Overall Study|Withdrawal by Subject|4
6338060|NCT03201003|10090797|FG001|Overall Study|Withdrawal by Subject|1
6338061|NCT03201003|10090796|FG000|Overall Study|Lost to Follow-up|2
6338062|NCT03201003|10090797|FG001|Overall Study|Lost to Follow-up|0
6338063|NCT03201003|10090796|FG000|Overall Study|Protocol Violation|1
6338064|NCT03201003|10090797|FG001|Overall Study|Protocol Violation|0
6338065|NCT03201211|10090806|FG000|Overall Study|Adverse Event|1
6338066|NCT03201211|10090807|FG001|Overall Study|Adverse Event|0
6338067|NCT03201211|10090808|FG002|Overall Study|Adverse Event|0
6338068|NCT03201211|10090806|FG000|Overall Study|Protocol Violation|1
6338069|NCT03201211|10090807|FG001|Overall Study|Protocol Violation|0
6338070|NCT03201211|10090808|FG002|Overall Study|Protocol Violation|0
6338071|NCT03201211|10090806|FG000|Overall Study|CONSENT WITHDRAWAL NOT DUE TO ADV. EVENT|0
6338072|NCT03201211|10090807|FG001|Overall Study|CONSENT WITHDRAWAL NOT DUE TO ADV. EVENT|0
6338073|NCT03201211|10090808|FG002|Overall Study|CONSENT WITHDRAWAL NOT DUE TO ADV. EVENT|1
6338074|NCT03201211|10090806|FG000|Overall Study|OTHER unknown reasons|0
6338075|NCT03201211|10090807|FG001|Overall Study|OTHER unknown reasons|1
6338076|NCT03201211|10090808|FG002|Overall Study|OTHER unknown reasons|0
6338077|NCT03201562|10090819|FG000|Overall Study|Physician Decision|0
6338078|NCT03201562|10090820|FG001|Overall Study|Physician Decision|0
6338079|NCT03201562|10090821|FG002|Overall Study|Physician Decision|1
6338080|NCT03201562|10090819|FG000|Overall Study|Adverse Event|0
6338081|NCT03201562|10090820|FG001|Overall Study|Adverse Event|0
6338082|NCT03201562|10090821|FG002|Overall Study|Adverse Event|1
6338083|NCT03201562|10090819|FG000|Overall Study|Lost to Follow-up|0
6338084|NCT03201562|10090820|FG001|Overall Study|Lost to Follow-up|1
6338085|NCT03201562|10090821|FG002|Overall Study|Lost to Follow-up|2
6338086|NCT03201809|10090831|FG000|Overall Study|Lost to Follow-up|2
6338087|NCT03201809|10090832|FG001|Overall Study|Lost to Follow-up|0
6338088|NCT03201900|10090838|FG000|Treatment Phase (Up to 62 Weeks)|Adverse Event|9
6338089|NCT03201900|10090838|FG000|Treatment Phase (Up to 62 Weeks)|Subject Choice|1
6338090|NCT03201900|10090838|FG000|Treatment Phase (Up to 62 Weeks)|Inadequate therapeutic effect|6
6338091|NCT03201900|10090838|FG000|Treatment Phase (Up to 62 Weeks)|Lost to Follow-up|2
6338092|NCT03201900|10090838|FG000|Treatment Phase (Up to 62 Weeks)|Withdrawal of consent|6
6338093|NCT03201900|10090838|FG000|Treatment Phase (Up to 62 Weeks)|Other than specified|11
6338094|NCT03201900|10090838|FG000|Treatment Phase (Up to 62 Weeks)|Not treated|2
6338095|NCT03201900|10090838|FG000|Extension Phase (From Week 63 to 156)|Subject choice|1
6338096|NCT03201900|10090838|FG000|Extension Phase (From Week 63 to 156)|Pregnancy|1
6338097|NCT03201900|10090838|FG000|Extension Phase (From Week 63 to 156)|Inadequate therapeutic effect|1
6338098|NCT03201900|10090838|FG000|Extension Phase (From Week 63 to 156)|Lost to Follow-up|1
6338099|NCT03201900|10090838|FG000|Extension Phase (From Week 63 to 156)|Withdrawal of consent|3
6338100|NCT03201900|10090838|FG000|Extension Phase (From Week 63 to 156)|Other|1
6338101|NCT03202511|10090861|FG000|Overall Study|Withdrawal by Subject|1
6338102|NCT03202511|10090862|FG001|Overall Study|Withdrawal by Subject|0
6338103|NCT03203291|10090877|FG000|Overall Study|Withdrawal by Subject|1
6338104|NCT03203447|10090883|FG000|Overall Study|Withdrawal by Subject|2
6338105|NCT03203447|10090884|FG001|Overall Study|Withdrawal by Subject|1
6338106|NCT03203447|10090883|FG000|Overall Study|Lost to Follow-up|1
6338107|NCT03203447|10090884|FG001|Overall Study|Lost to Follow-up|10
6338108|NCT03203447|10090883|FG000|Overall Study|Includes premature discontinuation due to study termination and unknown|159
6338109|NCT03203447|10090884|FG001|Overall Study|Includes premature discontinuation due to study termination and unknown|152
6338110|NCT03204279|10090913|FG000|Overall Study|Withdrawal by Subject|0
6338111|NCT03204279|10090914|FG001|Overall Study|Withdrawal by Subject|1
6338112|NCT03204981|10090943|FG000|Overall Study|Physician Decision|2
6338113|NCT03204981|10090943|FG000|Overall Study|Screen failures (no inducible VT or PVCs)|4
6338114|NCT03205046|10090951|FG000|Overall Study|Death|10
6338115|NCT03205046|10090952|FG001|Overall Study|Death|6
6338116|NCT03205046|10090951|FG000|Overall Study|Withdrawal by Subject|1
6338117|NCT03205046|10090952|FG001|Overall Study|Withdrawal by Subject|2
6338118|NCT03205046|10090951|FG000|Overall Study|Lost to Follow-up|0
6338119|NCT03205046|10090952|FG001|Overall Study|Lost to Follow-up|1
6338120|NCT03205046|10090951|FG000|Overall Study|Study terminated by sponsor|2
6338121|NCT03205046|10090952|FG001|Overall Study|Study terminated by sponsor|1
6338122|NCT03205150|10090961|FG000|Overall Study|Protocol deviation|1
6338123|NCT03205150|10090962|FG001|Overall Study|Protocol deviation|3
6338124|NCT03205150|10090963|FG002|Overall Study|Protocol deviation|0
6338125|NCT03205150|10090961|FG000|Overall Study|Patient/guardian decision|0
6338126|NCT03205150|10090962|FG001|Overall Study|Patient/guardian decision|3
6338127|NCT03205150|10090963|FG002|Overall Study|Patient/guardian decision|0
6338128|NCT03205150|10090961|FG000|Overall Study|Adverse Event|1
6338129|NCT03205150|10090962|FG001|Overall Study|Adverse Event|1
6338130|NCT03205150|10090963|FG002|Overall Study|Adverse Event|1
6338131|NCT03205150|10090961|FG000|Overall Study|Lost to Follow-up|0
6338132|NCT03205150|10090962|FG001|Overall Study|Lost to Follow-up|0
6338133|NCT03205150|10090963|FG002|Overall Study|Lost to Follow-up|1
6338134|NCT03205488|10090975|FG000|Overall Study|Adverse Event|1
6338135|NCT03205488|10090976|FG001|Overall Study|Adverse Event|2
6338136|NCT03205488|10090977|FG002|Overall Study|Adverse Event|4
6338137|NCT03205488|10090975|FG000|Overall Study|Protocol Violation|0
6338138|NCT03205488|10090976|FG001|Overall Study|Protocol Violation|0
6338139|NCT03205488|10090977|FG002|Overall Study|Protocol Violation|1
6338140|NCT03205566|10090991|FG000|Phase 1|Protocol Violation|1
6338141|NCT03205566|10090992|FG001|Phase 1|Protocol Violation|1
6338142|NCT03206749|10091005|FG000|Overall Study|Withdrawal of consent|5
6338143|NCT03206749|10091006|FG001|Overall Study|Withdrawal of consent|3
6338144|NCT03206749|10091007|FG002|Overall Study|Withdrawal of consent|6
6338145|NCT03206749|10091005|FG000|Overall Study|Lost to Follow-up|0
6338146|NCT03206749|10091006|FG001|Overall Study|Lost to Follow-up|0
6338147|NCT03206749|10091007|FG002|Overall Study|Lost to Follow-up|1
6338148|NCT03206788|10091018|FG000|Overall Study|Withdrawal by Subject|0
6338149|NCT03206788|10091019|FG001|Overall Study|Withdrawal by Subject|1
6338150|NCT03206788|10091018|FG000|Overall Study|Adverse Event|0
6338151|NCT03206788|10091019|FG001|Overall Study|Adverse Event|1
6338152|NCT03206788|10091018|FG000|Overall Study|Physician Decision|0
6338153|NCT03206788|10091019|FG001|Overall Study|Physician Decision|1
6338154|NCT03206918|10091025|FG000|Overall Study|Death|11
6338155|NCT03206918|10091025|FG000|Overall Study|Withdrawal by Subject|5
6338156|NCT03206918|10091025|FG000|Overall Study|Study terminated by sponsor|12
6338157|NCT03206918|10091025|FG000|Overall Study|Lost to Follow-up|3
6338158|NCT03206918|10091025|FG000|Overall Study|Transferred to extension study BGB-3111-LTE1 (NCT04170283)|60
6338159|NCT03206970|10091030|FG000|Overall Study|Death|21
6338160|NCT03206970|10091030|FG000|Overall Study|Withdrawal by Subject|13
6338161|NCT03206970|10091030|FG000|Overall Study|Lost to Follow-up|3
6338162|NCT03206970|10091030|FG000|Overall Study|Primary and secondary objectives were met and remaining participants transferred to LTE by sponsor|49
6338163|NCT03207243|10091058|FG000|Overall Study|Adverse Event|2
6168546|NCT01236352|9813652|FG005|Overall Study|Maximum clinical benefit|0
6338164|NCT03207243|10091059|FG001|Overall Study|Adverse Event|2
6338165|NCT03207243|10091058|FG000|Overall Study|Loss of Asthma Control|47
6338166|NCT03207243|10091059|FG001|Overall Study|Loss of Asthma Control|31
6338167|NCT03207243|10091058|FG000|Overall Study|Withdrawal by Subject|2
6338168|NCT03207243|10091059|FG001|Overall Study|Withdrawal by Subject|4
6338169|NCT03207243|10091058|FG000|Overall Study|Physician Decision|1
6338170|NCT03207243|10091059|FG001|Overall Study|Physician Decision|1
6338171|NCT03207243|10091058|FG000|Overall Study|Lost to Follow-up|0
6338172|NCT03207243|10091059|FG001|Overall Study|Lost to Follow-up|1
6338173|NCT03207243|10091058|FG000|Overall Study|Protocol Specified Withdrawal Criteria|7
6338174|NCT03207243|10091059|FG001|Overall Study|Protocol Specified Withdrawal Criteria|2
6338175|NCT03207243|10091058|FG000|Overall Study|Protocol Violation|0
6338176|NCT03207243|10091059|FG001|Overall Study|Protocol Violation|3
6338177|NCT03207750|10091099|FG000|Overall Study|Adverse Event|3
6338178|NCT03207750|10091100|FG001|Overall Study|Adverse Event|2
6338179|NCT03207750|10091099|FG000|Overall Study|Lost to Follow-up|21
6338180|NCT03207750|10091100|FG001|Overall Study|Lost to Follow-up|29
6338181|NCT03207750|10091099|FG000|Overall Study|Protocol Violation|0
6338182|NCT03207750|10091100|FG001|Overall Study|Protocol Violation|1
6338183|NCT03207750|10091099|FG000|Overall Study|CONSENT WITHDRAWAL, NOT DUE TO AN AE|11
6338184|NCT03207750|10091100|FG001|Overall Study|CONSENT WITHDRAWAL, NOT DUE TO AN AE|13
6338185|NCT03207750|10091099|FG000|Overall Study|MIGRATED / MOVED FROM THE STUDY AREA|7
6338186|NCT03207750|10091100|FG001|Overall Study|MIGRATED / MOVED FROM THE STUDY AREA|10
6338187|NCT03207750|10091099|FG000|Overall Study|NOT WILLING TO PARTICIPATE THIS VISIT|10
6338188|NCT03207750|10091100|FG001|Overall Study|NOT WILLING TO PARTICIPATE THIS VISIT|5
6338189|NCT03207750|10091099|FG000|Overall Study|NOT WILLING / NOT ABLE TO BE CONTACTED|1
6338190|NCT03207750|10091100|FG001|Overall Study|NOT WILLING / NOT ABLE TO BE CONTACTED|2
6338191|NCT03207750|10091099|FG000|Overall Study|OTHER, NOT SPECIFIED|5
6338192|NCT03207750|10091100|FG001|Overall Study|OTHER, NOT SPECIFIED|4
6338193|NCT03207763|10091108|FG000|Overall Study|Lost to Follow-up|1
6338194|NCT03207763|10091109|FG001|Overall Study|Lost to Follow-up|0
6338195|NCT03208088|10091124|FG000|Period 2|Withdrawal by Subject|0
6338196|NCT03208088|10091125|FG001|Period 2|Withdrawal by Subject|0
6338197|NCT03208088|10091126|FG002|Period 2|Withdrawal by Subject|0
6338198|NCT03208088|10091127|FG003|Period 2|Withdrawal by Subject|0
6338199|NCT03208088|10091128|FG004|Period 2|Withdrawal by Subject|0
6338200|NCT03208088|10091129|FG005|Period 2|Withdrawal by Subject|0
6338201|NCT03208088|10091130|FG006|Period 2|Withdrawal by Subject|0
6338202|NCT03208088|10091131|FG007|Period 2|Withdrawal by Subject|0
6338203|NCT03208088|10091132|FG008|Period 2|Withdrawal by Subject|1
6338204|NCT03208088|10091133|FG009|Period 2|Withdrawal by Subject|0
6338205|NCT03208088|10091124|FG000|Period 3|Unsatisfactory Test Article|0
6338206|NCT03208088|10091125|FG001|Period 3|Unsatisfactory Test Article|0
6338207|NCT03208088|10091126|FG002|Period 3|Unsatisfactory Test Article|0
6338208|NCT03208088|10091127|FG003|Period 3|Unsatisfactory Test Article|1
6338209|NCT03208088|10091128|FG004|Period 3|Unsatisfactory Test Article|0
6338210|NCT03208088|10091129|FG005|Period 3|Unsatisfactory Test Article|0
6338211|NCT03208088|10091130|FG006|Period 3|Unsatisfactory Test Article|0
6338212|NCT03208088|10091131|FG007|Period 3|Unsatisfactory Test Article|0
6338213|NCT03208088|10091132|FG008|Period 3|Unsatisfactory Test Article|0
6338214|NCT03208088|10091133|FG009|Period 3|Unsatisfactory Test Article|0
6338215|NCT03208088|10091124|FG000|Period 4|Unsatisfactory Test Article|0
6338216|NCT03208088|10091125|FG001|Period 4|Unsatisfactory Test Article|0
6338217|NCT03208088|10091126|FG002|Period 4|Unsatisfactory Test Article|0
6338218|NCT03208088|10091127|FG003|Period 4|Unsatisfactory Test Article|1
6338219|NCT03208088|10091128|FG004|Period 4|Unsatisfactory Test Article|0
6338220|NCT03208088|10091129|FG005|Period 4|Unsatisfactory Test Article|0
6338221|NCT03208088|10091130|FG006|Period 4|Unsatisfactory Test Article|0
6338222|NCT03208088|10091131|FG007|Period 4|Unsatisfactory Test Article|0
6338223|NCT03208088|10091132|FG008|Period 4|Unsatisfactory Test Article|0
6338224|NCT03208088|10091133|FG009|Period 4|Unsatisfactory Test Article|0
6338225|NCT03208933|10091169|FG000|Overall Study|Death|3
6338226|NCT03208933|10091169|FG000|Overall Study|Withdrawal by Subject|3
6338227|NCT03208933|10091169|FG000|Overall Study|Adverse Event|1
6338228|NCT03208933|10091169|FG000|Overall Study|Lost to Follow-up|2
6338229|NCT03208933|10091169|FG000|Overall Study|Physician Decision|3
6338230|NCT03208933|10091169|FG000|Overall Study|Protocol Violation|1
6338231|NCT03209362|10091180|FG000|Overall Study|Adverse Event|0
6338232|NCT03209362|10091181|FG001|Overall Study|Adverse Event|1
6338233|NCT03209362|10091180|FG000|Overall Study|Lost to Follow-up|0
6338234|NCT03209362|10091181|FG001|Overall Study|Lost to Follow-up|1
6338235|NCT03209362|10091180|FG000|Overall Study|Withdrawal by Subject|2
6338236|NCT03209362|10091181|FG001|Overall Study|Withdrawal by Subject|0
6338237|NCT03209362|10091180|FG000|Overall Study|Other|0
6338238|NCT03209362|10091181|FG001|Overall Study|Other|1
6338239|NCT03209492|10091187|FG000|Overall Study|Case Report Forms Uncollected|5
6338240|NCT03209518|10091198|FG000|Overall Study|Case Report Forms Uncollected|1
6338241|NCT03209518|10091198|FG000|Overall Study|Protocol Deviation|1
6338242|NCT03209570|10091204|FG000|Overall Study|Death|1
6338243|NCT03209570|10091205|FG001|Overall Study|Death|0
6338244|NCT03209570|10091204|FG000|Overall Study|Incomplete Data|8
6338245|NCT03209570|10091205|FG001|Overall Study|Incomplete Data|10
6338246|NCT03209570|10091204|FG000|Overall Study|Protocol Violation|1
6338247|NCT03209570|10091205|FG001|Overall Study|Protocol Violation|0
6338248|NCT03209570|10091204|FG000|Overall Study|Withdrawal by Subject|0
6338249|NCT03209570|10091205|FG001|Overall Study|Withdrawal by Subject|3
6338250|NCT03209973|10091222|FG000|Overall Study|Withdrawal by Subject|7
6338251|NCT03209973|10091222|FG000|Overall Study|Lost to Follow-up|2
6338252|NCT03209973|10091222|FG000|Overall Study|Death|8
6338253|NCT03209973|10091222|FG000|Overall Study|Transferred to Long Term Extension (LTE) study|32
6338254|NCT03209973|10091222|FG000|Overall Study|Sponsor Decision|18
6338255|NCT03209973|10091222|FG000|Overall Study|Participant Withdrew Due to Higher Risk than Benefit of Treatment|1
6338256|NCT03209973|10091222|FG000|Overall Study|Participant Refused to Return to Treatment|2
6338257|NCT03210220|10091239|FG000|Overall Study|Physician Decision|1
6338258|NCT03210220|10091240|FG001|Overall Study|Physician Decision|0
6338259|NCT03210259|10091248|FG000|12-Week Run-in Period|Adverse Event|1
6338260|NCT03210259|10091249|FG001|12-Week Run-in Period|Adverse Event|0
6338261|NCT03210259|10091250|FG002|12-Week Run-in Period|Adverse Event|0
6338262|NCT03210259|10091248|FG000|12-Week Run-in Period|Death|1
6338263|NCT03210259|10091249|FG001|12-Week Run-in Period|Death|0
6338264|NCT03210259|10091250|FG002|12-Week Run-in Period|Death|0
6338265|NCT03210259|10091248|FG000|12-Week Run-in Period|Withdrawal by Subject|9
6338266|NCT03210259|10091249|FG001|12-Week Run-in Period|Withdrawal by Subject|0
6338267|NCT03210259|10091250|FG002|12-Week Run-in Period|Withdrawal by Subject|0
6338268|NCT03210259|10091248|FG000|12-Week Run-in Period|Lost to Follow-up|4
6338269|NCT03210259|10091249|FG001|12-Week Run-in Period|Lost to Follow-up|0
6338270|NCT03210259|10091250|FG002|12-Week Run-in Period|Lost to Follow-up|0
6338271|NCT03210259|10091248|FG000|12-Week Run-in Period|Lack of Efficacy|6
6338272|NCT03210259|10091249|FG001|12-Week Run-in Period|Lack of Efficacy|0
6338273|NCT03210259|10091250|FG002|12-Week Run-in Period|Lack of Efficacy|0
6338274|NCT03210259|10091248|FG000|48-Week Randomized Responder Period|Missed study visit|0
6338275|NCT03210259|10091249|FG001|48-Week Randomized Responder Period|Missed study visit|1
6338276|NCT03210259|10091250|FG002|48-Week Randomized Responder Period|Missed study visit|2
6338277|NCT03210259|10091248|FG000|48-Week Randomized Responder Period|Lost to Follow-up|0
6338278|NCT03210259|10091249|FG001|48-Week Randomized Responder Period|Lost to Follow-up|3
6338279|NCT03210259|10091250|FG002|48-Week Randomized Responder Period|Lost to Follow-up|8
6338280|NCT03210259|10091248|FG000|48-Week Randomized Responder Period|Pregnancy|0
6338281|NCT03210259|10091249|FG001|48-Week Randomized Responder Period|Pregnancy|1
6338282|NCT03210259|10091250|FG002|48-Week Randomized Responder Period|Pregnancy|0
6338283|NCT03210259|10091248|FG000|48-Week Randomized Responder Period|Physician Decision|0
6338284|NCT03210259|10091249|FG001|48-Week Randomized Responder Period|Physician Decision|0
6338285|NCT03210259|10091250|FG002|48-Week Randomized Responder Period|Physician Decision|1
6338286|NCT03210259|10091248|FG000|48-Week Randomized Responder Period|Withdrawal by Subject|0
6338287|NCT03210259|10091249|FG001|48-Week Randomized Responder Period|Withdrawal by Subject|5
6338288|NCT03210259|10091250|FG002|48-Week Randomized Responder Period|Withdrawal by Subject|17
6338289|NCT03210259|10091248|FG000|48-Week Randomized Responder Period|Adverse Event|0
6338290|NCT03210259|10091249|FG001|48-Week Randomized Responder Period|Adverse Event|1
6338291|NCT03210259|10091250|FG002|48-Week Randomized Responder Period|Adverse Event|1
6338292|NCT03210519|10091277|FG000|Overall Study|Adverse Event|2
6338293|NCT03210519|10091278|FG001|Overall Study|Adverse Event|0
6338294|NCT03210961|10091303|FG000|Overall Study|Adverse Event|0
6338295|NCT03210961|10091304|FG001|Overall Study|Adverse Event|0
6338296|NCT03210961|10091305|FG002|Overall Study|Adverse Event|0
6338297|NCT03210961|10091306|FG003|Overall Study|Adverse Event|0
6338298|NCT03210961|10091307|FG004|Overall Study|Adverse Event|0
6338299|NCT03210961|10091308|FG005|Overall Study|Adverse Event|0
6338300|NCT03210961|10091309|FG006|Overall Study|Adverse Event|0
6338301|NCT03210961|10091310|FG007|Overall Study|Adverse Event|0
6338302|NCT03210961|10091311|FG008|Overall Study|Adverse Event|0
6338303|NCT03210961|10091312|FG009|Overall Study|Adverse Event|0
6338304|NCT03210961|10091313|FG010|Overall Study|Adverse Event|0
6338305|NCT03210961|10091314|FG011|Overall Study|Adverse Event|0
6338306|NCT03210961|10091315|FG012|Overall Study|Adverse Event|0
6338307|NCT03210961|10091316|FG013|Overall Study|Adverse Event|1
6338308|NCT03210961|10091317|FG014|Overall Study|Adverse Event|0
6338309|NCT03210961|10091303|FG000|Overall Study|Lost to Follow-up|0
6338310|NCT03210961|10091304|FG001|Overall Study|Lost to Follow-up|0
6338311|NCT03210961|10091305|FG002|Overall Study|Lost to Follow-up|0
6338312|NCT03210961|10091306|FG003|Overall Study|Lost to Follow-up|0
6338313|NCT03210961|10091307|FG004|Overall Study|Lost to Follow-up|0
6338314|NCT03210961|10091308|FG005|Overall Study|Lost to Follow-up|0
6338315|NCT03210961|10091309|FG006|Overall Study|Lost to Follow-up|0
6338316|NCT03210961|10091310|FG007|Overall Study|Lost to Follow-up|0
6338317|NCT03210961|10091311|FG008|Overall Study|Lost to Follow-up|0
6338318|NCT03210961|10091312|FG009|Overall Study|Lost to Follow-up|0
6338319|NCT03210961|10091313|FG010|Overall Study|Lost to Follow-up|0
6338320|NCT03210961|10091314|FG011|Overall Study|Lost to Follow-up|0
6338321|NCT03210961|10091315|FG012|Overall Study|Lost to Follow-up|0
6338322|NCT03210961|10091316|FG013|Overall Study|Lost to Follow-up|0
6338323|NCT03210961|10091317|FG014|Overall Study|Lost to Follow-up|1
6338324|NCT03210961|10091303|FG000|Overall Study|Withdrawal by Subject|0
6338325|NCT03210961|10091304|FG001|Overall Study|Withdrawal by Subject|0
6338326|NCT03210961|10091305|FG002|Overall Study|Withdrawal by Subject|0
6338327|NCT03210961|10091306|FG003|Overall Study|Withdrawal by Subject|0
6338328|NCT03210961|10091307|FG004|Overall Study|Withdrawal by Subject|0
6338329|NCT03210961|10091308|FG005|Overall Study|Withdrawal by Subject|0
6338330|NCT03210961|10091309|FG006|Overall Study|Withdrawal by Subject|0
6338331|NCT03210961|10091310|FG007|Overall Study|Withdrawal by Subject|0
6338332|NCT03210961|10091311|FG008|Overall Study|Withdrawal by Subject|0
6338333|NCT03210961|10091312|FG009|Overall Study|Withdrawal by Subject|0
6338334|NCT03210961|10091313|FG010|Overall Study|Withdrawal by Subject|0
6338335|NCT03210961|10091314|FG011|Overall Study|Withdrawal by Subject|0
6338336|NCT03210961|10091315|FG012|Overall Study|Withdrawal by Subject|0
6338337|NCT03210961|10091316|FG013|Overall Study|Withdrawal by Subject|0
6338338|NCT03210961|10091317|FG014|Overall Study|Withdrawal by Subject|1
6338339|NCT03210961|10091303|FG000|Overall Study|No Longer Meets Eligibility Criteria|0
6338340|NCT03210961|10091304|FG001|Overall Study|No Longer Meets Eligibility Criteria|0
6338341|NCT03210961|10091305|FG002|Overall Study|No Longer Meets Eligibility Criteria|0
6338342|NCT03210961|10091306|FG003|Overall Study|No Longer Meets Eligibility Criteria|0
6338343|NCT03210961|10091307|FG004|Overall Study|No Longer Meets Eligibility Criteria|0
6338344|NCT03210961|10091308|FG005|Overall Study|No Longer Meets Eligibility Criteria|0
6338345|NCT03210961|10091309|FG006|Overall Study|No Longer Meets Eligibility Criteria|0
6338346|NCT03210961|10091310|FG007|Overall Study|No Longer Meets Eligibility Criteria|0
6338347|NCT03210961|10091311|FG008|Overall Study|No Longer Meets Eligibility Criteria|0
6338348|NCT03210961|10091312|FG009|Overall Study|No Longer Meets Eligibility Criteria|0
6338349|NCT03210961|10091313|FG010|Overall Study|No Longer Meets Eligibility Criteria|0
6338350|NCT03210961|10091314|FG011|Overall Study|No Longer Meets Eligibility Criteria|0
6338351|NCT03210961|10091315|FG012|Overall Study|No Longer Meets Eligibility Criteria|0
6338352|NCT03210961|10091316|FG013|Overall Study|No Longer Meets Eligibility Criteria|1
6338353|NCT03210961|10091317|FG014|Overall Study|No Longer Meets Eligibility Criteria|0
6338354|NCT03210961|10091303|FG000|Overall Study|Other|0
6338355|NCT03210961|10091304|FG001|Overall Study|Other|0
6338356|NCT03210961|10091305|FG002|Overall Study|Other|0
6338357|NCT03210961|10091306|FG003|Overall Study|Other|1
6338358|NCT03210961|10091307|FG004|Overall Study|Other|0
6338359|NCT03210961|10091308|FG005|Overall Study|Other|0
6338360|NCT03210961|10091309|FG006|Overall Study|Other|1
6338361|NCT03210961|10091310|FG007|Overall Study|Other|0
6338362|NCT03210961|10091311|FG008|Overall Study|Other|0
6338363|NCT03210961|10091312|FG009|Overall Study|Other|0
6338364|NCT03210961|10091313|FG010|Overall Study|Other|1
6338365|NCT03210961|10091314|FG011|Overall Study|Other|0
6338366|NCT03210961|10091315|FG012|Overall Study|Other|2
6338367|NCT03210961|10091316|FG013|Overall Study|Other|2
6338368|NCT03210961|10091317|FG014|Overall Study|Other|0
6338369|NCT03211156|10091377|FG000|Overall Study|Withdrawal by Subject|0
6338370|NCT03211156|10091378|FG001|Overall Study|Withdrawal by Subject|2
6338371|NCT03211156|10091377|FG000|Overall Study|Lost to Follow-up|1
6338372|NCT03211156|10091378|FG001|Overall Study|Lost to Follow-up|1
6338373|NCT03211156|10091377|FG000|Overall Study|Adverse Event|1
6338374|NCT03211156|10091378|FG001|Overall Study|Adverse Event|0
6338375|NCT03212261|10091397|FG000|Overall Study|Became ineligible d/t tech|2
6338376|NCT03212261|10091397|FG000|Overall Study|Tech Trouble- No first study visit|1
6338377|NCT03212261|10091397|FG000|Overall Study|Lost to Follow-up|7
6338378|NCT03212261|10091397|FG000|Overall Study|Family Emergency|1
6338379|NCT03212261|10091397|FG000|Overall Study|Too busy/ No time|5
6338380|NCT03212326|10091402|FG000|Overall Study|Physician Decision|4
6338381|NCT03212365|10091408|FG000|Overall Study|Discharged prior to Xa level|12
6338382|NCT03212365|10091409|FG001|Overall Study|Discharged prior to Xa level|8
6338383|NCT03212365|10091408|FG000|Overall Study|Bled requiring enoxaparin cessation|4
6338384|NCT03212365|10091409|FG001|Overall Study|Bled requiring enoxaparin cessation|2
6338385|NCT03212365|10091408|FG000|Overall Study|Refused study medication|3
6338386|NCT03212365|10091409|FG001|Overall Study|Refused study medication|0
6338387|NCT03212365|10091408|FG000|Overall Study|Initiated heparin infusion on floor|1
6338388|NCT03212365|10091409|FG001|Overall Study|Initiated heparin infusion on floor|1
6338389|NCT03212365|10091408|FG000|Overall Study|Unexpected return to OR|1
6338390|NCT03212365|10091409|FG001|Overall Study|Unexpected return to OR|1
6338391|NCT03212365|10091408|FG000|Overall Study|Medication distribution error|1
6338392|NCT03212365|10091409|FG001|Overall Study|Medication distribution error|0
6338393|NCT03212365|10091408|FG000|Overall Study|Required epidural placement|1
6338394|NCT03212365|10091409|FG001|Overall Study|Required epidural placement|0
6338395|NCT03212365|10091408|FG000|Overall Study|Withdrawal by Subject|0
6338396|NCT03212365|10091409|FG001|Overall Study|Withdrawal by Subject|1
6338397|NCT03212365|10091408|FG000|Overall Study|developed acute renal failure|0
6338398|NCT03212365|10091409|FG001|Overall Study|developed acute renal failure|1
6338399|NCT03212521|10091415|FG000|Overall Study|Adverse Event|1
6338400|NCT03212521|10091415|FG000|Overall Study|Lost to Follow-up|4
6338401|NCT03212521|10091415|FG000|Overall Study|Withdrawal by Subject|1
6338402|NCT03212521|10091415|FG000|Overall Study|Other|1
6338403|NCT03212690|10091437|FG000|Overall Study|Protocol Violation|1
6338404|NCT03213210|10091441|FG000|Overall Study|Lost to Follow-up|2
6338405|NCT03213210|10091441|FG000|Overall Study|Study termination|3
6338406|NCT03213366|10091447|FG000|Overall Study|Lost to Follow-up|9
6338407|NCT03213366|10091448|FG001|Overall Study|Lost to Follow-up|4
6338408|NCT03213509|10091473|FG000|Overall Study|Did not consent for verbal autopsy|4
6338409|NCT03213509|10091474|FG001|Overall Study|Did not consent for verbal autopsy|5
6338410|NCT03213626|10091481|FG000|Overall Study|Adverse Event|1
6338411|NCT03213626|10091481|FG000|Overall Study|Progressive Disease|6
6338412|NCT03213938|10091487|FG000|Overall Study|Lost to Follow-up|4
6338413|NCT03213938|10091488|FG001|Overall Study|Lost to Follow-up|3
6338414|NCT03213938|10091487|FG000|Overall Study|Lack of Efficacy|1
6338415|NCT03213938|10091488|FG001|Overall Study|Lack of Efficacy|0
6338416|NCT03213938|10091487|FG000|Overall Study|Decline to participate|5
6338417|NCT03213938|10091488|FG001|Overall Study|Decline to participate|4
6338418|NCT03213938|10091487|FG000|Overall Study|Without reason|4
6338419|NCT03213938|10091488|FG001|Overall Study|Without reason|5
6338420|NCT03214081|10091494|FG000|Overall Study|Case Report Forms Uncollected|9
6338421|NCT03214081|10091494|FG000|Overall Study|Protocol Deviation|54
6338422|NCT03214094|10091498|FG000|Overall Study|Case Report Forms Uncollected|14
6338423|NCT03214094|10091498|FG000|Overall Study|Protocol Deviation|46
6338424|NCT03214198|10091502|FG000|Overall Study|Case Report Forms Uncollected|18
6338425|NCT03214198|10091502|FG000|Overall Study|Protocol Deviation|18
6338426|NCT03214224|10091506|FG000|Overall Study|Protocol Violation|1
6338427|NCT03214224|10091506|FG000|Overall Study|Withdrawal by Subject|2
6338428|NCT03214224|10091506|FG000|Overall Study|Practice controls or therapists|6
6338429|NCT03214367|10091516|FG000|Lead-in Period|Withdrawal by Subject|50
6338430|NCT03214367|10091517|FG001|Lead-in Period|Withdrawal by Subject|0
6338431|NCT03214367|10091518|FG002|Lead-in Period|Withdrawal by Subject|0
6338432|NCT03214367|10091519|FG003|Lead-in Period|Withdrawal by Subject|0
6338433|NCT03214367|10091520|FG004|Lead-in Period|Withdrawal by Subject|2
6338434|NCT03214367|10091521|FG005|Lead-in Period|Withdrawal by Subject|0
6338435|NCT03214367|10091522|FG006|Lead-in Period|Withdrawal by Subject|0
6338436|NCT03214367|10091523|FG007|Lead-in Period|Withdrawal by Subject|0
6338437|NCT03214367|10091516|FG000|Lead-in Period|Adverse Event|3
6338438|NCT03214367|10091517|FG001|Lead-in Period|Adverse Event|0
6338439|NCT03214367|10091518|FG002|Lead-in Period|Adverse Event|0
6338440|NCT03214367|10091519|FG003|Lead-in Period|Adverse Event|0
6338441|NCT03214367|10091520|FG004|Lead-in Period|Adverse Event|0
6338442|NCT03214367|10091521|FG005|Lead-in Period|Adverse Event|0
6338443|NCT03214367|10091522|FG006|Lead-in Period|Adverse Event|0
6338444|NCT03214367|10091523|FG007|Lead-in Period|Adverse Event|0
6338445|NCT03214367|10091516|FG000|Lead-in Period|Lost to Follow-up|12
6338446|NCT03214367|10091517|FG001|Lead-in Period|Lost to Follow-up|0
6338447|NCT03214367|10091518|FG002|Lead-in Period|Lost to Follow-up|0
6338448|NCT03214367|10091519|FG003|Lead-in Period|Lost to Follow-up|0
6338449|NCT03214367|10091520|FG004|Lead-in Period|Lost to Follow-up|0
6338450|NCT03214367|10091521|FG005|Lead-in Period|Lost to Follow-up|0
6338451|NCT03214367|10091522|FG006|Lead-in Period|Lost to Follow-up|0
6338452|NCT03214367|10091523|FG007|Lead-in Period|Lost to Follow-up|0
6338453|NCT03214367|10091516|FG000|Lead-in Period|Sponsor Decision|11
6338454|NCT03214367|10091517|FG001|Lead-in Period|Sponsor Decision|0
6338455|NCT03214367|10091518|FG002|Lead-in Period|Sponsor Decision|0
6338456|NCT03214367|10091519|FG003|Lead-in Period|Sponsor Decision|0
6338457|NCT03214367|10091520|FG004|Lead-in Period|Sponsor Decision|0
6338458|NCT03214367|10091521|FG005|Lead-in Period|Sponsor Decision|0
6338459|NCT03214367|10091522|FG006|Lead-in Period|Sponsor Decision|0
6338460|NCT03214367|10091523|FG007|Lead-in Period|Sponsor Decision|0
6338461|NCT03214367|10091516|FG000|Lead-in Period|Physician Decision|12
6338462|NCT03214367|10091517|FG001|Lead-in Period|Physician Decision|0
6338463|NCT03214367|10091518|FG002|Lead-in Period|Physician Decision|0
6338464|NCT03214367|10091519|FG003|Lead-in Period|Physician Decision|0
6338465|NCT03214367|10091520|FG004|Lead-in Period|Physician Decision|0
6338466|NCT03214367|10091521|FG005|Lead-in Period|Physician Decision|0
6338467|NCT03214367|10091522|FG006|Lead-in Period|Physician Decision|0
6338468|NCT03214367|10091523|FG007|Lead-in Period|Physician Decision|0
6338469|NCT03214367|10091516|FG000|Lead-in Period|Protocol Violation|5
6338470|NCT03214367|10091517|FG001|Lead-in Period|Protocol Violation|0
6338471|NCT03214367|10091518|FG002|Lead-in Period|Protocol Violation|0
6338472|NCT03214367|10091519|FG003|Lead-in Period|Protocol Violation|0
6083216|NCT00634244|9691582|FG000|Overall Study|Never started treatment|0
6083217|NCT00634244|9691583|FG001|Overall Study|Never started treatment|1
6083218|NCT00634244|9691584|FG002|Overall Study|Never started treatment|0
6338473|NCT03214367|10091520|FG004|Lead-in Period|Protocol Violation|0
6338474|NCT03214367|10091521|FG005|Lead-in Period|Protocol Violation|0
6338475|NCT03214367|10091522|FG006|Lead-in Period|Protocol Violation|0
6338476|NCT03214367|10091523|FG007|Lead-in Period|Protocol Violation|0
6338477|NCT03214367|10091516|FG000|Lead-in Period|Treatment Interruption|1
6338478|NCT03214367|10091517|FG001|Lead-in Period|Treatment Interruption|0
6338479|NCT03214367|10091518|FG002|Lead-in Period|Treatment Interruption|0
6338480|NCT03214367|10091519|FG003|Lead-in Period|Treatment Interruption|0
6338481|NCT03214367|10091520|FG004|Lead-in Period|Treatment Interruption|0
6338482|NCT03214367|10091521|FG005|Lead-in Period|Treatment Interruption|0
6338483|NCT03214367|10091522|FG006|Lead-in Period|Treatment Interruption|0
6338484|NCT03214367|10091523|FG007|Lead-in Period|Treatment Interruption|0
6338485|NCT03214367|10091516|FG000|Treatment Period|Adverse Event|0
6338486|NCT03214367|10091517|FG001|Treatment Period|Adverse Event|1
6338487|NCT03214367|10091518|FG002|Treatment Period|Adverse Event|4
6338488|NCT03214367|10091519|FG003|Treatment Period|Adverse Event|2
6338489|NCT03214367|10091520|FG004|Treatment Period|Adverse Event|0
6083219|NCT00634244|9691582|FG000|Overall Study|Death|1
6083220|NCT00634244|9691583|FG001|Overall Study|Death|6
6083221|NCT00634244|9691584|FG002|Overall Study|Death|0
6083222|NCT00634244|9691582|FG000|Overall Study|Adverse Event|0
6083223|NCT00634244|9691583|FG001|Overall Study|Adverse Event|2
6083224|NCT00634244|9691584|FG002|Overall Study|Adverse Event|0
6083225|NCT00634244|9691582|FG000|Overall Study|Withdrawal by Subject|0
6083226|NCT00634244|9691583|FG001|Overall Study|Withdrawal by Subject|1
6083227|NCT00634244|9691584|FG002|Overall Study|Withdrawal by Subject|0
6083228|NCT00634244|9691582|FG000|Overall Study|Physician Decision|0
6083229|NCT00634244|9691583|FG001|Overall Study|Physician Decision|1
6083230|NCT00634244|9691584|FG002|Overall Study|Physician Decision|0
6083231|NCT00634244|9691582|FG000|Overall Study|Disease progression/relapse|0
6083232|NCT00634244|9691583|FG001|Overall Study|Disease progression/relapse|1
6083233|NCT00634244|9691584|FG002|Overall Study|Disease progression/relapse|0
6083234|NCT00634244|9691582|FG000|Overall Study|Other complicating disease|0
6083235|NCT00634244|9691583|FG001|Overall Study|Other complicating disease|1
6083236|NCT00634244|9691584|FG002|Overall Study|Other complicating disease|0
6087730|NCT00670111|9698176|FG000|Enrollment to One Month|Ebrolled Patients but not Implanted|0
6087731|NCT00670111|9698177|FG001|Enrollment to One Month|Ebrolled Patients but not Implanted|0
6087732|NCT00670111|9698178|FG002|Enrollment to One Month|Ebrolled Patients but not Implanted|6
6087733|NCT00670111|9698176|FG000|Enrollment to One Month|Physician Decision|1
6338490|NCT03214367|10091521|FG005|Treatment Period|Adverse Event|0
6338491|NCT03214367|10091522|FG006|Treatment Period|Adverse Event|0
6338492|NCT03214367|10091523|FG007|Treatment Period|Adverse Event|0
6338493|NCT03214367|10091516|FG000|Treatment Period|Death|0
6338494|NCT03214367|10091517|FG001|Treatment Period|Death|1
6338495|NCT03214367|10091518|FG002|Treatment Period|Death|1
6338496|NCT03214367|10091519|FG003|Treatment Period|Death|1
6338497|NCT03214367|10091520|FG004|Treatment Period|Death|0
6338498|NCT03214367|10091521|FG005|Treatment Period|Death|0
6338499|NCT03214367|10091522|FG006|Treatment Period|Death|0
6338500|NCT03214367|10091523|FG007|Treatment Period|Death|0
6338501|NCT03214367|10091516|FG000|Treatment Period|Lost to Follow-up|0
6338502|NCT03214367|10091517|FG001|Treatment Period|Lost to Follow-up|5
6338503|NCT03214367|10091518|FG002|Treatment Period|Lost to Follow-up|3
6338504|NCT03214367|10091519|FG003|Treatment Period|Lost to Follow-up|2
6338505|NCT03214367|10091520|FG004|Treatment Period|Lost to Follow-up|0
6087734|NCT00670111|9698177|FG001|Enrollment to One Month|Physician Decision|0
6087735|NCT00670111|9698178|FG002|Enrollment to One Month|Physician Decision|0
6087736|NCT00670228|9698197|FG000|Overall Study|Adverse Event|1
6087737|NCT00670228|9698198|FG001|Overall Study|Adverse Event|0
6087738|NCT00670228|9698197|FG000|Overall Study|Death or MACE|0
6087739|NCT00670228|9698198|FG001|Overall Study|Death or MACE|1
6087740|NCT00670228|9698197|FG000|Overall Study|Not treated|2
6087741|NCT00670228|9698198|FG001|Overall Study|Not treated|2
6087742|NCT00670228|9698197|FG000|Overall Study|Not meeting the selection criteria|2
6087743|NCT00670228|9698198|FG001|Overall Study|Not meeting the selection criteria|0
6087744|NCT00670306|9698223|FG000|Overall Study|Adverse Event|8
6087745|NCT00670306|9698223|FG000|Overall Study|Lack of Efficacy|10
6087746|NCT00670306|9698223|FG000|Overall Study|Withdrawal by Subject|9
6087747|NCT00670306|9698223|FG000|Overall Study|Physician Decision|1
6087748|NCT00670306|9698223|FG000|Overall Study|Lost to Follow-up|8
6087749|NCT00670306|9698223|FG000|Overall Study|incl/excl criterias did not meet|19
6087750|NCT00670449|9698231|FG000|Overall Study|Adverse Event|6
6087751|NCT00670449|9698232|FG001|Overall Study|Adverse Event|2
6087752|NCT00670449|9698233|FG002|Overall Study|Adverse Event|8
6087753|NCT00670449|9698234|FG003|Overall Study|Adverse Event|5
6338506|NCT03214367|10091521|FG005|Treatment Period|Lost to Follow-up|2
6338507|NCT03214367|10091522|FG006|Treatment Period|Lost to Follow-up|1
6338508|NCT03214367|10091523|FG007|Treatment Period|Lost to Follow-up|0
6338509|NCT03214367|10091516|FG000|Treatment Period|Sponsor Decision|0
6338510|NCT03214367|10091517|FG001|Treatment Period|Sponsor Decision|3
6338511|NCT03214367|10091518|FG002|Treatment Period|Sponsor Decision|0
6338512|NCT03214367|10091519|FG003|Treatment Period|Sponsor Decision|0
6338513|NCT03214367|10091520|FG004|Treatment Period|Sponsor Decision|0
6338514|NCT03214367|10091521|FG005|Treatment Period|Sponsor Decision|0
6338515|NCT03214367|10091522|FG006|Treatment Period|Sponsor Decision|0
6338516|NCT03214367|10091523|FG007|Treatment Period|Sponsor Decision|0
6338517|NCT03214367|10091516|FG000|Treatment Period|Physician Decision|0
6338518|NCT03214367|10091517|FG001|Treatment Period|Physician Decision|1
6338519|NCT03214367|10091518|FG002|Treatment Period|Physician Decision|2
6338520|NCT03214367|10091519|FG003|Treatment Period|Physician Decision|0
6338521|NCT03214367|10091520|FG004|Treatment Period|Physician Decision|0
6338522|NCT03214367|10091521|FG005|Treatment Period|Physician Decision|0
6338523|NCT03214367|10091522|FG006|Treatment Period|Physician Decision|0
6338524|NCT03214367|10091523|FG007|Treatment Period|Physician Decision|0
6338525|NCT03214367|10091516|FG000|Treatment Period|Protocol Violation|0
6338526|NCT03214367|10091517|FG001|Treatment Period|Protocol Violation|3
6338527|NCT03214367|10091518|FG002|Treatment Period|Protocol Violation|0
6338528|NCT03214367|10091519|FG003|Treatment Period|Protocol Violation|0
6338529|NCT03214367|10091520|FG004|Treatment Period|Protocol Violation|0
6338530|NCT03214367|10091521|FG005|Treatment Period|Protocol Violation|0
6338531|NCT03214367|10091522|FG006|Treatment Period|Protocol Violation|0
6338532|NCT03214367|10091523|FG007|Treatment Period|Protocol Violation|0
6338533|NCT03214367|10091516|FG000|Treatment Period|Withdrawal by Subject|0
6338534|NCT03214367|10091517|FG001|Treatment Period|Withdrawal by Subject|20
6338535|NCT03214367|10091518|FG002|Treatment Period|Withdrawal by Subject|23
6338536|NCT03214367|10091519|FG003|Treatment Period|Withdrawal by Subject|14
6338537|NCT03214367|10091520|FG004|Treatment Period|Withdrawal by Subject|0
6338538|NCT03214367|10091521|FG005|Treatment Period|Withdrawal by Subject|1
6338539|NCT03214367|10091522|FG006|Treatment Period|Withdrawal by Subject|1
6338540|NCT03214367|10091523|FG007|Treatment Period|Withdrawal by Subject|1
6338541|NCT03214380|10091541|FG000|Lead-in|Adverse Event|3
6338542|NCT03214380|10091542|FG001|Lead-in|Adverse Event|0
6338543|NCT03214380|10091543|FG002|Lead-in|Adverse Event|0
6338544|NCT03214380|10091544|FG003|Lead-in|Adverse Event|1
6338545|NCT03214380|10091545|FG004|Lead-in|Adverse Event|0
6338546|NCT03214380|10091546|FG005|Lead-in|Adverse Event|0
6338547|NCT03214380|10091541|FG000|Lead-in|Lost to Follow-up|4
6338548|NCT03214380|10091542|FG001|Lead-in|Lost to Follow-up|0
6338549|NCT03214380|10091543|FG002|Lead-in|Lost to Follow-up|0
6338550|NCT03214380|10091544|FG003|Lead-in|Lost to Follow-up|1
6338551|NCT03214380|10091545|FG004|Lead-in|Lost to Follow-up|0
6338552|NCT03214380|10091546|FG005|Lead-in|Lost to Follow-up|0
6338553|NCT03214380|10091541|FG000|Lead-in|Eligibility Criteria|3
6338554|NCT03214380|10091542|FG001|Lead-in|Eligibility Criteria|0
6338555|NCT03214380|10091543|FG002|Lead-in|Eligibility Criteria|0
6338556|NCT03214380|10091544|FG003|Lead-in|Eligibility Criteria|0
6338557|NCT03214380|10091545|FG004|Lead-in|Eligibility Criteria|0
6338558|NCT03214380|10091546|FG005|Lead-in|Eligibility Criteria|0
6338559|NCT03214380|10091541|FG000|Lead-in|Physician Decision|6
6338560|NCT03214380|10091542|FG001|Lead-in|Physician Decision|0
6338561|NCT03214380|10091543|FG002|Lead-in|Physician Decision|0
6338562|NCT03214380|10091544|FG003|Lead-in|Physician Decision|0
6338563|NCT03214380|10091545|FG004|Lead-in|Physician Decision|0
6338564|NCT03214380|10091546|FG005|Lead-in|Physician Decision|0
6338565|NCT03214380|10091541|FG000|Lead-in|Protocol Deviation|7
6338566|NCT03214380|10091542|FG001|Lead-in|Protocol Deviation|0
6338567|NCT03214380|10091543|FG002|Lead-in|Protocol Deviation|0
6338568|NCT03214380|10091544|FG003|Lead-in|Protocol Deviation|3
6338569|NCT03214380|10091545|FG004|Lead-in|Protocol Deviation|0
6338570|NCT03214380|10091546|FG005|Lead-in|Protocol Deviation|0
6338571|NCT03214380|10091541|FG000|Lead-in|Withdrawal by Subject|41
6338572|NCT03214380|10091542|FG001|Lead-in|Withdrawal by Subject|0
6338573|NCT03214380|10091543|FG002|Lead-in|Withdrawal by Subject|0
6338574|NCT03214380|10091544|FG003|Lead-in|Withdrawal by Subject|14
6338575|NCT03214380|10091545|FG004|Lead-in|Withdrawal by Subject|0
6338576|NCT03214380|10091546|FG005|Lead-in|Withdrawal by Subject|0
6338577|NCT03214380|10091541|FG000|Lead-in|Family Emergency|1
6338578|NCT03214380|10091542|FG001|Lead-in|Family Emergency|0
6338579|NCT03214380|10091543|FG002|Lead-in|Family Emergency|0
6338580|NCT03214380|10091544|FG003|Lead-in|Family Emergency|0
6338581|NCT03214380|10091545|FG004|Lead-in|Family Emergency|0
6338582|NCT03214380|10091546|FG005|Lead-in|Family Emergency|0
6338583|NCT03214380|10091541|FG000|Lead-in|Natural Disaster|9
6338584|NCT03214380|10091542|FG001|Lead-in|Natural Disaster|0
6338585|NCT03214380|10091543|FG002|Lead-in|Natural Disaster|0
6338586|NCT03214380|10091544|FG003|Lead-in|Natural Disaster|0
6338587|NCT03214380|10091545|FG004|Lead-in|Natural Disaster|0
6338588|NCT03214380|10091546|FG005|Lead-in|Natural Disaster|0
6338589|NCT03214380|10091541|FG000|Lead-in|Non Compliance|1
6338590|NCT03214380|10091542|FG001|Lead-in|Non Compliance|0
6338591|NCT03214380|10091543|FG002|Lead-in|Non Compliance|0
6338592|NCT03214380|10091544|FG003|Lead-in|Non Compliance|0
6338593|NCT03214380|10091545|FG004|Lead-in|Non Compliance|0
6338594|NCT03214380|10091546|FG005|Lead-in|Non Compliance|0
6338595|NCT03214380|10091541|FG000|Lead-in|Participant Schedule|2
6338596|NCT03214380|10091542|FG001|Lead-in|Participant Schedule|0
6338597|NCT03214380|10091543|FG002|Lead-in|Participant Schedule|0
6338598|NCT03214380|10091544|FG003|Lead-in|Participant Schedule|0
6338599|NCT03214380|10091545|FG004|Lead-in|Participant Schedule|0
6338600|NCT03214380|10091546|FG005|Lead-in|Participant Schedule|0
6338601|NCT03214380|10091541|FG000|Treatment Period|Adverse Event|0
6338602|NCT03214380|10091542|FG001|Treatment Period|Adverse Event|1
6338603|NCT03214380|10091543|FG002|Treatment Period|Adverse Event|1
6338604|NCT03214380|10091544|FG003|Treatment Period|Adverse Event|0
6338605|NCT03214380|10091545|FG004|Treatment Period|Adverse Event|1
6338606|NCT03214380|10091546|FG005|Treatment Period|Adverse Event|0
6338607|NCT03214380|10091541|FG000|Treatment Period|Non-Compliance with Study Drug|0
6338608|NCT03214380|10091542|FG001|Treatment Period|Non-Compliance with Study Drug|0
6338609|NCT03214380|10091543|FG002|Treatment Period|Non-Compliance with Study Drug|0
6338610|NCT03214380|10091544|FG003|Treatment Period|Non-Compliance with Study Drug|0
6338611|NCT03214380|10091545|FG004|Treatment Period|Non-Compliance with Study Drug|1
6338612|NCT03214380|10091546|FG005|Treatment Period|Non-Compliance with Study Drug|0
6338613|NCT03214380|10091541|FG000|Treatment Period|Withdrawal by Subject|0
6338614|NCT03214380|10091542|FG001|Treatment Period|Withdrawal by Subject|10
6338615|NCT03214380|10091543|FG002|Treatment Period|Withdrawal by Subject|8
6338616|NCT03214380|10091544|FG003|Treatment Period|Withdrawal by Subject|0
6338617|NCT03214380|10091545|FG004|Treatment Period|Withdrawal by Subject|7
6338618|NCT03214380|10091546|FG005|Treatment Period|Withdrawal by Subject|11
6338619|NCT03214380|10091541|FG000|Treatment Period|Death|0
6338620|NCT03214380|10091542|FG001|Treatment Period|Death|1
6338621|NCT03214380|10091543|FG002|Treatment Period|Death|2
6338622|NCT03214380|10091544|FG003|Treatment Period|Death|0
6338623|NCT03214380|10091545|FG004|Treatment Period|Death|0
6338624|NCT03214380|10091546|FG005|Treatment Period|Death|0
6338625|NCT03214380|10091541|FG000|Treatment Period|Lost to Follow-up|0
6338626|NCT03214380|10091542|FG001|Treatment Period|Lost to Follow-up|6
6338627|NCT03214380|10091543|FG002|Treatment Period|Lost to Follow-up|3
6338628|NCT03214380|10091544|FG003|Treatment Period|Lost to Follow-up|0
6338629|NCT03214380|10091545|FG004|Treatment Period|Lost to Follow-up|0
6338630|NCT03214380|10091546|FG005|Treatment Period|Lost to Follow-up|0
6338631|NCT03214380|10091541|FG000|Treatment Period|Participant schedule|0
6338632|NCT03214380|10091542|FG001|Treatment Period|Participant schedule|0
6338633|NCT03214380|10091543|FG002|Treatment Period|Participant schedule|1
6338634|NCT03214380|10091544|FG003|Treatment Period|Participant schedule|0
6338635|NCT03214380|10091545|FG004|Treatment Period|Participant schedule|0
6338636|NCT03214380|10091546|FG005|Treatment Period|Participant schedule|0
6338637|NCT03214380|10091541|FG000|Treatment Period|Treatment Interruption|0
6338638|NCT03214380|10091542|FG001|Treatment Period|Treatment Interruption|0
6338639|NCT03214380|10091543|FG002|Treatment Period|Treatment Interruption|1
6338640|NCT03214380|10091544|FG003|Treatment Period|Treatment Interruption|0
6338641|NCT03214380|10091545|FG004|Treatment Period|Treatment Interruption|0
6338642|NCT03214380|10091546|FG005|Treatment Period|Treatment Interruption|0
6338643|NCT03214406|10091560|FG000|Overall Study|did not meet enrollment criteria|9
6338644|NCT03214406|10091561|FG001|Overall Study|did not meet enrollment criteria|13
6338645|NCT03214406|10091560|FG000|Overall Study|Withdrawal by Subject|1
6338646|NCT03214406|10091561|FG001|Overall Study|Withdrawal by Subject|0
6338647|NCT03214406|10091560|FG000|Overall Study|Lost to Follow-up|0
6338648|NCT03214406|10091561|FG001|Overall Study|Lost to Follow-up|2
6338649|NCT03214588|10091570|FG000|Overall Study|Adverse Event|1
6338650|NCT03214588|10091571|FG001|Overall Study|Adverse Event|0
6338651|NCT03214588|10091572|FG002|Overall Study|Adverse Event|2
6338652|NCT03214588|10091570|FG000|Overall Study|Reason Not Specified|0
6338653|NCT03214588|10091571|FG001|Overall Study|Reason Not Specified|1
6338654|NCT03214588|10091572|FG002|Overall Study|Reason Not Specified|0
6338655|NCT03214640|10091584|FG000|Overall Study|Protocol Violation|1
6338656|NCT03214640|10091585|FG001|Overall Study|Protocol Violation|2
6338657|NCT03214640|10091586|FG002|Overall Study|Protocol Violation|1
6338658|NCT03214640|10091587|FG003|Overall Study|Protocol Violation|4
6338659|NCT03214952|10091597|FG000|Overall Study|Protocol Deviation|45
6338660|NCT03214952|10091597|FG000|Overall Study|Case Report Forms Uncollected|13
6338661|NCT03215667|10091601|FG000|Overall Study|Physician Decision|4
6338662|NCT03215758|10091607|FG000|Overall Study|Technical Problems|1
6338663|NCT03215758|10091608|FG001|Overall Study|Technical Problems|0
6338664|NCT03215758|10091607|FG000|Overall Study|Protocol deviation|0
6338665|NCT03215758|10091608|FG001|Overall Study|Protocol deviation|1
6338666|NCT03215758|10091607|FG000|Overall Study|Physician Decision|0
6338667|NCT03215758|10091608|FG001|Overall Study|Physician Decision|1
6083237|NCT00634504|9691615|FG000|Overall Study|Protocol Violation|1
6083238|NCT00634504|9691616|FG001|Overall Study|Protocol Violation|0
6338668|NCT03215758|10091607|FG000|Overall Study|Death|0
6338669|NCT03215758|10091608|FG001|Overall Study|Death|1
6338670|NCT03215758|10091607|FG000|Overall Study|Adverse Event|1
6338671|NCT03215758|10091608|FG001|Overall Study|Adverse Event|2
6338672|NCT03215758|10091607|FG000|Overall Study|Subject/Guardian Decision|3
6338673|NCT03215758|10091608|FG001|Overall Study|Subject/Guardian Decision|3
6338674|NCT03215771|10091614|FG000|Overall Study|Withdrawal by Subject|2
6338675|NCT03215771|10091614|FG000|Overall Study|Physician Decision|1
6338676|NCT03216226|10091638|FG000|Overall Study|Adverse Event|3
6338677|NCT03216226|10091639|FG001|Overall Study|Adverse Event|0
6338678|NCT03216226|10091638|FG000|Overall Study|Protocol Violation|1
6338679|NCT03216226|10091639|FG001|Overall Study|Protocol Violation|3
6338680|NCT03216226|10091638|FG000|Overall Study|Patient unable to take time off work to come in for the third injection|1
6338681|NCT03216226|10091639|FG001|Overall Study|Patient unable to take time off work to come in for the third injection|0
6338682|NCT03216226|10091638|FG000|Overall Study|Deviation from protocol window during visit as patient had to leave for work|0
6338683|NCT03216226|10091639|FG001|Overall Study|Deviation from protocol window during visit as patient had to leave for work|1
6338684|NCT03216226|10091638|FG000|Overall Study|Patient withdrawn prior to treatment. Patient veins unsuitable for blood draws|0
6338685|NCT03216226|10091639|FG001|Overall Study|Patient withdrawn prior to treatment. Patient veins unsuitable for blood draws|1
6338686|NCT03216265|10091648|FG000|Overall Study|Adverse Event|2
6042898|NCT00385736|9641357|FG001|Safety Analysis Set|Protocol Violation|1
6042899|NCT00385736|9641358|FG002|Safety Analysis Set|Protocol Violation|6
6338687|NCT03216265|10091649|FG001|Overall Study|Adverse Event|0
6338688|NCT03216265|10091650|FG002|Overall Study|Adverse Event|2
6338689|NCT03216265|10091648|FG000|Overall Study|Lost to Follow-up|0
6338690|NCT03216265|10091649|FG001|Overall Study|Lost to Follow-up|1
6338691|NCT03216265|10091650|FG002|Overall Study|Lost to Follow-up|0
6338692|NCT03216265|10091648|FG000|Overall Study|Withdrawal by Subject|0
6338693|NCT03216265|10091649|FG001|Overall Study|Withdrawal by Subject|0
6338694|NCT03216265|10091650|FG002|Overall Study|Withdrawal by Subject|1
6338695|NCT03216746|10091689|FG000|Overall Study|Lost to Follow-up|6
6338696|NCT03216746|10091690|FG001|Overall Study|Lost to Follow-up|8
6338697|NCT03216746|10091691|FG002|Overall Study|Lost to Follow-up|5
6338698|NCT03216746|10091692|FG003|Overall Study|Lost to Follow-up|6
6338699|NCT03216850|10091702|FG000|Overall Study|Pre-analytical error|6
6338700|NCT03216954|10091739|FG000|Overall Study|Adverse Event|0
6338701|NCT03216954|10091740|FG001|Overall Study|Adverse Event|0
6338702|NCT03216954|10091741|FG002|Overall Study|Adverse Event|1
6338703|NCT03216954|10091742|FG003|Overall Study|Adverse Event|0
6338704|NCT03216954|10091743|FG004|Overall Study|Adverse Event|1
6338705|NCT03216954|10091739|FG000|Overall Study|Withdrawal by Subject|2
6338706|NCT03216954|10091740|FG001|Overall Study|Withdrawal by Subject|0
6338707|NCT03216954|10091741|FG002|Overall Study|Withdrawal by Subject|0
6338708|NCT03216954|10091742|FG003|Overall Study|Withdrawal by Subject|0
6338709|NCT03216954|10091743|FG004|Overall Study|Withdrawal by Subject|0
6338710|NCT03216954|10091739|FG000|Overall Study|Subject used cocaine during participation, which is an exclusion criterion.|0
6338711|NCT03216954|10091740|FG001|Overall Study|Subject used cocaine during participation, which is an exclusion criterion.|1
6338712|NCT03216954|10091741|FG002|Overall Study|Subject used cocaine during participation, which is an exclusion criterion.|0
6338713|NCT03216954|10091742|FG003|Overall Study|Subject used cocaine during participation, which is an exclusion criterion.|0
6338714|NCT03216954|10091743|FG004|Overall Study|Subject used cocaine during participation, which is an exclusion criterion.|0
6338715|NCT03217968|10091751|FG000|Overall Study|Withdrawal by Subject|4
6338716|NCT03217968|10091751|FG000|Overall Study|Lost to Follow-up|1
6338717|NCT03217968|10091751|FG000|Overall Study|Protocol Violation|6
6338718|NCT03218397|10091757|FG000|Overall Study|Prior positive blood culture|8
6338719|NCT03218397|10091758|FG001|Overall Study|Prior positive blood culture|13
6338720|NCT03218397|10091757|FG000|Overall Study|Comfort care|8
6338721|NCT03218397|10091758|FG001|Overall Study|Comfort care|5
6338722|NCT03218397|10091757|FG000|Overall Study|Comfort care and positive blood culture|1
6338723|NCT03218397|10091758|FG001|Overall Study|Comfort care and positive blood culture|0
6338724|NCT03218397|10091757|FG000|Overall Study|Comfort care and mixed culture|0
6338725|NCT03218397|10091758|FG001|Overall Study|Comfort care and mixed culture|1
6338726|NCT03218397|10091757|FG000|Overall Study|Mixed culture|2
6338727|NCT03218397|10091758|FG001|Overall Study|Mixed culture|2
6338728|NCT03218397|10091757|FG000|Overall Study|Inaccessible hospital records|2
6338729|NCT03218397|10091758|FG001|Overall Study|Inaccessible hospital records|5
6042900|NCT00385736|9641356|FG000|Safety Analysis Set|Other|1
6042901|NCT00385736|9641357|FG001|Safety Analysis Set|Other|4
6338730|NCT03218397|10091757|FG000|Overall Study|No gram-negative bacilli (GNB)|0
6338731|NCT03218397|10091758|FG001|Overall Study|No gram-negative bacilli (GNB)|2
6338732|NCT03218397|10091757|FG000|Overall Study|Randomized during laboratory off hours|2
6338733|NCT03218397|10091758|FG001|Overall Study|Randomized during laboratory off hours|1
6338734|NCT03218787|10091786|FG000|Overall Study|Lost to Follow-up|12
6338735|NCT03218787|10091786|FG000|Overall Study|Withdrawal by Subject|72
6338736|NCT03218787|10091786|FG000|Overall Study|Physician Decision|11
6338737|NCT03218787|10091786|FG000|Overall Study|Death|111
6338738|NCT03219216|10091792|FG000|Overall Study|Lost to Follow-up|0
6338739|NCT03219216|10091793|FG001|Overall Study|Lost to Follow-up|1
6338740|NCT03219723|10091824|FG000|Overall Study|Case Report Forms Uncollected|6
6338741|NCT03219723|10091824|FG000|Overall Study|Protocol Deviation|4
6338742|NCT03220217|10091890|FG000|Overall Study|Withdrawal by Subject|0
6338743|NCT03220217|10091891|FG001|Overall Study|Withdrawal by Subject|1
6338744|NCT03220217|10091892|FG002|Overall Study|Withdrawal by Subject|0
6338745|NCT03220217|10091890|FG000|Overall Study|Subject Missed Procedure|0
6338746|NCT03220217|10091891|FG001|Overall Study|Subject Missed Procedure|0
6338747|NCT03220217|10091892|FG002|Overall Study|Subject Missed Procedure|1
6338748|NCT03220737|10091943|FG000|Main Study (Day 1 - 181)|Withdrawal by Subject|4
6338749|NCT03220737|10091944|FG001|Main Study (Day 1 - 181)|Withdrawal by Subject|1
6338750|NCT03220737|10091945|FG002|Main Study (Day 1 - 181)|Withdrawal by Subject|4
6338751|NCT03220737|10091946|FG003|Main Study (Day 1 - 181)|Withdrawal by Subject|1
6338752|NCT03220737|10091947|FG004|Main Study (Day 1 - 181)|Withdrawal by Subject|4
6338753|NCT03220737|10091948|FG005|Main Study (Day 1 - 181)|Withdrawal by Subject|0
6338754|NCT03220737|10091949|FG006|Main Study (Day 1 - 181)|Withdrawal by Subject|0
6338755|NCT03220737|10091943|FG000|Main Study (Day 1 - 181)|Lost to Follow-up|2
6338756|NCT03220737|10091944|FG001|Main Study (Day 1 - 181)|Lost to Follow-up|1
6338757|NCT03220737|10091945|FG002|Main Study (Day 1 - 181)|Lost to Follow-up|6
6338758|NCT03220737|10091946|FG003|Main Study (Day 1 - 181)|Lost to Follow-up|1
6338759|NCT03220737|10091947|FG004|Main Study (Day 1 - 181)|Lost to Follow-up|13
6338760|NCT03220737|10091948|FG005|Main Study (Day 1 - 181)|Lost to Follow-up|1
6338761|NCT03220737|10091949|FG006|Main Study (Day 1 - 181)|Lost to Follow-up|0
6338762|NCT03220737|10091943|FG000|Main Study (Day 1 - 181)|Protocol Violation|0
6338763|NCT03220737|10091944|FG001|Main Study (Day 1 - 181)|Protocol Violation|0
6338764|NCT03220737|10091945|FG002|Main Study (Day 1 - 181)|Protocol Violation|1
6338765|NCT03220737|10091946|FG003|Main Study (Day 1 - 181)|Protocol Violation|1
6338766|NCT03220737|10091947|FG004|Main Study (Day 1 - 181)|Protocol Violation|3
6338767|NCT03220737|10091948|FG005|Main Study (Day 1 - 181)|Protocol Violation|0
6338768|NCT03220737|10091949|FG006|Main Study (Day 1 - 181)|Protocol Violation|1
6338769|NCT03220737|10091943|FG000|Main Study (Day 1 - 181)|Failed Exl 8 and randomized in error|0
6338770|NCT03220737|10091944|FG001|Main Study (Day 1 - 181)|Failed Exl 8 and randomized in error|0
6338771|NCT03220737|10091945|FG002|Main Study (Day 1 - 181)|Failed Exl 8 and randomized in error|1
6338772|NCT03220737|10091946|FG003|Main Study (Day 1 - 181)|Failed Exl 8 and randomized in error|0
6338773|NCT03220737|10091947|FG004|Main Study (Day 1 - 181)|Failed Exl 8 and randomized in error|0
6338774|NCT03220737|10091948|FG005|Main Study (Day 1 - 181)|Failed Exl 8 and randomized in error|0
6338775|NCT03220737|10091949|FG006|Main Study (Day 1 - 181)|Failed Exl 8 and randomized in error|0
6338776|NCT03220737|10091943|FG000|Placebo Crossover (Day 181-365)|Lost to Follow-up|0
6338777|NCT03220737|10091944|FG001|Placebo Crossover (Day 181-365)|Lost to Follow-up|0
6338778|NCT03220737|10091945|FG002|Placebo Crossover (Day 181-365)|Lost to Follow-up|0
6338779|NCT03220737|10091946|FG003|Placebo Crossover (Day 181-365)|Lost to Follow-up|0
6338780|NCT03220737|10091947|FG004|Placebo Crossover (Day 181-365)|Lost to Follow-up|2
6338781|NCT03220737|10091948|FG005|Placebo Crossover (Day 181-365)|Lost to Follow-up|0
6338782|NCT03220737|10091949|FG006|Placebo Crossover (Day 181-365)|Lost to Follow-up|0
6338783|NCT03220737|10091943|FG000|Long-term Follow-up (Day 365-730)|Withdrawal by Subject|1
6338784|NCT03220737|10091944|FG001|Long-term Follow-up (Day 365-730)|Withdrawal by Subject|0
6338785|NCT03220737|10091945|FG002|Long-term Follow-up (Day 365-730)|Withdrawal by Subject|0
6338786|NCT03220737|10091946|FG003|Long-term Follow-up (Day 365-730)|Withdrawal by Subject|0
6338787|NCT03220737|10091947|FG004|Long-term Follow-up (Day 365-730)|Withdrawal by Subject|0
6338788|NCT03220737|10091948|FG005|Long-term Follow-up (Day 365-730)|Withdrawal by Subject|0
6338789|NCT03220737|10091949|FG006|Long-term Follow-up (Day 365-730)|Withdrawal by Subject|0
6338790|NCT03220737|10091943|FG000|Long-term Follow-up (Day 365-730)|Lost to Follow-up|9
6338791|NCT03220737|10091944|FG001|Long-term Follow-up (Day 365-730)|Lost to Follow-up|0
6338792|NCT03220737|10091945|FG002|Long-term Follow-up (Day 365-730)|Lost to Follow-up|0
6338793|NCT03220737|10091946|FG003|Long-term Follow-up (Day 365-730)|Lost to Follow-up|0
6338794|NCT03220737|10091947|FG004|Long-term Follow-up (Day 365-730)|Lost to Follow-up|0
6338795|NCT03220737|10091948|FG005|Long-term Follow-up (Day 365-730)|Lost to Follow-up|0
6338796|NCT03220737|10091949|FG006|Long-term Follow-up (Day 365-730)|Lost to Follow-up|0
6338797|NCT03220737|10091943|FG000|Long-term Follow-up (Day 365-730)|Subject did not want lab drawn|1
6338798|NCT03220737|10091944|FG001|Long-term Follow-up (Day 365-730)|Subject did not want lab drawn|0
6338799|NCT03220737|10091945|FG002|Long-term Follow-up (Day 365-730)|Subject did not want lab drawn|0
6338800|NCT03220737|10091946|FG003|Long-term Follow-up (Day 365-730)|Subject did not want lab drawn|0
6338801|NCT03220737|10091947|FG004|Long-term Follow-up (Day 365-730)|Subject did not want lab drawn|0
6338802|NCT03220737|10091948|FG005|Long-term Follow-up (Day 365-730)|Subject did not want lab drawn|0
6338803|NCT03220737|10091949|FG006|Long-term Follow-up (Day 365-730)|Subject did not want lab drawn|0
6338804|NCT03221387|10091984|FG000|Overall Study|Lost to Follow-up|1
6338805|NCT03221387|10091984|FG000|Overall Study|Lung transplant|1
6338806|NCT03222141|10092012|FG000|Overall Study|Death|15
6338807|NCT03222141|10092012|FG000|Overall Study|Lost to Follow-up|3
6338808|NCT03222349|10092017|FG000|Overall Study|Treatment B not done|5
6338809|NCT03222349|10092018|FG001|Overall Study|Treatment B not done|0
6338810|NCT03222349|10092017|FG000|Overall Study|Lost to Follow-up|1
6338811|NCT03222349|10092018|FG001|Overall Study|Lost to Follow-up|2
6338812|NCT03222349|10092017|FG000|Overall Study|Withdrawal by Subject|1
6338813|NCT03222349|10092018|FG001|Overall Study|Withdrawal by Subject|0
6338814|NCT03222349|10092017|FG000|Overall Study|Treatment A not done|0
6338815|NCT03222349|10092018|FG001|Overall Study|Treatment A not done|5
6338816|NCT03222349|10092017|FG000|Overall Study|Study terminated by sponsor|1
6338817|NCT03222349|10092018|FG001|Overall Study|Study terminated by sponsor|0
6338818|NCT03222583|10092057|FG000|Overall Study|Withdrawal by Subject|3
6338819|NCT03222583|10092058|FG001|Overall Study|Withdrawal by Subject|3
6338820|NCT03222583|10092057|FG000|Overall Study|Lost to Follow-up|1
6338821|NCT03222583|10092058|FG001|Overall Study|Lost to Follow-up|0
6338822|NCT03222583|10092057|FG000|Overall Study|Other|1
6338823|NCT03222583|10092058|FG001|Overall Study|Other|3
6338824|NCT03223909|10092106|FG000|Overall Study|Protocol Violation|48
6338825|NCT03223909|10092107|FG001|Overall Study|Protocol Violation|45
6338826|NCT03223909|10092108|FG002|Overall Study|Protocol Violation|16
6338827|NCT03224130|10092118|FG000|Overall Study|consent issue|0
6338828|NCT03224130|10092119|FG001|Overall Study|consent issue|1
6338829|NCT03224182|10092127|FG000|Overall Study|Study Drug Not Instilled|6
6338830|NCT03224182|10092128|FG001|Overall Study|Study Drug Not Instilled|1
6338831|NCT03224182|10092127|FG000|Overall Study|Histology Other than Low- to Intermediate-Risk NMIBC|22
6338832|NCT03224182|10092128|FG001|Overall Study|Histology Other than Low- to Intermediate-Risk NMIBC|11
6338833|NCT03224182|10092127|FG000|Overall Study|Withdrew of Consent|4
6338834|NCT03224182|10092128|FG001|Overall Study|Withdrew of Consent|2
6338835|NCT03224182|10092127|FG000|Overall Study|Investigator Decision|3
6338836|NCT03224182|10092128|FG001|Overall Study|Investigator Decision|1
6338837|NCT03224182|10092127|FG000|Overall Study|Sponsor Decision|26
6338838|NCT03224182|10092128|FG001|Overall Study|Sponsor Decision|12
6338839|NCT03224182|10092127|FG000|Overall Study|Participant Refused Follow-up Procedures/Cystoscopy|4
6338840|NCT03224182|10092128|FG001|Overall Study|Participant Refused Follow-up Procedures/Cystoscopy|0
6338841|NCT03224182|10092127|FG000|Overall Study|Lost to Follow-up|1
6338842|NCT03224182|10092128|FG001|Overall Study|Lost to Follow-up|0
6338843|NCT03224182|10092127|FG000|Overall Study|Participant Had Recurrence|11
6338844|NCT03224182|10092128|FG001|Overall Study|Participant Had Recurrence|5
6338845|NCT03224182|10092127|FG000|Overall Study|Death|0
6338846|NCT03224182|10092128|FG001|Overall Study|Death|1
6338847|NCT03224182|10092127|FG000|Overall Study|Reason not Specified|3
6338848|NCT03224182|10092128|FG001|Overall Study|Reason not Specified|3
6338849|NCT03224182|10092127|FG000|Overall Study|Other|1
6338850|NCT03224182|10092128|FG001|Overall Study|Other|0
6338851|NCT03224234|10092138|FG000|Main Study|Lost to Follow-up|5
6338852|NCT03224234|10092139|FG001|Main Study|Lost to Follow-up|5
6338853|NCT03224325|10092173|FG000|Overall Study|Adverse Event|1
6338854|NCT03224325|10092174|FG001|Overall Study|Adverse Event|0
6338855|NCT03224325|10092175|FG002|Overall Study|Adverse Event|0
6338856|NCT03224325|10092176|FG003|Overall Study|Adverse Event|0
6338857|NCT03224325|10092177|FG004|Overall Study|Adverse Event|0
6338858|NCT03224325|10092178|FG005|Overall Study|Adverse Event|0
6338859|NCT03224325|10092179|FG006|Overall Study|Adverse Event|1
6338860|NCT03224325|10092173|FG000|Overall Study|Withdrawal by Subject|0
6338861|NCT03224325|10092174|FG001|Overall Study|Withdrawal by Subject|0
6338862|NCT03224325|10092175|FG002|Overall Study|Withdrawal by Subject|0
6338863|NCT03224325|10092176|FG003|Overall Study|Withdrawal by Subject|1
6338864|NCT03224325|10092177|FG004|Overall Study|Withdrawal by Subject|0
6338865|NCT03224325|10092178|FG005|Overall Study|Withdrawal by Subject|0
6338866|NCT03224325|10092179|FG006|Overall Study|Withdrawal by Subject|0
6338867|NCT03224598|10092298|FG000|Overall Study|Lost to Follow-up|0
6338868|NCT03224598|10092299|FG001|Overall Study|Lost to Follow-up|2
6338869|NCT03224598|10092300|FG002|Overall Study|Lost to Follow-up|0
6338870|NCT03224598|10092298|FG000|Overall Study|Other|0
6338871|NCT03224598|10092299|FG001|Overall Study|Other|1
6338872|NCT03224598|10092300|FG002|Overall Study|Other|0
6338873|NCT03226249|10092348|FG000|2-4 Cycles of AVD +/- Chemo & RT, PET#4|Transferred to another state|1
6338874|NCT03226249|10092348|FG000|PEM Consolidation (1-2 Years)|Per Protocol not eligible|29
6338875|NCT03226249|10092348|FG000|Survival Follow-up|Patients still in follow-up.|30
6338876|NCT03226275|10092356|FG000|Treatment Period 1 (8 Days)|Did not pass blood pressure examination|0
6338877|NCT03226275|10092357|FG001|Treatment Period 1 (8 Days)|Did not pass blood pressure examination|0
6338878|NCT03226275|10092358|FG002|Treatment Period 1 (8 Days)|Did not pass blood pressure examination|1
6338879|NCT03226275|10092359|FG003|Treatment Period 1 (8 Days)|Did not pass blood pressure examination|0
6338880|NCT03226275|10092356|FG000|Treatment Period 1 (8 Days)|Protocol non-compliance|0
6338881|NCT03226275|10092357|FG001|Treatment Period 1 (8 Days)|Protocol non-compliance|0
6338882|NCT03226275|10092358|FG002|Treatment Period 1 (8 Days)|Protocol non-compliance|0
6338883|NCT03226275|10092359|FG003|Treatment Period 1 (8 Days)|Protocol non-compliance|1
6338884|NCT03226353|10092369|FG000|Overall Study|Withdrawal by Subject|1
6338885|NCT03226353|10092369|FG000|Overall Study|Screen Failure|5
6338886|NCT03226392|10092395|FG000|Overall Study|Protocol Deviation|1
6338887|NCT03226392|10092396|FG001|Overall Study|Protocol Deviation|0
6338888|NCT03226392|10092395|FG000|Overall Study|Physician Decision|1
6338889|NCT03226392|10092396|FG001|Overall Study|Physician Decision|0
6338890|NCT03226392|10092395|FG000|Overall Study|Lost to Follow-up|1
6338891|NCT03226392|10092396|FG001|Overall Study|Lost to Follow-up|0
6338892|NCT03226392|10092395|FG000|Overall Study|Adverse Event|1
6338893|NCT03226392|10092396|FG001|Overall Study|Adverse Event|0
6338894|NCT03226392|10092395|FG000|Overall Study|Technical Problems|0
6338895|NCT03226392|10092396|FG001|Overall Study|Technical Problems|2
6338896|NCT03226392|10092395|FG000|Overall Study|Subject/Guardian Decision|7
6338897|NCT03226392|10092396|FG001|Overall Study|Subject/Guardian Decision|6
6338898|NCT03226769|10092419|FG000|Overall Study|Withdrawal by Subject|0
6338899|NCT03226769|10092420|FG001|Overall Study|Withdrawal by Subject|1
6338900|NCT03227445|10092435|FG000|Period 1 (28 Days)|Adverse Event|1
6338901|NCT03227445|10092436|FG001|Period 1 (28 Days)|Adverse Event|2
6338902|NCT03227445|10092437|FG002|Period 1 (28 Days)|Adverse Event|0
6338903|NCT03227445|10092438|FG003|Period 1 (28 Days)|Adverse Event|1
6338904|NCT03227445|10092435|FG000|Period 1 (28 Days)|Protocol Violation|1
6338905|NCT03227445|10092436|FG001|Period 1 (28 Days)|Protocol Violation|0
6338906|NCT03227445|10092437|FG002|Period 1 (28 Days)|Protocol Violation|0
6338907|NCT03227445|10092438|FG003|Period 1 (28 Days)|Protocol Violation|0
6338908|NCT03227445|10092435|FG000|Period 1 (28 Days)|Withdrawal by Subject|0
6338909|NCT03227445|10092436|FG001|Period 1 (28 Days)|Withdrawal by Subject|0
6338910|NCT03227445|10092437|FG002|Period 1 (28 Days)|Withdrawal by Subject|1
6338911|NCT03227445|10092438|FG003|Period 1 (28 Days)|Withdrawal by Subject|1
6338912|NCT03227445|10092435|FG000|Period 2 (28 Days)|Adverse Event|1
6338913|NCT03227445|10092436|FG001|Period 2 (28 Days)|Adverse Event|0
6338914|NCT03227445|10092437|FG002|Period 2 (28 Days)|Adverse Event|2
6338915|NCT03227445|10092438|FG003|Period 2 (28 Days)|Adverse Event|1
6338916|NCT03227445|10092435|FG000|Period 2 (28 Days)|Protocol Violation|0
6338917|NCT03227445|10092436|FG001|Period 2 (28 Days)|Protocol Violation|0
6338918|NCT03227445|10092437|FG002|Period 2 (28 Days)|Protocol Violation|0
6338919|NCT03227445|10092438|FG003|Period 2 (28 Days)|Protocol Violation|1
6338920|NCT03227445|10092435|FG000|Period 2 (28 Days)|Withdrawal by Subject|0
6338921|NCT03227445|10092436|FG001|Period 2 (28 Days)|Withdrawal by Subject|1
6338922|NCT03227445|10092437|FG002|Period 2 (28 Days)|Withdrawal by Subject|0
6338923|NCT03227445|10092438|FG003|Period 2 (28 Days)|Withdrawal by Subject|1
6338924|NCT03227692|10092449|FG000|Overall Study|Protocol Violation|1
6338925|NCT03227692|10092450|FG001|Overall Study|Protocol Violation|1
6338926|NCT03227692|10092449|FG000|Overall Study|Lost to Follow-up|4
6338927|NCT03227692|10092450|FG001|Overall Study|Lost to Follow-up|2
6338928|NCT03227692|10092449|FG000|Overall Study|Adverse Event|0
6338929|NCT03227692|10092450|FG001|Overall Study|Adverse Event|2
6338930|NCT03227861|10092456|FG000|Main Study Period (Week 0 to Week 48)|Lost to Follow-up|4
6338931|NCT03227861|10092456|FG000|Main Study Period (Week 0 to Week 48)|Withdrawal by Subject|1
6338932|NCT03227861|10092456|FG000|Main Study Period (Week 0 to Week 48)|Adverse Event|1
6338933|NCT03227861|10092456|FG000|Main Study Period (Week 0 to Week 48)|Protocol Violation|1
6338934|NCT03227861|10092456|FG000|Main Study Period (Week 0 to Week 48)|Other|5
6338935|NCT03227861|10092456|FG000|Extension Period (Week 48 to Week 96)|Transition to Commercial D/C/F/TAF|55
6338936|NCT03227861|10092456|FG000|Extension Period (Week 48 to Week 96)|Transition to Other ARV Treatment|16
6338937|NCT03227861|10092456|FG000|Extension Period (Week 48 to Week 96)|Lost to Follow-up|6
6338938|NCT03227861|10092456|FG000|Extension Period (Week 48 to Week 96)|Adverse Event|1
6338939|NCT03227861|10092456|FG000|Extension Period (Week 48 to Week 96)|Other|2
6338940|NCT03228212|10092471|FG000|Period 1|Adverse Event|1
6338941|NCT03228212|10092472|FG001|Period 1|Adverse Event|0
6338942|NCT03228212|10092471|FG000|Period 1|no longer meets eligibility criteria|0
6338943|NCT03228212|10092472|FG001|Period 1|no longer meets eligibility criteria|1
6338944|NCT03228212|10092471|FG000|Period 2|Lost to Follow-up|1
6338945|NCT03228212|10092472|FG001|Period 2|Lost to Follow-up|0
6338946|NCT03228420|10092480|FG000|Overall Study|Lost to Follow-up|5
6338947|NCT03228420|10092481|FG001|Overall Study|Lost to Follow-up|3
6338948|NCT03228420|10092480|FG000|Overall Study|Withdrawal by Subject|10
6338949|NCT03228420|10092481|FG001|Overall Study|Withdrawal by Subject|0
6338950|NCT03228420|10092480|FG000|Overall Study|Adverse Event|5
6338951|NCT03228420|10092481|FG001|Overall Study|Adverse Event|2
6338952|NCT03228433|10092493|FG000|Overall Study|Lost to Follow-up|1
6338953|NCT03228433|10092494|FG001|Overall Study|Lost to Follow-up|0
6338954|NCT03228433|10092495|FG002|Overall Study|Lost to Follow-up|0
6338955|NCT03228433|10092496|FG003|Overall Study|Lost to Follow-up|0
6338956|NCT03228433|10092497|FG004|Overall Study|Lost to Follow-up|0
6338957|NCT03228433|10092498|FG005|Overall Study|Lost to Follow-up|0
6042902|NCT00385736|9641358|FG002|Safety Analysis Set|Other|4
6338958|NCT03228433|10092493|FG000|Overall Study|Positive alcohol test|0
6338959|NCT03228433|10092494|FG001|Overall Study|Positive alcohol test|0
6042903|NCT00385762|9641369|FG000|Overall Study|Adverse Event|1
6338960|NCT03228433|10092495|FG002|Overall Study|Positive alcohol test|0
6338961|NCT03228433|10092496|FG003|Overall Study|Positive alcohol test|1
6338962|NCT03228433|10092497|FG004|Overall Study|Positive alcohol test|0
6338963|NCT03228433|10092498|FG005|Overall Study|Positive alcohol test|0
6338964|NCT03228836|10092520|FG000|Overall Study|Adverse Event|3
6338965|NCT03228836|10092520|FG000|Overall Study|Withdrawal by Subject|1
6338966|NCT03228836|10092520|FG000|Overall Study|Death|1
6338967|NCT03228836|10092520|FG000|Overall Study|Physician Decision|1
6338968|NCT03228836|10092520|FG000|Overall Study|Disease Progression|7
6338969|NCT03228836|10092520|FG000|Overall Study|Other|4
6338970|NCT03229109|10092535|FG000|Overall Study|Withdrawal by Subject|0
6338971|NCT03229109|10092536|FG001|Overall Study|Withdrawal by Subject|0
6338972|NCT03229109|10092537|FG002|Overall Study|Withdrawal by Subject|0
6338973|NCT03229109|10092538|FG003|Overall Study|Withdrawal by Subject|1
6042904|NCT00385762|9641369|FG000|Overall Study|Lost to Follow-up|1
6042905|NCT00385827|9641395|FG000|Part 1|Adverse Event|1
6042906|NCT00385827|9641396|FG001|Part 1|Adverse Event|0
6338974|NCT03229486|10092563|FG000|Overall Study|Protocol Violation|0
6338975|NCT03229486|10092564|FG001|Overall Study|Protocol Violation|1
6338976|NCT03229759|10092570|FG000|Overall Study|Screen Failure|30
6338977|NCT03230864|10092583|FG000|Prospective Confirmation (PC) Period|Adverse Event|3
6338978|NCT03230864|10092584|FG001|Prospective Confirmation (PC) Period|Adverse Event|0
6338979|NCT03230864|10092585|FG002|Prospective Confirmation (PC) Period|Adverse Event|0
6338980|NCT03230864|10092586|FG003|Prospective Confirmation (PC) Period|Adverse Event|0
6338981|NCT03230864|10092583|FG000|Prospective Confirmation (PC) Period|Lack of Efficacy|0
6338982|NCT03230864|10092584|FG001|Prospective Confirmation (PC) Period|Lack of Efficacy|2
6338983|NCT03230864|10092585|FG002|Prospective Confirmation (PC) Period|Lack of Efficacy|0
6338984|NCT03230864|10092586|FG003|Prospective Confirmation (PC) Period|Lack of Efficacy|0
6338985|NCT03230864|10092583|FG000|Prospective Confirmation (PC) Period|Protocol Violation|1
6338986|NCT03230864|10092584|FG001|Prospective Confirmation (PC) Period|Protocol Violation|2
6338987|NCT03230864|10092585|FG002|Prospective Confirmation (PC) Period|Protocol Violation|0
6338988|NCT03230864|10092586|FG003|Prospective Confirmation (PC) Period|Protocol Violation|0
6338989|NCT03230864|10092583|FG000|Prospective Confirmation (PC) Period|Withdrawal by Subject|4
6338990|NCT03230864|10092584|FG001|Prospective Confirmation (PC) Period|Withdrawal by Subject|1
6338991|NCT03230864|10092585|FG002|Prospective Confirmation (PC) Period|Withdrawal by Subject|0
6338992|NCT03230864|10092586|FG003|Prospective Confirmation (PC) Period|Withdrawal by Subject|0
6338993|NCT03230864|10092583|FG000|Prospective Confirmation (PC) Period|Did not fulfill rand criteria DBT|14
6338994|NCT03230864|10092584|FG001|Prospective Confirmation (PC) Period|Did not fulfill rand criteria DBT|5
6338995|NCT03230864|10092585|FG002|Prospective Confirmation (PC) Period|Did not fulfill rand criteria DBT|0
6338996|NCT03230864|10092586|FG003|Prospective Confirmation (PC) Period|Did not fulfill rand criteria DBT|0
6338997|NCT03230864|10092583|FG000|Prospective Confirmation (PC) Period|Sponsor Decision|9
6338998|NCT03230864|10092584|FG001|Prospective Confirmation (PC) Period|Sponsor Decision|9
6338999|NCT03230864|10092585|FG002|Prospective Confirmation (PC) Period|Sponsor Decision|0
6339000|NCT03230864|10092586|FG003|Prospective Confirmation (PC) Period|Sponsor Decision|0
6339001|NCT03230864|10092583|FG000|Prospective Confirmation (PC) Period|Study Personnel Decision|1
6339002|NCT03230864|10092584|FG001|Prospective Confirmation (PC) Period|Study Personnel Decision|0
6339003|NCT03230864|10092585|FG002|Prospective Confirmation (PC) Period|Study Personnel Decision|0
6339004|NCT03230864|10092586|FG003|Prospective Confirmation (PC) Period|Study Personnel Decision|0
6339005|NCT03230864|10092583|FG000|Double Blind Treatment (DBT) Period|Adverse Event|0
6339006|NCT03230864|10092584|FG001|Double Blind Treatment (DBT) Period|Adverse Event|0
6339007|NCT03230864|10092585|FG002|Double Blind Treatment (DBT) Period|Adverse Event|5
6339008|NCT03230864|10092586|FG003|Double Blind Treatment (DBT) Period|Adverse Event|1
6339009|NCT03230864|10092583|FG000|Double Blind Treatment (DBT) Period|Withdrawal by Subject|0
6339010|NCT03230864|10092584|FG001|Double Blind Treatment (DBT) Period|Withdrawal by Subject|0
6339011|NCT03230864|10092585|FG002|Double Blind Treatment (DBT) Period|Withdrawal by Subject|1
6339012|NCT03230864|10092586|FG003|Double Blind Treatment (DBT) Period|Withdrawal by Subject|1
6339013|NCT03230864|10092583|FG000|Double Blind Treatment (DBT) Period|Sponsor Decision|0
6339014|NCT03230864|10092584|FG001|Double Blind Treatment (DBT) Period|Sponsor Decision|0
6339015|NCT03230864|10092585|FG002|Double Blind Treatment (DBT) Period|Sponsor Decision|2
6339016|NCT03230864|10092586|FG003|Double Blind Treatment (DBT) Period|Sponsor Decision|0
6339017|NCT03231228|10092598|FG000|Overall Study|Lost to Follow-up|2
6339018|NCT03231228|10092599|FG001|Overall Study|Lost to Follow-up|0
6339019|NCT03231228|10092598|FG000|Overall Study|Physician Decision|1
6339020|NCT03231228|10092599|FG001|Overall Study|Physician Decision|0
6339021|NCT03231371|10092609|FG000|Overall Study|Withdrawal by Subject|1
6339022|NCT03231371|10092609|FG000|Overall Study|chose or were ineligible to have MRI|12
6339023|NCT03231709|10092615|FG000|Treatment Period 1|Reason not Specified|0
6339024|NCT03231709|10092616|FG001|Treatment Period 1|Reason not Specified|1
6339025|NCT03231709|10092615|FG000|Treatment Period 2|Pretreatment Event/Adverse Event|0
6339026|NCT03231709|10092616|FG001|Treatment Period 2|Pretreatment Event/Adverse Event|1
6339027|NCT03231800|10092628|FG000|Overall Study|Lost to Follow-up|0
6339028|NCT03231800|10092629|FG001|Overall Study|Lost to Follow-up|2
6339029|NCT03231800|10092628|FG000|Overall Study|Protocol Violation|1
6339030|NCT03231800|10092629|FG001|Overall Study|Protocol Violation|1
6339031|NCT03231800|10092628|FG000|Overall Study|reason not provided|2
6339032|NCT03231800|10092629|FG001|Overall Study|reason not provided|0
6339033|NCT03231943|10092651|FG000|Part 1, Period 2 (up to Day 30)|Adverse Event|0
6339034|NCT03231943|10092652|FG001|Part 1, Period 2 (up to Day 30)|Adverse Event|1
6339035|NCT03231943|10092653|FG002|Part 1, Period 2 (up to Day 30)|Adverse Event|1
6339036|NCT03231943|10092654|FG003|Part 1, Period 2 (up to Day 30)|Adverse Event|0
6339037|NCT03231943|10092655|FG004|Part 1, Period 2 (up to Day 30)|Adverse Event|0
6339038|NCT03231943|10092656|FG005|Part 1, Period 2 (up to Day 30)|Adverse Event|0
6339039|NCT03231943|10092657|FG006|Part 1, Period 2 (up to Day 30)|Adverse Event|0
6339040|NCT03231943|10092658|FG007|Part 1, Period 2 (up to Day 30)|Adverse Event|0
6339041|NCT03231943|10092659|FG008|Part 1, Period 2 (up to Day 30)|Adverse Event|0
6339042|NCT03231943|10092660|FG009|Part 1, Period 2 (up to Day 30)|Adverse Event|0
6339043|NCT03231943|10092661|FG010|Part 1, Period 2 (up to Day 30)|Adverse Event|0
6339044|NCT03231943|10092662|FG011|Part 1, Period 2 (up to Day 30)|Adverse Event|0
6339045|NCT03231943|10092663|FG012|Part 1, Period 2 (up to Day 30)|Adverse Event|0
6339046|NCT03231943|10092651|FG000|Part 1, Period 2 (up to Day 30)|Withdrawal by Subject|0
6339047|NCT03231943|10092652|FG001|Part 1, Period 2 (up to Day 30)|Withdrawal by Subject|1
6339048|NCT03231943|10092653|FG002|Part 1, Period 2 (up to Day 30)|Withdrawal by Subject|0
6339049|NCT03231943|10092654|FG003|Part 1, Period 2 (up to Day 30)|Withdrawal by Subject|0
6339050|NCT03231943|10092655|FG004|Part 1, Period 2 (up to Day 30)|Withdrawal by Subject|0
6339051|NCT03231943|10092656|FG005|Part 1, Period 2 (up to Day 30)|Withdrawal by Subject|0
6339052|NCT03231943|10092657|FG006|Part 1, Period 2 (up to Day 30)|Withdrawal by Subject|0
6339053|NCT03231943|10092658|FG007|Part 1, Period 2 (up to Day 30)|Withdrawal by Subject|0
6339054|NCT03231943|10092659|FG008|Part 1, Period 2 (up to Day 30)|Withdrawal by Subject|0
6339055|NCT03231943|10092660|FG009|Part 1, Period 2 (up to Day 30)|Withdrawal by Subject|0
6339056|NCT03231943|10092661|FG010|Part 1, Period 2 (up to Day 30)|Withdrawal by Subject|0
6339057|NCT03231943|10092662|FG011|Part 1, Period 2 (up to Day 30)|Withdrawal by Subject|0
6339058|NCT03231943|10092663|FG012|Part 1, Period 2 (up to Day 30)|Withdrawal by Subject|0
6339059|NCT03231943|10092651|FG000|Part 1, Period 3 (up to Day 45)|Adverse Event|1
6339060|NCT03231943|10092652|FG001|Part 1, Period 3 (up to Day 45)|Adverse Event|0
6339061|NCT03231943|10092653|FG002|Part 1, Period 3 (up to Day 45)|Adverse Event|0
6339062|NCT03231943|10092654|FG003|Part 1, Period 3 (up to Day 45)|Adverse Event|0
6339063|NCT03231943|10092655|FG004|Part 1, Period 3 (up to Day 45)|Adverse Event|0
6339064|NCT03231943|10092656|FG005|Part 1, Period 3 (up to Day 45)|Adverse Event|0
6339065|NCT03231943|10092657|FG006|Part 1, Period 3 (up to Day 45)|Adverse Event|0
6339066|NCT03231943|10092658|FG007|Part 1, Period 3 (up to Day 45)|Adverse Event|0
6339067|NCT03231943|10092659|FG008|Part 1, Period 3 (up to Day 45)|Adverse Event|0
6339068|NCT03231943|10092660|FG009|Part 1, Period 3 (up to Day 45)|Adverse Event|0
6339069|NCT03231943|10092661|FG010|Part 1, Period 3 (up to Day 45)|Adverse Event|0
6339070|NCT03231943|10092662|FG011|Part 1, Period 3 (up to Day 45)|Adverse Event|0
6339071|NCT03231943|10092663|FG012|Part 1, Period 3 (up to Day 45)|Adverse Event|0
6339072|NCT03231943|10092651|FG000|Part 2|Adverse Event|0
6339073|NCT03231943|10092652|FG001|Part 2|Adverse Event|0
6339074|NCT03231943|10092653|FG002|Part 2|Adverse Event|0
6339075|NCT03231943|10092654|FG003|Part 2|Adverse Event|0
6339076|NCT03231943|10092655|FG004|Part 2|Adverse Event|0
6339077|NCT03231943|10092656|FG005|Part 2|Adverse Event|0
6339078|NCT03231943|10092657|FG006|Part 2|Adverse Event|0
6339079|NCT03231943|10092658|FG007|Part 2|Adverse Event|0
6339080|NCT03231943|10092659|FG008|Part 2|Adverse Event|0
6339081|NCT03231943|10092660|FG009|Part 2|Adverse Event|0
6339082|NCT03231943|10092661|FG010|Part 2|Adverse Event|1
6339083|NCT03231943|10092662|FG011|Part 2|Adverse Event|0
6339084|NCT03231943|10092663|FG012|Part 2|Adverse Event|0
6339085|NCT03231943|10092651|FG000|Part 2|Withdrawal by Subject|0
6339086|NCT03231943|10092652|FG001|Part 2|Withdrawal by Subject|0
6339087|NCT03231943|10092653|FG002|Part 2|Withdrawal by Subject|0
6339088|NCT03231943|10092654|FG003|Part 2|Withdrawal by Subject|0
6339089|NCT03231943|10092655|FG004|Part 2|Withdrawal by Subject|0
6339090|NCT03231943|10092656|FG005|Part 2|Withdrawal by Subject|0
6339091|NCT03231943|10092657|FG006|Part 2|Withdrawal by Subject|0
6339092|NCT03231943|10092658|FG007|Part 2|Withdrawal by Subject|0
6339093|NCT03231943|10092659|FG008|Part 2|Withdrawal by Subject|0
6339094|NCT03231943|10092660|FG009|Part 2|Withdrawal by Subject|0
6339095|NCT03231943|10092661|FG010|Part 2|Withdrawal by Subject|0
6339096|NCT03231943|10092662|FG011|Part 2|Withdrawal by Subject|1
6339097|NCT03231943|10092663|FG012|Part 2|Withdrawal by Subject|0
6339098|NCT03232281|10092712|FG000|Overall Study|Adverse Event|1
6339099|NCT03232281|10092713|FG001|Overall Study|Adverse Event|1
6339100|NCT03232281|10092712|FG000|Overall Study|Withdrawal by Subject|5
6339101|NCT03232281|10092713|FG001|Overall Study|Withdrawal by Subject|4
6339102|NCT03232281|10092712|FG000|Overall Study|Protocol Deviation|1
6339103|NCT03232281|10092713|FG001|Overall Study|Protocol Deviation|1
6339104|NCT03232333|10092719|FG000|Overall Study|Infection or Osteomyelitis|9
6339105|NCT03232333|10092719|FG000|Overall Study|Lost to Follow-up|4
6339106|NCT03232333|10092719|FG000|Overall Study|Withdrawal by Subject|2
6339107|NCT03232567|10092727|FG000|Overall Study|Withdrawal by Subject|0
6339108|NCT03232567|10092728|FG001|Overall Study|Withdrawal by Subject|1
6339109|NCT03232567|10092729|FG002|Overall Study|Withdrawal by Subject|0
6339110|NCT03232567|10092730|FG003|Overall Study|Withdrawal by Subject|0
6339111|NCT03232983|10092763|FG000|Period 1|Physician Decision|0
6339112|NCT03232983|10092764|FG001|Period 1|Physician Decision|0
6339113|NCT03232983|10092765|FG002|Period 1|Physician Decision|1
6339114|NCT03232983|10092766|FG003|Period 1|Physician Decision|0
6339115|NCT03232983|10092763|FG000|Washout Period 2|Physician Decision|0
6339116|NCT03232983|10092764|FG001|Washout Period 2|Physician Decision|0
6339117|NCT03232983|10092765|FG002|Washout Period 2|Physician Decision|1
6339118|NCT03232983|10092766|FG003|Washout Period 2|Physician Decision|0
6339119|NCT03232983|10092763|FG000|Washout Period 2|Withdrawal by Subject|0
6339120|NCT03232983|10092764|FG001|Washout Period 2|Withdrawal by Subject|0
6339121|NCT03232983|10092765|FG002|Washout Period 2|Withdrawal by Subject|0
6339122|NCT03232983|10092766|FG003|Washout Period 2|Withdrawal by Subject|1
6339123|NCT03232983|10092763|FG000|Period 4|Withdrawal by Subject|1
6339124|NCT03232983|10092764|FG001|Period 4|Withdrawal by Subject|0
6339125|NCT03232983|10092765|FG002|Period 4|Withdrawal by Subject|0
6339126|NCT03232983|10092766|FG003|Period 4|Withdrawal by Subject|0
6339127|NCT03233009|10092778|FG000|Overall Study|Lost to Follow-up|1
6339128|NCT03233230|10092795|FG000|Overall Study|Adverse Event|6
6339129|NCT03233230|10092796|FG001|Overall Study|Adverse Event|3
6339130|NCT03233230|10092797|FG002|Overall Study|Adverse Event|6
6339131|NCT03233230|10092798|FG003|Overall Study|Adverse Event|3
6339132|NCT03233230|10092795|FG000|Overall Study|Protocol Violation|1
6339133|NCT03233230|10092796|FG001|Overall Study|Protocol Violation|2
6339134|NCT03233230|10092797|FG002|Overall Study|Protocol Violation|1
6339135|NCT03233230|10092798|FG003|Overall Study|Protocol Violation|1
6339136|NCT03233230|10092795|FG000|Overall Study|Lack of Efficacy|1
6339137|NCT03233230|10092796|FG001|Overall Study|Lack of Efficacy|0
6339138|NCT03233230|10092797|FG002|Overall Study|Lack of Efficacy|0
6339139|NCT03233230|10092798|FG003|Overall Study|Lack of Efficacy|0
6339140|NCT03233230|10092795|FG000|Overall Study|Other|5
6339141|NCT03233230|10092796|FG001|Overall Study|Other|5
6339142|NCT03233230|10092797|FG002|Overall Study|Other|5
6339143|NCT03233230|10092798|FG003|Overall Study|Other|3
6339144|NCT03233230|10092795|FG000|Overall Study|Withdrawal by Subject|2
6339145|NCT03233230|10092796|FG001|Overall Study|Withdrawal by Subject|2
6339146|NCT03233230|10092797|FG002|Overall Study|Withdrawal by Subject|0
6339147|NCT03233230|10092798|FG003|Overall Study|Withdrawal by Subject|1
6339148|NCT03233230|10092795|FG000|Overall Study|Lost to Follow-up|0
6339149|NCT03233230|10092796|FG001|Overall Study|Lost to Follow-up|3
6339150|NCT03233230|10092797|FG002|Overall Study|Lost to Follow-up|0
6339151|NCT03233230|10092798|FG003|Overall Study|Lost to Follow-up|0
6339152|NCT03233308|10092808|FG000|Overall Study|Adverse Event|1
6339153|NCT03233308|10092808|FG000|Overall Study|Protocol Violation|1
6339154|NCT03233438|10092821|FG000|Overall Study|Lost to Follow-up|4
6339155|NCT03233438|10092822|FG001|Overall Study|Lost to Follow-up|9
6339156|NCT03233438|10092821|FG000|Overall Study|Withdrawal by Subject|2
6339157|NCT03233438|10092822|FG001|Overall Study|Withdrawal by Subject|1
6339158|NCT03233438|10092821|FG000|Overall Study|No recording of dalbavancin|0
6339159|NCT03233438|10092822|FG001|Overall Study|No recording of dalbavancin|1
6339160|NCT03233529|10092828|FG000|Double-Blind Period (Day 1 to Day 15)|Adverse Event|1
6339161|NCT03233529|10092828|FG000|Open-Label Period (Day 15 to Day 71)|Adverse Event|1
6339162|NCT03234036|10092861|FG000|Part 1:Washout Period 1 (Up to 10 Days)|Adverse Event|1
6339163|NCT03234036|10092862|FG001|Part 1:Washout Period 1 (Up to 10 Days)|Adverse Event|1
6339164|NCT03234036|10092863|FG002|Part 1:Washout Period 1 (Up to 10 Days)|Adverse Event|0
6339165|NCT03234036|10092864|FG003|Part 1:Washout Period 1 (Up to 10 Days)|Adverse Event|0
6339166|NCT03234465|10092891|FG000|Overall Study|Adverse Event|4
6339167|NCT03234465|10092892|FG001|Overall Study|Adverse Event|2
6339168|NCT03234465|10092891|FG000|Overall Study|Death|0
6339169|NCT03234465|10092892|FG001|Overall Study|Death|1
6339170|NCT03234465|10092891|FG000|Overall Study|Lost to Follow-up|1
6339171|NCT03234465|10092892|FG001|Overall Study|Lost to Follow-up|1
6339172|NCT03234465|10092891|FG000|Overall Study|Withdrawal by Subject|12
6339173|NCT03234465|10092892|FG001|Overall Study|Withdrawal by Subject|27
6339174|NCT03234465|10092891|FG000|Overall Study|Symptomatic deterioration|0
6339175|NCT03234465|10092892|FG001|Overall Study|Symptomatic deterioration|1
6339176|NCT03234465|10092891|FG000|Overall Study|Non-compliance|2
6339177|NCT03234465|10092892|FG001|Overall Study|Non-compliance|0
6339178|NCT03234465|10092891|FG000|Overall Study|Other|14
6339179|NCT03234465|10092892|FG001|Overall Study|Other|8
6339180|NCT03234608|10092900|FG000|Overall Study|Lost to Follow-up|23
6339181|NCT03234608|10092901|FG001|Overall Study|Lost to Follow-up|21
6339182|NCT03235050|10092912|FG000|Overall Study|Adverse Event|0
6339183|NCT03235050|10092913|FG001|Overall Study|Adverse Event|0
6339184|NCT03235050|10092914|FG002|Overall Study|Adverse Event|1
6339185|NCT03235050|10092915|FG003|Overall Study|Adverse Event|4
6339186|NCT03235050|10092916|FG004|Overall Study|Adverse Event|1
6339187|NCT03235050|10092912|FG000|Overall Study|Death|0
6339188|NCT03235050|10092913|FG001|Overall Study|Death|0
6339189|NCT03235050|10092914|FG002|Overall Study|Death|0
6339190|NCT03235050|10092915|FG003|Overall Study|Death|2
6339191|NCT03235050|10092916|FG004|Overall Study|Death|1
6339192|NCT03235050|10092912|FG000|Overall Study|Lost to Follow-up|1
6339193|NCT03235050|10092913|FG001|Overall Study|Lost to Follow-up|2
6339194|NCT03235050|10092914|FG002|Overall Study|Lost to Follow-up|1
6339195|NCT03235050|10092915|FG003|Overall Study|Lost to Follow-up|2
6339196|NCT03235050|10092916|FG004|Overall Study|Lost to Follow-up|0
6339197|NCT03235050|10092912|FG000|Overall Study|Withdrawal by Subject|3
6339198|NCT03235050|10092913|FG001|Overall Study|Withdrawal by Subject|2
6339199|NCT03235050|10092914|FG002|Overall Study|Withdrawal by Subject|2
6339200|NCT03235050|10092915|FG003|Overall Study|Withdrawal by Subject|5
6339201|NCT03235050|10092916|FG004|Overall Study|Withdrawal by Subject|7
6339202|NCT03235050|10092912|FG000|Overall Study|Other reasons|0
6339203|NCT03235050|10092913|FG001|Overall Study|Other reasons|1
6339204|NCT03235050|10092914|FG002|Overall Study|Other reasons|0
6339205|NCT03235050|10092915|FG003|Overall Study|Other reasons|1
6339206|NCT03235050|10092916|FG004|Overall Study|Other reasons|2
6339207|NCT03235089|10092928|FG000|Overall Study|Lost to Follow-up|1
6339208|NCT03235089|10092929|FG001|Overall Study|Lost to Follow-up|1
6339209|NCT03235089|10092928|FG000|Overall Study|Physician Decision|2
6339210|NCT03235089|10092929|FG001|Overall Study|Physician Decision|2
6339211|NCT03235115|10092936|FG000|First Intervention (1 Hour, Visit 2)|Lost to Follow-up|0
6339212|NCT03235115|10092937|FG001|First Intervention (1 Hour, Visit 2)|Lost to Follow-up|0
6339213|NCT03235115|10092938|FG002|First Intervention (1 Hour, Visit 2)|Lost to Follow-up|0
6339214|NCT03235115|10092939|FG003|First Intervention (1 Hour, Visit 2)|Lost to Follow-up|0
6339215|NCT03235115|10092940|FG004|First Intervention (1 Hour, Visit 2)|Lost to Follow-up|0
6339216|NCT03235115|10092941|FG005|First Intervention (1 Hour, Visit 2)|Lost to Follow-up|1
6339217|NCT03235154|10092949|FG000|Overall Study|Withdrawal by Subject|1
6339218|NCT03235154|10092949|FG000|Overall Study|Adverse Event|1
6339219|NCT03235154|10092949|FG000|Overall Study|Lost to Follow-up|2
6339220|NCT03235284|10092962|FG000|Overall Study|Adverse Event|1
6339221|NCT03235284|10092963|FG001|Overall Study|Adverse Event|2
6339222|NCT03235284|10092964|FG002|Overall Study|Adverse Event|1
6339223|NCT03235349|10092972|FG000|Overall Study|Adverse Event|1
6339224|NCT03235349|10092972|FG000|Overall Study|Other|1
6339225|NCT03235479|10092982|FG000|Overall Study|Lost to Follow-up|8
6339226|NCT03235479|10092983|FG001|Overall Study|Lost to Follow-up|11
6339227|NCT03235479|10092982|FG000|Overall Study|Not Experienced Moderate/Severe Migraine|23
6339228|NCT03235479|10092983|FG001|Overall Study|Not Experienced Moderate/Severe Migraine|17
6339229|NCT03235479|10092982|FG000|Overall Study|Pregnancy|1
6339230|NCT03235479|10092983|FG001|Overall Study|Pregnancy|0
6339231|NCT03235479|10092982|FG000|Overall Study|Protocol Deviation|1
6339232|NCT03235479|10092983|FG001|Overall Study|Protocol Deviation|3
6339233|NCT03235479|10092982|FG000|Overall Study|Technical Problems|3
6339234|NCT03235479|10092983|FG001|Overall Study|Technical Problems|2
6339235|NCT03235479|10092982|FG000|Overall Study|Withdrawal by Subject|2
6339236|NCT03235479|10092983|FG001|Overall Study|Withdrawal by Subject|2
6339237|NCT03235479|10092982|FG000|Overall Study|Other Reasons|3
6339238|NCT03235479|10092983|FG001|Overall Study|Other Reasons|5
6339239|NCT03235726|10092997|FG000|Part 1 (Cohort B and C- Days 1 to 14)|Withdrawal by Subject|0
6339240|NCT03235726|10092998|FG001|Part 1 (Cohort B and C- Days 1 to 14)|Withdrawal by Subject|0
6339241|NCT03235726|10092999|FG002|Part 1 (Cohort B and C- Days 1 to 14)|Withdrawal by Subject|0
6339242|NCT03235726|10093000|FG003|Part 1 (Cohort B and C- Days 1 to 14)|Withdrawal by Subject|0
6339243|NCT03235726|10093001|FG004|Part 1 (Cohort B and C- Days 1 to 14)|Withdrawal by Subject|1
6339244|NCT03235726|10093002|FG005|Part 1 (Cohort B and C- Days 1 to 14)|Withdrawal by Subject|0
6339245|NCT03235726|10093003|FG006|Part 1 (Cohort B and C- Days 1 to 14)|Withdrawal by Subject|0
6339246|NCT03235726|10093004|FG007|Part 1 (Cohort B and C- Days 1 to 14)|Withdrawal by Subject|0
6339247|NCT03235726|10093005|FG008|Part 1 (Cohort B and C- Days 1 to 14)|Withdrawal by Subject|0
6339248|NCT03235726|10093006|FG009|Part 1 (Cohort B and C- Days 1 to 14)|Withdrawal by Subject|0
6339249|NCT03235726|10092997|FG000|Part 1 (Cohort B and C- Days 1 to 14)|Drug was prematurely discontinued|0
6339250|NCT03235726|10092998|FG001|Part 1 (Cohort B and C- Days 1 to 14)|Drug was prematurely discontinued|0
6339251|NCT03235726|10092999|FG002|Part 1 (Cohort B and C- Days 1 to 14)|Drug was prematurely discontinued|0
6339252|NCT03235726|10093000|FG003|Part 1 (Cohort B and C- Days 1 to 14)|Drug was prematurely discontinued|0
6339253|NCT03235726|10093001|FG004|Part 1 (Cohort B and C- Days 1 to 14)|Drug was prematurely discontinued|1
6339254|NCT03235726|10093002|FG005|Part 1 (Cohort B and C- Days 1 to 14)|Drug was prematurely discontinued|0
6339255|NCT03235726|10093003|FG006|Part 1 (Cohort B and C- Days 1 to 14)|Drug was prematurely discontinued|0
6339256|NCT03235726|10093004|FG007|Part 1 (Cohort B and C- Days 1 to 14)|Drug was prematurely discontinued|0
6339257|NCT03235726|10093005|FG008|Part 1 (Cohort B and C- Days 1 to 14)|Drug was prematurely discontinued|0
6339258|NCT03235726|10093006|FG009|Part 1 (Cohort B and C- Days 1 to 14)|Drug was prematurely discontinued|0
6339259|NCT03236246|10093047|FG000|24-Week Dose Titration Period|Withdrawal by Subject|8
6339260|NCT03236246|10093048|FG001|24-Week Dose Titration Period|Withdrawal by Subject|7
6042907|NCT00385827|9641397|FG002|Part 1|Adverse Event|0
6042908|NCT00385827|9641395|FG000|Part 1|Death|2
6042909|NCT00385827|9641396|FG001|Part 1|Death|0
6042910|NCT00385827|9641397|FG002|Part 1|Death|0
6042911|NCT00385827|9641395|FG000|Part 1|Lack of Efficacy|5
6042912|NCT00385827|9641396|FG001|Part 1|Lack of Efficacy|0
6042913|NCT00385827|9641397|FG002|Part 1|Lack of Efficacy|0
6042914|NCT00385827|9641395|FG000|Part 1|Other|1
6042915|NCT00385827|9641396|FG001|Part 1|Other|0
6042916|NCT00385827|9641397|FG002|Part 1|Other|0
6083239|NCT00634543|9691624|FG000|Overall Study|Other|1
6083240|NCT00634543|9691625|FG001|Overall Study|Other|2
6042917|NCT00385827|9641395|FG000|Part 2|Adverse Event|0
6042918|NCT00385827|9641396|FG001|Part 2|Adverse Event|6
6083241|NCT00634543|9691624|FG000|Overall Study|Protocol Violation|3
6083242|NCT00634543|9691625|FG001|Overall Study|Protocol Violation|3
6083243|NCT00634543|9691624|FG000|Overall Study|Adverse Event|11
6083244|NCT00634543|9691625|FG001|Overall Study|Adverse Event|11
6083245|NCT00634543|9691624|FG000|Overall Study|Withdrawal by Subject|4
6339261|NCT03236246|10093047|FG000|24-Week Dose Titration Period|Lost to Follow-up|0
6339262|NCT03236246|10093048|FG001|24-Week Dose Titration Period|Lost to Follow-up|2
6339263|NCT03236246|10093047|FG000|24-Week Dose Titration Period|Study Drug Non-Compliance|3
6339264|NCT03236246|10093048|FG001|24-Week Dose Titration Period|Study Drug Non-Compliance|2
6339265|NCT03236246|10093047|FG000|24-Week Dose Titration Period|Investigator Judgement|1
6339266|NCT03236246|10093048|FG001|24-Week Dose Titration Period|Investigator Judgement|1
6339267|NCT03236246|10093047|FG000|24-Week Dose Titration Period|Prohibited Therapy|1
6339268|NCT03236246|10093048|FG001|24-Week Dose Titration Period|Prohibited Therapy|1
6339269|NCT03236246|10093047|FG000|24-Week Dose Titration Period|Start Chronic Dialysis/Kidney Transplant|0
6339270|NCT03236246|10093048|FG001|24-Week Dose Titration Period|Start Chronic Dialysis/Kidney Transplant|1
6339271|NCT03236246|10093047|FG000|24-Week Dose Titration Period|Death|3
6339272|NCT03236246|10093048|FG001|24-Week Dose Titration Period|Death|1
6339273|NCT03236246|10093047|FG000|24-Week Dose Titration Period|Protocol Violation|0
6339274|NCT03236246|10093048|FG001|24-Week Dose Titration Period|Protocol Violation|2
6339275|NCT03236246|10093047|FG000|24-Week Dose Titration Period|Adverse Event|7
6339276|NCT03236246|10093048|FG001|24-Week Dose Titration Period|Adverse Event|8
6339277|NCT03236246|10093047|FG000|24-Week Dose Titration Period|Captured as Other|1
6339278|NCT03236246|10093048|FG001|24-Week Dose Titration Period|Captured as Other|2
6339279|NCT03236246|10093047|FG000|24-Week Dose Maintenance Period|Withdrawal by Subject|1
6339280|NCT03236246|10093048|FG001|24-Week Dose Maintenance Period|Withdrawal by Subject|3
6339281|NCT03236246|10093047|FG000|24-Week Dose Maintenance Period|Lost to Follow-up|1
6339282|NCT03236246|10093048|FG001|24-Week Dose Maintenance Period|Lost to Follow-up|1
6339283|NCT03236246|10093047|FG000|24-Week Dose Maintenance Period|Prohibited Therapy|1
6339284|NCT03236246|10093048|FG001|24-Week Dose Maintenance Period|Prohibited Therapy|0
6339285|NCT03236246|10093047|FG000|24-Week Dose Maintenance Period|Death|0
6339286|NCT03236246|10093048|FG001|24-Week Dose Maintenance Period|Death|1
6339287|NCT03236246|10093047|FG000|24-Week Dose Maintenance Period|Adverse Event|0
6339288|NCT03236246|10093048|FG001|24-Week Dose Maintenance Period|Adverse Event|1
6339289|NCT03236506|10093057|FG000|Overall Study|Death|1
6339290|NCT03236506|10093058|FG001|Overall Study|Death|1
6339291|NCT03236506|10093059|FG002|Overall Study|Death|1
6339292|NCT03236506|10093057|FG000|Overall Study|Withdrawal by Subject|3
6339293|NCT03236506|10093058|FG001|Overall Study|Withdrawal by Subject|3
6339294|NCT03236506|10093059|FG002|Overall Study|Withdrawal by Subject|4
6339295|NCT03236506|10093057|FG000|Overall Study|Did not initiate treatment|2
6339296|NCT03236506|10093058|FG001|Overall Study|Did not initiate treatment|1
6339297|NCT03236506|10093059|FG002|Overall Study|Did not initiate treatment|2
6339298|NCT03236779|10093069|FG000|Overall Study|Lost to Follow-up|13
6339299|NCT03236779|10093070|FG001|Overall Study|Lost to Follow-up|21
6339300|NCT03237013|10093081|FG000|Immediate Post-treatment to 1-mo F/u|Lost to Follow-up|43
6339301|NCT03237013|10093082|FG001|Immediate Post-treatment to 1-mo F/u|Lost to Follow-up|30
6339302|NCT03237013|10093083|FG002|Immediate Post-treatment to 1-mo F/u|Lost to Follow-up|37
6339303|NCT03237065|10093093|FG000|Overall Study|Adverse Event|0
6339304|NCT03237065|10093094|FG001|Overall Study|Adverse Event|2
6339305|NCT03237065|10093093|FG000|Overall Study|Protocol Violation|0
6339306|NCT03237065|10093094|FG001|Overall Study|Protocol Violation|1
6339307|NCT03237065|10093093|FG000|Overall Study|Withdrawal by Subject|3
6339308|NCT03237065|10093094|FG001|Overall Study|Withdrawal by Subject|0
6339309|NCT03237065|10093093|FG000|Overall Study|Lost to Follow-up|1
6339310|NCT03237065|10093094|FG001|Overall Study|Lost to Follow-up|0
6339311|NCT03237065|10093093|FG000|Overall Study|Unable to obtain venous access|0
6339312|NCT03237065|10093094|FG001|Overall Study|Unable to obtain venous access|1
6339313|NCT03237481|10093123|FG000|Overall Study|Lost to Follow-up|1
6339314|NCT03237481|10093124|FG001|Overall Study|Lost to Follow-up|0
6339315|NCT03237481|10093125|FG002|Overall Study|Lost to Follow-up|0
6339316|NCT03237481|10093123|FG000|Overall Study|Protocol Violation|1
6339317|NCT03237481|10093124|FG001|Overall Study|Protocol Violation|0
6339318|NCT03237481|10093125|FG002|Overall Study|Protocol Violation|0
6339319|NCT03237481|10093123|FG000|Overall Study|Withdrawal by Subject|3
6339320|NCT03237481|10093124|FG001|Overall Study|Withdrawal by Subject|2
6339321|NCT03237481|10093125|FG002|Overall Study|Withdrawal by Subject|1
6339322|NCT03237845|10093135|FG000|Overall Study|Adverse Event|0
6339323|NCT03237845|10093136|FG001|Overall Study|Adverse Event|1
6339324|NCT03237845|10093135|FG000|Overall Study|Lost to Follow-up|13
6339325|NCT03237845|10093136|FG001|Overall Study|Lost to Follow-up|10
6339326|NCT03237845|10093135|FG000|Overall Study|Not Experienced Moderate/Severe Migraine|26
6339327|NCT03237845|10093136|FG001|Overall Study|Not Experienced Moderate/Severe Migraine|31
6339328|NCT03237845|10093135|FG000|Overall Study|Non-Compliance With Study Treatment|0
6339329|NCT03237845|10093136|FG001|Overall Study|Non-Compliance With Study Treatment|1
6339330|NCT03237845|10093135|FG000|Overall Study|Physician Decision|1
6339331|NCT03237845|10093136|FG001|Overall Study|Physician Decision|2
6083246|NCT00634543|9691625|FG001|Overall Study|Withdrawal by Subject|4
6083247|NCT00634543|9691624|FG000|Overall Study|Lost to Follow-up|0
6083248|NCT00634543|9691625|FG001|Overall Study|Lost to Follow-up|1
6339332|NCT03237845|10093135|FG000|Overall Study|Pregnancy|1
6339333|NCT03237845|10093136|FG001|Overall Study|Pregnancy|0
6339334|NCT03237845|10093135|FG000|Overall Study|Protocol Deviation|0
6339335|NCT03237845|10093136|FG001|Overall Study|Protocol Deviation|1
6339336|NCT03237845|10093135|FG000|Overall Study|Technical Problems|8
6339337|NCT03237845|10093136|FG001|Overall Study|Technical Problems|1
6339338|NCT03237845|10093135|FG000|Overall Study|Withdrawal by Subject|3
6339339|NCT03237845|10093136|FG001|Overall Study|Withdrawal by Subject|3
6339340|NCT03237845|10093135|FG000|Overall Study|Other Reasons|4
6339341|NCT03237845|10093136|FG001|Overall Study|Other Reasons|0
6339342|NCT03238001|10093146|FG000|Visit 1 (Primary Endpoint Cohort)|Protocol Violation|2
6339343|NCT03238001|10093146|FG000|Visit 1 (Primary Endpoint Cohort)|Unanalyzable test result|2
6339344|NCT03238001|10093146|FG000|Visit 2 (Secondary Endpoint Cohort)|Lost to Follow-up|16
6339345|NCT03238001|10093146|FG000|Visit 2 (Secondary Endpoint Cohort)|Unanalyzable test result|2
6339346|NCT03238001|10093146|FG000|Visit 2 (Secondary Endpoint Cohort)|Withdrawal by Subject|3
6339347|NCT03238001|10093146|FG000|Visit 2 (Secondary Endpoint Cohort)|Met exclusion criteria at visit 2|3
6339348|NCT03238001|10093146|FG000|Visit 2 (Secondary Endpoint Cohort)|Study completion|1
6339349|NCT03238001|10093146|FG000|Visit 2 (Secondary Endpoint Cohort)|Protocol Violation|4
6339350|NCT03238352|10093161|FG000|Overall Study|Lost to Follow-up|0
6339351|NCT03238352|10093162|FG001|Overall Study|Lost to Follow-up|2
6339352|NCT03238352|10093163|FG002|Overall Study|Lost to Follow-up|1
6339353|NCT03238352|10093161|FG000|Overall Study|Withdrawal by Subject|0
6339354|NCT03238352|10093162|FG001|Overall Study|Withdrawal by Subject|1
6339355|NCT03238352|10093163|FG002|Overall Study|Withdrawal by Subject|0
6339356|NCT03238417|10093173|FG000|Overall|non-response|955
6339357|NCT03238417|10093174|FG001|Overall|non-response|1920
6339358|NCT03238417|10093173|FG000|Overall|partial completion|48
6339359|NCT03238417|10093174|FG001|Overall|partial completion|68
6339360|NCT03238417|10093173|FG000|Baseline|Partial completion|17
6339361|NCT03238417|10093174|FG001|Baseline|Partial completion|48
6339362|NCT03238417|10093173|FG000|Baseline|non-response|372
6339363|NCT03238417|10093174|FG001|Baseline|non-response|669
6339364|NCT03238417|10093173|FG000|12-month|non-response|296
6339365|NCT03238417|10093174|FG001|12-month|non-response|669
6339366|NCT03238417|10093173|FG000|12-month|partial completion|23
6339367|NCT03238417|10093174|FG001|12-month|partial completion|37
6339368|NCT03238417|10093173|FG000|24-month|non-response|287
6339369|NCT03238417|10093174|FG001|24-month|non-response|594
6339370|NCT03238417|10093173|FG000|24-month|partial completion|8
6339371|NCT03238417|10093174|FG001|24-month|partial completion|31
6339372|NCT03238651|10093185|FG000|Overall Study|Other|0
6339373|NCT03238651|10093186|FG001|Overall Study|Other|0
6339374|NCT03238651|10093187|FG002|Overall Study|Other|0
6339375|NCT03238651|10093188|FG003|Overall Study|Other|0
6339376|NCT03238651|10093189|FG004|Overall Study|Other|1
6339377|NCT03238651|10093185|FG000|Overall Study|Progressive Disease|2
6339378|NCT03238651|10093186|FG001|Overall Study|Progressive Disease|2
6339379|NCT03238651|10093187|FG002|Overall Study|Progressive Disease|2
6339380|NCT03238651|10093188|FG003|Overall Study|Progressive Disease|2
6339381|NCT03238651|10093189|FG004|Overall Study|Progressive Disease|0
6339382|NCT03238651|10093185|FG000|Overall Study|Withdrawal by Subject|0
6339383|NCT03238651|10093186|FG001|Overall Study|Withdrawal by Subject|1
6339384|NCT03238651|10093187|FG002|Overall Study|Withdrawal by Subject|0
6339385|NCT03238651|10093188|FG003|Overall Study|Withdrawal by Subject|1
6339386|NCT03238651|10093189|FG004|Overall Study|Withdrawal by Subject|0
6339387|NCT03238651|10093185|FG000|Overall Study|Adverse Event|1
6339388|NCT03238651|10093186|FG001|Overall Study|Adverse Event|3
6339389|NCT03238651|10093187|FG002|Overall Study|Adverse Event|2
6339390|NCT03238651|10093188|FG003|Overall Study|Adverse Event|0
6339391|NCT03238651|10093189|FG004|Overall Study|Adverse Event|0
6339392|NCT03238781|10093205|FG000|Overall Study|Adverse Event|1
6339393|NCT03238781|10093206|FG001|Overall Study|Adverse Event|1
6339394|NCT03238781|10093207|FG002|Overall Study|Adverse Event|2
6339395|NCT03238781|10093205|FG000|Overall Study|Lost to Follow-up|2
6339396|NCT03238781|10093206|FG001|Overall Study|Lost to Follow-up|1
6339397|NCT03238781|10093207|FG002|Overall Study|Lost to Follow-up|2
6339398|NCT03238781|10093205|FG000|Overall Study|Withdrawal by Subject|23
6339399|NCT03238781|10093206|FG001|Overall Study|Withdrawal by Subject|14
6339400|NCT03238781|10093207|FG002|Overall Study|Withdrawal by Subject|16
6339401|NCT03238781|10093205|FG000|Overall Study|Decision by sponsor|0
6339402|NCT03238781|10093206|FG001|Overall Study|Decision by sponsor|1
6339403|NCT03238781|10093207|FG002|Overall Study|Decision by sponsor|0
6339404|NCT03238911|10093217|FG000|Overall Study|Withdrawal by Subject|1
6339405|NCT03238911|10093218|FG001|Overall Study|Withdrawal by Subject|2
6339406|NCT03238911|10093217|FG000|Overall Study|Lost to Follow-up|2
6339407|NCT03238911|10093218|FG001|Overall Study|Lost to Follow-up|1
6339408|NCT03238924|10093227|FG000|Overall Study|Withdrawal by Subject|2
6339409|NCT03238924|10093228|FG001|Overall Study|Withdrawal by Subject|2
6339410|NCT03238963|10093236|FG000|Overall Study|Prohibited medication given due to hospital stay|1
6339411|NCT03238963|10093237|FG001|Overall Study|Prohibited medication given due to hospital stay|0
6339412|NCT03238963|10093236|FG000|Overall Study|Withdrawal by Subject|1
6339413|NCT03238963|10093237|FG001|Overall Study|Withdrawal by Subject|1
6339414|NCT03238963|10093236|FG000|Overall Study|Lost to Follow-up|1
6339415|NCT03238963|10093237|FG001|Overall Study|Lost to Follow-up|0
6339416|NCT03238963|10093236|FG000|Overall Study|Protocol Violation|1
6339417|NCT03238963|10093237|FG001|Overall Study|Protocol Violation|1
6339418|NCT03238963|10093236|FG000|Overall Study|Adverse Event|1
6339419|NCT03238963|10093237|FG001|Overall Study|Adverse Event|0
6339420|NCT03239470|10093248|FG000|Polyclonal Treg Infusion|Baseline Pemphigus Disease Area Index (PDAI) >12, thus ineligible for PolyTregs infusion.|1
6339421|NCT03239470|10093249|FG001|Polyclonal Treg Infusion|Baseline Pemphigus Disease Area Index (PDAI) >12, thus ineligible for PolyTregs infusion.|0
6339422|NCT03239483|10093255|FG000|Overall Study|Lost to Follow-up|1
6339423|NCT03239483|10093256|FG001|Overall Study|Lost to Follow-up|0
6339424|NCT03239483|10093255|FG000|Overall Study|Withdrawal by Subject|1
6339425|NCT03239483|10093256|FG001|Overall Study|Withdrawal by Subject|0
6339426|NCT03239873|10093309|FG000|Overall Study|Lost to Follow-up|15
6339427|NCT03239873|10093310|FG001|Overall Study|Lost to Follow-up|16
6339428|NCT03239873|10093309|FG000|Overall Study|Physician Decision|1
6339429|NCT03239873|10093310|FG001|Overall Study|Physician Decision|0
6339430|NCT03239873|10093309|FG000|Overall Study|Withdrawal by Parent/Guardian|12
6339431|NCT03239873|10093310|FG001|Overall Study|Withdrawal by Parent/Guardian|11
6339432|NCT03239873|10093309|FG000|Overall Study|Withdrawal by Subject|2
6339433|NCT03239873|10093310|FG001|Overall Study|Withdrawal by Subject|0
6339434|NCT03239873|10093309|FG000|Overall Study|Contraindication to study medication|1
6339435|NCT03239873|10093310|FG001|Overall Study|Contraindication to study medication|0
6339436|NCT03239873|10093309|FG000|Overall Study|Protocol Violation|1
6339437|NCT03239873|10093310|FG001|Overall Study|Protocol Violation|0
6339438|NCT03240081|10093318|FG000|Overall Study|Withdrawal by Subject|0
6339439|NCT03240081|10093319|FG001|Overall Study|Withdrawal by Subject|2
6339440|NCT03240081|10093318|FG000|Overall Study|Lost to Follow-up|0
6339441|NCT03240081|10093319|FG001|Overall Study|Lost to Follow-up|1
6339442|NCT03240133|10093328|FG000|Overall Study|Withdrawal by Subject|0
6339443|NCT03240133|10093329|FG001|Overall Study|Withdrawal by Subject|1
6339444|NCT03240133|10093330|FG002|Overall Study|Withdrawal by Subject|0
6339445|NCT03240133|10093328|FG000|Overall Study|Adverse Event|1
6339446|NCT03240133|10093329|FG001|Overall Study|Adverse Event|1
6339447|NCT03240133|10093330|FG002|Overall Study|Adverse Event|0
6339448|NCT03240133|10093328|FG000|Overall Study|Rash|1
6339449|NCT03240133|10093329|FG001|Overall Study|Rash|0
6339450|NCT03240133|10093330|FG002|Overall Study|Rash|0
6339451|NCT03240133|10093328|FG000|Overall Study|sponsor closure/completion of Part 1 of the study|1
6339452|NCT03240133|10093329|FG001|Overall Study|sponsor closure/completion of Part 1 of the study|0
6339453|NCT03240133|10093330|FG002|Overall Study|sponsor closure/completion of Part 1 of the study|0
6339454|NCT03240133|10093328|FG000|Overall Study|Intercurrent illness.|0
6339455|NCT03240133|10093329|FG001|Overall Study|Intercurrent illness.|1
6339456|NCT03240133|10093330|FG002|Overall Study|Intercurrent illness.|0
6339457|NCT03240133|10093328|FG000|Overall Study|Sponsor/competent authority/IRB/IEC discontinuation|0
6339458|NCT03240133|10093329|FG001|Overall Study|Sponsor/competent authority/IRB/IEC discontinuation|0
6339459|NCT03240133|10093330|FG002|Overall Study|Sponsor/competent authority/IRB/IEC discontinuation|1
6339460|NCT03240575|10093358|FG000|Overall Study|Adverse Event|0
6339461|NCT03240575|10093359|FG001|Overall Study|Adverse Event|2
6339462|NCT03240575|10093360|FG002|Overall Study|Adverse Event|0
6339463|NCT03240575|10093361|FG003|Overall Study|Adverse Event|1
6339464|NCT03240575|10093358|FG000|Overall Study|Withdrawal by Subject|2
6339465|NCT03240575|10093359|FG001|Overall Study|Withdrawal by Subject|11
6339466|NCT03240575|10093360|FG002|Overall Study|Withdrawal by Subject|0
6339467|NCT03240575|10093361|FG003|Overall Study|Withdrawal by Subject|1
6339468|NCT03240575|10093358|FG000|Overall Study|Other|0
6339469|NCT03240575|10093359|FG001|Overall Study|Other|1
6339470|NCT03240575|10093360|FG002|Overall Study|Other|0
6339471|NCT03240575|10093361|FG003|Overall Study|Other|0
6339472|NCT03241342|10093381|FG000|Overall Study|Adverse Event|5
6339473|NCT03241342|10093382|FG001|Overall Study|Adverse Event|8
6339474|NCT03241342|10093383|FG002|Overall Study|Adverse Event|4
6339475|NCT03241342|10093381|FG000|Overall Study|Lack of Efficacy|0
6339476|NCT03241342|10093382|FG001|Overall Study|Lack of Efficacy|0
6339477|NCT03241342|10093383|FG002|Overall Study|Lack of Efficacy|1
6339478|NCT03241342|10093381|FG000|Overall Study|noncompliance with study drug|2
6339479|NCT03241342|10093382|FG001|Overall Study|noncompliance with study drug|1
6339480|NCT03241342|10093383|FG002|Overall Study|noncompliance with study drug|1
6339481|NCT03241342|10093381|FG000|Overall Study|sponsor decision|0
6339482|NCT03241342|10093382|FG001|Overall Study|sponsor decision|1
6339483|NCT03241342|10093383|FG002|Overall Study|sponsor decision|2
6339484|NCT03241342|10093381|FG000|Overall Study|not reported|15
6339485|NCT03241342|10093382|FG001|Overall Study|not reported|21
6339486|NCT03241342|10093383|FG002|Overall Study|not reported|19
6339487|NCT03241368|10093391|FG000|Overall Study|MRE Stricture or Patency Capsule Failure|25
6339488|NCT03241368|10093391|FG000|Overall Study|Lost to Follow-up|1
6339489|NCT03241368|10093391|FG000|Overall Study|Physician Decision|6
6339490|NCT03241368|10093391|FG000|Overall Study|Withdrawal by Subject|6
6339491|NCT03241368|10093391|FG000|Overall Study|Protocol Violation|1
6339492|NCT03241927|10093423|FG000|Overall Study|study terminated|1
6339493|NCT03241927|10093424|FG001|Overall Study|study terminated|0
6339494|NCT03242018|10093433|FG000|Overall Study|Adverse Event|7
6339495|NCT03242018|10093434|FG001|Overall Study|Adverse Event|7
6339496|NCT03242018|10093435|FG002|Overall Study|Adverse Event|6
6339497|NCT03242018|10093433|FG000|Overall Study|Lost to Follow-up|2
6339498|NCT03242018|10093434|FG001|Overall Study|Lost to Follow-up|2
6339499|NCT03242018|10093435|FG002|Overall Study|Lost to Follow-up|2
6339500|NCT03242018|10093433|FG000|Overall Study|At the Participant's Own Request|5
6339501|NCT03242018|10093434|FG001|Overall Study|At the Participant's Own Request|1
6339502|NCT03242018|10093435|FG002|Overall Study|At the Participant's Own Request|4
6339503|NCT03242018|10093433|FG000|Overall Study|Reason Not Specified|3
6339504|NCT03242018|10093434|FG001|Overall Study|Reason Not Specified|4
6339505|NCT03242018|10093435|FG002|Overall Study|Reason Not Specified|1
6339506|NCT03242018|10093433|FG000|Overall Study|Study Terminated by Sponsor|1
6339507|NCT03242018|10093434|FG001|Overall Study|Study Terminated by Sponsor|0
6339508|NCT03242018|10093435|FG002|Overall Study|Study Terminated by Sponsor|1
6339509|NCT03242252|10093451|FG000|Overall Study|At the Participant's own Request|18
6339510|NCT03242252|10093452|FG001|Overall Study|At the Participant's own Request|10
6339511|NCT03242252|10093453|FG002|Overall Study|At the Participant's own Request|15
6339512|NCT03242252|10093451|FG000|Overall Study|Adverse Event|8
6339513|NCT03242252|10093452|FG001|Overall Study|Adverse Event|6
6339514|NCT03242252|10093453|FG002|Overall Study|Adverse Event|9
6339515|NCT03242252|10093451|FG000|Overall Study|Poor Compliance to Protocol|0
6339516|NCT03242252|10093452|FG001|Overall Study|Poor Compliance to Protocol|2
6339517|NCT03242252|10093453|FG002|Overall Study|Poor Compliance to Protocol|3
6339518|NCT03242252|10093451|FG000|Overall Study|Study Terminated by Sponsor|1
6339519|NCT03242252|10093452|FG001|Overall Study|Study Terminated by Sponsor|0
6339520|NCT03242252|10093453|FG002|Overall Study|Study Terminated by Sponsor|0
6339521|NCT03242252|10093451|FG000|Overall Study|Reason not Specified|4
6339522|NCT03242252|10093452|FG001|Overall Study|Reason not Specified|4
6339523|NCT03242252|10093453|FG002|Overall Study|Reason not Specified|1
6339524|NCT03242252|10093451|FG000|Overall Study|Lost to Follow-up|5
6339525|NCT03242252|10093452|FG001|Overall Study|Lost to Follow-up|1
6339526|NCT03242252|10093453|FG002|Overall Study|Lost to Follow-up|4
6339527|NCT03242434|10093473|FG000|Overall Study|Death|0
6339528|NCT03242434|10093474|FG001|Overall Study|Death|2
6339529|NCT03242759|10093487|FG000|Overall Study|Adverse Event|5
6339530|NCT03242759|10093488|FG001|Overall Study|Adverse Event|1
6339531|NCT03242759|10093487|FG000|Overall Study|Withdrawal by Subject|4
6339532|NCT03242759|10093488|FG001|Overall Study|Withdrawal by Subject|3
6339533|NCT03242759|10093487|FG000|Overall Study|Lost to Follow-up|3
6339534|NCT03242759|10093488|FG001|Overall Study|Lost to Follow-up|1
6339535|NCT03242759|10093487|FG000|Overall Study|Administrative problems|1
6339536|NCT03242759|10093488|FG001|Overall Study|Administrative problems|1
6339537|NCT03242759|10093487|FG000|Overall Study|Death|22
6339538|NCT03242759|10093488|FG001|Overall Study|Death|0
6339539|NCT03242759|10093487|FG000|Overall Study|Change visit schedule|0
6339540|NCT03242759|10093488|FG001|Overall Study|Change visit schedule|1
6339541|NCT03242863|10093494|FG000|Study Week 1|Withdrawal by Subject|0
6339542|NCT03242863|10093495|FG001|Study Week 1|Withdrawal by Subject|1
6339543|NCT03242863|10093496|FG002|Study Week 1|Withdrawal by Subject|0
6339544|NCT03242863|10093497|FG003|Study Week 1|Withdrawal by Subject|0
6339545|NCT03242863|10093498|FG004|Study Week 1|Withdrawal by Subject|3
6339546|NCT03242863|10093499|FG005|Study Week 1|Withdrawal by Subject|0
6339547|NCT03242928|10093509|FG000|Overall Study|Adverse Event|2
6339548|NCT03242928|10093510|FG001|Overall Study|Adverse Event|1
6339549|NCT03242928|10093509|FG000|Overall Study|Lost to Follow-up|2
6339550|NCT03242928|10093510|FG001|Overall Study|Lost to Follow-up|0
6339551|NCT03242928|10093509|FG000|Overall Study|Physician Decision|0
6339552|NCT03242928|10093510|FG001|Overall Study|Physician Decision|1
6339553|NCT03242928|10093509|FG000|Overall Study|Withdrawal by Subject|5
6339554|NCT03242928|10093510|FG001|Overall Study|Withdrawal by Subject|3
6339555|NCT03243084|10093540|FG000|Washout (1-3 Weeks)|Lost to Follow-up|1
6339556|NCT03243084|10093541|FG001|Washout (1-3 Weeks)|Lost to Follow-up|0
6339557|NCT03243305|10093548|FG000|Overall Study|Lost to Follow-up|250
6339558|NCT03243305|10093548|FG000|Overall Study|Withdrawal by Subject|170
6339559|NCT03243305|10093548|FG000|Overall Study|Pregnancy|104
6339560|NCT03243305|10093548|FG000|Overall Study|Non-Compliance with Study Drug|38
6339561|NCT03243305|10093548|FG000|Overall Study|Adverse Event|23
6339562|NCT03243305|10093548|FG000|Overall Study|No sexually active|26
6339563|NCT03243305|10093548|FG000|Overall Study|Physician Decision|22
6339564|NCT03243305|10093548|FG000|Overall Study|Protocol Violation|22
6339565|NCT03243305|10093548|FG000|Overall Study|Study method no longer primary method|12
6339566|NCT03243305|10093548|FG000|Overall Study|Study Terminated by Sponsor|1
6339567|NCT03243305|10093548|FG000|Overall Study|Early terminations|267
6339568|NCT03243630|10093552|FG000|Overall Study|Protocol Violation|1
6339569|NCT03243630|10093552|FG000|Overall Study|Physician Decision|1
6339570|NCT03244618|10093571|FG000|Overall Study|Lost to Follow-up|3
6339571|NCT03244618|10093572|FG001|Overall Study|Lost to Follow-up|4
6339572|NCT03244618|10093571|FG000|Overall Study|Protocol Violation|4
6339573|NCT03244618|10093572|FG001|Overall Study|Protocol Violation|3
6339574|NCT03244618|10093571|FG000|Overall Study|Withdrawal by Subject|0
6339575|NCT03244618|10093572|FG001|Overall Study|Withdrawal by Subject|2
6339576|NCT03244800|10093582|FG000|Overall Study|Adverse Event|0
6339577|NCT03244800|10093583|FG001|Overall Study|Adverse Event|1
6339578|NCT03244800|10093584|FG002|Overall Study|Adverse Event|0
6339579|NCT03244800|10093585|FG003|Overall Study|Adverse Event|1
6339580|NCT03244800|10093582|FG000|Overall Study|Withdrew treatment|0
6339581|NCT03244800|10093583|FG001|Overall Study|Withdrew treatment|0
6339582|NCT03244800|10093584|FG002|Overall Study|Withdrew treatment|0
6339583|NCT03244800|10093585|FG003|Overall Study|Withdrew treatment|1
6339584|NCT03244917|10093604|FG000|Overall Study|Lost to Follow-up|2
6339585|NCT03244917|10093605|FG001|Overall Study|Lost to Follow-up|2
6339586|NCT03245398|10093622|FG000|Overall Study|Travelled to another island|1
6339587|NCT03245398|10093623|FG001|Overall Study|Travelled to another island|0
6339588|NCT03245619|10093657|FG000|Part A (Up to Day 22)|Physician Decision|4
6339589|NCT03245619|10093658|FG001|Part A (Up to Day 22)|Physician Decision|6
6339590|NCT03245619|10093659|FG002|Part A (Up to Day 22)|Physician Decision|6
6339591|NCT03245619|10093660|FG003|Part A (Up to Day 22)|Physician Decision|0
6339592|NCT03245619|10093661|FG004|Part A (Up to Day 22)|Physician Decision|0
6339593|NCT03245619|10093662|FG005|Part A (Up to Day 22)|Physician Decision|0
6339594|NCT03245619|10093663|FG006|Part A (Up to Day 22)|Physician Decision|0
6339595|NCT03245619|10093664|FG007|Part A (Up to Day 22)|Physician Decision|0
6339596|NCT03245619|10093665|FG008|Part A (Up to Day 22)|Physician Decision|0
6339597|NCT03245619|10093666|FG009|Part A (Up to Day 22)|Physician Decision|0
6339598|NCT03245619|10093667|FG010|Part A (Up to Day 22)|Physician Decision|0
6339599|NCT03245619|10093668|FG011|Part A (Up to Day 22)|Physician Decision|0
6339600|NCT03245619|10093669|FG012|Part A (Up to Day 22)|Physician Decision|0
6339601|NCT03245619|10093670|FG013|Part A (Up to Day 22)|Physician Decision|0
6339602|NCT03245619|10093671|FG014|Part A (Up to Day 22)|Physician Decision|0
6339603|NCT03245619|10093672|FG015|Part A (Up to Day 22)|Physician Decision|0
6339604|NCT03245619|10093673|FG016|Part A (Up to Day 22)|Physician Decision|0
6339605|NCT03245723|10093734|FG000|Overall Study|Bigeminy precluding hypoxia exposure|1
6339606|NCT03245723|10093735|FG001|Overall Study|Bigeminy precluding hypoxia exposure|0
6339607|NCT03245723|10093734|FG000|Overall Study|Claustrophobia from wearing the mask|1
6339608|NCT03245723|10093735|FG001|Overall Study|Claustrophobia from wearing the mask|0
6339609|NCT03245723|10093734|FG000|Overall Study|Having to abruptly stop the scan to use the restroom|2
6339610|NCT03245723|10093735|FG001|Overall Study|Having to abruptly stop the scan to use the restroom|0
6339611|NCT03245723|10093734|FG000|Overall Study|Image acquisition/reconstruction failure|1
6339612|NCT03245723|10093735|FG001|Overall Study|Image acquisition/reconstruction failure|1
6083249|NCT00634569|9691633|FG000|Overall Study|Withdrawal by Subject|0
6083250|NCT00634569|9691634|FG001|Overall Study|Withdrawal by Subject|4
6083251|NCT00634569|9691633|FG000|Overall Study|Physician Decision|0
6339613|NCT03245736|10093741|FG000|Overall Study|Adverse Event|1
6339614|NCT03245736|10093741|FG000|Overall Study|Progressive Disease|4
6339615|NCT03246061|10093756|FG000|Overall Study|Still in follow-up|15
6339616|NCT03246061|10093757|FG001|Overall Study|Still in follow-up|21
6339617|NCT03246152|10093765|FG000|Overall Study|Lost to Follow-up|2
6339618|NCT03246152|10093765|FG000|Overall Study|Protocol Violation|1
6339619|NCT03246646|10093771|FG000|Overall Study|deemed ineligible and administratively withdrawn|1
6339620|NCT03246646|10093772|FG001|Overall Study|deemed ineligible and administratively withdrawn|0
6339621|NCT03246646|10093771|FG000|Overall Study|Withdrawal by Subject|3
6339622|NCT03246646|10093772|FG001|Overall Study|Withdrawal by Subject|0
6339623|NCT03246646|10093771|FG000|Overall Study|Lost to Follow-up|7
6339624|NCT03246646|10093772|FG001|Overall Study|Lost to Follow-up|0
6339625|NCT03246672|10093778|FG000|Overall Study|Lost to Follow-up|2
6339626|NCT03246724|10093786|FG000|Overall Study|Withdrawal by Subject|5
6339627|NCT03246724|10093787|FG001|Overall Study|Withdrawal by Subject|2
6339628|NCT03246724|10093788|FG002|Overall Study|Withdrawal by Subject|4
6339629|NCT03246724|10093789|FG003|Overall Study|Withdrawal by Subject|2
6339630|NCT03246724|10093786|FG000|Overall Study|Ineligible on day of surgery|7
6339631|NCT03246724|10093787|FG001|Overall Study|Ineligible on day of surgery|2
6339632|NCT03246724|10093788|FG002|Overall Study|Ineligible on day of surgery|0
6339633|NCT03246724|10093789|FG003|Overall Study|Ineligible on day of surgery|3
6339634|NCT03246724|10093786|FG000|Overall Study|Study completed before surgical date|2
6339635|NCT03246724|10093787|FG001|Overall Study|Study completed before surgical date|1
6339636|NCT03246724|10093788|FG002|Overall Study|Study completed before surgical date|8
6339637|NCT03246724|10093789|FG003|Overall Study|Study completed before surgical date|1
6339638|NCT03246724|10093786|FG000|Overall Study|Transferred to other arm|0
6339639|NCT03246724|10093787|FG001|Overall Study|Transferred to other arm|0
6339640|NCT03246724|10093788|FG002|Overall Study|Transferred to other arm|1
6339641|NCT03246724|10093789|FG003|Overall Study|Transferred to other arm|0
6339642|NCT03246724|10093786|FG000|Overall Study|Unable to obtain medication timely|0
6339643|NCT03246724|10093787|FG001|Overall Study|Unable to obtain medication timely|2
6339644|NCT03246724|10093788|FG002|Overall Study|Unable to obtain medication timely|2
6339645|NCT03246724|10093789|FG003|Overall Study|Unable to obtain medication timely|1
6339646|NCT03246724|10093786|FG000|Overall Study|Re-consented to participate|0
6339647|NCT03246724|10093787|FG001|Overall Study|Re-consented to participate|0
6339648|NCT03246724|10093788|FG002|Overall Study|Re-consented to participate|0
6339649|NCT03246724|10093789|FG003|Overall Study|Re-consented to participate|1
6339650|NCT03247517|10093813|FG000|Overall Study|Adverse Event|0
6339651|NCT03247517|10093814|FG001|Overall Study|Adverse Event|4
6339652|NCT03247517|10093815|FG002|Overall Study|Adverse Event|2
6339653|NCT03247517|10093813|FG000|Overall Study|Lost to Follow-up|2
6339654|NCT03247517|10093814|FG001|Overall Study|Lost to Follow-up|6
6339655|NCT03247517|10093815|FG002|Overall Study|Lost to Follow-up|4
6339656|NCT03247517|10093813|FG000|Overall Study|Consent withdrawn by caregiver|1
6339657|NCT03247517|10093814|FG001|Overall Study|Consent withdrawn by caregiver|4
6339658|NCT03247517|10093815|FG002|Overall Study|Consent withdrawn by caregiver|7
6339659|NCT03247517|10093813|FG000|Overall Study|Assent/consent withdrawn by subject|2
6339660|NCT03247517|10093814|FG001|Overall Study|Assent/consent withdrawn by subject|3
6339661|NCT03247517|10093815|FG002|Overall Study|Assent/consent withdrawn by subject|1
6339662|NCT03247517|10093813|FG000|Overall Study|Protocol Violation|0
6339663|NCT03247517|10093814|FG001|Overall Study|Protocol Violation|2
6339664|NCT03247517|10093815|FG002|Overall Study|Protocol Violation|0
6339665|NCT03247517|10093813|FG000|Overall Study|Multiple reasons|3
6339666|NCT03247517|10093814|FG001|Overall Study|Multiple reasons|1
6339667|NCT03247517|10093815|FG002|Overall Study|Multiple reasons|0
6339668|NCT03247530|10093826|FG000|Overall Study|Withdrawal by caregiver|19
6339669|NCT03247530|10093827|FG001|Overall Study|Withdrawal by caregiver|8
6339670|NCT03247530|10093828|FG002|Overall Study|Withdrawal by caregiver|10
6339671|NCT03247530|10093826|FG000|Overall Study|Lost to Follow-up|3
6339672|NCT03247530|10093827|FG001|Overall Study|Lost to Follow-up|9
6339673|NCT03247530|10093828|FG002|Overall Study|Lost to Follow-up|6
6339674|NCT03247530|10093826|FG000|Overall Study|Adverse Event|2
6339675|NCT03247530|10093827|FG001|Overall Study|Adverse Event|5
6339676|NCT03247530|10093828|FG002|Overall Study|Adverse Event|2
6339677|NCT03247530|10093826|FG000|Overall Study|Failure to follow procedure|1
6339678|NCT03247530|10093827|FG001|Overall Study|Failure to follow procedure|1
6339679|NCT03247530|10093828|FG002|Overall Study|Failure to follow procedure|1
6339680|NCT03247530|10093826|FG000|Overall Study|Withdrawal by Subject|1
6339681|NCT03247530|10093827|FG001|Overall Study|Withdrawal by Subject|1
6339682|NCT03247530|10093828|FG002|Overall Study|Withdrawal by Subject|0
6339683|NCT03247530|10093826|FG000|Overall Study|Study medication misuse|0
6339684|NCT03247530|10093827|FG001|Overall Study|Study medication misuse|1
6339685|NCT03247530|10093828|FG002|Overall Study|Study medication misuse|0
6339686|NCT03247530|10093826|FG000|Overall Study|Other, multiple categories|1
6339687|NCT03247530|10093827|FG001|Overall Study|Other, multiple categories|3
6339688|NCT03247530|10093828|FG002|Overall Study|Other, multiple categories|1
6339689|NCT03247543|10093842|FG000|Overall Study|Adverse Event|3
6339690|NCT03247543|10093843|FG001|Overall Study|Adverse Event|6
6339691|NCT03247543|10093844|FG002|Overall Study|Adverse Event|4
6339692|NCT03247543|10093842|FG000|Overall Study|Lost to Follow-up|10
6339693|NCT03247543|10093843|FG001|Overall Study|Lost to Follow-up|7
6339694|NCT03247543|10093844|FG002|Overall Study|Lost to Follow-up|8
6339695|NCT03247543|10093842|FG000|Overall Study|Consent withdrawn by caregiver|2
6339696|NCT03247543|10093843|FG001|Overall Study|Consent withdrawn by caregiver|2
6339697|NCT03247543|10093844|FG002|Overall Study|Consent withdrawn by caregiver|9
6339698|NCT03247543|10093842|FG000|Overall Study|Withdrawal by Subject|0
6339699|NCT03247543|10093843|FG001|Overall Study|Withdrawal by Subject|0
6339700|NCT03247543|10093844|FG002|Overall Study|Withdrawal by Subject|1
6339701|NCT03247543|10093842|FG000|Overall Study|Failure to Follow study procedures|1
6339702|NCT03247543|10093843|FG001|Overall Study|Failure to Follow study procedures|3
6339703|NCT03247543|10093844|FG002|Overall Study|Failure to Follow study procedures|1
6339704|NCT03247543|10093842|FG000|Overall Study|Lack of Efficacy|1
6339705|NCT03247543|10093843|FG001|Overall Study|Lack of Efficacy|0
6339706|NCT03247543|10093844|FG002|Overall Study|Lack of Efficacy|0
6339707|NCT03247543|10093842|FG000|Overall Study|Non-compliance with study visits|0
6339708|NCT03247543|10093843|FG001|Overall Study|Non-compliance with study visits|1
6339709|NCT03247543|10093844|FG002|Overall Study|Non-compliance with study visits|0
6339710|NCT03247556|10093857|FG000|Overall Study|Adverse Event|1
6339711|NCT03247556|10093858|FG001|Overall Study|Adverse Event|4
6339712|NCT03247556|10093859|FG002|Overall Study|Adverse Event|5
6339713|NCT03247556|10093857|FG000|Overall Study|Lost to Follow-up|5
6339714|NCT03247556|10093858|FG001|Overall Study|Lost to Follow-up|5
6339715|NCT03247556|10093859|FG002|Overall Study|Lost to Follow-up|4
6339716|NCT03247556|10093857|FG000|Overall Study|Consent Withdrawn by Caregiver|4
6339717|NCT03247556|10093858|FG001|Overall Study|Consent Withdrawn by Caregiver|1
6339718|NCT03247556|10093859|FG002|Overall Study|Consent Withdrawn by Caregiver|5
6339719|NCT03247556|10093857|FG000|Overall Study|Assent/consent Withdrawn by Subject|0
6339720|NCT03247556|10093858|FG001|Overall Study|Assent/consent Withdrawn by Subject|2
6339721|NCT03247556|10093859|FG002|Overall Study|Assent/consent Withdrawn by Subject|2
6339722|NCT03247556|10093857|FG000|Overall Study|Protocol Violation|2
6339723|NCT03247556|10093858|FG001|Overall Study|Protocol Violation|0
6339724|NCT03247556|10093859|FG002|Overall Study|Protocol Violation|1
6339725|NCT03247556|10093857|FG000|Overall Study|Subject did not meet inclusion criteria|0
6339726|NCT03247556|10093858|FG001|Overall Study|Subject did not meet inclusion criteria|0
6339727|NCT03247556|10093859|FG002|Overall Study|Subject did not meet inclusion criteria|1
6339728|NCT03247673|10093870|FG000|Overall Study|Withdrawal by Subject|1
6339729|NCT03247673|10093871|FG001|Overall Study|Withdrawal by Subject|0
6339730|NCT03247673|10093872|FG002|Overall Study|Withdrawal by Subject|3
6339731|NCT03247673|10093870|FG000|Overall Study|Lost to Follow-up|0
6339732|NCT03247673|10093871|FG001|Overall Study|Lost to Follow-up|0
6339733|NCT03247673|10093872|FG002|Overall Study|Lost to Follow-up|1
6339734|NCT03247686|10093882|FG000|Overall Study|Withdrawal by Subject|1
6339735|NCT03247686|10093883|FG001|Overall Study|Withdrawal by Subject|2
6339736|NCT03247816|10093907|FG000|Overall Study|Adverse Event|12
6339737|NCT03247816|10093907|FG000|Overall Study|Physician Decision|3
6339738|NCT03247816|10093907|FG000|Overall Study|Lack of Efficacy|1
6339739|NCT03247816|10093907|FG000|Overall Study|Lost to Follow-up|10
6339740|NCT03247816|10093907|FG000|Overall Study|Missing Feraccru stop date|3
6339741|NCT03248037|10093924|FG000|Overall Study|Withdrawal by Subject|6
6339742|NCT03248037|10093925|FG001|Overall Study|Withdrawal by Subject|9
6339743|NCT03248037|10093924|FG000|Overall Study|Adverse Event|15
6339744|NCT03248037|10093925|FG001|Overall Study|Adverse Event|0
6339745|NCT03248492|10093945|FG000|Overall Study|Ongoing|23
6339746|NCT03248492|10093946|FG001|Overall Study|Ongoing|26
6339747|NCT03248492|10093947|FG002|Overall Study|Ongoing|3
6339748|NCT03248492|10093948|FG003|Overall Study|Ongoing|85
6339749|NCT03248492|10093949|FG004|Overall Study|Ongoing|2
6339750|NCT03248492|10093945|FG000|Overall Study|Progressive disease per RECIST v1.1|16
6339751|NCT03248492|10093946|FG001|Overall Study|Progressive disease per RECIST v1.1|12
6339752|NCT03248492|10093947|FG002|Overall Study|Progressive disease per RECIST v1.1|9
6339753|NCT03248492|10093948|FG003|Overall Study|Progressive disease per RECIST v1.1|22
6339754|NCT03248492|10093949|FG004|Overall Study|Progressive disease per RECIST v1.1|0
6339755|NCT03248492|10093945|FG000|Overall Study|Adverse Event|6
6339756|NCT03248492|10093946|FG001|Overall Study|Adverse Event|6
6339757|NCT03248492|10093947|FG002|Overall Study|Adverse Event|8
6339758|NCT03248492|10093948|FG003|Overall Study|Adverse Event|8
6083252|NCT00634569|9691634|FG001|Overall Study|Physician Decision|1
6339759|NCT03248492|10093949|FG004|Overall Study|Adverse Event|1
6339760|NCT03248492|10093945|FG000|Overall Study|Withdrawal by Subject|3
6339761|NCT03248492|10093946|FG001|Overall Study|Withdrawal by Subject|3
6339762|NCT03248492|10093947|FG002|Overall Study|Withdrawal by Subject|0
6339763|NCT03248492|10093948|FG003|Overall Study|Withdrawal by Subject|3
6339764|NCT03248492|10093949|FG004|Overall Study|Withdrawal by Subject|1
6339765|NCT03248492|10093945|FG000|Overall Study|Physician Decision|1
6339766|NCT03248492|10093946|FG001|Overall Study|Physician Decision|0
6339767|NCT03248492|10093947|FG002|Overall Study|Physician Decision|1
6339768|NCT03248492|10093948|FG003|Overall Study|Physician Decision|2
6339769|NCT03248492|10093949|FG004|Overall Study|Physician Decision|0
6339770|NCT03248492|10093945|FG000|Overall Study|Death|1
6339771|NCT03248492|10093946|FG001|Overall Study|Death|0
6339772|NCT03248492|10093947|FG002|Overall Study|Death|0
6339773|NCT03248492|10093948|FG003|Overall Study|Death|6
6339774|NCT03248492|10093949|FG004|Overall Study|Death|0
6339775|NCT03248492|10093945|FG000|Overall Study|Other|0
6339776|NCT03248492|10093946|FG001|Overall Study|Other|1
6339777|NCT03248492|10093947|FG002|Overall Study|Other|0
6339778|NCT03248492|10093948|FG003|Overall Study|Other|4
6339779|NCT03248492|10093949|FG004|Overall Study|Other|0
6339780|NCT03248882|10093974|FG000|Overall Study|Adverse Event|3
6339781|NCT03248882|10093975|FG001|Overall Study|Adverse Event|3
6339782|NCT03248882|10093976|FG002|Overall Study|Adverse Event|2
6339783|NCT03248882|10093977|FG003|Overall Study|Adverse Event|6
6339784|NCT03248882|10093978|FG004|Overall Study|Adverse Event|9
6339785|NCT03248882|10093974|FG000|Overall Study|Lost to Follow-up|0
6339786|NCT03248882|10093975|FG001|Overall Study|Lost to Follow-up|0
6339787|NCT03248882|10093976|FG002|Overall Study|Lost to Follow-up|0
6339788|NCT03248882|10093977|FG003|Overall Study|Lost to Follow-up|0
6339789|NCT03248882|10093978|FG004|Overall Study|Lost to Follow-up|1
6339790|NCT03248882|10093974|FG000|Overall Study|Protocol Violation|2
6339791|NCT03248882|10093975|FG001|Overall Study|Protocol Violation|0
6339792|NCT03248882|10093976|FG002|Overall Study|Protocol Violation|2
6339793|NCT03248882|10093977|FG003|Overall Study|Protocol Violation|0
6339794|NCT03248882|10093978|FG004|Overall Study|Protocol Violation|1
6339795|NCT03248882|10093974|FG000|Overall Study|Withdrawal by Subject|2
6339796|NCT03248882|10093975|FG001|Overall Study|Withdrawal by Subject|2
6339797|NCT03248882|10093976|FG002|Overall Study|Withdrawal by Subject|3
6339798|NCT03248882|10093977|FG003|Overall Study|Withdrawal by Subject|4
6339799|NCT03248882|10093978|FG004|Overall Study|Withdrawal by Subject|2
6339800|NCT03249454|10094037|FG000|Overall Study|Withdrawal by Subject|0
6339801|NCT03249454|10094038|FG001|Overall Study|Withdrawal by Subject|0
6339802|NCT03249454|10094039|FG002|Overall Study|Withdrawal by Subject|0
6339803|NCT03249454|10094040|FG003|Overall Study|Withdrawal by Subject|0
6339804|NCT03249454|10094041|FG004|Overall Study|Withdrawal by Subject|0
6339805|NCT03249454|10094042|FG005|Overall Study|Withdrawal by Subject|0
6339806|NCT03249454|10094043|FG006|Overall Study|Withdrawal by Subject|0
6339807|NCT03249454|10094044|FG007|Overall Study|Withdrawal by Subject|0
6339808|NCT03249454|10094045|FG008|Overall Study|Withdrawal by Subject|0
6339809|NCT03249454|10094046|FG009|Overall Study|Withdrawal by Subject|1
6339810|NCT03249454|10094047|FG010|Overall Study|Withdrawal by Subject|1
6339811|NCT03249909|10094073|FG000|Overall Study|Withdrawal by Subject|3
6339812|NCT03249909|10094074|FG001|Overall Study|Withdrawal by Subject|0
6339813|NCT03249909|10094075|FG002|Overall Study|Withdrawal by Subject|0
6339814|NCT03249909|10094073|FG000|Overall Study|Adverse Event|3
6339815|NCT03249909|10094074|FG001|Overall Study|Adverse Event|0
6339816|NCT03249909|10094075|FG002|Overall Study|Adverse Event|0
6339817|NCT03249909|10094073|FG000|Overall Study|Lost to Follow-up|0
6339818|NCT03249909|10094074|FG001|Overall Study|Lost to Follow-up|1
6339819|NCT03249909|10094075|FG002|Overall Study|Lost to Follow-up|0
6339820|NCT03249935|10094086|FG000|Overall Study|Discharged from facility early|36
6339821|NCT03249935|10094086|FG000|Overall Study|Negative for chlamydia at enrollment|4
6339822|NCT03249935|10094086|FG000|Overall Study|Protocol Violation|5
6339823|NCT03250182|10094092|FG000|Overall Study|Withdrawal by Subject|1
6339824|NCT03251482|10094126|FG000|Overall Study|Withdrawal by Subject|0
6339825|NCT03251482|10094127|FG001|Overall Study|Withdrawal by Subject|1
6339826|NCT03251482|10094128|FG002|Overall Study|Withdrawal by Subject|0
6339827|NCT03251482|10094129|FG003|Overall Study|Withdrawal by Subject|0
6339828|NCT03251482|10094130|FG004|Overall Study|Withdrawal by Subject|0
6339829|NCT03251963|10094148|FG000|Overall Study|inappropriate Xa level timing|6
6339830|NCT03251963|10094149|FG001|Overall Study|inappropriate Xa level timing|3
6339831|NCT03251963|10094148|FG000|Overall Study|no peak Xa level drawn|2
6339832|NCT03251963|10094149|FG001|Overall Study|no peak Xa level drawn|0
6339833|NCT03251963|10094148|FG000|Overall Study|bled prior to Xa level|1
6339834|NCT03251963|10094149|FG001|Overall Study|bled prior to Xa level|2
6339835|NCT03252015|10094159|FG000|Overall Study|Withdrawal by Subject|0
6339836|NCT03252015|10094160|FG001|Overall Study|Withdrawal by Subject|1
6339837|NCT03252015|10094161|FG002|Overall Study|Withdrawal by Subject|1
6339838|NCT03252015|10094162|FG003|Overall Study|Withdrawal by Subject|0
6339839|NCT03252015|10094159|FG000|Overall Study|Adverse Event|1
6339840|NCT03252015|10094160|FG001|Overall Study|Adverse Event|0
6339841|NCT03252015|10094161|FG002|Overall Study|Adverse Event|0
6339842|NCT03252015|10094162|FG003|Overall Study|Adverse Event|1
6339843|NCT03252145|10094188|FG000|Overall Study|Withdrawal by Subject|1
6339844|NCT03252145|10094189|FG001|Overall Study|Withdrawal by Subject|0
6339845|NCT03252145|10094188|FG000|Overall Study|Complicating Disease|1
6339846|NCT03252145|10094189|FG001|Overall Study|Complicating Disease|2
6339847|NCT03253094|10094226|FG000|Overall Study|Adverse Event|2
6339848|NCT03253094|10094227|FG001|Overall Study|Adverse Event|0
6339849|NCT03253094|10094228|FG002|Overall Study|Adverse Event|0
6339850|NCT03253094|10094229|FG003|Overall Study|Adverse Event|0
6339851|NCT03253094|10094230|FG004|Overall Study|Adverse Event|0
6339852|NCT03253094|10094231|FG005|Overall Study|Adverse Event|0
6339853|NCT03253094|10094226|FG000|Overall Study|Lack of Efficacy|0
6339854|NCT03253094|10094227|FG001|Overall Study|Lack of Efficacy|0
6339855|NCT03253094|10094228|FG002|Overall Study|Lack of Efficacy|2
6339856|NCT03253094|10094229|FG003|Overall Study|Lack of Efficacy|1
6339857|NCT03253094|10094230|FG004|Overall Study|Lack of Efficacy|2
6339858|NCT03253094|10094231|FG005|Overall Study|Lack of Efficacy|1
6339859|NCT03253094|10094226|FG000|Overall Study|Lost to Follow-up|0
6339860|NCT03253094|10094227|FG001|Overall Study|Lost to Follow-up|0
6339861|NCT03253094|10094228|FG002|Overall Study|Lost to Follow-up|1
6339862|NCT03253094|10094229|FG003|Overall Study|Lost to Follow-up|1
6339863|NCT03253094|10094230|FG004|Overall Study|Lost to Follow-up|0
6339864|NCT03253094|10094231|FG005|Overall Study|Lost to Follow-up|1
6339865|NCT03253094|10094226|FG000|Overall Study|Physician Decision|1
6339866|NCT03253094|10094227|FG001|Overall Study|Physician Decision|0
6339867|NCT03253094|10094228|FG002|Overall Study|Physician Decision|0
6339868|NCT03253094|10094229|FG003|Overall Study|Physician Decision|1
6339869|NCT03253094|10094230|FG004|Overall Study|Physician Decision|0
6339870|NCT03253094|10094231|FG005|Overall Study|Physician Decision|2
6339871|NCT03253094|10094226|FG000|Overall Study|Withdrawal by Subject|1
6339872|NCT03253094|10094227|FG001|Overall Study|Withdrawal by Subject|2
6339873|NCT03253094|10094228|FG002|Overall Study|Withdrawal by Subject|1
6339874|NCT03253094|10094229|FG003|Overall Study|Withdrawal by Subject|0
6339875|NCT03253094|10094230|FG004|Overall Study|Withdrawal by Subject|3
6339876|NCT03253094|10094231|FG005|Overall Study|Withdrawal by Subject|0
6339877|NCT03253094|10094226|FG000|Overall Study|Other|0
6339878|NCT03253094|10094227|FG001|Overall Study|Other|1
6339879|NCT03253094|10094228|FG002|Overall Study|Other|2
6339880|NCT03253094|10094229|FG003|Overall Study|Other|1
6339881|NCT03253094|10094230|FG004|Overall Study|Other|0
6339882|NCT03253094|10094231|FG005|Overall Study|Other|0
6339883|NCT03254108|10094250|FG000|Overall Study|Adverse Event|0
6339884|NCT03254108|10094251|FG001|Overall Study|Adverse Event|2
6339885|NCT03254108|10094252|FG002|Overall Study|Adverse Event|0
6339886|NCT03254108|10094253|FG003|Overall Study|Adverse Event|1
6339887|NCT03254108|10094254|FG004|Overall Study|Adverse Event|1
6339888|NCT03254108|10094250|FG000|Overall Study|AST/ALT is increased to 3 times upper limit of normal or higher|0
6339889|NCT03254108|10094251|FG001|Overall Study|AST/ALT is increased to 3 times upper limit of normal or higher|0
6339890|NCT03254108|10094252|FG002|Overall Study|AST/ALT is increased to 3 times upper limit of normal or higher|0
6339891|NCT03254108|10094253|FG003|Overall Study|AST/ALT is increased to 3 times upper limit of normal or higher|0
6339892|NCT03254108|10094254|FG004|Overall Study|AST/ALT is increased to 3 times upper limit of normal or higher|2
6339893|NCT03254134|10094268|FG000|Overall Study|Not eligible patients|599
6339894|NCT03254134|10094269|FG001|Overall Study|Not eligible patients|3630
6339895|NCT03254459|10094281|FG000|Overall Study|Adverse Event|7
6339896|NCT03254459|10094282|FG001|Overall Study|Adverse Event|20
6339897|NCT03254459|10094281|FG000|Overall Study|Withdrawal by Subject Consent|3
6339898|NCT03254459|10094282|FG001|Overall Study|Withdrawal by Subject Consent|1
6339899|NCT03254459|10094281|FG000|Overall Study|Lost to Follow-up|0
6339900|NCT03254459|10094282|FG001|Overall Study|Lost to Follow-up|1
6339901|NCT03254459|10094281|FG000|Overall Study|Miscellaneous|0
6339902|NCT03254459|10094282|FG001|Overall Study|Miscellaneous|1
6339903|NCT03254602|10094288|FG000|Overall Study|Lost to Follow-up|4
6339904|NCT03255187|10094298|FG000|Periodfrom Enrollment to First Follow-up|Withdrawal by Subject|1
6339905|NCT03255187|10094299|FG001|Periodfrom Enrollment to First Follow-up|Withdrawal by Subject|3
6339906|NCT03255187|10094298|FG000|Period From First to Second Follow-up|Withdrawal by Subject|0
6339907|NCT03255187|10094299|FG001|Period From First to Second Follow-up|Withdrawal by Subject|1
6339908|NCT03255291|10094311|FG000|Overall Study|Determined to be ineligible|10
6339909|NCT03255291|10094312|FG001|Overall Study|Determined to be ineligible|12
6339910|NCT03255291|10094313|FG002|Overall Study|Determined to be ineligible|6
6339911|NCT03255291|10094314|FG003|Overall Study|Determined to be ineligible|6
6339912|NCT03255291|10094315|FG004|Overall Study|Determined to be ineligible|5
6339913|NCT03255291|10094316|FG005|Overall Study|Determined to be ineligible|10
6339914|NCT03255291|10094311|FG000|Overall Study|Baseline data collection issues|3
6339915|NCT03255291|10094312|FG001|Overall Study|Baseline data collection issues|0
6339916|NCT03255291|10094313|FG002|Overall Study|Baseline data collection issues|0
6339917|NCT03255291|10094314|FG003|Overall Study|Baseline data collection issues|0
6339918|NCT03255291|10094315|FG004|Overall Study|Baseline data collection issues|2
6339919|NCT03255291|10094316|FG005|Overall Study|Baseline data collection issues|0
6339920|NCT03255382|10094336|FG000|Overall Study|Adverse Event|3
6339921|NCT03255382|10094337|FG001|Overall Study|Adverse Event|0
6339922|NCT03255382|10094336|FG000|Overall Study|Lost to Follow-up|2
6339923|NCT03255382|10094337|FG001|Overall Study|Lost to Follow-up|0
6339924|NCT03255382|10094336|FG000|Overall Study|Withdrawal by Subject|2
6339925|NCT03255382|10094337|FG001|Overall Study|Withdrawal by Subject|0
6339926|NCT03255382|10094336|FG000|Overall Study|Other|6
6339927|NCT03255382|10094337|FG001|Overall Study|Other|0
6339928|NCT03255655|10094346|FG000|Overall Study|Lost to Follow-up|7
6339929|NCT03255655|10094347|FG001|Overall Study|Lost to Follow-up|4
6339930|NCT03255733|10094353|FG000|Overall Study|Lost to Follow-up|4
6339931|NCT03255824|10094359|FG000|Overall Study|Under-sedation|2
6339932|NCT03255824|10094360|FG001|Overall Study|Under-sedation|1
6339933|NCT03255941|10094374|FG000|Overall Study|Not eligible or refused injection|37
6339934|NCT03255941|10094375|FG001|Overall Study|Not eligible or refused injection|44
6339935|NCT03255941|10094376|FG002|Overall Study|Not eligible or refused injection|5
6339936|NCT03255941|10094377|FG003|Overall Study|Not eligible or refused injection|6
6339937|NCT03255941|10094374|FG000|Overall Study|Did not complete exit interview|1
6339938|NCT03255941|10094375|FG001|Overall Study|Did not complete exit interview|2
6339939|NCT03255941|10094376|FG002|Overall Study|Did not complete exit interview|0
6339940|NCT03255941|10094377|FG003|Overall Study|Did not complete exit interview|0
6339941|NCT03255980|10094403|FG000|Overall Study|Grade =>3 Skin Toxicity|1
6339942|NCT03255980|10094404|FG001|Overall Study|Grade =>3 Skin Toxicity|4
6339943|NCT03255980|10094405|FG002|Overall Study|Grade =>3 Skin Toxicity|6
6339944|NCT03255980|10094406|FG003|Overall Study|Grade =>3 Skin Toxicity|5
6339945|NCT03255980|10094403|FG000|Overall Study|Adverse Event|1
6339946|NCT03255980|10094404|FG001|Overall Study|Adverse Event|1
6339947|NCT03255980|10094405|FG002|Overall Study|Adverse Event|0
6339948|NCT03255980|10094406|FG003|Overall Study|Adverse Event|1
6339949|NCT03255980|10094403|FG000|Overall Study|Lack of compliance to study or assessmen|0
6339950|NCT03255980|10094404|FG001|Overall Study|Lack of compliance to study or assessmen|1
6339951|NCT03255980|10094405|FG002|Overall Study|Lack of compliance to study or assessmen|0
6339952|NCT03255980|10094406|FG003|Overall Study|Lack of compliance to study or assessmen|0
6339953|NCT03255980|10094403|FG000|Overall Study|Lost to Follow-up|1
6339954|NCT03255980|10094404|FG001|Overall Study|Lost to Follow-up|1
6339955|NCT03255980|10094405|FG002|Overall Study|Lost to Follow-up|0
6339956|NCT03255980|10094406|FG003|Overall Study|Lost to Follow-up|3
6339957|NCT03255980|10094403|FG000|Overall Study|Withdrawal by Subject|0
6339958|NCT03255980|10094404|FG001|Overall Study|Withdrawal by Subject|1
6339959|NCT03255980|10094405|FG002|Overall Study|Withdrawal by Subject|0
6339960|NCT03255980|10094406|FG003|Overall Study|Withdrawal by Subject|3
6339961|NCT03256526|10094449|FG000|Overall Study|Adverse Event|1
6339962|NCT03256526|10094450|FG001|Overall Study|Adverse Event|0
6339963|NCT03256526|10094451|FG002|Overall Study|Adverse Event|1
6339964|NCT03256526|10094449|FG000|Overall Study|Lost to Follow-up|1
6339965|NCT03256526|10094450|FG001|Overall Study|Lost to Follow-up|0
6339966|NCT03256526|10094451|FG002|Overall Study|Lost to Follow-up|2
6339967|NCT03256552|10094459|FG000|Overall Study|Protocol Violation|1
6339968|NCT03256552|10094459|FG000|Overall Study|Physician Decision|1
6339969|NCT03256552|10094459|FG000|Overall Study|Adverse Event|1
6339970|NCT03256552|10094459|FG000|Overall Study|Withdrawal by Subject|2
6339971|NCT03256578|10094471|FG000|Overall Study|Excluded Post Randomization|66
6339972|NCT03256578|10094472|FG001|Overall Study|Excluded Post Randomization|56
6339973|NCT03256695|10094478|FG000|Overall Study|Adverse Event|8
6339974|NCT03256695|10094478|FG000|Overall Study|Death|2
6339975|NCT03256695|10094478|FG000|Overall Study|Withdrawal by Subject|14
6339976|NCT03256695|10094478|FG000|Overall Study|Non-compliance with study drug|1
6339977|NCT03256695|10094478|FG000|Overall Study|Lost to Follow-up|3
6339978|NCT03256695|10094478|FG000|Overall Study|Lack of Efficacy|3
6339979|NCT03256695|10094478|FG000|Overall Study|Protocol Violation|5
6339980|NCT03256695|10094478|FG000|Overall Study|Other than specified|3
6339981|NCT03256851|10094488|FG000|Overall Study|Withdrawal by Subject|1
6339982|NCT03256851|10094489|FG001|Overall Study|Withdrawal by Subject|0
6339983|NCT03257358|10094515|FG000|Overall Study|Adverse Event|25
6339984|NCT03257358|10094516|FG001|Overall Study|Adverse Event|12
6339985|NCT03257358|10094515|FG000|Overall Study|Lack of Efficacy|1
6339986|NCT03257358|10094516|FG001|Overall Study|Lack of Efficacy|1
6339987|NCT03257358|10094515|FG000|Overall Study|Lost to Follow-up|12
6339988|NCT03257358|10094516|FG001|Overall Study|Lost to Follow-up|4
6339989|NCT03257358|10094515|FG000|Overall Study|Non-compliance with fingolimod treatment|4
6339990|NCT03257358|10094516|FG001|Overall Study|Non-compliance with fingolimod treatment|2
6339991|NCT03257358|10094515|FG000|Overall Study|Physician Decision|2
6339992|NCT03257358|10094516|FG001|Overall Study|Physician Decision|2
6339993|NCT03257358|10094515|FG000|Overall Study|Protocol Violation|5
6339994|NCT03257358|10094516|FG001|Overall Study|Protocol Violation|3
6339995|NCT03257358|10094515|FG000|Overall Study|Technical problems|4
6339996|NCT03257358|10094516|FG001|Overall Study|Technical problems|1
6339997|NCT03257358|10094515|FG000|Overall Study|Withdrawal by Subject|8
6339998|NCT03257358|10094516|FG001|Overall Study|Withdrawal by Subject|3
6339999|NCT03257358|10094515|FG000|Overall Study|Withdrawal of informed consent|9
6340000|NCT03257358|10094516|FG001|Overall Study|Withdrawal of informed consent|5
6340001|NCT03257358|10094515|FG000|Overall Study|New therapy for study indication|1
6340002|NCT03257358|10094516|FG001|Overall Study|New therapy for study indication|0
6340003|NCT03257358|10094515|FG000|Overall Study|No longer requires treatment|0
6340004|NCT03257358|10094516|FG001|Overall Study|No longer requires treatment|1
6340005|NCT03257371|10094522|FG000|Overall Study|Lost to Follow-up|1
6340006|NCT03257410|10094528|FG000|Overall Study|Adverse Event|2
6340007|NCT03257410|10094529|FG001|Overall Study|Adverse Event|3
6340008|NCT03257410|10094528|FG000|Overall Study|Protocol Violation|1
6340009|NCT03257410|10094529|FG001|Overall Study|Protocol Violation|2
6340010|NCT03257410|10094528|FG000|Overall Study|Lost to Follow-up|1
6340011|NCT03257410|10094529|FG001|Overall Study|Lost to Follow-up|0
6340012|NCT03257410|10094528|FG000|Overall Study|Withdrawal by Subject|1
6340013|NCT03257410|10094529|FG001|Overall Study|Withdrawal by Subject|2
6340014|NCT03257410|10094528|FG000|Overall Study|Physician Decision|1
6340015|NCT03257410|10094529|FG001|Overall Study|Physician Decision|1
6340016|NCT03257410|10094528|FG000|Overall Study|Renal transplantation|2
6340017|NCT03257410|10094529|FG001|Overall Study|Renal transplantation|0
6340018|NCT03257410|10094528|FG000|Overall Study|Switch to peritoneal dialysis|1
6340019|NCT03257410|10094529|FG001|Overall Study|Switch to peritoneal dialysis|0
6340020|NCT03257410|10094528|FG000|Overall Study|Death|3
6340021|NCT03257410|10094529|FG001|Overall Study|Death|2
6340022|NCT03257410|10094528|FG000|Overall Study|Change to another dialysis center|2
6340023|NCT03257410|10094529|FG001|Overall Study|Change to another dialysis center|2
6340024|NCT03257410|10094528|FG000|Overall Study|Missing 3 consecutive study treatments|5
6340025|NCT03257410|10094529|FG001|Overall Study|Missing 3 consecutive study treatments|6
6340026|NCT03257410|10094528|FG000|Overall Study|Miscellaneous|2
6340027|NCT03257410|10094529|FG001|Overall Study|Miscellaneous|2
6340028|NCT03257410|10094528|FG000|Overall Study|Other|0
6340029|NCT03257410|10094529|FG001|Overall Study|Other|1
6340030|NCT03257657|10094537|FG000|Overall Study|Lost to Follow-up|0
6340031|NCT03257657|10094538|FG001|Overall Study|Lost to Follow-up|3
6340032|NCT03257657|10094537|FG000|Overall Study|Withdrawn|0
6340033|NCT03257657|10094538|FG001|Overall Study|Withdrawn|1
6340034|NCT03257657|10094537|FG000|Overall Study|Noted not eligible right after enrolled|0
6340035|NCT03257657|10094538|FG001|Overall Study|Noted not eligible right after enrolled|1
6340036|NCT03257813|10094547|FG000|Overall Study|Protocol Violation|6
6083253|NCT00634647|9691648|FG000|Overall Study|death on study|3
6083254|NCT00634647|9691648|FG000|Overall Study|refused further treatment|3
6083255|NCT00634647|9691648|FG000|Overall Study|declined to participate before treatment|1
6083256|NCT00634751|9691656|FG000|Phase I: 200mg Sorafenib+2DOC|Death|1
6083257|NCT00634751|9691657|FG001|Phase I: 200mg Sorafenib+2DOC|Death|0
6083258|NCT00634751|9691658|FG002|Phase I: 200mg Sorafenib+2DOC|Death|0
6083259|NCT00634751|9691659|FG003|Phase I: 200mg Sorafenib+2DOC|Death|0
6083260|NCT00634751|9691656|FG000|Phase I: 400mg Sorafenib BID+2DOC|Death|0
6083261|NCT00634751|9691657|FG001|Phase I: 400mg Sorafenib BID+2DOC|Death|1
6083262|NCT00634751|9691658|FG002|Phase I: 400mg Sorafenib BID+2DOC|Death|0
6083263|NCT00634751|9691659|FG003|Phase I: 400mg Sorafenib BID+2DOC|Death|0
6083264|NCT00634751|9691656|FG000|Pancreatic and Bilial Tract Cancer|Death|0
6083265|NCT00634751|9691657|FG001|Pancreatic and Bilial Tract Cancer|Death|0
6083266|NCT00634751|9691658|FG002|Pancreatic and Bilial Tract Cancer|Death|1
6083267|NCT00634751|9691659|FG003|Pancreatic and Bilial Tract Cancer|Death|1
6083268|NCT00634803|9691672|FG000|Overall Study|Lost to Follow-up|6
6083269|NCT00634803|9691673|FG001|Overall Study|Lost to Follow-up|7
6083270|NCT00634803|9691674|FG002|Overall Study|Lost to Follow-up|7
6083271|NCT00634842|9691684|FG000|Overall Study|Adverse Event|2
6083272|NCT00634842|9691685|FG001|Overall Study|Adverse Event|3
6083273|NCT00634842|9691684|FG000|Overall Study|Protocol Violation|8
6083274|NCT00634842|9691685|FG001|Overall Study|Protocol Violation|4
6083275|NCT00634842|9691684|FG000|Overall Study|Move to another state|1
6083276|NCT00634842|9691685|FG001|Overall Study|Move to another state|0
6340037|NCT03257813|10094548|FG001|Overall Study|Protocol Violation|3
6340038|NCT03257865|10094559|FG000|Overall Study|Adverse Event|4
6340039|NCT03257865|10094560|FG001|Overall Study|Adverse Event|8
6340040|NCT03257865|10094559|FG000|Overall Study|Lack of Efficacy|1
6340041|NCT03257865|10094560|FG001|Overall Study|Lack of Efficacy|2
6340042|NCT03257865|10094559|FG000|Overall Study|Non-compliance with Study Drug|0
6340043|NCT03257865|10094560|FG001|Overall Study|Non-compliance with Study Drug|2
6340044|NCT03257865|10094559|FG000|Overall Study|Withdrawal by Subject|23
6340045|NCT03257865|10094560|FG001|Overall Study|Withdrawal by Subject|17
6340046|NCT03257865|10094559|FG000|Overall Study|Physician Decision|3
6340047|NCT03257865|10094560|FG001|Overall Study|Physician Decision|1
6340048|NCT03257865|10094559|FG000|Overall Study|Other|0
6340049|NCT03257865|10094560|FG001|Overall Study|Other|1
6340050|NCT03257865|10094559|FG000|Overall Study|Lost to Follow-up|4
6340051|NCT03257865|10094560|FG001|Overall Study|Lost to Follow-up|4
6340052|NCT03257995|10094566|FG000|Overall Study|Adverse Event|0
6340053|NCT03257995|10094567|FG001|Overall Study|Adverse Event|1
6340054|NCT03257995|10094568|FG002|Overall Study|Adverse Event|0
6340055|NCT03257995|10094569|FG003|Overall Study|Adverse Event|0
6340056|NCT03257995|10094570|FG004|Overall Study|Adverse Event|0
6340057|NCT03257995|10094571|FG005|Overall Study|Adverse Event|0
6340058|NCT03257995|10094566|FG000|Overall Study|Protocol deviation|0
6340059|NCT03257995|10094567|FG001|Overall Study|Protocol deviation|0
6340060|NCT03257995|10094568|FG002|Overall Study|Protocol deviation|0
6340061|NCT03257995|10094569|FG003|Overall Study|Protocol deviation|0
6340062|NCT03257995|10094570|FG004|Overall Study|Protocol deviation|0
6340063|NCT03257995|10094571|FG005|Overall Study|Protocol deviation|2
6340064|NCT03258710|10094593|FG000|Overall Study|Adverse Event|1
6340065|NCT03258710|10094593|FG000|Overall Study|Protocol-defined stopping criteria|1
6340066|NCT03258710|10094593|FG000|Overall Study|Physician Decision|1
6340067|NCT03258762|10094599|FG000|Overall Study|Lost to Follow-up|0
6340068|NCT03258762|10094600|FG001|Overall Study|Lost to Follow-up|1
6340069|NCT03258814|10094609|FG000|Overall Study|Early Termination|4
6340070|NCT03258814|10094610|FG001|Overall Study|Early Termination|3
6340071|NCT03258814|10094611|FG002|Overall Study|Early Termination|10
6340072|NCT03259087|10094623|FG000|Part 1 and Period 1 of Part 2|Adverse Event|0
6340073|NCT03259087|10094624|FG001|Part 1 and Period 1 of Part 2|Adverse Event|0
6340074|NCT03259087|10094625|FG002|Part 1 and Period 1 of Part 2|Adverse Event|0
6083277|NCT00634842|9691684|FG000|Overall Study|Inclusion criteria were not met|1
6083278|NCT00634842|9691685|FG001|Overall Study|Inclusion criteria were not met|0
6083279|NCT00634842|9691684|FG000|Overall Study|Lost to Follow-up|1
6340075|NCT03259087|10094626|FG003|Part 1 and Period 1 of Part 2|Adverse Event|0
6340076|NCT03259087|10094627|FG004|Part 1 and Period 1 of Part 2|Adverse Event|1
6340077|NCT03259087|10094623|FG000|Period 2 of Part 2|Adverse Event|0
6340078|NCT03259087|10094624|FG001|Period 2 of Part 2|Adverse Event|0
6340079|NCT03259087|10094625|FG002|Period 2 of Part 2|Adverse Event|0
6168547|NCT01236352|9813653|FG006|Overall Study|Maximum clinical benefit|3
6168548|NCT01236352|9813654|FG007|Overall Study|Maximum clinical benefit|1
6168549|NCT01236352|9813655|FG008|Overall Study|Maximum clinical benefit|1
6168550|NCT01236352|9813656|FG009|Overall Study|Maximum clinical benefit|4
6168551|NCT01236352|9813657|FG010|Overall Study|Maximum clinical benefit|2
6168552|NCT01236352|9813647|FG000|Overall Study|Subject request to discontinue treatment|0
6168553|NCT01236352|9813648|FG001|Overall Study|Subject request to discontinue treatment|0
6168554|NCT01236352|9813649|FG002|Overall Study|Subject request to discontinue treatment|1
6168555|NCT01236352|9813650|FG003|Overall Study|Subject request to discontinue treatment|1
6168556|NCT01236352|9813651|FG004|Overall Study|Subject request to discontinue treatment|0
6168557|NCT01236352|9813652|FG005|Overall Study|Subject request to discontinue treatment|1
6168558|NCT01236352|9813653|FG006|Overall Study|Subject request to discontinue treatment|0
6168559|NCT01236352|9813654|FG007|Overall Study|Subject request to discontinue treatment|0
6168560|NCT01236352|9813655|FG008|Overall Study|Subject request to discontinue treatment|0
6168561|NCT01236352|9813656|FG009|Overall Study|Subject request to discontinue treatment|1
6168562|NCT01236352|9813657|FG010|Overall Study|Subject request to discontinue treatment|4
6168563|NCT01236352|9813647|FG000|Overall Study|Subject to receive drug via EAP|1
6168564|NCT01236352|9813648|FG001|Overall Study|Subject to receive drug via EAP|1
6168565|NCT01236352|9813649|FG002|Overall Study|Subject to receive drug via EAP|1
6168566|NCT01236352|9813650|FG003|Overall Study|Subject to receive drug via EAP|0
6168567|NCT01236352|9813651|FG004|Overall Study|Subject to receive drug via EAP|0
6168568|NCT01236352|9813652|FG005|Overall Study|Subject to receive drug via EAP|0
6168569|NCT01236352|9813653|FG006|Overall Study|Subject to receive drug via EAP|0
6168570|NCT01236352|9813654|FG007|Overall Study|Subject to receive drug via EAP|2
6168571|NCT01236352|9813655|FG008|Overall Study|Subject to receive drug via EAP|0
6340080|NCT03259087|10094626|FG003|Period 2 of Part 2|Adverse Event|0
6340081|NCT03259087|10094627|FG004|Period 2 of Part 2|Adverse Event|1
6340082|NCT03259308|10094680|FG000|Overall Study|Adverse Event|5
6340083|NCT03259308|10094681|FG001|Overall Study|Adverse Event|4
6340084|NCT03259308|10094682|FG002|Overall Study|Adverse Event|1
6340085|NCT03259308|10094680|FG000|Overall Study|Withdrawal by Subject|2
6340086|NCT03259308|10094681|FG001|Overall Study|Withdrawal by Subject|1
6340087|NCT03259308|10094682|FG002|Overall Study|Withdrawal by Subject|3
6340088|NCT03259308|10094680|FG000|Overall Study|Lost to Follow-up|0
6340089|NCT03259308|10094681|FG001|Overall Study|Lost to Follow-up|0
6340090|NCT03259308|10094682|FG002|Overall Study|Lost to Follow-up|1
6340091|NCT03259308|10094680|FG000|Overall Study|Pregnancy|0
6340092|NCT03259308|10094681|FG001|Overall Study|Pregnancy|0
6340093|NCT03259308|10094682|FG002|Overall Study|Pregnancy|1
6340094|NCT03259308|10094680|FG000|Overall Study|Protocol Deviation|0
6340095|NCT03259308|10094681|FG001|Overall Study|Protocol Deviation|3
6340096|NCT03259308|10094682|FG002|Overall Study|Protocol Deviation|0
6340097|NCT03259308|10094680|FG000|Overall Study|Lack of Efficacy|0
6340098|NCT03259308|10094681|FG001|Overall Study|Lack of Efficacy|0
6340099|NCT03259308|10094682|FG002|Overall Study|Lack of Efficacy|1
6340100|NCT03259334|10094693|FG000|Overall Study|Adverse Event|3
6340101|NCT03259334|10094694|FG001|Overall Study|Adverse Event|8
6340102|NCT03259334|10094695|FG002|Overall Study|Adverse Event|5
6340103|NCT03259334|10094693|FG000|Overall Study|Withdrawal by Subject|4
6042919|NCT00385827|9641397|FG002|Part 2|Adverse Event|10
6042920|NCT00385827|9641395|FG000|Part 2|Death|0
6042921|NCT00385827|9641396|FG001|Part 2|Death|0
6042922|NCT00385827|9641397|FG002|Part 2|Death|2
6042923|NCT00385827|9641395|FG000|Part 2|Lack of Efficacy|0
6042924|NCT00385827|9641396|FG001|Part 2|Lack of Efficacy|14
6042925|NCT00385827|9641397|FG002|Part 2|Lack of Efficacy|13
6042926|NCT00385827|9641395|FG000|Part 2|Randomized but not treated|0
6042927|NCT00385827|9641396|FG001|Part 2|Randomized but not treated|2
6042928|NCT00385827|9641397|FG002|Part 2|Randomized but not treated|2
6042929|NCT00385827|9641395|FG000|Part 2|Other|0
6042930|NCT00385827|9641396|FG001|Part 2|Other|11
6042931|NCT00385827|9641397|FG002|Part 2|Other|21
6042932|NCT00385840|9641409|FG000|Overall Study|Adverse Event|1
6042933|NCT00385840|9641410|FG001|Overall Study|Adverse Event|1
6042934|NCT00385840|9641409|FG000|Overall Study|Lost to Follow-up|3
6042935|NCT00385840|9641410|FG001|Overall Study|Lost to Follow-up|13
6042936|NCT00385918|9641418|FG000|Feasibility & Baseline Measurement Phase|outside of inclusion criteria|0
6042937|NCT00385918|9641419|FG001|Feasibility & Baseline Measurement Phase|outside of inclusion criteria|0
6042938|NCT00385918|9641420|FG002|Feasibility & Baseline Measurement Phase|outside of inclusion criteria|8
6042939|NCT00385918|9641418|FG000|Feasibility & Baseline Measurement Phase|Withdrawal by Subject|0
6042940|NCT00385918|9641419|FG001|Feasibility & Baseline Measurement Phase|Withdrawal by Subject|0
6042941|NCT00385918|9641420|FG002|Feasibility & Baseline Measurement Phase|Withdrawal by Subject|5
6340104|NCT03259334|10094694|FG001|Overall Study|Withdrawal by Subject|2
6340105|NCT03259334|10094695|FG002|Overall Study|Withdrawal by Subject|4
6340106|NCT03259334|10094693|FG000|Overall Study|Physician Decision|1
6340107|NCT03259334|10094694|FG001|Overall Study|Physician Decision|0
6340108|NCT03259334|10094695|FG002|Overall Study|Physician Decision|0
6340109|NCT03259334|10094693|FG000|Overall Study|Lost to Follow-up|0
6340110|NCT03259334|10094694|FG001|Overall Study|Lost to Follow-up|2
6340111|NCT03259334|10094695|FG002|Overall Study|Lost to Follow-up|1
6340112|NCT03259334|10094693|FG000|Overall Study|Protocol Deviation|0
6340113|NCT03259334|10094694|FG001|Overall Study|Protocol Deviation|3
6340114|NCT03259334|10094695|FG002|Overall Study|Protocol Deviation|2
6340115|NCT03259334|10094693|FG000|Overall Study|Lack of Efficacy|2
6340116|NCT03259334|10094694|FG001|Overall Study|Lack of Efficacy|0
6340117|NCT03259334|10094695|FG002|Overall Study|Lack of Efficacy|1
6340118|NCT03259334|10094693|FG000|Overall Study|Randomized but never treated|0
6340119|NCT03259334|10094694|FG001|Overall Study|Randomized but never treated|2
6340120|NCT03259334|10094695|FG002|Overall Study|Randomized but never treated|0
6340121|NCT03259425|10094703|FG000|Overall Study|Disease progression to an extent that didn't allow surgery|1
6340122|NCT03259490|10094709|FG000|Period 1|Withdrawal by Subject|0
6340123|NCT03259490|10094710|FG001|Period 1|Withdrawal by Subject|1
6340124|NCT03259490|10094709|FG000|Period 2|Protocol Violation|1
6340125|NCT03259490|10094710|FG001|Period 2|Protocol Violation|0
6340126|NCT03259555|10094718|FG000|Overall Study|Adverse Event|6
6340127|NCT03259555|10094719|FG001|Overall Study|Adverse Event|4
6340128|NCT03259555|10094718|FG000|Overall Study|Lack of Efficacy|6
6340129|NCT03259555|10094719|FG001|Overall Study|Lack of Efficacy|4
6340130|NCT03259555|10094718|FG000|Overall Study|Lost to Follow-up|0
6340131|NCT03259555|10094719|FG001|Overall Study|Lost to Follow-up|2
6340132|NCT03259555|10094718|FG000|Overall Study|Non-Compliance With Study Drug|1
6340133|NCT03259555|10094719|FG001|Overall Study|Non-Compliance With Study Drug|0
6340134|NCT03259555|10094718|FG000|Overall Study|Progressive Disease|0
6340135|NCT03259555|10094719|FG001|Overall Study|Progressive Disease|2
6340136|NCT03259555|10094718|FG000|Overall Study|Withdrawal by Subject|19
6340137|NCT03259555|10094719|FG001|Overall Study|Withdrawal by Subject|16
6340138|NCT03259555|10094718|FG000|Overall Study|Physician Decision|1
6340139|NCT03259555|10094719|FG001|Overall Study|Physician Decision|2
6340140|NCT03259555|10094718|FG000|Overall Study|Other|1
6340141|NCT03259555|10094719|FG001|Overall Study|Other|0
6340142|NCT03259789|10094728|FG000|Overall Study|Adverse Event|3
6340143|NCT03259789|10094729|FG001|Overall Study|Adverse Event|2
6340144|NCT03259789|10094730|FG002|Overall Study|Adverse Event|1
6340145|NCT03259789|10094728|FG000|Overall Study|Withdrawal by Subject|9
6340146|NCT03259789|10094729|FG001|Overall Study|Withdrawal by Subject|5
6340147|NCT03259789|10094730|FG002|Overall Study|Withdrawal by Subject|1
6340148|NCT03259789|10094728|FG000|Overall Study|Lost to Follow-up|5
6340149|NCT03259789|10094729|FG001|Overall Study|Lost to Follow-up|9
6340150|NCT03259789|10094730|FG002|Overall Study|Lost to Follow-up|4
6340151|NCT03259789|10094728|FG000|Overall Study|Physician Decision|0
6340152|NCT03259789|10094729|FG001|Overall Study|Physician Decision|1
6340153|NCT03259789|10094730|FG002|Overall Study|Physician Decision|0
6340154|NCT03260205|10094744|FG000|Overall Study|Adverse Event|2
6340155|NCT03260205|10094745|FG001|Overall Study|Adverse Event|0
6340156|NCT03260205|10094746|FG002|Overall Study|Adverse Event|2
6340157|NCT03260205|10094747|FG003|Overall Study|Adverse Event|2
6340158|NCT03260205|10094748|FG004|Overall Study|Adverse Event|4
6340159|NCT03260205|10094744|FG000|Overall Study|Lost to Follow-up|2
6340160|NCT03260205|10094745|FG001|Overall Study|Lost to Follow-up|2
6340161|NCT03260205|10094746|FG002|Overall Study|Lost to Follow-up|1
6340162|NCT03260205|10094747|FG003|Overall Study|Lost to Follow-up|1
6340163|NCT03260205|10094748|FG004|Overall Study|Lost to Follow-up|5
6340164|NCT03260205|10094744|FG000|Overall Study|Protocol Violation|0
6340165|NCT03260205|10094745|FG001|Overall Study|Protocol Violation|0
6340166|NCT03260205|10094746|FG002|Overall Study|Protocol Violation|2
6340167|NCT03260205|10094747|FG003|Overall Study|Protocol Violation|0
6340168|NCT03260205|10094748|FG004|Overall Study|Protocol Violation|1
6340169|NCT03260205|10094744|FG000|Overall Study|Withdrawal by Participant or Parent/LAR|4
6340170|NCT03260205|10094745|FG001|Overall Study|Withdrawal by Participant or Parent/LAR|5
6340171|NCT03260205|10094746|FG002|Overall Study|Withdrawal by Participant or Parent/LAR|1
6340172|NCT03260205|10094747|FG003|Overall Study|Withdrawal by Participant or Parent/LAR|0
6340173|NCT03260205|10094748|FG004|Overall Study|Withdrawal by Participant or Parent/LAR|2
6340174|NCT03260205|10094744|FG000|Overall Study|Other: Unspecified|0
6340175|NCT03260205|10094745|FG001|Overall Study|Other: Unspecified|0
6340176|NCT03260205|10094746|FG002|Overall Study|Other: Unspecified|3
6340177|NCT03260205|10094747|FG003|Overall Study|Other: Unspecified|1
6340178|NCT03260205|10094748|FG004|Overall Study|Other: Unspecified|1
6340179|NCT03260205|10094744|FG000|Overall Study|Participant Who Did Not Received AnyDose|1
6340180|NCT03260205|10094745|FG001|Overall Study|Participant Who Did Not Received AnyDose|1
6340181|NCT03260205|10094746|FG002|Overall Study|Participant Who Did Not Received AnyDose|2
6340182|NCT03260205|10094747|FG003|Overall Study|Participant Who Did Not Received AnyDose|3
6340183|NCT03260205|10094748|FG004|Overall Study|Participant Who Did Not Received AnyDose|1
6340184|NCT03261037|10094809|FG000|Overall Study|Withdrawal by Subject|2
6340185|NCT03261037|10094810|FG001|Overall Study|Withdrawal by Subject|13
6340186|NCT03261037|10094811|FG002|Overall Study|Withdrawal by Subject|0
6340187|NCT03261037|10094812|FG003|Overall Study|Withdrawal by Subject|18
6340188|NCT03261037|10094809|FG000|Overall Study|Non-compliance with study procedures|0
6340189|NCT03261037|10094810|FG001|Overall Study|Non-compliance with study procedures|2
6340190|NCT03261037|10094811|FG002|Overall Study|Non-compliance with study procedures|0
6340191|NCT03261037|10094812|FG003|Overall Study|Non-compliance with study procedures|6
6340192|NCT03261037|10094809|FG000|Overall Study|Participant moving away and can no longer be in study|0
6340193|NCT03261037|10094810|FG001|Overall Study|Participant moving away and can no longer be in study|1
6340194|NCT03261037|10094811|FG002|Overall Study|Participant moving away and can no longer be in study|0
6340195|NCT03261037|10094812|FG003|Overall Study|Participant moving away and can no longer be in study|0
6340196|NCT03261037|10094809|FG000|Overall Study|Participant came out of study due to investigator discretion|0
6340197|NCT03261037|10094810|FG001|Overall Study|Participant came out of study due to investigator discretion|2
6340198|NCT03261037|10094811|FG002|Overall Study|Participant came out of study due to investigator discretion|0
6340199|NCT03261037|10094812|FG003|Overall Study|Participant came out of study due to investigator discretion|0
6340200|NCT03261037|10094809|FG000|Overall Study|Diagnosed but protocol deviation|1
6340201|NCT03261037|10094810|FG001|Overall Study|Diagnosed but protocol deviation|0
6340202|NCT03261037|10094811|FG002|Overall Study|Diagnosed but protocol deviation|0
6340203|NCT03261037|10094812|FG003|Overall Study|Diagnosed but protocol deviation|0
6340204|NCT03261037|10094809|FG000|Overall Study|Participant did not want to continue the study|0
6340205|NCT03261037|10094810|FG001|Overall Study|Participant did not want to continue the study|1
6340206|NCT03261037|10094811|FG002|Overall Study|Participant did not want to continue the study|0
6340207|NCT03261037|10094812|FG003|Overall Study|Participant did not want to continue the study|0
6340208|NCT03261037|10094809|FG000|Overall Study|Participant did not want to continue the diagnostic procedures|0
6340209|NCT03261037|10094810|FG001|Overall Study|Participant did not want to continue the diagnostic procedures|0
6340210|NCT03261037|10094811|FG002|Overall Study|Participant did not want to continue the diagnostic procedures|0
6340211|NCT03261037|10094812|FG003|Overall Study|Participant did not want to continue the diagnostic procedures|1
6340212|NCT03261037|10094809|FG000|Overall Study|Participant presented clinical improvement|0
6340213|NCT03261037|10094810|FG001|Overall Study|Participant presented clinical improvement|2
6340214|NCT03261037|10094811|FG002|Overall Study|Participant presented clinical improvement|0
6340215|NCT03261037|10094812|FG003|Overall Study|Participant presented clinical improvement|0
6340216|NCT03261037|10094809|FG000|Overall Study|Technical difficulties|0
6340217|NCT03261037|10094810|FG001|Overall Study|Technical difficulties|0
6340218|NCT03261037|10094811|FG002|Overall Study|Technical difficulties|0
6340219|NCT03261037|10094812|FG003|Overall Study|Technical difficulties|1
6340220|NCT03261037|10094809|FG000|Overall Study|Equipment failed to work|0
6340221|NCT03261037|10094810|FG001|Overall Study|Equipment failed to work|0
6340222|NCT03261037|10094811|FG002|Overall Study|Equipment failed to work|0
6340223|NCT03261037|10094812|FG003|Overall Study|Equipment failed to work|1
6340224|NCT03261037|10094809|FG000|Overall Study|End of study for participant and no follow up|0
6340225|NCT03261037|10094810|FG001|Overall Study|End of study for participant and no follow up|0
6340226|NCT03261037|10094811|FG002|Overall Study|End of study for participant and no follow up|0
6340227|NCT03261037|10094812|FG003|Overall Study|End of study for participant and no follow up|1
6340228|NCT03261037|10094809|FG000|Overall Study|Participant was too weak to continue in study|1
6340229|NCT03261037|10094810|FG001|Overall Study|Participant was too weak to continue in study|0
6340230|NCT03261037|10094811|FG002|Overall Study|Participant was too weak to continue in study|0
6340231|NCT03261037|10094812|FG003|Overall Study|Participant was too weak to continue in study|0
6340232|NCT03261167|10094825|FG000|Double Blind(Treatment cyc1,Upto Week48)|Adverse Event|0
6340233|NCT03261167|10094826|FG001|Double Blind(Treatment cyc1,Upto Week48)|Adverse Event|3
6340234|NCT03261167|10094825|FG000|Double Blind(Treatment cyc1,Upto Week48)|Withdrawal by Subject|3
6340235|NCT03261167|10094826|FG001|Double Blind(Treatment cyc1,Upto Week48)|Withdrawal by Subject|1
6340236|NCT03261167|10094825|FG000|Open-label(Treatment cycle2,Upto Week48)|Protocol defined stopping criteria|1
6340237|NCT03261167|10094826|FG001|Open-label(Treatment cycle2,Upto Week48)|Protocol defined stopping criteria|0
6340238|NCT03261167|10094825|FG000|Open-label(Treatment cycle2,Upto Week48)|Withdrawal by Subject|1
6340239|NCT03261167|10094826|FG001|Open-label(Treatment cycle2,Upto Week48)|Withdrawal by Subject|0
6340240|NCT03261167|10094825|FG000|Open-label(Treatment cycle3,Upto Week48)|Withdrawal by Subject|1
6340241|NCT03261167|10094826|FG001|Open-label(Treatment cycle3,Upto Week48)|Withdrawal by Subject|1
6340242|NCT03261336|10094838|FG000|Overall Study|Adverse Event|1
6340243|NCT03261947|10094847|FG000|Overall Study|Death|10
6340244|NCT03261947|10094848|FG001|Overall Study|Death|13
6340245|NCT03261947|10094849|FG002|Overall Study|Death|17
6340246|NCT03261947|10094850|FG003|Overall Study|Death|12
6340247|NCT03261947|10094851|FG004|Overall Study|Death|8
6340248|NCT03261947|10094847|FG000|Overall Study|Lost to Follow-up|0
6340249|NCT03261947|10094848|FG001|Overall Study|Lost to Follow-up|0
6340250|NCT03261947|10094849|FG002|Overall Study|Lost to Follow-up|2
6340251|NCT03261947|10094850|FG003|Overall Study|Lost to Follow-up|1
6340252|NCT03261947|10094851|FG004|Overall Study|Lost to Follow-up|0
6340253|NCT03261947|10094847|FG000|Overall Study|Withdrawal by Subject|0
6340254|NCT03261947|10094848|FG001|Overall Study|Withdrawal by Subject|0
6340255|NCT03261947|10094849|FG002|Overall Study|Withdrawal by Subject|3
6340256|NCT03261947|10094850|FG003|Overall Study|Withdrawal by Subject|0
6340257|NCT03261947|10094851|FG004|Overall Study|Withdrawal by Subject|1
6340258|NCT03261947|10094847|FG000|Overall Study|Site Terminated by Sponsor|0
6340259|NCT03261947|10094848|FG001|Overall Study|Site Terminated by Sponsor|0
6340260|NCT03261947|10094849|FG002|Overall Study|Site Terminated by Sponsor|4
6340261|NCT03261947|10094850|FG003|Overall Study|Site Terminated by Sponsor|7
6340262|NCT03261947|10094851|FG004|Overall Study|Site Terminated by Sponsor|5
6340263|NCT03261947|10094847|FG000|Overall Study|Reason not Specified|2
6340264|NCT03261947|10094848|FG001|Overall Study|Reason not Specified|0
6340265|NCT03261947|10094849|FG002|Overall Study|Reason not Specified|4
6340266|NCT03261947|10094850|FG003|Overall Study|Reason not Specified|1
6340267|NCT03261947|10094851|FG004|Overall Study|Reason not Specified|3
6340268|NCT03262012|10094888|FG000|Overall Study|Withdrawal by Subject|15
6340269|NCT03262012|10094889|FG001|Overall Study|Withdrawal by Subject|13
6340270|NCT03262012|10094890|FG002|Overall Study|Withdrawal by Subject|8
6340271|NCT03262012|10094891|FG003|Overall Study|Withdrawal by Subject|7
6340272|NCT03262012|10094888|FG000|Overall Study|Adverse Event|10
6340273|NCT03262012|10094889|FG001|Overall Study|Adverse Event|12
6340274|NCT03262012|10094890|FG002|Overall Study|Adverse Event|4
6340275|NCT03262012|10094891|FG003|Overall Study|Adverse Event|6
6340276|NCT03262012|10094888|FG000|Overall Study|Physician Decision|2
6340277|NCT03262012|10094889|FG001|Overall Study|Physician Decision|5
6340278|NCT03262012|10094890|FG002|Overall Study|Physician Decision|1
6340279|NCT03262012|10094891|FG003|Overall Study|Physician Decision|0
6340280|NCT03262012|10094888|FG000|Overall Study|Lack of Efficacy|0
6340281|NCT03262012|10094889|FG001|Overall Study|Lack of Efficacy|5
6340282|NCT03262012|10094890|FG002|Overall Study|Lack of Efficacy|1
6340283|NCT03262012|10094891|FG003|Overall Study|Lack of Efficacy|2
6340284|NCT03262012|10094888|FG000|Overall Study|Protocol Discontinuation Criteria|0
6340285|NCT03262012|10094889|FG001|Overall Study|Protocol Discontinuation Criteria|1
6340286|NCT03262012|10094890|FG002|Overall Study|Protocol Discontinuation Criteria|0
6340287|NCT03262012|10094891|FG003|Overall Study|Protocol Discontinuation Criteria|0
6340288|NCT03262038|10094903|FG000|Overall Study|Withdrawal by Subject|0
6340289|NCT03262038|10094904|FG001|Overall Study|Withdrawal by Subject|1
6340290|NCT03262233|10094914|FG000|Overall Study|Withdrawal by Subject|12
6340291|NCT03262233|10094915|FG001|Overall Study|Withdrawal by Subject|8
6340292|NCT03262233|10094916|FG002|Overall Study|Withdrawal by Subject|21
6340293|NCT03262233|10094917|FG003|Overall Study|Withdrawal by Subject|13
6340294|NCT03262233|10094914|FG000|Overall Study|Declined due to shock|1
6340295|NCT03262233|10094915|FG001|Overall Study|Declined due to shock|2
6340296|NCT03262233|10094916|FG002|Overall Study|Declined due to shock|2
6340297|NCT03262233|10094917|FG003|Overall Study|Declined due to shock|3
6340298|NCT03262233|10094914|FG000|Overall Study|Protocol Violation|5
6340299|NCT03262233|10094915|FG001|Overall Study|Protocol Violation|10
6340300|NCT03262233|10094916|FG002|Overall Study|Protocol Violation|2
6340301|NCT03262233|10094917|FG003|Overall Study|Protocol Violation|13
6340302|NCT03262233|10094914|FG000|Overall Study|data collection artifact|0
6340303|NCT03262233|10094915|FG001|Overall Study|data collection artifact|1
6340304|NCT03262233|10094916|FG002|Overall Study|data collection artifact|0
6340305|NCT03262233|10094917|FG003|Overall Study|data collection artifact|0
6340306|NCT03262389|10094928|FG000|Overall Study|Machine malfunction Day 1, no return Day 2|1
6340307|NCT03262389|10094928|FG000|Overall Study|opted out of the study once his clinical FDG PET CT was done.|1
6340308|NCT03262389|10094928|FG000|Overall Study|opted out of PET/MR|1
6340309|NCT03262441|10094932|FG000|Overall Study|Withdrawal by Subject|1
6340310|NCT03263442|10094938|FG000|Inpatient Phase|Death|1
6340311|NCT03263442|10094939|FG001|Inpatient Phase|Death|0
6340312|NCT03263442|10094938|FG000|Inpatient Phase|Withdrawal by Subject|1
6340313|NCT03263442|10094939|FG001|Inpatient Phase|Withdrawal by Subject|0
6340314|NCT03263442|10094938|FG000|Inpatient Phase|Inadequate Drug Exposure|0
6340315|NCT03263442|10094939|FG001|Inpatient Phase|Inadequate Drug Exposure|1
6340316|NCT03263442|10094938|FG000|1-month Follow-Up|Lost to Follow-up|1
6340317|NCT03263442|10094939|FG001|1-month Follow-Up|Lost to Follow-up|0
6340318|NCT03263442|10094938|FG000|3-month Follow-Up|Lost to Follow-up|1
6340319|NCT03263442|10094939|FG001|3-month Follow-Up|Lost to Follow-up|3
6083280|NCT00634842|9691685|FG001|Overall Study|Lost to Follow-up|2
6083281|NCT00634842|9691684|FG000|Overall Study|Physician Decision|1
6083282|NCT00634842|9691685|FG001|Overall Study|Physician Decision|0
6083283|NCT00634842|9691684|FG000|Overall Study|Withdrawal by Subject|1
6083284|NCT00634842|9691685|FG001|Overall Study|Withdrawal by Subject|3
6083285|NCT00634842|9691684|FG000|Overall Study|Lack of time and intolerance to drug|0
6083286|NCT00634842|9691685|FG001|Overall Study|Lack of time and intolerance to drug|1
6083287|NCT00634842|9691684|FG000|Overall Study|Discontinued due to injection|0
6083288|NCT00634842|9691685|FG001|Overall Study|Discontinued due to injection|2
6083289|NCT00634842|9691684|FG000|Overall Study|No need of study drug to treat diabetes|0
6083290|NCT00634842|9691685|FG001|Overall Study|No need of study drug to treat diabetes|1
6083291|NCT00634842|9691684|FG000|Overall Study|No wish to keep taking Avandia|0
6083292|NCT00634842|9691685|FG001|Overall Study|No wish to keep taking Avandia|1
6083293|NCT00634842|9691684|FG000|Overall Study|Subject off study drug for too long|0
6083294|NCT00634842|9691685|FG001|Overall Study|Subject off study drug for too long|1
6083295|NCT00634907|9691693|FG000|Overall Study|Withdrawal by Subject|3
6083296|NCT00634907|9691694|FG001|Overall Study|Withdrawal by Subject|0
6340320|NCT03263442|10094938|FG000|6-month Follow-Up|Lost to Follow-up|2
6340321|NCT03263442|10094939|FG001|6-month Follow-Up|Lost to Follow-up|2
6340322|NCT03263702|10094949|FG000|Overall Study|Lost to Follow-up|2
6340323|NCT03263702|10094950|FG001|Overall Study|Lost to Follow-up|2
6340324|NCT03263702|10094949|FG000|Overall Study|Withdrawal by Subject|1
6340325|NCT03263702|10094950|FG001|Overall Study|Withdrawal by Subject|2
6340326|NCT03263780|10094956|FG000|Overall Study|Withdrawal by Subject|3
6340327|NCT03263780|10094956|FG000|Overall Study|Ineligible (incomplete post-HIFU)|7
6340328|NCT03264066|10094966|FG000|Overall Study|Adverse Event|1
6340329|NCT03264066|10094967|FG001|Overall Study|Adverse Event|1
6340330|NCT03264066|10094968|FG002|Overall Study|Adverse Event|0
6340331|NCT03264066|10094969|FG003|Overall Study|Adverse Event|0
6340332|NCT03264066|10094970|FG004|Overall Study|Adverse Event|0
6340333|NCT03264066|10094971|FG005|Overall Study|Adverse Event|0
6340334|NCT03264066|10094966|FG000|Overall Study|Death|12
6340335|NCT03264066|10094967|FG001|Overall Study|Death|12
6340336|NCT03264066|10094968|FG002|Overall Study|Death|8
6340337|NCT03264066|10094969|FG003|Overall Study|Death|10
6340338|NCT03264066|10094970|FG004|Overall Study|Death|6
6340339|NCT03264066|10094971|FG005|Overall Study|Death|1
6340340|NCT03264066|10094966|FG000|Overall Study|Lost to Follow-up|1
6340341|NCT03264066|10094967|FG001|Overall Study|Lost to Follow-up|0
6340342|NCT03264066|10094968|FG002|Overall Study|Lost to Follow-up|0
6340343|NCT03264066|10094969|FG003|Overall Study|Lost to Follow-up|0
6340344|NCT03264066|10094970|FG004|Overall Study|Lost to Follow-up|0
6340345|NCT03264066|10094971|FG005|Overall Study|Lost to Follow-up|0
6340346|NCT03264066|10094966|FG000|Overall Study|Progressive Disease|0
6340347|NCT03264066|10094967|FG001|Overall Study|Progressive Disease|2
6340348|NCT03264066|10094968|FG002|Overall Study|Progressive Disease|1
6340349|NCT03264066|10094969|FG003|Overall Study|Progressive Disease|0
6340350|NCT03264066|10094970|FG004|Overall Study|Progressive Disease|0
6340351|NCT03264066|10094971|FG005|Overall Study|Progressive Disease|0
6340352|NCT03264066|10094966|FG000|Overall Study|Study Terminated by Sponsor|5
6340353|NCT03264066|10094967|FG001|Overall Study|Study Terminated by Sponsor|5
6340354|NCT03264066|10094968|FG002|Overall Study|Study Terminated by Sponsor|8
6340355|NCT03264066|10094969|FG003|Overall Study|Study Terminated by Sponsor|5
6340356|NCT03264066|10094970|FG004|Overall Study|Study Terminated by Sponsor|1
6340357|NCT03264066|10094971|FG005|Overall Study|Study Terminated by Sponsor|2
6340358|NCT03264066|10094966|FG000|Overall Study|Withdrawal by Subject|1
6340359|NCT03264066|10094967|FG001|Overall Study|Withdrawal by Subject|0
6340360|NCT03264066|10094968|FG002|Overall Study|Withdrawal by Subject|0
6340361|NCT03264066|10094969|FG003|Overall Study|Withdrawal by Subject|5
6340362|NCT03264066|10094970|FG004|Overall Study|Withdrawal by Subject|0
6340363|NCT03264066|10094971|FG005|Overall Study|Withdrawal by Subject|0
6340364|NCT03264456|10095020|FG000|Overall Study|Withdrawal by Subject|3
6340365|NCT03264456|10095020|FG000|Overall Study|Lost to Follow-up|1
6340366|NCT03265119|10095026|FG000|Overall Study|Adverse Event|2
6340367|NCT03265119|10095027|FG001|Overall Study|Adverse Event|1
6340368|NCT03265119|10095026|FG000|Overall Study|Lack of Efficacy|3
6340369|NCT03265119|10095027|FG001|Overall Study|Lack of Efficacy|0
6340370|NCT03265119|10095026|FG000|Overall Study|Protocol Violation|1
6340371|NCT03265119|10095027|FG001|Overall Study|Protocol Violation|2
6340372|NCT03265119|10095026|FG000|Overall Study|Withdrawal by Subject|2
6340373|NCT03265119|10095027|FG001|Overall Study|Withdrawal by Subject|4
6340374|NCT03265119|10095026|FG000|Overall Study|Lost to Follow-up|1
6340375|NCT03265119|10095027|FG001|Overall Study|Lost to Follow-up|0
6340376|NCT03265119|10095026|FG000|Overall Study|Lack of Compliance|1
6340377|NCT03265119|10095027|FG001|Overall Study|Lack of Compliance|0
6340378|NCT03265132|10095035|FG000|Overall Study|Adverse Event|0
6340379|NCT03265132|10095036|FG001|Overall Study|Adverse Event|1
6340380|NCT03265132|10095035|FG000|Overall Study|Lack of Efficacy|0
6340381|NCT03265132|10095036|FG001|Overall Study|Lack of Efficacy|2
6340382|NCT03265132|10095035|FG000|Overall Study|Progressive disease|0
6340383|NCT03265132|10095036|FG001|Overall Study|Progressive disease|2
6340384|NCT03265132|10095035|FG000|Overall Study|Withdrawal by Subject|0
6340385|NCT03265132|10095036|FG001|Overall Study|Withdrawal by Subject|1
6340386|NCT03265600|10095046|FG000|Overall Study|Lost to Follow-up|17
6340387|NCT03265600|10095047|FG001|Overall Study|Lost to Follow-up|5
6340388|NCT03265600|10095046|FG000|Overall Study|Withdrawal by Subject|4
6340389|NCT03265600|10095047|FG001|Overall Study|Withdrawal by Subject|2
6340390|NCT03265600|10095046|FG000|Overall Study|Partially completed 8 wk or 24 wk survey|3
6340391|NCT03265600|10095047|FG001|Overall Study|Partially completed 8 wk or 24 wk survey|5
6340392|NCT03265938|10095053|FG000|Overall Study|Withdrawal by Subject|1
6340393|NCT03265938|10095053|FG000|Overall Study|Physician Decision|1
6340394|NCT03265938|10095053|FG000|Overall Study|friable mass|6
6340395|NCT03266094|10095058|FG000|Overall Study|Lost to Follow-up|1
6340396|NCT03266094|10095058|FG000|Overall Study|Withdrawal by Subject|1
6340397|NCT03266107|10095064|FG000|Enrollment to Procedure|Failure to Access Due to Hardened Bone|1
6340398|NCT03266107|10095064|FG000|Enrollment to Procedure|Study stopped prior to Procedure|2
6340399|NCT03266107|10095064|FG000|3-Month Follow-up Visit|Lost to Follow-up|1
6340400|NCT03266107|10095064|FG000|12-Month Follow-up Visit|Lost to Follow-up|1
6340401|NCT03266172|10095073|FG000|Part A: Period 1(2 Days)|Withdrawal by Subject|1
6340402|NCT03266172|10095074|FG001|Part A: Period 1(2 Days)|Withdrawal by Subject|0
6340403|NCT03266172|10095075|FG002|Part A: Period 1(2 Days)|Withdrawal by Subject|0
6340404|NCT03266172|10095073|FG000|Part A: Washout Period (7 Days)|Adverse Event|1
6340405|NCT03266172|10095074|FG001|Part A: Washout Period (7 Days)|Adverse Event|0
6340406|NCT03266172|10095075|FG002|Part A: Washout Period (7 Days)|Adverse Event|0
6340407|NCT03266172|10095073|FG000|Part A: Washout Period (7 Days)|Withdrawal by Subject|1
6340408|NCT03266172|10095074|FG001|Part A: Washout Period (7 Days)|Withdrawal by Subject|0
6340409|NCT03266172|10095075|FG002|Part A: Washout Period (7 Days)|Withdrawal by Subject|0
6340410|NCT03266172|10095073|FG000|Part B: Washout (7 Days)|Withdrawal by Subject|0
6340411|NCT03266172|10095074|FG001|Part B: Washout (7 Days)|Withdrawal by Subject|2
6340412|NCT03266172|10095075|FG002|Part B: Washout (7 Days)|Withdrawal by Subject|0
6340413|NCT03266172|10095073|FG000|Part C Washout Period (7 Days)|Withdrawal by Subject|0
6340414|NCT03266172|10095074|FG001|Part C Washout Period (7 Days)|Withdrawal by Subject|0
6340415|NCT03266172|10095075|FG002|Part C Washout Period (7 Days)|Withdrawal by Subject|1
6340416|NCT03266172|10095073|FG000|Part C Washout Period (7 Days)|Withdrawal by Subject|0
6340417|NCT03266172|10095074|FG001|Part C Washout Period (7 Days)|Withdrawal by Subject|0
6340418|NCT03266172|10095075|FG002|Part C Washout Period (7 Days)|Withdrawal by Subject|1
6340419|NCT03266588|10095137|FG000|Observational Period|Screen Failure: Eligibility Criteria|439
6340420|NCT03266588|10095138|FG001|Observational Period|Screen Failure: Eligibility Criteria|228
6340421|NCT03266588|10095139|FG002|Observational Period|Screen Failure: Eligibility Criteria|140
6340422|NCT03266588|10095137|FG000|Observational Period|Withdrawal by Subject|44
6340423|NCT03266588|10095138|FG001|Observational Period|Withdrawal by Subject|22
6340424|NCT03266588|10095139|FG002|Observational Period|Withdrawal by Subject|13
6340425|NCT03266588|10095137|FG000|Observational Period|Non-compliance|18
6340426|NCT03266588|10095138|FG001|Observational Period|Non-compliance|12
6340427|NCT03266588|10095139|FG002|Observational Period|Non-compliance|10
6340428|NCT03266588|10095137|FG000|Observational Period|Lost to Follow-up|8
6340429|NCT03266588|10095138|FG001|Observational Period|Lost to Follow-up|12
6340430|NCT03266588|10095139|FG002|Observational Period|Lost to Follow-up|4
6340431|NCT03266588|10095137|FG000|Observational Period|Eligibility Failure- Baseline Lab Values|3
6340432|NCT03266588|10095138|FG001|Observational Period|Eligibility Failure- Baseline Lab Values|1
6340433|NCT03266588|10095139|FG002|Observational Period|Eligibility Failure- Baseline Lab Values|0
6340434|NCT03266588|10095137|FG000|Observational Period|Protocol Deviation|1
6340435|NCT03266588|10095138|FG001|Observational Period|Protocol Deviation|0
6340436|NCT03266588|10095139|FG002|Observational Period|Protocol Deviation|0
6340437|NCT03266588|10095137|FG000|Observational Period|Other Reasons|3
6340438|NCT03266588|10095138|FG001|Observational Period|Other Reasons|0
6340439|NCT03266588|10095139|FG002|Observational Period|Other Reasons|1
6340440|NCT03266588|10095137|FG000|Long-term Treatment Period|Adverse Event|33
6340441|NCT03266588|10095138|FG001|Long-term Treatment Period|Adverse Event|17
6340442|NCT03266588|10095139|FG002|Long-term Treatment Period|Adverse Event|8
6340443|NCT03266588|10095137|FG000|Long-term Treatment Period|Lack of Efficacy|41
6340444|NCT03266588|10095138|FG001|Long-term Treatment Period|Lack of Efficacy|31
6340445|NCT03266588|10095139|FG002|Long-term Treatment Period|Lack of Efficacy|5
6340446|NCT03266588|10095137|FG000|Long-term Treatment Period|Lost to Follow-up|39
6340447|NCT03266588|10095138|FG001|Long-term Treatment Period|Lost to Follow-up|37
6340448|NCT03266588|10095139|FG002|Long-term Treatment Period|Lost to Follow-up|8
6340449|NCT03266588|10095137|FG000|Long-term Treatment Period|Non-Compliance|126
6340450|NCT03266588|10095138|FG001|Long-term Treatment Period|Non-Compliance|57
6340451|NCT03266588|10095139|FG002|Long-term Treatment Period|Non-Compliance|7
6340452|NCT03266588|10095137|FG000|Long-term Treatment Period|Pregnancy|11
6340453|NCT03266588|10095138|FG001|Long-term Treatment Period|Pregnancy|5
6340454|NCT03266588|10095139|FG002|Long-term Treatment Period|Pregnancy|0
6340455|NCT03266588|10095137|FG000|Long-term Treatment Period|Protocol Deviation|17
6340456|NCT03266588|10095138|FG001|Long-term Treatment Period|Protocol Deviation|10
6340457|NCT03266588|10095139|FG002|Long-term Treatment Period|Protocol Deviation|4
6340458|NCT03266588|10095137|FG000|Long-term Treatment Period|Screen Failure: Eligibility Criteria|33
6340459|NCT03266588|10095138|FG001|Long-term Treatment Period|Screen Failure: Eligibility Criteria|17
6340460|NCT03266588|10095139|FG002|Long-term Treatment Period|Screen Failure: Eligibility Criteria|17
6340461|NCT03266588|10095137|FG000|Long-term Treatment Period|Withdrawal by Subject|100
6340462|NCT03266588|10095138|FG001|Long-term Treatment Period|Withdrawal by Subject|63
6340463|NCT03266588|10095139|FG002|Long-term Treatment Period|Withdrawal by Subject|16
6340464|NCT03266588|10095137|FG000|Long-term Treatment Period|No Migraine Treated by Week 8 Visit|1
6340465|NCT03266588|10095138|FG001|Long-term Treatment Period|No Migraine Treated by Week 8 Visit|2
6340466|NCT03266588|10095139|FG002|Long-term Treatment Period|No Migraine Treated by Week 8 Visit|0
6340467|NCT03266588|10095137|FG000|Long-term Treatment Period|Other Reasons|5
6340468|NCT03266588|10095138|FG001|Long-term Treatment Period|Other Reasons|0
6340469|NCT03266588|10095139|FG002|Long-term Treatment Period|Other Reasons|0
6340470|NCT03266588|10095137|FG000|Long-term Treatment Period|Positive Sheehan-STS Score > 0|0
6340471|NCT03266588|10095138|FG001|Long-term Treatment Period|Positive Sheehan-STS Score > 0|1
6340472|NCT03266588|10095139|FG002|Long-term Treatment Period|Positive Sheehan-STS Score > 0|0
6340473|NCT03267212|10095147|FG000|First Intervention|Lost to Follow-up|0
6340474|NCT03267212|10095148|FG001|First Intervention|Lost to Follow-up|2
6340475|NCT03267212|10095147|FG000|First Intervention|Withdrawal by Subject|1
6340476|NCT03267212|10095148|FG001|First Intervention|Withdrawal by Subject|1
6340477|NCT03267212|10095147|FG000|Washout (Min 2 Days / Max 7 Days)|Physician Decision|1
6340478|NCT03267212|10095148|FG001|Washout (Min 2 Days / Max 7 Days)|Physician Decision|0
6340479|NCT03267264|10095158|FG000|Overall Study|Withdrawal by Subject|1
6340480|NCT03267264|10095159|FG001|Overall Study|Withdrawal by Subject|0
6340481|NCT03267264|10095160|FG002|Overall Study|Withdrawal by Subject|2
6340482|NCT03267264|10095161|FG003|Overall Study|Withdrawal by Subject|4
6340483|NCT03267511|10095178|FG000|Overall Study|Lost to Follow-up|0
6340484|NCT03267511|10095179|FG001|Overall Study|Lost to Follow-up|0
6340485|NCT03267511|10095180|FG002|Overall Study|Lost to Follow-up|0
6340486|NCT03267511|10095181|FG003|Overall Study|Lost to Follow-up|1
6340487|NCT03267576|10095195|FG000|Period 2: Day 44 to 71|Lost to Follow-up|0
6340488|NCT03267576|10095196|FG001|Period 2: Day 44 to 71|Lost to Follow-up|1
6340489|NCT03267576|10095195|FG000|Period 2: Day 44 to 71|Withdrawal by Subject|1
6340490|NCT03267576|10095196|FG001|Period 2: Day 44 to 71|Withdrawal by Subject|1
6340491|NCT03267940|10095208|FG000|Run-in Portion (Max. Exposure: 508 Days)|Investigator or Sponsor Decision|1
6340492|NCT03267940|10095209|FG001|Run-in Portion (Max. Exposure: 508 Days)|Investigator or Sponsor Decision|2
6340493|NCT03267940|10095210|FG002|Run-in Portion (Max. Exposure: 508 Days)|Investigator or Sponsor Decision|0
6340494|NCT03267940|10095211|FG003|Run-in Portion (Max. Exposure: 508 Days)|Investigator or Sponsor Decision|0
6340495|NCT03267940|10095212|FG004|Run-in Portion (Max. Exposure: 508 Days)|Investigator or Sponsor Decision|0
6340496|NCT03267940|10095213|FG005|Run-in Portion (Max. Exposure: 508 Days)|Investigator or Sponsor Decision|0
6340497|NCT03267940|10095208|FG000|Run-in Portion (Max. Exposure: 508 Days)|Withdrawal by Subject|0
6340498|NCT03267940|10095209|FG001|Run-in Portion (Max. Exposure: 508 Days)|Withdrawal by Subject|1
6340499|NCT03267940|10095210|FG002|Run-in Portion (Max. Exposure: 508 Days)|Withdrawal by Subject|0
6340500|NCT03267940|10095211|FG003|Run-in Portion (Max. Exposure: 508 Days)|Withdrawal by Subject|0
6340501|NCT03267940|10095212|FG004|Run-in Portion (Max. Exposure: 508 Days)|Withdrawal by Subject|0
6340502|NCT03267940|10095213|FG005|Run-in Portion (Max. Exposure: 508 Days)|Withdrawal by Subject|0
6340503|NCT03267940|10095208|FG000|Run-in Portion (Max. Exposure: 508 Days)|Sponsor Terminated Study|0
6340504|NCT03267940|10095209|FG001|Run-in Portion (Max. Exposure: 508 Days)|Sponsor Terminated Study|1
6340505|NCT03267940|10095210|FG002|Run-in Portion (Max. Exposure: 508 Days)|Sponsor Terminated Study|0
6340506|NCT03267940|10095211|FG003|Run-in Portion (Max. Exposure: 508 Days)|Sponsor Terminated Study|0
6340507|NCT03267940|10095212|FG004|Run-in Portion (Max. Exposure: 508 Days)|Sponsor Terminated Study|0
6340508|NCT03267940|10095213|FG005|Run-in Portion (Max. Exposure: 508 Days)|Sponsor Terminated Study|0
6340509|NCT03267940|10095208|FG000|Run-in Portion (Max. Exposure: 508 Days)|Death|7
6340510|NCT03267940|10095209|FG001|Run-in Portion (Max. Exposure: 508 Days)|Death|3
6340511|NCT03267940|10095210|FG002|Run-in Portion (Max. Exposure: 508 Days)|Death|0
6340512|NCT03267940|10095211|FG003|Run-in Portion (Max. Exposure: 508 Days)|Death|0
6340513|NCT03267940|10095212|FG004|Run-in Portion (Max. Exposure: 508 Days)|Death|0
6340514|NCT03267940|10095213|FG005|Run-in Portion (Max. Exposure: 508 Days)|Death|0
6340515|NCT03267940|10095208|FG000|Expansion (Maximum Exposure: 421 Days)|Other than specified|0
6340516|NCT03267940|10095209|FG001|Expansion (Maximum Exposure: 421 Days)|Other than specified|0
6340517|NCT03267940|10095210|FG002|Expansion (Maximum Exposure: 421 Days)|Other than specified|0
6340518|NCT03267940|10095211|FG003|Expansion (Maximum Exposure: 421 Days)|Other than specified|3
6340519|NCT03267940|10095212|FG004|Expansion (Maximum Exposure: 421 Days)|Other than specified|2
6340520|NCT03267940|10095213|FG005|Expansion (Maximum Exposure: 421 Days)|Other than specified|0
6340521|NCT03267940|10095208|FG000|Expansion (Maximum Exposure: 421 Days)|Investigator or Sponsor Decision|0
6340522|NCT03267940|10095209|FG001|Expansion (Maximum Exposure: 421 Days)|Investigator or Sponsor Decision|0
6340523|NCT03267940|10095210|FG002|Expansion (Maximum Exposure: 421 Days)|Investigator or Sponsor Decision|2
6340524|NCT03267940|10095211|FG003|Expansion (Maximum Exposure: 421 Days)|Investigator or Sponsor Decision|1
6340525|NCT03267940|10095212|FG004|Expansion (Maximum Exposure: 421 Days)|Investigator or Sponsor Decision|2
6340526|NCT03267940|10095213|FG005|Expansion (Maximum Exposure: 421 Days)|Investigator or Sponsor Decision|0
6340527|NCT03267940|10095208|FG000|Expansion (Maximum Exposure: 421 Days)|Withdrawal by Subject|0
6340528|NCT03267940|10095209|FG001|Expansion (Maximum Exposure: 421 Days)|Withdrawal by Subject|0
6340529|NCT03267940|10095210|FG002|Expansion (Maximum Exposure: 421 Days)|Withdrawal by Subject|2
6340530|NCT03267940|10095211|FG003|Expansion (Maximum Exposure: 421 Days)|Withdrawal by Subject|1
6340531|NCT03267940|10095212|FG004|Expansion (Maximum Exposure: 421 Days)|Withdrawal by Subject|1
6340532|NCT03267940|10095213|FG005|Expansion (Maximum Exposure: 421 Days)|Withdrawal by Subject|1
6340533|NCT03267940|10095208|FG000|Expansion (Maximum Exposure: 421 Days)|Sponsor Terminated Study|0
6340534|NCT03267940|10095209|FG001|Expansion (Maximum Exposure: 421 Days)|Sponsor Terminated Study|0
6340535|NCT03267940|10095210|FG002|Expansion (Maximum Exposure: 421 Days)|Sponsor Terminated Study|7
6340536|NCT03267940|10095211|FG003|Expansion (Maximum Exposure: 421 Days)|Sponsor Terminated Study|4
6340537|NCT03267940|10095212|FG004|Expansion (Maximum Exposure: 421 Days)|Sponsor Terminated Study|5
6340538|NCT03267940|10095213|FG005|Expansion (Maximum Exposure: 421 Days)|Sponsor Terminated Study|3
6340539|NCT03267940|10095208|FG000|Expansion (Maximum Exposure: 421 Days)|Death|0
6340540|NCT03267940|10095209|FG001|Expansion (Maximum Exposure: 421 Days)|Death|0
6340541|NCT03267940|10095210|FG002|Expansion (Maximum Exposure: 421 Days)|Death|10
6340542|NCT03267940|10095211|FG003|Expansion (Maximum Exposure: 421 Days)|Death|13
6340543|NCT03267940|10095212|FG004|Expansion (Maximum Exposure: 421 Days)|Death|0
6340544|NCT03267940|10095213|FG005|Expansion (Maximum Exposure: 421 Days)|Death|6
6340545|NCT03268590|10095239|FG000|Overall Study|Previously unknown exclusion criteria|1
6340546|NCT03268746|10095246|FG000|Overall Study|Withdrawal by Subject|1
6340547|NCT03268941|10095261|FG000|Part 1 (Days 1 to 9)|Withdrawal by Subject|0
6340548|NCT03268941|10095262|FG001|Part 1 (Days 1 to 9)|Withdrawal by Subject|0
6340549|NCT03268941|10095263|FG002|Part 1 (Days 1 to 9)|Withdrawal by Subject|0
6340550|NCT03268941|10095264|FG003|Part 1 (Days 1 to 9)|Withdrawal by Subject|1
6340551|NCT03268941|10095265|FG004|Part 1 (Days 1 to 9)|Withdrawal by Subject|0
6340552|NCT03268941|10095266|FG005|Part 1 (Days 1 to 9)|Withdrawal by Subject|0
6340553|NCT03268941|10095267|FG006|Part 1 (Days 1 to 9)|Withdrawal by Subject|0
6340554|NCT03268941|10095261|FG000|Part 1 (Days 1 to 9)|Adverse Event|0
6340555|NCT03268941|10095262|FG001|Part 1 (Days 1 to 9)|Adverse Event|0
6340556|NCT03268941|10095263|FG002|Part 1 (Days 1 to 9)|Adverse Event|0
6340557|NCT03268941|10095264|FG003|Part 1 (Days 1 to 9)|Adverse Event|1
6340558|NCT03268941|10095265|FG004|Part 1 (Days 1 to 9)|Adverse Event|0
6340559|NCT03268941|10095266|FG005|Part 1 (Days 1 to 9)|Adverse Event|0
6340560|NCT03268941|10095267|FG006|Part 1 (Days 1 to 9)|Adverse Event|0
6340561|NCT03268941|10095261|FG000|Part 1 (Days 1 to 9)|Protocol Deviation|1
6340562|NCT03268941|10095262|FG001|Part 1 (Days 1 to 9)|Protocol Deviation|0
6340563|NCT03268941|10095263|FG002|Part 1 (Days 1 to 9)|Protocol Deviation|0
6340564|NCT03268941|10095264|FG003|Part 1 (Days 1 to 9)|Protocol Deviation|0
6340565|NCT03268941|10095265|FG004|Part 1 (Days 1 to 9)|Protocol Deviation|0
6340566|NCT03268941|10095266|FG005|Part 1 (Days 1 to 9)|Protocol Deviation|0
6340567|NCT03268941|10095267|FG006|Part 1 (Days 1 to 9)|Protocol Deviation|0
6340568|NCT03268941|10095261|FG000|Part 2: Days 17 to 25|Reason not specified|0
6340569|NCT03268941|10095262|FG001|Part 2: Days 17 to 25|Reason not specified|0
6340570|NCT03268941|10095263|FG002|Part 2: Days 17 to 25|Reason not specified|0
6340571|NCT03268941|10095264|FG003|Part 2: Days 17 to 25|Reason not specified|0
6340572|NCT03268941|10095265|FG004|Part 2: Days 17 to 25|Reason not specified|0
6340573|NCT03268941|10095266|FG005|Part 2: Days 17 to 25|Reason not specified|0
6340574|NCT03268941|10095267|FG006|Part 2: Days 17 to 25|Reason not specified|1
6340575|NCT03268941|10095261|FG000|Part 2: Days 17 to 25|Withdrawal by Subject|0
6340576|NCT03268941|10095262|FG001|Part 2: Days 17 to 25|Withdrawal by Subject|0
6340577|NCT03268941|10095263|FG002|Part 2: Days 17 to 25|Withdrawal by Subject|0
6340578|NCT03268941|10095264|FG003|Part 2: Days 17 to 25|Withdrawal by Subject|0
6340579|NCT03268941|10095265|FG004|Part 2: Days 17 to 25|Withdrawal by Subject|0
6340580|NCT03268941|10095266|FG005|Part 2: Days 17 to 25|Withdrawal by Subject|0
6340581|NCT03268941|10095267|FG006|Part 2: Days 17 to 25|Withdrawal by Subject|1
6340582|NCT03269552|10095295|FG000|Overall Study|Adverse Event|2
6042942|NCT00385918|9641418|FG000|Feasibility & Baseline Measurement Phase|Physician Decision|0
6042943|NCT00385918|9641419|FG001|Feasibility & Baseline Measurement Phase|Physician Decision|0
6042944|NCT00385918|9641420|FG002|Feasibility & Baseline Measurement Phase|Physician Decision|1
6042945|NCT00385918|9641418|FG000|Intervention Phase After Randomization|Withdrawal by Subject|1
6042946|NCT00385918|9641419|FG001|Intervention Phase After Randomization|Withdrawal by Subject|0
6042947|NCT00385918|9641420|FG002|Intervention Phase After Randomization|Withdrawal by Subject|0
6042948|NCT00385918|9641418|FG000|Intervention Phase After Randomization|Physician Decision|1
6042949|NCT00385918|9641419|FG001|Intervention Phase After Randomization|Physician Decision|0
6042950|NCT00385918|9641420|FG002|Intervention Phase After Randomization|Physician Decision|0
6042951|NCT00385918|9641418|FG000|Intervention Phase After Randomization|Lost to Follow-up|1
6042952|NCT00385918|9641419|FG001|Intervention Phase After Randomization|Lost to Follow-up|0
6042953|NCT00385918|9641420|FG002|Intervention Phase After Randomization|Lost to Follow-up|0
6042954|NCT00385944|9641429|FG000|1st Maintenance Dose Period|Physician Decision|1
6042955|NCT00385944|9641430|FG001|1st Maintenance Dose Period|Physician Decision|0
6042956|NCT00385944|9641431|FG002|1st Maintenance Dose Period|Physician Decision|0
6042957|NCT00385944|9641429|FG000|1st Maintenance Dose Period|Entry Criteria Exclusion|0
6340583|NCT03270085|10095302|FG000|Overall Study|Withdrawal by Subject|1
6340584|NCT03270085|10095303|FG001|Overall Study|Withdrawal by Subject|0
6340585|NCT03270644|10095338|FG000|Day 1 Lasmiditan Reference|Physician Decision|1
6340586|NCT03270644|10095338|FG000|Day 4 - 10 Propranolol Reference|Adverse Event|1
6340587|NCT03270657|10095349|FG000|Overall Study|Withdrawal by Subject|1
6340588|NCT03271307|10095367|FG000|Overall Study|Lost to Follow-up|0
6340589|NCT03271307|10095368|FG001|Overall Study|Lost to Follow-up|0
6340590|NCT03271307|10095369|FG002|Overall Study|Lost to Follow-up|0
6340591|NCT03271307|10095370|FG003|Overall Study|Lost to Follow-up|28
6340592|NCT03271307|10095371|FG004|Overall Study|Lost to Follow-up|91
6340593|NCT03271528|10095403|FG000|Medication Dispense/Exposure Period 1|Adverse Event|1
6340594|NCT03271528|10095404|FG001|Medication Dispense/Exposure Period 1|Adverse Event|0
6340595|NCT03271528|10095403|FG000|Medication Dispense/Exposure Period 1|Protocol Violation|1
6340596|NCT03271528|10095404|FG001|Medication Dispense/Exposure Period 1|Protocol Violation|0
6340597|NCT03271528|10095403|FG000|Medication Dispense/Exposure Period 1|Lost to Follow-up|0
6340598|NCT03271528|10095404|FG001|Medication Dispense/Exposure Period 1|Lost to Follow-up|1
6340599|NCT03271528|10095403|FG000|Medication Dispense/Exposure Period 1|Participation discontinued due to COVID-19 research pause|0
6340600|NCT03271528|10095404|FG001|Medication Dispense/Exposure Period 1|Participation discontinued due to COVID-19 research pause|1
6340601|NCT03271528|10095403|FG000|Alcohol Trial 1, Washout Period 1|Lost to Follow-up|1
6340602|NCT03271528|10095404|FG001|Alcohol Trial 1, Washout Period 1|Lost to Follow-up|1
6340603|NCT03271528|10095403|FG000|Alcohol Trial 1, Washout Period 1|Failed urine drug screen at time of Alcohol Trial 1|1
6340604|NCT03271528|10095404|FG001|Alcohol Trial 1, Washout Period 1|Failed urine drug screen at time of Alcohol Trial 1|0
6340605|NCT03271528|10095403|FG000|Medication Dispense/Exposure Period 2|Lost to Follow-up|1
6340606|NCT03271528|10095404|FG001|Medication Dispense/Exposure Period 2|Lost to Follow-up|0
6340607|NCT03273153|10095412|FG000|Overall Study|Remain on Study|161
6340608|NCT03273153|10095413|FG001|Overall Study|Remain on Study|159
6340609|NCT03273153|10095412|FG000|Overall Study|Death|41
6340610|NCT03273153|10095413|FG001|Overall Study|Death|45
6340611|NCT03273153|10095412|FG000|Overall Study|Lost to Follow-up|3
6340612|NCT03273153|10095413|FG001|Overall Study|Lost to Follow-up|3
6340613|NCT03273153|10095412|FG000|Overall Study|Protocol Violation|3
6340614|NCT03273153|10095413|FG001|Overall Study|Protocol Violation|0
6340615|NCT03273153|10095412|FG000|Overall Study|Withdrawal by Subject|16
6340616|NCT03273153|10095413|FG001|Overall Study|Withdrawal by Subject|13
6340617|NCT03273153|10095412|FG000|Overall Study|Symptomatic Deterioration|0
6340618|NCT03273153|10095413|FG001|Overall Study|Symptomatic Deterioration|1
6340619|NCT03273153|10095412|FG000|Overall Study|Other|0
6340620|NCT03273153|10095413|FG001|Overall Study|Other|1
6340621|NCT03273166|10095419|FG000|Overall Study|Withdrawn prior to Completion|31
6340622|NCT03273257|10095426|FG000|Overall Study|Death|0
6340623|NCT03273257|10095427|FG001|Overall Study|Death|1
6340624|NCT03273257|10095426|FG000|Overall Study|Inability to schedule PEA according to the protocol due to the COVID pandemic|1
6340625|NCT03273257|10095427|FG001|Overall Study|Inability to schedule PEA according to the protocol due to the COVID pandemic|1
6340626|NCT03273257|10095426|FG000|Overall Study|Study terminated|3
6340627|NCT03273257|10095427|FG001|Overall Study|Study terminated|2
6340628|NCT03273387|10095453|FG000|Overall Study|Death|2
6340629|NCT03273387|10095454|FG001|Overall Study|Death|2
6340630|NCT03273387|10095453|FG000|Overall Study|Withdrawal by Subject|1
6340631|NCT03273387|10095454|FG001|Overall Study|Withdrawal by Subject|1
6340632|NCT03273946|10095488|FG000|Overall Study|Withdrawal by Subject|5
6340633|NCT03273946|10095488|FG000|Overall Study|Unwillingness of the guardian|1
6340634|NCT03273946|10095488|FG000|Overall Study|Participant refused to use the drug|2
6340635|NCT03273946|10095488|FG000|Overall Study|Participant relative refused to use drug|1
6340636|NCT03274076|10095494|FG000|24 Weeks Double Blind|Withdrawal by Subject|0
6340637|NCT03274076|10095495|FG001|24 Weeks Double Blind|Withdrawal by Subject|1
6340638|NCT03274076|10095496|FG002|24 Weeks Double Blind|Withdrawal by Subject|0
6340639|NCT03274076|10095497|FG003|24 Weeks Double Blind|Withdrawal by Subject|0
6340640|NCT03274076|10095494|FG000|24 Weeks Open Label|Adverse Event|0
6340641|NCT03274076|10095495|FG001|24 Weeks Open Label|Adverse Event|0
6340642|NCT03274076|10095496|FG002|24 Weeks Open Label|Adverse Event|2
6340643|NCT03274076|10095497|FG003|24 Weeks Open Label|Adverse Event|0
6340644|NCT03274076|10095494|FG000|24 Weeks Open Label|Withdrawal by Subject|0
6340645|NCT03274076|10095495|FG001|24 Weeks Open Label|Withdrawal by Subject|0
6340646|NCT03274076|10095496|FG002|24 Weeks Open Label|Withdrawal by Subject|0
6340647|NCT03274076|10095497|FG003|24 Weeks Open Label|Withdrawal by Subject|1
6042958|NCT00385944|9641430|FG001|1st Maintenance Dose Period|Entry Criteria Exclusion|1
6042959|NCT00385944|9641431|FG002|1st Maintenance Dose Period|Entry Criteria Exclusion|0
6042960|NCT00385944|9641429|FG000|1st Maintenance Dose Period|Invalid Pharmacodynamic Data|3
6042961|NCT00385944|9641430|FG001|1st Maintenance Dose Period|Invalid Pharmacodynamic Data|0
6042962|NCT00385944|9641431|FG002|1st Maintenance Dose Period|Invalid Pharmacodynamic Data|0
6042963|NCT00385944|9641429|FG000|2nd Maintenance Dose Period|Invalid PD Data|2
6042964|NCT00385944|9641430|FG001|2nd Maintenance Dose Period|Invalid PD Data|3
6042965|NCT00385944|9641431|FG002|2nd Maintenance Dose Period|Invalid PD Data|0
6042966|NCT00386009|9641453|FG000|Overall Study|Adverse Event|0
6168572|NCT01236352|9813656|FG009|Overall Study|Subject to receive drug via EAP|4
6340648|NCT03274440|10095516|FG000|Overall Study|Time commitment too great|1
6340649|NCT03274440|10095517|FG001|Overall Study|Time commitment too great|0
6340650|NCT03274440|10095518|FG002|Overall Study|Time commitment too great|0
6340651|NCT03274440|10095519|FG003|Overall Study|Time commitment too great|1
6340652|NCT03274440|10095520|FG004|Overall Study|Time commitment too great|0
6340653|NCT03274440|10095521|FG005|Overall Study|Time commitment too great|0
6340654|NCT03274453|10095533|FG000|Overall Study|Lost to Follow-up|2
6340655|NCT03274453|10095534|FG001|Overall Study|Lost to Follow-up|5
6340656|NCT03274453|10095535|FG002|Overall Study|Lost to Follow-up|4
6340657|NCT03274453|10095536|FG003|Overall Study|Lost to Follow-up|1
6340658|NCT03274453|10095533|FG000|Overall Study|Physician Decision|2
6340659|NCT03274453|10095534|FG001|Overall Study|Physician Decision|0
6340660|NCT03274453|10095535|FG002|Overall Study|Physician Decision|0
6340661|NCT03274453|10095536|FG003|Overall Study|Physician Decision|3
6340662|NCT03274453|10095533|FG000|Overall Study|Surgery Cancelled|0
6340663|NCT03274453|10095534|FG001|Overall Study|Surgery Cancelled|1
6340664|NCT03274453|10095535|FG002|Overall Study|Surgery Cancelled|0
6340665|NCT03274453|10095536|FG003|Overall Study|Surgery Cancelled|0
6340666|NCT03274466|10095548|FG000|Overall Study|Withdrawal by Subject|7
6340667|NCT03274466|10095549|FG001|Overall Study|Withdrawal by Subject|3
6340668|NCT03274466|10095548|FG000|Overall Study|Protocol Specified Withdrawal|5
6340669|NCT03274466|10095549|FG001|Overall Study|Protocol Specified Withdrawal|11
6340670|NCT03274466|10095548|FG000|Overall Study|Lost to Follow-up|5
6340671|NCT03274466|10095549|FG001|Overall Study|Lost to Follow-up|7
6340672|NCT03274466|10095548|FG000|Overall Study|Subject Non-compliance|0
6340673|NCT03274466|10095549|FG001|Overall Study|Subject Non-compliance|1
6340674|NCT03274466|10095548|FG000|Overall Study|Adverse Event|3
6340675|NCT03274466|10095549|FG001|Overall Study|Adverse Event|3
6168573|NCT01236352|9813657|FG010|Overall Study|Subject to receive drug via EAP|0
6340676|NCT03274466|10095548|FG000|Overall Study|Physician Decision|0
6340677|NCT03274466|10095549|FG001|Overall Study|Physician Decision|1
6340678|NCT03274466|10095548|FG000|Overall Study|Protocol Violation|3
6340679|NCT03274466|10095549|FG001|Overall Study|Protocol Violation|3
6340680|NCT03274986|10095582|FG000|Overall Study|Withdrawal by Subject|0
6340681|NCT03274986|10095583|FG001|Overall Study|Withdrawal by Subject|1
6340682|NCT03274986|10095582|FG000|Overall Study|Lost to Follow-up|0
6340683|NCT03274986|10095583|FG001|Overall Study|Lost to Follow-up|1
6340684|NCT03275246|10095603|FG000|Overall Study|Protocol Violation|5
6340685|NCT03275246|10095603|FG000|Overall Study|The study was stopped before the patient reached the final 1 year follow-up|1
6340686|NCT03275389|10095617|FG000|Overall Study|Lost to Follow-up|10
6340687|NCT03275389|10095618|FG001|Overall Study|Lost to Follow-up|10
6340688|NCT03275389|10095619|FG002|Overall Study|Lost to Follow-up|19
6340689|NCT03275389|10095620|FG003|Overall Study|Lost to Follow-up|12
6340690|NCT03275389|10095621|FG004|Overall Study|Lost to Follow-up|11
6340691|NCT03275389|10095622|FG005|Overall Study|Lost to Follow-up|12
6340692|NCT03275389|10095623|FG006|Overall Study|Lost to Follow-up|21
6340693|NCT03275389|10095624|FG007|Overall Study|Lost to Follow-up|15
6340694|NCT03275389|10095625|FG008|Overall Study|Lost to Follow-up|12
6340695|NCT03275389|10095626|FG009|Overall Study|Lost to Follow-up|14
6340696|NCT03275389|10095617|FG000|Overall Study|SERIOUS ADVERSE EVENT AND/OR PIMD|0
6340697|NCT03275389|10095618|FG001|Overall Study|SERIOUS ADVERSE EVENT AND/OR PIMD|0
6340698|NCT03275389|10095619|FG002|Overall Study|SERIOUS ADVERSE EVENT AND/OR PIMD|0
6340699|NCT03275389|10095620|FG003|Overall Study|SERIOUS ADVERSE EVENT AND/OR PIMD|0
6340700|NCT03275389|10095621|FG004|Overall Study|SERIOUS ADVERSE EVENT AND/OR PIMD|0
6340701|NCT03275389|10095622|FG005|Overall Study|SERIOUS ADVERSE EVENT AND/OR PIMD|1
6340702|NCT03275389|10095623|FG006|Overall Study|SERIOUS ADVERSE EVENT AND/OR PIMD|0
6340703|NCT03275389|10095624|FG007|Overall Study|SERIOUS ADVERSE EVENT AND/OR PIMD|0
6340704|NCT03275389|10095625|FG008|Overall Study|SERIOUS ADVERSE EVENT AND/OR PIMD|0
6340705|NCT03275389|10095626|FG009|Overall Study|SERIOUS ADVERSE EVENT AND/OR PIMD|1
6340706|NCT03275389|10095617|FG000|Overall Study|CONSENT WITHDRAWAL NOT DUE TO ADV. EVENT|1
6340707|NCT03275389|10095618|FG001|Overall Study|CONSENT WITHDRAWAL NOT DUE TO ADV. EVENT|0
6340708|NCT03275389|10095619|FG002|Overall Study|CONSENT WITHDRAWAL NOT DUE TO ADV. EVENT|0
6340709|NCT03275389|10095620|FG003|Overall Study|CONSENT WITHDRAWAL NOT DUE TO ADV. EVENT|5
6340710|NCT03275389|10095621|FG004|Overall Study|CONSENT WITHDRAWAL NOT DUE TO ADV. EVENT|3
6340711|NCT03275389|10095622|FG005|Overall Study|CONSENT WITHDRAWAL NOT DUE TO ADV. EVENT|3
6340712|NCT03275389|10095623|FG006|Overall Study|CONSENT WITHDRAWAL NOT DUE TO ADV. EVENT|3
6340713|NCT03275389|10095624|FG007|Overall Study|CONSENT WITHDRAWAL NOT DUE TO ADV. EVENT|3
6340714|NCT03275389|10095625|FG008|Overall Study|CONSENT WITHDRAWAL NOT DUE TO ADV. EVENT|2
6340715|NCT03275389|10095626|FG009|Overall Study|CONSENT WITHDRAWAL NOT DUE TO ADV. EVENT|2
6340716|NCT03275389|10095617|FG000|Overall Study|MIGRATED / MOVED FROM THE STUDY AREA|0
6340717|NCT03275389|10095618|FG001|Overall Study|MIGRATED / MOVED FROM THE STUDY AREA|2
6340718|NCT03275389|10095619|FG002|Overall Study|MIGRATED / MOVED FROM THE STUDY AREA|0
6340719|NCT03275389|10095620|FG003|Overall Study|MIGRATED / MOVED FROM THE STUDY AREA|3
6340720|NCT03275389|10095621|FG004|Overall Study|MIGRATED / MOVED FROM THE STUDY AREA|0
6340721|NCT03275389|10095622|FG005|Overall Study|MIGRATED / MOVED FROM THE STUDY AREA|0
6340722|NCT03275389|10095623|FG006|Overall Study|MIGRATED / MOVED FROM THE STUDY AREA|1
6340723|NCT03275389|10095624|FG007|Overall Study|MIGRATED / MOVED FROM THE STUDY AREA|0
6340724|NCT03275389|10095625|FG008|Overall Study|MIGRATED / MOVED FROM THE STUDY AREA|0
6340725|NCT03275389|10095626|FG009|Overall Study|MIGRATED / MOVED FROM THE STUDY AREA|0
6340726|NCT03275389|10095617|FG000|Overall Study|NOT WILLING TO PARTICIPATE THIS VISIT|0
6340727|NCT03275389|10095618|FG001|Overall Study|NOT WILLING TO PARTICIPATE THIS VISIT|0
6340728|NCT03275389|10095619|FG002|Overall Study|NOT WILLING TO PARTICIPATE THIS VISIT|1
6340729|NCT03275389|10095620|FG003|Overall Study|NOT WILLING TO PARTICIPATE THIS VISIT|0
6340730|NCT03275389|10095621|FG004|Overall Study|NOT WILLING TO PARTICIPATE THIS VISIT|0
6340731|NCT03275389|10095622|FG005|Overall Study|NOT WILLING TO PARTICIPATE THIS VISIT|0
6340732|NCT03275389|10095623|FG006|Overall Study|NOT WILLING TO PARTICIPATE THIS VISIT|0
6340733|NCT03275389|10095624|FG007|Overall Study|NOT WILLING TO PARTICIPATE THIS VISIT|0
6340734|NCT03275389|10095625|FG008|Overall Study|NOT WILLING TO PARTICIPATE THIS VISIT|0
6340735|NCT03275389|10095626|FG009|Overall Study|NOT WILLING TO PARTICIPATE THIS VISIT|1
6340736|NCT03275389|10095617|FG000|Overall Study|Other|0
6340737|NCT03275389|10095618|FG001|Overall Study|Other|4
6340738|NCT03275389|10095619|FG002|Overall Study|Other|3
6340739|NCT03275389|10095620|FG003|Overall Study|Other|2
6340740|NCT03275389|10095621|FG004|Overall Study|Other|2
6340741|NCT03275389|10095622|FG005|Overall Study|Other|2
6340742|NCT03275389|10095623|FG006|Overall Study|Other|0
6340743|NCT03275389|10095624|FG007|Overall Study|Other|0
6340744|NCT03275389|10095625|FG008|Overall Study|Other|1
6340745|NCT03275389|10095626|FG009|Overall Study|Other|0
6340746|NCT03276026|10095680|FG000|Overall Study|Protocol Violation|1
6340747|NCT03276026|10095681|FG001|Overall Study|Protocol Violation|0
6340748|NCT03276078|10095687|FG000|Overall Study|Adverse Event|1
6340749|NCT03276975|10095711|FG000|Overall Study|Withdrawal by Subject|1
6340750|NCT03276975|10095712|FG001|Overall Study|Withdrawal by Subject|0
6340751|NCT03277352|10095731|FG000|Overall Study|Study Terminated By Sponsor|2
6340752|NCT03277352|10095731|FG000|Overall Study|Withdrawal by Subject|4
6340753|NCT03277352|10095731|FG000|Overall Study|Death|4
6340754|NCT03277794|10095751|FG000|Overall Study|Lost to Follow-up|2
6340755|NCT03277794|10095752|FG001|Overall Study|Lost to Follow-up|4
6340756|NCT03277794|10095751|FG000|Overall Study|Withdrew due to high acuity|1
6340757|NCT03277794|10095752|FG001|Overall Study|Withdrew due to high acuity|0
6340758|NCT03277846|10095761|FG000|Overall Study|Inpatient stay too brief|12
6340759|NCT03277846|10095762|FG001|Overall Study|Inpatient stay too brief|11
6340760|NCT03278028|10095770|FG000|Overall Study|Lost to Follow-up|1
6340761|NCT03278028|10095771|FG001|Overall Study|Lost to Follow-up|0
6340762|NCT03278028|10095770|FG000|Overall Study|Withdrawal by Subject|3
6340763|NCT03278028|10095771|FG001|Overall Study|Withdrawal by Subject|1
6340764|NCT03278028|10095770|FG000|Overall Study|Pregnancy|0
6340765|NCT03278028|10095771|FG001|Overall Study|Pregnancy|1
6340766|NCT03278106|10095795|FG000|Overall Study|No protocol treatment|1
6340767|NCT03278613|10095810|FG000|Overall Study|Lost to Follow-up|3
6340768|NCT03278613|10095811|FG001|Overall Study|Lost to Follow-up|1
6340769|NCT03280108|10095849|FG000|Overall Study|Lost to Follow-up|2
6340770|NCT03280108|10095850|FG001|Overall Study|Lost to Follow-up|0
6340771|NCT03280121|10095861|FG000|Overall Study|Physician Decision|1
6340772|NCT03280121|10095861|FG000|Overall Study|Lost to Follow-up|1
6340773|NCT03280121|10095861|FG000|Overall Study|screen failure - 3 hernia too small and 1 pH too low|4
6340774|NCT03280264|10095865|FG000|Overall Study|Adverse Event|1
6340775|NCT03280264|10095865|FG000|Overall Study|Physician Decision|1
6340776|NCT03280264|10095865|FG000|Overall Study|Withdrawal by Subject|1
6340777|NCT03280381|10095872|FG000|Overall Study|Physician Decision|0
6340778|NCT03280381|10095873|FG001|Overall Study|Physician Decision|2
6340779|NCT03280537|10095882|FG000|Overall Study|Withdrawal by Subject|2
6340780|NCT03280537|10095883|FG001|Overall Study|Withdrawal by Subject|4
6340781|NCT03280550|10095891|FG000|Overall Study|Withdrawal by Subject|2
6340782|NCT03280550|10095892|FG001|Overall Study|Withdrawal by Subject|2
6340783|NCT03280550|10095891|FG000|Overall Study|Physician Decision|0
6340784|NCT03280550|10095892|FG001|Overall Study|Physician Decision|1
6340785|NCT03280615|10095900|FG000|Overall Study|Lost to Follow-up|1
6340786|NCT03280615|10095901|FG001|Overall Study|Lost to Follow-up|2
6340787|NCT03280615|10095900|FG000|Overall Study|Adverse Event|1
6340788|NCT03280615|10095901|FG001|Overall Study|Adverse Event|1
6340789|NCT03280615|10095900|FG000|Overall Study|Withdrawal by Subject|2
6340790|NCT03280615|10095901|FG001|Overall Study|Withdrawal by Subject|2
6340791|NCT03281304|10095913|FG000|Overall Study|Adverse Event|5
6340792|NCT03281304|10095914|FG001|Overall Study|Adverse Event|2
6340793|NCT03281304|10095913|FG000|Overall Study|Lack of Efficacy|2
6340794|NCT03281304|10095914|FG001|Overall Study|Lack of Efficacy|0
6340795|NCT03281304|10095913|FG000|Overall Study|Pregnancy|1
6340796|NCT03281304|10095914|FG001|Overall Study|Pregnancy|0
6340797|NCT03281304|10095913|FG000|Overall Study|Withdrawal by Subject|5
6340798|NCT03281304|10095914|FG001|Overall Study|Withdrawal by Subject|10
6340799|NCT03281577|10095928|FG000|Overall Study|Adverse Event|0
6340800|NCT03281577|10095929|FG001|Overall Study|Adverse Event|0
6340801|NCT03281577|10095930|FG002|Overall Study|Adverse Event|0
6340802|NCT03281577|10095931|FG003|Overall Study|Adverse Event|1
6340803|NCT03281577|10095928|FG000|Overall Study|Withdrawal by Subject|1
6340804|NCT03281577|10095929|FG001|Overall Study|Withdrawal by Subject|0
6340805|NCT03281577|10095930|FG002|Overall Study|Withdrawal by Subject|0
6340806|NCT03281577|10095931|FG003|Overall Study|Withdrawal by Subject|0
6340807|NCT03281668|10095944|FG000|Overall Study|Physician Decision|1
6340808|NCT03281668|10095944|FG000|Overall Study|scheduling conflict, family circumstance|2
6340809|NCT03281668|10095944|FG000|Overall Study|Withdrawal by Subject|4
6340810|NCT03281668|10095944|FG000|Overall Study|Lost to Follow-up|1
6340811|NCT03281876|10095950|FG000|Overall Study|Adverse Event|4
6340812|NCT03281876|10095951|FG001|Overall Study|Adverse Event|15
6340813|NCT03281876|10095950|FG000|Overall Study|Lost to Follow-up|1
6340814|NCT03281876|10095951|FG001|Overall Study|Lost to Follow-up|4
6340815|NCT03281876|10095950|FG000|Overall Study|Withdrawal by Subject|11
6340816|NCT03281876|10095951|FG001|Overall Study|Withdrawal by Subject|15
6340817|NCT03281876|10095950|FG000|Overall Study|MIGRATED / MOVED FROM THE STUDY AREA|2
6340818|NCT03281876|10095951|FG001|Overall Study|MIGRATED / MOVED FROM THE STUDY AREA|0
6340819|NCT03281876|10095950|FG000|Overall Study|OTHER|5
6340820|NCT03281876|10095951|FG001|Overall Study|OTHER|5
6340821|NCT03282227|10095968|FG000|Overall Study|Exposure Goals Achieved|60
6340822|NCT03282227|10095968|FG000|Overall Study|Non-compliance w/ protocol requirements|79
6340823|NCT03282227|10095968|FG000|Overall Study|Adverse Event|15
6340824|NCT03282227|10095968|FG000|Overall Study|Lost to Follow-up|21
6340825|NCT03282227|10095968|FG000|Overall Study|Withdrawal by Subject|20
6340826|NCT03282227|10095968|FG000|Overall Study|Lack of Efficacy|12
6340827|NCT03282227|10095968|FG000|Overall Study|Sponsor decision|3
6340828|NCT03282227|10095968|FG000|Overall Study|Physician Decision|2
6340829|NCT03282227|10095968|FG000|Overall Study|Pregnancy|2
6340830|NCT03282227|10095968|FG000|Overall Study|Other|1
6340831|NCT03282357|10095972|FG000|Overall Study|Lost to Follow-up|3
6340832|NCT03282357|10095972|FG000|Overall Study|Withdrawal by Subject|4
6340833|NCT03282357|10095972|FG000|Overall Study|Adverse Event|1
6340834|NCT03282357|10095972|FG000|Overall Study|Other|9
6340835|NCT03283098|10096002|FG000|Overall Study|Withdrawal by Subject|0
6340836|NCT03283098|10096003|FG001|Overall Study|Withdrawal by Subject|1
6340837|NCT03283319|10096015|FG000|Overall Study|Lost to Follow-up|5
6340838|NCT03283319|10096016|FG001|Overall Study|Lost to Follow-up|4
6340839|NCT03283319|10096017|FG002|Overall Study|Lost to Follow-up|5
6340840|NCT03283319|10096018|FG003|Overall Study|Lost to Follow-up|5
6340841|NCT03283319|10096019|FG004|Overall Study|Lost to Follow-up|4
6340842|NCT03283319|10096020|FG005|Overall Study|Lost to Follow-up|3
6340843|NCT03283319|10096015|FG000|Overall Study|Withdrawal by Subject|2
6340844|NCT03283319|10096016|FG001|Overall Study|Withdrawal by Subject|2
6340845|NCT03283319|10096017|FG002|Overall Study|Withdrawal by Subject|2
6340846|NCT03283319|10096018|FG003|Overall Study|Withdrawal by Subject|1
6340847|NCT03283319|10096019|FG004|Overall Study|Withdrawal by Subject|0
6340848|NCT03283319|10096020|FG005|Overall Study|Withdrawal by Subject|1
6340849|NCT03283319|10096015|FG000|Overall Study|BARDA regulatory agency or IRB decision|0
6340850|NCT03283319|10096016|FG001|Overall Study|BARDA regulatory agency or IRB decision|0
6340851|NCT03283319|10096017|FG002|Overall Study|BARDA regulatory agency or IRB decision|0
6340852|NCT03283319|10096018|FG003|Overall Study|BARDA regulatory agency or IRB decision|1
6340853|NCT03283319|10096019|FG004|Overall Study|BARDA regulatory agency or IRB decision|0
6340854|NCT03283319|10096020|FG005|Overall Study|BARDA regulatory agency or IRB decision|0
6340855|NCT03283553|10096045|FG000|Patient Participant Flow|Death|5
6340856|NCT03283553|10096046|FG001|Patient Participant Flow|Death|10
6340857|NCT03283553|10096045|FG000|Patient Participant Flow|Withdrawal by Subject|4
6340858|NCT03283553|10096046|FG001|Patient Participant Flow|Withdrawal by Subject|2
6340859|NCT03283553|10096045|FG000|Patient Participant Flow|Lost to Follow-up|1
6340860|NCT03283553|10096046|FG001|Patient Participant Flow|Lost to Follow-up|1
6340861|NCT03283553|10096045|FG000|Care Partner Participant Flow|Withdrawal by Subject|4
6340862|NCT03283553|10096046|FG001|Care Partner Participant Flow|Withdrawal by Subject|3
6340863|NCT03283553|10096045|FG000|Care Partner Participant Flow|Lost to Follow-up|1
6340864|NCT03283553|10096046|FG001|Care Partner Participant Flow|Lost to Follow-up|1
6340865|NCT03283553|10096045|FG000|Care Partner Participant Flow|Discontinued because patient death|5
6340866|NCT03283553|10096046|FG001|Care Partner Participant Flow|Discontinued because patient death|11
6340867|NCT03283696|10096056|FG000|Overall Study|Physician Decision|5
6340868|NCT03283696|10096057|FG001|Overall Study|Physician Decision|6
6340869|NCT03283696|10096056|FG000|Overall Study|Withdrawal by Subject|2
6340870|NCT03283696|10096057|FG001|Overall Study|Withdrawal by Subject|0
6340871|NCT03284229|10096079|FG000|Overall Study|Lost to Follow-up|3
6340872|NCT03284424|10096115|FG000|Overall Study|Death|56
6340873|NCT03284424|10096116|FG001|Overall Study|Death|13
6340874|NCT03284424|10096115|FG000|Overall Study|Lost to Follow-up|1
6340875|NCT03284424|10096116|FG001|Overall Study|Lost to Follow-up|0
6340876|NCT03284424|10096115|FG000|Overall Study|Physician Decision|1
6340877|NCT03284424|10096116|FG001|Overall Study|Physician Decision|0
6340878|NCT03284424|10096115|FG000|Overall Study|Withdrawal by Subject|3
6340879|NCT03284424|10096116|FG001|Overall Study|Withdrawal by Subject|2
6340880|NCT03284424|10096115|FG000|Overall Study|Ongoing in study|44
6340881|NCT03284424|10096116|FG001|Overall Study|Ongoing in study|39
6340882|NCT03284710|10096125|FG000|Overall Study|Withdrawal by Subject|1
6340883|NCT03284710|10096126|FG001|Overall Study|Withdrawal by Subject|0
6340884|NCT03284710|10096127|FG002|Overall Study|Withdrawal by Subject|1
6340885|NCT03284710|10096128|FG003|Overall Study|Withdrawal by Subject|6
6340886|NCT03284710|10096125|FG000|Overall Study|Lost to Follow-up|3
6340887|NCT03284710|10096126|FG001|Overall Study|Lost to Follow-up|3
6340888|NCT03284710|10096127|FG002|Overall Study|Lost to Follow-up|1
6340889|NCT03284710|10096128|FG003|Overall Study|Lost to Follow-up|0
6340890|NCT03284710|10096125|FG000|Overall Study|Physician Decision|1
6340891|NCT03284710|10096126|FG001|Overall Study|Physician Decision|0
6340892|NCT03284710|10096127|FG002|Overall Study|Physician Decision|0
6340893|NCT03284710|10096128|FG003|Overall Study|Physician Decision|0
6340894|NCT03284710|10096125|FG000|Overall Study|Participant Unable to Adhere to Visit Schedule|1
6340895|NCT03284710|10096126|FG001|Overall Study|Participant Unable to Adhere to Visit Schedule|0
6340896|NCT03284710|10096127|FG002|Overall Study|Participant Unable to Adhere to Visit Schedule|0
6340897|NCT03284710|10096128|FG003|Overall Study|Participant Unable to Adhere to Visit Schedule|1
6340898|NCT03284710|10096125|FG000|Overall Study|HIV Infection|0
6340899|NCT03284710|10096126|FG001|Overall Study|HIV Infection|2
6340900|NCT03284710|10096127|FG002|Overall Study|HIV Infection|2
6083297|NCT00634907|9691693|FG000|Overall Study|Physician Decision|3
6340901|NCT03284710|10096128|FG003|Overall Study|HIV Infection|1
6340902|NCT03285113|10096152|FG000|Overall Study|Unable to implant leads|2
6340903|NCT03285295|10096161|FG000|Alinity s HBsAg|Protocol Violation|11
6340904|NCT03285295|10096162|FG001|Alinity s HBsAg|Protocol Violation|0
6340905|NCT03285295|10096163|FG002|Alinity s HBsAg|Protocol Violation|0
6340906|NCT03285295|10096164|FG003|Alinity s HBsAg|Protocol Violation|0
6340907|NCT03285295|10096165|FG004|Alinity s HBsAg|Protocol Violation|0
6340908|NCT03285295|10096161|FG000|Alinity s HBsAg|No Result on Comparator Assay|17
6340909|NCT03285295|10096162|FG001|Alinity s HBsAg|No Result on Comparator Assay|0
6340910|NCT03285295|10096163|FG002|Alinity s HBsAg|No Result on Comparator Assay|0
6340911|NCT03285295|10096164|FG003|Alinity s HBsAg|No Result on Comparator Assay|0
6340912|NCT03285295|10096165|FG004|Alinity s HBsAg|No Result on Comparator Assay|0
6340913|NCT03285295|10096161|FG000|Alinity s HBsAg|No Results Generated|74
6340914|NCT03285295|10096162|FG001|Alinity s HBsAg|No Results Generated|6
6340915|NCT03285295|10096163|FG002|Alinity s HBsAg|No Results Generated|0
6340916|NCT03285295|10096164|FG003|Alinity s HBsAg|No Results Generated|0
6340917|NCT03285295|10096165|FG004|Alinity s HBsAg|No Results Generated|0
6340918|NCT03285295|10096161|FG000|Alinity s HTLV I/II|Protocol Violation|6
6340919|NCT03285295|10096162|FG001|Alinity s HTLV I/II|Protocol Violation|0
6340920|NCT03285295|10096163|FG002|Alinity s HTLV I/II|Protocol Violation|0
6340921|NCT03285295|10096164|FG003|Alinity s HTLV I/II|Protocol Violation|0
6340922|NCT03285295|10096165|FG004|Alinity s HTLV I/II|Protocol Violation|0
6340923|NCT03285295|10096161|FG000|Alinity s HTLV I/II|No Result on Comparator Assay|15
6340924|NCT03285295|10096162|FG001|Alinity s HTLV I/II|No Result on Comparator Assay|0
6340925|NCT03285295|10096163|FG002|Alinity s HTLV I/II|No Result on Comparator Assay|0
6340926|NCT03285295|10096164|FG003|Alinity s HTLV I/II|No Result on Comparator Assay|0
6340927|NCT03285295|10096165|FG004|Alinity s HTLV I/II|No Result on Comparator Assay|0
6340928|NCT03285295|10096161|FG000|Alinity s HTLV I/II|No Results Generated|70
6340929|NCT03285295|10096162|FG001|Alinity s HTLV I/II|No Results Generated|0
6340930|NCT03285295|10096163|FG002|Alinity s HTLV I/II|No Results Generated|0
6340931|NCT03285295|10096164|FG003|Alinity s HTLV I/II|No Results Generated|0
6340932|NCT03285295|10096165|FG004|Alinity s HTLV I/II|No Results Generated|0
6340933|NCT03285295|10096161|FG000|Alinity s HTLV I/II Follow-Up|Lost to Follow-up|4
6340934|NCT03285295|10096162|FG001|Alinity s HTLV I/II Follow-Up|Lost to Follow-up|0
6340935|NCT03285295|10096163|FG002|Alinity s HTLV I/II Follow-Up|Lost to Follow-up|0
6340936|NCT03285295|10096164|FG003|Alinity s HTLV I/II Follow-Up|Lost to Follow-up|0
6340937|NCT03285295|10096165|FG004|Alinity s HTLV I/II Follow-Up|Lost to Follow-up|0
6340938|NCT03285295|10096161|FG000|Alinity s Anti-HCV|Protocol Violation|12
6340939|NCT03285295|10096162|FG001|Alinity s Anti-HCV|Protocol Violation|0
6340940|NCT03285295|10096163|FG002|Alinity s Anti-HCV|Protocol Violation|0
6340941|NCT03285295|10096164|FG003|Alinity s Anti-HCV|Protocol Violation|0
6340942|NCT03285295|10096165|FG004|Alinity s Anti-HCV|Protocol Violation|0
6340943|NCT03285295|10096161|FG000|Alinity s Anti-HCV|No Results on Comparator Assay|13
6340944|NCT03285295|10096162|FG001|Alinity s Anti-HCV|No Results on Comparator Assay|0
6340945|NCT03285295|10096163|FG002|Alinity s Anti-HCV|No Results on Comparator Assay|0
6340946|NCT03285295|10096164|FG003|Alinity s Anti-HCV|No Results on Comparator Assay|0
6340947|NCT03285295|10096165|FG004|Alinity s Anti-HCV|No Results on Comparator Assay|0
6340948|NCT03285295|10096161|FG000|Alinity s Anti-HCV|No Results Generated|71
6340949|NCT03285295|10096162|FG001|Alinity s Anti-HCV|No Results Generated|0
6340950|NCT03285295|10096163|FG002|Alinity s Anti-HCV|No Results Generated|0
6340951|NCT03285295|10096164|FG003|Alinity s Anti-HCV|No Results Generated|0
6340952|NCT03285295|10096165|FG004|Alinity s Anti-HCV|No Results Generated|0
6340953|NCT03285295|10096161|FG000|Alinity s Anti-HCV Follow-Up|Lost to Follow-up|18
6340954|NCT03285295|10096162|FG001|Alinity s Anti-HCV Follow-Up|Lost to Follow-up|0
6340955|NCT03285295|10096163|FG002|Alinity s Anti-HCV Follow-Up|Lost to Follow-up|0
6340956|NCT03285295|10096164|FG003|Alinity s Anti-HCV Follow-Up|Lost to Follow-up|0
6340957|NCT03285295|10096165|FG004|Alinity s Anti-HCV Follow-Up|Lost to Follow-up|0
6042967|NCT00386009|9641454|FG001|Overall Study|Adverse Event|2
6042968|NCT00386009|9641453|FG000|Overall Study|Death|1
6042969|NCT00386009|9641454|FG001|Overall Study|Death|0
6042970|NCT00386009|9641453|FG000|Overall Study|Entry Criteria Not Met|0
6042971|NCT00386009|9641454|FG001|Overall Study|Entry Criteria Not Met|2
6042972|NCT00386009|9641453|FG000|Overall Study|Lost to Follow-up|1
6042973|NCT00386009|9641454|FG001|Overall Study|Lost to Follow-up|1
6042974|NCT00386009|9641453|FG000|Overall Study|Protocol Violation|1
6042975|NCT00386009|9641454|FG001|Overall Study|Protocol Violation|0
6042976|NCT00386009|9641453|FG000|Overall Study|Sponsor Decision|1
6340958|NCT03285295|10096161|FG000|Alinity s HIV Ag/Ab Combo|Protocol Violation|11
6340959|NCT03285295|10096162|FG001|Alinity s HIV Ag/Ab Combo|Protocol Violation|0
6340960|NCT03285295|10096163|FG002|Alinity s HIV Ag/Ab Combo|Protocol Violation|0
6340961|NCT03285295|10096164|FG003|Alinity s HIV Ag/Ab Combo|Protocol Violation|0
6340962|NCT03285295|10096165|FG004|Alinity s HIV Ag/Ab Combo|Protocol Violation|0
6340963|NCT03285295|10096161|FG000|Alinity s HIV Ag/Ab Combo|No Results on Comparator Assay|16
6340964|NCT03285295|10096162|FG001|Alinity s HIV Ag/Ab Combo|No Results on Comparator Assay|0
6340965|NCT03285295|10096163|FG002|Alinity s HIV Ag/Ab Combo|No Results on Comparator Assay|0
6340966|NCT03285295|10096164|FG003|Alinity s HIV Ag/Ab Combo|No Results on Comparator Assay|0
6340967|NCT03285295|10096165|FG004|Alinity s HIV Ag/Ab Combo|No Results on Comparator Assay|0
6340968|NCT03285295|10096161|FG000|Alinity s HIV Ag/Ab Combo|No Results Generated|72
6340969|NCT03285295|10096162|FG001|Alinity s HIV Ag/Ab Combo|No Results Generated|0
6340970|NCT03285295|10096163|FG002|Alinity s HIV Ag/Ab Combo|No Results Generated|0
6340971|NCT03285295|10096164|FG003|Alinity s HIV Ag/Ab Combo|No Results Generated|0
6340972|NCT03285295|10096165|FG004|Alinity s HIV Ag/Ab Combo|No Results Generated|0
6340973|NCT03285295|10096161|FG000|Alinity s HIV Ag/Ab Combo Follow-Up|Lost to Follow-up|11
6340974|NCT03285295|10096162|FG001|Alinity s HIV Ag/Ab Combo Follow-Up|Lost to Follow-up|0
6340975|NCT03285295|10096163|FG002|Alinity s HIV Ag/Ab Combo Follow-Up|Lost to Follow-up|0
6340976|NCT03285295|10096164|FG003|Alinity s HIV Ag/Ab Combo Follow-Up|Lost to Follow-up|0
6340977|NCT03285295|10096165|FG004|Alinity s HIV Ag/Ab Combo Follow-Up|Lost to Follow-up|0
6340978|NCT03285295|10096161|FG000|Alinity s Anti-HBc|Protocol Violation|8
6340979|NCT03285295|10096162|FG001|Alinity s Anti-HBc|Protocol Violation|0
6340980|NCT03285295|10096163|FG002|Alinity s Anti-HBc|Protocol Violation|0
6340981|NCT03285295|10096164|FG003|Alinity s Anti-HBc|Protocol Violation|0
6340982|NCT03285295|10096165|FG004|Alinity s Anti-HBc|Protocol Violation|0
6340983|NCT03285295|10096161|FG000|Alinity s Anti-HBc|No Results on Comparator Assay|13
6340984|NCT03285295|10096162|FG001|Alinity s Anti-HBc|No Results on Comparator Assay|1
6340985|NCT03285295|10096163|FG002|Alinity s Anti-HBc|No Results on Comparator Assay|0
6340986|NCT03285295|10096164|FG003|Alinity s Anti-HBc|No Results on Comparator Assay|0
6340987|NCT03285295|10096165|FG004|Alinity s Anti-HBc|No Results on Comparator Assay|0
6340988|NCT03285295|10096161|FG000|Alinity s Anti-HBc|No Results Generated|70
6340989|NCT03285295|10096162|FG001|Alinity s Anti-HBc|No Results Generated|0
6340990|NCT03285295|10096163|FG002|Alinity s Anti-HBc|No Results Generated|0
6340991|NCT03285295|10096164|FG003|Alinity s Anti-HBc|No Results Generated|0
6340992|NCT03285295|10096165|FG004|Alinity s Anti-HBc|No Results Generated|0
6340993|NCT03285295|10096161|FG000|Alinity s Anti-HBc Follow-Up|Lost to Follow-up|14
6340994|NCT03285295|10096162|FG001|Alinity s Anti-HBc Follow-Up|Lost to Follow-up|0
6340995|NCT03285295|10096163|FG002|Alinity s Anti-HBc Follow-Up|Lost to Follow-up|0
6340996|NCT03285295|10096164|FG003|Alinity s Anti-HBc Follow-Up|Lost to Follow-up|0
6340997|NCT03285295|10096165|FG004|Alinity s Anti-HBc Follow-Up|Lost to Follow-up|0
6340998|NCT03285295|10096161|FG000|Alinity s Chagas|Protocol Violation|76
6340999|NCT03285295|10096162|FG001|Alinity s Chagas|Protocol Violation|0
6341000|NCT03285295|10096163|FG002|Alinity s Chagas|Protocol Violation|0
6341001|NCT03285295|10096164|FG003|Alinity s Chagas|Protocol Violation|0
6341002|NCT03285295|10096165|FG004|Alinity s Chagas|Protocol Violation|0
6341003|NCT03285295|10096161|FG000|Alinity s Chagas|No Results on Comparator Assay|38
6341004|NCT03285295|10096162|FG001|Alinity s Chagas|No Results on Comparator Assay|0
6341005|NCT03285295|10096163|FG002|Alinity s Chagas|No Results on Comparator Assay|0
6341006|NCT03285295|10096164|FG003|Alinity s Chagas|No Results on Comparator Assay|0
6341007|NCT03285295|10096165|FG004|Alinity s Chagas|No Results on Comparator Assay|0
6341008|NCT03285295|10096161|FG000|Alinity s Chagas|No Results Generated|105
6341009|NCT03285295|10096162|FG001|Alinity s Chagas|No Results Generated|0
6341010|NCT03285295|10096163|FG002|Alinity s Chagas|No Results Generated|0
6341011|NCT03285295|10096164|FG003|Alinity s Chagas|No Results Generated|0
6341012|NCT03285295|10096165|FG004|Alinity s Chagas|No Results Generated|0
6341013|NCT03285295|10096161|FG000|Alinity s Chagas Follow-Up|Lost to Follow-up|13
6341014|NCT03285295|10096162|FG001|Alinity s Chagas Follow-Up|Lost to Follow-up|0
6341015|NCT03285295|10096163|FG002|Alinity s Chagas Follow-Up|Lost to Follow-up|0
6341016|NCT03285295|10096164|FG003|Alinity s Chagas Follow-Up|Lost to Follow-up|0
6341017|NCT03285295|10096165|FG004|Alinity s Chagas Follow-Up|Lost to Follow-up|0
6341018|NCT03285308|10096196|FG000|Overall Study|Adverse Event|3
6341019|NCT03285308|10096197|FG001|Overall Study|Adverse Event|7
6341020|NCT03285308|10096196|FG000|Overall Study|Withdrawal by Subject|8
6341021|NCT03285308|10096197|FG001|Overall Study|Withdrawal by Subject|9
6341022|NCT03285308|10096196|FG000|Overall Study|Lost to Follow-up|3
6341023|NCT03285308|10096197|FG001|Overall Study|Lost to Follow-up|1
6341024|NCT03285308|10096196|FG000|Overall Study|Protocol Deviation|6
6341025|NCT03285308|10096197|FG001|Overall Study|Protocol Deviation|5
6341026|NCT03285308|10096196|FG000|Overall Study|Reason not Specified|0
6341027|NCT03285308|10096197|FG001|Overall Study|Reason not Specified|1
6083298|NCT00634907|9691694|FG001|Overall Study|Physician Decision|9
6083299|NCT00634907|9691693|FG000|Overall Study|Withdrawal by Subject|11
6083300|NCT00634907|9691694|FG001|Overall Study|Withdrawal by Subject|8
6083301|NCT00634920|9691703|FG000|Period 1 - Pre-Randomization|Adverse Event|0
6083302|NCT00634920|9691704|FG001|Period 1 - Pre-Randomization|Adverse Event|0
6083303|NCT00634920|9691705|FG002|Period 1 - Pre-Randomization|Adverse Event|36
6083304|NCT00634920|9691703|FG000|Period 1 - Pre-Randomization|Wound healing problems|0
6083305|NCT00634920|9691704|FG001|Period 1 - Pre-Randomization|Wound healing problems|0
6083306|NCT00634920|9691705|FG002|Period 1 - Pre-Randomization|Wound healing problems|16
6341028|NCT03285477|10096218|FG000|Treatment and Response Assessment Period|Death|1
6341029|NCT03285477|10096219|FG001|Treatment and Response Assessment Period|Death|0
6341030|NCT03285477|10096218|FG000|Treatment and Response Assessment Period|Withdrawn of Consent|1
6341031|NCT03285477|10096219|FG001|Treatment and Response Assessment Period|Withdrawn of Consent|0
6341032|NCT03285477|10096218|FG000|Recurrence Follow-up Period|Lost to Follow-up|0
6341033|NCT03285477|10096219|FG001|Recurrence Follow-up Period|Lost to Follow-up|1
6341034|NCT03285477|10096218|FG000|Recurrence Follow-up Period|Withdrawal of consent|1
6341035|NCT03285477|10096219|FG001|Recurrence Follow-up Period|Withdrawal of consent|3
6341036|NCT03285477|10096218|FG000|Recurrence Follow-up Period|AK recurrence during the Recurrence Follow-Up Period|5
6341037|NCT03285477|10096219|FG001|Recurrence Follow-up Period|AK recurrence during the Recurrence Follow-Up Period|51
6341038|NCT03285490|10096228|FG000|Recurrence Follow-up Period|Withdrawal by Subject|0
6341039|NCT03285490|10096229|FG001|Recurrence Follow-up Period|Withdrawal by Subject|1
6341040|NCT03285490|10096228|FG000|Recurrence Follow-up Period|AK recurrence during Recurrence Follow-Up Period|18
6341041|NCT03285490|10096229|FG001|Recurrence Follow-up Period|AK recurrence during Recurrence Follow-Up Period|60
6341042|NCT03285594|10096266|FG000|Overall Study|At the Participant's Own Request|10
6341043|NCT03285594|10096267|FG001|Overall Study|At the Participant's Own Request|5
6341044|NCT03285594|10096268|FG002|Overall Study|At the Participant's Own Request|21
6341045|NCT03285594|10096266|FG000|Overall Study|Adverse Event|2
6341046|NCT03285594|10096267|FG001|Overall Study|Adverse Event|2
6341047|NCT03285594|10096268|FG002|Overall Study|Adverse Event|6
6341048|NCT03285594|10096266|FG000|Overall Study|Poor Compliance to Protocol|0
6341049|NCT03285594|10096267|FG001|Overall Study|Poor Compliance to Protocol|0
6341050|NCT03285594|10096268|FG002|Overall Study|Poor Compliance to Protocol|1
6341051|NCT03285594|10096266|FG000|Overall Study|Lost to Follow-up|0
6341052|NCT03285594|10096267|FG001|Overall Study|Lost to Follow-up|0
6341053|NCT03285594|10096268|FG002|Overall Study|Lost to Follow-up|1
6341054|NCT03285594|10096266|FG000|Overall Study|Reason Not Specified|3
6341055|NCT03285594|10096267|FG001|Overall Study|Reason Not Specified|4
6341056|NCT03285594|10096268|FG002|Overall Study|Reason Not Specified|8
6341057|NCT03285646|10096279|FG000|Overall Study|Adverse Event|1
6341058|NCT03285646|10096280|FG001|Overall Study|Adverse Event|0
6341059|NCT03285646|10096279|FG000|Overall Study|Withdrawal by Subject|10
6341060|NCT03285646|10096280|FG001|Overall Study|Withdrawal by Subject|2
6341061|NCT03285646|10096279|FG000|Overall Study|Lost to Follow-up|2
6341062|NCT03285646|10096280|FG001|Overall Study|Lost to Follow-up|1
6341063|NCT03285646|10096279|FG000|Overall Study|Investigator/Sponsor Decision|0
6341064|NCT03285646|10096280|FG001|Overall Study|Investigator/Sponsor Decision|1
6341065|NCT03285711|10096289|FG000|Blinded Phase (Up to Week 16)|Adverse Event|2
6341066|NCT03285711|10096290|FG001|Blinded Phase (Up to Week 16)|Adverse Event|1
6341067|NCT03285711|10096291|FG002|Blinded Phase (Up to Week 16)|Adverse Event|0
6341068|NCT03285711|10096292|FG003|Blinded Phase (Up to Week 16)|Adverse Event|0
6341069|NCT03285711|10096289|FG000|Blinded Phase (Up to Week 16)|Protocol Violation|1
6341070|NCT03285711|10096290|FG001|Blinded Phase (Up to Week 16)|Protocol Violation|0
6341071|NCT03285711|10096291|FG002|Blinded Phase (Up to Week 16)|Protocol Violation|0
6341072|NCT03285711|10096292|FG003|Blinded Phase (Up to Week 16)|Protocol Violation|0
6341073|NCT03285711|10096289|FG000|Blinded Phase (Week 16 to 32)|Lack of Efficacy|0
6341074|NCT03285711|10096290|FG001|Blinded Phase (Week 16 to 32)|Lack of Efficacy|0
6341075|NCT03285711|10096291|FG002|Blinded Phase (Week 16 to 32)|Lack of Efficacy|1
6341076|NCT03285711|10096292|FG003|Blinded Phase (Week 16 to 32)|Lack of Efficacy|0
6341077|NCT03285711|10096289|FG000|Extended Blinded Phase (Week 32 to 52)|Lack of Efficacy|0
6341078|NCT03285711|10096290|FG001|Extended Blinded Phase (Week 32 to 52)|Lack of Efficacy|1
6341079|NCT03285711|10096291|FG002|Extended Blinded Phase (Week 32 to 52)|Lack of Efficacy|0
6341080|NCT03285711|10096292|FG003|Extended Blinded Phase (Week 32 to 52)|Lack of Efficacy|0
6341081|NCT03285958|10096308|FG000|Overall Study|Lost to Follow-up|1
6341082|NCT03285958|10096309|FG001|Overall Study|Lost to Follow-up|1
6341083|NCT03285958|10096308|FG000|Overall Study|Withdrawal by Subject|1
6341084|NCT03285958|10096309|FG001|Overall Study|Withdrawal by Subject|0
6341085|NCT03285958|10096308|FG000|Overall Study|Not able to attend required orientation|3
6341086|NCT03285958|10096309|FG001|Overall Study|Not able to attend required orientation|0
6341087|NCT03286218|10096328|FG000|Qualification Phase Period 1|Adverse Event|1
6341088|NCT03286218|10096329|FG001|Qualification Phase Period 1|Adverse Event|0
6341089|NCT03286218|10096330|FG002|Qualification Phase Period 1|Adverse Event|0
6341090|NCT03286218|10096331|FG003|Qualification Phase Period 1|Adverse Event|0
6341091|NCT03286218|10096332|FG004|Qualification Phase Period 1|Adverse Event|0
6341092|NCT03286218|10096333|FG005|Qualification Phase Period 1|Adverse Event|0
6341093|NCT03286218|10096334|FG006|Qualification Phase Period 1|Adverse Event|0
6341094|NCT03286218|10096335|FG007|Qualification Phase Period 1|Adverse Event|0
6341095|NCT03286218|10096336|FG008|Qualification Phase Period 1|Adverse Event|0
6341096|NCT03286218|10096337|FG009|Qualification Phase Period 1|Adverse Event|0
6341097|NCT03286218|10096338|FG010|Qualification Phase Period 1|Adverse Event|0
6341098|NCT03286218|10096339|FG011|Qualification Phase Period 1|Adverse Event|0
6341099|NCT03286218|10096328|FG000|Qualification Phase Period 1|Withdrawal by Subject|0
6341100|NCT03286218|10096329|FG001|Qualification Phase Period 1|Withdrawal by Subject|1
6341101|NCT03286218|10096330|FG002|Qualification Phase Period 1|Withdrawal by Subject|0
6341102|NCT03286218|10096331|FG003|Qualification Phase Period 1|Withdrawal by Subject|0
6341103|NCT03286218|10096332|FG004|Qualification Phase Period 1|Withdrawal by Subject|0
6341104|NCT03286218|10096333|FG005|Qualification Phase Period 1|Withdrawal by Subject|0
6341105|NCT03286218|10096334|FG006|Qualification Phase Period 1|Withdrawal by Subject|0
6341106|NCT03286218|10096335|FG007|Qualification Phase Period 1|Withdrawal by Subject|0
6341107|NCT03286218|10096336|FG008|Qualification Phase Period 1|Withdrawal by Subject|0
6341108|NCT03286218|10096337|FG009|Qualification Phase Period 1|Withdrawal by Subject|0
6341109|NCT03286218|10096338|FG010|Qualification Phase Period 1|Withdrawal by Subject|0
6341110|NCT03286218|10096339|FG011|Qualification Phase Period 1|Withdrawal by Subject|0
6341111|NCT03286218|10096328|FG000|Qualification Phase Period 2|Adverse Event|0
6341112|NCT03286218|10096329|FG001|Qualification Phase Period 2|Adverse Event|1
6341113|NCT03286218|10096330|FG002|Qualification Phase Period 2|Adverse Event|0
6341114|NCT03286218|10096331|FG003|Qualification Phase Period 2|Adverse Event|0
6341115|NCT03286218|10096332|FG004|Qualification Phase Period 2|Adverse Event|0
6341116|NCT03286218|10096333|FG005|Qualification Phase Period 2|Adverse Event|0
6341117|NCT03286218|10096334|FG006|Qualification Phase Period 2|Adverse Event|0
6341118|NCT03286218|10096335|FG007|Qualification Phase Period 2|Adverse Event|0
6341119|NCT03286218|10096336|FG008|Qualification Phase Period 2|Adverse Event|0
6341120|NCT03286218|10096337|FG009|Qualification Phase Period 2|Adverse Event|0
6341121|NCT03286218|10096338|FG010|Qualification Phase Period 2|Adverse Event|0
6341122|NCT03286218|10096339|FG011|Qualification Phase Period 2|Adverse Event|0
6341123|NCT03286218|10096328|FG000|Qualification Phase Period 2|Failure to meet randomization criteria|14
6341124|NCT03286218|10096329|FG001|Qualification Phase Period 2|Failure to meet randomization criteria|15
6341125|NCT03286218|10096330|FG002|Qualification Phase Period 2|Failure to meet randomization criteria|0
6341126|NCT03286218|10096331|FG003|Qualification Phase Period 2|Failure to meet randomization criteria|0
6341127|NCT03286218|10096332|FG004|Qualification Phase Period 2|Failure to meet randomization criteria|0
6341128|NCT03286218|10096333|FG005|Qualification Phase Period 2|Failure to meet randomization criteria|0
6341129|NCT03286218|10096334|FG006|Qualification Phase Period 2|Failure to meet randomization criteria|0
6341130|NCT03286218|10096335|FG007|Qualification Phase Period 2|Failure to meet randomization criteria|0
6341131|NCT03286218|10096336|FG008|Qualification Phase Period 2|Failure to meet randomization criteria|0
6341132|NCT03286218|10096337|FG009|Qualification Phase Period 2|Failure to meet randomization criteria|0
6341133|NCT03286218|10096338|FG010|Qualification Phase Period 2|Failure to meet randomization criteria|0
6341134|NCT03286218|10096339|FG011|Qualification Phase Period 2|Failure to meet randomization criteria|0
6341135|NCT03286218|10096328|FG000|Qualification Phase Period 2|Lost to Follow-up|0
6341136|NCT03286218|10096329|FG001|Qualification Phase Period 2|Lost to Follow-up|1
6341137|NCT03286218|10096330|FG002|Qualification Phase Period 2|Lost to Follow-up|0
6341138|NCT03286218|10096331|FG003|Qualification Phase Period 2|Lost to Follow-up|0
6341139|NCT03286218|10096332|FG004|Qualification Phase Period 2|Lost to Follow-up|0
6341140|NCT03286218|10096333|FG005|Qualification Phase Period 2|Lost to Follow-up|0
6341141|NCT03286218|10096334|FG006|Qualification Phase Period 2|Lost to Follow-up|0
6341142|NCT03286218|10096335|FG007|Qualification Phase Period 2|Lost to Follow-up|0
6341143|NCT03286218|10096336|FG008|Qualification Phase Period 2|Lost to Follow-up|0
6341144|NCT03286218|10096337|FG009|Qualification Phase Period 2|Lost to Follow-up|0
6341145|NCT03286218|10096338|FG010|Qualification Phase Period 2|Lost to Follow-up|0
6341146|NCT03286218|10096339|FG011|Qualification Phase Period 2|Lost to Follow-up|0
6341147|NCT03286218|10096328|FG000|Qualification Phase Period 2|Protocol Violation|2
6341148|NCT03286218|10096329|FG001|Qualification Phase Period 2|Protocol Violation|0
6341149|NCT03286218|10096330|FG002|Qualification Phase Period 2|Protocol Violation|0
6341150|NCT03286218|10096331|FG003|Qualification Phase Period 2|Protocol Violation|0
6341151|NCT03286218|10096332|FG004|Qualification Phase Period 2|Protocol Violation|0
6341152|NCT03286218|10096333|FG005|Qualification Phase Period 2|Protocol Violation|0
6341153|NCT03286218|10096334|FG006|Qualification Phase Period 2|Protocol Violation|0
6341154|NCT03286218|10096335|FG007|Qualification Phase Period 2|Protocol Violation|0
6341155|NCT03286218|10096336|FG008|Qualification Phase Period 2|Protocol Violation|0
6341156|NCT03286218|10096337|FG009|Qualification Phase Period 2|Protocol Violation|0
6341157|NCT03286218|10096338|FG010|Qualification Phase Period 2|Protocol Violation|0
6341158|NCT03286218|10096339|FG011|Qualification Phase Period 2|Protocol Violation|0
6341159|NCT03286218|10096328|FG000|Qualification Phase Period 2|Withdrawal by Subject|1
6341160|NCT03286218|10096329|FG001|Qualification Phase Period 2|Withdrawal by Subject|2
6341161|NCT03286218|10096330|FG002|Qualification Phase Period 2|Withdrawal by Subject|0
6341162|NCT03286218|10096331|FG003|Qualification Phase Period 2|Withdrawal by Subject|0
6341163|NCT03286218|10096332|FG004|Qualification Phase Period 2|Withdrawal by Subject|0
6341164|NCT03286218|10096333|FG005|Qualification Phase Period 2|Withdrawal by Subject|0
6341165|NCT03286218|10096334|FG006|Qualification Phase Period 2|Withdrawal by Subject|0
6341166|NCT03286218|10096335|FG007|Qualification Phase Period 2|Withdrawal by Subject|0
6341167|NCT03286218|10096336|FG008|Qualification Phase Period 2|Withdrawal by Subject|0
6341168|NCT03286218|10096337|FG009|Qualification Phase Period 2|Withdrawal by Subject|0
6341169|NCT03286218|10096338|FG010|Qualification Phase Period 2|Withdrawal by Subject|0
6341170|NCT03286218|10096339|FG011|Qualification Phase Period 2|Withdrawal by Subject|0
6341171|NCT03286218|10096328|FG000|Treatment Phase Period 1|Withdrawal by Subject|0
5972107|NCT00950989|9557709|FG000|Overall Study|Adverse Event|2
5972108|NCT00950989|9557710|FG001|Overall Study|Adverse Event|1
5972109|NCT00950989|9557711|FG002|Overall Study|Adverse Event|1
6341172|NCT03286218|10096329|FG001|Treatment Phase Period 1|Withdrawal by Subject|0
6341173|NCT03286218|10096330|FG002|Treatment Phase Period 1|Withdrawal by Subject|1
6341174|NCT03286218|10096331|FG003|Treatment Phase Period 1|Withdrawal by Subject|1
6341175|NCT03286218|10096332|FG004|Treatment Phase Period 1|Withdrawal by Subject|0
6341176|NCT03286218|10096333|FG005|Treatment Phase Period 1|Withdrawal by Subject|1
6341177|NCT03286218|10096334|FG006|Treatment Phase Period 1|Withdrawal by Subject|0
6341178|NCT03286218|10096335|FG007|Treatment Phase Period 1|Withdrawal by Subject|0
6341179|NCT03286218|10096336|FG008|Treatment Phase Period 1|Withdrawal by Subject|0
6341180|NCT03286218|10096337|FG009|Treatment Phase Period 1|Withdrawal by Subject|0
6341181|NCT03286218|10096338|FG010|Treatment Phase Period 1|Withdrawal by Subject|0
6341182|NCT03286218|10096339|FG011|Treatment Phase Period 1|Withdrawal by Subject|1
6341183|NCT03286218|10096328|FG000|Treatment Phase Period 4|Withdrawal by Subject|0
6341184|NCT03286218|10096329|FG001|Treatment Phase Period 4|Withdrawal by Subject|0
6341185|NCT03286218|10096330|FG002|Treatment Phase Period 4|Withdrawal by Subject|0
6341186|NCT03286218|10096331|FG003|Treatment Phase Period 4|Withdrawal by Subject|0
6341187|NCT03286218|10096332|FG004|Treatment Phase Period 4|Withdrawal by Subject|0
6341188|NCT03286218|10096333|FG005|Treatment Phase Period 4|Withdrawal by Subject|0
6341189|NCT03286218|10096334|FG006|Treatment Phase Period 4|Withdrawal by Subject|0
6341190|NCT03286218|10096335|FG007|Treatment Phase Period 4|Withdrawal by Subject|0
6341191|NCT03286218|10096336|FG008|Treatment Phase Period 4|Withdrawal by Subject|0
6341192|NCT03286218|10096337|FG009|Treatment Phase Period 4|Withdrawal by Subject|0
6341193|NCT03286218|10096338|FG010|Treatment Phase Period 4|Withdrawal by Subject|0
6341194|NCT03286218|10096339|FG011|Treatment Phase Period 4|Withdrawal by Subject|1
6341195|NCT03286400|10096370|FG000|Overall Study|Death|10
6341196|NCT03286400|10096370|FG000|Overall Study|Lost to Follow-up|10
6341197|NCT03286400|10096370|FG000|Overall Study|Physician Decision|1
6341198|NCT03286400|10096370|FG000|Overall Study|Scheduling difficulty|4
6341199|NCT03286543|10096385|FG000|Consented|Screen failure before randomization|2
6083307|NCT00634920|9691703|FG000|Period 1 - Pre-Randomization|Rejections|0
6083308|NCT00634920|9691704|FG001|Period 1 - Pre-Randomization|Rejections|0
6083309|NCT00634920|9691705|FG002|Period 1 - Pre-Randomization|Rejections|55
6341200|NCT03286543|10096386|FG001|Consented|Screen failure before randomization|0
6341201|NCT03286543|10096387|FG002|Consented|Screen failure before randomization|0
6341202|NCT03286543|10096385|FG000|Consented|Screen failure before enrollment|4
6341203|NCT03286543|10096386|FG001|Consented|Screen failure before enrollment|0
6341204|NCT03286543|10096387|FG002|Consented|Screen failure before enrollment|0
6341205|NCT03286543|10096385|FG000|Consented|TKA cancelled after enrollment|1
6341206|NCT03286543|10096386|FG001|Consented|TKA cancelled after enrollment|0
6341207|NCT03286543|10096387|FG002|Consented|TKA cancelled after enrollment|0
6341208|NCT03286543|10096385|FG000|Consented|Withdrawn from study|12
6341209|NCT03286543|10096386|FG001|Consented|Withdrawn from study|0
6341210|NCT03286543|10096387|FG002|Consented|Withdrawn from study|0
6341211|NCT03286543|10096385|FG000|Study Enrollment|TKA cancelled after enrollment|0
6341212|NCT03286543|10096386|FG001|Study Enrollment|TKA cancelled after enrollment|0
6341213|NCT03286543|10096387|FG002|Study Enrollment|TKA cancelled after enrollment|1
6341214|NCT03286543|10096385|FG000|Study Enrollment|Withdrawn from study|0
6341215|NCT03286543|10096386|FG001|Study Enrollment|Withdrawn from study|6
6341216|NCT03286543|10096387|FG002|Study Enrollment|Withdrawn from study|6
6341217|NCT03286751|10096393|FG000|Washout Period 1|Withdrawal by Subject|0
6341218|NCT03286751|10096394|FG001|Washout Period 1|Withdrawal by Subject|0
6341219|NCT03286751|10096395|FG002|Washout Period 1|Withdrawal by Subject|0
6341220|NCT03286751|10096396|FG003|Washout Period 1|Withdrawal by Subject|0
6341221|NCT03286751|10096397|FG004|Washout Period 1|Withdrawal by Subject|1
6341222|NCT03286751|10096398|FG005|Washout Period 1|Withdrawal by Subject|0
6341223|NCT03286751|10096393|FG000|Washout Period 2|Personal Reasons|0
6341224|NCT03286751|10096394|FG001|Washout Period 2|Personal Reasons|1
6341225|NCT03286751|10096395|FG002|Washout Period 2|Personal Reasons|0
6341226|NCT03286751|10096396|FG003|Washout Period 2|Personal Reasons|0
6341227|NCT03286751|10096397|FG004|Washout Period 2|Personal Reasons|0
6341228|NCT03286751|10096398|FG005|Washout Period 2|Personal Reasons|0
6341229|NCT03286751|10096393|FG000|Washout Period 5|Adverse Event|0
6341230|NCT03286751|10096394|FG001|Washout Period 5|Adverse Event|0
6341231|NCT03286751|10096395|FG002|Washout Period 5|Adverse Event|0
6083310|NCT00634920|9691703|FG000|Period 1 - Pre-Randomization|Withdrawal by Subject|0
6341232|NCT03286751|10096396|FG003|Washout Period 5|Adverse Event|0
6341233|NCT03286751|10096397|FG004|Washout Period 5|Adverse Event|1
6341234|NCT03286751|10096398|FG005|Washout Period 5|Adverse Event|0
6341235|NCT03287219|10096433|FG000|Overall Study|Protocol Violation|0
6341236|NCT03287219|10096434|FG001|Overall Study|Protocol Violation|2
6341237|NCT03287622|10096508|FG000|Overall Study|Withdrawal by Subject|1
6341238|NCT03287622|10096509|FG001|Overall Study|Withdrawal by Subject|0
6341239|NCT03287622|10096508|FG000|Overall Study|Lost to Follow-up|27
6341240|NCT03287622|10096509|FG001|Overall Study|Lost to Follow-up|15
6341241|NCT03287622|10096508|FG000|Overall Study|No prescripion after surgery|28
6341242|NCT03287622|10096509|FG001|Overall Study|No prescripion after surgery|31
6341243|NCT03287622|10096508|FG000|Overall Study|prolonged Length of stay|2
6341244|NCT03287622|10096509|FG001|Overall Study|prolonged Length of stay|0
6341245|NCT03287622|10096508|FG000|Overall Study|surgery related|0
6341246|NCT03287622|10096509|FG001|Overall Study|surgery related|2
6341247|NCT03287635|10096522|FG000|Overall Study|Lost to Follow-up|5
6341248|NCT03287635|10096522|FG000|Overall Study|Withdrawal by Subject|1
6341249|NCT03287635|10096522|FG000|Overall Study|Physician Decision|1
6341250|NCT03287791|10096534|FG000|Overall Study|Insufficient Therapeutic Response|0
6341251|NCT03287791|10096535|FG001|Overall Study|Insufficient Therapeutic Response|0
6341252|NCT03287791|10096536|FG002|Overall Study|Insufficient Therapeutic Response|1
6341253|NCT03287791|10096534|FG000|Overall Study|Adverse Event|0
6341254|NCT03287791|10096535|FG001|Overall Study|Adverse Event|4
6341255|NCT03287791|10096536|FG002|Overall Study|Adverse Event|3
6341256|NCT03287791|10096534|FG000|Overall Study|Withdrawal by Subject|12
6341257|NCT03287791|10096535|FG001|Overall Study|Withdrawal by Subject|12
6341258|NCT03287791|10096536|FG002|Overall Study|Withdrawal by Subject|17
6341259|NCT03287791|10096534|FG000|Overall Study|Missed more than 6 consecutive doses|3
6341260|NCT03287791|10096535|FG001|Overall Study|Missed more than 6 consecutive doses|2
6341261|NCT03287791|10096536|FG002|Overall Study|Missed more than 6 consecutive doses|2
6341262|NCT03287791|10096534|FG000|Overall Study|Lost to Follow-up|8
6341263|NCT03287791|10096535|FG001|Overall Study|Lost to Follow-up|14
6341264|NCT03287791|10096536|FG002|Overall Study|Lost to Follow-up|11
6341265|NCT03287791|10096534|FG000|Overall Study|Protocol Violation|7
6341266|NCT03287791|10096535|FG001|Overall Study|Protocol Violation|2
6341267|NCT03287791|10096536|FG002|Overall Study|Protocol Violation|1
6341268|NCT03287791|10096534|FG000|Overall Study|Participant was enrolled at 2 sites|1
6341269|NCT03287791|10096535|FG001|Overall Study|Participant was enrolled at 2 sites|0
6341270|NCT03287791|10096536|FG002|Overall Study|Participant was enrolled at 2 sites|1
6341271|NCT03287791|10096534|FG000|Overall Study|Too much time between 2 visits|0
6341272|NCT03287791|10096535|FG001|Overall Study|Too much time between 2 visits|1
6341273|NCT03287791|10096536|FG002|Overall Study|Too much time between 2 visits|0
6341274|NCT03287791|10096534|FG000|Overall Study|Non-compliance|0
6341275|NCT03287791|10096535|FG001|Overall Study|Non-compliance|1
6341276|NCT03287791|10096536|FG002|Overall Study|Non-compliance|0
6341277|NCT03287791|10096534|FG000|Overall Study|Did not meet inclusion criteria|1
6341278|NCT03287791|10096535|FG001|Overall Study|Did not meet inclusion criteria|0
6341279|NCT03287791|10096536|FG002|Overall Study|Did not meet inclusion criteria|0
6341280|NCT03287804|10096544|FG000|Overall Study|Death|1
6341281|NCT03287804|10096544|FG000|Overall Study|Physician Decision|2
6341282|NCT03287804|10096544|FG000|Overall Study|Progressive disease|8
6341283|NCT03287869|10096551|FG000|Overall Study|Adverse Event|14
6341284|NCT03287869|10096552|FG001|Overall Study|Adverse Event|12
6341285|NCT03287869|10096551|FG000|Overall Study|Lack of Efficacy|1
6341286|NCT03287869|10096552|FG001|Overall Study|Lack of Efficacy|0
6341287|NCT03287869|10096551|FG000|Overall Study|Lost to Follow-up|13
6341288|NCT03287869|10096552|FG001|Overall Study|Lost to Follow-up|19
6341289|NCT03287869|10096551|FG000|Overall Study|Non-Compliance With Study Drug|5
6341290|NCT03287869|10096552|FG001|Overall Study|Non-Compliance With Study Drug|9
6341291|NCT03287869|10096551|FG000|Overall Study|Progressive Disease|1
6341292|NCT03287869|10096552|FG001|Overall Study|Progressive Disease|0
6341293|NCT03287869|10096551|FG000|Overall Study|Protocol Deviation|2
6341294|NCT03287869|10096552|FG001|Overall Study|Protocol Deviation|1
6341295|NCT03287869|10096551|FG000|Overall Study|Withdrawal by Subject|36
6341296|NCT03287869|10096552|FG001|Overall Study|Withdrawal by Subject|43
6341297|NCT03287869|10096551|FG000|Overall Study|Early Closure of the Site|0
6341298|NCT03287869|10096552|FG001|Overall Study|Early Closure of the Site|1
6341299|NCT03287869|10096551|FG000|Overall Study|Physician Decision|5
6341300|NCT03287869|10096552|FG001|Overall Study|Physician Decision|5
6341301|NCT03287869|10096551|FG000|Overall Study|Reason not Specified|6
6341302|NCT03287869|10096552|FG001|Overall Study|Reason not Specified|3
6341303|NCT03288714|10096560|FG000|Overall Study|Lost to Follow-up|2
6341304|NCT03288714|10096561|FG001|Overall Study|Lost to Follow-up|1
6341305|NCT03288714|10096560|FG000|Overall Study|Non-compliance with study schedule|2
6341306|NCT03288714|10096561|FG001|Overall Study|Non-compliance with study schedule|0
6341307|NCT03288714|10096560|FG000|Overall Study|Withdrawal by Subject|3
6341308|NCT03288714|10096561|FG001|Overall Study|Withdrawal by Subject|1
6341309|NCT03288714|10096560|FG000|Overall Study|Clinical Worsening|2
6341310|NCT03288714|10096561|FG001|Overall Study|Clinical Worsening|1
6341311|NCT03288714|10096560|FG000|Overall Study|Adverse Event|1
6341312|NCT03288714|10096561|FG001|Overall Study|Adverse Event|0
6341313|NCT03288779|10096569|FG000|Overall Study|Withdrawal by Subject|3
6341314|NCT03288987|10096575|FG000|Overall Study|Protocol Violation|10
6341315|NCT03288987|10096576|FG001|Overall Study|Protocol Violation|4
6341316|NCT03289208|10096598|FG000|Overall Study|Adverse Event|1
6341317|NCT03289208|10096599|FG001|Overall Study|Adverse Event|0
6341318|NCT03289208|10096600|FG002|Overall Study|Adverse Event|0
6341319|NCT03289455|10096624|FG000|Overall Study|Death|1
6341320|NCT03289455|10096625|FG001|Overall Study|Death|0
6341321|NCT03289455|10096626|FG002|Overall Study|Death|0
6341322|NCT03289455|10096624|FG000|Overall Study|Sponsor decision due to covid19 restrictions|0
6341323|NCT03289455|10096625|FG001|Overall Study|Sponsor decision due to covid19 restrictions|1
6341324|NCT03289455|10096626|FG002|Overall Study|Sponsor decision due to covid19 restrictions|0
6341325|NCT03289455|10096624|FG000|Overall Study|No CART persistence in MRD negativity. Patient proceeded with HSCT|0
6341326|NCT03289455|10096625|FG001|Overall Study|No CART persistence in MRD negativity. Patient proceeded with HSCT|0
6341327|NCT03289455|10096626|FG002|Overall Study|No CART persistence in MRD negativity. Patient proceeded with HSCT|1
6341328|NCT03289455|10096624|FG000|Overall Study|Progressive disease|3
6341329|NCT03289455|10096625|FG001|Overall Study|Progressive disease|4
6341330|NCT03289455|10096626|FG002|Overall Study|Progressive disease|5
6341331|NCT03289533|10096645|FG000|Overall Study|Death|12
6341332|NCT03289533|10096645|FG000|Overall Study|Terminated from study by sponsor|10
6341333|NCT03289676|10096651|FG000|Overall Study|Withdrawal by Subject|2
6341334|NCT03289676|10096652|FG001|Overall Study|Withdrawal by Subject|0
6341335|NCT03289676|10096651|FG000|Overall Study|Protocol Violation|2
6341336|NCT03289676|10096652|FG001|Overall Study|Protocol Violation|0
6341337|NCT03289676|10096651|FG000|Overall Study|Lost to Follow-up|0
6341338|NCT03289676|10096652|FG001|Overall Study|Lost to Follow-up|1
6341339|NCT03290300|10096676|FG000|Overall Study|Lost to Follow-up|3
6341340|NCT03291288|10096729|FG000|Drug-drug Interaction Phase|Adverse Event|2
6341341|NCT03291288|10096730|FG001|Drug-drug Interaction Phase|Adverse Event|0
6341342|NCT03291288|10096729|FG000|Drug-drug Interaction Phase|Disease progression|1
6341343|NCT03291288|10096730|FG001|Drug-drug Interaction Phase|Disease progression|0
6341344|NCT03291288|10096729|FG000|Drug-drug Interaction Phase|Other|3
6341345|NCT03291288|10096730|FG001|Drug-drug Interaction Phase|Other|0
6341346|NCT03291288|10096729|FG000|Pexidartinib Only|Ongoing|0
6341347|NCT03291288|10096730|FG001|Pexidartinib Only|Ongoing|2
6341348|NCT03292016|10096759|FG000|Second Washout|Adverse Event|0
6341349|NCT03292016|10096760|FG001|Second Washout|Adverse Event|1
6341350|NCT03292016|10096761|FG002|Second Washout|Adverse Event|0
6341351|NCT03292016|10096762|FG003|Second Washout|Adverse Event|0
6341352|NCT03292016|10096763|FG004|Second Washout|Adverse Event|0
6341353|NCT03292016|10096764|FG005|Second Washout|Adverse Event|0
6341354|NCT03292406|10096775|FG000|Overall Study|Progressive Disease|6
6341355|NCT03292406|10096776|FG001|Overall Study|Progressive Disease|3
6341356|NCT03292406|10096777|FG002|Overall Study|Progressive Disease|4
6341357|NCT03292406|10096775|FG000|Overall Study|Adverse Event|7
6341358|NCT03292406|10096776|FG001|Overall Study|Adverse Event|1
6341359|NCT03292406|10096777|FG002|Overall Study|Adverse Event|4
6341360|NCT03292406|10096775|FG000|Overall Study|Withdrawal by Subject|0
6341361|NCT03292406|10096776|FG001|Overall Study|Withdrawal by Subject|7
6341362|NCT03292406|10096777|FG002|Overall Study|Withdrawal by Subject|2
6341363|NCT03292406|10096775|FG000|Overall Study|Protocol Violation|0
6341364|NCT03292406|10096776|FG001|Overall Study|Protocol Violation|1
6341365|NCT03292406|10096777|FG002|Overall Study|Protocol Violation|1
6341366|NCT03292406|10096775|FG000|Overall Study|Other|0
6341367|NCT03292406|10096776|FG001|Overall Study|Other|1
6341368|NCT03292406|10096777|FG002|Overall Study|Other|2
6341369|NCT03292432|10096787|FG000|Overall Study|Lost to Follow-up|11
6341370|NCT03292432|10096788|FG001|Overall Study|Lost to Follow-up|8
6341371|NCT03292432|10096787|FG000|Overall Study|Death|2
6341372|NCT03292432|10096788|FG001|Overall Study|Death|1
6341373|NCT03292432|10096787|FG000|Overall Study|Withdrawal by Subject|1
6341374|NCT03292432|10096788|FG001|Overall Study|Withdrawal by Subject|2
6341375|NCT03292432|10096787|FG000|Overall Study|Site closed before any data collected|1
6341376|NCT03292432|10096788|FG001|Overall Study|Site closed before any data collected|0
6341377|NCT03292640|10096809|FG000|Overall Study|Withdrawal by Subject|17
6341378|NCT03292640|10096810|FG001|Overall Study|Withdrawal by Subject|16
6341379|NCT03292640|10096809|FG000|Overall Study|Adverse Event|20
6341380|NCT03292640|10096810|FG001|Overall Study|Adverse Event|2
6341381|NCT03292640|10096809|FG000|Overall Study|Lost to Follow-up|24
6341382|NCT03292640|10096810|FG001|Overall Study|Lost to Follow-up|24
6341383|NCT03292653|10096823|FG000|Overall Study|Adverse Event|0
6341384|NCT03292653|10096824|FG001|Overall Study|Adverse Event|0
6341385|NCT03292653|10096825|FG002|Overall Study|Adverse Event|1
6341386|NCT03292653|10096823|FG000|Overall Study|Did not Receive Treatment|1
6341387|NCT03292653|10096824|FG001|Overall Study|Did not Receive Treatment|0
6341388|NCT03292653|10096825|FG002|Overall Study|Did not Receive Treatment|0
6341389|NCT03293394|10096884|FG000|Follow-up (6 Months)|Adverse Event|4
6341390|NCT03293394|10096885|FG001|Follow-up (6 Months)|Adverse Event|2
6341391|NCT03293485|10096891|FG000|Overall Study|Death|1
6341392|NCT03293485|10096891|FG000|Overall Study|Screen Failure|2
6341393|NCT03293485|10096891|FG000|Overall Study|Withdrawal by Subject|2
6341394|NCT03293654|10096900|FG000|Overall Study|Lost to Follow-up|0
6341395|NCT03293654|10096901|FG001|Overall Study|Lost to Follow-up|1
6341396|NCT03293654|10096902|FG002|Overall Study|Lost to Follow-up|0
6341397|NCT03294317|10096914|FG000|Overall Study|Physician Decision|1
6341398|NCT03294317|10096914|FG000|Overall Study|Withdrawal by Subject|6
6341399|NCT03294317|10096914|FG000|Overall Study|Lost to Follow-up|1
6341400|NCT03294317|10096914|FG000|Overall Study|Did not meet inclusion/exclusion criteria|1
6341401|NCT03294317|10096914|FG000|Overall Study|Failed HB lead implant|8
6341402|NCT03294317|10096914|FG000|Overall Study|Received CRT instead|1
6341403|NCT03294317|10096914|FG000|Overall Study|Exited after lead revision|2
6341404|NCT03294538|10096921|FG000|Overall Study|Adverse Event|0
6341405|NCT03294538|10096922|FG001|Overall Study|Adverse Event|1
6341406|NCT03294538|10096923|FG002|Overall Study|Adverse Event|1
6341407|NCT03294538|10096921|FG000|Overall Study|Lost to Follow-up|1
6341408|NCT03294538|10096922|FG001|Overall Study|Lost to Follow-up|0
6341409|NCT03294538|10096923|FG002|Overall Study|Lost to Follow-up|0
6341410|NCT03294538|10096921|FG000|Overall Study|Outside of Visit Window|4
6341411|NCT03294538|10096922|FG001|Overall Study|Outside of Visit Window|4
6341412|NCT03294538|10096923|FG002|Overall Study|Outside of Visit Window|1
6341413|NCT03294681|10096940|FG000|Overall Study|Withdrawal by Subject|1
6341414|NCT03294941|10096955|FG000|Overall Study|Withdrawal by Subject|0
6341415|NCT03294941|10096956|FG001|Overall Study|Withdrawal by Subject|2
6341416|NCT03295201|10096965|FG000|Overall Study|Lost to Follow-up|1
6341417|NCT03295201|10096966|FG001|Overall Study|Lost to Follow-up|1
6341418|NCT03295201|10096965|FG000|Overall Study|Hospital admission|0
6341419|NCT03295201|10096966|FG001|Overall Study|Hospital admission|1
6341420|NCT03295318|10096984|FG000|Overall Study|Withdrawal by Subject prior to initial vaccination|1
6341421|NCT03295318|10096985|FG001|Overall Study|Withdrawal by Subject prior to initial vaccination|0
6341422|NCT03295318|10096986|FG002|Overall Study|Withdrawal by Subject prior to initial vaccination|0
6341423|NCT03295318|10096984|FG000|Overall Study|Death|1
6341424|NCT03295318|10096985|FG001|Overall Study|Death|1
6341425|NCT03295318|10096986|FG002|Overall Study|Death|1
6341426|NCT03295318|10096984|FG000|Overall Study|Protocol Violation|4
6341427|NCT03295318|10096985|FG001|Overall Study|Protocol Violation|3
6341428|NCT03295318|10096986|FG002|Overall Study|Protocol Violation|3
6341429|NCT03295318|10096984|FG000|Overall Study|Withdrawal by Subject|0
6341430|NCT03295318|10096985|FG001|Overall Study|Withdrawal by Subject|0
6341431|NCT03295318|10096986|FG002|Overall Study|Withdrawal by Subject|1
6341432|NCT03295318|10096984|FG000|Overall Study|Subject discontinued due to travel|0
6341433|NCT03295318|10096985|FG001|Overall Study|Subject discontinued due to travel|1
6341434|NCT03295318|10096986|FG002|Overall Study|Subject discontinued due to travel|0
6341435|NCT03295721|10097020|FG000|Overall Study|Adverse Event|1
6341436|NCT03295721|10097021|FG001|Overall Study|Adverse Event|0
6341437|NCT03295721|10097022|FG002|Overall Study|Adverse Event|0
6341438|NCT03295721|10097020|FG000|Overall Study|Lost to Follow-up|1
6341439|NCT03295721|10097021|FG001|Overall Study|Lost to Follow-up|1
6341440|NCT03295721|10097022|FG002|Overall Study|Lost to Follow-up|1
6341441|NCT03295721|10097020|FG000|Overall Study|Withdrawal by Subject|1
6341442|NCT03295721|10097021|FG001|Overall Study|Withdrawal by Subject|0
6341443|NCT03295721|10097022|FG002|Overall Study|Withdrawal by Subject|1
6341444|NCT03295721|10097020|FG000|Overall Study|Death|0
6341445|NCT03295721|10097021|FG001|Overall Study|Death|0
6341446|NCT03295721|10097022|FG002|Overall Study|Death|1
6341447|NCT03296527|10097070|FG000|Overall Study|Adverse Event|15
6341448|NCT03296527|10097071|FG001|Overall Study|Adverse Event|33
6341449|NCT03296527|10097070|FG000|Overall Study|Protocol Deviation|4
6341450|NCT03296527|10097071|FG001|Overall Study|Protocol Deviation|0
6341451|NCT03296527|10097070|FG000|Overall Study|Subject withdrew consent|3
6341452|NCT03296527|10097071|FG001|Overall Study|Subject withdrew consent|1
6341453|NCT03296527|10097070|FG000|Overall Study|Discontinuations due to risk of ovarian hyperstimulation syndrome [OHSS]|9
6341454|NCT03296527|10097071|FG001|Overall Study|Discontinuations due to risk of ovarian hyperstimulation syndrome [OHSS]|14
6341455|NCT03296527|10097070|FG000|Overall Study|Discontinuations due to withdrawal from trial|2
6341456|NCT03296527|10097071|FG001|Overall Study|Discontinuations due to withdrawal from trial|3
6341457|NCT03296527|10097070|FG000|Overall Study|Discontinuations due to thin endometrium or poor endometrial receptivity|0
6341458|NCT03296527|10097071|FG001|Overall Study|Discontinuations due to thin endometrium or poor endometrial receptivity|2
6341459|NCT03296527|10097070|FG000|Overall Study|Discontinuation due to liquid in uterus|1
6341460|NCT03296527|10097071|FG001|Overall Study|Discontinuation due to liquid in uterus|0
6341461|NCT03296527|10097070|FG000|Overall Study|Discontinuation due to risk of Human Immunodeficiency Virus|1
6341462|NCT03296527|10097071|FG001|Overall Study|Discontinuation due to risk of Human Immunodeficiency Virus|0
6341463|NCT03296566|10097080|FG000|Overall Study|Lost to Follow-up|19
6341464|NCT03296566|10097081|FG001|Overall Study|Lost to Follow-up|46
6341465|NCT03296566|10097080|FG000|Overall Study|Withdrawal by Subject|0
6341466|NCT03296566|10097081|FG001|Overall Study|Withdrawal by Subject|3
6341467|NCT03297021|10097136|FG000|Overall Study|Incomplete/illegible data sheet|4
6341468|NCT03297021|10097137|FG001|Overall Study|Incomplete/illegible data sheet|2
6341469|NCT03297021|10097138|FG002|Overall Study|Incomplete/illegible data sheet|3
6341470|NCT03297021|10097136|FG000|Overall Study|Missing Post-Op Data|1
6341471|NCT03297021|10097137|FG001|Overall Study|Missing Post-Op Data|2
6341472|NCT03297021|10097138|FG002|Overall Study|Missing Post-Op Data|1
6341473|NCT03297216|10097152|FG000|Overall Study|Death|0
6341474|NCT03297216|10097153|FG001|Overall Study|Death|1
6341475|NCT03297216|10097152|FG000|Overall Study|Miscarriage|0
6341476|NCT03297216|10097153|FG001|Overall Study|Miscarriage|2
6341477|NCT03297216|10097152|FG000|Overall Study|Lost to Follow-up|3
6341478|NCT03297216|10097153|FG001|Overall Study|Lost to Follow-up|2
6341479|NCT03297294|10097168|FG000|Double-Blind Treatment Period (DB)|Study terminated by sponsor|30
6341480|NCT03297294|10097169|FG001|Double-Blind Treatment Period (DB)|Study terminated by sponsor|31
6341481|NCT03297294|10097170|FG002|Double-Blind Treatment Period (DB)|Study terminated by sponsor|0
6341482|NCT03297294|10097171|FG003|Double-Blind Treatment Period (DB)|Study terminated by sponsor|0
6341483|NCT03297294|10097172|FG004|Double-Blind Treatment Period (DB)|Study terminated by sponsor|0
6341484|NCT03297294|10097168|FG000|Double-Blind Treatment Period (DB)|Withdrawal by Subject|4
6341485|NCT03297294|10097169|FG001|Double-Blind Treatment Period (DB)|Withdrawal by Subject|4
6341486|NCT03297294|10097170|FG002|Double-Blind Treatment Period (DB)|Withdrawal by Subject|0
6341487|NCT03297294|10097171|FG003|Double-Blind Treatment Period (DB)|Withdrawal by Subject|0
6341488|NCT03297294|10097172|FG004|Double-Blind Treatment Period (DB)|Withdrawal by Subject|0
6341489|NCT03297294|10097168|FG000|Double-Blind Treatment Period (DB)|Adverse Event|3
6341490|NCT03297294|10097169|FG001|Double-Blind Treatment Period (DB)|Adverse Event|1
6341491|NCT03297294|10097170|FG002|Double-Blind Treatment Period (DB)|Adverse Event|0
6341492|NCT03297294|10097171|FG003|Double-Blind Treatment Period (DB)|Adverse Event|0
6341493|NCT03297294|10097172|FG004|Double-Blind Treatment Period (DB)|Adverse Event|0
6341494|NCT03297294|10097168|FG000|Double-Blind Treatment Period (DB)|Physician Decision|1
6341495|NCT03297294|10097169|FG001|Double-Blind Treatment Period (DB)|Physician Decision|1
6168574|NCT01236352|9813647|FG000|Overall Study|Patient moving to allogeneic transplant|0
6168575|NCT01236352|9813648|FG001|Overall Study|Patient moving to allogeneic transplant|0
6168576|NCT01236352|9813649|FG002|Overall Study|Patient moving to allogeneic transplant|0
6168577|NCT01236352|9813650|FG003|Overall Study|Patient moving to allogeneic transplant|0
6168578|NCT01236352|9813651|FG004|Overall Study|Patient moving to allogeneic transplant|0
6193363|NCT01437540|9851007|FG001|Overall Study|Adverse Event|13
6341496|NCT03297294|10097170|FG002|Double-Blind Treatment Period (DB)|Physician Decision|0
6341497|NCT03297294|10097171|FG003|Double-Blind Treatment Period (DB)|Physician Decision|0
6341498|NCT03297294|10097172|FG004|Double-Blind Treatment Period (DB)|Physician Decision|0
6341499|NCT03297294|10097168|FG000|Treatment Withdrawal Period (TW)|Study terminated by sponsor|0
6341500|NCT03297294|10097169|FG001|Treatment Withdrawal Period (TW)|Study terminated by sponsor|0
6341501|NCT03297294|10097170|FG002|Treatment Withdrawal Period (TW)|Study terminated by sponsor|0
6341502|NCT03297294|10097171|FG003|Treatment Withdrawal Period (TW)|Study terminated by sponsor|1
6341503|NCT03297294|10097172|FG004|Treatment Withdrawal Period (TW)|Study terminated by sponsor|0
6341504|NCT03297398|10097187|FG000|Overall Study|Sponsor's decision|6
6341505|NCT03297398|10097188|FG001|Overall Study|Sponsor's decision|9
6341506|NCT03297398|10097189|FG002|Overall Study|Sponsor's decision|7
6341507|NCT03297398|10097187|FG000|Overall Study|Adverse Event|1
6341508|NCT03297398|10097188|FG001|Overall Study|Adverse Event|4
6341509|NCT03297398|10097189|FG002|Overall Study|Adverse Event|4
6341510|NCT03297398|10097187|FG000|Overall Study|Withdrawal by Subject|1
6341511|NCT03297398|10097188|FG001|Overall Study|Withdrawal by Subject|2
6341512|NCT03297398|10097189|FG002|Overall Study|Withdrawal by Subject|2
6341513|NCT03297398|10097187|FG000|Overall Study|Protocol Violation|0
6341514|NCT03297398|10097188|FG001|Overall Study|Protocol Violation|2
6341515|NCT03297398|10097189|FG002|Overall Study|Protocol Violation|0
6341516|NCT03297398|10097187|FG000|Overall Study|Physician Decision|0
6341517|NCT03297398|10097188|FG001|Overall Study|Physician Decision|0
6341518|NCT03297398|10097189|FG002|Overall Study|Physician Decision|1
6341519|NCT03297398|10097187|FG000|Overall Study|Lost to Follow-up|0
6341520|NCT03297398|10097188|FG001|Overall Study|Lost to Follow-up|0
6341521|NCT03297398|10097189|FG002|Overall Study|Lost to Follow-up|1
6083311|NCT00634920|9691704|FG001|Period 1 - Pre-Randomization|Withdrawal by Subject|0
6083312|NCT00634920|9691705|FG002|Period 1 - Pre-Randomization|Withdrawal by Subject|21
6341522|NCT03298412|10097237|FG000|Run-in Period|Other, Not Specified|1
6341523|NCT03298412|10097237|FG000|Run-in Period|Disease Progression|1
6341524|NCT03298412|10097237|FG000|Run-in Period|Ineligibility Determined|1
6341525|NCT03298412|10097237|FG000|Run-in Period|Decision by Sponsor|6
6341526|NCT03299101|10097262|FG000|Overall Study|Lost to Follow-up|1
6341527|NCT03299101|10097262|FG000|Overall Study|Withdrawal by Subject|5
6341528|NCT03299101|10097262|FG000|Overall Study|Surgery was changed|3
6341529|NCT03299101|10097262|FG000|Overall Study|Not enough time to complete prehab|1
6341530|NCT03299244|10097268|FG000|Overall Study|Withdrawal by Subject|34
6341531|NCT03299244|10097269|FG001|Overall Study|Withdrawal by Subject|29
6341532|NCT03299244|10097268|FG000|Overall Study|Decision by Sponsor|4
6341533|NCT03299244|10097269|FG001|Overall Study|Decision by Sponsor|5
6341534|NCT03299244|10097268|FG000|Overall Study|Death|9
6341535|NCT03299244|10097269|FG001|Overall Study|Death|4
6341536|NCT03299686|10097278|FG000|Treatment Epoch|Subject/Guardian Decision|2
6341537|NCT03299686|10097279|FG001|Treatment Epoch|Subject/Guardian Decision|0
6341538|NCT03299686|10097278|FG000|Treatment Epoch|Physician Decision|1
6341539|NCT03299686|10097279|FG001|Treatment Epoch|Physician Decision|0
6341540|NCT03299686|10097278|FG000|Treatment Epoch|Adverse Event|8
6083313|NCT00634920|9691703|FG000|Period 1 - Pre-Randomization|Non-Compliance|0
6083314|NCT00634920|9691704|FG001|Period 1 - Pre-Randomization|Non-Compliance|0
6083315|NCT00634920|9691705|FG002|Period 1 - Pre-Randomization|Non-Compliance|3
6083316|NCT00634920|9691703|FG000|Period 1 - Pre-Randomization|Other issues|0
6083317|NCT00634920|9691704|FG001|Period 1 - Pre-Randomization|Other issues|0
6083318|NCT00634920|9691705|FG002|Period 1 - Pre-Randomization|Other issues|6
6341541|NCT03299686|10097279|FG001|Treatment Epoch|Adverse Event|4
6341542|NCT03299686|10097278|FG000|Follow-up Epoch|Subject/Guardian Decision|0
6341543|NCT03299686|10097279|FG001|Follow-up Epoch|Subject/Guardian Decision|1
6341544|NCT03299881|10097287|FG000|Overall Study|Study Termination|17
6341545|NCT03299881|10097288|FG001|Overall Study|Study Termination|13
6341546|NCT03300050|10097299|FG000|Overall Study|Lost to Follow-up|2
6341547|NCT03300050|10097300|FG001|Overall Study|Lost to Follow-up|1
6341548|NCT03300050|10097301|FG002|Overall Study|Lost to Follow-up|0
6341549|NCT03300050|10097302|FG003|Overall Study|Lost to Follow-up|0
6341550|NCT03300050|10097303|FG004|Overall Study|Lost to Follow-up|1
6341551|NCT03300050|10097299|FG000|Overall Study|Withdrawal by Subject|1
6341552|NCT03300050|10097300|FG001|Overall Study|Withdrawal by Subject|1
6341553|NCT03300050|10097301|FG002|Overall Study|Withdrawal by Subject|1
6341554|NCT03300050|10097302|FG003|Overall Study|Withdrawal by Subject|0
6341555|NCT03300050|10097303|FG004|Overall Study|Withdrawal by Subject|0
6341556|NCT03300050|10097299|FG000|Overall Study|Death|0
6341557|NCT03300050|10097300|FG001|Overall Study|Death|0
6341558|NCT03300050|10097301|FG002|Overall Study|Death|1
6341559|NCT03300050|10097302|FG003|Overall Study|Death|0
6341560|NCT03300050|10097303|FG004|Overall Study|Death|0
6341561|NCT03300050|10097299|FG000|Overall Study|Not Eligible at Randomization|0
6341562|NCT03300050|10097300|FG001|Overall Study|Not Eligible at Randomization|0
6341563|NCT03300050|10097301|FG002|Overall Study|Not Eligible at Randomization|1
6341564|NCT03300050|10097302|FG003|Overall Study|Not Eligible at Randomization|1
6341565|NCT03300050|10097303|FG004|Overall Study|Not Eligible at Randomization|0
6341566|NCT03300570|10097326|FG000|Overall Study|Adverse Event|0
6341567|NCT03300570|10097327|FG001|Overall Study|Adverse Event|1
6341568|NCT03300570|10097326|FG000|Overall Study|Withdrawal by Subject|1
6341569|NCT03300570|10097327|FG001|Overall Study|Withdrawal by Subject|0
6341570|NCT03300570|10097326|FG000|Overall Study|Inadequate bowel prep|1
6341571|NCT03300570|10097327|FG001|Overall Study|Inadequate bowel prep|0
6083319|NCT00634920|9691703|FG000|Period 2 - Post-Randomization|Adverse Event|37
6341572|NCT03301155|10097358|FG000|Overall Study|Сompliance with exclusion criteria|8
6341573|NCT03301155|10097359|FG001|Overall Study|Сompliance with exclusion criteria|7
6341574|NCT03301623|10097406|FG000|Overall Study|Death|3
6341575|NCT03301623|10097407|FG001|Overall Study|Death|1
6341576|NCT03301623|10097406|FG000|Overall Study|Withdrawal by Subject|11
6341577|NCT03301623|10097407|FG001|Overall Study|Withdrawal by Subject|13
6341578|NCT03301623|10097406|FG000|Overall Study|Lost to Follow-up|3
6341579|NCT03301623|10097407|FG001|Overall Study|Lost to Follow-up|1
6341580|NCT03301649|10097416|FG000|Overall Study|Need alternate therapy due to live lice|17
6341581|NCT03301649|10097417|FG001|Overall Study|Need alternate therapy due to live lice|25
6341582|NCT03301649|10097418|FG002|Overall Study|Need alternate therapy due to live lice|81
6341583|NCT03301649|10097416|FG000|Overall Study|Lost to Follow-up|11
6341584|NCT03301649|10097417|FG001|Overall Study|Lost to Follow-up|11
6341585|NCT03301649|10097418|FG002|Overall Study|Lost to Follow-up|3
6341586|NCT03301649|10097416|FG000|Overall Study|Protocol Violation|0
6341587|NCT03301649|10097417|FG001|Overall Study|Protocol Violation|1
6341588|NCT03301649|10097418|FG002|Overall Study|Protocol Violation|1
6341589|NCT03301649|10097416|FG000|Overall Study|Withdrawal by Subject|10
6341590|NCT03301649|10097417|FG001|Overall Study|Withdrawal by Subject|4
6341591|NCT03301649|10097418|FG002|Overall Study|Withdrawal by Subject|0
6341592|NCT03301649|10097416|FG000|Overall Study|Other than specified|5
6341593|NCT03301649|10097417|FG001|Overall Study|Other than specified|3
6341594|NCT03301649|10097418|FG002|Overall Study|Other than specified|0
6341595|NCT03301714|10097429|FG000|Overall Study|Lost to Follow-up|10
6341596|NCT03301714|10097430|FG001|Overall Study|Lost to Follow-up|4
6341597|NCT03301714|10097431|FG002|Overall Study|Lost to Follow-up|4
6341598|NCT03301714|10097429|FG000|Overall Study|Did not receive allocated intervention|0
6341599|NCT03301714|10097430|FG001|Overall Study|Did not receive allocated intervention|2
6341600|NCT03301714|10097431|FG002|Overall Study|Did not receive allocated intervention|3
6341601|NCT03301740|10097444|FG000|Phase 2 Intervention (3 Weeks)|Kidney Transplant|1
6341602|NCT03301740|10097445|FG001|Phase 2 Intervention (3 Weeks)|Kidney Transplant|0
6341603|NCT03301740|10097444|FG000|Phase 4 Intervention (3 Weeks)|Prolonged Hospitalization|1
6341604|NCT03301740|10097445|FG001|Phase 4 Intervention (3 Weeks)|Prolonged Hospitalization|0
6341605|NCT03301831|10097460|FG000|Overall Study|Lost to Follow-up|5
6341606|NCT03301831|10097461|FG001|Overall Study|Lost to Follow-up|3
6341607|NCT03301831|10097460|FG000|Overall Study|Protocol Violation|4
6341608|NCT03301831|10097461|FG001|Overall Study|Protocol Violation|0
6341609|NCT03301831|10097460|FG000|Overall Study|Withdrawal by Subject|11
6341610|NCT03301831|10097461|FG001|Overall Study|Withdrawal by Subject|0
6341611|NCT03301844|10097469|FG000|Overall Study|suspected colon cancer|1
6341612|NCT03301844|10097470|FG001|Overall Study|suspected colon cancer|1
6341613|NCT03302559|10097489|FG000|Overall Study|Adverse Event|2
6341614|NCT03302559|10097489|FG000|Overall Study|Lost to Follow-up|1
6341615|NCT03302559|10097489|FG000|Overall Study|Withdrew Consent|3
6341616|NCT03302936|10097522|FG000|Overall Study|Protocol Violation|3
6341617|NCT03302936|10097523|FG001|Overall Study|Protocol Violation|4
6341618|NCT03302975|10097533|FG000|Overall Study|Lost to Follow-up|4
6341619|NCT03303079|10097540|FG000|Overall Study|Adverse Event|0
6341620|NCT03303079|10097541|FG001|Overall Study|Adverse Event|1
6341621|NCT03303079|10097542|FG002|Overall Study|Adverse Event|3
6341622|NCT03303079|10097540|FG000|Overall Study|Protocol Violation|5
6341623|NCT03303079|10097541|FG001|Overall Study|Protocol Violation|4
6341624|NCT03303079|10097542|FG002|Overall Study|Protocol Violation|7
6341625|NCT03303079|10097540|FG000|Overall Study|Withdrawal by Subject|2
6341626|NCT03303079|10097541|FG001|Overall Study|Withdrawal by Subject|4
6341627|NCT03303079|10097542|FG002|Overall Study|Withdrawal by Subject|2
6341628|NCT03303079|10097540|FG000|Overall Study|Other than specified|0
6341629|NCT03303079|10097541|FG001|Overall Study|Other than specified|2
6341630|NCT03303079|10097542|FG002|Overall Study|Other than specified|0
6341631|NCT03303092|10097553|FG000|Overall Study|Adverse Event|1
6341632|NCT03303092|10097554|FG001|Overall Study|Adverse Event|0
6341633|NCT03303092|10097555|FG002|Overall Study|Adverse Event|1
6341634|NCT03303092|10097553|FG000|Overall Study|Protocol Violation|1
6341635|NCT03303092|10097554|FG001|Overall Study|Protocol Violation|5
6341636|NCT03303092|10097555|FG002|Overall Study|Protocol Violation|1
6341637|NCT03303092|10097553|FG000|Overall Study|Withdrawal by Subject|1
6341638|NCT03303092|10097554|FG001|Overall Study|Withdrawal by Subject|1
6341639|NCT03303092|10097555|FG002|Overall Study|Withdrawal by Subject|3
6341640|NCT03303105|10097565|FG000|Overall Study|Adverse Event|0
6341641|NCT03303105|10097566|FG001|Overall Study|Adverse Event|2
6341642|NCT03303105|10097565|FG000|Overall Study|Lack of Efficacy|1
6341643|NCT03303105|10097566|FG001|Overall Study|Lack of Efficacy|0
6341644|NCT03303105|10097565|FG000|Overall Study|Protocol Violation|1
6341645|NCT03303105|10097566|FG001|Overall Study|Protocol Violation|0
6341646|NCT03303105|10097565|FG000|Overall Study|Withdrawal by Subject|0
6341647|NCT03303105|10097566|FG001|Overall Study|Withdrawal by Subject|2
6341648|NCT03303417|10097595|FG000|Overall Study|Withdrawal by Subject|1
6341649|NCT03303417|10097596|FG001|Overall Study|Withdrawal by Subject|1
6341650|NCT03303521|10097604|FG000|Overall Study|Withdrawal by Subject|2
6341651|NCT03303521|10097605|FG001|Overall Study|Withdrawal by Subject|0
6341652|NCT03303521|10097604|FG000|Overall Study|Death|1
6341653|NCT03303521|10097605|FG001|Overall Study|Death|0
6341654|NCT03303521|10097604|FG000|Overall Study|Kidney transplantation|0
6341655|NCT03303521|10097605|FG001|Overall Study|Kidney transplantation|1
6341656|NCT03303521|10097604|FG000|Overall Study|Investigational product discontinuation|0
6341657|NCT03303521|10097605|FG001|Overall Study|Investigational product discontinuation|1
6341658|NCT03303521|10097604|FG000|Overall Study|Transferred to non-study dialysis center|1
6341659|NCT03303521|10097605|FG001|Overall Study|Transferred to non-study dialysis center|0
6341660|NCT03303521|10097604|FG000|Overall Study|Non-comliance to study protocol|0
6341661|NCT03303521|10097605|FG001|Overall Study|Non-comliance to study protocol|1
6341662|NCT03303521|10097604|FG000|Overall Study|Adverse Event|1
6341663|NCT03303521|10097605|FG001|Overall Study|Adverse Event|0
6341664|NCT03304184|10097666|FG000|Overall Study|Withdrawal by Subject|1
6341665|NCT03304184|10097667|FG001|Overall Study|Withdrawal by Subject|2
6341666|NCT03304522|10097676|FG000|Overall Study|Adverse Event|0
6341667|NCT03304522|10097677|FG001|Overall Study|Adverse Event|4
6341668|NCT03304522|10097676|FG000|Overall Study|Withdrawal of consent (due to lack of efficacy)|1
6341669|NCT03304522|10097677|FG001|Overall Study|Withdrawal of consent (due to lack of efficacy)|1
6341670|NCT03304522|10097676|FG000|Overall Study|Withdrawal of consent (for other reason)|0
6341671|NCT03304522|10097677|FG001|Overall Study|Withdrawal of consent (for other reason)|2
6341672|NCT03304522|10097676|FG000|Overall Study|Other|0
6341673|NCT03304522|10097677|FG001|Overall Study|Other|1
6341674|NCT03304626|10097685|FG000|Overall Study|Adverse Event|1
6341675|NCT03304626|10097686|FG001|Overall Study|Adverse Event|0
6341676|NCT03304626|10097685|FG000|Overall Study|Lack of Efficacy|1
6341677|NCT03304626|10097686|FG001|Overall Study|Lack of Efficacy|1
6341678|NCT03304873|10097695|FG000|Overall Study|Lost to Follow-up|1
6341679|NCT03304873|10097696|FG001|Overall Study|Lost to Follow-up|8
6341680|NCT03305081|10097704|FG000|Overall Study|Lost to Follow-up|10
6341681|NCT03305081|10097705|FG001|Overall Study|Lost to Follow-up|15
6341682|NCT03305419|10097728|FG000|Part A Period 1 (1Day) + Washout (7days)|Adverse Event|0
6341683|NCT03305419|10097729|FG001|Part A Period 1 (1Day) + Washout (7days)|Adverse Event|1
6341684|NCT03305419|10097730|FG002|Part A Period 1 (1Day) + Washout (7days)|Adverse Event|0
6341685|NCT03305419|10097731|FG003|Part A Period 1 (1Day) + Washout (7days)|Adverse Event|0
6341686|NCT03305419|10097732|FG004|Part A Period 1 (1Day) + Washout (7days)|Adverse Event|0
6341687|NCT03305419|10097733|FG005|Part A Period 1 (1Day) + Washout (7days)|Adverse Event|0
6341688|NCT03305419|10097734|FG006|Part A Period 1 (1Day) + Washout (7days)|Adverse Event|0
6341689|NCT03305419|10097735|FG007|Part A Period 1 (1Day) + Washout (7days)|Adverse Event|0
6341690|NCT03305419|10097728|FG000|Part A Period 2 (1Day) + Washout (7days)|Adverse Event|1
6341691|NCT03305419|10097729|FG001|Part A Period 2 (1Day) + Washout (7days)|Adverse Event|0
6341692|NCT03305419|10097730|FG002|Part A Period 2 (1Day) + Washout (7days)|Adverse Event|0
6341693|NCT03305419|10097731|FG003|Part A Period 2 (1Day) + Washout (7days)|Adverse Event|0
6341694|NCT03305419|10097732|FG004|Part A Period 2 (1Day) + Washout (7days)|Adverse Event|0
6341695|NCT03305419|10097733|FG005|Part A Period 2 (1Day) + Washout (7days)|Adverse Event|0
6341696|NCT03305419|10097734|FG006|Part A Period 2 (1Day) + Washout (7days)|Adverse Event|0
6341697|NCT03305419|10097735|FG007|Part A Period 2 (1Day) + Washout (7days)|Adverse Event|0
6341698|NCT03305419|10097728|FG000|Part A Period 2 (1Day) + Washout (7days)|Physician Decision|1
6341699|NCT03305419|10097729|FG001|Part A Period 2 (1Day) + Washout (7days)|Physician Decision|0
6341700|NCT03305419|10097730|FG002|Part A Period 2 (1Day) + Washout (7days)|Physician Decision|0
6341701|NCT03305419|10097731|FG003|Part A Period 2 (1Day) + Washout (7days)|Physician Decision|0
6341702|NCT03305419|10097732|FG004|Part A Period 2 (1Day) + Washout (7days)|Physician Decision|0
6341703|NCT03305419|10097733|FG005|Part A Period 2 (1Day) + Washout (7days)|Physician Decision|0
6341704|NCT03305419|10097734|FG006|Part A Period 2 (1Day) + Washout (7days)|Physician Decision|0
6341705|NCT03305419|10097735|FG007|Part A Period 2 (1Day) + Washout (7days)|Physician Decision|0
6341706|NCT03305419|10097728|FG000|Part B (14 Days)|Adverse Event|0
6341707|NCT03305419|10097729|FG001|Part B (14 Days)|Adverse Event|0
6341708|NCT03305419|10097730|FG002|Part B (14 Days)|Adverse Event|0
6341709|NCT03305419|10097731|FG003|Part B (14 Days)|Adverse Event|0
6341710|NCT03305419|10097732|FG004|Part B (14 Days)|Adverse Event|1
6341711|NCT03305419|10097733|FG005|Part B (14 Days)|Adverse Event|2
6341712|NCT03305419|10097734|FG006|Part B (14 Days)|Adverse Event|4
6341713|NCT03305419|10097735|FG007|Part B (14 Days)|Adverse Event|0
6341714|NCT03305419|10097728|FG000|Part B (14 Days)|Physician Decision|0
6341715|NCT03305419|10097729|FG001|Part B (14 Days)|Physician Decision|0
6341716|NCT03305419|10097730|FG002|Part B (14 Days)|Physician Decision|0
6341717|NCT03305419|10097731|FG003|Part B (14 Days)|Physician Decision|0
6341718|NCT03305419|10097732|FG004|Part B (14 Days)|Physician Decision|2
6341719|NCT03305419|10097733|FG005|Part B (14 Days)|Physician Decision|8
6341720|NCT03305419|10097734|FG006|Part B (14 Days)|Physician Decision|1
6341721|NCT03305419|10097735|FG007|Part B (14 Days)|Physician Decision|0
6341722|NCT03305575|10097760|FG000|Overall Study|Physician Decision|1
6341723|NCT03305575|10097761|FG001|Overall Study|Physician Decision|0
6341724|NCT03305666|10097773|FG000|Overall Study|ORIF cancelled due to patient's cognitive decline, withdrawn from study at this time|2
6341725|NCT03305666|10097774|FG001|Overall Study|ORIF cancelled due to patient's cognitive decline, withdrawn from study at this time|0
6341726|NCT03305731|10097780|FG000|Overall Study|Protocol Violation|1
6341727|NCT03305770|10097786|FG000|Overall Study|Physician Decision - prior to dispense|0
6341728|NCT03305770|10097787|FG001|Overall Study|Physician Decision - prior to dispense|1
6341729|NCT03305770|10097786|FG000|Overall Study|Subject moved|1
6341730|NCT03305770|10097787|FG001|Overall Study|Subject moved|0
6341731|NCT03305809|10097799|FG000|Overall Study|Adverse Event|2
6341732|NCT03305809|10097800|FG001|Overall Study|Adverse Event|2
6341733|NCT03305809|10097801|FG002|Overall Study|Adverse Event|6
6341734|NCT03305809|10097802|FG003|Overall Study|Adverse Event|6
6341735|NCT03305809|10097799|FG000|Overall Study|Death|0
6341736|NCT03305809|10097800|FG001|Overall Study|Death|0
6341737|NCT03305809|10097801|FG002|Overall Study|Death|1
6341738|NCT03305809|10097802|FG003|Overall Study|Death|1
6341739|NCT03305809|10097799|FG000|Overall Study|Lost to Follow-up|1
6341740|NCT03305809|10097800|FG001|Overall Study|Lost to Follow-up|2
6341741|NCT03305809|10097801|FG002|Overall Study|Lost to Follow-up|0
6341742|NCT03305809|10097802|FG003|Overall Study|Lost to Follow-up|0
6341743|NCT03305809|10097799|FG000|Overall Study|Sponsor Decision|1
6341744|NCT03305809|10097800|FG001|Overall Study|Sponsor Decision|0
6341745|NCT03305809|10097801|FG002|Overall Study|Sponsor Decision|1
6341746|NCT03305809|10097802|FG003|Overall Study|Sponsor Decision|8
6341747|NCT03305809|10097799|FG000|Overall Study|Physician Decision|0
6341748|NCT03305809|10097800|FG001|Overall Study|Physician Decision|0
6341749|NCT03305809|10097801|FG002|Overall Study|Physician Decision|2
6341750|NCT03305809|10097802|FG003|Overall Study|Physician Decision|4
6341751|NCT03305809|10097799|FG000|Overall Study|Progressive Disease|0
6341752|NCT03305809|10097800|FG001|Overall Study|Progressive Disease|0
6341753|NCT03305809|10097801|FG002|Overall Study|Progressive Disease|1
6341754|NCT03305809|10097802|FG003|Overall Study|Progressive Disease|0
6341755|NCT03305809|10097799|FG000|Overall Study|Protocol Violation|1
6341756|NCT03305809|10097800|FG001|Overall Study|Protocol Violation|0
6341757|NCT03305809|10097801|FG002|Overall Study|Protocol Violation|2
6341758|NCT03305809|10097802|FG003|Overall Study|Protocol Violation|3
6341759|NCT03305809|10097799|FG000|Overall Study|Withdrawal due to Assessment Committee Decision|0
6341760|NCT03305809|10097800|FG001|Overall Study|Withdrawal due to Assessment Committee Decision|0
6341761|NCT03305809|10097801|FG002|Overall Study|Withdrawal due to Assessment Committee Decision|0
6341762|NCT03305809|10097802|FG003|Overall Study|Withdrawal due to Assessment Committee Decision|2
6341763|NCT03305809|10097799|FG000|Overall Study|Withdrawal by Subject|2
6341764|NCT03305809|10097800|FG001|Overall Study|Withdrawal by Subject|4
6341765|NCT03305809|10097801|FG002|Overall Study|Withdrawal by Subject|5
6341766|NCT03305809|10097802|FG003|Overall Study|Withdrawal by Subject|2
6341767|NCT03305809|10097799|FG000|Overall Study|Withdrawal due to Caregiver Circumstances|0
6341768|NCT03305809|10097800|FG001|Overall Study|Withdrawal due to Caregiver Circumstances|0
6341769|NCT03305809|10097801|FG002|Overall Study|Withdrawal due to Caregiver Circumstances|1
6341770|NCT03305809|10097802|FG003|Overall Study|Withdrawal due to Caregiver Circumstances|1
6341771|NCT03306043|10097831|FG000|Overall Study|Adverse Event|1
6341772|NCT03306043|10097831|FG000|Overall Study|Lost to Follow-up|1
6341773|NCT03306043|10097831|FG000|Overall Study|Withdrawal by Subject|2
6341774|NCT03306277|10097839|FG000|Overall Study|Death|1
6341775|NCT03306277|10097839|FG000|Overall Study|Adverse Event|1
6341776|NCT03306277|10097839|FG000|Overall Study|Withdrawal by Subject|1
6341777|NCT03306433|10097864|FG000|Overall Study|Lost to Follow-up|3
6341778|NCT03306433|10097864|FG000|Overall Study|Patient did not have teeth extracted|1
6341779|NCT03306433|10097864|FG000|Overall Study|Teeth not sent to the lab or participant only had two teeth for extraction|3
6341780|NCT03307174|10097919|FG000|Overall Study|Unplanned ICU Administrion|5
6341781|NCT03307174|10097920|FG001|Overall Study|Unplanned ICU Administrion|3
6341782|NCT03307174|10097919|FG000|Overall Study|Aborted Surgery|1
6341783|NCT03307174|10097920|FG001|Overall Study|Aborted Surgery|2
6341784|NCT03307174|10097919|FG000|Overall Study|Hypotension|6
6341785|NCT03307174|10097920|FG001|Overall Study|Hypotension|0
6341786|NCT03307174|10097919|FG000|Overall Study|Nonfunctional epidural|1
6341787|NCT03307174|10097920|FG001|Overall Study|Nonfunctional epidural|1
6341788|NCT03307174|10097919|FG000|Overall Study|Planned epidural removal|1
6341789|NCT03307174|10097920|FG001|Overall Study|Planned epidural removal|0
6341790|NCT03307174|10097919|FG000|Overall Study|Intrathecal catheter placement|0
6341791|NCT03307174|10097920|FG001|Overall Study|Intrathecal catheter placement|1
6341792|NCT03307252|10097937|FG000|Part 2, Period 1|Treatment not received|0
6341793|NCT03307252|10097938|FG001|Part 2, Period 1|Treatment not received|0
6341794|NCT03307252|10097939|FG002|Part 2, Period 1|Treatment not received|0
6341795|NCT03307252|10097940|FG003|Part 2, Period 1|Treatment not received|0
6341796|NCT03307252|10097941|FG004|Part 2, Period 1|Treatment not received|0
6341797|NCT03307252|10097942|FG005|Part 2, Period 1|Treatment not received|1
6341798|NCT03307252|10097943|FG006|Part 2, Period 1|Treatment not received|0
6341799|NCT03307252|10097944|FG007|Part 2, Period 1|Treatment not received|0
6341800|NCT03307252|10097945|FG008|Part 2, Period 1|Treatment not received|0
6341801|NCT03307252|10097946|FG009|Part 2, Period 1|Treatment not received|0
6341802|NCT03307252|10097947|FG010|Part 2, Period 1|Treatment not received|0
6341803|NCT03307252|10097937|FG000|Part 2, Period 3|Other than listed|0
6168579|NCT01236352|9813652|FG005|Overall Study|Patient moving to allogeneic transplant|0
6168580|NCT01236352|9813653|FG006|Overall Study|Patient moving to allogeneic transplant|1
6168581|NCT01236352|9813654|FG007|Overall Study|Patient moving to allogeneic transplant|0
6168582|NCT01236352|9813655|FG008|Overall Study|Patient moving to allogeneic transplant|0
6168583|NCT01236352|9813656|FG009|Overall Study|Patient moving to allogeneic transplant|0
6168584|NCT01236352|9813657|FG010|Overall Study|Patient moving to allogeneic transplant|0
6168585|NCT01236352|9813647|FG000|Overall Study|Relapse of Splenomegaly and symptoms|0
6168586|NCT01236352|9813648|FG001|Overall Study|Relapse of Splenomegaly and symptoms|0
6168587|NCT01236352|9813649|FG002|Overall Study|Relapse of Splenomegaly and symptoms|0
6168588|NCT01236352|9813650|FG003|Overall Study|Relapse of Splenomegaly and symptoms|0
6168589|NCT01236352|9813651|FG004|Overall Study|Relapse of Splenomegaly and symptoms|0
6168590|NCT01236352|9813652|FG005|Overall Study|Relapse of Splenomegaly and symptoms|0
6168591|NCT01236352|9813653|FG006|Overall Study|Relapse of Splenomegaly and symptoms|0
6168592|NCT01236352|9813654|FG007|Overall Study|Relapse of Splenomegaly and symptoms|0
6341804|NCT03307252|10097938|FG001|Part 2, Period 3|Other than listed|0
6341805|NCT03307252|10097939|FG002|Part 2, Period 3|Other than listed|0
6341806|NCT03307252|10097940|FG003|Part 2, Period 3|Other than listed|0
6341807|NCT03307252|10097941|FG004|Part 2, Period 3|Other than listed|1
6341808|NCT03307252|10097942|FG005|Part 2, Period 3|Other than listed|0
6341809|NCT03307252|10097943|FG006|Part 2, Period 3|Other than listed|0
6341810|NCT03307252|10097944|FG007|Part 2, Period 3|Other than listed|0
6341811|NCT03307252|10097945|FG008|Part 2, Period 3|Other than listed|0
6341812|NCT03307252|10097946|FG009|Part 2, Period 3|Other than listed|0
6341813|NCT03307252|10097947|FG010|Part 2, Period 3|Other than listed|0
6341814|NCT03307252|10097937|FG000|Part 2, Period 4|Other than listed|0
6341815|NCT03307252|10097938|FG001|Part 2, Period 4|Other than listed|0
6341816|NCT03307252|10097939|FG002|Part 2, Period 4|Other than listed|0
6341817|NCT03307252|10097940|FG003|Part 2, Period 4|Other than listed|0
6341818|NCT03307252|10097941|FG004|Part 2, Period 4|Other than listed|0
6341819|NCT03307252|10097942|FG005|Part 2, Period 4|Other than listed|0
6341820|NCT03307252|10097943|FG006|Part 2, Period 4|Other than listed|1
6341821|NCT03307252|10097944|FG007|Part 2, Period 4|Other than listed|0
6341822|NCT03307252|10097945|FG008|Part 2, Period 4|Other than listed|0
6341823|NCT03307252|10097946|FG009|Part 2, Period 4|Other than listed|0
6341824|NCT03307252|10097947|FG010|Part 2, Period 4|Other than listed|0
6341825|NCT03307252|10097937|FG000|Part 3, Washout Period 3 (7 Days)|Treatment not received due to AE|0
6341826|NCT03307252|10097938|FG001|Part 3, Washout Period 3 (7 Days)|Treatment not received due to AE|0
6341827|NCT03307252|10097939|FG002|Part 3, Washout Period 3 (7 Days)|Treatment not received due to AE|0
6341828|NCT03307252|10097940|FG003|Part 3, Washout Period 3 (7 Days)|Treatment not received due to AE|0
6341829|NCT03307252|10097941|FG004|Part 3, Washout Period 3 (7 Days)|Treatment not received due to AE|0
6341830|NCT03307252|10097942|FG005|Part 3, Washout Period 3 (7 Days)|Treatment not received due to AE|0
6341831|NCT03307252|10097943|FG006|Part 3, Washout Period 3 (7 Days)|Treatment not received due to AE|0
6341832|NCT03307252|10097944|FG007|Part 3, Washout Period 3 (7 Days)|Treatment not received due to AE|0
6341833|NCT03307252|10097945|FG008|Part 3, Washout Period 3 (7 Days)|Treatment not received due to AE|0
6341834|NCT03307252|10097946|FG009|Part 3, Washout Period 3 (7 Days)|Treatment not received due to AE|0
6341835|NCT03307252|10097947|FG010|Part 3, Washout Period 3 (7 Days)|Treatment not received due to AE|1
6341836|NCT03307837|10097969|FG000|Overall Study|Withdrawal by Subject|0
6341837|NCT03307837|10097970|FG001|Overall Study|Withdrawal by Subject|0
6341838|NCT03307837|10097971|FG002|Overall Study|Withdrawal by Subject|1
6341839|NCT03307837|10097972|FG003|Overall Study|Withdrawal by Subject|0
6341840|NCT03307837|10097973|FG004|Overall Study|Withdrawal by Subject|0
6341841|NCT03307837|10097974|FG005|Overall Study|Withdrawal by Subject|1
6341842|NCT03307837|10097969|FG000|Overall Study|Lost to Follow-up|1
6341843|NCT03307837|10097970|FG001|Overall Study|Lost to Follow-up|1
6341844|NCT03307837|10097971|FG002|Overall Study|Lost to Follow-up|0
6341845|NCT03307837|10097972|FG003|Overall Study|Lost to Follow-up|0
6341846|NCT03307837|10097973|FG004|Overall Study|Lost to Follow-up|0
6341847|NCT03307837|10097974|FG005|Overall Study|Lost to Follow-up|1
6341848|NCT03308942|10098050|FG000|Stage 1 (up to a Maximum of 29 Months)|Withdrawal by Subject|2
6341849|NCT03308942|10098051|FG001|Stage 1 (up to a Maximum of 29 Months)|Withdrawal by Subject|2
6341850|NCT03308942|10098052|FG002|Stage 1 (up to a Maximum of 29 Months)|Withdrawal by Subject|2
6341851|NCT03308942|10098053|FG003|Stage 1 (up to a Maximum of 29 Months)|Withdrawal by Subject|0
6341852|NCT03308942|10098054|FG004|Stage 1 (up to a Maximum of 29 Months)|Withdrawal by Subject|0
6341853|NCT03308942|10098050|FG000|Stage 1 (up to a Maximum of 29 Months)|Death|8
6341854|NCT03308942|10098051|FG001|Stage 1 (up to a Maximum of 29 Months)|Death|15
6341855|NCT03308942|10098052|FG002|Stage 1 (up to a Maximum of 29 Months)|Death|1
6341856|NCT03308942|10098053|FG003|Stage 1 (up to a Maximum of 29 Months)|Death|0
6341857|NCT03308942|10098054|FG004|Stage 1 (up to a Maximum of 29 Months)|Death|0
6341858|NCT03308942|10098050|FG000|Stage 1 (up to a Maximum of 29 Months)|Ongoing at the time of analysis|7
6341859|NCT03308942|10098051|FG001|Stage 1 (up to a Maximum of 29 Months)|Ongoing at the time of analysis|4
6341860|NCT03308942|10098052|FG002|Stage 1 (up to a Maximum of 29 Months)|Ongoing at the time of analysis|0
6341861|NCT03308942|10098053|FG003|Stage 1 (up to a Maximum of 29 Months)|Ongoing at the time of analysis|0
6341862|NCT03308942|10098054|FG004|Stage 1 (up to a Maximum of 29 Months)|Ongoing at the time of analysis|0
6341863|NCT03308942|10098050|FG000|Stage 2 (up to a Maximum of 17 Months)|Withdrawal by Subject|0
6341864|NCT03308942|10098051|FG001|Stage 2 (up to a Maximum of 17 Months)|Withdrawal by Subject|0
6341865|NCT03308942|10098052|FG002|Stage 2 (up to a Maximum of 17 Months)|Withdrawal by Subject|0
6341866|NCT03308942|10098053|FG003|Stage 2 (up to a Maximum of 17 Months)|Withdrawal by Subject|3
6341867|NCT03308942|10098054|FG004|Stage 2 (up to a Maximum of 17 Months)|Withdrawal by Subject|0
6341868|NCT03308942|10098050|FG000|Stage 2 (up to a Maximum of 17 Months)|Death|0
6341869|NCT03308942|10098051|FG001|Stage 2 (up to a Maximum of 17 Months)|Death|0
6168593|NCT01236352|9813655|FG008|Overall Study|Relapse of Splenomegaly and symptoms|0
6341870|NCT03308942|10098052|FG002|Stage 2 (up to a Maximum of 17 Months)|Death|0
6341871|NCT03308942|10098053|FG003|Stage 2 (up to a Maximum of 17 Months)|Death|4
6341872|NCT03308942|10098054|FG004|Stage 2 (up to a Maximum of 17 Months)|Death|0
6341873|NCT03308942|10098050|FG000|Stage 2 (up to a Maximum of 17 Months)|Ongoing at the time of analysis|0
6341874|NCT03308942|10098051|FG001|Stage 2 (up to a Maximum of 17 Months)|Ongoing at the time of analysis|0
6341875|NCT03308942|10098052|FG002|Stage 2 (up to a Maximum of 17 Months)|Ongoing at the time of analysis|0
6341876|NCT03308942|10098053|FG003|Stage 2 (up to a Maximum of 17 Months)|Ongoing at the time of analysis|5
6168594|NCT01236352|9813656|FG009|Overall Study|Relapse of Splenomegaly and symptoms|0
6168595|NCT01236352|9813657|FG010|Overall Study|Relapse of Splenomegaly and symptoms|1
6168596|NCT01236352|9813647|FG000|Overall Study|Lack of response to drug|0
6168597|NCT01236352|9813648|FG001|Overall Study|Lack of response to drug|0
6341877|NCT03308942|10098054|FG004|Stage 2 (up to a Maximum of 17 Months)|Ongoing at the time of analysis|0
6341878|NCT03308968|10098070|FG000|Double-Blind Period (12 Weeks)|Adverse Event|3
6341879|NCT03308968|10098071|FG001|Double-Blind Period (12 Weeks)|Adverse Event|1
6341880|NCT03308968|10098072|FG002|Double-Blind Period (12 Weeks)|Adverse Event|4
6341881|NCT03308968|10098070|FG000|Double-Blind Period (12 Weeks)|Withdrawal by Subject|2
6341882|NCT03308968|10098071|FG001|Double-Blind Period (12 Weeks)|Withdrawal by Subject|2
6341883|NCT03308968|10098072|FG002|Double-Blind Period (12 Weeks)|Withdrawal by Subject|3
6341884|NCT03308968|10098070|FG000|Double-Blind Period (12 Weeks)|Protocol Violation|6
6341885|NCT03308968|10098071|FG001|Double-Blind Period (12 Weeks)|Protocol Violation|0
6341886|NCT03308968|10098072|FG002|Double-Blind Period (12 Weeks)|Protocol Violation|2
6341887|NCT03308968|10098070|FG000|Double-Blind Period (12 Weeks)|Non-compliance to study procedures|1
6341888|NCT03308968|10098071|FG001|Double-Blind Period (12 Weeks)|Non-compliance to study procedures|1
6341889|NCT03308968|10098072|FG002|Double-Blind Period (12 Weeks)|Non-compliance to study procedures|0
6341890|NCT03308968|10098070|FG000|Double-Blind Period (12 Weeks)|Lost to Follow-up|1
6341891|NCT03308968|10098071|FG001|Double-Blind Period (12 Weeks)|Lost to Follow-up|0
6341892|NCT03308968|10098072|FG002|Double-Blind Period (12 Weeks)|Lost to Follow-up|0
6341893|NCT03308968|10098070|FG000|Double-Blind Period (12 Weeks)|Lack of Efficacy|1
6341894|NCT03308968|10098071|FG001|Double-Blind Period (12 Weeks)|Lack of Efficacy|1
6341895|NCT03308968|10098072|FG002|Double-Blind Period (12 Weeks)|Lack of Efficacy|0
6083320|NCT00634920|9691704|FG001|Period 2 - Post-Randomization|Adverse Event|9
6083321|NCT00634920|9691705|FG002|Period 2 - Post-Randomization|Adverse Event|0
6341896|NCT03308968|10098070|FG000|Double-Blind Period (12 Weeks)|Other than specified|1
6341897|NCT03308968|10098071|FG001|Double-Blind Period (12 Weeks)|Other than specified|0
6341898|NCT03308968|10098072|FG002|Double-Blind Period (12 Weeks)|Other than specified|2
6341899|NCT03308968|10098070|FG000|Open-Label Period (12 Weeks)|Other than specified|1
6341900|NCT03308968|10098071|FG001|Open-Label Period (12 Weeks)|Other than specified|2
6341901|NCT03308968|10098072|FG002|Open-Label Period (12 Weeks)|Other than specified|1
6341902|NCT03308968|10098070|FG000|Open-Label Period (12 Weeks)|Adverse Event|4
6341903|NCT03308968|10098071|FG001|Open-Label Period (12 Weeks)|Adverse Event|1
6341904|NCT03308968|10098072|FG002|Open-Label Period (12 Weeks)|Adverse Event|1
6341905|NCT03308968|10098070|FG000|Open-Label Period (12 Weeks)|Withdrawal by Subject|5
6341906|NCT03308968|10098071|FG001|Open-Label Period (12 Weeks)|Withdrawal by Subject|5
6341907|NCT03308968|10098072|FG002|Open-Label Period (12 Weeks)|Withdrawal by Subject|7
6341908|NCT03308968|10098070|FG000|Open-Label Period (12 Weeks)|Protocol Violation|0
6341909|NCT03308968|10098071|FG001|Open-Label Period (12 Weeks)|Protocol Violation|1
6341910|NCT03308968|10098072|FG002|Open-Label Period (12 Weeks)|Protocol Violation|1
6341911|NCT03308968|10098070|FG000|Open-Label Period (12 Weeks)|Non-compliance to study procedures|0
6341912|NCT03308968|10098071|FG001|Open-Label Period (12 Weeks)|Non-compliance to study procedures|0
6341913|NCT03308968|10098072|FG002|Open-Label Period (12 Weeks)|Non-compliance to study procedures|1
6341914|NCT03308968|10098070|FG000|Open-Label Period (12 Weeks)|Lost to Follow-up|0
6341915|NCT03308968|10098071|FG001|Open-Label Period (12 Weeks)|Lost to Follow-up|1
6341916|NCT03308968|10098072|FG002|Open-Label Period (12 Weeks)|Lost to Follow-up|1
6341917|NCT03308968|10098070|FG000|Open-Label Period (12 Weeks)|Lack of Efficacy|1
6341918|NCT03308968|10098071|FG001|Open-Label Period (12 Weeks)|Lack of Efficacy|2
6341919|NCT03308968|10098072|FG002|Open-Label Period (12 Weeks)|Lack of Efficacy|0
6341920|NCT03309020|10098085|FG000|Overall Study|Death|1
6341921|NCT03309020|10098086|FG001|Overall Study|Death|0
6341922|NCT03309020|10098085|FG000|Overall Study|Did not undergo surgery|2
6341923|NCT03309020|10098086|FG001|Overall Study|Did not undergo surgery|1
6341924|NCT03309202|10098098|FG000|Overall Study|Lost to Follow-up|1
6341925|NCT03309202|10098099|FG001|Overall Study|Lost to Follow-up|0
6341926|NCT03309202|10098100|FG002|Overall Study|Lost to Follow-up|0
6341927|NCT03309202|10098101|FG003|Overall Study|Lost to Follow-up|0
6341928|NCT03309605|10098132|FG000|Overall Study|Adverse Event|0
6341929|NCT03309605|10098133|FG001|Overall Study|Adverse Event|0
6341930|NCT03309605|10098134|FG002|Overall Study|Adverse Event|0
6341931|NCT03309605|10098135|FG003|Overall Study|Adverse Event|1
6341932|NCT03309605|10098136|FG004|Overall Study|Adverse Event|0
6341933|NCT03309605|10098137|FG005|Overall Study|Adverse Event|0
6341934|NCT03309605|10098138|FG006|Overall Study|Adverse Event|2
6341935|NCT03309605|10098139|FG007|Overall Study|Adverse Event|1
6341936|NCT03309605|10098132|FG000|Overall Study|Withdrawal by Subject|0
6341937|NCT03309605|10098133|FG001|Overall Study|Withdrawal by Subject|0
6341938|NCT03309605|10098134|FG002|Overall Study|Withdrawal by Subject|0
6341939|NCT03309605|10098135|FG003|Overall Study|Withdrawal by Subject|0
6341940|NCT03309605|10098136|FG004|Overall Study|Withdrawal by Subject|1
6341941|NCT03309605|10098137|FG005|Overall Study|Withdrawal by Subject|0
6341942|NCT03309605|10098138|FG006|Overall Study|Withdrawal by Subject|1
6341943|NCT03309605|10098139|FG007|Overall Study|Withdrawal by Subject|1
6341944|NCT03309696|10098159|FG000|Overall Study|Analysis of TEP data could not be completed|0
6341945|NCT03309696|10098160|FG001|Overall Study|Analysis of TEP data could not be completed|5
6341946|NCT03309696|10098161|FG002|Overall Study|Analysis of TEP data could not be completed|0
6341947|NCT03309696|10098162|FG003|Overall Study|Analysis of TEP data could not be completed|0
6341948|NCT03309943|10098191|FG000|Overall Study|Withdrawal by Subject|0
6341949|NCT03309943|10098192|FG001|Overall Study|Withdrawal by Subject|1
6341950|NCT03309943|10098191|FG000|Overall Study|Inappropriate behavior towards staff|0
6341951|NCT03309943|10098192|FG001|Overall Study|Inappropriate behavior towards staff|1
6341952|NCT03310021|10098218|FG000|Overall Study|Withdrawal by Subject|0
6341953|NCT03310021|10098219|FG001|Overall Study|Withdrawal by Subject|0
6341954|NCT03310021|10098220|FG002|Overall Study|Withdrawal by Subject|0
6341955|NCT03310021|10098221|FG003|Overall Study|Withdrawal by Subject|0
6341956|NCT03310021|10098222|FG004|Overall Study|Withdrawal by Subject|0
6341957|NCT03310021|10098223|FG005|Overall Study|Withdrawal by Subject|0
6341958|NCT03310021|10098224|FG006|Overall Study|Withdrawal by Subject|1
6341959|NCT03310021|10098225|FG007|Overall Study|Withdrawal by Subject|0
6341960|NCT03310021|10098226|FG008|Overall Study|Withdrawal by Subject|0
6341961|NCT03310021|10098227|FG009|Overall Study|Withdrawal by Subject|0
6341962|NCT03310021|10098228|FG010|Overall Study|Withdrawal by Subject|0
6341963|NCT03310021|10098229|FG011|Overall Study|Withdrawal by Subject|0
6341964|NCT03310021|10098230|FG012|Overall Study|Withdrawal by Subject|0
6341965|NCT03310021|10098231|FG013|Overall Study|Withdrawal by Subject|0
6341966|NCT03310021|10098232|FG014|Overall Study|Withdrawal by Subject|0
6341967|NCT03310021|10098233|FG015|Overall Study|Withdrawal by Subject|0
6341968|NCT03310021|10098234|FG016|Overall Study|Withdrawal by Subject|0
6341969|NCT03310021|10098235|FG017|Overall Study|Withdrawal by Subject|0
6341970|NCT03310021|10098236|FG018|Overall Study|Withdrawal by Subject|0
6341971|NCT03310021|10098237|FG019|Overall Study|Withdrawal by Subject|0
6341972|NCT03310021|10098218|FG000|Overall Study|Lost to Follow-up|0
6341973|NCT03310021|10098219|FG001|Overall Study|Lost to Follow-up|0
6341974|NCT03310021|10098220|FG002|Overall Study|Lost to Follow-up|0
6341975|NCT03310021|10098221|FG003|Overall Study|Lost to Follow-up|0
6341976|NCT03310021|10098222|FG004|Overall Study|Lost to Follow-up|0
6341977|NCT03310021|10098223|FG005|Overall Study|Lost to Follow-up|0
6341978|NCT03310021|10098224|FG006|Overall Study|Lost to Follow-up|0
6341979|NCT03310021|10098225|FG007|Overall Study|Lost to Follow-up|0
6341980|NCT03310021|10098226|FG008|Overall Study|Lost to Follow-up|0
6341981|NCT03310021|10098227|FG009|Overall Study|Lost to Follow-up|0
6341982|NCT03310021|10098228|FG010|Overall Study|Lost to Follow-up|1
6341983|NCT03310021|10098229|FG011|Overall Study|Lost to Follow-up|0
6341984|NCT03310021|10098230|FG012|Overall Study|Lost to Follow-up|0
6341985|NCT03310021|10098231|FG013|Overall Study|Lost to Follow-up|0
6341986|NCT03310021|10098232|FG014|Overall Study|Lost to Follow-up|0
6341987|NCT03310021|10098233|FG015|Overall Study|Lost to Follow-up|0
6341988|NCT03310021|10098234|FG016|Overall Study|Lost to Follow-up|0
6341989|NCT03310021|10098235|FG017|Overall Study|Lost to Follow-up|0
6341990|NCT03310021|10098236|FG018|Overall Study|Lost to Follow-up|0
6341991|NCT03310021|10098237|FG019|Overall Study|Lost to Follow-up|0
6341992|NCT03310268|10098282|FG000|Overall Study|(Not specified)|1
6341993|NCT03310268|10098283|FG001|Overall Study|(Not specified)|5
6341994|NCT03310268|10098284|FG002|Overall Study|(Not specified)|0
6341995|NCT03310411|10098292|FG000|Period 1|Adverse Event|0
6341996|NCT03310411|10098293|FG001|Period 1|Adverse Event|0
6341997|NCT03310411|10098294|FG002|Period 1|Adverse Event|0
6341998|NCT03310411|10098295|FG003|Period 1|Adverse Event|1
6341999|NCT03310580|10098330|FG000|Overall Study|Adverse Event|0
6342000|NCT03310580|10098331|FG001|Overall Study|Adverse Event|1
6342001|NCT03310580|10098332|FG002|Overall Study|Adverse Event|0
6342002|NCT03310723|10098343|FG000|Overall Study|Withdrawal by Subject|0
6342003|NCT03310723|10098344|FG001|Overall Study|Withdrawal by Subject|1
6342004|NCT03310723|10098343|FG000|Overall Study|Protocol Violation|0
6342005|NCT03310723|10098344|FG001|Overall Study|Protocol Violation|2
6342006|NCT03310775|10098352|FG000|Overall Study|Lost to Follow-up|2
6342007|NCT03310775|10098353|FG001|Overall Study|Lost to Follow-up|3
6342008|NCT03310775|10098352|FG000|Overall Study|aggravation of depression|0
6342009|NCT03310775|10098353|FG001|Overall Study|aggravation of depression|1
6342010|NCT03310970|10098359|FG000|Overall Study|Withdrawal by Subject|0
6342011|NCT03310970|10098360|FG001|Overall Study|Withdrawal by Subject|1
6342012|NCT03311230|10098371|FG000|Overall Study|Withdrawal by Subject|1
6342013|NCT03311230|10098372|FG001|Overall Study|Withdrawal by Subject|4
6342014|NCT03311230|10098373|FG002|Overall Study|Withdrawal by Subject|2
6342015|NCT03311230|10098374|FG003|Overall Study|Withdrawal by Subject|7
6342016|NCT03311230|10098371|FG000|Overall Study|Unrelated injury|0
6342017|NCT03311230|10098372|FG001|Overall Study|Unrelated injury|1
6342018|NCT03311230|10098373|FG002|Overall Study|Unrelated injury|0
6342019|NCT03311230|10098374|FG003|Overall Study|Unrelated injury|0
6342020|NCT03311373|10098384|FG000|Overall Study|Adverse Event|1
6342021|NCT03311373|10098384|FG000|Overall Study|Protocol Discontinuation Criteria|3
6342022|NCT03311373|10098384|FG000|Overall Study|Lost to Follow-up|1
6342023|NCT03311373|10098384|FG000|Overall Study|Physician Decision|1
6342024|NCT03311373|10098384|FG000|Overall Study|Withdrawal by Subject|3
6342025|NCT03311646|10098394|FG000|Overall Study|Physician Decision|1
6342026|NCT03311646|10098394|FG000|Overall Study|Withdrawal by Subject|5
6342027|NCT03311646|10098394|FG000|Overall Study|Lost to Follow-up|5
6342028|NCT03311646|10098394|FG000|Overall Study|PI Withdrawal for Positive Drug Screen|4
6342029|NCT03311659|10098399|FG000|Overall Study|Protocol Violation|1
6342030|NCT03311724|10098407|FG000|Overall Study|Physician Decision|0
6342031|NCT03311724|10098408|FG001|Overall Study|Physician Decision|0
6342032|NCT03311724|10098409|FG002|Overall Study|Physician Decision|0
6342033|NCT03311724|10098410|FG003|Overall Study|Physician Decision|1
6342034|NCT03311724|10098407|FG000|Overall Study|Protocol Violation|1
6342035|NCT03311724|10098408|FG001|Overall Study|Protocol Violation|0
6342036|NCT03311724|10098409|FG002|Overall Study|Protocol Violation|1
6342037|NCT03311724|10098410|FG003|Overall Study|Protocol Violation|0
6342038|NCT03311724|10098407|FG000|Overall Study|Withdrawal by Subject|1
6342039|NCT03311724|10098408|FG001|Overall Study|Withdrawal by Subject|1
6342040|NCT03311724|10098409|FG002|Overall Study|Withdrawal by Subject|0
6342041|NCT03311724|10098410|FG003|Overall Study|Withdrawal by Subject|0
6342042|NCT03311724|10098407|FG000|Overall Study|Lost to Follow-up|1
6342043|NCT03311724|10098408|FG001|Overall Study|Lost to Follow-up|0
6342044|NCT03311724|10098409|FG002|Overall Study|Lost to Follow-up|0
6342045|NCT03311724|10098410|FG003|Overall Study|Lost to Follow-up|0
6342046|NCT03311724|10098407|FG000|Overall Study|Sponsor Decision|0
6342047|NCT03311724|10098408|FG001|Overall Study|Sponsor Decision|0
6342048|NCT03311724|10098409|FG002|Overall Study|Sponsor Decision|1
6342049|NCT03311724|10098410|FG003|Overall Study|Sponsor Decision|0
6342050|NCT03311841|10098428|FG000|14-day Wash-out|Adverse Event|0
6042977|NCT00386009|9641454|FG001|Overall Study|Sponsor Decision|1
6042978|NCT00386009|9641453|FG000|Overall Study|Withdrawal by Subject|5
6042979|NCT00386009|9641454|FG001|Overall Study|Withdrawal by Subject|4
6342051|NCT03311841|10098429|FG001|14-day Wash-out|Adverse Event|1
6342052|NCT03311841|10098430|FG002|14-day Wash-out|Adverse Event|0
6342053|NCT03311841|10098431|FG003|14-day Wash-out|Adverse Event|0
6342054|NCT03311841|10098432|FG004|14-day Wash-out|Adverse Event|0
6342055|NCT03311841|10098428|FG000|14-day Wash-out|Non-Compliance With Study Drug|0
6342056|NCT03311841|10098429|FG001|14-day Wash-out|Non-Compliance With Study Drug|0
6342057|NCT03311841|10098430|FG002|14-day Wash-out|Non-Compliance With Study Drug|0
6342058|NCT03311841|10098431|FG003|14-day Wash-out|Non-Compliance With Study Drug|1
6342059|NCT03311841|10098432|FG004|14-day Wash-out|Non-Compliance With Study Drug|0
6342060|NCT03312114|10098471|FG000|Overall Study|All the five enrolled dropped out of the|5
6342061|NCT03312218|10098478|FG000|Overall Study|Never signed in to access the app|54
6342062|NCT03312218|10098479|FG001|Overall Study|Never signed in to access the app|58
6342063|NCT03312231|10098490|FG000|Overall Study|Lost to Follow-up|2
6342064|NCT03312231|10098491|FG001|Overall Study|Lost to Follow-up|6
6342065|NCT03312231|10098492|FG002|Overall Study|Lost to Follow-up|1
6342066|NCT03312231|10098493|FG003|Overall Study|Lost to Follow-up|3
6342067|NCT03312231|10098494|FG004|Overall Study|Lost to Follow-up|1
6342068|NCT03312231|10098490|FG000|Overall Study|Withdrawal by Subject|0
6342069|NCT03312231|10098491|FG001|Overall Study|Withdrawal by Subject|3
6342070|NCT03312231|10098492|FG002|Overall Study|Withdrawal by Subject|1
6342071|NCT03312231|10098493|FG003|Overall Study|Withdrawal by Subject|0
6342072|NCT03312231|10098494|FG004|Overall Study|Withdrawal by Subject|0
6342073|NCT03312231|10098490|FG000|Overall Study|Death|0
6342074|NCT03312231|10098491|FG001|Overall Study|Death|1
6342075|NCT03312231|10098492|FG002|Overall Study|Death|1
6342076|NCT03312231|10098493|FG003|Overall Study|Death|0
6342077|NCT03312231|10098494|FG004|Overall Study|Death|0
6342078|NCT03312231|10098490|FG000|Overall Study|Study Vaccination not Received|1
6342079|NCT03312231|10098491|FG001|Overall Study|Study Vaccination not Received|1
6342080|NCT03312231|10098492|FG002|Overall Study|Study Vaccination not Received|1
6342081|NCT03312231|10098493|FG003|Overall Study|Study Vaccination not Received|0
6342082|NCT03312231|10098494|FG004|Overall Study|Study Vaccination not Received|0
6342083|NCT03312543|10098525|FG000|Before Treatment (Screening to Baseline)|Lost to Follow-up|0
6342084|NCT03312543|10098526|FG001|Before Treatment (Screening to Baseline)|Lost to Follow-up|2
6342085|NCT03312543|10098525|FG000|Before Treatment (Screening to Baseline)|Withdrawal by Subject|1
6342086|NCT03312543|10098526|FG001|Before Treatment (Screening to Baseline)|Withdrawal by Subject|2
6342087|NCT03312543|10098525|FG000|Treatment (Baseline to Week 12)|Withdrawal by Subject|3
6342088|NCT03312543|10098526|FG001|Treatment (Baseline to Week 12)|Withdrawal by Subject|4
6342089|NCT03312543|10098525|FG000|Treatment (Baseline to Week 12)|Protocol Violation|1
6342090|NCT03312543|10098526|FG001|Treatment (Baseline to Week 12)|Protocol Violation|1
6342091|NCT03312543|10098525|FG000|Regression (Week 12 to Week 24)|Protocol Violation|1
6342092|NCT03312543|10098526|FG001|Regression (Week 12 to Week 24)|Protocol Violation|1
6342093|NCT03312543|10098525|FG000|Regression (Week 12 to Week 24)|Death|0
6342094|NCT03312543|10098526|FG001|Regression (Week 12 to Week 24)|Death|1
6342095|NCT03312933|10098536|FG000|Overall Study|Protocol Violation|15
6342096|NCT03312933|10098536|FG000|Overall Study|Lost to Follow-up|36
6342097|NCT03312933|10098536|FG000|Overall Study|Withdrawal by Subject|3
6342098|NCT03313037|10098542|FG000|Overall Study|Protocol Violation|4
6342099|NCT03313037|10098543|FG001|Overall Study|Protocol Violation|1
6342100|NCT03313037|10098542|FG000|Overall Study|Other|1
6342101|NCT03313037|10098543|FG001|Overall Study|Other|1
6342102|NCT03313037|10098542|FG000|Overall Study|Withdrawal by Subject|4
6342103|NCT03313037|10098543|FG001|Overall Study|Withdrawal by Subject|3
6342104|NCT03313037|10098542|FG000|Overall Study|No longer meets eligibility criteria|1
6342105|NCT03313037|10098543|FG001|Overall Study|No longer meets eligibility criteria|7
6342106|NCT03313037|10098542|FG000|Overall Study|Lost to Follow-up|9
6342107|NCT03313037|10098543|FG001|Overall Study|Lost to Follow-up|8
6342108|NCT03313037|10098542|FG000|Overall Study|Randomized but not treated|1
6342109|NCT03313037|10098543|FG001|Overall Study|Randomized but not treated|0
6342110|NCT03313050|10098553|FG000|Stage 2: 12 Months|Adverse Event|0
6342111|NCT03313050|10098554|FG001|Stage 2: 12 Months|Adverse Event|0
6342112|NCT03313050|10098555|FG002|Stage 2: 12 Months|Adverse Event|0
6342113|NCT03313050|10098556|FG003|Stage 2: 12 Months|Adverse Event|1
6342114|NCT03313050|10098553|FG000|Stage 2: 12 Months|Death|0
6342115|NCT03313050|10098554|FG001|Stage 2: 12 Months|Death|0
6342116|NCT03313050|10098555|FG002|Stage 2: 12 Months|Death|3
6342117|NCT03313050|10098556|FG003|Stage 2: 12 Months|Death|0
6342118|NCT03313050|10098553|FG000|Stage 2: 12 Months|Lost to Follow-up|0
6342119|NCT03313050|10098554|FG001|Stage 2: 12 Months|Lost to Follow-up|0
6342120|NCT03313050|10098555|FG002|Stage 2: 12 Months|Lost to Follow-up|1
6342121|NCT03313050|10098556|FG003|Stage 2: 12 Months|Lost to Follow-up|5
6342122|NCT03313050|10098553|FG000|Stage 2: 12 Months|No Longer Meets Eligibility Criteria|0
6342123|NCT03313050|10098554|FG001|Stage 2: 12 Months|No Longer Meets Eligibility Criteria|0
6342124|NCT03313050|10098555|FG002|Stage 2: 12 Months|No Longer Meets Eligibility Criteria|0
6342125|NCT03313050|10098556|FG003|Stage 2: 12 Months|No Longer Meets Eligibility Criteria|3
6342126|NCT03313050|10098553|FG000|Stage 2: 12 Months|Protocol deviation|0
6342127|NCT03313050|10098554|FG001|Stage 2: 12 Months|Protocol deviation|0
6342128|NCT03313050|10098555|FG002|Stage 2: 12 Months|Protocol deviation|7
6342129|NCT03313050|10098556|FG003|Stage 2: 12 Months|Protocol deviation|7
6342130|NCT03313050|10098553|FG000|Stage 2: 12 Months|Withdrawal by Subject|0
6342131|NCT03313050|10098554|FG001|Stage 2: 12 Months|Withdrawal by Subject|0
6342132|NCT03313050|10098555|FG002|Stage 2: 12 Months|Withdrawal by Subject|0
6342133|NCT03313050|10098556|FG003|Stage 2: 12 Months|Withdrawal by Subject|3
6342134|NCT03313050|10098553|FG000|Stage 2: 12 Months|Other|0
6342135|NCT03313050|10098554|FG001|Stage 2: 12 Months|Other|0
6342136|NCT03313050|10098555|FG002|Stage 2: 12 Months|Other|0
6342137|NCT03313050|10098556|FG003|Stage 2: 12 Months|Other|1
6342138|NCT03313076|10098570|FG000|Overall Study|Withdrawal by Subject|2
6342139|NCT03313076|10098571|FG001|Overall Study|Withdrawal by Subject|0
6342140|NCT03313076|10098572|FG002|Overall Study|Withdrawal by Subject|0
6342141|NCT03313076|10098573|FG003|Overall Study|Withdrawal by Subject|0
6342142|NCT03313076|10098570|FG000|Overall Study|Lost to Follow-up|0
6342143|NCT03313076|10098571|FG001|Overall Study|Lost to Follow-up|2
6342144|NCT03313076|10098572|FG002|Overall Study|Lost to Follow-up|2
6342145|NCT03313076|10098573|FG003|Overall Study|Lost to Follow-up|2
6342146|NCT03313310|10098591|FG000|Phase 2|Lost to Follow-up|4
6342147|NCT03313310|10098592|FG001|Phase 2|Lost to Follow-up|0
6342148|NCT03313310|10098591|FG000|Phase 3|Lost to Follow-up|0
6342149|NCT03313310|10098592|FG001|Phase 3|Lost to Follow-up|1
6342150|NCT03314233|10098598|FG000|Overall Study|No longer eligible at time of delivery|1
6342151|NCT03314519|10098604|FG000|Overall Study|Protocol Violation|3
6342152|NCT03314519|10098605|FG001|Overall Study|Protocol Violation|2
6342153|NCT03314662|10098614|FG000|Overall Study|Withdrawal by Subject|1
6342154|NCT03314662|10098615|FG001|Overall Study|Withdrawal by Subject|1
6342155|NCT03314662|10098616|FG002|Overall Study|Withdrawal by Subject|1
6342156|NCT03314662|10098614|FG000|Overall Study|Lost to Follow-up|5
6342157|NCT03314662|10098615|FG001|Overall Study|Lost to Follow-up|4
6342158|NCT03314662|10098616|FG002|Overall Study|Lost to Follow-up|4
6342159|NCT03314662|10098614|FG000|Overall Study|Death|2
6342160|NCT03314662|10098615|FG001|Overall Study|Death|0
6342161|NCT03314662|10098616|FG002|Overall Study|Death|0
6342162|NCT03314857|10098641|FG000|Overall Study|Death|4
6342163|NCT03314857|10098641|FG000|Overall Study|Physician Decision|1
6342164|NCT03315208|10098660|FG000|Overall Study|Lost to Follow-up|11
6342165|NCT03315208|10098661|FG001|Overall Study|Lost to Follow-up|6
6342166|NCT03315208|10098660|FG000|Overall Study|Withdrawal by Subject|2
6342167|NCT03315208|10098661|FG001|Overall Study|Withdrawal by Subject|0
6342168|NCT03315286|10098670|FG000|Overall Study|Lost to Follow-up|0
6342169|NCT03315286|10098671|FG001|Overall Study|Lost to Follow-up|3
6342170|NCT03315286|10098670|FG000|Overall Study|Withdrawal by Subject|1
6342171|NCT03315286|10098671|FG001|Overall Study|Withdrawal by Subject|0
6342172|NCT03315286|10098670|FG000|Overall Study|Protocol Violation|0
6342173|NCT03315286|10098671|FG001|Overall Study|Protocol Violation|1
6342174|NCT03315689|10098696|FG000|Double-blind Period = 28 Days|Withdrawal by Subject|1
6342175|NCT03315689|10098697|FG001|Double-blind Period = 28 Days|Withdrawal by Subject|0
6342176|NCT03315689|10098696|FG000|Open Label Extension = 52 Weeks|Withdrawal by Subject|0
6342177|NCT03315689|10098697|FG001|Open Label Extension = 52 Weeks|Withdrawal by Subject|2
6342178|NCT03315689|10098696|FG000|Open Label Extension = 52 Weeks|Lost to Follow-up|0
6342179|NCT03315689|10098697|FG001|Open Label Extension = 52 Weeks|Lost to Follow-up|1
6342180|NCT03315793|10098719|FG000|Overall Study|Adverse Event|4
6342181|NCT03315793|10098720|FG001|Overall Study|Adverse Event|2
6342182|NCT03315793|10098719|FG000|Overall Study|Protocol Deviation|1
6342183|NCT03315793|10098720|FG001|Overall Study|Protocol Deviation|0
6342184|NCT03315793|10098719|FG000|Overall Study|Difficult for regular visit|0
6342185|NCT03315793|10098720|FG001|Overall Study|Difficult for regular visit|1
6342186|NCT03316131|10098737|FG000|Treatment Period 2|Protocol deviation|1
6342187|NCT03316131|10098738|FG001|Treatment Period 2|Protocol deviation|0
6342188|NCT03316170|10098746|FG000|Overall Study|Death|1
6342189|NCT03316170|10098747|FG001|Overall Study|Death|0
6342190|NCT03316170|10098746|FG000|Overall Study|Lost to Follow-up|6
6342191|NCT03316170|10098747|FG001|Overall Study|Lost to Follow-up|7
6342192|NCT03316547|10098766|FG000|Overall Study|Death|3
6342193|NCT03316547|10098767|FG001|Overall Study|Death|1
6342194|NCT03316547|10098766|FG000|Overall Study|Lost to Follow-up|6
6342195|NCT03316547|10098767|FG001|Overall Study|Lost to Follow-up|6
6342196|NCT03316547|10098766|FG000|Overall Study|Withdrawal by Subject|3
6342197|NCT03316547|10098767|FG001|Overall Study|Withdrawal by Subject|2
6342198|NCT03316547|10098766|FG000|Overall Study|Transfer to another hospital|6
6342199|NCT03316547|10098767|FG001|Overall Study|Transfer to another hospital|4
6342200|NCT03316911|10098777|FG000|Overall Study|Lost to Follow-up|33
6342201|NCT03316911|10098778|FG001|Overall Study|Lost to Follow-up|29
6342202|NCT03317379|10098827|FG000|Overall Study|Lost to Follow-up|0
6342203|NCT03317379|10098828|FG001|Overall Study|Lost to Follow-up|3
6342204|NCT03317379|10098829|FG002|Overall Study|Lost to Follow-up|2
6342205|NCT03318315|10098853|FG000|Overall Study|Lost to Follow-up|3
6342206|NCT03318315|10098854|FG001|Overall Study|Lost to Follow-up|2
6342207|NCT03318315|10098855|FG002|Overall Study|Lost to Follow-up|1
6342208|NCT03318315|10098853|FG000|Overall Study|Protocol Violation|1
6083322|NCT00634920|9691703|FG000|Period 2 - Post-Randomization|Rejection|11
6083323|NCT00634920|9691704|FG001|Period 2 - Post-Randomization|Rejection|5
6083324|NCT00634920|9691705|FG002|Period 2 - Post-Randomization|Rejection|0
6083325|NCT00634920|9691703|FG000|Period 2 - Post-Randomization|Death|2
6342209|NCT03318315|10098854|FG001|Overall Study|Protocol Violation|1
6342210|NCT03318315|10098855|FG002|Overall Study|Protocol Violation|1
6342211|NCT03318315|10098853|FG000|Overall Study|Withdrawal by Subject|0
6342212|NCT03318315|10098854|FG001|Overall Study|Withdrawal by Subject|0
6342213|NCT03318315|10098855|FG002|Overall Study|Withdrawal by Subject|2
6342214|NCT03318783|10098877|FG000|Overall Study|Withdrawal by Subject|0
6342215|NCT03318783|10098878|FG001|Overall Study|Withdrawal by Subject|1
6342216|NCT03318783|10098877|FG000|Overall Study|Death|0
6342217|NCT03318783|10098878|FG001|Overall Study|Death|1
6342218|NCT03319212|10098921|FG000|Overall Study|Discontinued as moving out of local area|0
6342219|NCT03319212|10098922|FG001|Overall Study|Discontinued as moving out of local area|1
6342220|NCT03319212|10098921|FG000|Overall Study|Adverse Event|2
6342221|NCT03319212|10098922|FG001|Overall Study|Adverse Event|2
6342222|NCT03319212|10098921|FG000|Overall Study|Withdrawal by Subject|0
6342223|NCT03319212|10098922|FG001|Overall Study|Withdrawal by Subject|1
6342224|NCT03319212|10098921|FG000|Overall Study|Lost to Follow-up|0
6342225|NCT03319212|10098922|FG001|Overall Study|Lost to Follow-up|1
6342226|NCT03319212|10098921|FG000|Overall Study|Physician Decision|1
6342227|NCT03319212|10098922|FG001|Overall Study|Physician Decision|0
6342228|NCT03319719|10098936|FG000|Overall Study|Lost to Follow-up|1
6342229|NCT03319953|10098950|FG000|Period 2 (Day 49 to 154)|Withdrawal by Subject|1
6342230|NCT03319953|10098951|FG001|Period 2 (Day 49 to 154)|Withdrawal by Subject|0
6342231|NCT03319953|10098952|FG002|Period 2 (Day 49 to 154)|Withdrawal by Subject|0
6342232|NCT03319953|10098953|FG003|Period 2 (Day 49 to 154)|Withdrawal by Subject|0
6342233|NCT03319953|10098950|FG000|Period 2 (Day 49 to 154)|Reason not Specified|0
6342234|NCT03319953|10098951|FG001|Period 2 (Day 49 to 154)|Reason not Specified|0
6342235|NCT03319953|10098952|FG002|Period 2 (Day 49 to 154)|Reason not Specified|1
6342236|NCT03319953|10098953|FG003|Period 2 (Day 49 to 154)|Reason not Specified|1
6342237|NCT03320057|10098961|FG000|Overall Study|Lost to Follow-up|4
6342238|NCT03320057|10098962|FG001|Overall Study|Lost to Follow-up|17
6342239|NCT03320057|10098961|FG000|Overall Study|Did not take mifepristone or misoprostol|2
6342240|NCT03320057|10098962|FG001|Overall Study|Did not take mifepristone or misoprostol|0
6342241|NCT03320369|10098972|FG000|Overall Study|Adverse Event|1
6342242|NCT03320369|10098972|FG000|Overall Study|Withdrawal by Subject|2
6342243|NCT03320824|10098978|FG000|Overall Study|Withdrawal by Subject|8
6342244|NCT03320824|10098979|FG001|Overall Study|Withdrawal by Subject|1
6342245|NCT03320824|10098978|FG000|Overall Study|Lost to Follow-up|10
6342246|NCT03320824|10098979|FG001|Overall Study|Lost to Follow-up|1
6342247|NCT03320824|10098978|FG000|Overall Study|moved out of state|0
6342248|NCT03320824|10098979|FG001|Overall Study|moved out of state|1
6342249|NCT03320824|10098978|FG000|Overall Study|could not complete final visit|0
6342250|NCT03320824|10098979|FG001|Overall Study|could not complete final visit|1
6342251|NCT03320850|10098995|FG000|Overall Study|Lost to Follow-up|0
6342252|NCT03320850|10098996|FG001|Overall Study|Lost to Follow-up|0
6342253|NCT03320850|10098997|FG002|Overall Study|Lost to Follow-up|0
6342254|NCT03320850|10098998|FG003|Overall Study|Lost to Follow-up|0
6342255|NCT03320850|10098999|FG004|Overall Study|Lost to Follow-up|1
6342256|NCT03320850|10099000|FG005|Overall Study|Lost to Follow-up|2
6342257|NCT03320850|10099001|FG006|Overall Study|Lost to Follow-up|2
6342258|NCT03320850|10099002|FG007|Overall Study|Lost to Follow-up|0
6342259|NCT03320850|10099003|FG008|Overall Study|Lost to Follow-up|6
6342260|NCT03320850|10099004|FG009|Overall Study|Lost to Follow-up|4
6342261|NCT03320850|10098995|FG000|Overall Study|Withdrawal by Subject|0
6342262|NCT03320850|10098996|FG001|Overall Study|Withdrawal by Subject|0
6342263|NCT03320850|10098997|FG002|Overall Study|Withdrawal by Subject|0
6342264|NCT03320850|10098998|FG003|Overall Study|Withdrawal by Subject|0
6342265|NCT03320850|10098999|FG004|Overall Study|Withdrawal by Subject|1
6342266|NCT03320850|10099000|FG005|Overall Study|Withdrawal by Subject|2
6342267|NCT03320850|10099001|FG006|Overall Study|Withdrawal by Subject|4
6342268|NCT03320850|10099002|FG007|Overall Study|Withdrawal by Subject|5
6342269|NCT03320850|10099003|FG008|Overall Study|Withdrawal by Subject|2
6342270|NCT03320850|10099004|FG009|Overall Study|Withdrawal by Subject|1
6342271|NCT03320850|10098995|FG000|Overall Study|Lack of Efficacy|0
6342272|NCT03320850|10098996|FG001|Overall Study|Lack of Efficacy|0
6342273|NCT03320850|10098997|FG002|Overall Study|Lack of Efficacy|0
6342274|NCT03320850|10098998|FG003|Overall Study|Lack of Efficacy|1
6342275|NCT03320850|10098999|FG004|Overall Study|Lack of Efficacy|0
6342276|NCT03320850|10099000|FG005|Overall Study|Lack of Efficacy|1
6342277|NCT03320850|10099001|FG006|Overall Study|Lack of Efficacy|0
6342278|NCT03320850|10099002|FG007|Overall Study|Lack of Efficacy|2
6342279|NCT03320850|10099003|FG008|Overall Study|Lack of Efficacy|0
6342280|NCT03320850|10099004|FG009|Overall Study|Lack of Efficacy|3
6342281|NCT03320850|10098995|FG000|Overall Study|Failure to Meet Randomization Criteria|0
6342282|NCT03320850|10098996|FG001|Overall Study|Failure to Meet Randomization Criteria|0
6342283|NCT03320850|10098997|FG002|Overall Study|Failure to Meet Randomization Criteria|0
6342284|NCT03320850|10098998|FG003|Overall Study|Failure to Meet Randomization Criteria|0
6342285|NCT03320850|10098999|FG004|Overall Study|Failure to Meet Randomization Criteria|0
6342286|NCT03320850|10099000|FG005|Overall Study|Failure to Meet Randomization Criteria|1
6342287|NCT03320850|10099001|FG006|Overall Study|Failure to Meet Randomization Criteria|0
6342288|NCT03320850|10099002|FG007|Overall Study|Failure to Meet Randomization Criteria|0
6342289|NCT03320850|10099003|FG008|Overall Study|Failure to Meet Randomization Criteria|0
6342290|NCT03320850|10099004|FG009|Overall Study|Failure to Meet Randomization Criteria|0
6342291|NCT03320850|10098995|FG000|Overall Study|Adverse Event|0
6342292|NCT03320850|10098996|FG001|Overall Study|Adverse Event|0
6342293|NCT03320850|10098997|FG002|Overall Study|Adverse Event|0
6342294|NCT03320850|10098998|FG003|Overall Study|Adverse Event|0
6342295|NCT03320850|10098999|FG004|Overall Study|Adverse Event|0
6342296|NCT03320850|10099000|FG005|Overall Study|Adverse Event|2
6342297|NCT03320850|10099001|FG006|Overall Study|Adverse Event|1
6342298|NCT03320850|10099002|FG007|Overall Study|Adverse Event|0
6342299|NCT03320850|10099003|FG008|Overall Study|Adverse Event|2
6342300|NCT03320850|10099004|FG009|Overall Study|Adverse Event|0
6342301|NCT03320850|10098995|FG000|Overall Study|Reason Not Specified|0
6342302|NCT03320850|10098996|FG001|Overall Study|Reason Not Specified|0
6342303|NCT03320850|10098997|FG002|Overall Study|Reason Not Specified|0
6342304|NCT03320850|10098998|FG003|Overall Study|Reason Not Specified|0
6342305|NCT03320850|10098999|FG004|Overall Study|Reason Not Specified|0
6342306|NCT03320850|10099000|FG005|Overall Study|Reason Not Specified|1
6168598|NCT01236352|9813649|FG002|Overall Study|Lack of response to drug|0
6168599|NCT01236352|9813650|FG003|Overall Study|Lack of response to drug|0
6168600|NCT01236352|9813651|FG004|Overall Study|Lack of response to drug|0
6168601|NCT01236352|9813652|FG005|Overall Study|Lack of response to drug|0
6168602|NCT01236352|9813653|FG006|Overall Study|Lack of response to drug|0
6168603|NCT01236352|9813654|FG007|Overall Study|Lack of response to drug|0
6168604|NCT01236352|9813655|FG008|Overall Study|Lack of response to drug|0
6168605|NCT01236352|9813656|FG009|Overall Study|Lack of response to drug|1
6168606|NCT01236352|9813657|FG010|Overall Study|Lack of response to drug|1
6168607|NCT01236352|9813647|FG000|Overall Study|Patient transferred to IST|0
6168608|NCT01236352|9813648|FG001|Overall Study|Patient transferred to IST|0
6168609|NCT01236352|9813649|FG002|Overall Study|Patient transferred to IST|0
6168610|NCT01236352|9813650|FG003|Overall Study|Patient transferred to IST|0
6168611|NCT01236352|9813651|FG004|Overall Study|Patient transferred to IST|0
6168612|NCT01236352|9813652|FG005|Overall Study|Patient transferred to IST|0
6168613|NCT01236352|9813653|FG006|Overall Study|Patient transferred to IST|0
6168614|NCT01236352|9813654|FG007|Overall Study|Patient transferred to IST|0
6168615|NCT01236352|9813655|FG008|Overall Study|Patient transferred to IST|0
6168616|NCT01236352|9813656|FG009|Overall Study|Patient transferred to IST|2
6168617|NCT01236352|9813657|FG010|Overall Study|Patient transferred to IST|6
6168618|NCT01236365|9813683|FG000|Overall Study|Lost to Follow-up|0
6168619|NCT01236365|9813684|FG001|Overall Study|Lost to Follow-up|2
6168620|NCT01236365|9813683|FG000|Overall Study|Moved Out of State|1
6168621|NCT01236365|9813684|FG001|Overall Study|Moved Out of State|0
6168622|NCT01236365|9813683|FG000|Overall Study|Dropped at Randomization due to high LFT|1
6168623|NCT01236365|9813684|FG001|Overall Study|Dropped at Randomization due to high LFT|0
6168624|NCT01236521|9813715|FG000|Overall Study|Withdrawal by Subject|12
6168625|NCT01236521|9813716|FG001|Overall Study|Withdrawal by Subject|17
6168626|NCT01236521|9813715|FG000|Overall Study|Death|2
6168627|NCT01236521|9813716|FG001|Overall Study|Death|1
6168628|NCT01236521|9813715|FG000|Overall Study|Lost to Follow-up|7
6168629|NCT01236521|9813716|FG001|Overall Study|Lost to Follow-up|7
6168630|NCT01236534|9813724|FG000|Overall Study|Adverse Event|3
6168631|NCT01236534|9813725|FG001|Overall Study|Adverse Event|0
6168632|NCT01236573|9813742|FG000|Phase 1-Dose Escalation-Cohorts 5-10|Death during treatment|0
6168633|NCT01236573|9813743|FG001|Phase 1-Dose Escalation-Cohorts 5-10|Death during treatment|0
6168634|NCT01236573|9813744|FG002|Phase 1-Dose Escalation-Cohorts 5-10|Death during treatment|0
6168635|NCT01236573|9813745|FG003|Phase 1-Dose Escalation-Cohorts 5-10|Death during treatment|0
6168636|NCT01236573|9813746|FG004|Phase 1-Dose Escalation-Cohorts 5-10|Death during treatment|0
6168637|NCT01236573|9813747|FG005|Phase 1-Dose Escalation-Cohorts 5-10|Death during treatment|0
6168638|NCT01236573|9813748|FG006|Phase 1-Dose Escalation-Cohorts 5-10|Death during treatment|1
6168639|NCT01236573|9813749|FG007|Phase 1-Dose Escalation-Cohorts 5-10|Death during treatment|0
6168640|NCT01236573|9813750|FG008|Phase 1-Dose Escalation-Cohorts 5-10|Death during treatment|1
6168641|NCT01236573|9813751|FG009|Phase 1-Dose Escalation-Cohorts 5-10|Death during treatment|1
6168642|NCT01236573|9813752|FG010|Phase 1-Dose Escalation-Cohorts 5-10|Death during treatment|0
6168643|NCT01236573|9813742|FG000|Phase 1-Dose Escalation-Cohorts 5-10|Not treated|0
6168644|NCT01236573|9813743|FG001|Phase 1-Dose Escalation-Cohorts 5-10|Not treated|0
6168645|NCT01236573|9813744|FG002|Phase 1-Dose Escalation-Cohorts 5-10|Not treated|0
6168646|NCT01236573|9813745|FG003|Phase 1-Dose Escalation-Cohorts 5-10|Not treated|0
6168647|NCT01236573|9813746|FG004|Phase 1-Dose Escalation-Cohorts 5-10|Not treated|0
6168648|NCT01236573|9813747|FG005|Phase 1-Dose Escalation-Cohorts 5-10|Not treated|0
6168649|NCT01236573|9813748|FG006|Phase 1-Dose Escalation-Cohorts 5-10|Not treated|0
6168650|NCT01236573|9813749|FG007|Phase 1-Dose Escalation-Cohorts 5-10|Not treated|0
6168651|NCT01236573|9813750|FG008|Phase 1-Dose Escalation-Cohorts 5-10|Not treated|1
6168652|NCT01236573|9813751|FG009|Phase 1-Dose Escalation-Cohorts 5-10|Not treated|0
6168653|NCT01236573|9813752|FG010|Phase 1-Dose Escalation-Cohorts 5-10|Not treated|0
6168654|NCT01236573|9813742|FG000|Phase 2- MTD/Anti-IL-12 Cells-Cohort 11|Did not receive cells|0
6168655|NCT01236573|9813743|FG001|Phase 2- MTD/Anti-IL-12 Cells-Cohort 11|Did not receive cells|0
6168656|NCT01236573|9813744|FG002|Phase 2- MTD/Anti-IL-12 Cells-Cohort 11|Did not receive cells|0
6168657|NCT01236573|9813745|FG003|Phase 2- MTD/Anti-IL-12 Cells-Cohort 11|Did not receive cells|0
6168658|NCT01236573|9813746|FG004|Phase 2- MTD/Anti-IL-12 Cells-Cohort 11|Did not receive cells|0
6168659|NCT01236573|9813747|FG005|Phase 2- MTD/Anti-IL-12 Cells-Cohort 11|Did not receive cells|0
6168660|NCT01236573|9813748|FG006|Phase 2- MTD/Anti-IL-12 Cells-Cohort 11|Did not receive cells|0
6168661|NCT01236573|9813749|FG007|Phase 2- MTD/Anti-IL-12 Cells-Cohort 11|Did not receive cells|0
6168662|NCT01236573|9813750|FG008|Phase 2- MTD/Anti-IL-12 Cells-Cohort 11|Did not receive cells|0
6342307|NCT03320850|10099001|FG006|Overall Study|Reason Not Specified|0
6342308|NCT03320850|10099002|FG007|Overall Study|Reason Not Specified|0
6342309|NCT03320850|10099003|FG008|Overall Study|Reason Not Specified|0
6342310|NCT03320850|10099004|FG009|Overall Study|Reason Not Specified|1
6342311|NCT03320941|10099036|FG000|Overall Study|subject/guardian decision|0
6342312|NCT03320941|10099037|FG001|Overall Study|subject/guardian decision|0
6342313|NCT03320941|10099038|FG002|Overall Study|subject/guardian decision|0
6342314|NCT03320941|10099039|FG003|Overall Study|subject/guardian decision|1
6342315|NCT03320941|10099040|FG004|Overall Study|subject/guardian decision|0
6342316|NCT03321006|10099054|FG000|Overall Study|Death|1
6342317|NCT03321006|10099055|FG001|Overall Study|Death|0
6342318|NCT03321006|10099054|FG000|Overall Study|Lack of Efficacy|1
6342319|NCT03321006|10099055|FG001|Overall Study|Lack of Efficacy|0
6342320|NCT03321396|10099074|FG000|Overall Study|Physician Decision|1
6342321|NCT03321721|10099081|FG000|Overall Study|Lost to Follow-up|4
6342322|NCT03321721|10099082|FG001|Overall Study|Lost to Follow-up|8
6342323|NCT03321721|10099083|FG002|Overall Study|Lost to Follow-up|11
6342324|NCT03322423|10099092|FG000|Period 1|Subject no longer eligible|0
6342325|NCT03322423|10099093|FG001|Period 1|Subject no longer eligible|1
6342326|NCT03322423|10099092|FG000|Period 1|Withdrawal by Subject|0
6342327|NCT03322423|10099093|FG001|Period 1|Withdrawal by Subject|1
6342328|NCT03322423|10099092|FG000|Period 1|Incorrect Lens Dispensed|1
6342329|NCT03322423|10099093|FG001|Period 1|Incorrect Lens Dispensed|0
6342330|NCT03322423|10099092|FG000|Period 1|Unsatisfactory Lens Fitting|1
6342331|NCT03322423|10099093|FG001|Period 1|Unsatisfactory Lens Fitting|0
6342332|NCT03322423|10099092|FG000|Period 2|Dispensed incorrect lens in left eye|0
6342333|NCT03322423|10099093|FG001|Period 2|Dispensed incorrect lens in left eye|1
6342334|NCT03322423|10099092|FG000|Period 2|Protocol Violation|1
6342335|NCT03322423|10099093|FG001|Period 2|Protocol Violation|0
6342336|NCT03322423|10099092|FG000|Period 2|Subject not eligible for Pytergiumectomy|0
6342337|NCT03322423|10099093|FG001|Period 2|Subject not eligible for Pytergiumectomy|1
6342338|NCT03322462|10099099|FG000|Overall Study|Technical difficulties|2
6342339|NCT03322462|10099099|FG000|Overall Study|Other|1
6342340|NCT03322514|10099107|FG000|Overall Study|Withdrawal by Subject|1
6342341|NCT03322514|10099108|FG001|Overall Study|Withdrawal by Subject|1
6342342|NCT03323086|10099134|FG000|Overall Study|Lost to Follow-up|3
6342343|NCT03323086|10099135|FG001|Overall Study|Lost to Follow-up|2
6342344|NCT03323164|10099143|FG000|Overall Study|Poor quality imaging/scans|2
6342345|NCT03323164|10099144|FG001|Overall Study|Poor quality imaging/scans|2
6342346|NCT03324581|10099189|FG000|Overall Study|Adverse Event|18
6342347|NCT03324581|10099190|FG001|Overall Study|Adverse Event|11
6342348|NCT03324581|10099191|FG002|Overall Study|Adverse Event|7
6342349|NCT03324581|10099189|FG000|Overall Study|Lack of Efficacy|0
6342350|NCT03324581|10099190|FG001|Overall Study|Lack of Efficacy|1
6342351|NCT03324581|10099191|FG002|Overall Study|Lack of Efficacy|0
6342352|NCT03324581|10099189|FG000|Overall Study|Lost to Follow-up|5
6342353|NCT03324581|10099190|FG001|Overall Study|Lost to Follow-up|3
6342354|NCT03324581|10099191|FG002|Overall Study|Lost to Follow-up|6
6342355|NCT03324581|10099189|FG000|Overall Study|Non-Compliance With Investigational Medicinal Product (IMP)|2
6342356|NCT03324581|10099190|FG001|Overall Study|Non-Compliance With Investigational Medicinal Product (IMP)|2
6342357|NCT03324581|10099191|FG002|Overall Study|Non-Compliance With Investigational Medicinal Product (IMP)|0
6342358|NCT03324581|10099189|FG000|Overall Study|Physician Decision|0
6342359|NCT03324581|10099190|FG001|Overall Study|Physician Decision|1
6342360|NCT03324581|10099191|FG002|Overall Study|Physician Decision|2
6342361|NCT03324581|10099189|FG000|Overall Study|Protocol Deviation|8
6342362|NCT03324581|10099190|FG001|Overall Study|Protocol Deviation|9
6342363|NCT03324581|10099191|FG002|Overall Study|Protocol Deviation|4
6342364|NCT03324581|10099189|FG000|Overall Study|Withdrawal by Subject|6
6342365|NCT03324581|10099190|FG001|Overall Study|Withdrawal by Subject|8
6342366|NCT03324581|10099191|FG002|Overall Study|Withdrawal by Subject|6
6342367|NCT03324581|10099189|FG000|Overall Study|Day 56 Visit was 15 Days Out of the Visit Window|0
6342368|NCT03324581|10099190|FG001|Overall Study|Day 56 Visit was 15 Days Out of the Visit Window|1
6342369|NCT03324581|10099191|FG002|Overall Study|Day 56 Visit was 15 Days Out of the Visit Window|0
6342370|NCT03325010|10099208|FG000|Overall Study|Adverse Event|3
6342371|NCT03325010|10099209|FG001|Overall Study|Adverse Event|8
6342372|NCT03325010|10099208|FG000|Overall Study|Protocol Violation|1
6342373|NCT03325010|10099209|FG001|Overall Study|Protocol Violation|8
6342374|NCT03325010|10099208|FG000|Overall Study|Withdrawal by Subject|1
6342375|NCT03325010|10099209|FG001|Overall Study|Withdrawal by Subject|3
6342376|NCT03325010|10099208|FG000|Overall Study|Lost to Follow-up|1
6342377|NCT03325010|10099209|FG001|Overall Study|Lost to Follow-up|0
6342378|NCT03325010|10099208|FG000|Overall Study|Physician Decision|1
6342379|NCT03325010|10099209|FG001|Overall Study|Physician Decision|1
6342380|NCT03325010|10099208|FG000|Overall Study|Lack of Efficacy|2
6342381|NCT03325010|10099209|FG001|Overall Study|Lack of Efficacy|0
6342382|NCT03325556|10099215|FG000|Open-label Period|Lack of Response in OL period|70
6342383|NCT03325556|10099216|FG001|Open-label Period|Lack of Response in OL period|0
6342384|NCT03325556|10099217|FG002|Open-label Period|Lack of Response in OL period|0
6342385|NCT03325556|10099215|FG000|Open-label Period|Adverse Event|27
6342386|NCT03325556|10099216|FG001|Open-label Period|Adverse Event|0
6342387|NCT03325556|10099217|FG002|Open-label Period|Adverse Event|0
6342388|NCT03325556|10099215|FG000|Open-label Period|Death|1
6342389|NCT03325556|10099216|FG001|Open-label Period|Death|0
6342390|NCT03325556|10099217|FG002|Open-label Period|Death|0
6342391|NCT03325556|10099215|FG000|Open-label Period|Lost to Follow-up|1
6342392|NCT03325556|10099216|FG001|Open-label Period|Lost to Follow-up|0
6342393|NCT03325556|10099217|FG002|Open-label Period|Lost to Follow-up|0
6342394|NCT03325556|10099215|FG000|Open-label Period|Non-compliance with study drug|5
6342395|NCT03325556|10099216|FG001|Open-label Period|Non-compliance with study drug|0
6342396|NCT03325556|10099217|FG002|Open-label Period|Non-compliance with study drug|0
6342397|NCT03325556|10099215|FG000|Open-label Period|Use of prohibited medication|1
6342398|NCT03325556|10099216|FG001|Open-label Period|Use of prohibited medication|0
6342399|NCT03325556|10099217|FG002|Open-label Period|Use of prohibited medication|0
6342400|NCT03325556|10099215|FG000|Open-label Period|Protocol Violation|4
6342401|NCT03325556|10099216|FG001|Open-label Period|Protocol Violation|0
6342402|NCT03325556|10099217|FG002|Open-label Period|Protocol Violation|0
6342403|NCT03325556|10099215|FG000|Open-label Period|Withdrawal by Subject|17
6342404|NCT03325556|10099216|FG001|Open-label Period|Withdrawal by Subject|0
6193364|NCT01437540|9851006|FG000|Overall Study|Withdrawal by Subject|31
6342405|NCT03325556|10099217|FG002|Open-label Period|Withdrawal by Subject|0
6342406|NCT03325556|10099215|FG000|Open-label Period|Not otherwise specified|8
6342407|NCT03325556|10099216|FG001|Open-label Period|Not otherwise specified|0
6342408|NCT03325556|10099217|FG002|Open-label Period|Not otherwise specified|0
6342409|NCT03325556|10099215|FG000|Open-label Period|Administrative discont. at study termination|41
6342410|NCT03325556|10099216|FG001|Open-label Period|Administrative discont. at study termination|0
6342411|NCT03325556|10099217|FG002|Open-label Period|Administrative discont. at study termination|0
6342412|NCT03325556|10099215|FG000|Double-blind Period|Relapse|0
6342413|NCT03325556|10099216|FG001|Double-blind Period|Relapse|15
6342414|NCT03325556|10099217|FG002|Double-blind Period|Relapse|34
6342415|NCT03325556|10099215|FG000|Double-blind Period|Adverse Event|0
6342416|NCT03325556|10099216|FG001|Double-blind Period|Adverse Event|3
6342417|NCT03325556|10099217|FG002|Double-blind Period|Adverse Event|1
6342418|NCT03325556|10099215|FG000|Double-blind Period|Noncompliance with study drug|0
6342419|NCT03325556|10099216|FG001|Double-blind Period|Noncompliance with study drug|0
6342420|NCT03325556|10099217|FG002|Double-blind Period|Noncompliance with study drug|1
6342421|NCT03325556|10099215|FG000|Double-blind Period|Use of prohibited medication|0
6342422|NCT03325556|10099216|FG001|Double-blind Period|Use of prohibited medication|1
6342423|NCT03325556|10099217|FG002|Double-blind Period|Use of prohibited medication|0
6342424|NCT03325556|10099215|FG000|Double-blind Period|Physician Decision|0
6342425|NCT03325556|10099216|FG001|Double-blind Period|Physician Decision|0
6342426|NCT03325556|10099217|FG002|Double-blind Period|Physician Decision|1
6342427|NCT03325556|10099215|FG000|Double-blind Period|Withdrawal by Subject|0
6342428|NCT03325556|10099216|FG001|Double-blind Period|Withdrawal by Subject|6
6342429|NCT03325556|10099217|FG002|Double-blind Period|Withdrawal by Subject|4
6342430|NCT03325556|10099215|FG000|Double-blind Period|Not otherwise specified|0
6342431|NCT03325556|10099216|FG001|Double-blind Period|Not otherwise specified|1
6342432|NCT03325556|10099217|FG002|Double-blind Period|Not otherwise specified|5
6342433|NCT03325556|10099215|FG000|Double-blind Period|Administrative discont. at study termination|0
6342434|NCT03325556|10099216|FG001|Double-blind Period|Administrative discont. at study termination|35
6342435|NCT03325556|10099217|FG002|Double-blind Period|Administrative discont. at study termination|31
6342436|NCT03325673|10099226|FG000|Overall Study|Adverse Event|4
6342437|NCT03325673|10099227|FG001|Overall Study|Adverse Event|0
6342438|NCT03325881|10099246|FG000|Overall Study|Protocol Violation|0
6342439|NCT03325881|10099247|FG001|Overall Study|Protocol Violation|1
6342440|NCT03325881|10099246|FG000|Overall Study|Withdrawal by Subject|0
6342441|NCT03325881|10099247|FG001|Overall Study|Withdrawal by Subject|2
6342442|NCT03325881|10099246|FG000|Overall Study|Lack of Efficacy|2
6342443|NCT03325881|10099247|FG001|Overall Study|Lack of Efficacy|0
6342444|NCT03325881|10099246|FG000|Overall Study|Not treated|1
6342445|NCT03325881|10099247|FG001|Overall Study|Not treated|0
6342446|NCT03325894|10099257|FG000|Overall Study|Adverse Event|2
6342447|NCT03325894|10099258|FG001|Overall Study|Adverse Event|3
6342448|NCT03325894|10099257|FG000|Overall Study|Protocol Violation|1
6342449|NCT03325894|10099258|FG001|Overall Study|Protocol Violation|2
6342450|NCT03325894|10099257|FG000|Overall Study|Withdrawal by Subject|10
6342451|NCT03325894|10099258|FG001|Overall Study|Withdrawal by Subject|6
6342452|NCT03325894|10099257|FG000|Overall Study|Lost to Follow-up|4
6342453|NCT03325894|10099258|FG001|Overall Study|Lost to Follow-up|9
6342454|NCT03325894|10099257|FG000|Overall Study|Lack of Efficacy|8
6342455|NCT03325894|10099258|FG001|Overall Study|Lack of Efficacy|14
6342456|NCT03325894|10099257|FG000|Overall Study|Study Terminated by Sponsor|38
6342457|NCT03325894|10099258|FG001|Overall Study|Study Terminated by Sponsor|43
6342458|NCT03325894|10099257|FG000|Overall Study|Other (Not received Treatment)|1
6342459|NCT03325894|10099258|FG001|Overall Study|Other (Not received Treatment)|0
6342460|NCT03326323|10099267|FG000|Overall Study|Unable to receive ANH protocol|3
6342461|NCT03326518|10099274|FG000|Overall Study|Protocol Violation|1
6342462|NCT03326518|10099275|FG001|Overall Study|Protocol Violation|0
6342463|NCT03326518|10099276|FG002|Overall Study|Protocol Violation|0
6342464|NCT03326518|10099274|FG000|Overall Study|Withdrawal by Subject|1
6342465|NCT03326518|10099275|FG001|Overall Study|Withdrawal by Subject|0
6342466|NCT03326518|10099276|FG002|Overall Study|Withdrawal by Subject|0
6342467|NCT03326518|10099274|FG000|Overall Study|Lost to Follow-up|1
6342468|NCT03326518|10099275|FG001|Overall Study|Lost to Follow-up|0
6342469|NCT03326518|10099276|FG002|Overall Study|Lost to Follow-up|1
6342470|NCT03327220|10099359|FG000|Overall Study|Adverse Event (AE)/Serious Adverse Event (SAE)|1
6342471|NCT03327220|10099360|FG001|Overall Study|Adverse Event (AE)/Serious Adverse Event (SAE)|2
6342472|NCT03327220|10099359|FG000|Overall Study|Investigator Decision|2
6342473|NCT03327220|10099360|FG001|Overall Study|Investigator Decision|0
6342474|NCT03327220|10099359|FG000|Overall Study|Missed Visit 6 (Week 6 Visit)|0
6342475|NCT03327220|10099360|FG001|Overall Study|Missed Visit 6 (Week 6 Visit)|1
6342476|NCT03327220|10099359|FG000|Overall Study|Fungal infection|1
6342477|NCT03327220|10099360|FG001|Overall Study|Fungal infection|0
6342478|NCT03327220|10099359|FG000|Overall Study|Discharged to Rehabilitation|0
6342479|NCT03327220|10099360|FG001|Overall Study|Discharged to Rehabilitation|1
6342480|NCT03327220|10099359|FG000|Overall Study|Missing|1
6342481|NCT03327220|10099360|FG001|Overall Study|Missing|0
6342482|NCT03327402|10099366|FG000|Overall Study|Withdrawal by Subject|1
6342483|NCT03327402|10099366|FG000|Overall Study|Other (Visit Out-Of-Window)|1
6342484|NCT03328182|10099380|FG000|Overall Study|Withdrawal by Subject|1
6342485|NCT03328182|10099380|FG000|Overall Study|Protocol Violation|2
6342486|NCT03328182|10099380|FG000|Overall Study|No Product Evaluated|1
6342487|NCT03328325|10099393|FG000|Overall Study|Lost to Follow-up|4
6342488|NCT03328325|10099393|FG000|Overall Study|Physician Decision|1
6342489|NCT03328325|10099393|FG000|Overall Study|Withdrawal by Subject|3
6342490|NCT03328325|10099393|FG000|Overall Study|Early Study Termination due to COVID-19 pandemic|3
6342491|NCT03328832|10099403|FG000|Overall Study|Lost to Follow-up|0
6342492|NCT03328832|10099404|FG001|Overall Study|Lost to Follow-up|1
6342493|NCT03328897|10099413|FG000|Randomized-treatment Epoch|Adverse Event|4
6342494|NCT03328897|10099414|FG001|Randomized-treatment Epoch|Adverse Event|1
6342495|NCT03328897|10099415|FG002|Randomized-treatment Epoch|Adverse Event|1
6342496|NCT03328897|10099413|FG000|Randomized-treatment Epoch|Lost to Follow-up|0
6342497|NCT03328897|10099414|FG001|Randomized-treatment Epoch|Lost to Follow-up|1
6342498|NCT03328897|10099415|FG002|Randomized-treatment Epoch|Lost to Follow-up|0
6342499|NCT03328897|10099413|FG000|Randomized-treatment Epoch|Pregnancy|3
6342500|NCT03328897|10099414|FG001|Randomized-treatment Epoch|Pregnancy|0
6342501|NCT03328897|10099415|FG002|Randomized-treatment Epoch|Pregnancy|0
6342502|NCT03328897|10099413|FG000|Randomized-treatment Epoch|Patient/guardian decision|8
6342503|NCT03328897|10099414|FG001|Randomized-treatment Epoch|Patient/guardian decision|3
6342504|NCT03328897|10099415|FG002|Randomized-treatment Epoch|Patient/guardian decision|1
6342505|NCT03328897|10099413|FG000|Randomized-treatment Epoch|Lack of Efficacy|1
6342506|NCT03328897|10099414|FG001|Randomized-treatment Epoch|Lack of Efficacy|0
6342507|NCT03328897|10099415|FG002|Randomized-treatment Epoch|Lack of Efficacy|0
6342508|NCT03328897|10099413|FG000|Follow-up Epoch|Adverse Event|4
6342509|NCT03328897|10099414|FG001|Follow-up Epoch|Adverse Event|0
6342510|NCT03328897|10099415|FG002|Follow-up Epoch|Adverse Event|1
6083326|NCT00634920|9691704|FG001|Period 2 - Post-Randomization|Death|5
6342511|NCT03328897|10099413|FG000|Follow-up Epoch|Lack of Efficacy|1
6342512|NCT03328897|10099414|FG001|Follow-up Epoch|Lack of Efficacy|1
6342513|NCT03328897|10099415|FG002|Follow-up Epoch|Lack of Efficacy|1
6342514|NCT03328897|10099413|FG000|Follow-up Epoch|Lost to Follow-up|0
6083327|NCT00634920|9691705|FG002|Period 2 - Post-Randomization|Death|0
6083328|NCT00634920|9691703|FG000|Period 2 - Post-Randomization|consent withdrawal, non compliance|9
6083329|NCT00634920|9691704|FG001|Period 2 - Post-Randomization|consent withdrawal, non compliance|13
6083330|NCT00634920|9691705|FG002|Period 2 - Post-Randomization|consent withdrawal, non compliance|0
6087754|NCT00670449|9698231|FG000|Overall Study|Protocol Deviation|1
6342515|NCT03328897|10099414|FG001|Follow-up Epoch|Lost to Follow-up|1
6342516|NCT03328897|10099415|FG002|Follow-up Epoch|Lost to Follow-up|0
6342517|NCT03328897|10099413|FG000|Follow-up Epoch|Pregnancy|1
6342518|NCT03328897|10099414|FG001|Follow-up Epoch|Pregnancy|0
6342519|NCT03328897|10099415|FG002|Follow-up Epoch|Pregnancy|0
6342520|NCT03328897|10099413|FG000|Follow-up Epoch|Patient/guardian decision|2
6342521|NCT03328897|10099414|FG001|Follow-up Epoch|Patient/guardian decision|1
6342522|NCT03328897|10099415|FG002|Follow-up Epoch|Patient/guardian decision|0
6342523|NCT03329196|10099430|FG000|Overall Study|Adverse Event|10
6342524|NCT03329196|10099431|FG001|Overall Study|Adverse Event|5
6342525|NCT03329196|10099430|FG000|Overall Study|Physician Decision|2
6342526|NCT03329196|10099431|FG001|Overall Study|Physician Decision|2
6342527|NCT03329196|10099430|FG000|Overall Study|Withdrawal by Subject|11
6342528|NCT03329196|10099431|FG001|Overall Study|Withdrawal by Subject|3
6342529|NCT03329196|10099430|FG000|Overall Study|Hepatic function abnormalities|0
6342530|NCT03329196|10099431|FG001|Overall Study|Hepatic function abnormalities|1
6342531|NCT03329196|10099430|FG000|Overall Study|Conducting rescue therapy before Week 24|2
6342532|NCT03329196|10099431|FG001|Overall Study|Conducting rescue therapy before Week 24|1
6342533|NCT03329196|10099430|FG000|Overall Study|Difficult to control Hb|2
6342534|NCT03329196|10099431|FG001|Overall Study|Difficult to control Hb|3
6342535|NCT03329196|10099430|FG000|Overall Study|Dialysis or renal transplant|13
6342536|NCT03329196|10099431|FG001|Overall Study|Dialysis or renal transplant|15
6342537|NCT03329573|10099451|FG000|Treatment Period 1 (Up to 5 Days)|Adverse Event|0
6342538|NCT03329573|10099452|FG001|Treatment Period 1 (Up to 5 Days)|Adverse Event|1
6342539|NCT03329573|10099453|FG002|Treatment Period 1 (Up to 5 Days)|Adverse Event|0
6342540|NCT03329573|10099454|FG003|Treatment Period 1 (Up to 5 Days)|Adverse Event|0
6342541|NCT03329573|10099451|FG000|Treatment Period 1 (Up to 5 Days)|Withdrawal by Subject|1
6342542|NCT03329573|10099452|FG001|Treatment Period 1 (Up to 5 Days)|Withdrawal by Subject|2
6342543|NCT03329573|10099453|FG002|Treatment Period 1 (Up to 5 Days)|Withdrawal by Subject|0
6342544|NCT03329573|10099454|FG003|Treatment Period 1 (Up to 5 Days)|Withdrawal by Subject|0
6342545|NCT03329573|10099451|FG000|Treatment Period 2 (Day 12 to Day 26)|Withdrawal by Subject|1
6342546|NCT03329573|10099452|FG001|Treatment Period 2 (Day 12 to Day 26)|Withdrawal by Subject|0
6342547|NCT03329573|10099453|FG002|Treatment Period 2 (Day 12 to Day 26)|Withdrawal by Subject|0
6342548|NCT03329573|10099454|FG003|Treatment Period 2 (Day 12 to Day 26)|Withdrawal by Subject|0
6342549|NCT03329573|10099451|FG000|Treatment Period 2 (Day 12 to Day 26)|Adverse Event|0
6342550|NCT03329573|10099452|FG001|Treatment Period 2 (Day 12 to Day 26)|Adverse Event|1
6342551|NCT03329573|10099453|FG002|Treatment Period 2 (Day 12 to Day 26)|Adverse Event|0
6342552|NCT03329573|10099454|FG003|Treatment Period 2 (Day 12 to Day 26)|Adverse Event|0
6342553|NCT03329846|10099466|FG000|Overall Study|Disease progression|4
6342554|NCT03329846|10099467|FG001|Overall Study|Disease progression|6
6342555|NCT03329846|10099466|FG000|Overall Study|Study drug toxicity|1
6342556|NCT03329846|10099467|FG001|Overall Study|Study drug toxicity|0
6342557|NCT03329846|10099466|FG000|Overall Study|Participant request to discontinue treatment|0
6342558|NCT03329846|10099467|FG001|Overall Study|Participant request to discontinue treatment|1
6342559|NCT03329846|10099466|FG000|Overall Study|Participant withdrew consent|1
6342560|NCT03329846|10099467|FG001|Overall Study|Participant withdrew consent|0
6342561|NCT03329846|10099466|FG000|Overall Study|Other reasons|2
6342562|NCT03329846|10099467|FG001|Overall Study|Other reasons|2
6342563|NCT03329885|10099479|FG000|Overall Study|Sponsor discontinued the study early|0
6342564|NCT03329885|10099480|FG001|Overall Study|Sponsor discontinued the study early|0
6342565|NCT03329885|10099481|FG002|Overall Study|Sponsor discontinued the study early|0
6342566|NCT03329885|10099482|FG003|Overall Study|Sponsor discontinued the study early|0
6342567|NCT03329885|10099483|FG004|Overall Study|Sponsor discontinued the study early|0
6342568|NCT03329885|10099484|FG005|Overall Study|Sponsor discontinued the study early|0
6342569|NCT03329885|10099485|FG006|Overall Study|Sponsor discontinued the study early|1
6342570|NCT03329885|10099486|FG007|Overall Study|Sponsor discontinued the study early|1
6342571|NCT03329885|10099487|FG008|Overall Study|Sponsor discontinued the study early|0
6342572|NCT03329989|10099520|FG000|Overall Study|Withdrawal by Subject|9
6342573|NCT03329989|10099520|FG000|Overall Study|Lost to Follow-up|8
6342574|NCT03329989|10099520|FG000|Overall Study|Adverse Event|5
6342575|NCT03329989|10099520|FG000|Overall Study|Protocol Violation|1
6342576|NCT03330002|10099524|FG000|Overall Study|Lost to Follow-up|15
6342577|NCT03330002|10099524|FG000|Overall Study|Death|7
6342578|NCT03330119|10099536|FG000|Overall Study|Received general anesthesia, Explarel or Naloxone; Return to OR; switched groups|166
6342579|NCT03330119|10099537|FG001|Overall Study|Received general anesthesia, Explarel or Naloxone; Return to OR; switched groups|282
6342580|NCT03330236|10099545|FG000|Overall Study|Death|2
6342581|NCT03330236|10099546|FG001|Overall Study|Death|1
6342582|NCT03330236|10099545|FG000|Overall Study|Withdrawal by Subject|2
6342583|NCT03330236|10099546|FG001|Overall Study|Withdrawal by Subject|4
6342584|NCT03330236|10099545|FG000|Overall Study|Lost to Follow-up|0
6342585|NCT03330236|10099546|FG001|Overall Study|Lost to Follow-up|2
6342586|NCT03330236|10099545|FG000|Overall Study|Physician Decision|2
6342587|NCT03330236|10099546|FG001|Overall Study|Physician Decision|0
6342588|NCT03330236|10099545|FG000|Overall Study|Protocol Violation|4
6342589|NCT03330236|10099546|FG001|Overall Study|Protocol Violation|3
6342590|NCT03330236|10099545|FG000|Overall Study|SedLine malfunction/blinding|19
6342591|NCT03330236|10099546|FG001|Overall Study|SedLine malfunction/blinding|14
6342592|NCT03330236|10099545|FG000|Overall Study|Volatile anesthetics used|11
6342593|NCT03330236|10099546|FG001|Overall Study|Volatile anesthetics used|8
6342594|NCT03330236|10099545|FG000|Overall Study|Surgery aborted/converted to open|60
6342595|NCT03330236|10099546|FG001|Overall Study|Surgery aborted/converted to open|52
6342596|NCT03330288|10099583|FG000|Overall Study|Other reason|1
6342597|NCT03330288|10099584|FG001|Overall Study|Other reason|1
6342598|NCT03330288|10099583|FG000|Overall Study|Switching to a different disease-modifying delayed-release drug SYSADOA|1
6342599|NCT03330288|10099584|FG001|Overall Study|Switching to a different disease-modifying delayed-release drug SYSADOA|0
6342600|NCT03330288|10099583|FG000|Overall Study|Adverse Event|1
6342601|NCT03330288|10099584|FG001|Overall Study|Adverse Event|0
6342602|NCT03330288|10099583|FG000|Overall Study|Withdrawal by Subject|1
6342603|NCT03330288|10099584|FG001|Overall Study|Withdrawal by Subject|0
6083331|NCT00634920|9691703|FG000|Period 2 - Post-Randomization|Patients did not receive study drug|2
6083332|NCT00634920|9691704|FG001|Period 2 - Post-Randomization|Patients did not receive study drug|0
6083333|NCT00634920|9691705|FG002|Period 2 - Post-Randomization|Patients did not receive study drug|0
6168663|NCT01236573|9813751|FG009|Phase 2- MTD/Anti-IL-12 Cells-Cohort 11|Did not receive cells|0
6168664|NCT01236573|9813752|FG010|Phase 2- MTD/Anti-IL-12 Cells-Cohort 11|Did not receive cells|1
6192186|NCT01428583|9849306|FG000|Overall Study|Confirmed positive urine drug test|8
6192187|NCT01428583|9849306|FG000|Overall Study|Sponsor's request|3
6192188|NCT01428583|9849306|FG000|Overall Study|Other|6
6192189|NCT01428661|9849313|FG000|Double-Masked Phase|Protocol Violation|9
6192190|NCT01428661|9849314|FG001|Double-Masked Phase|Protocol Violation|4
6192191|NCT01428661|9849315|FG002|Double-Masked Phase|Protocol Violation|0
6192192|NCT01428661|9849313|FG000|Double-Masked Phase|Adverse Event|13
6342604|NCT03330288|10099583|FG000|Overall Study|Lost to Follow-up|26
6342605|NCT03330288|10099584|FG001|Overall Study|Lost to Follow-up|7
6342606|NCT03331042|10099615|FG000|Overall Study|Protocol Violation|1
6342607|NCT03331042|10099616|FG001|Overall Study|Protocol Violation|0
6342608|NCT03331042|10099617|FG002|Overall Study|Protocol Violation|0
6342609|NCT03331042|10099618|FG003|Overall Study|Protocol Violation|0
6342610|NCT03331042|10099615|FG000|Overall Study|Physician Decision|0
6342611|NCT03331042|10099616|FG001|Overall Study|Physician Decision|0
6342612|NCT03331042|10099617|FG002|Overall Study|Physician Decision|1
6342613|NCT03331042|10099618|FG003|Overall Study|Physician Decision|0
6342614|NCT03331042|10099615|FG000|Overall Study|Lost to Follow-up|0
6342615|NCT03331042|10099616|FG001|Overall Study|Lost to Follow-up|0
6342616|NCT03331042|10099617|FG002|Overall Study|Lost to Follow-up|0
6342617|NCT03331042|10099618|FG003|Overall Study|Lost to Follow-up|1
6342618|NCT03331315|10099645|FG000|Overall Study|Physician Decision|18
6342619|NCT03331315|10099646|FG001|Overall Study|Physician Decision|14
6342620|NCT03331666|10099656|FG000|Overall Study|Due to Covid-19 pandemic, the trial was prematurely terminated|2
6342621|NCT03331666|10099657|FG001|Overall Study|Due to Covid-19 pandemic, the trial was prematurely terminated|2
6342622|NCT03332160|10099683|FG000|Overall Study|Withdrawal by Subject|1
6342623|NCT03332160|10099684|FG001|Overall Study|Withdrawal by Subject|1
6342624|NCT03332160|10099683|FG000|Overall Study|Adverse Event|0
6342625|NCT03332160|10099684|FG001|Overall Study|Adverse Event|1
6342626|NCT03332160|10099683|FG000|Overall Study|Developed Exclusion Criteria|0
6342627|NCT03332160|10099684|FG001|Overall Study|Developed Exclusion Criteria|1
6342628|NCT03332160|10099683|FG000|Overall Study|Non-adherence to treatment|0
6342629|NCT03332160|10099684|FG001|Overall Study|Non-adherence to treatment|2
6342630|NCT03332212|10099695|FG000|Overall Study|Not treated|0
6342631|NCT03332212|10099696|FG001|Overall Study|Not treated|1
6342632|NCT03332212|10099697|FG002|Overall Study|Not treated|0
6342633|NCT03332212|10099698|FG003|Overall Study|Not treated|0
6342634|NCT03332212|10099695|FG000|Overall Study|Adverse Event|0
6342635|NCT03332212|10099696|FG001|Overall Study|Adverse Event|0
6342636|NCT03332212|10099697|FG002|Overall Study|Adverse Event|0
6342637|NCT03332212|10099698|FG003|Overall Study|Adverse Event|1
6342638|NCT03332212|10099695|FG000|Overall Study|worsening of disease under study|1
6342639|NCT03332212|10099696|FG001|Overall Study|worsening of disease under study|1
6342640|NCT03332212|10099697|FG002|Overall Study|worsening of disease under study|0
6342641|NCT03332212|10099698|FG003|Overall Study|worsening of disease under study|0
6342642|NCT03332628|10099719|FG000|Overall Study|Physician Decision|2
6342643|NCT03332771|10099728|FG000|Overall Study|Adverse Event|6
6342644|NCT03332771|10099729|FG001|Overall Study|Adverse Event|4
6342645|NCT03332771|10099730|FG002|Overall Study|Adverse Event|1
6342646|NCT03332771|10099731|FG003|Overall Study|Adverse Event|3
6342647|NCT03332771|10099728|FG000|Overall Study|Poor Compliance to Protocol|0
6342648|NCT03332771|10099729|FG001|Overall Study|Poor Compliance to Protocol|1
6342649|NCT03332771|10099730|FG002|Overall Study|Poor Compliance to Protocol|0
6342650|NCT03332771|10099731|FG003|Overall Study|Poor Compliance to Protocol|1
6342651|NCT03332771|10099728|FG000|Overall Study|Lost to Follow-up|2
6342652|NCT03332771|10099729|FG001|Overall Study|Lost to Follow-up|2
6342653|NCT03332771|10099730|FG002|Overall Study|Lost to Follow-up|1
6342654|NCT03332771|10099731|FG003|Overall Study|Lost to Follow-up|2
6342655|NCT03332771|10099728|FG000|Overall Study|At the Participant's own request|20
6342656|NCT03332771|10099729|FG001|Overall Study|At the Participant's own request|26
6342657|NCT03332771|10099730|FG002|Overall Study|At the Participant's own request|14
6342658|NCT03332771|10099731|FG003|Overall Study|At the Participant's own request|23
6342659|NCT03332771|10099728|FG000|Overall Study|Reason Not Specified|6
6342660|NCT03332771|10099729|FG001|Overall Study|Reason Not Specified|18
6342661|NCT03332771|10099730|FG002|Overall Study|Reason Not Specified|16
6342662|NCT03332771|10099731|FG003|Overall Study|Reason Not Specified|19
6342663|NCT03332784|10099761|FG000|Parts 1 and 2 - Period 1 (1 Day)|Adverse Event|0
6342664|NCT03332784|10099762|FG001|Parts 1 and 2 - Period 1 (1 Day)|Adverse Event|1
6342665|NCT03332784|10099763|FG002|Parts 1 and 2 - Period 1 (1 Day)|Adverse Event|0
6342666|NCT03332784|10099764|FG003|Parts 1 and 2 - Period 1 (1 Day)|Adverse Event|0
6342667|NCT03332784|10099765|FG004|Parts 1 and 2 - Period 1 (1 Day)|Adverse Event|0
6342668|NCT03332784|10099766|FG005|Parts 1 and 2 - Period 1 (1 Day)|Adverse Event|0
6342669|NCT03332784|10099767|FG006|Parts 1 and 2 - Period 1 (1 Day)|Adverse Event|0
6342670|NCT03332784|10099768|FG007|Parts 1 and 2 - Period 1 (1 Day)|Adverse Event|0
6342671|NCT03332784|10099769|FG008|Parts 1 and 2 - Period 1 (1 Day)|Adverse Event|0
6342672|NCT03332784|10099770|FG009|Parts 1 and 2 - Period 1 (1 Day)|Adverse Event|0
6342673|NCT03332784|10099771|FG010|Parts 1 and 2 - Period 1 (1 Day)|Adverse Event|0
6342674|NCT03332784|10099772|FG011|Parts 1 and 2 - Period 1 (1 Day)|Adverse Event|0
6342675|NCT03332784|10099773|FG012|Parts 1 and 2 - Period 1 (1 Day)|Adverse Event|0
6342676|NCT03332784|10099774|FG013|Parts 1 and 2 - Period 1 (1 Day)|Adverse Event|0
6342677|NCT03332784|10099775|FG014|Parts 1 and 2 - Period 1 (1 Day)|Adverse Event|1
6342678|NCT03332784|10099776|FG015|Parts 1 and 2 - Period 1 (1 Day)|Adverse Event|0
6342679|NCT03332784|10099777|FG016|Parts 1 and 2 - Period 1 (1 Day)|Adverse Event|0
6342680|NCT03332784|10099778|FG017|Parts 1 and 2 - Period 1 (1 Day)|Adverse Event|0
6342681|NCT03332784|10099779|FG018|Parts 1 and 2 - Period 1 (1 Day)|Adverse Event|0
6342682|NCT03332784|10099780|FG019|Parts 1 and 2 - Period 1 (1 Day)|Adverse Event|0
6342683|NCT03333109|10099841|FG000|Double-blind Treatment Period (DBTP)|Adverse Event|0
6342684|NCT03333109|10099842|FG001|Double-blind Treatment Period (DBTP)|Adverse Event|0
6342685|NCT03333109|10099843|FG002|Double-blind Treatment Period (DBTP)|Adverse Event|2
6342686|NCT03333109|10099841|FG000|Double-blind Treatment Period (DBTP)|Lost to Follow-up|0
6342687|NCT03333109|10099842|FG001|Double-blind Treatment Period (DBTP)|Lost to Follow-up|0
6342688|NCT03333109|10099843|FG002|Double-blind Treatment Period (DBTP)|Lost to Follow-up|1
6342689|NCT03333109|10099841|FG000|Double-blind Treatment Period (DBTP)|Physician Decision|4
6342690|NCT03333109|10099842|FG001|Double-blind Treatment Period (DBTP)|Physician Decision|0
6342691|NCT03333109|10099843|FG002|Double-blind Treatment Period (DBTP)|Physician Decision|1
6342692|NCT03333109|10099841|FG000|Double-blind Treatment Period (DBTP)|Pregnancy|1
6342693|NCT03333109|10099842|FG001|Double-blind Treatment Period (DBTP)|Pregnancy|0
6342694|NCT03333109|10099843|FG002|Double-blind Treatment Period (DBTP)|Pregnancy|0
6342695|NCT03333109|10099841|FG000|Double-blind Treatment Period (DBTP)|Withdrawal by Subject|9
6342696|NCT03333109|10099842|FG001|Double-blind Treatment Period (DBTP)|Withdrawal by Subject|6
6342697|NCT03333109|10099843|FG002|Double-blind Treatment Period (DBTP)|Withdrawal by Subject|5
6342698|NCT03333109|10099841|FG000|Double-blind Treatment Period (DBTP)|Randomized but not treated|3
6342699|NCT03333109|10099842|FG001|Double-blind Treatment Period (DBTP)|Randomized but not treated|0
6342700|NCT03333109|10099843|FG002|Double-blind Treatment Period (DBTP)|Randomized but not treated|3
6342701|NCT03333109|10099841|FG000|Safety Follow-up Period|Lost to Follow-up|6
6342702|NCT03333109|10099842|FG001|Safety Follow-up Period|Lost to Follow-up|2
6342703|NCT03333109|10099843|FG002|Safety Follow-up Period|Lost to Follow-up|1
6342704|NCT03333109|10099841|FG000|Safety Follow-up Period|Withdrawal by Subject|7
6342705|NCT03333109|10099842|FG001|Safety Follow-up Period|Withdrawal by Subject|2
6342706|NCT03333109|10099843|FG002|Safety Follow-up Period|Withdrawal by Subject|12
6342707|NCT03333876|10099872|FG000|Screening Period|Screen Failure|4
6342708|NCT03333876|10099872|FG000|Nasal Dilator|Bed Partner Lost to follow up|6
6342709|NCT03333876|10099872|FG000|Mandibular Advancement|Adverse Event|2
6342710|NCT03333876|10099872|FG000|Mandibular Advancement|Product Damage|2
6342711|NCT03333941|10099885|FG000|Overall Study|Lost to Follow-up|10
6342712|NCT03333941|10099885|FG000|Overall Study|Death|2
6342713|NCT03333941|10099885|FG000|Overall Study|Adverse Event|1
6342714|NCT03334175|10099891|FG000|Overall Study|Lost to Follow-up|0
6342715|NCT03334175|10099892|FG001|Overall Study|Lost to Follow-up|1
6342716|NCT03334188|10099900|FG000|Overall Study|Withdrawal by Subject|0
6342717|NCT03334188|10099901|FG001|Overall Study|Withdrawal by Subject|1
6342718|NCT03334188|10099900|FG000|Overall Study|Death|1
6342719|NCT03334188|10099901|FG001|Overall Study|Death|0
6342720|NCT03334188|10099900|FG000|Overall Study|Never had qualifying clinic visit|7
6342721|NCT03334188|10099901|FG001|Overall Study|Never had qualifying clinic visit|7
6342722|NCT03334214|10099910|FG000|Overall Study|Adverse Event or Serious Adverse Event|0
6342723|NCT03334214|10099911|FG001|Overall Study|Adverse Event or Serious Adverse Event|1
6342724|NCT03334214|10099910|FG000|Overall Study|Withdrawal by Subject|0
6342725|NCT03334214|10099911|FG001|Overall Study|Withdrawal by Subject|1
6342726|NCT03334214|10099910|FG000|Overall Study|Other|1
6342727|NCT03334214|10099911|FG001|Overall Study|Other|0
6342728|NCT03334396|10099926|FG000|Overall Study|Adverse Event|1
6342729|NCT03334396|10099927|FG001|Overall Study|Adverse Event|0
6342730|NCT03334396|10099928|FG002|Overall Study|Adverse Event|1
6342731|NCT03334396|10099929|FG003|Overall Study|Adverse Event|0
6342732|NCT03334396|10099930|FG004|Overall Study|Adverse Event|0
6342733|NCT03334396|10099931|FG005|Overall Study|Adverse Event|0
6342734|NCT03334396|10099932|FG006|Overall Study|Adverse Event|0
6342735|NCT03334396|10099933|FG007|Overall Study|Adverse Event|0
6342736|NCT03334396|10099926|FG000|Overall Study|Lack of Efficacy|10
6342737|NCT03334396|10099927|FG001|Overall Study|Lack of Efficacy|4
6342738|NCT03334396|10099928|FG002|Overall Study|Lack of Efficacy|1
6342739|NCT03334396|10099929|FG003|Overall Study|Lack of Efficacy|3
6342740|NCT03334396|10099930|FG004|Overall Study|Lack of Efficacy|1
6342741|NCT03334396|10099931|FG005|Overall Study|Lack of Efficacy|0
6342742|NCT03334396|10099932|FG006|Overall Study|Lack of Efficacy|0
6342743|NCT03334396|10099933|FG007|Overall Study|Lack of Efficacy|1
6342744|NCT03334396|10099926|FG000|Overall Study|Lost to Follow-up|0
6342745|NCT03334396|10099927|FG001|Overall Study|Lost to Follow-up|0
6342746|NCT03334396|10099928|FG002|Overall Study|Lost to Follow-up|1
6342747|NCT03334396|10099929|FG003|Overall Study|Lost to Follow-up|0
6342748|NCT03334396|10099930|FG004|Overall Study|Lost to Follow-up|0
6342749|NCT03334396|10099931|FG005|Overall Study|Lost to Follow-up|0
6342750|NCT03334396|10099932|FG006|Overall Study|Lost to Follow-up|1
6342751|NCT03334396|10099933|FG007|Overall Study|Lost to Follow-up|0
6342752|NCT03334396|10099926|FG000|Overall Study|Physician Decision|1
6342753|NCT03334396|10099927|FG001|Overall Study|Physician Decision|0
6342754|NCT03334396|10099928|FG002|Overall Study|Physician Decision|0
6342755|NCT03334396|10099929|FG003|Overall Study|Physician Decision|0
6342756|NCT03334396|10099930|FG004|Overall Study|Physician Decision|0
6342757|NCT03334396|10099931|FG005|Overall Study|Physician Decision|0
6342758|NCT03334396|10099932|FG006|Overall Study|Physician Decision|0
6342759|NCT03334396|10099933|FG007|Overall Study|Physician Decision|0
6342760|NCT03334396|10099926|FG000|Overall Study|Withdrawal by Subject|10
6342761|NCT03334396|10099927|FG001|Overall Study|Withdrawal by Subject|5
6342762|NCT03334396|10099928|FG002|Overall Study|Withdrawal by Subject|7
6342763|NCT03334396|10099929|FG003|Overall Study|Withdrawal by Subject|2
6342764|NCT03334396|10099930|FG004|Overall Study|Withdrawal by Subject|2
6342765|NCT03334396|10099931|FG005|Overall Study|Withdrawal by Subject|1
6342766|NCT03334396|10099932|FG006|Overall Study|Withdrawal by Subject|2
6342767|NCT03334396|10099933|FG007|Overall Study|Withdrawal by Subject|0
6342768|NCT03334396|10099926|FG000|Overall Study|Pregnancy|0
6342769|NCT03334396|10099927|FG001|Overall Study|Pregnancy|1
6342770|NCT03334396|10099928|FG002|Overall Study|Pregnancy|0
6342771|NCT03334396|10099929|FG003|Overall Study|Pregnancy|0
6342772|NCT03334396|10099930|FG004|Overall Study|Pregnancy|0
6342773|NCT03334396|10099931|FG005|Overall Study|Pregnancy|0
6342774|NCT03334396|10099932|FG006|Overall Study|Pregnancy|0
6342775|NCT03334396|10099933|FG007|Overall Study|Pregnancy|0
6342776|NCT03334396|10099926|FG000|Overall Study|Ineligible|0
6342777|NCT03334396|10099927|FG001|Overall Study|Ineligible|1
6342778|NCT03334396|10099928|FG002|Overall Study|Ineligible|0
6342779|NCT03334396|10099929|FG003|Overall Study|Ineligible|0
6342780|NCT03334396|10099930|FG004|Overall Study|Ineligible|0
6342781|NCT03334396|10099931|FG005|Overall Study|Ineligible|0
6342782|NCT03334396|10099932|FG006|Overall Study|Ineligible|0
6342783|NCT03334396|10099933|FG007|Overall Study|Ineligible|0
6342784|NCT03334396|10099926|FG000|Overall Study|Started New Job|1
6342785|NCT03334396|10099927|FG001|Overall Study|Started New Job|0
6342786|NCT03334396|10099928|FG002|Overall Study|Started New Job|0
6342787|NCT03334396|10099929|FG003|Overall Study|Started New Job|0
6342788|NCT03334396|10099930|FG004|Overall Study|Started New Job|0
6342789|NCT03334396|10099931|FG005|Overall Study|Started New Job|0
6342790|NCT03334396|10099932|FG006|Overall Study|Started New Job|0
6342791|NCT03334396|10099933|FG007|Overall Study|Started New Job|0
6342792|NCT03334422|10099954|FG000|Overall Study|Adverse Event|1
6342793|NCT03334422|10099955|FG001|Overall Study|Adverse Event|3
6342794|NCT03334422|10099956|FG002|Overall Study|Adverse Event|2
6342795|NCT03334422|10099957|FG003|Overall Study|Adverse Event|2
6342796|NCT03334422|10099954|FG000|Overall Study|Lack of Efficacy|10
6342797|NCT03334422|10099955|FG001|Overall Study|Lack of Efficacy|2
6342798|NCT03334422|10099956|FG002|Overall Study|Lack of Efficacy|7
6342799|NCT03334422|10099957|FG003|Overall Study|Lack of Efficacy|3
6342800|NCT03334422|10099954|FG000|Overall Study|Withdrawal by Subject|8
6342801|NCT03334422|10099955|FG001|Overall Study|Withdrawal by Subject|3
6342802|NCT03334422|10099956|FG002|Overall Study|Withdrawal by Subject|1
6342803|NCT03334422|10099957|FG003|Overall Study|Withdrawal by Subject|0
6342804|NCT03334422|10099954|FG000|Overall Study|Lost to Follow-up|0
6342805|NCT03334422|10099955|FG001|Overall Study|Lost to Follow-up|0
6342806|NCT03334422|10099956|FG002|Overall Study|Lost to Follow-up|0
6342807|NCT03334422|10099957|FG003|Overall Study|Lost to Follow-up|1
6342808|NCT03334422|10099954|FG000|Overall Study|Inability to obtain laboratory samples|0
6342809|NCT03334422|10099955|FG001|Overall Study|Inability to obtain laboratory samples|1
6342810|NCT03334422|10099956|FG002|Overall Study|Inability to obtain laboratory samples|0
6342811|NCT03334422|10099957|FG003|Overall Study|Inability to obtain laboratory samples|0
6342812|NCT03334422|10099954|FG000|Overall Study|Pregnancy|0
6342813|NCT03334422|10099955|FG001|Overall Study|Pregnancy|1
6342814|NCT03334422|10099956|FG002|Overall Study|Pregnancy|0
6342815|NCT03334422|10099957|FG003|Overall Study|Pregnancy|0
6342816|NCT03334448|10099972|FG000|Washout|Personal Reason|0
6342817|NCT03334448|10099973|FG001|Washout|Personal Reason|1
6342818|NCT03334448|10099974|FG002|Washout|Personal Reason|0
6342819|NCT03334448|10099975|FG003|Washout|Personal Reason|0
6342820|NCT03334448|10099972|FG000|Washout|Protocol Violation|0
6342821|NCT03334448|10099973|FG001|Washout|Protocol Violation|0
6342822|NCT03334448|10099974|FG002|Washout|Protocol Violation|0
6342823|NCT03334448|10099975|FG003|Washout|Protocol Violation|1
6342824|NCT03334630|10099983|FG000|Overall Study|Withdrawal by Subject|7
6342825|NCT03334630|10099984|FG001|Overall Study|Withdrawal by Subject|7
6342826|NCT03334630|10099983|FG000|Overall Study|Lost to Follow-up|3
6342827|NCT03334630|10099984|FG001|Overall Study|Lost to Follow-up|1
6342828|NCT03334630|10099983|FG000|Overall Study|Adverse Event|0
6342829|NCT03334630|10099984|FG001|Overall Study|Adverse Event|1
6342830|NCT03334630|10099983|FG000|Overall Study|Physician Decision|1
6342831|NCT03334630|10099984|FG001|Overall Study|Physician Decision|1
6342832|NCT03334630|10099983|FG000|Overall Study|Enrollment closed|2
6342833|NCT03334630|10099984|FG001|Overall Study|Enrollment closed|1
6342834|NCT03334630|10099983|FG000|Overall Study|Subject not treated with study ablation due to technical difficulties|0
6342835|NCT03334630|10099984|FG001|Overall Study|Subject not treated with study ablation due to technical difficulties|1
6342836|NCT03334630|10099983|FG000|Overall Study|Subject unable to complete 12-month follow-up visit|1
6342837|NCT03334630|10099984|FG001|Overall Study|Subject unable to complete 12-month follow-up visit|1
6342838|NCT03334695|10099992|FG000|Overall Study|Lost to Follow-up|3
6083334|NCT00634933|9691714|FG000|Part A: Baseline to Week 24|Adverse Event|4
6083335|NCT00634933|9691715|FG001|Part A: Baseline to Week 24|Adverse Event|4
6168665|NCT01236755|9813790|FG000|Spectacles Wearing Phase|Withdrawal by Subject|8
6342839|NCT03334695|10099993|FG001|Overall Study|Lost to Follow-up|3
6342840|NCT03334695|10099992|FG000|Overall Study|Physician Decision|1
6342841|NCT03334695|10099993|FG001|Overall Study|Physician Decision|2
6342842|NCT03334695|10099992|FG000|Overall Study|Protocol Violation|0
6342843|NCT03334695|10099993|FG001|Overall Study|Protocol Violation|1
6342844|NCT03334721|10100003|FG000|Overall Study|Withdrawal by Subject|1
6342845|NCT03334721|10100004|FG001|Overall Study|Withdrawal by Subject|0
6342846|NCT03334721|10100003|FG000|Overall Study|No longer met inclusion/exclusion criter|1
6342847|NCT03334721|10100004|FG001|Overall Study|No longer met inclusion/exclusion criter|0
6342848|NCT03334747|10100036|FG000|Treatment Phase|Technical problems|0
6342849|NCT03334747|10100037|FG001|Treatment Phase|Technical problems|0
6342850|NCT03334747|10100038|FG002|Treatment Phase|Technical problems|0
6342851|NCT03334747|10100039|FG003|Treatment Phase|Technical problems|0
6342852|NCT03334747|10100040|FG004|Treatment Phase|Technical problems|1
6342853|NCT03334747|10100041|FG005|Treatment Phase|Technical problems|0
6342854|NCT03334747|10100042|FG006|Treatment Phase|Technical problems|0
6342855|NCT03334747|10100043|FG007|Treatment Phase|Technical problems|0
6342856|NCT03334747|10100044|FG008|Treatment Phase|Technical problems|0
6342857|NCT03334747|10100036|FG000|Treatment Phase|Subject/guardian decision|1
6342858|NCT03334747|10100037|FG001|Treatment Phase|Subject/guardian decision|0
6342859|NCT03334747|10100038|FG002|Treatment Phase|Subject/guardian decision|0
6342860|NCT03334747|10100039|FG003|Treatment Phase|Subject/guardian decision|0
6342861|NCT03334747|10100040|FG004|Treatment Phase|Subject/guardian decision|0
6342862|NCT03334747|10100041|FG005|Treatment Phase|Subject/guardian decision|1
6342863|NCT03334747|10100042|FG006|Treatment Phase|Subject/guardian decision|0
6342864|NCT03334747|10100043|FG007|Treatment Phase|Subject/guardian decision|0
6342865|NCT03334747|10100044|FG008|Treatment Phase|Subject/guardian decision|0
6342866|NCT03334747|10100036|FG000|Follow-Up Phase|Subject/guardian decision|0
6342867|NCT03334747|10100037|FG001|Follow-Up Phase|Subject/guardian decision|0
6342868|NCT03334747|10100038|FG002|Follow-Up Phase|Subject/guardian decision|0
6342869|NCT03334747|10100039|FG003|Follow-Up Phase|Subject/guardian decision|0
6342870|NCT03334747|10100040|FG004|Follow-Up Phase|Subject/guardian decision|0
6342871|NCT03334747|10100041|FG005|Follow-Up Phase|Subject/guardian decision|0
6342872|NCT03334747|10100042|FG006|Follow-Up Phase|Subject/guardian decision|1
6342873|NCT03334747|10100043|FG007|Follow-Up Phase|Subject/guardian decision|0
6342874|NCT03334747|10100044|FG008|Follow-Up Phase|Subject/guardian decision|1
6342875|NCT03334903|10100086|FG000|Overall Study|Use of medical marijuana - determined ineligible later in study|1
6342876|NCT03334903|10100087|FG001|Overall Study|Use of medical marijuana - determined ineligible later in study|0
6342877|NCT03334903|10100086|FG000|Overall Study|Protocol Violation|1
6342878|NCT03334903|10100087|FG001|Overall Study|Protocol Violation|3
6342879|NCT03334903|10100086|FG000|Overall Study|Surgery postponed|1
6342880|NCT03334903|10100087|FG001|Overall Study|Surgery postponed|0
6342881|NCT03334903|10100086|FG000|Overall Study|Adverse Event|1
6342882|NCT03334903|10100087|FG001|Overall Study|Adverse Event|1
6342883|NCT03334903|10100086|FG000|Overall Study|Withdrawal by Subject|0
6342884|NCT03334903|10100087|FG001|Overall Study|Withdrawal by Subject|1
6342885|NCT03335150|10100095|FG000|Overall Study|Withdrawal by Subject|10
6342886|NCT03335150|10100096|FG001|Overall Study|Withdrawal by Subject|4
6342887|NCT03335150|10100095|FG000|Overall Study|Adverse Event|0
6342888|NCT03335150|10100096|FG001|Overall Study|Adverse Event|1
6342889|NCT03335566|10100172|FG000|Overall Study|Adverse Event|0
6342890|NCT03335566|10100173|FG001|Overall Study|Adverse Event|1
6342891|NCT03335566|10100172|FG000|Overall Study|Lost to Follow-up|1
6342892|NCT03335566|10100173|FG001|Overall Study|Lost to Follow-up|0
6342893|NCT03335566|10100172|FG000|Overall Study|Technical Problems|1
6342894|NCT03335566|10100173|FG001|Overall Study|Technical Problems|0
6342895|NCT03335566|10100172|FG000|Overall Study|Protocol Violation|1
6342896|NCT03335566|10100173|FG001|Overall Study|Protocol Violation|0
6342897|NCT03335566|10100172|FG000|Overall Study|Other than specified above|1
6342898|NCT03335566|10100173|FG001|Overall Study|Other than specified above|2
6342899|NCT03336502|10100202|FG000|Overall Study|Physician Decision|0
6342900|NCT03336502|10100203|FG001|Overall Study|Physician Decision|1
6342901|NCT03336502|10100202|FG000|Overall Study|Prohibited Drugs|1
6342902|NCT03336502|10100203|FG001|Overall Study|Prohibited Drugs|1
6342903|NCT03336502|10100202|FG000|Overall Study|Death|1
6342904|NCT03336502|10100203|FG001|Overall Study|Death|2
6342905|NCT03336502|10100202|FG000|Overall Study|Adverse Event|2
6342906|NCT03336502|10100203|FG001|Overall Study|Adverse Event|5
6342907|NCT03337139|10100224|FG000|Phase I|Withdrawal by Subject|10
6342908|NCT03337139|10100225|FG001|Phase I|Withdrawal by Subject|0
6342909|NCT03337152|10100233|FG000|Overall Study|Physician Decision|1
6342910|NCT03337152|10100234|FG001|Overall Study|Physician Decision|0
6342911|NCT03337152|10100233|FG000|Overall Study|Lost to Follow-up|1
6342912|NCT03337152|10100234|FG001|Overall Study|Lost to Follow-up|3
6342913|NCT03337152|10100233|FG000|Overall Study|Adverse Event|3
6342914|NCT03337152|10100234|FG001|Overall Study|Adverse Event|1
6342915|NCT03337152|10100233|FG000|Overall Study|Stopped drug dosing due to study halt|6
6342916|NCT03337152|10100234|FG001|Overall Study|Stopped drug dosing due to study halt|7
6342917|NCT03337308|10100246|FG000|Overall Study|Adverse Event|2
6342918|NCT03337308|10100247|FG001|Overall Study|Adverse Event|3
6342919|NCT03337308|10100248|FG002|Overall Study|Adverse Event|3
6342920|NCT03337308|10100249|FG003|Overall Study|Adverse Event|1
6342921|NCT03337308|10100246|FG000|Overall Study|Lost to Follow-up|1
6342922|NCT03337308|10100247|FG001|Overall Study|Lost to Follow-up|2
6342923|NCT03337308|10100248|FG002|Overall Study|Lost to Follow-up|0
6342924|NCT03337308|10100249|FG003|Overall Study|Lost to Follow-up|0
6342925|NCT03337308|10100246|FG000|Overall Study|Withdrawal by Subject|2
6342926|NCT03337308|10100247|FG001|Overall Study|Withdrawal by Subject|1
6342927|NCT03337308|10100248|FG002|Overall Study|Withdrawal by Subject|2
6342928|NCT03337308|10100249|FG003|Overall Study|Withdrawal by Subject|1
6342929|NCT03337308|10100246|FG000|Overall Study|Protocol Violation|0
6342930|NCT03337308|10100247|FG001|Overall Study|Protocol Violation|1
6342931|NCT03337308|10100248|FG002|Overall Study|Protocol Violation|0
6342932|NCT03337308|10100249|FG003|Overall Study|Protocol Violation|0
6342933|NCT03337477|10100261|FG000|Overall Study|not categorized into the listed ones|11
6342934|NCT03337477|10100262|FG001|Overall Study|not categorized into the listed ones|9
6342935|NCT03337477|10100261|FG000|Overall Study|Withdrawal by Subject|0
6342936|NCT03337477|10100262|FG001|Overall Study|Withdrawal by Subject|1
6342937|NCT03337477|10100261|FG000|Overall Study|Death|0
6342938|NCT03337477|10100262|FG001|Overall Study|Death|1
6342939|NCT03337477|10100261|FG000|Overall Study|Lost to Follow-up|0
6342940|NCT03337477|10100262|FG001|Overall Study|Lost to Follow-up|2
6342941|NCT03337490|10100273|FG000|Overall Study|Withdrawal by Subject|1
6342942|NCT03337490|10100274|FG001|Overall Study|Withdrawal by Subject|0
6342943|NCT03337490|10100275|FG002|Overall Study|Withdrawal by Subject|0
6342944|NCT03337490|10100273|FG000|Overall Study|Lack of Efficacy|10
6342945|NCT03337490|10100274|FG001|Overall Study|Lack of Efficacy|12
6342946|NCT03337490|10100275|FG002|Overall Study|Lack of Efficacy|35
6342947|NCT03337490|10100273|FG000|Overall Study|Physician Decision|0
6342948|NCT03337490|10100274|FG001|Overall Study|Physician Decision|1
6342949|NCT03337490|10100275|FG002|Overall Study|Physician Decision|0
6342950|NCT03337490|10100273|FG000|Overall Study|Lost to Follow-up|0
6342951|NCT03337490|10100274|FG001|Overall Study|Lost to Follow-up|1
6342952|NCT03337490|10100275|FG002|Overall Study|Lost to Follow-up|0
6342953|NCT03337542|10100283|FG000|Overall Study|Withdrew Consent|17
6342954|NCT03337542|10100283|FG000|Overall Study|Allergic Adverse Event|1
6342955|NCT03337542|10100283|FG000|Overall Study|Chronic /Recurrent GI Adverse Event/Symptoms|1
6342956|NCT03337542|10100283|FG000|Overall Study|Lost to Follow-up|1
6342957|NCT03337542|10100283|FG000|Overall Study|Unable to Participate in Study Due to Relocation|1
6342958|NCT03338010|10100290|FG000|Overall Study|Withdrawal by Subject|14
6342959|NCT03338010|10100291|FG001|Overall Study|Withdrawal by Subject|8
6342960|NCT03338010|10100290|FG000|Overall Study|Lost to Follow-up|4
6083336|NCT00634933|9691716|FG002|Part A: Baseline to Week 24|Adverse Event|8
6083337|NCT00634933|9691717|FG003|Part A: Baseline to Week 24|Adverse Event|0
6168666|NCT01236755|9813790|FG000|Spectacles Wearing Phase|Lost to Follow-up|9
6342961|NCT03338010|10100291|FG001|Overall Study|Lost to Follow-up|2
6342962|NCT03338010|10100290|FG000|Overall Study|Adverse Event|3
6342963|NCT03338010|10100291|FG001|Overall Study|Adverse Event|2
6342964|NCT03338010|10100290|FG000|Overall Study|Physician Decision|2
6342965|NCT03338010|10100291|FG001|Overall Study|Physician Decision|2
6168667|NCT01236755|9813790|FG000|Orthokeratology Wearing Phase|Withdrawal by Subject|5
6168668|NCT01236755|9813790|FG000|Orthokeratology Wearing Phase|Poor Refractive Correction / Centration|3
6168669|NCT01237054|9813824|FG000|Overall Study|imaging 10C0096|1
6168670|NCT01237223|9813855|FG000|Single Blind(Run-in Period, 4 Weeks)|Adverse Event|29
6168671|NCT01237223|9813856|FG001|Single Blind(Run-in Period, 4 Weeks)|Adverse Event|0
6168672|NCT01237223|9813857|FG002|Single Blind(Run-in Period, 4 Weeks)|Adverse Event|0
6168673|NCT01237223|9813858|FG003|Single Blind(Run-in Period, 4 Weeks)|Adverse Event|0
6168674|NCT01237223|9813859|FG004|Single Blind(Run-in Period, 4 Weeks)|Adverse Event|0
6168675|NCT01237223|9813860|FG005|Single Blind(Run-in Period, 4 Weeks)|Adverse Event|0
6168676|NCT01237223|9813855|FG000|Single Blind(Run-in Period, 4 Weeks)|Abnormal laboratory value(s)|25
6168677|NCT01237223|9813856|FG001|Single Blind(Run-in Period, 4 Weeks)|Abnormal laboratory value(s)|0
6168678|NCT01237223|9813857|FG002|Single Blind(Run-in Period, 4 Weeks)|Abnormal laboratory value(s)|0
6168679|NCT01237223|9813858|FG003|Single Blind(Run-in Period, 4 Weeks)|Abnormal laboratory value(s)|0
6168680|NCT01237223|9813859|FG004|Single Blind(Run-in Period, 4 Weeks)|Abnormal laboratory value(s)|0
6168681|NCT01237223|9813860|FG005|Single Blind(Run-in Period, 4 Weeks)|Abnormal laboratory value(s)|0
6168682|NCT01237223|9813855|FG000|Single Blind(Run-in Period, 4 Weeks)|Abnormal test procedure result(s)|308
6168683|NCT01237223|9813856|FG001|Single Blind(Run-in Period, 4 Weeks)|Abnormal test procedure result(s)|0
6168684|NCT01237223|9813857|FG002|Single Blind(Run-in Period, 4 Weeks)|Abnormal test procedure result(s)|0
6168685|NCT01237223|9813858|FG003|Single Blind(Run-in Period, 4 Weeks)|Abnormal test procedure result(s)|0
6168686|NCT01237223|9813859|FG004|Single Blind(Run-in Period, 4 Weeks)|Abnormal test procedure result(s)|0
6168687|NCT01237223|9813860|FG005|Single Blind(Run-in Period, 4 Weeks)|Abnormal test procedure result(s)|0
6168688|NCT01237223|9813855|FG000|Single Blind(Run-in Period, 4 Weeks)|Subject withdrew consent|28
6168689|NCT01237223|9813856|FG001|Single Blind(Run-in Period, 4 Weeks)|Subject withdrew consent|0
6168690|NCT01237223|9813857|FG002|Single Blind(Run-in Period, 4 Weeks)|Subject withdrew consent|0
6168691|NCT01237223|9813858|FG003|Single Blind(Run-in Period, 4 Weeks)|Subject withdrew consent|0
6168692|NCT01237223|9813859|FG004|Single Blind(Run-in Period, 4 Weeks)|Subject withdrew consent|0
6168693|NCT01237223|9813860|FG005|Single Blind(Run-in Period, 4 Weeks)|Subject withdrew consent|0
6168694|NCT01237223|9813855|FG000|Single Blind(Run-in Period, 4 Weeks)|Protocol deviation(s)|8
6168695|NCT01237223|9813856|FG001|Single Blind(Run-in Period, 4 Weeks)|Protocol deviation(s)|0
6168696|NCT01237223|9813857|FG002|Single Blind(Run-in Period, 4 Weeks)|Protocol deviation(s)|0
6168697|NCT01237223|9813858|FG003|Single Blind(Run-in Period, 4 Weeks)|Protocol deviation(s)|0
6168698|NCT01237223|9813859|FG004|Single Blind(Run-in Period, 4 Weeks)|Protocol deviation(s)|0
6168699|NCT01237223|9813860|FG005|Single Blind(Run-in Period, 4 Weeks)|Protocol deviation(s)|0
6168700|NCT01237223|9813855|FG000|Double Blind (Treatment Period, 8 Weeks)|Adverse Event|12
6168701|NCT01237223|9813856|FG001|Double Blind (Treatment Period, 8 Weeks)|Adverse Event|4
6168702|NCT01237223|9813857|FG002|Double Blind (Treatment Period, 8 Weeks)|Adverse Event|3
6168703|NCT01237223|9813858|FG003|Double Blind (Treatment Period, 8 Weeks)|Adverse Event|2
6168704|NCT01237223|9813859|FG004|Double Blind (Treatment Period, 8 Weeks)|Adverse Event|2
6168705|NCT01237223|9813860|FG005|Double Blind (Treatment Period, 8 Weeks)|Adverse Event|1
6168706|NCT01237223|9813855|FG000|Double Blind (Treatment Period, 8 Weeks)|Unsatisfactory therapeutic effect|20
6168707|NCT01237223|9813856|FG001|Double Blind (Treatment Period, 8 Weeks)|Unsatisfactory therapeutic effect|6
6168708|NCT01237223|9813857|FG002|Double Blind (Treatment Period, 8 Weeks)|Unsatisfactory therapeutic effect|7
6168709|NCT01237223|9813858|FG003|Double Blind (Treatment Period, 8 Weeks)|Unsatisfactory therapeutic effect|1
6168710|NCT01237223|9813859|FG004|Double Blind (Treatment Period, 8 Weeks)|Unsatisfactory therapeutic effect|0
6168711|NCT01237223|9813860|FG005|Double Blind (Treatment Period, 8 Weeks)|Unsatisfactory therapeutic effect|1
6168712|NCT01237223|9813855|FG000|Double Blind (Treatment Period, 8 Weeks)|Withdrawal by Subject|1
6168713|NCT01237223|9813856|FG001|Double Blind (Treatment Period, 8 Weeks)|Withdrawal by Subject|4
6168714|NCT01237223|9813857|FG002|Double Blind (Treatment Period, 8 Weeks)|Withdrawal by Subject|4
6168715|NCT01237223|9813858|FG003|Double Blind (Treatment Period, 8 Weeks)|Withdrawal by Subject|0
6168716|NCT01237223|9813859|FG004|Double Blind (Treatment Period, 8 Weeks)|Withdrawal by Subject|1
6168717|NCT01237223|9813860|FG005|Double Blind (Treatment Period, 8 Weeks)|Withdrawal by Subject|1
6168718|NCT01237223|9813855|FG000|Double Blind (Treatment Period, 8 Weeks)|Administrative problems|0
6168719|NCT01237223|9813856|FG001|Double Blind (Treatment Period, 8 Weeks)|Administrative problems|0
6168720|NCT01237223|9813857|FG002|Double Blind (Treatment Period, 8 Weeks)|Administrative problems|0
6168721|NCT01237223|9813858|FG003|Double Blind (Treatment Period, 8 Weeks)|Administrative problems|0
6168722|NCT01237223|9813859|FG004|Double Blind (Treatment Period, 8 Weeks)|Administrative problems|0
6168723|NCT01237223|9813860|FG005|Double Blind (Treatment Period, 8 Weeks)|Administrative problems|1
6168724|NCT01237223|9813855|FG000|Double Blind (Treatment Period, 8 Weeks)|Protocol deviation(s)|0
6168725|NCT01237223|9813856|FG001|Double Blind (Treatment Period, 8 Weeks)|Protocol deviation(s)|1
6168726|NCT01237223|9813857|FG002|Double Blind (Treatment Period, 8 Weeks)|Protocol deviation(s)|1
6168727|NCT01237223|9813858|FG003|Double Blind (Treatment Period, 8 Weeks)|Protocol deviation(s)|2
6168728|NCT01237223|9813859|FG004|Double Blind (Treatment Period, 8 Weeks)|Protocol deviation(s)|1
6168729|NCT01237223|9813860|FG005|Double Blind (Treatment Period, 8 Weeks)|Protocol deviation(s)|1
6168730|NCT01237327|9813889|FG000|Overall Study|Protocol Violation: Core Study|1
6168731|NCT01237327|9813890|FG001|Overall Study|Protocol Violation: Core Study|0
6168732|NCT01237327|9813889|FG000|Overall Study|Completed 26 weeks treatment:Core Study|3
6168733|NCT01237327|9813890|FG001|Overall Study|Completed 26 weeks treatment:Core Study|2
6168734|NCT01237327|9813889|FG000|Overall Study|Progression of Disease: Core Study|18
6168735|NCT01237327|9813890|FG001|Overall Study|Progression of Disease: Core Study|22
6168736|NCT01237327|9813889|FG000|Overall Study|Progression of Disease: Extension Study|15
6168737|NCT01237327|9813890|FG001|Overall Study|Progression of Disease: Extension Study|13
6168738|NCT01237327|9813889|FG000|Overall Study|Protocol Specific Withdrawal Criteria|1
6168739|NCT01237327|9813890|FG001|Overall Study|Protocol Specific Withdrawal Criteria|0
6168740|NCT01237327|9813889|FG000|Overall Study|Withdrawal by Subject|1
6168741|NCT01237327|9813890|FG001|Overall Study|Withdrawal by Subject|3
6168742|NCT01237327|9813889|FG000|Overall Study|Lost to Follow-up|3
6168743|NCT01237327|9813890|FG001|Overall Study|Lost to Follow-up|0
6168744|NCT01237340|9813896|FG000|Overall Study|Adverse Event|3
6168745|NCT01237340|9813896|FG000|Overall Study|Withdrawal by Subject|1
6168746|NCT01237340|9813896|FG000|Overall Study|Early termination of the trial|36
6168747|NCT01237587|9813909|FG000|Double Blind Treatment (Acute Phase)|Adverse Event|5
6168748|NCT01237587|9813910|FG001|Double Blind Treatment (Acute Phase)|Adverse Event|1
6168749|NCT01237587|9813909|FG000|Double Blind Treatment (Acute Phase)|Lack of Efficacy|1
6168750|NCT01237587|9813910|FG001|Double Blind Treatment (Acute Phase)|Lack of Efficacy|3
6168751|NCT01237587|9813909|FG000|Double Blind Treatment (Acute Phase)|Lost to Follow-up|2
6168752|NCT01237587|9813910|FG001|Double Blind Treatment (Acute Phase)|Lost to Follow-up|3
6168753|NCT01237587|9813909|FG000|Double Blind Treatment (Acute Phase)|Parent/Caregiver Decision|2
6168754|NCT01237587|9813910|FG001|Double Blind Treatment (Acute Phase)|Parent/Caregiver Decision|4
6168755|NCT01237587|9813909|FG000|Double Blind Treatment (Acute Phase)|Protocol Violation|4
6342966|NCT03338010|10100290|FG000|Overall Study|Non-Compliance with Study Drug|0
6342967|NCT03338010|10100291|FG001|Overall Study|Non-Compliance with Study Drug|3
6342968|NCT03338010|10100290|FG000|Overall Study|Protocol Violation|0
6342969|NCT03338010|10100291|FG001|Overall Study|Protocol Violation|1
6342970|NCT03338023|10100299|FG000|Overall Study|Withdrawal by Subject|3
6342971|NCT03338023|10100300|FG001|Overall Study|Withdrawal by Subject|4
6342972|NCT03338023|10100299|FG000|Overall Study|Protocol Violation|3
6342973|NCT03338023|10100300|FG001|Overall Study|Protocol Violation|3
6342974|NCT03338023|10100299|FG000|Overall Study|Lost to Follow-up|2
6342975|NCT03338023|10100300|FG001|Overall Study|Lost to Follow-up|1
6342976|NCT03338023|10100299|FG000|Overall Study|Physician Decision|1
6342977|NCT03338023|10100300|FG001|Overall Study|Physician Decision|2
6342978|NCT03338062|10100323|FG000|Overall Study|Alternative Therapy|1
6342979|NCT03338062|10100324|FG001|Overall Study|Alternative Therapy|0
6342980|NCT03338296|10100333|FG000|Overall Study|Adverse Event|0
6342981|NCT03338296|10100334|FG001|Overall Study|Adverse Event|1
6342982|NCT03338296|10100333|FG000|Overall Study|Withdrawal by Subject|14
6342983|NCT03338296|10100334|FG001|Overall Study|Withdrawal by Subject|13
6342984|NCT03338296|10100333|FG000|Overall Study|Lost to Follow-up|10
6342985|NCT03338296|10100334|FG001|Overall Study|Lost to Follow-up|10
6342986|NCT03338296|10100333|FG000|Overall Study|Study Terminated by Sponsor|77
6342987|NCT03338296|10100334|FG001|Overall Study|Study Terminated by Sponsor|76
6342988|NCT03338296|10100333|FG000|Overall Study|Other|2
6342989|NCT03338296|10100334|FG001|Overall Study|Other|7
6342990|NCT03338296|10100333|FG000|Overall Study|Missing|0
6342991|NCT03338296|10100334|FG001|Overall Study|Missing|1
6342992|NCT03338400|10100342|FG000|Overall Study|Lost to Follow-up|1
6342993|NCT03338400|10100343|FG001|Overall Study|Lost to Follow-up|2
6342994|NCT03338569|10100376|FG000|Overall Study|Physician Decision|8
6342995|NCT03338569|10100377|FG001|Overall Study|Physician Decision|3
6342996|NCT03338569|10100376|FG000|Overall Study|Withdrawal by Subject|0
6342997|NCT03338569|10100377|FG001|Overall Study|Withdrawal by Subject|1
6342998|NCT03338569|10100376|FG000|Overall Study|Lost to Follow-up|0
6342999|NCT03338569|10100377|FG001|Overall Study|Lost to Follow-up|1
6343000|NCT03338673|10100385|FG000|Overall Study|Lost to Follow-up|1
6343001|NCT03338673|10100386|FG001|Overall Study|Lost to Follow-up|1
6343002|NCT03338816|10100410|FG000|6-Month Double-blind Period|Adverse Event|0
6343003|NCT03338816|10100411|FG001|6-Month Double-blind Period|Adverse Event|1
6343004|NCT03338816|10100410|FG000|Open-Label Extension Period|Ongoing in Study|46
6343005|NCT03338816|10100411|FG001|Open-Label Extension Period|Ongoing in Study|47
6343006|NCT03338855|10100419|FG000|Overall Study|Withdrawn as birth control pill stopped|1
6343007|NCT03338855|10100420|FG001|Overall Study|Withdrawn as birth control pill stopped|0
6343008|NCT03338894|10100426|FG000|Overall Study|not able able to attend 9 or more classes|10
6343009|NCT03338998|10100432|FG000|Treatment Period|Withdrawal by Subject|1
6343010|NCT03338998|10100433|FG001|Treatment Period|Withdrawal by Subject|1
6343011|NCT03338998|10100432|FG000|Treatment Period|Adverse Event|0
6343012|NCT03338998|10100433|FG001|Treatment Period|Adverse Event|2
6343013|NCT03338998|10100432|FG000|Treatment Period|Protocol deviation|1
6343014|NCT03338998|10100433|FG001|Treatment Period|Protocol deviation|0
6343015|NCT03338998|10100432|FG000|Treatment Period|Physician Decision|2
6343016|NCT03338998|10100433|FG001|Treatment Period|Physician Decision|0
6343017|NCT03338998|10100432|FG000|Treatment Period|Subject failed swallow test|4
6343018|NCT03338998|10100433|FG001|Treatment Period|Subject failed swallow test|0
6343019|NCT03338998|10100432|FG000|Safety Follow-Up Period|Adverse Event|0
6343020|NCT03338998|10100433|FG001|Safety Follow-Up Period|Adverse Event|1
6343021|NCT03338998|10100432|FG000|Safety Follow-Up Period|Protocol deviation|1
6343022|NCT03338998|10100433|FG001|Safety Follow-Up Period|Protocol deviation|0
6343023|NCT03338998|10100432|FG000|Safety Follow-Up Period|Lost to Follow-up|1
6343024|NCT03338998|10100433|FG001|Safety Follow-Up Period|Lost to Follow-up|0
6343025|NCT03339219|10100453|FG000|Overall Study|Death|12
6343026|NCT03339219|10100453|FG000|Overall Study|Site Terminated by Sponsor|22
6343027|NCT03339219|10100453|FG000|Overall Study|Withdrawal by Subject|1
6343028|NCT03339297|10100459|FG000|Overall Study|Relapse of Hematologic Disease|1
6343029|NCT03339297|10100460|FG001|Overall Study|Relapse of Hematologic Disease|0
6343030|NCT03339297|10100459|FG000|Overall Study|Death|10
6343031|NCT03339297|10100460|FG001|Overall Study|Death|7
6343032|NCT03339297|10100459|FG000|Overall Study|Hepatic Candidosis|1
6343033|NCT03339297|10100460|FG001|Overall Study|Hepatic Candidosis|0
6343034|NCT03339297|10100459|FG000|Overall Study|Adverse Event, Serious Fatal|0
6343035|NCT03339297|10100460|FG001|Overall Study|Adverse Event, Serious Fatal|2
6343036|NCT03339297|10100459|FG000|Overall Study|Consent Withdrawn by Participant|3
6343037|NCT03339297|10100460|FG001|Overall Study|Consent Withdrawn by Participant|3
6343038|NCT03339297|10100459|FG000|Overall Study|Disease Relapse|2
6343039|NCT03339297|10100460|FG001|Overall Study|Disease Relapse|0
6343040|NCT03339297|10100459|FG000|Overall Study|Physician Decision|1
6343041|NCT03339297|10100460|FG001|Overall Study|Physician Decision|1
6343042|NCT03339297|10100459|FG000|Overall Study|Relapse of Disease New Transplant Performed|1
6343043|NCT03339297|10100460|FG001|Overall Study|Relapse of Disease New Transplant Performed|0
6343044|NCT03339297|10100459|FG000|Overall Study|Problems with Donor and Diagnosis of Early Relapse|1
6343045|NCT03339297|10100460|FG001|Overall Study|Problems with Donor and Diagnosis of Early Relapse|0
6343046|NCT03339297|10100459|FG000|Overall Study|Early Termination, Did Not Proceed to Transplant|1
6343047|NCT03339297|10100460|FG001|Overall Study|Early Termination, Did Not Proceed to Transplant|0
6343048|NCT03339297|10100459|FG000|Overall Study|Adverse Event, Non-fatal|1
6343049|NCT03339297|10100460|FG001|Overall Study|Adverse Event, Non-fatal|0
6343050|NCT03339297|10100459|FG000|Overall Study|Patient Relapsed and Did Not Proceed to Transplant|0
6343051|NCT03339297|10100460|FG001|Overall Study|Patient Relapsed and Did Not Proceed to Transplant|1
6343052|NCT03339297|10100459|FG000|Overall Study|Patient Was Not Eligible|1
6343053|NCT03339297|10100460|FG001|Overall Study|Patient Was Not Eligible|0
6343054|NCT03339453|10100468|FG000|First Visit of Glucagon Treatment|Adverse Event|0
6343055|NCT03339453|10100469|FG001|First Visit of Glucagon Treatment|Adverse Event|1
6343056|NCT03339583|10100490|FG000|First Intervention (14 Days)|Adverse Event|1
6343057|NCT03339583|10100491|FG001|First Intervention (14 Days)|Adverse Event|0
6343058|NCT03339583|10100490|FG000|Second Intervention (14 Days)|unrelated acute exacerbation|0
6343059|NCT03339583|10100491|FG001|Second Intervention (14 Days)|unrelated acute exacerbation|1
6343060|NCT03339583|10100490|FG000|Second Intervention (14 Days)|Adverse Event|0
6343061|NCT03339583|10100491|FG001|Second Intervention (14 Days)|Adverse Event|1
6343062|NCT03339583|10100490|FG000|Follow-up (14 Days)|Physician Decision|6
6343063|NCT03339583|10100491|FG001|Follow-up (14 Days)|Physician Decision|3
6343064|NCT03339713|10100501|FG000|Overall Study|Lost to Follow-up|2
6343065|NCT03339713|10100502|FG001|Overall Study|Lost to Follow-up|1
6343066|NCT03339713|10100501|FG000|Overall Study|Protocol Violation|1
6343067|NCT03339713|10100502|FG001|Overall Study|Protocol Violation|0
6343068|NCT03339713|10100501|FG000|Overall Study|Withdrawal by Subject|1
6343069|NCT03339713|10100502|FG001|Overall Study|Withdrawal by Subject|1
6343070|NCT03339726|10100513|FG000|Overall Study|Withdrawal by Subject|1
6343071|NCT03339726|10100514|FG001|Overall Study|Withdrawal by Subject|0
6343072|NCT03339726|10100515|FG002|Overall Study|Withdrawal by Subject|0
6343073|NCT03339726|10100513|FG000|Overall Study|Lost to Follow-up|0
6343074|NCT03339726|10100514|FG001|Overall Study|Lost to Follow-up|1
6343075|NCT03339726|10100515|FG002|Overall Study|Lost to Follow-up|0
6343076|NCT03339999|10100527|FG000|Overall Study|Adverse Event|1
6343077|NCT03339999|10100528|FG001|Overall Study|Adverse Event|2
6343078|NCT03339999|10100529|FG002|Overall Study|Adverse Event|2
6343079|NCT03339999|10100530|FG003|Overall Study|Adverse Event|1
6343080|NCT03339999|10100527|FG000|Overall Study|Lack of Efficacy|0
6343081|NCT03339999|10100528|FG001|Overall Study|Lack of Efficacy|1
6343082|NCT03339999|10100529|FG002|Overall Study|Lack of Efficacy|0
6343083|NCT03339999|10100530|FG003|Overall Study|Lack of Efficacy|0
6343084|NCT03339999|10100527|FG000|Overall Study|Lost to Follow-up|0
6343085|NCT03339999|10100528|FG001|Overall Study|Lost to Follow-up|0
6343086|NCT03339999|10100529|FG002|Overall Study|Lost to Follow-up|0
6343087|NCT03339999|10100530|FG003|Overall Study|Lost to Follow-up|1
6343088|NCT03339999|10100527|FG000|Overall Study|Study Terminated by Sponsor|6
6343089|NCT03339999|10100528|FG001|Overall Study|Study Terminated by Sponsor|3
6343090|NCT03339999|10100529|FG002|Overall Study|Study Terminated by Sponsor|4
6343091|NCT03339999|10100530|FG003|Overall Study|Study Terminated by Sponsor|3
6343092|NCT03340025|10100545|FG000|Overall Study|Lost to Follow-up|2
6343093|NCT03340025|10100546|FG001|Overall Study|Lost to Follow-up|2
6343094|NCT03340961|10100630|FG000|Overall Study|Adverse Event|1
6343095|NCT03340961|10100631|FG001|Overall Study|Adverse Event|3
6343096|NCT03340961|10100632|FG002|Overall Study|Adverse Event|2
6343097|NCT03340961|10100633|FG003|Overall Study|Adverse Event|4
6343098|NCT03340961|10100630|FG000|Overall Study|Lost to Follow-up|0
6343099|NCT03340961|10100631|FG001|Overall Study|Lost to Follow-up|1
6343100|NCT03340961|10100632|FG002|Overall Study|Lost to Follow-up|0
6168756|NCT01237587|9813910|FG001|Double Blind Treatment (Acute Phase)|Protocol Violation|3
6343101|NCT03340961|10100633|FG003|Overall Study|Lost to Follow-up|1
6343102|NCT03340961|10100630|FG000|Overall Study|Withdrawal by Subject|3
6343103|NCT03340961|10100631|FG001|Overall Study|Withdrawal by Subject|2
6343104|NCT03340961|10100632|FG002|Overall Study|Withdrawal by Subject|4
6343105|NCT03340961|10100633|FG003|Overall Study|Withdrawal by Subject|7
6343106|NCT03340961|10100630|FG000|Overall Study|Use of prohibited treatment|0
6343107|NCT03340961|10100631|FG001|Overall Study|Use of prohibited treatment|3
6343108|NCT03340961|10100632|FG002|Overall Study|Use of prohibited treatment|2
6343109|NCT03340961|10100633|FG003|Overall Study|Use of prohibited treatment|4
6343110|NCT03340961|10100630|FG000|Overall Study|Wrongful enrollment (I/E criteria not me|0
6343111|NCT03340961|10100631|FG001|Overall Study|Wrongful enrollment (I/E criteria not me|1
6343112|NCT03340961|10100632|FG002|Overall Study|Wrongful enrollment (I/E criteria not me|0
6343113|NCT03340961|10100633|FG003|Overall Study|Wrongful enrollment (I/E criteria not me|1
6343114|NCT03340961|10100630|FG000|Overall Study|Subject developed an exclusion criterion|0
6343115|NCT03340961|10100631|FG001|Overall Study|Subject developed an exclusion criterion|1
6343116|NCT03340961|10100632|FG002|Overall Study|Subject developed an exclusion criterion|0
6343117|NCT03340961|10100633|FG003|Overall Study|Subject developed an exclusion criterion|0
6343118|NCT03340961|10100630|FG000|Overall Study|Protocol Violation|1
6343119|NCT03340961|10100631|FG001|Overall Study|Protocol Violation|0
6343120|NCT03340961|10100632|FG002|Overall Study|Protocol Violation|1
6343121|NCT03340961|10100633|FG003|Overall Study|Protocol Violation|0
6343122|NCT03340961|10100630|FG000|Overall Study|Adverse Event|1
6343123|NCT03340961|10100631|FG001|Overall Study|Adverse Event|1
6343124|NCT03340961|10100632|FG002|Overall Study|Adverse Event|0
6343125|NCT03340961|10100633|FG003|Overall Study|Adverse Event|0
6343126|NCT03340961|10100630|FG000|Overall Study|Lack of Efficacy|0
6343127|NCT03340961|10100631|FG001|Overall Study|Lack of Efficacy|0
6343128|NCT03340961|10100632|FG002|Overall Study|Lack of Efficacy|0
6343129|NCT03340961|10100633|FG003|Overall Study|Lack of Efficacy|1
6343130|NCT03341273|10100645|FG000|Overall Study|Lost to Follow-up|7
6343131|NCT03341273|10100646|FG001|Overall Study|Lost to Follow-up|7
6343132|NCT03341273|10100645|FG000|Overall Study|Withdrawal by Subject|4
6343133|NCT03341273|10100646|FG001|Overall Study|Withdrawal by Subject|2
6343134|NCT03341273|10100645|FG000|Overall Study|Physician Decision|1
6343135|NCT03341273|10100646|FG001|Overall Study|Physician Decision|0
6343136|NCT03341273|10100645|FG000|Overall Study|Protocol Violation|0
6343137|NCT03341273|10100646|FG001|Overall Study|Protocol Violation|1
6343138|NCT03341273|10100645|FG000|Overall Study|Enrolled but Treatment Not Administered|6
6343139|NCT03341273|10100646|FG001|Overall Study|Enrolled but Treatment Not Administered|1
6343140|NCT03341273|10100645|FG000|Overall Study|Became ineligible after enrollment|1
6343141|NCT03341273|10100646|FG001|Overall Study|Became ineligible after enrollment|0
6343142|NCT03341273|10100645|FG000|Overall Study|Not Eligible at Enrollment|0
6343143|NCT03341273|10100646|FG001|Overall Study|Not Eligible at Enrollment|1
6343144|NCT03341273|10100645|FG000|Overall Study|Participant incarcerated|1
6343145|NCT03341273|10100646|FG001|Overall Study|Participant incarcerated|0
6343146|NCT03341299|10100652|FG000|Washout (A Minimum of 21 Hours)|Adverse Event|0
6343147|NCT03341299|10100653|FG001|Washout (A Minimum of 21 Hours)|Adverse Event|0
6343148|NCT03341299|10100654|FG002|Washout (A Minimum of 21 Hours)|Adverse Event|1
6343149|NCT03341299|10100655|FG003|Washout (A Minimum of 21 Hours)|Adverse Event|0
6343150|NCT03341312|10100667|FG000|Period 1|Withdrawal by Subject|0
6343151|NCT03341312|10100668|FG001|Period 1|Withdrawal by Subject|1
6343152|NCT03341312|10100669|FG002|Period 1|Withdrawal by Subject|0
6343153|NCT03341312|10100670|FG003|Period 1|Withdrawal by Subject|0
6343154|NCT03341507|10100682|FG000|Overall Study|Cormack-Lehane grade 1 or 2a during conventional laryngoscopy|34
6343155|NCT03341533|10100688|FG000|Overall Study|Withdrawal by Subject|1
6343156|NCT03341533|10100689|FG001|Overall Study|Withdrawal by Subject|1
6343157|NCT03341533|10100688|FG000|Overall Study|Not eligible after randomization|2
6343158|NCT03341533|10100689|FG001|Overall Study|Not eligible after randomization|1
6343159|NCT03341637|10100701|FG000|Overall Study|Lost to Follow-up|1
6343160|NCT03341637|10100702|FG001|Overall Study|Lost to Follow-up|0
6343161|NCT03341637|10100701|FG000|Overall Study|Withdrawal by Subject|3
6343162|NCT03341637|10100702|FG001|Overall Study|Withdrawal by Subject|3
6343163|NCT03341637|10100701|FG000|Overall Study|Reason not Specified|1
6343164|NCT03341637|10100702|FG001|Overall Study|Reason not Specified|1
6343165|NCT03341923|10100732|FG000|Period 2, Second 14 Days of Wear|Adverse Event|0
6343166|NCT03341923|10100733|FG001|Period 2, Second 14 Days of Wear|Adverse Event|1
6343167|NCT03342404|10100752|FG000|Overall Study|Withdrawal by Subject|9
6343168|NCT03342404|10100753|FG001|Overall Study|Withdrawal by Subject|10
6343169|NCT03342404|10100752|FG000|Overall Study|Lack of Efficacy|1
6343170|NCT03342404|10100753|FG001|Overall Study|Lack of Efficacy|17
6343171|NCT03342404|10100752|FG000|Overall Study|Adverse Event|3
6343172|NCT03342404|10100753|FG001|Overall Study|Adverse Event|4
6192193|NCT01428661|9849314|FG001|Double-Masked Phase|Adverse Event|4
6343173|NCT03342404|10100752|FG000|Overall Study|Noncompliance with study drug|1
6343174|NCT03342404|10100753|FG001|Overall Study|Noncompliance with study drug|0
6343175|NCT03342404|10100752|FG000|Overall Study|Other reasons|1
6343176|NCT03342404|10100753|FG001|Overall Study|Other reasons|0
6343177|NCT03342469|10100761|FG000|Overall Study|Withdrawal by Subject|0
6343178|NCT03342469|10100762|FG001|Overall Study|Withdrawal by Subject|1
6343179|NCT03342469|10100763|FG002|Overall Study|Withdrawal by Subject|0
6343180|NCT03342469|10100764|FG003|Overall Study|Withdrawal by Subject|0
6343181|NCT03342560|10100775|FG000|Overall Study|Lost to Follow-up|2
6343182|NCT03342690|10100783|FG000|Overall Study|Missing Information|9
6343183|NCT03342690|10100783|FG000|Overall Study|Protocol Violation|16
6343184|NCT03342898|10100790|FG000|Overall Study|Adverse Event|3
6343185|NCT03342898|10100791|FG001|Overall Study|Adverse Event|1
6343186|NCT03342898|10100792|FG002|Overall Study|Adverse Event|0
6343187|NCT03342898|10100790|FG000|Overall Study|Lost to Follow-up|44
6343188|NCT03342898|10100791|FG001|Overall Study|Lost to Follow-up|40
6343189|NCT03342898|10100792|FG002|Overall Study|Lost to Follow-up|42
6343190|NCT03342898|10100790|FG000|Overall Study|Withdrawal of Consent|5
6343191|NCT03342898|10100791|FG001|Overall Study|Withdrawal of Consent|9
6343192|NCT03342898|10100792|FG002|Overall Study|Withdrawal of Consent|11
6343193|NCT03342898|10100790|FG000|Overall Study|Death|0
6343194|NCT03342898|10100791|FG001|Overall Study|Death|1
6343195|NCT03342898|10100792|FG002|Overall Study|Death|1
6343196|NCT03342898|10100790|FG000|Overall Study|Reason not Specified|2
6343197|NCT03342898|10100791|FG001|Overall Study|Reason not Specified|2
6343198|NCT03342898|10100792|FG002|Overall Study|Reason not Specified|0
6343199|NCT03342963|10100804|FG000|Overall Study|Adverse Event|1
6343200|NCT03342963|10100805|FG001|Overall Study|Adverse Event|2
6343201|NCT03342963|10100806|FG002|Overall Study|Adverse Event|0
6343202|NCT03342963|10100807|FG003|Overall Study|Adverse Event|0
6343203|NCT03342963|10100804|FG000|Overall Study|Withdrawal by Subject|1
6168757|NCT01237587|9813909|FG000|Double Blind Treatment (Acute Phase)|Withdrawal by Subject|3
6192194|NCT01428661|9849315|FG002|Double-Masked Phase|Adverse Event|0
6343204|NCT03342963|10100805|FG001|Overall Study|Withdrawal by Subject|0
6343205|NCT03342963|10100806|FG002|Overall Study|Withdrawal by Subject|0
6343206|NCT03342963|10100807|FG003|Overall Study|Withdrawal by Subject|0
6343207|NCT03343067|10100820|FG000|Double Blind Period: Month 3 to Month 6|Study Terminated by Sponsor|0
6343208|NCT03343067|10100821|FG001|Double Blind Period: Month 3 to Month 6|Study Terminated by Sponsor|3
6343209|NCT03343067|10100822|FG002|Double Blind Period: Month 3 to Month 6|Study Terminated by Sponsor|1
6343210|NCT03343639|10100841|FG000|Overall Study|Withdrawal by Subject|10
6343211|NCT03343639|10100842|FG001|Overall Study|Withdrawal by Subject|6
6343212|NCT03343639|10100841|FG000|Overall Study|Lost to Follow-up|4
6343213|NCT03343639|10100842|FG001|Overall Study|Lost to Follow-up|5
6343214|NCT03343639|10100841|FG000|Overall Study|Protocol Violation|0
6343215|NCT03343639|10100842|FG001|Overall Study|Protocol Violation|1
6343216|NCT03343704|10100850|FG000|Overall Study|Refused to complete follow up|0
6343217|NCT03343704|10100851|FG001|Overall Study|Refused to complete follow up|1
6343218|NCT03343704|10100850|FG000|Overall Study|Death|0
6343219|NCT03343704|10100851|FG001|Overall Study|Death|1
6343220|NCT03343704|10100850|FG000|Overall Study|Reluctant to collect blood and received telephone follow up|1
6343221|NCT03343704|10100851|FG001|Overall Study|Reluctant to collect blood and received telephone follow up|0
6343222|NCT03344172|10100861|FG000|Overall Study|Received <1 dose of treatment|1
6343223|NCT03344172|10100862|FG001|Overall Study|Received <1 dose of treatment|0
6343224|NCT03344640|10100878|FG000|Overall Study|Adverse Event|1
6343225|NCT03344640|10100879|FG001|Overall Study|Adverse Event|0
6343226|NCT03344640|10100878|FG000|Overall Study|Physician Decision|1
6343227|NCT03344640|10100879|FG001|Overall Study|Physician Decision|1
6343228|NCT03344640|10100878|FG000|Overall Study|Withdrawal by Subject|1
6343229|NCT03344640|10100879|FG001|Overall Study|Withdrawal by Subject|2
6343230|NCT03344640|10100878|FG000|Follow-up Epoch|Withdrawal by Subject|0
6343231|NCT03344640|10100879|FG001|Follow-up Epoch|Withdrawal by Subject|2
6343232|NCT03345407|10100922|FG000|Overall Study|Withdrawal by Subject|11
6343233|NCT03345407|10100923|FG001|Overall Study|Withdrawal by Subject|1
6343234|NCT03345407|10100924|FG002|Overall Study|Withdrawal by Subject|5
6343235|NCT03345407|10100925|FG003|Overall Study|Withdrawal by Subject|6
6343236|NCT03345407|10100926|FG004|Overall Study|Withdrawal by Subject|3
6343237|NCT03345407|10100927|FG005|Overall Study|Withdrawal by Subject|6
6343238|NCT03345407|10100928|FG006|Overall Study|Withdrawal by Subject|16
6343239|NCT03345407|10100922|FG000|Overall Study|Physician Decision|3
6343240|NCT03345407|10100923|FG001|Overall Study|Physician Decision|1
6343241|NCT03345407|10100924|FG002|Overall Study|Physician Decision|0
6343242|NCT03345407|10100925|FG003|Overall Study|Physician Decision|0
6343243|NCT03345407|10100926|FG004|Overall Study|Physician Decision|1
6343244|NCT03345407|10100927|FG005|Overall Study|Physician Decision|2
6343245|NCT03345407|10100928|FG006|Overall Study|Physician Decision|3
6343246|NCT03345407|10100922|FG000|Overall Study|Lost to Follow-up|2
6343247|NCT03345407|10100923|FG001|Overall Study|Lost to Follow-up|0
6343248|NCT03345407|10100924|FG002|Overall Study|Lost to Follow-up|1
6343249|NCT03345407|10100925|FG003|Overall Study|Lost to Follow-up|0
6343250|NCT03345407|10100926|FG004|Overall Study|Lost to Follow-up|1
6343251|NCT03345407|10100927|FG005|Overall Study|Lost to Follow-up|2
6343252|NCT03345407|10100928|FG006|Overall Study|Lost to Follow-up|3
6343253|NCT03345407|10100922|FG000|Overall Study|Protocol-defined stopping criteria|9
6343254|NCT03345407|10100923|FG001|Overall Study|Protocol-defined stopping criteria|0
6343255|NCT03345407|10100924|FG002|Overall Study|Protocol-defined stopping criteria|0
6343256|NCT03345407|10100925|FG003|Overall Study|Protocol-defined stopping criteria|0
6343257|NCT03345407|10100926|FG004|Overall Study|Protocol-defined stopping criteria|2
6343258|NCT03345407|10100927|FG005|Overall Study|Protocol-defined stopping criteria|1
6343259|NCT03345407|10100928|FG006|Overall Study|Protocol-defined stopping criteria|1
6343260|NCT03345407|10100922|FG000|Overall Study|Protocol Violation|2
6343261|NCT03345407|10100923|FG001|Overall Study|Protocol Violation|0
6343262|NCT03345407|10100924|FG002|Overall Study|Protocol Violation|0
6343263|NCT03345407|10100925|FG003|Overall Study|Protocol Violation|0
6343264|NCT03345407|10100926|FG004|Overall Study|Protocol Violation|1
6343265|NCT03345407|10100927|FG005|Overall Study|Protocol Violation|0
6343266|NCT03345407|10100928|FG006|Overall Study|Protocol Violation|3
6343267|NCT03345407|10100922|FG000|Overall Study|Lack of Efficacy|1
6343268|NCT03345407|10100923|FG001|Overall Study|Lack of Efficacy|1
6343269|NCT03345407|10100924|FG002|Overall Study|Lack of Efficacy|1
6343270|NCT03345407|10100925|FG003|Overall Study|Lack of Efficacy|1
6343271|NCT03345407|10100926|FG004|Overall Study|Lack of Efficacy|1
6343272|NCT03345407|10100927|FG005|Overall Study|Lack of Efficacy|0
6343273|NCT03345407|10100928|FG006|Overall Study|Lack of Efficacy|3
6343274|NCT03345407|10100922|FG000|Overall Study|Adverse Event|4
6343275|NCT03345407|10100923|FG001|Overall Study|Adverse Event|0
6343276|NCT03345407|10100924|FG002|Overall Study|Adverse Event|5
6343277|NCT03345407|10100925|FG003|Overall Study|Adverse Event|4
6343278|NCT03345407|10100926|FG004|Overall Study|Adverse Event|6
6343279|NCT03345407|10100927|FG005|Overall Study|Adverse Event|5
6343280|NCT03345407|10100928|FG006|Overall Study|Adverse Event|16
6343281|NCT03345472|10100950|FG000|Implant to 3 Months|Withdrawal by Subject|2
6343282|NCT03345472|10100950|FG000|Implant to 3 Months|Physician Decision|1
6343283|NCT03345472|10100950|FG000|Implant to 3 Months|Adverse Event|1
6343284|NCT03345472|10100950|FG000|3 Months to 12 Months|Physician Decision|3
6343285|NCT03345472|10100950|FG000|3 Months to 12 Months|Lost to Follow-up|2
6343286|NCT03345472|10100950|FG000|3 Months to 12 Months|Withdrawal by Subject|1
6343287|NCT03345472|10100950|FG000|3 Months to 12 Months|Adverse Event|1
6343288|NCT03345472|10100950|FG000|3 Months to 12 Months|Death|1
6343289|NCT03345914|10100957|FG000|Overall Study|Transition to another study at week 16|80
6343290|NCT03345914|10100958|FG001|Overall Study|Transition to another study at week 16|86
6343291|NCT03345914|10100959|FG002|Overall Study|Transition to another study at week 16|78
6343292|NCT03345914|10100957|FG000|Overall Study|Transition to OLE during follow-up|37
6343293|NCT03345914|10100958|FG001|Overall Study|Transition to OLE during follow-up|33
6343294|NCT03345914|10100959|FG002|Overall Study|Transition to OLE during follow-up|39
6343295|NCT03345914|10100957|FG000|Overall Study|Physician Decision|0
6343296|NCT03345914|10100958|FG001|Overall Study|Physician Decision|1
6343297|NCT03345914|10100959|FG002|Overall Study|Physician Decision|1
6343298|NCT03345914|10100957|FG000|Overall Study|Withdrawal by Subject|5
6343299|NCT03345914|10100958|FG001|Overall Study|Withdrawal by Subject|1
6343300|NCT03345914|10100959|FG002|Overall Study|Withdrawal by Subject|2
6343301|NCT03345914|10100957|FG000|Overall Study|Other|1
6343302|NCT03345914|10100958|FG001|Overall Study|Other|1
6343303|NCT03345914|10100959|FG002|Overall Study|Other|1
6343304|NCT03345914|10100957|FG000|Overall Study|Ongoing|0
6343305|NCT03345914|10100958|FG001|Overall Study|Ongoing|0
6343306|NCT03345914|10100959|FG002|Overall Study|Ongoing|1
6343307|NCT03345979|10100969|FG000|Overall Study|Withdrawal by Subject|20
6343308|NCT03345979|10100970|FG001|Overall Study|Withdrawal by Subject|31
6343309|NCT03345979|10100969|FG000|Overall Study|Adverse Event|10
6343310|NCT03345979|10100970|FG001|Overall Study|Adverse Event|11
6343311|NCT03345979|10100969|FG000|Overall Study|Lost to Follow-up|8
6343312|NCT03345979|10100970|FG001|Overall Study|Lost to Follow-up|9
6343313|NCT03345979|10100969|FG000|Overall Study|Lack of Efficacy|4
6343314|NCT03345979|10100970|FG001|Overall Study|Lack of Efficacy|2
6343315|NCT03345979|10100969|FG000|Overall Study|Protocol Violation|1
6343316|NCT03345979|10100970|FG001|Overall Study|Protocol Violation|3
6343317|NCT03345979|10100969|FG000|Overall Study|Physician Decision|0
6343318|NCT03345979|10100970|FG001|Overall Study|Physician Decision|2
6343319|NCT03346057|10100980|FG000|Overall Study|Death|1
6343320|NCT03346057|10100981|FG001|Overall Study|Death|2
6343321|NCT03346057|10100982|FG002|Overall Study|Death|0
6343322|NCT03346057|10100983|FG003|Overall Study|Death|0
6343323|NCT03346057|10100980|FG000|Overall Study|Lost to Follow-up|0
6343324|NCT03346057|10100981|FG001|Overall Study|Lost to Follow-up|2
6343325|NCT03346057|10100982|FG002|Overall Study|Lost to Follow-up|1
6343326|NCT03346057|10100983|FG003|Overall Study|Lost to Follow-up|0
6343327|NCT03346057|10100980|FG000|Overall Study|Ineligible For Study - Not Treated|0
6343328|NCT03346057|10100981|FG001|Overall Study|Ineligible For Study - Not Treated|1
6343329|NCT03346057|10100982|FG002|Overall Study|Ineligible For Study - Not Treated|0
6343330|NCT03346057|10100983|FG003|Overall Study|Ineligible For Study - Not Treated|0
6343331|NCT03346057|10100980|FG000|Overall Study|Renal Insufficiency - Not Treated|1
6343332|NCT03346057|10100981|FG001|Overall Study|Renal Insufficiency - Not Treated|0
6343333|NCT03346057|10100982|FG002|Overall Study|Renal Insufficiency - Not Treated|0
6343334|NCT03346057|10100983|FG003|Overall Study|Renal Insufficiency - Not Treated|0
6343335|NCT03346057|10100980|FG000|Overall Study|Physician Decision|3
6343336|NCT03346057|10100981|FG001|Overall Study|Physician Decision|2
6343337|NCT03346057|10100982|FG002|Overall Study|Physician Decision|0
6343338|NCT03346057|10100983|FG003|Overall Study|Physician Decision|2
6343339|NCT03346057|10100980|FG000|Overall Study|Randomization Mistake - Not Treated|1
6343340|NCT03346057|10100981|FG001|Overall Study|Randomization Mistake - Not Treated|1
6343341|NCT03346057|10100982|FG002|Overall Study|Randomization Mistake - Not Treated|0
6343342|NCT03346057|10100983|FG003|Overall Study|Randomization Mistake - Not Treated|0
6343343|NCT03346057|10100980|FG000|Overall Study|Withdrawal by Subject|1
6343344|NCT03346057|10100981|FG001|Overall Study|Withdrawal by Subject|0
6343345|NCT03346057|10100982|FG002|Overall Study|Withdrawal by Subject|0
6343346|NCT03346057|10100983|FG003|Overall Study|Withdrawal by Subject|0
6343347|NCT03346070|10100998|FG000|Overall Study|Death|0
6343348|NCT03346070|10100999|FG001|Overall Study|Death|0
6343349|NCT03346070|10101000|FG002|Overall Study|Death|0
6343350|NCT03346070|10101001|FG003|Overall Study|Death|0
6343351|NCT03346070|10101002|FG004|Overall Study|Death|1
6343352|NCT03346070|10100998|FG000|Overall Study|Lost to Follow-up|0
6343353|NCT03346070|10100999|FG001|Overall Study|Lost to Follow-up|1
6343354|NCT03346070|10101000|FG002|Overall Study|Lost to Follow-up|2
6343355|NCT03346070|10101001|FG003|Overall Study|Lost to Follow-up|0
6343356|NCT03346070|10101002|FG004|Overall Study|Lost to Follow-up|0
6343357|NCT03346070|10100998|FG000|Overall Study|Physician Decision|0
6343358|NCT03346070|10100999|FG001|Overall Study|Physician Decision|0
6343359|NCT03346070|10101000|FG002|Overall Study|Physician Decision|0
6343360|NCT03346070|10101001|FG003|Overall Study|Physician Decision|1
6343361|NCT03346070|10101002|FG004|Overall Study|Physician Decision|1
6343362|NCT03346070|10100998|FG000|Overall Study|Withdrawal by Subject|1
6343363|NCT03346070|10100999|FG001|Overall Study|Withdrawal by Subject|0
6343364|NCT03346070|10101000|FG002|Overall Study|Withdrawal by Subject|0
6343365|NCT03346070|10101001|FG003|Overall Study|Withdrawal by Subject|1
6343366|NCT03346070|10101002|FG004|Overall Study|Withdrawal by Subject|0
6343367|NCT03346070|10100998|FG000|Overall Study|Study medication not received as planned|2
6343368|NCT03346070|10100999|FG001|Overall Study|Study medication not received as planned|3
6343369|NCT03346070|10101000|FG002|Overall Study|Study medication not received as planned|2
6343370|NCT03346070|10101001|FG003|Overall Study|Study medication not received as planned|3
6343371|NCT03346070|10101002|FG004|Overall Study|Study medication not received as planned|2
6343372|NCT03346070|10100998|FG000|Overall Study|Screen Failure|0
6343373|NCT03346070|10100999|FG001|Overall Study|Screen Failure|0
6343374|NCT03346070|10101000|FG002|Overall Study|Screen Failure|0
6343375|NCT03346070|10101001|FG003|Overall Study|Screen Failure|1
6343376|NCT03346070|10101002|FG004|Overall Study|Screen Failure|1
6343377|NCT03346759|10101027|FG000|Enrollment to Baseline Data Collected|Lost to Follow-up|2
6343378|NCT03346759|10101028|FG001|Enrollment to Baseline Data Collected|Lost to Follow-up|3
6343379|NCT03346759|10101027|FG000|First Menstrual Cycle|Withdrawal by Subject|1
6343380|NCT03346759|10101028|FG001|First Menstrual Cycle|Withdrawal by Subject|0
6343381|NCT03346759|10101027|FG000|Second Menstrual Cycle|Lost to Follow-up|1
6343382|NCT03346759|10101028|FG001|Second Menstrual Cycle|Lost to Follow-up|0
6343383|NCT03347188|10101055|FG000|Double-blind (DB) Period (12 Weeks)|Protocol Violation|2
6343384|NCT03347188|10101056|FG001|Double-blind (DB) Period (12 Weeks)|Protocol Violation|2
6343385|NCT03347188|10101055|FG000|Double-blind (DB) Period (12 Weeks)|Withdrawal by Subject|4
6343386|NCT03347188|10101056|FG001|Double-blind (DB) Period (12 Weeks)|Withdrawal by Subject|8
6343387|NCT03347188|10101055|FG000|Double-blind (DB) Period (12 Weeks)|Lost to Follow-up|7
6343388|NCT03347188|10101056|FG001|Double-blind (DB) Period (12 Weeks)|Lost to Follow-up|4
6343389|NCT03347188|10101055|FG000|Double-blind (DB) Period (12 Weeks)|Adverse Event|1
6343390|NCT03347188|10101056|FG001|Double-blind (DB) Period (12 Weeks)|Adverse Event|1
6343391|NCT03347188|10101055|FG000|Double-blind (DB) Period (12 Weeks)|Other than specified|1
6343392|NCT03347188|10101056|FG001|Double-blind (DB) Period (12 Weeks)|Other than specified|2
6343393|NCT03347188|10101055|FG000|Open-label (OL) Period (12 Weeks)|Entered for ADA assessment only, not treated|26
6343394|NCT03347188|10101056|FG001|Open-label (OL) Period (12 Weeks)|Entered for ADA assessment only, not treated|28
6343395|NCT03347188|10101055|FG000|Open-label (OL) Period (12 Weeks)|Withdrawal by Subject|1
6343396|NCT03347188|10101056|FG001|Open-label (OL) Period (12 Weeks)|Withdrawal by Subject|0
6343397|NCT03347188|10101055|FG000|Open-label (OL) Period (12 Weeks)|Other than specified|0
6343398|NCT03347188|10101056|FG001|Open-label (OL) Period (12 Weeks)|Other than specified|1
6343399|NCT03347279|10101064|FG000|Overall Study|Withdrawal by Subject|8
6343400|NCT03347279|10101065|FG001|Overall Study|Withdrawal by Subject|15
6343401|NCT03347279|10101064|FG000|Overall Study|Death|0
6343402|NCT03347279|10101065|FG001|Overall Study|Death|2
6343403|NCT03347279|10101064|FG000|Overall Study|Lost to Follow-up|5
6343404|NCT03347279|10101065|FG001|Overall Study|Lost to Follow-up|2
6343405|NCT03347279|10101064|FG000|Overall Study|Did not receive treatment / Non-compliance with protocol / did not complete safety follow-up visits|3
6343406|NCT03347279|10101065|FG001|Overall Study|Did not receive treatment / Non-compliance with protocol / did not complete safety follow-up visits|4
6343407|NCT03347695|10101073|FG000|Overall Study|Death|0
6343408|NCT03347695|10101074|FG001|Overall Study|Death|4
6343409|NCT03347695|10101073|FG000|Overall Study|Lost to Follow-up|0
6343410|NCT03347695|10101074|FG001|Overall Study|Lost to Follow-up|1
6343411|NCT03349034|10101093|FG000|Overall Study|catheters dislodged during transport|2
6343412|NCT03349034|10101094|FG001|Overall Study|catheters dislodged during transport|0
6343413|NCT03349034|10101093|FG000|Overall Study|intubated for >48 hrs following surgery|1
6343414|NCT03349034|10101094|FG001|Overall Study|intubated for >48 hrs following surgery|1
6343415|NCT03349034|10101093|FG000|Overall Study|soft tissue flap used|1
6343416|NCT03349034|10101094|FG001|Overall Study|soft tissue flap used|0
6343417|NCT03349034|10101093|FG000|Overall Study|Other|0
6343418|NCT03349034|10101094|FG001|Overall Study|Other|1
6343419|NCT03349060|10101105|FG000|Overall Study|Adverse Event|9
6343420|NCT03349060|10101106|FG001|Overall Study|Adverse Event|9
6343421|NCT03349060|10101107|FG002|Overall Study|Adverse Event|7
6343422|NCT03349060|10101105|FG000|Overall Study|Lack of Efficacy|1
6343423|NCT03349060|10101106|FG001|Overall Study|Lack of Efficacy|0
6343424|NCT03349060|10101107|FG002|Overall Study|Lack of Efficacy|2
6343425|NCT03349060|10101105|FG000|Overall Study|Lost to Follow-up|2
6343426|NCT03349060|10101106|FG001|Overall Study|Lost to Follow-up|1
6343427|NCT03349060|10101107|FG002|Overall Study|Lost to Follow-up|1
6343428|NCT03349060|10101105|FG000|Overall Study|Protocol Violation|2
6343429|NCT03349060|10101106|FG001|Overall Study|Protocol Violation|2
6343430|NCT03349060|10101107|FG002|Overall Study|Protocol Violation|1
6343431|NCT03349060|10101105|FG000|Overall Study|Withdrawal by Subject|5
6343432|NCT03349060|10101106|FG001|Overall Study|Withdrawal by Subject|3
6343433|NCT03349060|10101107|FG002|Overall Study|Withdrawal by Subject|4
6343434|NCT03349060|10101105|FG000|Overall Study|Medication error,no linked adverse event|0
6343435|NCT03349060|10101106|FG001|Overall Study|Medication error,no linked adverse event|0
6343436|NCT03349060|10101107|FG002|Overall Study|Medication error,no linked adverse event|1
6343437|NCT03349060|10101105|FG000|Overall Study|Withdrawal By Parent/Guardian|0
6343438|NCT03349060|10101106|FG001|Overall Study|Withdrawal By Parent/Guardian|1
6343439|NCT03349060|10101107|FG002|Overall Study|Withdrawal By Parent/Guardian|0
6343440|NCT03349060|10101105|FG000|Overall Study|Other|2
6343441|NCT03349060|10101106|FG001|Overall Study|Other|1
6343442|NCT03349060|10101107|FG002|Overall Study|Other|0
6343443|NCT03349099|10101117|FG000|Overall Study|Physician Decision|3
6343444|NCT03349099|10101118|FG001|Overall Study|Physician Decision|4
6343445|NCT03349099|10101117|FG000|Overall Study|Stone migrated from the kidney|1
6343446|NCT03349099|10101118|FG001|Overall Study|Stone migrated from the kidney|0
6343447|NCT03349333|10101124|FG000|Overall Study|Progression of Disease|36
6343448|NCT03349333|10101124|FG000|Overall Study|Adverse Event|11
6343449|NCT03349333|10101124|FG000|Overall Study|Other|6
6343450|NCT03349333|10101124|FG000|Overall Study|Withdrawal by Subject|5
6343451|NCT03349333|10101124|FG000|Overall Study|Conditions interfere with participation|2
6343452|NCT03349333|10101124|FG000|Overall Study|Physician Decision|2
6343453|NCT03349333|10101124|FG000|Overall Study|3-week lapse between pralatrexate doses|1
6343454|NCT03349333|10101124|FG000|Overall Study|Patients in treatment less than 24 month|8
6343455|NCT03349437|10101128|FG000|Screening|Screen Fail|4
6343456|NCT03349437|10101129|FG001|Screening|Screen Fail|0
6343457|NCT03349437|10101130|FG002|Screening|Screen Fail|0
6343458|NCT03349437|10101128|FG000|Screening|Withdrawn|1
6343459|NCT03349437|10101129|FG001|Screening|Withdrawn|0
6343460|NCT03349437|10101130|FG002|Screening|Withdrawn|0
6343461|NCT03349515|10101139|FG000|Overall Study|Lack of Efficacy|2
6343462|NCT03349515|10101140|FG001|Overall Study|Lack of Efficacy|0
6343463|NCT03349515|10101139|FG000|Overall Study|Physician Decision|3
6343464|NCT03349515|10101140|FG001|Overall Study|Physician Decision|1
6343465|NCT03349710|10101182|FG000|Treatment Period|Death|0
6343466|NCT03349710|10101183|FG001|Treatment Period|Death|0
6343467|NCT03349710|10101184|FG002|Treatment Period|Death|1
6343468|NCT03349710|10101185|FG003|Treatment Period|Death|0
6343469|NCT03349710|10101182|FG000|Treatment Period|Disease Progression|0
6343470|NCT03349710|10101183|FG001|Treatment Period|Disease Progression|2
6343471|NCT03349710|10101184|FG002|Treatment Period|Disease Progression|0
6343472|NCT03349710|10101185|FG003|Treatment Period|Disease Progression|1
6343473|NCT03349710|10101182|FG000|Treatment Period|Study Drug Toxicity|1
6343474|NCT03349710|10101183|FG001|Treatment Period|Study Drug Toxicity|0
6343475|NCT03349710|10101184|FG002|Treatment Period|Study Drug Toxicity|1
6343476|NCT03349710|10101185|FG003|Treatment Period|Study Drug Toxicity|1
6343477|NCT03349710|10101182|FG000|Treatment Period|Adverse event unrelated to Study Drug|2
6343478|NCT03349710|10101183|FG001|Treatment Period|Adverse event unrelated to Study Drug|1
6343479|NCT03349710|10101184|FG002|Treatment Period|Adverse event unrelated to Study Drug|1
6343480|NCT03349710|10101185|FG003|Treatment Period|Adverse event unrelated to Study Drug|1
6343481|NCT03349710|10101182|FG000|Treatment Period|admin reason by sponsor|0
6343482|NCT03349710|10101183|FG001|Treatment Period|admin reason by sponsor|7
6343483|NCT03349710|10101184|FG002|Treatment Period|admin reason by sponsor|0
6343484|NCT03349710|10101185|FG003|Treatment Period|admin reason by sponsor|19
6343485|NCT03349710|10101182|FG000|Treatment Period|Other Reason|2
6343486|NCT03349710|10101183|FG001|Treatment Period|Other Reason|0
6343487|NCT03349710|10101184|FG002|Treatment Period|Other Reason|2
6343488|NCT03349710|10101185|FG003|Treatment Period|Other Reason|1
6343489|NCT03349710|10101182|FG000|Treatment Period|completed|6
6343490|NCT03349710|10101183|FG001|Treatment Period|completed|0
6343491|NCT03349710|10101184|FG002|Treatment Period|completed|18
6343492|NCT03349710|10101185|FG003|Treatment Period|completed|1
6343493|NCT03349710|10101182|FG000|Treatment Period|participant request to discontinue|0
6343494|NCT03349710|10101183|FG001|Treatment Period|participant request to discontinue|0
6343495|NCT03349710|10101184|FG002|Treatment Period|participant request to discontinue|4
6343496|NCT03349710|10101185|FG003|Treatment Period|participant request to discontinue|0
6343497|NCT03349710|10101182|FG000|Treatment Period|participant withdrew consent|1
6343498|NCT03349710|10101183|FG001|Treatment Period|participant withdrew consent|0
6343499|NCT03349710|10101184|FG002|Treatment Period|participant withdrew consent|0
6343500|NCT03349710|10101185|FG003|Treatment Period|participant withdrew consent|0
6343501|NCT03350256|10101208|FG000|Overall Study|Inclusion/exclusion violation|4
6343502|NCT03350256|10101208|FG000|Overall Study|Recommended for other therapies|2
6343503|NCT03350256|10101208|FG000|Overall Study|Protocol Violation|3
6343504|NCT03350256|10101208|FG000|Overall Study|Non compliance|2
6343505|NCT03350256|10101208|FG000|Overall Study|Denial by insurance|1
6343506|NCT03350256|10101208|FG000|Overall Study|Adverse Event|2
6343507|NCT03350256|10101208|FG000|Overall Study|Trial failure|12
6343508|NCT03350256|10101208|FG000|Overall Study|Did not proceed to permanent implant|3
6343509|NCT03350256|10101208|FG000|Overall Study|Withdrawal by Subject|3
6343510|NCT03350256|10101208|FG000|Overall Study|Subject moving out of state|1
6343511|NCT03350256|10101208|FG000|Overall Study|Lost to Follow-up|1
6343512|NCT03350256|10101208|FG000|Overall Study|Lack of Efficacy|2
6343513|NCT03350672|10101219|FG000|Overall Study|Withdrawal by Subject|7
6343514|NCT03350672|10101220|FG001|Overall Study|Withdrawal by Subject|0
6343515|NCT03350672|10101221|FG002|Overall Study|Withdrawal by Subject|0
6343516|NCT03351114|10101258|FG000|Overall Study|Withdrawal by Subject|1
6343517|NCT03351231|10101262|FG000|Combination Therapy Period|Administrative reason by the Sponsor|1
6343518|NCT03351231|10101262|FG000|Combination Therapy Period|Disease progression|2
6343519|NCT03351231|10101262|FG000|Combination Therapy Period|Study drug toxicity|1
6343520|NCT03351231|10101262|FG000|Combination Therapy Period|Adverse Event unrelated to study drug|1
6343521|NCT03351231|10101262|FG000|Safety Follow-Up Period|Participant withdrew consent|1
6343522|NCT03351231|10101262|FG000|Safety Follow-Up Period|Other reason|2
6343523|NCT03351335|10101269|FG000|Overall Study|Failure to maintain inclusion/exclusion|0
6168758|NCT01237587|9813910|FG001|Double Blind Treatment (Acute Phase)|Withdrawal by Subject|4
6168759|NCT01237587|9813909|FG000|Open Label Treatment (Extension Phase)|Lost to Follow-up|4
6168760|NCT01237587|9813910|FG001|Open Label Treatment (Extension Phase)|Lost to Follow-up|3
6168761|NCT01237587|9813909|FG000|Open Label Treatment (Extension Phase)|Adverse Event|5
6168762|NCT01237587|9813910|FG001|Open Label Treatment (Extension Phase)|Adverse Event|5
6168763|NCT01237587|9813909|FG000|Open Label Treatment (Extension Phase)|Lack of Efficacy|2
6168764|NCT01237587|9813910|FG001|Open Label Treatment (Extension Phase)|Lack of Efficacy|4
6168765|NCT01237587|9813909|FG000|Open Label Treatment (Extension Phase)|Parent/Guardian Decision|2
6168766|NCT01237587|9813910|FG001|Open Label Treatment (Extension Phase)|Parent/Guardian Decision|4
6168767|NCT01237587|9813909|FG000|Open Label Treatment (Extension Phase)|Withdrawal by Subject|0
6168768|NCT01237587|9813910|FG001|Open Label Treatment (Extension Phase)|Withdrawal by Subject|5
6168769|NCT01237587|9813909|FG000|Open Label Treatment (Extension Phase)|Sponsor Decision|1
6168770|NCT01237587|9813910|FG001|Open Label Treatment (Extension Phase)|Sponsor Decision|0
6168771|NCT01237587|9813909|FG000|Open Label Treatment (Extension Phase)|Physician Decision|4
6168772|NCT01237587|9813910|FG001|Open Label Treatment (Extension Phase)|Physician Decision|4
6343524|NCT03351335|10101270|FG001|Overall Study|Failure to maintain inclusion/exclusion|0
6343525|NCT03351335|10101271|FG002|Overall Study|Failure to maintain inclusion/exclusion|4
6343526|NCT03351478|10101282|FG000|Overall Study|At the subject's own request|11
6343527|NCT03351478|10101283|FG001|Overall Study|At the subject's own request|12
6343528|NCT03351478|10101284|FG002|Overall Study|At the subject's own request|5
6343529|NCT03351478|10101282|FG000|Overall Study|Adverse Event|1
6343530|NCT03351478|10101283|FG001|Overall Study|Adverse Event|2
6343531|NCT03351478|10101284|FG002|Overall Study|Adverse Event|1
6343532|NCT03351478|10101282|FG000|Overall Study|Poor compliance to protocol|1
6343533|NCT03351478|10101283|FG001|Overall Study|Poor compliance to protocol|0
6343534|NCT03351478|10101284|FG002|Overall Study|Poor compliance to protocol|0
6343535|NCT03351478|10101282|FG000|Overall Study|Reason not Specified|1
6343536|NCT03351478|10101283|FG001|Overall Study|Reason not Specified|3
6343537|NCT03351478|10101284|FG002|Overall Study|Reason not Specified|0
6343538|NCT03351478|10101282|FG000|Overall Study|Lost to Follow-up|0
6343539|NCT03351478|10101283|FG001|Overall Study|Lost to Follow-up|0
6343540|NCT03351478|10101284|FG002|Overall Study|Lost to Follow-up|1
6343541|NCT03351608|10101297|FG000|Overall Study|Lost to Follow-up|0
6343542|NCT03351608|10101298|FG001|Overall Study|Lost to Follow-up|1
6343543|NCT03351608|10101299|FG002|Overall Study|Lost to Follow-up|1
6343544|NCT03351608|10101300|FG003|Overall Study|Lost to Follow-up|1
6343545|NCT03351608|10101301|FG004|Overall Study|Lost to Follow-up|1
6343546|NCT03351608|10101297|FG000|Overall Study|Physician Decision|1
6343547|NCT03351608|10101298|FG001|Overall Study|Physician Decision|0
6343548|NCT03351608|10101299|FG002|Overall Study|Physician Decision|0
6343549|NCT03351608|10101300|FG003|Overall Study|Physician Decision|2
6343550|NCT03351608|10101301|FG004|Overall Study|Physician Decision|1
6343551|NCT03351608|10101297|FG000|Overall Study|Randomized by mistake, no treatment given|0
6343552|NCT03351608|10101298|FG001|Overall Study|Randomized by mistake, no treatment given|0
6343553|NCT03351608|10101299|FG002|Overall Study|Randomized by mistake, no treatment given|0
6343554|NCT03351608|10101300|FG003|Overall Study|Randomized by mistake, no treatment given|1
6343555|NCT03351608|10101301|FG004|Overall Study|Randomized by mistake, no treatment given|0
6343556|NCT03351608|10101297|FG000|Overall Study|Withdrawal by parent/guardian|0
6343557|NCT03351608|10101298|FG001|Overall Study|Withdrawal by parent/guardian|0
6343558|NCT03351608|10101299|FG002|Overall Study|Withdrawal by parent/guardian|1
6343559|NCT03351608|10101300|FG003|Overall Study|Withdrawal by parent/guardian|1
6343560|NCT03351608|10101301|FG004|Overall Study|Withdrawal by parent/guardian|0
6343561|NCT03351608|10101297|FG000|Overall Study|Other|0
6343562|NCT03351608|10101298|FG001|Overall Study|Other|1
6343563|NCT03351608|10101299|FG002|Overall Study|Other|1
6343564|NCT03351608|10101300|FG003|Overall Study|Other|3
6343565|NCT03351608|10101301|FG004|Overall Study|Other|0
6343566|NCT03351738|10101357|FG000|Overall Study|Withdrawal by Subject|0
6343567|NCT03351738|10101358|FG001|Overall Study|Withdrawal by Subject|1
6343568|NCT03351738|10101359|FG002|Overall Study|Withdrawal by Subject|0
6343569|NCT03351738|10101360|FG003|Overall Study|Withdrawal by Subject|1
6343570|NCT03351738|10101361|FG004|Overall Study|Withdrawal by Subject|0
6343571|NCT03351738|10101362|FG005|Overall Study|Withdrawal by Subject|0
6343572|NCT03352414|10101400|FG000|Overall Study|Ineligible by operative criteria|12
6343573|NCT03352414|10101401|FG001|Overall Study|Ineligible by operative criteria|10
6343574|NCT03352453|10101411|FG000|Overall Study|Miscellaneous Reasons|1
6343575|NCT03352453|10101412|FG001|Overall Study|Miscellaneous Reasons|2
6343576|NCT03352453|10101411|FG000|Overall Study|Lack of Efficacy|1
6343577|NCT03352453|10101412|FG001|Overall Study|Lack of Efficacy|0
6343578|NCT03352453|10101411|FG000|Overall Study|Withdrawal by Subject|8
6343579|NCT03352453|10101412|FG001|Overall Study|Withdrawal by Subject|14
6343580|NCT03352453|10101411|FG000|Overall Study|Study Terminated by Sponsor|2
6343581|NCT03352453|10101412|FG001|Overall Study|Study Terminated by Sponsor|1
6343582|NCT03352453|10101411|FG000|Overall Study|Protocol Deviation|1
6343583|NCT03352453|10101412|FG001|Overall Study|Protocol Deviation|0
6343584|NCT03352453|10101411|FG000|Overall Study|Lost to Follow-up|7
6343585|NCT03352453|10101412|FG001|Overall Study|Lost to Follow-up|6
6343586|NCT03352453|10101411|FG000|Overall Study|Adverse Event|2
6343587|NCT03352453|10101412|FG001|Overall Study|Adverse Event|9
6343588|NCT03352713|10101427|FG000|Overall Study|Lost to Follow-up|8
6343589|NCT03352713|10101427|FG000|Overall Study|Withdrawn by investigator|5
6343590|NCT03352713|10101427|FG000|Overall Study|Completed 0 EMAs|8
6343591|NCT03352713|10101427|FG000|Overall Study|Device incompatible/stolen|5
6343592|NCT03353220|10101431|FG000|Third Intervention (6 Months) - Phase 2|Study was stopped due to unavailable study drug supply|4
6343593|NCT03353220|10101432|FG001|Third Intervention (6 Months) - Phase 2|Study was stopped due to unavailable study drug supply|7
6343594|NCT03353740|10101442|FG000|Overall Study|Images for these participants not viable|52
6343595|NCT03354429|10101466|FG000|Overall Study|Withdrawal by Subject|8
6343596|NCT03354429|10101467|FG001|Overall Study|Withdrawal by Subject|7
6343597|NCT03354429|10101466|FG000|Overall Study|Lost to Follow-up|1
6343598|NCT03354429|10101467|FG001|Overall Study|Lost to Follow-up|0
6343599|NCT03354637|10101485|FG000|Double-blind Period|Protocol Violation|2
6343600|NCT03354637|10101486|FG001|Double-blind Period|Protocol Violation|0
6343601|NCT03354637|10101487|FG002|Double-blind Period|Protocol Violation|0
6343602|NCT03354637|10101485|FG000|Double-blind Period|Adverse Event|1
6343603|NCT03354637|10101486|FG001|Double-blind Period|Adverse Event|2
6343604|NCT03354637|10101487|FG002|Double-blind Period|Adverse Event|0
6343605|NCT03354637|10101485|FG000|Double-blind Period|Lost to Follow-up|3
6343606|NCT03354637|10101486|FG001|Double-blind Period|Lost to Follow-up|4
6343607|NCT03354637|10101487|FG002|Double-blind Period|Lost to Follow-up|3
6343608|NCT03354637|10101485|FG000|Double-blind Period|Withdrawal by Subject|10
6343609|NCT03354637|10101486|FG001|Double-blind Period|Withdrawal by Subject|6
6343610|NCT03354637|10101487|FG002|Double-blind Period|Withdrawal by Subject|4
6343611|NCT03354637|10101485|FG000|Double-blind Period|Incomplete Efficacy Data Collection|1
6343612|NCT03354637|10101486|FG001|Double-blind Period|Incomplete Efficacy Data Collection|1
6343613|NCT03354637|10101487|FG002|Double-blind Period|Incomplete Efficacy Data Collection|0
6343614|NCT03354637|10101485|FG000|Open Label Extension|Adverse Event|0
6343615|NCT03354637|10101486|FG001|Open Label Extension|Adverse Event|0
6343616|NCT03354637|10101487|FG002|Open Label Extension|Adverse Event|1
6343617|NCT03354637|10101485|FG000|Open Label Extension|Lost to Follow-up|0
6343618|NCT03354637|10101486|FG001|Open Label Extension|Lost to Follow-up|0
6343619|NCT03354637|10101487|FG002|Open Label Extension|Lost to Follow-up|2
6343620|NCT03354637|10101485|FG000|Open Label Extension|Withdrawal by Subject|0
6343621|NCT03354637|10101486|FG001|Open Label Extension|Withdrawal by Subject|0
6343622|NCT03354637|10101487|FG002|Open Label Extension|Withdrawal by Subject|5
6343623|NCT03354637|10101485|FG000|Open Label Extension|Study Terminated by Sponsor|0
6343624|NCT03354637|10101486|FG001|Open Label Extension|Study Terminated by Sponsor|0
6343625|NCT03354637|10101487|FG002|Open Label Extension|Study Terminated by Sponsor|17
6343626|NCT03354637|10101485|FG000|Open Label Extension|Subject Noncompliance|0
6343627|NCT03354637|10101486|FG001|Open Label Extension|Subject Noncompliance|0
6343628|NCT03354637|10101487|FG002|Open Label Extension|Subject Noncompliance|1
6343629|NCT03354637|10101485|FG000|Open Label Extension|Lack of Efficacy|0
6343630|NCT03354637|10101486|FG001|Open Label Extension|Lack of Efficacy|0
6343631|NCT03354637|10101487|FG002|Open Label Extension|Lack of Efficacy|1
6343632|NCT03354637|10101485|FG000|Open Label Extension|Physician Decision|0
6343633|NCT03354637|10101486|FG001|Open Label Extension|Physician Decision|0
6343634|NCT03354637|10101487|FG002|Open Label Extension|Physician Decision|1
6343635|NCT03354663|10101496|FG000|Enrollment to Catheter Insertion|Did not meet inc/exc criteria|4
6343636|NCT03354663|10101496|FG000|Enrollment to Catheter Insertion|Adverse Event|1
6343637|NCT03354663|10101496|FG000|Completed 30-day Visit|Withdrawal by Subject|1
6343638|NCT03354663|10101496|FG000|Completed 30-day Visit|Missed Visit|1
6343639|NCT03355326|10101515|FG000|Overall Study|Protocol Violation|3
6343640|NCT03355326|10101516|FG001|Overall Study|Protocol Violation|3
6343641|NCT03355742|10101522|FG000|Overall Study|Lost to Follow-up|4
6343642|NCT03355742|10101522|FG000|Overall Study|Withdrawal by Subject|29
6343643|NCT03355742|10101522|FG000|Overall Study|Physician Decision|6
6343644|NCT03355742|10101522|FG000|Overall Study|Death|55
6343645|NCT03355742|10101522|FG000|Overall Study|Administrative Closure of the Study, Other Status Change Reason, Missed Visit, Protocol Violation|5
6343646|NCT03356145|10101532|FG000|Overall Study|Withdrawal by Subject|2
6343647|NCT03356145|10101533|FG001|Overall Study|Withdrawal by Subject|1
6343648|NCT03356145|10101532|FG000|Overall Study|Did not meet inclusion criteria|1
6343649|NCT03356145|10101533|FG001|Overall Study|Did not meet inclusion criteria|0
6343650|NCT03356977|10101539|FG000|Overall Study|Lost to Follow-up|3
6343651|NCT03356977|10101539|FG000|Overall Study|Withdrawal by parent/guardian|2
6343652|NCT03357341|10101545|FG000|Overall Study|Withdrawal by Subject|3
6343653|NCT03357341|10101546|FG001|Overall Study|Withdrawal by Subject|6
6343654|NCT03357341|10101545|FG000|Overall Study|Lost to Follow-up|4
6343655|NCT03357341|10101546|FG001|Overall Study|Lost to Follow-up|5
6343656|NCT03357341|10101545|FG000|Overall Study|Death|0
6343657|NCT03357341|10101546|FG001|Overall Study|Death|1
6343658|NCT03357471|10101568|FG000|Overall Study|Adverse Event|1
6343659|NCT03357471|10101569|FG001|Overall Study|Adverse Event|0
6343660|NCT03357471|10101568|FG000|Overall Study|Lost to Follow-up|1
6343661|NCT03357471|10101569|FG001|Overall Study|Lost to Follow-up|0
6343662|NCT03357731|10101584|FG000|Overall Study|Withdrew consent due to personal reasons|0
6343663|NCT03357731|10101585|FG001|Overall Study|Withdrew consent due to personal reasons|0
6343664|NCT03357731|10101586|FG002|Overall Study|Withdrew consent due to personal reasons|0
6343665|NCT03357731|10101587|FG003|Overall Study|Withdrew consent due to personal reasons|0
6343666|NCT03357731|10101588|FG004|Overall Study|Withdrew consent due to personal reasons|1
6343667|NCT03357731|10101589|FG005|Overall Study|Withdrew consent due to personal reasons|0
6343668|NCT03357731|10101584|FG000|Overall Study|Acute bradycardia and hypotension|0
6343669|NCT03357731|10101585|FG001|Overall Study|Acute bradycardia and hypotension|0
6343670|NCT03357731|10101586|FG002|Overall Study|Acute bradycardia and hypotension|0
6343671|NCT03357731|10101587|FG003|Overall Study|Acute bradycardia and hypotension|1
6343672|NCT03357731|10101588|FG004|Overall Study|Acute bradycardia and hypotension|0
6343673|NCT03357731|10101589|FG005|Overall Study|Acute bradycardia and hypotension|0
6343674|NCT03357731|10101584|FG000|Overall Study|Adverse Event|0
6343675|NCT03357731|10101585|FG001|Overall Study|Adverse Event|0
6343676|NCT03357731|10101586|FG002|Overall Study|Adverse Event|0
6343677|NCT03357731|10101587|FG003|Overall Study|Adverse Event|0
6343678|NCT03357731|10101588|FG004|Overall Study|Adverse Event|0
6343679|NCT03357731|10101589|FG005|Overall Study|Adverse Event|1
6343680|NCT03357731|10101584|FG000|Overall Study|Hypotension|0
6343681|NCT03357731|10101585|FG001|Overall Study|Hypotension|0
6343682|NCT03357731|10101586|FG002|Overall Study|Hypotension|1
6343683|NCT03357731|10101587|FG003|Overall Study|Hypotension|1
6343684|NCT03357731|10101588|FG004|Overall Study|Hypotension|0
6343685|NCT03357731|10101589|FG005|Overall Study|Hypotension|0
6343686|NCT03357731|10101584|FG000|Overall Study|Lost to Follow-up|0
6343687|NCT03357731|10101585|FG001|Overall Study|Lost to Follow-up|0
6343688|NCT03357731|10101586|FG002|Overall Study|Lost to Follow-up|0
6343689|NCT03357731|10101587|FG003|Overall Study|Lost to Follow-up|1
6343690|NCT03357731|10101588|FG004|Overall Study|Lost to Follow-up|0
6343691|NCT03357731|10101589|FG005|Overall Study|Lost to Follow-up|0
6343692|NCT03358147|10101602|FG000|Overall Study|Withdrawal by Subject|13
6343693|NCT03358147|10101603|FG001|Overall Study|Withdrawal by Subject|19
6343694|NCT03358147|10101604|FG002|Overall Study|Withdrawal by Subject|16
6343695|NCT03358147|10101605|FG003|Overall Study|Withdrawal by Subject|10
6343696|NCT03358147|10101606|FG004|Overall Study|Withdrawal by Subject|5
6343697|NCT03358147|10101602|FG000|Overall Study|Adverse Event|3
6343698|NCT03358147|10101603|FG001|Overall Study|Adverse Event|9
6343699|NCT03358147|10101604|FG002|Overall Study|Adverse Event|7
6343700|NCT03358147|10101605|FG003|Overall Study|Adverse Event|5
6343701|NCT03358147|10101606|FG004|Overall Study|Adverse Event|2
6343702|NCT03358147|10101602|FG000|Overall Study|Lost to Follow-up|4
6343703|NCT03358147|10101603|FG001|Overall Study|Lost to Follow-up|3
6343704|NCT03358147|10101604|FG002|Overall Study|Lost to Follow-up|7
6343705|NCT03358147|10101605|FG003|Overall Study|Lost to Follow-up|6
6343706|NCT03358147|10101606|FG004|Overall Study|Lost to Follow-up|4
6343707|NCT03358147|10101602|FG000|Overall Study|Major Protocol Deviation|11
6343708|NCT03358147|10101603|FG001|Overall Study|Major Protocol Deviation|3
6343709|NCT03358147|10101604|FG002|Overall Study|Major Protocol Deviation|2
6343710|NCT03358147|10101605|FG003|Overall Study|Major Protocol Deviation|3
6343711|NCT03358147|10101606|FG004|Overall Study|Major Protocol Deviation|1
6343712|NCT03358147|10101602|FG000|Overall Study|Protocol specified criteria|2
6343713|NCT03358147|10101603|FG001|Overall Study|Protocol specified criteria|3
6343714|NCT03358147|10101604|FG002|Overall Study|Protocol specified criteria|0
6343715|NCT03358147|10101605|FG003|Overall Study|Protocol specified criteria|3
6343716|NCT03358147|10101606|FG004|Overall Study|Protocol specified criteria|1
6343717|NCT03358147|10101602|FG000|Overall Study|Physician Decision|1
6343718|NCT03358147|10101603|FG001|Overall Study|Physician Decision|0
6343719|NCT03358147|10101604|FG002|Overall Study|Physician Decision|1
6343720|NCT03358147|10101605|FG003|Overall Study|Physician Decision|6
6343721|NCT03358147|10101606|FG004|Overall Study|Physician Decision|1
6343722|NCT03358147|10101602|FG000|Overall Study|Administrative reasons|0
6343723|NCT03358147|10101603|FG001|Overall Study|Administrative reasons|1
6343724|NCT03358147|10101604|FG002|Overall Study|Administrative reasons|0
6343725|NCT03358147|10101605|FG003|Overall Study|Administrative reasons|3
6343726|NCT03358147|10101606|FG004|Overall Study|Administrative reasons|0
6343727|NCT03358147|10101602|FG000|Overall Study|Lack of Efficacy|0
6343728|NCT03358147|10101603|FG001|Overall Study|Lack of Efficacy|1
6343729|NCT03358147|10101604|FG002|Overall Study|Lack of Efficacy|1
6343730|NCT03358147|10101605|FG003|Overall Study|Lack of Efficacy|0
6343731|NCT03358147|10101606|FG004|Overall Study|Lack of Efficacy|0
6343732|NCT03358238|10101620|FG000|Overall Study|Withdrawal by Subject|0
6343733|NCT03358238|10101621|FG001|Overall Study|Withdrawal by Subject|1
6343734|NCT03358290|10101643|FG000|Overall Study|Study discontinued by Sponsor|0
6343735|NCT03358290|10101644|FG001|Overall Study|Study discontinued by Sponsor|1
6343736|NCT03358290|10101645|FG002|Overall Study|Study discontinued by Sponsor|1
6343737|NCT03358290|10101646|FG003|Overall Study|Study discontinued by Sponsor|0
6343738|NCT03358290|10101647|FG004|Overall Study|Study discontinued by Sponsor|0
6343739|NCT03358290|10101643|FG000|Overall Study|Adverse Event|0
6343740|NCT03358290|10101644|FG001|Overall Study|Adverse Event|0
6343741|NCT03358290|10101645|FG002|Overall Study|Adverse Event|1
6343742|NCT03358290|10101646|FG003|Overall Study|Adverse Event|2
6343743|NCT03358290|10101647|FG004|Overall Study|Adverse Event|0
6343744|NCT03358290|10101643|FG000|Overall Study|Withdrawal by Subject|0
6343745|NCT03358290|10101644|FG001|Overall Study|Withdrawal by Subject|0
6343746|NCT03358290|10101645|FG002|Overall Study|Withdrawal by Subject|0
6343747|NCT03358290|10101646|FG003|Overall Study|Withdrawal by Subject|0
6343748|NCT03358290|10101647|FG004|Overall Study|Withdrawal by Subject|1
6343749|NCT03358329|10101659|FG000|Overall Study|Lost to Follow-up|2
6343750|NCT03358329|10101659|FG000|Overall Study|Withdrawal by Subject|2
6343751|NCT03358407|10101684|FG000|P2:PartA-Cohort1(4days)+Washout(48hours)|Adverse Event|0
6343752|NCT03358407|10101685|FG001|P2:PartA-Cohort1(4days)+Washout(48hours)|Adverse Event|0
6343753|NCT03358407|10101686|FG002|P2:PartA-Cohort1(4days)+Washout(48hours)|Adverse Event|1
6343754|NCT03358407|10101687|FG003|P2:PartA-Cohort1(4days)+Washout(48hours)|Adverse Event|0
6343755|NCT03358407|10101688|FG004|P2:PartA-Cohort1(4days)+Washout(48hours)|Adverse Event|0
6343756|NCT03358407|10101689|FG005|P2:PartA-Cohort1(4days)+Washout(48hours)|Adverse Event|0
6343757|NCT03358407|10101690|FG006|P2:PartA-Cohort1(4days)+Washout(48hours)|Adverse Event|0
6343758|NCT03358407|10101691|FG007|P2:PartA-Cohort1(4days)+Washout(48hours)|Adverse Event|0
6343759|NCT03358407|10101692|FG008|P2:PartA-Cohort1(4days)+Washout(48hours)|Adverse Event|0
6343760|NCT03358407|10101693|FG009|P2:PartA-Cohort1(4days)+Washout(48hours)|Adverse Event|0
6343761|NCT03358407|10101684|FG000|P4:PartA-Cohort1(4days)+Washout(48hours)|Withdrawal by Subject|0
6343762|NCT03358407|10101685|FG001|P4:PartA-Cohort1(4days)+Washout(48hours)|Withdrawal by Subject|0
6343763|NCT03358407|10101686|FG002|P4:PartA-Cohort1(4days)+Washout(48hours)|Withdrawal by Subject|0
6343764|NCT03358407|10101687|FG003|P4:PartA-Cohort1(4days)+Washout(48hours)|Withdrawal by Subject|0
6343765|NCT03358407|10101688|FG004|P4:PartA-Cohort1(4days)+Washout(48hours)|Withdrawal by Subject|1
6343766|NCT03358407|10101689|FG005|P4:PartA-Cohort1(4days)+Washout(48hours)|Withdrawal by Subject|0
6343767|NCT03358407|10101690|FG006|P4:PartA-Cohort1(4days)+Washout(48hours)|Withdrawal by Subject|0
6343768|NCT03358407|10101691|FG007|P4:PartA-Cohort1(4days)+Washout(48hours)|Withdrawal by Subject|0
6343769|NCT03358407|10101692|FG008|P4:PartA-Cohort1(4days)+Washout(48hours)|Withdrawal by Subject|0
6343770|NCT03358407|10101693|FG009|P4:PartA-Cohort1(4days)+Washout(48hours)|Withdrawal by Subject|0
6343771|NCT03358407|10101684|FG000|P1:PartA-Cohort2(4days)+Washout(48hours)|Adverse Event|0
6343772|NCT03358407|10101685|FG001|P1:PartA-Cohort2(4days)+Washout(48hours)|Adverse Event|0
6343773|NCT03358407|10101686|FG002|P1:PartA-Cohort2(4days)+Washout(48hours)|Adverse Event|0
6343774|NCT03358407|10101687|FG003|P1:PartA-Cohort2(4days)+Washout(48hours)|Adverse Event|0
6343775|NCT03358407|10101688|FG004|P1:PartA-Cohort2(4days)+Washout(48hours)|Adverse Event|0
6343776|NCT03358407|10101689|FG005|P1:PartA-Cohort2(4days)+Washout(48hours)|Adverse Event|1
6343777|NCT03358407|10101690|FG006|P1:PartA-Cohort2(4days)+Washout(48hours)|Adverse Event|0
6343778|NCT03358407|10101691|FG007|P1:PartA-Cohort2(4days)+Washout(48hours)|Adverse Event|2
6343779|NCT03358407|10101692|FG008|P1:PartA-Cohort2(4days)+Washout(48hours)|Adverse Event|0
6343780|NCT03358407|10101693|FG009|P1:PartA-Cohort2(4days)+Washout(48hours)|Adverse Event|0
6343781|NCT03358407|10101684|FG000|P1:PartA-Cohort2(4days)+Washout(48hours)|Physician Decision|0
6343782|NCT03358407|10101685|FG001|P1:PartA-Cohort2(4days)+Washout(48hours)|Physician Decision|0
6343783|NCT03358407|10101686|FG002|P1:PartA-Cohort2(4days)+Washout(48hours)|Physician Decision|0
6343784|NCT03358407|10101687|FG003|P1:PartA-Cohort2(4days)+Washout(48hours)|Physician Decision|0
6343785|NCT03358407|10101688|FG004|P1:PartA-Cohort2(4days)+Washout(48hours)|Physician Decision|0
6343786|NCT03358407|10101689|FG005|P1:PartA-Cohort2(4days)+Washout(48hours)|Physician Decision|1
6343787|NCT03358407|10101690|FG006|P1:PartA-Cohort2(4days)+Washout(48hours)|Physician Decision|0
6343788|NCT03358407|10101691|FG007|P1:PartA-Cohort2(4days)+Washout(48hours)|Physician Decision|1
6343789|NCT03358407|10101692|FG008|P1:PartA-Cohort2(4days)+Washout(48hours)|Physician Decision|0
6343790|NCT03358407|10101693|FG009|P1:PartA-Cohort2(4days)+Washout(48hours)|Physician Decision|0
6343791|NCT03358407|10101684|FG000|P1:PartA-Cohort2(4days)+Washout(48hours)|Withdrawal by Subject|0
6343792|NCT03358407|10101685|FG001|P1:PartA-Cohort2(4days)+Washout(48hours)|Withdrawal by Subject|0
6343793|NCT03358407|10101686|FG002|P1:PartA-Cohort2(4days)+Washout(48hours)|Withdrawal by Subject|0
6343794|NCT03358407|10101687|FG003|P1:PartA-Cohort2(4days)+Washout(48hours)|Withdrawal by Subject|0
6343795|NCT03358407|10101688|FG004|P1:PartA-Cohort2(4days)+Washout(48hours)|Withdrawal by Subject|0
6343796|NCT03358407|10101689|FG005|P1:PartA-Cohort2(4days)+Washout(48hours)|Withdrawal by Subject|1
6343797|NCT03358407|10101690|FG006|P1:PartA-Cohort2(4days)+Washout(48hours)|Withdrawal by Subject|1
6343798|NCT03358407|10101691|FG007|P1:PartA-Cohort2(4days)+Washout(48hours)|Withdrawal by Subject|0
6343799|NCT03358407|10101692|FG008|P1:PartA-Cohort2(4days)+Washout(48hours)|Withdrawal by Subject|0
6343800|NCT03358407|10101693|FG009|P1:PartA-Cohort2(4days)+Washout(48hours)|Withdrawal by Subject|0
6343801|NCT03358407|10101684|FG000|P2:PartA-Cohort2(4days)+Followup(14days)|Study closed/terminated|0
6343802|NCT03358407|10101685|FG001|P2:PartA-Cohort2(4days)+Followup(14days)|Study closed/terminated|0
6343803|NCT03358407|10101686|FG002|P2:PartA-Cohort2(4days)+Followup(14days)|Study closed/terminated|0
6343804|NCT03358407|10101687|FG003|P2:PartA-Cohort2(4days)+Followup(14days)|Study closed/terminated|0
6343805|NCT03358407|10101688|FG004|P2:PartA-Cohort2(4days)+Followup(14days)|Study closed/terminated|0
6343806|NCT03358407|10101689|FG005|P2:PartA-Cohort2(4days)+Followup(14days)|Study closed/terminated|3
6343807|NCT03358407|10101690|FG006|P2:PartA-Cohort2(4days)+Followup(14days)|Study closed/terminated|3
6343808|NCT03358407|10101691|FG007|P2:PartA-Cohort2(4days)+Followup(14days)|Study closed/terminated|6
6168773|NCT01237587|9813909|FG000|Taper Phase|Adverse Event|0
6168774|NCT01237587|9813910|FG001|Taper Phase|Adverse Event|2
6168775|NCT01237587|9813909|FG000|Taper Phase|Protocol Violation|2
6168776|NCT01237587|9813910|FG001|Taper Phase|Protocol Violation|0
6343809|NCT03358407|10101692|FG008|P2:PartA-Cohort2(4days)+Followup(14days)|Study closed/terminated|0
6343810|NCT03358407|10101693|FG009|P2:PartA-Cohort2(4days)+Followup(14days)|Study closed/terminated|0
6343811|NCT03358472|10101724|FG000|Overall Study|Death|6
6343812|NCT03358472|10101725|FG001|Overall Study|Death|3
6343813|NCT03358472|10101726|FG002|Overall Study|Death|10
6343814|NCT03358472|10101724|FG000|Overall Study|Physician Decision|0
6343815|NCT03358472|10101725|FG001|Overall Study|Physician Decision|1
6343816|NCT03358472|10101726|FG002|Overall Study|Physician Decision|0
6343817|NCT03358472|10101724|FG000|Overall Study|Withdrawal by Subject|0
6343818|NCT03358472|10101725|FG001|Overall Study|Withdrawal by Subject|0
6343819|NCT03358472|10101726|FG002|Overall Study|Withdrawal by Subject|1
6343820|NCT03358472|10101724|FG000|Overall Study|On-going at clinical cut off date|9
6343821|NCT03358472|10101725|FG001|Overall Study|On-going at clinical cut off date|6
6343822|NCT03358472|10101726|FG002|Overall Study|On-going at clinical cut off date|5
6343823|NCT03359395|10101745|FG000|First Intervention A / B|Withdrawal by Subject|1
6343824|NCT03359395|10101746|FG001|First Intervention A / B|Withdrawal by Subject|0
6343825|NCT03359395|10101745|FG000|First Intervention A / B|Lost to Follow-up|2
6343826|NCT03359395|10101746|FG001|First Intervention A / B|Lost to Follow-up|3
6343827|NCT03359395|10101745|FG000|Second Intervention B/A|Exclusion criteria|0
6343828|NCT03359395|10101746|FG001|Second Intervention B/A|Exclusion criteria|1
6343829|NCT03359395|10101745|FG000|Second Intervention B/A|Lost to Follow-up|3
6343830|NCT03359395|10101746|FG001|Second Intervention B/A|Lost to Follow-up|2
6343831|NCT03359473|10101756|FG000|Overall Study|Adverse Event|0
6343832|NCT03359473|10101757|FG001|Overall Study|Adverse Event|2
6343833|NCT03359473|10101758|FG002|Overall Study|Adverse Event|5
6343834|NCT03359473|10101759|FG003|Overall Study|Adverse Event|3
6343835|NCT03359473|10101756|FG000|Overall Study|Lost to Follow-up|0
6343836|NCT03359473|10101757|FG001|Overall Study|Lost to Follow-up|1
6343837|NCT03359473|10101758|FG002|Overall Study|Lost to Follow-up|0
6343838|NCT03359473|10101759|FG003|Overall Study|Lost to Follow-up|0
6343839|NCT03359473|10101756|FG000|Overall Study|Physician Decision|0
6343840|NCT03359473|10101757|FG001|Overall Study|Physician Decision|1
6343841|NCT03359473|10101758|FG002|Overall Study|Physician Decision|0
6343842|NCT03359473|10101759|FG003|Overall Study|Physician Decision|1
6343843|NCT03359473|10101756|FG000|Overall Study|Withdrawal by Subject|1
6343844|NCT03359473|10101757|FG001|Overall Study|Withdrawal by Subject|2
6343845|NCT03359473|10101758|FG002|Overall Study|Withdrawal by Subject|1
6343846|NCT03359473|10101759|FG003|Overall Study|Withdrawal by Subject|0
6343847|NCT03359473|10101756|FG000|Overall Study|Protocol-defined stopping criteria|1
6343848|NCT03359473|10101757|FG001|Overall Study|Protocol-defined stopping criteria|0
6343849|NCT03359473|10101758|FG002|Overall Study|Protocol-defined stopping criteria|0
6343850|NCT03359473|10101759|FG003|Overall Study|Protocol-defined stopping criteria|1
6343851|NCT03359590|10101772|FG000|First Intervention|Withdrawal by Subject|1
6343852|NCT03359590|10101773|FG001|First Intervention|Withdrawal by Subject|1
6343853|NCT03359590|10101772|FG000|First Intervention|Protocol Violation|0
6343854|NCT03359590|10101773|FG001|First Intervention|Protocol Violation|1
6343855|NCT03359850|10101790|FG000|PK Phase (Up to Day 8)|Physician Decision|0
6343856|NCT03359850|10101791|FG001|PK Phase (Up to Day 8)|Physician Decision|1
6343857|NCT03359850|10101790|FG000|PK Phase (Up to Day 8)|Adverse Event|1
6343858|NCT03359850|10101791|FG001|PK Phase (Up to Day 8)|Adverse Event|0
6343859|NCT03359850|10101790|FG000|Extension Phase (Up to 28 Months)|Death|2
6343860|NCT03359850|10101791|FG001|Extension Phase (Up to 28 Months)|Death|4
6343861|NCT03359850|10101790|FG000|Extension Phase (Up to 28 Months)|Withdrawal by Subject|1
6343862|NCT03359850|10101791|FG001|Extension Phase (Up to 28 Months)|Withdrawal by Subject|2
6343863|NCT03359850|10101790|FG000|Extension Phase (Up to 28 Months)|Disease Progression|5
6343864|NCT03359850|10101791|FG001|Extension Phase (Up to 28 Months)|Disease Progression|0
6343865|NCT03360071|10101805|FG000|Overall Study|Lost to Follow-up|1
6343866|NCT03360071|10101806|FG001|Overall Study|Lost to Follow-up|0
6343867|NCT03360344|10101834|FG000|Overall Study|Withdrawal by Subject|0
6343868|NCT03360344|10101835|FG001|Overall Study|Withdrawal by Subject|1
6343869|NCT03360344|10101836|FG002|Overall Study|Withdrawal by Subject|1
6343870|NCT03360747|10101844|FG000|Overall Study|Voluntary Withdrawal|1
6343871|NCT03361137|10101853|FG000|Overall Study|Reason not specified|1
6343872|NCT03361137|10101854|FG001|Overall Study|Reason not specified|0
6343873|NCT03361137|10101855|FG002|Overall Study|Reason not specified|0
6343874|NCT03361137|10101856|FG003|Overall Study|Reason not specified|0
6343875|NCT03361137|10101857|FG004|Overall Study|Reason not specified|0
6343876|NCT03361176|10101873|FG000|Overall Study|Lost to Follow-up|1
6343877|NCT03361176|10101874|FG001|Overall Study|Lost to Follow-up|2
6343878|NCT03361176|10101873|FG000|Overall Study|Adverse Event|0
6343879|NCT03361176|10101874|FG001|Overall Study|Adverse Event|2
6343880|NCT03361176|10101873|FG000|Overall Study|Withdrawal by Subject|0
6343881|NCT03361176|10101874|FG001|Overall Study|Withdrawal by Subject|1
6343882|NCT03361293|10101882|FG000|Overall Study|Lost to Follow-up|0
6343883|NCT03361293|10101883|FG001|Overall Study|Lost to Follow-up|2
6343884|NCT03361293|10101882|FG000|Overall Study|Withdrawal by Subject|1
6343885|NCT03361293|10101883|FG001|Overall Study|Withdrawal by Subject|3
6343886|NCT03361423|10101891|FG000|Overall Study|Withdrawal by Subject|4
6343887|NCT03361423|10101892|FG001|Overall Study|Withdrawal by Subject|3
6343888|NCT03361423|10101891|FG000|Overall Study|Did not treat|19
6343889|NCT03361423|10101892|FG001|Overall Study|Did not treat|18
6343890|NCT03361423|10101891|FG000|Overall Study|Started >60 minutes from migraine onset|0
6343891|NCT03361423|10101892|FG001|Overall Study|Started >60 minutes from migraine onset|1
6343892|NCT03361423|10101891|FG000|Overall Study|Missing data|4
6343893|NCT03361423|10101892|FG001|Overall Study|Missing data|1
6343894|NCT03361605|10101898|FG000|Overall Study|Analyzable data not available|3
6343895|NCT03363321|10101939|FG000|Overall Study|Withdrawal by Subject|0
6343896|NCT03363321|10101940|FG001|Overall Study|Withdrawal by Subject|1
6343897|NCT03363321|10101941|FG002|Overall Study|Withdrawal by Subject|0
6343898|NCT03363321|10101942|FG003|Overall Study|Withdrawal by Subject|1
6343899|NCT03363321|10101943|FG004|Overall Study|Withdrawal by Subject|0
6343900|NCT03363776|10101959|FG000|Overall Study|Progressive disease|2
6343901|NCT03363776|10101960|FG001|Overall Study|Progressive disease|3
6343902|NCT03363776|10101961|FG002|Overall Study|Progressive disease|1
6343903|NCT03363776|10101959|FG000|Overall Study|Study drug toxicity|0
6343904|NCT03363776|10101960|FG001|Overall Study|Study drug toxicity|0
6343905|NCT03363776|10101961|FG002|Overall Study|Study drug toxicity|1
6343906|NCT03363776|10101959|FG000|Overall Study|Death|1
6343907|NCT03363776|10101960|FG001|Overall Study|Death|0
6343908|NCT03363776|10101961|FG002|Overall Study|Death|0
6343909|NCT03363906|10102001|FG000|Period 1 (Reference or Test)|Adverse Event|1
6343910|NCT03363906|10102002|FG001|Period 1 (Reference or Test)|Adverse Event|2
6343911|NCT03363906|10102001|FG000|Period 2 (Test or Reference)|Adverse Event|2
6343912|NCT03363906|10102002|FG001|Period 2 (Test or Reference)|Adverse Event|0
6343913|NCT03363906|10102001|FG000|Period 2 (Test or Reference)|Withdrawal by Subject|1
6343914|NCT03363906|10102002|FG001|Period 2 (Test or Reference)|Withdrawal by Subject|1
6343915|NCT03363906|10102001|FG000|Period 2 (Test or Reference)|Lost to Follow-up|1
6083338|NCT00634933|9691718|FG004|Part A: Baseline to Week 24|Adverse Event|0
6083339|NCT00634933|9691714|FG000|Part A: Baseline to Week 24|Death|1
6343916|NCT03363906|10102002|FG001|Period 2 (Test or Reference)|Lost to Follow-up|0
6343917|NCT03364023|10102008|FG000|Overall Study|Lost to Follow-up|3
6343918|NCT03364023|10102008|FG000|Overall Study|Death|14
6343919|NCT03364049|10102016|FG000|Overall Study|Death|6
6343920|NCT03364049|10102017|FG001|Overall Study|Death|4
6343921|NCT03364049|10102018|FG002|Overall Study|Death|5
6343922|NCT03364049|10102019|FG003|Overall Study|Death|14
6343923|NCT03364049|10102016|FG000|Overall Study|In survival phase status at study closure. Participant transferred to pembrolizumab extension study|0
6343924|NCT03364049|10102017|FG001|Overall Study|In survival phase status at study closure. Participant transferred to pembrolizumab extension study|1
6343925|NCT03364049|10102018|FG002|Overall Study|In survival phase status at study closure. Participant transferred to pembrolizumab extension study|0
6343926|NCT03364049|10102019|FG003|Overall Study|In survival phase status at study closure. Participant transferred to pembrolizumab extension study|0
6343927|NCT03364049|10102016|FG000|Overall Study|Withdrawal by Subject|0
6343928|NCT03364049|10102017|FG001|Overall Study|Withdrawal by Subject|1
6343929|NCT03364049|10102018|FG002|Overall Study|Withdrawal by Subject|1
6343930|NCT03364049|10102019|FG003|Overall Study|Withdrawal by Subject|1
6343931|NCT03364192|10102029|FG000|Overall Study|Ineligible|10
6343932|NCT03364192|10102029|FG000|Overall Study|Withdrawal by Subject|5
6343933|NCT03364192|10102029|FG000|Overall Study|Lost to Follow-up|1
6343934|NCT03364309|10102037|FG000|Induction Period|Adverse Event|4
6343935|NCT03364309|10102038|FG001|Induction Period|Adverse Event|0
6343936|NCT03364309|10102039|FG002|Induction Period|Adverse Event|1
6343937|NCT03364309|10102040|FG003|Induction Period|Adverse Event|0
6343938|NCT03364309|10102041|FG004|Induction Period|Adverse Event|0
6343939|NCT03364309|10102042|FG005|Induction Period|Adverse Event|0
6343940|NCT03364309|10102043|FG006|Induction Period|Adverse Event|0
6343941|NCT03364309|10102044|FG007|Induction Period|Adverse Event|0
6343942|NCT03364309|10102045|FG008|Induction Period|Adverse Event|0
6343943|NCT03364309|10102046|FG009|Induction Period|Adverse Event|0
6343944|NCT03364309|10102047|FG010|Induction Period|Adverse Event|0
6343945|NCT03364309|10102048|FG011|Induction Period|Adverse Event|0
6343946|NCT03364309|10102049|FG012|Induction Period|Adverse Event|0
6343947|NCT03364309|10102050|FG013|Induction Period|Adverse Event|0
6343948|NCT03364309|10102051|FG014|Induction Period|Adverse Event|0
6343949|NCT03364309|10102052|FG015|Induction Period|Adverse Event|0
6343950|NCT03364309|10102053|FG016|Induction Period|Adverse Event|0
6343951|NCT03364309|10102054|FG017|Induction Period|Adverse Event|0
6343952|NCT03364309|10102055|FG018|Induction Period|Adverse Event|0
6343953|NCT03364309|10102037|FG000|Induction Period|Withdrawal by Subject|1
6343954|NCT03364309|10102038|FG001|Induction Period|Withdrawal by Subject|3
6343955|NCT03364309|10102039|FG002|Induction Period|Withdrawal by Subject|0
6343956|NCT03364309|10102040|FG003|Induction Period|Withdrawal by Subject|0
6343957|NCT03364309|10102041|FG004|Induction Period|Withdrawal by Subject|0
6343958|NCT03364309|10102042|FG005|Induction Period|Withdrawal by Subject|0
6343959|NCT03364309|10102043|FG006|Induction Period|Withdrawal by Subject|0
6343960|NCT03364309|10102044|FG007|Induction Period|Withdrawal by Subject|0
6343961|NCT03364309|10102045|FG008|Induction Period|Withdrawal by Subject|0
6343962|NCT03364309|10102046|FG009|Induction Period|Withdrawal by Subject|0
6343963|NCT03364309|10102047|FG010|Induction Period|Withdrawal by Subject|0
6343964|NCT03364309|10102048|FG011|Induction Period|Withdrawal by Subject|0
6343965|NCT03364309|10102049|FG012|Induction Period|Withdrawal by Subject|0
6343966|NCT03364309|10102050|FG013|Induction Period|Withdrawal by Subject|0
6343967|NCT03364309|10102051|FG014|Induction Period|Withdrawal by Subject|0
6343968|NCT03364309|10102052|FG015|Induction Period|Withdrawal by Subject|0
6343969|NCT03364309|10102053|FG016|Induction Period|Withdrawal by Subject|0
6343970|NCT03364309|10102054|FG017|Induction Period|Withdrawal by Subject|0
6343971|NCT03364309|10102055|FG018|Induction Period|Withdrawal by Subject|0
6343972|NCT03364309|10102037|FG000|Induction Period|Lost to Follow-up|1
6343973|NCT03364309|10102038|FG001|Induction Period|Lost to Follow-up|0
6343974|NCT03364309|10102039|FG002|Induction Period|Lost to Follow-up|0
6343975|NCT03364309|10102040|FG003|Induction Period|Lost to Follow-up|0
6343976|NCT03364309|10102041|FG004|Induction Period|Lost to Follow-up|0
6343977|NCT03364309|10102042|FG005|Induction Period|Lost to Follow-up|0
6343978|NCT03364309|10102043|FG006|Induction Period|Lost to Follow-up|0
6343979|NCT03364309|10102044|FG007|Induction Period|Lost to Follow-up|0
6343980|NCT03364309|10102045|FG008|Induction Period|Lost to Follow-up|0
6343981|NCT03364309|10102046|FG009|Induction Period|Lost to Follow-up|0
6343982|NCT03364309|10102047|FG010|Induction Period|Lost to Follow-up|0
6343983|NCT03364309|10102048|FG011|Induction Period|Lost to Follow-up|0
6343984|NCT03364309|10102049|FG012|Induction Period|Lost to Follow-up|0
6343985|NCT03364309|10102050|FG013|Induction Period|Lost to Follow-up|0
6343986|NCT03364309|10102051|FG014|Induction Period|Lost to Follow-up|0
6343987|NCT03364309|10102052|FG015|Induction Period|Lost to Follow-up|0
6343988|NCT03364309|10102053|FG016|Induction Period|Lost to Follow-up|0
6343989|NCT03364309|10102054|FG017|Induction Period|Lost to Follow-up|0
6343990|NCT03364309|10102055|FG018|Induction Period|Lost to Follow-up|0
6343991|NCT03364309|10102037|FG000|Induction Period|Physician Decision|0
6343992|NCT03364309|10102038|FG001|Induction Period|Physician Decision|1
6343993|NCT03364309|10102039|FG002|Induction Period|Physician Decision|0
6343994|NCT03364309|10102040|FG003|Induction Period|Physician Decision|0
6343995|NCT03364309|10102041|FG004|Induction Period|Physician Decision|0
6343996|NCT03364309|10102042|FG005|Induction Period|Physician Decision|0
6343997|NCT03364309|10102043|FG006|Induction Period|Physician Decision|0
6343998|NCT03364309|10102044|FG007|Induction Period|Physician Decision|0
6343999|NCT03364309|10102045|FG008|Induction Period|Physician Decision|0
6344000|NCT03364309|10102046|FG009|Induction Period|Physician Decision|0
6344001|NCT03364309|10102047|FG010|Induction Period|Physician Decision|0
6344002|NCT03364309|10102048|FG011|Induction Period|Physician Decision|0
6344003|NCT03364309|10102049|FG012|Induction Period|Physician Decision|0
6344004|NCT03364309|10102050|FG013|Induction Period|Physician Decision|0
6344005|NCT03364309|10102051|FG014|Induction Period|Physician Decision|0
6344006|NCT03364309|10102052|FG015|Induction Period|Physician Decision|0
6344007|NCT03364309|10102053|FG016|Induction Period|Physician Decision|0
6344008|NCT03364309|10102054|FG017|Induction Period|Physician Decision|0
6344009|NCT03364309|10102055|FG018|Induction Period|Physician Decision|0
6344010|NCT03364309|10102037|FG000|Maintenance Period|Withdrawal by Subject|0
6344011|NCT03364309|10102038|FG001|Maintenance Period|Withdrawal by Subject|0
6344012|NCT03364309|10102039|FG002|Maintenance Period|Withdrawal by Subject|0
6344013|NCT03364309|10102040|FG003|Maintenance Period|Withdrawal by Subject|1
6344014|NCT03364309|10102041|FG004|Maintenance Period|Withdrawal by Subject|3
6344015|NCT03364309|10102042|FG005|Maintenance Period|Withdrawal by Subject|1
6344016|NCT03364309|10102043|FG006|Maintenance Period|Withdrawal by Subject|3
6344017|NCT03364309|10102044|FG007|Maintenance Period|Withdrawal by Subject|0
6344018|NCT03364309|10102045|FG008|Maintenance Period|Withdrawal by Subject|1
6344019|NCT03364309|10102046|FG009|Maintenance Period|Withdrawal by Subject|1
6344020|NCT03364309|10102047|FG010|Maintenance Period|Withdrawal by Subject|2
6344021|NCT03364309|10102048|FG011|Maintenance Period|Withdrawal by Subject|0
6344022|NCT03364309|10102049|FG012|Maintenance Period|Withdrawal by Subject|0
6344023|NCT03364309|10102050|FG013|Maintenance Period|Withdrawal by Subject|0
6344024|NCT03364309|10102051|FG014|Maintenance Period|Withdrawal by Subject|0
6344025|NCT03364309|10102052|FG015|Maintenance Period|Withdrawal by Subject|0
6344026|NCT03364309|10102053|FG016|Maintenance Period|Withdrawal by Subject|0
6344027|NCT03364309|10102054|FG017|Maintenance Period|Withdrawal by Subject|0
6344028|NCT03364309|10102055|FG018|Maintenance Period|Withdrawal by Subject|0
6344029|NCT03364309|10102037|FG000|Maintenance Period|Adverse Event|0
6344030|NCT03364309|10102038|FG001|Maintenance Period|Adverse Event|0
6344031|NCT03364309|10102039|FG002|Maintenance Period|Adverse Event|0
6344032|NCT03364309|10102040|FG003|Maintenance Period|Adverse Event|0
6344033|NCT03364309|10102041|FG004|Maintenance Period|Adverse Event|2
6344034|NCT03364309|10102042|FG005|Maintenance Period|Adverse Event|0
6344035|NCT03364309|10102043|FG006|Maintenance Period|Adverse Event|3
6344036|NCT03364309|10102044|FG007|Maintenance Period|Adverse Event|0
6344037|NCT03364309|10102045|FG008|Maintenance Period|Adverse Event|1
6344038|NCT03364309|10102046|FG009|Maintenance Period|Adverse Event|0
6344039|NCT03364309|10102047|FG010|Maintenance Period|Adverse Event|2
6344040|NCT03364309|10102048|FG011|Maintenance Period|Adverse Event|0
6344041|NCT03364309|10102049|FG012|Maintenance Period|Adverse Event|0
6344042|NCT03364309|10102050|FG013|Maintenance Period|Adverse Event|0
6344043|NCT03364309|10102051|FG014|Maintenance Period|Adverse Event|0
6344044|NCT03364309|10102052|FG015|Maintenance Period|Adverse Event|0
6344045|NCT03364309|10102053|FG016|Maintenance Period|Adverse Event|0
6344046|NCT03364309|10102054|FG017|Maintenance Period|Adverse Event|0
6344047|NCT03364309|10102055|FG018|Maintenance Period|Adverse Event|0
6344048|NCT03364309|10102037|FG000|Maintenance Period|Relapsed|0
6344049|NCT03364309|10102038|FG001|Maintenance Period|Relapsed|0
6344050|NCT03364309|10102039|FG002|Maintenance Period|Relapsed|0
6344051|NCT03364309|10102040|FG003|Maintenance Period|Relapsed|43
6344052|NCT03364309|10102041|FG004|Maintenance Period|Relapsed|7
6344053|NCT03364309|10102042|FG005|Maintenance Period|Relapsed|45
6344054|NCT03364309|10102043|FG006|Maintenance Period|Relapsed|10
6344055|NCT03364309|10102044|FG007|Maintenance Period|Relapsed|2
6344056|NCT03364309|10102045|FG008|Maintenance Period|Relapsed|0
6344057|NCT03364309|10102046|FG009|Maintenance Period|Relapsed|0
6344058|NCT03364309|10102047|FG010|Maintenance Period|Relapsed|0
6344059|NCT03364309|10102048|FG011|Maintenance Period|Relapsed|0
6344060|NCT03364309|10102049|FG012|Maintenance Period|Relapsed|0
6344061|NCT03364309|10102050|FG013|Maintenance Period|Relapsed|0
6344062|NCT03364309|10102051|FG014|Maintenance Period|Relapsed|0
6344063|NCT03364309|10102052|FG015|Maintenance Period|Relapsed|0
6344064|NCT03364309|10102053|FG016|Maintenance Period|Relapsed|0
6344065|NCT03364309|10102054|FG017|Maintenance Period|Relapsed|0
6344066|NCT03364309|10102055|FG018|Maintenance Period|Relapsed|0
6344067|NCT03364309|10102037|FG000|Maintenance Period|Lack of Efficacy|0
6344068|NCT03364309|10102038|FG001|Maintenance Period|Lack of Efficacy|0
6344069|NCT03364309|10102039|FG002|Maintenance Period|Lack of Efficacy|0
6344070|NCT03364309|10102040|FG003|Maintenance Period|Lack of Efficacy|0
6344071|NCT03364309|10102041|FG004|Maintenance Period|Lack of Efficacy|0
6344072|NCT03364309|10102042|FG005|Maintenance Period|Lack of Efficacy|0
6344073|NCT03364309|10102043|FG006|Maintenance Period|Lack of Efficacy|0
6344074|NCT03364309|10102044|FG007|Maintenance Period|Lack of Efficacy|0
6344075|NCT03364309|10102045|FG008|Maintenance Period|Lack of Efficacy|1
6344076|NCT03364309|10102046|FG009|Maintenance Period|Lack of Efficacy|3
6344077|NCT03364309|10102047|FG010|Maintenance Period|Lack of Efficacy|2
6344078|NCT03364309|10102048|FG011|Maintenance Period|Lack of Efficacy|0
6344079|NCT03364309|10102049|FG012|Maintenance Period|Lack of Efficacy|0
6344080|NCT03364309|10102050|FG013|Maintenance Period|Lack of Efficacy|0
6344081|NCT03364309|10102051|FG014|Maintenance Period|Lack of Efficacy|0
6344082|NCT03364309|10102052|FG015|Maintenance Period|Lack of Efficacy|0
6344083|NCT03364309|10102053|FG016|Maintenance Period|Lack of Efficacy|0
6344084|NCT03364309|10102054|FG017|Maintenance Period|Lack of Efficacy|0
6344085|NCT03364309|10102055|FG018|Maintenance Period|Lack of Efficacy|0
6344086|NCT03364309|10102037|FG000|Maintenance Period|Death|0
6344087|NCT03364309|10102038|FG001|Maintenance Period|Death|0
6344088|NCT03364309|10102039|FG002|Maintenance Period|Death|0
6344089|NCT03364309|10102040|FG003|Maintenance Period|Death|0
6344090|NCT03364309|10102041|FG004|Maintenance Period|Death|0
6344091|NCT03364309|10102042|FG005|Maintenance Period|Death|0
6344092|NCT03364309|10102043|FG006|Maintenance Period|Death|0
6344093|NCT03364309|10102044|FG007|Maintenance Period|Death|0
6344094|NCT03364309|10102045|FG008|Maintenance Period|Death|1
6344095|NCT03364309|10102046|FG009|Maintenance Period|Death|0
6344096|NCT03364309|10102047|FG010|Maintenance Period|Death|0
6344097|NCT03364309|10102048|FG011|Maintenance Period|Death|0
6344098|NCT03364309|10102049|FG012|Maintenance Period|Death|0
6344099|NCT03364309|10102050|FG013|Maintenance Period|Death|0
6344100|NCT03364309|10102051|FG014|Maintenance Period|Death|0
6344101|NCT03364309|10102052|FG015|Maintenance Period|Death|0
6344102|NCT03364309|10102053|FG016|Maintenance Period|Death|0
6344103|NCT03364309|10102054|FG017|Maintenance Period|Death|0
6344104|NCT03364309|10102055|FG018|Maintenance Period|Death|0
6344105|NCT03364309|10102037|FG000|Maintenance Period|Lost to Follow-up|0
6344106|NCT03364309|10102038|FG001|Maintenance Period|Lost to Follow-up|0
6344107|NCT03364309|10102039|FG002|Maintenance Period|Lost to Follow-up|0
6344108|NCT03364309|10102040|FG003|Maintenance Period|Lost to Follow-up|0
6344109|NCT03364309|10102041|FG004|Maintenance Period|Lost to Follow-up|0
6344110|NCT03364309|10102042|FG005|Maintenance Period|Lost to Follow-up|0
6344111|NCT03364309|10102043|FG006|Maintenance Period|Lost to Follow-up|0
6344112|NCT03364309|10102044|FG007|Maintenance Period|Lost to Follow-up|0
6344113|NCT03364309|10102045|FG008|Maintenance Period|Lost to Follow-up|1
6344114|NCT03364309|10102046|FG009|Maintenance Period|Lost to Follow-up|0
6344115|NCT03364309|10102047|FG010|Maintenance Period|Lost to Follow-up|0
6344116|NCT03364309|10102048|FG011|Maintenance Period|Lost to Follow-up|0
6344117|NCT03364309|10102049|FG012|Maintenance Period|Lost to Follow-up|0
6344118|NCT03364309|10102050|FG013|Maintenance Period|Lost to Follow-up|0
6344119|NCT03364309|10102051|FG014|Maintenance Period|Lost to Follow-up|0
6344120|NCT03364309|10102052|FG015|Maintenance Period|Lost to Follow-up|0
6344121|NCT03364309|10102053|FG016|Maintenance Period|Lost to Follow-up|0
6344122|NCT03364309|10102054|FG017|Maintenance Period|Lost to Follow-up|0
6344123|NCT03364309|10102055|FG018|Maintenance Period|Lost to Follow-up|0
6344124|NCT03364309|10102037|FG000|Maintenance Period|Miscellaneous|0
6344125|NCT03364309|10102038|FG001|Maintenance Period|Miscellaneous|0
6344126|NCT03364309|10102039|FG002|Maintenance Period|Miscellaneous|0
6344127|NCT03364309|10102040|FG003|Maintenance Period|Miscellaneous|0
6344128|NCT03364309|10102041|FG004|Maintenance Period|Miscellaneous|0
6344129|NCT03364309|10102042|FG005|Maintenance Period|Miscellaneous|0
6344130|NCT03364309|10102043|FG006|Maintenance Period|Miscellaneous|0
6344131|NCT03364309|10102044|FG007|Maintenance Period|Miscellaneous|0
6344132|NCT03364309|10102045|FG008|Maintenance Period|Miscellaneous|1
6344133|NCT03364309|10102046|FG009|Maintenance Period|Miscellaneous|0
6344134|NCT03364309|10102047|FG010|Maintenance Period|Miscellaneous|0
6344135|NCT03364309|10102048|FG011|Maintenance Period|Miscellaneous|0
6344136|NCT03364309|10102049|FG012|Maintenance Period|Miscellaneous|0
6344137|NCT03364309|10102050|FG013|Maintenance Period|Miscellaneous|0
6344138|NCT03364309|10102051|FG014|Maintenance Period|Miscellaneous|0
6344139|NCT03364309|10102052|FG015|Maintenance Period|Miscellaneous|0
6344140|NCT03364309|10102053|FG016|Maintenance Period|Miscellaneous|0
6344141|NCT03364309|10102054|FG017|Maintenance Period|Miscellaneous|0
6344142|NCT03364309|10102055|FG018|Maintenance Period|Miscellaneous|0
6344143|NCT03364309|10102037|FG000|Re-treatment (Maintenance) Period|Withdrawal by Subject|0
6344144|NCT03364309|10102038|FG001|Re-treatment (Maintenance) Period|Withdrawal by Subject|0
6083340|NCT00634933|9691715|FG001|Part A: Baseline to Week 24|Death|0
6083341|NCT00634933|9691716|FG002|Part A: Baseline to Week 24|Death|0
6083342|NCT00634933|9691717|FG003|Part A: Baseline to Week 24|Death|0
6344145|NCT03364309|10102039|FG002|Re-treatment (Maintenance) Period|Withdrawal by Subject|0
6344146|NCT03364309|10102040|FG003|Re-treatment (Maintenance) Period|Withdrawal by Subject|0
6344147|NCT03364309|10102041|FG004|Re-treatment (Maintenance) Period|Withdrawal by Subject|0
6344148|NCT03364309|10102042|FG005|Re-treatment (Maintenance) Period|Withdrawal by Subject|0
6344149|NCT03364309|10102043|FG006|Re-treatment (Maintenance) Period|Withdrawal by Subject|0
6344150|NCT03364309|10102044|FG007|Re-treatment (Maintenance) Period|Withdrawal by Subject|0
6344151|NCT03364309|10102045|FG008|Re-treatment (Maintenance) Period|Withdrawal by Subject|0
6344152|NCT03364309|10102046|FG009|Re-treatment (Maintenance) Period|Withdrawal by Subject|0
6344153|NCT03364309|10102047|FG010|Re-treatment (Maintenance) Period|Withdrawal by Subject|0
6344154|NCT03364309|10102048|FG011|Re-treatment (Maintenance) Period|Withdrawal by Subject|0
6344155|NCT03364309|10102049|FG012|Re-treatment (Maintenance) Period|Withdrawal by Subject|0
6344156|NCT03364309|10102050|FG013|Re-treatment (Maintenance) Period|Withdrawal by Subject|1
6344157|NCT03364309|10102051|FG014|Re-treatment (Maintenance) Period|Withdrawal by Subject|1
6344158|NCT03364309|10102052|FG015|Re-treatment (Maintenance) Period|Withdrawal by Subject|1
6344159|NCT03364309|10102053|FG016|Re-treatment (Maintenance) Period|Withdrawal by Subject|0
6344160|NCT03364309|10102054|FG017|Re-treatment (Maintenance) Period|Withdrawal by Subject|0
6344161|NCT03364309|10102055|FG018|Re-treatment (Maintenance) Period|Withdrawal by Subject|0
6344162|NCT03364309|10102037|FG000|Re-treatment (Maintenance) Period|Adverse Event|0
6344163|NCT03364309|10102038|FG001|Re-treatment (Maintenance) Period|Adverse Event|0
6344164|NCT03364309|10102039|FG002|Re-treatment (Maintenance) Period|Adverse Event|0
6344165|NCT03364309|10102040|FG003|Re-treatment (Maintenance) Period|Adverse Event|0
6344166|NCT03364309|10102041|FG004|Re-treatment (Maintenance) Period|Adverse Event|0
6344167|NCT03364309|10102042|FG005|Re-treatment (Maintenance) Period|Adverse Event|0
6344168|NCT03364309|10102043|FG006|Re-treatment (Maintenance) Period|Adverse Event|0
6344169|NCT03364309|10102044|FG007|Re-treatment (Maintenance) Period|Adverse Event|0
6344170|NCT03364309|10102045|FG008|Re-treatment (Maintenance) Period|Adverse Event|0
6344171|NCT03364309|10102046|FG009|Re-treatment (Maintenance) Period|Adverse Event|0
6344172|NCT03364309|10102047|FG010|Re-treatment (Maintenance) Period|Adverse Event|0
6344173|NCT03364309|10102048|FG011|Re-treatment (Maintenance) Period|Adverse Event|0
6344174|NCT03364309|10102049|FG012|Re-treatment (Maintenance) Period|Adverse Event|0
6344175|NCT03364309|10102050|FG013|Re-treatment (Maintenance) Period|Adverse Event|0
6344176|NCT03364309|10102051|FG014|Re-treatment (Maintenance) Period|Adverse Event|1
6344177|NCT03364309|10102052|FG015|Re-treatment (Maintenance) Period|Adverse Event|0
6344178|NCT03364309|10102053|FG016|Re-treatment (Maintenance) Period|Adverse Event|0
6344179|NCT03364309|10102054|FG017|Re-treatment (Maintenance) Period|Adverse Event|0
6344180|NCT03364309|10102055|FG018|Re-treatment (Maintenance) Period|Adverse Event|0
6344181|NCT03364309|10102037|FG000|Re-treatment (Maintenance) Period|Relapse|0
6344182|NCT03364309|10102038|FG001|Re-treatment (Maintenance) Period|Relapse|0
6344183|NCT03364309|10102039|FG002|Re-treatment (Maintenance) Period|Relapse|0
6344184|NCT03364309|10102040|FG003|Re-treatment (Maintenance) Period|Relapse|0
6344185|NCT03364309|10102041|FG004|Re-treatment (Maintenance) Period|Relapse|0
6344186|NCT03364309|10102042|FG005|Re-treatment (Maintenance) Period|Relapse|0
6344187|NCT03364309|10102043|FG006|Re-treatment (Maintenance) Period|Relapse|0
6344188|NCT03364309|10102044|FG007|Re-treatment (Maintenance) Period|Relapse|0
6344189|NCT03364309|10102045|FG008|Re-treatment (Maintenance) Period|Relapse|0
6344190|NCT03364309|10102046|FG009|Re-treatment (Maintenance) Period|Relapse|0
6344191|NCT03364309|10102047|FG010|Re-treatment (Maintenance) Period|Relapse|0
6344192|NCT03364309|10102048|FG011|Re-treatment (Maintenance) Period|Relapse|0
6344193|NCT03364309|10102049|FG012|Re-treatment (Maintenance) Period|Relapse|1
6344194|NCT03364309|10102050|FG013|Re-treatment (Maintenance) Period|Relapse|0
6344195|NCT03364309|10102051|FG014|Re-treatment (Maintenance) Period|Relapse|0
6344196|NCT03364309|10102052|FG015|Re-treatment (Maintenance) Period|Relapse|1
6344197|NCT03364309|10102053|FG016|Re-treatment (Maintenance) Period|Relapse|0
6344198|NCT03364309|10102054|FG017|Re-treatment (Maintenance) Period|Relapse|0
6344199|NCT03364309|10102055|FG018|Re-treatment (Maintenance) Period|Relapse|0
6344200|NCT03364309|10102037|FG000|Post-Treatment Followup Period|Withdrawal by Subject|0
6344201|NCT03364309|10102038|FG001|Post-Treatment Followup Period|Withdrawal by Subject|0
6344202|NCT03364309|10102039|FG002|Post-Treatment Followup Period|Withdrawal by Subject|0
6344203|NCT03364309|10102040|FG003|Post-Treatment Followup Period|Withdrawal by Subject|0
6344204|NCT03364309|10102041|FG004|Post-Treatment Followup Period|Withdrawal by Subject|0
6344205|NCT03364309|10102042|FG005|Post-Treatment Followup Period|Withdrawal by Subject|0
6344206|NCT03364309|10102043|FG006|Post-Treatment Followup Period|Withdrawal by Subject|0
6344207|NCT03364309|10102044|FG007|Post-Treatment Followup Period|Withdrawal by Subject|0
6344208|NCT03364309|10102045|FG008|Post-Treatment Followup Period|Withdrawal by Subject|0
6344209|NCT03364309|10102046|FG009|Post-Treatment Followup Period|Withdrawal by Subject|0
6344210|NCT03364309|10102047|FG010|Post-Treatment Followup Period|Withdrawal by Subject|0
6344211|NCT03364309|10102048|FG011|Post-Treatment Followup Period|Withdrawal by Subject|0
6344212|NCT03364309|10102049|FG012|Post-Treatment Followup Period|Withdrawal by Subject|0
6344213|NCT03364309|10102050|FG013|Post-Treatment Followup Period|Withdrawal by Subject|0
6344214|NCT03364309|10102051|FG014|Post-Treatment Followup Period|Withdrawal by Subject|0
6344215|NCT03364309|10102052|FG015|Post-Treatment Followup Period|Withdrawal by Subject|0
6344216|NCT03364309|10102053|FG016|Post-Treatment Followup Period|Withdrawal by Subject|3
6344217|NCT03364309|10102054|FG017|Post-Treatment Followup Period|Withdrawal by Subject|19
6344218|NCT03364309|10102055|FG018|Post-Treatment Followup Period|Withdrawal by Subject|1
6344219|NCT03364309|10102037|FG000|Post-Treatment Followup Period|Adverse Event|0
6344220|NCT03364309|10102038|FG001|Post-Treatment Followup Period|Adverse Event|0
6344221|NCT03364309|10102039|FG002|Post-Treatment Followup Period|Adverse Event|0
6344222|NCT03364309|10102040|FG003|Post-Treatment Followup Period|Adverse Event|0
6344223|NCT03364309|10102041|FG004|Post-Treatment Followup Period|Adverse Event|0
6344224|NCT03364309|10102042|FG005|Post-Treatment Followup Period|Adverse Event|0
6344225|NCT03364309|10102043|FG006|Post-Treatment Followup Period|Adverse Event|0
6344226|NCT03364309|10102044|FG007|Post-Treatment Followup Period|Adverse Event|0
6344227|NCT03364309|10102045|FG008|Post-Treatment Followup Period|Adverse Event|0
6344228|NCT03364309|10102046|FG009|Post-Treatment Followup Period|Adverse Event|0
6344229|NCT03364309|10102047|FG010|Post-Treatment Followup Period|Adverse Event|0
6344230|NCT03364309|10102048|FG011|Post-Treatment Followup Period|Adverse Event|0
6344231|NCT03364309|10102049|FG012|Post-Treatment Followup Period|Adverse Event|0
6344232|NCT03364309|10102050|FG013|Post-Treatment Followup Period|Adverse Event|0
6344233|NCT03364309|10102051|FG014|Post-Treatment Followup Period|Adverse Event|0
6344234|NCT03364309|10102052|FG015|Post-Treatment Followup Period|Adverse Event|0
6344235|NCT03364309|10102053|FG016|Post-Treatment Followup Period|Adverse Event|2
6344236|NCT03364309|10102054|FG017|Post-Treatment Followup Period|Adverse Event|6
6344237|NCT03364309|10102055|FG018|Post-Treatment Followup Period|Adverse Event|1
6344238|NCT03364309|10102037|FG000|Post-Treatment Followup Period|Lost to Follow-up|0
6344239|NCT03364309|10102038|FG001|Post-Treatment Followup Period|Lost to Follow-up|0
6344240|NCT03364309|10102039|FG002|Post-Treatment Followup Period|Lost to Follow-up|0
6344241|NCT03364309|10102040|FG003|Post-Treatment Followup Period|Lost to Follow-up|0
6344242|NCT03364309|10102041|FG004|Post-Treatment Followup Period|Lost to Follow-up|0
6344243|NCT03364309|10102042|FG005|Post-Treatment Followup Period|Lost to Follow-up|0
6344244|NCT03364309|10102043|FG006|Post-Treatment Followup Period|Lost to Follow-up|0
6344245|NCT03364309|10102044|FG007|Post-Treatment Followup Period|Lost to Follow-up|0
6344246|NCT03364309|10102045|FG008|Post-Treatment Followup Period|Lost to Follow-up|0
6344247|NCT03364309|10102046|FG009|Post-Treatment Followup Period|Lost to Follow-up|0
6344248|NCT03364309|10102047|FG010|Post-Treatment Followup Period|Lost to Follow-up|0
6344249|NCT03364309|10102048|FG011|Post-Treatment Followup Period|Lost to Follow-up|0
6344250|NCT03364309|10102049|FG012|Post-Treatment Followup Period|Lost to Follow-up|0
6344251|NCT03364309|10102050|FG013|Post-Treatment Followup Period|Lost to Follow-up|0
6344252|NCT03364309|10102051|FG014|Post-Treatment Followup Period|Lost to Follow-up|0
6344253|NCT03364309|10102052|FG015|Post-Treatment Followup Period|Lost to Follow-up|0
6344254|NCT03364309|10102053|FG016|Post-Treatment Followup Period|Lost to Follow-up|0
6344255|NCT03364309|10102054|FG017|Post-Treatment Followup Period|Lost to Follow-up|2
6344256|NCT03364309|10102055|FG018|Post-Treatment Followup Period|Lost to Follow-up|0
6344257|NCT03364309|10102037|FG000|Post-Treatment Followup Period|Miscellaneous|0
6344258|NCT03364309|10102038|FG001|Post-Treatment Followup Period|Miscellaneous|0
6344259|NCT03364309|10102039|FG002|Post-Treatment Followup Period|Miscellaneous|0
6344260|NCT03364309|10102040|FG003|Post-Treatment Followup Period|Miscellaneous|0
6344261|NCT03364309|10102041|FG004|Post-Treatment Followup Period|Miscellaneous|0
6344262|NCT03364309|10102042|FG005|Post-Treatment Followup Period|Miscellaneous|0
6344263|NCT03364309|10102043|FG006|Post-Treatment Followup Period|Miscellaneous|0
6344264|NCT03364309|10102044|FG007|Post-Treatment Followup Period|Miscellaneous|0
6344265|NCT03364309|10102045|FG008|Post-Treatment Followup Period|Miscellaneous|0
6344266|NCT03364309|10102046|FG009|Post-Treatment Followup Period|Miscellaneous|0
6344267|NCT03364309|10102047|FG010|Post-Treatment Followup Period|Miscellaneous|0
6344268|NCT03364309|10102048|FG011|Post-Treatment Followup Period|Miscellaneous|0
6344269|NCT03364309|10102049|FG012|Post-Treatment Followup Period|Miscellaneous|0
6344270|NCT03364309|10102050|FG013|Post-Treatment Followup Period|Miscellaneous|0
6344271|NCT03364309|10102051|FG014|Post-Treatment Followup Period|Miscellaneous|0
6344272|NCT03364309|10102052|FG015|Post-Treatment Followup Period|Miscellaneous|0
6344273|NCT03364309|10102053|FG016|Post-Treatment Followup Period|Miscellaneous|0
6344274|NCT03364309|10102054|FG017|Post-Treatment Followup Period|Miscellaneous|4
6344275|NCT03364309|10102055|FG018|Post-Treatment Followup Period|Miscellaneous|0
6344276|NCT03364335|10102084|FG000|Overall Study|Adverse Event|3
6344277|NCT03364335|10102085|FG001|Overall Study|Adverse Event|4
6344278|NCT03364335|10102086|FG002|Overall Study|Adverse Event|1
6344279|NCT03364335|10102087|FG003|Overall Study|Adverse Event|2
6344280|NCT03364335|10102088|FG004|Overall Study|Adverse Event|0
6344281|NCT03364335|10102084|FG000|Overall Study|Lost to Follow-up|7
6344282|NCT03364335|10102085|FG001|Overall Study|Lost to Follow-up|7
6344283|NCT03364335|10102086|FG002|Overall Study|Lost to Follow-up|10
6344284|NCT03364335|10102087|FG003|Overall Study|Lost to Follow-up|11
6344285|NCT03364335|10102088|FG004|Overall Study|Lost to Follow-up|11
6344286|NCT03364608|10102100|FG000|Overall Study|Withdrawal by Subject|4
6344287|NCT03364608|10102100|FG000|Overall Study|Protocol Violation|2
6344288|NCT03364608|10102100|FG000|Overall Study|Lost to Follow-up|2
6344289|NCT03364673|10102112|FG000|Overall Study|Withdrawal by Subject|2
6344290|NCT03364673|10102112|FG000|Overall Study|Injury unrelated to study|3
6344291|NCT03364738|10102116|FG000|Overall Study|Early termination due to Food and Drug Administration recall of rhPTH(1-84) (Natpara)|6
6344292|NCT03364738|10102116|FG000|Overall Study|Withdrawal by Subject|1
6344293|NCT03364738|10102116|FG000|Overall Study|Adverse Event|1
6344294|NCT03364751|10102125|FG000|Overall Study|Withdrawal by Subject|1
6344295|NCT03364751|10102126|FG001|Overall Study|Withdrawal by Subject|0
6344296|NCT03364751|10102127|FG002|Overall Study|Withdrawal by Subject|0
6344297|NCT03364751|10102128|FG003|Overall Study|Withdrawal by Subject|0
6344298|NCT03364751|10102125|FG000|Overall Study|Lost to Follow-up|0
6344299|NCT03364751|10102126|FG001|Overall Study|Lost to Follow-up|1
6344300|NCT03364751|10102127|FG002|Overall Study|Lost to Follow-up|0
6344301|NCT03364751|10102128|FG003|Overall Study|Lost to Follow-up|0
6344302|NCT03365011|10102144|FG000|Overall Study|Withdrawal by Subject|1
6344303|NCT03365011|10102145|FG001|Overall Study|Withdrawal by Subject|2
6344304|NCT03365934|10102168|FG000|Overall Study|Adverse Event|1
6344305|NCT03365934|10102168|FG000|Overall Study|Withdrawal by Subject|1
6344306|NCT03367793|10102198|FG000|Treatment 2 Dispense to 2 Months Wear|Physician Decision|0
6344307|NCT03367793|10102199|FG001|Treatment 2 Dispense to 2 Months Wear|Physician Decision|0
6344308|NCT03367793|10102200|FG002|Treatment 2 Dispense to 2 Months Wear|Physician Decision|1
6344309|NCT03367793|10102201|FG003|Treatment 2 Dispense to 2 Months Wear|Physician Decision|0
6344310|NCT03367793|10102202|FG004|Treatment 2 Dispense to 2 Months Wear|Physician Decision|0
6344311|NCT03367793|10102203|FG005|Treatment 2 Dispense to 2 Months Wear|Physician Decision|0
6344312|NCT03368807|10102227|FG000|Period 1 (Blinded CGM)|Withdrawal by Subject|3
6344313|NCT03368807|10102227|FG000|Period 1 (Blinded CGM)|Protocol Violation|1
6344314|NCT03368807|10102227|FG000|Period 1 (Blinded CGM)|Sponsor Decision|1
6344315|NCT03368807|10102227|FG000|Period 1 (Blinded CGM)|Lost to Follow-up|1
6344316|NCT03368859|10102235|FG000|Overall Study|Withdrew Consent|5
6344317|NCT03368859|10102236|FG001|Overall Study|Withdrew Consent|4
6344318|NCT03368859|10102235|FG000|Overall Study|Death|12
6344319|NCT03368859|10102236|FG001|Overall Study|Death|6
6344320|NCT03368859|10102235|FG000|Overall Study|Study terminated by Sponsor|18
6344321|NCT03368859|10102236|FG001|Overall Study|Study terminated by Sponsor|23
6344322|NCT03368859|10102235|FG000|Overall Study|Other|1
6344323|NCT03368859|10102236|FG001|Overall Study|Other|1
6344324|NCT03369236|10102266|FG000|Double-blind Treatment Period|Accidental unblinding|0
6344325|NCT03369236|10102267|FG001|Double-blind Treatment Period|Accidental unblinding|1
6344326|NCT03369236|10102266|FG000|Open-label Extension Period|Lack of Efficacy|2
6344327|NCT03369236|10102267|FG001|Open-label Extension Period|Lack of Efficacy|1
6344328|NCT03369236|10102266|FG000|Open-label Extension Period|Adverse Event|0
6344329|NCT03369236|10102267|FG001|Open-label Extension Period|Adverse Event|1
6344330|NCT03369236|10102266|FG000|Open-label Extension Period|Sponsor decision to close study|3
6344331|NCT03369236|10102267|FG001|Open-label Extension Period|Sponsor decision to close study|4
6344332|NCT03369418|10102296|FG000|Overall Study|Withdrawal by Subject|3
6344333|NCT03369418|10102297|FG001|Overall Study|Withdrawal by Subject|3
6344334|NCT03369704|10102305|FG000|Treatment Epoch|technical problems|1
6344335|NCT03369704|10102306|FG001|Treatment Epoch|technical problems|0
6344336|NCT03369704|10102305|FG000|Treatment Epoch|Protocol Violation|1
6344337|NCT03369704|10102306|FG001|Treatment Epoch|Protocol Violation|0
6344338|NCT03369704|10102305|FG000|Treatment Epoch|Lost to Follow-up|0
6344339|NCT03369704|10102306|FG001|Treatment Epoch|Lost to Follow-up|1
6344340|NCT03369704|10102305|FG000|Treatment Epoch|Lack of Efficacy|0
6344341|NCT03369704|10102306|FG001|Treatment Epoch|Lack of Efficacy|2
6344342|NCT03369704|10102305|FG000|Treatment Epoch|Adverse Event|2
6344343|NCT03369704|10102306|FG001|Treatment Epoch|Adverse Event|0
6344344|NCT03369704|10102305|FG000|Follow-up Epoch|Lost to Follow-up|1
6344345|NCT03369704|10102306|FG001|Follow-up Epoch|Lost to Follow-up|0
6344346|NCT03369951|10102316|FG000|Overall Study|Withdrawal by Subject|3
6344347|NCT03369951|10102316|FG000|Overall Study|Death|1
6344348|NCT03369951|10102316|FG000|Overall Study|Lost to Follow-up|1
6344349|NCT03369951|10102316|FG000|Overall Study|Protocol Violation|1
6344350|NCT03370289|10102333|FG000|Overall Study|Screen Failure|1
6344351|NCT03370289|10102333|FG000|Overall Study|Sample Size Sufficient|4
6344352|NCT03370302|10102343|FG000|Dose Escalation Phase|Other|0
6344353|NCT03370302|10102344|FG001|Dose Escalation Phase|Other|1
6344354|NCT03370302|10102345|FG002|Dose Escalation Phase|Other|1
6344355|NCT03370302|10102346|FG003|Dose Escalation Phase|Other|0
6344356|NCT03370302|10102347|FG004|Dose Escalation Phase|Other|0
6344357|NCT03370302|10102348|FG005|Dose Escalation Phase|Other|0
6344358|NCT03370302|10102343|FG000|Dose Escalation Phase|Withdrawal by Subject|0
6344359|NCT03370302|10102344|FG001|Dose Escalation Phase|Withdrawal by Subject|1
6344360|NCT03370302|10102345|FG002|Dose Escalation Phase|Withdrawal by Subject|2
6344361|NCT03370302|10102346|FG003|Dose Escalation Phase|Withdrawal by Subject|0
6344362|NCT03370302|10102347|FG004|Dose Escalation Phase|Withdrawal by Subject|0
6344363|NCT03370302|10102348|FG005|Dose Escalation Phase|Withdrawal by Subject|2
6344364|NCT03370302|10102343|FG000|Dose Escalation Phase|Adverse Event|1
6344365|NCT03370302|10102344|FG001|Dose Escalation Phase|Adverse Event|0
6344366|NCT03370302|10102345|FG002|Dose Escalation Phase|Adverse Event|2
6344367|NCT03370302|10102346|FG003|Dose Escalation Phase|Adverse Event|0
6344368|NCT03370302|10102347|FG004|Dose Escalation Phase|Adverse Event|0
6344369|NCT03370302|10102348|FG005|Dose Escalation Phase|Adverse Event|0
6344370|NCT03370302|10102343|FG000|Dose Escalation Phase|Progressive Disease|2
6344371|NCT03370302|10102344|FG001|Dose Escalation Phase|Progressive Disease|4
6344372|NCT03370302|10102345|FG002|Dose Escalation Phase|Progressive Disease|2
6344373|NCT03370302|10102346|FG003|Dose Escalation Phase|Progressive Disease|0
6344374|NCT03370302|10102347|FG004|Dose Escalation Phase|Progressive Disease|3
6344375|NCT03370302|10102348|FG005|Dose Escalation Phase|Progressive Disease|1
6344376|NCT03370302|10102343|FG000|Dose Expansion Phase|Progressive Disease|0
6344377|NCT03370302|10102344|FG001|Dose Expansion Phase|Progressive Disease|0
6344378|NCT03370302|10102345|FG002|Dose Expansion Phase|Progressive Disease|0
6344379|NCT03370302|10102346|FG003|Dose Expansion Phase|Progressive Disease|6
6344380|NCT03370302|10102347|FG004|Dose Expansion Phase|Progressive Disease|0
6344381|NCT03370302|10102348|FG005|Dose Expansion Phase|Progressive Disease|0
6344382|NCT03370419|10102366|FG000|Overall Study|Lost to Follow-up|16
6344383|NCT03370471|10102372|FG000|Overall Study|Withdrawal by Subject|6
6344384|NCT03370471|10102373|FG001|Overall Study|Withdrawal by Subject|1
6344385|NCT03370471|10102372|FG000|Overall Study|Unable to access veins for blood draw|0
6344386|NCT03370471|10102373|FG001|Overall Study|Unable to access veins for blood draw|1
6344387|NCT03370471|10102372|FG000|Overall Study|Screen fail|1
6344388|NCT03370471|10102373|FG001|Overall Study|Screen fail|0
6344389|NCT03370770|10102381|FG000|Overall Study|Patient was followed in another hospital center|1
6344390|NCT03370770|10102381|FG000|Overall Study|Progressive Disease|98
6344391|NCT03370770|10102381|FG000|Overall Study|Adverse Event|2
6344392|NCT03370770|10102381|FG000|Overall Study|Death|5
6344393|NCT03371355|10102389|FG000|Overall Study|Investigator judgment|0
6344394|NCT03371355|10102390|FG001|Overall Study|Investigator judgment|0
6344395|NCT03371355|10102391|FG002|Overall Study|Investigator judgment|1
6344396|NCT03371355|10102392|FG003|Overall Study|Investigator judgment|1
6344397|NCT03371355|10102389|FG000|Overall Study|Voluntary withdrawal|1
6344398|NCT03371355|10102390|FG001|Overall Study|Voluntary withdrawal|0
6344399|NCT03371355|10102391|FG002|Overall Study|Voluntary withdrawal|1
6344400|NCT03371355|10102392|FG003|Overall Study|Voluntary withdrawal|2
6344401|NCT03371355|10102389|FG000|Overall Study|Adverse Event|0
6344402|NCT03371355|10102390|FG001|Overall Study|Adverse Event|1
6344403|NCT03371355|10102391|FG002|Overall Study|Adverse Event|2
6344404|NCT03371355|10102392|FG003|Overall Study|Adverse Event|3
6344405|NCT03371355|10102389|FG000|Overall Study|Reason not Specified|0
6344406|NCT03371355|10102390|FG001|Overall Study|Reason not Specified|1
6344407|NCT03371355|10102391|FG002|Overall Study|Reason not Specified|0
6344408|NCT03371355|10102392|FG003|Overall Study|Reason not Specified|1
6344409|NCT03371381|10102406|FG000|Overall Study|Death|5
6344410|NCT03371381|10102406|FG000|Overall Study|Study terminated by sponsor|3
6344411|NCT03371381|10102406|FG000|Overall Study|Other|4
6344412|NCT03371459|10102410|FG000|Washout|Lost to Follow-up|0
6344413|NCT03371459|10102411|FG001|Washout|Lost to Follow-up|1
6344414|NCT03371732|10102419|FG000|Overall Study|Withdrawal by Subject|9
6344415|NCT03371732|10102420|FG001|Overall Study|Withdrawal by Subject|3
6344416|NCT03371732|10102419|FG000|Overall Study|Refusal to continue|3
6344417|NCT03371732|10102420|FG001|Overall Study|Refusal to continue|4
6344418|NCT03372083|10102432|FG000|Overall Study|Adverse Event|3
6344419|NCT03372083|10102432|FG000|Overall Study|Physician Decision|1
6344420|NCT03372083|10102432|FG000|Overall Study|Withdrawal by Subject|1
6344421|NCT03372096|10102436|FG000|Overall Study|Study Closed|8
6344422|NCT03372369|10102445|FG000|Qualification Period|Withdrawal by Subject|16
6344423|NCT03372369|10102446|FG001|Qualification Period|Withdrawal by Subject|13
6344424|NCT03372369|10102445|FG000|Qualification Period|Inconsistent Eligibility Results|10
6344425|NCT03372369|10102446|FG001|Qualification Period|Inconsistent Eligibility Results|9
6344426|NCT03372369|10102445|FG000|Intervention and Follow-Up Period|Withdrawal by Subject|3
6344427|NCT03372369|10102446|FG001|Intervention and Follow-Up Period|Withdrawal by Subject|3
6344428|NCT03372551|10102476|FG000|First Intervention (1 Week)|Withdrawal by Subject|1
6344429|NCT03372551|10102477|FG001|First Intervention (1 Week)|Withdrawal by Subject|0
6344430|NCT03372603|10102490|FG000|Wash-out Period (14-21 Days)|Sponsor terminated study treatment|1
6344431|NCT03372603|10102491|FG001|Wash-out Period (14-21 Days)|Sponsor terminated study treatment|0
6344432|NCT03372603|10102490|FG000|Treatment Period 2 (Up to 7 Days)|Study closed/Terminated|1
6344433|NCT03372603|10102491|FG001|Treatment Period 2 (Up to 7 Days)|Study closed/Terminated|0
6344434|NCT03373383|10102528|FG000|Treatment Period: Wk0-16|Adverse Event|7
6344435|NCT03373383|10102529|FG001|Treatment Period: Wk0-16|Adverse Event|6
6344436|NCT03373383|10102530|FG002|Treatment Period: Wk0-16|Adverse Event|11
6344437|NCT03373383|10102531|FG003|Treatment Period: Wk0-16|Adverse Event|15
6344438|NCT03373383|10102532|FG004|Treatment Period: Wk0-16|Adverse Event|21
6344439|NCT03373383|10102528|FG000|Treatment Period: Wk0-16|Lack of Efficacy|2
6344440|NCT03373383|10102529|FG001|Treatment Period: Wk0-16|Lack of Efficacy|1
6344441|NCT03373383|10102530|FG002|Treatment Period: Wk0-16|Lack of Efficacy|0
6344442|NCT03373383|10102531|FG003|Treatment Period: Wk0-16|Lack of Efficacy|0
6344443|NCT03373383|10102532|FG004|Treatment Period: Wk0-16|Lack of Efficacy|0
6344444|NCT03373383|10102528|FG000|Treatment Period: Wk0-16|Protocol Violation|0
6344445|NCT03373383|10102529|FG001|Treatment Period: Wk0-16|Protocol Violation|4
6344446|NCT03373383|10102530|FG002|Treatment Period: Wk0-16|Protocol Violation|2
6344447|NCT03373383|10102531|FG003|Treatment Period: Wk0-16|Protocol Violation|1
6344448|NCT03373383|10102532|FG004|Treatment Period: Wk0-16|Protocol Violation|0
6344449|NCT03373383|10102528|FG000|Treatment Period: Wk0-16|Lost to Follow-up|2
6344450|NCT03373383|10102529|FG001|Treatment Period: Wk0-16|Lost to Follow-up|0
6344451|NCT03373383|10102530|FG002|Treatment Period: Wk0-16|Lost to Follow-up|0
6344452|NCT03373383|10102531|FG003|Treatment Period: Wk0-16|Lost to Follow-up|0
6344453|NCT03373383|10102532|FG004|Treatment Period: Wk0-16|Lost to Follow-up|0
6344454|NCT03373383|10102528|FG000|Treatment Period: Wk0-16|Withdrawal by Subject|2
6344455|NCT03373383|10102529|FG001|Treatment Period: Wk0-16|Withdrawal by Subject|3
6344456|NCT03373383|10102530|FG002|Treatment Period: Wk0-16|Withdrawal by Subject|2
6083343|NCT00634933|9691718|FG004|Part A: Baseline to Week 24|Death|0
6168777|NCT01237587|9813909|FG000|Taper Phase|Lack of Efficacy|2
6083344|NCT00634933|9691714|FG000|Part A: Baseline to Week 24|Failed to Return|1
6083345|NCT00634933|9691715|FG001|Part A: Baseline to Week 24|Failed to Return|0
6083346|NCT00634933|9691716|FG002|Part A: Baseline to Week 24|Failed to Return|0
6083347|NCT00634933|9691717|FG003|Part A: Baseline to Week 24|Failed to Return|0
6083348|NCT00634933|9691718|FG004|Part A: Baseline to Week 24|Failed to Return|0
6083349|NCT00634933|9691714|FG000|Part A: Baseline to Week 24|Investigator Request|1
6083350|NCT00634933|9691715|FG001|Part A: Baseline to Week 24|Investigator Request|1
6227419|NCT01717040|9900135|FG000|Overall Study|Lost to Follow-up|2
6227420|NCT01717040|9900136|FG001|Overall Study|Lost to Follow-up|3
6227421|NCT01717040|9900135|FG000|Overall Study|Lack of Efficacy|1
6168778|NCT01237587|9813910|FG001|Taper Phase|Lack of Efficacy|5
6168779|NCT01237587|9813909|FG000|Taper Phase|Parent/Guardian Decision|0
6168780|NCT01237587|9813910|FG001|Taper Phase|Parent/Guardian Decision|2
6168781|NCT01237587|9813909|FG000|Taper Phase|Sponsor Decision|1
6168782|NCT01237587|9813910|FG001|Taper Phase|Sponsor Decision|0
6168783|NCT01237587|9813909|FG000|Taper Phase|Withdrawal by Subject|0
6168784|NCT01237587|9813910|FG001|Taper Phase|Withdrawal by Subject|1
6168785|NCT01237678|9813926|FG000|Phase I - IMGN901+Carboplatin+Etoposide|Adverse Event|5
6168786|NCT01237678|9813927|FG001|Phase I - IMGN901+Carboplatin+Etoposide|Adverse Event|0
6168787|NCT01237678|9813928|FG002|Phase I - IMGN901+Carboplatin+Etoposide|Adverse Event|0
6168788|NCT01237678|9813926|FG000|Phase I - IMGN901+Carboplatin+Etoposide|Lack of Efficacy|24
6168789|NCT01237678|9813927|FG001|Phase I - IMGN901+Carboplatin+Etoposide|Lack of Efficacy|0
6168790|NCT01237678|9813928|FG002|Phase I - IMGN901+Carboplatin+Etoposide|Lack of Efficacy|0
6168791|NCT01237678|9813926|FG000|Phase I - IMGN901+Carboplatin+Etoposide|Withdrawal by Subject|3
6168792|NCT01237678|9813927|FG001|Phase I - IMGN901+Carboplatin+Etoposide|Withdrawal by Subject|0
6168793|NCT01237678|9813928|FG002|Phase I - IMGN901+Carboplatin+Etoposide|Withdrawal by Subject|0
6344457|NCT03373383|10102531|FG003|Treatment Period: Wk0-16|Withdrawal by Subject|3
6344458|NCT03373383|10102532|FG004|Treatment Period: Wk0-16|Withdrawal by Subject|3
6344459|NCT03373383|10102528|FG000|Treatment Period: Wk0-16|As advised by the sponsor|0
6344460|NCT03373383|10102529|FG001|Treatment Period: Wk0-16|As advised by the sponsor|1
6344461|NCT03373383|10102530|FG002|Treatment Period: Wk0-16|As advised by the sponsor|0
6344462|NCT03373383|10102531|FG003|Treatment Period: Wk0-16|As advised by the sponsor|0
6344463|NCT03373383|10102532|FG004|Treatment Period: Wk0-16|As advised by the sponsor|0
6344464|NCT03373383|10102528|FG000|Treatment Period: Wk0-16|By opinion of investigator|0
6344465|NCT03373383|10102529|FG001|Treatment Period: Wk0-16|By opinion of investigator|0
6344466|NCT03373383|10102530|FG002|Treatment Period: Wk0-16|By opinion of investigator|0
6344467|NCT03373383|10102531|FG003|Treatment Period: Wk0-16|By opinion of investigator|1
6344468|NCT03373383|10102532|FG004|Treatment Period: Wk0-16|By opinion of investigator|0
6344469|NCT03373383|10102528|FG000|Treatment Period: Wk0-16|Sponsor decision|0
6344470|NCT03373383|10102529|FG001|Treatment Period: Wk0-16|Sponsor decision|0
6344471|NCT03373383|10102530|FG002|Treatment Period: Wk0-16|Sponsor decision|0
6344472|NCT03373383|10102531|FG003|Treatment Period: Wk0-16|Sponsor decision|1
6344473|NCT03373383|10102532|FG004|Treatment Period: Wk0-16|Sponsor decision|0
6344474|NCT03373383|10102528|FG000|Post-Treatment Period: Wk16-23|Participant decided not to roll over|1
6344475|NCT03373383|10102529|FG001|Post-Treatment Period: Wk16-23|Participant decided not to roll over|0
6344476|NCT03373383|10102530|FG002|Post-Treatment Period: Wk16-23|Participant decided not to roll over|0
6344477|NCT03373383|10102531|FG003|Post-Treatment Period: Wk16-23|Participant decided not to roll over|0
6344478|NCT03373383|10102532|FG004|Post-Treatment Period: Wk16-23|Participant decided not to roll over|0
6344479|NCT03374189|10102594|FG000|Overall Study|Lost to Follow-up|1
6344480|NCT03374189|10102595|FG001|Overall Study|Lost to Follow-up|0
6344481|NCT03374358|10102603|FG000|Overall Study|Withdrawal by Subject|0
6344482|NCT03374358|10102604|FG001|Overall Study|Withdrawal by Subject|2
6344483|NCT03374488|10102612|FG000|Overall Study|Death|13
6344484|NCT03374488|10102613|FG001|Overall Study|Death|13
6344485|NCT03374488|10102612|FG000|Overall Study|Withdrawal by Subject|3
6344486|NCT03374488|10102613|FG001|Overall Study|Withdrawal by Subject|1
6344487|NCT03374488|10102612|FG000|Overall Study|Physician Decision|3
6344488|NCT03374488|10102613|FG001|Overall Study|Physician Decision|0
6344489|NCT03374995|10102635|FG000|Overall Study|Withdrawal by Subject|0
6344490|NCT03374995|10102636|FG001|Overall Study|Withdrawal by Subject|1
6344491|NCT03376321|10102676|FG000|Overall Study|Other|5
6344492|NCT03376321|10102677|FG001|Overall Study|Other|1
6344493|NCT03376321|10102676|FG000|Overall Study|Withdrawal by Subject|8
6344494|NCT03376321|10102677|FG001|Overall Study|Withdrawal by Subject|14
6344495|NCT03376321|10102676|FG000|Overall Study|Lost to Follow-up|1
6344496|NCT03376321|10102677|FG001|Overall Study|Lost to Follow-up|7
6344497|NCT03376321|10102676|FG000|Overall Study|Death|4
6344498|NCT03376321|10102677|FG001|Overall Study|Death|0
6344499|NCT03376321|10102676|FG000|Overall Study|Randomized, not treated|5
6344500|NCT03376321|10102677|FG001|Overall Study|Randomized, not treated|3
6344501|NCT03376516|10102683|FG000|Overall Study|Not treated|1
6344502|NCT03376516|10102683|FG000|Overall Study|Consent withdrawn|1
6344503|NCT03377556|10102720|FG000|Overall Study|Adverse Event|5
6344504|NCT03377556|10102720|FG000|Overall Study|Refusal unrelated to adverse events|1
6344505|NCT03377556|10102720|FG000|Overall Study|Progression/relapse|38
6344506|NCT03377556|10102720|FG000|Overall Study|Death|3
6344507|NCT03377634|10102726|FG000|Study Period|Adverse Event|1
6344508|NCT03377634|10102727|FG001|Study Period|Adverse Event|0
6344509|NCT03377634|10102726|FG000|Study Period|Withdrawal by Subject|1
6344510|NCT03377634|10102727|FG001|Study Period|Withdrawal by Subject|0
6344511|NCT03378635|10102745|FG000|Overall Study|Adverse Event|1
6344512|NCT03378635|10102746|FG001|Overall Study|Adverse Event|0
6344513|NCT03378635|10102747|FG002|Overall Study|Adverse Event|0
6344514|NCT03378635|10102745|FG000|Overall Study|Withdrawal by Subject|1
6344515|NCT03378635|10102746|FG001|Overall Study|Withdrawal by Subject|0
6344516|NCT03378635|10102747|FG002|Overall Study|Withdrawal by Subject|0
6344517|NCT03379259|10102780|FG000|Overall Study|Commenced new anti-cancer therapy|1
6344518|NCT03379259|10102781|FG001|Overall Study|Commenced new anti-cancer therapy|0
6344519|NCT03379259|10102782|FG002|Overall Study|Commenced new anti-cancer therapy|0
6344520|NCT03379259|10102783|FG003|Overall Study|Commenced new anti-cancer therapy|0
6344521|NCT03379259|10102784|FG004|Overall Study|Commenced new anti-cancer therapy|0
6344522|NCT03379259|10102785|FG005|Overall Study|Commenced new anti-cancer therapy|0
6344523|NCT03379259|10102780|FG000|Overall Study|Death|0
6344524|NCT03379259|10102781|FG001|Overall Study|Death|1
6344525|NCT03379259|10102782|FG002|Overall Study|Death|2
6344526|NCT03379259|10102783|FG003|Overall Study|Death|1
6344527|NCT03379259|10102784|FG004|Overall Study|Death|4
6344528|NCT03379259|10102785|FG005|Overall Study|Death|2
6344529|NCT03379259|10102780|FG000|Overall Study|Withdrawal by Subject|0
6344530|NCT03379259|10102781|FG001|Overall Study|Withdrawal by Subject|0
6344531|NCT03379259|10102782|FG002|Overall Study|Withdrawal by Subject|1
6344532|NCT03379259|10102783|FG003|Overall Study|Withdrawal by Subject|0
6344533|NCT03379259|10102784|FG004|Overall Study|Withdrawal by Subject|2
6344534|NCT03379259|10102785|FG005|Overall Study|Withdrawal by Subject|0
6344535|NCT03379259|10102780|FG000|Overall Study|Study terminated by sponsor|0
6083351|NCT00634933|9691716|FG002|Part A: Baseline to Week 24|Investigator Request|1
6083352|NCT00634933|9691717|FG003|Part A: Baseline to Week 24|Investigator Request|0
6344536|NCT03379259|10102781|FG001|Overall Study|Study terminated by sponsor|0
6344537|NCT03379259|10102782|FG002|Overall Study|Study terminated by sponsor|0
6344538|NCT03379259|10102783|FG003|Overall Study|Study terminated by sponsor|1
6344539|NCT03379259|10102784|FG004|Overall Study|Study terminated by sponsor|1
6344540|NCT03379259|10102785|FG005|Overall Study|Study terminated by sponsor|4
6344541|NCT03379259|10102780|FG000|Overall Study|Disease progression|0
6344542|NCT03379259|10102781|FG001|Overall Study|Disease progression|0
6344543|NCT03379259|10102782|FG002|Overall Study|Disease progression|0
6344544|NCT03379259|10102783|FG003|Overall Study|Disease progression|1
6344545|NCT03379259|10102784|FG004|Overall Study|Disease progression|0
6344546|NCT03379259|10102785|FG005|Overall Study|Disease progression|1
6344547|NCT03379259|10102780|FG000|Overall Study|Lost to Follow-up|0
6344548|NCT03379259|10102781|FG001|Overall Study|Lost to Follow-up|0
6344549|NCT03379259|10102782|FG002|Overall Study|Lost to Follow-up|0
6344550|NCT03379259|10102783|FG003|Overall Study|Lost to Follow-up|0
6344551|NCT03379259|10102784|FG004|Overall Study|Lost to Follow-up|1
6344552|NCT03379259|10102785|FG005|Overall Study|Lost to Follow-up|0
6344553|NCT03379259|10102780|FG000|Overall Study|Deteriorating condition|0
6344554|NCT03379259|10102781|FG001|Overall Study|Deteriorating condition|0
6344555|NCT03379259|10102782|FG002|Overall Study|Deteriorating condition|0
6344556|NCT03379259|10102783|FG003|Overall Study|Deteriorating condition|0
6344557|NCT03379259|10102784|FG004|Overall Study|Deteriorating condition|1
6344558|NCT03379259|10102785|FG005|Overall Study|Deteriorating condition|0
6344559|NCT03379376|10102802|FG000|Overall Study|Lost to Follow-up|2
6344560|NCT03379376|10102802|FG000|Overall Study|Did not wish to complete follow up|1
6344561|NCT03379376|10102802|FG000|Overall Study|Overwhelmed, didn't want to continue|1
6344562|NCT03379376|10102802|FG000|Overall Study|Death|1
6344563|NCT03379753|10102855|FG000|Overall Study|Withdrawal by Subject|2
6344564|NCT03379753|10102856|FG001|Overall Study|Withdrawal by Subject|1
6344565|NCT03379753|10102855|FG000|Overall Study|not having correct procedure|1
6344566|NCT03379753|10102856|FG001|Overall Study|not having correct procedure|2
6344567|NCT03379753|10102855|FG000|Overall Study|No primary outcome|12
6344568|NCT03379753|10102856|FG001|Overall Study|No primary outcome|22
6344569|NCT03380091|10102878|FG000|Overall Study|Withdrawal by Subject|2
6344570|NCT03380091|10102879|FG001|Overall Study|Withdrawal by Subject|1
6344571|NCT03380390|10102887|FG000|Overall Study|Adverse Event|3
6344572|NCT03380429|10102896|FG000|Overall Study|Physician Decision|0
6344573|NCT03380429|10102897|FG001|Overall Study|Physician Decision|1
6344574|NCT03380429|10102898|FG002|Overall Study|Physician Decision|0
6344575|NCT03380429|10102899|FG003|Overall Study|Physician Decision|1
6344576|NCT03380429|10102900|FG004|Overall Study|Physician Decision|1
6083353|NCT00634933|9691718|FG004|Part A: Baseline to Week 24|Investigator Request|0
6083354|NCT00634933|9691714|FG000|Part A: Baseline to Week 24|Lost to Follow-up|0
6227422|NCT01717040|9900136|FG001|Overall Study|Lack of Efficacy|1
6344577|NCT03380429|10102896|FG000|Overall Study|Withdrawal by Subject|3
6344578|NCT03380429|10102897|FG001|Overall Study|Withdrawal by Subject|3
6344579|NCT03380429|10102898|FG002|Overall Study|Withdrawal by Subject|5
6344580|NCT03380429|10102899|FG003|Overall Study|Withdrawal by Subject|2
6344581|NCT03380429|10102900|FG004|Overall Study|Withdrawal by Subject|1
6344582|NCT03380429|10102896|FG000|Overall Study|Lost to Follow-up|0
6344583|NCT03380429|10102897|FG001|Overall Study|Lost to Follow-up|2
6344584|NCT03380429|10102898|FG002|Overall Study|Lost to Follow-up|4
6344585|NCT03380429|10102899|FG003|Overall Study|Lost to Follow-up|3
6344586|NCT03380429|10102900|FG004|Overall Study|Lost to Follow-up|1
6344587|NCT03380429|10102896|FG000|Overall Study|Protocol Violation|1
6344588|NCT03380429|10102897|FG001|Overall Study|Protocol Violation|0
6344589|NCT03380429|10102898|FG002|Overall Study|Protocol Violation|1
6344590|NCT03380429|10102899|FG003|Overall Study|Protocol Violation|0
6344591|NCT03380429|10102900|FG004|Overall Study|Protocol Violation|1
6344592|NCT03380429|10102896|FG000|Overall Study|Lack of Efficacy|0
6344593|NCT03380429|10102897|FG001|Overall Study|Lack of Efficacy|0
6344594|NCT03380429|10102898|FG002|Overall Study|Lack of Efficacy|0
6344595|NCT03380429|10102899|FG003|Overall Study|Lack of Efficacy|2
6344596|NCT03380429|10102900|FG004|Overall Study|Lack of Efficacy|1
6344597|NCT03380429|10102896|FG000|Overall Study|Adverse Event|1
6344598|NCT03380429|10102897|FG001|Overall Study|Adverse Event|1
6344599|NCT03380429|10102898|FG002|Overall Study|Adverse Event|1
6344600|NCT03380429|10102899|FG003|Overall Study|Adverse Event|2
6344601|NCT03380429|10102900|FG004|Overall Study|Adverse Event|0
6344602|NCT03381196|10102945|FG000|Overall Study|Withdrawal by Subject|7
6344603|NCT03381196|10102946|FG001|Overall Study|Withdrawal by Subject|7
6344604|NCT03381196|10102945|FG000|Overall Study|Other|0
6344605|NCT03381196|10102946|FG001|Overall Study|Other|1
6344606|NCT03381196|10102945|FG000|Overall Study|Lost to Follow-up|5
6344607|NCT03381196|10102946|FG001|Overall Study|Lost to Follow-up|4
6344608|NCT03381196|10102945|FG000|Overall Study|Death|0
6344609|NCT03381196|10102946|FG001|Overall Study|Death|1
6344610|NCT03381196|10102945|FG000|Overall Study|Adverse Event|1
6344611|NCT03381196|10102946|FG001|Overall Study|Adverse Event|0
6344612|NCT03381196|10102945|FG000|Overall Study|Randomized, not treated|3
6344613|NCT03381196|10102946|FG001|Overall Study|Randomized, not treated|6
6344614|NCT03381248|10102954|FG000|Overall Study|Withdrawal by Subject|5
6344615|NCT03381248|10102955|FG001|Overall Study|Withdrawal by Subject|3
6344616|NCT03381248|10102954|FG000|Overall Study|Lost to Follow-up|3
6344617|NCT03381248|10102955|FG001|Overall Study|Lost to Follow-up|2
6344618|NCT03381248|10102954|FG000|Overall Study|Lack of Efficacy|1
6344619|NCT03381248|10102955|FG001|Overall Study|Lack of Efficacy|0
6344620|NCT03381248|10102954|FG000|Overall Study|Adverse Event|2
6344621|NCT03381248|10102955|FG001|Overall Study|Adverse Event|0
6344622|NCT03381248|10102954|FG000|Overall Study|Protocol Violation|2
6344623|NCT03381248|10102955|FG001|Overall Study|Protocol Violation|1
6344624|NCT03381339|10102963|FG000|Overall Study|Protocol Violation|4
6344625|NCT03381339|10102964|FG001|Overall Study|Protocol Violation|3
6344626|NCT03381339|10102963|FG000|Overall Study|Lost to Follow-up|0
6344627|NCT03381339|10102964|FG001|Overall Study|Lost to Follow-up|1
6344628|NCT03382262|10102996|FG000|Overall Study|Physician Decision|0
6344629|NCT03382262|10102997|FG001|Overall Study|Physician Decision|0
6344630|NCT03382262|10102998|FG002|Overall Study|Physician Decision|1
6344631|NCT03382262|10102999|FG003|Overall Study|Physician Decision|0
6344632|NCT03382262|10102996|FG000|Overall Study|Withdrawal by Subject|0
6344633|NCT03382262|10102997|FG001|Overall Study|Withdrawal by Subject|0
6344634|NCT03382262|10102998|FG002|Overall Study|Withdrawal by Subject|0
6344635|NCT03382262|10102999|FG003|Overall Study|Withdrawal by Subject|1
6344636|NCT03382418|10103012|FG000|Overall Study|Withdrawal by Subject|1
6344637|NCT03382418|10103013|FG001|Overall Study|Withdrawal by Subject|0
6344638|NCT03382418|10103014|FG002|Overall Study|Withdrawal by Subject|0
6344639|NCT03382418|10103012|FG000|Overall Study|Lost to Follow-up|2
6344640|NCT03382418|10103013|FG001|Overall Study|Lost to Follow-up|3
6344641|NCT03382418|10103014|FG002|Overall Study|Lost to Follow-up|0
6344642|NCT03382821|10103043|FG000|Overall Study|Did not receive allocated intervention.|0
6344643|NCT03382821|10103044|FG001|Overall Study|Did not receive allocated intervention.|3
6344644|NCT03382899|10103057|FG000|Overall Study|Ineligibility Determined|0
6344645|NCT03382899|10103058|FG001|Overall Study|Ineligibility Determined|1
6344646|NCT03382899|10103057|FG000|Overall Study|Lost to Follow-up|0
6344647|NCT03382899|10103058|FG001|Overall Study|Lost to Follow-up|1
6344648|NCT03382899|10103057|FG000|Overall Study|Sponsor's decision|31
6344649|NCT03382899|10103058|FG001|Overall Study|Sponsor's decision|28
6344650|NCT03382899|10103057|FG000|Overall Study|Withdrawal by Subject|0
6083355|NCT00634933|9691715|FG001|Part A: Baseline to Week 24|Lost to Follow-up|1
6083356|NCT00634933|9691716|FG002|Part A: Baseline to Week 24|Lost to Follow-up|1
6083357|NCT00634933|9691717|FG003|Part A: Baseline to Week 24|Lost to Follow-up|0
6083358|NCT00634933|9691718|FG004|Part A: Baseline to Week 24|Lost to Follow-up|0
6083359|NCT00634933|9691714|FG000|Part A: Baseline to Week 24|Withdrawal by Subject|0
6344651|NCT03382899|10103058|FG001|Overall Study|Withdrawal by Subject|5
6344652|NCT03382912|10103066|FG000|Overall Study|Physician Decision|0
6344653|NCT03382912|10103067|FG001|Overall Study|Physician Decision|1
6344654|NCT03382912|10103066|FG000|Overall Study|Sponsor Decision|6
6344655|NCT03382912|10103067|FG001|Overall Study|Sponsor Decision|6
6344656|NCT03382912|10103066|FG000|Overall Study|Withdrawal by Subject|0
6344657|NCT03382912|10103067|FG001|Overall Study|Withdrawal by Subject|5
6344658|NCT03383146|10103075|FG000|Overall Study|Screen Failure|1
6344659|NCT03383146|10103076|FG001|Overall Study|Screen Failure|0
6344660|NCT03383146|10103075|FG000|Overall Study|Adverse Event|6
6344661|NCT03383146|10103076|FG001|Overall Study|Adverse Event|18
6344662|NCT03383146|10103075|FG000|Overall Study|Lack of Efficacy|0
6344663|NCT03383146|10103076|FG001|Overall Study|Lack of Efficacy|3
6344664|NCT03383146|10103075|FG000|Overall Study|Withdrawal by Subject|20
6083360|NCT00634933|9691715|FG001|Part A: Baseline to Week 24|Withdrawal by Subject|3
6083361|NCT00634933|9691716|FG002|Part A: Baseline to Week 24|Withdrawal by Subject|3
6344665|NCT03383146|10103076|FG001|Overall Study|Withdrawal by Subject|36
6344666|NCT03383146|10103075|FG000|Overall Study|Lost to Follow-up|5
6344667|NCT03383146|10103076|FG001|Overall Study|Lost to Follow-up|15
6344668|NCT03383146|10103075|FG000|Overall Study|Death|0
6344669|NCT03383146|10103076|FG001|Overall Study|Death|2
6344670|NCT03383146|10103075|FG000|Overall Study|Physician Decision|0
6344671|NCT03383146|10103076|FG001|Overall Study|Physician Decision|1
6344672|NCT03383146|10103075|FG000|Overall Study|Protocol Deviation|1
6344673|NCT03383146|10103076|FG001|Overall Study|Protocol Deviation|8
6344674|NCT03383146|10103075|FG000|Overall Study|Study Terminated by the Sponsor|48
6344675|NCT03383146|10103076|FG001|Overall Study|Study Terminated by the Sponsor|95
6344676|NCT03383146|10103075|FG000|Overall Study|Reason not Specified|4
6344677|NCT03383146|10103076|FG001|Overall Study|Reason not Specified|6
6344678|NCT03383614|10103138|FG000|Overall Study|Withdrawal by Subject|0
6344679|NCT03383614|10103139|FG001|Overall Study|Withdrawal by Subject|1
6344680|NCT03383614|10103140|FG002|Overall Study|Withdrawal by Subject|0
6344681|NCT03383614|10103141|FG003|Overall Study|Withdrawal by Subject|0
6344682|NCT03383783|10103164|FG000|Overall Study|Withdrawal by Subject|2
6344683|NCT03383887|10103180|FG000|Overall Study|Lost to Follow-up|0
6344684|NCT03383887|10103181|FG001|Overall Study|Lost to Follow-up|1
6344685|NCT03384316|10103201|FG000|Overall Study|Screen failure|0
6344686|NCT03384316|10103202|FG001|Overall Study|Screen failure|1
6344687|NCT03384693|10103219|FG000|Overall Study|Adverse Event|3
6344688|NCT03384745|10103229|FG000|Placebo Controlled Induction (W0 - W12)|Adverse Event|0
6344689|NCT03384745|10103230|FG001|Placebo Controlled Induction (W0 - W12)|Adverse Event|0
6344690|NCT03384745|10103231|FG002|Placebo Controlled Induction (W0 - W12)|Adverse Event|1
6344691|NCT03384745|10103232|FG003|Placebo Controlled Induction (W0 - W12)|Adverse Event|2
6344692|NCT03384745|10103233|FG004|Placebo Controlled Induction (W0 - W12)|Adverse Event|0
6344693|NCT03384745|10103234|FG005|Placebo Controlled Induction (W0 - W12)|Adverse Event|0
6344694|NCT03384745|10103229|FG000|Placebo Controlled Induction (W0 - W12)|Withdrawal by Subject|0
6344695|NCT03384745|10103230|FG001|Placebo Controlled Induction (W0 - W12)|Withdrawal by Subject|0
6344696|NCT03384745|10103231|FG002|Placebo Controlled Induction (W0 - W12)|Withdrawal by Subject|0
6344697|NCT03384745|10103232|FG003|Placebo Controlled Induction (W0 - W12)|Withdrawal by Subject|0
6344698|NCT03384745|10103233|FG004|Placebo Controlled Induction (W0 - W12)|Withdrawal by Subject|3
6344699|NCT03384745|10103234|FG005|Placebo Controlled Induction (W0 - W12)|Withdrawal by Subject|1
6344700|NCT03384745|10103229|FG000|Placebo Controlled Induction (W0 - W12)|Lost to Follow-up|0
6344701|NCT03384745|10103230|FG001|Placebo Controlled Induction (W0 - W12)|Lost to Follow-up|1
6344702|NCT03384745|10103231|FG002|Placebo Controlled Induction (W0 - W12)|Lost to Follow-up|1
6344703|NCT03384745|10103232|FG003|Placebo Controlled Induction (W0 - W12)|Lost to Follow-up|0
6344704|NCT03384745|10103233|FG004|Placebo Controlled Induction (W0 - W12)|Lost to Follow-up|0
6344705|NCT03384745|10103234|FG005|Placebo Controlled Induction (W0 - W12)|Lost to Follow-up|1
6344706|NCT03384745|10103229|FG000|Placebo Controlled Induction (W0 - W12)|Protocol Violation|0
6344707|NCT03384745|10103230|FG001|Placebo Controlled Induction (W0 - W12)|Protocol Violation|0
6344708|NCT03384745|10103231|FG002|Placebo Controlled Induction (W0 - W12)|Protocol Violation|1
6344709|NCT03384745|10103232|FG003|Placebo Controlled Induction (W0 - W12)|Protocol Violation|0
6344710|NCT03384745|10103233|FG004|Placebo Controlled Induction (W0 - W12)|Protocol Violation|0
6344711|NCT03384745|10103234|FG005|Placebo Controlled Induction (W0 - W12)|Protocol Violation|0
6344712|NCT03384745|10103229|FG000|Maintenance/Escalation (W12-W24)|Adverse Event|0
6344713|NCT03384745|10103230|FG001|Maintenance/Escalation (W12-W24)|Adverse Event|0
6344714|NCT03384745|10103231|FG002|Maintenance/Escalation (W12-W24)|Adverse Event|0
6344715|NCT03384745|10103232|FG003|Maintenance/Escalation (W12-W24)|Adverse Event|1
6344716|NCT03384745|10103233|FG004|Maintenance/Escalation (W12-W24)|Adverse Event|1
6344717|NCT03384745|10103234|FG005|Maintenance/Escalation (W12-W24)|Adverse Event|0
6344718|NCT03384745|10103229|FG000|Maintenance/Escalation (W12-W24)|Withdrawal by Subject|0
6344719|NCT03384745|10103230|FG001|Maintenance/Escalation (W12-W24)|Withdrawal by Subject|0
6344720|NCT03384745|10103231|FG002|Maintenance/Escalation (W12-W24)|Withdrawal by Subject|0
6344721|NCT03384745|10103232|FG003|Maintenance/Escalation (W12-W24)|Withdrawal by Subject|0
6344722|NCT03384745|10103233|FG004|Maintenance/Escalation (W12-W24)|Withdrawal by Subject|1
6344723|NCT03384745|10103234|FG005|Maintenance/Escalation (W12-W24)|Withdrawal by Subject|0
6344724|NCT03384745|10103229|FG000|Maintenance/Escalation (W12-W24)|Lack of Efficacy|0
6344725|NCT03384745|10103230|FG001|Maintenance/Escalation (W12-W24)|Lack of Efficacy|0
6344726|NCT03384745|10103231|FG002|Maintenance/Escalation (W12-W24)|Lack of Efficacy|1
6344727|NCT03384745|10103232|FG003|Maintenance/Escalation (W12-W24)|Lack of Efficacy|1
6344728|NCT03384745|10103233|FG004|Maintenance/Escalation (W12-W24)|Lack of Efficacy|0
6344729|NCT03384745|10103234|FG005|Maintenance/Escalation (W12-W24)|Lack of Efficacy|0
6344730|NCT03384745|10103229|FG000|Response Assess/Dose Hold (W24-W48)|Adverse Event|1
6344731|NCT03384745|10103230|FG001|Response Assess/Dose Hold (W24-W48)|Adverse Event|1
6344732|NCT03384745|10103231|FG002|Response Assess/Dose Hold (W24-W48)|Adverse Event|3
6344733|NCT03384745|10103232|FG003|Response Assess/Dose Hold (W24-W48)|Adverse Event|0
6344734|NCT03384745|10103233|FG004|Response Assess/Dose Hold (W24-W48)|Adverse Event|1
6344735|NCT03384745|10103234|FG005|Response Assess/Dose Hold (W24-W48)|Adverse Event|0
6344736|NCT03384745|10103229|FG000|Response Assess/Dose Hold (W24-W48)|Withdrawal by Subject|0
6344737|NCT03384745|10103230|FG001|Response Assess/Dose Hold (W24-W48)|Withdrawal by Subject|1
6344738|NCT03384745|10103231|FG002|Response Assess/Dose Hold (W24-W48)|Withdrawal by Subject|1
6344739|NCT03384745|10103232|FG003|Response Assess/Dose Hold (W24-W48)|Withdrawal by Subject|2
6344740|NCT03384745|10103233|FG004|Response Assess/Dose Hold (W24-W48)|Withdrawal by Subject|0
6344741|NCT03384745|10103234|FG005|Response Assess/Dose Hold (W24-W48)|Withdrawal by Subject|2
6344742|NCT03384745|10103229|FG000|Response Assess/Dose Hold (W24-W48)|Lost to Follow-up|0
6344743|NCT03384745|10103230|FG001|Response Assess/Dose Hold (W24-W48)|Lost to Follow-up|0
6344744|NCT03384745|10103231|FG002|Response Assess/Dose Hold (W24-W48)|Lost to Follow-up|0
6344745|NCT03384745|10103232|FG003|Response Assess/Dose Hold (W24-W48)|Lost to Follow-up|2
6344746|NCT03384745|10103233|FG004|Response Assess/Dose Hold (W24-W48)|Lost to Follow-up|0
6344747|NCT03384745|10103234|FG005|Response Assess/Dose Hold (W24-W48)|Lost to Follow-up|0
6344748|NCT03384745|10103229|FG000|Response Assess/Dose Hold (W24-W48)|Death|0
6344749|NCT03384745|10103230|FG001|Response Assess/Dose Hold (W24-W48)|Death|1
6344750|NCT03384745|10103231|FG002|Response Assess/Dose Hold (W24-W48)|Death|0
6344751|NCT03384745|10103232|FG003|Response Assess/Dose Hold (W24-W48)|Death|0
6344752|NCT03384745|10103233|FG004|Response Assess/Dose Hold (W24-W48)|Death|0
6344753|NCT03384745|10103234|FG005|Response Assess/Dose Hold (W24-W48)|Death|0
6344754|NCT03384940|10103257|FG000|Overall Study|Progressive disease|36
6344755|NCT03384940|10103258|FG001|Overall Study|Progressive disease|11
6344756|NCT03384940|10103259|FG002|Overall Study|Progressive disease|13
6344757|NCT03384940|10103257|FG000|Overall Study|Clinical progression|4
6344758|NCT03384940|10103258|FG001|Overall Study|Clinical progression|0
6344759|NCT03384940|10103259|FG002|Overall Study|Clinical progression|3
6344760|NCT03384940|10103257|FG000|Overall Study|Adverse Event|7
6344761|NCT03384940|10103258|FG001|Overall Study|Adverse Event|1
6344762|NCT03384940|10103259|FG002|Overall Study|Adverse Event|1
6344763|NCT03384940|10103257|FG000|Overall Study|Withdrawal by Subject|3
6344764|NCT03384940|10103258|FG001|Overall Study|Withdrawal by Subject|1
6344765|NCT03384940|10103259|FG002|Overall Study|Withdrawal by Subject|0
6344766|NCT03384940|10103257|FG000|Overall Study|Physician Decision|1
6344767|NCT03384940|10103258|FG001|Overall Study|Physician Decision|1
6344768|NCT03384940|10103259|FG002|Overall Study|Physician Decision|0
6344769|NCT03384940|10103257|FG000|Overall Study|Death|2
6344770|NCT03384940|10103258|FG001|Overall Study|Death|1
6344771|NCT03384940|10103259|FG002|Overall Study|Death|0
6344772|NCT03384940|10103257|FG000|Overall Study|Other|0
6344773|NCT03384940|10103258|FG001|Overall Study|Other|0
6344774|NCT03384940|10103259|FG002|Overall Study|Other|1
6344775|NCT03384966|10103279|FG000|Randomized at End of Screening Period|Physician decision due to adverse event|1
6344776|NCT03384966|10103280|FG001|Randomized at End of Screening Period|Physician decision due to adverse event|0
6344777|NCT03384966|10103281|FG002|Randomized at End of Screening Period|Physician decision due to adverse event|0
6344778|NCT03384966|10103279|FG000|Follow-up Period|Adverse Event|1
6344779|NCT03384966|10103280|FG001|Follow-up Period|Adverse Event|0
6344780|NCT03384966|10103281|FG002|Follow-up Period|Adverse Event|0
6344781|NCT03386032|10103301|FG000|Overall Study|Lack of Efficacy|6
6344782|NCT03386032|10103302|FG001|Overall Study|Lack of Efficacy|2
6344783|NCT03386032|10103303|FG002|Overall Study|Lack of Efficacy|0
6344784|NCT03386032|10103301|FG000|Overall Study|Adverse Event|2
6344785|NCT03386032|10103302|FG001|Overall Study|Adverse Event|2
6344786|NCT03386032|10103303|FG002|Overall Study|Adverse Event|0
6344787|NCT03386032|10103301|FG000|Overall Study|Withdrawal by Subject|1
6344788|NCT03386032|10103302|FG001|Overall Study|Withdrawal by Subject|0
6344789|NCT03386032|10103303|FG002|Overall Study|Withdrawal by Subject|0
6344790|NCT03386032|10103301|FG000|Overall Study|Lost to Follow-up|9
6344791|NCT03386032|10103302|FG001|Overall Study|Lost to Follow-up|3
6344792|NCT03386032|10103303|FG002|Overall Study|Lost to Follow-up|0
6344793|NCT03386344|10103323|FG000|Overall Study|Adverse Event|6
6344794|NCT03386344|10103324|FG001|Overall Study|Adverse Event|3
6344795|NCT03386344|10103325|FG002|Overall Study|Adverse Event|1
6344796|NCT03386344|10103323|FG000|Overall Study|Poor Compliance to Protocol|0
6344797|NCT03386344|10103324|FG001|Overall Study|Poor Compliance to Protocol|1
6344798|NCT03386344|10103325|FG002|Overall Study|Poor Compliance to Protocol|0
6344799|NCT03386344|10103323|FG000|Overall Study|Study Terminated by Sponsor|101
6344800|NCT03386344|10103324|FG001|Overall Study|Study Terminated by Sponsor|102
6344801|NCT03386344|10103325|FG002|Overall Study|Study Terminated by Sponsor|106
6344802|NCT03386344|10103323|FG000|Overall Study|Lost to Follow-up|3
6344803|NCT03386344|10103324|FG001|Overall Study|Lost to Follow-up|2
6344804|NCT03386344|10103325|FG002|Overall Study|Lost to Follow-up|1
6344805|NCT03386344|10103323|FG000|Overall Study|At the Participant's own Request|7
6344806|NCT03386344|10103324|FG001|Overall Study|At the Participant's own Request|7
6344807|NCT03386344|10103325|FG002|Overall Study|At the Participant's own Request|8
6344808|NCT03386344|10103323|FG000|Overall Study|Reason not Specified|0
6344809|NCT03386344|10103324|FG001|Overall Study|Reason not Specified|1
6344810|NCT03386344|10103325|FG002|Overall Study|Reason not Specified|0
6344811|NCT03386435|10103335|FG000|Overall Study|Protocol Violation|5
6344812|NCT03386435|10103336|FG001|Overall Study|Protocol Violation|7
6344813|NCT03386448|10103344|FG000|Overall Study|Adverse Event|0
6344814|NCT03386448|10103345|FG001|Overall Study|Adverse Event|2
6344815|NCT03386474|10103353|FG000|Overall Study|Death|1
6344816|NCT03386474|10103354|FG001|Overall Study|Death|0
6344817|NCT03386474|10103353|FG000|Overall Study|Adverse Event|0
6344818|NCT03386474|10103354|FG001|Overall Study|Adverse Event|1
6344819|NCT03386994|10103368|FG000|Overall Study|Lung transplant|1
6344820|NCT03386994|10103368|FG000|Overall Study|Adverse Event|14
6344821|NCT03386994|10103368|FG000|Overall Study|Lost to Follow-up|4
6344822|NCT03386994|10103368|FG000|Overall Study|Withdrawal by Subject|3
6344823|NCT03386994|10103368|FG000|Overall Study|Death|16
6344824|NCT03387020|10103386|FG000|Overall Study|Adverse Event|0
6344825|NCT03387020|10103387|FG001|Overall Study|Adverse Event|2
6344826|NCT03387020|10103388|FG002|Overall Study|Adverse Event|0
6344827|NCT03387020|10103386|FG000|Overall Study|Withdrawal by Subject|2
6344828|NCT03387020|10103387|FG001|Overall Study|Withdrawal by Subject|0
6344829|NCT03387020|10103388|FG002|Overall Study|Withdrawal by Subject|0
6344830|NCT03387046|10103412|FG000|Overall Study|Adverse Event|1
6344831|NCT03387046|10103413|FG001|Overall Study|Adverse Event|1
6344832|NCT03387462|10103433|FG000|Overall Study|Lost to Follow-up|1
6344833|NCT03387683|10103439|FG000|Overall Study|In receipt of disallowed medication|1
6344834|NCT03387683|10103440|FG001|Overall Study|In receipt of disallowed medication|0
6344835|NCT03387683|10103439|FG000|Overall Study|Did not receive treatment|1
6344836|NCT03387683|10103440|FG001|Overall Study|Did not receive treatment|0
6344837|NCT03388164|10103457|FG000|Overall Study|Withdrawal by Subject|3
6344838|NCT03388164|10103458|FG001|Overall Study|Withdrawal by Subject|1
6344839|NCT03389308|10103491|FG000|Overall Study|Withdrawal by Subject|5
6344840|NCT03389308|10103491|FG000|Overall Study|Lost to Follow-up|3
6344841|NCT03389308|10103491|FG000|Overall Study|Adverse Event|2
6344842|NCT03389308|10103491|FG000|Overall Study|Sponsor Request|2
6344843|NCT03389555|10103497|FG000|Overall Study|Protocol Violation|1
6344844|NCT03389555|10103498|FG001|Overall Study|Protocol Violation|3
6344845|NCT03389555|10103497|FG000|Overall Study|Death|1
6344846|NCT03389555|10103498|FG001|Overall Study|Death|0
6344847|NCT03389893|10103527|FG000|Randomized Double Blind Period|Withdrawal by Subject|1
6344848|NCT03389893|10103528|FG001|Randomized Double Blind Period|Withdrawal by Subject|0
6344849|NCT03389893|10103529|FG002|Randomized Double Blind Period|Withdrawal by Subject|0
6344850|NCT03389893|10103530|FG003|Randomized Double Blind Period|Withdrawal by Subject|0
6344851|NCT03389893|10103527|FG000|Open Label Extension and Follow-Up|Lost to Follow-up|0
6344852|NCT03389893|10103528|FG001|Open Label Extension and Follow-Up|Lost to Follow-up|0
6344853|NCT03389893|10103529|FG002|Open Label Extension and Follow-Up|Lost to Follow-up|2
6344854|NCT03389893|10103530|FG003|Open Label Extension and Follow-Up|Lost to Follow-up|1
6344855|NCT03389893|10103527|FG000|Open Label Extension and Follow-Up|Physician Decision|0
6344856|NCT03389893|10103528|FG001|Open Label Extension and Follow-Up|Physician Decision|0
6344857|NCT03389893|10103529|FG002|Open Label Extension and Follow-Up|Physician Decision|1
6344858|NCT03389893|10103530|FG003|Open Label Extension and Follow-Up|Physician Decision|0
6344859|NCT03389893|10103527|FG000|Open Label Extension and Follow-Up|Participant Moved|0
6344860|NCT03389893|10103528|FG001|Open Label Extension and Follow-Up|Participant Moved|0
6344861|NCT03389893|10103529|FG002|Open Label Extension and Follow-Up|Participant Moved|1
6344862|NCT03389893|10103530|FG003|Open Label Extension and Follow-Up|Participant Moved|0
6344863|NCT03390101|10103539|FG000|Weeks 0-12|Withdrawal by Subject|0
6344864|NCT03390101|10103540|FG001|Weeks 0-12|Withdrawal by Subject|1
6344865|NCT03390101|10103541|FG002|Weeks 0-12|Withdrawal by Subject|1
6344866|NCT03390101|10103539|FG000|Weeks 0-12|Lost to Follow-up|0
6344867|NCT03390101|10103540|FG001|Weeks 0-12|Lost to Follow-up|1
6344868|NCT03390101|10103541|FG002|Weeks 0-12|Lost to Follow-up|0
6344869|NCT03390101|10103539|FG000|Weeks 12-54|Withdrawal by Subject|0
6344870|NCT03390101|10103540|FG001|Weeks 12-54|Withdrawal by Subject|3
6344871|NCT03390101|10103541|FG002|Weeks 12-54|Withdrawal by Subject|1
6344872|NCT03390101|10103539|FG000|Weeks 12-54|Pregnancy|1
6344873|NCT03390101|10103540|FG001|Weeks 12-54|Pregnancy|0
6344874|NCT03390101|10103541|FG002|Weeks 12-54|Pregnancy|0
6344875|NCT03390101|10103539|FG000|Weeks 12-54|Adverse Event|2
6344876|NCT03390101|10103540|FG001|Weeks 12-54|Adverse Event|1
6344877|NCT03390101|10103541|FG002|Weeks 12-54|Adverse Event|1
6344878|NCT03390166|10103560|FG000|Overall Study|Death|0
6344879|NCT03390166|10103561|FG001|Overall Study|Death|1
6344880|NCT03390166|10103560|FG000|Overall Study|Lost to Follow-up|6
6344881|NCT03390166|10103561|FG001|Overall Study|Lost to Follow-up|4
6344882|NCT03390166|10103560|FG000|Overall Study|Physician Decision|2
6344883|NCT03390166|10103561|FG001|Overall Study|Physician Decision|1
6344884|NCT03390166|10103560|FG000|Overall Study|Move from study area|3
6344885|NCT03390166|10103561|FG001|Overall Study|Move from study area|2
6344886|NCT03390166|10103560|FG000|Overall Study|To militarycamp for conscript|1
6168794|NCT01237678|9813926|FG000|Phase I - IMGN901+Carboplatin+Etoposide|Incorrect Original Diagnosis|1
6168795|NCT01237678|9813927|FG001|Phase I - IMGN901+Carboplatin+Etoposide|Incorrect Original Diagnosis|0
6344887|NCT03390166|10103561|FG001|Overall Study|To militarycamp for conscript|0
6344888|NCT03390166|10103560|FG000|Overall Study|To drug therapy course|0
6168796|NCT01237678|9813928|FG002|Phase I - IMGN901+Carboplatin+Etoposide|Incorrect Original Diagnosis|0
6344889|NCT03390166|10103561|FG001|Overall Study|To drug therapy course|1
6344890|NCT03390166|10103560|FG000|Overall Study|Move to work oversea|0
6344891|NCT03390166|10103561|FG001|Overall Study|Move to work oversea|1
6344892|NCT03390426|10103575|FG000|Overall Study|Protocol Violation|0
6344893|NCT03390426|10103576|FG001|Overall Study|Protocol Violation|1
6344894|NCT03391765|10103609|FG000|Overall Study|Adverse Event|2
6344895|NCT03391765|10103610|FG001|Overall Study|Adverse Event|0
6344896|NCT03391765|10103611|FG002|Overall Study|Adverse Event|0
6344897|NCT03391765|10103612|FG003|Overall Study|Adverse Event|2
6344898|NCT03391765|10103609|FG000|Overall Study|Withdrew consent|5
6344899|NCT03391765|10103610|FG001|Overall Study|Withdrew consent|7
6344900|NCT03391765|10103611|FG002|Overall Study|Withdrew consent|2
6344901|NCT03391765|10103612|FG003|Overall Study|Withdrew consent|5
6344902|NCT03391765|10103609|FG000|Overall Study|Other, not specified|44
6344903|NCT03391765|10103610|FG001|Overall Study|Other, not specified|38
6344904|NCT03391765|10103611|FG002|Overall Study|Other, not specified|21
6344905|NCT03391765|10103612|FG003|Overall Study|Other, not specified|16
6344906|NCT03392168|10103639|FG000|Period 2: Cohort 2|Lost to Follow-up|0
6344907|NCT03392168|10103640|FG001|Period 2: Cohort 2|Lost to Follow-up|1
6344908|NCT03392168|10103641|FG002|Period 2: Cohort 2|Lost to Follow-up|1
6344909|NCT03392168|10103642|FG003|Period 2: Cohort 2|Lost to Follow-up|1
6344910|NCT03392168|10103639|FG000|Period 2: Cohort 2|Other|0
6344911|NCT03392168|10103640|FG001|Period 2: Cohort 2|Other|1
6344912|NCT03392168|10103641|FG002|Period 2: Cohort 2|Other|0
6344913|NCT03392168|10103642|FG003|Period 2: Cohort 2|Other|0
6344914|NCT03392194|10103653|FG000|Overall Study|Withdrawal by Subject|1
6344915|NCT03392194|10103654|FG001|Overall Study|Withdrawal by Subject|2
6344916|NCT03392194|10103653|FG000|Overall Study|Conflicts with personal schedule|1
6344917|NCT03392194|10103654|FG001|Overall Study|Conflicts with personal schedule|0
6344918|NCT03393000|10103676|FG000|Overall Study|Death|11
6344919|NCT03393000|10103676|FG000|Overall Study|Withdrawal by Subject|2
6344920|NCT03393000|10103676|FG000|Overall Study|Physician Decision|1
6344921|NCT03393806|10103723|FG000|Overall Study|Physician Decision|1
6344922|NCT03393806|10103724|FG001|Overall Study|Physician Decision|0
6344923|NCT03394391|10103733|FG000|Overall Study|Lost to Follow-up|1
6344924|NCT03394391|10103734|FG001|Overall Study|Lost to Follow-up|2
6344925|NCT03394508|10103742|FG000|Overall Study|Protocol Violation|0
6344926|NCT03394508|10103743|FG001|Overall Study|Protocol Violation|3
6344927|NCT03394508|10103742|FG000|Overall Study|Lost to Follow-up|1
6344928|NCT03394508|10103743|FG001|Overall Study|Lost to Follow-up|0
6344929|NCT03394885|10103757|FG000|Overall Study|Adverse Event|4
6344930|NCT03394885|10103757|FG000|Overall Study|Lack of Efficacy|1
6344931|NCT03394885|10103757|FG000|Overall Study|Physician Decision|1
6344932|NCT03394885|10103757|FG000|Overall Study|Withdrawal by Subject|8
6344933|NCT03394885|10103757|FG000|Overall Study|Alternative Therapy|1
6344934|NCT03394924|10103764|FG000|Overall Study|Adverse Event|0
6344935|NCT03394924|10103765|FG001|Overall Study|Adverse Event|5
6344936|NCT03394924|10103766|FG002|Overall Study|Adverse Event|0
6344937|NCT03394924|10103764|FG000|Overall Study|Withdrawal by Subject|2
6344938|NCT03394924|10103765|FG001|Overall Study|Withdrawal by Subject|0
6344939|NCT03394924|10103766|FG002|Overall Study|Withdrawal by Subject|0
6344940|NCT03394924|10103764|FG000|Overall Study|Lost to Follow-up|0
6344941|NCT03394924|10103765|FG001|Overall Study|Lost to Follow-up|1
6344942|NCT03394924|10103766|FG002|Overall Study|Lost to Follow-up|0
6344943|NCT03394924|10103764|FG000|Overall Study|Did not meet all inclusion criteria|1
6344944|NCT03394924|10103765|FG001|Overall Study|Did not meet all inclusion criteria|0
6344945|NCT03394924|10103766|FG002|Overall Study|Did not meet all inclusion criteria|0
6344946|NCT03395353|10103776|FG000|Overall Study|Adverse Event|20
6344947|NCT03395353|10103776|FG000|Overall Study|Protocol Violation|1
6344948|NCT03395353|10103776|FG000|Overall Study|Lack of Efficacy|3
6344949|NCT03395353|10103776|FG000|Overall Study|Withdrawal by Subject|24
6344950|NCT03395353|10103776|FG000|Overall Study|Discontinued visit|1
6344951|NCT03395353|10103776|FG000|Overall Study|Refrain from visit due to COVID-19|1
6344952|NCT03395353|10103776|FG000|Overall Study|Physician Decision|4
6344953|NCT03395353|10103776|FG000|Overall Study|Early termination of overall study|33
6344954|NCT03396835|10103817|FG000|Overall Study|Withdrawn prior to completion|1
6344955|NCT03396835|10103817|FG000|Overall Study|Did not meet criteria for data analysis|1
6344956|NCT03396913|10103823|FG000|Overall Study|Lost to Follow-up|0
6344957|NCT03396913|10103824|FG001|Overall Study|Lost to Follow-up|6
6344958|NCT03397771|10103861|FG000|Overall Study|2 erroneously randomized, never treated|3
6344959|NCT03397771|10103862|FG001|Overall Study|2 erroneously randomized, never treated|1
6344960|NCT03397771|10103861|FG000|Overall Study|Withdrawal by Subject|1
6344961|NCT03397771|10103862|FG001|Overall Study|Withdrawal by Subject|3
6344962|NCT03397771|10103861|FG000|Overall Study|Protocol Violation|2
6344963|NCT03397771|10103862|FG001|Overall Study|Protocol Violation|2
6344964|NCT03397771|10103861|FG000|Overall Study|Adverse Event|2
6344965|NCT03397771|10103862|FG001|Overall Study|Adverse Event|1
6344966|NCT03399786|10103984|FG000|Double-blind Treatment Period (DBTP)|Withdrawal by Subject|1
6344967|NCT03399786|10103985|FG001|Double-blind Treatment Period (DBTP)|Withdrawal by Subject|0
6344968|NCT03399786|10103986|FG002|Double-blind Treatment Period (DBTP)|Withdrawal by Subject|0
6344969|NCT03399786|10103987|FG003|Double-blind Treatment Period (DBTP)|Withdrawal by Subject|0
6344970|NCT03399786|10103984|FG000|Open-label Treatment Period (OLTP)|Noncompliance with protocol by the participant|0
6344971|NCT03399786|10103985|FG001|Open-label Treatment Period (OLTP)|Noncompliance with protocol by the participant|0
6344972|NCT03399786|10103986|FG002|Open-label Treatment Period (OLTP)|Noncompliance with protocol by the participant|1
6344973|NCT03399786|10103987|FG003|Open-label Treatment Period (OLTP)|Noncompliance with protocol by the participant|0
6344974|NCT03399786|10103984|FG000|Open-label Treatment Period (OLTP)|Pregnancy|0
6344975|NCT03399786|10103985|FG001|Open-label Treatment Period (OLTP)|Pregnancy|0
6344976|NCT03399786|10103986|FG002|Open-label Treatment Period (OLTP)|Pregnancy|0
6344977|NCT03399786|10103987|FG003|Open-label Treatment Period (OLTP)|Pregnancy|1
6344978|NCT03400033|10103997|FG000|Overall Study|Withdrawal by Subject|1
6344979|NCT03400033|10103998|FG001|Overall Study|Withdrawal by Subject|2
6344980|NCT03400787|10104053|FG000|Overall Study|Lost to Follow-up|1
6344981|NCT03400787|10104054|FG001|Overall Study|Lost to Follow-up|0
6344982|NCT03400787|10104053|FG000|Overall Study|Death|1
6344983|NCT03400787|10104054|FG001|Overall Study|Death|0
6344984|NCT03400787|10104053|FG000|Overall Study|Protocol Violation|0
6344985|NCT03400787|10104054|FG001|Overall Study|Protocol Violation|2
6344986|NCT03400787|10104053|FG000|Overall Study|Unblinded before 3-month follow-upa-|0
6344987|NCT03400787|10104054|FG001|Overall Study|Unblinded before 3-month follow-upa-|6
6344988|NCT03400852|10104071|FG000|Blinded Treatment Period|Physician Decision|0
6344989|NCT03400852|10104072|FG001|Blinded Treatment Period|Physician Decision|1
6344990|NCT03400852|10104073|FG002|Blinded Treatment Period|Physician Decision|0
6344991|NCT03400852|10104071|FG000|Blinded Treatment Period|Adverse Event|1
6344992|NCT03400852|10104072|FG001|Blinded Treatment Period|Adverse Event|1
6344993|NCT03400852|10104073|FG002|Blinded Treatment Period|Adverse Event|0
6344994|NCT03400852|10104071|FG000|Blinded Treatment Period|Study terminated by sponsor|8
6344995|NCT03400852|10104072|FG001|Blinded Treatment Period|Study terminated by sponsor|4
6344996|NCT03400852|10104073|FG002|Blinded Treatment Period|Study terminated by sponsor|0
6344997|NCT03400852|10104071|FG000|Open Label Period|Physician Decision|0
6344998|NCT03400852|10104072|FG001|Open Label Period|Physician Decision|0
6344999|NCT03400852|10104073|FG002|Open Label Period|Physician Decision|1
6345000|NCT03400852|10104071|FG000|Open Label Period|Study terminated by sponsor|0
6345001|NCT03400852|10104072|FG001|Open Label Period|Study terminated by sponsor|0
6345002|NCT03400852|10104073|FG002|Open Label Period|Study terminated by sponsor|21
6345003|NCT03400956|10104084|FG000|Treatment Period 1|Adverse Event|0
6345004|NCT03400956|10104085|FG001|Treatment Period 1|Adverse Event|1
6345005|NCT03400956|10104086|FG002|Treatment Period 1|Adverse Event|0
6345006|NCT03400956|10104084|FG000|Treatment Period 1|Lost to Follow-up|0
6345007|NCT03400956|10104085|FG001|Treatment Period 1|Lost to Follow-up|0
6345008|NCT03400956|10104086|FG002|Treatment Period 1|Lost to Follow-up|1
6345009|NCT03400956|10104084|FG000|Treatment Period 1|Protocol Violation|0
6345010|NCT03400956|10104085|FG001|Treatment Period 1|Protocol Violation|2
6345011|NCT03400956|10104086|FG002|Treatment Period 1|Protocol Violation|0
6345012|NCT03400956|10104084|FG000|Treatment Period 1|Study terminated by sponsor|3
6345013|NCT03400956|10104085|FG001|Treatment Period 1|Study terminated by sponsor|1
6345014|NCT03400956|10104086|FG002|Treatment Period 1|Study terminated by sponsor|1
6345015|NCT03400956|10104084|FG000|Treatment Period 1|Withdrawal by Subject|0
6345016|NCT03400956|10104085|FG001|Treatment Period 1|Withdrawal by Subject|2
6345017|NCT03400956|10104086|FG002|Treatment Period 1|Withdrawal by Subject|4
6345018|NCT03400956|10104084|FG000|Treatment Period 1|Other|1
6345019|NCT03400956|10104085|FG001|Treatment Period 1|Other|2
6345020|NCT03400956|10104086|FG002|Treatment Period 1|Other|3
6345021|NCT03400956|10104084|FG000|Post-treatment Period 1|Adverse Event|0
6345022|NCT03400956|10104085|FG001|Post-treatment Period 1|Adverse Event|0
6345023|NCT03400956|10104086|FG002|Post-treatment Period 1|Adverse Event|1
6345024|NCT03400956|10104084|FG000|Post-treatment Period 1|Physician Decision|2
6345025|NCT03400956|10104085|FG001|Post-treatment Period 1|Physician Decision|3
6345026|NCT03400956|10104086|FG002|Post-treatment Period 1|Physician Decision|0
6345027|NCT03400956|10104084|FG000|Post-treatment Period 1|Study terminated by sponsor|11
6345028|NCT03400956|10104085|FG001|Post-treatment Period 1|Study terminated by sponsor|10
6345029|NCT03400956|10104086|FG002|Post-treatment Period 1|Study terminated by sponsor|11
6345030|NCT03400956|10104084|FG000|Post-treatment Period 1|Withdrawal by Subject|5
6168797|NCT01237678|9813926|FG000|Phase II|Adverse Event|0
6168798|NCT01237678|9813927|FG001|Phase II|Adverse Event|39
6168799|NCT01237678|9813928|FG002|Phase II|Adverse Event|9
6168800|NCT01237678|9813926|FG000|Phase II|Death|0
6168801|NCT01237678|9813927|FG001|Phase II|Death|0
6168802|NCT01237678|9813928|FG002|Phase II|Death|2
6168803|NCT01237678|9813926|FG000|Phase II|Lack of Efficacy|0
6168804|NCT01237678|9813927|FG001|Phase II|Lack of Efficacy|25
6168805|NCT01237678|9813928|FG002|Phase II|Lack of Efficacy|3
6168806|NCT01237678|9813926|FG000|Phase II|Withdrawal by Subject|0
6168807|NCT01237678|9813927|FG001|Phase II|Withdrawal by Subject|1
6168808|NCT01237678|9813928|FG002|Phase II|Withdrawal by Subject|5
6168809|NCT01237678|9813926|FG000|Phase II|Completed Cycles 4-6|0
6168810|NCT01237678|9813927|FG001|Phase II|Completed Cycles 4-6|11
6168811|NCT01237678|9813928|FG002|Phase II|Completed Cycles 4-6|21
6168812|NCT01237678|9813926|FG000|Phase II|Sponsor Decision/Study Closed|0
6168813|NCT01237678|9813927|FG001|Phase II|Sponsor Decision/Study Closed|18
6168814|NCT01237678|9813928|FG002|Phase II|Sponsor Decision/Study Closed|7
6168815|NCT01237678|9813926|FG000|Phase II|Randomized but were not treated|0
6168816|NCT01237678|9813927|FG001|Phase II|Randomized but were not treated|4
6168817|NCT01237678|9813928|FG002|Phase II|Randomized but were not treated|3
6168818|NCT01237899|9813963|FG000|Washout Period of at Least 7 Days|Adverse Event|0
6168819|NCT01237899|9813964|FG001|Washout Period of at Least 7 Days|Adverse Event|0
6168820|NCT01237899|9813965|FG002|Washout Period of at Least 7 Days|Adverse Event|1
6168821|NCT01237899|9813966|FG003|Washout Period of at Least 7 Days|Adverse Event|0
6168822|NCT01237899|9813967|FG004|Washout Period of at Least 7 Days|Adverse Event|0
6168823|NCT01237899|9813968|FG005|Washout Period of at Least 7 Days|Adverse Event|0
6168824|NCT01237899|9813969|FG006|Washout Period of at Least 7 Days|Adverse Event|0
6168825|NCT01237899|9813970|FG007|Washout Period of at Least 7 Days|Adverse Event|0
6168826|NCT01237899|9813971|FG008|Washout Period of at Least 7 Days|Adverse Event|0
6168827|NCT01237899|9813972|FG009|Washout Period of at Least 7 Days|Adverse Event|0
6168828|NCT01237899|9813973|FG010|Washout Period of at Least 7 Days|Adverse Event|0
6168829|NCT01237951|9813991|FG000|Overall Study|Death|1
6168830|NCT01238120|9813999|FG000|Overall Study|Withdrawal by Subject|4
6168831|NCT01238120|9814000|FG001|Overall Study|Withdrawal by Subject|1
6168832|NCT01238120|9814001|FG002|Overall Study|Withdrawal by Subject|2
6168833|NCT01238120|9814002|FG003|Overall Study|Withdrawal by Subject|5
6168834|NCT01238120|9813999|FG000|Overall Study|Lost to Follow-up|2
6168835|NCT01238120|9814000|FG001|Overall Study|Lost to Follow-up|0
6168836|NCT01238120|9814001|FG002|Overall Study|Lost to Follow-up|1
6168837|NCT01238120|9814002|FG003|Overall Study|Lost to Follow-up|1
6168838|NCT01238120|9813999|FG000|Overall Study|Withdrawn due to Medical Problem|2
6345031|NCT03400956|10104085|FG001|Post-treatment Period 1|Withdrawal by Subject|0
6345032|NCT03400956|10104086|FG002|Post-treatment Period 1|Withdrawal by Subject|0
6345033|NCT03400956|10104084|FG000|Post-treatment Period 1|Other|4
6168839|NCT01238120|9814000|FG001|Overall Study|Withdrawn due to Medical Problem|0
6168840|NCT01238120|9814001|FG002|Overall Study|Withdrawn due to Medical Problem|1
6168841|NCT01238120|9814002|FG003|Overall Study|Withdrawn due to Medical Problem|0
6168842|NCT01238172|9814014|FG000|Overall Study|Ineligible: based on Eligibility Review|2
6345034|NCT03400956|10104085|FG001|Post-treatment Period 1|Other|3
6168843|NCT01238172|9814015|FG001|Overall Study|Ineligible: based on Eligibility Review|5
6168844|NCT01238172|9814014|FG000|Overall Study|Ineligible: based on Central Path Review|9
6345035|NCT03400956|10104086|FG002|Post-treatment Period 1|Other|4
6345036|NCT03400956|10104084|FG000|Treatment Period 2|Adverse Event|2
6345037|NCT03400956|10104085|FG001|Treatment Period 2|Adverse Event|1
6345038|NCT03400956|10104086|FG002|Treatment Period 2|Adverse Event|1
6345039|NCT03400956|10104084|FG000|Treatment Period 2|Lost to Follow-up|1
6345040|NCT03400956|10104085|FG001|Treatment Period 2|Lost to Follow-up|1
6345041|NCT03400956|10104086|FG002|Treatment Period 2|Lost to Follow-up|0
6345042|NCT03400956|10104084|FG000|Treatment Period 2|Withdrawal by Subject|0
6345043|NCT03400956|10104085|FG001|Treatment Period 2|Withdrawal by Subject|0
6345044|NCT03400956|10104086|FG002|Treatment Period 2|Withdrawal by Subject|3
6345045|NCT03400956|10104084|FG000|Treatment Period 2|Other|1
6345046|NCT03400956|10104085|FG001|Treatment Period 2|Other|1
6345047|NCT03400956|10104086|FG002|Treatment Period 2|Other|0
6345048|NCT03400956|10104084|FG000|Follow-up Period|Withdrawal by Subject|0
6345049|NCT03400956|10104085|FG001|Follow-up Period|Withdrawal by Subject|0
6345050|NCT03400956|10104086|FG002|Follow-up Period|Withdrawal by Subject|1
6345051|NCT03400956|10104084|FG000|Follow-up Period|Other|0
6345052|NCT03400956|10104085|FG001|Follow-up Period|Other|0
6345053|NCT03400956|10104086|FG002|Follow-up Period|Other|1
6345054|NCT03401229|10104099|FG000|Overall Study|Lost to Follow-up|2
6345055|NCT03401229|10104100|FG001|Overall Study|Lost to Follow-up|1
6345056|NCT03401229|10104099|FG000|Overall Study|Other|1
6345057|NCT03401229|10104100|FG001|Overall Study|Other|3
6345058|NCT03401229|10104099|FG000|Overall Study|Adverse Event|8
6345059|NCT03401229|10104100|FG001|Overall Study|Adverse Event|6
6345060|NCT03401229|10104099|FG000|Overall Study|Withdrawal by Subject|29
6345061|NCT03401229|10104100|FG001|Overall Study|Withdrawal by Subject|26
6345062|NCT03401229|10104099|FG000|Overall Study|COVID-19|0
6345063|NCT03401229|10104100|FG001|Overall Study|COVID-19|1
6345064|NCT03401450|10104108|FG000|Overall Study|Lost to Follow-up|4
6345065|NCT03401450|10104109|FG001|Overall Study|Lost to Follow-up|6
6345066|NCT03401450|10104108|FG000|Overall Study|Anesthesia plan changed|2
6345067|NCT03401450|10104109|FG001|Overall Study|Anesthesia plan changed|2
6345068|NCT03401450|10104108|FG000|Overall Study|Did not complete medication diary|4
6345069|NCT03401450|10104109|FG001|Overall Study|Did not complete medication diary|2
6345070|NCT03401450|10104108|FG000|Overall Study|post surgery medication change|2
6345071|NCT03401450|10104109|FG001|Overall Study|post surgery medication change|1
6345072|NCT03401450|10104108|FG000|Overall Study|Cancelled surgery|0
6345073|NCT03401450|10104109|FG001|Overall Study|Cancelled surgery|2
6345074|NCT03402126|10104124|FG000|Overall Study|Lost to Follow-up|6
6345075|NCT03402126|10104124|FG000|Overall Study|Protocol Violation|10
6345076|NCT03402126|10104124|FG000|Overall Study|Sponsor request/Study termination|29
6345077|NCT03402126|10104124|FG000|Overall Study|Study product no longer in use|1
6345078|NCT03402126|10104124|FG000|Overall Study|Technical problems|1
6345079|NCT03402126|10104124|FG000|Overall Study|Withdrawal by Subject|6
6345080|NCT03402126|10104124|FG000|Overall Study|Physician Decision|2
6345081|NCT03402126|10104124|FG000|Overall Study|upgrade to Cardiac Resynchronization Therapy-Defibrillator/stage IV cancer|3
6345082|NCT03402126|10104124|FG000|Overall Study|Death|4
6345083|NCT03402386|10104141|FG000|Overall Study|Adverse Event|3
6345084|NCT03402386|10104141|FG000|Overall Study|Physician Decision|1
6345085|NCT03402386|10104141|FG000|Overall Study|Difficult to control Hb|2
6345086|NCT03402750|10104160|FG000|Overall Study|Lost to Follow-up|2
6345087|NCT03402750|10104161|FG001|Overall Study|Lost to Follow-up|1
6345088|NCT03402893|10104167|FG000|Overall Study|Withdrawal by Subject|1
6345089|NCT03403036|10104193|FG000|Overall Study|Lack of Efficacy|5
6345090|NCT03403192|10104201|FG000|Overall Study|Lost to Follow-up|1
6345091|NCT03403192|10104202|FG001|Overall Study|Lost to Follow-up|2
6345092|NCT03403192|10104203|FG002|Overall Study|Lost to Follow-up|0
6345093|NCT03403192|10104204|FG003|Overall Study|Lost to Follow-up|0
6345094|NCT03403192|10104201|FG000|Overall Study|Unable to respond|0
6345095|NCT03403192|10104202|FG001|Overall Study|Unable to respond|1
6345096|NCT03403192|10104203|FG002|Overall Study|Unable to respond|0
6345097|NCT03403192|10104204|FG003|Overall Study|Unable to respond|0
6345098|NCT03403192|10104201|FG000|Overall Study|Incomplete|3
6345099|NCT03403192|10104202|FG001|Overall Study|Incomplete|1
6345100|NCT03403192|10104203|FG002|Overall Study|Incomplete|3
6345101|NCT03403192|10104204|FG003|Overall Study|Incomplete|6
6345102|NCT03403374|10104279|FG000|Overall Study|Lost to Follow-up|1
6345103|NCT03403400|10104286|FG000|Overall Study|Lost to Follow-up|1
6168845|NCT01238172|9814015|FG001|Overall Study|Ineligible: based on Central Path Review|19
6168846|NCT01238575|9814051|FG000|Overall Study|Lack of Efficacy|2
6168847|NCT01238575|9814052|FG001|Overall Study|Lack of Efficacy|4
6168848|NCT01238575|9814051|FG000|Overall Study|Adverse Event|2
6168849|NCT01238575|9814052|FG001|Overall Study|Adverse Event|0
6168850|NCT01238588|9814058|FG000|Overall Study|Withdrawal by Subject|1
6168851|NCT01238588|9814058|FG000|Overall Study|Physician Decision|2
6168852|NCT01238822|9814070|FG000|Overall Study|COULD NOT SWALLOW PILLS|3
6345104|NCT03403400|10104287|FG001|Overall Study|Lost to Follow-up|0
6345105|NCT03403400|10104288|FG002|Overall Study|Lost to Follow-up|1
6345106|NCT03403400|10104286|FG000|Overall Study|Hospitalization|1
6168853|NCT01238835|9814080|FG000|Overall Study|Death|124
6168854|NCT01238835|9814080|FG000|Overall Study|Withdrawal by Subject|9
6345107|NCT03403400|10104287|FG001|Overall Study|Hospitalization|0
6345108|NCT03403400|10104288|FG002|Overall Study|Hospitalization|0
6345109|NCT03403400|10104286|FG000|Overall Study|Benign Paroxysmal Positional Vertigo|0
6345110|NCT03403400|10104287|FG001|Overall Study|Benign Paroxysmal Positional Vertigo|0
6345111|NCT03403400|10104288|FG002|Overall Study|Benign Paroxysmal Positional Vertigo|1
6345112|NCT03403413|10104311|FG000|Overall Study|Lack of Efficacy|2
6345113|NCT03403426|10104317|FG000|Overall Study|Death|1
6345114|NCT03403426|10104317|FG000|Overall Study|Lost to Follow-up|2
6345115|NCT03403751|10104419|FG000|Overall Study|Death|5
6345116|NCT03403751|10104420|FG001|Overall Study|Death|6
6345117|NCT03403751|10104419|FG000|Overall Study|Discontinuation (includes missing from Day 29)|2
6345118|NCT03403751|10104420|FG001|Overall Study|Discontinuation (includes missing from Day 29)|2
6345119|NCT03404206|10104437|FG000|Overall Study|Withdrawal by Subject|1
6345120|NCT03404206|10104438|FG001|Overall Study|Withdrawal by Subject|1
6345121|NCT03404206|10104439|FG002|Overall Study|Withdrawal by Subject|0
6345122|NCT03404206|10104437|FG000|Overall Study|Lost to Follow-up|3
6345123|NCT03404206|10104438|FG001|Overall Study|Lost to Follow-up|1
6345124|NCT03404206|10104439|FG002|Overall Study|Lost to Follow-up|0
6345125|NCT03404674|10104484|FG000|Overall Study|Inability to Attend Future Visits|0
6345126|NCT03404674|10104485|FG001|Overall Study|Inability to Attend Future Visits|1
6345127|NCT03404674|10104486|FG002|Overall Study|Inability to Attend Future Visits|1
6345128|NCT03404674|10104487|FG003|Overall Study|Inability to Attend Future Visits|0
6345129|NCT03404674|10104488|FG004|Overall Study|Inability to Attend Future Visits|0
6345130|NCT03404674|10104489|FG005|Overall Study|Inability to Attend Future Visits|0
6345131|NCT03404674|10104484|FG000|Overall Study|Behavioral Problems|0
6345132|NCT03404674|10104485|FG001|Overall Study|Behavioral Problems|0
6345133|NCT03404674|10104486|FG002|Overall Study|Behavioral Problems|1
6345134|NCT03404674|10104487|FG003|Overall Study|Behavioral Problems|0
6345135|NCT03404674|10104488|FG004|Overall Study|Behavioral Problems|0
6345136|NCT03404674|10104489|FG005|Overall Study|Behavioral Problems|0
6345137|NCT03404674|10104484|FG000|Overall Study|Started a Medication that Precluded Eligibility|0
6345138|NCT03404674|10104485|FG001|Overall Study|Started a Medication that Precluded Eligibility|0
6345139|NCT03404674|10104486|FG002|Overall Study|Started a Medication that Precluded Eligibility|0
6345140|NCT03404674|10104487|FG003|Overall Study|Started a Medication that Precluded Eligibility|1
6345141|NCT03404674|10104488|FG004|Overall Study|Started a Medication that Precluded Eligibility|0
6345142|NCT03404674|10104489|FG005|Overall Study|Started a Medication that Precluded Eligibility|1
6345143|NCT03404843|10104506|FG000|Overall Study|Study difficulties unrelated to Tx|4
6345144|NCT03404843|10104507|FG001|Overall Study|Study difficulties unrelated to Tx|1
6345145|NCT03405818|10104535|FG000|Overall Study|Withdrawal by Subject|4
6345146|NCT03405818|10104535|FG000|Overall Study|Lost to Follow-up|4
6345147|NCT03405935|10104539|FG000|Overall Study|Adverse Event|3
6345148|NCT03405935|10104539|FG000|Overall Study|Death|2
6345149|NCT03405935|10104539|FG000|Overall Study|Withdrawal by Subject|1
6345150|NCT03405935|10104539|FG000|Overall Study|Lost to Follow-up|2
6345151|NCT03406260|10104549|FG000|Period 1|Adverse Event|0
6345152|NCT03406260|10104550|FG001|Period 1|Adverse Event|0
6345153|NCT03406260|10104551|FG002|Period 1|Adverse Event|0
6345154|NCT03406260|10104552|FG003|Period 1|Adverse Event|0
6345155|NCT03406260|10104553|FG004|Period 1|Adverse Event|1
6345156|NCT03406260|10104554|FG005|Period 1|Adverse Event|0
6345157|NCT03406962|10104620|FG000|Overall Study|Death|2
6345158|NCT03406962|10104620|FG000|Overall Study|Adverse Event|1
6345159|NCT03407118|10104634|FG000|Period 2|Withdrawal by Subject|1
6345160|NCT03407118|10104635|FG001|Period 2|Withdrawal by Subject|0
6345161|NCT03407170|10104641|FG000|Overall Study|Adverse Event|1
6083362|NCT00634933|9691717|FG003|Part A: Baseline to Week 24|Withdrawal by Subject|0
6083363|NCT00634933|9691718|FG004|Part A: Baseline to Week 24|Withdrawal by Subject|0
6345162|NCT03407430|10104651|FG000|Washout|Protocol Violation|1
6345163|NCT03407430|10104652|FG001|Washout|Protocol Violation|0
6345164|NCT03407482|10104665|FG000|Overall Study|Adverse Event|12
6345165|NCT03407482|10104665|FG000|Overall Study|Disease Relapse|1
6345166|NCT03407482|10104665|FG000|Overall Study|Lost to Follow-up|1
6345167|NCT03407482|10104665|FG000|Overall Study|Non-Compliance With Study Drug|1
6345168|NCT03407482|10104665|FG000|Overall Study|Pregnancy|2
6345169|NCT03407482|10104665|FG000|Overall Study|Protocol Violation|1
6345170|NCT03407482|10104665|FG000|Overall Study|Study Terminated By Sponsor|106
6345171|NCT03407482|10104665|FG000|Overall Study|Withdrawal by Subject|6
6345172|NCT03407482|10104665|FG000|Overall Study|Data Entry Error|1
6345173|NCT03408483|10104725|FG000|Overall Study|Physician Decision|3
6345174|NCT03408483|10104726|FG001|Overall Study|Physician Decision|3
6345175|NCT03408483|10104725|FG000|Overall Study|Lost to Follow-up|3
6345176|NCT03408483|10104726|FG001|Overall Study|Lost to Follow-up|0
6345177|NCT03408639|10104734|FG000|Overall Study|Death|5
6345178|NCT03408639|10104735|FG001|Overall Study|Death|5
6345179|NCT03408639|10104734|FG000|Overall Study|Lost to Follow-up|1
6345180|NCT03408639|10104735|FG001|Overall Study|Lost to Follow-up|4
6345181|NCT03408639|10104734|FG000|Overall Study|Withdrawal by Subject|2
6345182|NCT03408639|10104735|FG001|Overall Study|Withdrawal by Subject|7
6345183|NCT03408639|10104734|FG000|Overall Study|Physician Decision|3
6345184|NCT03408639|10104735|FG001|Overall Study|Physician Decision|6
6345185|NCT03409107|10104773|FG000|Overall Study|Withdrawal by Subject|4
6345186|NCT03409107|10104774|FG001|Overall Study|Withdrawal by Subject|2
6345187|NCT03409107|10104773|FG000|Overall Study|Physician Decision|1
6345188|NCT03409107|10104774|FG001|Overall Study|Physician Decision|0
6345189|NCT03409107|10104773|FG000|Overall Study|Lost to Follow-up|7
6345190|NCT03409107|10104774|FG001|Overall Study|Lost to Follow-up|2
6345191|NCT03409107|10104773|FG000|Overall Study|Adverse Event|5
6345192|NCT03409107|10104774|FG001|Overall Study|Adverse Event|3
6345193|NCT03410056|10104784|FG000|Overall Study|Decision by Sponsor|0
6345194|NCT03410056|10104785|FG001|Overall Study|Decision by Sponsor|0
6345195|NCT03410056|10104786|FG002|Overall Study|Decision by Sponsor|3
6345196|NCT03410056|10104787|FG003|Overall Study|Decision by Sponsor|0
6345197|NCT03410056|10104788|FG004|Overall Study|Decision by Sponsor|0
6345198|NCT03410056|10104789|FG005|Overall Study|Decision by Sponsor|0
6345199|NCT03410056|10104790|FG006|Overall Study|Decision by Sponsor|0
6345200|NCT03410056|10104784|FG000|Overall Study|Withdrawal by Subject|0
6345201|NCT03410056|10104785|FG001|Overall Study|Withdrawal by Subject|2
6345202|NCT03410056|10104786|FG002|Overall Study|Withdrawal by Subject|5
6345203|NCT03410056|10104787|FG003|Overall Study|Withdrawal by Subject|5
6345204|NCT03410056|10104788|FG004|Overall Study|Withdrawal by Subject|0
6345205|NCT03410056|10104789|FG005|Overall Study|Withdrawal by Subject|0
6345206|NCT03410056|10104790|FG006|Overall Study|Withdrawal by Subject|0
6345207|NCT03411902|10104834|FG000|Overall Study|Lost to Follow-up|3
6345208|NCT03411902|10104835|FG001|Overall Study|Lost to Follow-up|0
6345209|NCT03412019|10104843|FG000|Overall Study|Withdrawal by Subject|1
6345210|NCT03412019|10104844|FG001|Overall Study|Withdrawal by Subject|1
6345211|NCT03412084|10104852|FG000|Overall Study|Withdrawal by Subject|2
6345212|NCT03412084|10104853|FG001|Overall Study|Withdrawal by Subject|0
6345213|NCT03412084|10104852|FG000|Overall Study|Participant moved|1
6345214|NCT03412084|10104853|FG001|Overall Study|Participant moved|0
6345215|NCT03412084|10104852|FG000|Overall Study|Lost to Follow-up|1
6345216|NCT03412084|10104853|FG001|Overall Study|Lost to Follow-up|1
6345217|NCT03412734|10104861|FG000|Overall Study|Incorrect labeling of samples|2
6345218|NCT03412734|10104862|FG001|Overall Study|Incorrect labeling of samples|0
6345219|NCT03412734|10104861|FG000|Overall Study|Exclusion criteria - patient receiving Flagyl for treatment|1
6345220|NCT03412734|10104862|FG001|Overall Study|Exclusion criteria - patient receiving Flagyl for treatment|0
6345221|NCT03412929|10104868|FG000|Overall Study|Protocol Violation|3
6345222|NCT03414047|10104885|FG000|Overall Study|Adverse Event|0
6345223|NCT03414047|10104886|FG001|Overall Study|Adverse Event|0
6345224|NCT03414047|10104887|FG002|Overall Study|Adverse Event|1
6345225|NCT03414047|10104888|FG003|Overall Study|Adverse Event|1
6345226|NCT03414047|10104885|FG000|Overall Study|Physician Decision|1
6345227|NCT03414047|10104886|FG001|Overall Study|Physician Decision|0
6345228|NCT03414047|10104887|FG002|Overall Study|Physician Decision|0
6345229|NCT03414047|10104888|FG003|Overall Study|Physician Decision|1
6345230|NCT03414047|10104885|FG000|Overall Study|Withdrawal by Subject|1
6345231|NCT03414047|10104886|FG001|Overall Study|Withdrawal by Subject|0
6345232|NCT03414047|10104887|FG002|Overall Study|Withdrawal by Subject|2
6345233|NCT03414047|10104888|FG003|Overall Study|Withdrawal by Subject|0
6345234|NCT03414359|10104901|FG000|Overall Study|Lack of Efficacy|1
6345235|NCT03414359|10104902|FG001|Overall Study|Lack of Efficacy|1
6345236|NCT03414359|10104901|FG000|Overall Study|Protocol Violation|0
6345237|NCT03414359|10104902|FG001|Overall Study|Protocol Violation|1
6345238|NCT03415178|10104917|FG000|Parallel-Arm Period (up to Week 4)|Randomized but not treated|0
6345239|NCT03415178|10104918|FG001|Parallel-Arm Period (up to Week 4)|Randomized but not treated|2
6345240|NCT03415178|10104917|FG000|Single Arm Period (up to Week 16)|Adverse Event|0
6345241|NCT03415178|10104918|FG001|Single Arm Period (up to Week 16)|Adverse Event|1
6345242|NCT03416127|10104951|FG000|Overall Study|Withdrawal by Subject|0
6345243|NCT03416127|10104952|FG001|Overall Study|Withdrawal by Subject|1
6345244|NCT03416127|10104953|FG002|Overall Study|Withdrawal by Subject|1
6345245|NCT03417024|10105002|FG000|Overall Study|Study Termination prior to follow-up|11
6345246|NCT03417024|10105002|FG000|Overall Study|Physician Decision|2
6345247|NCT03417141|10105006|FG000|Overall Study|Withdrawal by Subject|1
6345248|NCT03417141|10105006|FG000|Overall Study|Protocol Violation|3
6345249|NCT03417219|10105012|FG000|Overall Study|Lost to Follow-up|0
6345250|NCT03417219|10105013|FG001|Overall Study|Lost to Follow-up|3
6345251|NCT03417505|10105023|FG000|First Lens Type (30 Days)|Lost to Follow-up|1
6345252|NCT03417505|10105024|FG001|First Lens Type (30 Days)|Lost to Follow-up|1
6345253|NCT03417830|10105074|FG000|Part A (up to 26 Days)|Study Closed/Terminated|1
6345254|NCT03417830|10105075|FG001|Part A (up to 26 Days)|Study Closed/Terminated|0
6345255|NCT03418324|10105112|FG000|Overall Study|Death|0
6345256|NCT03418324|10105113|FG001|Overall Study|Death|1
6345257|NCT03418324|10105112|FG000|Overall Study|Physician Decision|1
6345258|NCT03418324|10105113|FG001|Overall Study|Physician Decision|1
6345259|NCT03418376|10105123|FG000|Overall Study|Musculoskeletal injury|1
6345260|NCT03418376|10105124|FG001|Overall Study|Musculoskeletal injury|2
6345261|NCT03418376|10105125|FG002|Overall Study|Musculoskeletal injury|1
6345262|NCT03418376|10105126|FG003|Overall Study|Musculoskeletal injury|0
6345263|NCT03418376|10105123|FG000|Overall Study|Personal reasons|0
6345264|NCT03418376|10105124|FG001|Overall Study|Personal reasons|2
6345265|NCT03418376|10105125|FG002|Overall Study|Personal reasons|2
6345266|NCT03418376|10105126|FG003|Overall Study|Personal reasons|1
6345267|NCT03418376|10105123|FG000|Overall Study|Exacerbation|0
6345268|NCT03418376|10105124|FG001|Overall Study|Exacerbation|1
6345269|NCT03418376|10105125|FG002|Overall Study|Exacerbation|0
6345270|NCT03418376|10105126|FG003|Overall Study|Exacerbation|0
6168855|NCT01238835|9814080|FG000|Overall Study|Lost to Follow-up|1
6168856|NCT01238835|9814080|FG000|Overall Study|Site early discontinuation|2
6168857|NCT01238848|9814086|FG000|Overall Study|Physician Decision|13
6168858|NCT01238848|9814087|FG001|Overall Study|Physician Decision|5
6168859|NCT01238861|9814099|FG000|Overall Study|Lost to Follow-up|4
6168860|NCT01238861|9814100|FG001|Overall Study|Lost to Follow-up|2
6168861|NCT01238861|9814101|FG002|Overall Study|Lost to Follow-up|3
6168862|NCT01238861|9814102|FG003|Overall Study|Lost to Follow-up|1
6168863|NCT01238861|9814103|FG004|Overall Study|Lost to Follow-up|1
6168864|NCT01238861|9814104|FG005|Overall Study|Lost to Follow-up|2
6168865|NCT01238861|9814099|FG000|Overall Study|Unplanned surgery|1
6168866|NCT01238861|9814100|FG001|Overall Study|Unplanned surgery|0
6168867|NCT01238861|9814101|FG002|Overall Study|Unplanned surgery|0
6168868|NCT01238861|9814102|FG003|Overall Study|Unplanned surgery|0
6168869|NCT01238861|9814103|FG004|Overall Study|Unplanned surgery|0
6168870|NCT01238861|9814104|FG005|Overall Study|Unplanned surgery|0
6168871|NCT01238861|9814099|FG000|Overall Study|Did not meet entry ACQ-6 criteria|0
6168872|NCT01238861|9814100|FG001|Overall Study|Did not meet entry ACQ-6 criteria|0
6168873|NCT01238861|9814101|FG002|Overall Study|Did not meet entry ACQ-6 criteria|1
6168874|NCT01238861|9814102|FG003|Overall Study|Did not meet entry ACQ-6 criteria|0
6168875|NCT01238861|9814103|FG004|Overall Study|Did not meet entry ACQ-6 criteria|1
6168876|NCT01238861|9814104|FG005|Overall Study|Did not meet entry ACQ-6 criteria|1
6168877|NCT01238861|9814099|FG000|Overall Study|Incorrect enrollment/randomization|0
6168878|NCT01238861|9814100|FG001|Overall Study|Incorrect enrollment/randomization|0
6168879|NCT01238861|9814101|FG002|Overall Study|Incorrect enrollment/randomization|1
6168880|NCT01238861|9814102|FG003|Overall Study|Incorrect enrollment/randomization|0
6168881|NCT01238861|9814103|FG004|Overall Study|Incorrect enrollment/randomization|1
6168882|NCT01238861|9814104|FG005|Overall Study|Incorrect enrollment/randomization|0
6168883|NCT01238861|9814099|FG000|Overall Study|Subject traveled to Argentina by 1 year|0
6168884|NCT01238861|9814100|FG001|Overall Study|Subject traveled to Argentina by 1 year|0
6168885|NCT01238861|9814101|FG002|Overall Study|Subject traveled to Argentina by 1 year|1
6168886|NCT01238861|9814102|FG003|Overall Study|Subject traveled to Argentina by 1 year|0
6168887|NCT01238861|9814103|FG004|Overall Study|Subject traveled to Argentina by 1 year|0
6168888|NCT01238861|9814104|FG005|Overall Study|Subject traveled to Argentina by 1 year|0
6168889|NCT01238861|9814099|FG000|Overall Study|Subject moved out of state/area|0
6168890|NCT01238861|9814100|FG001|Overall Study|Subject moved out of state/area|0
6168891|NCT01238861|9814101|FG002|Overall Study|Subject moved out of state/area|1
6168892|NCT01238861|9814102|FG003|Overall Study|Subject moved out of state/area|1
6168893|NCT01238861|9814103|FG004|Overall Study|Subject moved out of state/area|0
6168894|NCT01238861|9814104|FG005|Overall Study|Subject moved out of state/area|0
6168895|NCT01238861|9814099|FG000|Overall Study|Strongyloides stercoralis antibodies +|0
6168896|NCT01238861|9814100|FG001|Overall Study|Strongyloides stercoralis antibodies +|0
6168897|NCT01238861|9814101|FG002|Overall Study|Strongyloides stercoralis antibodies +|0
6168898|NCT01238861|9814102|FG003|Overall Study|Strongyloides stercoralis antibodies +|1
6168899|NCT01238861|9814103|FG004|Overall Study|Strongyloides stercoralis antibodies +|0
6168900|NCT01238861|9814104|FG005|Overall Study|Strongyloides stercoralis antibodies +|0
6042980|NCT00386022|9641462|FG000|Plus Estrogen|Lost to Follow-up|2
6042981|NCT00386022|9641463|FG001|Plus Estrogen|Lost to Follow-up|0
6042982|NCT00386022|9641462|FG000|Plus Estrogen|Adverse Event|0
6042983|NCT00386022|9641463|FG001|Plus Estrogen|Adverse Event|1
6042984|NCT00386100|9641473|FG000|Overall Study|Did not receive study medication|6
6042985|NCT00386100|9641474|FG001|Overall Study|Did not receive study medication|4
6042986|NCT00386100|9641473|FG000|Overall Study|Adverse Event|15
6042987|NCT00386100|9641474|FG001|Overall Study|Adverse Event|25
6042988|NCT00386100|9641473|FG000|Overall Study|Death|0
6042989|NCT00386100|9641474|FG001|Overall Study|Death|1
6042990|NCT00386100|9641473|FG000|Overall Study|Insufficient therapeutic effect|30
6042991|NCT00386100|9641474|FG001|Overall Study|Insufficient therapeutic effect|6
6042992|NCT00386100|9641473|FG000|Overall Study|Lost to Follow-up|29
6345271|NCT03418545|10105138|FG000|Overall Study|Withdrawal by Participant|2
6345272|NCT03418545|10105139|FG001|Overall Study|Withdrawal by Participant|4
6345273|NCT03418545|10105138|FG000|Overall Study|Lost to Follow-up|3
6345274|NCT03418545|10105139|FG001|Overall Study|Lost to Follow-up|5
6345275|NCT03418545|10105138|FG000|Overall Study|Reason Not Specified|0
6345276|NCT03418545|10105139|FG001|Overall Study|Reason Not Specified|1
6345277|NCT03418545|10105138|FG000|Overall Study|Missing Completion Status|0
6345278|NCT03418545|10105139|FG001|Overall Study|Missing Completion Status|1
6345279|NCT03418571|10105150|FG000|Overall Study|Consent withdrawn by legal guardian|1
6345280|NCT03418571|10105151|FG001|Overall Study|Consent withdrawn by legal guardian|0
6345281|NCT03419403|10105186|FG000|Overall Study|Withdrawal by Subject|5
6345282|NCT03419403|10105187|FG001|Overall Study|Withdrawal by Subject|2
6345283|NCT03419403|10105188|FG002|Overall Study|Withdrawal by Subject|5
6345284|NCT03419403|10105189|FG003|Overall Study|Withdrawal by Subject|1
6345285|NCT03419403|10105186|FG000|Overall Study|Progressive disease (per protocol)|0
6345286|NCT03419403|10105187|FG001|Overall Study|Progressive disease (per protocol)|2
6345287|NCT03419403|10105188|FG002|Overall Study|Progressive disease (per protocol)|2
6345288|NCT03419403|10105189|FG003|Overall Study|Progressive disease (per protocol)|0
6345289|NCT03419403|10105186|FG000|Overall Study|Other, not specified|6
6345290|NCT03419403|10105187|FG001|Overall Study|Other, not specified|4
6345291|NCT03419403|10105188|FG002|Overall Study|Other, not specified|5
6345292|NCT03419403|10105189|FG003|Overall Study|Other, not specified|1
6345293|NCT03419403|10105186|FG000|Overall Study|Left study due to COVID-19 restrictions|1
6345294|NCT03419403|10105187|FG001|Overall Study|Left study due to COVID-19 restrictions|1
6345295|NCT03419403|10105188|FG002|Overall Study|Left study due to COVID-19 restrictions|0
6345296|NCT03419403|10105189|FG003|Overall Study|Left study due to COVID-19 restrictions|0
6345297|NCT03419598|10105214|FG000|Overall Study|Poor quality CT scans could not be adequately segmented to create virtual patient tibial geometry|2
6345298|NCT03419962|10105229|FG000|Overall Study|Change to other medication|1
6345299|NCT03419962|10105229|FG000|Overall Study|Refusal of continuing with trial drug|1
6345300|NCT03419962|10105229|FG000|Overall Study|Lost to Follow-up|3
6345301|NCT03419962|10105229|FG000|Overall Study|Difficulty in inhaling the doses|1
6345302|NCT03419962|10105229|FG000|Overall Study|Missing completion data|31
6345303|NCT03420300|10105233|FG000|Overall Study|Death|2
6345304|NCT03421379|10105259|FG000|Period 1|Withdrawal by Subject|0
6345305|NCT03421379|10105260|FG001|Period 1|Withdrawal by Subject|1
6345306|NCT03421379|10105259|FG000|Period 1|Physician Decision|1
6345307|NCT03421379|10105260|FG001|Period 1|Physician Decision|1
6345308|NCT03421379|10105259|FG000|Period 1|Did not receive treatment|1
6345309|NCT03421379|10105260|FG001|Period 1|Did not receive treatment|2
6345310|NCT03421431|10105269|FG000|Overall Study|Adverse Event|2
6345311|NCT03421431|10105270|FG001|Overall Study|Adverse Event|1
6345312|NCT03421431|10105271|FG002|Overall Study|Adverse Event|12
6345313|NCT03421431|10105269|FG000|Overall Study|Lost to Follow-up|1
6345314|NCT03421431|10105270|FG001|Overall Study|Lost to Follow-up|1
6345315|NCT03421431|10105271|FG002|Overall Study|Lost to Follow-up|1
6345316|NCT03421431|10105269|FG000|Overall Study|Withdrawal by Subject|3
6345317|NCT03421431|10105270|FG001|Overall Study|Withdrawal by Subject|2
6083364|NCT00634933|9691714|FG000|Part A: Baseline to Week 24|Lack of Efficacy|3
6083365|NCT00634933|9691715|FG001|Part A: Baseline to Week 24|Lack of Efficacy|1
6083366|NCT00634933|9691716|FG002|Part A: Baseline to Week 24|Lack of Efficacy|0
6083367|NCT00634933|9691717|FG003|Part A: Baseline to Week 24|Lack of Efficacy|0
6083368|NCT00634933|9691718|FG004|Part A: Baseline to Week 24|Lack of Efficacy|0
6345318|NCT03421431|10105271|FG002|Overall Study|Withdrawal by Subject|1
6345319|NCT03421431|10105269|FG000|Overall Study|Protocol Violation|0
6345320|NCT03421431|10105270|FG001|Overall Study|Protocol Violation|1
6345321|NCT03421431|10105271|FG002|Overall Study|Protocol Violation|0
6345322|NCT03421431|10105269|FG000|Overall Study|Participant met Stopping Rules|0
6345323|NCT03421431|10105270|FG001|Overall Study|Participant met Stopping Rules|1
6345324|NCT03421431|10105271|FG002|Overall Study|Participant met Stopping Rules|0
6345325|NCT03421730|10105281|FG000|First Intervention (Day 1, Visit 2)|Withdrawal by subject or legal guardian|0
6345326|NCT03421730|10105282|FG001|First Intervention (Day 1, Visit 2)|Withdrawal by subject or legal guardian|2
6345327|NCT03421730|10105283|FG002|First Intervention (Day 1, Visit 2)|Withdrawal by subject or legal guardian|0
6042993|NCT00386100|9641474|FG001|Overall Study|Lost to Follow-up|29
6042994|NCT00386100|9641473|FG000|Overall Study|Non-compliance|18
6042995|NCT00386100|9641474|FG001|Overall Study|Non-compliance|19
6042996|NCT00386100|9641473|FG000|Overall Study|Protocol Violation|5
6345328|NCT03421730|10105284|FG003|First Intervention (Day 1, Visit 2)|Withdrawal by subject or legal guardian|0
6345329|NCT03421730|10105285|FG004|First Intervention (Day 1, Visit 2)|Withdrawal by subject or legal guardian|0
6345330|NCT03421730|10105286|FG005|First Intervention (Day 1, Visit 2)|Withdrawal by subject or legal guardian|0
6345331|NCT03421730|10105287|FG006|First Intervention (Day 1, Visit 2)|Withdrawal by subject or legal guardian|0
6345332|NCT03421730|10105288|FG007|First Intervention (Day 1, Visit 2)|Withdrawal by subject or legal guardian|0
6345333|NCT03421730|10105289|FG008|First Intervention (Day 1, Visit 2)|Withdrawal by subject or legal guardian|0
6345334|NCT03421730|10105290|FG009|First Intervention (Day 1, Visit 2)|Withdrawal by subject or legal guardian|0
6345335|NCT03421730|10105291|FG010|First Intervention (Day 1, Visit 2)|Withdrawal by subject or legal guardian|0
6345336|NCT03421730|10105292|FG011|First Intervention (Day 1, Visit 2)|Withdrawal by subject or legal guardian|0
6345337|NCT03421730|10105281|FG000|Washout (Days 4 to 10)|Withdrawal by subject or legal guardian|0
6345338|NCT03421730|10105282|FG001|Washout (Days 4 to 10)|Withdrawal by subject or legal guardian|0
6345339|NCT03421730|10105283|FG002|Washout (Days 4 to 10)|Withdrawal by subject or legal guardian|0
6345340|NCT03421730|10105284|FG003|Washout (Days 4 to 10)|Withdrawal by subject or legal guardian|0
6345341|NCT03421730|10105285|FG004|Washout (Days 4 to 10)|Withdrawal by subject or legal guardian|2
6345342|NCT03421730|10105286|FG005|Washout (Days 4 to 10)|Withdrawal by subject or legal guardian|0
6345343|NCT03421730|10105287|FG006|Washout (Days 4 to 10)|Withdrawal by subject or legal guardian|0
6345344|NCT03421730|10105288|FG007|Washout (Days 4 to 10)|Withdrawal by subject or legal guardian|0
6345345|NCT03421730|10105289|FG008|Washout (Days 4 to 10)|Withdrawal by subject or legal guardian|0
6345346|NCT03421730|10105290|FG009|Washout (Days 4 to 10)|Withdrawal by subject or legal guardian|0
6345347|NCT03421730|10105291|FG010|Washout (Days 4 to 10)|Withdrawal by subject or legal guardian|0
6345348|NCT03421730|10105292|FG011|Washout (Days 4 to 10)|Withdrawal by subject or legal guardian|0
6345349|NCT03422159|10105317|FG000|Overall Study|Exclusion due to terminal disease|2
6345350|NCT03422159|10105318|FG001|Overall Study|Exclusion due to terminal disease|1
6345351|NCT03422172|10105326|FG000|Oral lead-in Phase (4 Weeks)|Adverse Event|1
6345352|NCT03422172|10105326|FG000|Injection Phase (Week 5 to Week 41)|Lost to Follow-up|1
6345353|NCT03422172|10105326|FG000|Injection Phase (Week 5 to Week 41)|Withdrawal by Subject|3
6345354|NCT03422250|10105339|FG000|Intervention|Adverse Event|0
6345355|NCT03422250|10105340|FG001|Intervention|Adverse Event|1
6345356|NCT03422250|10105341|FG002|Intervention|Adverse Event|0
6345357|NCT03422250|10105342|FG003|Intervention|Adverse Event|1
6345358|NCT03422250|10105339|FG000|Intervention|safety (psoriasis, cortical vascular lesions on MRI)|1
6345359|NCT03422250|10105340|FG001|Intervention|safety (psoriasis, cortical vascular lesions on MRI)|0
6345360|NCT03422250|10105341|FG002|Intervention|safety (psoriasis, cortical vascular lesions on MRI)|2
6345361|NCT03422250|10105342|FG003|Intervention|safety (psoriasis, cortical vascular lesions on MRI)|0
6345362|NCT03422250|10105339|FG000|Follow-up|Withdrawal by Subject|0
6345363|NCT03422250|10105340|FG001|Follow-up|Withdrawal by Subject|0
6345364|NCT03422250|10105341|FG002|Follow-up|Withdrawal by Subject|0
6345365|NCT03422250|10105342|FG003|Follow-up|Withdrawal by Subject|1
6345366|NCT03422250|10105339|FG000|Follow-up|Adverse Event|0
6345367|NCT03422250|10105340|FG001|Follow-up|Adverse Event|0
6345368|NCT03422250|10105341|FG002|Follow-up|Adverse Event|0
6345369|NCT03422250|10105342|FG003|Follow-up|Adverse Event|1
6345370|NCT03423173|10105362|FG000|Overall Study|Randomized but not vaccinated|1
6345371|NCT03423173|10105363|FG001|Overall Study|Randomized but not vaccinated|0
6345372|NCT03423173|10105364|FG002|Overall Study|Randomized but not vaccinated|2
6345373|NCT03423173|10105365|FG003|Overall Study|Randomized but not vaccinated|1
6345374|NCT03423173|10105362|FG000|Overall Study|Adverse Event|1
6345375|NCT03423173|10105363|FG001|Overall Study|Adverse Event|1
6345376|NCT03423173|10105364|FG002|Overall Study|Adverse Event|1
6345377|NCT03423173|10105365|FG003|Overall Study|Adverse Event|1
6345378|NCT03423173|10105362|FG000|Overall Study|Lost to Follow-up|10
6345379|NCT03423173|10105363|FG001|Overall Study|Lost to Follow-up|19
6345380|NCT03423173|10105364|FG002|Overall Study|Lost to Follow-up|17
6345381|NCT03423173|10105365|FG003|Overall Study|Lost to Follow-up|22
6345382|NCT03423173|10105362|FG000|Overall Study|Withdrawal of consent|4
6345383|NCT03423173|10105363|FG001|Overall Study|Withdrawal of consent|10
6345384|NCT03423173|10105364|FG002|Overall Study|Withdrawal of consent|4
6345385|NCT03423173|10105365|FG003|Overall Study|Withdrawal of consent|5
6345386|NCT03423173|10105362|FG000|Overall Study|Death|1
6345387|NCT03423173|10105363|FG001|Overall Study|Death|0
6345388|NCT03423173|10105364|FG002|Overall Study|Death|0
6345389|NCT03423173|10105365|FG003|Overall Study|Death|0
6168901|NCT01238861|9814099|FG000|Overall Study|Personal problems|0
6168902|NCT01238861|9814100|FG001|Overall Study|Personal problems|0
6168903|NCT01238861|9814101|FG002|Overall Study|Personal problems|0
6168904|NCT01238861|9814102|FG003|Overall Study|Personal problems|1
6168905|NCT01238861|9814103|FG004|Overall Study|Personal problems|0
6168906|NCT01238861|9814104|FG005|Overall Study|Personal problems|0
6168907|NCT01238861|9814099|FG000|Overall Study|Unable to continue visits|0
6168908|NCT01238861|9814100|FG001|Overall Study|Unable to continue visits|0
6168909|NCT01238861|9814101|FG002|Overall Study|Unable to continue visits|0
6168910|NCT01238861|9814102|FG003|Overall Study|Unable to continue visits|1
6168911|NCT01238861|9814103|FG004|Overall Study|Unable to continue visits|0
6168912|NCT01238861|9814104|FG005|Overall Study|Unable to continue visits|1
6168913|NCT01238861|9814099|FG000|Overall Study|Serious adverse event|0
6345390|NCT03423173|10105362|FG000|Overall Study|Reason not Specified|2
6345391|NCT03423173|10105363|FG001|Overall Study|Reason not Specified|5
6345392|NCT03423173|10105364|FG002|Overall Study|Reason not Specified|3
6345393|NCT03423173|10105365|FG003|Overall Study|Reason not Specified|1
6345394|NCT03423238|10105386|FG000|Overall Study|Lost to Follow-up|1
6345395|NCT03423238|10105387|FG001|Overall Study|Lost to Follow-up|0
6345396|NCT03423238|10105386|FG000|Overall Study|Withdrawal by Subject|1
6345397|NCT03423238|10105387|FG001|Overall Study|Withdrawal by Subject|0
6345398|NCT03424044|10105403|FG000|First Rest Period (1-12 Weeks)|Withdrawal by Subject|0
6345399|NCT03424044|10105404|FG001|First Rest Period (1-12 Weeks)|Withdrawal by Subject|0
6345400|NCT03424044|10105405|FG002|First Rest Period (1-12 Weeks)|Withdrawal by Subject|1
6345401|NCT03424044|10105406|FG003|First Rest Period (1-12 Weeks)|Withdrawal by Subject|0
6345402|NCT03424044|10105407|FG004|First Rest Period (1-12 Weeks)|Withdrawal by Subject|0
6345403|NCT03424044|10105408|FG005|First Rest Period (1-12 Weeks)|Withdrawal by Subject|0
6345404|NCT03424044|10105409|FG006|First Rest Period (1-12 Weeks)|Withdrawal by Subject|0
6345405|NCT03424044|10105410|FG007|First Rest Period (1-12 Weeks)|Withdrawal by Subject|0
6345406|NCT03424044|10105411|FG008|First Rest Period (1-12 Weeks)|Withdrawal by Subject|0
6345407|NCT03424044|10105403|FG000|First Intervention (76 Hours)|Adverse Event|0
6345408|NCT03424044|10105404|FG001|First Intervention (76 Hours)|Adverse Event|0
6345409|NCT03424044|10105405|FG002|First Intervention (76 Hours)|Adverse Event|0
6345410|NCT03424044|10105406|FG003|First Intervention (76 Hours)|Adverse Event|0
6345411|NCT03424044|10105407|FG004|First Intervention (76 Hours)|Adverse Event|1
6345412|NCT03424044|10105408|FG005|First Intervention (76 Hours)|Adverse Event|0
6345413|NCT03424044|10105409|FG006|First Intervention (76 Hours)|Adverse Event|0
6345414|NCT03424044|10105410|FG007|First Intervention (76 Hours)|Adverse Event|0
6345415|NCT03424044|10105411|FG008|First Intervention (76 Hours)|Adverse Event|0
6345416|NCT03424044|10105403|FG000|First Intervention (76 Hours)|device issues|0
6345417|NCT03424044|10105404|FG001|First Intervention (76 Hours)|device issues|0
6345418|NCT03424044|10105405|FG002|First Intervention (76 Hours)|device issues|0
6345419|NCT03424044|10105406|FG003|First Intervention (76 Hours)|device issues|0
6345420|NCT03424044|10105407|FG004|First Intervention (76 Hours)|device issues|0
6345421|NCT03424044|10105408|FG005|First Intervention (76 Hours)|device issues|0
6345422|NCT03424044|10105409|FG006|First Intervention (76 Hours)|device issues|1
6345423|NCT03424044|10105410|FG007|First Intervention (76 Hours)|device issues|1
6345424|NCT03424044|10105411|FG008|First Intervention (76 Hours)|device issues|1
6345425|NCT03424044|10105403|FG000|Third Intervention (76 Hours)|Adverse Event|1
6345426|NCT03424044|10105404|FG001|Third Intervention (76 Hours)|Adverse Event|0
6345427|NCT03424044|10105405|FG002|Third Intervention (76 Hours)|Adverse Event|0
6345428|NCT03424044|10105406|FG003|Third Intervention (76 Hours)|Adverse Event|0
6345429|NCT03424044|10105407|FG004|Third Intervention (76 Hours)|Adverse Event|0
6345430|NCT03424044|10105408|FG005|Third Intervention (76 Hours)|Adverse Event|0
6345431|NCT03424044|10105409|FG006|Third Intervention (76 Hours)|Adverse Event|1
6345432|NCT03424044|10105410|FG007|Third Intervention (76 Hours)|Adverse Event|0
6345433|NCT03424044|10105411|FG008|Third Intervention (76 Hours)|Adverse Event|0
6345434|NCT03424044|10105403|FG000|Third Intervention (76 Hours)|Withdrawal by Subject|0
6345435|NCT03424044|10105404|FG001|Third Intervention (76 Hours)|Withdrawal by Subject|0
6345436|NCT03424044|10105405|FG002|Third Intervention (76 Hours)|Withdrawal by Subject|0
6345437|NCT03424044|10105406|FG003|Third Intervention (76 Hours)|Withdrawal by Subject|1
6345438|NCT03424044|10105407|FG004|Third Intervention (76 Hours)|Withdrawal by Subject|0
6345439|NCT03424044|10105408|FG005|Third Intervention (76 Hours)|Withdrawal by Subject|0
6345440|NCT03424044|10105409|FG006|Third Intervention (76 Hours)|Withdrawal by Subject|0
6345441|NCT03424044|10105410|FG007|Third Intervention (76 Hours)|Withdrawal by Subject|0
6345442|NCT03424044|10105411|FG008|Third Intervention (76 Hours)|Withdrawal by Subject|0
6345443|NCT03424239|10105445|FG000|Overall Study|Withdrawal by Subject|2
6345444|NCT03424265|10105451|FG000|Overall Study|screening failure|1
6345445|NCT03424265|10105452|FG001|Overall Study|screening failure|0
6345446|NCT03424265|10105451|FG000|Overall Study|Withdrawal by Subject|0
6345447|NCT03424265|10105452|FG001|Overall Study|Withdrawal by Subject|2
6345448|NCT03425188|10105482|FG000|Overall Study|Withdrawal by Subject|1
6345449|NCT03425253|10105487|FG000|Overall Study|Adverse Event|2
6345450|NCT03425253|10105487|FG000|Overall Study|Lost to Follow-up|3
6345451|NCT03425253|10105487|FG000|Overall Study|Withdrew Consent|6
6345452|NCT03425253|10105487|FG000|Overall Study|Did not Meet all Eligibility Criteria Defined in the Protocol|5
6345453|NCT03425396|10105497|FG000|Overall Study|Lost to Follow-up|2
6345454|NCT03425396|10105498|FG001|Overall Study|Lost to Follow-up|5
6345455|NCT03425396|10105499|FG002|Overall Study|Lost to Follow-up|2
6345456|NCT03425396|10105500|FG003|Overall Study|Lost to Follow-up|0
6345457|NCT03425396|10105501|FG004|Overall Study|Lost to Follow-up|0
6345458|NCT03425396|10105497|FG000|Overall Study|Withdrawal by Subject|0
6345459|NCT03425396|10105498|FG001|Overall Study|Withdrawal by Subject|1
6345460|NCT03425396|10105499|FG002|Overall Study|Withdrawal by Subject|0
6345461|NCT03425396|10105500|FG003|Overall Study|Withdrawal by Subject|1
6345462|NCT03425396|10105501|FG004|Overall Study|Withdrawal by Subject|0
6345463|NCT03425396|10105497|FG000|Overall Study|Other|0
6345464|NCT03425396|10105498|FG001|Overall Study|Other|1
6345465|NCT03425396|10105499|FG002|Overall Study|Other|1
6345466|NCT03425396|10105500|FG003|Overall Study|Other|0
6345467|NCT03425396|10105501|FG004|Overall Study|Other|1
6345468|NCT03426267|10105526|FG000|Overall Study|Physician Decision|1
6345469|NCT03426267|10105527|FG001|Overall Study|Physician Decision|4
6345470|NCT03426267|10105526|FG000|Overall Study|Lost to Follow-up|1
6345471|NCT03426267|10105527|FG001|Overall Study|Lost to Follow-up|0
6345472|NCT03426267|10105526|FG000|Overall Study|Withdrawal by Subject|4
6345473|NCT03426267|10105527|FG001|Overall Study|Withdrawal by Subject|10
6345474|NCT03426267|10105526|FG000|Overall Study|Protocol Violation|1
6345475|NCT03426267|10105527|FG001|Overall Study|Protocol Violation|3
6345476|NCT03426267|10105526|FG000|Overall Study|Adverse Event|9
6345477|NCT03426267|10105527|FG001|Overall Study|Adverse Event|27
6345478|NCT03426267|10105526|FG000|Overall Study|Prohibited Treatment Intake|2
6345479|NCT03426267|10105527|FG001|Overall Study|Prohibited Treatment Intake|3
6345480|NCT03426267|10105526|FG000|Overall Study|Lack of Efficacy|0
6345481|NCT03426267|10105527|FG001|Overall Study|Lack of Efficacy|25
6345482|NCT03426267|10105526|FG000|Overall Study|other|3
6345483|NCT03426267|10105527|FG001|Overall Study|other|0
6345484|NCT03426345|10105535|FG000|Overall Study|Adverse Event|4
6345485|NCT03426345|10105536|FG001|Overall Study|Adverse Event|4
6345486|NCT03426345|10105535|FG000|Overall Study|Lack of Efficacy|1
6345487|NCT03426345|10105536|FG001|Overall Study|Lack of Efficacy|0
6345488|NCT03426345|10105535|FG000|Overall Study|Withdrawal by Subject|5
6345489|NCT03426345|10105536|FG001|Overall Study|Withdrawal by Subject|6
6345490|NCT03426345|10105535|FG000|Overall Study|Lost to Follow-up|3
6345491|NCT03426345|10105536|FG001|Overall Study|Lost to Follow-up|1
6345492|NCT03426345|10105535|FG000|Overall Study|Protocol Deviation|3
6345493|NCT03426345|10105536|FG001|Overall Study|Protocol Deviation|4
6345494|NCT03426345|10105535|FG000|Overall Study|Reason Not Specified|1
6345495|NCT03426345|10105536|FG001|Overall Study|Reason Not Specified|2
6345496|NCT03426345|10105535|FG000|Overall Study|Missing Completion Status|1
6345497|NCT03426345|10105536|FG001|Overall Study|Missing Completion Status|0
6345498|NCT03426436|10105543|FG000|Overall Study|Incorrect lead placement|12
6345499|NCT03426436|10105543|FG000|Overall Study|Withdrawal by Subject|2
6345500|NCT03426436|10105543|FG000|Overall Study|Consent issue|1
6345501|NCT03426436|10105543|FG000|Overall Study|ECGs not saved|4
6345502|NCT03426631|10105547|FG000|Overall Study|Lost to Follow-up|0
6345503|NCT03426631|10105548|FG001|Overall Study|Lost to Follow-up|1
6345504|NCT03426787|10105554|FG000|Overall Study|Withdrawal by Subject|6
6345505|NCT03426787|10105554|FG000|Overall Study|Lost to Follow-up|7
6345506|NCT03426787|10105554|FG000|Overall Study|Unrelated to intervention death|1
6345507|NCT03426995|10105583|FG000|Part A: Cohort 1-Period 1 (Day1)|Protocol defined stopping criteria|0
6345508|NCT03426995|10105584|FG001|Part A: Cohort 1-Period 1 (Day1)|Protocol defined stopping criteria|0
6345509|NCT03426995|10105585|FG002|Part A: Cohort 1-Period 1 (Day1)|Protocol defined stopping criteria|1
6345510|NCT03426995|10105586|FG003|Part A: Cohort 1-Period 1 (Day1)|Protocol defined stopping criteria|0
6345511|NCT03426995|10105587|FG004|Part A: Cohort 1-Period 1 (Day1)|Protocol defined stopping criteria|0
6345512|NCT03426995|10105588|FG005|Part A: Cohort 1-Period 1 (Day1)|Protocol defined stopping criteria|0
6345513|NCT03426995|10105589|FG006|Part A: Cohort 1-Period 1 (Day1)|Protocol defined stopping criteria|0
6345514|NCT03426995|10105590|FG007|Part A: Cohort 1-Period 1 (Day1)|Protocol defined stopping criteria|0
6345515|NCT03426995|10105591|FG008|Part A: Cohort 1-Period 1 (Day1)|Protocol defined stopping criteria|0
6345516|NCT03426995|10105592|FG009|Part A: Cohort 1-Period 1 (Day1)|Protocol defined stopping criteria|0
6345517|NCT03426995|10105593|FG010|Part A: Cohort 1-Period 1 (Day1)|Protocol defined stopping criteria|0
6345518|NCT03426995|10105594|FG011|Part A: Cohort 1-Period 1 (Day1)|Protocol defined stopping criteria|0
6345519|NCT03426995|10105595|FG012|Part A: Cohort 1-Period 1 (Day1)|Protocol defined stopping criteria|0
6345520|NCT03426995|10105596|FG013|Part A: Cohort 1-Period 1 (Day1)|Protocol defined stopping criteria|0
6345521|NCT03426995|10105597|FG014|Part A: Cohort 1-Period 1 (Day1)|Protocol defined stopping criteria|0
6345522|NCT03426995|10105598|FG015|Part A: Cohort 1-Period 1 (Day1)|Protocol defined stopping criteria|0
6345523|NCT03426995|10105599|FG016|Part A: Cohort 1-Period 1 (Day1)|Protocol defined stopping criteria|0
6345524|NCT03426995|10105600|FG017|Part A: Cohort 1-Period 1 (Day1)|Protocol defined stopping criteria|0
6345525|NCT03426995|10105601|FG018|Part A: Cohort 1-Period 1 (Day1)|Protocol defined stopping criteria|0
6345526|NCT03426995|10105583|FG000|Part A: Cohort 1-Period 2 (Day1)|Protocol Violation|0
6345527|NCT03426995|10105584|FG001|Part A: Cohort 1-Period 2 (Day1)|Protocol Violation|0
6345528|NCT03426995|10105585|FG002|Part A: Cohort 1-Period 2 (Day1)|Protocol Violation|0
6345529|NCT03426995|10105586|FG003|Part A: Cohort 1-Period 2 (Day1)|Protocol Violation|0
6345530|NCT03426995|10105587|FG004|Part A: Cohort 1-Period 2 (Day1)|Protocol Violation|0
6345531|NCT03426995|10105588|FG005|Part A: Cohort 1-Period 2 (Day1)|Protocol Violation|1
6345532|NCT03426995|10105589|FG006|Part A: Cohort 1-Period 2 (Day1)|Protocol Violation|0
6345533|NCT03426995|10105590|FG007|Part A: Cohort 1-Period 2 (Day1)|Protocol Violation|0
6345534|NCT03426995|10105591|FG008|Part A: Cohort 1-Period 2 (Day1)|Protocol Violation|0
6345535|NCT03426995|10105592|FG009|Part A: Cohort 1-Period 2 (Day1)|Protocol Violation|0
6345536|NCT03426995|10105593|FG010|Part A: Cohort 1-Period 2 (Day1)|Protocol Violation|0
6345537|NCT03426995|10105594|FG011|Part A: Cohort 1-Period 2 (Day1)|Protocol Violation|0
6345538|NCT03426995|10105595|FG012|Part A: Cohort 1-Period 2 (Day1)|Protocol Violation|0
6345539|NCT03426995|10105596|FG013|Part A: Cohort 1-Period 2 (Day1)|Protocol Violation|0
6345540|NCT03426995|10105597|FG014|Part A: Cohort 1-Period 2 (Day1)|Protocol Violation|0
6345541|NCT03426995|10105598|FG015|Part A: Cohort 1-Period 2 (Day1)|Protocol Violation|0
6345542|NCT03426995|10105599|FG016|Part A: Cohort 1-Period 2 (Day1)|Protocol Violation|0
6345543|NCT03426995|10105600|FG017|Part A: Cohort 1-Period 2 (Day1)|Protocol Violation|0
6345544|NCT03426995|10105601|FG018|Part A: Cohort 1-Period 2 (Day1)|Protocol Violation|0
6345545|NCT03426995|10105583|FG000|Part A: Cohort 1-Period 2 (Day1)|Adverse Event|0
6345546|NCT03426995|10105584|FG001|Part A: Cohort 1-Period 2 (Day1)|Adverse Event|0
6345547|NCT03426995|10105585|FG002|Part A: Cohort 1-Period 2 (Day1)|Adverse Event|0
6345548|NCT03426995|10105586|FG003|Part A: Cohort 1-Period 2 (Day1)|Adverse Event|0
6345549|NCT03426995|10105587|FG004|Part A: Cohort 1-Period 2 (Day1)|Adverse Event|1
6345550|NCT03426995|10105588|FG005|Part A: Cohort 1-Period 2 (Day1)|Adverse Event|1
6345551|NCT03426995|10105589|FG006|Part A: Cohort 1-Period 2 (Day1)|Adverse Event|0
6345552|NCT03426995|10105590|FG007|Part A: Cohort 1-Period 2 (Day1)|Adverse Event|0
6345553|NCT03426995|10105591|FG008|Part A: Cohort 1-Period 2 (Day1)|Adverse Event|0
6345554|NCT03426995|10105592|FG009|Part A: Cohort 1-Period 2 (Day1)|Adverse Event|0
6345555|NCT03426995|10105593|FG010|Part A: Cohort 1-Period 2 (Day1)|Adverse Event|0
6345556|NCT03426995|10105594|FG011|Part A: Cohort 1-Period 2 (Day1)|Adverse Event|0
6345557|NCT03426995|10105595|FG012|Part A: Cohort 1-Period 2 (Day1)|Adverse Event|0
6345558|NCT03426995|10105596|FG013|Part A: Cohort 1-Period 2 (Day1)|Adverse Event|0
6345559|NCT03426995|10105597|FG014|Part A: Cohort 1-Period 2 (Day1)|Adverse Event|0
6345560|NCT03426995|10105598|FG015|Part A: Cohort 1-Period 2 (Day1)|Adverse Event|0
6345561|NCT03426995|10105599|FG016|Part A: Cohort 1-Period 2 (Day1)|Adverse Event|0
6345562|NCT03426995|10105600|FG017|Part A: Cohort 1-Period 2 (Day1)|Adverse Event|0
6345563|NCT03426995|10105601|FG018|Part A: Cohort 1-Period 2 (Day1)|Adverse Event|0
6345564|NCT03426995|10105583|FG000|Part A: Cohort 2-Period 4 (Day1)|Lost to Follow-up|0
6345565|NCT03426995|10105584|FG001|Part A: Cohort 2-Period 4 (Day1)|Lost to Follow-up|0
6345566|NCT03426995|10105585|FG002|Part A: Cohort 2-Period 4 (Day1)|Lost to Follow-up|0
6345567|NCT03426995|10105586|FG003|Part A: Cohort 2-Period 4 (Day1)|Lost to Follow-up|0
6345568|NCT03426995|10105587|FG004|Part A: Cohort 2-Period 4 (Day1)|Lost to Follow-up|0
6345569|NCT03426995|10105588|FG005|Part A: Cohort 2-Period 4 (Day1)|Lost to Follow-up|0
6345570|NCT03426995|10105589|FG006|Part A: Cohort 2-Period 4 (Day1)|Lost to Follow-up|0
6345571|NCT03426995|10105590|FG007|Part A: Cohort 2-Period 4 (Day1)|Lost to Follow-up|0
6345572|NCT03426995|10105591|FG008|Part A: Cohort 2-Period 4 (Day1)|Lost to Follow-up|0
6345573|NCT03426995|10105592|FG009|Part A: Cohort 2-Period 4 (Day1)|Lost to Follow-up|0
6345574|NCT03426995|10105593|FG010|Part A: Cohort 2-Period 4 (Day1)|Lost to Follow-up|1
6345575|NCT03426995|10105594|FG011|Part A: Cohort 2-Period 4 (Day1)|Lost to Follow-up|0
6345576|NCT03426995|10105595|FG012|Part A: Cohort 2-Period 4 (Day1)|Lost to Follow-up|0
6345577|NCT03426995|10105596|FG013|Part A: Cohort 2-Period 4 (Day1)|Lost to Follow-up|0
6345578|NCT03426995|10105597|FG014|Part A: Cohort 2-Period 4 (Day1)|Lost to Follow-up|0
6345579|NCT03426995|10105598|FG015|Part A: Cohort 2-Period 4 (Day1)|Lost to Follow-up|0
6345580|NCT03426995|10105599|FG016|Part A: Cohort 2-Period 4 (Day1)|Lost to Follow-up|0
6345581|NCT03426995|10105600|FG017|Part A: Cohort 2-Period 4 (Day1)|Lost to Follow-up|0
6345582|NCT03426995|10105601|FG018|Part A: Cohort 2-Period 4 (Day1)|Lost to Follow-up|0
6345583|NCT03426995|10105583|FG000|Part A: Cohort 2-Period 4 (Day1)|Adverse Event|0
6345584|NCT03426995|10105584|FG001|Part A: Cohort 2-Period 4 (Day1)|Adverse Event|0
6345585|NCT03426995|10105585|FG002|Part A: Cohort 2-Period 4 (Day1)|Adverse Event|0
6345586|NCT03426995|10105586|FG003|Part A: Cohort 2-Period 4 (Day1)|Adverse Event|0
6345587|NCT03426995|10105587|FG004|Part A: Cohort 2-Period 4 (Day1)|Adverse Event|0
6345588|NCT03426995|10105588|FG005|Part A: Cohort 2-Period 4 (Day1)|Adverse Event|0
6345589|NCT03426995|10105589|FG006|Part A: Cohort 2-Period 4 (Day1)|Adverse Event|0
6345590|NCT03426995|10105590|FG007|Part A: Cohort 2-Period 4 (Day1)|Adverse Event|1
6345591|NCT03426995|10105591|FG008|Part A: Cohort 2-Period 4 (Day1)|Adverse Event|0
6345592|NCT03426995|10105592|FG009|Part A: Cohort 2-Period 4 (Day1)|Adverse Event|0
6345593|NCT03426995|10105593|FG010|Part A: Cohort 2-Period 4 (Day1)|Adverse Event|0
6345594|NCT03426995|10105594|FG011|Part A: Cohort 2-Period 4 (Day1)|Adverse Event|0
6345595|NCT03426995|10105595|FG012|Part A: Cohort 2-Period 4 (Day1)|Adverse Event|0
6345596|NCT03426995|10105596|FG013|Part A: Cohort 2-Period 4 (Day1)|Adverse Event|0
6345597|NCT03426995|10105597|FG014|Part A: Cohort 2-Period 4 (Day1)|Adverse Event|0
6345598|NCT03426995|10105598|FG015|Part A: Cohort 2-Period 4 (Day1)|Adverse Event|0
6345599|NCT03426995|10105599|FG016|Part A: Cohort 2-Period 4 (Day1)|Adverse Event|0
6345600|NCT03426995|10105600|FG017|Part A: Cohort 2-Period 4 (Day1)|Adverse Event|0
6345601|NCT03426995|10105601|FG018|Part A: Cohort 2-Period 4 (Day1)|Adverse Event|0
6345602|NCT03426995|10105583|FG000|Part C: Cohorts 4 to 8 (Days 1 to 14)|Study Closed/Terminated|0
6345603|NCT03426995|10105584|FG001|Part C: Cohorts 4 to 8 (Days 1 to 14)|Study Closed/Terminated|0
6345604|NCT03426995|10105585|FG002|Part C: Cohorts 4 to 8 (Days 1 to 14)|Study Closed/Terminated|0
6345605|NCT03426995|10105586|FG003|Part C: Cohorts 4 to 8 (Days 1 to 14)|Study Closed/Terminated|0
6345606|NCT03426995|10105587|FG004|Part C: Cohorts 4 to 8 (Days 1 to 14)|Study Closed/Terminated|0
6345607|NCT03426995|10105588|FG005|Part C: Cohorts 4 to 8 (Days 1 to 14)|Study Closed/Terminated|0
6345608|NCT03426995|10105589|FG006|Part C: Cohorts 4 to 8 (Days 1 to 14)|Study Closed/Terminated|0
6345609|NCT03426995|10105590|FG007|Part C: Cohorts 4 to 8 (Days 1 to 14)|Study Closed/Terminated|0
6345610|NCT03426995|10105591|FG008|Part C: Cohorts 4 to 8 (Days 1 to 14)|Study Closed/Terminated|0
6345611|NCT03426995|10105592|FG009|Part C: Cohorts 4 to 8 (Days 1 to 14)|Study Closed/Terminated|0
6345612|NCT03426995|10105593|FG010|Part C: Cohorts 4 to 8 (Days 1 to 14)|Study Closed/Terminated|0
6345613|NCT03426995|10105594|FG011|Part C: Cohorts 4 to 8 (Days 1 to 14)|Study Closed/Terminated|0
6345614|NCT03426995|10105595|FG012|Part C: Cohorts 4 to 8 (Days 1 to 14)|Study Closed/Terminated|0
6345615|NCT03426995|10105596|FG013|Part C: Cohorts 4 to 8 (Days 1 to 14)|Study Closed/Terminated|0
6345616|NCT03426995|10105597|FG014|Part C: Cohorts 4 to 8 (Days 1 to 14)|Study Closed/Terminated|8
6345617|NCT03426995|10105598|FG015|Part C: Cohorts 4 to 8 (Days 1 to 14)|Study Closed/Terminated|9
6345618|NCT03426995|10105599|FG016|Part C: Cohorts 4 to 8 (Days 1 to 14)|Study Closed/Terminated|0
6345619|NCT03426995|10105600|FG017|Part C: Cohorts 4 to 8 (Days 1 to 14)|Study Closed/Terminated|0
6345620|NCT03426995|10105601|FG018|Part C: Cohorts 4 to 8 (Days 1 to 14)|Study Closed/Terminated|0
6345621|NCT03426995|10105583|FG000|Part C: Cohorts 4 to 8 (Days 1 to 14)|Adverse Event|0
6345622|NCT03426995|10105584|FG001|Part C: Cohorts 4 to 8 (Days 1 to 14)|Adverse Event|0
6345623|NCT03426995|10105585|FG002|Part C: Cohorts 4 to 8 (Days 1 to 14)|Adverse Event|0
6345624|NCT03426995|10105586|FG003|Part C: Cohorts 4 to 8 (Days 1 to 14)|Adverse Event|0
6345625|NCT03426995|10105587|FG004|Part C: Cohorts 4 to 8 (Days 1 to 14)|Adverse Event|0
6345626|NCT03426995|10105588|FG005|Part C: Cohorts 4 to 8 (Days 1 to 14)|Adverse Event|0
6345627|NCT03426995|10105589|FG006|Part C: Cohorts 4 to 8 (Days 1 to 14)|Adverse Event|0
6345628|NCT03426995|10105590|FG007|Part C: Cohorts 4 to 8 (Days 1 to 14)|Adverse Event|0
6345629|NCT03426995|10105591|FG008|Part C: Cohorts 4 to 8 (Days 1 to 14)|Adverse Event|0
6345630|NCT03426995|10105592|FG009|Part C: Cohorts 4 to 8 (Days 1 to 14)|Adverse Event|0
6345631|NCT03426995|10105593|FG010|Part C: Cohorts 4 to 8 (Days 1 to 14)|Adverse Event|0
6345632|NCT03426995|10105594|FG011|Part C: Cohorts 4 to 8 (Days 1 to 14)|Adverse Event|0
6345633|NCT03426995|10105595|FG012|Part C: Cohorts 4 to 8 (Days 1 to 14)|Adverse Event|0
6345634|NCT03426995|10105596|FG013|Part C: Cohorts 4 to 8 (Days 1 to 14)|Adverse Event|0
6345635|NCT03426995|10105597|FG014|Part C: Cohorts 4 to 8 (Days 1 to 14)|Adverse Event|1
6345636|NCT03426995|10105598|FG015|Part C: Cohorts 4 to 8 (Days 1 to 14)|Adverse Event|3
6345637|NCT03426995|10105599|FG016|Part C: Cohorts 4 to 8 (Days 1 to 14)|Adverse Event|0
6345638|NCT03426995|10105600|FG017|Part C: Cohorts 4 to 8 (Days 1 to 14)|Adverse Event|0
6345639|NCT03426995|10105601|FG018|Part C: Cohorts 4 to 8 (Days 1 to 14)|Adverse Event|0
6345640|NCT03427073|10105656|FG000|Overall Study|Disease Progression|1
6345641|NCT03427073|10105657|FG001|Overall Study|Disease Progression|1
6345642|NCT03427073|10105658|FG002|Overall Study|Disease Progression|1
6345643|NCT03427073|10105659|FG003|Overall Study|Disease Progression|3
6345644|NCT03427073|10105660|FG004|Overall Study|Disease Progression|3
6345645|NCT03427073|10105661|FG005|Overall Study|Disease Progression|4
6345646|NCT03427073|10105662|FG006|Overall Study|Disease Progression|2
6345647|NCT03427073|10105663|FG007|Overall Study|Disease Progression|3
6345648|NCT03427073|10105656|FG000|Overall Study|Physician Decision|0
6345649|NCT03427073|10105657|FG001|Overall Study|Physician Decision|0
6345650|NCT03427073|10105658|FG002|Overall Study|Physician Decision|0
6345651|NCT03427073|10105659|FG003|Overall Study|Physician Decision|0
6345652|NCT03427073|10105660|FG004|Overall Study|Physician Decision|0
6345653|NCT03427073|10105661|FG005|Overall Study|Physician Decision|0
6345654|NCT03427073|10105662|FG006|Overall Study|Physician Decision|1
6345655|NCT03427073|10105663|FG007|Overall Study|Physician Decision|1
6345656|NCT03427268|10105690|FG000|Overall Study|Progressive disease|25
6345657|NCT03427268|10105690|FG000|Overall Study|Never treated|2
6345658|NCT03427268|10105690|FG000|Overall Study|Compassionate use|1
6345659|NCT03427268|10105690|FG000|Overall Study|Withdrawal by Subject|1
6345660|NCT03427268|10105690|FG000|Overall Study|Adverse Event|3
6345661|NCT03427619|10105694|FG000|Overall Study|Physician Decision|3
6345662|NCT03427619|10105694|FG000|Overall Study|Withdrawal by Subject|4
6345663|NCT03427619|10105694|FG000|Overall Study|Lost to Follow-up|5
6345664|NCT03427619|10105694|FG000|Overall Study|Administrative|4
6345665|NCT03427619|10105694|FG000|Overall Study|Other|2
6345666|NCT03427619|10105694|FG000|Overall Study|Unknown or Missing Completion Status|48
6345667|NCT03427892|10105698|FG000|Overall Study|Lost to Follow-up|2
6345668|NCT03428100|10105710|FG000|Overall Study|Adverse Event|1
6345669|NCT03428100|10105711|FG001|Overall Study|Adverse Event|0
6345670|NCT03428100|10105712|FG002|Overall Study|Adverse Event|3
6345671|NCT03428100|10105713|FG003|Overall Study|Adverse Event|1
6345672|NCT03428100|10105710|FG000|Overall Study|Lack of Efficacy|16
6345673|NCT03428100|10105711|FG001|Overall Study|Lack of Efficacy|10
6345674|NCT03428100|10105712|FG002|Overall Study|Lack of Efficacy|7
6345675|NCT03428100|10105713|FG003|Overall Study|Lack of Efficacy|6
6345676|NCT03428100|10105710|FG000|Overall Study|Protocol Deviation|0
6345677|NCT03428100|10105711|FG001|Overall Study|Protocol Deviation|2
6345678|NCT03428100|10105712|FG002|Overall Study|Protocol Deviation|2
6345679|NCT03428100|10105713|FG003|Overall Study|Protocol Deviation|0
6345680|NCT03428100|10105710|FG000|Overall Study|Withdrawal by Subject|4
6345681|NCT03428100|10105711|FG001|Overall Study|Withdrawal by Subject|0
6345682|NCT03428100|10105712|FG002|Overall Study|Withdrawal by Subject|0
6345683|NCT03428100|10105713|FG003|Overall Study|Withdrawal by Subject|0
6345684|NCT03428100|10105710|FG000|Overall Study|Physician Decision|0
6345685|NCT03428100|10105711|FG001|Overall Study|Physician Decision|1
6345686|NCT03428100|10105712|FG002|Overall Study|Physician Decision|0
6345687|NCT03428100|10105713|FG003|Overall Study|Physician Decision|0
6345688|NCT03428152|10105735|FG000|Overall Study|Physician Decision|4
6345689|NCT03428152|10105736|FG001|Overall Study|Physician Decision|2
6345690|NCT03428152|10105735|FG000|Overall Study|Protocol Violation|3
6345691|NCT03428152|10105736|FG001|Overall Study|Protocol Violation|5
6345692|NCT03428152|10105735|FG000|Overall Study|Lack of Efficacy|0
6345693|NCT03428152|10105736|FG001|Overall Study|Lack of Efficacy|4
6345694|NCT03428360|10105759|FG000|Overall Study|Informed consent withdrawn|5
6345695|NCT03428360|10105759|FG000|Overall Study|Withdrawal by Subject|4
6345696|NCT03428360|10105759|FG000|Overall Study|Lost to Follow-up|5
6345697|NCT03428360|10105759|FG000|Overall Study|Physician Decision|2
6345698|NCT03428360|10105759|FG000|Overall Study|Informed consent withdrawn|5
6345699|NCT03428360|10105759|FG000|Overall Study|Study terminated by sponsor|10
6345700|NCT03428360|10105759|FG000|Overall Study|Non-compliant with study|1
6345701|NCT03428360|10105759|FG000|Overall Study|Non-compliant with study drug|3
6345702|NCT03428360|10105759|FG000|Overall Study|Death|3
6345703|NCT03428360|10105759|FG000|Overall Study|Adverse Event|1
6345704|NCT03428360|10105759|FG000|Overall Study|Not on antiepileptic drug|1
6345705|NCT03428750|10105769|FG000|Overall Study|Withdrawal by Subject|11
6345706|NCT03428750|10105770|FG001|Overall Study|Withdrawal by Subject|10
6345707|NCT03428750|10105769|FG000|Overall Study|Lost to Follow-up|3
6345708|NCT03428750|10105770|FG001|Overall Study|Lost to Follow-up|9
6345709|NCT03428750|10105769|FG000|Overall Study|Adverse Event|9
6345710|NCT03428750|10105770|FG001|Overall Study|Adverse Event|1
6345711|NCT03428750|10105769|FG000|Overall Study|Protocol Violation|1
6345712|NCT03428750|10105770|FG001|Overall Study|Protocol Violation|0
6345713|NCT03428750|10105769|FG000|Overall Study|Administrative|0
6345714|NCT03428750|10105770|FG001|Overall Study|Administrative|1
6345715|NCT03428815|10105801|FG000|Overall Study|Lost to Follow-up|2
6345716|NCT03428815|10105802|FG001|Overall Study|Lost to Follow-up|2
6345717|NCT03428815|10105801|FG000|Overall Study|suspension of study activities due to Covid-19 pandemic|5
6345718|NCT03428815|10105802|FG001|Overall Study|suspension of study activities due to Covid-19 pandemic|2
6345719|NCT03428815|10105801|FG000|Overall Study|Intermittent fitting issues that affected reliability of data|3
6345720|NCT03428815|10105802|FG001|Overall Study|Intermittent fitting issues that affected reliability of data|1
6345721|NCT03428997|10105808|FG000|Overall Study|Sponsor decision.|1
6345722|NCT03428997|10105808|FG000|Overall Study|Withdrawal by Subject|3
6345723|NCT03428997|10105808|FG000|Overall Study|Lost to Follow-up|4
6345724|NCT03429556|10105833|FG000|Overall Study|Lost to Follow-up|0
6345725|NCT03429556|10105834|FG001|Overall Study|Lost to Follow-up|1
6345726|NCT03429556|10105835|FG002|Overall Study|Lost to Follow-up|0
6345727|NCT03429556|10105836|FG003|Overall Study|Lost to Follow-up|0
6345728|NCT03430245|10105864|FG000|Overall Study|Withdrawal by Subject|6
6345729|NCT03430245|10105864|FG000|Overall Study|Lost to Follow-up|1
6345730|NCT03430856|10105881|FG000|Overall Study|Adverse Event|0
6345731|NCT03430856|10105882|FG001|Overall Study|Adverse Event|1
6345732|NCT03430856|10105883|FG002|Overall Study|Adverse Event|0
6345733|NCT03430856|10105881|FG000|Overall Study|Rescue criteria|1
6345734|NCT03430856|10105882|FG001|Overall Study|Rescue criteria|1
6345735|NCT03430856|10105883|FG002|Overall Study|Rescue criteria|0
6345736|NCT03430856|10105881|FG000|Overall Study|Voluntary withdrawal of consent|1
6345737|NCT03430856|10105882|FG001|Overall Study|Voluntary withdrawal of consent|1
6345738|NCT03430856|10105883|FG002|Overall Study|Voluntary withdrawal of consent|1
6345739|NCT03430986|10105896|FG000|24-week Control Period|Adverse Event|1
6345740|NCT03430986|10105897|FG001|24-week Control Period|Adverse Event|0
6345741|NCT03430986|10105896|FG000|24-week Control Period|Lost to Follow-up|2
6345742|NCT03430986|10105897|FG001|24-week Control Period|Lost to Follow-up|2
6345743|NCT03430986|10105896|FG000|24-week Control Period|Withdrawal by Participant|5
6345744|NCT03430986|10105897|FG001|24-week Control Period|Withdrawal by Participant|0
6345745|NCT03430986|10105896|FG000|24-week Control Period|Protocol Deviation|0
6345746|NCT03430986|10105897|FG001|24-week Control Period|Protocol Deviation|2
6345747|NCT03430986|10105896|FG000|24-week Post-Control Period|Lost to Follow-up|1
6345748|NCT03430986|10105897|FG001|24-week Post-Control Period|Lost to Follow-up|1
6345749|NCT03430986|10105896|FG000|24-week Post-Control Period|Withdrawal by Participant|0
6345750|NCT03430986|10105897|FG001|24-week Post-Control Period|Withdrawal by Participant|1
6345751|NCT03431337|10105929|FG000|Overall Study|Lost to Follow-up|21
6345752|NCT03431337|10105930|FG001|Overall Study|Lost to Follow-up|19
6345753|NCT03431337|10105929|FG000|Overall Study|Withdrawal by Subject|8
6345754|NCT03431337|10105930|FG001|Overall Study|Withdrawal by Subject|3
6345755|NCT03431441|10105940|FG000|Overall Study|Withdrawal by Subject|2
6345756|NCT03431441|10105940|FG000|Overall Study|Adverse Event|2
6345757|NCT03431441|10105940|FG000|Overall Study|Dispensed Incorrect Replacement Lens|1
6345758|NCT03431857|10105944|FG000|Overall Study|Death|6
6345759|NCT03431857|10105944|FG000|Overall Study|Lost to Follow-up|41
6345760|NCT03431857|10105944|FG000|Overall Study|Adverse Event|6
6345761|NCT03431857|10105944|FG000|Overall Study|Withdrawal by Subject|1
6345762|NCT03432390|10105950|FG000|Apnea Period|Protocol Violation|2
6345763|NCT03432390|10105951|FG001|Apnea Period|Protocol Violation|2
6345764|NCT03432533|10105959|FG000|Overall Study|Lost to Follow-up|1
6345765|NCT03432533|10105960|FG001|Overall Study|Lost to Follow-up|2
6345766|NCT03432533|10105959|FG000|Overall Study|Withdrawal by Subject|14
6345767|NCT03432533|10105960|FG001|Overall Study|Withdrawal by Subject|9
6345768|NCT03432858|10105969|FG000|Overall Study|Protocol Violation|2
6345769|NCT03432858|10105970|FG001|Overall Study|Protocol Violation|1
6345770|NCT03432858|10105971|FG002|Overall Study|Protocol Violation|9
6345771|NCT03432858|10105969|FG000|Overall Study|Withdrawal by Subject|0
6345772|NCT03432858|10105970|FG001|Overall Study|Withdrawal by Subject|1
6345773|NCT03432858|10105971|FG002|Overall Study|Withdrawal by Subject|1
6345774|NCT03432858|10105969|FG000|Overall Study|Procedure canceled/rescheduled|0
6345775|NCT03432858|10105970|FG001|Overall Study|Procedure canceled/rescheduled|9
6345776|NCT03432858|10105971|FG002|Overall Study|Procedure canceled/rescheduled|6
6345777|NCT03432858|10105969|FG000|Overall Study|Required postop mobilization with splinting|0
6345778|NCT03432858|10105970|FG001|Overall Study|Required postop mobilization with splinting|0
6345779|NCT03432858|10105971|FG002|Overall Study|Required postop mobilization with splinting|1
6345780|NCT03433482|10105983|FG000|Overall Study|Lost to Follow-up|1
6345781|NCT03433482|10105984|FG001|Overall Study|Lost to Follow-up|0
6345782|NCT03433482|10105985|FG002|Overall Study|Lost to Follow-up|1
6345783|NCT03433482|10105986|FG003|Overall Study|Lost to Follow-up|1
6345784|NCT03433482|10105983|FG000|Overall Study|Withdrawal by Subject|0
6345785|NCT03433482|10105984|FG001|Overall Study|Withdrawal by Subject|0
6345786|NCT03433482|10105985|FG002|Overall Study|Withdrawal by Subject|1
6345787|NCT03433482|10105986|FG003|Overall Study|Withdrawal by Subject|0
6345788|NCT03433482|10105983|FG000|Overall Study|Unknown reason|0
6345789|NCT03433482|10105984|FG001|Overall Study|Unknown reason|0
6345790|NCT03433482|10105985|FG002|Overall Study|Unknown reason|2
6345791|NCT03433482|10105986|FG003|Overall Study|Unknown reason|0
6345792|NCT03433677|10105998|FG000|Period 1|Protocol Violation|1
6345793|NCT03433677|10105999|FG001|Period 1|Protocol Violation|0
6345794|NCT03433677|10105998|FG000|Period 2|Withdrawal by Subject|1
6345795|NCT03433677|10105999|FG001|Period 2|Withdrawal by Subject|1
6345796|NCT03433703|10106006|FG000|Overall Study|Study terminated by Sponsor|2
6345797|NCT03433755|10106014|FG000|Overall Study|Lost to Follow-up|1
6345798|NCT03433755|10106015|FG001|Overall Study|Lost to Follow-up|0
6345799|NCT03433755|10106016|FG002|Overall Study|Lost to Follow-up|0
6345800|NCT03433755|10106017|FG003|Overall Study|Lost to Follow-up|0
6345801|NCT03433755|10106014|FG000|Overall Study|Decision by Sponsor|1
6345802|NCT03433755|10106015|FG001|Overall Study|Decision by Sponsor|0
6345803|NCT03433755|10106016|FG002|Overall Study|Decision by Sponsor|0
6345804|NCT03433755|10106017|FG003|Overall Study|Decision by Sponsor|0
6083369|NCT00634933|9691714|FG000|Part A: Baseline to Week 24|Other|1
6083370|NCT00634933|9691715|FG001|Part A: Baseline to Week 24|Other|8
6083371|NCT00634933|9691716|FG002|Part A: Baseline to Week 24|Other|5
6083372|NCT00634933|9691717|FG003|Part A: Baseline to Week 24|Other|0
6083373|NCT00634933|9691718|FG004|Part A: Baseline to Week 24|Other|0
6083374|NCT00634933|9691714|FG000|Between Part A and Part B|Physician Decision|0
6345805|NCT03434249|10106044|FG000|Overall Study|Adverse Event|1
6345806|NCT03434249|10106045|FG001|Overall Study|Adverse Event|0
6345807|NCT03434249|10106044|FG000|Overall Study|Lost to Follow-up|0
6345808|NCT03434249|10106045|FG001|Overall Study|Lost to Follow-up|1
6345809|NCT03434249|10106044|FG000|Overall Study|Non-compliance of family|2
6345810|NCT03434249|10106045|FG001|Overall Study|Non-compliance of family|1
6345811|NCT03434249|10106044|FG000|Overall Study|Difficulties in completing daily diary|2
6345812|NCT03434249|10106045|FG001|Overall Study|Difficulties in completing daily diary|1
6345813|NCT03434834|10106055|FG000|Overall Study|unable to swallow OCT probe|16
6345814|NCT03434977|10106061|FG000|Washout Period (at Least 6 Days)|Adverse Event|0
6345815|NCT03434977|10106062|FG001|Washout Period (at Least 6 Days)|Adverse Event|1
6345816|NCT03435055|10106068|FG000|Screening|Physician Decision|2
6345817|NCT03435055|10106068|FG000|Received Intervention|Did not complete nitrous administration|3
6345818|NCT03435081|10106082|FG000|Overall Study|Lack of Efficacy|6
6345819|NCT03435081|10106083|FG001|Overall Study|Lack of Efficacy|5
6345820|NCT03435081|10106084|FG002|Overall Study|Lack of Efficacy|0
6345821|NCT03435081|10106082|FG000|Overall Study|Adverse Event|2
6345822|NCT03435081|10106083|FG001|Overall Study|Adverse Event|2
6345823|NCT03435081|10106084|FG002|Overall Study|Adverse Event|2
6345824|NCT03435081|10106082|FG000|Overall Study|Withdrawal by Subject|8
6345825|NCT03435081|10106083|FG001|Overall Study|Withdrawal by Subject|7
6345826|NCT03435081|10106084|FG002|Overall Study|Withdrawal by Subject|10
6345827|NCT03435081|10106082|FG000|Overall Study|Lost to Follow-up|3
6345828|NCT03435081|10106083|FG001|Overall Study|Lost to Follow-up|1
6345829|NCT03435081|10106084|FG002|Overall Study|Lost to Follow-up|4
6345830|NCT03435081|10106082|FG000|Overall Study|Pregnancy|1
6345831|NCT03435081|10106083|FG001|Overall Study|Pregnancy|0
6345832|NCT03435081|10106084|FG002|Overall Study|Pregnancy|0
6345833|NCT03435081|10106082|FG000|Overall Study|Non-compliance|1
6345834|NCT03435081|10106083|FG001|Overall Study|Non-compliance|0
6345835|NCT03435081|10106084|FG002|Overall Study|Non-compliance|2
6345836|NCT03435081|10106082|FG000|Overall Study|Inadequate Response|0
6345837|NCT03435081|10106083|FG001|Overall Study|Inadequate Response|1
6345838|NCT03435081|10106084|FG002|Overall Study|Inadequate Response|0
6345839|NCT03435081|10106082|FG000|Overall Study|Withdrawal Due to Caregiver Circumstance|0
6345840|NCT03435081|10106083|FG001|Overall Study|Withdrawal Due to Caregiver Circumstance|0
6345841|NCT03435081|10106084|FG002|Overall Study|Withdrawal Due to Caregiver Circumstance|1
6345842|NCT03435211|10106093|FG000|Overall Study|Unable to achieve minimum desaturation level|1
6345843|NCT03435224|10106097|FG000|Overall Study|Unable to achieve a minimum desaturation level|4
6345844|NCT03435497|10106103|FG000|Overall Study|Lost to Follow-up|1
6345845|NCT03435497|10106104|FG001|Overall Study|Lost to Follow-up|0
6345846|NCT03435497|10106103|FG000|Overall Study|Death|1
6345847|NCT03435497|10106104|FG001|Overall Study|Death|0
6345848|NCT03435497|10106103|FG000|Overall Study|Withdrawal by Subject|0
6345849|NCT03435497|10106104|FG001|Overall Study|Withdrawal by Subject|4
6345850|NCT03435497|10106103|FG000|Overall Study|Wrong survey administered|0
6345851|NCT03435497|10106104|FG001|Overall Study|Wrong survey administered|2
6345852|NCT03435692|10106134|FG000|Overall Study|Lack of Efficacy|2
6345853|NCT03435692|10106135|FG001|Overall Study|Lack of Efficacy|2
6345854|NCT03435692|10106136|FG002|Overall Study|Lack of Efficacy|0
6345855|NCT03436082|10106159|FG000|Overall Study|Did not undergo procedure|1
6345856|NCT03436082|10106160|FG001|Overall Study|Did not undergo procedure|0
6345857|NCT03436420|10106177|FG000|Overall Study|Lack of Efficacy|3
6345858|NCT03436732|10106183|FG000|Overall Study|Not treated-enrolled in different study|1
6345859|NCT03436732|10106184|FG001|Overall Study|Not treated-enrolled in different study|0
6345860|NCT03436732|10106183|FG000|Overall Study|Off study after cycle 1|1
6345861|NCT03436732|10106184|FG001|Overall Study|Off study after cycle 1|0
6345862|NCT03436732|10106183|FG000|Overall Study|Adverse Event|2
6345863|NCT03436732|10106184|FG001|Overall Study|Adverse Event|0
6345864|NCT03436732|10106183|FG000|Overall Study|Death|0
6345865|NCT03436732|10106184|FG001|Overall Study|Death|1
6345866|NCT03437265|10106220|FG000|Overall Study|Protocol Violation|6
6345867|NCT03437447|10106227|FG000|Treatment Period 1|Withdrawal by Subject|0
6345868|NCT03437447|10106228|FG001|Treatment Period 1|Withdrawal by Subject|0
6345869|NCT03437447|10106229|FG002|Treatment Period 1|Withdrawal by Subject|1
6345870|NCT03437512|10106239|FG000|Randomized|Withdrawal by Subject|0
6345871|NCT03437512|10106240|FG001|Randomized|Withdrawal by Subject|2
6345872|NCT03437512|10106239|FG000|Completed Study Follow up|Could not complete study due to COVID-19 research pause|2
6345873|NCT03437512|10106240|FG001|Completed Study Follow up|Could not complete study due to COVID-19 research pause|1
6345874|NCT03437577|10106258|FG000|Pre-Randomization|Withdrawal by Subject|0
6345875|NCT03437577|10106259|FG001|Pre-Randomization|Withdrawal by Subject|0
6345876|NCT03437577|10106260|FG002|Pre-Randomization|Withdrawal by Subject|10
6345877|NCT03437577|10106258|FG000|Post-Randomization|Physician Decision|0
6345878|NCT03437577|10106259|FG001|Post-Randomization|Physician Decision|2
6345879|NCT03437577|10106260|FG002|Post-Randomization|Physician Decision|0
6345880|NCT03437733|10106268|FG000|Overall Study|Eligibility criteria not met|0
6345881|NCT03437733|10106269|FG001|Overall Study|Eligibility criteria not met|3
6345882|NCT03438006|10106278|FG000|Overall Study|Adverse Event|1
6345883|NCT03438006|10106278|FG000|Overall Study|Lost to Follow-up|67
6345884|NCT03438006|10106278|FG000|Overall Study|CONSENT WITHDRAWAL NOT DUE TO ADV. EVENT|47
6345885|NCT03438006|10106278|FG000|Overall Study|NOT WILLING / NOT ABLE TO BE CONTACTED|3
6345886|NCT03438383|10106294|FG000|Overall Study|Protocol Violation|9
6168914|NCT01238861|9814100|FG001|Overall Study|Serious adverse event|0
6168915|NCT01238861|9814101|FG002|Overall Study|Serious adverse event|0
6168916|NCT01238861|9814102|FG003|Overall Study|Serious adverse event|0
6345887|NCT03438383|10106295|FG001|Overall Study|Protocol Violation|3
6345888|NCT03438396|10106301|FG000|Overall Study|Ongoing on study treatment|4
6345889|NCT03438396|10106301|FG000|Overall Study|Ongoing in survival follow-up|33
6345890|NCT03438396|10106301|FG000|Overall Study|Withdrawal by Subject|4
6345891|NCT03438396|10106301|FG000|Overall Study|Lost to Follow-up|2
6345892|NCT03438396|10106301|FG000|Overall Study|Death|58
6345893|NCT03438396|10106301|FG000|Overall Study|Not treated|1
6345894|NCT03438539|10106311|FG000|Overall Study|Lost to Follow-up|8
6345895|NCT03438539|10106312|FG001|Overall Study|Lost to Follow-up|4
6345896|NCT03438539|10106313|FG002|Overall Study|Lost to Follow-up|10
6345897|NCT03438539|10106314|FG003|Overall Study|Lost to Follow-up|9
6345898|NCT03438539|10106315|FG004|Overall Study|Lost to Follow-up|3
6345899|NCT03438539|10106316|FG005|Overall Study|Lost to Follow-up|8
6345900|NCT03439072|10106339|FG000|Overall Study|Withdrawal by Subject|2
6345901|NCT03439072|10106340|FG001|Overall Study|Withdrawal by Subject|3
6345902|NCT03439072|10106339|FG000|Overall Study|Physician Decision|0
6345903|NCT03439072|10106340|FG001|Overall Study|Physician Decision|1
6345904|NCT03439137|10106348|FG000|Overall Study|Adverse Event|16
6345905|NCT03439137|10106349|FG001|Overall Study|Adverse Event|12
6345906|NCT03439137|10106348|FG000|Overall Study|Physician Decision|0
6345907|NCT03439137|10106349|FG001|Overall Study|Physician Decision|5
6345908|NCT03439137|10106348|FG000|Overall Study|Withdrawal by Subject|14
6345909|NCT03439137|10106349|FG001|Overall Study|Withdrawal by Subject|4
6345910|NCT03439137|10106348|FG000|Overall Study|Conducting rescue therapy|2
6345911|NCT03439137|10106349|FG001|Overall Study|Conducting rescue therapy|1
6345912|NCT03439137|10106348|FG000|Overall Study|Difficult to control Hb|10
6345913|NCT03439137|10106349|FG001|Overall Study|Difficult to control Hb|2
6345914|NCT03439137|10106348|FG000|Overall Study|Initiation of a renal transplant|0
6345915|NCT03439137|10106349|FG001|Overall Study|Initiation of a renal transplant|2
6345916|NCT03439189|10106355|FG000|Overall Study|Protocol Violation|19
6345917|NCT03439189|10106355|FG000|Overall Study|Lack of Efficacy|63
6345918|NCT03440320|10106373|FG000|Overall Study|Withdrawal by Subject|0
6345919|NCT03440320|10106374|FG001|Overall Study|Withdrawal by Subject|1
6345920|NCT03440411|10106386|FG000|Overall Study|Adverse Event|0
6345921|NCT03440411|10106387|FG001|Overall Study|Adverse Event|0
6345922|NCT03440411|10106388|FG002|Overall Study|Adverse Event|1
6345923|NCT03440411|10106389|FG003|Overall Study|Adverse Event|0
6345924|NCT03440411|10106386|FG000|Overall Study|PD|2
6345925|NCT03440411|10106387|FG001|Overall Study|PD|1
6345926|NCT03440411|10106388|FG002|Overall Study|PD|1
6345927|NCT03440411|10106389|FG003|Overall Study|PD|1
6345928|NCT03440411|10106386|FG000|Overall Study|Withdrawal by Subject|1
6345929|NCT03440411|10106387|FG001|Overall Study|Withdrawal by Subject|0
6345930|NCT03440411|10106388|FG002|Overall Study|Withdrawal by Subject|0
6345931|NCT03440411|10106389|FG003|Overall Study|Withdrawal by Subject|0
6345932|NCT03440411|10106386|FG000|Overall Study|Closed study by sponsor|0
6345933|NCT03440411|10106387|FG001|Overall Study|Closed study by sponsor|0
6345934|NCT03440411|10106388|FG002|Overall Study|Closed study by sponsor|0
6345935|NCT03440411|10106389|FG003|Overall Study|Closed study by sponsor|1
6345936|NCT03440918|10106433|FG000|Overall Study|Protocol Violation|0
6345937|NCT03440918|10106434|FG001|Overall Study|Protocol Violation|16
6345938|NCT03440944|10106442|FG000|Overall Study|Physician Decision|1
6345939|NCT03440944|10106443|FG001|Overall Study|Physician Decision|0
6345940|NCT03440944|10106442|FG000|Overall Study|No Acceptable Vasculature|0
6345941|NCT03440944|10106443|FG001|Overall Study|No Acceptable Vasculature|1
6345942|NCT03441789|10106535|FG000|Overall Study|Withdrawal by Subject|1
6345943|NCT03441789|10106536|FG001|Overall Study|Withdrawal by Subject|1
6345944|NCT03441789|10106535|FG000|Overall Study|Adverse Event|0
6345945|NCT03441789|10106536|FG001|Overall Study|Adverse Event|1
6345946|NCT03441789|10106535|FG000|Overall Study|Protocol Violation|0
6345947|NCT03441789|10106536|FG001|Overall Study|Protocol Violation|1
6345948|NCT03441789|10106535|FG000|Overall Study|Lost to Follow-up|0
6345949|NCT03441789|10106536|FG001|Overall Study|Lost to Follow-up|1
6345950|NCT03441984|10106544|FG000|Part 1: Period 2 (Up to Day 4 )|Positive urine drug screen lab value|0
6345951|NCT03441984|10106545|FG001|Part 1: Period 2 (Up to Day 4 )|Positive urine drug screen lab value|0
6345952|NCT03441984|10106546|FG002|Part 1: Period 2 (Up to Day 4 )|Positive urine drug screen lab value|1
6345953|NCT03441984|10106547|FG003|Part 1: Period 2 (Up to Day 4 )|Positive urine drug screen lab value|0
6345954|NCT03441984|10106548|FG004|Part 1: Period 2 (Up to Day 4 )|Positive urine drug screen lab value|0
6345955|NCT03441984|10106549|FG005|Part 1: Period 2 (Up to Day 4 )|Positive urine drug screen lab value|0
6345956|NCT03441984|10106550|FG006|Part 1: Period 2 (Up to Day 4 )|Positive urine drug screen lab value|0
6345957|NCT03441984|10106551|FG007|Part 1: Period 2 (Up to Day 4 )|Positive urine drug screen lab value|0
6345958|NCT03441984|10106552|FG008|Part 1: Period 2 (Up to Day 4 )|Positive urine drug screen lab value|0
6345959|NCT03441984|10106553|FG009|Part 1: Period 2 (Up to Day 4 )|Positive urine drug screen lab value|0
6345960|NCT03441984|10106554|FG010|Part 1: Period 2 (Up to Day 4 )|Positive urine drug screen lab value|0
6345961|NCT03441984|10106555|FG011|Part 1: Period 2 (Up to Day 4 )|Positive urine drug screen lab value|0
6345962|NCT03442296|10106583|FG000|3 Month Follow-up|Death|3
6345963|NCT03442296|10106584|FG001|3 Month Follow-up|Death|1
6345964|NCT03442296|10106583|FG000|3 Month Follow-up|Lost to Follow-up|1
6345965|NCT03442296|10106584|FG001|3 Month Follow-up|Lost to Follow-up|1
6345966|NCT03442296|10106583|FG000|3 Month Follow-up|Withdrawal by Subject|1
6345967|NCT03442296|10106584|FG001|3 Month Follow-up|Withdrawal by Subject|0
6345968|NCT03442296|10106583|FG000|3 Month Follow-up|Obtained Hearing Aids|0
6345969|NCT03442296|10106584|FG001|3 Month Follow-up|Obtained Hearing Aids|1
6345970|NCT03442296|10106583|FG000|12 Month Follow-up|Incomplete measurement|1
6345971|NCT03442296|10106584|FG001|12 Month Follow-up|Incomplete measurement|1
6345972|NCT03442569|10106590|FG000|Overall Study|Subject was ineligible after enrollment|1
6345973|NCT03442595|10106596|FG000|Overall Study|Lost to Follow-up|94
6345974|NCT03442595|10106597|FG001|Overall Study|Lost to Follow-up|0
6345975|NCT03442777|10106620|FG000|Overall Study|Not included in analysis as assessed only once and no pressure ulcer or category 1 at any site|8
6345976|NCT03442777|10106621|FG001|Overall Study|Not included in analysis as assessed only once and no pressure ulcer or category 1 at any site|13
6345977|NCT03442777|10106622|FG002|Overall Study|Not included in analysis as assessed only once and no pressure ulcer or category 1 at any site|7
6083375|NCT00634933|9691715|FG001|Between Part A and Part B|Physician Decision|1
6083376|NCT00634933|9691716|FG002|Between Part A and Part B|Physician Decision|0
6083377|NCT00634933|9691717|FG003|Between Part A and Part B|Physician Decision|0
6083378|NCT00634933|9691718|FG004|Between Part A and Part B|Physician Decision|0
6345978|NCT03442829|10106630|FG000|Overall Study|Scheduling clash|3
6345979|NCT03442829|10106631|FG001|Overall Study|Scheduling clash|1
6345980|NCT03442829|10106630|FG000|Overall Study|Illness unrelated to study|1
6345981|NCT03442829|10106631|FG001|Overall Study|Illness unrelated to study|1
6345982|NCT03443024|10106655|FG000|Overall Study|Adverse Event|2
6345983|NCT03443024|10106656|FG001|Overall Study|Adverse Event|4
6083379|NCT00634933|9691714|FG000|Part B: Week 24 to Week 52|Adverse Event|0
6083380|NCT00634933|9691715|FG001|Part B: Week 24 to Week 52|Adverse Event|1
6083381|NCT00634933|9691716|FG002|Part B: Week 24 to Week 52|Adverse Event|1
6083382|NCT00634933|9691717|FG003|Part B: Week 24 to Week 52|Adverse Event|1
6083383|NCT00634933|9691718|FG004|Part B: Week 24 to Week 52|Adverse Event|0
6083384|NCT00634933|9691714|FG000|Part B: Week 24 to Week 52|Discontinuation of Study by Sponsor|0
6083385|NCT00634933|9691715|FG001|Part B: Week 24 to Week 52|Discontinuation of Study by Sponsor|11
6083386|NCT00634933|9691716|FG002|Part B: Week 24 to Week 52|Discontinuation of Study by Sponsor|14
6083387|NCT00634933|9691717|FG003|Part B: Week 24 to Week 52|Discontinuation of Study by Sponsor|3
6083388|NCT00634933|9691718|FG004|Part B: Week 24 to Week 52|Discontinuation of Study by Sponsor|7
6087755|NCT00670449|9698232|FG001|Overall Study|Protocol Deviation|2
6345984|NCT03443024|10106657|FG002|Overall Study|Adverse Event|3
6345985|NCT03443024|10106658|FG003|Overall Study|Adverse Event|1
6345986|NCT03443024|10106655|FG000|Overall Study|Lost to Follow-up|9
6345987|NCT03443024|10106656|FG001|Overall Study|Lost to Follow-up|9
6345988|NCT03443024|10106657|FG002|Overall Study|Lost to Follow-up|7
6345989|NCT03443024|10106658|FG003|Overall Study|Lost to Follow-up|5
6345990|NCT03443024|10106655|FG000|Overall Study|Withdrawal by Subject|8
6345991|NCT03443024|10106656|FG001|Overall Study|Withdrawal by Subject|15
6345992|NCT03443024|10106657|FG002|Overall Study|Withdrawal by Subject|9
6345993|NCT03443024|10106658|FG003|Overall Study|Withdrawal by Subject|23
6345994|NCT03443024|10106655|FG000|Overall Study|Physician Decision|1
6345995|NCT03443024|10106656|FG001|Overall Study|Physician Decision|2
6345996|NCT03443024|10106657|FG002|Overall Study|Physician Decision|0
6345997|NCT03443024|10106658|FG003|Overall Study|Physician Decision|1
6345998|NCT03443024|10106655|FG000|Overall Study|Sponsor Decision|1
6345999|NCT03443024|10106656|FG001|Overall Study|Sponsor Decision|1
6346000|NCT03443024|10106657|FG002|Overall Study|Sponsor Decision|0
6346001|NCT03443024|10106658|FG003|Overall Study|Sponsor Decision|0
6346002|NCT03443024|10106655|FG000|Overall Study|Protocol Deviation|0
6346003|NCT03443024|10106656|FG001|Overall Study|Protocol Deviation|0
6346004|NCT03443024|10106657|FG002|Overall Study|Protocol Deviation|0
6346005|NCT03443024|10106658|FG003|Overall Study|Protocol Deviation|2
6346006|NCT03443414|10106684|FG000|Overall Study|Adverse Event|6
6346007|NCT03443414|10106685|FG001|Overall Study|Adverse Event|0
6346008|NCT03443414|10106686|FG002|Overall Study|Adverse Event|4
6346009|NCT03443414|10106687|FG003|Overall Study|Adverse Event|2
6346010|NCT03443414|10106688|FG004|Overall Study|Adverse Event|3
6346011|NCT03443414|10106684|FG000|Overall Study|Withdrawal by Subject|3
6346012|NCT03443414|10106685|FG001|Overall Study|Withdrawal by Subject|2
6346013|NCT03443414|10106686|FG002|Overall Study|Withdrawal by Subject|2
6346014|NCT03443414|10106687|FG003|Overall Study|Withdrawal by Subject|2
6346015|NCT03443414|10106688|FG004|Overall Study|Withdrawal by Subject|1
6346016|NCT03443414|10106684|FG000|Overall Study|Death|0
6346017|NCT03443414|10106685|FG001|Overall Study|Death|1
6346018|NCT03443414|10106686|FG002|Overall Study|Death|0
6346019|NCT03443414|10106687|FG003|Overall Study|Death|1
6346020|NCT03443414|10106688|FG004|Overall Study|Death|0
6346021|NCT03443414|10106684|FG000|Overall Study|Reason not specified|2
6346022|NCT03443414|10106685|FG001|Overall Study|Reason not specified|0
6346023|NCT03443414|10106686|FG002|Overall Study|Reason not specified|0
6346024|NCT03443414|10106687|FG003|Overall Study|Reason not specified|0
6346025|NCT03443414|10106688|FG004|Overall Study|Reason not specified|1
6346026|NCT03443427|10106702|FG000|Overall Study|Adverse Event|2
6346027|NCT03443427|10106703|FG001|Overall Study|Adverse Event|3
6346028|NCT03443427|10106702|FG000|Overall Study|CONSENT WITHDRAWAL NOT DUE TO ADV. EVENT|6
6346029|NCT03443427|10106703|FG001|Overall Study|CONSENT WITHDRAWAL NOT DUE TO ADV. EVENT|2
6346030|NCT03443427|10106702|FG000|Overall Study|Other|4
6346031|NCT03443427|10106703|FG001|Overall Study|Other|6
6346032|NCT03443713|10106712|FG000|First at Home Period (9-14 Days)|Withdrawal by Subject|0
6346033|NCT03443713|10106713|FG001|First at Home Period (9-14 Days)|Withdrawal by Subject|0
6346034|NCT03443713|10106714|FG002|First at Home Period (9-14 Days)|Withdrawal by Subject|1
6346035|NCT03444155|10106737|FG000|First Intervention (6 Weeks)|Adverse Event|1
6346036|NCT03444155|10106738|FG001|First Intervention (6 Weeks)|Adverse Event|0
6346037|NCT03444584|10106746|FG000|Overall Study|Withdrawal by Subject|0
6346038|NCT03444584|10106747|FG001|Overall Study|Withdrawal by Subject|1
6346039|NCT03444584|10106746|FG000|Overall Study|Other|0
6346040|NCT03444584|10106747|FG001|Overall Study|Other|1
6346041|NCT03444766|10106754|FG000|Overall Study|Other Reasons|2
6346042|NCT03444766|10106754|FG000|Overall Study|Participant Withdrew Consent|5
6346043|NCT03444766|10106754|FG000|Overall Study|Lost to Follow-up|2
6346044|NCT03444766|10106754|FG000|Overall Study|Death|2
6346045|NCT03444766|10106754|FG000|Overall Study|Adverse Event Unrelated to Study Drug|6
6346046|NCT03444766|10106754|FG000|Overall Study|Disease Progression|49
6346047|NCT03445065|10106770|FG000|Overall Study|Withdrawal by Subject|3
6346048|NCT03445065|10106771|FG001|Overall Study|Withdrawal by Subject|6
6346049|NCT03445065|10106772|FG002|Overall Study|Withdrawal by Subject|2
6346050|NCT03445065|10106773|FG003|Overall Study|Withdrawal by Subject|2
6346051|NCT03445065|10106770|FG000|Overall Study|Other|4
6346052|NCT03445065|10106771|FG001|Overall Study|Other|3
6346053|NCT03445065|10106772|FG002|Overall Study|Other|3
6346054|NCT03445065|10106773|FG003|Overall Study|Other|1
6346055|NCT03446781|10106880|FG000|Overall Study|Lost to Follow-up|11
6346056|NCT03446781|10106881|FG001|Overall Study|Lost to Follow-up|5
6346057|NCT03446781|10106880|FG000|Overall Study|Withdrawal by Subject|9
6346058|NCT03446781|10106881|FG001|Overall Study|Withdrawal by Subject|7
6346059|NCT03446781|10106880|FG000|Overall Study|Adverse Event|8
6346060|NCT03446781|10106881|FG001|Overall Study|Adverse Event|2
6346061|NCT03446781|10106880|FG000|Overall Study|Protocol Violation|0
6346062|NCT03446781|10106881|FG001|Overall Study|Protocol Violation|3
6346063|NCT03446885|10106922|FG000|Overall Study|Lost to Follow-up|1
6346064|NCT03446885|10106923|FG001|Overall Study|Lost to Follow-up|0
6346065|NCT03446885|10106922|FG000|Overall Study|Did not complete entire visit|1
6346066|NCT03446885|10106923|FG001|Overall Study|Did not complete entire visit|0
6346067|NCT03447249|10106942|FG000|Overall Study|Adverse Event|1
6346068|NCT03447249|10106943|FG001|Overall Study|Adverse Event|0
6346069|NCT03447249|10106942|FG000|Overall Study|Withdrawal of consent (not due to AE)|1
6346070|NCT03447249|10106943|FG001|Overall Study|Withdrawal of consent (not due to AE)|0
6346071|NCT03447249|10106942|FG000|Overall Study|Other|3
6346072|NCT03447249|10106943|FG001|Overall Study|Other|0
6346073|NCT03447353|10106951|FG000|Overall Study|Failure at Screening Visit|2
6346074|NCT03447353|10106951|FG000|Overall Study|Lost to Follow-up|4
6346075|NCT03447353|10106951|FG000|Overall Study|Scheduling Conflicts|3
6346076|NCT03447353|10106951|FG000|Overall Study|Withdrew - Nausea Study V1, Sim Drive|1
6346077|NCT03447730|10106964|FG000|Overall Study|Adverse Event|0
6346078|NCT03447730|10106965|FG001|Overall Study|Adverse Event|2
6346079|NCT03447730|10106966|FG002|Overall Study|Adverse Event|0
6346080|NCT03447821|10106977|FG000|Overall Study|Withdrawal by Subject|1
6346081|NCT03447821|10106978|FG001|Overall Study|Withdrawal by Subject|1
6346082|NCT03447821|10106979|FG002|Overall Study|Withdrawal by Subject|0
6346083|NCT03447821|10106977|FG000|Overall Study|Lost to Follow-up|0
6346084|NCT03447821|10106978|FG001|Overall Study|Lost to Follow-up|0
6346085|NCT03447821|10106979|FG002|Overall Study|Lost to Follow-up|1
6346086|NCT03448224|10106998|FG000|Overall Study|Provided same answer to every question|1
6346087|NCT03448224|10106999|FG001|Overall Study|Provided same answer to every question|0
6346088|NCT03448406|10107007|FG000|Overall Study|Noncompliance of scheduled visits|1
6346089|NCT03448406|10107008|FG001|Overall Study|Noncompliance of scheduled visits|2
6346090|NCT03448406|10107007|FG000|Overall Study|Withdrawal by Subject|1
6346091|NCT03448406|10107008|FG001|Overall Study|Withdrawal by Subject|2
6346092|NCT03448406|10107007|FG000|Overall Study|Protocol Violation|1
6346093|NCT03448406|10107008|FG001|Overall Study|Protocol Violation|0
6346094|NCT03448406|10107007|FG000|Overall Study|Adverse Event|8
6346095|NCT03448406|10107008|FG001|Overall Study|Adverse Event|9
6346096|NCT03448419|10107016|FG000|Overall Study|Adverse Event|10
6346097|NCT03448419|10107017|FG001|Overall Study|Adverse Event|9
6346098|NCT03448419|10107016|FG000|Overall Study|Lost to Follow-up|0
6346099|NCT03448419|10107017|FG001|Overall Study|Lost to Follow-up|2
6346100|NCT03448419|10107016|FG000|Overall Study|Withdrawal by Subject|3
6346101|NCT03448419|10107017|FG001|Overall Study|Withdrawal by Subject|1
6346102|NCT03448419|10107016|FG000|Overall Study|Not treated|0
6346103|NCT03448419|10107017|FG001|Overall Study|Not treated|1
6346104|NCT03448419|10107016|FG000|Overall Study|Patient did not attend all visits|0
6346105|NCT03448419|10107017|FG001|Overall Study|Patient did not attend all visits|2
6346106|NCT03448419|10107016|FG000|Overall Study|Withdrawn by Sponsor|0
6346107|NCT03448419|10107017|FG001|Overall Study|Withdrawn by Sponsor|1
6346108|NCT03448536|10107027|FG000|Overall Study|Protocol Violation|2
6346109|NCT03448536|10107028|FG001|Overall Study|Protocol Violation|0
6346110|NCT03448536|10107027|FG000|Overall Study|Pregnancy|1
6346111|NCT03448536|10107028|FG001|Overall Study|Pregnancy|0
6346112|NCT03448536|10107027|FG000|Overall Study|Withdrawal by Subject|1
6346113|NCT03448536|10107028|FG001|Overall Study|Withdrawal by Subject|2
6168917|NCT01238861|9814103|FG004|Overall Study|Serious adverse event|0
6168918|NCT01238861|9814104|FG005|Overall Study|Serious adverse event|1
6168919|NCT01238861|9814099|FG000|Overall Study|Lack of compliance|0
6346114|NCT03448536|10107027|FG000|Overall Study|Lost to Follow-up|3
6346115|NCT03448536|10107028|FG001|Overall Study|Lost to Follow-up|2
6346116|NCT03448536|10107027|FG000|Overall Study|Inadequate pain reporter|1
6346117|NCT03448536|10107028|FG001|Overall Study|Inadequate pain reporter|0
6346118|NCT03448536|10107027|FG000|Overall Study|Other|3
6346119|NCT03448536|10107028|FG001|Overall Study|Other|0
6346120|NCT03448536|10107027|FG000|Overall Study|Physician Decision|1
6346121|NCT03448536|10107028|FG001|Overall Study|Physician Decision|0
6346122|NCT03449030|10107044|FG000|Overall Study|Withdrawal by Subject|0
6346123|NCT03449030|10107045|FG001|Overall Study|Withdrawal by Subject|0
6346124|NCT03449030|10107046|FG002|Overall Study|Withdrawal by Subject|0
6346125|NCT03449030|10107047|FG003|Overall Study|Withdrawal by Subject|1
6346126|NCT03449030|10107048|FG004|Overall Study|Withdrawal by Subject|1
6346127|NCT03449030|10107049|FG005|Overall Study|Withdrawal by Subject|1
6346128|NCT03449030|10107050|FG006|Overall Study|Withdrawal by Subject|1
6346129|NCT03449030|10107051|FG007|Overall Study|Withdrawal by Subject|2
6346130|NCT03449030|10107052|FG008|Overall Study|Withdrawal by Subject|0
6346131|NCT03449030|10107053|FG009|Overall Study|Withdrawal by Subject|0
6346132|NCT03449030|10107044|FG000|Overall Study|Symptomatic Deterioration|0
6346133|NCT03449030|10107045|FG001|Overall Study|Symptomatic Deterioration|1
6346134|NCT03449030|10107046|FG002|Overall Study|Symptomatic Deterioration|0
6346135|NCT03449030|10107047|FG003|Overall Study|Symptomatic Deterioration|0
6346136|NCT03449030|10107048|FG004|Overall Study|Symptomatic Deterioration|0
6346137|NCT03449030|10107049|FG005|Overall Study|Symptomatic Deterioration|1
6346138|NCT03449030|10107050|FG006|Overall Study|Symptomatic Deterioration|1
6346139|NCT03449030|10107051|FG007|Overall Study|Symptomatic Deterioration|0
6346140|NCT03449030|10107052|FG008|Overall Study|Symptomatic Deterioration|2
6346141|NCT03449030|10107053|FG009|Overall Study|Symptomatic Deterioration|0
6346142|NCT03449030|10107044|FG000|Overall Study|Progressive Disease|1
6346143|NCT03449030|10107045|FG001|Overall Study|Progressive Disease|0
6346144|NCT03449030|10107046|FG002|Overall Study|Progressive Disease|1
6346145|NCT03449030|10107047|FG003|Overall Study|Progressive Disease|4
6346146|NCT03449030|10107048|FG004|Overall Study|Progressive Disease|5
6346147|NCT03449030|10107049|FG005|Overall Study|Progressive Disease|3
6346148|NCT03449030|10107050|FG006|Overall Study|Progressive Disease|0
6346149|NCT03449030|10107051|FG007|Overall Study|Progressive Disease|1
6346150|NCT03449030|10107052|FG008|Overall Study|Progressive Disease|1
6346151|NCT03449030|10107053|FG009|Overall Study|Progressive Disease|1
6346152|NCT03449030|10107044|FG000|Overall Study|Adverse Event|0
6346153|NCT03449030|10107045|FG001|Overall Study|Adverse Event|0
6346154|NCT03449030|10107046|FG002|Overall Study|Adverse Event|0
6346155|NCT03449030|10107047|FG003|Overall Study|Adverse Event|0
6346156|NCT03449030|10107048|FG004|Overall Study|Adverse Event|0
6346157|NCT03449030|10107049|FG005|Overall Study|Adverse Event|2
6346158|NCT03449030|10107050|FG006|Overall Study|Adverse Event|0
6346159|NCT03449030|10107051|FG007|Overall Study|Adverse Event|0
6346160|NCT03449030|10107052|FG008|Overall Study|Adverse Event|0
6346161|NCT03449030|10107053|FG009|Overall Study|Adverse Event|0
6346162|NCT03449030|10107044|FG000|Overall Study|Death|0
6346163|NCT03449030|10107045|FG001|Overall Study|Death|0
6346164|NCT03449030|10107046|FG002|Overall Study|Death|0
6346165|NCT03449030|10107047|FG003|Overall Study|Death|0
6346166|NCT03449030|10107048|FG004|Overall Study|Death|1
6346167|NCT03449030|10107049|FG005|Overall Study|Death|0
6346168|NCT03449030|10107050|FG006|Overall Study|Death|0
6346169|NCT03449030|10107051|FG007|Overall Study|Death|0
6346170|NCT03449030|10107052|FG008|Overall Study|Death|0
6346171|NCT03449030|10107053|FG009|Overall Study|Death|0
6346172|NCT03449134|10107079|FG000|52-Week Treatment Period|Death|2
6346173|NCT03449134|10107080|FG001|52-Week Treatment Period|Death|1
6346174|NCT03449134|10107081|FG002|52-Week Treatment Period|Death|0
6346175|NCT03449134|10107079|FG000|52-Week Treatment Period|Lost to Follow-up|2
6346176|NCT03449134|10107080|FG001|52-Week Treatment Period|Lost to Follow-up|1
6346177|NCT03449134|10107081|FG002|52-Week Treatment Period|Lost to Follow-up|1
6346178|NCT03449134|10107079|FG000|52-Week Treatment Period|Physician Decision|2
6346179|NCT03449134|10107080|FG001|52-Week Treatment Period|Physician Decision|3
6346180|NCT03449134|10107081|FG002|52-Week Treatment Period|Physician Decision|3
6346181|NCT03449134|10107079|FG000|52-Week Treatment Period|Screen Failure|1
6346182|NCT03449134|10107080|FG001|52-Week Treatment Period|Screen Failure|0
6346183|NCT03449134|10107081|FG002|52-Week Treatment Period|Screen Failure|1
6346184|NCT03449134|10107079|FG000|52-Week Treatment Period|Withdrawal by Subject|37
6346185|NCT03449134|10107080|FG001|52-Week Treatment Period|Withdrawal by Subject|39
6346186|NCT03449134|10107081|FG002|52-Week Treatment Period|Withdrawal by Subject|55
6346187|NCT03449134|10107079|FG000|52-Week Treatment Period|Site Closure|1
6346188|NCT03449134|10107080|FG001|52-Week Treatment Period|Site Closure|0
6346189|NCT03449134|10107081|FG002|52-Week Treatment Period|Site Closure|0
6346190|NCT03449147|10107095|FG000|52-week Treatment Period|Death|0
6168920|NCT01238861|9814100|FG001|Overall Study|Lack of compliance|0
6346191|NCT03449147|10107096|FG001|52-week Treatment Period|Death|1
6346192|NCT03449147|10107097|FG002|52-week Treatment Period|Death|0
6168921|NCT01238861|9814101|FG002|Overall Study|Lack of compliance|0
6346193|NCT03449147|10107095|FG000|52-week Treatment Period|Lost to Follow-up|6
6346194|NCT03449147|10107096|FG001|52-week Treatment Period|Lost to Follow-up|2
6346195|NCT03449147|10107097|FG002|52-week Treatment Period|Lost to Follow-up|5
6346196|NCT03449147|10107095|FG000|52-week Treatment Period|Other|0
6346197|NCT03449147|10107096|FG001|52-week Treatment Period|Other|1
6346198|NCT03449147|10107097|FG002|52-week Treatment Period|Other|2
6346199|NCT03449147|10107095|FG000|52-week Treatment Period|Physician Decision|1
6346200|NCT03449147|10107096|FG001|52-week Treatment Period|Physician Decision|0
6346201|NCT03449147|10107097|FG002|52-week Treatment Period|Physician Decision|3
6346202|NCT03449147|10107095|FG000|52-week Treatment Period|Screen Failure|1
6346203|NCT03449147|10107096|FG001|52-week Treatment Period|Screen Failure|2
6346204|NCT03449147|10107097|FG002|52-week Treatment Period|Screen Failure|0
6346205|NCT03449147|10107095|FG000|52-week Treatment Period|Withdrawal by Subject|46
6346206|NCT03449147|10107096|FG001|52-week Treatment Period|Withdrawal by Subject|68
6346207|NCT03449147|10107097|FG002|52-week Treatment Period|Withdrawal by Subject|74
6346208|NCT03449147|10107095|FG000|12-Week Off-Treatment Durability Period|Withdrawal by Subject|1
6346209|NCT03449147|10107096|FG001|12-Week Off-Treatment Durability Period|Withdrawal by Subject|0
6346210|NCT03449147|10107097|FG002|12-Week Off-Treatment Durability Period|Withdrawal by Subject|0
6346211|NCT03449147|10107095|FG000|12-Week Off-Treatment Durability Period|Other|0
6346212|NCT03449147|10107096|FG001|12-Week Off-Treatment Durability Period|Other|1
6346213|NCT03449147|10107097|FG002|12-Week Off-Treatment Durability Period|Other|0
6346214|NCT03449446|10107145|FG000|Overall Study|Randomized but Never Treated|0
6346215|NCT03449446|10107146|FG001|Overall Study|Randomized but Never Treated|0
6346216|NCT03449446|10107147|FG002|Overall Study|Randomized but Never Treated|1
6346217|NCT03449446|10107148|FG003|Overall Study|Randomized but Never Treated|1
6346218|NCT03449446|10107149|FG004|Overall Study|Randomized but Never Treated|1
6346219|NCT03449446|10107150|FG005|Overall Study|Randomized but Never Treated|0
6346220|NCT03449446|10107151|FG006|Overall Study|Randomized but Never Treated|0
6346221|NCT03449446|10107145|FG000|Overall Study|Unknown Reason|33
6346222|NCT03449446|10107146|FG001|Overall Study|Unknown Reason|1
6346223|NCT03449446|10107147|FG002|Overall Study|Unknown Reason|1
6346224|NCT03449446|10107148|FG003|Overall Study|Unknown Reason|1
6346225|NCT03449446|10107149|FG004|Overall Study|Unknown Reason|2
6346226|NCT03449446|10107150|FG005|Overall Study|Unknown Reason|2
6346227|NCT03449446|10107151|FG006|Overall Study|Unknown Reason|0
6346228|NCT03449446|10107145|FG000|Overall Study|Withdrew Consent|1
6346229|NCT03449446|10107146|FG001|Overall Study|Withdrew Consent|3
6346230|NCT03449446|10107147|FG002|Overall Study|Withdrew Consent|1
6346231|NCT03449446|10107148|FG003|Overall Study|Withdrew Consent|4
6346232|NCT03449446|10107149|FG004|Overall Study|Withdrew Consent|4
6346233|NCT03449446|10107150|FG005|Overall Study|Withdrew Consent|4
6346234|NCT03449446|10107151|FG006|Overall Study|Withdrew Consent|1
6346235|NCT03449446|10107145|FG000|Overall Study|Adverse Event|1
6346236|NCT03449446|10107146|FG001|Overall Study|Adverse Event|2
6346237|NCT03449446|10107147|FG002|Overall Study|Adverse Event|1
6346238|NCT03449446|10107148|FG003|Overall Study|Adverse Event|0
6346239|NCT03449446|10107149|FG004|Overall Study|Adverse Event|0
6346240|NCT03449446|10107150|FG005|Overall Study|Adverse Event|2
6346241|NCT03449446|10107151|FG006|Overall Study|Adverse Event|0
6346242|NCT03449446|10107145|FG000|Overall Study|Lost to Follow-up|0
6346243|NCT03449446|10107146|FG001|Overall Study|Lost to Follow-up|0
6346244|NCT03449446|10107147|FG002|Overall Study|Lost to Follow-up|2
6346245|NCT03449446|10107148|FG003|Overall Study|Lost to Follow-up|1
6346246|NCT03449446|10107149|FG004|Overall Study|Lost to Follow-up|3
6346247|NCT03449446|10107150|FG005|Overall Study|Lost to Follow-up|0
6346248|NCT03449446|10107151|FG006|Overall Study|Lost to Follow-up|0
6346249|NCT03449446|10107145|FG000|Overall Study|Investigator's Discretion|0
6346250|NCT03449446|10107146|FG001|Overall Study|Investigator's Discretion|1
6346251|NCT03449446|10107147|FG002|Overall Study|Investigator's Discretion|1
6346252|NCT03449446|10107148|FG003|Overall Study|Investigator's Discretion|2
6346253|NCT03449446|10107149|FG004|Overall Study|Investigator's Discretion|0
6346254|NCT03449446|10107150|FG005|Overall Study|Investigator's Discretion|0
6346255|NCT03449446|10107151|FG006|Overall Study|Investigator's Discretion|0
6346256|NCT03449446|10107145|FG000|Overall Study|Non Compliance with Study Drug|1
6346257|NCT03449446|10107146|FG001|Overall Study|Non Compliance with Study Drug|0
6346258|NCT03449446|10107147|FG002|Overall Study|Non Compliance with Study Drug|0
6346259|NCT03449446|10107148|FG003|Overall Study|Non Compliance with Study Drug|0
6346260|NCT03449446|10107149|FG004|Overall Study|Non Compliance with Study Drug|0
6346261|NCT03449446|10107150|FG005|Overall Study|Non Compliance with Study Drug|0
6346262|NCT03449446|10107151|FG006|Overall Study|Non Compliance with Study Drug|0
6346263|NCT03449446|10107145|FG000|Overall Study|Protocol Violation|0
6346264|NCT03449446|10107146|FG001|Overall Study|Protocol Violation|0
6346265|NCT03449446|10107147|FG002|Overall Study|Protocol Violation|0
6346266|NCT03449446|10107148|FG003|Overall Study|Protocol Violation|0
6346267|NCT03449446|10107149|FG004|Overall Study|Protocol Violation|1
6346268|NCT03449446|10107150|FG005|Overall Study|Protocol Violation|1
6346269|NCT03449446|10107151|FG006|Overall Study|Protocol Violation|0
6346270|NCT03449446|10107145|FG000|Overall Study|Death|0
6346271|NCT03449446|10107146|FG001|Overall Study|Death|0
6346272|NCT03449446|10107147|FG002|Overall Study|Death|0
6346273|NCT03449446|10107148|FG003|Overall Study|Death|0
6346274|NCT03449446|10107149|FG004|Overall Study|Death|1
6346275|NCT03449446|10107150|FG005|Overall Study|Death|0
6346276|NCT03449446|10107151|FG006|Overall Study|Death|0
6346277|NCT03449979|10107171|FG000|Overall Study|Technical difficulty|0
6346278|NCT03449979|10107172|FG001|Overall Study|Technical difficulty|0
6346279|NCT03449979|10107173|FG002|Overall Study|Technical difficulty|0
6346280|NCT03449979|10107174|FG003|Overall Study|Technical difficulty|1
6346281|NCT03450070|10107184|FG000|Overall Study|Withdrawal by Subject|8
6346282|NCT03451071|10107215|FG000|First Vaccine|Withdrawal by Subject|1
6346283|NCT03451071|10107215|FG000|Second Vaccine|Lost to Follow-up|19
6346284|NCT03451071|10107215|FG000|Third Vaccine|Lost to Follow-up|22
6346285|NCT03451071|10107215|FG000|Final Questionnaire and Blood Draw|Lost to Follow-up|4
6346286|NCT03451084|10107223|FG000|Overall Study|Withdrawal by Subject|2
6346287|NCT03451084|10107224|FG001|Overall Study|Withdrawal by Subject|1
6346288|NCT03451084|10107225|FG002|Overall Study|Withdrawal by Subject|2
6346289|NCT03451084|10107226|FG003|Overall Study|Withdrawal by Subject|1
6346290|NCT03451084|10107223|FG000|Overall Study|Disease recurrence|0
6346291|NCT03451084|10107224|FG001|Overall Study|Disease recurrence|2
6346292|NCT03451084|10107225|FG002|Overall Study|Disease recurrence|0
6346293|NCT03451084|10107226|FG003|Overall Study|Disease recurrence|0
6346294|NCT03451084|10107223|FG000|Overall Study|Lack of Efficacy|0
6346295|NCT03451084|10107224|FG001|Overall Study|Lack of Efficacy|3
6346296|NCT03451084|10107225|FG002|Overall Study|Lack of Efficacy|0
6346297|NCT03451084|10107226|FG003|Overall Study|Lack of Efficacy|1
6346298|NCT03451084|10107223|FG000|Overall Study|Death|1
6346299|NCT03451084|10107224|FG001|Overall Study|Death|0
6346300|NCT03451084|10107225|FG002|Overall Study|Death|2
6346301|NCT03451084|10107226|FG003|Overall Study|Death|0
6346302|NCT03451084|10107223|FG000|Overall Study|Physician Decision|0
6346303|NCT03451084|10107224|FG001|Overall Study|Physician Decision|0
6346304|NCT03451084|10107225|FG002|Overall Study|Physician Decision|2
6346305|NCT03451084|10107226|FG003|Overall Study|Physician Decision|2
6346306|NCT03451084|10107223|FG000|Overall Study|Disease progression (n=4), study closed by sponsor (n=1)|3
6346307|NCT03451084|10107224|FG001|Overall Study|Disease progression (n=4), study closed by sponsor (n=1)|0
6346308|NCT03451084|10107225|FG002|Overall Study|Disease progression (n=4), study closed by sponsor (n=1)|0
6346309|NCT03451084|10107226|FG003|Overall Study|Disease progression (n=4), study closed by sponsor (n=1)|2
6346310|NCT03451721|10107236|FG000|Overall Study|Death|1
6346311|NCT03451773|10107242|FG000|Overall Study|Death on study|1
6346312|NCT03451773|10107243|FG001|Overall Study|Death on study|5
6346313|NCT03451773|10107242|FG000|Overall Study|Death during follow-up period|0
6346314|NCT03451773|10107243|FG001|Overall Study|Death during follow-up period|1
6346315|NCT03452189|10107287|FG000|First Intervention (3 Months)|Adverse Event|1
6346316|NCT03452189|10107288|FG001|First Intervention (3 Months)|Adverse Event|0
6346317|NCT03452189|10107287|FG000|First Intervention (3 Months)|insufficient samples of plasma and stool|4
6346318|NCT03452189|10107288|FG001|First Intervention (3 Months)|insufficient samples of plasma and stool|0
6346319|NCT03452527|10107305|FG000|Overall Study|Withdrawal by Subject|1
6346320|NCT03452527|10107306|FG001|Overall Study|Withdrawal by Subject|1
6346321|NCT03452527|10107305|FG000|Overall Study|Study Terminated|2
6346322|NCT03452527|10107306|FG001|Overall Study|Study Terminated|3
6346323|NCT03452943|10107314|FG000|Titration Period (7 Weeks)|Adverse Event|1
6346324|NCT03452943|10107315|FG001|Titration Period (7 Weeks)|Adverse Event|1
6346325|NCT03452943|10107314|FG000|Titration Period (7 Weeks)|Protocol Violation|0
6346326|NCT03452943|10107315|FG001|Titration Period (7 Weeks)|Protocol Violation|1
6346327|NCT03452943|10107314|FG000|Titration Period (7 Weeks)|Withdrawal by Subject|3
6346328|NCT03452943|10107315|FG001|Titration Period (7 Weeks)|Withdrawal by Subject|2
6346329|NCT03452943|10107314|FG000|Titration Period (7 Weeks)|Lost to Follow-up|1
6346330|NCT03452943|10107315|FG001|Titration Period (7 Weeks)|Lost to Follow-up|0
6346331|NCT03452943|10107314|FG000|Maintenance Period (5 Weeks)|Adverse Event|1
6346332|NCT03452943|10107315|FG001|Maintenance Period (5 Weeks)|Adverse Event|0
6346333|NCT03452943|10107314|FG000|Maintenance Period (5 Weeks)|Withdrawal by Subject|2
6346334|NCT03452943|10107315|FG001|Maintenance Period (5 Weeks)|Withdrawal by Subject|0
6346335|NCT03453151|10107342|FG000|Overall Study|Withdrawal by Subject|1
6346336|NCT03453151|10107342|FG000|Overall Study|Physician Decision|3
6346337|NCT03454412|10107374|FG000|Baseline Assesment|Physician Decision|12
6346338|NCT03455543|10107416|FG000|Part A: Randomized Treatment (17 Weeks)|Adverse Event|2
6346339|NCT03455543|10107417|FG001|Part A: Randomized Treatment (17 Weeks)|Adverse Event|5
6346340|NCT03455543|10107418|FG002|Part A: Randomized Treatment (17 Weeks)|Adverse Event|0
6346341|NCT03455543|10107416|FG000|Part A: Randomized Treatment (17 Weeks)|Withdrawal by Subject|7
6346342|NCT03455543|10107417|FG001|Part A: Randomized Treatment (17 Weeks)|Withdrawal by Subject|2
6346343|NCT03455543|10107418|FG002|Part A: Randomized Treatment (17 Weeks)|Withdrawal by Subject|0
6346344|NCT03455543|10107416|FG000|Part A: Randomized Treatment (17 Weeks)|Physician Decision|2
6346345|NCT03455543|10107417|FG001|Part A: Randomized Treatment (17 Weeks)|Physician Decision|0
6346346|NCT03455543|10107418|FG002|Part A: Randomized Treatment (17 Weeks)|Physician Decision|0
6346347|NCT03455543|10107416|FG000|Part B: Open-label Extension (24 Weeks)|Adverse Event|0
6346348|NCT03455543|10107417|FG001|Part B: Open-label Extension (24 Weeks)|Adverse Event|0
6346349|NCT03455543|10107418|FG002|Part B: Open-label Extension (24 Weeks)|Adverse Event|3
6346350|NCT03455543|10107416|FG000|Part B: Open-label Extension (24 Weeks)|Withdrawal by Subject|0
6346351|NCT03455543|10107417|FG001|Part B: Open-label Extension (24 Weeks)|Withdrawal by Subject|0
6346352|NCT03455543|10107418|FG002|Part B: Open-label Extension (24 Weeks)|Withdrawal by Subject|20
6346353|NCT03455543|10107416|FG000|Part B: Open-label Extension (24 Weeks)|Lack of Efficacy|0
6346354|NCT03455543|10107417|FG001|Part B: Open-label Extension (24 Weeks)|Lack of Efficacy|0
6346355|NCT03455543|10107418|FG002|Part B: Open-label Extension (24 Weeks)|Lack of Efficacy|7
6346356|NCT03455543|10107416|FG000|Part B: Open-label Extension (24 Weeks)|Lost to Follow-up|0
6346357|NCT03455543|10107417|FG001|Part B: Open-label Extension (24 Weeks)|Lost to Follow-up|0
6346358|NCT03455543|10107418|FG002|Part B: Open-label Extension (24 Weeks)|Lost to Follow-up|4
6346359|NCT03455543|10107416|FG000|Part B: Open-label Extension (24 Weeks)|Out of window for visits|0
6346360|NCT03455543|10107417|FG001|Part B: Open-label Extension (24 Weeks)|Out of window for visits|0
6346361|NCT03455543|10107418|FG002|Part B: Open-label Extension (24 Weeks)|Out of window for visits|2
6346362|NCT03455543|10107416|FG000|Part B: Open-label Extension (24 Weeks)|Device interfered with home speakers|0
6346363|NCT03455543|10107417|FG001|Part B: Open-label Extension (24 Weeks)|Device interfered with home speakers|0
6346364|NCT03455543|10107418|FG002|Part B: Open-label Extension (24 Weeks)|Device interfered with home speakers|1
6346365|NCT03456856|10107435|FG000|Overall Study|Lost to Follow-up|2
6346366|NCT03456856|10107435|FG000|Overall Study|Withdrawal by Subject|1
6346367|NCT03456960|10107445|FG000|Washout Period (at Least 14 Days)|Withdrawal by Subject|0
6346368|NCT03456960|10107446|FG001|Washout Period (at Least 14 Days)|Withdrawal by Subject|0
6346369|NCT03456960|10107447|FG002|Washout Period (at Least 14 Days)|Withdrawal by Subject|1
6346370|NCT03456960|10107448|FG003|Washout Period (at Least 14 Days)|Withdrawal by Subject|2
6346371|NCT03456960|10107449|FG004|Washout Period (at Least 14 Days)|Withdrawal by Subject|0
6346372|NCT03456960|10107450|FG005|Washout Period (at Least 14 Days)|Withdrawal by Subject|0
6346373|NCT03456960|10107445|FG000|Period 2 (1 Day)|Adverse Event|1
6346374|NCT03456960|10107446|FG001|Period 2 (1 Day)|Adverse Event|0
6346375|NCT03456960|10107447|FG002|Period 2 (1 Day)|Adverse Event|0
6346376|NCT03456960|10107448|FG003|Period 2 (1 Day)|Adverse Event|1
6346377|NCT03456960|10107449|FG004|Period 2 (1 Day)|Adverse Event|0
6346378|NCT03456960|10107450|FG005|Period 2 (1 Day)|Adverse Event|0
6346379|NCT03457103|10107468|FG000|Overall Study|illness/hospitalization|4
6346380|NCT03457103|10107469|FG001|Overall Study|illness/hospitalization|2
6346381|NCT03457103|10107468|FG000|Overall Study|Lost to Follow-up|2
6346382|NCT03457103|10107469|FG001|Overall Study|Lost to Follow-up|1
6346383|NCT03457103|10107468|FG000|Overall Study|Withdrawal by Subject|1
6346384|NCT03457103|10107469|FG001|Overall Study|Withdrawal by Subject|2
6346385|NCT03457103|10107468|FG000|Overall Study|financial/ insurance issues|1
6346386|NCT03457103|10107469|FG001|Overall Study|financial/ insurance issues|1
6346387|NCT03457636|10107484|FG000|Overall Study|Lost to Follow-up|2
6346388|NCT03457727|10107492|FG000|Part 2, Washout Period 1 (5 Days)|Adverse Event|0
6346389|NCT03457727|10107493|FG001|Part 2, Washout Period 1 (5 Days)|Adverse Event|0
6346390|NCT03457727|10107494|FG002|Part 2, Washout Period 1 (5 Days)|Adverse Event|0
6346391|NCT03457727|10107495|FG003|Part 2, Washout Period 1 (5 Days)|Adverse Event|1
6346392|NCT03458702|10107531|FG000|Study Condition A (Yoga or Rest)|Lost to Follow-up|4
6346393|NCT03458702|10107532|FG001|Study Condition A (Yoga or Rest)|Lost to Follow-up|6
6346394|NCT03458702|10107531|FG000|Study Condition B (Yoga or Rest)|Lost to Follow-up|4
6346395|NCT03458702|10107532|FG001|Study Condition B (Yoga or Rest)|Lost to Follow-up|2
6346396|NCT03459040|10107542|FG000|Overall Study|Death|8
6346397|NCT03459040|10107542|FG000|Overall Study|Withdrawal by Subject|1
6346398|NCT03459196|10107554|FG000|Overall Study|Subject didn't receive study catheter|2
6346399|NCT03461146|10107615|FG000|Overall Study|Adverse Event|2
6346400|NCT03461146|10107615|FG000|Overall Study|Physician Decision|1
6346401|NCT03461757|10107621|FG000|Overall Study|Adverse Event|1
6346402|NCT03461757|10107622|FG001|Overall Study|Adverse Event|0
6346403|NCT03461757|10107621|FG000|Overall Study|Lost to Follow-up|13
6346404|NCT03461757|10107622|FG001|Overall Study|Lost to Follow-up|7
6346405|NCT03461757|10107621|FG000|Overall Study|Not Experienced Moderate/Severe Migraine|28
6346406|NCT03461757|10107622|FG001|Overall Study|Not Experienced Moderate/Severe Migraine|25
6346407|NCT03461757|10107621|FG000|Overall Study|Non-compliance with study treatment|0
6346408|NCT03461757|10107622|FG001|Overall Study|Non-compliance with study treatment|1
6346409|NCT03461757|10107621|FG000|Overall Study|Pregnancy|2
6346410|NCT03461757|10107622|FG001|Overall Study|Pregnancy|0
6346411|NCT03461757|10107621|FG000|Overall Study|Protocol Violation|1
6346412|NCT03461757|10107622|FG001|Overall Study|Protocol Violation|1
6346413|NCT03461757|10107621|FG000|Overall Study|Withdrawal by Subject|7
6346414|NCT03461757|10107622|FG001|Overall Study|Withdrawal by Subject|7
6346415|NCT03461757|10107621|FG000|Overall Study|Other Reasons|1
6346416|NCT03461757|10107622|FG001|Overall Study|Other Reasons|4
6346417|NCT03462082|10107637|FG000|Open Label Phase|Symptom worsening (Treatment failure)|0
6346418|NCT03462082|10107638|FG001|Open Label Phase|Symptom worsening (Treatment failure)|0
6346419|NCT03462082|10107639|FG002|Open Label Phase|Symptom worsening (Treatment failure)|0
6346420|NCT03462082|10107640|FG003|Open Label Phase|Symptom worsening (Treatment failure)|0
6346421|NCT03462082|10107641|FG004|Open Label Phase|Symptom worsening (Treatment failure)|0
6346422|NCT03462082|10107642|FG005|Open Label Phase|Symptom worsening (Treatment failure)|0
6346423|NCT03462082|10107643|FG006|Open Label Phase|Symptom worsening (Treatment failure)|1
6346424|NCT03462082|10107644|FG007|Open Label Phase|Symptom worsening (Treatment failure)|2
6346425|NCT03462576|10107657|FG000|Overall Study|Protocol Violation|5
6346426|NCT03462576|10107658|FG001|Overall Study|Protocol Violation|11
6346427|NCT03462576|10107659|FG002|Overall Study|Protocol Violation|7
6346428|NCT03462576|10107657|FG000|Overall Study|Device Malfunction|0
6346429|NCT03462576|10107658|FG001|Overall Study|Device Malfunction|0
6346430|NCT03462576|10107659|FG002|Overall Study|Device Malfunction|1
6346431|NCT03462680|10107669|FG000|Overall Study|Withdrawal by Subject|3
6346432|NCT03462680|10107670|FG001|Overall Study|Withdrawal by Subject|5
6346433|NCT03463031|10107698|FG000|Overall Study|Withdrawal by Subject|4
6346434|NCT03463031|10107699|FG001|Overall Study|Withdrawal by Subject|2
6346435|NCT03463031|10107698|FG000|Overall Study|Investigator/Sponsor Decision|0
6346436|NCT03463031|10107699|FG001|Overall Study|Investigator/Sponsor Decision|1
6346437|NCT03463031|10107698|FG000|Overall Study|Lost to Follow-up|1
6346438|NCT03463031|10107699|FG001|Overall Study|Lost to Follow-up|1
6346439|NCT03463031|10107698|FG000|Overall Study|Adverse Event|4
6346440|NCT03463031|10107699|FG001|Overall Study|Adverse Event|1
6346441|NCT03463031|10107698|FG000|Overall Study|Use of prohibited medication by subject|1
6346442|NCT03463031|10107699|FG001|Overall Study|Use of prohibited medication by subject|0
6346443|NCT03464383|10107741|FG000|Overall Study|Lost to Follow-up|1
6346444|NCT03464383|10107742|FG001|Overall Study|Lost to Follow-up|0
6346445|NCT03464383|10107743|FG002|Overall Study|Lost to Follow-up|0
6346446|NCT03464383|10107741|FG000|Overall Study|Withdrawal by Subject|0
6346447|NCT03464383|10107742|FG001|Overall Study|Withdrawal by Subject|1
6346448|NCT03464383|10107743|FG002|Overall Study|Withdrawal by Subject|0
6346449|NCT03464422|10107752|FG000|Overall Study|Lost to Follow-up|2
6346450|NCT03464422|10107752|FG000|Overall Study|Withdrawal by Subject|2
6346451|NCT03465436|10107762|FG000|Period 1|Protocol Violation|0
6346452|NCT03465436|10107763|FG001|Period 1|Protocol Violation|0
6346453|NCT03465436|10107764|FG002|Period 1|Protocol Violation|1
6346454|NCT03465436|10107765|FG003|Period 1|Protocol Violation|0
6346455|NCT03465436|10107762|FG000|Period 2|Protocol Violation|0
6346456|NCT03465436|10107763|FG001|Period 2|Protocol Violation|1
6346457|NCT03465436|10107764|FG002|Period 2|Protocol Violation|0
6346458|NCT03465436|10107765|FG003|Period 2|Protocol Violation|0
6346459|NCT03465436|10107762|FG000|Period 3|Protocol Violation|1
6346460|NCT03465436|10107763|FG001|Period 3|Protocol Violation|1
6346461|NCT03465436|10107764|FG002|Period 3|Protocol Violation|0
6346462|NCT03465436|10107765|FG003|Period 3|Protocol Violation|0
6346463|NCT03465436|10107762|FG000|Period 4|Protocol Violation|0
6346464|NCT03465436|10107763|FG001|Period 4|Protocol Violation|0
6346465|NCT03465436|10107764|FG002|Period 4|Protocol Violation|1
6346466|NCT03465436|10107765|FG003|Period 4|Protocol Violation|0
6346467|NCT03465709|10107777|FG000|Overall Study|Study/Site Terminated by Sponsor|14
6346468|NCT03465709|10107777|FG000|Overall Study|Withdrawal by Subject|3
6346469|NCT03465722|10107785|FG000|End of Treatment|Patient Refused Treatment|3
6346470|NCT03465722|10107786|FG001|End of Treatment|Patient Refused Treatment|1
6346471|NCT03465722|10107785|FG000|End of Treatment|Withdrawal by Subject|6
6346472|NCT03465722|10107786|FG001|End of Treatment|Withdrawal by Subject|1
6346473|NCT03465722|10107785|FG000|End of Treatment|Adverse Event|30
6346474|NCT03465722|10107786|FG001|End of Treatment|Adverse Event|23
6346475|NCT03465722|10107785|FG000|End of Treatment|Disease Progression (Confirmed by Central Review)|102
6346476|NCT03465722|10107786|FG001|End of Treatment|Disease Progression (Confirmed by Central Review)|101
6346477|NCT03465722|10107785|FG000|End of Treatment|Clinical Progression|17
6346478|NCT03465722|10107786|FG001|End of Treatment|Clinical Progression|5
6346479|NCT03465722|10107785|FG000|End of Treatment|Physician Decision|4
6346480|NCT03465722|10107786|FG001|End of Treatment|Physician Decision|5
6346481|NCT03465722|10107785|FG000|End of Treatment|Lost to Follow-up|3
6346482|NCT03465722|10107786|FG001|End of Treatment|Lost to Follow-up|1
6346483|NCT03465722|10107785|FG000|End of Treatment|Administrative/Other|6
6346484|NCT03465722|10107786|FG001|End of Treatment|Administrative/Other|3
6346485|NCT03465722|10107785|FG000|End of Treatment|Treatment Ongoing|68
6346486|NCT03465722|10107786|FG001|End of Treatment|Treatment Ongoing|94
6346487|NCT03465722|10107785|FG000|End of Treatment|Randomized But Not Treated|1
6346488|NCT03465722|10107786|FG001|End of Treatment|Randomized But Not Treated|2
6346489|NCT03465722|10107785|FG000|End of Study|Withdrawal by Subject|17
6346490|NCT03465722|10107786|FG001|End of Study|Withdrawal by Subject|7
6346491|NCT03465722|10107785|FG000|End of Study|Death|57
6346492|NCT03465722|10107786|FG001|End of Study|Death|57
6346493|NCT03465722|10107785|FG000|End of Study|Lost to Follow-up|5
6346494|NCT03465722|10107786|FG001|End of Study|Lost to Follow-up|2
6346495|NCT03465722|10107785|FG000|End of Study|Administrative/Other|4
6346496|NCT03465722|10107786|FG001|End of Study|Administrative/Other|2
6346497|NCT03465722|10107785|FG000|End of Study|On Treatment or in Follow Up|157
6346498|NCT03465722|10107786|FG001|End of Study|On Treatment or in Follow Up|168
6346499|NCT03465878|10107794|FG000|Period 1-Part A First Intervention Day 1|Withdrawal by Subject|0
6346500|NCT03465878|10107795|FG001|Period 1-Part A First Intervention Day 1|Withdrawal by Subject|1
6346501|NCT03465878|10107796|FG002|Period 1-Part A First Intervention Day 1|Withdrawal by Subject|0
6346502|NCT03465878|10107797|FG003|Period 1-Part A First Intervention Day 1|Withdrawal by Subject|0
6346503|NCT03465878|10107794|FG000|Period 1-Part B First Intervention Day 1|Withdrawal by Subject|0
6346504|NCT03465878|10107795|FG001|Period 1-Part B First Intervention Day 1|Withdrawal by Subject|0
6168922|NCT01238861|9814102|FG003|Overall Study|Lack of compliance|0
6346505|NCT03465878|10107796|FG002|Period 1-Part B First Intervention Day 1|Withdrawal by Subject|0
6346506|NCT03465878|10107797|FG003|Period 1-Part B First Intervention Day 1|Withdrawal by Subject|1
6346507|NCT03465878|10107794|FG000|Period 1-Part B First Intervention Day 1|Physician Decision|0
6346508|NCT03465878|10107795|FG001|Period 1-Part B First Intervention Day 1|Physician Decision|0
6346509|NCT03465878|10107796|FG002|Period 1-Part B First Intervention Day 1|Physician Decision|0
6346510|NCT03465878|10107797|FG003|Period 1-Part B First Intervention Day 1|Physician Decision|1
6346511|NCT03465904|10107825|FG000|Overall Study|Withdrawal by Subject|9
6346512|NCT03465904|10107826|FG001|Overall Study|Withdrawal by Subject|5
6346513|NCT03465904|10107825|FG000|Overall Study|Lost to Follow-up|10
6346514|NCT03465904|10107826|FG001|Overall Study|Lost to Follow-up|9
6346515|NCT03465904|10107825|FG000|Overall Study|Protocol Violation|8
6346516|NCT03465904|10107826|FG001|Overall Study|Protocol Violation|5
6346517|NCT03465904|10107825|FG000|Overall Study|Ineligible for mITT analysis|62
6346518|NCT03465904|10107826|FG001|Overall Study|Ineligible for mITT analysis|47
6346519|NCT03466060|10107861|FG000|Period 1|Test Lens Damage|0
6346520|NCT03466060|10107862|FG001|Period 1|Test Lens Damage|2
6346521|NCT03466060|10107863|FG002|Period 1|Test Lens Damage|0
6346522|NCT03466060|10107864|FG003|Period 1|Test Lens Damage|0
6346523|NCT03466060|10107865|FG004|Period 1|Test Lens Damage|0
6346524|NCT03466060|10107866|FG005|Period 1|Test Lens Damage|0
6346525|NCT03466060|10107861|FG000|Period 1|Withdrawal by Subject|0
6346526|NCT03466060|10107862|FG001|Period 1|Withdrawal by Subject|0
6346527|NCT03466060|10107863|FG002|Period 1|Withdrawal by Subject|2
6346528|NCT03466060|10107864|FG003|Period 1|Withdrawal by Subject|0
6346529|NCT03466060|10107865|FG004|Period 1|Withdrawal by Subject|0
6346530|NCT03466060|10107866|FG005|Period 1|Withdrawal by Subject|0
6346531|NCT03466060|10107861|FG000|Period 1|Lost to Follow-up|0
6346532|NCT03466060|10107862|FG001|Period 1|Lost to Follow-up|0
6346533|NCT03466060|10107863|FG002|Period 1|Lost to Follow-up|0
6346534|NCT03466060|10107864|FG003|Period 1|Lost to Follow-up|1
6346535|NCT03466060|10107865|FG004|Period 1|Lost to Follow-up|0
6346536|NCT03466060|10107866|FG005|Period 1|Lost to Follow-up|0
6346537|NCT03466060|10107861|FG000|Period 1|Grade 2 Conjunctivitis|0
6346538|NCT03466060|10107862|FG001|Period 1|Grade 2 Conjunctivitis|0
6346539|NCT03466060|10107863|FG002|Period 1|Grade 2 Conjunctivitis|1
6346540|NCT03466060|10107864|FG003|Period 1|Grade 2 Conjunctivitis|0
6346541|NCT03466060|10107865|FG004|Period 1|Grade 2 Conjunctivitis|0
6346542|NCT03466060|10107866|FG005|Period 1|Grade 2 Conjunctivitis|0
6346543|NCT03466060|10107861|FG000|Period 2|Lens Handling Difficulties|0
6346544|NCT03466060|10107862|FG001|Period 2|Lens Handling Difficulties|0
6346545|NCT03466060|10107863|FG002|Period 2|Lens Handling Difficulties|1
6346546|NCT03466060|10107864|FG003|Period 2|Lens Handling Difficulties|0
6346547|NCT03466060|10107865|FG004|Period 2|Lens Handling Difficulties|0
6346548|NCT03466060|10107866|FG005|Period 2|Lens Handling Difficulties|0
6346549|NCT03466073|10107886|FG000|Overall Study|Death|1
6346550|NCT03466073|10107887|FG001|Overall Study|Death|0
6346551|NCT03466073|10107888|FG002|Overall Study|Death|0
6346552|NCT03466073|10107889|FG003|Overall Study|Death|0
6346553|NCT03466073|10107890|FG004|Overall Study|Death|0
6346554|NCT03466073|10107891|FG005|Overall Study|Death|1
6346555|NCT03466086|10107912|FG000|Period 1|Sponsor decision due to study timeline|1
6346556|NCT03466086|10107913|FG001|Period 1|Sponsor decision due to study timeline|0
6346557|NCT03466086|10107912|FG000|Period 1|Withdrawal by Subject|1
6346558|NCT03466086|10107913|FG001|Period 1|Withdrawal by Subject|0
6346559|NCT03466099|10107922|FG000|Overall Study|Adverse Event|1
6346560|NCT03466099|10107923|FG001|Overall Study|Adverse Event|1
6346561|NCT03466099|10107924|FG002|Overall Study|Adverse Event|1
6346562|NCT03466099|10107922|FG000|Overall Study|Withdrawal by Subject|2
6346563|NCT03466099|10107923|FG001|Overall Study|Withdrawal by Subject|3
6168923|NCT01238861|9814103|FG004|Overall Study|Lack of compliance|0
6168924|NCT01238861|9814104|FG005|Overall Study|Lack of compliance|1
6346564|NCT03466099|10107924|FG002|Overall Study|Withdrawal by Subject|1
6346565|NCT03466099|10107922|FG000|Overall Study|Use of rescue medication|8
6346566|NCT03466099|10107923|FG001|Overall Study|Use of rescue medication|9
6346567|NCT03466099|10107924|FG002|Overall Study|Use of rescue medication|13
6346568|NCT03466099|10107922|FG000|Overall Study|Rescued without meeting criteria|4
6346569|NCT03466099|10107923|FG001|Overall Study|Rescued without meeting criteria|1
6346570|NCT03466099|10107924|FG002|Overall Study|Rescued without meeting criteria|1
6346571|NCT03466099|10107922|FG000|Overall Study|Subject compliance|2
6346572|NCT03466099|10107923|FG001|Overall Study|Subject compliance|0
6346573|NCT03466099|10107924|FG002|Overall Study|Subject compliance|0
6346574|NCT03466099|10107922|FG000|Overall Study|Worsening disease|0
6346575|NCT03466099|10107923|FG001|Overall Study|Worsening disease|0
6346576|NCT03466099|10107924|FG002|Overall Study|Worsening disease|1
6346577|NCT03467217|10107948|FG000|Overall Study|Trial stopped early|5
6346578|NCT03467217|10107949|FG001|Overall Study|Trial stopped early|2
6346579|NCT03467217|10107948|FG000|Overall Study|Clinic closed due to COVID-19 pandemic|5
6346580|NCT03467217|10107949|FG001|Overall Study|Clinic closed due to COVID-19 pandemic|2
6346581|NCT03467217|10107948|FG000|Overall Study|Lost to Follow-up|0
6346582|NCT03467217|10107949|FG001|Overall Study|Lost to Follow-up|2
6346583|NCT03467425|10107980|FG000|Overall Study|Adverse Event|9
6346584|NCT03467425|10107981|FG001|Overall Study|Adverse Event|9
6346585|NCT03467425|10107980|FG000|Overall Study|Lack of Efficacy|3
6346586|NCT03467425|10107981|FG001|Overall Study|Lack of Efficacy|1
6346587|NCT03467425|10107980|FG000|Overall Study|Protocol Violation|0
6346588|NCT03467425|10107981|FG001|Overall Study|Protocol Violation|1
6346589|NCT03467425|10107980|FG000|Overall Study|Lost to Follow-up|18
6346590|NCT03467425|10107981|FG001|Overall Study|Lost to Follow-up|25
6346591|NCT03467425|10107980|FG000|Overall Study|Physician Decision|2
6168925|NCT01238861|9814099|FG000|Overall Study|Adverse Event|0
6346592|NCT03467425|10107981|FG001|Overall Study|Physician Decision|1
6346593|NCT03467425|10107980|FG000|Overall Study|Withdrawal by Subject|15
6346594|NCT03467425|10107981|FG001|Overall Study|Withdrawal by Subject|17
6168926|NCT01238861|9814100|FG001|Overall Study|Adverse Event|1
6168927|NCT01238861|9814101|FG002|Overall Study|Adverse Event|0
6168928|NCT01238861|9814102|FG003|Overall Study|Adverse Event|0
6168929|NCT01238861|9814103|FG004|Overall Study|Adverse Event|0
6168930|NCT01238861|9814104|FG005|Overall Study|Adverse Event|0
6346595|NCT03467763|10108003|FG000|Overall Study|Lost to Follow-up|1
6346596|NCT03467763|10108003|FG000|Overall Study|Protocol Violation|2
6346597|NCT03467945|10108013|FG000|Treatment Period 2|Withdrawal by Subject|0
6346598|NCT03467945|10108014|FG001|Treatment Period 2|Withdrawal by Subject|1
6346599|NCT03467945|10108015|FG002|Treatment Period 2|Withdrawal by Subject|0
6346600|NCT03467945|10108016|FG003|Treatment Period 2|Withdrawal by Subject|0
6346601|NCT03467945|10108013|FG000|Treatment Period 3|Withdrawal by Subject|1
6346602|NCT03467945|10108014|FG001|Treatment Period 3|Withdrawal by Subject|0
6346603|NCT03467945|10108015|FG002|Treatment Period 3|Withdrawal by Subject|2
6346604|NCT03467945|10108016|FG003|Treatment Period 3|Withdrawal by Subject|1
6346605|NCT03467971|10108029|FG000|Treatment Period 2|Withdrawal by Subject|0
6346606|NCT03467971|10108030|FG001|Treatment Period 2|Withdrawal by Subject|1
6346607|NCT03468543|10108048|FG000|Overall Study|Protocol stopping rules met|3
6346608|NCT03468855|10108063|FG000|Overall Study|Adverse Event|2
6346609|NCT03468855|10108063|FG000|Overall Study|Lost to Follow-up|5
6346610|NCT03468855|10108063|FG000|Overall Study|Withdrawal by Subject|3
6346611|NCT03468855|10108063|FG000|Overall Study|Inclusion/Exclusion Enrollment Violator|1
6346612|NCT03469336|10108085|FG000|Overall Study|Adverse Event|1
6346613|NCT03469349|10108097|FG000|Overall Study|Withdrawal by Subject|1
6346614|NCT03469349|10108098|FG001|Overall Study|Withdrawal by Subject|3
6346615|NCT03469349|10108097|FG000|Overall Study|Progressive Disease|0
6346616|NCT03469349|10108098|FG001|Overall Study|Progressive Disease|1
6346617|NCT03469349|10108097|FG000|Overall Study|Lost to Follow-up|2
6346618|NCT03469349|10108098|FG001|Overall Study|Lost to Follow-up|2
6346619|NCT03469349|10108097|FG000|Overall Study|Adverse Event|2
6346620|NCT03469349|10108098|FG001|Overall Study|Adverse Event|4
6346621|NCT03470194|10108110|FG000|Overall Study|Lost to Follow-up|11
6346622|NCT03470194|10108111|FG001|Overall Study|Lost to Follow-up|17
6346623|NCT03470545|10108123|FG000|Overall Study|Death|0
6346624|NCT03470545|10108124|FG001|Overall Study|Death|1
6346625|NCT03470545|10108123|FG000|Overall Study|Did not complete Week 30 assessments due to scheduling conflict|1
6346626|NCT03470545|10108124|FG001|Overall Study|Did not complete Week 30 assessments due to scheduling conflict|0
6346627|NCT03470545|10108123|FG000|Overall Study|Adverse Event|2
6346628|NCT03470545|10108124|FG001|Overall Study|Adverse Event|0
6346629|NCT03470545|10108123|FG000|Overall Study|Withdrawal by Subject|1
6346630|NCT03470545|10108124|FG001|Overall Study|Withdrawal by Subject|1
6346631|NCT03470545|10108123|FG000|Overall Study|Week 30 not completed due to circumstances surrounding the COVID-19 pandemic|0
6346632|NCT03470545|10108124|FG001|Overall Study|Week 30 not completed due to circumstances surrounding the COVID-19 pandemic|1
6346633|NCT03471078|10108147|FG000|Overall Study|Withdrawal by Subject|9
6346634|NCT03471078|10108148|FG001|Overall Study|Withdrawal by Subject|1
6346635|NCT03471078|10108147|FG000|Overall Study|Adverse Event|4
6346636|NCT03471078|10108148|FG001|Overall Study|Adverse Event|1
6346637|NCT03471078|10108147|FG000|Overall Study|Physician Decision|3
6346638|NCT03471078|10108148|FG001|Overall Study|Physician Decision|2
6346639|NCT03471078|10108147|FG000|Overall Study|Death|2
6346640|NCT03471078|10108148|FG001|Overall Study|Death|0
6346641|NCT03471078|10108147|FG000|Overall Study|Other|3
6346642|NCT03471078|10108148|FG001|Overall Study|Other|2
6346643|NCT03471871|10108165|FG000|Treatment Period 1(HV:1 Day, OSA:8 Days)|Work Demand: Return to work|0
6346644|NCT03471871|10108166|FG001|Treatment Period 1(HV:1 Day, OSA:8 Days)|Work Demand: Return to work|0
6346645|NCT03471871|10108167|FG002|Treatment Period 1(HV:1 Day, OSA:8 Days)|Work Demand: Return to work|1
6083389|NCT00634933|9691714|FG000|Part B: Week 24 to Week 52|Physician Decision|0
6083390|NCT00634933|9691715|FG001|Part B: Week 24 to Week 52|Physician Decision|1
6346646|NCT03471871|10108168|FG003|Treatment Period 1(HV:1 Day, OSA:8 Days)|Work Demand: Return to work|0
6083391|NCT00634933|9691716|FG002|Part B: Week 24 to Week 52|Physician Decision|1
6168931|NCT01238861|9814099|FG000|Overall Study|Withdrawal by Subject|6
6168932|NCT01238861|9814100|FG001|Overall Study|Withdrawal by Subject|5
6168933|NCT01238861|9814101|FG002|Overall Study|Withdrawal by Subject|4
6168934|NCT01238861|9814102|FG003|Overall Study|Withdrawal by Subject|8
6168935|NCT01238861|9814103|FG004|Overall Study|Withdrawal by Subject|10
6168936|NCT01238861|9814104|FG005|Overall Study|Withdrawal by Subject|9
6168937|NCT01238900|9814125|FG000|<12 Months Post Stent Removal|Lost to Follow-up|4
6168938|NCT01238900|9814125|FG000|<12 Months Post Stent Removal|persistent stricture after stenting|1
6168939|NCT01238991|9814140|FG000|Overall Study|Adverse Event|1
6168940|NCT01238991|9814141|FG001|Overall Study|Adverse Event|0
6168941|NCT01238991|9814142|FG002|Overall Study|Adverse Event|3
6168942|NCT01238991|9814143|FG003|Overall Study|Adverse Event|1
6168943|NCT01238991|9814144|FG004|Overall Study|Adverse Event|1
6168944|NCT01238991|9814145|FG005|Overall Study|Adverse Event|0
6168945|NCT01238991|9814146|FG006|Overall Study|Adverse Event|1
6168946|NCT01238991|9814147|FG007|Overall Study|Adverse Event|1
6083392|NCT00634933|9691717|FG003|Part B: Week 24 to Week 52|Physician Decision|0
6083393|NCT00634933|9691718|FG004|Part B: Week 24 to Week 52|Physician Decision|0
6346647|NCT03471871|10108169|FG004|Treatment Period 1(HV:1 Day, OSA:8 Days)|Work Demand: Return to work|0
6346648|NCT03471871|10108165|FG000|Treatment Period 1(HV:1 Day, OSA:8 Days)|Protocol deviation|0
6346649|NCT03471871|10108166|FG001|Treatment Period 1(HV:1 Day, OSA:8 Days)|Protocol deviation|0
6346650|NCT03471871|10108167|FG002|Treatment Period 1(HV:1 Day, OSA:8 Days)|Protocol deviation|0
6346651|NCT03471871|10108168|FG003|Treatment Period 1(HV:1 Day, OSA:8 Days)|Protocol deviation|1
6346652|NCT03471871|10108169|FG004|Treatment Period 1(HV:1 Day, OSA:8 Days)|Protocol deviation|1
6346653|NCT03471871|10108165|FG000|Treatment Period 2(HV:1 Day, OSA:8 Days)|Other|0
6346654|NCT03471871|10108166|FG001|Treatment Period 2(HV:1 Day, OSA:8 Days)|Other|0
6346655|NCT03471871|10108167|FG002|Treatment Period 2(HV:1 Day, OSA:8 Days)|Other|0
6346656|NCT03471871|10108168|FG003|Treatment Period 2(HV:1 Day, OSA:8 Days)|Other|0
6346657|NCT03471871|10108169|FG004|Treatment Period 2(HV:1 Day, OSA:8 Days)|Other|1
6346658|NCT03471871|10108165|FG000|Follow Up (14 Days for Both HV and OSA)|Protocol Deviation|0
6346659|NCT03471871|10108166|FG001|Follow Up (14 Days for Both HV and OSA)|Protocol Deviation|0
6346660|NCT03471871|10108167|FG002|Follow Up (14 Days for Both HV and OSA)|Protocol Deviation|0
6346661|NCT03471871|10108168|FG003|Follow Up (14 Days for Both HV and OSA)|Protocol Deviation|0
6346662|NCT03471871|10108169|FG004|Follow Up (14 Days for Both HV and OSA)|Protocol Deviation|1
6346663|NCT03471871|10108165|FG000|Follow Up (14 Days for Both HV and OSA)|Did Return to Clinic|0
6346664|NCT03471871|10108166|FG001|Follow Up (14 Days for Both HV and OSA)|Did Return to Clinic|0
6346665|NCT03471871|10108167|FG002|Follow Up (14 Days for Both HV and OSA)|Did Return to Clinic|0
6346666|NCT03471871|10108168|FG003|Follow Up (14 Days for Both HV and OSA)|Did Return to Clinic|1
6346667|NCT03471871|10108169|FG004|Follow Up (14 Days for Both HV and OSA)|Did Return to Clinic|0
6346668|NCT03472014|10108190|FG000|Overall Study|Lost to Follow-up|4
6346669|NCT03472326|10108205|FG000|Part 2: Combination Therapy|Study Terminated by Sponsor|0
6346670|NCT03472326|10108206|FG001|Part 2: Combination Therapy|Study Terminated by Sponsor|0
6346671|NCT03472326|10108207|FG002|Part 2: Combination Therapy|Study Terminated by Sponsor|1
6346672|NCT03472326|10108208|FG003|Part 2: Combination Therapy|Study Terminated by Sponsor|2
6346673|NCT03472326|10108205|FG000|Part 2: Combination Therapy|Pregnancy|0
6346674|NCT03472326|10108206|FG001|Part 2: Combination Therapy|Pregnancy|0
6346675|NCT03472326|10108207|FG002|Part 2: Combination Therapy|Pregnancy|0
6346676|NCT03472326|10108208|FG003|Part 2: Combination Therapy|Pregnancy|1
6346677|NCT03472534|10108226|FG000|Overall Study|Withdrawal by Subject|9
6346678|NCT03472534|10108226|FG000|Overall Study|Adverse Event|2
6346679|NCT03472547|10108230|FG000|Overall Study|Withdrawal by Subject|30
6346680|NCT03473197|10108242|FG000|Overall Study|Adverse Event|4
6346681|NCT03473197|10108242|FG000|Overall Study|Lost to Follow-up|1
6346682|NCT03473197|10108242|FG000|Overall Study|Withdrawal by Subject|5
6346683|NCT03473236|10108256|FG000|Overall Study|Withdrawal by Subject|0
6346684|NCT03473236|10108257|FG001|Overall Study|Withdrawal by Subject|0
6346685|NCT03473236|10108258|FG002|Overall Study|Withdrawal by Subject|0
6346686|NCT03473236|10108259|FG003|Overall Study|Withdrawal by Subject|0
6346687|NCT03473236|10108260|FG004|Overall Study|Withdrawal by Subject|0
6346688|NCT03473236|10108261|FG005|Overall Study|Withdrawal by Subject|1
6346689|NCT03473236|10108262|FG006|Overall Study|Withdrawal by Subject|0
6346690|NCT03473236|10108263|FG007|Overall Study|Withdrawal by Subject|0
6346691|NCT03473236|10108264|FG008|Overall Study|Withdrawal by Subject|1
6346692|NCT03473236|10108265|FG009|Overall Study|Withdrawal by Subject|0
6346693|NCT03473301|10108298|FG000|Overall Study|Protocol Violation|4
6346694|NCT03473301|10108299|FG001|Overall Study|Protocol Violation|0
6346695|NCT03473301|10108300|FG002|Overall Study|Protocol Violation|0
6346696|NCT03473301|10108298|FG000|Overall Study|Withdrawal by Subject|0
6346697|NCT03473301|10108299|FG001|Overall Study|Withdrawal by Subject|1
6346698|NCT03473301|10108300|FG002|Overall Study|Withdrawal by Subject|0
6346699|NCT03473301|10108298|FG000|Overall Study|Missed study visit due to pandemic restrictions|7
6346700|NCT03473301|10108299|FG001|Overall Study|Missed study visit due to pandemic restrictions|5
6346701|NCT03473301|10108300|FG002|Overall Study|Missed study visit due to pandemic restrictions|6
6346702|NCT03473808|10108319|FG000|Overall Study|Withdrawal by Subject|1
6346703|NCT03474081|10108329|FG000|Overall Study|Adverse Event|6
6346704|NCT03474081|10108330|FG001|Overall Study|Adverse Event|3
6346705|NCT03474081|10108329|FG000|Overall Study|Lost to Follow-up|2
6346706|NCT03474081|10108330|FG001|Overall Study|Lost to Follow-up|1
6346707|NCT03474081|10108329|FG000|Overall Study|Physician Decision|3
6346708|NCT03474081|10108330|FG001|Overall Study|Physician Decision|2
6346709|NCT03474081|10108329|FG000|Overall Study|Withdrawal by Subject|5
6346710|NCT03474081|10108330|FG001|Overall Study|Withdrawal by Subject|7
6346711|NCT03474081|10108329|FG000|Overall Study|Investigator site closed|1
6346712|NCT03474081|10108330|FG001|Overall Study|Investigator site closed|0
6346713|NCT03475056|10108360|FG000|Overall Study|Lost to Follow-up|0
6346714|NCT03475056|10108361|FG001|Overall Study|Lost to Follow-up|1
6346715|NCT03475056|10108360|FG000|Overall Study|Moved from Area|0
6346716|NCT03475056|10108361|FG001|Overall Study|Moved from Area|2
6346717|NCT03475316|10108370|FG000|6 Month Intervention|Adverse Event|2
6346718|NCT03475316|10108371|FG001|6 Month Intervention|Adverse Event|1
6346719|NCT03475316|10108370|FG000|6 Month Intervention|Withdrawal by Subject|2
6346720|NCT03475316|10108371|FG001|6 Month Intervention|Withdrawal by Subject|0
6346721|NCT03475316|10108370|FG000|6 Month Intervention|Study stopped due to COVID pandemic|1
6346722|NCT03475316|10108371|FG001|6 Month Intervention|Study stopped due to COVID pandemic|3
6346723|NCT03475316|10108370|FG000|9 Months|Study stopped due to COVID pandemic|3
6346724|NCT03475316|10108371|FG001|9 Months|Study stopped due to COVID pandemic|4
6346725|NCT03475875|10108377|FG000|Period 1|Lost to Follow-up|1
6346726|NCT03475875|10108378|FG001|Period 1|Lost to Follow-up|0
6346727|NCT03475875|10108377|FG000|Period 1|Adverse Event|2
6346728|NCT03475875|10108378|FG001|Period 1|Adverse Event|1
6346729|NCT03475875|10108377|FG000|Period 2|Adverse Event|3
6346730|NCT03475875|10108378|FG001|Period 2|Adverse Event|0
6346731|NCT03475875|10108377|FG000|Period 2|Protocol Violation|0
6346732|NCT03475875|10108378|FG001|Period 2|Protocol Violation|1
6346733|NCT03476798|10108411|FG000|Overall Study|Death|1
6346734|NCT03476798|10108411|FG000|Overall Study|Withdrawal by Subject|2
6346735|NCT03476798|10108411|FG000|Overall Study|Protocol Violation|2
6346736|NCT03477838|10108455|FG000|Overall Study|Lost to Follow-up|14
6346737|NCT03478371|10108473|FG000|Overall Study|non-compliance|1
6346738|NCT03478371|10108473|FG000|Overall Study|Lost to Follow-up|4
6346739|NCT03478644|10108485|FG000|Phase 2|Withdrawal by Subject|2
6346740|NCT03478644|10108486|FG001|Phase 2|Withdrawal by Subject|1
6346741|NCT03478644|10108485|FG000|Phase 2|Lost to Follow-up|1
6346742|NCT03478644|10108486|FG001|Phase 2|Lost to Follow-up|0
6346743|NCT03478657|10108494|FG000|Overall Study|Withdrawal by Subject|0
6346744|NCT03478657|10108495|FG001|Overall Study|Withdrawal by Subject|1
6346745|NCT03478683|10108503|FG000|Overall Study|Adverse Event|5
6346746|NCT03478683|10108504|FG001|Overall Study|Adverse Event|3
6346747|NCT03478683|10108503|FG000|Overall Study|Lost to Follow-up|0
6346748|NCT03478683|10108504|FG001|Overall Study|Lost to Follow-up|5
6346749|NCT03478683|10108503|FG000|Overall Study|Physician Decision|1
6346750|NCT03478683|10108504|FG001|Overall Study|Physician Decision|3
6346751|NCT03478683|10108503|FG000|Overall Study|Withdrawal by Subject|7
6346752|NCT03478683|10108504|FG001|Overall Study|Withdrawal by Subject|7
6346753|NCT03478696|10108512|FG000|Overall Study|Adverse Event|1
6346754|NCT03478696|10108513|FG001|Overall Study|Adverse Event|5
6346755|NCT03478696|10108512|FG000|Overall Study|Lost to Follow-up|1
6346756|NCT03478696|10108513|FG001|Overall Study|Lost to Follow-up|0
6346757|NCT03478696|10108512|FG000|Overall Study|Physician Decision|6
6346758|NCT03478696|10108513|FG001|Overall Study|Physician Decision|3
6346759|NCT03478696|10108512|FG000|Overall Study|Withdrawal by Subject|9
6346760|NCT03478696|10108513|FG001|Overall Study|Withdrawal by Subject|4
6346761|NCT03478787|10108521|FG000|Overall Study|Adverse Event|5
6346762|NCT03478787|10108522|FG001|Overall Study|Adverse Event|1
6346763|NCT03478787|10108521|FG000|Overall Study|Protocol Violation|3
6346764|NCT03478787|10108522|FG001|Overall Study|Protocol Violation|0
6346765|NCT03478787|10108521|FG000|Overall Study|Lack of Efficacy|7
6346766|NCT03478787|10108522|FG001|Overall Study|Lack of Efficacy|1
6346767|NCT03478787|10108521|FG000|Overall Study|Lost to Follow-up|9
6346768|NCT03478787|10108522|FG001|Overall Study|Lost to Follow-up|5
6346769|NCT03478787|10108521|FG000|Overall Study|Withdrawal by Subject|2
6346770|NCT03478787|10108522|FG001|Overall Study|Withdrawal by Subject|6
6346771|NCT03478787|10108521|FG000|Overall Study|Other, Not Specified|3
6346772|NCT03478787|10108522|FG001|Overall Study|Other, Not Specified|0
6346773|NCT03478891|10108531|FG000|Overall Study|Enrolled, but product never administered|0
6346774|NCT03478891|10108532|FG001|Overall Study|Enrolled, but product never administered|0
6346775|NCT03478891|10108533|FG002|Overall Study|Enrolled, but product never administered|1
6346776|NCT03478891|10108531|FG000|Overall Study|Moved from area|0
6346777|NCT03478891|10108532|FG001|Overall Study|Moved from area|0
6346778|NCT03478891|10108533|FG002|Overall Study|Moved from area|1
6346779|NCT03478891|10108531|FG000|Overall Study|Lost to Follow-up|1
6346780|NCT03478891|10108532|FG001|Overall Study|Lost to Follow-up|0
6346781|NCT03478891|10108533|FG002|Overall Study|Lost to Follow-up|1
6346782|NCT03478969|10108559|FG000|Overall Study|Withdrawal by Subject|4
6346783|NCT03478969|10108560|FG001|Overall Study|Withdrawal by Subject|7
6346784|NCT03478969|10108561|FG002|Overall Study|Withdrawal by Subject|6
6346785|NCT03478969|10108559|FG000|Overall Study|Adverse Event|2
6346786|NCT03478969|10108560|FG001|Overall Study|Adverse Event|0
6346787|NCT03478969|10108561|FG002|Overall Study|Adverse Event|1
6346788|NCT03478969|10108559|FG000|Overall Study|Pregnancy|1
6346789|NCT03478969|10108560|FG001|Overall Study|Pregnancy|0
6346790|NCT03478969|10108561|FG002|Overall Study|Pregnancy|0
6346791|NCT03478969|10108559|FG000|Overall Study|Personal Reasons|1
6346792|NCT03478969|10108560|FG001|Overall Study|Personal Reasons|0
6346793|NCT03478969|10108561|FG002|Overall Study|Personal Reasons|1
6346794|NCT03478969|10108559|FG000|Overall Study|Covid-19|1
6346795|NCT03478969|10108560|FG001|Overall Study|Covid-19|4
6346796|NCT03478969|10108561|FG002|Overall Study|Covid-19|3
6346797|NCT03478969|10108559|FG000|Overall Study|Multiple Reasons|0
6346798|NCT03478969|10108560|FG001|Overall Study|Multiple Reasons|1
6346799|NCT03478969|10108561|FG002|Overall Study|Multiple Reasons|1
6346800|NCT03478969|10108559|FG000|Overall Study|Eligibility Criteria|0
6346801|NCT03478969|10108560|FG001|Overall Study|Eligibility Criteria|0
6346802|NCT03478969|10108561|FG002|Overall Study|Eligibility Criteria|5
6346803|NCT03478969|10108559|FG000|Overall Study|Lost to Follow-up|0
6346804|NCT03478969|10108560|FG001|Overall Study|Lost to Follow-up|0
6346805|NCT03478969|10108561|FG002|Overall Study|Lost to Follow-up|1
6346806|NCT03479216|10108590|FG000|Overall Study|Withdrawal by Subject|3
6083394|NCT00634933|9691714|FG000|Part B: Week 24 to Week 52|Protocol Violation|0
6083395|NCT00634933|9691715|FG001|Part B: Week 24 to Week 52|Protocol Violation|0
6346807|NCT03479216|10108591|FG001|Overall Study|Withdrawal by Subject|2
6346808|NCT03479216|10108590|FG000|Overall Study|Physician Decision|2
6346809|NCT03479216|10108591|FG001|Overall Study|Physician Decision|3
6346810|NCT03480009|10108609|FG000|Overall Study|Lost to Follow-up|4
6346811|NCT03480009|10108610|FG001|Overall Study|Lost to Follow-up|5
6346812|NCT03480009|10108611|FG002|Overall Study|Lost to Follow-up|4
6346813|NCT03480009|10108612|FG003|Overall Study|Lost to Follow-up|0
6346814|NCT03480022|10108627|FG000|Overall Study|Pregnancy|2
6346815|NCT03480022|10108628|FG001|Overall Study|Pregnancy|0
6346816|NCT03480022|10108627|FG000|Overall Study|Adverse Event|6
6346817|NCT03480022|10108628|FG001|Overall Study|Adverse Event|0
6346818|NCT03480022|10108627|FG000|Overall Study|Lack of Efficacy|0
6346819|NCT03480022|10108628|FG001|Overall Study|Lack of Efficacy|2
6346820|NCT03480022|10108627|FG000|Overall Study|Physician Decision|0
6346821|NCT03480022|10108628|FG001|Overall Study|Physician Decision|1
6346822|NCT03480022|10108627|FG000|Overall Study|Withdrawal by Subject|2
6346823|NCT03480022|10108628|FG001|Overall Study|Withdrawal by Subject|0
6346824|NCT03480022|10108627|FG000|Overall Study|Medication concerns|1
6346825|NCT03480022|10108628|FG001|Overall Study|Medication concerns|0
6346826|NCT03480022|10108627|FG000|Overall Study|Family member COVID exposure|0
6346827|NCT03480022|10108628|FG001|Overall Study|Family member COVID exposure|1
6346828|NCT03480152|10108645|FG000|Phase I|Signed consent. Died before treatment.|1
6346829|NCT03480152|10108646|FG001|Phase I|Signed consent. Died before treatment.|0
6087756|NCT00670449|9698233|FG002|Overall Study|Protocol Deviation|0
6346830|NCT03480152|10108647|FG002|Phase I|Signed consent. Died before treatment.|0
6346831|NCT03480243|10108655|FG000|Padsevonil (Period 2)|Consent withdrawal by subject|1
6346832|NCT03480243|10108655|FG000|Padsevonil and Erythromycin (Period 3b)|Un-cooperative behaviour|1
6346833|NCT03480425|10108668|FG000|Overall Study|Force transducer technical failure|1
6346834|NCT03480750|10108684|FG000|Overall Study|Withdrawal by Subject|0
6346835|NCT03480750|10108685|FG001|Overall Study|Withdrawal by Subject|1
6346836|NCT03480750|10108686|FG002|Overall Study|Withdrawal by Subject|0
6346837|NCT03480750|10108687|FG003|Overall Study|Withdrawal by Subject|0
6346838|NCT03480750|10108688|FG004|Overall Study|Withdrawal by Subject|0
6346839|NCT03480750|10108689|FG005|Overall Study|Withdrawal by Subject|0
6346840|NCT03480750|10108684|FG000|Overall Study|The interruption in Trientine shippment|0
6346841|NCT03480750|10108685|FG001|Overall Study|The interruption in Trientine shippment|0
6346842|NCT03480750|10108686|FG002|Overall Study|The interruption in Trientine shippment|0
6346843|NCT03480750|10108687|FG003|Overall Study|The interruption in Trientine shippment|0
6346844|NCT03480750|10108688|FG004|Overall Study|The interruption in Trientine shippment|0
6346845|NCT03480750|10108689|FG005|Overall Study|The interruption in Trientine shippment|1
6346846|NCT03480763|10108714|FG000|Overall Study|Withdrawal by Subject|18
6346847|NCT03480763|10108715|FG001|Overall Study|Withdrawal by Subject|10
6346848|NCT03480763|10108714|FG000|Overall Study|Lost to Follow-up|4
6346849|NCT03480763|10108715|FG001|Overall Study|Lost to Follow-up|7
6346850|NCT03480763|10108714|FG000|Overall Study|non-study pneumococcal vaccine|1
6346851|NCT03480763|10108715|FG001|Overall Study|non-study pneumococcal vaccine|0
6346852|NCT03480763|10108714|FG000|Overall Study|oncological treatment|0
6346853|NCT03480763|10108715|FG001|Overall Study|oncological treatment|2
6346854|NCT03480763|10108714|FG000|Overall Study|pain with vaccination|1
6346855|NCT03480763|10108715|FG001|Overall Study|pain with vaccination|0
6346856|NCT03480841|10108727|FG000|Overall Study|Lost to Follow-up|2
6346857|NCT03480932|10108747|FG000|Overall Study|Death|1
6346858|NCT03480932|10108748|FG001|Overall Study|Death|1
6346859|NCT03480932|10108749|FG002|Overall Study|Death|0
6346860|NCT03480932|10108747|FG000|Overall Study|Lost to Follow-up|0
6346861|NCT03480932|10108748|FG001|Overall Study|Lost to Follow-up|2
6346862|NCT03480932|10108749|FG002|Overall Study|Lost to Follow-up|3
6346863|NCT03480932|10108747|FG000|Overall Study|Incarcerated|2
6346864|NCT03480932|10108748|FG001|Overall Study|Incarcerated|2
6346865|NCT03480932|10108749|FG002|Overall Study|Incarcerated|2
6346866|NCT03481309|10108772|FG000|Washout (at Least 3 Days)|Withdrawal by Subject|1
6346867|NCT03481309|10108773|FG001|Washout (at Least 3 Days)|Withdrawal by Subject|0
6346868|NCT03481309|10108774|FG002|Washout (at Least 3 Days)|Withdrawal by Subject|0
6346869|NCT03481309|10108775|FG003|Washout (at Least 3 Days)|Withdrawal by Subject|0
6346870|NCT03481309|10108776|FG004|Washout (at Least 3 Days)|Withdrawal by Subject|0
6346871|NCT03481309|10108777|FG005|Washout (at Least 3 Days)|Withdrawal by Subject|0
6346872|NCT03481725|10108796|FG000|Overall Study|Withdrawal by Subject|1
6346873|NCT03481725|10108797|FG001|Overall Study|Withdrawal by Subject|0
6346874|NCT03481816|10108807|FG000|Starting Dose|Refused further vaccines after 1 dose|1
6346875|NCT03481816|10108808|FG001|Starting Dose|Refused further vaccines after 1 dose|0
6346876|NCT03481816|10108807|FG000|Dose Expansion|Off treatment due to progressive disease|0
6346877|NCT03481816|10108808|FG001|Dose Expansion|Off treatment due to progressive disease|5
6346878|NCT03481816|10108807|FG000|Dose Expansion|Withdrawal by Subject|0
6346879|NCT03481816|10108808|FG001|Dose Expansion|Withdrawal by Subject|2
6346880|NCT03481816|10108807|FG000|Dose Expansion|Physician Decision|0
6346881|NCT03481816|10108808|FG001|Dose Expansion|Physician Decision|5
6346882|NCT03482011|10108818|FG000|Induction Period (16 Weeks)|Adverse Event|1
6346883|NCT03482011|10108819|FG001|Induction Period (16 Weeks)|Adverse Event|3
6346884|NCT03482011|10108820|FG002|Induction Period (16 Weeks)|Adverse Event|0
6346885|NCT03482011|10108821|FG003|Induction Period (16 Weeks)|Adverse Event|0
6346886|NCT03482011|10108822|FG004|Induction Period (16 Weeks)|Adverse Event|0
6346887|NCT03482011|10108823|FG005|Induction Period (16 Weeks)|Adverse Event|0
6346888|NCT03482011|10108824|FG006|Induction Period (16 Weeks)|Adverse Event|0
6346889|NCT03482011|10108825|FG007|Induction Period (16 Weeks)|Adverse Event|0
6346890|NCT03482011|10108818|FG000|Induction Period (16 Weeks)|Lack of Efficacy|3
6346891|NCT03482011|10108819|FG001|Induction Period (16 Weeks)|Lack of Efficacy|1
6346892|NCT03482011|10108820|FG002|Induction Period (16 Weeks)|Lack of Efficacy|0
6346893|NCT03482011|10108821|FG003|Induction Period (16 Weeks)|Lack of Efficacy|0
6346894|NCT03482011|10108822|FG004|Induction Period (16 Weeks)|Lack of Efficacy|0
6346895|NCT03482011|10108823|FG005|Induction Period (16 Weeks)|Lack of Efficacy|0
6346896|NCT03482011|10108824|FG006|Induction Period (16 Weeks)|Lack of Efficacy|0
6346897|NCT03482011|10108825|FG007|Induction Period (16 Weeks)|Lack of Efficacy|0
6346898|NCT03482011|10108818|FG000|Induction Period (16 Weeks)|Lost to Follow-up|0
6346899|NCT03482011|10108819|FG001|Induction Period (16 Weeks)|Lost to Follow-up|1
6346900|NCT03482011|10108820|FG002|Induction Period (16 Weeks)|Lost to Follow-up|0
6346901|NCT03482011|10108821|FG003|Induction Period (16 Weeks)|Lost to Follow-up|0
6346902|NCT03482011|10108822|FG004|Induction Period (16 Weeks)|Lost to Follow-up|0
6346903|NCT03482011|10108823|FG005|Induction Period (16 Weeks)|Lost to Follow-up|0
6346904|NCT03482011|10108824|FG006|Induction Period (16 Weeks)|Lost to Follow-up|0
6346905|NCT03482011|10108825|FG007|Induction Period (16 Weeks)|Lost to Follow-up|0
6083396|NCT00634933|9691716|FG002|Part B: Week 24 to Week 52|Protocol Violation|0
6083397|NCT00634933|9691717|FG003|Part B: Week 24 to Week 52|Protocol Violation|0
6346906|NCT03482011|10108818|FG000|Induction Period (16 Weeks)|Screen Failure|0
6346907|NCT03482011|10108819|FG001|Induction Period (16 Weeks)|Screen Failure|1
6346908|NCT03482011|10108820|FG002|Induction Period (16 Weeks)|Screen Failure|0
6346909|NCT03482011|10108821|FG003|Induction Period (16 Weeks)|Screen Failure|0
6346910|NCT03482011|10108822|FG004|Induction Period (16 Weeks)|Screen Failure|0
6346911|NCT03482011|10108823|FG005|Induction Period (16 Weeks)|Screen Failure|0
6346912|NCT03482011|10108824|FG006|Induction Period (16 Weeks)|Screen Failure|0
6346913|NCT03482011|10108825|FG007|Induction Period (16 Weeks)|Screen Failure|0
6346914|NCT03482011|10108818|FG000|Induction Period (16 Weeks)|Withdrawal by Subject|2
6083398|NCT00634933|9691718|FG004|Part B: Week 24 to Week 52|Protocol Violation|1
6083399|NCT00634933|9691714|FG000|Part B: Week 24 to Week 52|Withdrawal by Subject|0
6346915|NCT03482011|10108819|FG001|Induction Period (16 Weeks)|Withdrawal by Subject|5
6346916|NCT03482011|10108820|FG002|Induction Period (16 Weeks)|Withdrawal by Subject|0
6346917|NCT03482011|10108821|FG003|Induction Period (16 Weeks)|Withdrawal by Subject|0
6346918|NCT03482011|10108822|FG004|Induction Period (16 Weeks)|Withdrawal by Subject|0
6346919|NCT03482011|10108823|FG005|Induction Period (16 Weeks)|Withdrawal by Subject|0
6346920|NCT03482011|10108824|FG006|Induction Period (16 Weeks)|Withdrawal by Subject|0
6346921|NCT03482011|10108825|FG007|Induction Period (16 Weeks)|Withdrawal by Subject|0
6346922|NCT03482011|10108818|FG000|Maintenance Period (36 Weeks)|Adverse Event|0
6346923|NCT03482011|10108819|FG001|Maintenance Period (36 Weeks)|Adverse Event|0
6346924|NCT03482011|10108820|FG002|Maintenance Period (36 Weeks)|Adverse Event|0
6346925|NCT03482011|10108821|FG003|Maintenance Period (36 Weeks)|Adverse Event|0
6346926|NCT03482011|10108822|FG004|Maintenance Period (36 Weeks)|Adverse Event|0
6346927|NCT03482011|10108823|FG005|Maintenance Period (36 Weeks)|Adverse Event|1
6346928|NCT03482011|10108824|FG006|Maintenance Period (36 Weeks)|Adverse Event|1
6346929|NCT03482011|10108825|FG007|Maintenance Period (36 Weeks)|Adverse Event|4
6346930|NCT03482011|10108818|FG000|Maintenance Period (36 Weeks)|Lack of Efficacy|0
6346931|NCT03482011|10108819|FG001|Maintenance Period (36 Weeks)|Lack of Efficacy|0
6346932|NCT03482011|10108820|FG002|Maintenance Period (36 Weeks)|Lack of Efficacy|1
6346933|NCT03482011|10108821|FG003|Maintenance Period (36 Weeks)|Lack of Efficacy|2
6346934|NCT03482011|10108822|FG004|Maintenance Period (36 Weeks)|Lack of Efficacy|1
6346935|NCT03482011|10108823|FG005|Maintenance Period (36 Weeks)|Lack of Efficacy|1
6346936|NCT03482011|10108824|FG006|Maintenance Period (36 Weeks)|Lack of Efficacy|0
6346937|NCT03482011|10108825|FG007|Maintenance Period (36 Weeks)|Lack of Efficacy|9
6346938|NCT03482011|10108818|FG000|Maintenance Period (36 Weeks)|Lost to Follow-up|0
6346939|NCT03482011|10108819|FG001|Maintenance Period (36 Weeks)|Lost to Follow-up|0
6346940|NCT03482011|10108820|FG002|Maintenance Period (36 Weeks)|Lost to Follow-up|0
6346941|NCT03482011|10108821|FG003|Maintenance Period (36 Weeks)|Lost to Follow-up|0
6346942|NCT03482011|10108822|FG004|Maintenance Period (36 Weeks)|Lost to Follow-up|2
6346943|NCT03482011|10108823|FG005|Maintenance Period (36 Weeks)|Lost to Follow-up|0
6346944|NCT03482011|10108824|FG006|Maintenance Period (36 Weeks)|Lost to Follow-up|0
6346945|NCT03482011|10108825|FG007|Maintenance Period (36 Weeks)|Lost to Follow-up|1
6346946|NCT03482011|10108818|FG000|Maintenance Period (36 Weeks)|Physician Decision|0
6346947|NCT03482011|10108819|FG001|Maintenance Period (36 Weeks)|Physician Decision|0
6346948|NCT03482011|10108820|FG002|Maintenance Period (36 Weeks)|Physician Decision|0
6346949|NCT03482011|10108821|FG003|Maintenance Period (36 Weeks)|Physician Decision|1
6346950|NCT03482011|10108822|FG004|Maintenance Period (36 Weeks)|Physician Decision|0
6346951|NCT03482011|10108823|FG005|Maintenance Period (36 Weeks)|Physician Decision|1
6346952|NCT03482011|10108824|FG006|Maintenance Period (36 Weeks)|Physician Decision|1
6346953|NCT03482011|10108825|FG007|Maintenance Period (36 Weeks)|Physician Decision|1
6346954|NCT03482011|10108818|FG000|Maintenance Period (36 Weeks)|Withdrawal by Subject|0
6346955|NCT03482011|10108819|FG001|Maintenance Period (36 Weeks)|Withdrawal by Subject|0
6346956|NCT03482011|10108820|FG002|Maintenance Period (36 Weeks)|Withdrawal by Subject|0
6346957|NCT03482011|10108821|FG003|Maintenance Period (36 Weeks)|Withdrawal by Subject|1
6346958|NCT03482011|10108822|FG004|Maintenance Period (36 Weeks)|Withdrawal by Subject|2
6346959|NCT03482011|10108823|FG005|Maintenance Period (36 Weeks)|Withdrawal by Subject|1
6346960|NCT03482011|10108824|FG006|Maintenance Period (36 Weeks)|Withdrawal by Subject|2
6346961|NCT03482011|10108825|FG007|Maintenance Period (36 Weeks)|Withdrawal by Subject|2
6346962|NCT03482011|10108818|FG000|Follow-up Period (12 Weeks)|Withdrawal by Subject|0
6346963|NCT03482011|10108819|FG001|Follow-up Period (12 Weeks)|Withdrawal by Subject|0
6346964|NCT03482011|10108820|FG002|Follow-up Period (12 Weeks)|Withdrawal by Subject|0
6346965|NCT03482011|10108821|FG003|Follow-up Period (12 Weeks)|Withdrawal by Subject|2
6346966|NCT03482011|10108822|FG004|Follow-up Period (12 Weeks)|Withdrawal by Subject|0
6346967|NCT03482011|10108823|FG005|Follow-up Period (12 Weeks)|Withdrawal by Subject|1
6346968|NCT03482011|10108824|FG006|Follow-up Period (12 Weeks)|Withdrawal by Subject|1
6346969|NCT03482011|10108825|FG007|Follow-up Period (12 Weeks)|Withdrawal by Subject|5
6346970|NCT03482011|10108818|FG000|Follow-up Period (12 Weeks)|Adverse Event|0
6346971|NCT03482011|10108819|FG001|Follow-up Period (12 Weeks)|Adverse Event|0
6346972|NCT03482011|10108820|FG002|Follow-up Period (12 Weeks)|Adverse Event|0
6346973|NCT03482011|10108821|FG003|Follow-up Period (12 Weeks)|Adverse Event|0
6346974|NCT03482011|10108822|FG004|Follow-up Period (12 Weeks)|Adverse Event|0
6346975|NCT03482011|10108823|FG005|Follow-up Period (12 Weeks)|Adverse Event|0
6346976|NCT03482011|10108824|FG006|Follow-up Period (12 Weeks)|Adverse Event|1
6346977|NCT03482011|10108825|FG007|Follow-up Period (12 Weeks)|Adverse Event|4
6346978|NCT03482011|10108818|FG000|Follow-up Period (12 Weeks)|Lack of Efficacy|0
6083400|NCT00634933|9691715|FG001|Part B: Week 24 to Week 52|Withdrawal by Subject|0
6083401|NCT00634933|9691716|FG002|Part B: Week 24 to Week 52|Withdrawal by Subject|0
6083402|NCT00634933|9691717|FG003|Part B: Week 24 to Week 52|Withdrawal by Subject|2
6083403|NCT00634933|9691718|FG004|Part B: Week 24 to Week 52|Withdrawal by Subject|1
6083404|NCT00634933|9691714|FG000|Part B: Week 24 to Week 52|Lack of Efficacy|0
6083405|NCT00634933|9691715|FG001|Part B: Week 24 to Week 52|Lack of Efficacy|1
6083406|NCT00634933|9691716|FG002|Part B: Week 24 to Week 52|Lack of Efficacy|1
6083407|NCT00634933|9691717|FG003|Part B: Week 24 to Week 52|Lack of Efficacy|0
6083408|NCT00634933|9691718|FG004|Part B: Week 24 to Week 52|Lack of Efficacy|0
6346979|NCT03482011|10108819|FG001|Follow-up Period (12 Weeks)|Lack of Efficacy|0
6346980|NCT03482011|10108820|FG002|Follow-up Period (12 Weeks)|Lack of Efficacy|1
6346981|NCT03482011|10108821|FG003|Follow-up Period (12 Weeks)|Lack of Efficacy|3
6346982|NCT03482011|10108822|FG004|Follow-up Period (12 Weeks)|Lack of Efficacy|0
6346983|NCT03482011|10108823|FG005|Follow-up Period (12 Weeks)|Lack of Efficacy|0
6346984|NCT03482011|10108824|FG006|Follow-up Period (12 Weeks)|Lack of Efficacy|0
6346985|NCT03482011|10108825|FG007|Follow-up Period (12 Weeks)|Lack of Efficacy|6
6346986|NCT03482011|10108818|FG000|Follow-up Period (12 Weeks)|Physician Decision|0
6346987|NCT03482011|10108819|FG001|Follow-up Period (12 Weeks)|Physician Decision|0
6346988|NCT03482011|10108820|FG002|Follow-up Period (12 Weeks)|Physician Decision|0
6346989|NCT03482011|10108821|FG003|Follow-up Period (12 Weeks)|Physician Decision|0
6346990|NCT03482011|10108822|FG004|Follow-up Period (12 Weeks)|Physician Decision|0
6346991|NCT03482011|10108823|FG005|Follow-up Period (12 Weeks)|Physician Decision|0
6346992|NCT03482011|10108824|FG006|Follow-up Period (12 Weeks)|Physician Decision|0
6346993|NCT03482011|10108825|FG007|Follow-up Period (12 Weeks)|Physician Decision|1
6346994|NCT03482011|10108818|FG000|Follow-up Period (12 Weeks)|Lost to Follow-up|0
6346995|NCT03482011|10108819|FG001|Follow-up Period (12 Weeks)|Lost to Follow-up|0
6346996|NCT03482011|10108820|FG002|Follow-up Period (12 Weeks)|Lost to Follow-up|0
6346997|NCT03482011|10108821|FG003|Follow-up Period (12 Weeks)|Lost to Follow-up|0
6346998|NCT03482011|10108822|FG004|Follow-up Period (12 Weeks)|Lost to Follow-up|0
6346999|NCT03482011|10108823|FG005|Follow-up Period (12 Weeks)|Lost to Follow-up|0
6347000|NCT03482011|10108824|FG006|Follow-up Period (12 Weeks)|Lost to Follow-up|0
6347001|NCT03482011|10108825|FG007|Follow-up Period (12 Weeks)|Lost to Follow-up|1
6347002|NCT03482453|10108862|FG000|Parts 2, 3 Intervention Period 1 (1 Day)|Adverse Event|0
6347003|NCT03482453|10108863|FG001|Parts 2, 3 Intervention Period 1 (1 Day)|Adverse Event|0
6347004|NCT03482453|10108864|FG002|Parts 2, 3 Intervention Period 1 (1 Day)|Adverse Event|0
6347005|NCT03482453|10108865|FG003|Parts 2, 3 Intervention Period 1 (1 Day)|Adverse Event|0
6347006|NCT03482453|10108866|FG004|Parts 2, 3 Intervention Period 1 (1 Day)|Adverse Event|0
6347007|NCT03482453|10108867|FG005|Parts 2, 3 Intervention Period 1 (1 Day)|Adverse Event|0
6347008|NCT03482453|10108868|FG006|Parts 2, 3 Intervention Period 1 (1 Day)|Adverse Event|0
6347009|NCT03482453|10108869|FG007|Parts 2, 3 Intervention Period 1 (1 Day)|Adverse Event|0
6347010|NCT03482453|10108870|FG008|Parts 2, 3 Intervention Period 1 (1 Day)|Adverse Event|0
6347011|NCT03482453|10108871|FG009|Parts 2, 3 Intervention Period 1 (1 Day)|Adverse Event|0
6347012|NCT03482453|10108872|FG010|Parts 2, 3 Intervention Period 1 (1 Day)|Adverse Event|1
6347013|NCT03482453|10108873|FG011|Parts 2, 3 Intervention Period 1 (1 Day)|Adverse Event|0
6347014|NCT03482635|10108927|FG000|Overall Study|Lack of Efficacy|0
6347015|NCT03482635|10108928|FG001|Overall Study|Lack of Efficacy|0
6347016|NCT03482635|10108929|FG002|Overall Study|Lack of Efficacy|1
6347017|NCT03482635|10108930|FG003|Overall Study|Lack of Efficacy|3
6347018|NCT03482635|10108927|FG000|Overall Study|Adverse Event|2
6347019|NCT03482635|10108928|FG001|Overall Study|Adverse Event|2
6347020|NCT03482635|10108929|FG002|Overall Study|Adverse Event|0
6347021|NCT03482635|10108930|FG003|Overall Study|Adverse Event|3
6347022|NCT03482635|10108927|FG000|Overall Study|Withdrawal by Subject|2
6347023|NCT03482635|10108928|FG001|Overall Study|Withdrawal by Subject|1
6347024|NCT03482635|10108929|FG002|Overall Study|Withdrawal by Subject|0
6347025|NCT03482635|10108930|FG003|Overall Study|Withdrawal by Subject|1
6347026|NCT03482635|10108927|FG000|Overall Study|Withdrawn by Principle Investigator|1
6347027|NCT03482635|10108928|FG001|Overall Study|Withdrawn by Principle Investigator|0
6347028|NCT03482635|10108929|FG002|Overall Study|Withdrawn by Principle Investigator|0
6347029|NCT03482635|10108930|FG003|Overall Study|Withdrawn by Principle Investigator|0
6083409|NCT00634933|9691714|FG000|Part B: Week 24 to Week 52|Other|0
6083410|NCT00634933|9691715|FG001|Part B: Week 24 to Week 52|Other|0
6083411|NCT00634933|9691716|FG002|Part B: Week 24 to Week 52|Other|5
6083412|NCT00634933|9691717|FG003|Part B: Week 24 to Week 52|Other|0
6083413|NCT00634933|9691718|FG004|Part B: Week 24 to Week 52|Other|1
6083414|NCT00635024|9691730|FG000|Overall Study|Adverse Event|1
6083415|NCT00635050|9691734|FG000|Overall Study|Withdrawal by Subject|1
6083416|NCT00635089|9691741|FG000|Overall Study|Adverse Event|7
6083417|NCT00635089|9691741|FG000|Overall Study|Lack of Efficacy|28
6083418|NCT00635089|9691741|FG000|Overall Study|Protocol Deviation|4
6083419|NCT00635089|9691741|FG000|Overall Study|Lost to Follow-up|8
6083420|NCT00635089|9691741|FG000|Overall Study|Other|31
6083421|NCT00635102|9691760|FG000|Overall Study|Withdrawal by Subject|7
6083422|NCT00635102|9691761|FG001|Overall Study|Withdrawal by Subject|8
6083423|NCT00635154|9691778|FG000|Overall Study|Alternative Treatment|8
6083424|NCT00635154|9691778|FG000|Overall Study|Other|4
6083425|NCT00635154|9691778|FG000|Overall Study|Still on treatment|21
6083426|NCT00635219|9691789|FG000|Overall Study|Adverse Event|12
6083427|NCT00635219|9691790|FG001|Overall Study|Adverse Event|10
6083428|NCT00635219|9691791|FG002|Overall Study|Adverse Event|18
6083429|NCT00635219|9691792|FG003|Overall Study|Adverse Event|15
6083430|NCT00635219|9691793|FG004|Overall Study|Adverse Event|19
6347030|NCT03482635|10108927|FG000|Overall Study|Not treated|0
6347031|NCT03482635|10108928|FG001|Overall Study|Not treated|0
6347032|NCT03482635|10108929|FG002|Overall Study|Not treated|0
6347033|NCT03482635|10108930|FG003|Overall Study|Not treated|1
6347034|NCT03482882|10108949|FG000|Overall Study|Adverse Event|3
6347035|NCT03482882|10108949|FG000|Overall Study|Lost to Follow-up|1
6347036|NCT03482882|10108949|FG000|Overall Study|Protocol Violation|2
6083431|NCT00635219|9691789|FG000|Overall Study|Lack of Efficacy|5
6083432|NCT00635219|9691790|FG001|Overall Study|Lack of Efficacy|6
6083433|NCT00635219|9691791|FG002|Overall Study|Lack of Efficacy|3
6347037|NCT03482882|10108949|FG000|Overall Study|Not further specified|1
6347038|NCT03483623|10108968|FG000|Overall Study|43 complete sets achieved|1
6347039|NCT03483961|10109011|FG000|Overall Study|Lost to Follow-up|7
6347040|NCT03483961|10109012|FG001|Overall Study|Lost to Follow-up|6
6347041|NCT03483961|10109013|FG002|Overall Study|Lost to Follow-up|6
6347042|NCT03483961|10109014|FG003|Overall Study|Lost to Follow-up|6
6347043|NCT03483961|10109015|FG004|Overall Study|Lost to Follow-up|6
6347044|NCT03483961|10109016|FG005|Overall Study|Lost to Follow-up|4
6347045|NCT03483961|10109017|FG006|Overall Study|Lost to Follow-up|4
6347046|NCT03483961|10109018|FG007|Overall Study|Lost to Follow-up|11
6347047|NCT03483961|10109019|FG008|Overall Study|Lost to Follow-up|1
6347048|NCT03483961|10109020|FG009|Overall Study|Lost to Follow-up|0
6347049|NCT03483961|10109011|FG000|Overall Study|Withdrawal by Subject|3
6347050|NCT03483961|10109012|FG001|Overall Study|Withdrawal by Subject|4
6347051|NCT03483961|10109013|FG002|Overall Study|Withdrawal by Subject|5
6347052|NCT03483961|10109014|FG003|Overall Study|Withdrawal by Subject|3
6347053|NCT03483961|10109015|FG004|Overall Study|Withdrawal by Subject|4
6347054|NCT03483961|10109016|FG005|Overall Study|Withdrawal by Subject|2
6347055|NCT03483961|10109017|FG006|Overall Study|Withdrawal by Subject|1
6347056|NCT03483961|10109018|FG007|Overall Study|Withdrawal by Subject|2
6347057|NCT03483961|10109019|FG008|Overall Study|Withdrawal by Subject|1
6347058|NCT03483961|10109020|FG009|Overall Study|Withdrawal by Subject|0
6347059|NCT03483961|10109011|FG000|Overall Study|Other than AE, death, PI decision, LTFU, noncompliance, study terminated, or withdrawal of consent|1
6347060|NCT03483961|10109012|FG001|Overall Study|Other than AE, death, PI decision, LTFU, noncompliance, study terminated, or withdrawal of consent|0
6347061|NCT03483961|10109013|FG002|Overall Study|Other than AE, death, PI decision, LTFU, noncompliance, study terminated, or withdrawal of consent|0
6347062|NCT03483961|10109014|FG003|Overall Study|Other than AE, death, PI decision, LTFU, noncompliance, study terminated, or withdrawal of consent|0
6347063|NCT03483961|10109015|FG004|Overall Study|Other than AE, death, PI decision, LTFU, noncompliance, study terminated, or withdrawal of consent|0
6347064|NCT03483961|10109016|FG005|Overall Study|Other than AE, death, PI decision, LTFU, noncompliance, study terminated, or withdrawal of consent|0
6347065|NCT03483961|10109017|FG006|Overall Study|Other than AE, death, PI decision, LTFU, noncompliance, study terminated, or withdrawal of consent|0
6347066|NCT03483961|10109018|FG007|Overall Study|Other than AE, death, PI decision, LTFU, noncompliance, study terminated, or withdrawal of consent|0
6347067|NCT03483961|10109019|FG008|Overall Study|Other than AE, death, PI decision, LTFU, noncompliance, study terminated, or withdrawal of consent|0
6347068|NCT03483961|10109020|FG009|Overall Study|Other than AE, death, PI decision, LTFU, noncompliance, study terminated, or withdrawal of consent|0
6347069|NCT03483961|10109011|FG000|Overall Study|Adverse Event|0
6347070|NCT03483961|10109012|FG001|Overall Study|Adverse Event|0
6347071|NCT03483961|10109013|FG002|Overall Study|Adverse Event|1
6347072|NCT03483961|10109014|FG003|Overall Study|Adverse Event|0
6347073|NCT03483961|10109015|FG004|Overall Study|Adverse Event|0
6347074|NCT03483961|10109016|FG005|Overall Study|Adverse Event|0
6347075|NCT03483961|10109017|FG006|Overall Study|Adverse Event|0
6347076|NCT03483961|10109018|FG007|Overall Study|Adverse Event|0
6347077|NCT03483961|10109019|FG008|Overall Study|Adverse Event|0
6347078|NCT03483961|10109020|FG009|Overall Study|Adverse Event|0
6347079|NCT03484273|10109041|FG000|Overall Study|Equipment Malfunction|1
6347080|NCT03484273|10109041|FG000|Overall Study|Data excluded from analysis|1
6347081|NCT03484429|10109055|FG000|Overall Study|Withdrawal by Subject|1
6347082|NCT03484429|10109056|FG001|Overall Study|Withdrawal by Subject|0
6347083|NCT03484429|10109055|FG000|Overall Study|Adverse Event|2
6347084|NCT03484429|10109056|FG001|Overall Study|Adverse Event|0
6347085|NCT03485222|10109064|FG000|Overall Study|Death|0
6347086|NCT03485222|10109065|FG001|Overall Study|Death|1
6347087|NCT03485222|10109064|FG000|Overall Study|Lost to Follow-up|2
6347088|NCT03485222|10109065|FG001|Overall Study|Lost to Follow-up|1
6347089|NCT03485495|10109073|FG000|Overall Study|Non-compliance with inclusion criteria|1
6347090|NCT03485495|10109074|FG001|Overall Study|Non-compliance with inclusion criteria|0
6347091|NCT03486392|10109089|FG000|Overall Study|Lost to Follow-up|0
6347092|NCT03486392|10109090|FG001|Overall Study|Lost to Follow-up|0
6347093|NCT03486392|10109091|FG002|Overall Study|Lost to Follow-up|8
6347094|NCT03486392|10109092|FG003|Overall Study|Lost to Follow-up|5
6347095|NCT03486392|10109093|FG004|Overall Study|Lost to Follow-up|2
6347096|NCT03486392|10109089|FG000|Overall Study|Withdrawal by Subject|3
6347097|NCT03486392|10109090|FG001|Overall Study|Withdrawal by Subject|0
6347098|NCT03486392|10109091|FG002|Overall Study|Withdrawal by Subject|6
6347099|NCT03486392|10109092|FG003|Overall Study|Withdrawal by Subject|4
6347100|NCT03486392|10109093|FG004|Overall Study|Withdrawal by Subject|1
6347101|NCT03486392|10109089|FG000|Overall Study|Death|0
6347102|NCT03486392|10109090|FG001|Overall Study|Death|0
6347103|NCT03486392|10109091|FG002|Overall Study|Death|0
6347104|NCT03486392|10109092|FG003|Overall Study|Death|0
6347105|NCT03486392|10109093|FG004|Overall Study|Death|1
6347106|NCT03486834|10109108|FG000|Overall Study|Withdrawal by Subject|46
6347107|NCT03486834|10109109|FG001|Overall Study|Withdrawal by Subject|46
6347108|NCT03486834|10109110|FG002|Overall Study|Withdrawal by Subject|52
6347109|NCT03486834|10109108|FG000|Overall Study|Adverse Event|8
6347110|NCT03486834|10109109|FG001|Overall Study|Adverse Event|7
6347111|NCT03486834|10109110|FG002|Overall Study|Adverse Event|0
6347112|NCT03486834|10109108|FG000|Overall Study|Lost to Follow-up|41
6347113|NCT03486834|10109109|FG001|Overall Study|Lost to Follow-up|24
6347114|NCT03486834|10109110|FG002|Overall Study|Lost to Follow-up|39
6347115|NCT03486834|10109108|FG000|Overall Study|Non-compliance with Study Drug|2
6347116|NCT03486834|10109109|FG001|Overall Study|Non-compliance with Study Drug|2
6347117|NCT03486834|10109110|FG002|Overall Study|Non-compliance with Study Drug|0
6347118|NCT03486834|10109108|FG000|Overall Study|Physician Decision|5
6347119|NCT03486834|10109109|FG001|Overall Study|Physician Decision|2
6347120|NCT03486834|10109110|FG002|Overall Study|Physician Decision|3
6347121|NCT03486834|10109108|FG000|Overall Study|Pregnancy|10
6347122|NCT03486834|10109109|FG001|Overall Study|Pregnancy|12
6347123|NCT03486834|10109110|FG002|Overall Study|Pregnancy|12
6347124|NCT03486834|10109108|FG000|Overall Study|Protocol Deviation|2
6347125|NCT03486834|10109109|FG001|Overall Study|Protocol Deviation|3
6347126|NCT03486834|10109110|FG002|Overall Study|Protocol Deviation|3
6347127|NCT03486834|10109108|FG000|Overall Study|Withdrawal by Parent/Guardian|1
6347128|NCT03486834|10109109|FG001|Overall Study|Withdrawal by Parent/Guardian|2
6347129|NCT03486834|10109110|FG002|Overall Study|Withdrawal by Parent/Guardian|2
6347130|NCT03486834|10109108|FG000|Overall Study|Randomized but not treated|4
6347131|NCT03486834|10109109|FG001|Overall Study|Randomized but not treated|4
6347132|NCT03486834|10109110|FG002|Overall Study|Randomized but not treated|1
6347133|NCT03487445|10109205|FG000|Randomization|Not treated for administrative reasons|1
6347134|NCT03487445|10109206|FG001|Randomization|Not treated for administrative reasons|0
6347135|NCT03487549|10109214|FG000|Overall Study|Protocol Violation|0
6347136|NCT03487549|10109215|FG001|Overall Study|Protocol Violation|1
6347137|NCT03487549|10109214|FG000|Overall Study|Lost to Follow-up|2
6347138|NCT03487549|10109215|FG001|Overall Study|Lost to Follow-up|1
6347139|NCT03487549|10109214|FG000|Overall Study|Withdrawal by Subject|2
6042997|NCT00386100|9641474|FG001|Overall Study|Protocol Violation|3
6042998|NCT00386100|9641473|FG000|Overall Study|Withdrawal by Subject|32
6042999|NCT00386100|9641474|FG001|Overall Study|Withdrawal by Subject|31
6043000|NCT00386100|9641473|FG000|Overall Study|Bone mass density (BMD) loss >6%|4
6043001|NCT00386100|9641474|FG001|Overall Study|Bone mass density (BMD) loss >6%|4
6043002|NCT00386100|9641473|FG000|Overall Study|BMD <2.5|1
6043003|NCT00386100|9641474|FG001|Overall Study|BMD <2.5|0
6043004|NCT00386100|9641473|FG000|Overall Study|Consecutive elevated Hba1C|1
6043005|NCT00386100|9641474|FG001|Overall Study|Consecutive elevated Hba1C|0
6043006|NCT00386100|9641473|FG000|Overall Study|Visit 11 DXA showed excessive bone loss|0
6043007|NCT00386100|9641474|FG001|Overall Study|Visit 11 DXA showed excessive bone loss|1
6043008|NCT00386100|9641473|FG000|Overall Study|Laboratory findings|1
6043009|NCT00386100|9641474|FG001|Overall Study|Laboratory findings|0
6043010|NCT00386100|9641473|FG000|Overall Study|Participant's concern due to CPK levels|1
6043011|NCT00386100|9641474|FG001|Overall Study|Participant's concern due to CPK levels|0
6043012|NCT00386100|9641473|FG000|Overall Study|Participant moving out of state|2
6043013|NCT00386100|9641474|FG001|Overall Study|Participant moving out of state|0
6043014|NCT00386100|9641473|FG000|Overall Study|Excessive bone loss vs. baseline value|0
6043015|NCT00386100|9641474|FG001|Overall Study|Excessive bone loss vs. baseline value|1
6043016|NCT00386100|9641473|FG000|Overall Study|Didn't meet entry criteria|1
6043017|NCT00386100|9641474|FG001|Overall Study|Didn't meet entry criteria|1
6043018|NCT00386100|9641473|FG000|Overall Study|Participant's PCP wanted to stop drug|1
6043019|NCT00386100|9641474|FG001|Overall Study|Participant's PCP wanted to stop drug|0
6043020|NCT00386100|9641473|FG000|Overall Study|Osteoporosis findings on Visit 2 DXA|0
6043021|NCT00386100|9641474|FG001|Overall Study|Osteoporosis findings on Visit 2 DXA|1
6043022|NCT00386100|9641473|FG000|Overall Study|Bad metabolic control & patient security|1
6043023|NCT00386100|9641474|FG001|Overall Study|Bad metabolic control & patient security|0
6043024|NCT00386100|9641473|FG000|Overall Study|Bone loss by DXA bone scan|1
6043025|NCT00386100|9641474|FG001|Overall Study|Bone loss by DXA bone scan|0
6043026|NCT00386100|9641473|FG000|Overall Study|DBP 93 mmHg at randomization|1
6043027|NCT00386100|9641474|FG001|Overall Study|DBP 93 mmHg at randomization|0
6043028|NCT00386100|9641473|FG000|Overall Study|7.6% bone loss|1
6043029|NCT00386100|9641474|FG001|Overall Study|7.6% bone loss|0
6043030|NCT00386100|9641473|FG000|Overall Study|Osteoporosis|0
6043031|NCT00386100|9641474|FG001|Overall Study|Osteoporosis|1
6043032|NCT00386100|9641473|FG000|Overall Study|Positive pregnancy test|1
6043033|NCT00386100|9641474|FG001|Overall Study|Positive pregnancy test|3
6043034|NCT00386100|9641473|FG000|Overall Study|Out of country for 5 months|1
6043035|NCT00386100|9641474|FG001|Overall Study|Out of country for 5 months|0
6043036|NCT00386100|9641473|FG000|Overall Study|Hb1Ac >8%|0
6043037|NCT00386100|9641474|FG001|Overall Study|Hb1Ac >8%|1
6043038|NCT00386100|9641473|FG000|Overall Study|Participant randomized in error|1
6043039|NCT00386100|9641474|FG001|Overall Study|Participant randomized in error|0
6043040|NCT00386152|9641483|FG000|Overall Study|Adverse Event|6
6043041|NCT00386152|9641484|FG001|Overall Study|Adverse Event|5
6043042|NCT00386152|9641485|FG002|Overall Study|Adverse Event|4
6043043|NCT00386152|9641483|FG000|Overall Study|Chang from original chemo stratification|4
6043044|NCT00386152|9641484|FG001|Overall Study|Chang from original chemo stratification|5
6043045|NCT00386152|9641485|FG002|Overall Study|Chang from original chemo stratification|6
6043046|NCT00386152|9641483|FG000|Overall Study|Death|3
6043047|NCT00386152|9641484|FG001|Overall Study|Death|0
6043048|NCT00386152|9641485|FG002|Overall Study|Death|1
6043049|NCT00386152|9641483|FG000|Overall Study|Disease progression|7
6043050|NCT00386152|9641484|FG001|Overall Study|Disease progression|4
6043051|NCT00386152|9641485|FG002|Overall Study|Disease progression|5
6043052|NCT00386152|9641483|FG000|Overall Study|Physician Decision|13
6043053|NCT00386152|9641484|FG001|Overall Study|Physician Decision|10
6043054|NCT00386152|9641485|FG002|Overall Study|Physician Decision|4
6043055|NCT00386152|9641483|FG000|Overall Study|Lost to Follow-up|1
6043056|NCT00386152|9641484|FG001|Overall Study|Lost to Follow-up|0
6043057|NCT00386152|9641485|FG002|Overall Study|Lost to Follow-up|0
6347140|NCT03487549|10109215|FG001|Overall Study|Withdrawal by Subject|0
6347141|NCT03487848|10109234|FG000|Overall Study|Lost to Follow-up|1
6347142|NCT03488108|10109240|FG000|First Intervention (12 Weeks)|Withdrawal by Subject|0
6347143|NCT03488108|10109241|FG001|First Intervention (12 Weeks)|Withdrawal by Subject|1
6347144|NCT03488108|10109240|FG000|Second Intervention (12 Weeks)|Withdrawal by Subject|1
6347145|NCT03488108|10109241|FG001|Second Intervention (12 Weeks)|Withdrawal by Subject|0
6347146|NCT03488225|10109249|FG000|Overall Study|Off Protocol Therapy|2
6347147|NCT03488225|10109249|FG000|Overall Study|Stem Cell Transplant|2
6347148|NCT03488238|10109253|FG000|Overall Study|Equipment malfunction|1
6347149|NCT03488238|10109253|FG000|Overall Study|Adverse Event|1
6347150|NCT03488927|10109273|FG000|Overall Study|Withdrawal by Subject|44
6347151|NCT03488927|10109274|FG001|Overall Study|Withdrawal by Subject|118
6347152|NCT03488927|10109275|FG002|Overall Study|Withdrawal by Subject|217
6347153|NCT03489304|10109283|FG000|Overall Study|Lost to Follow-up|4
6347154|NCT03489343|10109294|FG000|Overall Study|Documented progressive disease|1
6347155|NCT03489343|10109295|FG001|Overall Study|Documented progressive disease|0
6347156|NCT03489343|10109296|FG002|Overall Study|Documented progressive disease|3
6347157|NCT03489343|10109297|FG003|Overall Study|Documented progressive disease|1
6168947|NCT01238991|9814148|FG008|Overall Study|Adverse Event|0
6168948|NCT01238991|9814149|FG009|Overall Study|Adverse Event|0
6168949|NCT01238991|9814140|FG000|Overall Study|Death|0
6168950|NCT01238991|9814141|FG001|Overall Study|Death|0
6168951|NCT01238991|9814142|FG002|Overall Study|Death|0
6168952|NCT01238991|9814143|FG003|Overall Study|Death|1
6168953|NCT01238991|9814144|FG004|Overall Study|Death|0
6168954|NCT01238991|9814145|FG005|Overall Study|Death|0
6168955|NCT01238991|9814146|FG006|Overall Study|Death|0
6168956|NCT01238991|9814147|FG007|Overall Study|Death|0
6168957|NCT01238991|9814148|FG008|Overall Study|Death|0
6168958|NCT01238991|9814149|FG009|Overall Study|Death|0
6168959|NCT01238991|9814140|FG000|Overall Study|Lack of Efficacy|0
6168960|NCT01238991|9814141|FG001|Overall Study|Lack of Efficacy|0
6168961|NCT01238991|9814142|FG002|Overall Study|Lack of Efficacy|1
6168962|NCT01238991|9814143|FG003|Overall Study|Lack of Efficacy|0
6168963|NCT01238991|9814144|FG004|Overall Study|Lack of Efficacy|0
6168964|NCT01238991|9814145|FG005|Overall Study|Lack of Efficacy|0
6168965|NCT01238991|9814146|FG006|Overall Study|Lack of Efficacy|0
6168966|NCT01238991|9814147|FG007|Overall Study|Lack of Efficacy|0
6168967|NCT01238991|9814148|FG008|Overall Study|Lack of Efficacy|1
6168968|NCT01238991|9814149|FG009|Overall Study|Lack of Efficacy|0
6168969|NCT01238991|9814140|FG000|Overall Study|Withdrawal by Subject|0
6168970|NCT01238991|9814141|FG001|Overall Study|Withdrawal by Subject|0
6168971|NCT01238991|9814142|FG002|Overall Study|Withdrawal by Subject|1
6168972|NCT01238991|9814143|FG003|Overall Study|Withdrawal by Subject|0
6168973|NCT01238991|9814144|FG004|Overall Study|Withdrawal by Subject|0
6168974|NCT01238991|9814145|FG005|Overall Study|Withdrawal by Subject|0
6168975|NCT01238991|9814146|FG006|Overall Study|Withdrawal by Subject|0
6168976|NCT01238991|9814147|FG007|Overall Study|Withdrawal by Subject|0
6168977|NCT01238991|9814148|FG008|Overall Study|Withdrawal by Subject|0
6168978|NCT01238991|9814149|FG009|Overall Study|Withdrawal by Subject|0
6168979|NCT01238991|9814140|FG000|Overall Study|Study Terminated by Sponsor|0
6168980|NCT01238991|9814141|FG001|Overall Study|Study Terminated by Sponsor|0
6168981|NCT01238991|9814142|FG002|Overall Study|Study Terminated by Sponsor|0
6168982|NCT01238991|9814143|FG003|Overall Study|Study Terminated by Sponsor|0
6168983|NCT01238991|9814144|FG004|Overall Study|Study Terminated by Sponsor|1
6168984|NCT01238991|9814145|FG005|Overall Study|Study Terminated by Sponsor|0
6168985|NCT01238991|9814146|FG006|Overall Study|Study Terminated by Sponsor|7
6168986|NCT01238991|9814147|FG007|Overall Study|Study Terminated by Sponsor|4
6168987|NCT01238991|9814148|FG008|Overall Study|Study Terminated by Sponsor|2
6168988|NCT01238991|9814149|FG009|Overall Study|Study Terminated by Sponsor|2
6168989|NCT01238991|9814140|FG000|Overall Study|Caregiver's request|0
6168990|NCT01238991|9814141|FG001|Overall Study|Caregiver's request|0
6168991|NCT01238991|9814142|FG002|Overall Study|Caregiver's request|0
6168992|NCT01238991|9814143|FG003|Overall Study|Caregiver's request|0
6168993|NCT01238991|9814144|FG004|Overall Study|Caregiver's request|0
6168994|NCT01238991|9814145|FG005|Overall Study|Caregiver's request|0
6168995|NCT01238991|9814146|FG006|Overall Study|Caregiver's request|0
6168996|NCT01238991|9814147|FG007|Overall Study|Caregiver's request|0
6168997|NCT01238991|9814148|FG008|Overall Study|Caregiver's request|1
6168998|NCT01238991|9814149|FG009|Overall Study|Caregiver's request|0
6168999|NCT01238991|9814140|FG000|Overall Study|Admission to a nursing home|1
6169000|NCT01238991|9814141|FG001|Overall Study|Admission to a nursing home|0
6169001|NCT01238991|9814142|FG002|Overall Study|Admission to a nursing home|1
6169002|NCT01238991|9814143|FG003|Overall Study|Admission to a nursing home|0
6347158|NCT03489343|10109298|FG004|Overall Study|Documented progressive disease|3
6043058|NCT00386152|9641483|FG000|Overall Study|Completed chemotherapy|4
6043059|NCT00386152|9641484|FG001|Overall Study|Completed chemotherapy|5
6043060|NCT00386152|9641485|FG002|Overall Study|Completed chemotherapy|1
6347159|NCT03489343|10109299|FG005|Overall Study|Documented progressive disease|5
6347160|NCT03489343|10109300|FG006|Overall Study|Documented progressive disease|4
6347161|NCT03489343|10109294|FG000|Overall Study|Adverse Event|0
6347162|NCT03489343|10109295|FG001|Overall Study|Adverse Event|1
6347163|NCT03489343|10109296|FG002|Overall Study|Adverse Event|0
6347164|NCT03489343|10109297|FG003|Overall Study|Adverse Event|0
6347165|NCT03489343|10109298|FG004|Overall Study|Adverse Event|0
6347166|NCT03489343|10109299|FG005|Overall Study|Adverse Event|1
6347167|NCT03489343|10109300|FG006|Overall Study|Adverse Event|0
6347168|NCT03489343|10109294|FG000|Overall Study|Withdrawal by Subject|0
6347169|NCT03489343|10109295|FG001|Overall Study|Withdrawal by Subject|0
6347170|NCT03489343|10109296|FG002|Overall Study|Withdrawal by Subject|0
6347171|NCT03489343|10109297|FG003|Overall Study|Withdrawal by Subject|1
6347172|NCT03489343|10109298|FG004|Overall Study|Withdrawal by Subject|0
6347173|NCT03489343|10109299|FG005|Overall Study|Withdrawal by Subject|1
6347174|NCT03489343|10109300|FG006|Overall Study|Withdrawal by Subject|1
6347175|NCT03489343|10109294|FG000|Overall Study|Clinical progression|0
6347176|NCT03489343|10109295|FG001|Overall Study|Clinical progression|0
6347177|NCT03489343|10109296|FG002|Overall Study|Clinical progression|0
6347178|NCT03489343|10109297|FG003|Overall Study|Clinical progression|1
6347179|NCT03489343|10109298|FG004|Overall Study|Clinical progression|0
6347180|NCT03489343|10109299|FG005|Overall Study|Clinical progression|0
6347181|NCT03489343|10109300|FG006|Overall Study|Clinical progression|1
6347182|NCT03489369|10109320|FG000|Overall Study|Documented Progressive Disease|3
6347183|NCT03489369|10109321|FG001|Overall Study|Documented Progressive Disease|2
6347184|NCT03489369|10109322|FG002|Overall Study|Documented Progressive Disease|3
6347185|NCT03489369|10109323|FG003|Overall Study|Documented Progressive Disease|6
6347186|NCT03489369|10109320|FG000|Overall Study|Clinical Progression (Worsening of Clini|0
6347187|NCT03489369|10109321|FG001|Overall Study|Clinical Progression (Worsening of Clini|1
6347188|NCT03489369|10109322|FG002|Overall Study|Clinical Progression (Worsening of Clini|0
6347189|NCT03489369|10109323|FG003|Overall Study|Clinical Progression (Worsening of Clini|0
6347190|NCT03489551|10109333|FG000|Overall Study|Withdrawal by Subject|2
6347191|NCT03489720|10109339|FG000|Overall Study|Withdrawal by Subject|2
6347192|NCT03489720|10109340|FG001|Overall Study|Withdrawal by Subject|0
6083434|NCT00635219|9691792|FG003|Overall Study|Lack of Efficacy|4
6083435|NCT00635219|9691793|FG004|Overall Study|Lack of Efficacy|6
6083436|NCT00635219|9691789|FG000|Overall Study|Non-compliance With Study Product|0
6083437|NCT00635219|9691790|FG001|Overall Study|Non-compliance With Study Product|0
6083438|NCT00635219|9691791|FG002|Overall Study|Non-compliance With Study Product|0
6083439|NCT00635219|9691792|FG003|Overall Study|Non-compliance With Study Product|2
6083440|NCT00635219|9691793|FG004|Overall Study|Non-compliance With Study Product|1
6083441|NCT00635219|9691789|FG000|Overall Study|Protocol Violation|0
6083442|NCT00635219|9691790|FG001|Overall Study|Protocol Violation|2
6083443|NCT00635219|9691791|FG002|Overall Study|Protocol Violation|3
6083444|NCT00635219|9691792|FG003|Overall Study|Protocol Violation|2
6083445|NCT00635219|9691793|FG004|Overall Study|Protocol Violation|4
6083446|NCT00635219|9691789|FG000|Overall Study|Withdrawal of Consent|8
6083447|NCT00635219|9691790|FG001|Overall Study|Withdrawal of Consent|6
6083448|NCT00635219|9691791|FG002|Overall Study|Withdrawal of Consent|8
6083449|NCT00635219|9691792|FG003|Overall Study|Withdrawal of Consent|11
6083450|NCT00635219|9691793|FG004|Overall Study|Withdrawal of Consent|8
6083451|NCT00635219|9691789|FG000|Overall Study|Lost to Follow-up|0
6083452|NCT00635219|9691790|FG001|Overall Study|Lost to Follow-up|0
6083453|NCT00635219|9691791|FG002|Overall Study|Lost to Follow-up|2
6083454|NCT00635219|9691792|FG003|Overall Study|Lost to Follow-up|0
6083455|NCT00635219|9691793|FG004|Overall Study|Lost to Follow-up|3
6083456|NCT00635219|9691789|FG000|Overall Study|Administrative or Other Reasons|0
6083457|NCT00635219|9691790|FG001|Overall Study|Administrative or Other Reasons|1
6083458|NCT00635219|9691791|FG002|Overall Study|Administrative or Other Reasons|1
6083459|NCT00635219|9691792|FG003|Overall Study|Administrative or Other Reasons|0
6083460|NCT00635219|9691793|FG004|Overall Study|Administrative or Other Reasons|1
6083461|NCT00635349|9691828|FG000|Overall Study|Other|8
6083462|NCT00635349|9691829|FG001|Overall Study|Other|6
6083463|NCT00635349|9691828|FG000|Overall Study|Protocol Violation|18
6083464|NCT00635349|9691829|FG001|Overall Study|Protocol Violation|22
6083465|NCT00635349|9691828|FG000|Overall Study|Withdrawal by Subject|3
6083466|NCT00635349|9691829|FG001|Overall Study|Withdrawal by Subject|8
6083467|NCT00635349|9691828|FG000|Overall Study|Lost to Follow-up|4
6083468|NCT00635349|9691829|FG001|Overall Study|Lost to Follow-up|3
6083469|NCT00635349|9691828|FG000|Overall Study|Adverse Event|11
6083470|NCT00635349|9691829|FG001|Overall Study|Adverse Event|9
6083471|NCT00635427|9691849|FG000|Overall Study|Refusal Of Required DiagnosticEvaluation|0
6083472|NCT00635427|9691850|FG001|Overall Study|Refusal Of Required DiagnosticEvaluation|0
6083473|NCT00635427|9691851|FG002|Overall Study|Refusal Of Required DiagnosticEvaluation|1
6347193|NCT03489863|10109361|FG000|Overall Study|Withdrawal by Subject|0
6347194|NCT03489863|10109362|FG001|Overall Study|Withdrawal by Subject|1
6083474|NCT00635427|9691852|FG003|Overall Study|Refusal Of Required DiagnosticEvaluation|0
6083475|NCT00635427|9691853|FG004|Overall Study|Refusal Of Required DiagnosticEvaluation|0
6083476|NCT00635427|9691849|FG000|Overall Study|Death|0
6347195|NCT03490032|10109379|FG000|Overall Study|family issue (child custody)|1
6347196|NCT03490032|10109380|FG001|Overall Study|family issue (child custody)|0
6347197|NCT03490032|10109381|FG002|Overall Study|family issue (child custody)|0
6347198|NCT03490981|10109414|FG000|Overall Study|Lost to Follow-up|1
6347199|NCT03490981|10109415|FG001|Overall Study|Lost to Follow-up|2
6083477|NCT00635427|9691850|FG001|Overall Study|Death|0
6083478|NCT00635427|9691851|FG002|Overall Study|Death|0
6083479|NCT00635427|9691852|FG003|Overall Study|Death|1
6083480|NCT00635427|9691853|FG004|Overall Study|Death|0
6083481|NCT00635427|9691849|FG000|Overall Study|Termination Of Study By Sponsor|12
6083482|NCT00635427|9691850|FG001|Overall Study|Termination Of Study By Sponsor|6
6083483|NCT00635427|9691851|FG002|Overall Study|Termination Of Study By Sponsor|10
6169003|NCT01238991|9814144|FG004|Overall Study|Admission to a nursing home|0
6169004|NCT01238991|9814145|FG005|Overall Study|Admission to a nursing home|0
6169005|NCT01238991|9814146|FG006|Overall Study|Admission to a nursing home|0
6169006|NCT01238991|9814147|FG007|Overall Study|Admission to a nursing home|0
6169007|NCT01238991|9814148|FG008|Overall Study|Admission to a nursing home|0
6169008|NCT01238991|9814149|FG009|Overall Study|Admission to a nursing home|0
6169009|NCT01239043|9814176|FG000|Overall Study|Protocol Violation|2
6169010|NCT01239043|9814177|FG001|Overall Study|Protocol Violation|1
6169011|NCT01239121|9814191|FG000|Overall Study|Withdrawal by Subject|2
6169012|NCT01239121|9814192|FG001|Overall Study|Withdrawal by Subject|4
6169013|NCT01239121|9814193|FG002|Overall Study|Withdrawal by Subject|0
6169014|NCT01239160|9814203|FG000|Overall Study|Lost to Follow-up|3
6083484|NCT00635427|9691852|FG003|Overall Study|Termination Of Study By Sponsor|6
6083485|NCT00635427|9691853|FG004|Overall Study|Termination Of Study By Sponsor|6
6083486|NCT00635427|9691849|FG000|Overall Study|Withdrawal Of Consent|0
6083487|NCT00635427|9691850|FG001|Overall Study|Withdrawal Of Consent|0
6169015|NCT01239160|9814204|FG001|Overall Study|Lost to Follow-up|5
6169016|NCT01239160|9814205|FG002|Overall Study|Lost to Follow-up|0
6347200|NCT03491150|10109423|FG000|Overall Study|Adverse Event|1
6347201|NCT03491150|10109424|FG001|Overall Study|Adverse Event|0
6347202|NCT03491150|10109423|FG000|Overall Study|Study Terminated by Sponsor|74
6347203|NCT03491150|10109424|FG001|Overall Study|Study Terminated by Sponsor|70
6347204|NCT03491150|10109423|FG000|Overall Study|Other|0
6347205|NCT03491150|10109424|FG001|Overall Study|Other|1
6347206|NCT03491150|10109423|FG000|Overall Study|Withdrawal by Subject|1
6347207|NCT03491150|10109424|FG001|Overall Study|Withdrawal by Subject|2
6347208|NCT03491553|10109440|FG000|Main Study (Up to Week 48)|Adverse Event|0
6347209|NCT03491553|10109441|FG001|Main Study (Up to Week 48)|Adverse Event|0
6347210|NCT03491553|10109442|FG002|Main Study (Up to Week 48)|Adverse Event|0
6347211|NCT03491553|10109443|FG003|Main Study (Up to Week 48)|Adverse Event|1
6347212|NCT03491553|10109444|FG004|Main Study (Up to Week 48)|Adverse Event|0
6347213|NCT03491553|10109445|FG005|Main Study (Up to Week 48)|Adverse Event|0
6347214|NCT03491553|10109440|FG000|Main Study (Up to Week 48)|Withdrew Consent|1
6347215|NCT03491553|10109441|FG001|Main Study (Up to Week 48)|Withdrew Consent|1
6347216|NCT03491553|10109442|FG002|Main Study (Up to Week 48)|Withdrew Consent|0
6347217|NCT03491553|10109443|FG003|Main Study (Up to Week 48)|Withdrew Consent|0
6347218|NCT03491553|10109444|FG004|Main Study (Up to Week 48)|Withdrew Consent|0
6347219|NCT03491553|10109445|FG005|Main Study (Up to Week 48)|Withdrew Consent|0
6347220|NCT03492281|10109494|FG000|Overall Study|Withdrawal by Subject|21
6347221|NCT03492281|10109495|FG001|Overall Study|Withdrawal by Subject|14
6347222|NCT03492281|10109496|FG002|Overall Study|Withdrawal by Subject|13
6347223|NCT03492281|10109494|FG000|Overall Study|Lost to Follow-up|14
6347224|NCT03492281|10109495|FG001|Overall Study|Lost to Follow-up|15
6347225|NCT03492281|10109496|FG002|Overall Study|Lost to Follow-up|10
6347226|NCT03492281|10109494|FG000|Overall Study|Adverse Event|6
6347227|NCT03492281|10109495|FG001|Overall Study|Adverse Event|8
6347228|NCT03492281|10109496|FG002|Overall Study|Adverse Event|13
6347229|NCT03492281|10109494|FG000|Overall Study|Lack of Efficacy|3
6347230|NCT03492281|10109495|FG001|Overall Study|Lack of Efficacy|0
6347231|NCT03492281|10109496|FG002|Overall Study|Lack of Efficacy|1
6347232|NCT03492281|10109494|FG000|Overall Study|Physician Decision|1
6347233|NCT03492281|10109495|FG001|Overall Study|Physician Decision|0
6347234|NCT03492281|10109496|FG002|Overall Study|Physician Decision|3
6347235|NCT03492281|10109494|FG000|Overall Study|Protocol Violation|0
6347236|NCT03492281|10109495|FG001|Overall Study|Protocol Violation|2
6347237|NCT03492281|10109496|FG002|Overall Study|Protocol Violation|1
6347238|NCT03492281|10109494|FG000|Overall Study|Withdrawn Due to Sponsor|1
6347239|NCT03492281|10109495|FG001|Overall Study|Withdrawn Due to Sponsor|0
6347240|NCT03492281|10109496|FG002|Overall Study|Withdrawn Due to Sponsor|1
6347241|NCT03492281|10109494|FG000|Overall Study|Death|0
6347242|NCT03492281|10109495|FG001|Overall Study|Death|0
6347243|NCT03492281|10109496|FG002|Overall Study|Death|1
6347244|NCT03492281|10109494|FG000|Overall Study|Captured as Other in Database|8
6043061|NCT00386152|9641483|FG000|Overall Study|Protocol Violation|3
6043062|NCT00386152|9641484|FG001|Overall Study|Protocol Violation|5
6043063|NCT00386152|9641485|FG002|Overall Study|Protocol Violation|2
6043064|NCT00386152|9641483|FG000|Overall Study|Withdrawal by Subject|3
6043065|NCT00386152|9641484|FG001|Overall Study|Withdrawal by Subject|6
6043066|NCT00386152|9641485|FG002|Overall Study|Withdrawal by Subject|10
6347245|NCT03492281|10109495|FG001|Overall Study|Captured as Other in Database|6
6347246|NCT03492281|10109496|FG002|Overall Study|Captured as Other in Database|3
6347247|NCT03492554|10109546|FG000|Overall Study|Protocol Violation|0
6347248|NCT03492554|10109547|FG001|Overall Study|Protocol Violation|14
6347249|NCT03493386|10109556|FG000|Part 1, Washout Period (at Least 5 Days)|Withdrawal by Subject|0
6347250|NCT03493386|10109557|FG001|Part 1, Washout Period (at Least 5 Days)|Withdrawal by Subject|1
6347251|NCT03493386|10109558|FG002|Part 1, Washout Period (at Least 5 Days)|Withdrawal by Subject|0
6347252|NCT03493386|10109559|FG003|Part 1, Washout Period (at Least 5 Days)|Withdrawal by Subject|0
6347253|NCT03493542|10109578|FG000|Overall Study|Ongoing|2
6347254|NCT03493542|10109579|FG001|Overall Study|Ongoing|3
6347255|NCT03493542|10109578|FG000|Overall Study|Withdrawal by parent or guardian|3
6347256|NCT03493542|10109579|FG001|Overall Study|Withdrawal by parent or guardian|0
6043067|NCT00386308|9641521|FG000|Overall Study|Adverse Event|3
6043068|NCT00386308|9641522|FG001|Overall Study|Adverse Event|3
6043069|NCT00386308|9641521|FG000|Overall Study|Protocol Violation|2
6043070|NCT00386308|9641522|FG001|Overall Study|Protocol Violation|5
6043071|NCT00386308|9641521|FG000|Overall Study|Lack of Efficacy|0
6043072|NCT00386308|9641522|FG001|Overall Study|Lack of Efficacy|2
6043073|NCT00386308|9641521|FG000|Overall Study|Lost to Follow-up|10
6347257|NCT03493542|10109578|FG000|Overall Study|Withdrawal by Subject|2
6347258|NCT03493542|10109579|FG001|Overall Study|Withdrawal by Subject|6
6347259|NCT03493698|10109589|FG000|Treatment Period C|Adverse Event|1
6347260|NCT03493698|10109589|FG000|Treatment Period C|Withdrawal by Subject|1
6347261|NCT03494725|10109627|FG000|Overall Study|Withdrawal by Subject|0
6347262|NCT03494725|10109628|FG001|Overall Study|Withdrawal by Subject|2
6347263|NCT03494725|10109627|FG000|Overall Study|Antibiotic use|1
6347264|NCT03494725|10109628|FG001|Overall Study|Antibiotic use|0
6347265|NCT03494816|10109640|FG000|Overall Study|Protocol Violation|2
6347266|NCT03494816|10109640|FG000|Overall Study|Physician Decision|2
6347267|NCT03494816|10109640|FG000|Overall Study|Did not start trial treatment|1
6347268|NCT03494816|10109640|FG000|Overall Study|Adverse Event|1
6043074|NCT00386308|9641522|FG001|Overall Study|Lost to Follow-up|6
6347269|NCT03494985|10109652|FG000|Overall Study|Adverse Event|3
6347270|NCT03494985|10109653|FG001|Overall Study|Adverse Event|2
6347271|NCT03494985|10109654|FG002|Overall Study|Adverse Event|3
6347272|NCT03494985|10109655|FG003|Overall Study|Adverse Event|0
6347273|NCT03494985|10109652|FG000|Overall Study|Other (Withdrawal of consent)|2
6347274|NCT03494985|10109653|FG001|Overall Study|Other (Withdrawal of consent)|3
6347275|NCT03494985|10109654|FG002|Overall Study|Other (Withdrawal of consent)|2
6347276|NCT03494985|10109655|FG003|Overall Study|Other (Withdrawal of consent)|5
6347277|NCT03494985|10109652|FG000|Overall Study|Other (Not specified)|0
6347278|NCT03494985|10109653|FG001|Overall Study|Other (Not specified)|1
6347279|NCT03494985|10109654|FG002|Overall Study|Other (Not specified)|1
6347280|NCT03494985|10109655|FG003|Overall Study|Other (Not specified)|0
6347281|NCT03495102|10109668|FG000|Overall Study|Adverse Event|5
6347282|NCT03495102|10109669|FG001|Overall Study|Adverse Event|7
6347283|NCT03495102|10109670|FG002|Overall Study|Adverse Event|10
6347284|NCT03495102|10109668|FG000|Overall Study|Death|3
6347285|NCT03495102|10109669|FG001|Overall Study|Death|4
6347286|NCT03495102|10109670|FG002|Overall Study|Death|4
6347287|NCT03495102|10109668|FG000|Overall Study|Lost to Follow-up|15
6347288|NCT03495102|10109669|FG001|Overall Study|Lost to Follow-up|16
6347289|NCT03495102|10109670|FG002|Overall Study|Lost to Follow-up|17
6347290|NCT03495102|10109668|FG000|Overall Study|Physician Decision|2
6347291|NCT03495102|10109669|FG001|Overall Study|Physician Decision|0
6347292|NCT03495102|10109670|FG002|Overall Study|Physician Decision|2
6347293|NCT03495102|10109668|FG000|Overall Study|Withdrawal by Subject|25
6347294|NCT03495102|10109669|FG001|Overall Study|Withdrawal by Subject|36
6347295|NCT03495102|10109670|FG002|Overall Study|Withdrawal by Subject|18
6347296|NCT03495102|10109668|FG000|Overall Study|Protocol Violation|1
6347297|NCT03495102|10109669|FG001|Overall Study|Protocol Violation|1
6347298|NCT03495102|10109670|FG002|Overall Study|Protocol Violation|0
6347299|NCT03495102|10109668|FG000|Overall Study|Site Closure|3
6347300|NCT03495102|10109669|FG001|Overall Study|Site Closure|1
6347301|NCT03495102|10109670|FG002|Overall Study|Site Closure|2
6347302|NCT03495102|10109668|FG000|Overall Study|Non-compliance|1
6347303|NCT03495102|10109669|FG001|Overall Study|Non-compliance|0
6347304|NCT03495102|10109670|FG002|Overall Study|Non-compliance|0
6347305|NCT03495102|10109668|FG000|Overall Study|Participant Duplicated at Another Site|0
6347306|NCT03495102|10109669|FG001|Overall Study|Participant Duplicated at Another Site|0
6347307|NCT03495102|10109670|FG002|Overall Study|Participant Duplicated at Another Site|1
6347308|NCT03495102|10109668|FG000|Overall Study|Primary Care Physician Recommendation|0
6347309|NCT03495102|10109669|FG001|Overall Study|Primary Care Physician Recommendation|1
6347310|NCT03495102|10109670|FG002|Overall Study|Primary Care Physician Recommendation|0
6347311|NCT03495102|10109668|FG000|Overall Study|Relocated to Another Country|0
6347312|NCT03495102|10109669|FG001|Overall Study|Relocated to Another Country|1
6347313|NCT03495102|10109670|FG002|Overall Study|Relocated to Another Country|0
6347314|NCT03495102|10109668|FG000|Overall Study|Participant was in Rehabilitation|1
6347315|NCT03495102|10109669|FG001|Overall Study|Participant was in Rehabilitation|0
6347316|NCT03495102|10109670|FG002|Overall Study|Participant was in Rehabilitation|0
6347317|NCT03495817|10109687|FG000|26 Week Open Label|Adverse Event|3
6347318|NCT03495817|10109687|FG000|26 Week Open Label|Withdrawal by Subject|4
6347319|NCT03495817|10109687|FG000|26 Week Open Label|Lost to Follow-up|1
6347320|NCT03495817|10109687|FG000|26 Week Extension|Lost to Follow-up|2
6347321|NCT03495869|10109699|FG000|Overall Study|Lost to Follow-up|4
6347322|NCT03495869|10109700|FG001|Overall Study|Lost to Follow-up|17
6347323|NCT03495869|10109701|FG002|Overall Study|Lost to Follow-up|8
6347324|NCT03495869|10109702|FG003|Overall Study|Lost to Follow-up|14
6347325|NCT03495869|10109699|FG000|Overall Study|Withdrawal by Subject|0
6347326|NCT03495869|10109700|FG001|Overall Study|Withdrawal by Subject|3
6347327|NCT03495869|10109701|FG002|Overall Study|Withdrawal by Subject|0
6169017|NCT01239160|9814203|FG000|Overall Study|Withdrawal by Subject|17
6169018|NCT01239160|9814204|FG001|Overall Study|Withdrawal by Subject|6
6169019|NCT01239160|9814205|FG002|Overall Study|Withdrawal by Subject|2
6169020|NCT01239160|9814203|FG000|Overall Study|Physician Decision|5
6169021|NCT01239160|9814204|FG001|Overall Study|Physician Decision|7
6169022|NCT01239160|9814205|FG002|Overall Study|Physician Decision|2
6169023|NCT01239160|9814203|FG000|Overall Study|Early Termination Due to Study Closure|0
6169024|NCT01239160|9814204|FG001|Overall Study|Early Termination Due to Study Closure|1
6169025|NCT01239160|9814205|FG002|Overall Study|Early Termination Due to Study Closure|6
6169026|NCT01239316|9814215|FG000|Overall Study|Progression/Relapse|11
6169027|NCT01239316|9814215|FG000|Overall Study|Adverse Event|1
6169028|NCT01239342|9814221|FG000|Overall Study|Adverse Event|1
6169029|NCT01239342|9814222|FG001|Overall Study|Adverse Event|0
6169030|NCT01239342|9814221|FG000|Overall Study|Withdrawal by Subject|1
6169031|NCT01239342|9814222|FG001|Overall Study|Withdrawal by Subject|5
6169032|NCT01239342|9814221|FG000|Overall Study|Reason Unknown|1
6347328|NCT03495869|10109702|FG003|Overall Study|Withdrawal by Subject|3
6347329|NCT03495869|10109699|FG000|Overall Study|Dropped from study|0
6347330|NCT03495869|10109700|FG001|Overall Study|Dropped from study|7
6169033|NCT01239342|9814222|FG001|Overall Study|Reason Unknown|1
6169034|NCT01239381|9814232|FG000|Overall Study|Protocol Violation|1
6169035|NCT01239381|9814232|FG000|Overall Study|Withdrawal by Subject|1
6347331|NCT03495869|10109701|FG002|Overall Study|Dropped from study|2
6347332|NCT03495869|10109702|FG003|Overall Study|Dropped from study|4
6347333|NCT03495908|10109714|FG000|Overall Study|Withdrawal by Subject|3
6347334|NCT03495908|10109715|FG001|Overall Study|Withdrawal by Subject|1
6347335|NCT03495908|10109714|FG000|Overall Study|Lost to Follow-up|1
6347336|NCT03495908|10109715|FG001|Overall Study|Lost to Follow-up|4
6347337|NCT03495908|10109714|FG000|Overall Study|Adverse Event|0
6347338|NCT03495908|10109715|FG001|Overall Study|Adverse Event|2
6347339|NCT03495908|10109714|FG000|Overall Study|Death|1
6347340|NCT03495908|10109715|FG001|Overall Study|Death|0
6347341|NCT03495908|10109714|FG000|Overall Study|Physician Decision|5
6347342|NCT03495908|10109715|FG001|Overall Study|Physician Decision|4
6347343|NCT03495908|10109714|FG000|Overall Study|No documented reason|0
6347344|NCT03495908|10109715|FG001|Overall Study|No documented reason|2
6347345|NCT03496298|10109734|FG000|Overall Study|Adverse Event|49
6347346|NCT03496298|10109735|FG001|Overall Study|Adverse Event|68
6347347|NCT03496298|10109736|FG002|Overall Study|Adverse Event|79
6347348|NCT03496298|10109734|FG000|Overall Study|Study terminated by Sponsor|1050
6347349|NCT03496298|10109735|FG001|Overall Study|Study terminated by Sponsor|1063
6347350|NCT03496298|10109736|FG002|Overall Study|Study terminated by Sponsor|1071
6347351|NCT03496298|10109734|FG000|Overall Study|Physician decision (other than Adverse event)|12
6347352|NCT03496298|10109735|FG001|Overall Study|Physician decision (other than Adverse event)|17
6347353|NCT03496298|10109736|FG002|Overall Study|Physician decision (other than Adverse event)|10
6347354|NCT03496298|10109734|FG000|Overall Study|Withdrawal by Subject|176
6347355|NCT03496298|10109735|FG001|Overall Study|Withdrawal by Subject|154
6347356|NCT03496298|10109736|FG002|Overall Study|Withdrawal by Subject|151
6347357|NCT03496298|10109734|FG000|Overall Study|Other|29
6347358|NCT03496298|10109735|FG001|Overall Study|Other|20
6347359|NCT03496298|10109736|FG002|Overall Study|Other|23
6347360|NCT03496298|10109734|FG000|Overall Study|Randomized and not treated|1
6347361|NCT03496298|10109735|FG001|Overall Study|Randomized and not treated|1
6347362|NCT03496298|10109736|FG002|Overall Study|Randomized and not treated|1
6347363|NCT03497039|10109808|FG000|Overall Study|Withdrawal by Subject|1
6347364|NCT03497039|10109809|FG001|Overall Study|Withdrawal by Subject|0
6347365|NCT03497039|10109808|FG000|Overall Study|Protocol Violation|0
6347366|NCT03497039|10109809|FG001|Overall Study|Protocol Violation|1
6347367|NCT03497130|10109817|FG000|Overall Study|Lost to Follow-up|1
6347368|NCT03497130|10109818|FG001|Overall Study|Lost to Follow-up|1
6347369|NCT03497429|10109826|FG000|Overall Study|Progressive disease|3
6347370|NCT03497429|10109827|FG001|Overall Study|Progressive disease|4
6083488|NCT00635427|9691851|FG002|Overall Study|Withdrawal Of Consent|0
6083489|NCT00635427|9691852|FG003|Overall Study|Withdrawal Of Consent|2
6083490|NCT00635427|9691853|FG004|Overall Study|Withdrawal Of Consent|2
6083491|NCT00635492|9691883|FG000|Overall Study|Death|12
6083492|NCT00635492|9691884|FG001|Overall Study|Death|40
6083493|NCT00635492|9691883|FG000|Overall Study|Lost to Follow-up|151
6083494|NCT00635492|9691884|FG001|Overall Study|Lost to Follow-up|172
6083495|NCT00635492|9691883|FG000|Overall Study|Physician Decision|32
6083496|NCT00635492|9691884|FG001|Overall Study|Physician Decision|22
6083497|NCT00635492|9691883|FG000|Overall Study|Sponsor decision|2
6083498|NCT00635492|9691884|FG001|Overall Study|Sponsor decision|3
6083499|NCT00635492|9691883|FG000|Overall Study|Withdrawal by Subject|82
6083500|NCT00635492|9691884|FG001|Overall Study|Withdrawal by Subject|45
6083501|NCT00635570|9691896|FG000|Overall Study|Lost to Follow-up|8
6083502|NCT00635570|9691897|FG001|Overall Study|Lost to Follow-up|8
6083503|NCT00635570|9691896|FG000|Overall Study|Withdrawal by Subject|1
6083504|NCT00635570|9691897|FG001|Overall Study|Withdrawal by Subject|1
6083505|NCT00635570|9691896|FG000|Overall Study|Adverse Event|2
6083506|NCT00635570|9691897|FG001|Overall Study|Adverse Event|0
6083507|NCT00635570|9691896|FG000|Overall Study|Physician Decision|1
6083508|NCT00635570|9691897|FG001|Overall Study|Physician Decision|0
6083509|NCT00635570|9691896|FG000|Overall Study|Did not complete survey|2
6083510|NCT00635570|9691897|FG001|Overall Study|Did not complete survey|1
6083511|NCT00635570|9691896|FG000|Overall Study|Early termination(No sexual activity)|1
6083512|NCT00635570|9691897|FG001|Overall Study|Early termination(No sexual activity)|1
6083513|NCT00635648|9691912|FG000|Overall Study|Adverse Event|12
6083514|NCT00635648|9691912|FG000|Overall Study|Withdrawal by Subject|9
6083515|NCT00635648|9691912|FG000|Overall Study|Physician Decision|4
6083516|NCT00635648|9691912|FG000|Overall Study|Rapid progression of baseline disease|4
6083517|NCT00635648|9691912|FG000|Overall Study|Use of other antifungal agent needed|1
6083518|NCT00635648|9691912|FG000|Overall Study|No improvement after 7-10 days treatment|4
6083519|NCT00635648|9691912|FG000|Overall Study|Noncompliance with protocol|1
6083520|NCT00635648|9691912|FG000|Overall Study|Other reason|2
6083521|NCT00635661|9691916|FG000|Overall Study|Withdrawal by Subject|4
6083522|NCT00635778|9691945|FG000|Overall Study|Adverse Event|1
6347371|NCT03497429|10109826|FG000|Overall Study|Adverse Event|0
6347372|NCT03497429|10109827|FG001|Overall Study|Adverse Event|2
6347373|NCT03498287|10109898|FG000|Overall Study|Withdrawal by Subject|3
6347374|NCT03498287|10109899|FG001|Overall Study|Withdrawal by Subject|0
6347375|NCT03498287|10109898|FG000|Overall Study|Protocol Violation|0
6347376|NCT03498287|10109899|FG001|Overall Study|Protocol Violation|4
6347377|NCT03498287|10109898|FG000|Overall Study|Adverse Event|0
6347378|NCT03498287|10109899|FG001|Overall Study|Adverse Event|1
6083523|NCT00635778|9691946|FG001|Overall Study|Adverse Event|0
6083524|NCT00635778|9691947|FG002|Overall Study|Adverse Event|0
6347379|NCT03499028|10109917|FG000|Overall Study|Lost to Follow-up|12
6347380|NCT03499028|10109918|FG001|Overall Study|Lost to Follow-up|9
6347381|NCT03499028|10109917|FG000|Overall Study|Withdrawal by Subject|5
6169036|NCT01239394|9814237|FG000|Overall Study|Adverse Event|1
6169037|NCT01239472|9814243|FG000|Overall Study|Withdrawal by Subject|5
6169038|NCT01239472|9814244|FG001|Overall Study|Withdrawal by Subject|1
6169039|NCT01239472|9814243|FG000|Overall Study|Adverse Event|0
6169040|NCT01239472|9814244|FG001|Overall Study|Adverse Event|1
6169041|NCT01239472|9814243|FG000|Overall Study|Lack of Efficacy|0
6169042|NCT01239472|9814244|FG001|Overall Study|Lack of Efficacy|1
6169043|NCT01239732|9814269|FG000|Overall Study|Termination of study per protocol|667
6169044|NCT01239732|9814269|FG000|Overall Study|Death|226
6169045|NCT01239732|9814269|FG000|Overall Study|Withdrawal by Subject|87
6169046|NCT01239732|9814269|FG000|Overall Study|Adverse Event|6
6169047|NCT01239732|9814269|FG000|Overall Study|Protocol Violation|3
6169048|NCT01239732|9814269|FG000|Overall Study|Participant non compliance|5
6169049|NCT01239732|9814269|FG000|Overall Study|Study termination by sponsor|2
6169050|NCT01239732|9814269|FG000|Overall Study|Investigator's decision|4
6169051|NCT01239732|9814269|FG000|Overall Study|Treatment failure|2
6169052|NCT01239732|9814269|FG000|Overall Study|Other|19
6169053|NCT01239745|9814273|FG000|Overall Study|Study terminated by sponsor|45
6169054|NCT01239745|9814273|FG000|Overall Study|Adverse Event|1
6169055|NCT01239797|9814279|FG000|Treated Participants|Disease Progression|153
6169056|NCT01239797|9814280|FG001|Treated Participants|Disease Progression|161
6169057|NCT01239797|9814279|FG000|Treated Participants|Study Drug Toxicity|30
6169058|NCT01239797|9814280|FG001|Treated Participants|Study Drug Toxicity|44
6169059|NCT01239797|9814279|FG000|Treated Participants|Adverse Event Unrelated to Study Drug|22
6169060|NCT01239797|9814280|FG001|Treated Participants|Adverse Event Unrelated to Study Drug|32
6169061|NCT01239797|9814279|FG000|Treated Participants|Withdrawal by Subject|27
6169062|NCT01239797|9814280|FG001|Treated Participants|Withdrawal by Subject|23
6169063|NCT01239797|9814279|FG000|Treated Participants|Non-specified|1
6169064|NCT01239797|9814280|FG001|Treated Participants|Non-specified|11
6169065|NCT01239797|9814279|FG000|Treated Participants|Death|1
6169066|NCT01239797|9814280|FG001|Treated Participants|Death|1
6169067|NCT01239797|9814279|FG000|Treated Participants|Subject No Longer Meets Study Criteria|1
6169068|NCT01239797|9814280|FG001|Treated Participants|Subject No Longer Meets Study Criteria|1
6169069|NCT01239797|9814279|FG000|Treated Participants|Poor/Non-compliance|0
6169070|NCT01239797|9814280|FG001|Treated Participants|Poor/Non-compliance|1
6169071|NCT01239992|9814286|FG000|Overall Study|Withdrawal by Subject|2
6169072|NCT01240135|9814301|FG000|Period Two, 14 Days of Wear|Withdrawal by Subject|1
6169073|NCT01240135|9814302|FG001|Period Two, 14 Days of Wear|Withdrawal by Subject|1
6169074|NCT01240135|9814301|FG000|Period Two, 14 Days of Wear|Adverse Event|0
6169075|NCT01240135|9814302|FG001|Period Two, 14 Days of Wear|Adverse Event|1
6169076|NCT01240200|9814310|FG000|12-week Crossover Phase - Period 1|Withdrawal by Subject|2
6169077|NCT01240200|9814311|FG001|12-week Crossover Phase - Period 1|Withdrawal by Subject|1
6169078|NCT01240356|9814326|FG000|Overall Study|Withdrawal by Subject|2
6169079|NCT01240356|9814327|FG001|Overall Study|Withdrawal by Subject|0
6169080|NCT01240356|9814326|FG000|Overall Study|MRI contraindication|1
6169081|NCT01240356|9814327|FG001|Overall Study|MRI contraindication|0
6169082|NCT01240382|9814338|FG000|Overall Study|Adverse Event|2
6169083|NCT01240382|9814339|FG001|Overall Study|Adverse Event|1
6169084|NCT01240382|9814338|FG000|Overall Study|Lack of Efficacy|0
6169085|NCT01240382|9814339|FG001|Overall Study|Lack of Efficacy|2
6169086|NCT01240382|9814338|FG000|Overall Study|Fear of adverse events|0
6227423|NCT01717040|9900135|FG000|Overall Study|Adverse Event|1
6227424|NCT01717040|9900136|FG001|Overall Study|Adverse Event|0
6227425|NCT01717040|9900135|FG000|Overall Study|Required Medication Change|0
6227426|NCT01717040|9900136|FG001|Overall Study|Required Medication Change|1
6227427|NCT01717040|9900135|FG000|Overall Study|New Substance Use Disorder|1
6227428|NCT01717040|9900136|FG001|Overall Study|New Substance Use Disorder|0
6227429|NCT01717287|9900152|FG000|Overall Study|Lost to Follow-up|0
6227430|NCT01717287|9900153|FG001|Overall Study|Lost to Follow-up|2
6227431|NCT01717287|9900152|FG000|Overall Study|Protocol Violation|0
6227432|NCT01717287|9900153|FG001|Overall Study|Protocol Violation|1
6227433|NCT01717313|9900161|FG000|Phase A (Weeks 0 to 24)|Death|0
6227434|NCT01717313|9900162|FG001|Phase A (Weeks 0 to 24)|Death|1
6227435|NCT01717313|9900161|FG000|Phase A (Weeks 0 to 24)|Lost to Follow-up|1
6227436|NCT01717313|9900162|FG001|Phase A (Weeks 0 to 24)|Lost to Follow-up|3
6227437|NCT01717313|9900161|FG000|Phase A (Weeks 0 to 24)|Withdrawal by Subject|12
6227438|NCT01717313|9900162|FG001|Phase A (Weeks 0 to 24)|Withdrawal by Subject|6
6227439|NCT01717313|9900161|FG000|Phase A (Weeks 0 to 24)|Adverse Event|4
6227440|NCT01717313|9900162|FG001|Phase A (Weeks 0 to 24)|Adverse Event|2
6227441|NCT01717313|9900161|FG000|Phase A (Weeks 0 to 24)|Non-Compliance with Study Drug|1
6227442|NCT01717313|9900162|FG001|Phase A (Weeks 0 to 24)|Non-Compliance with Study Drug|1
6227443|NCT01717313|9900161|FG000|Interphase|Completed Phase A Did Not Enter Phase B|1
6227444|NCT01717313|9900162|FG001|Interphase|Completed Phase A Did Not Enter Phase B|0
6227445|NCT01717313|9900161|FG000|Phase B (Weeks 24 to 54)|Study Terminated by Sponsor|4
6347382|NCT03499028|10109918|FG001|Overall Study|Withdrawal by Subject|8
6169087|NCT01240382|9814339|FG001|Overall Study|Fear of adverse events|1
6347383|NCT03499028|10109917|FG000|Overall Study|Unplanned SNF discharge|5
6347384|NCT03499028|10109918|FG001|Overall Study|Unplanned SNF discharge|8
6347385|NCT03499067|10109926|FG000|First Intervention|Physician Decision|2
6347386|NCT03499067|10109927|FG001|First Intervention|Physician Decision|1
6347387|NCT03499067|10109926|FG000|First Intervention|Withdrawal by Subject|3
6347388|NCT03499067|10109927|FG001|First Intervention|Withdrawal by Subject|6
6347389|NCT03499353|10109933|FG000|Treatment|Adverse Event|3
6347390|NCT03499353|10109933|FG000|Treatment|Progressive Disease|10
6347391|NCT03499353|10109933|FG000|Treatment|Other|1
6347392|NCT03499353|10109933|FG000|Treatment|Withdrawal by Subject|2
6347393|NCT03499353|10109933|FG000|Long-Term Follow-up|Death|2
6347394|NCT03499353|10109933|FG000|Long-Term Follow-up|Study Terminated By Sponsor|55
6347395|NCT03499353|10109933|FG000|Long-Term Follow-up|Withdrawal by Subject|1
6347396|NCT03499873|10109940|FG000|Overall Study|Withdrawal by Subject|4
6347397|NCT03499873|10109941|FG001|Overall Study|Withdrawal by Subject|6
6347398|NCT03499873|10109942|FG002|Overall Study|Withdrawal by Subject|1
6347399|NCT03499873|10109940|FG000|Overall Study|Subjects condition worsened|0
6347400|NCT03499873|10109941|FG001|Overall Study|Subjects condition worsened|3
6347401|NCT03499873|10109942|FG002|Overall Study|Subjects condition worsened|11
6347402|NCT03499873|10109940|FG000|Overall Study|Adverse Event|8
6347403|NCT03499873|10109941|FG001|Overall Study|Adverse Event|3
6347404|NCT03499873|10109942|FG002|Overall Study|Adverse Event|6
6347405|NCT03499873|10109940|FG000|Overall Study|Physician Decision|1
6347406|NCT03499873|10109941|FG001|Overall Study|Physician Decision|0
6347407|NCT03499873|10109942|FG002|Overall Study|Physician Decision|0
6347408|NCT03499873|10109940|FG000|Overall Study|Administrative reasons|0
6347409|NCT03499873|10109941|FG001|Overall Study|Administrative reasons|1
6347410|NCT03499873|10109942|FG002|Overall Study|Administrative reasons|0
6347411|NCT03499873|10109940|FG000|Overall Study|Concomitant therapy|5
6347412|NCT03499873|10109941|FG001|Overall Study|Concomitant therapy|4
6347413|NCT03499873|10109942|FG002|Overall Study|Concomitant therapy|7
6347414|NCT03499873|10109940|FG000|Overall Study|Miscellaneous|1
6347415|NCT03499873|10109941|FG001|Overall Study|Miscellaneous|2
6347416|NCT03499873|10109942|FG002|Overall Study|Miscellaneous|2
6347417|NCT03499873|10109940|FG000|Overall Study|Investigational Product (IP) Missed dose compliance|1
6347418|NCT03499873|10109941|FG001|Overall Study|Investigational Product (IP) Missed dose compliance|1
6347419|NCT03499873|10109942|FG002|Overall Study|Investigational Product (IP) Missed dose compliance|0
6347420|NCT03500094|10109950|FG000|Overall Study|Withdrawal by Subject|1
6347421|NCT03500094|10109950|FG000|Overall Study|Withdrawal by Parent or Legally-authorized Representative|1
6347422|NCT03500094|10109950|FG000|Overall Study|Lost to Follow-up|1
6347423|NCT03500198|10109958|FG000|Overall Study|Lost to Follow-up|0
6347424|NCT03500198|10109959|FG001|Overall Study|Lost to Follow-up|1
6347425|NCT03500211|10109969|FG000|Overall Study|Withdrawal by Subject|1
6347426|NCT03500211|10109970|FG001|Overall Study|Withdrawal by Subject|1
6347427|NCT03500224|10109976|FG000|Overall Study|Withdrawal by Subject|2
6347428|NCT03500419|10109995|FG000|Overall Study|Withdrawal by Subject|2
6347429|NCT03500419|10109996|FG001|Overall Study|Withdrawal by Subject|25
6347430|NCT03500679|10110004|FG000|Overall Study|Lost to Follow-up|6
6347431|NCT03500679|10110005|FG001|Overall Study|Lost to Follow-up|3
6347432|NCT03500679|10110004|FG000|Overall Study|Withdrawal by Subject|3
6347433|NCT03500679|10110005|FG001|Overall Study|Withdrawal by Subject|0
6347434|NCT03501277|10110084|FG000|Intervention Period 1 (4 Days)|Other|0
6347435|NCT03501277|10110085|FG001|Intervention Period 1 (4 Days)|Other|0
6347436|NCT03501277|10110086|FG002|Intervention Period 1 (4 Days)|Other|1
6347437|NCT03501277|10110087|FG003|Intervention Period 1 (4 Days)|Other|0
6347438|NCT03501277|10110084|FG000|Intervention Period 1 (4 Days)|Adverse Event|0
6347439|NCT03501277|10110085|FG001|Intervention Period 1 (4 Days)|Adverse Event|0
6347440|NCT03501277|10110086|FG002|Intervention Period 1 (4 Days)|Adverse Event|0
6347441|NCT03501277|10110087|FG003|Intervention Period 1 (4 Days)|Adverse Event|1
6347442|NCT03501277|10110084|FG000|Intervention Period 2 (4 Days)|Adverse Event|0
6083525|NCT00635778|9691948|FG003|Overall Study|Adverse Event|3
6083526|NCT00635778|9691949|FG004|Overall Study|Adverse Event|3
6347443|NCT03501277|10110085|FG001|Intervention Period 2 (4 Days)|Adverse Event|0
6347444|NCT03501277|10110086|FG002|Intervention Period 2 (4 Days)|Adverse Event|0
6347445|NCT03501277|10110087|FG003|Intervention Period 2 (4 Days)|Adverse Event|1
6347446|NCT03501277|10110084|FG000|Intervention Period 3 (4 Days)|Adverse Event|0
6347447|NCT03501277|10110085|FG001|Intervention Period 3 (4 Days)|Adverse Event|0
6347448|NCT03501277|10110086|FG002|Intervention Period 3 (4 Days)|Adverse Event|0
6347449|NCT03501277|10110087|FG003|Intervention Period 3 (4 Days)|Adverse Event|1
6347450|NCT03502616|10110114|FG000|Up to Week 16|Withdrawal by Subject|1
6347451|NCT03502616|10110115|FG001|Up to Week 16|Withdrawal by Subject|2
6347452|NCT03502616|10110114|FG000|Up to Week 16|Lost to Follow-up|0
6347453|NCT03502616|10110115|FG001|Up to Week 16|Lost to Follow-up|1
6347454|NCT03502616|10110114|FG000|Up to Week 16|Randomized, but not treated|1
6347455|NCT03502616|10110115|FG001|Up to Week 16|Randomized, but not treated|0
6347456|NCT03502616|10110114|FG000|Week 16 to Week 48|Withdrawal by Subject|6
6347457|NCT03502616|10110115|FG001|Week 16 to Week 48|Withdrawal by Subject|6
6347458|NCT03502616|10110114|FG000|Week 16 to Week 48|Lost to Follow-up|1
6347459|NCT03502616|10110115|FG001|Week 16 to Week 48|Lost to Follow-up|0
6347460|NCT03502681|10110125|FG000|Overall Study|Adverse Event|1
6347461|NCT03502681|10110126|FG001|Overall Study|Adverse Event|1
6347462|NCT03502681|10110125|FG000|Overall Study|Disease Progression|2
6347463|NCT03502681|10110126|FG001|Overall Study|Disease Progression|1
6347464|NCT03502798|10110133|FG000|Overall Study|equipment failure|0
6347465|NCT03502798|10110134|FG001|Overall Study|equipment failure|7
6347466|NCT03503162|10110162|FG000|Overall Study|did not meet eligibility|1
6347467|NCT03503188|10110168|FG000|Overall Study|Non eligible in the sub study|0
6347468|NCT03503188|10110169|FG001|Overall Study|Non eligible in the sub study|1
6347469|NCT03504189|10110197|FG000|Overall Study|Withdrawal by Subject|1
6347470|NCT03504189|10110197|FG000|Overall Study|Screening Failure|1
6347471|NCT03504189|10110197|FG000|Overall Study|Device Failure|2
6347472|NCT03504852|10110213|FG000|Overall Study|Withdrawal of informed consent|2
6347473|NCT03504852|10110214|FG001|Overall Study|Withdrawal of informed consent|1
6347474|NCT03504852|10110215|FG002|Overall Study|Withdrawal of informed consent|0
6347475|NCT03504852|10110213|FG000|Overall Study|Withdrawal by Subject|5
6347476|NCT03504852|10110214|FG001|Overall Study|Withdrawal by Subject|5
6347477|NCT03504852|10110215|FG002|Overall Study|Withdrawal by Subject|1
6347478|NCT03504852|10110213|FG000|Overall Study|Lost to Follow-up|4
6347479|NCT03504852|10110214|FG001|Overall Study|Lost to Follow-up|1
6347480|NCT03504852|10110215|FG002|Overall Study|Lost to Follow-up|0
6347481|NCT03504852|10110213|FG000|Overall Study|New therapy for study indication|1
6347482|NCT03504852|10110214|FG001|Overall Study|New therapy for study indication|0
6347483|NCT03504852|10110215|FG002|Overall Study|New therapy for study indication|0
6347484|NCT03504852|10110213|FG000|Overall Study|Lack of Efficacy|1
6347485|NCT03504852|10110214|FG001|Overall Study|Lack of Efficacy|2
6347486|NCT03504852|10110215|FG002|Overall Study|Lack of Efficacy|0
6347487|NCT03504852|10110213|FG000|Overall Study|Death|0
6347488|NCT03504852|10110214|FG001|Overall Study|Death|1
6347489|NCT03504852|10110215|FG002|Overall Study|Death|0
6347490|NCT03504852|10110213|FG000|Overall Study|Adverse Event|4
6347491|NCT03504852|10110214|FG001|Overall Study|Adverse Event|8
6347492|NCT03504852|10110215|FG002|Overall Study|Adverse Event|2
6347493|NCT03504917|10110227|FG000|Blinded Treatment Period|Protocol Violation|1
6347494|NCT03504917|10110228|FG001|Blinded Treatment Period|Protocol Violation|0
6347495|NCT03504917|10110227|FG000|Blinded Treatment Period|Withdrawal by Subject|12
6347496|NCT03504917|10110228|FG001|Blinded Treatment Period|Withdrawal by Subject|9
6347497|NCT03504917|10110227|FG000|Blinded Treatment Period|Lack of Efficacy|1
6347498|NCT03504917|10110228|FG001|Blinded Treatment Period|Lack of Efficacy|1
6347499|NCT03504917|10110227|FG000|Blinded Treatment Period|Lost to Follow-up|1
6347500|NCT03504917|10110228|FG001|Blinded Treatment Period|Lost to Follow-up|4
6347501|NCT03504917|10110227|FG000|Blinded Treatment Period|Adverse Event|4
6347502|NCT03504917|10110228|FG001|Blinded Treatment Period|Adverse Event|4
6347503|NCT03504917|10110227|FG000|Blinded Treatment Period|Physician Decision|1
6347504|NCT03504917|10110228|FG001|Blinded Treatment Period|Physician Decision|0
6347505|NCT03504917|10110227|FG000|Blinded Treatment Period|Unable due to leaving the study site, non-interest, withdrawal, and a partner inability|1
6347506|NCT03504917|10110228|FG001|Blinded Treatment Period|Unable due to leaving the study site, non-interest, withdrawal, and a partner inability|3
6347507|NCT03504917|10110227|FG000|Blinded Treatment Period|Study terminated by sponsor|39
6347508|NCT03504917|10110228|FG001|Blinded Treatment Period|Study terminated by sponsor|34
6347509|NCT03504917|10110227|FG000|Blinded Treatment Period|Non-compliance with study drug|0
6347510|NCT03504917|10110228|FG001|Blinded Treatment Period|Non-compliance with study drug|1
6347511|NCT03504917|10110227|FG000|Open Label Extension Treatment Period|The participant left the study site|0
6347512|NCT03504917|10110228|FG001|Open Label Extension Treatment Period|The participant left the study site|1
6347513|NCT03504917|10110227|FG000|Open Label Extension Treatment Period|Withdrawal by Subject|8
6347514|NCT03504917|10110228|FG001|Open Label Extension Treatment Period|Withdrawal by Subject|2
6347515|NCT03504917|10110227|FG000|Open Label Extension Treatment Period|Lost to Follow-up|1
6347516|NCT03504917|10110228|FG001|Open Label Extension Treatment Period|Lost to Follow-up|4
6347517|NCT03504917|10110227|FG000|Open Label Extension Treatment Period|Lack of Efficacy|3
6347518|NCT03504917|10110228|FG001|Open Label Extension Treatment Period|Lack of Efficacy|1
6347519|NCT03504917|10110227|FG000|Open Label Extension Treatment Period|Adverse Event|7
6347520|NCT03504917|10110228|FG001|Open Label Extension Treatment Period|Adverse Event|0
6347521|NCT03504917|10110227|FG000|Open Label Extension Treatment Period|Non-compliance with study drug|0
6347522|NCT03504917|10110228|FG001|Open Label Extension Treatment Period|Non-compliance with study drug|1
6347523|NCT03504917|10110227|FG000|Open Label Extension Treatment Period|Study terminated by sponsor|81
6347524|NCT03504917|10110228|FG001|Open Label Extension Treatment Period|Study terminated by sponsor|88
6347525|NCT03505593|10110261|FG000|Overall Study|Withdrawal by Subject|1
6347526|NCT03505593|10110261|FG000|Overall Study|Died before procedure|1
6347527|NCT03505593|10110261|FG000|Overall Study|Anatomical abnormality|1
6347528|NCT03505593|10110261|FG000|Overall Study|Unable to pass through esophagus|1
6347529|NCT03505593|10110261|FG000|Overall Study|Obstruction by Endotracheal tube|1
6347530|NCT03506425|10110287|FG000|Overall Study|Adverse Event|1
6347531|NCT03506425|10110288|FG001|Overall Study|Adverse Event|3
6347532|NCT03506425|10110289|FG002|Overall Study|Adverse Event|0
6083527|NCT00635778|9691950|FG005|Overall Study|Adverse Event|6
6083528|NCT00635778|9691951|FG006|Overall Study|Adverse Event|1
6083529|NCT00635778|9691945|FG000|Overall Study|Withdrawal by Subject|0
6083530|NCT00635778|9691946|FG001|Overall Study|Withdrawal by Subject|0
6083531|NCT00635778|9691947|FG002|Overall Study|Withdrawal by Subject|0
6347533|NCT03506425|10110287|FG000|Overall Study|Death|1
6347534|NCT03506425|10110288|FG001|Overall Study|Death|0
6347535|NCT03506425|10110289|FG002|Overall Study|Death|0
6347536|NCT03506425|10110287|FG000|Overall Study|Withdrawal by Subject|0
6347537|NCT03506425|10110288|FG001|Overall Study|Withdrawal by Subject|0
6347538|NCT03506425|10110289|FG002|Overall Study|Withdrawal by Subject|1
6347539|NCT03506477|10110300|FG000|Overall Study|Withdrawal by Subject|1
6347540|NCT03506477|10110301|FG001|Overall Study|Withdrawal by Subject|0
6347541|NCT03508050|10110342|FG000|Overall Study|Pleural adhesions|1
6347542|NCT03508050|10110343|FG001|Overall Study|Pleural adhesions|0
6347543|NCT03508050|10110342|FG000|Overall Study|Mucus plug|1
6347544|NCT03508050|10110343|FG001|Overall Study|Mucus plug|0
6347545|NCT03508050|10110342|FG000|Overall Study|Negative biopsy, surgery cancelled|3
6347546|NCT03508050|10110343|FG001|Overall Study|Negative biopsy, surgery cancelled|1
6347547|NCT03508050|10110342|FG000|Overall Study|Sustained desaturation|0
6347548|NCT03508050|10110343|FG001|Overall Study|Sustained desaturation|1
6347549|NCT03508609|10110350|FG000|Overall Study|Withdrawal by Subject|1
6347550|NCT03508830|10110371|FG000|Overall Study|Withdrawal by Subject|3
6347551|NCT03508830|10110372|FG001|Overall Study|Withdrawal by Subject|4
6347552|NCT03508830|10110371|FG000|Overall Study|Physician Decision|2
6347553|NCT03508830|10110372|FG001|Overall Study|Physician Decision|2
6347554|NCT03508843|10110378|FG000|Overall Study|Withdrawal by Subject|1
6347555|NCT03508843|10110378|FG000|Overall Study|technical difficulties|2
6347556|NCT03509350|10110384|FG000|Overall Study|Withdrawal by Subject|0
6347557|NCT03509350|10110385|FG001|Overall Study|Withdrawal by Subject|2
6347558|NCT03509675|10110393|FG000|First Intervention (7 Days)|Lost to Follow-up|3
6347559|NCT03509675|10110394|FG001|First Intervention (7 Days)|Lost to Follow-up|3
6347560|NCT03509675|10110393|FG000|First Intervention (7 Days)|Lack of Efficacy|2
6347561|NCT03509675|10110394|FG001|First Intervention (7 Days)|Lack of Efficacy|1
6169088|NCT01240551|9814347|FG000|Overall Study|Refused further treatment|3
6169089|NCT01240551|9814348|FG001|Overall Study|Refused further treatment|2
6169090|NCT01240551|9814347|FG000|Overall Study|Lost to Follow-up|1
6169091|NCT01240551|9814348|FG001|Overall Study|Lost to Follow-up|1
6169092|NCT01240590|9814359|FG000|Phase I|Refused further treatment|0
6169093|NCT01240590|9814360|FG001|Phase I|Refused further treatment|0
6169094|NCT01240590|9814361|FG002|Phase I|Refused further treatment|3
6169095|NCT01240590|9814362|FG003|Phase I|Refused further treatment|0
6169096|NCT01240590|9814363|FG004|Phase I|Refused further treatment|0
6169097|NCT01240590|9814359|FG000|Phase II|Refused further treatment|0
6169098|NCT01240590|9814360|FG001|Phase II|Refused further treatment|0
6169099|NCT01240590|9814361|FG002|Phase II|Refused further treatment|0
6169100|NCT01240590|9814362|FG003|Phase II|Refused further treatment|2
6169101|NCT01240590|9814363|FG004|Phase II|Refused further treatment|1
6169102|NCT01240746|9814392|FG000|Overall Study|Adverse Event|2
6169103|NCT01240746|9814393|FG001|Overall Study|Adverse Event|0
6169104|NCT01240746|9814394|FG002|Overall Study|Adverse Event|10
6169105|NCT01240746|9814392|FG000|Overall Study|Lost to Follow-up|23
6169106|NCT01240746|9814393|FG001|Overall Study|Lost to Follow-up|20
6169107|NCT01240746|9814394|FG002|Overall Study|Lost to Follow-up|102
6169108|NCT01240746|9814392|FG000|Overall Study|Protocol Violation|24
6169109|NCT01240746|9814393|FG001|Overall Study|Protocol Violation|15
6169110|NCT01240746|9814394|FG002|Overall Study|Protocol Violation|72
6169111|NCT01240746|9814392|FG000|Overall Study|Withdrawal by Subject|10
6169112|NCT01240746|9814393|FG001|Overall Study|Withdrawal by Subject|13
6169113|NCT01240746|9814394|FG002|Overall Study|Withdrawal by Subject|59
6169114|NCT01240785|9814404|FG000|Overall Study|Lost to Follow-up|1
6169115|NCT01240785|9814405|FG001|Overall Study|Lost to Follow-up|0
6169116|NCT01240785|9814404|FG000|Overall Study|Protocol Violation|0
6169117|NCT01240785|9814405|FG001|Overall Study|Protocol Violation|3
6169118|NCT01240811|9814414|FG000|Overall Study|Physician Decision|0
6169119|NCT01240811|9814415|FG001|Overall Study|Physician Decision|1
6169120|NCT01240811|9814416|FG002|Overall Study|Physician Decision|0
6169121|NCT01240811|9814414|FG000|Overall Study|Withdrawal by Subject|0
6169122|NCT01240811|9814415|FG001|Overall Study|Withdrawal by Subject|0
6169123|NCT01240811|9814416|FG002|Overall Study|Withdrawal by Subject|1
6169124|NCT01240863|9814428|FG000|Open-label Titration Period|Adverse Event|47
6169125|NCT01240863|9814429|FG001|Open-label Titration Period|Adverse Event|0
6169126|NCT01240863|9814430|FG002|Open-label Titration Period|Adverse Event|0
6169127|NCT01240863|9814428|FG000|Open-label Titration Period|Lack of Efficacy|19
6169128|NCT01240863|9814429|FG001|Open-label Titration Period|Lack of Efficacy|0
6169129|NCT01240863|9814430|FG002|Open-label Titration Period|Lack of Efficacy|0
6169130|NCT01240863|9814428|FG000|Open-label Titration Period|Withdrawal by Subject|9
6169131|NCT01240863|9814429|FG001|Open-label Titration Period|Withdrawal by Subject|0
6169132|NCT01240863|9814430|FG002|Open-label Titration Period|Withdrawal by Subject|0
6169133|NCT01240863|9814428|FG000|Open-label Titration Period|Protocol Violation|7
6169134|NCT01240863|9814429|FG001|Open-label Titration Period|Protocol Violation|0
6169135|NCT01240863|9814430|FG002|Open-label Titration Period|Protocol Violation|0
6347562|NCT03509675|10110393|FG000|Second Intervention )7 Days)|Withdrawal by Subject|1
6347563|NCT03509675|10110394|FG001|Second Intervention )7 Days)|Withdrawal by Subject|0
6347564|NCT03509675|10110393|FG000|Second Intervention )7 Days)|Lost Rinse B|1
6347565|NCT03509675|10110394|FG001|Second Intervention )7 Days)|Lost Rinse B|0
6347566|NCT03509948|10110415|FG000|Overall Study|Protocol Violation|0
6347567|NCT03509948|10110416|FG001|Overall Study|Protocol Violation|1
6169136|NCT01240863|9814428|FG000|Open-label Titration Period|Noncompliance to study drug admin|3
6169137|NCT01240863|9814429|FG001|Open-label Titration Period|Noncompliance to study drug admin|0
6169138|NCT01240863|9814430|FG002|Open-label Titration Period|Noncompliance to study drug admin|0
6169139|NCT01240863|9814428|FG000|Open-label Titration Period|Noncompliance to study procedures|3
6169140|NCT01240863|9814429|FG001|Open-label Titration Period|Noncompliance to study procedures|0
6169141|NCT01240863|9814430|FG002|Open-label Titration Period|Noncompliance to study procedures|0
6169142|NCT01240863|9814428|FG000|Open-label Titration Period|Dropped out prior to dosing|2
6169143|NCT01240863|9814429|FG001|Open-label Titration Period|Dropped out prior to dosing|0
6169144|NCT01240863|9814430|FG002|Open-label Titration Period|Dropped out prior to dosing|0
6169145|NCT01240863|9814428|FG000|Open-label Titration Period|Other|7
6169146|NCT01240863|9814429|FG001|Open-label Titration Period|Other|0
6347568|NCT03510182|10110426|FG000|Overall Study|Withdrawal by Subject|2
6347569|NCT03510273|10110444|FG000|Overall Study|Withdrawal by Subject|2
6347570|NCT03510273|10110444|FG000|Overall Study|Care outside study, ineligible to cont.|3
6347571|NCT03510273|10110444|FG000|Overall Study|Moved away from study area|4
6083532|NCT00635778|9691948|FG003|Overall Study|Withdrawal by Subject|1
6083533|NCT00635778|9691949|FG004|Overall Study|Withdrawal by Subject|0
6083534|NCT00635778|9691950|FG005|Overall Study|Withdrawal by Subject|1
6083535|NCT00635778|9691951|FG006|Overall Study|Withdrawal by Subject|1
6169147|NCT01240863|9814430|FG002|Open-label Titration Period|Other|0
6169148|NCT01240863|9814428|FG000|Double-blind Treatment Period (12 Weeks)|Adverse Event|0
6169149|NCT01240863|9814429|FG001|Double-blind Treatment Period (12 Weeks)|Adverse Event|4
6169150|NCT01240863|9814430|FG002|Double-blind Treatment Period (12 Weeks)|Adverse Event|10
6169151|NCT01240863|9814428|FG000|Double-blind Treatment Period (12 Weeks)|Lack of Efficacy|0
6083536|NCT00635778|9691945|FG000|Overall Study|Progressive disease|0
6083537|NCT00635778|9691946|FG001|Overall Study|Progressive disease|3
6083538|NCT00635778|9691947|FG002|Overall Study|Progressive disease|3
6083539|NCT00635778|9691948|FG003|Overall Study|Progressive disease|4
6083540|NCT00635778|9691949|FG004|Overall Study|Progressive disease|5
6083541|NCT00635778|9691950|FG005|Overall Study|Progressive disease|14
6083542|NCT00635778|9691951|FG006|Overall Study|Progressive disease|4
6083543|NCT00635804|9691976|FG000|Overall Study|Adverse Event|0
6083544|NCT00635804|9691977|FG001|Overall Study|Adverse Event|0
6083545|NCT00635804|9691978|FG002|Overall Study|Adverse Event|0
6083546|NCT00635804|9691979|FG003|Overall Study|Adverse Event|0
6083547|NCT00635804|9691980|FG004|Overall Study|Adverse Event|0
6083548|NCT00635804|9691981|FG005|Overall Study|Adverse Event|1
6083549|NCT00635804|9691982|FG006|Overall Study|Adverse Event|0
6083550|NCT00635804|9691983|FG007|Overall Study|Adverse Event|0
6083551|NCT00635804|9691976|FG000|Overall Study|Withdrawal by Subject|1
6083552|NCT00635804|9691977|FG001|Overall Study|Withdrawal by Subject|0
6083553|NCT00635804|9691978|FG002|Overall Study|Withdrawal by Subject|0
6347572|NCT03510455|10110452|FG000|Overall Study|Physician Decision|1
6347573|NCT03510663|10110485|FG000|Overall Study|Withdrawal by Subject|0
6347574|NCT03510663|10110486|FG001|Overall Study|Withdrawal by Subject|1
6347575|NCT03510663|10110487|FG002|Overall Study|Withdrawal by Subject|0
6347576|NCT03510663|10110488|FG003|Overall Study|Withdrawal by Subject|0
6347577|NCT03510663|10110489|FG004|Overall Study|Withdrawal by Subject|0
6347578|NCT03510663|10110490|FG005|Overall Study|Withdrawal by Subject|0
6347579|NCT03510663|10110491|FG006|Overall Study|Withdrawal by Subject|0
6347580|NCT03510663|10110492|FG007|Overall Study|Withdrawal by Subject|0
6347581|NCT03510715|10110504|FG000|Overall Study|Adverse Event|1
6347582|NCT03510715|10110505|FG001|Overall Study|Adverse Event|0
6347583|NCT03510910|10110514|FG000|Overall Study|Incomplete Survey|2
6347584|NCT03510910|10110515|FG001|Overall Study|Incomplete Survey|3
6347585|NCT03511053|10110530|FG000|Overall Study|Withdrawal by Subject|1
6347586|NCT03511105|10110536|FG000|Overall Study|Adverse Event|1
6347587|NCT03511105|10110537|FG001|Overall Study|Adverse Event|0
6347588|NCT03511105|10110536|FG000|Overall Study|Withdrew consent|1
6347589|NCT03511105|10110537|FG001|Overall Study|Withdrew consent|0
6347590|NCT03511326|10110544|FG000|Overall Study|Withdrawal by Subject|1
6347591|NCT03511378|10110550|FG000|Overall Study|Withdrawal by Subject|2
6347592|NCT03511378|10110551|FG001|Overall Study|Withdrawal by Subject|2
6347593|NCT03511378|10110550|FG000|Overall Study|Patient not coming or schedule visit|1
6347594|NCT03511378|10110551|FG001|Overall Study|Patient not coming or schedule visit|0
6347595|NCT03512028|10110588|FG000|Overall Study|Withdrawal by Subject|2
6347596|NCT03512028|10110589|FG001|Overall Study|Withdrawal by Subject|0
6347597|NCT03512028|10110588|FG000|Overall Study|Protocol Violation|2
6347598|NCT03512028|10110589|FG001|Overall Study|Protocol Violation|0
6347599|NCT03512288|10110618|FG000|Overall Study|Adverse Event|1
6169152|NCT01240863|9814429|FG001|Double-blind Treatment Period (12 Weeks)|Lack of Efficacy|17
6169153|NCT01240863|9814430|FG002|Double-blind Treatment Period (12 Weeks)|Lack of Efficacy|5
6169154|NCT01240863|9814428|FG000|Double-blind Treatment Period (12 Weeks)|Withdrawal by Subject|0
6169155|NCT01240863|9814429|FG001|Double-blind Treatment Period (12 Weeks)|Withdrawal by Subject|3
6169156|NCT01240863|9814430|FG002|Double-blind Treatment Period (12 Weeks)|Withdrawal by Subject|5
6169157|NCT01240863|9814428|FG000|Double-blind Treatment Period (12 Weeks)|Protocol Violation|0
6169158|NCT01240863|9814429|FG001|Double-blind Treatment Period (12 Weeks)|Protocol Violation|9
6169159|NCT01240863|9814430|FG002|Double-blind Treatment Period (12 Weeks)|Protocol Violation|14
6169160|NCT01240863|9814428|FG000|Double-blind Treatment Period (12 Weeks)|Noncompliance to study drug admin|0
6169161|NCT01240863|9814429|FG001|Double-blind Treatment Period (12 Weeks)|Noncompliance to study drug admin|9
6169162|NCT01240863|9814430|FG002|Double-blind Treatment Period (12 Weeks)|Noncompliance to study drug admin|11
6169163|NCT01240863|9814428|FG000|Double-blind Treatment Period (12 Weeks)|Noncompliance to study procedures|0
6169164|NCT01240863|9814429|FG001|Double-blind Treatment Period (12 Weeks)|Noncompliance to study procedures|2
6169165|NCT01240863|9814430|FG002|Double-blind Treatment Period (12 Weeks)|Noncompliance to study procedures|2
6169166|NCT01240863|9814428|FG000|Double-blind Treatment Period (12 Weeks)|Other|0
6169167|NCT01240863|9814429|FG001|Double-blind Treatment Period (12 Weeks)|Other|1
6169168|NCT01240863|9814430|FG002|Double-blind Treatment Period (12 Weeks)|Other|5
6169169|NCT01240863|9814428|FG000|Double-blind Treatment Period (12 Weeks)|Physician Decision|0
6169170|NCT01240863|9814429|FG001|Double-blind Treatment Period (12 Weeks)|Physician Decision|1
6169171|NCT01240863|9814430|FG002|Double-blind Treatment Period (12 Weeks)|Physician Decision|0
6169172|NCT01240915|9814450|FG000|Overall Study|Adverse Event|0
6169173|NCT01240915|9814451|FG001|Overall Study|Adverse Event|0
6169174|NCT01240915|9814452|FG002|Overall Study|Adverse Event|0
6169175|NCT01240915|9814453|FG003|Overall Study|Adverse Event|1
6169176|NCT01240915|9814454|FG004|Overall Study|Adverse Event|0
6169177|NCT01240915|9814455|FG005|Overall Study|Adverse Event|2
6169178|NCT01240915|9814456|FG006|Overall Study|Adverse Event|0
6169179|NCT01240915|9814457|FG007|Overall Study|Adverse Event|0
6169180|NCT01240915|9814458|FG008|Overall Study|Adverse Event|1
6169181|NCT01240915|9814450|FG000|Overall Study|Lost to Follow-up|0
6169182|NCT01240915|9814451|FG001|Overall Study|Lost to Follow-up|0
6169183|NCT01240915|9814452|FG002|Overall Study|Lost to Follow-up|0
6169184|NCT01240915|9814453|FG003|Overall Study|Lost to Follow-up|0
6169185|NCT01240915|9814454|FG004|Overall Study|Lost to Follow-up|1
6169186|NCT01240915|9814455|FG005|Overall Study|Lost to Follow-up|1
6169187|NCT01240915|9814456|FG006|Overall Study|Lost to Follow-up|0
6169188|NCT01240915|9814457|FG007|Overall Study|Lost to Follow-up|1
6169189|NCT01240915|9814458|FG008|Overall Study|Lost to Follow-up|1
6169190|NCT01240915|9814450|FG000|Overall Study|Withdrawal by Subject|2
6169191|NCT01240915|9814451|FG001|Overall Study|Withdrawal by Subject|1
6169192|NCT01240915|9814452|FG002|Overall Study|Withdrawal by Subject|0
6169193|NCT01240915|9814453|FG003|Overall Study|Withdrawal by Subject|2
6169194|NCT01240915|9814454|FG004|Overall Study|Withdrawal by Subject|0
6347600|NCT03512288|10110619|FG001|Overall Study|Adverse Event|0
6347601|NCT03512288|10110618|FG000|Overall Study|Lost to Follow-up|12
6347602|NCT03512288|10110619|FG001|Overall Study|Lost to Follow-up|15
6347603|NCT03512288|10110618|FG000|Overall Study|Physician Decision|0
6347604|NCT03512288|10110619|FG001|Overall Study|Physician Decision|2
6169195|NCT01240915|9814455|FG005|Overall Study|Withdrawal by Subject|4
6169196|NCT01240915|9814456|FG006|Overall Study|Withdrawal by Subject|2
6347605|NCT03512288|10110618|FG000|Overall Study|Protocol Violation|6
6347606|NCT03512288|10110619|FG001|Overall Study|Protocol Violation|4
6347607|NCT03512288|10110618|FG000|Overall Study|Medication error without associated adverse event|1
6347608|NCT03512288|10110619|FG001|Overall Study|Medication error without associated adverse event|0
6347609|NCT03512288|10110618|FG000|Overall Study|No longer met eligibility criteria|5
6347610|NCT03512288|10110619|FG001|Overall Study|No longer met eligibility criteria|2
6347611|NCT03512288|10110618|FG000|Overall Study|Withdrawal by parent/guardian|14
6347612|NCT03512288|10110619|FG001|Overall Study|Withdrawal by parent/guardian|18
6347613|NCT03512288|10110618|FG000|Overall Study|Other|1
6347614|NCT03512288|10110619|FG001|Overall Study|Other|1
6347615|NCT03512288|10110618|FG000|Overall Study|Randomized but not treated|1
6347616|NCT03512288|10110619|FG001|Overall Study|Randomized but not treated|1
6347617|NCT03512353|10110625|FG000|Overall Study|Sponsor Decision|3
6347618|NCT03512353|10110625|FG000|Overall Study|Death|1
6347619|NCT03513588|10110645|FG000|Overall Study|Lost to Follow-up|0
6347620|NCT03513588|10110646|FG001|Overall Study|Lost to Follow-up|1
6347621|NCT03513588|10110647|FG002|Overall Study|Lost to Follow-up|1
6347622|NCT03513588|10110645|FG000|Overall Study|Study dosing paused by sponsor|1
6347623|NCT03513588|10110646|FG001|Overall Study|Study dosing paused by sponsor|1
6347624|NCT03513588|10110647|FG002|Overall Study|Study dosing paused by sponsor|0
6347625|NCT03513588|10110645|FG000|Overall Study|Death|0
6347626|NCT03513588|10110646|FG001|Overall Study|Death|0
6347627|NCT03513588|10110647|FG002|Overall Study|Death|1
6347628|NCT03514641|10110699|FG000|603A: 0-12 Week Study Period|Protocol Violation|3
6347629|NCT03514641|10110700|FG001|603A: 0-12 Week Study Period|Protocol Violation|3
6347630|NCT03514641|10110701|FG002|603A: 0-12 Week Study Period|Protocol Violation|0
6347631|NCT03514641|10110702|FG003|603A: 0-12 Week Study Period|Protocol Violation|0
6347632|NCT03514641|10110699|FG000|603A: 0-12 Week Study Period|Adverse Event|5
6347633|NCT03514641|10110700|FG001|603A: 0-12 Week Study Period|Adverse Event|2
6347634|NCT03514641|10110701|FG002|603A: 0-12 Week Study Period|Adverse Event|0
6347635|NCT03514641|10110702|FG003|603A: 0-12 Week Study Period|Adverse Event|0
6347636|NCT03514641|10110699|FG000|603A: 0-12 Week Study Period|Withdrawal by Subject|7
6347637|NCT03514641|10110700|FG001|603A: 0-12 Week Study Period|Withdrawal by Subject|5
6347638|NCT03514641|10110701|FG002|603A: 0-12 Week Study Period|Withdrawal by Subject|0
6347639|NCT03514641|10110702|FG003|603A: 0-12 Week Study Period|Withdrawal by Subject|0
6347640|NCT03514641|10110699|FG000|603A: 0-12 Week Study Period|Lost to Follow-up|10
6347641|NCT03514641|10110700|FG001|603A: 0-12 Week Study Period|Lost to Follow-up|9
6347642|NCT03514641|10110701|FG002|603A: 0-12 Week Study Period|Lost to Follow-up|0
6347643|NCT03514641|10110702|FG003|603A: 0-12 Week Study Period|Lost to Follow-up|0
6347644|NCT03514641|10110699|FG000|603A: 0-12 Week Study Period|Physician Decision|1
6347645|NCT03514641|10110700|FG001|603A: 0-12 Week Study Period|Physician Decision|0
6347646|NCT03514641|10110701|FG002|603A: 0-12 Week Study Period|Physician Decision|0
6347647|NCT03514641|10110702|FG003|603A: 0-12 Week Study Period|Physician Decision|0
6347648|NCT03514641|10110699|FG000|603A: 0-12 Week Study Period|Lack of Efficacy|1
6347649|NCT03514641|10110700|FG001|603A: 0-12 Week Study Period|Lack of Efficacy|0
6347650|NCT03514641|10110701|FG002|603A: 0-12 Week Study Period|Lack of Efficacy|0
6347651|NCT03514641|10110702|FG003|603A: 0-12 Week Study Period|Lack of Efficacy|0
6347652|NCT03514641|10110699|FG000|603A: 0-12 Week Study Period|24 hr ABPM not enough readings|0
6347653|NCT03514641|10110700|FG001|603A: 0-12 Week Study Period|24 hr ABPM not enough readings|1
6347654|NCT03514641|10110701|FG002|603A: 0-12 Week Study Period|24 hr ABPM not enough readings|0
6347655|NCT03514641|10110702|FG003|603A: 0-12 Week Study Period|24 hr ABPM not enough readings|0
6347656|NCT03514641|10110699|FG000|603B: 24-36 Week Study Period|Protocol Violation|0
6347657|NCT03514641|10110700|FG001|603B: 24-36 Week Study Period|Protocol Violation|0
6347658|NCT03514641|10110701|FG002|603B: 24-36 Week Study Period|Protocol Violation|0
6347659|NCT03514641|10110702|FG003|603B: 24-36 Week Study Period|Protocol Violation|2
6347660|NCT03514641|10110699|FG000|603B: 24-36 Week Study Period|Adverse Event|0
6347661|NCT03514641|10110700|FG001|603B: 24-36 Week Study Period|Adverse Event|0
6347662|NCT03514641|10110701|FG002|603B: 24-36 Week Study Period|Adverse Event|3
6347663|NCT03514641|10110702|FG003|603B: 24-36 Week Study Period|Adverse Event|1
6347664|NCT03514641|10110699|FG000|603B: 24-36 Week Study Period|Withdrawal by Subject|0
6347665|NCT03514641|10110700|FG001|603B: 24-36 Week Study Period|Withdrawal by Subject|0
6347666|NCT03514641|10110701|FG002|603B: 24-36 Week Study Period|Withdrawal by Subject|2
6347667|NCT03514641|10110702|FG003|603B: 24-36 Week Study Period|Withdrawal by Subject|3
6347668|NCT03514641|10110699|FG000|603B: 24-36 Week Study Period|Lost to Follow-up|0
6347669|NCT03514641|10110700|FG001|603B: 24-36 Week Study Period|Lost to Follow-up|0
6347670|NCT03514641|10110701|FG002|603B: 24-36 Week Study Period|Lost to Follow-up|6
6347671|NCT03514641|10110702|FG003|603B: 24-36 Week Study Period|Lost to Follow-up|6
6347672|NCT03514641|10110699|FG000|603B: 24-36 Week Study Period|24 hr ABPM not enough readings|0
6347673|NCT03514641|10110700|FG001|603B: 24-36 Week Study Period|24 hr ABPM not enough readings|0
6347674|NCT03514641|10110701|FG002|603B: 24-36 Week Study Period|24 hr ABPM not enough readings|3
6347675|NCT03514641|10110702|FG003|603B: 24-36 Week Study Period|24 hr ABPM not enough readings|3
6347676|NCT03515824|10110735|FG000|Overall Study|Death|3
6347677|NCT03515824|10110736|FG001|Overall Study|Death|2
6347678|NCT03515824|10110737|FG002|Overall Study|Death|6
6347679|NCT03515824|10110738|FG003|Overall Study|Death|0
6347680|NCT03515824|10110735|FG000|Overall Study|Lost to Follow-up|0
6347681|NCT03515824|10110736|FG001|Overall Study|Lost to Follow-up|1
6347682|NCT03515824|10110737|FG002|Overall Study|Lost to Follow-up|1
6347683|NCT03515824|10110738|FG003|Overall Study|Lost to Follow-up|0
6347684|NCT03515824|10110735|FG000|Overall Study|Study terminated by sponsor|0
6347685|NCT03515824|10110736|FG001|Overall Study|Study terminated by sponsor|1
6347686|NCT03515824|10110737|FG002|Overall Study|Study terminated by sponsor|6
6347687|NCT03515824|10110738|FG003|Overall Study|Study terminated by sponsor|0
6347688|NCT03515824|10110735|FG000|Overall Study|Status not recorded|0
6347689|NCT03515824|10110736|FG001|Overall Study|Status not recorded|0
6347690|NCT03515824|10110737|FG002|Overall Study|Status not recorded|2
6347691|NCT03515824|10110738|FG003|Overall Study|Status not recorded|0
6347692|NCT03515941|10110748|FG000|Overall Study|Adverse Event|1
6347693|NCT03515941|10110749|FG001|Overall Study|Adverse Event|0
6347694|NCT03517436|10110765|FG000|Overall Study|Death|3
6347695|NCT03517436|10110765|FG000|Overall Study|Withdrawal by Subject|4
6347696|NCT03517436|10110765|FG000|Overall Study|Did not receive study valve.|1
6347697|NCT03517566|10110774|FG000|Overall Study|Adverse Event|5
6347698|NCT03517566|10110775|FG001|Overall Study|Adverse Event|2
6347699|NCT03517566|10110776|FG002|Overall Study|Adverse Event|2
6347700|NCT03517566|10110777|FG003|Overall Study|Adverse Event|8
6347701|NCT03517566|10110778|FG004|Overall Study|Adverse Event|7
6347702|NCT03517566|10110774|FG000|Overall Study|Lack of Efficacy|3
6347703|NCT03517566|10110775|FG001|Overall Study|Lack of Efficacy|2
6347704|NCT03517566|10110776|FG002|Overall Study|Lack of Efficacy|1
6083554|NCT00635804|9691979|FG003|Overall Study|Withdrawal by Subject|0
6169197|NCT01240915|9814457|FG007|Overall Study|Withdrawal by Subject|3
6169198|NCT01240915|9814458|FG008|Overall Study|Withdrawal by Subject|3
6169199|NCT01240915|9814450|FG000|Overall Study|Other|0
6169200|NCT01240915|9814451|FG001|Overall Study|Other|0
6169201|NCT01240915|9814452|FG002|Overall Study|Other|0
5972110|NCT00950989|9557712|FG003|Overall Study|Adverse Event|0
6347705|NCT03517566|10110777|FG003|Overall Study|Lack of Efficacy|1
6347706|NCT03517566|10110778|FG004|Overall Study|Lack of Efficacy|4
6347707|NCT03517566|10110774|FG000|Overall Study|Lost to Follow-up|3
6347708|NCT03517566|10110775|FG001|Overall Study|Lost to Follow-up|1
6347709|NCT03517566|10110776|FG002|Overall Study|Lost to Follow-up|1
6347710|NCT03517566|10110777|FG003|Overall Study|Lost to Follow-up|1
6347711|NCT03517566|10110778|FG004|Overall Study|Lost to Follow-up|0
6347712|NCT03517566|10110774|FG000|Overall Study|Physician Decision|1
6347713|NCT03517566|10110775|FG001|Overall Study|Physician Decision|1
6347714|NCT03517566|10110776|FG002|Overall Study|Physician Decision|0
6347715|NCT03517566|10110777|FG003|Overall Study|Physician Decision|1
6347716|NCT03517566|10110778|FG004|Overall Study|Physician Decision|0
6347717|NCT03517566|10110774|FG000|Overall Study|Pregnancy|0
6347718|NCT03517566|10110775|FG001|Overall Study|Pregnancy|1
6347719|NCT03517566|10110776|FG002|Overall Study|Pregnancy|0
6347720|NCT03517566|10110777|FG003|Overall Study|Pregnancy|0
6347721|NCT03517566|10110778|FG004|Overall Study|Pregnancy|0
6347722|NCT03517566|10110774|FG000|Overall Study|Protocol Deviation|0
6347723|NCT03517566|10110775|FG001|Overall Study|Protocol Deviation|1
6347724|NCT03517566|10110776|FG002|Overall Study|Protocol Deviation|0
6347725|NCT03517566|10110777|FG003|Overall Study|Protocol Deviation|1
6347726|NCT03517566|10110778|FG004|Overall Study|Protocol Deviation|1
6347727|NCT03517566|10110774|FG000|Overall Study|Study terminated by Sponsor|11
6347728|NCT03517566|10110775|FG001|Overall Study|Study terminated by Sponsor|5
6347729|NCT03517566|10110776|FG002|Overall Study|Study terminated by Sponsor|6
6347730|NCT03517566|10110777|FG003|Overall Study|Study terminated by Sponsor|14
6347731|NCT03517566|10110778|FG004|Overall Study|Study terminated by Sponsor|12
6347732|NCT03517566|10110774|FG000|Overall Study|Subject Decision /Guardian Decision|9
6347733|NCT03517566|10110775|FG001|Overall Study|Subject Decision /Guardian Decision|8
6347734|NCT03517566|10110776|FG002|Overall Study|Subject Decision /Guardian Decision|5
6347735|NCT03517566|10110777|FG003|Overall Study|Subject Decision /Guardian Decision|8
6347736|NCT03517566|10110778|FG004|Overall Study|Subject Decision /Guardian Decision|8
6347737|NCT03518008|10110791|FG000|Period 2, Second Week of Wear|Family emergency|0
6347738|NCT03518008|10110792|FG001|Period 2, Second Week of Wear|Family emergency|1
6347739|NCT03518125|10110804|FG000|Overall Study|Lost to Follow-up|0
6347740|NCT03518125|10110805|FG001|Overall Study|Lost to Follow-up|2
6347741|NCT03518125|10110806|FG002|Overall Study|Lost to Follow-up|0
6347742|NCT03518125|10110807|FG003|Overall Study|Lost to Follow-up|0
6347743|NCT03518125|10110808|FG004|Overall Study|Lost to Follow-up|3
6347744|NCT03518125|10110809|FG005|Overall Study|Lost to Follow-up|5
6347745|NCT03518125|10110804|FG000|Overall Study|Physician Decision|0
6347746|NCT03518125|10110805|FG001|Overall Study|Physician Decision|1
6347747|NCT03518125|10110806|FG002|Overall Study|Physician Decision|0
6347748|NCT03518125|10110807|FG003|Overall Study|Physician Decision|0
6347749|NCT03518125|10110808|FG004|Overall Study|Physician Decision|0
6347750|NCT03518125|10110809|FG005|Overall Study|Physician Decision|0
6347751|NCT03518125|10110804|FG000|Overall Study|Withdrawal by Subject|1
6347752|NCT03518125|10110805|FG001|Overall Study|Withdrawal by Subject|1
6347753|NCT03518125|10110806|FG002|Overall Study|Withdrawal by Subject|0
6347754|NCT03518125|10110807|FG003|Overall Study|Withdrawal by Subject|1
6347755|NCT03518125|10110808|FG004|Overall Study|Withdrawal by Subject|1
6347756|NCT03518125|10110809|FG005|Overall Study|Withdrawal by Subject|3
6347757|NCT03518125|10110804|FG000|Overall Study|Missed Day 394 Visit|1
6347758|NCT03518125|10110805|FG001|Overall Study|Missed Day 394 Visit|0
6347759|NCT03518125|10110806|FG002|Overall Study|Missed Day 394 Visit|0
6347760|NCT03518125|10110807|FG003|Overall Study|Missed Day 394 Visit|0
6347761|NCT03518125|10110808|FG004|Overall Study|Missed Day 394 Visit|0
6347762|NCT03518125|10110809|FG005|Overall Study|Missed Day 394 Visit|0
6347763|NCT03518658|10110826|FG000|Overall Study|Other|51
6347764|NCT03518658|10110827|FG001|Overall Study|Other|0
6347765|NCT03518840|10110835|FG000|Overall Study|Lost to Follow-up|6
6347766|NCT03519087|10110844|FG000|Clinic Evaluation|Physician Decision|15
6347767|NCT03519087|10110845|FG001|Clinic Evaluation|Physician Decision|18
6347768|NCT03519087|10110846|FG002|Clinic Evaluation|Physician Decision|0
6169202|NCT01240915|9814453|FG003|Overall Study|Other|0
6169203|NCT01240915|9814454|FG004|Overall Study|Other|2
6169204|NCT01240915|9814455|FG005|Overall Study|Other|0
6169205|NCT01240915|9814456|FG006|Overall Study|Other|0
6169206|NCT01240915|9814457|FG007|Overall Study|Other|0
6169207|NCT01240915|9814458|FG008|Overall Study|Other|0
6169208|NCT01240915|9814450|FG000|Overall Study|Insufficient Clinical Response|0
6169209|NCT01240915|9814451|FG001|Overall Study|Insufficient Clinical Response|0
6169210|NCT01240915|9814452|FG002|Overall Study|Insufficient Clinical Response|0
6169211|NCT01240915|9814453|FG003|Overall Study|Insufficient Clinical Response|0
6169212|NCT01240915|9814454|FG004|Overall Study|Insufficient Clinical Response|1
6169213|NCT01240915|9814455|FG005|Overall Study|Insufficient Clinical Response|3
6169214|NCT01240915|9814456|FG006|Overall Study|Insufficient Clinical Response|6
6347769|NCT03519087|10110847|FG003|Clinic Evaluation|Physician Decision|0
6347770|NCT03519087|10110848|FG004|Clinic Evaluation|Physician Decision|0
6169215|NCT01240915|9814457|FG007|Overall Study|Insufficient Clinical Response|0
6169216|NCT01240915|9814458|FG008|Overall Study|Insufficient Clinical Response|3
6169217|NCT01241240|9814482|FG000|Overall Study|Adverse Event|5
6169218|NCT01241240|9814483|FG001|Overall Study|Adverse Event|4
6347771|NCT03519087|10110844|FG000|Clinic Evaluation|Protocol Violation|1
6347772|NCT03519087|10110845|FG001|Clinic Evaluation|Protocol Violation|0
6347773|NCT03519087|10110846|FG002|Clinic Evaluation|Protocol Violation|0
6347774|NCT03519087|10110847|FG003|Clinic Evaluation|Protocol Violation|0
6347775|NCT03519087|10110848|FG004|Clinic Evaluation|Protocol Violation|0
6347776|NCT03519087|10110844|FG000|Re-randomization for Treatment|Withdrawal by Subject|25
6347777|NCT03519087|10110845|FG001|Re-randomization for Treatment|Withdrawal by Subject|29
6347778|NCT03519087|10110846|FG002|Re-randomization for Treatment|Withdrawal by Subject|0
6347779|NCT03519087|10110847|FG003|Re-randomization for Treatment|Withdrawal by Subject|0
6347780|NCT03519087|10110848|FG004|Re-randomization for Treatment|Withdrawal by Subject|0
6347781|NCT03519087|10110844|FG000|Re-randomization for Treatment|Not appropriate|2
6347782|NCT03519087|10110845|FG001|Re-randomization for Treatment|Not appropriate|3
6347783|NCT03519087|10110846|FG002|Re-randomization for Treatment|Not appropriate|0
6347784|NCT03519087|10110847|FG003|Re-randomization for Treatment|Not appropriate|0
6347785|NCT03519087|10110848|FG004|Re-randomization for Treatment|Not appropriate|0
6083555|NCT00635804|9691980|FG004|Overall Study|Withdrawal by Subject|0
6083556|NCT00635804|9691981|FG005|Overall Study|Withdrawal by Subject|0
6083557|NCT00635804|9691982|FG006|Overall Study|Withdrawal by Subject|0
6083558|NCT00635804|9691983|FG007|Overall Study|Withdrawal by Subject|0
6083559|NCT00635999|9692035|FG000|Overall Study|Withdrawal by Subject|4
6083560|NCT00635999|9692036|FG001|Overall Study|Withdrawal by Subject|2
6347786|NCT03519087|10110844|FG000|Laboratory Testing|Lost to Follow-up|0
6347787|NCT03519087|10110845|FG001|Laboratory Testing|Lost to Follow-up|0
6347788|NCT03519087|10110846|FG002|Laboratory Testing|Lost to Follow-up|2
6347789|NCT03519087|10110847|FG003|Laboratory Testing|Lost to Follow-up|3
6347790|NCT03519087|10110848|FG004|Laboratory Testing|Lost to Follow-up|6
6347791|NCT03519087|10110844|FG000|Laboratory Testing|Protocol Violation|0
6347792|NCT03519087|10110845|FG001|Laboratory Testing|Protocol Violation|0
6347793|NCT03519087|10110846|FG002|Laboratory Testing|Protocol Violation|0
6347794|NCT03519087|10110847|FG003|Laboratory Testing|Protocol Violation|1
6347795|NCT03519087|10110848|FG004|Laboratory Testing|Protocol Violation|0
6347796|NCT03519204|10110866|FG000|Overall Study|Lost to Follow-up|3
6347797|NCT03519204|10110867|FG001|Overall Study|Lost to Follow-up|8
6347798|NCT03519204|10110866|FG000|Overall Study|Withdrawal by Subject|9
6347799|NCT03519204|10110867|FG001|Overall Study|Withdrawal by Subject|7
6347800|NCT03519204|10110866|FG000|Overall Study|Other Miscellaneous Reasons|1
6347801|NCT03519204|10110867|FG001|Overall Study|Other Miscellaneous Reasons|0
6347802|NCT03519516|10110900|FG000|Overall Study|Adverse Event|0
6347803|NCT03519516|10110901|FG001|Overall Study|Adverse Event|1
6347804|NCT03519854|10110925|FG000|Overall Study|Technical Error|0
6347805|NCT03519854|10110926|FG001|Overall Study|Technical Error|0
6347806|NCT03519854|10110927|FG002|Overall Study|Technical Error|1
6347807|NCT03519854|10110928|FG003|Overall Study|Technical Error|0
6347808|NCT03519854|10110929|FG004|Overall Study|Technical Error|0
6347809|NCT03519854|10110930|FG005|Overall Study|Technical Error|0
6347810|NCT03519854|10110931|FG006|Overall Study|Technical Error|0
6347811|NCT03519854|10110932|FG007|Overall Study|Technical Error|0
6347812|NCT03519854|10110933|FG008|Overall Study|Technical Error|0
6347813|NCT03519854|10110934|FG009|Overall Study|Technical Error|0
6347814|NCT03519854|10110935|FG010|Overall Study|Technical Error|0
6347815|NCT03519854|10110936|FG011|Overall Study|Technical Error|0
6347816|NCT03519854|10110937|FG012|Overall Study|Technical Error|0
6347817|NCT03519854|10110938|FG013|Overall Study|Technical Error|0
6347818|NCT03519854|10110939|FG014|Overall Study|Technical Error|0
6347819|NCT03519854|10110940|FG015|Overall Study|Technical Error|0
6347820|NCT03519854|10110941|FG016|Overall Study|Technical Error|0
6347821|NCT03519854|10110942|FG017|Overall Study|Technical Error|0
6347822|NCT03519867|10110990|FG000|Overall Study|Adverse Event|1
6347823|NCT03519867|10110991|FG001|Overall Study|Adverse Event|1
6347824|NCT03519867|10110992|FG002|Overall Study|Adverse Event|0
6347825|NCT03519867|10110993|FG003|Overall Study|Adverse Event|0
6347826|NCT03519867|10110994|FG004|Overall Study|Adverse Event|0
6347827|NCT03519867|10110995|FG005|Overall Study|Adverse Event|0
6347828|NCT03519867|10110996|FG006|Overall Study|Adverse Event|0
6347829|NCT03519867|10110997|FG007|Overall Study|Adverse Event|0
6347830|NCT03519867|10110998|FG008|Overall Study|Adverse Event|0
6347831|NCT03519867|10110999|FG009|Overall Study|Adverse Event|0
6347832|NCT03519867|10110990|FG000|Overall Study|Protocol Violation|0
6347833|NCT03519867|10110991|FG001|Overall Study|Protocol Violation|0
6347834|NCT03519867|10110992|FG002|Overall Study|Protocol Violation|0
6347835|NCT03519867|10110993|FG003|Overall Study|Protocol Violation|0
6347836|NCT03519867|10110994|FG004|Overall Study|Protocol Violation|0
6347837|NCT03519867|10110995|FG005|Overall Study|Protocol Violation|1
6347838|NCT03519867|10110996|FG006|Overall Study|Protocol Violation|0
6347839|NCT03519867|10110997|FG007|Overall Study|Protocol Violation|0
6347840|NCT03519867|10110998|FG008|Overall Study|Protocol Violation|0
6347841|NCT03519867|10110999|FG009|Overall Study|Protocol Violation|0
6347842|NCT03519867|10110990|FG000|Overall Study|Admin. of relaxant other than Zemuron®|0
6347843|NCT03519867|10110991|FG001|Overall Study|Admin. of relaxant other than Zemuron®|0
6347844|NCT03519867|10110992|FG002|Overall Study|Admin. of relaxant other than Zemuron®|0
6347845|NCT03519867|10110993|FG003|Overall Study|Admin. of relaxant other than Zemuron®|0
6347846|NCT03519867|10110994|FG004|Overall Study|Admin. of relaxant other than Zemuron®|0
6347847|NCT03519867|10110995|FG005|Overall Study|Admin. of relaxant other than Zemuron®|0
6083561|NCT00635999|9692037|FG002|Overall Study|Withdrawal by Subject|1
6083562|NCT00636155|9692058|FG000|Overall Study|Adverse Event|8
6083563|NCT00636155|9692058|FG000|Overall Study|Lack of Efficacy|1
6083564|NCT00636155|9692058|FG000|Overall Study|Withdrawal by Subject|3
6347848|NCT03519867|10110996|FG006|Overall Study|Admin. of relaxant other than Zemuron®|1
6347849|NCT03519867|10110997|FG007|Overall Study|Admin. of relaxant other than Zemuron®|0
6347850|NCT03519867|10110998|FG008|Overall Study|Admin. of relaxant other than Zemuron®|0
6347851|NCT03519867|10110999|FG009|Overall Study|Admin. of relaxant other than Zemuron®|0
6347852|NCT03519867|10110990|FG000|Overall Study|Admin. of other reversal agent|1
6347853|NCT03519867|10110991|FG001|Overall Study|Admin. of other reversal agent|1
6347854|NCT03519867|10110992|FG002|Overall Study|Admin. of other reversal agent|0
6347855|NCT03519867|10110993|FG003|Overall Study|Admin. of other reversal agent|0
6347856|NCT03519867|10110994|FG004|Overall Study|Admin. of other reversal agent|0
6347857|NCT03519867|10110995|FG005|Overall Study|Admin. of other reversal agent|1
6347858|NCT03519867|10110996|FG006|Overall Study|Admin. of other reversal agent|0
6347859|NCT03519867|10110997|FG007|Overall Study|Admin. of other reversal agent|0
6347860|NCT03519867|10110998|FG008|Overall Study|Admin. of other reversal agent|0
6347861|NCT03519867|10110999|FG009|Overall Study|Admin. of other reversal agent|0
6347862|NCT03519867|10110990|FG000|Overall Study|Reason not provided|1
6347863|NCT03519867|10110991|FG001|Overall Study|Reason not provided|1
6347864|NCT03519867|10110992|FG002|Overall Study|Reason not provided|1
6347865|NCT03519867|10110993|FG003|Overall Study|Reason not provided|1
6347866|NCT03519867|10110994|FG004|Overall Study|Reason not provided|0
6347867|NCT03519867|10110995|FG005|Overall Study|Reason not provided|1
6347868|NCT03519867|10110996|FG006|Overall Study|Reason not provided|0
6347869|NCT03519867|10110997|FG007|Overall Study|Reason not provided|1
6347870|NCT03519867|10110998|FG008|Overall Study|Reason not provided|1
6347871|NCT03519867|10110999|FG009|Overall Study|Reason not provided|0
6347872|NCT03519919|10111021|FG000|Overall Study|Withdrawal by Subject|1
6347873|NCT03519919|10111021|FG000|Overall Study|Lack of Efficacy|1
6347874|NCT03519919|10111021|FG000|Overall Study|Screen Failure|1
6347875|NCT03519932|10111051|FG000|First Intervention|Adverse Event|1
6347876|NCT03519932|10111052|FG001|First Intervention|Adverse Event|3
6347877|NCT03520387|10111095|FG000|Pre-Randomization|Withdrawal by Subject|1
6347878|NCT03520387|10111096|FG001|Pre-Randomization|Withdrawal by Subject|0
6347879|NCT03520387|10111097|FG002|Pre-Randomization|Withdrawal by Subject|0
6347880|NCT03520387|10111098|FG003|Pre-Randomization|Withdrawal by Subject|0
6347881|NCT03520387|10111099|FG004|Pre-Randomization|Withdrawal by Subject|0
6347882|NCT03520387|10111095|FG000|Pre-Randomization|Failed eligibility criteria or run-in period criteria|2
6347883|NCT03520387|10111096|FG001|Pre-Randomization|Failed eligibility criteria or run-in period criteria|0
6347884|NCT03520387|10111097|FG002|Pre-Randomization|Failed eligibility criteria or run-in period criteria|0
6347885|NCT03520387|10111098|FG003|Pre-Randomization|Failed eligibility criteria or run-in period criteria|0
6347886|NCT03520387|10111099|FG004|Pre-Randomization|Failed eligibility criteria or run-in period criteria|0
6347887|NCT03520400|10111112|FG000|Overall Study|Physician Decision|15
6347888|NCT03520400|10111113|FG001|Overall Study|Physician Decision|7
6347889|NCT03520920|10111122|FG000|Overall Study|Death|13
6347890|NCT03520920|10111123|FG001|Overall Study|Death|1
6347891|NCT03520920|10111124|FG002|Overall Study|Death|0
6347892|NCT03520920|10111122|FG000|Overall Study|Withdrawal by Subject|2
6347893|NCT03520920|10111123|FG001|Overall Study|Withdrawal by Subject|1
6347894|NCT03520920|10111124|FG002|Overall Study|Withdrawal by Subject|0
6347895|NCT03520920|10111122|FG000|Overall Study|Study Terminated by the Sponsor|5
6347896|NCT03520920|10111123|FG001|Overall Study|Study Terminated by the Sponsor|14
6347897|NCT03520920|10111124|FG002|Overall Study|Study Terminated by the Sponsor|5
6347898|NCT03520959|10111140|FG000|Overall Study|Study terminated by Sponsor|0
6347899|NCT03520959|10111141|FG001|Overall Study|Study terminated by Sponsor|1
6347900|NCT03521115|10111167|FG000|Time 1 Survey (6 Months Post Baseline)|Lost to Follow-up|56
6347901|NCT03521115|10111168|FG001|Time 1 Survey (6 Months Post Baseline)|Lost to Follow-up|40
6347902|NCT03521115|10111167|FG000|Time 2 Survey (12 Months Post Baseline)|Lost to Follow-up|3
6347903|NCT03521115|10111168|FG001|Time 2 Survey (12 Months Post Baseline)|Lost to Follow-up|1
6347904|NCT03521141|10111183|FG000|Overall Study|Death|1
6347905|NCT03521141|10111184|FG001|Overall Study|Death|0
6347906|NCT03521141|10111185|FG002|Overall Study|Death|1
6347907|NCT03521193|10111195|FG000|Overall Study|Withdrawal by Subject|8
6347908|NCT03521193|10111196|FG001|Overall Study|Withdrawal by Subject|0
6347909|NCT03521193|10111195|FG000|Overall Study|non compliant to ASA treatment|8
6347910|NCT03521193|10111196|FG001|Overall Study|non compliant to ASA treatment|0
6347911|NCT03521635|10111231|FG000|Overall Study|Adverse Event|1
6347912|NCT03521635|10111232|FG001|Overall Study|Adverse Event|1
6347913|NCT03521635|10111231|FG000|Overall Study|Refused to complete study visit|1
6347914|NCT03521635|10111232|FG001|Overall Study|Refused to complete study visit|0
6347915|NCT03521635|10111231|FG000|Overall Study|Refused to continue trial medication|2
6347916|NCT03521635|10111232|FG001|Overall Study|Refused to continue trial medication|2
6347917|NCT03521635|10111231|FG000|Overall Study|Lost to Follow-up|0
6347918|NCT03521635|10111232|FG001|Overall Study|Lost to Follow-up|1
6347919|NCT03521635|10111231|FG000|Overall Study|Meet exclusion criteria|0
6347920|NCT03521635|10111232|FG001|Overall Study|Meet exclusion criteria|1
6347921|NCT03521635|10111231|FG000|Overall Study|Patient not taken study medicine|0
6347922|NCT03521635|10111232|FG001|Overall Study|Patient not taken study medicine|1
6347923|NCT03521791|10111240|FG000|Overall Study|Protocol Violation|7
6347924|NCT03521791|10111241|FG001|Overall Study|Protocol Violation|17
6347925|NCT03521817|10111249|FG000|Overall Study|Protocol Violation|0
6347926|NCT03521817|10111250|FG001|Overall Study|Protocol Violation|1
6347927|NCT03522506|10111279|FG000|Washout Period 1 (7 Days)|Withdrawal by Subject|0
6347928|NCT03522506|10111280|FG001|Washout Period 1 (7 Days)|Withdrawal by Subject|0
6347929|NCT03522506|10111281|FG002|Washout Period 1 (7 Days)|Withdrawal by Subject|0
6347930|NCT03522506|10111282|FG003|Washout Period 1 (7 Days)|Withdrawal by Subject|1
6347931|NCT03522506|10111279|FG000|Washout Period 2 (7 Days)|Withdrawal by Subject|0
6347932|NCT03522506|10111280|FG001|Washout Period 2 (7 Days)|Withdrawal by Subject|0
6347933|NCT03522506|10111281|FG002|Washout Period 2 (7 Days)|Withdrawal by Subject|0
6347934|NCT03522506|10111282|FG003|Washout Period 2 (7 Days)|Withdrawal by Subject|1
6347935|NCT03522675|10111296|FG000|Overall Study|Screen fail|1
6347936|NCT03522675|10111296|FG000|Overall Study|Non-reactive to histamine|1
6347937|NCT03522948|10111304|FG000|Overall Study|Lost to Follow-up|1
6347938|NCT03523715|10111310|FG000|Overall Study|Lost to Follow-up|11
6347939|NCT03523715|10111311|FG001|Overall Study|Lost to Follow-up|14
6347940|NCT03523715|10111310|FG000|Overall Study|Did not meet inclusion criteria|1
6347941|NCT03523715|10111311|FG001|Overall Study|Did not meet inclusion criteria|0
6347942|NCT03523715|10111310|FG000|Overall Study|Internally inconsistent reporting|0
6347943|NCT03523715|10111311|FG001|Overall Study|Internally inconsistent reporting|2
6347944|NCT03523871|10111317|FG000|Overall Study|Death|1
6347945|NCT03524157|10111337|FG000|Overall Study|cytology not readable|0
6347946|NCT03524157|10111338|FG001|Overall Study|cytology not readable|0
6347947|NCT03524157|10111339|FG002|Overall Study|cytology not readable|1
6347948|NCT03525119|10111359|FG000|Overall Study|Adverse Event|0
6347949|NCT03525119|10111360|FG001|Overall Study|Adverse Event|1
6347950|NCT03525119|10111361|FG002|Overall Study|Adverse Event|0
6347951|NCT03525119|10111359|FG000|Overall Study|Lost to Follow-up|32
6347952|NCT03525119|10111360|FG001|Overall Study|Lost to Follow-up|33
6347953|NCT03525119|10111361|FG002|Overall Study|Lost to Follow-up|37
6347954|NCT03525119|10111359|FG000|Overall Study|Withdrawal by Subject|5
6347955|NCT03525119|10111360|FG001|Overall Study|Withdrawal by Subject|4
6347956|NCT03525119|10111361|FG002|Overall Study|Withdrawal by Subject|2
6347957|NCT03525119|10111359|FG000|Overall Study|Reason not Specified|2
6347958|NCT03525119|10111360|FG001|Overall Study|Reason not Specified|1
6347959|NCT03525119|10111361|FG002|Overall Study|Reason not Specified|2
6347960|NCT03525119|10111359|FG000|Overall Study|Randomized but not Vaccinated|1
6347961|NCT03525119|10111360|FG001|Overall Study|Randomized but not Vaccinated|0
6347962|NCT03525119|10111361|FG002|Overall Study|Randomized but not Vaccinated|2
6347963|NCT03525444|10111382|FG000|Overall Study|Adverse Event|0
6347964|NCT03525444|10111383|FG001|Overall Study|Adverse Event|1
6347965|NCT03525444|10111382|FG000|Overall Study|Withdrawal of consent (not due to AE)|0
6347966|NCT03525444|10111383|FG001|Overall Study|Withdrawal of consent (not due to AE)|1
6347967|NCT03525444|10111382|FG000|Overall Study|Other|0
6347968|NCT03525444|10111383|FG001|Overall Study|Other|1
6347969|NCT03525834|10111399|FG000|Overall Study|Progressive disease|1
6347970|NCT03526458|10111413|FG000|Overall Study|Surgeries rescheduled or cancelled due to COVID|2
6347971|NCT03526458|10111414|FG001|Overall Study|Surgeries rescheduled or cancelled due to COVID|2
6347972|NCT03526458|10111413|FG000|Overall Study|Stone passed, surgery cancelled|2
6347973|NCT03526458|10111414|FG001|Overall Study|Stone passed, surgery cancelled|1
6347974|NCT03526458|10111413|FG000|Overall Study|Withdrawal by Subject|1
6347975|NCT03526458|10111414|FG001|Overall Study|Withdrawal by Subject|0
6347976|NCT03526458|10111413|FG000|Overall Study|Physician Decision|2
6347977|NCT03526458|10111414|FG001|Overall Study|Physician Decision|1
6347978|NCT03526458|10111413|FG000|Overall Study|Lack of equipment|1
6347979|NCT03526458|10111414|FG001|Overall Study|Lack of equipment|1
6347980|NCT03526861|10111423|FG000|Initial Treatment Period|Not dosed|1
6347981|NCT03526861|10111424|FG001|Initial Treatment Period|Not dosed|1
6347982|NCT03526861|10111425|FG002|Initial Treatment Period|Not dosed|1
6347983|NCT03526861|10111426|FG003|Initial Treatment Period|Not dosed|0
6347984|NCT03526861|10111427|FG004|Initial Treatment Period|Not dosed|0
6347985|NCT03526861|10111428|FG005|Initial Treatment Period|Not dosed|0
6347986|NCT03526861|10111429|FG006|Initial Treatment Period|Not dosed|0
6347987|NCT03526861|10111430|FG007|Initial Treatment Period|Not dosed|0
6347988|NCT03526861|10111431|FG008|Initial Treatment Period|Not dosed|0
6347989|NCT03526861|10111423|FG000|Initial Treatment Period|Randomised at site with quality/GCP issues identified, subject withdrawn from the trial|3
6347990|NCT03526861|10111424|FG001|Initial Treatment Period|Randomised at site with quality/GCP issues identified, subject withdrawn from the trial|1
6347991|NCT03526861|10111425|FG002|Initial Treatment Period|Randomised at site with quality/GCP issues identified, subject withdrawn from the trial|5
6347992|NCT03526861|10111426|FG003|Initial Treatment Period|Randomised at site with quality/GCP issues identified, subject withdrawn from the trial|0
6347993|NCT03526861|10111427|FG004|Initial Treatment Period|Randomised at site with quality/GCP issues identified, subject withdrawn from the trial|0
6347994|NCT03526861|10111428|FG005|Initial Treatment Period|Randomised at site with quality/GCP issues identified, subject withdrawn from the trial|0
6347995|NCT03526861|10111429|FG006|Initial Treatment Period|Randomised at site with quality/GCP issues identified, subject withdrawn from the trial|0
6347996|NCT03526861|10111430|FG007|Initial Treatment Period|Randomised at site with quality/GCP issues identified, subject withdrawn from the trial|0
6347997|NCT03526861|10111431|FG008|Initial Treatment Period|Randomised at site with quality/GCP issues identified, subject withdrawn from the trial|0
6347998|NCT03526861|10111423|FG000|Initial Treatment Period|Subject discontinued IMP before Week 16|3
6347999|NCT03526861|10111424|FG001|Initial Treatment Period|Subject discontinued IMP before Week 16|5
6348000|NCT03526861|10111425|FG002|Initial Treatment Period|Subject discontinued IMP before Week 16|8
6348001|NCT03526861|10111426|FG003|Initial Treatment Period|Subject discontinued IMP before Week 16|0
6348002|NCT03526861|10111427|FG004|Initial Treatment Period|Subject discontinued IMP before Week 16|0
6348003|NCT03526861|10111428|FG005|Initial Treatment Period|Subject discontinued IMP before Week 16|0
6348004|NCT03526861|10111429|FG006|Initial Treatment Period|Subject discontinued IMP before Week 16|0
6348005|NCT03526861|10111430|FG007|Initial Treatment Period|Subject discontinued IMP before Week 16|0
6348006|NCT03526861|10111431|FG008|Initial Treatment Period|Subject discontinued IMP before Week 16|0
6348007|NCT03526861|10111423|FG000|Maintenance Treatment Period|Subject discontinued IMP between Week 16 and Week 52|0
6348008|NCT03526861|10111424|FG001|Maintenance Treatment Period|Subject discontinued IMP between Week 16 and Week 52|0
6348009|NCT03526861|10111425|FG002|Maintenance Treatment Period|Subject discontinued IMP between Week 16 and Week 52|0
6348010|NCT03526861|10111426|FG003|Maintenance Treatment Period|Subject discontinued IMP between Week 16 and Week 52|1
6348011|NCT03526861|10111427|FG004|Maintenance Treatment Period|Subject discontinued IMP between Week 16 and Week 52|1
6348012|NCT03526861|10111428|FG005|Maintenance Treatment Period|Subject discontinued IMP between Week 16 and Week 52|0
6348013|NCT03526861|10111429|FG006|Maintenance Treatment Period|Subject discontinued IMP between Week 16 and Week 52|1
6348014|NCT03526861|10111430|FG007|Maintenance Treatment Period|Subject discontinued IMP between Week 16 and Week 52|0
6348015|NCT03526861|10111431|FG008|Maintenance Treatment Period|Subject discontinued IMP between Week 16 and Week 52|0
6348016|NCT03526861|10111423|FG000|Maintenance Treatment Period|Subject transferred to open-label treatment|0
6348017|NCT03526861|10111424|FG001|Maintenance Treatment Period|Subject transferred to open-label treatment|0
6348018|NCT03526861|10111425|FG002|Maintenance Treatment Period|Subject transferred to open-label treatment|0
6348019|NCT03526861|10111426|FG003|Maintenance Treatment Period|Subject transferred to open-label treatment|6
6348020|NCT03526861|10111427|FG004|Maintenance Treatment Period|Subject transferred to open-label treatment|5
6043075|NCT00386308|9641521|FG000|Overall Study|Withdrawal by Subject|6
6043076|NCT00386308|9641522|FG001|Overall Study|Withdrawal by Subject|2
6043077|NCT00386308|9641521|FG000|Overall Study|Other Event|8
6043078|NCT00386308|9641522|FG001|Overall Study|Other Event|1
6043079|NCT00386334|9641530|FG000|Double Blind Period|Adverse Event|9
6043080|NCT00386334|9641531|FG001|Double Blind Period|Adverse Event|14
6043081|NCT00386334|9641530|FG000|Double Blind Period|Protocol Violation|1
6043082|NCT00386334|9641531|FG001|Double Blind Period|Protocol Violation|1
6043083|NCT00386334|9641530|FG000|Double Blind Period|Withdrawal by Subject|9
6043084|NCT00386334|9641531|FG001|Double Blind Period|Withdrawal by Subject|13
6043085|NCT00386334|9641530|FG000|Double Blind Period|Lack of Efficacy|20
6043086|NCT00386334|9641531|FG001|Double Blind Period|Lack of Efficacy|11
6043087|NCT00386334|9641530|FG000|Double Blind Period|Didnt Meet Entry/Randomization Criteria|4
6043088|NCT00386334|9641531|FG001|Double Blind Period|Didnt Meet Entry/Randomization Criteria|5
6043089|NCT00386334|9641530|FG000|Double Blind Period|Other|3
6043090|NCT00386334|9641531|FG001|Double Blind Period|Other|3
6043091|NCT00386334|9641530|FG000|Follow up:2 Week Placebo, 2 Week no Drug|Withdrawal by Subject|3
6043092|NCT00386334|9641531|FG001|Follow up:2 Week Placebo, 2 Week no Drug|Withdrawal by Subject|1
6043093|NCT00386360|9641539|FG000|Overall Study|Adverse Event|4
6043094|NCT00386360|9641540|FG001|Overall Study|Adverse Event|2
6043095|NCT00386360|9641539|FG000|Overall Study|Physician Decision|2
6043096|NCT00386360|9641540|FG001|Overall Study|Physician Decision|2
6043097|NCT00386360|9641539|FG000|Overall Study|Lost to Follow-up|0
6043098|NCT00386360|9641540|FG001|Overall Study|Lost to Follow-up|2
6043099|NCT00386360|9641539|FG000|Overall Study|Protocol Violation|0
6083565|NCT00636155|9692058|FG000|Overall Study|Stem cell transplant|1
6083566|NCT00636155|9692058|FG000|Overall Study|Physician Decision|5
6083567|NCT00636168|9692064|FG000|Randomized to Study Drug|Withdrawal by Subject|2
6348021|NCT03526861|10111428|FG005|Maintenance Treatment Period|Subject transferred to open-label treatment|4
6348022|NCT03526861|10111429|FG006|Maintenance Treatment Period|Subject transferred to open-label treatment|5
6348023|NCT03526861|10111430|FG007|Maintenance Treatment Period|Subject transferred to open-label treatment|2
6348024|NCT03526861|10111431|FG008|Maintenance Treatment Period|Subject transferred to open-label treatment|0
6348025|NCT03526861|10111423|FG000|Maintenance Treatment Period|Randomised at site with quality/GCP issues identified, subject withdrawn from the trial|0
6348026|NCT03526861|10111424|FG001|Maintenance Treatment Period|Randomised at site with quality/GCP issues identified, subject withdrawn from the trial|0
6348027|NCT03526861|10111425|FG002|Maintenance Treatment Period|Randomised at site with quality/GCP issues identified, subject withdrawn from the trial|0
6348028|NCT03526861|10111426|FG003|Maintenance Treatment Period|Randomised at site with quality/GCP issues identified, subject withdrawn from the trial|1
6348029|NCT03526861|10111427|FG004|Maintenance Treatment Period|Randomised at site with quality/GCP issues identified, subject withdrawn from the trial|0
6348030|NCT03526861|10111428|FG005|Maintenance Treatment Period|Randomised at site with quality/GCP issues identified, subject withdrawn from the trial|0
6348031|NCT03526861|10111429|FG006|Maintenance Treatment Period|Randomised at site with quality/GCP issues identified, subject withdrawn from the trial|0
6083568|NCT00636168|9692065|FG001|Randomized to Study Drug|Withdrawal by Subject|2
6169219|NCT01241240|9814482|FG000|Overall Study|Lost to Follow-up|2
6169220|NCT01241240|9814483|FG001|Overall Study|Lost to Follow-up|4
6169221|NCT01241240|9814482|FG000|Overall Study|Personal Reasons|1
6169222|NCT01241240|9814483|FG001|Overall Study|Personal Reasons|1
6043100|NCT00386360|9641540|FG001|Overall Study|Protocol Violation|3
6043101|NCT00386360|9641539|FG000|Overall Study|Withdrawal by Subject|3
6083569|NCT00636168|9692064|FG000|Randomized to Study Drug|Adverse Event|1
6083570|NCT00636168|9692065|FG001|Randomized to Study Drug|Adverse Event|0
6169223|NCT01241292|9814491|FG000|Overall Study|Administrative Reason by Sponsor|1
6348032|NCT03526861|10111430|FG007|Maintenance Treatment Period|Randomised at site with quality/GCP issues identified, subject withdrawn from the trial|0
6348033|NCT03526861|10111431|FG008|Maintenance Treatment Period|Randomised at site with quality/GCP issues identified, subject withdrawn from the trial|0
6348034|NCT03526861|10111423|FG000|Open-label Treatment Period|Subject discontinued IMP between Week 16 and Week 52|0
6348035|NCT03526861|10111424|FG001|Open-label Treatment Period|Subject discontinued IMP between Week 16 and Week 52|0
6348036|NCT03526861|10111425|FG002|Open-label Treatment Period|Subject discontinued IMP between Week 16 and Week 52|0
6348037|NCT03526861|10111426|FG003|Open-label Treatment Period|Subject discontinued IMP between Week 16 and Week 52|0
6348038|NCT03526861|10111427|FG004|Open-label Treatment Period|Subject discontinued IMP between Week 16 and Week 52|0
6348039|NCT03526861|10111428|FG005|Open-label Treatment Period|Subject discontinued IMP between Week 16 and Week 52|0
6348040|NCT03526861|10111429|FG006|Open-label Treatment Period|Subject discontinued IMP between Week 16 and Week 52|0
6348041|NCT03526861|10111430|FG007|Open-label Treatment Period|Subject discontinued IMP between Week 16 and Week 52|0
6348042|NCT03526861|10111431|FG008|Open-label Treatment Period|Subject discontinued IMP between Week 16 and Week 52|19
6348043|NCT03526861|10111423|FG000|Open-label Treatment Period|Completed treatment (received the last planned dose of IMP) and withdrew from the trial at Week 50|0
6348044|NCT03526861|10111424|FG001|Open-label Treatment Period|Completed treatment (received the last planned dose of IMP) and withdrew from the trial at Week 50|0
6348045|NCT03526861|10111425|FG002|Open-label Treatment Period|Completed treatment (received the last planned dose of IMP) and withdrew from the trial at Week 50|0
6348046|NCT03526861|10111426|FG003|Open-label Treatment Period|Completed treatment (received the last planned dose of IMP) and withdrew from the trial at Week 50|0
6348047|NCT03526861|10111427|FG004|Open-label Treatment Period|Completed treatment (received the last planned dose of IMP) and withdrew from the trial at Week 50|0
6348048|NCT03526861|10111428|FG005|Open-label Treatment Period|Completed treatment (received the last planned dose of IMP) and withdrew from the trial at Week 50|0
6348049|NCT03526861|10111429|FG006|Open-label Treatment Period|Completed treatment (received the last planned dose of IMP) and withdrew from the trial at Week 50|0
6348050|NCT03526861|10111430|FG007|Open-label Treatment Period|Completed treatment (received the last planned dose of IMP) and withdrew from the trial at Week 50|0
6348051|NCT03526861|10111431|FG008|Open-label Treatment Period|Completed treatment (received the last planned dose of IMP) and withdrew from the trial at Week 50|1
6348052|NCT03526861|10111423|FG000|Open-label Treatment Period|Randomised at site with quality/GCP issues identified, subject withdrawn from the trial|0
6348053|NCT03526861|10111424|FG001|Open-label Treatment Period|Randomised at site with quality/GCP issues identified, subject withdrawn from the trial|0
6348054|NCT03526861|10111425|FG002|Open-label Treatment Period|Randomised at site with quality/GCP issues identified, subject withdrawn from the trial|0
6348055|NCT03526861|10111426|FG003|Open-label Treatment Period|Randomised at site with quality/GCP issues identified, subject withdrawn from the trial|0
6348056|NCT03526861|10111427|FG004|Open-label Treatment Period|Randomised at site with quality/GCP issues identified, subject withdrawn from the trial|0
6348057|NCT03526861|10111428|FG005|Open-label Treatment Period|Randomised at site with quality/GCP issues identified, subject withdrawn from the trial|0
6169224|NCT01241292|9814492|FG001|Overall Study|Administrative Reason by Sponsor|0
6169225|NCT01241292|9814491|FG000|Overall Study|Disease Progression|2
6169226|NCT01241292|9814492|FG001|Overall Study|Disease Progression|0
6169227|NCT01241292|9814491|FG000|Overall Study|Study Drug Toxicity|0
6169228|NCT01241292|9814492|FG001|Overall Study|Study Drug Toxicity|1
6083571|NCT00636168|9692064|FG000|Randomized to Study Drug|No longer meets study criteria|1
6083572|NCT00636168|9692065|FG001|Randomized to Study Drug|No longer meets study criteria|0
6083573|NCT00636168|9692064|FG000|Treated With Study Drug|Recurrence of disease|135
6083574|NCT00636168|9692065|FG001|Treated With Study Drug|Recurrence of disease|282
6083575|NCT00636168|9692064|FG000|Treated With Study Drug|Adverse Event|250
6083576|NCT00636168|9692065|FG001|Treated With Study Drug|Adverse Event|22
6083577|NCT00636168|9692064|FG000|Treated With Study Drug|Participant withdrew consent|16
6083578|NCT00636168|9692065|FG001|Treated With Study Drug|Participant withdrew consent|21
6083579|NCT00636168|9692064|FG000|Treated With Study Drug|Poor/non-compliance|1
6083580|NCT00636168|9692065|FG001|Treated With Study Drug|Poor/non-compliance|3
6083581|NCT00636168|9692064|FG000|Treated With Study Drug|Death|3
6083582|NCT00636168|9692065|FG001|Treated With Study Drug|Death|0
6083583|NCT00636168|9692064|FG000|Treated With Study Drug|Pregnancy|1
6083584|NCT00636168|9692065|FG001|Treated With Study Drug|Pregnancy|0
6083585|NCT00636168|9692064|FG000|Treated With Study Drug|No longer meets study criteria|1
6083586|NCT00636168|9692065|FG001|Treated With Study Drug|No longer meets study criteria|0
6083587|NCT00636168|9692064|FG000|Treated With Study Drug|Other reason|1
6083588|NCT00636168|9692065|FG001|Treated With Study Drug|Other reason|3
6083589|NCT00636168|9692064|FG000|Long Term Follow-Up|Lost to Follow-up|3
6083590|NCT00636168|9692065|FG001|Long Term Follow-Up|Lost to Follow-up|3
6083591|NCT00636168|9692064|FG000|Long Term Follow-Up|Participant withdrew consent|0
6083592|NCT00636168|9692065|FG001|Long Term Follow-Up|Participant withdrew consent|2
6083593|NCT00636168|9692064|FG000|Long Term Follow-Up|Death|8
6083594|NCT00636168|9692065|FG001|Long Term Follow-Up|Death|9
6083595|NCT00636181|9692074|FG000|Overall Study|Withdrawal by Subject|8
6083596|NCT00636181|9692075|FG001|Overall Study|Withdrawal by Subject|6
6083597|NCT00636181|9692076|FG002|Overall Study|Withdrawal by Subject|10
6348058|NCT03526861|10111429|FG006|Open-label Treatment Period|Randomised at site with quality/GCP issues identified, subject withdrawn from the trial|0
6348059|NCT03526861|10111430|FG007|Open-label Treatment Period|Randomised at site with quality/GCP issues identified, subject withdrawn from the trial|0
6348060|NCT03526861|10111431|FG008|Open-label Treatment Period|Randomised at site with quality/GCP issues identified, subject withdrawn from the trial|8
6348061|NCT03527160|10111453|FG000|Overall Study|No urine collected|13
6348062|NCT03527160|10111453|FG000|Overall Study|No clinical serum creatinine collected|6
6348063|NCT03527160|10111453|FG000|Overall Study|Did not meet inclusion|2
6348064|NCT03527173|10111462|FG000|Overall Study|Lost to Follow-up|4
6348065|NCT03527173|10111463|FG001|Overall Study|Lost to Follow-up|2
6348066|NCT03527173|10111462|FG000|Overall Study|ELIGIBILITY CRITERIA NOT FULFILLED|1
6348067|NCT03527173|10111463|FG001|Overall Study|ELIGIBILITY CRITERIA NOT FULFILLED|0
6348068|NCT03527173|10111462|FG000|Overall Study|CONSENT WITHDRAWAL NOT DUE TO ADV. EVENT|1
6348069|NCT03527173|10111463|FG001|Overall Study|CONSENT WITHDRAWAL NOT DUE TO ADV. EVENT|5
6348070|NCT03527173|10111462|FG000|Overall Study|NOT WILLING TO PARTICIPATE THIS VISIT|1
6348071|NCT03527173|10111463|FG001|Overall Study|NOT WILLING TO PARTICIPATE THIS VISIT|0
6348072|NCT03527550|10111471|FG000|Overall Study|Lost to Follow-up|4
6348073|NCT03527550|10111472|FG001|Overall Study|Lost to Follow-up|2
6348074|NCT03527550|10111471|FG000|Overall Study|Withdrawal by Subject|4
6348075|NCT03527550|10111472|FG001|Overall Study|Withdrawal by Subject|1
6348076|NCT03527550|10111471|FG000|Overall Study|Participant reported exclusion criterion after study enrollment.|1
6348077|NCT03527550|10111472|FG001|Overall Study|Participant reported exclusion criterion after study enrollment.|0
6348078|NCT03527745|10111506|FG000|Overall Study|Lost to Follow-up|3
6348079|NCT03527745|10111507|FG001|Overall Study|Lost to Follow-up|6
6348080|NCT03527745|10111508|FG002|Overall Study|Lost to Follow-up|7
6348081|NCT03527745|10111509|FG003|Overall Study|Lost to Follow-up|9
6169229|NCT01241292|9814491|FG000|Overall Study|Participant Discontinued Treatment|0
6169230|NCT01241292|9814492|FG001|Overall Study|Participant Discontinued Treatment|2
6169231|NCT01241318|9814504|FG000|Overall Study|Woman: false pregnancies|27
6169232|NCT01241318|9814505|FG001|Overall Study|Woman: false pregnancies|15
6348082|NCT03527745|10111510|FG004|Overall Study|Lost to Follow-up|0
6169233|NCT01241318|9814504|FG000|Overall Study|Woman: miscarriage/abortion|46
6169234|NCT01241318|9814505|FG001|Overall Study|Woman: miscarriage/abortion|38
6169235|NCT01241318|9814504|FG000|Overall Study|Withdrawal by Subject|175
6169236|NCT01241318|9814505|FG001|Overall Study|Withdrawal by Subject|46
6169237|NCT01241318|9814504|FG000|Overall Study|Lost to Follow-up|740
6169238|NCT01241318|9814505|FG001|Overall Study|Lost to Follow-up|455
6169239|NCT01241318|9814504|FG000|Overall Study|Death|2
6169240|NCT01241318|9814505|FG001|Overall Study|Death|4
6169241|NCT01241318|9814504|FG000|Overall Study|Withdrew/Lost to Follow after delivery|60
6169242|NCT01241318|9814505|FG001|Overall Study|Withdrew/Lost to Follow after delivery|38
6169243|NCT01241318|9814504|FG000|Overall Study|Woman: Stillborn infant|129
6169244|NCT01241318|9814505|FG001|Overall Study|Woman: Stillborn infant|146
6169245|NCT01241448|9814551|FG000|Overall Study|Adverse Event|1
6169246|NCT01241448|9814552|FG001|Overall Study|Adverse Event|0
6169247|NCT01241448|9814553|FG002|Overall Study|Adverse Event|2
6169248|NCT01241448|9814554|FG003|Overall Study|Adverse Event|2
6169249|NCT01241448|9814551|FG000|Overall Study|Lost to Follow-up|2
6169250|NCT01241448|9814552|FG001|Overall Study|Lost to Follow-up|1
6169251|NCT01241448|9814553|FG002|Overall Study|Lost to Follow-up|1
6169252|NCT01241448|9814554|FG003|Overall Study|Lost to Follow-up|1
6169253|NCT01241448|9814551|FG000|Overall Study|Physician Decision|0
6169254|NCT01241448|9814552|FG001|Overall Study|Physician Decision|2
6169255|NCT01241448|9814553|FG002|Overall Study|Physician Decision|0
6169256|NCT01241448|9814554|FG003|Overall Study|Physician Decision|0
6169257|NCT01241448|9814551|FG000|Overall Study|Protocol Violation|10
6169258|NCT01241448|9814552|FG001|Overall Study|Protocol Violation|5
6169259|NCT01241448|9814553|FG002|Overall Study|Protocol Violation|3
6169260|NCT01241448|9814554|FG003|Overall Study|Protocol Violation|6
6169261|NCT01241448|9814551|FG000|Overall Study|Sponsor Decision|17
6169262|NCT01241448|9814552|FG001|Overall Study|Sponsor Decision|14
6169263|NCT01241448|9814553|FG002|Overall Study|Sponsor Decision|12
6169264|NCT01241448|9814554|FG003|Overall Study|Sponsor Decision|6
6169265|NCT01241448|9814551|FG000|Overall Study|Withdrawal by Subject|4
6169266|NCT01241448|9814552|FG001|Overall Study|Withdrawal by Subject|5
6169267|NCT01241448|9814553|FG002|Overall Study|Withdrawal by Subject|3
6169268|NCT01241448|9814554|FG003|Overall Study|Withdrawal by Subject|6
6169269|NCT01241448|9814551|FG000|Overall Study|Excluded due to data integrity issues|3
6169270|NCT01241448|9814552|FG001|Overall Study|Excluded due to data integrity issues|2
6169271|NCT01241448|9814553|FG002|Overall Study|Excluded due to data integrity issues|2
6169272|NCT01241448|9814554|FG003|Overall Study|Excluded due to data integrity issues|2
6169273|NCT01241461|9814567|FG000|Overall Study|Progressive Disease|3
6169274|NCT01241461|9814568|FG001|Overall Study|Progressive Disease|6
6169275|NCT01241552|9814596|FG000|Overall Study|Lack of Efficacy|1
6169276|NCT01241552|9814597|FG001|Overall Study|Lack of Efficacy|0
6348083|NCT03527745|10111511|FG005|Overall Study|Lost to Follow-up|2
6169277|NCT01241552|9814598|FG002|Overall Study|Lack of Efficacy|0
6169278|NCT01241552|9814599|FG003|Overall Study|Lack of Efficacy|0
6169279|NCT01241552|9814596|FG000|Overall Study|Death|26
6169280|NCT01241552|9814597|FG001|Overall Study|Death|30
6169281|NCT01241552|9814598|FG002|Overall Study|Death|20
6169282|NCT01241552|9814599|FG003|Overall Study|Death|25
6348084|NCT03527745|10111512|FG006|Overall Study|Lost to Follow-up|3
6348085|NCT03527745|10111513|FG007|Overall Study|Lost to Follow-up|2
6348086|NCT03527745|10111514|FG008|Overall Study|Lost to Follow-up|3
6348087|NCT03527745|10111515|FG009|Overall Study|Lost to Follow-up|2
6348088|NCT03527745|10111516|FG010|Overall Study|Lost to Follow-up|1
6348089|NCT03527745|10111517|FG011|Overall Study|Lost to Follow-up|1
6348090|NCT03527745|10111518|FG012|Overall Study|Lost to Follow-up|0
6348091|NCT03527745|10111519|FG013|Overall Study|Lost to Follow-up|0
6348092|NCT03527745|10111520|FG014|Overall Study|Lost to Follow-up|0
6348093|NCT03527745|10111521|FG015|Overall Study|Lost to Follow-up|0
6348094|NCT03527745|10111522|FG016|Overall Study|Lost to Follow-up|1
6348095|NCT03527745|10111523|FG017|Overall Study|Lost to Follow-up|0
6348096|NCT03527745|10111524|FG018|Overall Study|Lost to Follow-up|0
6348097|NCT03527745|10111525|FG019|Overall Study|Lost to Follow-up|1
6348098|NCT03527745|10111526|FG020|Overall Study|Lost to Follow-up|1
6348099|NCT03527745|10111527|FG021|Overall Study|Lost to Follow-up|5
6348100|NCT03527745|10111528|FG022|Overall Study|Lost to Follow-up|6
6348101|NCT03527745|10111529|FG023|Overall Study|Lost to Follow-up|8
6348102|NCT03527745|10111530|FG024|Overall Study|Lost to Follow-up|1
6348103|NCT03527745|10111531|FG025|Overall Study|Lost to Follow-up|3
6348104|NCT03527966|10111589|FG000|Overall Study|Lost to Follow-up|3
6348105|NCT03527966|10111590|FG001|Overall Study|Lost to Follow-up|0
6348106|NCT03528174|10111596|FG000|Overall Study|Adverse Event|1
6348107|NCT03528174|10111596|FG000|Overall Study|sensors dislodged|1
6348108|NCT03528369|10111603|FG000|Overall Study|Withdrawal by Subject|2
6348109|NCT03528369|10111604|FG001|Overall Study|Withdrawal by Subject|0
6348110|NCT03528369|10111605|FG002|Overall Study|Withdrawal by Subject|0
6348111|NCT03528369|10111603|FG000|Overall Study|Lost to Follow-up|1
6348112|NCT03528369|10111604|FG001|Overall Study|Lost to Follow-up|0
6348113|NCT03528369|10111605|FG002|Overall Study|Lost to Follow-up|0
6348114|NCT03528369|10111603|FG000|Overall Study|Adverse Event|0
6348115|NCT03528369|10111604|FG001|Overall Study|Adverse Event|1
6348116|NCT03528369|10111605|FG002|Overall Study|Adverse Event|0
6348117|NCT03528551|10111625|FG000|Overall Study|Lost to Follow-up|0
6348118|NCT03528551|10111626|FG001|Overall Study|Lost to Follow-up|1
6348119|NCT03528551|10111627|FG002|Overall Study|Lost to Follow-up|0
6348120|NCT03528551|10111625|FG000|Overall Study|Transferred to other arm/group|2
6348121|NCT03528551|10111626|FG001|Overall Study|Transferred to other arm/group|3
6348122|NCT03528551|10111627|FG002|Overall Study|Transferred to other arm/group|0
6348123|NCT03528551|10111625|FG000|Overall Study|Withdrawal by parent/guardian|0
6348124|NCT03528551|10111626|FG001|Overall Study|Withdrawal by parent/guardian|5
6348125|NCT03528551|10111627|FG002|Overall Study|Withdrawal by parent/guardian|0
6348126|NCT03528551|10111625|FG000|Overall Study|Protocol Violation|0
6348127|NCT03528551|10111626|FG001|Overall Study|Protocol Violation|3
6348128|NCT03528551|10111627|FG002|Overall Study|Protocol Violation|0
6348129|NCT03528551|10111625|FG000|Overall Study|Withdrawal by Subject|0
6348130|NCT03528551|10111626|FG001|Overall Study|Withdrawal by Subject|7
6348131|NCT03528551|10111627|FG002|Overall Study|Withdrawal by Subject|0
6348132|NCT03528577|10111636|FG000|Sequence 1|Failed Spirometry|1
6348133|NCT03528577|10111636|FG000|Sequence 1|Restricted medication|1
6348134|NCT03528577|10111636|FG000|Sequence 2|Adverse Event|1
6169283|NCT01241552|9814596|FG000|Overall Study|Adverse Event|1
6169284|NCT01241552|9814597|FG001|Overall Study|Adverse Event|1
6169285|NCT01241552|9814598|FG002|Overall Study|Adverse Event|0
6169286|NCT01241552|9814599|FG003|Overall Study|Adverse Event|0
6169287|NCT01241552|9814596|FG000|Overall Study|Technical Problems|2
6169288|NCT01241552|9814597|FG001|Overall Study|Technical Problems|0
6169289|NCT01241552|9814598|FG002|Overall Study|Technical Problems|2
6169290|NCT01241552|9814599|FG003|Overall Study|Technical Problems|2
6169291|NCT01241552|9814596|FG000|Overall Study|Progressive Disease|0
6169292|NCT01241552|9814597|FG001|Overall Study|Progressive Disease|0
6169293|NCT01241552|9814598|FG002|Overall Study|Progressive Disease|1
6169294|NCT01241552|9814599|FG003|Overall Study|Progressive Disease|2
6169295|NCT01241552|9814596|FG000|Overall Study|Protocol Violation|0
6169296|NCT01241552|9814597|FG001|Overall Study|Protocol Violation|2
6169297|NCT01241552|9814598|FG002|Overall Study|Protocol Violation|6
6169298|NCT01241552|9814599|FG003|Overall Study|Protocol Violation|1
6169299|NCT01241552|9814596|FG000|Overall Study|Withdrawal by Subject|7
6348135|NCT03528577|10111636|FG000|Sequence 2|Withdrawal by Subject|1
6169300|NCT01241552|9814597|FG001|Overall Study|Withdrawal by Subject|15
6348136|NCT03528577|10111636|FG000|Sequence 2|Failed Spirometry|1
6348137|NCT03528577|10111636|FG000|Sequence 3|Failed Spirometry|1
6348138|NCT03528577|10111636|FG000|Sequence 4|Failed Spirometry|2
6348139|NCT03528577|10111636|FG000|Sequence 4|Adverse Event|1
6348140|NCT03529162|10111645|FG000|Overall Study|Lost to Follow-up|2
6348141|NCT03529162|10111646|FG001|Overall Study|Lost to Follow-up|2
6348142|NCT03530345|10111676|FG000|Treatment Period A/Follow-up Period 1|Lost to Follow-up|1
6348143|NCT03530345|10111677|FG001|Treatment Period A/Follow-up Period 1|Lost to Follow-up|0
6348144|NCT03530345|10111676|FG000|Treatment Period A/Follow-up Period 1|Withdrawal by Subject|3
6169301|NCT01241552|9814598|FG002|Overall Study|Withdrawal by Subject|14
6169302|NCT01241552|9814599|FG003|Overall Study|Withdrawal by Subject|15
6169303|NCT01241552|9814596|FG000|Overall Study|Physician Decision|2
6169304|NCT01241552|9814597|FG001|Overall Study|Physician Decision|4
6169305|NCT01241552|9814598|FG002|Overall Study|Physician Decision|2
6169306|NCT01241552|9814599|FG003|Overall Study|Physician Decision|3
6348145|NCT03530345|10111677|FG001|Treatment Period A/Follow-up Period 1|Withdrawal by Subject|1
6348146|NCT03530345|10111676|FG000|Treatment Period A/Follow-up Period 1|Other reasons for discontinuation|17
6348147|NCT03530345|10111677|FG001|Treatment Period A/Follow-up Period 1|Other reasons for discontinuation|21
6348148|NCT03530345|10111676|FG000|Treatment Period B/Follow-up Period 2|Other reasons for discontinuation|5
6348149|NCT03530345|10111677|FG001|Treatment Period B/Follow-up Period 2|Other reasons for discontinuation|7
6348150|NCT03531840|10111767|FG000|Overall Study|Death on study|3
6348151|NCT03531840|10111768|FG001|Overall Study|Death on study|2
6348152|NCT03531840|10111769|FG002|Overall Study|Death on study|1
6348153|NCT03531840|10111770|FG003|Overall Study|Death on study|2
6348154|NCT03531840|10111767|FG000|Overall Study|Death during follow up|2
6348155|NCT03531840|10111768|FG001|Overall Study|Death during follow up|3
6348156|NCT03531840|10111769|FG002|Overall Study|Death during follow up|4
6348157|NCT03531840|10111770|FG003|Overall Study|Death during follow up|1
6348158|NCT03531905|10111788|FG000|Overall Study|Withdrawal by Subject|3
6348159|NCT03531905|10111789|FG001|Overall Study|Withdrawal by Subject|3
6348160|NCT03531905|10111790|FG002|Overall Study|Withdrawal by Subject|2
6348161|NCT03531905|10111788|FG000|Overall Study|Lost to Follow-up|2
6348162|NCT03531905|10111789|FG001|Overall Study|Lost to Follow-up|2
6348163|NCT03531905|10111790|FG002|Overall Study|Lost to Follow-up|1
6348164|NCT03531905|10111788|FG000|Overall Study|Participant was out of town|1
6348165|NCT03531905|10111789|FG001|Overall Study|Participant was out of town|0
6348166|NCT03531905|10111790|FG002|Overall Study|Participant was out of town|0
6348167|NCT03531905|10111788|FG000|Overall Study|Could not speak with the participant|1
6348168|NCT03531905|10111789|FG001|Overall Study|Could not speak with the participant|0
6348169|NCT03531905|10111790|FG002|Overall Study|Could not speak with the participant|0
6348170|NCT03532009|10111802|FG000|Overall Study|Other|1
6348171|NCT03532009|10111803|FG001|Overall Study|Other|1
6348172|NCT03532009|10111802|FG000|Overall Study|Death|1
6348173|NCT03532009|10111803|FG001|Overall Study|Death|1
6348174|NCT03532009|10111802|FG000|Overall Study|Withdrawal by Patient|0
6348175|NCT03532009|10111803|FG001|Overall Study|Withdrawal by Patient|2
6348176|NCT03532048|10111811|FG000|Overall Study|Lost to Follow-up|12
6348177|NCT03532048|10111812|FG001|Overall Study|Lost to Follow-up|17
6348178|NCT03532048|10111811|FG000|Overall Study|Withdrawal by Subject|7
6348179|NCT03532048|10111812|FG001|Overall Study|Withdrawal by Subject|0
6348180|NCT03533114|10111852|FG000|Overall|Adverse Event|16
6348181|NCT03533114|10111853|FG001|Overall|Adverse Event|11
6348182|NCT03533114|10111852|FG000|Overall|Consent Withdrawal by Participant|7
6348183|NCT03533114|10111853|FG001|Overall|Consent Withdrawal by Participant|6
6348184|NCT03533114|10111852|FG000|Overall|Lack of Efficacy|5
6348185|NCT03533114|10111853|FG001|Overall|Lack of Efficacy|3
6348186|NCT03533114|10111852|FG000|Overall|Lost to Follow-up|1
6348187|NCT03533114|10111853|FG001|Overall|Lost to Follow-up|1
6348188|NCT03533114|10111852|FG000|Overall|Physician Decision|0
6348189|NCT03533114|10111853|FG001|Overall|Physician Decision|2
6348190|NCT03533114|10111852|FG000|Overall|Protocol deviation|1
6348191|NCT03533114|10111853|FG001|Overall|Protocol deviation|1
6348192|NCT03533114|10111852|FG000|Overall|Failure to meet randomization criteria|1
6348193|NCT03533114|10111853|FG001|Overall|Failure to meet randomization criteria|2
6348194|NCT03533114|10111852|FG000|Overall|Non-Compliance with study drug|0
6348195|NCT03533114|10111853|FG001|Overall|Non-Compliance with study drug|1
6348196|NCT03533114|10111852|FG000|Overall|Other|0
6348197|NCT03533114|10111853|FG001|Overall|Other|1
6348198|NCT03533114|10111852|FG000|Open Label Titration and Optimization|Adverse Event|11
6348199|NCT03533114|10111853|FG001|Open Label Titration and Optimization|Adverse Event|8
6348200|NCT03533114|10111852|FG000|Open Label Titration and Optimization|Consent Withdrawal by Participant|2
6348201|NCT03533114|10111853|FG001|Open Label Titration and Optimization|Consent Withdrawal by Participant|1
6348202|NCT03533114|10111852|FG000|Open Label Titration and Optimization|Lack of Efficacy|3
6348203|NCT03533114|10111853|FG001|Open Label Titration and Optimization|Lack of Efficacy|1
6348204|NCT03533114|10111852|FG000|Open Label Titration and Optimization|Lost to Follow-up|0
6348205|NCT03533114|10111853|FG001|Open Label Titration and Optimization|Lost to Follow-up|1
6348206|NCT03533114|10111852|FG000|Open Label Titration and Optimization|Protocol Deviation|0
6348207|NCT03533114|10111853|FG001|Open Label Titration and Optimization|Protocol Deviation|1
6348208|NCT03533114|10111852|FG000|Open Label Titration and Optimization|Non-Compliance with Study Drug|0
6348209|NCT03533114|10111853|FG001|Open Label Titration and Optimization|Non-Compliance with Study Drug|1
6348210|NCT03533114|10111852|FG000|Stable Dose|Adverse Event|0
6348211|NCT03533114|10111853|FG001|Stable Dose|Adverse Event|2
6348212|NCT03533114|10111852|FG000|Stable Dose|Consent Withdrawal by Participant|1
6348213|NCT03533114|10111853|FG001|Stable Dose|Consent Withdrawal by Participant|0
6348214|NCT03533114|10111852|FG000|Stable Dose|Lack of Efficacy|1
6348215|NCT03533114|10111853|FG001|Stable Dose|Lack of Efficacy|0
6348216|NCT03533114|10111852|FG000|Double Blind Randomized-Withdrawal|Adverse Event|1
6348217|NCT03533114|10111853|FG001|Double Blind Randomized-Withdrawal|Adverse Event|1
6348218|NCT03533114|10111852|FG000|Double Blind Randomized-Withdrawal|Failure to Meet Randomization Criteria|1
6348219|NCT03533114|10111853|FG001|Double Blind Randomized-Withdrawal|Failure to Meet Randomization Criteria|0
6348220|NCT03533114|10111852|FG000|Open-Label Safety Extension|Adverse Event|3
6348221|NCT03533114|10111853|FG001|Open-Label Safety Extension|Adverse Event|0
6348222|NCT03533114|10111852|FG000|Open-Label Safety Extension|Consent Withdrawal by Participant|2
6348223|NCT03533114|10111853|FG001|Open-Label Safety Extension|Consent Withdrawal by Participant|3
6348224|NCT03533114|10111852|FG000|Open-Label Safety Extension|Lack of Efficacy|1
6348225|NCT03533114|10111853|FG001|Open-Label Safety Extension|Lack of Efficacy|0
6348226|NCT03533114|10111852|FG000|Open-Label Safety Extension|Lost to Follow-up|1
6348227|NCT03533114|10111853|FG001|Open-Label Safety Extension|Lost to Follow-up|0
6348228|NCT03533114|10111852|FG000|Open-Label Safety Extension|Protocol Deviation|1
6348229|NCT03533114|10111853|FG001|Open-Label Safety Extension|Protocol Deviation|0
6348230|NCT03533608|10111883|FG000|Overall Study|Withdrawal by Subject|3
6348231|NCT03533608|10111883|FG000|Overall Study|Physician Decision|2
6348232|NCT03535194|10111928|FG000|Induction Period|Adverse Event|2
6169307|NCT01241552|9814596|FG000|Overall Study|Lost to Follow-up|2
6169308|NCT01241552|9814597|FG001|Overall Study|Lost to Follow-up|11
6169309|NCT01241552|9814598|FG002|Overall Study|Lost to Follow-up|15
6169310|NCT01241552|9814599|FG003|Overall Study|Lost to Follow-up|16
6169311|NCT01241591|9814618|FG000|Overall Study|Lack of Efficacy|5
6169312|NCT01241591|9814619|FG001|Overall Study|Lack of Efficacy|2
6169313|NCT01241591|9814620|FG002|Overall Study|Lack of Efficacy|2
6169314|NCT01241591|9814621|FG003|Overall Study|Lack of Efficacy|3
6169315|NCT01241591|9814618|FG000|Overall Study|Protocol Violation|5
6169316|NCT01241591|9814619|FG001|Overall Study|Protocol Violation|2
6169317|NCT01241591|9814620|FG002|Overall Study|Protocol Violation|3
6169318|NCT01241591|9814621|FG003|Overall Study|Protocol Violation|0
6169319|NCT01241591|9814618|FG000|Overall Study|Lost to Follow-up|1
6169320|NCT01241591|9814619|FG001|Overall Study|Lost to Follow-up|2
6169321|NCT01241591|9814620|FG002|Overall Study|Lost to Follow-up|2
6169322|NCT01241591|9814621|FG003|Overall Study|Lost to Follow-up|2
6169323|NCT01241591|9814618|FG000|Overall Study|Screen Failure|3
6169324|NCT01241591|9814619|FG001|Overall Study|Screen Failure|2
6348233|NCT03535194|10111929|FG001|Induction Period|Adverse Event|2
6169325|NCT01241591|9814620|FG002|Overall Study|Screen Failure|1
6169326|NCT01241591|9814621|FG003|Overall Study|Screen Failure|0
6169327|NCT01241591|9814618|FG000|Overall Study|Withdrawal by Subject|6
6169328|NCT01241591|9814619|FG001|Overall Study|Withdrawal by Subject|4
6348234|NCT03535194|10111930|FG002|Induction Period|Adverse Event|1
6348235|NCT03535194|10111931|FG003|Induction Period|Adverse Event|3
6348236|NCT03535194|10111932|FG004|Induction Period|Adverse Event|0
6348237|NCT03535194|10111928|FG000|Induction Period|Death|0
6169329|NCT01241591|9814620|FG002|Overall Study|Withdrawal by Subject|2
6348238|NCT03535194|10111929|FG001|Induction Period|Death|1
6348239|NCT03535194|10111930|FG002|Induction Period|Death|0
6348240|NCT03535194|10111931|FG003|Induction Period|Death|0
6348241|NCT03535194|10111932|FG004|Induction Period|Death|0
6348242|NCT03535194|10111928|FG000|Induction Period|Lack of Efficacy|1
6348243|NCT03535194|10111929|FG001|Induction Period|Lack of Efficacy|3
6348244|NCT03535194|10111930|FG002|Induction Period|Lack of Efficacy|2
6348245|NCT03535194|10111931|FG003|Induction Period|Lack of Efficacy|2
6348246|NCT03535194|10111932|FG004|Induction Period|Lack of Efficacy|0
6348247|NCT03535194|10111928|FG000|Induction Period|Lost to Follow-up|3
6348248|NCT03535194|10111929|FG001|Induction Period|Lost to Follow-up|5
6348249|NCT03535194|10111930|FG002|Induction Period|Lost to Follow-up|2
6348250|NCT03535194|10111931|FG003|Induction Period|Lost to Follow-up|3
6348251|NCT03535194|10111932|FG004|Induction Period|Lost to Follow-up|0
6348252|NCT03535194|10111928|FG000|Induction Period|Physician Decision|1
6348253|NCT03535194|10111929|FG001|Induction Period|Physician Decision|1
6348254|NCT03535194|10111930|FG002|Induction Period|Physician Decision|0
6348255|NCT03535194|10111931|FG003|Induction Period|Physician Decision|0
6348256|NCT03535194|10111932|FG004|Induction Period|Physician Decision|0
6348257|NCT03535194|10111928|FG000|Induction Period|Protocol Violation|1
6348258|NCT03535194|10111929|FG001|Induction Period|Protocol Violation|0
6348259|NCT03535194|10111930|FG002|Induction Period|Protocol Violation|0
6348260|NCT03535194|10111931|FG003|Induction Period|Protocol Violation|1
6348261|NCT03535194|10111932|FG004|Induction Period|Protocol Violation|0
6348262|NCT03535194|10111928|FG000|Induction Period|Screen Failure|0
6348263|NCT03535194|10111929|FG001|Induction Period|Screen Failure|1
6348264|NCT03535194|10111930|FG002|Induction Period|Screen Failure|0
6348265|NCT03535194|10111931|FG003|Induction Period|Screen Failure|0
6348266|NCT03535194|10111932|FG004|Induction Period|Screen Failure|0
6348267|NCT03535194|10111928|FG000|Induction Period|Withdrawal by Subject|3
6348268|NCT03535194|10111929|FG001|Induction Period|Withdrawal by Subject|4
6348269|NCT03535194|10111930|FG002|Induction Period|Withdrawal by Subject|3
6348270|NCT03535194|10111931|FG003|Induction Period|Withdrawal by Subject|2
6348271|NCT03535194|10111932|FG004|Induction Period|Withdrawal by Subject|0
6348272|NCT03535194|10111928|FG000|Maintenance Period|Adverse Event|6
6348273|NCT03535194|10111929|FG001|Maintenance Period|Adverse Event|5
6348274|NCT03535194|10111930|FG002|Maintenance Period|Adverse Event|1
6348275|NCT03535194|10111931|FG003|Maintenance Period|Adverse Event|11
6348276|NCT03535194|10111932|FG004|Maintenance Period|Adverse Event|4
6348277|NCT03535194|10111928|FG000|Maintenance Period|Lack of Efficacy|3
6348278|NCT03535194|10111929|FG001|Maintenance Period|Lack of Efficacy|2
6348279|NCT03535194|10111930|FG002|Maintenance Period|Lack of Efficacy|5
6348280|NCT03535194|10111931|FG003|Maintenance Period|Lack of Efficacy|9
6348281|NCT03535194|10111932|FG004|Maintenance Period|Lack of Efficacy|0
6348282|NCT03535194|10111928|FG000|Maintenance Period|Lost to Follow-up|4
6348283|NCT03535194|10111929|FG001|Maintenance Period|Lost to Follow-up|2
6348284|NCT03535194|10111930|FG002|Maintenance Period|Lost to Follow-up|1
6348285|NCT03535194|10111931|FG003|Maintenance Period|Lost to Follow-up|5
6348286|NCT03535194|10111932|FG004|Maintenance Period|Lost to Follow-up|2
6348287|NCT03535194|10111928|FG000|Maintenance Period|Other|1
6348288|NCT03535194|10111929|FG001|Maintenance Period|Other|2
6348289|NCT03535194|10111930|FG002|Maintenance Period|Other|0
6348290|NCT03535194|10111931|FG003|Maintenance Period|Other|0
6348291|NCT03535194|10111932|FG004|Maintenance Period|Other|0
6348292|NCT03535194|10111928|FG000|Maintenance Period|Physician Decision|1
6348293|NCT03535194|10111929|FG001|Maintenance Period|Physician Decision|2
6348294|NCT03535194|10111930|FG002|Maintenance Period|Physician Decision|0
6169330|NCT01241591|9814621|FG003|Overall Study|Withdrawal by Subject|2
6169331|NCT01241591|9814618|FG000|Overall Study|Other|0
6169332|NCT01241591|9814619|FG001|Overall Study|Other|1
6169333|NCT01241591|9814620|FG002|Overall Study|Other|0
6169334|NCT01241591|9814621|FG003|Overall Study|Other|1
6169335|NCT01241591|9814618|FG000|Overall Study|Adverse Event|3
6169336|NCT01241591|9814619|FG001|Overall Study|Adverse Event|11
6169337|NCT01241591|9814620|FG002|Overall Study|Adverse Event|12
6169338|NCT01241591|9814621|FG003|Overall Study|Adverse Event|4
6169339|NCT01241604|9814631|FG000|Screening Period|Screen Failure|3
6169340|NCT01241604|9814632|FG001|Screening Period|Screen Failure|0
6169341|NCT01241604|9814633|FG002|Screening Period|Screen Failure|0
6169342|NCT01241760|9814642|FG000|Overall Study|Adverse Event|1
6348295|NCT03535194|10111931|FG003|Maintenance Period|Physician Decision|2
6348296|NCT03535194|10111932|FG004|Maintenance Period|Physician Decision|0
6348297|NCT03535194|10111928|FG000|Maintenance Period|Pregnancy|0
6348298|NCT03535194|10111929|FG001|Maintenance Period|Pregnancy|0
6348299|NCT03535194|10111930|FG002|Maintenance Period|Pregnancy|0
6348300|NCT03535194|10111931|FG003|Maintenance Period|Pregnancy|2
6348301|NCT03535194|10111932|FG004|Maintenance Period|Pregnancy|0
6169343|NCT01241760|9814643|FG001|Overall Study|Adverse Event|0
6169344|NCT01241760|9814642|FG000|Overall Study|Lost to Follow-up|18
6169345|NCT01241760|9814643|FG001|Overall Study|Lost to Follow-up|22
6169346|NCT01241760|9814642|FG000|Overall Study|Withdrawal by Subject|13
6348302|NCT03535194|10111928|FG000|Maintenance Period|Protocol Violation|0
6348303|NCT03535194|10111929|FG001|Maintenance Period|Protocol Violation|1
6348304|NCT03535194|10111930|FG002|Maintenance Period|Protocol Violation|0
6348305|NCT03535194|10111931|FG003|Maintenance Period|Protocol Violation|0
6169347|NCT01241760|9814643|FG001|Overall Study|Withdrawal by Subject|13
6348306|NCT03535194|10111932|FG004|Maintenance Period|Protocol Violation|0
6348307|NCT03535194|10111928|FG000|Maintenance Period|Withdrawal by Subject|7
6348308|NCT03535194|10111929|FG001|Maintenance Period|Withdrawal by Subject|2
6348309|NCT03535194|10111930|FG002|Maintenance Period|Withdrawal by Subject|1
6348310|NCT03535194|10111931|FG003|Maintenance Period|Withdrawal by Subject|8
6348311|NCT03535194|10111932|FG004|Maintenance Period|Withdrawal by Subject|0
6348312|NCT03535194|10111928|FG000|Post-Treatment Followup Period|Adverse Event|4
6348313|NCT03535194|10111929|FG001|Post-Treatment Followup Period|Adverse Event|5
6043102|NCT00386360|9641540|FG001|Overall Study|Withdrawal by Subject|6
6043103|NCT00386360|9641539|FG000|Overall Study|Did not take any study medication|0
6043104|NCT00386360|9641540|FG001|Overall Study|Did not take any study medication|2
6043105|NCT00386425|9641549|FG000|Overall Study|Physician Decision|3
6043106|NCT00386425|9641550|FG001|Overall Study|Physician Decision|0
6043107|NCT00386425|9641551|FG002|Overall Study|Physician Decision|0
6043108|NCT00386425|9641549|FG000|Overall Study|Withdrawal by Subject|0
6083598|NCT00636194|9692086|FG000|Overall Study|Study related symptoms and complaints|1
6083599|NCT00636194|9692087|FG001|Overall Study|Study related symptoms and complaints|0
6169348|NCT01241760|9814642|FG000|Overall Study|Switch To Commercially Available Medicat|1
6169349|NCT01241760|9814643|FG001|Overall Study|Switch To Commercially Available Medicat|4
6169350|NCT01241760|9814642|FG000|Overall Study|Other|1
6169351|NCT01241760|9814643|FG001|Overall Study|Other|1
6169352|NCT01242085|9814671|FG000|Overall Study|Withdrawal by Subject|4
6169353|NCT01242085|9814672|FG001|Overall Study|Withdrawal by Subject|2
6169354|NCT01242085|9814673|FG002|Overall Study|Withdrawal by Subject|0
6169355|NCT01242085|9814671|FG000|Overall Study|medically unable to have surgery|4
6169356|NCT01242085|9814672|FG001|Overall Study|medically unable to have surgery|5
6169357|NCT01242085|9814673|FG002|Overall Study|medically unable to have surgery|0
6169358|NCT01242111|9814679|FG000|Overall Study|Adverse Event|1
6169359|NCT01242111|9814679|FG000|Overall Study|Withdrawal by Subject|1
6169360|NCT01242111|9814679|FG000|Overall Study|Did not consent to MOR-100 follow-up|1
6348314|NCT03535194|10111930|FG002|Post-Treatment Followup Period|Adverse Event|1
6043109|NCT00386425|9641550|FG001|Overall Study|Withdrawal by Subject|1
6169361|NCT01242176|9814683|FG000|Washout Period of 7 Days|Adverse Event|0
6169362|NCT01242176|9814684|FG001|Washout Period of 7 Days|Adverse Event|2
6169363|NCT01242176|9814683|FG000|Washout Period of 7 Days|Non-compliant with protocol|1
6169364|NCT01242176|9814684|FG001|Washout Period of 7 Days|Non-compliant with protocol|0
6169365|NCT01242371|9814701|FG000|Overall Study|Withdrawal by Subject|2
6169366|NCT01242371|9814702|FG001|Overall Study|Withdrawal by Subject|2
6169367|NCT01242371|9814701|FG000|Overall Study|Protocol Violation|0
6169368|NCT01242371|9814702|FG001|Overall Study|Protocol Violation|3
6169369|NCT01242514|9814711|FG000|Overall Study|e.g., project closure|1042
6169370|NCT01242514|9814712|FG001|Overall Study|e.g., project closure|305
6169371|NCT01242514|9814713|FG002|Overall Study|e.g., project closure|171
6169372|NCT01242514|9814711|FG000|Overall Study|Subject decision|33
6169373|NCT01242514|9814712|FG001|Overall Study|Subject decision|8
6169374|NCT01242514|9814713|FG002|Overall Study|Subject decision|2
6169375|NCT01242514|9814711|FG000|Overall Study|Severe non-compliance to protocol|5
6169376|NCT01242514|9814712|FG001|Overall Study|Severe non-compliance to protocol|2
6169377|NCT01242514|9814713|FG002|Overall Study|Severe non-compliance to protocol|1
6169378|NCT01242514|9814711|FG000|Overall Study|Lack of therapeutic response|99
6169379|NCT01242514|9814712|FG001|Overall Study|Lack of therapeutic response|16
6169380|NCT01242514|9814713|FG002|Overall Study|Lack of therapeutic response|10
6169381|NCT01242514|9814711|FG000|Overall Study|Dev. of study specific discont. criteria|21
6169382|NCT01242514|9814712|FG001|Overall Study|Dev. of study specific discont. criteria|3
6169383|NCT01242514|9814713|FG002|Overall Study|Dev. of study specific discont. criteria|5
6169384|NCT01242514|9814711|FG000|Overall Study|Lost to Follow-up|14
6169385|NCT01242514|9814712|FG001|Overall Study|Lost to Follow-up|5
6169386|NCT01242514|9814713|FG002|Overall Study|Lost to Follow-up|4
6169387|NCT01242514|9814711|FG000|Overall Study|Adverse Event|129
6169388|NCT01242514|9814712|FG001|Overall Study|Adverse Event|18
6169389|NCT01242514|9814713|FG002|Overall Study|Adverse Event|19
6169390|NCT01242748|9814753|FG000|Overall Study|Adverse Event|10
6169391|NCT01242748|9814754|FG001|Overall Study|Adverse Event|5
6169392|NCT01242748|9814753|FG000|Overall Study|Lost to Follow-up|6
6169393|NCT01242748|9814754|FG001|Overall Study|Lost to Follow-up|2
6169394|NCT01242748|9814753|FG000|Overall Study|Physician Decision|3
6169395|NCT01242748|9814754|FG001|Overall Study|Physician Decision|2
6169396|NCT01242748|9814753|FG000|Overall Study|Protocol Violation|1
6348315|NCT03535194|10111931|FG003|Post-Treatment Followup Period|Adverse Event|8
6043110|NCT00386425|9641551|FG002|Overall Study|Withdrawal by Subject|0
6043111|NCT00386607|9641572|FG000|Core|Adverse Event|40
6043112|NCT00386607|9641573|FG001|Core|Adverse Event|0
6043113|NCT00386607|9641572|FG000|Core|Abnormal laboratory value(s)|3
6043114|NCT00386607|9641573|FG001|Core|Abnormal laboratory value(s)|0
6043115|NCT00386607|9641572|FG000|Core|Unsatisfactory therapeutic effect|23
6043116|NCT00386607|9641573|FG001|Core|Unsatisfactory therapeutic effect|0
6043117|NCT00386607|9641572|FG000|Core|Condition no longer requires study drug|4
6043118|NCT00386607|9641573|FG001|Core|Condition no longer requires study drug|0
6043119|NCT00386607|9641572|FG000|Core|Patient withdrew consent|15
6043120|NCT00386607|9641573|FG001|Core|Patient withdrew consent|0
6043121|NCT00386607|9641572|FG000|Core|Lost to Follow-up|23
6348316|NCT03535194|10111932|FG004|Post-Treatment Followup Period|Adverse Event|0
6348317|NCT03535194|10111928|FG000|Post-Treatment Followup Period|Lack of Efficacy|3
6348318|NCT03535194|10111929|FG001|Post-Treatment Followup Period|Lack of Efficacy|4
6348319|NCT03535194|10111930|FG002|Post-Treatment Followup Period|Lack of Efficacy|5
6348320|NCT03535194|10111931|FG003|Post-Treatment Followup Period|Lack of Efficacy|4
6348321|NCT03535194|10111932|FG004|Post-Treatment Followup Period|Lack of Efficacy|0
6348322|NCT03535194|10111928|FG000|Post-Treatment Followup Period|Lost to Follow-up|1
6348323|NCT03535194|10111929|FG001|Post-Treatment Followup Period|Lost to Follow-up|1
6348324|NCT03535194|10111930|FG002|Post-Treatment Followup Period|Lost to Follow-up|1
6348325|NCT03535194|10111931|FG003|Post-Treatment Followup Period|Lost to Follow-up|0
6348326|NCT03535194|10111932|FG004|Post-Treatment Followup Period|Lost to Follow-up|0
6348327|NCT03535194|10111928|FG000|Post-Treatment Followup Period|Other|1
6348328|NCT03535194|10111929|FG001|Post-Treatment Followup Period|Other|0
6348329|NCT03535194|10111930|FG002|Post-Treatment Followup Period|Other|0
6348330|NCT03535194|10111931|FG003|Post-Treatment Followup Period|Other|5
6348331|NCT03535194|10111932|FG004|Post-Treatment Followup Period|Other|0
6348332|NCT03535194|10111928|FG000|Post-Treatment Followup Period|Physician Decision|0
6348333|NCT03535194|10111929|FG001|Post-Treatment Followup Period|Physician Decision|2
6348334|NCT03535194|10111930|FG002|Post-Treatment Followup Period|Physician Decision|1
6348335|NCT03535194|10111931|FG003|Post-Treatment Followup Period|Physician Decision|1
6348336|NCT03535194|10111932|FG004|Post-Treatment Followup Period|Physician Decision|0
6348337|NCT03535194|10111928|FG000|Post-Treatment Followup Period|Withdrawal by Subject|2
6348338|NCT03535194|10111929|FG001|Post-Treatment Followup Period|Withdrawal by Subject|2
6348339|NCT03535194|10111930|FG002|Post-Treatment Followup Period|Withdrawal by Subject|3
6348340|NCT03535194|10111931|FG003|Post-Treatment Followup Period|Withdrawal by Subject|6
6348341|NCT03535194|10111932|FG004|Post-Treatment Followup Period|Withdrawal by Subject|0
6348342|NCT03535844|10111968|FG000|Overall Study|Withdrawal by Subject|0
6169397|NCT01242748|9814754|FG001|Overall Study|Protocol Violation|0
6169398|NCT01242748|9814753|FG000|Overall Study|Withdrawal by Subject|10
6169399|NCT01242748|9814754|FG001|Overall Study|Withdrawal by Subject|2
6169400|NCT01242748|9814753|FG000|Overall Study|Miscellaneous reasons|8
6169401|NCT01242748|9814754|FG001|Overall Study|Miscellaneous reasons|3
6169402|NCT01242813|9814760|FG000|Overall Study|Lost to Follow-up|2
6169403|NCT01243151|9814773|FG000|Overall Study|Adverse Event|0
6169404|NCT01243151|9814774|FG001|Overall Study|Adverse Event|1
6169405|NCT01243151|9814775|FG002|Overall Study|Adverse Event|0
6169406|NCT01243151|9814776|FG003|Overall Study|Adverse Event|0
6169407|NCT01243151|9814777|FG004|Overall Study|Adverse Event|0
6169408|NCT01243151|9814773|FG000|Overall Study|Protocol Violation|0
6169409|NCT01243151|9814774|FG001|Overall Study|Protocol Violation|0
6169410|NCT01243151|9814775|FG002|Overall Study|Protocol Violation|1
6169411|NCT01243151|9814776|FG003|Overall Study|Protocol Violation|0
6169412|NCT01243151|9814777|FG004|Overall Study|Protocol Violation|0
6169413|NCT01243151|9814773|FG000|Overall Study|Other|0
6169414|NCT01243151|9814774|FG001|Overall Study|Other|0
6169415|NCT01243151|9814775|FG002|Overall Study|Other|0
6169416|NCT01243151|9814776|FG003|Overall Study|Other|1
6169417|NCT01243151|9814777|FG004|Overall Study|Other|0
6169418|NCT01243151|9814773|FG000|Overall Study|Randomized but not treated|0
6169419|NCT01243151|9814774|FG001|Overall Study|Randomized but not treated|0
6169420|NCT01243151|9814775|FG002|Overall Study|Randomized but not treated|0
6169421|NCT01243151|9814776|FG003|Overall Study|Randomized but not treated|1
6169422|NCT01243151|9814777|FG004|Overall Study|Randomized but not treated|0
6169423|NCT01243177|9814795|FG000|Overall Study|Lack of Efficacy|47
6169424|NCT01243177|9814796|FG001|Overall Study|Lack of Efficacy|31
6169425|NCT01243177|9814795|FG000|Overall Study|Protocol Violation|11
6169426|NCT01243177|9814796|FG001|Overall Study|Protocol Violation|10
6169427|NCT01243177|9814795|FG000|Overall Study|Lost to Follow-up|15
6169428|NCT01243177|9814796|FG001|Overall Study|Lost to Follow-up|18
6169429|NCT01243177|9814795|FG000|Overall Study|Withdrawal by Subject|46
6169430|NCT01243177|9814796|FG001|Overall Study|Withdrawal by Subject|38
6169431|NCT01243177|9814795|FG000|Overall Study|AE, serious fatal|0
6169432|NCT01243177|9814796|FG001|Overall Study|AE, serious fatal|1
6169433|NCT01243177|9814795|FG000|Overall Study|SAE, non-fatal|7
6169434|NCT01243177|9814796|FG001|Overall Study|SAE, non-fatal|9
6169435|NCT01243177|9814795|FG000|Overall Study|AE, non-serious non-fatal|40
6169436|NCT01243177|9814796|FG001|Overall Study|AE, non-serious non-fatal|58
6169437|NCT01243177|9814795|FG000|Overall Study|SAE, fatal + SAE, non-fatal|1
6169438|NCT01243177|9814796|FG001|Overall Study|SAE, fatal + SAE, non-fatal|0
6169439|NCT01243177|9814795|FG000|Overall Study|SAE,non-fatal+AE,non-serious non-fatal|0
6169440|NCT01243177|9814796|FG001|Overall Study|SAE,non-fatal+AE,non-serious non-fatal|1
6169441|NCT01243177|9814795|FG000|Overall Study|Other Reason|11
6169442|NCT01243177|9814796|FG001|Overall Study|Other Reason|12
6169443|NCT01243242|9814804|FG000|Overall Study|Adverse Event|1
6169444|NCT01243242|9814805|FG001|Overall Study|Adverse Event|1
6169445|NCT01243242|9814804|FG000|Overall Study|Withdrawal by Subject|1
6169446|NCT01243242|9814805|FG001|Overall Study|Withdrawal by Subject|1
6169447|NCT01243242|9814804|FG000|Overall Study|Physician Decision|0
6169448|NCT01243242|9814805|FG001|Overall Study|Physician Decision|1
6348343|NCT03535844|10111969|FG001|Overall Study|Withdrawal by Subject|1
6348344|NCT03535974|10111978|FG000|First Intervention Weeks 0-6 (V1-V2)|Adverse Event|0
6348345|NCT03535974|10111979|FG001|First Intervention Weeks 0-6 (V1-V2)|Adverse Event|1
6348346|NCT03535974|10111980|FG002|First Intervention Weeks 0-6 (V1-V2)|Adverse Event|0
6348347|NCT03535974|10111978|FG000|First Intervention Weeks 0-6 (V1-V2)|Withdrawal by Subject|2
6348348|NCT03535974|10111979|FG001|First Intervention Weeks 0-6 (V1-V2)|Withdrawal by Subject|1
6348349|NCT03535974|10111980|FG002|First Intervention Weeks 0-6 (V1-V2)|Withdrawal by Subject|0
6348350|NCT03536663|10111988|FG000|Endexo|Protocol Violation|1
6348351|NCT03536949|10112016|FG000|Overall Study|Adverse Event|4
6348352|NCT03536949|10112017|FG001|Overall Study|Adverse Event|0
6348353|NCT03536949|10112016|FG000|Overall Study|Lost to Follow-up|2
6348354|NCT03536949|10112017|FG001|Overall Study|Lost to Follow-up|1
6348355|NCT03536949|10112016|FG000|Overall Study|Withdrawal by Subject|6
6348356|NCT03536949|10112017|FG001|Overall Study|Withdrawal by Subject|0
6348357|NCT03536949|10112016|FG000|Overall Study|Non-compliance|2
6348358|NCT03536949|10112017|FG001|Overall Study|Non-compliance|1
6348359|NCT03537261|10112038|FG000|Overall Study|Lost to Follow-up|4
6348360|NCT03537261|10112039|FG001|Overall Study|Lost to Follow-up|5
6348361|NCT03537261|10112038|FG000|Overall Study|Withdrawal by Subject|4
6348362|NCT03537261|10112039|FG001|Overall Study|Withdrawal by Subject|6
6348363|NCT03537261|10112038|FG000|Overall Study|Did not return study questionnaires|0
6348364|NCT03537261|10112039|FG001|Overall Study|Did not return study questionnaires|1
6348365|NCT03537651|10112090|FG000|Overall Study|Adverse Event|2
6348366|NCT03537651|10112090|FG000|Overall Study|Withdrawal of Consent (not due to AE)|2
6348367|NCT03537651|10112090|FG000|Overall Study|Commercial Drug is Available for Participant|56
6169449|NCT01243242|9814804|FG000|Overall Study|sponsor decision|0
6169450|NCT01243242|9814805|FG001|Overall Study|sponsor decision|1
6169451|NCT01243242|9814804|FG000|Overall Study|non compliance|1
6169452|NCT01243242|9814805|FG001|Overall Study|non compliance|0
6169453|NCT01243268|9814811|FG000|Overall Study|Lost to Follow-up|4
6169454|NCT01243268|9814811|FG000|Overall Study|Protocol Violation|51
6169455|NCT01243268|9814811|FG000|Overall Study|Deviation with contract date|7
6169456|NCT01243268|9814811|FG000|Overall Study|Duplicate subject|2
6169457|NCT01243411|9814832|FG000|Overall Study|Withdrawal by Subject|18
6169458|NCT01243411|9814832|FG000|Overall Study|Lost to Follow-up|10
6169459|NCT01243411|9814832|FG000|Overall Study|Adverse Event|5
6169460|NCT01243411|9814832|FG000|Overall Study|Other|8
6169461|NCT01243424|9814838|FG000|Discontinuation From Study (Treated Set)|Consent Withdrawn (Status Alive)|49
6169462|NCT01243424|9814839|FG001|Discontinuation From Study (Treated Set)|Consent Withdrawn (Status Alive)|37
6169463|NCT01243424|9814838|FG000|Discontinuation From Study (Treated Set)|Consent Withdrawn (Status Unknown)|14
6169464|NCT01243424|9814839|FG001|Discontinuation From Study (Treated Set)|Consent Withdrawn (Status Unknown)|12
6169465|NCT01243424|9814838|FG000|Discontinuation From Study (Treated Set)|Site Closure (Status Alive)|15
6169466|NCT01243424|9814839|FG001|Discontinuation From Study (Treated Set)|Site Closure (Status Alive)|22
6169467|NCT01243424|9814838|FG000|Discontinuation From Study (Treated Set)|Site Closure (Status Unknown)|0
6169468|NCT01243424|9814839|FG001|Discontinuation From Study (Treated Set)|Site Closure (Status Unknown)|1
6169469|NCT01243424|9814838|FG000|Discontinuation From Study (Treated Set)|LostToFollowUpfor3P-MACE(StatusAlive)|38
6169470|NCT01243424|9814839|FG001|Discontinuation From Study (Treated Set)|LostToFollowUpfor3P-MACE(StatusAlive)|35
6169471|NCT01243424|9814838|FG000|Discontinuation From Study (Treated Set)|LostToFollowUpfor3P-MACE(StatusUnknown)|8
6169472|NCT01243424|9814839|FG001|Discontinuation From Study (Treated Set)|LostToFollowUpfor3P-MACE(StatusUnknown)|8
6169473|NCT01243424|9814838|FG000|Discontinuation From Study (Treated Set)|Not treated|5
6169474|NCT01243424|9814839|FG001|Discontinuation From Study (Treated Set)|Not treated|4
6169475|NCT01243424|9814838|FG000|Discontinuation From Treatment|Not treated|5
6169476|NCT01243424|9814839|FG001|Discontinuation From Treatment|Not treated|4
6169477|NCT01243424|9814838|FG000|Discontinuation From Treatment|Adverse Event|457
6169478|NCT01243424|9814839|FG001|Discontinuation From Treatment|Adverse Event|523
6169479|NCT01243424|9814838|FG000|Discontinuation From Treatment|Lack of Efficacy|61
6169480|NCT01243424|9814839|FG001|Discontinuation From Treatment|Lack of Efficacy|41
6169481|NCT01243424|9814838|FG000|Discontinuation From Treatment|Protocol Violation|46
6169482|NCT01243424|9814839|FG001|Discontinuation From Treatment|Protocol Violation|47
6169483|NCT01243424|9814838|FG000|Discontinuation From Treatment|Lost to Follow-up|24
6169484|NCT01243424|9814839|FG001|Discontinuation From Treatment|Lost to Follow-up|28
6169485|NCT01243424|9814838|FG000|Discontinuation From Treatment|Withdrawal by Subject|309
6169486|NCT01243424|9814839|FG001|Discontinuation From Treatment|Withdrawal by Subject|328
6169487|NCT01243424|9814838|FG000|Discontinuation From Treatment|Other than listed above|230
6169488|NCT01243424|9814839|FG001|Discontinuation From Treatment|Other than listed above|211
6192195|NCT01428661|9849313|FG000|Double-Masked Phase|Lost to Follow-up|14
6192196|NCT01428661|9849314|FG001|Double-Masked Phase|Lost to Follow-up|14
6192197|NCT01428661|9849315|FG002|Double-Masked Phase|Lost to Follow-up|0
6192198|NCT01428661|9849313|FG000|Double-Masked Phase|Withdrawal by Subject|18
6192199|NCT01428661|9849314|FG001|Double-Masked Phase|Withdrawal by Subject|20
6192200|NCT01428661|9849315|FG002|Double-Masked Phase|Withdrawal by Subject|0
6192201|NCT01428661|9849313|FG000|Double-Masked Phase|Lack of Efficacy|2
6192202|NCT01428661|9849314|FG001|Double-Masked Phase|Lack of Efficacy|1
6192203|NCT01428661|9849315|FG002|Double-Masked Phase|Lack of Efficacy|0
6192204|NCT01428661|9849313|FG000|Double-Masked Phase|*Various|1
6192205|NCT01428661|9849314|FG001|Double-Masked Phase|*Various|6
6348368|NCT03537651|10112090|FG000|Overall Study|Other|1
6348369|NCT03538431|10112109|FG000|Overall Study|Physician Decision|0
6348370|NCT03538431|10112110|FG001|Overall Study|Physician Decision|1
6348371|NCT03538431|10112109|FG000|Overall Study|Withdrawal by Subject|1
6348372|NCT03538431|10112110|FG001|Overall Study|Withdrawal by Subject|0
6348373|NCT03538743|10112136|FG000|Overall Study|Adverse Event|0
6348374|NCT03538743|10112137|FG001|Overall Study|Adverse Event|0
6348375|NCT03538743|10112138|FG002|Overall Study|Adverse Event|1
6348376|NCT03538743|10112139|FG003|Overall Study|Adverse Event|1
6348377|NCT03538743|10112140|FG004|Overall Study|Adverse Event|0
6348378|NCT03538743|10112141|FG005|Overall Study|Adverse Event|0
6348379|NCT03538743|10112142|FG006|Overall Study|Adverse Event|0
6348380|NCT03538743|10112143|FG007|Overall Study|Adverse Event|0
6348381|NCT03538743|10112144|FG008|Overall Study|Adverse Event|0
6169489|NCT01243671|9814892|FG000|Overall Study|Adverse Event|3
6169490|NCT01243671|9814892|FG000|Overall Study|Anti-adalimumab antibody positive|1
6169491|NCT01243671|9814892|FG000|Overall Study|Other|1
6169492|NCT01243762|9814903|FG000|Part 1 (Dose Escalation/MTD)|Adverse Event|0
6169493|NCT01243762|9814904|FG001|Part 1 (Dose Escalation/MTD)|Adverse Event|2
6169494|NCT01243762|9814905|FG002|Part 1 (Dose Escalation/MTD)|Adverse Event|0
6169495|NCT01243762|9814906|FG003|Part 1 (Dose Escalation/MTD)|Adverse Event|0
6169496|NCT01243762|9814907|FG004|Part 1 (Dose Escalation/MTD)|Adverse Event|1
6169497|NCT01243762|9814908|FG005|Part 1 (Dose Escalation/MTD)|Adverse Event|1
6169498|NCT01243762|9814909|FG006|Part 1 (Dose Escalation/MTD)|Adverse Event|0
6169499|NCT01243762|9814903|FG000|Part 1 (Dose Escalation/MTD)|Physician Decision|0
6169500|NCT01243762|9814904|FG001|Part 1 (Dose Escalation/MTD)|Physician Decision|1
6169501|NCT01243762|9814905|FG002|Part 1 (Dose Escalation/MTD)|Physician Decision|0
6169502|NCT01243762|9814906|FG003|Part 1 (Dose Escalation/MTD)|Physician Decision|1
6169503|NCT01243762|9814907|FG004|Part 1 (Dose Escalation/MTD)|Physician Decision|0
6169504|NCT01243762|9814908|FG005|Part 1 (Dose Escalation/MTD)|Physician Decision|0
6169505|NCT01243762|9814909|FG006|Part 1 (Dose Escalation/MTD)|Physician Decision|0
6169506|NCT01243762|9814903|FG000|Part 1 (Dose Escalation/MTD)|Progressive Disease|3
6169507|NCT01243762|9814904|FG001|Part 1 (Dose Escalation/MTD)|Progressive Disease|2
6169508|NCT01243762|9814905|FG002|Part 1 (Dose Escalation/MTD)|Progressive Disease|3
6169509|NCT01243762|9814906|FG003|Part 1 (Dose Escalation/MTD)|Progressive Disease|5
6169510|NCT01243762|9814907|FG004|Part 1 (Dose Escalation/MTD)|Progressive Disease|5
6169511|NCT01243762|9814908|FG005|Part 1 (Dose Escalation/MTD)|Progressive Disease|2
6169512|NCT01243762|9814909|FG006|Part 1 (Dose Escalation/MTD)|Progressive Disease|0
6169513|NCT01243762|9814903|FG000|Part 1 (Dose Escalation/MTD)|Withdrawal by Subject|0
6169514|NCT01243762|9814904|FG001|Part 1 (Dose Escalation/MTD)|Withdrawal by Subject|3
6169515|NCT01243762|9814905|FG002|Part 1 (Dose Escalation/MTD)|Withdrawal by Subject|0
6169516|NCT01243762|9814906|FG003|Part 1 (Dose Escalation/MTD)|Withdrawal by Subject|0
6169517|NCT01243762|9814907|FG004|Part 1 (Dose Escalation/MTD)|Withdrawal by Subject|0
6169518|NCT01243762|9814908|FG005|Part 1 (Dose Escalation/MTD)|Withdrawal by Subject|0
6169519|NCT01243762|9814909|FG006|Part 1 (Dose Escalation/MTD)|Withdrawal by Subject|0
6169520|NCT01243762|9814903|FG000|Part 2 (Dose Confirmation/Efficacy)|Adverse Event|0
6169521|NCT01243762|9814904|FG001|Part 2 (Dose Confirmation/Efficacy)|Adverse Event|1
6169522|NCT01243762|9814905|FG002|Part 2 (Dose Confirmation/Efficacy)|Adverse Event|0
6169523|NCT01243762|9814906|FG003|Part 2 (Dose Confirmation/Efficacy)|Adverse Event|0
6169524|NCT01243762|9814907|FG004|Part 2 (Dose Confirmation/Efficacy)|Adverse Event|0
6169525|NCT01243762|9814908|FG005|Part 2 (Dose Confirmation/Efficacy)|Adverse Event|0
6169526|NCT01243762|9814909|FG006|Part 2 (Dose Confirmation/Efficacy)|Adverse Event|3
6169527|NCT01243762|9814903|FG000|Part 2 (Dose Confirmation/Efficacy)|Progressive Disease|1
6169528|NCT01243762|9814904|FG001|Part 2 (Dose Confirmation/Efficacy)|Progressive Disease|3
6169529|NCT01243762|9814905|FG002|Part 2 (Dose Confirmation/Efficacy)|Progressive Disease|0
6169530|NCT01243762|9814906|FG003|Part 2 (Dose Confirmation/Efficacy)|Progressive Disease|1
6169531|NCT01243762|9814907|FG004|Part 2 (Dose Confirmation/Efficacy)|Progressive Disease|2
6169532|NCT01243762|9814908|FG005|Part 2 (Dose Confirmation/Efficacy)|Progressive Disease|0
6169533|NCT01243762|9814909|FG006|Part 2 (Dose Confirmation/Efficacy)|Progressive Disease|3
6169534|NCT01243762|9814903|FG000|Part 2 (Dose Confirmation/Efficacy)|Withdrawal by Subject|0
6169535|NCT01243762|9814904|FG001|Part 2 (Dose Confirmation/Efficacy)|Withdrawal by Subject|1
6169536|NCT01243762|9814905|FG002|Part 2 (Dose Confirmation/Efficacy)|Withdrawal by Subject|0
6169537|NCT01243762|9814906|FG003|Part 2 (Dose Confirmation/Efficacy)|Withdrawal by Subject|0
6169538|NCT01243762|9814907|FG004|Part 2 (Dose Confirmation/Efficacy)|Withdrawal by Subject|1
6169539|NCT01243762|9814908|FG005|Part 2 (Dose Confirmation/Efficacy)|Withdrawal by Subject|0
6169540|NCT01243762|9814909|FG006|Part 2 (Dose Confirmation/Efficacy)|Withdrawal by Subject|0
6169541|NCT01243762|9814903|FG000|Part 2 (Dose Confirmation/Efficacy)|Physician Decision|0
6169542|NCT01243762|9814904|FG001|Part 2 (Dose Confirmation/Efficacy)|Physician Decision|0
6169543|NCT01243762|9814905|FG002|Part 2 (Dose Confirmation/Efficacy)|Physician Decision|0
6169544|NCT01243762|9814906|FG003|Part 2 (Dose Confirmation/Efficacy)|Physician Decision|1
6169545|NCT01243762|9814907|FG004|Part 2 (Dose Confirmation/Efficacy)|Physician Decision|1
6169546|NCT01243762|9814908|FG005|Part 2 (Dose Confirmation/Efficacy)|Physician Decision|0
6169547|NCT01243762|9814909|FG006|Part 2 (Dose Confirmation/Efficacy)|Physician Decision|0
6169548|NCT01243775|9814928|FG000|Overall Study|Withdrawal by Subject|2
6348382|NCT03538743|10112136|FG000|Overall Study|Non-Treatment-Related Reasons|0
6348383|NCT03538743|10112137|FG001|Overall Study|Non-Treatment-Related Reasons|0
6348384|NCT03538743|10112138|FG002|Overall Study|Non-Treatment-Related Reasons|0
6348385|NCT03538743|10112139|FG003|Overall Study|Non-Treatment-Related Reasons|0
6348386|NCT03538743|10112140|FG004|Overall Study|Non-Treatment-Related Reasons|0
6348387|NCT03538743|10112141|FG005|Overall Study|Non-Treatment-Related Reasons|0
6169549|NCT01243944|9814934|FG000|Overall Study|Adverse Event|15
6169550|NCT01243944|9814935|FG001|Overall Study|Adverse Event|13
6169551|NCT01243944|9814934|FG000|Overall Study|Lost to Follow-up|2
6169552|NCT01243944|9814935|FG001|Overall Study|Lost to Follow-up|1
6169553|NCT01243944|9814934|FG000|Overall Study|Physician Decision|2
6169554|NCT01243944|9814935|FG001|Overall Study|Physician Decision|7
6169555|NCT01243944|9814934|FG000|Overall Study|Disease progression|12
6169556|NCT01243944|9814935|FG001|Overall Study|Disease progression|11
6169557|NCT01243944|9814934|FG000|Overall Study|Protocol deviation|1
6169558|NCT01243944|9814935|FG001|Overall Study|Protocol deviation|1
6169559|NCT01243944|9814934|FG000|Overall Study|Participant decision|10
6169560|NCT01243944|9814935|FG001|Overall Study|Participant decision|15
6169561|NCT01243944|9814934|FG000|Overall Study|Death|2
6169562|NCT01243944|9814935|FG001|Overall Study|Death|3
6169563|NCT01243944|9814934|FG000|Overall Study|Non-compliance with study treatment|1
6169564|NCT01243944|9814935|FG001|Overall Study|Non-compliance with study treatment|0
6169565|NCT01244035|9814948|FG000|Part 1: Period 1|Adverse Event|0
6169566|NCT01244035|9814949|FG001|Part 1: Period 1|Adverse Event|0
6169567|NCT01244035|9814950|FG002|Part 1: Period 1|Adverse Event|0
6169568|NCT01244035|9814951|FG003|Part 1: Period 1|Adverse Event|0
6169569|NCT01244035|9814952|FG004|Part 1: Period 1|Adverse Event|0
6169570|NCT01244035|9814953|FG005|Part 1: Period 1|Adverse Event|1
6169571|NCT01244035|9814948|FG000|Part 1: Period 1|Withdrawal by Subject|0
6169572|NCT01244035|9814949|FG001|Part 1: Period 1|Withdrawal by Subject|2
6169573|NCT01244035|9814950|FG002|Part 1: Period 1|Withdrawal by Subject|0
6169574|NCT01244035|9814951|FG003|Part 1: Period 1|Withdrawal by Subject|0
6169575|NCT01244035|9814952|FG004|Part 1: Period 1|Withdrawal by Subject|0
6169576|NCT01244035|9814953|FG005|Part 1: Period 1|Withdrawal by Subject|0
6169577|NCT01244035|9814948|FG000|Part 1: Period 1|Fulfilled Stopping Criteria|1
6169578|NCT01244035|9814949|FG001|Part 1: Period 1|Fulfilled Stopping Criteria|0
6169579|NCT01244035|9814950|FG002|Part 1: Period 1|Fulfilled Stopping Criteria|2
6169580|NCT01244035|9814951|FG003|Part 1: Period 1|Fulfilled Stopping Criteria|0
6169581|NCT01244035|9814952|FG004|Part 1: Period 1|Fulfilled Stopping Criteria|1
6169582|NCT01244035|9814953|FG005|Part 1: Period 1|Fulfilled Stopping Criteria|1
6169583|NCT01244035|9814948|FG000|Part 1: Period 2|Fulfilled Stopping Criteria|0
6169584|NCT01244035|9814949|FG001|Part 1: Period 2|Fulfilled Stopping Criteria|0
6169585|NCT01244035|9814950|FG002|Part 1: Period 2|Fulfilled Stopping Criteria|1
6169586|NCT01244035|9814951|FG003|Part 1: Period 2|Fulfilled Stopping Criteria|0
6169587|NCT01244035|9814952|FG004|Part 1: Period 2|Fulfilled Stopping Criteria|0
6169588|NCT01244035|9814953|FG005|Part 1: Period 2|Fulfilled Stopping Criteria|0
6169589|NCT01244035|9814948|FG000|Part 1: Period 3|Adverse Event|0
6169590|NCT01244035|9814949|FG001|Part 1: Period 3|Adverse Event|0
6169591|NCT01244035|9814950|FG002|Part 1: Period 3|Adverse Event|0
6169592|NCT01244035|9814951|FG003|Part 1: Period 3|Adverse Event|0
6169593|NCT01244035|9814952|FG004|Part 1: Period 3|Adverse Event|0
6169594|NCT01244035|9814953|FG005|Part 1: Period 3|Adverse Event|1
6169595|NCT01244035|9814948|FG000|Part 1: Period 3|Withdrawal by Subject|0
6169596|NCT01244035|9814949|FG001|Part 1: Period 3|Withdrawal by Subject|0
6169597|NCT01244035|9814950|FG002|Part 1: Period 3|Withdrawal by Subject|0
6169598|NCT01244035|9814951|FG003|Part 1: Period 3|Withdrawal by Subject|0
6169599|NCT01244035|9814952|FG004|Part 1: Period 3|Withdrawal by Subject|1
6169600|NCT01244035|9814953|FG005|Part 1: Period 3|Withdrawal by Subject|0
6169601|NCT01244035|9814948|FG000|Part 1: Period 3|Protocol Deviation|0
6169602|NCT01244035|9814949|FG001|Part 1: Period 3|Protocol Deviation|1
6169603|NCT01244035|9814950|FG002|Part 1: Period 3|Protocol Deviation|0
6169604|NCT01244035|9814951|FG003|Part 1: Period 3|Protocol Deviation|0
6169605|NCT01244035|9814952|FG004|Part 1: Period 3|Protocol Deviation|0
6169606|NCT01244035|9814953|FG005|Part 1: Period 3|Protocol Deviation|0
6169607|NCT01244061|9814975|FG000|Overall Study|Death|1
6169608|NCT01244061|9814976|FG001|Overall Study|Death|0
6169609|NCT01244061|9814975|FG000|Overall Study|Did not meet entrance criteria|1
6169610|NCT01244061|9814976|FG001|Overall Study|Did not meet entrance criteria|0
6169611|NCT01244061|9814975|FG000|Overall Study|Lack of Efficacy|1
6169612|NCT01244061|9814976|FG001|Overall Study|Lack of Efficacy|3
6169613|NCT01244061|9814975|FG000|Overall Study|Lost to Follow-up|34
6169614|NCT01244061|9814976|FG001|Overall Study|Lost to Follow-up|30
6169615|NCT01244061|9814975|FG000|Overall Study|Withdrawal by Subject|29
6169616|NCT01244061|9814976|FG001|Overall Study|Withdrawal by Subject|46
6169617|NCT01244061|9814975|FG000|Overall Study|Other|8
6169618|NCT01244061|9814976|FG001|Overall Study|Other|19
6348388|NCT03538743|10112142|FG006|Overall Study|Non-Treatment-Related Reasons|0
6348389|NCT03538743|10112143|FG007|Overall Study|Non-Treatment-Related Reasons|0
6169619|NCT01244061|9814975|FG000|Overall Study|Protocol Violation|1
6169620|NCT01244061|9814976|FG001|Overall Study|Protocol Violation|1
6169621|NCT01244061|9814975|FG000|Overall Study|Adverse Event|5
6169622|NCT01244061|9814976|FG001|Overall Study|Adverse Event|2
6169623|NCT01244061|9814975|FG000|Overall Study|Randomized but not treated|2
6169624|NCT01244061|9814976|FG001|Overall Study|Randomized but not treated|2
6169625|NCT01244126|9814985|FG000|Overall Study|Protocol Violation|3
6169626|NCT01244126|9814986|FG001|Overall Study|Protocol Violation|3
6169627|NCT01244126|9814987|FG002|Overall Study|Protocol Violation|9
6169628|NCT01244191|9814997|FG000|Overall Study|Progressive disease|295
6169629|NCT01244191|9814998|FG001|Overall Study|Progressive disease|350
6169630|NCT01244191|9814997|FG000|Overall Study|Clinical disease progression|54
6169631|NCT01244191|9814998|FG001|Overall Study|Clinical disease progression|36
6169632|NCT01244191|9814997|FG000|Overall Study|Adverse Event|65
6169633|NCT01244191|9814998|FG001|Overall Study|Adverse Event|48
6169634|NCT01244191|9814997|FG000|Overall Study|Death|22
6169635|NCT01244191|9814998|FG001|Overall Study|Death|29
6169636|NCT01244191|9814997|FG000|Overall Study|Lost to Follow-up|0
6169637|NCT01244191|9814998|FG001|Overall Study|Lost to Follow-up|2
6169638|NCT01244191|9814997|FG000|Overall Study|Protocol Violation|1
6169639|NCT01244191|9814998|FG001|Overall Study|Protocol Violation|2
6169640|NCT01244191|9814997|FG000|Overall Study|Withdrawal by Subject|31
6169641|NCT01244191|9814998|FG001|Overall Study|Withdrawal by Subject|23
6169642|NCT01244191|9814997|FG000|Overall Study|'Missing' or 'Terminated by sponsor'|12
6169643|NCT01244191|9814998|FG001|Overall Study|'Missing' or 'Terminated by sponsor'|8
6169644|NCT01244425|9815014|FG000|Overall Study|Withdrawal by Subject|2
6169645|NCT01244425|9815015|FG001|Overall Study|Withdrawal by Subject|2
6169646|NCT01244425|9815014|FG000|Overall Study|Adverse Event|1
6169647|NCT01244425|9815015|FG001|Overall Study|Adverse Event|1
6169648|NCT01244490|9815048|FG000|Overall Study|Lack of Efficacy|14
6169649|NCT01244490|9815049|FG001|Overall Study|Lack of Efficacy|5
6169650|NCT01244490|9815050|FG002|Overall Study|Lack of Efficacy|5
6169651|NCT01244490|9815048|FG000|Overall Study|Withdrawal by Subject|4
6169652|NCT01244490|9815049|FG001|Overall Study|Withdrawal by Subject|4
6169653|NCT01244490|9815050|FG002|Overall Study|Withdrawal by Subject|9
6169654|NCT01244490|9815048|FG000|Overall Study|Adverse Event|1
6169655|NCT01244490|9815049|FG001|Overall Study|Adverse Event|9
6169656|NCT01244490|9815050|FG002|Overall Study|Adverse Event|5
6169657|NCT01244490|9815048|FG000|Overall Study|Lost to Follow-up|0
6169658|NCT01244490|9815049|FG001|Overall Study|Lost to Follow-up|6
6169659|NCT01244490|9815050|FG002|Overall Study|Lost to Follow-up|3
6169660|NCT01244490|9815048|FG000|Overall Study|Other|0
6169661|NCT01244490|9815049|FG001|Overall Study|Other|0
6169662|NCT01244490|9815050|FG002|Overall Study|Other|1
6169663|NCT01244516|9815065|FG000|Period 1 (Baseline to 1-week Visit)|Protocol Violation|4
6169664|NCT01244516|9815066|FG001|Period 1 (Baseline to 1-week Visit)|Protocol Violation|5
6169665|NCT01244516|9815067|FG002|Period 1 (Baseline to 1-week Visit)|Protocol Violation|2
6169666|NCT01244516|9815065|FG000|Period 1 (Baseline to 1-week Visit)|Poor Vision|0
6169667|NCT01244516|9815066|FG001|Period 1 (Baseline to 1-week Visit)|Poor Vision|1
6169668|NCT01244516|9815067|FG002|Period 1 (Baseline to 1-week Visit)|Poor Vision|0
6169669|NCT01244516|9815065|FG000|Period 1 (Baseline to 1-week Visit)|Poor comfort|0
6169670|NCT01244516|9815066|FG001|Period 1 (Baseline to 1-week Visit)|Poor comfort|0
6169671|NCT01244516|9815067|FG002|Period 1 (Baseline to 1-week Visit)|Poor comfort|1
6169672|NCT01244516|9815065|FG000|Period 2 (1-week to 2-week Visit)|Adverse Event|2
6169673|NCT01244516|9815066|FG001|Period 2 (1-week to 2-week Visit)|Adverse Event|0
6169674|NCT01244516|9815067|FG002|Period 2 (1-week to 2-week Visit)|Adverse Event|0
6169675|NCT01244516|9815065|FG000|Period 2 (1-week to 2-week Visit)|Protocol Violation|1
6169676|NCT01244516|9815066|FG001|Period 2 (1-week to 2-week Visit)|Protocol Violation|0
6169677|NCT01244516|9815067|FG002|Period 2 (1-week to 2-week Visit)|Protocol Violation|1
6169678|NCT01244516|9815065|FG000|Period 2 (1-week to 2-week Visit)|Lost to Follow-up|0
6169679|NCT01244516|9815066|FG001|Period 2 (1-week to 2-week Visit)|Lost to Follow-up|1
6169680|NCT01244516|9815067|FG002|Period 2 (1-week to 2-week Visit)|Lost to Follow-up|0
6169681|NCT01244516|9815065|FG000|Period 2 (1-week to 2-week Visit)|Poor Comfort|0
6169682|NCT01244516|9815066|FG001|Period 2 (1-week to 2-week Visit)|Poor Comfort|0
6169683|NCT01244516|9815067|FG002|Period 2 (1-week to 2-week Visit)|Poor Comfort|1
6169684|NCT01244893|9815104|FG000|Baseline|Protocol Violation|0
6169685|NCT01244893|9815105|FG001|Baseline|Protocol Violation|1
6169686|NCT01244893|9815104|FG000|1-Week Follow Up|Lost to Follow-up|1
6169687|NCT01244893|9815105|FG001|1-Week Follow Up|Lost to Follow-up|0
6169688|NCT01244906|9815116|FG000|Overall Study|Death|2
6169689|NCT01244906|9815116|FG000|Overall Study|Progression of disease post treatment|6
6169690|NCT01244984|9815123|FG000|Overall Study|Adverse Event|2
6169691|NCT01244984|9815124|FG001|Overall Study|Adverse Event|11
6169692|NCT01244984|9815125|FG002|Overall Study|Adverse Event|2
6169693|NCT01244984|9815123|FG000|Overall Study|Protocol Violation|1
6169694|NCT01244984|9815124|FG001|Overall Study|Protocol Violation|0
6169695|NCT01244984|9815125|FG002|Overall Study|Protocol Violation|0
6169696|NCT01244984|9815123|FG000|Overall Study|Protocol Defined Stopping Criteria|1
6169697|NCT01244984|9815124|FG001|Overall Study|Protocol Defined Stopping Criteria|1
6169698|NCT01244984|9815125|FG002|Overall Study|Protocol Defined Stopping Criteria|0
6169699|NCT01244984|9815123|FG000|Overall Study|Withdrawal by Subject|1
6169700|NCT01244984|9815124|FG001|Overall Study|Withdrawal by Subject|2
6169701|NCT01244984|9815125|FG002|Overall Study|Withdrawal by Subject|2
6169702|NCT01245049|9815136|FG000|Overall Study|Migrated/moved from study area|0
6169703|NCT01245049|9815137|FG001|Overall Study|Migrated/moved from study area|1
6169704|NCT01245049|9815136|FG000|Overall Study|Withdrawal by Subject|0
6169705|NCT01245049|9815137|FG001|Overall Study|Withdrawal by Subject|1
6348390|NCT03538743|10112144|FG008|Overall Study|Non-Treatment-Related Reasons|3
6348391|NCT03538743|10112136|FG000|Overall Study|Withdrawal by Subject|0
6169706|NCT01245049|9815136|FG000|Overall Study|Lost to Follow-up|1
6169707|NCT01245049|9815137|FG001|Overall Study|Lost to Follow-up|2
6169708|NCT01245062|9815145|FG000|Randomization and Crossover Phase|Lost to Follow-up|4
6169709|NCT01245062|9815146|FG001|Randomization and Crossover Phase|Lost to Follow-up|2
6169710|NCT01245062|9815147|FG002|Randomization and Crossover Phase|Lost to Follow-up|0
6169711|NCT01245062|9815145|FG000|Randomization and Crossover Phase|Physician Decision|2
6169712|NCT01245062|9815146|FG001|Randomization and Crossover Phase|Physician Decision|4
6169713|NCT01245062|9815147|FG002|Randomization and Crossover Phase|Physician Decision|0
6169714|NCT01245062|9815145|FG000|Randomization and Crossover Phase|Withdrew Consent|12
6169715|NCT01245062|9815146|FG001|Randomization and Crossover Phase|Withdrew Consent|11
6169716|NCT01245062|9815147|FG002|Randomization and Crossover Phase|Withdrew Consent|0
6169717|NCT01245062|9815145|FG000|Randomization and Crossover Phase|Study closed/ terminated|23
6169718|NCT01245062|9815146|FG001|Randomization and Crossover Phase|Study closed/ terminated|14
6169719|NCT01245062|9815147|FG002|Randomization and Crossover Phase|Study closed/ terminated|0
6169720|NCT01245062|9815145|FG000|Cross-over Phase|Lost to Follow-up|0
6169721|NCT01245062|9815146|FG001|Cross-over Phase|Lost to Follow-up|0
6169722|NCT01245062|9815147|FG002|Cross-over Phase|Lost to Follow-up|1
6169723|NCT01245062|9815145|FG000|Cross-over Phase|Physician Decision|0
6169724|NCT01245062|9815146|FG001|Cross-over Phase|Physician Decision|0
6169725|NCT01245062|9815147|FG002|Cross-over Phase|Physician Decision|1
6169726|NCT01245062|9815145|FG000|Cross-over Phase|Withdrew Consent|0
6169727|NCT01245062|9815146|FG001|Cross-over Phase|Withdrew Consent|0
6169728|NCT01245062|9815147|FG002|Cross-over Phase|Withdrew Consent|4
6169729|NCT01245062|9815145|FG000|Cross-over Phase|Study closed/ terminated|0
6169730|NCT01245062|9815146|FG001|Cross-over Phase|Study closed/ terminated|0
6169731|NCT01245062|9815147|FG002|Cross-over Phase|Study closed/ terminated|11
6169732|NCT01245101|9815157|FG000|Period 1 (Treatment)|Withdrawal by Subject|2
6169733|NCT01245101|9815158|FG001|Period 1 (Treatment)|Withdrawal by Subject|0
6169734|NCT01245101|9815157|FG000|Period 2 (Washout)|Withdrawal by Subject|1
6169735|NCT01245101|9815158|FG001|Period 2 (Washout)|Withdrawal by Subject|0
6169736|NCT01245101|9815157|FG000|Period 3 (Treatment)|Withdrawal by Subject|1
6169737|NCT01245101|9815158|FG001|Period 3 (Treatment)|Withdrawal by Subject|0
6169738|NCT01245140|9815166|FG000|Overall Study|Adverse Event|1
6169739|NCT01245140|9815167|FG001|Overall Study|Adverse Event|3
6169740|NCT01245140|9815166|FG000|Overall Study|Lack of Efficacy|2
6169741|NCT01245140|9815167|FG001|Overall Study|Lack of Efficacy|4
6169742|NCT01245140|9815166|FG000|Overall Study|Protocol Violation|0
6169743|NCT01245140|9815167|FG001|Overall Study|Protocol Violation|1
6169744|NCT01245140|9815166|FG000|Overall Study|Withdrawal by Subject|0
6169745|NCT01245140|9815167|FG001|Overall Study|Withdrawal by Subject|1
6169746|NCT01245140|9815166|FG000|Overall Study|Refused Treatment/Did Not Coopera|0
6169747|NCT01245140|9815167|FG001|Overall Study|Refused Treatment/Did Not Coopera|1
6169748|NCT01245283|9815187|FG000|Overall Study|Lost to Follow-up|14
6169749|NCT01245283|9815188|FG001|Overall Study|Lost to Follow-up|11
6169750|NCT01245283|9815189|FG002|Overall Study|Lost to Follow-up|11
6169751|NCT01245374|9815200|FG000|Overall Study|Protocol Violation|1
6169752|NCT01245374|9815200|FG000|Overall Study|Withdrawal by Subject|3
6169753|NCT01245387|9815205|FG000|Overall Study|Lost to Follow-up|106
6169754|NCT01245387|9815205|FG000|Overall Study|Lack of Efficacy|195
6169755|NCT01245387|9815205|FG000|Overall Study|Adverse Event|9
6169756|NCT01245387|9815205|FG000|Overall Study|Death|3
6169757|NCT01245387|9815205|FG000|Overall Study|Other|131
6169758|NCT01245387|9815205|FG000|Overall Study|Missing discontinuation status|369
6169759|NCT01245673|9815240|FG000|MAGE-A3, Hiltonol®, PVC After T Cells|Off Study due to Disease Progression|1
6169760|NCT01245751|9815262|FG000|Part 1: Day 1 to Week 52 (1 Year)|Death|2
6169761|NCT01245751|9815263|FG001|Part 1: Day 1 to Week 52 (1 Year)|Death|1
6169762|NCT01245751|9815264|FG002|Part 1: Day 1 to Week 52 (1 Year)|Death|0
6169763|NCT01245751|9815265|FG003|Part 1: Day 1 to Week 52 (1 Year)|Death|0
6169764|NCT01245751|9815262|FG000|Part 1: Day 1 to Week 52 (1 Year)|Lost to Follow-up|0
6169765|NCT01245751|9815263|FG001|Part 1: Day 1 to Week 52 (1 Year)|Lost to Follow-up|0
6169766|NCT01245751|9815264|FG002|Part 1: Day 1 to Week 52 (1 Year)|Lost to Follow-up|0
6169767|NCT01245751|9815265|FG003|Part 1: Day 1 to Week 52 (1 Year)|Lost to Follow-up|2
6169768|NCT01245751|9815262|FG000|Part 1: Day 1 to Week 52 (1 Year)|Withdrawal by Subject|0
6169769|NCT01245751|9815263|FG001|Part 1: Day 1 to Week 52 (1 Year)|Withdrawal by Subject|4
6169770|NCT01245751|9815264|FG002|Part 1: Day 1 to Week 52 (1 Year)|Withdrawal by Subject|0
6169771|NCT01245751|9815265|FG003|Part 1: Day 1 to Week 52 (1 Year)|Withdrawal by Subject|0
6169772|NCT01245764|9815280|FG000|Study Phase A|Other|3
6169773|NCT01245764|9815281|FG001|Study Phase A|Other|2
6169774|NCT01245764|9815282|FG002|Study Phase A|Other|3
6169775|NCT01245764|9815283|FG003|Study Phase A|Other|1
6169776|NCT01245764|9815280|FG000|Study Phase A|Protocol Violation|6
6169777|NCT01245764|9815281|FG001|Study Phase A|Protocol Violation|3
6348392|NCT03538743|10112137|FG001|Overall Study|Withdrawal by Subject|0
6169778|NCT01245764|9815282|FG002|Study Phase A|Protocol Violation|2
6169779|NCT01245764|9815283|FG003|Study Phase A|Protocol Violation|2
6169780|NCT01245764|9815280|FG000|Study Phase A|Lost to Follow-up|0
6169781|NCT01245764|9815281|FG001|Study Phase A|Lost to Follow-up|0
6348393|NCT03538743|10112138|FG002|Overall Study|Withdrawal by Subject|0
6348394|NCT03538743|10112139|FG003|Overall Study|Withdrawal by Subject|1
6348395|NCT03538743|10112140|FG004|Overall Study|Withdrawal by Subject|0
6348396|NCT03538743|10112141|FG005|Overall Study|Withdrawal by Subject|0
6348397|NCT03538743|10112142|FG006|Overall Study|Withdrawal by Subject|0
6348398|NCT03538743|10112143|FG007|Overall Study|Withdrawal by Subject|0
6348399|NCT03538743|10112144|FG008|Overall Study|Withdrawal by Subject|0
6348400|NCT03539432|10112204|FG000|Overall Study|Lost to Follow-up|0
6348401|NCT03539432|10112205|FG001|Overall Study|Lost to Follow-up|1
6348402|NCT03539484|10112218|FG000|Overall Study|Death|1
6348403|NCT03539484|10112219|FG001|Overall Study|Death|0
6348404|NCT03539484|10112220|FG002|Overall Study|Death|0
6348405|NCT03539484|10112221|FG003|Overall Study|Death|2
6348406|NCT03539484|10112222|FG004|Overall Study|Death|8
6348407|NCT03539484|10112223|FG005|Overall Study|Death|3
6348408|NCT03539484|10112224|FG006|Overall Study|Death|0
6348409|NCT03539484|10112218|FG000|Overall Study|Lost to Follow-up|0
6348410|NCT03539484|10112219|FG001|Overall Study|Lost to Follow-up|1
6348411|NCT03539484|10112220|FG002|Overall Study|Lost to Follow-up|0
6348412|NCT03539484|10112221|FG003|Overall Study|Lost to Follow-up|0
6348413|NCT03539484|10112222|FG004|Overall Study|Lost to Follow-up|1
6348414|NCT03539484|10112223|FG005|Overall Study|Lost to Follow-up|0
6348415|NCT03539484|10112224|FG006|Overall Study|Lost to Follow-up|0
6348416|NCT03539484|10112218|FG000|Overall Study|Withdrawal by Subject|0
6348417|NCT03539484|10112219|FG001|Overall Study|Withdrawal by Subject|0
6348418|NCT03539484|10112220|FG002|Overall Study|Withdrawal by Subject|0
6348419|NCT03539484|10112221|FG003|Overall Study|Withdrawal by Subject|0
6348420|NCT03539484|10112222|FG004|Overall Study|Withdrawal by Subject|2
6348421|NCT03539484|10112223|FG005|Overall Study|Withdrawal by Subject|0
6348422|NCT03539484|10112224|FG006|Overall Study|Withdrawal by Subject|1
6348423|NCT03539484|10112218|FG000|Overall Study|Study Terminated by Sponsor|0
6348424|NCT03539484|10112219|FG001|Overall Study|Study Terminated by Sponsor|0
6348425|NCT03539484|10112220|FG002|Overall Study|Study Terminated by Sponsor|1
6348426|NCT03539484|10112221|FG003|Overall Study|Study Terminated by Sponsor|1
6169782|NCT01245764|9815282|FG002|Study Phase A|Lost to Follow-up|5
6169783|NCT01245764|9815283|FG003|Study Phase A|Lost to Follow-up|0
6169784|NCT01246206|9815356|FG000|Overall Study|Patient did not receive study regiments.|1
6169785|NCT01246466|9815385|FG000|Overall Study|Death|1
6169786|NCT01246466|9815385|FG000|Overall Study|Withdrawal by Subject|1
6169787|NCT01246583|9815398|FG000|Overall Study|Lost to Follow-up|0
6169788|NCT01246583|9815399|FG001|Overall Study|Lost to Follow-up|0
6169789|NCT01246583|9815400|FG002|Overall Study|Lost to Follow-up|0
6169790|NCT01246583|9815401|FG003|Overall Study|Lost to Follow-up|1
6169791|NCT01246583|9815398|FG000|Overall Study|Protocol Violation|0
6169792|NCT01246583|9815399|FG001|Overall Study|Protocol Violation|0
6169793|NCT01246583|9815400|FG002|Overall Study|Protocol Violation|1
6169794|NCT01246583|9815401|FG003|Overall Study|Protocol Violation|0
6169795|NCT01246583|9815398|FG000|Overall Study|Withdrawal by Subject|1
6169796|NCT01246583|9815399|FG001|Overall Study|Withdrawal by Subject|0
6169797|NCT01246583|9815400|FG002|Overall Study|Withdrawal by Subject|0
6169798|NCT01246583|9815401|FG003|Overall Study|Withdrawal by Subject|0
6169799|NCT01246960|9815436|FG000|Overall Study|Lost to Follow-up|3
6169800|NCT01246960|9815437|FG001|Overall Study|Lost to Follow-up|1
6169801|NCT01246960|9815436|FG000|Overall Study|Withdrawal (by participant or physician)|3
6169802|NCT01246960|9815437|FG001|Overall Study|Withdrawal (by participant or physician)|3
6169803|NCT01246973|9815445|FG000|Overall Study|Other|38
6169804|NCT01246973|9815446|FG001|Overall Study|Other|25
6169805|NCT01246973|9815445|FG000|Overall Study|Adverse Event|16
6169806|NCT01246973|9815446|FG001|Overall Study|Adverse Event|9
6169807|NCT01246973|9815445|FG000|Overall Study|Withdrawal by Subject|7
6169808|NCT01246973|9815446|FG001|Overall Study|Withdrawal by Subject|13
6169809|NCT01246986|9815459|FG000|Overall Study|Lost to Follow-up|0
6169810|NCT01246986|9815460|FG001|Overall Study|Lost to Follow-up|1
6169811|NCT01246986|9815461|FG002|Overall Study|Lost to Follow-up|3
6169812|NCT01246986|9815462|FG003|Overall Study|Lost to Follow-up|0
6169813|NCT01246986|9815463|FG004|Overall Study|Lost to Follow-up|0
6169814|NCT01246986|9815464|FG005|Overall Study|Lost to Follow-up|1
6169815|NCT01246986|9815465|FG006|Overall Study|Lost to Follow-up|0
6169816|NCT01246986|9815459|FG000|Overall Study|Withdrawal by Subject|3
6169817|NCT01246986|9815460|FG001|Overall Study|Withdrawal by Subject|4
6348427|NCT03539484|10112222|FG004|Overall Study|Study Terminated by Sponsor|2
6348428|NCT03539484|10112223|FG005|Overall Study|Study Terminated by Sponsor|2
6348429|NCT03539484|10112224|FG006|Overall Study|Study Terminated by Sponsor|1
6348430|NCT03539549|10112245|FG000|Overall Study|Adverse Event|12
6169818|NCT01246986|9815461|FG002|Overall Study|Withdrawal by Subject|3
6169819|NCT01246986|9815462|FG003|Overall Study|Withdrawal by Subject|0
6169820|NCT01246986|9815463|FG004|Overall Study|Withdrawal by Subject|4
6169821|NCT01246986|9815464|FG005|Overall Study|Withdrawal by Subject|0
6169822|NCT01246986|9815465|FG006|Overall Study|Withdrawal by Subject|0
6348431|NCT03539549|10112245|FG000|Overall Study|Lost to Follow-up|1
6348432|NCT03539549|10112245|FG000|Overall Study|Death|2
6348433|NCT03539549|10112245|FG000|Overall Study|Progressive Disease|1
6169823|NCT01246999|9815500|FG000|Overall Study|Lost to Follow-up|0
6169824|NCT01246999|9815501|FG001|Overall Study|Lost to Follow-up|1
6169825|NCT01246999|9815502|FG002|Overall Study|Lost to Follow-up|0
6348434|NCT03539549|10112245|FG000|Overall Study|Reason not Specified|1
6348435|NCT03540030|10112251|FG000|Overall Study|Withdrawal by Subject|2
6348436|NCT03540030|10112252|FG001|Overall Study|Withdrawal by Subject|1
6348437|NCT03540030|10112251|FG000|Overall Study|screen fail|7
6348438|NCT03540030|10112252|FG001|Overall Study|screen fail|1
6348439|NCT03540030|10112251|FG000|Overall Study|never had surgery after signing consent|9
6348440|NCT03540030|10112252|FG001|Overall Study|never had surgery after signing consent|1
6348441|NCT03540160|10112274|FG000|Overall Study|Protocol Violation|1
6348442|NCT03540160|10112274|FG000|Overall Study|Physician Decision|8
6348443|NCT03540160|10112274|FG000|Overall Study|Lack of Efficacy|60
6348444|NCT03540160|10112274|FG000|Overall Study|Pregnancy|1
6348445|NCT03540160|10112274|FG000|Overall Study|Adverse Event|20
6348446|NCT03540160|10112274|FG000|Overall Study|Withdrawal by Subject|68
6348447|NCT03540160|10112274|FG000|Overall Study|COVID-19|2
6348448|NCT03540160|10112274|FG000|Overall Study|Study Closure|10
6348449|NCT03540160|10112274|FG000|Overall Study|Lost to Follow-up|18
6348450|NCT03540160|10112274|FG000|Overall Study|Sponsor decision|191
6348451|NCT03541044|10112278|FG000|Study Period 2: Up to Day 8|Protocol Violation|1
6169826|NCT01246999|9815503|FG003|Overall Study|Lost to Follow-up|0
6169827|NCT01246999|9815500|FG000|Overall Study|Withdrawal by Subject|0
6169828|NCT01246999|9815501|FG001|Overall Study|Withdrawal by Subject|0
6169829|NCT01246999|9815502|FG002|Overall Study|Withdrawal by Subject|0
6169830|NCT01246999|9815503|FG003|Overall Study|Withdrawal by Subject|2
6169831|NCT01247090|9815528|FG000|Overall Study|Physician Decision|1
6169832|NCT01247090|9815529|FG001|Overall Study|Physician Decision|0
6169833|NCT01247090|9815530|FG002|Overall Study|Physician Decision|0
6169834|NCT01247090|9815528|FG000|Overall Study|Withdrawal by Subject|0
6169835|NCT01247090|9815529|FG001|Overall Study|Withdrawal by Subject|1
6169836|NCT01247090|9815530|FG002|Overall Study|Withdrawal by Subject|0
6169837|NCT01247350|9815575|FG000|Overall Study|Adverse Event|0
6169838|NCT01247350|9815576|FG001|Overall Study|Adverse Event|0
6169839|NCT01247350|9815577|FG002|Overall Study|Adverse Event|1
6169840|NCT01247350|9815578|FG003|Overall Study|Adverse Event|0
6169841|NCT01247350|9815579|FG004|Overall Study|Adverse Event|0
6169842|NCT01247350|9815575|FG000|Overall Study|Withdrawal by Subject|0
6169843|NCT01247350|9815576|FG001|Overall Study|Withdrawal by Subject|0
6169844|NCT01247350|9815577|FG002|Overall Study|Withdrawal by Subject|0
6169845|NCT01247350|9815578|FG003|Overall Study|Withdrawal by Subject|1
6169846|NCT01247350|9815579|FG004|Overall Study|Withdrawal by Subject|0
6169847|NCT01247350|9815575|FG000|Overall Study|Entry criteria not met|0
6169848|NCT01247350|9815576|FG001|Overall Study|Entry criteria not met|0
6169849|NCT01247350|9815577|FG002|Overall Study|Entry criteria not met|0
6169850|NCT01247350|9815578|FG003|Overall Study|Entry criteria not met|0
6169851|NCT01247350|9815579|FG004|Overall Study|Entry criteria not met|1
6169852|NCT01247922|9815647|FG000|Overall Study|Disease progression|4
6169853|NCT01248013|9815660|FG000|Overall Study|Withdrawal by Subject|14
6169854|NCT01248065|9815666|FG000|Overall Study|Lost to Follow-up|3
6169855|NCT01248065|9815667|FG001|Overall Study|Lost to Follow-up|5
6169856|NCT01248065|9815666|FG000|Overall Study|Withdrawal by Subject|14
6169857|NCT01248065|9815667|FG001|Overall Study|Withdrawal by Subject|11
6169858|NCT01248065|9815666|FG000|Overall Study|Adverse Event|3
6169859|NCT01248065|9815667|FG001|Overall Study|Adverse Event|0
6169860|NCT01248065|9815666|FG000|Overall Study|Third treatment failure event|3
6169861|NCT01248065|9815667|FG001|Overall Study|Third treatment failure event|1
6169862|NCT01248065|9815666|FG000|Overall Study|Other|3
6169863|NCT01248065|9815667|FG001|Overall Study|Other|5
6169864|NCT01248364|9815697|FG000|Overall Study|Adverse Event|0
6169865|NCT01248364|9815698|FG001|Overall Study|Adverse Event|1
6169866|NCT01248364|9815699|FG002|Overall Study|Adverse Event|0
6169867|NCT01248364|9815700|FG003|Overall Study|Adverse Event|0
6169868|NCT01248455|9815725|FG000|Overall Study|switched to alternate treatment|1
6169869|NCT01248468|9815732|FG000|Overall Study|Administrative problem|1
6169870|NCT01248468|9815733|FG001|Overall Study|Administrative problem|0
6169871|NCT01248468|9815734|FG002|Overall Study|Administrative problem|0
6169872|NCT01248468|9815732|FG000|Overall Study|Lost to Follow-up|9
6169873|NCT01248468|9815733|FG001|Overall Study|Lost to Follow-up|12
6169874|NCT01248468|9815734|FG002|Overall Study|Lost to Follow-up|4
6169875|NCT01248468|9815732|FG000|Overall Study|Pregnancy|1
6169876|NCT01248468|9815733|FG001|Overall Study|Pregnancy|0
6169877|NCT01248468|9815734|FG002|Overall Study|Pregnancy|0
6169878|NCT01248468|9815732|FG000|Overall Study|Withdrawal by Subject|4
6169879|NCT01248468|9815733|FG001|Overall Study|Withdrawal by Subject|2
6348452|NCT03541044|10112279|FG001|Study Period 2: Up to Day 8|Protocol Violation|0
6348453|NCT03541044|10112278|FG000|Study Period 2: Up to Day 8|Withdrawal by Subject|1
6169880|NCT01248468|9815734|FG002|Overall Study|Withdrawal by Subject|0
6169881|NCT01248715|9815753|FG000|Overall Study|Not influenza positive|501
6169882|NCT01248715|9815754|FG001|Overall Study|Not influenza positive|510
6169883|NCT01248728|9815762|FG000|Overall Study|Adverse Event|1
6169884|NCT01248728|9815763|FG001|Overall Study|Adverse Event|1
6169885|NCT01248728|9815762|FG000|Overall Study|Withdrawal by Subject|2
6169886|NCT01248728|9815763|FG001|Overall Study|Withdrawal by Subject|1
6169887|NCT01248728|9815762|FG000|Overall Study|Lack of Efficacy|1
6169888|NCT01248728|9815763|FG001|Overall Study|Lack of Efficacy|0
6348454|NCT03541044|10112279|FG001|Study Period 2: Up to Day 8|Withdrawal by Subject|0
6348455|NCT03543137|10112379|FG000|Study Period 2: Up to Day 8|Withdrawal by Subject|1
6348456|NCT03543137|10112380|FG001|Study Period 2: Up to Day 8|Withdrawal by Subject|0
6348457|NCT03543137|10112379|FG000|Study Period 2: Up to Day 8|Protocol Violation|1
6348458|NCT03543137|10112380|FG001|Study Period 2: Up to Day 8|Protocol Violation|0
6348459|NCT03543137|10112379|FG000|Study Period 2: Up to Day 8|Adverse Event|0
6348460|NCT03543137|10112380|FG001|Study Period 2: Up to Day 8|Adverse Event|1
6348461|NCT03544333|10112428|FG000|Overall Study|Withdrawal by Subject|1
6348462|NCT03544333|10112429|FG001|Overall Study|Withdrawal by Subject|0
6348463|NCT03545503|10112456|FG000|Overall Study|Protocol Violation|14
6348464|NCT03545503|10112457|FG001|Overall Study|Protocol Violation|16
6348465|NCT03545984|10112474|FG000|Overall Study|CSF cases not present during rotation|11
6348466|NCT03545984|10112475|FG001|Overall Study|CSF cases not present during rotation|9
6348467|NCT03546621|10112504|FG000|Overall Study|Withdrawal by Subject|0
6348468|NCT03546621|10112505|FG001|Overall Study|Withdrawal by Subject|1
6348469|NCT03546621|10112506|FG002|Overall Study|Withdrawal by Subject|2
6348470|NCT03546621|10112507|FG003|Overall Study|Withdrawal by Subject|1
6348471|NCT03546621|10112504|FG000|Overall Study|Lost to Follow-up|0
6348472|NCT03546621|10112505|FG001|Overall Study|Lost to Follow-up|1
6348473|NCT03546621|10112506|FG002|Overall Study|Lost to Follow-up|0
6348474|NCT03546621|10112507|FG003|Overall Study|Lost to Follow-up|0
6348475|NCT03546621|10112504|FG000|Overall Study|Adverse Event|0
6348476|NCT03546621|10112505|FG001|Overall Study|Adverse Event|1
6348477|NCT03546621|10112506|FG002|Overall Study|Adverse Event|0
6348478|NCT03546621|10112507|FG003|Overall Study|Adverse Event|1
6348479|NCT03546621|10112504|FG000|Overall Study|Progressive disease|0
6348480|NCT03546621|10112505|FG001|Overall Study|Progressive disease|0
6348481|NCT03546621|10112506|FG002|Overall Study|Progressive disease|0
6348482|NCT03546621|10112507|FG003|Overall Study|Progressive disease|1
6348483|NCT03546647|10112517|FG000|Overall Study|Adverse Event|1
6348484|NCT03546647|10112518|FG001|Overall Study|Adverse Event|0
6348485|NCT03546816|10112526|FG000|Overall Study|Adverse Event|5
6348486|NCT03546816|10112527|FG001|Overall Study|Adverse Event|3
6348487|NCT03546816|10112526|FG000|Overall Study|Lack of Efficacy|2
6348488|NCT03546816|10112527|FG001|Overall Study|Lack of Efficacy|4
6348489|NCT03546816|10112526|FG000|Overall Study|Pregnancy|1
6348490|NCT03546816|10112527|FG001|Overall Study|Pregnancy|0
6348491|NCT03546816|10112526|FG000|Overall Study|Physician Decision|2
6348492|NCT03546816|10112527|FG001|Overall Study|Physician Decision|0
6348493|NCT03546816|10112526|FG000|Overall Study|Withdrawal by Subject|8
6348494|NCT03546816|10112527|FG001|Overall Study|Withdrawal by Subject|10
6348495|NCT03546816|10112526|FG000|Overall Study|Lost to Follow-up|3
6348496|NCT03546816|10112527|FG001|Overall Study|Lost to Follow-up|2
6348497|NCT03546842|10112535|FG000|Overall Study|Protocol Violation|1
6348498|NCT03546842|10112535|FG000|Overall Study|Withdrawal by Subject|2
6348499|NCT03547154|10112541|FG000|Overall Study|Disease Progression/Recurrence|6
6348500|NCT03547154|10112542|FG001|Overall Study|Disease Progression/Recurrence|14
6348501|NCT03547154|10112541|FG000|Overall Study|Adverse Event|26
6348502|NCT03547154|10112542|FG001|Overall Study|Adverse Event|31
6348503|NCT03547154|10112541|FG000|Overall Study|Protocol Violation|6
6348504|NCT03547154|10112542|FG001|Overall Study|Protocol Violation|1
6348505|NCT03547154|10112541|FG000|Overall Study|Physician Decision|4
6348506|NCT03547154|10112542|FG001|Overall Study|Physician Decision|3
6348507|NCT03547154|10112541|FG000|Overall Study|Insufficient Therapeutic Response|13
6348508|NCT03547154|10112542|FG001|Overall Study|Insufficient Therapeutic Response|10
6348509|NCT03547154|10112541|FG000|Overall Study|Withdrawal by Subject|10
6348510|NCT03547154|10112542|FG001|Overall Study|Withdrawal by Subject|6
6348511|NCT03547154|10112541|FG000|Overall Study|Not Selected|0
6348512|NCT03547154|10112542|FG001|Overall Study|Not Selected|1
6348513|NCT03547154|10112541|FG000|Overall Study|Continued treatment beyond 12 mo.|58
6348514|NCT03547154|10112542|FG001|Overall Study|Continued treatment beyond 12 mo.|50
6348515|NCT03547167|10112550|FG000|Overall Study|Withdrawal by Subject|34
6348516|NCT03547167|10112551|FG001|Overall Study|Withdrawal by Subject|12
6348517|NCT03547167|10112550|FG000|Overall Study|Screen Failure|0
6348518|NCT03547167|10112551|FG001|Overall Study|Screen Failure|1
6348519|NCT03547167|10112550|FG000|Overall Study|Lost to Follow-up|59
6348520|NCT03547167|10112551|FG001|Overall Study|Lost to Follow-up|15
6348521|NCT03547167|10112550|FG000|Overall Study|Death|4
6348522|NCT03547167|10112551|FG001|Overall Study|Death|2
6348523|NCT03547531|10112563|FG000|Overall Study|not coming in data collection : sick|2
6348524|NCT03547531|10112564|FG001|Overall Study|not coming in data collection : sick|2
6348525|NCT03547531|10112563|FG000|Overall Study|having family occasion|0
6348526|NCT03547531|10112564|FG001|Overall Study|having family occasion|2
6348527|NCT03547583|10112573|FG000|Overall Study|Adverse Event|16
6348528|NCT03547583|10112574|FG001|Overall Study|Adverse Event|11
6348529|NCT03547583|10112575|FG002|Overall Study|Adverse Event|10
6348530|NCT03547583|10112573|FG000|Overall Study|Death|11
6348531|NCT03547583|10112574|FG001|Overall Study|Death|7
6348532|NCT03547583|10112575|FG002|Overall Study|Death|4
6348533|NCT03547583|10112573|FG000|Overall Study|Lost to Follow-up|1
6348534|NCT03547583|10112574|FG001|Overall Study|Lost to Follow-up|0
6348535|NCT03547583|10112575|FG002|Overall Study|Lost to Follow-up|0
6348536|NCT03547583|10112573|FG000|Overall Study|Non-compliance with study drug|0
6169889|NCT01248780|9815777|FG000|Overall Study|Lack of Efficacy|2
6169890|NCT01248780|9815778|FG001|Overall Study|Lack of Efficacy|0
6169891|NCT01248780|9815777|FG000|Overall Study|Lost to Follow-up|0
6169892|NCT01248780|9815778|FG001|Overall Study|Lost to Follow-up|1
6169893|NCT01248780|9815777|FG000|Overall Study|Death|0
6169894|NCT01248780|9815778|FG001|Overall Study|Death|1
6169895|NCT01248780|9815777|FG000|Overall Study|Adverse Event|2
6169896|NCT01248780|9815778|FG001|Overall Study|Adverse Event|7
6169897|NCT01248780|9815777|FG000|Overall Study|Protocol Violation|1
6169898|NCT01248780|9815778|FG001|Overall Study|Protocol Violation|1
6169899|NCT01248780|9815777|FG000|Overall Study|Withdrawal by Subject|4
6169900|NCT01248780|9815778|FG001|Overall Study|Withdrawal by Subject|4
6169901|NCT01248780|9815777|FG000|Overall Study|Not treated|0
6169902|NCT01248780|9815778|FG001|Overall Study|Not treated|1
6169903|NCT01248793|9815786|FG000|Overall Study|Lost to Follow-up|0
6169904|NCT01248793|9815787|FG001|Overall Study|Lost to Follow-up|1
6169905|NCT01248793|9815786|FG000|Overall Study|Adverse Event|1
6169906|NCT01248793|9815787|FG001|Overall Study|Adverse Event|1
6169907|NCT01248793|9815786|FG000|Overall Study|Protocol Violation|0
6169908|NCT01248793|9815787|FG001|Overall Study|Protocol Violation|1
6169909|NCT01248793|9815786|FG000|Overall Study|Withdrawal by Subject|3
6169910|NCT01248793|9815787|FG001|Overall Study|Withdrawal by Subject|3
6169911|NCT01248884|9815796|FG000|Overall Study|Withdrawal by Subject|1
6169912|NCT01248884|9815797|FG001|Overall Study|Withdrawal by Subject|3
6169913|NCT01248884|9815798|FG002|Overall Study|Withdrawal by Subject|1
6169914|NCT01248884|9815796|FG000|Overall Study|Adverse Event|1
6169915|NCT01248884|9815797|FG001|Overall Study|Adverse Event|0
6169916|NCT01248884|9815798|FG002|Overall Study|Adverse Event|0
6169917|NCT01248936|9815808|FG000|Overall Study|Sponsor Decision|259
6169918|NCT01248936|9815808|FG000|Overall Study|Progression of Disease|50
6169919|NCT01248936|9815808|FG000|Overall Study|Death|26
6169920|NCT01248936|9815808|FG000|Overall Study|Withdrawal of Consent|20
6169921|NCT01248936|9815808|FG000|Overall Study|Adverse Event|8
6169922|NCT01248936|9815808|FG000|Overall Study|Lost to Follow-up|7
6169923|NCT01248936|9815808|FG000|Overall Study|Refused Treatment|1
6169924|NCT01248936|9815808|FG000|Overall Study|Other reason|3
6169925|NCT01248949|9815818|FG000|Overall Study|Lost to Follow-up|2
6169926|NCT01248949|9815819|FG001|Overall Study|Lost to Follow-up|2
6169927|NCT01248949|9815820|FG002|Overall Study|Lost to Follow-up|2
6169928|NCT01248949|9815821|FG003|Overall Study|Lost to Follow-up|1
6169929|NCT01248949|9815822|FG004|Overall Study|Lost to Follow-up|0
6169930|NCT01248949|9815818|FG000|Overall Study|Withdrawal by Subject|5
6169931|NCT01248949|9815819|FG001|Overall Study|Withdrawal by Subject|3
6169932|NCT01248949|9815820|FG002|Overall Study|Withdrawal by Subject|11
6169933|NCT01248949|9815821|FG003|Overall Study|Withdrawal by Subject|3
6169934|NCT01248949|9815822|FG004|Overall Study|Withdrawal by Subject|1
6169935|NCT01248949|9815818|FG000|Overall Study|Death|22
6169936|NCT01248949|9815819|FG001|Overall Study|Death|7
6169937|NCT01248949|9815820|FG002|Overall Study|Death|21
6169938|NCT01248949|9815821|FG003|Overall Study|Death|6
6169939|NCT01248949|9815822|FG004|Overall Study|Death|2
6169940|NCT01248949|9815818|FG000|Overall Study|Alternative Therapy|1
6169941|NCT01248949|9815819|FG001|Overall Study|Alternative Therapy|0
6169942|NCT01248949|9815820|FG002|Overall Study|Alternative Therapy|0
6169943|NCT01248949|9815821|FG003|Overall Study|Alternative Therapy|0
6169944|NCT01248949|9815822|FG004|Overall Study|Alternative Therapy|0
6169945|NCT01248949|9815818|FG000|Overall Study|Alternative Therapy.|1
6169946|NCT01248949|9815819|FG001|Overall Study|Alternative Therapy.|0
6169947|NCT01248949|9815820|FG002|Overall Study|Alternative Therapy.|0
6169948|NCT01248949|9815821|FG003|Overall Study|Alternative Therapy.|0
6169949|NCT01248949|9815822|FG004|Overall Study|Alternative Therapy.|0
6169950|NCT01248949|9815818|FG000|Overall Study|Palliative Radiation To Brain Metastases|1
6169951|NCT01248949|9815819|FG001|Overall Study|Palliative Radiation To Brain Metastases|0
6169952|NCT01248949|9815820|FG002|Overall Study|Palliative Radiation To Brain Metastases|0
6169953|NCT01248949|9815821|FG003|Overall Study|Palliative Radiation To Brain Metastases|0
6169954|NCT01248949|9815822|FG004|Overall Study|Palliative Radiation To Brain Metastases|0
6169955|NCT01248949|9815818|FG000|Overall Study|Entered Hospice And Refused Follow Up|0
6169956|NCT01248949|9815819|FG001|Overall Study|Entered Hospice And Refused Follow Up|0
6169957|NCT01248949|9815820|FG002|Overall Study|Entered Hospice And Refused Follow Up|0
6169958|NCT01248949|9815821|FG003|Overall Study|Entered Hospice And Refused Follow Up|0
6169959|NCT01248949|9815822|FG004|Overall Study|Entered Hospice And Refused Follow Up|1
6169960|NCT01248949|9815818|FG000|Overall Study|Participant Went To Hospice|0
6348537|NCT03547583|10112574|FG001|Overall Study|Non-compliance with study drug|0
6348538|NCT03547583|10112575|FG002|Overall Study|Non-compliance with study drug|1
6348539|NCT03547583|10112573|FG000|Overall Study|Physician Decision|1
6348540|NCT03547583|10112574|FG001|Overall Study|Physician Decision|0
6348541|NCT03547583|10112575|FG002|Overall Study|Physician Decision|3
6348542|NCT03547583|10112573|FG000|Overall Study|Protocol Violation|2
6348543|NCT03547583|10112574|FG001|Overall Study|Protocol Violation|1
6348544|NCT03547583|10112575|FG002|Overall Study|Protocol Violation|1
6348545|NCT03547583|10112573|FG000|Overall Study|Withdrawal by Subject|12
6348546|NCT03547583|10112574|FG001|Overall Study|Withdrawal by Subject|19
6348547|NCT03547583|10112575|FG002|Overall Study|Withdrawal by Subject|10
6348548|NCT03547583|10112573|FG000|Overall Study|Other|2
6348549|NCT03547583|10112574|FG001|Overall Study|Other|2
6348550|NCT03547583|10112575|FG002|Overall Study|Other|3
6348551|NCT03547635|10112589|FG000|Overall Study|Adverse Event|5
6348552|NCT03547635|10112590|FG001|Overall Study|Adverse Event|2
6348553|NCT03547635|10112591|FG002|Overall Study|Adverse Event|3
6348554|NCT03547635|10112589|FG000|Overall Study|Lost to Follow-up|1
6348555|NCT03547635|10112590|FG001|Overall Study|Lost to Follow-up|3
6348556|NCT03547635|10112591|FG002|Overall Study|Lost to Follow-up|4
6348557|NCT03547635|10112589|FG000|Overall Study|Withdrawal by Subject|1
6348558|NCT03547635|10112590|FG001|Overall Study|Withdrawal by Subject|0
6348559|NCT03547635|10112591|FG002|Overall Study|Withdrawal by Subject|0
6348560|NCT03547635|10112589|FG000|Overall Study|Withdrawal By PI|0
6348561|NCT03547635|10112590|FG001|Overall Study|Withdrawal By PI|1
6348562|NCT03547635|10112591|FG002|Overall Study|Withdrawal By PI|0
6348563|NCT03547635|10112589|FG000|Overall Study|Withdrawal by Sponsor|0
6348564|NCT03547635|10112590|FG001|Overall Study|Withdrawal by Sponsor|0
6348565|NCT03547635|10112591|FG002|Overall Study|Withdrawal by Sponsor|1
6348566|NCT03547635|10112589|FG000|Overall Study|Errant Randomization before Treatment|0
6348567|NCT03547635|10112590|FG001|Overall Study|Errant Randomization before Treatment|1
6348568|NCT03547635|10112591|FG002|Overall Study|Errant Randomization before Treatment|0
6348569|NCT03547635|10112589|FG000|Overall Study|Withdrawal by Subject|1
6348570|NCT03547635|10112590|FG001|Overall Study|Withdrawal by Subject|0
6348571|NCT03547635|10112591|FG002|Overall Study|Withdrawal by Subject|0
6169961|NCT01248949|9815819|FG001|Overall Study|Participant Went To Hospice|0
6169962|NCT01248949|9815820|FG002|Overall Study|Participant Went To Hospice|1
6169963|NCT01248949|9815821|FG003|Overall Study|Participant Went To Hospice|0
6169964|NCT01248949|9815822|FG004|Overall Study|Participant Went To Hospice|0
6169965|NCT01248949|9815818|FG000|Overall Study|Per Sponsor Request o Discontinue Drug|1
6169966|NCT01248949|9815819|FG001|Overall Study|Per Sponsor Request o Discontinue Drug|0
6169967|NCT01248949|9815820|FG002|Overall Study|Per Sponsor Request o Discontinue Drug|0
6169968|NCT01248949|9815821|FG003|Overall Study|Per Sponsor Request o Discontinue Drug|0
6169969|NCT01248949|9815822|FG004|Overall Study|Per Sponsor Request o Discontinue Drug|0
6169970|NCT01248949|9815818|FG000|Overall Study|Pi Decision Due To Declining Status|0
6169971|NCT01248949|9815819|FG001|Overall Study|Pi Decision Due To Declining Status|0
6169972|NCT01248949|9815820|FG002|Overall Study|Pi Decision Due To Declining Status|1
6169973|NCT01248949|9815821|FG003|Overall Study|Pi Decision Due To Declining Status|0
6169974|NCT01248949|9815822|FG004|Overall Study|Pi Decision Due To Declining Status|0
6169975|NCT01248949|9815818|FG000|Overall Study|Pi Discretion Due To Hospitalisation|0
6169976|NCT01248949|9815819|FG001|Overall Study|Pi Discretion Due To Hospitalisation|1
6169977|NCT01248949|9815820|FG002|Overall Study|Pi Discretion Due To Hospitalisation|0
6169978|NCT01248949|9815821|FG003|Overall Study|Pi Discretion Due To Hospitalisation|0
6169979|NCT01248949|9815822|FG004|Overall Study|Pi Discretion Due To Hospitalisation|0
6169980|NCT01248949|9815818|FG000|Overall Study|Lesion In ThoracicSpine Requires Therapy|0
6169981|NCT01248949|9815819|FG001|Overall Study|Lesion In ThoracicSpine Requires Therapy|0
6169982|NCT01248949|9815820|FG002|Overall Study|Lesion In ThoracicSpine Requires Therapy|1
6169983|NCT01248949|9815821|FG003|Overall Study|Lesion In ThoracicSpine Requires Therapy|0
6169984|NCT01248949|9815822|FG004|Overall Study|Lesion In ThoracicSpine Requires Therapy|0
6169985|NCT01248962|9815836|FG000|Overall Study|Withdrawal by Subject|1
6169986|NCT01248962|9815837|FG001|Overall Study|Withdrawal by Subject|1
6169987|NCT01248962|9815836|FG000|Overall Study|Adverse Event|2
6169988|NCT01248962|9815837|FG001|Overall Study|Adverse Event|1
6169989|NCT01248962|9815836|FG000|Overall Study|Complete Response after 4 Cycles|1
6169990|NCT01248962|9815837|FG001|Overall Study|Complete Response after 4 Cycles|0
6169991|NCT01248962|9815836|FG000|Overall Study|Complete Response after 3 Cycles|0
6169992|NCT01248962|9815837|FG001|Overall Study|Complete Response after 3 Cycles|1
6169993|NCT01248962|9815836|FG000|Overall Study|Progression of Disease prior to 5 Cycles|12
6169994|NCT01248962|9815837|FG001|Overall Study|Progression of Disease prior to 5 Cycles|13
6169995|NCT01249092|9815848|FG000|Overall Study|Expected side effect of nausea/dyspepsia|1
6169996|NCT01249092|9815848|FG000|Overall Study|Unable to tolerate expected SE -nausea|1
6169997|NCT01249118|9815854|FG000|First Washout Period|Physician Decision|0
6169998|NCT01249118|9815855|FG001|First Washout Period|Physician Decision|1
6169999|NCT01249118|9815856|FG002|First Washout Period|Physician Decision|0
6348572|NCT03547687|10112599|FG000|Overall Study|Withdrawal by Subject|1
6170000|NCT01249131|9815863|FG000|Washout Period of 10 Days|Adverse Event|0
6348573|NCT03547687|10112599|FG000|Overall Study|Death|1
6348574|NCT03548337|10112605|FG000|Infant Series|Withdrawal by Parent/Guardian|8
6348575|NCT03548337|10112606|FG001|Infant Series|Withdrawal by Parent/Guardian|8
6348576|NCT03548337|10112605|FG000|Infant Series|No Longer Met Eligibility Criteria|1
6348577|NCT03548337|10112606|FG001|Infant Series|No Longer Met Eligibility Criteria|0
6348578|NCT03548337|10112605|FG000|Infant Series|Lost to Follow-up|2
6348579|NCT03548337|10112606|FG001|Infant Series|Lost to Follow-up|1
6348580|NCT03548337|10112605|FG000|Infant Series|Adverse Event|0
6348581|NCT03548337|10112606|FG001|Infant Series|Adverse Event|2
6348582|NCT03548337|10112605|FG000|Infant Series|Randomized but Not Vaccinated|1
6348583|NCT03548337|10112606|FG001|Infant Series|Randomized but Not Vaccinated|0
6348584|NCT03548337|10112605|FG000|Toddler Dose|Withdrawal by parent/guardian|1
6348585|NCT03548337|10112606|FG001|Toddler Dose|Withdrawal by parent/guardian|1
6348586|NCT03548935|10112620|FG000|Overall Study|Withdrawal by Subject|26
6348587|NCT03548935|10112621|FG001|Overall Study|Withdrawal by Subject|17
6348588|NCT03548935|10112620|FG000|Overall Study|Lost to Follow-up|39
6348589|NCT03548935|10112621|FG001|Overall Study|Lost to Follow-up|28
6348590|NCT03548935|10112620|FG000|Overall Study|Death|1
6348591|NCT03548935|10112621|FG001|Overall Study|Death|1
6348592|NCT03549117|10112629|FG000|Overall Study|Withdrawal by Subject|1
6348593|NCT03549117|10112630|FG001|Overall Study|Withdrawal by Subject|0
6348594|NCT03549130|10112638|FG000|Overall Study|Adverse Event|0
6348595|NCT03549130|10112639|FG001|Overall Study|Adverse Event|1
6348596|NCT03549130|10112638|FG000|Overall Study|Lost to Follow-up|0
6348597|NCT03549130|10112639|FG001|Overall Study|Lost to Follow-up|1
6348598|NCT03549338|10112659|FG000|Overall Study|Progressive Disease|1
6348599|NCT03549338|10112660|FG001|Overall Study|Progressive Disease|0
6348600|NCT03549338|10112661|FG002|Overall Study|Progressive Disease|0
6348601|NCT03549338|10112659|FG000|Overall Study|Clinical Progression|0
6348602|NCT03549338|10112660|FG001|Overall Study|Clinical Progression|1
6348603|NCT03549338|10112661|FG002|Overall Study|Clinical Progression|0
6348604|NCT03549429|10112669|FG000|Overall Study|Protocol Violation|5
6348605|NCT03549429|10112670|FG001|Overall Study|Protocol Violation|3
6348606|NCT03550209|10112697|FG000|Overall Study|Lost to Follow-up|1
6348607|NCT03550209|10112698|FG001|Overall Study|Lost to Follow-up|0
6348608|NCT03550209|10112699|FG002|Overall Study|Lost to Follow-up|1
6348609|NCT03550209|10112700|FG003|Overall Study|Lost to Follow-up|0
6348610|NCT03550209|10112697|FG000|Overall Study|Withdrawal by Subject|0
6348611|NCT03550209|10112698|FG001|Overall Study|Withdrawal by Subject|3
6348612|NCT03550209|10112699|FG002|Overall Study|Withdrawal by Subject|1
6348613|NCT03550209|10112700|FG003|Overall Study|Withdrawal by Subject|2
6348614|NCT03550209|10112697|FG000|Overall Study|Excluded due to ineligibility after randomization|0
6348615|NCT03550209|10112698|FG001|Overall Study|Excluded due to ineligibility after randomization|0
6348616|NCT03550209|10112699|FG002|Overall Study|Excluded due to ineligibility after randomization|0
6348617|NCT03550209|10112700|FG003|Overall Study|Excluded due to ineligibility after randomization|2
6348618|NCT03550313|10112713|FG000|Overall Study|Adverse Event|0
6348619|NCT03550313|10112714|FG001|Overall Study|Adverse Event|1
6348620|NCT03550313|10112715|FG002|Overall Study|Adverse Event|0
6348621|NCT03550313|10112713|FG000|Overall Study|Lost to Follow-up|5
6348622|NCT03550313|10112714|FG001|Overall Study|Lost to Follow-up|7
6348623|NCT03550313|10112715|FG002|Overall Study|Lost to Follow-up|12
6348624|NCT03550313|10112713|FG000|Overall Study|Study terminated by sponsor|44
6348625|NCT03550313|10112714|FG001|Overall Study|Study terminated by sponsor|37
6348626|NCT03550313|10112715|FG002|Overall Study|Study terminated by sponsor|48
6348627|NCT03550313|10112713|FG000|Overall Study|No longer met eligibility criteria|3
6348628|NCT03550313|10112714|FG001|Overall Study|No longer met eligibility criteria|5
6348629|NCT03550313|10112715|FG002|Overall Study|No longer met eligibility criteria|6
6348630|NCT03550313|10112713|FG000|Overall Study|Withdrawal by parent/guardian|20
6348631|NCT03550313|10112714|FG001|Overall Study|Withdrawal by parent/guardian|18
6348632|NCT03550313|10112715|FG002|Overall Study|Withdrawal by parent/guardian|26
6348633|NCT03550313|10112713|FG000|Overall Study|Other|4
6348634|NCT03550313|10112714|FG001|Overall Study|Other|2
6348635|NCT03550313|10112715|FG002|Overall Study|Other|2
6348636|NCT03550313|10112713|FG000|Overall Study|Randomized but not vaccinated|3
6348637|NCT03550313|10112714|FG001|Overall Study|Randomized but not vaccinated|23
6348638|NCT03550313|10112715|FG002|Overall Study|Randomized but not vaccinated|2
6348639|NCT03550313|10112713|FG000|Overall Study|Sites terminated due to quality issues|18
6348640|NCT03550313|10112714|FG001|Overall Study|Sites terminated due to quality issues|17
6348641|NCT03550313|10112715|FG002|Overall Study|Sites terminated due to quality issues|18
6348642|NCT03550378|10112726|FG000|Overall Study|Death|0
6348643|NCT03550378|10112727|FG001|Overall Study|Death|1
6348644|NCT03551730|10112759|FG000|Overall Study|Adverse Event|1
6348645|NCT03551730|10112760|FG001|Overall Study|Adverse Event|0
6348646|NCT03551730|10112761|FG002|Overall Study|Adverse Event|0
6348647|NCT03551730|10112762|FG003|Overall Study|Adverse Event|0
6348648|NCT03551743|10112776|FG000|Overall Study|Adverse Event|1
6348649|NCT03551743|10112777|FG001|Overall Study|Adverse Event|0
6348650|NCT03551743|10112778|FG002|Overall Study|Adverse Event|0
6348651|NCT03551743|10112779|FG003|Overall Study|Adverse Event|0
6348652|NCT03551743|10112776|FG000|Overall Study|Withdrawal by Subject|1
6348653|NCT03551743|10112777|FG001|Overall Study|Withdrawal by Subject|0
6348654|NCT03551743|10112778|FG002|Overall Study|Withdrawal by Subject|0
6348655|NCT03551743|10112779|FG003|Overall Study|Withdrawal by Subject|0
6348656|NCT03552198|10112797|FG000|Overall Study|Lost to Follow-up|42
6348657|NCT03552198|10112798|FG001|Overall Study|Lost to Follow-up|48
6348658|NCT03552198|10112799|FG002|Overall Study|Lost to Follow-up|15
6348659|NCT03552198|10112800|FG003|Overall Study|Lost to Follow-up|19
6083600|NCT00636194|9692086|FG000|Overall Study|Protocol Violation|2
6170001|NCT01249131|9815864|FG001|Washout Period of 10 Days|Adverse Event|0
6170002|NCT01249131|9815865|FG002|Washout Period of 10 Days|Adverse Event|0
6170003|NCT01249131|9815866|FG003|Washout Period of 10 Days|Adverse Event|0
6170004|NCT01249131|9815867|FG004|Washout Period of 10 Days|Adverse Event|1
6170005|NCT01249131|9815868|FG005|Washout Period of 10 Days|Adverse Event|0
6170006|NCT01249261|9815878|FG000|Overall Study|Withdrawal by Subject|1
6170007|NCT01249261|9815879|FG001|Overall Study|Withdrawal by Subject|0
6170008|NCT01249274|9815887|FG000|Overall Study|Lost to Follow-up|3
6170009|NCT01249274|9815888|FG001|Overall Study|Lost to Follow-up|4
6170010|NCT01249274|9815887|FG000|Overall Study|Received inpatient substance treatment|1
6170011|NCT01249274|9815888|FG001|Overall Study|Received inpatient substance treatment|2
6170012|NCT01249365|9815896|FG000|Overall Study|Lost to Follow-up|1
6170013|NCT01249404|9815903|FG000|Overall Study|Study treatment not received|0
6170014|NCT01249404|9815904|FG001|Overall Study|Study treatment not received|1
6170015|NCT01249404|9815905|FG002|Overall Study|Study treatment not received|2
6170016|NCT01249404|9815903|FG000|Overall Study|No MAS Score at baseline and/or Week 4|2
6170017|NCT01249404|9815904|FG001|Overall Study|No MAS Score at baseline and/or Week 4|0
6170018|NCT01249404|9815905|FG002|Overall Study|No MAS Score at baseline and/or Week 4|2
6170019|NCT01249404|9815903|FG000|Overall Study|Adverse Event|2
6170020|NCT01249404|9815904|FG001|Overall Study|Adverse Event|2
6170021|NCT01249404|9815905|FG002|Overall Study|Adverse Event|2
6170022|NCT01249404|9815903|FG000|Overall Study|Withdrawal by Subject|2
6170023|NCT01249404|9815904|FG001|Overall Study|Withdrawal by Subject|2
6170024|NCT01249404|9815905|FG002|Overall Study|Withdrawal by Subject|0
6170025|NCT01249404|9815903|FG000|Overall Study|Botulinum toxin (BTX) in upper limb|1
6170026|NCT01249404|9815904|FG001|Overall Study|Botulinum toxin (BTX) in upper limb|2
6170027|NCT01249404|9815905|FG002|Overall Study|Botulinum toxin (BTX) in upper limb|1
6170028|NCT01249404|9815903|FG000|Overall Study|Non compliance to visit schedule|0
6170029|NCT01249404|9815904|FG001|Overall Study|Non compliance to visit schedule|1
6170030|NCT01249404|9815905|FG002|Overall Study|Non compliance to visit schedule|0
6170031|NCT01249417|9815916|FG000|Randomised Population|Study treatment not received|0
6170032|NCT01249417|9815917|FG001|Randomised Population|Study treatment not received|0
6170033|NCT01249417|9815918|FG002|Randomised Population|Study treatment not received|2
6170034|NCT01249417|9815916|FG000|Randomised Population|No MAS score at baseline and/or Week 4|1
6170035|NCT01249417|9815917|FG001|Randomised Population|No MAS score at baseline and/or Week 4|1
6170036|NCT01249417|9815918|FG002|Randomised Population|No MAS score at baseline and/or Week 4|2
6170037|NCT01249417|9815916|FG000|Treatment Phase - ITT Population|Other|0
6170038|NCT01249417|9815917|FG001|Treatment Phase - ITT Population|Other|0
6170039|NCT01249417|9815918|FG002|Treatment Phase - ITT Population|Other|1
6170040|NCT01249417|9815916|FG000|Treatment Phase - ITT Population|Adverse Event|0
6170041|NCT01249417|9815917|FG001|Treatment Phase - ITT Population|Adverse Event|0
6170042|NCT01249417|9815918|FG002|Treatment Phase - ITT Population|Adverse Event|1
6170043|NCT01249417|9815916|FG000|Treatment Phase - ITT Population|Withdrawal by Subject|1
6170044|NCT01249417|9815917|FG001|Treatment Phase - ITT Population|Withdrawal by Subject|3
6170045|NCT01249417|9815918|FG002|Treatment Phase - ITT Population|Withdrawal by Subject|1
6170046|NCT01249417|9815916|FG000|Treatment Phase - ITT Population|Lost to Follow-up|0
6170047|NCT01249417|9815917|FG001|Treatment Phase - ITT Population|Lost to Follow-up|1
6170048|NCT01249417|9815918|FG002|Treatment Phase - ITT Population|Lost to Follow-up|1
6192206|NCT01428661|9849315|FG002|Double-Masked Phase|*Various|0
6192207|NCT01428661|9849313|FG000|Open Label Extension|Protocol Violation|0
6192208|NCT01428661|9849314|FG001|Open Label Extension|Protocol Violation|0
6192209|NCT01428661|9849315|FG002|Open Label Extension|Protocol Violation|9
6192210|NCT01428661|9849313|FG000|Open Label Extension|Adverse Event|0
6192211|NCT01428661|9849314|FG001|Open Label Extension|Adverse Event|0
6192212|NCT01428661|9849315|FG002|Open Label Extension|Adverse Event|15
6192213|NCT01428661|9849313|FG000|Open Label Extension|Lost to Follow-up|0
6192214|NCT01428661|9849314|FG001|Open Label Extension|Lost to Follow-up|0
6192215|NCT01428661|9849315|FG002|Open Label Extension|Lost to Follow-up|38
6192216|NCT01428661|9849313|FG000|Open Label Extension|Withdrawal by Subject|0
6192217|NCT01428661|9849314|FG001|Open Label Extension|Withdrawal by Subject|0
6192218|NCT01428661|9849315|FG002|Open Label Extension|Withdrawal by Subject|49
6192219|NCT01428661|9849313|FG000|Open Label Extension|Lack of Efficacy|0
6192220|NCT01428661|9849314|FG001|Open Label Extension|Lack of Efficacy|0
6192221|NCT01428661|9849315|FG002|Open Label Extension|Lack of Efficacy|24
6192222|NCT01428661|9849313|FG000|Open Label Extension|**Various|0
6192223|NCT01428661|9849314|FG001|Open Label Extension|**Various|0
6192224|NCT01428661|9849315|FG002|Open Label Extension|**Various|185
6192225|NCT01428713|9849323|FG000|Overall Study|Non-compliance|2
6192226|NCT01428713|9849324|FG001|Overall Study|Non-compliance|2
6083601|NCT00636194|9692087|FG001|Overall Study|Protocol Violation|0
6083602|NCT00636207|9692096|FG000|Overall Study|Adverse Event|1
6083603|NCT00636207|9692097|FG001|Overall Study|Adverse Event|0
6083604|NCT00636207|9692098|FG002|Overall Study|Adverse Event|0
6083605|NCT00636207|9692099|FG003|Overall Study|Adverse Event|0
6348660|NCT03552198|10112797|FG000|Overall Study|Incomplete/unmatched questionnaire|6
6348661|NCT03552198|10112798|FG001|Overall Study|Incomplete/unmatched questionnaire|7
6348662|NCT03552198|10112799|FG002|Overall Study|Incomplete/unmatched questionnaire|2
6348663|NCT03552198|10112800|FG003|Overall Study|Incomplete/unmatched questionnaire|2
6170049|NCT01249651|9815935|FG000|Overall Study|Withdrawal by Subject|4
6170050|NCT01249651|9815935|FG000|Overall Study|Adverse Event|1
6170051|NCT01249651|9815935|FG000|Overall Study|Protocol Violation|1
6170052|NCT01249651|9815935|FG000|Overall Study|Sponsor Decision|1
6170053|NCT01249664|9815941|FG000|Overall Study|Withdrawal by Subject|5
6170054|NCT01249664|9815942|FG001|Overall Study|Withdrawal by Subject|0
6170055|NCT01249664|9815941|FG000|Overall Study|Adverse Event|1
6170056|NCT01249664|9815942|FG001|Overall Study|Adverse Event|0
6170057|NCT01249833|9815952|FG000|Overall Study|Lost to Follow-up|0
6170058|NCT01249833|9815953|FG001|Overall Study|Lost to Follow-up|1
6170059|NCT01250002|9815994|FG000|Overall Study|Change to open surgical procedure|4
6170060|NCT01250002|9815995|FG001|Overall Study|Change to open surgical procedure|3
6170061|NCT01250054|9816001|FG000|Period 2, One Week of Wear|Unacceptable subjective vision|1
6170062|NCT01250054|9816002|FG001|Period 2, One Week of Wear|Unacceptable subjective vision|0
6170063|NCT01250119|9816008|FG000|Diagnostic Phase|Failed to Produce a Test Results|69
6170064|NCT01250119|9816009|FG001|Diagnostic Phase|Failed to Produce a Test Results|0
6170065|NCT01250119|9816008|FG000|Diagnostic Phase|Participants Not Tested|44
6170066|NCT01250119|9816009|FG001|Diagnostic Phase|Participants Not Tested|0
6170067|NCT01250119|9816008|FG000|Treatment Phase|Progressive Disease|0
6170068|NCT01250119|9816009|FG001|Treatment Phase|Progressive Disease|32
6170069|NCT01250119|9816008|FG000|Treatment Phase|Death|0
6170070|NCT01250119|9816009|FG001|Treatment Phase|Death|2
6170071|NCT01250119|9816008|FG000|Treatment Phase|Withdrawal by Subject|0
6170072|NCT01250119|9816009|FG001|Treatment Phase|Withdrawal by Subject|1
6170073|NCT01250119|9816008|FG000|Treatment Phase|Adverse Event|0
6170074|NCT01250119|9816009|FG001|Treatment Phase|Adverse Event|2
6170075|NCT01250119|9816008|FG000|Treatment Phase|Unknown reason|0
6170076|NCT01250119|9816009|FG001|Treatment Phase|Unknown reason|4
6170077|NCT01250145|9816018|FG000|Overall Study|Adverse Event|2
6170078|NCT01250145|9816019|FG001|Overall Study|Adverse Event|1
6170079|NCT01250145|9816018|FG000|Overall Study|Withdrawal by Subject|0
6170080|NCT01250145|9816019|FG001|Overall Study|Withdrawal by Subject|4
6170081|NCT01250171|9816042|FG000|Overall Study|Administrative reasons|1
6170082|NCT01250171|9816043|FG001|Overall Study|Administrative reasons|0
6170083|NCT01250171|9816044|FG002|Overall Study|Administrative reasons|0
6170084|NCT01250379|9816080|FG000|Overall Study|Death|141
6170085|NCT01250379|9816081|FG001|Overall Study|Death|148
6170086|NCT01250379|9816080|FG000|Overall Study|Withdrawal by Subject|32
6170087|NCT01250379|9816081|FG001|Overall Study|Withdrawal by Subject|20
6170088|NCT01250379|9816080|FG000|Overall Study|Physician Decision|11
6170089|NCT01250379|9816081|FG001|Overall Study|Physician Decision|3
6170090|NCT01250379|9816080|FG000|Overall Study|Protocol Violation|2
6170091|NCT01250379|9816081|FG001|Overall Study|Protocol Violation|8
6170092|NCT01250379|9816080|FG000|Overall Study|Lost to Follow-up|9
6170093|NCT01250379|9816081|FG001|Overall Study|Lost to Follow-up|6
6170094|NCT01250379|9816080|FG000|Overall Study|Adverse Event|5
6170095|NCT01250379|9816081|FG001|Overall Study|Adverse Event|4
6170096|NCT01250379|9816080|FG000|Overall Study|Other|0
6170097|NCT01250379|9816081|FG001|Overall Study|Other|4
6170098|NCT01250379|9816080|FG000|Overall Study|Participant noncompliance|2
6170099|NCT01250379|9816081|FG001|Overall Study|Participant noncompliance|0
6170100|NCT01250418|9816089|FG000|Overall Study|monitor data failure|1
6170101|NCT01250418|9816090|FG001|Overall Study|monitor data failure|1
6170102|NCT01250509|9816098|FG000|Overall Study|Lost to Follow-up|5
6170103|NCT01250509|9816099|FG001|Overall Study|Lost to Follow-up|2
6170104|NCT01250756|9816126|FG000|Infant Series|Withdrawal by Subject|4
6170105|NCT01250756|9816127|FG001|Infant Series|Withdrawal by Subject|5
6170106|NCT01250756|9816126|FG000|Infant Series|Randomized, Not Vaccinated|2
6170107|NCT01250756|9816127|FG001|Infant Series|Randomized, Not Vaccinated|2
6170108|NCT01250756|9816126|FG000|Infant Series|Other|22
6170109|NCT01250756|9816127|FG001|Infant Series|Other|0
6170110|NCT01250756|9816126|FG000|After Infant Series|Adverse Event|5
6170111|NCT01250756|9816127|FG001|After Infant Series|Adverse Event|2
6170112|NCT01250756|9816126|FG000|After Infant Series|Withdrawal by Subject|4
6170113|NCT01250756|9816127|FG001|After Infant Series|Withdrawal by Subject|1
6170114|NCT01250756|9816126|FG000|After Infant Series|Other|2
6170115|NCT01250756|9816127|FG001|After Infant Series|Other|1
6170116|NCT01250756|9816126|FG000|Toddler Dose|Adverse Event|0
6170117|NCT01250756|9816127|FG001|Toddler Dose|Adverse Event|1
6170118|NCT01250756|9816126|FG000|After Toddler Dose|Adverse Event|0
6170119|NCT01250756|9816127|FG001|After Toddler Dose|Adverse Event|1
6170120|NCT01250769|9816143|FG000|Overall Study|Withdrawal by Subject|0
6170121|NCT01250769|9816144|FG001|Overall Study|Withdrawal by Subject|1
6170122|NCT01250769|9816145|FG002|Overall Study|Withdrawal by Subject|1
6170123|NCT01250769|9816146|FG003|Overall Study|Withdrawal by Subject|0
6170124|NCT01250769|9816143|FG000|Overall Study|Adverse Event|0
6170125|NCT01250769|9816144|FG001|Overall Study|Adverse Event|0
6170126|NCT01250769|9816145|FG002|Overall Study|Adverse Event|1
6170127|NCT01250769|9816146|FG003|Overall Study|Adverse Event|0
6170128|NCT01250873|9816163|FG000|Period 1: LY2216684 (Days 1-3)|Adverse Event|2
6348664|NCT03552198|10112797|FG000|Overall Study|Did not receive air alerts|1
6348665|NCT03552198|10112798|FG001|Overall Study|Did not receive air alerts|0
6348666|NCT03552198|10112799|FG002|Overall Study|Did not receive air alerts|0
6348667|NCT03552198|10112800|FG003|Overall Study|Did not receive air alerts|1
6170129|NCT01250873|9816163|FG000|Period 3:LY2216684+Sertraline(Days11-13)|Adverse Event|1
6170130|NCT01250925|9816179|FG000|Overall Study|Lost to Follow-up|1
6170131|NCT01250925|9816180|FG001|Overall Study|Lost to Follow-up|1
6170132|NCT01250925|9816181|FG002|Overall Study|Lost to Follow-up|0
6170133|NCT01250925|9816179|FG000|Overall Study|Withdrawal by Subject|2
6170134|NCT01250925|9816180|FG001|Overall Study|Withdrawal by Subject|0
6170135|NCT01250925|9816181|FG002|Overall Study|Withdrawal by Subject|0
6170136|NCT01250925|9816179|FG000|Overall Study|Protocol Violation|2
6170137|NCT01250925|9816180|FG001|Overall Study|Protocol Violation|0
6170138|NCT01250925|9816181|FG002|Overall Study|Protocol Violation|0
6170139|NCT01250925|9816179|FG000|Overall Study|Physician Decision|0
6170140|NCT01250925|9816180|FG001|Overall Study|Physician Decision|2
6170141|NCT01250925|9816181|FG002|Overall Study|Physician Decision|1
6170142|NCT01250925|9816179|FG000|Overall Study|Adverse Event|0
6170143|NCT01250925|9816180|FG001|Overall Study|Adverse Event|0
6170144|NCT01250925|9816181|FG002|Overall Study|Adverse Event|1
6170145|NCT01251146|9816218|FG000|Overall Study|Lost to Follow-up|3
6170146|NCT01251146|9816219|FG001|Overall Study|Lost to Follow-up|10
6170147|NCT01251276|9816227|FG000|Overall Study|Protocol Violation|1
6170148|NCT01251276|9816228|FG001|Overall Study|Protocol Violation|0
6170149|NCT01251276|9816227|FG000|Overall Study|Lost to Follow-up|0
6170150|NCT01251276|9816228|FG001|Overall Study|Lost to Follow-up|1
6170151|NCT01251354|9816263|FG000|Overall Study|Adverse Event|1
6170152|NCT01251354|9816263|FG000|Overall Study|Investigator's Decision|1
6170153|NCT01251354|9816263|FG000|Overall Study|Disease Progression|4
6170154|NCT01251367|9816267|FG000|Overall Study|Protocol Violation|1
6170155|NCT01251367|9816267|FG000|Overall Study|Lack of Efficacy|2
6170156|NCT01251367|9816267|FG000|Overall Study|Adverse Event|19
6170157|NCT01251367|9816267|FG000|Overall Study|Withdrawal by Subject|36
6170158|NCT01251367|9816267|FG000|Overall Study|Lost to Follow-up|5
6170159|NCT01251367|9816267|FG000|Overall Study|Subject Required Alternative Treatment|7
6170160|NCT01251367|9816267|FG000|Overall Study|No Study Drug Available|1
6170161|NCT01251367|9816267|FG000|Overall Study|Subject had Personal or Medical Issues|4
6170162|NCT01251367|9816267|FG000|Overall Study|End of Study Visit Performed in Error|1
6170163|NCT01251380|9816271|FG000|Overall Study|Other (Not otherwise specified)|12
6170164|NCT01251380|9816271|FG000|Overall Study|Withdrawal by Subject|6
6170165|NCT01251380|9816271|FG000|Overall Study|Lack of Efficacy|1
6170166|NCT01251380|9816271|FG000|Overall Study|Adverse Event|1
6170167|NCT01251380|9816271|FG000|Overall Study|Lost to Follow-up|2
6170168|NCT01251614|9816324|FG000|Overall Study|Adverse Event|1
6170169|NCT01251614|9816325|FG001|Overall Study|Adverse Event|0
6170170|NCT01251614|9816326|FG002|Overall Study|Adverse Event|1
6170171|NCT01251614|9816324|FG000|Overall Study|Lack of Efficacy|1
6170172|NCT01251614|9816325|FG001|Overall Study|Lack of Efficacy|9
6170173|NCT01251614|9816326|FG002|Overall Study|Lack of Efficacy|4
6170174|NCT01251614|9816324|FG000|Overall Study|Clearing of Psoriatic Lesions|1
6170175|NCT01251614|9816325|FG001|Overall Study|Clearing of Psoriatic Lesions|0
6170176|NCT01251614|9816326|FG002|Overall Study|Clearing of Psoriatic Lesions|0
6170177|NCT01251614|9816324|FG000|Overall Study|Pregnancy|0
6170178|NCT01251614|9816325|FG001|Overall Study|Pregnancy|0
6170179|NCT01251614|9816326|FG002|Overall Study|Pregnancy|2
6170180|NCT01251614|9816324|FG000|Overall Study|Loss of Disease Control|0
6170181|NCT01251614|9816325|FG001|Overall Study|Loss of Disease Control|1
6170182|NCT01251614|9816326|FG002|Overall Study|Loss of Disease Control|0
6170183|NCT01251614|9816324|FG000|Overall Study|Withdrawal by Subject|0
6170184|NCT01251614|9816325|FG001|Overall Study|Withdrawal by Subject|2
6170185|NCT01251614|9816326|FG002|Overall Study|Withdrawal by Subject|1
6170186|NCT01251614|9816324|FG000|Overall Study|Lost to Follow-up|0
6170187|NCT01251614|9816325|FG001|Overall Study|Lost to Follow-up|1
6170188|NCT01251614|9816326|FG002|Overall Study|Lost to Follow-up|0
6170189|NCT01251653|9816353|FG000|Overall Study|Progressive Disease|1
6170190|NCT01251653|9816354|FG001|Overall Study|Progressive Disease|7
6170191|NCT01251653|9816355|FG002|Overall Study|Progressive Disease|16
6170192|NCT01251653|9816356|FG003|Overall Study|Progressive Disease|4
6170193|NCT01251653|9816357|FG004|Overall Study|Progressive Disease|0
6170194|NCT01251653|9816358|FG005|Overall Study|Progressive Disease|17
6170195|NCT01251653|9816359|FG006|Overall Study|Progressive Disease|14
6170196|NCT01251653|9816360|FG007|Overall Study|Progressive Disease|7
6170197|NCT01251653|9816361|FG008|Overall Study|Progressive Disease|5
6170198|NCT01251653|9816353|FG000|Overall Study|Dose-limiting toxicity|0
6348668|NCT03552523|10112819|FG000|Overall Study|Withdrawal by Subject|1
6170199|NCT01251653|9816354|FG001|Overall Study|Dose-limiting toxicity|1
6170200|NCT01251653|9816355|FG002|Overall Study|Dose-limiting toxicity|1
6170201|NCT01251653|9816356|FG003|Overall Study|Dose-limiting toxicity|1
6170202|NCT01251653|9816357|FG004|Overall Study|Dose-limiting toxicity|0
6170203|NCT01251653|9816358|FG005|Overall Study|Dose-limiting toxicity|0
6170204|NCT01251653|9816359|FG006|Overall Study|Dose-limiting toxicity|2
6170205|NCT01251653|9816360|FG007|Overall Study|Dose-limiting toxicity|0
6170206|NCT01251653|9816361|FG008|Overall Study|Dose-limiting toxicity|0
6348669|NCT03552523|10112820|FG001|Overall Study|Withdrawal by Subject|1
6348670|NCT03552549|10112839|FG000|Overall Study|Disease progression|25
6348671|NCT03552549|10112840|FG001|Overall Study|Disease progression|17
6348672|NCT03552549|10112839|FG000|Overall Study|Adverse event in first 12 months|12
6348673|NCT03552549|10112840|FG001|Overall Study|Adverse event in first 12 months|8
6348674|NCT03552549|10112839|FG000|Overall Study|Withdrawal by Subject|7
6348675|NCT03552549|10112840|FG001|Overall Study|Withdrawal by Subject|7
6348676|NCT03552549|10112839|FG000|Overall Study|Unknown (no reason provided)|4
6348677|NCT03552549|10112840|FG001|Overall Study|Unknown (no reason provided)|2
6348678|NCT03552549|10112839|FG000|Overall Study|Not in participant's best interest|2
6348679|NCT03552549|10112840|FG001|Overall Study|Not in participant's best interest|1
6348680|NCT03552549|10112839|FG000|Overall Study|Did not complete study treatment|2
6348681|NCT03552549|10112840|FG001|Overall Study|Did not complete study treatment|3
6348682|NCT03552549|10112839|FG000|Overall Study|Did not meet eligibility criteria|1
6348683|NCT03552549|10112840|FG001|Overall Study|Did not meet eligibility criteria|0
6348684|NCT03552549|10112839|FG000|Overall Study|Administrative|0
6348685|NCT03552549|10112840|FG001|Overall Study|Administrative|14
6348686|NCT03552757|10112849|FG000|Overall Study|Withdrawal by Subject|10
6348687|NCT03552757|10112850|FG001|Overall Study|Withdrawal by Subject|5
6348688|NCT03552757|10112851|FG002|Overall Study|Withdrawal by Subject|12
6348689|NCT03552757|10112849|FG000|Overall Study|Lost to Follow-up|2
6348690|NCT03552757|10112850|FG001|Overall Study|Lost to Follow-up|7
6348691|NCT03552757|10112851|FG002|Overall Study|Lost to Follow-up|7
6043122|NCT00386607|9641573|FG001|Core|Lost to Follow-up|0
6043123|NCT00386607|9641572|FG000|Core|Administrative problems|1
6348692|NCT03552757|10112849|FG000|Overall Study|Death|1
6348693|NCT03552757|10112850|FG001|Overall Study|Death|1
6043124|NCT00386607|9641573|FG001|Core|Administrative problems|0
6043125|NCT00386607|9641572|FG000|Core|Protocol Deviation|6
6043126|NCT00386607|9641573|FG001|Core|Protocol Deviation|0
6043127|NCT00386607|9641572|FG000|Extension|Adverse Event|0
6043128|NCT00386607|9641573|FG001|Extension|Adverse Event|6
6043129|NCT00386607|9641572|FG000|Extension|Abnormal laboratory value(s)|0
6348694|NCT03552757|10112851|FG002|Overall Study|Death|1
6348695|NCT03553758|10112862|FG000|Overall Study|Lost to Follow-up|1
6348696|NCT03553823|10112870|FG000|Overall Study|Physician Decision|0
6348697|NCT03553823|10112871|FG001|Overall Study|Physician Decision|1
6348698|NCT03554005|10112892|FG000|Overall Study|Not in participant's best interest|0
6348699|NCT03554005|10112893|FG001|Overall Study|Not in participant's best interest|0
6348700|NCT03554005|10112894|FG002|Overall Study|Not in participant's best interest|0
6348701|NCT03554005|10112895|FG003|Overall Study|Not in participant's best interest|0
6348702|NCT03554005|10112896|FG004|Overall Study|Not in participant's best interest|0
6348703|NCT03554005|10112897|FG005|Overall Study|Not in participant's best interest|1
6348704|NCT03554005|10112892|FG000|Overall Study|Disease Progression|1
6348705|NCT03554005|10112893|FG001|Overall Study|Disease Progression|1
6348706|NCT03554005|10112894|FG002|Overall Study|Disease Progression|1
6348707|NCT03554005|10112895|FG003|Overall Study|Disease Progression|1
6348708|NCT03554005|10112896|FG004|Overall Study|Disease Progression|5
6348709|NCT03554005|10112897|FG005|Overall Study|Disease Progression|6
6348710|NCT03554005|10112892|FG000|Overall Study|Adverse Event|0
6348711|NCT03554005|10112893|FG001|Overall Study|Adverse Event|0
6348712|NCT03554005|10112894|FG002|Overall Study|Adverse Event|0
6348713|NCT03554005|10112895|FG003|Overall Study|Adverse Event|0
6348714|NCT03554005|10112896|FG004|Overall Study|Adverse Event|0
6348715|NCT03554005|10112897|FG005|Overall Study|Adverse Event|3
6348716|NCT03554005|10112892|FG000|Overall Study|Physician Decision|0
6348717|NCT03554005|10112893|FG001|Overall Study|Physician Decision|0
6348718|NCT03554005|10112894|FG002|Overall Study|Physician Decision|0
6348719|NCT03554005|10112895|FG003|Overall Study|Physician Decision|0
6348720|NCT03554005|10112896|FG004|Overall Study|Physician Decision|1
6348721|NCT03554005|10112897|FG005|Overall Study|Physician Decision|0
6348722|NCT03554005|10112892|FG000|Overall Study|Other|0
6348723|NCT03554005|10112893|FG001|Overall Study|Other|0
6348724|NCT03554005|10112894|FG002|Overall Study|Other|0
6348725|NCT03554005|10112895|FG003|Overall Study|Other|0
6348726|NCT03554005|10112896|FG004|Overall Study|Other|0
6348727|NCT03554005|10112897|FG005|Overall Study|Other|1
6348728|NCT03554018|10112913|FG000|Overall Study|Lost to Follow-up|3
6348729|NCT03554018|10112914|FG001|Overall Study|Lost to Follow-up|7
6348730|NCT03554486|10112922|FG000|Run-in Period (2 Weeks)|Need for steroid injection|1
6348731|NCT03554486|10112923|FG001|Run-in Period (2 Weeks)|Need for steroid injection|0
6348732|NCT03554486|10112924|FG002|Run-in Period (2 Weeks)|Need for steroid injection|0
6348733|NCT03554486|10112922|FG000|Run-in Period (2 Weeks)|Lost to Follow-up|2
6348734|NCT03554486|10112923|FG001|Run-in Period (2 Weeks)|Lost to Follow-up|0
6348735|NCT03554486|10112924|FG002|Run-in Period (2 Weeks)|Lost to Follow-up|0
6348736|NCT03554486|10112922|FG000|Treatment Period 1 (2 Weeks)|Withdrawal by Subject|0
6348737|NCT03554486|10112923|FG001|Treatment Period 1 (2 Weeks)|Withdrawal by Subject|1
6348738|NCT03554486|10112924|FG002|Treatment Period 1 (2 Weeks)|Withdrawal by Subject|1
6043130|NCT00386607|9641573|FG001|Extension|Abnormal laboratory value(s)|1
6043131|NCT00386607|9641572|FG000|Extension|Administrative problems|0
6043132|NCT00386607|9641573|FG001|Extension|Administrative problems|1
6043133|NCT00386607|9641572|FG000|Extension|Lost to Follow-up|0
6043134|NCT00386607|9641573|FG001|Extension|Lost to Follow-up|3
6043135|NCT00386607|9641572|FG000|Extension|Patient withdrew consent|0
6043136|NCT00386607|9641573|FG001|Extension|Patient withdrew consent|5
6348739|NCT03554629|10112931|FG000|Overall Study|Inadequate data|6
6348740|NCT03554772|10112972|FG000|Overall Study|Lost to Follow-up|0
6348741|NCT03554772|10112973|FG001|Overall Study|Lost to Follow-up|0
6348742|NCT03554772|10112974|FG002|Overall Study|Lost to Follow-up|0
6348743|NCT03554772|10112975|FG003|Overall Study|Lost to Follow-up|2
6348744|NCT03555266|10112995|FG000|Overall Study|Protocol Violation|6
6348745|NCT03555266|10112996|FG001|Overall Study|Protocol Violation|4
6348746|NCT03555305|10113002|FG000|Period 1|Physician Decision|0
6348747|NCT03555305|10113003|FG001|Period 1|Physician Decision|1
6348748|NCT03555305|10113002|FG000|Period 1|Adverse Event|0
6348749|NCT03555305|10113003|FG001|Period 1|Adverse Event|1
6348750|NCT03555435|10113012|FG000|Overall Study|Lost to Follow-up|17
6348751|NCT03555435|10113013|FG001|Overall Study|Lost to Follow-up|19
6348752|NCT03555435|10113014|FG002|Overall Study|Lost to Follow-up|8
6348753|NCT03555565|10113022|FG000|Overall Study|Case Report Forms Uncollected|2
6348754|NCT03555565|10113022|FG000|Overall Study|Protocol Deviation|13
6348755|NCT03555890|10113030|FG000|Part 2:Washout Period (at Least 5 Days)|Withdrawal by Subject|0
6348756|NCT03555890|10113031|FG001|Part 2:Washout Period (at Least 5 Days)|Withdrawal by Subject|0
6348757|NCT03555890|10113032|FG002|Part 2:Washout Period (at Least 5 Days)|Withdrawal by Subject|0
6348758|NCT03555890|10113033|FG003|Part 2:Washout Period (at Least 5 Days)|Withdrawal by Subject|1
6348759|NCT03556891|10113065|FG000|Overall Study|Adverse Event|4
6348760|NCT03556891|10113065|FG000|Overall Study|MRI Need|3
6348761|NCT03556891|10113065|FG000|Overall Study|Device Failure|1
6348762|NCT03556891|10113065|FG000|Overall Study|Death|1
6348763|NCT03556891|10113065|FG000|Overall Study|Lost to Follow-up|1
6083606|NCT00636207|9692100|FG004|Overall Study|Adverse Event|0
6083607|NCT00636207|9692101|FG005|Overall Study|Adverse Event|0
6348764|NCT03556891|10113065|FG000|Overall Study|Missing at random|1
6348765|NCT03556891|10113065|FG000|Overall Study|Missing due to COVID|1
6348766|NCT03556891|10113065|FG000|Overall Study|Protocol Violation|1
6348767|NCT03557034|10113071|FG000|Overall Study|Withdrawal by Subject|1
6348768|NCT03557034|10113072|FG001|Overall Study|Withdrawal by Subject|0
6348769|NCT03557775|10113129|FG000|Overall Study|Withdrawal by Subject|1
6348770|NCT03557775|10113130|FG001|Overall Study|Withdrawal by Subject|2
6348771|NCT03557775|10113131|FG002|Overall Study|Withdrawal by Subject|4
6348772|NCT03557775|10113129|FG000|Overall Study|Physician Decision|0
6348773|NCT03557775|10113130|FG001|Overall Study|Physician Decision|1
6348774|NCT03557775|10113131|FG002|Overall Study|Physician Decision|0
6348775|NCT03557801|10113142|FG000|Overall Study|Protocol Violation|1
6348776|NCT03557801|10113143|FG001|Overall Study|Protocol Violation|0
6348777|NCT03557801|10113144|FG002|Overall Study|Protocol Violation|0
6348778|NCT03557801|10113142|FG000|Overall Study|Withdrawal by Subject|1
6348779|NCT03557801|10113143|FG001|Overall Study|Withdrawal by Subject|0
6348780|NCT03557801|10113144|FG002|Overall Study|Withdrawal by Subject|3
6348781|NCT03557801|10113142|FG000|Overall Study|Lost to Follow-up|0
6348782|NCT03557801|10113143|FG001|Overall Study|Lost to Follow-up|1
6348783|NCT03557801|10113144|FG002|Overall Study|Lost to Follow-up|0
6348784|NCT03558516|10113172|FG000|Overall Study|Protocol Violation|2
6348785|NCT03558516|10113173|FG001|Overall Study|Protocol Violation|2
6348786|NCT03558555|10113181|FG000|Overall Study|Lost to Follow-up|2
6348787|NCT03558555|10113182|FG001|Overall Study|Lost to Follow-up|1
6348788|NCT03558672|10113188|FG000|Overall Study|Study Early Termination|10
6348789|NCT03558997|10113196|FG000|Overall Study|Adverse Event|0
6348790|NCT03558997|10113197|FG001|Overall Study|Adverse Event|2
6348791|NCT03558997|10113198|FG002|Overall Study|Adverse Event|5
6348792|NCT03558997|10113199|FG003|Overall Study|Adverse Event|1
6348793|NCT03558997|10113196|FG000|Overall Study|Physician Decision|0
6348794|NCT03558997|10113197|FG001|Overall Study|Physician Decision|0
6348795|NCT03558997|10113198|FG002|Overall Study|Physician Decision|1
6348796|NCT03558997|10113199|FG003|Overall Study|Physician Decision|0
6348797|NCT03558997|10113196|FG000|Overall Study|Withdrawal by Subject|1
6348798|NCT03558997|10113197|FG001|Overall Study|Withdrawal by Subject|0
6348799|NCT03558997|10113198|FG002|Overall Study|Withdrawal by Subject|1
6348800|NCT03558997|10113199|FG003|Overall Study|Withdrawal by Subject|1
6348801|NCT03558997|10113196|FG000|Overall Study|Lost to Follow-up|0
6348802|NCT03558997|10113197|FG001|Overall Study|Lost to Follow-up|0
6348803|NCT03558997|10113198|FG002|Overall Study|Lost to Follow-up|1
6348804|NCT03558997|10113199|FG003|Overall Study|Lost to Follow-up|0
6348805|NCT03559062|10113215|FG000|Overall Study|Other|0
6348806|NCT03559062|10113216|FG001|Overall Study|Other|1
6348807|NCT03559062|10113217|FG002|Overall Study|Other|0
6348808|NCT03559218|10113259|FG000|Overall Study|Withdrawal by Subject|1
6348809|NCT03559218|10113260|FG001|Overall Study|Withdrawal by Subject|0
6348810|NCT03559257|10113268|FG000|Double Blind Treatment Period|Withdrawal by Subject|2
6348811|NCT03559257|10113269|FG001|Double Blind Treatment Period|Withdrawal by Subject|1
6348812|NCT03559257|10113268|FG000|Double Blind Treatment Period|Protocol Violation|1
6348813|NCT03559257|10113269|FG001|Double Blind Treatment Period|Protocol Violation|4
6348814|NCT03559257|10113268|FG000|Double Blind Treatment Period|Lack of Efficacy|1
6348815|NCT03559257|10113269|FG001|Double Blind Treatment Period|Lack of Efficacy|1
6348816|NCT03559257|10113268|FG000|Double Blind Treatment Period|Adverse Event|0
6348817|NCT03559257|10113269|FG001|Double Blind Treatment Period|Adverse Event|1
6348818|NCT03559257|10113268|FG000|Double Blind Treatment Period|Screen Failure|0
6348819|NCT03559257|10113269|FG001|Double Blind Treatment Period|Screen Failure|1
6348820|NCT03559257|10113268|FG000|Open-label Treatment Period|Adverse Event|1
6348821|NCT03559257|10113269|FG001|Open-label Treatment Period|Adverse Event|4
6348822|NCT03559257|10113268|FG000|Open-label Treatment Period|Lack of Efficacy|3
6348823|NCT03559257|10113269|FG001|Open-label Treatment Period|Lack of Efficacy|2
6348824|NCT03559257|10113268|FG000|Open-label Treatment Period|Withdrawal by Subject|3
6348825|NCT03559257|10113269|FG001|Open-label Treatment Period|Withdrawal by Subject|0
6348826|NCT03559257|10113268|FG000|Open-label Treatment Period|Protocol Violation|2
6348827|NCT03559257|10113269|FG001|Open-label Treatment Period|Protocol Violation|0
6348828|NCT03559257|10113268|FG000|Open-label Treatment Period|Lost to Follow-up|1
6348829|NCT03559257|10113269|FG001|Open-label Treatment Period|Lost to Follow-up|0
6348830|NCT03559257|10113268|FG000|Open-label Treatment Period|Physician Decision|0
6348831|NCT03559257|10113269|FG001|Open-label Treatment Period|Physician Decision|1
6348832|NCT03559517|10113281|FG000|Overall Study|Withdrawal by Subject|1
6348833|NCT03559517|10113282|FG001|Overall Study|Withdrawal by Subject|0
6348834|NCT03559517|10113283|FG002|Overall Study|Withdrawal by Subject|0
6348835|NCT03559530|10113291|FG000|Overall Study|non-location of medical records|44
6348836|NCT03559530|10113292|FG001|Overall Study|non-location of medical records|0
6348837|NCT03559530|10113291|FG000|Overall Study|culture results not considered for treat|29
6348838|NCT03559530|10113292|FG001|Overall Study|culture results not considered for treat|0
6348839|NCT03559530|10113291|FG000|Overall Study|duplicate cases|8
6348840|NCT03559530|10113292|FG001|Overall Study|duplicate cases|0
6348841|NCT03559530|10113291|FG000|Overall Study|other species of Acinetobacte|7
6348842|NCT03559530|10113292|FG001|Overall Study|other species of Acinetobacte|0
6348843|NCT03559530|10113291|FG000|Overall Study|contamination / colonization|3
6348844|NCT03559530|10113292|FG001|Overall Study|contamination / colonization|0
6348845|NCT03560245|10113332|FG000|Overall Study|Withdrawal by Subject|3
6348846|NCT03560245|10113333|FG001|Overall Study|Withdrawal by Subject|2
6348847|NCT03560245|10113332|FG000|Overall Study|Adverse Event|1
6348848|NCT03560245|10113333|FG001|Overall Study|Adverse Event|1
6348849|NCT03560245|10113332|FG000|Overall Study|Protocol Violation|1
6348850|NCT03560245|10113333|FG001|Overall Study|Protocol Violation|0
6348851|NCT03560245|10113332|FG000|Overall Study|Death|0
6348852|NCT03560245|10113333|FG001|Overall Study|Death|1
6348853|NCT03560245|10113332|FG000|Overall Study|Lost to Follow-up|0
6348854|NCT03560245|10113333|FG001|Overall Study|Lost to Follow-up|1
6348855|NCT03560245|10113332|FG000|Overall Study|Physician Decision|0
6348856|NCT03560245|10113333|FG001|Overall Study|Physician Decision|1
6348857|NCT03560245|10113332|FG000|Overall Study|Other|0
6348858|NCT03560245|10113333|FG001|Overall Study|Other|1
6348859|NCT03560518|10113344|FG000|Double Blind Treatment Period|Miscellaneous Reasons|1
6348860|NCT03560518|10113345|FG001|Double Blind Treatment Period|Miscellaneous Reasons|0
6348861|NCT03560518|10113346|FG002|Double Blind Treatment Period|Miscellaneous Reasons|0
6348862|NCT03560518|10113344|FG000|Double Blind Treatment Period|Study Terminated by the Sponsor|6
6348863|NCT03560518|10113345|FG001|Double Blind Treatment Period|Study Terminated by the Sponsor|9
6348864|NCT03560518|10113346|FG002|Double Blind Treatment Period|Study Terminated by the Sponsor|10
6348865|NCT03560518|10113344|FG000|Double Blind Treatment Period|Protocol Violation|1
6348866|NCT03560518|10113345|FG001|Double Blind Treatment Period|Protocol Violation|2
6348867|NCT03560518|10113346|FG002|Double Blind Treatment Period|Protocol Violation|0
6348868|NCT03560518|10113344|FG000|Double Blind Treatment Period|Pregnancy|0
6348869|NCT03560518|10113345|FG001|Double Blind Treatment Period|Pregnancy|2
6348870|NCT03560518|10113346|FG002|Double Blind Treatment Period|Pregnancy|0
6348871|NCT03560518|10113344|FG000|Double Blind Treatment Period|Lost to Follow-up|5
6348872|NCT03560518|10113345|FG001|Double Blind Treatment Period|Lost to Follow-up|6
6348873|NCT03560518|10113346|FG002|Double Blind Treatment Period|Lost to Follow-up|6
6348874|NCT03560518|10113344|FG000|Double Blind Treatment Period|Withdrawal by Subject|10
6348875|NCT03560518|10113345|FG001|Double Blind Treatment Period|Withdrawal by Subject|6
6348876|NCT03560518|10113346|FG002|Double Blind Treatment Period|Withdrawal by Subject|5
6348877|NCT03560518|10113344|FG000|Double Blind Treatment Period|Lack of Efficacy|2
6348878|NCT03560518|10113345|FG001|Double Blind Treatment Period|Lack of Efficacy|1
6348879|NCT03560518|10113346|FG002|Double Blind Treatment Period|Lack of Efficacy|1
6348880|NCT03560518|10113344|FG000|Double Blind Treatment Period|Adverse Event|0
6348881|NCT03560518|10113345|FG001|Double Blind Treatment Period|Adverse Event|3
6348882|NCT03560518|10113346|FG002|Double Blind Treatment Period|Adverse Event|1
6348883|NCT03560739|10113358|FG000|Overall Study|Adverse Event|0
6348884|NCT03560739|10113359|FG001|Overall Study|Adverse Event|1
6348885|NCT03560739|10113360|FG002|Overall Study|Adverse Event|0
6348886|NCT03560739|10113361|FG003|Overall Study|Adverse Event|0
6348887|NCT03560869|10113371|FG000|Overall Study|Withdrawal by Subject|3
6348888|NCT03560869|10113372|FG001|Overall Study|Withdrawal by Subject|4
6348889|NCT03560869|10113371|FG000|Overall Study|Screening failure|4
6348890|NCT03560869|10113372|FG001|Overall Study|Screening failure|4
6348891|NCT03560869|10113371|FG000|Overall Study|Withdrawal by PI|0
6348892|NCT03560869|10113372|FG001|Overall Study|Withdrawal by PI|1
6348893|NCT03560986|10113380|FG000|Treatment Period A/Follow-up Period 1|Withdrawal by Subject|3
6348894|NCT03560986|10113381|FG001|Treatment Period A/Follow-up Period 1|Withdrawal by Subject|1
6348895|NCT03560986|10113380|FG000|Treatment Period A/Follow-up Period 1|Lost to Follow-up|1
6348896|NCT03560986|10113381|FG001|Treatment Period A/Follow-up Period 1|Lost to Follow-up|1
6348897|NCT03560986|10113380|FG000|Treatment Period A/Follow-up Period 1|Protocol Violation|0
6348898|NCT03560986|10113381|FG001|Treatment Period A/Follow-up Period 1|Protocol Violation|1
6348899|NCT03560986|10113380|FG000|Treatment Period A/Follow-up Period 1|Disc. before end of Follow-up Period 1|32
6348900|NCT03560986|10113381|FG001|Treatment Period A/Follow-up Period 1|Disc. before end of Follow-up Period 1|35
6348901|NCT03560986|10113380|FG000|Treatment Period B/Follow-up Period 2|Adverse Event|1
6348902|NCT03560986|10113381|FG001|Treatment Period B/Follow-up Period 2|Adverse Event|0
6348903|NCT03560986|10113380|FG000|Treatment Period B/Follow-up Period 2|Withdrawal by Subject|0
6348904|NCT03560986|10113381|FG001|Treatment Period B/Follow-up Period 2|Withdrawal by Subject|1
6348905|NCT03560986|10113380|FG000|Treatment Period B/Follow-up Period 2|Disc. before end of Follow-up Period 2|7
6348906|NCT03560986|10113381|FG001|Treatment Period B/Follow-up Period 2|Disc. before end of Follow-up Period 2|7
6348907|NCT03561090|10113395|FG000|Overall Study|Adverse Event|11
6348908|NCT03561090|10113396|FG001|Overall Study|Adverse Event|7
6348909|NCT03561090|10113395|FG000|Overall Study|Non-Compliance With Study Drug|2
6348910|NCT03561090|10113396|FG001|Overall Study|Non-Compliance With Study Drug|0
6348911|NCT03561090|10113395|FG000|Overall Study|Protocol Violation|2
6348912|NCT03561090|10113396|FG001|Overall Study|Protocol Violation|2
6348913|NCT03561090|10113395|FG000|Overall Study|Withdrawal by Subject|7
6348914|NCT03561090|10113396|FG001|Overall Study|Withdrawal by Subject|7
6348915|NCT03561090|10113395|FG000|Overall Study|Lost to Follow-up|7
6348916|NCT03561090|10113396|FG001|Overall Study|Lost to Follow-up|2
6348917|NCT03561090|10113395|FG000|Overall Study|Study Terminated by Sponsor|10
6348918|NCT03561090|10113396|FG001|Overall Study|Study Terminated by Sponsor|15
6348919|NCT03561090|10113395|FG000|Overall Study|Randomized by Mistake|1
6348920|NCT03561090|10113396|FG001|Overall Study|Randomized by Mistake|1
6348921|NCT03561090|10113395|FG000|Overall Study|Other Not Specified|0
6348922|NCT03561090|10113396|FG001|Overall Study|Other Not Specified|2
6348923|NCT03561883|10113406|FG000|Overall Study|Adverse Event|10
6348924|NCT03561883|10113407|FG001|Overall Study|Adverse Event|13
6348925|NCT03561883|10113406|FG000|Overall Study|Non-Compliance With Study Drug|1
6348926|NCT03561883|10113407|FG001|Overall Study|Non-Compliance With Study Drug|2
6348927|NCT03561883|10113406|FG000|Overall Study|Protocol Violation|2
6348928|NCT03561883|10113407|FG001|Overall Study|Protocol Violation|3
6348929|NCT03561883|10113406|FG000|Overall Study|Withdrawal by Subject|14
6348930|NCT03561883|10113407|FG001|Overall Study|Withdrawal by Subject|6
6348931|NCT03561883|10113406|FG000|Overall Study|Lost to Follow-up|2
6348932|NCT03561883|10113407|FG001|Overall Study|Lost to Follow-up|6
6348933|NCT03561883|10113406|FG000|Overall Study|Study Terminated by Sponsor|12
6348934|NCT03561883|10113407|FG001|Overall Study|Study Terminated by Sponsor|11
6348935|NCT03561883|10113406|FG000|Overall Study|Physician Decision|1
6348936|NCT03561883|10113407|FG001|Overall Study|Physician Decision|0
6348937|NCT03561883|10113406|FG000|Overall Study|Randomized by Mistake|1
6348938|NCT03561883|10113407|FG001|Overall Study|Randomized by Mistake|0
6348939|NCT03561883|10113406|FG000|Overall Study|Other, Not Specified|3
6348940|NCT03561883|10113407|FG001|Overall Study|Other, Not Specified|2
6348941|NCT03562117|10113416|FG000|Part 1, Up to 3 Days|Adverse Event|1
6348942|NCT03562117|10113417|FG001|Part 1, Up to 3 Days|Adverse Event|0
6348943|NCT03562117|10113418|FG002|Part 1, Up to 3 Days|Adverse Event|0
6348944|NCT03562481|10113437|FG000|First Intervention|Lost to Follow-up|1
6348945|NCT03562481|10113438|FG001|First Intervention|Lost to Follow-up|0
6348946|NCT03565068|10113552|FG000|Overall Study|Protocol Violation|0
6348947|NCT03565068|10113553|FG001|Overall Study|Protocol Violation|0
6348948|NCT03565068|10113554|FG002|Overall Study|Protocol Violation|0
6348949|NCT03565068|10113555|FG003|Overall Study|Protocol Violation|0
6348950|NCT03565068|10113556|FG004|Overall Study|Protocol Violation|1
6348951|NCT03565068|10113557|FG005|Overall Study|Protocol Violation|0
6348952|NCT03565068|10113558|FG006|Overall Study|Protocol Violation|0
6348953|NCT03565068|10113559|FG007|Overall Study|Protocol Violation|1
6348954|NCT03565068|10113560|FG008|Overall Study|Protocol Violation|0
6348955|NCT03565068|10113552|FG000|Overall Study|Sponsor decision|0
6348956|NCT03565068|10113553|FG001|Overall Study|Sponsor decision|0
6348957|NCT03565068|10113554|FG002|Overall Study|Sponsor decision|0
6348958|NCT03565068|10113555|FG003|Overall Study|Sponsor decision|0
6348959|NCT03565068|10113556|FG004|Overall Study|Sponsor decision|1
6348960|NCT03565068|10113557|FG005|Overall Study|Sponsor decision|1
6348961|NCT03565068|10113558|FG006|Overall Study|Sponsor decision|0
6348962|NCT03565068|10113559|FG007|Overall Study|Sponsor decision|0
6348963|NCT03565068|10113560|FG008|Overall Study|Sponsor decision|0
6348964|NCT03565068|10113552|FG000|Overall Study|Withdrawal by Subject|0
6348965|NCT03565068|10113553|FG001|Overall Study|Withdrawal by Subject|0
6348966|NCT03565068|10113554|FG002|Overall Study|Withdrawal by Subject|1
6348967|NCT03565068|10113555|FG003|Overall Study|Withdrawal by Subject|0
6348968|NCT03565068|10113556|FG004|Overall Study|Withdrawal by Subject|2
6348969|NCT03565068|10113557|FG005|Overall Study|Withdrawal by Subject|0
6348970|NCT03565068|10113558|FG006|Overall Study|Withdrawal by Subject|1
6348971|NCT03565068|10113559|FG007|Overall Study|Withdrawal by Subject|5
6348972|NCT03565068|10113560|FG008|Overall Study|Withdrawal by Subject|1
6348973|NCT03565068|10113552|FG000|Overall Study|Physician Decision|0
6348974|NCT03565068|10113553|FG001|Overall Study|Physician Decision|0
6348975|NCT03565068|10113554|FG002|Overall Study|Physician Decision|0
6348976|NCT03565068|10113555|FG003|Overall Study|Physician Decision|0
6348977|NCT03565068|10113556|FG004|Overall Study|Physician Decision|0
6348978|NCT03565068|10113557|FG005|Overall Study|Physician Decision|0
6348979|NCT03565068|10113558|FG006|Overall Study|Physician Decision|0
6348980|NCT03565068|10113559|FG007|Overall Study|Physician Decision|1
6348981|NCT03565068|10113560|FG008|Overall Study|Physician Decision|0
6348982|NCT03565068|10113552|FG000|Overall Study|Lost to Follow-up|0
6348983|NCT03565068|10113553|FG001|Overall Study|Lost to Follow-up|0
6348984|NCT03565068|10113554|FG002|Overall Study|Lost to Follow-up|0
6348985|NCT03565068|10113555|FG003|Overall Study|Lost to Follow-up|0
6348986|NCT03565068|10113556|FG004|Overall Study|Lost to Follow-up|0
6348987|NCT03565068|10113557|FG005|Overall Study|Lost to Follow-up|0
6348988|NCT03565068|10113558|FG006|Overall Study|Lost to Follow-up|0
6348989|NCT03565068|10113559|FG007|Overall Study|Lost to Follow-up|1
6348990|NCT03565068|10113560|FG008|Overall Study|Lost to Follow-up|0
6348991|NCT03565211|10113617|FG000|Overall Study|Withdrawal by Subject|2
6348992|NCT03565211|10113617|FG000|Overall Study|Lost to Follow-up|1
6348993|NCT03565211|10113617|FG000|Overall Study|Adverse Event|44
6348994|NCT03565211|10113617|FG000|Overall Study|Personal issues|1
6348995|NCT03565315|10113625|FG000|Overall Study|IND Sponsor/PI Voluntary Study Pause|0
6348996|NCT03565315|10113626|FG001|Overall Study|IND Sponsor/PI Voluntary Study Pause|0
6348997|NCT03565315|10113627|FG002|Overall Study|IND Sponsor/PI Voluntary Study Pause|0
6348998|NCT03565315|10113628|FG003|Overall Study|IND Sponsor/PI Voluntary Study Pause|1
6348999|NCT03565887|10113677|FG000|Overall Study|Adverse Event|1
6349000|NCT03565887|10113678|FG001|Overall Study|Adverse Event|0
6349001|NCT03565887|10113677|FG000|Overall Study|Withdrawal by Subject|0
6349002|NCT03565887|10113678|FG001|Overall Study|Withdrawal by Subject|2
6349003|NCT03566238|10113687|FG000|Overall Study|Adverse Event|0
6349004|NCT03566238|10113688|FG001|Overall Study|Adverse Event|1
6349005|NCT03566238|10113689|FG002|Overall Study|Adverse Event|0
6349006|NCT03566238|10113687|FG000|Overall Study|Lack of Efficacy|4
6349007|NCT03566238|10113688|FG001|Overall Study|Lack of Efficacy|2
6349008|NCT03566238|10113689|FG002|Overall Study|Lack of Efficacy|5
6349009|NCT03566238|10113687|FG000|Overall Study|Other|1
6349010|NCT03566238|10113688|FG001|Overall Study|Other|0
6349011|NCT03566238|10113689|FG002|Overall Study|Other|0
6349012|NCT03566485|10113699|FG000|Overall Study|Disease progression|5
6349013|NCT03566485|10113700|FG001|Overall Study|Disease progression|4
6349014|NCT03566485|10113699|FG000|Overall Study|Clinical progression|0
6349015|NCT03566485|10113700|FG001|Overall Study|Clinical progression|1
6349016|NCT03566485|10113699|FG000|Overall Study|Toxicity|0
6349017|NCT03566485|10113700|FG001|Overall Study|Toxicity|2
6349018|NCT03566550|10113708|FG000|Overall Study|Withdrawal by Subject|0
6349019|NCT03566550|10113709|FG001|Overall Study|Withdrawal by Subject|1
6349020|NCT03566680|10113715|FG000|Overall Study|Pregnancy|1
6349021|NCT03566680|10113715|FG000|Overall Study|Lost to Follow-up|13
6349022|NCT03566680|10113715|FG000|Overall Study|Withdrawal by Subject|3
6349023|NCT03566810|10113723|FG000|Treatment Period 1 (Day 1-Day 3)|Enrolled, but never treated|0
6349024|NCT03566810|10113724|FG001|Treatment Period 1 (Day 1-Day 3)|Enrolled, but never treated|1
6083608|NCT00636207|9692102|FG006|Overall Study|Adverse Event|0
6083609|NCT00636207|9692096|FG000|Overall Study|Withdrawal by Subject|0
6083610|NCT00636207|9692097|FG001|Overall Study|Withdrawal by Subject|1
6349025|NCT03566810|10113725|FG002|Treatment Period 1 (Day 1-Day 3)|Enrolled, but never treated|0
6349026|NCT03566810|10113726|FG003|Treatment Period 1 (Day 1-Day 3)|Enrolled, but never treated|0
6349027|NCT03566823|10113739|FG000|Overall Study|Lack of Efficacy|0
6349028|NCT03566823|10113740|FG001|Overall Study|Lack of Efficacy|1
6349029|NCT03566823|10113741|FG002|Overall Study|Lack of Efficacy|0
6349030|NCT03566823|10113739|FG000|Overall Study|Withdrawal by Subject|1
6349031|NCT03566823|10113740|FG001|Overall Study|Withdrawal by Subject|2
6349032|NCT03566823|10113741|FG002|Overall Study|Withdrawal by Subject|0
6349033|NCT03566823|10113739|FG000|Overall Study|Adverse Event|1
6349034|NCT03566823|10113740|FG001|Overall Study|Adverse Event|0
6349035|NCT03566823|10113741|FG002|Overall Study|Adverse Event|2
6349036|NCT03566979|10113753|FG000|Overall Study|Withdrawal by Subject|2
6349037|NCT03566979|10113754|FG001|Overall Study|Withdrawal by Subject|0
6349038|NCT03566979|10113755|FG002|Overall Study|Withdrawal by Subject|1
6349039|NCT03566979|10113756|FG003|Overall Study|Withdrawal by Subject|1
6349040|NCT03566979|10113753|FG000|Overall Study|Lost to Follow-up|2
6349041|NCT03566979|10113754|FG001|Overall Study|Lost to Follow-up|7
6349042|NCT03566979|10113755|FG002|Overall Study|Lost to Follow-up|9
6349043|NCT03566979|10113756|FG003|Overall Study|Lost to Follow-up|5
6349044|NCT03566979|10113753|FG000|Overall Study|Adverse Event|1
6349045|NCT03566979|10113754|FG001|Overall Study|Adverse Event|0
6349046|NCT03566979|10113755|FG002|Overall Study|Adverse Event|0
6349047|NCT03566979|10113756|FG003|Overall Study|Adverse Event|0
6349048|NCT03567291|10113782|FG000|Period I|Adverse Event|14
6349049|NCT03567291|10113783|FG001|Period I|Adverse Event|0
6349050|NCT03567291|10113784|FG002|Period I|Adverse Event|0
6349051|NCT03567291|10113785|FG003|Period I|Adverse Event|0
6349052|NCT03567291|10113782|FG000|Period I|Protocol Violation|1
6349053|NCT03567291|10113783|FG001|Period I|Protocol Violation|0
6170207|NCT01251653|9816353|FG000|Overall Study|Adverse Event|1
6170208|NCT01251653|9816354|FG001|Overall Study|Adverse Event|0
6349054|NCT03567291|10113784|FG002|Period I|Protocol Violation|0
6349055|NCT03567291|10113785|FG003|Period I|Protocol Violation|0
6349056|NCT03567291|10113782|FG000|Period I|Withdrawal by Subject|23
6349057|NCT03567291|10113783|FG001|Period I|Withdrawal by Subject|0
6349058|NCT03567291|10113784|FG002|Period I|Withdrawal by Subject|0
6349059|NCT03567291|10113785|FG003|Period I|Withdrawal by Subject|0
6349060|NCT03567291|10113782|FG000|Period I|Lost to Follow-up|2
6349061|NCT03567291|10113783|FG001|Period I|Lost to Follow-up|0
6349062|NCT03567291|10113784|FG002|Period I|Lost to Follow-up|0
6349063|NCT03567291|10113785|FG003|Period I|Lost to Follow-up|0
6349064|NCT03567291|10113782|FG000|Period I|Terminated by sponsor|44
6349065|NCT03567291|10113783|FG001|Period I|Terminated by sponsor|0
6349066|NCT03567291|10113784|FG002|Period I|Terminated by sponsor|0
6349067|NCT03567291|10113785|FG003|Period I|Terminated by sponsor|0
6349068|NCT03567291|10113782|FG000|Period I|Missing or unknown|7
6349069|NCT03567291|10113783|FG001|Period I|Missing or unknown|0
6349070|NCT03567291|10113784|FG002|Period I|Missing or unknown|0
6349071|NCT03567291|10113785|FG003|Period I|Missing or unknown|0
6349072|NCT03567291|10113782|FG000|Period II|Adverse Event|0
6349073|NCT03567291|10113783|FG001|Period II|Adverse Event|1
6349074|NCT03567291|10113784|FG002|Period II|Adverse Event|0
6349075|NCT03567291|10113785|FG003|Period II|Adverse Event|0
6349076|NCT03567291|10113782|FG000|Period II|Missing or unknown|0
6349077|NCT03567291|10113783|FG001|Period II|Missing or unknown|2
6349078|NCT03567291|10113784|FG002|Period II|Missing or unknown|1
6349079|NCT03567291|10113785|FG003|Period II|Missing or unknown|0
6349080|NCT03567291|10113782|FG000|Period III|Adverse Event|0
6349081|NCT03567291|10113783|FG001|Period III|Adverse Event|0
6349082|NCT03567291|10113784|FG002|Period III|Adverse Event|0
6349083|NCT03567291|10113785|FG003|Period III|Adverse Event|4
6349084|NCT03567291|10113782|FG000|Period III|Withdrawal by Subject|0
6349085|NCT03567291|10113783|FG001|Period III|Withdrawal by Subject|0
6349086|NCT03567291|10113784|FG002|Period III|Withdrawal by Subject|0
6349087|NCT03567291|10113785|FG003|Period III|Withdrawal by Subject|4
6349088|NCT03567291|10113782|FG000|Period III|Lost to Follow-up|0
6349089|NCT03567291|10113783|FG001|Period III|Lost to Follow-up|0
6349090|NCT03567291|10113784|FG002|Period III|Lost to Follow-up|0
6349091|NCT03567291|10113785|FG003|Period III|Lost to Follow-up|1
6349092|NCT03567291|10113782|FG000|Period III|Terminated by sponsor|0
6349093|NCT03567291|10113783|FG001|Period III|Terminated by sponsor|0
6349094|NCT03567291|10113784|FG002|Period III|Terminated by sponsor|0
6349095|NCT03567291|10113785|FG003|Period III|Terminated by sponsor|68
6349096|NCT03567291|10113782|FG000|Period III|Missing or unknown|0
6349097|NCT03567291|10113783|FG001|Period III|Missing or unknown|0
6349098|NCT03567291|10113784|FG002|Period III|Missing or unknown|0
6349099|NCT03567291|10113785|FG003|Period III|Missing or unknown|8
6349100|NCT03567382|10113793|FG000|Overall Study|Lost to Follow-up|1
6349101|NCT03567382|10113794|FG001|Overall Study|Lost to Follow-up|21
6349102|NCT03567382|10113795|FG002|Overall Study|Lost to Follow-up|1
6349103|NCT03567382|10113796|FG003|Overall Study|Lost to Follow-up|21
6349104|NCT03567382|10113793|FG000|Overall Study|Withdrawal by Subject|2
6349105|NCT03567382|10113794|FG001|Overall Study|Withdrawal by Subject|14
6349106|NCT03567382|10113795|FG002|Overall Study|Withdrawal by Subject|1
6349107|NCT03567382|10113796|FG003|Overall Study|Withdrawal by Subject|12
6349108|NCT03567616|10113809|FG000|Overall Study|Disease progression|4
6349109|NCT03567616|10113809|FG000|Overall Study|Withdrawal by Subject|1
6349110|NCT03567616|10113809|FG000|Overall Study|Physician Decision|1
6349111|NCT03567616|10113809|FG000|Overall Study|Death|1
6349112|NCT03567616|10113809|FG000|Overall Study|Adverse Event|1
6349113|NCT03567980|10113816|FG000|Overall Study|Adverse Event|1
6349114|NCT03568500|10113823|FG000|Overall Study|Lost to Follow-up|1
6349115|NCT03568500|10113824|FG001|Overall Study|Lost to Follow-up|1
6349116|NCT03568500|10113825|FG002|Overall Study|Lost to Follow-up|2
6349117|NCT03568500|10113823|FG000|Overall Study|Adverse Event|1
6349118|NCT03568500|10113824|FG001|Overall Study|Adverse Event|1
6349119|NCT03568500|10113825|FG002|Overall Study|Adverse Event|2
6349120|NCT03568500|10113823|FG000|Overall Study|Physician Decision|1
6349121|NCT03568500|10113824|FG001|Overall Study|Physician Decision|0
6349122|NCT03568500|10113825|FG002|Overall Study|Physician Decision|0
6349123|NCT03568500|10113823|FG000|Overall Study|Withdrawal by Subject|4
6349124|NCT03568500|10113824|FG001|Overall Study|Withdrawal by Subject|2
6349125|NCT03568500|10113825|FG002|Overall Study|Withdrawal by Subject|0
6349126|NCT03568500|10113823|FG000|Overall Study|Technical Problems|2
6349127|NCT03568500|10113824|FG001|Overall Study|Technical Problems|1
6349128|NCT03568500|10113825|FG002|Overall Study|Technical Problems|0
6349129|NCT03568500|10113823|FG000|Overall Study|Participant Noncompliance|1
6349130|NCT03568500|10113824|FG001|Overall Study|Participant Noncompliance|1
6349131|NCT03568500|10113825|FG002|Overall Study|Participant Noncompliance|0
6349132|NCT03568942|10113848|FG000|Overall Study|Family emergency|1
6349133|NCT03568942|10113848|FG000|Overall Study|Lost to Follow-up|1
6349134|NCT03569098|10113877|FG000|Double-Blind Treatment Cycle 1|Withdrawal by Subject|5
6349135|NCT03569098|10113878|FG001|Double-Blind Treatment Cycle 1|Withdrawal by Subject|2
6349136|NCT03569098|10113879|FG002|Double-Blind Treatment Cycle 1|Withdrawal by Subject|5
6349137|NCT03569098|10113877|FG000|Double-Blind Treatment Cycle 1|Study terminated by sponsor|0
6349138|NCT03569098|10113878|FG001|Double-Blind Treatment Cycle 1|Study terminated by sponsor|6
6349139|NCT03569098|10113879|FG002|Double-Blind Treatment Cycle 1|Study terminated by sponsor|3
6349140|NCT03569098|10113877|FG000|Double-Blind Treatment Cycle 1|Lost to Follow-up|1
6349141|NCT03569098|10113878|FG001|Double-Blind Treatment Cycle 1|Lost to Follow-up|1
6349142|NCT03569098|10113879|FG002|Double-Blind Treatment Cycle 1|Lost to Follow-up|0
6349143|NCT03569098|10113877|FG000|Double-Blind Treatment Cycle 1|Technical problems|0
6349144|NCT03569098|10113878|FG001|Double-Blind Treatment Cycle 1|Technical problems|0
6349145|NCT03569098|10113879|FG002|Double-Blind Treatment Cycle 1|Technical problems|2
6349146|NCT03569098|10113877|FG000|Double-Blind Treatment Cycle 1|Physician Decision|1
6349147|NCT03569098|10113878|FG001|Double-Blind Treatment Cycle 1|Physician Decision|0
6349148|NCT03569098|10113879|FG002|Double-Blind Treatment Cycle 1|Physician Decision|0
6349149|NCT03569098|10113877|FG000|Double-Blind Treatment Cycle 1|Protocol deviation|0
6349150|NCT03569098|10113878|FG001|Double-Blind Treatment Cycle 1|Protocol deviation|1
6349151|NCT03569098|10113879|FG002|Double-Blind Treatment Cycle 1|Protocol deviation|0
6349152|NCT03569098|10113877|FG000|Double-Blind Treatment Cycle 1|Other|1
6349153|NCT03569098|10113878|FG001|Double-Blind Treatment Cycle 1|Other|0
6349154|NCT03569098|10113879|FG002|Double-Blind Treatment Cycle 1|Other|1
6349155|NCT03569098|10113877|FG000|Open-Label Treatment Cycle 2|Study terminated by sponsor|0
6349156|NCT03569098|10113878|FG001|Open-Label Treatment Cycle 2|Study terminated by sponsor|21
6349157|NCT03569098|10113879|FG002|Open-Label Treatment Cycle 2|Study terminated by sponsor|0
6349158|NCT03569098|10113877|FG000|Open-Label Treatment Cycle 2|Withdrawal by Subject|0
6349159|NCT03569098|10113878|FG001|Open-Label Treatment Cycle 2|Withdrawal by Subject|11
6349160|NCT03569098|10113879|FG002|Open-Label Treatment Cycle 2|Withdrawal by Subject|0
6349161|NCT03569098|10113877|FG000|Open-Label Treatment Cycle 2|Lost to Follow-up|0
6349162|NCT03569098|10113878|FG001|Open-Label Treatment Cycle 2|Lost to Follow-up|3
6349163|NCT03569098|10113879|FG002|Open-Label Treatment Cycle 2|Lost to Follow-up|0
6349164|NCT03569098|10113877|FG000|Open-Label Treatment Cycle 3|Withdrawal by Subject|0
6349165|NCT03569098|10113878|FG001|Open-Label Treatment Cycle 3|Withdrawal by Subject|0
6349166|NCT03569098|10113879|FG002|Open-Label Treatment Cycle 3|Withdrawal by Subject|4
6349167|NCT03569098|10113877|FG000|Open-Label Treatment Cycle 3|Study terminated by sponsor|0
6349168|NCT03569098|10113878|FG001|Open-Label Treatment Cycle 3|Study terminated by sponsor|1
6349169|NCT03569098|10113879|FG002|Open-Label Treatment Cycle 3|Study terminated by sponsor|1
6349170|NCT03569098|10113877|FG000|Open-Label Treatment Cycle 3|Lost to Follow-up|0
6349171|NCT03569098|10113878|FG001|Open-Label Treatment Cycle 3|Lost to Follow-up|0
6349172|NCT03569098|10113879|FG002|Open-Label Treatment Cycle 3|Lost to Follow-up|1
6349173|NCT03569202|10113892|FG000|Part 3|Physician Decision|1
6349174|NCT03569202|10113893|FG001|Part 3|Physician Decision|0
6349175|NCT03569202|10113892|FG000|Part 3|Other|1
6349176|NCT03569202|10113893|FG001|Part 3|Other|1
6349177|NCT03569371|10113899|FG000|Overall Study|Lack of Efficacy|1
6349178|NCT03569371|10113899|FG000|Overall Study|Lost to Follow-up|1
6349179|NCT03569371|10113899|FG000|Overall Study|Adverse Event|1
6349180|NCT03570554|10113970|FG000|Overall Study|Non-compliance with study drug|0
6349181|NCT03570554|10113971|FG001|Overall Study|Non-compliance with study drug|0
6349182|NCT03570554|10113972|FG002|Overall Study|Non-compliance with study drug|1
6349183|NCT03570554|10113973|FG003|Overall Study|Non-compliance with study drug|0
6349184|NCT03570554|10113970|FG000|Overall Study|Adverse Event|0
6349185|NCT03570554|10113971|FG001|Overall Study|Adverse Event|0
6349186|NCT03570554|10113972|FG002|Overall Study|Adverse Event|0
6349187|NCT03570554|10113973|FG003|Overall Study|Adverse Event|1
6349188|NCT03571256|10114017|FG000|Overall Study|Adverse Event|3
6349189|NCT03571256|10114018|FG001|Overall Study|Adverse Event|0
6349190|NCT03571256|10114019|FG002|Overall Study|Adverse Event|1
6349191|NCT03571256|10114017|FG000|Overall Study|Withdrawal by Subject|3
6349192|NCT03571256|10114018|FG001|Overall Study|Withdrawal by Subject|1
6349193|NCT03571256|10114019|FG002|Overall Study|Withdrawal by Subject|1
6349194|NCT03571256|10114017|FG000|Overall Study|Other than specified|0
6349195|NCT03571256|10114018|FG001|Overall Study|Other than specified|1
6349196|NCT03571256|10114019|FG002|Overall Study|Other than specified|1
6349197|NCT03571256|10114017|FG000|Overall Study|Protocol Violation|0
6349198|NCT03571256|10114018|FG001|Overall Study|Protocol Violation|1
6349199|NCT03571256|10114019|FG002|Overall Study|Protocol Violation|1
6349200|NCT03571516|10114031|FG000|Overall Study|Severe diarrhea|1
6349201|NCT03571516|10114032|FG001|Overall Study|Severe diarrhea|0
6349202|NCT03571516|10114031|FG000|Overall Study|Withdrawal by Subject|0
6349203|NCT03571516|10114032|FG001|Overall Study|Withdrawal by Subject|1
6349204|NCT03572062|10114102|FG000|Overall Study|Adverse Event|0
6349205|NCT03572062|10114103|FG001|Overall Study|Adverse Event|0
6349206|NCT03572062|10114104|FG002|Overall Study|Adverse Event|0
6349207|NCT03572062|10114105|FG003|Overall Study|Adverse Event|0
6349208|NCT03572062|10114106|FG004|Overall Study|Adverse Event|0
6349209|NCT03572062|10114107|FG005|Overall Study|Adverse Event|0
6349210|NCT03572062|10114108|FG006|Overall Study|Adverse Event|0
6349211|NCT03572062|10114109|FG007|Overall Study|Adverse Event|0
6349212|NCT03572062|10114110|FG008|Overall Study|Adverse Event|1
6349213|NCT03572062|10114111|FG009|Overall Study|Adverse Event|3
6349214|NCT03572062|10114102|FG000|Overall Study|Death|0
6349215|NCT03572062|10114103|FG001|Overall Study|Death|0
6349216|NCT03572062|10114104|FG002|Overall Study|Death|0
6349217|NCT03572062|10114105|FG003|Overall Study|Death|0
6349218|NCT03572062|10114106|FG004|Overall Study|Death|0
6349219|NCT03572062|10114107|FG005|Overall Study|Death|1
6349220|NCT03572062|10114108|FG006|Overall Study|Death|0
6349221|NCT03572062|10114109|FG007|Overall Study|Death|0
6349222|NCT03572062|10114110|FG008|Overall Study|Death|0
6349223|NCT03572062|10114111|FG009|Overall Study|Death|0
6349224|NCT03572062|10114102|FG000|Overall Study|Lost to Follow-up|0
6349225|NCT03572062|10114103|FG001|Overall Study|Lost to Follow-up|0
6349226|NCT03572062|10114104|FG002|Overall Study|Lost to Follow-up|0
6349227|NCT03572062|10114105|FG003|Overall Study|Lost to Follow-up|0
6349228|NCT03572062|10114106|FG004|Overall Study|Lost to Follow-up|0
6349229|NCT03572062|10114107|FG005|Overall Study|Lost to Follow-up|1
6349230|NCT03572062|10114108|FG006|Overall Study|Lost to Follow-up|1
6349231|NCT03572062|10114109|FG007|Overall Study|Lost to Follow-up|0
6349232|NCT03572062|10114110|FG008|Overall Study|Lost to Follow-up|0
6349233|NCT03572062|10114111|FG009|Overall Study|Lost to Follow-up|0
6349234|NCT03572062|10114102|FG000|Overall Study|No Longer Meets Eligibility Criteria|0
6083611|NCT00636207|9692098|FG002|Overall Study|Withdrawal by Subject|0
6083612|NCT00636207|9692099|FG003|Overall Study|Withdrawal by Subject|0
6083613|NCT00636207|9692100|FG004|Overall Study|Withdrawal by Subject|1
6349235|NCT03572062|10114103|FG001|Overall Study|No Longer Meets Eligibility Criteria|0
6349236|NCT03572062|10114104|FG002|Overall Study|No Longer Meets Eligibility Criteria|0
6349237|NCT03572062|10114105|FG003|Overall Study|No Longer Meets Eligibility Criteria|0
6349238|NCT03572062|10114106|FG004|Overall Study|No Longer Meets Eligibility Criteria|0
6349239|NCT03572062|10114107|FG005|Overall Study|No Longer Meets Eligibility Criteria|0
6349240|NCT03572062|10114108|FG006|Overall Study|No Longer Meets Eligibility Criteria|0
6349241|NCT03572062|10114109|FG007|Overall Study|No Longer Meets Eligibility Criteria|0
6349242|NCT03572062|10114110|FG008|Overall Study|No Longer Meets Eligibility Criteria|1
6349243|NCT03572062|10114111|FG009|Overall Study|No Longer Meets Eligibility Criteria|0
6349244|NCT03572062|10114102|FG000|Overall Study|Study Terminated By Sponsor|0
6349245|NCT03572062|10114103|FG001|Overall Study|Study Terminated By Sponsor|0
6349246|NCT03572062|10114104|FG002|Overall Study|Study Terminated By Sponsor|0
6349247|NCT03572062|10114105|FG003|Overall Study|Study Terminated By Sponsor|0
6349248|NCT03572062|10114106|FG004|Overall Study|Study Terminated By Sponsor|0
6349249|NCT03572062|10114107|FG005|Overall Study|Study Terminated By Sponsor|0
6349250|NCT03572062|10114108|FG006|Overall Study|Study Terminated By Sponsor|0
6349251|NCT03572062|10114109|FG007|Overall Study|Study Terminated By Sponsor|0
6349252|NCT03572062|10114110|FG008|Overall Study|Study Terminated By Sponsor|29
6349253|NCT03572062|10114111|FG009|Overall Study|Study Terminated By Sponsor|27
6349254|NCT03572062|10114102|FG000|Overall Study|Physician Decision|0
6349255|NCT03572062|10114103|FG001|Overall Study|Physician Decision|0
6349256|NCT03572062|10114104|FG002|Overall Study|Physician Decision|0
6349257|NCT03572062|10114105|FG003|Overall Study|Physician Decision|0
6349258|NCT03572062|10114106|FG004|Overall Study|Physician Decision|0
6349259|NCT03572062|10114107|FG005|Overall Study|Physician Decision|0
6349260|NCT03572062|10114108|FG006|Overall Study|Physician Decision|0
6349261|NCT03572062|10114109|FG007|Overall Study|Physician Decision|0
6349262|NCT03572062|10114110|FG008|Overall Study|Physician Decision|1
6349263|NCT03572062|10114111|FG009|Overall Study|Physician Decision|0
6349264|NCT03572062|10114102|FG000|Overall Study|Withdrawal by Subject|0
6349265|NCT03572062|10114103|FG001|Overall Study|Withdrawal by Subject|0
6349266|NCT03572062|10114104|FG002|Overall Study|Withdrawal by Subject|0
6349267|NCT03572062|10114105|FG003|Overall Study|Withdrawal by Subject|0
6349268|NCT03572062|10114106|FG004|Overall Study|Withdrawal by Subject|0
6349269|NCT03572062|10114107|FG005|Overall Study|Withdrawal by Subject|0
6349270|NCT03572062|10114108|FG006|Overall Study|Withdrawal by Subject|0
6349271|NCT03572062|10114109|FG007|Overall Study|Withdrawal by Subject|0
6349272|NCT03572062|10114110|FG008|Overall Study|Withdrawal by Subject|0
6349273|NCT03572062|10114111|FG009|Overall Study|Withdrawal by Subject|1
6349274|NCT03572062|10114102|FG000|Overall Study|Randomized But Not Treated|0
6349275|NCT03572062|10114103|FG001|Overall Study|Randomized But Not Treated|0
6349276|NCT03572062|10114104|FG002|Overall Study|Randomized But Not Treated|0
6349277|NCT03572062|10114105|FG003|Overall Study|Randomized But Not Treated|0
6349278|NCT03572062|10114106|FG004|Overall Study|Randomized But Not Treated|1
6349279|NCT03572062|10114107|FG005|Overall Study|Randomized But Not Treated|2
6349280|NCT03572062|10114108|FG006|Overall Study|Randomized But Not Treated|0
6083614|NCT00636207|9692101|FG005|Overall Study|Withdrawal by Subject|0
6349281|NCT03572062|10114109|FG007|Overall Study|Randomized But Not Treated|1
6349282|NCT03572062|10114110|FG008|Overall Study|Randomized But Not Treated|0
6349283|NCT03572062|10114111|FG009|Overall Study|Randomized But Not Treated|0
6349284|NCT03572218|10114133|FG000|Overall Study|Lost to Follow-up|3
6349285|NCT03572218|10114134|FG001|Overall Study|Lost to Follow-up|2
6349286|NCT03572218|10114133|FG000|Overall Study|No longer available for study visits|2
6349287|NCT03572218|10114134|FG001|Overall Study|No longer available for study visits|1
6349288|NCT03572218|10114133|FG000|Overall Study|No longer interested|1
6349289|NCT03572218|10114134|FG001|Overall Study|No longer interested|2
6349290|NCT03573323|10114179|FG000|Blinded Treatment Period (Weeks 0-24)|Screen Failure|1
6349291|NCT03573323|10114180|FG001|Blinded Treatment Period (Weeks 0-24)|Screen Failure|1
6349292|NCT03573323|10114179|FG000|Blinded Treatment Period (Weeks 0-24)|Adverse Event|15
6349293|NCT03573323|10114180|FG001|Blinded Treatment Period (Weeks 0-24)|Adverse Event|8
6349294|NCT03573323|10114179|FG000|Blinded Treatment Period (Weeks 0-24)|Protocol Violation|3
6349295|NCT03573323|10114180|FG001|Blinded Treatment Period (Weeks 0-24)|Protocol Violation|8
6349296|NCT03573323|10114179|FG000|Blinded Treatment Period (Weeks 0-24)|Withdrawal by Subject|17
6349297|NCT03573323|10114180|FG001|Blinded Treatment Period (Weeks 0-24)|Withdrawal by Subject|9
6349298|NCT03573323|10114179|FG000|Blinded Treatment Period (Weeks 0-24)|Lack of Efficacy|2
6349299|NCT03573323|10114180|FG001|Blinded Treatment Period (Weeks 0-24)|Lack of Efficacy|3
6349300|NCT03573323|10114179|FG000|Blinded Treatment Period (Weeks 0-24)|Pregnancy|1
6349301|NCT03573323|10114180|FG001|Blinded Treatment Period (Weeks 0-24)|Pregnancy|2
6349302|NCT03573323|10114179|FG000|Blinded Treatment Period (Weeks 0-24)|Physician Decision|1
6349303|NCT03573323|10114180|FG001|Blinded Treatment Period (Weeks 0-24)|Physician Decision|0
6349304|NCT03573323|10114179|FG000|Blinded Treatment Period (Weeks 0-24)|Lost to Follow-up|14
6349305|NCT03573323|10114180|FG001|Blinded Treatment Period (Weeks 0-24)|Lost to Follow-up|13
6349306|NCT03573323|10114179|FG000|Blinded Treatment Period (Weeks 0-24)|Sponsor Decision|0
6349307|NCT03573323|10114180|FG001|Blinded Treatment Period (Weeks 0-24)|Sponsor Decision|1
6349308|NCT03573323|10114179|FG000|Blinded Treatment Period (Weeks 0-24)|Alkaline Phosphatase (ALP) level reached|0
6349309|NCT03573323|10114180|FG001|Blinded Treatment Period (Weeks 0-24)|Alkaline Phosphatase (ALP) level reached|1
6349310|NCT03573323|10114179|FG000|Blinded Treatment Period (Weeks 0-24)|Noncompliant to protocol procedures|1
6349311|NCT03573323|10114180|FG001|Blinded Treatment Period (Weeks 0-24)|Noncompliant to protocol procedures|2
6349312|NCT03573323|10114179|FG000|Post-Treatment Follow Up (Weeks 25-36)|Withdrawal by Subject|22
6349313|NCT03573323|10114180|FG001|Post-Treatment Follow Up (Weeks 25-36)|Withdrawal by Subject|12
6349314|NCT03573323|10114179|FG000|Post-Treatment Follow Up (Weeks 25-36)|Lack of Efficacy|8
6349315|NCT03573323|10114180|FG001|Post-Treatment Follow Up (Weeks 25-36)|Lack of Efficacy|19
6349316|NCT03573323|10114179|FG000|Post-Treatment Follow Up (Weeks 25-36)|Physician Decision|4
6349317|NCT03573323|10114180|FG001|Post-Treatment Follow Up (Weeks 25-36)|Physician Decision|3
6349318|NCT03573323|10114179|FG000|Post-Treatment Follow Up (Weeks 25-36)|Did not wish to return to study|3
6349319|NCT03573323|10114180|FG001|Post-Treatment Follow Up (Weeks 25-36)|Did not wish to return to study|2
6349320|NCT03573323|10114179|FG000|Post-Treatment Follow Up (Weeks 25-36)|Discontinued Trt and Completed Follow Up|14
6349321|NCT03573323|10114180|FG001|Post-Treatment Follow Up (Weeks 25-36)|Discontinued Trt and Completed Follow Up|8
6349322|NCT03573323|10114179|FG000|Post-Treatment Follow Up (Weeks 25-36)|Not Compliant to Protocol Procedures|8
6349323|NCT03573323|10114180|FG001|Post-Treatment Follow Up (Weeks 25-36)|Not Compliant to Protocol Procedures|11
6349324|NCT03573323|10114179|FG000|Post-Treatment Follow Up (Weeks 25-36)|Sponsor Decision|0
6349325|NCT03573323|10114180|FG001|Post-Treatment Follow Up (Weeks 25-36)|Sponsor Decision|1
6349326|NCT03573323|10114179|FG000|Post-Treatment Follow Up (Weeks 25-36)|Repeat Infections|0
6349327|NCT03573323|10114180|FG001|Post-Treatment Follow Up (Weeks 25-36)|Repeat Infections|1
6349328|NCT03573505|10114192|FG000|Overall Study|Adverse Event|1
6349329|NCT03573505|10114193|FG001|Overall Study|Adverse Event|1
6349330|NCT03573505|10114192|FG000|Overall Study|Consent withdrawn|0
6349331|NCT03573505|10114193|FG001|Overall Study|Consent withdrawn|1
6349332|NCT03573505|10114192|FG000|Overall Study|Disease progression|0
6349333|NCT03573505|10114193|FG001|Overall Study|Disease progression|1
6349334|NCT03573505|10114192|FG000|Overall Study|Site Terminated by Sponsor|1
6349335|NCT03573505|10114193|FG001|Overall Study|Site Terminated by Sponsor|1
6349336|NCT03573505|10114192|FG000|Overall Study|Study terminated by sponsor|50
6349337|NCT03573505|10114193|FG001|Overall Study|Study terminated by sponsor|45
6349338|NCT03573505|10114192|FG000|Overall Study|Reason not specified|0
6349339|NCT03573505|10114193|FG001|Overall Study|Reason not specified|1
6349340|NCT03573505|10114192|FG000|Overall Study|Death|0
6349341|NCT03573505|10114193|FG001|Overall Study|Death|4
6349342|NCT03573804|10114200|FG000|Overall Study|claustrophobia or MRI table problems|10
6349343|NCT03573830|10114212|FG000|Overall Study|Dropped without completing treatment|0
6349344|NCT03573830|10114213|FG001|Overall Study|Dropped without completing treatment|7
6349345|NCT03573830|10114212|FG000|Overall Study|Lost to Follow-up|4
6349346|NCT03573830|10114213|FG001|Overall Study|Lost to Follow-up|0
6349347|NCT03573908|10114220|FG000|Treatment Period|Adverse Event|4
6349348|NCT03573908|10114221|FG001|Treatment Period|Adverse Event|9
6349349|NCT03573908|10114222|FG002|Treatment Period|Adverse Event|0
6349350|NCT03573908|10114223|FG003|Treatment Period|Adverse Event|0
6349351|NCT03573908|10114224|FG004|Treatment Period|Adverse Event|0
6349352|NCT03573908|10114220|FG000|Treatment Period|Protocol Violation|1
6349353|NCT03573908|10114221|FG001|Treatment Period|Protocol Violation|0
6349354|NCT03573908|10114222|FG002|Treatment Period|Protocol Violation|0
6349355|NCT03573908|10114223|FG003|Treatment Period|Protocol Violation|0
6349356|NCT03573908|10114224|FG004|Treatment Period|Protocol Violation|0
6349357|NCT03573908|10114220|FG000|Treatment Period|Withdrawal by Subject|7
6349358|NCT03573908|10114221|FG001|Treatment Period|Withdrawal by Subject|5
6349359|NCT03573908|10114222|FG002|Treatment Period|Withdrawal by Subject|0
6349360|NCT03573908|10114223|FG003|Treatment Period|Withdrawal by Subject|0
6349361|NCT03573908|10114224|FG004|Treatment Period|Withdrawal by Subject|0
6349362|NCT03573908|10114220|FG000|Treatment Period|Lost to Follow-up|7
6349363|NCT03573908|10114221|FG001|Treatment Period|Lost to Follow-up|6
6349364|NCT03573908|10114222|FG002|Treatment Period|Lost to Follow-up|0
6349365|NCT03573908|10114223|FG003|Treatment Period|Lost to Follow-up|0
6349366|NCT03573908|10114224|FG004|Treatment Period|Lost to Follow-up|0
6349367|NCT03573908|10114220|FG000|Treatment Period|Pregnancy|1
6349368|NCT03573908|10114221|FG001|Treatment Period|Pregnancy|0
6349369|NCT03573908|10114222|FG002|Treatment Period|Pregnancy|0
6349370|NCT03573908|10114223|FG003|Treatment Period|Pregnancy|0
6349371|NCT03573908|10114224|FG004|Treatment Period|Pregnancy|0
6349372|NCT03573908|10114220|FG000|Treatment Period|Other, Not Specified|4
6349373|NCT03573908|10114221|FG001|Treatment Period|Other, Not Specified|6
6349374|NCT03573908|10114222|FG002|Treatment Period|Other, Not Specified|0
6349375|NCT03573908|10114223|FG003|Treatment Period|Other, Not Specified|0
6349376|NCT03573908|10114224|FG004|Treatment Period|Other, Not Specified|0
6349377|NCT03573908|10114220|FG000|Randomized Withdrawal Period|Adverse Event|0
6349378|NCT03573908|10114221|FG001|Randomized Withdrawal Period|Adverse Event|0
6349379|NCT03573908|10114222|FG002|Randomized Withdrawal Period|Adverse Event|3
6349380|NCT03573908|10114223|FG003|Randomized Withdrawal Period|Adverse Event|0
6349381|NCT03573908|10114224|FG004|Randomized Withdrawal Period|Adverse Event|0
6349382|NCT03573908|10114220|FG000|Randomized Withdrawal Period|Withdrawal by Subject|0
6349383|NCT03573908|10114221|FG001|Randomized Withdrawal Period|Withdrawal by Subject|0
6349384|NCT03573908|10114222|FG002|Randomized Withdrawal Period|Withdrawal by Subject|0
6349385|NCT03573908|10114223|FG003|Randomized Withdrawal Period|Withdrawal by Subject|0
6349386|NCT03573908|10114224|FG004|Randomized Withdrawal Period|Withdrawal by Subject|2
6349387|NCT03573908|10114220|FG000|Randomized Withdrawal Period|Lost to Follow-up|0
6349388|NCT03573908|10114221|FG001|Randomized Withdrawal Period|Lost to Follow-up|0
6349389|NCT03573908|10114222|FG002|Randomized Withdrawal Period|Lost to Follow-up|1
6349390|NCT03573908|10114223|FG003|Randomized Withdrawal Period|Lost to Follow-up|0
6349391|NCT03573908|10114224|FG004|Randomized Withdrawal Period|Lost to Follow-up|0
6349392|NCT03573908|10114220|FG000|Randomized Withdrawal Period|Other, Not Specified|0
6349393|NCT03573908|10114221|FG001|Randomized Withdrawal Period|Other, Not Specified|0
6349394|NCT03573908|10114222|FG002|Randomized Withdrawal Period|Other, Not Specified|4
6349395|NCT03573908|10114223|FG003|Randomized Withdrawal Period|Other, Not Specified|2
6349396|NCT03573908|10114224|FG004|Randomized Withdrawal Period|Other, Not Specified|0
6349397|NCT03574753|10114250|FG000|Overall Study|Adverse Event|3
6349398|NCT03574753|10114250|FG000|Overall Study|Progression/relapse|19
6349399|NCT03574753|10114250|FG000|Overall Study|Death|1
6349400|NCT03575702|10114261|FG000|Overall Study|Withdrawal by Subject|1
6349401|NCT03575702|10114262|FG001|Overall Study|Withdrawal by Subject|1
6349402|NCT03575702|10114261|FG000|Overall Study|Lost to Follow-up|1
6349403|NCT03575702|10114262|FG001|Overall Study|Lost to Follow-up|2
6349404|NCT03575702|10114261|FG000|Overall Study|Protocol Violation|0
6349405|NCT03575702|10114262|FG001|Overall Study|Protocol Violation|1
6349406|NCT03575702|10114261|FG000|Overall Study|Patient non compliance|4
6083615|NCT00636207|9692102|FG006|Overall Study|Withdrawal by Subject|0
6083616|NCT00636363|9692130|FG000|Overall Study|Conjunctivitis|0
6083617|NCT00636363|9692131|FG001|Overall Study|Conjunctivitis|0
6083618|NCT00636363|9692132|FG002|Overall Study|Conjunctivitis|1
6083619|NCT00636363|9692130|FG000|Overall Study|Adverse Event|0
6083620|NCT00636363|9692131|FG001|Overall Study|Adverse Event|0
6083621|NCT00636363|9692132|FG002|Overall Study|Adverse Event|1
6083622|NCT00636363|9692130|FG000|Overall Study|Positive slit lamp finding|0
6349407|NCT03575702|10114262|FG001|Overall Study|Patient non compliance|0
6349408|NCT03575806|10114279|FG000|Overall Study|Withdrawal by Subject|0
6349409|NCT03575806|10114280|FG001|Overall Study|Withdrawal by Subject|2
6349410|NCT03575806|10114279|FG000|Overall Study|Protocol Violation|0
6349411|NCT03575806|10114280|FG001|Overall Study|Protocol Violation|2
6349412|NCT03575871|10114289|FG000|Overall Study|Adverse Event|5
6349413|NCT03575871|10114290|FG001|Overall Study|Adverse Event|5
6349414|NCT03575871|10114291|FG002|Overall Study|Adverse Event|8
6349415|NCT03575871|10114289|FG000|Overall Study|Death|1
6349416|NCT03575871|10114290|FG001|Overall Study|Death|0
6349417|NCT03575871|10114291|FG002|Overall Study|Death|0
6349418|NCT03575871|10114289|FG000|Overall Study|Lack of Efficacy|5
6349419|NCT03575871|10114290|FG001|Overall Study|Lack of Efficacy|4
6349420|NCT03575871|10114291|FG002|Overall Study|Lack of Efficacy|7
6349421|NCT03575871|10114289|FG000|Overall Study|Lost to Follow-up|1
6349422|NCT03575871|10114290|FG001|Overall Study|Lost to Follow-up|1
6349423|NCT03575871|10114291|FG002|Overall Study|Lost to Follow-up|1
6349424|NCT03575871|10114289|FG000|Overall Study|Protocol Deviation|1
6349425|NCT03575871|10114290|FG001|Overall Study|Protocol Deviation|1
6349426|NCT03575871|10114291|FG002|Overall Study|Protocol Deviation|1
6349427|NCT03575871|10114289|FG000|Overall Study|Withdrawal by Subject|6
6349428|NCT03575871|10114290|FG001|Overall Study|Withdrawal by Subject|1
6349429|NCT03575871|10114291|FG002|Overall Study|Withdrawal by Subject|9
6349430|NCT03575871|10114289|FG000|Overall Study|Other than specified|2
6349431|NCT03575871|10114290|FG001|Overall Study|Other than specified|2
6349432|NCT03575871|10114291|FG002|Overall Study|Other than specified|0
6349433|NCT03575975|10114309|FG000|Overall Study|Lost to Follow-up|1
6349434|NCT03575975|10114310|FG001|Overall Study|Lost to Follow-up|0
6349435|NCT03575975|10114311|FG002|Overall Study|Lost to Follow-up|0
6349436|NCT03576066|10114319|FG000|Overall Study|Noncompliance with study drug|0
6349437|NCT03576066|10114320|FG001|Overall Study|Noncompliance with study drug|1
6349438|NCT03576768|10114352|FG000|Overall Study|Lost to Follow-up|3
6349439|NCT03576768|10114353|FG001|Overall Study|Lost to Follow-up|3
6349440|NCT03576768|10114354|FG002|Overall Study|Lost to Follow-up|0
6349441|NCT03576768|10114355|FG003|Overall Study|Lost to Follow-up|0
6349442|NCT03577730|10114390|FG000|Overall Study|Physician Decision|3
6349443|NCT03577730|10114391|FG001|Overall Study|Physician Decision|1
6349444|NCT03577730|10114390|FG000|Overall Study|Did not receive allocated intervention|1
6349445|NCT03577730|10114391|FG001|Overall Study|Did not receive allocated intervention|0
6349446|NCT03578146|10114403|FG000|Overall Study|Did Not Receive Treatment|1
6349447|NCT03578146|10114404|FG001|Overall Study|Did Not Receive Treatment|0
6349448|NCT03578146|10114405|FG002|Overall Study|Did Not Receive Treatment|0
6349449|NCT03578146|10114406|FG003|Overall Study|Did Not Receive Treatment|0
6349450|NCT03578146|10114407|FG004|Overall Study|Did Not Receive Treatment|0
6349451|NCT03578146|10114408|FG005|Overall Study|Did Not Receive Treatment|2
6349452|NCT03578146|10114403|FG000|Overall Study|Lost to Follow-up|0
6349453|NCT03578146|10114404|FG001|Overall Study|Lost to Follow-up|1
6349454|NCT03578146|10114405|FG002|Overall Study|Lost to Follow-up|1
6349455|NCT03578146|10114406|FG003|Overall Study|Lost to Follow-up|0
6349456|NCT03578146|10114407|FG004|Overall Study|Lost to Follow-up|0
6349457|NCT03578146|10114408|FG005|Overall Study|Lost to Follow-up|1
6349458|NCT03579290|10114435|FG000|Overall Study|Lost to Follow-up|9
6349459|NCT03579719|10114447|FG000|Overall Study|Protocol deviation, pre-existent disease|1
6349460|NCT03579940|10114462|FG000|Period 2|Withdrawal by Subject|0
6349461|NCT03579940|10114463|FG001|Period 2|Withdrawal by Subject|0
6349462|NCT03579940|10114464|FG002|Period 2|Withdrawal by Subject|1
6349463|NCT03579940|10114465|FG003|Period 2|Withdrawal by Subject|0
6349464|NCT03579940|10114466|FG004|Period 2|Withdrawal by Subject|0
6349465|NCT03579940|10114467|FG005|Period 2|Withdrawal by Subject|0
6349466|NCT03579940|10114468|FG006|Period 2|Withdrawal by Subject|0
6349467|NCT03579940|10114469|FG007|Period 2|Withdrawal by Subject|0
6349468|NCT03579940|10114470|FG008|Period 2|Withdrawal by Subject|0
6349469|NCT03579940|10114471|FG009|Period 2|Withdrawal by Subject|0
6083623|NCT00636363|9692131|FG001|Overall Study|Positive slit lamp finding|2
6349470|NCT03579940|10114472|FG010|Period 2|Withdrawal by Subject|0
6349471|NCT03581825|10114527|FG000|Period 1|Lens Discomfort|1
6349472|NCT03581825|10114528|FG001|Period 1|Lens Discomfort|0
6349473|NCT03581825|10114527|FG000|Period 2|Unsatisfactory Vision to Test|0
6349474|NCT03581825|10114528|FG001|Period 2|Unsatisfactory Vision to Test|1
6349475|NCT03582215|10114542|FG000|Overall Study|Adverse Event|1
6349476|NCT03582215|10114543|FG001|Overall Study|Adverse Event|0
6349477|NCT03582215|10114544|FG002|Overall Study|Adverse Event|0
6349478|NCT03582215|10114545|FG003|Overall Study|Adverse Event|0
6349479|NCT03582215|10114546|FG004|Overall Study|Adverse Event|0
6349480|NCT03582215|10114547|FG005|Overall Study|Adverse Event|0
6349481|NCT03582215|10114548|FG006|Overall Study|Adverse Event|2
6349482|NCT03582215|10114549|FG007|Overall Study|Adverse Event|2
6349483|NCT03582813|10114609|FG000|Overall Study|Lost to Follow-up|18
6349484|NCT03582813|10114610|FG001|Overall Study|Lost to Follow-up|21
6349485|NCT03582813|10114609|FG000|Overall Study|Withdrawal by Subject|1
6349486|NCT03582813|10114610|FG001|Overall Study|Withdrawal by Subject|0
6349487|NCT03582826|10114618|FG000|Overall Study|Lost to Follow-up|39
6349488|NCT03582826|10114619|FG001|Overall Study|Lost to Follow-up|0
6349489|NCT03582826|10114618|FG000|Overall Study|Withdrawal by Subject|2
6349490|NCT03582826|10114619|FG001|Overall Study|Withdrawal by Subject|0
6349491|NCT03582943|10114636|FG000|Allocated to Groups|Withdrawal by Subject|1
6349492|NCT03582943|10114637|FG001|Allocated to Groups|Withdrawal by Subject|1
6349493|NCT03582943|10114636|FG000|Intervention and Follow up|Withdrawal by Subject|4
6349494|NCT03582943|10114637|FG001|Intervention and Follow up|Withdrawal by Subject|2
6349495|NCT03582943|10114636|FG000|Analyzed|Protocol Violation|4
6349496|NCT03582943|10114637|FG001|Analyzed|Protocol Violation|1
6349497|NCT03583372|10114647|FG000|Overall Study|Withdrawal by Subject|6
6349498|NCT03583372|10114648|FG001|Overall Study|Withdrawal by Subject|11
6349499|NCT03583372|10114649|FG002|Overall Study|Withdrawal by Subject|7
6349500|NCT03583372|10114650|FG003|Overall Study|Withdrawal by Subject|8
6349501|NCT03583372|10114647|FG000|Overall Study|Lost to Follow-up|4
6349502|NCT03583372|10114648|FG001|Overall Study|Lost to Follow-up|6
6349503|NCT03583372|10114649|FG002|Overall Study|Lost to Follow-up|3
6349504|NCT03583372|10114650|FG003|Overall Study|Lost to Follow-up|2
6349505|NCT03583372|10114647|FG000|Overall Study|Adverse Event|1
6349506|NCT03583372|10114648|FG001|Overall Study|Adverse Event|3
6349507|NCT03583372|10114649|FG002|Overall Study|Adverse Event|4
6349508|NCT03583372|10114650|FG003|Overall Study|Adverse Event|4
6349509|NCT03583372|10114647|FG000|Overall Study|Physician Decision|0
6349510|NCT03583372|10114648|FG001|Overall Study|Physician Decision|1
6349511|NCT03583372|10114649|FG002|Overall Study|Physician Decision|1
6349512|NCT03583372|10114650|FG003|Overall Study|Physician Decision|1
6349513|NCT03583372|10114647|FG000|Overall Study|Lack of Efficacy|0
6349514|NCT03583372|10114648|FG001|Overall Study|Lack of Efficacy|1
6349515|NCT03583372|10114649|FG002|Overall Study|Lack of Efficacy|0
6349516|NCT03583372|10114650|FG003|Overall Study|Lack of Efficacy|1
6349517|NCT03583372|10114647|FG000|Overall Study|Death|1
6349518|NCT03583372|10114648|FG001|Overall Study|Death|0
6349519|NCT03583372|10114649|FG002|Overall Study|Death|0
6349520|NCT03583372|10114650|FG003|Overall Study|Death|0
6349521|NCT03583372|10114647|FG000|Overall Study|Protocol Violation|0
6349522|NCT03583372|10114648|FG001|Overall Study|Protocol Violation|1
6349523|NCT03583372|10114649|FG002|Overall Study|Protocol Violation|0
6349524|NCT03583372|10114650|FG003|Overall Study|Protocol Violation|0
6349525|NCT03583372|10114647|FG000|Overall Study|Subject Withdrawn due to Sponsor|0
6349526|NCT03583372|10114648|FG001|Overall Study|Subject Withdrawn due to Sponsor|0
6349527|NCT03583372|10114649|FG002|Overall Study|Subject Withdrawn due to Sponsor|0
6349528|NCT03583372|10114650|FG003|Overall Study|Subject Withdrawn due to Sponsor|1
6349529|NCT03583372|10114647|FG000|Overall Study|Did Not Receive Study Drug|0
6349530|NCT03583372|10114648|FG001|Overall Study|Did Not Receive Study Drug|1
6349531|NCT03583372|10114649|FG002|Overall Study|Did Not Receive Study Drug|0
6349532|NCT03583372|10114650|FG003|Overall Study|Did Not Receive Study Drug|0
6349533|NCT03583372|10114647|FG000|Overall Study|Captured as Other in the Database|1
6349534|NCT03583372|10114648|FG001|Overall Study|Captured as Other in the Database|2
6349535|NCT03583372|10114649|FG002|Overall Study|Captured as Other in the Database|4
6349536|NCT03583372|10114650|FG003|Overall Study|Captured as Other in the Database|1
6349537|NCT03583385|10114660|FG000|Treatment Period 1|Withdrawal by Subject|1
6349538|NCT03583385|10114661|FG001|Treatment Period 1|Withdrawal by Subject|1
6349539|NCT03583385|10114660|FG000|Treatment Period 2|Adverse Event|1
6349540|NCT03583385|10114661|FG001|Treatment Period 2|Adverse Event|0
6349541|NCT03583450|10114669|FG000|Overall Study|hardware malfunction (battery depletion)|1
6349542|NCT03583450|10114670|FG001|Overall Study|hardware malfunction (battery depletion)|0
6349543|NCT03583606|10114681|FG000|Overall Study|Lost to Follow-up|0
6349544|NCT03583606|10114682|FG001|Overall Study|Lost to Follow-up|1
6349545|NCT03583606|10114683|FG002|Overall Study|Lost to Follow-up|0
6349546|NCT03583606|10114681|FG000|Overall Study|Ineligible at baseline|1
6349547|NCT03583606|10114682|FG001|Overall Study|Ineligible at baseline|0
6349548|NCT03583606|10114683|FG002|Overall Study|Ineligible at baseline|0
6349549|NCT03584009|10114694|FG000|Overall Study|Death|18
6349550|NCT03584009|10114695|FG001|Overall Study|Death|9
6349551|NCT03584009|10114694|FG000|Overall Study|Lost to Follow-up|0
6349552|NCT03584009|10114695|FG001|Overall Study|Lost to Follow-up|1
6349553|NCT03584009|10114694|FG000|Overall Study|Physician Decision|1
6349554|NCT03584009|10114695|FG001|Overall Study|Physician Decision|1
6349555|NCT03584009|10114694|FG000|Overall Study|Withdrawal by Subject|3
6349556|NCT03584009|10114695|FG001|Overall Study|Withdrawal by Subject|1
6349557|NCT03584009|10114694|FG000|Overall Study|Ongoing in study|29
6349558|NCT03584009|10114695|FG001|Overall Study|Ongoing in study|40
6349559|NCT03585244|10114708|FG000|Overall Study|Withdrawal by Subject|15
6349560|NCT03585296|10114712|FG000|Overall Study|Adverse Event|1
6349561|NCT03585296|10114712|FG000|Overall Study|Lost to Follow-up|2
6349562|NCT03585296|10114712|FG000|Overall Study|Withdrawal by Subject|2
6349563|NCT03585504|10114718|FG000|Overall Study|Lost to Follow-up|26
6349564|NCT03585504|10114719|FG001|Overall Study|Lost to Follow-up|29
6349565|NCT03585712|10114730|FG000|Treatment Period 1|Protocol Violation|1
6349566|NCT03585712|10114731|FG001|Treatment Period 1|Protocol Violation|0
6349567|NCT03585712|10114732|FG002|Treatment Period 1|Protocol Violation|0
6349568|NCT03585712|10114730|FG000|Treatment Periods 2 and 3|Protocol Violation|0
6349569|NCT03585712|10114731|FG001|Treatment Periods 2 and 3|Protocol Violation|1
6349570|NCT03585712|10114732|FG002|Treatment Periods 2 and 3|Protocol Violation|1
6349571|NCT03585712|10114730|FG000|Treatment Periods 2 and 3|Withdrawal by Subject|0
6349572|NCT03585712|10114731|FG001|Treatment Periods 2 and 3|Withdrawal by Subject|2
6349573|NCT03585712|10114732|FG002|Treatment Periods 2 and 3|Withdrawal by Subject|0
6349574|NCT03585712|10114730|FG000|Treatment Periods 2 and 3|Physician Decision|0
6349575|NCT03585712|10114731|FG001|Treatment Periods 2 and 3|Physician Decision|0
6349576|NCT03585712|10114732|FG002|Treatment Periods 2 and 3|Physician Decision|2
6349577|NCT03585959|10114759|FG000|Overall Study|Physician Decision|1
6349578|NCT03585959|10114759|FG000|Overall Study|Unsuccessful Procedure|2
6349579|NCT03586167|10114767|FG000|Overall Study|Other|1
6349580|NCT03586167|10114768|FG001|Overall Study|Other|0
6349581|NCT03586544|10114776|FG000|First Intervention|Adverse Event|0
6349582|NCT03586544|10114777|FG001|First Intervention|Adverse Event|1
6349583|NCT03586544|10114776|FG000|Second Intervention|Withdrawal by Subject|0
6349584|NCT03586544|10114777|FG001|Second Intervention|Withdrawal by Subject|1
6349585|NCT03586648|10114788|FG000|Period 1|Withdrawal by Subject|0
6349586|NCT03586648|10114789|FG001|Period 1|Withdrawal by Subject|1
6349587|NCT03586648|10114788|FG000|Period 1|Lost to Follow-up|1
6349588|NCT03586648|10114789|FG001|Period 1|Lost to Follow-up|1
6349589|NCT03586648|10114788|FG000|Period 1|Adverse Event|1
6349590|NCT03586648|10114789|FG001|Period 1|Adverse Event|0
6349591|NCT03586648|10114788|FG000|Period 1|Study related symptoms or complaints|2
6349592|NCT03586648|10114789|FG001|Period 1|Study related symptoms or complaints|1
6349593|NCT03586648|10114788|FG000|Period 1|Physician Decision|0
6349594|NCT03586648|10114789|FG001|Period 1|Physician Decision|1
6349595|NCT03586648|10114788|FG000|Period 2|Adverse Event|1
6349596|NCT03586648|10114789|FG001|Period 2|Adverse Event|0
6349597|NCT03586726|10114795|FG000|Overall Study|Withdrawal by Subject|1
6349598|NCT03586830|10114803|FG000|Overall Study|Site terminated by Sponsor|1
6349599|NCT03586830|10114804|FG001|Overall Study|Site terminated by Sponsor|4
6349600|NCT03586830|10114805|FG002|Overall Study|Site terminated by Sponsor|3
6349601|NCT03586830|10114806|FG003|Overall Study|Site terminated by Sponsor|3
6349602|NCT03586830|10114803|FG000|Overall Study|Lost to Follow-up|0
6349603|NCT03586830|10114804|FG001|Overall Study|Lost to Follow-up|2
6349604|NCT03586830|10114805|FG002|Overall Study|Lost to Follow-up|2
6349605|NCT03586830|10114806|FG003|Overall Study|Lost to Follow-up|1
6349606|NCT03586830|10114803|FG000|Overall Study|Withdrawal by Subject|1
6349607|NCT03586830|10114804|FG001|Overall Study|Withdrawal by Subject|0
6349608|NCT03586830|10114805|FG002|Overall Study|Withdrawal by Subject|3
6349609|NCT03586830|10114806|FG003|Overall Study|Withdrawal by Subject|1
6349610|NCT03587974|10114852|FG000|Overall Study|caregiver demented, care recipient died|3
6349611|NCT03587974|10114853|FG001|Overall Study|caregiver demented, care recipient died|3
6349612|NCT03587974|10114852|FG000|Overall Study|Withdrawal by Subject|2
6349613|NCT03587974|10114853|FG001|Overall Study|Withdrawal by Subject|1
6349614|NCT03588572|10114861|FG000|Visitation 1|Lack of Efficacy|1
6349615|NCT03588572|10114862|FG001|Visitation 1|Lack of Efficacy|1
6349616|NCT03588572|10114861|FG000|Visitation 2|Lost to Follow-up|1
6349617|NCT03588572|10114862|FG001|Visitation 2|Lost to Follow-up|1
6349618|NCT03588572|10114861|FG000|Visitation 2|Lack of Efficacy|0
6349619|NCT03588572|10114862|FG001|Visitation 2|Lack of Efficacy|1
6349620|NCT03588572|10114861|FG000|Visitation 2|Withdrawal by Subject|1
6349621|NCT03588572|10114862|FG001|Visitation 2|Withdrawal by Subject|0
6349622|NCT03588572|10114861|FG000|Visitation 3|Lost to Follow-up|1
6349623|NCT03588572|10114862|FG001|Visitation 3|Lost to Follow-up|1
6349624|NCT03588572|10114861|FG000|Visitation 3|Physician Decision|1
6349625|NCT03588572|10114862|FG001|Visitation 3|Physician Decision|1
6349626|NCT03588572|10114861|FG000|Visitation 3|Withdrawal by Subject|1
6349627|NCT03588572|10114862|FG001|Visitation 3|Withdrawal by Subject|0
6349628|NCT03588741|10114868|FG000|Overall Study|Withdrawal by Subject|1
6349629|NCT03588910|10114878|FG000|Overall Study|Withdrawal by Subject|1
6043137|NCT00386607|9641572|FG000|Extension|Unsatisfactory therapeutic effect|0
6043138|NCT00386607|9641573|FG001|Extension|Unsatisfactory therapeutic effect|1
6043139|NCT00386776|9641585|FG000|Overall Study|Withdrawal by Subject|8
6043140|NCT00387010|9641597|FG000|Dose Titration Period|Adverse Event|12
6043141|NCT00387010|9641597|FG000|Dose Titration Period|Lack of Efficacy|5
6043142|NCT00387010|9641597|FG000|Dose Titration Period|Withdrawal by Subject|3
6043143|NCT00387010|9641597|FG000|Dose Titration Period|Protocol Violation|1
6349630|NCT03588910|10114879|FG001|Overall Study|Withdrawal by Subject|0
6349631|NCT03588910|10114878|FG000|Overall Study|Allergy|2
6349632|NCT03588910|10114879|FG001|Overall Study|Allergy|0
6349633|NCT03588910|10114878|FG000|Overall Study|Protocol Violation|0
6349634|NCT03588910|10114879|FG001|Overall Study|Protocol Violation|3
6349635|NCT03588910|10114878|FG000|Overall Study|Did not complete Day 1 Survey|5
6349636|NCT03588910|10114879|FG001|Overall Study|Did not complete Day 1 Survey|10
6043144|NCT00387010|9641597|FG000|Dose Titration Period|Lost to Follow-up|2
6043145|NCT00387010|9641597|FG000|Dose Titration Period|Noncompliance with study medication|8
6043146|NCT00387010|9641597|FG000|Dose Titration Period|Noncompliance with study procedures|7
6043147|NCT00387010|9641597|FG000|Treatment Period|Adverse Event|4
6043148|NCT00387010|9641597|FG000|Treatment Period|Withdrawal by Subject|1
6043149|NCT00387010|9641597|FG000|Treatment Period|Noncompliance with study medication|2
6043150|NCT00387010|9641597|FG000|Treatment Period|Noncompliance with study procedures|3
6043151|NCT00387010|9641597|FG000|Treatment Period|Participant reported study drug stolen|1
6043152|NCT00387088|9641614|FG000|Overall Study|Adverse Event|143
6043153|NCT00387088|9641615|FG001|Overall Study|Adverse Event|156
6043154|NCT00387088|9641614|FG000|Overall Study|Protocol Violation|47
6043155|NCT00387088|9641615|FG001|Overall Study|Protocol Violation|35
6043156|NCT00387088|9641614|FG000|Overall Study|Withdrawal by Subject|20
6043157|NCT00387088|9641615|FG001|Overall Study|Withdrawal by Subject|35
6043158|NCT00387088|9641614|FG000|Overall Study|Lack of Efficacy|28
6349637|NCT03588910|10114878|FG000|Overall Study|Did not complete Day 7 Survey|5
6349638|NCT03588910|10114879|FG001|Overall Study|Did not complete Day 7 Survey|2
6349639|NCT03589807|10114891|FG000|Overall Study|Lost to Follow-up|0
6349640|NCT03589807|10114892|FG001|Overall Study|Lost to Follow-up|2
6349641|NCT03589807|10114893|FG002|Overall Study|Lost to Follow-up|2
6349642|NCT03589807|10114894|FG003|Overall Study|Lost to Follow-up|3
6349643|NCT03589807|10114895|FG004|Overall Study|Lost to Follow-up|1
6349644|NCT03589807|10114896|FG005|Overall Study|Lost to Follow-up|1
6349645|NCT03589807|10114891|FG000|Overall Study|Withdrawal by Subject|0
6349646|NCT03589807|10114892|FG001|Overall Study|Withdrawal by Subject|5
6349647|NCT03589807|10114893|FG002|Overall Study|Withdrawal by Subject|0
6349648|NCT03589807|10114894|FG003|Overall Study|Withdrawal by Subject|0
6349649|NCT03589807|10114895|FG004|Overall Study|Withdrawal by Subject|0
6349650|NCT03589807|10114896|FG005|Overall Study|Withdrawal by Subject|0
6349651|NCT03589807|10114891|FG000|Overall Study|Protocol Violation|0
6349652|NCT03589807|10114892|FG001|Overall Study|Protocol Violation|0
6349653|NCT03589807|10114893|FG002|Overall Study|Protocol Violation|0
6349654|NCT03589807|10114894|FG003|Overall Study|Protocol Violation|1
6349655|NCT03589807|10114895|FG004|Overall Study|Protocol Violation|0
6349656|NCT03589807|10114896|FG005|Overall Study|Protocol Violation|0
6349657|NCT03589807|10114891|FG000|Overall Study|Enrolled but treatment not administered|0
6349658|NCT03589807|10114892|FG001|Overall Study|Enrolled but treatment not administered|0
6349659|NCT03589807|10114893|FG002|Overall Study|Enrolled but treatment not administered|0
6349660|NCT03589807|10114894|FG003|Overall Study|Enrolled but treatment not administered|0
6349661|NCT03589807|10114895|FG004|Overall Study|Enrolled but treatment not administered|1
6349662|NCT03589807|10114896|FG005|Overall Study|Enrolled but treatment not administered|0
6349663|NCT03589885|10114916|FG000|Treatment Period 1-Randomized Set|Adverse Event|0
6349664|NCT03589885|10114917|FG001|Treatment Period 1-Randomized Set|Adverse Event|1
6349665|NCT03589885|10114918|FG002|Treatment Period 1-Randomized Set|Adverse Event|0
6349666|NCT03589885|10114919|FG003|Treatment Period 1-Randomized Set|Adverse Event|0
6349667|NCT03589885|10114920|FG004|Treatment Period 1-Randomized Set|Adverse Event|0
6349668|NCT03589885|10114916|FG000|Treatment Period 1-Randomized Set|Lack of Efficacy|0
6349669|NCT03589885|10114917|FG001|Treatment Period 1-Randomized Set|Lack of Efficacy|0
6349670|NCT03589885|10114918|FG002|Treatment Period 1-Randomized Set|Lack of Efficacy|2
6349671|NCT03589885|10114919|FG003|Treatment Period 1-Randomized Set|Lack of Efficacy|0
6349672|NCT03589885|10114920|FG004|Treatment Period 1-Randomized Set|Lack of Efficacy|0
6349673|NCT03589885|10114916|FG000|Treatment Period 1-Randomized Set|Lost to Follow-up|0
6349674|NCT03589885|10114917|FG001|Treatment Period 1-Randomized Set|Lost to Follow-up|1
6349675|NCT03589885|10114918|FG002|Treatment Period 1-Randomized Set|Lost to Follow-up|0
6349676|NCT03589885|10114919|FG003|Treatment Period 1-Randomized Set|Lost to Follow-up|0
6349677|NCT03589885|10114920|FG004|Treatment Period 1-Randomized Set|Lost to Follow-up|0
6349678|NCT03589885|10114916|FG000|Treatment Period 1-Randomized Set|Withdrawal by Subject|0
6349679|NCT03589885|10114917|FG001|Treatment Period 1-Randomized Set|Withdrawal by Subject|0
6349680|NCT03589885|10114918|FG002|Treatment Period 1-Randomized Set|Withdrawal by Subject|1
6349681|NCT03589885|10114919|FG003|Treatment Period 1-Randomized Set|Withdrawal by Subject|0
6349682|NCT03589885|10114920|FG004|Treatment Period 1-Randomized Set|Withdrawal by Subject|0
6349683|NCT03589885|10114916|FG000|Treatment Period 2-Randomized Set|Adverse Event|0
6349684|NCT03589885|10114917|FG001|Treatment Period 2-Randomized Set|Adverse Event|1
6349685|NCT03589885|10114918|FG002|Treatment Period 2-Randomized Set|Adverse Event|0
6349686|NCT03589885|10114919|FG003|Treatment Period 2-Randomized Set|Adverse Event|0
6349687|NCT03589885|10114920|FG004|Treatment Period 2-Randomized Set|Adverse Event|0
6349688|NCT03589885|10114916|FG000|Treatment Period 2-Randomized Set|Pregnancy|1
6349689|NCT03589885|10114917|FG001|Treatment Period 2-Randomized Set|Pregnancy|0
6349690|NCT03589885|10114918|FG002|Treatment Period 2-Randomized Set|Pregnancy|0
6349691|NCT03589885|10114919|FG003|Treatment Period 2-Randomized Set|Pregnancy|0
6349692|NCT03589885|10114920|FG004|Treatment Period 2-Randomized Set|Pregnancy|0
6349693|NCT03589885|10114916|FG000|Treatment Period 2-Randomized Set|Lost to Follow-up|0
6349694|NCT03589885|10114917|FG001|Treatment Period 2-Randomized Set|Lost to Follow-up|3
6349695|NCT03589885|10114918|FG002|Treatment Period 2-Randomized Set|Lost to Follow-up|1
6349696|NCT03589885|10114919|FG003|Treatment Period 2-Randomized Set|Lost to Follow-up|0
6043159|NCT00387088|9641615|FG001|Overall Study|Lack of Efficacy|67
6043160|NCT00387088|9641614|FG000|Overall Study|Lost to Follow-up|22
6349697|NCT03589885|10114920|FG004|Treatment Period 2-Randomized Set|Lost to Follow-up|1
6349698|NCT03589885|10114916|FG000|Treatment Period 2-Randomized Set|Withdrawal by Subject|0
6349699|NCT03589885|10114917|FG001|Treatment Period 2-Randomized Set|Withdrawal by Subject|1
6349700|NCT03589885|10114918|FG002|Treatment Period 2-Randomized Set|Withdrawal by Subject|0
6349701|NCT03589885|10114919|FG003|Treatment Period 2-Randomized Set|Withdrawal by Subject|0
6349702|NCT03589885|10114920|FG004|Treatment Period 2-Randomized Set|Withdrawal by Subject|0
6349703|NCT03590613|10114938|FG000|Period 2, 4 Days|Physician Decision|0
6349704|NCT03590613|10114939|FG001|Period 2, 4 Days|Physician Decision|0
6349705|NCT03590613|10114940|FG002|Period 2, 4 Days|Physician Decision|0
6349706|NCT03590613|10114941|FG003|Period 2, 4 Days|Physician Decision|1
6349707|NCT03591146|10114965|FG000|TLC590 190mg and Naropin 150mg|Lost to Follow-up|0
6349708|NCT03591146|10114966|FG001|TLC590 190mg and Naropin 150mg|Lost to Follow-up|0
6349709|NCT03591146|10114967|FG002|TLC590 190mg and Naropin 150mg|Lost to Follow-up|0
6349710|NCT03591146|10114968|FG003|TLC590 190mg and Naropin 150mg|Lost to Follow-up|0
6349711|NCT03591146|10114969|FG004|TLC590 190mg and Naropin 150mg|Lost to Follow-up|1
6349712|NCT03591146|10114965|FG000|TLC590 380mg and Naropin 150mg|Lost to Follow-up|0
6349713|NCT03591146|10114966|FG001|TLC590 380mg and Naropin 150mg|Lost to Follow-up|1
6349714|NCT03591146|10114967|FG002|TLC590 380mg and Naropin 150mg|Lost to Follow-up|0
6349715|NCT03591146|10114968|FG003|TLC590 380mg and Naropin 150mg|Lost to Follow-up|0
6349716|NCT03591146|10114969|FG004|TLC590 380mg and Naropin 150mg|Lost to Follow-up|0
6349717|NCT03591146|10114965|FG000|TLC590 380mg and Naropin 150mg|Withdrawal by Subject|0
6349718|NCT03591146|10114966|FG001|TLC590 380mg and Naropin 150mg|Withdrawal by Subject|0
6349719|NCT03591146|10114967|FG002|TLC590 380mg and Naropin 150mg|Withdrawal by Subject|0
6349720|NCT03591146|10114968|FG003|TLC590 380mg and Naropin 150mg|Withdrawal by Subject|0
6349721|NCT03591146|10114969|FG004|TLC590 380mg and Naropin 150mg|Withdrawal by Subject|1
6349722|NCT03591146|10114965|FG000|TLC590 570mg and Naropin 150mg|Lost to Follow-up|0
6349723|NCT03591146|10114966|FG001|TLC590 570mg and Naropin 150mg|Lost to Follow-up|0
6349724|NCT03591146|10114967|FG002|TLC590 570mg and Naropin 150mg|Lost to Follow-up|1
6349725|NCT03591146|10114968|FG003|TLC590 570mg and Naropin 150mg|Lost to Follow-up|0
6349726|NCT03591146|10114969|FG004|TLC590 570mg and Naropin 150mg|Lost to Follow-up|1
6349727|NCT03591406|10114983|FG000|Overall Study|Adverse Event|5
6349728|NCT03591406|10114984|FG001|Overall Study|Adverse Event|3
6349729|NCT03591406|10114983|FG000|Overall Study|Protocol Violation|2
6349730|NCT03591406|10114984|FG001|Overall Study|Protocol Violation|1
6349731|NCT03591406|10114983|FG000|Overall Study|Withdrawal by Subject|0
6349732|NCT03591406|10114984|FG001|Overall Study|Withdrawal by Subject|5
6349733|NCT03592745|10115001|FG000|Overall Study|Adverse Event|0
6349734|NCT03592745|10115002|FG001|Overall Study|Adverse Event|2
6349735|NCT03592745|10115001|FG000|Overall Study|Lost to Follow-up|2
6349736|NCT03592745|10115002|FG001|Overall Study|Lost to Follow-up|0
6349737|NCT03592745|10115001|FG000|Overall Study|study temporary closure due to covid-19 pandemic|1
6349738|NCT03592745|10115002|FG001|Overall Study|study temporary closure due to covid-19 pandemic|1
6349739|NCT03593681|10115025|FG000|Overall Study|Inadequate sample collected|12
6349740|NCT03593681|10115025|FG000|Overall Study|Hysteroscope attempted but unable to find ostia|11
6349741|NCT03593681|10115025|FG000|Overall Study|Protocol Violation|3
6349742|NCT03593681|10115025|FG000|Overall Study|Withdrawal by Subject|3
6349743|NCT03593681|10115025|FG000|Overall Study|Procedure not attempted|3
6349744|NCT03593681|10115025|FG000|Overall Study|Adverse Event|2
6349745|NCT03593681|10115025|FG000|Overall Study|Physician Decision|1
6349746|NCT03593876|10115046|FG000|Overall Study|Withdrawal by Subject|1
6349747|NCT03593876|10115046|FG000|Overall Study|Discharged home before intervention completion|2
6349748|NCT03594071|10115063|FG000|Overall Study|Re-operation|3
6349749|NCT03594071|10115063|FG000|Overall Study|Missed visit|2
6349750|NCT03594227|10115071|FG000|Overall Study|Adverse Event|2
6349751|NCT03594227|10115072|FG001|Overall Study|Adverse Event|1
6349752|NCT03594227|10115073|FG002|Overall Study|Adverse Event|0
6349753|NCT03594227|10115074|FG003|Overall Study|Adverse Event|2
6349754|NCT03594227|10115071|FG000|Overall Study|Lost to Follow-up|1
6349755|NCT03594227|10115072|FG001|Overall Study|Lost to Follow-up|1
6349756|NCT03594227|10115073|FG002|Overall Study|Lost to Follow-up|1
6349757|NCT03594227|10115074|FG003|Overall Study|Lost to Follow-up|0
6349758|NCT03594227|10115071|FG000|Overall Study|Withdrawal by Subject|1
6349759|NCT03594227|10115072|FG001|Overall Study|Withdrawal by Subject|1
6349760|NCT03594227|10115073|FG002|Overall Study|Withdrawal by Subject|1
6349761|NCT03594227|10115074|FG003|Overall Study|Withdrawal by Subject|1
6349762|NCT03594227|10115071|FG000|Overall Study|Pregnancy|0
6349763|NCT03594227|10115072|FG001|Overall Study|Pregnancy|1
6349764|NCT03594227|10115073|FG002|Overall Study|Pregnancy|0
6349765|NCT03594227|10115074|FG003|Overall Study|Pregnancy|0
6349766|NCT03594227|10115071|FG000|Overall Study|Sponsor Decision|0
6349767|NCT03594227|10115072|FG001|Overall Study|Sponsor Decision|0
6349768|NCT03594227|10115073|FG002|Overall Study|Sponsor Decision|0
6349769|NCT03594227|10115074|FG003|Overall Study|Sponsor Decision|1
6349770|NCT03594227|10115071|FG000|Overall Study|Programmatic Analysis Non-completer|1
6349771|NCT03594227|10115072|FG001|Overall Study|Programmatic Analysis Non-completer|0
6349772|NCT03594227|10115073|FG002|Overall Study|Programmatic Analysis Non-completer|1
6349773|NCT03594227|10115074|FG003|Overall Study|Programmatic Analysis Non-completer|1
6349774|NCT03595176|10115109|FG000|Overall Study|Death|0
6349775|NCT03595176|10115110|FG001|Overall Study|Death|2
6349776|NCT03595176|10115109|FG000|Overall Study|Lost to Follow-up|0
6349777|NCT03595176|10115110|FG001|Overall Study|Lost to Follow-up|1
6349778|NCT03595280|10115122|FG000|Overall Study|Lost to Follow-up|6
6349779|NCT03595280|10115123|FG001|Overall Study|Lost to Follow-up|9
6349780|NCT03595280|10115124|FG002|Overall Study|Lost to Follow-up|15
6349781|NCT03595618|10115154|FG000|Overall Study|Adverse Event|16
6349782|NCT03595618|10115155|FG001|Overall Study|Adverse Event|17
6349783|NCT03595618|10115156|FG002|Overall Study|Adverse Event|20
6349784|NCT03595618|10115157|FG003|Overall Study|Adverse Event|8
6349785|NCT03595618|10115154|FG000|Overall Study|Withdrawal by Subject|12
6349786|NCT03595618|10115155|FG001|Overall Study|Withdrawal by Subject|14
6349787|NCT03595618|10115156|FG002|Overall Study|Withdrawal by Subject|14
6349788|NCT03595618|10115157|FG003|Overall Study|Withdrawal by Subject|10
6349789|NCT03595618|10115154|FG000|Overall Study|Lost to Follow-up|6
6349790|NCT03595618|10115155|FG001|Overall Study|Lost to Follow-up|4
6349791|NCT03595618|10115156|FG002|Overall Study|Lost to Follow-up|5
6349792|NCT03595618|10115157|FG003|Overall Study|Lost to Follow-up|6
6349793|NCT03595618|10115154|FG000|Overall Study|Protocol Violation|2
6349794|NCT03595618|10115155|FG001|Overall Study|Protocol Violation|0
6349795|NCT03595618|10115156|FG002|Overall Study|Protocol Violation|6
6349796|NCT03595618|10115157|FG003|Overall Study|Protocol Violation|2
6349797|NCT03595618|10115154|FG000|Overall Study|Physician Decision|0
6349798|NCT03595618|10115155|FG001|Overall Study|Physician Decision|0
6349799|NCT03595618|10115156|FG002|Overall Study|Physician Decision|1
6349800|NCT03595618|10115157|FG003|Overall Study|Physician Decision|2
6349801|NCT03595618|10115154|FG000|Overall Study|Miscellaneous|7
6349802|NCT03595618|10115155|FG001|Overall Study|Miscellaneous|5
6349803|NCT03595618|10115156|FG002|Overall Study|Miscellaneous|10
6349804|NCT03595618|10115157|FG003|Overall Study|Miscellaneous|6
6349805|NCT03595904|10115169|FG000|Overall Study|Protocol Violation|3
6349806|NCT03595904|10115170|FG001|Overall Study|Protocol Violation|1
6349807|NCT03595904|10115169|FG000|Overall Study|Deemed medically ineligible for direct access colonoscopy|4
6349808|NCT03595904|10115170|FG001|Overall Study|Deemed medically ineligible for direct access colonoscopy|3
6349809|NCT03595904|10115169|FG000|Overall Study|Insurance complications|1
6349810|NCT03595904|10115170|FG001|Overall Study|Insurance complications|0
6349811|NCT03595904|10115169|FG000|Overall Study|COVID-19 halt in non-essential appointments during 6 month follow up|2
6349812|NCT03595904|10115170|FG001|Overall Study|COVID-19 halt in non-essential appointments during 6 month follow up|1
6349813|NCT03596151|10115176|FG000|Overall Study|Withdrawal by Subject|1
6349814|NCT03596177|10115182|FG000|Single Blind Period|Withdrawal by Subject|1
6349815|NCT03596177|10115183|FG001|Single Blind Period|Withdrawal by Subject|1
6349816|NCT03596177|10115182|FG000|Single Blind Period|Other|1
6349817|NCT03596177|10115183|FG001|Single Blind Period|Other|0
6349818|NCT03596177|10115182|FG000|Double Blind Period|Withdrawal by Subject|0
6349819|NCT03596177|10115183|FG001|Double Blind Period|Withdrawal by Subject|1
6349820|NCT03596177|10115182|FG000|Double Blind Period|Other|0
6349821|NCT03596177|10115183|FG001|Double Blind Period|Other|4
6349822|NCT03596177|10115182|FG000|Double Blind Period|Death during safety follow-up|0
6349823|NCT03596177|10115183|FG001|Double Blind Period|Death during safety follow-up|1
6349824|NCT03597022|10115205|FG000|Overall Study|Premature termination of the study|7
6349825|NCT03597022|10115206|FG001|Overall Study|Premature termination of the study|7
6349826|NCT03597022|10115207|FG002|Overall Study|Premature termination of the study|8
6349827|NCT03597022|10115205|FG000|Overall Study|Serious adverse event|1
6349828|NCT03597022|10115206|FG001|Overall Study|Serious adverse event|1
6349829|NCT03597022|10115207|FG002|Overall Study|Serious adverse event|0
6349830|NCT03597061|10115217|FG000|Overall Study|Lost to Follow-up|1
6349831|NCT03597061|10115218|FG001|Overall Study|Lost to Follow-up|0
6349832|NCT03597061|10115217|FG000|Overall Study|Protocol Violation|0
6349833|NCT03597061|10115218|FG001|Overall Study|Protocol Violation|1
6349834|NCT03597139|10115226|FG000|Overall Study|Adverse Event|3
6349835|NCT03597139|10115227|FG001|Overall Study|Adverse Event|0
6349836|NCT03597139|10115226|FG000|Overall Study|Protocol Non-compliance|1
6349837|NCT03597139|10115227|FG001|Overall Study|Protocol Non-compliance|0
6349838|NCT03597347|10115240|FG000|Overall Study|Withdrawal by Subject|1
6349839|NCT03597347|10115241|FG001|Overall Study|Withdrawal by Subject|1
6349840|NCT03597347|10115242|FG002|Overall Study|Withdrawal by Subject|0
6349841|NCT03597347|10115240|FG000|Overall Study|Withdrawal due to Covid-19|3
6349842|NCT03597347|10115241|FG001|Overall Study|Withdrawal due to Covid-19|0
6349843|NCT03597347|10115242|FG002|Overall Study|Withdrawal due to Covid-19|0
6349844|NCT03597347|10115240|FG000|Overall Study|Sponsor decision to terminate study|3
6349845|NCT03597347|10115241|FG001|Overall Study|Sponsor decision to terminate study|2
6349846|NCT03597347|10115242|FG002|Overall Study|Sponsor decision to terminate study|4
6349847|NCT03597529|10115252|FG000|Overall Study|Lost to Follow-up|10
6349848|NCT03597529|10115253|FG001|Overall Study|Lost to Follow-up|12
6349849|NCT03597529|10115252|FG000|Overall Study|Physician Decision|3
6349850|NCT03597529|10115253|FG001|Overall Study|Physician Decision|1
6349851|NCT03597529|10115252|FG000|Overall Study|Withdrawal by Subject|6
6349852|NCT03597529|10115253|FG001|Overall Study|Withdrawal by Subject|3
6349853|NCT03597529|10115252|FG000|Overall Study|Non-compliant with study activities|1
6349854|NCT03597529|10115253|FG001|Overall Study|Non-compliant with study activities|2
6349855|NCT03599089|10115282|FG000|Overall Study|Lost to Follow-up|1
6349856|NCT03599089|10115283|FG001|Overall Study|Lost to Follow-up|0
6349857|NCT03599089|10115284|FG002|Overall Study|Lost to Follow-up|0
6349858|NCT03599089|10115285|FG003|Overall Study|Lost to Follow-up|0
6349859|NCT03599089|10115282|FG000|Overall Study|Withdrawal by Subject|2
6349860|NCT03599089|10115283|FG001|Overall Study|Withdrawal by Subject|1
6349861|NCT03599089|10115284|FG002|Overall Study|Withdrawal by Subject|0
6349862|NCT03599089|10115285|FG003|Overall Study|Withdrawal by Subject|0
6349863|NCT03599089|10115282|FG000|Overall Study|Lack of Efficacy|0
6349864|NCT03599089|10115283|FG001|Overall Study|Lack of Efficacy|0
6349865|NCT03599089|10115284|FG002|Overall Study|Lack of Efficacy|1
6349866|NCT03599089|10115285|FG003|Overall Study|Lack of Efficacy|2
6349867|NCT03599193|10115297|FG000|Overall Study|Adverse Event|0
6349868|NCT03599193|10115298|FG001|Overall Study|Adverse Event|2
6349869|NCT03599193|10115297|FG000|Overall Study|Withdrawal by Subject|1
6349870|NCT03599193|10115298|FG001|Overall Study|Withdrawal by Subject|0
6349871|NCT03599193|10115297|FG000|Overall Study|Protocol Violation|1
6349872|NCT03599193|10115298|FG001|Overall Study|Protocol Violation|0
6349873|NCT03599193|10115297|FG000|Overall Study|Lost to Follow-up|0
6349874|NCT03599193|10115298|FG001|Overall Study|Lost to Follow-up|1
6349875|NCT03599349|10115316|FG000|Overall Study|Lost to Follow-up|1
6349876|NCT03599362|10115320|FG000|Overall Study|Screen Failure|3
6349877|NCT03600376|10115353|FG000|Overall Study|Adverse Event|1
6349878|NCT03600376|10115354|FG001|Overall Study|Adverse Event|1
6349879|NCT03600376|10115353|FG000|Overall Study|Transferred to other facility|1
6349880|NCT03600376|10115354|FG001|Overall Study|Transferred to other facility|0
6349881|NCT03600376|10115353|FG000|Overall Study|Investigator Decision|0
6349882|NCT03600376|10115354|FG001|Overall Study|Investigator Decision|4
6349883|NCT03600376|10115353|FG000|Overall Study|Determined to be ineligible for study|0
6349884|NCT03600376|10115354|FG001|Overall Study|Determined to be ineligible for study|1
6349885|NCT03600428|10115362|FG000|Overall Study|Not eligible|0
6349886|NCT03600428|10115363|FG001|Overall Study|Not eligible|1
6349887|NCT03600428|10115362|FG000|Overall Study|Lost to Follow-up|5
6349888|NCT03600428|10115363|FG001|Overall Study|Lost to Follow-up|4
6349889|NCT03601052|10115369|FG000|Overall Study|Lost to Follow-up|2
6349890|NCT03601715|10115381|FG000|Second Intervention|Lost to Follow-up|1
6349891|NCT03601715|10115382|FG001|Second Intervention|Lost to Follow-up|1
6349892|NCT03601715|10115383|FG002|Second Intervention|Lost to Follow-up|0
6349893|NCT03602053|10115394|FG000|Overall Study|Withdrawal by Subject|7
6349894|NCT03602053|10115395|FG001|Overall Study|Withdrawal by Subject|9
6349895|NCT03602053|10115396|FG002|Overall Study|Withdrawal by Subject|7
6349896|NCT03602053|10115394|FG000|Overall Study|Lost to Follow-up|5
6349897|NCT03602053|10115395|FG001|Overall Study|Lost to Follow-up|6
6349898|NCT03602053|10115396|FG002|Overall Study|Lost to Follow-up|0
6349899|NCT03602053|10115394|FG000|Overall Study|Protocol Violation|3
6349900|NCT03602053|10115395|FG001|Overall Study|Protocol Violation|0
6349901|NCT03602053|10115396|FG002|Overall Study|Protocol Violation|4
6349902|NCT03602053|10115394|FG000|Overall Study|Physician Decision|1
6349903|NCT03602053|10115395|FG001|Overall Study|Physician Decision|0
6349904|NCT03602053|10115396|FG002|Overall Study|Physician Decision|0
6349905|NCT03602053|10115394|FG000|Overall Study|migration|2
6349906|NCT03602053|10115395|FG001|Overall Study|migration|3
6349907|NCT03602053|10115396|FG002|Overall Study|migration|0
6349908|NCT03602053|10115394|FG000|Overall Study|Other|1
6349909|NCT03602053|10115395|FG001|Overall Study|Other|0
6349910|NCT03602053|10115396|FG002|Overall Study|Other|0
6349911|NCT03602339|10115408|FG000|Overall Study|Withdrawal by Subject|9
6349912|NCT03602339|10115408|FG000|Overall Study|Physician Decision|2
6349913|NCT03602339|10115408|FG000|Overall Study|Other reason|4
6349914|NCT03602482|10115417|FG000|Overall Study|Withdrawal by Subject|6
6349915|NCT03602482|10115418|FG001|Overall Study|Withdrawal by Subject|7
6349916|NCT03602482|10115419|FG002|Overall Study|Withdrawal by Subject|0
6349917|NCT03602482|10115420|FG003|Overall Study|Withdrawal by Subject|0
6349918|NCT03603028|10115433|FG000|Overall Study|Withdrawal by Subject|1
6349919|NCT03603652|10115491|FG000|Overall Study|Death|2
6349920|NCT03604341|10115501|FG000|Overall Study|Withdrawal by Subject|1
6349921|NCT03604341|10115502|FG001|Overall Study|Withdrawal by Subject|1
6349922|NCT03604341|10115501|FG000|Overall Study|Adverse Event|1
6349923|NCT03604341|10115502|FG001|Overall Study|Adverse Event|0
6349924|NCT03604341|10115501|FG000|Overall Study|Protocol Violation|0
6349925|NCT03604341|10115502|FG001|Overall Study|Protocol Violation|1
6349926|NCT03604497|10115508|FG000|Overall Study|Protocol Violation|52
6349927|NCT03604523|10115518|FG000|Overall Study|Physician Decision|1
6349928|NCT03604523|10115519|FG001|Overall Study|Physician Decision|0
6349929|NCT03605212|10115542|FG000|Treatment Period|Adverse Event|1
6349930|NCT03605212|10115543|FG001|Treatment Period|Adverse Event|0
6349931|NCT03605212|10115544|FG002|Treatment Period|Adverse Event|0
6349932|NCT03605212|10115545|FG003|Treatment Period|Adverse Event|0
6349933|NCT03605212|10115546|FG004|Treatment Period|Adverse Event|0
6349934|NCT03605212|10115542|FG000|Treatment Period|Physician Decision|0
6349935|NCT03605212|10115543|FG001|Treatment Period|Physician Decision|0
6349936|NCT03605212|10115544|FG002|Treatment Period|Physician Decision|0
6349937|NCT03605212|10115545|FG003|Treatment Period|Physician Decision|0
6349938|NCT03605212|10115546|FG004|Treatment Period|Physician Decision|1
6349939|NCT03605693|10115561|FG000|Overall Study|Lost to Follow-up|4
6349940|NCT03605693|10115562|FG001|Overall Study|Lost to Follow-up|0
6349941|NCT03605693|10115561|FG000|Overall Study|Physician Decision|1
6349942|NCT03605693|10115562|FG001|Overall Study|Physician Decision|0
6349943|NCT03605745|10115568|FG000|Overall Study|Study was terminated for business reasons|47
6349944|NCT03605836|10115576|FG000|OL Placebo Run-in Period [1 Week]|Adverse Event|2
6349945|NCT03605836|10115577|FG001|OL Placebo Run-in Period [1 Week]|Adverse Event|0
6349946|NCT03605836|10115578|FG002|OL Placebo Run-in Period [1 Week]|Adverse Event|0
6349947|NCT03605836|10115579|FG003|OL Placebo Run-in Period [1 Week]|Adverse Event|0
6349948|NCT03605836|10115576|FG000|OL Placebo Run-in Period [1 Week]|Lack of Efficacy|2
6349949|NCT03605836|10115577|FG001|OL Placebo Run-in Period [1 Week]|Lack of Efficacy|0
6349950|NCT03605836|10115578|FG002|OL Placebo Run-in Period [1 Week]|Lack of Efficacy|0
6349951|NCT03605836|10115579|FG003|OL Placebo Run-in Period [1 Week]|Lack of Efficacy|0
6349952|NCT03605836|10115576|FG000|OL Placebo Run-in Period [1 Week]|Lost to Follow-up|8
6349953|NCT03605836|10115577|FG001|OL Placebo Run-in Period [1 Week]|Lost to Follow-up|0
6349954|NCT03605836|10115578|FG002|OL Placebo Run-in Period [1 Week]|Lost to Follow-up|0
6349955|NCT03605836|10115579|FG003|OL Placebo Run-in Period [1 Week]|Lost to Follow-up|0
6349956|NCT03605836|10115576|FG000|OL Placebo Run-in Period [1 Week]|Non-Compliance With Study Drug|4
6349957|NCT03605836|10115577|FG001|OL Placebo Run-in Period [1 Week]|Non-Compliance With Study Drug|0
6349958|NCT03605836|10115578|FG002|OL Placebo Run-in Period [1 Week]|Non-Compliance With Study Drug|0
6349959|NCT03605836|10115579|FG003|OL Placebo Run-in Period [1 Week]|Non-Compliance With Study Drug|0
6349960|NCT03605836|10115576|FG000|OL Placebo Run-in Period [1 Week]|Protocol Deviation|4
6349961|NCT03605836|10115577|FG001|OL Placebo Run-in Period [1 Week]|Protocol Deviation|0
6349962|NCT03605836|10115578|FG002|OL Placebo Run-in Period [1 Week]|Protocol Deviation|0
6349963|NCT03605836|10115579|FG003|OL Placebo Run-in Period [1 Week]|Protocol Deviation|0
6349964|NCT03605836|10115576|FG000|OL Placebo Run-in Period [1 Week]|Withdrawal by Subject|17
6349965|NCT03605836|10115577|FG001|OL Placebo Run-in Period [1 Week]|Withdrawal by Subject|0
6349966|NCT03605836|10115578|FG002|OL Placebo Run-in Period [1 Week]|Withdrawal by Subject|0
6349967|NCT03605836|10115579|FG003|OL Placebo Run-in Period [1 Week]|Withdrawal by Subject|0
6349968|NCT03605836|10115576|FG000|OL Placebo Run-in Period [1 Week]|Site Terminated by Sponsor|5
6349969|NCT03605836|10115577|FG001|OL Placebo Run-in Period [1 Week]|Site Terminated by Sponsor|0
6349970|NCT03605836|10115578|FG002|OL Placebo Run-in Period [1 Week]|Site Terminated by Sponsor|0
6349971|NCT03605836|10115579|FG003|OL Placebo Run-in Period [1 Week]|Site Terminated by Sponsor|0
6349972|NCT03605836|10115576|FG000|OL Placebo Run-in Period [1 Week]|Physician Decision|7
6349973|NCT03605836|10115577|FG001|OL Placebo Run-in Period [1 Week]|Physician Decision|0
6349974|NCT03605836|10115578|FG002|OL Placebo Run-in Period [1 Week]|Physician Decision|0
6349975|NCT03605836|10115579|FG003|OL Placebo Run-in Period [1 Week]|Physician Decision|0
6349976|NCT03605836|10115576|FG000|OL Placebo Run-in Period [1 Week]|Reason not Related to COVID-19|85
6349977|NCT03605836|10115577|FG001|OL Placebo Run-in Period [1 Week]|Reason not Related to COVID-19|0
6349978|NCT03605836|10115578|FG002|OL Placebo Run-in Period [1 Week]|Reason not Related to COVID-19|0
6349979|NCT03605836|10115579|FG003|OL Placebo Run-in Period [1 Week]|Reason not Related to COVID-19|0
6349980|NCT03605836|10115576|FG000|OL Placebo Run-in Period [1 Week]|COVID-19 Related|15
6349981|NCT03605836|10115577|FG001|OL Placebo Run-in Period [1 Week]|COVID-19 Related|0
6349982|NCT03605836|10115578|FG002|OL Placebo Run-in Period [1 Week]|COVID-19 Related|0
6349983|NCT03605836|10115579|FG003|OL Placebo Run-in Period [1 Week]|COVID-19 Related|0
6349984|NCT03605836|10115576|FG000|OL Placebo Run-in Period [1 Week]|Discontinued Prior to the Treatment.|1
6349985|NCT03605836|10115577|FG001|OL Placebo Run-in Period [1 Week]|Discontinued Prior to the Treatment.|0
6349986|NCT03605836|10115578|FG002|OL Placebo Run-in Period [1 Week]|Discontinued Prior to the Treatment.|0
6349987|NCT03605836|10115579|FG003|OL Placebo Run-in Period [1 Week]|Discontinued Prior to the Treatment.|0
6349988|NCT03605836|10115576|FG000|Double-blind Treatment Period [6 Weeks]|Randomized but Not Treated in Double-Blind Treatment Period|0
6349989|NCT03605836|10115577|FG001|Double-blind Treatment Period [6 Weeks]|Randomized but Not Treated in Double-Blind Treatment Period|2
6083624|NCT00636363|9692132|FG002|Overall Study|Positive slit lamp finding|1
6083625|NCT00636363|9692130|FG000|Overall Study|Study related symptoms/complaints|8
6083626|NCT00636363|9692131|FG001|Overall Study|Study related symptoms/complaints|7
6083627|NCT00636363|9692132|FG002|Overall Study|Study related symptoms/complaints|4
6083628|NCT00636363|9692130|FG000|Overall Study|Met ineligibility criteria|0
6083629|NCT00636363|9692131|FG001|Overall Study|Met ineligibility criteria|0
6083630|NCT00636363|9692132|FG002|Overall Study|Met ineligibility criteria|3
6349990|NCT03605836|10115578|FG002|Double-blind Treatment Period [6 Weeks]|Randomized but Not Treated in Double-Blind Treatment Period|4
6349991|NCT03605836|10115579|FG003|Double-blind Treatment Period [6 Weeks]|Randomized but Not Treated in Double-Blind Treatment Period|4
6349992|NCT03605836|10115576|FG000|Double-blind Treatment Period [6 Weeks]|Adverse Event|0
6349993|NCT03605836|10115577|FG001|Double-blind Treatment Period [6 Weeks]|Adverse Event|5
6349994|NCT03605836|10115578|FG002|Double-blind Treatment Period [6 Weeks]|Adverse Event|8
6349995|NCT03605836|10115579|FG003|Double-blind Treatment Period [6 Weeks]|Adverse Event|0
6349996|NCT03605836|10115576|FG000|Double-blind Treatment Period [6 Weeks]|Lack of Efficacy|0
6349997|NCT03605836|10115577|FG001|Double-blind Treatment Period [6 Weeks]|Lack of Efficacy|0
6349998|NCT03605836|10115578|FG002|Double-blind Treatment Period [6 Weeks]|Lack of Efficacy|2
6349999|NCT03605836|10115579|FG003|Double-blind Treatment Period [6 Weeks]|Lack of Efficacy|1
6350000|NCT03605836|10115576|FG000|Double-blind Treatment Period [6 Weeks]|Lost to Follow-up|0
6350001|NCT03605836|10115577|FG001|Double-blind Treatment Period [6 Weeks]|Lost to Follow-up|3
6350002|NCT03605836|10115578|FG002|Double-blind Treatment Period [6 Weeks]|Lost to Follow-up|5
6350003|NCT03605836|10115579|FG003|Double-blind Treatment Period [6 Weeks]|Lost to Follow-up|1
6350004|NCT03605836|10115576|FG000|Double-blind Treatment Period [6 Weeks]|Non-compliance with Study Drug|0
6350005|NCT03605836|10115577|FG001|Double-blind Treatment Period [6 Weeks]|Non-compliance with Study Drug|1
6350006|NCT03605836|10115578|FG002|Double-blind Treatment Period [6 Weeks]|Non-compliance with Study Drug|0
6350007|NCT03605836|10115579|FG003|Double-blind Treatment Period [6 Weeks]|Non-compliance with Study Drug|4
6350008|NCT03605836|10115576|FG000|Double-blind Treatment Period [6 Weeks]|Pregnancy|0
6350009|NCT03605836|10115577|FG001|Double-blind Treatment Period [6 Weeks]|Pregnancy|1
6350010|NCT03605836|10115578|FG002|Double-blind Treatment Period [6 Weeks]|Pregnancy|0
6350011|NCT03605836|10115579|FG003|Double-blind Treatment Period [6 Weeks]|Pregnancy|0
6350012|NCT03605836|10115576|FG000|Double-blind Treatment Period [6 Weeks]|Protocol Deviation|0
6350013|NCT03605836|10115577|FG001|Double-blind Treatment Period [6 Weeks]|Protocol Deviation|5
6350014|NCT03605836|10115578|FG002|Double-blind Treatment Period [6 Weeks]|Protocol Deviation|1
6350015|NCT03605836|10115579|FG003|Double-blind Treatment Period [6 Weeks]|Protocol Deviation|1
6350016|NCT03605836|10115576|FG000|Double-blind Treatment Period [6 Weeks]|Withdrawal by Subject|0
6350017|NCT03605836|10115577|FG001|Double-blind Treatment Period [6 Weeks]|Withdrawal by Subject|10
6350018|NCT03605836|10115578|FG002|Double-blind Treatment Period [6 Weeks]|Withdrawal by Subject|6
6350019|NCT03605836|10115579|FG003|Double-blind Treatment Period [6 Weeks]|Withdrawal by Subject|4
6350020|NCT03605836|10115576|FG000|Double-blind Treatment Period [6 Weeks]|Physician Decision|0
6350021|NCT03605836|10115577|FG001|Double-blind Treatment Period [6 Weeks]|Physician Decision|3
6350022|NCT03605836|10115578|FG002|Double-blind Treatment Period [6 Weeks]|Physician Decision|1
6350023|NCT03605836|10115579|FG003|Double-blind Treatment Period [6 Weeks]|Physician Decision|0
6350024|NCT03605836|10115576|FG000|Double-blind Treatment Period [6 Weeks]|Reason not Specified|0
6350025|NCT03605836|10115577|FG001|Double-blind Treatment Period [6 Weeks]|Reason not Specified|6
6350026|NCT03605836|10115578|FG002|Double-blind Treatment Period [6 Weeks]|Reason not Specified|16
6350027|NCT03605836|10115579|FG003|Double-blind Treatment Period [6 Weeks]|Reason not Specified|7
6350028|NCT03605836|10115576|FG000|Double-blind Treatment Period [6 Weeks]|Covid-19 Related|0
6350029|NCT03605836|10115577|FG001|Double-blind Treatment Period [6 Weeks]|Covid-19 Related|0
6350030|NCT03605836|10115578|FG002|Double-blind Treatment Period [6 Weeks]|Covid-19 Related|2
6350031|NCT03605836|10115579|FG003|Double-blind Treatment Period [6 Weeks]|Covid-19 Related|1
6350032|NCT03606460|10115612|FG000|Overall Study|Lost to Follow-up|1
6350033|NCT03606460|10115613|FG001|Overall Study|Lost to Follow-up|8
6350034|NCT03607682|10115629|FG000|Overall Study|Withdrawal by Subject|1
6350035|NCT03607682|10115629|FG000|Overall Study|Disease progression|1
6350036|NCT03607695|10115633|FG000|10 Week|Local and institutional restrictions on research enacted due to COVID-19 pandemic|1
6350037|NCT03607695|10115633|FG000|16 Week|Local and institutional restrictions on research enacted due to COVID-19 pandemic|2
6350038|NCT03608774|10115656|FG000|Overall Study|Lost to Follow-up|5
6350039|NCT03608774|10115657|FG001|Overall Study|Lost to Follow-up|5
6350040|NCT03608774|10115656|FG000|Overall Study|Withdrawal by Subject|1
6350041|NCT03608774|10115657|FG001|Overall Study|Withdrawal by Subject|0
6350042|NCT03608774|10115656|FG000|Overall Study|Protocol Violation|1
6350043|NCT03608774|10115657|FG001|Overall Study|Protocol Violation|0
6350044|NCT03608774|10115656|FG000|Overall Study|Not eligible at enrollment|0
6350045|NCT03608774|10115657|FG001|Overall Study|Not eligible at enrollment|1
6350046|NCT03608774|10115656|FG000|Overall Study|Health related event|0
6350047|NCT03608774|10115657|FG001|Overall Study|Health related event|1
6350048|NCT03609619|10115678|FG000|Overall Study|Adverse Event|1
6350049|NCT03609619|10115679|FG001|Overall Study|Adverse Event|0
6350050|NCT03609619|10115678|FG000|Overall Study|Lack of Efficacy|1
6350051|NCT03609619|10115679|FG001|Overall Study|Lack of Efficacy|2
6350052|NCT03609619|10115678|FG000|Overall Study|Protocol Violation|5
6350053|NCT03609619|10115679|FG001|Overall Study|Protocol Violation|0
6350054|NCT03609619|10115678|FG000|Overall Study|Withdrawal by Subject|2
6350055|NCT03609619|10115679|FG001|Overall Study|Withdrawal by Subject|3
6350056|NCT03609619|10115678|FG000|Overall Study|Lost to Follow-up|1
6350057|NCT03609619|10115679|FG001|Overall Study|Lost to Follow-up|1
6350058|NCT03610048|10115694|FG000|Overall Study|Study terminated by sponsor|84
6350059|NCT03610048|10115694|FG000|Overall Study|Adverse Event|32
6350060|NCT03610048|10115694|FG000|Overall Study|Withdrawal by Subject|31
6350061|NCT03610048|10115694|FG000|Overall Study|Lost to Follow-up|8
6350062|NCT03610048|10115694|FG000|Overall Study|Other|4
6350063|NCT03610048|10115694|FG000|Overall Study|Physician Decision|1
6350064|NCT03610048|10115694|FG000|Overall Study|Pregnancy|1
6350065|NCT03610165|10115700|FG000|Overall Study|Device didn't work|0
6350066|NCT03610165|10115701|FG001|Overall Study|Device didn't work|1
6350067|NCT03610269|10115707|FG000|Overall Study|Physician Decision|10
6350068|NCT03610269|10115707|FG000|Overall Study|Protocol Violation|1
6350069|NCT03610269|10115707|FG000|Overall Study|Unable to draw blood|1
6350070|NCT03610269|10115707|FG000|Overall Study|Screen fail|4
6350071|NCT03610581|10115731|FG000|Overall Study|Study terminated by sponsor|2
6350072|NCT03610581|10115732|FG001|Overall Study|Study terminated by sponsor|0
6350073|NCT03610581|10115731|FG000|Overall Study|Other|0
6350074|NCT03610581|10115732|FG001|Overall Study|Other|1
6350075|NCT03610581|10115731|FG000|Overall Study|Withdrawal by Subject|1
6350076|NCT03610581|10115732|FG001|Overall Study|Withdrawal by Subject|0
6350077|NCT03611075|10115765|FG000|Overall Study|Physician Decision|0
6350078|NCT03611075|10115766|FG001|Overall Study|Physician Decision|1
6350079|NCT03611075|10115767|FG002|Overall Study|Physician Decision|1
6350080|NCT03611075|10115768|FG003|Overall Study|Physician Decision|0
6350081|NCT03611075|10115769|FG004|Overall Study|Physician Decision|0
6350082|NCT03611075|10115770|FG005|Overall Study|Physician Decision|0
6350083|NCT03611075|10115771|FG006|Overall Study|Physician Decision|0
6350084|NCT03611075|10115772|FG007|Overall Study|Physician Decision|0
6350085|NCT03611075|10115773|FG008|Overall Study|Physician Decision|0
6350086|NCT03611075|10115765|FG000|Overall Study|Lost to Follow-up|1
6350087|NCT03611075|10115766|FG001|Overall Study|Lost to Follow-up|0
6350088|NCT03611075|10115767|FG002|Overall Study|Lost to Follow-up|0
6350089|NCT03611075|10115768|FG003|Overall Study|Lost to Follow-up|2
6350090|NCT03611075|10115769|FG004|Overall Study|Lost to Follow-up|0
6350091|NCT03611075|10115770|FG005|Overall Study|Lost to Follow-up|0
6350092|NCT03611075|10115771|FG006|Overall Study|Lost to Follow-up|0
6350093|NCT03611075|10115772|FG007|Overall Study|Lost to Follow-up|0
6350094|NCT03611075|10115773|FG008|Overall Study|Lost to Follow-up|0
6350095|NCT03611075|10115765|FG000|Overall Study|Withdrawal by Subject|0
6350096|NCT03611075|10115766|FG001|Overall Study|Withdrawal by Subject|1
6350097|NCT03611075|10115767|FG002|Overall Study|Withdrawal by Subject|1
6350098|NCT03611075|10115768|FG003|Overall Study|Withdrawal by Subject|1
6350099|NCT03611075|10115769|FG004|Overall Study|Withdrawal by Subject|0
6350100|NCT03611075|10115770|FG005|Overall Study|Withdrawal by Subject|0
6350101|NCT03611075|10115771|FG006|Overall Study|Withdrawal by Subject|1
6350102|NCT03611075|10115772|FG007|Overall Study|Withdrawal by Subject|0
6350103|NCT03611075|10115773|FG008|Overall Study|Withdrawal by Subject|0
6350104|NCT03611075|10115765|FG000|Overall Study|Reason unknown|0
6350105|NCT03611075|10115766|FG001|Overall Study|Reason unknown|0
6350106|NCT03611075|10115767|FG002|Overall Study|Reason unknown|0
6350107|NCT03611075|10115768|FG003|Overall Study|Reason unknown|1
6350108|NCT03611075|10115769|FG004|Overall Study|Reason unknown|0
6350109|NCT03611075|10115770|FG005|Overall Study|Reason unknown|0
6350110|NCT03611075|10115771|FG006|Overall Study|Reason unknown|1
6350111|NCT03611075|10115772|FG007|Overall Study|Reason unknown|0
6350112|NCT03611075|10115773|FG008|Overall Study|Reason unknown|0
6350113|NCT03611582|10115818|FG000|Overall Study|Adverse Event|26
6350114|NCT03611582|10115819|FG001|Overall Study|Adverse Event|6
6350115|NCT03611582|10115818|FG000|Overall Study|Protocol Violation|0
6350116|NCT03611582|10115819|FG001|Overall Study|Protocol Violation|1
6350117|NCT03611582|10115818|FG000|Overall Study|Pregnancy|1
6350118|NCT03611582|10115819|FG001|Overall Study|Pregnancy|2
6350119|NCT03611582|10115818|FG000|Overall Study|Lack of Efficacy|0
6350120|NCT03611582|10115819|FG001|Overall Study|Lack of Efficacy|1
6350121|NCT03611582|10115818|FG000|Overall Study|At the discretion of the investigator|1
6350122|NCT03611582|10115819|FG001|Overall Study|At the discretion of the investigator|0
6350123|NCT03611582|10115818|FG000|Overall Study|Safety concern as judged by the investigator|1
6350124|NCT03611582|10115819|FG001|Overall Study|Safety concern as judged by the investigator|2
6350125|NCT03611582|10115818|FG000|Overall Study|Withdrawal by Subject|4
6350126|NCT03611582|10115819|FG001|Overall Study|Withdrawal by Subject|3
6350127|NCT03611582|10115818|FG000|Overall Study|Lost to Follow-up|18
6350128|NCT03611582|10115819|FG001|Overall Study|Lost to Follow-up|7
6350129|NCT03611582|10115818|FG000|Overall Study|other|17
6350130|NCT03611582|10115819|FG001|Overall Study|other|16
6350131|NCT03613129|10115851|FG000|Pre-treatment Assessment|Protocol Violation|2
6350132|NCT03613129|10115852|FG001|Pre-treatment Assessment|Protocol Violation|0
6350133|NCT03613129|10115853|FG002|Pre-treatment Assessment|Protocol Violation|0
6350134|NCT03613129|10115854|FG003|Pre-treatment Assessment|Protocol Violation|0
6350135|NCT03613129|10115855|FG004|Pre-treatment Assessment|Protocol Violation|0
6350136|NCT03613129|10115851|FG000|Pre-treatment Assessment|Withdrawal by Subject|1
6350137|NCT03613129|10115852|FG001|Pre-treatment Assessment|Withdrawal by Subject|0
6350138|NCT03613129|10115853|FG002|Pre-treatment Assessment|Withdrawal by Subject|0
6350139|NCT03613129|10115854|FG003|Pre-treatment Assessment|Withdrawal by Subject|0
6350140|NCT03613129|10115855|FG004|Pre-treatment Assessment|Withdrawal by Subject|0
6350141|NCT03613454|10115869|FG000|Overall Study|Protocol Violation|1
6350142|NCT03613454|10115870|FG001|Overall Study|Protocol Violation|0
6350143|NCT03613454|10115869|FG000|Overall Study|Protocol Violation|0
6350144|NCT03613454|10115870|FG001|Overall Study|Protocol Violation|1
6350145|NCT03613649|10115904|FG000|Second Treatment|Lost to Follow-up|0
6350146|NCT03613649|10115905|FG001|Second Treatment|Lost to Follow-up|0
6350147|NCT03613649|10115906|FG002|Second Treatment|Lost to Follow-up|1
6350148|NCT03613649|10115907|FG003|Second Treatment|Lost to Follow-up|0
6350149|NCT03613649|10115908|FG004|Second Treatment|Lost to Follow-up|0
6350150|NCT03613649|10115909|FG005|Second Treatment|Lost to Follow-up|0
6350151|NCT03613649|10115910|FG006|Second Treatment|Lost to Follow-up|0
6350152|NCT03613649|10115911|FG007|Second Treatment|Lost to Follow-up|0
6350153|NCT03613649|10115912|FG008|Second Treatment|Lost to Follow-up|0
6350154|NCT03613649|10115913|FG009|Second Treatment|Lost to Follow-up|0
6350155|NCT03613649|10115914|FG010|Second Treatment|Lost to Follow-up|0
6350156|NCT03613649|10115915|FG011|Second Treatment|Lost to Follow-up|0
6350157|NCT03613649|10115904|FG000|Second Treatment|Withdrawal by Subject|0
6350158|NCT03613649|10115905|FG001|Second Treatment|Withdrawal by Subject|0
6350159|NCT03613649|10115906|FG002|Second Treatment|Withdrawal by Subject|0
6350160|NCT03613649|10115907|FG003|Second Treatment|Withdrawal by Subject|0
6350161|NCT03613649|10115908|FG004|Second Treatment|Withdrawal by Subject|1
6350162|NCT03613649|10115909|FG005|Second Treatment|Withdrawal by Subject|0
6350163|NCT03613649|10115910|FG006|Second Treatment|Withdrawal by Subject|0
6350164|NCT03613649|10115911|FG007|Second Treatment|Withdrawal by Subject|0
6350165|NCT03613649|10115912|FG008|Second Treatment|Withdrawal by Subject|0
6350166|NCT03613649|10115913|FG009|Second Treatment|Withdrawal by Subject|0
6350167|NCT03613649|10115914|FG010|Second Treatment|Withdrawal by Subject|0
6350168|NCT03613649|10115915|FG011|Second Treatment|Withdrawal by Subject|0
6350169|NCT03613649|10115904|FG000|Third Treatment|Lost to Follow-up|0
6350170|NCT03613649|10115905|FG001|Third Treatment|Lost to Follow-up|0
6350171|NCT03613649|10115906|FG002|Third Treatment|Lost to Follow-up|0
6350172|NCT03613649|10115907|FG003|Third Treatment|Lost to Follow-up|0
6350173|NCT03613649|10115908|FG004|Third Treatment|Lost to Follow-up|1
6350174|NCT03613649|10115909|FG005|Third Treatment|Lost to Follow-up|0
6350175|NCT03613649|10115910|FG006|Third Treatment|Lost to Follow-up|0
6350176|NCT03613649|10115911|FG007|Third Treatment|Lost to Follow-up|0
6350177|NCT03613649|10115912|FG008|Third Treatment|Lost to Follow-up|0
6350178|NCT03613649|10115913|FG009|Third Treatment|Lost to Follow-up|0
6350179|NCT03613649|10115914|FG010|Third Treatment|Lost to Follow-up|0
6350180|NCT03613649|10115915|FG011|Third Treatment|Lost to Follow-up|1
6350181|NCT03613649|10115904|FG000|Third Treatment|Protocol Violation|0
6350182|NCT03613649|10115905|FG001|Third Treatment|Protocol Violation|0
6350183|NCT03613649|10115906|FG002|Third Treatment|Protocol Violation|0
6350184|NCT03613649|10115907|FG003|Third Treatment|Protocol Violation|0
6350185|NCT03613649|10115908|FG004|Third Treatment|Protocol Violation|0
6350186|NCT03613649|10115909|FG005|Third Treatment|Protocol Violation|0
6350187|NCT03613649|10115910|FG006|Third Treatment|Protocol Violation|1
6350188|NCT03613649|10115911|FG007|Third Treatment|Protocol Violation|0
6350189|NCT03613649|10115912|FG008|Third Treatment|Protocol Violation|0
6350190|NCT03613649|10115913|FG009|Third Treatment|Protocol Violation|0
6350191|NCT03613649|10115914|FG010|Third Treatment|Protocol Violation|0
6350192|NCT03613649|10115915|FG011|Third Treatment|Protocol Violation|1
6350193|NCT03613649|10115904|FG000|Fourth Treatment|Protocol Violation|1
6350194|NCT03613649|10115905|FG001|Fourth Treatment|Protocol Violation|0
6350195|NCT03613649|10115906|FG002|Fourth Treatment|Protocol Violation|0
6350196|NCT03613649|10115907|FG003|Fourth Treatment|Protocol Violation|0
6350197|NCT03613649|10115908|FG004|Fourth Treatment|Protocol Violation|1
6083631|NCT00636363|9692130|FG000|Overall Study|Missed > 1 visit|0
6083632|NCT00636363|9692131|FG001|Overall Study|Missed > 1 visit|1
6350198|NCT03613649|10115909|FG005|Fourth Treatment|Protocol Violation|0
6350199|NCT03613649|10115910|FG006|Fourth Treatment|Protocol Violation|0
6350200|NCT03613649|10115911|FG007|Fourth Treatment|Protocol Violation|0
6350201|NCT03613649|10115912|FG008|Fourth Treatment|Protocol Violation|0
6350202|NCT03613649|10115913|FG009|Fourth Treatment|Protocol Violation|0
6350203|NCT03613649|10115914|FG010|Fourth Treatment|Protocol Violation|0
6350204|NCT03613649|10115915|FG011|Fourth Treatment|Protocol Violation|0
6350205|NCT03613649|10115904|FG000|Fourth Treatment|Physician Decision|0
6350206|NCT03613649|10115905|FG001|Fourth Treatment|Physician Decision|0
6350207|NCT03613649|10115906|FG002|Fourth Treatment|Physician Decision|0
6350208|NCT03613649|10115907|FG003|Fourth Treatment|Physician Decision|0
6350209|NCT03613649|10115908|FG004|Fourth Treatment|Physician Decision|0
6350210|NCT03613649|10115909|FG005|Fourth Treatment|Physician Decision|0
6350211|NCT03613649|10115910|FG006|Fourth Treatment|Physician Decision|1
6350212|NCT03613649|10115911|FG007|Fourth Treatment|Physician Decision|0
6350213|NCT03613649|10115912|FG008|Fourth Treatment|Physician Decision|0
6350214|NCT03613649|10115913|FG009|Fourth Treatment|Physician Decision|0
6350215|NCT03613649|10115914|FG010|Fourth Treatment|Physician Decision|0
6350216|NCT03613649|10115915|FG011|Fourth Treatment|Physician Decision|0
6350217|NCT03614078|10115945|FG000|Overall Study|Withdrawal by Subject|2
6350218|NCT03614078|10115946|FG001|Overall Study|Withdrawal by Subject|2
6350219|NCT03614078|10115947|FG002|Overall Study|Withdrawal by Subject|3
6350220|NCT03614078|10115945|FG000|Overall Study|Participant Did Not Return for Visit|0
6350221|NCT03614078|10115946|FG001|Overall Study|Participant Did Not Return for Visit|1
6350222|NCT03614078|10115947|FG002|Overall Study|Participant Did Not Return for Visit|0
6350223|NCT03614078|10115945|FG000|Overall Study|High Neutrophils|0
6350224|NCT03614078|10115946|FG001|Overall Study|High Neutrophils|0
6350225|NCT03614078|10115947|FG002|Overall Study|High Neutrophils|2
6350226|NCT03614078|10115945|FG000|Overall Study|Patient Did Not Meet Eligibility|1
6350227|NCT03614078|10115946|FG001|Overall Study|Patient Did Not Meet Eligibility|0
6350228|NCT03614078|10115947|FG002|Overall Study|Patient Did Not Meet Eligibility|0
6350229|NCT03614078|10115945|FG000|Overall Study|Exacerbation of Psoriasis|0
6350230|NCT03614078|10115946|FG001|Overall Study|Exacerbation of Psoriasis|1
6350231|NCT03614078|10115947|FG002|Overall Study|Exacerbation of Psoriasis|0
6170209|NCT01251653|9816355|FG002|Overall Study|Adverse Event|2
6350232|NCT03614078|10115945|FG000|Overall Study|Adverse Event|0
6350233|NCT03614078|10115946|FG001|Overall Study|Adverse Event|2
6350234|NCT03614078|10115947|FG002|Overall Study|Adverse Event|0
6350235|NCT03614078|10115945|FG000|Overall Study|Dizziness and Rash|0
6350236|NCT03614078|10115946|FG001|Overall Study|Dizziness and Rash|1
6350237|NCT03614078|10115947|FG002|Overall Study|Dizziness and Rash|0
6350238|NCT03614156|10115969|FG000|Open-Label Treatment Period|Protocol-specified withdrawal met|6
6350239|NCT03614156|10115970|FG001|Open-Label Treatment Period|Protocol-specified withdrawal met|0
6350240|NCT03614156|10115971|FG002|Open-Label Treatment Period|Protocol-specified withdrawal met|0
6350241|NCT03614156|10115972|FG003|Open-Label Treatment Period|Protocol-specified withdrawal met|0
6350242|NCT03614156|10115969|FG000|Open-Label Treatment Period|Adverse Event|7
6350243|NCT03614156|10115970|FG001|Open-Label Treatment Period|Adverse Event|0
6350244|NCT03614156|10115971|FG002|Open-Label Treatment Period|Adverse Event|0
6350245|NCT03614156|10115972|FG003|Open-Label Treatment Period|Adverse Event|0
6350246|NCT03614156|10115969|FG000|Open-Label Treatment Period|Lack of Efficacy|18
6350247|NCT03614156|10115970|FG001|Open-Label Treatment Period|Lack of Efficacy|0
6350248|NCT03614156|10115971|FG002|Open-Label Treatment Period|Lack of Efficacy|0
6350249|NCT03614156|10115972|FG003|Open-Label Treatment Period|Lack of Efficacy|0
6043161|NCT00387088|9641615|FG001|Overall Study|Lost to Follow-up|28
6043162|NCT00387088|9641614|FG000|Overall Study|Other|58
6043163|NCT00387088|9641615|FG001|Overall Study|Other|52
6043164|NCT00387127|9641623|FG000|Overall Study|Lost to Follow-up|0
6043165|NCT00387127|9641624|FG001|Overall Study|Lost to Follow-up|4
6043166|NCT00387127|9641623|FG000|Overall Study|Death|16
6043167|NCT00387127|9641624|FG001|Overall Study|Death|16
6043168|NCT00387127|9641623|FG000|Overall Study|Physician Decision|0
6043169|NCT00387127|9641624|FG001|Overall Study|Physician Decision|1
6043170|NCT00387127|9641623|FG000|Overall Study|Withdrawal by Subject|3
6043171|NCT00387127|9641624|FG001|Overall Study|Withdrawal by Subject|2
6350250|NCT03614156|10115969|FG000|Open-Label Treatment Period|Withdrawal by Subject|36
6350251|NCT03614156|10115970|FG001|Open-Label Treatment Period|Withdrawal by Subject|0
6350252|NCT03614156|10115971|FG002|Open-Label Treatment Period|Withdrawal by Subject|0
6350253|NCT03614156|10115972|FG003|Open-Label Treatment Period|Withdrawal by Subject|0
6350254|NCT03614156|10115969|FG000|Open-Label Treatment Period|Lost to Follow-up|10
6350255|NCT03614156|10115970|FG001|Open-Label Treatment Period|Lost to Follow-up|0
6350256|NCT03614156|10115971|FG002|Open-Label Treatment Period|Lost to Follow-up|0
6350257|NCT03614156|10115972|FG003|Open-Label Treatment Period|Lost to Follow-up|0
6350258|NCT03614156|10115969|FG000|Open-Label Treatment Period|Protocol Violation|2
6350259|NCT03614156|10115970|FG001|Open-Label Treatment Period|Protocol Violation|0
6350260|NCT03614156|10115971|FG002|Open-Label Treatment Period|Protocol Violation|0
6350261|NCT03614156|10115972|FG003|Open-Label Treatment Period|Protocol Violation|0
6350262|NCT03614156|10115969|FG000|Open-Label Treatment Period|Non-compliance with study drug|1
6350263|NCT03614156|10115970|FG001|Open-Label Treatment Period|Non-compliance with study drug|0
6350264|NCT03614156|10115971|FG002|Open-Label Treatment Period|Non-compliance with study drug|0
6350265|NCT03614156|10115972|FG003|Open-Label Treatment Period|Non-compliance with study drug|0
6350266|NCT03614156|10115969|FG000|Open-Label Treatment Period|Study terminated by sponsor|74
6350267|NCT03614156|10115970|FG001|Open-Label Treatment Period|Study terminated by sponsor|0
6350268|NCT03614156|10115971|FG002|Open-Label Treatment Period|Study terminated by sponsor|0
6350269|NCT03614156|10115972|FG003|Open-Label Treatment Period|Study terminated by sponsor|0
6350270|NCT03614156|10115969|FG000|Double-Blind Treatment Period (DBTP)|Adverse Event|0
6350271|NCT03614156|10115970|FG001|Double-Blind Treatment Period (DBTP)|Adverse Event|2
6350272|NCT03614156|10115971|FG002|Double-Blind Treatment Period (DBTP)|Adverse Event|0
6350273|NCT03614156|10115972|FG003|Double-Blind Treatment Period (DBTP)|Adverse Event|1
6350274|NCT03614156|10115969|FG000|Double-Blind Treatment Period (DBTP)|Withdrawal by Subject|0
6350275|NCT03614156|10115970|FG001|Double-Blind Treatment Period (DBTP)|Withdrawal by Subject|4
6350276|NCT03614156|10115971|FG002|Double-Blind Treatment Period (DBTP)|Withdrawal by Subject|1
6350277|NCT03614156|10115972|FG003|Double-Blind Treatment Period (DBTP)|Withdrawal by Subject|1
6350278|NCT03614156|10115969|FG000|Double-Blind Treatment Period (DBTP)|Lost to Follow-up|0
6350279|NCT03614156|10115970|FG001|Double-Blind Treatment Period (DBTP)|Lost to Follow-up|0
6350280|NCT03614156|10115971|FG002|Double-Blind Treatment Period (DBTP)|Lost to Follow-up|3
6350281|NCT03614156|10115972|FG003|Double-Blind Treatment Period (DBTP)|Lost to Follow-up|4
6350282|NCT03614156|10115969|FG000|Double-Blind Treatment Period (DBTP)|Protocol Violation|0
6350283|NCT03614156|10115970|FG001|Double-Blind Treatment Period (DBTP)|Protocol Violation|1
6350284|NCT03614156|10115971|FG002|Double-Blind Treatment Period (DBTP)|Protocol Violation|1
6350285|NCT03614156|10115972|FG003|Double-Blind Treatment Period (DBTP)|Protocol Violation|1
6350286|NCT03614156|10115969|FG000|Double-Blind Treatment Period (DBTP)|Study terminated by sponsor|0
6350287|NCT03614156|10115970|FG001|Double-Blind Treatment Period (DBTP)|Study terminated by sponsor|22
6350288|NCT03614156|10115971|FG002|Double-Blind Treatment Period (DBTP)|Study terminated by sponsor|26
6350289|NCT03614156|10115972|FG003|Double-Blind Treatment Period (DBTP)|Study terminated by sponsor|38
6350290|NCT03614156|10115969|FG000|Double-Blind Treatment Period (DBTP)|Miscellaneous Reasons|0
6350291|NCT03614156|10115970|FG001|Double-Blind Treatment Period (DBTP)|Miscellaneous Reasons|1
6350292|NCT03614156|10115971|FG002|Double-Blind Treatment Period (DBTP)|Miscellaneous Reasons|0
6350293|NCT03614156|10115972|FG003|Double-Blind Treatment Period (DBTP)|Miscellaneous Reasons|0
6350294|NCT03614156|10115969|FG000|Safety Follow-Up Period|Miscellaneous Reasons|2
6350295|NCT03614156|10115970|FG001|Safety Follow-Up Period|Miscellaneous Reasons|0
6350296|NCT03614156|10115971|FG002|Safety Follow-Up Period|Miscellaneous Reasons|0
6350297|NCT03614156|10115972|FG003|Safety Follow-Up Period|Miscellaneous Reasons|0
6350298|NCT03614156|10115969|FG000|Safety Follow-Up Period|Withdrawal by Subject|0
6350299|NCT03614156|10115970|FG001|Safety Follow-Up Period|Withdrawal by Subject|0
6350300|NCT03614156|10115971|FG002|Safety Follow-Up Period|Withdrawal by Subject|1
6350301|NCT03614156|10115972|FG003|Safety Follow-Up Period|Withdrawal by Subject|0
6350302|NCT03614156|10115969|FG000|Safety Follow-Up Period|Lost to Follow-up|1
6350303|NCT03614156|10115970|FG001|Safety Follow-Up Period|Lost to Follow-up|0
6350304|NCT03614156|10115971|FG002|Safety Follow-Up Period|Lost to Follow-up|0
6350305|NCT03614156|10115972|FG003|Safety Follow-Up Period|Lost to Follow-up|1
6350306|NCT03614975|10115989|FG000|Overall Study|Physician Decision|7
6350307|NCT03614975|10115990|FG001|Overall Study|Physician Decision|5
6350308|NCT03614975|10115989|FG000|Overall Study|Withdrawal by Subject|2
6350309|NCT03614975|10115990|FG001|Overall Study|Withdrawal by Subject|2
6350310|NCT03614975|10115989|FG000|Overall Study|Specimens not in lab batch shipment|1
6350311|NCT03614975|10115990|FG001|Overall Study|Specimens not in lab batch shipment|1
6350312|NCT03615404|10116021|FG000|Overall Study|Death|1
6350313|NCT03615404|10116021|FG000|Overall Study|vaccine did not pass quality assurance|1
6350314|NCT03615482|10116027|FG000|Overall Study|Death|1
6350315|NCT03615482|10116028|FG001|Overall Study|Death|0
6350316|NCT03615482|10116027|FG000|Overall Study|Lost to Follow-up|7
6350317|NCT03615482|10116028|FG001|Overall Study|Lost to Follow-up|7
6350318|NCT03615482|10116027|FG000|Overall Study|Physician Decision|2
6350319|NCT03615482|10116028|FG001|Overall Study|Physician Decision|3
6350320|NCT03615482|10116027|FG000|Overall Study|Withdrawal by Subject|7
6350321|NCT03615482|10116028|FG001|Overall Study|Withdrawal by Subject|7
6350322|NCT03615924|10116073|FG000|Overall Study|Withdrawal by Subject|2
6350323|NCT03615924|10116074|FG001|Overall Study|Withdrawal by Subject|5
6350324|NCT03615924|10116073|FG000|Overall Study|Death|3
6350325|NCT03615924|10116074|FG001|Overall Study|Death|1
6350326|NCT03615924|10116073|FG000|Overall Study|Lost to Follow-up|1
6350327|NCT03615924|10116074|FG001|Overall Study|Lost to Follow-up|0
6350328|NCT03615924|10116073|FG000|Overall Study|Randomized in error|1
6350329|NCT03615924|10116074|FG001|Overall Study|Randomized in error|0
6350330|NCT03615924|10116073|FG000|Overall Study|Study termination by Sponsor|94
6350331|NCT03615924|10116074|FG001|Overall Study|Study termination by Sponsor|86
6350332|NCT03616106|10116082|FG000|Overall Study|Removed by PI|6
6350333|NCT03616106|10116083|FG001|Overall Study|Removed by PI|0
6350334|NCT03616106|10116082|FG000|Overall Study|Withdrawal by Subject|1
6350335|NCT03616106|10116083|FG001|Overall Study|Withdrawal by Subject|1
6350336|NCT03616106|10116082|FG000|Overall Study|Lost to Follow-up|7
6350337|NCT03616106|10116083|FG001|Overall Study|Lost to Follow-up|0
6350338|NCT03616600|10116100|FG000|Overall Study|Withdrawal by Subject|1
6350339|NCT03616600|10116101|FG001|Overall Study|Withdrawal by Subject|0
6350340|NCT03616977|10116117|FG000|Period 1|Physician Decision|0
6350341|NCT03616977|10116118|FG001|Period 1|Physician Decision|1
6350342|NCT03616977|10116117|FG000|Period 3|Adverse Event|1
6350343|NCT03616977|10116118|FG001|Period 3|Adverse Event|1
6350344|NCT03617588|10116131|FG000|Overall Study|Withdrawal by Subject|1
6350345|NCT03617588|10116132|FG001|Overall Study|Withdrawal by Subject|0
6350346|NCT03617770|10116144|FG000|Overall Study|Lost to Follow-up|1
6350347|NCT03617770|10116145|FG001|Overall Study|Lost to Follow-up|0
6350348|NCT03617861|10116153|FG000|Second Intervention (1 Day)|Adverse Event|0
6350349|NCT03617861|10116154|FG001|Second Intervention (1 Day)|Adverse Event|0
6350350|NCT03617861|10116155|FG002|Second Intervention (1 Day)|Adverse Event|1
6350351|NCT03617861|10116156|FG003|Second Intervention (1 Day)|Adverse Event|0
6350352|NCT03618628|10116208|FG000|Overall Study|Death|1
6350353|NCT03618628|10116208|FG000|Overall Study|Lost to Follow-up|1
6350354|NCT03618823|10116214|FG000|Overall Study|Lost to Follow-up|63
6350355|NCT03618823|10116215|FG001|Overall Study|Lost to Follow-up|61
6350356|NCT03619837|10116241|FG000|Screening|received organs from HCV-negative donors|47
6350357|NCT03619837|10116241|FG000|Screening|died on the wait-list|2
6350358|NCT03619837|10116241|FG000|Screening|remained on the wait list|40
6350359|NCT03619837|10116241|FG000|Screening|didn't meet eligibility criteria|3
6350360|NCT03619837|10116241|FG000|Screening|withdrew consent|2
6350361|NCT03619837|10116241|FG000|Screening|never listed for HCV-viremic donor|1
6350362|NCT03619837|10116241|FG000|Screening|developed exclusion criteria|2
6350363|NCT03619837|10116241|FG000|Screening|excluded by the investigator due to non-compliance|1
6350364|NCT03620162|10116259|FG000|Overall Study|Physician Decision|4
6350365|NCT03620162|10116260|FG001|Overall Study|Physician Decision|0
6350366|NCT03620162|10116261|FG002|Overall Study|Physician Decision|1
6350367|NCT03620162|10116262|FG003|Overall Study|Physician Decision|0
6350368|NCT03620162|10116263|FG004|Overall Study|Physician Decision|2
6350369|NCT03620162|10116259|FG000|Overall Study|Lost to Follow-up|2
6350370|NCT03620162|10116260|FG001|Overall Study|Lost to Follow-up|6
6350371|NCT03620162|10116261|FG002|Overall Study|Lost to Follow-up|7
6350372|NCT03620162|10116262|FG003|Overall Study|Lost to Follow-up|3
6350373|NCT03620162|10116263|FG004|Overall Study|Lost to Follow-up|2
6350374|NCT03620162|10116259|FG000|Overall Study|Consent withdrawn by parent/guardian|9
6350375|NCT03620162|10116260|FG001|Overall Study|Consent withdrawn by parent/guardian|8
6350376|NCT03620162|10116261|FG002|Overall Study|Consent withdrawn by parent/guardian|25
6350377|NCT03620162|10116262|FG003|Overall Study|Consent withdrawn by parent/guardian|17
6350378|NCT03620162|10116263|FG004|Overall Study|Consent withdrawn by parent/guardian|9
6350379|NCT03620708|10116289|FG000|Overall Study|Lost to Follow-up|1
6350380|NCT03620708|10116290|FG001|Overall Study|Lost to Follow-up|1
6350381|NCT03620708|10116291|FG002|Overall Study|Lost to Follow-up|2
6350382|NCT03620708|10116289|FG000|Overall Study|Withdrawal by Subject|0
6350383|NCT03620708|10116290|FG001|Overall Study|Withdrawal by Subject|0
6350384|NCT03620708|10116291|FG002|Overall Study|Withdrawal by Subject|1
6350385|NCT03621189|10116317|FG000|Overall Study|Withdrawal by Subject|0
6350386|NCT03621189|10116318|FG001|Overall Study|Withdrawal by Subject|3
6350387|NCT03621189|10116317|FG000|Overall Study|Physician Decision|0
6350388|NCT03621189|10116318|FG001|Overall Study|Physician Decision|2
6350389|NCT03622112|10116353|FG000|Overall Study|Withdrawal by Subject|6
6350390|NCT03622112|10116354|FG001|Overall Study|Withdrawal by Subject|2
6350391|NCT03622112|10116355|FG002|Overall Study|Withdrawal by Subject|4
6350392|NCT03622112|10116356|FG003|Overall Study|Withdrawal by Subject|2
6350393|NCT03622112|10116357|FG004|Overall Study|Withdrawal by Subject|1
6350394|NCT03622112|10116358|FG005|Overall Study|Withdrawal by Subject|2
6350395|NCT03622112|10116359|FG006|Overall Study|Withdrawal by Subject|2
6350396|NCT03622112|10116353|FG000|Overall Study|Death|0
6350397|NCT03622112|10116354|FG001|Overall Study|Death|0
6350398|NCT03622112|10116355|FG002|Overall Study|Death|0
6350399|NCT03622112|10116356|FG003|Overall Study|Death|1
6350400|NCT03622112|10116357|FG004|Overall Study|Death|0
6350401|NCT03622112|10116358|FG005|Overall Study|Death|0
6350402|NCT03622112|10116359|FG006|Overall Study|Death|0
6350403|NCT03622112|10116353|FG000|Overall Study|Lost to Follow-up|1
6350404|NCT03622112|10116354|FG001|Overall Study|Lost to Follow-up|1
6350405|NCT03622112|10116355|FG002|Overall Study|Lost to Follow-up|0
6350406|NCT03622112|10116356|FG003|Overall Study|Lost to Follow-up|0
6350407|NCT03622112|10116357|FG004|Overall Study|Lost to Follow-up|0
6350408|NCT03622112|10116358|FG005|Overall Study|Lost to Follow-up|0
6350409|NCT03622112|10116359|FG006|Overall Study|Lost to Follow-up|0
6350410|NCT03622112|10116353|FG000|Overall Study|Study-specific withdrawal criteria|10
6350411|NCT03622112|10116354|FG001|Overall Study|Study-specific withdrawal criteria|8
6350412|NCT03622112|10116355|FG002|Overall Study|Study-specific withdrawal criteria|7
6350413|NCT03622112|10116356|FG003|Overall Study|Study-specific withdrawal criteria|6
6350414|NCT03622112|10116357|FG004|Overall Study|Study-specific withdrawal criteria|4
6350415|NCT03622112|10116358|FG005|Overall Study|Study-specific withdrawal criteria|18
6350416|NCT03622112|10116359|FG006|Overall Study|Study-specific withdrawal criteria|4
6350417|NCT03622112|10116353|FG000|Overall Study|Protocol Violation|2
6350418|NCT03622112|10116354|FG001|Overall Study|Protocol Violation|0
6350419|NCT03622112|10116355|FG002|Overall Study|Protocol Violation|1
6350420|NCT03622112|10116356|FG003|Overall Study|Protocol Violation|1
6350421|NCT03622112|10116357|FG004|Overall Study|Protocol Violation|0
6350422|NCT03622112|10116358|FG005|Overall Study|Protocol Violation|0
6350423|NCT03622112|10116359|FG006|Overall Study|Protocol Violation|0
6350424|NCT03622112|10116353|FG000|Overall Study|Adverse Event|6
6350425|NCT03622112|10116354|FG001|Overall Study|Adverse Event|8
6350426|NCT03622112|10116355|FG002|Overall Study|Adverse Event|4
6350427|NCT03622112|10116356|FG003|Overall Study|Adverse Event|11
6350428|NCT03622112|10116357|FG004|Overall Study|Adverse Event|4
6350429|NCT03622112|10116358|FG005|Overall Study|Adverse Event|20
6350430|NCT03622112|10116359|FG006|Overall Study|Adverse Event|2
6350431|NCT03622112|10116353|FG000|Overall Study|Reason not specified|0
6350432|NCT03622112|10116354|FG001|Overall Study|Reason not specified|1
6350433|NCT03622112|10116355|FG002|Overall Study|Reason not specified|0
6350434|NCT03622112|10116356|FG003|Overall Study|Reason not specified|1
6350435|NCT03622112|10116357|FG004|Overall Study|Reason not specified|1
6350436|NCT03622112|10116358|FG005|Overall Study|Reason not specified|2
6350437|NCT03622112|10116359|FG006|Overall Study|Reason not specified|1
6350438|NCT03624192|10116412|FG000|Overall Study|Lost to Follow-up|1
6350439|NCT03624192|10116413|FG001|Overall Study|Lost to Follow-up|1
6350440|NCT03624504|10116421|FG000|Overall Study|Unsuccessful Implant|1
6350441|NCT03624946|10116446|FG000|Overall Study|Lost to Follow-up|0
6350442|NCT03624946|10116447|FG001|Overall Study|Lost to Follow-up|1
6350443|NCT03624972|10116460|FG000|Overall Study|Lost to Follow-up|2
6350444|NCT03624972|10116461|FG001|Overall Study|Lost to Follow-up|0
6350445|NCT03624972|10116462|FG002|Overall Study|Lost to Follow-up|0
6350446|NCT03624972|10116460|FG000|Overall Study|Withdrawal by Subject|0
6350447|NCT03624972|10116461|FG001|Overall Study|Withdrawal by Subject|2
6350448|NCT03624972|10116462|FG002|Overall Study|Withdrawal by Subject|0
6350449|NCT03627065|10116497|FG000|Overall Study|Study Terminated by sponsor|1
6350450|NCT03627065|10116497|FG000|Overall Study|Withdrawal by Subject|2
6350451|NCT03627195|10116507|FG000|Overall Study|OTHER (LACK OF EFFICACY)|1
6350452|NCT03627195|10116508|FG001|Overall Study|OTHER (LACK OF EFFICACY)|0
6350453|NCT03627195|10116509|FG002|Overall Study|OTHER (LACK OF EFFICACY)|0
6350454|NCT03627195|10116510|FG003|Overall Study|OTHER (LACK OF EFFICACY)|0
6350455|NCT03627195|10116511|FG004|Overall Study|OTHER (LACK OF EFFICACY)|0
6350456|NCT03627195|10116512|FG005|Overall Study|OTHER (LACK OF EFFICACY)|0
6350457|NCT03627416|10116532|FG000|Overall Study|Adverse Event|0
6350458|NCT03627416|10116533|FG001|Overall Study|Adverse Event|1
6350459|NCT03627494|10116551|FG000|Part A Washout 2 (7 Days)|Adverse Event|1
6350460|NCT03627494|10116552|FG001|Part A Washout 2 (7 Days)|Adverse Event|0
6350461|NCT03627494|10116553|FG002|Part A Washout 2 (7 Days)|Adverse Event|1
6350462|NCT03627494|10116554|FG003|Part A Washout 2 (7 Days)|Adverse Event|0
6350463|NCT03627494|10116555|FG004|Part A Washout 2 (7 Days)|Adverse Event|0
6350464|NCT03627494|10116556|FG005|Part A Washout 2 (7 Days)|Adverse Event|0
6350465|NCT03627494|10116557|FG006|Part A Washout 2 (7 Days)|Adverse Event|0
6350466|NCT03627494|10116558|FG007|Part A Washout 2 (7 Days)|Adverse Event|0
6350467|NCT03627494|10116559|FG008|Part A Washout 2 (7 Days)|Adverse Event|0
6350468|NCT03627494|10116560|FG009|Part A Washout 2 (7 Days)|Adverse Event|0
6350469|NCT03627494|10116561|FG010|Part A Washout 2 (7 Days)|Adverse Event|0
6350470|NCT03627494|10116562|FG011|Part A Washout 2 (7 Days)|Adverse Event|0
6350471|NCT03627494|10116551|FG000|Part B (Maximum of 34 Days)|Adverse Event|0
6350472|NCT03627494|10116552|FG001|Part B (Maximum of 34 Days)|Adverse Event|0
6350473|NCT03627494|10116553|FG002|Part B (Maximum of 34 Days)|Adverse Event|0
6350474|NCT03627494|10116554|FG003|Part B (Maximum of 34 Days)|Adverse Event|0
6350475|NCT03627494|10116555|FG004|Part B (Maximum of 34 Days)|Adverse Event|0
6350476|NCT03627494|10116556|FG005|Part B (Maximum of 34 Days)|Adverse Event|0
6350477|NCT03627494|10116557|FG006|Part B (Maximum of 34 Days)|Adverse Event|0
6350478|NCT03627494|10116558|FG007|Part B (Maximum of 34 Days)|Adverse Event|0
6350479|NCT03627494|10116559|FG008|Part B (Maximum of 34 Days)|Adverse Event|2
6350480|NCT03627494|10116560|FG009|Part B (Maximum of 34 Days)|Adverse Event|0
6350481|NCT03627494|10116561|FG010|Part B (Maximum of 34 Days)|Adverse Event|0
6350482|NCT03627494|10116562|FG011|Part B (Maximum of 34 Days)|Adverse Event|0
6350483|NCT03627494|10116551|FG000|Part C Washout 1 (7 Days)|Adverse Event|0
6350484|NCT03627494|10116552|FG001|Part C Washout 1 (7 Days)|Adverse Event|0
6350485|NCT03627494|10116553|FG002|Part C Washout 1 (7 Days)|Adverse Event|0
6350486|NCT03627494|10116554|FG003|Part C Washout 1 (7 Days)|Adverse Event|0
6350487|NCT03627494|10116555|FG004|Part C Washout 1 (7 Days)|Adverse Event|0
6350488|NCT03627494|10116556|FG005|Part C Washout 1 (7 Days)|Adverse Event|0
6350489|NCT03627494|10116557|FG006|Part C Washout 1 (7 Days)|Adverse Event|0
6350490|NCT03627494|10116558|FG007|Part C Washout 1 (7 Days)|Adverse Event|0
6350491|NCT03627494|10116559|FG008|Part C Washout 1 (7 Days)|Adverse Event|0
6350492|NCT03627494|10116560|FG009|Part C Washout 1 (7 Days)|Adverse Event|0
6350493|NCT03627494|10116561|FG010|Part C Washout 1 (7 Days)|Adverse Event|1
6350494|NCT03627494|10116562|FG011|Part C Washout 1 (7 Days)|Adverse Event|1
6350495|NCT03627767|10116604|FG000|Open-label (OL) Run-in Period (12 Weeks)|Adverse Event|48
6350496|NCT03627767|10116605|FG001|Open-label (OL) Run-in Period (12 Weeks)|Adverse Event|0
6350497|NCT03627767|10116606|FG002|Open-label (OL) Run-in Period (12 Weeks)|Adverse Event|0
6350498|NCT03627767|10116607|FG003|Open-label (OL) Run-in Period (12 Weeks)|Adverse Event|0
6350499|NCT03627767|10116608|FG004|Open-label (OL) Run-in Period (12 Weeks)|Adverse Event|0
6350500|NCT03627767|10116604|FG000|Open-label (OL) Run-in Period (12 Weeks)|Death|1
6350501|NCT03627767|10116605|FG001|Open-label (OL) Run-in Period (12 Weeks)|Death|0
6350502|NCT03627767|10116606|FG002|Open-label (OL) Run-in Period (12 Weeks)|Death|0
6350503|NCT03627767|10116607|FG003|Open-label (OL) Run-in Period (12 Weeks)|Death|0
6350504|NCT03627767|10116608|FG004|Open-label (OL) Run-in Period (12 Weeks)|Death|0
6350505|NCT03627767|10116604|FG000|Open-label (OL) Run-in Period (12 Weeks)|Lack of Efficacy|315
6350506|NCT03627767|10116605|FG001|Open-label (OL) Run-in Period (12 Weeks)|Lack of Efficacy|0
6350507|NCT03627767|10116606|FG002|Open-label (OL) Run-in Period (12 Weeks)|Lack of Efficacy|0
6350508|NCT03627767|10116607|FG003|Open-label (OL) Run-in Period (12 Weeks)|Lack of Efficacy|0
6350509|NCT03627767|10116608|FG004|Open-label (OL) Run-in Period (12 Weeks)|Lack of Efficacy|0
6350510|NCT03627767|10116604|FG000|Open-label (OL) Run-in Period (12 Weeks)|Lost to Follow-up|13
6350511|NCT03627767|10116605|FG001|Open-label (OL) Run-in Period (12 Weeks)|Lost to Follow-up|0
6350512|NCT03627767|10116606|FG002|Open-label (OL) Run-in Period (12 Weeks)|Lost to Follow-up|0
6083633|NCT00636363|9692132|FG002|Overall Study|Missed > 1 visit|3
6083634|NCT00636363|9692130|FG000|Overall Study|Lack of motivation|1
6350513|NCT03627767|10116607|FG003|Open-label (OL) Run-in Period (12 Weeks)|Lost to Follow-up|0
6350514|NCT03627767|10116608|FG004|Open-label (OL) Run-in Period (12 Weeks)|Lost to Follow-up|0
6350515|NCT03627767|10116604|FG000|Open-label (OL) Run-in Period (12 Weeks)|Protocol Violation|11
6350516|NCT03627767|10116605|FG001|Open-label (OL) Run-in Period (12 Weeks)|Protocol Violation|0
6350517|NCT03627767|10116606|FG002|Open-label (OL) Run-in Period (12 Weeks)|Protocol Violation|0
6350518|NCT03627767|10116607|FG003|Open-label (OL) Run-in Period (12 Weeks)|Protocol Violation|0
6350519|NCT03627767|10116608|FG004|Open-label (OL) Run-in Period (12 Weeks)|Protocol Violation|0
6350520|NCT03627767|10116604|FG000|Open-label (OL) Run-in Period (12 Weeks)|Withdrawal by Subject|40
6350521|NCT03627767|10116605|FG001|Open-label (OL) Run-in Period (12 Weeks)|Withdrawal by Subject|0
6350522|NCT03627767|10116606|FG002|Open-label (OL) Run-in Period (12 Weeks)|Withdrawal by Subject|0
6350523|NCT03627767|10116607|FG003|Open-label (OL) Run-in Period (12 Weeks)|Withdrawal by Subject|0
6350524|NCT03627767|10116608|FG004|Open-label (OL) Run-in Period (12 Weeks)|Withdrawal by Subject|0
6350525|NCT03627767|10116604|FG000|Open-label (OL) Run-in Period (12 Weeks)|Medication Error Without Associated Adverse Event|1
6350526|NCT03627767|10116605|FG001|Open-label (OL) Run-in Period (12 Weeks)|Medication Error Without Associated Adverse Event|0
6350527|NCT03627767|10116606|FG002|Open-label (OL) Run-in Period (12 Weeks)|Medication Error Without Associated Adverse Event|0
6350528|NCT03627767|10116607|FG003|Open-label (OL) Run-in Period (12 Weeks)|Medication Error Without Associated Adverse Event|0
6350529|NCT03627767|10116608|FG004|Open-label (OL) Run-in Period (12 Weeks)|Medication Error Without Associated Adverse Event|0
6350530|NCT03627767|10116604|FG000|Open-label (OL) Run-in Period (12 Weeks)|Withdrawal By Parent/Guardian|2
6350531|NCT03627767|10116605|FG001|Open-label (OL) Run-in Period (12 Weeks)|Withdrawal By Parent/Guardian|0
6350532|NCT03627767|10116606|FG002|Open-label (OL) Run-in Period (12 Weeks)|Withdrawal By Parent/Guardian|0
6350533|NCT03627767|10116607|FG003|Open-label (OL) Run-in Period (12 Weeks)|Withdrawal By Parent/Guardian|0
6170210|NCT01251653|9816356|FG003|Overall Study|Adverse Event|1
6350534|NCT03627767|10116608|FG004|Open-label (OL) Run-in Period (12 Weeks)|Withdrawal By Parent/Guardian|0
6350535|NCT03627767|10116604|FG000|Open-label (OL) Run-in Period (12 Weeks)|Other|4
6350536|NCT03627767|10116605|FG001|Open-label (OL) Run-in Period (12 Weeks)|Other|0
6350537|NCT03627767|10116606|FG002|Open-label (OL) Run-in Period (12 Weeks)|Other|0
6350538|NCT03627767|10116607|FG003|Open-label (OL) Run-in Period (12 Weeks)|Other|0
6350539|NCT03627767|10116608|FG004|Open-label (OL) Run-in Period (12 Weeks)|Other|0
6350540|NCT03627767|10116604|FG000|Open-label (OL) Run-in Period (12 Weeks)|Randomized but not treated|2
6350541|NCT03627767|10116605|FG001|Open-label (OL) Run-in Period (12 Weeks)|Randomized but not treated|0
6350542|NCT03627767|10116606|FG002|Open-label (OL) Run-in Period (12 Weeks)|Randomized but not treated|0
6350543|NCT03627767|10116607|FG003|Open-label (OL) Run-in Period (12 Weeks)|Randomized but not treated|0
6350544|NCT03627767|10116608|FG004|Open-label (OL) Run-in Period (12 Weeks)|Randomized but not treated|0
6350545|NCT03627767|10116604|FG000|Double-blind Treatment Period (40 Weeks)|Adverse Event|0
6350546|NCT03627767|10116605|FG001|Double-blind Treatment Period (40 Weeks)|Adverse Event|6
6350547|NCT03627767|10116606|FG002|Double-blind Treatment Period (40 Weeks)|Adverse Event|7
6350548|NCT03627767|10116607|FG003|Double-blind Treatment Period (40 Weeks)|Adverse Event|19
6350549|NCT03627767|10116608|FG004|Double-blind Treatment Period (40 Weeks)|Adverse Event|0
6350550|NCT03627767|10116604|FG000|Double-blind Treatment Period (40 Weeks)|Lost to Follow-up|0
6350551|NCT03627767|10116605|FG001|Double-blind Treatment Period (40 Weeks)|Lost to Follow-up|0
6350552|NCT03627767|10116606|FG002|Double-blind Treatment Period (40 Weeks)|Lost to Follow-up|2
6350553|NCT03627767|10116607|FG003|Double-blind Treatment Period (40 Weeks)|Lost to Follow-up|3
6350554|NCT03627767|10116608|FG004|Double-blind Treatment Period (40 Weeks)|Lost to Follow-up|0
6350555|NCT03627767|10116604|FG000|Double-blind Treatment Period (40 Weeks)|Protocol Violation|0
6350556|NCT03627767|10116605|FG001|Double-blind Treatment Period (40 Weeks)|Protocol Violation|1
6350557|NCT03627767|10116606|FG002|Double-blind Treatment Period (40 Weeks)|Protocol Violation|5
6350558|NCT03627767|10116607|FG003|Double-blind Treatment Period (40 Weeks)|Protocol Violation|2
6350559|NCT03627767|10116608|FG004|Double-blind Treatment Period (40 Weeks)|Protocol Violation|0
6350560|NCT03627767|10116604|FG000|Double-blind Treatment Period (40 Weeks)|Withdrawal by Subject|0
6350561|NCT03627767|10116605|FG001|Double-blind Treatment Period (40 Weeks)|Withdrawal by Subject|9
6350562|NCT03627767|10116606|FG002|Double-blind Treatment Period (40 Weeks)|Withdrawal by Subject|6
6350563|NCT03627767|10116607|FG003|Double-blind Treatment Period (40 Weeks)|Withdrawal by Subject|10
6350564|NCT03627767|10116608|FG004|Double-blind Treatment Period (40 Weeks)|Withdrawal by Subject|0
6350565|NCT03627767|10116604|FG000|Double-blind Treatment Period (40 Weeks)|Withdrawal By Parent/Guardian|0
6350566|NCT03627767|10116605|FG001|Double-blind Treatment Period (40 Weeks)|Withdrawal By Parent/Guardian|0
6350567|NCT03627767|10116606|FG002|Double-blind Treatment Period (40 Weeks)|Withdrawal By Parent/Guardian|1
6350568|NCT03627767|10116607|FG003|Double-blind Treatment Period (40 Weeks)|Withdrawal By Parent/Guardian|0
6350569|NCT03627767|10116608|FG004|Double-blind Treatment Period (40 Weeks)|Withdrawal By Parent/Guardian|0
6350570|NCT03627767|10116604|FG000|Double-blind Treatment Period (40 Weeks)|Other|0
6350571|NCT03627767|10116605|FG001|Double-blind Treatment Period (40 Weeks)|Other|0
6350572|NCT03627767|10116606|FG002|Double-blind Treatment Period (40 Weeks)|Other|1
6350573|NCT03627767|10116607|FG003|Double-blind Treatment Period (40 Weeks)|Other|1
6350574|NCT03627767|10116608|FG004|Double-blind Treatment Period (40 Weeks)|Other|0
6350575|NCT03627767|10116604|FG000|Open-label Rescue Period (12 Weeks)|Adverse Event|0
6350576|NCT03627767|10116605|FG001|Open-label Rescue Period (12 Weeks)|Adverse Event|0
6350577|NCT03627767|10116606|FG002|Open-label Rescue Period (12 Weeks)|Adverse Event|0
6350578|NCT03627767|10116607|FG003|Open-label Rescue Period (12 Weeks)|Adverse Event|0
6350579|NCT03627767|10116608|FG004|Open-label Rescue Period (12 Weeks)|Adverse Event|9
6350580|NCT03627767|10116604|FG000|Open-label Rescue Period (12 Weeks)|Lost to Follow-up|0
6350581|NCT03627767|10116605|FG001|Open-label Rescue Period (12 Weeks)|Lost to Follow-up|0
6350582|NCT03627767|10116606|FG002|Open-label Rescue Period (12 Weeks)|Lost to Follow-up|0
6350583|NCT03627767|10116607|FG003|Open-label Rescue Period (12 Weeks)|Lost to Follow-up|0
6350584|NCT03627767|10116608|FG004|Open-label Rescue Period (12 Weeks)|Lost to Follow-up|1
6350585|NCT03627767|10116604|FG000|Open-label Rescue Period (12 Weeks)|Withdrawal by Subject|0
6350586|NCT03627767|10116605|FG001|Open-label Rescue Period (12 Weeks)|Withdrawal by Subject|0
6350587|NCT03627767|10116606|FG002|Open-label Rescue Period (12 Weeks)|Withdrawal by Subject|0
6350588|NCT03627767|10116607|FG003|Open-label Rescue Period (12 Weeks)|Withdrawal by Subject|0
6350589|NCT03627767|10116608|FG004|Open-label Rescue Period (12 Weeks)|Withdrawal by Subject|9
6350590|NCT03627767|10116604|FG000|Open-label Rescue Period (12 Weeks)|Other|0
6350591|NCT03627767|10116605|FG001|Open-label Rescue Period (12 Weeks)|Other|0
6350592|NCT03627767|10116606|FG002|Open-label Rescue Period (12 Weeks)|Other|0
6350593|NCT03627767|10116607|FG003|Open-label Rescue Period (12 Weeks)|Other|0
6350594|NCT03627767|10116608|FG004|Open-label Rescue Period (12 Weeks)|Other|1
6350595|NCT03627832|10116621|FG000|Overall Study|Withdrawal by Subject|10
6350596|NCT03627832|10116622|FG001|Overall Study|Withdrawal by Subject|1
6350597|NCT03628417|10116628|FG000|Overall Study|Death|1
6350598|NCT03628417|10116629|FG001|Overall Study|Death|1
6350599|NCT03628508|10116647|FG000|Overall Study|Lost to Follow-up|1
6350600|NCT03628599|10116653|FG000|Overall Study|Adverse Event|0
6350601|NCT03628599|10116654|FG001|Overall Study|Adverse Event|1
6350602|NCT03628898|10116677|FG000|Overall Study|Device deficiency|1
6083635|NCT00636363|9692131|FG001|Overall Study|Lack of motivation|0
6083636|NCT00636363|9692132|FG002|Overall Study|Lack of motivation|1
6350603|NCT03628924|10116684|FG000|Placebo Controlled Period (Week 0 - 16)|Lost to Follow-up|2
6350604|NCT03628924|10116685|FG001|Placebo Controlled Period (Week 0 - 16)|Lost to Follow-up|0
6350605|NCT03628924|10116686|FG002|Placebo Controlled Period (Week 0 - 16)|Lost to Follow-up|0
6350606|NCT03628924|10116687|FG003|Placebo Controlled Period (Week 0 - 16)|Lost to Follow-up|0
6350607|NCT03628924|10116688|FG004|Placebo Controlled Period (Week 0 - 16)|Lost to Follow-up|0
6350608|NCT03628924|10116689|FG005|Placebo Controlled Period (Week 0 - 16)|Lost to Follow-up|0
6350609|NCT03628924|10116690|FG006|Placebo Controlled Period (Week 0 - 16)|Lost to Follow-up|0
6350610|NCT03628924|10116684|FG000|Placebo Controlled Period (Week 0 - 16)|Withdrawal by Subject|0
6350611|NCT03628924|10116685|FG001|Placebo Controlled Period (Week 0 - 16)|Withdrawal by Subject|0
6350612|NCT03628924|10116686|FG002|Placebo Controlled Period (Week 0 - 16)|Withdrawal by Subject|1
6350613|NCT03628924|10116687|FG003|Placebo Controlled Period (Week 0 - 16)|Withdrawal by Subject|0
6350614|NCT03628924|10116688|FG004|Placebo Controlled Period (Week 0 - 16)|Withdrawal by Subject|0
6350615|NCT03628924|10116689|FG005|Placebo Controlled Period (Week 0 - 16)|Withdrawal by Subject|0
6350616|NCT03628924|10116690|FG006|Placebo Controlled Period (Week 0 - 16)|Withdrawal by Subject|0
6350617|NCT03628924|10116684|FG000|Placebo Controlled Period (Week 0 - 16)|Protocol Violation|1
6350618|NCT03628924|10116685|FG001|Placebo Controlled Period (Week 0 - 16)|Protocol Violation|2
6350619|NCT03628924|10116686|FG002|Placebo Controlled Period (Week 0 - 16)|Protocol Violation|1
6350620|NCT03628924|10116687|FG003|Placebo Controlled Period (Week 0 - 16)|Protocol Violation|0
6350621|NCT03628924|10116688|FG004|Placebo Controlled Period (Week 0 - 16)|Protocol Violation|0
6350622|NCT03628924|10116689|FG005|Placebo Controlled Period (Week 0 - 16)|Protocol Violation|0
6350623|NCT03628924|10116690|FG006|Placebo Controlled Period (Week 0 - 16)|Protocol Violation|0
6350624|NCT03628924|10116684|FG000|Placebo Controlled Period (Week 0 - 16)|Adverse Event|0
6170211|NCT01251653|9816357|FG004|Overall Study|Adverse Event|1
6170212|NCT01251653|9816358|FG005|Overall Study|Adverse Event|0
6170213|NCT01251653|9816359|FG006|Overall Study|Adverse Event|2
6170214|NCT01251653|9816360|FG007|Overall Study|Adverse Event|2
6350625|NCT03628924|10116685|FG001|Placebo Controlled Period (Week 0 - 16)|Adverse Event|1
6350626|NCT03628924|10116686|FG002|Placebo Controlled Period (Week 0 - 16)|Adverse Event|0
6350627|NCT03628924|10116687|FG003|Placebo Controlled Period (Week 0 - 16)|Adverse Event|0
6350628|NCT03628924|10116688|FG004|Placebo Controlled Period (Week 0 - 16)|Adverse Event|0
6350629|NCT03628924|10116689|FG005|Placebo Controlled Period (Week 0 - 16)|Adverse Event|0
6350630|NCT03628924|10116690|FG006|Placebo Controlled Period (Week 0 - 16)|Adverse Event|0
6350631|NCT03628924|10116684|FG000|Placebo Controlled Period (Week 0 - 16)|Lack of Efficacy|3
6350632|NCT03628924|10116685|FG001|Placebo Controlled Period (Week 0 - 16)|Lack of Efficacy|0
6350633|NCT03628924|10116686|FG002|Placebo Controlled Period (Week 0 - 16)|Lack of Efficacy|1
6350634|NCT03628924|10116687|FG003|Placebo Controlled Period (Week 0 - 16)|Lack of Efficacy|0
6350635|NCT03628924|10116688|FG004|Placebo Controlled Period (Week 0 - 16)|Lack of Efficacy|0
6350636|NCT03628924|10116689|FG005|Placebo Controlled Period (Week 0 - 16)|Lack of Efficacy|0
6350637|NCT03628924|10116690|FG006|Placebo Controlled Period (Week 0 - 16)|Lack of Efficacy|0
6350638|NCT03628924|10116684|FG000|Active Treatment Period (Week 16-48)|Lost to Follow-up|0
6350639|NCT03628924|10116685|FG001|Active Treatment Period (Week 16-48)|Lost to Follow-up|0
6350640|NCT03628924|10116686|FG002|Active Treatment Period (Week 16-48)|Lost to Follow-up|0
6350641|NCT03628924|10116687|FG003|Active Treatment Period (Week 16-48)|Lost to Follow-up|1
6350642|NCT03628924|10116688|FG004|Active Treatment Period (Week 16-48)|Lost to Follow-up|1
6350643|NCT03628924|10116689|FG005|Active Treatment Period (Week 16-48)|Lost to Follow-up|2
6350644|NCT03628924|10116690|FG006|Active Treatment Period (Week 16-48)|Lost to Follow-up|1
6350645|NCT03628924|10116684|FG000|Active Treatment Period (Week 16-48)|Adverse Event|0
6350646|NCT03628924|10116685|FG001|Active Treatment Period (Week 16-48)|Adverse Event|0
6170215|NCT01251653|9816361|FG008|Overall Study|Adverse Event|1
6170216|NCT01251653|9816353|FG000|Overall Study|Withdrawal by Subject|1
6170217|NCT01251653|9816354|FG001|Overall Study|Withdrawal by Subject|0
6350647|NCT03628924|10116686|FG002|Active Treatment Period (Week 16-48)|Adverse Event|0
6350648|NCT03628924|10116687|FG003|Active Treatment Period (Week 16-48)|Adverse Event|1
6350649|NCT03628924|10116688|FG004|Active Treatment Period (Week 16-48)|Adverse Event|0
6350650|NCT03628924|10116689|FG005|Active Treatment Period (Week 16-48)|Adverse Event|2
6350651|NCT03628924|10116690|FG006|Active Treatment Period (Week 16-48)|Adverse Event|4
6350652|NCT03628924|10116684|FG000|Active Treatment Period (Week 16-48)|Protocol Violation|0
6350653|NCT03628924|10116685|FG001|Active Treatment Period (Week 16-48)|Protocol Violation|0
6350654|NCT03628924|10116686|FG002|Active Treatment Period (Week 16-48)|Protocol Violation|0
6350655|NCT03628924|10116687|FG003|Active Treatment Period (Week 16-48)|Protocol Violation|1
6350656|NCT03628924|10116688|FG004|Active Treatment Period (Week 16-48)|Protocol Violation|1
6350657|NCT03628924|10116689|FG005|Active Treatment Period (Week 16-48)|Protocol Violation|0
6350658|NCT03628924|10116690|FG006|Active Treatment Period (Week 16-48)|Protocol Violation|1
6350659|NCT03628924|10116684|FG000|Active Treatment Period (Week 16-48)|Lack of Efficacy|0
6350660|NCT03628924|10116685|FG001|Active Treatment Period (Week 16-48)|Lack of Efficacy|0
6350661|NCT03628924|10116686|FG002|Active Treatment Period (Week 16-48)|Lack of Efficacy|0
6350662|NCT03628924|10116687|FG003|Active Treatment Period (Week 16-48)|Lack of Efficacy|5
6350663|NCT03628924|10116688|FG004|Active Treatment Period (Week 16-48)|Lack of Efficacy|1
6350664|NCT03628924|10116689|FG005|Active Treatment Period (Week 16-48)|Lack of Efficacy|4
6350665|NCT03628924|10116690|FG006|Active Treatment Period (Week 16-48)|Lack of Efficacy|2
6350666|NCT03628924|10116684|FG000|Active Treatment Period (Week 16-48)|Withdrawal by Subject|0
6170218|NCT01251653|9816355|FG002|Overall Study|Withdrawal by Subject|1
6350667|NCT03628924|10116685|FG001|Active Treatment Period (Week 16-48)|Withdrawal by Subject|0
6350668|NCT03628924|10116686|FG002|Active Treatment Period (Week 16-48)|Withdrawal by Subject|0
6350669|NCT03628924|10116687|FG003|Active Treatment Period (Week 16-48)|Withdrawal by Subject|0
6350670|NCT03628924|10116688|FG004|Active Treatment Period (Week 16-48)|Withdrawal by Subject|1
6350671|NCT03628924|10116689|FG005|Active Treatment Period (Week 16-48)|Withdrawal by Subject|5
6350672|NCT03628924|10116690|FG006|Active Treatment Period (Week 16-48)|Withdrawal by Subject|3
6350673|NCT03629028|10116704|FG000|Overall Study|Lost to Follow-up|26
6350674|NCT03629028|10116705|FG001|Overall Study|Lost to Follow-up|23
6350675|NCT03629028|10116704|FG000|Overall Study|Pregnancy|4
6350676|NCT03629028|10116705|FG001|Overall Study|Pregnancy|2
6350677|NCT03629028|10116704|FG000|Overall Study|intolerance to examination|2
6350678|NCT03629028|10116705|FG001|Overall Study|intolerance to examination|0
6350679|NCT03629041|10116721|FG000|Visit 2 (2 Weeks ± 3 Days From Visit 1)|Withdrawal by Subject|0
6350680|NCT03629041|10116722|FG001|Visit 2 (2 Weeks ± 3 Days From Visit 1)|Withdrawal by Subject|1
6350681|NCT03629041|10116723|FG002|Visit 2 (2 Weeks ± 3 Days From Visit 1)|Withdrawal by Subject|0
6350682|NCT03629041|10116724|FG003|Visit 2 (2 Weeks ± 3 Days From Visit 1)|Withdrawal by Subject|0
6350683|NCT03629054|10116744|FG000|Period 2 (4 Days)|Not treated|0
6350684|NCT03629054|10116745|FG001|Period 2 (4 Days)|Not treated|1
6350685|NCT03629184|10116753|FG000|Overall Study|Withdrawal by Subject|2
6350686|NCT03629184|10116754|FG001|Overall Study|Withdrawal by Subject|1
6350687|NCT03629184|10116753|FG000|Overall Study|Physician Decision|1
6350688|NCT03629184|10116754|FG001|Overall Study|Physician Decision|0
6350689|NCT03629249|10116763|FG000|Overall Study|Study terminated by sponsor|197
6350690|NCT03629249|10116764|FG001|Overall Study|Study terminated by sponsor|197
6350691|NCT03629249|10116765|FG002|Overall Study|Study terminated by sponsor|194
6350692|NCT03629249|10116763|FG000|Overall Study|Protocol deviation|0
6350693|NCT03629249|10116764|FG001|Overall Study|Protocol deviation|2
6350694|NCT03629249|10116765|FG002|Overall Study|Protocol deviation|5
6350695|NCT03629249|10116763|FG000|Overall Study|Subject decision|1
6350696|NCT03629249|10116764|FG001|Overall Study|Subject decision|1
6350697|NCT03629249|10116765|FG002|Overall Study|Subject decision|3
6350698|NCT03629249|10116763|FG000|Overall Study|Adverse Event|1
6350699|NCT03629249|10116764|FG001|Overall Study|Adverse Event|1
6350700|NCT03629249|10116765|FG002|Overall Study|Adverse Event|0
6350701|NCT03629249|10116763|FG000|Overall Study|Death|1
6350702|NCT03629249|10116764|FG001|Overall Study|Death|0
6350703|NCT03629249|10116765|FG002|Overall Study|Death|0
6350704|NCT03629249|10116763|FG000|Overall Study|Physician Decision|1
6350705|NCT03629249|10116764|FG001|Overall Study|Physician Decision|0
6350706|NCT03629249|10116765|FG002|Overall Study|Physician Decision|0
6350707|NCT03629886|10116779|FG000|Overall Study|Migrated / moved from the study area|0
6350708|NCT03629886|10116780|FG001|Overall Study|Migrated / moved from the study area|55
6350709|NCT03629886|10116779|FG000|Overall Study|Consent withdrawal, not due to an AE|0
6350710|NCT03629886|10116780|FG001|Overall Study|Consent withdrawal, not due to an AE|50
6350711|NCT03629886|10116779|FG000|Overall Study|Study vaccine not administrated|0
6350712|NCT03629886|10116780|FG001|Overall Study|Study vaccine not administrated|3
6350713|NCT03629886|10116779|FG000|Overall Study|Didn't meet inclusion/exclusion criteria|0
6350714|NCT03629886|10116780|FG001|Overall Study|Didn't meet inclusion/exclusion criteria|28
6350715|NCT03629886|10116779|FG000|Overall Study|Refused vaccination step of the study|0
6350716|NCT03629886|10116780|FG001|Overall Study|Refused vaccination step of the study|44
6350717|NCT03630016|10116796|FG000|Overall Study|Poor Sensor Placement|1
6350718|NCT03630302|10116818|FG000|Surgery|hardware issue prevented LFP recordings|1
6350719|NCT03630302|10116818|FG000|3 Month Visit|Adverse Event|2
6350720|NCT03630302|10116818|FG000|Data Post Analyses|IRB issues prevented data from being analyzed and transferred|2
6350721|NCT03631355|10116833|FG000|Overall Study|Lost to Follow-up|1
6350722|NCT03631355|10116834|FG001|Overall Study|Lost to Follow-up|2
6350723|NCT03631732|10116851|FG000|Randomized Phase Up to Week 24|Lost to Follow-up|3
6350724|NCT03631732|10116852|FG001|Randomized Phase Up to Week 24|Lost to Follow-up|0
6350725|NCT03631732|10116851|FG000|Randomized Phase Up to Week 24|Withdrew Consent|1
6350726|NCT03631732|10116852|FG001|Randomized Phase Up to Week 24|Withdrew Consent|2
6350727|NCT03631732|10116851|FG000|Randomized Phase Up to Week 24|Adverse Event|2
6350728|NCT03631732|10116852|FG001|Randomized Phase Up to Week 24|Adverse Event|0
6350729|NCT03631732|10116851|FG000|Randomized Phase Up to Week 24|Randomized but not treated|1
6170219|NCT01251653|9816356|FG003|Overall Study|Withdrawal by Subject|0
6350730|NCT03631732|10116852|FG001|Randomized Phase Up to Week 24|Randomized but not treated|0
6350731|NCT03631732|10116851|FG000|B/F/TAF Treatment Phase (After Week 24)|Lost to Follow-up|6
6350732|NCT03631732|10116852|FG001|B/F/TAF Treatment Phase (After Week 24)|Lost to Follow-up|1
6350733|NCT03631732|10116851|FG000|B/F/TAF Treatment Phase (After Week 24)|Withdrew Consent|3
6350734|NCT03631732|10116852|FG001|B/F/TAF Treatment Phase (After Week 24)|Withdrew Consent|3
6350735|NCT03631732|10116851|FG000|B/F/TAF Treatment Phase (After Week 24)|Adverse Event|4
6350736|NCT03631732|10116852|FG001|B/F/TAF Treatment Phase (After Week 24)|Adverse Event|1
6350737|NCT03631732|10116851|FG000|B/F/TAF Treatment Phase (After Week 24)|Death|1
6350738|NCT03631732|10116852|FG001|B/F/TAF Treatment Phase (After Week 24)|Death|0
6350739|NCT03631732|10116851|FG000|B/F/TAF Treatment Phase (After Week 24)|Investigator's discretion|1
6350740|NCT03631732|10116852|FG001|B/F/TAF Treatment Phase (After Week 24)|Investigator's discretion|0
6043172|NCT00387127|9641623|FG000|Overall Study|Required by Protocol Amendment #4|12
6350741|NCT03631732|10116851|FG000|B/F/TAF Treatment Phase (After Week 24)|Lack of Efficacy|1
6350742|NCT03631732|10116852|FG001|B/F/TAF Treatment Phase (After Week 24)|Lack of Efficacy|0
6350743|NCT03633331|10116909|FG000|Overall Study|Withdrawal by Subject|1
6350744|NCT03633825|10116947|FG000|Enrollment|Did not post on network|5066
6350745|NCT03633825|10116948|FG001|Enrollment|Did not post on network|5080
6350746|NCT03633825|10116947|FG000|Enrollment|Post not classified as crisis|13967
6350747|NCT03633825|10116948|FG001|Enrollment|Post not classified as crisis|13757
6350748|NCT03633825|10116947|FG000|Follow up|Lost to Follow-up|478
6350749|NCT03633825|10116948|FG001|Follow up|Lost to Follow-up|450
6350750|NCT03633903|10116956|FG000|Overall Study|Withdrawal by Subject|1
6350751|NCT03633903|10116957|FG001|Overall Study|Withdrawal by Subject|2
6350752|NCT03633903|10116956|FG000|Overall Study|Lost to Follow-up|5
6350753|NCT03633903|10116957|FG001|Overall Study|Lost to Follow-up|5
6350754|NCT03633929|10116963|FG000|Overall Study|Lost to Follow-up|1
6350755|NCT03633929|10116963|FG000|Overall Study|Did not login to software. Did not participate|3
6350756|NCT03634085|10116969|FG000|Overall Study|Adverse Event|1
6350757|NCT03634085|10116970|FG001|Overall Study|Adverse Event|0
6350758|NCT03634085|10116969|FG000|Overall Study|Withdrawal by Subject|0
6350759|NCT03634085|10116970|FG001|Overall Study|Withdrawal by Subject|2
6350760|NCT03634579|10116996|FG000|Overall Study|study termination|9
6350761|NCT03634800|10117000|FG000|Overall Study|Adverse Event|1
6350762|NCT03634800|10117000|FG000|Overall Study|Disease Progression|4
6350763|NCT03634800|10117000|FG000|Overall Study|Withdrawal by Subject|1
6350764|NCT03635086|10117019|FG000|Overall Study|Withdrawal of consent|0
6350765|NCT03635086|10117020|FG001|Overall Study|Withdrawal of consent|0
6350766|NCT03635086|10117021|FG002|Overall Study|Withdrawal of consent|1
6350767|NCT03635086|10117022|FG003|Overall Study|Withdrawal of consent|0
6350768|NCT03635086|10117023|FG004|Overall Study|Withdrawal of consent|0
6350769|NCT03635086|10117019|FG000|Overall Study|Adverse Event|0
6350770|NCT03635086|10117020|FG001|Overall Study|Adverse Event|1
6350771|NCT03635086|10117021|FG002|Overall Study|Adverse Event|0
6350772|NCT03635086|10117022|FG003|Overall Study|Adverse Event|0
6350773|NCT03635086|10117023|FG004|Overall Study|Adverse Event|0
6350774|NCT03635086|10117019|FG000|Overall Study|Lost to Follow-up|1
6350775|NCT03635086|10117020|FG001|Overall Study|Lost to Follow-up|0
6350776|NCT03635086|10117021|FG002|Overall Study|Lost to Follow-up|0
6350777|NCT03635086|10117022|FG003|Overall Study|Lost to Follow-up|0
6350778|NCT03635086|10117023|FG004|Overall Study|Lost to Follow-up|0
6350779|NCT03635320|10117038|FG000|Overall Study|not implanted the device|1
6350780|NCT03635320|10117039|FG001|Overall Study|not implanted the device|2
6350781|NCT03635320|10117038|FG000|Overall Study|Withdrawal by Subject|11
6350782|NCT03635320|10117039|FG001|Overall Study|Withdrawal by Subject|6
6350783|NCT03635775|10117049|FG000|Overall Study|Did not meet final inclusion criteria based on initial evaluation|0
6350784|NCT03635775|10117050|FG001|Overall Study|Did not meet final inclusion criteria based on initial evaluation|0
6350785|NCT03635775|10117051|FG002|Overall Study|Did not meet final inclusion criteria based on initial evaluation|0
6350786|NCT03635775|10117052|FG003|Overall Study|Did not meet final inclusion criteria based on initial evaluation|1
6350787|NCT03635957|10117062|FG000|Run-In Period|Lost to Follow-up|1
6350788|NCT03635957|10117062|FG000|Pegloticase + IMM Period|Lack of Efficacy|3
6350789|NCT03636893|10117098|FG000|Overall Study|Death|0
6350790|NCT03636893|10117099|FG001|Overall Study|Death|1
6350791|NCT03636893|10117098|FG000|Overall Study|Protocol Violation|0
6350792|NCT03636893|10117099|FG001|Overall Study|Protocol Violation|3
6350793|NCT03636893|10117098|FG000|Overall Study|Withdrawal by Subject|1
6350794|NCT03636893|10117099|FG001|Overall Study|Withdrawal by Subject|2
6350795|NCT03636893|10117098|FG000|Overall Study|Refusal to surgery|4
6350796|NCT03636893|10117099|FG001|Overall Study|Refusal to surgery|3
6350797|NCT03636893|10117098|FG000|Overall Study|Early surgery (for acute bleeding)|3
6350798|NCT03636893|10117099|FG001|Overall Study|Early surgery (for acute bleeding)|0
6350799|NCT03636893|10117098|FG000|Overall Study|Adverse Event|1
6350800|NCT03636893|10117099|FG001|Overall Study|Adverse Event|1
6350801|NCT03638635|10117175|FG000|Initial Hospitalization|Study terminated prematurely|0
6350802|NCT03638635|10117176|FG001|Initial Hospitalization|Study terminated prematurely|1
6350803|NCT03638635|10117175|FG000|Initial Hospitalization|Withdrawal by study personnel|0
6083637|NCT00636363|9692130|FG000|Overall Study|Protocol Violation|0
6350804|NCT03638635|10117176|FG001|Initial Hospitalization|Withdrawal by study personnel|1
6350805|NCT03638635|10117175|FG000|Follow-Up (30 Days After Discharge)|Study terminated prematurely|39
6350806|NCT03638635|10117176|FG001|Follow-Up (30 Days After Discharge)|Study terminated prematurely|22
6350807|NCT03639675|10117190|FG000|Overall Study|Withdrawal by Subject|1
6083638|NCT00636363|9692131|FG001|Overall Study|Protocol Violation|3
6350808|NCT03639779|10117200|FG000|Overall Study|Lost to Follow-up|1
6350809|NCT03639987|10117218|FG000|Overall Study|Study terminated by sponsor|26
6350810|NCT03639987|10117219|FG001|Overall Study|Study terminated by sponsor|25
6350811|NCT03639987|10117218|FG000|Overall Study|Lost to Follow-up|0
6350812|NCT03639987|10117219|FG001|Overall Study|Lost to Follow-up|1
6350813|NCT03640052|10117225|FG000|Overall Study|Lost to Follow-up|0
6350814|NCT03640052|10117226|FG001|Overall Study|Lost to Follow-up|1
6350815|NCT03640052|10117227|FG002|Overall Study|Lost to Follow-up|0
6350816|NCT03640052|10117228|FG003|Overall Study|Lost to Follow-up|0
6350817|NCT03640052|10117229|FG004|Overall Study|Lost to Follow-up|0
6170220|NCT01251653|9816357|FG004|Overall Study|Withdrawal by Subject|1
6350818|NCT03640507|10117244|FG000|Overall Study|Withdrawal by Subject|0
6350819|NCT03640507|10117245|FG001|Overall Study|Withdrawal by Subject|0
6350820|NCT03640507|10117246|FG002|Overall Study|Withdrawal by Subject|1
6350821|NCT03640559|10117256|FG000|Overall Study|Physician Decision|1
6350822|NCT03640559|10117257|FG001|Overall Study|Physician Decision|1
6350823|NCT03640559|10117256|FG000|Overall Study|Withdrawal by Subject|1
6350824|NCT03640559|10117257|FG001|Overall Study|Withdrawal by Subject|0
6350825|NCT03641508|10117274|FG000|First Injection|Lost to Follow-up|2
6350826|NCT03641508|10117275|FG001|First Injection|Lost to Follow-up|0
6350827|NCT03642262|10117285|FG000|Period 1|Withdrawal by Subject|1
6350828|NCT03642262|10117286|FG001|Period 1|Withdrawal by Subject|1
6350829|NCT03642262|10117285|FG000|Period 1|Adverse Event|0
6350830|NCT03642262|10117286|FG001|Period 1|Adverse Event|1
6350831|NCT03642717|10117302|FG000|Overall Study|Lost to Follow-up|2
6350832|NCT03642717|10117302|FG000|Overall Study|Inclusion/exclusion criteria violation|33
6350833|NCT03642717|10117302|FG000|Overall Study|Taken study drug prior to contract date|3
6350834|NCT03642873|10117307|FG000|Third Intervention (1 Day)|Screen failure|0
6350835|NCT03642873|10117308|FG001|Third Intervention (1 Day)|Screen failure|0
6350836|NCT03642873|10117309|FG002|Third Intervention (1 Day)|Screen failure|0
6350837|NCT03642873|10117310|FG003|Third Intervention (1 Day)|Screen failure|0
6350838|NCT03642873|10117311|FG004|Third Intervention (1 Day)|Screen failure|1
6350839|NCT03642873|10117312|FG005|Third Intervention (1 Day)|Screen failure|0
6350840|NCT03643432|10117326|FG000|Overall Study|Lost to Follow-up|1
6350841|NCT03643432|10117327|FG001|Overall Study|Lost to Follow-up|0
6350842|NCT03643575|10117333|FG000|Washout: 7 Days|Withdrew consent due to illness|0
6350843|NCT03643575|10117334|FG001|Washout: 7 Days|Withdrew consent due to illness|0
6350844|NCT03643575|10117335|FG002|Washout: 7 Days|Withdrew consent due to illness|0
6350845|NCT03643575|10117336|FG003|Washout: 7 Days|Withdrew consent due to illness|1
6350846|NCT03643575|10117337|FG004|Washout: 7 Days|Withdrew consent due to illness|0
6350847|NCT03643575|10117338|FG005|Washout: 7 Days|Withdrew consent due to illness|0
6350848|NCT03643575|10117333|FG000|Washout: 7 Days|Adverse Event|1
6350849|NCT03643575|10117334|FG001|Washout: 7 Days|Adverse Event|0
6350850|NCT03643575|10117335|FG002|Washout: 7 Days|Adverse Event|0
6350851|NCT03643575|10117336|FG003|Washout: 7 Days|Adverse Event|0
6350852|NCT03643575|10117337|FG004|Washout: 7 Days|Adverse Event|0
6350853|NCT03643575|10117338|FG005|Washout: 7 Days|Adverse Event|0
6350854|NCT03643575|10117333|FG000|Washout: 7 Days|Non compliance check in|0
6350855|NCT03643575|10117334|FG001|Washout: 7 Days|Non compliance check in|1
6350856|NCT03643575|10117335|FG002|Washout: 7 Days|Non compliance check in|0
6350857|NCT03643575|10117336|FG003|Washout: 7 Days|Non compliance check in|0
6350858|NCT03643575|10117337|FG004|Washout: 7 Days|Non compliance check in|0
6350859|NCT03643575|10117338|FG005|Washout: 7 Days|Non compliance check in|0
6350860|NCT03643952|10117350|FG000|Overall Study|Lack of Efficacy|1
6350861|NCT03644173|10117373|FG000|Participants at Last Visit (Pre-surveys)|Lost to Follow-up|21
6350862|NCT03644173|10117373|FG000|Participants at the 1-month Follow up|Lost to Follow-up|2
6350863|NCT03644173|10117373|FG000|Participants at the 1-month Follow up|Death|2
6350864|NCT03644173|10117373|FG000|Participants at the 3-month Follow up|Lost to Follow-up|2
6350865|NCT03645421|10117391|FG000|Overall Study|Adverse Event|0
6350866|NCT03645421|10117392|FG001|Overall Study|Adverse Event|0
6350867|NCT03645421|10117393|FG002|Overall Study|Adverse Event|4
6350868|NCT03645421|10117394|FG003|Overall Study|Adverse Event|1
6350869|NCT03645421|10117391|FG000|Overall Study|Withdrawal by patient|0
6350870|NCT03645421|10117392|FG001|Overall Study|Withdrawal by patient|0
6350871|NCT03645421|10117393|FG002|Overall Study|Withdrawal by patient|0
6350872|NCT03645421|10117394|FG003|Overall Study|Withdrawal by patient|3
6350873|NCT03645421|10117391|FG000|Overall Study|Study specific withdrawal criteria|0
6350874|NCT03645421|10117392|FG001|Overall Study|Study specific withdrawal criteria|0
6350875|NCT03645421|10117393|FG002|Overall Study|Study specific withdrawal criteria|1
6350876|NCT03645421|10117394|FG003|Overall Study|Study specific withdrawal criteria|0
6350877|NCT03645434|10117407|FG000|Period 1|Adverse Event|0
6350878|NCT03645434|10117408|FG001|Period 1|Adverse Event|0
6350879|NCT03645434|10117409|FG002|Period 1|Adverse Event|0
6083639|NCT00636363|9692132|FG002|Overall Study|Protocol Violation|0
6083640|NCT00636363|9692130|FG000|Overall Study|Lost to Follow-up|3
6083641|NCT00636363|9692131|FG001|Overall Study|Lost to Follow-up|4
6083642|NCT00636363|9692132|FG002|Overall Study|Lost to Follow-up|2
6350880|NCT03645434|10117410|FG003|Period 1|Adverse Event|1
6350881|NCT03645434|10117411|FG004|Period 1|Adverse Event|0
6350882|NCT03645434|10117412|FG005|Period 1|Adverse Event|0
6350883|NCT03645434|10117407|FG000|Period 1|COPD exacerbation|0
6350884|NCT03645434|10117408|FG001|Period 1|COPD exacerbation|0
6350885|NCT03645434|10117409|FG002|Period 1|COPD exacerbation|0
6350886|NCT03645434|10117410|FG003|Period 1|COPD exacerbation|0
6350887|NCT03645434|10117411|FG004|Period 1|COPD exacerbation|1
6350888|NCT03645434|10117412|FG005|Period 1|COPD exacerbation|0
6350889|NCT03646305|10117462|FG000|Overall Study|Lost to Follow-up|4
6350890|NCT03646305|10117463|FG001|Overall Study|Lost to Follow-up|2
6350891|NCT03646305|10117464|FG002|Overall Study|Lost to Follow-up|2
6350892|NCT03646305|10117465|FG003|Overall Study|Lost to Follow-up|1
6350893|NCT03646305|10117462|FG000|Overall Study|Withdrawal by Subject|1
6350894|NCT03646305|10117463|FG001|Overall Study|Withdrawal by Subject|0
6350895|NCT03646305|10117464|FG002|Overall Study|Withdrawal by Subject|0
6350896|NCT03646305|10117465|FG003|Overall Study|Withdrawal by Subject|1
6350897|NCT03646656|10117481|FG000|Overall Study|Lost to Follow-up|1
6350898|NCT03646656|10117482|FG001|Overall Study|Lost to Follow-up|0
6350899|NCT03646656|10117481|FG000|Overall Study|Withdrawal by Subject|2
6350900|NCT03646656|10117482|FG001|Overall Study|Withdrawal by Subject|0
6350901|NCT03647267|10117507|FG000|Overall Study|Lost to Follow-up|1
6350902|NCT03647267|10117508|FG001|Overall Study|Lost to Follow-up|0
6350903|NCT03647709|10117520|FG000|Overall Study|Lost to Follow-up|5
6350904|NCT03647709|10117520|FG000|Overall Study|Physician Decision|6
6350905|NCT03647709|10117520|FG000|Overall Study|Withdrawal by Subject|3
6350906|NCT03648879|10117530|FG000|Overall Study|Subject determined to have Cadherin-1 (CDH1) variant of uncertain significance.|1
6350907|NCT03649412|10117536|FG000|Part A, Washout Period 1 (7 Days)|Physician Decision|1
6350908|NCT03649412|10117537|FG001|Part A, Washout Period 1 (7 Days)|Physician Decision|0
6350909|NCT03649412|10117536|FG000|Part A, Washout Period 4 (7 Days)|Adverse Event|1
6350910|NCT03649412|10117537|FG001|Part A, Washout Period 4 (7 Days)|Adverse Event|0
6350911|NCT03649412|10117536|FG000|Part A, Washout Period 4 (7 Days)|Withdrawal by Subject|1
6350912|NCT03649412|10117537|FG001|Part A, Washout Period 4 (7 Days)|Withdrawal by Subject|0
6350913|NCT03649412|10117536|FG000|Part A, Washout Period 5 (7 Days)|Adverse Event|1
6350914|NCT03649412|10117537|FG001|Part A, Washout Period 5 (7 Days)|Adverse Event|0
6350915|NCT03649412|10117536|FG000|Part B, Washout Period 1 (7 Days)|Adverse Event|0
6350916|NCT03649412|10117537|FG001|Part B, Washout Period 1 (7 Days)|Adverse Event|1
6350917|NCT03649412|10117536|FG000|Part B, Washout Period 5 (7 Days)|Adverse Event|0
6350918|NCT03649412|10117537|FG001|Part B, Washout Period 5 (7 Days)|Adverse Event|1
6350919|NCT03649477|10117583|FG000|Overall Study|Adverse Event|2
6350920|NCT03649477|10117584|FG001|Overall Study|Adverse Event|0
6350921|NCT03649477|10117585|FG002|Overall Study|Adverse Event|0
6350922|NCT03650387|10117630|FG000|Overall Study|Withdrawal by Subject|13
6350923|NCT03650387|10117630|FG000|Overall Study|Lost to Follow-up|12
6350924|NCT03650387|10117630|FG000|Overall Study|Adverse Event (Not related)|1
6350925|NCT03650387|10117630|FG000|Overall Study|Due to COVID-19 Pandemic|8
6350926|NCT03650400|10117645|FG000|Overall Study|Study terminated by sponsor|0
6350927|NCT03650400|10117646|FG001|Overall Study|Study terminated by sponsor|5
6350928|NCT03650452|10117654|FG000|Overall Study|Physician Decision|1
6350929|NCT03650452|10117655|FG001|Overall Study|Physician Decision|0
6350930|NCT03650452|10117654|FG000|Overall Study|Withdrawal by Parent/Guardian|3
6350931|NCT03650452|10117655|FG001|Overall Study|Withdrawal by Parent/Guardian|1
6350932|NCT03650452|10117654|FG000|Overall Study|Adverse Event|3
6350933|NCT03650452|10117655|FG001|Overall Study|Adverse Event|4
6350934|NCT03650452|10117654|FG000|Overall Study|Early Withdrawal from Study Treatment|3
6350935|NCT03650452|10117655|FG001|Overall Study|Early Withdrawal from Study Treatment|0
6350936|NCT03652610|10117680|FG000|Overall Study|Lost to Follow-up|1
6350937|NCT03652610|10117681|FG001|Overall Study|Lost to Follow-up|0
6350938|NCT03652610|10117680|FG000|Overall Study|Withdrawal by Subject|3
6350939|NCT03652610|10117681|FG001|Overall Study|Withdrawal by Subject|5
6350940|NCT03652662|10117689|FG000|Overall Study|Withdrawal by Subject|2
6350941|NCT03652662|10117690|FG001|Overall Study|Withdrawal by Subject|1
6350942|NCT03652662|10117689|FG000|Overall Study|Lost to Follow-up|1
6350943|NCT03652662|10117690|FG001|Overall Study|Lost to Follow-up|0
6350944|NCT03652675|10117698|FG000|Overall Study|Lost to Follow-up|4
6350945|NCT03652675|10117699|FG001|Overall Study|Lost to Follow-up|4
6350946|NCT03652818|10117710|FG000|Overall Study|Adverse Event|1
6350947|NCT03652818|10117711|FG001|Overall Study|Adverse Event|0
6350948|NCT03652818|10117712|FG002|Overall Study|Adverse Event|0
6350949|NCT03652818|10117713|FG003|Overall Study|Adverse Event|0
6350950|NCT03652818|10117714|FG004|Overall Study|Adverse Event|0
6350951|NCT03652818|10117710|FG000|Overall Study|Physician Decision|1
6350952|NCT03652818|10117711|FG001|Overall Study|Physician Decision|0
6350953|NCT03652818|10117712|FG002|Overall Study|Physician Decision|0
6350954|NCT03652818|10117713|FG003|Overall Study|Physician Decision|0
6350955|NCT03652818|10117714|FG004|Overall Study|Physician Decision|0
6350956|NCT03652818|10117710|FG000|Overall Study|Lost to Follow-up|0
6350957|NCT03652818|10117711|FG001|Overall Study|Lost to Follow-up|1
6350958|NCT03652818|10117712|FG002|Overall Study|Lost to Follow-up|2
6350959|NCT03652818|10117713|FG003|Overall Study|Lost to Follow-up|1
6350960|NCT03652818|10117714|FG004|Overall Study|Lost to Follow-up|1
6350961|NCT03653208|10117735|FG000|Overall Study|Withdrawal by Subject|0
6350962|NCT03653208|10117736|FG001|Overall Study|Withdrawal by Subject|0
6350963|NCT03653208|10117737|FG002|Overall Study|Withdrawal by Subject|0
6350964|NCT03653208|10117738|FG003|Overall Study|Withdrawal by Subject|0
6350965|NCT03653208|10117739|FG004|Overall Study|Withdrawal by Subject|1
6350966|NCT03653208|10117740|FG005|Overall Study|Withdrawal by Subject|0
6350967|NCT03653208|10117741|FG006|Overall Study|Withdrawal by Subject|0
6350968|NCT03653208|10117742|FG007|Overall Study|Withdrawal by Subject|1
6350969|NCT03653208|10117743|FG008|Overall Study|Withdrawal by Subject|1
6350970|NCT03653416|10117774|FG000|Overall Study|Protocol Violation|6
6350971|NCT03653416|10117775|FG001|Overall Study|Protocol Violation|1
6350972|NCT03653429|10117783|FG000|Overall Study|Physician Decision|4
6350973|NCT03653429|10117784|FG001|Overall Study|Physician Decision|10
6350974|NCT03654326|10117792|FG000|Overall Study|Withdrawal by Subject|5
6350975|NCT03654326|10117793|FG001|Overall Study|Withdrawal by Subject|3
6350976|NCT03654326|10117792|FG000|Overall Study|Physician Decision|0
6350977|NCT03654326|10117793|FG001|Overall Study|Physician Decision|1
6350978|NCT03654326|10117792|FG000|Overall Study|Unable to adhere to study schedule|0
6350979|NCT03654326|10117793|FG001|Overall Study|Unable to adhere to study schedule|1
6350980|NCT03654326|10117792|FG000|Overall Study|Lost to Follow-up|1
6350981|NCT03654326|10117793|FG001|Overall Study|Lost to Follow-up|1
6350982|NCT03654560|10117810|FG000|Overall Study|Death|3
6350983|NCT03654560|10117811|FG001|Overall Study|Death|1
6350984|NCT03654560|10117810|FG000|Overall Study|Lost to Follow-up|1
6350985|NCT03654560|10117811|FG001|Overall Study|Lost to Follow-up|0
6350986|NCT03655106|10117823|FG000|Overall Study|Withdrawal by Subject|3
6350987|NCT03655106|10117824|FG001|Overall Study|Withdrawal by Subject|2
6350988|NCT03655106|10117823|FG000|Overall Study|Lost to Follow-up|2
6350989|NCT03655106|10117824|FG001|Overall Study|Lost to Follow-up|1
6350990|NCT03655106|10117823|FG000|Overall Study|Duplicate Enrollment|1
6350991|NCT03655106|10117824|FG001|Overall Study|Duplicate Enrollment|1
6350992|NCT03655106|10117823|FG000|Overall Study|Protocol Violation|3
6350993|NCT03655106|10117824|FG001|Overall Study|Protocol Violation|0
6350994|NCT03655405|10117836|FG000|Overall Study|Death after initial data collection|4
6350995|NCT03655405|10117837|FG001|Overall Study|Death after initial data collection|2
6350996|NCT03655405|10117836|FG000|Overall Study|Died before initial data collection|1
6350997|NCT03655405|10117837|FG001|Overall Study|Died before initial data collection|2
6350998|NCT03655405|10117836|FG000|Overall Study|Protocol Violation|0
6350999|NCT03655405|10117837|FG001|Overall Study|Protocol Violation|1
6351000|NCT03655951|10117854|FG000|Overall Study|Lost to Follow-up|39
6351001|NCT03655951|10117855|FG001|Overall Study|Lost to Follow-up|20
6351002|NCT03655951|10117854|FG000|Overall Study|Withdrawal by Subject|0
6351003|NCT03655951|10117855|FG001|Overall Study|Withdrawal by Subject|1
6351004|NCT03657095|10117869|FG000|Overall Study|Withdrawal by Subject|1
6351005|NCT03657095|10117870|FG001|Overall Study|Withdrawal by Subject|1
6351006|NCT03657095|10117869|FG000|Overall Study|Adverse Event|0
6351007|NCT03657095|10117870|FG001|Overall Study|Adverse Event|3
6351008|NCT03657095|10117869|FG000|Overall Study|Study Terminated by Sponsor|58
6351009|NCT03657095|10117870|FG001|Overall Study|Study Terminated by Sponsor|49
6351010|NCT03657277|10117899|FG000|Overall Study|Physician Decision|2
6351011|NCT03657277|10117899|FG000|Overall Study|Lost to Follow-up|1
6351012|NCT03657277|10117899|FG000|Overall Study|Covid-19 Research Halt at University of Iowa-Withdrawal of subjects|8
6351013|NCT03658811|10117912|FG000|Overall Study|Lost to Follow-up|3
6351014|NCT03658876|10117918|FG000|Overall Study|Protocol Violation|3
6351015|NCT03658876|10117919|FG001|Overall Study|Protocol Violation|2
6351016|NCT03658876|10117918|FG000|Overall Study|Withdrawal by Subject|2
6351017|NCT03658876|10117919|FG001|Overall Study|Withdrawal by Subject|0
6351018|NCT03658876|10117918|FG000|Overall Study|Death|0
6351019|NCT03658876|10117919|FG001|Overall Study|Death|1
6351020|NCT03658876|10117918|FG000|Overall Study|Intercurrent illness|6
6351021|NCT03658876|10117919|FG001|Overall Study|Intercurrent illness|4
6351022|NCT03658876|10117918|FG000|Overall Study|Transplantation/other operation|1
6351023|NCT03658876|10117919|FG001|Overall Study|Transplantation/other operation|5
6351024|NCT03658889|10117927|FG000|Overall Study|Protocol Violation|2
6351025|NCT03658889|10117928|FG001|Overall Study|Protocol Violation|0
6351026|NCT03661983|10117999|FG000|Open Label Stabilization Phase|Adverse Event|5
6351027|NCT03661983|10118000|FG001|Open Label Stabilization Phase|Adverse Event|0
6351028|NCT03661983|10118001|FG002|Open Label Stabilization Phase|Adverse Event|0
6351029|NCT03661983|10118002|FG003|Open Label Stabilization Phase|Adverse Event|0
6351030|NCT03661983|10117999|FG000|Open Label Stabilization Phase|Lack of Efficacy|1
6351031|NCT03661983|10118000|FG001|Open Label Stabilization Phase|Lack of Efficacy|0
6351032|NCT03661983|10118001|FG002|Open Label Stabilization Phase|Lack of Efficacy|0
6351033|NCT03661983|10118002|FG003|Open Label Stabilization Phase|Lack of Efficacy|0
6351034|NCT03661983|10117999|FG000|Open Label Stabilization Phase|Withdrawal by Parent/Guardian|2
6351035|NCT03661983|10118000|FG001|Open Label Stabilization Phase|Withdrawal by Parent/Guardian|0
6351036|NCT03661983|10118001|FG002|Open Label Stabilization Phase|Withdrawal by Parent/Guardian|0
6351037|NCT03661983|10118002|FG003|Open Label Stabilization Phase|Withdrawal by Parent/Guardian|0
6351038|NCT03661983|10117999|FG000|Open Label Stabilization Phase|Study Terminated by Sponsor|3
6351039|NCT03661983|10118000|FG001|Open Label Stabilization Phase|Study Terminated by Sponsor|0
6351040|NCT03661983|10118001|FG002|Open Label Stabilization Phase|Study Terminated by Sponsor|0
6351041|NCT03661983|10118002|FG003|Open Label Stabilization Phase|Study Terminated by Sponsor|0
6351042|NCT03661983|10117999|FG000|Double-blind Randomized Phase|Adverse Event|0
6351043|NCT03661983|10118000|FG001|Double-blind Randomized Phase|Adverse Event|1
6351044|NCT03661983|10118001|FG002|Double-blind Randomized Phase|Adverse Event|0
6351045|NCT03661983|10118002|FG003|Double-blind Randomized Phase|Adverse Event|0
6351046|NCT03661983|10117999|FG000|Double-blind Randomized Phase|Disease Relapse|0
6351047|NCT03661983|10118000|FG001|Double-blind Randomized Phase|Disease Relapse|0
6351048|NCT03661983|10118001|FG002|Double-blind Randomized Phase|Disease Relapse|0
6351049|NCT03661983|10118002|FG003|Double-blind Randomized Phase|Disease Relapse|6
6351050|NCT03661983|10117999|FG000|Double-blind Randomized Phase|Withdrawal by Parent/Guardian|0
6351051|NCT03661983|10118000|FG001|Double-blind Randomized Phase|Withdrawal by Parent/Guardian|0
6351052|NCT03661983|10118001|FG002|Double-blind Randomized Phase|Withdrawal by Parent/Guardian|0
6351053|NCT03661983|10118002|FG003|Double-blind Randomized Phase|Withdrawal by Parent/Guardian|1
6351054|NCT03661983|10117999|FG000|Double-blind Randomized Phase|Study Terminated by Sponsor|0
6351055|NCT03661983|10118000|FG001|Double-blind Randomized Phase|Study Terminated by Sponsor|1
6351056|NCT03661983|10118001|FG002|Double-blind Randomized Phase|Study Terminated by Sponsor|1
6351057|NCT03661983|10118002|FG003|Double-blind Randomized Phase|Study Terminated by Sponsor|1
6351058|NCT03662334|10118032|FG000|Part 2: Treatment Period 2 (2 Days)|Intended Changes to Clamp Procedure|1
6351059|NCT03662334|10118033|FG001|Part 2: Treatment Period 2 (2 Days)|Intended Changes to Clamp Procedure|0
6351060|NCT03662750|10118049|FG000|Overall Study|Withdrawal by Subject|1
6351061|NCT03662789|10118055|FG000|Overall Study|Lost to Follow-up|1
6351062|NCT03662789|10118056|FG001|Overall Study|Lost to Follow-up|2
6351063|NCT03662789|10118055|FG000|Overall Study|Could not perform treadmill test|4
6351064|NCT03662789|10118056|FG001|Overall Study|Could not perform treadmill test|4
6351065|NCT03662789|10118055|FG000|Overall Study|Death|0
6351066|NCT03662789|10118056|FG001|Overall Study|Death|1
6351067|NCT03662997|10118066|FG000|Overall Study|Adverse Event|0
6351068|NCT03662997|10118067|FG001|Overall Study|Adverse Event|2
6351069|NCT03662997|10118068|FG002|Overall Study|Adverse Event|0
6351070|NCT03662997|10118069|FG003|Overall Study|Adverse Event|0
6351071|NCT03663179|10118100|FG000|Overall Study|Withdrawal by Subject|2
6351072|NCT03663179|10118101|FG001|Overall Study|Withdrawal by Subject|0
6351073|NCT03663179|10118100|FG000|Overall Study|Lost to Follow-up|1
6351074|NCT03663179|10118101|FG001|Overall Study|Lost to Follow-up|1
6351075|NCT03663179|10118100|FG000|Overall Study|Revealed exclusionary condition|1
6351076|NCT03663179|10118101|FG001|Overall Study|Revealed exclusionary condition|0
6351077|NCT03663569|10118125|FG000|Overall Study|Discontinuation of study|11
6351078|NCT03663569|10118125|FG000|Overall Study|Never taken Spiolto® Respimat®|1
6351079|NCT03663569|10118125|FG000|Overall Study|Deceased patient|6
6351080|NCT03663569|10118125|FG000|Overall Study|Lost to Follow-up|18
6351081|NCT03663569|10118125|FG000|Overall Study|Withdrawal of consent|5
6351082|NCT03663569|10118125|FG000|Overall Study|Patient's request|11
6351083|NCT03663569|10118125|FG000|Overall Study|Adverse Event|4
6351084|NCT03663569|10118125|FG000|Overall Study|Not come to second visit|3
6351085|NCT03663569|10118125|FG000|Overall Study|Not meet inclusion / exclusion criterion|3
6351086|NCT03663569|10118125|FG000|Overall Study|Serious adverse event|1
6351087|NCT03663582|10118129|FG000|Overall Study|Physician Decision|1
6351088|NCT03666858|10118195|FG000|Cohort 1|Adverse Event|1
6351089|NCT03666858|10118196|FG001|Cohort 1|Adverse Event|0
6351090|NCT03666858|10118195|FG000|Cohort 2|Adverse Event|0
6351091|NCT03666858|10118196|FG001|Cohort 2|Adverse Event|1
6351092|NCT03667053|10118205|FG000|Overall Study|Withdrawal by Subject|1
6351093|NCT03667053|10118206|FG001|Overall Study|Withdrawal by Subject|0
6351094|NCT03667053|10118207|FG002|Overall Study|Withdrawal by Subject|0
6351095|NCT03668600|10118226|FG000|Overall Study|Study Terminated by the Sponsor|157
6351096|NCT03668600|10118226|FG000|Overall Study|Protocol Violation|1
6351097|NCT03668600|10118226|FG000|Overall Study|Pregnancy|1
6351098|NCT03668600|10118226|FG000|Overall Study|Lost to Follow-up|7
6351099|NCT03668600|10118226|FG000|Overall Study|Withdrawal by Subject|56
6351100|NCT03668600|10118226|FG000|Overall Study|Lack of Efficacy|7
6351101|NCT03668600|10118226|FG000|Overall Study|Adverse Event|1
6351102|NCT03668613|10118232|FG000|Overall Study|Adverse Event|0
6351103|NCT03668613|10118233|FG001|Overall Study|Adverse Event|2
6351104|NCT03668613|10118232|FG000|Overall Study|Lack of Efficacy|0
6351105|NCT03668613|10118233|FG001|Overall Study|Lack of Efficacy|1
6351106|NCT03669081|10118242|FG000|Overall Study|Data could not be validated|1
6351107|NCT03669081|10118243|FG001|Overall Study|Data could not be validated|1
6351108|NCT03669549|10118267|FG000|Overall Study|Adverse Event|4
6351109|NCT03669549|10118267|FG000|Overall Study|Withdrawal by Subject|1
6351110|NCT03669549|10118267|FG000|Overall Study|Study terminated by the Sponsor|1
6351111|NCT03669861|10118275|FG000|Overall Study|Disease Flare|5
6351112|NCT03669861|10118275|FG000|Overall Study|Lack of Efficacy|2
6083643|NCT00636363|9692130|FG000|Overall Study|Withdrawal by Subject|1
6083644|NCT00636363|9692131|FG001|Overall Study|Withdrawal by Subject|3
6083645|NCT00636363|9692132|FG002|Overall Study|Withdrawal by Subject|2
6083646|NCT00636441|9692154|FG000|Overall Study|Adverse Event|0
6083647|NCT00636441|9692155|FG001|Overall Study|Adverse Event|1
6083648|NCT00636441|9692156|FG002|Overall Study|Adverse Event|1
6083649|NCT00636441|9692157|FG003|Overall Study|Adverse Event|0
6083650|NCT00636441|9692158|FG004|Overall Study|Adverse Event|0
6083651|NCT00636441|9692159|FG005|Overall Study|Adverse Event|1
6083652|NCT00636441|9692160|FG006|Overall Study|Adverse Event|0
6083653|NCT00636441|9692154|FG000|Overall Study|Late, ineligible|0
6083654|NCT00636441|9692155|FG001|Overall Study|Late, ineligible|0
6083655|NCT00636441|9692156|FG002|Overall Study|Late, ineligible|0
6351113|NCT03670537|10118309|FG000|Overall Study|Protocol Violation|1
6351114|NCT03670641|10118313|FG000|Overall Study|Lost to Follow-up|3
6351115|NCT03670810|10118323|FG000|Overall Study|Adverse Event|36
6351116|NCT03670810|10118324|FG001|Overall Study|Adverse Event|38
6351117|NCT03670810|10118325|FG002|Overall Study|Adverse Event|2
6351118|NCT03670810|10118326|FG003|Overall Study|Adverse Event|4
6351119|NCT03670810|10118323|FG000|Overall Study|Lack of Efficacy|8
6351120|NCT03670810|10118324|FG001|Overall Study|Lack of Efficacy|8
6351121|NCT03670810|10118325|FG002|Overall Study|Lack of Efficacy|3
6351122|NCT03670810|10118326|FG003|Overall Study|Lack of Efficacy|4
6351123|NCT03670810|10118323|FG000|Overall Study|Lost to Follow-up|6
6351124|NCT03670810|10118324|FG001|Overall Study|Lost to Follow-up|6
6351125|NCT03670810|10118325|FG002|Overall Study|Lost to Follow-up|4
6351126|NCT03670810|10118326|FG003|Overall Study|Lost to Follow-up|6
6351127|NCT03670810|10118323|FG000|Overall Study|Non-compliance with Study Drug|0
6351128|NCT03670810|10118324|FG001|Overall Study|Non-compliance with Study Drug|2
6351129|NCT03670810|10118325|FG002|Overall Study|Non-compliance with Study Drug|3
6351130|NCT03670810|10118326|FG003|Overall Study|Non-compliance with Study Drug|0
6351131|NCT03670810|10118323|FG000|Overall Study|Missing|1
6351132|NCT03670810|10118324|FG001|Overall Study|Missing|1
6351133|NCT03670810|10118325|FG002|Overall Study|Missing|0
6351134|NCT03670810|10118326|FG003|Overall Study|Missing|1
6351135|NCT03670810|10118323|FG000|Overall Study|Physician Decision|3
6351136|NCT03670810|10118324|FG001|Overall Study|Physician Decision|0
6351137|NCT03670810|10118325|FG002|Overall Study|Physician Decision|1
6351138|NCT03670810|10118326|FG003|Overall Study|Physician Decision|0
6351139|NCT03670810|10118323|FG000|Overall Study|Pregnancy|1
6351140|NCT03670810|10118324|FG001|Overall Study|Pregnancy|1
6351141|NCT03670810|10118325|FG002|Overall Study|Pregnancy|0
6351142|NCT03670810|10118326|FG003|Overall Study|Pregnancy|0
6351143|NCT03670810|10118323|FG000|Overall Study|Protocol Violation|2
6351144|NCT03670810|10118324|FG001|Overall Study|Protocol Violation|12
6351145|NCT03670810|10118325|FG002|Overall Study|Protocol Violation|8
6351146|NCT03670810|10118326|FG003|Overall Study|Protocol Violation|4
6351147|NCT03670810|10118323|FG000|Overall Study|Withdrawal by Subject|20
6351148|NCT03670810|10118324|FG001|Overall Study|Withdrawal by Subject|20
6351149|NCT03670810|10118325|FG002|Overall Study|Withdrawal by Subject|8
6351150|NCT03670810|10118326|FG003|Overall Study|Withdrawal by Subject|9
6351151|NCT03670810|10118323|FG000|Overall Study|Continuing Study|27
6351152|NCT03670810|10118324|FG001|Overall Study|Continuing Study|29
6351153|NCT03670810|10118325|FG002|Overall Study|Continuing Study|12
6351154|NCT03670810|10118326|FG003|Overall Study|Continuing Study|10
6351155|NCT03672006|10118338|FG000|Overall Study|exclusion criteria met|0
6351156|NCT03672006|10118339|FG001|Overall Study|exclusion criteria met|1
6351157|NCT03672097|10118356|FG000|Period 1|Withdrawal by Subject|2
6351158|NCT03672097|10118356|FG000|Period 1|Adverse Event|1
6351159|NCT03672097|10118356|FG000|Period 1|Did not receive treatment|1
6351160|NCT03672097|10118356|FG000|Period 2|Withdrawal by Subject|3
6351161|NCT03672097|10118356|FG000|Period 2|Other|1
6351162|NCT03672396|10118364|FG000|Overall Study|Withdrawal by Subject|4
6351163|NCT03672396|10118364|FG000|Overall Study|Physician Decision|1
6351164|NCT03672396|10118364|FG000|Overall Study|Adverse Event|1
6351165|NCT03673670|10118374|FG000|Treatment Period 1 (3 Days)|Withdrawal by Subject|1
6351166|NCT03673670|10118375|FG001|Treatment Period 1 (3 Days)|Withdrawal by Subject|0
6351167|NCT03673670|10118376|FG002|Treatment Period 1 (3 Days)|Withdrawal by Subject|0
6351168|NCT03673670|10118377|FG003|Treatment Period 1 (3 Days)|Withdrawal by Subject|0
6351169|NCT03673670|10118378|FG004|Treatment Period 1 (3 Days)|Withdrawal by Subject|0
6351170|NCT03673670|10118379|FG005|Treatment Period 1 (3 Days)|Withdrawal by Subject|0
6351171|NCT03673670|10118374|FG000|Treatment Period 1 (3 Days)|Physician Decision|0
6351172|NCT03673670|10118375|FG001|Treatment Period 1 (3 Days)|Physician Decision|0
6351173|NCT03673670|10118376|FG002|Treatment Period 1 (3 Days)|Physician Decision|1
6351174|NCT03673670|10118377|FG003|Treatment Period 1 (3 Days)|Physician Decision|0
6351175|NCT03673670|10118378|FG004|Treatment Period 1 (3 Days)|Physician Decision|0
6351176|NCT03673670|10118379|FG005|Treatment Period 1 (3 Days)|Physician Decision|0
6351177|NCT03673670|10118374|FG000|Treatment Period 1 (3 Days)|Adverse Event|0
6351178|NCT03673670|10118375|FG001|Treatment Period 1 (3 Days)|Adverse Event|0
6351179|NCT03673670|10118376|FG002|Treatment Period 1 (3 Days)|Adverse Event|0
6351180|NCT03673670|10118377|FG003|Treatment Period 1 (3 Days)|Adverse Event|0
6351181|NCT03673670|10118378|FG004|Treatment Period 1 (3 Days)|Adverse Event|0
6351182|NCT03673670|10118379|FG005|Treatment Period 1 (3 Days)|Adverse Event|1
6351183|NCT03673670|10118374|FG000|Treatment Period 1 (3 Days)|Alpha 1 antitrypsin deficiency|0
6351184|NCT03673670|10118375|FG001|Treatment Period 1 (3 Days)|Alpha 1 antitrypsin deficiency|0
6351185|NCT03673670|10118376|FG002|Treatment Period 1 (3 Days)|Alpha 1 antitrypsin deficiency|0
6351186|NCT03673670|10118377|FG003|Treatment Period 1 (3 Days)|Alpha 1 antitrypsin deficiency|0
6351187|NCT03673670|10118378|FG004|Treatment Period 1 (3 Days)|Alpha 1 antitrypsin deficiency|0
6351188|NCT03673670|10118379|FG005|Treatment Period 1 (3 Days)|Alpha 1 antitrypsin deficiency|1
6351189|NCT03673670|10118374|FG000|Treatment Period 2 (3 Days)|Adverse Event|0
6351190|NCT03673670|10118375|FG001|Treatment Period 2 (3 Days)|Adverse Event|0
6351191|NCT03673670|10118376|FG002|Treatment Period 2 (3 Days)|Adverse Event|1
6351192|NCT03673670|10118377|FG003|Treatment Period 2 (3 Days)|Adverse Event|0
6351193|NCT03673670|10118378|FG004|Treatment Period 2 (3 Days)|Adverse Event|1
6351194|NCT03673670|10118379|FG005|Treatment Period 2 (3 Days)|Adverse Event|0
6351195|NCT03673670|10118374|FG000|Washout Period 2 (7-14 Days)|Pre-dose FEV1 not 20% baseline|0
6351196|NCT03673670|10118375|FG001|Washout Period 2 (7-14 Days)|Pre-dose FEV1 not 20% baseline|0
6351197|NCT03673670|10118376|FG002|Washout Period 2 (7-14 Days)|Pre-dose FEV1 not 20% baseline|0
6351198|NCT03673670|10118377|FG003|Washout Period 2 (7-14 Days)|Pre-dose FEV1 not 20% baseline|0
6351199|NCT03673670|10118378|FG004|Washout Period 2 (7-14 Days)|Pre-dose FEV1 not 20% baseline|1
6351200|NCT03673670|10118379|FG005|Washout Period 2 (7-14 Days)|Pre-dose FEV1 not 20% baseline|0
6351201|NCT03673670|10118374|FG000|Treatment Period 3 (3 Days)|Adverse Event|0
6351202|NCT03673670|10118375|FG001|Treatment Period 3 (3 Days)|Adverse Event|0
6351203|NCT03673670|10118376|FG002|Treatment Period 3 (3 Days)|Adverse Event|0
6351204|NCT03673670|10118377|FG003|Treatment Period 3 (3 Days)|Adverse Event|0
6351205|NCT03673670|10118378|FG004|Treatment Period 3 (3 Days)|Adverse Event|1
6351206|NCT03673670|10118379|FG005|Treatment Period 3 (3 Days)|Adverse Event|0
6351207|NCT03674177|10118400|FG000|Overall Study|Lost to Follow-up|2
6351208|NCT03674177|10118401|FG001|Overall Study|Lost to Follow-up|1
6351209|NCT03674177|10118402|FG002|Overall Study|Lost to Follow-up|0
6351210|NCT03674177|10118403|FG003|Overall Study|Lost to Follow-up|2
6351211|NCT03674281|10118416|FG000|Overall Study|screen failure|2
6351212|NCT03674281|10118417|FG001|Overall Study|screen failure|0
6351213|NCT03674281|10118418|FG002|Overall Study|screen failure|0
6351214|NCT03674281|10118416|FG000|Overall Study|Withdrawal by Subject|1
6351215|NCT03674281|10118417|FG001|Overall Study|Withdrawal by Subject|3
6351216|NCT03674281|10118418|FG002|Overall Study|Withdrawal by Subject|3
6351217|NCT03675776|10118477|FG000|Double Blind Treatment Period|Study Terminated by Sponsor|5
6351218|NCT03675776|10118478|FG001|Double Blind Treatment Period|Study Terminated by Sponsor|6
6351219|NCT03675776|10118479|FG002|Double Blind Treatment Period|Study Terminated by Sponsor|8
6351220|NCT03675776|10118477|FG000|Double Blind Treatment Period|Lack of Efficacy|1
6351221|NCT03675776|10118478|FG001|Double Blind Treatment Period|Lack of Efficacy|0
6351222|NCT03675776|10118479|FG002|Double Blind Treatment Period|Lack of Efficacy|0
6351223|NCT03676634|10118491|FG000|Overall Study|Red blood cell loss|1
6351224|NCT03676634|10118491|FG000|Overall Study|Out-of-limit pulse|2
6351225|NCT03677375|10118543|FG000|Overall Study|Incomplete procedure|8
6351226|NCT03677375|10118543|FG000|Overall Study|Adverse Event|3
6351227|NCT03677375|10118543|FG000|Overall Study|Physician Decision|1
6351228|NCT03677401|10118549|FG000|Overall Study|Adverse Event|4
6351229|NCT03677401|10118550|FG001|Overall Study|Adverse Event|14
6351230|NCT03677401|10118549|FG000|Overall Study|Lack of Efficacy|3
6351231|NCT03677401|10118550|FG001|Overall Study|Lack of Efficacy|1
6351232|NCT03677401|10118549|FG000|Overall Study|Withdrawal by Subject|2
6351233|NCT03677401|10118550|FG001|Overall Study|Withdrawal by Subject|2
6351234|NCT03677401|10118549|FG000|Overall Study|Sponsor decision|0
6351235|NCT03677401|10118550|FG001|Overall Study|Sponsor decision|1
6351236|NCT03677401|10118549|FG000|Overall Study|Reason Unspecified|1
6351237|NCT03677401|10118550|FG001|Overall Study|Reason Unspecified|0
6351238|NCT03677869|10118556|FG000|Overall Study|Withdrawal by Subject|1
6351239|NCT03678103|10118560|FG000|Overall Study|Withdrawn prior to completion|4
6351240|NCT03678285|10118564|FG000|Overall Study|Adverse Event|2
6351241|NCT03678285|10118564|FG000|Overall Study|Withdrawal by subject prior to start of workout|1
6351242|NCT03678285|10118564|FG000|Overall Study|Dehydrated prior to start of workout|1
6351243|NCT03678870|10118574|FG000|Overall Study|prescribed non- protocol medications|10
6351244|NCT03678870|10118575|FG001|Overall Study|prescribed non- protocol medications|6
6351245|NCT03678870|10118574|FG000|Overall Study|Lost to Follow-up|3
6351246|NCT03678870|10118575|FG001|Overall Study|Lost to Follow-up|2
6351247|NCT03679741|10118590|FG000|Period 1|No longer meet eligibility criteria|1
6351248|NCT03679741|10118591|FG001|Period 1|No longer meet eligibility criteria|0
6351249|NCT03679741|10118590|FG000|Period 1|Lost to Follow-up|0
6351250|NCT03679741|10118591|FG001|Period 1|Lost to Follow-up|1
6351251|NCT03679741|10118590|FG000|Period 1|Adverse Event|1
6351252|NCT03679741|10118591|FG001|Period 1|Adverse Event|1
6351253|NCT03679741|10118590|FG000|Period 1|Withdrawal by Subject|0
6351254|NCT03679741|10118591|FG001|Period 1|Withdrawal by Subject|1
6351255|NCT03679741|10118590|FG000|Period 2|Adverse Event|2
6351256|NCT03679741|10118591|FG001|Period 2|Adverse Event|1
6351257|NCT03679741|10118590|FG000|Period 2|Withdrawal by Subject|1
6351258|NCT03679741|10118591|FG001|Period 2|Withdrawal by Subject|1
6351259|NCT03680521|10118644|FG000|Overall Study|Ongoing in long-term follow up|7
6351260|NCT03680521|10118645|FG001|Overall Study|Ongoing in long-term follow up|11
6351261|NCT03680742|10118654|FG000|Overall Study|Unsuccessful Implant Attempt|2
6351262|NCT03681093|10118661|FG000|Overall Study|Subject decision|0
6351263|NCT03681093|10118662|FG001|Overall Study|Subject decision|2
6351264|NCT03681093|10118663|FG002|Overall Study|Subject decision|1
6351265|NCT03681119|10118673|FG000|Overall Study|No specific reason|4
6351266|NCT03681119|10118674|FG001|Overall Study|No specific reason|0
6351267|NCT03681119|10118673|FG000|Overall Study|Sickness|2
6351268|NCT03681119|10118674|FG001|Overall Study|Sickness|0
6351269|NCT03681353|10118678|FG000|Overall Study|Lost to Follow-up|2
6351270|NCT03681353|10118678|FG000|Overall Study|Withdrawal by Subject|3
6351271|NCT03681353|10118678|FG000|Overall Study|withdrawn by PI|2
6351272|NCT03681405|10118684|FG000|Overall Study|Found to be ineligible after randomized|1
6351273|NCT03681405|10118685|FG001|Overall Study|Found to be ineligible after randomized|0
6351274|NCT03681951|10118731|FG000|Part1: Monotherapy DE (Up to Day 95)|Lost to Follow-up|1
6351275|NCT03681951|10118732|FG001|Part1: Monotherapy DE (Up to Day 95)|Lost to Follow-up|0
6351276|NCT03681951|10118733|FG002|Part1: Monotherapy DE (Up to Day 95)|Lost to Follow-up|0
6351277|NCT03681951|10118734|FG003|Part1: Monotherapy DE (Up to Day 95)|Lost to Follow-up|0
6351278|NCT03681951|10118735|FG004|Part1: Monotherapy DE (Up to Day 95)|Lost to Follow-up|0
6351279|NCT03681951|10118736|FG005|Part1: Monotherapy DE (Up to Day 95)|Lost to Follow-up|0
6351280|NCT03681951|10118737|FG006|Part1: Monotherapy DE (Up to Day 95)|Lost to Follow-up|0
6351281|NCT03681951|10118738|FG007|Part1: Monotherapy DE (Up to Day 95)|Lost to Follow-up|0
6351282|NCT03681951|10118731|FG000|Part1: Monotherapy DE (Up to Day 95)|Physician Decision|4
6351283|NCT03681951|10118732|FG001|Part1: Monotherapy DE (Up to Day 95)|Physician Decision|0
6351284|NCT03681951|10118733|FG002|Part1: Monotherapy DE (Up to Day 95)|Physician Decision|0
6351285|NCT03681951|10118734|FG003|Part1: Monotherapy DE (Up to Day 95)|Physician Decision|0
6351286|NCT03681951|10118735|FG004|Part1: Monotherapy DE (Up to Day 95)|Physician Decision|0
6351287|NCT03681951|10118736|FG005|Part1: Monotherapy DE (Up to Day 95)|Physician Decision|0
6351288|NCT03681951|10118737|FG006|Part1: Monotherapy DE (Up to Day 95)|Physician Decision|0
6351289|NCT03681951|10118738|FG007|Part1: Monotherapy DE (Up to Day 95)|Physician Decision|0
6351290|NCT03681951|10118731|FG000|Part1: Monotherapy DE (Up to Day 95)|Withdrawal by Subject|3
6351291|NCT03681951|10118732|FG001|Part1: Monotherapy DE (Up to Day 95)|Withdrawal by Subject|0
6351292|NCT03681951|10118733|FG002|Part1: Monotherapy DE (Up to Day 95)|Withdrawal by Subject|0
6351293|NCT03681951|10118734|FG003|Part1: Monotherapy DE (Up to Day 95)|Withdrawal by Subject|0
6351294|NCT03681951|10118735|FG004|Part1: Monotherapy DE (Up to Day 95)|Withdrawal by Subject|0
6351295|NCT03681951|10118736|FG005|Part1: Monotherapy DE (Up to Day 95)|Withdrawal by Subject|0
6351296|NCT03681951|10118737|FG006|Part1: Monotherapy DE (Up to Day 95)|Withdrawal by Subject|0
6351297|NCT03681951|10118738|FG007|Part1: Monotherapy DE (Up to Day 95)|Withdrawal by Subject|0
6351298|NCT03682107|10118766|FG000|Overall Study|Withdrawal by Subject|0
6351299|NCT03682107|10118767|FG001|Overall Study|Withdrawal by Subject|1
6351300|NCT03682107|10118768|FG002|Overall Study|Withdrawal by Subject|0
6351301|NCT03682107|10118769|FG003|Overall Study|Withdrawal by Subject|0
6351302|NCT03682107|10118770|FG004|Overall Study|Withdrawal by Subject|0
6351303|NCT03682120|10118786|FG000|Overall Study|Lost to Follow-up|11
6351304|NCT03682120|10118787|FG001|Overall Study|Lost to Follow-up|4
6351305|NCT03682120|10118788|FG002|Overall Study|Lost to Follow-up|5
6351306|NCT03682120|10118789|FG003|Overall Study|Lost to Follow-up|2
6351307|NCT03682120|10118786|FG000|Overall Study|Physician Decision|1
6351308|NCT03682120|10118787|FG001|Overall Study|Physician Decision|0
6351309|NCT03682120|10118788|FG002|Overall Study|Physician Decision|0
6351310|NCT03682120|10118789|FG003|Overall Study|Physician Decision|0
6351311|NCT03682120|10118786|FG000|Overall Study|Withdrawal by Subject|1
6351312|NCT03682120|10118787|FG001|Overall Study|Withdrawal by Subject|2
6351313|NCT03682120|10118788|FG002|Overall Study|Withdrawal by Subject|3
6351314|NCT03682120|10118789|FG003|Overall Study|Withdrawal by Subject|0
6351315|NCT03682120|10118786|FG000|Overall Study|Death|0
6351316|NCT03682120|10118787|FG001|Overall Study|Death|1
6351317|NCT03682120|10118788|FG002|Overall Study|Death|0
6351318|NCT03682120|10118789|FG003|Overall Study|Death|0
6351319|NCT03682120|10118786|FG000|Overall Study|Enrolled but Treatment Not Administered|0
6351320|NCT03682120|10118787|FG001|Overall Study|Enrolled but Treatment Not Administered|1
6351321|NCT03682120|10118788|FG002|Overall Study|Enrolled but Treatment Not Administered|0
6351322|NCT03682120|10118789|FG003|Overall Study|Enrolled but Treatment Not Administered|0
6351323|NCT03682302|10118805|FG000|Overall Study|Lost to Follow-up|1
6351324|NCT03682302|10118806|FG001|Overall Study|Lost to Follow-up|2
6351325|NCT03682302|10118807|FG002|Overall Study|Lost to Follow-up|0
6351326|NCT03682302|10118808|FG003|Overall Study|Lost to Follow-up|1
6351327|NCT03682302|10118805|FG000|Overall Study|Study drug was not administered|0
6351328|NCT03682302|10118806|FG001|Overall Study|Study drug was not administered|0
6351329|NCT03682302|10118807|FG002|Overall Study|Study drug was not administered|1
6351330|NCT03682302|10118808|FG003|Overall Study|Study drug was not administered|1
6351331|NCT03682705|10118824|FG000|Overall Study|Adverse Event|1
6351332|NCT03682705|10118825|FG001|Overall Study|Adverse Event|1
6351333|NCT03682705|10118826|FG002|Overall Study|Adverse Event|1
6351334|NCT03682705|10118827|FG003|Overall Study|Adverse Event|0
6351335|NCT03682705|10118828|FG004|Overall Study|Adverse Event|1
6351336|NCT03682705|10118829|FG005|Overall Study|Adverse Event|1
6351337|NCT03682705|10118824|FG000|Overall Study|Withdrawal by Subject|1
6351338|NCT03682705|10118825|FG001|Overall Study|Withdrawal by Subject|3
6351339|NCT03682705|10118826|FG002|Overall Study|Withdrawal by Subject|2
6351340|NCT03682705|10118827|FG003|Overall Study|Withdrawal by Subject|4
6351341|NCT03682705|10118828|FG004|Overall Study|Withdrawal by Subject|0
6351342|NCT03682705|10118829|FG005|Overall Study|Withdrawal by Subject|1
6351343|NCT03682705|10118824|FG000|Overall Study|Other, not specified|0
6351344|NCT03682705|10118825|FG001|Overall Study|Other, not specified|0
6351345|NCT03682705|10118826|FG002|Overall Study|Other, not specified|0
6351346|NCT03682705|10118827|FG003|Overall Study|Other, not specified|1
6351347|NCT03682705|10118828|FG004|Overall Study|Other, not specified|2
6351348|NCT03682705|10118829|FG005|Overall Study|Other, not specified|0
6351349|NCT03682705|10118824|FG000|Overall Study|Lost to Follow-up|0
6351350|NCT03682705|10118825|FG001|Overall Study|Lost to Follow-up|0
6351351|NCT03682705|10118826|FG002|Overall Study|Lost to Follow-up|0
6351352|NCT03682705|10118827|FG003|Overall Study|Lost to Follow-up|0
6351353|NCT03682705|10118828|FG004|Overall Study|Lost to Follow-up|3
6351354|NCT03682705|10118829|FG005|Overall Study|Lost to Follow-up|0
6351355|NCT03683576|10118865|FG000|Overall Study|Withdrawal by Subject|2
6351356|NCT03683576|10118866|FG001|Overall Study|Withdrawal by Subject|0
6351357|NCT03683576|10118867|FG002|Overall Study|Withdrawal by Subject|8
6351358|NCT03683576|10118868|FG003|Overall Study|Withdrawal by Subject|3
6351359|NCT03683576|10118865|FG000|Overall Study|Adverse Event|3
6351360|NCT03683576|10118866|FG001|Overall Study|Adverse Event|0
6351361|NCT03683576|10118867|FG002|Overall Study|Adverse Event|0
6351362|NCT03683576|10118868|FG003|Overall Study|Adverse Event|4
6351363|NCT03683576|10118865|FG000|Overall Study|Lack of Efficacy|1
6351364|NCT03683576|10118866|FG001|Overall Study|Lack of Efficacy|0
6351365|NCT03683576|10118867|FG002|Overall Study|Lack of Efficacy|1
6351366|NCT03683576|10118868|FG003|Overall Study|Lack of Efficacy|1
6351367|NCT03683576|10118865|FG000|Overall Study|Lost to Follow-up|0
6351368|NCT03683576|10118866|FG001|Overall Study|Lost to Follow-up|1
6351369|NCT03683576|10118867|FG002|Overall Study|Lost to Follow-up|2
6351370|NCT03683576|10118868|FG003|Overall Study|Lost to Follow-up|0
6351371|NCT03683576|10118865|FG000|Overall Study|Other, Not Specified|0
6351372|NCT03683576|10118866|FG001|Overall Study|Other, Not Specified|2
6351373|NCT03683576|10118867|FG002|Overall Study|Other, Not Specified|0
6351374|NCT03683576|10118868|FG003|Overall Study|Other, Not Specified|0
6351375|NCT03683576|10118865|FG000|Overall Study|Protocol Violation|0
6351376|NCT03683576|10118866|FG001|Overall Study|Protocol Violation|1
6351377|NCT03683576|10118867|FG002|Overall Study|Protocol Violation|1
6351378|NCT03683576|10118868|FG003|Overall Study|Protocol Violation|0
6351379|NCT03683719|10118883|FG000|Overall Study|Lack of Efficacy|1
6351380|NCT03683719|10118884|FG001|Overall Study|Lack of Efficacy|3
6351381|NCT03683719|10118885|FG002|Overall Study|Lack of Efficacy|4
6351382|NCT03683719|10118886|FG003|Overall Study|Lack of Efficacy|0
6351383|NCT03683719|10118887|FG004|Overall Study|Lack of Efficacy|4
6351384|NCT03683719|10118883|FG000|Overall Study|Adverse Event|6
6351385|NCT03683719|10118884|FG001|Overall Study|Adverse Event|6
6351386|NCT03683719|10118885|FG002|Overall Study|Adverse Event|0
6351387|NCT03683719|10118886|FG003|Overall Study|Adverse Event|1
6351388|NCT03683719|10118887|FG004|Overall Study|Adverse Event|3
6351389|NCT03683719|10118883|FG000|Overall Study|Withdrawal by Subject|4
6351390|NCT03683719|10118884|FG001|Overall Study|Withdrawal by Subject|4
6351391|NCT03683719|10118885|FG002|Overall Study|Withdrawal by Subject|3
6351392|NCT03683719|10118886|FG003|Overall Study|Withdrawal by Subject|5
6351393|NCT03683719|10118887|FG004|Overall Study|Withdrawal by Subject|5
6351394|NCT03683719|10118883|FG000|Overall Study|Lost to Follow-up|1
6351395|NCT03683719|10118884|FG001|Overall Study|Lost to Follow-up|0
6351396|NCT03683719|10118885|FG002|Overall Study|Lost to Follow-up|0
6351397|NCT03683719|10118886|FG003|Overall Study|Lost to Follow-up|1
6351398|NCT03683719|10118887|FG004|Overall Study|Lost to Follow-up|1
6351399|NCT03683719|10118883|FG000|Overall Study|Other personal reasons|0
6351400|NCT03683719|10118884|FG001|Overall Study|Other personal reasons|0
6351401|NCT03683719|10118885|FG002|Overall Study|Other personal reasons|1
6351402|NCT03683719|10118886|FG003|Overall Study|Other personal reasons|0
5972111|NCT00489307|9557727|FG000|Overall Study|Death|1
6351403|NCT03683719|10118887|FG004|Overall Study|Other personal reasons|1
6351404|NCT03683758|10118901|FG000|Overall Study|Non-study commitment conflict|1
6351405|NCT03683758|10118902|FG001|Overall Study|Non-study commitment conflict|3
6351406|NCT03683758|10118901|FG000|Overall Study|Illness preventing participation|1
6351407|NCT03683758|10118902|FG001|Overall Study|Illness preventing participation|0
6351408|NCT03683758|10118901|FG000|Overall Study|Adverse Event|1
6351409|NCT03683758|10118902|FG001|Overall Study|Adverse Event|0
6351410|NCT03684044|10118916|FG000|Overall Study|Adverse Event|3
6351411|NCT03684044|10118917|FG001|Overall Study|Adverse Event|0
6351412|NCT03684044|10118916|FG000|Overall Study|Death|4
6351413|NCT03684044|10118917|FG001|Overall Study|Death|7
6351414|NCT03684044|10118916|FG000|Overall Study|Lost to Follow-up|3
6351415|NCT03684044|10118917|FG001|Overall Study|Lost to Follow-up|2
6351416|NCT03684044|10118916|FG000|Overall Study|Patient Not Available|0
6351417|NCT03684044|10118917|FG001|Overall Study|Patient Not Available|2
6351418|NCT03684044|10118916|FG000|Overall Study|Physician Decision|1
6351419|NCT03684044|10118917|FG001|Overall Study|Physician Decision|0
6351420|NCT03684044|10118916|FG000|Overall Study|Withdrawal by Subject|11
6351421|NCT03684044|10118917|FG001|Overall Study|Withdrawal by Subject|9
6351422|NCT03684642|10118935|FG000|Overall Study|Adverse Event|6
6351423|NCT03684642|10118936|FG001|Overall Study|Adverse Event|15
6351424|NCT03684642|10118937|FG002|Overall Study|Adverse Event|11
6351425|NCT03684642|10118935|FG000|Overall Study|Withdrawal by Subject|35
6351426|NCT03684642|10118936|FG001|Overall Study|Withdrawal by Subject|53
6351427|NCT03684642|10118937|FG002|Overall Study|Withdrawal by Subject|23
6351428|NCT03684642|10118935|FG000|Overall Study|Lack of Efficacy|0
6351429|NCT03684642|10118936|FG001|Overall Study|Lack of Efficacy|0
6351430|NCT03684642|10118937|FG002|Overall Study|Lack of Efficacy|1
6351431|NCT03684642|10118935|FG000|Overall Study|Poor compliance to protocol|0
6351432|NCT03684642|10118936|FG001|Overall Study|Poor compliance to protocol|4
6351433|NCT03684642|10118937|FG002|Overall Study|Poor compliance to protocol|1
6351434|NCT03684642|10118935|FG000|Overall Study|Other than specified|62
6351435|NCT03684642|10118936|FG001|Overall Study|Other than specified|60
6351436|NCT03684642|10118937|FG002|Overall Study|Other than specified|67
6351437|NCT03684642|10118935|FG000|Overall Study|Randomized and not treated|0
6351438|NCT03684642|10118936|FG001|Overall Study|Randomized and not treated|0
6351439|NCT03684642|10118937|FG002|Overall Study|Randomized and not treated|1
6351440|NCT03684642|10118935|FG000|Overall Study|Missing completion status but alive at last contact|0
6351441|NCT03684642|10118936|FG001|Overall Study|Missing completion status but alive at last contact|1
6351442|NCT03684642|10118937|FG002|Overall Study|Missing completion status but alive at last contact|2
6351443|NCT03684928|10118945|FG000|First Intervention|Lost to Follow-up|0
6351444|NCT03684928|10118946|FG001|First Intervention|Lost to Follow-up|1
6351445|NCT03684928|10118945|FG000|First Intervention|Withdrawal by Subject|0
6351446|NCT03684928|10118946|FG001|First Intervention|Withdrawal by Subject|2
6351447|NCT03684928|10118945|FG000|Second Intervention|Soft Tissue Injury|1
6351448|NCT03684928|10118946|FG001|Second Intervention|Soft Tissue Injury|0
6351449|NCT03685344|10118956|FG000|Overall Study|Withdrawal by Subject|1
6351450|NCT03685344|10118957|FG001|Overall Study|Withdrawal by Subject|1
6351451|NCT03685344|10118958|FG002|Overall Study|Withdrawal by Subject|2
6351452|NCT03685344|10118959|FG003|Overall Study|Withdrawal by Subject|0
6351453|NCT03685344|10118956|FG000|Overall Study|Physician Decision|1
6351454|NCT03685344|10118957|FG001|Overall Study|Physician Decision|1
6351455|NCT03685344|10118958|FG002|Overall Study|Physician Decision|5
6351456|NCT03685344|10118959|FG003|Overall Study|Physician Decision|0
6351457|NCT03685344|10118956|FG000|Overall Study|Death|1
6351458|NCT03685344|10118957|FG001|Overall Study|Death|1
6351459|NCT03685344|10118958|FG002|Overall Study|Death|0
6351460|NCT03685344|10118959|FG003|Overall Study|Death|0
6351461|NCT03685643|10118980|FG000|Overall Study|Lost to Follow-up|14
6351462|NCT03685643|10118981|FG001|Overall Study|Lost to Follow-up|22
6351463|NCT03686033|10119000|FG000|Treatment Period 2 (1 Day)|Adverse Event|0
6351464|NCT03686033|10119001|FG001|Treatment Period 2 (1 Day)|Adverse Event|0
6351465|NCT03686033|10119002|FG002|Treatment Period 2 (1 Day)|Adverse Event|0
6351466|NCT03686033|10119003|FG003|Treatment Period 2 (1 Day)|Adverse Event|0
6351467|NCT03686033|10119004|FG004|Treatment Period 2 (1 Day)|Adverse Event|1
6351468|NCT03686033|10119005|FG005|Treatment Period 2 (1 Day)|Adverse Event|0
6351469|NCT03686176|10119022|FG000|Overall Study|Procedure cancelled|1
6351470|NCT03686176|10119023|FG001|Overall Study|Procedure cancelled|0
6351471|NCT03686176|10119024|FG002|Overall Study|Procedure cancelled|0
6351472|NCT03686176|10119022|FG000|Overall Study|VR Malfunction|1
6351473|NCT03686176|10119023|FG001|Overall Study|VR Malfunction|0
6351474|NCT03686176|10119024|FG002|Overall Study|VR Malfunction|0
6351475|NCT03687125|10119034|FG000|Overall Study|Progressive Disease|2
6351476|NCT03687125|10119035|FG001|Overall Study|Progressive Disease|1
6351477|NCT03687125|10119034|FG000|Overall Study|Protocol Violation|1
6351478|NCT03687125|10119035|FG001|Overall Study|Protocol Violation|0
6351479|NCT03687372|10119045|FG000|Overall Study|Lost to Follow-up|12
6351480|NCT03687372|10119046|FG001|Overall Study|Lost to Follow-up|21
6351481|NCT03687372|10119045|FG000|Overall Study|Withdrawal by Subject|4
6351482|NCT03687372|10119046|FG001|Overall Study|Withdrawal by Subject|17
6351483|NCT03687372|10119045|FG000|Overall Study|Investigator Decision|1
6351484|NCT03687372|10119046|FG001|Overall Study|Investigator Decision|1
6351485|NCT03687736|10119110|FG000|Overall Study|Lost to Follow-up|7
6351486|NCT03687736|10119110|FG000|Overall Study|Withdrawal by Subject|3
6351487|NCT03687827|10119116|FG000|Treatment Period 1|Death|0
6351488|NCT03687827|10119117|FG001|Treatment Period 1|Death|1
6351489|NCT03687827|10119116|FG000|Treatment Period 1|Lost to Follow-up|2
6351490|NCT03687827|10119117|FG001|Treatment Period 1|Lost to Follow-up|2
6351491|NCT03687827|10119116|FG000|Treatment Period 1|Physician Decision|5
6351492|NCT03687827|10119117|FG001|Treatment Period 1|Physician Decision|2
6351493|NCT03687827|10119116|FG000|Treatment Period 1|Withdrawal by Subject|7
6351494|NCT03687827|10119117|FG001|Treatment Period 1|Withdrawal by Subject|3
6351495|NCT03687827|10119116|FG000|Treatment Period 2|Physician Decision|4
6351496|NCT03687827|10119117|FG001|Treatment Period 2|Physician Decision|1
6351497|NCT03687827|10119116|FG000|Treatment Period 2|Withdrawal by Subject|1
6351498|NCT03687827|10119117|FG001|Treatment Period 2|Withdrawal by Subject|2
6351499|NCT03687970|10119125|FG000|Overall Study|visit scheduling conflicts|2
6351500|NCT03687970|10119126|FG001|Overall Study|visit scheduling conflicts|0
6351501|NCT03688620|10119152|FG000|Overall Study|Other|0
6351502|NCT03688620|10119153|FG001|Overall Study|Other|0
6351503|NCT03688620|10119154|FG002|Overall Study|Other|1
6351504|NCT03688620|10119152|FG000|Overall Study|Unwilling to attend the scheduled visit|0
6351505|NCT03688620|10119153|FG001|Overall Study|Unwilling to attend the scheduled visit|1
6351506|NCT03688620|10119154|FG002|Overall Study|Unwilling to attend the scheduled visit|0
6351507|NCT03688620|10119152|FG000|Overall Study|Lost to Follow-up|16
6351508|NCT03688620|10119153|FG001|Overall Study|Lost to Follow-up|0
6351509|NCT03688620|10119154|FG002|Overall Study|Lost to Follow-up|1
6351510|NCT03688620|10119152|FG000|Overall Study|Withdrawal by Subject|0
6351511|NCT03688620|10119153|FG001|Overall Study|Withdrawal by Subject|0
6351512|NCT03688620|10119154|FG002|Overall Study|Withdrawal by Subject|6
6351513|NCT03688711|10119170|FG000|Overall Study|Withdrawal by Subject|0
6351514|NCT03688711|10119171|FG001|Overall Study|Withdrawal by Subject|1
6351515|NCT03688880|10119179|FG000|Overall Study|Withdrawal by Subject|0
6351516|NCT03688880|10119180|FG001|Overall Study|Withdrawal by Subject|2
6351517|NCT03688880|10119179|FG000|Overall Study|Use of non-permitted concurrent therapy|0
6351518|NCT03688880|10119180|FG001|Overall Study|Use of non-permitted concurrent therapy|2
6351519|NCT03688880|10119179|FG000|Overall Study|Lost to Follow-up|4
6351520|NCT03688880|10119180|FG001|Overall Study|Lost to Follow-up|7
6351521|NCT03688880|10119179|FG000|Overall Study|Adverse Event|0
6351522|NCT03688880|10119180|FG001|Overall Study|Adverse Event|2
6351523|NCT03688880|10119179|FG000|Overall Study|Device deficiencies|0
6351524|NCT03688880|10119180|FG001|Overall Study|Device deficiencies|2
6351525|NCT03688880|10119179|FG000|Overall Study|Other|10
6351526|NCT03688880|10119180|FG001|Overall Study|Other|16
6351527|NCT03689452|10119188|FG000|Overall Study|Lost to Follow-up|1
6351528|NCT03689452|10119189|FG001|Overall Study|Lost to Follow-up|1
6351529|NCT03691779|10119216|FG000|Part B (24 Weeks)|Adverse Event|0
6351530|NCT03691779|10119217|FG001|Part B (24 Weeks)|Adverse Event|1
6351531|NCT03691779|10119216|FG000|Part B (24 Weeks)|Withdrawal of consent (not due to AE)|0
6351532|NCT03691779|10119217|FG001|Part B (24 Weeks)|Withdrawal of consent (not due to AE)|1
6351533|NCT03691831|10119226|FG000|Overall Study|Lost to Follow-up|16
6351534|NCT03691831|10119227|FG001|Overall Study|Lost to Follow-up|12
6351535|NCT03691831|10119226|FG000|Overall Study|Withdrawal by Subject|9
6083656|NCT00636441|9692157|FG003|Overall Study|Late, ineligible|0
6083657|NCT00636441|9692158|FG004|Overall Study|Late, ineligible|0
6083658|NCT00636441|9692159|FG005|Overall Study|Late, ineligible|0
6083659|NCT00636441|9692160|FG006|Overall Study|Late, ineligible|1
6083660|NCT00636441|9692154|FG000|Overall Study|Screen Failure|0
6083661|NCT00636441|9692155|FG001|Overall Study|Screen Failure|0
6083662|NCT00636441|9692156|FG002|Overall Study|Screen Failure|0
6351536|NCT03691831|10119227|FG001|Overall Study|Withdrawal by Subject|17
6351537|NCT03691831|10119226|FG000|Overall Study|Investigator Decision|2
6351538|NCT03691831|10119227|FG001|Overall Study|Investigator Decision|2
6351539|NCT03691948|10119254|FG000|Overall Study|Lost to Follow-up|1
6351540|NCT03691948|10119255|FG001|Overall Study|Lost to Follow-up|3
6351541|NCT03692676|10119266|FG000|Overall Study|exclude patients with prior use|4424
6351542|NCT03692676|10119267|FG001|Overall Study|exclude patients with prior use|24726
6351543|NCT03692676|10119268|FG002|Overall Study|exclude patients with prior use|0
6351544|NCT03692676|10119269|FG003|Overall Study|exclude patients with prior use|0
6351545|NCT03692676|10119266|FG000|Overall Study|exclude patients without concurrent ICS/LABA FDC use|2480
6351546|NCT03692676|10119267|FG001|Overall Study|exclude patients without concurrent ICS/LABA FDC use|19037
6351547|NCT03692676|10119268|FG002|Overall Study|exclude patients without concurrent ICS/LABA FDC use|0
6351548|NCT03692676|10119269|FG003|Overall Study|exclude patients without concurrent ICS/LABA FDC use|0
6351549|NCT03692676|10119266|FG000|Overall Study|exclude patients without prior recorded asthma diagnosis|881
6351550|NCT03692676|10119267|FG001|Overall Study|exclude patients without prior recorded asthma diagnosis|563
6351551|NCT03692676|10119268|FG002|Overall Study|exclude patients without prior recorded asthma diagnosis|6281
6351552|NCT03692676|10119269|FG003|Overall Study|exclude patients without prior recorded asthma diagnosis|558
6351553|NCT03692676|10119266|FG000|Overall Study|exclude patients less than 18 years of age on index date|8
6351554|NCT03692676|10119267|FG001|Overall Study|exclude patients less than 18 years of age on index date|613
6351555|NCT03692676|10119268|FG002|Overall Study|exclude patients less than 18 years of age on index date|836
6351556|NCT03692676|10119269|FG003|Overall Study|exclude patients less than 18 years of age on index date|193
6083663|NCT00636441|9692157|FG003|Overall Study|Screen Failure|0
6351557|NCT03692676|10119266|FG000|Overall Study|exclude patients with less than 1 year prior continous UTS enrollment|149
6351558|NCT03692676|10119267|FG001|Overall Study|exclude patients with less than 1 year prior continous UTS enrollment|717
6351559|NCT03692676|10119268|FG002|Overall Study|exclude patients with less than 1 year prior continous UTS enrollment|1723
6351560|NCT03692676|10119269|FG003|Overall Study|exclude patients with less than 1 year prior continous UTS enrollment|273
6351561|NCT03692676|10119266|FG000|Overall Study|exclude patients with prior LAMA use (any time prior to index date)|1208
6351562|NCT03692676|10119267|FG001|Overall Study|exclude patients with prior LAMA use (any time prior to index date)|759
6351563|NCT03692676|10119268|FG002|Overall Study|exclude patients with prior LAMA use (any time prior to index date)|7419
6351564|NCT03692676|10119269|FG003|Overall Study|exclude patients with prior LAMA use (any time prior to index date)|684
6351565|NCT03692676|10119266|FG000|Overall Study|exclude patients with prior recorded COPD diagnosis|275
6351566|NCT03692676|10119267|FG001|Overall Study|exclude patients with prior recorded COPD diagnosis|218
6351567|NCT03692676|10119268|FG002|Overall Study|exclude patients with prior recorded COPD diagnosis|1515
6351568|NCT03692676|10119269|FG003|Overall Study|exclude patients with prior recorded COPD diagnosis|173
6351569|NCT03692676|10119266|FG000|Overall Study|exclude patients with multiple FDC prescriptions on index date|0
6351570|NCT03692676|10119267|FG001|Overall Study|exclude patients with multiple FDC prescriptions on index date|0
6351571|NCT03692676|10119268|FG002|Overall Study|exclude patients with multiple FDC prescriptions on index date|1147
6351572|NCT03692676|10119269|FG003|Overall Study|exclude patients with multiple FDC prescriptions on index date|4
6351573|NCT03692676|10119266|FG000|Overall Study|exclude patients with prior use of same substances and device|0
6351574|NCT03692676|10119267|FG001|Overall Study|exclude patients with prior use of same substances and device|0
6351575|NCT03692676|10119268|FG002|Overall Study|exclude patients with prior use of same substances and device|3700
6351576|NCT03692676|10119269|FG003|Overall Study|exclude patients with prior use of same substances and device|0
6351577|NCT03692676|10119266|FG000|Overall Study|exclude patients without ICS/LABA FDC prescription within 3 months prior to index date|0
6351578|NCT03692676|10119267|FG001|Overall Study|exclude patients without ICS/LABA FDC prescription within 3 months prior to index date|0
6351579|NCT03692676|10119268|FG002|Overall Study|exclude patients without ICS/LABA FDC prescription within 3 months prior to index date|14965
6351580|NCT03692676|10119269|FG003|Overall Study|exclude patients without ICS/LABA FDC prescription within 3 months prior to index date|1198
6351581|NCT03692676|10119266|FG000|Overall Study|exclude patients with different substance(s)/device at preceding prescription|0
6351582|NCT03692676|10119267|FG001|Overall Study|exclude patients with different substance(s)/device at preceding prescription|0
6351583|NCT03692676|10119268|FG002|Overall Study|exclude patients with different substance(s)/device at preceding prescription|0
6351584|NCT03692676|10119269|FG003|Overall Study|exclude patients with different substance(s)/device at preceding prescription|223
6351585|NCT03692676|10119266|FG000|Overall Study|Other|0
6351586|NCT03692676|10119267|FG001|Overall Study|Other|805
6351587|NCT03692676|10119268|FG002|Overall Study|Other|758
6351588|NCT03692676|10119269|FG003|Overall Study|Other|277
6351589|NCT03692676|10119266|FG000|Overall Study|exclude patients with multiple substance(s)/device at preceding prescription|0
6351590|NCT03692676|10119267|FG001|Overall Study|exclude patients with multiple substance(s)/device at preceding prescription|0
6351591|NCT03692676|10119268|FG002|Overall Study|exclude patients with multiple substance(s)/device at preceding prescription|0
6351592|NCT03692676|10119269|FG003|Overall Study|exclude patients with multiple substance(s)/device at preceding prescription|3
6351593|NCT03693625|10119281|FG000|Overall Study|Adverse Event|2
6351594|NCT03693625|10119282|FG001|Overall Study|Adverse Event|0
6351595|NCT03693625|10119281|FG000|Overall Study|Study Terminated By Sponsor|20
6351596|NCT03693625|10119282|FG001|Overall Study|Study Terminated By Sponsor|7
6351597|NCT03693625|10119281|FG000|Overall Study|Withdrawal by Subject|1
6351598|NCT03693625|10119282|FG001|Overall Study|Withdrawal by Subject|1
6351599|NCT03693950|10119305|FG000|Overall Study|Withdrawal by Subject|1
6351600|NCT03693950|10119306|FG001|Overall Study|Withdrawal by Subject|0
6351601|NCT03693989|10119314|FG000|Overall Study|Protocol Violation|3
6351602|NCT03693989|10119315|FG001|Overall Study|Protocol Violation|4
6351603|NCT03694197|10119321|FG000|Overall Study|Adverse Event|9
6351604|NCT03694197|10119321|FG000|Overall Study|Protocol became inconvenient to participate|1
6351605|NCT03694197|10119321|FG000|Overall Study|Physician Decision|4
6351606|NCT03694197|10119321|FG000|Overall Study|Study terminated by sponsor|1350
6351607|NCT03694197|10119321|FG000|Overall Study|Participant moved|5
6351608|NCT03694197|10119321|FG000|Overall Study|Participant withdrew consent|10
6351609|NCT03694197|10119321|FG000|Overall Study|Related to IMP administration|1
6351610|NCT03694197|10119321|FG000|Overall Study|Not disclosed|5
6351611|NCT03694210|10119325|FG000|Overall Study|Death|1
6351612|NCT03694210|10119325|FG000|Overall Study|Screen Failure|7
6351613|NCT03694548|10119333|FG000|Part A Survey|Protocol Violation|3
6351614|NCT03694548|10119334|FG001|Part A Survey|Protocol Violation|3
6351615|NCT03694548|10119335|FG002|Part A Survey|Protocol Violation|0
6351616|NCT03694548|10119333|FG000|Part B Yoga Program|Protocol Violation|0
6351617|NCT03694548|10119334|FG001|Part B Yoga Program|Protocol Violation|0
6351618|NCT03694548|10119335|FG002|Part B Yoga Program|Protocol Violation|3
6351619|NCT03694548|10119333|FG000|Part B Yoga Program|Did not attend intervention|0
6083664|NCT00636441|9692158|FG004|Overall Study|Screen Failure|0
6083665|NCT00636441|9692159|FG005|Overall Study|Screen Failure|0
6083666|NCT00636441|9692160|FG006|Overall Study|Screen Failure|17
6083667|NCT00636506|9692171|FG000|Overall Study|Lost to Follow-up|8
6351620|NCT03694548|10119334|FG001|Part B Yoga Program|Did not attend intervention|0
6351621|NCT03694548|10119335|FG002|Part B Yoga Program|Did not attend intervention|8
6351622|NCT03694925|10119361|FG000|Overall Study|Inadequate laboratory testing|0
6351623|NCT03694925|10119362|FG001|Overall Study|Inadequate laboratory testing|3
6351624|NCT03694925|10119363|FG002|Overall Study|Inadequate laboratory testing|0
6351625|NCT03695094|10119375|FG000|Overall Study|Adverse Event|1
6351626|NCT03695094|10119376|FG001|Overall Study|Adverse Event|1
6351627|NCT03695094|10119375|FG000|Overall Study|Withdrawal by Subject|1
6351628|NCT03695094|10119376|FG001|Overall Study|Withdrawal by Subject|0
6351629|NCT03695367|10119386|FG000|Overall Study|Missed the Day 28 visit.|1
6351630|NCT03695367|10119387|FG001|Overall Study|Missed the Day 28 visit.|0
6351631|NCT03695367|10119386|FG000|Overall Study|Lost to Follow-up|0
6351632|NCT03695367|10119387|FG001|Overall Study|Lost to Follow-up|1
6351633|NCT03695367|10119386|FG000|Overall Study|Withdrawal by Subject|0
6351634|NCT03695367|10119387|FG001|Overall Study|Withdrawal by Subject|1
6351635|NCT03695367|10119386|FG000|Overall Study|One subject missed the Day 28 visit and one subject missed the Day 10 and Day 28 visits.|0
6351636|NCT03695367|10119387|FG001|Overall Study|One subject missed the Day 28 visit and one subject missed the Day 10 and Day 28 visits.|2
6351637|NCT03695393|10119395|FG000|Overall Study|Death|3
6351638|NCT03695393|10119396|FG001|Overall Study|Death|1
6351639|NCT03695393|10119395|FG000|Overall Study|Lost to Follow-up|0
6351640|NCT03695393|10119396|FG001|Overall Study|Lost to Follow-up|1
6351641|NCT03696108|10119408|FG000|Overall Study|Physician Decision|1
6351642|NCT03696108|10119409|FG001|Overall Study|Physician Decision|0
6351643|NCT03696108|10119408|FG000|Overall Study|Withdrawal by Subject|3
6351644|NCT03696108|10119409|FG001|Overall Study|Withdrawal by Subject|6
6083668|NCT00636506|9692171|FG000|Overall Study|Explanted|1
6083669|NCT00636506|9692171|FG000|Overall Study|Withdrawal by Subject|6
6351645|NCT03696342|10119417|FG000|Overall Study|Lost to Follow-up|1
6351646|NCT03696342|10119418|FG001|Overall Study|Lost to Follow-up|0
6351647|NCT03696576|10119426|FG000|Overall Study|Soreness of throat after therapy|1
6351648|NCT03696576|10119427|FG001|Overall Study|Soreness of throat after therapy|1
6351649|NCT03696576|10119426|FG000|Overall Study|Lost to Follow-up|2
6351650|NCT03696576|10119427|FG001|Overall Study|Lost to Follow-up|4
6351651|NCT03697252|10119472|FG000|Overall Study|Adverse Event|3
6351652|NCT03697252|10119473|FG001|Overall Study|Adverse Event|2
6351653|NCT03697252|10119472|FG000|Overall Study|Withdrawal by Subject|14
6351654|NCT03697252|10119473|FG001|Overall Study|Withdrawal by Subject|14
6351655|NCT03697252|10119472|FG000|Overall Study|Lost to Follow-up|0
6351656|NCT03697252|10119473|FG001|Overall Study|Lost to Follow-up|1
6351657|NCT03697252|10119472|FG000|Overall Study|Physician Decision|1
6351658|NCT03697252|10119473|FG001|Overall Study|Physician Decision|1
6351659|NCT03697252|10119472|FG000|Overall Study|Other|0
6351660|NCT03697252|10119473|FG001|Overall Study|Other|1
6351661|NCT03697460|10119479|FG000|Overall Study|Withdrawal by Subject|3
6351662|NCT03697993|10119485|FG000|Overall Study|Became Ineligible after Enrollment|1
6351663|NCT03697993|10119486|FG001|Overall Study|Became Ineligible after Enrollment|3
6351664|NCT03697993|10119485|FG000|Overall Study|Enrolled but Treatment not Administered|2
6351665|NCT03697993|10119486|FG001|Overall Study|Enrolled but Treatment not Administered|1
6351666|NCT03697993|10119485|FG000|Overall Study|Lost to Follow-up|3
6351667|NCT03697993|10119486|FG001|Overall Study|Lost to Follow-up|0
6351668|NCT03697993|10119485|FG000|Overall Study|Physician Decision|4
6351669|NCT03697993|10119486|FG001|Overall Study|Physician Decision|0
6351670|NCT03697993|10119485|FG000|Overall Study|Initial Urine Culture Negative|0
6351671|NCT03697993|10119486|FG001|Overall Study|Initial Urine Culture Negative|1
6351672|NCT03698331|10119495|FG000|Overall Study|Adverse Event|2
6351673|NCT03698331|10119496|FG001|Overall Study|Adverse Event|3
6351674|NCT03698331|10119495|FG000|Overall Study|Withdrawal by Subject|1
6351675|NCT03698331|10119496|FG001|Overall Study|Withdrawal by Subject|1
6351676|NCT03698331|10119495|FG000|Overall Study|Lost to Follow-up|0
6351677|NCT03698331|10119496|FG001|Overall Study|Lost to Follow-up|2
6351678|NCT03698331|10119495|FG000|Overall Study|Non-compliance with study drug|1
6351679|NCT03698331|10119496|FG001|Overall Study|Non-compliance with study drug|0
6351680|NCT03698591|10119504|FG000|Overall Study|Withdrawal by Subject|2
6351681|NCT03698591|10119505|FG001|Overall Study|Withdrawal by Subject|2
6351682|NCT03698591|10119504|FG000|Overall Study|Failed drug screen|1
6351683|NCT03698591|10119505|FG001|Overall Study|Failed drug screen|1
6351684|NCT03698591|10119504|FG000|Overall Study|Failed health screen|0
6351685|NCT03698591|10119505|FG001|Overall Study|Failed health screen|1
6351686|NCT03698591|10119504|FG000|Overall Study|Ineligible for financial compensation|1
6351687|NCT03698591|10119505|FG001|Overall Study|Ineligible for financial compensation|0
6351688|NCT03698591|10119504|FG000|Overall Study|Equipment Error|1
6351689|NCT03698591|10119505|FG001|Overall Study|Equipment Error|0
6351690|NCT03698591|10119504|FG000|Overall Study|Could not establish TMS dosage|0
6351691|NCT03698591|10119505|FG001|Overall Study|Could not establish TMS dosage|1
6351692|NCT03699124|10119514|FG000|Overall Study|Adverse Event|6
6351693|NCT03699124|10119515|FG001|Overall Study|Adverse Event|5
6351694|NCT03699124|10119516|FG002|Overall Study|Adverse Event|2
6351695|NCT03699124|10119514|FG000|Overall Study|Death|0
6351696|NCT03699124|10119515|FG001|Overall Study|Death|2
6351697|NCT03699124|10119516|FG002|Overall Study|Death|0
6351698|NCT03699124|10119514|FG000|Overall Study|Lost to Follow-up|20
6351699|NCT03699124|10119515|FG001|Overall Study|Lost to Follow-up|16
6351700|NCT03699124|10119516|FG002|Overall Study|Lost to Follow-up|15
6351701|NCT03699124|10119514|FG000|Overall Study|Protocol Violation|1
6351702|NCT03699124|10119515|FG001|Overall Study|Protocol Violation|0
6170221|NCT01251653|9816358|FG005|Overall Study|Withdrawal by Subject|1
6170222|NCT01251653|9816359|FG006|Overall Study|Withdrawal by Subject|0
6170223|NCT01251653|9816360|FG007|Overall Study|Withdrawal by Subject|1
6170224|NCT01251653|9816361|FG008|Overall Study|Withdrawal by Subject|0
6170225|NCT01251653|9816353|FG000|Overall Study|Other reason not mentioned above|0
6170226|NCT01251653|9816354|FG001|Overall Study|Other reason not mentioned above|0
6170227|NCT01251653|9816355|FG002|Overall Study|Other reason not mentioned above|0
6170228|NCT01251653|9816356|FG003|Overall Study|Other reason not mentioned above|0
6170229|NCT01251653|9816357|FG004|Overall Study|Other reason not mentioned above|0
6170230|NCT01251653|9816358|FG005|Overall Study|Other reason not mentioned above|0
6170231|NCT01251653|9816359|FG006|Overall Study|Other reason not mentioned above|0
6170232|NCT01251653|9816360|FG007|Overall Study|Other reason not mentioned above|2
6170233|NCT01251653|9816361|FG008|Overall Study|Other reason not mentioned above|0
6351703|NCT03699124|10119516|FG002|Overall Study|Protocol Violation|0
6351704|NCT03699124|10119514|FG000|Overall Study|Withdrawal by Subject|13
6351705|NCT03699124|10119515|FG001|Overall Study|Withdrawal by Subject|14
6170234|NCT01251744|9816399|FG000|Overall Study|Lost to Follow-up|1
6351706|NCT03699124|10119516|FG002|Overall Study|Withdrawal by Subject|13
6351707|NCT03699124|10119514|FG000|Overall Study|Other reasons|5
6351708|NCT03699124|10119515|FG001|Overall Study|Other reasons|3
6170235|NCT01251744|9816400|FG001|Overall Study|Lost to Follow-up|0
6170236|NCT01251770|9816432|FG000|Overall Study|Protocol Violation|13
6170237|NCT01251770|9816433|FG001|Overall Study|Protocol Violation|7
6351709|NCT03699124|10119516|FG002|Overall Study|Other reasons|10
6351710|NCT03700320|10119526|FG000|Overall Study|Adverse Event|5
6351711|NCT03700320|10119527|FG001|Overall Study|Adverse Event|31
6351712|NCT03700320|10119526|FG000|Overall Study|Lack of Efficacy|2
6351713|NCT03700320|10119527|FG001|Overall Study|Lack of Efficacy|5
6351714|NCT03700320|10119526|FG000|Overall Study|Withdrawal by Subject|29
6351715|NCT03700320|10119527|FG001|Overall Study|Withdrawal by Subject|75
6351716|NCT03700320|10119526|FG000|Overall Study|Lost to Follow-up|16
6351717|NCT03700320|10119527|FG001|Overall Study|Lost to Follow-up|23
6351718|NCT03700320|10119526|FG000|Overall Study|Pregnancy|2
6351719|NCT03700320|10119527|FG001|Overall Study|Pregnancy|4
6351720|NCT03700320|10119526|FG000|Overall Study|Protocol Deviation|7
6351721|NCT03700320|10119527|FG001|Overall Study|Protocol Deviation|31
6351722|NCT03700320|10119526|FG000|Overall Study|Non-compliance with Study Drug|1
6351723|NCT03700320|10119527|FG001|Overall Study|Non-compliance with Study Drug|3
6351724|NCT03700320|10119526|FG000|Overall Study|Reason not Specified|0
6351725|NCT03700320|10119527|FG001|Overall Study|Reason not Specified|1
6351726|NCT03700385|10119537|FG000|Overall Study|Lost to Follow-up|1
6351727|NCT03700671|10119543|FG000|Overall Study|Lack of Efficacy|1
6351728|NCT03700671|10119544|FG001|Overall Study|Lack of Efficacy|2
6351729|NCT03700736|10119554|FG000|Overall Study|Pregnancy|1
6351730|NCT03700736|10119555|FG001|Overall Study|Pregnancy|1
6351731|NCT03700736|10119554|FG000|Overall Study|Withdrawal by Subject|2
6351732|NCT03700736|10119555|FG001|Overall Study|Withdrawal by Subject|6
6351733|NCT03700892|10119566|FG000|Second Intervention (Single 1-Day Visit)|Withdrawal by Subject|0
6351734|NCT03700892|10119567|FG001|Second Intervention (Single 1-Day Visit)|Withdrawal by Subject|1
6351735|NCT03700892|10119568|FG002|Second Intervention (Single 1-Day Visit)|Withdrawal by Subject|0
6351736|NCT03701074|10119588|FG000|Overall Study|Physician Decision|1
6351737|NCT03701074|10119589|FG001|Overall Study|Physician Decision|0
6351738|NCT03702010|10119597|FG000|Follow-up (30days)|Lack of Efficacy|2
6351739|NCT03702010|10119598|FG001|Follow-up (30days)|Lack of Efficacy|2
6083670|NCT00636506|9692171|FG000|Overall Study|Procedure aborted|1
6083671|NCT00636610|9692195|FG000|Overall Study|Adverse Event|4
6351740|NCT03702166|10119610|FG000|Overall Study|Lost to Follow-up|1
6351741|NCT03702166|10119610|FG000|Overall Study|Withdrawal by Subject|1
6351742|NCT03703336|10119621|FG000|Overall Study|Parent withdrew consent|29
6351743|NCT03703336|10119622|FG001|Overall Study|Parent withdrew consent|8
6351744|NCT03703336|10119621|FG000|Overall Study|Migration|3
6351745|NCT03703336|10119622|FG001|Overall Study|Migration|3
6351746|NCT03703336|10119621|FG000|Overall Study|Protocol Violation|3
6351747|NCT03703336|10119622|FG001|Overall Study|Protocol Violation|1
6351748|NCT03703336|10119621|FG000|Overall Study|Physician Decision|2
6351749|NCT03703336|10119622|FG001|Overall Study|Physician Decision|0
6351750|NCT03703336|10119621|FG000|Overall Study|Adverse Event|0
6351751|NCT03703336|10119622|FG001|Overall Study|Adverse Event|2
6351752|NCT03703336|10119621|FG000|Overall Study|Lost to Follow-up|1
6351753|NCT03703336|10119622|FG001|Overall Study|Lost to Follow-up|0
6351754|NCT03703466|10119631|FG000|Overall Study|Death|2
6351755|NCT03703466|10119632|FG001|Overall Study|Death|1
6351756|NCT03703466|10119633|FG002|Overall Study|Death|0
6351757|NCT03703466|10119631|FG000|Overall Study|Protocol Violation|1
6351758|NCT03703466|10119632|FG001|Overall Study|Protocol Violation|0
6351759|NCT03703466|10119633|FG002|Overall Study|Protocol Violation|0
6351760|NCT03703466|10119631|FG000|Overall Study|Withdrawal by Subject|0
6351761|NCT03703466|10119632|FG001|Overall Study|Withdrawal by Subject|3
6351762|NCT03703466|10119633|FG002|Overall Study|Withdrawal by Subject|0
6351763|NCT03703466|10119631|FG000|Overall Study|Completed < 3 Cycles As Of Data Cut-Off|1
6351764|NCT03703466|10119632|FG001|Overall Study|Completed < 3 Cycles As Of Data Cut-Off|2
6351765|NCT03703466|10119633|FG002|Overall Study|Completed < 3 Cycles As Of Data Cut-Off|2
6351766|NCT03703817|10119644|FG000|Overall Study|Not meeting eligibility criteria|7
6351767|NCT03703817|10119645|FG001|Overall Study|Not meeting eligibility criteria|4
6351768|NCT03704194|10119653|FG000|Overall Study|Withdrawal by Subject|0
6351769|NCT03704194|10119654|FG001|Overall Study|Withdrawal by Subject|1
6351770|NCT03705494|10119693|FG000|Overall Study|Lost to Follow-up|2
6351771|NCT03705494|10119694|FG001|Overall Study|Lost to Follow-up|1
6351772|NCT03705494|10119693|FG000|Overall Study|Withdrawal by Subject|5
6351773|NCT03705494|10119694|FG001|Overall Study|Withdrawal by Subject|2
6351774|NCT03705793|10119702|FG000|Overall Study|Lost to Follow-up|3
6351775|NCT03705793|10119703|FG001|Overall Study|Lost to Follow-up|4
6351776|NCT03705793|10119702|FG000|Overall Study|Withdrawal by Subject|2
6351777|NCT03705793|10119703|FG001|Overall Study|Withdrawal by Subject|1
6351778|NCT03706040|10119712|FG000|Period A (Week 0 to Week 16)|Adverse Event|3
6351779|NCT03706040|10119713|FG001|Period A (Week 0 to Week 16)|Adverse Event|2
6351780|NCT03706040|10119714|FG002|Period A (Week 0 to Week 16)|Adverse Event|1
6351781|NCT03706040|10119715|FG003|Period A (Week 0 to Week 16)|Adverse Event|0
6351782|NCT03706040|10119716|FG004|Period A (Week 0 to Week 16)|Adverse Event|0
6351783|NCT03706040|10119717|FG005|Period A (Week 0 to Week 16)|Adverse Event|0
6351784|NCT03706040|10119718|FG006|Period A (Week 0 to Week 16)|Adverse Event|0
6351785|NCT03706040|10119712|FG000|Period A (Week 0 to Week 16)|Withdrew Consent|3
6351786|NCT03706040|10119713|FG001|Period A (Week 0 to Week 16)|Withdrew Consent|5
6351787|NCT03706040|10119714|FG002|Period A (Week 0 to Week 16)|Withdrew Consent|4
6351788|NCT03706040|10119715|FG003|Period A (Week 0 to Week 16)|Withdrew Consent|0
6083672|NCT00636610|9692196|FG001|Overall Study|Adverse Event|4
6351789|NCT03706040|10119716|FG004|Period A (Week 0 to Week 16)|Withdrew Consent|0
6351790|NCT03706040|10119717|FG005|Period A (Week 0 to Week 16)|Withdrew Consent|0
6351791|NCT03706040|10119718|FG006|Period A (Week 0 to Week 16)|Withdrew Consent|0
6351792|NCT03706040|10119712|FG000|Period A (Week 0 to Week 16)|Lost to Follow-up|1
6351793|NCT03706040|10119713|FG001|Period A (Week 0 to Week 16)|Lost to Follow-up|1
6351794|NCT03706040|10119714|FG002|Period A (Week 0 to Week 16)|Lost to Follow-up|4
6351795|NCT03706040|10119715|FG003|Period A (Week 0 to Week 16)|Lost to Follow-up|0
6351796|NCT03706040|10119716|FG004|Period A (Week 0 to Week 16)|Lost to Follow-up|0
6351797|NCT03706040|10119717|FG005|Period A (Week 0 to Week 16)|Lost to Follow-up|0
6351798|NCT03706040|10119718|FG006|Period A (Week 0 to Week 16)|Lost to Follow-up|0
6351799|NCT03706040|10119712|FG000|Period A (Week 0 to Week 16)|Other|2
6351800|NCT03706040|10119713|FG001|Period A (Week 0 to Week 16)|Other|0
6351801|NCT03706040|10119714|FG002|Period A (Week 0 to Week 16)|Other|2
6351802|NCT03706040|10119715|FG003|Period A (Week 0 to Week 16)|Other|0
6351803|NCT03706040|10119716|FG004|Period A (Week 0 to Week 16)|Other|0
6351804|NCT03706040|10119717|FG005|Period A (Week 0 to Week 16)|Other|0
6351805|NCT03706040|10119718|FG006|Period A (Week 0 to Week 16)|Other|0
6351806|NCT03706040|10119712|FG000|Period B (Week 16 to Week 52)|Adverse Event|0
6351807|NCT03706040|10119713|FG001|Period B (Week 16 to Week 52)|Adverse Event|0
6351808|NCT03706040|10119714|FG002|Period B (Week 16 to Week 52)|Adverse Event|0
6351809|NCT03706040|10119715|FG003|Period B (Week 16 to Week 52)|Adverse Event|1
6351810|NCT03706040|10119716|FG004|Period B (Week 16 to Week 52)|Adverse Event|2
6351811|NCT03706040|10119717|FG005|Period B (Week 16 to Week 52)|Adverse Event|3
6351812|NCT03706040|10119718|FG006|Period B (Week 16 to Week 52)|Adverse Event|0
6351813|NCT03706040|10119712|FG000|Period B (Week 16 to Week 52)|Withdrew Consent|0
6351814|NCT03706040|10119713|FG001|Period B (Week 16 to Week 52)|Withdrew Consent|0
6351815|NCT03706040|10119714|FG002|Period B (Week 16 to Week 52)|Withdrew Consent|0
6351816|NCT03706040|10119715|FG003|Period B (Week 16 to Week 52)|Withdrew Consent|3
6351817|NCT03706040|10119716|FG004|Period B (Week 16 to Week 52)|Withdrew Consent|2
6351818|NCT03706040|10119717|FG005|Period B (Week 16 to Week 52)|Withdrew Consent|1
6351819|NCT03706040|10119718|FG006|Period B (Week 16 to Week 52)|Withdrew Consent|10
6351820|NCT03706040|10119712|FG000|Period B (Week 16 to Week 52)|Lost to Follow-up|0
6351821|NCT03706040|10119713|FG001|Period B (Week 16 to Week 52)|Lost to Follow-up|0
6351822|NCT03706040|10119714|FG002|Period B (Week 16 to Week 52)|Lost to Follow-up|0
6351823|NCT03706040|10119715|FG003|Period B (Week 16 to Week 52)|Lost to Follow-up|0
6351824|NCT03706040|10119716|FG004|Period B (Week 16 to Week 52)|Lost to Follow-up|0
6351825|NCT03706040|10119717|FG005|Period B (Week 16 to Week 52)|Lost to Follow-up|1
6351826|NCT03706040|10119718|FG006|Period B (Week 16 to Week 52)|Lost to Follow-up|1
6351827|NCT03706040|10119712|FG000|Period B (Week 16 to Week 52)|Other|0
6083673|NCT00636610|9692195|FG000|Overall Study|Death|6
6083674|NCT00636610|9692196|FG001|Overall Study|Death|3
6351828|NCT03706040|10119713|FG001|Period B (Week 16 to Week 52)|Other|0
6351829|NCT03706040|10119714|FG002|Period B (Week 16 to Week 52)|Other|0
6351830|NCT03706040|10119715|FG003|Period B (Week 16 to Week 52)|Other|4
6351831|NCT03706040|10119716|FG004|Period B (Week 16 to Week 52)|Other|5
6351832|NCT03706040|10119717|FG005|Period B (Week 16 to Week 52)|Other|23
6351833|NCT03706040|10119718|FG006|Period B (Week 16 to Week 52)|Other|17
6351834|NCT03706456|10119743|FG000|Overall Study|Lack of Efficacy|1
6351835|NCT03706456|10119743|FG000|Overall Study|Ongoing|21
6351836|NCT03707522|10119795|FG000|Overall Study|Lost to Follow-up|24
6351837|NCT03707522|10119796|FG001|Overall Study|Lost to Follow-up|27
6351838|NCT03707522|10119797|FG002|Overall Study|Lost to Follow-up|41
6351839|NCT03707522|10119798|FG003|Overall Study|Lost to Follow-up|36
6351840|NCT03707587|10119810|FG000|Overall Study|Death|0
6351841|NCT03707587|10119811|FG001|Overall Study|Death|1
6351842|NCT03707821|10119819|FG000|Overall Study|Protocol Violation|0
6351843|NCT03707821|10119820|FG001|Overall Study|Protocol Violation|1
6351844|NCT03707821|10119819|FG000|Overall Study|Unsatisfactory Visual Response|1
6351845|NCT03707821|10119820|FG001|Overall Study|Unsatisfactory Visual Response|0
6351846|NCT03707821|10119819|FG000|Overall Study|Unsatisfactory Lens Fitting|1
6351847|NCT03707821|10119820|FG001|Overall Study|Unsatisfactory Lens Fitting|0
6351848|NCT03707912|10119828|FG000|Overall Study|Violation of inclusion criteria|1
6351849|NCT03707912|10119829|FG001|Overall Study|Violation of inclusion criteria|0
6351850|NCT03708211|10119837|FG000|Overall Study|Progressive Disease|10
6351851|NCT03708211|10119838|FG001|Overall Study|Progressive Disease|7
6351852|NCT03708211|10119837|FG000|Overall Study|Withdrawal by Subject|0
6351853|NCT03708211|10119838|FG001|Overall Study|Withdrawal by Subject|1
6351854|NCT03708211|10119837|FG000|Overall Study|Other|2
6351855|NCT03708211|10119838|FG001|Overall Study|Other|0
6351856|NCT03708744|10119869|FG000|Overall Study|Withdrawal by Subject|0
6351857|NCT03708744|10119870|FG001|Overall Study|Withdrawal by Subject|0
6351858|NCT03708744|10119871|FG002|Overall Study|Withdrawal by Subject|1
6351859|NCT03708744|10119872|FG003|Overall Study|Withdrawal by Subject|0
6351860|NCT03709654|10119899|FG000|Overall Study|Lost to Follow-up|1
6351861|NCT03709654|10119900|FG001|Overall Study|Lost to Follow-up|1
6351862|NCT03709654|10119899|FG000|Overall Study|Withdrawal by Subject|1
6351863|NCT03709654|10119900|FG001|Overall Study|Withdrawal by Subject|1
6351864|NCT03709654|10119899|FG000|Overall Study|Adverse Event|1
6351865|NCT03709654|10119900|FG001|Overall Study|Adverse Event|0
6351866|NCT03709823|10119919|FG000|Overall Study|Adverse Event|0
6083675|NCT00636610|9692195|FG000|Overall Study|Physician decision to withdraw patient|15
6351867|NCT03709823|10119920|FG001|Overall Study|Adverse Event|0
6351868|NCT03709823|10119921|FG002|Overall Study|Adverse Event|1
6351869|NCT03709823|10119922|FG003|Overall Study|Adverse Event|0
6351870|NCT03709823|10119923|FG004|Overall Study|Adverse Event|0
6351871|NCT03709823|10119924|FG005|Overall Study|Adverse Event|0
6351872|NCT03709823|10119919|FG000|Overall Study|Lost to Follow-up|2
6351873|NCT03709823|10119920|FG001|Overall Study|Lost to Follow-up|2
6351874|NCT03709823|10119921|FG002|Overall Study|Lost to Follow-up|2
6351875|NCT03709823|10119922|FG003|Overall Study|Lost to Follow-up|1
6351876|NCT03709823|10119923|FG004|Overall Study|Lost to Follow-up|1
6351877|NCT03709823|10119924|FG005|Overall Study|Lost to Follow-up|0
6083676|NCT00636610|9692196|FG001|Overall Study|Physician decision to withdraw patient|9
6083677|NCT00636610|9692195|FG000|Overall Study|Subject decision to withdraw|15
6083678|NCT00636610|9692196|FG001|Overall Study|Subject decision to withdraw|11
6083679|NCT00636610|9692195|FG000|Overall Study|Disease progression - radiographic|41
6083680|NCT00636610|9692196|FG001|Overall Study|Disease progression - radiographic|51
6083681|NCT00636610|9692195|FG000|Overall Study|Disease progression - clinical|8
6351878|NCT03709823|10119919|FG000|Overall Study|Withdrawal by Subject|1
6351879|NCT03709823|10119920|FG001|Overall Study|Withdrawal by Subject|3
6351880|NCT03709823|10119921|FG002|Overall Study|Withdrawal by Subject|0
6351881|NCT03709823|10119922|FG003|Overall Study|Withdrawal by Subject|0
6351882|NCT03709823|10119923|FG004|Overall Study|Withdrawal by Subject|0
6351883|NCT03709823|10119924|FG005|Overall Study|Withdrawal by Subject|0
6351884|NCT03709823|10119919|FG000|Overall Study|Other, Not Specified|0
6351885|NCT03709823|10119920|FG001|Overall Study|Other, Not Specified|0
6351886|NCT03709823|10119921|FG002|Overall Study|Other, Not Specified|0
6351887|NCT03709823|10119922|FG003|Overall Study|Other, Not Specified|1
6351888|NCT03709823|10119923|FG004|Overall Study|Other, Not Specified|0
6351889|NCT03709823|10119924|FG005|Overall Study|Other, Not Specified|0
6351890|NCT03710083|10119941|FG000|Overall Study|Withdrawal by Subject|2
6351891|NCT03710083|10119941|FG000|Overall Study|Unsuccessful Procedure|1
6351892|NCT03710161|10119947|FG000|Overall Study|Study halted due to COVID pandemic|3
6351893|NCT03710161|10119948|FG001|Overall Study|Study halted due to COVID pandemic|2
6351894|NCT03710590|10119974|FG000|Overall Study|Lost to follow up, study stopped due to COVID-19, other reasons|10
6351895|NCT03710590|10119975|FG001|Overall Study|Lost to follow up, study stopped due to COVID-19, other reasons|8
6351896|NCT03710889|10119981|FG000|Overall Study|Adverse Event|2
6351897|NCT03710889|10119981|FG000|Overall Study|Protocol Deviation|1
6351898|NCT03712280|10120010|FG000|Overall Study|Randomized, but not treated due to Adverse Event|0
6351899|NCT03712280|10120011|FG001|Overall Study|Randomized, but not treated due to Adverse Event|1
6351900|NCT03712280|10120012|FG002|Overall Study|Randomized, but not treated due to Adverse Event|0
6351901|NCT03712280|10120013|FG003|Overall Study|Randomized, but not treated due to Adverse Event|1
6351902|NCT03712280|10120010|FG000|Overall Study|Withdrawal by Participant or Caregiver|1
6351903|NCT03712280|10120011|FG001|Overall Study|Withdrawal by Participant or Caregiver|0
6351904|NCT03712280|10120012|FG002|Overall Study|Withdrawal by Participant or Caregiver|0
6351905|NCT03712280|10120013|FG003|Overall Study|Withdrawal by Participant or Caregiver|0
6351906|NCT03712280|10120010|FG000|Overall Study|Adverse Event|0
6351907|NCT03712280|10120011|FG001|Overall Study|Adverse Event|0
6351908|NCT03712280|10120012|FG002|Overall Study|Adverse Event|1
6351909|NCT03712280|10120013|FG003|Overall Study|Adverse Event|0
6351910|NCT03712449|10120025|FG000|Overall Study|Withdraw Consent|0
6351911|NCT03712449|10120026|FG001|Overall Study|Withdraw Consent|1
6351912|NCT03712917|10120048|FG000|Overall Study|Pregnancy|0
6351913|NCT03712917|10120049|FG001|Overall Study|Pregnancy|0
6351914|NCT03712917|10120050|FG002|Overall Study|Pregnancy|1
6351915|NCT03712917|10120048|FG000|Overall Study|Adverse Event|0
6351916|NCT03712917|10120049|FG001|Overall Study|Adverse Event|4
6351917|NCT03712917|10120050|FG002|Overall Study|Adverse Event|3
6351918|NCT03712917|10120048|FG000|Overall Study|Lost to Follow-up|9
6351919|NCT03712917|10120049|FG001|Overall Study|Lost to Follow-up|4
6351920|NCT03712917|10120050|FG002|Overall Study|Lost to Follow-up|5
6351921|NCT03712930|10120058|FG000|Overall Study|Death|7
6351922|NCT03712930|10120058|FG000|Overall Study|Physician Decision|1
6351923|NCT03712930|10120058|FG000|Overall Study|Study Terminated by Sponsor|3
6083682|NCT00636610|9692196|FG001|Overall Study|Disease progression - clinical|3
6083683|NCT00636610|9692195|FG000|Overall Study|Reason for discontinuation not available|3
6351924|NCT03712930|10120058|FG000|Overall Study|Progressive Disease|2
6351925|NCT03714022|10120073|FG000|Overall Study|Adverse Event|1
6351926|NCT03714022|10120074|FG001|Overall Study|Adverse Event|0
6351927|NCT03714022|10120073|FG000|Overall Study|Consent withdrawal|0
6351928|NCT03714022|10120074|FG001|Overall Study|Consent withdrawal|1
6351929|NCT03714022|10120073|FG000|Overall Study|Lost to Follow-up|3
6083684|NCT00636610|9692196|FG001|Overall Study|Reason for discontinuation not available|2
6351930|NCT03714022|10120074|FG001|Overall Study|Lost to Follow-up|2
6351931|NCT03714672|10120097|FG000|Overall Study|Adverse Event|0
6351932|NCT03714672|10120098|FG001|Overall Study|Adverse Event|0
6351933|NCT03714672|10120099|FG002|Overall Study|Adverse Event|3
6351934|NCT03714672|10120100|FG003|Overall Study|Adverse Event|0
6351935|NCT03714672|10120097|FG000|Overall Study|Physician Decision|0
6351936|NCT03714672|10120098|FG001|Overall Study|Physician Decision|1
6351937|NCT03714672|10120099|FG002|Overall Study|Physician Decision|0
6351938|NCT03714672|10120100|FG003|Overall Study|Physician Decision|0
6351939|NCT03714672|10120097|FG000|Overall Study|Other Reason|1
6351940|NCT03714672|10120098|FG001|Overall Study|Other Reason|2
6351941|NCT03714672|10120099|FG002|Overall Study|Other Reason|1
6351942|NCT03714672|10120100|FG003|Overall Study|Other Reason|1
6351943|NCT03714672|10120097|FG000|Overall Study|Lost to Follow-up|1
6351944|NCT03714672|10120098|FG001|Overall Study|Lost to Follow-up|1
6351945|NCT03714672|10120099|FG002|Overall Study|Lost to Follow-up|0
6351946|NCT03714672|10120100|FG003|Overall Study|Lost to Follow-up|0
6351947|NCT03715530|10120131|FG000|Overall Study|Lost to Follow-up|3
6351948|NCT03715530|10120132|FG001|Overall Study|Lost to Follow-up|1
6351949|NCT03715530|10120133|FG002|Overall Study|Lost to Follow-up|2
6351950|NCT03716024|10120152|FG000|Overall Study|Randomized, not Treated|7
6351951|NCT03716024|10120153|FG001|Overall Study|Randomized, not Treated|8
6351952|NCT03716024|10120152|FG000|Overall Study|Adverse Event|1
6351953|NCT03716024|10120153|FG001|Overall Study|Adverse Event|2
6351954|NCT03716024|10120152|FG000|Overall Study|Treatment Failure|1
6351955|NCT03716024|10120153|FG001|Overall Study|Treatment Failure|0
6351956|NCT03716024|10120152|FG000|Overall Study|Lost to Follow-up|2
6351957|NCT03716024|10120153|FG001|Overall Study|Lost to Follow-up|6
6351958|NCT03716024|10120152|FG000|Overall Study|Withdrawal by Subject|0
6351959|NCT03716024|10120153|FG001|Overall Study|Withdrawal by Subject|1
6351960|NCT03716024|10120152|FG000|Overall Study|Missing Reason|0
6351961|NCT03716024|10120153|FG001|Overall Study|Missing Reason|1
6351962|NCT03716050|10120167|FG000|Overall Study|Lost to Follow-up|0
6351963|NCT03716050|10120168|FG001|Overall Study|Lost to Follow-up|0
6351964|NCT03716050|10120169|FG002|Overall Study|Lost to Follow-up|1
6351965|NCT03716050|10120170|FG003|Overall Study|Lost to Follow-up|0
6351966|NCT03716050|10120171|FG004|Overall Study|Lost to Follow-up|0
6351967|NCT03716050|10120172|FG005|Overall Study|Lost to Follow-up|0
6351968|NCT03716050|10120173|FG006|Overall Study|Lost to Follow-up|0
6351969|NCT03716050|10120174|FG007|Overall Study|Lost to Follow-up|0
6351970|NCT03716050|10120167|FG000|Overall Study|Physician Decision|0
6351971|NCT03716050|10120168|FG001|Overall Study|Physician Decision|0
6351972|NCT03716050|10120169|FG002|Overall Study|Physician Decision|0
6351973|NCT03716050|10120170|FG003|Overall Study|Physician Decision|1
6351974|NCT03716050|10120171|FG004|Overall Study|Physician Decision|0
6351975|NCT03716050|10120172|FG005|Overall Study|Physician Decision|0
6351976|NCT03716050|10120173|FG006|Overall Study|Physician Decision|0
6351977|NCT03716050|10120174|FG007|Overall Study|Physician Decision|0
6351978|NCT03716050|10120167|FG000|Overall Study|Protocol Violation|0
6351979|NCT03716050|10120168|FG001|Overall Study|Protocol Violation|0
6351980|NCT03716050|10120169|FG002|Overall Study|Protocol Violation|0
6351981|NCT03716050|10120170|FG003|Overall Study|Protocol Violation|1
6351982|NCT03716050|10120171|FG004|Overall Study|Protocol Violation|0
6351983|NCT03716050|10120172|FG005|Overall Study|Protocol Violation|0
6351984|NCT03716050|10120173|FG006|Overall Study|Protocol Violation|0
6351985|NCT03716050|10120174|FG007|Overall Study|Protocol Violation|2
6351986|NCT03717012|10120202|FG000|Overall Study|Due to trial termination|1
6351987|NCT03717012|10120203|FG001|Overall Study|Due to trial termination|2
6351988|NCT03717012|10120202|FG000|Overall Study|Protocol Violation|0
6351989|NCT03717012|10120203|FG001|Overall Study|Protocol Violation|2
6351990|NCT03717012|10120202|FG000|Overall Study|Adverse Event|0
6351991|NCT03717012|10120203|FG001|Overall Study|Adverse Event|1
6351992|NCT03717012|10120202|FG000|Overall Study|Lung transplant|0
6351993|NCT03717012|10120203|FG001|Overall Study|Lung transplant|1
6351994|NCT03717064|10120218|FG000|Period 2|Adverse Event|1
6351995|NCT03718000|10120241|FG000|Overall Study|Relocation|2
6351996|NCT03718000|10120242|FG001|Overall Study|Relocation|4
6351997|NCT03718000|10120241|FG000|Overall Study|Pregnancy|0
6351998|NCT03718000|10120242|FG001|Overall Study|Pregnancy|1
6351999|NCT03719586|10120276|FG000|Overall Study|"not completed simply refers to pts who could not be contemporaneously compared to the ZMapp arm"|8
6352000|NCT03719586|10120277|FG001|Overall Study|"not completed simply refers to pts who could not be contemporaneously compared to the ZMapp arm"|7
6352001|NCT03719586|10120278|FG002|Overall Study|"not completed simply refers to pts who could not be contemporaneously compared to the ZMapp arm"|4
6352002|NCT03719586|10120279|FG003|Overall Study|"not completed simply refers to pts who could not be contemporaneously compared to the ZMapp arm"|0
6352003|NCT03720470|10120313|FG000|Treatment Period: First Part 16 Weeks|Adverse Event|5
6352004|NCT03720470|10120314|FG001|Treatment Period: First Part 16 Weeks|Adverse Event|0
6352005|NCT03720470|10120315|FG002|Treatment Period: First Part 16 Weeks|Adverse Event|0
6352006|NCT03720470|10120316|FG003|Treatment Period: First Part 16 Weeks|Adverse Event|5
6352007|NCT03720470|10120317|FG004|Treatment Period: First Part 16 Weeks|Adverse Event|8
6352008|NCT03720470|10120318|FG005|Treatment Period: First Part 16 Weeks|Adverse Event|6
6352009|NCT03720470|10120313|FG000|Treatment Period: First Part 16 Weeks|Lack of Efficacy|0
6352010|NCT03720470|10120314|FG001|Treatment Period: First Part 16 Weeks|Lack of Efficacy|0
6352011|NCT03720470|10120315|FG002|Treatment Period: First Part 16 Weeks|Lack of Efficacy|0
6352012|NCT03720470|10120316|FG003|Treatment Period: First Part 16 Weeks|Lack of Efficacy|1
6352013|NCT03720470|10120317|FG004|Treatment Period: First Part 16 Weeks|Lack of Efficacy|0
6352014|NCT03720470|10120318|FG005|Treatment Period: First Part 16 Weeks|Lack of Efficacy|1
6352015|NCT03720470|10120313|FG000|Treatment Period: First Part 16 Weeks|Lost to Follow-up|1
6352016|NCT03720470|10120314|FG001|Treatment Period: First Part 16 Weeks|Lost to Follow-up|0
6352017|NCT03720470|10120315|FG002|Treatment Period: First Part 16 Weeks|Lost to Follow-up|0
6352018|NCT03720470|10120316|FG003|Treatment Period: First Part 16 Weeks|Lost to Follow-up|2
6352019|NCT03720470|10120317|FG004|Treatment Period: First Part 16 Weeks|Lost to Follow-up|1
6352020|NCT03720470|10120318|FG005|Treatment Period: First Part 16 Weeks|Lost to Follow-up|2
6352021|NCT03720470|10120313|FG000|Treatment Period: First Part 16 Weeks|Pregnancy|0
6352022|NCT03720470|10120314|FG001|Treatment Period: First Part 16 Weeks|Pregnancy|0
6352023|NCT03720470|10120315|FG002|Treatment Period: First Part 16 Weeks|Pregnancy|0
6352024|NCT03720470|10120316|FG003|Treatment Period: First Part 16 Weeks|Pregnancy|0
6352025|NCT03720470|10120317|FG004|Treatment Period: First Part 16 Weeks|Pregnancy|1
6352026|NCT03720470|10120318|FG005|Treatment Period: First Part 16 Weeks|Pregnancy|1
6352027|NCT03720470|10120313|FG000|Treatment Period: First Part 16 Weeks|Protocol deviation|2
6352028|NCT03720470|10120314|FG001|Treatment Period: First Part 16 Weeks|Protocol deviation|0
6352029|NCT03720470|10120315|FG002|Treatment Period: First Part 16 Weeks|Protocol deviation|0
6352030|NCT03720470|10120316|FG003|Treatment Period: First Part 16 Weeks|Protocol deviation|2
6352031|NCT03720470|10120317|FG004|Treatment Period: First Part 16 Weeks|Protocol deviation|2
6352032|NCT03720470|10120318|FG005|Treatment Period: First Part 16 Weeks|Protocol deviation|1
6352033|NCT03720470|10120313|FG000|Treatment Period: First Part 16 Weeks|Withdrawal by Subject|5
6352034|NCT03720470|10120314|FG001|Treatment Period: First Part 16 Weeks|Withdrawal by Subject|0
6352035|NCT03720470|10120315|FG002|Treatment Period: First Part 16 Weeks|Withdrawal by Subject|0
6352036|NCT03720470|10120316|FG003|Treatment Period: First Part 16 Weeks|Withdrawal by Subject|9
6352037|NCT03720470|10120317|FG004|Treatment Period: First Part 16 Weeks|Withdrawal by Subject|3
6352038|NCT03720470|10120318|FG005|Treatment Period: First Part 16 Weeks|Withdrawal by Subject|6
6352039|NCT03720470|10120313|FG000|Treatment Period: First Part 16 Weeks|Medication Error Without Associated Adverse Event|0
6352040|NCT03720470|10120314|FG001|Treatment Period: First Part 16 Weeks|Medication Error Without Associated Adverse Event|0
6352041|NCT03720470|10120315|FG002|Treatment Period: First Part 16 Weeks|Medication Error Without Associated Adverse Event|0
6352042|NCT03720470|10120316|FG003|Treatment Period: First Part 16 Weeks|Medication Error Without Associated Adverse Event|1
6352043|NCT03720470|10120317|FG004|Treatment Period: First Part 16 Weeks|Medication Error Without Associated Adverse Event|1
6352044|NCT03720470|10120318|FG005|Treatment Period: First Part 16 Weeks|Medication Error Without Associated Adverse Event|0
6352045|NCT03720470|10120313|FG000|Treatment Period: First Part 16 Weeks|Other|1
6352046|NCT03720470|10120314|FG001|Treatment Period: First Part 16 Weeks|Other|0
6352047|NCT03720470|10120315|FG002|Treatment Period: First Part 16 Weeks|Other|0
6352048|NCT03720470|10120316|FG003|Treatment Period: First Part 16 Weeks|Other|1
6352049|NCT03720470|10120317|FG004|Treatment Period: First Part 16 Weeks|Other|2
6352050|NCT03720470|10120318|FG005|Treatment Period: First Part 16 Weeks|Other|2
6352051|NCT03720470|10120313|FG000|Treatment Period: First Part 16 Weeks|Randomized But Not Treated|0
6352052|NCT03720470|10120314|FG001|Treatment Period: First Part 16 Weeks|Randomized But Not Treated|0
6352053|NCT03720470|10120315|FG002|Treatment Period: First Part 16 Weeks|Randomized But Not Treated|0
6352054|NCT03720470|10120316|FG003|Treatment Period: First Part 16 Weeks|Randomized But Not Treated|0
6352055|NCT03720470|10120317|FG004|Treatment Period: First Part 16 Weeks|Randomized But Not Treated|0
6352056|NCT03720470|10120318|FG005|Treatment Period: First Part 16 Weeks|Randomized But Not Treated|1
6352057|NCT03720470|10120313|FG000|Treatment Period: Final 4 Weeks|Adverse Event|0
6352058|NCT03720470|10120314|FG001|Treatment Period: Final 4 Weeks|Adverse Event|0
6352059|NCT03720470|10120315|FG002|Treatment Period: Final 4 Weeks|Adverse Event|0
6352060|NCT03720470|10120316|FG003|Treatment Period: Final 4 Weeks|Adverse Event|2
6352061|NCT03720470|10120317|FG004|Treatment Period: Final 4 Weeks|Adverse Event|1
6352062|NCT03720470|10120318|FG005|Treatment Period: Final 4 Weeks|Adverse Event|1
6352063|NCT03720470|10120313|FG000|Treatment Period: Final 4 Weeks|Lack of Efficacy|0
6352064|NCT03720470|10120314|FG001|Treatment Period: Final 4 Weeks|Lack of Efficacy|0
6352065|NCT03720470|10120315|FG002|Treatment Period: Final 4 Weeks|Lack of Efficacy|1
6352066|NCT03720470|10120316|FG003|Treatment Period: Final 4 Weeks|Lack of Efficacy|0
6352067|NCT03720470|10120317|FG004|Treatment Period: Final 4 Weeks|Lack of Efficacy|0
6352068|NCT03720470|10120318|FG005|Treatment Period: Final 4 Weeks|Lack of Efficacy|0
6352069|NCT03720470|10120313|FG000|Treatment Period: Final 4 Weeks|Lost to Follow-up|0
6352070|NCT03720470|10120314|FG001|Treatment Period: Final 4 Weeks|Lost to Follow-up|0
6352071|NCT03720470|10120315|FG002|Treatment Period: Final 4 Weeks|Lost to Follow-up|0
6352072|NCT03720470|10120316|FG003|Treatment Period: Final 4 Weeks|Lost to Follow-up|1
6352073|NCT03720470|10120317|FG004|Treatment Period: Final 4 Weeks|Lost to Follow-up|0
6352074|NCT03720470|10120318|FG005|Treatment Period: Final 4 Weeks|Lost to Follow-up|1
6352075|NCT03720470|10120313|FG000|Treatment Period: Final 4 Weeks|Pregnancy|0
6352076|NCT03720470|10120314|FG001|Treatment Period: Final 4 Weeks|Pregnancy|0
6352077|NCT03720470|10120315|FG002|Treatment Period: Final 4 Weeks|Pregnancy|0
6352078|NCT03720470|10120316|FG003|Treatment Period: Final 4 Weeks|Pregnancy|0
6352079|NCT03720470|10120317|FG004|Treatment Period: Final 4 Weeks|Pregnancy|0
6352080|NCT03720470|10120318|FG005|Treatment Period: Final 4 Weeks|Pregnancy|1
6352081|NCT03720470|10120313|FG000|Treatment Period: Final 4 Weeks|Protocol Deviation|0
6352082|NCT03720470|10120314|FG001|Treatment Period: Final 4 Weeks|Protocol Deviation|0
6352083|NCT03720470|10120315|FG002|Treatment Period: Final 4 Weeks|Protocol Deviation|1
6352084|NCT03720470|10120316|FG003|Treatment Period: Final 4 Weeks|Protocol Deviation|0
6352085|NCT03720470|10120317|FG004|Treatment Period: Final 4 Weeks|Protocol Deviation|0
6352086|NCT03720470|10120318|FG005|Treatment Period: Final 4 Weeks|Protocol Deviation|0
6352087|NCT03720470|10120313|FG000|Treatment Period: Final 4 Weeks|Withdrawal by Subject|0
6352088|NCT03720470|10120314|FG001|Treatment Period: Final 4 Weeks|Withdrawal by Subject|1
6352089|NCT03720470|10120315|FG002|Treatment Period: Final 4 Weeks|Withdrawal by Subject|0
6352090|NCT03720470|10120316|FG003|Treatment Period: Final 4 Weeks|Withdrawal by Subject|2
6352091|NCT03720470|10120317|FG004|Treatment Period: Final 4 Weeks|Withdrawal by Subject|2
6352092|NCT03720470|10120318|FG005|Treatment Period: Final 4 Weeks|Withdrawal by Subject|2
6352093|NCT03720470|10120313|FG000|Treatment Period: Final 4 Weeks|Other|0
6352094|NCT03720470|10120314|FG001|Treatment Period: Final 4 Weeks|Other|1
6352095|NCT03720470|10120315|FG002|Treatment Period: Final 4 Weeks|Other|0
6352096|NCT03720470|10120316|FG003|Treatment Period: Final 4 Weeks|Other|2
6352097|NCT03720470|10120317|FG004|Treatment Period: Final 4 Weeks|Other|1
6352098|NCT03720470|10120318|FG005|Treatment Period: Final 4 Weeks|Other|0
6352099|NCT03720652|10120340|FG000|Overall Study|Withdrawal by Subject|2
6352100|NCT03720652|10120341|FG001|Overall Study|Withdrawal by Subject|7
6352101|NCT03720652|10120340|FG000|Overall Study|Lost to Follow-up|0
6352102|NCT03720652|10120341|FG001|Overall Study|Lost to Follow-up|4
6352103|NCT03720847|10120349|FG000|Washout|Physician Decision|1
6352104|NCT03720847|10120350|FG001|Washout|Physician Decision|2
6352105|NCT03721172|10120379|FG000|Placebo-controlled Phase|Adverse Event|7
6352106|NCT03721172|10120380|FG001|Placebo-controlled Phase|Adverse Event|7
6352107|NCT03721172|10120381|FG002|Placebo-controlled Phase|Adverse Event|0
6352108|NCT03721172|10120379|FG000|Placebo-controlled Phase|Lack of Efficacy|4
6352109|NCT03721172|10120380|FG001|Placebo-controlled Phase|Lack of Efficacy|0
6352110|NCT03721172|10120381|FG002|Placebo-controlled Phase|Lack of Efficacy|0
6352111|NCT03721172|10120379|FG000|Placebo-controlled Phase|Non-compliance with study drug|0
6352112|NCT03721172|10120380|FG001|Placebo-controlled Phase|Non-compliance with study drug|1
6352113|NCT03721172|10120381|FG002|Placebo-controlled Phase|Non-compliance with study drug|0
6352114|NCT03721172|10120379|FG000|Placebo-controlled Phase|Lost to Follow-up|15
6352115|NCT03721172|10120380|FG001|Placebo-controlled Phase|Lost to Follow-up|13
6352116|NCT03721172|10120381|FG002|Placebo-controlled Phase|Lost to Follow-up|0
6352117|NCT03721172|10120379|FG000|Placebo-controlled Phase|Withdrawal by Subject|23
6352118|NCT03721172|10120380|FG001|Placebo-controlled Phase|Withdrawal by Subject|18
6352119|NCT03721172|10120381|FG002|Placebo-controlled Phase|Withdrawal by Subject|0
6352120|NCT03721172|10120379|FG000|Placebo-controlled Phase|Other|3
6352121|NCT03721172|10120380|FG001|Placebo-controlled Phase|Other|0
6352122|NCT03721172|10120381|FG002|Placebo-controlled Phase|Other|0
6352123|NCT03721172|10120379|FG000|Apremilast Extension Phase|Adverse Event|0
6352124|NCT03721172|10120380|FG001|Apremilast Extension Phase|Adverse Event|0
6352125|NCT03721172|10120381|FG002|Apremilast Extension Phase|Adverse Event|10
6352126|NCT03721172|10120379|FG000|Apremilast Extension Phase|Lack of Efficacy|0
6352127|NCT03721172|10120380|FG001|Apremilast Extension Phase|Lack of Efficacy|0
6352128|NCT03721172|10120381|FG002|Apremilast Extension Phase|Lack of Efficacy|2
6352129|NCT03721172|10120379|FG000|Apremilast Extension Phase|Non-compliance with study drug|0
6352130|NCT03721172|10120380|FG001|Apremilast Extension Phase|Non-compliance with study drug|0
6352131|NCT03721172|10120381|FG002|Apremilast Extension Phase|Non-compliance with study drug|1
6352132|NCT03721172|10120379|FG000|Apremilast Extension Phase|Lost to Follow-up|0
6352133|NCT03721172|10120380|FG001|Apremilast Extension Phase|Lost to Follow-up|0
6352134|NCT03721172|10120381|FG002|Apremilast Extension Phase|Lost to Follow-up|20
6352135|NCT03721172|10120379|FG000|Apremilast Extension Phase|Protocol Violation|0
6352136|NCT03721172|10120380|FG001|Apremilast Extension Phase|Protocol Violation|0
6352137|NCT03721172|10120381|FG002|Apremilast Extension Phase|Protocol Violation|1
6352138|NCT03721172|10120379|FG000|Apremilast Extension Phase|Physician Decision|0
6352139|NCT03721172|10120380|FG001|Apremilast Extension Phase|Physician Decision|0
6352140|NCT03721172|10120381|FG002|Apremilast Extension Phase|Physician Decision|1
6352141|NCT03721172|10120379|FG000|Apremilast Extension Phase|Withdrawal by Subject|0
6352142|NCT03721172|10120380|FG001|Apremilast Extension Phase|Withdrawal by Subject|0
6352143|NCT03721172|10120381|FG002|Apremilast Extension Phase|Withdrawal by Subject|21
6352144|NCT03721172|10120379|FG000|Apremilast Extension Phase|Other|0
6352145|NCT03721172|10120380|FG001|Apremilast Extension Phase|Other|0
6352146|NCT03721172|10120381|FG002|Apremilast Extension Phase|Other|3
6352147|NCT03721172|10120379|FG000|Apremilast Extension Phase|Other (Related to COVID-19)|0
6352148|NCT03721172|10120380|FG001|Apremilast Extension Phase|Other (Related to COVID-19)|0
6352149|NCT03721172|10120381|FG002|Apremilast Extension Phase|Other (Related to COVID-19)|7
6352150|NCT03722030|10120400|FG000|Overall Study|Withdrawal by Subject|1
6352151|NCT03722030|10120401|FG001|Overall Study|Withdrawal by Subject|0
6170238|NCT01251887|9816442|FG000|Overall Study|Scheduling conflict|1
6170239|NCT01251887|9816443|FG001|Overall Study|Scheduling conflict|2
6170240|NCT01251887|9816444|FG002|Overall Study|Scheduling conflict|2
6170241|NCT01251887|9816442|FG000|Overall Study|Physician Decision|0
6170242|NCT01251887|9816443|FG001|Overall Study|Physician Decision|1
6170243|NCT01251887|9816444|FG002|Overall Study|Physician Decision|0
6170244|NCT01251965|9816455|FG000|Overall Study|Participant/physician decision|1
6352152|NCT03722238|10120410|FG000|Overall Study|Protocol Violation|1
6352153|NCT03722238|10120411|FG001|Overall Study|Protocol Violation|0
6352154|NCT03722238|10120410|FG000|Overall Study|Physician Decision|1
6352155|NCT03722238|10120411|FG001|Overall Study|Physician Decision|0
6352156|NCT03722238|10120410|FG000|Overall Study|Death|1
6352157|NCT03722238|10120411|FG001|Overall Study|Death|0
6352158|NCT03722238|10120410|FG000|Overall Study|Lost to Follow-up|6
6352159|NCT03722238|10120411|FG001|Overall Study|Lost to Follow-up|0
6352160|NCT03722238|10120410|FG000|Overall Study|Partial missing data|44
6352161|NCT03722238|10120411|FG001|Overall Study|Partial missing data|1
6352162|NCT03722238|10120410|FG000|Overall Study|Withdrawal by Subject|2
6352163|NCT03722238|10120411|FG001|Overall Study|Withdrawal by Subject|0
6352164|NCT03722238|10120410|FG000|Overall Study|Other|4
6352165|NCT03722238|10120411|FG001|Overall Study|Other|0
6352166|NCT03722238|10120410|FG000|Overall Study|Not returned to sign consent, download electronic diary application or to purchase study medication|2
6352167|NCT03722238|10120411|FG001|Overall Study|Not returned to sign consent, download electronic diary application or to purchase study medication|0
6352168|NCT03722238|10120410|FG000|Overall Study|Did not meet risk classification group criteria|90
6352169|NCT03722238|10120411|FG001|Overall Study|Did not meet risk classification group criteria|0
6352170|NCT03722238|10120410|FG000|Overall Study|Did not sign consent|17
6352171|NCT03722238|10120411|FG001|Overall Study|Did not sign consent|0
6352172|NCT03722238|10120410|FG000|Overall Study|Other eligibility criteria not met pre-consent|22
6352173|NCT03722238|10120411|FG001|Overall Study|Other eligibility criteria not met pre-consent|0
6352174|NCT03722238|10120410|FG000|Overall Study|Not willing to purchase study medication|142
6352175|NCT03722238|10120411|FG001|Overall Study|Not willing to purchase study medication|0
6352176|NCT03722238|10120410|FG000|Overall Study|Did not qualify at re-screening and medical conditions|133
6352177|NCT03722238|10120411|FG001|Overall Study|Did not qualify at re-screening and medical conditions|0
6352178|NCT03722264|10120417|FG000|Overall Study|Physician Decision|3
6352179|NCT03722446|10120425|FG000|Overall Study|Protocol Violation|15
6352180|NCT03722446|10120426|FG001|Overall Study|Protocol Violation|2
6352181|NCT03722524|10120432|FG000|Overall Study|Protocol Violation|86
6352182|NCT03722524|10120432|FG000|Overall Study|Adverse Event|7
6352183|NCT03722524|10120432|FG000|Overall Study|Lost to Follow-up|1
6352184|NCT03722524|10120432|FG000|Overall Study|Reason is not stated|1
6352185|NCT03722524|10120432|FG000|Overall Study|Physician Decision|1
6352186|NCT03722524|10120432|FG000|Overall Study|Patient's decision (refusal to continue participation)|3
6352187|NCT03722576|10120436|FG000|Overall Study|Withdrawal by Subject|3
6352188|NCT03722576|10120436|FG000|Overall Study|Adverse Event|2
6352189|NCT03722576|10120436|FG000|Overall Study|Physician Decision|1
6352190|NCT03722576|10120436|FG000|Overall Study|Lost to Follow-up|1
6352191|NCT03722784|10120442|FG000|Overall Study|Withdrawal by Subject|1
6352192|NCT03722784|10120443|FG001|Overall Study|Withdrawal by Subject|0
6352193|NCT03722784|10120442|FG000|Overall Study|Physician Decision|1
6352194|NCT03722784|10120443|FG001|Overall Study|Physician Decision|1
6352195|NCT03722784|10120442|FG000|Overall Study|Protocol Violation|0
6352196|NCT03722784|10120443|FG001|Overall Study|Protocol Violation|1
6352197|NCT03723915|10120450|FG000|Screening|Failed to meet screening requirements.|2
6352198|NCT03723915|10120450|FG000|On Treatment|Failed to meet treatment requirements|2
6352199|NCT03724812|10120454|FG000|Overall Study|Missed Visit|1
6083685|NCT00636636|9692206|FG000|Overall Study|Other reason|4
6352200|NCT03724812|10120454|FG000|Overall Study|Death|2
6352201|NCT03724812|10120454|FG000|Overall Study|Withdrawal by Subject|1
6352202|NCT03725982|10120461|FG000|First Intervention|Withdrawal by Subject|0
6352203|NCT03725982|10120462|FG001|First Intervention|Withdrawal by Subject|1
6352204|NCT03725982|10120461|FG000|First Intervention|Physician Decision|1
6352205|NCT03725982|10120462|FG001|First Intervention|Physician Decision|1
6352206|NCT03727841|10120476|FG000|Overall Study|Physician Decision|2
6352207|NCT03727841|10120477|FG001|Overall Study|Physician Decision|1
6352208|NCT03736967|10120487|FG000|Overall Study|Withdrawal by Subject|26
6352209|NCT03736967|10120488|FG001|Overall Study|Withdrawal by Subject|25
6352210|NCT03736967|10120489|FG002|Overall Study|Withdrawal by Subject|23
6352211|NCT03736967|10120490|FG003|Overall Study|Withdrawal by Subject|26
6352212|NCT03736967|10120487|FG000|Overall Study|Lost to Follow-up|3
6352213|NCT03736967|10120488|FG001|Overall Study|Lost to Follow-up|2
6352214|NCT03736967|10120489|FG002|Overall Study|Lost to Follow-up|1
6352215|NCT03736967|10120490|FG003|Overall Study|Lost to Follow-up|1
6352216|NCT03736967|10120487|FG000|Overall Study|Physician Decision|1
6352217|NCT03736967|10120488|FG001|Overall Study|Physician Decision|0
6352218|NCT03736967|10120489|FG002|Overall Study|Physician Decision|0
6352219|NCT03736967|10120490|FG003|Overall Study|Physician Decision|1
6352220|NCT03736967|10120487|FG000|Overall Study|Adverse Event|0
6083686|NCT00636636|9692207|FG001|Overall Study|Other reason|6
6352221|NCT03736967|10120488|FG001|Overall Study|Adverse Event|1
6352222|NCT03736967|10120489|FG002|Overall Study|Adverse Event|0
6352223|NCT03736967|10120490|FG003|Overall Study|Adverse Event|1
6352224|NCT03736967|10120487|FG000|Overall Study|Death|0
6352225|NCT03736967|10120488|FG001|Overall Study|Death|0
6352226|NCT03736967|10120489|FG002|Overall Study|Death|0
6352227|NCT03736967|10120490|FG003|Overall Study|Death|1
6352228|NCT03736967|10120487|FG000|Overall Study|Randomized but never treated|1
6352229|NCT03736967|10120488|FG001|Overall Study|Randomized but never treated|0
6083687|NCT00636636|9692206|FG000|Overall Study|Adverse Event|19
6352230|NCT03736967|10120489|FG002|Overall Study|Randomized but never treated|0
6352231|NCT03736967|10120490|FG003|Overall Study|Randomized but never treated|0
6352232|NCT03739840|10120507|FG000|Treatment Period: Wk0-16|Adverse Event|2
6352233|NCT03739840|10120508|FG001|Treatment Period: Wk0-16|Adverse Event|6
6352234|NCT03739840|10120509|FG002|Treatment Period: Wk0-16|Adverse Event|6
6352235|NCT03739840|10120510|FG003|Treatment Period: Wk0-16|Adverse Event|12
6352236|NCT03739840|10120507|FG000|Treatment Period: Wk0-16|Lack of Efficacy|0
6352237|NCT03739840|10120508|FG001|Treatment Period: Wk0-16|Lack of Efficacy|1
6352238|NCT03739840|10120509|FG002|Treatment Period: Wk0-16|Lack of Efficacy|0
6352239|NCT03739840|10120510|FG003|Treatment Period: Wk0-16|Lack of Efficacy|3
6352240|NCT03739840|10120507|FG000|Treatment Period: Wk0-16|Protocol Violation|0
6352241|NCT03739840|10120508|FG001|Treatment Period: Wk0-16|Protocol Violation|0
6352242|NCT03739840|10120509|FG002|Treatment Period: Wk0-16|Protocol Violation|1
6352243|NCT03739840|10120510|FG003|Treatment Period: Wk0-16|Protocol Violation|0
6352244|NCT03739840|10120507|FG000|Treatment Period: Wk0-16|Consent Withdrawn|1
6352245|NCT03739840|10120508|FG001|Treatment Period: Wk0-16|Consent Withdrawn|3
6352246|NCT03739840|10120509|FG002|Treatment Period: Wk0-16|Consent Withdrawn|1
6352247|NCT03739840|10120510|FG003|Treatment Period: Wk0-16|Consent Withdrawn|1
6352248|NCT03739840|10120507|FG000|Treatment Period: Wk0-16|Program Termination|3
6352249|NCT03739840|10120508|FG001|Treatment Period: Wk0-16|Program Termination|0
6352250|NCT03739840|10120509|FG002|Treatment Period: Wk0-16|Program Termination|1
6352251|NCT03739840|10120510|FG003|Treatment Period: Wk0-16|Program Termination|1
6352252|NCT03739840|10120507|FG000|Treatment Period: Wk0-16|Sponsor Closed Study- Subject Was Discontinued|1
6352253|NCT03739840|10120508|FG001|Treatment Period: Wk0-16|Sponsor Closed Study- Subject Was Discontinued|0
6352254|NCT03739840|10120509|FG002|Treatment Period: Wk0-16|Sponsor Closed Study- Subject Was Discontinued|0
6352255|NCT03739840|10120510|FG003|Treatment Period: Wk0-16|Sponsor Closed Study- Subject Was Discontinued|0
6352256|NCT03739840|10120507|FG000|Treatment Period: Wk0-16|Sponsors Decision|3
6352257|NCT03739840|10120508|FG001|Treatment Period: Wk0-16|Sponsors Decision|2
6352258|NCT03739840|10120509|FG002|Treatment Period: Wk0-16|Sponsors Decision|1
6352259|NCT03739840|10120510|FG003|Treatment Period: Wk0-16|Sponsors Decision|3
6352260|NCT03739840|10120507|FG000|Treatment Period: Wk0-16|Promotor Decision|0
6352261|NCT03739840|10120508|FG001|Treatment Period: Wk0-16|Promotor Decision|1
6352262|NCT03739840|10120509|FG002|Treatment Period: Wk0-16|Promotor Decision|0
6352263|NCT03739840|10120510|FG003|Treatment Period: Wk0-16|Promotor Decision|0
6352264|NCT03739840|10120507|FG000|Treatment Period: Wk0-16|Per Sponsor Study Closed|0
6352265|NCT03739840|10120508|FG001|Treatment Period: Wk0-16|Per Sponsor Study Closed|1
6352266|NCT03739840|10120509|FG002|Treatment Period: Wk0-16|Per Sponsor Study Closed|0
6352267|NCT03739840|10120510|FG003|Treatment Period: Wk0-16|Per Sponsor Study Closed|0
6352268|NCT03739840|10120507|FG000|Treatment Period: Wk0-16|Premature Program Termination|0
6352269|NCT03739840|10120508|FG001|Treatment Period: Wk0-16|Premature Program Termination|1
6352270|NCT03739840|10120509|FG002|Treatment Period: Wk0-16|Premature Program Termination|0
6352271|NCT03739840|10120510|FG003|Treatment Period: Wk0-16|Premature Program Termination|0
6352272|NCT03739840|10120507|FG000|Treatment Period: Wk0-16|Trial Closed By Sponsor|0
6352273|NCT03739840|10120508|FG001|Treatment Period: Wk0-16|Trial Closed By Sponsor|1
6352274|NCT03739840|10120509|FG002|Treatment Period: Wk0-16|Trial Closed By Sponsor|0
6352275|NCT03739840|10120510|FG003|Treatment Period: Wk0-16|Trial Closed By Sponsor|0
6352276|NCT03739840|10120507|FG000|Treatment Period: Wk0-16|Study Early Closure|0
6352277|NCT03739840|10120508|FG001|Treatment Period: Wk0-16|Study Early Closure|0
6352278|NCT03739840|10120509|FG002|Treatment Period: Wk0-16|Study Early Closure|1
6352279|NCT03739840|10120510|FG003|Treatment Period: Wk0-16|Study Early Closure|0
6352280|NCT03739840|10120507|FG000|Treatment Period: Wk0-16|Premature Study Termination By Sponsor|0
6352281|NCT03739840|10120508|FG001|Treatment Period: Wk0-16|Premature Study Termination By Sponsor|0
6352282|NCT03739840|10120509|FG002|Treatment Period: Wk0-16|Premature Study Termination By Sponsor|1
6352283|NCT03739840|10120510|FG003|Treatment Period: Wk0-16|Premature Study Termination By Sponsor|0
6352284|NCT03739840|10120507|FG000|Treatment Period: Wk0-16|Premature Closure Of The Study|0
6352285|NCT03739840|10120508|FG001|Treatment Period: Wk0-16|Premature Closure Of The Study|0
6352286|NCT03739840|10120509|FG002|Treatment Period: Wk0-16|Premature Closure Of The Study|1
6352287|NCT03739840|10120510|FG003|Treatment Period: Wk0-16|Premature Closure Of The Study|0
6352288|NCT03739840|10120507|FG000|Treatment Period: Wk0-16|Study Has Been Cancelled By The Sponsor|0
6352289|NCT03739840|10120508|FG001|Treatment Period: Wk0-16|Study Has Been Cancelled By The Sponsor|0
6352290|NCT03739840|10120509|FG002|Treatment Period: Wk0-16|Study Has Been Cancelled By The Sponsor|0
6352291|NCT03739840|10120510|FG003|Treatment Period: Wk0-16|Study Has Been Cancelled By The Sponsor|1
6352292|NCT03739840|10120507|FG000|Treatment Period: Wk0-16|Due To Sponsor Instruction|0
6352293|NCT03739840|10120508|FG001|Treatment Period: Wk0-16|Due To Sponsor Instruction|0
6352294|NCT03739840|10120509|FG002|Treatment Period: Wk0-16|Due To Sponsor Instruction|0
6352295|NCT03739840|10120510|FG003|Treatment Period: Wk0-16|Due To Sponsor Instruction|1
6352296|NCT03739840|10120507|FG000|Treatment Period: Wk0-16|Trial Was Closed By Sponsor|0
6352297|NCT03739840|10120508|FG001|Treatment Period: Wk0-16|Trial Was Closed By Sponsor|0
6352298|NCT03739840|10120509|FG002|Treatment Period: Wk0-16|Trial Was Closed By Sponsor|0
6352299|NCT03739840|10120510|FG003|Treatment Period: Wk0-16|Trial Was Closed By Sponsor|1
6352300|NCT03739840|10120507|FG000|Post-Treatment Period: Wk16-23|Adverse Event|3
6352301|NCT03739840|10120508|FG001|Post-Treatment Period: Wk16-23|Adverse Event|0
6352302|NCT03739840|10120509|FG002|Post-Treatment Period: Wk16-23|Adverse Event|0
6352303|NCT03739840|10120510|FG003|Post-Treatment Period: Wk16-23|Adverse Event|0
6352304|NCT03739840|10120507|FG000|Post-Treatment Period: Wk16-23|Consent Withdrawn|0
6352305|NCT03739840|10120508|FG001|Post-Treatment Period: Wk16-23|Consent Withdrawn|0
6352306|NCT03739840|10120509|FG002|Post-Treatment Period: Wk16-23|Consent Withdrawn|0
6352307|NCT03739840|10120510|FG003|Post-Treatment Period: Wk16-23|Consent Withdrawn|1
6352308|NCT03739840|10120507|FG000|Post-Treatment Period: Wk16-23|Sponsor Decision To Terminate The Study|1
6352309|NCT03739840|10120508|FG001|Post-Treatment Period: Wk16-23|Sponsor Decision To Terminate The Study|0
6352310|NCT03739840|10120509|FG002|Post-Treatment Period: Wk16-23|Sponsor Decision To Terminate The Study|0
6352311|NCT03739840|10120510|FG003|Post-Treatment Period: Wk16-23|Sponsor Decision To Terminate The Study|0
6352312|NCT03739840|10120507|FG000|Post-Treatment Period: Wk16-23|Sponsor's Decision|0
6352313|NCT03739840|10120508|FG001|Post-Treatment Period: Wk16-23|Sponsor's Decision|1
6352314|NCT03739840|10120509|FG002|Post-Treatment Period: Wk16-23|Sponsor's Decision|0
5972112|NCT00489307|9557728|FG001|Overall Study|Death|1
5972113|NCT00489307|9557727|FG000|Overall Study|Lost to Follow-up|2
6083688|NCT00636636|9692207|FG001|Overall Study|Adverse Event|8
6083689|NCT00636636|9692206|FG000|Overall Study|Lack of Efficacy|7
5972114|NCT00489307|9557728|FG001|Overall Study|Lost to Follow-up|2
5972115|NCT00489307|9557727|FG000|Overall Study|Physician Decision|1
5972116|NCT00489307|9557728|FG001|Overall Study|Physician Decision|0
5972117|NCT00489307|9557727|FG000|Overall Study|Withdrawal by Subject|2
5972118|NCT00489307|9557728|FG001|Overall Study|Withdrawal by Subject|4
5972119|NCT00489307|9557727|FG000|Overall Study|Hospitalization unrelated to treatment|10
5972120|NCT00489307|9557728|FG001|Overall Study|Hospitalization unrelated to treatment|7
5972121|NCT00489307|9557727|FG000|Overall Study|Surgery after assignment|1
5972122|NCT00489307|9557728|FG001|Overall Study|Surgery after assignment|0
5972123|NCT00489307|9557727|FG000|Overall Study|Did not fill up the forms|2
5972124|NCT00489307|9557728|FG001|Overall Study|Did not fill up the forms|1
5972125|NCT00489307|9557727|FG000|Overall Study|Patient or family refusal|5
5972126|NCT00489307|9557728|FG001|Overall Study|Patient or family refusal|9
5972127|NCT00072410|9557736|FG000|Overall Study|Progressive disease|0
5972128|NCT00072410|9557737|FG001|Overall Study|Progressive disease|3
5972217|NCT04409262|9557954|FG001|Overall Study|Death|97
5972218|NCT04409262|9557953|FG000|Overall Study|Lost to Follow-up|12
5972219|NCT04409262|9557954|FG001|Overall Study|Lost to Follow-up|23
5972220|NCT04409262|9557953|FG000|Overall Study|Lack of Staff|0
5972221|NCT04409262|9557954|FG001|Overall Study|Lack of Staff|1
5972222|NCT04409262|9557953|FG000|Overall Study|Protocol Violation|3
5972223|NCT04409262|9557954|FG001|Overall Study|Protocol Violation|1
5972224|NCT04409262|9557953|FG000|Overall Study|Withdrawal by Subject|5
5972225|NCT04409262|9557954|FG001|Overall Study|Withdrawal by Subject|10
5972226|NCT04305912|9557963|FG000|First Intervention|COVID-19 Suspension|2
5972227|NCT04305912|9557964|FG001|First Intervention|COVID-19 Suspension|0
5972228|NCT04305912|9557963|FG000|First Intervention|Withdrawal by Subject|0
5972229|NCT04305912|9557964|FG001|First Intervention|Withdrawal by Subject|1
5972230|NCT04305912|9557963|FG000|Second Intervention|Adverse Event|0
5972231|NCT04305912|9557964|FG001|Second Intervention|Adverse Event|1
5972287|NCT03730662|9558035|FG000|Treatment Period (52 Weeks)|Lost to Follow-up|4
5972288|NCT03730662|9558036|FG001|Treatment Period (52 Weeks)|Lost to Follow-up|2
5972289|NCT03730662|9558037|FG002|Treatment Period (52 Weeks)|Lost to Follow-up|2
5972290|NCT03730662|9558038|FG003|Treatment Period (52 Weeks)|Lost to Follow-up|11
5972291|NCT03730662|9558035|FG000|Treatment Period (52 Weeks)|Physician Decision|1
5972292|NCT03730662|9558036|FG001|Treatment Period (52 Weeks)|Physician Decision|1
5972293|NCT03730662|9558037|FG002|Treatment Period (52 Weeks)|Physician Decision|0
5972294|NCT03730662|9558038|FG003|Treatment Period (52 Weeks)|Physician Decision|3
5972295|NCT03730662|9558035|FG000|Treatment Period (52 Weeks)|Protocol Violation|0
5972296|NCT03730662|9558036|FG001|Treatment Period (52 Weeks)|Protocol Violation|1
5972297|NCT03730662|9558037|FG002|Treatment Period (52 Weeks)|Protocol Violation|0
6352315|NCT03739840|10120510|FG003|Post-Treatment Period: Wk16-23|Sponsor's Decision|0
6352316|NCT03739840|10120507|FG000|Post-Treatment Period: Wk16-23|Sponsor Closed Study- Subject Was Discontinued|0
6352317|NCT03739840|10120508|FG001|Post-Treatment Period: Wk16-23|Sponsor Closed Study- Subject Was Discontinued|1
6352318|NCT03739840|10120509|FG002|Post-Treatment Period: Wk16-23|Sponsor Closed Study- Subject Was Discontinued|0
6352319|NCT03739840|10120510|FG003|Post-Treatment Period: Wk16-23|Sponsor Closed Study- Subject Was Discontinued|0
6352320|NCT03739840|10120507|FG000|Post-Treatment Period: Wk16-23|Sponsor Decision + Subject Refusal|0
6352321|NCT03739840|10120508|FG001|Post-Treatment Period: Wk16-23|Sponsor Decision + Subject Refusal|0
6352322|NCT03739840|10120509|FG002|Post-Treatment Period: Wk16-23|Sponsor Decision + Subject Refusal|1
6352323|NCT03739840|10120510|FG003|Post-Treatment Period: Wk16-23|Sponsor Decision + Subject Refusal|0
6352324|NCT03739840|10120507|FG000|Post-Treatment Period: Wk16-23|Early Study Closure|0
6352325|NCT03739840|10120508|FG001|Post-Treatment Period: Wk16-23|Early Study Closure|0
6352326|NCT03739840|10120509|FG002|Post-Treatment Period: Wk16-23|Early Study Closure|1
6352327|NCT03739840|10120510|FG003|Post-Treatment Period: Wk16-23|Early Study Closure|0
6352328|NCT03739840|10120507|FG000|Post-Treatment Period: Wk16-23|Trial Closed By Sponsor Decision|0
6352329|NCT03739840|10120508|FG001|Post-Treatment Period: Wk16-23|Trial Closed By Sponsor Decision|0
6352330|NCT03739840|10120509|FG002|Post-Treatment Period: Wk16-23|Trial Closed By Sponsor Decision|1
6352331|NCT03739840|10120510|FG003|Post-Treatment Period: Wk16-23|Trial Closed By Sponsor Decision|0
6352332|NCT03753763|10120569|FG000|Overall Study|Adverse Event|2
6352333|NCT03753763|10120570|FG001|Overall Study|Adverse Event|0
6352334|NCT03753763|10120569|FG000|Overall Study|Withdrawal by Subject|3
6352335|NCT03753763|10120570|FG001|Overall Study|Withdrawal by Subject|1
6352336|NCT03753763|10120569|FG000|Overall Study|clinical deterioration|1
6352337|NCT03753763|10120570|FG001|Overall Study|clinical deterioration|0
6352338|NCT03756571|10120578|FG000|Overall Study|Lost to Follow-up|1
6352339|NCT03756571|10120579|FG001|Overall Study|Lost to Follow-up|1
6352340|NCT03763877|10120606|FG000|Overall Study|Withdrawal by Subject|3
6352341|NCT03763877|10120607|FG001|Overall Study|Withdrawal by Subject|1
6352342|NCT03763877|10120608|FG002|Overall Study|Withdrawal by Subject|3
6352343|NCT03763877|10120609|FG003|Overall Study|Withdrawal by Subject|4
6352344|NCT03763877|10120606|FG000|Overall Study|Adverse Event|1
6352345|NCT03763877|10120607|FG001|Overall Study|Adverse Event|1
6352346|NCT03763877|10120608|FG002|Overall Study|Adverse Event|3
6352347|NCT03763877|10120609|FG003|Overall Study|Adverse Event|1
6352348|NCT03763877|10120606|FG000|Overall Study|Protocol Violation|1
6352349|NCT03763877|10120607|FG001|Overall Study|Protocol Violation|1
6352350|NCT03763877|10120608|FG002|Overall Study|Protocol Violation|0
6352351|NCT03763877|10120609|FG003|Overall Study|Protocol Violation|0
6352352|NCT03763877|10120606|FG000|Overall Study|Lost to Follow-up|0
6352353|NCT03763877|10120607|FG001|Overall Study|Lost to Follow-up|1
6352354|NCT03763877|10120608|FG002|Overall Study|Lost to Follow-up|1
6352355|NCT03763877|10120609|FG003|Overall Study|Lost to Follow-up|0
6352356|NCT03772587|10120632|FG000|Overall Study|COVID-19|0
6352357|NCT03772587|10120633|FG001|Overall Study|COVID-19|0
6352358|NCT03772587|10120634|FG002|Overall Study|COVID-19|1
6352359|NCT03772587|10120635|FG003|Overall Study|COVID-19|1
6352360|NCT03772587|10120636|FG004|Overall Study|COVID-19|0
6352361|NCT03772587|10120632|FG000|Overall Study|Withdrawal by Subject|1
6352362|NCT03772587|10120633|FG001|Overall Study|Withdrawal by Subject|0
6352363|NCT03772587|10120634|FG002|Overall Study|Withdrawal by Subject|0
6352364|NCT03772587|10120635|FG003|Overall Study|Withdrawal by Subject|0
6352365|NCT03772587|10120636|FG004|Overall Study|Withdrawal by Subject|0
6352366|NCT03789292|10120660|FG000|Treatment Period I (Week 0 to Week 26)|Adverse Event|7
6352367|NCT03789292|10120661|FG001|Treatment Period I (Week 0 to Week 26)|Adverse Event|8
6352368|NCT03789292|10120662|FG002|Treatment Period I (Week 0 to Week 26)|Adverse Event|0
6352369|NCT03789292|10120660|FG000|Treatment Period I (Week 0 to Week 26)|Lost to Follow-up|2
6352370|NCT03789292|10120661|FG001|Treatment Period I (Week 0 to Week 26)|Lost to Follow-up|0
6352371|NCT03789292|10120662|FG002|Treatment Period I (Week 0 to Week 26)|Lost to Follow-up|0
6352372|NCT03789292|10120660|FG000|Treatment Period I (Week 0 to Week 26)|Physician Decision|1
6352373|NCT03789292|10120661|FG001|Treatment Period I (Week 0 to Week 26)|Physician Decision|0
6352374|NCT03789292|10120662|FG002|Treatment Period I (Week 0 to Week 26)|Physician Decision|0
6352375|NCT03789292|10120660|FG000|Treatment Period I (Week 0 to Week 26)|Protocol Violation|1
6352376|NCT03789292|10120661|FG001|Treatment Period I (Week 0 to Week 26)|Protocol Violation|1
6352377|NCT03789292|10120662|FG002|Treatment Period I (Week 0 to Week 26)|Protocol Violation|0
6352378|NCT03789292|10120660|FG000|Treatment Period I (Week 0 to Week 26)|Withdrawal by Subject|9
6352379|NCT03789292|10120661|FG001|Treatment Period I (Week 0 to Week 26)|Withdrawal by Subject|8
6352380|NCT03789292|10120662|FG002|Treatment Period I (Week 0 to Week 26)|Withdrawal by Subject|0
6352381|NCT03789292|10120660|FG000|Treatment Period I (Week 0 to Week 26)|Significant dose delay|1
6352382|NCT03789292|10120661|FG001|Treatment Period I (Week 0 to Week 26)|Significant dose delay|0
6352383|NCT03789292|10120662|FG002|Treatment Period I (Week 0 to Week 26)|Significant dose delay|0
6352384|NCT03789292|10120660|FG000|Treatment Period I (Week 0 to Week 26)|Patient decision|0
6352385|NCT03789292|10120661|FG001|Treatment Period I (Week 0 to Week 26)|Patient decision|2
6352386|NCT03789292|10120662|FG002|Treatment Period I (Week 0 to Week 26)|Patient decision|0
6352387|NCT03789292|10120660|FG000|Treatment Period II (Week 26 to Week 52)|Adverse Event|3
6352388|NCT03789292|10120661|FG001|Treatment Period II (Week 26 to Week 52)|Adverse Event|3
6352389|NCT03789292|10120662|FG002|Treatment Period II (Week 26 to Week 52)|Adverse Event|6
6352390|NCT03789292|10120660|FG000|Treatment Period II (Week 26 to Week 52)|Lost to Follow-up|0
6352391|NCT03789292|10120661|FG001|Treatment Period II (Week 26 to Week 52)|Lost to Follow-up|0
6352392|NCT03789292|10120662|FG002|Treatment Period II (Week 26 to Week 52)|Lost to Follow-up|1
6352393|NCT03789292|10120660|FG000|Treatment Period II (Week 26 to Week 52)|Physician Decision|1
6352394|NCT03789292|10120661|FG001|Treatment Period II (Week 26 to Week 52)|Physician Decision|0
6352395|NCT03789292|10120662|FG002|Treatment Period II (Week 26 to Week 52)|Physician Decision|0
6352396|NCT03789292|10120660|FG000|Treatment Period II (Week 26 to Week 52)|Withdrawal by Subject|9
6352397|NCT03789292|10120661|FG001|Treatment Period II (Week 26 to Week 52)|Withdrawal by Subject|2
6352398|NCT03789292|10120662|FG002|Treatment Period II (Week 26 to Week 52)|Withdrawal by Subject|2
6352399|NCT03789292|10120660|FG000|Treatment Period II (Week 26 to Week 52)|Significant dose delay|1
6352400|NCT03789292|10120661|FG001|Treatment Period II (Week 26 to Week 52)|Significant dose delay|0
6352401|NCT03789292|10120662|FG002|Treatment Period II (Week 26 to Week 52)|Significant dose delay|0
6352402|NCT03789292|10120660|FG000|Treatment Period II (Week 26 to Week 52)|Could not visit the site due to COVID-19 pandemic|2
6352403|NCT03789292|10120661|FG001|Treatment Period II (Week 26 to Week 52)|Could not visit the site due to COVID-19 pandemic|1
6352404|NCT03789292|10120662|FG002|Treatment Period II (Week 26 to Week 52)|Could not visit the site due to COVID-19 pandemic|0
6352405|NCT03805438|10120689|FG000|Overall Study|Lack of Efficacy|1
6352406|NCT03805438|10120689|FG000|Overall Study|Protocol Violation|1
6352407|NCT03817528|10120701|FG000|Overall Study|Withdrawal by Subject|1
6352408|NCT03817528|10120701|FG000|Overall Study|Adverse Event|2
6352409|NCT03829228|10120728|FG000|Overall Study|Protocol Violation|1
6352410|NCT03830333|10120747|FG000|Overall Study|Death|0
6352411|NCT03830333|10120748|FG001|Overall Study|Death|1
6352412|NCT03830333|10120747|FG000|Overall Study|Withdrawal by Subject|5
6352413|NCT03830333|10120748|FG001|Overall Study|Withdrawal by Subject|1
6352414|NCT03830333|10120747|FG000|Overall Study|Discontinuations associated with failure to return for follow-up assessments due to COVID-19|3
6352415|NCT03830333|10120748|FG001|Overall Study|Discontinuations associated with failure to return for follow-up assessments due to COVID-19|2
6352416|NCT03831880|10120756|FG000|Period 1 (12 Weeks)|Adverse event, not serious|0
6352417|NCT03831880|10120757|FG001|Period 1 (12 Weeks)|Adverse event, not serious|1
6352418|NCT03831880|10120756|FG000|Period 2 (12 Weeks)|Protocol Deviation|0
6352419|NCT03831880|10120757|FG001|Period 2 (12 Weeks)|Protocol Deviation|1
6352420|NCT03831945|10120767|FG000|Overall Study|Received study agent, never started second Analytical Treatment Interruption (ATI) due to COVID-19|4
6352421|NCT03831945|10120768|FG001|Overall Study|Received study agent, never started second Analytical Treatment Interruption (ATI) due to COVID-19|4
6352422|NCT03831945|10120767|FG000|Overall Study|Received study agent, never started second analytical Treatment Interruption due to unprotected sex|1
6352423|NCT03831945|10120768|FG001|Overall Study|Received study agent, never started second analytical Treatment Interruption due to unprotected sex|1
6352424|NCT03831945|10120767|FG000|Overall Study|Received study agent, second analytical treatment interruption (ATI) ended early due to COVID-19|2
6352425|NCT03831945|10120768|FG001|Overall Study|Received study agent, second analytical treatment interruption (ATI) ended early due to COVID-19|1
6352426|NCT03840174|10120787|FG000|Overall Study|Withdrawal by Subject|1
6352427|NCT03840174|10120788|FG001|Overall Study|Withdrawal by Subject|0
6352428|NCT03840174|10120789|FG002|Overall Study|Withdrawal by Subject|0
6352429|NCT03840174|10120790|FG003|Overall Study|Withdrawal by Subject|0
6352430|NCT03857841|10120819|FG000|Overall Study|Death|1
6352431|NCT03857841|10120820|FG001|Overall Study|Death|0
6352432|NCT03857841|10120821|FG002|Overall Study|Death|0
6352433|NCT03857841|10120822|FG003|Overall Study|Death|0
6352434|NCT03857841|10120819|FG000|Overall Study|Study Terminated by Sponsor|1
6352435|NCT03857841|10120820|FG001|Overall Study|Study Terminated by Sponsor|0
6352436|NCT03857841|10120821|FG002|Overall Study|Study Terminated by Sponsor|0
6352437|NCT03857841|10120822|FG003|Overall Study|Study Terminated by Sponsor|0
6352438|NCT03862625|10120847|FG000|Overall Study|Lost to Follow-up|0
6352439|NCT03862625|10120848|FG001|Overall Study|Lost to Follow-up|1
6352440|NCT03877224|10120876|FG000|Overall Study|Death|3
6352441|NCT03877224|10120877|FG001|Overall Study|Death|2
6352442|NCT03877224|10120876|FG000|Overall Study|Withdrawal by Subject|1
6352443|NCT03877224|10120877|FG001|Overall Study|Withdrawal by Subject|6
6352444|NCT03877224|10120876|FG000|Overall Study|Participant is alive, just unable to come for visits|1
6352445|NCT03877224|10120877|FG001|Overall Study|Participant is alive, just unable to come for visits|0
6352446|NCT03885596|10120896|FG000|Overall Study|Withdrawal by Subject|2
6352447|NCT03885596|10120897|FG001|Overall Study|Withdrawal by Subject|1
6352448|NCT03885596|10120898|FG002|Overall Study|Withdrawal by Subject|0
6352449|NCT03885596|10120899|FG003|Overall Study|Withdrawal by Subject|0
6352450|NCT03885661|10120914|FG000|Overall Study|Withdrawal by Subject|0
6352451|NCT03885661|10120915|FG001|Overall Study|Withdrawal by Subject|1
6352452|NCT03885661|10120914|FG000|Overall Study|Unwilling to undergo required study procedure|1
6352453|NCT03885661|10120915|FG001|Overall Study|Unwilling to undergo required study procedure|0
6352454|NCT03886493|10120921|FG000|Overall Study|Adverse Event|1
6352455|NCT03888235|10120928|FG000|Overall Study|Lost to Follow-up|1
6352456|NCT03888235|10120929|FG001|Overall Study|Lost to Follow-up|1
6352457|NCT03888235|10120930|FG002|Overall Study|Lost to Follow-up|0
6352458|NCT03900416|10121002|FG000|Six Week Follow-up|Lost to Follow-up|1
6352459|NCT03900416|10121003|FG001|Six Week Follow-up|Lost to Follow-up|0
6352460|NCT03900416|10121002|FG000|Six Week Follow-up|Withdrawal by Subject|1
6352461|NCT03900416|10121003|FG001|Six Week Follow-up|Withdrawal by Subject|0
6352462|NCT03900416|10121002|FG000|Twelve Week Follow-up|Lost to Follow-up|0
6352463|NCT03900416|10121003|FG001|Twelve Week Follow-up|Lost to Follow-up|2
6352464|NCT03900416|10121002|FG000|Twelve Week Follow-up|Withdrawal by Subject|0
6352465|NCT03900416|10121003|FG001|Twelve Week Follow-up|Withdrawal by Subject|1
6352466|NCT03900416|10121002|FG000|Twelve Week Follow-up|Adverse Event|1
6352467|NCT03900416|10121003|FG001|Twelve Week Follow-up|Adverse Event|1
6352468|NCT03900416|10121002|FG000|Six Month Follow-up|Lost to Follow-up|4
6352469|NCT03900416|10121003|FG001|Six Month Follow-up|Lost to Follow-up|3
6352470|NCT03900416|10121002|FG000|Six Month Follow-up|Withdrawal by Subject|1
6352471|NCT03900416|10121003|FG001|Six Month Follow-up|Withdrawal by Subject|1
6352472|NCT03905863|10121011|FG000|Overall Study|Adverse Event|2
6352473|NCT03905863|10121012|FG001|Overall Study|Adverse Event|4
6352474|NCT03905863|10121011|FG000|Overall Study|Withdrawal by Subject|2
6352475|NCT03905863|10121012|FG001|Overall Study|Withdrawal by Subject|2
6352476|NCT03905863|10121011|FG000|Overall Study|Physician Decision|0
6352477|NCT03905863|10121012|FG001|Overall Study|Physician Decision|3
6352478|NCT03905863|10121011|FG000|Overall Study|Lost to Follow-up|1
6352479|NCT03905863|10121012|FG001|Overall Study|Lost to Follow-up|0
6352480|NCT03905863|10121011|FG000|Overall Study|Protocol Violation|0
6352481|NCT03905863|10121012|FG001|Overall Study|Protocol Violation|2
6352482|NCT03905863|10121011|FG000|Overall Study|Death|0
6352483|NCT03905863|10121012|FG001|Overall Study|Death|1
6352484|NCT03909971|10121029|FG000|Overall Study|Other Reasons Not Specified|0
6352485|NCT03909971|10121030|FG001|Overall Study|Other Reasons Not Specified|1
6352486|NCT03909971|10121029|FG000|Overall Study|Global Deterioration of Health Status|2
6352487|NCT03909971|10121030|FG001|Overall Study|Global Deterioration of Health Status|1
6352488|NCT03909971|10121029|FG000|Overall Study|Progressive Disease|6
6352489|NCT03909971|10121030|FG001|Overall Study|Progressive Disease|14
6352490|NCT03909971|10121029|FG000|Overall Study|Death|2
6352491|NCT03909971|10121030|FG001|Overall Study|Death|6
6352492|NCT03920215|10121041|FG000|Overall Study|Lost to Follow-up|1
6352493|NCT03920215|10121042|FG001|Overall Study|Lost to Follow-up|2
6352494|NCT03920215|10121043|FG002|Overall Study|Lost to Follow-up|0
6352495|NCT03920215|10121044|FG003|Overall Study|Lost to Follow-up|0
6352496|NCT03920215|10121041|FG000|Overall Study|Death|0
6352497|NCT03920215|10121042|FG001|Overall Study|Death|0
6352498|NCT03920215|10121043|FG002|Overall Study|Death|0
6352499|NCT03920215|10121044|FG003|Overall Study|Death|1
6352500|NCT03921151|10121056|FG000|Overall Study|Withdrawal by Subject|11
6352501|NCT03921151|10121057|FG001|Overall Study|Withdrawal by Subject|16
6352502|NCT03927911|10121078|FG000|Overall Study|problems with eDiary|0
6352503|NCT03927911|10121079|FG001|Overall Study|problems with eDiary|1
6352504|NCT03927911|10121080|FG002|Overall Study|problems with eDiary|0
6352505|NCT03927911|10121081|FG003|Overall Study|problems with eDiary|1
6352506|NCT03927911|10121082|FG004|Overall Study|problems with eDiary|0
6170245|NCT01251965|9816456|FG001|Overall Study|Participant/physician decision|2
6170246|NCT01251965|9816457|FG002|Overall Study|Participant/physician decision|0
6170247|NCT01251965|9816455|FG000|Overall Study|Death|0
6170248|NCT01251965|9816456|FG001|Overall Study|Death|0
6352507|NCT03927911|10121083|FG005|Overall Study|problems with eDiary|4
6352508|NCT03927911|10121078|FG000|Overall Study|Adverse Event|0
6352509|NCT03927911|10121079|FG001|Overall Study|Adverse Event|0
6352510|NCT03927911|10121080|FG002|Overall Study|Adverse Event|0
6352511|NCT03927911|10121081|FG003|Overall Study|Adverse Event|0
6170249|NCT01251965|9816457|FG002|Overall Study|Death|11
6352512|NCT03927911|10121082|FG004|Overall Study|Adverse Event|0
6352513|NCT03927911|10121083|FG005|Overall Study|Adverse Event|1
6352514|NCT03927911|10121078|FG000|Overall Study|not treated -study terminated by sponsor|0
6352515|NCT03927911|10121079|FG001|Overall Study|not treated -study terminated by sponsor|1
6352516|NCT03927911|10121080|FG002|Overall Study|not treated -study terminated by sponsor|0
6352517|NCT03927911|10121081|FG003|Overall Study|not treated -study terminated by sponsor|0
6352518|NCT03927911|10121082|FG004|Overall Study|not treated -study terminated by sponsor|0
6352519|NCT03927911|10121083|FG005|Overall Study|not treated -study terminated by sponsor|0
6352520|NCT03927911|10121078|FG000|Overall Study|Surgery cancelled|0
6352521|NCT03927911|10121079|FG001|Overall Study|Surgery cancelled|0
6352522|NCT03927911|10121080|FG002|Overall Study|Surgery cancelled|0
6352523|NCT03927911|10121081|FG003|Overall Study|Surgery cancelled|1
6352524|NCT03927911|10121082|FG004|Overall Study|Surgery cancelled|0
6352525|NCT03927911|10121083|FG005|Overall Study|Surgery cancelled|1
6352526|NCT03927911|10121078|FG000|Overall Study|Protocol Violation|0
6352527|NCT03927911|10121079|FG001|Overall Study|Protocol Violation|0
6352528|NCT03927911|10121080|FG002|Overall Study|Protocol Violation|0
6352529|NCT03927911|10121081|FG003|Overall Study|Protocol Violation|0
6352530|NCT03927911|10121082|FG004|Overall Study|Protocol Violation|0
6352531|NCT03927911|10121083|FG005|Overall Study|Protocol Violation|1
6352532|NCT03938857|10121110|FG000|Overall Study|Physician Decision|1
6352533|NCT03938857|10121111|FG001|Overall Study|Physician Decision|0
6352534|NCT03938857|10121112|FG002|Overall Study|Physician Decision|0
6352535|NCT03938857|10121113|FG003|Overall Study|Physician Decision|0
6352536|NCT03945981|10121127|FG000|Overall Study|Lost to Follow-up|12
6352537|NCT03945981|10121127|FG000|Overall Study|Physician Decision|4
6352538|NCT03945981|10121127|FG000|Overall Study|Withdrawal by Subject|6
6352539|NCT03945981|10121127|FG000|Overall Study|Protocol Violation|1
6352540|NCT03954834|10121144|FG000|Overall Study|Adverse Event|1
6352541|NCT03954834|10121145|FG001|Overall Study|Adverse Event|3
6352542|NCT03954834|10121146|FG002|Overall Study|Adverse Event|1
6352543|NCT03954834|10121147|FG003|Overall Study|Adverse Event|1
6352544|NCT03954834|10121144|FG000|Overall Study|Death|0
6352545|NCT03954834|10121145|FG001|Overall Study|Death|0
6352546|NCT03954834|10121146|FG002|Overall Study|Death|0
6352547|NCT03954834|10121147|FG003|Overall Study|Death|1
6352548|NCT03954834|10121144|FG000|Overall Study|Physician Decision|0
6352549|NCT03954834|10121145|FG001|Overall Study|Physician Decision|1
6352550|NCT03954834|10121146|FG002|Overall Study|Physician Decision|0
6352551|NCT03954834|10121147|FG003|Overall Study|Physician Decision|2
6352552|NCT03954834|10121144|FG000|Overall Study|Protocol Violation|1
6352553|NCT03954834|10121145|FG001|Overall Study|Protocol Violation|0
6352554|NCT03954834|10121146|FG002|Overall Study|Protocol Violation|0
6352555|NCT03954834|10121147|FG003|Overall Study|Protocol Violation|1
6352556|NCT03954834|10121144|FG000|Overall Study|Withdrawal by Subject|2
6352557|NCT03954834|10121145|FG001|Overall Study|Withdrawal by Subject|3
6352558|NCT03954834|10121146|FG002|Overall Study|Withdrawal by Subject|13
6352559|NCT03954834|10121147|FG003|Overall Study|Withdrawal by Subject|6
6352560|NCT03954834|10121144|FG000|Overall Study|Participant left the country|0
6352561|NCT03954834|10121145|FG001|Overall Study|Participant left the country|0
6352562|NCT03954834|10121146|FG002|Overall Study|Participant left the country|1
6352563|NCT03954834|10121147|FG003|Overall Study|Participant left the country|0
6352564|NCT03954834|10121144|FG000|Overall Study|Lost to Follow-up|3
6352565|NCT03954834|10121145|FG001|Overall Study|Lost to Follow-up|2
6352566|NCT03954834|10121146|FG002|Overall Study|Lost to Follow-up|3
6352567|NCT03954834|10121147|FG003|Overall Study|Lost to Follow-up|5
6352568|NCT03961529|10121174|FG000|Overall Study|Adverse Event|13
6352569|NCT03961529|10121175|FG001|Overall Study|Adverse Event|5
6352570|NCT03961529|10121176|FG002|Overall Study|Adverse Event|2
6352571|NCT03961529|10121174|FG000|Overall Study|Withdrawal by Subject|17
6352572|NCT03961529|10121175|FG001|Overall Study|Withdrawal by Subject|2
6352573|NCT03961529|10121176|FG002|Overall Study|Withdrawal by Subject|1
6352574|NCT03961529|10121174|FG000|Overall Study|Withdrawal by parent/guardian|0
6352575|NCT03961529|10121175|FG001|Overall Study|Withdrawal by parent/guardian|7
6352576|NCT03961529|10121176|FG002|Overall Study|Withdrawal by parent/guardian|0
6352577|NCT03961529|10121174|FG000|Overall Study|Physician Decision|2
6352578|NCT03961529|10121175|FG001|Overall Study|Physician Decision|1
6352579|NCT03961529|10121176|FG002|Overall Study|Physician Decision|1
6352580|NCT03961529|10121174|FG000|Overall Study|Lost to Follow-up|2
6352581|NCT03961529|10121175|FG001|Overall Study|Lost to Follow-up|1
6352582|NCT03961529|10121176|FG002|Overall Study|Lost to Follow-up|0
6352583|NCT03961529|10121174|FG000|Overall Study|Lack of Efficacy|2
6352584|NCT03961529|10121175|FG001|Overall Study|Lack of Efficacy|0
6352585|NCT03961529|10121176|FG002|Overall Study|Lack of Efficacy|1
6352586|NCT03961529|10121174|FG000|Overall Study|Other|6
6352587|NCT03961529|10121175|FG001|Overall Study|Other|1
6352588|NCT03961529|10121176|FG002|Overall Study|Other|0
6352589|NCT03968159|10121186|FG000|Overall Study|Adverse Event|4
6043173|NCT00387127|9641624|FG001|Overall Study|Required by Protocol Amendment #4|10
6352590|NCT03968159|10121187|FG001|Overall Study|Adverse Event|4
6352591|NCT03968159|10121186|FG000|Overall Study|Lost to Follow-up|1
6352592|NCT03968159|10121187|FG001|Overall Study|Lost to Follow-up|1
6352593|NCT03968159|10121186|FG000|Overall Study|Use of prohibited medication|0
6352594|NCT03968159|10121187|FG001|Overall Study|Use of prohibited medication|1
6352595|NCT03968159|10121186|FG000|Overall Study|Protocol Violation|2
6352596|NCT03968159|10121187|FG001|Overall Study|Protocol Violation|2
6352597|NCT03968159|10121186|FG000|Overall Study|Withdrawal by Subject|4
6352598|NCT03968159|10121187|FG001|Overall Study|Withdrawal by Subject|6
6352599|NCT03968159|10121186|FG000|Overall Study|Lack of Efficacy|0
6352600|NCT03968159|10121187|FG001|Overall Study|Lack of Efficacy|1
6352601|NCT03968159|10121186|FG000|Overall Study|Not further specified|2
6352602|NCT03968159|10121187|FG001|Overall Study|Not further specified|0
6352603|NCT03970824|10121205|FG000|Overall Study|Withdrawal by Subject|1
6352604|NCT03970824|10121206|FG001|Overall Study|Withdrawal by Subject|1
6352605|NCT03970824|10121207|FG002|Overall Study|Withdrawal by Subject|3
6352606|NCT03970824|10121205|FG000|Overall Study|Lost to Follow-up|0
6352607|NCT03970824|10121206|FG001|Overall Study|Lost to Follow-up|2
6352608|NCT03970824|10121207|FG002|Overall Study|Lost to Follow-up|1
6352609|NCT03970824|10121205|FG000|Overall Study|Adverse Event|1
6352610|NCT03970824|10121206|FG001|Overall Study|Adverse Event|0
6352611|NCT03970824|10121207|FG002|Overall Study|Adverse Event|0
6352612|NCT03982069|10121253|FG000|Overall Study|Lost to Follow-up|5
6352613|NCT03982069|10121254|FG001|Overall Study|Lost to Follow-up|5
6352614|NCT03982069|10121255|FG002|Overall Study|Lost to Follow-up|3
6352615|NCT03982069|10121256|FG003|Overall Study|Lost to Follow-up|5
6352616|NCT03982069|10121253|FG000|Overall Study|Physician Decision|0
6352617|NCT03982069|10121254|FG001|Overall Study|Physician Decision|1
6352618|NCT03982069|10121255|FG002|Overall Study|Physician Decision|0
6352619|NCT03982069|10121256|FG003|Overall Study|Physician Decision|0
6352620|NCT03982069|10121253|FG000|Overall Study|Withdrawal by Subject|2
6352621|NCT03982069|10121254|FG001|Overall Study|Withdrawal by Subject|1
6352622|NCT03982069|10121255|FG002|Overall Study|Withdrawal by Subject|5
6352623|NCT03982069|10121256|FG003|Overall Study|Withdrawal by Subject|2
6352624|NCT03982069|10121253|FG000|Overall Study|Specimen loss|3
6352625|NCT03982069|10121254|FG001|Overall Study|Specimen loss|3
6352626|NCT03982069|10121255|FG002|Overall Study|Specimen loss|1
6352627|NCT03982069|10121256|FG003|Overall Study|Specimen loss|1
6352628|NCT03984812|10121275|FG000|Part 1 (Up to Day 28)|Withdrawal by Subject|0
6352629|NCT03984812|10121276|FG001|Part 1 (Up to Day 28)|Withdrawal by Subject|0
6352630|NCT03984812|10121277|FG002|Part 1 (Up to Day 28)|Withdrawal by Subject|1
6352631|NCT03984812|10121278|FG003|Part 1 (Up to Day 28)|Withdrawal by Subject|0
6352632|NCT03984812|10121279|FG004|Part 1 (Up to Day 28)|Withdrawal by Subject|0
6352633|NCT03984812|10121280|FG005|Part 1 (Up to Day 28)|Withdrawal by Subject|0
6352634|NCT03984812|10121281|FG006|Part 1 (Up to Day 28)|Withdrawal by Subject|0
6352635|NCT03984812|10121282|FG007|Part 1 (Up to Day 28)|Withdrawal by Subject|0
6352636|NCT03984812|10121283|FG008|Part 1 (Up to Day 28)|Withdrawal by Subject|0
6352637|NCT03984812|10121284|FG009|Part 1 (Up to Day 28)|Withdrawal by Subject|0
6352638|NCT03984812|10121285|FG010|Part 1 (Up to Day 28)|Withdrawal by Subject|0
6352639|NCT04006171|10121348|FG000|Overall Study|Withdrawal by Subject|8
6352640|NCT04006171|10121349|FG001|Overall Study|Withdrawal by Subject|7
6352641|NCT04006171|10121348|FG000|Overall Study|missing serum samples|2
6352642|NCT04006171|10121349|FG001|Overall Study|missing serum samples|2
6352643|NCT04006171|10121348|FG000|Overall Study|insufficient sample volume|2
6352644|NCT04006171|10121349|FG001|Overall Study|insufficient sample volume|3
6083690|NCT00636636|9692207|FG001|Overall Study|Lack of Efficacy|12
6083691|NCT00636636|9692206|FG000|Overall Study|Protocol Violation|2
6083692|NCT00636636|9692207|FG001|Overall Study|Protocol Violation|2
6083693|NCT00636636|9692206|FG000|Overall Study|Lost to Follow-up|0
6083694|NCT00636636|9692207|FG001|Overall Study|Lost to Follow-up|1
6083695|NCT00636636|9692206|FG000|Overall Study|Death|0
6083696|NCT00636636|9692207|FG001|Overall Study|Death|1
6083697|NCT00636636|9692206|FG000|Overall Study|Withdrawal by Subject|4
6083698|NCT00636636|9692207|FG001|Overall Study|Withdrawal by Subject|9
6083699|NCT00636675|9692228|FG000|Overall Study|Lost to Follow-up|121
6083700|NCT00636675|9692229|FG001|Overall Study|Lost to Follow-up|31
6083701|NCT00636675|9692228|FG000|Overall Study|Withdrawal by Subject|19
6083702|NCT00636675|9692229|FG001|Overall Study|Withdrawal by Subject|10
6083703|NCT00636792|9692244|FG000|Overall Study|Adverse Event|16
6083704|NCT00636792|9692244|FG000|Overall Study|Physician Decision|7
6083705|NCT00636792|9692244|FG000|Overall Study|Progressive Disease|4
6352645|NCT04013529|10121376|FG000|Overall Study|Withdrawal by Subject|1
6352646|NCT04013529|10121377|FG001|Overall Study|Withdrawal by Subject|1
6352647|NCT04018066|10121392|FG000|Overall Study|participants started taking medications during the study period|3
6352648|NCT04018066|10121392|FG000|Overall Study|participant dropped out due to schedule conflicts.|1
6352649|NCT04041440|10121437|FG000|Overall Study|Withdrawal by Subject|0
6352650|NCT04041440|10121438|FG001|Overall Study|Withdrawal by Subject|1
6352651|NCT04041440|10121437|FG000|Overall Study|Lost to Follow-up|0
6352652|NCT04041440|10121438|FG001|Overall Study|Lost to Follow-up|1
6352653|NCT04041570|10121447|FG000|Overall Study|Moved from Area|0
6352654|NCT04041570|10121448|FG001|Overall Study|Moved from Area|2
6352655|NCT04043143|10121457|FG000|Overall Study|Lost to Follow-up|5
6352656|NCT04043143|10121458|FG001|Overall Study|Lost to Follow-up|5
6352657|NCT04043143|10121457|FG000|Overall Study|screen failure|1
6352658|NCT04043143|10121458|FG001|Overall Study|screen failure|0
6083706|NCT00636792|9692244|FG000|Overall Study|Withdrawal by Subject|3
6083707|NCT00636792|9692244|FG000|Overall Study|Other|3
6083708|NCT00636818|9692252|FG000|Overall Study|Adverse Event|1
6083709|NCT00636818|9692252|FG000|Overall Study|Lost to Follow-up|2
6083710|NCT00636818|9692252|FG000|Overall Study|Entry Criteria Exclusion|3
6083711|NCT00636818|9692252|FG000|Overall Study|Protocol Violation|1
6352659|NCT04052204|10121483|FG000|Overall Study|Death|1
6352660|NCT04052204|10121484|FG001|Overall Study|Death|0
6352661|NCT04052204|10121485|FG002|Overall Study|Death|0
6352662|NCT04052204|10121483|FG000|Overall Study|Progressive disease|1
6352663|NCT04052204|10121484|FG001|Overall Study|Progressive disease|0
6352664|NCT04052204|10121485|FG002|Overall Study|Progressive disease|0
6352665|NCT04052204|10121483|FG000|Overall Study|Other|1
6352666|NCT04052204|10121484|FG001|Overall Study|Other|0
6352667|NCT04052204|10121485|FG002|Overall Study|Other|0
6083712|NCT00636818|9692252|FG000|Overall Study|Withdrawal by Subject|4
6083713|NCT00636961|9692258|FG000|Period 1|Administrative problems|1
6170250|NCT01252095|9816477|FG000|Overall Study|Disease progression|1
6170251|NCT01252095|9816478|FG001|Overall Study|Disease progression|0
6170252|NCT01252134|9816484|FG000|Period 1, 8 Hours|Personal Reasons|0
6170253|NCT01252134|9816485|FG001|Period 1, 8 Hours|Personal Reasons|1
6170254|NCT01252134|9816486|FG002|Period 1, 8 Hours|Personal Reasons|1
6352668|NCT04067011|10121505|FG000|Overall Study|Not Treated|8
6352669|NCT04067011|10121506|FG001|Overall Study|Not Treated|7
6352670|NCT04067011|10121507|FG002|Overall Study|Not Treated|5
6352671|NCT04067011|10121505|FG000|Overall Study|Adverse Event|2
6352672|NCT04067011|10121506|FG001|Overall Study|Adverse Event|1
6352673|NCT04067011|10121507|FG002|Overall Study|Adverse Event|0
6352674|NCT04067011|10121505|FG000|Overall Study|Withdrawal by Subject|6
6352675|NCT04067011|10121506|FG001|Overall Study|Withdrawal by Subject|2
6352676|NCT04067011|10121507|FG002|Overall Study|Withdrawal by Subject|1
6352677|NCT04067011|10121505|FG000|Overall Study|Lost to Follow-up|0
6352678|NCT04067011|10121506|FG001|Overall Study|Lost to Follow-up|0
6352679|NCT04067011|10121507|FG002|Overall Study|Lost to Follow-up|1
6352680|NCT04067011|10121505|FG000|Overall Study|Physician Decision|1
6352681|NCT04067011|10121506|FG001|Overall Study|Physician Decision|1
6352682|NCT04067011|10121507|FG002|Overall Study|Physician Decision|0
6352683|NCT04067011|10121505|FG000|Overall Study|Other Reasons|2
6352684|NCT04067011|10121506|FG001|Overall Study|Other Reasons|0
6352685|NCT04067011|10121507|FG002|Overall Study|Other Reasons|1
6352686|NCT04067011|10121505|FG000|Overall Study|Missing|0
6352687|NCT04067011|10121506|FG001|Overall Study|Missing|2
6352688|NCT04067011|10121507|FG002|Overall Study|Missing|0
6352689|NCT04072159|10121519|FG000|Overall Study|Lost to Follow-up|6
6352690|NCT04072159|10121520|FG001|Overall Study|Lost to Follow-up|6
6352691|NCT04072159|10121519|FG000|Overall Study|Withdrawal by Subject|2
6352692|NCT04072159|10121520|FG001|Overall Study|Withdrawal by Subject|0
6352693|NCT04094870|10121539|FG000|Overall Study|Lost to Follow-up|1
6352694|NCT04094870|10121540|FG001|Overall Study|Lost to Follow-up|1
6352695|NCT04123405|10121581|FG000|Overall Study|Adverse Event|1
6352696|NCT04123405|10121582|FG001|Overall Study|Adverse Event|2
6352697|NCT04123405|10121583|FG002|Overall Study|Adverse Event|3
6352698|NCT04123405|10121584|FG003|Overall Study|Adverse Event|3
6352699|NCT04123405|10121581|FG000|Overall Study|Exclusion criteria met|1
6352700|NCT04123405|10121582|FG001|Overall Study|Exclusion criteria met|2
6352701|NCT04123405|10121583|FG002|Overall Study|Exclusion criteria met|0
6352702|NCT04123405|10121584|FG003|Overall Study|Exclusion criteria met|2
6352703|NCT04123405|10121581|FG000|Overall Study|Withdrawal by Subject|1
6352704|NCT04123405|10121582|FG001|Overall Study|Withdrawal by Subject|3
6352705|NCT04123405|10121583|FG002|Overall Study|Withdrawal by Subject|0
6352706|NCT04123405|10121584|FG003|Overall Study|Withdrawal by Subject|2
6352707|NCT04123405|10121581|FG000|Overall Study|Contact to subject lost|0
6352708|NCT04123405|10121582|FG001|Overall Study|Contact to subject lost|0
6352709|NCT04123405|10121583|FG002|Overall Study|Contact to subject lost|0
6352710|NCT04123405|10121584|FG003|Overall Study|Contact to subject lost|1
6352711|NCT04123405|10121581|FG000|Overall Study|screening failure|1
6352712|NCT04123405|10121582|FG001|Overall Study|screening failure|0
6352713|NCT04123405|10121583|FG002|Overall Study|screening failure|0
6352714|NCT04123405|10121584|FG003|Overall Study|screening failure|0
6352715|NCT04147715|10121627|FG000|Overall Study|Adverse Event|0
6352716|NCT04147715|10121628|FG001|Overall Study|Adverse Event|0
6352717|NCT04147715|10121629|FG002|Overall Study|Adverse Event|0
6352718|NCT04147715|10121630|FG003|Overall Study|Adverse Event|0
6352719|NCT04147715|10121631|FG004|Overall Study|Adverse Event|0
6352720|NCT04147715|10121632|FG005|Overall Study|Adverse Event|0
6352721|NCT04147715|10121633|FG006|Overall Study|Adverse Event|0
6352722|NCT04147715|10121634|FG007|Overall Study|Adverse Event|2
6352723|NCT04147715|10121635|FG008|Overall Study|Adverse Event|1
6352724|NCT04147715|10121636|FG009|Overall Study|Adverse Event|0
6352725|NCT04147715|10121637|FG010|Overall Study|Adverse Event|0
6352726|NCT04147715|10121638|FG011|Overall Study|Adverse Event|0
6352727|NCT04154605|10121712|FG000|Overall Study|Procedure Canceled|1
6352728|NCT04154605|10121713|FG001|Overall Study|Procedure Canceled|1
6352729|NCT04154605|10121712|FG000|Overall Study|Missed follow up|1
6352730|NCT04154605|10121713|FG001|Overall Study|Missed follow up|1
6352731|NCT04154605|10121712|FG000|Overall Study|Withdrawal by Subject|1
6352732|NCT04154605|10121713|FG001|Overall Study|Withdrawal by Subject|0
6352733|NCT04160091|10121723|FG000|Overall Study|Terminated by Sponsor|7
6352734|NCT04160091|10121724|FG001|Overall Study|Terminated by Sponsor|3
6352735|NCT04160091|10121725|FG002|Overall Study|Terminated by Sponsor|5
6352736|NCT04160091|10121726|FG003|Overall Study|Terminated by Sponsor|2
6352737|NCT04160091|10121723|FG000|Overall Study|Noncompliance|0
6352738|NCT04160091|10121724|FG001|Overall Study|Noncompliance|0
6352739|NCT04160091|10121725|FG002|Overall Study|Noncompliance|0
6352740|NCT04160091|10121726|FG003|Overall Study|Noncompliance|1
6352741|NCT04160091|10121723|FG000|Overall Study|Withdrawal by Subject|0
6352742|NCT04160091|10121724|FG001|Overall Study|Withdrawal by Subject|0
6352743|NCT04160091|10121725|FG002|Overall Study|Withdrawal by Subject|0
6352744|NCT04160091|10121726|FG003|Overall Study|Withdrawal by Subject|1
6352745|NCT04164758|10121743|FG000|Overall Study|COVID-19 withdrawal of consent|1
6352746|NCT04164758|10121744|FG001|Overall Study|COVID-19 withdrawal of consent|0
6352747|NCT04164758|10121745|FG002|Overall Study|COVID-19 withdrawal of consent|0
6352748|NCT04164758|10121743|FG000|Overall Study|Adverse Event|0
6352749|NCT04164758|10121744|FG001|Overall Study|Adverse Event|1
6352750|NCT04164758|10121745|FG002|Overall Study|Adverse Event|0
6352751|NCT04165031|10121759|FG000|Overall Study|Adverse Event|1
6352752|NCT04165031|10121760|FG001|Overall Study|Adverse Event|1
6352753|NCT04165031|10121761|FG002|Overall Study|Adverse Event|0
6352754|NCT04165031|10121762|FG003|Overall Study|Adverse Event|0
6352755|NCT04165031|10121763|FG004|Overall Study|Adverse Event|0
6352756|NCT04165031|10121764|FG005|Overall Study|Adverse Event|0
6352757|NCT04165031|10121759|FG000|Overall Study|Withdrawal by Subject|0
6352758|NCT04165031|10121760|FG001|Overall Study|Withdrawal by Subject|0
6352759|NCT04165031|10121761|FG002|Overall Study|Withdrawal by Subject|1
6352760|NCT04165031|10121762|FG003|Overall Study|Withdrawal by Subject|0
6352761|NCT04165031|10121763|FG004|Overall Study|Withdrawal by Subject|0
6352762|NCT04165031|10121764|FG005|Overall Study|Withdrawal by Subject|0
6352763|NCT04171414|10121783|FG000|Overall Study|Death|1
6352764|NCT04171414|10121783|FG000|Overall Study|Withdrawal by Subject|1
6352765|NCT04175808|10121787|FG000|Part A|Miscellaneous|2
6352766|NCT04175808|10121788|FG001|Part A|Miscellaneous|0
6352767|NCT04175808|10121789|FG002|Part A|Miscellaneous|0
6352768|NCT04175808|10121790|FG003|Part A|Miscellaneous|0
6352769|NCT04175808|10121791|FG004|Part A|Miscellaneous|0
6352770|NCT04175808|10121792|FG005|Part A|Miscellaneous|0
6352771|NCT04175808|10121793|FG006|Part A|Miscellaneous|0
6352772|NCT04178720|10121811|FG000|Overall Study|Withdrawal by Subject|2
6352773|NCT04178720|10121812|FG001|Overall Study|Withdrawal by Subject|0
6352774|NCT04178720|10121811|FG000|Overall Study|Relocation|0
6352775|NCT04178720|10121812|FG001|Overall Study|Relocation|1
6352776|NCT04218110|10121855|FG000|Overall Study|Withdrawal by Subject|0
6352777|NCT04218110|10121856|FG001|Overall Study|Withdrawal by Subject|0
6352778|NCT04218110|10121857|FG002|Overall Study|Withdrawal by Subject|0
6352779|NCT04218110|10121858|FG003|Overall Study|Withdrawal by Subject|1
6352780|NCT04222725|10121872|FG000|Overall Study|Adverse Event|0
6352781|NCT04222725|10121873|FG001|Overall Study|Adverse Event|1
6352782|NCT04222725|10121874|FG002|Overall Study|Adverse Event|0
6352783|NCT04222725|10121875|FG003|Overall Study|Adverse Event|0
6352784|NCT04258995|10121961|FG000|Overall Study|Lost to Follow-up|1
6352785|NCT04258995|10121962|FG001|Overall Study|Lost to Follow-up|1
6352786|NCT04317040|10122001|FG000|Overall Study|Lost to Follow-up|2
6352787|NCT04317040|10122002|FG001|Overall Study|Lost to Follow-up|0
6352788|NCT04317040|10122001|FG000|Overall Study|Death|16
6352789|NCT04317040|10122002|FG001|Overall Study|Death|18
6352790|NCT04317040|10122001|FG000|Overall Study|Withdrawal by Subject|0
6352791|NCT04317040|10122002|FG001|Overall Study|Withdrawal by Subject|1
6352792|NCT04317040|10122001|FG000|Overall Study|Incomplete assessments|0
6352793|NCT04317040|10122002|FG001|Overall Study|Incomplete assessments|1
6352794|NCT04319159|10122019|FG000|Overall Study|Screening failure|13
6352795|NCT04319159|10122019|FG000|Overall Study|Re-screening due to COVID-19 implications|2
6352796|NCT04319159|10122019|FG000|Overall Study|Withdrawal by Subject|1
6352797|NCT04331899|10122049|FG000|Trial Period (28 Days)|Withdrawal by Subject|2
6352798|NCT04331899|10122050|FG001|Trial Period (28 Days)|Withdrawal by Subject|2
6352799|NCT04334148|10122058|FG000|Overall Study|positive nasal swab at baseline|0
6352800|NCT04334148|10122059|FG001|Overall Study|positive nasal swab at baseline|1
6352801|NCT04347954|10122079|FG000|Overall Study|Did not present to study site for allocated intervention|3
6352802|NCT04347954|10122080|FG001|Overall Study|Did not present to study site for allocated intervention|0
6352803|NCT04347954|10122081|FG002|Overall Study|Did not present to study site for allocated intervention|3
6352804|NCT04347954|10122079|FG000|Overall Study|Lost to Follow-up|0
6352805|NCT04347954|10122080|FG001|Overall Study|Lost to Follow-up|1
6352806|NCT04347954|10122081|FG002|Overall Study|Lost to Follow-up|0
6352807|NCT04349098|10122091|FG000|Overall Study|Death|16
6352808|NCT04349098|10122092|FG001|Overall Study|Death|8
6352809|NCT04349098|10122091|FG000|Overall Study|Lost to Follow-up|11
6352810|NCT04349098|10122092|FG001|Overall Study|Lost to Follow-up|8
6352811|NCT04349098|10122091|FG000|Overall Study|Withdrawal by Subject|8
6352812|NCT04349098|10122092|FG001|Overall Study|Withdrawal by Subject|5
6352813|NCT04349098|10122091|FG000|Overall Study|Other|3
6352814|NCT04349098|10122092|FG001|Overall Study|Other|5
6352815|NCT04353037|10122102|FG000|Overall Study|Lost to Follow-up|0
6352816|NCT04353037|10122103|FG001|Overall Study|Lost to Follow-up|1
6352817|NCT04353037|10122104|FG002|Overall Study|Lost to Follow-up|2
6352818|NCT04353037|10122105|FG003|Overall Study|Lost to Follow-up|3
6352819|NCT04353037|10122102|FG000|Overall Study|Withdrawal by Subject|0
6352820|NCT04353037|10122103|FG001|Overall Study|Withdrawal by Subject|2
6352821|NCT04353037|10122104|FG002|Overall Study|Withdrawal by Subject|3
6352822|NCT04353037|10122105|FG003|Overall Study|Withdrawal by Subject|5
6352823|NCT04353037|10122102|FG000|Overall Study|Adverse Event|0
6352824|NCT04353037|10122103|FG001|Overall Study|Adverse Event|0
6352825|NCT04353037|10122104|FG002|Overall Study|Adverse Event|2
6352826|NCT04353037|10122105|FG003|Overall Study|Adverse Event|0
6352827|NCT04353037|10122102|FG000|Overall Study|Exposure Change|0
6352828|NCT04353037|10122103|FG001|Overall Study|Exposure Change|0
6352829|NCT04353037|10122104|FG002|Overall Study|Exposure Change|0
6352830|NCT04353037|10122105|FG003|Overall Study|Exposure Change|2
6352831|NCT04355767|10122125|FG000|Overall Study|Withdrawal by Subject|2
6352832|NCT04355767|10122126|FG001|Overall Study|Withdrawal by Subject|2
6352833|NCT04355767|10122125|FG000|Overall Study|Death|5
6352834|NCT04355767|10122126|FG001|Overall Study|Death|1
6352835|NCT04356573|10122134|FG000|Overall Study|Didn't Qualify|1
6352836|NCT04356573|10122135|FG001|Overall Study|Didn't Qualify|0
6352837|NCT04358068|10122147|FG000|Overall Study|Did not initiate study treatment|2
6352838|NCT04358068|10122148|FG001|Overall Study|Did not initiate study treatment|2
6352839|NCT04366349|10122160|FG000|Overall Study|Withdrawal by Subject|1
6352840|NCT04366349|10122161|FG001|Overall Study|Withdrawal by Subject|0
6352841|NCT04366349|10122162|FG002|Overall Study|Withdrawal by Subject|0
6352842|NCT04366349|10122163|FG003|Overall Study|Withdrawal by Subject|0
6352843|NCT04366349|10122164|FG004|Overall Study|Withdrawal by Subject|0
6352844|NCT04366349|10122165|FG005|Overall Study|Withdrawal by Subject|0
6352845|NCT04388826|10122209|FG000|Overall Study|Lost to Follow-up|3
6352846|NCT04388826|10122210|FG001|Overall Study|Lost to Follow-up|2
6352847|NCT04388826|10122209|FG000|Overall Study|Adverse Event|1
6352848|NCT04388826|10122210|FG001|Overall Study|Adverse Event|0
6352849|NCT04398732|10122222|FG000|Overall Study|Participants Who Did Not Meet Entrance Criteria|50
6352850|NCT04401293|10122230|FG000|Overall Study|Withdrawal by Subject|1
6352851|NCT04401293|10122231|FG001|Overall Study|Withdrawal by Subject|3
6352852|NCT04411628|10122241|FG000|Overall Study|Withdrawal by Subject|1
6352853|NCT04411628|10122242|FG001|Overall Study|Withdrawal by Subject|1
6352854|NCT04411628|10122243|FG002|Overall Study|Withdrawal by Subject|2
6352855|NCT04411628|10122244|FG003|Overall Study|Withdrawal by Subject|0
6352856|NCT04411628|10122241|FG000|Overall Study|Lost to Follow-up|0
6352857|NCT04411628|10122242|FG001|Overall Study|Lost to Follow-up|1
6352858|NCT04411628|10122243|FG002|Overall Study|Lost to Follow-up|0
6352859|NCT04411628|10122244|FG003|Overall Study|Lost to Follow-up|0
6352860|NCT04428411|10122296|FG000|Overall Study|Lost to Follow-up|114
6352861|NCT04435184|10122305|FG000|Overall Study|follow-up blood draws missing|3
6352862|NCT04435184|10122306|FG001|Overall Study|follow-up blood draws missing|5
6352863|NCT04476784|10122314|FG000|First Wear Period (30 Days ± 2 Days)|Withdrawal by Subject|1
6352864|NCT04476784|10122315|FG001|First Wear Period (30 Days ± 2 Days)|Withdrawal by Subject|0
6352865|NCT04495283|10122347|FG000|Overall Study|Physician Decision|0
6352866|NCT04495283|10122348|FG001|Overall Study|Physician Decision|0
6352867|NCT04495283|10122349|FG002|Overall Study|Physician Decision|1
6352868|NCT04495283|10122347|FG000|Overall Study|Withdrawal by Subject|0
6352869|NCT04495283|10122348|FG001|Overall Study|Withdrawal by Subject|1
6352870|NCT04495283|10122349|FG002|Overall Study|Withdrawal by Subject|1
6352871|NCT04495283|10122347|FG000|Overall Study|Other|1
6352872|NCT04495283|10122348|FG001|Overall Study|Other|0
6352873|NCT04495283|10122349|FG002|Overall Study|Other|1
6352874|NCT04497948|10122360|FG000|Overall Study|Death|2
6352875|NCT04501952|10122387|FG000|Overall Study|Adverse Event|0
6352876|NCT04501952|10122388|FG001|Overall Study|Adverse Event|3
6352877|NCT04501952|10122387|FG000|Overall Study|Investigator's Discretion|0
6352878|NCT04501952|10122388|FG001|Overall Study|Investigator's Discretion|1
6352879|NCT04501952|10122387|FG000|Overall Study|Protocol Violation|1
6352880|NCT04501952|10122388|FG001|Overall Study|Protocol Violation|1
6352881|NCT04501952|10122387|FG000|Overall Study|Withdrew Consent|5
6352882|NCT04501952|10122388|FG001|Overall Study|Withdrew Consent|4
6352883|NCT04501952|10122387|FG000|Overall Study|Lost to Follow-up|7
6352884|NCT04501952|10122388|FG001|Overall Study|Lost to Follow-up|2
6352885|NCT04501952|10122387|FG000|Overall Study|Randomized and Never Treated|13
6352886|NCT04501952|10122388|FG001|Overall Study|Randomized and Never Treated|9
6352887|NCT04504032|10122397|FG000|Overall Study|Adverse Event|1
6352888|NCT04504032|10122398|FG001|Overall Study|Adverse Event|2
6352889|NCT04504032|10122397|FG000|Overall Study|Lost to Follow-up|6
6352890|NCT04504032|10122398|FG001|Overall Study|Lost to Follow-up|9
6352891|NCT04504032|10122397|FG000|Overall Study|Protocol Violation|2
6352892|NCT04504032|10122398|FG001|Overall Study|Protocol Violation|0
6352893|NCT04504032|10122397|FG000|Overall Study|Study terminated by sponsor|1
6352894|NCT04504032|10122398|FG001|Overall Study|Study terminated by sponsor|2
6352895|NCT04504032|10122397|FG000|Overall Study|Withdrawal by Subject|9
6352896|NCT04504032|10122398|FG001|Overall Study|Withdrawal by Subject|11
6352897|NCT04504032|10122397|FG000|Overall Study|Disease progression prior to dosing|15
6352898|NCT04504032|10122398|FG001|Overall Study|Disease progression prior to dosing|3
6352899|NCT04504032|10122397|FG000|Overall Study|Drug supply issues|1
6352900|NCT04504032|10122398|FG001|Overall Study|Drug supply issues|1
6352901|NCT04504032|10122397|FG000|Overall Study|Progressed to moderate/severe COVID-19|1
6352902|NCT04504032|10122398|FG001|Overall Study|Progressed to moderate/severe COVID-19|0
6352903|NCT04507763|10122404|FG000|Overall Study|Participants did not meet entrance criteria|201
6352904|NCT04507867|10122413|FG000|Overall Study|Death|7
6170255|NCT01252134|9816487|FG003|Period 1, 8 Hours|Personal Reasons|0
6352905|NCT04507867|10122414|FG001|Overall Study|Death|1
6352906|NCT04527978|10122459|FG000|First Wear Period (8 -0/+3 Days)|Adverse Event|1
6352907|NCT04527978|10122460|FG001|First Wear Period (8 -0/+3 Days)|Adverse Event|0
6352908|NCT04529109|10122481|FG000|Period 1|Unsatisfactory Lens Fitting due to Test Article|0
6352909|NCT04529109|10122482|FG001|Period 1|Unsatisfactory Lens Fitting due to Test Article|1
6352910|NCT04601103|10122597|FG000|Overall Study|Needed crown & cleaning|0
6352911|NCT04601103|10122598|FG001|Overall Study|Needed crown & cleaning|0
6352912|NCT04601103|10122599|FG002|Overall Study|Needed crown & cleaning|1
6352913|NCT04601103|10122597|FG000|Overall Study|study was terminated|18
6352914|NCT04601103|10122598|FG001|Overall Study|study was terminated|18
6352915|NCT04601103|10122599|FG002|Overall Study|study was terminated|16
6352916|NCT04664855|10122627|FG000|Overall Study|Withdrawal by Subject|0
6352917|NCT04664855|10122628|FG001|Overall Study|Withdrawal by Subject|2
6352918|NCT04701658|10122634|FG000|Overall Study|Lost to Follow-up|6
6352919|NCT04706416|10122640|FG000|Overall Study|Lost to Follow-up|2
6352920|NCT04706416|10122641|FG001|Overall Study|Lost to Follow-up|0
6352921|NCT04727749|10122661|FG000|Overall Study|Lost to Follow-up|10
6352922|NCT04727749|10122662|FG001|Overall Study|Lost to Follow-up|3
6352923|NCT04854707|10122684|FG000|Overall Study|Lack of Efficacy|78
6352924|NCT04854707|10122685|FG001|Overall Study|Lack of Efficacy|59
6352925|NCT04854707|10122686|FG002|Overall Study|Lack of Efficacy|30
6352926|NCT04947436|10122781|FG000|Overall Study|Lost to Follow-up|3
6352927|NCT04947436|10122782|FG001|Overall Study|Lost to Follow-up|7
6352928|NCT04947436|10122783|FG002|Overall Study|Lost to Follow-up|5
6352929|NCT04947436|10122781|FG000|Overall Study|Death|1
6352930|NCT04947436|10122782|FG001|Overall Study|Death|1
6352931|NCT04947436|10122783|FG002|Overall Study|Death|1
6352932|NCT05002972|10122791|FG000|Overall Study|Withdrawal by Subject|2
6352933|NCT05002985|10122795|FG000|Overall Study|Withdrawal by Subject|1
6352934|NCT04512482|10122801|FG000|Second Intervention (1 Day)|Protocol Violation|2
6352935|NCT04512482|10122802|FG001|Second Intervention (1 Day)|Protocol Violation|1
6352936|NCT04523831|10122827|FG000|Overall Study|Lost to Follow-up|15
6352937|NCT04523831|10122828|FG001|Overall Study|Lost to Follow-up|17
6352938|NCT04523831|10122827|FG000|Overall Study|Death|0
6352939|NCT04523831|10122828|FG001|Overall Study|Death|3
6352940|NCT04523831|10122827|FG000|Overall Study|Adverse Event|2
6352941|NCT04523831|10122828|FG001|Overall Study|Adverse Event|0
6352942|NCT04521777|10122837|FG000|Overall Study|Death|2
6352943|NCT04521777|10122837|FG000|Overall Study|Withdrawal by Subject|2
6352944|NCT04507776|10122867|FG000|Overall Study|Participants did not meet the entrance criteria|201
6352945|NCT04502979|10122878|FG000|Overall Study|Lost to Follow-up|1
6352946|NCT04502979|10122879|FG001|Overall Study|Lost to Follow-up|3
6352947|NCT04502979|10122878|FG000|Overall Study|Withdrawal by Subject|2
6352948|NCT04502979|10122879|FG001|Overall Study|Withdrawal by Subject|1
6352949|NCT04498403|10122922|FG000|Overall Study|Adverse Event|1
6352950|NCT04498403|10122923|FG001|Overall Study|Adverse Event|0
6352951|NCT04498403|10122922|FG000|Overall Study|Study Terminated By Sponsor|29
6352952|NCT04498403|10122923|FG001|Overall Study|Study Terminated By Sponsor|10
6352953|NCT04495374|10122931|FG000|Overall Study|Protocol Violation|2
6352954|NCT04495374|10122932|FG001|Overall Study|Protocol Violation|1
6352955|NCT04491994|10122956|FG000|Overall Study|Withdrawal by Subject|10
6352956|NCT04491994|10122957|FG001|Overall Study|Withdrawal by Subject|5
6352957|NCT04491994|10122956|FG000|Overall Study|developed fever > 3 days|4
6352958|NCT04491994|10122957|FG001|Overall Study|developed fever > 3 days|1
6352959|NCT04491994|10122956|FG000|Overall Study|Protocol Violation|11
6352960|NCT04491994|10122957|FG001|Overall Study|Protocol Violation|2
6352961|NCT04491994|10122956|FG000|Overall Study|Lost to Follow-up|4
6352962|NCT04491994|10122957|FG001|Overall Study|Lost to Follow-up|3
6352963|NCT04490499|10122980|FG000|Overall Study|Withdrawal by Subject|2
6352964|NCT04486235|10122990|FG000|Overall Study|Pregnancy|1
6352965|NCT04486235|10122991|FG001|Overall Study|Pregnancy|0
6352966|NCT04486235|10122990|FG000|Overall Study|Lost to Follow-up|1
6352967|NCT04486235|10122991|FG001|Overall Study|Lost to Follow-up|0
6352968|NCT04483011|10123000|FG000|Washout (7 Days)|Withdrawal by Subject|0
6352969|NCT04483011|10123001|FG001|Washout (7 Days)|Withdrawal by Subject|1
6352970|NCT04475588|10123011|FG000|Overall Study|Adverse Event|2
6352971|NCT04475588|10123012|FG001|Overall Study|Adverse Event|0
6352972|NCT04474405|10123038|FG000|Overall Study|Withdrawal by Subject|0
6352973|NCT04474405|10123039|FG001|Overall Study|Withdrawal by Subject|0
6352974|NCT04474405|10123040|FG002|Overall Study|Withdrawal by Subject|1
6352975|NCT04474405|10123041|FG003|Overall Study|Withdrawal by Subject|0
6352976|NCT04474405|10123042|FG004|Overall Study|Withdrawal by Subject|1
6352977|NCT04474405|10123043|FG005|Overall Study|Withdrawal by Subject|0
6352978|NCT04474405|10123038|FG000|Overall Study|Other|0
6352979|NCT04474405|10123039|FG001|Overall Study|Other|0
6352980|NCT04474405|10123040|FG002|Overall Study|Other|0
6352981|NCT04474405|10123041|FG003|Overall Study|Other|0
6352982|NCT04474405|10123042|FG004|Overall Study|Other|3
6352983|NCT04474405|10123043|FG005|Overall Study|Other|0
6352984|NCT04468347|10123065|FG000|Overall Study|Withdrawal by Subject|0
6352985|NCT04468347|10123066|FG001|Overall Study|Withdrawal by Subject|1
6352986|NCT04468347|10123067|FG002|Overall Study|Withdrawal by Subject|3
6352987|NCT04468347|10123068|FG003|Overall Study|Withdrawal by Subject|3
6352988|NCT04468347|10123065|FG000|Overall Study|Lost to Follow-up|0
6352989|NCT04468347|10123066|FG001|Overall Study|Lost to Follow-up|0
6352990|NCT04468347|10123067|FG002|Overall Study|Lost to Follow-up|1
6352991|NCT04468347|10123068|FG003|Overall Study|Lost to Follow-up|1
6352992|NCT04468347|10123065|FG000|Overall Study|Physician Decision|1
6352993|NCT04468347|10123066|FG001|Overall Study|Physician Decision|0
6352994|NCT04468347|10123067|FG002|Overall Study|Physician Decision|2
6352995|NCT04468347|10123068|FG003|Overall Study|Physician Decision|0
6352996|NCT04468347|10123065|FG000|Overall Study|Protocol Violation|1
6352997|NCT04468347|10123066|FG001|Overall Study|Protocol Violation|0
6352998|NCT04468347|10123067|FG002|Overall Study|Protocol Violation|0
6083714|NCT00636961|9692259|FG001|Period 1|Administrative problems|1
6083715|NCT00636961|9692258|FG000|Period 2|Adverse Event|1
6083716|NCT00636961|9692259|FG001|Period 2|Adverse Event|0
6083717|NCT00636987|9692265|FG000|Overall Study|Death|44
6083718|NCT00636987|9692265|FG000|Overall Study|Explanted|13
6352999|NCT04468347|10123068|FG003|Overall Study|Protocol Violation|0
6083719|NCT00636987|9692265|FG000|Overall Study|Lost to Follow-up|63
6353000|NCT04465422|10123093|FG000|Overall Study|Lost to Follow-up|0
6353001|NCT04465422|10123094|FG001|Overall Study|Lost to Follow-up|2
6353002|NCT04448561|10123113|FG000|Overall Study|Noncompliance|1
6353003|NCT04448561|10123114|FG001|Overall Study|Noncompliance|0
6353004|NCT04450381|10123189|FG000|Overall Study|Protocol Violation|4
6353005|NCT04450381|10123189|FG000|Overall Study|Wrong device setting|2
6353006|NCT04449341|10123195|FG000|Overall Study|Protocol Violation|1
6083720|NCT00636987|9692265|FG000|Overall Study|5 year visit window not complete|69
6083721|NCT00637000|9692275|FG000|Overall Study|Withdrawal by Subject|4
6083722|NCT00637000|9692276|FG001|Overall Study|Withdrawal by Subject|3
6083723|NCT00637156|9692284|FG000|Overall Study|Withdrawal by Subject|0
6083724|NCT00637156|9692285|FG001|Overall Study|Withdrawal by Subject|7
6083725|NCT00637156|9692284|FG000|Overall Study|Death|0
6083726|NCT00637156|9692285|FG001|Overall Study|Death|1
6353007|NCT04449341|10123196|FG001|Overall Study|Protocol Violation|0
6353008|NCT04439214|10123211|FG000|Overall Study|Adverse Event|13
6353009|NCT04439214|10123211|FG000|Overall Study|Disease progression|16
6353010|NCT04439214|10123211|FG000|Overall Study|Death|1
6353011|NCT04439214|10123211|FG000|Overall Study|Withdrawal by Subject|2
6353012|NCT04439214|10123211|FG000|Overall Study|Declining health|1
6353013|NCT04439214|10123211|FG000|Overall Study|Still receiving treatment at the time of the analysis|9
6353014|NCT04439214|10123211|FG000|Overall Study|Ineligible|5
6353015|NCT04439240|10123215|FG000|Overall Study|Ineligible|2
6353016|NCT04439240|10123215|FG000|Overall Study|Never started treatment|2
6353017|NCT04439240|10123215|FG000|Overall Study|Adverse Event|12
6353018|NCT04439240|10123215|FG000|Overall Study|Death|2
6353019|NCT04439240|10123215|FG000|Overall Study|Disease progression|25
6353020|NCT04439240|10123215|FG000|Overall Study|Other diseases|2
6353021|NCT04439240|10123215|FG000|Overall Study|Withdrawal by Subject|3
6353022|NCT04439240|10123215|FG000|Overall Study|Clinical concerns for progression and increasing tumor marker|1
6353023|NCT04439240|10123215|FG000|Overall Study|Symptomatic decline|1
6353024|NCT04439240|10123215|FG000|Overall Study|Pogression of the lymphadenopathy|1
6353025|NCT04439240|10123215|FG000|Overall Study|Clinical progression|1
6353026|NCT04438785|10123221|FG000|Overall Study|change of weight, give up intervention|2
6353027|NCT04438785|10123222|FG001|Overall Study|change of weight, give up intervention|10
6353028|NCT04428502|10123311|FG000|Overall Study|Did not meet entrance criteria|14
6353029|NCT04428424|10123316|FG000|Overall Study|Does not meet entrance criteria|132
6353030|NCT04428424|10123316|FG000|Overall Study|Lost to Follow-up|115
6353031|NCT04425863|10123360|FG000|Overall Study|Death|0
6353032|NCT04425863|10123361|FG001|Overall Study|Death|0
6353033|NCT04425863|10123362|FG002|Overall Study|Death|1
6353034|NCT04422561|10123395|FG000|Overall Study|Lost to Follow-up|25
6353035|NCT04422561|10123396|FG001|Overall Study|Lost to Follow-up|11
6353036|NCT04419311|10123413|FG000|Overall Study|Lost to Follow-up|1
6353037|NCT04419311|10123414|FG001|Overall Study|Lost to Follow-up|0
6353038|NCT04411667|10123434|FG000|Overall Study|Physician Decision|1
6353039|NCT04411667|10123435|FG001|Overall Study|Physician Decision|0
6353040|NCT04407507|10123447|FG000|Overall Study|Withdrawal by Subject|0
6353041|NCT04407507|10123448|FG001|Overall Study|Withdrawal by Subject|1
6353042|NCT04406194|10123456|FG000|Period 1|Withdrawal by Subject|0
6353043|NCT04406194|10123457|FG001|Period 1|Withdrawal by Subject|1
6353044|NCT04404010|10123477|FG000|Overall Study|Mistakenly enrolled, withdrawn after randomization (did not meet eligibility criteria)|1
6353045|NCT04404010|10123478|FG001|Overall Study|Mistakenly enrolled, withdrawn after randomization (did not meet eligibility criteria)|0
6353046|NCT04403399|10123488|FG000|Period 2|Physician Decision|0
6353047|NCT04403399|10123489|FG001|Period 2|Physician Decision|1
6353048|NCT04401202|10123519|FG000|Overall Study|Lost to Follow-up|2
6353049|NCT04401202|10123520|FG001|Overall Study|Lost to Follow-up|2
6353050|NCT04401202|10123519|FG000|Overall Study|Adverse Event|0
6353051|NCT04401202|10123520|FG001|Overall Study|Adverse Event|1
6353052|NCT04401202|10123519|FG000|Overall Study|Hospitalized|4
6353053|NCT04401202|10123520|FG001|Overall Study|Hospitalized|1
6353054|NCT04400682|10123529|FG000|Period 1|Withdrawal by Subject|1
6353055|NCT04400682|10123530|FG001|Period 1|Withdrawal by Subject|4
6353056|NCT04399161|10123539|FG000|Overall Study|Withdrawal by Subject|1
6353057|NCT04399161|10123540|FG001|Overall Study|Withdrawal by Subject|0
6353058|NCT04399161|10123541|FG002|Overall Study|Withdrawal by Subject|2
6353059|NCT04399161|10123539|FG000|Overall Study|Protocol Violation|1
6353060|NCT04399161|10123540|FG001|Overall Study|Protocol Violation|2
6353061|NCT04399161|10123541|FG002|Overall Study|Protocol Violation|0
6353062|NCT04399122|10123560|FG000|Overall Study|Lost to Follow-up|2
6353063|NCT04399122|10123561|FG001|Overall Study|Lost to Follow-up|0
6353064|NCT04399122|10123560|FG000|Overall Study|Withdrawal by Subject|1
6353065|NCT04399122|10123561|FG001|Overall Study|Withdrawal by Subject|0
6353066|NCT04397445|10123567|FG000|Overall Study|Withdrawal by Subject|1
6353067|NCT04397445|10123568|FG001|Overall Study|Withdrawal by Subject|0
6353068|NCT04397445|10123569|FG002|Overall Study|Withdrawal by Subject|0
6353069|NCT04397445|10123570|FG003|Overall Study|Withdrawal by Subject|0
6353070|NCT04396639|10123596|FG000|Overall Study|Withdrawal by Subject|1
6353071|NCT04396639|10123596|FG000|Overall Study|Other|1
6353072|NCT04393493|10123615|FG000|First 4 Days of Intervention|Early improvement|5
6353073|NCT04393493|10123616|FG001|First 4 Days of Intervention|Early improvement|7
6353074|NCT04391842|10123715|FG000|Overall Study|Withdrawal by Subject|2
6353075|NCT04386902|10123728|FG000|Overall Study|Withdrawal by Subject|5
6353076|NCT04386902|10123728|FG000|Overall Study|Technical problems in the recording|5
6353077|NCT04384523|10123747|FG000|Overall Study|Lost to Follow-up|0
6083727|NCT00637156|9692284|FG000|Overall Study|Lost to Follow-up|10
6353078|NCT04384523|10123748|FG001|Overall Study|Lost to Follow-up|0
6353079|NCT04384523|10123749|FG002|Overall Study|Lost to Follow-up|0
6083728|NCT00637156|9692285|FG001|Overall Study|Lost to Follow-up|16
6353080|NCT04384523|10123750|FG003|Overall Study|Lost to Follow-up|0
6353081|NCT04384523|10123751|FG004|Overall Study|Lost to Follow-up|0
6353082|NCT04384523|10123752|FG005|Overall Study|Lost to Follow-up|1
6353083|NCT04384523|10123747|FG000|Overall Study|Protocol Violation|0
6353084|NCT04384523|10123748|FG001|Overall Study|Protocol Violation|1
6353085|NCT04384523|10123749|FG002|Overall Study|Protocol Violation|0
6353086|NCT04384523|10123750|FG003|Overall Study|Protocol Violation|0
6353087|NCT04384523|10123751|FG004|Overall Study|Protocol Violation|0
6353088|NCT04384523|10123752|FG005|Overall Study|Protocol Violation|0
6353089|NCT04384523|10123747|FG000|Overall Study|Withdrawal by Subject|1
6353090|NCT04384523|10123748|FG001|Overall Study|Withdrawal by Subject|0
6353091|NCT04384523|10123749|FG002|Overall Study|Withdrawal by Subject|0
6353092|NCT04384523|10123750|FG003|Overall Study|Withdrawal by Subject|0
6353093|NCT04384523|10123751|FG004|Overall Study|Withdrawal by Subject|0
6083729|NCT00637195|9692293|FG000|Overall Study|Lost to Follow-up|1
6083730|NCT00637195|9692294|FG001|Overall Study|Lost to Follow-up|0
6083731|NCT00637195|9692293|FG000|Overall Study|Other|2
6083732|NCT00637195|9692294|FG001|Overall Study|Other|0
6083733|NCT00637195|9692293|FG000|Overall Study|Withdrawal by Subject|0
6083734|NCT00637195|9692294|FG001|Overall Study|Withdrawal by Subject|1
6083735|NCT00637273|9692314|FG000|Overall Study|Adverse Event|11
6083736|NCT00637273|9692315|FG001|Overall Study|Adverse Event|5
6083737|NCT00637273|9692316|FG002|Overall Study|Adverse Event|7
6353094|NCT04384523|10123752|FG005|Overall Study|Withdrawal by Subject|0
6353095|NCT04382066|10123797|FG000|Overall Study|Adverse Event|1
6353096|NCT04382066|10123798|FG001|Overall Study|Adverse Event|0
6353097|NCT04382066|10123799|FG002|Overall Study|Adverse Event|0
6353098|NCT04382066|10123797|FG000|Overall Study|Death|1
6353099|NCT04382066|10123798|FG001|Overall Study|Death|0
6353100|NCT04382066|10123799|FG002|Overall Study|Death|1
6353101|NCT04380688|10123860|FG000|Overall Study|Death|2
6353102|NCT04380688|10123861|FG001|Overall Study|Death|2
6353103|NCT04380688|10123860|FG000|Overall Study|Lost to Follow-up|2
6353104|NCT04380688|10123861|FG001|Overall Study|Lost to Follow-up|4
6353105|NCT04380688|10123860|FG000|Overall Study|Withdrawal by Subject|3
6353106|NCT04380688|10123861|FG001|Overall Study|Withdrawal by Subject|3
6353107|NCT04376060|10123867|FG000|Overall Study|Physician Decision|1
6353108|NCT04372186|10123886|FG000|Overall Study|Death|24
6353109|NCT04372186|10123887|FG001|Overall Study|Death|11
6353110|NCT04372186|10123886|FG000|Overall Study|Transferred to a different facility for care|0
6353111|NCT04372186|10123887|FG001|Overall Study|Transferred to a different facility for care|2
6083738|NCT00637273|9692314|FG000|Overall Study|Lost to Follow-up|8
6083739|NCT00637273|9692315|FG001|Overall Study|Lost to Follow-up|9
6083740|NCT00637273|9692316|FG002|Overall Study|Lost to Follow-up|13
6353112|NCT04370028|10123961|FG000|Overall Study|Withdrawal by Subject|695
6353113|NCT04370028|10123961|FG000|Overall Study|Protocol Violation|9
6353114|NCT04370028|10123961|FG000|Overall Study|Adverse Event|3
6353115|NCT04363736|10123974|FG000|Overall Study|Withdrawal by Subject|1
6353116|NCT04363736|10123975|FG001|Overall Study|Withdrawal by Subject|0
6353117|NCT04363736|10123974|FG000|Overall Study|Lost to Follow-up|10
6353118|NCT04363736|10123975|FG001|Overall Study|Lost to Follow-up|7
6353119|NCT04363736|10123974|FG000|Overall Study|Death|8
6353120|NCT04363736|10123975|FG001|Overall Study|Death|6
6353121|NCT04365699|10123993|FG000|Overall Study|Death|2
6353122|NCT04365699|10123994|FG001|Overall Study|Death|5
6353123|NCT04365699|10123995|FG002|Overall Study|Death|15
6353124|NCT04362137|10124028|FG000|Overall Study|Death|9
6353125|NCT04362137|10124029|FG001|Overall Study|Death|3
6353126|NCT04362137|10124028|FG000|Overall Study|Patient decision|6
6353127|NCT04362137|10124029|FG001|Overall Study|Patient decision|3
6353128|NCT04362137|10124028|FG000|Overall Study|Adverse Event|1
6353129|NCT04362137|10124029|FG001|Overall Study|Adverse Event|0
6353130|NCT04362137|10124028|FG000|Overall Study|Lost to Follow-up|1
6353131|NCT04362137|10124029|FG001|Overall Study|Lost to Follow-up|0
6353132|NCT04362137|10124028|FG000|Overall Study|Protocol deviation|1
6353133|NCT04362137|10124029|FG001|Overall Study|Protocol deviation|0
6353134|NCT04359771|10124037|FG000|Overall Study|Lack of Efficacy|2
6353135|NCT04359771|10124038|FG001|Overall Study|Lack of Efficacy|2
6353136|NCT04358081|10124051|FG000|Treatment Phase of Study|Withdrawal by Subject|0
6353137|NCT04358081|10124052|FG001|Treatment Phase of Study|Withdrawal by Subject|1
6353138|NCT04358081|10124053|FG002|Treatment Phase of Study|Withdrawal by Subject|1
6353139|NCT04358081|10124051|FG000|Treatment Phase of Study|Adverse Event|1
6353140|NCT04358081|10124052|FG001|Treatment Phase of Study|Adverse Event|0
6353141|NCT04358081|10124053|FG002|Treatment Phase of Study|Adverse Event|1
6353142|NCT04358081|10124051|FG000|Treatment Phase of Study|Physician Decision|2
6353143|NCT04358081|10124052|FG001|Treatment Phase of Study|Physician Decision|0
6353144|NCT04358081|10124053|FG002|Treatment Phase of Study|Physician Decision|1
6353145|NCT04358081|10124051|FG000|Treatment Phase of Study|Protocol Violation|1
6353146|NCT04358081|10124052|FG001|Treatment Phase of Study|Protocol Violation|0
6353147|NCT04358081|10124053|FG002|Treatment Phase of Study|Protocol Violation|0
6353148|NCT04358081|10124051|FG000|Study Completion Phase|Death|0
6353149|NCT04358081|10124052|FG001|Study Completion Phase|Death|0
6353150|NCT04358081|10124053|FG002|Study Completion Phase|Death|1
6353151|NCT04358081|10124051|FG000|Study Completion Phase|Lost to Follow-up|1
6353152|NCT04358081|10124052|FG001|Study Completion Phase|Lost to Follow-up|0
6353153|NCT04358081|10124053|FG002|Study Completion Phase|Lost to Follow-up|1
6353154|NCT04356937|10124065|FG000|Treatment (mITT Population)|Intubated before receiving study treatment|0
6353155|NCT04356937|10124066|FG001|Treatment (mITT Population)|Intubated before receiving study treatment|1
6353156|NCT04355663|10124075|FG000|Overall Study|Physician Decision|2
6353157|NCT04355663|10124076|FG001|Overall Study|Physician Decision|7
6353158|NCT04355663|10124077|FG002|Overall Study|Physician Decision|0
6353159|NCT04355663|10124075|FG000|Overall Study|Adverse Event|0
6353160|NCT04355663|10124076|FG001|Overall Study|Adverse Event|0
6353161|NCT04355663|10124077|FG002|Overall Study|Adverse Event|1
6353162|NCT04355663|10124075|FG000|Overall Study|Withdrawal by Subject|0
6353163|NCT04355663|10124076|FG001|Overall Study|Withdrawal by Subject|8
6353164|NCT04355663|10124077|FG002|Overall Study|Withdrawal by Subject|3
6353165|NCT04354870|10124087|FG000|Overall Study|Lost to Follow-up|32
6353166|NCT04354870|10124088|FG001|Overall Study|Lost to Follow-up|12
6353167|NCT04354870|10124087|FG000|Overall Study|Withdrawal by Subject|10
6353168|NCT04354870|10124088|FG001|Overall Study|Withdrawal by Subject|16
6353169|NCT04354870|10124087|FG000|Overall Study|Did not complete all study visits|6
6353170|NCT04354870|10124088|FG001|Overall Study|Did not complete all study visits|5
6353171|NCT04350788|10124114|FG000|Overall Study|Lost to Follow-up|6
6353172|NCT04350788|10124115|FG001|Overall Study|Lost to Follow-up|2
6353173|NCT04350788|10124114|FG000|Overall Study|Withdrawal by Subject|2
6353174|NCT04350788|10124115|FG001|Overall Study|Withdrawal by Subject|4
6353175|NCT04350788|10124114|FG000|Overall Study|Protocol Violation|4
6353176|NCT04350788|10124115|FG001|Overall Study|Protocol Violation|0
6353177|NCT04349917|10124128|FG000|First Intervention (2-4 Hours)|Withdrawal by Subject|0
6353178|NCT04349917|10124129|FG001|First Intervention (2-4 Hours)|Withdrawal by Subject|1
6353179|NCT04349917|10124128|FG000|First Intervention (2-4 Hours)|Unable to Swallow Pill|0
6353180|NCT04349917|10124129|FG001|First Intervention (2-4 Hours)|Unable to Swallow Pill|1
6353181|NCT04348851|10124140|FG000|Post-Test 1|Withdrawal by Subject|0
6353182|NCT04348851|10124141|FG001|Post-Test 1|Withdrawal by Subject|1
6353183|NCT04348851|10124142|FG002|Post-Test 1|Withdrawal by Subject|0
6353184|NCT04348851|10124143|FG003|Post-Test 1|Withdrawal by Subject|0
6353185|NCT04348851|10124140|FG000|Post-Test 1|Lost to Follow-up|0
6353186|NCT04348851|10124141|FG001|Post-Test 1|Lost to Follow-up|1
6353187|NCT04348851|10124142|FG002|Post-Test 1|Lost to Follow-up|0
6353188|NCT04348851|10124143|FG003|Post-Test 1|Lost to Follow-up|0
6353189|NCT04348851|10124140|FG000|Post-Test 2|Stroke survivor death|0
6353190|NCT04348851|10124141|FG001|Post-Test 2|Stroke survivor death|1
6353191|NCT04348851|10124142|FG002|Post-Test 2|Stroke survivor death|0
6353192|NCT04348851|10124143|FG003|Post-Test 2|Stroke survivor death|1
6353193|NCT04346199|10124164|FG000|Overall Study|Death|8
6353194|NCT04346199|10124165|FG001|Overall Study|Death|9
6353195|NCT04346199|10124164|FG000|Overall Study|Lost to Follow-up|0
6353196|NCT04346199|10124165|FG001|Overall Study|Lost to Follow-up|1
6353197|NCT04346199|10124164|FG000|Overall Study|Study terminated by sponsor incorrectly entered in database - participants completed the study|2
6353198|NCT04346199|10124165|FG001|Overall Study|Study terminated by sponsor incorrectly entered in database - participants completed the study|0
6353199|NCT04346199|10124164|FG000|Overall Study|Withdrawal by Subject|5
6353200|NCT04346199|10124165|FG001|Overall Study|Withdrawal by Subject|1
6353201|NCT04345653|10124171|FG000|Overall Study|Withdrawal by Subject|2
6353202|NCT04343261|10124176|FG000|Overall Study|Adverse Event|1
6353203|NCT04343261|10124176|FG000|Overall Study|received inadequate amount of antibodies|7
6353204|NCT04342897|10124208|FG000|Overall Study|Death|7
6353205|NCT04342897|10124209|FG001|Overall Study|Death|4
6353206|NCT04342897|10124208|FG000|Overall Study|Lost to Follow-up|6
6353207|NCT04342897|10124209|FG001|Overall Study|Lost to Follow-up|6
6353208|NCT04342897|10124208|FG000|Overall Study|Withdrawal by Subject|1
6353209|NCT04342897|10124209|FG001|Overall Study|Withdrawal by Subject|2
6353210|NCT04340557|10124221|FG000|Overall Study|Transferred to ICU and/or death|1
6353211|NCT04340557|10124222|FG001|Overall Study|Transferred to ICU and/or death|2
6353212|NCT04339972|10124230|FG000|Overall Study|Scheduling Issues|3
6353213|NCT04339972|10124231|FG001|Overall Study|Scheduling Issues|3
6353214|NCT04339972|10124230|FG000|Overall Study|dropout|1
6353215|NCT04339972|10124231|FG001|Overall Study|dropout|1
6353216|NCT04339972|10124230|FG000|Overall Study|Technical issues|1
6353217|NCT04339972|10124231|FG001|Overall Study|Technical issues|0
6353218|NCT04339972|10124230|FG000|Overall Study|Claustraphobia|0
6353219|NCT04339972|10124231|FG001|Overall Study|Claustraphobia|1
6353220|NCT04339296|10124239|FG000|Overall Study|Refuse to participate after allocation|1
6353221|NCT04339296|10124240|FG001|Overall Study|Refuse to participate after allocation|1
6353222|NCT04339296|10124239|FG000|Overall Study|Withdrew after completion of baseline|2
6353223|NCT04339296|10124240|FG001|Overall Study|Withdrew after completion of baseline|1
6353224|NCT04339296|10124239|FG000|Overall Study|Lost to Follow-up|0
6353225|NCT04339296|10124240|FG001|Overall Study|Lost to Follow-up|4
6353226|NCT04339296|10124239|FG000|Overall Study|Discontinued intervention|5
6353227|NCT04339296|10124240|FG001|Overall Study|Discontinued intervention|3
6353228|NCT04336475|10124270|FG000|Overall Study|pain|1
6353229|NCT04336475|10124271|FG001|Overall Study|pain|0
6353230|NCT04336475|10124270|FG000|Overall Study|upper respiratory infection|1
6353231|NCT04336475|10124271|FG001|Overall Study|upper respiratory infection|0
6353232|NCT04336475|10124270|FG000|Overall Study|Lost to Follow-up|0
6353233|NCT04336475|10124271|FG001|Overall Study|Lost to Follow-up|2
6353234|NCT04335929|10124277|FG000|Overall Study|Lost to Follow-up|10
6353235|NCT04335812|10124283|FG000|Overall Study|Withdrawal by Subject|1
6353236|NCT04335812|10124284|FG001|Overall Study|Withdrawal by Subject|3
6353237|NCT04335812|10124283|FG000|Overall Study|Lost to Follow-up|12
6353238|NCT04335812|10124284|FG001|Overall Study|Lost to Follow-up|12
6353239|NCT04335812|10124283|FG000|Overall Study|Did not engage in the intervention|22
6353240|NCT04335812|10124284|FG001|Overall Study|Did not engage in the intervention|18
6353241|NCT04335136|10124292|FG000|Overall Study|Death|8
6353242|NCT04335136|10124293|FG001|Overall Study|Death|4
6353243|NCT04335136|10124292|FG000|Overall Study|Lost to Follow-up|2
6353244|NCT04335136|10124293|FG001|Overall Study|Lost to Follow-up|0
6353245|NCT04335136|10124292|FG000|Overall Study|Protocol Violation|1
6353246|NCT04335136|10124293|FG001|Overall Study|Protocol Violation|0
6353247|NCT04335136|10124292|FG000|Overall Study|Withdrawal by Subject|1
6353248|NCT04335136|10124293|FG001|Overall Study|Withdrawal by Subject|1
6353249|NCT04335136|10124292|FG000|Overall Study|Health-threatening condition|0
6353250|NCT04335136|10124293|FG001|Overall Study|Health-threatening condition|1
6353251|NCT04335136|10124292|FG000|Overall Study|Adverse Event|0
6353252|NCT04335136|10124293|FG001|Overall Study|Adverse Event|1
6353253|NCT04335136|10124292|FG000|Overall Study|Erroneously randomized|2
6353254|NCT04335136|10124293|FG001|Overall Study|Erroneously randomized|0
6353255|NCT04333199|10124343|FG000|Evaluated Patients|Lost to Follow-up|0
6353256|NCT04333199|10124344|FG001|Evaluated Patients|Lost to Follow-up|1
6353257|NCT04333199|10124345|FG002|Evaluated Patients|Lost to Follow-up|2
6353258|NCT04332419|10124406|FG000|Overall Study|Withdrawal by Subject|1
6353259|NCT04332107|10124421|FG000|Day 3|Lost to Follow-up|23
6353260|NCT04332107|10124422|FG001|Day 3|Lost to Follow-up|14
6353261|NCT04332107|10124421|FG000|Day 3|Missing outcome data|3
6353262|NCT04332107|10124422|FG001|Day 3|Missing outcome data|6
6353263|NCT04332107|10124421|FG000|Day 14|Lost to Follow-up|13
6353264|NCT04332107|10124422|FG001|Day 14|Lost to Follow-up|4
6353265|NCT04332107|10124421|FG000|Day 14|Missing outcome data|4
6353266|NCT04332107|10124422|FG001|Day 14|Missing outcome data|4
6353267|NCT04332107|10124421|FG000|Day 21|Lost to Follow-up|10
6353268|NCT04332107|10124422|FG001|Day 21|Lost to Follow-up|2
6353269|NCT04329923|10124456|FG000|Overall Study|Withdrawal by Subject|1
6353270|NCT04329923|10124457|FG001|Overall Study|Withdrawal by Subject|4
6353271|NCT04329923|10124458|FG002|Overall Study|Withdrawal by Subject|1
6353272|NCT04329923|10124459|FG003|Overall Study|Withdrawal by Subject|1
6353273|NCT04329923|10124460|FG004|Overall Study|Withdrawal by Subject|1
6353274|NCT04329923|10124461|FG005|Overall Study|Withdrawal by Subject|1
6353275|NCT04329923|10124456|FG000|Overall Study|early termination of study|0
6353276|NCT04329923|10124457|FG001|Overall Study|early termination of study|0
6353277|NCT04329923|10124458|FG002|Overall Study|early termination of study|0
6353278|NCT04329923|10124459|FG003|Overall Study|early termination of study|0
6353279|NCT04329923|10124460|FG004|Overall Study|early termination of study|1
6353280|NCT04329923|10124461|FG005|Overall Study|early termination of study|2
6353281|NCT04329923|10124456|FG000|Overall Study|positive SARS-COV2 PCR at baseline|0
6353282|NCT04329923|10124457|FG001|Overall Study|positive SARS-COV2 PCR at baseline|0
6353283|NCT04329923|10124458|FG002|Overall Study|positive SARS-COV2 PCR at baseline|0
6353284|NCT04329923|10124459|FG003|Overall Study|positive SARS-COV2 PCR at baseline|0
6353285|NCT04329923|10124460|FG004|Overall Study|positive SARS-COV2 PCR at baseline|0
6353286|NCT04329923|10124461|FG005|Overall Study|positive SARS-COV2 PCR at baseline|2
6353287|NCT04328467|10124478|FG000|Overall Study|Did not meet inclusion criteria after randomization|4
6353288|NCT04328467|10124479|FG001|Overall Study|Did not meet inclusion criteria after randomization|2
6353289|NCT04328467|10124480|FG002|Overall Study|Did not meet inclusion criteria after randomization|1
6170256|NCT01252134|9816488|FG004|Period 1, 8 Hours|Personal Reasons|0
6353290|NCT04322526|10124490|FG000|First Intervention (1 Day)|Withdrawal by Subject|1
6353291|NCT04322526|10124491|FG001|First Intervention (1 Day)|Withdrawal by Subject|1
6353292|NCT04322526|10124490|FG000|Washout (1 Week)|Lost to Follow-up|1
6353293|NCT04322526|10124491|FG001|Washout (1 Week)|Lost to Follow-up|2
6353294|NCT04322682|10124508|FG000|Overall Study|Withdrawal by Subject|33
6353295|NCT04322682|10124509|FG001|Overall Study|Withdrawal by Subject|47
6353296|NCT04322682|10124508|FG000|Overall Study|Death|5
6353297|NCT04322682|10124509|FG001|Overall Study|Death|9
6353298|NCT04322682|10124508|FG000|Overall Study|Lost to Follow-up|4
6353299|NCT04322682|10124509|FG001|Overall Study|Lost to Follow-up|8
6353300|NCT04322682|10124508|FG000|Overall Study|Admitted to Hospital and Intubated|1
6353301|NCT04322682|10124509|FG001|Overall Study|Admitted to Hospital and Intubated|0
6353302|NCT04320615|10124560|FG000|Overall Study|Withdrawal by Subject|4
6353303|NCT04320615|10124561|FG001|Overall Study|Withdrawal by Subject|10
6353304|NCT04320615|10124560|FG000|Overall Study|Physician Decision|2
6353305|NCT04320615|10124561|FG001|Overall Study|Physician Decision|0
6353306|NCT04320615|10124560|FG000|Overall Study|Other|2
6353307|NCT04320615|10124561|FG001|Overall Study|Other|0
6353308|NCT04320615|10124560|FG000|Overall Study|Lost to Follow-up|5
6353309|NCT04320615|10124561|FG001|Overall Study|Lost to Follow-up|23
6353310|NCT04320615|10124560|FG000|Overall Study|Death|35
6353311|NCT04320615|10124561|FG001|Overall Study|Death|71
6353312|NCT04318535|10124571|FG000|Period2washout(Atleast 7 Days Post-dose)|Lost to Follow-up|0
6353313|NCT04318535|10124572|FG001|Period2washout(Atleast 7 Days Post-dose)|Lost to Follow-up|1
6353314|NCT04318535|10124573|FG002|Period2washout(Atleast 7 Days Post-dose)|Lost to Follow-up|0
6353315|NCT04314037|10124594|FG000|Treatment Period 2|Adverse Event|1
6353316|NCT04314037|10124595|FG001|Treatment Period 2|Adverse Event|0
6353317|NCT04314037|10124594|FG000|Treatment Period 3|Protocol Violation|1
6353318|NCT04314037|10124595|FG001|Treatment Period 3|Protocol Violation|0
6353319|NCT04314037|10124594|FG000|Treatment Period 3|Adverse Event|0
6353320|NCT04314037|10124595|FG001|Treatment Period 3|Adverse Event|1
6353321|NCT04315298|10124626|FG000|Overall Study|Withdrawal by Subject|0
6353322|NCT04315298|10124627|FG001|Overall Study|Withdrawal by Subject|0
6353323|NCT04315298|10124628|FG002|Overall Study|Withdrawal by Subject|0
6353324|NCT04315298|10124629|FG003|Overall Study|Withdrawal by Subject|2
6353325|NCT04315298|10124630|FG004|Overall Study|Withdrawal by Subject|2
6353326|NCT04315298|10124631|FG005|Overall Study|Withdrawal by Subject|2
6353327|NCT04315298|10124632|FG006|Overall Study|Withdrawal by Subject|0
6353328|NCT04315298|10124633|FG007|Overall Study|Withdrawal by Subject|1
6353329|NCT04315298|10124634|FG008|Overall Study|Withdrawal by Subject|1
6353330|NCT04315298|10124635|FG009|Overall Study|Withdrawal by Subject|1
6353331|NCT04315298|10124636|FG010|Overall Study|Withdrawal by Subject|0
6353332|NCT04315298|10124637|FG011|Overall Study|Withdrawal by Subject|0
6353333|NCT04315298|10124638|FG012|Overall Study|Withdrawal by Subject|0
6353334|NCT04315298|10124639|FG013|Overall Study|Withdrawal by Subject|0
6353335|NCT04315298|10124640|FG014|Overall Study|Withdrawal by Subject|0
6353336|NCT04315298|10124641|FG015|Overall Study|Withdrawal by Subject|0
6353337|NCT04315298|10124642|FG016|Overall Study|Withdrawal by Subject|0
6353338|NCT04315298|10124643|FG017|Overall Study|Withdrawal by Subject|0
6353339|NCT04315298|10124644|FG018|Overall Study|Withdrawal by Subject|0
6353340|NCT04315298|10124626|FG000|Overall Study|Physician Decision|0
6353341|NCT04315298|10124627|FG001|Overall Study|Physician Decision|0
6353342|NCT04315298|10124628|FG002|Overall Study|Physician Decision|0
6353343|NCT04315298|10124629|FG003|Overall Study|Physician Decision|0
6353344|NCT04315298|10124630|FG004|Overall Study|Physician Decision|1
6353345|NCT04315298|10124631|FG005|Overall Study|Physician Decision|0
6353346|NCT04315298|10124632|FG006|Overall Study|Physician Decision|0
6353347|NCT04315298|10124633|FG007|Overall Study|Physician Decision|0
6353348|NCT04315298|10124634|FG008|Overall Study|Physician Decision|0
6353349|NCT04315298|10124635|FG009|Overall Study|Physician Decision|0
6353350|NCT04315298|10124636|FG010|Overall Study|Physician Decision|0
6353351|NCT04315298|10124637|FG011|Overall Study|Physician Decision|0
6353352|NCT04315298|10124638|FG012|Overall Study|Physician Decision|0
6353353|NCT04315298|10124639|FG013|Overall Study|Physician Decision|0
6353354|NCT04315298|10124640|FG014|Overall Study|Physician Decision|0
6353355|NCT04315298|10124641|FG015|Overall Study|Physician Decision|0
6353356|NCT04315298|10124642|FG016|Overall Study|Physician Decision|0
6353357|NCT04315298|10124643|FG017|Overall Study|Physician Decision|0
6353358|NCT04315298|10124644|FG018|Overall Study|Physician Decision|0
6170257|NCT01252134|9816489|FG005|Period 1, 8 Hours|Personal Reasons|0
6353359|NCT04315298|10124626|FG000|Overall Study|Lost to Follow-up|5
6353360|NCT04315298|10124627|FG001|Overall Study|Lost to Follow-up|10
6353361|NCT04315298|10124628|FG002|Overall Study|Lost to Follow-up|6
6353362|NCT04315298|10124629|FG003|Overall Study|Lost to Follow-up|8
6353363|NCT04315298|10124630|FG004|Overall Study|Lost to Follow-up|12
6353364|NCT04315298|10124631|FG005|Overall Study|Lost to Follow-up|13
6353365|NCT04315298|10124632|FG006|Overall Study|Lost to Follow-up|9
6353366|NCT04315298|10124633|FG007|Overall Study|Lost to Follow-up|16
6353367|NCT04315298|10124634|FG008|Overall Study|Lost to Follow-up|14
6353368|NCT04315298|10124635|FG009|Overall Study|Lost to Follow-up|0
6353369|NCT04315298|10124636|FG010|Overall Study|Lost to Follow-up|2
6353370|NCT04315298|10124637|FG011|Overall Study|Lost to Follow-up|1
6353371|NCT04315298|10124638|FG012|Overall Study|Lost to Follow-up|0
6353372|NCT04315298|10124639|FG013|Overall Study|Lost to Follow-up|0
6353373|NCT04315298|10124640|FG014|Overall Study|Lost to Follow-up|0
6353374|NCT04315298|10124641|FG015|Overall Study|Lost to Follow-up|2
6353375|NCT04315298|10124642|FG016|Overall Study|Lost to Follow-up|0
6353376|NCT04315298|10124643|FG017|Overall Study|Lost to Follow-up|0
6353377|NCT04315298|10124644|FG018|Overall Study|Lost to Follow-up|0
6353378|NCT04315298|10124626|FG000|Overall Study|Death|24
6353379|NCT04315298|10124627|FG001|Overall Study|Death|60
6353380|NCT04315298|10124628|FG002|Overall Study|Death|49
6353381|NCT04315298|10124629|FG003|Overall Study|Death|59
6353382|NCT04315298|10124630|FG004|Overall Study|Death|70
6353383|NCT04315298|10124631|FG005|Overall Study|Death|114
6353384|NCT04315298|10124632|FG006|Overall Study|Death|9
6353385|NCT04315298|10124633|FG007|Overall Study|Death|12
6353386|NCT04315298|10124634|FG008|Overall Study|Death|21
6353387|NCT04315298|10124635|FG009|Overall Study|Death|16
6353388|NCT04315298|10124636|FG010|Overall Study|Death|40
6353389|NCT04315298|10124637|FG011|Overall Study|Death|40
6353390|NCT04315298|10124638|FG012|Overall Study|Death|3
6353391|NCT04315298|10124639|FG013|Overall Study|Death|4
6353392|NCT04315298|10124640|FG014|Overall Study|Death|6
6353393|NCT04315298|10124641|FG015|Overall Study|Death|4
6353394|NCT04315298|10124642|FG016|Overall Study|Death|3
6353395|NCT04315298|10124643|FG017|Overall Study|Death|1
6353396|NCT04315298|10124644|FG018|Overall Study|Death|0
6353397|NCT04308239|10124754|FG000|Pre-intervention Evaluation (1 Week)|Did not attend due to schedule conflict|2
6353398|NCT04308239|10124755|FG001|Pre-intervention Evaluation (1 Week)|Did not attend due to schedule conflict|1
6353399|NCT04308239|10124754|FG000|Pre-intervention Evaluation (1 Week)|testing error during evaluation|1
6353400|NCT04308239|10124755|FG001|Pre-intervention Evaluation (1 Week)|testing error during evaluation|2
6353401|NCT04308239|10124754|FG000|Post-intervention Evaluation (1 Week)|Withdrawal by Subject|1
6353402|NCT04308239|10124755|FG001|Post-intervention Evaluation (1 Week)|Withdrawal by Subject|2
6353403|NCT04308239|10124754|FG000|Post-intervention Evaluation (1 Week)|testing error during evaluation|0
6353404|NCT04308239|10124755|FG001|Post-intervention Evaluation (1 Week)|testing error during evaluation|2
6353405|NCT04308668|10124767|FG000|Overall Study|Lost to Follow-up|32
6353406|NCT04308668|10124768|FG001|Overall Study|Lost to Follow-up|38
6353407|NCT04308668|10124767|FG000|Overall Study|Withdrawal by Subject|4
6353408|NCT04308668|10124768|FG001|Overall Study|Withdrawal by Subject|4
6353409|NCT04307940|10124777|FG000|Overall Study|Adverse Event|1
6353410|NCT04307940|10124778|FG001|Overall Study|Adverse Event|0
6353411|NCT04307940|10124779|FG002|Overall Study|Adverse Event|0
6353412|NCT04307940|10124777|FG000|Overall Study|Withdrawal by Subject|2
6353413|NCT04307940|10124778|FG001|Overall Study|Withdrawal by Subject|3
6353414|NCT04307940|10124779|FG002|Overall Study|Withdrawal by Subject|1
6353415|NCT04307940|10124777|FG000|Overall Study|Lost to Follow-up|2
6353416|NCT04307940|10124778|FG001|Overall Study|Lost to Follow-up|0
6353417|NCT04307940|10124779|FG002|Overall Study|Lost to Follow-up|1
6353418|NCT04302545|10124789|FG000|Overall Study|Lost to Follow-up|3
6353419|NCT04302545|10124790|FG001|Overall Study|Lost to Follow-up|4
6353420|NCT04297241|10124812|FG000|Overall Study|Withdrawal by Subject|1
6353421|NCT04297241|10124812|FG000|Overall Study|Adverse Event|1
6353422|NCT04297241|10124812|FG000|Overall Study|Physician Decision|3
6353423|NCT04295356|10124841|FG000|Overall Study|Physician Decision|1
6353424|NCT04295356|10124842|FG001|Overall Study|Physician Decision|0
6353425|NCT04295356|10124841|FG000|Overall Study|Lost to Follow-up|0
6353426|NCT04295356|10124842|FG001|Overall Study|Lost to Follow-up|3
6353427|NCT04295356|10124841|FG000|Overall Study|Protocol Violation|0
6353428|NCT04295356|10124842|FG001|Overall Study|Protocol Violation|1
6353429|NCT04292535|10124866|FG000|Overall Study|Withdrawal by Subject|0
6353430|NCT04292535|10124867|FG001|Overall Study|Withdrawal by Subject|0
6353431|NCT04292535|10124868|FG002|Overall Study|Withdrawal by Subject|0
6353432|NCT04292535|10124869|FG003|Overall Study|Withdrawal by Subject|0
6353433|NCT04292535|10124870|FG004|Overall Study|Withdrawal by Subject|0
6353434|NCT04292535|10124871|FG005|Overall Study|Withdrawal by Subject|0
6353435|NCT04292535|10124872|FG006|Overall Study|Withdrawal by Subject|0
6353436|NCT04292535|10124873|FG007|Overall Study|Withdrawal by Subject|1
6353437|NCT04292535|10124874|FG008|Overall Study|Withdrawal by Subject|0
6353438|NCT04292535|10124875|FG009|Overall Study|Withdrawal by Subject|0
6353439|NCT04292535|10124876|FG010|Overall Study|Withdrawal by Subject|0
6353440|NCT04292535|10124877|FG011|Overall Study|Withdrawal by Subject|0
6353441|NCT04292535|10124878|FG012|Overall Study|Withdrawal by Subject|0
6353442|NCT04292535|10124879|FG013|Overall Study|Withdrawal by Subject|0
6353443|NCT04292535|10124866|FG000|Overall Study|Condition stopped due to Blood Sugar Below 70 mg/dL|0
6353444|NCT04292535|10124867|FG001|Overall Study|Condition stopped due to Blood Sugar Below 70 mg/dL|0
6353445|NCT04292535|10124868|FG002|Overall Study|Condition stopped due to Blood Sugar Below 70 mg/dL|0
6353446|NCT04292535|10124869|FG003|Overall Study|Condition stopped due to Blood Sugar Below 70 mg/dL|0
6353447|NCT04292535|10124870|FG004|Overall Study|Condition stopped due to Blood Sugar Below 70 mg/dL|0
6353448|NCT04292535|10124871|FG005|Overall Study|Condition stopped due to Blood Sugar Below 70 mg/dL|0
6353449|NCT04292535|10124872|FG006|Overall Study|Condition stopped due to Blood Sugar Below 70 mg/dL|0
6353450|NCT04292535|10124873|FG007|Overall Study|Condition stopped due to Blood Sugar Below 70 mg/dL|1
6353451|NCT04292535|10124874|FG008|Overall Study|Condition stopped due to Blood Sugar Below 70 mg/dL|0
6353452|NCT04292535|10124875|FG009|Overall Study|Condition stopped due to Blood Sugar Below 70 mg/dL|0
6353453|NCT04292535|10124876|FG010|Overall Study|Condition stopped due to Blood Sugar Below 70 mg/dL|0
6353454|NCT04292535|10124877|FG011|Overall Study|Condition stopped due to Blood Sugar Below 70 mg/dL|0
6353455|NCT04292535|10124878|FG012|Overall Study|Condition stopped due to Blood Sugar Below 70 mg/dL|1
6353456|NCT04292535|10124879|FG013|Overall Study|Condition stopped due to Blood Sugar Below 70 mg/dL|1
6353457|NCT04292535|10124866|FG000|Overall Study|Report of Dizziness|0
6353458|NCT04292535|10124867|FG001|Overall Study|Report of Dizziness|0
6353459|NCT04292535|10124868|FG002|Overall Study|Report of Dizziness|0
6353460|NCT04292535|10124869|FG003|Overall Study|Report of Dizziness|0
6353461|NCT04292535|10124870|FG004|Overall Study|Report of Dizziness|0
6353462|NCT04292535|10124871|FG005|Overall Study|Report of Dizziness|0
6353463|NCT04292535|10124872|FG006|Overall Study|Report of Dizziness|0
6353464|NCT04292535|10124873|FG007|Overall Study|Report of Dizziness|0
6353465|NCT04292535|10124874|FG008|Overall Study|Report of Dizziness|0
6353466|NCT04292535|10124875|FG009|Overall Study|Report of Dizziness|0
6353467|NCT04292535|10124876|FG010|Overall Study|Report of Dizziness|0
6353468|NCT04292535|10124877|FG011|Overall Study|Report of Dizziness|0
6353469|NCT04292535|10124878|FG012|Overall Study|Report of Dizziness|0
6353470|NCT04292535|10124879|FG013|Overall Study|Report of Dizziness|1
6353471|NCT04292535|10124866|FG000|Overall Study|Equipment Failure|0
6353472|NCT04292535|10124867|FG001|Overall Study|Equipment Failure|0
6353473|NCT04292535|10124868|FG002|Overall Study|Equipment Failure|0
6353474|NCT04292535|10124869|FG003|Overall Study|Equipment Failure|0
6353475|NCT04292535|10124870|FG004|Overall Study|Equipment Failure|0
6353476|NCT04292535|10124871|FG005|Overall Study|Equipment Failure|0
6353477|NCT04292535|10124872|FG006|Overall Study|Equipment Failure|0
6353478|NCT04292535|10124873|FG007|Overall Study|Equipment Failure|0
6170258|NCT01252186|9816504|FG000|Overall Study|Adverse Event|9
6170259|NCT01252186|9816505|FG001|Overall Study|Adverse Event|6
6170260|NCT01252186|9816506|FG002|Overall Study|Adverse Event|8
6170261|NCT01252186|9816504|FG000|Overall Study|Withdrawal by Subject|2
6170262|NCT01252186|9816505|FG001|Overall Study|Withdrawal by Subject|5
6170263|NCT01252186|9816506|FG002|Overall Study|Withdrawal by Subject|2
6170264|NCT01252186|9816504|FG000|Overall Study|Physician Decision|0
6170265|NCT01252186|9816505|FG001|Overall Study|Physician Decision|0
6353479|NCT04292535|10124874|FG008|Overall Study|Equipment Failure|0
6353480|NCT04292535|10124875|FG009|Overall Study|Equipment Failure|0
6353481|NCT04292535|10124876|FG010|Overall Study|Equipment Failure|0
6353482|NCT04292535|10124877|FG011|Overall Study|Equipment Failure|1
6353483|NCT04292535|10124878|FG012|Overall Study|Equipment Failure|0
6353484|NCT04292535|10124879|FG013|Overall Study|Equipment Failure|0
6353485|NCT04292171|10124911|FG000|Overall Study|Pharmacy error|2
6353486|NCT04292171|10124912|FG001|Overall Study|Pharmacy error|0
6353487|NCT04292171|10124911|FG000|Overall Study|Delivered prior to procedure|0
6353488|NCT04292171|10124912|FG001|Overall Study|Delivered prior to procedure|1
6353489|NCT04292899|10124922|FG000|Overall Study|Death|21
6353490|NCT04292899|10124923|FG001|Overall Study|Death|28
6353491|NCT04292899|10124924|FG002|Overall Study|Death|188
6353492|NCT04292899|10124925|FG003|Overall Study|Death|371
6353493|NCT04292899|10124922|FG000|Overall Study|Lost to Follow-up|8
6353494|NCT04292899|10124923|FG001|Overall Study|Lost to Follow-up|4
6353495|NCT04292899|10124924|FG002|Overall Study|Lost to Follow-up|22
6353496|NCT04292899|10124925|FG003|Overall Study|Lost to Follow-up|235
6353497|NCT04292899|10124922|FG000|Overall Study|Withdrew consent|1
6353498|NCT04292899|10124923|FG001|Overall Study|Withdrew consent|0
6353499|NCT04292899|10124924|FG002|Overall Study|Withdrew consent|11
6353500|NCT04292899|10124925|FG003|Overall Study|Withdrew consent|32
6353501|NCT04292899|10124922|FG000|Overall Study|Adverse Event|2
6353502|NCT04292899|10124923|FG001|Overall Study|Adverse Event|1
6353503|NCT04292899|10124924|FG002|Overall Study|Adverse Event|2
6353504|NCT04292899|10124925|FG003|Overall Study|Adverse Event|2
6353505|NCT04292899|10124922|FG000|Overall Study|Investigator's Discretion|0
6353506|NCT04292899|10124923|FG001|Overall Study|Investigator's Discretion|0
6353507|NCT04292899|10124924|FG002|Overall Study|Investigator's Discretion|0
6353508|NCT04292899|10124925|FG003|Overall Study|Investigator's Discretion|3
6353509|NCT04292899|10124922|FG000|Overall Study|Non-compliance With Study Drug|0
6353510|NCT04292899|10124923|FG001|Overall Study|Non-compliance With Study Drug|0
6353511|NCT04292899|10124924|FG002|Overall Study|Non-compliance With Study Drug|0
6353512|NCT04292899|10124925|FG003|Overall Study|Non-compliance With Study Drug|1
6353513|NCT04292899|10124922|FG000|Overall Study|Protocol Violation|0
6353514|NCT04292899|10124923|FG001|Overall Study|Protocol Violation|0
6353515|NCT04292899|10124924|FG002|Overall Study|Protocol Violation|0
6353516|NCT04292899|10124925|FG003|Overall Study|Protocol Violation|1
6353517|NCT04292730|10124937|FG000|Overall Study|Lost to Follow-up|8
6353518|NCT04292730|10124938|FG001|Overall Study|Lost to Follow-up|12
6353519|NCT04292730|10124939|FG002|Overall Study|Lost to Follow-up|12
6353520|NCT04292730|10124940|FG003|Overall Study|Lost to Follow-up|48
6353521|NCT04292730|10124937|FG000|Overall Study|Death|2
6353522|NCT04292730|10124938|FG001|Overall Study|Death|2
6353523|NCT04292730|10124939|FG002|Overall Study|Death|4
6353524|NCT04292730|10124940|FG003|Overall Study|Death|12
6353525|NCT04292730|10124937|FG000|Overall Study|Withdrew Consent|2
6353526|NCT04292730|10124938|FG001|Overall Study|Withdrew Consent|2
6353527|NCT04292730|10124939|FG002|Overall Study|Withdrew Consent|5
6353528|NCT04292730|10124940|FG003|Overall Study|Withdrew Consent|6
6353529|NCT04292730|10124937|FG000|Overall Study|Non-Compliance with Study Drug|0
6353530|NCT04292730|10124938|FG001|Overall Study|Non-Compliance with Study Drug|1
6083741|NCT00637273|9692314|FG000|Overall Study|Protocol Violation|2
6170266|NCT01252186|9816506|FG002|Overall Study|Physician Decision|1
6353531|NCT04292730|10124939|FG002|Overall Study|Non-Compliance with Study Drug|0
6353532|NCT04292730|10124940|FG003|Overall Study|Non-Compliance with Study Drug|0
6353533|NCT04292730|10124937|FG000|Overall Study|Protocol Violation|0
6353534|NCT04292730|10124938|FG001|Overall Study|Protocol Violation|0
6353535|NCT04292730|10124939|FG002|Overall Study|Protocol Violation|1
6353536|NCT04292730|10124940|FG003|Overall Study|Protocol Violation|0
6353537|NCT04292730|10124937|FG000|Overall Study|Randomized but not Treated|8
6353538|NCT04292730|10124938|FG001|Overall Study|Randomized but not Treated|4
6353539|NCT04292730|10124939|FG002|Overall Study|Randomized but not Treated|0
6353540|NCT04292730|10124940|FG003|Overall Study|Randomized but not Treated|14
6353541|NCT04289623|10124973|FG000|Wave 1 Emails|Email was not delivered|268
6353542|NCT04289623|10124974|FG001|Wave 1 Emails|Email was not delivered|257
6353543|NCT04289623|10124975|FG002|Wave 1 Emails|Email was not delivered|0
6353544|NCT04289623|10124976|FG003|Wave 1 Emails|Email was not delivered|0
6353545|NCT04289623|10124977|FG004|Wave 1 Emails|Email was not delivered|0
6353546|NCT04289623|10124978|FG005|Wave 1 Emails|Email was not delivered|0
6353547|NCT04276207|10124992|FG000|Period 1|Withdrawal by Subject|0
6353548|NCT04276207|10124993|FG001|Period 1|Withdrawal by Subject|1
6353549|NCT04287517|10125023|FG000|Overall Study|Withdrawal by Subject|1
6353550|NCT04287517|10125024|FG001|Overall Study|Withdrawal by Subject|1
6353551|NCT04275336|10125094|FG000|Overall Study|First venipuncture failed|4
6353552|NCT04275336|10125095|FG001|Overall Study|First venipuncture failed|6
6353553|NCT04275336|10125096|FG002|Overall Study|First venipuncture failed|5
6353554|NCT04275336|10125094|FG000|Overall Study|Unscheduled venipuncture|9
6353555|NCT04275336|10125095|FG001|Overall Study|Unscheduled venipuncture|13
6353556|NCT04275336|10125096|FG002|Overall Study|Unscheduled venipuncture|7
6353557|NCT04275336|10125094|FG000|Overall Study|Failed specimen of saliva|4
6353558|NCT04275336|10125095|FG001|Overall Study|Failed specimen of saliva|3
6353559|NCT04275336|10125096|FG002|Overall Study|Failed specimen of saliva|4
6353560|NCT04272775|10125109|FG000|Overall Study|Study Terminated by Sponsor|1
6353561|NCT04272775|10125110|FG001|Overall Study|Study Terminated by Sponsor|0
6353562|NCT04272775|10125109|FG000|Overall Study|Protocol Violation|0
6353563|NCT04272775|10125110|FG001|Overall Study|Protocol Violation|1
6353564|NCT04272775|10125109|FG000|Overall Study|Symptomatic Deterioration|1
6353565|NCT04272775|10125110|FG001|Overall Study|Symptomatic Deterioration|1
6353566|NCT04272775|10125109|FG000|Overall Study|Withdrawal by Subject|1
6353567|NCT04272775|10125110|FG001|Overall Study|Withdrawal by Subject|2
6353568|NCT04272775|10125109|FG000|Overall Study|Adverse Event|1
6353569|NCT04272775|10125110|FG001|Overall Study|Adverse Event|2
6353570|NCT04272775|10125109|FG000|Overall Study|Progressive Disease|3
6353571|NCT04272775|10125110|FG001|Overall Study|Progressive Disease|1
6353572|NCT04271605|10125142|FG000|Overall Study|The study was terminated because of the duration of funding was only one year.|5
6353573|NCT04268316|10125153|FG000|Overall Study|Withdrawal by Subject|2
6353574|NCT04268316|10125154|FG001|Overall Study|Withdrawal by Subject|1
6353575|NCT04268316|10125155|FG002|Overall Study|Withdrawal by Subject|0
6353576|NCT04263142|10125198|FG000|Part 2 Period 1 (Day 1)|Adverse Event|0
6353577|NCT04263142|10125199|FG001|Part 2 Period 1 (Day 1)|Adverse Event|0
6353578|NCT04263142|10125200|FG002|Part 2 Period 1 (Day 1)|Adverse Event|0
6353579|NCT04263142|10125201|FG003|Part 2 Period 1 (Day 1)|Adverse Event|0
6353580|NCT04263142|10125202|FG004|Part 2 Period 1 (Day 1)|Adverse Event|1
6353581|NCT04263142|10125198|FG000|Part 2 Period 2 (Day 1)|Physician Decision|0
6353582|NCT04263142|10125199|FG001|Part 2 Period 2 (Day 1)|Physician Decision|0
6353583|NCT04263142|10125200|FG002|Part 2 Period 2 (Day 1)|Physician Decision|0
6353584|NCT04263142|10125201|FG003|Part 2 Period 2 (Day 1)|Physician Decision|0
6353585|NCT04263142|10125202|FG004|Part 2 Period 2 (Day 1)|Physician Decision|1
6353586|NCT04256785|10125217|FG000|Overall Study|Adverse Event|8
6353587|NCT04256785|10125218|FG001|Overall Study|Adverse Event|6
6353588|NCT04256785|10125217|FG000|Overall Study|Lack of Efficacy|3
6353589|NCT04256785|10125218|FG001|Overall Study|Lack of Efficacy|4
6353590|NCT04256785|10125217|FG000|Overall Study|Lost to Follow-up|7
6353591|NCT04256785|10125218|FG001|Overall Study|Lost to Follow-up|7
6353592|NCT04256785|10125217|FG000|Overall Study|Protocol Violation|1
6353593|NCT04256785|10125218|FG001|Overall Study|Protocol Violation|0
6353594|NCT04256785|10125217|FG000|Overall Study|Withdrawal by Subject|4
6353595|NCT04256785|10125218|FG001|Overall Study|Withdrawal by Subject|1
6353596|NCT04256785|10125217|FG000|Overall Study|Surgery or quarantined due to Covid-19|5
6353597|NCT04256785|10125218|FG001|Overall Study|Surgery or quarantined due to Covid-19|7
6353598|NCT04249336|10125243|FG000|Overall Study|Lost to Follow-up|3
6353599|NCT04249336|10125244|FG001|Overall Study|Lost to Follow-up|3
6353600|NCT04249336|10125245|FG002|Overall Study|Lost to Follow-up|3
6353601|NCT04249336|10125246|FG003|Overall Study|Lost to Follow-up|3
6353602|NCT04247061|10125274|FG000|Overall Study|Could not attend dental clinic visit due to state mandated closure due to Covid-19 pandemic|6
6353603|NCT04247061|10125274|FG000|Overall Study|Subjects canceled their dental hygiene appt. (& thus the research visit) due to Covid-19 concerns|2
6353604|NCT04247061|10125274|FG000|Overall Study|Participant indicated inability to wear VR headset at dental appt.|1
6353605|NCT04245202|10125280|FG000|Overall Study|Lack of Efficacy|10
6353606|NCT04245202|10125281|FG001|Overall Study|Lack of Efficacy|1
6353607|NCT04238650|10125312|FG000|Overall Study|Withdrawal by Subject|0
6353608|NCT04238650|10125313|FG001|Overall Study|Withdrawal by Subject|1
6353609|NCT04238663|10125322|FG000|Overall Study|Lost to Follow-up|0
6353610|NCT04238663|10125323|FG001|Overall Study|Lost to Follow-up|1
6353611|NCT04238663|10125324|FG002|Overall Study|Lost to Follow-up|0
6353612|NCT04222699|10125398|FG000|Overall Study|Lost to Follow-up|2
6353613|NCT04206293|10125421|FG000|Overall Study|Consent withdrawal|1
6353614|NCT04228302|10125432|FG000|Overall Study|Adverse Event|0
6353615|NCT04228302|10125433|FG001|Overall Study|Adverse Event|0
6353616|NCT04228302|10125434|FG002|Overall Study|Adverse Event|0
6353617|NCT04228302|10125435|FG003|Overall Study|Adverse Event|0
6353618|NCT04228302|10125436|FG004|Overall Study|Adverse Event|1
6353619|NCT04228302|10125437|FG005|Overall Study|Adverse Event|0
6353620|NCT04223687|10125475|FG000|Overall Study|Missing primary outcome|1
6353621|NCT04223687|10125476|FG001|Overall Study|Missing primary outcome|0
6353622|NCT04223232|10125482|FG000|Overall Study|Withdrawal by Subject|1
6353623|NCT04189224|10125486|FG000|Period 2|Adverse Event|0
6353624|NCT04189224|10125487|FG001|Period 2|Adverse Event|1
6353625|NCT04214600|10125495|FG000|Overall Study|Lost to Follow-up|9
6353626|NCT04214600|10125496|FG001|Overall Study|Lost to Follow-up|14
6353627|NCT04202497|10125503|FG000|Baseline Scan (Day-1)|Metabolites of [18F]MNI-1054 could not be analyzed|1
6353628|NCT04202497|10125504|FG001|Baseline Scan (Day-1)|Metabolites of [18F]MNI-1054 could not be analyzed|0
6353629|NCT04202497|10125505|FG002|Baseline Scan (Day-1)|Metabolites of [18F]MNI-1054 could not be analyzed|0
6353630|NCT04202497|10125506|FG003|Baseline Scan (Day-1)|Metabolites of [18F]MNI-1054 could not be analyzed|0
6353631|NCT04209530|10125533|FG000|Overall Study|Terminated due to the major disruption in study visits and protocol assessments due to COVID-19|4
6353632|NCT04209530|10125534|FG001|Overall Study|Terminated due to the major disruption in study visits and protocol assessments due to COVID-19|2
6353633|NCT04209530|10125533|FG000|Overall Study|Withdrawal by Subject|0
6353634|NCT04209530|10125534|FG001|Overall Study|Withdrawal by Subject|1
6353635|NCT04207840|10125554|FG000|Washout Period 1 (2-7 Days)|Withdrawal by Subject|0
6353636|NCT04207840|10125555|FG001|Washout Period 1 (2-7 Days)|Withdrawal by Subject|0
6353637|NCT04207840|10125556|FG002|Washout Period 1 (2-7 Days)|Withdrawal by Subject|1
6353638|NCT04207840|10125554|FG000|Washout Period 2 (2-7 Days)|Withdrawal by Subject|0
6353639|NCT04207840|10125555|FG001|Washout Period 2 (2-7 Days)|Withdrawal by Subject|0
6353640|NCT04207840|10125556|FG002|Washout Period 2 (2-7 Days)|Withdrawal by Subject|1
6353641|NCT04206384|10125591|FG000|Overall Study|Withdrawal by Subject|8
6353642|NCT04206384|10125591|FG000|Overall Study|Adverse Event|2
6353643|NCT04195893|10125612|FG000|Second Intervention|Withdrawal by Subject|1
6353644|NCT04195893|10125613|FG001|Second Intervention|Withdrawal by Subject|0
6353645|NCT04195581|10125628|FG000|Comfilcon A With All in One Light|Withdrawal by Subject|4
6353646|NCT04195581|10125628|FG000|Comfilcon A With Hy-Care|Withdrawal by Subject|5
6353647|NCT04195581|10125628|FG000|Comfilcon A With Refine One Step|Withdrawal by Subject|1
6353648|NCT04195581|10125628|FG000|Fanfilcon A With All in One Light|Withdrawal by Subject|1
6353649|NCT04195581|10125628|FG000|Fanfilcon A With Hy-Care|Withdrawal by Subject|3
6353650|NCT04195581|10125628|FG000|Fanfilcon A With Refine One Step|Withdrawal by Subject|2
6353651|NCT04194151|10125652|FG000|Overall Study|Physician Decision|1
6353652|NCT04194151|10125653|FG001|Overall Study|Physician Decision|1
6353653|NCT04194151|10125654|FG002|Overall Study|Physician Decision|1
6353654|NCT04194151|10125655|FG003|Overall Study|Physician Decision|1
6353655|NCT04194151|10125656|FG004|Overall Study|Physician Decision|0
6353656|NCT04194151|10125657|FG005|Overall Study|Physician Decision|1
6353657|NCT04194151|10125652|FG000|Overall Study|Monitorization problem|0
6353658|NCT04194151|10125653|FG001|Overall Study|Monitorization problem|1
6353659|NCT04194151|10125654|FG002|Overall Study|Monitorization problem|0
6353660|NCT04194151|10125655|FG003|Overall Study|Monitorization problem|0
6353661|NCT04194151|10125656|FG004|Overall Study|Monitorization problem|0
6353662|NCT04194151|10125657|FG005|Overall Study|Monitorization problem|0
6353663|NCT04194008|10125671|FG000|Baseline (Run-in) Phase|Fail to comply with Run-in phase criteria|19
6353664|NCT04194008|10125671|FG000|Baseline (Run-in) Phase|Withdrawal by Subject|6
6353665|NCT04194008|10125671|FG000|Baseline (Run-in) Phase|Lost to Follow-up|2
6353666|NCT04194008|10125671|FG000|Treatment Phase With Nerivio|Withdrawal by Subject|3
6353667|NCT04194008|10125671|FG000|Treatment Phase With Nerivio|Missing data|4
6353668|NCT04194008|10125671|FG000|Treatment Phase With Nerivio|Lost to Follow-up|1
6353669|NCT04189081|10125682|FG000|Overall Study|Lost to Follow-up|1
6353670|NCT04189081|10125683|FG001|Overall Study|Lost to Follow-up|0
6353671|NCT04189081|10125684|FG002|Overall Study|Lost to Follow-up|0
6353672|NCT04189081|10125682|FG000|Overall Study|Withdrawal by Subject|0
6353673|NCT04189081|10125683|FG001|Overall Study|Withdrawal by Subject|0
6353674|NCT04189081|10125684|FG002|Overall Study|Withdrawal by Subject|1
6353675|NCT04186806|10125705|FG000|Period 1: 7 Days|Adverse Event|1
6353676|NCT04186806|10125706|FG001|Period 1: 7 Days|Adverse Event|0
6353677|NCT04179838|10125740|FG000|First Intervention (1 Day)|Withdrawal by Subject|0
6353678|NCT04179838|10125741|FG001|First Intervention (1 Day)|Withdrawal by Subject|3
6353679|NCT04179838|10125740|FG000|Second Intervention (1 Day)|Protocol Violation|0
6353680|NCT04179838|10125741|FG001|Second Intervention (1 Day)|Protocol Violation|1
6353681|NCT04179461|10125747|FG000|Overall Study|Lost to Follow-up|4
6353682|NCT04178590|10125775|FG000|Overall Study|Pregnancy|1
6353683|NCT04178590|10125775|FG000|Overall Study|Lost to Follow-up|1
6353684|NCT04177862|10125803|FG000|Overall Study|Protocol Violation|2
6353685|NCT04177862|10125804|FG001|Overall Study|Protocol Violation|7
6353686|NCT04173741|10125879|FG000|Overall Study|IVC measurement cannot be done|1
6353687|NCT04173741|10125880|FG001|Overall Study|IVC measurement cannot be done|1
6353688|NCT04169061|10125886|FG000|Overall Study|Adverse Event|2
6353689|NCT04169061|10125886|FG000|Overall Study|Death|1
6353690|NCT04169061|10125886|FG000|Overall Study|Withdrawal by Subject|1
6353691|NCT04169061|10125886|FG000|Overall Study|Protocol Violation|1
6353692|NCT04157738|10125892|FG000|Overall Study|Moved out of state|0
6353693|NCT04157738|10125893|FG001|Overall Study|Moved out of state|2
6353694|NCT04157738|10125892|FG000|Overall Study|Did not show up to the Follow-up appointment|1
6353695|NCT04157738|10125893|FG001|Overall Study|Did not show up to the Follow-up appointment|0
6353696|NCT04156646|10125901|FG000|Treatment Period 3 (6 Days)|Withdrawal by Subject|0
6353697|NCT04156646|10125902|FG001|Treatment Period 3 (6 Days)|Withdrawal by Subject|1
6353698|NCT04170686|10125913|FG000|Screening|Physician Decision|12
6353699|NCT04170686|10125914|FG001|Screening|Physician Decision|13
6353700|NCT04170686|10125913|FG000|Randomization and Treatment|Lost to Follow-up|26
6353701|NCT04170686|10125914|FG001|Randomization and Treatment|Lost to Follow-up|15
6353702|NCT04162795|10125966|FG000|Overall Study|Other|16
6353703|NCT04162795|10125966|FG000|Overall Study|Screen failures|10
6353704|NCT04161807|10125970|FG000|Overall Study|Withdrawal by Subject|2
6353705|NCT04161807|10125970|FG000|Overall Study|Performed only 1 treatment|2
6353706|NCT04161144|10125976|FG000|Overall Study|Withdrawal by Subject|0
6353707|NCT04161144|10125977|FG001|Overall Study|Withdrawal by Subject|1
6353708|NCT04161144|10125976|FG000|Overall Study|Protocol Violation|1
6353709|NCT04161144|10125977|FG001|Overall Study|Protocol Violation|0
6353710|NCT04161079|10125983|FG000|Clinical Investigation 2010-040|Adverse Event|1
6353711|NCT04152083|10126002|FG000|Overall Study|Lost to Follow-up|2
6353712|NCT04152083|10126003|FG001|Overall Study|Lost to Follow-up|1
6353713|NCT04152083|10126002|FG000|Overall Study|Adverse Event|1
6353714|NCT04152083|10126003|FG001|Overall Study|Adverse Event|0
6353715|NCT04152083|10126002|FG000|Overall Study|Randomized but not treated|3
6353716|NCT04152083|10126003|FG001|Overall Study|Randomized but not treated|2
6353717|NCT04155047|10126015|FG000|Overall Study|Adverse Event|1
6353718|NCT04155047|10126016|FG001|Overall Study|Adverse Event|0
6353719|NCT04155047|10126015|FG000|Overall Study|COVID-19: SUBJECT REFUSED STUDY VISITS DUE TO COVID-19 THREAT|1
6353720|NCT04155047|10126016|FG001|Overall Study|COVID-19: SUBJECT REFUSED STUDY VISITS DUE TO COVID-19 THREAT|0
6353721|NCT04150250|10126045|FG000|Overall Study|Lost to Follow-up|0
6353722|NCT04150250|10126046|FG001|Overall Study|Lost to Follow-up|2
6353723|NCT04149353|10126131|FG000|Overall Study|Study terminated|1
6353724|NCT04136444|10126151|FG000|Overall Study|Sponsor request due to undisclosed concomitant medication|0
6353725|NCT04136444|10126152|FG001|Overall Study|Sponsor request due to undisclosed concomitant medication|1
6353726|NCT04147611|10126186|FG000|Overall Study|Physician Decision|0
6353727|NCT04147611|10126187|FG001|Overall Study|Physician Decision|1
6353728|NCT04142216|10126256|FG000|Overall Study|Hospitalization|0
6353729|NCT04142216|10126257|FG001|Overall Study|Hospitalization|2
6353730|NCT04142216|10126256|FG000|Overall Study|Death|3
6353731|NCT04142216|10126257|FG001|Overall Study|Death|1
6353732|NCT04142216|10126256|FG000|Overall Study|Referral to another hemodialysis unit|3
6353733|NCT04142216|10126257|FG001|Overall Study|Referral to another hemodialysis unit|2
6353734|NCT04142216|10126256|FG000|Overall Study|Use of clove|0
6353735|NCT04142216|10126257|FG001|Overall Study|Use of clove|1
6353736|NCT04142450|10126268|FG000|Overall Study|Screen Failure|1
6353737|NCT04142450|10126268|FG000|Overall Study|Lost to Follow-up|1
6353738|NCT04140890|10126274|FG000|Overall Study|Withdrawal by Subject|0
6353739|NCT04140890|10126275|FG001|Overall Study|Withdrawal by Subject|1
6353740|NCT04139018|10126286|FG000|Overall Study|Screen fail|1
6353741|NCT04139018|10126287|FG001|Overall Study|Screen fail|0
6353742|NCT04139018|10126286|FG000|Overall Study|Withdrawal by Subject|2
6353743|NCT04139018|10126287|FG001|Overall Study|Withdrawal by Subject|0
6353744|NCT04139018|10126286|FG000|Overall Study|Lost to Follow-up|0
6353745|NCT04139018|10126287|FG001|Overall Study|Lost to Follow-up|1
6353746|NCT04138810|10126295|FG000|Overall Study|Withdrawal by Subject|0
6353747|NCT04138810|10126296|FG001|Overall Study|Withdrawal by Subject|1
6353748|NCT04138810|10126295|FG000|Overall Study|Subject cancelled surgery|1
6353749|NCT04138810|10126296|FG001|Overall Study|Subject cancelled surgery|0
6353750|NCT04131556|10126302|FG000|Overall Study|Adverse Event|1
6353751|NCT04131556|10126302|FG000|Overall Study|Withdrawal by Subject|1
6353752|NCT04126174|10126309|FG000|Overall Study|Lost to Follow-up|3
6353753|NCT04126174|10126310|FG001|Overall Study|Lost to Follow-up|3
6353754|NCT04138043|10126354|FG000|Overall Study|Withdrawal by Subject|0
6353755|NCT04138043|10126355|FG001|Overall Study|Withdrawal by Subject|1
6353756|NCT04132336|10126388|FG000|Overall Study|Investigator Decision|0
6353757|NCT04132336|10126389|FG001|Overall Study|Investigator Decision|1
6353758|NCT04132336|10126390|FG002|Overall Study|Investigator Decision|0
6353759|NCT04132336|10126391|FG003|Overall Study|Investigator Decision|0
6353760|NCT04132336|10126392|FG004|Overall Study|Investigator Decision|0
6353761|NCT04132336|10126393|FG005|Overall Study|Investigator Decision|0
6353762|NCT04132336|10126394|FG006|Overall Study|Investigator Decision|0
6353763|NCT04128293|10126434|FG000|Washout Period 2 (Up to 7 Days)|Study Closed/Terminated|4
6353764|NCT04128293|10126435|FG001|Washout Period 2 (Up to 7 Days)|Study Closed/Terminated|4
6353765|NCT04128293|10126436|FG002|Washout Period 2 (Up to 7 Days)|Study Closed/Terminated|4
6353766|NCT04128293|10126437|FG003|Washout Period 2 (Up to 7 Days)|Study Closed/Terminated|4
6353767|NCT04126343|10126458|FG000|Overall Study|Adverse Event|0
6353768|NCT04126343|10126459|FG001|Overall Study|Adverse Event|0
6353769|NCT04126343|10126460|FG002|Overall Study|Adverse Event|0
6353770|NCT04126343|10126461|FG003|Overall Study|Adverse Event|0
6353771|NCT04126343|10126462|FG004|Overall Study|Adverse Event|0
6353772|NCT04126343|10126463|FG005|Overall Study|Adverse Event|1
6083742|NCT00637273|9692315|FG001|Overall Study|Protocol Violation|4
6083743|NCT00637273|9692316|FG002|Overall Study|Protocol Violation|1
6083744|NCT00637273|9692314|FG000|Overall Study|Withdrawal of Consent|18
6083745|NCT00637273|9692315|FG001|Overall Study|Withdrawal of Consent|6
6083746|NCT00637273|9692316|FG002|Overall Study|Withdrawal of Consent|18
6083747|NCT00637273|9692314|FG000|Overall Study|Investigator Decision|1
6083748|NCT00637273|9692315|FG001|Overall Study|Investigator Decision|3
6083749|NCT00637273|9692316|FG002|Overall Study|Investigator Decision|1
6083750|NCT00637273|9692314|FG000|Overall Study|Administrative|2
6083751|NCT00637273|9692315|FG001|Overall Study|Administrative|0
6353773|NCT04126343|10126458|FG000|Overall Study|Withdrawal by Subject|0
6353774|NCT04126343|10126459|FG001|Overall Study|Withdrawal by Subject|0
6353775|NCT04126343|10126460|FG002|Overall Study|Withdrawal by Subject|0
6353776|NCT04126343|10126461|FG003|Overall Study|Withdrawal by Subject|1
6353777|NCT04126343|10126462|FG004|Overall Study|Withdrawal by Subject|0
6353778|NCT04126343|10126463|FG005|Overall Study|Withdrawal by Subject|0
6353779|NCT04126343|10126458|FG000|Overall Study|Related to COVID-19 pandemic|3
6353780|NCT04126343|10126459|FG001|Overall Study|Related to COVID-19 pandemic|4
6353781|NCT04126343|10126460|FG002|Overall Study|Related to COVID-19 pandemic|3
6353782|NCT04126343|10126461|FG003|Overall Study|Related to COVID-19 pandemic|3
6353783|NCT04126343|10126462|FG004|Overall Study|Related to COVID-19 pandemic|3
6353784|NCT04126343|10126463|FG005|Overall Study|Related to COVID-19 pandemic|3
6353785|NCT04124952|10126482|FG000|Overall Study|Lost to Follow-up|1
6353786|NCT04123665|10126488|FG000|Overall Study|Withdrawal by Subject|7
6353787|NCT04123665|10126489|FG001|Overall Study|Withdrawal by Subject|0
6353788|NCT04123665|10126488|FG000|Overall Study|Lost to Follow-up|1
6083752|NCT00637273|9692316|FG002|Overall Study|Administrative|0
6353789|NCT04123665|10126489|FG001|Overall Study|Lost to Follow-up|0
6353790|NCT04122534|10126495|FG000|Overall Study|Lost to Follow-up|4
6353791|NCT04117607|10126511|FG000|Overall Study|Early Termination|0
6353792|NCT04117607|10126512|FG001|Overall Study|Early Termination|1
6083753|NCT00637273|9692314|FG000|Overall Study|Loss of Glucose Control|1
6083754|NCT00637273|9692315|FG001|Overall Study|Loss of Glucose Control|1
6083755|NCT00637273|9692316|FG002|Overall Study|Loss of Glucose Control|1
6083756|NCT00637377|9692337|FG000|Overall Study|Adverse Event|2
6083757|NCT00637377|9692338|FG001|Overall Study|Adverse Event|6
6083758|NCT00637377|9692339|FG002|Overall Study|Adverse Event|8
6083759|NCT00637377|9692340|FG003|Overall Study|Adverse Event|9
6083760|NCT00637377|9692337|FG000|Overall Study|Death|1
6083761|NCT00637377|9692338|FG001|Overall Study|Death|3
6083762|NCT00637377|9692339|FG002|Overall Study|Death|2
6083763|NCT00637377|9692340|FG003|Overall Study|Death|1
6083764|NCT00637377|9692337|FG000|Overall Study|Lack of Efficacy|0
6083765|NCT00637377|9692338|FG001|Overall Study|Lack of Efficacy|0
6083766|NCT00637377|9692339|FG002|Overall Study|Lack of Efficacy|1
6083767|NCT00637377|9692340|FG003|Overall Study|Lack of Efficacy|1
6083768|NCT00637377|9692337|FG000|Overall Study|Lost to Follow-up|4
6083769|NCT00637377|9692338|FG001|Overall Study|Lost to Follow-up|1
6083770|NCT00637377|9692339|FG002|Overall Study|Lost to Follow-up|2
6083771|NCT00637377|9692340|FG003|Overall Study|Lost to Follow-up|2
6083772|NCT00637377|9692337|FG000|Overall Study|Protocol Violation|2
6083773|NCT00637377|9692338|FG001|Overall Study|Protocol Violation|1
6083774|NCT00637377|9692339|FG002|Overall Study|Protocol Violation|1
6083775|NCT00637377|9692340|FG003|Overall Study|Protocol Violation|0
6083776|NCT00637377|9692337|FG000|Overall Study|Withdrawal by Subject|11
6083777|NCT00637377|9692338|FG001|Overall Study|Withdrawal by Subject|15
6083778|NCT00637377|9692339|FG002|Overall Study|Withdrawal by Subject|13
6083779|NCT00637377|9692340|FG003|Overall Study|Withdrawal by Subject|11
6083780|NCT00637377|9692337|FG000|Overall Study|Other (no further information available)|7
6083781|NCT00637377|9692338|FG001|Overall Study|Other (no further information available)|6
6083782|NCT00637377|9692339|FG002|Overall Study|Other (no further information available)|10
6083783|NCT00637377|9692340|FG003|Overall Study|Other (no further information available)|5
6083784|NCT00637572|9692361|FG000|Overall Study|Adverse Event|1
6083785|NCT00637572|9692362|FG001|Overall Study|Adverse Event|2
6083786|NCT00637572|9692361|FG000|Overall Study|Death|0
6083787|NCT00637572|9692362|FG001|Overall Study|Death|1
6353793|NCT04117607|10126513|FG002|Overall Study|Early Termination|0
6353794|NCT04117607|10126514|FG003|Overall Study|Early Termination|0
6353795|NCT04117607|10126515|FG004|Overall Study|Early Termination|0
6353796|NCT04117607|10126516|FG005|Overall Study|Early Termination|0
6353797|NCT04117607|10126517|FG006|Overall Study|Early Termination|1
6353798|NCT04117607|10126518|FG007|Overall Study|Early Termination|0
6353799|NCT04117607|10126519|FG008|Overall Study|Early Termination|0
6353800|NCT04117607|10126520|FG009|Overall Study|Early Termination|0
6353801|NCT04117607|10126521|FG010|Overall Study|Early Termination|0
6353802|NCT04117607|10126522|FG011|Overall Study|Early Termination|0
6353803|NCT04117607|10126523|FG012|Overall Study|Early Termination|0
6353804|NCT04117607|10126524|FG013|Overall Study|Early Termination|0
6353805|NCT04096365|10126549|FG000|Overall Study|Adverse Event|1
6353806|NCT04080297|10126555|FG000|Overall Study|Adverse Event|1
6353807|NCT04080297|10126556|FG001|Overall Study|Adverse Event|3
6353808|NCT04080297|10126555|FG000|Overall Study|concurrent illness|1
6353809|NCT04080297|10126556|FG001|Overall Study|concurrent illness|0
6353810|NCT04115358|10126565|FG000|Overall Study|exfoliation|0
6353811|NCT04115358|10126566|FG001|Overall Study|exfoliation|0
6353812|NCT04115358|10126567|FG002|Overall Study|exfoliation|1
6353813|NCT04113694|10126591|FG000|Overall Study|Adverse Event|2
6353814|NCT04113694|10126591|FG000|Overall Study|Lost to Follow-up|2
6353815|NCT04113694|10126591|FG000|Overall Study|Withdrawal by Subject|6
6353816|NCT04113694|10126591|FG000|Overall Study|Withdrawal due to not meeting inclusion and exclusion criteria|1
6353817|NCT04106817|10126647|FG000|Overall Study|Lost to Follow-up|1
6353818|NCT04106817|10126648|FG001|Overall Study|Lost to Follow-up|0
6353819|NCT04106817|10126649|FG002|Overall Study|Lost to Follow-up|0
6353820|NCT04105972|10126659|FG000|Overall Study|Adverse Event|2
6353821|NCT04105972|10126660|FG001|Overall Study|Adverse Event|1
6353822|NCT04105218|10126668|FG000|Overall Study|Withdrawal by Subject|3
6353823|NCT04105218|10126669|FG001|Overall Study|Withdrawal by Subject|2
6353824|NCT04105218|10126668|FG000|Overall Study|Study was terminated; unable to complete study visits|1
6353825|NCT04105218|10126669|FG001|Overall Study|Study was terminated; unable to complete study visits|3
6353826|NCT04105218|10126668|FG000|Overall Study|Failed screening tests|2
6353827|NCT04105218|10126669|FG001|Overall Study|Failed screening tests|1
6353828|NCT04102540|10126684|FG000|Overall Study|Withdrawn by PI|2
6353829|NCT04102540|10126684|FG000|Overall Study|Lost to Follow-up|6
6353830|NCT04102345|10126690|FG000|Overall Study|Withdrawal by Subject|1
6353831|NCT04102345|10126691|FG001|Overall Study|Withdrawal by Subject|0
6083788|NCT00637572|9692361|FG000|Overall Study|Lost to Follow-up|0
6083789|NCT00637572|9692362|FG001|Overall Study|Lost to Follow-up|1
6083790|NCT00637572|9692361|FG000|Overall Study|Physician Decision|1
6083791|NCT00637572|9692362|FG001|Overall Study|Physician Decision|1
6083792|NCT00637572|9692361|FG000|Overall Study|Withdrawal by Subject|0
6083793|NCT00637572|9692362|FG001|Overall Study|Withdrawal by Subject|2
6083794|NCT00637572|9692361|FG000|Overall Study|Illicit Drug Use|1
6083795|NCT00637572|9692362|FG001|Overall Study|Illicit Drug Use|0
6353832|NCT04099277|10126731|FG000|Overall Study|Physician Decision|1
6353833|NCT04099277|10126731|FG000|Overall Study|Withdrawal by Subject|1
6353834|NCT04098809|10126737|FG000|Overall Study|Withdrawal by Subject|1
6353835|NCT04098809|10126738|FG001|Overall Study|Withdrawal by Subject|3
6353836|NCT04098809|10126737|FG000|Overall Study|Physician Decision|2
6353837|NCT04098809|10126738|FG001|Overall Study|Physician Decision|1
6353838|NCT04098458|10126757|FG000|Overall Study|Death|1
6353839|NCT04098458|10126757|FG000|Overall Study|did not meet study inclusion criteria|3
6353840|NCT04095286|10126762|FG000|Period 1 (4 Days) + Washout (7days)|Met Protocol-defined Stopping Criteria|0
6353841|NCT04095286|10126763|FG001|Period 1 (4 Days) + Washout (7days)|Met Protocol-defined Stopping Criteria|1
6353842|NCT04095286|10126764|FG002|Period 1 (4 Days) + Washout (7days)|Met Protocol-defined Stopping Criteria|0
6353843|NCT04095286|10126765|FG003|Period 1 (4 Days) + Washout (7days)|Met Protocol-defined Stopping Criteria|0
6353844|NCT04095286|10126766|FG004|Period 1 (4 Days) + Washout (7days)|Met Protocol-defined Stopping Criteria|0
6353845|NCT04095286|10126767|FG005|Period 1 (4 Days) + Washout (7days)|Met Protocol-defined Stopping Criteria|0
6353846|NCT04095286|10126762|FG000|Period 1 (4 Days) + Washout (7days)|Withdrawal by Subject|1
6353847|NCT04095286|10126763|FG001|Period 1 (4 Days) + Washout (7days)|Withdrawal by Subject|0
6353848|NCT04095286|10126764|FG002|Period 1 (4 Days) + Washout (7days)|Withdrawal by Subject|0
6353849|NCT04095286|10126765|FG003|Period 1 (4 Days) + Washout (7days)|Withdrawal by Subject|0
6353850|NCT04095286|10126766|FG004|Period 1 (4 Days) + Washout (7days)|Withdrawal by Subject|0
6353851|NCT04095286|10126767|FG005|Period 1 (4 Days) + Washout (7days)|Withdrawal by Subject|0
6353852|NCT04095286|10126762|FG000|Period 1 (4 Days) + Washout (7days)|Adverse Event|0
6353853|NCT04095286|10126763|FG001|Period 1 (4 Days) + Washout (7days)|Adverse Event|0
6353854|NCT04095286|10126764|FG002|Period 1 (4 Days) + Washout (7days)|Adverse Event|1
6353855|NCT04095286|10126765|FG003|Period 1 (4 Days) + Washout (7days)|Adverse Event|0
6353856|NCT04095286|10126766|FG004|Period 1 (4 Days) + Washout (7days)|Adverse Event|0
6353857|NCT04095286|10126767|FG005|Period 1 (4 Days) + Washout (7days)|Adverse Event|0
6353858|NCT04095286|10126762|FG000|Period 2 (4 Days) + Washout (7days)|Met Protocol-defined Stopping Criteria|0
6353859|NCT04095286|10126763|FG001|Period 2 (4 Days) + Washout (7days)|Met Protocol-defined Stopping Criteria|0
6353860|NCT04095286|10126764|FG002|Period 2 (4 Days) + Washout (7days)|Met Protocol-defined Stopping Criteria|2
6353861|NCT04095286|10126765|FG003|Period 2 (4 Days) + Washout (7days)|Met Protocol-defined Stopping Criteria|0
6353862|NCT04095286|10126766|FG004|Period 2 (4 Days) + Washout (7days)|Met Protocol-defined Stopping Criteria|0
6353863|NCT04095286|10126767|FG005|Period 2 (4 Days) + Washout (7days)|Met Protocol-defined Stopping Criteria|0
6353864|NCT04095286|10126762|FG000|Period 2 (4 Days) + Washout (7days)|Adverse Event|0
6353865|NCT04095286|10126763|FG001|Period 2 (4 Days) + Washout (7days)|Adverse Event|0
6353866|NCT04095286|10126764|FG002|Period 2 (4 Days) + Washout (7days)|Adverse Event|0
6353867|NCT04095286|10126765|FG003|Period 2 (4 Days) + Washout (7days)|Adverse Event|0
6353868|NCT04095286|10126766|FG004|Period 2 (4 Days) + Washout (7days)|Adverse Event|1
6353869|NCT04095286|10126767|FG005|Period 2 (4 Days) + Washout (7days)|Adverse Event|0
6353870|NCT04094883|10126775|FG000|Overall Study|Withdrawal by Subject|1
6353871|NCT04091659|10126781|FG000|Overall Study|Protocol Violation|3
6353872|NCT04091659|10126782|FG001|Overall Study|Protocol Violation|0
6353873|NCT04091659|10126781|FG000|Overall Study|Lost to Follow-up|0
6353874|NCT04091659|10126782|FG001|Overall Study|Lost to Follow-up|1
6353875|NCT04090242|10126807|FG000|Overall Study|Withdrawal by Subject|1
6353876|NCT04090242|10126808|FG001|Overall Study|Withdrawal by Subject|0
6353877|NCT04089761|10126815|FG000|"Run In Phase"|Not eligible to proceed to the treatment phase|14
6353878|NCT04089761|10126815|FG000|"Run In Phase"|Lost to Follow-up|1
6353879|NCT04089761|10126815|FG000|"Treatment Phase"|No evaluable data|5
6353880|NCT04089761|10126815|FG000|"Treatment Phase"|Lost to Follow-up|1
6353881|NCT04079803|10126822|FG000|Overall Study|Withdrawal by Subject|0
6353882|NCT04079803|10126823|FG001|Overall Study|Withdrawal by Subject|0
6353883|NCT04079803|10126824|FG002|Overall Study|Withdrawal by Subject|1
6353884|NCT04086641|10126867|FG000|Foot 1 (Two Week Utilization)|COVID-19|1
6353885|NCT04086641|10126868|FG001|Foot 1 (Two Week Utilization)|COVID-19|2
6353886|NCT04085289|10126886|FG000|Overall Study|Withdrawal by Subject|0
6353887|NCT04085289|10126887|FG001|Overall Study|Withdrawal by Subject|0
6353888|NCT04085289|10126888|FG002|Overall Study|Withdrawal by Subject|1
6353889|NCT04082663|10126899|FG000|Overall Study|Adverse Event|6
6353890|NCT04082663|10126899|FG000|Overall Study|Lost to Follow-up|1
6353891|NCT04079790|10126980|FG000|Part 1, Period 1(Day 1 to Day 4)|Withdrawal by Subject|1
6353892|NCT04079790|10126981|FG001|Part 1, Period 1(Day 1 to Day 4)|Withdrawal by Subject|0
6353893|NCT04079790|10126982|FG002|Part 1, Period 1(Day 1 to Day 4)|Withdrawal by Subject|0
6353894|NCT04079790|10126983|FG003|Part 1, Period 1(Day 1 to Day 4)|Withdrawal by Subject|0
6353895|NCT04079790|10126980|FG000|Part 2, Period 1 (Day 1 to Day 3)|Withdrawal by Subject|0
6353896|NCT04079790|10126981|FG001|Part 2, Period 1 (Day 1 to Day 3)|Withdrawal by Subject|0
6353897|NCT04079790|10126982|FG002|Part 2, Period 1 (Day 1 to Day 3)|Withdrawal by Subject|1
6353898|NCT04079790|10126983|FG003|Part 2, Period 1 (Day 1 to Day 3)|Withdrawal by Subject|0
6353899|NCT04079790|10126980|FG000|Part 2, Period 1 (Day 1 to Day 3)|Unable to swallow|0
6353900|NCT04079790|10126981|FG001|Part 2, Period 1 (Day 1 to Day 3)|Unable to swallow|0
6353901|NCT04079790|10126982|FG002|Part 2, Period 1 (Day 1 to Day 3)|Unable to swallow|2
6353902|NCT04079790|10126983|FG003|Part 2, Period 1 (Day 1 to Day 3)|Unable to swallow|0
6353903|NCT04073407|10127074|FG000|Part 1|Withdrawal by Subject|1
6353904|NCT04073407|10127075|FG001|Part 1|Withdrawal by Subject|0
6353905|NCT04073407|10127074|FG000|Part 1|Subjects discontinued in response to restrictions on the study due to impact of COVID-19 pandemic|4
6353906|NCT04073407|10127075|FG001|Part 1|Subjects discontinued in response to restrictions on the study due to impact of COVID-19 pandemic|1
6353907|NCT04073407|10127074|FG000|Part 2|Withdrawal by Subject|0
6353908|NCT04073407|10127075|FG001|Part 2|Withdrawal by Subject|1
6353909|NCT04073368|10127085|FG000|Overall Study|Adverse Event|2
6353910|NCT04073368|10127086|FG001|Overall Study|Adverse Event|0
6353911|NCT04073368|10127087|FG002|Overall Study|Adverse Event|1
6353912|NCT04073368|10127088|FG003|Overall Study|Adverse Event|1
6353913|NCT04073368|10127085|FG000|Overall Study|Withdrawal by Subject|2
6353914|NCT04073368|10127086|FG001|Overall Study|Withdrawal by Subject|2
6353915|NCT04073368|10127087|FG002|Overall Study|Withdrawal by Subject|1
6353916|NCT04073368|10127088|FG003|Overall Study|Withdrawal by Subject|1
6353917|NCT04073368|10127085|FG000|Overall Study|Lost to Follow-up|1
6353918|NCT04073368|10127086|FG001|Overall Study|Lost to Follow-up|1
6353919|NCT04073368|10127087|FG002|Overall Study|Lost to Follow-up|1
6353920|NCT04073368|10127088|FG003|Overall Study|Lost to Follow-up|0
6353921|NCT04073368|10127085|FG000|Overall Study|Protocol Violation|0
6353922|NCT04073368|10127086|FG001|Overall Study|Protocol Violation|1
6353923|NCT04073368|10127087|FG002|Overall Study|Protocol Violation|0
6353924|NCT04073368|10127088|FG003|Overall Study|Protocol Violation|0
6353925|NCT04073368|10127085|FG000|Overall Study|Subject noncompliance|7
6353926|NCT04073368|10127086|FG001|Overall Study|Subject noncompliance|4
6353927|NCT04073368|10127087|FG002|Overall Study|Subject noncompliance|0
6353928|NCT04073368|10127088|FG003|Overall Study|Subject noncompliance|0
6353929|NCT04073186|10127098|FG000|First Wearing Cycle|Time required to complete last two study visits exceeds study deadline|1
6353930|NCT04073186|10127098|FG000|First Wearing Cycle|Withdrawal by Subject|1
6353931|NCT04073186|10127098|FG000|First Wearing Cycle|Protocol Violation|1
6353932|NCT04073186|10127098|FG000|First Wearing Cycle|Lens Discomfort|2
6353933|NCT04073186|10127098|FG000|First Wearing Cycle|Unsatisfactory Visual Response due to Test Article|1
6353934|NCT04073186|10127098|FG000|Second Wearing Cycle|Adverse Event|1
6353935|NCT04071301|10127166|FG000|Overall Study|Withdrawal by Subject|6
6353936|NCT04071301|10127166|FG000|Overall Study|Death|1
6353937|NCT04071158|10127175|FG000|Overall Study|Lost to Follow-up|1
6353938|NCT04071158|10127176|FG001|Overall Study|Lost to Follow-up|2
6353939|NCT04071158|10127177|FG002|Overall Study|Lost to Follow-up|3
6353940|NCT04071158|10127178|FG003|Overall Study|Lost to Follow-up|3
6353941|NCT04071158|10127179|FG004|Overall Study|Lost to Follow-up|5
6353942|NCT04071158|10127175|FG000|Overall Study|Randomized but not treated|2
6353943|NCT04071158|10127176|FG001|Overall Study|Randomized but not treated|2
6353944|NCT04071158|10127177|FG002|Overall Study|Randomized but not treated|0
6353945|NCT04071158|10127178|FG003|Overall Study|Randomized but not treated|0
6353946|NCT04071158|10127179|FG004|Overall Study|Randomized but not treated|0
6043174|NCT00387127|9641623|FG000|Overall Study|Serious Adverse Event|1
6353947|NCT04069715|10127220|FG000|Overall Study|Lost to Follow-up|1
6353948|NCT04069715|10127221|FG001|Overall Study|Lost to Follow-up|1
6353949|NCT04069715|10127220|FG000|Overall Study|Physician Decision|1
6353950|NCT04069715|10127221|FG001|Overall Study|Physician Decision|1
6353951|NCT04069715|10127220|FG000|Overall Study|Withdrawal by Subject|3
6353952|NCT04069715|10127221|FG001|Overall Study|Withdrawal by Subject|3
6353953|NCT04050722|10127229|FG000|Overall Study|Withdrawal by Subject|1
6353954|NCT04050722|10127230|FG001|Overall Study|Withdrawal by Subject|0
6353955|NCT04067141|10127251|FG000|First Intervention|Withdrawal by Subject|0
6353956|NCT04067141|10127252|FG001|First Intervention|Withdrawal by Subject|1
6353957|NCT04067141|10127251|FG000|Second Intervention|Adverse Event|0
6353958|NCT04067141|10127252|FG001|Second Intervention|Adverse Event|2
6353959|NCT04049578|10127258|FG000|Overall Study|Physician Decision|1
6353960|NCT04067401|10127264|FG000|Overall Study|Withdrawal by Subject|7
6353961|NCT04067401|10127265|FG001|Overall Study|Withdrawal by Subject|0
6353962|NCT04067401|10127264|FG000|Overall Study|no data provided|1
6353963|NCT04067401|10127265|FG001|Overall Study|no data provided|0
6353964|NCT04067050|10127273|FG000|One Month|Lost to Follow-up|4
6353965|NCT04067050|10127274|FG001|One Month|Lost to Follow-up|0
6353966|NCT04067050|10127273|FG000|Two Month|Lost to Follow-up|1
6353967|NCT04067050|10127274|FG001|Two Month|Lost to Follow-up|0
6353968|NCT04067050|10127273|FG000|Two Month|Adverse Event|1
6353969|NCT04067050|10127274|FG001|Two Month|Adverse Event|0
6353970|NCT04060654|10127310|FG000|Overall Study|Withdrawal by Subject|1
6353971|NCT04060654|10127310|FG000|Overall Study|Lost to Follow-up|5
6353972|NCT04058353|10127323|FG000|Overall Study|Adverse Event|2
6353973|NCT04058353|10127324|FG001|Overall Study|Adverse Event|1
6353974|NCT04058353|10127323|FG000|Overall Study|Physician Decision|1
6353975|NCT04058353|10127324|FG001|Overall Study|Physician Decision|0
6353976|NCT04058353|10127323|FG000|Overall Study|Other|1
6353977|NCT04058353|10127324|FG001|Overall Study|Other|0
6353978|NCT04054765|10127356|FG000|Baseline|Withdrawal by Subject|5
6353979|NCT04054765|10127357|FG001|Baseline|Withdrawal by Subject|3
6353980|NCT04054765|10127356|FG000|Post-Gameplay / 1-week Follow up|Withdrawal by Subject|8
6353981|NCT04054765|10127357|FG001|Post-Gameplay / 1-week Follow up|Withdrawal by Subject|3
6353982|NCT04054765|10127356|FG000|3-month Follow up|Withdrawal by Subject|0
6353983|NCT04054765|10127357|FG001|3-month Follow up|Withdrawal by Subject|3
6353984|NCT04054765|10127356|FG000|6-month Follow up|Lost to Follow-up|32
6353985|NCT04054765|10127357|FG001|6-month Follow up|Lost to Follow-up|32
6353986|NCT04054011|10127363|FG000|Overall Study|COVID|3
6353987|NCT04059094|10127374|FG000|Overall Study|Adverse Event|0
6353988|NCT04059094|10127375|FG001|Overall Study|Adverse Event|0
6353989|NCT04059094|10127376|FG002|Overall Study|Adverse Event|0
6353990|NCT04059094|10127377|FG003|Overall Study|Adverse Event|0
6353991|NCT04059094|10127378|FG004|Overall Study|Adverse Event|1
6353992|NCT04059094|10127374|FG000|Overall Study|Not willing to travel due to COVID-19 pandemic|0
6353993|NCT04059094|10127375|FG001|Overall Study|Not willing to travel due to COVID-19 pandemic|2
6353994|NCT04059094|10127376|FG002|Overall Study|Not willing to travel due to COVID-19 pandemic|0
6353995|NCT04059094|10127377|FG003|Overall Study|Not willing to travel due to COVID-19 pandemic|0
6353996|NCT04059094|10127378|FG004|Overall Study|Not willing to travel due to COVID-19 pandemic|0
6353997|NCT04046341|10127403|FG000|Overall Study|Lost to Follow-up|2
6353998|NCT04046341|10127403|FG000|Overall Study|Withdrawal by Subject|1
6353999|NCT04043416|10127418|FG000|Washout|Change in health condition|0
6354000|NCT04043416|10127419|FG001|Washout|Change in health condition|1
6354001|NCT04054193|10127481|FG000|Cycle 1|Physician Decision|1
6354002|NCT04054193|10127481|FG000|Cycle 1|Consent withdrawn by parent/guardian|1
6354003|NCT04054193|10127481|FG000|Cycle 1|Allocated but not treated|3
6354004|NCT04054193|10127481|FG000|Cycles 2-3|Physician Decision|2
6354005|NCT04054193|10127481|FG000|Cycles 2-3|Consent withdrawn by parent/guardian|2
6354006|NCT04054193|10127481|FG000|Cycles 2-3|Various reasons|17
6354007|NCT04050618|10127488|FG000|First Intervention|Withdrawal by Subject|2
6354008|NCT04050618|10127489|FG001|First Intervention|Withdrawal by Subject|0
6354009|NCT04050618|10127488|FG000|Second Intervention|Withdrawal by Subject|1
6354010|NCT04050618|10127489|FG001|Second Intervention|Withdrawal by Subject|0
6354011|NCT04053465|10127502|FG000|Overall Study|Withdrawal by Subject|4
6354012|NCT04053465|10127503|FG001|Overall Study|Withdrawal by Subject|4
6354013|NCT04049552|10127522|FG000|Overall Study|Lost to Follow-up|1
6354014|NCT04053023|10127530|FG000|Part A: Period 2 (Day 20 to Day 38)|Adverse Event|1
6354015|NCT04053023|10127531|FG001|Part A: Period 2 (Day 20 to Day 38)|Adverse Event|0
6354016|NCT04050865|10127556|FG000|Overall Study|Adverse Event|1
6354017|NCT04050865|10127557|FG001|Overall Study|Adverse Event|0
6354018|NCT04050865|10127556|FG000|Overall Study|no insert|1
6354019|NCT04050865|10127557|FG001|Overall Study|no insert|0
6354020|NCT04050865|10127556|FG000|Overall Study|Only 1 insert|2
6354021|NCT04050865|10127557|FG001|Overall Study|Only 1 insert|3
6354022|NCT04050865|10127556|FG000|Overall Study|Physician Decision|0
6354023|NCT04050865|10127557|FG001|Overall Study|Physician Decision|1
6354024|NCT04050865|10127556|FG000|Overall Study|Withdrawal by Subject|0
6354025|NCT04050865|10127557|FG001|Overall Study|Withdrawal by Subject|1
6354026|NCT04050371|10127575|FG000|Overall Study|Withdrawal by Subject|1
6354027|NCT04050371|10127576|FG001|Overall Study|Withdrawal by Subject|0
6354028|NCT04048681|10127586|FG000|Overall Study|family emergency|0
6354029|NCT04048681|10127587|FG001|Overall Study|family emergency|0
6354030|NCT04048681|10127588|FG002|Overall Study|family emergency|0
6354031|NCT04048681|10127589|FG003|Overall Study|family emergency|1
6354032|NCT04048681|10127590|FG004|Overall Study|family emergency|0
6354033|NCT04046250|10127600|FG000|Overall Study|Death|0
6354034|NCT04046250|10127601|FG001|Overall Study|Death|1
6354035|NCT04046250|10127600|FG000|Overall Study|Withdrawal by Subject|3
6354036|NCT04046250|10127601|FG001|Overall Study|Withdrawal by Subject|3
6354037|NCT04044352|10127616|FG000|Overall Study|Lost to Follow-up|9
6354038|NCT04044352|10127616|FG000|Overall Study|Withdrawal by Subject|2
6354039|NCT04043728|10127624|FG000|Overall Study|Lost to Follow-up|1
6354040|NCT04043728|10127625|FG001|Overall Study|Lost to Follow-up|2
6354041|NCT04043728|10127626|FG002|Overall Study|Lost to Follow-up|0
6354042|NCT04041414|10127655|FG000|Overall Study|Lost to Follow-up|1
6354043|NCT04041414|10127656|FG001|Overall Study|Lost to Follow-up|2
6354044|NCT04041700|10127669|FG000|Overall Study|Pregnancy|1
6354045|NCT04041700|10127669|FG000|Overall Study|Unable to visit the site due to the Covid-19 travel restrictions|1
6354046|NCT04040933|10127673|FG000|Overall Study|Protocol Violation|1
6354047|NCT04040933|10127673|FG000|Overall Study|Withdrawal by Subject|2
6354048|NCT04029519|10127714|FG000|Overall Study|Protocol Violation|1
6354049|NCT04029519|10127714|FG000|Overall Study|Withdrawal by Subject|3
6354050|NCT04029519|10127714|FG000|Overall Study|Lost to Follow-up|1
6354051|NCT04039919|10127723|FG000|Treatment Period 1|Withdrawal by Subject|1
6354052|NCT04039919|10127724|FG001|Treatment Period 1|Withdrawal by Subject|0
6354053|NCT04039919|10127725|FG002|Treatment Period 1|Withdrawal by Subject|0
6354054|NCT04039919|10127726|FG003|Treatment Period 1|Withdrawal by Subject|0
6354055|NCT04039919|10127727|FG004|Treatment Period 1|Withdrawal by Subject|0
6354056|NCT04039919|10127723|FG000|Treatment Period 1|Sponsor's decision|0
6354057|NCT04039919|10127724|FG001|Treatment Period 1|Sponsor's decision|0
6354058|NCT04039919|10127725|FG002|Treatment Period 1|Sponsor's decision|0
6354059|NCT04039919|10127726|FG003|Treatment Period 1|Sponsor's decision|0
6354060|NCT04039919|10127727|FG004|Treatment Period 1|Sponsor's decision|16
6354061|NCT04039919|10127723|FG000|Treatment Period 5|Withdrawal by Subject|1
6354062|NCT04039919|10127724|FG001|Treatment Period 5|Withdrawal by Subject|0
6354063|NCT04039919|10127725|FG002|Treatment Period 5|Withdrawal by Subject|0
6354064|NCT04039919|10127726|FG003|Treatment Period 5|Withdrawal by Subject|0
6354065|NCT04039919|10127727|FG004|Treatment Period 5|Withdrawal by Subject|0
6354066|NCT04037748|10127776|FG000|Treatment Period 1|Withdrawal by Subject|3
6354067|NCT04037748|10127777|FG001|Treatment Period 1|Withdrawal by Subject|0
6354068|NCT04037748|10127776|FG000|Treatment Period 1|Adverse Event|1
6354069|NCT04037748|10127777|FG001|Treatment Period 1|Adverse Event|1
6354070|NCT04037748|10127776|FG000|Treatment Period 1|Protocol Violation|4
6354071|NCT04037748|10127777|FG001|Treatment Period 1|Protocol Violation|5
6354072|NCT04037748|10127776|FG000|Treatment Period 2|Adverse Event|0
6354073|NCT04037748|10127777|FG001|Treatment Period 2|Adverse Event|1
6354074|NCT04037748|10127776|FG000|Treatment Period 2|Protocol Violation|2
6354075|NCT04037748|10127777|FG001|Treatment Period 2|Protocol Violation|0
6354076|NCT04027686|10127794|FG000|Overall Study|Lost to Follow-up|2
6354077|NCT04027686|10127795|FG001|Overall Study|Lost to Follow-up|0
6354078|NCT04027686|10127794|FG000|Overall Study|Withdrawal by Subject|0
6354079|NCT04027686|10127795|FG001|Overall Study|Withdrawal by Subject|1
6354080|NCT04036110|10127825|FG000|Overall Study|Lost to Follow-up|3
6354081|NCT04036110|10127826|FG001|Overall Study|Lost to Follow-up|2
6354082|NCT04036110|10127827|FG002|Overall Study|Lost to Follow-up|1
6354083|NCT04036110|10127825|FG000|Overall Study|Study Suspended|4
6354084|NCT04036110|10127826|FG001|Overall Study|Study Suspended|5
6354085|NCT04036110|10127827|FG002|Overall Study|Study Suspended|1
6354086|NCT04035577|10127844|FG000|Overall Study|Lost to Follow-up|1
6354087|NCT04035577|10127844|FG000|Overall Study|Withdrawal by Subject|1
6354088|NCT04035564|10127852|FG000|Overall Study|Protocol Violation|1
6354089|NCT04035564|10127853|FG001|Overall Study|Protocol Violation|2
6354090|NCT04035564|10127852|FG000|Overall Study|No laboratory available|2
6354091|NCT04035564|10127853|FG001|Overall Study|No laboratory available|2
6354092|NCT04035564|10127852|FG000|Overall Study|Guardian declined consent|1
6354093|NCT04035564|10127853|FG001|Overall Study|Guardian declined consent|2
6354094|NCT04032977|10127861|FG000|Overall Study|Withdrawal by Subject|6
6354095|NCT04032977|10127862|FG001|Overall Study|Withdrawal by Subject|1
6354096|NCT04032977|10127861|FG000|Overall Study|Lost to Follow-up|2
6354097|NCT04032977|10127862|FG001|Overall Study|Lost to Follow-up|7
6354098|NCT04032977|10127861|FG000|Overall Study|Pregnancy|1
6354099|NCT04032977|10127862|FG001|Overall Study|Pregnancy|0
6354100|NCT04032652|10127870|FG000|Overall Study|The study was terminated and the PI has|1
6354101|NCT04032652|10127871|FG001|Overall Study|The study was terminated and the PI has|1
6354102|NCT04032613|10127891|FG000|Overall Study|Did not complete post-program assessment|5
6354103|NCT04032613|10127892|FG001|Overall Study|Did not complete post-program assessment|2
6354104|NCT04032171|10127900|FG000|Overall Study|Study Termination|1
6354105|NCT04032171|10127901|FG001|Overall Study|Study Termination|0
6354106|NCT04032158|10127909|FG000|Overall Study|Study Termination|2
6354107|NCT04032158|10127910|FG001|Overall Study|Study Termination|1
6354108|NCT04031404|10127916|FG000|Baseline|Lost to Follow-up|0
6354109|NCT04031404|10127917|FG001|Baseline|Lost to Follow-up|1
6354110|NCT04031404|10127916|FG000|Baseline|Did not meet full inclusion/exclusion.|2
6354111|NCT04031404|10127917|FG001|Baseline|Did not meet full inclusion/exclusion.|4
6354112|NCT04031404|10127916|FG000|Pre-randomization|Withdrawn for COVID19 precautions|1
6354113|NCT04031404|10127917|FG001|Pre-randomization|Withdrawn for COVID19 precautions|3
6354114|NCT04031404|10127916|FG000|Pre-randomization|Disqualified by TMS safety screening|1
6354115|NCT04031404|10127917|FG001|Pre-randomization|Disqualified by TMS safety screening|0
6354116|NCT04031404|10127916|FG000|Washout (5 Day Min)|Lost to Follow-up|1
6354117|NCT04031404|10127917|FG001|Washout (5 Day Min)|Lost to Follow-up|0
6354118|NCT04029961|10127962|FG000|Overall Study|Withdrawal after participant advisal they viewed exact same education intervention prior to visit|1
6354119|NCT04029961|10127963|FG001|Overall Study|Withdrawal after participant advisal they viewed exact same education intervention prior to visit|0
6354120|NCT04029961|10127962|FG000|Overall Study|Change in Treatment Course|0
6354121|NCT04029961|10127963|FG001|Overall Study|Change in Treatment Course|1
6354122|NCT04025684|10127973|FG000|Overall Study|Withdrawal by Subject|1
6354123|NCT04025684|10127974|FG001|Overall Study|Withdrawal by Subject|1
6354124|NCT04025684|10127975|FG002|Overall Study|Withdrawal by Subject|0
6354125|NCT04025684|10127976|FG003|Overall Study|Withdrawal by Subject|0
6354126|NCT04025684|10127973|FG000|Overall Study|Multiple reasons|1
6354127|NCT04025684|10127974|FG001|Overall Study|Multiple reasons|3
6354128|NCT04025684|10127975|FG002|Overall Study|Multiple reasons|0
6354129|NCT04025684|10127976|FG003|Overall Study|Multiple reasons|1
6354130|NCT04019054|10127988|FG000|Overall Study|Inadvertent Enrollment, discovered to meet exclusion criteria after enrollment|0
6354131|NCT04019054|10127989|FG001|Overall Study|Inadvertent Enrollment, discovered to meet exclusion criteria after enrollment|1
6354132|NCT04019054|10127988|FG000|Overall Study|Withdrawal by Subject|3
6354133|NCT04019054|10127989|FG001|Overall Study|Withdrawal by Subject|1
6354134|NCT04016311|10128122|FG000|Overall Study|Withdrawal by Subject|1
6354135|NCT04016311|10128123|FG001|Overall Study|Withdrawal by Subject|0
6354136|NCT04023682|10128216|FG000|Overall Study|Clinical schedules did not allow continued participation|6
6354137|NCT04023994|10128263|FG000|Overall Study|Lost to Follow-up|0
6354138|NCT04023994|10128264|FG001|Overall Study|Lost to Follow-up|1
6354139|NCT04023994|10128265|FG002|Overall Study|Lost to Follow-up|2
6354140|NCT04023994|10128266|FG003|Overall Study|Lost to Follow-up|0
6354141|NCT04023994|10128267|FG004|Overall Study|Lost to Follow-up|0
6354142|NCT04023994|10128268|FG005|Overall Study|Lost to Follow-up|0
6354143|NCT04023994|10128263|FG000|Overall Study|Withdrawal by Subject|0
6354144|NCT04023994|10128264|FG001|Overall Study|Withdrawal by Subject|0
6354145|NCT04023994|10128265|FG002|Overall Study|Withdrawal by Subject|0
6354146|NCT04023994|10128266|FG003|Overall Study|Withdrawal by Subject|1
6354147|NCT04023994|10128267|FG004|Overall Study|Withdrawal by Subject|0
6354148|NCT04023994|10128268|FG005|Overall Study|Withdrawal by Subject|0
6354149|NCT04017611|10128311|FG000|Overall Study|Withdrawn prior to completion|1
6354150|NCT04015232|10128317|FG000|Overall Study|Withdrawal by Subject|7
6354151|NCT04015232|10128318|FG001|Overall Study|Withdrawal by Subject|4
6354152|NCT04015232|10128317|FG000|Overall Study|Protocol Violation|1
6354153|NCT04015232|10128318|FG001|Overall Study|Protocol Violation|0
6354154|NCT04015232|10128317|FG000|Overall Study|Medical Grounds|3
6354155|NCT04015232|10128318|FG001|Overall Study|Medical Grounds|3
6354156|NCT04014062|10128358|FG000|Period I: Dosing|Medical Grounds|4
6354157|NCT04014062|10128359|FG001|Period I: Dosing|Medical Grounds|5
6354158|NCT04014062|10128358|FG000|Period I: Dosing|Withdrawal by Subject|3
6354159|NCT04014062|10128359|FG001|Period I: Dosing|Withdrawal by Subject|1
6354160|NCT04013191|10128396|FG000|Overall Study|Adverse Event|1
6354161|NCT04013191|10128397|FG001|Overall Study|Adverse Event|0
6354162|NCT04011735|10128414|FG000|Overall Study|Withdrawal by Subject|1
6354163|NCT04011735|10128415|FG001|Overall Study|Withdrawal by Subject|0
6354164|NCT04011735|10128416|FG002|Overall Study|Withdrawal by Subject|1
6354165|NCT04011735|10128414|FG000|Overall Study|Met exclusion criteria after study entry|0
6354166|NCT04011735|10128415|FG001|Overall Study|Met exclusion criteria after study entry|1
6354167|NCT04011735|10128416|FG002|Overall Study|Met exclusion criteria after study entry|0
6354168|NCT04009577|10128430|FG000|Core Study|Adverse Event|1
6354169|NCT04009577|10128431|FG001|Core Study|Adverse Event|0
6354170|NCT04009577|10128432|FG002|Core Study|Adverse Event|2
6354171|NCT04009577|10128433|FG003|Core Study|Adverse Event|4
6354172|NCT04009577|10128430|FG000|Core Study|Withdrawal by Subject|0
6354173|NCT04009577|10128431|FG001|Core Study|Withdrawal by Subject|0
6354174|NCT04009577|10128432|FG002|Core Study|Withdrawal by Subject|2
6354175|NCT04009577|10128433|FG003|Core Study|Withdrawal by Subject|0
6354176|NCT04009577|10128430|FG000|Core Study|Other|0
6354177|NCT04009577|10128431|FG001|Core Study|Other|0
6354178|NCT04009577|10128432|FG002|Core Study|Other|0
6354179|NCT04009577|10128433|FG003|Core Study|Other|1
6354180|NCT04009577|10128430|FG000|Extension Phase|Adverse Event|0
6354181|NCT04009577|10128431|FG001|Extension Phase|Adverse Event|0
6354182|NCT04009577|10128432|FG002|Extension Phase|Adverse Event|0
6354183|NCT04009577|10128433|FG003|Extension Phase|Adverse Event|1
6354184|NCT04009577|10128430|FG000|Extension Phase|Inadequate therapeutic effect|0
6354185|NCT04009577|10128431|FG001|Extension Phase|Inadequate therapeutic effect|0
6354186|NCT04009577|10128432|FG002|Extension Phase|Inadequate therapeutic effect|1
6354187|NCT04009577|10128433|FG003|Extension Phase|Inadequate therapeutic effect|0
6354188|NCT04009577|10128430|FG000|Extension Phase|Withdrawal by Subject|0
6354189|NCT04009577|10128431|FG001|Extension Phase|Withdrawal by Subject|0
6354190|NCT04009577|10128432|FG002|Extension Phase|Withdrawal by Subject|1
6354191|NCT04009577|10128433|FG003|Extension Phase|Withdrawal by Subject|0
6354192|NCT04009577|10128430|FG000|Extension Phase|Not Treated|0
6354193|NCT04009577|10128431|FG001|Extension Phase|Not Treated|0
6354194|NCT04009577|10128432|FG002|Extension Phase|Not Treated|2
6354195|NCT04009577|10128433|FG003|Extension Phase|Not Treated|0
6354196|NCT04007159|10128459|FG000|Induction Phase|(missed study visits)|16
6354197|NCT04007159|10128459|FG000|Induction Phase|Withdrawal by Subject|4
6354198|NCT04007159|10128459|FG000|Induction Phase|Adverse Event|2
6354199|NCT04007159|10128459|FG000|Challenge Phase|missed study visits|3
6354200|NCT04007107|10128470|FG000|Treatment Period 2 (Day 1)|Withdrawal by Subject|0
6354201|NCT04007107|10128471|FG001|Treatment Period 2 (Day 1)|Withdrawal by Subject|1
6354202|NCT04007107|10128472|FG002|Treatment Period 2 (Day 1)|Withdrawal by Subject|0
6354203|NCT04007107|10128473|FG003|Treatment Period 2 (Day 1)|Withdrawal by Subject|0
6354204|NCT04005885|10128489|FG000|First Intervention|Withdrawal by Subject|1
6354205|NCT04005885|10128490|FG001|First Intervention|Withdrawal by Subject|1
6354206|NCT04005885|10128489|FG000|Second Intervention|Withdrawal by Subject|0
6354207|NCT04005885|10128490|FG001|Second Intervention|Withdrawal by Subject|2
6354208|NCT04000815|10128504|FG000|Overall Study|Lost to Follow-up|9
6354209|NCT04000815|10128505|FG001|Overall Study|Lost to Follow-up|2
6354210|NCT04000815|10128506|FG002|Overall Study|Lost to Follow-up|3
6354211|NCT04000815|10128504|FG000|Overall Study|Withdrawal by Subject|4
6354212|NCT04000815|10128505|FG001|Overall Study|Withdrawal by Subject|3
6354213|NCT04000815|10128506|FG002|Overall Study|Withdrawal by Subject|2
6354214|NCT04000815|10128504|FG000|Overall Study|Right ovarian cyst occured|1
6354215|NCT04000815|10128505|FG001|Overall Study|Right ovarian cyst occured|0
6354216|NCT04000815|10128506|FG002|Overall Study|Right ovarian cyst occured|0
6354217|NCT04000815|10128504|FG000|Overall Study|Hypertension occured on follow up|0
6354218|NCT04000815|10128505|FG001|Overall Study|Hypertension occured on follow up|0
6354219|NCT04000815|10128506|FG002|Overall Study|Hypertension occured on follow up|2
6354220|NCT04006366|10128531|FG000|Overall Study|Withdrawal by Subject|1
6354221|NCT04006145|10128537|FG000|Overall Study|Lost to Follow-up|0
6354222|NCT04006145|10128538|FG001|Overall Study|Lost to Follow-up|1
6354223|NCT04006145|10128537|FG000|Overall Study|Other|1
6354224|NCT04006145|10128538|FG001|Overall Study|Other|2
6354225|NCT04005755|10128544|FG000|Overall Study|Adverse Event|6
6354226|NCT04005755|10128544|FG000|Overall Study|Physician Decision|3
6354227|NCT04005755|10128544|FG000|Overall Study|Administrative reason, temporary site closure due to COVID-19|4
6354228|NCT04005755|10128544|FG000|Overall Study|Withdrawal by Subject|3
6354229|NCT04005755|10128544|FG000|Overall Study|Lost to Follow-up|1
6354230|NCT03993288|10128567|FG000|Overall Study|Lost to Follow-up|2
6354231|NCT03993288|10128568|FG001|Overall Study|Lost to Follow-up|1
6354232|NCT03993288|10128567|FG000|Overall Study|non-compliance to the inclusion criteria|0
6354233|NCT03993288|10128568|FG001|Overall Study|non-compliance to the inclusion criteria|1
6354234|NCT03993288|10128567|FG000|Overall Study|wrong randomization|0
6354235|NCT03993288|10128568|FG001|Overall Study|wrong randomization|1
6354236|NCT03993288|10128567|FG000|Overall Study|improper enrollment|0
6354237|NCT03993288|10128568|FG001|Overall Study|improper enrollment|1
6354238|NCT03993288|10128567|FG000|Overall Study|prescribed with prohibited concomitant therapy|1
6354239|NCT03993288|10128568|FG001|Overall Study|prescribed with prohibited concomitant therapy|0
6354240|NCT03993288|10128567|FG000|Overall Study|developed SAE|2
6354241|NCT03993288|10128568|FG001|Overall Study|developed SAE|0
6354242|NCT03993288|10128567|FG000|Overall Study|consent withdrawal|1
6354243|NCT03993288|10128568|FG001|Overall Study|consent withdrawal|0
6354244|NCT03993288|10128567|FG000|Overall Study|did not follow the treatment schedule|1
6354245|NCT03993288|10128568|FG001|Overall Study|did not follow the treatment schedule|0
6354246|NCT03993288|10128567|FG000|Overall Study|did not follow the treatment regimen|1
6354247|NCT03993288|10128568|FG001|Overall Study|did not follow the treatment regimen|0
6354248|NCT03993288|10128567|FG000|Overall Study|Adverse Event|1
6354249|NCT03993288|10128568|FG001|Overall Study|Adverse Event|0
6354250|NCT03993288|10128567|FG000|Overall Study|Withdrawal by Subject|1
6354251|NCT03993288|10128568|FG001|Overall Study|Withdrawal by Subject|1
6354252|NCT03978832|10128599|FG000|Overall Study|Adverse Event|1
6354253|NCT03978832|10128599|FG000|Overall Study|Lost to Follow-up|1
6354254|NCT03978832|10128599|FG000|Overall Study|Withdrawal by Subject|6
6354255|NCT03978832|10128599|FG000|Overall Study|Physician Decision|2
6354256|NCT03978832|10128599|FG000|Overall Study|did not pass screening criteria|44
6354257|NCT04004260|10128640|FG000|Overall Study|Withdrawal by Subject|7
6354258|NCT04004260|10128641|FG001|Overall Study|Withdrawal by Subject|3
6354259|NCT04004260|10128640|FG000|Overall Study|Lost to Follow-up|22
6354260|NCT04004260|10128641|FG001|Overall Study|Lost to Follow-up|12
6354261|NCT04004260|10128640|FG000|Overall Study|Did not engage in intervention|13
6354262|NCT04004260|10128641|FG001|Overall Study|Did not engage in intervention|17
6354263|NCT04002960|10128674|FG000|Overall Study|Withdrawn prior to Completion|2
6354264|NCT04002648|10128684|FG000|Overall Study|Lost to Follow-up|2
6354265|NCT04002648|10128685|FG001|Overall Study|Lost to Follow-up|0
6354266|NCT03990649|10128714|FG000|Part A: DB Treatment Period (15 Weeks)|Adverse Event|0
6354267|NCT03990649|10128715|FG001|Part A: DB Treatment Period (15 Weeks)|Adverse Event|1
6354268|NCT03990649|10128716|FG002|Part A: DB Treatment Period (15 Weeks)|Adverse Event|0
6354269|NCT03990649|10128714|FG000|Part A: DB Treatment Period (15 Weeks)|Lost to Follow-up|0
6354270|NCT03990649|10128715|FG001|Part A: DB Treatment Period (15 Weeks)|Lost to Follow-up|1
6354271|NCT03990649|10128716|FG002|Part A: DB Treatment Period (15 Weeks)|Lost to Follow-up|0
6354272|NCT03990649|10128714|FG000|Part A: DB Treatment Period (15 Weeks)|Withdrawal by Subject|2
6354273|NCT03990649|10128715|FG001|Part A: DB Treatment Period (15 Weeks)|Withdrawal by Subject|0
6354274|NCT03990649|10128716|FG002|Part A: DB Treatment Period (15 Weeks)|Withdrawal by Subject|0
6354275|NCT03990649|10128714|FG000|Part A: DB Treatment Period (15 Weeks)|Reason not Specified|1
6354276|NCT03990649|10128715|FG001|Part A: DB Treatment Period (15 Weeks)|Reason not Specified|1
6354277|NCT03990649|10128716|FG002|Part A: DB Treatment Period (15 Weeks)|Reason not Specified|0
6354278|NCT03990649|10128714|FG000|Part B: OL Extension Period (14 Weeks)|Adverse Event|0
6354279|NCT03990649|10128715|FG001|Part B: OL Extension Period (14 Weeks)|Adverse Event|0
6354280|NCT03990649|10128716|FG002|Part B: OL Extension Period (14 Weeks)|Adverse Event|1
6354281|NCT03990649|10128714|FG000|Part B: OL Extension Period (14 Weeks)|Withdrawal by Subject|0
6354282|NCT03990649|10128715|FG001|Part B: OL Extension Period (14 Weeks)|Withdrawal by Subject|0
6354283|NCT03990649|10128716|FG002|Part B: OL Extension Period (14 Weeks)|Withdrawal by Subject|2
6354284|NCT03990649|10128714|FG000|Part B: OL Extension Period (14 Weeks)|Reason not Specified|0
6354285|NCT03990649|10128715|FG001|Part B: OL Extension Period (14 Weeks)|Reason not Specified|0
6354286|NCT03990649|10128716|FG002|Part B: OL Extension Period (14 Weeks)|Reason not Specified|1
6354287|NCT04000581|10128734|FG000|Overall Study|Withdrawal by Subject|0
6354288|NCT04000581|10128735|FG001|Overall Study|Withdrawal by Subject|1
6354289|NCT03996694|10128741|FG000|First Washout (7 Days)|positive urine drug screen|0
6354290|NCT03996694|10128742|FG001|First Washout (7 Days)|positive urine drug screen|0
6354291|NCT03996694|10128743|FG002|First Washout (7 Days)|positive urine drug screen|1
6354292|NCT03996694|10128744|FG003|First Washout (7 Days)|positive urine drug screen|0
6354293|NCT03996694|10128745|FG004|First Washout (7 Days)|positive urine drug screen|0
6354294|NCT03996694|10128746|FG005|First Washout (7 Days)|positive urine drug screen|0
6354295|NCT03996694|10128741|FG000|First Washout (7 Days)|Adverse Event|0
6354296|NCT03996694|10128742|FG001|First Washout (7 Days)|Adverse Event|1
6354297|NCT03996694|10128743|FG002|First Washout (7 Days)|Adverse Event|0
6354298|NCT03996694|10128744|FG003|First Washout (7 Days)|Adverse Event|0
6354299|NCT03996694|10128745|FG004|First Washout (7 Days)|Adverse Event|0
6354300|NCT03996694|10128746|FG005|First Washout (7 Days)|Adverse Event|0
6354301|NCT03996694|10128741|FG000|First Washout (7 Days)|Lost to Follow-up|0
6354302|NCT03996694|10128742|FG001|First Washout (7 Days)|Lost to Follow-up|0
6354303|NCT03996694|10128743|FG002|First Washout (7 Days)|Lost to Follow-up|1
6354304|NCT03996694|10128744|FG003|First Washout (7 Days)|Lost to Follow-up|0
6354305|NCT03996694|10128745|FG004|First Washout (7 Days)|Lost to Follow-up|0
6354306|NCT03996694|10128746|FG005|First Washout (7 Days)|Lost to Follow-up|0
6354307|NCT03996694|10128741|FG000|Third Washout (7 Days)|Withdrawal by Subject|0
6354308|NCT03996694|10128742|FG001|Third Washout (7 Days)|Withdrawal by Subject|0
6354309|NCT03996694|10128743|FG002|Third Washout (7 Days)|Withdrawal by Subject|0
6354310|NCT03996694|10128744|FG003|Third Washout (7 Days)|Withdrawal by Subject|0
6354311|NCT03996694|10128745|FG004|Third Washout (7 Days)|Withdrawal by Subject|1
6354312|NCT03996694|10128746|FG005|Third Washout (7 Days)|Withdrawal by Subject|0
6354313|NCT03988907|10128762|FG000|Overall Study|Unable to complete visit|0
6354314|NCT03988907|10128763|FG001|Overall Study|Unable to complete visit|1
6354315|NCT03988088|10128777|FG000|Single-Dose Pharmacokinetic Study|Adverse Event|0
6354316|NCT03988088|10128778|FG001|Single-Dose Pharmacokinetic Study|Adverse Event|1
6354317|NCT03988088|10128779|FG002|Single-Dose Pharmacokinetic Study|Adverse Event|0
6354318|NCT03988088|10128780|FG003|Single-Dose Pharmacokinetic Study|Adverse Event|0
6354319|NCT03988088|10128777|FG000|Open-Label Addendum|Lost to Follow-up|0
6354320|NCT03988088|10128778|FG001|Open-Label Addendum|Lost to Follow-up|0
6354321|NCT03988088|10128779|FG002|Open-Label Addendum|Lost to Follow-up|1
6354322|NCT03988088|10128780|FG003|Open-Label Addendum|Lost to Follow-up|0
6354323|NCT03980522|10128793|FG000|Treatment Period|Adverse Event|1
6354324|NCT03980522|10128794|FG001|Treatment Period|Adverse Event|0
6354325|NCT03980522|10128795|FG002|Treatment Period|Adverse Event|0
6354326|NCT03980522|10128796|FG003|Treatment Period|Adverse Event|0
6354327|NCT03980522|10128797|FG004|Treatment Period|Adverse Event|0
6354328|NCT03995784|10128813|FG000|Overall Study|One subject discontinued on Day 7 due to injection site reactions after Day 1, 2, and 3 doses|1
6354329|NCT03993392|10128824|FG000|Overall Study|Withdrawal by Subject|3
6354330|NCT03993392|10128824|FG000|Overall Study|Lost to Follow-up|2
6354331|NCT03993392|10128824|FG000|Overall Study|Did not meet Day 1 check-in criteria|1
6354332|NCT03981822|10128847|FG000|Overall Study|Lost to Follow-up|0
6354333|NCT03981822|10128848|FG001|Overall Study|Lost to Follow-up|1
6354334|NCT03981822|10128849|FG002|Overall Study|Lost to Follow-up|1
6354335|NCT03981822|10128850|FG003|Overall Study|Lost to Follow-up|0
6354336|NCT03981822|10128851|FG004|Overall Study|Lost to Follow-up|6
6354337|NCT03981822|10128852|FG005|Overall Study|Lost to Follow-up|4
6354338|NCT03981822|10128853|FG006|Overall Study|Lost to Follow-up|4
6354339|NCT03981822|10128854|FG007|Overall Study|Lost to Follow-up|2
6354340|NCT03981822|10128847|FG000|Overall Study|Withdrawal by Subject|0
6354341|NCT03981822|10128848|FG001|Overall Study|Withdrawal by Subject|1
6354342|NCT03981822|10128849|FG002|Overall Study|Withdrawal by Subject|0
6354343|NCT03981822|10128850|FG003|Overall Study|Withdrawal by Subject|0
6354344|NCT03981822|10128851|FG004|Overall Study|Withdrawal by Subject|0
6354345|NCT03981822|10128852|FG005|Overall Study|Withdrawal by Subject|1
6354346|NCT03981822|10128853|FG006|Overall Study|Withdrawal by Subject|0
6354347|NCT03981822|10128854|FG007|Overall Study|Withdrawal by Subject|2
6354348|NCT03981822|10128847|FG000|Overall Study|COVID-19 Related|0
6354349|NCT03981822|10128848|FG001|Overall Study|COVID-19 Related|0
6354350|NCT03981822|10128849|FG002|Overall Study|COVID-19 Related|0
6354351|NCT03981822|10128850|FG003|Overall Study|COVID-19 Related|0
6354352|NCT03981822|10128851|FG004|Overall Study|COVID-19 Related|2
6354353|NCT03981822|10128852|FG005|Overall Study|COVID-19 Related|1
6354354|NCT03981822|10128853|FG006|Overall Study|COVID-19 Related|2
6354355|NCT03981822|10128854|FG007|Overall Study|COVID-19 Related|1
6354356|NCT03991494|10128907|FG000|Overall Study|Progressive Disease|4
6354357|NCT03988803|10128926|FG000|Period 2|Prematurely discontinued from medication|2
6354358|NCT03988803|10128926|FG000|Period 2|Adverse Event|1
6354359|NCT03987932|10128937|FG000|Overall Study|Lost to Follow-up|2
6354360|NCT03987932|10128938|FG001|Overall Study|Lost to Follow-up|1
6354361|NCT03987932|10128939|FG002|Overall Study|Lost to Follow-up|1
6354362|NCT03987932|10128937|FG000|Overall Study|Non-study related elective surgery|0
6354363|NCT03987932|10128938|FG001|Overall Study|Non-study related elective surgery|0
6354364|NCT03987932|10128939|FG002|Overall Study|Non-study related elective surgery|1
6354365|NCT03987191|10128949|FG000|Overall Study|COVID-19 related research disruption|0
6354366|NCT03987191|10128950|FG001|Overall Study|COVID-19 related research disruption|2
6354367|NCT03988842|10128956|FG000|Overall Study|Death|1
6354368|NCT03981861|10128961|FG000|Overall Study|Withdrawal by Subject|3
6354369|NCT03974334|10128965|FG000|Overall Study|Lost to Follow-up|1
6354370|NCT03987074|10128993|FG000|Overall Study|Withdrew Consent|1
6354371|NCT03987074|10128994|FG001|Overall Study|Withdrew Consent|1
6354372|NCT03987074|10128995|FG002|Overall Study|Withdrew Consent|0
6354373|NCT03987074|10128996|FG003|Overall Study|Withdrew Consent|2
6354374|NCT03987074|10128997|FG004|Overall Study|Withdrew Consent|1
6354375|NCT03987074|10128993|FG000|Overall Study|Adverse Event|2
6354376|NCT03987074|10128994|FG001|Overall Study|Adverse Event|1
6354377|NCT03987074|10128995|FG002|Overall Study|Adverse Event|0
6354378|NCT03987074|10128996|FG003|Overall Study|Adverse Event|0
6354379|NCT03987074|10128997|FG004|Overall Study|Adverse Event|1
6354380|NCT03987074|10128993|FG000|Overall Study|Lost to Follow-up|0
6354381|NCT03987074|10128994|FG001|Overall Study|Lost to Follow-up|0
6354382|NCT03987074|10128995|FG002|Overall Study|Lost to Follow-up|1
6354383|NCT03987074|10128996|FG003|Overall Study|Lost to Follow-up|1
6354384|NCT03987074|10128997|FG004|Overall Study|Lost to Follow-up|0
6354385|NCT03987074|10128993|FG000|Overall Study|Investigator's Discretion|0
6354386|NCT03987074|10128994|FG001|Overall Study|Investigator's Discretion|0
6354387|NCT03987074|10128995|FG002|Overall Study|Investigator's Discretion|0
6354388|NCT03987074|10128996|FG003|Overall Study|Investigator's Discretion|1
6354389|NCT03987074|10128997|FG004|Overall Study|Investigator's Discretion|0
6354390|NCT03979820|10129031|FG000|Overall Study|Protocol Violation|1
6354391|NCT03979820|10129032|FG001|Overall Study|Protocol Violation|0
6354392|NCT03979820|10129033|FG002|Overall Study|Protocol Violation|0
6354393|NCT03979820|10129034|FG003|Overall Study|Protocol Violation|0
6354394|NCT03979820|10129031|FG000|Overall Study|Withdrawal by Subject|0
6354395|NCT03979820|10129032|FG001|Overall Study|Withdrawal by Subject|0
6354396|NCT03979820|10129033|FG002|Overall Study|Withdrawal by Subject|1
6354397|NCT03979820|10129034|FG003|Overall Study|Withdrawal by Subject|0
6354398|NCT03979820|10129031|FG000|Overall Study|Permanent discontinuation of the trial due to Covid-19 pandemic|5
6354399|NCT03979820|10129032|FG001|Overall Study|Permanent discontinuation of the trial due to Covid-19 pandemic|0
6354400|NCT03979820|10129033|FG002|Overall Study|Permanent discontinuation of the trial due to Covid-19 pandemic|0
6354401|NCT03979820|10129034|FG003|Overall Study|Permanent discontinuation of the trial due to Covid-19 pandemic|10
6354402|NCT03972137|10129048|FG000|Overall Study|Lost to Follow-up|2
6354403|NCT03972137|10129048|FG000|Overall Study|Withdrawal by Subject|4
6354404|NCT03970395|10129066|FG000|Overall Study|Withdrawal by Subject|3
6354405|NCT03970395|10129067|FG001|Overall Study|Withdrawal by Subject|4
6354406|NCT03970395|10129066|FG000|Overall Study|Lost to Follow-up|4
6354407|NCT03970395|10129067|FG001|Overall Study|Lost to Follow-up|8
6354408|NCT03987620|10129079|FG000|Overall Study|Lack of Efficacy or Use of antifungal therapy|43
6354409|NCT03987620|10129080|FG001|Overall Study|Lack of Efficacy or Use of antifungal therapy|41
6354410|NCT03987620|10129079|FG000|Overall Study|Adverse Event|3
6354411|NCT03987620|10129080|FG001|Overall Study|Adverse Event|0
6354412|NCT03987620|10129079|FG000|Overall Study|Lost to Follow-up|1
6354413|NCT03987620|10129080|FG001|Overall Study|Lost to Follow-up|2
6354414|NCT03987620|10129079|FG000|Overall Study|Physician Decision|0
6354415|NCT03987620|10129080|FG001|Overall Study|Physician Decision|1
6354416|NCT03987620|10129079|FG000|Overall Study|Pregnancy|1
6354417|NCT03987620|10129080|FG001|Overall Study|Pregnancy|0
6354418|NCT03987620|10129079|FG000|Overall Study|Withdrawal by Subject|7
6354419|NCT03987620|10129080|FG001|Overall Study|Withdrawal by Subject|1
6354420|NCT03987620|10129079|FG000|Overall Study|Other|2
6354421|NCT03987620|10129080|FG001|Overall Study|Other|5
6354422|NCT03983317|10129086|FG000|Overall Study|Physician Decision|5
6354423|NCT03984825|10129149|FG000|Treatment Period 1 (Day 1 to 10)|Sponsor decision|2
6354424|NCT03984825|10129149|FG000|Treatment Period 2 (Day 11 to 21)|Physician Decision|1
6354425|NCT03984825|10129149|FG000|Treatment Period 2 (Day 11 to 21)|Adverse Event|3
6354426|NCT03982433|10129162|FG000|Overall Study|Lost to Follow-up|1
6354427|NCT03976466|10129172|FG000|Overall Study|Lost to Follow-up|1
6354428|NCT03976466|10129173|FG001|Overall Study|Lost to Follow-up|3
6354429|NCT03979638|10129183|FG000|Period 1|Physician Decision|1
6354430|NCT03979638|10129184|FG001|Period 1|Physician Decision|1
6354431|NCT03979638|10129183|FG000|Period 1|Withdrawal by Subject|4
6354432|NCT03979638|10129184|FG001|Period 1|Withdrawal by Subject|3
6354433|NCT03979638|10129183|FG000|Period 1|Study terminated by Sponsor|1
6354434|NCT03979638|10129184|FG001|Period 1|Study terminated by Sponsor|3
6354435|NCT03979638|10129183|FG000|Period 1|Protocol Violation|1
6354436|NCT03979638|10129184|FG001|Period 1|Protocol Violation|0
6354437|NCT03979638|10129183|FG000|Period 2|Study terminated by Sponsor|1
6354438|NCT03979638|10129184|FG001|Period 2|Study terminated by Sponsor|1
6354439|NCT03979274|10129199|FG000|Treatment Period 2|Withdrawal by Subject|0
6354440|NCT03979274|10129200|FG001|Treatment Period 2|Withdrawal by Subject|1
6354441|NCT03977727|10129217|FG000|Second Treatment|Lost to Follow-up|0
6354442|NCT03977727|10129218|FG001|Second Treatment|Lost to Follow-up|3
6354443|NCT03977155|10129227|FG000|Overall Study|Adverse Event|3
6354444|NCT03977155|10129228|FG001|Overall Study|Adverse Event|0
6354445|NCT03977155|10129229|FG002|Overall Study|Adverse Event|0
6354446|NCT03977155|10129227|FG000|Overall Study|Lost to Follow-up|0
6354447|NCT03977155|10129228|FG001|Overall Study|Lost to Follow-up|1
6354448|NCT03977155|10129229|FG002|Overall Study|Lost to Follow-up|0
6354449|NCT03977155|10129227|FG000|Overall Study|Withdrawal by Subject|1
6354450|NCT03977155|10129228|FG001|Overall Study|Withdrawal by Subject|1
6354451|NCT03977155|10129229|FG002|Overall Study|Withdrawal by Subject|2
6354452|NCT03977155|10129227|FG000|Overall Study|Participant was unable to come in for the Visit|1
6354453|NCT03977155|10129228|FG001|Overall Study|Participant was unable to come in for the Visit|0
6354454|NCT03977155|10129229|FG002|Overall Study|Participant was unable to come in for the Visit|0
6354455|NCT03970733|10129251|FG000|Overall Study|Withdrawal by Subject|0
6354456|NCT03970733|10129252|FG001|Overall Study|Withdrawal by Subject|5
6354457|NCT03970733|10129253|FG002|Overall Study|Withdrawal by Subject|1
6354458|NCT03970733|10129251|FG000|Overall Study|e.g.: moved from study area|1
6354459|NCT03970733|10129252|FG001|Overall Study|e.g.: moved from study area|0
6354460|NCT03970733|10129253|FG002|Overall Study|e.g.: moved from study area|0
6354461|NCT03970733|10129251|FG000|Overall Study|Lost to Follow-up|2
6354462|NCT03970733|10129252|FG001|Overall Study|Lost to Follow-up|1
6354463|NCT03970733|10129253|FG002|Overall Study|Lost to Follow-up|1
6354464|NCT03970733|10129251|FG000|Overall Study|Other|1
6354465|NCT03970733|10129252|FG001|Overall Study|Other|0
6354466|NCT03970733|10129253|FG002|Overall Study|Other|0
6354467|NCT03968978|10129263|FG000|Overall Study|Adverse Event|1
6354468|NCT03968978|10129264|FG001|Overall Study|Adverse Event|0
6354469|NCT03967444|10129281|FG000|Overall Study|Lost to Follow-up|1
6354470|NCT03967444|10129282|FG001|Overall Study|Lost to Follow-up|2
6354471|NCT03966911|10129294|FG000|Overall Study|Adverse Event|1
6354472|NCT03966911|10129295|FG001|Overall Study|Adverse Event|1
6354473|NCT03966911|10129294|FG000|Overall Study|Withdrawal by Subject|8
6354474|NCT03966911|10129295|FG001|Overall Study|Withdrawal by Subject|2
6354475|NCT03966911|10129294|FG000|Overall Study|Unable to complete study visits due to COVID-19|0
6354476|NCT03966911|10129295|FG001|Overall Study|Unable to complete study visits due to COVID-19|13
6354477|NCT03966365|10129305|FG000|Overall Study|Protocol Violation|1
6354478|NCT03966365|10129306|FG001|Overall Study|Protocol Violation|0
6354479|NCT03965403|10129312|FG000|Overall Study|Subject not meeting eligibility criteria|1
6354480|NCT03965351|10129369|FG000|First Intervention (4 Weeks)|Lost to Follow-up|0
6354481|NCT03965351|10129370|FG001|First Intervention (4 Weeks)|Lost to Follow-up|1
6354482|NCT03965351|10129369|FG000|Second Intervention (4 Weeks)|Adverse Event|0
6354483|NCT03965351|10129370|FG001|Second Intervention (4 Weeks)|Adverse Event|1
6354484|NCT03958955|10129385|FG000|Overall Study|Adverse Event|1
6354485|NCT03965052|10129393|FG000|Overall Study|Protocol Violation|1
6354486|NCT03965052|10129394|FG001|Overall Study|Protocol Violation|0
6354487|NCT03963401|10129423|FG000|Initial Period (Day 1 - Week 16)|Adverse Event|1
6354488|NCT03963401|10129424|FG001|Initial Period (Day 1 - Week 16)|Adverse Event|2
6354489|NCT03963401|10129425|FG002|Initial Period (Day 1 - Week 16)|Adverse Event|0
6354490|NCT03963401|10129426|FG003|Initial Period (Day 1 - Week 16)|Adverse Event|0
6354491|NCT03963401|10129427|FG004|Initial Period (Day 1 - Week 16)|Adverse Event|1
6354492|NCT03963401|10129428|FG005|Initial Period (Day 1 - Week 16)|Adverse Event|2
6354493|NCT03963401|10129423|FG000|Initial Period (Day 1 - Week 16)|Lack of Efficacy|0
6354494|NCT03963401|10129424|FG001|Initial Period (Day 1 - Week 16)|Lack of Efficacy|0
6354495|NCT03963401|10129425|FG002|Initial Period (Day 1 - Week 16)|Lack of Efficacy|1
6354496|NCT03963401|10129426|FG003|Initial Period (Day 1 - Week 16)|Lack of Efficacy|1
6354497|NCT03963401|10129427|FG004|Initial Period (Day 1 - Week 16)|Lack of Efficacy|0
6354498|NCT03963401|10129428|FG005|Initial Period (Day 1 - Week 16)|Lack of Efficacy|0
6354499|NCT03963401|10129423|FG000|Initial Period (Day 1 - Week 16)|Withdrawal by Subject|2
6354500|NCT03963401|10129424|FG001|Initial Period (Day 1 - Week 16)|Withdrawal by Subject|1
6354501|NCT03963401|10129425|FG002|Initial Period (Day 1 - Week 16)|Withdrawal by Subject|1
6354502|NCT03963401|10129426|FG003|Initial Period (Day 1 - Week 16)|Withdrawal by Subject|1
6354503|NCT03963401|10129427|FG004|Initial Period (Day 1 - Week 16)|Withdrawal by Subject|2
6354504|NCT03963401|10129428|FG005|Initial Period (Day 1 - Week 16)|Withdrawal by Subject|0
6354505|NCT03963401|10129423|FG000|Initial Period (Day 1 - Week 16)|Randomized but Not Treated|0
6354506|NCT03963401|10129424|FG001|Initial Period (Day 1 - Week 16)|Randomized but Not Treated|1
6354507|NCT03963401|10129425|FG002|Initial Period (Day 1 - Week 16)|Randomized but Not Treated|0
6354508|NCT03963401|10129426|FG003|Initial Period (Day 1 - Week 16)|Randomized but Not Treated|0
6354509|NCT03963401|10129427|FG004|Initial Period (Day 1 - Week 16)|Randomized but Not Treated|0
6354510|NCT03963401|10129428|FG005|Initial Period (Day 1 - Week 16)|Randomized but Not Treated|0
6354511|NCT03963401|10129423|FG000|Extension Period (Week 17 - Week 52)|Adverse Event|6
6354512|NCT03963401|10129424|FG001|Extension Period (Week 17 - Week 52)|Adverse Event|3
6354513|NCT03963401|10129425|FG002|Extension Period (Week 17 - Week 52)|Adverse Event|2
6354514|NCT03963401|10129426|FG003|Extension Period (Week 17 - Week 52)|Adverse Event|0
6354515|NCT03963401|10129427|FG004|Extension Period (Week 17 - Week 52)|Adverse Event|4
6354516|NCT03963401|10129428|FG005|Extension Period (Week 17 - Week 52)|Adverse Event|3
6354517|NCT03963401|10129423|FG000|Extension Period (Week 17 - Week 52)|Lack of Efficacy|1
6354518|NCT03963401|10129424|FG001|Extension Period (Week 17 - Week 52)|Lack of Efficacy|0
6354519|NCT03963401|10129425|FG002|Extension Period (Week 17 - Week 52)|Lack of Efficacy|1
6354520|NCT03963401|10129426|FG003|Extension Period (Week 17 - Week 52)|Lack of Efficacy|0
6354521|NCT03963401|10129427|FG004|Extension Period (Week 17 - Week 52)|Lack of Efficacy|0
6354522|NCT03963401|10129428|FG005|Extension Period (Week 17 - Week 52)|Lack of Efficacy|0
6354523|NCT03963401|10129423|FG000|Extension Period (Week 17 - Week 52)|Lost to Follow-up|0
6354524|NCT03963401|10129424|FG001|Extension Period (Week 17 - Week 52)|Lost to Follow-up|0
6354525|NCT03963401|10129425|FG002|Extension Period (Week 17 - Week 52)|Lost to Follow-up|1
6354526|NCT03963401|10129426|FG003|Extension Period (Week 17 - Week 52)|Lost to Follow-up|0
6354527|NCT03963401|10129427|FG004|Extension Period (Week 17 - Week 52)|Lost to Follow-up|0
6354528|NCT03963401|10129428|FG005|Extension Period (Week 17 - Week 52)|Lost to Follow-up|0
6354529|NCT03963401|10129423|FG000|Extension Period (Week 17 - Week 52)|Non-Compliance With Study Drug|1
6354530|NCT03963401|10129424|FG001|Extension Period (Week 17 - Week 52)|Non-Compliance With Study Drug|0
6354531|NCT03963401|10129425|FG002|Extension Period (Week 17 - Week 52)|Non-Compliance With Study Drug|0
6354532|NCT03963401|10129426|FG003|Extension Period (Week 17 - Week 52)|Non-Compliance With Study Drug|0
6354533|NCT03963401|10129427|FG004|Extension Period (Week 17 - Week 52)|Non-Compliance With Study Drug|0
6354534|NCT03963401|10129428|FG005|Extension Period (Week 17 - Week 52)|Non-Compliance With Study Drug|0
6354535|NCT03963401|10129423|FG000|Extension Period (Week 17 - Week 52)|Withdrawal by Subject|4
6354536|NCT03963401|10129424|FG001|Extension Period (Week 17 - Week 52)|Withdrawal by Subject|1
6354537|NCT03963401|10129425|FG002|Extension Period (Week 17 - Week 52)|Withdrawal by Subject|0
6354538|NCT03963401|10129426|FG003|Extension Period (Week 17 - Week 52)|Withdrawal by Subject|0
6354539|NCT03963401|10129427|FG004|Extension Period (Week 17 - Week 52)|Withdrawal by Subject|1
6354540|NCT03963401|10129428|FG005|Extension Period (Week 17 - Week 52)|Withdrawal by Subject|1
6354541|NCT03963401|10129423|FG000|Extension Period (Week 17 - Week 52)|No Longer Meets Eligibility Criteria|1
6354542|NCT03963401|10129424|FG001|Extension Period (Week 17 - Week 52)|No Longer Meets Eligibility Criteria|0
6354543|NCT03963401|10129425|FG002|Extension Period (Week 17 - Week 52)|No Longer Meets Eligibility Criteria|0
6354544|NCT03963401|10129426|FG003|Extension Period (Week 17 - Week 52)|No Longer Meets Eligibility Criteria|0
6354545|NCT03963401|10129427|FG004|Extension Period (Week 17 - Week 52)|No Longer Meets Eligibility Criteria|0
6354546|NCT03963401|10129428|FG005|Extension Period (Week 17 - Week 52)|No Longer Meets Eligibility Criteria|0
6354547|NCT03963401|10129423|FG000|Extension Period (Week 17 - Week 52)|Other|1
6354548|NCT03963401|10129424|FG001|Extension Period (Week 17 - Week 52)|Other|1
6354549|NCT03963401|10129425|FG002|Extension Period (Week 17 - Week 52)|Other|0
6354550|NCT03963401|10129426|FG003|Extension Period (Week 17 - Week 52)|Other|1
6354551|NCT03963401|10129427|FG004|Extension Period (Week 17 - Week 52)|Other|1
6354552|NCT03963401|10129428|FG005|Extension Period (Week 17 - Week 52)|Other|1
6354553|NCT03962790|10129455|FG000|Period 1|Adverse Event|0
6354554|NCT03962790|10129456|FG001|Period 1|Adverse Event|1
6354555|NCT03962790|10129455|FG000|Period 1|Failed to meet all eligibility criteria|1
6354556|NCT03962790|10129456|FG001|Period 1|Failed to meet all eligibility criteria|1
6354557|NCT03962790|10129455|FG000|Period 1|No Longer Meets Eligibility Criteria|1
6354558|NCT03962790|10129456|FG001|Period 1|No Longer Meets Eligibility Criteria|0
6354559|NCT03962790|10129455|FG000|Period 1|Withdrawal by Subject|1
6354560|NCT03962790|10129456|FG001|Period 1|Withdrawal by Subject|0
6354561|NCT03956225|10129464|FG000|Overall Study|Lack of Efficacy|1
6354562|NCT03956225|10129465|FG001|Overall Study|Lack of Efficacy|1
6354563|NCT03956225|10129464|FG000|Overall Study|Lost to Follow-up|0
6354564|NCT03956225|10129465|FG001|Overall Study|Lost to Follow-up|1
6354565|NCT03956225|10129464|FG000|Overall Study|Withdrawal by Subject|2
6354566|NCT03956225|10129465|FG001|Overall Study|Withdrawal by Subject|1
6354567|NCT03956225|10129464|FG000|Overall Study|Other Reasons|2
6354568|NCT03956225|10129465|FG001|Overall Study|Other Reasons|1
6354569|NCT03958149|10129483|FG000|Overall Study|Withdrawal by Subject|0
6354570|NCT03958149|10129484|FG001|Overall Study|Withdrawal by Subject|1
6354571|NCT03953183|10129496|FG000|Overall Study|Physician Decision|0
6354572|NCT03953183|10129497|FG001|Overall Study|Physician Decision|1
6354573|NCT03953183|10129496|FG000|Overall Study|Withdrawal by Subject|0
6354574|NCT03953183|10129497|FG001|Overall Study|Withdrawal by Subject|1
6354575|NCT03962738|10129518|FG000|Overall Study|Protocol Deviation|3
6354576|NCT03962738|10129519|FG001|Overall Study|Protocol Deviation|0
6354577|NCT03962738|10129520|FG002|Overall Study|Protocol Deviation|1
6354578|NCT03962738|10129521|FG003|Overall Study|Protocol Deviation|1
6354579|NCT03962738|10129518|FG000|Overall Study|Withdrawal by Subject|4
6354580|NCT03962738|10129519|FG001|Overall Study|Withdrawal by Subject|0
6354581|NCT03962738|10129520|FG002|Overall Study|Withdrawal by Subject|0
6354582|NCT03962738|10129521|FG003|Overall Study|Withdrawal by Subject|0
6354583|NCT03962738|10129518|FG000|Overall Study|Lost to Follow-up|0
6354584|NCT03962738|10129519|FG001|Overall Study|Lost to Follow-up|0
6354585|NCT03962738|10129520|FG002|Overall Study|Lost to Follow-up|1
6354586|NCT03962738|10129521|FG003|Overall Study|Lost to Follow-up|0
6354587|NCT03962101|10129539|FG000|Overall Study|Adverse Event|1
6354588|NCT03962101|10129539|FG000|Overall Study|Physician Decision|2
6354589|NCT03962101|10129539|FG000|Overall Study|Not related to medical events|1
6354590|NCT03959137|10129544|FG000|Overall Study|Protocol Violation|6
6354591|NCT03946124|10129548|FG000|Overall Study|Withdrawal by Subject|19
6354592|NCT03961308|10129554|FG000|Overall Study|Withdrawal by Subject|1
6354593|NCT03961308|10129555|FG001|Overall Study|Withdrawal by Subject|0
6354594|NCT03961308|10129554|FG000|Overall Study|Other|1
6354595|NCT03961308|10129555|FG001|Overall Study|Other|0
6354596|NCT03961308|10129554|FG000|Overall Study|Lost to Follow-up|0
6354597|NCT03961308|10129555|FG001|Overall Study|Lost to Follow-up|1
6354598|NCT03961308|10129554|FG000|Overall Study|Adverse Event|0
6354599|NCT03961308|10129555|FG001|Overall Study|Adverse Event|1
6354600|NCT03956862|10129581|FG000|Overall Study|Lost to Follow-up|1
6354601|NCT03956862|10129582|FG001|Overall Study|Lost to Follow-up|1
6354602|NCT03956862|10129581|FG000|Overall Study|Withdrawal by Subject|1
6354603|NCT03956862|10129582|FG001|Overall Study|Withdrawal by Subject|1
6354604|NCT03954444|10129591|FG000|Overall Study|Withdrawal by Subject|5
6354605|NCT03954444|10129592|FG001|Overall Study|Withdrawal by Subject|5
6354606|NCT03954444|10129593|FG002|Overall Study|Withdrawal by Subject|5
6354607|NCT03954444|10129591|FG000|Overall Study|Adverse Event|1
6354608|NCT03954444|10129592|FG001|Overall Study|Adverse Event|3
6354609|NCT03954444|10129593|FG002|Overall Study|Adverse Event|2
6354610|NCT03954444|10129591|FG000|Overall Study|Protocol Violation|0
6354611|NCT03954444|10129592|FG001|Overall Study|Protocol Violation|3
6354612|NCT03954444|10129593|FG002|Overall Study|Protocol Violation|5
6354613|NCT03954444|10129591|FG000|Overall Study|Use of prohibited therapy|1
6354614|NCT03954444|10129592|FG001|Overall Study|Use of prohibited therapy|1
6354615|NCT03954444|10129593|FG002|Overall Study|Use of prohibited therapy|2
6354616|NCT03954444|10129591|FG000|Overall Study|Lost to Follow-up|1
6354617|NCT03954444|10129592|FG001|Overall Study|Lost to Follow-up|0
6354618|NCT03954444|10129593|FG002|Overall Study|Lost to Follow-up|1
6354619|NCT03954444|10129591|FG000|Overall Study|Non-compliant with study drug application|2
6354620|NCT03954444|10129592|FG001|Overall Study|Non-compliant with study drug application|2
6354621|NCT03954444|10129593|FG002|Overall Study|Non-compliant with study drug application|0
6354622|NCT03954444|10129591|FG000|Overall Study|Administrative reasons|0
6354623|NCT03954444|10129592|FG001|Overall Study|Administrative reasons|0
6354624|NCT03954444|10129593|FG002|Overall Study|Administrative reasons|1
6354625|NCT03954444|10129591|FG000|Overall Study|Miscellaneous|3
6354626|NCT03954444|10129592|FG001|Overall Study|Miscellaneous|2
6354627|NCT03954444|10129593|FG002|Overall Study|Miscellaneous|1
6354628|NCT03953820|10129601|FG000|Two-Sequence, Two-Way Crossover|Adverse Event|1
6354629|NCT03953820|10129602|FG001|Two-Sequence, Two-Way Crossover|Adverse Event|0
6354630|NCT03953820|10129603|FG002|Two-Sequence, Two-Way Crossover|Adverse Event|0
6354631|NCT03953820|10129601|FG000|Two-Sequence, Two-Way Crossover|Physician Decision|1
6354632|NCT03953820|10129602|FG001|Two-Sequence, Two-Way Crossover|Physician Decision|0
6354633|NCT03953820|10129603|FG002|Two-Sequence, Two-Way Crossover|Physician Decision|0
6354634|NCT03951766|10129616|FG000|Treatment Phase|Lost to Follow-up|1
6354635|NCT03951766|10129616|FG000|Follow-up Phase|Lost to Follow-up|10
6354636|NCT03950856|10129646|FG000|Overall Study|Death|1
6354637|NCT03950856|10129647|FG001|Overall Study|Death|2
6354638|NCT03950856|10129648|FG002|Overall Study|Death|0
6354639|NCT03950856|10129649|FG003|Overall Study|Death|0
6354640|NCT03950856|10129646|FG000|Overall Study|Lost to Follow-up|5
6354641|NCT03950856|10129647|FG001|Overall Study|Lost to Follow-up|6
6354642|NCT03950856|10129648|FG002|Overall Study|Lost to Follow-up|8
6354643|NCT03950856|10129649|FG003|Overall Study|Lost to Follow-up|2
6354644|NCT03950856|10129646|FG000|Overall Study|Protocol Violation|2
6354645|NCT03950856|10129647|FG001|Overall Study|Protocol Violation|0
6354646|NCT03950856|10129648|FG002|Overall Study|Protocol Violation|0
6354647|NCT03950856|10129649|FG003|Overall Study|Protocol Violation|1
6354648|NCT03950856|10129646|FG000|Overall Study|Withdrawal by Subject|4
6354649|NCT03950856|10129647|FG001|Overall Study|Withdrawal by Subject|1
6354650|NCT03950856|10129648|FG002|Overall Study|Withdrawal by Subject|3
6354651|NCT03950856|10129649|FG003|Overall Study|Withdrawal by Subject|1
6354652|NCT03950856|10129646|FG000|Overall Study|Unable to phone|7
6354653|NCT03950856|10129647|FG001|Overall Study|Unable to phone|6
6354654|NCT03950856|10129648|FG002|Overall Study|Unable to phone|7
6354655|NCT03950856|10129649|FG003|Overall Study|Unable to phone|2
6354656|NCT03956550|10129702|FG000|Overall Study|Sponsor decision|65
6354657|NCT03956550|10129703|FG001|Overall Study|Sponsor decision|66
6354658|NCT03956550|10129704|FG002|Overall Study|Sponsor decision|64
6354659|NCT03956550|10129702|FG000|Overall Study|Adverse Event|0
6354660|NCT03956550|10129703|FG001|Overall Study|Adverse Event|1
6354661|NCT03956550|10129704|FG002|Overall Study|Adverse Event|0
6354662|NCT03956550|10129702|FG000|Overall Study|Withdrawal by Subject|5
6354663|NCT03956550|10129703|FG001|Overall Study|Withdrawal by Subject|5
6354664|NCT03956550|10129704|FG002|Overall Study|Withdrawal by Subject|6
6354665|NCT03958656|10129756|FG000|Overall Study|Received anti-myeloma prescription (Rx)|0
6354666|NCT03958656|10129757|FG001|Overall Study|Received anti-myeloma prescription (Rx)|1
6354667|NCT03958656|10129758|FG002|Overall Study|Received anti-myeloma prescription (Rx)|0
6354668|NCT03958656|10129759|FG003|Overall Study|Received anti-myeloma prescription (Rx)|0
6354669|NCT03958656|10129756|FG000|Overall Study|No longer meets eligibility criteria|0
6354670|NCT03958656|10129757|FG001|Overall Study|No longer meets eligibility criteria|0
6354671|NCT03958656|10129758|FG002|Overall Study|No longer meets eligibility criteria|1
6354672|NCT03958656|10129759|FG003|Overall Study|No longer meets eligibility criteria|0
6354673|NCT03958656|10129756|FG000|Overall Study|Started anti-cancer treatment|0
6354674|NCT03958656|10129757|FG001|Overall Study|Started anti-cancer treatment|0
6354675|NCT03958656|10129758|FG002|Overall Study|Started anti-cancer treatment|1
6354676|NCT03958656|10129759|FG003|Overall Study|Started anti-cancer treatment|0
6354677|NCT03951805|10129782|FG000|Overall Study|Adverse Event|1
6354678|NCT03951805|10129783|FG001|Overall Study|Adverse Event|0
6354679|NCT03951805|10129784|FG002|Overall Study|Adverse Event|0
6354680|NCT03951805|10129785|FG003|Overall Study|Adverse Event|0
6354681|NCT03950622|10129810|FG000|Overall Study|Withdrawal by Subject|1
6354682|NCT03950622|10129811|FG001|Overall Study|Withdrawal by Subject|0
6354683|NCT03950622|10129810|FG000|Overall Study|Protocol Deviation|0
6354684|NCT03950622|10129811|FG001|Overall Study|Protocol Deviation|1
6354685|NCT03950622|10129810|FG000|Overall Study|Physician Decision|1
6354686|NCT03950622|10129811|FG001|Overall Study|Physician Decision|0
6354687|NCT03950622|10129810|FG000|Overall Study|Lost to Follow-up|5
6354688|NCT03950622|10129811|FG001|Overall Study|Lost to Follow-up|5
6354689|NCT03950622|10129810|FG000|Overall Study|Death|1
6354690|NCT03950622|10129811|FG001|Overall Study|Death|1
6354691|NCT03948581|10129841|FG000|Overall Study|Lost to Follow-up|0
6354692|NCT03948581|10129842|FG001|Overall Study|Lost to Follow-up|1
6354693|NCT03948334|10129863|FG000|Overall Study|Adverse Event|1
6354694|NCT03948334|10129864|FG001|Overall Study|Adverse Event|4
6354695|NCT03948334|10129863|FG000|Overall Study|Lack of Efficacy|2
6354696|NCT03948334|10129864|FG001|Overall Study|Lack of Efficacy|0
6083796|NCT00638027|9692392|FG000|Overall Study|Adverse Event|0
6083797|NCT00638027|9692393|FG001|Overall Study|Adverse Event|2
6083798|NCT00638157|9692401|FG000|Overall Study|Adverse Event|0
6083799|NCT00638157|9692402|FG001|Overall Study|Adverse Event|1
6083800|NCT00638157|9692401|FG000|Overall Study|Clinical (symptomatic) failure|1
6083801|NCT00638157|9692402|FG001|Overall Study|Clinical (symptomatic) failure|1
6083802|NCT00638157|9692401|FG000|Overall Study|Microbiological failure|1
6083803|NCT00638157|9692402|FG001|Overall Study|Microbiological failure|0
6083804|NCT00638157|9692401|FG000|Overall Study|Lost to Follow-up|1
6083805|NCT00638157|9692402|FG001|Overall Study|Lost to Follow-up|0
6354697|NCT03948334|10129863|FG000|Overall Study|Lost to Follow-up|1
6354698|NCT03948334|10129864|FG001|Overall Study|Lost to Follow-up|0
6354699|NCT03948334|10129863|FG000|Overall Study|Physician Decision|1
6354700|NCT03948334|10129864|FG001|Overall Study|Physician Decision|0
6354701|NCT03948334|10129863|FG000|Overall Study|Pregnancy|0
6354702|NCT03948334|10129864|FG001|Overall Study|Pregnancy|1
6354703|NCT03948334|10129863|FG000|Overall Study|Protocol Deviation|1
6083806|NCT00638157|9692401|FG000|Overall Study|Physician Decision|1
6354704|NCT03948334|10129864|FG001|Overall Study|Protocol Deviation|0
6354705|NCT03948334|10129863|FG000|Overall Study|Study terminated by Sponsor|50
6354706|NCT03948334|10129864|FG001|Overall Study|Study terminated by Sponsor|51
6354707|NCT03948334|10129863|FG000|Overall Study|Subject Decision /Guardian Decision|4
6354708|NCT03948334|10129864|FG001|Overall Study|Subject Decision /Guardian Decision|7
6354709|NCT03944707|10129891|FG000|Overall Study|Adverse Event|0
6354710|NCT03944707|10129892|FG001|Overall Study|Adverse Event|2
6354711|NCT03944707|10129891|FG000|Overall Study|Study terminated by sponsor|12
6354712|NCT03944707|10129892|FG001|Overall Study|Study terminated by sponsor|7
6354713|NCT03944707|10129891|FG000|Overall Study|Subject decision|0
6354714|NCT03944707|10129892|FG001|Overall Study|Subject decision|1
6354715|NCT03943095|10129909|FG000|Overall Study|Incorrectly dispensed wrong box kit|0
6354716|NCT03943095|10129910|FG001|Overall Study|Incorrectly dispensed wrong box kit|1
6354717|NCT03943095|10129909|FG000|Overall Study|Withdrawal by Subject|1
6354718|NCT03943095|10129910|FG001|Overall Study|Withdrawal by Subject|0
6083807|NCT00638157|9692402|FG001|Overall Study|Physician Decision|0
6083808|NCT00638157|9692401|FG000|Overall Study|Other|1
6083809|NCT00638157|9692402|FG001|Overall Study|Other|2
6083810|NCT00638157|9692401|FG000|Overall Study|Randomized, not treated|2
6354719|NCT03943290|10129926|FG000|Overall Study|Sponsor Terminated Study|6
6354720|NCT03943290|10129927|FG001|Overall Study|Sponsor Terminated Study|1
6354721|NCT03943290|10129928|FG002|Overall Study|Sponsor Terminated Study|11
6354722|NCT03943290|10129929|FG003|Overall Study|Sponsor Terminated Study|6
6354723|NCT03943290|10129930|FG004|Overall Study|Sponsor Terminated Study|7
6354724|NCT03943290|10129931|FG005|Overall Study|Sponsor Terminated Study|6
6354725|NCT03943290|10129932|FG006|Overall Study|Sponsor Terminated Study|6
6354726|NCT03943290|10129933|FG007|Overall Study|Sponsor Terminated Study|7
6354727|NCT03943290|10129934|FG008|Overall Study|Sponsor Terminated Study|8
6354728|NCT03943290|10129926|FG000|Overall Study|Lost to Follow-up|1
6354729|NCT03943290|10129927|FG001|Overall Study|Lost to Follow-up|0
6354730|NCT03943290|10129928|FG002|Overall Study|Lost to Follow-up|1
6354731|NCT03943290|10129929|FG003|Overall Study|Lost to Follow-up|0
6354732|NCT03943290|10129930|FG004|Overall Study|Lost to Follow-up|0
6354733|NCT03943290|10129931|FG005|Overall Study|Lost to Follow-up|0
6354734|NCT03943290|10129932|FG006|Overall Study|Lost to Follow-up|0
6354735|NCT03943290|10129933|FG007|Overall Study|Lost to Follow-up|1
6354736|NCT03943290|10129934|FG008|Overall Study|Lost to Follow-up|0
6354737|NCT03943290|10129926|FG000|Overall Study|Withdrawal by Subject|0
6354738|NCT03943290|10129927|FG001|Overall Study|Withdrawal by Subject|0
6354739|NCT03943290|10129928|FG002|Overall Study|Withdrawal by Subject|1
6354740|NCT03943290|10129929|FG003|Overall Study|Withdrawal by Subject|0
6354741|NCT03943290|10129930|FG004|Overall Study|Withdrawal by Subject|0
6354742|NCT03943290|10129931|FG005|Overall Study|Withdrawal by Subject|0
6354743|NCT03943290|10129932|FG006|Overall Study|Withdrawal by Subject|0
6354744|NCT03943290|10129933|FG007|Overall Study|Withdrawal by Subject|0
6354745|NCT03943290|10129934|FG008|Overall Study|Withdrawal by Subject|0
6354746|NCT03942042|10129969|FG000|Induction Dosing Period (12 Weeks)|Adverse Event|0
6354747|NCT03942042|10129970|FG001|Induction Dosing Period (12 Weeks)|Adverse Event|1
6354748|NCT03942042|10129969|FG000|Induction Dosing Period (12 Weeks)|Lack of Efficacy|1
6354749|NCT03942042|10129970|FG001|Induction Dosing Period (12 Weeks)|Lack of Efficacy|0
6354750|NCT03923530|10129989|FG000|Overall Study|Withdrawal by Subject|1
6354751|NCT03923530|10129989|FG000|Overall Study|screen failure|3
6354752|NCT03914417|10129993|FG000|Overall Study|Withdrawal by Subject|2
6354753|NCT03913377|10129999|FG000|Period 1|Test Article no longer available|0
6354754|NCT03913377|10130000|FG001|Period 1|Test Article no longer available|1
6354755|NCT03913377|10130001|FG002|Period 1|Test Article no longer available|0
6354756|NCT03913377|10129999|FG000|Period 1|No Longer Meets Eligibility Criteria|0
6354757|NCT03913377|10130000|FG001|Period 1|No Longer Meets Eligibility Criteria|0
6354758|NCT03913377|10130001|FG002|Period 1|No Longer Meets Eligibility Criteria|1
6354759|NCT03937778|10130012|FG000|Overall Study|Withdrawal by Subject|1
6354760|NCT03937778|10130012|FG000|Overall Study|Unable to obtain loss of A-beta sensation prior to loss of C-fiber sensation|1
6354761|NCT03937479|10130021|FG000|Overall Study|Adverse Event|2
6354762|NCT03937479|10130022|FG001|Overall Study|Adverse Event|3
6354763|NCT03937479|10130023|FG002|Overall Study|Adverse Event|0
6354764|NCT03937479|10130024|FG003|Overall Study|Adverse Event|0
6354765|NCT03937479|10130025|FG004|Overall Study|Adverse Event|1
6354766|NCT03937479|10130021|FG000|Overall Study|Withdrawal by Subject|3
6354767|NCT03937479|10130022|FG001|Overall Study|Withdrawal by Subject|5
6354768|NCT03937479|10130023|FG002|Overall Study|Withdrawal by Subject|2
6354769|NCT03937479|10130024|FG003|Overall Study|Withdrawal by Subject|2
6354770|NCT03937479|10130025|FG004|Overall Study|Withdrawal by Subject|1
6354771|NCT03937479|10130021|FG000|Overall Study|Protocol Violation|5
6354772|NCT03937479|10130022|FG001|Overall Study|Protocol Violation|6
6354773|NCT03937479|10130023|FG002|Overall Study|Protocol Violation|4
6354774|NCT03937479|10130024|FG003|Overall Study|Protocol Violation|3
6354775|NCT03937479|10130025|FG004|Overall Study|Protocol Violation|2
6354776|NCT03937479|10130021|FG000|Overall Study|Lost to Follow-up|0
6354777|NCT03937479|10130022|FG001|Overall Study|Lost to Follow-up|1
6354778|NCT03937479|10130023|FG002|Overall Study|Lost to Follow-up|0
6354779|NCT03937479|10130024|FG003|Overall Study|Lost to Follow-up|1
6354780|NCT03937479|10130025|FG004|Overall Study|Lost to Follow-up|0
6354781|NCT03937479|10130021|FG000|Overall Study|Physician Decision|0
6354782|NCT03937479|10130022|FG001|Overall Study|Physician Decision|0
6354783|NCT03937479|10130023|FG002|Overall Study|Physician Decision|1
6354784|NCT03937479|10130024|FG003|Overall Study|Physician Decision|0
6354785|NCT03937479|10130025|FG004|Overall Study|Physician Decision|1
6354786|NCT03936244|10130061|FG000|Overall Study|Lost to Follow-up|5
6354787|NCT03936244|10130062|FG001|Overall Study|Lost to Follow-up|1
6354788|NCT03936244|10130061|FG000|Overall Study|Physician Decision|7
6354789|NCT03936244|10130062|FG001|Overall Study|Physician Decision|3
6354790|NCT03935126|10130069|FG000|Overall Study|Study termination by sponsor|3
6354791|NCT03933462|10130088|FG000|Overall Study|Adverse Event|2
6354792|NCT03933462|10130089|FG001|Overall Study|Adverse Event|0
6354793|NCT03931330|10130104|FG000|Overall Study|Physician Decision|1
6354794|NCT03931785|10130147|FG000|Overall Study|Lost to Follow-up|4
6354795|NCT03931785|10130148|FG001|Overall Study|Lost to Follow-up|1
6354796|NCT03931785|10130149|FG002|Overall Study|Lost to Follow-up|4
6354797|NCT03931785|10130150|FG003|Overall Study|Lost to Follow-up|3
6354798|NCT03931785|10130147|FG000|Overall Study|Adverse Event|1
6354799|NCT03931785|10130148|FG001|Overall Study|Adverse Event|0
6354800|NCT03931785|10130149|FG002|Overall Study|Adverse Event|3
6354801|NCT03931785|10130150|FG003|Overall Study|Adverse Event|4
6354802|NCT03931785|10130147|FG000|Overall Study|Protocol Violation|0
6354803|NCT03931785|10130148|FG001|Overall Study|Protocol Violation|1
6354804|NCT03931785|10130149|FG002|Overall Study|Protocol Violation|0
6354805|NCT03931785|10130150|FG003|Overall Study|Protocol Violation|0
6354806|NCT03931785|10130147|FG000|Overall Study|Noncompliance With Study drug|0
6354807|NCT03931785|10130148|FG001|Overall Study|Noncompliance With Study drug|1
6354808|NCT03931785|10130149|FG002|Overall Study|Noncompliance With Study drug|0
6354809|NCT03931785|10130150|FG003|Overall Study|Noncompliance With Study drug|0
6354810|NCT03931785|10130147|FG000|Overall Study|Other Not specified|0
6354811|NCT03931785|10130148|FG001|Overall Study|Other Not specified|2
6354812|NCT03931785|10130149|FG002|Overall Study|Other Not specified|2
6354813|NCT03931785|10130150|FG003|Overall Study|Other Not specified|2
6354814|NCT03931785|10130147|FG000|Overall Study|Withdrawal by Subject|0
6354815|NCT03931785|10130148|FG001|Overall Study|Withdrawal by Subject|2
6354816|NCT03931785|10130149|FG002|Overall Study|Withdrawal by Subject|4
6354817|NCT03931785|10130150|FG003|Overall Study|Withdrawal by Subject|1
6354818|NCT03931785|10130147|FG000|Overall Study|Pregnancy|0
6354819|NCT03931785|10130148|FG001|Overall Study|Pregnancy|0
6354820|NCT03931785|10130149|FG002|Overall Study|Pregnancy|0
6354821|NCT03931785|10130150|FG003|Overall Study|Pregnancy|1
6354822|NCT03927846|10130166|FG000|Overall Study|Lost to Follow-up|10
6354823|NCT03927846|10130167|FG001|Overall Study|Lost to Follow-up|11
6354824|NCT03927105|10130173|FG000|Overall Study|Death|1
6354825|NCT03927105|10130173|FG000|Overall Study|In observation for potential re-treatment|2
6354826|NCT03927105|10130173|FG000|Overall Study|Subject was never treated due to new medical problems causing ineligibility prior to treatment.|1
6354827|NCT03923933|10130179|FG000|Overall Study|Lost to Follow-up|1
6354828|NCT03923933|10130180|FG001|Overall Study|Lost to Follow-up|0
6354829|NCT03923933|10130179|FG000|Overall Study|Withdrawal by Subject|0
6354830|NCT03923933|10130180|FG001|Overall Study|Withdrawal by Subject|1
6354831|NCT03909295|10130186|FG000|Overall Study|Adverse Event|2
6354832|NCT03909295|10130186|FG000|Overall Study|Study terminated by sponsor|50
6354833|NCT03908970|10130192|FG000|Overall Study|Adverse Event|7
6354834|NCT03908970|10130193|FG001|Overall Study|Adverse Event|21
6354835|NCT03908970|10130192|FG000|Overall Study|Physician Decision|1
6354836|NCT03908970|10130193|FG001|Overall Study|Physician Decision|4
6354837|NCT03908970|10130192|FG000|Overall Study|Withdrawal by Subject|9
6354838|NCT03908970|10130193|FG001|Overall Study|Withdrawal by Subject|22
6354839|NCT03897179|10130199|FG000|Overall Study|Withdrawal by Subject|1
6354840|NCT03927950|10130263|FG000|Overall Study|Adverse Event|9
6354841|NCT03920670|10130285|FG000|Overall Study|Protocol Violation|2
6354842|NCT03920670|10130286|FG001|Overall Study|Protocol Violation|2
6354843|NCT03920670|10130285|FG000|Overall Study|Adverse Event|1
6354844|NCT03920670|10130286|FG001|Overall Study|Adverse Event|0
6354845|NCT03898063|10130307|FG000|Overall Study|Withdrawal by Subject|10
6354846|NCT03898063|10130308|FG001|Overall Study|Withdrawal by Subject|8
6354847|NCT03909100|10130354|FG000|Overall Study|Protocol Deviation|2
6354848|NCT03909100|10130354|FG000|Overall Study|Technical Problems|4
6354849|NCT03909100|10130354|FG000|Overall Study|Withdrawal by Subject|4
6354850|NCT03909100|10130354|FG000|Overall Study|Lost to Follow-up|1
6354851|NCT03909100|10130354|FG000|Overall Study|Reason not Specified|4
6354852|NCT03905642|10130361|FG000|Overall Study|Withdrawal by Subject|3
6354853|NCT03905642|10130361|FG000|Overall Study|Pregnancy|1
6354854|NCT03905642|10130361|FG000|Overall Study|Adverse Event|1
6354855|NCT03905642|10130361|FG000|Overall Study|Lack of Efficacy|1
6354856|NCT03905642|10130361|FG000|Overall Study|Completed study but not 24 of 28 days|2
6354857|NCT03892889|10130365|FG000|Overall Study|Adverse Event|17
6354858|NCT03892889|10130365|FG000|Overall Study|Lack of Efficacy|1
6354859|NCT03892889|10130365|FG000|Overall Study|Lost to Follow-up|46
6354860|NCT03892889|10130365|FG000|Overall Study|Non-compliance with study drug|22
6354861|NCT03892889|10130365|FG000|Overall Study|Pregnancy|1
6354862|NCT03892889|10130365|FG000|Overall Study|Protocol Deviation|3
6354863|NCT03892889|10130365|FG000|Overall Study|Withdrawal by Subject|50
6354864|NCT03892889|10130365|FG000|Overall Study|Withdrawal by Caregiver|1
6354865|NCT03892889|10130365|FG000|Overall Study|Study Terminated by Sponsor|50
6354866|NCT03892889|10130365|FG000|Overall Study|Physician Decision|8
6354867|NCT03892889|10130365|FG000|Overall Study|Reason not Specified|5
6354868|NCT03921723|10130369|FG000|Period 2 (4 Days)|Withdrawal by Subject|3
6354869|NCT03921723|10130369|FG000|Period 3 (4 Days)|Withdrawal by Subject|1
6354870|NCT03918239|10130413|FG000|Overall Study|Lost to Follow-up|3
6354871|NCT03918239|10130414|FG001|Overall Study|Lost to Follow-up|1
6354872|NCT03918239|10130413|FG000|Overall Study|Pregnancy|0
6354873|NCT03918239|10130414|FG001|Overall Study|Pregnancy|2
6354874|NCT03918239|10130413|FG000|Overall Study|Withdrawal by Subject|3
6354875|NCT03918239|10130414|FG001|Overall Study|Withdrawal by Subject|3
6354876|NCT03918239|10130413|FG000|Overall Study|positive urine drug screening results|4
6354877|NCT03918239|10130414|FG001|Overall Study|positive urine drug screening results|1
6354878|NCT03917823|10130422|FG000|Overall Study|Lost to Follow-up|1
6354879|NCT03917823|10130423|FG001|Overall Study|Lost to Follow-up|1
6354880|NCT03917823|10130422|FG000|Overall Study|Withdrawal by Subject|0
6354881|NCT03917823|10130423|FG001|Overall Study|Withdrawal by Subject|1
6354882|NCT03902613|10130444|FG000|Overall Study|Physician Decision|1
6354883|NCT03902574|10130451|FG000|Overall Study|Urinary drug test was positive on Day 20|0
6354884|NCT03902574|10130452|FG001|Overall Study|Urinary drug test was positive on Day 20|0
6354885|NCT03902574|10130453|FG002|Overall Study|Urinary drug test was positive on Day 20|1
6354886|NCT03914950|10130461|FG000|Overall Study|Physician Decision|54
6083811|NCT00638157|9692402|FG001|Overall Study|Randomized, not treated|0
6083812|NCT00638183|9692409|FG000|Overall Study|Adverse Event|23
6354887|NCT03911843|10130473|FG000|Overall Study|Adverse Event|2
6354888|NCT03911843|10130474|FG001|Overall Study|Adverse Event|0
6354889|NCT03911843|10130473|FG000|Overall Study|Protocol Violation|2
6354890|NCT03911843|10130474|FG001|Overall Study|Protocol Violation|0
6354891|NCT03911843|10130473|FG000|Overall Study|Lost to Follow-up|0
6354892|NCT03911843|10130474|FG001|Overall Study|Lost to Follow-up|1
6354893|NCT03894813|10130491|FG000|Overall Study|Adverse Event|1
6354894|NCT03894813|10130492|FG001|Overall Study|Adverse Event|1
6354895|NCT03894813|10130491|FG000|Overall Study|Lack of Efficacy|3
6354896|NCT03894813|10130492|FG001|Overall Study|Lack of Efficacy|3
6354897|NCT03894813|10130491|FG000|Overall Study|Lost to Follow-up|1
6354898|NCT03894813|10130492|FG001|Overall Study|Lost to Follow-up|0
6354899|NCT03894813|10130491|FG000|Overall Study|Pregnancy|2
6354900|NCT03894813|10130492|FG001|Overall Study|Pregnancy|1
6354901|NCT03894813|10130491|FG000|Overall Study|Protocol Violation|3
6354902|NCT03894813|10130492|FG001|Overall Study|Protocol Violation|7
6354903|NCT03894813|10130491|FG000|Overall Study|Withdrawal by Subject|1
6354904|NCT03894813|10130492|FG001|Overall Study|Withdrawal by Subject|3
6354905|NCT03894813|10130491|FG000|Overall Study|Complain of the research staff and refused to continue the trial|0
6354906|NCT03894813|10130492|FG001|Overall Study|Complain of the research staff and refused to continue the trial|1
6354907|NCT03911960|10130500|FG000|Overall Study|Lost to Follow-up|5
6354908|NCT03911960|10130501|FG001|Overall Study|Lost to Follow-up|3
6354909|NCT03907072|10130511|FG000|Overall Study|Study Terminated by Sponsor|2
6354910|NCT03907072|10130512|FG001|Overall Study|Study Terminated by Sponsor|2
6354911|NCT03907072|10130513|FG002|Overall Study|Study Terminated by Sponsor|2
6354912|NCT03911401|10130533|FG000|Overall Study|Adverse Event|1
6354913|NCT03911401|10130534|FG001|Overall Study|Adverse Event|2
6354914|NCT03911401|10130535|FG002|Overall Study|Adverse Event|5
6354915|NCT03911401|10130533|FG000|Overall Study|Lack of Efficacy|1
6354916|NCT03911401|10130534|FG001|Overall Study|Lack of Efficacy|1
6354917|NCT03911401|10130535|FG002|Overall Study|Lack of Efficacy|8
6354918|NCT03911401|10130533|FG000|Overall Study|Physician Decision|0
6354919|NCT03911401|10130534|FG001|Overall Study|Physician Decision|0
6354920|NCT03911401|10130535|FG002|Overall Study|Physician Decision|1
6354921|NCT03911401|10130533|FG000|Overall Study|Withdrawal by Subject|1
6354922|NCT03911401|10130534|FG001|Overall Study|Withdrawal by Subject|2
6354923|NCT03911401|10130535|FG002|Overall Study|Withdrawal by Subject|0
6354924|NCT03911401|10130533|FG000|Overall Study|Withdrawal by parent/guardian|4
6354925|NCT03911401|10130534|FG001|Overall Study|Withdrawal by parent/guardian|4
6354926|NCT03911401|10130535|FG002|Overall Study|Withdrawal by parent/guardian|11
6354927|NCT03904420|10130562|FG000|Overall Study|Study terminated|2
6354928|NCT03904420|10130563|FG001|Overall Study|Study terminated|2
6354929|NCT03903822|10130577|FG000|Treatment Phase (6 Weeks)|Adverse Event|3
6354930|NCT03903822|10130578|FG001|Treatment Phase (6 Weeks)|Adverse Event|3
6354931|NCT03903822|10130579|FG002|Treatment Phase (6 Weeks)|Adverse Event|1
6354932|NCT03903822|10130580|FG003|Treatment Phase (6 Weeks)|Adverse Event|1
6354933|NCT03903822|10130581|FG004|Treatment Phase (6 Weeks)|Adverse Event|1
6354934|NCT03903822|10130582|FG005|Treatment Phase (6 Weeks)|Adverse Event|6
6354935|NCT03903822|10130583|FG006|Treatment Phase (6 Weeks)|Adverse Event|1
6354936|NCT03903822|10130584|FG007|Treatment Phase (6 Weeks)|Adverse Event|0
6354937|NCT03903822|10130577|FG000|Treatment Phase (6 Weeks)|Lack of Efficacy|0
6354938|NCT03903822|10130578|FG001|Treatment Phase (6 Weeks)|Lack of Efficacy|0
6354939|NCT03903822|10130579|FG002|Treatment Phase (6 Weeks)|Lack of Efficacy|0
6354940|NCT03903822|10130580|FG003|Treatment Phase (6 Weeks)|Lack of Efficacy|0
6354941|NCT03903822|10130581|FG004|Treatment Phase (6 Weeks)|Lack of Efficacy|1
6354942|NCT03903822|10130582|FG005|Treatment Phase (6 Weeks)|Lack of Efficacy|1
6354943|NCT03903822|10130583|FG006|Treatment Phase (6 Weeks)|Lack of Efficacy|0
6354944|NCT03903822|10130584|FG007|Treatment Phase (6 Weeks)|Lack of Efficacy|0
6354945|NCT03903822|10130577|FG000|Treatment Phase (6 Weeks)|Lost to Follow-up|0
6354946|NCT03903822|10130578|FG001|Treatment Phase (6 Weeks)|Lost to Follow-up|0
6354947|NCT03903822|10130579|FG002|Treatment Phase (6 Weeks)|Lost to Follow-up|0
6354948|NCT03903822|10130580|FG003|Treatment Phase (6 Weeks)|Lost to Follow-up|0
6354949|NCT03903822|10130581|FG004|Treatment Phase (6 Weeks)|Lost to Follow-up|0
6354950|NCT03903822|10130582|FG005|Treatment Phase (6 Weeks)|Lost to Follow-up|0
6354951|NCT03903822|10130583|FG006|Treatment Phase (6 Weeks)|Lost to Follow-up|1
6354952|NCT03903822|10130584|FG007|Treatment Phase (6 Weeks)|Lost to Follow-up|1
6354953|NCT03903822|10130577|FG000|Treatment Phase (6 Weeks)|Physician Decision|0
6354954|NCT03903822|10130578|FG001|Treatment Phase (6 Weeks)|Physician Decision|2
6354955|NCT03903822|10130579|FG002|Treatment Phase (6 Weeks)|Physician Decision|0
6354956|NCT03903822|10130580|FG003|Treatment Phase (6 Weeks)|Physician Decision|0
6354957|NCT03903822|10130581|FG004|Treatment Phase (6 Weeks)|Physician Decision|0
6354958|NCT03903822|10130582|FG005|Treatment Phase (6 Weeks)|Physician Decision|0
6354959|NCT03903822|10130583|FG006|Treatment Phase (6 Weeks)|Physician Decision|0
6354960|NCT03903822|10130584|FG007|Treatment Phase (6 Weeks)|Physician Decision|0
6354961|NCT03903822|10130577|FG000|Treatment Phase (6 Weeks)|Pregnancy|0
6354962|NCT03903822|10130578|FG001|Treatment Phase (6 Weeks)|Pregnancy|0
6354963|NCT03903822|10130579|FG002|Treatment Phase (6 Weeks)|Pregnancy|0
6354964|NCT03903822|10130580|FG003|Treatment Phase (6 Weeks)|Pregnancy|1
6354965|NCT03903822|10130581|FG004|Treatment Phase (6 Weeks)|Pregnancy|1
6354966|NCT03903822|10130582|FG005|Treatment Phase (6 Weeks)|Pregnancy|0
6354967|NCT03903822|10130583|FG006|Treatment Phase (6 Weeks)|Pregnancy|0
6354968|NCT03903822|10130584|FG007|Treatment Phase (6 Weeks)|Pregnancy|0
6354969|NCT03903822|10130577|FG000|Treatment Phase (6 Weeks)|Protocol Violation|0
6354970|NCT03903822|10130578|FG001|Treatment Phase (6 Weeks)|Protocol Violation|0
6354971|NCT03903822|10130579|FG002|Treatment Phase (6 Weeks)|Protocol Violation|0
6354972|NCT03903822|10130580|FG003|Treatment Phase (6 Weeks)|Protocol Violation|1
6354973|NCT03903822|10130581|FG004|Treatment Phase (6 Weeks)|Protocol Violation|0
6354974|NCT03903822|10130582|FG005|Treatment Phase (6 Weeks)|Protocol Violation|0
6354975|NCT03903822|10130583|FG006|Treatment Phase (6 Weeks)|Protocol Violation|0
6354976|NCT03903822|10130584|FG007|Treatment Phase (6 Weeks)|Protocol Violation|0
6354977|NCT03903822|10130577|FG000|Treatment Phase (6 Weeks)|Withdrawal by Subject|2
6354978|NCT03903822|10130578|FG001|Treatment Phase (6 Weeks)|Withdrawal by Subject|4
6354979|NCT03903822|10130579|FG002|Treatment Phase (6 Weeks)|Withdrawal by Subject|2
6354980|NCT03903822|10130580|FG003|Treatment Phase (6 Weeks)|Withdrawal by Subject|2
6354981|NCT03903822|10130581|FG004|Treatment Phase (6 Weeks)|Withdrawal by Subject|1
6354982|NCT03903822|10130582|FG005|Treatment Phase (6 Weeks)|Withdrawal by Subject|2
6354983|NCT03903822|10130583|FG006|Treatment Phase (6 Weeks)|Withdrawal by Subject|3
6354984|NCT03903822|10130584|FG007|Treatment Phase (6 Weeks)|Withdrawal by Subject|3
6354985|NCT03903822|10130577|FG000|Treatment Phase (6 Weeks)|Refused Further Treatment|2
6354986|NCT03903822|10130578|FG001|Treatment Phase (6 Weeks)|Refused Further Treatment|0
6354987|NCT03903822|10130579|FG002|Treatment Phase (6 Weeks)|Refused Further Treatment|0
6354988|NCT03903822|10130580|FG003|Treatment Phase (6 Weeks)|Refused Further Treatment|0
6354989|NCT03903822|10130581|FG004|Treatment Phase (6 Weeks)|Refused Further Treatment|0
6354990|NCT03903822|10130582|FG005|Treatment Phase (6 Weeks)|Refused Further Treatment|1
6354991|NCT03903822|10130583|FG006|Treatment Phase (6 Weeks)|Refused Further Treatment|0
6354992|NCT03903822|10130584|FG007|Treatment Phase (6 Weeks)|Refused Further Treatment|0
6083813|NCT00638183|9692409|FG000|Overall Study|Lack of Efficacy|14
6354993|NCT03903822|10130577|FG000|Treatment Phase (6 Weeks)|Other|2
6354994|NCT03903822|10130578|FG001|Treatment Phase (6 Weeks)|Other|1
6354995|NCT03903822|10130579|FG002|Treatment Phase (6 Weeks)|Other|0
6354996|NCT03903822|10130580|FG003|Treatment Phase (6 Weeks)|Other|0
6354997|NCT03903822|10130581|FG004|Treatment Phase (6 Weeks)|Other|1
6354998|NCT03903822|10130582|FG005|Treatment Phase (6 Weeks)|Other|1
6170267|NCT01252186|9816504|FG000|Overall Study|Non-compliance|0
6170268|NCT01252186|9816505|FG001|Overall Study|Non-compliance|3
6083814|NCT00638183|9692409|FG000|Overall Study|Physician Decision|9
6170269|NCT01252186|9816506|FG002|Overall Study|Non-compliance|4
6170270|NCT01252186|9816504|FG000|Overall Study|Protocol Violation|0
6170271|NCT01252186|9816505|FG001|Overall Study|Protocol Violation|0
6170272|NCT01252186|9816506|FG002|Overall Study|Protocol Violation|1
6170273|NCT01252186|9816504|FG000|Overall Study|Pregnancy|2
6170274|NCT01252186|9816505|FG001|Overall Study|Pregnancy|2
6354999|NCT03903822|10130583|FG006|Treatment Phase (6 Weeks)|Other|0
6355000|NCT03903822|10130584|FG007|Treatment Phase (6 Weeks)|Other|0
6355001|NCT03903822|10130577|FG000|Follow up Phase (4 Weeks)|Adverse Event|3
6355002|NCT03903822|10130578|FG001|Follow up Phase (4 Weeks)|Adverse Event|2
6355003|NCT03903822|10130579|FG002|Follow up Phase (4 Weeks)|Adverse Event|1
6355004|NCT03903822|10130580|FG003|Follow up Phase (4 Weeks)|Adverse Event|1
6355005|NCT03903822|10130581|FG004|Follow up Phase (4 Weeks)|Adverse Event|0
6355006|NCT03903822|10130582|FG005|Follow up Phase (4 Weeks)|Adverse Event|5
6355007|NCT03903822|10130583|FG006|Follow up Phase (4 Weeks)|Adverse Event|1
6355008|NCT03903822|10130584|FG007|Follow up Phase (4 Weeks)|Adverse Event|0
6355009|NCT03903822|10130577|FG000|Follow up Phase (4 Weeks)|Lack of Efficacy|0
6355010|NCT03903822|10130578|FG001|Follow up Phase (4 Weeks)|Lack of Efficacy|0
6355011|NCT03903822|10130579|FG002|Follow up Phase (4 Weeks)|Lack of Efficacy|0
6355012|NCT03903822|10130580|FG003|Follow up Phase (4 Weeks)|Lack of Efficacy|0
6355013|NCT03903822|10130581|FG004|Follow up Phase (4 Weeks)|Lack of Efficacy|1
6355014|NCT03903822|10130582|FG005|Follow up Phase (4 Weeks)|Lack of Efficacy|0
6355015|NCT03903822|10130583|FG006|Follow up Phase (4 Weeks)|Lack of Efficacy|0
6355016|NCT03903822|10130584|FG007|Follow up Phase (4 Weeks)|Lack of Efficacy|0
6355017|NCT03903822|10130577|FG000|Follow up Phase (4 Weeks)|Lost to Follow-up|2
6355018|NCT03903822|10130578|FG001|Follow up Phase (4 Weeks)|Lost to Follow-up|0
6355019|NCT03903822|10130579|FG002|Follow up Phase (4 Weeks)|Lost to Follow-up|0
6355020|NCT03903822|10130580|FG003|Follow up Phase (4 Weeks)|Lost to Follow-up|0
6355021|NCT03903822|10130581|FG004|Follow up Phase (4 Weeks)|Lost to Follow-up|0
6355022|NCT03903822|10130582|FG005|Follow up Phase (4 Weeks)|Lost to Follow-up|0
6355023|NCT03903822|10130583|FG006|Follow up Phase (4 Weeks)|Lost to Follow-up|1
6355024|NCT03903822|10130584|FG007|Follow up Phase (4 Weeks)|Lost to Follow-up|3
6355025|NCT03903822|10130577|FG000|Follow up Phase (4 Weeks)|Pregnancy|0
6355026|NCT03903822|10130578|FG001|Follow up Phase (4 Weeks)|Pregnancy|0
6355027|NCT03903822|10130579|FG002|Follow up Phase (4 Weeks)|Pregnancy|0
6355028|NCT03903822|10130580|FG003|Follow up Phase (4 Weeks)|Pregnancy|1
6355029|NCT03903822|10130581|FG004|Follow up Phase (4 Weeks)|Pregnancy|1
6355030|NCT03903822|10130582|FG005|Follow up Phase (4 Weeks)|Pregnancy|0
6355031|NCT03903822|10130583|FG006|Follow up Phase (4 Weeks)|Pregnancy|0
6355032|NCT03903822|10130584|FG007|Follow up Phase (4 Weeks)|Pregnancy|0
6355033|NCT03903822|10130577|FG000|Follow up Phase (4 Weeks)|Withdrawal by Subject|2
6355034|NCT03903822|10130578|FG001|Follow up Phase (4 Weeks)|Withdrawal by Subject|5
6355035|NCT03903822|10130579|FG002|Follow up Phase (4 Weeks)|Withdrawal by Subject|3
6355036|NCT03903822|10130580|FG003|Follow up Phase (4 Weeks)|Withdrawal by Subject|2
6355037|NCT03903822|10130581|FG004|Follow up Phase (4 Weeks)|Withdrawal by Subject|2
6355038|NCT03903822|10130582|FG005|Follow up Phase (4 Weeks)|Withdrawal by Subject|2
6355039|NCT03903822|10130583|FG006|Follow up Phase (4 Weeks)|Withdrawal by Subject|3
6355040|NCT03903822|10130584|FG007|Follow up Phase (4 Weeks)|Withdrawal by Subject|3
6355041|NCT03903822|10130577|FG000|Follow up Phase (4 Weeks)|Refused Further Study Procedures|0
6355042|NCT03903822|10130578|FG001|Follow up Phase (4 Weeks)|Refused Further Study Procedures|0
6355043|NCT03903822|10130579|FG002|Follow up Phase (4 Weeks)|Refused Further Study Procedures|0
6355044|NCT03903822|10130580|FG003|Follow up Phase (4 Weeks)|Refused Further Study Procedures|0
6355045|NCT03903822|10130581|FG004|Follow up Phase (4 Weeks)|Refused Further Study Procedures|0
6355046|NCT03903822|10130582|FG005|Follow up Phase (4 Weeks)|Refused Further Study Procedures|1
6355047|NCT03903822|10130583|FG006|Follow up Phase (4 Weeks)|Refused Further Study Procedures|0
6355048|NCT03903822|10130584|FG007|Follow up Phase (4 Weeks)|Refused Further Study Procedures|0
6355049|NCT03903822|10130577|FG000|Follow up Phase (4 Weeks)|Other|1
6355050|NCT03903822|10130578|FG001|Follow up Phase (4 Weeks)|Other|1
6355051|NCT03903822|10130579|FG002|Follow up Phase (4 Weeks)|Other|0
6355052|NCT03903822|10130580|FG003|Follow up Phase (4 Weeks)|Other|0
6355053|NCT03903822|10130581|FG004|Follow up Phase (4 Weeks)|Other|0
6355054|NCT03903822|10130582|FG005|Follow up Phase (4 Weeks)|Other|0
6355055|NCT03903822|10130583|FG006|Follow up Phase (4 Weeks)|Other|0
6355056|NCT03903822|10130584|FG007|Follow up Phase (4 Weeks)|Other|0
6355057|NCT03905096|10130604|FG000|Period 2 for Trial Part 1 and 2|Adverse Event|1
6170275|NCT01252186|9816506|FG002|Overall Study|Pregnancy|0
6170276|NCT01252186|9816504|FG000|Overall Study|Sponsor Request|2
6355058|NCT03905096|10130605|FG001|Period 2 for Trial Part 1 and 2|Adverse Event|0
6355059|NCT03899064|10130618|FG000|Overall Study|Lost to Follow-up|1
6355060|NCT03899064|10130618|FG000|Overall Study|Protocol Violation|2
6355061|NCT03899064|10130618|FG000|Overall Study|Withdrawal by Subject|2
6170277|NCT01252186|9816505|FG001|Overall Study|Sponsor Request|1
6355062|NCT03899064|10130618|FG000|Overall Study|Other|2
6355063|NCT03894969|10130627|FG000|Overall Study|Adverse Event|0
6355064|NCT03894969|10130628|FG001|Overall Study|Adverse Event|2
6355065|NCT03894969|10130629|FG002|Overall Study|Adverse Event|0
6355066|NCT03894969|10130630|FG003|Overall Study|Adverse Event|3
6355067|NCT03894969|10130631|FG004|Overall Study|Adverse Event|3
6355068|NCT03894969|10130627|FG000|Overall Study|Lost to Follow-up|1
6355069|NCT03894969|10130628|FG001|Overall Study|Lost to Follow-up|0
6355070|NCT03894969|10130629|FG002|Overall Study|Lost to Follow-up|1
6355071|NCT03894969|10130630|FG003|Overall Study|Lost to Follow-up|0
6355072|NCT03894969|10130631|FG004|Overall Study|Lost to Follow-up|0
6355073|NCT03894969|10130627|FG000|Overall Study|Withdrawal by Subject|1
6355074|NCT03894969|10130628|FG001|Overall Study|Withdrawal by Subject|1
6355075|NCT03894969|10130629|FG002|Overall Study|Withdrawal by Subject|1
6355076|NCT03894969|10130630|FG003|Overall Study|Withdrawal by Subject|3
6355077|NCT03894969|10130631|FG004|Overall Study|Withdrawal by Subject|8
6355078|NCT03894969|10130627|FG000|Overall Study|Other|0
6355079|NCT03894969|10130628|FG001|Overall Study|Other|0
6355080|NCT03894969|10130629|FG002|Overall Study|Other|0
6355081|NCT03894969|10130630|FG003|Overall Study|Other|0
6355082|NCT03894969|10130631|FG004|Overall Study|Other|3
6355083|NCT03903159|10130644|FG000|Overall Study|Discharged with Staff Approval|2
6355084|NCT03903159|10130644|FG000|Overall Study|Discharged at Staff Request|2
6355085|NCT03903159|10130644|FG000|Overall Study|Discharged Against Staff Advice|1
6355086|NCT03902392|10130650|FG000|Overall Study|Lost to Follow-up|7
6355087|NCT03902392|10130651|FG001|Overall Study|Lost to Follow-up|7
6355088|NCT03900728|10130707|FG000|Overall Study|No text responses|0
6355089|NCT03900728|10130708|FG001|Overall Study|No text responses|0
6355090|NCT03900728|10130709|FG002|Overall Study|No text responses|4
6355091|NCT03895372|10130748|FG000|Investigational Treatment Period|Adverse Event|1
6355092|NCT03895372|10130749|FG001|Investigational Treatment Period|Adverse Event|0
6355093|NCT03895372|10130750|FG002|Investigational Treatment Period|Adverse Event|0
6355094|NCT03895372|10130751|FG003|Investigational Treatment Period|Adverse Event|0
6355095|NCT03895372|10130752|FG004|Investigational Treatment Period|Adverse Event|0
6355096|NCT03895372|10130753|FG005|Investigational Treatment Period|Adverse Event|0
6355097|NCT03895372|10130754|FG006|Investigational Treatment Period|Adverse Event|4
6355098|NCT03895372|10130755|FG007|Investigational Treatment Period|Adverse Event|3
6355099|NCT03895372|10130748|FG000|Investigational Treatment Period|Lack of Efficacy|1
6355100|NCT03895372|10130749|FG001|Investigational Treatment Period|Lack of Efficacy|0
6355101|NCT03895372|10130750|FG002|Investigational Treatment Period|Lack of Efficacy|0
6355102|NCT03895372|10130751|FG003|Investigational Treatment Period|Lack of Efficacy|0
6355103|NCT03895372|10130752|FG004|Investigational Treatment Period|Lack of Efficacy|0
6355104|NCT03895372|10130753|FG005|Investigational Treatment Period|Lack of Efficacy|0
6355105|NCT03895372|10130754|FG006|Investigational Treatment Period|Lack of Efficacy|0
6355106|NCT03895372|10130755|FG007|Investigational Treatment Period|Lack of Efficacy|0
6355107|NCT03895372|10130748|FG000|Investigational Treatment Period|Lost to Follow-up|0
6355108|NCT03895372|10130749|FG001|Investigational Treatment Period|Lost to Follow-up|0
6355109|NCT03895372|10130750|FG002|Investigational Treatment Period|Lost to Follow-up|0
6355110|NCT03895372|10130751|FG003|Investigational Treatment Period|Lost to Follow-up|0
6355111|NCT03895372|10130752|FG004|Investigational Treatment Period|Lost to Follow-up|0
6355112|NCT03895372|10130753|FG005|Investigational Treatment Period|Lost to Follow-up|0
6355113|NCT03895372|10130754|FG006|Investigational Treatment Period|Lost to Follow-up|1
6355114|NCT03895372|10130755|FG007|Investigational Treatment Period|Lost to Follow-up|0
6355115|NCT03895372|10130748|FG000|Investigational Treatment Period|Other|0
6355116|NCT03895372|10130749|FG001|Investigational Treatment Period|Other|0
6355117|NCT03895372|10130750|FG002|Investigational Treatment Period|Other|0
6355118|NCT03895372|10130751|FG003|Investigational Treatment Period|Other|0
6355119|NCT03895372|10130752|FG004|Investigational Treatment Period|Other|0
6355120|NCT03895372|10130753|FG005|Investigational Treatment Period|Other|1
6355121|NCT03895372|10130754|FG006|Investigational Treatment Period|Other|0
6355122|NCT03895372|10130755|FG007|Investigational Treatment Period|Other|2
6355123|NCT03895372|10130748|FG000|Investigational Treatment Period|Protocol Violation|0
6355124|NCT03895372|10130749|FG001|Investigational Treatment Period|Protocol Violation|0
6355125|NCT03895372|10130750|FG002|Investigational Treatment Period|Protocol Violation|0
6355126|NCT03895372|10130751|FG003|Investigational Treatment Period|Protocol Violation|1
6355127|NCT03895372|10130752|FG004|Investigational Treatment Period|Protocol Violation|0
6355128|NCT03895372|10130753|FG005|Investigational Treatment Period|Protocol Violation|0
6355129|NCT03895372|10130754|FG006|Investigational Treatment Period|Protocol Violation|0
6355130|NCT03895372|10130755|FG007|Investigational Treatment Period|Protocol Violation|0
6355131|NCT03895372|10130748|FG000|Investigational Treatment Period|Withdrawal by Subject|2
6355132|NCT03895372|10130749|FG001|Investigational Treatment Period|Withdrawal by Subject|3
6355133|NCT03895372|10130750|FG002|Investigational Treatment Period|Withdrawal by Subject|1
6355134|NCT03895372|10130751|FG003|Investigational Treatment Period|Withdrawal by Subject|1
6355135|NCT03895372|10130752|FG004|Investigational Treatment Period|Withdrawal by Subject|0
6355136|NCT03895372|10130753|FG005|Investigational Treatment Period|Withdrawal by Subject|1
6355137|NCT03895372|10130754|FG006|Investigational Treatment Period|Withdrawal by Subject|3
6355138|NCT03895372|10130755|FG007|Investigational Treatment Period|Withdrawal by Subject|0
6355139|NCT03895372|10130748|FG000|Extension Treatment Period|Adverse Event|0
6355140|NCT03895372|10130749|FG001|Extension Treatment Period|Adverse Event|1
6355141|NCT03895372|10130750|FG002|Extension Treatment Period|Adverse Event|0
6355142|NCT03895372|10130751|FG003|Extension Treatment Period|Adverse Event|1
6355143|NCT03895372|10130752|FG004|Extension Treatment Period|Adverse Event|0
6355144|NCT03895372|10130753|FG005|Extension Treatment Period|Adverse Event|0
6355145|NCT03895372|10130754|FG006|Extension Treatment Period|Adverse Event|3
6355146|NCT03895372|10130755|FG007|Extension Treatment Period|Adverse Event|3
6355147|NCT03895372|10130748|FG000|Extension Treatment Period|Other|1
6355148|NCT03895372|10130749|FG001|Extension Treatment Period|Other|3
6355149|NCT03895372|10130750|FG002|Extension Treatment Period|Other|0
6355150|NCT03895372|10130751|FG003|Extension Treatment Period|Other|0
6355151|NCT03895372|10130752|FG004|Extension Treatment Period|Other|1
6355152|NCT03895372|10130753|FG005|Extension Treatment Period|Other|0
6355153|NCT03895372|10130754|FG006|Extension Treatment Period|Other|0
6355154|NCT03895372|10130755|FG007|Extension Treatment Period|Other|2
6355155|NCT03895372|10130748|FG000|Extension Treatment Period|Pregnancy|0
6355156|NCT03895372|10130749|FG001|Extension Treatment Period|Pregnancy|0
6355157|NCT03895372|10130750|FG002|Extension Treatment Period|Pregnancy|0
6355158|NCT03895372|10130751|FG003|Extension Treatment Period|Pregnancy|0
6355159|NCT03895372|10130752|FG004|Extension Treatment Period|Pregnancy|1
6355160|NCT03895372|10130753|FG005|Extension Treatment Period|Pregnancy|0
6355161|NCT03895372|10130754|FG006|Extension Treatment Period|Pregnancy|0
6355162|NCT03895372|10130755|FG007|Extension Treatment Period|Pregnancy|0
6355163|NCT03895372|10130748|FG000|Extension Treatment Period|Withdrawal by Subject|2
6355164|NCT03895372|10130749|FG001|Extension Treatment Period|Withdrawal by Subject|1
6355165|NCT03895372|10130750|FG002|Extension Treatment Period|Withdrawal by Subject|0
6355166|NCT03895372|10130751|FG003|Extension Treatment Period|Withdrawal by Subject|0
6355167|NCT03895372|10130752|FG004|Extension Treatment Period|Withdrawal by Subject|1
6355168|NCT03895372|10130753|FG005|Extension Treatment Period|Withdrawal by Subject|1
6355169|NCT03895372|10130754|FG006|Extension Treatment Period|Withdrawal by Subject|1
6355170|NCT03895372|10130755|FG007|Extension Treatment Period|Withdrawal by Subject|1
6355171|NCT03896022|10130781|FG000|Overall Study|Withdrawal by Subject|1
6355172|NCT03896022|10130782|FG001|Overall Study|Withdrawal by Subject|0
6355173|NCT03896022|10130783|FG002|Overall Study|Withdrawal by Subject|0
6355174|NCT03896022|10130781|FG000|Overall Study|Did not have procedure|3
6355175|NCT03896022|10130782|FG001|Overall Study|Did not have procedure|0
6355176|NCT03896022|10130783|FG002|Overall Study|Did not have procedure|0
6355177|NCT03891862|10130795|FG000|Open-label Period|Adverse Event|2
6355178|NCT03891862|10130796|FG001|Open-label Period|Adverse Event|0
6355179|NCT03891862|10130797|FG002|Open-label Period|Adverse Event|0
6355180|NCT03891862|10130795|FG000|Open-label Period|Protocol Violation|5
6355181|NCT03891862|10130796|FG001|Open-label Period|Protocol Violation|0
6355182|NCT03891862|10130797|FG002|Open-label Period|Protocol Violation|0
6355183|NCT03891862|10130795|FG000|Open-label Period|Withdrawal by Subject|6
6355184|NCT03891862|10130796|FG001|Open-label Period|Withdrawal by Subject|0
6355185|NCT03891862|10130797|FG002|Open-label Period|Withdrawal by Subject|0
6355186|NCT03891862|10130795|FG000|Open-label Period|Death|1
6355187|NCT03891862|10130796|FG001|Open-label Period|Death|0
6355188|NCT03891862|10130797|FG002|Open-label Period|Death|0
6355189|NCT03891862|10130795|FG000|Open-label Period|Lost to Follow-up|2
6083815|NCT00638183|9692409|FG000|Overall Study|Lost to Follow-up|46
6083816|NCT00638183|9692409|FG000|Overall Study|Other reason not defined above|27
6083817|NCT00638235|9692422|FG000|Overall Study|Lost to Follow-up|31
6083818|NCT00638235|9692423|FG001|Overall Study|Lost to Follow-up|3
6083819|NCT00638235|9692424|FG002|Overall Study|Lost to Follow-up|18
6083820|NCT00638235|9692425|FG003|Overall Study|Lost to Follow-up|10
6083821|NCT00638235|9692426|FG004|Overall Study|Lost to Follow-up|13
6083822|NCT00638235|9692427|FG005|Overall Study|Lost to Follow-up|26
6083823|NCT00638235|9692428|FG006|Overall Study|Lost to Follow-up|0
6083824|NCT00638235|9692429|FG007|Overall Study|Lost to Follow-up|1
6083825|NCT00638235|9692430|FG008|Overall Study|Lost to Follow-up|18
6083826|NCT00638378|9692479|FG000|Overall Study|Death|2
6083827|NCT00638378|9692479|FG000|Overall Study|Adverse Event|1
6083828|NCT00638378|9692479|FG000|Overall Study|Disease progression|15
6083829|NCT00638378|9692479|FG000|Overall Study|Physician Decision|4
6083830|NCT00638404|9692485|FG000|Overall Study|Physician Decision|8
6083831|NCT00638404|9692486|FG001|Overall Study|Physician Decision|0
6083832|NCT00638443|9692496|FG000|First Intervention|Adverse Event|2
6083833|NCT00638443|9692497|FG001|First Intervention|Adverse Event|1
6355190|NCT03891862|10130796|FG001|Open-label Period|Lost to Follow-up|0
6355191|NCT03891862|10130797|FG002|Open-label Period|Lost to Follow-up|0
6355192|NCT03891862|10130795|FG000|Placebo-controlled Period and Follow-up|Adverse Event|0
6355193|NCT03891862|10130796|FG001|Placebo-controlled Period and Follow-up|Adverse Event|1
6355194|NCT03891862|10130797|FG002|Placebo-controlled Period and Follow-up|Adverse Event|1
6355195|NCT03891862|10130795|FG000|Placebo-controlled Period and Follow-up|Protocol Violation|0
6355196|NCT03891862|10130796|FG001|Placebo-controlled Period and Follow-up|Protocol Violation|2
6355197|NCT03891862|10130797|FG002|Placebo-controlled Period and Follow-up|Protocol Violation|1
6355198|NCT03891862|10130795|FG000|Placebo-controlled Period and Follow-up|Withdrawal by Subject|0
6355199|NCT03891862|10130796|FG001|Placebo-controlled Period and Follow-up|Withdrawal by Subject|1
6083834|NCT00638456|9692507|FG000|Overall Study|Withdrawal by Subject|6
6083835|NCT00638456|9692508|FG001|Overall Study|Withdrawal by Subject|2
6355200|NCT03891862|10130797|FG002|Placebo-controlled Period and Follow-up|Withdrawal by Subject|2
6355201|NCT03891862|10130795|FG000|Placebo-controlled Period and Follow-up|Lost to Follow-up|0
6355202|NCT03891862|10130796|FG001|Placebo-controlled Period and Follow-up|Lost to Follow-up|2
6355203|NCT03891862|10130797|FG002|Placebo-controlled Period and Follow-up|Lost to Follow-up|0
6355204|NCT03892564|10130825|FG000|Overall Study|Withdrawal by Subject|2
6355205|NCT03892707|10130832|FG000|Overall Study|Screen failure|6
6355206|NCT03892707|10130833|FG001|Overall Study|Screen failure|0
6355207|NCT03892707|10130832|FG000|Overall Study|Pain resolution|0
6355208|NCT03892707|10130833|FG001|Overall Study|Pain resolution|4
6355209|NCT03892707|10130832|FG000|Overall Study|Withdrawal by Subject|0
6355210|NCT03892707|10130833|FG001|Overall Study|Withdrawal by Subject|1
6355211|NCT03892707|10130832|FG000|Overall Study|Other (long business trip)|0
6355212|NCT03892707|10130833|FG001|Overall Study|Other (long business trip)|1
6355213|NCT03891641|10130852|FG000|Overall Study|Study Stoppage Due to COVID-19|2
6355214|NCT03891641|10130853|FG001|Overall Study|Study Stoppage Due to COVID-19|2
6355215|NCT03889704|10130859|FG000|Overall Study|Study terminated due to pandemic|1
6355216|NCT03888391|10130873|FG000|Overall Study|Lost to Follow-up|15
6355217|NCT03888482|10130879|FG000|Second Wear (8 -1/+2 Days)|Adverse Event|0
6355218|NCT03888482|10130880|FG001|Second Wear (8 -1/+2 Days)|Adverse Event|1
6355219|NCT03888482|10130879|FG000|Second Wear (8 -1/+2 Days)|Other|1
6355220|NCT03888482|10130880|FG001|Second Wear (8 -1/+2 Days)|Other|0
6355221|NCT03887442|10130915|FG000|Overall Study|Adverse Event|1
6355222|NCT03887442|10130916|FG001|Overall Study|Adverse Event|0
6355223|NCT03878602|10130940|FG000|Overall Study|cord blood donation|7
6355224|NCT03878602|10130941|FG001|Overall Study|cord blood donation|1
6355225|NCT03878602|10130940|FG000|Overall Study|incomplete data collection|2
6355226|NCT03878602|10130941|FG001|Overall Study|incomplete data collection|0
6355227|NCT03875118|10130951|FG000|Overall Study|Withdrawal by Subject|4
6355228|NCT03875118|10130952|FG001|Overall Study|Withdrawal by Subject|4
6355229|NCT03873987|10130960|FG000|Overall Study|Adverse Event|1
6355230|NCT03873987|10130961|FG001|Overall Study|Adverse Event|0
6355231|NCT03873987|10130960|FG000|Overall Study|staff was unable to start a new IV line|1
6355232|NCT03873987|10130961|FG001|Overall Study|staff was unable to start a new IV line|0
6355233|NCT03873987|10130960|FG000|Overall Study|Lost to Follow-up|0
6355234|NCT03873987|10130961|FG001|Overall Study|Lost to Follow-up|1
6355235|NCT03878758|10130987|FG000|Overall Study|Withdrawal by Subject|1
6355236|NCT03878758|10130987|FG000|Overall Study|Protocol defined|2
6355237|NCT03878758|10130987|FG000|Overall Study|Improper consent documentation|1
6355238|NCT03849300|10131004|FG000|Overall Study|move out to different area|1
6355239|NCT03849300|10131005|FG001|Overall Study|move out to different area|3
6355240|NCT03849300|10131006|FG002|Overall Study|move out to different area|1
6355241|NCT03849300|10131007|FG003|Overall Study|move out to different area|4
6355242|NCT03849300|10131004|FG000|Overall Study|scheduling/transportation conflict|4
6355243|NCT03849300|10131005|FG001|Overall Study|scheduling/transportation conflict|4
6355244|NCT03849300|10131006|FG002|Overall Study|scheduling/transportation conflict|3
6355245|NCT03849300|10131007|FG003|Overall Study|scheduling/transportation conflict|2
6355246|NCT03883113|10131049|FG000|Overall Study|Physician Decision|4
6355247|NCT03883113|10131050|FG001|Overall Study|Physician Decision|2
6355248|NCT03883113|10131049|FG000|Overall Study|Challenge Criteria Not Met / Sponsor Decision|9
6355249|NCT03883113|10131050|FG001|Overall Study|Challenge Criteria Not Met / Sponsor Decision|7
6355250|NCT03883113|10131049|FG000|Overall Study|Pregnancy|1
6355251|NCT03883113|10131050|FG001|Overall Study|Pregnancy|0
6355252|NCT03883113|10131049|FG000|Overall Study|Adverse Event|0
6355253|NCT03883113|10131050|FG001|Overall Study|Adverse Event|1
6355254|NCT03883113|10131049|FG000|Overall Study|Withdrawal by Subject|1
6355255|NCT03883113|10131050|FG001|Overall Study|Withdrawal by Subject|2
6355256|NCT03883113|10131049|FG000|Overall Study|Lost to Follow-up|1
6355257|NCT03883113|10131050|FG001|Overall Study|Lost to Follow-up|0
6355258|NCT03880227|10131072|FG000|First Visit|Withdrawal by Subject|1
6355259|NCT03880227|10131073|FG001|First Visit|Withdrawal by Subject|0
6355260|NCT03880227|10131074|FG002|First Visit|Withdrawal by Subject|0
6355261|NCT03880227|10131075|FG003|First Visit|Withdrawal by Subject|0
6355262|NCT03880227|10131072|FG000|1 Week Washout/ Delay|Lost to Follow-up|0
6355263|NCT03880227|10131073|FG001|1 Week Washout/ Delay|Lost to Follow-up|1
6355264|NCT03880227|10131074|FG002|1 Week Washout/ Delay|Lost to Follow-up|0
6355265|NCT03880227|10131075|FG003|1 Week Washout/ Delay|Lost to Follow-up|0
6355266|NCT03880227|10131072|FG000|1 Week Washout/ Delay|Withdrawal by Subject|0
6355267|NCT03880227|10131073|FG001|1 Week Washout/ Delay|Withdrawal by Subject|0
6355268|NCT03880227|10131074|FG002|1 Week Washout/ Delay|Withdrawal by Subject|2
6355269|NCT03880227|10131075|FG003|1 Week Washout/ Delay|Withdrawal by Subject|0
6355270|NCT03880227|10131072|FG000|1 Week Washout/ Delay|Incompatibility with technical component (eyetracking)|0
6355271|NCT03880227|10131073|FG001|1 Week Washout/ Delay|Incompatibility with technical component (eyetracking)|0
6355272|NCT03880227|10131074|FG002|1 Week Washout/ Delay|Incompatibility with technical component (eyetracking)|1
6355273|NCT03880227|10131075|FG003|1 Week Washout/ Delay|Incompatibility with technical component (eyetracking)|0
6355274|NCT03876743|10131089|FG000|Overall Study|Lost to Follow-up|6
6355275|NCT03876743|10131090|FG001|Overall Study|Lost to Follow-up|4
6355276|NCT03876743|10131091|FG002|Overall Study|Lost to Follow-up|4
6355277|NCT03876743|10131092|FG003|Overall Study|Lost to Follow-up|7
6355278|NCT03885934|10131112|FG000|Overall Study|Withdrawn by Parent/Guardian|1
6355279|NCT03885934|10131113|FG001|Overall Study|Withdrawn by Parent/Guardian|0
6355280|NCT03885934|10131114|FG002|Overall Study|Withdrawn by Parent/Guardian|0
6355281|NCT03885934|10131115|FG003|Overall Study|Withdrawn by Parent/Guardian|0
6355282|NCT03885934|10131116|FG004|Overall Study|Withdrawn by Parent/Guardian|0
6355283|NCT03885934|10131117|FG005|Overall Study|Withdrawn by Parent/Guardian|0
6355284|NCT03885726|10131131|FG000|Overall Study|Staffing issues/lost interest|1
6355285|NCT03885726|10131131|FG000|Overall Study|Early discharge from hospital|3
6355286|NCT03883386|10131156|FG000|First Assignment|Lost to Follow-up|1
6355287|NCT03883386|10131157|FG001|First Assignment|Lost to Follow-up|0
6355288|NCT03883386|10131156|FG000|First Assignment|Withdrawal by Subject|1
6355289|NCT03883386|10131157|FG001|First Assignment|Withdrawal by Subject|1
6355290|NCT03882801|10131169|FG000|Period 1|Adverse Event|0
6355291|NCT03882801|10131170|FG001|Period 1|Adverse Event|1
6355292|NCT03882801|10131169|FG000|Period 1|Non-compliance with study drug|1
6355293|NCT03882801|10131170|FG001|Period 1|Non-compliance with study drug|1
6355294|NCT03882801|10131169|FG000|Period 1|Never treated with study drug|1
6355295|NCT03882801|10131170|FG001|Period 1|Never treated with study drug|0
6355296|NCT03882801|10131169|FG000|Washout Period|Physician Decision|0
6355297|NCT03882801|10131170|FG001|Washout Period|Physician Decision|1
6355298|NCT03882801|10131169|FG000|Period 2|Non-compliance with study drug|0
6355299|NCT03882801|10131170|FG001|Period 2|Non-compliance with study drug|1
6355300|NCT03882424|10131181|FG000|Overall Study|Lost to Follow-up|3
6355301|NCT03882424|10131182|FG001|Overall Study|Lost to Follow-up|0
6355302|NCT03882424|10131183|FG002|Overall Study|Lost to Follow-up|0
6355303|NCT03882424|10131181|FG000|Overall Study|schedule conflict|1
6355304|NCT03882424|10131182|FG001|Overall Study|schedule conflict|0
6355305|NCT03882424|10131183|FG002|Overall Study|schedule conflict|0
6355306|NCT03880266|10131216|FG000|Overall Study|Withdrawal by Subject|0
6355307|NCT03880266|10131217|FG001|Overall Study|Withdrawal by Subject|1
6355308|NCT03880266|10131218|FG002|Overall Study|Withdrawal by Subject|1
6355309|NCT03880266|10131219|FG003|Overall Study|Withdrawal by Subject|0
6355310|NCT03880266|10131220|FG004|Overall Study|Withdrawal by Subject|0
6355311|NCT03880266|10131221|FG005|Overall Study|Withdrawal by Subject|0
6355312|NCT03880266|10131222|FG006|Overall Study|Withdrawal by Subject|0
6355313|NCT03880266|10131223|FG007|Overall Study|Withdrawal by Subject|0
6355314|NCT03878160|10131266|FG000|Overall Study|Lost to Follow-up|1
6083836|NCT00638508|9692516|FG000|Overall Study|Physician Decision|5
6083837|NCT00638508|9692517|FG001|Overall Study|Physician Decision|2
6083838|NCT00638690|9692534|FG000|Overall Study|Death|655
6083839|NCT00638690|9692535|FG001|Overall Study|Death|335
6083840|NCT00638690|9692534|FG000|Overall Study|Withdrawal by Subject|22
6083841|NCT00638690|9692535|FG001|Overall Study|Withdrawal by Subject|5
6083842|NCT00638690|9692534|FG000|Overall Study|Lost to Follow-up|4
6083843|NCT00638690|9692535|FG001|Overall Study|Lost to Follow-up|2
6083844|NCT00638846|9692561|FG000|Overall Study|Adverse Event|0
6083845|NCT00638846|9692562|FG001|Overall Study|Adverse Event|1
6083846|NCT00638846|9692561|FG000|Overall Study|Lost to Follow-up|3
6083847|NCT00638846|9692562|FG001|Overall Study|Lost to Follow-up|2
6083848|NCT00638846|9692561|FG000|Overall Study|lens issue|1
6355315|NCT03878160|10131267|FG001|Overall Study|Lost to Follow-up|1
6355316|NCT03878160|10131268|FG002|Overall Study|Lost to Follow-up|1
6355317|NCT03878160|10131266|FG000|Overall Study|Did not meet eligibility criteria, withdrawn by PI|1
6355318|NCT03878160|10131267|FG001|Overall Study|Did not meet eligibility criteria, withdrawn by PI|0
6355319|NCT03878160|10131268|FG002|Overall Study|Did not meet eligibility criteria, withdrawn by PI|0
6355320|NCT03864627|10131278|FG000|Overall Study|Adverse Event|0
6355321|NCT03864627|10131279|FG001|Overall Study|Adverse Event|1
6355322|NCT03864627|10131278|FG000|Overall Study|Lack of Efficacy|0
6355323|NCT03864627|10131279|FG001|Overall Study|Lack of Efficacy|1
6355324|NCT03864627|10131278|FG000|Overall Study|Lost to Follow-up|0
6355325|NCT03864627|10131279|FG001|Overall Study|Lost to Follow-up|1
6355326|NCT03864627|10131278|FG000|Overall Study|Withdrawal by Subject|4
6355327|NCT03864627|10131279|FG001|Overall Study|Withdrawal by Subject|8
6355328|NCT03864627|10131278|FG000|Overall Study|Study terminated by sponsor|0
6355329|NCT03864627|10131279|FG001|Overall Study|Study terminated by sponsor|1
6355330|NCT03848403|10131294|FG000|Period 2 (Day 8)|Adverse Event|1
6355331|NCT03848403|10131295|FG001|Period 2 (Day 8)|Adverse Event|2
6355332|NCT03848403|10131296|FG002|Period 2 (Day 8)|Adverse Event|2
6355333|NCT03848403|10131294|FG000|Period 2 (Day 8)|Physician Decision|0
6083849|NCT00638846|9692562|FG001|Overall Study|lens issue|3
6083850|NCT00638963|9692584|FG000|Overall Study|Withdrawal by Subject|1
6083851|NCT00638963|9692585|FG001|Overall Study|Withdrawal by Subject|0
6083852|NCT00638989|9692594|FG000|Overall Study|Lost to Follow-up|0
6355334|NCT03848403|10131295|FG001|Period 2 (Day 8)|Physician Decision|1
6355335|NCT03848403|10131296|FG002|Period 2 (Day 8)|Physician Decision|0
6083853|NCT00638989|9692595|FG001|Overall Study|Lost to Follow-up|0
6355336|NCT03848403|10131294|FG000|Period 2 (Day 8)|Sponsor Decision|8
6355337|NCT03848403|10131295|FG001|Period 2 (Day 8)|Sponsor Decision|6
6355338|NCT03848403|10131296|FG002|Period 2 (Day 8)|Sponsor Decision|5
6355339|NCT03878108|10131363|FG000|Overall Study|Adverse Event|1
6355340|NCT03878108|10131364|FG001|Overall Study|Adverse Event|0
6355341|NCT03877237|10131380|FG000|Overall Study|Adverse Event|1
6355342|NCT03877237|10131381|FG001|Overall Study|Adverse Event|2
6355343|NCT03877237|10131380|FG000|Overall Study|Death|3
6355344|NCT03877237|10131381|FG001|Overall Study|Death|2
6355345|NCT03877237|10131380|FG000|Overall Study|Physician Decision|1
6355346|NCT03877237|10131381|FG001|Overall Study|Physician Decision|0
6355347|NCT03877237|10131380|FG000|Overall Study|Withdrawal by Subject|0
6355348|NCT03877237|10131381|FG001|Overall Study|Withdrawal by Subject|2
6355349|NCT03859323|10131410|FG000|Overall Study|Lost to Follow-up|0
6355350|NCT03859323|10131411|FG001|Overall Study|Lost to Follow-up|0
6355351|NCT03859323|10131412|FG002|Overall Study|Lost to Follow-up|0
6355352|NCT03859323|10131413|FG003|Overall Study|Lost to Follow-up|0
6355353|NCT03859323|10131414|FG004|Overall Study|Lost to Follow-up|0
6355354|NCT03859323|10131415|FG005|Overall Study|Lost to Follow-up|0
6355355|NCT03859323|10131416|FG006|Overall Study|Lost to Follow-up|1
6355356|NCT03859323|10131417|FG007|Overall Study|Lost to Follow-up|0
6355357|NCT03859323|10131418|FG008|Overall Study|Lost to Follow-up|0
6355358|NCT03859323|10131419|FG009|Overall Study|Lost to Follow-up|0
6355359|NCT03859323|10131420|FG010|Overall Study|Lost to Follow-up|0
6355360|NCT03859323|10131421|FG011|Overall Study|Lost to Follow-up|0
6355361|NCT03859323|10131422|FG012|Overall Study|Lost to Follow-up|0
6355362|NCT03859323|10131410|FG000|Overall Study|Withdrawal by Subject|0
6355363|NCT03859323|10131411|FG001|Overall Study|Withdrawal by Subject|0
6355364|NCT03859323|10131412|FG002|Overall Study|Withdrawal by Subject|1
6355365|NCT03859323|10131413|FG003|Overall Study|Withdrawal by Subject|0
6355366|NCT03859323|10131414|FG004|Overall Study|Withdrawal by Subject|0
6355367|NCT03859323|10131415|FG005|Overall Study|Withdrawal by Subject|1
6355368|NCT03859323|10131416|FG006|Overall Study|Withdrawal by Subject|0
6355369|NCT03859323|10131417|FG007|Overall Study|Withdrawal by Subject|0
6355370|NCT03859323|10131418|FG008|Overall Study|Withdrawal by Subject|0
6355371|NCT03859323|10131419|FG009|Overall Study|Withdrawal by Subject|1
6355372|NCT03859323|10131420|FG010|Overall Study|Withdrawal by Subject|1
6355373|NCT03859323|10131421|FG011|Overall Study|Withdrawal by Subject|2
6355374|NCT03859323|10131422|FG012|Overall Study|Withdrawal by Subject|1
6355375|NCT03859323|10131410|FG000|Overall Study|Pregnancy|0
6355376|NCT03859323|10131411|FG001|Overall Study|Pregnancy|0
6355377|NCT03859323|10131412|FG002|Overall Study|Pregnancy|0
6355378|NCT03859323|10131413|FG003|Overall Study|Pregnancy|0
6355379|NCT03859323|10131414|FG004|Overall Study|Pregnancy|0
6355380|NCT03859323|10131415|FG005|Overall Study|Pregnancy|0
6355381|NCT03859323|10131416|FG006|Overall Study|Pregnancy|0
6355382|NCT03859323|10131417|FG007|Overall Study|Pregnancy|0
6355383|NCT03859323|10131418|FG008|Overall Study|Pregnancy|0
6355384|NCT03859323|10131419|FG009|Overall Study|Pregnancy|1
6355385|NCT03859323|10131420|FG010|Overall Study|Pregnancy|0
6355386|NCT03859323|10131421|FG011|Overall Study|Pregnancy|0
6355387|NCT03859323|10131422|FG012|Overall Study|Pregnancy|0
6355388|NCT03875508|10131487|FG000|Overall Study|Adverse Event|1
6355389|NCT03875508|10131487|FG000|Overall Study|Lost to Follow-up|8
6355390|NCT03875508|10131487|FG000|Overall Study|Lack of Efficacy|1
6355391|NCT03875508|10131487|FG000|Overall Study|Other, not specified|2
6355392|NCT03869333|10131495|FG000|Overall Study|Lost to Follow-up|1
6355393|NCT03869333|10131496|FG001|Overall Study|Lost to Follow-up|0
6355394|NCT03869333|10131497|FG002|Overall Study|Lost to Follow-up|0
6355395|NCT03869333|10131498|FG003|Overall Study|Lost to Follow-up|0
6355396|NCT03869333|10131495|FG000|Overall Study|Pregnancy|1
6355397|NCT03869333|10131496|FG001|Overall Study|Pregnancy|0
6355398|NCT03869333|10131497|FG002|Overall Study|Pregnancy|0
6355399|NCT03869333|10131498|FG003|Overall Study|Pregnancy|0
6355400|NCT03869333|10131495|FG000|Overall Study|Physician Decision|0
6355401|NCT03869333|10131496|FG001|Overall Study|Physician Decision|1
6355402|NCT03869333|10131497|FG002|Overall Study|Physician Decision|0
6355403|NCT03869333|10131498|FG003|Overall Study|Physician Decision|0
6355404|NCT03864900|10131510|FG000|Overall Study|Withdrawal by Subject|1
6355405|NCT03864900|10131511|FG001|Overall Study|Withdrawal by Subject|1
6355406|NCT03864900|10131510|FG000|Overall Study|medical reason: change anticoagulation drug, Hemorrhage, operation|2
6355407|NCT03864900|10131511|FG001|Overall Study|medical reason: change anticoagulation drug, Hemorrhage, operation|5
6355408|NCT03875482|10131536|FG000|Overall Study|Adverse Event|0
6355409|NCT03875482|10131537|FG001|Overall Study|Adverse Event|1
6355410|NCT03875482|10131536|FG000|Overall Study|Withdrew consent|5
6355411|NCT03875482|10131537|FG001|Overall Study|Withdrew consent|6
6355412|NCT03875482|10131536|FG000|Overall Study|Lost to Follow-up|8
6355413|NCT03875482|10131537|FG001|Overall Study|Lost to Follow-up|2
6355414|NCT03875482|10131536|FG000|Overall Study|Lack of Efficacy|0
6355415|NCT03875482|10131537|FG001|Overall Study|Lack of Efficacy|11
6355416|NCT03874013|10131555|FG000|Overall Study|Adverse Event|0
6355417|NCT03874013|10131556|FG001|Overall Study|Adverse Event|1
6355418|NCT03873116|10131565|FG000|Overall Study|Study drug discontinuation due to rash|0
6355419|NCT03873116|10131566|FG001|Overall Study|Study drug discontinuation due to rash|0
6355420|NCT03873116|10131567|FG002|Overall Study|Study drug discontinuation due to rash|1
6355421|NCT03872843|10131577|FG000|Overall Study|Lost to Follow-up|5
6355422|NCT03872843|10131578|FG001|Overall Study|Lost to Follow-up|7
6355423|NCT03870997|10131590|FG000|Overall Study|Did not complete mid-study/final survey|10544
6355424|NCT03870997|10131591|FG001|Overall Study|Did not complete mid-study/final survey|10431
6355425|NCT03870997|10131592|FG002|Overall Study|Did not complete mid-study/final survey|10978
6355426|NCT03870997|10131593|FG003|Overall Study|Did not complete mid-study/final survey|10947
6355427|NCT03870997|10131594|FG004|Overall Study|Did not complete mid-study/final survey|10588
6355428|NCT03870997|10131595|FG005|Overall Study|Did not complete mid-study/final survey|10531
6355429|NCT03869684|10131607|FG000|Overall Study|Adverse Event|0
6355430|NCT03869684|10131608|FG001|Overall Study|Adverse Event|3
6355431|NCT03869684|10131609|FG002|Overall Study|Adverse Event|1
6355432|NCT03869684|10131607|FG000|Overall Study|Withdrawal by Subject|1
6355433|NCT03869684|10131608|FG001|Overall Study|Withdrawal by Subject|0
6355434|NCT03869684|10131609|FG002|Overall Study|Withdrawal by Subject|0
6355435|NCT03869684|10131607|FG000|Overall Study|Lost to Follow-up|1
6355436|NCT03869684|10131608|FG001|Overall Study|Lost to Follow-up|0
6355437|NCT03869684|10131609|FG002|Overall Study|Lost to Follow-up|0
6355438|NCT03869684|10131607|FG000|Overall Study|Study prematurely terminated by sponsor|0
6355439|NCT03869684|10131608|FG001|Overall Study|Study prematurely terminated by sponsor|0
6355440|NCT03869684|10131609|FG002|Overall Study|Study prematurely terminated by sponsor|2
6083854|NCT00638989|9692596|FG002|Overall Study|Lost to Follow-up|1
6083855|NCT00639002|9692606|FG000|Overall Study|Death|1
6083856|NCT00639002|9692606|FG000|Overall Study|Adverse Event|1
6083857|NCT00639002|9692606|FG000|Overall Study|Protocol Violation|1
6355441|NCT03848416|10131663|FG000|Overall Study|Withdrawal by Subject|1
6355442|NCT03848416|10131664|FG001|Overall Study|Withdrawal by Subject|0
6355443|NCT03848416|10131665|FG002|Overall Study|Withdrawal by Subject|0
6355444|NCT03848416|10131663|FG000|Overall Study|Death|0
6355445|NCT03848416|10131664|FG001|Overall Study|Death|0
6355446|NCT03848416|10131665|FG002|Overall Study|Death|1
6355447|NCT03847987|10131675|FG000|Overall Study|Lost to Follow-up|1
6355448|NCT03847987|10131676|FG001|Overall Study|Lost to Follow-up|0
6355449|NCT03847987|10131675|FG000|Overall Study|Adverse Event|2
6355450|NCT03847987|10131676|FG001|Overall Study|Adverse Event|0
6355451|NCT03853551|10131738|FG000|Overall Study|Death|2
6355452|NCT03853551|10131738|FG000|Overall Study|7 patients discontinued the study because of disease progression.|7
6355453|NCT03870555|10131745|FG000|Period 3 (2 Days)|Adverse Event|1
6355454|NCT03870555|10131746|FG001|Period 3 (2 Days)|Adverse Event|0
6355455|NCT03870555|10131747|FG002|Period 3 (2 Days)|Adverse Event|0
6355456|NCT03851094|10131773|FG000|Overall Study|Withdrawal by Subject|0
6355457|NCT03851094|10131774|FG001|Overall Study|Withdrawal by Subject|1
6355458|NCT03851094|10131773|FG000|Overall Study|Participant lost device|0
6355459|NCT03851094|10131774|FG001|Overall Study|Participant lost device|1
6355460|NCT03851094|10131773|FG000|Overall Study|Participant returned device|0
6355461|NCT03851094|10131774|FG001|Overall Study|Participant returned device|2
6355462|NCT03868631|10131797|FG000|Baseline to Week 6|Adverse Event|0
6355463|NCT03868631|10131798|FG001|Baseline to Week 6|Adverse Event|3
6355464|NCT03868631|10131797|FG000|Baseline to Week 6|Protocol Violation|1
6355465|NCT03868631|10131798|FG001|Baseline to Week 6|Protocol Violation|1
6355466|NCT03868631|10131797|FG000|Baseline to Week 6|Withdrawal by Subject|3
6083858|NCT00639002|9692606|FG000|Overall Study|Disease progression|3
6083859|NCT00639002|9692606|FG000|Overall Study|Physician Decision|6
6083860|NCT00639002|9692606|FG000|Overall Study|Lack of Efficacy|1
6083861|NCT00639223|9692631|FG000|Overall Study|Lost to Follow-up|0
6083862|NCT00639223|9692632|FG001|Overall Study|Lost to Follow-up|2
6355467|NCT03868631|10131798|FG001|Baseline to Week 6|Withdrawal by Subject|0
6355468|NCT03868631|10131797|FG000|Week 6 to Week 12 (Study Completion)|Adverse Event|2
6355469|NCT03868631|10131798|FG001|Week 6 to Week 12 (Study Completion)|Adverse Event|0
6355470|NCT03868631|10131797|FG000|Week 6 to Week 12 (Study Completion)|Protocol Violation|1
6355471|NCT03868631|10131798|FG001|Week 6 to Week 12 (Study Completion)|Protocol Violation|0
6355472|NCT03868631|10131797|FG000|Week 6 to Week 12 (Study Completion)|Withdrawal by Subject|1
6355473|NCT03868631|10131798|FG001|Week 6 to Week 12 (Study Completion)|Withdrawal by Subject|1
6355474|NCT03865953|10131806|FG000|First Intervention (4 Weeks)|Lost to Follow-up|2
6355475|NCT03865953|10131807|FG001|First Intervention (4 Weeks)|Lost to Follow-up|0
6355476|NCT03865953|10131806|FG000|First Intervention (4 Weeks)|Protocol Violation|0
6355477|NCT03865953|10131807|FG001|First Intervention (4 Weeks)|Protocol Violation|1
6355478|NCT03865953|10131806|FG000|Second Intervention (4 Weeks)|Lost to Follow-up|0
6355479|NCT03865953|10131807|FG001|Second Intervention (4 Weeks)|Lost to Follow-up|2
6355480|NCT03865381|10131813|FG000|Overall Study|Protocol Violation/Non-Compliance|3
6355481|NCT03865381|10131813|FG000|Overall Study|Withdrawal by Subject|2
6355482|NCT03868059|10131841|FG000|Overall Study|Adverse Event|3
6355483|NCT03868059|10131841|FG000|Overall Study|Lost to Follow-up|3
6355484|NCT03868059|10131841|FG000|Overall Study|Withdrawal by Subject|6
6355485|NCT03865407|10131856|FG000|Overall Study|Adverse Event|1
6355486|NCT03865407|10131857|FG001|Overall Study|Adverse Event|0
6355487|NCT03865407|10131856|FG000|Overall Study|Withdrawal by Subject|1
6355488|NCT03865407|10131857|FG001|Overall Study|Withdrawal by Subject|0
6355489|NCT03865407|10131856|FG000|Overall Study|Medical change caused patient to no longer meet inclusion/exclusion criteria|1
6355490|NCT03865407|10131857|FG001|Overall Study|Medical change caused patient to no longer meet inclusion/exclusion criteria|0
6355491|NCT03864653|10131876|FG000|Overall Study|Withdrawal by Subject|1
6355492|NCT03853213|10131893|FG000|Overall Study|Extenuating Circumstances (COVID-19 pandemic)|1
6355493|NCT03853213|10131894|FG001|Overall Study|Extenuating Circumstances (COVID-19 pandemic)|0
6355494|NCT03853213|10131893|FG000|Overall Study|Other (e.g., too busy)|0
6355495|NCT03853213|10131894|FG001|Overall Study|Other (e.g., too busy)|2
6355496|NCT03847610|10131900|FG000|Overall Study|Withdrawal by Subject|1
6355497|NCT03850093|10131907|FG000|Overall Study|Withdrawal by Subject|1
6355498|NCT03850093|10131908|FG001|Overall Study|Withdrawal by Subject|0
6355499|NCT03850093|10131909|FG002|Overall Study|Withdrawal by Subject|2
6355500|NCT03861936|10131990|FG000|Overall Study|Withdrawal by Subject|4
6355501|NCT03861936|10131991|FG001|Overall Study|Withdrawal by Subject|1
6355502|NCT03861936|10131992|FG002|Overall Study|Withdrawal by Subject|3
6355503|NCT03861936|10131990|FG000|Overall Study|Lost to Follow-up|5
6355504|NCT03861936|10131991|FG001|Overall Study|Lost to Follow-up|3
6355505|NCT03861936|10131992|FG002|Overall Study|Lost to Follow-up|3
6355506|NCT03861936|10131990|FG000|Overall Study|Physician Decision|0
6355507|NCT03861936|10131991|FG001|Overall Study|Physician Decision|1
6355508|NCT03861936|10131992|FG002|Overall Study|Physician Decision|0
6355509|NCT03861936|10131990|FG000|Overall Study|Protocol Deviation|0
6355510|NCT03861936|10131991|FG001|Overall Study|Protocol Deviation|0
6355511|NCT03861936|10131992|FG002|Overall Study|Protocol Deviation|1
6355512|NCT03861936|10131990|FG000|Overall Study|Reason not Specified|5
6355513|NCT03861936|10131991|FG001|Overall Study|Reason not Specified|5
6083863|NCT00639379|9692638|FG000|Period 1 - 2 Weeks|Lost to Follow-up|2
6355514|NCT03861936|10131992|FG002|Overall Study|Reason not Specified|3
6355515|NCT03850509|10132032|FG000|Overall Study|Study Terminated by the Sponsor (Due to COVID-19 Situation)|2
6355516|NCT03850509|10132033|FG001|Overall Study|Study Terminated by the Sponsor (Due to COVID-19 Situation)|1
6355517|NCT03851016|10132118|FG000|First Intervention (3 Weeks)|Withdrawal by Subject|1
6355518|NCT03851016|10132119|FG001|First Intervention (3 Weeks)|Withdrawal by Subject|2
6355519|NCT03850496|10132128|FG000|Overall Study|Withdrawal by Subject|1
6355520|NCT03850496|10132129|FG001|Overall Study|Withdrawal by Subject|0
6355521|NCT03850496|10132130|FG002|Overall Study|Withdrawal by Subject|0
6355522|NCT03850496|10132128|FG000|Overall Study|Lost to Follow-up|0
6355523|NCT03850496|10132129|FG001|Overall Study|Lost to Follow-up|1
6355524|NCT03850496|10132130|FG002|Overall Study|Lost to Follow-up|4
6355525|NCT03848949|10132140|FG000|Overall Study|Lost to Follow-up|5
6355526|NCT03848949|10132141|FG001|Overall Study|Lost to Follow-up|7
6355527|NCT03844945|10132169|FG000|Overall Study|Adverse Event|1
6355528|NCT03844945|10132170|FG001|Overall Study|Adverse Event|1
6355529|NCT03844945|10132171|FG002|Overall Study|Adverse Event|4
6355530|NCT03844945|10132172|FG003|Overall Study|Adverse Event|0
6355531|NCT03844945|10132169|FG000|Overall Study|Withdrawal by Subject|0
6355532|NCT03844945|10132170|FG001|Overall Study|Withdrawal by Subject|0
6355533|NCT03844945|10132171|FG002|Overall Study|Withdrawal by Subject|1
6355534|NCT03844945|10132172|FG003|Overall Study|Withdrawal by Subject|0
6355535|NCT03844945|10132169|FG000|Overall Study|Lack of Efficacy|0
6355536|NCT03844945|10132170|FG001|Overall Study|Lack of Efficacy|0
6355537|NCT03844945|10132171|FG002|Overall Study|Lack of Efficacy|0
6355538|NCT03844945|10132172|FG003|Overall Study|Lack of Efficacy|1
6355539|NCT03843632|10132195|FG000|Overall Study|Withdrawal by Subject|1
6355540|NCT03843632|10132196|FG001|Overall Study|Withdrawal by Subject|0
6355541|NCT03843632|10132197|FG002|Overall Study|Withdrawal by Subject|0
6355542|NCT03843632|10132198|FG003|Overall Study|Withdrawal by Subject|0
6355543|NCT03840811|10132211|FG000|Overall Study|Lost to Follow-up|0
6355544|NCT03840811|10132212|FG001|Overall Study|Lost to Follow-up|0
6355545|NCT03840811|10132213|FG002|Overall Study|Lost to Follow-up|1
6355546|NCT03837028|10132225|FG000|Overall Study|Lost to Follow-up|4
6355547|NCT03837028|10132226|FG001|Overall Study|Lost to Follow-up|0
6355548|NCT03837028|10132227|FG002|Overall Study|Lost to Follow-up|2
6355549|NCT03837028|10132228|FG003|Overall Study|Lost to Follow-up|0
6355550|NCT03837028|10132225|FG000|Overall Study|Withdrawal by Subject|12
6355551|NCT03837028|10132226|FG001|Overall Study|Withdrawal by Subject|11
6355552|NCT03837028|10132227|FG002|Overall Study|Withdrawal by Subject|11
6355553|NCT03837028|10132228|FG003|Overall Study|Withdrawal by Subject|7
6355554|NCT03841331|10132271|FG000|Overall Study|Withdrawal by Subject|4
6355555|NCT03841331|10132272|FG001|Overall Study|Withdrawal by Subject|9
6355556|NCT03841331|10132271|FG000|Overall Study|Lost to Follow-up|5
6355557|NCT03841331|10132272|FG001|Overall Study|Lost to Follow-up|1
6355558|NCT03840135|10132287|FG000|Overall Study|Protocol Violation|6
6355559|NCT03840135|10132288|FG001|Overall Study|Protocol Violation|1
6355560|NCT03840135|10132287|FG000|Overall Study|Withdrawal by Subject|1
6355561|NCT03840135|10132288|FG001|Overall Study|Withdrawal by Subject|0
6355562|NCT03839641|10132300|FG000|Overall Study|Withdrawal by Subject|1
6355563|NCT03839641|10132301|FG001|Overall Study|Withdrawal by Subject|1
6355564|NCT03839212|10132309|FG000|Overall Study|COVID-19 related suspension of research activities.|4
6355565|NCT03839355|10132315|FG000|Overall Study|Withdrawal by Subject|1
6355566|NCT03839355|10132316|FG001|Overall Study|Withdrawal by Subject|0
6355567|NCT03838731|10132333|FG000|Overall Study|Pregnancy|0
6355568|NCT03838731|10132334|FG001|Overall Study|Pregnancy|1
6355569|NCT03838731|10132333|FG000|Overall Study|Withdrawal of consent|1
6355570|NCT03838731|10132334|FG001|Overall Study|Withdrawal of consent|0
6355571|NCT03838198|10132342|FG000|Phase 2: Added Booster Call or Not|Withdrawal by Subject|0
6355572|NCT03838198|10132343|FG001|Phase 2: Added Booster Call or Not|Withdrawal by Subject|0
6355573|NCT03838198|10132344|FG002|Phase 2: Added Booster Call or Not|Withdrawal by Subject|1
6355574|NCT03838198|10132345|FG003|Phase 2: Added Booster Call or Not|Withdrawal by Subject|0
6355575|NCT03838198|10132342|FG000|Phase 2: Added Booster Call or Not|"In this SMART trial design, this group was randomized to no booster call."|0
6355576|NCT03838198|10132343|FG001|Phase 2: Added Booster Call or Not|"In this SMART trial design, this group was randomized to no booster call."|22
6355577|NCT03838198|10132344|FG002|Phase 2: Added Booster Call or Not|"In this SMART trial design, this group was randomized to no booster call."|0
6355578|NCT03838198|10132345|FG003|Phase 2: Added Booster Call or Not|"In this SMART trial design, this group was randomized to no booster call."|22
6355579|NCT03836677|10132464|FG000|Period 1|Adverse Event|0
6355580|NCT03836677|10132465|FG001|Period 1|Adverse Event|1
6355581|NCT03836677|10132464|FG000|Period 2|Severe non-compliance to protocol|1
6355582|NCT03836677|10132465|FG001|Period 2|Severe non-compliance to protocol|0
6355583|NCT03827564|10132485|FG000|Overall Study|Discontinued due to Study Termination|1
6355584|NCT03827564|10132486|FG001|Overall Study|Discontinued due to Study Termination|0
6355585|NCT03824236|10132495|FG000|Overall Study|Lost to Follow-up|0
6355586|NCT03824236|10132496|FG001|Overall Study|Lost to Follow-up|0
6355587|NCT03824236|10132497|FG002|Overall Study|Lost to Follow-up|1
6355588|NCT03810235|10132518|FG000|Overall Study|Withdrawal by Subject|2
6355589|NCT03810235|10132519|FG001|Overall Study|Withdrawal by Subject|0
6355590|NCT03836664|10132538|FG000|Overall Study|Didn't complete forms and lost drug|3
6355591|NCT03836664|10132539|FG001|Overall Study|Didn't complete forms and lost drug|3
6355592|NCT03832738|10132552|FG000|Overall Study|Withdrawal by Subject|6
6355593|NCT03832738|10132553|FG001|Overall Study|Withdrawal by Subject|7
6355594|NCT03832738|10132554|FG002|Overall Study|Withdrawal by Subject|16
6355595|NCT03832738|10132552|FG000|Overall Study|Physician Decision|0
6355596|NCT03832738|10132553|FG001|Overall Study|Physician Decision|1
6355597|NCT03832738|10132554|FG002|Overall Study|Physician Decision|2
6355598|NCT03832738|10132552|FG000|Overall Study|Adverse Event|2
6355599|NCT03832738|10132553|FG001|Overall Study|Adverse Event|3
6355600|NCT03832738|10132554|FG002|Overall Study|Adverse Event|1
6355601|NCT03832738|10132552|FG000|Overall Study|Pregnancy|0
6355602|NCT03832738|10132553|FG001|Overall Study|Pregnancy|1
6355603|NCT03832738|10132554|FG002|Overall Study|Pregnancy|0
6355604|NCT03823391|10132564|FG000|Period 2: Weeks 12 to Week 24|Adverse Event|1
6355605|NCT03823391|10132565|FG001|Period 2: Weeks 12 to Week 24|Adverse Event|1
6355606|NCT03823391|10132564|FG000|Period 2: Weeks 12 to Week 24|Withdrawal by Subject|1
6355607|NCT03823391|10132565|FG001|Period 2: Weeks 12 to Week 24|Withdrawal by Subject|0
6355608|NCT03808298|10132587|FG000|Overall Study|Adverse Event|3
6355609|NCT03808298|10132587|FG000|Overall Study|Physician Decision|1
6355610|NCT03808298|10132587|FG000|Overall Study|Withdrawal by Subject|1
6355611|NCT03808298|10132587|FG000|Overall Study|Positive Urine Drug Screen at Check-in|3
6355612|NCT03836729|10132616|FG000|Treatment Period 2 (Up to Day 7)|Adverse Event|1
6355613|NCT03835975|10132629|FG000|Overall Study|Lost to Follow-up|1
6355614|NCT03835975|10132630|FG001|Overall Study|Lost to Follow-up|1
6355615|NCT03835975|10132631|FG002|Overall Study|Lost to Follow-up|0
6355616|NCT03835975|10132632|FG003|Overall Study|Lost to Follow-up|0
6355617|NCT03835975|10132633|FG004|Overall Study|Lost to Follow-up|0
6083864|NCT00639379|9692639|FG001|Period 1 - 2 Weeks|Lost to Follow-up|0
6083865|NCT00639379|9692638|FG000|Period 1 - 2 Weeks|lens issue|3
6083866|NCT00639379|9692639|FG001|Period 1 - 2 Weeks|lens issue|0
6083867|NCT00639457|9692668|FG000|Overall Study|Withdrawal by Subject|2
6083868|NCT00639457|9692669|FG001|Overall Study|Withdrawal by Subject|3
6083869|NCT00639509|9692675|FG000|Overall Study|Death|1
6087757|NCT00670449|9698234|FG003|Overall Study|Protocol Deviation|1
6355618|NCT03835975|10132629|FG000|Overall Study|No longer met eligibility criteria|0
6355619|NCT03835975|10132630|FG001|Overall Study|No longer met eligibility criteria|1
6355620|NCT03835975|10132631|FG002|Overall Study|No longer met eligibility criteria|0
6355621|NCT03835975|10132632|FG003|Overall Study|No longer met eligibility criteria|0
6355622|NCT03835975|10132633|FG004|Overall Study|No longer met eligibility criteria|0
6355623|NCT03835975|10132629|FG000|Overall Study|Protocol Violation|1
6355624|NCT03835975|10132630|FG001|Overall Study|Protocol Violation|1
6355625|NCT03835975|10132631|FG002|Overall Study|Protocol Violation|2
6083870|NCT00639678|9692683|FG000|Overall Study|Withdrawal by Subject|3
6083871|NCT00639678|9692684|FG001|Overall Study|Withdrawal by Subject|0
6083872|NCT00639678|9692685|FG002|Overall Study|Withdrawal by Subject|4
6083873|NCT00639678|9692686|FG003|Overall Study|Withdrawal by Subject|0
6083874|NCT00639678|9692683|FG000|Overall Study|Lost to Follow-up|1
6083875|NCT00639678|9692684|FG001|Overall Study|Lost to Follow-up|0
6083876|NCT00639678|9692685|FG002|Overall Study|Lost to Follow-up|6
6083877|NCT00639678|9692686|FG003|Overall Study|Lost to Follow-up|0
6083878|NCT00639678|9692683|FG000|Overall Study|Adverse Event|0
6083879|NCT00639678|9692684|FG001|Overall Study|Adverse Event|1
6355626|NCT03835975|10132632|FG003|Overall Study|Protocol Violation|0
6355627|NCT03835975|10132633|FG004|Overall Study|Protocol Violation|0
6355628|NCT03835975|10132629|FG000|Overall Study|Withdrawal by Subject|1
6355629|NCT03835975|10132630|FG001|Overall Study|Withdrawal by Subject|0
6355630|NCT03835975|10132631|FG002|Overall Study|Withdrawal by Subject|1
6355631|NCT03835975|10132632|FG003|Overall Study|Withdrawal by Subject|1
6355632|NCT03835975|10132633|FG004|Overall Study|Withdrawal by Subject|0
6355633|NCT03835221|10132688|FG000|Methafilcon A|Withdrawal by Subject|1
6355634|NCT03819634|10132694|FG000|Overall Study|Physician Decision|2
6355635|NCT03812679|10132698|FG000|Overall Study|Adverse Event|2
6355636|NCT03812679|10132698|FG000|Overall Study|Missed >4 consecutive therapy days|1
6355637|NCT03812679|10132698|FG000|Overall Study|Renal transplant|1
6355638|NCT03812679|10132698|FG000|Overall Study|Withdrawal by Subject|1
6355639|NCT03812679|10132698|FG000|Overall Study|Termination of study|2
6355640|NCT03812679|10132698|FG000|Overall Study|Water device replacement|1
6355641|NCT03801148|10132753|FG000|Period 1 (2 Days)|Adverse Event|1
6355642|NCT03801148|10132754|FG001|Period 1 (2 Days)|Adverse Event|1
6355643|NCT03801148|10132755|FG002|Period 1 (2 Days)|Adverse Event|0
6355644|NCT03801148|10132756|FG003|Period 1 (2 Days)|Adverse Event|0
6355645|NCT03801148|10132753|FG000|Washout Period (at Least 5 Days)|Lost to Follow-up|0
6355646|NCT03801148|10132754|FG001|Washout Period (at Least 5 Days)|Lost to Follow-up|0
6355647|NCT03801148|10132755|FG002|Washout Period (at Least 5 Days)|Lost to Follow-up|0
6083880|NCT00639678|9692685|FG002|Overall Study|Adverse Event|0
6355648|NCT03801148|10132756|FG003|Washout Period (at Least 5 Days)|Lost to Follow-up|1
6355649|NCT03801148|10132753|FG000|Washout Period (at Least 5 Days)|Withdrawal by Subject|0
6355650|NCT03801148|10132754|FG001|Washout Period (at Least 5 Days)|Withdrawal by Subject|0
6355651|NCT03801148|10132755|FG002|Washout Period (at Least 5 Days)|Withdrawal by Subject|1
6355652|NCT03801148|10132756|FG003|Washout Period (at Least 5 Days)|Withdrawal by Subject|0
6355653|NCT03801148|10132753|FG000|Follow-Up (12 Days)|Lost to Follow-up|0
6355654|NCT03801148|10132754|FG001|Follow-Up (12 Days)|Lost to Follow-up|1
6355655|NCT03801148|10132755|FG002|Follow-Up (12 Days)|Lost to Follow-up|1
6355656|NCT03801148|10132756|FG003|Follow-Up (12 Days)|Lost to Follow-up|0
6355657|NCT03832322|10132772|FG000|Overall Study|Failed cecal intubation in 2nd exam|3
6355658|NCT03832322|10132773|FG001|Overall Study|Failed cecal intubation in 2nd exam|1
6355659|NCT03832387|10132783|FG000|Overall Study|Protocol Violation|2
6355660|NCT03832387|10132784|FG001|Overall Study|Protocol Violation|6
6355661|NCT03832387|10132783|FG000|Overall Study|EXCLUSION CRITERIA|3
6355662|NCT03832387|10132784|FG001|Overall Study|EXCLUSION CRITERIA|1
6083881|NCT00639678|9692686|FG003|Overall Study|Adverse Event|0
6083882|NCT00639678|9692683|FG000|Overall Study|Lack of Compliance|0
6355663|NCT03807739|10132807|FG000|Overall Study|Adverse Event|1
6355664|NCT03807739|10132808|FG001|Overall Study|Adverse Event|0
6355665|NCT03807739|10132809|FG002|Overall Study|Adverse Event|0
6355666|NCT03807739|10132810|FG003|Overall Study|Adverse Event|0
6355667|NCT03807739|10132807|FG000|Overall Study|Withdrawal by Subject|1
6355668|NCT03807739|10132808|FG001|Overall Study|Withdrawal by Subject|0
6355669|NCT03807739|10132809|FG002|Overall Study|Withdrawal by Subject|0
6355670|NCT03807739|10132810|FG003|Overall Study|Withdrawal by Subject|0
6355671|NCT03831282|10132820|FG000|Overall Study|Could not place sensor|1
6355672|NCT03824912|10132827|FG000|Overall Study|Lost to Follow-up|18
6355673|NCT03824912|10132828|FG001|Overall Study|Lost to Follow-up|15
6355674|NCT03824912|10132829|FG002|Overall Study|Lost to Follow-up|8
6355675|NCT03824912|10132827|FG000|Overall Study|Negative Baseline Culture Result|118
6355676|NCT03824912|10132828|FG001|Overall Study|Negative Baseline Culture Result|112
6355677|NCT03824912|10132829|FG002|Overall Study|Negative Baseline Culture Result|57
6355678|NCT03824912|10132827|FG000|Overall Study|Non-Compliance with Study Drug|0
6355679|NCT03824912|10132828|FG001|Overall Study|Non-Compliance with Study Drug|0
6355680|NCT03824912|10132829|FG002|Overall Study|Non-Compliance with Study Drug|1
6355681|NCT03824912|10132827|FG000|Overall Study|Protocol Violation|1
6355682|NCT03824912|10132828|FG001|Overall Study|Protocol Violation|4
6355683|NCT03824912|10132829|FG002|Overall Study|Protocol Violation|1
6355684|NCT03824912|10132827|FG000|Overall Study|Withdrawal by Subject|3
6355685|NCT03824912|10132828|FG001|Overall Study|Withdrawal by Subject|2
6355686|NCT03824912|10132829|FG002|Overall Study|Withdrawal by Subject|1
6355687|NCT03824912|10132827|FG000|Overall Study|Participation in another study|0
6355688|NCT03824912|10132828|FG001|Overall Study|Participation in another study|1
6355689|NCT03824912|10132829|FG002|Overall Study|Participation in another study|0
6355690|NCT03822884|10132843|FG000|Overall Study|Withdrawal by Subject|0
6355691|NCT03822884|10132844|FG001|Overall Study|Withdrawal by Subject|0
6355692|NCT03822884|10132845|FG002|Overall Study|Withdrawal by Subject|0
6355693|NCT03822884|10132846|FG003|Overall Study|Withdrawal by Subject|0
6355694|NCT03822884|10132847|FG004|Overall Study|Withdrawal by Subject|1
6355695|NCT03822884|10132848|FG005|Overall Study|Withdrawal by Subject|0
6355696|NCT03810014|10132864|FG000|Overall Study|Pregnancy|2
6355697|NCT03810014|10132865|FG001|Overall Study|Pregnancy|2
6355698|NCT03810014|10132866|FG002|Overall Study|Pregnancy|0
6355699|NCT03810014|10132867|FG003|Overall Study|Pregnancy|2
6355700|NCT03830892|10132892|FG000|Overall Study|Physician Decision|2
6355701|NCT03830892|10132893|FG001|Overall Study|Physician Decision|3
6355702|NCT03830892|10132892|FG000|Overall Study|Study terminated due to COVID|4
6355703|NCT03830892|10132893|FG001|Overall Study|Study terminated due to COVID|0
6355704|NCT03830892|10132892|FG000|Overall Study|Protocol Violation|0
6355705|NCT03830892|10132893|FG001|Overall Study|Protocol Violation|1
6355706|NCT03830892|10132892|FG000|Overall Study|Withdrawal by Subject|0
6355707|NCT03830892|10132893|FG001|Overall Study|Withdrawal by Subject|2
6355708|NCT03825042|10132905|FG000|Overall Study|Adverse Event|1
6355709|NCT03825042|10132906|FG001|Overall Study|Adverse Event|0
6355710|NCT03825042|10132905|FG000|Overall Study|Withdrawal by Subject|1
6355711|NCT03825042|10132906|FG001|Overall Study|Withdrawal by Subject|0
6355712|NCT03823378|10132918|FG000|Overall Study|Adverse Event|2
6355713|NCT03823378|10132919|FG001|Overall Study|Adverse Event|2
6355714|NCT03823378|10132920|FG002|Overall Study|Adverse Event|0
6355715|NCT03823378|10132921|FG003|Overall Study|Adverse Event|0
6355716|NCT03823378|10132922|FG004|Overall Study|Adverse Event|0
6355717|NCT03823378|10132923|FG005|Overall Study|Adverse Event|0
6355718|NCT03823378|10132918|FG000|Overall Study|Lost to Follow-up|0
6355719|NCT03823378|10132919|FG001|Overall Study|Lost to Follow-up|1
6355720|NCT03823378|10132920|FG002|Overall Study|Lost to Follow-up|0
6355721|NCT03823378|10132921|FG003|Overall Study|Lost to Follow-up|0
6355722|NCT03823378|10132922|FG004|Overall Study|Lost to Follow-up|1
6355723|NCT03823378|10132923|FG005|Overall Study|Lost to Follow-up|0
6355724|NCT03823378|10132918|FG000|Overall Study|Withdrawal by Subject|0
6355725|NCT03823378|10132919|FG001|Overall Study|Withdrawal by Subject|1
6355726|NCT03823378|10132920|FG002|Overall Study|Withdrawal by Subject|4
6355727|NCT03823378|10132921|FG003|Overall Study|Withdrawal by Subject|2
6355728|NCT03823378|10132922|FG004|Overall Study|Withdrawal by Subject|0
6355729|NCT03823378|10132923|FG005|Overall Study|Withdrawal by Subject|1
6355730|NCT03823378|10132918|FG000|Overall Study|Other, not specified|19
6355731|NCT03823378|10132919|FG001|Overall Study|Other, not specified|12
6355732|NCT03823378|10132920|FG002|Overall Study|Other, not specified|6
6355733|NCT03823378|10132921|FG003|Overall Study|Other, not specified|8
6355734|NCT03823378|10132922|FG004|Overall Study|Other, not specified|17
6355735|NCT03823378|10132923|FG005|Overall Study|Other, not specified|7
6355736|NCT03831191|10132941|FG000|Induction Period (16 Weeks)|Adverse Event|2
6355737|NCT03831191|10132942|FG001|Induction Period (16 Weeks)|Adverse Event|1
6355738|NCT03831191|10132943|FG002|Induction Period (16 Weeks)|Adverse Event|3
6355739|NCT03831191|10132944|FG003|Induction Period (16 Weeks)|Adverse Event|4
6355740|NCT03831191|10132945|FG004|Induction Period (16 Weeks)|Adverse Event|0
6355741|NCT03831191|10132946|FG005|Induction Period (16 Weeks)|Adverse Event|0
6355742|NCT03831191|10132947|FG006|Induction Period (16 Weeks)|Adverse Event|0
6355743|NCT03831191|10132948|FG007|Induction Period (16 Weeks)|Adverse Event|0
6355744|NCT03831191|10132949|FG008|Induction Period (16 Weeks)|Adverse Event|0
6355745|NCT03831191|10132950|FG009|Induction Period (16 Weeks)|Adverse Event|0
6355746|NCT03831191|10132951|FG010|Induction Period (16 Weeks)|Adverse Event|0
6355747|NCT03831191|10132952|FG011|Induction Period (16 Weeks)|Adverse Event|0
6355748|NCT03831191|10132953|FG012|Induction Period (16 Weeks)|Adverse Event|0
6355749|NCT03831191|10132954|FG013|Induction Period (16 Weeks)|Adverse Event|0
6355750|NCT03831191|10132955|FG014|Induction Period (16 Weeks)|Adverse Event|0
6355751|NCT03831191|10132941|FG000|Induction Period (16 Weeks)|Lack of Efficacy|2
6355752|NCT03831191|10132942|FG001|Induction Period (16 Weeks)|Lack of Efficacy|3
6355753|NCT03831191|10132943|FG002|Induction Period (16 Weeks)|Lack of Efficacy|0
6355754|NCT03831191|10132944|FG003|Induction Period (16 Weeks)|Lack of Efficacy|0
6355755|NCT03831191|10132945|FG004|Induction Period (16 Weeks)|Lack of Efficacy|0
6355756|NCT03831191|10132946|FG005|Induction Period (16 Weeks)|Lack of Efficacy|0
6355757|NCT03831191|10132947|FG006|Induction Period (16 Weeks)|Lack of Efficacy|0
6355758|NCT03831191|10132948|FG007|Induction Period (16 Weeks)|Lack of Efficacy|0
6355759|NCT03831191|10132949|FG008|Induction Period (16 Weeks)|Lack of Efficacy|0
6355760|NCT03831191|10132950|FG009|Induction Period (16 Weeks)|Lack of Efficacy|0
6355761|NCT03831191|10132951|FG010|Induction Period (16 Weeks)|Lack of Efficacy|0
6355762|NCT03831191|10132952|FG011|Induction Period (16 Weeks)|Lack of Efficacy|0
6355763|NCT03831191|10132953|FG012|Induction Period (16 Weeks)|Lack of Efficacy|0
6355764|NCT03831191|10132954|FG013|Induction Period (16 Weeks)|Lack of Efficacy|0
6355765|NCT03831191|10132955|FG014|Induction Period (16 Weeks)|Lack of Efficacy|0
6355766|NCT03831191|10132941|FG000|Induction Period (16 Weeks)|Pregnancy|0
6355767|NCT03831191|10132942|FG001|Induction Period (16 Weeks)|Pregnancy|0
6355768|NCT03831191|10132943|FG002|Induction Period (16 Weeks)|Pregnancy|1
6355769|NCT03831191|10132944|FG003|Induction Period (16 Weeks)|Pregnancy|0
6355770|NCT03831191|10132945|FG004|Induction Period (16 Weeks)|Pregnancy|0
6355771|NCT03831191|10132946|FG005|Induction Period (16 Weeks)|Pregnancy|0
6355772|NCT03831191|10132947|FG006|Induction Period (16 Weeks)|Pregnancy|0
6355773|NCT03831191|10132948|FG007|Induction Period (16 Weeks)|Pregnancy|0
6355774|NCT03831191|10132949|FG008|Induction Period (16 Weeks)|Pregnancy|0
6355775|NCT03831191|10132950|FG009|Induction Period (16 Weeks)|Pregnancy|0
6355776|NCT03831191|10132951|FG010|Induction Period (16 Weeks)|Pregnancy|0
6355777|NCT03831191|10132952|FG011|Induction Period (16 Weeks)|Pregnancy|0
6355778|NCT03831191|10132953|FG012|Induction Period (16 Weeks)|Pregnancy|0
6355779|NCT03831191|10132954|FG013|Induction Period (16 Weeks)|Pregnancy|0
6355780|NCT03831191|10132955|FG014|Induction Period (16 Weeks)|Pregnancy|0
6355781|NCT03831191|10132941|FG000|Induction Period (16 Weeks)|Protocol Violation|0
6355782|NCT03831191|10132942|FG001|Induction Period (16 Weeks)|Protocol Violation|0
6355783|NCT03831191|10132943|FG002|Induction Period (16 Weeks)|Protocol Violation|0
6355784|NCT03831191|10132944|FG003|Induction Period (16 Weeks)|Protocol Violation|2
6355785|NCT03831191|10132945|FG004|Induction Period (16 Weeks)|Protocol Violation|0
6355786|NCT03831191|10132946|FG005|Induction Period (16 Weeks)|Protocol Violation|0
6355787|NCT03831191|10132947|FG006|Induction Period (16 Weeks)|Protocol Violation|0
6355788|NCT03831191|10132948|FG007|Induction Period (16 Weeks)|Protocol Violation|0
6355789|NCT03831191|10132949|FG008|Induction Period (16 Weeks)|Protocol Violation|0
6355790|NCT03831191|10132950|FG009|Induction Period (16 Weeks)|Protocol Violation|0
6355791|NCT03831191|10132951|FG010|Induction Period (16 Weeks)|Protocol Violation|0
6355792|NCT03831191|10132952|FG011|Induction Period (16 Weeks)|Protocol Violation|0
6355793|NCT03831191|10132953|FG012|Induction Period (16 Weeks)|Protocol Violation|0
6355794|NCT03831191|10132954|FG013|Induction Period (16 Weeks)|Protocol Violation|0
6355795|NCT03831191|10132955|FG014|Induction Period (16 Weeks)|Protocol Violation|0
6355796|NCT03831191|10132941|FG000|Induction Period (16 Weeks)|Withdrawal by Subject|7
6355797|NCT03831191|10132942|FG001|Induction Period (16 Weeks)|Withdrawal by Subject|2
6355798|NCT03831191|10132943|FG002|Induction Period (16 Weeks)|Withdrawal by Subject|1
6355799|NCT03831191|10132944|FG003|Induction Period (16 Weeks)|Withdrawal by Subject|3
6355800|NCT03831191|10132945|FG004|Induction Period (16 Weeks)|Withdrawal by Subject|0
6355801|NCT03831191|10132946|FG005|Induction Period (16 Weeks)|Withdrawal by Subject|0
6355802|NCT03831191|10132947|FG006|Induction Period (16 Weeks)|Withdrawal by Subject|0
6355803|NCT03831191|10132948|FG007|Induction Period (16 Weeks)|Withdrawal by Subject|0
6355804|NCT03831191|10132949|FG008|Induction Period (16 Weeks)|Withdrawal by Subject|0
6355805|NCT03831191|10132950|FG009|Induction Period (16 Weeks)|Withdrawal by Subject|0
6355806|NCT03831191|10132951|FG010|Induction Period (16 Weeks)|Withdrawal by Subject|0
6355807|NCT03831191|10132952|FG011|Induction Period (16 Weeks)|Withdrawal by Subject|0
6355808|NCT03831191|10132953|FG012|Induction Period (16 Weeks)|Withdrawal by Subject|0
6355809|NCT03831191|10132954|FG013|Induction Period (16 Weeks)|Withdrawal by Subject|0
6355810|NCT03831191|10132955|FG014|Induction Period (16 Weeks)|Withdrawal by Subject|0
6355811|NCT03831191|10132941|FG000|Induction Period (16 Weeks)|Study Terminated by Sponsor|12
6355812|NCT03831191|10132942|FG001|Induction Period (16 Weeks)|Study Terminated by Sponsor|15
6355813|NCT03831191|10132943|FG002|Induction Period (16 Weeks)|Study Terminated by Sponsor|16
6355814|NCT03831191|10132944|FG003|Induction Period (16 Weeks)|Study Terminated by Sponsor|13
6355815|NCT03831191|10132945|FG004|Induction Period (16 Weeks)|Study Terminated by Sponsor|0
6355816|NCT03831191|10132946|FG005|Induction Period (16 Weeks)|Study Terminated by Sponsor|0
6355817|NCT03831191|10132947|FG006|Induction Period (16 Weeks)|Study Terminated by Sponsor|0
6355818|NCT03831191|10132948|FG007|Induction Period (16 Weeks)|Study Terminated by Sponsor|0
6355819|NCT03831191|10132949|FG008|Induction Period (16 Weeks)|Study Terminated by Sponsor|0
6355820|NCT03831191|10132950|FG009|Induction Period (16 Weeks)|Study Terminated by Sponsor|0
6355821|NCT03831191|10132951|FG010|Induction Period (16 Weeks)|Study Terminated by Sponsor|0
6355822|NCT03831191|10132952|FG011|Induction Period (16 Weeks)|Study Terminated by Sponsor|0
6355823|NCT03831191|10132953|FG012|Induction Period (16 Weeks)|Study Terminated by Sponsor|0
6355824|NCT03831191|10132954|FG013|Induction Period (16 Weeks)|Study Terminated by Sponsor|0
6355825|NCT03831191|10132955|FG014|Induction Period (16 Weeks)|Study Terminated by Sponsor|0
6355826|NCT03831191|10132941|FG000|Induction Period (16 Weeks)|Sponsor Decision|0
6355827|NCT03831191|10132942|FG001|Induction Period (16 Weeks)|Sponsor Decision|0
6355828|NCT03831191|10132943|FG002|Induction Period (16 Weeks)|Sponsor Decision|0
6355829|NCT03831191|10132944|FG003|Induction Period (16 Weeks)|Sponsor Decision|1
6355830|NCT03831191|10132945|FG004|Induction Period (16 Weeks)|Sponsor Decision|0
6355831|NCT03831191|10132946|FG005|Induction Period (16 Weeks)|Sponsor Decision|0
6355832|NCT03831191|10132947|FG006|Induction Period (16 Weeks)|Sponsor Decision|0
6355833|NCT03831191|10132948|FG007|Induction Period (16 Weeks)|Sponsor Decision|0
6355834|NCT03831191|10132949|FG008|Induction Period (16 Weeks)|Sponsor Decision|0
6355835|NCT03831191|10132950|FG009|Induction Period (16 Weeks)|Sponsor Decision|0
6355836|NCT03831191|10132951|FG010|Induction Period (16 Weeks)|Sponsor Decision|0
6355837|NCT03831191|10132952|FG011|Induction Period (16 Weeks)|Sponsor Decision|0
6355838|NCT03831191|10132953|FG012|Induction Period (16 Weeks)|Sponsor Decision|0
6355839|NCT03831191|10132954|FG013|Induction Period (16 Weeks)|Sponsor Decision|0
6355840|NCT03831191|10132955|FG014|Induction Period (16 Weeks)|Sponsor Decision|0
6355841|NCT03831191|10132941|FG000|Maintenance Period (36 Weeks)|Study Terminated by Sponsor|0
6355842|NCT03831191|10132942|FG001|Maintenance Period (36 Weeks)|Study Terminated by Sponsor|0
6355843|NCT03831191|10132943|FG002|Maintenance Period (36 Weeks)|Study Terminated by Sponsor|0
6355844|NCT03831191|10132944|FG003|Maintenance Period (36 Weeks)|Study Terminated by Sponsor|0
6355845|NCT03831191|10132945|FG004|Maintenance Period (36 Weeks)|Study Terminated by Sponsor|4
6355846|NCT03831191|10132946|FG005|Maintenance Period (36 Weeks)|Study Terminated by Sponsor|5
6355847|NCT03831191|10132947|FG006|Maintenance Period (36 Weeks)|Study Terminated by Sponsor|2
6355848|NCT03831191|10132948|FG007|Maintenance Period (36 Weeks)|Study Terminated by Sponsor|4
6355849|NCT03831191|10132949|FG008|Maintenance Period (36 Weeks)|Study Terminated by Sponsor|8
6355850|NCT03831191|10132950|FG009|Maintenance Period (36 Weeks)|Study Terminated by Sponsor|1
6355851|NCT03831191|10132951|FG010|Maintenance Period (36 Weeks)|Study Terminated by Sponsor|4
6355852|NCT03831191|10132952|FG011|Maintenance Period (36 Weeks)|Study Terminated by Sponsor|7
6355853|NCT03831191|10132953|FG012|Maintenance Period (36 Weeks)|Study Terminated by Sponsor|1
6355854|NCT03831191|10132954|FG013|Maintenance Period (36 Weeks)|Study Terminated by Sponsor|1
6355855|NCT03831191|10132955|FG014|Maintenance Period (36 Weeks)|Study Terminated by Sponsor|6
6355856|NCT03831191|10132941|FG000|Maintenance Period (36 Weeks)|Withdrawal by Subject|0
6355857|NCT03831191|10132942|FG001|Maintenance Period (36 Weeks)|Withdrawal by Subject|0
6355858|NCT03831191|10132943|FG002|Maintenance Period (36 Weeks)|Withdrawal by Subject|0
6355859|NCT03831191|10132944|FG003|Maintenance Period (36 Weeks)|Withdrawal by Subject|0
6355860|NCT03831191|10132945|FG004|Maintenance Period (36 Weeks)|Withdrawal by Subject|0
6355861|NCT03831191|10132946|FG005|Maintenance Period (36 Weeks)|Withdrawal by Subject|0
6355862|NCT03831191|10132947|FG006|Maintenance Period (36 Weeks)|Withdrawal by Subject|0
6355863|NCT03831191|10132948|FG007|Maintenance Period (36 Weeks)|Withdrawal by Subject|0
6355864|NCT03831191|10132949|FG008|Maintenance Period (36 Weeks)|Withdrawal by Subject|0
6355865|NCT03831191|10132950|FG009|Maintenance Period (36 Weeks)|Withdrawal by Subject|0
6355866|NCT03831191|10132951|FG010|Maintenance Period (36 Weeks)|Withdrawal by Subject|0
6355867|NCT03831191|10132952|FG011|Maintenance Period (36 Weeks)|Withdrawal by Subject|0
6355868|NCT03831191|10132953|FG012|Maintenance Period (36 Weeks)|Withdrawal by Subject|0
6355869|NCT03831191|10132954|FG013|Maintenance Period (36 Weeks)|Withdrawal by Subject|0
6355870|NCT03831191|10132955|FG014|Maintenance Period (36 Weeks)|Withdrawal by Subject|2
6355871|NCT03831191|10132941|FG000|Maintenance Period (36 Weeks)|Lost to Follow-up|0
6355872|NCT03831191|10132942|FG001|Maintenance Period (36 Weeks)|Lost to Follow-up|0
6355873|NCT03831191|10132943|FG002|Maintenance Period (36 Weeks)|Lost to Follow-up|0
6355874|NCT03831191|10132944|FG003|Maintenance Period (36 Weeks)|Lost to Follow-up|0
6355875|NCT03831191|10132945|FG004|Maintenance Period (36 Weeks)|Lost to Follow-up|0
6355876|NCT03831191|10132946|FG005|Maintenance Period (36 Weeks)|Lost to Follow-up|0
6355877|NCT03831191|10132947|FG006|Maintenance Period (36 Weeks)|Lost to Follow-up|0
6355878|NCT03831191|10132948|FG007|Maintenance Period (36 Weeks)|Lost to Follow-up|0
6355879|NCT03831191|10132949|FG008|Maintenance Period (36 Weeks)|Lost to Follow-up|0
6355880|NCT03831191|10132950|FG009|Maintenance Period (36 Weeks)|Lost to Follow-up|0
6355881|NCT03831191|10132951|FG010|Maintenance Period (36 Weeks)|Lost to Follow-up|0
6355882|NCT03831191|10132952|FG011|Maintenance Period (36 Weeks)|Lost to Follow-up|0
6355883|NCT03831191|10132953|FG012|Maintenance Period (36 Weeks)|Lost to Follow-up|0
6355884|NCT03831191|10132954|FG013|Maintenance Period (36 Weeks)|Lost to Follow-up|0
6355885|NCT03831191|10132955|FG014|Maintenance Period (36 Weeks)|Lost to Follow-up|1
6355886|NCT03830281|10132990|FG000|Lead-in Period (2 Weeks)|Adverse Event|2
6355887|NCT03830281|10132991|FG001|Lead-in Period (2 Weeks)|Adverse Event|0
6355888|NCT03830281|10132990|FG000|Lead-in Period (2 Weeks)|Not Met Eligibility Criteria|6
6355889|NCT03830281|10132991|FG001|Lead-in Period (2 Weeks)|Not Met Eligibility Criteria|0
6355890|NCT03830281|10132990|FG000|Lead-in Period (2 Weeks)|Physician Decision|2
6355891|NCT03830281|10132991|FG001|Lead-in Period (2 Weeks)|Physician Decision|0
6355892|NCT03830281|10132990|FG000|Lead-in Period (2 Weeks)|Withdrawal by Subject|29
6355893|NCT03830281|10132991|FG001|Lead-in Period (2 Weeks)|Withdrawal by Subject|0
6355894|NCT03830281|10132990|FG000|Treatment Period (16 Weeks)|Adverse Event|1
6355895|NCT03830281|10132991|FG001|Treatment Period (16 Weeks)|Adverse Event|7
6355896|NCT03830281|10132990|FG000|Treatment Period (16 Weeks)|Lost to Follow-up|4
6355897|NCT03830281|10132991|FG001|Treatment Period (16 Weeks)|Lost to Follow-up|3
6355898|NCT03830281|10132990|FG000|Treatment Period (16 Weeks)|Sponsor Decision|1
6355899|NCT03830281|10132991|FG001|Treatment Period (16 Weeks)|Sponsor Decision|1
6355900|NCT03830281|10132990|FG000|Treatment Period (16 Weeks)|Physician Decision|1
6355901|NCT03830281|10132991|FG001|Treatment Period (16 Weeks)|Physician Decision|0
6355902|NCT03830281|10132990|FG000|Treatment Period (16 Weeks)|Withdrawal by Subject|5
6355903|NCT03830281|10132991|FG001|Treatment Period (16 Weeks)|Withdrawal by Subject|6
6355904|NCT03827395|10133007|FG000|Overall Study|Lost to Follow-up|1
6355905|NCT03827395|10133008|FG001|Overall Study|Lost to Follow-up|0
6355906|NCT03827395|10133007|FG000|Overall Study|Protocol Violation|1
6355907|NCT03827395|10133008|FG001|Overall Study|Protocol Violation|0
6355908|NCT03827395|10133007|FG000|Overall Study|Became ineligible after enrollment|1
6355909|NCT03827395|10133008|FG001|Overall Study|Became ineligible after enrollment|2
6355910|NCT03819218|10133014|FG000|Overall Study|Protocol Violation|1
6355911|NCT03828487|10133027|FG000|Overall Study|Physician Decision|1
6355912|NCT03828617|10133035|FG000|Overall Study|Lost to Follow-up|22
6355913|NCT03828617|10133036|FG001|Overall Study|Lost to Follow-up|12
6355914|NCT03828617|10133037|FG002|Overall Study|Lost to Follow-up|23
6355915|NCT03828617|10133038|FG003|Overall Study|Lost to Follow-up|7
6355916|NCT03828617|10133035|FG000|Overall Study|No longer met eligibility criteria|0
6355917|NCT03828617|10133036|FG001|Overall Study|No longer met eligibility criteria|1
6355918|NCT03828617|10133037|FG002|Overall Study|No longer met eligibility criteria|1
6355919|NCT03828617|10133038|FG003|Overall Study|No longer met eligibility criteria|3
6355920|NCT03828617|10133035|FG000|Overall Study|Protocol Violation|0
6355921|NCT03828617|10133036|FG001|Overall Study|Protocol Violation|2
6355922|NCT03828617|10133037|FG002|Overall Study|Protocol Violation|0
6355923|NCT03828617|10133038|FG003|Overall Study|Protocol Violation|0
6355924|NCT03828617|10133035|FG000|Overall Study|Withdrawal by Subject|2
6355925|NCT03828617|10133036|FG001|Overall Study|Withdrawal by Subject|0
6355926|NCT03828617|10133037|FG002|Overall Study|Withdrawal by Subject|2
6355927|NCT03828617|10133038|FG003|Overall Study|Withdrawal by Subject|0
6355928|NCT03828539|10133049|FG000|Overall Study|Adverse Event|3
6355929|NCT03828539|10133050|FG001|Overall Study|Adverse Event|12
6355930|NCT03828539|10133049|FG000|Overall Study|Patient's/guardian's decision|3
6355931|NCT03828539|10133050|FG001|Overall Study|Patient's/guardian's decision|5
6355932|NCT03828539|10133049|FG000|Overall Study|Lost to Follow-up|4
6355933|NCT03828539|10133050|FG001|Overall Study|Lost to Follow-up|2
6355934|NCT03828539|10133049|FG000|Overall Study|Protocol Violation|3
6355935|NCT03828539|10133050|FG001|Overall Study|Protocol Violation|2
6355936|NCT03828539|10133049|FG000|Overall Study|Withdrawal of informed consent|2
6355937|NCT03828539|10133050|FG001|Overall Study|Withdrawal of informed consent|1
6355938|NCT03828539|10133049|FG000|Overall Study|New therapy for study indication|1
6355939|NCT03828539|10133050|FG001|Overall Study|New therapy for study indication|0
6355940|NCT03824704|10133056|FG000|Overall Study|Study Terminated by Sponsor|1
6355941|NCT03817879|10133071|FG000|Overall Study|Drop out|5
6355942|NCT03817879|10133072|FG001|Overall Study|Drop out|12
6355943|NCT03817879|10133071|FG000|Overall Study|Withdrawal by Subject|0
6355944|NCT03817879|10133072|FG001|Overall Study|Withdrawal by Subject|1
6355945|NCT03811834|10133078|FG000|Period 1 ( 7 Days)|Adverse Event|1
6355946|NCT03806127|10133093|FG000|Overall Study|Withdrawal by Subject|4
6355947|NCT03806127|10133094|FG001|Overall Study|Withdrawal by Subject|5
6355948|NCT03806127|10133093|FG000|Overall Study|Protocol Violation|3
6355949|NCT03806127|10133094|FG001|Overall Study|Protocol Violation|1
6355950|NCT03806127|10133093|FG000|Overall Study|Adverse Event|3
6355951|NCT03806127|10133094|FG001|Overall Study|Adverse Event|0
6355952|NCT03806127|10133093|FG000|Overall Study|Unable to Complete Procedures|0
6355953|NCT03806127|10133094|FG001|Overall Study|Unable to Complete Procedures|1
6355954|NCT03806127|10133093|FG000|Overall Study|Pregnancy|0
6355955|NCT03806127|10133094|FG001|Overall Study|Pregnancy|1
6355956|NCT03806127|10133093|FG000|Overall Study|Lost to Follow-up|5
6355957|NCT03806127|10133094|FG001|Overall Study|Lost to Follow-up|1
6355958|NCT03806127|10133093|FG000|Overall Study|Physician Decision|1
6355959|NCT03806127|10133094|FG001|Overall Study|Physician Decision|1
6355960|NCT03806127|10133093|FG000|Overall Study|Could Not Come Due to Covid|1
6355961|NCT03806127|10133094|FG001|Overall Study|Could Not Come Due to Covid|0
6355962|NCT03806127|10133093|FG000|Overall Study|Prescribed Exclusionary Medication (Med)|1
6355963|NCT03806127|10133094|FG001|Overall Study|Prescribed Exclusionary Medication (Med)|0
6355964|NCT03806127|10133093|FG000|Overall Study|Ran Out of Study Meds (Covid Quarantine)|1
6355965|NCT03806127|10133094|FG001|Overall Study|Ran Out of Study Meds (Covid Quarantine)|0
6355966|NCT03806127|10133093|FG000|Overall Study|Covid 19 Restrictions|2
6355967|NCT03806127|10133094|FG001|Overall Study|Covid 19 Restrictions|0
6355968|NCT03806127|10133093|FG000|Overall Study|Withdrawn Due to Work/School Schedule|0
6355969|NCT03806127|10133094|FG001|Overall Study|Withdrawn Due to Work/School Schedule|1
6355970|NCT03806127|10133093|FG000|Overall Study|Covid 19 Concern; Possible Site Closure|0
6355971|NCT03806127|10133094|FG001|Overall Study|Covid 19 Concern; Possible Site Closure|1
6355972|NCT03827473|10133102|FG000|Overall Study|Withdrawal by Subject|1
6355973|NCT03827473|10133103|FG001|Overall Study|Withdrawal by Subject|0
6355974|NCT03826914|10133111|FG000|Overall Study|Withdrawal by Subject|1
6355975|NCT03826914|10133112|FG001|Overall Study|Withdrawal by Subject|1
6355976|NCT03808688|10133135|FG000|Overall Study|Adverse Event|13
6355977|NCT03808688|10133136|FG001|Overall Study|Adverse Event|17
6355978|NCT03808688|10133135|FG000|Overall Study|Lack of Efficacy|2
6355979|NCT03808688|10133136|FG001|Overall Study|Lack of Efficacy|0
6355980|NCT03808688|10133135|FG000|Overall Study|Lost to Follow-up|0
6355981|NCT03808688|10133136|FG001|Overall Study|Lost to Follow-up|2
6355982|NCT03808688|10133135|FG000|Overall Study|Withdrawal by Subject|1
6355983|NCT03808688|10133136|FG001|Overall Study|Withdrawal by Subject|0
6355984|NCT03808688|10133135|FG000|Overall Study|Intolerance to Conjunctival Hyperemia|1
6355985|NCT03808688|10133136|FG001|Overall Study|Intolerance to Conjunctival Hyperemia|0
6355986|NCT03808688|10133135|FG000|Overall Study|IOP Too High|1
6355987|NCT03808688|10133136|FG001|Overall Study|IOP Too High|1
6355988|NCT03808688|10133135|FG000|Overall Study|IOP Too High, Nerve/Visual Field Changes|0
6355989|NCT03808688|10133136|FG001|Overall Study|IOP Too High, Nerve/Visual Field Changes|1
6355990|NCT03808688|10133135|FG000|Overall Study|Visit Out of Window|0
6355991|NCT03808688|10133136|FG001|Overall Study|Visit Out of Window|1
6355992|NCT03808688|10133135|FG000|Overall Study|Medication Non-Compliance|0
6355993|NCT03808688|10133136|FG001|Overall Study|Medication Non-Compliance|1
6355994|NCT03811093|10133146|FG000|Overall Study|Lack of Efficacy, Withdrawal by Subject|0
6355995|NCT03811093|10133147|FG001|Overall Study|Lack of Efficacy, Withdrawal by Subject|4
6355996|NCT03811093|10133146|FG000|Overall Study|Unable to measure body fat percentage|2
6355997|NCT03811093|10133147|FG001|Overall Study|Unable to measure body fat percentage|0
6355998|NCT03822182|10133159|FG000|Overall Study|Protocol Violation|0
6355999|NCT03822182|10133160|FG001|Overall Study|Protocol Violation|1
6356000|NCT03822182|10133161|FG002|Overall Study|Protocol Violation|1
6356001|NCT03822416|10133172|FG000|Overall Study|Lost to Follow-up|1
6356002|NCT03822416|10133173|FG001|Overall Study|Lost to Follow-up|0
6356003|NCT03822416|10133172|FG000|Overall Study|Withdrawal by Subject|0
6356004|NCT03822416|10133173|FG001|Overall Study|Withdrawal by Subject|1
6356005|NCT03809104|10133179|FG000|Overall Study|Withdrawal by Subject|3
6356006|NCT03806231|10133194|FG000|Overall Study|Physician Decision|1
6356007|NCT03806231|10133195|FG001|Overall Study|Physician Decision|0
6356008|NCT03806231|10133194|FG000|Overall Study|Withdrawal by Subject|1
6356009|NCT03806231|10133195|FG001|Overall Study|Withdrawal by Subject|0
6356010|NCT03804710|10133203|FG000|Overall Study|Adverse Event|0
6356011|NCT03804710|10133204|FG001|Overall Study|Adverse Event|3
6356012|NCT03804710|10133203|FG000|Overall Study|Withdrawal by Subject|2
6356013|NCT03804710|10133204|FG001|Overall Study|Withdrawal by Subject|1
6356014|NCT03804710|10133203|FG000|Overall Study|Other|0
6356015|NCT03804710|10133204|FG001|Overall Study|Other|1
6356016|NCT03821064|10133248|FG000|Overall Study|did not meet study eligibility criteria of needing adjuvant radiation per NCCN guidelines on path|1
6356017|NCT03820024|10133263|FG000|Overall Study|Physician Decision|1
6356018|NCT03820024|10133264|FG001|Overall Study|Physician Decision|2
6356019|NCT03816761|10133289|FG000|First Treatment Period (7 Days)|Withdrawal by Subject|0
6356020|NCT03816761|10133290|FG001|First Treatment Period (7 Days)|Withdrawal by Subject|0
6356021|NCT03816761|10133291|FG002|First Treatment Period (7 Days)|Withdrawal by Subject|0
6356022|NCT03816761|10133292|FG003|First Treatment Period (7 Days)|Withdrawal by Subject|0
6356023|NCT03816761|10133293|FG004|First Treatment Period (7 Days)|Withdrawal by Subject|0
6356024|NCT03816761|10133294|FG005|First Treatment Period (7 Days)|Withdrawal by Subject|1
6356025|NCT03816761|10133289|FG000|Second Treatment Period (7 Days)|Unclassified|0
6356026|NCT03816761|10133290|FG001|Second Treatment Period (7 Days)|Unclassified|0
6356027|NCT03816761|10133291|FG002|Second Treatment Period (7 Days)|Unclassified|0
6356028|NCT03816761|10133292|FG003|Second Treatment Period (7 Days)|Unclassified|1
6356029|NCT03816761|10133293|FG004|Second Treatment Period (7 Days)|Unclassified|0
6356030|NCT03816761|10133294|FG005|Second Treatment Period (7 Days)|Unclassified|0
6356031|NCT03812510|10133359|FG000|Overall Study|Lost to Follow-up|39
6356032|NCT03812510|10133359|FG000|Overall Study|Withdrawal by Subject|42
6356033|NCT03812510|10133359|FG000|Overall Study|Physician Decision|2
6356034|NCT03812510|10133359|FG000|Overall Study|Study Terminated by Sponsor|9
6356035|NCT03812510|10133359|FG000|Overall Study|Did Not Start Study Medication|55
6356036|NCT03812510|10133359|FG000|Overall Study|Adverse Event|5
6356037|NCT03802994|10133369|FG000|Overall Study|Lost to Follow-up|0
6356038|NCT03802994|10133370|FG001|Overall Study|Lost to Follow-up|2
6356039|NCT03802994|10133371|FG002|Overall Study|Lost to Follow-up|3
6356040|NCT03802994|10133372|FG003|Overall Study|Lost to Follow-up|2
6356041|NCT03802994|10133373|FG004|Overall Study|Lost to Follow-up|2
6356042|NCT03810183|10133398|FG000|Overall Study|Study terminated by Sponsor|2
6356043|NCT03810183|10133399|FG001|Overall Study|Study terminated by Sponsor|1
6356044|NCT03805971|10133439|FG000|Overall Study|Withdrawal by Subject|1
6356045|NCT03805971|10133439|FG000|Overall Study|Protocol Violation|2
6356046|NCT03802916|10133446|FG000|Overall Study|Adverse Event|0
6356047|NCT03802916|10133447|FG001|Overall Study|Adverse Event|1
6356048|NCT03802916|10133446|FG000|Overall Study|Withdrawal by Subject|0
6356049|NCT03802916|10133447|FG001|Overall Study|Withdrawal by Subject|1
6356050|NCT03809039|10133464|FG000|Part 1|Withdrawal by Subject|1
6356051|NCT03809039|10133465|FG001|Part 1|Withdrawal by Subject|0
6356052|NCT03809039|10133466|FG002|Part 1|Withdrawal by Subject|0
6356053|NCT03809039|10133467|FG003|Part 1|Withdrawal by Subject|1
6356054|NCT03809039|10133468|FG004|Part 1|Withdrawal by Subject|0
6356055|NCT03809039|10133469|FG005|Part 1|Withdrawal by Subject|0
6356056|NCT03809039|10133470|FG006|Part 1|Withdrawal by Subject|0
6356057|NCT03809039|10133471|FG007|Part 1|Withdrawal by Subject|0
6356058|NCT03809039|10133472|FG008|Part 1|Withdrawal by Subject|0
6356059|NCT03809039|10133464|FG000|Part 3|Withdrawn by study termination|0
6356060|NCT03809039|10133465|FG001|Part 3|Withdrawn by study termination|0
6356061|NCT03809039|10133466|FG002|Part 3|Withdrawn by study termination|0
6356062|NCT03809039|10133467|FG003|Part 3|Withdrawn by study termination|0
6356063|NCT03809039|10133468|FG004|Part 3|Withdrawn by study termination|0
6356064|NCT03809039|10133469|FG005|Part 3|Withdrawn by study termination|0
6356065|NCT03809039|10133470|FG006|Part 3|Withdrawn by study termination|0
6356066|NCT03809039|10133471|FG007|Part 3|Withdrawn by study termination|2
6356067|NCT03809039|10133472|FG008|Part 3|Withdrawn by study termination|6
6356068|NCT03807700|10133507|FG000|Overall Study|Withdrawal by Subject|2
6356069|NCT03807700|10133508|FG001|Overall Study|Withdrawal by Subject|1
6356070|NCT03804918|10133515|FG000|Overall Study|Participant did not use the app|1
6356071|NCT03803475|10133531|FG000|Overall Study|Physician Decision|1
6356072|NCT03801928|10133584|FG000|Overall Study|Adverse Event|1
6356073|NCT03801928|10133585|FG001|Overall Study|Adverse Event|0
6356074|NCT03801928|10133586|FG002|Overall Study|Adverse Event|1
6356075|NCT03801928|10133587|FG003|Overall Study|Adverse Event|2
6356076|NCT03801928|10133588|FG004|Overall Study|Adverse Event|0
6356077|NCT03801928|10133589|FG005|Overall Study|Adverse Event|2
6356078|NCT03801928|10133584|FG000|Overall Study|Lack of Efficacy|0
6356079|NCT03801928|10133585|FG001|Overall Study|Lack of Efficacy|0
6356080|NCT03801928|10133586|FG002|Overall Study|Lack of Efficacy|1
6356081|NCT03801928|10133587|FG003|Overall Study|Lack of Efficacy|0
6356082|NCT03801928|10133588|FG004|Overall Study|Lack of Efficacy|0
6356083|NCT03801928|10133589|FG005|Overall Study|Lack of Efficacy|0
6356084|NCT03801928|10133584|FG000|Overall Study|Lost to Follow-up|5
6356085|NCT03801928|10133585|FG001|Overall Study|Lost to Follow-up|1
6356086|NCT03801928|10133586|FG002|Overall Study|Lost to Follow-up|1
6356087|NCT03801928|10133587|FG003|Overall Study|Lost to Follow-up|4
6356088|NCT03801928|10133588|FG004|Overall Study|Lost to Follow-up|4
6356089|NCT03801928|10133589|FG005|Overall Study|Lost to Follow-up|2
6356090|NCT03801928|10133584|FG000|Overall Study|Withdrawal by Subject|0
6356091|NCT03801928|10133585|FG001|Overall Study|Withdrawal by Subject|0
6356092|NCT03801928|10133586|FG002|Overall Study|Withdrawal by Subject|2
6356093|NCT03801928|10133587|FG003|Overall Study|Withdrawal by Subject|1
6356094|NCT03801928|10133588|FG004|Overall Study|Withdrawal by Subject|0
6356095|NCT03801928|10133589|FG005|Overall Study|Withdrawal by Subject|0
6356096|NCT03801928|10133584|FG000|Overall Study|Other|0
6356097|NCT03801928|10133585|FG001|Overall Study|Other|2
6356098|NCT03801928|10133586|FG002|Overall Study|Other|0
6356099|NCT03801928|10133587|FG003|Overall Study|Other|1
6356100|NCT03801928|10133588|FG004|Overall Study|Other|0
6356101|NCT03801928|10133589|FG005|Overall Study|Other|1
6356102|NCT03800173|10133611|FG000|Overall Study|Lost to Follow-up|0
6356103|NCT03800173|10133612|FG001|Overall Study|Lost to Follow-up|0
6356104|NCT03800173|10133613|FG002|Overall Study|Lost to Follow-up|0
6356105|NCT03800173|10133614|FG003|Overall Study|Lost to Follow-up|0
6356106|NCT03800173|10133615|FG004|Overall Study|Lost to Follow-up|1
6356107|NCT03799211|10133650|FG000|Overall Study|Lost to Follow-up|2
6356108|NCT03799211|10133651|FG001|Overall Study|Lost to Follow-up|13
6356109|NCT03799211|10133650|FG000|Overall Study|Withdrawal by Subject|2
6356110|NCT03799211|10133651|FG001|Overall Study|Withdrawal by Subject|0
6356111|NCT03798717|10133665|FG000|Overall Study|Failed Screening|0
6356112|NCT03798717|10133666|FG001|Overall Study|Failed Screening|0
6356113|NCT03798717|10133667|FG002|Overall Study|Failed Screening|0
6356114|NCT03798717|10133668|FG003|Overall Study|Failed Screening|0
6356115|NCT03798717|10133669|FG004|Overall Study|Failed Screening|0
6356116|NCT03798717|10133670|FG005|Overall Study|Failed Screening|1
6356117|NCT03798717|10133665|FG000|Overall Study|Physician Decision|1
6356118|NCT03798717|10133666|FG001|Overall Study|Physician Decision|0
6356119|NCT03798717|10133667|FG002|Overall Study|Physician Decision|1
6356120|NCT03798717|10133668|FG003|Overall Study|Physician Decision|0
6356121|NCT03798717|10133669|FG004|Overall Study|Physician Decision|0
6356122|NCT03798717|10133670|FG005|Overall Study|Physician Decision|0
6356123|NCT03798717|10133665|FG000|Overall Study|Withdrawal by Subject|0
6356124|NCT03798717|10133666|FG001|Overall Study|Withdrawal by Subject|0
6356125|NCT03798717|10133667|FG002|Overall Study|Withdrawal by Subject|0
6356126|NCT03798717|10133668|FG003|Overall Study|Withdrawal by Subject|1
6356127|NCT03798717|10133669|FG004|Overall Study|Withdrawal by Subject|0
6356128|NCT03798717|10133670|FG005|Overall Study|Withdrawal by Subject|0
6356129|NCT03798717|10133665|FG000|Overall Study|Lost to Follow-up|1
6356130|NCT03798717|10133666|FG001|Overall Study|Lost to Follow-up|0
6356131|NCT03798717|10133667|FG002|Overall Study|Lost to Follow-up|0
6356132|NCT03798717|10133668|FG003|Overall Study|Lost to Follow-up|1
6356133|NCT03798717|10133669|FG004|Overall Study|Lost to Follow-up|0
6356134|NCT03798717|10133670|FG005|Overall Study|Lost to Follow-up|0
6356135|NCT03798717|10133665|FG000|Overall Study|Adverse Event|0
6356136|NCT03798717|10133666|FG001|Overall Study|Adverse Event|1
6356137|NCT03798717|10133667|FG002|Overall Study|Adverse Event|0
6356138|NCT03798717|10133668|FG003|Overall Study|Adverse Event|0
6356139|NCT03798717|10133669|FG004|Overall Study|Adverse Event|0
6356140|NCT03798717|10133670|FG005|Overall Study|Adverse Event|0
6356141|NCT03798717|10133665|FG000|Overall Study|COVID-19 (coronavirus disease) Lockdown|0
6356142|NCT03798717|10133666|FG001|Overall Study|COVID-19 (coronavirus disease) Lockdown|0
6356143|NCT03798717|10133667|FG002|Overall Study|COVID-19 (coronavirus disease) Lockdown|0
6356144|NCT03798717|10133668|FG003|Overall Study|COVID-19 (coronavirus disease) Lockdown|0
6356145|NCT03798717|10133669|FG004|Overall Study|COVID-19 (coronavirus disease) Lockdown|1
6356146|NCT03798717|10133670|FG005|Overall Study|COVID-19 (coronavirus disease) Lockdown|0
6356147|NCT03798483|10133679|FG000|Overall Study|Lost to Follow-up|2
6356148|NCT03798366|10133689|FG000|Overall Study|Lost to Follow-up|0
6356149|NCT03798366|10133690|FG001|Overall Study|Lost to Follow-up|1
6356150|NCT03799952|10133698|FG000|Overall Study|Program was too easy, discontinued|1
6356151|NCT03799952|10133699|FG001|Overall Study|Program was too easy, discontinued|0
6356152|NCT03799952|10133698|FG000|Overall Study|Lost to Follow-up|0
6356153|NCT03799952|10133699|FG001|Overall Study|Lost to Follow-up|2
6356154|NCT03796728|10133733|FG000|Overall Study|Lost to Follow-up|8
6356155|NCT03796728|10133733|FG000|Overall Study|Reason not Specified|16
6356156|NCT03797144|10133739|FG000|Enrollment|Protocol Violation|4
6356157|NCT03797144|10133740|FG001|Enrollment|Protocol Violation|1
6356158|NCT03797144|10133739|FG000|Surgery|Protocol Violation|1
6356159|NCT03797144|10133740|FG001|Surgery|Protocol Violation|0
6356160|NCT03797144|10133739|FG000|3 Month|Early termination cut-off date|2
6356161|NCT03797144|10133740|FG001|3 Month|Early termination cut-off date|0
6356162|NCT03797144|10133739|FG000|12 Month|Early termination cut-off date|8
6356163|NCT03797144|10133740|FG001|12 Month|Early termination cut-off date|9
6356164|NCT03797144|10133739|FG000|24 Month|Early termination cut-off date|1
6356165|NCT03797144|10133740|FG001|24 Month|Early termination cut-off date|1
6356166|NCT03782571|10133747|FG000|Period 1|Withdrawal by Subject|1
6356167|NCT03782571|10133748|FG001|Period 1|Withdrawal by Subject|0
6356168|NCT03782571|10133749|FG002|Period 1|Withdrawal by Subject|0
6356169|NCT03782571|10133750|FG003|Period 1|Withdrawal by Subject|0
6356170|NCT03782571|10133747|FG000|Period 3|Subject Unable to Attend V5|1
6356171|NCT03782571|10133748|FG001|Period 3|Subject Unable to Attend V5|0
6356172|NCT03782571|10133749|FG002|Period 3|Subject Unable to Attend V5|0
6356173|NCT03782571|10133750|FG003|Period 3|Subject Unable to Attend V5|0
6356174|NCT03782571|10133747|FG000|Period 3|Adverse Event|1
6356175|NCT03782571|10133748|FG001|Period 3|Adverse Event|0
6356176|NCT03782571|10133749|FG002|Period 3|Adverse Event|0
6356177|NCT03782571|10133750|FG003|Period 3|Adverse Event|0
6356178|NCT03796039|10133773|FG000|Overall Study|Death|2
6356179|NCT03796039|10133774|FG001|Overall Study|Death|1
6356180|NCT03796039|10133773|FG000|Overall Study|Withdrawal by Subject|7
6356181|NCT03796039|10133774|FG001|Overall Study|Withdrawal by Subject|4
6356182|NCT03783780|10133780|FG000|Overall Study|Withdrawn prior to completion|1
6356183|NCT03780959|10133788|FG000|Part 1|Adverse Event|1
6356184|NCT03780959|10133789|FG001|Part 1|Adverse Event|0
6356185|NCT03780959|10133790|FG002|Part 1|Adverse Event|0
6356186|NCT03780959|10133788|FG000|Part 1|Withdrawal by Subject|1
6356187|NCT03780959|10133789|FG001|Part 1|Withdrawal by Subject|0
6356188|NCT03780959|10133790|FG002|Part 1|Withdrawal by Subject|0
6356189|NCT03780959|10133788|FG000|Part 1|Withdrawal by Parent/Guardian|1
6356190|NCT03780959|10133789|FG001|Part 1|Withdrawal by Parent/Guardian|0
6356191|NCT03780959|10133790|FG002|Part 1|Withdrawal by Parent/Guardian|0
6356192|NCT03780959|10133788|FG000|Part 1|Response Status|2
6356193|NCT03780959|10133789|FG001|Part 1|Response Status|0
6356194|NCT03780959|10133790|FG002|Part 1|Response Status|0
6356195|NCT03780959|10133788|FG000|Part 2|Withdrawal by Parent/Guardian|0
6356196|NCT03780959|10133789|FG001|Part 2|Withdrawal by Parent/Guardian|1
6356197|NCT03780959|10133790|FG002|Part 2|Withdrawal by Parent/Guardian|0
6356198|NCT03780959|10133788|FG000|Part 2|Response Status|0
6356199|NCT03780959|10133789|FG001|Part 2|Response Status|18
6356200|NCT03780959|10133790|FG002|Part 2|Response Status|6
6356201|NCT03792477|10133830|FG000|Overall Study|Adverse Event|0
6356202|NCT03792477|10133831|FG001|Overall Study|Adverse Event|0
6356203|NCT03792477|10133832|FG002|Overall Study|Adverse Event|0
6356204|NCT03792477|10133833|FG003|Overall Study|Adverse Event|1
6356205|NCT03792477|10133834|FG004|Overall Study|Adverse Event|0
6356206|NCT03792477|10133830|FG000|Overall Study|Lost to Follow-up|0
6356207|NCT03792477|10133831|FG001|Overall Study|Lost to Follow-up|0
6356208|NCT03792477|10133832|FG002|Overall Study|Lost to Follow-up|2
6356209|NCT03792477|10133833|FG003|Overall Study|Lost to Follow-up|0
6356210|NCT03792477|10133834|FG004|Overall Study|Lost to Follow-up|0
6356211|NCT03792477|10133830|FG000|Overall Study|Other|0
6356212|NCT03792477|10133831|FG001|Overall Study|Other|0
6356213|NCT03792477|10133832|FG002|Overall Study|Other|0
6356214|NCT03792477|10133833|FG003|Overall Study|Other|0
6356215|NCT03792477|10133834|FG004|Overall Study|Other|1
6356216|NCT03783962|10133842|FG000|Overall Study|Lost to Follow-up|3
6356217|NCT03783962|10133843|FG001|Overall Study|Lost to Follow-up|6
6356218|NCT03783962|10133842|FG000|Overall Study|Protocol Violation|0
6356219|NCT03783962|10133843|FG001|Overall Study|Protocol Violation|1
6356220|NCT03793556|10133898|FG000|Overall Study|Withdrawal by Subject|12
6356221|NCT03793556|10133899|FG001|Overall Study|Withdrawal by Subject|1
6356222|NCT03793556|10133898|FG000|Overall Study|Lost to Follow-up|1
6356223|NCT03793556|10133899|FG001|Overall Study|Lost to Follow-up|1
6356224|NCT03785548|10133910|FG000|Overall Study|age > 80|1
6356225|NCT03785548|10133911|FG001|Overall Study|age > 80|0
6356226|NCT03785548|10133910|FG000|Overall Study|no Postop queries|1
6356227|NCT03785548|10133911|FG001|Overall Study|no Postop queries|0
6356228|NCT03773133|10133923|FG000|Overall Study|Screen Failure|8
6356229|NCT03792672|10133928|FG000|Washout Period 3 (10 Days)|Withdrawal by Subject|1
6356230|NCT03792672|10133929|FG001|Washout Period 3 (10 Days)|Withdrawal by Subject|0
6356231|NCT03792672|10133930|FG002|Washout Period 3 (10 Days)|Withdrawal by Subject|0
6356232|NCT03792672|10133931|FG003|Washout Period 3 (10 Days)|Withdrawal by Subject|2
6356233|NCT03792672|10133932|FG004|Washout Period 3 (10 Days)|Withdrawal by Subject|0
6356234|NCT03792672|10133933|FG005|Washout Period 3 (10 Days)|Withdrawal by Subject|0
6356235|NCT03792672|10133928|FG000|Washout Period 3 (10 Days)|Physician Decision|0
6356236|NCT03792672|10133929|FG001|Washout Period 3 (10 Days)|Physician Decision|0
6356237|NCT03792672|10133930|FG002|Washout Period 3 (10 Days)|Physician Decision|1
6356238|NCT03792672|10133931|FG003|Washout Period 3 (10 Days)|Physician Decision|0
6356239|NCT03792672|10133932|FG004|Washout Period 3 (10 Days)|Physician Decision|0
6356240|NCT03792672|10133933|FG005|Washout Period 3 (10 Days)|Physician Decision|0
6356241|NCT03792672|10133928|FG000|Treatment Period 4 (2 Days)|Other|1
6356242|NCT03792672|10133929|FG001|Treatment Period 4 (2 Days)|Other|0
6356243|NCT03792672|10133930|FG002|Treatment Period 4 (2 Days)|Other|0
6356244|NCT03792672|10133931|FG003|Treatment Period 4 (2 Days)|Other|0
6356245|NCT03792672|10133932|FG004|Treatment Period 4 (2 Days)|Other|0
6356246|NCT03792672|10133933|FG005|Treatment Period 4 (2 Days)|Other|0
6356247|NCT03787615|10134042|FG000|Overall Study|Withdrawal by Subject|2
6356248|NCT03787615|10134042|FG000|Overall Study|Lost to Follow-up|2
6356249|NCT03786718|10134047|FG000|Overall Study|Lost to Follow-up|3
6356250|NCT03786718|10134047|FG000|Overall Study|Withdrawal by Subject|1
6356251|NCT03786718|10134047|FG000|Overall Study|Did not use the intervention|2
6356252|NCT03786718|10134047|FG000|Overall Study|diagnosis changed from type 2 to type 1|1
6356253|NCT03784963|10134056|FG000|Overall Study|Study terminated by PI for low/no enrollment. All efforts were taken to gather all possible data.|12
6356254|NCT03784963|10134057|FG001|Overall Study|Study terminated by PI for low/no enrollment. All efforts were taken to gather all possible data.|10
6356255|NCT03784963|10134058|FG002|Overall Study|Study terminated by PI for low/no enrollment. All efforts were taken to gather all possible data.|1
6356256|NCT03784963|10134059|FG003|Overall Study|Study terminated by PI for low/no enrollment. All efforts were taken to gather all possible data.|0
6356257|NCT03787212|10134080|FG000|Period 1|Study Termination|2
6356258|NCT03787212|10134081|FG001|Period 1|Study Termination|2
6356259|NCT03783702|10134102|FG000|Overall Study|Lost to Follow-up|6
6356260|NCT03783702|10134103|FG001|Overall Study|Lost to Follow-up|8
6356261|NCT03783702|10134102|FG000|Overall Study|Protocol Violation|1
6356262|NCT03783702|10134103|FG001|Overall Study|Protocol Violation|3
6356263|NCT03783039|10134161|FG000|Overall Study|Death|2
6356264|NCT03783039|10134162|FG001|Overall Study|Death|1
6356265|NCT03776175|10134190|FG000|Treatment Period (42 Days)|Adverse Event|0
6356266|NCT03776175|10134191|FG001|Treatment Period (42 Days)|Adverse Event|1
6356267|NCT03776175|10134192|FG002|Treatment Period (42 Days)|Adverse Event|1
6356268|NCT03776175|10134193|FG003|Treatment Period (42 Days)|Adverse Event|0
6356269|NCT03776175|10134190|FG000|Treatment Period (42 Days)|Lost to Follow-up|0
6356270|NCT03776175|10134191|FG001|Treatment Period (42 Days)|Lost to Follow-up|0
6356271|NCT03776175|10134192|FG002|Treatment Period (42 Days)|Lost to Follow-up|0
6356272|NCT03776175|10134193|FG003|Treatment Period (42 Days)|Lost to Follow-up|2
6356273|NCT03776175|10134190|FG000|Treatment Period (42 Days)|Participants screened at other site|0
6356274|NCT03776175|10134191|FG001|Treatment Period (42 Days)|Participants screened at other site|2
6356275|NCT03776175|10134192|FG002|Treatment Period (42 Days)|Participants screened at other site|0
6356276|NCT03776175|10134193|FG003|Treatment Period (42 Days)|Participants screened at other site|0
6356277|NCT03776175|10134190|FG000|Treatment Period (42 Days)|Withdrawal by Subject|1
6356278|NCT03776175|10134191|FG001|Treatment Period (42 Days)|Withdrawal by Subject|2
6356279|NCT03776175|10134192|FG002|Treatment Period (42 Days)|Withdrawal by Subject|3
6356280|NCT03776175|10134193|FG003|Treatment Period (42 Days)|Withdrawal by Subject|0
6356281|NCT03776175|10134190|FG000|Treatment Period (42 Days)|Unable to attend study visits|0
6356282|NCT03776175|10134191|FG001|Treatment Period (42 Days)|Unable to attend study visits|2
6356283|NCT03776175|10134192|FG002|Treatment Period (42 Days)|Unable to attend study visits|0
6356284|NCT03776175|10134193|FG003|Treatment Period (42 Days)|Unable to attend study visits|0
6356285|NCT03776175|10134190|FG000|Follow-Up Period (35 Days)|Lost to Follow-up|0
6356286|NCT03776175|10134191|FG001|Follow-Up Period (35 Days)|Lost to Follow-up|0
6356287|NCT03776175|10134192|FG002|Follow-Up Period (35 Days)|Lost to Follow-up|0
6356288|NCT03776175|10134193|FG003|Follow-Up Period (35 Days)|Lost to Follow-up|2
6356289|NCT03771963|10134203|FG000|Overall Study|Lost to Follow-up|22
6356290|NCT03771963|10134203|FG000|Overall Study|Withdrawal of Consent|10
6356291|NCT03771352|10134207|FG000|Overall Study|Screen failure|2
6356292|NCT03771352|10134207|FG000|Overall Study|Withdrawal by Subject|2
6356293|NCT03773796|10134211|FG000|Overall Study|Adverse Event|1
6356294|NCT03773796|10134211|FG000|Overall Study|Withdrawal by Subject|1
6356295|NCT03773796|10134211|FG000|Overall Study|Lack of Efficacy|1
6356296|NCT03781375|10134228|FG000|Double-blind Phase|Adverse Event|0
6356297|NCT03781375|10134229|FG001|Double-blind Phase|Adverse Event|1
6356298|NCT03781375|10134228|FG000|Double-blind Phase|Lack of Response|6
6356299|NCT03781375|10134229|FG001|Double-blind Phase|Lack of Response|2
6356300|NCT03781375|10134228|FG000|Double-blind Phase|Other|1
6356301|NCT03781375|10134229|FG001|Double-blind Phase|Other|3
6356302|NCT03781375|10134228|FG000|Open-label Phase|Protocol Issues|0
6356303|NCT03781375|10134229|FG001|Open-label Phase|Protocol Issues|1
6356304|NCT03781375|10134228|FG000|Open-label Phase|Suboptimal Clinical Response|1
6356305|NCT03781375|10134229|FG001|Open-label Phase|Suboptimal Clinical Response|0
6356306|NCT03781375|10134228|FG000|Open-label Phase|Other|2
6356307|NCT03781375|10134229|FG001|Open-label Phase|Other|2
6356308|NCT03781336|10134238|FG000|Overall Study|Withdrawal by Subject|2
6356309|NCT03781336|10134239|FG001|Overall Study|Withdrawal by Subject|2
6356310|NCT03780400|10134245|FG000|Overall Study|Lost to Follow-up|5
6356311|NCT03780400|10134245|FG000|Overall Study|Withdrawal by Subject|2
6356312|NCT03779503|10134258|FG000|First Intervention|Adverse Event|0
6356313|NCT03779503|10134259|FG001|First Intervention|Adverse Event|1
6356314|NCT03779503|10134258|FG000|First Intervention|Withdrawal by Subject|1
6356315|NCT03779503|10134259|FG001|First Intervention|Withdrawal by Subject|0
6356316|NCT03777059|10134293|FG000|DB Treatment Period (Up to Week 12)|Adverse Event|6
6356317|NCT03777059|10134294|FG001|DB Treatment Period (Up to Week 12)|Adverse Event|9
6356318|NCT03777059|10134295|FG002|DB Treatment Period (Up to Week 12)|Adverse Event|4
6356319|NCT03777059|10134296|FG003|DB Treatment Period (Up to Week 12)|Adverse Event|6
6356320|NCT03777059|10134293|FG000|DB Treatment Period (Up to Week 12)|Lack of Efficacy|1
6356321|NCT03777059|10134294|FG001|DB Treatment Period (Up to Week 12)|Lack of Efficacy|0
6356322|NCT03777059|10134295|FG002|DB Treatment Period (Up to Week 12)|Lack of Efficacy|0
6356323|NCT03777059|10134296|FG003|DB Treatment Period (Up to Week 12)|Lack of Efficacy|1
6356324|NCT03777059|10134293|FG000|DB Treatment Period (Up to Week 12)|Withdrawal by Subject|8
6356325|NCT03777059|10134294|FG001|DB Treatment Period (Up to Week 12)|Withdrawal by Subject|9
6356326|NCT03777059|10134295|FG002|DB Treatment Period (Up to Week 12)|Withdrawal by Subject|8
6356327|NCT03777059|10134296|FG003|DB Treatment Period (Up to Week 12)|Withdrawal by Subject|10
6356328|NCT03777059|10134293|FG000|DB Treatment Period (Up to Week 12)|Lost to Follow-up|3
6356329|NCT03777059|10134294|FG001|DB Treatment Period (Up to Week 12)|Lost to Follow-up|3
6356330|NCT03777059|10134295|FG002|DB Treatment Period (Up to Week 12)|Lost to Follow-up|4
6356331|NCT03777059|10134296|FG003|DB Treatment Period (Up to Week 12)|Lost to Follow-up|5
6356332|NCT03777059|10134293|FG000|DB Treatment Period (Up to Week 12)|Pregnancy|0
6356333|NCT03777059|10134294|FG001|DB Treatment Period (Up to Week 12)|Pregnancy|1
6356334|NCT03777059|10134295|FG002|DB Treatment Period (Up to Week 12)|Pregnancy|0
6356335|NCT03777059|10134296|FG003|DB Treatment Period (Up to Week 12)|Pregnancy|0
6356336|NCT03777059|10134293|FG000|DB Treatment Period (Up to Week 12)|Protocol Deviation|4
6356337|NCT03777059|10134294|FG001|DB Treatment Period (Up to Week 12)|Protocol Deviation|5
6356338|NCT03777059|10134295|FG002|DB Treatment Period (Up to Week 12)|Protocol Deviation|7
6356339|NCT03777059|10134296|FG003|DB Treatment Period (Up to Week 12)|Protocol Deviation|8
6356340|NCT03777059|10134293|FG000|DB Treatment Period (Up to Week 12)|Reason Not Specified|0
6356341|NCT03777059|10134294|FG001|DB Treatment Period (Up to Week 12)|Reason Not Specified|2
6356342|NCT03777059|10134295|FG002|DB Treatment Period (Up to Week 12)|Reason Not Specified|0
6356343|NCT03777059|10134296|FG003|DB Treatment Period (Up to Week 12)|Reason Not Specified|1
6356344|NCT03777059|10134293|FG000|Follow-Up Period (Weeks 12 to 16)|Withdrawal by Subject|5
6356345|NCT03777059|10134294|FG001|Follow-Up Period (Weeks 12 to 16)|Withdrawal by Subject|3
6356346|NCT03777059|10134295|FG002|Follow-Up Period (Weeks 12 to 16)|Withdrawal by Subject|4
6356347|NCT03777059|10134296|FG003|Follow-Up Period (Weeks 12 to 16)|Withdrawal by Subject|5
6356348|NCT03777059|10134293|FG000|Follow-Up Period (Weeks 12 to 16)|Lost to Follow-up|0
6356349|NCT03777059|10134294|FG001|Follow-Up Period (Weeks 12 to 16)|Lost to Follow-up|1
6356350|NCT03777059|10134295|FG002|Follow-Up Period (Weeks 12 to 16)|Lost to Follow-up|0
6356351|NCT03777059|10134296|FG003|Follow-Up Period (Weeks 12 to 16)|Lost to Follow-up|3
6356352|NCT03777059|10134293|FG000|Follow-Up Period (Weeks 12 to 16)|Protocol Deviation|0
6356353|NCT03777059|10134294|FG001|Follow-Up Period (Weeks 12 to 16)|Protocol Deviation|1
6356354|NCT03777059|10134295|FG002|Follow-Up Period (Weeks 12 to 16)|Protocol Deviation|1
6356355|NCT03777059|10134296|FG003|Follow-Up Period (Weeks 12 to 16)|Protocol Deviation|0
6356356|NCT03777059|10134293|FG000|Follow-Up Period (Weeks 12 to 16)|Reason Not Specified|0
6356357|NCT03777059|10134294|FG001|Follow-Up Period (Weeks 12 to 16)|Reason Not Specified|0
6356358|NCT03777059|10134295|FG002|Follow-Up Period (Weeks 12 to 16)|Reason Not Specified|1
6356359|NCT03777059|10134296|FG003|Follow-Up Period (Weeks 12 to 16)|Reason Not Specified|1
6356360|NCT03772522|10134308|FG000|Pre-intervention|Withdrawal by Subject|3
6356361|NCT03772522|10134309|FG001|Pre-intervention|Withdrawal by Subject|4
6356362|NCT03772522|10134308|FG000|Intervention|Withdrawal by Subject|1
6356363|NCT03772522|10134309|FG001|Intervention|Withdrawal by Subject|0
6356364|NCT03772522|10134308|FG000|Post-intervention Follow-up|Lost to Follow-up|1
6356365|NCT03772522|10134309|FG001|Post-intervention Follow-up|Lost to Follow-up|0
6356366|NCT03772327|10134321|FG000|Overall Study|Lost to Follow-up|3
6356367|NCT03772327|10134322|FG001|Overall Study|Lost to Follow-up|4
6356368|NCT03772327|10134321|FG000|Overall Study|Withdrawal by Subject|2
6356369|NCT03772327|10134322|FG001|Overall Study|Withdrawal by Subject|3
6356370|NCT03774576|10134332|FG000|Period 2|Adverse Event|1
6356371|NCT03772041|10134360|FG000|Overall Study|Adverse Event|8
6356372|NCT03772041|10134361|FG001|Overall Study|Adverse Event|3
6356373|NCT03772041|10134360|FG000|Overall Study|Withdrawal by Subject|0
6356374|NCT03772041|10134361|FG001|Overall Study|Withdrawal by Subject|2
6356375|NCT03772041|10134360|FG000|Overall Study|Protocol Violation|4
6356376|NCT03772041|10134361|FG001|Overall Study|Protocol Violation|2
6356377|NCT03772041|10134360|FG000|Overall Study|Physician Decision|2
6356378|NCT03772041|10134361|FG001|Overall Study|Physician Decision|3
6356379|NCT03775681|10134367|FG000|Overall Study|Physician Decision|3
6356380|NCT03774823|10134373|FG000|Overall Study|Withdrawal by Subject|1
6356381|NCT03774823|10134374|FG001|Overall Study|Withdrawal by Subject|1
6356382|NCT03774433|10134389|FG000|Overall Study|Participants who completed less than 12 EMAs are not included in the final analysis|14
6356383|NCT03769896|10134412|FG000|Open-label Phase|Lack of Efficacy|5
6356384|NCT03769896|10134413|FG001|Open-label Phase|Lack of Efficacy|0
6356385|NCT03769896|10134412|FG000|Open-label Phase|Adverse Event|3
6356386|NCT03769896|10134413|FG001|Open-label Phase|Adverse Event|0
6356387|NCT03769896|10134412|FG000|Open-label Phase|Withdrawal by Subject|1
6356388|NCT03769896|10134413|FG001|Open-label Phase|Withdrawal by Subject|0
6356389|NCT03769649|10134420|FG000|Overall Study|Lost to Follow-up|4
6356390|NCT03768726|10134434|FG000|Treatment Phase|Adverse Event|2
6356391|NCT03768726|10134435|FG001|Treatment Phase|Adverse Event|2
6356392|NCT03768726|10134434|FG000|Treatment Phase|Lost to Follow-up|1
6356393|NCT03768726|10134435|FG001|Treatment Phase|Lost to Follow-up|0
6356394|NCT03768726|10134434|FG000|Treatment Phase|Withdrawal By Parent/Guardian|2
6356395|NCT03768726|10134435|FG001|Treatment Phase|Withdrawal By Parent/Guardian|0
6356396|NCT03768726|10134434|FG000|Treatment Phase|Withdrawal by Subject|3
6356397|NCT03768726|10134435|FG001|Treatment Phase|Withdrawal by Subject|1
6356398|NCT03768726|10134434|FG000|Follow-Up|Adverse Event|2
6356399|NCT03768726|10134435|FG001|Follow-Up|Adverse Event|2
6356400|NCT03768726|10134434|FG000|Follow-Up|Withdrawal By Parent/Guardian|1
6356401|NCT03768726|10134435|FG001|Follow-Up|Withdrawal By Parent/Guardian|1
6356402|NCT03768726|10134434|FG000|Follow-Up|Withdrawal by Subject|2
6356403|NCT03768726|10134435|FG001|Follow-Up|Withdrawal by Subject|0
6356404|NCT03768726|10134434|FG000|Follow-Up|Other|1
6356405|NCT03768726|10134435|FG001|Follow-Up|Other|0
6356406|NCT03768206|10134443|FG000|Overall Study|Lost to Follow-up|2
6356407|NCT03768206|10134444|FG001|Overall Study|Lost to Follow-up|1
6356408|NCT03768206|10134443|FG000|Overall Study|Withdrawal by Subject|0
6356409|NCT03768206|10134444|FG001|Overall Study|Withdrawal by Subject|1
6356410|NCT03767894|10134451|FG000|Overall Study|Withdrawal by Subject|1
6356411|NCT03766646|10134484|FG000|Overall Study|Withdrawal by Subject|1
6356412|NCT03766646|10134485|FG001|Overall Study|Withdrawal by Subject|0
6356413|NCT03766646|10134484|FG000|Overall Study|Protocol Violation|0
6356414|NCT03766646|10134485|FG001|Overall Study|Protocol Violation|3
6356415|NCT03765164|10134557|FG000|Pre-intervention|Withdrawal by Subject|5
6356416|NCT03765164|10134558|FG001|Pre-intervention|Withdrawal by Subject|6
6356417|NCT03765138|10134564|FG000|Overall Study|Lost to Follow-up|1
6356418|NCT03762681|10134632|FG000|Part 1|Withdrawal by Subject|0
6356419|NCT03762681|10134633|FG001|Part 1|Withdrawal by Subject|0
6356420|NCT03762681|10134634|FG002|Part 1|Withdrawal by Subject|0
6356421|NCT03762681|10134635|FG003|Part 1|Withdrawal by Subject|1
6356422|NCT03762681|10134636|FG004|Part 1|Withdrawal by Subject|0
6356423|NCT03762681|10134637|FG005|Part 1|Withdrawal by Subject|0
6356424|NCT03762681|10134638|FG006|Part 1|Withdrawal by Subject|0
6356425|NCT03762681|10134639|FG007|Part 1|Withdrawal by Subject|0
6356426|NCT03762681|10134632|FG000|Part 2a|Pandemic Travel Restrictions|0
6356427|NCT03762681|10134633|FG001|Part 2a|Pandemic Travel Restrictions|0
6356428|NCT03762681|10134634|FG002|Part 2a|Pandemic Travel Restrictions|0
6356429|NCT03762681|10134635|FG003|Part 2a|Pandemic Travel Restrictions|0
6356430|NCT03762681|10134636|FG004|Part 2a|Pandemic Travel Restrictions|0
6356431|NCT03762681|10134637|FG005|Part 2a|Pandemic Travel Restrictions|0
6356432|NCT03762681|10134638|FG006|Part 2a|Pandemic Travel Restrictions|0
6356433|NCT03762681|10134639|FG007|Part 2a|Pandemic Travel Restrictions|1
6356434|NCT03762668|10134668|FG000|Period 1, First Week of Wear|Withdrawal by Subject|0
6356435|NCT03762668|10134669|FG001|Period 1, First Week of Wear|Withdrawal by Subject|1
6356436|NCT03762616|10134675|FG000|Overall Study|Protocol Violation|2
6356437|NCT03762200|10134690|FG000|Overall Study|Death|2
6356438|NCT03761147|10134705|FG000|Overall Study|Withdrawal by Subject|6
6356439|NCT03761147|10134706|FG001|Overall Study|Withdrawal by Subject|1
6356440|NCT03761147|10134705|FG000|Overall Study|Adverse Event|1
6356441|NCT03761147|10134706|FG001|Overall Study|Adverse Event|3
6356442|NCT03760510|10134820|FG000|Overall Study|Not ventilated for 24 hours|105
6356443|NCT03760510|10134821|FG001|Overall Study|Not ventilated for 24 hours|97
6356444|NCT03760250|10134827|FG000|Overall Study|Withdrawal by Subject|1
6356445|NCT03760250|10134827|FG000|Overall Study|Physician Decision|1
6356446|NCT03759600|10134831|FG000|Overall Study|Ongoing at Data Cut-off|16
6356447|NCT03759600|10134831|FG000|Overall Study|Adverse Event|1
6356448|NCT03759600|10134831|FG000|Overall Study|Progressive Disease|3
6356449|NCT03759340|10134835|FG000|Overall Study|Adverse Event|2
6356450|NCT03759340|10134835|FG000|Overall Study|Lost to Follow-up|1
6356451|NCT03759340|10134835|FG000|Overall Study|Withdrawal by Subject|15
6356452|NCT03759340|10134835|FG000|Overall Study|Study Terminated by Sponsor|38
6356453|NCT03757988|10134858|FG000|Overall Study|Withdrawal by Subject|1
6356454|NCT03757234|10134879|FG000|Overall Study|Adverse Event|0
6356455|NCT03757234|10134880|FG001|Overall Study|Adverse Event|0
6356456|NCT03757234|10134881|FG002|Overall Study|Adverse Event|0
6356457|NCT03757234|10134882|FG003|Overall Study|Adverse Event|0
6356458|NCT03757234|10134883|FG004|Overall Study|Adverse Event|1
6356459|NCT03757234|10134879|FG000|Overall Study|Lost to Follow-up|1
6356460|NCT03757234|10134880|FG001|Overall Study|Lost to Follow-up|0
6356461|NCT03757234|10134881|FG002|Overall Study|Lost to Follow-up|0
6356462|NCT03757234|10134882|FG003|Overall Study|Lost to Follow-up|0
6356463|NCT03757234|10134883|FG004|Overall Study|Lost to Follow-up|1
6356464|NCT03757234|10134879|FG000|Overall Study|Withdrawal by Subject|1
6356465|NCT03757234|10134880|FG001|Overall Study|Withdrawal by Subject|1
6356466|NCT03757234|10134881|FG002|Overall Study|Withdrawal by Subject|0
6356467|NCT03757234|10134882|FG003|Overall Study|Withdrawal by Subject|1
6356468|NCT03757234|10134883|FG004|Overall Study|Withdrawal by Subject|2
6356469|NCT03757234|10134879|FG000|Overall Study|Other|1
6356470|NCT03757234|10134880|FG001|Overall Study|Other|1
6356471|NCT03757234|10134881|FG002|Overall Study|Other|0
6356472|NCT03757234|10134882|FG003|Overall Study|Other|0
6356473|NCT03757234|10134883|FG004|Overall Study|Other|0
6356474|NCT03756883|10134911|FG000|Overall Study|Adverse Event|2
6356475|NCT03756883|10134912|FG001|Overall Study|Adverse Event|2
6356476|NCT03756883|10134913|FG002|Overall Study|Adverse Event|2
6356477|NCT03756883|10134911|FG000|Overall Study|Lack of Efficacy|0
6356478|NCT03756883|10134912|FG001|Overall Study|Lack of Efficacy|1
6356479|NCT03756883|10134913|FG002|Overall Study|Lack of Efficacy|2
6356480|NCT03756883|10134911|FG000|Overall Study|Lost to Follow-up|3
6356481|NCT03756883|10134912|FG001|Overall Study|Lost to Follow-up|3
6356482|NCT03756883|10134913|FG002|Overall Study|Lost to Follow-up|0
6356483|NCT03756883|10134911|FG000|Overall Study|Protocol Violation|2
6356484|NCT03756883|10134912|FG001|Overall Study|Protocol Violation|0
6356485|NCT03756883|10134913|FG002|Overall Study|Protocol Violation|1
6356486|NCT03756883|10134911|FG000|Overall Study|Significant Worsening of Condition requiring Therapy|0
6083883|NCT00639678|9692684|FG001|Overall Study|Lack of Compliance|0
6083884|NCT00639678|9692685|FG002|Overall Study|Lack of Compliance|1
6083885|NCT00639678|9692686|FG003|Overall Study|Lack of Compliance|0
6083886|NCT00639769|9692702|FG000|Overall Study|Death|2
6356487|NCT03756883|10134912|FG001|Overall Study|Significant Worsening of Condition requiring Therapy|0
6356488|NCT03756883|10134913|FG002|Overall Study|Significant Worsening of Condition requiring Therapy|2
6356489|NCT03756883|10134911|FG000|Overall Study|Withdrawal by Subject|4
6356490|NCT03756883|10134912|FG001|Overall Study|Withdrawal by Subject|1
6356491|NCT03756883|10134913|FG002|Overall Study|Withdrawal by Subject|0
6356492|NCT03756883|10134911|FG000|Overall Study|Other Reasons|2
6356493|NCT03756883|10134912|FG001|Overall Study|Other Reasons|4
6083887|NCT00639769|9692702|FG000|Overall Study|Adverse Event|7
6356494|NCT03756883|10134913|FG002|Overall Study|Other Reasons|0
6356495|NCT03756285|10134932|FG000|Overall Study|Lost to Follow-up|0
6356496|NCT03756285|10134933|FG001|Overall Study|Lost to Follow-up|1
6170278|NCT01252186|9816506|FG002|Overall Study|Sponsor Request|0
6170279|NCT01252186|9816504|FG000|Overall Study|Lost to Follow-up|10
6356497|NCT03756285|10134932|FG000|Overall Study|Study discontinued due to Other (Protocol deviation:subject meets exclusion criteria 20.)|0
6356498|NCT03756285|10134933|FG001|Overall Study|Study discontinued due to Other (Protocol deviation:subject meets exclusion criteria 20.)|1
6356499|NCT03756285|10134932|FG000|Overall Study|Study discontinued due to Other (Dosing discontinued due to COVID-19)|3
6356500|NCT03756285|10134933|FG001|Overall Study|Study discontinued due to Other (Dosing discontinued due to COVID-19)|3
6356501|NCT03756129|10134946|FG000|Overall Study|Adverse Event|1
6356502|NCT03756129|10134947|FG001|Overall Study|Adverse Event|1
6356503|NCT03756129|10134948|FG002|Overall Study|Adverse Event|0
6356504|NCT03756129|10134949|FG003|Overall Study|Adverse Event|2
6356505|NCT03756129|10134950|FG004|Overall Study|Adverse Event|0
6356506|NCT03756129|10134951|FG005|Overall Study|Adverse Event|0
6356507|NCT03756129|10134946|FG000|Overall Study|Withdrawal by Subject|2
6356508|NCT03756129|10134947|FG001|Overall Study|Withdrawal by Subject|1
6356509|NCT03756129|10134948|FG002|Overall Study|Withdrawal by Subject|3
6356510|NCT03756129|10134949|FG003|Overall Study|Withdrawal by Subject|1
6356511|NCT03756129|10134950|FG004|Overall Study|Withdrawal by Subject|1
6356512|NCT03756129|10134951|FG005|Overall Study|Withdrawal by Subject|3
6356513|NCT03756129|10134946|FG000|Overall Study|Lost to Follow-up|0
6356514|NCT03756129|10134947|FG001|Overall Study|Lost to Follow-up|0
6356515|NCT03756129|10134948|FG002|Overall Study|Lost to Follow-up|0
6356516|NCT03756129|10134949|FG003|Overall Study|Lost to Follow-up|0
6356517|NCT03756129|10134950|FG004|Overall Study|Lost to Follow-up|0
6356518|NCT03756129|10134951|FG005|Overall Study|Lost to Follow-up|1
6356519|NCT03756129|10134946|FG000|Overall Study|Physician Decision|0
6356520|NCT03756129|10134947|FG001|Overall Study|Physician Decision|0
6356521|NCT03756129|10134948|FG002|Overall Study|Physician Decision|0
6356522|NCT03756129|10134949|FG003|Overall Study|Physician Decision|0
6356523|NCT03756129|10134950|FG004|Overall Study|Physician Decision|0
6356524|NCT03756129|10134951|FG005|Overall Study|Physician Decision|1
6170280|NCT01252186|9816505|FG001|Overall Study|Lost to Follow-up|10
6170281|NCT01252186|9816506|FG002|Overall Study|Lost to Follow-up|11
6170282|NCT01252186|9816504|FG000|Overall Study|Other - Miscellaneous Reasons|5
6170283|NCT01252186|9816505|FG001|Overall Study|Other - Miscellaneous Reasons|5
6170284|NCT01252186|9816506|FG002|Overall Study|Other - Miscellaneous Reasons|7
6170285|NCT01252238|9816517|FG000|Overall Study|Sponsor terminated study|4
6170286|NCT01252238|9816518|FG001|Overall Study|Sponsor terminated study|4
6170287|NCT01252238|9816519|FG002|Overall Study|Sponsor terminated study|4
6170288|NCT01252251|9816530|FG000|Overall Study|Withdrawal by Subject|1
6170289|NCT01252290|9816539|FG000|Overall Study|Withdrawal by Subject|1
6356525|NCT03755882|10134987|FG000|Period 1|Protocol Violation|1
6356526|NCT03755882|10134988|FG001|Period 1|Protocol Violation|0
6356527|NCT03755882|10134987|FG000|Period 1|Unsatisfactory Lens Fitting Test Article|3
6356528|NCT03755882|10134988|FG001|Period 1|Unsatisfactory Lens Fitting Test Article|0
6356529|NCT03755661|10134996|FG000|Overall Study|Lost to Follow-up|1
6356530|NCT03755661|10134997|FG001|Overall Study|Lost to Follow-up|0
6356531|NCT03754582|10135003|FG000|Treatment Phase|Adverse Event|0
6356532|NCT03754582|10135004|FG001|Treatment Phase|Adverse Event|1
6356533|NCT03754582|10135005|FG002|Treatment Phase|Adverse Event|0
6356534|NCT03754582|10135003|FG000|Follow-up Phase|Other|0
6356535|NCT03754582|10135004|FG001|Follow-up Phase|Other|0
6356536|NCT03754582|10135005|FG002|Follow-up Phase|Other|1
6356537|NCT03752528|10135038|FG000|Part A|Lost to Follow-up|1
6356538|NCT03752528|10135038|FG000|Part A|Protocol Violation|1
6356539|NCT03752528|10135038|FG000|Part B|Protocol Violation|1
6356540|NCT03752528|10135038|FG000|Part B|Study terminated by sponsor|3
6356541|NCT03752151|10135045|FG000|Overall Study|Withdrawal by Subject|1
6356542|NCT03752151|10135045|FG000|Overall Study|Protocol Violation|1
6356543|NCT03751657|10135052|FG000|Overall Study|Physician Decision|0
6356544|NCT03751657|10135053|FG001|Overall Study|Physician Decision|1
6356545|NCT03751657|10135052|FG000|Overall Study|Withdrawal by Subject|1
6356546|NCT03751657|10135053|FG001|Overall Study|Withdrawal by Subject|1
6356547|NCT03751657|10135052|FG000|Overall Study|Lost to Follow-up|2
6356548|NCT03751657|10135053|FG001|Overall Study|Lost to Follow-up|1
6356549|NCT03751280|10135061|FG000|Overall Study|Adverse Event|0
6356550|NCT03751280|10135062|FG001|Overall Study|Adverse Event|1
6356551|NCT03751280|10135061|FG000|Overall Study|Lost to Follow-up|3
6356552|NCT03751280|10135062|FG001|Overall Study|Lost to Follow-up|5
6356553|NCT03751280|10135061|FG000|Overall Study|Physician Decision|0
6356554|NCT03751280|10135062|FG001|Overall Study|Physician Decision|2
6356555|NCT03751280|10135061|FG000|Overall Study|Protocol Violation|0
6356556|NCT03751280|10135062|FG001|Overall Study|Protocol Violation|2
6356557|NCT03751280|10135061|FG000|Overall Study|Withdrawal by Subject|5
6356558|NCT03751280|10135062|FG001|Overall Study|Withdrawal by Subject|2
6356559|NCT03751020|10135072|FG000|Overall Study|Withdrawal by Subject|2
6356560|NCT03751020|10135073|FG001|Overall Study|Withdrawal by Subject|0
6356561|NCT03751020|10135074|FG002|Overall Study|Withdrawal by Subject|0
6356562|NCT03751020|10135072|FG000|Overall Study|Lost to Follow-up|7
6356563|NCT03751020|10135073|FG001|Overall Study|Lost to Follow-up|4
6356564|NCT03751020|10135074|FG002|Overall Study|Lost to Follow-up|10
6356565|NCT03750955|10135084|FG000|Hygiene Phase of 2 Weeks|Withdrawal by Subject|2
6356566|NCT03750955|10135085|FG001|Hygiene Phase of 2 Weeks|Withdrawal by Subject|2
6356567|NCT03750955|10135084|FG000|Hygiene Phase of 2 Weeks|Not eligible at Baseline (start of gingivitis induction phase)|1
6356568|NCT03750955|10135085|FG001|Hygiene Phase of 2 Weeks|Not eligible at Baseline (start of gingivitis induction phase)|1
6356569|NCT03750695|10135093|FG000|Overall Study|Lost to Follow-up|0
6356570|NCT03750695|10135094|FG001|Overall Study|Lost to Follow-up|1
6356571|NCT03748706|10135202|FG000|Overall Study|Lost to Follow-up|1
6356572|NCT03746405|10135230|FG000|Overall Study|Withdrawal by Subject|3
6356573|NCT03746405|10135231|FG001|Overall Study|Withdrawal by Subject|0
6356574|NCT03746405|10135230|FG000|Overall Study|technical difficulties|0
6356575|NCT03746405|10135231|FG001|Overall Study|technical difficulties|2
6356576|NCT03745937|10135241|FG000|Overall Study|Withdrawal by Subject|0
6356577|NCT03745937|10135242|FG001|Overall Study|Withdrawal by Subject|0
6356578|NCT03745937|10135243|FG002|Overall Study|Withdrawal by Subject|0
6356579|NCT03745937|10135244|FG003|Overall Study|Withdrawal by Subject|1
6356580|NCT03745937|10135241|FG000|Overall Study|Not-specifed|0
6356581|NCT03745937|10135242|FG001|Overall Study|Not-specifed|1
6356582|NCT03745937|10135243|FG002|Overall Study|Not-specifed|0
6356583|NCT03745937|10135244|FG003|Overall Study|Not-specifed|1
6356584|NCT03745222|10135258|FG000|Overall Study|Withdrawal by Subject|0
6356585|NCT03745222|10135259|FG001|Overall Study|Withdrawal by Subject|1
6356586|NCT03745222|10135260|FG002|Overall Study|Withdrawal by Subject|0
6356587|NCT03743038|10135295|FG000|Overall Study|Physician Decision|1
6356588|NCT03742271|10135318|FG000|Overall Study|Unsatisfactory Visual Response|1
6356589|NCT03742271|10135318|FG000|Overall Study|Withdrawal by Subject|3
6356590|NCT03742271|10135318|FG000|Overall Study|Lost to Follow-up|4
6356591|NCT03742271|10135318|FG000|Overall Study|Failed Insertion & removal|3
6356592|NCT03742271|10135318|FG000|Overall Study|Protocol Violation|1
6356593|NCT03741062|10135353|FG000|Overall Study|Protocol Violation|1
6356594|NCT03741062|10135354|FG001|Overall Study|Protocol Violation|0
6356595|NCT03739866|10135385|FG000|Overall Study|Lost to Follow-up|0
6356596|NCT03739866|10135386|FG001|Overall Study|Lost to Follow-up|0
6356597|NCT03739866|10135387|FG002|Overall Study|Lost to Follow-up|0
6356598|NCT03739866|10135388|FG003|Overall Study|Lost to Follow-up|1
6356599|NCT03739866|10135389|FG004|Overall Study|Lost to Follow-up|0
6356600|NCT03739866|10135390|FG005|Overall Study|Lost to Follow-up|0
6356601|NCT03739866|10135391|FG006|Overall Study|Lost to Follow-up|0
6356602|NCT03739866|10135392|FG007|Overall Study|Lost to Follow-up|0
6356603|NCT03739866|10135385|FG000|Overall Study|Enrolled but not treated|0
6356604|NCT03739866|10135386|FG001|Overall Study|Enrolled but not treated|0
6356605|NCT03739866|10135387|FG002|Overall Study|Enrolled but not treated|1
6356606|NCT03739866|10135388|FG003|Overall Study|Enrolled but not treated|0
6356607|NCT03739866|10135389|FG004|Overall Study|Enrolled but not treated|1
6356608|NCT03739866|10135390|FG005|Overall Study|Enrolled but not treated|0
6356609|NCT03739866|10135391|FG006|Overall Study|Enrolled but not treated|0
6356610|NCT03739866|10135392|FG007|Overall Study|Enrolled but not treated|0
6356611|NCT03739528|10135420|FG000|Overall Study|Not treated|8
6356612|NCT03739528|10135421|FG001|Overall Study|Not treated|12
6356613|NCT03739528|10135420|FG000|Overall Study|Treatment and study discontinued|6
6356614|NCT03739528|10135421|FG001|Overall Study|Treatment and study discontinued|2
6356615|NCT03739528|10135420|FG000|Overall Study|Treatment discontinued + study completed|1
6356616|NCT03739528|10135421|FG001|Overall Study|Treatment discontinued + study completed|3
6356617|NCT03739242|10135432|FG000|Overall Study|Withdrawal by Subject|1
6356618|NCT03739242|10135433|FG001|Overall Study|Withdrawal by Subject|1
6356619|NCT03739242|10135432|FG000|Overall Study|Protocol Violation|0
6356620|NCT03739242|10135433|FG001|Overall Study|Protocol Violation|1
6356621|NCT03738865|10135441|FG000|Overall Study|Withdrawal by Subject|3
6356622|NCT03738865|10135442|FG001|Overall Study|Withdrawal by Subject|3
6356623|NCT03738865|10135441|FG000|Overall Study|Adverse Event|2
6356624|NCT03738865|10135442|FG001|Overall Study|Adverse Event|0
6356625|NCT03738865|10135441|FG000|Overall Study|Physician Decision|0
6356626|NCT03738865|10135442|FG001|Overall Study|Physician Decision|1
6356627|NCT03738475|10135459|FG000|Overall Study|Participant Non-Compliance|1
6356628|NCT03738475|10135460|FG001|Overall Study|Participant Non-Compliance|0
6356629|NCT03738241|10135476|FG000|Overall Study|Withdrawal by Subject|0
6356630|NCT03738241|10135477|FG001|Overall Study|Withdrawal by Subject|0
6356631|NCT03738241|10135478|FG002|Overall Study|Withdrawal by Subject|0
6356632|NCT03738241|10135479|FG003|Overall Study|Withdrawal by Subject|0
6356633|NCT03738241|10135480|FG004|Overall Study|Withdrawal by Subject|0
6356634|NCT03738241|10135481|FG005|Overall Study|Withdrawal by Subject|0
6356635|NCT03738241|10135482|FG006|Overall Study|Withdrawal by Subject|0
6356636|NCT03738241|10135483|FG007|Overall Study|Withdrawal by Subject|0
6356637|NCT03738241|10135484|FG008|Overall Study|Withdrawal by Subject|0
6356638|NCT03738241|10135485|FG009|Overall Study|Withdrawal by Subject|1
6356639|NCT03738241|10135476|FG000|Overall Study|Physician Decision|0
6356640|NCT03738241|10135477|FG001|Overall Study|Physician Decision|0
6356641|NCT03738241|10135478|FG002|Overall Study|Physician Decision|0
6356642|NCT03738241|10135479|FG003|Overall Study|Physician Decision|0
6356643|NCT03738241|10135480|FG004|Overall Study|Physician Decision|0
6356644|NCT03738241|10135481|FG005|Overall Study|Physician Decision|0
6356645|NCT03738241|10135482|FG006|Overall Study|Physician Decision|0
6356646|NCT03738241|10135483|FG007|Overall Study|Physician Decision|0
6356647|NCT03738241|10135484|FG008|Overall Study|Physician Decision|1
6356648|NCT03738241|10135485|FG009|Overall Study|Physician Decision|0
6356649|NCT03738241|10135476|FG000|Overall Study|Adverse Event|1
6356650|NCT03738241|10135477|FG001|Overall Study|Adverse Event|0
6356651|NCT03738241|10135478|FG002|Overall Study|Adverse Event|0
6356652|NCT03738241|10135479|FG003|Overall Study|Adverse Event|0
6356653|NCT03738241|10135480|FG004|Overall Study|Adverse Event|0
6356654|NCT03738241|10135481|FG005|Overall Study|Adverse Event|0
6356655|NCT03738241|10135482|FG006|Overall Study|Adverse Event|0
6356656|NCT03738241|10135483|FG007|Overall Study|Adverse Event|0
6356657|NCT03738241|10135484|FG008|Overall Study|Adverse Event|0
6356658|NCT03738241|10135485|FG009|Overall Study|Adverse Event|0
6356659|NCT03736785|10135542|FG000|Overall Study|Adverse Event|1
6356660|NCT03736785|10135543|FG001|Overall Study|Adverse Event|1
6356661|NCT03736785|10135544|FG002|Overall Study|Adverse Event|1
6356662|NCT03736785|10135542|FG000|Overall Study|Death|1
6356663|NCT03736785|10135543|FG001|Overall Study|Death|0
6356664|NCT03736785|10135544|FG002|Overall Study|Death|1
6356665|NCT03736785|10135542|FG000|Overall Study|Lost to Follow-up|0
6356666|NCT03736785|10135543|FG001|Overall Study|Lost to Follow-up|2
6356667|NCT03736785|10135544|FG002|Overall Study|Lost to Follow-up|3
6356668|NCT03736785|10135542|FG000|Overall Study|Non compliance with study drug|1
6356669|NCT03736785|10135543|FG001|Overall Study|Non compliance with study drug|1
6356670|NCT03736785|10135544|FG002|Overall Study|Non compliance with study drug|0
6356671|NCT03736785|10135542|FG000|Overall Study|Physician Decision|0
6356672|NCT03736785|10135543|FG001|Overall Study|Physician Decision|1
6356673|NCT03736785|10135544|FG002|Overall Study|Physician Decision|1
6356674|NCT03736785|10135542|FG000|Overall Study|Protocol Violation|1
6356675|NCT03736785|10135543|FG001|Overall Study|Protocol Violation|4
6356676|NCT03736785|10135544|FG002|Overall Study|Protocol Violation|3
6356677|NCT03736785|10135542|FG000|Overall Study|Sponsor Decision|1
6356678|NCT03736785|10135543|FG001|Overall Study|Sponsor Decision|0
6356679|NCT03736785|10135544|FG002|Overall Study|Sponsor Decision|0
6356680|NCT03736785|10135542|FG000|Overall Study|Unknown/Missing data|3
6356681|NCT03736785|10135543|FG001|Overall Study|Unknown/Missing data|2
6083888|NCT00639769|9692702|FG000|Overall Study|Lack of Efficacy|1
6083889|NCT00639769|9692702|FG000|Overall Study|Disease progression|26
6083890|NCT00639769|9692702|FG000|Overall Study|Withdrawal by Subject|4
6356682|NCT03736785|10135544|FG002|Overall Study|Unknown/Missing data|1
6356683|NCT03736785|10135542|FG000|Overall Study|Withdrawal by Subject|9
6356684|NCT03736785|10135543|FG001|Overall Study|Withdrawal by Subject|6
6356685|NCT03736785|10135544|FG002|Overall Study|Withdrawal by Subject|4
6356686|NCT03736031|10135555|FG000|Overall Study|Death|2
6356687|NCT03736031|10135556|FG001|Overall Study|Death|4
6356688|NCT03736031|10135555|FG000|Overall Study|Lost to Follow-up|21
6356689|NCT03736031|10135556|FG001|Overall Study|Lost to Follow-up|2
6356690|NCT03736031|10135555|FG000|Overall Study|Withdrawal by Subject|9
6356691|NCT03736031|10135556|FG001|Overall Study|Withdrawal by Subject|0
6356692|NCT03734991|10135568|FG000|Overall Study|Adverse Event|4
6356693|NCT03734991|10135569|FG001|Overall Study|Adverse Event|0
6356694|NCT03734991|10135568|FG000|Overall Study|Lost to Follow-up|4
6356695|NCT03734991|10135569|FG001|Overall Study|Lost to Follow-up|0
6356696|NCT03734991|10135568|FG000|Overall Study|Physician Decision|0
6356697|NCT03734991|10135569|FG001|Overall Study|Physician Decision|1
6356698|NCT03734991|10135568|FG000|Overall Study|Pregnancy|1
6356699|NCT03734991|10135569|FG001|Overall Study|Pregnancy|0
6356700|NCT03734991|10135568|FG000|Overall Study|Withdrawal by Subject|6
6356701|NCT03734991|10135569|FG001|Overall Study|Withdrawal by Subject|3
6356702|NCT03734991|10135568|FG000|Overall Study|Lack of efficacy and or/use of antifungal therapy|49
6356703|NCT03734991|10135569|FG001|Overall Study|Lack of efficacy and or/use of antifungal therapy|41
6356704|NCT03734991|10135568|FG000|Overall Study|Other|2
6356705|NCT03734991|10135569|FG001|Overall Study|Other|2
6356706|NCT03733899|10135583|FG000|Period 1|Protocol Violation|0
6356707|NCT03733899|10135584|FG001|Period 1|Protocol Violation|0
6356708|NCT03733899|10135585|FG002|Period 1|Protocol Violation|0
6356709|NCT03733899|10135586|FG003|Period 1|Protocol Violation|0
6356710|NCT03733899|10135587|FG004|Period 1|Protocol Violation|0
6356711|NCT03733899|10135588|FG005|Period 1|Protocol Violation|1
6356712|NCT03733899|10135583|FG000|Period 2|Unscuccessful Treatment|0
6356713|NCT03733899|10135584|FG001|Period 2|Unscuccessful Treatment|1
6356714|NCT03733899|10135585|FG002|Period 2|Unscuccessful Treatment|0
6356715|NCT03733899|10135586|FG003|Period 2|Unscuccessful Treatment|0
6356716|NCT03733899|10135587|FG004|Period 2|Unscuccessful Treatment|0
6356717|NCT03733899|10135588|FG005|Period 2|Unscuccessful Treatment|0
6356718|NCT03733899|10135583|FG000|Period 3|Withdrawal by Subject|1
6356719|NCT03733899|10135584|FG001|Period 3|Withdrawal by Subject|0
6356720|NCT03733899|10135585|FG002|Period 3|Withdrawal by Subject|0
6356721|NCT03733899|10135586|FG003|Period 3|Withdrawal by Subject|0
6356722|NCT03733899|10135587|FG004|Period 3|Withdrawal by Subject|0
6356723|NCT03733899|10135588|FG005|Period 3|Withdrawal by Subject|0
6356724|NCT03733470|10135607|FG000|Overall Study|PI Decision|1
6356725|NCT03733470|10135608|FG001|Overall Study|PI Decision|1
6356726|NCT03733301|10135617|FG000|Overall Study|Screen Fail|1
6356727|NCT03733301|10135618|FG001|Overall Study|Screen Fail|0
6356728|NCT03733301|10135619|FG002|Overall Study|Screen Fail|0
6356729|NCT03733301|10135617|FG000|Overall Study|Non-compliance|1
6356730|NCT03733301|10135618|FG001|Overall Study|Non-compliance|0
6356731|NCT03733301|10135619|FG002|Overall Study|Non-compliance|0
6356732|NCT03733301|10135617|FG000|Overall Study|Lack of Efficacy|2
6356733|NCT03733301|10135618|FG001|Overall Study|Lack of Efficacy|3
6356734|NCT03733301|10135619|FG002|Overall Study|Lack of Efficacy|0
6356735|NCT03733301|10135617|FG000|Overall Study|Adverse Event|0
6356736|NCT03733301|10135618|FG001|Overall Study|Adverse Event|1
6356737|NCT03733301|10135619|FG002|Overall Study|Adverse Event|3
6356738|NCT03733301|10135617|FG000|Overall Study|Withdrawal by Subject|3
6356739|NCT03733301|10135618|FG001|Overall Study|Withdrawal by Subject|5
6356740|NCT03733301|10135619|FG002|Overall Study|Withdrawal by Subject|1
6356741|NCT03732638|10135630|FG000|Overall Study|Adverse Event|5
6356742|NCT03732638|10135631|FG001|Overall Study|Adverse Event|2
6356743|NCT03732638|10135630|FG000|Overall Study|Eligibility failure due to baseline laboratory values|8
6083891|NCT00640016|9692714|FG000|Overall Study|Withdrawal by Subject|0
6083892|NCT00640016|9692715|FG001|Overall Study|Withdrawal by Subject|1
6083893|NCT00640016|9692716|FG002|Overall Study|Withdrawal by Subject|0
6083894|NCT00640016|9692717|FG003|Overall Study|Withdrawal by Subject|0
6083895|NCT00640016|9692714|FG000|Overall Study|Study termination|2
6083896|NCT00640016|9692715|FG001|Overall Study|Study termination|1
6083897|NCT00640016|9692716|FG002|Overall Study|Study termination|3
6083898|NCT00640016|9692717|FG003|Overall Study|Study termination|2
6083899|NCT00640016|9692714|FG000|Overall Study|Adverse Event|0
6083900|NCT00640016|9692715|FG001|Overall Study|Adverse Event|0
6356744|NCT03732638|10135631|FG001|Overall Study|Eligibility failure due to baseline laboratory values|13
6356745|NCT03732638|10135630|FG000|Overall Study|Lack of Efficacy|1
6356746|NCT03732638|10135631|FG001|Overall Study|Lack of Efficacy|1
6356747|NCT03732638|10135630|FG000|Overall Study|Lost to Follow-up|19
6356748|NCT03732638|10135631|FG001|Overall Study|Lost to Follow-up|12
6356749|NCT03732638|10135630|FG000|Overall Study|Non-compliance|6
6356750|NCT03732638|10135631|FG001|Overall Study|Non-compliance|5
6356751|NCT03732638|10135630|FG000|Overall Study|Physician Decision|0
6083901|NCT00640016|9692716|FG002|Overall Study|Adverse Event|0
6356752|NCT03732638|10135631|FG001|Overall Study|Physician Decision|1
6356753|NCT03732638|10135630|FG000|Overall Study|Protocol deviation|4
6356754|NCT03732638|10135631|FG001|Overall Study|Protocol deviation|5
6356755|NCT03732638|10135630|FG000|Overall Study|Withdrawal by Subject|11
6356756|NCT03732638|10135631|FG001|Overall Study|Withdrawal by Subject|22
6356757|NCT03732248|10135640|FG000|Overall Study|Withdrawal by Subject|1
6356758|NCT03732248|10135641|FG001|Overall Study|Withdrawal by Subject|0
6356759|NCT03731182|10135649|FG000|Overall Study|Lost to Follow-up|2
6356760|NCT03731182|10135650|FG001|Overall Study|Lost to Follow-up|0
6356761|NCT03731182|10135649|FG000|Overall Study|Physician Decision|1
6083902|NCT00640016|9692717|FG003|Overall Study|Adverse Event|1
6356762|NCT03731182|10135650|FG001|Overall Study|Physician Decision|0
6356763|NCT03731182|10135649|FG000|Overall Study|Withdrawal By Parent/Guardian|2
6356764|NCT03731182|10135650|FG001|Overall Study|Withdrawal By Parent/Guardian|0
6356765|NCT03730961|10135659|FG000|Overall Study|Adverse Event|0
6356766|NCT03730961|10135660|FG001|Overall Study|Adverse Event|1
6356767|NCT03730103|10135676|FG000|Overall Study|Did not meet inclusion criteria|0
6356768|NCT03730103|10135677|FG001|Overall Study|Did not meet inclusion criteria|5
6356769|NCT03728140|10135707|FG000|Overall Study|Abnormal embryo transfer operation|10
6356770|NCT03728140|10135708|FG001|Overall Study|Abnormal embryo transfer operation|7
6356771|NCT03727347|10135727|FG000|Overall Study|Withdrawal by Subject|2
6356772|NCT03727347|10135727|FG000|Overall Study|Lost to Follow-up|1
6356773|NCT03726996|10135740|FG000|Overall Study|Parent's decision|2
6356774|NCT03726996|10135740|FG000|Overall Study|Study early termination|2
6356775|NCT03725852|10135755|FG000|Overall Study|Death|1
6356776|NCT03725852|10135756|FG001|Overall Study|Death|0
6356777|NCT03725852|10135755|FG000|Overall Study|Withdrawal by Subject|1
6356778|NCT03725852|10135756|FG001|Overall Study|Withdrawal by Subject|0
6356779|NCT03725852|10135755|FG000|Overall Study|Travel restrictions due to COVID-19|2
6356780|NCT03725852|10135756|FG001|Overall Study|Travel restrictions due to COVID-19|0
6356781|NCT03725722|10135767|FG000|Overall Study|Lack of Efficacy|2
6356782|NCT03725722|10135768|FG001|Overall Study|Lack of Efficacy|1
6356783|NCT03725722|10135769|FG002|Overall Study|Lack of Efficacy|2
6356784|NCT03725722|10135770|FG003|Overall Study|Lack of Efficacy|0
6356785|NCT03725722|10135771|FG004|Overall Study|Lack of Efficacy|2
6356786|NCT03725722|10135767|FG000|Overall Study|Adverse Event|2
6356787|NCT03725722|10135768|FG001|Overall Study|Adverse Event|2
6356788|NCT03725722|10135769|FG002|Overall Study|Adverse Event|1
6356789|NCT03725722|10135770|FG003|Overall Study|Adverse Event|0
6356790|NCT03725722|10135771|FG004|Overall Study|Adverse Event|6
6356791|NCT03725722|10135767|FG000|Overall Study|Withdrawal by Subject|4
6356792|NCT03725722|10135768|FG001|Overall Study|Withdrawal by Subject|1
6356793|NCT03725722|10135769|FG002|Overall Study|Withdrawal by Subject|0
6356794|NCT03725722|10135770|FG003|Overall Study|Withdrawal by Subject|4
6356795|NCT03725722|10135771|FG004|Overall Study|Withdrawal by Subject|4
6356796|NCT03725722|10135767|FG000|Overall Study|Lost to Follow-up|3
6356797|NCT03725722|10135768|FG001|Overall Study|Lost to Follow-up|1
6356798|NCT03725722|10135769|FG002|Overall Study|Lost to Follow-up|2
6356799|NCT03725722|10135770|FG003|Overall Study|Lost to Follow-up|2
6356800|NCT03725722|10135771|FG004|Overall Study|Lost to Follow-up|1
6356801|NCT03725722|10135767|FG000|Overall Study|Personal reasons|0
6356802|NCT03725722|10135768|FG001|Overall Study|Personal reasons|0
6356803|NCT03725722|10135769|FG002|Overall Study|Personal reasons|1
6356804|NCT03725722|10135770|FG003|Overall Study|Personal reasons|0
6356805|NCT03725722|10135771|FG004|Overall Study|Personal reasons|1
6356806|NCT03725722|10135767|FG000|Overall Study|COVID-19 situation|0
6356807|NCT03725722|10135768|FG001|Overall Study|COVID-19 situation|1
6356808|NCT03725722|10135769|FG002|Overall Study|COVID-19 situation|0
6356809|NCT03725722|10135770|FG003|Overall Study|COVID-19 situation|0
6356810|NCT03725722|10135771|FG004|Overall Study|COVID-19 situation|0
6356811|NCT03725085|10135792|FG000|Overall Study|Lost to Follow-up|2
6356812|NCT03724981|10135808|FG000|First Device|Protocol Violation|1
6356813|NCT03724981|10135809|FG001|First Device|Protocol Violation|1
6356814|NCT03724968|10135819|FG000|Overall Study|Insurance issues|0
6356815|NCT03724968|10135820|FG001|Overall Study|Insurance issues|1
6356816|NCT03724968|10135819|FG000|Overall Study|Study closed|0
6356817|NCT03724968|10135820|FG001|Overall Study|Study closed|1
6170290|NCT01252355|9816546|FG000|Overall Study|Adverse Event|9
6170291|NCT01252355|9816547|FG001|Overall Study|Adverse Event|17
6170292|NCT01252355|9816548|FG002|Overall Study|Adverse Event|22
6170293|NCT01252355|9816546|FG000|Overall Study|Lack of Efficacy|6
6170294|NCT01252355|9816547|FG001|Overall Study|Lack of Efficacy|4
6170295|NCT01252355|9816548|FG002|Overall Study|Lack of Efficacy|2
6170296|NCT01252355|9816546|FG000|Overall Study|Lost to Follow-up|0
6170297|NCT01252355|9816547|FG001|Overall Study|Lost to Follow-up|0
6170298|NCT01252355|9816548|FG002|Overall Study|Lost to Follow-up|1
6170299|NCT01252355|9816546|FG000|Overall Study|Poor Compliance to Protocol|1
6170300|NCT01252355|9816547|FG001|Overall Study|Poor Compliance to Protocol|1
6170301|NCT01252355|9816548|FG002|Overall Study|Poor Compliance to Protocol|1
6170302|NCT01252355|9816546|FG000|Overall Study|Progressive Disease|2
6170303|NCT01252355|9816547|FG001|Overall Study|Progressive Disease|0
6170304|NCT01252355|9816548|FG002|Overall Study|Progressive Disease|0
6170305|NCT01252355|9816546|FG000|Overall Study|Sponsor Early Termination of Study|149
6170306|NCT01252355|9816547|FG001|Overall Study|Sponsor Early Termination of Study|149
6170307|NCT01252355|9816548|FG002|Overall Study|Sponsor Early Termination of Study|146
6170308|NCT01252355|9816546|FG000|Overall Study|Randomized but not Treated|2
6170309|NCT01252355|9816547|FG001|Overall Study|Randomized but not Treated|0
6170310|NCT01252355|9816548|FG002|Overall Study|Randomized but not Treated|0
6170311|NCT01252355|9816546|FG000|Overall Study|Other Than Above|8
6170312|NCT01252355|9816547|FG001|Overall Study|Other Than Above|7
6170313|NCT01252355|9816548|FG002|Overall Study|Other Than Above|7
6170314|NCT01252563|9816556|FG000|Overall Study|Contract Deviation|41
6170315|NCT01252563|9816556|FG000|Overall Study|Centralized Registration Deviation|30
6170316|NCT01252563|9816556|FG000|Overall Study|Lost to Follow-up|161
6170317|NCT01252563|9816556|FG000|Overall Study|No visit after first day of treatment|194
6170318|NCT01252563|9816556|FG000|Overall Study|No drug administration|6
6170319|NCT01252667|9816597|FG000|Overall Study|Transplant aborted post-conditioning|0
6170320|NCT01252667|9816598|FG001|Overall Study|Transplant aborted post-conditioning|0
6356818|NCT03723070|10135884|FG000|Overall Study|Lost to Follow-up|2
6356819|NCT03723070|10135884|FG000|Overall Study|Physician Decision|1
6356820|NCT03723070|10135884|FG000|Overall Study|Ended the study at 1 month follow-up visit as per applicable protocol at that time|6
6356821|NCT03720210|10135888|FG000|Overall Study|Lost to Follow-up|1
6356822|NCT03718143|10135896|FG000|Overall Study|Death|1
6356823|NCT03718143|10135897|FG001|Overall Study|Death|0
6356824|NCT03718143|10135898|FG002|Overall Study|Death|0
6356825|NCT03718143|10135896|FG000|Overall Study|Progression of Disease|1
6356826|NCT03718143|10135897|FG001|Overall Study|Progression of Disease|0
6356827|NCT03718143|10135898|FG002|Overall Study|Progression of Disease|0
6356828|NCT03718143|10135896|FG000|Overall Study|Withdrawal of Informed Consent|1
6356829|NCT03718143|10135897|FG001|Overall Study|Withdrawal of Informed Consent|2
6356830|NCT03718143|10135898|FG002|Overall Study|Withdrawal of Informed Consent|1
6356831|NCT03709576|10135906|FG000|Overall Study|progression prior to enrollment|1
6356832|NCT03704636|10135911|FG000|Overall Study|Inadequate Venous Flow|3
6356833|NCT03694821|10135935|FG000|Overall Study|Study terminated|4
6356834|NCT03694821|10135936|FG001|Overall Study|Study terminated|8
6356835|NCT03694821|10135937|FG002|Overall Study|Study terminated|4
6356836|NCT03686969|10135947|FG000|Overall Study|Study terminated|1
6356837|NCT03686969|10135948|FG001|Overall Study|Study terminated|0
6356838|NCT03682367|10135956|FG000|Overall Study|Protocol Violation|2
6356839|NCT03682367|10135957|FG001|Overall Study|Protocol Violation|1
6356840|NCT03682367|10135956|FG000|Overall Study|Closed Study Early|0
6356841|NCT03682367|10135957|FG001|Overall Study|Closed Study Early|3
6356842|NCT03680911|10135965|FG000|At Home Treatment|Study Termination|3
6356843|NCT03680911|10135966|FG001|At Home Treatment|Study Termination|0
6356844|NCT03680911|10135965|FG000|At Home Treatment|Lost to Follow-up|0
6356845|NCT03680911|10135966|FG001|At Home Treatment|Lost to Follow-up|1
6356846|NCT03680911|10135965|FG000|At Home Treatment|Withdrawal by Subject|0
6356847|NCT03680911|10135966|FG001|At Home Treatment|Withdrawal by Subject|2
6356848|NCT03680911|10135965|FG000|Visit 3 (4 Month Follow up)|Study Termination|0
6356849|NCT03680911|10135966|FG001|Visit 3 (4 Month Follow up)|Study Termination|1
6356850|NCT03656692|10135972|FG000|Overall Study|Worsening of disease activity|2
6356851|NCT03656692|10135972|FG000|Overall Study|Physician Decision|1
6356852|NCT03648983|10135976|FG000|Overall Study|Study was terminated due to PI departure|95
6083903|NCT00640042|9692734|FG000|Enrollment|Did not receive study drug|83
6356853|NCT03643159|10135983|FG000|Overall Study|Adverse Event|1
6356854|NCT03643159|10135983|FG000|Overall Study|Withdrawal by Subject|1
6356855|NCT03630120|10136001|FG000|Overall Study|Disease progression|0
6356856|NCT03630120|10136002|FG001|Overall Study|Disease progression|1
6356857|NCT03630120|10136003|FG002|Overall Study|Disease progression|1
6356858|NCT03630120|10136004|FG003|Overall Study|Disease progression|1
6356859|NCT03615144|10136031|FG000|Overall Study|Participant no longer eligible for this protocol|1
6356860|NCT03615144|10136032|FG001|Overall Study|Participant no longer eligible for this protocol|0
6356861|NCT03605303|10136038|FG000|Period 1|Study Terminated|2
6356862|NCT03605303|10136039|FG001|Period 1|Study Terminated|1
6356863|NCT03600740|10136045|FG000|Overall Study|Surgical plan was altered-subject not eligible|1
6356864|NCT03598140|10136051|FG000|Overall Study|enrolled but didn't start|1
6356865|NCT03598140|10136052|FG001|Overall Study|enrolled but didn't start|0
6356866|NCT03598036|10136060|FG000|Overall Study|Withdrawal by Subject|1
6356867|NCT03598036|10136061|FG001|Overall Study|Withdrawal by Subject|0
6356868|NCT03590743|10136080|FG000|Overall Study|Withdrawal by Subject|0
6356869|NCT03590743|10136081|FG001|Overall Study|Withdrawal by Subject|1
6356870|NCT03580382|10136089|FG000|Overall Study|Early Termination of Study|0
6356871|NCT03580382|10136090|FG001|Overall Study|Early Termination of Study|3
6356872|NCT03571646|10136097|FG000|Overall Study|Adverse Event|1
6356873|NCT03571646|10136098|FG001|Overall Study|Adverse Event|0
6356874|NCT03571646|10136097|FG000|Overall Study|Withdrawal by Subject|1
6356875|NCT03571646|10136098|FG001|Overall Study|Withdrawal by Subject|1
6356876|NCT03543358|10136121|FG000|Overall Study|Death|1
6356877|NCT03543358|10136122|FG001|Overall Study|Death|0
6356878|NCT03543358|10136121|FG000|Overall Study|Disease Progression|1
6356879|NCT03543358|10136122|FG001|Overall Study|Disease Progression|0
6356880|NCT03543358|10136121|FG000|Overall Study|Parent Study Closure|1
6356881|NCT03543358|10136122|FG001|Overall Study|Parent Study Closure|0
6356882|NCT03509207|10136150|FG000|Overall Study|Death|2
6356883|NCT03500341|10136167|FG000|Overall Study|Withdrawn prior to Completion|2
6356884|NCT03500159|10136173|FG000|Overall Study|Study Terminated|2
6356885|NCT03500159|10136174|FG001|Overall Study|Study Terminated|1
6356886|NCT03477903|10136200|FG000|Overall Study|Study Terminated by Sponsor|1
6356887|NCT03469258|10136204|FG000|Overall Study|Upon surgery, did not meet criteria|4
6356888|NCT03466658|10136208|FG000|Overall Study|Withdrawal by Subject|3
6356889|NCT03465891|10136216|FG000|Overall Study|Withdrawal by Subject|0
6356890|NCT03465891|10136217|FG001|Overall Study|Withdrawal by Subject|1
6356891|NCT03465891|10136216|FG000|Overall Study|Disease progression|1
6356892|NCT03465891|10136217|FG001|Overall Study|Disease progression|0
6356893|NCT03387059|10136295|FG000|Overall Study|Study termination|5
6356894|NCT03387059|10136296|FG001|Overall Study|Study termination|4
6356895|NCT03379233|10136313|FG000|Overall Study|Technical issues with Concept 2 inhalers|1
6356896|NCT03379233|10136314|FG001|Overall Study|Technical issues with Concept 2 inhalers|6
6356897|NCT03361228|10136330|FG000|Overall Study|Other|1
6356898|NCT03361228|10136331|FG001|Overall Study|Other|1
6356899|NCT03361228|10136330|FG000|Overall Study|Death|3
6356900|NCT03361228|10136331|FG001|Overall Study|Death|0
6356901|NCT03359174|10136346|FG000|Overall Study|Adverse Event|1
6356902|NCT03348904|10136357|FG000|Overall Study|Administrative reason by the sponsor|0
6356903|NCT03348904|10136358|FG001|Overall Study|Administrative reason by the sponsor|1
6356904|NCT03348904|10136359|FG002|Overall Study|Administrative reason by the sponsor|0
6356905|NCT03345901|10136367|FG000|Overall Study|The study was terminated|18
6356906|NCT03344562|10136374|FG000|Overall Study|Withdrawal by Subject|2
6356907|NCT03344562|10136375|FG001|Overall Study|Withdrawal by Subject|0
6356908|NCT03342638|10136383|FG000|Overall Study|Withdrawal by Subject|1
6356909|NCT03342638|10136384|FG001|Overall Study|Withdrawal by Subject|0
6356910|NCT03342638|10136383|FG000|Overall Study|Physician Decision|0
6356911|NCT03342638|10136384|FG001|Overall Study|Physician Decision|1
6356912|NCT03339401|10136401|FG000|Overall Study|Death|2
6356913|NCT03339401|10136402|FG001|Overall Study|Death|1
6356914|NCT03339401|10136401|FG000|Overall Study|Withdrawal by Subject|2
6356915|NCT03339401|10136402|FG001|Overall Study|Withdrawal by Subject|0
6356916|NCT03339401|10136401|FG000|Overall Study|Study terminated|4
6356917|NCT03339401|10136402|FG001|Overall Study|Study terminated|3
6356918|NCT03339401|10136401|FG000|Overall Study|Investigator Decision|1
6356919|NCT03339401|10136402|FG001|Overall Study|Investigator Decision|0
6356920|NCT03339245|10136410|FG000|Overall Study|Adverse Event|1
6356921|NCT03339245|10136411|FG001|Overall Study|Adverse Event|1
6356922|NCT03339245|10136410|FG000|Overall Study|Withdrawal by Subject|1
6356923|NCT03339245|10136411|FG001|Overall Study|Withdrawal by Subject|0
6356924|NCT03329404|10136423|FG000|Overall Study|The study was suspended.|1
6356925|NCT03329404|10136424|FG001|Overall Study|The study was suspended.|4
6356926|NCT03326869|10136432|FG000|Overall Study|Study data has been lost to natural disa|1
6356927|NCT03326869|10136433|FG001|Overall Study|Study data has been lost to natural disa|1
6356928|NCT03305055|10136458|FG000|Overall Study|Withdrawal by Subject|0
6356929|NCT03305055|10136459|FG001|Overall Study|Withdrawal by Subject|1
6356930|NCT03305055|10136458|FG000|Overall Study|Adverse Event|1
6356931|NCT03305055|10136459|FG001|Overall Study|Adverse Event|1
6356932|NCT03303469|10136465|FG000|Overall Study|Lost to Follow-up|2
6356933|NCT03302247|10136469|FG000|Overall Study|the study has closed prematurely|2
6356934|NCT03302247|10136469|FG000|Overall Study|Death|1
6356935|NCT03300024|10136475|FG000|Overall Study|Physician Decision|4
6356936|NCT03300024|10136476|FG001|Overall Study|Physician Decision|6
6356937|NCT03283709|10136486|FG000|Overall Study|trial terminated|0
6356938|NCT03283709|10136487|FG001|Overall Study|trial terminated|1
6356939|NCT03263806|10136522|FG000|Overall Study|Elevated Troponin (failed screen)|1
6356940|NCT03263806|10136523|FG001|Overall Study|Elevated Troponin (failed screen)|0
6356941|NCT03263806|10136522|FG000|Overall Study|Withdrawal by Subject|0
6356942|NCT03263806|10136523|FG001|Overall Study|Withdrawal by Subject|1
6356943|NCT03263806|10136522|FG000|Overall Study|Study Termination|5
6356944|NCT03263806|10136523|FG001|Overall Study|Study Termination|6
6356945|NCT03261531|10136529|FG000|Overall Study|Withdrawal by Subject|4
6356946|NCT03219372|10136548|FG000|Overall Study|Withdrawal by Subject|1
6356947|NCT03219372|10136549|FG001|Overall Study|Withdrawal by Subject|0
6356948|NCT03217175|10136555|FG000|Overall Study|Physician Decision|4
6356949|NCT03217175|10136556|FG001|Overall Study|Physician Decision|1
6356950|NCT03223662|10136583|FG000|Overall Study|Physician Decision|1
6356951|NCT03223662|10136583|FG000|Overall Study|Study closure|1
6356952|NCT03212144|10136589|FG000|First Sequence (4 Weeks)|Lost to Follow-up|1
6356953|NCT03212144|10136590|FG001|First Sequence (4 Weeks)|Lost to Follow-up|0
6356954|NCT03212144|10136589|FG000|Second Sequence (4 Weeks)|Lost to Follow-up|1
6356955|NCT03212144|10136590|FG001|Second Sequence (4 Weeks)|Lost to Follow-up|1
6356956|NCT03204539|10136606|FG000|Overall Study|Loss of funding|0
6356957|NCT03204539|10136607|FG001|Overall Study|Loss of funding|1
6356958|NCT03206216|10136615|FG000|Overall Study|Withdrawal by Subject|0
6356959|NCT03206216|10136616|FG001|Overall Study|Withdrawal by Subject|1
6356960|NCT03195660|10136622|FG000|Overall Study|The study was terminated|2
6356961|NCT03166618|10136632|FG000|Overall Study|Study was Terminated|0
6356962|NCT03166618|10136633|FG001|Overall Study|Study was Terminated|1
6356963|NCT03169530|10136641|FG000|Overall Study|Study ended by NIH|15
6356964|NCT03169530|10136642|FG001|Overall Study|Study ended by NIH|17
6356965|NCT03151226|10136657|FG000|Overall Study|Withdrawal by Subject|2
6356966|NCT03151226|10136657|FG000|Overall Study|not wear device correctly|1
6356967|NCT03168906|10136672|FG000|Overall Study|Lack of Efficacy|6
6356968|NCT03168906|10136673|FG001|Overall Study|Lack of Efficacy|6
6356969|NCT03178201|10136680|FG000|Overall Study|Off study|5
6356970|NCT03172026|10136686|FG000|Overall Study|Withdrawal by Subject|1
6356971|NCT03172026|10136687|FG001|Overall Study|Withdrawal by Subject|0
6356972|NCT03172026|10136686|FG000|Overall Study|COVID restrictions|1
6356973|NCT03172026|10136687|FG001|Overall Study|COVID restrictions|0
6356974|NCT03152526|10136696|FG000|Overall Study|Withdrawal by Subject|0
6356975|NCT03152526|10136697|FG001|Overall Study|Withdrawal by Subject|1
6356976|NCT03123393|10136732|FG000|Overall Study|Study Terminated by Sponsor|6
6356977|NCT03123393|10136733|FG001|Overall Study|Study Terminated by Sponsor|9
6356978|NCT03123393|10136732|FG000|Overall Study|Withdrawal by Subject|2
6356979|NCT03123393|10136733|FG001|Overall Study|Withdrawal by Subject|1
6356980|NCT03123393|10136732|FG000|Overall Study|Reason not Specified|13
6356981|NCT03123393|10136733|FG001|Overall Study|Reason not Specified|13
6356982|NCT03119662|10136745|FG000|Overall Study|Withdrawal by Subject|0
6356983|NCT03119662|10136746|FG001|Overall Study|Withdrawal by Subject|1
6356984|NCT03120676|10136761|FG000|Overall Study|Not treated|1
6356985|NCT03113071|10136786|FG000|Overall Study|Withdrawal by Subject|1
6356986|NCT03113071|10136787|FG001|Overall Study|Withdrawal by Subject|0
6356987|NCT03110900|10136795|FG000|Overall Study|Sponsor withdrew|1
6356988|NCT03110900|10136796|FG001|Overall Study|Sponsor withdrew|1
6356989|NCT03078868|10136802|FG000|Overall Study|Physician Decision|3
6356990|NCT03065933|10136815|FG000|Overall Study|study terminated|5
6356991|NCT03070002|10136819|FG000|Follow up for 2 Years|Death|1
6356992|NCT03058705|10136823|FG000|Overall Study|Withdrawal by Subject|2
6356993|NCT03058705|10136823|FG000|Overall Study|Physician Decision|2
6356994|NCT03053518|10136845|FG000|Overall Study|Withdrawal by Subject|3
6356995|NCT03053518|10136845|FG000|Overall Study|Lost to Follow-up|2
6356996|NCT03053518|10136845|FG000|Overall Study|Ineligible|5
6356997|NCT03050398|10136849|FG000|Overall Study|Study terminated by sponsor|8
6356998|NCT03029832|10136867|FG000|Overall Study|Safety Follow-Up Completed|2
6356999|NCT03029832|10136868|FG001|Overall Study|Safety Follow-Up Completed|0
6357000|NCT03029832|10136867|FG000|Overall Study|Death due to Disease Progression|1
6357001|NCT03029832|10136868|FG001|Overall Study|Death due to Disease Progression|0
6357002|NCT03029832|10136867|FG000|Overall Study|Study Terminated By Sponsor|1
6357003|NCT03029832|10136868|FG001|Overall Study|Study Terminated By Sponsor|1
6357004|NCT03010423|10136903|FG000|Overall Study|Study termination|8
6357005|NCT02991430|10136919|FG000|Treatment Period 1|Adverse Event|1
6357006|NCT02991430|10136920|FG001|Treatment Period 1|Adverse Event|0
6357007|NCT02991430|10136921|FG002|Treatment Period 1|Adverse Event|2
6357008|NCT02991430|10136919|FG000|Treatment Period 1|Withdrawal by Subject|0
6357009|NCT02991430|10136920|FG001|Treatment Period 1|Withdrawal by Subject|4
6357010|NCT02991430|10136921|FG002|Treatment Period 1|Withdrawal by Subject|0
6357011|NCT02991430|10136919|FG000|Treatment Period 2|Study Termination|6
6357012|NCT02991430|10136920|FG001|Treatment Period 2|Study Termination|3
6357013|NCT02991430|10136921|FG002|Treatment Period 2|Study Termination|3
6357014|NCT02991430|10136919|FG000|Treatment Period 2|Lost to Follow-up|0
6357015|NCT02991430|10136920|FG001|Treatment Period 2|Lost to Follow-up|0
6357016|NCT02991430|10136921|FG002|Treatment Period 2|Lost to Follow-up|1
6357017|NCT02991430|10136919|FG000|Post-treatment Observation Period|Study Termination|3
6357018|NCT02991430|10136920|FG001|Post-treatment Observation Period|Study Termination|6
6357019|NCT02991430|10136921|FG002|Post-treatment Observation Period|Study Termination|5
6357020|NCT02978833|10136954|FG000|Overall Study|Study terminated|1
6357021|NCT02978833|10136955|FG001|Overall Study|Study terminated|1
6357022|NCT02966223|10136992|FG000|Overall Study|Physician Decision|3
6357023|NCT02966223|10136992|FG000|Overall Study|Withdrawal by Subject|11
6357024|NCT02966223|10136992|FG000|Overall Study|Lost to Follow-up|1
6357025|NCT02965846|10136999|FG000|Overall Study|Lost to Follow-up|1
6357026|NCT02965846|10137000|FG001|Overall Study|Lost to Follow-up|0
6357027|NCT02965846|10137001|FG002|Overall Study|Lost to Follow-up|0
6357028|NCT02965846|10136999|FG000|Overall Study|Withdrawal by Subject|0
6357029|NCT02965846|10137000|FG001|Overall Study|Withdrawal by Subject|1
6357030|NCT02965846|10137001|FG002|Overall Study|Withdrawal by Subject|0
6357031|NCT02965846|10136999|FG000|Overall Study|Study Terminated By Sponsor|4
6357032|NCT02965846|10137000|FG001|Overall Study|Study Terminated By Sponsor|4
6357033|NCT02965846|10137001|FG002|Overall Study|Study Terminated By Sponsor|0
6357034|NCT02965846|10136999|FG000|Overall Study|Participants not randomized|0
6357035|NCT02965846|10137000|FG001|Overall Study|Participants not randomized|0
6357036|NCT02965846|10137001|FG002|Overall Study|Participants not randomized|33
6357037|NCT02956005|10137022|FG000|Overall Study|Not eligible|1
6357038|NCT02956005|10137022|FG000|Overall Study|Withdrawal by Subject|3
6357039|NCT02956005|10137022|FG000|Overall Study|Physician Decision|12
6357040|NCT02940223|10137037|FG000|Overall Study|Failed Requirement|2
6357041|NCT02940223|10137038|FG001|Overall Study|Failed Requirement|0
6357042|NCT02954159|10137046|FG000|Overall Study|Study ended prematurely due to low enrol|1
6357043|NCT02954159|10137047|FG001|Overall Study|Study ended prematurely due to low enrol|0
6357044|NCT02954159|10137046|FG000|Overall Study|Withdrawal by Subject|0
6357045|NCT02954159|10137047|FG001|Overall Study|Withdrawal by Subject|1
6357046|NCT02954952|10137056|FG000|Overall Study|Withdrawal by Subject|1
6357047|NCT02954952|10137057|FG001|Overall Study|Withdrawal by Subject|0
6357048|NCT02954952|10137058|FG002|Overall Study|Withdrawal by Subject|0
6357049|NCT02954952|10137056|FG000|Overall Study|No data collected|0
6357050|NCT02954952|10137057|FG001|Overall Study|No data collected|1
6357051|NCT02954952|10137058|FG002|Overall Study|No data collected|0
6357052|NCT02947022|10137070|FG000|Overall Study|Study Stopped|1
6357053|NCT02950480|10137085|FG000|Overall Study|Withdrawal by Subject|1
6357054|NCT02950480|10137086|FG001|Overall Study|Withdrawal by Subject|0
6357055|NCT02949947|10137094|FG000|Overall Study|Non Compliance|0
6357056|NCT02949947|10137095|FG001|Overall Study|Non Compliance|1
6357057|NCT02949947|10137094|FG000|Overall Study|Insurance change|1
6357058|NCT02949947|10137095|FG001|Overall Study|Insurance change|0
6357059|NCT02947100|10137101|FG000|Overall Study|study terminated early|3
6357060|NCT02947100|10137101|FG000|Overall Study|did not meet inclusion criteria|1
6357061|NCT02908516|10137122|FG000|Overall Study|Study Terminated|3
6357062|NCT02908516|10137123|FG001|Overall Study|Study Terminated|3
6357063|NCT02923830|10137131|FG000|Overall Study|Physician Decision|13
6357064|NCT02923830|10137132|FG001|Overall Study|Physician Decision|15
6357065|NCT02920450|10137138|FG000|Overall Study|Death|1
6357066|NCT02920450|10137139|FG001|Overall Study|Death|0
6357067|NCT02920450|10137140|FG002|Overall Study|Death|0
6357068|NCT02920450|10137141|FG003|Overall Study|Death|0
6357069|NCT02920450|10137138|FG000|Overall Study|Withdrawal by Subject|1
6357070|NCT02920450|10137139|FG001|Overall Study|Withdrawal by Subject|0
6357071|NCT02920450|10137140|FG002|Overall Study|Withdrawal by Subject|0
6357072|NCT02920450|10137141|FG003|Overall Study|Withdrawal by Subject|0
6357073|NCT02920177|10137150|FG000|Overall Study|Withdrawal by Subject|1
6357074|NCT02920177|10137151|FG001|Overall Study|Withdrawal by Subject|1
6357075|NCT02920177|10137150|FG000|Overall Study|Physician Decision|1
6357076|NCT02920177|10137151|FG001|Overall Study|Physician Decision|0
6357077|NCT02920177|10137150|FG000|Overall Study|Lost to Follow-up|0
6357078|NCT02920177|10137151|FG001|Overall Study|Lost to Follow-up|1
6357079|NCT02926638|10137159|FG000|Overall Study|Progression|2
6357080|NCT02926638|10137160|FG001|Overall Study|Progression|5
6357081|NCT02926638|10137159|FG000|Overall Study|Ineligible|1
6357082|NCT02926638|10137160|FG001|Overall Study|Ineligible|0
6357083|NCT02926638|10137159|FG000|Overall Study|Not protocol specified|1
6357084|NCT02926638|10137160|FG001|Overall Study|Not protocol specified|0
6357085|NCT02920242|10137169|FG000|Overall Study|Withdrawal by Subject|1
6357086|NCT02920242|10137170|FG001|Overall Study|Withdrawal by Subject|0
6357087|NCT02920242|10137171|FG002|Overall Study|Withdrawal by Subject|1
6357088|NCT02920242|10137169|FG000|Overall Study|Did not meet inc./exc. criteria|1
6357089|NCT02920242|10137170|FG001|Overall Study|Did not meet inc./exc. criteria|0
6357090|NCT02920242|10137171|FG002|Overall Study|Did not meet inc./exc. criteria|0
6357091|NCT02899728|10137203|FG000|Overall Study|Withdrawal by Subject|1
6357092|NCT02899728|10137204|FG001|Overall Study|Withdrawal by Subject|1
6357093|NCT02875067|10137210|FG000|Overall Study|Withdrawal by Subject|1
6357094|NCT02875067|10137210|FG000|Overall Study|Withdrawal by Termination of Study|5
6357095|NCT02860169|10137225|FG000|Part A|Withdrawal by Subject|1
6357096|NCT02860169|10137225|FG000|Part A|Other (Screening failure)|6
6357097|NCT02860169|10137225|FG000|Part A|Other (Survey not completed)|3
6357098|NCT02860169|10137225|FG000|Part A|Other (did not completed consent)|1
6357099|NCT02860169|10137225|FG000|Part B|Other (Screening failure)|10
6357100|NCT02860169|10137225|FG000|Part B|Withdrawal by Subject|1
6357101|NCT02860169|10137225|FG000|Part C|Other (Screening failure)|1
6357102|NCT02865395|10137234|FG000|Overall Study|Physician Decision|6
6357103|NCT02865395|10137235|FG001|Overall Study|Physician Decision|10
6357104|NCT02865395|10137236|FG002|Overall Study|Physician Decision|7
6357105|NCT02868892|10137244|FG000|Overall Study|Investigator left site and no follow-up|6
6357106|NCT02865083|10137250|FG000|Overall Study|Early Termination|3
6357107|NCT02865083|10137251|FG001|Overall Study|Early Termination|1
6357108|NCT02865122|10137260|FG000|Overall Study|Adverse Event|1
6357109|NCT02865122|10137261|FG001|Overall Study|Adverse Event|0
6357110|NCT02865122|10137262|FG002|Overall Study|Adverse Event|0
6357111|NCT02865915|10137272|FG000|Overall Study|Pregnancy|1
6357112|NCT02865915|10137273|FG001|Overall Study|Pregnancy|0
6357113|NCT02865915|10137272|FG000|Overall Study|Withdrawal by Subject|1
6357114|NCT02865915|10137273|FG001|Overall Study|Withdrawal by Subject|1
6357115|NCT02865915|10137272|FG000|Overall Study|Adverse Event|0
6357116|NCT02865915|10137273|FG001|Overall Study|Adverse Event|4
6357117|NCT02865915|10137272|FG000|Overall Study|Lost to Follow-up|0
6357118|NCT02865915|10137273|FG001|Overall Study|Lost to Follow-up|1
6357119|NCT02865915|10137272|FG000|Overall Study|Protocol Violation|0
6357120|NCT02865915|10137273|FG001|Overall Study|Protocol Violation|1
6357121|NCT02865915|10137272|FG000|Overall Study|Study terminated by sponsor|23
6357122|NCT02865915|10137273|FG001|Overall Study|Study terminated by sponsor|18
6357123|NCT02865915|10137272|FG000|Overall Study|Dosing group discontinued|0
6357124|NCT02865915|10137273|FG001|Overall Study|Dosing group discontinued|5
6357125|NCT02855411|10137279|FG000|Overall Study|Study terminated by sponsor|21
6357126|NCT02855411|10137279|FG000|Overall Study|Does not meet entrance criteria|14
6357127|NCT02828124|10137287|FG000|Overall Study|Disease Progression|1
6357128|NCT02828124|10137288|FG001|Overall Study|Disease Progression|2
6357129|NCT02828124|10137289|FG002|Overall Study|Disease Progression|1
6357130|NCT02828124|10137290|FG003|Overall Study|Disease Progression|4
6357131|NCT02828124|10137287|FG000|Overall Study|AE Unrelated to Study Drug|0
6357132|NCT02828124|10137288|FG001|Overall Study|AE Unrelated to Study Drug|0
6357133|NCT02828124|10137289|FG002|Overall Study|AE Unrelated to Study Drug|0
6357134|NCT02828124|10137290|FG003|Overall Study|AE Unrelated to Study Drug|1
6357135|NCT02828124|10137287|FG000|Overall Study|Subject Withdrew Consent|0
6357136|NCT02828124|10137288|FG001|Overall Study|Subject Withdrew Consent|0
6357137|NCT02828124|10137289|FG002|Overall Study|Subject Withdrew Consent|0
6357138|NCT02828124|10137290|FG003|Overall Study|Subject Withdrew Consent|1
6357139|NCT02825043|10137309|FG000|Overall Study|Lost to Follow-up|4
6357140|NCT02819804|10137313|FG000|Complete Cycle 1 (28 Days)|Progressive disease/no response|1
6357141|NCT02809118|10137320|FG000|Overall Study|Withdrawal by Subject|0
6357142|NCT02809118|10137321|FG001|Overall Study|Withdrawal by Subject|1
6357143|NCT02809118|10137322|FG002|Overall Study|Withdrawal by Subject|1
6357144|NCT02806960|10137358|FG000|Period 1|Study Terminated (withdrawn by sponsor)|3
6357145|NCT02806960|10137359|FG001|Period 1|Study Terminated (withdrawn by sponsor)|3
6357146|NCT02806960|10137360|FG002|Period 1|Study Terminated (withdrawn by sponsor)|3
6357147|NCT02806960|10137361|FG003|Period 1|Study Terminated (withdrawn by sponsor)|3
6357148|NCT02815397|10137371|FG000|Overall Study|Physician Decision|2
6357149|NCT02802592|10137375|FG000|Overall Study|Study terminated due to loss of funding|4
6357150|NCT02730793|10137400|FG000|Overall Study|Physician Decision|0
6357151|NCT02730793|10137401|FG001|Overall Study|Physician Decision|1
6357152|NCT02730793|10137400|FG000|Overall Study|Withdrawal by Subject|0
6357153|NCT02730793|10137401|FG001|Overall Study|Withdrawal by Subject|1
6357154|NCT02760602|10137418|FG000|Overall Study|Withdrawal by Subject|1
6357155|NCT02760602|10137419|FG001|Overall Study|Withdrawal by Subject|0
6357156|NCT02760602|10137418|FG000|Overall Study|Terminated by sponsor|12
6357157|NCT02760602|10137419|FG001|Overall Study|Terminated by sponsor|13
6357158|NCT02757521|10137427|FG000|Overall Study|Adverse Event|1
6357159|NCT02757521|10137428|FG001|Overall Study|Adverse Event|0
6357160|NCT02725671|10137481|FG000|Overall Study|Lost to Follow-up|1
6357161|NCT02732327|10137502|FG000|Overall Study|Protocol Violation|0
6357162|NCT02732327|10137503|FG001|Overall Study|Protocol Violation|1
6357163|NCT02726399|10137509|FG000|Overall Study|Participant Non-Compliance|1
6357164|NCT02726399|10137509|FG000|Overall Study|Adverse Event|2
6357165|NCT02726399|10137509|FG000|Overall Study|Progression of disease|4
6357166|NCT02720510|10137515|FG000|Overall Study|Study Terminated by the sponsor|2
6357167|NCT02720510|10137516|FG001|Overall Study|Study Terminated by the sponsor|0
6357168|NCT02720510|10137515|FG000|Overall Study|Adverse Event|0
6357169|NCT02720510|10137516|FG001|Overall Study|Adverse Event|1
6357170|NCT02720510|10137515|FG000|Overall Study|Physician Decision|1
6357171|NCT02720510|10137516|FG001|Overall Study|Physician Decision|2
6357172|NCT02715765|10137525|FG000|Overall Study|Study Termination|3
6357173|NCT02715765|10137526|FG001|Overall Study|Study Termination|0
6357174|NCT02715765|10137527|FG002|Overall Study|Study Termination|0
6357175|NCT02717130|10137546|FG000|Overall Study|Withdrawal by Subject|1
6357176|NCT02717130|10137546|FG000|Overall Study|Adverse Event|1
6357177|NCT02717130|10137546|FG000|Overall Study|Physician Decision|1
6357178|NCT02717130|10137546|FG000|Overall Study|Study Closure|4
6357179|NCT02685202|10137550|FG000|Overall Study|Lost to Follow-up|9
6357180|NCT02709083|10137554|FG000|Overall Study|Original PI left institution|7
6357181|NCT02693171|10137558|FG000|Overall Study|Adverse Event|1
6357182|NCT02693171|10137558|FG000|Overall Study|Discontinuation of Study by Sponsor|8
6357183|NCT02696226|10137566|FG000|Overall Study|Study terminated - lack of enrollment|1
6357184|NCT02696226|10137567|FG001|Overall Study|Study terminated - lack of enrollment|0
6357185|NCT02696226|10137568|FG002|Overall Study|Study terminated - lack of enrollment|2
6357186|NCT02696226|10137569|FG003|Overall Study|Study terminated - lack of enrollment|0
6357187|NCT02693743|10137581|FG000|Overall Study|Physician Decision|1
6357188|NCT02693743|10137582|FG001|Overall Study|Physician Decision|0
6357189|NCT02706691|10137588|FG000|Overall Study|Adverse Event|1
6357190|NCT02694757|10137606|FG000|Overall Study|Lack of Efficacy|3
6357191|NCT02693002|10137612|FG000|Overall Study|Withdrawal by Subject|1
6357192|NCT02693002|10137613|FG001|Overall Study|Withdrawal by Subject|0
6357193|NCT02689518|10137619|FG000|Overall Study|Withdrawal by Subject|3
6357194|NCT02673684|10137650|FG000|Overall Study|Study not completed d/t loss of funding|9
6357195|NCT02673684|10137651|FG001|Overall Study|Study not completed d/t loss of funding|8
6357196|NCT02674204|10137661|FG000|Overall Study|Adverse Event|1
6357197|NCT02674204|10137662|FG001|Overall Study|Adverse Event|0
6357198|NCT02671461|10137684|FG000|Treatment|Adverse Event|0
6357199|NCT02671461|10137685|FG001|Treatment|Adverse Event|0
6357200|NCT02671461|10137686|FG002|Treatment|Adverse Event|1
6357201|NCT02671461|10137684|FG000|Treatment|Administrative Reason by Sponsor|1
6357202|NCT02671461|10137685|FG001|Treatment|Administrative Reason by Sponsor|3
6357203|NCT02671461|10137686|FG002|Treatment|Administrative Reason by Sponsor|4
6357204|NCT02671461|10137684|FG000|Treatment|Randomized, not treated|1
6357205|NCT02671461|10137685|FG001|Treatment|Randomized, not treated|0
6357206|NCT02671461|10137686|FG002|Treatment|Randomized, not treated|0
6357207|NCT02671461|10137684|FG000|Follow-up|Withdrawal by Subject|1
6357208|NCT02671461|10137685|FG001|Follow-up|Withdrawal by Subject|0
6357209|NCT02671461|10137686|FG002|Follow-up|Withdrawal by Subject|0
6357210|NCT02671461|10137684|FG000|Follow-up|Lost to Follow-up|0
6357211|NCT02671461|10137685|FG001|Follow-up|Lost to Follow-up|0
6357212|NCT02671461|10137686|FG002|Follow-up|Lost to Follow-up|1
6357213|NCT02671461|10137684|FG000|Follow-up|Administrative Reason by Sponsor|0
6357214|NCT02671461|10137685|FG001|Follow-up|Administrative Reason by Sponsor|1
6357215|NCT02671461|10137686|FG002|Follow-up|Administrative Reason by Sponsor|0
6357216|NCT02653495|10137757|FG000|Overall Study|Lost to Follow-up|2
6357217|NCT02653495|10137758|FG001|Overall Study|Lost to Follow-up|0
6357218|NCT02653495|10137757|FG000|Overall Study|Screening Failure|10
6357219|NCT02653495|10137758|FG001|Overall Study|Screening Failure|0
6357220|NCT02639390|10137770|FG000|Overall Study|Subject unable to comply with treatment schedule.|0
6357221|NCT02639390|10137771|FG001|Overall Study|Subject unable to comply with treatment schedule.|2
6357222|NCT02634606|10137777|FG000|Overall Study|unable to obtain the drug at start|13
6357223|NCT02636283|10137791|FG000|Overall Study|Adverse Event|2
6357224|NCT02636283|10137792|FG001|Overall Study|Adverse Event|0
6357225|NCT02636283|10137791|FG000|Overall Study|Trial Terminated Prematurely|0
6357226|NCT02636283|10137792|FG001|Overall Study|Trial Terminated Prematurely|3
6357227|NCT02638129|10137800|FG000|Overall Study|Study terminated|28
6357228|NCT02638129|10137801|FG001|Overall Study|Study terminated|30
6357229|NCT02615990|10137809|FG000|Overall Study|study terminated|1
6357230|NCT02615990|10137810|FG001|Overall Study|study terminated|1
6357231|NCT02640677|10137816|FG000|Overall Study|Lost to Follow-up|1
6357232|NCT02640677|10137816|FG000|Overall Study|Withdrawal by Subject|1
6357233|NCT02623959|10137826|FG000|Overall Study|Progression|0
6357234|NCT02623959|10137827|FG001|Overall Study|Progression|1
6357235|NCT02631148|10137837|FG000|Overall Study|8 were ineligible|8
6357236|NCT02631148|10137838|FG001|Overall Study|8 were ineligible|0
6357237|NCT02631148|10137837|FG000|Overall Study|Withdrawal by Subject|1
6357238|NCT02631148|10137838|FG001|Overall Study|Withdrawal by Subject|0
6357239|NCT02631148|10137837|FG000|Overall Study|PAH not available to study participant|1
6357240|NCT02631148|10137838|FG001|Overall Study|PAH not available to study participant|0
6357241|NCT02630472|10137846|FG000|Overall Study|Physician Decision|10
6357242|NCT02630472|10137847|FG001|Overall Study|Physician Decision|0
6357243|NCT02626520|10137856|FG000|Overall Study|Physician Decision|1
6357244|NCT02626520|10137857|FG001|Overall Study|Physician Decision|1
6357245|NCT02626520|10137856|FG000|Overall Study|Adverse Event|0
6357246|NCT02626520|10137857|FG001|Overall Study|Adverse Event|4
6357247|NCT02626520|10137856|FG000|Overall Study|Lack of Efficacy|0
6357248|NCT02626520|10137857|FG001|Overall Study|Lack of Efficacy|2
6357249|NCT02626520|10137856|FG000|Overall Study|Did not start protocol therapy|0
6357250|NCT02626520|10137857|FG001|Overall Study|Did not start protocol therapy|2
6357251|NCT02626520|10137856|FG000|Overall Study|Study terminated|0
6357252|NCT02626520|10137857|FG001|Overall Study|Study terminated|1
6357253|NCT02614898|10137865|FG000|Overall Study|Participated until study termination|10
6357254|NCT02614898|10137866|FG001|Overall Study|Participated until study termination|26
6357255|NCT02614898|10137865|FG000|Overall Study|Lost to Follow-up|0
6357256|NCT02614898|10137866|FG001|Overall Study|Lost to Follow-up|2
6357257|NCT02614898|10137865|FG000|Overall Study|Physician Decision|1
6357258|NCT02614898|10137866|FG001|Overall Study|Physician Decision|8
6357259|NCT02614898|10137865|FG000|Overall Study|Study Terminated by Sponsor|3
6357260|NCT02614898|10137866|FG001|Overall Study|Study Terminated by Sponsor|0
6357261|NCT02614898|10137865|FG000|Overall Study|Withdrawal by Subject|0
6357262|NCT02614898|10137866|FG001|Overall Study|Withdrawal by Subject|2
6357263|NCT02614898|10137865|FG000|Overall Study|Withdrawal by Parent/Guardian|1
6357264|NCT02614898|10137866|FG001|Overall Study|Withdrawal by Parent/Guardian|1
6357265|NCT02614898|10137865|FG000|Overall Study|Other-Additional Information Unavailable|0
6357266|NCT02614898|10137866|FG001|Overall Study|Other-Additional Information Unavailable|11
6357267|NCT02614898|10137865|FG000|Overall Study|Missing|0
6357268|NCT02614898|10137866|FG001|Overall Study|Missing|1
6357269|NCT02622828|10137873|FG000|Overall Study|participant withdrew|3
6357270|NCT02619812|10137899|FG000|Overall Study|Withdrawal by Subject|0
6357271|NCT02619812|10137900|FG001|Overall Study|Withdrawal by Subject|0
6357272|NCT02619812|10137901|FG002|Overall Study|Withdrawal by Subject|1
6357273|NCT02619812|10137902|FG003|Overall Study|Withdrawal by Subject|2
6357274|NCT02612285|10137912|FG000|Overall Study|Withdrawal by Subject|1
6357275|NCT02606279|10137922|FG000|Overall Study|Lost to Follow-up|0
6357276|NCT02606279|10137923|FG001|Overall Study|Lost to Follow-up|1
6357277|NCT02605824|10137931|FG000|Overall Study|Physician Decision|1
6357278|NCT02605824|10137932|FG001|Overall Study|Physician Decision|0
6357279|NCT02598622|10137940|FG000|Overall Study|Withdrawal by Subject|3
6357280|NCT02598622|10137941|FG001|Overall Study|Withdrawal by Subject|0
6357281|NCT02598622|10137940|FG000|Overall Study|Physician Decision|3
6357282|NCT02598622|10137941|FG001|Overall Study|Physician Decision|0
6357283|NCT02582749|10137962|FG000|Overall Study|Study terminated by funder|5
6357284|NCT02582749|10137963|FG001|Overall Study|Study terminated by funder|10
6357285|NCT02582749|10137962|FG000|Overall Study|Withdrawal by Subject|0
6357286|NCT02582749|10137963|FG001|Overall Study|Withdrawal by Subject|1
6357287|NCT02569957|10137996|FG000|Overall Study|Withdrawal by Subject|0
6083904|NCT00640133|9692740|FG000|Open Label Phase (Month 4-12)|Lack of Efficacy|1
6083905|NCT00640133|9692741|FG001|Open Label Phase (Month 4-12)|Lack of Efficacy|0
6083906|NCT00640133|9692740|FG000|Open Label Phase (Month 4-12)|Withdrawal by Subject|1
6083907|NCT00640133|9692741|FG001|Open Label Phase (Month 4-12)|Withdrawal by Subject|0
6083908|NCT00640133|9692740|FG000|Open Label Phase (Month 4-12)|Adverse Event|1
6357288|NCT02569957|10137997|FG001|Overall Study|Withdrawal by Subject|1
6357289|NCT02575365|10138016|FG000|Overall Study|Lost to Follow-up|4
6357290|NCT02547129|10138026|FG000|Overall Study|Difficulty with ongoing infection|1
6357291|NCT02547129|10138027|FG001|Overall Study|Difficulty with ongoing infection|0
6357292|NCT02533531|10138066|FG000|Overall Study|Device did not turn on|1
6357293|NCT02520726|10138082|FG000|Overall Study|Lost to Follow-up|3
6357294|NCT02520726|10138083|FG001|Overall Study|Lost to Follow-up|2
6357295|NCT02519712|10138093|FG000|Overall Study|Disease Relapse|1
6357296|NCT02519712|10138093|FG000|Overall Study|Disease Progression|1
6357297|NCT02519712|10138093|FG000|Overall Study|Accruals are donors|2
6357298|NCT02516228|10138101|FG000|Overall Study|Lost to Follow-up|1
6357299|NCT02516228|10138101|FG000|Overall Study|Withdrawal by Subject|1
6357300|NCT02516228|10138101|FG000|Overall Study|Physician Decision|1
6357301|NCT02506101|10138141|FG000|Overall Study|Transportation issues|1
6357302|NCT02506101|10138142|FG001|Overall Study|Transportation issues|0
6357303|NCT02506101|10138141|FG000|Overall Study|No enrollment and staff unavailability|1
6357304|NCT02506101|10138142|FG001|Overall Study|No enrollment and staff unavailability|0
6357305|NCT02500901|10138161|FG000|Overall Study|Disease ProgressionDD|2
6357306|NCT02483533|10138167|FG000|Overall Study|Lack of Efficacy|50
6357307|NCT02483533|10138168|FG001|Overall Study|Lack of Efficacy|50
6357308|NCT02496039|10138174|FG000|Overall Study|Adverse Event|3
6357309|NCT02496039|10138174|FG000|Overall Study|Protocol Violation|1
6357310|NCT02494206|10138183|FG000|Overall Study|Adverse Event|1
6357311|NCT02494206|10138183|FG000|Overall Study|Disease Progression|1
6357312|NCT02473445|10138187|FG000|Overall Study|Withdrawal by Subject|2
6357313|NCT02473445|10138187|FG000|Overall Study|Sponsor Decision|20
6357314|NCT02491411|10138191|FG000|Overall Study|Physician Decision|4
6357315|NCT02476994|10138197|FG000|Overall Study|Based on feedback from FDA|1
6357316|NCT02476994|10138198|FG001|Overall Study|Based on feedback from FDA|0
6357317|NCT02473523|10138204|FG000|Overall Study|Death|1
6357318|NCT02473523|10138204|FG000|Overall Study|Lost to Follow-up|1
6357319|NCT02472639|10138223|FG000|Overall Study|Physician Decision|4
6357320|NCT02472639|10138224|FG001|Overall Study|Physician Decision|3
6357321|NCT02469415|10138230|FG000|Overall Study|Withdrawal by Subject|1
6357322|NCT02469415|10138230|FG000|Overall Study|Investigational agent placed on hold|2
6357323|NCT02452359|10138242|FG000|Overall Study|Adverse Event|1
6357324|NCT02452359|10138242|FG000|Overall Study|Lost to Follow-up|15
6357325|NCT02452359|10138242|FG000|Overall Study|Pregnancy|1
6357326|NCT02452359|10138242|FG000|Overall Study|Withdrawal by Subject|4
6357327|NCT02452398|10138250|FG000|Overall Study|Adverse Event|1
6357328|NCT02452398|10138250|FG000|Overall Study|Lost to Follow-up|28
6357329|NCT02452398|10138250|FG000|Overall Study|Physician Decision|2
6357330|NCT02452398|10138250|FG000|Overall Study|Withdrawal by Subject|6
6357331|NCT02452398|10138250|FG000|Overall Study|Moved away|4
6357332|NCT02447887|10138254|FG000|Overall Study|Study was terminated|3
6083909|NCT00640133|9692741|FG001|Open Label Phase (Month 4-12)|Adverse Event|0
6357333|NCT02439970|10138275|FG000|Overall Study|Study Terminated|2
6357334|NCT02439970|10138276|FG001|Overall Study|Study Terminated|3
6357335|NCT02439957|10138284|FG000|Overall Study|Study Terminated|3
6357336|NCT02439957|10138285|FG001|Overall Study|Study Terminated|3
6357337|NCT02441036|10138296|FG000|Overall Study|No tissue resected|0
6357338|NCT02441036|10138297|FG001|Overall Study|No tissue resected|1
6357339|NCT02441036|10138298|FG002|Overall Study|No tissue resected|0
6357340|NCT02441036|10138299|FG003|Overall Study|No tissue resected|1
6357341|NCT02441036|10138300|FG004|Overall Study|No tissue resected|0
6357342|NCT02430532|10138337|FG000|Overall Study|Sponsor Decision to Stop Study Early|30
6357343|NCT02430532|10138338|FG001|Overall Study|Sponsor Decision to Stop Study Early|25
6357344|NCT02430532|10138337|FG000|Overall Study|Consent Withdrawn|0
6357345|NCT02430532|10138338|FG001|Overall Study|Consent Withdrawn|2
6357346|NCT02430532|10138337|FG000|Overall Study|Adverse Event|0
6357347|NCT02430532|10138338|FG001|Overall Study|Adverse Event|1
6357348|NCT02428231|10138348|FG000|Overall Study|Other|10
6357349|NCT02428231|10138349|FG001|Overall Study|Other|16
6357350|NCT02428231|10138348|FG000|Overall Study|Required Symptomatic Therapy|0
6357351|NCT02428231|10138349|FG001|Overall Study|Required Symptomatic Therapy|1
6357352|NCT02428231|10138348|FG000|Overall Study|Adverse Event|3
6357353|NCT02428231|10138349|FG001|Overall Study|Adverse Event|0
6357354|NCT02424565|10138355|FG000|Period 1 (D0)|Protocol Violation|0
6357355|NCT02424565|10138356|FG001|Period 1 (D0)|Protocol Violation|1
6357356|NCT02422303|10138377|FG000|Overall Study|Lost to Follow-up|1
6357357|NCT02422303|10138378|FG001|Overall Study|Lost to Follow-up|1
6357358|NCT02414152|10138401|FG000|Overall Study|Withdrawal by Subject|1
6357359|NCT02414152|10138401|FG000|Overall Study|Lack of Efficacy|1
6357360|NCT02410551|10138405|FG000|Overall Study|Adverse Event|1
6357361|NCT02410551|10138405|FG000|Overall Study|Withdrawal by Subject|1
6357362|NCT02410551|10138405|FG000|Overall Study|FDA Clinical hold-patients taken off|2
6357363|NCT02410954|10138416|FG000|Overall Study|Unable to collect usable data due to initial protocol issues|6
6357364|NCT02410954|10138417|FG001|Overall Study|Unable to collect usable data due to initial protocol issues|0
6357365|NCT02410954|10138416|FG000|Overall Study|Instrument malfunction generated unusable data|8
6357366|NCT02410954|10138417|FG001|Overall Study|Instrument malfunction generated unusable data|0
6357367|NCT02409355|10138429|FG000|Overall Study|Withdrawal by Subject|1
6357368|NCT02409355|10138430|FG001|Overall Study|Withdrawal by Subject|0
6357369|NCT02409355|10138429|FG000|Overall Study|Death|1
6357370|NCT02409355|10138430|FG001|Overall Study|Death|1
6357371|NCT02409355|10138429|FG000|Overall Study|Study terminated by Sponsor|2
6357372|NCT02409355|10138430|FG001|Overall Study|Study terminated by Sponsor|3
6357373|NCT02404545|10138455|FG000|Overall Study|Sponsor Termination|6
6357374|NCT02404545|10138456|FG001|Overall Study|Sponsor Termination|6
6357375|NCT02392377|10138465|FG000|Overall Study|Withdrawal by Subject|0
6357376|NCT02392377|10138466|FG001|Overall Study|Withdrawal by Subject|1
6357377|NCT02394665|10138500|FG000|Overall Study|Physician Decision|1
6357378|NCT02394665|10138501|FG001|Overall Study|Physician Decision|0
6357379|NCT02394665|10138502|FG002|Overall Study|Physician Decision|0
6357380|NCT02390362|10138521|FG000|Overall Study|Withdrawal by Subject|0
6357381|NCT02390362|10138522|FG001|Overall Study|Withdrawal by Subject|1
6357382|NCT02388776|10138528|FG000|Overall Study|Death|1
6357383|NCT02388776|10138528|FG000|Overall Study|Lost to Follow-up|1
6357384|NCT02383433|10138533|FG000|Overall Study|Disease progression|2
6357385|NCT02379390|10138561|FG000|Overall Study|Adverse Event|1
6357386|NCT02379390|10138562|FG001|Overall Study|Adverse Event|1
6357387|NCT02379390|10138561|FG000|Overall Study|Investigator's decision|1
6357388|NCT02379390|10138562|FG001|Overall Study|Investigator's decision|0
6357389|NCT02379390|10138561|FG000|Overall Study|Study Termination|0
6357390|NCT02379390|10138562|FG001|Overall Study|Study Termination|1
6357391|NCT02361580|10138586|FG000|Overall Study|Lost to Follow-up|6
6357392|NCT02361580|10138587|FG001|Overall Study|Lost to Follow-up|3
6357393|NCT02370888|10138618|FG000|Overall Study|disease progression|2
6357394|NCT02370888|10138618|FG000|Overall Study|did not meet chimerism criteria|6
6357395|NCT02365233|10138642|FG000|Overall Study|IRB withheld the data|1
6357396|NCT02365233|10138643|FG001|Overall Study|IRB withheld the data|2
6357397|NCT02365233|10138644|FG002|Overall Study|IRB withheld the data|2
6357398|NCT02347943|10138655|FG000|Overall Study|Study was cancelled|140
6357399|NCT02347943|10138656|FG001|Overall Study|Study was cancelled|67
6357400|NCT02347943|10138657|FG002|Overall Study|Study was cancelled|45
6357401|NCT02365207|10138665|FG000|Overall Study|Withdrawal by Subject|1
6357402|NCT02365207|10138665|FG000|Overall Study|Physician Decision|1
6357403|NCT02360111|10138669|FG000|Overall Study|Death|2
6357404|NCT02353468|10138673|FG000|Overall Study|Study terminated|3
6357405|NCT02346877|10138701|FG000|Overall Study|Adverse Event|1
6357406|NCT02346877|10138702|FG001|Overall Study|Adverse Event|0
6357407|NCT02346877|10138701|FG000|Overall Study|Administrative Decision|1
6357408|NCT02346877|10138702|FG001|Overall Study|Administrative Decision|0
6357409|NCT02346877|10138701|FG000|Overall Study|Sponsor Decision|12
6357410|NCT02346877|10138702|FG001|Overall Study|Sponsor Decision|0
6357411|NCT02346877|10138701|FG000|Overall Study|Missing|5
6357412|NCT02346877|10138702|FG001|Overall Study|Missing|0
6357413|NCT02353572|10138725|FG000|Overall Study|Withdrawal by Subject|1
6357414|NCT02353572|10138725|FG000|Overall Study|Study terminated|2
6357415|NCT02343263|10138741|FG000|Overall Study|Physician Decision|5
6357416|NCT02343263|10138742|FG001|Overall Study|Physician Decision|3
6357417|NCT02343263|10138743|FG002|Overall Study|Physician Decision|1
6357418|NCT02343159|10138758|FG000|Overall Study|Early Study Termination|16
6357419|NCT02343159|10138759|FG001|Overall Study|Early Study Termination|19
6357420|NCT02343159|10138760|FG002|Overall Study|Early Study Termination|23
6357421|NCT02343159|10138758|FG000|Overall Study|Physician Decision|2
6357422|NCT02343159|10138759|FG001|Overall Study|Physician Decision|0
6357423|NCT02343159|10138760|FG002|Overall Study|Physician Decision|1
6357424|NCT02343159|10138758|FG000|Overall Study|Withdrawal by Subject|3
6357425|NCT02343159|10138759|FG001|Overall Study|Withdrawal by Subject|0
6357426|NCT02343159|10138760|FG002|Overall Study|Withdrawal by Subject|2
6357427|NCT02343159|10138758|FG000|Overall Study|Lost to Follow-up|0
6357428|NCT02343159|10138759|FG001|Overall Study|Lost to Follow-up|2
6357429|NCT02343159|10138760|FG002|Overall Study|Lost to Follow-up|2
6357430|NCT02343159|10138758|FG000|Overall Study|Adverse Event|4
6357431|NCT02343159|10138759|FG001|Overall Study|Adverse Event|4
6357432|NCT02343159|10138760|FG002|Overall Study|Adverse Event|2
6357433|NCT02343159|10138758|FG000|Overall Study|Sponsor Decision|0
6357434|NCT02343159|10138759|FG001|Overall Study|Sponsor Decision|1
6357435|NCT02343159|10138760|FG002|Overall Study|Sponsor Decision|0
6357436|NCT02343159|10138758|FG000|Overall Study|Enrollment Error|1
6357437|NCT02343159|10138759|FG001|Overall Study|Enrollment Error|0
6357438|NCT02343159|10138760|FG002|Overall Study|Enrollment Error|0
6357439|NCT02336425|10138777|FG000|Overall Study|Study terminated.|2
6357440|NCT02336425|10138778|FG001|Overall Study|Study terminated.|2
6357441|NCT02336425|10138779|FG002|Overall Study|Study terminated.|3
6357442|NCT02336425|10138780|FG003|Overall Study|Study terminated.|3
6357443|NCT02308735|10138841|FG000|Overall Study|Physician Decision|2
6357444|NCT02308735|10138842|FG001|Overall Study|Physician Decision|0
6357445|NCT02308735|10138843|FG002|Overall Study|Physician Decision|0
6357446|NCT02308735|10138844|FG003|Overall Study|Physician Decision|2
6357447|NCT02299206|10138854|FG000|Overall Study|Lost to Follow-up|1
6357448|NCT02299206|10138854|FG000|Overall Study|Withdrawal by Subject|1
6357449|NCT02302859|10138860|FG000|Overall Study|Lost Phone|1
6357450|NCT02302859|10138861|FG001|Overall Study|Lost Phone|1
6357451|NCT02302859|10138860|FG000|Overall Study|Withdrawal by Subject|0
6357452|NCT02302859|10138861|FG001|Overall Study|Withdrawal by Subject|1
6357453|NCT02299934|10138867|FG000|Overall Study|Termination of study|13
6357454|NCT02294981|10138894|FG000|Overall Study|Lost to Follow-up|1
6357455|NCT02284906|10138901|FG000|Overall Study|Pretreatment Event/Adverse Event|0
6357456|NCT02284906|10138902|FG001|Overall Study|Pretreatment Event/Adverse Event|1
6357457|NCT02284906|10138903|FG002|Overall Study|Pretreatment Event/Adverse Event|0
6357458|NCT02284906|10138901|FG000|Overall Study|Major Protocol Deviation|0
6357459|NCT02284906|10138902|FG001|Overall Study|Major Protocol Deviation|1
6357460|NCT02284906|10138903|FG002|Overall Study|Major Protocol Deviation|0
6357461|NCT02284906|10138901|FG000|Overall Study|Voluntary Withdrawal|2
6357462|NCT02284906|10138902|FG001|Overall Study|Voluntary Withdrawal|4
6357463|NCT02284906|10138903|FG002|Overall Study|Voluntary Withdrawal|5
6357464|NCT02284906|10138901|FG000|Overall Study|Study Termination|0
6357465|NCT02284906|10138902|FG001|Overall Study|Study Termination|11
6357466|NCT02284906|10138903|FG002|Overall Study|Study Termination|14
6357467|NCT02284906|10138901|FG000|Overall Study|Reason not Specified|1
6357468|NCT02284906|10138902|FG001|Overall Study|Reason not Specified|1
6357469|NCT02284906|10138903|FG002|Overall Study|Reason not Specified|0
6357470|NCT02287025|10138913|FG000|Overall Study|Not treated|2
6357471|NCT02287025|10138914|FG001|Overall Study|Not treated|0
6357472|NCT02287025|10138913|FG000|Overall Study|Progression of disease|3
6357473|NCT02287025|10138914|FG001|Overall Study|Progression of disease|2
6357474|NCT02287025|10138913|FG000|Overall Study|Adverse Event|2
6357475|NCT02287025|10138914|FG001|Overall Study|Adverse Event|4
6357476|NCT02287025|10138913|FG000|Overall Study|Withdrawal by Subject|2
6357477|NCT02287025|10138914|FG001|Overall Study|Withdrawal by Subject|2
6357478|NCT02287025|10138913|FG000|Overall Study|Screening failed|1
6357479|NCT02287025|10138914|FG001|Overall Study|Screening failed|1
6357480|NCT02276560|10138929|FG000|Overall Study|Adverse Event|1
6357481|NCT02276560|10138930|FG001|Overall Study|Adverse Event|0
6357482|NCT02276560|10138931|FG002|Overall Study|Adverse Event|0
6357483|NCT02284373|10138946|FG000|Overall Study|Withdrawal by Subject|0
6357484|NCT02284373|10138947|FG001|Overall Study|Withdrawal by Subject|1
6357485|NCT02284373|10138948|FG002|Overall Study|Withdrawal by Subject|0
6357486|NCT02284373|10138946|FG000|Overall Study|Other|0
6357487|NCT02284373|10138947|FG001|Overall Study|Other|1
6357488|NCT02284373|10138948|FG002|Overall Study|Other|0
6357489|NCT02284373|10138946|FG000|Overall Study|Lost to Follow-up|0
6357490|NCT02284373|10138947|FG001|Overall Study|Lost to Follow-up|1
6357491|NCT02284373|10138948|FG002|Overall Study|Lost to Follow-up|0
6170321|NCT01252667|9816599|FG002|Overall Study|Transplant aborted post-conditioning|0
6170322|NCT01252667|9816600|FG003|Overall Study|Transplant aborted post-conditioning|0
6170323|NCT01252667|9816601|FG004|Overall Study|Transplant aborted post-conditioning|0
6170324|NCT01252667|9816602|FG005|Overall Study|Transplant aborted post-conditioning|1
6170325|NCT01252810|9816643|FG000|Overall Study|Withdrawal by Subject|4
6170326|NCT01252810|9816644|FG001|Overall Study|Withdrawal by Subject|1
6170327|NCT01252810|9816643|FG000|Overall Study|Lost to Follow-up|0
6170328|NCT01252810|9816644|FG001|Overall Study|Lost to Follow-up|1
6170329|NCT01252810|9816643|FG000|Overall Study|Physician Decision|2
6170330|NCT01252810|9816644|FG001|Overall Study|Physician Decision|1
6170331|NCT01252810|9816643|FG000|Overall Study|Various reasons|8
6170332|NCT01252810|9816644|FG001|Overall Study|Various reasons|0
6170333|NCT01252940|9816652|FG000|Main Study Phase|Randomized but not treated|4
6170334|NCT01252940|9816653|FG001|Main Study Phase|Randomized but not treated|2
6170335|NCT01252940|9816652|FG000|Main Study Phase|Adverse Event|3
6170336|NCT01252940|9816653|FG001|Main Study Phase|Adverse Event|1
6357492|NCT02285270|10138956|FG000|Overall Study|Lost to Follow-up|1
6357493|NCT02285270|10138956|FG000|Overall Study|Physician Decision|3
6357494|NCT02285270|10138956|FG000|Overall Study|Determined to be ineligible|1
6357495|NCT02275481|10138962|FG000|Overall Study|Death|2
6170337|NCT01252940|9816652|FG000|Main Study Phase|Lack of Efficacy|1
6170338|NCT01252940|9816653|FG001|Main Study Phase|Lack of Efficacy|0
6170339|NCT01252940|9816652|FG000|Main Study Phase|Lost to Follow-up|6
6170340|NCT01252940|9816653|FG001|Main Study Phase|Lost to Follow-up|1
6170341|NCT01252940|9816652|FG000|Main Study Phase|Physician Decision|1
6357496|NCT02275481|10138963|FG001|Overall Study|Death|1
6357497|NCT02275481|10138962|FG000|Overall Study|Lost to Follow-up|2
6357498|NCT02275481|10138963|FG001|Overall Study|Lost to Follow-up|0
6357499|NCT02275481|10138962|FG000|Overall Study|Withdrawal by Subject|3
6357500|NCT02275481|10138963|FG001|Overall Study|Withdrawal by Subject|0
6357501|NCT02275481|10138962|FG000|Overall Study|all other reasons combined|2
6357502|NCT02275481|10138963|FG001|Overall Study|all other reasons combined|1
6357503|NCT02275481|10138962|FG000|Overall Study|Physician Decision|0
6357504|NCT02275481|10138963|FG001|Overall Study|Physician Decision|1
6357505|NCT02273752|10138973|FG000|Overall Study|Trial was terminated early|2
6357506|NCT02270684|10138979|FG000|Overall Study|Lost to Follow-up|0
6357507|NCT02270684|10138980|FG001|Overall Study|Lost to Follow-up|3
6083910|NCT00640146|9692751|FG000|Overall Study|Adverse Event|2
6083911|NCT00640146|9692752|FG001|Overall Study|Adverse Event|0
6083912|NCT00640146|9692751|FG000|Overall Study|Lost to Follow-up|0
6083913|NCT00640146|9692752|FG001|Overall Study|Lost to Follow-up|1
6170342|NCT01252940|9816653|FG001|Main Study Phase|Physician Decision|0
6170343|NCT01252940|9816652|FG000|Main Study Phase|Protocol Violation|4
6357508|NCT02270684|10138979|FG000|Overall Study|Study terminated|1
6357509|NCT02270684|10138980|FG001|Overall Study|Study terminated|0
6357510|NCT02271594|10138997|FG000|Overall Study|Study closed; recruiting failure|19
6357511|NCT02271594|10138998|FG001|Overall Study|Study closed; recruiting failure|12
6357512|NCT02263365|10139008|FG000|Overall Study|Physician Decision|22
6357513|NCT02263365|10139009|FG001|Overall Study|Physician Decision|18
6357514|NCT02241551|10139043|FG000|Overall Study|Adverse Event|1
6357515|NCT02241551|10139044|FG001|Overall Study|Adverse Event|0
6357516|NCT02246114|10139054|FG000|Overall Study|miscarriage|1
6357517|NCT02246114|10139055|FG001|Overall Study|miscarriage|0
6357518|NCT02232880|10139061|FG000|Overall Study|study stopped prior to randomization|1
6357519|NCT02244944|10139083|FG000|Overall Study|Withdrawal by Subject|1
6357520|NCT02244944|10139083|FG000|Overall Study|Study Terminated|1
6357521|NCT02241187|10139087|FG000|Overall Study|Protocol closed due to lack of accrual.|2
6357522|NCT02239926|10139093|FG000|Overall Study|Withdrawal by Subject|0
6357523|NCT02239926|10139094|FG001|Overall Study|Withdrawal by Subject|1
6357524|NCT02231892|10139103|FG000|Overall Study|Lost to Follow-up|1
6357525|NCT02231892|10139104|FG001|Overall Study|Lost to Follow-up|0
6357526|NCT02231892|10139105|FG002|Overall Study|Lost to Follow-up|3
6357527|NCT02231892|10139103|FG000|Overall Study|Withdrawal by Subject|4
6357528|NCT02231892|10139104|FG001|Overall Study|Withdrawal by Subject|3
6357529|NCT02231892|10139105|FG002|Overall Study|Withdrawal by Subject|15
6357530|NCT02231892|10139103|FG000|Overall Study|Physician Decision|0
6357531|NCT02231892|10139104|FG001|Overall Study|Physician Decision|2
6357532|NCT02231892|10139105|FG002|Overall Study|Physician Decision|4
6357533|NCT02231892|10139103|FG000|Overall Study|Motor activity when stimulating ante ACC|4
6357534|NCT02231892|10139104|FG001|Overall Study|Motor activity when stimulating ante ACC|7
6357535|NCT02231892|10139105|FG002|Overall Study|Motor activity when stimulating ante ACC|12
6357536|NCT02231892|10139103|FG000|Overall Study|Participant motor threshold was >83%|0
6357537|NCT02231892|10139104|FG001|Overall Study|Participant motor threshold was >83%|0
6357538|NCT02231892|10139105|FG002|Overall Study|Participant motor threshold was >83%|9
6357539|NCT02231892|10139103|FG000|Overall Study|Could not find motor threshold|2
6357540|NCT02231892|10139104|FG001|Overall Study|Could not find motor threshold|0
6357541|NCT02231892|10139105|FG002|Overall Study|Could not find motor threshold|1
6357542|NCT02231892|10139103|FG000|Overall Study|Could not find reliable motor hotspot|0
6357543|NCT02231892|10139104|FG001|Overall Study|Could not find reliable motor hotspot|0
6357544|NCT02231892|10139105|FG002|Overall Study|Could not find reliable motor hotspot|1
6357545|NCT02241343|10139119|FG000|Overall Study|Adverse Event|1
6170344|NCT01252940|9816653|FG001|Main Study Phase|Protocol Violation|2
6170345|NCT01252940|9816652|FG000|Main Study Phase|Withdrawal by Subject|6
6170346|NCT01252940|9816653|FG001|Main Study Phase|Withdrawal by Subject|5
6083914|NCT00640146|9692751|FG000|Overall Study|Lack of Efficacy|0
6357546|NCT02224599|10139154|FG000|Overall Study|Physician Decision|1
6357547|NCT02224599|10139154|FG000|Overall Study|Progression of Disease|1
6357548|NCT02201472|10139158|FG000|Overall Study|Lack of Efficacy|2
6357549|NCT02200042|10139181|FG000|Overall Study|Withdrawal by Subject|0
6357550|NCT02200042|10139182|FG001|Overall Study|Withdrawal by Subject|1
6357551|NCT02181790|10139190|FG000|Overall Study|study terminated|2
6357552|NCT02181790|10139191|FG001|Overall Study|study terminated|0
6357553|NCT02177266|10139219|FG000|Overall Study|Adverse Event|0
6357554|NCT02177266|10139220|FG001|Overall Study|Adverse Event|1
6357555|NCT02177266|10139219|FG000|Overall Study|Withdrawal by Subject|1
6357556|NCT02177266|10139220|FG001|Overall Study|Withdrawal by Subject|0
6357557|NCT02170298|10139237|FG000|Overall Study|Withdrawal by Subject|0
6357558|NCT02170298|10139238|FG001|Overall Study|Withdrawal by Subject|1
6357559|NCT02170298|10139237|FG000|Overall Study|unblinded, rerandomized to intervention|1
6357560|NCT02170298|10139238|FG001|Overall Study|unblinded, rerandomized to intervention|0
6357561|NCT02169830|10139260|FG000|Diet Intervention (4 Weeks)|Lost to Follow-up|0
6357562|NCT02169830|10139261|FG001|Diet Intervention (4 Weeks)|Lost to Follow-up|0
6357563|NCT02169830|10139262|FG002|Diet Intervention (4 Weeks)|Lost to Follow-up|1
6357564|NCT02169830|10139260|FG000|Second Intervention (8 Weeks)|Lost to Follow-up|1
6357565|NCT02169830|10139261|FG001|Second Intervention (8 Weeks)|Lost to Follow-up|0
6357566|NCT02169830|10139262|FG002|Second Intervention (8 Weeks)|Lost to Follow-up|0
6357567|NCT02169830|10139260|FG000|Second Intervention (8 Weeks)|Withdrawal by Subject|2
6357568|NCT02169830|10139261|FG001|Second Intervention (8 Weeks)|Withdrawal by Subject|5
6357569|NCT02169830|10139262|FG002|Second Intervention (8 Weeks)|Withdrawal by Subject|0
6357570|NCT02169830|10139260|FG000|Third Intervention (8 Weeks)|Lost to Follow-up|0
6357571|NCT02169830|10139261|FG001|Third Intervention (8 Weeks)|Lost to Follow-up|1
6357572|NCT02169830|10139262|FG002|Third Intervention (8 Weeks)|Lost to Follow-up|0
6357573|NCT02169830|10139260|FG000|Third Intervention (8 Weeks)|Withdrawal by Subject|0
6357574|NCT02169830|10139261|FG001|Third Intervention (8 Weeks)|Withdrawal by Subject|1
6357575|NCT02169830|10139262|FG002|Third Intervention (8 Weeks)|Withdrawal by Subject|0
6357576|NCT02163187|10139272|FG000|Overall Study|Device removed|1
6357577|NCT02163187|10139273|FG001|Overall Study|Device removed|0
6357578|NCT02163187|10139272|FG000|Overall Study|Progressive disease|1
6357579|NCT02163187|10139273|FG001|Overall Study|Progressive disease|0
6357580|NCT02161016|10139279|FG000|Overall Study|withdrawn by IRB|1
6357581|NCT02159040|10139283|FG000|Overall Study|Death|1
6357582|NCT02168270|10139287|FG000|Overall Study|Lack of Efficacy|4
6357583|NCT02157116|10139291|FG000|Overall Study|Withdrawal by Subject|4
6357584|NCT02157116|10139291|FG000|Overall Study|Physician Decision|3
6357585|NCT02157116|10139291|FG000|Overall Study|Failed Screening|2
6357586|NCT02154087|10139295|FG000|Overall Study|Study Termination|1
6357587|NCT02152566|10139303|FG000|Overall Study|Lost to Follow-up|1
6357588|NCT02152566|10139303|FG000|Overall Study|Withdrawal by Subject|2
6357589|NCT02145390|10139320|FG000|Overall Study|Withdrawal by Subject|1
6357590|NCT02150863|10139353|FG000|Overall Study|Lost to Follow-up|0
6357591|NCT02150863|10139354|FG001|Overall Study|Lost to Follow-up|1
6357592|NCT02150863|10139355|FG002|Overall Study|Lost to Follow-up|0
6357593|NCT02131155|10139391|FG000|Overall Study|Adverse Event|1
6357594|NCT02131155|10139392|FG001|Overall Study|Adverse Event|0
6357595|NCT02131155|10139391|FG000|Overall Study|Treatment completed|1
6357596|NCT02131155|10139392|FG001|Overall Study|Treatment completed|0
6357597|NCT02131155|10139391|FG000|Overall Study|Primary tumour recurrence|2
6357598|NCT02131155|10139392|FG001|Overall Study|Primary tumour recurrence|1
6357599|NCT02131155|10139391|FG000|Overall Study|Refused to continue study medication|1
6357600|NCT02131155|10139392|FG001|Overall Study|Refused to continue study medication|0
6357601|NCT02131155|10139391|FG000|Overall Study|Study early termination|20
6357602|NCT02131155|10139392|FG001|Overall Study|Study early termination|10
6357603|NCT02117050|10139398|FG000|Overall Study|Subject Enrolled but not Dosed|1
6357604|NCT02105116|10139420|FG000|Overall Study|not eligible for step 2 of trial|5
6357605|NCT02105116|10139420|FG000|Overall Study|Death|1
6357606|NCT02099344|10139437|FG000|Overall Study|Physician Decision|1
6357607|NCT02099344|10139438|FG001|Overall Study|Physician Decision|0
6357608|NCT02096042|10139455|FG000|Overall Study|Disease Progression|1
6357609|NCT02096042|10139456|FG001|Overall Study|Disease Progression|0
6357610|NCT02096042|10139457|FG002|Overall Study|Disease Progression|0
6357611|NCT02088957|10139464|FG000|Overall Study|Lack of Efficacy|1
6357612|NCT02088957|10139465|FG001|Overall Study|Lack of Efficacy|0
6357613|NCT02093689|10139474|FG000|Overall Study|Physician Decision|4
6357614|NCT02093689|10139475|FG001|Overall Study|Physician Decision|0
6357615|NCT02093689|10139476|FG002|Overall Study|Physician Decision|0
6357616|NCT02091752|10139482|FG000|Overall Study|Study terminated by Sponsor|2
6357617|NCT02091752|10139482|FG000|Overall Study|Adverse Event|1
6357618|NCT02068547|10139488|FG000|Overall Study|Lost to Follow-up|3
6357619|NCT02068547|10139489|FG001|Overall Study|Lost to Follow-up|3
6357620|NCT02068547|10139488|FG000|Overall Study|Physician Decision|1
6357621|NCT02068547|10139489|FG001|Overall Study|Physician Decision|0
6357622|NCT02081183|10139527|FG000|Overall Study|Lost to Follow-up|0
6357623|NCT02081183|10139528|FG001|Overall Study|Lost to Follow-up|1
6357624|NCT02081183|10139527|FG000|Overall Study|Protocol Violation|1
6357625|NCT02081183|10139528|FG001|Overall Study|Protocol Violation|0
6357626|NCT02081183|10139527|FG000|Overall Study|Other|3
6357627|NCT02081183|10139528|FG001|Overall Study|Other|3
6357628|NCT02067104|10139548|FG000|Overall Study|Study termination due to low accrual|4
6357629|NCT02067104|10139549|FG001|Overall Study|Study termination due to low accrual|5
6357630|NCT02057874|10139559|FG000|Overall Study|participant did not return for scan|1
6357631|NCT02058537|10139573|FG000|Overall Study|Withdrawal by Subject|1
6357632|NCT02038153|10139586|FG000|Overall Study|Withdrawal by Subject|1
6357633|NCT02054910|10139592|FG000|Overall Study|Lost to Follow-up|4
6357634|NCT02054910|10139593|FG001|Overall Study|Lost to Follow-up|1
6357635|NCT02044302|10139603|FG000|Overall Study|study terminated|2
6357636|NCT02044302|10139604|FG001|Overall Study|study terminated|0
6357637|NCT02046226|10139608|FG000|Overall Study|Lost to Follow-up|7
6357638|NCT02044848|10139615|FG000|Overall Study|Administrative Problems|2
6357639|NCT02044848|10139616|FG001|Overall Study|Administrative Problems|3
6357640|NCT02042950|10139622|FG000|Overall Study|Progressive Disease|4
6357641|NCT02048904|10139626|FG000|Overall Study|Withdrawal by Subject|7
6357642|NCT02048904|10139626|FG000|Overall Study|Physician Decision|70
6357643|NCT02044822|10139630|FG000|Overall Study|Study Terminated by Sponsor|77
6357644|NCT02044822|10139630|FG000|Overall Study|Investigator's Discretion|10
6357645|NCT02044822|10139630|FG000|Overall Study|Withdrew Consent|3
6357646|NCT02044822|10139630|FG000|Overall Study|Initiation of Anti-Neoplastic Therapy|2
6357647|NCT02044822|10139630|FG000|Overall Study|Lost to Follow-up|1
6357648|NCT02042924|10139634|FG000|Overall Study|Early Death|1
6357649|NCT02017522|10139642|FG000|Overall Study|Withdrawal by Subject|1
6357650|NCT02030015|10139647|FG000|Overall Study|Withdrawal by Subject|3
6357651|NCT02030015|10139647|FG000|Overall Study|Death|13
6357652|NCT02015663|10139653|FG000|Overall Study|unsatisfactory therapeutic effect|1
6357653|NCT02015663|10139654|FG001|Overall Study|unsatisfactory therapeutic effect|0
6357654|NCT02015663|10139653|FG000|Overall Study|Withdrawal by Subject|1
6357655|NCT02015663|10139654|FG001|Overall Study|Withdrawal by Subject|0
6357656|NCT02015663|10139653|FG000|Overall Study|Protocol Violation|0
6357657|NCT02015663|10139654|FG001|Overall Study|Protocol Violation|1
6357658|NCT02015663|10139653|FG000|Overall Study|Adverse Event|3
6357659|NCT02015663|10139654|FG001|Overall Study|Adverse Event|0
6357660|NCT02015663|10139653|FG000|Overall Study|Administrative problems|10
6357661|NCT02015663|10139654|FG001|Overall Study|Administrative problems|11
6357662|NCT02029846|10139663|FG000|Overall Study|n=1 each arm|1
6357663|NCT02029846|10139664|FG001|Overall Study|n=1 each arm|1
6357664|NCT02011542|10139701|FG000|Overall Study|Physician Decision|1
6357665|NCT02008370|10139705|FG000|Overall Study|Lost to Follow-up|7
6357666|NCT02005445|10139726|FG000|Overall Study|Dual study enrollment|0
6357667|NCT02005445|10139727|FG001|Overall Study|Dual study enrollment|1
6357668|NCT02006927|10139746|FG000|Overall Study|Adverse Event|2
6357669|NCT02006927|10139746|FG000|Overall Study|Withdrawal by Subject|1
6357670|NCT01996982|10139750|FG000|Overall Study|PI/team left institution|7
6357671|NCT01986751|10139760|FG000|Overall Study|improperly consented|10
6357672|NCT01986751|10139761|FG001|Overall Study|improperly consented|2
6357673|NCT01977729|10139820|FG000|Overall Study|Study terminated|1
6357674|NCT01982253|10139833|FG000|Overall Study|Withdrawal by Subject|1
6357675|NCT01982253|10139834|FG001|Overall Study|Withdrawal by Subject|0
6357676|NCT01982253|10139835|FG002|Overall Study|Withdrawal by Subject|0
6357677|NCT01982253|10139833|FG000|Overall Study|Study terminated by sponsor|1
6357678|NCT01982253|10139834|FG001|Overall Study|Study terminated by sponsor|4
6357679|NCT01982253|10139835|FG002|Overall Study|Study terminated by sponsor|4
6357680|NCT01984268|10139843|FG000|Overall Study|Study Terminated|15
6357681|NCT01980875|10139863|FG000|Overall Study|Withdrew Consent|1
6357682|NCT01980875|10139864|FG001|Overall Study|Withdrew Consent|1
6357683|NCT01980875|10139865|FG002|Overall Study|Withdrew Consent|1
6357684|NCT01980875|10139863|FG000|Overall Study|Study Terminated by Sponsor|7
6357685|NCT01980875|10139864|FG001|Overall Study|Study Terminated by Sponsor|24
6357686|NCT01980875|10139865|FG002|Overall Study|Study Terminated by Sponsor|22
6357687|NCT01980875|10139863|FG000|Overall Study|Lost to Follow-up|0
6357688|NCT01980875|10139864|FG001|Overall Study|Lost to Follow-up|0
6357689|NCT01980875|10139865|FG002|Overall Study|Lost to Follow-up|1
6357690|NCT01970462|10139911|FG000|Overall Study|Lost to Follow-up|0
6357691|NCT01970462|10139912|FG001|Overall Study|Lost to Follow-up|2
6357692|NCT01969565|10139918|FG000|Overall Study|Withdrawal by Subject|1
6357693|NCT01968226|10139923|FG000|Overall Study|[F-18] RDG-K5 was not available|2
6357694|NCT01962974|10139942|FG000|Overall Study|Study termination|7
6357695|NCT01951378|10139959|FG000|Overall Study|Study Terminated-Not completed|23
6357696|NCT01951378|10139960|FG001|Overall Study|Study Terminated-Not completed|17
6357697|NCT01944059|10139983|FG000|Overall Study|Lost to Follow-up|1
6357698|NCT01944059|10139983|FG000|Overall Study|Physician Decision|3
6357699|NCT01944059|10139983|FG000|Overall Study|Withdrawal by Subject|1
6357700|NCT01944059|10139983|FG000|Overall Study|Adverse Event|2
6357701|NCT01935947|10139991|FG000|Overall Study|Adverse Event|0
6357702|NCT01935947|10139992|FG001|Overall Study|Adverse Event|2
6357703|NCT01935947|10139993|FG002|Overall Study|Adverse Event|0
6357704|NCT01935947|10139991|FG000|Overall Study|Diease Progression|2
6357705|NCT01935947|10139992|FG001|Overall Study|Diease Progression|2
6357706|NCT01935947|10139993|FG002|Overall Study|Diease Progression|2
6357707|NCT01935947|10139991|FG000|Overall Study|Death|1
6357708|NCT01935947|10139992|FG001|Overall Study|Death|0
6357709|NCT01935947|10139993|FG002|Overall Study|Death|0
6357710|NCT01939223|10140006|FG000|Overall Study|AE not assoc. with disease recurrence|1
6357711|NCT01939223|10140007|FG001|Overall Study|AE not assoc. with disease recurrence|1
6357712|NCT01939223|10140006|FG000|Overall Study|Disease recurrence (radiological)|1
6357713|NCT01939223|10140007|FG001|Overall Study|Disease recurrence (radiological)|3
6357714|NCT01939223|10140006|FG000|Overall Study|Study stopped by Sponsor|5
6357715|NCT01939223|10140007|FG001|Overall Study|Study stopped by Sponsor|7
6357716|NCT01939223|10140006|FG000|Overall Study|Withdrawal by Subject|6
6357717|NCT01939223|10140007|FG001|Overall Study|Withdrawal by Subject|0
6357718|NCT01938716|10140013|FG000|Overall Study|Physician Decision|2
6357719|NCT01938716|10140013|FG000|Overall Study|Withdrawal by Subject|2
6357720|NCT01936974|10140019|FG000|Overall Study|Physician Decision|2
6357721|NCT01936974|10140020|FG001|Overall Study|Physician Decision|5
6357722|NCT01934504|10140047|FG000|Overall Study|Protocol Deviation|0
6357723|NCT01934504|10140048|FG001|Overall Study|Protocol Deviation|0
6357724|NCT01934504|10140049|FG002|Overall Study|Protocol Deviation|0
6357725|NCT01934504|10140050|FG003|Overall Study|Protocol Deviation|2
6357726|NCT01934504|10140047|FG000|Overall Study|Study Terminated by Sponsor|1
6357727|NCT01934504|10140048|FG001|Overall Study|Study Terminated by Sponsor|0
6357728|NCT01934504|10140049|FG002|Overall Study|Study Terminated by Sponsor|5
6357729|NCT01934504|10140050|FG003|Overall Study|Study Terminated by Sponsor|5
6357730|NCT01928082|10140060|FG000|Overall Study|Study terminated.|1
6357731|NCT01928615|10140064|FG000|Overall Study|Study Terminated by Sponsor|2
6357732|NCT01911793|10140071|FG000|Overall Study|Physician Decision|1
6357733|NCT01911793|10140072|FG001|Overall Study|Physician Decision|5
6357734|NCT01912404|10140080|FG000|Overall Study|Due to personal reasons|1
6357735|NCT01912404|10140081|FG001|Overall Study|Due to personal reasons|0
6357736|NCT01910389|10140089|FG000|Overall Study|Withdrawal by Subject|2
6357737|NCT01910389|10140090|FG001|Overall Study|Withdrawal by Subject|0
6357738|NCT01910389|10140089|FG000|Overall Study|Study Closed|13
6357739|NCT01910389|10140090|FG001|Overall Study|Study Closed|8
6357740|NCT01913327|10140116|FG000|Overall Study|Withdrawal by Subject|0
6357741|NCT01913327|10140117|FG001|Overall Study|Withdrawal by Subject|1
6357742|NCT01902888|10140123|FG000|Overall Study|Study Terminated|3
6357743|NCT01901224|10140127|FG000|Overall Study|study was not funded and terminated|2
6357744|NCT01910441|10140133|FG000|Overall Study|Sponsor decision|0
6357745|NCT01910441|10140134|FG001|Overall Study|Sponsor decision|2
6357746|NCT01910441|10140133|FG000|Overall Study|Lost to Follow-up|6
6357747|NCT01910441|10140134|FG001|Overall Study|Lost to Follow-up|5
6357748|NCT01910441|10140133|FG000|Overall Study|Withdrawal by Subject|0
6357749|NCT01910441|10140134|FG001|Overall Study|Withdrawal by Subject|1
6357750|NCT01910441|10140133|FG000|Overall Study|Non-compliance|0
6357751|NCT01910441|10140134|FG001|Overall Study|Non-compliance|1
6357752|NCT01910441|10140133|FG000|Overall Study|Adverse Event|1
6357753|NCT01910441|10140134|FG001|Overall Study|Adverse Event|0
6357754|NCT01910441|10140133|FG000|Overall Study|Physician Decision|0
6357755|NCT01910441|10140134|FG001|Overall Study|Physician Decision|1
6357756|NCT01902966|10140140|FG000|Overall Study|Death|1
6357757|NCT01902966|10140140|FG000|Overall Study|Physician Decision|1
6357758|NCT01902966|10140140|FG000|Overall Study|Withdrawal by Subject|1
6357759|NCT01900730|10140155|FG000|Overall Study|Withdrawal by Subject|1
6357760|NCT01900730|10140156|FG001|Overall Study|Withdrawal by Subject|0
6357761|NCT01900730|10140155|FG000|Overall Study|Screen Failure|1
6357762|NCT01900730|10140156|FG001|Overall Study|Screen Failure|0
6357763|NCT01900626|10140184|FG000|Overall Study|study was closed due to low enrollment|1
6357764|NCT01900626|10140185|FG001|Overall Study|study was closed due to low enrollment|1
6357765|NCT01884077|10140207|FG000|Overall Study|screen fail|0
6357766|NCT01884077|10140208|FG001|Overall Study|screen fail|2
6357767|NCT01884077|10140207|FG000|Overall Study|canceled surgery|2
6357768|NCT01884077|10140208|FG001|Overall Study|canceled surgery|0
6357769|NCT01884077|10140207|FG000|Overall Study|Lost to Follow-up|0
6357770|NCT01884077|10140208|FG001|Overall Study|Lost to Follow-up|4
6357771|NCT01884077|10140207|FG000|Overall Study|study closed|6
6357772|NCT01884077|10140208|FG001|Overall Study|study closed|4
6357773|NCT01887288|10140240|FG000|Overall Study|The study was terminated and the PI has|16
6357774|NCT01861717|10140283|FG000|Overall Study|Lost to Follow-up|1
6357775|NCT01861717|10140283|FG000|Overall Study|Withdrawal by Subject|1
6357776|NCT01866709|10140290|FG000|Overall Study|Adverse Event|1
6357777|NCT01866709|10140291|FG001|Overall Study|Adverse Event|0
6357778|NCT01860040|10140299|FG000|Overall Study|Withdrawal by Subject|1
6357779|NCT01860040|10140300|FG001|Overall Study|Withdrawal by Subject|0
6357780|NCT01856322|10140345|FG000|Overall Study|off study due to lack of accrual|0
6357781|NCT01856322|10140346|FG001|Overall Study|off study due to lack of accrual|0
6357782|NCT01856322|10140347|FG002|Overall Study|off study due to lack of accrual|3
6357783|NCT01853176|10140356|FG000|Overall Study|Study terminated|4
6357784|NCT01853176|10140357|FG001|Overall Study|Study terminated|0
6357785|NCT01857271|10140363|FG000|Overall Study|Lost to Follow-up|1
6357786|NCT01853982|10140378|FG000|Overall Study|Withdrawal by Subject|1
6357787|NCT01853982|10140379|FG001|Overall Study|Withdrawal by Subject|0
6357788|NCT01853982|10140378|FG000|Overall Study|Death|1
6357789|NCT01853982|10140379|FG001|Overall Study|Death|0
6357790|NCT01853982|10140378|FG000|Overall Study|Lost to Follow-up|0
6357791|NCT01853982|10140379|FG001|Overall Study|Lost to Follow-up|1
6357792|NCT01831596|10140410|FG000|Overall Study|Other|8
6357793|NCT01821963|10140423|FG000|Overall Study|Adverse Event|1
6357794|NCT01821898|10140429|FG000|Overall Study|Withdrawal by Subject|2
6357795|NCT01821898|10140430|FG001|Overall Study|Withdrawal by Subject|1
6357796|NCT01829477|10140461|FG000|Overall Study|Study Terminated by Sponsor|15
6357797|NCT01829477|10140462|FG001|Overall Study|Study Terminated by Sponsor|15
6357798|NCT01829477|10140461|FG000|Overall Study|Withdrawal by Subject|1
6357799|NCT01829477|10140462|FG001|Overall Study|Withdrawal by Subject|0
6357800|NCT01803711|10140470|FG000|Overall Study|Adverse Event|1
6357801|NCT01803711|10140471|FG001|Overall Study|Adverse Event|1
6357802|NCT01806051|10140499|FG000|Overall Study|Withdrawal by Subject|6
6357803|NCT01810302|10140526|FG000|Overall Study|Death|1
6357804|NCT01810302|10140527|FG001|Overall Study|Death|0
6357805|NCT01810302|10140526|FG000|Overall Study|Physician Decision|0
6357806|NCT01810302|10140527|FG001|Overall Study|Physician Decision|1
6357807|NCT01806961|10140533|FG000|Overall Study|sponsor decision|16
6357808|NCT01783015|10140543|FG000|Blinded Treatment|Adverse Event|0
6083915|NCT00640146|9692752|FG001|Overall Study|Lack of Efficacy|1
6083916|NCT00640146|9692751|FG000|Overall Study|Withdrawal by Subject|1
6083917|NCT00640146|9692752|FG001|Overall Study|Withdrawal by Subject|1
6357809|NCT01783015|10140544|FG001|Blinded Treatment|Adverse Event|1
6357810|NCT01783015|10140545|FG002|Blinded Treatment|Adverse Event|0
6357811|NCT01783015|10140543|FG000|Blinded Treatment|Protocol Violation|0
6357812|NCT01783015|10140544|FG001|Blinded Treatment|Protocol Violation|1
6357813|NCT01783015|10140545|FG002|Blinded Treatment|Protocol Violation|0
6357814|NCT01783015|10140543|FG000|Blinded Treatment|Withdrawal by Subject|0
6357815|NCT01783015|10140544|FG001|Blinded Treatment|Withdrawal by Subject|1
6357816|NCT01783015|10140545|FG002|Blinded Treatment|Withdrawal by Subject|0
6357817|NCT01783015|10140543|FG000|Blinded Treatment|Study Terminated by Sponsor|2
6357818|NCT01783015|10140544|FG001|Blinded Treatment|Study Terminated by Sponsor|0
6357819|NCT01783015|10140545|FG002|Blinded Treatment|Study Terminated by Sponsor|0
6357820|NCT01783015|10140543|FG000|Open Label Treatment|Study Terminated by Sponsor|0
6357821|NCT01783015|10140544|FG001|Open Label Treatment|Study Terminated by Sponsor|0
6357822|NCT01783015|10140545|FG002|Open Label Treatment|Study Terminated by Sponsor|6
6357823|NCT01781026|10140579|FG000|Overall Study|Lack of Efficacy|2
6357824|NCT01777854|10140605|FG000|Overall Study|Physician Decision|3
6357825|NCT01777854|10140606|FG001|Overall Study|Physician Decision|3
6357826|NCT01772719|10140614|FG000|Overall Study|Withdrawal by Subject|3
6357827|NCT01772719|10140614|FG000|Overall Study|Adverse Event|2
6357828|NCT01772719|10140614|FG000|Overall Study|Protocol Violation|1
6357829|NCT01772719|10140614|FG000|Overall Study|Lost to Follow-up|1
6357830|NCT01764997|10140626|FG000|Run-in Period|Adverse Event|15
6357831|NCT01764997|10140627|FG001|Run-in Period|Adverse Event|0
6357832|NCT01764997|10140628|FG002|Run-in Period|Adverse Event|0
6357833|NCT01764997|10140629|FG003|Run-in Period|Adverse Event|0
6357834|NCT01764997|10140630|FG004|Run-in Period|Adverse Event|0
6357835|NCT01764997|10140626|FG000|Run-in Period|Lack of Efficacy|5
6357836|NCT01764997|10140627|FG001|Run-in Period|Lack of Efficacy|0
6357837|NCT01764997|10140628|FG002|Run-in Period|Lack of Efficacy|0
6357838|NCT01764997|10140629|FG003|Run-in Period|Lack of Efficacy|0
6083918|NCT00640146|9692751|FG000|Overall Study|Randomized but not treated|1
6357839|NCT01764997|10140630|FG004|Run-in Period|Lack of Efficacy|0
6357840|NCT01764997|10140626|FG000|Run-in Period|Poor compliance to protocol|1
6357841|NCT01764997|10140627|FG001|Run-in Period|Poor compliance to protocol|0
6357842|NCT01764997|10140628|FG002|Run-in Period|Poor compliance to protocol|0
6357843|NCT01764997|10140629|FG003|Run-in Period|Poor compliance to protocol|0
6083919|NCT00640146|9692752|FG001|Overall Study|Randomized but not treated|3
6357844|NCT01764997|10140630|FG004|Run-in Period|Poor compliance to protocol|0
6357845|NCT01764997|10140626|FG000|Run-in Period|Other than specified above|17
6357846|NCT01764997|10140627|FG001|Run-in Period|Other than specified above|0
6083920|NCT00640224|9692762|FG000|Overall Study|Lost to Follow-up|5
6083921|NCT00640224|9692763|FG001|Overall Study|Lost to Follow-up|2
6083922|NCT00640224|9692764|FG002|Overall Study|Lost to Follow-up|0
6083923|NCT00640224|9692765|FG003|Overall Study|Lost to Follow-up|0
6083924|NCT00640224|9692762|FG000|Overall Study|Withdrawal by Subject|1
6083925|NCT00640224|9692763|FG001|Overall Study|Withdrawal by Subject|0
6083926|NCT00640224|9692764|FG002|Overall Study|Withdrawal by Subject|0
6083927|NCT00640224|9692765|FG003|Overall Study|Withdrawal by Subject|0
6083928|NCT00640224|9692762|FG000|Overall Study|Headaches|0
6083929|NCT00640224|9692763|FG001|Overall Study|Headaches|1
6357847|NCT01764997|10140628|FG002|Run-in Period|Other than specified above|0
6357848|NCT01764997|10140629|FG003|Run-in Period|Other than specified above|0
6357849|NCT01764997|10140630|FG004|Run-in Period|Other than specified above|0
6083930|NCT00640224|9692764|FG002|Overall Study|Headaches|0
6357850|NCT01764997|10140626|FG000|Study Drug Treatment Period|Adverse Event|0
6357851|NCT01764997|10140627|FG001|Study Drug Treatment Period|Adverse Event|1
6357852|NCT01764997|10140628|FG002|Study Drug Treatment Period|Adverse Event|0
6357853|NCT01764997|10140629|FG003|Study Drug Treatment Period|Adverse Event|0
6357854|NCT01764997|10140630|FG004|Study Drug Treatment Period|Adverse Event|24
6357855|NCT01764997|10140626|FG000|Study Drug Treatment Period|Lack of Efficacy|0
6357856|NCT01764997|10140627|FG001|Study Drug Treatment Period|Lack of Efficacy|0
6357857|NCT01764997|10140628|FG002|Study Drug Treatment Period|Lack of Efficacy|0
6357858|NCT01764997|10140629|FG003|Study Drug Treatment Period|Lack of Efficacy|0
6357859|NCT01764997|10140630|FG004|Study Drug Treatment Period|Lack of Efficacy|2
6357860|NCT01764997|10140626|FG000|Study Drug Treatment Period|Other than specified above|0
6357861|NCT01764997|10140627|FG001|Study Drug Treatment Period|Other than specified above|0
6357862|NCT01764997|10140628|FG002|Study Drug Treatment Period|Other than specified above|0
6357863|NCT01764997|10140629|FG003|Study Drug Treatment Period|Other than specified above|0
6357864|NCT01764997|10140630|FG004|Study Drug Treatment Period|Other than specified above|10
6357865|NCT01769443|10140646|FG000|Overall Study|Study closure|1
6357866|NCT01769443|10140647|FG001|Overall Study|Study closure|0
6357867|NCT01749826|10140669|FG000|Overall Study|Study Terminated|20
6357868|NCT01749826|10140670|FG001|Overall Study|Study Terminated|0
6083931|NCT00640224|9692765|FG003|Overall Study|Headaches|0
6083932|NCT00640289|9692878|FG000|Overall Study|Death|3
6083933|NCT00640289|9692878|FG000|Overall Study|Withdrawal by Subject|1
6083934|NCT00640289|9692878|FG000|Overall Study|Lost to Follow-up|1
6357869|NCT01752023|10140731|FG000|Overall Study|Physician Decision|2
6357870|NCT01752023|10140732|FG001|Overall Study|Physician Decision|1
6357871|NCT01740154|10140742|FG000|Overall Study|Adverse Event|1
6357872|NCT01748890|10140746|FG000|Overall Study|Insufficient recruitment for analysis|4
6357873|NCT01748162|10140752|FG000|Overall Study|no additional croup episodes to evaluate|2
6357874|NCT01748162|10140753|FG001|Overall Study|no additional croup episodes to evaluate|2
6357875|NCT01748162|10140752|FG000|Overall Study|participant consented but did not begin|0
6357876|NCT01748162|10140753|FG001|Overall Study|participant consented but did not begin|1
6357877|NCT01748162|10140752|FG000|Overall Study|reasons not available|3
6357878|NCT01748162|10140753|FG001|Overall Study|reasons not available|2
6357879|NCT01732926|10140778|FG000|Overall Study|Study Terminated by Sponsor|168
6357880|NCT01732926|10140779|FG001|Overall Study|Study Terminated by Sponsor|80
6357881|NCT01732926|10140778|FG000|Overall Study|Withdrawal by Subject|46
6357882|NCT01732926|10140779|FG001|Overall Study|Withdrawal by Subject|8
6357883|NCT01732926|10140778|FG000|Overall Study|Physician Decision|24
6357884|NCT01732926|10140779|FG001|Overall Study|Physician Decision|11
6357885|NCT01732926|10140778|FG000|Overall Study|Other Reason|21
6357886|NCT01732926|10140779|FG001|Overall Study|Other Reason|4
6357887|NCT01732926|10140778|FG000|Overall Study|Initiation of Other Anti-Cancer Therapy|7
6357888|NCT01732926|10140779|FG001|Overall Study|Initiation of Other Anti-Cancer Therapy|6
6357889|NCT01732926|10140778|FG000|Overall Study|Blind Broken by Subject or Study Site|1
6357890|NCT01732926|10140779|FG001|Overall Study|Blind Broken by Subject or Study Site|1
6357891|NCT01732913|10140796|FG000|Overall Study|Study Terminated by Sponsor|105
6357892|NCT01732913|10140797|FG001|Overall Study|Study Terminated by Sponsor|55
6357893|NCT01732913|10140796|FG000|Overall Study|Withdrawal by Subject|27
6357894|NCT01732913|10140797|FG001|Overall Study|Withdrawal by Subject|4
6357895|NCT01732913|10140796|FG000|Overall Study|Physician Decision|14
6357896|NCT01732913|10140797|FG001|Overall Study|Physician Decision|7
6357897|NCT01732913|10140796|FG000|Overall Study|Other|7
6357898|NCT01732913|10140797|FG001|Overall Study|Other|1
6357899|NCT01732913|10140796|FG000|Overall Study|Initiation of Other Anti-Cancer Therapy|3
6357900|NCT01732913|10140797|FG001|Overall Study|Initiation of Other Anti-Cancer Therapy|2
6357901|NCT01716052|10140809|FG000|Overall Study|Withdrawal of funding|1
6357902|NCT01716052|10140810|FG001|Overall Study|Withdrawal of funding|1
6357903|NCT01712854|10140825|FG000|Overall Study|Physician Decision|1
6357904|NCT01708057|10140852|FG000|Overall Study|Withdrawal due to study termination.|1
6357905|NCT01708057|10140853|FG001|Overall Study|Withdrawal due to study termination.|1
6357906|NCT01708057|10140854|FG002|Overall Study|Withdrawal due to study termination.|1
6357907|NCT01693367|10140874|FG000|Overall Study|Withdrawal by Subject|1
6357908|NCT01693367|10140875|FG001|Overall Study|Withdrawal by Subject|1
6357909|NCT01693367|10140874|FG000|Overall Study|Physician Decision|0
6357910|NCT01693367|10140875|FG001|Overall Study|Physician Decision|1
6357911|NCT01697800|10140896|FG000|Overall Study|Death|0
6357912|NCT01697800|10140897|FG001|Overall Study|Death|1
6357913|NCT01700348|10140903|FG000|Overall Study|Withdrawal by Subject|22
6357914|NCT01700348|10140903|FG000|Overall Study|Lost to Follow-up|1
6357915|NCT01689974|10140948|FG000|Overall Study|Termination of Study|5
6357916|NCT01689974|10140949|FG001|Overall Study|Termination of Study|5
6357917|NCT01676961|10140955|FG000|Overall Study|Death|3
6357918|NCT01676961|10140955|FG000|Overall Study|Lost to Follow-up|1
6357919|NCT01676961|10140955|FG000|Overall Study|Withdrawal by Subject|1
6357920|NCT01675011|10141023|FG000|Overall Study|Trial terminated by Sponsor|3
6357921|NCT01675011|10141024|FG001|Overall Study|Trial terminated by Sponsor|1
6357922|NCT01668147|10141052|FG000|Overall Study|Withdrawal by Subject|6
6357923|NCT01676701|10141062|FG000|Overall Study|Protocol Violation|1
6357924|NCT01676701|10141063|FG001|Overall Study|Protocol Violation|0
6357925|NCT01676701|10141062|FG000|Overall Study|Sponsor Decision|3
6357926|NCT01676701|10141063|FG001|Overall Study|Sponsor Decision|4
6357927|NCT01662102|10141078|FG000|Overall Study|Sponsor's decision|1
6357928|NCT01662102|10141079|FG001|Overall Study|Sponsor's decision|0
6357929|NCT01659554|10141086|FG000|Overall Study|Study Termination|4
6357930|NCT01658813|10141090|FG000|Overall Study|Disease progression|3
6357931|NCT01642732|10141118|FG000|Overall Study|Withdrawal by Subject|1
6357932|NCT01648270|10141131|FG000|Intravenous Buprenorphine|Withdrawal by Subject|12
6357933|NCT01641601|10141147|FG000|Overall Study|Study discontinued.|3
6357934|NCT01641601|10141148|FG001|Overall Study|Study discontinued.|5
6357935|NCT01627899|10141176|FG000|Overall Study|Study terminated early by sponsor.|5
6357936|NCT01632020|10141182|FG000|Overall Study|Withdrawal by Subject|1
6357937|NCT01632020|10141183|FG001|Overall Study|Withdrawal by Subject|0
6357938|NCT01632020|10141182|FG000|Overall Study|Adverse Event|1
6357939|NCT01632020|10141183|FG001|Overall Study|Adverse Event|0
6357940|NCT01619800|10141195|FG000|Overall Study|study terminated|2
6357941|NCT01619800|10141196|FG001|Overall Study|study terminated|0
6357942|NCT01614067|10141213|FG000|Overall Study|Pregnancy|1
6357943|NCT01614067|10141214|FG001|Overall Study|Pregnancy|0
6357944|NCT01614067|10141213|FG000|Overall Study|Physician Decision|6
6357945|NCT01614067|10141214|FG001|Overall Study|Physician Decision|5
6357946|NCT01614067|10141213|FG000|Overall Study|Withdrawal by Subject|0
6357947|NCT01614067|10141214|FG001|Overall Study|Withdrawal by Subject|1
6357948|NCT01614067|10141213|FG000|Overall Study|Study terminated early by sponsor and was unable to collect data|8
6357949|NCT01614067|10141214|FG001|Overall Study|Study terminated early by sponsor and was unable to collect data|9
6357950|NCT01605019|10141227|FG000|Overall Study|pt did not meet transplant endpoint|3
6357951|NCT01605019|10141228|FG001|Overall Study|pt did not meet transplant endpoint|0
6357952|NCT01609231|10141236|FG000|Overall Study|Adverse Event|1
6357953|NCT01609231|10141237|FG001|Overall Study|Adverse Event|3
6357954|NCT01609231|10141236|FG000|Overall Study|Physician Decision|1
6357955|NCT01609231|10141237|FG001|Overall Study|Physician Decision|0
6357956|NCT01609231|10141236|FG000|Overall Study|Withdrawal by Subject|1
6357957|NCT01609231|10141237|FG001|Overall Study|Withdrawal by Subject|0
6357958|NCT01603043|10141263|FG000|Overall Study|Study Futility|7
6357959|NCT01603043|10141264|FG001|Overall Study|Study Futility|3
6357960|NCT01605370|10141272|FG000|Overall Study|Adverse Event|1
6357961|NCT01605370|10141273|FG001|Overall Study|Adverse Event|0
6357962|NCT01605617|10141281|FG000|First Intervention|Adverse Event|0
6357963|NCT01605617|10141282|FG001|First Intervention|Adverse Event|1
6357964|NCT01605617|10141281|FG000|Washout Period of 4 Weeks|Study Terminated|2
6357965|NCT01605617|10141282|FG001|Washout Period of 4 Weeks|Study Terminated|1
6357966|NCT01603121|10141299|FG000|Second Intervention, 10 Hours|Adverse Event|1
6357967|NCT01603121|10141300|FG001|Second Intervention, 10 Hours|Adverse Event|0
6357968|NCT01603394|10141313|FG000|Overall Study|Adverse Event|1
6357969|NCT01592383|10141317|FG000|Overall Study|Adverse Event|1
6357970|NCT01591096|10141339|FG000|Overall Study|Adverse Event|1
6357971|NCT01576575|10141356|FG000|Buprenorphine Control|Withdrawal by Subject|3
6357972|NCT01576575|10141356|FG000|Buprenorphine + Rifampin|Withdrawal by Subject|3
6357973|NCT01576575|10141356|FG000|Buprenorphine + Grapefruit|Withdrawal by Subject|1
6357974|NCT01582100|10141380|FG000|Overall Study|Adverse Event|1
6357975|NCT01582100|10141380|FG000|Overall Study|Withdrawal by Subject|1
6357976|NCT01575028|10141393|FG000|Overall Study|Physician Decision|0
6357977|NCT01575028|10141394|FG001|Overall Study|Physician Decision|1
6357978|NCT01578785|10141402|FG000|Overall Study|Withdrawal by Subject|0
6357979|NCT01578785|10141403|FG001|Overall Study|Withdrawal by Subject|1
6357980|NCT01578785|10141402|FG000|Overall Study|Study terminated by sponsor|59
6357981|NCT01578785|10141403|FG001|Overall Study|Study terminated by sponsor|118
6357982|NCT01576549|10141409|FG000|Overall Study|Sponsor Decision|2
6357983|NCT01561989|10141429|FG000|Overall Study|accural target not met.|5
6357984|NCT01561989|10141430|FG001|Overall Study|accural target not met.|6
6357985|NCT01564732|10141438|FG000|Overall Study|Early termination by the study sponsor|6
6357986|NCT01564732|10141439|FG001|Overall Study|Early termination by the study sponsor|5
6357987|NCT01560507|10141448|FG000|Overall Study|Lost to Follow-up|3
6357988|NCT01560507|10141449|FG001|Overall Study|Lost to Follow-up|1
6357989|NCT01560507|10141450|FG002|Overall Study|Lost to Follow-up|2
6357990|NCT01560507|10141448|FG000|Overall Study|Withdrawal by Subject|1
6357991|NCT01560507|10141449|FG001|Overall Study|Withdrawal by Subject|1
6357992|NCT01560507|10141450|FG002|Overall Study|Withdrawal by Subject|0
6357993|NCT01555073|10141494|FG000|Overall Study|Lost to Follow-up|1
6357994|NCT01555073|10141495|FG001|Overall Study|Lost to Follow-up|2
6357995|NCT01555073|10141496|FG002|Overall Study|Lost to Follow-up|0
6357996|NCT01555073|10141497|FG003|Overall Study|Lost to Follow-up|5
6357997|NCT01541397|10141532|FG000|Overall Study|Study ended prior to data collection|4
6357998|NCT01541397|10141533|FG001|Overall Study|Study ended prior to data collection|2
6357999|NCT01546207|10141539|FG000|Overall Study|Death|1
6358000|NCT01547728|10141547|FG000|Overall Study|Change in procedure and equipment|1
6358001|NCT01547728|10141547|FG000|Overall Study|Drug not ready for subject|1
6358002|NCT01547728|10141547|FG000|Overall Study|Screen failure|39
6358003|NCT01546883|10141564|FG000|Overall Study|Withdrawal by Subject|3
6358004|NCT01546883|10141564|FG000|Overall Study|Adverse Event|4
6358005|NCT01546883|10141564|FG000|Overall Study|Lost to Follow-up|2
6358006|NCT01546883|10141564|FG000|Overall Study|early closure of study|2
6358007|NCT01546883|10141564|FG000|Overall Study|other unrelated illness|1
6358008|NCT01536015|10141574|FG000|Overall Study|Adverse Event|1
6358009|NCT01536015|10141575|FG001|Overall Study|Adverse Event|4
6358010|NCT01536015|10141574|FG000|Overall Study|Lost to Follow-up|0
6358011|NCT01536015|10141575|FG001|Overall Study|Lost to Follow-up|1
6358012|NCT01536015|10141574|FG000|Overall Study|Inclusion Criterion not met|2
6358013|NCT01536015|10141575|FG001|Overall Study|Inclusion Criterion not met|0
6358014|NCT01536015|10141574|FG000|Overall Study|Study closure|5
6358015|NCT01536015|10141575|FG001|Overall Study|Study closure|5
6358016|NCT01534676|10141601|FG000|Overall Study|Study closed due to poor enrollment|2
6358017|NCT01534676|10141602|FG001|Overall Study|Study closed due to poor enrollment|1
6358018|NCT01530087|10141626|FG000|Overall Study|Physician Decision|2
6358019|NCT01531387|10141663|FG000|Overall Study|Early termination of study|11
6358020|NCT01531387|10141664|FG001|Overall Study|Early termination of study|11
6358021|NCT01527292|10141683|FG000|Overall Study|Physician Decision|0
6358022|NCT01527292|10141684|FG001|Overall Study|Physician Decision|3
6358023|NCT01528696|10141703|FG000|Overall Study|See detailed description|18
6358024|NCT01528696|10141704|FG001|Overall Study|See detailed description|19
6358025|NCT01520714|10141738|FG000|Overall Study|Protocol Violation|0
6358026|NCT01520714|10141739|FG001|Overall Study|Protocol Violation|3
6358027|NCT01520714|10141738|FG000|Overall Study|Adverse Event|0
6358028|NCT01520714|10141739|FG001|Overall Study|Adverse Event|2
6358029|NCT01520714|10141738|FG000|Overall Study|Lack of Efficacy|0
6358030|NCT01520714|10141739|FG001|Overall Study|Lack of Efficacy|1
6358031|NCT01516034|10141754|FG000|Overall Study|Physician Decision|1
6358032|NCT01516034|10141754|FG000|Overall Study|Lack of Efficacy|7
6358033|NCT01510756|10141779|FG000|Overall Study|Death|1
6358034|NCT01510756|10141779|FG000|Overall Study|Lack of Efficacy|2
6358035|NCT01510756|10141779|FG000|Overall Study|Physician Decision|1
6358036|NCT01509053|10141805|FG000|Oral Aripirazole (Phase A)|Sponsor discontinued study|11
6358037|NCT01509053|10141805|FG000|Aripiprazole IM Depot Treatment Phase(B)|Adverse Event|1
6358038|NCT01509053|10141805|FG000|Aripiprazole IM Depot Treatment Phase(B)|Sponsor discontinued study|13
6358039|NCT01509053|10141805|FG000|Aripiprazole IM Depot Treatment Phase(B)|Subject was withdrawn by investigator|1
6358040|NCT01509053|10141805|FG000|Aripiprazole IM Depot Treatment Phase(B)|Subject withdrew consent|1
6043175|NCT00387127|9641624|FG001|Overall Study|Serious Adverse Event|1
6083935|NCT00640289|9692878|FG000|Overall Study|Data collected under different amendment|2
6083936|NCT00640289|9692878|FG000|Overall Study|Transferred to another center|1
6083937|NCT00640289|9692878|FG000|Overall Study|Missing status|5
6083938|NCT00640315|9692884|FG000|Overall Study|Withdrawal by Subject|0
6083939|NCT00640315|9692885|FG001|Overall Study|Withdrawal by Subject|1
6083940|NCT00640328|9692897|FG000|First Treatment Period (Weeks 0-24)|Adverse Event|0
6083941|NCT00640328|9692898|FG001|First Treatment Period (Weeks 0-24)|Adverse Event|1
6083942|NCT00640328|9692899|FG002|First Treatment Period (Weeks 0-24)|Adverse Event|0
6083943|NCT00640328|9692900|FG003|First Treatment Period (Weeks 0-24)|Adverse Event|0
6083944|NCT00640328|9692901|FG004|First Treatment Period (Weeks 0-24)|Adverse Event|0
6083945|NCT00640328|9692902|FG005|First Treatment Period (Weeks 0-24)|Adverse Event|0
6358041|NCT01509053|10141805|FG000|Aripiprazole IM Depot Extension Phase(C)|Sponsor discontinued study|3
6358042|NCT01478113|10141854|FG000|Overall Study|Withdrawal by Subject|0
6358043|NCT01478113|10141855|FG001|Overall Study|Withdrawal by Subject|1
6358044|NCT01478113|10141854|FG000|Overall Study|Physician Decision|1
6358045|NCT01478113|10141855|FG001|Overall Study|Physician Decision|0
6358046|NCT01482598|10141873|FG000|Overall Study|Death|7
6358047|NCT01482598|10141874|FG001|Overall Study|Death|10
6358048|NCT01482598|10141873|FG000|Overall Study|Physician Decision|0
6358049|NCT01482598|10141874|FG001|Overall Study|Physician Decision|3
6358050|NCT01482598|10141873|FG000|Overall Study|Withdrawal by Subject|4
6043176|NCT00387127|9641623|FG000|Overall Study|Sponsor Unblinded|1
6043177|NCT00387127|9641624|FG001|Overall Study|Sponsor Unblinded|0
6043178|NCT00387153|9641632|FG000|Overall Study|Adverse Event|1
6043179|NCT00387153|9641632|FG000|Overall Study|Disease Progression|3
6043180|NCT00387153|9641632|FG000|Overall Study|Lack of Response|4
6043181|NCT00387348|9641648|FG000|Overall Study|Death|1
6043182|NCT00387348|9641649|FG001|Overall Study|Death|1
6043183|NCT00387348|9641650|FG002|Overall Study|Death|0
6043184|NCT00387348|9641648|FG000|Overall Study|Physician Decision|1
6043185|NCT00387348|9641649|FG001|Overall Study|Physician Decision|0
6043186|NCT00387348|9641650|FG002|Overall Study|Physician Decision|1
6043187|NCT00387348|9641648|FG000|Overall Study|Withdrawal by Subject|0
6083946|NCT00640328|9692897|FG000|Second Treatment Period (Weeks 24-48)|Adverse Event|0
6083947|NCT00640328|9692898|FG001|Second Treatment Period (Weeks 24-48)|Adverse Event|0
6083948|NCT00640328|9692899|FG002|Second Treatment Period (Weeks 24-48)|Adverse Event|0
6083949|NCT00640328|9692900|FG003|Second Treatment Period (Weeks 24-48)|Adverse Event|0
6083950|NCT00640328|9692901|FG004|Second Treatment Period (Weeks 24-48)|Adverse Event|1
6083951|NCT00640328|9692902|FG005|Second Treatment Period (Weeks 24-48)|Adverse Event|0
6083952|NCT00640328|9692897|FG000|IFUP (Week 48 to Individual Termination)|Withdrawal by Subject|0
6083953|NCT00640328|9692898|FG001|IFUP (Week 48 to Individual Termination)|Withdrawal by Subject|0
6083954|NCT00640328|9692899|FG002|IFUP (Week 48 to Individual Termination)|Withdrawal by Subject|1
6083955|NCT00640328|9692900|FG003|IFUP (Week 48 to Individual Termination)|Withdrawal by Subject|0
6083956|NCT00640328|9692901|FG004|IFUP (Week 48 to Individual Termination)|Withdrawal by Subject|0
6083957|NCT00640328|9692902|FG005|IFUP (Week 48 to Individual Termination)|Withdrawal by Subject|0
6083958|NCT00640328|9692897|FG000|IFUP (Week 48 to Individual Termination)|Not Recommended - Informed Consent Form|0
6083959|NCT00640328|9692898|FG001|IFUP (Week 48 to Individual Termination)|Not Recommended - Informed Consent Form|1
6083960|NCT00640328|9692899|FG002|IFUP (Week 48 to Individual Termination)|Not Recommended - Informed Consent Form|0
6358051|NCT01482598|10141874|FG001|Overall Study|Withdrawal by Subject|5
6358052|NCT01482598|10141873|FG000|Overall Study|Lost to Follow-up|5
6358053|NCT01482598|10141874|FG001|Overall Study|Lost to Follow-up|4
6358054|NCT01473732|10141894|FG000|Overall Study|Adverse Event|1
6358055|NCT01473732|10141895|FG001|Overall Study|Adverse Event|0
6358056|NCT01473732|10141894|FG000|Overall Study|Death|1
6358057|NCT01473732|10141895|FG001|Overall Study|Death|0
6358058|NCT01465230|10141910|FG000|Overall Study|Withdrawal by Subject|2
6358059|NCT01463293|10141932|FG000|Overall Study|Lost to Follow-up|1
6358060|NCT01463293|10141933|FG001|Overall Study|Lost to Follow-up|4
6358061|NCT01463293|10141934|FG002|Overall Study|Lost to Follow-up|5
6358062|NCT01463293|10141932|FG000|Overall Study|Adverse Event|1
6358063|NCT01463293|10141933|FG001|Overall Study|Adverse Event|2
6358064|NCT01463293|10141934|FG002|Overall Study|Adverse Event|0
6358065|NCT01463293|10141932|FG000|Overall Study|Withdrawal by Subject|4
6358066|NCT01463293|10141933|FG001|Overall Study|Withdrawal by Subject|10
6358067|NCT01463293|10141934|FG002|Overall Study|Withdrawal by Subject|5
6358068|NCT01463293|10141932|FG000|Overall Study|Other|0
6358069|NCT01463293|10141933|FG001|Overall Study|Other|0
6358070|NCT01463293|10141934|FG002|Overall Study|Other|2
6358071|NCT01457053|10141942|FG000|Overall Study|Unable to undergo selected treatment|1
6358072|NCT01457053|10141943|FG001|Overall Study|Unable to undergo selected treatment|1
6358073|NCT01451723|10141951|FG000|Overall Study|study halted|6
6358074|NCT01451723|10141952|FG001|Overall Study|study halted|5
6358075|NCT01440517|10141962|FG000|Overall Study|Subject withdrawn prior to dosing|1
6358076|NCT01440595|10141968|FG000|Overall Study|Lost to Follow-up|0
6358077|NCT01440595|10141969|FG001|Overall Study|Lost to Follow-up|1
6358078|NCT01440595|10141970|FG002|Overall Study|Lost to Follow-up|0
6358079|NCT01440595|10141968|FG000|Overall Study|Study terminated by sponsor.|1
6358080|NCT01440595|10141969|FG001|Overall Study|Study terminated by sponsor.|2
6358081|NCT01440595|10141970|FG002|Overall Study|Study terminated by sponsor.|1
6358082|NCT01446796|10141976|FG000|Overall Study|Withdrawal by Subject|1
6358083|NCT01446796|10141977|FG001|Overall Study|Withdrawal by Subject|0
6358084|NCT01443923|10141987|FG000|Overall Study|Adverse Event|1
6358085|NCT01443923|10141988|FG001|Overall Study|Adverse Event|0
6358086|NCT01439347|10141996|FG000|Overall Study|Death|10
6358087|NCT01439347|10141997|FG001|Overall Study|Death|9
6358088|NCT01439347|10141996|FG000|Overall Study|Withdrawal by Subject|0
6358089|NCT01439347|10141997|FG001|Overall Study|Withdrawal by Subject|1
6358090|NCT01439347|10141996|FG000|Overall Study|Physician Decision|1
6358091|NCT01439347|10141997|FG001|Overall Study|Physician Decision|0
6358092|NCT01439347|10141996|FG000|Overall Study|Sponsor Terminated Study|2
6358093|NCT01439347|10141997|FG001|Overall Study|Sponsor Terminated Study|3
6358094|NCT01433471|10142022|FG000|Overall Study|Withdrawal by Subject|0
6358095|NCT01433471|10142023|FG001|Overall Study|Withdrawal by Subject|1
6358096|NCT01436084|10142031|FG000|Overall Study|Disease Progression|2
6358097|NCT01436084|10142031|FG000|Overall Study|Withdrawal by Subject|1
6358098|NCT01436084|10142031|FG000|Overall Study|Early Closure of Study|1
6358099|NCT01415986|10142059|FG000|Overall Study|Lost to Follow-up|1
6358100|NCT01410799|10142064|FG000|Overall Study|PI decision|13
6358101|NCT01426113|10142070|FG000|Overall Study|Study Discontinued|1
6358102|NCT01426113|10142071|FG001|Overall Study|Study Discontinued|1
6358103|NCT01426113|10142070|FG000|Overall Study|Adverse Event|0
6358104|NCT01426113|10142071|FG001|Overall Study|Adverse Event|1
6358105|NCT01420965|10142089|FG000|Overall Study|Withdrawal by Subject|1
6358106|NCT01420965|10142090|FG001|Overall Study|Withdrawal by Subject|0
6358107|NCT01420965|10142091|FG002|Overall Study|Withdrawal by Subject|0
6358108|NCT01420965|10142089|FG000|Overall Study|Adverse Event|0
6087758|NCT00670449|9698231|FG000|Overall Study|Administrative Problems|0
6358109|NCT01420965|10142090|FG001|Overall Study|Adverse Event|1
6358110|NCT01420965|10142091|FG002|Overall Study|Adverse Event|0
6358111|NCT01417377|10142099|FG000|Overall Study|Lost to Follow-up|12
6358112|NCT01417377|10142099|FG000|Overall Study|Enrolled, but not treated|1
6358113|NCT01416272|10142103|FG000|Overall Study|Unacceptable distance visual acuity|2
6358114|NCT01416272|10142103|FG000|Overall Study|Lost to Follow-up|1
6358115|NCT01416272|10142103|FG000|Overall Study|Study related complaints|1
6358116|NCT01414166|10142109|FG000|Overall Study|Adverse Event|10
6358117|NCT01414166|10142110|FG001|Overall Study|Adverse Event|2
6358118|NCT01414166|10142109|FG000|Overall Study|Lost to Follow-up|4
6358119|NCT01414166|10142110|FG001|Overall Study|Lost to Follow-up|1
6358120|NCT01414166|10142109|FG000|Overall Study|Non-compliance with study drug|2
6358121|NCT01414166|10142110|FG001|Overall Study|Non-compliance with study drug|0
6358122|NCT01414166|10142109|FG000|Overall Study|Physician Decision|2
6358123|NCT01414166|10142110|FG001|Overall Study|Physician Decision|0
6358124|NCT01414166|10142109|FG000|Overall Study|Protocol Violation|2
6358125|NCT01414166|10142110|FG001|Overall Study|Protocol Violation|0
6358126|NCT01414166|10142109|FG000|Overall Study|Study terminated by Sponsor|68
6358127|NCT01414166|10142110|FG001|Overall Study|Study terminated by Sponsor|75
6358128|NCT01414166|10142109|FG000|Overall Study|Withdrawal by Subject|3
6358129|NCT01414166|10142110|FG001|Overall Study|Withdrawal by Subject|5
6358130|NCT01409031|10142137|FG000|Overall Study|transferred to other hosp|1
6358131|NCT01409031|10142138|FG001|Overall Study|transferred to other hosp|0
6358132|NCT01403194|10142161|FG000|Overall Study|Screen Failure|2
6358133|NCT01403194|10142161|FG000|Overall Study|Lost to Follow-up|8
6358134|NCT01397552|10142167|FG000|Overall Study|Adverse Event|1
6358135|NCT01397552|10142168|FG001|Overall Study|Adverse Event|0
6358136|NCT01397552|10142167|FG000|Overall Study|Withdrawal by Subject|2
6358137|NCT01397552|10142168|FG001|Overall Study|Withdrawal by Subject|1
6358138|NCT01392170|10142174|FG000|Overall Study|Withdrawal by Subject|1
6358139|NCT01392170|10142174|FG000|Overall Study|Ineligible|1
6358140|NCT01389817|10142180|FG000|Overall Study|Physician Decision|1
6083961|NCT00640328|9692900|FG003|IFUP (Week 48 to Individual Termination)|Not Recommended - Informed Consent Form|1
6083962|NCT00640328|9692901|FG004|IFUP (Week 48 to Individual Termination)|Not Recommended - Informed Consent Form|0
6083963|NCT00640328|9692902|FG005|IFUP (Week 48 to Individual Termination)|Not Recommended - Informed Consent Form|0
6083964|NCT00640341|9692926|FG000|Overall Study|Adverse Event|0
6083965|NCT00640341|9692927|FG001|Overall Study|Adverse Event|0
6358141|NCT01389817|10142181|FG001|Overall Study|Physician Decision|0
6358142|NCT01389817|10142180|FG000|Overall Study|Lost to Follow-up|1
6358143|NCT01389817|10142181|FG001|Overall Study|Lost to Follow-up|0
6358144|NCT01389817|10142180|FG000|Overall Study|Withdrawal by Subject|2
6358145|NCT01389817|10142181|FG001|Overall Study|Withdrawal by Subject|0
6358146|NCT01390181|10142191|FG000|Overall Study|Lost to Follow-up|1
6358147|NCT01390181|10142191|FG000|Overall Study|Study Terminated due to Low Accrual|3
6358148|NCT01372618|10142226|FG000|Overall Study|PI Died. Study Terminated|9
6358149|NCT01379274|10142234|FG000|Overall Study|funding withdrawn|1
6358150|NCT01369641|10142247|FG000|Overall Study|Withdrawal by Subject|1
6358151|NCT01359254|10142262|FG000|Overall Study|Death|1
6358152|NCT01359254|10142263|FG001|Overall Study|Death|0
6358153|NCT01352416|10142300|FG000|Overall Study|Physician Decision|1
6358154|NCT01352416|10142301|FG001|Overall Study|Physician Decision|2
6358155|NCT01352416|10142302|FG002|Overall Study|Physician Decision|2
6358156|NCT01352416|10142303|FG003|Overall Study|Physician Decision|1
6358157|NCT01349595|10142319|FG000|Overall Study|Lack of funding|2
6358158|NCT01349595|10142320|FG001|Overall Study|Lack of funding|2
6358159|NCT01347840|10142339|FG000|Overall Study|Withdrawal by Subject|1
6358160|NCT01335997|10142350|FG000|Period I and II|Adverse Event|63
6358161|NCT01335997|10142351|FG001|Period I and II|Adverse Event|43
6358162|NCT01335997|10142350|FG000|Period I and II|Noncompliance with Study Drug|1
6358163|NCT01335997|10142351|FG001|Period I and II|Noncompliance with Study Drug|1
6358164|NCT01335997|10142350|FG000|Period I and II|Lost to Follow-up|3
6358165|NCT01335997|10142351|FG001|Period I and II|Lost to Follow-up|5
6358166|NCT01335997|10142350|FG000|Period I and II|Withdrawal by Subject|9
6358167|NCT01335997|10142351|FG001|Period I and II|Withdrawal by Subject|4
6358168|NCT01335997|10142350|FG000|Period I and II|Study Terminated by Sponsor|406
6358169|NCT01335997|10142351|FG001|Period I and II|Study Terminated by Sponsor|415
6358170|NCT01335997|10142350|FG000|Period I and II|Protocol Violation|9
6358171|NCT01335997|10142351|FG001|Period I and II|Protocol Violation|10
6358172|NCT01335997|10142350|FG000|Period I and II|Physician Decision|2
6358173|NCT01335997|10142351|FG001|Period I and II|Physician Decision|1
6358174|NCT01335997|10142350|FG000|Period III|Adverse Event|0
6358175|NCT01335997|10142351|FG001|Period III|Adverse Event|2
6358176|NCT01335997|10142350|FG000|Period III|Study Terminated by Sponsor|77
6358177|NCT01335997|10142351|FG001|Period III|Study Terminated by Sponsor|76
6358178|NCT01335997|10142350|FG000|Period III|Protocol Violation|0
6358179|NCT01335997|10142351|FG001|Period III|Protocol Violation|1
6358180|NCT01335997|10142350|FG000|Period III|Lost to Follow-up|1
6358181|NCT01335997|10142351|FG001|Period III|Lost to Follow-up|0
6358182|NCT01341587|10142374|FG000|Overall Study|Lost to Follow-up|2
6358183|NCT01341587|10142375|FG001|Overall Study|Lost to Follow-up|0
6358184|NCT01341587|10142374|FG000|Overall Study|stopped using the meters|2
6358185|NCT01341587|10142375|FG001|Overall Study|stopped using the meters|10
6358186|NCT01332799|10142387|FG000|Overall Study|Insufficient funding|10
6358187|NCT01332799|10142388|FG001|Overall Study|Insufficient funding|10
6358188|NCT01329549|10142394|FG000|Overall Study|Withdrawal by Subject|1
6358189|NCT01329549|10142394|FG000|Overall Study|Adverse Event|1
6358190|NCT01326845|10142400|FG000|Overall Study|Administrative Problems|5
6358191|NCT01326845|10142401|FG001|Overall Study|Administrative Problems|2
6358192|NCT01326845|10142400|FG000|Overall Study|Adverse Event|1
6358193|NCT01326845|10142401|FG001|Overall Study|Adverse Event|0
6358194|NCT01326845|10142400|FG000|Overall Study|Misisng|1
6358195|NCT01326845|10142401|FG001|Overall Study|Misisng|3
6358196|NCT01329341|10142407|FG000|Overall Study|Withdrawal by Subject|44
6358197|NCT01320683|10142420|FG000|Overall Study|Positive antibody response|1
6358198|NCT01313273|10142426|FG000|Overall Study|INCLUSION CRITERIA 4 NOT RESPECTED|1
6358199|NCT01313273|10142427|FG001|Overall Study|INCLUSION CRITERIA 4 NOT RESPECTED|0
6358200|NCT01313273|10142426|FG000|Overall Study|Withdrawal by Subject|1
6358201|NCT01313273|10142427|FG001|Overall Study|Withdrawal by Subject|0
6358202|NCT01313273|10142426|FG000|Overall Study|Screening Chromogranin A-in normal range|0
6358203|NCT01313273|10142427|FG001|Overall Study|Screening Chromogranin A-in normal range|1
6358204|NCT01321008|10142433|FG000|Overall Study|Early Study Termination|1
6358205|NCT01310803|10142439|FG000|Overall Study|Subject terminated by Sponsor|1
6358206|NCT01310803|10142440|FG001|Overall Study|Subject terminated by Sponsor|0
6358207|NCT01313923|10142459|FG000|Overall Study|Physician Decision|3
6358208|NCT01321697|10142463|FG000|Overall Study|Study Terminated|7
6358209|NCT01312428|10142469|FG000|Overall Study|Study Termination|3
6358210|NCT01312428|10142470|FG001|Overall Study|Study Termination|4
6358211|NCT01290822|10142528|FG000|Overall Study|Withdrawal by Subject|1
6358212|NCT01290822|10142528|FG000|Overall Study|Physician Decision|10
6358213|NCT01290718|10142532|FG000|Overall Study|Early termination of the study|4
6358214|NCT01293123|10142538|FG000|Overall Study|Lost to Follow-up|0
6358215|NCT01293123|10142539|FG001|Overall Study|Lost to Follow-up|1
6358216|NCT01294046|10142545|FG000|Overall Study|Infection and surgical explant|1
6358217|NCT01294046|10142545|FG000|Overall Study|Eligibility criteria expanded|1
6358218|NCT01294046|10142545|FG000|Overall Study|Stimulation response inadqequate|1
6358219|NCT01281124|10142589|FG000|Overall Study|Death|1
6358220|NCT01282216|10142601|FG000|Overall Study|Graft failure|0
6358221|NCT01282216|10142602|FG001|Overall Study|Graft failure|0
6358222|NCT01282216|10142603|FG002|Overall Study|Graft failure|3
6358223|NCT01282216|10142604|FG003|Overall Study|Graft failure|2
6358224|NCT01282216|10142601|FG000|Overall Study|Physician Decision|0
6358225|NCT01282216|10142602|FG001|Overall Study|Physician Decision|0
6358226|NCT01282216|10142603|FG002|Overall Study|Physician Decision|11
6358227|NCT01282216|10142604|FG003|Overall Study|Physician Decision|0
6358228|NCT01282216|10142601|FG000|Overall Study|Relapse|0
6358229|NCT01282216|10142602|FG001|Overall Study|Relapse|0
6358230|NCT01282216|10142603|FG002|Overall Study|Relapse|17
6358231|NCT01282216|10142604|FG003|Overall Study|Relapse|6
6358232|NCT01282216|10142601|FG000|Overall Study|Death|0
6358233|NCT01282216|10142602|FG001|Overall Study|Death|0
6358234|NCT01282216|10142603|FG002|Overall Study|Death|2
6358235|NCT01282216|10142604|FG003|Overall Study|Death|0
6358236|NCT01284491|10142610|FG000|Overall Study|Study termination|13
6358237|NCT01274533|10142642|FG000|Overall Study|Withdrawal by Subject|1
6358238|NCT01274533|10142642|FG000|Overall Study|Non-compliance|1
6358239|NCT01274533|10142642|FG000|Overall Study|Disease progression|2
6358240|NCT01279616|10142646|FG000|Overall Study|donor could not be located|5
6358241|NCT01279616|10142646|FG000|Overall Study|no signs of sickle cell disease|2
6358242|NCT01276054|10142652|FG000|Overall Study|No one to oversee trial after P.I. left|2
6358243|NCT01276054|10142653|FG001|Overall Study|No one to oversee trial after P.I. left|2
6358244|NCT01264965|10142659|FG000|Overall Study|Withdrawal by Subject|10
6358245|NCT01266824|10142665|FG000|Overall Study|Study terminated prior to completion|2
6358246|NCT01266824|10142666|FG001|Overall Study|Study terminated prior to completion|3
6358247|NCT01264835|10142672|FG000|Overall Study|Lost to Follow-up|1
6358248|NCT01274429|10142676|FG000|Overall Study|Study closed do to lack of funding|5
6358249|NCT01273064|10142685|FG000|Overall Study|Adverse Event|5
6358250|NCT01273064|10142686|FG001|Overall Study|Adverse Event|1
6358251|NCT01273064|10142687|FG002|Overall Study|Adverse Event|3
6358252|NCT01273064|10142688|FG003|Overall Study|Adverse Event|2
6358253|NCT01273064|10142689|FG004|Overall Study|Adverse Event|1
6358254|NCT01273064|10142685|FG000|Overall Study|Withdrawal by Subject|4
6358255|NCT01273064|10142686|FG001|Overall Study|Withdrawal by Subject|2
6358256|NCT01273064|10142687|FG002|Overall Study|Withdrawal by Subject|2
6358257|NCT01273064|10142688|FG003|Overall Study|Withdrawal by Subject|2
6358258|NCT01273064|10142689|FG004|Overall Study|Withdrawal by Subject|0
6358259|NCT01273064|10142685|FG000|Overall Study|Study Termination|13
6358260|NCT01273064|10142686|FG001|Overall Study|Study Termination|27
6358261|NCT01273064|10142687|FG002|Overall Study|Study Termination|26
6358262|NCT01273064|10142688|FG003|Overall Study|Study Termination|16
6358263|NCT01273064|10142689|FG004|Overall Study|Study Termination|8
6358264|NCT01273064|10142685|FG000|Overall Study|Lost to Follow-up|1
6358265|NCT01273064|10142686|FG001|Overall Study|Lost to Follow-up|0
6358266|NCT01273064|10142687|FG002|Overall Study|Lost to Follow-up|0
6358267|NCT01273064|10142688|FG003|Overall Study|Lost to Follow-up|0
6358268|NCT01273064|10142689|FG004|Overall Study|Lost to Follow-up|0
6358269|NCT01273064|10142685|FG000|Overall Study|Physician Decision|0
6358270|NCT01273064|10142686|FG001|Overall Study|Physician Decision|0
6358271|NCT01273064|10142687|FG002|Overall Study|Physician Decision|0
6358272|NCT01273064|10142688|FG003|Overall Study|Physician Decision|0
6358273|NCT01273064|10142689|FG004|Overall Study|Physician Decision|1
6358274|NCT01274559|10142703|FG000|Overall Study|Adverse Event|57
6358275|NCT01274559|10142704|FG001|Overall Study|Adverse Event|13
6358276|NCT01274559|10142703|FG000|Overall Study|Death|1
6358277|NCT01274559|10142704|FG001|Overall Study|Death|1
6358278|NCT01274559|10142703|FG000|Overall Study|Lost to Follow-up|3
6358279|NCT01274559|10142704|FG001|Overall Study|Lost to Follow-up|3
6358280|NCT01274559|10142703|FG000|Overall Study|Non-compliance with Study Drug|2
6358281|NCT01274559|10142704|FG001|Overall Study|Non-compliance with Study Drug|4
6358282|NCT01274559|10142703|FG000|Overall Study|Physician Decision|2
6358283|NCT01274559|10142704|FG001|Overall Study|Physician Decision|1
6358284|NCT01274559|10142703|FG000|Overall Study|Protocol Violation|28
6358285|NCT01274559|10142704|FG001|Overall Study|Protocol Violation|23
6358286|NCT01274559|10142703|FG000|Overall Study|Study Terminated by Sponsor|79
6358287|NCT01274559|10142704|FG001|Overall Study|Study Terminated by Sponsor|87
6358288|NCT01274559|10142703|FG000|Overall Study|Withdrawal by Subject|25
6358289|NCT01274559|10142704|FG001|Overall Study|Withdrawal by Subject|13
6358290|NCT01267825|10142738|FG000|Overall Study|study terminated. no data collected.|1
6358291|NCT01267825|10142739|FG001|Overall Study|study terminated. no data collected.|0
6358292|NCT01259284|10142748|FG000|Overall Study|Study Termination|2
6358293|NCT01259284|10142749|FG001|Overall Study|Study Termination|0
6358294|NCT01259284|10142750|FG002|Overall Study|Study Termination|0
6358295|NCT01249157|10142758|FG000|Overall Study|Withdrawal by Subject|1
6358296|NCT01263028|10142762|FG000|Overall Study|Withdrawal by Subject|1
6358297|NCT01263028|10142762|FG000|Overall Study|Adverse Event|1
6358298|NCT01263028|10142762|FG000|Overall Study|Study terminated due to low enrollment.|4
6358299|NCT01259024|10142774|FG000|Overall Study|Physician Decision|1
6358300|NCT01251952|10142778|FG000|Overall Study|Adverse Event|1
6358301|NCT01251120|10142784|FG000|Overall Study|Lack of Efficacy|0
6358302|NCT01251120|10142785|FG001|Overall Study|Lack of Efficacy|1
6358303|NCT01248130|10142793|FG000|Overall Study|Protocol Violation|1
6358304|NCT01248130|10142794|FG001|Overall Study|Protocol Violation|0
6358305|NCT01248130|10142793|FG000|Overall Study|Ineligible|1
6358306|NCT01248130|10142794|FG001|Overall Study|Ineligible|0
6358307|NCT01243892|10142802|FG000|Overall Study|Did not meet eligibility criteria|2
6358308|NCT01243892|10142803|FG001|Overall Study|Did not meet eligibility criteria|0
6358309|NCT01246011|10142812|FG000|Overall Study|If needed warfarin clinically, withdrawn|0
6358310|NCT01246011|10142813|FG001|Overall Study|If needed warfarin clinically, withdrawn|0
6358311|NCT01246011|10142814|FG002|Overall Study|If needed warfarin clinically, withdrawn|3
6358312|NCT01246011|10142812|FG000|Overall Study|Withdrawal by Subject|0
6358313|NCT01246011|10142813|FG001|Overall Study|Withdrawal by Subject|0
6358314|NCT01246011|10142814|FG002|Overall Study|Withdrawal by Subject|1
6358315|NCT01242020|10142825|FG000|Overall Study|Withdrawal by Subject|2
6358316|NCT01242020|10142826|FG001|Overall Study|Withdrawal by Subject|0
6358317|NCT01242020|10142825|FG000|Overall Study|Failed screening|1
6358318|NCT01242020|10142826|FG001|Overall Study|Failed screening|0
6358319|NCT01244620|10142832|FG000|Overall Study|Study terminated|4
6358320|NCT01244620|10142833|FG001|Overall Study|Study terminated|4
6358321|NCT01244620|10142834|FG002|Overall Study|Study terminated|4
6358322|NCT01244620|10142835|FG003|Overall Study|Study terminated|4
6358323|NCT01241279|10142851|FG000|Overall Study|Lost to Follow-up|0
6358324|NCT01241279|10142852|FG001|Overall Study|Lost to Follow-up|1
6358325|NCT01230788|10142858|FG000|Overall Study|Prescribed exclusion drug|1
6358326|NCT01239680|10142864|FG000|Overall Study|Withdrawal by Subject|2
6358327|NCT01239680|10142865|FG001|Overall Study|Withdrawal by Subject|0
6358328|NCT01230307|10142896|FG000|Overall Study|LVAD Placement|0
6358329|NCT01230307|10142897|FG001|Overall Study|LVAD Placement|2
6358330|NCT01230489|10142903|FG000|Overall Study|Death|2
6358331|NCT01230489|10142903|FG000|Overall Study|Adverse Event|2
6358332|NCT01230489|10142903|FG000|Overall Study|Treatment modality changed|1
6358333|NCT01217060|10142959|FG000|Overall Study|Withdrawal by Subject|1
6358334|NCT01217047|10142967|FG000|Overall Study|Lost to Follow-up|0
6358335|NCT01217047|10142968|FG001|Overall Study|Lost to Follow-up|1
6358336|NCT01217047|10142969|FG002|Overall Study|Lost to Follow-up|0
6358337|NCT01206101|10142980|FG000|Overall Study|Adverse Event|1
6358338|NCT01206101|10142981|FG001|Overall Study|Adverse Event|0
6358339|NCT01206101|10142980|FG000|Overall Study|Physician Decision|0
6358340|NCT01206101|10142981|FG001|Overall Study|Physician Decision|1
6358341|NCT01206101|10142980|FG000|Overall Study|Unclassified|1
6358342|NCT01206101|10142981|FG001|Overall Study|Unclassified|0
6358343|NCT01209520|10143004|FG000|Overall Study|Withdrawal by Subject|3
6358344|NCT01207102|10143025|FG000|Overall Study|Withdrawal by Subject|5
6358345|NCT01207102|10143025|FG000|Overall Study|Adverse Event|2
6358346|NCT01207102|10143025|FG000|Overall Study|progression|2
6358347|NCT01207102|10143025|FG000|Overall Study|Withdrawal by Treating Physician|1
6358348|NCT01206439|10143043|FG000|Overall Study|subject did not meet inclusion criteria|1
6358349|NCT01198548|10143065|FG000|Overall Study|Disease Progression|9
6358350|NCT01198548|10143065|FG000|Overall Study|Administrative Decision|1
6358351|NCT01193556|10143088|FG000|Overall Study|Study termination|26
6358352|NCT01193556|10143089|FG001|Overall Study|Study termination|25
6358353|NCT01189435|10143095|FG000|Overall Study|Withdrawal by Subject|1
6358354|NCT01189435|10143095|FG000|Overall Study|Physician Decision|1
6358355|NCT01193530|10143101|FG000|Overall Study|Withdrawal by Subject|2
6358356|NCT01193530|10143102|FG001|Overall Study|Withdrawal by Subject|2
6358357|NCT01193530|10143101|FG000|Overall Study|Began Contraindicated Therapy|1
6358358|NCT01193530|10143102|FG001|Overall Study|Began Contraindicated Therapy|0
6358359|NCT01193530|10143101|FG000|Overall Study|Lost Light Box|0
6358360|NCT01193530|10143102|FG001|Overall Study|Lost Light Box|1
6358361|NCT01193530|10143101|FG000|Overall Study|Returned home - out of state|0
6358362|NCT01193530|10143102|FG001|Overall Study|Returned home - out of state|1
6358363|NCT01193530|10143101|FG000|Overall Study|Non-Compliance|0
6358364|NCT01193530|10143102|FG001|Overall Study|Non-Compliance|1
6358365|NCT01183221|10143136|FG000|3 Weeks Wash Out|Lost to Follow-up|1
6358366|NCT01183221|10143137|FG001|3 Weeks Wash Out|Lost to Follow-up|1
6358367|NCT01189227|10143145|FG000|Overall Study|Study terminated due to low accrual|6
6358368|NCT01189227|10143146|FG001|Overall Study|Study terminated due to low accrual|3
6358369|NCT01179737|10143165|FG000|Cohort 1 & Cohort 2|Adverse Event|3
6358370|NCT01179737|10143166|FG001|Cohort 1 & Cohort 2|Adverse Event|1
6358371|NCT01179737|10143167|FG002|Cohort 1 & Cohort 2|Adverse Event|1
6358372|NCT01179737|10143168|FG003|Cohort 1 & Cohort 2|Adverse Event|0
6358373|NCT01179737|10143165|FG000|Cohort 1 & Cohort 2|Withdrew consent|2
6358374|NCT01179737|10143166|FG001|Cohort 1 & Cohort 2|Withdrew consent|0
6358375|NCT01179737|10143167|FG002|Cohort 1 & Cohort 2|Withdrew consent|0
6358376|NCT01179737|10143168|FG003|Cohort 1 & Cohort 2|Withdrew consent|0
6358377|NCT01179737|10143165|FG000|Cohort 1 & Cohort 2|Administrative problems|0
6358378|NCT01179737|10143166|FG001|Cohort 1 & Cohort 2|Administrative problems|0
6358379|NCT01179737|10143167|FG002|Cohort 1 & Cohort 2|Administrative problems|2
6358380|NCT01179737|10143168|FG003|Cohort 1 & Cohort 2|Administrative problems|4
6358381|NCT01179737|10143165|FG000|Cohort 1 & Cohort 2|Death|0
6358382|NCT01179737|10143166|FG001|Cohort 1 & Cohort 2|Death|0
6358383|NCT01179737|10143167|FG002|Cohort 1 & Cohort 2|Death|1
6358384|NCT01179737|10143168|FG003|Cohort 1 & Cohort 2|Death|0
6358385|NCT01179737|10143165|FG000|Cohort 1 & Cohort 2|Withdrew consent without EOS 1 visit|0
6358386|NCT01179737|10143166|FG001|Cohort 1 & Cohort 2|Withdrew consent without EOS 1 visit|1
6358387|NCT01179737|10143167|FG002|Cohort 1 & Cohort 2|Withdrew consent without EOS 1 visit|0
6358388|NCT01179737|10143168|FG003|Cohort 1 & Cohort 2|Withdrew consent without EOS 1 visit|0
6358389|NCT01179737|10143165|FG000|Cohort 1 & Cohort 2 Expansion|Death|1
6358390|NCT01179737|10143166|FG001|Cohort 1 & Cohort 2 Expansion|Death|0
6358391|NCT01179737|10143167|FG002|Cohort 1 & Cohort 2 Expansion|Death|0
6358392|NCT01179737|10143168|FG003|Cohort 1 & Cohort 2 Expansion|Death|0
6358393|NCT01179737|10143165|FG000|Extension|The study was terminated|3
6358394|NCT01179737|10143166|FG001|Extension|The study was terminated|0
6358395|NCT01179737|10143167|FG002|Extension|The study was terminated|0
6358396|NCT01179737|10143168|FG003|Extension|The study was terminated|0
6358397|NCT01183468|10143181|FG000|Overall Study|Lost to Follow-up|2
6358398|NCT01183468|10143182|FG001|Overall Study|Lost to Follow-up|1
6358399|NCT01183468|10143183|FG002|Overall Study|Lost to Follow-up|0
6358400|NCT01183468|10143184|FG003|Overall Study|Lost to Follow-up|0
6358401|NCT01183468|10143181|FG000|Overall Study|Physician Decision|1
6358402|NCT01183468|10143182|FG001|Overall Study|Physician Decision|0
6358403|NCT01183468|10143183|FG002|Overall Study|Physician Decision|0
6358404|NCT01183468|10143184|FG003|Overall Study|Physician Decision|0
6358405|NCT01183468|10143181|FG000|Overall Study|Withdrawal by Subject|0
6358406|NCT01183468|10143182|FG001|Overall Study|Withdrawal by Subject|1
6358407|NCT01183468|10143183|FG002|Overall Study|Withdrawal by Subject|0
6358408|NCT01183468|10143184|FG003|Overall Study|Withdrawal by Subject|0
6358409|NCT01181921|10143192|FG000|Overall Study|Lost to Follow-up|1
6358410|NCT01188798|10143198|FG000|Overall Study|Death|0
6358411|NCT01188798|10143199|FG001|Overall Study|Death|1
6358412|NCT01188798|10143198|FG000|Overall Study|Required additional transplant|1
6358413|NCT01188798|10143199|FG001|Overall Study|Required additional transplant|1
6358414|NCT01188798|10143198|FG000|Overall Study|Protocol closure|1
6358415|NCT01188798|10143199|FG001|Overall Study|Protocol closure|1
6358416|NCT01174368|10143206|FG000|Overall Study|Withdrawal by Subject|1
6358417|NCT01183884|10143214|FG000|Overall Study|Progressive Disease|26
6358418|NCT01183884|10143214|FG000|Overall Study|Adverse Event|3
6358419|NCT01183884|10143214|FG000|Overall Study|Withdrawal by Subject|1
6043188|NCT00387348|9641649|FG001|Overall Study|Withdrawal by Subject|2
6358420|NCT01183884|10143214|FG000|Overall Study|Other Complicating Disease|3
6358421|NCT01183884|10143214|FG000|Overall Study|Not Treated|1
6358422|NCT01183884|10143214|FG000|Overall Study|Other|4
6358423|NCT01166178|10143224|FG000|Overall Study|Withdrawal by Subject|1
6358424|NCT01166178|10143225|FG001|Overall Study|Withdrawal by Subject|0
6358425|NCT01166178|10143224|FG000|Overall Study|Study was terminated|20
6358426|NCT01166178|10143225|FG001|Overall Study|Study was terminated|8
6358427|NCT01176513|10143231|FG000|Overall Study|Withdrew subjects prior to dosing|3
6358428|NCT01179399|10143239|FG000|Overall Study|Adverse Event|1
6358429|NCT01179399|10143239|FG000|Overall Study|Lack of Efficacy|30
6358430|NCT01179399|10143239|FG000|Overall Study|Withdrawal by Subject|1
6358431|NCT01171534|10143254|FG000|Overall Study|Lost to Follow-up|0
6358432|NCT01171534|10143255|FG001|Overall Study|Lost to Follow-up|2
6358433|NCT01171534|10143254|FG000|Overall Study|screen failure|0
6358434|NCT01171534|10143255|FG001|Overall Study|screen failure|1
6358435|NCT01162304|10143291|FG000|Overall Study|Beck scale to high|11
6358436|NCT01147393|10143343|FG000|Dose Level 1|Dose limiting Toxicity|2
6358437|NCT01147393|10143343|FG000|Dose Level -1|Dose Limited Toxicity|1
6358438|NCT01147536|10143356|FG000|Overall Study|Administrative study close|2
6358439|NCT01147536|10143356|FG000|Overall Study|Death|1
6358440|NCT01133288|10143369|FG000|Eligibility Assessment|met exclusion criteria|5
6083966|NCT00640341|9692928|FG002|Overall Study|Adverse Event|1
6358441|NCT01133288|10143369|FG000|Intervention Allocation|study terminated|2
6358442|NCT01142128|10143377|FG000|Overall Study|Physician Decision|1
6358443|NCT01142128|10143377|FG000|Overall Study|Lost to Follow-up|1
6358444|NCT01142128|10143377|FG000|Overall Study|Withdrawal by Subject|2
6358445|NCT01128114|10143396|FG000|Overall Study|Treatment Withdrawn|6
6358446|NCT01128114|10143396|FG000|Overall Study|Screening Failed|2
6358447|NCT01126879|10143402|FG000|Overall Study|Progressive Disease|3
6358448|NCT01126879|10143403|FG001|Overall Study|Progressive Disease|1
6358449|NCT01126879|10143402|FG000|Overall Study|Withdrawal by Subject|1
6358450|NCT01126879|10143403|FG001|Overall Study|Withdrawal by Subject|0
6358451|NCT01126879|10143402|FG000|Overall Study|Adverse Event|0
6358452|NCT01126879|10143403|FG001|Overall Study|Adverse Event|1
6358453|NCT01126879|10143402|FG000|Overall Study|Physician Decision|1
6358454|NCT01126879|10143403|FG001|Overall Study|Physician Decision|0
6358455|NCT01136811|10143409|FG000|Overall Study|Physician Decision|11
6358456|NCT01139125|10143422|FG000|Overall Study|Withdrawal by Subject|1
6358457|NCT01131455|10143446|FG000|Overall Study|Death of PI|6
6358458|NCT01131455|10143447|FG001|Overall Study|Death of PI|4
6358459|NCT01131455|10143448|FG002|Overall Study|Death of PI|0
6358460|NCT01123850|10143465|FG000|Overall Study|Slow enrollment|45
6358461|NCT01122381|10143498|FG000|Overall Study|study terminated early|0
6358462|NCT01122381|10143499|FG001|Overall Study|study terminated early|1
6358463|NCT01116232|10143505|FG000|Overall Study|Progressive diease|4
6358464|NCT01108523|10143533|FG000|Overall Study|Protocol Violation|4
6358465|NCT01106534|10143541|FG000|Overall Study|Withdrawal by Subject|18
6358466|NCT01106534|10143541|FG000|Overall Study|Lost to Follow-up|2
6358467|NCT01106534|10143541|FG000|Overall Study|Death|16
6358468|NCT01106534|10143541|FG000|Overall Study|Physician Decision|1
6358469|NCT01100658|10143550|FG000|Overall Study|Withdrawal by Subject|1
6358470|NCT01103180|10143556|FG000|Overall Study|Withdrawal by Subject|8
6358471|NCT01103180|10143557|FG001|Overall Study|Withdrawal by Subject|13
6358472|NCT01103180|10143556|FG000|Overall Study|Lost to Follow-up|13
6358473|NCT01103180|10143557|FG001|Overall Study|Lost to Follow-up|7
6358474|NCT01103180|10143556|FG000|Overall Study|Physician Decision|1
6358475|NCT01103180|10143557|FG001|Overall Study|Physician Decision|0
6358476|NCT01103180|10143556|FG000|Overall Study|Protocol Violation|0
6358477|NCT01103180|10143557|FG001|Overall Study|Protocol Violation|1
6358478|NCT01102140|10143574|FG000|Overall Study|Lost to Follow-up|1
6358479|NCT01102140|10143575|FG001|Overall Study|Lost to Follow-up|0
6358480|NCT01102140|10143574|FG000|Overall Study|Investigator terminated study|2
6358481|NCT01102140|10143575|FG001|Overall Study|Investigator terminated study|2
6358482|NCT01095250|10143587|FG000|Overall Study|administrative reasons|8
6358483|NCT01095250|10143588|FG001|Overall Study|administrative reasons|10
6358484|NCT01095250|10143589|FG002|Overall Study|administrative reasons|7
6358485|NCT01095250|10143590|FG003|Overall Study|administrative reasons|5
6358486|NCT01095250|10143587|FG000|Overall Study|Withdrawal by Subject|0
6358487|NCT01095250|10143588|FG001|Overall Study|Withdrawal by Subject|0
6358488|NCT01095250|10143589|FG002|Overall Study|Withdrawal by Subject|1
6358489|NCT01095250|10143590|FG003|Overall Study|Withdrawal by Subject|0
6358490|NCT01093846|10143607|FG000|Overall Study|Adverse Event|0
6358491|NCT01093846|10143608|FG001|Overall Study|Adverse Event|0
6358492|NCT01093846|10143609|FG002|Overall Study|Adverse Event|1
6358493|NCT01093846|10143607|FG000|Overall Study|Lack of Efficacy|0
6358494|NCT01093846|10143608|FG001|Overall Study|Lack of Efficacy|0
6358495|NCT01093846|10143609|FG002|Overall Study|Lack of Efficacy|4
6358496|NCT01093846|10143607|FG000|Overall Study|Condition no longer required study drug|1
6358497|NCT01093846|10143608|FG001|Overall Study|Condition no longer required study drug|1
6358498|NCT01093846|10143609|FG002|Overall Study|Condition no longer required study drug|1
6358499|NCT01093846|10143607|FG000|Overall Study|Administrative Problems|18
6358500|NCT01093846|10143608|FG001|Overall Study|Administrative Problems|17
6358501|NCT01093846|10143609|FG002|Overall Study|Administrative Problems|15
6358502|NCT01081886|10143622|FG000|Overall Study|Study termination|11
6358503|NCT01081886|10143623|FG001|Overall Study|Study termination|13
6358504|NCT01080768|10143644|FG000|Overall Study|Protocol Deviation|2
6358505|NCT01080768|10143645|FG001|Overall Study|Protocol Deviation|1
6358506|NCT01074502|10143655|FG000|Overall Study|Withdrawal by Subject|1
6358507|NCT01069861|10143668|FG000|Overall Study|Death|1
6358508|NCT01069861|10143668|FG000|Overall Study|Adverse Event|1
6358509|NCT01069861|10143668|FG000|Overall Study|Did not meet entrance criteria|1
6358510|NCT01069120|10143701|FG000|Overall Study|Study prematurely terminated|27
6358511|NCT01058642|10143720|FG000|Treatment Period 1|Adverse Event|0
6358512|NCT01058642|10143721|FG001|Treatment Period 1|Adverse Event|1
6358513|NCT01058642|10143722|FG002|Treatment Period 1|Adverse Event|1
6358514|NCT01058642|10143723|FG003|Treatment Period 1|Adverse Event|0
6358515|NCT01058642|10143720|FG000|Treatment Period 1|Physician Decision|0
6358516|NCT01058642|10143721|FG001|Treatment Period 1|Physician Decision|0
6358517|NCT01058642|10143722|FG002|Treatment Period 1|Physician Decision|1
6358518|NCT01058642|10143723|FG003|Treatment Period 1|Physician Decision|0
6358519|NCT01058642|10143720|FG000|Treatment Period 1|Withdrawal by Subject|1
6358520|NCT01058642|10143721|FG001|Treatment Period 1|Withdrawal by Subject|0
6358521|NCT01058642|10143722|FG002|Treatment Period 1|Withdrawal by Subject|0
6358522|NCT01058642|10143723|FG003|Treatment Period 1|Withdrawal by Subject|0
6358523|NCT01058642|10143720|FG000|Treatment Period 1|Lack of Efficacy|0
6358524|NCT01058642|10143721|FG001|Treatment Period 1|Lack of Efficacy|0
6358525|NCT01058642|10143722|FG002|Treatment Period 1|Lack of Efficacy|0
6358526|NCT01058642|10143723|FG003|Treatment Period 1|Lack of Efficacy|1
6358527|NCT01058642|10143720|FG000|Treatment Period 1|Protocol Violation|0
6358528|NCT01058642|10143721|FG001|Treatment Period 1|Protocol Violation|0
6358529|NCT01058642|10143722|FG002|Treatment Period 1|Protocol Violation|0
6358530|NCT01058642|10143723|FG003|Treatment Period 1|Protocol Violation|1
6358531|NCT01058642|10143720|FG000|Treatment Period 1|Lack of Compliance with Study Drug|1
6358532|NCT01058642|10143721|FG001|Treatment Period 1|Lack of Compliance with Study Drug|0
6358533|NCT01058642|10143722|FG002|Treatment Period 1|Lack of Compliance with Study Drug|0
6358534|NCT01058642|10143723|FG003|Treatment Period 1|Lack of Compliance with Study Drug|0
6358535|NCT01065818|10143731|FG000|Overall Study|Withdrawal by Subject|1
6358536|NCT01065818|10143731|FG000|Overall Study|Not a candidate for surgery|1
6358537|NCT01051921|10143735|FG000|Overall Study|Physician Decision|9
6358538|NCT01051921|10143735|FG000|Overall Study|Adverse Event|8
6358539|NCT01051921|10143735|FG000|Overall Study|Withdrawal by Subject|7
6358540|NCT01051921|10143735|FG000|Overall Study|Lost to Follow-up|4
6358541|NCT01051921|10143735|FG000|Overall Study|virological failure|1
6358542|NCT01051921|10143735|FG000|Overall Study|patient moved|1
6358543|NCT01058369|10143757|FG000|Overall Study|Adverse Event|1
6358544|NCT01058369|10143757|FG000|Overall Study|Early termination study|1
6358545|NCT01053221|10143767|FG000|Overall Study|The study was closed prematurely|5
6358546|NCT01053221|10143768|FG001|Overall Study|The study was closed prematurely|9
6358547|NCT01038752|10143776|FG000|Overall Study|Tumor Progression|2
6358548|NCT01038752|10143777|FG001|Overall Study|Tumor Progression|2
6358549|NCT01038752|10143776|FG000|Overall Study|Lost to Follow-up|3
6358550|NCT01038752|10143777|FG001|Overall Study|Lost to Follow-up|3
6358551|NCT01050218|10143783|FG000|Overall Study|Adverse Event|37
6358552|NCT01050218|10143783|FG000|Overall Study|Lack of Efficacy|8
6358553|NCT01050218|10143783|FG000|Overall Study|Protocol Violation|3
6358554|NCT01050218|10143783|FG000|Overall Study|Withdrawal by Subject|18
6358555|NCT01050218|10143783|FG000|Overall Study|Discontinued by sponsor|18
6358556|NCT01050218|10143783|FG000|Overall Study|Compliance|2
6358557|NCT01050218|10143783|FG000|Overall Study|Failed to return|7
6358558|NCT01050218|10143783|FG000|Overall Study|Serious Adverse Event|1
6358559|NCT01050218|10143783|FG000|Overall Study|Family emergency|1
6358560|NCT01045694|10143787|FG000|Overall Study|Withdrawal by Subject|2
6358561|NCT01031628|10143812|FG000|Overall Study|Study terminated early|0
6358562|NCT01031628|10143813|FG001|Overall Study|Study terminated early|1
6358563|NCT01031628|10143814|FG002|Overall Study|Study terminated early|3
6358564|NCT01031628|10143815|FG003|Overall Study|Study terminated early|0
6358565|NCT01030198|10143846|FG000|Overall Study|Could not measure efficacy accurately|0
6358566|NCT01030198|10143847|FG001|Overall Study|Could not measure efficacy accurately|7
6358567|NCT01028300|10143853|FG000|Overall Study|Study Terminated|4
6358568|NCT01022398|10143864|FG000|Overall Study|Study terminated|2
6358569|NCT01022398|10143865|FG001|Overall Study|Study terminated|2
6358570|NCT01019980|10143872|FG000|Overall Study|Drug not available.|2
6358571|NCT01019980|10143873|FG001|Overall Study|Drug not available.|0
6358572|NCT01017263|10143883|FG000|Overall Study|not eligible|12
6358573|NCT01018810|10143910|FG000|Overall Study|Withdrawal by Subject|0
6358574|NCT01018810|10143911|FG001|Overall Study|Withdrawal by Subject|1
6358575|NCT01018810|10143912|FG002|Overall Study|Withdrawal by Subject|0
6358576|NCT01018810|10143913|FG003|Overall Study|Withdrawal by Subject|0
6358577|NCT01018810|10143914|FG004|Overall Study|Withdrawal by Subject|0
6358578|NCT01018810|10143910|FG000|Overall Study|Sponsor Decision|2
6358579|NCT01018810|10143911|FG001|Overall Study|Sponsor Decision|0
6358580|NCT01018810|10143912|FG002|Overall Study|Sponsor Decision|1
6358581|NCT01018810|10143913|FG003|Overall Study|Sponsor Decision|1
6358582|NCT01018810|10143914|FG004|Overall Study|Sponsor Decision|1
6358583|NCT01014767|10143943|FG000|Overall Study|PI left institution, data unavailable|12
6358584|NCT01014767|10143944|FG001|Overall Study|PI left institution, data unavailable|1
6358585|NCT01014767|10143945|FG002|Overall Study|PI left institution, data unavailable|4
6358586|NCT01014767|10143946|FG003|Overall Study|PI left institution, data unavailable|1
6358587|NCT01013701|10143956|FG000|Overall Study|study prematurely terminated|7
6358588|NCT01012414|10143961|FG000|Overall Study|Withdrawal by Subject|2
6358589|NCT01012414|10143961|FG000|Overall Study|Lost to Follow-up|1
6358590|NCT01012414|10143961|FG000|Overall Study|Trial was stopped before completed|7
6358591|NCT01001390|10143980|FG000|Overall Study|Failure to wear AFO device|2
6358592|NCT01001390|10143981|FG001|Overall Study|Failure to wear AFO device|0
6358593|NCT01004510|10143999|FG000|Overall Study|Adverse Event|1
6358594|NCT01005914|10144003|FG000|Overall Study|Adverse Event|4
6358595|NCT01005914|10144003|FG000|Overall Study|Death|4
6358596|NCT01005914|10144003|FG000|Overall Study|Lack of Efficacy|1
6358597|NCT01005914|10144003|FG000|Overall Study|Withdrawal by Subject|1
6358598|NCT00996333|10144007|FG000|Overall Study|Screen failure|1
6358599|NCT00996333|10144007|FG000|Overall Study|Withdrawal by Subject|1
6358600|NCT00996333|10144007|FG000|Overall Study|Death|4
6358601|NCT00996333|10144007|FG000|Overall Study|Adverse Event|1
6358602|NCT00996333|10144007|FG000|Overall Study|Physician Decision|1
6358603|NCT00996333|10144007|FG000|Overall Study|Other|5
6358604|NCT00998738|10144011|FG000|Overall Study|Uknown|1
6358605|NCT00997386|10144019|FG000|Overall Study|Death|7
6358606|NCT00985738|10144025|FG000|Overall Study|Study closed prematurely|8
6358607|NCT00985738|10144026|FG001|Overall Study|Study closed prematurely|8
6358608|NCT00975611|10144119|FG000|Overall Study|Screen Fail|16
6358609|NCT00975611|10144119|FG000|Overall Study|Physician Decision|1
6358610|NCT00974922|10144144|FG000|Overall Study|study terminated|24
6358611|NCT00965146|10144159|FG000|Overall Study|Death|7
6358612|NCT00965146|10144159|FG000|Overall Study|Lost to Follow-up|22
6358613|NCT00965146|10144159|FG000|Overall Study|Withdrawal by Subject|17
6358614|NCT00965146|10144159|FG000|Overall Study|Unable to return|1
6358615|NCT00965146|10144159|FG000|Overall Study|Unwilling to return|11
6358616|NCT00965146|10144159|FG000|Overall Study|Intercurrent illness|1
6358617|NCT00965146|10144159|FG000|Overall Study|Revision / Removal of Study Implant|6
6358618|NCT00965146|10144159|FG000|Overall Study|Overall Study Termination|145
6358619|NCT00972023|10144163|FG000|Overall Study|Withdrawal by Subject|1
6358620|NCT00953329|10144182|FG000|Overall Study|Lack of Efficacy|1
6358621|NCT00958893|10144199|FG000|Overall Study|Study prematurely terminated|4
6358622|NCT00966654|10144203|FG000|Overall Study|Study was terminated,PI left institution|12
6358623|NCT00960154|10144211|FG000|Overall Study|Study termination|25
6358624|NCT00960154|10144212|FG001|Overall Study|Study termination|25
6358625|NCT00960752|10144221|FG000|Overall Study|Adverse Event|0
6358626|NCT00960752|10144222|FG001|Overall Study|Adverse Event|0
6358627|NCT00960752|10144223|FG002|Overall Study|Adverse Event|1
6358628|NCT00960752|10144221|FG000|Overall Study|Progression|0
6358629|NCT00960752|10144222|FG001|Overall Study|Progression|0
6358630|NCT00960752|10144223|FG002|Overall Study|Progression|1
6358631|NCT00958347|10144231|FG000|Overall Study|Death|43
6358632|NCT00958347|10144231|FG000|Overall Study|Withdrawal by Subject|23
6358633|NCT00958347|10144231|FG000|Overall Study|Lost to Follow-up|15
6358634|NCT00958347|10144231|FG000|Overall Study|revision/removal|10
6358635|NCT00958347|10144231|FG000|Overall Study|study termination|135
6358636|NCT00953615|10144244|FG000|Overall Study|Adverse Event|1
6358637|NCT00957034|10144256|FG000|Overall Study|Adverse Event|0
6358638|NCT00957034|10144257|FG001|Overall Study|Adverse Event|1
6358639|NCT00957034|10144258|FG002|Overall Study|Adverse Event|1
6358640|NCT00957034|10144256|FG000|Overall Study|Sponsor Terminated Study|6
6358641|NCT00957034|10144257|FG001|Overall Study|Sponsor Terminated Study|1
6358642|NCT00957034|10144258|FG002|Overall Study|Sponsor Terminated Study|5
6358643|NCT00957034|10144256|FG000|Overall Study|Withdrawal by Subject|0
6358644|NCT00957034|10144257|FG001|Overall Study|Withdrawal by Subject|2
6358645|NCT00957034|10144258|FG002|Overall Study|Withdrawal by Subject|0
6358646|NCT00949988|10144266|FG000|Overall Study|Withdrawal by Subject|3
6358647|NCT00948194|10144272|FG000|Overall Study|Blood drawn using incorrect test tube; sample invalid|1
6358648|NCT00948194|10144273|FG001|Overall Study|Blood drawn using incorrect test tube; sample invalid|0
6358649|NCT00946985|10144279|FG000|Stabilization Phase (25 Weeks)|Adverse Event|4
6358650|NCT00946985|10144279|FG000|Stabilization Phase (25 Weeks)|Lack of Efficacy|3
6358651|NCT00946985|10144279|FG000|Stabilization Phase (25 Weeks)|Lost to Follow-up|5
6358652|NCT00946985|10144279|FG000|Stabilization Phase (25 Weeks)|Withdrawal by Subject|4
6358653|NCT00946985|10144279|FG000|Stabilization Phase (25 Weeks)|Study Closed by Sponsor|139
6358654|NCT00946985|10144279|FG000|Stabilization Phase (25 Weeks)|Failed to Meet Stability Criteria|2
6358655|NCT00946985|10144279|FG000|Stabilization Phase (25 Weeks)|Prohibited Medication During Study|1
6358656|NCT00946985|10144279|FG000|Stabilization Phase (25 Weeks)|Patient Moved Away|2
6358657|NCT00946985|10144279|FG000|Relapse Prevention Phase (24 Months)|Study Closed by Sponsor|2
6358658|NCT00950690|10144287|FG000|Overall Study|Death|4
6358659|NCT00950690|10144287|FG000|Overall Study|Adverse Event|15
6358660|NCT00950690|10144287|FG000|Overall Study|Lack of Efficacy|22
6083967|NCT00640341|9692926|FG000|Overall Study|Positive Slit Lamp Findings|0
6083968|NCT00640341|9692927|FG001|Overall Study|Positive Slit Lamp Findings|0
6083969|NCT00640341|9692928|FG002|Overall Study|Positive Slit Lamp Findings|1
6083970|NCT00640341|9692926|FG000|Overall Study|Study Related Symptoms/Complaints|2
6083971|NCT00640341|9692927|FG001|Overall Study|Study Related Symptoms/Complaints|1
6083972|NCT00640341|9692928|FG002|Overall Study|Study Related Symptoms/Complaints|2
6083973|NCT00640341|9692926|FG000|Overall Study|Inability to Maintain Wearing Schedule|1
6170347|NCT01252940|9816652|FG000|Main Study Phase|Subject Non-compliance|1
6170348|NCT01252940|9816653|FG001|Main Study Phase|Subject Non-compliance|1
6170349|NCT01252940|9816652|FG000|Extension Phase|Adverse Event|2
6170350|NCT01252940|9816653|FG001|Extension Phase|Adverse Event|1
6358661|NCT00950690|10144287|FG000|Overall Study|Lost to Follow-up|40
6358662|NCT00950690|10144287|FG000|Overall Study|Other|163
6358663|NCT00944229|10144291|FG000|Overall Study|Withdrawal by Subject|11
6358664|NCT00944229|10144291|FG000|Overall Study|Physician Decision|14
6358665|NCT00941928|10144295|FG000|Overall Study|Withdrawal by Subject|1
6358666|NCT00941928|10144295|FG000|Overall Study|Disease Progression|1
6358667|NCT00947011|10144312|FG000|Overall Study|Study was terminated,PI left institution|12
6358668|NCT00943605|10144320|FG000|Overall Study|Study termination|30
6358669|NCT00943605|10144321|FG001|Overall Study|Study termination|30
6358670|NCT00942409|10144327|FG000|Overall Study|Lack of Efficacy|1
6358671|NCT00942409|10144327|FG000|Overall Study|study drug unavailable|2
6358672|NCT00936598|10144337|FG000|Overall Study|Withdrawal by Subject|1
6358673|NCT00936598|10144338|FG001|Overall Study|Withdrawal by Subject|0
6358674|NCT00936598|10144337|FG000|Overall Study|Ineligible after consent|1
6358675|NCT00936598|10144338|FG001|Overall Study|Ineligible after consent|0
6358676|NCT00934791|10144362|FG000|Overall Study|Withdrawal by Subject|1
6358677|NCT00934791|10144363|FG001|Overall Study|Withdrawal by Subject|0
6358678|NCT00925548|10144411|FG000|Overall Study|Discontinuation of trial by sponsor|10
6358679|NCT00925548|10144412|FG001|Overall Study|Discontinuation of trial by sponsor|5
6170351|NCT01252940|9816652|FG000|Extension Phase|Lack of Efficacy|1
6358680|NCT00926575|10144421|FG000|Overall Study|Adverse Event|1
6358681|NCT00926575|10144422|FG001|Overall Study|Adverse Event|1
6358682|NCT00926575|10144421|FG000|Overall Study|Death|4
6358683|NCT00926575|10144422|FG001|Overall Study|Death|4
6358684|NCT00926575|10144421|FG000|Overall Study|Lost to Follow-up|1
6358685|NCT00926575|10144422|FG001|Overall Study|Lost to Follow-up|1
6358686|NCT00926575|10144421|FG000|Overall Study|Physician Decision|1
6358687|NCT00926575|10144422|FG001|Overall Study|Physician Decision|2
6358688|NCT00926575|10144421|FG000|Overall Study|Protocol Violation|1
6358689|NCT00926575|10144422|FG001|Overall Study|Protocol Violation|0
6358690|NCT00926575|10144421|FG000|Overall Study|Withdrawal by Subject|8
6358691|NCT00926575|10144422|FG001|Overall Study|Withdrawal by Subject|9
6358692|NCT00918463|10144449|FG000|Overall Study|Death|1
6358693|NCT00918463|10144449|FG000|Overall Study|Lack of Efficacy|1
6358694|NCT00913692|10144453|FG000|Screening (4 Months)|Physician Decision|3
6358695|NCT00913692|10144453|FG000|Screening (4 Months)|Not eligible after screening phase.|6
6358696|NCT00913692|10144453|FG000|Treatment Phase 1 (5 Months)|Physician Decision|1
6358697|NCT00918645|10144460|FG000|Overall Study|Withdrawal by Subject|1
6358698|NCT00906035|10144493|FG000|Overall Study|Withdrawal by Subject|2
6358699|NCT00906035|10144494|FG001|Overall Study|Withdrawal by Subject|3
6358700|NCT00906035|10144495|FG002|Overall Study|Withdrawal by Subject|0
6358701|NCT00894790|10144526|FG000|Overall Study|Protocol Violation|0
6358702|NCT00894790|10144527|FG001|Overall Study|Protocol Violation|1
6358703|NCT00894790|10144526|FG000|Overall Study|Lost to Follow-up|0
6358704|NCT00894790|10144527|FG001|Overall Study|Lost to Follow-up|1
6358705|NCT00894790|10144526|FG000|Overall Study|Did not meet entrance criteria|1
6358706|NCT00894790|10144527|FG001|Overall Study|Did not meet entrance criteria|0
6358707|NCT00902668|10144533|FG000|Overall Study|Protocol stopped due to slow accrual.|3
6358708|NCT00881205|10144539|FG000|Overall Study|Adverse Event|8
6170352|NCT01252940|9816653|FG001|Extension Phase|Lack of Efficacy|0
6170353|NCT01252940|9816652|FG000|Extension Phase|Lost to Follow-up|5
6170354|NCT01252940|9816653|FG001|Extension Phase|Lost to Follow-up|0
6170355|NCT01252940|9816652|FG000|Extension Phase|Physician Decision|0
6170356|NCT01252940|9816653|FG001|Extension Phase|Physician Decision|1
6083974|NCT00640341|9692927|FG001|Overall Study|Inability to Maintain Wearing Schedule|1
6083975|NCT00640341|9692928|FG002|Overall Study|Inability to Maintain Wearing Schedule|0
6170357|NCT01252940|9816652|FG000|Extension Phase|Subject Non-compliance|1
6358709|NCT00881205|10144540|FG001|Overall Study|Adverse Event|3
6358710|NCT00881205|10144539|FG000|Overall Study|Withdrawal by Subject|1
6358711|NCT00881205|10144540|FG001|Overall Study|Withdrawal by Subject|2
6358712|NCT00881205|10144539|FG000|Overall Study|Lost to Follow-up|0
6358713|NCT00881205|10144540|FG001|Overall Study|Lost to Follow-up|1
6358714|NCT00881205|10144539|FG000|Overall Study|Administrative problems|1
6358715|NCT00881205|10144540|FG001|Overall Study|Administrative problems|1
6358716|NCT00881205|10144539|FG000|Overall Study|Condition no longer requires drug|1
6358717|NCT00881205|10144540|FG001|Overall Study|Condition no longer requires drug|0
6358718|NCT00903006|10144557|FG000|Overall Study|Withdrawal by Subject|2
6358719|NCT00903006|10144558|FG001|Overall Study|Withdrawal by Subject|0
6358720|NCT00903006|10144559|FG002|Overall Study|Withdrawal by Subject|0
6170358|NCT01252940|9816653|FG001|Extension Phase|Subject Non-compliance|0
6170359|NCT01252940|9816652|FG000|Extension Phase|Withdrawal by Subject|1
6170360|NCT01252940|9816653|FG001|Extension Phase|Withdrawal by Subject|1
6170361|NCT01252966|9816662|FG000|Overall Study|Lost to Follow-up|16
6358721|NCT00903006|10144560|FG003|Overall Study|Withdrawal by Subject|0
6358722|NCT00903006|10144557|FG000|Overall Study|Progressive Disease|0
6358723|NCT00903006|10144558|FG001|Overall Study|Progressive Disease|3
6358724|NCT00903006|10144559|FG002|Overall Study|Progressive Disease|1
6358725|NCT00903006|10144560|FG003|Overall Study|Progressive Disease|0
6358726|NCT00887315|10144577|FG000|Overall Study|Study termination|7
6358727|NCT00887315|10144578|FG001|Overall Study|Study termination|4
6358728|NCT00891904|10144584|FG000|Overall Study|Death|1
6358729|NCT00891904|10144584|FG000|Overall Study|Adverse Event|1
6358730|NCT00881608|10144593|FG000|Overall Study|Study prematurely terminated|11
6358731|NCT00889421|10144605|FG000|Overall Study|Lack of Efficacy|3
6358732|NCT00882310|10144622|FG000|Overall Study|Screen Failure|10
6358733|NCT00882310|10144622|FG000|Overall Study|Never received treatment|1
6358734|NCT00882310|10144622|FG000|Overall Study|Death|6
6358735|NCT00882310|10144622|FG000|Overall Study|Progression of disease|4
6358736|NCT00882310|10144622|FG000|Overall Study|Adverse Event|1
6358737|NCT00880542|10144626|FG000|Treatment Period (Sorafenib+Ifosfamide)|Adverse Event|1
6358738|NCT00880542|10144626|FG000|Treatment Period (Sorafenib+Ifosfamide)|disease progression|2
6358739|NCT00880542|10144626|FG000|REP: Surgical Resection|progressive disease|1
6358740|NCT00874939|10144634|FG000|Overall Study|Study terminated|4
6358741|NCT00877071|10144661|FG000|Overall Study|disease progression|2
6358742|NCT00878969|10144668|FG000|Overall Study|Physician Decision|5
6170362|NCT01252966|9816663|FG001|Overall Study|Lost to Follow-up|10
6358743|NCT00878969|10144669|FG001|Overall Study|Physician Decision|3
6358744|NCT00878969|10144670|FG002|Overall Study|Physician Decision|2
6358745|NCT00878969|10144668|FG000|Overall Study|Withdrawal by Subject|1
6358746|NCT00878969|10144669|FG001|Overall Study|Withdrawal by Subject|6
6358747|NCT00878969|10144670|FG002|Overall Study|Withdrawal by Subject|3
6358748|NCT00878969|10144668|FG000|Overall Study|kidney transplant|2
6358749|NCT00878969|10144669|FG001|Overall Study|kidney transplant|3
6358750|NCT00878969|10144670|FG002|Overall Study|kidney transplant|2
6358751|NCT00878969|10144668|FG000|Overall Study|Adverse Event|3
6358752|NCT00878969|10144669|FG001|Overall Study|Adverse Event|1
6358753|NCT00878969|10144670|FG002|Overall Study|Adverse Event|2
6358754|NCT00878969|10144668|FG000|Overall Study|Lost to Follow-up|2
6358755|NCT00878969|10144669|FG001|Overall Study|Lost to Follow-up|1
6358756|NCT00878969|10144670|FG002|Overall Study|Lost to Follow-up|0
6358757|NCT00878969|10144668|FG000|Overall Study|Protocol Violation|2
6083976|NCT00640341|9692926|FG000|Overall Study|Failure to Follow Subject Instructions|1
6358758|NCT00878969|10144669|FG001|Overall Study|Protocol Violation|0
6358759|NCT00878969|10144670|FG002|Overall Study|Protocol Violation|0
6358760|NCT00878969|10144668|FG000|Overall Study|Death|0
6358761|NCT00878969|10144669|FG001|Overall Study|Death|0
6358762|NCT00878969|10144670|FG002|Overall Study|Death|2
6358763|NCT00878969|10144668|FG000|Overall Study|Pregnancy|0
6358764|NCT00878969|10144669|FG001|Overall Study|Pregnancy|1
6358765|NCT00878969|10144670|FG002|Overall Study|Pregnancy|0
6358766|NCT00865514|10144678|FG000|Overall Study|Infusion cost exceeded funding|2
6358767|NCT00863512|10144695|FG000|Overall Study|Adverse Event|2
6358768|NCT00863512|10144696|FG001|Overall Study|Adverse Event|0
6358769|NCT00863512|10144695|FG000|Overall Study|Withdrawal by Subject|11
6358770|NCT00863512|10144696|FG001|Overall Study|Withdrawal by Subject|0
6358771|NCT00863512|10144695|FG000|Overall Study|Physician Decision|1
6358772|NCT00863512|10144696|FG001|Overall Study|Physician Decision|0
6358773|NCT00868998|10144702|FG000|Overall Study|Screen Failure|1
6358774|NCT00868998|10144702|FG000|Overall Study|Withdrawal by Subject|1
6358775|NCT00868998|10144702|FG000|Overall Study|Progression of disease|2
6358776|NCT00868998|10144702|FG000|Overall Study|Death|1
6358777|NCT00869258|10144706|FG000|Overall Study|Physician Decision|1
6358778|NCT00863330|10144710|FG000|Overall Study|study terminated early due to administra|6
6358779|NCT00853229|10144716|FG000|Phase 1: Initial Intervention|Early study termination, poor enrollment|8
6358780|NCT00853229|10144717|FG001|Phase 1: Initial Intervention|Early study termination, poor enrollment|8
6358781|NCT00860249|10144728|FG000|Overall Study|trial was terminated prior to completion|21
6358782|NCT00860249|10144729|FG001|Overall Study|trial was terminated prior to completion|18
6358783|NCT00860249|10144730|FG002|Overall Study|trial was terminated prior to completion|21
6358784|NCT00860158|10144738|FG000|Overall Study|Study Terminated|1
6358785|NCT00853567|10144745|FG000|Overall Study|Study prematurely terminated|71
6358786|NCT00849524|10144753|FG000|Overall Study|Lack of Efficacy|3
6358787|NCT00851682|10144768|FG000|Overall Study|screen failure|5
6358788|NCT00851682|10144769|FG001|Overall Study|screen failure|0
6358789|NCT00851747|10144791|FG000|Overall Study|Physician Decision|6
6358790|NCT00851747|10144792|FG001|Overall Study|Physician Decision|6
6358791|NCT00851747|10144793|FG002|Overall Study|Physician Decision|6
6358792|NCT00852241|10144800|FG000|Overall Study|Physician Decision|18
6358793|NCT00851552|10144804|FG000|Overall Study|Death|2
6358794|NCT00851552|10144804|FG000|Overall Study|Adverse Event|1
6358795|NCT00851552|10144804|FG000|Overall Study|Disease Progression|4
6358796|NCT00845845|10144814|FG000|Overall Study|Lost to Follow-up|0
6358797|NCT00845845|10144815|FG001|Overall Study|Lost to Follow-up|4
6358798|NCT00851591|10144823|FG000|Overall Study|Withdrawal by Subject|2
6358799|NCT00851591|10144824|FG001|Overall Study|Withdrawal by Subject|0
6358800|NCT00835679|10144861|FG000|Overall Study|Withdrawal by Subject|1
6358801|NCT00835679|10144862|FG001|Overall Study|Withdrawal by Subject|0
6358802|NCT00835679|10144863|FG002|Overall Study|Withdrawal by Subject|0
6358803|NCT00835679|10144864|FG003|Overall Study|Withdrawal by Subject|0
6358804|NCT00841035|10144878|FG000|Phase 1 Overall Study|Physician Decision|13
6358805|NCT00840827|10144896|FG000|Overall Study|Adverse Event|1
6358806|NCT00840827|10144896|FG000|Overall Study|Lack of Efficacy|4
6358807|NCT00840827|10144896|FG000|Overall Study|Physician Decision|1
6358808|NCT00832624|10144930|FG000|Overall Study|Study Terminated|10
6358809|NCT00827567|10144973|FG000|Overall Study|Progression of Disease/Screen Failure|4
6358810|NCT00815633|10144977|FG000|Overall Study|study terminated|1
6358811|NCT00814983|10144983|FG000|Overall Study|Screen failure|1
6358812|NCT00814983|10144984|FG001|Overall Study|Screen failure|0
6358813|NCT00814983|10144983|FG000|Overall Study|Withdrawal by Subject|1
6358814|NCT00814983|10144984|FG001|Overall Study|Withdrawal by Subject|0
6358815|NCT00814983|10144983|FG000|Overall Study|Graft failure|1
6358816|NCT00814983|10144984|FG001|Overall Study|Graft failure|0
6358817|NCT00819832|10145007|FG000|Overall Study|Sponsor Termination of Study|3
6170363|NCT01252966|9816662|FG000|Overall Study|Withdrawal by Subject|7
6170364|NCT01252966|9816663|FG001|Overall Study|Withdrawal by Subject|3
6170365|NCT01253018|9816673|FG000|Overall Study|Lost to Follow-up|1
6170366|NCT01253018|9816674|FG001|Overall Study|Lost to Follow-up|1
6170367|NCT01253018|9816673|FG000|Overall Study|Robot Repair Issues|2
6170368|NCT01253018|9816674|FG001|Overall Study|Robot Repair Issues|0
6170369|NCT01253018|9816673|FG000|Overall Study|Withdrawal by Subject|1
6170370|NCT01253018|9816674|FG001|Overall Study|Withdrawal by Subject|1
6358818|NCT00819832|10145008|FG001|Overall Study|Sponsor Termination of Study|0
6358819|NCT00819832|10145009|FG002|Overall Study|Sponsor Termination of Study|0
6358820|NCT00819832|10145010|FG003|Overall Study|Sponsor Termination of Study|0
6358821|NCT00819832|10145011|FG004|Overall Study|Sponsor Termination of Study|0
6358822|NCT00819832|10145012|FG005|Overall Study|Sponsor Termination of Study|0
6358823|NCT00814892|10145035|FG000|Overall Study|Disease Progression|1
6170371|NCT01253044|9816683|FG000|Overall Study|Lost to Follow-up|38
6170372|NCT01253044|9816684|FG001|Overall Study|Lost to Follow-up|29
6170373|NCT01253135|9816690|FG000|Original Protocol|Protocol Amendment|15
6170374|NCT01253135|9816690|FG000|Amended Protocol|Non-compliance|1
6170375|NCT01253174|9816702|FG000|Period 1|Randomized but not treated|0
6170376|NCT01253174|9816703|FG001|Period 1|Randomized but not treated|1
6170377|NCT01253174|9816704|FG002|Period 1|Randomized but not treated|1
6170378|NCT01253174|9816705|FG003|Period 1|Randomized but not treated|0
6170379|NCT01253174|9816706|FG004|Period 1|Randomized but not treated|1
6170380|NCT01253174|9816707|FG005|Period 1|Randomized but not treated|0
6170381|NCT01253174|9816702|FG000|Period 2|Adverse Event|0
6170382|NCT01253174|9816703|FG001|Period 2|Adverse Event|0
6170383|NCT01253174|9816704|FG002|Period 2|Adverse Event|1
6170384|NCT01253174|9816705|FG003|Period 2|Adverse Event|0
6170385|NCT01253174|9816706|FG004|Period 2|Adverse Event|0
6170386|NCT01253174|9816707|FG005|Period 2|Adverse Event|0
6170387|NCT01253174|9816702|FG000|Period 3|Withdrawal by Subject|0
6170388|NCT01253174|9816703|FG001|Period 3|Withdrawal by Subject|1
6170389|NCT01253174|9816704|FG002|Period 3|Withdrawal by Subject|0
6170390|NCT01253174|9816705|FG003|Period 3|Withdrawal by Subject|0
6170391|NCT01253174|9816706|FG004|Period 3|Withdrawal by Subject|1
6170392|NCT01253174|9816707|FG005|Period 3|Withdrawal by Subject|0
6358824|NCT00814892|10145035|FG000|Overall Study|Study Termination|1
6358825|NCT00802659|10145052|FG000|Overall Study|Physician Decision|0
6358826|NCT00802659|10145053|FG001|Overall Study|Physician Decision|1
6358827|NCT00802659|10145054|FG002|Overall Study|Physician Decision|0
6358828|NCT00802659|10145055|FG003|Overall Study|Physician Decision|0
6358829|NCT00807365|10145065|FG000|Overall Study|Study Terminated|5
6358830|NCT00814333|10145071|FG000|Enrollment|Lost to Follow-up|1
6358831|NCT00814333|10145072|FG001|Enrollment|Lost to Follow-up|0
6358832|NCT00808080|10145078|FG000|Overall Study|Patients Became Ineligible for infusion|6
6358833|NCT00802893|10145083|FG000|Overall Study|study terminated|3
6358834|NCT00809341|10145089|FG000|Overall Study|Physician Decision|0
6358835|NCT00809341|10145090|FG001|Overall Study|Physician Decision|1
6358836|NCT00808899|10145118|FG000|Overall Study|Death|1
6358837|NCT00808899|10145118|FG000|Overall Study|Physician Decision|3
6358838|NCT00803179|10145129|FG000|Overall Study|Lost to Follow-up|3
6358839|NCT00790452|10145168|FG000|Overall Study|Drug supply issue|1
6358840|NCT00790452|10145169|FG001|Overall Study|Drug supply issue|0
6358841|NCT00787917|10145181|FG000|Blinded Treatment|Adverse Event|1
6358842|NCT00787917|10145182|FG001|Blinded Treatment|Adverse Event|0
6358843|NCT00787917|10145181|FG000|Blinded Treatment|Lack of Efficacy|1
6358844|NCT00787917|10145182|FG001|Blinded Treatment|Lack of Efficacy|0
6358845|NCT00787917|10145181|FG000|Blinded Treatment|Administrative problems|3
6358846|NCT00787917|10145182|FG001|Blinded Treatment|Administrative problems|2
6358847|NCT00787917|10145181|FG000|Open Label|Unsatisfactory therapeutic effect|1
6358848|NCT00787917|10145182|FG001|Open Label|Unsatisfactory therapeutic effect|0
6358849|NCT00787917|10145181|FG000|Open Label|Administrative problems|3
6358850|NCT00787917|10145182|FG001|Open Label|Administrative problems|0
6358851|NCT00798590|10145192|FG000|Overall Study|P.I, Left institution. Study terminated|11
6358852|NCT00798590|10145193|FG001|Overall Study|P.I, Left institution. Study terminated|8
6358853|NCT00796510|10145201|FG000|Overall Study|Death|1
6358854|NCT00796510|10145202|FG001|Overall Study|Death|0
6358855|NCT00796510|10145201|FG000|Overall Study|Study Terminated|2
6358856|NCT00796510|10145202|FG001|Overall Study|Study Terminated|0
6358857|NCT00796861|10145208|FG000|Overall Study|Withdrawal by Subject|2
6358858|NCT00796861|10145208|FG000|Overall Study|Death|2
6170393|NCT01253174|9816702|FG000|Period 3|Pregnancy|0
6170394|NCT01253174|9816703|FG001|Period 3|Pregnancy|0
6170395|NCT01253174|9816704|FG002|Period 3|Pregnancy|1
6170396|NCT01253174|9816705|FG003|Period 3|Pregnancy|0
6170397|NCT01253174|9816706|FG004|Period 3|Pregnancy|0
6358859|NCT00791076|10145212|FG000|Overall Study|Study was terminated,PI left institution|8
6083977|NCT00640341|9692927|FG001|Overall Study|Failure to Follow Subject Instructions|0
6083978|NCT00640341|9692928|FG002|Overall Study|Failure to Follow Subject Instructions|0
6083979|NCT00640341|9692926|FG000|Overall Study|Lost to Follow-up|2
6083980|NCT00640341|9692927|FG001|Overall Study|Lost to Follow-up|0
6083981|NCT00640341|9692928|FG002|Overall Study|Lost to Follow-up|0
6083982|NCT00640341|9692926|FG000|Overall Study|Withdrawal by Subject|4
6083983|NCT00640341|9692927|FG001|Overall Study|Withdrawal by Subject|0
6083984|NCT00640341|9692928|FG002|Overall Study|Withdrawal by Subject|1
6083985|NCT00640341|9692926|FG000|Overall Study|Unacceptable Lens Movement|1
6083986|NCT00640341|9692927|FG001|Overall Study|Unacceptable Lens Movement|0
6083987|NCT00640341|9692928|FG002|Overall Study|Unacceptable Lens Movement|0
6083988|NCT00640341|9692926|FG000|Overall Study|Poor fit/Uncomfortable|4
6358860|NCT00796107|10145227|FG000|Overall Study|Lack of Efficacy|1
6358861|NCT00796107|10145227|FG000|Overall Study|Progressive Disease|5
6358862|NCT00785356|10145251|FG000|Overall Study|Study prematurely terminated|8
6358863|NCT00782483|10145259|FG000|Overall Study|Early Termination of Protocol - PI Reloc|6
6358864|NCT00784043|10145269|FG000|Overall Study|Withdrawal by Subject|8
6358865|NCT00784043|10145270|FG001|Overall Study|Withdrawal by Subject|5
6358866|NCT00784043|10145269|FG000|Overall Study|Protocol Terminated|23
6358867|NCT00784043|10145270|FG001|Overall Study|Protocol Terminated|1
6358868|NCT00774306|10145293|FG000|Overall Study|Adverse Event|3
6358869|NCT00774306|10145294|FG001|Overall Study|Adverse Event|0
6358870|NCT00774306|10145295|FG002|Overall Study|Adverse Event|0
6358871|NCT00774306|10145296|FG003|Overall Study|Adverse Event|0
6358872|NCT00774306|10145293|FG000|Overall Study|Protocol Violation|2
6358873|NCT00774306|10145294|FG001|Overall Study|Protocol Violation|0
6358874|NCT00774306|10145295|FG002|Overall Study|Protocol Violation|3
6358875|NCT00774306|10145296|FG003|Overall Study|Protocol Violation|0
6358876|NCT00774306|10145293|FG000|Overall Study|Withdrawal by Subject|6
6358877|NCT00774306|10145294|FG001|Overall Study|Withdrawal by Subject|1
6358878|NCT00774306|10145295|FG002|Overall Study|Withdrawal by Subject|1
6358879|NCT00774306|10145296|FG003|Overall Study|Withdrawal by Subject|0
6358880|NCT00774306|10145293|FG000|Overall Study|Lost to Follow-up|6
6358881|NCT00774306|10145294|FG001|Overall Study|Lost to Follow-up|0
6358882|NCT00774306|10145295|FG002|Overall Study|Lost to Follow-up|4
6358883|NCT00774306|10145296|FG003|Overall Study|Lost to Follow-up|5
6358884|NCT00774306|10145293|FG000|Overall Study|Death|1
6358885|NCT00774306|10145294|FG001|Overall Study|Death|1
6358886|NCT00774306|10145295|FG002|Overall Study|Death|0
6358887|NCT00774306|10145296|FG003|Overall Study|Death|0
6358888|NCT00779038|10145319|FG000|Overall Study|Study Prematurely Terminated|13
6358889|NCT00776100|10145334|FG000|Overall Study|Disease Progression|1
6358890|NCT00776100|10145335|FG001|Overall Study|Disease Progression|0
6358891|NCT00771316|10145343|FG000|Overall Study|Adverse Event|0
6358892|NCT00771316|10145344|FG001|Overall Study|Adverse Event|1
6358893|NCT00771316|10145343|FG000|Overall Study|Patient withdrew consent|1
6358894|NCT00771316|10145344|FG001|Overall Study|Patient withdrew consent|0
6358895|NCT00771316|10145343|FG000|Overall Study|Discontinued due to early termination|1
6358896|NCT00771316|10145344|FG001|Overall Study|Discontinued due to early termination|0
6358897|NCT00768040|10145365|FG000|Overall Study|Adverse Event|3
6358898|NCT00768040|10145366|FG001|Overall Study|Adverse Event|2
6358899|NCT00768040|10145365|FG000|Overall Study|Abnormal laboratory value|1
6358900|NCT00768040|10145366|FG001|Overall Study|Abnormal laboratory value|1
6358901|NCT00776555|10145374|FG000|Overall Study|Study terminated|3
6358902|NCT00776555|10145375|FG001|Overall Study|Study terminated|0
6358903|NCT00775190|10145383|FG000|Overall Study|Lost to Follow-up|2
6358904|NCT00775190|10145384|FG001|Overall Study|Lost to Follow-up|3
6358905|NCT00775190|10145383|FG000|Overall Study|Withdrawal by Subject|1
6358906|NCT00775190|10145384|FG001|Overall Study|Withdrawal by Subject|2
6358907|NCT00775190|10145383|FG000|Overall Study|Protocol Violation|1
6358908|NCT00775190|10145384|FG001|Overall Study|Protocol Violation|0
6358909|NCT00762723|10145397|FG000|Overall Study|Study Terminated slow enrollement|5
6358910|NCT00762723|10145398|FG001|Overall Study|Study Terminated slow enrollement|5
6358911|NCT00762723|10145399|FG002|Overall Study|Study Terminated slow enrollement|3
6358912|NCT00770965|10145411|FG000|Safety Set|Withdrawal by Subject|0
6358913|NCT00770965|10145412|FG001|Safety Set|Withdrawal by Subject|0
6358914|NCT00770965|10145413|FG002|Safety Set|Withdrawal by Subject|0
6358915|NCT00770965|10145414|FG003|Safety Set|Withdrawal by Subject|1
6358916|NCT00770965|10145411|FG000|Safety Set|Protocol deviation|0
6358917|NCT00770965|10145412|FG001|Safety Set|Protocol deviation|0
6358918|NCT00770965|10145413|FG002|Safety Set|Protocol deviation|1
6358919|NCT00770965|10145414|FG003|Safety Set|Protocol deviation|0
6358920|NCT00770965|10145411|FG000|Excluded Set|Administrative problems|14
6358921|NCT00770965|10145412|FG001|Excluded Set|Administrative problems|12
6358922|NCT00770965|10145413|FG002|Excluded Set|Administrative problems|12
6358923|NCT00770965|10145414|FG003|Excluded Set|Administrative problems|10
6358924|NCT00770965|10145411|FG000|Excluded Set|Withdrawal by Subject|1
6358925|NCT00770965|10145412|FG001|Excluded Set|Withdrawal by Subject|1
6358926|NCT00770965|10145413|FG002|Excluded Set|Withdrawal by Subject|2
6358927|NCT00770965|10145414|FG003|Excluded Set|Withdrawal by Subject|3
6358928|NCT00769002|10145428|FG000|Overall Study|Study was not completed, no data|9
6358929|NCT00769002|10145429|FG001|Overall Study|Study was not completed, no data|9
6358930|NCT00766636|10145436|FG000|Overall Study|Withdrawal by Subject|1
6358931|NCT00766636|10145437|FG001|Overall Study|Withdrawal by Subject|1
6358932|NCT00766636|10145436|FG000|Overall Study|Incomplete Treatment|0
6358933|NCT00766636|10145437|FG001|Overall Study|Incomplete Treatment|1
6358934|NCT00766636|10145436|FG000|Overall Study|Adverse Event|1
6358935|NCT00766636|10145437|FG001|Overall Study|Adverse Event|0
6358936|NCT00766636|10145436|FG000|Overall Study|Disease Progression|1
6358937|NCT00766636|10145437|FG001|Overall Study|Disease Progression|0
6358938|NCT00768248|10145445|FG000|Overall Study|Research coordinator didn't collect data|1
6358939|NCT00768248|10145446|FG001|Overall Study|Research coordinator didn't collect data|1
6358940|NCT00764699|10145456|FG000|Overall Study|PI left and study terminated|3
6358941|NCT00763009|10145464|FG000|Overall Study|Coronary Anatomy unsuitable|1
6358942|NCT00761176|10145471|FG000|Overall Study|Death|1
6358943|NCT00761176|10145472|FG001|Overall Study|Death|0
6358944|NCT00761176|10145471|FG000|Overall Study|Withdrawal by Subject|1
6358945|NCT00761176|10145472|FG001|Overall Study|Withdrawal by Subject|1
6358946|NCT00754793|10145497|FG000|Overall Study|voluntary withdrawn from study|0
6358947|NCT00754793|10145498|FG001|Overall Study|voluntary withdrawn from study|1
6358948|NCT00754052|10145506|FG000|Overall Study|Study terminated by Sponsor|5
6358949|NCT00754052|10145507|FG001|Overall Study|Study terminated by Sponsor|3
6358950|NCT00750204|10145529|FG000|Overall Study|study halted prematurely|1
6358951|NCT00750204|10145530|FG001|Overall Study|study halted prematurely|1
6358952|NCT00752986|10145552|FG000|Overall Study|Withdrawal by Subject|2
6358953|NCT00752986|10145553|FG001|Overall Study|Withdrawal by Subject|1
6358954|NCT00752986|10145554|FG002|Overall Study|Withdrawal by Subject|2
6358955|NCT00752986|10145552|FG000|Overall Study|Protocol Violation|3
6358956|NCT00752986|10145553|FG001|Overall Study|Protocol Violation|0
6358957|NCT00752986|10145554|FG002|Overall Study|Protocol Violation|0
6358958|NCT00754013|10145577|FG000|Overall Study|Lost to Follow-up|1
6358959|NCT00754013|10145578|FG001|Overall Study|Lost to Follow-up|1
6358960|NCT00754013|10145577|FG000|Overall Study|didn't return after study termed|3
6358961|NCT00754013|10145578|FG001|Overall Study|didn't return after study termed|4
6358962|NCT00735553|10145587|FG000|Overall Study|Study prematurely terminated|77
6358963|NCT00751933|10145595|FG000|Overall Study|Withdrawal by Subject|0
6358964|NCT00751933|10145596|FG001|Overall Study|Withdrawal by Subject|1
6358965|NCT00751933|10145597|FG002|Overall Study|Withdrawal by Subject|0
6358966|NCT00751933|10145598|FG003|Overall Study|Withdrawal by Subject|0
6358967|NCT00751933|10145595|FG000|Overall Study|Physician Decision|0
6358968|NCT00751933|10145596|FG001|Overall Study|Physician Decision|0
6358969|NCT00751933|10145597|FG002|Overall Study|Physician Decision|1
6358970|NCT00751933|10145598|FG003|Overall Study|Physician Decision|1
6358971|NCT00747461|10145615|FG000|Overall Study|study terminated by sponsor|5
6358972|NCT00736385|10145630|FG000|Overall Study|Withdrawal by Subject|2
6358973|NCT00736385|10145631|FG001|Overall Study|Withdrawal by Subject|2
6358974|NCT00736385|10145630|FG000|Overall Study|Adverse Event|0
6358975|NCT00736385|10145631|FG001|Overall Study|Adverse Event|1
6358976|NCT00739063|10145654|FG000|Overall Study|Screen failures|8
6358977|NCT00740597|10145658|FG000|Overall Study|insurance would not cover treatment|1
6358978|NCT00737282|10145677|FG000|Overall Study|Study prematurely terminated|175
6358979|NCT00739882|10145685|FG000|Double-blind Period|Adverse Event|1
6358980|NCT00739882|10145686|FG001|Double-blind Period|Adverse Event|2
6358981|NCT00739882|10145685|FG000|Double-blind Period|Protocol Violation|1
6358982|NCT00739882|10145686|FG001|Double-blind Period|Protocol Violation|0
6358983|NCT00739882|10145685|FG000|Double-blind Period|Lack of Efficacy|1
6358984|NCT00739882|10145686|FG001|Double-blind Period|Lack of Efficacy|1
6358985|NCT00739882|10145685|FG000|Double-blind Period|Other|16
6358986|NCT00739882|10145686|FG001|Double-blind Period|Other|8
6358987|NCT00739882|10145685|FG000|Open-label Period|Adverse Event|1
6358988|NCT00739882|10145686|FG001|Open-label Period|Adverse Event|0
6358989|NCT00739882|10145685|FG000|Open-label Period|Other|9
6358990|NCT00739882|10145686|FG001|Open-label Period|Other|5
6358991|NCT00735254|10145718|FG000|Overall Study|Protocol Violation|1
6358992|NCT00735254|10145719|FG001|Overall Study|Protocol Violation|1
6358993|NCT00735254|10145720|FG002|Overall Study|Protocol Violation|1
6358994|NCT00735254|10145721|FG003|Overall Study|Protocol Violation|0
6358995|NCT00729365|10145734|FG000|Overall Study|Physician Decision|33
6358996|NCT00729365|10145735|FG001|Overall Study|Physician Decision|6
6358997|NCT00729365|10145736|FG002|Overall Study|Physician Decision|7
6358998|NCT00724282|10145754|FG000|Overall Study|Withdrawal by Subject|3
6358999|NCT00724282|10145754|FG000|Overall Study|Physician Decision|1
6359000|NCT00730886|10145760|FG000|Overall Study|Lost to Follow-up|1
6359001|NCT00730886|10145761|FG001|Overall Study|Lost to Follow-up|0
6359002|NCT00730886|10145760|FG000|Overall Study|Physician Decision|1
6359003|NCT00730886|10145761|FG001|Overall Study|Physician Decision|0
6359004|NCT00729560|10145789|FG000|Overall Study|Withdrawal by Subject|3
6359005|NCT00714948|10145810|FG000|Overall Study|Adverse Event|2
6359006|NCT00720343|10145814|FG000|Overall Study|Physician Decision|3
6359007|NCT00720343|10145814|FG000|Overall Study|No data|3
6359008|NCT00718640|10145829|FG000|Overall Study|Adverse Event|4
6359009|NCT00718640|10145829|FG000|Overall Study|Death|1
6359010|NCT00718640|10145829|FG000|Overall Study|Unresolved toxicity after 2 weeks|2
6359011|NCT00720083|10145835|FG000|Overall Study|Ineligible|1
6359012|NCT00720083|10145836|FG001|Overall Study|Ineligible|2
6359013|NCT00717275|10145842|FG000|Overall Study|Premature study termination.|3
6359014|NCT00708734|10145846|FG000|Overall Study|scheduling conflict|2
6359015|NCT00708734|10145846|FG000|Overall Study|moved|1
6359016|NCT00708734|10145846|FG000|Overall Study|leg injury|1
6359017|NCT00708734|10145846|FG000|Overall Study|knee replacement|1
6359018|NCT00708734|10145846|FG000|Overall Study|vertigo|1
6359019|NCT00708734|10145846|FG000|Overall Study|leg fracture|1
6359020|NCT00711087|10145852|FG000|Overall Study|Lost to Follow-up|1
6359021|NCT00711087|10145853|FG001|Overall Study|Lost to Follow-up|0
6359022|NCT00706797|10145861|FG000|Overall Study|Lack of Efficacy|3
6359023|NCT00706797|10145862|FG001|Overall Study|Lack of Efficacy|0
6359024|NCT00706797|10145861|FG000|Overall Study|Adverse Event|0
6359025|NCT00706797|10145862|FG001|Overall Study|Adverse Event|3
6359026|NCT00706797|10145861|FG000|Overall Study|Withdrawal by Subject|8
6359027|NCT00706797|10145862|FG001|Overall Study|Withdrawal by Subject|1
6359028|NCT00706797|10145861|FG000|Overall Study|Death|1
6359029|NCT00706797|10145862|FG001|Overall Study|Death|0
6359030|NCT00706797|10145861|FG000|Overall Study|Discontinuation of study by sponsor|52
6359031|NCT00706797|10145862|FG001|Overall Study|Discontinuation of study by sponsor|63
6359032|NCT00706797|10145861|FG000|Overall Study|Protocol Violation|3
6359033|NCT00706797|10145862|FG001|Overall Study|Protocol Violation|2
6359034|NCT00706797|10145861|FG000|Overall Study|Lost to Follow-up|1
6359035|NCT00706797|10145862|FG001|Overall Study|Lost to Follow-up|2
6359036|NCT00706797|10145861|FG000|Overall Study|Other|1
6359037|NCT00706797|10145862|FG001|Overall Study|Other|0
6359038|NCT00713596|10145871|FG000|Overall Study|Study was terminated|2
6359039|NCT00713596|10145872|FG001|Overall Study|Study was terminated|3
6359040|NCT00713596|10145873|FG002|Overall Study|Study was terminated|2
6359041|NCT00703092|10145886|FG000|Overall Study|Withdrawal by Subject|2
6359042|NCT00713258|10145892|FG000|Overall Study|Adverse Event|2
6359043|NCT00713258|10145893|FG001|Overall Study|Adverse Event|4
6359044|NCT00713258|10145892|FG000|Overall Study|Non-Compliance|2
6359045|NCT00713258|10145893|FG001|Overall Study|Non-Compliance|1
6359046|NCT00713258|10145892|FG000|Overall Study|Other|1
6359047|NCT00713258|10145893|FG001|Overall Study|Other|1
6359048|NCT00707434|10145903|FG000|Overall Study|Adverse Event|1
6359049|NCT00707161|10145907|FG000|Overall Study|Physician Decision|6
6359050|NCT00708916|10145920|FG000|Overall Study|Subject Noncompliance|2
6359051|NCT00708916|10145920|FG000|Overall Study|Adverse Event|2
6359052|NCT00700778|10145925|FG000|Overall Study|Inconclusive data due to inadequate sample collection|2
6359053|NCT00699842|10145932|FG000|Overall Study|Death|0
6359054|NCT00699842|10145933|FG001|Overall Study|Death|1
6359055|NCT00699842|10145934|FG002|Overall Study|Death|0
6359056|NCT00702962|10145944|FG000|Overall Study|Progressive disease|0
6359057|NCT00702962|10145945|FG001|Overall Study|Progressive disease|1
6359058|NCT00702962|10145944|FG000|Overall Study|Hospitalized for other health disorder|1
6359059|NCT00702962|10145945|FG001|Overall Study|Hospitalized for other health disorder|0
6359060|NCT00703534|10145955|FG000|Overall Study|Adverse Event|14
6359061|NCT00703534|10145956|FG001|Overall Study|Adverse Event|3
6359062|NCT00703534|10145955|FG000|Overall Study|Withdrawal by Subject|8
6359063|NCT00703534|10145956|FG001|Overall Study|Withdrawal by Subject|7
6359064|NCT00703534|10145955|FG000|Overall Study|Incorrect Enrollment|6
6359065|NCT00703534|10145956|FG001|Overall Study|Incorrect Enrollment|6
6359066|NCT00703534|10145955|FG000|Overall Study|Lost to Follow-up|1
6359067|NCT00703534|10145956|FG001|Overall Study|Lost to Follow-up|4
6359068|NCT00703534|10145955|FG000|Overall Study|Severe Non Compliance|1
6359069|NCT00703534|10145956|FG001|Overall Study|Severe Non Compliance|5
6359070|NCT00698009|10145962|FG000|Overall Study|Withdrawal by Subject|1
6359071|NCT00702702|10145986|FG000|Overall Study|Study prematurely terminated|56
6359072|NCT00699413|10146005|FG000|Overall Study|Withdrawal by Subject|0
6359073|NCT00699413|10146006|FG001|Overall Study|Withdrawal by Subject|2
6359074|NCT00699413|10146005|FG000|Overall Study|Study terminated by sponsor|4
6359075|NCT00699413|10146006|FG001|Overall Study|Study terminated by sponsor|2
6359076|NCT00686972|10146016|FG000|Overall Study|P.I, Left institution. Study terminated|51
6359077|NCT00693017|10146022|FG000|Overall Study|Sponsor Decision|2
6359078|NCT00693017|10146023|FG001|Overall Study|Sponsor Decision|1
6359079|NCT00693017|10146022|FG000|Overall Study|Death|0
6359080|NCT00693017|10146023|FG001|Overall Study|Death|1
6359081|NCT00692003|10146062|FG000|Overall Study|Sponsor Decision|5
6359082|NCT00692003|10146063|FG001|Overall Study|Sponsor Decision|1
6359083|NCT00678288|10146071|FG000|Overall Study|Adverse Event|0
6359084|NCT00678288|10146072|FG001|Overall Study|Adverse Event|2
6359085|NCT00678288|10146071|FG000|Overall Study|Withdrawal by Subject|1
6359086|NCT00678288|10146072|FG001|Overall Study|Withdrawal by Subject|1
6359087|NCT00678288|10146071|FG000|Overall Study|Study terminated by the sponsor|2
6359088|NCT00678288|10146072|FG001|Overall Study|Study terminated by the sponsor|0
6359089|NCT00678288|10146071|FG000|Overall Study|Not compliant with study medication|0
6359090|NCT00678288|10146072|FG001|Overall Study|Not compliant with study medication|1
6359091|NCT00678288|10146071|FG000|Overall Study|Switch to commercial drug|0
6359092|NCT00678288|10146072|FG001|Overall Study|Switch to commercial drug|1
6359093|NCT00678288|10146071|FG000|Overall Study|Reason not reported|1
6359094|NCT00678288|10146072|FG001|Overall Study|Reason not reported|0
6359095|NCT00678288|10146071|FG000|Overall Study|Disease progression/recurrence/relapse|6
6359096|NCT00678288|10146072|FG001|Overall Study|Disease progression/recurrence/relapse|1
6359097|NCT00689052|10146084|FG000|Overall Study|Adverse Event|4
6359098|NCT00689052|10146085|FG001|Overall Study|Adverse Event|6
6359099|NCT00689052|10146084|FG000|Overall Study|Protocol Violation|1
6359100|NCT00689052|10146085|FG001|Overall Study|Protocol Violation|0
6359101|NCT00689052|10146084|FG000|Overall Study|Lost to Follow-up|2
6359102|NCT00689052|10146085|FG001|Overall Study|Lost to Follow-up|0
6359103|NCT00689052|10146084|FG000|Overall Study|Withdrawal by Subject|2
6359104|NCT00689052|10146085|FG001|Overall Study|Withdrawal by Subject|0
6359105|NCT00689052|10146084|FG000|Overall Study|Early termination of the trial|22
6359106|NCT00689052|10146085|FG001|Overall Study|Early termination of the trial|24
6359107|NCT00683917|10146105|FG000|Overall Study|Study prematurely terminated|10
6359108|NCT00686036|10146128|FG000|Overall Study|Adverse Event|3
6359109|NCT00686036|10146129|FG001|Overall Study|Adverse Event|0
6359110|NCT00686036|10146128|FG000|Overall Study|Withdrawal by Subject|3
6359111|NCT00686036|10146129|FG001|Overall Study|Withdrawal by Subject|1
6359112|NCT00686036|10146128|FG000|Overall Study|Study terminated by AstraZeneca|2
6359113|NCT00686036|10146129|FG001|Overall Study|Study terminated by AstraZeneca|1
6359114|NCT00686036|10146128|FG000|Overall Study|PSA ≥ 10ng/mL|1
6359115|NCT00686036|10146129|FG001|Overall Study|PSA ≥ 10ng/mL|0
6359116|NCT00686036|10146128|FG000|Overall Study|Other reasons not identified|0
6359117|NCT00686036|10146129|FG001|Overall Study|Other reasons not identified|4
6359118|NCT00683787|10146151|FG000|Overall Study|Progression|3
6359119|NCT00683787|10146152|FG001|Overall Study|Progression|3
6359120|NCT00683787|10146153|FG002|Overall Study|Progression|0
6359121|NCT00683787|10146151|FG000|Overall Study|Adverse Event|0
6359122|NCT00683787|10146152|FG001|Overall Study|Adverse Event|0
6359123|NCT00683787|10146153|FG002|Overall Study|Adverse Event|2
6359124|NCT00678041|10146168|FG000|Overall Study|Physician Decision|5
6359125|NCT00678041|10146169|FG001|Overall Study|Physician Decision|5
6359126|NCT00681629|10146187|FG000|Overall Study|Study termination|4
6359127|NCT00681629|10146188|FG001|Overall Study|Study termination|2
6359128|NCT00681629|10146187|FG000|Overall Study|Adverse Event|1
6359129|NCT00681629|10146188|FG001|Overall Study|Adverse Event|0
6359130|NCT00673361|10146248|FG000|Overall Study|Screen Failure|2
6359131|NCT00673179|10146265|FG000|Overall Study|Toxicity/Complications|3
6359132|NCT00673179|10146266|FG001|Overall Study|Toxicity/Complications|0
6359133|NCT00660348|10146285|FG000|Overall Study|Withdrawal by Subject|1
6359134|NCT00660348|10146286|FG001|Overall Study|Withdrawal by Subject|0
6359135|NCT00664066|10146292|FG000|Overall Study|Study terminated|3
6359136|NCT00667017|10146296|FG000|Overall Study|Withdrawal by Subject|1
6359137|NCT00665444|10146300|FG000|Overall Study|Physician Decision|1
6359138|NCT00665444|10146300|FG000|Overall Study|Study Terminated by Study Sponsor|1
6359139|NCT00660595|10146315|FG000|Overall Study|Lost to Follow-up|0
6359140|NCT00660595|10146316|FG001|Overall Study|Lost to Follow-up|1
6359141|NCT00660595|10146315|FG000|Overall Study|Did not consent to participate in study|12
6359142|NCT00660595|10146316|FG001|Overall Study|Did not consent to participate in study|8
6359143|NCT00660595|10146315|FG000|Overall Study|Participant left hospital|1
6359144|NCT00660595|10146316|FG001|Overall Study|Participant left hospital|0
6359145|NCT00660595|10146315|FG000|Overall Study|Non Specified reasons|5
6359146|NCT00660595|10146316|FG001|Overall Study|Non Specified reasons|0
6359147|NCT00646282|10146333|FG000|Overall Study|Protocol terminated|4
6359148|NCT00646282|10146334|FG001|Overall Study|Protocol terminated|4
6359149|NCT00657553|10146342|FG000|Overall Study|low accrual, no analysis run|5
6359150|NCT00657553|10146343|FG001|Overall Study|low accrual, no analysis run|5
6359151|NCT00648895|10146364|FG000|Overall Study|Lack of Efficacy|0
6359152|NCT00648895|10146365|FG001|Overall Study|Lack of Efficacy|1
6359153|NCT00647426|10146371|FG000|Overall Study|Withdrawal by Subject|2
6359154|NCT00645567|10146376|FG000|Overall Study|Adverse Event|1
6359155|NCT00637806|10146387|FG000|Double-blind Phase|Study Discontinued|2
6359156|NCT00637806|10146388|FG001|Double-blind Phase|Study Discontinued|0
6359157|NCT00637806|10146389|FG002|Double-blind Phase|Study Discontinued|1
6359158|NCT00637806|10146390|FG003|Double-blind Phase|Study Discontinued|0
6359159|NCT00637806|10146387|FG000|Extension Phase|Study Discontinued|0
6359160|NCT00637806|10146388|FG001|Extension Phase|Study Discontinued|0
6359161|NCT00637806|10146389|FG002|Extension Phase|Study Discontinued|0
6359162|NCT00637806|10146390|FG003|Extension Phase|Study Discontinued|1
6359163|NCT00629798|10146415|FG000|Overall Study|Not Treated|4
6359164|NCT00637728|10146425|FG000|Double-blind Phase|Adverse Event|1
6359165|NCT00637728|10146426|FG001|Double-blind Phase|Adverse Event|0
6359166|NCT00637728|10146427|FG002|Double-blind Phase|Adverse Event|0
6359167|NCT00637728|10146425|FG000|Double-blind Phase|Non-compliance|2
6359168|NCT00637728|10146426|FG001|Double-blind Phase|Non-compliance|0
6359169|NCT00637728|10146427|FG002|Double-blind Phase|Non-compliance|0
6359170|NCT00637728|10146425|FG000|Double-blind Phase|Study Discontinued|1
6359171|NCT00637728|10146426|FG001|Double-blind Phase|Study Discontinued|1
6359172|NCT00637728|10146427|FG002|Double-blind Phase|Study Discontinued|0
6359173|NCT00637416|10146462|FG000|Overall Study|Lost to Follow-up|1
6359174|NCT00637416|10146463|FG001|Overall Study|Lost to Follow-up|1
6359175|NCT00637416|10146462|FG000|Overall Study|Unable to take study drug|0
6359176|NCT00637416|10146463|FG001|Overall Study|Unable to take study drug|1
6359177|NCT00631137|10146513|FG000|Overall Study|Withdrawal by Subject|1
6359178|NCT00631137|10146514|FG001|Overall Study|Withdrawal by Subject|0
6359179|NCT00633061|10146531|FG000|Overall Study|Study closed|86
6359180|NCT00633061|10146532|FG001|Overall Study|Study closed|0
6359181|NCT00630292|10146544|FG000|Overall Study|Withdrawal by Subject|1
6359182|NCT00634010|10146550|FG000|Overall Study|Adverse Event|2
6359183|NCT00634010|10146551|FG001|Overall Study|Adverse Event|5
6359184|NCT00634010|10146550|FG000|Overall Study|Withdrawal by Subject|5
6359185|NCT00634010|10146551|FG001|Overall Study|Withdrawal by Subject|6
6359186|NCT00634010|10146550|FG000|Overall Study|Physician Decision|1
6359187|NCT00634010|10146551|FG001|Overall Study|Physician Decision|1
6359188|NCT00634010|10146550|FG000|Overall Study|Disease Progression|1
6359189|NCT00634010|10146551|FG001|Overall Study|Disease Progression|1
6359190|NCT00634010|10146550|FG000|Overall Study|Non-Compliant|1
6359191|NCT00634010|10146551|FG001|Overall Study|Non-Compliant|1
6359192|NCT00626561|10146601|FG000|Overall Study|Withdrawal by Subject|2
6359193|NCT00626561|10146601|FG000|Overall Study|Disease Progression|2
6359194|NCT00613730|10146605|FG000|Overall Study|Disease progression|2
6359195|NCT00613730|10146605|FG000|Overall Study|Administrative decision|1
6359196|NCT00625586|10146609|FG000|Overall Study|Adverse Event|1
6359197|NCT00625742|10146617|FG000|Overall Study|Disease Progression|2
6359198|NCT00625742|10146617|FG000|Overall Study|Withdrawal by Subject|1
6359199|NCT00625742|10146617|FG000|Overall Study|Adverse Event|4
6359200|NCT00625742|10146617|FG000|Overall Study|Lost to Follow-up|4
6359201|NCT00625742|10146617|FG000|Overall Study|Ineligible|1
6359202|NCT00619151|10146627|FG000|Overall Study|Study terminated prior to followup|1
6359203|NCT00619151|10146628|FG001|Overall Study|Study terminated prior to followup|0
6359204|NCT00622167|10146634|FG000|Overall Study|Did not meet angiographic criteria|20
6359205|NCT00616759|10146653|FG000|Overall Study|Physician Decision|2
6359206|NCT00616759|10146654|FG001|Overall Study|Physician Decision|0
6359207|NCT00616759|10146653|FG000|Overall Study|Withdrawal by Subject|1
6359208|NCT00616759|10146654|FG001|Overall Study|Withdrawal by Subject|2
6359209|NCT00616642|10146662|FG000|Overall Study|Withdrawal by Subject|0
6083989|NCT00640341|9692927|FG001|Overall Study|Poor fit/Uncomfortable|0
6083990|NCT00640341|9692928|FG002|Overall Study|Poor fit/Uncomfortable|0
6083991|NCT00640341|9692926|FG000|Overall Study|Ineligable at Baseline|5
6083992|NCT00640341|9692927|FG001|Overall Study|Ineligable at Baseline|3
6170398|NCT01253174|9816707|FG005|Period 3|Pregnancy|0
6170399|NCT01253187|9816716|FG000|Period 2|Withdrawal by Subject|0
6170400|NCT01253187|9816717|FG001|Period 2|Withdrawal by Subject|0
6170401|NCT01253187|9816718|FG002|Period 2|Withdrawal by Subject|0
6170402|NCT01253187|9816719|FG003|Period 2|Withdrawal by Subject|0
6083993|NCT00640341|9692928|FG002|Overall Study|Ineligable at Baseline|2
6083994|NCT00640341|9692926|FG000|Overall Study|Adverse event and positive slit lamp|1
6083995|NCT00640341|9692927|FG001|Overall Study|Adverse event and positive slit lamp|0
6083996|NCT00640341|9692928|FG002|Overall Study|Adverse event and positive slit lamp|0
6083997|NCT00640393|9692936|FG000|Part 1|Lost to Follow-up|2
6083998|NCT00640393|9692937|FG001|Part 1|Lost to Follow-up|0
6083999|NCT00640393|9692938|FG002|Part 1|Lost to Follow-up|0
6084000|NCT00640393|9692936|FG000|Part 1|Withdrawal by Subject|3
6170403|NCT01253187|9816720|FG004|Period 2|Withdrawal by Subject|1
6170404|NCT01253187|9816721|FG005|Period 2|Withdrawal by Subject|0
6170405|NCT01253187|9816716|FG000|Period 3|Pregnancy|1
6359210|NCT00616642|10146663|FG001|Overall Study|Withdrawal by Subject|1
6359211|NCT00619515|10146669|FG000|Overall Study|Study Termination by IRB|73
6359212|NCT00612677|10146677|FG000|Overall Study|study closed before treatment started|1
6359213|NCT00616603|10146684|FG000|Overall Study|Physician Decision|2
6359214|NCT00616603|10146685|FG001|Overall Study|Physician Decision|0
6359215|NCT00616603|10146686|FG002|Overall Study|Physician Decision|2
6359216|NCT00609765|10146727|FG000|Overall Study|Study ended prior to 12 months|1
6359217|NCT00595920|10146752|FG000|Overall Study|The OLTERMS study was discontinued by th|116
6359218|NCT00596947|10146758|FG000|Overall Study|study halted due to low enrollment|5
6084001|NCT00640393|9692937|FG001|Part 1|Withdrawal by Subject|0
6084002|NCT00640393|9692938|FG002|Part 1|Withdrawal by Subject|0
6084003|NCT00640393|9692936|FG000|Randomization|Withdrawn per protocol|17
6084004|NCT00640393|9692937|FG001|Randomization|Withdrawn per protocol|0
6084005|NCT00640393|9692938|FG002|Randomization|Withdrawn per protocol|0
6084006|NCT00640393|9692936|FG000|Randomization|Never randomized by site|2
6084007|NCT00640393|9692937|FG001|Randomization|Never randomized by site|0
6084008|NCT00640393|9692938|FG002|Randomization|Never randomized by site|0
6084009|NCT00640393|9692936|FG000|Part 2|Lost to Follow-up|0
6084010|NCT00640393|9692937|FG001|Part 2|Lost to Follow-up|2
6084011|NCT00640393|9692938|FG002|Part 2|Lost to Follow-up|2
6084012|NCT00640393|9692936|FG000|Part 2|Withdrawal by Subject|0
6084013|NCT00640393|9692937|FG001|Part 2|Withdrawal by Subject|6
6084014|NCT00640393|9692938|FG002|Part 2|Withdrawal by Subject|1
6084015|NCT00640393|9692936|FG000|Part 2|Non-adherence|0
6084016|NCT00640393|9692937|FG001|Part 2|Non-adherence|1
6084017|NCT00640393|9692938|FG002|Part 2|Non-adherence|0
6084018|NCT00640393|9692936|FG000|Part 2|Adverse Event|0
6084019|NCT00640393|9692937|FG001|Part 2|Adverse Event|1
6084020|NCT00640393|9692938|FG002|Part 2|Adverse Event|0
6084021|NCT00640510|9692948|FG000|Overall Study|Lack of Efficacy|0
6084022|NCT00640510|9692949|FG001|Overall Study|Lack of Efficacy|1
6084023|NCT00640510|9692948|FG000|Overall Study|Protocol Violation|1
6084024|NCT00640510|9692949|FG001|Overall Study|Protocol Violation|0
6084025|NCT00640510|9692948|FG000|Overall Study|Physician Decision|0
6084026|NCT00640510|9692949|FG001|Overall Study|Physician Decision|1
6084027|NCT00640562|9692957|FG000|Overall Study|Adverse Event|8
6084028|NCT00640562|9692958|FG001|Overall Study|Adverse Event|5
6084029|NCT00640562|9692957|FG000|Overall Study|Lack of Efficacy|1
6084030|NCT00640562|9692958|FG001|Overall Study|Lack of Efficacy|4
6084031|NCT00640562|9692957|FG000|Overall Study|Protocol Violation|2
6084032|NCT00640562|9692958|FG001|Overall Study|Protocol Violation|4
6084033|NCT00640562|9692957|FG000|Overall Study|Withdrawal by Subject|6
6084034|NCT00640562|9692958|FG001|Overall Study|Withdrawal by Subject|10
6084035|NCT00640562|9692957|FG000|Overall Study|Known risperidone intolerance|0
6084036|NCT00640562|9692958|FG001|Overall Study|Known risperidone intolerance|1
6084037|NCT00640562|9692957|FG000|Overall Study|Past use of Seroquel -stopped due to AE|0
6084038|NCT00640562|9692958|FG001|Overall Study|Past use of Seroquel -stopped due to AE|1
6084039|NCT00640562|9692957|FG000|Overall Study|Low study drug dose|0
6084040|NCT00640562|9692958|FG001|Overall Study|Low study drug dose|1
6084041|NCT00640562|9692957|FG000|Overall Study|Glycosylated Hemoglobin >8|1
6084042|NCT00640562|9692958|FG001|Overall Study|Glycosylated Hemoglobin >8|0
6084043|NCT00640601|9692964|FG000|Overall Study|Adverse Event|43
6084044|NCT00640601|9692964|FG000|Overall Study|Withdrawal by Subject|20
6084045|NCT00640601|9692964|FG000|Overall Study|Protocol Violation|6
6084046|NCT00640601|9692964|FG000|Overall Study|Lack of Efficacy|16
6084047|NCT00640601|9692964|FG000|Overall Study|Lost to Follow-up|9
6084048|NCT00640601|9692964|FG000|Overall Study|Physician Decision|8
6084049|NCT00640601|9692964|FG000|Overall Study|treatment naive, combination therapy|10
6084050|NCT00640614|9692970|FG000|Overall Study|Lost to Follow-up|1
6084051|NCT00640614|9692971|FG001|Overall Study|Lost to Follow-up|0
6084052|NCT00640835|9693036|FG000|Overall Study|Adverse Event|5
6084053|NCT00640835|9693037|FG001|Overall Study|Adverse Event|3
6084054|NCT00640835|9693036|FG000|Overall Study|Withdrawal by Subject|12
6084055|NCT00640835|9693037|FG001|Overall Study|Withdrawal by Subject|14
6084056|NCT00640835|9693036|FG000|Overall Study|Physician Decision|10
6084057|NCT00640835|9693037|FG001|Overall Study|Physician Decision|14
6084058|NCT00640835|9693036|FG000|Overall Study|Sponsor's Decision|11
6084059|NCT00640835|9693037|FG001|Overall Study|Sponsor's Decision|7
6084060|NCT00640835|9693036|FG000|Overall Study|Protocol Violation|2
6084061|NCT00640835|9693037|FG001|Overall Study|Protocol Violation|2
6084062|NCT00640835|9693036|FG000|Overall Study|Lost to Follow-up|17
6084063|NCT00640835|9693037|FG001|Overall Study|Lost to Follow-up|13
6084064|NCT00640835|9693036|FG000|Overall Study|Other Reason|19
6084065|NCT00640835|9693037|FG001|Overall Study|Other Reason|4
6084066|NCT00640926|9693046|FG000|Overall Study|Adverse Event|2
6084067|NCT00640926|9693047|FG001|Overall Study|Adverse Event|3
6084068|NCT00640926|9693048|FG002|Overall Study|Adverse Event|2
6084069|NCT00640926|9693046|FG000|Overall Study|Lack of Efficacy|0
6084070|NCT00640926|9693047|FG001|Overall Study|Lack of Efficacy|2
6084071|NCT00640926|9693048|FG002|Overall Study|Lack of Efficacy|1
6084072|NCT00640926|9693046|FG000|Overall Study|Protocol Violation|2
6084073|NCT00640926|9693047|FG001|Overall Study|Protocol Violation|0
6359219|NCT00596947|10146759|FG001|Overall Study|study halted due to low enrollment|3
6084074|NCT00640926|9693048|FG002|Overall Study|Protocol Violation|2
6084075|NCT00640926|9693046|FG000|Overall Study|Lost to Follow-up|3
6084076|NCT00640926|9693047|FG001|Overall Study|Lost to Follow-up|1
6084077|NCT00640926|9693048|FG002|Overall Study|Lost to Follow-up|2
6084078|NCT00640926|9693046|FG000|Overall Study|Withdrawal by Subject|1
6084079|NCT00640926|9693047|FG001|Overall Study|Withdrawal by Subject|0
6084080|NCT00640926|9693048|FG002|Overall Study|Withdrawal by Subject|1
6084081|NCT00641043|9693062|FG000|Overall Study|Adverse Event|6
6084082|NCT00641043|9693063|FG001|Overall Study|Adverse Event|4
6084083|NCT00641043|9693062|FG000|Overall Study|Protocol Violation|2
6084084|NCT00641043|9693063|FG001|Overall Study|Protocol Violation|3
6359220|NCT00596947|10146758|FG000|Overall Study|Lost to Follow-up|1
6359221|NCT00596947|10146759|FG001|Overall Study|Lost to Follow-up|0
6359222|NCT00584012|10146765|FG000|Overall Study|Withdrawal by Subject|1
6359223|NCT00577772|10146801|FG000|Overall Study|Lost to Follow-up|0
6359224|NCT00577772|10146802|FG001|Overall Study|Lost to Follow-up|1
6359225|NCT00592007|10146808|FG000|Overall Study|Withdrawal by Subject|1
6359226|NCT00592007|10146808|FG000|Overall Study|patient ineligible (out of lab range)|1
6084085|NCT00641043|9693062|FG000|Overall Study|Lost to Follow-up|3
6084086|NCT00641043|9693063|FG001|Overall Study|Lost to Follow-up|2
6084087|NCT00641043|9693062|FG000|Overall Study|Withdrawal by Subject|4
6084088|NCT00641043|9693063|FG001|Overall Study|Withdrawal by Subject|4
6084089|NCT00641043|9693062|FG000|Overall Study|Other incl. lack of efficacy|4
6084090|NCT00641043|9693063|FG001|Overall Study|Other incl. lack of efficacy|2
6084091|NCT00641056|9693071|FG000|Overall Study|Adverse Event|12
6084092|NCT00641056|9693072|FG001|Overall Study|Adverse Event|2
6084093|NCT00641056|9693071|FG000|Overall Study|Lost to Follow-up|2
6084094|NCT00641056|9693072|FG001|Overall Study|Lost to Follow-up|1
6084095|NCT00641056|9693071|FG000|Overall Study|Physician Decision|3
6084096|NCT00641056|9693072|FG001|Overall Study|Physician Decision|1
6084097|NCT00641056|9693071|FG000|Overall Study|Protocol Violation|2
6084098|NCT00641056|9693072|FG001|Overall Study|Protocol Violation|0
6084099|NCT00641056|9693071|FG000|Overall Study|Entry Criteria Not Met|3
6084100|NCT00641056|9693072|FG001|Overall Study|Entry Criteria Not Met|0
6084101|NCT00641056|9693071|FG000|Overall Study|Subject Decision|6
6084102|NCT00641056|9693072|FG001|Overall Study|Subject Decision|19
6084103|NCT00641056|9693071|FG000|Overall Study|Sponsor Decision|1
6084104|NCT00641056|9693072|FG001|Overall Study|Sponsor Decision|2
6084105|NCT00641147|9693084|FG000|Completed 4 Months.|Physician Decision|1
6084106|NCT00641147|9693085|FG001|Completed 4 Months.|Physician Decision|0
6084107|NCT00641147|9693084|FG000|Completed 4 Months.|Adverse Event|1
6170406|NCT01253187|9816717|FG001|Period 3|Pregnancy|0
6170407|NCT01253187|9816718|FG002|Period 3|Pregnancy|0
6170408|NCT01253187|9816719|FG003|Period 3|Pregnancy|0
6170409|NCT01253187|9816720|FG004|Period 3|Pregnancy|0
6170410|NCT01253187|9816721|FG005|Period 3|Pregnancy|0
6359227|NCT00595582|10146812|FG000|Overall Study|Pilot study that PI terminated|2
6359228|NCT00595582|10146812|FG000|Overall Study|Lost to Follow-up|1
6359229|NCT00595582|10146812|FG000|Overall Study|Adverse Event|2
6359230|NCT00595582|10146812|FG000|Overall Study|Physician Decision|5
6359231|NCT00588146|10146816|FG000|First Intervention (Baseline to 6 mo)|Adverse Event|4
6359232|NCT00588146|10146817|FG001|First Intervention (Baseline to 6 mo)|Adverse Event|3
6359233|NCT00590538|10146832|FG000|Overall Study|Study terminated before completed|2
6359234|NCT00583115|10146836|FG000|Overall Study|Death|1
6359235|NCT00582712|10146840|FG000|Overall Study|Adverse Event|1
6359236|NCT00582712|10146840|FG000|Overall Study|Lack of Efficacy|1
6359237|NCT00582712|10146840|FG000|Overall Study|Withdrawal by Subject|1
6359238|NCT00582712|10146840|FG000|Overall Study|Complicating disease requiring treatment|1
6359239|NCT00587795|10146871|FG000|Overall Study|Withdrawal by Subject|1
6359240|NCT00587795|10146872|FG001|Overall Study|Withdrawal by Subject|0
6359241|NCT00590135|10146878|FG000|Overall Study|Primary endpoint measure not obtainable|59
6359242|NCT00582036|10146885|FG000|Overall Study|Withdrawal by Subject|0
6359243|NCT00582036|10146886|FG001|Overall Study|Withdrawal by Subject|1
6359244|NCT00585585|10146892|FG000|Overall Study|Adverse Event|1
6359245|NCT00585221|10146896|FG000|Overall Study|Protocol Violation|8
6359246|NCT00581113|10146902|FG000|Overall Study|Withdrawal by Subject|0
6359247|NCT00581113|10146903|FG001|Overall Study|Withdrawal by Subject|1
6359248|NCT00579254|10146909|FG000|Overall Study|Lost to Follow-up|39
6359249|NCT00579254|10146909|FG000|Overall Study|Discontinued when study terminated|73
6359250|NCT00587223|10146913|FG000|Overall Study|Adverse Event|1
6359251|NCT00577395|10146944|FG000|Overall Study|Study was terminated early by Sponsor|7
6359252|NCT00577395|10146945|FG001|Overall Study|Study was terminated early by Sponsor|6
6359253|NCT00573391|10146953|FG000|Overall Study|study stopped|2
6359254|NCT00573391|10146954|FG001|Overall Study|study stopped|2
6359255|NCT00573391|10146953|FG000|Overall Study|Death|1
6359256|NCT00573391|10146954|FG001|Overall Study|Death|0
6359257|NCT00574080|10146998|FG000|Overall Study|Death|10
6359258|NCT00574080|10146999|FG001|Overall Study|Death|10
6359259|NCT00558558|10147005|FG000|Overall Study|Unable to swallow|1
6359260|NCT00558558|10147005|FG000|Overall Study|Withdrawal by Subject|1
6359261|NCT00558558|10147005|FG000|Overall Study|Lack of Efficacy|4
6359262|NCT00573937|10147015|FG000|Overall Study|Study Terminated|0
6359263|NCT00573937|10147016|FG001|Overall Study|Study Terminated|1
6359264|NCT00577317|10147024|FG000|Overall Study|Study Terminated|0
6359265|NCT00577317|10147025|FG001|Overall Study|Study Terminated|2
6359266|NCT00571922|10147033|FG000|Overall Study|Completion unknown|36
6359267|NCT00571922|10147034|FG001|Overall Study|Completion unknown|36
6359268|NCT00573157|10147046|FG000|Overall Study|Adverse Event|3
6359269|NCT00573157|10147047|FG001|Overall Study|Adverse Event|1
6084108|NCT00641147|9693085|FG001|Completed 4 Months.|Adverse Event|0
6084109|NCT00641147|9693084|FG000|Completed 8 Months.|Physician Decision|2
6084110|NCT00641147|9693085|FG001|Completed 8 Months.|Physician Decision|1
6170411|NCT01253187|9816716|FG000|Period 3|difficulty with blood sampling|0
6170412|NCT01253187|9816717|FG001|Period 3|difficulty with blood sampling|1
6359270|NCT00573157|10147046|FG000|Overall Study|Other|1
6359271|NCT00573157|10147047|FG001|Overall Study|Other|1
6359272|NCT00561912|10147066|FG000|Overall Study|ineligible|1
6359273|NCT00561795|10147072|FG000|Overall Study|Adverse Event|3
6359274|NCT00561795|10147073|FG001|Overall Study|Adverse Event|3
6359275|NCT00561795|10147074|FG002|Overall Study|Adverse Event|0
6359276|NCT00561795|10147075|FG003|Overall Study|Adverse Event|0
6359277|NCT00561795|10147072|FG000|Overall Study|Study Closed/Terminated|0
6359278|NCT00561795|10147073|FG001|Overall Study|Study Closed/Terminated|3
6359279|NCT00561795|10147074|FG002|Overall Study|Study Closed/Terminated|0
6359280|NCT00561795|10147075|FG003|Overall Study|Study Closed/Terminated|0
6359281|NCT00561795|10147072|FG000|Overall Study|Physician Decision|1
6359282|NCT00561795|10147073|FG001|Overall Study|Physician Decision|0
6359283|NCT00561795|10147074|FG002|Overall Study|Physician Decision|0
6359284|NCT00561795|10147075|FG003|Overall Study|Physician Decision|0
6359285|NCT00556075|10147111|FG000|Overall Study|Lost to Follow-up|3
6359286|NCT00556075|10147112|FG001|Overall Study|Lost to Follow-up|0
6359287|NCT00556075|10147113|FG002|Overall Study|Lost to Follow-up|3
6359288|NCT00556075|10147111|FG000|Overall Study|Withdrawal by Subject|3
6359289|NCT00556075|10147112|FG001|Overall Study|Withdrawal by Subject|3
6359290|NCT00556075|10147113|FG002|Overall Study|Withdrawal by Subject|0
6359291|NCT00556075|10147111|FG000|Overall Study|Protocol Violation|1
6359292|NCT00556075|10147112|FG001|Overall Study|Protocol Violation|1
6359293|NCT00556075|10147113|FG002|Overall Study|Protocol Violation|3
6359294|NCT00556075|10147111|FG000|Overall Study|Not eligible|1
6359295|NCT00556075|10147112|FG001|Overall Study|Not eligible|1
6359296|NCT00556075|10147113|FG002|Overall Study|Not eligible|2
6359297|NCT00556075|10147111|FG000|Overall Study|Adverse Event|1
6359298|NCT00556075|10147112|FG001|Overall Study|Adverse Event|2
6359299|NCT00556075|10147113|FG002|Overall Study|Adverse Event|0
6359300|NCT00556075|10147111|FG000|Overall Study|Personal issues|4
6359301|NCT00556075|10147112|FG001|Overall Study|Personal issues|1
6359302|NCT00556075|10147113|FG002|Overall Study|Personal issues|0
6359303|NCT00556075|10147111|FG000|Overall Study|Endometrial stripe not viewed on 2 tvu|0
6359304|NCT00556075|10147112|FG001|Overall Study|Endometrial stripe not viewed on 2 tvu|1
6359305|NCT00556075|10147113|FG002|Overall Study|Endometrial stripe not viewed on 2 tvu|0
6359306|NCT00556166|10147125|FG000|Overall Study|Withdrawal by Subject|1
6359307|NCT00539838|10147149|FG000|Overall Study|Fail to return|2
6359308|NCT00539838|10147150|FG001|Overall Study|Fail to return|0
6359309|NCT00539838|10147151|FG002|Overall Study|Fail to return|0
6359310|NCT00539838|10147149|FG000|Overall Study|Withdrawal by Subject|0
6359311|NCT00539838|10147150|FG001|Overall Study|Withdrawal by Subject|4
6359312|NCT00539838|10147151|FG002|Overall Study|Withdrawal by Subject|0
6359313|NCT00539838|10147149|FG000|Overall Study|Death|0
6359314|NCT00539838|10147150|FG001|Overall Study|Death|2
6359315|NCT00539838|10147151|FG002|Overall Study|Death|0
6359316|NCT00539838|10147149|FG000|Overall Study|Did not cooperate|1
6359317|NCT00539838|10147150|FG001|Overall Study|Did not cooperate|0
6359318|NCT00539838|10147151|FG002|Overall Study|Did not cooperate|1
6359319|NCT00539838|10147149|FG000|Overall Study|Administrative|4
6359320|NCT00539838|10147150|FG001|Overall Study|Administrative|0
6359321|NCT00539838|10147151|FG002|Overall Study|Administrative|8
6359322|NCT00549328|10147161|FG000|Overall Study|Adverse Event|2
6359323|NCT00549328|10147161|FG000|Overall Study|Disease Progression|10
6359324|NCT00549328|10147161|FG000|Overall Study|Death|1
6359325|NCT00549328|10147161|FG000|Overall Study|Use of Prohibited Medication|1
6359326|NCT00548327|10147167|FG000|Overall Study|Adverse Event|0
6359327|NCT00548327|10147168|FG001|Overall Study|Adverse Event|1
6359328|NCT00547300|10147199|FG000|Overall Study|Study was Administratively Terminated|25
6359329|NCT00547300|10147200|FG001|Overall Study|Study was Administratively Terminated|24
6359330|NCT00547300|10147199|FG000|Overall Study|Did not Meet Entry Criteria|0
6359331|NCT00547300|10147200|FG001|Overall Study|Did not Meet Entry Criteria|2
6359332|NCT00535262|10147232|FG000|Overall Study|No funding|3
6359333|NCT00537199|10147249|FG000|Overall Study|Study Terminated|1
6359334|NCT00536978|10147259|FG000|Overall Study|Not eligible for Adback Infusion|22
6359335|NCT00524485|10147263|FG000|Overall Study|Withdrawal by Subject|5
6359336|NCT00524134|10147285|FG000|Overall Study|Withdrawal by Subject|1
6359337|NCT00524134|10147285|FG000|Overall Study|Physician Decision|1
6359338|NCT00527748|10147289|FG000|Overall Study|Other|3
6359339|NCT00517699|10147293|FG000|Overall Study|Withdrawal by Subject|1
6359340|NCT00517699|10147293|FG000|Overall Study|Lack of Efficacy|1
6359341|NCT00517699|10147293|FG000|Overall Study|Administrative error|1
6359342|NCT00517699|10147293|FG000|Overall Study|Study terminated by Sponsor|2
6359343|NCT00528775|10147297|FG000|Overall Study|Other not specified|1
6359344|NCT00527982|10147333|FG000|Overall Study|Physician Decision|1
6359345|NCT00527982|10147334|FG001|Overall Study|Physician Decision|0
6359346|NCT00524459|10147340|FG000|Overall Study|Withdrawal by Subject|1
6359347|NCT00524459|10147340|FG000|Overall Study|Other|1
6359348|NCT00517361|10147344|FG000|Overall Study|Death|6
6359349|NCT00517361|10147344|FG000|Overall Study|The study was terminated|5
6359350|NCT00522457|10147356|FG000|Overall Study|Due to disease progression|16
6359351|NCT00522457|10147356|FG000|Overall Study|Adverse Event|2
6359352|NCT00526331|10147360|FG000|Overall Study|Sponsor Termination|55
6359353|NCT00522301|10147381|FG000|Overall Study|Withdrawal by Subject|1
6359354|NCT00522301|10147381|FG000|Overall Study|Adverse Event|5
6359355|NCT00517192|10147387|FG000|Overall Study|Adverse Event|1
6359356|NCT00517192|10147388|FG001|Overall Study|Adverse Event|1
6359357|NCT00517192|10147387|FG000|Overall Study|Lost to Follow-up|1
6359358|NCT00517192|10147388|FG001|Overall Study|Lost to Follow-up|1
6359359|NCT00517192|10147387|FG000|Overall Study|Withdrawal by Subject|1
6359360|NCT00517192|10147388|FG001|Overall Study|Withdrawal by Subject|0
6359361|NCT00517192|10147387|FG000|Overall Study|Early termination of the trial|16
6359362|NCT00517192|10147388|FG001|Overall Study|Early termination of the trial|18
6359363|NCT00503581|10147401|FG000|Overall Study|Study closed|3
6359364|NCT00503581|10147402|FG001|Overall Study|Study closed|4
6359365|NCT00503581|10147403|FG002|Overall Study|Study closed|2
6359366|NCT00509600|10147411|FG000|Overall Study|Adverse Event|1
6359367|NCT00515112|10147417|FG000|Overall Study|Death|0
6359368|NCT00515112|10147418|FG001|Overall Study|Death|1
6359369|NCT00515112|10147417|FG000|Overall Study|The study was terminated|3
6359370|NCT00515112|10147418|FG001|Overall Study|The study was terminated|2
6359371|NCT00508872|10147424|FG000|Overall Study|Lost to Follow-up|1
6359372|NCT00508872|10147424|FG000|Overall Study|Physician Decision|1
6359373|NCT00514813|10147432|FG000|Overall Study|Study terminated|14
6359374|NCT00514813|10147433|FG001|Overall Study|Study terminated|74
6359375|NCT00514813|10147434|FG002|Overall Study|Study terminated|40
6359376|NCT00514813|10147435|FG003|Overall Study|Study terminated|2
6359377|NCT00514813|10147432|FG000|Overall Study|Adverse Event|0
6359378|NCT00514813|10147433|FG001|Overall Study|Adverse Event|2
6359379|NCT00514813|10147434|FG002|Overall Study|Adverse Event|2
6359380|NCT00514813|10147435|FG003|Overall Study|Adverse Event|0
6359381|NCT00514813|10147432|FG000|Overall Study|Protocol Violation|1
6359382|NCT00514813|10147433|FG001|Overall Study|Protocol Violation|0
6359383|NCT00514813|10147434|FG002|Overall Study|Protocol Violation|0
6359384|NCT00514813|10147435|FG003|Overall Study|Protocol Violation|0
6359385|NCT00514813|10147432|FG000|Overall Study|Withdrawal by Subject|0
6359386|NCT00514813|10147433|FG001|Overall Study|Withdrawal by Subject|1
6359387|NCT00514813|10147434|FG002|Overall Study|Withdrawal by Subject|0
6359388|NCT00514813|10147435|FG003|Overall Study|Withdrawal by Subject|0
6359389|NCT00514813|10147432|FG000|Overall Study|Lack of Efficacy|0
6359390|NCT00514813|10147433|FG001|Overall Study|Lack of Efficacy|1
6359391|NCT00514813|10147434|FG002|Overall Study|Lack of Efficacy|0
6359392|NCT00514813|10147435|FG003|Overall Study|Lack of Efficacy|0
6359393|NCT00514813|10147432|FG000|Overall Study|Kidney transplant|0
6359394|NCT00514813|10147433|FG001|Overall Study|Kidney transplant|6
6359395|NCT00514813|10147434|FG002|Overall Study|Kidney transplant|2
6359396|NCT00514813|10147435|FG003|Overall Study|Kidney transplant|0
6359397|NCT00514813|10147432|FG000|Overall Study|Death|0
6359398|NCT00514813|10147433|FG001|Overall Study|Death|2
6359399|NCT00514813|10147434|FG002|Overall Study|Death|3
6359400|NCT00514813|10147435|FG003|Overall Study|Death|2
6359401|NCT00501228|10147468|FG000|Overall Study|Withdrawal by Subject|1
6359402|NCT00496782|10147474|FG000|Overall Study|Protocol Violation|1
6359403|NCT00496782|10147475|FG001|Overall Study|Protocol Violation|2
6359404|NCT00487578|10147487|FG000|Overall Study|Adverse Event|1
6359405|NCT00487578|10147488|FG001|Overall Study|Adverse Event|2
6043189|NCT00387348|9641650|FG002|Overall Study|Withdrawal by Subject|2
6043190|NCT00387348|9641648|FG000|Overall Study|Adverse Event|1
6043191|NCT00387348|9641649|FG001|Overall Study|Adverse Event|0
6043192|NCT00387348|9641650|FG002|Overall Study|Adverse Event|1
6043193|NCT00387426|9641663|FG000|Overall Study|Lack of Response|7
6043194|NCT00387426|9641663|FG000|Overall Study|Toxicities|4
6043195|NCT00387426|9641663|FG000|Overall Study|Disease Progression|3
6043196|NCT00387465|9641670|FG000|Overall Study|Withdrawal by Subject|0
6043197|NCT00387465|9641671|FG001|Overall Study|Withdrawal by Subject|1
6043198|NCT00387465|9641672|FG002|Overall Study|Withdrawal by Subject|0
6043199|NCT00387647|9641696|FG000|Overall Study|Death|18
6043200|NCT00387712|9641711|FG000|Overall Study|Physician Decision|6
6043201|NCT00387712|9641712|FG001|Overall Study|Physician Decision|4
6043202|NCT00387712|9641711|FG000|Overall Study|Lost to Follow-up|17
6359406|NCT00487578|10147487|FG000|Overall Study|Lack of Efficacy|0
6359407|NCT00487578|10147488|FG001|Overall Study|Lack of Efficacy|1
6359408|NCT00487578|10147487|FG000|Overall Study|Lost to Follow-up|0
6359409|NCT00487578|10147488|FG001|Overall Study|Lost to Follow-up|1
6359410|NCT00503009|10147497|FG000|Overall Study|Protocol Violation|1
6359411|NCT00503009|10147498|FG001|Overall Study|Protocol Violation|0
6359412|NCT00503009|10147499|FG002|Overall Study|Protocol Violation|1
6359413|NCT00503009|10147497|FG000|Overall Study|Withdrawal by Subject|0
6359414|NCT00503009|10147498|FG001|Overall Study|Withdrawal by Subject|1
6359415|NCT00503009|10147499|FG002|Overall Study|Withdrawal by Subject|1
6359416|NCT00503009|10147497|FG000|Overall Study|Physician Decision|0
6359417|NCT00503009|10147498|FG001|Overall Study|Physician Decision|1
6359418|NCT00503009|10147499|FG002|Overall Study|Physician Decision|1
6359419|NCT00499590|10147514|FG000|Overall Study|Study Terminated|112
6359420|NCT00499590|10147515|FG001|Overall Study|Study Terminated|112
6359421|NCT00499590|10147516|FG002|Overall Study|Study Terminated|112
6359422|NCT00499590|10147514|FG000|Overall Study|Not treated|1
6359423|NCT00499590|10147515|FG001|Overall Study|Not treated|0
6359424|NCT00499590|10147516|FG002|Overall Study|Not treated|1
6359425|NCT00503841|10147551|FG000|Overall Study|All screen failures|44
6359426|NCT00493025|10147557|FG000|Overall Study|Physician Decision|19
6359427|NCT00491400|10147564|FG000|Overall Study|Withdrawal by Subject|5
6359428|NCT00491400|10147565|FG001|Overall Study|Withdrawal by Subject|4
6359429|NCT00490776|10147573|FG000|Overall Study|Withdrawal by Subject|1
6359430|NCT00490776|10147573|FG000|Overall Study|Administrative Problems|1
6359431|NCT00490776|10147573|FG000|Overall Study|Death|1
6359432|NCT00490776|10147573|FG000|Overall Study|New Cancer Therapy|1
6359433|NCT00490776|10147573|FG000|Overall Study|Disease Progression|5
6359434|NCT00487162|10147579|FG000|Overall Study|Adverse Event|0
6359435|NCT00487162|10147580|FG001|Overall Study|Adverse Event|1
6359436|NCT00487162|10147579|FG000|Overall Study|Physician Decision|0
6359437|NCT00487162|10147580|FG001|Overall Study|Physician Decision|1
6359438|NCT00487162|10147579|FG000|Overall Study|Withdrawal by Subject|2
6359439|NCT00487162|10147580|FG001|Overall Study|Withdrawal by Subject|3
6359440|NCT00487981|10147586|FG000|Overall Study|Hypothyroidism diagnosis|1
6359441|NCT00491387|10147590|FG000|Overall Study|study terminated|20
6359442|NCT00483119|10147601|FG000|Overall Study|Adverse Event|0
6359443|NCT00483119|10147602|FG001|Overall Study|Adverse Event|1
6359444|NCT00483119|10147601|FG000|Overall Study|Physician Decision|1
6359445|NCT00483119|10147602|FG001|Overall Study|Physician Decision|0
6359446|NCT00470067|10147643|FG000|Overall Study|Death|1
6359447|NCT00470067|10147643|FG000|Overall Study|Disease Progression|6
6359448|NCT00475657|10147670|FG000|Overall Study|Death|1
6359449|NCT00475657|10147670|FG000|Overall Study|Sponsor's Decision|3
6359450|NCT00472082|10147674|FG000|Overall Study|Study prematurely terminated|5
6359451|NCT00467753|10147688|FG000|Overall Study|Lost to Follow-up|1
6359452|NCT00467753|10147689|FG001|Overall Study|Lost to Follow-up|2
6359453|NCT00467753|10147688|FG000|Overall Study|Adverse Event|2
6359454|NCT00467753|10147689|FG001|Overall Study|Adverse Event|0
6359455|NCT00456612|10147699|FG000|Overall Study|Withdrawal by Subject|3
6359456|NCT00469612|10147706|FG000|Overall Study|Study terminated before data collected|2
6359457|NCT00469612|10147707|FG001|Overall Study|Study terminated before data collected|0
6359458|NCT00461812|10147713|FG000|Overall Study|study terminated|10
6359459|NCT00461682|10147723|FG000|Overall Study|Protocol Violation|1
6359460|NCT00462904|10147729|FG000|Overall Study|Lost to Follow-up|1
6043203|NCT00387712|9641712|FG001|Overall Study|Lost to Follow-up|20
6043204|NCT00387712|9641711|FG000|Overall Study|Withdrawal by Subject|6
6359461|NCT00450333|10147737|FG000|Overall Study|Study terminated|47
6359462|NCT00450333|10147738|FG001|Overall Study|Study terminated|54
6359463|NCT00450333|10147739|FG002|Overall Study|Study terminated|16
6359464|NCT00450333|10147740|FG003|Overall Study|Study terminated|21
6359465|NCT00450333|10147737|FG000|Overall Study|Adverse Event|1
6359466|NCT00450333|10147738|FG001|Overall Study|Adverse Event|7
6359467|NCT00450333|10147739|FG002|Overall Study|Adverse Event|2
6359468|NCT00450333|10147740|FG003|Overall Study|Adverse Event|2
6359469|NCT00450333|10147737|FG000|Overall Study|Protocol Violation|1
6359470|NCT00450333|10147738|FG001|Overall Study|Protocol Violation|0
6359471|NCT00450333|10147739|FG002|Overall Study|Protocol Violation|1
6359472|NCT00450333|10147740|FG003|Overall Study|Protocol Violation|0
6359473|NCT00450333|10147737|FG000|Overall Study|Withdrawal by Subject|1
6359474|NCT00450333|10147738|FG001|Overall Study|Withdrawal by Subject|0
6359475|NCT00450333|10147739|FG002|Overall Study|Withdrawal by Subject|3
6359476|NCT00450333|10147740|FG003|Overall Study|Withdrawal by Subject|0
6359477|NCT00450333|10147737|FG000|Overall Study|Kidney transplant|1
6359478|NCT00450333|10147738|FG001|Overall Study|Kidney transplant|0
6359479|NCT00450333|10147739|FG002|Overall Study|Kidney transplant|1
6359480|NCT00450333|10147740|FG003|Overall Study|Kidney transplant|3
6359481|NCT00450333|10147737|FG000|Overall Study|Death|3
6359482|NCT00450333|10147738|FG001|Overall Study|Death|2
6359483|NCT00450333|10147739|FG002|Overall Study|Death|2
6359484|NCT00450333|10147740|FG003|Overall Study|Death|2
6359485|NCT00455143|10147750|FG000|Overall Study|Physician Decision|1
6359486|NCT00455143|10147750|FG000|Overall Study|Withdrawal by Subject|1
6359487|NCT00455143|10147750|FG000|Overall Study|Staff was not avail to follow patient|2
6359488|NCT00455143|10147750|FG000|Overall Study|No longer met Inclusion Criteria|1
6359489|NCT00455143|10147750|FG000|Overall Study|Surgical time, staff not available|1
6359490|NCT00454571|10147766|FG000|Overall Study|Adverse Event|2
6359491|NCT00454571|10147767|FG001|Overall Study|Adverse Event|0
6359492|NCT00454571|10147766|FG000|Overall Study|Physician Decision|0
6359493|NCT00454571|10147767|FG001|Overall Study|Physician Decision|1
6359494|NCT00454571|10147766|FG000|Overall Study|Protocol Violation|1
6359495|NCT00454571|10147767|FG001|Overall Study|Protocol Violation|0
6359496|NCT00454571|10147766|FG000|Overall Study|Withdrawal by Subject|10
6359497|NCT00454571|10147767|FG001|Overall Study|Withdrawal by Subject|5
6359498|NCT00452361|10147775|FG000|Overall Study|Adverse Event|8
6359499|NCT00452361|10147776|FG001|Overall Study|Adverse Event|0
6359500|NCT00452361|10147775|FG000|Overall Study|Withdrawal by Subject|0
6359501|NCT00452361|10147776|FG001|Overall Study|Withdrawal by Subject|1
6359502|NCT00452361|10147775|FG000|Overall Study|Premature termination|13
6359503|NCT00452361|10147776|FG001|Overall Study|Premature termination|9
6359504|NCT00443040|10147785|FG000|Overall Study|Withdrawal by Subject|1
6359505|NCT00443040|10147786|FG001|Overall Study|Withdrawal by Subject|0
6359506|NCT00443040|10147787|FG002|Overall Study|Withdrawal by Subject|0
6359507|NCT00443040|10147785|FG000|Overall Study|Converted to an open laparotomy|3
6359508|NCT00443040|10147786|FG001|Overall Study|Converted to an open laparotomy|0
6359509|NCT00443040|10147787|FG002|Overall Study|Converted to an open laparotomy|1
6359510|NCT00447421|10147795|FG000|Overall Study|Lack of Efficacy|1
6359511|NCT00447421|10147795|FG000|Overall Study|Adverse Event|3
6359512|NCT00447421|10147795|FG000|Overall Study|Sponsor Decision|2
6359513|NCT00441272|10147801|FG000|Overall Study|Study terminated prior to enrollment|25
6359514|NCT00441272|10147802|FG001|Overall Study|Study terminated prior to enrollment|25
6359515|NCT00440271|10147814|FG000|Overall Study|Protocol Violation|1
6359516|NCT00440271|10147815|FG001|Overall Study|Protocol Violation|1
6359517|NCT00440271|10147814|FG000|Overall Study|Adverse Event|0
6359518|NCT00440271|10147815|FG001|Overall Study|Adverse Event|1
6359519|NCT00440271|10147814|FG000|Overall Study|Lost to Follow-up|1
6359520|NCT00440271|10147815|FG001|Overall Study|Lost to Follow-up|0
6359521|NCT00440271|10147814|FG000|Overall Study|Withdrawal by Subject|0
6359522|NCT00440271|10147815|FG001|Overall Study|Withdrawal by Subject|2
6359523|NCT00440271|10147814|FG000|Overall Study|Lack of Efficacy|0
6359524|NCT00440271|10147815|FG001|Overall Study|Lack of Efficacy|1
6359525|NCT00440271|10147814|FG000|Overall Study|Due to closure of trial|8
6359526|NCT00440271|10147815|FG001|Overall Study|Due to closure of trial|10
6359527|NCT00440271|10147814|FG000|Overall Study|Other|2
6359528|NCT00440271|10147815|FG001|Overall Study|Other|0
6359529|NCT00429026|10147825|FG000|Overall Study|Inevaluable for response.|40
6359530|NCT00439569|10147836|FG000|Cohort 1 (500 mg/kg/Day)|Allergic reaction|1
6359531|NCT00439569|10147836|FG000|Cohort 1 (500 mg/kg/Day)|Less than 80% study drug compliance|3
6359532|NCT00439569|10147836|FG000|Cohort 2 (500 mg/kg/Day)|Less than 80% study drug compliance|1
6359533|NCT00422669|10147843|FG000|Overall Study|The study was terminated early.|98
6359534|NCT00422669|10147844|FG001|Overall Study|The study was terminated early.|100
6359535|NCT00422669|10147845|FG002|Overall Study|The study was terminated early.|7
6359536|NCT00434590|10147857|FG000|Overall Study|Administrative problems|5
6359537|NCT00434590|10147858|FG001|Overall Study|Administrative problems|5
6359538|NCT00424645|10147866|FG000|Overall Study|Death|1
6359539|NCT00424645|10147867|FG001|Overall Study|Death|0
6359540|NCT00430027|10147873|FG000|Overall Study|Study terminated|8
6359541|NCT00429858|10147877|FG000|Overall Study|Withdrawal by Subject|1
6359542|NCT00429858|10147877|FG000|Overall Study|Study Termination|1
6359543|NCT00425438|10147884|FG000|Overall Study|Termination by Sponsor|25
6359544|NCT00425438|10147885|FG001|Overall Study|Termination by Sponsor|27
6359545|NCT00422942|10147895|FG000|Overall Study|Study terminated by Sponsor|3
6359546|NCT00409344|10147901|FG000|Overall Study|no enrollment|0
6359547|NCT00409344|10147902|FG001|Overall Study|no enrollment|0
6359548|NCT00414453|10147908|FG000|Overall Study|Abnormal lab work|16
6359549|NCT00417248|10147918|FG000|Overall Study|Study Terminated|6
6359550|NCT00417248|10147918|FG000|Overall Study|Death|1
6359551|NCT00417248|10147918|FG000|Overall Study|Lack of Efficacy|1
6359552|NCT00418145|10147923|FG000|Overall Study|study terminated|6
6359553|NCT00409331|10147929|FG000|Overall Study|Physician Decision|1
6359554|NCT00391430|10147946|FG000|Overall Study|Withdrawal by Subject|3
6359555|NCT00391430|10147947|FG001|Overall Study|Withdrawal by Subject|0
6359556|NCT00391430|10147948|FG002|Overall Study|Withdrawal by Subject|12
6359557|NCT00384293|10147981|FG000|MK0524A Active Run-In, Pre-randomization|Adverse Event|120
6359558|NCT00384293|10147982|FG001|MK0524A Active Run-In, Pre-randomization|Adverse Event|0
6359559|NCT00384293|10147983|FG002|MK0524A Active Run-In, Pre-randomization|Adverse Event|0
6359560|NCT00384293|10147981|FG000|MK0524A Active Run-In, Pre-randomization|Lost to Follow-up|1
6359561|NCT00384293|10147982|FG001|MK0524A Active Run-In, Pre-randomization|Lost to Follow-up|0
6359562|NCT00384293|10147983|FG002|MK0524A Active Run-In, Pre-randomization|Lost to Follow-up|0
6359563|NCT00384293|10147981|FG000|MK0524A Active Run-In, Pre-randomization|Withdrawal by Subject|24
6359564|NCT00384293|10147982|FG001|MK0524A Active Run-In, Pre-randomization|Withdrawal by Subject|0
6359565|NCT00384293|10147983|FG002|MK0524A Active Run-In, Pre-randomization|Withdrawal by Subject|0
6359566|NCT00384293|10147981|FG000|MK0524A Active Run-In, Pre-randomization|Not cIMT eligible at Visit 3|340
6359567|NCT00384293|10147982|FG001|MK0524A Active Run-In, Pre-randomization|Not cIMT eligible at Visit 3|0
6359568|NCT00384293|10147983|FG002|MK0524A Active Run-In, Pre-randomization|Not cIMT eligible at Visit 3|0
6359569|NCT00384293|10147981|FG000|MK0524A Active Run-In, Pre-randomization|Trial Termination|16
6359570|NCT00384293|10147982|FG001|MK0524A Active Run-In, Pre-randomization|Trial Termination|0
6359571|NCT00384293|10147983|FG002|MK0524A Active Run-In, Pre-randomization|Trial Termination|0
6359572|NCT00384293|10147981|FG000|MK0524A Active Run-In, Pre-randomization|Certified Sonographer Not Available|2
6359573|NCT00384293|10147982|FG001|MK0524A Active Run-In, Pre-randomization|Certified Sonographer Not Available|0
6359574|NCT00384293|10147983|FG002|MK0524A Active Run-In, Pre-randomization|Certified Sonographer Not Available|0
6359575|NCT00384293|10147981|FG000|MK0524A Active Run-In, Pre-randomization|Patient Unable to Complete cIMT Scan|1
6359576|NCT00384293|10147982|FG001|MK0524A Active Run-In, Pre-randomization|Patient Unable to Complete cIMT Scan|0
6359577|NCT00384293|10147983|FG002|MK0524A Active Run-In, Pre-randomization|Patient Unable to Complete cIMT Scan|0
6359578|NCT00384293|10147981|FG000|Post-randomization Period|Adverse Event|0
6359579|NCT00384293|10147982|FG001|Post-randomization Period|Adverse Event|23
6359580|NCT00384293|10147983|FG002|Post-randomization Period|Adverse Event|7
6359581|NCT00384293|10147981|FG000|Post-randomization Period|Lost to Follow-up|0
6359582|NCT00384293|10147982|FG001|Post-randomization Period|Lost to Follow-up|2
6359583|NCT00384293|10147983|FG002|Post-randomization Period|Lost to Follow-up|1
6359584|NCT00384293|10147981|FG000|Post-randomization Period|Protocol Violation|0
6359585|NCT00384293|10147982|FG001|Post-randomization Period|Protocol Violation|1
6359586|NCT00384293|10147983|FG002|Post-randomization Period|Protocol Violation|0
6359587|NCT00384293|10147981|FG000|Post-randomization Period|Withdrawal by Subject|0
6359588|NCT00384293|10147982|FG001|Post-randomization Period|Withdrawal by Subject|8
6359589|NCT00384293|10147983|FG002|Post-randomization Period|Withdrawal by Subject|6
6359590|NCT00384293|10147981|FG000|Post-randomization Period|Trial Termination|0
6359591|NCT00384293|10147982|FG001|Post-randomization Period|Trial Termination|180
6359592|NCT00384293|10147983|FG002|Post-randomization Period|Trial Termination|204
6359593|NCT00384293|10147981|FG000|Post-randomization Period|Patient Randomized in Error|0
6359594|NCT00384293|10147982|FG001|Post-randomization Period|Patient Randomized in Error|0
6359595|NCT00384293|10147983|FG002|Post-randomization Period|Patient Randomized in Error|1
6359596|NCT00377455|10148004|FG000|Overall Study|Withdrawal by Subject|1
6359597|NCT00371462|10148010|FG000|Overall Study|Withdrawal by Subject|1
6359598|NCT00371462|10148011|FG001|Overall Study|Withdrawal by Subject|0
6359599|NCT00371462|10148010|FG000|Overall Study|Other|7
6359600|NCT00371462|10148011|FG001|Overall Study|Other|8
6359601|NCT00369265|10148019|FG000|Overall Study|Study terminated|4
6359602|NCT00369265|10148020|FG001|Overall Study|Study terminated|7
6359603|NCT00364689|10148033|FG000|Overall Study|Lost to Follow-up|1
6359604|NCT00352118|10148039|FG000|Overall Study|Physician Decision|4
6359605|NCT00356421|10148062|FG000|Overall Study|Lack of Efficacy|3
6359606|NCT00356421|10148063|FG001|Overall Study|Lack of Efficacy|0
6359607|NCT00356421|10148062|FG000|Overall Study|Withdrawal by Subject|9
6359608|NCT00356421|10148063|FG001|Overall Study|Withdrawal by Subject|2
6359609|NCT00356421|10148062|FG000|Overall Study|Related to study drug|15
6359610|NCT00356421|10148063|FG001|Overall Study|Related to study drug|12
6359611|NCT00356421|10148062|FG000|Overall Study|Not related to study drug|5
6359612|NCT00356421|10148063|FG001|Overall Study|Not related to study drug|3
6359613|NCT00350623|10148072|FG000|Overall Study|Lost to Follow-up|8
6359614|NCT00350623|10148073|FG001|Overall Study|Lost to Follow-up|3
6359615|NCT00350623|10148074|FG002|Overall Study|Lost to Follow-up|4
6359616|NCT00350623|10148072|FG000|Overall Study|Withdrawal by Subject|0
6359617|NCT00350623|10148073|FG001|Overall Study|Withdrawal by Subject|1
6359618|NCT00350623|10148074|FG002|Overall Study|Withdrawal by Subject|1
6359619|NCT00350623|10148072|FG000|Overall Study|patient traveling outside the country|0
6359620|NCT00350623|10148073|FG001|Overall Study|patient traveling outside the country|0
6359621|NCT00350623|10148074|FG002|Overall Study|patient traveling outside the country|1
6359622|NCT00350844|10148102|FG000|Overall Study|Lost to Follow-up|1
6359623|NCT00348556|10148106|FG000|Overall Study|Adverse Event|1
6359624|NCT00319839|10148110|FG000|Overall Study|Adverse Event|5
6359625|NCT00319839|10148110|FG000|Overall Study|Withdrawal by Subject|1
6359626|NCT00344019|10148117|FG000|Overall Study|did not meet final inclusion criteria|0
6359627|NCT00344019|10148118|FG001|Overall Study|did not meet final inclusion criteria|0
6359628|NCT00344019|10148119|FG002|Overall Study|did not meet final inclusion criteria|74
6359629|NCT00338455|10148132|FG000|Overall Study|Death|2
6359630|NCT00338455|10148133|FG001|Overall Study|Death|1
6359631|NCT00338455|10148132|FG000|Overall Study|Physician Decision|1
6359632|NCT00338455|10148133|FG001|Overall Study|Physician Decision|0
6359633|NCT00329108|10148141|FG000|Overall Study|Adverse Event|2
6359634|NCT00329108|10148142|FG001|Overall Study|Adverse Event|2
6359635|NCT00329108|10148141|FG000|Overall Study|Lack of Efficacy|3
6359636|NCT00329108|10148142|FG001|Overall Study|Lack of Efficacy|3
6359637|NCT00329108|10148141|FG000|Overall Study|Withdrawal by Subject|0
6170413|NCT01253187|9816718|FG002|Period 3|difficulty with blood sampling|0
6359638|NCT00329108|10148142|FG001|Overall Study|Withdrawal by Subject|2
6359639|NCT00329108|10148141|FG000|Overall Study|symptomatic deterioration|1
6359640|NCT00329108|10148142|FG001|Overall Study|symptomatic deterioration|1
6359641|NCT00329108|10148141|FG000|Overall Study|Subject no longer willing to participate|2
6359642|NCT00329108|10148142|FG001|Overall Study|Subject no longer willing to participate|2
6359643|NCT00329108|10148141|FG000|Overall Study|study terminated by sponsor|1
6359644|NCT00329108|10148142|FG001|Overall Study|study terminated by sponsor|0
6359645|NCT00329108|10148141|FG000|Overall Study|withdrew patient after SAE resolved|1
6359646|NCT00329108|10148142|FG001|Overall Study|withdrew patient after SAE resolved|0
6359647|NCT00329108|10148141|FG000|Overall Study|Protocol Violation|0
6359648|NCT00329108|10148142|FG001|Overall Study|Protocol Violation|2
6359649|NCT00333229|10148163|FG000|Overall Study|Lack of Efficacy|0
6359650|NCT00333229|10148164|FG001|Overall Study|Lack of Efficacy|1
6359651|NCT00314327|10148210|FG000|Overall Study|Withdrawal by Subject|1
6359652|NCT00308113|10148218|FG000|Overall Study|Protocol closure|0
6359653|NCT00308113|10148219|FG001|Overall Study|Protocol closure|0
6359654|NCT00308113|10148220|FG002|Overall Study|Protocol closure|0
6359655|NCT00308113|10148221|FG003|Overall Study|Protocol closure|1
6359656|NCT00298740|10148241|FG000|Overall Study|Lack of Efficacy|6
6359657|NCT00298740|10148241|FG000|Overall Study|Withdrawal by Subject|3
6359658|NCT00301080|10148245|FG000|Original Version (2 Arms & 4 Weeks)|Never received drug|1
6359659|NCT00301080|10148246|FG001|Original Version (2 Arms & 4 Weeks)|Never received drug|0
6359660|NCT00301080|10148247|FG002|Original Version (2 Arms & 4 Weeks)|Never received drug|0
6359661|NCT00301080|10148248|FG003|Original Version (2 Arms & 4 Weeks)|Never received drug|0
6359662|NCT00301080|10148249|FG004|Original Version (2 Arms & 4 Weeks)|Never received drug|0
6359663|NCT00290407|10148267|FG000|Overall Study|Physician Decision|2
6359664|NCT00295490|10148275|FG000|Overall Study|Protocol Violation|0
6359665|NCT00295490|10148276|FG001|Overall Study|Protocol Violation|0
6359666|NCT00295490|10148277|FG002|Overall Study|Protocol Violation|3
6359667|NCT00295490|10148278|FG003|Overall Study|Protocol Violation|3
6359668|NCT00295490|10148275|FG000|Overall Study|Withdrawal by Subject|0
6359669|NCT00295490|10148276|FG001|Overall Study|Withdrawal by Subject|2
6359670|NCT00295490|10148277|FG002|Overall Study|Withdrawal by Subject|0
6359671|NCT00295490|10148278|FG003|Overall Study|Withdrawal by Subject|1
6359672|NCT00295490|10148275|FG000|Overall Study|Lost to Follow-up|0
6359673|NCT00295490|10148276|FG001|Overall Study|Lost to Follow-up|0
6359674|NCT00295490|10148277|FG002|Overall Study|Lost to Follow-up|1
6359675|NCT00295490|10148278|FG003|Overall Study|Lost to Follow-up|0
6359676|NCT00295490|10148275|FG000|Overall Study|Adverse Event|1
6359677|NCT00295490|10148276|FG001|Overall Study|Adverse Event|0
6359678|NCT00295490|10148277|FG002|Overall Study|Adverse Event|0
6359679|NCT00295490|10148278|FG003|Overall Study|Adverse Event|0
6359680|NCT00295490|10148275|FG000|Overall Study|Other|0
6359681|NCT00295490|10148276|FG001|Overall Study|Other|2
6359682|NCT00295490|10148277|FG002|Overall Study|Other|0
6359683|NCT00295490|10148278|FG003|Overall Study|Other|1
6359684|NCT00268463|10148290|FG000|Overall Study|study terminated due to low accrual|10
6359685|NCT00268463|10148291|FG001|Overall Study|study terminated due to low accrual|12
6359686|NCT00276419|10148308|FG000|First Intervention|Adverse Event|1
6359687|NCT00276419|10148309|FG001|First Intervention|Adverse Event|0
6359688|NCT00276419|10148308|FG000|First Intervention|Withdrawal by Subject|0
6359689|NCT00276419|10148309|FG001|First Intervention|Withdrawal by Subject|2
6359690|NCT00271947|10148357|FG000|Overall Study|Lost to Follow-up|1
6359691|NCT00252174|10148377|FG000|Overall Study|Withdrawal by Subject|0
6170414|NCT01253187|9816719|FG003|Period 3|difficulty with blood sampling|0
6359692|NCT00252174|10148378|FG001|Overall Study|Withdrawal by Subject|1
6359693|NCT00252174|10148379|FG002|Overall Study|Withdrawal by Subject|0
6359694|NCT00256295|10148387|FG000|Overall Study|Withdrawal by Subject|3
6359695|NCT00256295|10148387|FG000|Overall Study|Death|1
6359696|NCT00239720|10148401|FG000|Overall Study|Adverse Event|1
6359697|NCT00239720|10148402|FG001|Overall Study|Adverse Event|0
6359698|NCT00239720|10148401|FG000|Overall Study|Lost to Follow-up|0
6359699|NCT00239720|10148402|FG001|Overall Study|Lost to Follow-up|1
6359700|NCT00250718|10148408|FG000|Overall Study|Death|1
6359701|NCT00250718|10148408|FG000|Overall Study|Adverse Event|1
6359702|NCT00250718|10148408|FG000|Overall Study|Withdrawal by Subject|1
6359703|NCT00206375|10148456|FG000|Overall Study|Lost to Follow-up|1
6359704|NCT00206375|10148457|FG001|Overall Study|Lost to Follow-up|0
6359705|NCT00206375|10148458|FG002|Overall Study|Lost to Follow-up|0
6359706|NCT00206375|10148456|FG000|Overall Study|Withdrawal by Subject|2
6359707|NCT00206375|10148457|FG001|Overall Study|Withdrawal by Subject|1
6359708|NCT00206375|10148458|FG002|Overall Study|Withdrawal by Subject|3
6359709|NCT00206375|10148456|FG000|Overall Study|Study terminated due to lack of funds|0
6359710|NCT00206375|10148457|FG001|Overall Study|Study terminated due to lack of funds|1
6359711|NCT00206375|10148458|FG002|Overall Study|Study terminated due to lack of funds|1
6359712|NCT00229931|10148468|FG000|Overall Study|Death|1
6359713|NCT00229931|10148469|FG001|Overall Study|Death|0
6359714|NCT00229931|10148468|FG000|Overall Study|Lost to Follow-up|3
6359715|NCT00229931|10148469|FG001|Overall Study|Lost to Follow-up|2
6359716|NCT00209131|10148477|FG000|Overall Study|Lack of personnel due to turnovers.|15
6359717|NCT00209131|10148478|FG001|Overall Study|Lack of personnel due to turnovers.|11
6359718|NCT00209027|10148508|FG000|Overall Study|study terminated|10
6359719|NCT00209027|10148509|FG001|Overall Study|study terminated|0
6359720|NCT00182637|10148515|FG000|Overall Study|Adverse Event|2
6359721|NCT00182637|10148515|FG000|Overall Study|Disease Progression|1
6359722|NCT00176488|10148520|FG000|Overall Study|Initiated Cycle 1 Day 1 only|1
6359723|NCT00162773|10148557|FG000|Overall Study|P.I, Left institution. Study terminated|22
6170415|NCT01253187|9816720|FG004|Period 3|difficulty with blood sampling|0
6359724|NCT00147238|10148587|FG000|Overall Study|Inevaluable|8
6359725|NCT00165503|10148591|FG000|Overall Study|Death|1
6359726|NCT00165503|10148591|FG000|Overall Study|Lost to Follow-up|12
6359727|NCT00165503|10148591|FG000|Overall Study|Unresectable|3
6359728|NCT00160563|10148598|FG000|Overall Study|Adverse Event|1
6359729|NCT00160563|10148599|FG001|Overall Study|Adverse Event|1
6359730|NCT00160563|10148600|FG002|Overall Study|Adverse Event|1
6359731|NCT00160563|10148598|FG000|Overall Study|Lost to Follow-up|1
6359732|NCT00160563|10148599|FG001|Overall Study|Lost to Follow-up|1
6359733|NCT00160563|10148600|FG002|Overall Study|Lost to Follow-up|2
6359734|NCT00160563|10148598|FG000|Overall Study|Protocol Violation|0
6359735|NCT00160563|10148599|FG001|Overall Study|Protocol Violation|0
6359736|NCT00160563|10148600|FG002|Overall Study|Protocol Violation|3
6359737|NCT00160563|10148598|FG000|Overall Study|Withdrawal by Subject|1
6359738|NCT00160563|10148599|FG001|Overall Study|Withdrawal by Subject|2
6359739|NCT00160563|10148600|FG002|Overall Study|Withdrawal by Subject|3
6359740|NCT00160563|10148598|FG000|Overall Study|Other (listed in the study report)|48
6359741|NCT00160563|10148599|FG001|Overall Study|Other (listed in the study report)|40
6359742|NCT00160563|10148600|FG002|Overall Study|Other (listed in the study report)|81
6359743|NCT00160563|10148598|FG000|Overall Study|Missing reason|0
6359744|NCT00160563|10148599|FG001|Overall Study|Missing reason|1
6359745|NCT00160563|10148600|FG002|Overall Study|Missing reason|0
6359746|NCT00142519|10148611|FG000|Overall Study|Not Treated|7
6359747|NCT00142519|10148612|FG001|Overall Study|Not Treated|9
6359748|NCT00142519|10148611|FG000|Overall Study|Protocol Violation|1
6359749|NCT00142519|10148612|FG001|Overall Study|Protocol Violation|0
6359750|NCT00142519|10148611|FG000|Overall Study|Withdrawal by Subject|10
6359751|NCT00142519|10148612|FG001|Overall Study|Withdrawal by Subject|7
6359752|NCT00138073|10148627|FG000|Overall Study|lack of resources|55
6359753|NCT00113386|10148633|FG000|Overall Study|Withdrawal by Subject|1
6359754|NCT00113386|10148634|FG001|Overall Study|Withdrawal by Subject|0
6359755|NCT00113386|10148633|FG000|Overall Study|Physician Decision|0
6359756|NCT00113386|10148634|FG001|Overall Study|Physician Decision|1
6359757|NCT00113386|10148633|FG000|Overall Study|Toxicity|3
6359758|NCT00113386|10148634|FG001|Overall Study|Toxicity|0
6359759|NCT00113386|10148633|FG000|Overall Study|Ineligible|1
6359760|NCT00113386|10148634|FG001|Overall Study|Ineligible|2
6359761|NCT00113386|10148633|FG000|Overall Study|Unknown - Lost to Follow-Up|2
6359762|NCT00113386|10148634|FG001|Overall Study|Unknown - Lost to Follow-Up|1
6359763|NCT00138151|10148640|FG000|Overall Study|Withdrawal by Subject|3
6359764|NCT00138151|10148640|FG000|Overall Study|Physician Decision|1
6359765|NCT00129974|10148644|FG000|Overall Study|Other|1
6359766|NCT00126659|10148651|FG000|Overall Study|Adverse Event|0
6359767|NCT00126659|10148652|FG001|Overall Study|Adverse Event|0
6359768|NCT00126659|10148653|FG002|Overall Study|Adverse Event|2
6359769|NCT00125268|10148670|FG000|Overall Study|Withdrawal by Subject|1
6359770|NCT00125268|10148671|FG001|Overall Study|Withdrawal by Subject|1
6359771|NCT00113399|10148679|FG000|Overall Study|Death|1
6359772|NCT00113399|10148680|FG001|Overall Study|Death|1
6359773|NCT00113399|10148679|FG000|Overall Study|Withdrawal by Subject|1
6359774|NCT00113399|10148680|FG001|Overall Study|Withdrawal by Subject|2
6359775|NCT00113399|10148679|FG000|Overall Study|Complete Response|0
6359776|NCT00113399|10148680|FG001|Overall Study|Complete Response|1
6359777|NCT00113399|10148679|FG000|Overall Study|Other|0
6359778|NCT00113399|10148680|FG001|Overall Study|Other|1
6359779|NCT00107614|10148690|FG000|Overall Study|Physician Decision|10
6359780|NCT00107614|10148690|FG000|Overall Study|Death|2
6359781|NCT00107315|10148694|FG000|Overall Study|Disease Progression|9
6359782|NCT00107315|10148694|FG000|Overall Study|Adverse Event|4
6359783|NCT00107315|10148694|FG000|Overall Study|Withdrawal by Subject|2
6359784|NCT00108433|10148700|FG000|Overall Study|Lack of Efficacy|1
6359785|NCT00108433|10148701|FG001|Overall Study|Lack of Efficacy|2
6359786|NCT00108433|10148700|FG000|Overall Study|Death|3
6359787|NCT00108433|10148701|FG001|Overall Study|Death|0
6359788|NCT00108433|10148700|FG000|Overall Study|Adverse Event|3
6359789|NCT00108433|10148701|FG001|Overall Study|Adverse Event|1
6359790|NCT00108433|10148700|FG000|Overall Study|Other|14
6359791|NCT00108433|10148701|FG001|Overall Study|Other|14
6359792|NCT00113919|10148707|FG000|Overall Study|Physician Decision|8
6359793|NCT00113919|10148707|FG000|Overall Study|Death|6
6359794|NCT00100828|10148720|FG000|Overall Study|Physician Decision|6
6359795|NCT00104728|10148724|FG000|Overall Study|screen failures|19
6359796|NCT00083915|10148743|FG000|Overall Study|Death|6
6359797|NCT00083915|10148744|FG001|Overall Study|Death|3
6359798|NCT00083915|10148743|FG000|Overall Study|Physician Decision|11
6359799|NCT00083915|10148744|FG001|Overall Study|Physician Decision|6
6359800|NCT00083915|10148743|FG000|Overall Study|Withdrawal by Subject|8
6359801|NCT00083915|10148744|FG001|Overall Study|Withdrawal by Subject|3
6359802|NCT00083915|10148743|FG000|Overall Study|disease progression|18
6359803|NCT00083915|10148744|FG001|Overall Study|disease progression|23
6359804|NCT00083915|10148743|FG000|Overall Study|Failure to collect|3
6359805|NCT00083915|10148744|FG001|Overall Study|Failure to collect|0
6359806|NCT00083915|10148743|FG000|Overall Study|No response|3
6359807|NCT00083915|10148744|FG001|Overall Study|No response|1
6359808|NCT00083915|10148743|FG000|Overall Study|Insurance issues|1
6359809|NCT00083915|10148744|FG001|Overall Study|Insurance issues|1
6359810|NCT00088829|10148763|FG000|Overall Study|PI left institution and study was close|22
6359811|NCT00085631|10148786|FG000|Overall Study|Missing Data|4
6359812|NCT00085631|10148787|FG001|Overall Study|Missing Data|11
6359813|NCT00085631|10148788|FG002|Overall Study|Missing Data|7
6359814|NCT00062751|10148800|FG000|Overall Study|Disease progression|24
6359815|NCT00062751|10148801|FG001|Overall Study|Disease progression|17
6359816|NCT00062751|10148802|FG002|Overall Study|Disease progression|24
6359817|NCT00062751|10148803|FG003|Overall Study|Disease progression|2
6359818|NCT00062751|10148804|FG004|Overall Study|Disease progression|2
6359819|NCT00062751|10148800|FG000|Overall Study|Adverse Event|4
6359820|NCT00062751|10148801|FG001|Overall Study|Adverse Event|7
6359821|NCT00062751|10148802|FG002|Overall Study|Adverse Event|2
6359822|NCT00062751|10148803|FG003|Overall Study|Adverse Event|2
6359823|NCT00062751|10148804|FG004|Overall Study|Adverse Event|2
6359824|NCT00062751|10148800|FG000|Overall Study|Other|2
6359825|NCT00062751|10148801|FG001|Overall Study|Other|3
6359826|NCT00062751|10148802|FG002|Overall Study|Other|1
6359827|NCT00062751|10148803|FG003|Overall Study|Other|0
6359828|NCT00062751|10148804|FG004|Overall Study|Other|1
6359829|NCT00062751|10148800|FG000|Overall Study|Withdrawal by Subject|1
6359830|NCT00062751|10148801|FG001|Overall Study|Withdrawal by Subject|2
6359831|NCT00062751|10148802|FG002|Overall Study|Withdrawal by Subject|2
6359832|NCT00062751|10148803|FG003|Overall Study|Withdrawal by Subject|1
6359833|NCT00062751|10148804|FG004|Overall Study|Withdrawal by Subject|0
6359834|NCT00062751|10148800|FG000|Overall Study|Symptomatic deterioration|1
6359835|NCT00062751|10148801|FG001|Overall Study|Symptomatic deterioration|1
6359836|NCT00062751|10148802|FG002|Overall Study|Symptomatic deterioration|0
6359837|NCT00062751|10148803|FG003|Overall Study|Symptomatic deterioration|0
6359838|NCT00062751|10148804|FG004|Overall Study|Symptomatic deterioration|1
6359839|NCT00062751|10148800|FG000|Overall Study|Death|1
6359840|NCT00062751|10148801|FG001|Overall Study|Death|0
6359841|NCT00062751|10148802|FG002|Overall Study|Death|1
6359842|NCT00062751|10148803|FG003|Overall Study|Death|0
6359843|NCT00062751|10148804|FG004|Overall Study|Death|0
6359844|NCT00066807|10148819|FG000|Overall Study|Study was terminated early|14
6359845|NCT00066807|10148820|FG001|Overall Study|Study was terminated early|15
6359846|NCT00038142|10148841|FG000|Overall Study|Ineligible|1
6359847|NCT00038142|10148842|FG001|Overall Study|Ineligible|0
6359848|NCT00038142|10148841|FG000|Overall Study|Progressive Disease|11
6359849|NCT00038142|10148842|FG001|Overall Study|Progressive Disease|7
6359850|NCT00038142|10148841|FG000|Overall Study|Death|1
6359851|NCT00038142|10148842|FG001|Overall Study|Death|0
6359852|NCT00038142|10148841|FG000|Overall Study|Adverse Event|1
6359853|NCT00038142|10148842|FG001|Overall Study|Adverse Event|0
6359854|NCT00038142|10148841|FG000|Overall Study|Unknown Reason|8
6359855|NCT00038142|10148842|FG001|Overall Study|Unknown Reason|0
6359856|NCT00006478|10148857|FG000|Overall Study|Vaccine could not be produced|1
6359857|NCT00006478|10148857|FG000|Overall Study|Physician Decision|6
6359858|NCT00006916|10148870|FG000|Overall Study|Device not inserted|4
6359859|NCT00006916|10148870|FG000|Overall Study|Complication of device insertion|1
6359860|NCT02009384|10148944|FG000|Overall Study|Death|2
6359861|NCT04558125|10148948|FG000|Overall Study|Death|1
6359862|NCT02401308|10148954|FG000|Overall Study|Study was terminated by the PI due to lack of enrollment.|0
6359863|NCT02401308|10148955|FG001|Overall Study|Study was terminated by the PI due to lack of enrollment.|1
6359864|NCT04381988|10148963|FG000|Overall Study|The study was terminated|4
6359865|NCT04381988|10148964|FG001|Overall Study|The study was terminated|0
6359866|NCT00479167|10148992|FG000|Overall Study|Withdrawal by Subject|1
6359867|NCT03998189|10148999|FG000|Overall Study|Lack of Efficacy|0
6359868|NCT03998189|10149000|FG001|Overall Study|Lack of Efficacy|1
6359869|NCT02934503|10149114|FG000|Overall Study|progression of disease|3
6359870|NCT02934503|10149114|FG000|Overall Study|Withdrawal by Subject|1
6359871|NCT02137252|10149120|FG000|Overall Study|trial terminated early|2
6359872|NCT02137252|10149121|FG001|Overall Study|trial terminated early|1
6359873|NCT01294670|10149136|FG000|Overall Study|Not treated|1
6359874|NCT01294670|10149137|FG001|Overall Study|Not treated|0
6359875|NCT01294670|10149138|FG002|Overall Study|Not treated|0
6359876|NCT01294670|10149139|FG003|Overall Study|Not treated|0
6359877|NCT01294670|10149140|FG004|Overall Study|Not treated|0
6359878|NCT03095287|10149152|FG000|Overall Study|Treatment Failure|1
6359879|NCT03095287|10149152|FG000|Overall Study|Adverse Event|1
6359880|NCT02930122|10149162|FG000|Overall Study|The trial was terminated prior to participating completing the study due to lack of funding.|3
6359881|NCT02930122|10149163|FG001|Overall Study|The trial was terminated prior to participating completing the study due to lack of funding.|3
6359882|NCT04144166|10149183|FG000|Overall Study|Discharged before study start|1
6359883|NCT04144166|10149183|FG000|Overall Study|Pregnancy|1
6359884|NCT04144166|10149183|FG000|Overall Study|Nail polish could not be removed from finger|1
6359885|NCT04090164|10149194|FG000|Overall Study|incomplete data on file|245
6359886|NCT04090164|10149195|FG001|Overall Study|incomplete data on file|0
6359887|NCT03997825|10149284|FG000|Overall Study|Death|3
6359888|NCT03997825|10149284|FG000|Overall Study|Lost to Follow-up|10
6359889|NCT03997825|10149284|FG000|Overall Study|Withdrawal by Subject|3
6359890|NCT03997825|10149284|FG000|Overall Study|Refused participation|1
6359891|NCT03764813|10149321|FG000|From Enrollment to the Age of 32 Weeks|Death before the age of 32 weeks|0
6359892|NCT03764813|10149322|FG001|From Enrollment to the Age of 32 Weeks|Death before the age of 32 weeks|1
6359893|NCT03764813|10149323|FG002|From Enrollment to the Age of 32 Weeks|Death before the age of 32 weeks|1
6359894|NCT03764813|10149324|FG003|From Enrollment to the Age of 32 Weeks|Death before the age of 32 weeks|0
6359895|NCT00078806|10149340|FG000|Part 1A|Adverse Event|2
6359896|NCT00078806|10149341|FG001|Part 1A|Adverse Event|0
6359897|NCT00078806|10149342|FG002|Part 1A|Adverse Event|0
6359898|NCT00078806|10149343|FG003|Part 1A|Adverse Event|0
6359899|NCT00078806|10149340|FG000|Part 1A|Lack of Efficacy|7
6359900|NCT00078806|10149341|FG001|Part 1A|Lack of Efficacy|0
6359901|NCT00078806|10149342|FG002|Part 1A|Lack of Efficacy|0
6359902|NCT00078806|10149343|FG003|Part 1A|Lack of Efficacy|0
6359903|NCT00078806|10149340|FG000|Part 1A|Other|1
6359904|NCT00078806|10149341|FG001|Part 1A|Other|0
6359905|NCT00078806|10149342|FG002|Part 1A|Other|0
6359906|NCT00078806|10149343|FG003|Part 1A|Other|0
6359907|NCT00078806|10149340|FG000|Part 1B|Adverse Event|1
6359908|NCT00078806|10149341|FG001|Part 1B|Adverse Event|0
6359909|NCT00078806|10149342|FG002|Part 1B|Adverse Event|0
6359910|NCT00078806|10149343|FG003|Part 1B|Adverse Event|0
6359911|NCT00078806|10149340|FG000|Part 1B|Lack of Efficacy|7
6359912|NCT00078806|10149341|FG001|Part 1B|Lack of Efficacy|0
6359913|NCT00078806|10149342|FG002|Part 1B|Lack of Efficacy|0
6359914|NCT00078806|10149343|FG003|Part 1B|Lack of Efficacy|0
6359915|NCT00078806|10149340|FG000|Part 2|Adverse Event|0
6359916|NCT00078806|10149341|FG001|Part 2|Adverse Event|1
6359917|NCT00078806|10149342|FG002|Part 2|Adverse Event|0
6359918|NCT00078806|10149343|FG003|Part 2|Adverse Event|0
6359919|NCT00162370|10149358|FG000|Efficacy Population|Lost to Follow-up|51
6359920|NCT00214500|10149374|FG000|Treatment Period|Adverse Event|1
6359921|NCT00214500|10149374|FG000|Extension Period|Withdrawal by Subject|2
6359922|NCT00283959|10149386|FG000|Extension Period|Low Compliance|1
6359923|NCT00290758|10149392|FG000|Pre-Intervention rFNA Through Follow-Up|Adverse Event|1
6359924|NCT00290758|10149393|FG001|Pre-Intervention rFNA Through Follow-Up|Adverse Event|2
6359925|NCT00290758|10149392|FG000|Pre-Intervention rFNA Through Follow-Up|ConMeds|1
6359926|NCT00290758|10149393|FG001|Pre-Intervention rFNA Through Follow-Up|ConMeds|0
6359927|NCT00290758|10149392|FG000|Pre-Intervention rFNA Through Follow-Up|Physician Decision|3
6359928|NCT00290758|10149393|FG001|Pre-Intervention rFNA Through Follow-Up|Physician Decision|1
6359929|NCT00290758|10149392|FG000|Pre-Intervention rFNA Through Follow-Up|Lost to Follow-up|1
6359930|NCT00290758|10149393|FG001|Pre-Intervention rFNA Through Follow-Up|Lost to Follow-up|1
6359931|NCT00290758|10149392|FG000|Pre-Intervention rFNA Through Follow-Up|Withdrawal by Subject|0
6359932|NCT00290758|10149393|FG001|Pre-Intervention rFNA Through Follow-Up|Withdrawal by Subject|5
6359933|NCT00290758|10149392|FG000|Pre-Intervention rFNA Through Follow-Up|Medical Contraindication|1
6359934|NCT00290758|10149393|FG001|Pre-Intervention rFNA Through Follow-Up|Medical Contraindication|0
6359935|NCT00290758|10149392|FG000|Pre-Intervention rFNA Through Follow-Up|Non Compliant|0
6359936|NCT00290758|10149393|FG001|Pre-Intervention rFNA Through Follow-Up|Non Compliant|1
6359937|NCT00290758|10149392|FG000|Post Intervention rFNA|<4000 Epithelial Cells|6
6359938|NCT00290758|10149393|FG001|Post Intervention rFNA|<4000 Epithelial Cells|5
6359939|NCT00310388|10149403|FG000|Primary Reporting Phase|Adverse Event|101
6359940|NCT00310388|10149404|FG001|Primary Reporting Phase|Adverse Event|0
6359941|NCT00310388|10149403|FG000|Primary Reporting Phase|Lack of Efficacy|56
6359942|NCT00310388|10149404|FG001|Primary Reporting Phase|Lack of Efficacy|0
6359943|NCT00310388|10149403|FG000|Primary Reporting Phase|Withdrawal by Subject|97
6359944|NCT00310388|10149404|FG001|Primary Reporting Phase|Withdrawal by Subject|0
6359945|NCT00310388|10149403|FG000|Primary Reporting Phase|Protocol Violation|10
6359946|NCT00310388|10149404|FG001|Primary Reporting Phase|Protocol Violation|0
6359947|NCT00310388|10149403|FG000|Primary Reporting Phase|Pregnancy|3
6359948|NCT00310388|10149404|FG001|Primary Reporting Phase|Pregnancy|0
6359949|NCT00310388|10149403|FG000|Primary Reporting Phase|Change in participant medical condition|3
6359950|NCT00310388|10149404|FG001|Primary Reporting Phase|Change in participant medical condition|0
6359951|NCT00310388|10149403|FG000|Primary Reporting Phase|Persistent ALT/AST above 3 times the ULN|3
6084111|NCT00641147|9693084|FG000|Completed 8 Months.|non compliance|1
6084112|NCT00641147|9693085|FG001|Completed 8 Months.|non compliance|0
6084113|NCT00641147|9693084|FG000|Completed 8 Months.|Withdrawal by Subject|0
6170416|NCT01253187|9816721|FG005|Period 3|difficulty with blood sampling|0
6359952|NCT00310388|10149404|FG001|Primary Reporting Phase|Persistent ALT/AST above 3 times the ULN|0
6359953|NCT00310388|10149403|FG000|Primary Reporting Phase|ALT/AST levels above 5 times the ULN|3
6359954|NCT00310388|10149404|FG001|Primary Reporting Phase|ALT/AST levels above 5 times the ULN|0
6359955|NCT00310388|10149403|FG000|Primary Reporting Phase|Physician Decision|2
6359956|NCT00310388|10149404|FG001|Primary Reporting Phase|Physician Decision|0
6359957|NCT00310388|10149403|FG000|Primary Reporting Phase|Request of the sponsor|19
6359958|NCT00310388|10149404|FG001|Primary Reporting Phase|Request of the sponsor|0
6359959|NCT00310388|10149403|FG000|Primary Reporting Phase|Failed to return|8
6359960|NCT00310388|10149404|FG001|Primary Reporting Phase|Failed to return|0
6359961|NCT00310388|10149403|FG000|Primary Reporting Phase|Participant request unrelated to study|2
6359962|NCT00310388|10149404|FG001|Primary Reporting Phase|Participant request unrelated to study|0
6359963|NCT00310388|10149403|FG000|Primary Reporting Phase|Participant request|2
6359964|NCT00310388|10149404|FG001|Primary Reporting Phase|Participant request|0
6359965|NCT00310388|10149403|FG000|Primary Reporting Phase|Ministry of Health decision|25
6359966|NCT00310388|10149404|FG001|Primary Reporting Phase|Ministry of Health decision|0
6359967|NCT00310388|10149403|FG000|Primary Reporting Phase|Discontinuation of study|1
6359968|NCT00310388|10149404|FG001|Primary Reporting Phase|Discontinuation of study|0
6359969|NCT00310388|10149403|FG000|Primary Reporting Phase|Participant Immigrated to New Zealand|1
6359970|NCT00310388|10149404|FG001|Primary Reporting Phase|Participant Immigrated to New Zealand|0
6359971|NCT00310388|10149403|FG000|Primary Reporting Phase|Termination of study at sponsor request|3
6359972|NCT00310388|10149404|FG001|Primary Reporting Phase|Termination of study at sponsor request|0
6359973|NCT00310388|10149403|FG000|Primary Reporting Phase|Ongoing SAE from parent study|1
6359974|NCT00310388|10149404|FG001|Primary Reporting Phase|Ongoing SAE from parent study|0
6084114|NCT00641147|9693085|FG001|Completed 8 Months.|Withdrawal by Subject|1
6359975|NCT00310388|10149403|FG000|Primary Reporting Phase|Due to pigmentation risk concerns|2
6359976|NCT00310388|10149404|FG001|Primary Reporting Phase|Due to pigmentation risk concerns|0
6359977|NCT00310388|10149403|FG000|Primary Reporting Phase|Participant passed away|1
6359978|NCT00310388|10149404|FG001|Primary Reporting Phase|Participant passed away|0
6359979|NCT00310388|10149403|FG000|Primary Reporting Phase|Participant retired the informed consent|1
6359980|NCT00310388|10149404|FG001|Primary Reporting Phase|Participant retired the informed consent|0
6359981|NCT00310388|10149403|FG000|Primary Reporting Phase|Missing|1
6359982|NCT00310388|10149404|FG001|Primary Reporting Phase|Missing|0
6359983|NCT00310388|10149403|FG000|Primary Reporting Phase|Other|1
6359984|NCT00310388|10149404|FG001|Primary Reporting Phase|Other|0
6359985|NCT00310388|10149403|FG000|Safety Follow-up Continuation Phase|Missing SFUCP disposition information|0
6359986|NCT00310388|10149404|FG001|Safety Follow-up Continuation Phase|Missing SFUCP disposition information|5
6359987|NCT00310388|10149403|FG000|Safety Follow-up Continuation Phase|Adverse Event|0
6359988|NCT00310388|10149404|FG001|Safety Follow-up Continuation Phase|Adverse Event|1
6359989|NCT00310388|10149403|FG000|Safety Follow-up Continuation Phase|Withdrawal by Subject|0
6359990|NCT00310388|10149404|FG001|Safety Follow-up Continuation Phase|Withdrawal by Subject|5
6359991|NCT00310388|10149403|FG000|Safety Follow-up Continuation Phase|Study Closed/Terminated|0
6359992|NCT00310388|10149404|FG001|Safety Follow-up Continuation Phase|Study Closed/Terminated|2
6359993|NCT00345358|10149413|FG000|Primary Vaccination Phase|Other|0
6359994|NCT00345358|10149414|FG001|Primary Vaccination Phase|Other|1
6359995|NCT00345358|10149415|FG002|Primary Vaccination Phase|Other|1
6359996|NCT00345358|10149416|FG003|Primary Vaccination Phase|Other|0
6359997|NCT00345358|10149413|FG000|Primary Vaccination Phase|Adverse event, non-fatal|3
6359998|NCT00345358|10149414|FG001|Primary Vaccination Phase|Adverse event, non-fatal|1
6359999|NCT00345358|10149415|FG002|Primary Vaccination Phase|Adverse event, non-fatal|1
6360000|NCT00345358|10149416|FG003|Primary Vaccination Phase|Adverse event, non-fatal|0
6360001|NCT00345358|10149413|FG000|Primary Vaccination Phase|Withdrawal by Subject|1
6360002|NCT00345358|10149414|FG001|Primary Vaccination Phase|Withdrawal by Subject|2
6360003|NCT00345358|10149415|FG002|Primary Vaccination Phase|Withdrawal by Subject|4
6360004|NCT00345358|10149416|FG003|Primary Vaccination Phase|Withdrawal by Subject|0
6360005|NCT00345358|10149413|FG000|Primary Vaccination Phase|Lost to Follow-up|1
6360006|NCT00345358|10149414|FG001|Primary Vaccination Phase|Lost to Follow-up|0
6360007|NCT00345358|10149415|FG002|Primary Vaccination Phase|Lost to Follow-up|2
6360008|NCT00345358|10149416|FG003|Primary Vaccination Phase|Lost to Follow-up|2
6360009|NCT00345358|10149413|FG000|Booster Vaccination Phase|Withdrawal by Subject|1
6360010|NCT00345358|10149414|FG001|Booster Vaccination Phase|Withdrawal by Subject|0
6360011|NCT00345358|10149415|FG002|Booster Vaccination Phase|Withdrawal by Subject|0
6360012|NCT00345358|10149416|FG003|Booster Vaccination Phase|Withdrawal by Subject|0
6360013|NCT00345358|10149413|FG000|Booster Vaccination Phase|Lost to Follow-up|3
6360014|NCT00345358|10149414|FG001|Booster Vaccination Phase|Lost to Follow-up|0
6360015|NCT00345358|10149415|FG002|Booster Vaccination Phase|Lost to Follow-up|0
6360016|NCT00345358|10149416|FG003|Booster Vaccination Phase|Lost to Follow-up|0
6360017|NCT00372229|10149432|FG000|Study Phase|Graft loss|0
6360018|NCT00372229|10149433|FG001|Study Phase|Graft loss|3
6360019|NCT00372229|10149432|FG000|Study Phase|Protocol Violation|3
6360020|NCT00372229|10149433|FG001|Study Phase|Protocol Violation|4
6360021|NCT00372229|10149432|FG000|Study Phase|Consent withdrawn|16
6360022|NCT00372229|10149433|FG001|Study Phase|Consent withdrawn|14
6360023|NCT00372229|10149432|FG000|Study Phase|Refused treatment/did not cooperate|3
6360024|NCT00372229|10149433|FG001|Study Phase|Refused treatment/did not cooperate|1
6360025|NCT00372229|10149432|FG000|Study Phase|Death|3
6360026|NCT00372229|10149433|FG001|Study Phase|Death|2
6360027|NCT00372229|10149432|FG000|Study Phase|Reason not specified|3
6360028|NCT00372229|10149433|FG001|Study Phase|Reason not specified|2
6360029|NCT00372229|10149432|FG000|Study Phase|Lost to Follow-up|3
6360030|NCT00372229|10149433|FG001|Study Phase|Lost to Follow-up|3
6360031|NCT00372229|10149432|FG000|Follow-Up Phase|Graft loss|8
6360032|NCT00372229|10149433|FG001|Follow-Up Phase|Graft loss|7
6360033|NCT00372229|10149432|FG000|Follow-Up Phase|Consent withdrawn|13
6360034|NCT00372229|10149433|FG001|Follow-Up Phase|Consent withdrawn|19
6360035|NCT00372229|10149432|FG000|Follow-Up Phase|Refused treatment/did not cooperate|0
6360036|NCT00372229|10149433|FG001|Follow-Up Phase|Refused treatment/did not cooperate|1
6360037|NCT00372229|10149432|FG000|Follow-Up Phase|Adverse event/intercurrent illness|1
6360038|NCT00372229|10149433|FG001|Follow-Up Phase|Adverse event/intercurrent illness|0
6360039|NCT00372229|10149432|FG000|Follow-Up Phase|Death|9
6360040|NCT00372229|10149433|FG001|Follow-Up Phase|Death|12
6360041|NCT00372229|10149432|FG000|Follow-Up Phase|Administrative|1
6360042|NCT00372229|10149433|FG001|Follow-Up Phase|Administrative|0
6360043|NCT00372229|10149432|FG000|Follow-Up Phase|Reason not specified|2
6360044|NCT00372229|10149433|FG001|Follow-Up Phase|Reason not specified|3
6360045|NCT00372229|10149432|FG000|Follow-Up Phase|Lost to Follow-up|12
6360046|NCT00372229|10149433|FG001|Follow-Up Phase|Lost to Follow-up|10
6360047|NCT00383708|10149443|FG000|Enrolment Through Start Treatment|Withdrawal by Subject|1
6360048|NCT00383708|10149443|FG000|Enrolment Through Start Treatment|Did not meet entry criteria|32
6360049|NCT00383708|10149443|FG000|Run-in Period|Protocol Violation|4
6360050|NCT00383708|10149443|FG000|Run-in Period|Adverse Event|2
6360051|NCT00383708|10149443|FG000|Run-in Period|Claustrophobia|1
6360052|NCT00383708|10149443|FG000|Co-administration Period|Adverse Event|5
6360053|NCT00413699|10149450|FG000|Initial Period|Death|25
6360054|NCT00413699|10149451|FG001|Initial Period|Death|30
6360055|NCT00413699|10149452|FG002|Initial Period|Death|0
6360056|NCT00413699|10149450|FG000|Initial Period|Lack of Efficacy|59
6360057|NCT00413699|10149451|FG001|Initial Period|Lack of Efficacy|115
6360058|NCT00413699|10149452|FG002|Initial Period|Lack of Efficacy|0
6360059|NCT00413699|10149450|FG000|Initial Period|Lost to Follow-up|31
6360060|NCT00413699|10149451|FG001|Initial Period|Lost to Follow-up|101
6360061|NCT00413699|10149452|FG002|Initial Period|Lost to Follow-up|0
6360062|NCT00413699|10149450|FG000|Initial Period|Protocol Violation|38
6360063|NCT00413699|10149451|FG001|Initial Period|Protocol Violation|89
6360064|NCT00413699|10149452|FG002|Initial Period|Protocol Violation|0
6360065|NCT00413699|10149450|FG000|Initial Period|Pregnancy|10
6360066|NCT00413699|10149451|FG001|Initial Period|Pregnancy|8
6360067|NCT00413699|10149452|FG002|Initial Period|Pregnancy|0
6360068|NCT00413699|10149450|FG000|Initial Period|Did not meet entrance criteria|2
6360069|NCT00413699|10149451|FG001|Initial Period|Did not meet entrance criteria|2
6360070|NCT00413699|10149452|FG002|Initial Period|Did not meet entrance criteria|0
6360071|NCT00413699|10149450|FG000|Initial Period|Medication error without adverse event|0
6360072|NCT00413699|10149451|FG001|Initial Period|Medication error without adverse event|1
6360073|NCT00413699|10149452|FG002|Initial Period|Medication error without adverse event|0
6360074|NCT00413699|10149450|FG000|Initial Period|Study terminated by Sponsor|0
6360075|NCT00413699|10149451|FG001|Initial Period|Study terminated by Sponsor|1
6360076|NCT00413699|10149452|FG002|Initial Period|Study terminated by Sponsor|0
6360077|NCT00413699|10149450|FG000|Initial Period|Other|67
6360078|NCT00413699|10149451|FG001|Initial Period|Other|211
6360079|NCT00413699|10149452|FG002|Initial Period|Other|0
6360080|NCT00413699|10149450|FG000|Initial Period|Adverse event related to study drug|178
6360081|NCT00413699|10149451|FG001|Initial Period|Adverse event related to study drug|527
6360082|NCT00413699|10149452|FG002|Initial Period|Adverse event related to study drug|0
6360083|NCT00413699|10149450|FG000|Initial Period|Adverse event not related to study drug|113
6360084|NCT00413699|10149451|FG001|Initial Period|Adverse event not related to study drug|248
6360085|NCT00413699|10149452|FG002|Initial Period|Adverse event not related to study drug|0
6360086|NCT00413699|10149450|FG000|Initial Period|Missing end of study page|0
6360087|NCT00413699|10149451|FG001|Initial Period|Missing end of study page|4
6360088|NCT00413699|10149452|FG002|Initial Period|Missing end of study page|0
6360089|NCT00413699|10149450|FG000|Initial Period|No longer willing to participate|116
6360090|NCT00413699|10149451|FG001|Initial Period|No longer willing to participate|368
6170417|NCT01253187|9816716|FG000|Period 3|non-compliance|0
6170418|NCT01253187|9816717|FG001|Period 3|non-compliance|0
6170419|NCT01253187|9816718|FG002|Period 3|non-compliance|0
6170420|NCT01253187|9816719|FG003|Period 3|non-compliance|0
6360091|NCT00413699|10149452|FG002|Initial Period|No longer willing to participate|0
6360092|NCT00413699|10149450|FG000|Extension Period|No Longer Willing to Participate|0
6360093|NCT00413699|10149451|FG001|Extension Period|No Longer Willing to Participate|0
6360094|NCT00413699|10149452|FG002|Extension Period|No Longer Willing to Participate|2
6360095|NCT00413699|10149450|FG000|Extension Period|Protocol Violation|0
6360096|NCT00413699|10149451|FG001|Extension Period|Protocol Violation|0
6360097|NCT00413699|10149452|FG002|Extension Period|Protocol Violation|1
6360098|NCT00413699|10149450|FG000|Extension Period|Adverse Event|0
6360099|NCT00413699|10149451|FG001|Extension Period|Adverse Event|0
6360100|NCT00413699|10149452|FG002|Extension Period|Adverse Event|2
6170421|NCT01253187|9816720|FG004|Period 3|non-compliance|1
6170422|NCT01253187|9816721|FG005|Period 3|non-compliance|0
6170423|NCT01253200|9816737|FG000|Overall Study|Death|1
6360101|NCT00436826|10149490|FG000|Double Blind Period (DBP)|Adverse Event|2
6170424|NCT01253200|9816738|FG001|Overall Study|Death|0
6170425|NCT01253200|9816739|FG002|Overall Study|Death|0
6170426|NCT01253200|9816740|FG003|Overall Study|Death|0
6170427|NCT01253200|9816741|FG004|Overall Study|Death|0
6170428|NCT01253200|9816737|FG000|Overall Study|Lost to Follow-up|1
6170429|NCT01253200|9816738|FG001|Overall Study|Lost to Follow-up|1
6170430|NCT01253200|9816739|FG002|Overall Study|Lost to Follow-up|0
6170431|NCT01253200|9816740|FG003|Overall Study|Lost to Follow-up|0
6170432|NCT01253200|9816741|FG004|Overall Study|Lost to Follow-up|0
6170433|NCT01253200|9816737|FG000|Overall Study|Withdrawal by Subject|2
6170434|NCT01253200|9816738|FG001|Overall Study|Withdrawal by Subject|0
6170435|NCT01253200|9816739|FG002|Overall Study|Withdrawal by Subject|0
6170436|NCT01253200|9816740|FG003|Overall Study|Withdrawal by Subject|0
6170437|NCT01253200|9816741|FG004|Overall Study|Withdrawal by Subject|0
6170438|NCT01253200|9816737|FG000|Overall Study|Protocol Violation|1
6170439|NCT01253200|9816738|FG001|Overall Study|Protocol Violation|4
6360102|NCT00436826|10149491|FG001|Double Blind Period (DBP)|Adverse Event|0
6360103|NCT00436826|10149492|FG002|Double Blind Period (DBP)|Adverse Event|0
6360104|NCT00436826|10149493|FG003|Double Blind Period (DBP)|Adverse Event|0
6360105|NCT00436826|10149494|FG004|Double Blind Period (DBP)|Adverse Event|0
6360106|NCT00436826|10149495|FG005|Double Blind Period (DBP)|Adverse Event|0
6360107|NCT00436826|10149490|FG000|Double Blind Period (DBP)|Protocol Violation|1
6360108|NCT00436826|10149491|FG001|Double Blind Period (DBP)|Protocol Violation|0
6360109|NCT00436826|10149492|FG002|Double Blind Period (DBP)|Protocol Violation|0
6360110|NCT00436826|10149493|FG003|Double Blind Period (DBP)|Protocol Violation|0
6360111|NCT00436826|10149494|FG004|Double Blind Period (DBP)|Protocol Violation|0
6360112|NCT00436826|10149495|FG005|Double Blind Period (DBP)|Protocol Violation|0
6360113|NCT00436826|10149490|FG000|Double Blind Period (DBP)|Other|10
6360114|NCT00436826|10149491|FG001|Double Blind Period (DBP)|Other|11
6360115|NCT00436826|10149492|FG002|Double Blind Period (DBP)|Other|0
6360116|NCT00436826|10149493|FG003|Double Blind Period (DBP)|Other|0
6360117|NCT00436826|10149494|FG004|Double Blind Period (DBP)|Other|0
6360118|NCT00436826|10149495|FG005|Double Blind Period (DBP)|Other|0
6360119|NCT00436826|10149490|FG000|Ext. Period (With Cladribine Treatment)|Lost to Follow-up|0
6360120|NCT00436826|10149491|FG001|Ext. Period (With Cladribine Treatment)|Lost to Follow-up|0
6360121|NCT00436826|10149492|FG002|Ext. Period (With Cladribine Treatment)|Lost to Follow-up|0
6360122|NCT00436826|10149493|FG003|Ext. Period (With Cladribine Treatment)|Lost to Follow-up|1
6360123|NCT00436826|10149494|FG004|Ext. Period (With Cladribine Treatment)|Lost to Follow-up|0
6360124|NCT00436826|10149495|FG005|Ext. Period (With Cladribine Treatment)|Lost to Follow-up|0
6360125|NCT00436826|10149490|FG000|Ext. Period (With Cladribine Treatment)|Other un-specified|0
6360126|NCT00436826|10149491|FG001|Ext. Period (With Cladribine Treatment)|Other un-specified|0
6360127|NCT00436826|10149492|FG002|Ext. Period (With Cladribine Treatment)|Other un-specified|46
6360128|NCT00436826|10149493|FG003|Ext. Period (With Cladribine Treatment)|Other un-specified|25
6360129|NCT00436826|10149494|FG004|Ext. Period (With Cladribine Treatment)|Other un-specified|0
6360130|NCT00436826|10149495|FG005|Ext. Period (With Cladribine Treatment)|Other un-specified|0
6360131|NCT00436826|10149490|FG000|Ext. Period (No Cladribine Treatment)|Sponsor's decision to terminate study|0
6360132|NCT00436826|10149491|FG001|Ext. Period (No Cladribine Treatment)|Sponsor's decision to terminate study|0
6360133|NCT00436826|10149492|FG002|Ext. Period (No Cladribine Treatment)|Sponsor's decision to terminate study|0
6360134|NCT00436826|10149493|FG003|Ext. Period (No Cladribine Treatment)|Sponsor's decision to terminate study|0
6360135|NCT00436826|10149494|FG004|Ext. Period (No Cladribine Treatment)|Sponsor's decision to terminate study|51
6360136|NCT00436826|10149495|FG005|Ext. Period (No Cladribine Treatment)|Sponsor's decision to terminate study|7
6360137|NCT00442546|10149514|FG000|Overall Study|Adverse Event|11
6360138|NCT00442546|10149515|FG001|Overall Study|Adverse Event|17
6360139|NCT00442546|10149516|FG002|Overall Study|Adverse Event|13
6360140|NCT00442546|10149514|FG000|Overall Study|Lost to Follow-up|1
6360141|NCT00442546|10149515|FG001|Overall Study|Lost to Follow-up|2
6360142|NCT00442546|10149516|FG002|Overall Study|Lost to Follow-up|1
6360143|NCT00442546|10149514|FG000|Overall Study|Other|4
6360144|NCT00442546|10149515|FG001|Overall Study|Other|9
6360145|NCT00442546|10149516|FG002|Overall Study|Other|6
6170440|NCT01253200|9816739|FG002|Overall Study|Protocol Violation|0
6170441|NCT01253200|9816740|FG003|Overall Study|Protocol Violation|0
6170442|NCT01253200|9816741|FG004|Overall Study|Protocol Violation|5
6170443|NCT01253200|9816737|FG000|Overall Study|intents|10
6170444|NCT01253200|9816738|FG001|Overall Study|intents|10
6170445|NCT01253200|9816739|FG002|Overall Study|intents|1
6170446|NCT01253200|9816740|FG003|Overall Study|intents|3
6360146|NCT00442546|10149514|FG000|Overall Study|Withdrawal by Subject|5
6360147|NCT00442546|10149515|FG001|Overall Study|Withdrawal by Subject|5
6360148|NCT00442546|10149516|FG002|Overall Study|Withdrawal by Subject|7
6360149|NCT00442546|10149514|FG000|Overall Study|Randomized But Not Treated|5
6360150|NCT00442546|10149515|FG001|Overall Study|Randomized But Not Treated|4
6360151|NCT00442546|10149516|FG002|Overall Study|Randomized But Not Treated|6
6360152|NCT04715932|10149528|FG000|Overall Study|Lost to Follow-up|1
6360153|NCT04715932|10149529|FG001|Overall Study|Lost to Follow-up|0
6360154|NCT04666441|10149543|FG000|Overall Study|Lost to Follow-up|1
6360155|NCT04666441|10149544|FG001|Overall Study|Lost to Follow-up|4
6360156|NCT04666441|10149545|FG002|Overall Study|Lost to Follow-up|1
6360157|NCT04666441|10149546|FG003|Overall Study|Lost to Follow-up|3
6360158|NCT04666441|10149547|FG004|Overall Study|Lost to Follow-up|0
6360159|NCT04666441|10149548|FG005|Overall Study|Lost to Follow-up|2
6360160|NCT04666441|10149549|FG006|Overall Study|Lost to Follow-up|2
6360161|NCT04666441|10149550|FG007|Overall Study|Lost to Follow-up|2
6360162|NCT04666441|10149543|FG000|Overall Study|Subject Decision|1
6360163|NCT04666441|10149544|FG001|Overall Study|Subject Decision|1
6360164|NCT04666441|10149545|FG002|Overall Study|Subject Decision|3
6360165|NCT04666441|10149546|FG003|Overall Study|Subject Decision|1
6360166|NCT04666441|10149547|FG004|Overall Study|Subject Decision|0
6360167|NCT04666441|10149548|FG005|Overall Study|Subject Decision|1
6360168|NCT04666441|10149549|FG006|Overall Study|Subject Decision|3
6360169|NCT04666441|10149550|FG007|Overall Study|Subject Decision|2
6360170|NCT04259346|10149604|FG000|Overall Study|Lost to Follow-up|1
6360171|NCT04259346|10149605|FG001|Overall Study|Lost to Follow-up|3
6360172|NCT04259346|10149604|FG000|Overall Study|Protocol Violation|1
6360173|NCT04259346|10149605|FG001|Overall Study|Protocol Violation|0
6360174|NCT04259346|10149604|FG000|Overall Study|Withdrawal by Subject|1
6360175|NCT04259346|10149605|FG001|Overall Study|Withdrawal by Subject|0
6360176|NCT04259346|10149604|FG000|Overall Study|Adverse Event|1
6360177|NCT04259346|10149605|FG001|Overall Study|Adverse Event|1
6360178|NCT03959423|10149613|FG000|Overall Study|Withdrawal by Subject|2
6360179|NCT03959423|10149614|FG001|Overall Study|Withdrawal by Subject|3
6360180|NCT03959423|10149613|FG000|Overall Study|Physician Decision|0
6360181|NCT03959423|10149614|FG001|Overall Study|Physician Decision|1
6360182|NCT03959423|10149613|FG000|Overall Study|Lost to Follow-up|1
6360183|NCT03959423|10149614|FG001|Overall Study|Lost to Follow-up|0
6360184|NCT03959423|10149613|FG000|Overall Study|Withdrawal by Parent/Guardian|6
6360185|NCT03959423|10149614|FG001|Overall Study|Withdrawal by Parent/Guardian|0
6360186|NCT03713320|10149622|FG000|Randomized Period|Adverse Event|1
6360187|NCT03713320|10149623|FG001|Randomized Period|Adverse Event|5
6360188|NCT03713320|10149624|FG002|Randomized Period|Adverse Event|0
6360189|NCT03713320|10149622|FG000|Randomized Period|Physician Decision|1
6360190|NCT03713320|10149623|FG001|Randomized Period|Physician Decision|1
6360191|NCT03713320|10149624|FG002|Randomized Period|Physician Decision|0
6360192|NCT03713320|10149622|FG000|Randomized Period|Withdrawal by Subject|4
6360193|NCT03713320|10149623|FG001|Randomized Period|Withdrawal by Subject|0
6360194|NCT03713320|10149624|FG002|Randomized Period|Withdrawal by Subject|0
6360195|NCT03713320|10149622|FG000|Randomized Period|Participant decision|3
6360196|NCT03713320|10149623|FG001|Randomized Period|Participant decision|1
6360197|NCT03713320|10149624|FG002|Randomized Period|Participant decision|0
6360198|NCT03713320|10149622|FG000|Randomized Period|Study terminated by sponsor|6
6360199|NCT03713320|10149623|FG001|Randomized Period|Study terminated by sponsor|3
6360200|NCT03713320|10149624|FG002|Randomized Period|Study terminated by sponsor|0
6360201|NCT03713320|10149622|FG000|Cobomarsen Crossover Period|Physician Decision|0
6360202|NCT03713320|10149623|FG001|Cobomarsen Crossover Period|Physician Decision|0
6360203|NCT03713320|10149624|FG002|Cobomarsen Crossover Period|Physician Decision|2
6360204|NCT03713320|10149622|FG000|Cobomarsen Crossover Period|Sponsor Decision to terminate trial|0
6360205|NCT03713320|10149623|FG001|Cobomarsen Crossover Period|Sponsor Decision to terminate trial|0
6360206|NCT03713320|10149624|FG002|Cobomarsen Crossover Period|Sponsor Decision to terminate trial|5
6360207|NCT03429049|10149633|FG000|Overall Study|Adverse Event|2
6360208|NCT03429049|10149634|FG001|Overall Study|Adverse Event|3
6360209|NCT03429049|10149633|FG000|Overall Study|Death|0
6360210|NCT03429049|10149634|FG001|Overall Study|Death|1
6360211|NCT03429049|10149633|FG000|Overall Study|Lack of Efficacy|4
6360212|NCT03429049|10149634|FG001|Overall Study|Lack of Efficacy|2
6360213|NCT03429049|10149633|FG000|Overall Study|Lost to Follow-up|9
6360214|NCT03429049|10149634|FG001|Overall Study|Lost to Follow-up|8
6360215|NCT03429049|10149633|FG000|Overall Study|Physician Decision|1
6360216|NCT03429049|10149634|FG001|Overall Study|Physician Decision|0
6360217|NCT03429049|10149633|FG000|Overall Study|Protocol Violation|3
6360218|NCT03429049|10149634|FG001|Overall Study|Protocol Violation|0
6360219|NCT03429049|10149633|FG000|Overall Study|Sponsor Decision|2
6360220|NCT03429049|10149634|FG001|Overall Study|Sponsor Decision|0
6360221|NCT03429049|10149633|FG000|Overall Study|Withdrawal by Subject|4
6360222|NCT03429049|10149634|FG001|Overall Study|Withdrawal by Subject|20
6360223|NCT03429049|10149633|FG000|Overall Study|Other reasons: UNABLE TO ADMINISTER IP, COLLECT ASPIRATE|3
6360224|NCT03429049|10149634|FG001|Overall Study|Other reasons: UNABLE TO ADMINISTER IP, COLLECT ASPIRATE|8
6360225|NCT03409731|10149640|FG000|Overall Study|Withdrawal by Subject|1
6360226|NCT03409731|10149640|FG000|Overall Study|Death|2
6360227|NCT03283566|10149646|FG000|Overall Study|Lost to Follow-up|1
6360228|NCT03283566|10149647|FG001|Overall Study|Lost to Follow-up|2
6360229|NCT03077412|10149656|FG000|Overall Study|Non-Responder [Crohn's Disease Activity Index (CDAI) and Perianal CDAI non-response] at Week 10|1
6360230|NCT03077412|10149657|FG001|Overall Study|Non-Responder [Crohn's Disease Activity Index (CDAI) and Perianal CDAI non-response] at Week 10|5
6360231|NCT03077412|10149658|FG002|Overall Study|Non-Responder [Crohn's Disease Activity Index (CDAI) and Perianal CDAI non-response] at Week 10|3
6360232|NCT03077412|10149656|FG000|Overall Study|Protocol-Specified Disease Worsening|1
6360233|NCT03077412|10149657|FG001|Overall Study|Protocol-Specified Disease Worsening|3
6360234|NCT03077412|10149658|FG002|Overall Study|Protocol-Specified Disease Worsening|3
6360235|NCT03077412|10149656|FG000|Overall Study|Adverse Event|1
6360236|NCT03077412|10149657|FG001|Overall Study|Adverse Event|2
6360237|NCT03077412|10149658|FG002|Overall Study|Adverse Event|2
6360238|NCT03077412|10149656|FG000|Overall Study|Investigator's Discretion|0
6360239|NCT03077412|10149657|FG001|Overall Study|Investigator's Discretion|1
6360240|NCT03077412|10149658|FG002|Overall Study|Investigator's Discretion|1
6360241|NCT03077412|10149656|FG000|Overall Study|Withdrew Consent|0
6360242|NCT03077412|10149657|FG001|Overall Study|Withdrew Consent|2
6360243|NCT03077412|10149658|FG002|Overall Study|Withdrew Consent|0
6360244|NCT02384850|10149703|FG000|Overall Study|Withdrawal by Subject|2
6360245|NCT02384850|10149704|FG001|Overall Study|Withdrawal by Subject|2
6360246|NCT02352090|10149713|FG000|Overall Study|general malaise|1
6360247|NCT02352090|10149714|FG001|Overall Study|general malaise|0
6360248|NCT02352090|10149715|FG002|Overall Study|general malaise|0
5972129|NCT04498247|9557784|FG000|Overall Study|Lost to Follow-up|0
6360249|NCT02352090|10149713|FG000|Overall Study|non-specified mild side-effects|0
6360250|NCT02352090|10149714|FG001|Overall Study|non-specified mild side-effects|0
6360251|NCT02352090|10149715|FG002|Overall Study|non-specified mild side-effects|2
6360252|NCT01078662|10149750|FG000|Overall Study|Death|41
6360253|NCT01078662|10149751|FG001|Overall Study|Death|103
6360254|NCT01078662|10149752|FG002|Overall Study|Death|18
6360255|NCT01078662|10149753|FG003|Overall Study|Death|5
6360256|NCT01078662|10149754|FG004|Overall Study|Death|8
6360257|NCT01078662|10149750|FG000|Overall Study|Patients reached data cut-off|12
6360258|NCT01078662|10149751|FG001|Overall Study|Patients reached data cut-off|53
6360259|NCT01078662|10149752|FG002|Overall Study|Patients reached data cut-off|2
6360260|NCT01078662|10149753|FG003|Overall Study|Patients reached data cut-off|2
6360261|NCT01078662|10149754|FG004|Overall Study|Patients reached data cut-off|3
6360262|NCT01078662|10149750|FG000|Overall Study|Withdrawal by Subject|4
6360263|NCT01078662|10149751|FG001|Overall Study|Withdrawal by Subject|11
6360264|NCT01078662|10149752|FG002|Overall Study|Withdrawal by Subject|1
6360265|NCT01078662|10149753|FG003|Overall Study|Withdrawal by Subject|0
6360266|NCT01078662|10149754|FG004|Overall Study|Withdrawal by Subject|0
6360267|NCT01078662|10149750|FG000|Overall Study|Protocol Violation|0
6360268|NCT01078662|10149751|FG001|Overall Study|Protocol Violation|1
6360269|NCT01078662|10149752|FG002|Overall Study|Protocol Violation|0
6360270|NCT01078662|10149753|FG003|Overall Study|Protocol Violation|0
6360271|NCT01078662|10149754|FG004|Overall Study|Protocol Violation|0
6360272|NCT01078662|10149750|FG000|Overall Study|Lost to Follow-up|1
6360273|NCT01078662|10149751|FG001|Overall Study|Lost to Follow-up|0
6360274|NCT01078662|10149752|FG002|Overall Study|Lost to Follow-up|0
6360275|NCT01078662|10149753|FG003|Overall Study|Lost to Follow-up|0
6360276|NCT01078662|10149754|FG004|Overall Study|Lost to Follow-up|0
6360277|NCT00971867|10149763|FG000|Overall Study|Adverse Event|4
6360278|NCT00971867|10149763|FG000|Overall Study|Participant Withdrew Consent|1
6360279|NCT00971867|10149763|FG000|Overall Study|Disease Progression|6
6360280|NCT00853307|10149769|FG000|Overall Study|Adverse Event|1
6360281|NCT00853307|10149770|FG001|Overall Study|Adverse Event|2
6360282|NCT00853307|10149769|FG000|Overall Study|Withdrawal by Subject|1
6360283|NCT00853307|10149770|FG001|Overall Study|Withdrawal by Subject|2
6360284|NCT00853307|10149769|FG000|Overall Study|Reason Not Specified|0
6360285|NCT00853307|10149770|FG001|Overall Study|Reason Not Specified|1
6360286|NCT00545129|10149784|FG000|Overall Study|Lack of Efficacy|2
6360287|NCT00545129|10149785|FG001|Overall Study|Lack of Efficacy|5
6360288|NCT00545129|10149784|FG000|Overall Study|Death|2
6360289|NCT00545129|10149785|FG001|Overall Study|Death|1
6360290|NCT00545129|10149784|FG000|Overall Study|Adverse Event|1
6360291|NCT00545129|10149785|FG001|Overall Study|Adverse Event|1
6360292|NCT00545129|10149784|FG000|Overall Study|Rollover to Study A4091029 (NCT00830180)|9
6360293|NCT00545129|10149785|FG001|Overall Study|Rollover to Study A4091029 (NCT00830180)|14
6360294|NCT00545129|10149784|FG000|Overall Study|Other|3
6360295|NCT00545129|10149785|FG001|Overall Study|Other|3
6360308|NCT00554606|10149803|FG000|Overall Study|Adverse Event|3
6360309|NCT00554606|10149803|FG000|Overall Study|Abnormal laboratory values|1
6360310|NCT00554606|10149803|FG000|Overall Study|Unsatisfactory therapeutic effect|14
6360311|NCT00554606|10149803|FG000|Overall Study|Subject withdrew consent|2
6360312|NCT00554606|10149803|FG000|Overall Study|Lost to Follow-up|2
6360313|NCT00554606|10149803|FG000|Overall Study|Administrative problems|60
6360314|NCT00554606|10149803|FG000|Overall Study|Death|1
6360315|NCT00554606|10149803|FG000|Overall Study|Protocol deviation|2
6360316|NCT00555009|10149811|FG000|Overall Study|Withdrawal by Subject|0
6360317|NCT00555009|10149812|FG001|Overall Study|Withdrawal by Subject|1
6360318|NCT00555009|10149811|FG000|Overall Study|Terminated by Sponsor|2
6360319|NCT00555009|10149812|FG001|Overall Study|Terminated by Sponsor|5
6360320|NCT00566995|10149841|FG000|Overall Study|Toxicity|4
6360321|NCT00566995|10149841|FG000|Overall Study|Withdrew consent|3
6360322|NCT00586924|10149851|FG000|Overall Study|Adverse event/serious adverse event|0
6360323|NCT00586924|10149852|FG001|Overall Study|Adverse event/serious adverse event|0
6360324|NCT00586924|10149853|FG002|Overall Study|Adverse event/serious adverse event|0
6360325|NCT00586924|10149854|FG003|Overall Study|Adverse event/serious adverse event|1
6360326|NCT00586924|10149855|FG004|Overall Study|Adverse event/serious adverse event|0
6170447|NCT01253200|9816741|FG004|Overall Study|intents|0
6170448|NCT01253200|9816737|FG000|Overall Study|Attempts|6
6170449|NCT01253200|9816738|FG001|Overall Study|Attempts|4
6360327|NCT00586924|10149856|FG005|Overall Study|Adverse event/serious adverse event|2
6360328|NCT00586924|10149851|FG000|Overall Study|Initiation of alternative cancer therapy|0
6360329|NCT00586924|10149852|FG001|Overall Study|Initiation of alternative cancer therapy|0
6360330|NCT00586924|10149853|FG002|Overall Study|Initiation of alternative cancer therapy|0
6360331|NCT00586924|10149854|FG003|Overall Study|Initiation of alternative cancer therapy|0
6360332|NCT00586924|10149855|FG004|Overall Study|Initiation of alternative cancer therapy|0
6360333|NCT00586924|10149856|FG005|Overall Study|Initiation of alternative cancer therapy|1
6360334|NCT00586924|10149851|FG000|Overall Study|Disease progression|0
6360335|NCT00586924|10149852|FG001|Overall Study|Disease progression|0
6360336|NCT00586924|10149853|FG002|Overall Study|Disease progression|0
6360337|NCT00586924|10149854|FG003|Overall Study|Disease progression|1
6360338|NCT00586924|10149855|FG004|Overall Study|Disease progression|1
6360339|NCT00586924|10149856|FG005|Overall Study|Disease progression|0
6360340|NCT00586924|10149851|FG000|Overall Study|Development of neutralizing antibodies|2
6360341|NCT00586924|10149852|FG001|Overall Study|Development of neutralizing antibodies|2
6360342|NCT00586924|10149853|FG002|Overall Study|Development of neutralizing antibodies|2
6360343|NCT00586924|10149854|FG003|Overall Study|Development of neutralizing antibodies|0
6360344|NCT00586924|10149855|FG004|Overall Study|Development of neutralizing antibodies|0
6360345|NCT00586924|10149856|FG005|Overall Study|Development of neutralizing antibodies|22
6360346|NCT00586924|10149851|FG000|Overall Study|Complete response|0
6360347|NCT00586924|10149852|FG001|Overall Study|Complete response|1
6360348|NCT00586924|10149853|FG002|Overall Study|Complete response|0
6360349|NCT00586924|10149854|FG003|Overall Study|Complete response|0
6360350|NCT00586924|10149855|FG004|Overall Study|Complete response|2
6360351|NCT00586924|10149856|FG005|Overall Study|Complete response|2
6360352|NCT00586924|10149851|FG000|Overall Study|Other|1
6360353|NCT00586924|10149852|FG001|Overall Study|Other|0
6360354|NCT00586924|10149853|FG002|Overall Study|Other|1
6360355|NCT00586924|10149854|FG003|Overall Study|Other|1
6360356|NCT00586924|10149855|FG004|Overall Study|Other|1
6360357|NCT00586924|10149856|FG005|Overall Study|Other|6
6360358|NCT00588861|10149872|FG000|Pre-Operative|Patients Did Not Complete Preop Data|95
6360359|NCT00588861|10149873|FG001|Pre-Operative|Patients Did Not Complete Preop Data|86
6360360|NCT00588861|10149872|FG000|6 Months|Patients did not return for follow-up|98
6360361|NCT00588861|10149873|FG001|6 Months|Patients did not return for follow-up|73
6360362|NCT00588861|10149872|FG000|1 Year|Patients did not return for follow-up|89
6360363|NCT00588861|10149873|FG001|1 Year|Patients did not return for follow-up|82
6360364|NCT00588861|10149872|FG000|2 Years|Patients did not return for follow-up|92
6360365|NCT00588861|10149873|FG001|2 Years|Patients did not return for follow-up|87
6360366|NCT00588861|10149872|FG000|4 Years|Patients did not return for follow-up|91
6360367|NCT00588861|10149873|FG001|4 Years|Patients did not return for follow-up|103
6360368|NCT00588861|10149872|FG000|6 Years|Patients did not return for follow-up|104
6360369|NCT00588861|10149873|FG001|6 Years|Patients did not return for follow-up|109
6360370|NCT00588861|10149872|FG000|8 Years|Patients did not return for follow-up|105
6360371|NCT00588861|10149873|FG001|8 Years|Patients did not return for follow-up|114
6360372|NCT00588861|10149872|FG000|10 Years|Incomplete due to study termination|107
6360373|NCT00588861|10149873|FG001|10 Years|Incomplete due to study termination|114
6360374|NCT04505722|10149881|FG000|Overall Study|Adverse Event|1
6170450|NCT01253200|9816739|FG002|Overall Study|Attempts|1
6360296|NCT00548093|10149793|FG000|Overall Study|Death|33
6360297|NCT00548093|10149794|FG001|Overall Study|Death|13
6360298|NCT00548093|10149793|FG000|Overall Study|Lost to Follow-up|3
6360299|NCT00548093|10149794|FG001|Overall Study|Lost to Follow-up|1
6360300|NCT00548093|10149793|FG000|Overall Study|Objective progression or relapse|1
6360301|NCT00548093|10149794|FG001|Overall Study|Objective progression or relapse|1
6360302|NCT00548093|10149793|FG000|Overall Study|Other|11
6360303|NCT00548093|10149794|FG001|Overall Study|Other|1
6360304|NCT00548093|10149793|FG000|Overall Study|Withdrawal by Subject|1
6360305|NCT00548093|10149794|FG001|Overall Study|Withdrawal by Subject|0
6360306|NCT00548093|10149793|FG000|Overall Study|Completed post-treatment follow-up|1
6360307|NCT00548093|10149794|FG001|Overall Study|Completed post-treatment follow-up|0
6360375|NCT04505722|10149882|FG001|Overall Study|Adverse Event|2
6360376|NCT04505722|10149881|FG000|Overall Study|Death|34
6360377|NCT04505722|10149882|FG001|Overall Study|Death|63
6360378|NCT04505722|10149881|FG000|Overall Study|Lost to Follow-up|271
6360379|NCT04505722|10149882|FG001|Overall Study|Lost to Follow-up|333
6360380|NCT04505722|10149881|FG000|Overall Study|Physician Decision|17
6170451|NCT01253200|9816740|FG003|Overall Study|Attempts|2
6170452|NCT01253200|9816741|FG004|Overall Study|Attempts|0
6170453|NCT01253226|9816755|FG000|Overall Study|Adverse Event|0
6170454|NCT01253226|9816756|FG001|Overall Study|Adverse Event|0
6170455|NCT01253226|9816757|FG002|Overall Study|Adverse Event|1
6170456|NCT01253226|9816758|FG003|Overall Study|Adverse Event|0
6170457|NCT01253226|9816759|FG004|Overall Study|Adverse Event|0
6360381|NCT04505722|10149882|FG001|Overall Study|Physician Decision|17
6360382|NCT04505722|10149881|FG000|Overall Study|Protocol Violation|0
6360383|NCT04505722|10149882|FG001|Overall Study|Protocol Violation|1
6360384|NCT04505722|10149881|FG000|Overall Study|Withdrawal by Subject|376
6360385|NCT04505722|10149882|FG001|Overall Study|Withdrawal by Subject|714
6360386|NCT04505722|10149881|FG000|Overall Study|Other|61
6360387|NCT04505722|10149882|FG001|Overall Study|Other|98
6360388|NCT04505722|10149881|FG000|Overall Study|Still ongoing|21138
6360389|NCT04505722|10149882|FG001|Overall Study|Still ongoing|20662
6360390|NCT04505722|10149881|FG000|Overall Study|Randomized not vaccinated|276
6360391|NCT04505722|10149882|FG001|Overall Study|Randomized not vaccinated|260
6170458|NCT01253226|9816755|FG000|Overall Study|Death|0
6360392|NCT03400943|10149892|FG000|Treatment Period 1|Adverse Event|0
6360393|NCT03400943|10149893|FG001|Treatment Period 1|Adverse Event|0
6360394|NCT03400943|10149894|FG002|Treatment Period 1|Adverse Event|0
6360395|NCT03400943|10149895|FG003|Treatment Period 1|Adverse Event|1
6360396|NCT03400943|10149892|FG000|Treatment Period 1|Lost to Follow-up|1
6360397|NCT03400943|10149893|FG001|Treatment Period 1|Lost to Follow-up|0
6360398|NCT03400943|10149894|FG002|Treatment Period 1|Lost to Follow-up|0
6170459|NCT01253226|9816756|FG001|Overall Study|Death|1
6170460|NCT01253226|9816757|FG002|Overall Study|Death|0
6170461|NCT01253226|9816758|FG003|Overall Study|Death|0
6170462|NCT01253226|9816759|FG004|Overall Study|Death|0
6170463|NCT01253226|9816755|FG000|Overall Study|Physician Decision|0
6170464|NCT01253226|9816756|FG001|Overall Study|Physician Decision|0
6170465|NCT01253226|9816757|FG002|Overall Study|Physician Decision|0
6170466|NCT01253226|9816758|FG003|Overall Study|Physician Decision|0
6170467|NCT01253226|9816759|FG004|Overall Study|Physician Decision|2
6170468|NCT01253226|9816755|FG000|Overall Study|Withdrawal by Subject|0
6170469|NCT01253226|9816756|FG001|Overall Study|Withdrawal by Subject|0
6170470|NCT01253226|9816757|FG002|Overall Study|Withdrawal by Subject|0
6170471|NCT01253226|9816758|FG003|Overall Study|Withdrawal by Subject|1
6170472|NCT01253226|9816759|FG004|Overall Study|Withdrawal by Subject|0
6170473|NCT01253265|9816776|FG000|Overall Study|Met Predefined Discontinuation Criteria|1
6360399|NCT03400943|10149895|FG003|Treatment Period 1|Lost to Follow-up|0
6360400|NCT03400943|10149892|FG000|Treatment Period 1|Protocol Violation|0
6360401|NCT03400943|10149893|FG001|Treatment Period 1|Protocol Violation|1
6360402|NCT03400943|10149894|FG002|Treatment Period 1|Protocol Violation|1
6360403|NCT03400943|10149895|FG003|Treatment Period 1|Protocol Violation|0
6360404|NCT03400943|10149892|FG000|Treatment Period 1|Study terminated by sponsor|2
6360405|NCT03400943|10149893|FG001|Treatment Period 1|Study terminated by sponsor|0
6360406|NCT03400943|10149894|FG002|Treatment Period 1|Study terminated by sponsor|0
6360407|NCT03400943|10149895|FG003|Treatment Period 1|Study terminated by sponsor|1
6360408|NCT03400943|10149892|FG000|Treatment Period 1|Withdrawal by Subject|0
6360409|NCT03400943|10149893|FG001|Treatment Period 1|Withdrawal by Subject|0
6360410|NCT03400943|10149894|FG002|Treatment Period 1|Withdrawal by Subject|3
6360411|NCT03400943|10149895|FG003|Treatment Period 1|Withdrawal by Subject|1
6360412|NCT03400943|10149892|FG000|Treatment Period 1|Other|2
6360413|NCT03400943|10149893|FG001|Treatment Period 1|Other|1
6360414|NCT03400943|10149894|FG002|Treatment Period 1|Other|2
6360415|NCT03400943|10149895|FG003|Treatment Period 1|Other|2
6360416|NCT03400943|10149892|FG000|Post-treatment Period 1|Adverse Event|2
6360417|NCT03400943|10149893|FG001|Post-treatment Period 1|Adverse Event|0
6360418|NCT03400943|10149894|FG002|Post-treatment Period 1|Adverse Event|0
6360419|NCT03400943|10149895|FG003|Post-treatment Period 1|Adverse Event|0
6360420|NCT03400943|10149892|FG000|Post-treatment Period 1|Protocol Violation|1
6360421|NCT03400943|10149893|FG001|Post-treatment Period 1|Protocol Violation|0
6360422|NCT03400943|10149894|FG002|Post-treatment Period 1|Protocol Violation|0
6360423|NCT03400943|10149895|FG003|Post-treatment Period 1|Protocol Violation|0
6360424|NCT03400943|10149892|FG000|Post-treatment Period 1|Study terminated by sponsor|5
6360425|NCT03400943|10149893|FG001|Post-treatment Period 1|Study terminated by sponsor|0
6360426|NCT03400943|10149894|FG002|Post-treatment Period 1|Study terminated by sponsor|5
6360427|NCT03400943|10149895|FG003|Post-treatment Period 1|Study terminated by sponsor|6
6360428|NCT03400943|10149892|FG000|Post-treatment Period 1|Withdrawal by Subject|1
6360429|NCT03400943|10149893|FG001|Post-treatment Period 1|Withdrawal by Subject|0
6360430|NCT03400943|10149894|FG002|Post-treatment Period 1|Withdrawal by Subject|2
6360431|NCT03400943|10149895|FG003|Post-treatment Period 1|Withdrawal by Subject|2
6170474|NCT01253265|9816777|FG001|Overall Study|Met Predefined Discontinuation Criteria|0
6170475|NCT01253265|9816778|FG002|Overall Study|Met Predefined Discontinuation Criteria|0
6170476|NCT01253265|9816779|FG003|Overall Study|Met Predefined Discontinuation Criteria|0
6170477|NCT01253265|9816780|FG004|Overall Study|Met Predefined Discontinuation Criteria|0
6170478|NCT01253265|9816776|FG000|Overall Study|Withdrawal by Subject|0
6170479|NCT01253265|9816777|FG001|Overall Study|Withdrawal by Subject|0
6170480|NCT01253265|9816778|FG002|Overall Study|Withdrawal by Subject|0
6170481|NCT01253265|9816779|FG003|Overall Study|Withdrawal by Subject|0
6170482|NCT01253265|9816780|FG004|Overall Study|Withdrawal by Subject|1
6170483|NCT01253291|9816797|FG000|Overall Study|Withdrawal by Subject|1
6170484|NCT01253291|9816798|FG001|Overall Study|Withdrawal by Subject|1
6170485|NCT01253291|9816799|FG002|Overall Study|Withdrawal by Subject|0
6170486|NCT01253291|9816800|FG003|Overall Study|Withdrawal by Subject|0
6170487|NCT01253291|9816801|FG004|Overall Study|Withdrawal by Subject|0
6170488|NCT01253291|9816797|FG000|Overall Study|Adverse Event|0
6170489|NCT01253291|9816798|FG001|Overall Study|Adverse Event|1
6170490|NCT01253291|9816799|FG002|Overall Study|Adverse Event|0
6170491|NCT01253291|9816800|FG003|Overall Study|Adverse Event|0
6170492|NCT01253291|9816801|FG004|Overall Study|Adverse Event|0
6170493|NCT01253291|9816797|FG000|Overall Study|Lack of Efficacy|1
6170494|NCT01253291|9816798|FG001|Overall Study|Lack of Efficacy|0
6170495|NCT01253291|9816799|FG002|Overall Study|Lack of Efficacy|0
6360432|NCT03400943|10149892|FG000|Post-treatment Period 1|Other|2
6360433|NCT03400943|10149893|FG001|Post-treatment Period 1|Other|0
6360434|NCT03400943|10149894|FG002|Post-treatment Period 1|Other|4
6360435|NCT03400943|10149895|FG003|Post-treatment Period 1|Other|5
6360436|NCT03400943|10149892|FG000|Treatment Period 2|Study terminated by sponsor|0
6360437|NCT03400943|10149893|FG001|Treatment Period 2|Study terminated by sponsor|1
6360438|NCT03400943|10149894|FG002|Treatment Period 2|Study terminated by sponsor|0
6360439|NCT03400943|10149895|FG003|Treatment Period 2|Study terminated by sponsor|0
6360440|NCT03400943|10149892|FG000|Treatment Period 2|Withdrawal by Subject|0
6360441|NCT03400943|10149893|FG001|Treatment Period 2|Withdrawal by Subject|1
6360442|NCT03400943|10149894|FG002|Treatment Period 2|Withdrawal by Subject|0
6360443|NCT03400943|10149895|FG003|Treatment Period 2|Withdrawal by Subject|0
6360444|NCT03400943|10149892|FG000|Treatment Period 2|Other|1
6360445|NCT03400943|10149893|FG001|Treatment Period 2|Other|6
6360446|NCT03400943|10149894|FG002|Treatment Period 2|Other|0
6360447|NCT03400943|10149895|FG003|Treatment Period 2|Other|0
6360448|NCT03400943|10149892|FG000|Follow-up Period|Withdrawal by Subject|1
6360449|NCT03400943|10149893|FG001|Follow-up Period|Withdrawal by Subject|0
6360450|NCT03400943|10149894|FG002|Follow-up Period|Withdrawal by Subject|0
6360451|NCT03400943|10149895|FG003|Follow-up Period|Withdrawal by Subject|0
6360452|NCT03288142|10149909|FG000|Overall Study|Lost to Follow-up|22
6360453|NCT03288142|10149910|FG001|Overall Study|Lost to Follow-up|15
6360454|NCT03112603|10149920|FG000|End of Randomization Period|Lost to Follow-up|1
6360455|NCT03112603|10149921|FG001|End of Randomization Period|Lost to Follow-up|0
6360456|NCT03112603|10149922|FG002|End of Randomization Period|Lost to Follow-up|0
6360457|NCT03112603|10149920|FG000|End of Randomization Period|Subject/Guardian Decision|4
6360458|NCT03112603|10149921|FG001|End of Randomization Period|Subject/Guardian Decision|11
6360459|NCT03112603|10149922|FG002|End of Randomization Period|Subject/Guardian Decision|0
6360460|NCT03112603|10149920|FG000|End of Randomization Period|Physician Decision|4
6360461|NCT03112603|10149921|FG001|End of Randomization Period|Physician Decision|14
6360462|NCT03112603|10149922|FG002|End of Randomization Period|Physician Decision|0
6360463|NCT03112603|10149920|FG000|End of Randomization Period|Failure to meet protocol continuation criteria|4
6360464|NCT03112603|10149921|FG001|End of Randomization Period|Failure to meet protocol continuation criteria|5
6360465|NCT03112603|10149922|FG002|End of Randomization Period|Failure to meet protocol continuation criteria|0
6360466|NCT03112603|10149920|FG000|End of Randomization Period|Death|8
6360467|NCT03112603|10149921|FG001|End of Randomization Period|Death|7
6360468|NCT03112603|10149922|FG002|End of Randomization Period|Death|0
6360469|NCT03112603|10149920|FG000|End of Randomization Period|Disease Relapse|9
6360470|NCT03112603|10149921|FG001|End of Randomization Period|Disease Relapse|7
6360471|NCT03112603|10149922|FG002|End of Randomization Period|Disease Relapse|0
6360472|NCT03112603|10149920|FG000|End of Randomization Period|Lack of Efficacy|24
6360473|NCT03112603|10149921|FG001|End of Randomization Period|Lack of Efficacy|70
6360474|NCT03112603|10149922|FG002|End of Randomization Period|Lack of Efficacy|0
6360475|NCT03112603|10149920|FG000|End of Randomization Period|Adverse Event|28
6360476|NCT03112603|10149921|FG001|End of Randomization Period|Adverse Event|8
6360477|NCT03112603|10149922|FG002|End of Randomization Period|Adverse Event|0
6360478|NCT03112603|10149920|FG000|End of Randomization Period|Ongoing Treatment|83
6360479|NCT03112603|10149921|FG001|End of Randomization Period|Ongoing Treatment|42
6360480|NCT03112603|10149922|FG002|End of Randomization Period|Ongoing Treatment|0
6360481|NCT03112603|10149920|FG000|End of Cross Over Period|Death|0
6360482|NCT03112603|10149921|FG001|End of Cross Over Period|Death|0
6360483|NCT03112603|10149922|FG002|End of Cross Over Period|Death|1
6360484|NCT03112603|10149920|FG000|End of Cross Over Period|Subject/Guardian Decision|0
6360485|NCT03112603|10149921|FG001|End of Cross Over Period|Subject/Guardian Decision|0
6360486|NCT03112603|10149922|FG002|End of Cross Over Period|Subject/Guardian Decision|3
6360487|NCT03112603|10149920|FG000|End of Cross Over Period|Physician Decision|0
6360488|NCT03112603|10149921|FG001|End of Cross Over Period|Physician Decision|0
6360489|NCT03112603|10149922|FG002|End of Cross Over Period|Physician Decision|3
6360490|NCT03112603|10149920|FG000|End of Cross Over Period|Lack of Efficacy|0
6360491|NCT03112603|10149921|FG001|End of Cross Over Period|Lack of Efficacy|0
6360492|NCT03112603|10149922|FG002|End of Cross Over Period|Lack of Efficacy|4
6360493|NCT03112603|10149920|FG000|End of Cross Over Period|Adverse Event|0
6360494|NCT03112603|10149921|FG001|End of Cross Over Period|Adverse Event|0
6360495|NCT03112603|10149922|FG002|End of Cross Over Period|Adverse Event|4
6360496|NCT03112603|10149920|FG000|End of Cross Over Period|Treatment Ongoing|0
6360497|NCT03112603|10149921|FG001|End of Cross Over Period|Treatment Ongoing|0
6360498|NCT03112603|10149922|FG002|End of Cross Over Period|Treatment Ongoing|46
6360499|NCT02949934|10149934|FG000|Natural Drinking Period|Adverse Event|1
6360500|NCT02949934|10149935|FG001|Natural Drinking Period|Adverse Event|0
6360501|NCT02949934|10149936|FG002|Natural Drinking Period|Adverse Event|0
6360502|NCT02949934|10149937|FG003|Natural Drinking Period|Adverse Event|1
6360503|NCT02949934|10149938|FG004|Natural Drinking Period|Adverse Event|0
6170496|NCT01253291|9816800|FG003|Overall Study|Lack of Efficacy|0
6170497|NCT01253291|9816801|FG004|Overall Study|Lack of Efficacy|0
6170498|NCT01253291|9816797|FG000|Overall Study|Physician Decision|2
6360504|NCT02949934|10149939|FG005|Natural Drinking Period|Adverse Event|0
6360505|NCT02949934|10149934|FG000|Natural Drinking Period|Lost to Follow-up|0
6360506|NCT02949934|10149935|FG001|Natural Drinking Period|Lost to Follow-up|0
6360507|NCT02949934|10149936|FG002|Natural Drinking Period|Lost to Follow-up|0
6360508|NCT02949934|10149937|FG003|Natural Drinking Period|Lost to Follow-up|0
6360509|NCT02949934|10149938|FG004|Natural Drinking Period|Lost to Follow-up|1
6360510|NCT02949934|10149939|FG005|Natural Drinking Period|Lost to Follow-up|0
6360511|NCT02949934|10149934|FG000|Neuroimaging|Protocol Violation|2
6084115|NCT00641147|9693084|FG000|Completed 12 Months.|Physician Decision|1
6084116|NCT00641147|9693085|FG001|Completed 12 Months.|Physician Decision|1
6170499|NCT01253291|9816798|FG001|Overall Study|Physician Decision|0
6360512|NCT02949934|10149935|FG001|Neuroimaging|Protocol Violation|0
6360513|NCT02949934|10149936|FG002|Neuroimaging|Protocol Violation|0
6360514|NCT02949934|10149937|FG003|Neuroimaging|Protocol Violation|0
6360515|NCT02949934|10149938|FG004|Neuroimaging|Protocol Violation|1
6360516|NCT02949934|10149939|FG005|Neuroimaging|Protocol Violation|0
6360517|NCT02949934|10149934|FG000|Neuroimaging|Motion artifacts in imaging data|1
6360518|NCT02949934|10149935|FG001|Neuroimaging|Motion artifacts in imaging data|0
6360519|NCT02949934|10149936|FG002|Neuroimaging|Motion artifacts in imaging data|1
6360520|NCT02949934|10149937|FG003|Neuroimaging|Motion artifacts in imaging data|0
6360521|NCT02949934|10149938|FG004|Neuroimaging|Motion artifacts in imaging data|1
6360522|NCT02949934|10149939|FG005|Neuroimaging|Motion artifacts in imaging data|0
6360523|NCT02949934|10149934|FG000|Neuroimaging|Not scanned|0
6360524|NCT02949934|10149935|FG001|Neuroimaging|Not scanned|0
6360525|NCT02949934|10149936|FG002|Neuroimaging|Not scanned|1
6360526|NCT02949934|10149937|FG003|Neuroimaging|Not scanned|0
6360527|NCT02949934|10149938|FG004|Neuroimaging|Not scanned|0
6360528|NCT02949934|10149939|FG005|Neuroimaging|Not scanned|2
6360529|NCT02949934|10149934|FG000|Bar Laboratory|Procedure not done due to COVID-19 pandemic|0
6360530|NCT02949934|10149935|FG001|Bar Laboratory|Procedure not done due to COVID-19 pandemic|5
6360531|NCT02949934|10149936|FG002|Bar Laboratory|Procedure not done due to COVID-19 pandemic|5
6360532|NCT02949934|10149937|FG003|Bar Laboratory|Procedure not done due to COVID-19 pandemic|3
6360533|NCT02949934|10149938|FG004|Bar Laboratory|Procedure not done due to COVID-19 pandemic|5
6360534|NCT02949934|10149939|FG005|Bar Laboratory|Procedure not done due to COVID-19 pandemic|1
6360535|NCT02949934|10149934|FG000|Bar Laboratory|Adverse Event|1
6360536|NCT02949934|10149935|FG001|Bar Laboratory|Adverse Event|0
6360537|NCT02949934|10149936|FG002|Bar Laboratory|Adverse Event|2
6360538|NCT02949934|10149937|FG003|Bar Laboratory|Adverse Event|0
6360539|NCT02949934|10149938|FG004|Bar Laboratory|Adverse Event|1
6360540|NCT02949934|10149939|FG005|Bar Laboratory|Adverse Event|0
6360541|NCT02949934|10149934|FG000|Bar Laboratory|Protocol Violation|0
6360542|NCT02949934|10149935|FG001|Bar Laboratory|Protocol Violation|0
6360543|NCT02949934|10149936|FG002|Bar Laboratory|Protocol Violation|0
6360544|NCT02949934|10149937|FG003|Bar Laboratory|Protocol Violation|1
6360545|NCT02949934|10149938|FG004|Bar Laboratory|Protocol Violation|0
6360546|NCT02949934|10149939|FG005|Bar Laboratory|Protocol Violation|0
6360547|NCT02908672|10149955|FG000|Overall Study|Death|112
6360548|NCT02908672|10149956|FG001|Overall Study|Death|93
6360549|NCT02908672|10149955|FG000|Overall Study|Lost to Follow-up|3
6360550|NCT02908672|10149956|FG001|Overall Study|Lost to Follow-up|3
6360551|NCT02908672|10149955|FG000|Overall Study|Other|2
6360552|NCT02908672|10149956|FG001|Overall Study|Other|0
6360553|NCT02908672|10149955|FG000|Overall Study|Protocol Violation|1
6360554|NCT02908672|10149956|FG001|Overall Study|Protocol Violation|1
6360555|NCT02908672|10149955|FG000|Overall Study|Withdrawal by Subject|13
6360556|NCT02908672|10149956|FG001|Overall Study|Withdrawal by Subject|18
6360557|NCT02908672|10149955|FG000|Overall Study|Study is ongoing|124
6360558|NCT02908672|10149956|FG001|Overall Study|Study is ongoing|141
6360559|NCT02908672|10149955|FG000|Overall Study|Discontinued the study during run-in|3
6360560|NCT02908672|10149956|FG001|Overall Study|Discontinued the study during run-in|0
6360561|NCT02767570|10149964|FG000|Overall Study|Lost to Follow-up|3
6360562|NCT02767570|10149965|FG001|Overall Study|Lost to Follow-up|0
6360563|NCT02767570|10149964|FG000|Overall Study|COVID shutdown|2
6360564|NCT02767570|10149965|FG001|Overall Study|COVID shutdown|5
6360565|NCT02767570|10149964|FG000|Overall Study|Increased pain|2
6360566|NCT02767570|10149965|FG001|Overall Study|Increased pain|0
6360567|NCT02767570|10149964|FG000|Overall Study|Withdrawal by Subject|1
6360568|NCT02767570|10149965|FG001|Overall Study|Withdrawal by Subject|3
6360569|NCT02767570|10149964|FG000|Overall Study|Unrelated medical issue|1
6360570|NCT02767570|10149965|FG001|Overall Study|Unrelated medical issue|1
6360571|NCT02767570|10149964|FG000|Overall Study|Received intra-articular injection|0
6360572|NCT02767570|10149965|FG001|Overall Study|Received intra-articular injection|1
6360573|NCT02702180|10149974|FG000|Double-blind Treatment Period|Withdrawal by Subject|1
6360574|NCT02702180|10149975|FG001|Double-blind Treatment Period|Withdrawal by Subject|1
6360575|NCT02702180|10149976|FG002|Double-blind Treatment Period|Withdrawal by Subject|0
6360576|NCT02702180|10149974|FG000|Double-blind Treatment Period|Adverse Event|0
6360577|NCT02702180|10149975|FG001|Double-blind Treatment Period|Adverse Event|0
6360578|NCT02702180|10149976|FG002|Double-blind Treatment Period|Adverse Event|1
6360579|NCT02702180|10149974|FG000|Double-blind Treatment Period|Lack of Efficacy|0
6360580|NCT02702180|10149975|FG001|Double-blind Treatment Period|Lack of Efficacy|0
6360581|NCT02702180|10149976|FG002|Double-blind Treatment Period|Lack of Efficacy|1
6360582|NCT02702180|10149974|FG000|Double-blind Treatment Period|Protocol Violation|0
6360583|NCT02702180|10149975|FG001|Double-blind Treatment Period|Protocol Violation|0
6360584|NCT02702180|10149976|FG002|Double-blind Treatment Period|Protocol Violation|2
6360585|NCT02702180|10149974|FG000|Open-label Treatment Period|Withdrawal by Subject|0
6360586|NCT02702180|10149975|FG001|Open-label Treatment Period|Withdrawal by Subject|1
6360587|NCT02702180|10149976|FG002|Open-label Treatment Period|Withdrawal by Subject|1
6360588|NCT02702180|10149974|FG000|Open-label Treatment Period|Withdrawn in error|0
6360589|NCT02702180|10149975|FG001|Open-label Treatment Period|Withdrawn in error|0
6360590|NCT02702180|10149976|FG002|Open-label Treatment Period|Withdrawn in error|1
6360591|NCT02545049|10149987|FG000|Overall Study|Withdrawal by Subject|1
6360592|NCT02545049|10149988|FG001|Overall Study|Withdrawal by Subject|7
6360593|NCT02545049|10149987|FG000|Overall Study|Lost to Follow-up|4
6360594|NCT02545049|10149988|FG001|Overall Study|Lost to Follow-up|6
6360595|NCT02545049|10149987|FG000|Overall Study|GCP violations|37
6360596|NCT02545049|10149988|FG001|Overall Study|GCP violations|48
6360597|NCT02448381|10149996|FG000|Overall Study|Adverse Event|2
6360598|NCT02448381|10149997|FG001|Overall Study|Adverse Event|0
6360599|NCT02448381|10149996|FG000|Overall Study|Lost to Follow-up|16
6360600|NCT02448381|10149997|FG001|Overall Study|Lost to Follow-up|9
6360601|NCT02448381|10149996|FG000|Overall Study|Physician Decision|1
6360602|NCT02448381|10149997|FG001|Overall Study|Physician Decision|1
6360603|NCT02448381|10149996|FG000|Overall Study|Pregnancy|1
6360604|NCT02448381|10149997|FG001|Overall Study|Pregnancy|0
6360605|NCT02448381|10149996|FG000|Overall Study|Withdrawal by Subject|13
6360606|NCT02448381|10149997|FG001|Overall Study|Withdrawal by Subject|9
6360607|NCT02448381|10149996|FG000|Overall Study|Noncompliance with Study Procedures|2
6360608|NCT02448381|10149997|FG001|Overall Study|Noncompliance with Study Procedures|0
6360609|NCT02151981|10150011|FG000|Overall Study|Death|184
6360610|NCT02151981|10150012|FG001|Overall Study|Death|88
6360611|NCT02151981|10150011|FG000|Overall Study|Lost to Follow-up|7
6360612|NCT02151981|10150012|FG001|Overall Study|Lost to Follow-up|1
6360613|NCT02151981|10150011|FG000|Overall Study|Withdrawal by Subject|27
6360614|NCT02151981|10150012|FG001|Overall Study|Withdrawal by Subject|21
6360615|NCT02151981|10150011|FG000|Overall Study|Ongoing Study at Data Cut-off|60
6360616|NCT02151981|10150012|FG001|Overall Study|Ongoing Study at Data Cut-off|27
6360617|NCT02151981|10150011|FG000|Overall Study|Eligibility criteria not fulfilled|0
6360618|NCT02151981|10150012|FG001|Overall Study|Eligibility criteria not fulfilled|1
6360619|NCT02151981|10150011|FG000|Overall Study|Patient had no clinical benefit|1
6360620|NCT02151981|10150012|FG001|Overall Study|Patient had no clinical benefit|0
6360621|NCT02151981|10150011|FG000|Overall Study|Unwilling to continue to follow up visit|0
6360622|NCT02151981|10150012|FG001|Overall Study|Unwilling to continue to follow up visit|1
6360623|NCT02151981|10150011|FG000|Overall Study|Study terminated|0
6360624|NCT02151981|10150012|FG001|Overall Study|Study terminated|1
6360625|NCT01972217|10150022|FG000|Part A: Open-label Safety Run-in Period|Withdrawal by Subject|0
6360626|NCT01972217|10150023|FG001|Part A: Open-label Safety Run-in Period|Withdrawal by Subject|1
6360627|NCT01972217|10150024|FG002|Part A: Open-label Safety Run-in Period|Withdrawal by Subject|0
6360628|NCT01972217|10150025|FG003|Part A: Open-label Safety Run-in Period|Withdrawal by Subject|0
6360629|NCT01972217|10150022|FG000|Part A: Open-label Safety Run-in Period|Condition under investigation worsened|1
6360630|NCT01972217|10150023|FG001|Part A: Open-label Safety Run-in Period|Condition under investigation worsened|9
6360631|NCT01972217|10150024|FG002|Part A: Open-label Safety Run-in Period|Condition under investigation worsened|0
6360632|NCT01972217|10150025|FG003|Part A: Open-label Safety Run-in Period|Condition under investigation worsened|0
6360633|NCT01972217|10150022|FG000|Part A: Open-label Safety Run-in Period|Adverse Event|0
6360634|NCT01972217|10150023|FG001|Part A: Open-label Safety Run-in Period|Adverse Event|1
6360635|NCT01972217|10150024|FG002|Part A: Open-label Safety Run-in Period|Adverse Event|0
6360636|NCT01972217|10150025|FG003|Part A: Open-label Safety Run-in Period|Adverse Event|0
6360637|NCT01972217|10150022|FG000|Part A: Open-label Safety Run-in Period|Death|0
6360638|NCT01972217|10150023|FG001|Part A: Open-label Safety Run-in Period|Death|1
6360639|NCT01972217|10150024|FG002|Part A: Open-label Safety Run-in Period|Death|0
6360640|NCT01972217|10150025|FG003|Part A: Open-label Safety Run-in Period|Death|0
6360641|NCT01972217|10150022|FG000|Part B Double-blind, Randomised Period|Death|0
6170500|NCT01253291|9816799|FG002|Overall Study|Physician Decision|0
6170501|NCT01253291|9816800|FG003|Overall Study|Physician Decision|0
6170502|NCT01253291|9816801|FG004|Overall Study|Physician Decision|2
6170503|NCT01253304|9816818|FG000|Overall Study|Adverse Event|0
6170504|NCT01253304|9816819|FG001|Overall Study|Adverse Event|0
6170505|NCT01253304|9816820|FG002|Overall Study|Adverse Event|0
6170506|NCT01253304|9816821|FG003|Overall Study|Adverse Event|1
6170507|NCT01253317|9816831|FG000|Overall Study|Adverse Event|2
6170508|NCT01253369|9816864|FG000|Overall Study|Adverse Event|4
6170509|NCT01253369|9816864|FG000|Overall Study|Withdrawal by Subject|2
6170510|NCT01253369|9816864|FG000|Overall Study|Death|1
6170511|NCT01253369|9816864|FG000|Overall Study|Progressive disease|23
6170512|NCT01253369|9816864|FG000|Overall Study|Not Evaluable|3
6170513|NCT01253408|9816871|FG000|Overall Study|Adverse Event|0
6170514|NCT01253408|9816872|FG001|Overall Study|Adverse Event|1
6170515|NCT01253408|9816873|FG002|Overall Study|Adverse Event|0
6170516|NCT01253421|9816885|FG000|Assessment and Scheduling|Found to be Ineligible|74
6170517|NCT01253421|9816886|FG001|Assessment and Scheduling|Found to be Ineligible|0
6170518|NCT01253421|9816887|FG002|Assessment and Scheduling|Found to be Ineligible|0
6360642|NCT01972217|10150023|FG001|Part B Double-blind, Randomised Period|Death|0
6360643|NCT01972217|10150024|FG002|Part B Double-blind, Randomised Period|Death|43
6360644|NCT01972217|10150025|FG003|Part B Double-blind, Randomised Period|Death|44
6360645|NCT01972217|10150022|FG000|Part B Double-blind, Randomised Period|Reason not recorded|0
6360646|NCT01972217|10150023|FG001|Part B Double-blind, Randomised Period|Reason not recorded|0
6360647|NCT01972217|10150024|FG002|Part B Double-blind, Randomised Period|Reason not recorded|1
6360648|NCT01972217|10150025|FG003|Part B Double-blind, Randomised Period|Reason not recorded|0
6360649|NCT01972217|10150022|FG000|Part B Double-blind, Randomised Period|Screen failure|0
6360650|NCT01972217|10150023|FG001|Part B Double-blind, Randomised Period|Screen failure|0
6360651|NCT01972217|10150024|FG002|Part B Double-blind, Randomised Period|Screen failure|0
6360652|NCT01972217|10150025|FG003|Part B Double-blind, Randomised Period|Screen failure|1
6360653|NCT01972217|10150022|FG000|Part B Double-blind, Randomised Period|Lost to Follow-up|0
6360654|NCT01972217|10150023|FG001|Part B Double-blind, Randomised Period|Lost to Follow-up|0
6360655|NCT01972217|10150024|FG002|Part B Double-blind, Randomised Period|Lost to Follow-up|2
6360656|NCT01972217|10150025|FG003|Part B Double-blind, Randomised Period|Lost to Follow-up|1
6360657|NCT01972217|10150022|FG000|Part B Double-blind, Randomised Period|Withdrawal by Subject|0
6360658|NCT01972217|10150023|FG001|Part B Double-blind, Randomised Period|Withdrawal by Subject|0
6360659|NCT01972217|10150024|FG002|Part B Double-blind, Randomised Period|Withdrawal by Subject|0
6360660|NCT01972217|10150025|FG003|Part B Double-blind, Randomised Period|Withdrawal by Subject|1
6360661|NCT01849874|10150039|FG000|Overall Study|Death|34
6360662|NCT01849874|10150040|FG001|Overall Study|Death|16
6360663|NCT01849874|10150039|FG000|Overall Study|Withdrawal by Subject|4
6360664|NCT01849874|10150040|FG001|Overall Study|Withdrawal by Subject|8
6360665|NCT01849874|10150039|FG000|Overall Study|Lost to Follow-up|0
6360666|NCT01849874|10150040|FG001|Overall Study|Lost to Follow-up|1
6360667|NCT01849874|10150039|FG000|Overall Study|Randomized but Never Treated|1
6084117|NCT00641147|9693084|FG000|Completed 12 Months.|Withdrawal by Subject|0
6084118|NCT00641147|9693085|FG001|Completed 12 Months.|Withdrawal by Subject|1
6084119|NCT00641147|9693084|FG000|Completed 16 Months.|Physician Decision|1
6084120|NCT00641147|9693085|FG001|Completed 16 Months.|Physician Decision|0
6084121|NCT00641147|9693084|FG000|Completed 16 Months.|Lost to Follow-up|1
6084122|NCT00641147|9693085|FG001|Completed 16 Months.|Lost to Follow-up|0
6084123|NCT00641667|9693106|FG000|Overall Study|Withdrawal by Subject|1
6084124|NCT00641667|9693106|FG000|Overall Study|Adverse Event|1
6084125|NCT00641667|9693106|FG000|Overall Study|Physician Decision|1
6084126|NCT00641667|9693106|FG000|Overall Study|Worsening of underlying disease|3
6084127|NCT00641706|9693112|FG000|Overall Study|Adverse Event|2
6084128|NCT00641706|9693113|FG001|Overall Study|Adverse Event|1
6084129|NCT00641706|9693112|FG000|Overall Study|Withdrawal by Subject|6
6084130|NCT00641706|9693113|FG001|Overall Study|Withdrawal by Subject|1
6084131|NCT00641706|9693112|FG000|Overall Study|Clinical Decline|1
6084132|NCT00641706|9693113|FG001|Overall Study|Clinical Decline|0
6084133|NCT00641706|9693112|FG000|Overall Study|Lead Investigator Decision|0
6084134|NCT00641706|9693113|FG001|Overall Study|Lead Investigator Decision|1
6084135|NCT00641719|9693121|FG000|Overall Study|Lack of Efficacy|1
6084136|NCT00641719|9693122|FG001|Overall Study|Lack of Efficacy|2
6084137|NCT00641719|9693121|FG000|Overall Study|Adverse Event|24
6084138|NCT00641719|9693122|FG001|Overall Study|Adverse Event|29
6084139|NCT00641719|9693121|FG000|Overall Study|Withdrawal by Subject|4
6084140|NCT00641719|9693122|FG001|Overall Study|Withdrawal by Subject|4
6084141|NCT00641719|9693121|FG000|Overall Study|Reason Not Specified|1
6084142|NCT00641719|9693122|FG001|Overall Study|Reason Not Specified|2
6084143|NCT00642018|9693157|FG000|Overall Study|Adverse Event|11
6084144|NCT00642018|9693158|FG001|Overall Study|Adverse Event|36
6084145|NCT00642018|9693157|FG000|Overall Study|Withdrawal by Subject|4
6084146|NCT00642018|9693158|FG001|Overall Study|Withdrawal by Subject|10
6084147|NCT00642018|9693157|FG000|Overall Study|Progressive Disease|13
6084148|NCT00642018|9693158|FG001|Overall Study|Progressive Disease|18
6084149|NCT00642018|9693157|FG000|Overall Study|Physician Decision|0
6084150|NCT00642018|9693158|FG001|Overall Study|Physician Decision|10
6084151|NCT00642018|9693157|FG000|Overall Study|Protocol Violation|0
6084152|NCT00642018|9693158|FG001|Overall Study|Protocol Violation|1
6084153|NCT00642018|9693157|FG000|Overall Study|Death|0
6084154|NCT00642018|9693158|FG001|Overall Study|Death|3
6084155|NCT00642018|9693157|FG000|Overall Study|Entry Criteria Not Met|0
6084156|NCT00642018|9693158|FG001|Overall Study|Entry Criteria Not Met|1
6084157|NCT00642174|9693167|FG000|Period 1 - Initial Drug|Entry Criteria Not Met|0
6084158|NCT00642174|9693168|FG001|Period 1 - Initial Drug|Entry Criteria Not Met|1
6084159|NCT00642278|9693181|FG000|Overall Study|Adverse Event|2
6084160|NCT00642278|9693182|FG001|Overall Study|Adverse Event|1
6084161|NCT00642278|9693183|FG002|Overall Study|Adverse Event|3
6084162|NCT00642278|9693184|FG003|Overall Study|Adverse Event|1
6084163|NCT00642278|9693185|FG004|Overall Study|Adverse Event|2
6084164|NCT00642278|9693186|FG005|Overall Study|Adverse Event|2
6360668|NCT01849874|10150040|FG001|Overall Study|Randomized but Never Treated|8
6084165|NCT00642278|9693187|FG006|Overall Study|Adverse Event|0
6084166|NCT00642278|9693181|FG000|Overall Study|Lack of Efficacy|0
6360669|NCT01849874|10150039|FG000|Overall Study|Ongoing|162
6360670|NCT01849874|10150040|FG001|Overall Study|Ongoing|69
6360671|NCT01724866|10150050|FG000|Overall Study|Adverse Event|0
6360672|NCT01724866|10150051|FG001|Overall Study|Adverse Event|0
6360673|NCT01724866|10150052|FG002|Overall Study|Adverse Event|1
6360674|NCT01724866|10150053|FG003|Overall Study|Adverse Event|1
6360675|NCT01724866|10150050|FG000|Overall Study|Initiation of Non-Protocol Therapy Either for Progressive Disease or Intolerance of TC Regimen|0
6360676|NCT01724866|10150051|FG001|Overall Study|Initiation of Non-Protocol Therapy Either for Progressive Disease or Intolerance of TC Regimen|2
6360677|NCT01724866|10150052|FG002|Overall Study|Initiation of Non-Protocol Therapy Either for Progressive Disease or Intolerance of TC Regimen|0
6360678|NCT01724866|10150053|FG003|Overall Study|Initiation of Non-Protocol Therapy Either for Progressive Disease or Intolerance of TC Regimen|0
6360679|NCT01724866|10150050|FG000|Overall Study|Investigator's Discretion|0
6360680|NCT01724866|10150051|FG001|Overall Study|Investigator's Discretion|1
6360681|NCT01724866|10150052|FG002|Overall Study|Investigator's Discretion|1
6360682|NCT01724866|10150053|FG003|Overall Study|Investigator's Discretion|0
6360683|NCT01724866|10150050|FG000|Overall Study|Need for Chemotherapy or Chemotherapy Regimen was Changed due to Amended HER2 Status|1
6360684|NCT01724866|10150051|FG001|Overall Study|Need for Chemotherapy or Chemotherapy Regimen was Changed due to Amended HER2 Status|0
6360685|NCT01724866|10150052|FG002|Overall Study|Need for Chemotherapy or Chemotherapy Regimen was Changed due to Amended HER2 Status|0
6360686|NCT01724866|10150053|FG003|Overall Study|Need for Chemotherapy or Chemotherapy Regimen was Changed due to Amended HER2 Status|0
6360687|NCT01724866|10150050|FG000|Overall Study|Participant Refused Further Treatment or Withdrew Consent|0
6360688|NCT01724866|10150051|FG001|Overall Study|Participant Refused Further Treatment or Withdrew Consent|2
6360689|NCT01724866|10150052|FG002|Overall Study|Participant Refused Further Treatment or Withdrew Consent|1
6360690|NCT01724866|10150053|FG003|Overall Study|Participant Refused Further Treatment or Withdrew Consent|0
6360691|NCT01670877|10150067|FG000|Part I and Part 2|Grade 2 vomiting and progressive disease|0
6360692|NCT01670877|10150068|FG001|Part I and Part 2|Grade 2 vomiting and progressive disease|1
6360693|NCT01670877|10150069|FG002|Part I and Part 2|Grade 2 vomiting and progressive disease|0
6360694|NCT01670877|10150070|FG003|Part I and Part 2|Grade 2 vomiting and progressive disease|0
6360695|NCT01670877|10150071|FG004|Part I and Part 2|Grade 2 vomiting and progressive disease|0
6360696|NCT01670877|10150072|FG005|Part I and Part 2|Grade 2 vomiting and progressive disease|0
6360697|NCT01670877|10150067|FG000|Part I and Part 2|Grade 3 diarrhea and withdrawal|0
6360698|NCT01670877|10150068|FG001|Part I and Part 2|Grade 3 diarrhea and withdrawal|0
6360699|NCT01670877|10150069|FG002|Part I and Part 2|Grade 3 diarrhea and withdrawal|1
6360700|NCT01670877|10150070|FG003|Part I and Part 2|Grade 3 diarrhea and withdrawal|0
6360701|NCT01670877|10150071|FG004|Part I and Part 2|Grade 3 diarrhea and withdrawal|0
6360702|NCT01670877|10150072|FG005|Part I and Part 2|Grade 3 diarrhea and withdrawal|0
6360703|NCT01670877|10150067|FG000|Part I and Part 2|Grade 2 vomiting|0
6360704|NCT01670877|10150068|FG001|Part I and Part 2|Grade 2 vomiting|0
6360705|NCT01670877|10150069|FG002|Part I and Part 2|Grade 2 vomiting|0
6360706|NCT01670877|10150070|FG003|Part I and Part 2|Grade 2 vomiting|1
6360707|NCT01670877|10150071|FG004|Part I and Part 2|Grade 2 vomiting|0
6360708|NCT01670877|10150072|FG005|Part I and Part 2|Grade 2 vomiting|0
6360709|NCT01670877|10150067|FG000|Part I and Part 2|Grade 3 dizziness and progressive disease|0
6360710|NCT01670877|10150068|FG001|Part I and Part 2|Grade 3 dizziness and progressive disease|0
6084167|NCT00642278|9693182|FG001|Overall Study|Lack of Efficacy|1
6084168|NCT00642278|9693183|FG002|Overall Study|Lack of Efficacy|0
6084169|NCT00642278|9693184|FG003|Overall Study|Lack of Efficacy|0
6084170|NCT00642278|9693185|FG004|Overall Study|Lack of Efficacy|0
6084171|NCT00642278|9693186|FG005|Overall Study|Lack of Efficacy|0
6084172|NCT00642278|9693187|FG006|Overall Study|Lack of Efficacy|0
6084173|NCT00642278|9693181|FG000|Overall Study|Lost to Follow-up|5
6084174|NCT00642278|9693182|FG001|Overall Study|Lost to Follow-up|1
6084175|NCT00642278|9693183|FG002|Overall Study|Lost to Follow-up|0
6084176|NCT00642278|9693184|FG003|Overall Study|Lost to Follow-up|1
6084177|NCT00642278|9693185|FG004|Overall Study|Lost to Follow-up|0
6084178|NCT00642278|9693186|FG005|Overall Study|Lost to Follow-up|1
6084179|NCT00642278|9693187|FG006|Overall Study|Lost to Follow-up|1
6084180|NCT00642278|9693181|FG000|Overall Study|Physician Decision|0
6084181|NCT00642278|9693182|FG001|Overall Study|Physician Decision|0
6360711|NCT01670877|10150069|FG002|Part I and Part 2|Grade 3 dizziness and progressive disease|0
6360712|NCT01670877|10150070|FG003|Part I and Part 2|Grade 3 dizziness and progressive disease|1
6360713|NCT01670877|10150071|FG004|Part I and Part 2|Grade 3 dizziness and progressive disease|0
6360714|NCT01670877|10150072|FG005|Part I and Part 2|Grade 3 dizziness and progressive disease|0
6360715|NCT01670877|10150067|FG000|Part I and Part 2|Grade 3 diarrhea and duodenal ulcer|0
6360716|NCT01670877|10150068|FG001|Part I and Part 2|Grade 3 diarrhea and duodenal ulcer|0
6360717|NCT01670877|10150069|FG002|Part I and Part 2|Grade 3 diarrhea and duodenal ulcer|0
6360718|NCT01670877|10150070|FG003|Part I and Part 2|Grade 3 diarrhea and duodenal ulcer|1
6360719|NCT01670877|10150071|FG004|Part I and Part 2|Grade 3 diarrhea and duodenal ulcer|0
6084182|NCT00642278|9693183|FG002|Overall Study|Physician Decision|0
6084183|NCT00642278|9693184|FG003|Overall Study|Physician Decision|1
6084184|NCT00642278|9693185|FG004|Overall Study|Physician Decision|0
6084185|NCT00642278|9693186|FG005|Overall Study|Physician Decision|0
6360720|NCT01670877|10150072|FG005|Part I and Part 2|Grade 3 diarrhea and duodenal ulcer|0
6360721|NCT01602380|10150088|FG000|Overall Study|Death|63
6360722|NCT01602380|10150089|FG001|Overall Study|Death|68
6360723|NCT01602380|10150088|FG000|Overall Study|Withdrawal by Subject|22
6360724|NCT01602380|10150089|FG001|Overall Study|Withdrawal by Subject|29
6360725|NCT01602380|10150088|FG000|Overall Study|Lost to Follow-up|6
6360726|NCT01602380|10150089|FG001|Overall Study|Lost to Follow-up|1
6360727|NCT01602380|10150088|FG000|Overall Study|Eligibility criteria not fulfilled|2
6084186|NCT00642278|9693187|FG006|Overall Study|Physician Decision|0
6084187|NCT00642278|9693181|FG000|Overall Study|Protocol Violation|0
6084188|NCT00642278|9693182|FG001|Overall Study|Protocol Violation|0
6084189|NCT00642278|9693183|FG002|Overall Study|Protocol Violation|1
6084190|NCT00642278|9693184|FG003|Overall Study|Protocol Violation|1
6084191|NCT00642278|9693185|FG004|Overall Study|Protocol Violation|0
6084192|NCT00642278|9693186|FG005|Overall Study|Protocol Violation|1
6084193|NCT00642278|9693187|FG006|Overall Study|Protocol Violation|2
6084194|NCT00642278|9693181|FG000|Overall Study|Withdrawal by Subject|1
6084195|NCT00642278|9693182|FG001|Overall Study|Withdrawal by Subject|1
6084196|NCT00642278|9693183|FG002|Overall Study|Withdrawal by Subject|1
6084197|NCT00642278|9693184|FG003|Overall Study|Withdrawal by Subject|3
6084198|NCT00642278|9693185|FG004|Overall Study|Withdrawal by Subject|6
6360728|NCT01602380|10150089|FG001|Overall Study|Eligibility criteria not fulfilled|3
6360729|NCT01412333|10150097|FG000|Overall Study|Death|1
6360730|NCT01412333|10150098|FG001|Overall Study|Death|1
6360731|NCT01412333|10150097|FG000|Overall Study|Physician Decision|0
6360732|NCT01412333|10150098|FG001|Overall Study|Physician Decision|1
6360733|NCT01412333|10150097|FG000|Overall Study|Reason not specified|16
6360734|NCT01412333|10150098|FG001|Overall Study|Reason not specified|10
6360735|NCT01412333|10150097|FG000|Overall Study|Non-compliance with study drug|1
6360736|NCT01412333|10150098|FG001|Overall Study|Non-compliance with study drug|1
6360737|NCT01412333|10150097|FG000|Overall Study|Protocol Violation|1
6360738|NCT01412333|10150098|FG001|Overall Study|Protocol Violation|1
6360739|NCT01412333|10150097|FG000|Overall Study|Non-compliance|1
6360740|NCT01412333|10150098|FG001|Overall Study|Non-compliance|3
6360741|NCT01412333|10150097|FG000|Overall Study|Lack of Efficacy|15
6360742|NCT01412333|10150098|FG001|Overall Study|Lack of Efficacy|6
6360743|NCT01412333|10150097|FG000|Overall Study|Pregnancy|3
6360744|NCT01412333|10150098|FG001|Overall Study|Pregnancy|0
6360745|NCT01412333|10150097|FG000|Overall Study|Consent withdrawn by participant|25
6360746|NCT01412333|10150098|FG001|Overall Study|Consent withdrawn by participant|12
6360747|NCT01412333|10150097|FG000|Overall Study|Adverse Event|25
6360748|NCT01412333|10150098|FG001|Overall Study|Adverse Event|16
6360749|NCT01412333|10150097|FG000|Overall Study|Lost to Follow-up|10
6360750|NCT01412333|10150098|FG001|Overall Study|Lost to Follow-up|6
6360751|NCT01247324|10150107|FG000|Overall Study|Death|1
6360752|NCT01247324|10150108|FG001|Overall Study|Death|0
6360753|NCT01247324|10150107|FG000|Overall Study|Physician Decision|0
6360754|NCT01247324|10150108|FG001|Overall Study|Physician Decision|1
6360755|NCT01247324|10150107|FG000|Overall Study|Non-compliance with study drug|3
6360756|NCT01247324|10150108|FG001|Overall Study|Non-compliance with study drug|0
6360757|NCT01247324|10150107|FG000|Overall Study|Lack of Efficacy|12
6360758|NCT01247324|10150108|FG001|Overall Study|Lack of Efficacy|8
6360759|NCT01247324|10150107|FG000|Overall Study|Non-compliance|2
6360760|NCT01247324|10150108|FG001|Overall Study|Non-compliance|0
6360761|NCT01247324|10150107|FG000|Overall Study|Pregnancy|2
6360762|NCT01247324|10150108|FG001|Overall Study|Pregnancy|3
6360763|NCT01247324|10150107|FG000|Overall Study|Protocol Violation|1
6360764|NCT01247324|10150108|FG001|Overall Study|Protocol Violation|2
6360765|NCT01247324|10150107|FG000|Overall Study|Reason not specified|11
6360766|NCT01247324|10150108|FG001|Overall Study|Reason not specified|8
6360767|NCT01247324|10150107|FG000|Overall Study|Consent withdrawn by participant|13
6360768|NCT01247324|10150108|FG001|Overall Study|Consent withdrawn by participant|8
6360769|NCT01247324|10150107|FG000|Overall Study|Adverse Event|25
6360770|NCT01247324|10150108|FG001|Overall Study|Adverse Event|13
6360771|NCT01247324|10150107|FG000|Overall Study|Lost to Follow-up|1
6360772|NCT01247324|10150108|FG001|Overall Study|Lost to Follow-up|1
6360773|NCT00667628|10150117|FG000|Overall Study|Lost to Follow-up|1
6360774|NCT00667628|10150118|FG001|Overall Study|Lost to Follow-up|0
6360775|NCT00667628|10150117|FG000|Overall Study|Death|6
6360776|NCT00667628|10150118|FG001|Overall Study|Death|6
6360777|NCT00667628|10150117|FG000|Overall Study|Investigator Considers in Best Interest|1
6360778|NCT00667628|10150118|FG001|Overall Study|Investigator Considers in Best Interest|0
6360779|NCT00667628|10150117|FG000|Overall Study|Sponsor Terminated Study|17
6360780|NCT00667628|10150118|FG001|Overall Study|Sponsor Terminated Study|21
6084199|NCT00642278|9693186|FG005|Overall Study|Withdrawal by Subject|2
6360781|NCT03581786|10150143|FG000|Overall Study|Death|17
6360782|NCT03581786|10150144|FG001|Overall Study|Death|12
6360783|NCT03581786|10150143|FG000|Overall Study|Withdrawal by Subject|2
6360784|NCT03581786|10150144|FG001|Overall Study|Withdrawal by Subject|4
6360785|NCT03581786|10150143|FG000|Overall Study|Lost to Follow-up|1
6360786|NCT03581786|10150144|FG001|Overall Study|Lost to Follow-up|0
6360787|NCT03581786|10150143|FG000|Overall Study|reason other than specified above|0
6360788|NCT03581786|10150144|FG001|Overall Study|reason other than specified above|1
6360789|NCT03581786|10150143|FG000|Overall Study|Ongoing in the study|123
6360790|NCT03581786|10150144|FG001|Overall Study|Ongoing in the study|129
6360791|NCT03486314|10150167|FG000|Part A|Adverse Event|1
6360792|NCT03486314|10150168|FG001|Part A|Adverse Event|0
6360793|NCT03486314|10150169|FG002|Part A|Adverse Event|0
6360794|NCT03486314|10150167|FG000|Part A|Symptomatic Deterioration|2
6360795|NCT03486314|10150168|FG001|Part A|Symptomatic Deterioration|0
6360796|NCT03486314|10150169|FG002|Part A|Symptomatic Deterioration|0
6360797|NCT02988713|10150177|FG000|Overall Study|Withdrawal by Subject|1
6360798|NCT02988713|10150177|FG000|Overall Study|Subject's failure to meet study inclusion or exclusion criteria after enrollment|2
6360799|NCT02794883|10150184|FG000|Pre-Surgical Treatment|Withdrawal by Subject|0
6360800|NCT02794883|10150185|FG001|Pre-Surgical Treatment|Withdrawal by Subject|0
6360801|NCT02794883|10150186|FG002|Pre-Surgical Treatment|Withdrawal by Subject|1
6360802|NCT02794883|10150184|FG000|Pre-Surgical Treatment|Progressive Disease|0
6360803|NCT02794883|10150185|FG001|Pre-Surgical Treatment|Progressive Disease|1
6360804|NCT02794883|10150186|FG002|Pre-Surgical Treatment|Progressive Disease|0
6360805|NCT02794883|10150184|FG000|Post-Surgery Treatment (Adjuvant)|Withdrawal by Subject|1
6360806|NCT02794883|10150185|FG001|Post-Surgery Treatment (Adjuvant)|Withdrawal by Subject|4
6360807|NCT02794883|10150186|FG002|Post-Surgery Treatment (Adjuvant)|Withdrawal by Subject|0
6360808|NCT02794883|10150184|FG000|Post-Surgery Treatment (Adjuvant)|Protocol Violation|1
6360809|NCT02794883|10150185|FG001|Post-Surgery Treatment (Adjuvant)|Protocol Violation|0
6360810|NCT02794883|10150186|FG002|Post-Surgery Treatment (Adjuvant)|Protocol Violation|0
6360811|NCT02794883|10150184|FG000|Post-Surgery Treatment (Adjuvant)|Progressive Disease|10
6360812|NCT02794883|10150185|FG001|Post-Surgery Treatment (Adjuvant)|Progressive Disease|6
6360813|NCT02794883|10150186|FG002|Post-Surgery Treatment (Adjuvant)|Progressive Disease|10
6360814|NCT02794883|10150184|FG000|Post-Surgery Treatment (Adjuvant)|Adverse Event|0
6360815|NCT02794883|10150185|FG001|Post-Surgery Treatment (Adjuvant)|Adverse Event|1
6360816|NCT02794883|10150186|FG002|Post-Surgery Treatment (Adjuvant)|Adverse Event|1
6360817|NCT02794883|10150184|FG000|Follow-up Period (up to 2 Years)|Death|12
6360818|NCT02794883|10150185|FG001|Follow-up Period (up to 2 Years)|Death|10
6360819|NCT02794883|10150186|FG002|Follow-up Period (up to 2 Years)|Death|10
6360820|NCT02677987|10150196|FG000|Overall Study|Withdrawal by Subject|3
6360821|NCT02677987|10150197|FG001|Overall Study|Withdrawal by Subject|0
6360822|NCT02677987|10150196|FG000|Overall Study|Lost to Follow-up|1
6360823|NCT02677987|10150197|FG001|Overall Study|Lost to Follow-up|0
6360824|NCT02659059|10150209|FG000|Overall Study|Completed|1
6360825|NCT02659059|10150210|FG001|Overall Study|Completed|0
6360826|NCT02659059|10150209|FG000|Overall Study|Other reasons|8
6360827|NCT02659059|10150210|FG001|Overall Study|Other reasons|2
6360828|NCT02659059|10150209|FG000|Overall Study|Disease Progression|120
6360829|NCT02659059|10150210|FG001|Overall Study|Disease Progression|16
6360830|NCT02659059|10150209|FG000|Overall Study|Study Drug toxicity|37
6360831|NCT02659059|10150210|FG001|Overall Study|Study Drug toxicity|9
6360832|NCT02659059|10150209|FG000|Overall Study|Death|2
6360833|NCT02659059|10150210|FG001|Overall Study|Death|1
6360834|NCT02659059|10150209|FG000|Overall Study|Adverse Event unrelated to Study drug|22
6360835|NCT02659059|10150210|FG001|Overall Study|Adverse Event unrelated to Study drug|4
6360836|NCT02659059|10150209|FG000|Overall Study|Participant request to discontinue study treatment|5
6360837|NCT02659059|10150210|FG001|Overall Study|Participant request to discontinue study treatment|0
6360838|NCT02659059|10150209|FG000|Overall Study|Participant withdrew consent|4
6360839|NCT02659059|10150210|FG001|Overall Study|Participant withdrew consent|0
6360840|NCT02659059|10150209|FG000|Overall Study|Lost to Follow-up|1
6360841|NCT02659059|10150210|FG001|Overall Study|Lost to Follow-up|0
6360842|NCT02337829|10150221|FG000|Overall Study|Death|0
6360843|NCT02337829|10150222|FG001|Overall Study|Death|1
6360844|NCT02337829|10150223|FG002|Overall Study|Death|0
6360845|NCT02337829|10150224|FG003|Overall Study|Death|0
6360846|NCT02337829|10150221|FG000|Overall Study|Study terminated by sponsor|12
6360847|NCT02337829|10150222|FG001|Overall Study|Study terminated by sponsor|10
6360848|NCT02337829|10150223|FG002|Overall Study|Study terminated by sponsor|5
6360849|NCT02337829|10150224|FG003|Overall Study|Study terminated by sponsor|6
6360850|NCT02337829|10150221|FG000|Overall Study|discontinued for other reasons|6
6360851|NCT02337829|10150222|FG001|Overall Study|discontinued for other reasons|3
6360852|NCT02337829|10150223|FG002|Overall Study|discontinued for other reasons|1
6360853|NCT02337829|10150224|FG003|Overall Study|discontinued for other reasons|4
6360854|NCT01928394|10150259|FG000|Treatment Period|Disease progression|17
6360855|NCT01928394|10150260|FG001|Treatment Period|Disease progression|2
6360856|NCT01928394|10150261|FG002|Treatment Period|Disease progression|12
6360857|NCT01928394|10150262|FG003|Treatment Period|Disease progression|48
6360858|NCT01928394|10150263|FG004|Treatment Period|Disease progression|3
6360859|NCT01928394|10150264|FG005|Treatment Period|Disease progression|25
6360860|NCT01928394|10150265|FG006|Treatment Period|Disease progression|38
6360861|NCT01928394|10150266|FG007|Treatment Period|Disease progression|16
6360862|NCT01928394|10150267|FG008|Treatment Period|Disease progression|3
6360863|NCT01928394|10150268|FG009|Treatment Period|Disease progression|11
6360864|NCT01928394|10150269|FG010|Treatment Period|Disease progression|22
6360865|NCT01928394|10150270|FG011|Treatment Period|Disease progression|73
6360866|NCT01928394|10150271|FG012|Treatment Period|Disease progression|38
6360867|NCT01928394|10150272|FG013|Treatment Period|Disease progression|118
6360868|NCT01928394|10150273|FG014|Treatment Period|Disease progression|59
6360869|NCT01928394|10150274|FG015|Treatment Period|Disease progression|1
6360870|NCT01928394|10150275|FG016|Treatment Period|Disease progression|43
6360871|NCT01928394|10150276|FG017|Treatment Period|Disease progression|56
6360872|NCT01928394|10150277|FG018|Treatment Period|Disease progression|50
6360873|NCT01928394|10150278|FG019|Treatment Period|Disease progression|71
6360874|NCT01928394|10150279|FG020|Treatment Period|Disease progression|30
6360875|NCT01928394|10150280|FG021|Treatment Period|Disease progression|31
6360876|NCT01928394|10150281|FG022|Treatment Period|Disease progression|31
6360877|NCT01928394|10150259|FG000|Treatment Period|Study drug toxicity|1
6360878|NCT01928394|10150260|FG001|Treatment Period|Study drug toxicity|1
6360879|NCT01928394|10150261|FG002|Treatment Period|Study drug toxicity|3
6360880|NCT01928394|10150262|FG003|Treatment Period|Study drug toxicity|3
6360881|NCT01928394|10150263|FG004|Treatment Period|Study drug toxicity|0
6360882|NCT01928394|10150264|FG005|Treatment Period|Study drug toxicity|9
6360883|NCT01928394|10150265|FG006|Treatment Period|Study drug toxicity|7
6360884|NCT01928394|10150266|FG007|Treatment Period|Study drug toxicity|1
6360885|NCT01928394|10150267|FG008|Treatment Period|Study drug toxicity|0
6360886|NCT01928394|10150268|FG009|Treatment Period|Study drug toxicity|5
6360887|NCT01928394|10150269|FG010|Treatment Period|Study drug toxicity|2
6360888|NCT01928394|10150270|FG011|Treatment Period|Study drug toxicity|3
6360889|NCT01928394|10150271|FG012|Treatment Period|Study drug toxicity|7
6360890|NCT01928394|10150272|FG013|Treatment Period|Study drug toxicity|5
6360891|NCT01928394|10150273|FG014|Treatment Period|Study drug toxicity|12
6360892|NCT01928394|10150274|FG015|Treatment Period|Study drug toxicity|0
6360893|NCT01928394|10150275|FG016|Treatment Period|Study drug toxicity|3
6360894|NCT01928394|10150276|FG017|Treatment Period|Study drug toxicity|3
6360895|NCT01928394|10150277|FG018|Treatment Period|Study drug toxicity|12
6360896|NCT01928394|10150278|FG019|Treatment Period|Study drug toxicity|15
6360897|NCT01928394|10150279|FG020|Treatment Period|Study drug toxicity|4
6360898|NCT01928394|10150280|FG021|Treatment Period|Study drug toxicity|7
6360899|NCT01928394|10150281|FG022|Treatment Period|Study drug toxicity|4
6360900|NCT01928394|10150259|FG000|Treatment Period|AE unrelated to study drug|0
6360901|NCT01928394|10150260|FG001|Treatment Period|AE unrelated to study drug|0
6360902|NCT01928394|10150261|FG002|Treatment Period|AE unrelated to study drug|2
6360903|NCT01928394|10150262|FG003|Treatment Period|AE unrelated to study drug|3
6360904|NCT01928394|10150263|FG004|Treatment Period|AE unrelated to study drug|0
6360905|NCT01928394|10150264|FG005|Treatment Period|AE unrelated to study drug|5
6360906|NCT01928394|10150265|FG006|Treatment Period|AE unrelated to study drug|1
6360907|NCT01928394|10150266|FG007|Treatment Period|AE unrelated to study drug|0
6360908|NCT01928394|10150267|FG008|Treatment Period|AE unrelated to study drug|0
6360909|NCT01928394|10150268|FG009|Treatment Period|AE unrelated to study drug|2
6360910|NCT01928394|10150269|FG010|Treatment Period|AE unrelated to study drug|0
6360911|NCT01928394|10150270|FG011|Treatment Period|AE unrelated to study drug|12
6360912|NCT01928394|10150271|FG012|Treatment Period|AE unrelated to study drug|6
6360913|NCT01928394|10150272|FG013|Treatment Period|AE unrelated to study drug|13
6360914|NCT01928394|10150273|FG014|Treatment Period|AE unrelated to study drug|6
6360915|NCT01928394|10150274|FG015|Treatment Period|AE unrelated to study drug|1
6360916|NCT01928394|10150275|FG016|Treatment Period|AE unrelated to study drug|1
6360917|NCT01928394|10150276|FG017|Treatment Period|AE unrelated to study drug|6
6360918|NCT01928394|10150277|FG018|Treatment Period|AE unrelated to study drug|3
6360919|NCT01928394|10150278|FG019|Treatment Period|AE unrelated to study drug|5
6360920|NCT01928394|10150279|FG020|Treatment Period|AE unrelated to study drug|1
6360921|NCT01928394|10150280|FG021|Treatment Period|AE unrelated to study drug|1
6360922|NCT01928394|10150281|FG022|Treatment Period|AE unrelated to study drug|0
6360923|NCT01928394|10150259|FG000|Treatment Period|Participant request to stop therapy|0
6360924|NCT01928394|10150260|FG001|Treatment Period|Participant request to stop therapy|0
6360925|NCT01928394|10150261|FG002|Treatment Period|Participant request to stop therapy|0
6360926|NCT01928394|10150262|FG003|Treatment Period|Participant request to stop therapy|0
6360927|NCT01928394|10150263|FG004|Treatment Period|Participant request to stop therapy|0
6360928|NCT01928394|10150264|FG005|Treatment Period|Participant request to stop therapy|3
6360929|NCT01928394|10150265|FG006|Treatment Period|Participant request to stop therapy|3
6360930|NCT01928394|10150266|FG007|Treatment Period|Participant request to stop therapy|0
6360931|NCT01928394|10150267|FG008|Treatment Period|Participant request to stop therapy|0
6360932|NCT01928394|10150268|FG009|Treatment Period|Participant request to stop therapy|0
6360933|NCT01928394|10150269|FG010|Treatment Period|Participant request to stop therapy|3
6360934|NCT01928394|10150270|FG011|Treatment Period|Participant request to stop therapy|2
6360935|NCT01928394|10150271|FG012|Treatment Period|Participant request to stop therapy|1
6360936|NCT01928394|10150272|FG013|Treatment Period|Participant request to stop therapy|2
6360937|NCT01928394|10150273|FG014|Treatment Period|Participant request to stop therapy|4
6360938|NCT01928394|10150274|FG015|Treatment Period|Participant request to stop therapy|0
6360939|NCT01928394|10150275|FG016|Treatment Period|Participant request to stop therapy|1
6360940|NCT01928394|10150276|FG017|Treatment Period|Participant request to stop therapy|3
6360941|NCT01928394|10150277|FG018|Treatment Period|Participant request to stop therapy|1
6360942|NCT01928394|10150278|FG019|Treatment Period|Participant request to stop therapy|1
6360943|NCT01928394|10150279|FG020|Treatment Period|Participant request to stop therapy|3
6360944|NCT01928394|10150280|FG021|Treatment Period|Participant request to stop therapy|1
6360945|NCT01928394|10150281|FG022|Treatment Period|Participant request to stop therapy|3
6360946|NCT01928394|10150259|FG000|Treatment Period|Participant withdrew consent|0
6360947|NCT01928394|10150260|FG001|Treatment Period|Participant withdrew consent|0
6360948|NCT01928394|10150261|FG002|Treatment Period|Participant withdrew consent|1
6360949|NCT01928394|10150262|FG003|Treatment Period|Participant withdrew consent|1
6360950|NCT01928394|10150263|FG004|Treatment Period|Participant withdrew consent|0
6360951|NCT01928394|10150264|FG005|Treatment Period|Participant withdrew consent|1
6360952|NCT01928394|10150265|FG006|Treatment Period|Participant withdrew consent|0
6360953|NCT01928394|10150266|FG007|Treatment Period|Participant withdrew consent|1
6360954|NCT01928394|10150267|FG008|Treatment Period|Participant withdrew consent|0
6360955|NCT01928394|10150268|FG009|Treatment Period|Participant withdrew consent|0
6360956|NCT01928394|10150269|FG010|Treatment Period|Participant withdrew consent|1
6360957|NCT01928394|10150270|FG011|Treatment Period|Participant withdrew consent|1
6360958|NCT01928394|10150271|FG012|Treatment Period|Participant withdrew consent|1
6360959|NCT01928394|10150272|FG013|Treatment Period|Participant withdrew consent|0
6360960|NCT01928394|10150273|FG014|Treatment Period|Participant withdrew consent|2
6360961|NCT01928394|10150274|FG015|Treatment Period|Participant withdrew consent|0
6360962|NCT01928394|10150275|FG016|Treatment Period|Participant withdrew consent|2
6360963|NCT01928394|10150276|FG017|Treatment Period|Participant withdrew consent|1
6360964|NCT01928394|10150277|FG018|Treatment Period|Participant withdrew consent|1
6360965|NCT01928394|10150278|FG019|Treatment Period|Participant withdrew consent|1
6360966|NCT01928394|10150279|FG020|Treatment Period|Participant withdrew consent|0
6360967|NCT01928394|10150280|FG021|Treatment Period|Participant withdrew consent|2
6360968|NCT01928394|10150281|FG022|Treatment Period|Participant withdrew consent|0
6360969|NCT01928394|10150259|FG000|Treatment Period|Poor/non-compliance|0
6360970|NCT01928394|10150260|FG001|Treatment Period|Poor/non-compliance|0
6360971|NCT01928394|10150261|FG002|Treatment Period|Poor/non-compliance|0
6360972|NCT01928394|10150262|FG003|Treatment Period|Poor/non-compliance|1
6360973|NCT01928394|10150263|FG004|Treatment Period|Poor/non-compliance|0
6360974|NCT01928394|10150264|FG005|Treatment Period|Poor/non-compliance|0
6360975|NCT01928394|10150265|FG006|Treatment Period|Poor/non-compliance|0
6360976|NCT01928394|10150266|FG007|Treatment Period|Poor/non-compliance|0
6360977|NCT01928394|10150267|FG008|Treatment Period|Poor/non-compliance|0
6360978|NCT01928394|10150268|FG009|Treatment Period|Poor/non-compliance|0
6360979|NCT01928394|10150269|FG010|Treatment Period|Poor/non-compliance|0
6360980|NCT01928394|10150270|FG011|Treatment Period|Poor/non-compliance|0
6360981|NCT01928394|10150271|FG012|Treatment Period|Poor/non-compliance|1
6360982|NCT01928394|10150272|FG013|Treatment Period|Poor/non-compliance|0
6360983|NCT01928394|10150273|FG014|Treatment Period|Poor/non-compliance|1
6360984|NCT01928394|10150274|FG015|Treatment Period|Poor/non-compliance|0
6360985|NCT01928394|10150275|FG016|Treatment Period|Poor/non-compliance|0
6360986|NCT01928394|10150276|FG017|Treatment Period|Poor/non-compliance|1
6360987|NCT01928394|10150277|FG018|Treatment Period|Poor/non-compliance|0
6360988|NCT01928394|10150278|FG019|Treatment Period|Poor/non-compliance|1
6360989|NCT01928394|10150279|FG020|Treatment Period|Poor/non-compliance|0
6360990|NCT01928394|10150280|FG021|Treatment Period|Poor/non-compliance|0
6360991|NCT01928394|10150281|FG022|Treatment Period|Poor/non-compliance|0
6360992|NCT01928394|10150259|FG000|Treatment Period|other reason|0
6360993|NCT01928394|10150260|FG001|Treatment Period|other reason|0
6360994|NCT01928394|10150261|FG002|Treatment Period|other reason|0
6360995|NCT01928394|10150262|FG003|Treatment Period|other reason|0
6360996|NCT01928394|10150263|FG004|Treatment Period|other reason|0
6360997|NCT01928394|10150264|FG005|Treatment Period|other reason|0
6360998|NCT01928394|10150265|FG006|Treatment Period|other reason|0
6360999|NCT01928394|10150266|FG007|Treatment Period|other reason|0
6361000|NCT01928394|10150267|FG008|Treatment Period|other reason|0
6361001|NCT01928394|10150268|FG009|Treatment Period|other reason|0
6361002|NCT01928394|10150269|FG010|Treatment Period|other reason|1
6361003|NCT01928394|10150270|FG011|Treatment Period|other reason|1
6361004|NCT01928394|10150271|FG012|Treatment Period|other reason|1
6361005|NCT01928394|10150272|FG013|Treatment Period|other reason|0
6361006|NCT01928394|10150273|FG014|Treatment Period|other reason|1
6361007|NCT01928394|10150274|FG015|Treatment Period|other reason|0
6361008|NCT01928394|10150275|FG016|Treatment Period|other reason|0
6361009|NCT01928394|10150276|FG017|Treatment Period|other reason|0
6361010|NCT01928394|10150277|FG018|Treatment Period|other reason|2
6361011|NCT01928394|10150278|FG019|Treatment Period|other reason|2
6361012|NCT01928394|10150279|FG020|Treatment Period|other reason|0
6361013|NCT01928394|10150280|FG021|Treatment Period|other reason|0
6361014|NCT01928394|10150281|FG022|Treatment Period|other reason|0
6361015|NCT01928394|10150259|FG000|Treatment Period|Maximum clinical benefit|0
6361016|NCT01928394|10150260|FG001|Treatment Period|Maximum clinical benefit|0
6361017|NCT01928394|10150261|FG002|Treatment Period|Maximum clinical benefit|0
6361018|NCT01928394|10150262|FG003|Treatment Period|Maximum clinical benefit|0
6361019|NCT01928394|10150263|FG004|Treatment Period|Maximum clinical benefit|0
6361020|NCT01928394|10150264|FG005|Treatment Period|Maximum clinical benefit|0
6361021|NCT01928394|10150265|FG006|Treatment Period|Maximum clinical benefit|0
6361022|NCT01928394|10150266|FG007|Treatment Period|Maximum clinical benefit|0
6361023|NCT01928394|10150267|FG008|Treatment Period|Maximum clinical benefit|0
6361024|NCT01928394|10150268|FG009|Treatment Period|Maximum clinical benefit|0
6361025|NCT01928394|10150269|FG010|Treatment Period|Maximum clinical benefit|1
6361026|NCT01928394|10150270|FG011|Treatment Period|Maximum clinical benefit|1
6361027|NCT01928394|10150271|FG012|Treatment Period|Maximum clinical benefit|0
6361028|NCT01928394|10150272|FG013|Treatment Period|Maximum clinical benefit|0
6361029|NCT01928394|10150273|FG014|Treatment Period|Maximum clinical benefit|1
6361030|NCT01928394|10150274|FG015|Treatment Period|Maximum clinical benefit|0
6361031|NCT01928394|10150275|FG016|Treatment Period|Maximum clinical benefit|0
6361032|NCT01928394|10150276|FG017|Treatment Period|Maximum clinical benefit|1
6361033|NCT01928394|10150277|FG018|Treatment Period|Maximum clinical benefit|1
6361034|NCT01928394|10150278|FG019|Treatment Period|Maximum clinical benefit|0
6361035|NCT01928394|10150279|FG020|Treatment Period|Maximum clinical benefit|2
6361036|NCT01928394|10150280|FG021|Treatment Period|Maximum clinical benefit|0
6361037|NCT01928394|10150281|FG022|Treatment Period|Maximum clinical benefit|0
6084200|NCT00642278|9693187|FG006|Overall Study|Withdrawal by Subject|2
6361038|NCT01928394|10150259|FG000|Treatment Period|Lost to Follow-up|0
6361039|NCT01928394|10150260|FG001|Treatment Period|Lost to Follow-up|0
6361040|NCT01928394|10150261|FG002|Treatment Period|Lost to Follow-up|0
6361041|NCT01928394|10150262|FG003|Treatment Period|Lost to Follow-up|0
6361042|NCT01928394|10150263|FG004|Treatment Period|Lost to Follow-up|0
6361043|NCT01928394|10150264|FG005|Treatment Period|Lost to Follow-up|0
6361044|NCT01928394|10150265|FG006|Treatment Period|Lost to Follow-up|0
6361045|NCT01928394|10150266|FG007|Treatment Period|Lost to Follow-up|0
6361046|NCT01928394|10150267|FG008|Treatment Period|Lost to Follow-up|0
6361047|NCT01928394|10150268|FG009|Treatment Period|Lost to Follow-up|0
6361048|NCT01928394|10150269|FG010|Treatment Period|Lost to Follow-up|0
6361049|NCT01928394|10150270|FG011|Treatment Period|Lost to Follow-up|0
6361050|NCT01928394|10150271|FG012|Treatment Period|Lost to Follow-up|0
6361051|NCT01928394|10150272|FG013|Treatment Period|Lost to Follow-up|0
6361052|NCT01928394|10150273|FG014|Treatment Period|Lost to Follow-up|0
6361053|NCT01928394|10150274|FG015|Treatment Period|Lost to Follow-up|0
6361054|NCT01928394|10150275|FG016|Treatment Period|Lost to Follow-up|0
6361055|NCT01928394|10150276|FG017|Treatment Period|Lost to Follow-up|0
6361056|NCT01928394|10150277|FG018|Treatment Period|Lost to Follow-up|0
6361057|NCT01928394|10150278|FG019|Treatment Period|Lost to Follow-up|0
6361058|NCT01928394|10150279|FG020|Treatment Period|Lost to Follow-up|0
6361059|NCT01928394|10150280|FG021|Treatment Period|Lost to Follow-up|0
6361060|NCT01928394|10150281|FG022|Treatment Period|Lost to Follow-up|1
6361061|NCT01928394|10150259|FG000|Treatment Period|Death|0
6361062|NCT01928394|10150260|FG001|Treatment Period|Death|0
6361063|NCT01928394|10150261|FG002|Treatment Period|Death|0
6361064|NCT01928394|10150262|FG003|Treatment Period|Death|0
6361065|NCT01928394|10150263|FG004|Treatment Period|Death|0
6361066|NCT01928394|10150264|FG005|Treatment Period|Death|0
6361067|NCT01928394|10150265|FG006|Treatment Period|Death|0
6361068|NCT01928394|10150266|FG007|Treatment Period|Death|0
6361069|NCT01928394|10150267|FG008|Treatment Period|Death|0
6361070|NCT01928394|10150268|FG009|Treatment Period|Death|0
6361071|NCT01928394|10150269|FG010|Treatment Period|Death|0
6361072|NCT01928394|10150270|FG011|Treatment Period|Death|0
6361073|NCT01928394|10150271|FG012|Treatment Period|Death|0
6361074|NCT01928394|10150272|FG013|Treatment Period|Death|1
6361075|NCT01928394|10150273|FG014|Treatment Period|Death|2
6361076|NCT01928394|10150274|FG015|Treatment Period|Death|0
6361077|NCT01928394|10150275|FG016|Treatment Period|Death|0
6361078|NCT01928394|10150276|FG017|Treatment Period|Death|0
6361079|NCT01928394|10150277|FG018|Treatment Period|Death|0
6361080|NCT01928394|10150278|FG019|Treatment Period|Death|0
6361081|NCT01928394|10150279|FG020|Treatment Period|Death|0
6361082|NCT01928394|10150280|FG021|Treatment Period|Death|0
6361083|NCT01928394|10150281|FG022|Treatment Period|Death|0
6361084|NCT01928394|10150259|FG000|Follow-up Period|Participant withdrew consent|3
6361085|NCT01928394|10150260|FG001|Follow-up Period|Participant withdrew consent|0
6361086|NCT01928394|10150261|FG002|Follow-up Period|Participant withdrew consent|1
6361087|NCT01928394|10150262|FG003|Follow-up Period|Participant withdrew consent|4
6361088|NCT01928394|10150263|FG004|Follow-up Period|Participant withdrew consent|0
6361089|NCT01928394|10150264|FG005|Follow-up Period|Participant withdrew consent|2
6361090|NCT01928394|10150265|FG006|Follow-up Period|Participant withdrew consent|5
6361091|NCT01928394|10150266|FG007|Follow-up Period|Participant withdrew consent|1
6361092|NCT01928394|10150267|FG008|Follow-up Period|Participant withdrew consent|0
6361093|NCT01928394|10150268|FG009|Follow-up Period|Participant withdrew consent|0
6361094|NCT01928394|10150269|FG010|Follow-up Period|Participant withdrew consent|5
6361095|NCT01928394|10150270|FG011|Follow-up Period|Participant withdrew consent|8
6361096|NCT01928394|10150271|FG012|Follow-up Period|Participant withdrew consent|2
6361097|NCT01928394|10150272|FG013|Follow-up Period|Participant withdrew consent|12
6361098|NCT01928394|10150273|FG014|Follow-up Period|Participant withdrew consent|7
6361099|NCT01928394|10150274|FG015|Follow-up Period|Participant withdrew consent|0
6361100|NCT01928394|10150275|FG016|Follow-up Period|Participant withdrew consent|5
6361101|NCT01928394|10150276|FG017|Follow-up Period|Participant withdrew consent|3
6361102|NCT01928394|10150277|FG018|Follow-up Period|Participant withdrew consent|2
6361103|NCT01928394|10150278|FG019|Follow-up Period|Participant withdrew consent|7
6361104|NCT01928394|10150279|FG020|Follow-up Period|Participant withdrew consent|4
6361105|NCT01928394|10150280|FG021|Follow-up Period|Participant withdrew consent|6
6361106|NCT01928394|10150281|FG022|Follow-up Period|Participant withdrew consent|2
6361107|NCT01928394|10150259|FG000|Follow-up Period|Death|0
6361108|NCT01928394|10150260|FG001|Follow-up Period|Death|0
6361109|NCT01928394|10150261|FG002|Follow-up Period|Death|2
6361110|NCT01928394|10150262|FG003|Follow-up Period|Death|6
6361111|NCT01928394|10150263|FG004|Follow-up Period|Death|0
6361112|NCT01928394|10150264|FG005|Follow-up Period|Death|6
6361113|NCT01928394|10150265|FG006|Follow-up Period|Death|6
6361114|NCT01928394|10150266|FG007|Follow-up Period|Death|2
6361115|NCT01928394|10150267|FG008|Follow-up Period|Death|1
6361116|NCT01928394|10150268|FG009|Follow-up Period|Death|2
6361117|NCT01928394|10150269|FG010|Follow-up Period|Death|4
6361118|NCT01928394|10150270|FG011|Follow-up Period|Death|12
6361119|NCT01928394|10150271|FG012|Follow-up Period|Death|11
6361120|NCT01928394|10150272|FG013|Follow-up Period|Death|25
6361121|NCT01928394|10150273|FG014|Follow-up Period|Death|18
6361122|NCT01928394|10150274|FG015|Follow-up Period|Death|0
6361123|NCT01928394|10150275|FG016|Follow-up Period|Death|6
6361124|NCT01928394|10150276|FG017|Follow-up Period|Death|5
6361125|NCT01928394|10150277|FG018|Follow-up Period|Death|13
6361126|NCT01928394|10150278|FG019|Follow-up Period|Death|13
6361127|NCT01928394|10150279|FG020|Follow-up Period|Death|5
6361128|NCT01928394|10150280|FG021|Follow-up Period|Death|3
6361129|NCT01928394|10150281|FG022|Follow-up Period|Death|2
6361130|NCT01928394|10150259|FG000|Follow-up Period|other reason|0
6361131|NCT01928394|10150260|FG001|Follow-up Period|other reason|0
6361132|NCT01928394|10150261|FG002|Follow-up Period|other reason|0
6361133|NCT01928394|10150262|FG003|Follow-up Period|other reason|0
6361134|NCT01928394|10150263|FG004|Follow-up Period|other reason|0
6361135|NCT01928394|10150264|FG005|Follow-up Period|other reason|0
6361136|NCT01928394|10150265|FG006|Follow-up Period|other reason|1
6361137|NCT01928394|10150266|FG007|Follow-up Period|other reason|3
6361138|NCT01928394|10150267|FG008|Follow-up Period|other reason|0
6361139|NCT01928394|10150268|FG009|Follow-up Period|other reason|0
6361140|NCT01928394|10150269|FG010|Follow-up Period|other reason|2
6361141|NCT01928394|10150270|FG011|Follow-up Period|other reason|1
6361142|NCT01928394|10150271|FG012|Follow-up Period|other reason|0
6361143|NCT01928394|10150272|FG013|Follow-up Period|other reason|1
6361144|NCT01928394|10150273|FG014|Follow-up Period|other reason|4
6361145|NCT01928394|10150274|FG015|Follow-up Period|other reason|0
6361146|NCT01928394|10150275|FG016|Follow-up Period|other reason|2
6361147|NCT01928394|10150276|FG017|Follow-up Period|other reason|0
6361148|NCT01928394|10150277|FG018|Follow-up Period|other reason|1
6361149|NCT01928394|10150278|FG019|Follow-up Period|other reason|1
6361150|NCT01928394|10150279|FG020|Follow-up Period|other reason|0
6361151|NCT01928394|10150280|FG021|Follow-up Period|other reason|0
6361152|NCT01928394|10150281|FG022|Follow-up Period|other reason|1
6361153|NCT01928394|10150259|FG000|Follow-up Period|Lost to Follow-up|0
6361154|NCT01928394|10150260|FG001|Follow-up Period|Lost to Follow-up|0
6361155|NCT01928394|10150261|FG002|Follow-up Period|Lost to Follow-up|0
6170519|NCT01253421|9816888|FG003|Assessment and Scheduling|Found to be Ineligible|0
6170520|NCT01253421|9816889|FG004|Assessment and Scheduling|Found to be Ineligible|0
6170521|NCT01253421|9816885|FG000|Assessment and Scheduling|Lost to Follow-up|17
6170522|NCT01253421|9816886|FG001|Assessment and Scheduling|Lost to Follow-up|0
6170523|NCT01253421|9816887|FG002|Assessment and Scheduling|Lost to Follow-up|0
6170524|NCT01253421|9816888|FG003|Assessment and Scheduling|Lost to Follow-up|0
6170525|NCT01253421|9816889|FG004|Assessment and Scheduling|Lost to Follow-up|0
6170526|NCT01253421|9816885|FG000|Assessment and Scheduling|Withdrawal by Subject|7
6170527|NCT01253421|9816886|FG001|Assessment and Scheduling|Withdrawal by Subject|0
6170528|NCT01253421|9816887|FG002|Assessment and Scheduling|Withdrawal by Subject|0
6170529|NCT01253421|9816888|FG003|Assessment and Scheduling|Withdrawal by Subject|0
6170530|NCT01253421|9816889|FG004|Assessment and Scheduling|Withdrawal by Subject|0
6170531|NCT01253421|9816885|FG000|Assessment and Scheduling|Physician Decision|1
6170532|NCT01253421|9816886|FG001|Assessment and Scheduling|Physician Decision|0
6170533|NCT01253421|9816887|FG002|Assessment and Scheduling|Physician Decision|0
6170534|NCT01253421|9816888|FG003|Assessment and Scheduling|Physician Decision|0
6361156|NCT01928394|10150262|FG003|Follow-up Period|Lost to Follow-up|0
6361157|NCT01928394|10150263|FG004|Follow-up Period|Lost to Follow-up|0
6361158|NCT01928394|10150264|FG005|Follow-up Period|Lost to Follow-up|0
6361159|NCT01928394|10150265|FG006|Follow-up Period|Lost to Follow-up|0
6361160|NCT01928394|10150266|FG007|Follow-up Period|Lost to Follow-up|0
6361161|NCT01928394|10150267|FG008|Follow-up Period|Lost to Follow-up|0
6361162|NCT01928394|10150268|FG009|Follow-up Period|Lost to Follow-up|0
6361163|NCT01928394|10150269|FG010|Follow-up Period|Lost to Follow-up|0
6361164|NCT01928394|10150270|FG011|Follow-up Period|Lost to Follow-up|1
6361165|NCT01928394|10150271|FG012|Follow-up Period|Lost to Follow-up|1
6361166|NCT01928394|10150272|FG013|Follow-up Period|Lost to Follow-up|0
6361167|NCT01928394|10150273|FG014|Follow-up Period|Lost to Follow-up|1
6361168|NCT01928394|10150274|FG015|Follow-up Period|Lost to Follow-up|0
6361169|NCT01928394|10150275|FG016|Follow-up Period|Lost to Follow-up|1
6361170|NCT01928394|10150276|FG017|Follow-up Period|Lost to Follow-up|0
6361171|NCT01928394|10150277|FG018|Follow-up Period|Lost to Follow-up|0
6361172|NCT01928394|10150278|FG019|Follow-up Period|Lost to Follow-up|0
6361173|NCT01928394|10150279|FG020|Follow-up Period|Lost to Follow-up|0
6361174|NCT01928394|10150280|FG021|Follow-up Period|Lost to Follow-up|0
6361175|NCT01928394|10150281|FG022|Follow-up Period|Lost to Follow-up|1
6361176|NCT01657500|10150331|FG000|Overall Study|set impropperly matched|3
6361177|NCT01657500|10150332|FG001|Overall Study|set impropperly matched|3
6361178|NCT01657500|10150331|FG000|Overall Study|Lost to Follow-up|2
6361179|NCT01657500|10150332|FG001|Overall Study|Lost to Follow-up|2
6084201|NCT00642278|9693181|FG000|Overall Study|Noncompliance with study drug regimen|0
6084202|NCT00642278|9693182|FG001|Overall Study|Noncompliance with study drug regimen|0
6361180|NCT04810221|10150338|FG000|Overall Study|Physician Decision|3
6361181|NCT04575038|10150344|FG000|Overall Study|Withdrawal by Subject|1
6361182|NCT04575038|10150345|FG001|Overall Study|Withdrawal by Subject|1
6361183|NCT04545567|10150353|FG000|Overall Study|tested positive for SARS-co-V2|1
6361184|NCT04545567|10150354|FG001|Overall Study|tested positive for SARS-co-V2|1
6361185|NCT04545567|10150353|FG000|Overall Study|Withdrawal by Subject|0
6361186|NCT04545567|10150354|FG001|Overall Study|Withdrawal by Subject|1
6361187|NCT04397757|10150366|FG000|Overall Study|Death|3
6361188|NCT04397757|10150367|FG001|Overall Study|Death|11
6361189|NCT04397757|10150366|FG000|Overall Study|Withdrawal by Subject|2
6361190|NCT04397757|10150367|FG001|Overall Study|Withdrawal by Subject|0
6361191|NCT04397757|10150366|FG000|Overall Study|Lost to Follow-up|4
6361192|NCT04397757|10150367|FG001|Overall Study|Lost to Follow-up|3
6361193|NCT04382651|10150389|FG000|Overall Study|Death|26
6361194|NCT04382651|10150390|FG001|Overall Study|Death|23
6361195|NCT04382651|10150389|FG000|Overall Study|Lost to Follow-up|3
6361196|NCT04382651|10150390|FG001|Overall Study|Lost to Follow-up|4
6361197|NCT04382651|10150389|FG000|Overall Study|Withdrawal by Subject|2
6361198|NCT04382651|10150390|FG001|Overall Study|Withdrawal by Subject|0
6361199|NCT04382651|10150389|FG000|Overall Study|Physician Decision|0
6361200|NCT04382651|10150390|FG001|Overall Study|Physician Decision|1
6361201|NCT04112303|10150423|FG000|Overall Study|Death|1
6361202|NCT03896477|10150430|FG000|Overall Study|Met Ineligibility Criteria During the Study|1
6361203|NCT03896477|10150431|FG001|Overall Study|Met Ineligibility Criteria During the Study|1
6361204|NCT03896477|10150432|FG002|Overall Study|Met Ineligibility Criteria During the Study|2
6361205|NCT03896477|10150430|FG000|Overall Study|Parent Requested Withdrawal|8
6361206|NCT03896477|10150431|FG001|Overall Study|Parent Requested Withdrawal|12
6361207|NCT03896477|10150432|FG002|Overall Study|Parent Requested Withdrawal|9
6361208|NCT03896477|10150430|FG000|Overall Study|Adverse Event|0
6361209|NCT03896477|10150431|FG001|Overall Study|Adverse Event|0
6361210|NCT03896477|10150432|FG002|Overall Study|Adverse Event|1
6361211|NCT03896477|10150430|FG000|Overall Study|Death|1
6361212|NCT03896477|10150431|FG001|Overall Study|Death|0
6361213|NCT03896477|10150432|FG002|Overall Study|Death|0
6361214|NCT03896477|10150430|FG000|Overall Study|Other|5
6361215|NCT03896477|10150431|FG001|Overall Study|Other|6
6361216|NCT03896477|10150432|FG002|Overall Study|Other|7
6361217|NCT03896477|10150430|FG000|Overall Study|Lost to Follow-up|2
6361218|NCT03896477|10150431|FG001|Overall Study|Lost to Follow-up|1
6361219|NCT03896477|10150432|FG002|Overall Study|Lost to Follow-up|1
6361237|NCT03463993|10150516|FG000|Overall Study|Lost to Follow-up|7
6361238|NCT03463993|10150517|FG001|Overall Study|Lost to Follow-up|8
6361239|NCT03463993|10150516|FG000|Overall Study|Withdrawal by Subject|2
6361240|NCT03463993|10150517|FG001|Overall Study|Withdrawal by Subject|0
6361241|NCT03463993|10150516|FG000|Overall Study|Protocol Violation|4
6361242|NCT03463993|10150517|FG001|Overall Study|Protocol Violation|1
6361243|NCT03463993|10150516|FG000|Overall Study|Had a vaginal delivery prior to caesarean delivery|9
6361244|NCT03463993|10150517|FG001|Overall Study|Had a vaginal delivery prior to caesarean delivery|11
6361245|NCT03463993|10150516|FG000|Overall Study|Had emergency caesarean delivery prior to elective caesarean delivery|7
6361246|NCT03463993|10150517|FG001|Overall Study|Had emergency caesarean delivery prior to elective caesarean delivery|6
6361247|NCT03364036|10150545|FG000|Overall Study|Adverse Event|1
6361248|NCT03364036|10150545|FG000|Overall Study|Lost to Follow-up|1
6361249|NCT03364036|10150545|FG000|Overall Study|Withdrew Consent|1
6361250|NCT03364036|10150545|FG000|Overall Study|Protocol Non-Compliance|1
6361251|NCT03364036|10150545|FG000|Overall Study|Other|2
6361252|NCT03205163|10150551|FG000|ATP (LDC: 3 Days; HDC: 4 Days)|Sponsor Decision|1
6361253|NCT03205163|10150552|FG001|ATP (LDC: 3 Days; HDC: 4 Days)|Sponsor Decision|0
6361254|NCT03178045|10150569|FG000|Overall Study|Withdrawal by Subject|5
6361255|NCT03178045|10150570|FG001|Overall Study|Withdrawal by Subject|7
6361256|NCT03178045|10150569|FG000|Overall Study|Surgery Cancelled/Relocated|34
6361257|NCT03178045|10150570|FG001|Overall Study|Surgery Cancelled/Relocated|30
6361258|NCT03178045|10150569|FG000|Overall Study|Procedure Ineligible Post-Operatively/Pr|47
6361259|NCT03178045|10150570|FG001|Overall Study|Procedure Ineligible Post-Operatively/Pr|46
6361260|NCT03145766|10150582|FG000|Active Vaccination Phase (Day 0-Day 56)|Other Adverse Event (AE)|1
6361261|NCT03145766|10150583|FG001|Active Vaccination Phase (Day 0-Day 56)|Other Adverse Event (AE)|1
6361262|NCT03145766|10150584|FG002|Active Vaccination Phase (Day 0-Day 56)|Other Adverse Event (AE)|0
6361263|NCT03145766|10150585|FG003|Active Vaccination Phase (Day 0-Day 56)|Other Adverse Event (AE)|1
6361264|NCT03145766|10150586|FG004|Active Vaccination Phase (Day 0-Day 56)|Other Adverse Event (AE)|2
6361265|NCT03145766|10150582|FG000|Active Vaccination Phase (Day 0-Day 56)|Non-compliance with the Protocol|0
6361266|NCT03145766|10150583|FG001|Active Vaccination Phase (Day 0-Day 56)|Non-compliance with the Protocol|0
6361267|NCT03145766|10150584|FG002|Active Vaccination Phase (Day 0-Day 56)|Non-compliance with the Protocol|1
6361268|NCT03145766|10150585|FG003|Active Vaccination Phase (Day 0-Day 56)|Non-compliance with the Protocol|2
6361269|NCT03145766|10150586|FG004|Active Vaccination Phase (Day 0-Day 56)|Non-compliance with the Protocol|1
6084203|NCT00642278|9693183|FG002|Overall Study|Noncompliance with study drug regimen|0
6087759|NCT00670449|9698232|FG001|Overall Study|Administrative Problems|2
6361270|NCT03145766|10150582|FG000|Active Vaccination Phase (Day 0-Day 56)|Lost to Follow-up|1
6361220|NCT03760185|10150443|FG000|Overall Study|Lost to Follow-up|1
6361221|NCT03760185|10150444|FG001|Overall Study|Lost to Follow-up|1
6361222|NCT03732534|10150452|FG000|Overall Study|Study terminated by Sponsor|6
6361223|NCT03692910|10150456|FG000|Overall Study|Lost to Follow-up|4
6361224|NCT03692910|10150457|FG001|Overall Study|Lost to Follow-up|0
6361225|NCT03692910|10150458|FG002|Overall Study|Lost to Follow-up|0
6361226|NCT03692910|10150456|FG000|Overall Study|Withdrawal by Subject|2
6361227|NCT03692910|10150457|FG001|Overall Study|Withdrawal by Subject|0
6361228|NCT03692910|10150458|FG002|Overall Study|Withdrawal by Subject|0
6361229|NCT03673956|10150468|FG000|Overall Study|Lost to Follow-up|1
6361230|NCT03673956|10150469|FG001|Overall Study|Lost to Follow-up|0
6361231|NCT03673956|10150470|FG002|Overall Study|Lost to Follow-up|0
6361232|NCT03673956|10150471|FG003|Overall Study|Lost to Follow-up|0
6361233|NCT03673956|10150468|FG000|Overall Study|Did not use the prescribed topical antibiotics as directed|1
6361234|NCT03673956|10150469|FG001|Overall Study|Did not use the prescribed topical antibiotics as directed|0
6361235|NCT03673956|10150470|FG002|Overall Study|Did not use the prescribed topical antibiotics as directed|0
6361236|NCT03673956|10150471|FG003|Overall Study|Did not use the prescribed topical antibiotics as directed|0
6361271|NCT03145766|10150583|FG001|Active Vaccination Phase (Day 0-Day 56)|Lost to Follow-up|1
6361272|NCT03145766|10150584|FG002|Active Vaccination Phase (Day 0-Day 56)|Lost to Follow-up|0
6361273|NCT03145766|10150585|FG003|Active Vaccination Phase (Day 0-Day 56)|Lost to Follow-up|3
6361274|NCT03145766|10150586|FG004|Active Vaccination Phase (Day 0-Day 56)|Lost to Follow-up|0
6361275|NCT03145766|10150582|FG000|Active Vaccination Phase (Day 0-Day 56)|Voluntary Withdrawal Not Due AE|4
6361276|NCT03145766|10150583|FG001|Active Vaccination Phase (Day 0-Day 56)|Voluntary Withdrawal Not Due AE|1
6361277|NCT03145766|10150584|FG002|Active Vaccination Phase (Day 0-Day 56)|Voluntary Withdrawal Not Due AE|1
6361278|NCT03145766|10150585|FG003|Active Vaccination Phase (Day 0-Day 56)|Voluntary Withdrawal Not Due AE|1
6361279|NCT03145766|10150586|FG004|Active Vaccination Phase (Day 0-Day 56)|Voluntary Withdrawal Not Due AE|0
6361280|NCT03145766|10150582|FG000|Follow-up Phase (Day 56 Till Month 7)|Non-compliance with the Protocol|2
6361281|NCT03145766|10150583|FG001|Follow-up Phase (Day 56 Till Month 7)|Non-compliance with the Protocol|0
6361282|NCT03145766|10150584|FG002|Follow-up Phase (Day 56 Till Month 7)|Non-compliance with the Protocol|0
6361283|NCT03145766|10150585|FG003|Follow-up Phase (Day 56 Till Month 7)|Non-compliance with the Protocol|1
6361284|NCT03145766|10150586|FG004|Follow-up Phase (Day 56 Till Month 7)|Non-compliance with the Protocol|0
6361285|NCT03145766|10150582|FG000|Follow-up Phase (Day 56 Till Month 7)|Lost to Follow-up|4
6361286|NCT03145766|10150583|FG001|Follow-up Phase (Day 56 Till Month 7)|Lost to Follow-up|1
6361287|NCT03145766|10150584|FG002|Follow-up Phase (Day 56 Till Month 7)|Lost to Follow-up|4
6361288|NCT03145766|10150585|FG003|Follow-up Phase (Day 56 Till Month 7)|Lost to Follow-up|2
6361289|NCT03145766|10150586|FG004|Follow-up Phase (Day 56 Till Month 7)|Lost to Follow-up|3
6361290|NCT03145766|10150582|FG000|Follow-up Phase (Day 56 Till Month 7)|Voluntary Withdrawal not due to AE|1
6361291|NCT03145766|10150583|FG001|Follow-up Phase (Day 56 Till Month 7)|Voluntary Withdrawal not due to AE|1
6361292|NCT03145766|10150584|FG002|Follow-up Phase (Day 56 Till Month 7)|Voluntary Withdrawal not due to AE|1
6361293|NCT03145766|10150585|FG003|Follow-up Phase (Day 56 Till Month 7)|Voluntary Withdrawal not due to AE|0
6361294|NCT03145766|10150586|FG004|Follow-up Phase (Day 56 Till Month 7)|Voluntary Withdrawal not due to AE|0
6361295|NCT03106987|10150603|FG000|Overall Study|Death|37
6361296|NCT03106987|10150604|FG001|Overall Study|Death|22
6361297|NCT03106987|10150605|FG002|Overall Study|Death|12
6361298|NCT03106987|10150606|FG003|Overall Study|Death|8
6361299|NCT03106987|10150603|FG000|Overall Study|Lost to Follow-up|2
6361300|NCT03106987|10150604|FG001|Overall Study|Lost to Follow-up|0
6361301|NCT03106987|10150605|FG002|Overall Study|Lost to Follow-up|2
6361302|NCT03106987|10150606|FG003|Overall Study|Lost to Follow-up|2
6361303|NCT03106987|10150603|FG000|Overall Study|Withdrawal by Subject|5
6361304|NCT03106987|10150604|FG001|Overall Study|Withdrawal by Subject|1
6361305|NCT03106987|10150605|FG002|Overall Study|Withdrawal by Subject|4
6361306|NCT03106987|10150606|FG003|Overall Study|Withdrawal by Subject|1
6361307|NCT03103087|10150619|FG000|Overall Study|Did not receive any study drug|1
6361308|NCT03103087|10150620|FG001|Overall Study|Did not receive any study drug|0
6361309|NCT03103087|10150621|FG002|Overall Study|Did not receive any study drug|0
6361310|NCT03103087|10150619|FG000|Overall Study|Protocol Violation|1
6361311|NCT03103087|10150620|FG001|Overall Study|Protocol Violation|2
6361312|NCT03103087|10150621|FG002|Overall Study|Protocol Violation|1
6361313|NCT03103087|10150619|FG000|Overall Study|Lack of Efficacy|2
6361314|NCT03103087|10150620|FG001|Overall Study|Lack of Efficacy|1
6361315|NCT03103087|10150621|FG002|Overall Study|Lack of Efficacy|1
6361316|NCT03103087|10150619|FG000|Overall Study|Pregnancy|0
6361317|NCT03103087|10150620|FG001|Overall Study|Pregnancy|0
6361318|NCT03103087|10150621|FG002|Overall Study|Pregnancy|1
6361319|NCT03103087|10150619|FG000|Overall Study|Adverse Event|2
6361320|NCT03103087|10150620|FG001|Overall Study|Adverse Event|15
6361321|NCT03103087|10150621|FG002|Overall Study|Adverse Event|6
6361322|NCT03103087|10150619|FG000|Overall Study|Withdrawal by Subject|13
6361323|NCT03103087|10150620|FG001|Overall Study|Withdrawal by Subject|6
6361324|NCT03103087|10150621|FG002|Overall Study|Withdrawal by Subject|6
6361325|NCT03103087|10150619|FG000|Overall Study|Lost to Follow-up|4
6361326|NCT03103087|10150620|FG001|Overall Study|Lost to Follow-up|2
6361327|NCT03103087|10150621|FG002|Overall Study|Lost to Follow-up|7
6361328|NCT03103087|10150619|FG000|Overall Study|Other reason not reported|1
6361329|NCT03103087|10150620|FG001|Overall Study|Other reason not reported|3
6361330|NCT03103087|10150621|FG002|Overall Study|Other reason not reported|5
6084204|NCT00642278|9693184|FG003|Overall Study|Noncompliance with study drug regimen|1
6084205|NCT00642278|9693185|FG004|Overall Study|Noncompliance with study drug regimen|0
6084206|NCT00642278|9693186|FG005|Overall Study|Noncompliance with study drug regimen|0
6084207|NCT00642278|9693187|FG006|Overall Study|Noncompliance with study drug regimen|0
6084208|NCT00642278|9693181|FG000|Overall Study|Other|2
6084209|NCT00642278|9693182|FG001|Overall Study|Other|1
6084210|NCT00642278|9693183|FG002|Overall Study|Other|0
6084211|NCT00642278|9693184|FG003|Overall Study|Other|1
6084212|NCT00642278|9693185|FG004|Overall Study|Other|0
6361331|NCT03049735|10150634|FG000|Overall Study|Discontinued due to AE (not dosed)|0
6361332|NCT03049735|10150635|FG001|Overall Study|Discontinued due to AE (not dosed)|0
6361333|NCT03049735|10150636|FG002|Overall Study|Discontinued due to AE (not dosed)|1
6361334|NCT03049735|10150634|FG000|Overall Study|Other|5
6361335|NCT03049735|10150635|FG001|Overall Study|Other|3
6361336|NCT03049735|10150636|FG002|Overall Study|Other|1
6361337|NCT03049735|10150634|FG000|Overall Study|Lack of Efficacy|4
6361338|NCT03049735|10150635|FG001|Overall Study|Lack of Efficacy|0
6361339|NCT03049735|10150636|FG002|Overall Study|Lack of Efficacy|3
6361340|NCT03049735|10150634|FG000|Overall Study|Protocol deviation|1
6361341|NCT03049735|10150635|FG001|Overall Study|Protocol deviation|0
6361342|NCT03049735|10150636|FG002|Overall Study|Protocol deviation|0
6361343|NCT03049735|10150634|FG000|Overall Study|Pregnancy|0
6361344|NCT03049735|10150635|FG001|Overall Study|Pregnancy|0
6361345|NCT03049735|10150636|FG002|Overall Study|Pregnancy|1
6361346|NCT03049735|10150634|FG000|Overall Study|Adverse Event|7
6361347|NCT03049735|10150635|FG001|Overall Study|Adverse Event|18
6361348|NCT03049735|10150636|FG002|Overall Study|Adverse Event|5
6361349|NCT03049735|10150634|FG000|Overall Study|Withdrawal by Subject|10
6361350|NCT03049735|10150635|FG001|Overall Study|Withdrawal by Subject|3
6361351|NCT03049735|10150636|FG002|Overall Study|Withdrawal by Subject|7
6361352|NCT03049735|10150634|FG000|Overall Study|Lost to Follow-up|1
6361353|NCT03049735|10150635|FG001|Overall Study|Lost to Follow-up|5
6361354|NCT03049735|10150636|FG002|Overall Study|Lost to Follow-up|5
6361355|NCT03021551|10150644|FG000|Overall Study|Equipment Issues|2
6361356|NCT03021551|10150644|FG000|Overall Study|Protocol Violation|1
6361357|NCT02990338|10150650|FG000|Overall Study|Adverse Event|19
6361358|NCT02990338|10150651|FG001|Overall Study|Adverse Event|11
6361359|NCT02990338|10150650|FG000|Overall Study|Progressive disease|88
6361360|NCT02990338|10150651|FG001|Overall Study|Progressive disease|66
6361361|NCT02990338|10150650|FG000|Overall Study|Poor compliance to protocol|0
6361362|NCT02990338|10150651|FG001|Overall Study|Poor compliance to protocol|1
6361363|NCT02990338|10150650|FG000|Overall Study|Withdrawal by Subject|6
6361364|NCT02990338|10150651|FG001|Overall Study|Withdrawal by Subject|5
6361365|NCT02990338|10150650|FG000|Overall Study|Other|1
6361366|NCT02990338|10150651|FG001|Overall Study|Other|4
6361367|NCT02990338|10150650|FG000|Overall Study|Randomized but not treated|4
6361368|NCT02990338|10150651|FG001|Overall Study|Randomized but not treated|2
6361369|NCT02932332|10150671|FG000|Overall Study|Withdrawal by Subject|1
6361370|NCT02932332|10150672|FG001|Overall Study|Withdrawal by Subject|1
6361371|NCT02932332|10150673|FG002|Overall Study|Withdrawal by Subject|0
6361372|NCT02932332|10150674|FG003|Overall Study|Withdrawal by Subject|1
6361373|NCT02932332|10150671|FG000|Overall Study|Chest pain|0
6361374|NCT02932332|10150672|FG001|Overall Study|Chest pain|0
6361375|NCT02932332|10150673|FG002|Overall Study|Chest pain|0
6361376|NCT02932332|10150674|FG003|Overall Study|Chest pain|1
6361377|NCT02932332|10150671|FG000|Overall Study|Not Dyspneic cough|1
6361378|NCT02932332|10150672|FG001|Overall Study|Not Dyspneic cough|2
6361379|NCT02932332|10150673|FG002|Overall Study|Not Dyspneic cough|1
6361380|NCT02932332|10150674|FG003|Overall Study|Not Dyspneic cough|0
6361381|NCT02588248|10150717|FG000|Overall Study|Physician Decision|4
6361382|NCT02588248|10150718|FG001|Overall Study|Physician Decision|3
6361383|NCT02535065|10150729|FG000|Overall Study|Death|13
6361384|NCT02535065|10150729|FG000|Overall Study|Lost to Follow-up|1
6361385|NCT02535065|10150729|FG000|Overall Study|Withdrawal by Subject|6
6361386|NCT02451358|10150741|FG000|Overall Study|Withdrawal by Subject|1
6361387|NCT02451358|10150742|FG001|Overall Study|Withdrawal by Subject|1
6170535|NCT01253421|9816889|FG004|Assessment and Scheduling|Physician Decision|0
6170536|NCT01253421|9816885|FG000|Drug+Scanning Visit|Physician Decision|0
6170537|NCT01253421|9816886|FG001|Drug+Scanning Visit|Physician Decision|0
6170538|NCT01253421|9816887|FG002|Drug+Scanning Visit|Physician Decision|0
6170539|NCT01253421|9816888|FG003|Drug+Scanning Visit|Physician Decision|0
6170540|NCT01253421|9816889|FG004|Drug+Scanning Visit|Physician Decision|1
6170541|NCT01253447|9816899|FG000|Overall Study|Adverse Event|2
6361388|NCT02451358|10150743|FG002|Overall Study|Withdrawal by Subject|0
6361389|NCT02451358|10150744|FG003|Overall Study|Withdrawal by Subject|0
6361390|NCT02451358|10150741|FG000|Overall Study|Protocol Violation|0
6361391|NCT02451358|10150742|FG001|Overall Study|Protocol Violation|1
6361392|NCT02451358|10150743|FG002|Overall Study|Protocol Violation|1
6361393|NCT02451358|10150744|FG003|Overall Study|Protocol Violation|0
6361394|NCT02178709|10150763|FG000|Overall Study|Adverse Event|5
6361395|NCT02178709|10150763|FG000|Overall Study|Death|2
6361396|NCT02178709|10150763|FG000|Overall Study|Withdrawal by Subject|2
6361397|NCT02178709|10150763|FG000|Overall Study|Physician Decision|2
6361398|NCT02178709|10150763|FG000|Overall Study|Disease Progression|5
6170542|NCT01253564|9816912|FG000|Overall Study|Disease Progression|22
6170543|NCT01253564|9816912|FG000|Overall Study|Withdrawal by Subject|1
6170544|NCT01253564|9816912|FG000|Overall Study|Serious Adverse Event|1
6170545|NCT01253577|9816916|FG000|Overall Study|Lost to Follow-up|3
6170546|NCT01253811|9816927|FG000|Overall Study|Withdrawal criteria|1
6361399|NCT01980017|10150773|FG000|Overall Study|Lost to Follow-up|30
6361400|NCT01980017|10150774|FG001|Overall Study|Lost to Follow-up|21
6361401|NCT01980017|10150773|FG000|Overall Study|Death|0
6361402|NCT01980017|10150774|FG001|Overall Study|Death|1
6361403|NCT01890759|10150785|FG000|Overall Study|Protocol Violation|0
6361404|NCT01890759|10150786|FG001|Overall Study|Protocol Violation|2
6361405|NCT01890759|10150785|FG000|Overall Study|Lost to Follow-up|0
6361406|NCT01890759|10150786|FG001|Overall Study|Lost to Follow-up|2
6361407|NCT01890759|10150785|FG000|Overall Study|Withdrawal by Subject|2
6361408|NCT01890759|10150786|FG001|Overall Study|Withdrawal by Subject|8
6361409|NCT01721746|10150799|FG000|Pre-Treatment|Participant request to discontinue Study treatment|0
6361410|NCT01721746|10150800|FG001|Pre-Treatment|Participant request to discontinue Study treatment|13
6361411|NCT01721746|10150799|FG000|Pre-Treatment|Withdrawal by Subject|1
6361412|NCT01721746|10150800|FG001|Pre-Treatment|Withdrawal by Subject|16
6361413|NCT01721746|10150799|FG000|Pre-Treatment|Poor/Non-compliance|1
6361414|NCT01721746|10150800|FG001|Pre-Treatment|Poor/Non-compliance|0
6361415|NCT01721746|10150799|FG000|Pre-Treatment|Participant no longer met study criteria|2
6361416|NCT01721746|10150800|FG001|Pre-Treatment|Participant no longer met study criteria|2
6361417|NCT01721746|10150799|FG000|Treatment|Disease Progression|192
6361418|NCT01721746|10150800|FG001|Treatment|Disease Progression|74
6361419|NCT01721746|10150799|FG000|Treatment|Study Drug Toxicity|19
6361420|NCT01721746|10150800|FG001|Treatment|Study Drug Toxicity|11
6361421|NCT01721746|10150799|FG000|Treatment|Adverse Event unrelated to Study Drug|6
6361422|NCT01721746|10150800|FG001|Treatment|Adverse Event unrelated to Study Drug|3
6361423|NCT01721746|10150799|FG000|Treatment|Participant request to discontinue Study treatment|26
6361424|NCT01721746|10150800|FG001|Treatment|Participant request to discontinue Study treatment|7
6361425|NCT01721746|10150799|FG000|Treatment|Participant withdrew consent|4
6361426|NCT01721746|10150800|FG001|Treatment|Participant withdrew consent|2
6361427|NCT01721746|10150799|FG000|Treatment|Maximum Clinical Benefit|9
6361428|NCT01721746|10150800|FG001|Treatment|Maximum Clinical Benefit|3
6361429|NCT01721746|10150799|FG000|Treatment|Poor/Non-compliance|2
6361430|NCT01721746|10150800|FG001|Treatment|Poor/Non-compliance|0
6361431|NCT01721746|10150799|FG000|Treatment|Participant no longer met Study criteria|4
6361432|NCT01721746|10150800|FG001|Treatment|Participant no longer met Study criteria|0
6361433|NCT01721746|10150799|FG000|Treatment|Other reasons|6
6361434|NCT01721746|10150800|FG001|Treatment|Other reasons|2
6361435|NCT01705977|10150809|FG000|Overall Study|Withdrawal by Subject|128
6361436|NCT01705977|10150810|FG001|Overall Study|Withdrawal by Subject|128
6361437|NCT01705977|10150809|FG000|Overall Study|Adverse Event|57
6361438|NCT01705977|10150810|FG001|Overall Study|Adverse Event|49
6361439|NCT01705977|10150809|FG000|Overall Study|Protocol Violation|2
6361440|NCT01705977|10150810|FG001|Overall Study|Protocol Violation|4
6361441|NCT01705977|10150809|FG000|Overall Study|Site closure|3
6361442|NCT01705977|10150810|FG001|Overall Study|Site closure|2
6361443|NCT01705977|10150809|FG000|Overall Study|Lost to Follow-up|33
6361444|NCT01705977|10150810|FG001|Overall Study|Lost to Follow-up|37
6361445|NCT01705977|10150809|FG000|Overall Study|Physician Decision|48
6361446|NCT01705977|10150810|FG001|Overall Study|Physician Decision|38
6361447|NCT01705977|10150809|FG000|Overall Study|Missing study conclusion form|2
6361448|NCT01705977|10150810|FG001|Overall Study|Missing study conclusion form|2
6361449|NCT01587040|10150820|FG000|Overall Study|Protocol Violation|0
6361450|NCT01587040|10150821|FG001|Overall Study|Protocol Violation|0
6361451|NCT01587040|10150822|FG002|Overall Study|Protocol Violation|1
6361452|NCT01587040|10150823|FG003|Overall Study|Protocol Violation|0
6361453|NCT01587040|10150820|FG000|Overall Study|Adverse Event|0
6361454|NCT01587040|10150821|FG001|Overall Study|Adverse Event|1
6361455|NCT01587040|10150822|FG002|Overall Study|Adverse Event|10
6361456|NCT01587040|10150823|FG003|Overall Study|Adverse Event|0
6361457|NCT01587040|10150820|FG000|Overall Study|Disease progression|12
6361458|NCT01587040|10150821|FG001|Overall Study|Disease progression|1
6361459|NCT01587040|10150822|FG002|Overall Study|Disease progression|15
6361460|NCT01587040|10150823|FG003|Overall Study|Disease progression|3
6361461|NCT01587040|10150820|FG000|Overall Study|Other than specified|5
6361462|NCT01587040|10150821|FG001|Overall Study|Other than specified|1
6361463|NCT01587040|10150822|FG002|Overall Study|Other than specified|11
6361464|NCT01587040|10150823|FG003|Overall Study|Other than specified|1
6361465|NCT01254409|10150841|FG000|Overall Study|Adverse Event|0
6361466|NCT01254409|10150842|FG001|Overall Study|Adverse Event|1
6361467|NCT01254409|10150843|FG002|Overall Study|Adverse Event|0
5972130|NCT04498247|9557785|FG001|Overall Study|Lost to Follow-up|0
6361468|NCT01254409|10150844|FG003|Overall Study|Adverse Event|0
6361469|NCT01253161|10150857|FG000|Overall Study|Adverse Event|1
6361470|NCT01084252|10150875|FG000|Phase 1 (120 Weeks)|Adverse Event|0
6361471|NCT01084252|10150876|FG001|Phase 1 (120 Weeks)|Adverse Event|0
6361472|NCT01084252|10150877|FG002|Phase 1 (120 Weeks)|Adverse Event|1
6361473|NCT01084252|10150878|FG003|Phase 1 (120 Weeks)|Adverse Event|1
6361474|NCT01084252|10150879|FG004|Phase 1 (120 Weeks)|Adverse Event|1
6361475|NCT01084252|10150880|FG005|Phase 1 (120 Weeks)|Adverse Event|0
6361476|NCT01084252|10150881|FG006|Phase 1 (120 Weeks)|Adverse Event|1
6361477|NCT01084252|10150882|FG007|Phase 1 (120 Weeks)|Adverse Event|0
6361478|NCT01084252|10150883|FG008|Phase 1 (120 Weeks)|Adverse Event|0
6361479|NCT01084252|10150884|FG009|Phase 1 (120 Weeks)|Adverse Event|0
6361480|NCT01084252|10150885|FG010|Phase 1 (120 Weeks)|Adverse Event|0
6361481|NCT01084252|10150886|FG011|Phase 1 (120 Weeks)|Adverse Event|0
6361482|NCT01084252|10150887|FG012|Phase 1 (120 Weeks)|Adverse Event|0
6361483|NCT01084252|10150888|FG013|Phase 1 (120 Weeks)|Adverse Event|0
6361484|NCT01084252|10150875|FG000|Phase 1 (120 Weeks)|Progressive disease|15
6361485|NCT01084252|10150876|FG001|Phase 1 (120 Weeks)|Progressive disease|5
6361486|NCT01084252|10150877|FG002|Phase 1 (120 Weeks)|Progressive disease|2
6361487|NCT01084252|10150878|FG003|Phase 1 (120 Weeks)|Progressive disease|22
6361488|NCT01084252|10150879|FG004|Phase 1 (120 Weeks)|Progressive disease|16
6361489|NCT01084252|10150880|FG005|Phase 1 (120 Weeks)|Progressive disease|6
6361490|NCT01084252|10150881|FG006|Phase 1 (120 Weeks)|Progressive disease|5
6361491|NCT01084252|10150882|FG007|Phase 1 (120 Weeks)|Progressive disease|6
6361492|NCT01084252|10150883|FG008|Phase 1 (120 Weeks)|Progressive disease|0
6361493|NCT01084252|10150884|FG009|Phase 1 (120 Weeks)|Progressive disease|0
6361494|NCT01084252|10150885|FG010|Phase 1 (120 Weeks)|Progressive disease|0
6361495|NCT01084252|10150886|FG011|Phase 1 (120 Weeks)|Progressive disease|0
6361496|NCT01084252|10150887|FG012|Phase 1 (120 Weeks)|Progressive disease|0
6361497|NCT01084252|10150888|FG013|Phase 1 (120 Weeks)|Progressive disease|0
6361498|NCT01084252|10150875|FG000|Phase 1 (120 Weeks)|Other than specified above|1
6361499|NCT01084252|10150876|FG001|Phase 1 (120 Weeks)|Other than specified above|1
6361500|NCT01084252|10150877|FG002|Phase 1 (120 Weeks)|Other than specified above|0
6361501|NCT01084252|10150878|FG003|Phase 1 (120 Weeks)|Other than specified above|3
6361502|NCT01084252|10150879|FG004|Phase 1 (120 Weeks)|Other than specified above|1
6361503|NCT01084252|10150880|FG005|Phase 1 (120 Weeks)|Other than specified above|0
6361504|NCT01084252|10150881|FG006|Phase 1 (120 Weeks)|Other than specified above|1
6361505|NCT01084252|10150882|FG007|Phase 1 (120 Weeks)|Other than specified above|1
6361506|NCT01084252|10150883|FG008|Phase 1 (120 Weeks)|Other than specified above|0
6361507|NCT01084252|10150884|FG009|Phase 1 (120 Weeks)|Other than specified above|0
6361508|NCT01084252|10150885|FG010|Phase 1 (120 Weeks)|Other than specified above|0
6361509|NCT01084252|10150886|FG011|Phase 1 (120 Weeks)|Other than specified above|0
6361510|NCT01084252|10150887|FG012|Phase 1 (120 Weeks)|Other than specified above|0
6361511|NCT01084252|10150888|FG013|Phase 1 (120 Weeks)|Other than specified above|0
6361512|NCT01084252|10150875|FG000|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Adverse Event|0
6361513|NCT01084252|10150876|FG001|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Adverse Event|0
6361514|NCT01084252|10150877|FG002|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Adverse Event|0
6361515|NCT01084252|10150878|FG003|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Adverse Event|0
6361516|NCT01084252|10150879|FG004|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Adverse Event|0
6361517|NCT01084252|10150880|FG005|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Adverse Event|0
6361518|NCT01084252|10150881|FG006|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Adverse Event|0
6361519|NCT01084252|10150882|FG007|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Adverse Event|0
6361520|NCT01084252|10150883|FG008|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Adverse Event|0
6361521|NCT01084252|10150884|FG009|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Adverse Event|2
6361522|NCT01084252|10150885|FG010|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Adverse Event|2
6361523|NCT01084252|10150886|FG011|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Adverse Event|1
6361524|NCT01084252|10150887|FG012|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Adverse Event|0
6361525|NCT01084252|10150888|FG013|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Adverse Event|0
6361526|NCT01084252|10150875|FG000|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Progressive disease|0
6361527|NCT01084252|10150876|FG001|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Progressive disease|0
6361528|NCT01084252|10150877|FG002|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Progressive disease|0
6361529|NCT01084252|10150878|FG003|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Progressive disease|0
6361530|NCT01084252|10150879|FG004|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Progressive disease|0
6361531|NCT01084252|10150880|FG005|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Progressive disease|0
6361532|NCT01084252|10150881|FG006|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Progressive disease|0
6361533|NCT01084252|10150882|FG007|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Progressive disease|0
6361534|NCT01084252|10150883|FG008|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Progressive disease|20
6361535|NCT01084252|10150884|FG009|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Progressive disease|18
6361536|NCT01084252|10150885|FG010|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Progressive disease|17
6361537|NCT01084252|10150886|FG011|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Progressive disease|19
6361538|NCT01084252|10150887|FG012|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Progressive disease|0
6361539|NCT01084252|10150888|FG013|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Progressive disease|0
6361540|NCT01084252|10150875|FG000|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Other than specified above|0
6361541|NCT01084252|10150876|FG001|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Other than specified above|0
6361542|NCT01084252|10150877|FG002|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Other than specified above|0
6361543|NCT01084252|10150878|FG003|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Other than specified above|0
6361544|NCT01084252|10150879|FG004|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Other than specified above|0
6361545|NCT01084252|10150880|FG005|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Other than specified above|0
6361546|NCT01084252|10150881|FG006|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Other than specified above|0
6361547|NCT01084252|10150882|FG007|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Other than specified above|0
6361548|NCT01084252|10150883|FG008|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Other than specified above|2
6361549|NCT01084252|10150884|FG009|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Other than specified above|0
6361550|NCT01084252|10150885|FG010|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Other than specified above|4
6361551|NCT01084252|10150886|FG011|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Other than specified above|3
6361552|NCT01084252|10150887|FG012|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Other than specified above|0
6361553|NCT01084252|10150888|FG013|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Other than specified above|0
6361554|NCT01084252|10150875|FG000|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Ongoing treatment|0
6361555|NCT01084252|10150876|FG001|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Ongoing treatment|0
6361556|NCT01084252|10150877|FG002|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Ongoing treatment|0
6361557|NCT01084252|10150878|FG003|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Ongoing treatment|0
6361558|NCT01084252|10150879|FG004|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Ongoing treatment|0
6361559|NCT01084252|10150880|FG005|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Ongoing treatment|0
6361560|NCT01084252|10150881|FG006|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Ongoing treatment|0
6361561|NCT01084252|10150882|FG007|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Ongoing treatment|0
6361562|NCT01084252|10150883|FG008|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Ongoing treatment|1
6361563|NCT01084252|10150884|FG009|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Ongoing treatment|4
6084213|NCT00642278|9693186|FG005|Overall Study|Other|1
6084214|NCT00642278|9693187|FG006|Overall Study|Other|0
6084215|NCT00642304|9693203|FG000|Overall Study|Adverse Event|1
6084216|NCT00642304|9693203|FG000|Overall Study|Death|1
6084217|NCT00642304|9693203|FG000|Overall Study|Blood transfusion|2
6084218|NCT00642304|9693203|FG000|Overall Study|Erythropoiesis Stimulating Agent Use.|1
6084219|NCT00642304|9693203|FG000|Overall Study|Transplantation|1
6084220|NCT00642356|9693209|FG000|Overall Study|Adverse Event|1
6084221|NCT00642356|9693210|FG001|Overall Study|Adverse Event|0
6084222|NCT00642356|9693209|FG000|Overall Study|Protocol Violation|0
6084223|NCT00642356|9693210|FG001|Overall Study|Protocol Violation|3
6084224|NCT00642356|9693209|FG000|Overall Study|Lack of Efficacy|1
6084225|NCT00642356|9693210|FG001|Overall Study|Lack of Efficacy|0
6084226|NCT00642369|9693218|FG000|Overall Study|Adverse Event|2
6084227|NCT00642369|9693219|FG001|Overall Study|Adverse Event|3
6361564|NCT01084252|10150885|FG010|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Ongoing treatment|2
6361565|NCT01084252|10150886|FG011|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Ongoing treatment|2
6361566|NCT01084252|10150887|FG012|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Ongoing treatment|0
6361567|NCT01084252|10150888|FG013|Phase 2 Stage 1(1a-77 Weeks;1b-53 Weeks)|Ongoing treatment|0
6361568|NCT01084252|10150875|FG000|Phase 2 Stage 2 (97 Weeks)|Adverse Event|0
6361569|NCT01084252|10150876|FG001|Phase 2 Stage 2 (97 Weeks)|Adverse Event|0
6361570|NCT01084252|10150877|FG002|Phase 2 Stage 2 (97 Weeks)|Adverse Event|0
6361571|NCT01084252|10150878|FG003|Phase 2 Stage 2 (97 Weeks)|Adverse Event|0
6361572|NCT01084252|10150879|FG004|Phase 2 Stage 2 (97 Weeks)|Adverse Event|0
6361573|NCT01084252|10150880|FG005|Phase 2 Stage 2 (97 Weeks)|Adverse Event|0
6361574|NCT01084252|10150881|FG006|Phase 2 Stage 2 (97 Weeks)|Adverse Event|0
6361575|NCT01084252|10150882|FG007|Phase 2 Stage 2 (97 Weeks)|Adverse Event|0
6361576|NCT01084252|10150883|FG008|Phase 2 Stage 2 (97 Weeks)|Adverse Event|0
6361577|NCT01084252|10150884|FG009|Phase 2 Stage 2 (97 Weeks)|Adverse Event|0
6361578|NCT01084252|10150885|FG010|Phase 2 Stage 2 (97 Weeks)|Adverse Event|0
6361579|NCT01084252|10150886|FG011|Phase 2 Stage 2 (97 Weeks)|Adverse Event|0
6361580|NCT01084252|10150887|FG012|Phase 2 Stage 2 (97 Weeks)|Adverse Event|13
6361581|NCT01084252|10150888|FG013|Phase 2 Stage 2 (97 Weeks)|Adverse Event|5
6361582|NCT01084252|10150875|FG000|Phase 2 Stage 2 (97 Weeks)|Progressive disease|0
6361583|NCT01084252|10150876|FG001|Phase 2 Stage 2 (97 Weeks)|Progressive disease|0
6361584|NCT01084252|10150877|FG002|Phase 2 Stage 2 (97 Weeks)|Progressive disease|0
6361585|NCT01084252|10150878|FG003|Phase 2 Stage 2 (97 Weeks)|Progressive disease|0
6361586|NCT01084252|10150879|FG004|Phase 2 Stage 2 (97 Weeks)|Progressive disease|0
6361587|NCT01084252|10150880|FG005|Phase 2 Stage 2 (97 Weeks)|Progressive disease|0
6361588|NCT01084252|10150881|FG006|Phase 2 Stage 2 (97 Weeks)|Progressive disease|0
6361589|NCT01084252|10150882|FG007|Phase 2 Stage 2 (97 Weeks)|Progressive disease|0
6361590|NCT01084252|10150883|FG008|Phase 2 Stage 2 (97 Weeks)|Progressive disease|0
6361591|NCT01084252|10150884|FG009|Phase 2 Stage 2 (97 Weeks)|Progressive disease|0
6170547|NCT01254019|9816964|FG000|Overall Study|Adverse Event|0
6170548|NCT01254019|9816965|FG001|Overall Study|Adverse Event|2
6170549|NCT01254019|9816964|FG000|Overall Study|Protocol Violation|1
6170550|NCT01254019|9816965|FG001|Overall Study|Protocol Violation|0
6361592|NCT01084252|10150885|FG010|Phase 2 Stage 2 (97 Weeks)|Progressive disease|0
6361593|NCT01084252|10150886|FG011|Phase 2 Stage 2 (97 Weeks)|Progressive disease|0
6170551|NCT01254019|9816964|FG000|Overall Study|Withdrawal by Subject|0
6084228|NCT00642369|9693218|FG000|Overall Study|Withdrawal by Subject|1
6361594|NCT01084252|10150887|FG012|Phase 2 Stage 2 (97 Weeks)|Progressive disease|70
6361595|NCT01084252|10150888|FG013|Phase 2 Stage 2 (97 Weeks)|Progressive disease|33
6361596|NCT01084252|10150875|FG000|Phase 2 Stage 2 (97 Weeks)|Poor compliance to protocol|0
6361597|NCT01084252|10150876|FG001|Phase 2 Stage 2 (97 Weeks)|Poor compliance to protocol|0
6361598|NCT01084252|10150877|FG002|Phase 2 Stage 2 (97 Weeks)|Poor compliance to protocol|0
6361599|NCT01084252|10150878|FG003|Phase 2 Stage 2 (97 Weeks)|Poor compliance to protocol|0
6361600|NCT01084252|10150879|FG004|Phase 2 Stage 2 (97 Weeks)|Poor compliance to protocol|0
6361601|NCT01084252|10150880|FG005|Phase 2 Stage 2 (97 Weeks)|Poor compliance to protocol|0
6361602|NCT01084252|10150881|FG006|Phase 2 Stage 2 (97 Weeks)|Poor compliance to protocol|0
6361603|NCT01084252|10150882|FG007|Phase 2 Stage 2 (97 Weeks)|Poor compliance to protocol|0
6361604|NCT01084252|10150883|FG008|Phase 2 Stage 2 (97 Weeks)|Poor compliance to protocol|0
6361605|NCT01084252|10150884|FG009|Phase 2 Stage 2 (97 Weeks)|Poor compliance to protocol|0
6361606|NCT01084252|10150885|FG010|Phase 2 Stage 2 (97 Weeks)|Poor compliance to protocol|0
6361607|NCT01084252|10150886|FG011|Phase 2 Stage 2 (97 Weeks)|Poor compliance to protocol|0
6361608|NCT01084252|10150887|FG012|Phase 2 Stage 2 (97 Weeks)|Poor compliance to protocol|1
6361609|NCT01084252|10150888|FG013|Phase 2 Stage 2 (97 Weeks)|Poor compliance to protocol|0
6361610|NCT01084252|10150875|FG000|Phase 2 Stage 2 (97 Weeks)|Other than specified above|0
6361611|NCT01084252|10150876|FG001|Phase 2 Stage 2 (97 Weeks)|Other than specified above|0
6361612|NCT01084252|10150877|FG002|Phase 2 Stage 2 (97 Weeks)|Other than specified above|0
6361613|NCT01084252|10150878|FG003|Phase 2 Stage 2 (97 Weeks)|Other than specified above|0
6361614|NCT01084252|10150879|FG004|Phase 2 Stage 2 (97 Weeks)|Other than specified above|0
6361615|NCT01084252|10150880|FG005|Phase 2 Stage 2 (97 Weeks)|Other than specified above|0
6361616|NCT01084252|10150881|FG006|Phase 2 Stage 2 (97 Weeks)|Other than specified above|0
6361617|NCT01084252|10150882|FG007|Phase 2 Stage 2 (97 Weeks)|Other than specified above|0
6361618|NCT01084252|10150883|FG008|Phase 2 Stage 2 (97 Weeks)|Other than specified above|0
6361619|NCT01084252|10150884|FG009|Phase 2 Stage 2 (97 Weeks)|Other than specified above|0
6361620|NCT01084252|10150885|FG010|Phase 2 Stage 2 (97 Weeks)|Other than specified above|0
6361621|NCT01084252|10150886|FG011|Phase 2 Stage 2 (97 Weeks)|Other than specified above|0
6361622|NCT01084252|10150887|FG012|Phase 2 Stage 2 (97 Weeks)|Other than specified above|12
6361623|NCT01084252|10150888|FG013|Phase 2 Stage 2 (97 Weeks)|Other than specified above|2
6361624|NCT01084252|10150875|FG000|Phase 2 Stage 2 (97 Weeks)|Ongoing treatment|0
6361625|NCT01084252|10150876|FG001|Phase 2 Stage 2 (97 Weeks)|Ongoing treatment|0
6361626|NCT01084252|10150877|FG002|Phase 2 Stage 2 (97 Weeks)|Ongoing treatment|0
6361627|NCT01084252|10150878|FG003|Phase 2 Stage 2 (97 Weeks)|Ongoing treatment|0
6361628|NCT01084252|10150879|FG004|Phase 2 Stage 2 (97 Weeks)|Ongoing treatment|0
6361629|NCT01084252|10150880|FG005|Phase 2 Stage 2 (97 Weeks)|Ongoing treatment|0
6361630|NCT01084252|10150881|FG006|Phase 2 Stage 2 (97 Weeks)|Ongoing treatment|0
6361631|NCT01084252|10150882|FG007|Phase 2 Stage 2 (97 Weeks)|Ongoing treatment|0
6361632|NCT01084252|10150883|FG008|Phase 2 Stage 2 (97 Weeks)|Ongoing treatment|0
6361633|NCT01084252|10150884|FG009|Phase 2 Stage 2 (97 Weeks)|Ongoing treatment|0
6361634|NCT01084252|10150885|FG010|Phase 2 Stage 2 (97 Weeks)|Ongoing treatment|0
6361635|NCT01084252|10150886|FG011|Phase 2 Stage 2 (97 Weeks)|Ongoing treatment|0
6361636|NCT01084252|10150887|FG012|Phase 2 Stage 2 (97 Weeks)|Ongoing treatment|13
6361637|NCT01084252|10150888|FG013|Phase 2 Stage 2 (97 Weeks)|Ongoing treatment|15
6361638|NCT01084252|10150875|FG000|Phase 2 Stage 2 (97 Weeks)|Enrolled, but not treated|0
6361639|NCT01084252|10150876|FG001|Phase 2 Stage 2 (97 Weeks)|Enrolled, but not treated|0
6361640|NCT01084252|10150877|FG002|Phase 2 Stage 2 (97 Weeks)|Enrolled, but not treated|0
6361641|NCT01084252|10150878|FG003|Phase 2 Stage 2 (97 Weeks)|Enrolled, but not treated|0
6361642|NCT01084252|10150879|FG004|Phase 2 Stage 2 (97 Weeks)|Enrolled, but not treated|0
6361643|NCT01084252|10150880|FG005|Phase 2 Stage 2 (97 Weeks)|Enrolled, but not treated|0
6361644|NCT01084252|10150881|FG006|Phase 2 Stage 2 (97 Weeks)|Enrolled, but not treated|0
6361645|NCT01084252|10150882|FG007|Phase 2 Stage 2 (97 Weeks)|Enrolled, but not treated|0
6361646|NCT01084252|10150883|FG008|Phase 2 Stage 2 (97 Weeks)|Enrolled, but not treated|0
6361647|NCT01084252|10150884|FG009|Phase 2 Stage 2 (97 Weeks)|Enrolled, but not treated|0
6361648|NCT01084252|10150885|FG010|Phase 2 Stage 2 (97 Weeks)|Enrolled, but not treated|0
6361649|NCT01084252|10150886|FG011|Phase 2 Stage 2 (97 Weeks)|Enrolled, but not treated|0
6361650|NCT01084252|10150887|FG012|Phase 2 Stage 2 (97 Weeks)|Enrolled, but not treated|1
6361651|NCT01084252|10150888|FG013|Phase 2 Stage 2 (97 Weeks)|Enrolled, but not treated|0
6361652|NCT00728962|10150975|FG000|Implant Placement Surgery|Adverse Event|8
6361653|NCT00728962|10150975|FG000|Implant Placement Surgery|Lost to Follow-up|1
6361654|NCT00728962|10150975|FG000|Implant Placement Surgery|Protocol Violation|1
6361655|NCT00728962|10150975|FG000|Permanent Prosthesis Placement|Adverse Event|3
6361656|NCT00728962|10150975|FG000|Two Year Post Placement Follow-up|Lost to Follow-up|3
6361657|NCT00728754|10150981|FG000|Permanent Prosthesis Placement|Adverse Event|1
6361658|NCT00728754|10150982|FG001|Permanent Prosthesis Placement|Adverse Event|1
6361659|NCT00728754|10150981|FG000|Permanent Prosthesis Placement|Lost to Follow-up|3
6361660|NCT00728754|10150982|FG001|Permanent Prosthesis Placement|Lost to Follow-up|3
6361661|NCT00728754|10150981|FG000|One Year Post Placement Follow-up|Adverse Event|1
6361662|NCT00728754|10150982|FG001|One Year Post Placement Follow-up|Adverse Event|0
6361663|NCT00723944|10150990|FG000|Permanent Prosthesis Placement|Adverse Event|1
6361664|NCT00723944|10150991|FG001|Permanent Prosthesis Placement|Adverse Event|7
6361665|NCT00723944|10150990|FG000|Permanent Prosthesis Placement|Lost to Follow-up|2
6361666|NCT00723944|10150991|FG001|Permanent Prosthesis Placement|Lost to Follow-up|2
6361667|NCT00723944|10150990|FG000|One Year Post Placement Follow-up|Lost to Follow-up|1
6361668|NCT00723944|10150991|FG001|One Year Post Placement Follow-up|Lost to Follow-up|4
6361669|NCT00467142|10150997|FG000|Overall Study|Withdrawal by Subject|1
6361670|NCT00467142|10150997|FG000|Overall Study|Adverse Event|1
6361671|NCT00467142|10150997|FG000|Overall Study|Protocol Violation|1
6361672|NCT04557371|10151034|FG000|Overall Study|Covid-19-related|0
6361673|NCT04557371|10151035|FG001|Overall Study|Covid-19-related|1
6361674|NCT04557371|10151036|FG002|Overall Study|Covid-19-related|0
6361675|NCT04557371|10151034|FG000|Overall Study|Withdrawal by Subject|0
6361676|NCT04557371|10151035|FG001|Overall Study|Withdrawal by Subject|1
6361677|NCT04557371|10151036|FG002|Overall Study|Withdrawal by Subject|0
6361678|NCT04557371|10151034|FG000|Overall Study|Adverse Event|1
6361679|NCT04557371|10151035|FG001|Overall Study|Adverse Event|0
6361680|NCT04557371|10151036|FG002|Overall Study|Adverse Event|0
6361681|NCT04369742|10151057|FG000|Overall Study|Lost to Follow-Up (Day 14)|7
6361682|NCT04369742|10151058|FG001|Overall Study|Lost to Follow-Up (Day 14)|4
6361683|NCT04369742|10151057|FG000|Overall Study|Lost to Follow-Up (Day 30)|7
6361684|NCT04369742|10151058|FG001|Overall Study|Lost to Follow-Up (Day 30)|7
6361685|NCT04346628|10151066|FG000|Overall Study|Lost to Follow-up|4
6361686|NCT04346628|10151067|FG001|Overall Study|Lost to Follow-up|4
6361687|NCT04346628|10151066|FG000|Overall Study|Withdrew (had personal reasons)|2
6361688|NCT04346628|10151067|FG001|Overall Study|Withdrew (had personal reasons)|5
6361689|NCT04346628|10151066|FG000|Overall Study|Withdrew (medication intolerant)|0
6361690|NCT04346628|10151067|FG001|Overall Study|Withdrew (medication intolerant)|3
6361691|NCT04346628|10151066|FG000|Overall Study|Withdrew (declined intervention)|0
6361692|NCT04346628|10151067|FG001|Overall Study|Withdrew (declined intervention)|1
6361693|NCT03969589|10151097|FG000|Overall Study|Lost to Follow-up|3
6361694|NCT03969589|10151098|FG001|Overall Study|Lost to Follow-up|2
6361695|NCT03969589|10151097|FG000|Overall Study|Declined Follow-Up|0
6361696|NCT03969589|10151098|FG001|Overall Study|Declined Follow-Up|1
6361697|NCT03917472|10151106|FG000|Overall Study|Physician Decision|4
6361698|NCT03917472|10151107|FG001|Overall Study|Physician Decision|0
6361699|NCT03917472|10151106|FG000|Overall Study|Adverse Event|3
6361700|NCT03917472|10151107|FG001|Overall Study|Adverse Event|1
6361701|NCT03917472|10151106|FG000|Overall Study|Death|7
6361702|NCT03917472|10151107|FG001|Overall Study|Death|5
6361703|NCT03917472|10151106|FG000|Overall Study|Withdrawal by Subject|11
6361704|NCT03917472|10151107|FG001|Overall Study|Withdrawal by Subject|4
6361705|NCT03917472|10151106|FG000|Overall Study|Lost to Follow-up|10
6361706|NCT03917472|10151107|FG001|Overall Study|Lost to Follow-up|5
6361707|NCT03655691|10151151|FG000|Overall Study|Adverse Event|0
6361708|NCT03655691|10151152|FG001|Overall Study|Adverse Event|0
6361709|NCT03655691|10151153|FG002|Overall Study|Adverse Event|1
6361710|NCT03655691|10151151|FG000|Overall Study|Lost to Follow-up|1
6170552|NCT01254019|9816965|FG001|Overall Study|Withdrawal by Subject|2
6361711|NCT03655691|10151152|FG001|Overall Study|Lost to Follow-up|1
6043205|NCT00387712|9641712|FG001|Overall Study|Withdrawal by Subject|12
6043206|NCT00387725|9641722|FG000|Overall Study|Adverse Event|0
6361712|NCT03655691|10151153|FG002|Overall Study|Lost to Follow-up|2
6361713|NCT03655691|10151151|FG000|Overall Study|Protocol Violation|0
6361714|NCT03655691|10151152|FG001|Overall Study|Protocol Violation|1
6361715|NCT03655691|10151153|FG002|Overall Study|Protocol Violation|0
6361716|NCT03655691|10151151|FG000|Overall Study|Withdrawal by Subject|1
6361717|NCT03655691|10151152|FG001|Overall Study|Withdrawal by Subject|1
6361718|NCT03655691|10151153|FG002|Overall Study|Withdrawal by Subject|0
6170553|NCT01254045|9816974|FG000|First/Baseline (1 Day at Week 1 )|Lost to Follow-up|1
6170554|NCT01254045|9816975|FG001|First/Baseline (1 Day at Week 1 )|Lost to Follow-up|0
6170555|NCT01254045|9816976|FG002|First/Baseline (1 Day at Week 1 )|Lost to Follow-up|0
6170556|NCT01254045|9816977|FG003|First/Baseline (1 Day at Week 1 )|Lost to Follow-up|0
6170557|NCT01254045|9816978|FG004|First/Baseline (1 Day at Week 1 )|Lost to Follow-up|0
6170558|NCT01254045|9816979|FG005|First/Baseline (1 Day at Week 1 )|Lost to Follow-up|0
6170559|NCT01254188|9816989|FG000|Overall Study|Disease Progression|6
6170560|NCT01254188|9816989|FG000|Overall Study|Protocol Violation|6
6170561|NCT01254188|9816989|FG000|Overall Study|Pregnancy|2
6170562|NCT01254188|9816989|FG000|Overall Study|Death|4
6170563|NCT01254188|9816989|FG000|Overall Study|Lost to Follow-up|5
6170564|NCT01254188|9816989|FG000|Overall Study|Withdrawal by Subject|7
6170565|NCT01254188|9816989|FG000|Overall Study|Adverse Event|43
6170566|NCT01254188|9816989|FG000|Overall Study|per investigator discretion|20
6170567|NCT01254227|9817002|FG000|Overall Study|Withdrawal by Subject|6
6170568|NCT01254227|9817002|FG000|Overall Study|Lost to Follow-up|6
6170569|NCT01254227|9817002|FG000|Overall Study|Adverse Event|5
6170570|NCT01254227|9817002|FG000|Overall Study|Abnormal test procedure result|5
6170571|NCT01254227|9817002|FG000|Overall Study|Administrative problems|2
6170572|NCT01254227|9817002|FG000|Overall Study|Death|1
6170573|NCT01254227|9817002|FG000|Overall Study|Protocol deviation|1
6170574|NCT01254292|9817008|FG000|Comparative Phase|Adverse Event|25
6170575|NCT01254292|9817009|FG001|Comparative Phase|Adverse Event|25
6170576|NCT01254292|9817008|FG000|Comparative Phase|Lost to Follow-up|3
6170577|NCT01254292|9817009|FG001|Comparative Phase|Lost to Follow-up|21
6170578|NCT01254292|9817008|FG000|Comparative Phase|Pregnancy|2
6361719|NCT03364686|10151165|FG000|Overall Study|Physician Decision|2
6361720|NCT03326856|10151183|FG000|Overall Study|Lost to Follow-up|1
6361721|NCT03326856|10151184|FG001|Overall Study|Lost to Follow-up|1
6361722|NCT03326856|10151185|FG002|Overall Study|Lost to Follow-up|0
6361723|NCT03326856|10151186|FG003|Overall Study|Lost to Follow-up|0
6361724|NCT03326856|10151187|FG004|Overall Study|Lost to Follow-up|0
6361725|NCT03287089|10151205|FG000|Overall Study|Lost to Follow-up|0
6361726|NCT03287089|10151206|FG001|Overall Study|Lost to Follow-up|2
6361727|NCT03287089|10151205|FG000|Overall Study|Physician Decision|0
6361728|NCT03287089|10151206|FG001|Overall Study|Physician Decision|2
6361729|NCT03287089|10151205|FG000|Overall Study|Withdrawal by Subject|0
6361730|NCT03287089|10151206|FG001|Overall Study|Withdrawal by Subject|2
6361731|NCT03240692|10151212|FG000|Overall Study|Physician Decision|1
6361732|NCT03240692|10151212|FG000|Overall Study|Withdrawal by Subject|1
6361733|NCT03227029|10151219|FG000|Overall Study|Child Wheezed (no treatment)|0
6361734|NCT03227029|10151220|FG001|Overall Study|Child Wheezed (no treatment)|1
6361735|NCT03227029|10151221|FG002|Overall Study|Child Wheezed (no treatment)|0
6361736|NCT03227029|10151219|FG000|Overall Study|No post RSV season visit due to COVID|3
6361737|NCT03227029|10151220|FG001|Overall Study|No post RSV season visit due to COVID|3
6361738|NCT03227029|10151221|FG002|Overall Study|No post RSV season visit due to COVID|2
6361739|NCT03227029|10151219|FG000|Overall Study|Not able to get to clinic|0
6361740|NCT03227029|10151220|FG001|Overall Study|Not able to get to clinic|0
6361741|NCT03227029|10151221|FG002|Overall Study|Not able to get to clinic|1
6361742|NCT03227029|10151219|FG000|Overall Study|Withdrawal by Subject|1
6361743|NCT03227029|10151220|FG001|Overall Study|Withdrawal by Subject|0
6361744|NCT03227029|10151221|FG002|Overall Study|Withdrawal by Subject|0
6361745|NCT03227029|10151219|FG000|Overall Study|Unable to receive treatment in time (no treatment)|0
6361746|NCT03227029|10151220|FG001|Overall Study|Unable to receive treatment in time (no treatment)|0
6361747|NCT03227029|10151221|FG002|Overall Study|Unable to receive treatment in time (no treatment)|1
6361748|NCT03182829|10151249|FG000|Overall Study|Protocol Violation|12
6361749|NCT03182829|10151250|FG001|Overall Study|Protocol Violation|12
6361750|NCT03182829|10151249|FG000|Overall Study|Other|4
6361751|NCT03182829|10151250|FG001|Overall Study|Other|3
6361752|NCT03181789|10151260|FG000|Overall Study|Withdrawal by Subject|0
6361753|NCT03181789|10151261|FG001|Overall Study|Withdrawal by Subject|1
6361754|NCT03181789|10151262|FG002|Overall Study|Withdrawal by Subject|1
6361755|NCT03181789|10151263|FG003|Overall Study|Withdrawal by Subject|0
6361756|NCT03181789|10151260|FG000|Overall Study|Lost to Follow-up|7
6361757|NCT03181789|10151261|FG001|Overall Study|Lost to Follow-up|1
6361758|NCT03181789|10151262|FG002|Overall Study|Lost to Follow-up|0
6361759|NCT03181789|10151263|FG003|Overall Study|Lost to Follow-up|0
6361760|NCT03181789|10151260|FG000|Overall Study|Participant unable to adhere to visit|0
6361761|NCT03181789|10151261|FG001|Overall Study|Participant unable to adhere to visit|1
6361762|NCT03181789|10151262|FG002|Overall Study|Participant unable to adhere to visit|0
6361763|NCT03181789|10151263|FG003|Overall Study|Participant unable to adhere to visit|0
6361764|NCT03164356|10151278|FG000|Overall Study|Lost to Follow-up|1
6361765|NCT03164356|10151279|FG001|Overall Study|Lost to Follow-up|1
6361766|NCT03164356|10151280|FG002|Overall Study|Lost to Follow-up|2
6361767|NCT03164356|10151281|FG003|Overall Study|Lost to Follow-up|1
6361768|NCT03164356|10151278|FG000|Overall Study|Physician Decision|0
6361769|NCT03164356|10151279|FG001|Overall Study|Physician Decision|0
6361770|NCT03164356|10151280|FG002|Overall Study|Physician Decision|3
6361771|NCT03164356|10151281|FG003|Overall Study|Physician Decision|0
6361772|NCT03164356|10151278|FG000|Overall Study|Protocol Violation|2
6361773|NCT03164356|10151279|FG001|Overall Study|Protocol Violation|1
6361774|NCT03164356|10151280|FG002|Overall Study|Protocol Violation|0
6361775|NCT03164356|10151281|FG003|Overall Study|Protocol Violation|0
6361776|NCT03164356|10151278|FG000|Overall Study|Withdrawal by Subject|1
6361777|NCT03164356|10151279|FG001|Overall Study|Withdrawal by Subject|0
6361778|NCT03164356|10151280|FG002|Overall Study|Withdrawal by Subject|0
6361779|NCT03164356|10151281|FG003|Overall Study|Withdrawal by Subject|0
6361780|NCT03164356|10151278|FG000|Overall Study|Study timeframe interrupted by COVID-19|1
6361781|NCT03164356|10151279|FG001|Overall Study|Study timeframe interrupted by COVID-19|0
6361782|NCT03164356|10151280|FG002|Overall Study|Study timeframe interrupted by COVID-19|0
6361783|NCT03164356|10151281|FG003|Overall Study|Study timeframe interrupted by COVID-19|1
6361784|NCT03164356|10151278|FG000|Overall Study|Subject Incarcerated|0
6361785|NCT03164356|10151279|FG001|Overall Study|Subject Incarcerated|1
6361786|NCT03164356|10151280|FG002|Overall Study|Subject Incarcerated|0
6361787|NCT03164356|10151281|FG003|Overall Study|Subject Incarcerated|0
6361788|NCT03164356|10151278|FG000|Overall Study|Prosthetist unable to participate|0
6361789|NCT03164356|10151279|FG001|Overall Study|Prosthetist unable to participate|2
6361790|NCT03164356|10151280|FG002|Overall Study|Prosthetist unable to participate|1
6361791|NCT03164356|10151281|FG003|Overall Study|Prosthetist unable to participate|0
6361792|NCT02975700|10151301|FG000|Overall Study|Adverse Event|1
6361793|NCT02975700|10151301|FG000|Overall Study|Progressive disease|3
6361794|NCT02975700|10151301|FG000|Overall Study|Failed screening criteria|2
6361795|NCT02941549|10151308|FG000|Overall Study|Adverse Event|1
6361796|NCT02941549|10151309|FG001|Overall Study|Adverse Event|0
6361797|NCT02941549|10151310|FG002|Overall Study|Adverse Event|0
6361798|NCT02941549|10151308|FG000|Overall Study|Withdrawal by Subject|2
6361799|NCT02941549|10151309|FG001|Overall Study|Withdrawal by Subject|1
6361800|NCT02941549|10151310|FG002|Overall Study|Withdrawal by Subject|2
6361801|NCT02927938|10151334|FG000|Overall Study|Death|0
6361802|NCT02927938|10151335|FG001|Overall Study|Death|1
6361803|NCT02927938|10151336|FG002|Overall Study|Death|0
6361804|NCT02927938|10151337|FG003|Overall Study|Death|4
6361805|NCT02927938|10151334|FG000|Overall Study|Early Study Termination|1
6361806|NCT02927938|10151335|FG001|Overall Study|Early Study Termination|5
6361807|NCT02927938|10151336|FG002|Overall Study|Early Study Termination|4
6361808|NCT02927938|10151337|FG003|Overall Study|Early Study Termination|3
6043207|NCT00387725|9641723|FG001|Overall Study|Adverse Event|0
6361809|NCT02823574|10151377|FG000|Pre-Treatment Period|Adverse Event Unrelated to Study drug|1
6361810|NCT02823574|10151378|FG001|Pre-Treatment Period|Adverse Event Unrelated to Study drug|0
6361811|NCT02823574|10151379|FG002|Pre-Treatment Period|Adverse Event Unrelated to Study drug|0
6361812|NCT02823574|10151380|FG003|Pre-Treatment Period|Adverse Event Unrelated to Study drug|0
6361813|NCT02823574|10151377|FG000|Pre-Treatment Period|Disease progression|0
6361814|NCT02823574|10151378|FG001|Pre-Treatment Period|Disease progression|0
6361815|NCT02823574|10151379|FG002|Pre-Treatment Period|Disease progression|1
6361816|NCT02823574|10151380|FG003|Pre-Treatment Period|Disease progression|0
6361817|NCT02823574|10151377|FG000|Treatment Period|Poor/Non Compliance|1
6361818|NCT02823574|10151378|FG001|Treatment Period|Poor/Non Compliance|0
6361819|NCT02823574|10151379|FG002|Treatment Period|Poor/Non Compliance|0
6361820|NCT02823574|10151380|FG003|Treatment Period|Poor/Non Compliance|1
6361821|NCT02823574|10151377|FG000|Treatment Period|Maximum Clinical Benefit|1
6361822|NCT02823574|10151378|FG001|Treatment Period|Maximum Clinical Benefit|0
6361823|NCT02823574|10151379|FG002|Treatment Period|Maximum Clinical Benefit|2
6361824|NCT02823574|10151380|FG003|Treatment Period|Maximum Clinical Benefit|0
6361825|NCT02823574|10151377|FG000|Treatment Period|Lost to Follow-up|1
6361826|NCT02823574|10151378|FG001|Treatment Period|Lost to Follow-up|0
6361827|NCT02823574|10151379|FG002|Treatment Period|Lost to Follow-up|0
6361828|NCT02823574|10151380|FG003|Treatment Period|Lost to Follow-up|0
6361829|NCT02823574|10151377|FG000|Treatment Period|Participant withdrew consent|2
6361830|NCT02823574|10151378|FG001|Treatment Period|Participant withdrew consent|0
6361831|NCT02823574|10151379|FG002|Treatment Period|Participant withdrew consent|0
6361832|NCT02823574|10151380|FG003|Treatment Period|Participant withdrew consent|0
6361833|NCT02823574|10151377|FG000|Treatment Period|Participant request to discontinue|4
6361834|NCT02823574|10151378|FG001|Treatment Period|Participant request to discontinue|0
6361835|NCT02823574|10151379|FG002|Treatment Period|Participant request to discontinue|2
6361836|NCT02823574|10151380|FG003|Treatment Period|Participant request to discontinue|3
6361837|NCT02823574|10151377|FG000|Treatment Period|Adverse Event unrelated to to study Drug|10
6361838|NCT02823574|10151378|FG001|Treatment Period|Adverse Event unrelated to to study Drug|2
6361839|NCT02823574|10151379|FG002|Treatment Period|Adverse Event unrelated to to study Drug|8
6361840|NCT02823574|10151380|FG003|Treatment Period|Adverse Event unrelated to to study Drug|1
6361841|NCT02823574|10151377|FG000|Treatment Period|Study Drug Toxicity|7
6361842|NCT02823574|10151378|FG001|Treatment Period|Study Drug Toxicity|2
6361843|NCT02823574|10151379|FG002|Treatment Period|Study Drug Toxicity|13
6361844|NCT02823574|10151380|FG003|Treatment Period|Study Drug Toxicity|3
6361845|NCT02823574|10151377|FG000|Treatment Period|Disease Progression|112
6361846|NCT02823574|10151378|FG001|Treatment Period|Disease Progression|60
6361847|NCT02823574|10151379|FG002|Treatment Period|Disease Progression|80
6361848|NCT02823574|10151380|FG003|Treatment Period|Disease Progression|41
6361849|NCT02823574|10151377|FG000|Treatment Period|participant no longer meets study criteria|0
6361850|NCT02823574|10151378|FG001|Treatment Period|participant no longer meets study criteria|0
6361851|NCT02823574|10151379|FG002|Treatment Period|participant no longer meets study criteria|1
6361852|NCT02823574|10151380|FG003|Treatment Period|participant no longer meets study criteria|0
6361853|NCT02823574|10151377|FG000|Treatment Period|Death|0
6361854|NCT02823574|10151378|FG001|Treatment Period|Death|0
6361855|NCT02823574|10151379|FG002|Treatment Period|Death|2
6361856|NCT02823574|10151380|FG003|Treatment Period|Death|1
6361857|NCT02823574|10151377|FG000|Treatment Period|Other reasons|1
6361858|NCT02823574|10151378|FG001|Treatment Period|Other reasons|2
6361859|NCT02823574|10151379|FG002|Treatment Period|Other reasons|0
6361860|NCT02823574|10151380|FG003|Treatment Period|Other reasons|1
6361861|NCT02743819|10151402|FG000|Overall Study|Lack of Efficacy|5
6361862|NCT02743819|10151402|FG000|Overall Study|Death|2
6361863|NCT02743819|10151402|FG000|Overall Study|Adverse Event|1
6361864|NCT02729753|10151408|FG000|Overall Study|Device Malfunction. No units in stock.|0
6084229|NCT00642369|9693219|FG001|Overall Study|Withdrawal by Subject|0
6084230|NCT00642369|9693218|FG000|Overall Study|misdiagnosis|0
6084231|NCT00642369|9693219|FG001|Overall Study|misdiagnosis|1
6084232|NCT00642369|9693218|FG000|Overall Study|Lack of Efficacy|2
6084233|NCT00642369|9693219|FG001|Overall Study|Lack of Efficacy|2
6084234|NCT00642460|9693229|FG000|Part I: 12 Week Double-Blind|Adverse Event|0
6084235|NCT00642460|9693230|FG001|Part I: 12 Week Double-Blind|Adverse Event|1
6084236|NCT00642460|9693231|FG002|Part I: 12 Week Double-Blind|Adverse Event|1
6084237|NCT00642460|9693232|FG003|Part I: 12 Week Double-Blind|Adverse Event|0
6084238|NCT00642460|9693233|FG004|Part I: 12 Week Double-Blind|Adverse Event|0
6084239|NCT00642460|9693234|FG005|Part I: 12 Week Double-Blind|Adverse Event|0
6084240|NCT00642460|9693229|FG000|Part I: 12 Week Double-Blind|Refused Treatment|1
6084241|NCT00642460|9693230|FG001|Part I: 12 Week Double-Blind|Refused Treatment|0
6361865|NCT02729753|10151409|FG001|Overall Study|Device Malfunction. No units in stock.|1
6361866|NCT02704130|10151420|FG000|Overall Study|Physician Decision|5
6361867|NCT02704130|10151421|FG001|Overall Study|Physician Decision|3
6361868|NCT02701192|10151427|FG000|Overall Study|Protocol Violation|2
6361869|NCT02701192|10151427|FG000|Overall Study|Lost to Follow-up|4
6361870|NCT02653482|10151461|FG000|Overall Study|Death|1
6361871|NCT02653482|10151462|FG001|Overall Study|Death|1
6361872|NCT02632409|10151470|FG000|Randomized|AE unrelated to study Drug|0
6361873|NCT02632409|10151471|FG001|Randomized|AE unrelated to study Drug|1
6087760|NCT00670449|9698233|FG002|Overall Study|Administrative Problems|0
6361874|NCT02632409|10151470|FG000|Randomized|Participant withdrew consent|2
6361875|NCT02632409|10151471|FG001|Randomized|Participant withdrew consent|1
6361876|NCT02632409|10151470|FG000|Randomized|No Longer meets study criteria|5
6361877|NCT02632409|10151471|FG001|Randomized|No Longer meets study criteria|0
6361878|NCT02632409|10151470|FG000|Randomized|other reasons|1
6361879|NCT02632409|10151471|FG001|Randomized|other reasons|0
6361880|NCT02632409|10151470|FG000|Treatment Period|Ongoing Treatment|20
6361881|NCT02632409|10151471|FG001|Treatment Period|Ongoing Treatment|21
6361882|NCT02632409|10151470|FG000|Treatment Period|Disease Recurrence|147
6361883|NCT02632409|10151471|FG001|Treatment Period|Disease Recurrence|90
6361884|NCT02632409|10151470|FG000|Treatment Period|Study Drug Toxicity|8
6361885|NCT02632409|10151471|FG001|Treatment Period|Study Drug Toxicity|49
6361886|NCT02632409|10151470|FG000|Treatment Period|Death|1
6361887|NCT02632409|10151471|FG001|Treatment Period|Death|0
6361888|NCT02632409|10151470|FG000|Treatment Period|AE unrelated to study drug|15
6361889|NCT02632409|10151471|FG001|Treatment Period|AE unrelated to study drug|16
6361890|NCT02632409|10151470|FG000|Treatment Period|Request to discontinue treatment|4
6361891|NCT02632409|10151471|FG001|Treatment Period|Request to discontinue treatment|19
6361892|NCT02632409|10151470|FG000|Treatment Period|Participant withdrew consent|7
6361893|NCT02632409|10151471|FG001|Treatment Period|Participant withdrew consent|5
6361894|NCT02632409|10151470|FG000|Treatment Period|Lost to Follow-up|0
6361895|NCT02632409|10151471|FG001|Treatment Period|Lost to Follow-up|1
6361896|NCT02632409|10151470|FG000|Treatment Period|Maximum clinical benefit|1
6361897|NCT02632409|10151471|FG001|Treatment Period|Maximum clinical benefit|0
6361898|NCT02632409|10151470|FG000|Treatment Period|No longer meets study criteria|3
6361899|NCT02632409|10151471|FG001|Treatment Period|No longer meets study criteria|0
6361900|NCT02632409|10151470|FG000|Treatment Period|Administrative Reason by sponsor|0
6361901|NCT02632409|10151471|FG001|Treatment Period|Administrative Reason by sponsor|1
6361902|NCT02632409|10151470|FG000|Treatment Period|Other Reasons|10
6361903|NCT02632409|10151471|FG001|Treatment Period|Other Reasons|6
6361904|NCT02612194|10151480|FG000|Overall Study|Death|5
6361905|NCT02612194|10151481|FG001|Overall Study|Death|0
6361906|NCT02612194|10151482|FG002|Overall Study|Death|2
6361907|NCT02612194|10151480|FG000|Overall Study|Early Study Termination|1
6361908|NCT02612194|10151481|FG001|Overall Study|Early Study Termination|0
6361909|NCT02612194|10151482|FG002|Overall Study|Early Study Termination|0
6361910|NCT02586207|10151489|FG000|Overall Study|Physician Decision|1
6361911|NCT02586207|10151489|FG000|Overall Study|Withdrawal by Subject|1
6361912|NCT02542397|10151493|FG000|Overall Study|Death|2
6361913|NCT02542397|10151493|FG000|Overall Study|Physician Decision|6
6361914|NCT02542397|10151493|FG000|Overall Study|Withdrawal by Subject|6
6361915|NCT02542397|10151493|FG000|Overall Study|Lost to Follow-up|2
6361916|NCT02519777|10151501|FG000|Overall Study|Death|1
6361917|NCT02519777|10151502|FG001|Overall Study|Death|0
6361918|NCT02519777|10151503|FG002|Overall Study|Death|0
6361919|NCT02519777|10151501|FG000|Overall Study|Lost to Follow-up|0
6361920|NCT02519777|10151502|FG001|Overall Study|Lost to Follow-up|4
6361921|NCT02519777|10151503|FG002|Overall Study|Lost to Follow-up|2
6361922|NCT02519777|10151501|FG000|Overall Study|Withdrawal by Subject|3
6361923|NCT02519777|10151502|FG001|Overall Study|Withdrawal by Subject|1
6361924|NCT02519777|10151503|FG002|Overall Study|Withdrawal by Subject|0
6361925|NCT02519777|10151501|FG000|Overall Study|Severe Debilitation|1
6361926|NCT02519777|10151502|FG001|Overall Study|Severe Debilitation|1
6361927|NCT02519777|10151503|FG002|Overall Study|Severe Debilitation|1
6361928|NCT02519777|10151501|FG000|Overall Study|Not able to get to clinic|1
6361929|NCT02519777|10151502|FG001|Overall Study|Not able to get to clinic|2
6361930|NCT02519777|10151503|FG002|Overall Study|Not able to get to clinic|1
6361931|NCT02484443|10151511|FG000|Overall Study|Lack of Efficacy|28
6361932|NCT02484443|10151511|FG000|Overall Study|Physician Decision|2
6361933|NCT02484443|10151511|FG000|Overall Study|Ineligible|2
6361934|NCT02395666|10151517|FG000|Overall Study|Physician Decision|3
6361935|NCT02395666|10151518|FG001|Overall Study|Physician Decision|0
6361936|NCT02395666|10151517|FG000|Overall Study|Lost to Follow-up|1
6361937|NCT02395666|10151518|FG001|Overall Study|Lost to Follow-up|0
6361938|NCT02395666|10151517|FG000|Overall Study|Withdrawal by Subject|2
6361939|NCT02395666|10151518|FG001|Overall Study|Withdrawal by Subject|1
6361940|NCT02357810|10151528|FG000|Registered and Started Treatment|Withdrawal by Subject|1
6361941|NCT02357810|10151528|FG000|Registered and Started Treatment|Found not to be eligible for the study|26
6361942|NCT02357810|10151528|FG000|Reached 12 Weeks Response|Adverse Event|5
6361943|NCT02357810|10151528|FG000|Reached 12 Weeks Response|Progressive Disease|39
6361944|NCT02357810|10151528|FG000|Reached 12 Weeks Response|Withdrawal by Subject|8
6361945|NCT02357810|10151528|FG000|Reached 12 Weeks Response|Protocol Violation|1
6361946|NCT02357810|10151528|FG000|Reached 12 Weeks Response|Death|1
6361947|NCT02357810|10151528|FG000|Reached 12 Weeks Response|Physician Decision|1
6361948|NCT02357810|10151528|FG000|Reached 12 Weeks Response|Other|1
6361949|NCT02357810|10151528|FG000|12 Week Response and Further Treatment|Adverse Event|5
6361950|NCT02357810|10151528|FG000|12 Week Response and Further Treatment|Withdrawal by Subject|1
6361951|NCT02357810|10151528|FG000|12 Week Response and Further Treatment|Progressive Disease|15
6361952|NCT02357810|10151528|FG000|12 Week Response and Further Treatment|Wound Complications|1
6361953|NCT02357810|10151528|FG000|Follow-up at Treatment Discontinuation|Withdrawal by Subject|4
6361954|NCT02357810|10151528|FG000|Follow-up at Treatment Discontinuation|Lost to Follow-up|3
6361955|NCT02343549|10151532|FG000|Overall Study|Death|11
6361956|NCT02343549|10151532|FG000|Overall Study|Withdrawal by Subject|2
6361957|NCT02328105|10151540|FG000|Overall Study|Death|6
6361958|NCT02328105|10151540|FG000|Overall Study|Withdrawal by Subject|1
6084242|NCT00642460|9693231|FG002|Part I: 12 Week Double-Blind|Refused Treatment|0
6084243|NCT00642460|9693232|FG003|Part I: 12 Week Double-Blind|Refused Treatment|0
6361959|NCT02328105|10151540|FG000|Overall Study|Still On Study in Follow-Up|4
6361960|NCT02315066|10151567|FG000|Overall Study|Lost to Follow-up|0
6361961|NCT02315066|10151568|FG001|Overall Study|Lost to Follow-up|1
6361962|NCT02315066|10151569|FG002|Overall Study|Lost to Follow-up|1
6361963|NCT02315066|10151570|FG003|Overall Study|Lost to Follow-up|0
6361964|NCT02315066|10151571|FG004|Overall Study|Lost to Follow-up|1
6361965|NCT02315066|10151572|FG005|Overall Study|Lost to Follow-up|0
6361966|NCT02315066|10151573|FG006|Overall Study|Lost to Follow-up|2
6361967|NCT02315066|10151574|FG007|Overall Study|Lost to Follow-up|1
6361968|NCT02315066|10151575|FG008|Overall Study|Lost to Follow-up|0
6361969|NCT02315066|10151576|FG009|Overall Study|Lost to Follow-up|0
6361970|NCT02315066|10151577|FG010|Overall Study|Lost to Follow-up|1
6361971|NCT02315066|10151578|FG011|Overall Study|Lost to Follow-up|2
6361972|NCT02315066|10151579|FG012|Overall Study|Lost to Follow-up|0
6361973|NCT02315066|10151580|FG013|Overall Study|Lost to Follow-up|4
6361974|NCT02315066|10151567|FG000|Overall Study|Death|2
6361975|NCT02315066|10151568|FG001|Overall Study|Death|7
6361976|NCT02315066|10151569|FG002|Overall Study|Death|6
6361977|NCT02315066|10151570|FG003|Overall Study|Death|11
6361978|NCT02315066|10151571|FG004|Overall Study|Death|10
6361979|NCT02315066|10151572|FG005|Overall Study|Death|3
6361980|NCT02315066|10151573|FG006|Overall Study|Death|9
6361981|NCT02315066|10151574|FG007|Overall Study|Death|9
6361982|NCT02315066|10151575|FG008|Overall Study|Death|10
6361983|NCT02315066|10151576|FG009|Overall Study|Death|8
6361984|NCT02315066|10151577|FG010|Overall Study|Death|10
6361985|NCT02315066|10151578|FG011|Overall Study|Death|7
6361986|NCT02315066|10151579|FG012|Overall Study|Death|8
6361987|NCT02315066|10151580|FG013|Overall Study|Death|21
6361988|NCT02315066|10151567|FG000|Overall Study|Other|0
6361989|NCT02315066|10151568|FG001|Overall Study|Other|0
6361990|NCT02315066|10151569|FG002|Overall Study|Other|0
6361991|NCT02315066|10151570|FG003|Overall Study|Other|0
6361992|NCT02315066|10151571|FG004|Overall Study|Other|0
6361993|NCT02315066|10151572|FG005|Overall Study|Other|0
6361994|NCT02315066|10151573|FG006|Overall Study|Other|0
6361995|NCT02315066|10151574|FG007|Overall Study|Other|1
6361996|NCT02315066|10151575|FG008|Overall Study|Other|1
6361997|NCT02315066|10151576|FG009|Overall Study|Other|2
6361998|NCT02315066|10151577|FG010|Overall Study|Other|0
6361999|NCT02315066|10151578|FG011|Overall Study|Other|0
6362000|NCT02315066|10151579|FG012|Overall Study|Other|0
6362001|NCT02315066|10151580|FG013|Overall Study|Other|0
6362002|NCT02315066|10151567|FG000|Overall Study|Subject refused further follow-up|0
6362003|NCT02315066|10151568|FG001|Overall Study|Subject refused further follow-up|2
6362004|NCT02315066|10151569|FG002|Overall Study|Subject refused further follow-up|2
6362005|NCT02315066|10151570|FG003|Overall Study|Subject refused further follow-up|0
6362006|NCT02315066|10151571|FG004|Overall Study|Subject refused further follow-up|0
6362007|NCT02315066|10151572|FG005|Overall Study|Subject refused further follow-up|0
6362008|NCT02315066|10151573|FG006|Overall Study|Subject refused further follow-up|2
6362009|NCT02315066|10151574|FG007|Overall Study|Subject refused further follow-up|3
6362010|NCT02315066|10151575|FG008|Overall Study|Subject refused further follow-up|0
6362011|NCT02315066|10151576|FG009|Overall Study|Subject refused further follow-up|1
6362012|NCT02315066|10151577|FG010|Overall Study|Subject refused further follow-up|1
6362013|NCT02315066|10151578|FG011|Overall Study|Subject refused further follow-up|2
6362014|NCT02315066|10151579|FG012|Overall Study|Subject refused further follow-up|2
6362015|NCT02315066|10151580|FG013|Overall Study|Subject refused further follow-up|4
6362016|NCT02315066|10151567|FG000|Overall Study|Study ongoing at date of cut-off|0
6362017|NCT02315066|10151568|FG001|Overall Study|Study ongoing at date of cut-off|0
6362018|NCT02315066|10151569|FG002|Overall Study|Study ongoing at date of cut-off|0
6362019|NCT02315066|10151570|FG003|Overall Study|Study ongoing at date of cut-off|0
6362020|NCT02315066|10151571|FG004|Overall Study|Study ongoing at date of cut-off|0
6170579|NCT01254292|9817009|FG001|Comparative Phase|Pregnancy|6
6362021|NCT02315066|10151572|FG005|Overall Study|Study ongoing at date of cut-off|0
6362022|NCT02315066|10151573|FG006|Overall Study|Study ongoing at date of cut-off|0
6362023|NCT02315066|10151574|FG007|Overall Study|Study ongoing at date of cut-off|0
6362024|NCT02315066|10151575|FG008|Overall Study|Study ongoing at date of cut-off|0
6362025|NCT02315066|10151576|FG009|Overall Study|Study ongoing at date of cut-off|0
6362026|NCT02315066|10151577|FG010|Overall Study|Study ongoing at date of cut-off|0
6362027|NCT02315066|10151578|FG011|Overall Study|Study ongoing at date of cut-off|0
6362028|NCT02315066|10151579|FG012|Overall Study|Study ongoing at date of cut-off|0
6362029|NCT02315066|10151580|FG013|Overall Study|Study ongoing at date of cut-off|1
6362030|NCT02256631|10151626|FG000|Overall Study|Lost to Follow-up|1
6362031|NCT02256631|10151627|FG001|Overall Study|Lost to Follow-up|1
6362032|NCT02256631|10151628|FG002|Overall Study|Lost to Follow-up|0
6170580|NCT01254292|9817008|FG000|Comparative Phase|Withdrawal by Subject|20
6362033|NCT02256631|10151629|FG003|Overall Study|Lost to Follow-up|2
6362034|NCT02256631|10151630|FG004|Overall Study|Lost to Follow-up|0
6362035|NCT02256631|10151631|FG005|Overall Study|Lost to Follow-up|1
6362036|NCT02256631|10151632|FG006|Overall Study|Lost to Follow-up|1
6362037|NCT02256631|10151626|FG000|Overall Study|Withdrawal by Subject|0
6362038|NCT02256631|10151627|FG001|Overall Study|Withdrawal by Subject|0
6362039|NCT02256631|10151628|FG002|Overall Study|Withdrawal by Subject|0
6362040|NCT02256631|10151629|FG003|Overall Study|Withdrawal by Subject|1
6362041|NCT02256631|10151630|FG004|Overall Study|Withdrawal by Subject|1
6362042|NCT02256631|10151631|FG005|Overall Study|Withdrawal by Subject|0
6362043|NCT02256631|10151632|FG006|Overall Study|Withdrawal by Subject|1
6362044|NCT02256631|10151626|FG000|Overall Study|Unable to get to clinic|0
6362045|NCT02256631|10151627|FG001|Overall Study|Unable to get to clinic|2
6362046|NCT02256631|10151628|FG002|Overall Study|Unable to get to clinic|0
6362047|NCT02256631|10151629|FG003|Overall Study|Unable to get to clinic|1
6362048|NCT02256631|10151630|FG004|Overall Study|Unable to get to clinic|0
6362049|NCT02256631|10151631|FG005|Overall Study|Unable to get to clinic|1
6362050|NCT02256631|10151632|FG006|Overall Study|Unable to get to clinic|2
6362051|NCT02173379|10151650|FG000|Overall Study|Lost to Follow-up|48
6362052|NCT02173379|10151651|FG001|Overall Study|Lost to Follow-up|34
6362053|NCT02173379|10151650|FG000|Overall Study|Withdrawal by Subject|14
6362054|NCT02173379|10151651|FG001|Overall Study|Withdrawal by Subject|17
6362055|NCT02173379|10151650|FG000|Overall Study|Physician Decision|7
6362056|NCT02173379|10151651|FG001|Overall Study|Physician Decision|4
6362057|NCT02173379|10151650|FG000|Overall Study|Death|22
6362058|NCT02173379|10151651|FG001|Overall Study|Death|22
6362059|NCT02080260|10151667|FG000|Overall Study|Death|18
6362060|NCT02080260|10151667|FG000|Overall Study|Withdrawal by Subject|1
6362061|NCT02051933|10151673|FG000|Overall Study|Physician Decision|0
6362062|NCT02051933|10151674|FG001|Overall Study|Physician Decision|1
6362063|NCT01802281|10151746|FG000|Overall Study|Death|1
6362064|NCT01802281|10151747|FG001|Overall Study|Death|2
6362065|NCT01802281|10151746|FG000|Overall Study|Withdrawal by Subject|2
6362066|NCT01802281|10151747|FG001|Overall Study|Withdrawal by Subject|1
6362067|NCT01802281|10151746|FG000|Overall Study|Ineligible|5
6362068|NCT01802281|10151747|FG001|Overall Study|Ineligible|3
6362069|NCT01774253|10151753|FG000|Overall Study|Lack of Efficacy|4
6362070|NCT01774253|10151753|FG000|Overall Study|Physician Decision|2
6362071|NCT01774253|10151753|FG000|Overall Study|Withdrawal by Subject|2
6362072|NCT01774253|10151753|FG000|Overall Study|Death|1
6362073|NCT01505608|10151763|FG000|Phase I|Lack of Efficacy|0
6362074|NCT01505608|10151764|FG001|Phase I|Lack of Efficacy|4
6362075|NCT01505608|10151763|FG000|Phase I|Adverse Event|0
6362076|NCT01505608|10151764|FG001|Phase I|Adverse Event|1
6362077|NCT01505608|10151763|FG000|Phase I|Withdrawal by Subject|0
6362078|NCT01505608|10151764|FG001|Phase I|Withdrawal by Subject|1
6362079|NCT01505608|10151763|FG000|Phase II|Lack of Efficacy|2
6362080|NCT01505608|10151764|FG001|Phase II|Lack of Efficacy|1
6362081|NCT01505608|10151763|FG000|Phase II|Protocol Violation|0
6362082|NCT01505608|10151764|FG001|Phase II|Protocol Violation|1
6362083|NCT01483820|10151773|FG000|Overall Study|Lack of Efficacy|6
6362084|NCT01483820|10151773|FG000|Overall Study|Adverse Event|1
6362085|NCT01483820|10151773|FG000|Overall Study|Death|1
6362086|NCT01355679|10151777|FG000|Overall Study|benign tumor types found at biopsy|2
6362087|NCT01166386|10151802|FG000|Overall Study|Withdrawal by Subject|3
6362088|NCT01166386|10151803|FG001|Overall Study|Withdrawal by Subject|5
6362089|NCT01114217|10151811|FG000|Overall Study|Adverse Event|5
6362090|NCT01114217|10151812|FG001|Overall Study|Adverse Event|3
6362091|NCT01114217|10151811|FG000|Overall Study|Lost to Follow-up|17
6362092|NCT01114217|10151812|FG001|Overall Study|Lost to Follow-up|33
6362093|NCT01114217|10151811|FG000|Overall Study|Withdrawal by Subject|21
6362094|NCT01114217|10151812|FG001|Overall Study|Withdrawal by Subject|28
6362095|NCT01114217|10151811|FG000|Overall Study|Other-Clerical Error|3
6362096|NCT01114217|10151812|FG001|Overall Study|Other-Clerical Error|0
6362097|NCT01114217|10151811|FG000|Overall Study|Other-Early termination|6
6362098|NCT01114217|10151812|FG001|Overall Study|Other-Early termination|10
6362099|NCT01114217|10151811|FG000|Overall Study|Other-Procedure|1
6362100|NCT01114217|10151812|FG001|Overall Study|Other-Procedure|1
6362101|NCT01114217|10151811|FG000|Overall Study|Other-Pregnancy|2
6362102|NCT01114217|10151812|FG001|Overall Study|Other-Pregnancy|4
6362103|NCT01114217|10151811|FG000|Overall Study|Other-Protocol Violation|1
6362104|NCT01114217|10151812|FG001|Overall Study|Other-Protocol Violation|3
6362105|NCT01114217|10151811|FG000|Overall Study|Other-Lack of Efficacy|1
6362106|NCT01114217|10151812|FG001|Overall Study|Other-Lack of Efficacy|0
6362107|NCT01114217|10151811|FG000|Overall Study|Other-Non Compliance|2
6362108|NCT01114217|10151812|FG001|Overall Study|Other-Non Compliance|0
6362109|NCT01114217|10151811|FG000|Overall Study|Other-Physician Decision|1
6362110|NCT01114217|10151812|FG001|Overall Study|Other-Physician Decision|1
6362111|NCT01114217|10151811|FG000|Overall Study|Other-Sponsor Decision|10
6362112|NCT01114217|10151812|FG001|Overall Study|Other-Sponsor Decision|12
6362113|NCT01114217|10151811|FG000|Overall Study|Other-Study Termination|0
6362114|NCT01114217|10151812|FG001|Overall Study|Other-Study Termination|1
6362115|NCT01114217|10151811|FG000|Overall Study|Other-Study Withdrawn|1
6362116|NCT01114217|10151812|FG001|Overall Study|Other-Study Withdrawn|1
6362117|NCT01114217|10151811|FG000|Overall Study|Other-Site Stopped Communicating|2
6362118|NCT01114217|10151812|FG001|Overall Study|Other-Site Stopped Communicating|0
6362119|NCT01114217|10151811|FG000|Overall Study|Other-Lost to Follow-up|1
6362120|NCT01114217|10151812|FG001|Overall Study|Other-Lost to Follow-up|0
6362121|NCT01114217|10151811|FG000|Overall Study|Other-Withdrawal by Subject|1
6362122|NCT01114217|10151812|FG001|Overall Study|Other-Withdrawal by Subject|1
6362123|NCT01114204|10151818|FG000|Overall Study|Adverse Event|3
6362124|NCT01114204|10151819|FG001|Overall Study|Adverse Event|2
6362125|NCT01114204|10151818|FG000|Overall Study|Lost to Follow-up|1
6362126|NCT01114204|10151819|FG001|Overall Study|Lost to Follow-up|0
6362127|NCT01114204|10151818|FG000|Overall Study|Withdrawal by Subject|10
6362128|NCT01114204|10151819|FG001|Overall Study|Withdrawal by Subject|6
6362129|NCT01114204|10151818|FG000|Overall Study|Death|1
6362130|NCT01114204|10151819|FG001|Overall Study|Death|0
6362131|NCT01114204|10151818|FG000|Overall Study|Other-Personal reasons|2
6362132|NCT01114204|10151819|FG001|Overall Study|Other-Personal reasons|0
6362133|NCT01114204|10151818|FG000|Overall Study|Other-Medical monitor request|1
6362134|NCT01114204|10151819|FG001|Overall Study|Other-Medical monitor request|0
6362135|NCT01114204|10151818|FG000|Overall Study|Other-Participant request|2
6362136|NCT01114204|10151819|FG001|Overall Study|Other-Participant request|0
6362137|NCT01114204|10151818|FG000|Overall Study|Other-Protocol Violation|1
6362138|NCT01114204|10151819|FG001|Overall Study|Other-Protocol Violation|0
6362139|NCT01114139|10151827|FG000|Overall Study|Adverse Event|3
6362140|NCT01114139|10151828|FG001|Overall Study|Adverse Event|2
6362141|NCT01114139|10151827|FG000|Overall Study|Lost to Follow-up|15
6362142|NCT01114139|10151828|FG001|Overall Study|Lost to Follow-up|3
6362143|NCT01114139|10151827|FG000|Overall Study|Withdrawal by Subject|17
6362144|NCT01114139|10151828|FG001|Overall Study|Withdrawal by Subject|6
6362145|NCT01114139|10151827|FG000|Overall Study|Other-Missed 1 visit|1
6362146|NCT01114139|10151828|FG001|Overall Study|Other-Missed 1 visit|0
6362147|NCT01114139|10151827|FG000|Overall Study|Other-Protocol Violation|1
6362148|NCT01114139|10151828|FG001|Overall Study|Other-Protocol Violation|0
6362149|NCT01114139|10151827|FG000|Overall Study|Other-Out of window for study drug dose|1
6362150|NCT01114139|10151828|FG001|Overall Study|Other-Out of window for study drug dose|0
6362151|NCT01114139|10151827|FG000|Overall Study|Other-Participant falsified records|0
6362152|NCT01114139|10151828|FG001|Overall Study|Other-Participant falsified records|1
6362153|NCT01114139|10151827|FG000|Overall Study|Other-Participant went on hospice|0
6362154|NCT01114139|10151828|FG001|Overall Study|Other-Participant went on hospice|1
6362155|NCT01114139|10151827|FG000|Overall Study|Other-Physician changed treatment|1
6362156|NCT01114139|10151828|FG001|Overall Study|Other-Physician changed treatment|0
6362157|NCT01114139|10151827|FG000|Overall Study|Other-Withdrew prior to receiving dose|1
6362158|NCT01114139|10151828|FG001|Overall Study|Other-Withdrew prior to receiving dose|3
6362159|NCT01059071|10151834|FG000|Overall Study|Lack of Efficacy|1
6362160|NCT01059071|10151835|FG001|Overall Study|Lack of Efficacy|4
6362161|NCT01059071|10151836|FG002|Overall Study|Lack of Efficacy|2
6362162|NCT01059071|10151837|FG003|Overall Study|Lack of Efficacy|3
6362163|NCT01059071|10151834|FG000|Overall Study|Withdrawal by Subject|1
6362164|NCT01059071|10151835|FG001|Overall Study|Withdrawal by Subject|0
6362165|NCT01059071|10151836|FG002|Overall Study|Withdrawal by Subject|0
6362166|NCT01059071|10151837|FG003|Overall Study|Withdrawal by Subject|2
6362167|NCT01059071|10151834|FG000|Overall Study|Physician Decision|0
6362168|NCT01059071|10151835|FG001|Overall Study|Physician Decision|0
6362169|NCT01059071|10151836|FG002|Overall Study|Physician Decision|0
6362170|NCT01059071|10151837|FG003|Overall Study|Physician Decision|1
6362171|NCT01027702|10151845|FG000|Overall Study|Received subsequent therapy|1
6362172|NCT01027702|10151846|FG001|Overall Study|Received subsequent therapy|2
6362173|NCT01027702|10151847|FG002|Overall Study|Received subsequent therapy|0
6362174|NCT01027702|10151848|FG003|Overall Study|Received subsequent therapy|4
6362175|NCT01027702|10151849|FG004|Overall Study|Received subsequent therapy|1
6362176|NCT01027702|10151850|FG005|Overall Study|Received subsequent therapy|0
6362177|NCT01027702|10151851|FG006|Overall Study|Received subsequent therapy|1
6362178|NCT01027702|10151845|FG000|Overall Study|Death|0
6362179|NCT01027702|10151846|FG001|Overall Study|Death|0
6362180|NCT01027702|10151847|FG002|Overall Study|Death|1
6362181|NCT01027702|10151848|FG003|Overall Study|Death|0
6362182|NCT01027702|10151849|FG004|Overall Study|Death|0
6362183|NCT01027702|10151850|FG005|Overall Study|Death|0
6362184|NCT01027702|10151851|FG006|Overall Study|Death|0
6362185|NCT00991887|10151864|FG000|Overall Study|Lost to Follow-up|2
6362186|NCT00991887|10151865|FG001|Overall Study|Lost to Follow-up|1
6362187|NCT00968864|10151871|FG000|Overall Study|Protocol exception/ not evaluable|1
6362188|NCT00934700|10151882|FG000|Overall Study|missing scan|5
6362189|NCT00934700|10151883|FG001|Overall Study|missing scan|9
6362190|NCT00934700|10151882|FG000|Overall Study|Death|8
6362191|NCT00934700|10151883|FG001|Overall Study|Death|3
6362192|NCT00867568|10151890|FG000|Overall Study|Lack of Efficacy|10
6362193|NCT00867568|10151890|FG000|Overall Study|Adverse Event|4
6362194|NCT00867568|10151890|FG000|Overall Study|Withdrawal by Subject|1
6362195|NCT00785291|10151897|FG000|Overall Study|Never began treatment|8
6362196|NCT00785291|10151898|FG001|Overall Study|Never began treatment|4
6362197|NCT00785291|10151899|FG002|Overall Study|Never began treatment|4
6362198|NCT00785291|10151897|FG000|Overall Study|Adverse Event|39
6362199|NCT00785291|10151898|FG001|Overall Study|Adverse Event|70
6362200|NCT00785291|10151899|FG002|Overall Study|Adverse Event|56
6362201|NCT00785291|10151897|FG000|Overall Study|Death|7
6362202|NCT00785291|10151898|FG001|Overall Study|Death|4
6362203|NCT00785291|10151899|FG002|Overall Study|Death|3
6362204|NCT00785291|10151897|FG000|Overall Study|Withdrawal by Subject|35
6362205|NCT00785291|10151898|FG001|Overall Study|Withdrawal by Subject|36
6362206|NCT00785291|10151899|FG002|Overall Study|Withdrawal by Subject|17
6362207|NCT00785291|10151897|FG000|Overall Study|Alternative Therapy|12
6362208|NCT00785291|10151898|FG001|Overall Study|Alternative Therapy|6
6362209|NCT00785291|10151899|FG002|Overall Study|Alternative Therapy|7
6362210|NCT00785291|10151897|FG000|Overall Study|Complicating illness|6
6362211|NCT00785291|10151898|FG001|Overall Study|Complicating illness|4
6170581|NCT01254292|9817009|FG001|Comparative Phase|Withdrawal by Subject|21
6170582|NCT01254292|9817008|FG000|Comparative Phase|Protocol Violation|1
6170583|NCT01254292|9817009|FG001|Comparative Phase|Protocol Violation|2
6170584|NCT01254292|9817008|FG000|Comparative Phase|Wish for pregnancy|4
6170585|NCT01254292|9817009|FG001|Comparative Phase|Wish for pregnancy|6
6362212|NCT00785291|10151899|FG002|Overall Study|Complicating illness|4
6362213|NCT00785291|10151897|FG000|Overall Study|Other Medical Reasons|29
6362214|NCT00785291|10151898|FG001|Overall Study|Other Medical Reasons|25
6362215|NCT00785291|10151899|FG002|Overall Study|Other Medical Reasons|15
6362216|NCT00770809|10151925|FG000|Overall Study|Adverse Event|9
6362217|NCT00770809|10151926|FG001|Overall Study|Adverse Event|1
6362218|NCT00770809|10151927|FG002|Overall Study|Adverse Event|12
6362219|NCT00770809|10151925|FG000|Overall Study|Death|1
6362220|NCT00770809|10151926|FG001|Overall Study|Death|0
6362221|NCT00770809|10151927|FG002|Overall Study|Death|0
6362222|NCT00770809|10151925|FG000|Overall Study|Withdrawal by Subject|3
6170586|NCT01254292|9817008|FG000|LCS12 Extension Phase|Wish for pregnancy|14
6362223|NCT00770809|10151926|FG001|Overall Study|Withdrawal by Subject|3
6362224|NCT00770809|10151927|FG002|Overall Study|Withdrawal by Subject|7
6362225|NCT00770809|10151925|FG000|Overall Study|Progression|2
6362226|NCT00770809|10151926|FG001|Overall Study|Progression|2
6362227|NCT00770809|10151927|FG002|Overall Study|Progression|0
6362228|NCT00770809|10151925|FG000|Overall Study|Complicating illness|0
6362229|NCT00770809|10151926|FG001|Overall Study|Complicating illness|0
6362230|NCT00770809|10151927|FG002|Overall Study|Complicating illness|1
6362231|NCT00770809|10151925|FG000|Overall Study|Other Medical Reasons|2
6362232|NCT00770809|10151926|FG001|Overall Study|Other Medical Reasons|4
6362233|NCT00770809|10151927|FG002|Overall Study|Other Medical Reasons|3
6362234|NCT00628446|10151940|FG000|Overall Study|Lost to Follow-up|3
6362235|NCT00628446|10151940|FG000|Overall Study|Withdrawal by Subject|1
6362236|NCT00628446|10151940|FG000|Overall Study|Protocol Violation|3
6362237|NCT00621751|10151947|FG000|Overall Study|Adverse Event|0
6362238|NCT00621751|10151948|FG001|Overall Study|Adverse Event|1
6362239|NCT00605215|10151957|FG000|Overall Study|Death|0
6362240|NCT00605215|10151958|FG001|Overall Study|Death|0
6362241|NCT00605215|10151959|FG002|Overall Study|Death|1
6362242|NCT00605215|10151957|FG000|Overall Study|Adverse Event|19
6362243|NCT00605215|10151958|FG001|Overall Study|Adverse Event|21
6362244|NCT00605215|10151959|FG002|Overall Study|Adverse Event|26
6362245|NCT00605215|10151957|FG000|Overall Study|Refusal to sign the re-consent form|8
6362246|NCT00605215|10151958|FG001|Overall Study|Refusal to sign the re-consent form|3
6362247|NCT00605215|10151959|FG002|Overall Study|Refusal to sign the re-consent form|3
6362248|NCT00605215|10151957|FG000|Overall Study|Withdrawal by Subject|39
6362249|NCT00605215|10151958|FG001|Overall Study|Withdrawal by Subject|37
6362250|NCT00605215|10151959|FG002|Overall Study|Withdrawal by Subject|27
6362251|NCT00605215|10151957|FG000|Overall Study|Request of Primary Care Physician or Investigator|6
6362252|NCT00605215|10151958|FG001|Overall Study|Request of Primary Care Physician or Investigator|4
6084244|NCT00642460|9693233|FG004|Part I: 12 Week Double-Blind|Refused Treatment|0
6084245|NCT00642460|9693234|FG005|Part I: 12 Week Double-Blind|Refused Treatment|0
6084246|NCT00642460|9693229|FG000|Part II: Open-Label Up to Week 92|Adverse Event|4
6084247|NCT00642460|9693230|FG001|Part II: Open-Label Up to Week 92|Adverse Event|2
6084248|NCT00642460|9693231|FG002|Part II: Open-Label Up to Week 92|Adverse Event|0
6084249|NCT00642460|9693232|FG003|Part II: Open-Label Up to Week 92|Adverse Event|0
6084250|NCT00642460|9693233|FG004|Part II: Open-Label Up to Week 92|Adverse Event|0
6084251|NCT00642460|9693234|FG005|Part II: Open-Label Up to Week 92|Adverse Event|0
6084252|NCT00642460|9693229|FG000|Part II: Open-Label Up to Week 92|Death|0
6084253|NCT00642460|9693230|FG001|Part II: Open-Label Up to Week 92|Death|1
6084254|NCT00642460|9693231|FG002|Part II: Open-Label Up to Week 92|Death|0
6084255|NCT00642460|9693232|FG003|Part II: Open-Label Up to Week 92|Death|2
6084256|NCT00642460|9693233|FG004|Part II: Open-Label Up to Week 92|Death|0
6084257|NCT00642460|9693234|FG005|Part II: Open-Label Up to Week 92|Death|0
6084258|NCT00642460|9693229|FG000|Part II: Open-Label Up to Week 92|Insufficient therapeutic response|2
6084259|NCT00642460|9693230|FG001|Part II: Open-Label Up to Week 92|Insufficient therapeutic response|3
6084260|NCT00642460|9693231|FG002|Part II: Open-Label Up to Week 92|Insufficient therapeutic response|0
6084261|NCT00642460|9693232|FG003|Part II: Open-Label Up to Week 92|Insufficient therapeutic response|0
6170587|NCT01254292|9817009|FG001|LCS12 Extension Phase|Wish for pregnancy|0
6170588|NCT01254292|9817008|FG000|LCS12 Extension Phase|Adverse Event|9
6362253|NCT00605215|10151959|FG002|Overall Study|Request of Primary Care Physician or Investigator|4
6362254|NCT00605215|10151957|FG000|Overall Study|Protocol Violation|3
6362255|NCT00605215|10151958|FG001|Overall Study|Protocol Violation|4
6362256|NCT00605215|10151959|FG002|Overall Study|Protocol Violation|1
6362257|NCT00605215|10151957|FG000|Overall Study|Pregnancy|8
6362258|NCT00605215|10151958|FG001|Overall Study|Pregnancy|5
6362259|NCT00605215|10151959|FG002|Overall Study|Pregnancy|4
6170589|NCT01254292|9817009|FG001|LCS12 Extension Phase|Adverse Event|0
6170590|NCT01254292|9817008|FG000|LCS12 Extension Phase|Withdrawal by Subject|7
6362260|NCT00605215|10151957|FG000|Overall Study|Lost to Follow-up|8
6362261|NCT00605215|10151958|FG001|Overall Study|Lost to Follow-up|5
6362262|NCT00605215|10151959|FG002|Overall Study|Lost to Follow-up|2
6362263|NCT00605215|10151957|FG000|Overall Study|Other than specified|0
6362264|NCT00605215|10151958|FG001|Overall Study|Other than specified|2
6362265|NCT00605215|10151959|FG002|Overall Study|Other than specified|1
6362266|NCT00552513|10151973|FG000|Overall Study|Lost to Follow-up|5
6362267|NCT00552513|10151974|FG001|Overall Study|Lost to Follow-up|1
6084262|NCT00642460|9693233|FG004|Part II: Open-Label Up to Week 92|Insufficient therapeutic response|0
6084263|NCT00642460|9693234|FG005|Part II: Open-Label Up to Week 92|Insufficient therapeutic response|0
6170591|NCT01254292|9817009|FG001|LCS12 Extension Phase|Withdrawal by Subject|0
6170592|NCT01254292|9817008|FG000|LCS12 Extension Phase|Other unknown|4
6170593|NCT01254292|9817009|FG001|LCS12 Extension Phase|Other unknown|0
6362268|NCT00368836|10151984|FG000|Phase II|Screen Failure|1
6362269|NCT00368836|10151984|FG000|Phase II|Withdrawal by Subject|1
6362270|NCT00368836|10151984|FG000|Phase II|unable to collect blood and/or breath|17
6362271|NCT00368836|10151984|FG000|Phase II|Protocol Violation|2
6362272|NCT00290511|10151991|FG000|Overall Study|Adverse Event|1
6362273|NCT00290511|10151991|FG000|Overall Study|Death|1
6362274|NCT00290511|10151991|FG000|Overall Study|Physician Decision|1
6362275|NCT00290511|10151991|FG000|Overall Study|Withdrawal by Subject|1
6362276|NCT00641537|10152004|FG000|96-week Period|Adverse Event|0
6362277|NCT00641537|10152005|FG001|96-week Period|Adverse Event|1
6362278|NCT00641537|10152006|FG002|96-week Period|Adverse Event|3
6362279|NCT00641537|10152007|FG003|96-week Period|Adverse Event|0
6362280|NCT00641537|10152008|FG004|96-week Period|Adverse Event|2
6362281|NCT00641537|10152009|FG005|96-week Period|Adverse Event|0
6362282|NCT00641537|10152010|FG006|96-week Period|Adverse Event|0
6362283|NCT00641537|10152011|FG007|96-week Period|Adverse Event|0
6362284|NCT00641537|10152004|FG000|96-week Period|Lost to Follow-up|3
6362285|NCT00641537|10152005|FG001|96-week Period|Lost to Follow-up|1
6362286|NCT00641537|10152006|FG002|96-week Period|Lost to Follow-up|2
6362287|NCT00641537|10152007|FG003|96-week Period|Lost to Follow-up|2
6362288|NCT00641537|10152008|FG004|96-week Period|Lost to Follow-up|4
6362289|NCT00641537|10152009|FG005|96-week Period|Lost to Follow-up|0
6362290|NCT00641537|10152010|FG006|96-week Period|Lost to Follow-up|1
6362291|NCT00641537|10152011|FG007|96-week Period|Lost to Follow-up|0
6362292|NCT00641537|10152004|FG000|96-week Period|Protocol Violation|0
6362293|NCT00641537|10152005|FG001|96-week Period|Protocol Violation|1
6362294|NCT00641537|10152006|FG002|96-week Period|Protocol Violation|0
6362295|NCT00641537|10152007|FG003|96-week Period|Protocol Violation|1
6362296|NCT00641537|10152008|FG004|96-week Period|Protocol Violation|0
6362297|NCT00641537|10152009|FG005|96-week Period|Protocol Violation|1
6362298|NCT00641537|10152010|FG006|96-week Period|Protocol Violation|0
6362299|NCT00641537|10152011|FG007|96-week Period|Protocol Violation|0
6362300|NCT00641537|10152004|FG000|96-week Period|Death|2
6362301|NCT00641537|10152005|FG001|96-week Period|Death|0
6362302|NCT00641537|10152006|FG002|96-week Period|Death|1
6362303|NCT00641537|10152007|FG003|96-week Period|Death|0
6362304|NCT00641537|10152008|FG004|96-week Period|Death|0
6362305|NCT00641537|10152009|FG005|96-week Period|Death|0
6362306|NCT00641537|10152010|FG006|96-week Period|Death|0
6362307|NCT00641537|10152011|FG007|96-week Period|Death|0
6362308|NCT00641537|10152004|FG000|96-week Period|Other|4
6362309|NCT00641537|10152005|FG001|96-week Period|Other|7
6362310|NCT00641537|10152006|FG002|96-week Period|Other|14
6362311|NCT00641537|10152007|FG003|96-week Period|Other|9
6362312|NCT00641537|10152008|FG004|96-week Period|Other|11
6362313|NCT00641537|10152009|FG005|96-week Period|Other|6
6362314|NCT00641537|10152010|FG006|96-week Period|Other|4
6362315|NCT00641537|10152011|FG007|96-week Period|Other|6
6362316|NCT00641537|10152004|FG000|24-Week Supplemental Follow-up Period|Lost to Follow-up|0
6362317|NCT00641537|10152005|FG001|24-Week Supplemental Follow-up Period|Lost to Follow-up|1
6362318|NCT00641537|10152006|FG002|24-Week Supplemental Follow-up Period|Lost to Follow-up|1
6362319|NCT00641537|10152007|FG003|24-Week Supplemental Follow-up Period|Lost to Follow-up|3
6362320|NCT00641537|10152008|FG004|24-Week Supplemental Follow-up Period|Lost to Follow-up|2
6362321|NCT00641537|10152009|FG005|24-Week Supplemental Follow-up Period|Lost to Follow-up|1
6362322|NCT00641537|10152010|FG006|24-Week Supplemental Follow-up Period|Lost to Follow-up|0
6362323|NCT00641537|10152011|FG007|24-Week Supplemental Follow-up Period|Lost to Follow-up|0
6362324|NCT00641537|10152004|FG000|24-Week Supplemental Follow-up Period|Other|0
6362325|NCT00641537|10152005|FG001|24-Week Supplemental Follow-up Period|Other|2
6362326|NCT00641537|10152006|FG002|24-Week Supplemental Follow-up Period|Other|2
6362327|NCT00641537|10152007|FG003|24-Week Supplemental Follow-up Period|Other|1
6362328|NCT00641537|10152008|FG004|24-Week Supplemental Follow-up Period|Other|3
6362329|NCT00641537|10152009|FG005|24-Week Supplemental Follow-up Period|Other|0
6362330|NCT00641537|10152010|FG006|24-Week Supplemental Follow-up Period|Other|1
6362331|NCT00641537|10152011|FG007|24-Week Supplemental Follow-up Period|Other|1
6362332|NCT00655824|10152029|FG000|Overall Study|Adverse Event|3
6362333|NCT00655824|10152029|FG000|Overall Study|Early Termination of Study by Sponsor|74
6362334|NCT00655824|10152029|FG000|Overall Study|Protocol Violation|1
6362335|NCT00655824|10152029|FG000|Overall Study|Withdrawal by Subject|4
6362336|NCT00655824|10152029|FG000|Overall Study|Deterioration of Trial Disease|2
6362337|NCT00663052|10152035|FG000|Overall Study|Adverse Event|6
6362338|NCT00663052|10152036|FG001|Overall Study|Adverse Event|3
6362339|NCT00663052|10152035|FG000|Overall Study|Discontinuation of Study by Sponsor|2
6362340|NCT00663052|10152036|FG001|Overall Study|Discontinuation of Study by Sponsor|0
6362341|NCT00663052|10152035|FG000|Overall Study|Protocol Violation|1
6362342|NCT00663052|10152036|FG001|Overall Study|Protocol Violation|0
6362343|NCT00663052|10152035|FG000|Overall Study|Withdrawal by Subject|2
6362344|NCT00663052|10152036|FG001|Overall Study|Withdrawal by Subject|5
6362345|NCT00663052|10152035|FG000|Overall Study|Unsatisfactory Response - Efficacy|1
6362346|NCT00663052|10152036|FG001|Overall Study|Unsatisfactory Response - Efficacy|1
6362347|NCT00663052|10152035|FG000|Overall Study|Other|0
6362348|NCT00663052|10152036|FG001|Overall Study|Other|1
6362349|NCT00686374|10152042|FG000|Overall Study|Lack of Efficacy|10
6362350|NCT00686374|10152042|FG000|Overall Study|Adverse Event|8
6362351|NCT00686374|10152042|FG000|Overall Study|Withdrew consent|5
6362352|NCT00686374|10152042|FG000|Overall Study|Lost to Follow-up|1
6362353|NCT00686374|10152042|FG000|Overall Study|Missing reason|33
6362354|NCT00686374|10152042|FG000|Overall Study|Other, not specified|4
6362355|NCT00698828|10152049|FG000|Overall Study|Adverse Event|3
6362356|NCT00698828|10152050|FG001|Overall Study|Adverse Event|4
6362357|NCT00698828|10152051|FG002|Overall Study|Adverse Event|4
6362358|NCT00698828|10152049|FG000|Overall Study|Death|0
6362359|NCT00698828|10152050|FG001|Overall Study|Death|0
6362360|NCT00698828|10152051|FG002|Overall Study|Death|1
6362361|NCT00698828|10152049|FG000|Overall Study|Exacerbation of COPD|1
6362362|NCT00698828|10152050|FG001|Overall Study|Exacerbation of COPD|3
6362363|NCT00698828|10152051|FG002|Overall Study|Exacerbation of COPD|0
6362364|NCT00698828|10152049|FG000|Overall Study|Exacerbation of COPD (Not treated)|1
6362365|NCT00698828|10152050|FG001|Overall Study|Exacerbation of COPD (Not treated)|0
6362366|NCT00698828|10152051|FG002|Overall Study|Exacerbation of COPD (Not treated)|0
6362367|NCT00698828|10152049|FG000|Overall Study|Investigator/Sponsor decision|1
6362368|NCT00698828|10152050|FG001|Overall Study|Investigator/Sponsor decision|0
6362369|NCT00698828|10152051|FG002|Overall Study|Investigator/Sponsor decision|2
6362370|NCT00698828|10152049|FG000|Overall Study|Lost to Follow-up|1
6362371|NCT00698828|10152050|FG001|Overall Study|Lost to Follow-up|1
6362372|NCT00698828|10152051|FG002|Overall Study|Lost to Follow-up|0
6362373|NCT00698828|10152049|FG000|Overall Study|Withdrew consent|0
6362374|NCT00698828|10152050|FG001|Overall Study|Withdrew consent|7
6362375|NCT00698828|10152051|FG002|Overall Study|Withdrew consent|4
6362376|NCT00698828|10152049|FG000|Overall Study|Withdrew consent (not treated)|2
6362377|NCT00698828|10152050|FG001|Overall Study|Withdrew consent (not treated)|0
6362378|NCT00698828|10152051|FG002|Overall Study|Withdrew consent (not treated)|0
6170594|NCT01254292|9817008|FG000|LCS12 Extension Phase|Pregnancy|2
6170595|NCT01254292|9817009|FG001|LCS12 Extension Phase|Pregnancy|0
6170596|NCT01254292|9817008|FG000|LCS12 Extension Phase|Lost to Follow-up|1
6170597|NCT01254292|9817009|FG001|LCS12 Extension Phase|Lost to Follow-up|0
6170598|NCT01254305|9817019|FG000|Overall Study|Adverse Event|6
6170599|NCT01254305|9817020|FG001|Overall Study|Adverse Event|3
6170600|NCT01254305|9817021|FG002|Overall Study|Adverse Event|2
6170601|NCT01254305|9817019|FG000|Overall Study|Lack of Efficacy|1
6170602|NCT01254305|9817020|FG001|Overall Study|Lack of Efficacy|0
6170603|NCT01254305|9817021|FG002|Overall Study|Lack of Efficacy|1
6170604|NCT01254305|9817019|FG000|Overall Study|Protocol Violation|1
6170605|NCT01254305|9817020|FG001|Overall Study|Protocol Violation|7
6170606|NCT01254305|9817021|FG002|Overall Study|Protocol Violation|3
6170607|NCT01254305|9817019|FG000|Overall Study|Withdrawal by Subject|4
6170608|NCT01254305|9817020|FG001|Overall Study|Withdrawal by Subject|2
6170609|NCT01254305|9817021|FG002|Overall Study|Withdrawal by Subject|4
6170610|NCT01254305|9817019|FG000|Overall Study|Lost to Follow-up|10
6170611|NCT01254305|9817020|FG001|Overall Study|Lost to Follow-up|6
6170612|NCT01254305|9817021|FG002|Overall Study|Lost to Follow-up|5
6170613|NCT01254305|9817019|FG000|Overall Study|Other Reasons|0
6170614|NCT01254305|9817020|FG001|Overall Study|Other Reasons|0
6170615|NCT01254305|9817021|FG002|Overall Study|Other Reasons|2
6170616|NCT01254318|9817032|FG000|Overall Study|Lost to Follow-up|5
6170617|NCT01254318|9817032|FG000|Overall Study|Death|47
6170618|NCT01254331|9817036|FG000|Initial Phase|Adverse Event|3
6170619|NCT01254331|9817036|FG000|Initial Phase|Withdrawal by Subject|1
6170620|NCT01254331|9817036|FG000|Initial Phase|Pregnancy|1
6170621|NCT01254331|9817036|FG000|Extension Phase|Lack of Efficacy|1
6170622|NCT01254331|9817036|FG000|Extension Phase|Lost to Follow-up|3
6170623|NCT01254344|9817042|FG000|Overall Study|Adverse Event|2
6170624|NCT01254344|9817043|FG001|Overall Study|Adverse Event|5
6170625|NCT01254344|9817042|FG000|Overall Study|Physician Decision|7
6170626|NCT01254344|9817043|FG001|Overall Study|Physician Decision|4
6170627|NCT01254344|9817042|FG000|Overall Study|Protocol Violation|1
6170628|NCT01254344|9817043|FG001|Overall Study|Protocol Violation|4
6170629|NCT01254344|9817042|FG000|Overall Study|Withdrawal by Subject|3
6170630|NCT01254344|9817043|FG001|Overall Study|Withdrawal by Subject|6
6170631|NCT01254565|9817070|FG000|Overall Study|Non-compliance to Study Procedures|0
6170632|NCT01254565|9817071|FG001|Overall Study|Non-compliance to Study Procedures|0
6170633|NCT01254565|9817072|FG002|Overall Study|Non-compliance to Study Procedures|0
6170634|NCT01254565|9817073|FG003|Overall Study|Non-compliance to Study Procedures|0
6170635|NCT01254565|9817074|FG004|Overall Study|Non-compliance to Study Procedures|1
6170636|NCT01254565|9817075|FG005|Overall Study|Non-compliance to Study Procedures|0
6170637|NCT01254565|9817070|FG000|Overall Study|Did not Receive Treatment|1
6362379|NCT00712933|10152059|FG000|Overall Study|Adverse Event|69
6362380|NCT00712933|10152059|FG000|Overall Study|Lack of Efficacy|6
6362381|NCT00712933|10152059|FG000|Overall Study|Lost to Follow-up|22
6362382|NCT00712933|10152059|FG000|Overall Study|Non-compliance with study drug|13
6084264|NCT00642460|9693229|FG000|Part II: Open-Label Up to Week 92|Refused treatment|3
6170638|NCT01254565|9817071|FG001|Overall Study|Did not Receive Treatment|1
6362383|NCT00712933|10152059|FG000|Overall Study|Other Pregnancy|37
6362384|NCT00712933|10152059|FG000|Overall Study|Sponsor decision|14
6362385|NCT00712933|10152059|FG000|Overall Study|Withdrew consent|4
6362386|NCT00712933|10152059|FG000|Overall Study|Hip replacement surgery|1
6362387|NCT00712933|10152059|FG000|Overall Study|Involved in Clinical research|3
6362388|NCT00712933|10152059|FG000|Overall Study|Participant hospitalized|1
6362389|NCT00712933|10152059|FG000|Overall Study|Participant travelled overseas|2
6362390|NCT00712933|10152059|FG000|Overall Study|Death of patient|1
6362391|NCT00712933|10152059|FG000|Overall Study|Other Physician decision|1
6362392|NCT00712933|10152059|FG000|Overall Study|Not committed to contraception|1
6362393|NCT00712933|10152059|FG000|Overall Study|Participant received medication|1
6362394|NCT00712933|10152059|FG000|Overall Study|Physician Decision|36
6362395|NCT00712933|10152059|FG000|Overall Study|Protocol Violation|4
6362396|NCT00712933|10152059|FG000|Overall Study|Withdrawal by Subject|151
6362397|NCT00725985|10152070|FG000|ITP- Treatment Disposition|Adverse Event|20
6362398|NCT00725985|10152071|FG001|ITP- Treatment Disposition|Adverse Event|10
6362399|NCT00725985|10152072|FG002|ITP- Treatment Disposition|Adverse Event|5
6362400|NCT00725985|10152073|FG003|ITP- Treatment Disposition|Adverse Event|0
6362401|NCT00725985|10152074|FG004|ITP- Treatment Disposition|Adverse Event|0
6362402|NCT00725985|10152075|FG005|ITP- Treatment Disposition|Adverse Event|0
6362403|NCT00725985|10152076|FG006|ITP- Treatment Disposition|Adverse Event|0
6362404|NCT00725985|10152077|FG007|ITP- Treatment Disposition|Adverse Event|0
6362405|NCT00725985|10152078|FG008|ITP- Treatment Disposition|Adverse Event|0
6362406|NCT00725985|10152079|FG009|ITP- Treatment Disposition|Adverse Event|0
6362407|NCT00725985|10152080|FG010|ITP- Treatment Disposition|Adverse Event|0
6362408|NCT00725985|10152081|FG011|ITP- Treatment Disposition|Adverse Event|0
6362409|NCT00725985|10152070|FG000|ITP- Treatment Disposition|Lost to Follow-up|0
6362410|NCT00725985|10152071|FG001|ITP- Treatment Disposition|Lost to Follow-up|0
6362411|NCT00725985|10152072|FG002|ITP- Treatment Disposition|Lost to Follow-up|2
6362412|NCT00725985|10152073|FG003|ITP- Treatment Disposition|Lost to Follow-up|0
6362413|NCT00725985|10152074|FG004|ITP- Treatment Disposition|Lost to Follow-up|0
6362414|NCT00725985|10152075|FG005|ITP- Treatment Disposition|Lost to Follow-up|0
6362415|NCT00725985|10152076|FG006|ITP- Treatment Disposition|Lost to Follow-up|0
6362416|NCT00725985|10152077|FG007|ITP- Treatment Disposition|Lost to Follow-up|0
6362417|NCT00725985|10152078|FG008|ITP- Treatment Disposition|Lost to Follow-up|0
6362418|NCT00725985|10152079|FG009|ITP- Treatment Disposition|Lost to Follow-up|0
6362419|NCT00725985|10152080|FG010|ITP- Treatment Disposition|Lost to Follow-up|0
6362420|NCT00725985|10152081|FG011|ITP- Treatment Disposition|Lost to Follow-up|0
6362421|NCT00725985|10152070|FG000|ITP- Treatment Disposition|Randomized but not treated|1
6362422|NCT00725985|10152071|FG001|ITP- Treatment Disposition|Randomized but not treated|0
6362423|NCT00725985|10152072|FG002|ITP- Treatment Disposition|Randomized but not treated|0
6362424|NCT00725985|10152073|FG003|ITP- Treatment Disposition|Randomized but not treated|0
6362425|NCT00725985|10152074|FG004|ITP- Treatment Disposition|Randomized but not treated|0
6362426|NCT00725985|10152075|FG005|ITP- Treatment Disposition|Randomized but not treated|0
6362427|NCT00725985|10152076|FG006|ITP- Treatment Disposition|Randomized but not treated|0
6362428|NCT00725985|10152077|FG007|ITP- Treatment Disposition|Randomized but not treated|0
6362429|NCT00725985|10152078|FG008|ITP- Treatment Disposition|Randomized but not treated|0
6362430|NCT00725985|10152079|FG009|ITP- Treatment Disposition|Randomized but not treated|0
6362431|NCT00725985|10152080|FG010|ITP- Treatment Disposition|Randomized but not treated|0
6362432|NCT00725985|10152081|FG011|ITP- Treatment Disposition|Randomized but not treated|0
6362433|NCT00725985|10152070|FG000|ITP- Treatment Disposition|Converted to CDMS|30
6362434|NCT00725985|10152071|FG001|ITP- Treatment Disposition|Converted to CDMS|27
6362435|NCT00725985|10152072|FG002|ITP- Treatment Disposition|Converted to CDMS|71
6362436|NCT00725985|10152073|FG003|ITP- Treatment Disposition|Converted to CDMS|0
6362437|NCT00725985|10152074|FG004|ITP- Treatment Disposition|Converted to CDMS|0
6362438|NCT00725985|10152075|FG005|ITP- Treatment Disposition|Converted to CDMS|0
6362439|NCT00725985|10152076|FG006|ITP- Treatment Disposition|Converted to CDMS|0
6084265|NCT00642460|9693230|FG001|Part II: Open-Label Up to Week 92|Refused treatment|1
6170639|NCT01254565|9817072|FG002|Overall Study|Did not Receive Treatment|0
6170640|NCT01254565|9817073|FG003|Overall Study|Did not Receive Treatment|0
6170641|NCT01254565|9817074|FG004|Overall Study|Did not Receive Treatment|3
6170642|NCT01254565|9817075|FG005|Overall Study|Did not Receive Treatment|4
6362440|NCT00725985|10152077|FG007|ITP- Treatment Disposition|Converted to CDMS|0
6362441|NCT00725985|10152078|FG008|ITP- Treatment Disposition|Converted to CDMS|0
6362442|NCT00725985|10152079|FG009|ITP- Treatment Disposition|Converted to CDMS|0
6362443|NCT00725985|10152080|FG010|ITP- Treatment Disposition|Converted to CDMS|0
6362444|NCT00725985|10152081|FG011|ITP- Treatment Disposition|Converted to CDMS|0
6362445|NCT00725985|10152070|FG000|ITP- Treatment Disposition|Other|50
6362446|NCT00725985|10152071|FG001|ITP- Treatment Disposition|Other|38
6362447|NCT00725985|10152072|FG002|ITP- Treatment Disposition|Other|24
6362448|NCT00725985|10152073|FG003|ITP- Treatment Disposition|Other|0
6362449|NCT00725985|10152074|FG004|ITP- Treatment Disposition|Other|0
6362450|NCT00725985|10152075|FG005|ITP- Treatment Disposition|Other|0
6362451|NCT00725985|10152076|FG006|ITP- Treatment Disposition|Other|0
6362452|NCT00725985|10152077|FG007|ITP- Treatment Disposition|Other|0
6362453|NCT00725985|10152078|FG008|ITP- Treatment Disposition|Other|0
6362454|NCT00725985|10152079|FG009|ITP- Treatment Disposition|Other|0
6362455|NCT00725985|10152080|FG010|ITP- Treatment Disposition|Other|0
6362456|NCT00725985|10152081|FG011|ITP- Treatment Disposition|Other|0
6362457|NCT00725985|10152070|FG000|OLMP (Up to 96 Weeks)|Adverse Event|0
6362458|NCT00725985|10152071|FG001|OLMP (Up to 96 Weeks)|Adverse Event|0
6362459|NCT00725985|10152072|FG002|OLMP (Up to 96 Weeks)|Adverse Event|0
6362460|NCT00725985|10152073|FG003|OLMP (Up to 96 Weeks)|Adverse Event|2
6362461|NCT00725985|10152074|FG004|OLMP (Up to 96 Weeks)|Adverse Event|2
6362462|NCT00725985|10152075|FG005|OLMP (Up to 96 Weeks)|Adverse Event|5
6362463|NCT00725985|10152076|FG006|OLMP (Up to 96 Weeks)|Adverse Event|0
6362464|NCT00725985|10152077|FG007|OLMP (Up to 96 Weeks)|Adverse Event|0
6362465|NCT00725985|10152078|FG008|OLMP (Up to 96 Weeks)|Adverse Event|0
6362466|NCT00725985|10152079|FG009|OLMP (Up to 96 Weeks)|Adverse Event|0
6362467|NCT00725985|10152080|FG010|OLMP (Up to 96 Weeks)|Adverse Event|0
6362468|NCT00725985|10152081|FG011|OLMP (Up to 96 Weeks)|Adverse Event|0
6362469|NCT00725985|10152070|FG000|OLMP (Up to 96 Weeks)|Death|0
6362470|NCT00725985|10152071|FG001|OLMP (Up to 96 Weeks)|Death|0
6362471|NCT00725985|10152072|FG002|OLMP (Up to 96 Weeks)|Death|0
6362472|NCT00725985|10152073|FG003|OLMP (Up to 96 Weeks)|Death|0
6043208|NCT00387725|9641724|FG002|Overall Study|Adverse Event|0
6170643|NCT01254565|9817070|FG000|Overall Study|Other|0
6170644|NCT01254565|9817071|FG001|Overall Study|Other|0
6170645|NCT01254565|9817072|FG002|Overall Study|Other|0
6170646|NCT01254565|9817073|FG003|Overall Study|Other|1
6170647|NCT01254565|9817074|FG004|Overall Study|Other|0
6170648|NCT01254565|9817075|FG005|Overall Study|Other|0
6170649|NCT01254604|9817091|FG000|Overall Study|Lost to Follow-up|1
6170650|NCT01254604|9817092|FG001|Overall Study|Lost to Follow-up|1
6170651|NCT01254604|9817091|FG000|Overall Study|Protocol Violation|2
6170652|NCT01254604|9817092|FG001|Overall Study|Protocol Violation|2
6170653|NCT01254604|9817091|FG000|Overall Study|Withdrawal by Subject|2
6170654|NCT01254604|9817092|FG001|Overall Study|Withdrawal by Subject|4
6170655|NCT01254604|9817091|FG000|Overall Study|Adverse Event|3
6170656|NCT01254604|9817092|FG001|Overall Study|Adverse Event|2
6192227|NCT01428713|9849323|FG000|Overall Study|Withdrawal by Subject|1
6192228|NCT01428713|9849324|FG001|Overall Study|Withdrawal by Subject|1
6192229|NCT01428713|9849323|FG000|Overall Study|Adverse Event|0
6192230|NCT01428713|9849324|FG001|Overall Study|Adverse Event|2
6192231|NCT01428882|9849336|FG000|Overall Study|Lack of Efficacy|2
6192232|NCT01428882|9849337|FG001|Overall Study|Lack of Efficacy|7
6192233|NCT01428882|9849336|FG000|Overall Study|Protocol Violation|4
6192234|NCT01428882|9849337|FG001|Overall Study|Protocol Violation|3
6192235|NCT01429051|9849343|FG000|Titration Phase|Death|1
6192236|NCT01429051|9849343|FG000|Titration Phase|Withdrawal by Subject|7
6192237|NCT01429051|9849343|FG000|Titration Phase|Physician Decision|1
6192238|NCT01429051|9849343|FG000|Titration Phase|Unsuccessful titration at any dose|1
6192239|NCT01429051|9849343|FG000|Titration Phase|Less than 3 BTP episodes per week|2
6192240|NCT01429051|9849343|FG000|Efficacy Phase|Adverse Event|1
6192241|NCT01429051|9849343|FG000|Efficacy Phase|Death|1
6192242|NCT01429051|9849343|FG000|Tolerability Phase|Death|5
6192243|NCT01429051|9849343|FG000|Tolerability Phase|Adverse Event|2
6192244|NCT01429051|9849343|FG000|Tolerability Phase|Withdrawal by Subject|5
6192245|NCT01429051|9849343|FG000|Tolerability Phase|Physician Decision|1
6192246|NCT01429051|9849343|FG000|Tolerability Phase|Other|2
6192247|NCT01429077|9849373|FG000|Overall Study|Lost to Follow-up|0
6192248|NCT01429077|9849374|FG001|Overall Study|Lost to Follow-up|3
6192249|NCT01429285|9849403|FG000|Overall Study|Protocol Violation|9
6192250|NCT01429285|9849404|FG001|Overall Study|Protocol Violation|4
6192251|NCT01429285|9849403|FG000|Overall Study|Missing Data|5
6192252|NCT01429285|9849404|FG001|Overall Study|Missing Data|3
6192253|NCT01429285|9849403|FG000|Overall Study|Erroneously Enrolled Twice|8
6192254|NCT01429285|9849404|FG001|Overall Study|Erroneously Enrolled Twice|2
6192255|NCT01429298|9849412|FG000|Overall Study|Protocol Violation|4
6192256|NCT01429298|9849413|FG001|Overall Study|Protocol Violation|6
6192257|NCT01429441|9849430|FG000|Overall Study|Adverse Event|5
6192258|NCT01429441|9849431|FG001|Overall Study|Adverse Event|1
6192259|NCT01429441|9849430|FG000|Overall Study|Death|0
6192260|NCT01429441|9849431|FG001|Overall Study|Death|2
6192261|NCT01429441|9849430|FG000|Overall Study|Lost to Follow-up|5
6192262|NCT01429441|9849431|FG001|Overall Study|Lost to Follow-up|2
6192263|NCT01429441|9849430|FG000|Overall Study|Physician Decision|1
6192264|NCT01429441|9849431|FG001|Overall Study|Physician Decision|0
6362473|NCT00725985|10152074|FG004|OLMP (Up to 96 Weeks)|Death|1
6362474|NCT00725985|10152075|FG005|OLMP (Up to 96 Weeks)|Death|0
6362475|NCT00725985|10152076|FG006|OLMP (Up to 96 Weeks)|Death|0
6362476|NCT00725985|10152077|FG007|OLMP (Up to 96 Weeks)|Death|0
6362477|NCT00725985|10152078|FG008|OLMP (Up to 96 Weeks)|Death|0
6362478|NCT00725985|10152079|FG009|OLMP (Up to 96 Weeks)|Death|0
6362479|NCT00725985|10152080|FG010|OLMP (Up to 96 Weeks)|Death|0
6362480|NCT00725985|10152081|FG011|OLMP (Up to 96 Weeks)|Death|0
6362481|NCT00725985|10152070|FG000|OLMP (Up to 96 Weeks)|Lost to Follow-up|0
6362482|NCT00725985|10152071|FG001|OLMP (Up to 96 Weeks)|Lost to Follow-up|0
6362483|NCT00725985|10152072|FG002|OLMP (Up to 96 Weeks)|Lost to Follow-up|0
6362484|NCT00725985|10152073|FG003|OLMP (Up to 96 Weeks)|Lost to Follow-up|1
6362485|NCT00725985|10152074|FG004|OLMP (Up to 96 Weeks)|Lost to Follow-up|0
6362486|NCT00725985|10152075|FG005|OLMP (Up to 96 Weeks)|Lost to Follow-up|0
6362487|NCT00725985|10152076|FG006|OLMP (Up to 96 Weeks)|Lost to Follow-up|0
6362488|NCT00725985|10152077|FG007|OLMP (Up to 96 Weeks)|Lost to Follow-up|0
6362489|NCT00725985|10152078|FG008|OLMP (Up to 96 Weeks)|Lost to Follow-up|0
6362490|NCT00725985|10152079|FG009|OLMP (Up to 96 Weeks)|Lost to Follow-up|0
6362491|NCT00725985|10152080|FG010|OLMP (Up to 96 Weeks)|Lost to Follow-up|0
6362492|NCT00725985|10152081|FG011|OLMP (Up to 96 Weeks)|Lost to Follow-up|0
6362493|NCT00725985|10152070|FG000|OLMP (Up to 96 Weeks)|Disease progression|0
6362494|NCT00725985|10152071|FG001|OLMP (Up to 96 Weeks)|Disease progression|0
6362495|NCT00725985|10152072|FG002|OLMP (Up to 96 Weeks)|Disease progression|0
6362496|NCT00725985|10152073|FG003|OLMP (Up to 96 Weeks)|Disease progression|0
6362497|NCT00725985|10152074|FG004|OLMP (Up to 96 Weeks)|Disease progression|0
6362498|NCT00725985|10152075|FG005|OLMP (Up to 96 Weeks)|Disease progression|4
6362499|NCT00725985|10152076|FG006|OLMP (Up to 96 Weeks)|Disease progression|0
6362500|NCT00725985|10152077|FG007|OLMP (Up to 96 Weeks)|Disease progression|0
6362501|NCT00725985|10152078|FG008|OLMP (Up to 96 Weeks)|Disease progression|0
6362502|NCT00725985|10152079|FG009|OLMP (Up to 96 Weeks)|Disease progression|0
6362503|NCT00725985|10152080|FG010|OLMP (Up to 96 Weeks)|Disease progression|0
6362504|NCT00725985|10152081|FG011|OLMP (Up to 96 Weeks)|Disease progression|0
6362505|NCT00725985|10152070|FG000|OLMP (Up to 96 Weeks)|Other|0
6362506|NCT00725985|10152071|FG001|OLMP (Up to 96 Weeks)|Other|0
6362507|NCT00725985|10152072|FG002|OLMP (Up to 96 Weeks)|Other|0
6362508|NCT00725985|10152073|FG003|OLMP (Up to 96 Weeks)|Other|15
6362509|NCT00725985|10152074|FG004|OLMP (Up to 96 Weeks)|Other|20
6362510|NCT00725985|10152075|FG005|OLMP (Up to 96 Weeks)|Other|44
6362511|NCT00725985|10152076|FG006|OLMP (Up to 96 Weeks)|Other|0
6362512|NCT00725985|10152077|FG007|OLMP (Up to 96 Weeks)|Other|0
6362513|NCT00725985|10152078|FG008|OLMP (Up to 96 Weeks)|Other|0
6362514|NCT00725985|10152079|FG009|OLMP (Up to 96 Weeks)|Other|0
6362515|NCT00725985|10152080|FG010|OLMP (Up to 96 Weeks)|Other|0
6362516|NCT00725985|10152081|FG011|OLMP (Up to 96 Weeks)|Other|0
6362517|NCT00725985|10152070|FG000|LTFU (Cladribine Treatment) (48 Weeks)|Adverse Event|0
6362518|NCT00725985|10152071|FG001|LTFU (Cladribine Treatment) (48 Weeks)|Adverse Event|0
6362519|NCT00725985|10152072|FG002|LTFU (Cladribine Treatment) (48 Weeks)|Adverse Event|0
6362520|NCT00725985|10152073|FG003|LTFU (Cladribine Treatment) (48 Weeks)|Adverse Event|0
6362521|NCT00725985|10152074|FG004|LTFU (Cladribine Treatment) (48 Weeks)|Adverse Event|0
6362522|NCT00725985|10152075|FG005|LTFU (Cladribine Treatment) (48 Weeks)|Adverse Event|0
6362523|NCT00725985|10152076|FG006|LTFU (Cladribine Treatment) (48 Weeks)|Adverse Event|0
6362524|NCT00725985|10152077|FG007|LTFU (Cladribine Treatment) (48 Weeks)|Adverse Event|1
6362525|NCT00725985|10152078|FG008|LTFU (Cladribine Treatment) (48 Weeks)|Adverse Event|0
6362526|NCT00725985|10152079|FG009|LTFU (Cladribine Treatment) (48 Weeks)|Adverse Event|0
6362527|NCT00725985|10152080|FG010|LTFU (Cladribine Treatment) (48 Weeks)|Adverse Event|0
6362528|NCT00725985|10152081|FG011|LTFU (Cladribine Treatment) (48 Weeks)|Adverse Event|0
6362529|NCT00725985|10152070|FG000|LTFU (Cladribine Treatment) (48 Weeks)|Lost to Follow-up|0
6362530|NCT00725985|10152071|FG001|LTFU (Cladribine Treatment) (48 Weeks)|Lost to Follow-up|0
6362531|NCT00725985|10152072|FG002|LTFU (Cladribine Treatment) (48 Weeks)|Lost to Follow-up|0
6362532|NCT00725985|10152073|FG003|LTFU (Cladribine Treatment) (48 Weeks)|Lost to Follow-up|0
6362533|NCT00725985|10152074|FG004|LTFU (Cladribine Treatment) (48 Weeks)|Lost to Follow-up|0
6362534|NCT00725985|10152075|FG005|LTFU (Cladribine Treatment) (48 Weeks)|Lost to Follow-up|0
6362535|NCT00725985|10152076|FG006|LTFU (Cladribine Treatment) (48 Weeks)|Lost to Follow-up|0
6362536|NCT00725985|10152077|FG007|LTFU (Cladribine Treatment) (48 Weeks)|Lost to Follow-up|0
6362537|NCT00725985|10152078|FG008|LTFU (Cladribine Treatment) (48 Weeks)|Lost to Follow-up|1
6362538|NCT00725985|10152079|FG009|LTFU (Cladribine Treatment) (48 Weeks)|Lost to Follow-up|0
6362539|NCT00725985|10152080|FG010|LTFU (Cladribine Treatment) (48 Weeks)|Lost to Follow-up|0
6362540|NCT00725985|10152081|FG011|LTFU (Cladribine Treatment) (48 Weeks)|Lost to Follow-up|0
6362541|NCT00725985|10152070|FG000|LTFU (Cladribine Treatment) (48 Weeks)|Other|0
6362542|NCT00725985|10152071|FG001|LTFU (Cladribine Treatment) (48 Weeks)|Other|0
6362543|NCT00725985|10152072|FG002|LTFU (Cladribine Treatment) (48 Weeks)|Other|0
6362544|NCT00725985|10152073|FG003|LTFU (Cladribine Treatment) (48 Weeks)|Other|0
6362545|NCT00725985|10152074|FG004|LTFU (Cladribine Treatment) (48 Weeks)|Other|0
6362546|NCT00725985|10152075|FG005|LTFU (Cladribine Treatment) (48 Weeks)|Other|0
6362547|NCT00725985|10152076|FG006|LTFU (Cladribine Treatment) (48 Weeks)|Other|9
6362548|NCT00725985|10152077|FG007|LTFU (Cladribine Treatment) (48 Weeks)|Other|8
6362549|NCT00725985|10152078|FG008|LTFU (Cladribine Treatment) (48 Weeks)|Other|16
6362550|NCT00725985|10152079|FG009|LTFU (Cladribine Treatment) (48 Weeks)|Other|0
6362551|NCT00725985|10152080|FG010|LTFU (Cladribine Treatment) (48 Weeks)|Other|0
6362552|NCT00725985|10152081|FG011|LTFU (Cladribine Treatment) (48 Weeks)|Other|0
6362553|NCT00725985|10152070|FG000|LTFU (No Cladribine) (48 Weeks)|Other|0
6362554|NCT00725985|10152071|FG001|LTFU (No Cladribine) (48 Weeks)|Other|0
6362555|NCT00725985|10152072|FG002|LTFU (No Cladribine) (48 Weeks)|Other|0
6362556|NCT00725985|10152073|FG003|LTFU (No Cladribine) (48 Weeks)|Other|0
6362557|NCT00725985|10152074|FG004|LTFU (No Cladribine) (48 Weeks)|Other|0
6362558|NCT00725985|10152075|FG005|LTFU (No Cladribine) (48 Weeks)|Other|0
6362559|NCT00725985|10152076|FG006|LTFU (No Cladribine) (48 Weeks)|Other|0
6362560|NCT00725985|10152077|FG007|LTFU (No Cladribine) (48 Weeks)|Other|0
6362561|NCT00725985|10152078|FG008|LTFU (No Cladribine) (48 Weeks)|Other|0
6362562|NCT00725985|10152079|FG009|LTFU (No Cladribine) (48 Weeks)|Other|34
6362563|NCT00725985|10152080|FG010|LTFU (No Cladribine) (48 Weeks)|Other|36
6362564|NCT00725985|10152081|FG011|LTFU (No Cladribine) (48 Weeks)|Other|14
6362565|NCT04860258|10152114|FG000|Overall Study|Withdrawal by Subject|0
6362566|NCT04860258|10152115|FG001|Overall Study|Withdrawal by Subject|0
6362567|NCT04860258|10152116|FG002|Overall Study|Withdrawal by Subject|4
6362568|NCT04860258|10152117|FG003|Overall Study|Withdrawal by Subject|1
6362569|NCT04860258|10152118|FG004|Overall Study|Withdrawal by Subject|4
6362570|NCT04860258|10152119|FG005|Overall Study|Withdrawal by Subject|1
6362571|NCT04860258|10152120|FG006|Overall Study|Withdrawal by Subject|0
6362572|NCT04428645|10152136|FG000|Second at Home Period (8 Weeks)|Withdrawal by Subject|1
6362573|NCT03787303|10152153|FG000|Overall Study|Death|1
6362574|NCT03787303|10152153|FG000|Overall Study|Premature Termination of Study|1
6362575|NCT03673098|10152163|FG000|Overall Study|Lost to Follow-up|2
6362576|NCT03673098|10152164|FG001|Overall Study|Lost to Follow-up|3
6362577|NCT03673098|10152163|FG000|Overall Study|Withdrawal by Subject|6
6362578|NCT03673098|10152164|FG001|Overall Study|Withdrawal by Subject|1
6362579|NCT03673098|10152163|FG000|Overall Study|Could not participate due to scheduling conflicts or health issues|2
6362580|NCT03673098|10152164|FG001|Overall Study|Could not participate due to scheduling conflicts or health issues|0
6362581|NCT03654651|10152179|FG000|First Intervention (6 Weeks)|Withdrawal by Subject|1
6362582|NCT03654651|10152180|FG001|First Intervention (6 Weeks)|Withdrawal by Subject|0
6362583|NCT03525678|10152190|FG000|Overall Study|Ongoing at the time of interim analysis|60
6362584|NCT03525678|10152191|FG001|Overall Study|Ongoing at the time of interim analysis|65
6362585|NCT03525678|10152192|FG002|Overall Study|Ongoing at the time of interim analysis|21
6362586|NCT03525678|10152190|FG000|Overall Study|Withdrawal by Subject|3
6362587|NCT03525678|10152191|FG001|Overall Study|Withdrawal by Subject|1
6170657|NCT01254630|9817102|FG000|Overall Study|Adverse Event|36
6170658|NCT01254630|9817103|FG001|Overall Study|Adverse Event|15
6170659|NCT01254630|9817104|FG002|Overall Study|Adverse Event|40
6170660|NCT01254630|9817105|FG003|Overall Study|Adverse Event|8
6170661|NCT01254630|9817102|FG000|Overall Study|Death|461
6170662|NCT01254630|9817103|FG001|Overall Study|Death|151
6170663|NCT01254630|9817104|FG002|Overall Study|Death|478
6170664|NCT01254630|9817105|FG003|Overall Study|Death|139
6170665|NCT01254630|9817102|FG000|Overall Study|Lost to Follow-up|80
6170666|NCT01254630|9817103|FG001|Overall Study|Lost to Follow-up|26
6170667|NCT01254630|9817104|FG002|Overall Study|Lost to Follow-up|89
6170668|NCT01254630|9817105|FG003|Overall Study|Lost to Follow-up|32
6170669|NCT01254630|9817102|FG000|Overall Study|Physician Decision|24
6170670|NCT01254630|9817103|FG001|Overall Study|Physician Decision|8
6170671|NCT01254630|9817104|FG002|Overall Study|Physician Decision|16
6170672|NCT01254630|9817105|FG003|Overall Study|Physician Decision|7
6170673|NCT01254630|9817102|FG000|Overall Study|Withdrawal by Subject|201
6170674|NCT01254630|9817103|FG001|Overall Study|Withdrawal by Subject|94
6170675|NCT01254630|9817104|FG002|Overall Study|Withdrawal by Subject|188
6170676|NCT01254630|9817105|FG003|Overall Study|Withdrawal by Subject|89
6170677|NCT01254630|9817102|FG000|Overall Study|Study terminated by sponsor|0
6170678|NCT01254630|9817103|FG001|Overall Study|Study terminated by sponsor|994
6170679|NCT01254630|9817104|FG002|Overall Study|Study terminated by sponsor|0
6170680|NCT01254630|9817105|FG003|Overall Study|Study terminated by sponsor|1010
6170681|NCT01254630|9817102|FG000|Overall Study|Status not recorded|0
6170682|NCT01254630|9817103|FG001|Overall Study|Status not recorded|0
6170683|NCT01254630|9817104|FG002|Overall Study|Status not recorded|1
6362588|NCT03525678|10152192|FG002|Overall Study|Withdrawal by Subject|0
6362589|NCT03525678|10152190|FG000|Overall Study|Physician Decision|1
6362590|NCT03525678|10152191|FG001|Overall Study|Physician Decision|2
6170684|NCT01254630|9817105|FG003|Overall Study|Status not recorded|0
6362591|NCT03525678|10152192|FG002|Overall Study|Physician Decision|0
6362592|NCT03525678|10152190|FG000|Overall Study|Lost to Follow-up|1
6362593|NCT03525678|10152191|FG001|Overall Study|Lost to Follow-up|0
6362594|NCT03525678|10152192|FG002|Overall Study|Lost to Follow-up|0
6362595|NCT03525678|10152190|FG000|Overall Study|Death|32
6362596|NCT03525678|10152191|FG001|Overall Study|Death|31
6362597|NCT03525678|10152192|FG002|Overall Study|Death|4
6362598|NCT03520569|10152200|FG000|Overall Study|Withdrawal by Subject|1
6362599|NCT03499899|10152213|FG000|Overall Study|Adverse Event|2
6362600|NCT03499899|10152214|FG001|Overall Study|Adverse Event|3
6362601|NCT03499899|10152215|FG002|Overall Study|Adverse Event|3
6362602|NCT03499899|10152213|FG000|Overall Study|Death|0
6362603|NCT03499899|10152214|FG001|Overall Study|Death|0
6362604|NCT03499899|10152215|FG002|Overall Study|Death|1
6362605|NCT03499899|10152213|FG000|Overall Study|Physician Decision|3
6362606|NCT03499899|10152214|FG001|Overall Study|Physician Decision|6
6362607|NCT03499899|10152215|FG002|Overall Study|Physician Decision|6
6362608|NCT03499899|10152213|FG000|Overall Study|Progressive disease|15
6362609|NCT03499899|10152214|FG001|Overall Study|Progressive disease|23
6362610|NCT03499899|10152215|FG002|Overall Study|Progressive disease|23
6362611|NCT03499899|10152213|FG000|Overall Study|Patient decision|0
6362612|NCT03499899|10152214|FG001|Overall Study|Patient decision|1
6362613|NCT03499899|10152215|FG002|Overall Study|Patient decision|1
6362614|NCT03499899|10152213|FG000|Overall Study|Terminated by sponsor (end of study definition was met)|0
6362615|NCT03499899|10152214|FG001|Overall Study|Terminated by sponsor (end of study definition was met)|1
6362616|NCT03499899|10152215|FG002|Overall Study|Terminated by sponsor (end of study definition was met)|0
6084266|NCT00642460|9693231|FG002|Part II: Open-Label Up to Week 92|Refused treatment|0
6084267|NCT00642460|9693232|FG003|Part II: Open-Label Up to Week 92|Refused treatment|0
6084268|NCT00642460|9693233|FG004|Part II: Open-Label Up to Week 92|Refused treatment|0
6084269|NCT00642460|9693234|FG005|Part II: Open-Label Up to Week 92|Refused treatment|0
6084270|NCT00642460|9693229|FG000|Part II: Open-Label Up to Week 92|Failure to return|0
6170685|NCT01254643|9817113|FG000|Overall Study|Withdrawal by Subject|1
6170686|NCT01254656|9817120|FG000|Overall Study|Discontinued due to termination of study|40
6170687|NCT01254656|9817121|FG001|Overall Study|Discontinued due to termination of study|39
6170688|NCT01254656|9817122|FG002|Overall Study|Discontinued due to termination of study|13
6170689|NCT01254656|9817120|FG000|Overall Study|Lack of Efficacy|3
6170690|NCT01254656|9817121|FG001|Overall Study|Lack of Efficacy|0
6170691|NCT01254656|9817122|FG002|Overall Study|Lack of Efficacy|0
6170692|NCT01254656|9817120|FG000|Overall Study|Lost to Follow-up|1
6170693|NCT01254656|9817121|FG001|Overall Study|Lost to Follow-up|0
6170694|NCT01254656|9817122|FG002|Overall Study|Lost to Follow-up|2
6084271|NCT00642460|9693230|FG001|Part II: Open-Label Up to Week 92|Failure to return|1
6084272|NCT00642460|9693231|FG002|Part II: Open-Label Up to Week 92|Failure to return|0
6084273|NCT00642460|9693232|FG003|Part II: Open-Label Up to Week 92|Failure to return|0
6084274|NCT00642460|9693233|FG004|Part II: Open-Label Up to Week 92|Failure to return|0
6084275|NCT00642460|9693234|FG005|Part II: Open-Label Up to Week 92|Failure to return|0
6084276|NCT00642460|9693229|FG000|Part II: Open-Label Up to Week 92|Administrative reasons|0
6170695|NCT01254656|9817120|FG000|Overall Study|Withdrawal by Subject|2
6170696|NCT01254656|9817121|FG001|Overall Study|Withdrawal by Subject|2
6170697|NCT01254656|9817122|FG002|Overall Study|Withdrawal by Subject|1
6170698|NCT01254656|9817120|FG000|Overall Study|Pregnancy|0
6170699|NCT01254656|9817121|FG001|Overall Study|Pregnancy|0
6170700|NCT01254656|9817122|FG002|Overall Study|Pregnancy|2
6170701|NCT01254656|9817120|FG000|Overall Study|Adverse Event|1
6170702|NCT01254656|9817121|FG001|Overall Study|Adverse Event|1
6170703|NCT01254656|9817122|FG002|Overall Study|Adverse Event|0
6170704|NCT01254656|9817120|FG000|Overall Study|Death|0
6170705|NCT01254656|9817121|FG001|Overall Study|Death|1
6170706|NCT01254656|9817122|FG002|Overall Study|Death|0
6170707|NCT01254669|9817132|FG000|Overall Study|Withdrawal by Subject|0
6170708|NCT01254669|9817133|FG001|Overall Study|Withdrawal by Subject|1
6170709|NCT01254669|9817132|FG000|Overall Study|time constraint|2
6170710|NCT01254669|9817133|FG001|Overall Study|time constraint|2
6170711|NCT01254669|9817132|FG000|Overall Study|called to clinic during intervention|1
6170712|NCT01254669|9817133|FG001|Overall Study|called to clinic during intervention|1
6170713|NCT01254721|9817143|FG000|Overall Study|Lost to Follow-up|0
6170714|NCT01254721|9817144|FG001|Overall Study|Lost to Follow-up|4
6362617|NCT03462563|10152225|FG000|Overall Study|Death|1
6170715|NCT01254721|9817143|FG000|Overall Study|Lack of Efficacy|4
6170716|NCT01254721|9817144|FG001|Overall Study|Lack of Efficacy|2
6170717|NCT01254721|9817143|FG000|Overall Study|Death|0
6170718|NCT01254721|9817144|FG001|Overall Study|Death|1
6170719|NCT01254721|9817143|FG000|Overall Study|technical problum|1
6170720|NCT01254721|9817144|FG001|Overall Study|technical problum|0
6170721|NCT01254721|9817143|FG000|Overall Study|Adverse Event|2
6170722|NCT01254721|9817144|FG001|Overall Study|Adverse Event|3
6170723|NCT01254721|9817143|FG000|Overall Study|Withdrawal by Subject|8
6170724|NCT01254721|9817144|FG001|Overall Study|Withdrawal by Subject|11
6170725|NCT01254721|9817143|FG000|Overall Study|Wrongly randomization|0
6362618|NCT03462563|10152226|FG001|Overall Study|Death|1
6362619|NCT03462563|10152225|FG000|Overall Study|Termination of study|2
6362620|NCT03462563|10152226|FG001|Overall Study|Termination of study|1
6362621|NCT03462563|10152225|FG000|Overall Study|Adverse Event|1
6362622|NCT03462563|10152226|FG001|Overall Study|Adverse Event|3
6362623|NCT03462563|10152225|FG000|Overall Study|Unspecified reason|10
6362624|NCT03462563|10152226|FG001|Overall Study|Unspecified reason|12
6362625|NCT03462563|10152225|FG000|Overall Study|Physician Decision|1
6362626|NCT03462563|10152226|FG001|Overall Study|Physician Decision|0
6362627|NCT03419741|10152234|FG000|Overall Study|Adverse Event|1
6362628|NCT03419741|10152235|FG001|Overall Study|Adverse Event|0
6362629|NCT03419741|10152234|FG000|Overall Study|Withdrawal by Subject|1
6362630|NCT03419741|10152235|FG001|Overall Study|Withdrawal by Subject|2
6362631|NCT02759185|10152254|FG000|Stage 1|Adverse Event|0
6362632|NCT02759185|10152255|FG001|Stage 1|Adverse Event|1
6362633|NCT02759185|10152256|FG002|Stage 1|Adverse Event|3
6362634|NCT02759185|10152257|FG003|Stage 1|Adverse Event|0
6362635|NCT02759185|10152258|FG004|Stage 1|Adverse Event|0
6362636|NCT02759185|10152259|FG005|Stage 1|Adverse Event|0
6362637|NCT02759185|10152260|FG006|Stage 1|Adverse Event|0
6362638|NCT02759185|10152254|FG000|Stage 1|Withdrawal by Subject|1
6362639|NCT02759185|10152255|FG001|Stage 1|Withdrawal by Subject|0
6362640|NCT02759185|10152256|FG002|Stage 1|Withdrawal by Subject|0
6362641|NCT02759185|10152257|FG003|Stage 1|Withdrawal by Subject|0
6362642|NCT02759185|10152258|FG004|Stage 1|Withdrawal by Subject|0
6362643|NCT02759185|10152259|FG005|Stage 1|Withdrawal by Subject|0
6362644|NCT02759185|10152260|FG006|Stage 1|Withdrawal by Subject|0
6362645|NCT02759185|10152254|FG000|Stage 2|Adverse Event|0
6362646|NCT02759185|10152255|FG001|Stage 2|Adverse Event|0
6362647|NCT02759185|10152256|FG002|Stage 2|Adverse Event|0
6362648|NCT02759185|10152257|FG003|Stage 2|Adverse Event|0
6362649|NCT02759185|10152258|FG004|Stage 2|Adverse Event|1
6362650|NCT02759185|10152259|FG005|Stage 2|Adverse Event|2
6362651|NCT02759185|10152260|FG006|Stage 2|Adverse Event|0
6362652|NCT02759185|10152254|FG000|Stage 2|Withdrawal by Subject|0
6362653|NCT02759185|10152255|FG001|Stage 2|Withdrawal by Subject|0
6362654|NCT02759185|10152256|FG002|Stage 2|Withdrawal by Subject|0
6362655|NCT02759185|10152257|FG003|Stage 2|Withdrawal by Subject|0
6362656|NCT02759185|10152258|FG004|Stage 2|Withdrawal by Subject|1
6362657|NCT02759185|10152259|FG005|Stage 2|Withdrawal by Subject|1
6170726|NCT01254721|9817144|FG001|Overall Study|Wrongly randomization|1
6170727|NCT01254747|9817154|FG000|Overall Study|Unacceptable subjective vision|0
6170728|NCT01254747|9817155|FG001|Overall Study|Unacceptable subjective vision|0
6170729|NCT01254747|9817156|FG002|Overall Study|Unacceptable subjective vision|0
6170730|NCT01254747|9817157|FG003|Overall Study|Unacceptable subjective vision|2
6170731|NCT01254747|9817154|FG000|Overall Study|Difficult removal handling|0
6170732|NCT01254747|9817155|FG001|Overall Study|Difficult removal handling|0
6170733|NCT01254747|9817156|FG002|Overall Study|Difficult removal handling|1
6170734|NCT01254747|9817157|FG003|Overall Study|Difficult removal handling|0
6170735|NCT01254747|9817154|FG000|Overall Study|Symptoms and problems|0
6170736|NCT01254747|9817155|FG001|Overall Study|Symptoms and problems|2
6170737|NCT01254747|9817156|FG002|Overall Study|Symptoms and problems|1
6170738|NCT01254747|9817157|FG003|Overall Study|Symptoms and problems|0
6170739|NCT01254747|9817154|FG000|Overall Study|Lost to Follow-up|0
6170740|NCT01254747|9817155|FG001|Overall Study|Lost to Follow-up|0
6170741|NCT01254747|9817156|FG002|Overall Study|Lost to Follow-up|1
6170742|NCT01254747|9817157|FG003|Overall Study|Lost to Follow-up|0
6170743|NCT01254747|9817154|FG000|Overall Study|Biomicroscopy|0
6170744|NCT01254747|9817155|FG001|Overall Study|Biomicroscopy|0
6170745|NCT01254747|9817156|FG002|Overall Study|Biomicroscopy|1
6170746|NCT01254747|9817157|FG003|Overall Study|Biomicroscopy|0
6170747|NCT01254747|9817154|FG000|Overall Study|Discomfort|0
6170748|NCT01254747|9817155|FG001|Overall Study|Discomfort|4
6170749|NCT01254747|9817156|FG002|Overall Study|Discomfort|0
6170750|NCT01254747|9817157|FG003|Overall Study|Discomfort|0
6170751|NCT01254890|9817199|FG000|Overall Study|Ineligible|0
6170752|NCT01254890|9817200|FG001|Overall Study|Ineligible|3
6170753|NCT01254890|9817199|FG000|Overall Study|Withdrawal by Subject|1
6170754|NCT01254890|9817200|FG001|Overall Study|Withdrawal by Subject|2
6170755|NCT01254890|9817199|FG000|Overall Study|Disease Progression|0
6170756|NCT01254890|9817200|FG001|Overall Study|Disease Progression|5
6170757|NCT01255163|9817211|FG000|Overall Study|Withdrawal by Subject|1
6170758|NCT01255163|9817212|FG001|Overall Study|Withdrawal by Subject|0
6170759|NCT01255163|9817211|FG000|Overall Study|Lost to Follow-up|2
6170760|NCT01255163|9817212|FG001|Overall Study|Lost to Follow-up|0
6170761|NCT01255163|9817211|FG000|Overall Study|Adverse Event|0
6170762|NCT01255163|9817212|FG001|Overall Study|Adverse Event|2
6170763|NCT01255163|9817211|FG000|Overall Study|AstraZeneca stopped support of the study|1
6170764|NCT01255163|9817212|FG001|Overall Study|AstraZeneca stopped support of the study|3
6170765|NCT01255306|9817222|FG000|Overall Study|Physician Decision|1
6170766|NCT01255306|9817223|FG001|Overall Study|Physician Decision|1
6170767|NCT01255423|9817234|FG000|Overall Study|Abnormal Laboratory value|3
6170768|NCT01255423|9817235|FG001|Overall Study|Abnormal Laboratory value|2
6170769|NCT01255423|9817234|FG000|Overall Study|Use of prohibited medications|0
6170770|NCT01255423|9817235|FG001|Overall Study|Use of prohibited medications|1
6170771|NCT01255436|9817243|FG000|Overall Study|Lost to Follow-up|178
6170772|NCT01255436|9817244|FG001|Overall Study|Lost to Follow-up|191
6170773|NCT01255436|9817243|FG000|Overall Study|Death, stroke, or MI|4
6170774|NCT01255436|9817244|FG001|Overall Study|Death, stroke, or MI|3
6362658|NCT02759185|10152260|FG006|Stage 2|Withdrawal by Subject|1
6362659|NCT02688530|10152295|FG000|Overall Study|Withdrawal by Subject|0
6362660|NCT02688530|10152296|FG001|Overall Study|Withdrawal by Subject|1
6362661|NCT02688530|10152297|FG002|Overall Study|Withdrawal by Subject|0
6362662|NCT02688530|10152298|FG003|Overall Study|Withdrawal by Subject|0
6362663|NCT02688530|10152295|FG000|Overall Study|Lost to Follow-up|0
6362664|NCT02688530|10152296|FG001|Overall Study|Lost to Follow-up|0
6362665|NCT02688530|10152297|FG002|Overall Study|Lost to Follow-up|2
6362666|NCT02688530|10152298|FG003|Overall Study|Lost to Follow-up|0
6362667|NCT02657434|10152314|FG000|Overall Study|On-Going in Study|77
6362668|NCT02657434|10152315|FG001|Overall Study|On-Going in Study|91
6362669|NCT02657434|10152314|FG000|Overall Study|Death|177
6362670|NCT02657434|10152315|FG001|Overall Study|Death|183
6362671|NCT02657434|10152314|FG000|Overall Study|Lost to Follow-up|2
6362672|NCT02657434|10152315|FG001|Overall Study|Lost to Follow-up|2
6362673|NCT02657434|10152314|FG000|Overall Study|Randomization by Error|2
6362674|NCT02657434|10152315|FG001|Overall Study|Randomization by Error|0
6362675|NCT02657434|10152314|FG000|Overall Study|Withdrawal by Subject|27
6362676|NCT02657434|10152315|FG001|Overall Study|Withdrawal by Subject|16
6362677|NCT02657434|10152314|FG000|Overall Study|Protocol Violation|1
6362678|NCT02657434|10152315|FG001|Overall Study|Protocol Violation|0
6362679|NCT02421939|10152324|FG000|Overall Study|Progressive disease|70
6362680|NCT02421939|10152325|FG001|Overall Study|Progressive disease|16
6362681|NCT02421939|10152324|FG000|Overall Study|Lack of Efficacy|21
6362682|NCT02421939|10152325|FG001|Overall Study|Lack of Efficacy|31
6362683|NCT02421939|10152324|FG000|Overall Study|Death|36
6362684|NCT02421939|10152325|FG001|Overall Study|Death|10
6362685|NCT02421939|10152324|FG000|Overall Study|Disease relapse|33
6362686|NCT02421939|10152325|FG001|Overall Study|Disease relapse|2
6362687|NCT02421939|10152324|FG000|Overall Study|Adverse Event|28
6362688|NCT02421939|10152325|FG001|Overall Study|Adverse Event|5
6362689|NCT02421939|10152324|FG000|Overall Study|Withdrawal by Subject|5
6362690|NCT02421939|10152325|FG001|Overall Study|Withdrawal by Subject|24
6362691|NCT02421939|10152324|FG000|Overall Study|Physician Decision|11
6362692|NCT02421939|10152325|FG001|Overall Study|Physician Decision|11
6170775|NCT01255592|9817257|FG000|Overall Study|Adverse Event|5
6170776|NCT01255592|9817258|FG001|Overall Study|Adverse Event|0
6170777|NCT01255592|9817257|FG000|Overall Study|Withdrawal by Subject|1
6170778|NCT01255592|9817258|FG001|Overall Study|Withdrawal by Subject|0
6170779|NCT01255592|9817257|FG000|Overall Study|Other|0
6170780|NCT01255592|9817258|FG001|Overall Study|Other|1
6170781|NCT01255631|9817267|FG000|Overall Study|poor enrollment, no data analyzed|9
6170782|NCT01255631|9817268|FG001|Overall Study|poor enrollment, no data analyzed|6
6170783|NCT01255670|9817276|FG000|Overall Study|Adverse Event|10
6170784|NCT01255670|9817277|FG001|Overall Study|Adverse Event|10
6170785|NCT01255670|9817276|FG000|Overall Study|Lost to Follow-up|16
6170786|NCT01255670|9817277|FG001|Overall Study|Lost to Follow-up|10
6170787|NCT01255722|9817286|FG000|Overall Study|Adverse Event|0
6170788|NCT01255722|9817287|FG001|Overall Study|Adverse Event|1
6170789|NCT01255722|9817288|FG002|Overall Study|Adverse Event|1
6170790|NCT01255722|9817286|FG000|Overall Study|asymptomatic patient|1
6170791|NCT01255722|9817287|FG001|Overall Study|asymptomatic patient|0
6170792|NCT01255722|9817288|FG002|Overall Study|asymptomatic patient|0
6170793|NCT01255722|9817286|FG000|Overall Study|beta-blocker contraindicated|2
6170794|NCT01255722|9817287|FG001|Overall Study|beta-blocker contraindicated|0
6170795|NCT01255722|9817288|FG002|Overall Study|beta-blocker contraindicated|0
6170796|NCT01255761|9817299|FG000|Overall Study|Adverse Event|29
6170797|NCT01255761|9817300|FG001|Overall Study|Adverse Event|43
6170798|NCT01255761|9817299|FG000|Overall Study|Lack of Efficacy|86
6170799|NCT01255761|9817300|FG001|Overall Study|Lack of Efficacy|74
6170800|NCT01255761|9817299|FG000|Overall Study|Protocol Violation|9
6170801|NCT01255761|9817300|FG001|Overall Study|Protocol Violation|5
6170802|NCT01255761|9817299|FG000|Overall Study|Lost to Follow-up|10
6170803|NCT01255761|9817300|FG001|Overall Study|Lost to Follow-up|8
6170804|NCT01255761|9817299|FG000|Overall Study|Withdrawal by Subject|11
6170805|NCT01255761|9817300|FG001|Overall Study|Withdrawal by Subject|27
6170806|NCT01255761|9817299|FG000|Overall Study|Other Reasons|37
6170807|NCT01255761|9817300|FG001|Overall Study|Other Reasons|18
6170808|NCT01255787|9817310|FG000|Overall Study|Pretreatment Event or Adverse Event (AE)|6
6170809|NCT01255787|9817311|FG001|Overall Study|Pretreatment Event or Adverse Event (AE)|2
6170810|NCT01255787|9817312|FG002|Overall Study|Pretreatment Event or Adverse Event (AE)|9
6170811|NCT01255787|9817313|FG003|Overall Study|Pretreatment Event or Adverse Event (AE)|9
6170812|NCT01255787|9817310|FG000|Overall Study|Major Protocol Deviation|1
6170813|NCT01255787|9817311|FG001|Overall Study|Major Protocol Deviation|1
6170814|NCT01255787|9817312|FG002|Overall Study|Major Protocol Deviation|0
6170815|NCT01255787|9817313|FG003|Overall Study|Major Protocol Deviation|4
6170816|NCT01255787|9817310|FG000|Overall Study|Lost to Follow-up|1
6170817|NCT01255787|9817311|FG001|Overall Study|Lost to Follow-up|2
6170818|NCT01255787|9817312|FG002|Overall Study|Lost to Follow-up|4
6170819|NCT01255787|9817313|FG003|Overall Study|Lost to Follow-up|2
6170820|NCT01255787|9817310|FG000|Overall Study|Withdrawal of Consent|3
6170821|NCT01255787|9817311|FG001|Overall Study|Withdrawal of Consent|9
6170822|NCT01255787|9817312|FG002|Overall Study|Withdrawal of Consent|3
6170823|NCT01255787|9817313|FG003|Overall Study|Withdrawal of Consent|4
6170824|NCT01255787|9817310|FG000|Overall Study|Pregnancy|0
6170825|NCT01255787|9817311|FG001|Overall Study|Pregnancy|0
6170826|NCT01255787|9817312|FG002|Overall Study|Pregnancy|0
6170827|NCT01255787|9817313|FG003|Overall Study|Pregnancy|1
6362693|NCT02421939|10152324|FG000|Overall Study|Completed 1 or 2 chemo cycles with CRs|0
6362694|NCT02421939|10152325|FG001|Overall Study|Completed 1 or 2 chemo cycles with CRs|19
6362695|NCT02421939|10152324|FG000|Overall Study|Miscellaneous|4
6362696|NCT02421939|10152325|FG001|Overall Study|Miscellaneous|5
6362697|NCT02421939|10152324|FG000|Overall Study|Protocol deviation|1
6362698|NCT02421939|10152325|FG001|Overall Study|Protocol deviation|1
6362699|NCT02383966|10152333|FG000|Overall Study|Ongoing at clinical cut-off date|25
6362700|NCT02383966|10152334|FG001|Overall Study|Ongoing at clinical cut-off date|4
6362701|NCT02383966|10152333|FG000|Overall Study|Randomized, but not treated|1
6362702|NCT02383966|10152334|FG001|Overall Study|Randomized, but not treated|3
6362703|NCT02073565|10152342|FG000|Cohort A|Withdrawal by Subject|1
6362704|NCT02073565|10152343|FG001|Cohort A|Withdrawal by Subject|0
6362705|NCT02073565|10152342|FG000|Cohort B|Withdrawal by Subject|1
6362706|NCT02073565|10152343|FG001|Cohort B|Withdrawal by Subject|2
6362707|NCT02073565|10152342|FG000|Cohort C|Withdrawal by Subject|0
6362708|NCT02073565|10152343|FG001|Cohort C|Withdrawal by Subject|2
6362709|NCT02073565|10152342|FG000|Cohort C|Lost to Follow-up|0
6362710|NCT02073565|10152343|FG001|Cohort C|Lost to Follow-up|2
6362711|NCT02060487|10152352|FG000|Overall Study|Other|1
6362712|NCT02060487|10152353|FG001|Overall Study|Other|2
6362713|NCT02060487|10152354|FG002|Overall Study|Other|1
6362714|NCT02060487|10152352|FG000|Overall Study|Lack of Efficacy|0
6362715|NCT02060487|10152353|FG001|Overall Study|Lack of Efficacy|1
6362716|NCT02060487|10152354|FG002|Overall Study|Lack of Efficacy|0
6362717|NCT02060487|10152352|FG000|Overall Study|Withdrawal by Subject|3
6362718|NCT02060487|10152353|FG001|Overall Study|Withdrawal by Subject|10
6362719|NCT02060487|10152354|FG002|Overall Study|Withdrawal by Subject|4
6362720|NCT02060487|10152352|FG000|Overall Study|Study Terminated By Sponsor|87
6362721|NCT02060487|10152353|FG001|Overall Study|Study Terminated By Sponsor|89
6362722|NCT02060487|10152354|FG002|Overall Study|Study Terminated By Sponsor|100
6362723|NCT02060487|10152352|FG000|Overall Study|Randomized in error|1
6362724|NCT02060487|10152353|FG001|Overall Study|Randomized in error|0
6362725|NCT02060487|10152354|FG002|Overall Study|Randomized in error|0
6362726|NCT02060487|10152352|FG000|Overall Study|Protocol Violation|0
6362727|NCT02060487|10152353|FG001|Overall Study|Protocol Violation|1
6362728|NCT02060487|10152354|FG002|Overall Study|Protocol Violation|1
6362729|NCT02060487|10152352|FG000|Overall Study|Lost to Follow-up|3
6362730|NCT02060487|10152353|FG001|Overall Study|Lost to Follow-up|0
6362731|NCT02060487|10152354|FG002|Overall Study|Lost to Follow-up|2
6362732|NCT02060487|10152352|FG000|Overall Study|Death|34
6362733|NCT02060487|10152353|FG001|Overall Study|Death|25
6362734|NCT02060487|10152354|FG002|Overall Study|Death|19
6362735|NCT02060487|10152352|FG000|Overall Study|Adverse Event|0
6362736|NCT02060487|10152353|FG001|Overall Study|Adverse Event|0
6362737|NCT02060487|10152354|FG002|Overall Study|Adverse Event|1
6362738|NCT00331773|10152399|FG000|Overall Study|Withdrawal by Subject|6
6362739|NCT00331773|10152400|FG001|Overall Study|Withdrawal by Subject|4
6362740|NCT00331773|10152399|FG000|Overall Study|Protocol Violation|10
6362741|NCT00331773|10152400|FG001|Overall Study|Protocol Violation|3
6170828|NCT01255787|9817310|FG000|Overall Study|Lack of Efficacy|2
6170829|NCT01255787|9817311|FG001|Overall Study|Lack of Efficacy|2
6170830|NCT01255787|9817312|FG002|Overall Study|Lack of Efficacy|2
6362742|NCT00788671|10152428|FG000|Overall Study|Death|2
6362743|NCT00788671|10152428|FG000|Overall Study|Unable to biopsy|1
6362744|NCT00788671|10152428|FG000|Overall Study|Withdrawal by Subject|4
6362745|NCT00788671|10152428|FG000|Overall Study|IUD expulsed|1
6084277|NCT00642460|9693230|FG001|Part II: Open-Label Up to Week 92|Administrative reasons|0
6084278|NCT00642460|9693231|FG002|Part II: Open-Label Up to Week 92|Administrative reasons|0
6084279|NCT00642460|9693232|FG003|Part II: Open-Label Up to Week 92|Administrative reasons|1
6362746|NCT00788671|10152428|FG000|Overall Study|Lost to follow up|2
6362747|NCT00799266|10152434|FG000|Overall Study|Adverse Event|0
6362748|NCT00799266|10152435|FG001|Overall Study|Adverse Event|1
6362749|NCT00799266|10152434|FG000|Overall Study|Subject withdrew consent|3
6362750|NCT00799266|10152435|FG001|Overall Study|Subject withdrew consent|0
6362751|NCT00844480|10152447|FG000|Overall Study|Withdrawal by Subject|2
6362752|NCT00844480|10152448|FG001|Overall Study|Withdrawal by Subject|3
6362753|NCT00873366|10152458|FG000|Overall Study|Off tamoxifen for reconstructive surgery|1
6362754|NCT00873366|10152458|FG000|Overall Study|Off tamoxifen due to side effects|2
6362755|NCT00873366|10152458|FG000|Overall Study|Refused to continue DM-BT testing|3
6362756|NCT00930722|10152494|FG000|Overall Study|Lost to Follow-up|16
6362757|NCT00930722|10152494|FG000|Overall Study|No longer willing to participate|9
6362758|NCT00930722|10152494|FG000|Overall Study|Study terminated by sponsor|2
6362759|NCT00940498|10152506|FG000|Overall Study|Death|2
6362760|NCT00940498|10152507|FG001|Overall Study|Death|0
6362761|NCT00940498|10152508|FG002|Overall Study|Death|0
6362762|NCT00940498|10152509|FG003|Overall Study|Death|1
6362763|NCT00940498|10152510|FG004|Overall Study|Death|5
6362764|NCT00940498|10152511|FG005|Overall Study|Death|0
6362765|NCT00940498|10152512|FG006|Overall Study|Death|1
6362766|NCT00940498|10152513|FG007|Overall Study|Death|0
6362767|NCT00940498|10152506|FG000|Overall Study|Lost to Follow-up|1
6362768|NCT00940498|10152507|FG001|Overall Study|Lost to Follow-up|1
6362769|NCT00940498|10152508|FG002|Overall Study|Lost to Follow-up|2
6362770|NCT00940498|10152509|FG003|Overall Study|Lost to Follow-up|0
6362771|NCT00940498|10152510|FG004|Overall Study|Lost to Follow-up|1
6362772|NCT00940498|10152511|FG005|Overall Study|Lost to Follow-up|0
6362773|NCT00940498|10152512|FG006|Overall Study|Lost to Follow-up|0
6362774|NCT00940498|10152513|FG007|Overall Study|Lost to Follow-up|1
6362775|NCT00940498|10152506|FG000|Overall Study|Disease Progression|0
6362776|NCT00940498|10152507|FG001|Overall Study|Disease Progression|0
6084280|NCT00642460|9693233|FG004|Part II: Open-Label Up to Week 92|Administrative reasons|0
6170831|NCT01255787|9817313|FG003|Overall Study|Lack of Efficacy|2
6170832|NCT01255787|9817310|FG000|Overall Study|Noncompliance with Study Drug|3
6170833|NCT01255787|9817311|FG001|Overall Study|Noncompliance with Study Drug|1
6170834|NCT01255787|9817312|FG002|Overall Study|Noncompliance with Study Drug|0
6170835|NCT01255787|9817313|FG003|Overall Study|Noncompliance with Study Drug|0
6170836|NCT01255904|9817354|FG000|Overall Study|Physician Decision|1
6170837|NCT01255904|9817355|FG001|Overall Study|Physician Decision|4
6170838|NCT01256008|9817364|FG000|Overall Study|Lost to Follow-up|6
6170839|NCT01256008|9817365|FG001|Overall Study|Lost to Follow-up|4
6170840|NCT01256008|9817366|FG002|Overall Study|Lost to Follow-up|11
6170841|NCT01256008|9817364|FG000|Overall Study|Withdrawal by Subject|2
6170842|NCT01256008|9817365|FG001|Overall Study|Withdrawal by Subject|3
6170843|NCT01256008|9817366|FG002|Overall Study|Withdrawal by Subject|10
6170844|NCT01256060|9817385|FG000|Overall Study|Lost to Follow-up|0
6170845|NCT01256060|9817386|FG001|Overall Study|Lost to Follow-up|1
6170846|NCT01256060|9817387|FG002|Overall Study|Lost to Follow-up|0
6170847|NCT01256060|9817388|FG003|Overall Study|Lost to Follow-up|0
6170848|NCT01256177|9817405|FG000|Overall Study|Withdrawal by Subject|23
6170849|NCT01256177|9817406|FG001|Overall Study|Withdrawal by Subject|22
6170850|NCT01256177|9817405|FG000|Overall Study|Lost to Follow-up|2
6170851|NCT01256177|9817406|FG001|Overall Study|Lost to Follow-up|2
6170852|NCT01256177|9817405|FG000|Overall Study|Adverse Event|8
6170853|NCT01256177|9817406|FG001|Overall Study|Adverse Event|9
6170854|NCT01256177|9817405|FG000|Overall Study|Severe Non-Compliance to Protocol|4
6170855|NCT01256177|9817406|FG001|Overall Study|Severe Non-Compliance to Protocol|2
6170856|NCT01256177|9817405|FG000|Overall Study|Condition under Investigation Worsened|1
6170857|NCT01256177|9817406|FG001|Overall Study|Condition under Investigation Worsened|0
6170858|NCT01256177|9817405|FG000|Overall Study|Lack of Efficacy|11
6170859|NCT01256177|9817406|FG001|Overall Study|Lack of Efficacy|2
6170860|NCT01256177|9817405|FG000|Overall Study|TG=593mg/dL, not fit to participate.|1
6170861|NCT01256177|9817406|FG001|Overall Study|TG=593mg/dL, not fit to participate.|0
6170862|NCT01256190|9817414|FG000|Overall Study|Lost to Follow-up|2
6170863|NCT01256190|9817415|FG001|Overall Study|Lost to Follow-up|0
6170864|NCT01256294|9817421|FG000|Overall Study|Adverse Event|1
6362777|NCT00940498|10152508|FG002|Overall Study|Disease Progression|1
6362778|NCT00940498|10152509|FG003|Overall Study|Disease Progression|1
6362779|NCT00940498|10152510|FG004|Overall Study|Disease Progression|0
6362780|NCT00940498|10152511|FG005|Overall Study|Disease Progression|1
6362781|NCT00940498|10152512|FG006|Overall Study|Disease Progression|0
6362782|NCT00940498|10152513|FG007|Overall Study|Disease Progression|0
6362783|NCT00940498|10152506|FG000|Overall Study|Physician Decision|0
6362784|NCT00940498|10152507|FG001|Overall Study|Physician Decision|0
6362785|NCT00940498|10152508|FG002|Overall Study|Physician Decision|0
6362786|NCT00940498|10152509|FG003|Overall Study|Physician Decision|0
6362787|NCT00940498|10152510|FG004|Overall Study|Physician Decision|2
6362788|NCT00940498|10152511|FG005|Overall Study|Physician Decision|0
6362789|NCT00940498|10152512|FG006|Overall Study|Physician Decision|0
6362790|NCT00940498|10152513|FG007|Overall Study|Physician Decision|0
6362791|NCT00940498|10152506|FG000|Overall Study|Not treated due to disease related pain|0
6362792|NCT00940498|10152507|FG001|Overall Study|Not treated due to disease related pain|0
6362793|NCT00940498|10152508|FG002|Overall Study|Not treated due to disease related pain|0
6362794|NCT00940498|10152509|FG003|Overall Study|Not treated due to disease related pain|0
6362795|NCT00940498|10152510|FG004|Overall Study|Not treated due to disease related pain|1
6362796|NCT00940498|10152511|FG005|Overall Study|Not treated due to disease related pain|0
6362797|NCT00940498|10152512|FG006|Overall Study|Not treated due to disease related pain|0
6362798|NCT00940498|10152513|FG007|Overall Study|Not treated due to disease related pain|0
6084281|NCT00642460|9693234|FG005|Part II: Open-Label Up to Week 92|Administrative reasons|0
6084282|NCT00642460|9693229|FG000|Part III: Open-Label Up to Week 260|Adverse Event|0
6084283|NCT00642460|9693230|FG001|Part III: Open-Label Up to Week 260|Adverse Event|0
6170865|NCT01256294|9817422|FG001|Overall Study|Adverse Event|0
6170866|NCT01256294|9817421|FG000|Overall Study|Withdrawal by Subject|1
6170867|NCT01256294|9817422|FG001|Overall Study|Withdrawal by Subject|1
6170868|NCT01256294|9817421|FG000|Overall Study|Protocol deviation|2
6170869|NCT01256294|9817422|FG001|Overall Study|Protocol deviation|1
6170870|NCT01256385|9817430|FG000|Overall Study|Physician Decision|1
6170871|NCT01256385|9817431|FG001|Overall Study|Physician Decision|1
6170872|NCT01256385|9817430|FG000|Overall Study|Withdrawal by Subject|2
6170873|NCT01256385|9817431|FG001|Overall Study|Withdrawal by Subject|2
6170874|NCT01256411|9817441|FG000|Extension by Maximum Treatment|Protocol deviation|0
6170875|NCT01256411|9817442|FG001|Extension by Maximum Treatment|Protocol deviation|0
6170876|NCT01256411|9817443|FG002|Extension by Maximum Treatment|Protocol deviation|1
6170877|NCT01256411|9817444|FG003|Extension by Maximum Treatment|Protocol deviation|0
6170878|NCT01256411|9817445|FG004|Extension by Maximum Treatment|Protocol deviation|0
6170879|NCT01256411|9817446|FG005|Extension by Maximum Treatment|Protocol deviation|0
6170880|NCT01256411|9817441|FG000|Extension by Maximum Treatment|Lost to Follow-up|1
6170881|NCT01256411|9817442|FG001|Extension by Maximum Treatment|Lost to Follow-up|2
6170882|NCT01256411|9817443|FG002|Extension by Maximum Treatment|Lost to Follow-up|0
6170883|NCT01256411|9817444|FG003|Extension by Maximum Treatment|Lost to Follow-up|0
6170884|NCT01256411|9817445|FG004|Extension by Maximum Treatment|Lost to Follow-up|0
6170885|NCT01256411|9817446|FG005|Extension by Maximum Treatment|Lost to Follow-up|0
6170886|NCT01256411|9817441|FG000|Extension by Maximum Treatment|Withdrawal by Subject|1
6170887|NCT01256411|9817442|FG001|Extension by Maximum Treatment|Withdrawal by Subject|6
6170888|NCT01256411|9817443|FG002|Extension by Maximum Treatment|Withdrawal by Subject|1
6170889|NCT01256411|9817444|FG003|Extension by Maximum Treatment|Withdrawal by Subject|0
6170890|NCT01256411|9817445|FG004|Extension by Maximum Treatment|Withdrawal by Subject|0
6170891|NCT01256411|9817446|FG005|Extension by Maximum Treatment|Withdrawal by Subject|0
6170892|NCT01256411|9817441|FG000|Extension by Maximum Treatment|Lack of Efficacy|1
6170893|NCT01256411|9817442|FG001|Extension by Maximum Treatment|Lack of Efficacy|0
6170894|NCT01256411|9817443|FG002|Extension by Maximum Treatment|Lack of Efficacy|1
6170895|NCT01256411|9817444|FG003|Extension by Maximum Treatment|Lack of Efficacy|0
6170896|NCT01256411|9817445|FG004|Extension by Maximum Treatment|Lack of Efficacy|0
6170897|NCT01256411|9817446|FG005|Extension by Maximum Treatment|Lack of Efficacy|0
6170898|NCT01256411|9817441|FG000|Extension by Maximum Treatment|Adverse Event|4
6170899|NCT01256411|9817442|FG001|Extension by Maximum Treatment|Adverse Event|2
6170900|NCT01256411|9817443|FG002|Extension by Maximum Treatment|Adverse Event|1
6170901|NCT01256411|9817444|FG003|Extension by Maximum Treatment|Adverse Event|0
6170902|NCT01256411|9817445|FG004|Extension by Maximum Treatment|Adverse Event|0
6170903|NCT01256411|9817446|FG005|Extension by Maximum Treatment|Adverse Event|0
6170904|NCT01256411|9817441|FG000|Extension by Mono or Combination Therapy|Adverse Event|0
6170905|NCT01256411|9817442|FG001|Extension by Mono or Combination Therapy|Adverse Event|0
6170906|NCT01256411|9817443|FG002|Extension by Mono or Combination Therapy|Adverse Event|0
6170907|NCT01256411|9817444|FG003|Extension by Mono or Combination Therapy|Adverse Event|0
6170908|NCT01256411|9817445|FG004|Extension by Mono or Combination Therapy|Adverse Event|6
6170909|NCT01256411|9817446|FG005|Extension by Mono or Combination Therapy|Adverse Event|1
6170910|NCT01256411|9817441|FG000|Extension by Mono or Combination Therapy|Protocol deviation|0
6170911|NCT01256411|9817442|FG001|Extension by Mono or Combination Therapy|Protocol deviation|0
6170912|NCT01256411|9817443|FG002|Extension by Mono or Combination Therapy|Protocol deviation|0
6170913|NCT01256411|9817444|FG003|Extension by Mono or Combination Therapy|Protocol deviation|0
6170914|NCT01256411|9817445|FG004|Extension by Mono or Combination Therapy|Protocol deviation|0
6170915|NCT01256411|9817446|FG005|Extension by Mono or Combination Therapy|Protocol deviation|1
6170916|NCT01256411|9817441|FG000|Extension by Mono or Combination Therapy|Lost to Follow-up|0
6170917|NCT01256411|9817442|FG001|Extension by Mono or Combination Therapy|Lost to Follow-up|0
6170918|NCT01256411|9817443|FG002|Extension by Mono or Combination Therapy|Lost to Follow-up|0
6170919|NCT01256411|9817444|FG003|Extension by Mono or Combination Therapy|Lost to Follow-up|0
6170920|NCT01256411|9817445|FG004|Extension by Mono or Combination Therapy|Lost to Follow-up|3
6170921|NCT01256411|9817446|FG005|Extension by Mono or Combination Therapy|Lost to Follow-up|0
6170922|NCT01256411|9817441|FG000|Extension by Mono or Combination Therapy|Withdrawal by Subject|0
6084284|NCT00642460|9693231|FG002|Part III: Open-Label Up to Week 260|Adverse Event|0
6084285|NCT00642460|9693232|FG003|Part III: Open-Label Up to Week 260|Adverse Event|0
6084286|NCT00642460|9693233|FG004|Part III: Open-Label Up to Week 260|Adverse Event|7
6084287|NCT00642460|9693234|FG005|Part III: Open-Label Up to Week 260|Adverse Event|6
6084288|NCT00642460|9693229|FG000|Part III: Open-Label Up to Week 260|Insufficient therapeutic response|0
6084289|NCT00642460|9693230|FG001|Part III: Open-Label Up to Week 260|Insufficient therapeutic response|0
6084290|NCT00642460|9693231|FG002|Part III: Open-Label Up to Week 260|Insufficient therapeutic response|0
6084291|NCT00642460|9693232|FG003|Part III: Open-Label Up to Week 260|Insufficient therapeutic response|0
6084292|NCT00642460|9693233|FG004|Part III: Open-Label Up to Week 260|Insufficient therapeutic response|3
6084293|NCT00642460|9693234|FG005|Part III: Open-Label Up to Week 260|Insufficient therapeutic response|4
6084294|NCT00642460|9693229|FG000|Part III: Open-Label Up to Week 260|Withdrawal by Subject|0
6084295|NCT00642460|9693230|FG001|Part III: Open-Label Up to Week 260|Withdrawal by Subject|0
6084296|NCT00642460|9693231|FG002|Part III: Open-Label Up to Week 260|Withdrawal by Subject|0
6084297|NCT00642460|9693232|FG003|Part III: Open-Label Up to Week 260|Withdrawal by Subject|0
6084298|NCT00642460|9693233|FG004|Part III: Open-Label Up to Week 260|Withdrawal by Subject|4
6084299|NCT00642460|9693234|FG005|Part III: Open-Label Up to Week 260|Withdrawal by Subject|1
6084300|NCT00642460|9693229|FG000|Part III: Open-Label Up to Week 260|Lost to Follow-up|0
6084301|NCT00642460|9693230|FG001|Part III: Open-Label Up to Week 260|Lost to Follow-up|0
6084302|NCT00642460|9693231|FG002|Part III: Open-Label Up to Week 260|Lost to Follow-up|0
6084303|NCT00642460|9693232|FG003|Part III: Open-Label Up to Week 260|Lost to Follow-up|0
6084304|NCT00642460|9693233|FG004|Part III: Open-Label Up to Week 260|Lost to Follow-up|1
6084305|NCT00642460|9693234|FG005|Part III: Open-Label Up to Week 260|Lost to Follow-up|1
6084306|NCT00642460|9693229|FG000|Part III: Open-Label Up to Week 260|Other|0
6084307|NCT00642460|9693230|FG001|Part III: Open-Label Up to Week 260|Other|0
6084308|NCT00642460|9693231|FG002|Part III: Open-Label Up to Week 260|Other|0
6084309|NCT00642460|9693232|FG003|Part III: Open-Label Up to Week 260|Other|0
6170923|NCT01256411|9817442|FG001|Extension by Mono or Combination Therapy|Withdrawal by Subject|0
6170924|NCT01256411|9817443|FG002|Extension by Mono or Combination Therapy|Withdrawal by Subject|0
6170925|NCT01256411|9817444|FG003|Extension by Mono or Combination Therapy|Withdrawal by Subject|0
6170926|NCT01256411|9817445|FG004|Extension by Mono or Combination Therapy|Withdrawal by Subject|7
6170927|NCT01256411|9817446|FG005|Extension by Mono or Combination Therapy|Withdrawal by Subject|1
6170928|NCT01256411|9817441|FG000|Extension by Mono or Combination Therapy|Lack of Efficacy|0
6170929|NCT01256411|9817442|FG001|Extension by Mono or Combination Therapy|Lack of Efficacy|0
6170930|NCT01256411|9817443|FG002|Extension by Mono or Combination Therapy|Lack of Efficacy|0
6170931|NCT01256411|9817444|FG003|Extension by Mono or Combination Therapy|Lack of Efficacy|0
6170932|NCT01256411|9817445|FG004|Extension by Mono or Combination Therapy|Lack of Efficacy|1
6170933|NCT01256411|9817446|FG005|Extension by Mono or Combination Therapy|Lack of Efficacy|1
6170934|NCT01256450|9817480|FG000|Open-label Titration|Adverse Event|39
6170935|NCT01256450|9817481|FG001|Open-label Titration|Adverse Event|0
6170936|NCT01256450|9817482|FG002|Open-label Titration|Adverse Event|0
6170937|NCT01256450|9817480|FG000|Open-label Titration|Lost to Follow-up|7
6170938|NCT01256450|9817481|FG001|Open-label Titration|Lost to Follow-up|0
6170939|NCT01256450|9817482|FG002|Open-label Titration|Lost to Follow-up|0
6170940|NCT01256450|9817480|FG000|Open-label Titration|Lack of analgesic effect|30
6170941|NCT01256450|9817481|FG001|Open-label Titration|Lack of analgesic effect|0
6170942|NCT01256450|9817482|FG002|Open-label Titration|Lack of analgesic effect|0
6170943|NCT01256450|9817480|FG000|Open-label Titration|Non-compliance|9
6170944|NCT01256450|9817481|FG001|Open-label Titration|Non-compliance|0
6170945|NCT01256450|9817482|FG002|Open-label Titration|Non-compliance|0
6170946|NCT01256450|9817480|FG000|Open-label Titration|Screen failure|1
6170947|NCT01256450|9817481|FG001|Open-label Titration|Screen failure|0
6170948|NCT01256450|9817482|FG002|Open-label Titration|Screen failure|0
6170949|NCT01256450|9817480|FG000|Open-label Titration|Other|13
6170950|NCT01256450|9817481|FG001|Open-label Titration|Other|0
6170951|NCT01256450|9817482|FG002|Open-label Titration|Other|0
6170952|NCT01256450|9817480|FG000|Double-blind Treatment|Adverse Event|0
6170953|NCT01256450|9817481|FG001|Double-blind Treatment|Adverse Event|8
6170954|NCT01256450|9817482|FG002|Double-blind Treatment|Adverse Event|6
6170955|NCT01256450|9817480|FG000|Double-blind Treatment|Lost to Follow-up|0
6170956|NCT01256450|9817481|FG001|Double-blind Treatment|Lost to Follow-up|1
6084310|NCT00642460|9693233|FG004|Part III: Open-Label Up to Week 260|Other|2
6084311|NCT00642460|9693234|FG005|Part III: Open-Label Up to Week 260|Other|2
6084312|NCT00642460|9693229|FG000|Part III: Open-Label Up to Week 260|Death|0
6084313|NCT00642460|9693230|FG001|Part III: Open-Label Up to Week 260|Death|0
6084314|NCT00642460|9693231|FG002|Part III: Open-Label Up to Week 260|Death|0
6084315|NCT00642460|9693232|FG003|Part III: Open-Label Up to Week 260|Death|0
6084316|NCT00642460|9693233|FG004|Part III: Open-Label Up to Week 260|Death|0
6084317|NCT00642460|9693234|FG005|Part III: Open-Label Up to Week 260|Death|3
6084318|NCT00642460|9693229|FG000|Part III: Open-Label Up to Week 260|Administrative reason|0
6084319|NCT00642460|9693230|FG001|Part III: Open-Label Up to Week 260|Administrative reason|0
6084320|NCT00642460|9693231|FG002|Part III: Open-Label Up to Week 260|Administrative reason|0
6084321|NCT00642460|9693232|FG003|Part III: Open-Label Up to Week 260|Administrative reason|0
6084322|NCT00642460|9693233|FG004|Part III: Open-Label Up to Week 260|Administrative reason|0
6170957|NCT01256450|9817482|FG002|Double-blind Treatment|Lost to Follow-up|7
6170958|NCT01256450|9817480|FG000|Double-blind Treatment|Withdrawal by Subject|0
6170959|NCT01256450|9817481|FG001|Double-blind Treatment|Withdrawal by Subject|0
6170960|NCT01256450|9817482|FG002|Double-blind Treatment|Withdrawal by Subject|1
6170961|NCT01256450|9817480|FG000|Double-blind Treatment|Lack of analgesic effect|0
6170962|NCT01256450|9817481|FG001|Double-blind Treatment|Lack of analgesic effect|5
6170963|NCT01256450|9817482|FG002|Double-blind Treatment|Lack of analgesic effect|6
6170964|NCT01256450|9817480|FG000|Double-blind Treatment|Non-compliance|0
6170965|NCT01256450|9817481|FG001|Double-blind Treatment|Non-compliance|5
6084323|NCT00642460|9693234|FG005|Part III: Open-Label Up to Week 260|Administrative reason|1
6084324|NCT00642460|9693229|FG000|Part III: Open-Label Up to Week 260|Refused treatment|0
6084325|NCT00642460|9693230|FG001|Part III: Open-Label Up to Week 260|Refused treatment|0
6084326|NCT00642460|9693231|FG002|Part III: Open-Label Up to Week 260|Refused treatment|0
6084327|NCT00642460|9693232|FG003|Part III: Open-Label Up to Week 260|Refused treatment|0
6084328|NCT00642460|9693233|FG004|Part III: Open-Label Up to Week 260|Refused treatment|8
6084329|NCT00642460|9693234|FG005|Part III: Open-Label Up to Week 260|Refused treatment|3
6084330|NCT00642473|9693246|FG000|Overall Study|Withdrawal by Subject|0
6084331|NCT00642473|9693247|FG001|Overall Study|Withdrawal by Subject|5
6084332|NCT00642473|9693246|FG000|Overall Study|Progression or death|2
6170966|NCT01256450|9817482|FG002|Double-blind Treatment|Non-compliance|4
6170967|NCT01256450|9817480|FG000|Double-blind Treatment|Opioid withdrawal symptoms|0
6170968|NCT01256450|9817481|FG001|Double-blind Treatment|Opioid withdrawal symptoms|0
6170969|NCT01256450|9817482|FG002|Double-blind Treatment|Opioid withdrawal symptoms|1
6170970|NCT01256450|9817480|FG000|Double-blind Treatment|Other|0
6170971|NCT01256450|9817481|FG001|Double-blind Treatment|Other|9
6170972|NCT01256450|9817482|FG002|Double-blind Treatment|Other|12
6170973|NCT01256476|9817491|FG000|Overall Study|Adverse Event|2
6170974|NCT01256476|9817492|FG001|Overall Study|Adverse Event|1
6170975|NCT01256476|9817491|FG000|Overall Study|Withdrawal by Subject|2
6170976|NCT01256476|9817492|FG001|Overall Study|Withdrawal by Subject|1
6170977|NCT01256476|9817491|FG000|Overall Study|Lost to Follow-up|1
6170978|NCT01256476|9817492|FG001|Overall Study|Lost to Follow-up|2
6170979|NCT01256476|9817491|FG000|Overall Study|Persistent ALT or AST elevation|1
6170980|NCT01256476|9817492|FG001|Overall Study|Persistent ALT or AST elevation|0
6170981|NCT01256476|9817491|FG000|Overall Study|Physician Decision|0
6170982|NCT01256476|9817492|FG001|Overall Study|Physician Decision|1
6170983|NCT01256476|9817491|FG000|Overall Study|Subject non-compliance|0
6170984|NCT01256476|9817492|FG001|Overall Study|Subject non-compliance|1
6170985|NCT01256476|9817491|FG000|Overall Study|LDL-C elevation exceeding 250 mg/dL|0
6170986|NCT01256476|9817492|FG001|Overall Study|LDL-C elevation exceeding 250 mg/dL|1
6170987|NCT01256502|9817498|FG000|Overall Study|Had scaffold removed|4
6170988|NCT01256502|9817498|FG000|Overall Study|Personal reasons|5
6170989|NCT01256502|9817498|FG000|Overall Study|Protocol deviation|1
6170990|NCT01256567|9817507|FG000|Overall Study|Withdrawal by Subject|1
6170991|NCT01256593|9817512|FG000|Overall Study|Protocol Violation|26
6170992|NCT01256593|9817512|FG000|Overall Study|No Drug Administration Information|2
6170993|NCT01256593|9817512|FG000|Overall Study|No Visit After Treatment|186
6170994|NCT01256658|9817518|FG000|Period 1|Lost to Follow-up|837
6170995|NCT01256658|9817519|FG001|Period 1|Lost to Follow-up|661
6170996|NCT01256658|9817518|FG000|Period 1|Withdrawal by Subject|35
6170997|NCT01256658|9817519|FG001|Period 1|Withdrawal by Subject|43
6170998|NCT01256658|9817518|FG000|Period 1|Death|48
6170999|NCT01256658|9817519|FG001|Period 1|Death|44
6171000|NCT01256671|9817528|FG000|Overall Study|Adverse Event|29
6171001|NCT01256671|9817528|FG000|Overall Study|Lost to Follow-up|16
6171002|NCT01256671|9817528|FG000|Overall Study|Withdrawal by Subject|31
6171003|NCT01256671|9817528|FG000|Overall Study|Physician Decision|3
6171004|NCT01256671|9817528|FG000|Overall Study|Lack of Efficacy|4
6171005|NCT01256671|9817528|FG000|Overall Study|Non-compliance/Sponsor Decision/Other|12
6171006|NCT01256684|9817535|FG000|Overall Study|Adverse Event|1
6171007|NCT01256684|9817536|FG001|Overall Study|Adverse Event|4
6171008|NCT01256684|9817537|FG002|Overall Study|Adverse Event|2
6171009|NCT01256684|9817535|FG000|Overall Study|Withdrawal by Subject|4
6084333|NCT00642473|9693247|FG001|Overall Study|Progression or death|4
6171010|NCT01256684|9817536|FG001|Overall Study|Withdrawal by Subject|0
6171011|NCT01256684|9817537|FG002|Overall Study|Withdrawal by Subject|2
6084334|NCT00642473|9693246|FG000|Overall Study|Other|2
6084335|NCT00642473|9693247|FG001|Overall Study|Other|2
6171012|NCT01256684|9817535|FG000|Overall Study|Physician Decision|0
6171013|NCT01256684|9817536|FG001|Overall Study|Physician Decision|1
6171014|NCT01256684|9817537|FG002|Overall Study|Physician Decision|0
6084336|NCT00642616|9693260|FG000|Overall Study|Adverse Event|2
6084337|NCT00642616|9693261|FG001|Overall Study|Adverse Event|0
6084338|NCT00642616|9693262|FG002|Overall Study|Adverse Event|1
6084339|NCT00642616|9693263|FG003|Overall Study|Adverse Event|0
6084340|NCT00642616|9693260|FG000|Overall Study|Study Terminated by Sponsor|7
6084341|NCT00642616|9693261|FG001|Overall Study|Study Terminated by Sponsor|6
6084342|NCT00642616|9693262|FG002|Overall Study|Study Terminated by Sponsor|4
6084343|NCT00642616|9693263|FG003|Overall Study|Study Terminated by Sponsor|5
6171015|NCT01256684|9817535|FG000|Overall Study|Lack of Efficacy|0
6171016|NCT01256684|9817536|FG001|Overall Study|Lack of Efficacy|1
6171017|NCT01256684|9817537|FG002|Overall Study|Lack of Efficacy|1
6171018|NCT01256684|9817535|FG000|Overall Study|Entry criteria not met/non-compliance|4
6171019|NCT01256684|9817536|FG001|Overall Study|Entry criteria not met/non-compliance|7
6171020|NCT01256684|9817537|FG002|Overall Study|Entry criteria not met/non-compliance|6
6171021|NCT01256788|9817548|FG000|Overall Study|Lost to Follow-up|5
6171022|NCT01256788|9817549|FG001|Overall Study|Lost to Follow-up|8
6171023|NCT01256788|9817550|FG002|Overall Study|Lost to Follow-up|3
6171024|NCT01256879|9817571|FG000|Overall Study|Withdrawal by Subject|1
6171025|NCT01257204|9817626|FG000|Treatment Period (up to Week 24)|Lack of Efficacy|0
6171026|NCT01257204|9817627|FG001|Treatment Period (up to Week 24)|Lack of Efficacy|1
6171027|NCT01257204|9817628|FG002|Treatment Period (up to Week 24)|Lack of Efficacy|3
6171028|NCT01257204|9817626|FG000|Treatment Period (up to Week 24)|Adverse Event|3
6171029|NCT01257204|9817627|FG001|Treatment Period (up to Week 24)|Adverse Event|1
6171030|NCT01257204|9817628|FG002|Treatment Period (up to Week 24)|Adverse Event|2
6171031|NCT01257204|9817626|FG000|Treatment Period (up to Week 24)|Withdrawal by Subject|1
6171032|NCT01257204|9817627|FG001|Treatment Period (up to Week 24)|Withdrawal by Subject|0
6171033|NCT01257204|9817628|FG002|Treatment Period (up to Week 24)|Withdrawal by Subject|1
6171034|NCT01257204|9817626|FG000|Treatment Period (up to Week 24)|Lost to Follow-up|0
6171035|NCT01257204|9817627|FG001|Treatment Period (up to Week 24)|Lost to Follow-up|2
6171036|NCT01257204|9817628|FG002|Treatment Period (up to Week 24)|Lost to Follow-up|0
6171037|NCT01257204|9817626|FG000|Treatment Period (up to Week 24)|Poor compliance/noncompliance|0
6171038|NCT01257204|9817627|FG001|Treatment Period (up to Week 24)|Poor compliance/noncompliance|0
6171039|NCT01257204|9817628|FG002|Treatment Period (up to Week 24)|Poor compliance/noncompliance|1
6171040|NCT01257204|9817626|FG000|Treatment Period (up to Week 24)|Participant's request to discontinue|1
6171041|NCT01257204|9817627|FG001|Treatment Period (up to Week 24)|Participant's request to discontinue|2
6171042|NCT01257204|9817628|FG002|Treatment Period (up to Week 24)|Participant's request to discontinue|2
6171043|NCT01257204|9817626|FG000|Follow-up Period (up to Week 48)|Withdrawal by Subject|0
6171044|NCT01257204|9817627|FG001|Follow-up Period (up to Week 48)|Withdrawal by Subject|2
6171045|NCT01257204|9817628|FG002|Follow-up Period (up to Week 48)|Withdrawal by Subject|1
6171046|NCT01257204|9817626|FG000|Follow-up Period (up to Week 48)|Lost to Follow-up|1
6171047|NCT01257204|9817627|FG001|Follow-up Period (up to Week 48)|Lost to Follow-up|4
6171048|NCT01257204|9817628|FG002|Follow-up Period (up to Week 48)|Lost to Follow-up|4
6171049|NCT01257204|9817626|FG000|Follow-up Period (up to Week 48)|Other|0
6171050|NCT01257204|9817627|FG001|Follow-up Period (up to Week 48)|Other|0
6171051|NCT01257204|9817628|FG002|Follow-up Period (up to Week 48)|Other|5
6171052|NCT01257230|9817664|FG000|Overall Study|Not Treated|0
6171053|NCT01257230|9817665|FG001|Overall Study|Not Treated|0
6171054|NCT01257230|9817666|FG002|Overall Study|Not Treated|1
6171055|NCT01257230|9817664|FG000|Overall Study|Adverse Event|2
6171056|NCT01257230|9817665|FG001|Overall Study|Adverse Event|0
6171057|NCT01257230|9817666|FG002|Overall Study|Adverse Event|0
6171058|NCT01257230|9817664|FG000|Overall Study|Lack of Efficacy|0
6171059|NCT01257230|9817665|FG001|Overall Study|Lack of Efficacy|1
6171060|NCT01257230|9817666|FG002|Overall Study|Lack of Efficacy|0
6171061|NCT01257230|9817664|FG000|Overall Study|Protocol Violation|3
6171062|NCT01257230|9817665|FG001|Overall Study|Protocol Violation|0
6171063|NCT01257230|9817666|FG002|Overall Study|Protocol Violation|1
6171064|NCT01257230|9817664|FG000|Overall Study|Withdrawal by Subject|0
6171065|NCT01257230|9817665|FG001|Overall Study|Withdrawal by Subject|4
6171066|NCT01257230|9817666|FG002|Overall Study|Withdrawal by Subject|1
6171067|NCT01257230|9817664|FG000|Overall Study|Other reason not defined above|1
6171068|NCT01257230|9817665|FG001|Overall Study|Other reason not defined above|5
6171069|NCT01257230|9817666|FG002|Overall Study|Other reason not defined above|3
6171070|NCT01257425|9817697|FG000|Overall Study|Lack of Efficacy|3
6171071|NCT01257425|9817698|FG001|Overall Study|Lack of Efficacy|3
6171072|NCT01257425|9817697|FG000|Overall Study|Adverse Event|1
6171073|NCT01257425|9817698|FG001|Overall Study|Adverse Event|1
6171074|NCT01257425|9817697|FG000|Overall Study|Protocol Violation|1
6171075|NCT01257425|9817698|FG001|Overall Study|Protocol Violation|1
6171076|NCT01257425|9817697|FG000|Overall Study|Withdrawal by Subject|0
6171077|NCT01257425|9817698|FG001|Overall Study|Withdrawal by Subject|1
6171078|NCT01257425|9817697|FG000|Overall Study|Death|1
6171079|NCT01257425|9817698|FG001|Overall Study|Death|0
6171080|NCT01257503|9817715|FG000|Overall Study|Lost to Follow-up|7
6084344|NCT00642616|9693260|FG000|Overall Study|Withdrawal by Subject|0
6171081|NCT01257503|9817716|FG001|Overall Study|Lost to Follow-up|10
6084345|NCT00642616|9693261|FG001|Overall Study|Withdrawal by Subject|1
6084346|NCT00642616|9693262|FG002|Overall Study|Withdrawal by Subject|1
6171082|NCT01257503|9817715|FG000|Overall Study|Over 5 years old at enrollment|0
6171083|NCT01257503|9817716|FG001|Overall Study|Over 5 years old at enrollment|1
6362799|NCT04553913|10152546|FG000|Overall Study|patient's block resolved prior to PACU|1
6362800|NCT04553913|10152546|FG000|Overall Study|did not use the device properly|5
6362801|NCT04009824|10152561|FG000|Overall Study|COVID-19 pandemic restriction/closure|2
6362802|NCT04009824|10152562|FG001|Overall Study|COVID-19 pandemic restriction/closure|3
6362803|NCT04009824|10152563|FG002|Overall Study|COVID-19 pandemic restriction/closure|5
6362804|NCT04009824|10152564|FG003|Overall Study|COVID-19 pandemic restriction/closure|2
6362805|NCT04009824|10152565|FG004|Overall Study|COVID-19 pandemic restriction/closure|3
6362806|NCT03449758|10152587|FG000|Overall Study|Major protocol deviation|1
6362807|NCT03449758|10152587|FG000|Overall Study|Treatment inefficacy|5
6362808|NCT03449758|10152587|FG000|Overall Study|Adverse Event|9
6362809|NCT03449758|10152587|FG000|Overall Study|Consent withdrawal|1
6362810|NCT03449758|10152587|FG000|Overall Study|Other unspecified reason|3
6362811|NCT03222973|10152594|FG000|Part 1 (Week 0 to Week 72)|Adverse Event|3
6362812|NCT03222973|10152595|FG001|Part 1 (Week 0 to Week 72)|Adverse Event|0
6362813|NCT03222973|10152596|FG002|Part 1 (Week 0 to Week 72)|Adverse Event|0
6362814|NCT03222973|10152597|FG003|Part 1 (Week 0 to Week 72)|Adverse Event|0
6362815|NCT03222973|10152594|FG000|Part 1 (Week 0 to Week 72)|Lost to Follow-up|1
6362816|NCT03222973|10152595|FG001|Part 1 (Week 0 to Week 72)|Lost to Follow-up|1
6362817|NCT03222973|10152596|FG002|Part 1 (Week 0 to Week 72)|Lost to Follow-up|0
6362818|NCT03222973|10152597|FG003|Part 1 (Week 0 to Week 72)|Lost to Follow-up|0
6362819|NCT03222973|10152594|FG000|Part 1 (Week 0 to Week 72)|Consent Withdrawn|12
6362820|NCT03222973|10152595|FG001|Part 1 (Week 0 to Week 72)|Consent Withdrawn|9
6362821|NCT03222973|10152596|FG002|Part 1 (Week 0 to Week 72)|Consent Withdrawn|0
6362822|NCT03222973|10152597|FG003|Part 1 (Week 0 to Week 72)|Consent Withdrawn|0
6362823|NCT03222973|10152594|FG000|Part 1 (Week 0 to Week 72)|Death|0
6362824|NCT03222973|10152595|FG001|Part 1 (Week 0 to Week 72)|Death|1
6362825|NCT03222973|10152596|FG002|Part 1 (Week 0 to Week 72)|Death|0
6362826|NCT03222973|10152597|FG003|Part 1 (Week 0 to Week 72)|Death|0
6362827|NCT03222973|10152594|FG000|Part 1 (Week 0 to Week 72)|Pregnancy|0
6362828|NCT03222973|10152595|FG001|Part 1 (Week 0 to Week 72)|Pregnancy|1
6362829|NCT03222973|10152596|FG002|Part 1 (Week 0 to Week 72)|Pregnancy|0
6362830|NCT03222973|10152597|FG003|Part 1 (Week 0 to Week 72)|Pregnancy|0
6362831|NCT03222973|10152594|FG000|Part 1 (Week 0 to Week 72)|Other|8
6362832|NCT03222973|10152595|FG001|Part 1 (Week 0 to Week 72)|Other|2
6362833|NCT03222973|10152596|FG002|Part 1 (Week 0 to Week 72)|Other|0
6362834|NCT03222973|10152597|FG003|Part 1 (Week 0 to Week 72)|Other|0
6362835|NCT03222973|10152594|FG000|Part 2 (Week 73 to Week 168)|Adverse Event|0
6362836|NCT03222973|10152595|FG001|Part 2 (Week 73 to Week 168)|Adverse Event|0
6362837|NCT03222973|10152596|FG002|Part 2 (Week 73 to Week 168)|Adverse Event|2
6362838|NCT03222973|10152597|FG003|Part 2 (Week 73 to Week 168)|Adverse Event|0
6362839|NCT03222973|10152594|FG000|Part 2 (Week 73 to Week 168)|Consent Withdrawn|0
6362840|NCT03222973|10152595|FG001|Part 2 (Week 73 to Week 168)|Consent Withdrawn|0
6362841|NCT03222973|10152596|FG002|Part 2 (Week 73 to Week 168)|Consent Withdrawn|10
6362842|NCT03222973|10152597|FG003|Part 2 (Week 73 to Week 168)|Consent Withdrawn|11
6362843|NCT03222973|10152594|FG000|Part 2 (Week 73 to Week 168)|Investigator Decision|0
6362844|NCT03222973|10152595|FG001|Part 2 (Week 73 to Week 168)|Investigator Decision|0
6362845|NCT03222973|10152596|FG002|Part 2 (Week 73 to Week 168)|Investigator Decision|2
6362846|NCT03222973|10152597|FG003|Part 2 (Week 73 to Week 168)|Investigator Decision|1
6362847|NCT03222973|10152594|FG000|Part 2 (Week 73 to Week 168)|Pregnancy|0
6362848|NCT03222973|10152595|FG001|Part 2 (Week 73 to Week 168)|Pregnancy|0
6362849|NCT03222973|10152596|FG002|Part 2 (Week 73 to Week 168)|Pregnancy|2
6362850|NCT03222973|10152597|FG003|Part 2 (Week 73 to Week 168)|Pregnancy|1
6362851|NCT03222973|10152594|FG000|Part 2 (Week 73 to Week 168)|Other|0
6362852|NCT03222973|10152595|FG001|Part 2 (Week 73 to Week 168)|Other|0
6362853|NCT03222973|10152596|FG002|Part 2 (Week 73 to Week 168)|Other|84
6362854|NCT03222973|10152597|FG003|Part 2 (Week 73 to Week 168)|Other|100
6362855|NCT03222973|10152594|FG000|Part 2 (Week 73 to Week 168)|Participants Not Dosed|0
6171084|NCT01257503|9817715|FG000|Overall Study|strep culture positive at enrollment|1
6171085|NCT01257503|9817716|FG001|Overall Study|strep culture positive at enrollment|0
6171086|NCT01257542|9817724|FG000|Overall Study|Protocol Violation|3
6171087|NCT01257542|9817725|FG001|Overall Study|Protocol Violation|5
6171088|NCT01257542|9817724|FG000|Overall Study|Withdrawal by Subject|0
6171089|NCT01257542|9817725|FG001|Overall Study|Withdrawal by Subject|2
6171090|NCT01257581|9817734|FG000|Overall Study|Early Termination|3
6171091|NCT01257581|9817735|FG001|Overall Study|Early Termination|1
6171092|NCT01257581|9817736|FG002|Overall Study|Early Termination|2
6171093|NCT01257581|9817734|FG000|Overall Study|Death|2
6171094|NCT01257581|9817735|FG001|Overall Study|Death|2
6171095|NCT01257581|9817736|FG002|Overall Study|Death|4
6362856|NCT03222973|10152595|FG001|Part 2 (Week 73 to Week 168)|Participants Not Dosed|0
6362857|NCT03222973|10152596|FG002|Part 2 (Week 73 to Week 168)|Participants Not Dosed|1
6084347|NCT00642616|9693263|FG003|Overall Study|Withdrawal by Subject|1
6171096|NCT01257698|9817746|FG000|Overall Study|Protocol Violation|4
6171097|NCT01257698|9817747|FG001|Overall Study|Protocol Violation|0
6171098|NCT01257737|9817755|FG000|Overall Study|Lost to Follow-up|1
6362858|NCT03222973|10152597|FG003|Part 2 (Week 73 to Week 168)|Participants Not Dosed|0
6362859|NCT03187262|10152607|FG000|Induction|Lack of Efficacy|2
6362860|NCT03187262|10152607|FG000|Induction|Progressive Disease|4
6362861|NCT03187262|10152607|FG000|Consolidation|Progressive Disease|5
6362862|NCT02987959|10152615|FG000|Overall Study|Grantor stopped supply of drugs|6
6362863|NCT02985541|10152619|FG000|Overall Study|Withdrawal by Subject|33
6362864|NCT02985541|10152619|FG000|Overall Study|Lost to Follow-up|26
6362865|NCT02985541|10152619|FG000|Overall Study|Adverse Event|27
6362866|NCT02985541|10152619|FG000|Overall Study|Physician Decision|2
6362867|NCT02985541|10152619|FG000|Overall Study|Pregnancy|2
6362868|NCT02985541|10152619|FG000|Overall Study|Wish for pregnancy|44
6362869|NCT02985541|10152619|FG000|Overall Study|Other reason|5
6362870|NCT02985541|10152619|FG000|Overall Study|Not valid for analysis|2
6362871|NCT02960893|10152625|FG000|Randomization Phase (8-week)|Adverse Event|5
6362872|NCT02960893|10152626|FG001|Randomization Phase (8-week)|Adverse Event|0
6362873|NCT02960893|10152625|FG000|Randomization Phase (8-week)|Withdrawal by Subject|2
6362874|NCT02960893|10152626|FG001|Randomization Phase (8-week)|Withdrawal by Subject|1
6362875|NCT02960893|10152625|FG000|Randomization Phase (8-week)|Reason Not Specified|0
6362876|NCT02960893|10152626|FG001|Randomization Phase (8-week)|Reason Not Specified|1
6362877|NCT02960893|10152625|FG000|Extension Phase (48-week)|Adverse Event|2
6362878|NCT02960893|10152626|FG001|Extension Phase (48-week)|Adverse Event|3
6362879|NCT02960893|10152625|FG000|Extension Phase (48-week)|Withdrawal by Subject|8
6362880|NCT02960893|10152626|FG001|Extension Phase (48-week)|Withdrawal by Subject|8
6362881|NCT02960893|10152625|FG000|Extension Phase (48-week)|Other Reason|2
6362882|NCT02960893|10152626|FG001|Extension Phase (48-week)|Other Reason|1
6362883|NCT02960893|10152625|FG000|Extension Phase (48-week)|Lost to Follow-up|1
6362884|NCT02960893|10152626|FG001|Extension Phase (48-week)|Lost to Follow-up|1
6362885|NCT02960893|10152625|FG000|Extension Phase (48-week)|Sponsors Decision|1
6362886|NCT02960893|10152626|FG001|Extension Phase (48-week)|Sponsors Decision|0
6362887|NCT02940522|10152641|FG000|Overall Study|Lost to Follow-up|1
6362888|NCT02940522|10152642|FG001|Overall Study|Lost to Follow-up|2
6362889|NCT02940522|10152641|FG000|Overall Study|Withdrawal by Subject|1
6362890|NCT02940522|10152642|FG001|Overall Study|Withdrawal by Subject|0
6362891|NCT02711137|10152663|FG000|Overall Study|Death|1
6362892|NCT02711137|10152664|FG001|Overall Study|Death|4
6362893|NCT02711137|10152665|FG002|Overall Study|Death|5
6362894|NCT02711137|10152666|FG003|Overall Study|Death|5
6362895|NCT02711137|10152667|FG004|Overall Study|Death|3
6362896|NCT02711137|10152668|FG005|Overall Study|Death|1
6362897|NCT02711137|10152669|FG006|Overall Study|Death|61
6362898|NCT02711137|10152670|FG007|Overall Study|Death|3
6362899|NCT02711137|10152671|FG008|Overall Study|Death|0
6171099|NCT01257737|9817756|FG001|Overall Study|Lost to Follow-up|2
6171100|NCT01257737|9817755|FG000|Overall Study|Liver transplant|1
6171101|NCT01257737|9817756|FG001|Overall Study|Liver transplant|0
6171102|NCT01257737|9817755|FG000|Overall Study|Relocation out of the country|0
6171103|NCT01257737|9817756|FG001|Overall Study|Relocation out of the country|1
6171104|NCT01257737|9817755|FG000|Overall Study|Withdrew from study|0
6171105|NCT01257737|9817756|FG001|Overall Study|Withdrew from study|1
6171106|NCT01258075|9817798|FG000|Overall Study|Adverse Event|8
6171107|NCT01258075|9817799|FG001|Overall Study|Adverse Event|3
6171108|NCT01258075|9817798|FG000|Overall Study|Lost to Follow-up|11
6171109|NCT01258075|9817799|FG001|Overall Study|Lost to Follow-up|6
6171110|NCT01258075|9817798|FG000|Overall Study|Withdrawal by Subject|10
6171111|NCT01258075|9817799|FG001|Overall Study|Withdrawal by Subject|7
6171112|NCT01258075|9817798|FG000|Overall Study|Hyperglycemia meeting protocol-specified discontinuation criteria|1
6171113|NCT01258075|9817799|FG001|Overall Study|Hyperglycemia meeting protocol-specified discontinuation criteria|2
6171114|NCT01258075|9817798|FG000|Overall Study|Other|12
6171115|NCT01258075|9817799|FG001|Overall Study|Other|5
6171116|NCT01258101|9817809|FG000|Overall Study|Adverse Event|5
6171117|NCT01258101|9817810|FG001|Overall Study|Adverse Event|6
6171118|NCT01258101|9817811|FG002|Overall Study|Adverse Event|0
6171119|NCT01258101|9817812|FG003|Overall Study|Adverse Event|0
6171120|NCT01258101|9817809|FG000|Overall Study|Extra exclusion criterion amended|2
6171121|NCT01258101|9817810|FG001|Overall Study|Extra exclusion criterion amended|1
6171122|NCT01258101|9817811|FG002|Overall Study|Extra exclusion criterion amended|1
6171123|NCT01258101|9817812|FG003|Overall Study|Extra exclusion criterion amended|1
6171124|NCT01258101|9817809|FG000|Overall Study|Informed consent has been withdrawn|2
6171125|NCT01258101|9817810|FG001|Overall Study|Informed consent has been withdrawn|2
6171126|NCT01258101|9817811|FG002|Overall Study|Informed consent has been withdrawn|1
6171127|NCT01258101|9817812|FG003|Overall Study|Informed consent has been withdrawn|1
6171128|NCT01258101|9817809|FG000|Overall Study|Patient is not able to attend visits|8
6171129|NCT01258101|9817810|FG001|Overall Study|Patient is not able to attend visits|9
6362900|NCT02711137|10152672|FG009|Overall Study|Death|1
6362901|NCT02711137|10152673|FG010|Overall Study|Death|1
6362902|NCT02711137|10152674|FG011|Overall Study|Death|1
6362903|NCT02711137|10152675|FG012|Overall Study|Death|0
6362904|NCT02711137|10152676|FG013|Overall Study|Death|0
6362905|NCT02711137|10152677|FG014|Overall Study|Death|0
6362906|NCT02711137|10152663|FG000|Overall Study|Study Terminated by Sponsor|0
6362907|NCT02711137|10152664|FG001|Overall Study|Study Terminated by Sponsor|0
6362908|NCT02711137|10152665|FG002|Overall Study|Study Terminated by Sponsor|1
6362909|NCT02711137|10152666|FG003|Overall Study|Study Terminated by Sponsor|0
6171130|NCT01258101|9817811|FG002|Overall Study|Patient is not able to attend visits|7
6171131|NCT01258101|9817812|FG003|Overall Study|Patient is not able to attend visits|6
6171132|NCT01258101|9817809|FG000|Overall Study|Patient´s compliance|4
6362910|NCT02711137|10152667|FG004|Overall Study|Study Terminated by Sponsor|0
6362911|NCT02711137|10152668|FG005|Overall Study|Study Terminated by Sponsor|0
6362912|NCT02711137|10152669|FG006|Overall Study|Study Terminated by Sponsor|1
6362913|NCT02711137|10152670|FG007|Overall Study|Study Terminated by Sponsor|0
6362914|NCT02711137|10152671|FG008|Overall Study|Study Terminated by Sponsor|0
6362915|NCT02711137|10152672|FG009|Overall Study|Study Terminated by Sponsor|0
6362916|NCT02711137|10152673|FG010|Overall Study|Study Terminated by Sponsor|0
6362917|NCT02711137|10152674|FG011|Overall Study|Study Terminated by Sponsor|0
6362918|NCT02711137|10152675|FG012|Overall Study|Study Terminated by Sponsor|0
6362919|NCT02711137|10152676|FG013|Overall Study|Study Terminated by Sponsor|0
6362920|NCT02711137|10152677|FG014|Overall Study|Study Terminated by Sponsor|0
6362921|NCT02711137|10152663|FG000|Overall Study|Physician Decision|1
6362922|NCT02711137|10152664|FG001|Overall Study|Physician Decision|0
6362923|NCT02711137|10152665|FG002|Overall Study|Physician Decision|2
6362924|NCT02711137|10152666|FG003|Overall Study|Physician Decision|1
6362925|NCT02711137|10152667|FG004|Overall Study|Physician Decision|1
6362926|NCT02711137|10152668|FG005|Overall Study|Physician Decision|0
6362927|NCT02711137|10152669|FG006|Overall Study|Physician Decision|12
6362928|NCT02711137|10152670|FG007|Overall Study|Physician Decision|2
6362929|NCT02711137|10152671|FG008|Overall Study|Physician Decision|1
6362930|NCT02711137|10152672|FG009|Overall Study|Physician Decision|1
6171133|NCT01258101|9817810|FG001|Overall Study|Patient´s compliance|3
6171134|NCT01258101|9817811|FG002|Overall Study|Patient´s compliance|1
6171135|NCT01258101|9817812|FG003|Overall Study|Patient´s compliance|2
6171136|NCT01258101|9817809|FG000|Overall Study|Lost to Follow-up|5
6171137|NCT01258101|9817810|FG001|Overall Study|Lost to Follow-up|5
6171138|NCT01258101|9817811|FG002|Overall Study|Lost to Follow-up|0
6171139|NCT01258101|9817812|FG003|Overall Study|Lost to Follow-up|6
6171140|NCT01258101|9817809|FG000|Overall Study|PCR positive at week 24|0
6171141|NCT01258101|9817810|FG001|Overall Study|PCR positive at week 24|0
6171142|NCT01258101|9817811|FG002|Overall Study|PCR positive at week 24|0
6171143|NCT01258101|9817812|FG003|Overall Study|PCR positive at week 24|1
6171144|NCT01258101|9817809|FG000|Overall Study|Other reason|7
6171145|NCT01258101|9817810|FG001|Overall Study|Other reason|8
6171146|NCT01258101|9817811|FG002|Overall Study|Other reason|1
6171147|NCT01258101|9817812|FG003|Overall Study|Other reason|8
6171148|NCT01258348|9817837|FG000|Overall Study|Adverse Event|1
6171149|NCT01258348|9817838|FG001|Overall Study|Adverse Event|1
6171150|NCT01258348|9817839|FG002|Overall Study|Adverse Event|3
6171151|NCT01258348|9817840|FG003|Overall Study|Adverse Event|2
6171152|NCT01258348|9817841|FG004|Overall Study|Adverse Event|4
6171153|NCT01258348|9817837|FG000|Overall Study|Progressive Disease|0
6171154|NCT01258348|9817838|FG001|Overall Study|Progressive Disease|3
6171155|NCT01258348|9817839|FG002|Overall Study|Progressive Disease|0
6171156|NCT01258348|9817840|FG003|Overall Study|Progressive Disease|2
6362931|NCT02711137|10152673|FG010|Overall Study|Physician Decision|3
6362932|NCT02711137|10152674|FG011|Overall Study|Physician Decision|2
6362933|NCT02711137|10152675|FG012|Overall Study|Physician Decision|1
6362934|NCT02711137|10152676|FG013|Overall Study|Physician Decision|1
6362935|NCT02711137|10152677|FG014|Overall Study|Physician Decision|2
6362936|NCT02711137|10152663|FG000|Overall Study|Other|0
6362937|NCT02711137|10152664|FG001|Overall Study|Other|1
6362938|NCT02711137|10152665|FG002|Overall Study|Other|0
6362939|NCT02711137|10152666|FG003|Overall Study|Other|0
6362940|NCT02711137|10152667|FG004|Overall Study|Other|0
6171157|NCT01258348|9817841|FG004|Overall Study|Progressive Disease|2
6171158|NCT01258348|9817837|FG000|Overall Study|Physician Decision|0
6171159|NCT01258348|9817838|FG001|Overall Study|Physician Decision|0
6171160|NCT01258348|9817839|FG002|Overall Study|Physician Decision|0
6171161|NCT01258348|9817840|FG003|Overall Study|Physician Decision|2
6171162|NCT01258348|9817841|FG004|Overall Study|Physician Decision|0
6171163|NCT01258348|9817837|FG000|Overall Study|Withdrawal by Subject|0
6171164|NCT01258348|9817838|FG001|Overall Study|Withdrawal by Subject|1
6171165|NCT01258348|9817839|FG002|Overall Study|Withdrawal by Subject|0
6171166|NCT01258348|9817840|FG003|Overall Study|Withdrawal by Subject|0
6171167|NCT01258348|9817841|FG004|Overall Study|Withdrawal by Subject|0
6171168|NCT01258595|9817912|FG000|Overall Study|Lost to Follow-up|1
6171169|NCT01258595|9817913|FG001|Overall Study|Lost to Follow-up|0
6171170|NCT01258595|9817912|FG000|Overall Study|Withdrawal by Subject|0
6171171|NCT01258595|9817913|FG001|Overall Study|Withdrawal by Subject|1
6171172|NCT01258608|9817921|FG000|Overall Study|Metastatic Hepatocellular Carcinoma|1
6171173|NCT01258608|9817922|FG001|Overall Study|Metastatic Hepatocellular Carcinoma|0
6171174|NCT01258608|9817921|FG000|Overall Study|Clinical progression|1
6171175|NCT01258608|9817922|FG001|Overall Study|Clinical progression|0
6362941|NCT02711137|10152668|FG005|Overall Study|Other|0
6362942|NCT02711137|10152669|FG006|Overall Study|Other|3
6362943|NCT02711137|10152670|FG007|Overall Study|Other|0
6171176|NCT01258608|9817921|FG000|Overall Study|Sponsor decision|0
6171177|NCT01258608|9817922|FG001|Overall Study|Sponsor decision|1
6171178|NCT01258608|9817921|FG000|Overall Study|Physician Decision|6
6171179|NCT01258608|9817922|FG001|Overall Study|Physician Decision|1
6171180|NCT01258608|9817921|FG000|Overall Study|Lost to Follow-up|0
6171181|NCT01258608|9817922|FG001|Overall Study|Lost to Follow-up|1
6362944|NCT02711137|10152671|FG008|Overall Study|Other|0
6362945|NCT02711137|10152672|FG009|Overall Study|Other|0
6171182|NCT01258608|9817921|FG000|Overall Study|Lack of compliance|1
6362946|NCT02711137|10152673|FG010|Overall Study|Other|0
6362947|NCT02711137|10152674|FG011|Overall Study|Other|0
6362948|NCT02711137|10152675|FG012|Overall Study|Other|0
6362949|NCT02711137|10152676|FG013|Overall Study|Other|0
6362950|NCT02711137|10152677|FG014|Overall Study|Other|1
6362951|NCT02711137|10152663|FG000|Overall Study|Withdrawal by Subject|1
6362952|NCT02711137|10152664|FG001|Overall Study|Withdrawal by Subject|0
6362953|NCT02711137|10152665|FG002|Overall Study|Withdrawal by Subject|0
6362954|NCT02711137|10152666|FG003|Overall Study|Withdrawal by Subject|1
6362955|NCT02711137|10152667|FG004|Overall Study|Withdrawal by Subject|1
6362956|NCT02711137|10152668|FG005|Overall Study|Withdrawal by Subject|0
6362957|NCT02711137|10152669|FG006|Overall Study|Withdrawal by Subject|7
6362958|NCT02711137|10152670|FG007|Overall Study|Withdrawal by Subject|0
6362959|NCT02711137|10152671|FG008|Overall Study|Withdrawal by Subject|0
6171183|NCT01258608|9817922|FG001|Overall Study|Lack of compliance|0
6171184|NCT01258608|9817921|FG000|Overall Study|Lack of Efficacy|0
6171185|NCT01258608|9817922|FG001|Overall Study|Lack of Efficacy|1
6171186|NCT01258608|9817921|FG000|Overall Study|Adverse Event|6
6171187|NCT01258608|9817922|FG001|Overall Study|Adverse Event|10
6171188|NCT01258608|9817921|FG000|Overall Study|Withdrawal by Subject|6
6171189|NCT01258608|9817922|FG001|Overall Study|Withdrawal by Subject|5
6171190|NCT01258660|9817931|FG000|Overall Study|Adverse Event|2
6171191|NCT01258660|9817932|FG001|Overall Study|Adverse Event|4
6171192|NCT01258660|9817931|FG000|Overall Study|Withdrawal by Subject|3
6171193|NCT01258660|9817932|FG001|Overall Study|Withdrawal by Subject|0
6171194|NCT01258660|9817931|FG000|Overall Study|due to relocation|2
6171195|NCT01258660|9817932|FG001|Overall Study|due to relocation|0
6171196|NCT01258660|9817931|FG000|Overall Study|Protocol Violation|0
6171197|NCT01258660|9817932|FG001|Overall Study|Protocol Violation|1
6171198|NCT01258660|9817931|FG000|Overall Study|Invalid for primary analysis data set|4
6171199|NCT01258660|9817932|FG001|Overall Study|Invalid for primary analysis data set|6
6171200|NCT01258738|9817941|FG000|Double-blind Period|Did not meet inclusion criteria|3
6171201|NCT01258738|9817942|FG001|Double-blind Period|Did not meet inclusion criteria|3
6171202|NCT01258738|9817941|FG000|Double-blind Period|Withdrawal by Subject|2
6171203|NCT01258738|9817942|FG001|Double-blind Period|Withdrawal by Subject|2
6171204|NCT01258738|9817941|FG000|Double-blind Period|Protocol Violation|1
6171205|NCT01258738|9817942|FG001|Double-blind Period|Protocol Violation|1
6171206|NCT01258738|9817941|FG000|Double-blind Period|Adverse Event|3
6171207|NCT01258738|9817942|FG001|Double-blind Period|Adverse Event|1
6171208|NCT01258738|9817941|FG000|Open-label Period|Did not meet inclusion criteria|0
6171209|NCT01258738|9817942|FG001|Open-label Period|Did not meet inclusion criteria|1
6171210|NCT01258738|9817941|FG000|Open-label Period|Insufficient clinical response|5
6171211|NCT01258738|9817942|FG001|Open-label Period|Insufficient clinical response|3
6171212|NCT01258738|9817941|FG000|Open-label Period|Lost to Follow-up|0
6171213|NCT01258738|9817942|FG001|Open-label Period|Lost to Follow-up|2
6171214|NCT01258738|9817941|FG000|Open-label Period|Withdrawal by Subject|5
6171215|NCT01258738|9817942|FG001|Open-label Period|Withdrawal by Subject|6
6171216|NCT01258738|9817941|FG000|Open-label Period|Protocol Violation|2
6171217|NCT01258738|9817942|FG001|Open-label Period|Protocol Violation|2
6171218|NCT01258738|9817941|FG000|Open-label Period|Adverse Event|4
6171219|NCT01258738|9817942|FG001|Open-label Period|Adverse Event|5
6171220|NCT01258738|9817941|FG000|Open-label Period|Other Reasons|0
6171221|NCT01258738|9817942|FG001|Open-label Period|Other Reasons|1
6171222|NCT01258738|9817941|FG000|Open-label Period|Withdrawn due to pregnancy|1
6171223|NCT01258738|9817942|FG001|Open-label Period|Withdrawn due to pregnancy|1
6171224|NCT01258998|9817975|FG000|Overall Study|Ineligible|1
6171225|NCT01259089|9817994|FG000|Reached First Response at 4 Weeks|Patient not treated on study|0
6171226|NCT01259089|9817995|FG001|Reached First Response at 4 Weeks|Patient not treated on study|0
6171227|NCT01259089|9817996|FG002|Reached First Response at 4 Weeks|Patient not treated on study|0
6171228|NCT01259089|9817997|FG003|Reached First Response at 4 Weeks|Patient not treated on study|0
6171229|NCT01259089|9817998|FG004|Reached First Response at 4 Weeks|Patient not treated on study|0
6171230|NCT01259089|9817999|FG005|Reached First Response at 4 Weeks|Patient not treated on study|1
6171231|NCT01259089|9817994|FG000|Reached First Response at 4 Weeks|Adverse Event|0
6171232|NCT01259089|9817995|FG001|Reached First Response at 4 Weeks|Adverse Event|0
6171233|NCT01259089|9817996|FG002|Reached First Response at 4 Weeks|Adverse Event|0
6171234|NCT01259089|9817997|FG003|Reached First Response at 4 Weeks|Adverse Event|0
6171235|NCT01259089|9817998|FG004|Reached First Response at 4 Weeks|Adverse Event|0
6171236|NCT01259089|9817999|FG005|Reached First Response at 4 Weeks|Adverse Event|1
6171237|NCT01259089|9817994|FG000|Confirmed Response at 8 Weeks|Withdrawal by Subject|0
6171238|NCT01259089|9817995|FG001|Confirmed Response at 8 Weeks|Withdrawal by Subject|0
6171239|NCT01259089|9817996|FG002|Confirmed Response at 8 Weeks|Withdrawal by Subject|0
6171240|NCT01259089|9817997|FG003|Confirmed Response at 8 Weeks|Withdrawal by Subject|0
6171241|NCT01259089|9817998|FG004|Confirmed Response at 8 Weeks|Withdrawal by Subject|0
6171242|NCT01259089|9817999|FG005|Confirmed Response at 8 Weeks|Withdrawal by Subject|1
6171243|NCT01259089|9817994|FG000|Confirmed Response at 8 Weeks|Adverse Event|0
6171244|NCT01259089|9817995|FG001|Confirmed Response at 8 Weeks|Adverse Event|0
6171245|NCT01259089|9817996|FG002|Confirmed Response at 8 Weeks|Adverse Event|0
6362960|NCT02711137|10152672|FG009|Overall Study|Withdrawal by Subject|0
6362961|NCT02711137|10152673|FG010|Overall Study|Withdrawal by Subject|0
6362962|NCT02711137|10152674|FG011|Overall Study|Withdrawal by Subject|0
6362963|NCT02711137|10152675|FG012|Overall Study|Withdrawal by Subject|0
6362964|NCT02711137|10152676|FG013|Overall Study|Withdrawal by Subject|1
6362965|NCT02711137|10152677|FG014|Overall Study|Withdrawal by Subject|0
6084348|NCT00642616|9693260|FG000|Overall Study|Protocol Violation|0
6171246|NCT01259089|9817997|FG003|Confirmed Response at 8 Weeks|Adverse Event|0
6171247|NCT01259089|9817998|FG004|Confirmed Response at 8 Weeks|Adverse Event|1
6171248|NCT01259089|9817999|FG005|Confirmed Response at 8 Weeks|Adverse Event|2
6171249|NCT01259089|9817994|FG000|Confirmed Response at 8 Weeks|Progressive disease|0
6171250|NCT01259089|9817995|FG001|Confirmed Response at 8 Weeks|Progressive disease|0
6171251|NCT01259089|9817996|FG002|Confirmed Response at 8 Weeks|Progressive disease|1
6171252|NCT01259089|9817997|FG003|Confirmed Response at 8 Weeks|Progressive disease|1
6171253|NCT01259089|9817998|FG004|Confirmed Response at 8 Weeks|Progressive disease|3
6171254|NCT01259089|9817999|FG005|Confirmed Response at 8 Weeks|Progressive disease|7
6171255|NCT01259089|9817994|FG000|Continued Treatment After 8 Weeks|Withdrawal by Subject|1
6171256|NCT01259089|9817995|FG001|Continued Treatment After 8 Weeks|Withdrawal by Subject|0
6171257|NCT01259089|9817996|FG002|Continued Treatment After 8 Weeks|Withdrawal by Subject|0
6171258|NCT01259089|9817997|FG003|Continued Treatment After 8 Weeks|Withdrawal by Subject|0
6171259|NCT01259089|9817998|FG004|Continued Treatment After 8 Weeks|Withdrawal by Subject|0
6171260|NCT01259089|9817999|FG005|Continued Treatment After 8 Weeks|Withdrawal by Subject|0
6171261|NCT01259089|9817994|FG000|Continued Treatment After 8 Weeks|Adverse Event|0
6171262|NCT01259089|9817995|FG001|Continued Treatment After 8 Weeks|Adverse Event|0
6171263|NCT01259089|9817996|FG002|Continued Treatment After 8 Weeks|Adverse Event|0
6171264|NCT01259089|9817997|FG003|Continued Treatment After 8 Weeks|Adverse Event|0
6171265|NCT01259089|9817998|FG004|Continued Treatment After 8 Weeks|Adverse Event|2
6171266|NCT01259089|9817999|FG005|Continued Treatment After 8 Weeks|Adverse Event|1
6171267|NCT01259089|9817994|FG000|Continued Treatment After 8 Weeks|Progressive disease|1
6171268|NCT01259089|9817995|FG001|Continued Treatment After 8 Weeks|Progressive disease|1
6171269|NCT01259089|9817996|FG002|Continued Treatment After 8 Weeks|Progressive disease|1
6171270|NCT01259089|9817997|FG003|Continued Treatment After 8 Weeks|Progressive disease|1
6171271|NCT01259089|9817998|FG004|Continued Treatment After 8 Weeks|Progressive disease|0
6171272|NCT01259089|9817999|FG005|Continued Treatment After 8 Weeks|Progressive disease|0
6171273|NCT01259089|9817994|FG000|Survival Follow up for Two Years|Death|3
6171274|NCT01259089|9817995|FG001|Survival Follow up for Two Years|Death|2
6171275|NCT01259089|9817996|FG002|Survival Follow up for Two Years|Death|2
6171276|NCT01259089|9817997|FG003|Survival Follow up for Two Years|Death|3
6171277|NCT01259089|9817998|FG004|Survival Follow up for Two Years|Death|6
6171278|NCT01259089|9817999|FG005|Survival Follow up for Two Years|Death|13
6171279|NCT01259089|9817994|FG000|Survival Follow up for Two Years|Lost to Follow-up|0
6171280|NCT01259089|9817995|FG001|Survival Follow up for Two Years|Lost to Follow-up|0
6171281|NCT01259089|9817996|FG002|Survival Follow up for Two Years|Lost to Follow-up|0
6171282|NCT01259089|9817997|FG003|Survival Follow up for Two Years|Lost to Follow-up|0
6084349|NCT00642616|9693261|FG001|Overall Study|Protocol Violation|0
6084350|NCT00642616|9693262|FG002|Overall Study|Protocol Violation|2
6084351|NCT00642616|9693263|FG003|Overall Study|Protocol Violation|0
6084352|NCT00642616|9693260|FG000|Overall Study|Physician Decision|0
6084353|NCT00642616|9693261|FG001|Overall Study|Physician Decision|0
6084354|NCT00642616|9693262|FG002|Overall Study|Physician Decision|1
6084355|NCT00642616|9693263|FG003|Overall Study|Physician Decision|1
6084356|NCT00642642|9693275|FG000|Treatment & Follow Up|Adverse Event|2
6084357|NCT00642642|9693275|FG000|Treatment & Follow Up|Withdrawal by Subject|5
6084358|NCT00642642|9693275|FG000|Treatment & Follow Up|Lost to Follow-up|10
6084359|NCT00642668|9693285|FG000|Overall Study|Lost to Follow-up|1
6084360|NCT00642668|9693285|FG000|Overall Study|Adverse Event|2
6362966|NCT02711137|10152663|FG000|Overall Study|Lost to Follow-up|1
6362967|NCT02711137|10152664|FG001|Overall Study|Lost to Follow-up|0
6362968|NCT02711137|10152665|FG002|Overall Study|Lost to Follow-up|0
6362969|NCT02711137|10152666|FG003|Overall Study|Lost to Follow-up|0
6362970|NCT02711137|10152667|FG004|Overall Study|Lost to Follow-up|0
6084361|NCT00642668|9693285|FG000|Overall Study|Death|2
6171283|NCT01259089|9817998|FG004|Survival Follow up for Two Years|Lost to Follow-up|0
6171284|NCT01259089|9817999|FG005|Survival Follow up for Two Years|Lost to Follow-up|2
6171285|NCT01259089|9817994|FG000|Survival Follow up for Two Years|stopped being followed as study closed|0
6171286|NCT01259089|9817995|FG001|Survival Follow up for Two Years|stopped being followed as study closed|0
6171287|NCT01259089|9817996|FG002|Survival Follow up for Two Years|stopped being followed as study closed|0
6171288|NCT01259089|9817997|FG003|Survival Follow up for Two Years|stopped being followed as study closed|0
6171289|NCT01259089|9817998|FG004|Survival Follow up for Two Years|stopped being followed as study closed|0
6171290|NCT01259089|9817999|FG005|Survival Follow up for Two Years|stopped being followed as study closed|4
6171291|NCT01259102|9818018|FG000|Overall Study|Adverse Event|1
6171292|NCT01259102|9818019|FG001|Overall Study|Adverse Event|0
6171293|NCT01259102|9818020|FG002|Overall Study|Adverse Event|1
6171294|NCT01259102|9818021|FG003|Overall Study|Adverse Event|1
6171295|NCT01259102|9818022|FG004|Overall Study|Adverse Event|0
6171296|NCT01259102|9818018|FG000|Overall Study|Other|0
6084362|NCT00642668|9693285|FG000|Overall Study|Insufficient Therapeutic Response|1
6084363|NCT00642668|9693285|FG000|Overall Study|Failure to Return|1
6084364|NCT00642668|9693285|FG000|Overall Study|Dialysis Initiation|5
6362971|NCT02711137|10152668|FG005|Overall Study|Lost to Follow-up|0
6362972|NCT02711137|10152669|FG006|Overall Study|Lost to Follow-up|2
6362973|NCT02711137|10152670|FG007|Overall Study|Lost to Follow-up|0
6362974|NCT02711137|10152671|FG008|Overall Study|Lost to Follow-up|0
6362975|NCT02711137|10152672|FG009|Overall Study|Lost to Follow-up|0
6362976|NCT02711137|10152673|FG010|Overall Study|Lost to Follow-up|0
6362977|NCT02711137|10152674|FG011|Overall Study|Lost to Follow-up|0
6362978|NCT02711137|10152675|FG012|Overall Study|Lost to Follow-up|0
6362979|NCT02711137|10152676|FG013|Overall Study|Lost to Follow-up|0
6362980|NCT02711137|10152677|FG014|Overall Study|Lost to Follow-up|0
6362981|NCT02630459|10152718|FG000|Double-Blind Treatment Phase (DBTP)|Protocol-specified criteria|0
6362982|NCT02630459|10152719|FG001|Double-Blind Treatment Phase (DBTP)|Protocol-specified criteria|1
6362983|NCT02630459|10152720|FG002|Double-Blind Treatment Phase (DBTP)|Protocol-specified criteria|0
6362984|NCT02630459|10152721|FG003|Double-Blind Treatment Phase (DBTP)|Protocol-specified criteria|2
6362985|NCT02630459|10152722|FG004|Double-Blind Treatment Phase (DBTP)|Protocol-specified criteria|0
6362986|NCT02630459|10152723|FG005|Double-Blind Treatment Phase (DBTP)|Protocol-specified criteria|0
6362987|NCT02630459|10152724|FG006|Double-Blind Treatment Phase (DBTP)|Protocol-specified criteria|0
6362988|NCT02630459|10152725|FG007|Double-Blind Treatment Phase (DBTP)|Protocol-specified criteria|0
6084365|NCT00642668|9693285|FG000|Overall Study|Blood Transfusion|2
6171297|NCT01259102|9818019|FG001|Overall Study|Other|0
6171298|NCT01259102|9818020|FG002|Overall Study|Other|1
6171299|NCT01259102|9818021|FG003|Overall Study|Other|1
6171300|NCT01259102|9818022|FG004|Overall Study|Other|1
6171301|NCT01259115|9818034|FG000|Period 1|Adverse Event|1
6171302|NCT01259115|9818035|FG001|Period 1|Adverse Event|0
6171303|NCT01259115|9818034|FG000|Period 1|Protocol Violation|2
6171304|NCT01259115|9818035|FG001|Period 1|Protocol Violation|0
6171305|NCT01259115|9818034|FG000|Period 1|Lost to Follow-up|0
6171306|NCT01259115|9818035|FG001|Period 1|Lost to Follow-up|1
6171307|NCT01259115|9818034|FG000|Period 2|Adverse Event|1
6171308|NCT01259115|9818035|FG001|Period 2|Adverse Event|0
6171309|NCT01259245|9818057|FG000|Overall Study|Withdrawal by Subject|27
6171310|NCT01259245|9818058|FG001|Overall Study|Withdrawal by Subject|24
6171311|NCT01259245|9818057|FG000|Overall Study|Death|1
6171312|NCT01259245|9818058|FG001|Overall Study|Death|2
6171313|NCT01259297|9818074|FG000|Double Blind Randomized Period|Death|1
6171314|NCT01259297|9818075|FG001|Double Blind Randomized Period|Death|1
6171315|NCT01259297|9818076|FG002|Double Blind Randomized Period|Death|1
6171316|NCT01259297|9818077|FG003|Double Blind Randomized Period|Death|2
6171317|NCT01259297|9818078|FG004|Double Blind Randomized Period|Death|1
6171318|NCT01259297|9818079|FG005|Double Blind Randomized Period|Death|5
6171319|NCT01259297|9818080|FG006|Double Blind Randomized Period|Death|2
6171320|NCT01259297|9818081|FG007|Double Blind Randomized Period|Death|1
6171321|NCT01259297|9818074|FG000|Double Blind Randomized Period|Withdrew informed consent/ refused visit|1
6171322|NCT01259297|9818075|FG001|Double Blind Randomized Period|Withdrew informed consent/ refused visit|1
6171323|NCT01259297|9818076|FG002|Double Blind Randomized Period|Withdrew informed consent/ refused visit|0
6171324|NCT01259297|9818077|FG003|Double Blind Randomized Period|Withdrew informed consent/ refused visit|2
6171325|NCT01259297|9818078|FG004|Double Blind Randomized Period|Withdrew informed consent/ refused visit|2
6171326|NCT01259297|9818079|FG005|Double Blind Randomized Period|Withdrew informed consent/ refused visit|1
6171327|NCT01259297|9818080|FG006|Double Blind Randomized Period|Withdrew informed consent/ refused visit|1
6171328|NCT01259297|9818081|FG007|Double Blind Randomized Period|Withdrew informed consent/ refused visit|1
6171329|NCT01259297|9818074|FG000|Double Blind Randomized Period|Other reasons|0
6171330|NCT01259297|9818075|FG001|Double Blind Randomized Period|Other reasons|1
6171331|NCT01259297|9818076|FG002|Double Blind Randomized Period|Other reasons|0
6171332|NCT01259297|9818077|FG003|Double Blind Randomized Period|Other reasons|0
6171333|NCT01259297|9818078|FG004|Double Blind Randomized Period|Other reasons|1
6171334|NCT01259297|9818079|FG005|Double Blind Randomized Period|Other reasons|2
6171335|NCT01259297|9818080|FG006|Double Blind Randomized Period|Other reasons|3
6171336|NCT01259297|9818081|FG007|Double Blind Randomized Period|Other reasons|1
6171337|NCT01259375|9818098|FG000|Overall Study|Adverse Event|1
6171338|NCT01259388|9818106|FG000|Overall Study|Adverse Event|3
6171339|NCT01259388|9818107|FG001|Overall Study|Adverse Event|0
6171340|NCT01259388|9818106|FG000|Overall Study|Withdrawal by Subject|1
6171341|NCT01259388|9818107|FG001|Overall Study|Withdrawal by Subject|1
6171342|NCT01259388|9818106|FG000|Overall Study|Physician Decision|1
6171343|NCT01259388|9818107|FG001|Overall Study|Physician Decision|0
6171344|NCT01259401|9818115|FG000|4-month Follow-up|Death|0
6171345|NCT01259401|9818116|FG001|4-month Follow-up|Death|1
6171346|NCT01259401|9818115|FG000|4-month Follow-up|Lost to Follow-up|0
6171347|NCT01259401|9818116|FG001|4-month Follow-up|Lost to Follow-up|1
6171348|NCT01259466|9818143|FG000|Overall Study|Withdrawal by Subject|1
6171349|NCT01259466|9818144|FG001|Overall Study|Withdrawal by Subject|9
6171350|NCT01259492|9818154|FG000|Period 1 (9 Weeks)|Adverse Event|13
6171351|NCT01259492|9818155|FG001|Period 1 (9 Weeks)|Adverse Event|18
6171352|NCT01259492|9818156|FG002|Period 1 (9 Weeks)|Adverse Event|26
6362989|NCT02630459|10152718|FG000|Double-Blind Treatment Phase (DBTP)|Sponsor decision|0
6362990|NCT02630459|10152719|FG001|Double-Blind Treatment Phase (DBTP)|Sponsor decision|0
6362991|NCT02630459|10152720|FG002|Double-Blind Treatment Phase (DBTP)|Sponsor decision|1
6362992|NCT02630459|10152721|FG003|Double-Blind Treatment Phase (DBTP)|Sponsor decision|0
6362993|NCT02630459|10152722|FG004|Double-Blind Treatment Phase (DBTP)|Sponsor decision|0
6362994|NCT02630459|10152723|FG005|Double-Blind Treatment Phase (DBTP)|Sponsor decision|0
6362995|NCT02630459|10152724|FG006|Double-Blind Treatment Phase (DBTP)|Sponsor decision|0
6362996|NCT02630459|10152725|FG007|Double-Blind Treatment Phase (DBTP)|Sponsor decision|0
6362997|NCT02630459|10152718|FG000|Double-Blind Treatment Phase (DBTP)|Withdrawal by Subject|2
6362998|NCT02630459|10152719|FG001|Double-Blind Treatment Phase (DBTP)|Withdrawal by Subject|1
6362999|NCT02630459|10152720|FG002|Double-Blind Treatment Phase (DBTP)|Withdrawal by Subject|4
6363000|NCT02630459|10152721|FG003|Double-Blind Treatment Phase (DBTP)|Withdrawal by Subject|1
6363001|NCT02630459|10152722|FG004|Double-Blind Treatment Phase (DBTP)|Withdrawal by Subject|0
6363002|NCT02630459|10152723|FG005|Double-Blind Treatment Phase (DBTP)|Withdrawal by Subject|0
6363003|NCT02630459|10152724|FG006|Double-Blind Treatment Phase (DBTP)|Withdrawal by Subject|0
6363004|NCT02630459|10152725|FG007|Double-Blind Treatment Phase (DBTP)|Withdrawal by Subject|0
6363005|NCT02630459|10152718|FG000|Double-Blind Treatment Phase (DBTP)|Subject missed week 24 assessment|1
6363006|NCT02630459|10152719|FG001|Double-Blind Treatment Phase (DBTP)|Subject missed week 24 assessment|0
6363007|NCT02630459|10152720|FG002|Double-Blind Treatment Phase (DBTP)|Subject missed week 24 assessment|0
6363008|NCT02630459|10152721|FG003|Double-Blind Treatment Phase (DBTP)|Subject missed week 24 assessment|0
6363009|NCT02630459|10152722|FG004|Double-Blind Treatment Phase (DBTP)|Subject missed week 24 assessment|0
6363010|NCT02630459|10152723|FG005|Double-Blind Treatment Phase (DBTP)|Subject missed week 24 assessment|0
6363011|NCT02630459|10152724|FG006|Double-Blind Treatment Phase (DBTP)|Subject missed week 24 assessment|0
6363012|NCT02630459|10152725|FG007|Double-Blind Treatment Phase (DBTP)|Subject missed week 24 assessment|0
6363013|NCT02630459|10152718|FG000|Open-Label Treatment Phase (OLTP)|Protocol-Specified Criteria|0
6363014|NCT02630459|10152719|FG001|Open-Label Treatment Phase (OLTP)|Protocol-Specified Criteria|0
6363015|NCT02630459|10152720|FG002|Open-Label Treatment Phase (OLTP)|Protocol-Specified Criteria|0
6363016|NCT02630459|10152721|FG003|Open-Label Treatment Phase (OLTP)|Protocol-Specified Criteria|0
6363017|NCT02630459|10152722|FG004|Open-Label Treatment Phase (OLTP)|Protocol-Specified Criteria|4
6363018|NCT02630459|10152723|FG005|Open-Label Treatment Phase (OLTP)|Protocol-Specified Criteria|1
6363019|NCT02630459|10152724|FG006|Open-Label Treatment Phase (OLTP)|Protocol-Specified Criteria|0
6363020|NCT02630459|10152725|FG007|Open-Label Treatment Phase (OLTP)|Protocol-Specified Criteria|0
6363021|NCT02630459|10152718|FG000|Open-Label Treatment Phase (OLTP)|Subject Request|0
6363022|NCT02630459|10152719|FG001|Open-Label Treatment Phase (OLTP)|Subject Request|0
6363023|NCT02630459|10152720|FG002|Open-Label Treatment Phase (OLTP)|Subject Request|0
6363024|NCT02630459|10152721|FG003|Open-Label Treatment Phase (OLTP)|Subject Request|0
6363025|NCT02630459|10152722|FG004|Open-Label Treatment Phase (OLTP)|Subject Request|24
6363026|NCT02630459|10152723|FG005|Open-Label Treatment Phase (OLTP)|Subject Request|3
6363027|NCT02630459|10152724|FG006|Open-Label Treatment Phase (OLTP)|Subject Request|0
6363028|NCT02630459|10152725|FG007|Open-Label Treatment Phase (OLTP)|Subject Request|0
6363029|NCT02630459|10152718|FG000|Open-Label Treatment Phase (OLTP)|Decision by Sponsor|0
6363030|NCT02630459|10152719|FG001|Open-Label Treatment Phase (OLTP)|Decision by Sponsor|0
6363031|NCT02630459|10152720|FG002|Open-Label Treatment Phase (OLTP)|Decision by Sponsor|0
6363032|NCT02630459|10152721|FG003|Open-Label Treatment Phase (OLTP)|Decision by Sponsor|0
6363033|NCT02630459|10152722|FG004|Open-Label Treatment Phase (OLTP)|Decision by Sponsor|1
6363034|NCT02630459|10152723|FG005|Open-Label Treatment Phase (OLTP)|Decision by Sponsor|0
6363035|NCT02630459|10152724|FG006|Open-Label Treatment Phase (OLTP)|Decision by Sponsor|0
6363036|NCT02630459|10152725|FG007|Open-Label Treatment Phase (OLTP)|Decision by Sponsor|0
6363037|NCT02545868|10152775|FG000|Optional Ocrelizumab Ext (OOE) Period|OOE period ongoing|33
6363038|NCT02545868|10152776|FG001|Optional Ocrelizumab Ext (OOE) Period|OOE period ongoing|35
6363039|NCT02545868|10152777|FG002|Optional Ocrelizumab Ext (OOE) Period|OOE period ongoing|34
6363040|NCT02470091|10152792|FG000|Overall Study|Withdrawal by Subject|1
6363041|NCT02470091|10152793|FG001|Overall Study|Withdrawal by Subject|0
6363042|NCT02470091|10152792|FG000|Overall Study|Ineligible|0
6363043|NCT02470091|10152793|FG001|Overall Study|Ineligible|2
6363044|NCT02440425|10152801|FG000|Overall Study|Death likely due to disease progression|1
6363045|NCT02440425|10152801|FG000|Overall Study|Withdrawal by Subject|2
6363046|NCT02440425|10152801|FG000|Overall Study|Adverse Event|1
6363047|NCT02440425|10152801|FG000|Overall Study|Adverse Event/Ineligible|1
6363048|NCT02343120|10152810|FG000|Part 1: Dose Escalation|Sponsor decision|1
6171353|NCT01259492|9818157|FG003|Period 1 (9 Weeks)|Adverse Event|3
6171354|NCT01259492|9818154|FG000|Period 1 (9 Weeks)|Lack of Efficacy|2
6171355|NCT01259492|9818155|FG001|Period 1 (9 Weeks)|Lack of Efficacy|2
6171356|NCT01259492|9818156|FG002|Period 1 (9 Weeks)|Lack of Efficacy|4
6171357|NCT01259492|9818157|FG003|Period 1 (9 Weeks)|Lack of Efficacy|11
6171358|NCT01259492|9818154|FG000|Period 1 (9 Weeks)|Withdrawal by Subject|5
6171359|NCT01259492|9818155|FG001|Period 1 (9 Weeks)|Withdrawal by Subject|8
6171360|NCT01259492|9818156|FG002|Period 1 (9 Weeks)|Withdrawal by Subject|6
6171361|NCT01259492|9818157|FG003|Period 1 (9 Weeks)|Withdrawal by Subject|7
6171362|NCT01259492|9818154|FG000|Period 1 (9 Weeks)|Lost to Follow-up|4
6171363|NCT01259492|9818155|FG001|Period 1 (9 Weeks)|Lost to Follow-up|6
6171364|NCT01259492|9818156|FG002|Period 1 (9 Weeks)|Lost to Follow-up|3
6171365|NCT01259492|9818157|FG003|Period 1 (9 Weeks)|Lost to Follow-up|4
6171366|NCT01259492|9818154|FG000|Period 1 (9 Weeks)|Administrative Problems|0
6171367|NCT01259492|9818155|FG001|Period 1 (9 Weeks)|Administrative Problems|1
6363049|NCT02343120|10152811|FG001|Part 1: Dose Escalation|Sponsor decision|2
6363050|NCT02343120|10152812|FG002|Part 1: Dose Escalation|Sponsor decision|3
6171368|NCT01259492|9818156|FG002|Period 1 (9 Weeks)|Administrative Problems|1
6171369|NCT01259492|9818157|FG003|Period 1 (9 Weeks)|Administrative Problems|2
6171370|NCT01259492|9818154|FG000|Period 1 (9 Weeks)|Protocol Violation|5
6171371|NCT01259492|9818155|FG001|Period 1 (9 Weeks)|Protocol Violation|6
6171372|NCT01259492|9818156|FG002|Period 1 (9 Weeks)|Protocol Violation|3
6171373|NCT01259492|9818157|FG003|Period 1 (9 Weeks)|Protocol Violation|1
6171374|NCT01259492|9818154|FG000|Period 2 (Week 10 to Week 14)|Adverse Event|3
6171375|NCT01259492|9818155|FG001|Period 2 (Week 10 to Week 14)|Adverse Event|4
6171376|NCT01259492|9818156|FG002|Period 2 (Week 10 to Week 14)|Adverse Event|7
6171377|NCT01259492|9818157|FG003|Period 2 (Week 10 to Week 14)|Adverse Event|8
6171378|NCT01259492|9818154|FG000|Period 2 (Week 10 to Week 14)|Lack of Efficacy|13
6171379|NCT01259492|9818155|FG001|Period 2 (Week 10 to Week 14)|Lack of Efficacy|7
6171380|NCT01259492|9818156|FG002|Period 2 (Week 10 to Week 14)|Lack of Efficacy|7
6171381|NCT01259492|9818157|FG003|Period 2 (Week 10 to Week 14)|Lack of Efficacy|13
6171382|NCT01259492|9818154|FG000|Period 2 (Week 10 to Week 14)|Withdrawal by Subject|6
6171383|NCT01259492|9818155|FG001|Period 2 (Week 10 to Week 14)|Withdrawal by Subject|2
6171384|NCT01259492|9818156|FG002|Period 2 (Week 10 to Week 14)|Withdrawal by Subject|8
6171385|NCT01259492|9818157|FG003|Period 2 (Week 10 to Week 14)|Withdrawal by Subject|4
6171386|NCT01259492|9818154|FG000|Period 2 (Week 10 to Week 14)|Lost to Follow-up|3
6171387|NCT01259492|9818155|FG001|Period 2 (Week 10 to Week 14)|Lost to Follow-up|3
6171388|NCT01259492|9818156|FG002|Period 2 (Week 10 to Week 14)|Lost to Follow-up|1
6171389|NCT01259492|9818157|FG003|Period 2 (Week 10 to Week 14)|Lost to Follow-up|3
6171390|NCT01259492|9818154|FG000|Period 2 (Week 10 to Week 14)|Protocol Violation|0
6171391|NCT01259492|9818155|FG001|Period 2 (Week 10 to Week 14)|Protocol Violation|2
6171392|NCT01259492|9818156|FG002|Period 2 (Week 10 to Week 14)|Protocol Violation|1
6171393|NCT01259492|9818157|FG003|Period 2 (Week 10 to Week 14)|Protocol Violation|0
6171394|NCT01259492|9818154|FG000|Period 3 (Week 15 to End of Week 40)|Adverse Event|5
6171395|NCT01259492|9818155|FG001|Period 3 (Week 15 to End of Week 40)|Adverse Event|11
6171396|NCT01259492|9818156|FG002|Period 3 (Week 15 to End of Week 40)|Adverse Event|6
6171397|NCT01259492|9818157|FG003|Period 3 (Week 15 to End of Week 40)|Adverse Event|5
6171398|NCT01259492|9818154|FG000|Period 3 (Week 15 to End of Week 40)|Abnormal Lab value(s)|0
6171399|NCT01259492|9818155|FG001|Period 3 (Week 15 to End of Week 40)|Abnormal Lab value(s)|0
6171400|NCT01259492|9818156|FG002|Period 3 (Week 15 to End of Week 40)|Abnormal Lab value(s)|0
6171401|NCT01259492|9818157|FG003|Period 3 (Week 15 to End of Week 40)|Abnormal Lab value(s)|1
6171402|NCT01259492|9818154|FG000|Period 3 (Week 15 to End of Week 40)|Abnormal Test Procedure Result(s)|0
6171403|NCT01259492|9818155|FG001|Period 3 (Week 15 to End of Week 40)|Abnormal Test Procedure Result(s)|0
6171404|NCT01259492|9818156|FG002|Period 3 (Week 15 to End of Week 40)|Abnormal Test Procedure Result(s)|1
6171405|NCT01259492|9818157|FG003|Period 3 (Week 15 to End of Week 40)|Abnormal Test Procedure Result(s)|0
6171406|NCT01259492|9818154|FG000|Period 3 (Week 15 to End of Week 40)|Lack of Efficacy|28
6171407|NCT01259492|9818155|FG001|Period 3 (Week 15 to End of Week 40)|Lack of Efficacy|42
6171408|NCT01259492|9818156|FG002|Period 3 (Week 15 to End of Week 40)|Lack of Efficacy|29
6171409|NCT01259492|9818157|FG003|Period 3 (Week 15 to End of Week 40)|Lack of Efficacy|62
6171410|NCT01259492|9818154|FG000|Period 3 (Week 15 to End of Week 40)|Patient no longer requires study drug|1
6171411|NCT01259492|9818155|FG001|Period 3 (Week 15 to End of Week 40)|Patient no longer requires study drug|0
6171412|NCT01259492|9818156|FG002|Period 3 (Week 15 to End of Week 40)|Patient no longer requires study drug|0
6171413|NCT01259492|9818157|FG003|Period 3 (Week 15 to End of Week 40)|Patient no longer requires study drug|0
6171414|NCT01259492|9818154|FG000|Period 3 (Week 15 to End of Week 40)|Withdrawal by Subject|12
6171415|NCT01259492|9818155|FG001|Period 3 (Week 15 to End of Week 40)|Withdrawal by Subject|6
6171416|NCT01259492|9818156|FG002|Period 3 (Week 15 to End of Week 40)|Withdrawal by Subject|4
6171417|NCT01259492|9818157|FG003|Period 3 (Week 15 to End of Week 40)|Withdrawal by Subject|3
6171418|NCT01259492|9818154|FG000|Period 3 (Week 15 to End of Week 40)|Lost to Follow-up|3
6171419|NCT01259492|9818155|FG001|Period 3 (Week 15 to End of Week 40)|Lost to Follow-up|4
6171420|NCT01259492|9818156|FG002|Period 3 (Week 15 to End of Week 40)|Lost to Follow-up|6
6171421|NCT01259492|9818157|FG003|Period 3 (Week 15 to End of Week 40)|Lost to Follow-up|3
6171422|NCT01259492|9818154|FG000|Period 3 (Week 15 to End of Week 40)|Administrative Problems|0
6171423|NCT01259492|9818155|FG001|Period 3 (Week 15 to End of Week 40)|Administrative Problems|0
6171424|NCT01259492|9818156|FG002|Period 3 (Week 15 to End of Week 40)|Administrative Problems|1
6171425|NCT01259492|9818157|FG003|Period 3 (Week 15 to End of Week 40)|Administrative Problems|0
6171426|NCT01259492|9818154|FG000|Period 3 (Week 15 to End of Week 40)|Protocol Violation|5
6171427|NCT01259492|9818155|FG001|Period 3 (Week 15 to End of Week 40)|Protocol Violation|6
6171428|NCT01259492|9818156|FG002|Period 3 (Week 15 to End of Week 40)|Protocol Violation|3
6171429|NCT01259492|9818157|FG003|Period 3 (Week 15 to End of Week 40)|Protocol Violation|7
6171430|NCT01259713|9818179|FG000|Overall Study|Adverse Event|54
6171431|NCT01259713|9818180|FG001|Overall Study|Adverse Event|23
6171432|NCT01259713|9818179|FG000|Overall Study|Death Not Related to IFI|8
6171433|NCT01259713|9818180|FG001|Overall Study|Death Not Related to IFI|1
6171434|NCT01259713|9818179|FG000|Overall Study|Investigators Discretion|14
6171435|NCT01259713|9818180|FG001|Overall Study|Investigators Discretion|6
6363051|NCT02343120|10152813|FG003|Part 1: Dose Escalation|Sponsor decision|2
6363052|NCT02343120|10152814|FG004|Part 1: Dose Escalation|Sponsor decision|0
6363053|NCT02343120|10152810|FG000|Part 1: Dose Escalation|Death|1
6363054|NCT02343120|10152811|FG001|Part 1: Dose Escalation|Death|2
6363055|NCT02343120|10152812|FG002|Part 1: Dose Escalation|Death|2
6363056|NCT02343120|10152813|FG003|Part 1: Dose Escalation|Death|2
6171436|NCT01259713|9818179|FG000|Overall Study|Lack of Efficacy|2
6171437|NCT01259713|9818180|FG001|Overall Study|Lack of Efficacy|0
6171438|NCT01259713|9818179|FG000|Overall Study|Protocol Violation|5
6171439|NCT01259713|9818180|FG001|Overall Study|Protocol Violation|4
6171440|NCT01259713|9818179|FG000|Overall Study|Subject Withdrew Consent|12
6171441|NCT01259713|9818180|FG001|Overall Study|Subject Withdrew Consent|7
6171442|NCT01259726|9818190|FG000|Overall Study|Death|1
6171443|NCT01259726|9818191|FG001|Overall Study|Death|0
6171444|NCT01259726|9818192|FG002|Overall Study|Death|0
6171445|NCT01259726|9818193|FG003|Overall Study|Death|0
6171446|NCT01259726|9818190|FG000|Overall Study|Physician Decision|2
6171447|NCT01259726|9818191|FG001|Overall Study|Physician Decision|0
6171448|NCT01259726|9818192|FG002|Overall Study|Physician Decision|1
6171449|NCT01259726|9818193|FG003|Overall Study|Physician Decision|1
6171450|NCT01259726|9818190|FG000|Overall Study|Withdrawal by Subject|1
6171451|NCT01259726|9818191|FG001|Overall Study|Withdrawal by Subject|3
6171452|NCT01259726|9818192|FG002|Overall Study|Withdrawal by Subject|2
6171453|NCT01259726|9818193|FG003|Overall Study|Withdrawal by Subject|1
6171454|NCT01259726|9818190|FG000|Overall Study|Lost to Follow-up|1
6171455|NCT01259726|9818191|FG001|Overall Study|Lost to Follow-up|1
6171456|NCT01259726|9818192|FG002|Overall Study|Lost to Follow-up|1
6171457|NCT01259726|9818193|FG003|Overall Study|Lost to Follow-up|3
6171458|NCT01259856|9818205|FG000|Overall Study|Adverse Event|12
6171459|NCT01259856|9818206|FG001|Overall Study|Adverse Event|9
6171460|NCT01259856|9818205|FG000|Overall Study|Death|0
6171461|NCT01259856|9818206|FG001|Overall Study|Death|1
6171462|NCT01259856|9818205|FG000|Overall Study|Lack of Efficacy|3
6171463|NCT01259856|9818206|FG001|Overall Study|Lack of Efficacy|1
6171464|NCT01259856|9818205|FG000|Overall Study|Lost to Follow-up|1
6171465|NCT01259856|9818206|FG001|Overall Study|Lost to Follow-up|1
6171466|NCT01259856|9818205|FG000|Overall Study|Physician Decision|2
6171467|NCT01259856|9818206|FG001|Overall Study|Physician Decision|1
6171468|NCT01259856|9818205|FG000|Overall Study|Withdrawal by Subject|9
6171469|NCT01259856|9818206|FG001|Overall Study|Withdrawal by Subject|10
6171470|NCT01259856|9818205|FG000|Overall Study|Treatment never started|0
6171471|NCT01259856|9818206|FG001|Overall Study|Treatment never started|6
6171472|NCT01259856|9818205|FG000|Overall Study|Study closure by sponsor|40
6171473|NCT01259856|9818206|FG001|Overall Study|Study closure by sponsor|41
6171474|NCT01259856|9818205|FG000|Overall Study|Patient developed other disease|0
6171475|NCT01259856|9818206|FG001|Overall Study|Patient developed other disease|1
6171476|NCT01259856|9818205|FG000|Overall Study|Transfer to another study|0
6171477|NCT01259856|9818206|FG001|Overall Study|Transfer to another study|1
6171478|NCT01259856|9818205|FG000|Overall Study|Unknown/missing|2
6171479|NCT01259856|9818206|FG001|Overall Study|Unknown/missing|2
6171480|NCT01259869|9818212|FG000|Overall Study|Duplicated registration|1
6192265|NCT01429441|9849430|FG000|Overall Study|Withdrawal by Subject|27
6192266|NCT01429441|9849431|FG001|Overall Study|Withdrawal by Subject|18
6192267|NCT01429584|9849462|FG000|Overall Study|Withdrawal by Subject|1
6192268|NCT01429584|9849463|FG001|Overall Study|Withdrawal by Subject|0
6192269|NCT01429584|9849462|FG000|Overall Study|Protocol Violation|0
6192270|NCT01429584|9849463|FG001|Overall Study|Protocol Violation|1
6192271|NCT01429623|9849471|FG000|Overall Study|Death|1
6192272|NCT01429623|9849472|FG001|Overall Study|Death|0
6192273|NCT01429623|9849471|FG000|Overall Study|Adverse Event|7
6192274|NCT01429623|9849472|FG001|Overall Study|Adverse Event|14
6192275|NCT01429623|9849471|FG000|Overall Study|Withdrawal by Subject|19
6192276|NCT01429623|9849472|FG001|Overall Study|Withdrawal by Subject|13
6192277|NCT01429623|9849471|FG000|Overall Study|Physician Decision|2
6192278|NCT01429623|9849472|FG001|Overall Study|Physician Decision|3
6192279|NCT01429623|9849471|FG000|Overall Study|Protocol Violation|3
6192280|NCT01429623|9849472|FG001|Overall Study|Protocol Violation|2
6192281|NCT01429623|9849471|FG000|Overall Study|Assorted|1
6192282|NCT01429623|9849472|FG001|Overall Study|Assorted|2
6192283|NCT01429623|9849471|FG000|Overall Study|Conversion to Alzheimer's disease|14
6192284|NCT01429623|9849472|FG001|Overall Study|Conversion to Alzheimer's disease|21
6192285|NCT01429623|9849471|FG000|Overall Study|No post baseline data|4
6363057|NCT02343120|10152814|FG004|Part 1: Dose Escalation|Death|1
6363058|NCT02343120|10152810|FG000|Part 1: Dose Escalation|Lost to Follow-up|1
6192286|NCT01429623|9849472|FG001|Overall Study|No post baseline data|4
6192287|NCT01429792|9849478|FG000|Overall Study|Other Reasons|67
6192288|NCT01429792|9849478|FG000|Overall Study|Unknown Disposition|94
6192289|NCT01429792|9849478|FG000|Overall Study|Negative HCV-RNA at Week 4|1
6192290|NCT01429792|9849478|FG000|Overall Study|Negative HCV-RNA at Week 12|4
6192291|NCT01429792|9849478|FG000|Overall Study|Decrease of less than 2-log in HCV RNA|32
6192292|NCT01429792|9849478|FG000|Overall Study|Positive HCV-RNA at Week 24|50
6192293|NCT01429792|9849478|FG000|Overall Study|Withdrawal by Subject|70
6192294|NCT01429792|9849478|FG000|Overall Study|Lost to Follow-up|88
6192295|NCT01430104|9849513|FG000|28-Day Teriparatide Treatment Period|Adverse Event|1
6363059|NCT02343120|10152811|FG001|Part 1: Dose Escalation|Lost to Follow-up|0
6363060|NCT02343120|10152812|FG002|Part 1: Dose Escalation|Lost to Follow-up|0
6363061|NCT02343120|10152813|FG003|Part 1: Dose Escalation|Lost to Follow-up|0
6363062|NCT02343120|10152814|FG004|Part 1: Dose Escalation|Lost to Follow-up|0
6363063|NCT02343120|10152810|FG000|Part 2: Expansion|Sponsor decision|0
6363064|NCT02343120|10152811|FG001|Part 2: Expansion|Sponsor decision|0
6363065|NCT02343120|10152812|FG002|Part 2: Expansion|Sponsor decision|0
6363066|NCT02343120|10152813|FG003|Part 2: Expansion|Sponsor decision|165
6363067|NCT02343120|10152814|FG004|Part 2: Expansion|Sponsor decision|67
6363068|NCT02343120|10152810|FG000|Part 2: Expansion|Death|0
6363069|NCT02343120|10152811|FG001|Part 2: Expansion|Death|0
6171481|NCT01260142|9818222|FG000|Treatment Period 1|Study on hold|1
6171482|NCT01260142|9818223|FG001|Treatment Period 1|Study on hold|1
6171483|NCT01260142|9818224|FG002|Treatment Period 1|Study on hold|0
6171484|NCT01260142|9818225|FG003|Treatment Period 1|Study on hold|0
6171485|NCT01260142|9818226|FG004|Treatment Period 1|Study on hold|1
6171486|NCT01260142|9818227|FG005|Treatment Period 1|Study on hold|2
6171487|NCT01260142|9818222|FG000|Treatment Period 1|Unexplained elevated sys. BP|0
6171488|NCT01260142|9818223|FG001|Treatment Period 1|Unexplained elevated sys. BP|0
6171489|NCT01260142|9818224|FG002|Treatment Period 1|Unexplained elevated sys. BP|0
6171490|NCT01260142|9818225|FG003|Treatment Period 1|Unexplained elevated sys. BP|0
6171491|NCT01260142|9818226|FG004|Treatment Period 1|Unexplained elevated sys. BP|1
6171492|NCT01260142|9818227|FG005|Treatment Period 1|Unexplained elevated sys. BP|0
6171493|NCT01260142|9818222|FG000|Treatment Period 1|Withdrawal by Subject|0
6171494|NCT01260142|9818223|FG001|Treatment Period 1|Withdrawal by Subject|0
6171495|NCT01260142|9818224|FG002|Treatment Period 1|Withdrawal by Subject|0
6171496|NCT01260142|9818225|FG003|Treatment Period 1|Withdrawal by Subject|0
6171497|NCT01260142|9818226|FG004|Treatment Period 1|Withdrawal by Subject|0
6171498|NCT01260142|9818227|FG005|Treatment Period 1|Withdrawal by Subject|1
6171499|NCT01260181|9818247|FG000|Overall Study|Decision of Investigator|1
6171500|NCT01260194|9818251|FG000|Overall Study|Withdrawal of Consent|1
6171501|NCT01260311|9818266|FG000|Overall Study|Adverse Event|11
6171502|NCT01260311|9818266|FG000|Overall Study|Lack of Efficacy|4
6171503|NCT01260311|9818266|FG000|Overall Study|Lost to Follow-up|25
6171504|NCT01260311|9818266|FG000|Overall Study|Withdrawal by Subject|6
6171505|NCT01260311|9818266|FG000|Overall Study|Financial Constraints|77
6171506|NCT01260311|9818266|FG000|Overall Study|Gone to Province|2
6171507|NCT01260311|9818266|FG000|Overall Study|Medication Stopped|1
6171508|NCT01260311|9818266|FG000|Overall Study|Fesoterodine Started Before Enrollment|1
6171509|NCT01260350|9818299|FG000|Overall Study|Lack of Efficacy|0
6171510|NCT01260350|9818300|FG001|Overall Study|Lack of Efficacy|0
6171511|NCT01260350|9818301|FG002|Overall Study|Lack of Efficacy|0
6171512|NCT01260350|9818302|FG003|Overall Study|Lack of Efficacy|0
6171513|NCT01260350|9818303|FG004|Overall Study|Lack of Efficacy|0
6171514|NCT01260350|9818304|FG005|Overall Study|Lack of Efficacy|0
6171515|NCT01260350|9818305|FG006|Overall Study|Lack of Efficacy|0
6171516|NCT01260350|9818306|FG007|Overall Study|Lack of Efficacy|0
6171517|NCT01260350|9818307|FG008|Overall Study|Lack of Efficacy|0
6171518|NCT01260350|9818308|FG009|Overall Study|Lack of Efficacy|0
6171519|NCT01260350|9818309|FG010|Overall Study|Lack of Efficacy|0
6171520|NCT01260350|9818310|FG011|Overall Study|Lack of Efficacy|0
6171521|NCT01260350|9818311|FG012|Overall Study|Lack of Efficacy|0
6171522|NCT01260350|9818312|FG013|Overall Study|Lack of Efficacy|0
6171523|NCT01260350|9818313|FG014|Overall Study|Lack of Efficacy|0
6171524|NCT01260350|9818314|FG015|Overall Study|Lack of Efficacy|0
6171525|NCT01260350|9818315|FG016|Overall Study|Lack of Efficacy|0
6171526|NCT01260350|9818316|FG017|Overall Study|Lack of Efficacy|1
6171527|NCT01260350|9818317|FG018|Overall Study|Lack of Efficacy|0
6171528|NCT01260350|9818318|FG019|Overall Study|Lack of Efficacy|0
6171529|NCT01260350|9818319|FG020|Overall Study|Lack of Efficacy|3
6171530|NCT01260350|9818320|FG021|Overall Study|Lack of Efficacy|0
6171531|NCT01260350|9818299|FG000|Overall Study|Did Not Complete Follow-up 12 Visit|0
6171532|NCT01260350|9818300|FG001|Overall Study|Did Not Complete Follow-up 12 Visit|0
6171533|NCT01260350|9818301|FG002|Overall Study|Did Not Complete Follow-up 12 Visit|0
6171534|NCT01260350|9818302|FG003|Overall Study|Did Not Complete Follow-up 12 Visit|0
6171535|NCT01260350|9818303|FG004|Overall Study|Did Not Complete Follow-up 12 Visit|0
6171536|NCT01260350|9818304|FG005|Overall Study|Did Not Complete Follow-up 12 Visit|0
6171537|NCT01260350|9818305|FG006|Overall Study|Did Not Complete Follow-up 12 Visit|0
6171538|NCT01260350|9818306|FG007|Overall Study|Did Not Complete Follow-up 12 Visit|0
6171539|NCT01260350|9818307|FG008|Overall Study|Did Not Complete Follow-up 12 Visit|1
6363070|NCT02343120|10152812|FG002|Part 2: Expansion|Death|0
6363071|NCT02343120|10152813|FG003|Part 2: Expansion|Death|74
6171540|NCT01260350|9818308|FG009|Overall Study|Did Not Complete Follow-up 12 Visit|0
6171541|NCT01260350|9818309|FG010|Overall Study|Did Not Complete Follow-up 12 Visit|0
6171542|NCT01260350|9818310|FG011|Overall Study|Did Not Complete Follow-up 12 Visit|0
6171543|NCT01260350|9818311|FG012|Overall Study|Did Not Complete Follow-up 12 Visit|0
6363072|NCT02343120|10152814|FG004|Part 2: Expansion|Death|17
6171544|NCT01260350|9818312|FG013|Overall Study|Did Not Complete Follow-up 12 Visit|0
6171545|NCT01260350|9818313|FG014|Overall Study|Did Not Complete Follow-up 12 Visit|0
6171546|NCT01260350|9818314|FG015|Overall Study|Did Not Complete Follow-up 12 Visit|0
6171547|NCT01260350|9818315|FG016|Overall Study|Did Not Complete Follow-up 12 Visit|0
6171548|NCT01260350|9818316|FG017|Overall Study|Did Not Complete Follow-up 12 Visit|0
6363073|NCT02343120|10152810|FG000|Part 2: Expansion|Withdrawal by Subject|0
6363074|NCT02343120|10152811|FG001|Part 2: Expansion|Withdrawal by Subject|0
6363075|NCT02343120|10152812|FG002|Part 2: Expansion|Withdrawal by Subject|0
6363076|NCT02343120|10152813|FG003|Part 2: Expansion|Withdrawal by Subject|28
6363077|NCT02343120|10152814|FG004|Part 2: Expansion|Withdrawal by Subject|2
6363078|NCT02343120|10152810|FG000|Part 2: Expansion|Lost to Follow-up|0
6363079|NCT02343120|10152811|FG001|Part 2: Expansion|Lost to Follow-up|0
6363080|NCT02343120|10152812|FG002|Part 2: Expansion|Lost to Follow-up|0
6363081|NCT02343120|10152813|FG003|Part 2: Expansion|Lost to Follow-up|5
6363082|NCT02343120|10152814|FG004|Part 2: Expansion|Lost to Follow-up|2
6171549|NCT01260350|9818317|FG018|Overall Study|Did Not Complete Follow-up 12 Visit|0
6171550|NCT01260350|9818318|FG019|Overall Study|Did Not Complete Follow-up 12 Visit|0
6171551|NCT01260350|9818319|FG020|Overall Study|Did Not Complete Follow-up 12 Visit|0
6171552|NCT01260350|9818320|FG021|Overall Study|Did Not Complete Follow-up 12 Visit|0
6171553|NCT01260467|9818378|FG000|Overall Study|Withdrawal by Subject|2
6171554|NCT01260584|9818397|FG000|Period 1|Protocol Violation|0
6171555|NCT01260584|9818398|FG001|Period 1|Protocol Violation|0
6171556|NCT01260584|9818399|FG002|Period 1|Protocol Violation|1
6171557|NCT01260584|9818400|FG003|Period 1|Protocol Violation|1
6171558|NCT01260584|9818397|FG000|Period 1|Adverse Event|0
6171559|NCT01260584|9818398|FG001|Period 1|Adverse Event|0
6171560|NCT01260584|9818399|FG002|Period 1|Adverse Event|1
6171561|NCT01260584|9818400|FG003|Period 1|Adverse Event|0
6171562|NCT01260584|9818397|FG000|Period 2|Protocol Violation|0
6171563|NCT01260584|9818398|FG001|Period 2|Protocol Violation|2
6171564|NCT01260584|9818399|FG002|Period 2|Protocol Violation|3
6171565|NCT01260584|9818400|FG003|Period 2|Protocol Violation|1
6171566|NCT01260584|9818397|FG000|Period 2|Adverse Event|1
6171567|NCT01260584|9818398|FG001|Period 2|Adverse Event|0
6171568|NCT01260584|9818399|FG002|Period 2|Adverse Event|2
6171569|NCT01260584|9818400|FG003|Period 2|Adverse Event|0
6171570|NCT01260584|9818397|FG000|Period 2|Withdrawal by Subject|0
6171571|NCT01260584|9818398|FG001|Period 2|Withdrawal by Subject|1
6171572|NCT01260584|9818399|FG002|Period 2|Withdrawal by Subject|0
6171573|NCT01260584|9818400|FG003|Period 2|Withdrawal by Subject|0
6171574|NCT01260701|9818444|FG000|Overall Study|Adverse Event|9
6171575|NCT01260701|9818444|FG000|Overall Study|Withdrawal by Subject|2
6171576|NCT01260701|9818444|FG000|Overall Study|Progression|53
6171577|NCT01260701|9818444|FG000|Overall Study|Death|2
6171578|NCT01260701|9818444|FG000|Overall Study|Not protocol specified|3
6171579|NCT01260701|9818444|FG000|Overall Study|Under review|1
6171580|NCT01260701|9818444|FG000|Overall Study|Ineligible|4
6171581|NCT01260701|9818444|FG000|Overall Study|Did not begin protocol therapy|1
6171582|NCT01260896|9818484|FG000|First Intervention|Withdrawn Due to Emesis|2
6171583|NCT01260896|9818485|FG001|First Intervention|Withdrawn Due to Emesis|0
6171584|NCT01260922|9818493|FG000|First Intervention|Withdrawal by Subject|0
6171585|NCT01260922|9818494|FG001|First Intervention|Withdrawal by Subject|1
6171586|NCT01260922|9818493|FG000|Washout of 28 Days|Withdrawal by Subject|4
6171587|NCT01260922|9818494|FG001|Washout of 28 Days|Withdrawal by Subject|2
6171588|NCT01260922|9818493|FG000|Second Intervention|Emesis|0
6171589|NCT01260922|9818494|FG001|Second Intervention|Emesis|2
6171590|NCT01260948|9818502|FG000|Washout of 28 Days|Withdrawal by Subject|1
6171591|NCT01260948|9818503|FG001|Washout of 28 Days|Withdrawal by Subject|3
6171592|NCT01260948|9818502|FG000|Second Intervention|Emesis|0
6171593|NCT01260948|9818503|FG001|Second Intervention|Emesis|1
6171594|NCT01261000|9818509|FG000|Overall Study|Screen failure|1
6171595|NCT01261325|9818521|FG000|Overall Study|Lack of Efficacy|1
6171596|NCT01261325|9818522|FG001|Overall Study|Lack of Efficacy|1
6171597|NCT01261325|9818523|FG002|Overall Study|Lack of Efficacy|0
6171598|NCT01261325|9818521|FG000|Overall Study|Withdrawal by Subject|2
6171599|NCT01261325|9818522|FG001|Overall Study|Withdrawal by Subject|2
6171600|NCT01261325|9818523|FG002|Overall Study|Withdrawal by Subject|4
6171601|NCT01261325|9818521|FG000|Overall Study|SAE, non-fatal|1
6171602|NCT01261325|9818522|FG001|Overall Study|SAE, non-fatal|5
6171603|NCT01261325|9818523|FG002|Overall Study|SAE, non-fatal|1
6171604|NCT01261325|9818521|FG000|Overall Study|AE, non-serious non-fatal|9
6171605|NCT01261325|9818522|FG001|Overall Study|AE, non-serious non-fatal|15
6171606|NCT01261325|9818523|FG002|Overall Study|AE, non-serious non-fatal|13
6171607|NCT01261325|9818521|FG000|Overall Study|SAE, non-fatal+AE, non-serious non-fatal|0
6171608|NCT01261325|9818522|FG001|Overall Study|SAE, non-fatal+AE, non-serious non-fatal|1
6171609|NCT01261325|9818523|FG002|Overall Study|SAE, non-fatal+AE, non-serious non-fatal|1
6171610|NCT01261325|9818521|FG000|Overall Study|Non Compliance|2
6171611|NCT01261325|9818522|FG001|Overall Study|Non Compliance|0
6171612|NCT01261325|9818523|FG002|Overall Study|Non Compliance|0
6363083|NCT02343120|10152810|FG000|Part 2: Expansion|Other|0
6363084|NCT02343120|10152811|FG001|Part 2: Expansion|Other|0
6171613|NCT01261325|9818521|FG000|Overall Study|Patient Randomized by Mistake|0
6171614|NCT01261325|9818522|FG001|Overall Study|Patient Randomized by Mistake|1
6171615|NCT01261325|9818523|FG002|Overall Study|Patient Randomized by Mistake|0
6171616|NCT01261325|9818521|FG000|Overall Study|Erroneously Randomized|1
6171617|NCT01261325|9818522|FG001|Overall Study|Erroneously Randomized|0
6171618|NCT01261325|9818523|FG002|Overall Study|Erroneously Randomized|0
6171619|NCT01261325|9818521|FG000|Overall Study|Screen Failure|1
6363085|NCT02343120|10152812|FG002|Part 2: Expansion|Other|0
6171620|NCT01261325|9818522|FG001|Overall Study|Screen Failure|0
6171621|NCT01261325|9818523|FG002|Overall Study|Screen Failure|0
6363086|NCT02343120|10152813|FG003|Part 2: Expansion|Other|1
6363087|NCT02343120|10152814|FG004|Part 2: Expansion|Other|5
6363088|NCT02343120|10152810|FG000|Part 2: Expansion|Adverse Event|0
6363089|NCT02343120|10152811|FG001|Part 2: Expansion|Adverse Event|0
6363090|NCT02343120|10152812|FG002|Part 2: Expansion|Adverse Event|0
6363091|NCT02343120|10152813|FG003|Part 2: Expansion|Adverse Event|1
6363092|NCT02343120|10152814|FG004|Part 2: Expansion|Adverse Event|1
6363093|NCT02066415|10152836|FG000|Overall Study|Decision by Sponsor|5
6363094|NCT02066415|10152837|FG001|Overall Study|Decision by Sponsor|4
6363095|NCT02066415|10152838|FG002|Overall Study|Decision by Sponsor|2
6363096|NCT02066415|10152836|FG000|Overall Study|Withdrawal by Subject|9
6363097|NCT02066415|10152837|FG001|Overall Study|Withdrawal by Subject|1
6363098|NCT02066415|10152838|FG002|Overall Study|Withdrawal by Subject|4
6363099|NCT02066415|10152836|FG000|Overall Study|Lost to Follow-up|7
6363100|NCT02066415|10152837|FG001|Overall Study|Lost to Follow-up|2
6363101|NCT02066415|10152838|FG002|Overall Study|Lost to Follow-up|2
6363102|NCT01952574|10152850|FG000|Double-blind Treatment Phase|Withdrawal by Subject|9
6363103|NCT01952574|10152851|FG001|Double-blind Treatment Phase|Withdrawal by Subject|3
6084366|NCT00642707|9693302|FG000|Overall Study|Adverse Event|0
6084367|NCT00642707|9693303|FG001|Overall Study|Adverse Event|0
6084368|NCT00642707|9693304|FG002|Overall Study|Adverse Event|0
6363104|NCT01952574|10152852|FG002|Double-blind Treatment Phase|Withdrawal by Subject|3
6363105|NCT01952574|10152853|FG003|Double-blind Treatment Phase|Withdrawal by Subject|4
6363106|NCT01952574|10152854|FG004|Double-blind Treatment Phase|Withdrawal by Subject|0
6084369|NCT00642707|9693305|FG003|Overall Study|Adverse Event|2
6084370|NCT00642707|9693302|FG000|Overall Study|Withdrawal by Subject|1
6084371|NCT00642707|9693303|FG001|Overall Study|Withdrawal by Subject|0
6084372|NCT00642707|9693304|FG002|Overall Study|Withdrawal by Subject|0
6363107|NCT01952574|10152855|FG005|Double-blind Treatment Phase|Withdrawal by Subject|0
6363108|NCT01952574|10152856|FG006|Double-blind Treatment Phase|Withdrawal by Subject|0
6363109|NCT01952574|10152850|FG000|Double-blind Treatment Phase|Sponsor Decision|6
6363110|NCT01952574|10152851|FG001|Double-blind Treatment Phase|Sponsor Decision|0
6363111|NCT01952574|10152852|FG002|Double-blind Treatment Phase|Sponsor Decision|5
6363112|NCT01952574|10152853|FG003|Double-blind Treatment Phase|Sponsor Decision|2
6363113|NCT01952574|10152854|FG004|Double-blind Treatment Phase|Sponsor Decision|0
6363114|NCT01952574|10152855|FG005|Double-blind Treatment Phase|Sponsor Decision|0
6363115|NCT01952574|10152856|FG006|Double-blind Treatment Phase|Sponsor Decision|0
6363116|NCT01952574|10152850|FG000|Double-blind Treatment Phase|Lost to Follow-up|2
6363117|NCT01952574|10152851|FG001|Double-blind Treatment Phase|Lost to Follow-up|0
6363118|NCT01952574|10152852|FG002|Double-blind Treatment Phase|Lost to Follow-up|1
6363119|NCT01952574|10152853|FG003|Double-blind Treatment Phase|Lost to Follow-up|0
6363120|NCT01952574|10152854|FG004|Double-blind Treatment Phase|Lost to Follow-up|0
6363121|NCT01952574|10152855|FG005|Double-blind Treatment Phase|Lost to Follow-up|0
6363122|NCT01952574|10152856|FG006|Double-blind Treatment Phase|Lost to Follow-up|0
6363123|NCT01952574|10152850|FG000|Open-label Treatment Phase|Withdrawal by Subject|0
6363124|NCT01952574|10152851|FG001|Open-label Treatment Phase|Withdrawal by Subject|0
6363125|NCT01952574|10152852|FG002|Open-label Treatment Phase|Withdrawal by Subject|0
6363126|NCT01952574|10152853|FG003|Open-label Treatment Phase|Withdrawal by Subject|0
6363127|NCT01952574|10152854|FG004|Open-label Treatment Phase|Withdrawal by Subject|121
6363128|NCT01952574|10152855|FG005|Open-label Treatment Phase|Withdrawal by Subject|0
6363129|NCT01952574|10152856|FG006|Open-label Treatment Phase|Withdrawal by Subject|0
6363130|NCT01952574|10152850|FG000|Open-label Treatment Phase|Decision by Sponsor|0
6363131|NCT01952574|10152851|FG001|Open-label Treatment Phase|Decision by Sponsor|0
6363132|NCT01952574|10152852|FG002|Open-label Treatment Phase|Decision by Sponsor|0
6363133|NCT01952574|10152853|FG003|Open-label Treatment Phase|Decision by Sponsor|0
6363134|NCT01952574|10152854|FG004|Open-label Treatment Phase|Decision by Sponsor|17
6363135|NCT01952574|10152855|FG005|Open-label Treatment Phase|Decision by Sponsor|0
6363136|NCT01952574|10152856|FG006|Open-label Treatment Phase|Decision by Sponsor|0
6363137|NCT01952574|10152850|FG000|Open-label Treatment Phase|Missing|0
6363138|NCT01952574|10152851|FG001|Open-label Treatment Phase|Missing|0
6363139|NCT01952574|10152852|FG002|Open-label Treatment Phase|Missing|0
6363140|NCT01952574|10152853|FG003|Open-label Treatment Phase|Missing|0
6363141|NCT01952574|10152854|FG004|Open-label Treatment Phase|Missing|4
6363142|NCT01952574|10152855|FG005|Open-label Treatment Phase|Missing|0
6363143|NCT01952574|10152856|FG006|Open-label Treatment Phase|Missing|0
6363144|NCT01952574|10152850|FG000|Open-label Treatment Phase|Lost to Follow-up|0
6363145|NCT01952574|10152851|FG001|Open-label Treatment Phase|Lost to Follow-up|0
6363146|NCT01952574|10152852|FG002|Open-label Treatment Phase|Lost to Follow-up|0
6363147|NCT01952574|10152853|FG003|Open-label Treatment Phase|Lost to Follow-up|0
6363148|NCT01952574|10152854|FG004|Open-label Treatment Phase|Lost to Follow-up|19
6084373|NCT00642707|9693305|FG003|Overall Study|Withdrawal by Subject|0
6363149|NCT01952574|10152855|FG005|Open-label Treatment Phase|Lost to Follow-up|0
6363150|NCT01952574|10152856|FG006|Open-label Treatment Phase|Lost to Follow-up|0
6363151|NCT01952574|10152850|FG000|Open-label Treatment Phase|Death|0
6363152|NCT01952574|10152851|FG001|Open-label Treatment Phase|Death|0
6363153|NCT01952574|10152852|FG002|Open-label Treatment Phase|Death|0
6363154|NCT01952574|10152853|FG003|Open-label Treatment Phase|Death|0
6363155|NCT01952574|10152854|FG004|Open-label Treatment Phase|Death|1
6171622|NCT01261325|9818521|FG000|Overall Study|Randomized in Error|0
6363156|NCT01952574|10152855|FG005|Open-label Treatment Phase|Death|0
6363157|NCT01952574|10152856|FG006|Open-label Treatment Phase|Death|0
6363158|NCT01952574|10152850|FG000|Clinical Home Use Substudy|Withdrawal by Subject|0
6363159|NCT01952574|10152851|FG001|Clinical Home Use Substudy|Withdrawal by Subject|0
6363160|NCT01952574|10152852|FG002|Clinical Home Use Substudy|Withdrawal by Subject|0
6363161|NCT01952574|10152853|FG003|Clinical Home Use Substudy|Withdrawal by Subject|0
6363162|NCT01952574|10152854|FG004|Clinical Home Use Substudy|Withdrawal by Subject|0
6363163|NCT01952574|10152855|FG005|Clinical Home Use Substudy|Withdrawal by Subject|1
6363164|NCT01952574|10152856|FG006|Clinical Home Use Substudy|Withdrawal by Subject|0
6363165|NCT01952574|10152850|FG000|Clinical Home Use Substudy|Decision by Sponsor|0
6363166|NCT01952574|10152851|FG001|Clinical Home Use Substudy|Decision by Sponsor|0
6363167|NCT01952574|10152852|FG002|Clinical Home Use Substudy|Decision by Sponsor|0
6363168|NCT01952574|10152853|FG003|Clinical Home Use Substudy|Decision by Sponsor|0
6363169|NCT01952574|10152854|FG004|Clinical Home Use Substudy|Decision by Sponsor|0
6363170|NCT01952574|10152855|FG005|Clinical Home Use Substudy|Decision by Sponsor|2
6363171|NCT01952574|10152856|FG006|Clinical Home Use Substudy|Decision by Sponsor|1
6363172|NCT01659151|10152881|FG000|Overall Study|Inadequate TIL growth|1
6363173|NCT01539863|10152896|FG000|Overall Study|Lost to Follow-up|5
6363174|NCT01539863|10152897|FG001|Overall Study|Lost to Follow-up|4
6363175|NCT01439165|10152918|FG000|Overall Study|Protocol Violation|3
6363176|NCT01439165|10152919|FG001|Overall Study|Protocol Violation|0
6363177|NCT01439165|10152918|FG000|Overall Study|Lost to Follow-up|11
6363178|NCT01439165|10152919|FG001|Overall Study|Lost to Follow-up|1
6363179|NCT01439165|10152918|FG000|Overall Study|Withdrawal by Subject|7
6363180|NCT01439165|10152919|FG001|Overall Study|Withdrawal by Subject|1
6363181|NCT01264679|10152925|FG000|Overall Study|Participation in Another Clinical Trial|1
6363182|NCT01264679|10152925|FG000|Overall Study|Physician Decision|1
6363183|NCT01264679|10152925|FG000|Overall Study|Sponsor's Suspension of Dosing|2
6363184|NCT01264679|10152925|FG000|Overall Study|Withdrawal by Subject|1
6363185|NCT01155388|10152932|FG000|Overall Study|Adverse Event|1
6363186|NCT01155388|10152933|FG001|Overall Study|Adverse Event|0
6363187|NCT01137435|10152940|FG000|Overall Study|Lost to Follow-up|24
6363188|NCT01137435|10152940|FG000|Overall Study|Off label usage|4
6363189|NCT01064817|10152957|FG000|Study Completion|Physician Decision|1
6363190|NCT01064817|10152958|FG001|Study Completion|Physician Decision|0
6363191|NCT01064817|10152957|FG000|Study Completion|Withdrawal by Subject|1
6363192|NCT01064817|10152958|FG001|Study Completion|Withdrawal by Subject|0
6363193|NCT01026220|10152964|FG000|Induction|Death|1
6363194|NCT01026220|10152965|FG001|Induction|Death|0
6363195|NCT01026220|10152966|FG002|Induction|Death|0
6363196|NCT01026220|10152964|FG000|Induction|Lack of Efficacy|2
6363197|NCT01026220|10152965|FG001|Induction|Lack of Efficacy|0
6084374|NCT00642746|9693317|FG000|Overall Study|Patient unevaluable|1
6363198|NCT01026220|10152966|FG002|Induction|Lack of Efficacy|0
6363199|NCT01026220|10152964|FG000|Induction|Physician Decision|12
6363200|NCT01026220|10152965|FG001|Induction|Physician Decision|0
6084375|NCT00642746|9693318|FG001|Overall Study|Patient unevaluable|0
6363201|NCT01026220|10152966|FG002|Induction|Physician Decision|0
6363202|NCT01026220|10152964|FG000|Induction|Withdrawal by Subject|9
6363203|NCT01026220|10152965|FG001|Induction|Withdrawal by Subject|0
6363204|NCT01026220|10152966|FG002|Induction|Withdrawal by Subject|0
6363205|NCT01026220|10152964|FG000|Induction|Ineligible|1
6363206|NCT01026220|10152965|FG001|Induction|Ineligible|0
6363207|NCT01026220|10152966|FG002|Induction|Ineligible|0
6363208|NCT01026220|10152964|FG000|Consolidation Maintenance|Death|0
6363209|NCT01026220|10152965|FG001|Consolidation Maintenance|Death|1
6363210|NCT01026220|10152966|FG002|Consolidation Maintenance|Death|0
6363211|NCT01026220|10152964|FG000|Consolidation Maintenance|Lack of Efficacy|0
6363212|NCT01026220|10152965|FG001|Consolidation Maintenance|Lack of Efficacy|1
6363213|NCT01026220|10152966|FG002|Consolidation Maintenance|Lack of Efficacy|1
6363214|NCT01026220|10152964|FG000|Consolidation Maintenance|Physician Decision|0
6363215|NCT01026220|10152965|FG001|Consolidation Maintenance|Physician Decision|2
6363216|NCT01026220|10152966|FG002|Consolidation Maintenance|Physician Decision|7
6363217|NCT01026220|10152964|FG000|Consolidation Maintenance|Withdrawal by Subject|0
6363218|NCT01026220|10152965|FG001|Consolidation Maintenance|Withdrawal by Subject|2
6363219|NCT01026220|10152966|FG002|Consolidation Maintenance|Withdrawal by Subject|6
6363220|NCT00567567|10152988|FG000|Overall Study|Adverse Event|0
6363221|NCT00567567|10152989|FG001|Overall Study|Adverse Event|2
6363222|NCT00567567|10152990|FG002|Overall Study|Adverse Event|5
6363223|NCT00567567|10152988|FG000|Overall Study|Death|8
6363224|NCT00567567|10152989|FG001|Overall Study|Death|1
6363225|NCT00567567|10152990|FG002|Overall Study|Death|5
6363226|NCT00567567|10152988|FG000|Overall Study|Lack of Efficacy|16
6363227|NCT00567567|10152989|FG001|Overall Study|Lack of Efficacy|17
6363228|NCT00567567|10152990|FG002|Overall Study|Lack of Efficacy|48
6363229|NCT00567567|10152988|FG000|Overall Study|Lost to Follow-up|0
6363230|NCT00567567|10152989|FG001|Overall Study|Lost to Follow-up|0
6363231|NCT00567567|10152990|FG002|Overall Study|Lost to Follow-up|1
6363232|NCT00567567|10152988|FG000|Overall Study|Physician Decision|16
6363233|NCT00567567|10152989|FG001|Overall Study|Physician Decision|18
6363234|NCT00567567|10152990|FG002|Overall Study|Physician Decision|84
6363235|NCT00567567|10152988|FG000|Overall Study|Withdrawal by Subject|0
6363236|NCT00567567|10152989|FG001|Overall Study|Withdrawal by Subject|0
6363237|NCT00567567|10152990|FG002|Overall Study|Withdrawal by Subject|2
6363238|NCT00567567|10152988|FG000|Overall Study|Ineligible|4
6363239|NCT00567567|10152989|FG001|Overall Study|Ineligible|0
6363240|NCT00567567|10152990|FG002|Overall Study|Ineligible|9
6363241|NCT00567567|10152988|FG000|Overall Study|Refusal by patient/parent/guardian|9
6363242|NCT00567567|10152989|FG001|Overall Study|Refusal by patient/parent/guardian|16
6363243|NCT00567567|10152990|FG002|Overall Study|Refusal by patient/parent/guardian|122
6363244|NCT00567567|10152988|FG000|Overall Study|Enrolled another COG therapeutic study|99
6363245|NCT00567567|10152989|FG001|Overall Study|Enrolled another COG therapeutic study|80
6363246|NCT00567567|10152990|FG002|Overall Study|Enrolled another COG therapeutic study|0
6363247|NCT00567567|10152988|FG000|Overall Study|Unable adequate stem cell for transplant|0
6363248|NCT00567567|10152989|FG001|Overall Study|Unable adequate stem cell for transplant|0
6363249|NCT00567567|10152990|FG002|Overall Study|Unable adequate stem cell for transplant|2
6363250|NCT00450450|10153002|FG000|Overall Study|Death|1
6363251|NCT00450450|10153003|FG001|Overall Study|Death|3
6363252|NCT00450450|10153002|FG000|Overall Study|Relapse|2
6363253|NCT00450450|10153003|FG001|Overall Study|Relapse|0
6363254|NCT00450450|10153002|FG000|Overall Study|Missing Data|2
6363255|NCT00450450|10153003|FG001|Overall Study|Missing Data|0
6363256|NCT00346164|10153024|FG000|Overall Study|Adverse Event|0
6363257|NCT00346164|10153025|FG001|Overall Study|Adverse Event|0
6363258|NCT00346164|10153026|FG002|Overall Study|Adverse Event|0
6363259|NCT00346164|10153027|FG003|Overall Study|Adverse Event|1
6363260|NCT00346164|10153024|FG000|Overall Study|Lack of Efficacy|0
6363261|NCT00346164|10153025|FG001|Overall Study|Lack of Efficacy|1
6363262|NCT00346164|10153026|FG002|Overall Study|Lack of Efficacy|7
6363263|NCT00346164|10153027|FG003|Overall Study|Lack of Efficacy|25
6363264|NCT00346164|10153024|FG000|Overall Study|Physician Decision|0
6363265|NCT00346164|10153025|FG001|Overall Study|Physician Decision|1
6363266|NCT00346164|10153026|FG002|Overall Study|Physician Decision|2
6363267|NCT00346164|10153027|FG003|Overall Study|Physician Decision|27
6363268|NCT00346164|10153024|FG000|Overall Study|Protocol Violation|6
6363269|NCT00346164|10153025|FG001|Overall Study|Protocol Violation|2
6363270|NCT00346164|10153026|FG002|Overall Study|Protocol Violation|10
6363271|NCT00346164|10153027|FG003|Overall Study|Protocol Violation|4
6363272|NCT00346164|10153024|FG000|Overall Study|Withdrawal by Subject|0
6363273|NCT00346164|10153025|FG001|Overall Study|Withdrawal by Subject|0
6363274|NCT00346164|10153026|FG002|Overall Study|Withdrawal by Subject|2
6363275|NCT00346164|10153027|FG003|Overall Study|Withdrawal by Subject|0
6363276|NCT00346164|10153024|FG000|Overall Study|Ineligible|11
6363277|NCT00346164|10153025|FG001|Overall Study|Ineligible|2
6363278|NCT00346164|10153026|FG002|Overall Study|Ineligible|2
6363279|NCT00346164|10153027|FG003|Overall Study|Ineligible|23
6363280|NCT00346164|10153024|FG000|Overall Study|Refusal of further protocol therapy|0
6363281|NCT00346164|10153025|FG001|Overall Study|Refusal of further protocol therapy|1
6363282|NCT00346164|10153026|FG002|Overall Study|Refusal of further protocol therapy|3
6363283|NCT00346164|10153027|FG003|Overall Study|Refusal of further protocol therapy|15
6363284|NCT00346164|10153024|FG000|Overall Study|Inability to start week 16 tx on time|0
6363285|NCT00346164|10153025|FG001|Overall Study|Inability to start week 16 tx on time|0
6363286|NCT00346164|10153026|FG002|Overall Study|Inability to start week 16 tx on time|0
6363287|NCT00346164|10153027|FG003|Overall Study|Inability to start week 16 tx on time|11
6363288|NCT00972179|10153060|FG000|Overall Study|Noncompliance|1
6363289|NCT00972179|10153061|FG001|Overall Study|Noncompliance|0
6363290|NCT00972179|10153062|FG002|Overall Study|Noncompliance|0
6363291|NCT00972179|10153063|FG003|Overall Study|Noncompliance|0
6363292|NCT00972179|10153064|FG004|Overall Study|Noncompliance|1
6363293|NCT00972179|10153065|FG005|Overall Study|Noncompliance|0
6363294|NCT00972179|10153066|FG006|Overall Study|Noncompliance|1
6363295|NCT00972179|10153060|FG000|Overall Study|Withdrawal by Subject|0
6363296|NCT00972179|10153061|FG001|Overall Study|Withdrawal by Subject|3
6363297|NCT00972179|10153062|FG002|Overall Study|Withdrawal by Subject|0
6363298|NCT00972179|10153063|FG003|Overall Study|Withdrawal by Subject|1
6363299|NCT00972179|10153064|FG004|Overall Study|Withdrawal by Subject|0
6363300|NCT00972179|10153065|FG005|Overall Study|Withdrawal by Subject|0
6171623|NCT01261325|9818522|FG001|Overall Study|Randomized in Error|0
6363301|NCT00972179|10153066|FG006|Overall Study|Withdrawal by Subject|2
6363302|NCT00972179|10153060|FG000|Overall Study|Administrative Decision|0
6363303|NCT00972179|10153061|FG001|Overall Study|Administrative Decision|0
6363304|NCT00972179|10153062|FG002|Overall Study|Administrative Decision|0
6363305|NCT00972179|10153063|FG003|Overall Study|Administrative Decision|0
6363306|NCT00972179|10153064|FG004|Overall Study|Administrative Decision|1
6363307|NCT00972179|10153065|FG005|Overall Study|Administrative Decision|0
6363308|NCT00972179|10153066|FG006|Overall Study|Administrative Decision|0
6363309|NCT00972179|10153060|FG000|Overall Study|Lost to Follow-up|0
6363310|NCT00972179|10153061|FG001|Overall Study|Lost to Follow-up|0
6363311|NCT00972179|10153062|FG002|Overall Study|Lost to Follow-up|1
6363312|NCT00972179|10153063|FG003|Overall Study|Lost to Follow-up|0
6363313|NCT00972179|10153064|FG004|Overall Study|Lost to Follow-up|0
6363314|NCT00972179|10153065|FG005|Overall Study|Lost to Follow-up|3
6363315|NCT00972179|10153066|FG006|Overall Study|Lost to Follow-up|1
6363316|NCT01009294|10153086|FG000|Overall Study|Study discontinued by Sponsor|6
6363317|NCT01072175|10153111|FG000|Part A (Drug-Drug Interaction)|Death|1
6363318|NCT01072175|10153112|FG001|Part A (Drug-Drug Interaction)|Death|0
6363319|NCT01072175|10153113|FG002|Part A (Drug-Drug Interaction)|Death|0
6363320|NCT01072175|10153114|FG003|Part A (Drug-Drug Interaction)|Death|0
6363321|NCT01072175|10153115|FG004|Part A (Drug-Drug Interaction)|Death|0
6363322|NCT01072175|10153116|FG005|Part A (Drug-Drug Interaction)|Death|0
6363323|NCT01072175|10153117|FG006|Part A (Drug-Drug Interaction)|Death|0
6363324|NCT01072175|10153118|FG007|Part A (Drug-Drug Interaction)|Death|0
6363325|NCT01072175|10153119|FG008|Part A (Drug-Drug Interaction)|Death|0
6363326|NCT01072175|10153120|FG009|Part A (Drug-Drug Interaction)|Death|0
6363327|NCT01072175|10153121|FG010|Part A (Drug-Drug Interaction)|Death|0
6363328|NCT01072175|10153122|FG011|Part A (Drug-Drug Interaction)|Death|0
6363329|NCT01072175|10153123|FG012|Part A (Drug-Drug Interaction)|Death|0
6363330|NCT01072175|10153111|FG000|Part A (Drug-Drug Interaction)|Physician Decision|6
6363331|NCT01072175|10153112|FG001|Part A (Drug-Drug Interaction)|Physician Decision|0
6363332|NCT01072175|10153113|FG002|Part A (Drug-Drug Interaction)|Physician Decision|0
6363333|NCT01072175|10153114|FG003|Part A (Drug-Drug Interaction)|Physician Decision|0
6363334|NCT01072175|10153115|FG004|Part A (Drug-Drug Interaction)|Physician Decision|0
6363335|NCT01072175|10153116|FG005|Part A (Drug-Drug Interaction)|Physician Decision|0
6363336|NCT01072175|10153117|FG006|Part A (Drug-Drug Interaction)|Physician Decision|0
6363337|NCT01072175|10153118|FG007|Part A (Drug-Drug Interaction)|Physician Decision|0
6363338|NCT01072175|10153119|FG008|Part A (Drug-Drug Interaction)|Physician Decision|0
6363339|NCT01072175|10153120|FG009|Part A (Drug-Drug Interaction)|Physician Decision|0
6363340|NCT01072175|10153121|FG010|Part A (Drug-Drug Interaction)|Physician Decision|0
6363341|NCT01072175|10153122|FG011|Part A (Drug-Drug Interaction)|Physician Decision|0
6363342|NCT01072175|10153123|FG012|Part A (Drug-Drug Interaction)|Physician Decision|0
6363343|NCT01072175|10153111|FG000|Part A (Drug-Drug Interaction)|Withdrawal by Subject|1
6363344|NCT01072175|10153112|FG001|Part A (Drug-Drug Interaction)|Withdrawal by Subject|0
6363345|NCT01072175|10153113|FG002|Part A (Drug-Drug Interaction)|Withdrawal by Subject|0
6363346|NCT01072175|10153114|FG003|Part A (Drug-Drug Interaction)|Withdrawal by Subject|0
6363347|NCT01072175|10153115|FG004|Part A (Drug-Drug Interaction)|Withdrawal by Subject|0
6363348|NCT01072175|10153116|FG005|Part A (Drug-Drug Interaction)|Withdrawal by Subject|0
6363349|NCT01072175|10153117|FG006|Part A (Drug-Drug Interaction)|Withdrawal by Subject|0
6363350|NCT01072175|10153118|FG007|Part A (Drug-Drug Interaction)|Withdrawal by Subject|0
6363351|NCT01072175|10153119|FG008|Part A (Drug-Drug Interaction)|Withdrawal by Subject|0
6363352|NCT01072175|10153120|FG009|Part A (Drug-Drug Interaction)|Withdrawal by Subject|0
6363353|NCT01072175|10153121|FG010|Part A (Drug-Drug Interaction)|Withdrawal by Subject|0
6363354|NCT01072175|10153122|FG011|Part A (Drug-Drug Interaction)|Withdrawal by Subject|0
6363355|NCT01072175|10153123|FG012|Part A (Drug-Drug Interaction)|Withdrawal by Subject|0
6363356|NCT01072175|10153111|FG000|Part B (Dose Escalation and Expansion)|Death|0
6363357|NCT01072175|10153112|FG001|Part B (Dose Escalation and Expansion)|Death|4
6363358|NCT01072175|10153113|FG002|Part B (Dose Escalation and Expansion)|Death|18
6363359|NCT01072175|10153114|FG003|Part B (Dose Escalation and Expansion)|Death|21
6363360|NCT01072175|10153115|FG004|Part B (Dose Escalation and Expansion)|Death|68
6363361|NCT01072175|10153116|FG005|Part B (Dose Escalation and Expansion)|Death|0
6363362|NCT01072175|10153117|FG006|Part B (Dose Escalation and Expansion)|Death|0
6363363|NCT01072175|10153118|FG007|Part B (Dose Escalation and Expansion)|Death|0
6363364|NCT01072175|10153119|FG008|Part B (Dose Escalation and Expansion)|Death|0
6363365|NCT01072175|10153120|FG009|Part B (Dose Escalation and Expansion)|Death|0
6363366|NCT01072175|10153121|FG010|Part B (Dose Escalation and Expansion)|Death|0
6363367|NCT01072175|10153122|FG011|Part B (Dose Escalation and Expansion)|Death|0
6363368|NCT01072175|10153123|FG012|Part B (Dose Escalation and Expansion)|Death|0
6363369|NCT01072175|10153111|FG000|Part B (Dose Escalation and Expansion)|Physician Decision|0
6363370|NCT01072175|10153112|FG001|Part B (Dose Escalation and Expansion)|Physician Decision|0
6363371|NCT01072175|10153113|FG002|Part B (Dose Escalation and Expansion)|Physician Decision|2
6363372|NCT01072175|10153114|FG003|Part B (Dose Escalation and Expansion)|Physician Decision|0
6363373|NCT01072175|10153115|FG004|Part B (Dose Escalation and Expansion)|Physician Decision|4
6363374|NCT01072175|10153116|FG005|Part B (Dose Escalation and Expansion)|Physician Decision|0
6363375|NCT01072175|10153117|FG006|Part B (Dose Escalation and Expansion)|Physician Decision|0
6363376|NCT01072175|10153118|FG007|Part B (Dose Escalation and Expansion)|Physician Decision|0
6363377|NCT01072175|10153119|FG008|Part B (Dose Escalation and Expansion)|Physician Decision|0
6363378|NCT01072175|10153120|FG009|Part B (Dose Escalation and Expansion)|Physician Decision|0
6363379|NCT01072175|10153121|FG010|Part B (Dose Escalation and Expansion)|Physician Decision|0
6363380|NCT01072175|10153122|FG011|Part B (Dose Escalation and Expansion)|Physician Decision|0
6363381|NCT01072175|10153123|FG012|Part B (Dose Escalation and Expansion)|Physician Decision|0
6363382|NCT01072175|10153111|FG000|Part B (Dose Escalation and Expansion)|Lost to Follow-up|0
6363383|NCT01072175|10153112|FG001|Part B (Dose Escalation and Expansion)|Lost to Follow-up|1
6363384|NCT01072175|10153113|FG002|Part B (Dose Escalation and Expansion)|Lost to Follow-up|0
6363385|NCT01072175|10153114|FG003|Part B (Dose Escalation and Expansion)|Lost to Follow-up|1
6363386|NCT01072175|10153115|FG004|Part B (Dose Escalation and Expansion)|Lost to Follow-up|6
6363387|NCT01072175|10153116|FG005|Part B (Dose Escalation and Expansion)|Lost to Follow-up|0
6363388|NCT01072175|10153117|FG006|Part B (Dose Escalation and Expansion)|Lost to Follow-up|0
6363389|NCT01072175|10153118|FG007|Part B (Dose Escalation and Expansion)|Lost to Follow-up|0
6363390|NCT01072175|10153119|FG008|Part B (Dose Escalation and Expansion)|Lost to Follow-up|0
6363391|NCT01072175|10153120|FG009|Part B (Dose Escalation and Expansion)|Lost to Follow-up|0
6363392|NCT01072175|10153121|FG010|Part B (Dose Escalation and Expansion)|Lost to Follow-up|0
6363393|NCT01072175|10153122|FG011|Part B (Dose Escalation and Expansion)|Lost to Follow-up|0
6363394|NCT01072175|10153123|FG012|Part B (Dose Escalation and Expansion)|Lost to Follow-up|0
6363395|NCT01072175|10153111|FG000|Part B (Dose Escalation and Expansion)|Study closed/terminated|0
6363396|NCT01072175|10153112|FG001|Part B (Dose Escalation and Expansion)|Study closed/terminated|0
6363397|NCT01072175|10153113|FG002|Part B (Dose Escalation and Expansion)|Study closed/terminated|3
6363398|NCT01072175|10153114|FG003|Part B (Dose Escalation and Expansion)|Study closed/terminated|2
6363399|NCT01072175|10153115|FG004|Part B (Dose Escalation and Expansion)|Study closed/terminated|10
6363400|NCT01072175|10153116|FG005|Part B (Dose Escalation and Expansion)|Study closed/terminated|0
6363401|NCT01072175|10153117|FG006|Part B (Dose Escalation and Expansion)|Study closed/terminated|0
6363402|NCT01072175|10153118|FG007|Part B (Dose Escalation and Expansion)|Study closed/terminated|0
6363403|NCT01072175|10153119|FG008|Part B (Dose Escalation and Expansion)|Study closed/terminated|0
6363404|NCT01072175|10153120|FG009|Part B (Dose Escalation and Expansion)|Study closed/terminated|0
6363405|NCT01072175|10153121|FG010|Part B (Dose Escalation and Expansion)|Study closed/terminated|0
6363406|NCT01072175|10153122|FG011|Part B (Dose Escalation and Expansion)|Study closed/terminated|0
6363407|NCT01072175|10153123|FG012|Part B (Dose Escalation and Expansion)|Study closed/terminated|0
6363408|NCT01072175|10153111|FG000|Part B (Dose Escalation and Expansion)|Withdrawal by Subject|0
6363409|NCT01072175|10153112|FG001|Part B (Dose Escalation and Expansion)|Withdrawal by Subject|1
6363410|NCT01072175|10153113|FG002|Part B (Dose Escalation and Expansion)|Withdrawal by Subject|0
6363411|NCT01072175|10153114|FG003|Part B (Dose Escalation and Expansion)|Withdrawal by Subject|3
6363412|NCT01072175|10153115|FG004|Part B (Dose Escalation and Expansion)|Withdrawal by Subject|6
6363413|NCT01072175|10153116|FG005|Part B (Dose Escalation and Expansion)|Withdrawal by Subject|0
6363414|NCT01072175|10153117|FG006|Part B (Dose Escalation and Expansion)|Withdrawal by Subject|0
6363415|NCT01072175|10153118|FG007|Part B (Dose Escalation and Expansion)|Withdrawal by Subject|0
6363416|NCT01072175|10153119|FG008|Part B (Dose Escalation and Expansion)|Withdrawal by Subject|0
6363417|NCT01072175|10153120|FG009|Part B (Dose Escalation and Expansion)|Withdrawal by Subject|0
6363418|NCT01072175|10153121|FG010|Part B (Dose Escalation and Expansion)|Withdrawal by Subject|0
6363419|NCT01072175|10153122|FG011|Part B (Dose Escalation and Expansion)|Withdrawal by Subject|0
6363420|NCT01072175|10153123|FG012|Part B (Dose Escalation and Expansion)|Withdrawal by Subject|0
6363421|NCT01072175|10153111|FG000|Part C (Phase II: Randomized Phase)|Death|0
6363422|NCT01072175|10153112|FG001|Part C (Phase II: Randomized Phase)|Death|0
6363423|NCT01072175|10153113|FG002|Part C (Phase II: Randomized Phase)|Death|0
6363424|NCT01072175|10153114|FG003|Part C (Phase II: Randomized Phase)|Death|0
6363425|NCT01072175|10153115|FG004|Part C (Phase II: Randomized Phase)|Death|0
6363426|NCT01072175|10153116|FG005|Part C (Phase II: Randomized Phase)|Death|44
6363427|NCT01072175|10153117|FG006|Part C (Phase II: Randomized Phase)|Death|34
6363428|NCT01072175|10153118|FG007|Part C (Phase II: Randomized Phase)|Death|39
6363429|NCT01072175|10153119|FG008|Part C (Phase II: Randomized Phase)|Death|0
6363430|NCT01072175|10153120|FG009|Part C (Phase II: Randomized Phase)|Death|0
6363431|NCT01072175|10153121|FG010|Part C (Phase II: Randomized Phase)|Death|0
6363432|NCT01072175|10153122|FG011|Part C (Phase II: Randomized Phase)|Death|0
6363433|NCT01072175|10153123|FG012|Part C (Phase II: Randomized Phase)|Death|0
6363434|NCT01072175|10153111|FG000|Part C (Phase II: Randomized Phase)|Physician Decision|0
6363435|NCT01072175|10153112|FG001|Part C (Phase II: Randomized Phase)|Physician Decision|0
6363436|NCT01072175|10153113|FG002|Part C (Phase II: Randomized Phase)|Physician Decision|0
6363437|NCT01072175|10153114|FG003|Part C (Phase II: Randomized Phase)|Physician Decision|0
6363438|NCT01072175|10153115|FG004|Part C (Phase II: Randomized Phase)|Physician Decision|0
6363439|NCT01072175|10153116|FG005|Part C (Phase II: Randomized Phase)|Physician Decision|1
6363440|NCT01072175|10153117|FG006|Part C (Phase II: Randomized Phase)|Physician Decision|1
6363441|NCT01072175|10153118|FG007|Part C (Phase II: Randomized Phase)|Physician Decision|1
6363442|NCT01072175|10153119|FG008|Part C (Phase II: Randomized Phase)|Physician Decision|0
6363443|NCT01072175|10153120|FG009|Part C (Phase II: Randomized Phase)|Physician Decision|0
6363444|NCT01072175|10153121|FG010|Part C (Phase II: Randomized Phase)|Physician Decision|0
6363445|NCT01072175|10153122|FG011|Part C (Phase II: Randomized Phase)|Physician Decision|0
6363446|NCT01072175|10153123|FG012|Part C (Phase II: Randomized Phase)|Physician Decision|0
6363447|NCT01072175|10153111|FG000|Part C (Phase II: Randomized Phase)|Lost to Follow-up|0
6363448|NCT01072175|10153112|FG001|Part C (Phase II: Randomized Phase)|Lost to Follow-up|0
6363449|NCT01072175|10153113|FG002|Part C (Phase II: Randomized Phase)|Lost to Follow-up|0
6363450|NCT01072175|10153114|FG003|Part C (Phase II: Randomized Phase)|Lost to Follow-up|0
6363451|NCT01072175|10153115|FG004|Part C (Phase II: Randomized Phase)|Lost to Follow-up|0
6363452|NCT01072175|10153116|FG005|Part C (Phase II: Randomized Phase)|Lost to Follow-up|0
6363453|NCT01072175|10153117|FG006|Part C (Phase II: Randomized Phase)|Lost to Follow-up|3
6363454|NCT01072175|10153118|FG007|Part C (Phase II: Randomized Phase)|Lost to Follow-up|3
6363455|NCT01072175|10153119|FG008|Part C (Phase II: Randomized Phase)|Lost to Follow-up|0
6363456|NCT01072175|10153120|FG009|Part C (Phase II: Randomized Phase)|Lost to Follow-up|0
6084376|NCT00642759|9693324|FG000|Overall Study|Protocol Violation|1
6084377|NCT00642772|9693329|FG000|Overall Study|Lost to Follow-up|3
6084378|NCT00642772|9693329|FG000|Overall Study|Withdrawal by Subject|7
6084379|NCT00642811|9693339|FG000|Overall Study|Adverse Event|2
6363457|NCT01072175|10153121|FG010|Part C (Phase II: Randomized Phase)|Lost to Follow-up|0
6084380|NCT00642811|9693340|FG001|Overall Study|Adverse Event|3
6084381|NCT00642811|9693341|FG002|Overall Study|Adverse Event|0
6084382|NCT00642811|9693342|FG003|Overall Study|Adverse Event|0
6084383|NCT00642811|9693343|FG004|Overall Study|Adverse Event|0
6084384|NCT00642811|9693344|FG005|Overall Study|Adverse Event|1
6084385|NCT00642811|9693339|FG000|Overall Study|Developement of discontinuation criteria|0
6084386|NCT00642811|9693340|FG001|Overall Study|Developement of discontinuation criteria|0
6084387|NCT00642811|9693341|FG002|Overall Study|Developement of discontinuation criteria|0
6084388|NCT00642811|9693342|FG003|Overall Study|Developement of discontinuation criteria|0
6084389|NCT00642811|9693343|FG004|Overall Study|Developement of discontinuation criteria|1
6084390|NCT00642811|9693344|FG005|Overall Study|Developement of discontinuation criteria|0
6084391|NCT00642811|9693339|FG000|Overall Study|Severe Non-compliance to protocol|1
6084392|NCT00642811|9693340|FG001|Overall Study|Severe Non-compliance to protocol|0
6084393|NCT00642811|9693341|FG002|Overall Study|Severe Non-compliance to protocol|0
6171624|NCT01261325|9818523|FG002|Overall Study|Randomized in Error|1
6363458|NCT01072175|10153122|FG011|Part C (Phase II: Randomized Phase)|Lost to Follow-up|0
6363459|NCT01072175|10153123|FG012|Part C (Phase II: Randomized Phase)|Lost to Follow-up|0
6363460|NCT01072175|10153111|FG000|Part C (Phase II: Randomized Phase)|Study closed/terminated|0
6363461|NCT01072175|10153112|FG001|Part C (Phase II: Randomized Phase)|Study closed/terminated|0
6363462|NCT01072175|10153113|FG002|Part C (Phase II: Randomized Phase)|Study closed/terminated|0
6363463|NCT01072175|10153114|FG003|Part C (Phase II: Randomized Phase)|Study closed/terminated|0
6363464|NCT01072175|10153115|FG004|Part C (Phase II: Randomized Phase)|Study closed/terminated|0
6363465|NCT01072175|10153116|FG005|Part C (Phase II: Randomized Phase)|Study closed/terminated|6
6363466|NCT01072175|10153117|FG006|Part C (Phase II: Randomized Phase)|Study closed/terminated|9
6363467|NCT01072175|10153118|FG007|Part C (Phase II: Randomized Phase)|Study closed/terminated|11
6363468|NCT01072175|10153119|FG008|Part C (Phase II: Randomized Phase)|Study closed/terminated|0
6363469|NCT01072175|10153120|FG009|Part C (Phase II: Randomized Phase)|Study closed/terminated|0
6363470|NCT01072175|10153121|FG010|Part C (Phase II: Randomized Phase)|Study closed/terminated|0
6363471|NCT01072175|10153122|FG011|Part C (Phase II: Randomized Phase)|Study closed/terminated|0
6363472|NCT01072175|10153123|FG012|Part C (Phase II: Randomized Phase)|Study closed/terminated|0
6363473|NCT01072175|10153111|FG000|Part C (Phase II: Randomized Phase)|Withdrawal by Subject|0
6363474|NCT01072175|10153112|FG001|Part C (Phase II: Randomized Phase)|Withdrawal by Subject|0
6363475|NCT01072175|10153113|FG002|Part C (Phase II: Randomized Phase)|Withdrawal by Subject|0
6363476|NCT01072175|10153114|FG003|Part C (Phase II: Randomized Phase)|Withdrawal by Subject|0
6171625|NCT01261325|9818521|FG000|Overall Study|Protocol Violation|0
6171626|NCT01261325|9818522|FG001|Overall Study|Protocol Violation|3
6171627|NCT01261325|9818523|FG002|Overall Study|Protocol Violation|1
6171628|NCT01261325|9818521|FG000|Overall Study|Lost to Follow-up|0
6171629|NCT01261325|9818522|FG001|Overall Study|Lost to Follow-up|1
6084394|NCT00642811|9693342|FG003|Overall Study|Severe Non-compliance to protocol|0
6084395|NCT00642811|9693343|FG004|Overall Study|Severe Non-compliance to protocol|0
6084396|NCT00642811|9693344|FG005|Overall Study|Severe Non-compliance to protocol|0
6084397|NCT00642811|9693339|FG000|Overall Study|Other|0
6171630|NCT01261325|9818523|FG002|Overall Study|Lost to Follow-up|3
6171631|NCT01261325|9818521|FG000|Overall Study|AE, serious fatal|0
6363477|NCT01072175|10153115|FG004|Part C (Phase II: Randomized Phase)|Withdrawal by Subject|0
6363478|NCT01072175|10153116|FG005|Part C (Phase II: Randomized Phase)|Withdrawal by Subject|3
6363479|NCT01072175|10153117|FG006|Part C (Phase II: Randomized Phase)|Withdrawal by Subject|7
6363480|NCT01072175|10153118|FG007|Part C (Phase II: Randomized Phase)|Withdrawal by Subject|0
6363481|NCT01072175|10153119|FG008|Part C (Phase II: Randomized Phase)|Withdrawal by Subject|0
6363482|NCT01072175|10153120|FG009|Part C (Phase II: Randomized Phase)|Withdrawal by Subject|0
6363483|NCT01072175|10153121|FG010|Part C (Phase II: Randomized Phase)|Withdrawal by Subject|0
6363484|NCT01072175|10153122|FG011|Part C (Phase II: Randomized Phase)|Withdrawal by Subject|0
6363485|NCT01072175|10153123|FG012|Part C (Phase II: Randomized Phase)|Withdrawal by Subject|0
6363486|NCT01072175|10153111|FG000|Part C (Phase II: Crossover Phase [CP])|Death|0
6363487|NCT01072175|10153112|FG001|Part C (Phase II: Crossover Phase [CP])|Death|0
6363488|NCT01072175|10153113|FG002|Part C (Phase II: Crossover Phase [CP])|Death|0
6363489|NCT01072175|10153114|FG003|Part C (Phase II: Crossover Phase [CP])|Death|0
6363490|NCT01072175|10153115|FG004|Part C (Phase II: Crossover Phase [CP])|Death|0
6363491|NCT01072175|10153116|FG005|Part C (Phase II: Crossover Phase [CP])|Death|0
6363492|NCT01072175|10153117|FG006|Part C (Phase II: Crossover Phase [CP])|Death|0
6363493|NCT01072175|10153118|FG007|Part C (Phase II: Crossover Phase [CP])|Death|0
6363494|NCT01072175|10153119|FG008|Part C (Phase II: Crossover Phase [CP])|Death|37
6363495|NCT01072175|10153120|FG009|Part C (Phase II: Crossover Phase [CP])|Death|0
6363496|NCT01072175|10153121|FG010|Part C (Phase II: Crossover Phase [CP])|Death|0
6363497|NCT01072175|10153122|FG011|Part C (Phase II: Crossover Phase [CP])|Death|0
6363498|NCT01072175|10153123|FG012|Part C (Phase II: Crossover Phase [CP])|Death|0
6363499|NCT01072175|10153111|FG000|Part C (Phase II: Crossover Phase [CP])|Physician Decision|0
6363500|NCT01072175|10153112|FG001|Part C (Phase II: Crossover Phase [CP])|Physician Decision|0
6363501|NCT01072175|10153113|FG002|Part C (Phase II: Crossover Phase [CP])|Physician Decision|0
6363502|NCT01072175|10153114|FG003|Part C (Phase II: Crossover Phase [CP])|Physician Decision|0
6363503|NCT01072175|10153115|FG004|Part C (Phase II: Crossover Phase [CP])|Physician Decision|0
6363504|NCT01072175|10153116|FG005|Part C (Phase II: Crossover Phase [CP])|Physician Decision|0
6363505|NCT01072175|10153117|FG006|Part C (Phase II: Crossover Phase [CP])|Physician Decision|0
6363506|NCT01072175|10153118|FG007|Part C (Phase II: Crossover Phase [CP])|Physician Decision|0
6363507|NCT01072175|10153119|FG008|Part C (Phase II: Crossover Phase [CP])|Physician Decision|1
6363508|NCT01072175|10153120|FG009|Part C (Phase II: Crossover Phase [CP])|Physician Decision|0
6363509|NCT01072175|10153121|FG010|Part C (Phase II: Crossover Phase [CP])|Physician Decision|0
6363510|NCT01072175|10153122|FG011|Part C (Phase II: Crossover Phase [CP])|Physician Decision|0
6363511|NCT01072175|10153123|FG012|Part C (Phase II: Crossover Phase [CP])|Physician Decision|0
6363512|NCT01072175|10153111|FG000|Part C (Phase II: Crossover Phase [CP])|Study closed/terminated|0
6363513|NCT01072175|10153112|FG001|Part C (Phase II: Crossover Phase [CP])|Study closed/terminated|0
6363514|NCT01072175|10153113|FG002|Part C (Phase II: Crossover Phase [CP])|Study closed/terminated|0
6363515|NCT01072175|10153114|FG003|Part C (Phase II: Crossover Phase [CP])|Study closed/terminated|0
6363516|NCT01072175|10153115|FG004|Part C (Phase II: Crossover Phase [CP])|Study closed/terminated|0
6363517|NCT01072175|10153116|FG005|Part C (Phase II: Crossover Phase [CP])|Study closed/terminated|0
6363518|NCT01072175|10153117|FG006|Part C (Phase II: Crossover Phase [CP])|Study closed/terminated|0
6363519|NCT01072175|10153118|FG007|Part C (Phase II: Crossover Phase [CP])|Study closed/terminated|0
6363520|NCT01072175|10153119|FG008|Part C (Phase II: Crossover Phase [CP])|Study closed/terminated|4
6363521|NCT01072175|10153120|FG009|Part C (Phase II: Crossover Phase [CP])|Study closed/terminated|0
6363522|NCT01072175|10153121|FG010|Part C (Phase II: Crossover Phase [CP])|Study closed/terminated|0
6363523|NCT01072175|10153122|FG011|Part C (Phase II: Crossover Phase [CP])|Study closed/terminated|0
6363524|NCT01072175|10153123|FG012|Part C (Phase II: Crossover Phase [CP])|Study closed/terminated|0
6363525|NCT01072175|10153111|FG000|Part C (Phase II: Crossover Phase [CP])|Withdrawal by Subject|0
6363526|NCT01072175|10153112|FG001|Part C (Phase II: Crossover Phase [CP])|Withdrawal by Subject|0
6363527|NCT01072175|10153113|FG002|Part C (Phase II: Crossover Phase [CP])|Withdrawal by Subject|0
6363528|NCT01072175|10153114|FG003|Part C (Phase II: Crossover Phase [CP])|Withdrawal by Subject|0
6363529|NCT01072175|10153115|FG004|Part C (Phase II: Crossover Phase [CP])|Withdrawal by Subject|0
6363530|NCT01072175|10153116|FG005|Part C (Phase II: Crossover Phase [CP])|Withdrawal by Subject|0
6363531|NCT01072175|10153117|FG006|Part C (Phase II: Crossover Phase [CP])|Withdrawal by Subject|0
6363532|NCT01072175|10153118|FG007|Part C (Phase II: Crossover Phase [CP])|Withdrawal by Subject|0
6363533|NCT01072175|10153119|FG008|Part C (Phase II: Crossover Phase [CP])|Withdrawal by Subject|3
6363534|NCT01072175|10153120|FG009|Part C (Phase II: Crossover Phase [CP])|Withdrawal by Subject|0
6363535|NCT01072175|10153121|FG010|Part C (Phase II: Crossover Phase [CP])|Withdrawal by Subject|0
6363536|NCT01072175|10153122|FG011|Part C (Phase II: Crossover Phase [CP])|Withdrawal by Subject|0
6363537|NCT01072175|10153123|FG012|Part C (Phase II: Crossover Phase [CP])|Withdrawal by Subject|0
6363538|NCT01072175|10153111|FG000|Part D (HPMC Capsules)|Death|0
6363539|NCT01072175|10153112|FG001|Part D (HPMC Capsules)|Death|0
6363540|NCT01072175|10153113|FG002|Part D (HPMC Capsules)|Death|0
6363541|NCT01072175|10153114|FG003|Part D (HPMC Capsules)|Death|0
6363542|NCT01072175|10153115|FG004|Part D (HPMC Capsules)|Death|0
6363543|NCT01072175|10153116|FG005|Part D (HPMC Capsules)|Death|0
6363544|NCT01072175|10153117|FG006|Part D (HPMC Capsules)|Death|0
6363545|NCT01072175|10153118|FG007|Part D (HPMC Capsules)|Death|0
6363546|NCT01072175|10153119|FG008|Part D (HPMC Capsules)|Death|0
6363547|NCT01072175|10153120|FG009|Part D (HPMC Capsules)|Death|10
6363548|NCT01072175|10153121|FG010|Part D (HPMC Capsules)|Death|12
6363549|NCT01072175|10153122|FG011|Part D (HPMC Capsules)|Death|28
6363550|NCT01072175|10153123|FG012|Part D (HPMC Capsules)|Death|26
6363551|NCT01072175|10153111|FG000|Part D (HPMC Capsules)|Physician Decision|0
6363552|NCT01072175|10153112|FG001|Part D (HPMC Capsules)|Physician Decision|0
6363553|NCT01072175|10153113|FG002|Part D (HPMC Capsules)|Physician Decision|0
6363554|NCT01072175|10153114|FG003|Part D (HPMC Capsules)|Physician Decision|0
6363555|NCT01072175|10153115|FG004|Part D (HPMC Capsules)|Physician Decision|0
6363556|NCT01072175|10153116|FG005|Part D (HPMC Capsules)|Physician Decision|0
6363557|NCT01072175|10153117|FG006|Part D (HPMC Capsules)|Physician Decision|0
6363558|NCT01072175|10153118|FG007|Part D (HPMC Capsules)|Physician Decision|0
6363559|NCT01072175|10153119|FG008|Part D (HPMC Capsules)|Physician Decision|0
6363560|NCT01072175|10153120|FG009|Part D (HPMC Capsules)|Physician Decision|0
6363561|NCT01072175|10153121|FG010|Part D (HPMC Capsules)|Physician Decision|1
6363562|NCT01072175|10153122|FG011|Part D (HPMC Capsules)|Physician Decision|1
6363563|NCT01072175|10153123|FG012|Part D (HPMC Capsules)|Physician Decision|1
6363564|NCT01072175|10153111|FG000|Part D (HPMC Capsules)|Lost to Follow-up|0
6363565|NCT01072175|10153112|FG001|Part D (HPMC Capsules)|Lost to Follow-up|0
6363566|NCT01072175|10153113|FG002|Part D (HPMC Capsules)|Lost to Follow-up|0
6363567|NCT01072175|10153114|FG003|Part D (HPMC Capsules)|Lost to Follow-up|0
6363568|NCT01072175|10153115|FG004|Part D (HPMC Capsules)|Lost to Follow-up|0
6363569|NCT01072175|10153116|FG005|Part D (HPMC Capsules)|Lost to Follow-up|0
6363570|NCT01072175|10153117|FG006|Part D (HPMC Capsules)|Lost to Follow-up|0
6363571|NCT01072175|10153118|FG007|Part D (HPMC Capsules)|Lost to Follow-up|0
6363572|NCT01072175|10153119|FG008|Part D (HPMC Capsules)|Lost to Follow-up|0
6363573|NCT01072175|10153120|FG009|Part D (HPMC Capsules)|Lost to Follow-up|0
6363574|NCT01072175|10153121|FG010|Part D (HPMC Capsules)|Lost to Follow-up|1
6363575|NCT01072175|10153122|FG011|Part D (HPMC Capsules)|Lost to Follow-up|1
6363576|NCT01072175|10153123|FG012|Part D (HPMC Capsules)|Lost to Follow-up|3
6363577|NCT01072175|10153111|FG000|Part D (HPMC Capsules)|Study closed/terminated|0
6363578|NCT01072175|10153112|FG001|Part D (HPMC Capsules)|Study closed/terminated|0
6363579|NCT01072175|10153113|FG002|Part D (HPMC Capsules)|Study closed/terminated|0
6363580|NCT01072175|10153114|FG003|Part D (HPMC Capsules)|Study closed/terminated|0
6363581|NCT01072175|10153115|FG004|Part D (HPMC Capsules)|Study closed/terminated|0
6363582|NCT01072175|10153116|FG005|Part D (HPMC Capsules)|Study closed/terminated|0
6363583|NCT01072175|10153117|FG006|Part D (HPMC Capsules)|Study closed/terminated|0
6363584|NCT01072175|10153118|FG007|Part D (HPMC Capsules)|Study closed/terminated|0
6363585|NCT01072175|10153119|FG008|Part D (HPMC Capsules)|Study closed/terminated|0
6363586|NCT01072175|10153120|FG009|Part D (HPMC Capsules)|Study closed/terminated|2
6363587|NCT01072175|10153121|FG010|Part D (HPMC Capsules)|Study closed/terminated|1
6363588|NCT01072175|10153122|FG011|Part D (HPMC Capsules)|Study closed/terminated|10
6363589|NCT01072175|10153123|FG012|Part D (HPMC Capsules)|Study closed/terminated|9
6363590|NCT01072175|10153111|FG000|Part D (HPMC Capsules)|Withdrawal by Subject|0
6363591|NCT01072175|10153112|FG001|Part D (HPMC Capsules)|Withdrawal by Subject|0
6363592|NCT01072175|10153113|FG002|Part D (HPMC Capsules)|Withdrawal by Subject|0
6363593|NCT01072175|10153114|FG003|Part D (HPMC Capsules)|Withdrawal by Subject|0
6363594|NCT01072175|10153115|FG004|Part D (HPMC Capsules)|Withdrawal by Subject|0
6363595|NCT01072175|10153116|FG005|Part D (HPMC Capsules)|Withdrawal by Subject|0
6363596|NCT01072175|10153117|FG006|Part D (HPMC Capsules)|Withdrawal by Subject|0
6363597|NCT01072175|10153118|FG007|Part D (HPMC Capsules)|Withdrawal by Subject|0
6363598|NCT01072175|10153119|FG008|Part D (HPMC Capsules)|Withdrawal by Subject|0
6363599|NCT01072175|10153120|FG009|Part D (HPMC Capsules)|Withdrawal by Subject|0
6363600|NCT01072175|10153121|FG010|Part D (HPMC Capsules)|Withdrawal by Subject|1
6363601|NCT01072175|10153122|FG011|Part D (HPMC Capsules)|Withdrawal by Subject|3
6363602|NCT01072175|10153123|FG012|Part D (HPMC Capsules)|Withdrawal by Subject|0
6363603|NCT01087203|10153157|FG000|Overall Study|Lost to Follow-up|2
6363604|NCT01087203|10153158|FG001|Overall Study|Lost to Follow-up|0
6363605|NCT01087203|10153157|FG000|Overall Study|Withdrawal by Subject|2
6363606|NCT01087203|10153158|FG001|Overall Study|Withdrawal by Subject|6
6363607|NCT01087203|10153157|FG000|Overall Study|Lack of Efficacy|1
6363608|NCT01087203|10153158|FG001|Overall Study|Lack of Efficacy|2
6363609|NCT01087203|10153157|FG000|Overall Study|Study terminated by sponsor|27
6363610|NCT01087203|10153158|FG001|Overall Study|Study terminated by sponsor|27
6363611|NCT01108055|10153169|FG000|Overall Study|Ineligible|11
6363612|NCT01108055|10153169|FG000|Overall Study|Not evaluable- didn't complete treatment|4
6363613|NCT01111019|10153173|FG000|Overall Study|Withdrew Prematurely|2
6363614|NCT01111019|10153173|FG000|Overall Study|Other|1
6363615|NCT01136967|10153179|FG000|Overall Study|Adverse Event|9
6363616|NCT01136967|10153180|FG001|Overall Study|Adverse Event|12
6363617|NCT01136967|10153179|FG000|Overall Study|Participant Choice|8
6363618|NCT01136967|10153180|FG001|Overall Study|Participant Choice|3
6363619|NCT01136967|10153179|FG000|Overall Study|Lost to Follow-up|0
6363620|NCT01136967|10153180|FG001|Overall Study|Lost to Follow-up|1
6363621|NCT01136967|10153179|FG000|Overall Study|Withdrawal by Subject|1
6363622|NCT01136967|10153180|FG001|Overall Study|Withdrawal by Subject|2
6363623|NCT01136967|10153179|FG000|Overall Study|Clinical Progression|3
6363624|NCT01136967|10153180|FG001|Overall Study|Clinical Progression|5
6363625|NCT01136967|10153179|FG000|Overall Study|Radiation|1
6363626|NCT01136967|10153180|FG001|Overall Study|Radiation|0
6363627|NCT01136967|10153179|FG000|Overall Study|Non-compliance|1
6363628|NCT01136967|10153180|FG001|Overall Study|Non-compliance|0
6363629|NCT01136967|10153179|FG000|Overall Study|Investigator's Choice|1
6363630|NCT01136967|10153180|FG001|Overall Study|Investigator's Choice|1
6363631|NCT01136967|10153179|FG000|Overall Study|Increase in Lesion Size|0
6363632|NCT01136967|10153180|FG001|Overall Study|Increase in Lesion Size|2
6363633|NCT01136967|10153179|FG000|Overall Study|Diagnosis of Second Primary Cancer|0
6363634|NCT01136967|10153180|FG001|Overall Study|Diagnosis of Second Primary Cancer|1
6363635|NCT01140451|10153197|FG000|Overall Study|Withdrawal by Subject|26
6363636|NCT01140451|10153198|FG001|Overall Study|Withdrawal by Subject|33
6363637|NCT01140451|10153197|FG000|Overall Study|Adverse Event|2
6363638|NCT01140451|10153198|FG001|Overall Study|Adverse Event|6
6363639|NCT01140451|10153197|FG000|Overall Study|Physician Decision|5
6363640|NCT01140451|10153198|FG001|Overall Study|Physician Decision|3
6363641|NCT01140451|10153197|FG000|Overall Study|Lost to Follow-up|2
6363642|NCT01140451|10153198|FG001|Overall Study|Lost to Follow-up|0
6363643|NCT01140451|10153197|FG000|Overall Study|Participants Planning Pregnancy|3
6363644|NCT01140451|10153198|FG001|Overall Study|Participants Planning Pregnancy|0
6363645|NCT01174563|10153205|FG000|Overall Study|Progressive Disease|45
6363646|NCT01174563|10153205|FG000|Overall Study|Death|5
6363647|NCT01174563|10153205|FG000|Overall Study|Investigator's Discretion|5
6363648|NCT01174563|10153205|FG000|Overall Study|Participant Withdrew Consent|3
6363649|NCT01174563|10153205|FG000|Overall Study|Rash Adverse Event|1
6363650|NCT01174563|10153205|FG000|Overall Study|Sponsor's decision|1
6363651|NCT01235962|10153285|FG000|Overall Study|Withdrawal by Subject|20
6363652|NCT01235962|10153286|FG001|Overall Study|Withdrawal by Subject|19
6363653|NCT01235962|10153287|FG002|Overall Study|Withdrawal by Subject|62
6363654|NCT01235962|10153288|FG003|Overall Study|Withdrawal by Subject|49
6363655|NCT01235962|10153285|FG000|Overall Study|Lost to Follow-up|21
6363656|NCT01235962|10153286|FG001|Overall Study|Lost to Follow-up|16
6363657|NCT01235962|10153287|FG002|Overall Study|Lost to Follow-up|47
6363658|NCT01235962|10153288|FG003|Overall Study|Lost to Follow-up|32
6363659|NCT01235962|10153285|FG000|Overall Study|Physician Decision|5
6363660|NCT01235962|10153286|FG001|Overall Study|Physician Decision|0
6363661|NCT01235962|10153287|FG002|Overall Study|Physician Decision|9
6363662|NCT01235962|10153288|FG003|Overall Study|Physician Decision|5
6363703|NCT01266031|10153361|FG000|Overall Study|Not treated|0
6363704|NCT01266031|10153362|FG001|Overall Study|Not treated|3
6363705|NCT01266031|10153363|FG002|Overall Study|Not treated|2
6363706|NCT01287741|10153384|FG000|Overall Study|Withdrawal by Subject|35
6363707|NCT01287741|10153385|FG001|Overall Study|Withdrawal by Subject|38
6363708|NCT01287741|10153384|FG000|Overall Study|Protocol Violation|2
6363709|NCT01287741|10153385|FG001|Overall Study|Protocol Violation|0
6363710|NCT01287741|10153384|FG000|Overall Study|Physician Decision|15
6363711|NCT01287741|10153385|FG001|Overall Study|Physician Decision|23
6363712|NCT01287741|10153384|FG000|Overall Study|Non-compliance|8
6363713|NCT01287741|10153385|FG001|Overall Study|Non-compliance|6
6363714|NCT01287741|10153384|FG000|Overall Study|Lost to Follow-up|10
6363715|NCT01287741|10153385|FG001|Overall Study|Lost to Follow-up|8
6363716|NCT01287741|10153384|FG000|Overall Study|Death|32
6363717|NCT01287741|10153385|FG001|Overall Study|Death|44
6363718|NCT01287741|10153384|FG000|Overall Study|Adverse Event|4
6363719|NCT01287741|10153385|FG001|Overall Study|Adverse Event|6
6363720|NCT01287741|10153384|FG000|Overall Study|Study terminated by Sponsor|307
6363721|NCT01287741|10153385|FG001|Overall Study|Study terminated by Sponsor|315
6363722|NCT01287741|10153384|FG000|Overall Study|Progressive disease|190
6363723|NCT01287741|10153385|FG001|Overall Study|Progressive disease|166
6363724|NCT01287741|10153384|FG000|Overall Study|Reason not specified|23
6363725|NCT01287741|10153385|FG001|Overall Study|Reason not specified|9
6363726|NCT01313689|10153402|FG000|24-Week Randomization 1|Adverse Event|10
6363727|NCT01313689|10153403|FG001|24-Week Randomization 1|Adverse Event|5
6363663|NCT01239368|10153316|FG000|Overall Study|Principal investigator discretion|1
6363664|NCT01239368|10153317|FG001|Overall Study|Principal investigator discretion|0
6363665|NCT01239368|10153318|FG002|Overall Study|Principal investigator discretion|0
6363666|NCT01239368|10153319|FG003|Overall Study|Principal investigator discretion|0
6363667|NCT01239368|10153320|FG004|Overall Study|Principal investigator discretion|1
6363668|NCT01239368|10153321|FG005|Overall Study|Principal investigator discretion|2
6363669|NCT01239368|10153322|FG006|Overall Study|Principal investigator discretion|0
6363670|NCT01239368|10153323|FG007|Overall Study|Principal investigator discretion|0
6363671|NCT01239368|10153324|FG008|Overall Study|Principal investigator discretion|0
6363672|NCT01239368|10153325|FG009|Overall Study|Principal investigator discretion|1
6363673|NCT01239368|10153316|FG000|Overall Study|Disease progression on study|1
6363674|NCT01239368|10153317|FG001|Overall Study|Disease progression on study|1
6363675|NCT01239368|10153318|FG002|Overall Study|Disease progression on study|1
6363676|NCT01239368|10153319|FG003|Overall Study|Disease progression on study|1
6363677|NCT01239368|10153320|FG004|Overall Study|Disease progression on study|4
6363678|NCT01239368|10153321|FG005|Overall Study|Disease progression on study|2
6363679|NCT01239368|10153322|FG006|Overall Study|Disease progression on study|5
6363680|NCT01239368|10153323|FG007|Overall Study|Disease progression on study|0
6363681|NCT01239368|10153324|FG008|Overall Study|Disease progression on study|0
6363682|NCT01239368|10153325|FG009|Overall Study|Disease progression on study|2
6363683|NCT01239368|10153316|FG000|Overall Study|Refused further treatment|0
6363684|NCT01239368|10153317|FG001|Overall Study|Refused further treatment|0
6363685|NCT01239368|10153318|FG002|Overall Study|Refused further treatment|0
6363686|NCT01239368|10153319|FG003|Overall Study|Refused further treatment|0
6363687|NCT01239368|10153320|FG004|Overall Study|Refused further treatment|0
6363688|NCT01239368|10153321|FG005|Overall Study|Refused further treatment|0
6363689|NCT01239368|10153322|FG006|Overall Study|Refused further treatment|0
6363690|NCT01239368|10153323|FG007|Overall Study|Refused further treatment|0
6363691|NCT01239368|10153324|FG008|Overall Study|Refused further treatment|0
6363692|NCT01239368|10153325|FG009|Overall Study|Refused further treatment|1
6363693|NCT01239368|10153316|FG000|Overall Study|Death|0
6363694|NCT01239368|10153317|FG001|Overall Study|Death|0
6363695|NCT01239368|10153318|FG002|Overall Study|Death|0
6363696|NCT01239368|10153319|FG003|Overall Study|Death|0
6363697|NCT01239368|10153320|FG004|Overall Study|Death|0
6363698|NCT01239368|10153321|FG005|Overall Study|Death|0
6363699|NCT01239368|10153322|FG006|Overall Study|Death|1
6363700|NCT01239368|10153323|FG007|Overall Study|Death|0
6363701|NCT01239368|10153324|FG008|Overall Study|Death|0
6363702|NCT01239368|10153325|FG009|Overall Study|Death|0
6363728|NCT01313689|10153404|FG002|24-Week Randomization 1|Adverse Event|0
6363729|NCT01313689|10153405|FG003|24-Week Randomization 1|Adverse Event|0
6363730|NCT01313689|10153406|FG004|24-Week Randomization 1|Adverse Event|0
6363731|NCT01313689|10153402|FG000|24-Week Randomization 1|Physician Decision|4
6363732|NCT01313689|10153403|FG001|24-Week Randomization 1|Physician Decision|5
6363733|NCT01313689|10153404|FG002|24-Week Randomization 1|Physician Decision|0
6363734|NCT01313689|10153405|FG003|24-Week Randomization 1|Physician Decision|0
6363735|NCT01313689|10153406|FG004|24-Week Randomization 1|Physician Decision|0
6363736|NCT01313689|10153402|FG000|24-Week Randomization 1|Withdrawal by Subject|5
6363737|NCT01313689|10153403|FG001|24-Week Randomization 1|Withdrawal by Subject|0
6363738|NCT01313689|10153404|FG002|24-Week Randomization 1|Withdrawal by Subject|0
6363739|NCT01313689|10153405|FG003|24-Week Randomization 1|Withdrawal by Subject|0
6363740|NCT01313689|10153406|FG004|24-Week Randomization 1|Withdrawal by Subject|0
6363741|NCT01313689|10153402|FG000|24-Week Randomization 2|Adverse Event|0
6363742|NCT01313689|10153403|FG001|24-Week Randomization 2|Adverse Event|0
6363743|NCT01313689|10153404|FG002|24-Week Randomization 2|Adverse Event|2
6363744|NCT01313689|10153405|FG003|24-Week Randomization 2|Adverse Event|0
6363745|NCT01313689|10153406|FG004|24-Week Randomization 2|Adverse Event|8
6363746|NCT01313689|10153402|FG000|24-Week Randomization 2|Withdrawal by Subject|0
6363747|NCT01313689|10153403|FG001|24-Week Randomization 2|Withdrawal by Subject|0
6363748|NCT01313689|10153404|FG002|24-Week Randomization 2|Withdrawal by Subject|1
6363749|NCT01313689|10153405|FG003|24-Week Randomization 2|Withdrawal by Subject|1
6363750|NCT01313689|10153406|FG004|24-Week Randomization 2|Withdrawal by Subject|3
6363751|NCT01313689|10153402|FG000|24-Week Randomization 2|Physician Decision|0
6363752|NCT01313689|10153403|FG001|24-Week Randomization 2|Physician Decision|0
6363753|NCT01313689|10153404|FG002|24-Week Randomization 2|Physician Decision|0
6363754|NCT01313689|10153405|FG003|24-Week Randomization 2|Physician Decision|0
6363755|NCT01313689|10153406|FG004|24-Week Randomization 2|Physician Decision|4
6363756|NCT01315353|10153428|FG000|Overall Study|Death|2
6363757|NCT01315353|10153429|FG001|Overall Study|Death|1
6363758|NCT01315353|10153430|FG002|Overall Study|Death|0
6363759|NCT01315353|10153428|FG000|Overall Study|Withdrawal by Subject|2
6363760|NCT01315353|10153429|FG001|Overall Study|Withdrawal by Subject|6
6363761|NCT01315353|10153430|FG002|Overall Study|Withdrawal by Subject|1
6363762|NCT01315353|10153428|FG000|Overall Study|Lost to Follow-up|13
6363763|NCT01315353|10153429|FG001|Overall Study|Lost to Follow-up|6
6363764|NCT01315353|10153430|FG002|Overall Study|Lost to Follow-up|6
6363765|NCT01315353|10153428|FG000|Overall Study|Unwilling to adhere to requirements|5
6363766|NCT01315353|10153429|FG001|Overall Study|Unwilling to adhere to requirements|5
6363767|NCT01315353|10153430|FG002|Overall Study|Unwilling to adhere to requirements|4
6363768|NCT01315353|10153428|FG000|Overall Study|Site closing|7
6363769|NCT01315353|10153429|FG001|Overall Study|Site closing|4
6363770|NCT01315353|10153430|FG002|Overall Study|Site closing|0
6363771|NCT01315353|10153428|FG000|Overall Study|Taken off study by site in error|0
6363772|NCT01315353|10153429|FG001|Overall Study|Taken off study by site in error|1
6363773|NCT01315353|10153430|FG002|Overall Study|Taken off study by site in error|0
6363774|NCT01315353|10153428|FG000|Overall Study|Inadvertent randomization/assignment|0
6363775|NCT01315353|10153429|FG001|Overall Study|Inadvertent randomization/assignment|0
6363776|NCT01315353|10153430|FG002|Overall Study|Inadvertent randomization/assignment|2
6171632|NCT01261325|9818522|FG001|Overall Study|AE, serious fatal|0
6171633|NCT01261325|9818523|FG002|Overall Study|AE, serious fatal|2
6171634|NCT01261338|9818536|FG000|Overall Study|Withdrawal by Subject|3
6363777|NCT01318993|10153438|FG000|Overall Study|Adverse Event|53
6363778|NCT01318993|10153438|FG000|Overall Study|Lack of Efficacy|121
6363779|NCT01318993|10153438|FG000|Overall Study|Protocol Violation|3
6363780|NCT01318993|10153438|FG000|Overall Study|Protocol based stopping criteria|6
6084398|NCT00642811|9693340|FG001|Overall Study|Other|1
6084399|NCT00642811|9693341|FG002|Overall Study|Other|0
6363781|NCT01318993|10153438|FG000|Overall Study|Study closed or terminated|174
6363782|NCT01318993|10153438|FG000|Overall Study|Lost to Follow-up|4
6363783|NCT01318993|10153438|FG000|Overall Study|Physician Decision|13
6363784|NCT01318993|10153438|FG000|Overall Study|Withdrawal by Subject|24
6363785|NCT01335685|10153446|FG000|Overall Study|Study Terminated by Sponsor|2
6363786|NCT01335685|10153447|FG001|Overall Study|Study Terminated by Sponsor|1
6363787|NCT01335685|10153448|FG002|Overall Study|Study Terminated by Sponsor|1
6363788|NCT01335685|10153449|FG003|Overall Study|Study Terminated by Sponsor|10
6363789|NCT01335685|10153450|FG004|Overall Study|Study Terminated by Sponsor|0
6363790|NCT01335685|10153451|FG005|Overall Study|Study Terminated by Sponsor|4
6363791|NCT01335685|10153452|FG006|Overall Study|Study Terminated by Sponsor|2
6363792|NCT01335685|10153453|FG007|Overall Study|Study Terminated by Sponsor|3
6363793|NCT01335685|10153446|FG000|Overall Study|Withdrawal by Subject|1
6363794|NCT01335685|10153447|FG001|Overall Study|Withdrawal by Subject|0
6363795|NCT01335685|10153448|FG002|Overall Study|Withdrawal by Subject|0
6363796|NCT01335685|10153449|FG003|Overall Study|Withdrawal by Subject|1
6363797|NCT01335685|10153450|FG004|Overall Study|Withdrawal by Subject|0
6363798|NCT01335685|10153451|FG005|Overall Study|Withdrawal by Subject|0
6363799|NCT01335685|10153452|FG006|Overall Study|Withdrawal by Subject|0
6363800|NCT01335685|10153453|FG007|Overall Study|Withdrawal by Subject|0
6363801|NCT01335685|10153446|FG000|Overall Study|Reason not Specified|0
6363802|NCT01335685|10153447|FG001|Overall Study|Reason not Specified|0
6363803|NCT01335685|10153448|FG002|Overall Study|Reason not Specified|1
6363804|NCT01335685|10153449|FG003|Overall Study|Reason not Specified|0
6363805|NCT01335685|10153450|FG004|Overall Study|Reason not Specified|0
6363806|NCT01335685|10153451|FG005|Overall Study|Reason not Specified|1
6363807|NCT01335685|10153452|FG006|Overall Study|Reason not Specified|0
6363808|NCT01335685|10153453|FG007|Overall Study|Reason not Specified|0
6363809|NCT01336621|10153476|FG000|Primary Reporting Phase (Upto 5.8 Years)|Adverse Event|11
6363810|NCT01336621|10153476|FG000|Primary Reporting Phase (Upto 5.8 Years)|Lack of Efficacy|2
6363811|NCT01336621|10153476|FG000|Primary Reporting Phase (Upto 5.8 Years)|Protocol Violation|12
6363812|NCT01336621|10153476|FG000|Primary Reporting Phase (Upto 5.8 Years)|Withdrawal by Subject|27
6363813|NCT01336621|10153476|FG000|Primary Reporting Phase (Upto 5.8 Years)|Other: study terminated|11
6363814|NCT01336621|10153476|FG000|Primary Reporting Phase (Upto 5.8 Years)|Physician Decision|2
6363815|NCT01336621|10153476|FG000|Primary Reporting Phase (Upto 5.8 Years)|Other: Reached stopping criteria|22
6363816|NCT01336621|10153476|FG000|Primary Reporting Phase (Upto 5.8 Years)|Other: lost to follow up|2
6363817|NCT01336621|10153476|FG000|Primary Reporting Phase (Upto 5.8 Years)|Other: Continued in SFUCP|9
6363818|NCT01336621|10153476|FG000|SFUCP (up to 2.6 Years)|Other: Reached stopping criteria|1
6363819|NCT01336621|10153476|FG000|SFUCP (up to 2.6 Years)|Adverse Event|1
6363820|NCT01336621|10153476|FG000|SFUCP (up to 2.6 Years)|Withdrawal by Subject|3
6363821|NCT01336621|10153476|FG000|SFUCP (up to 2.6 Years)|Physician Decision|1
6363822|NCT01336621|10153476|FG000|SFUCP (up to 2.6 Years)|Other: Study closed/terminated|3
6363823|NCT04170296|10153496|FG000|Overall Study|Adverse Event|1
6363824|NCT04170296|10153497|FG001|Overall Study|Adverse Event|0
6363825|NCT04170296|10153496|FG000|Overall Study|Withdrawal by Subject|3
6363826|NCT04170296|10153497|FG001|Overall Study|Withdrawal by Subject|2
6363827|NCT04170296|10153496|FG000|Overall Study|Lost to Follow-up|4
6363828|NCT04170296|10153497|FG001|Overall Study|Lost to Follow-up|2
6363829|NCT04039217|10153509|FG000|Overall Study|Lost to Follow-up|1
6363830|NCT03078192|10153563|FG000|Overall Study|Withdrawal by Subject|2
6363831|NCT03078192|10153564|FG001|Overall Study|Withdrawal by Subject|1
6363832|NCT03078192|10153563|FG000|Overall Study|screen failure|0
6363833|NCT03078192|10153564|FG001|Overall Study|screen failure|3
6363834|NCT02903823|10153579|FG000|Overall Study|Physician Decision|5
6363835|NCT02903823|10153579|FG000|Overall Study|Could not advance catheter|1
6084400|NCT00642811|9693342|FG003|Overall Study|Other|1
6084401|NCT00642811|9693343|FG004|Overall Study|Other|0
6084402|NCT00642811|9693344|FG005|Overall Study|Other|0
6084403|NCT00642850|9693358|FG000|Overall Study|Death|7
6084404|NCT00642850|9693358|FG000|Overall Study|Adverse Event|2
6084405|NCT00642850|9693358|FG000|Overall Study|Lack of Efficacy|1
6084406|NCT00642850|9693358|FG000|Overall Study|Protocol Violation|2
6084407|NCT00642850|9693358|FG000|Overall Study|Kidney transplantation|8
6084408|NCT00642850|9693358|FG000|Overall Study|Blood transfusion|6
6363836|NCT02903823|10153579|FG000|Overall Study|Catheter dislodgement|1
6363837|NCT01547117|10153601|FG000|Overall Study|Physician Decision|0
6363838|NCT01547117|10153602|FG001|Overall Study|Physician Decision|1
6363839|NCT01547117|10153603|FG002|Overall Study|Physician Decision|1
6363840|NCT01547117|10153604|FG003|Overall Study|Physician Decision|3
6363841|NCT01547117|10153601|FG000|Overall Study|Withdrawal by Subject|1
6084409|NCT00642850|9693358|FG000|Overall Study|Other reasons|7
6084410|NCT00642902|9693366|FG000|Overall Study|Adverse Event|0
6084411|NCT00642902|9693367|FG001|Overall Study|Adverse Event|1
6084412|NCT00642902|9693368|FG002|Overall Study|Adverse Event|3
6084413|NCT00642902|9693369|FG003|Overall Study|Adverse Event|1
6363842|NCT01547117|10153602|FG001|Overall Study|Withdrawal by Subject|2
6363843|NCT01547117|10153603|FG002|Overall Study|Withdrawal by Subject|1
6363844|NCT01547117|10153604|FG003|Overall Study|Withdrawal by Subject|2
6363845|NCT01431508|10153630|FG000|Overall Study|Lack of Efficacy|1
6363846|NCT01431508|10153630|FG000|Overall Study|Unable to Follow Protocol Procedures|1
6363847|NCT00871351|10153637|FG000|Overall Study|Withdrawal by Subject|1
6363848|NCT00871351|10153638|FG001|Overall Study|Withdrawal by Subject|0
6363849|NCT00871351|10153639|FG002|Overall Study|Withdrawal by Subject|0
6363850|NCT00871351|10153637|FG000|Overall Study|Adverse Event|3
6363851|NCT00871351|10153638|FG001|Overall Study|Adverse Event|1
6363852|NCT00871351|10153639|FG002|Overall Study|Adverse Event|0
6363853|NCT00832455|10153647|FG000|Overall Study|Adverse Event|13
6363854|NCT00832455|10153647|FG000|Overall Study|Lost to Follow-up|26
6363855|NCT00832455|10153647|FG000|Overall Study|Protocol Violation|4
6363856|NCT00832455|10153647|FG000|Overall Study|Withdrawal by Subject|17
6363857|NCT00832455|10153647|FG000|Overall Study|Screening Failure|2
6363858|NCT00832455|10153647|FG000|Overall Study|Stopped Medication|4
6363859|NCT00832455|10153647|FG000|Overall Study|Parent misunderstood study|1
6363860|NCT00832455|10153647|FG000|Overall Study|Parent dissatisfied|1
6363861|NCT00832455|10153647|FG000|Overall Study|No improvement|3
6363862|NCT00832455|10153647|FG000|Overall Study|Patient moved|1
6363863|NCT00812006|10153663|FG000|Overall Study|Lost to Follow-up|0
6363864|NCT00812006|10153664|FG001|Overall Study|Lost to Follow-up|0
6363865|NCT00812006|10153665|FG002|Overall Study|Lost to Follow-up|2
6363866|NCT00812006|10153663|FG000|Overall Study|Physician Decision|0
6363867|NCT00812006|10153664|FG001|Overall Study|Physician Decision|0
6363868|NCT00812006|10153665|FG002|Overall Study|Physician Decision|1
6363869|NCT00812006|10153663|FG000|Overall Study|Withdrawal by Subject|2
6363870|NCT00812006|10153664|FG001|Overall Study|Withdrawal by Subject|1
6363871|NCT00812006|10153665|FG002|Overall Study|Withdrawal by Subject|1
6363872|NCT00812006|10153663|FG000|Overall Study|Lack of Qualifying Event|4
6363873|NCT00812006|10153664|FG001|Overall Study|Lack of Qualifying Event|2
6363874|NCT00812006|10153665|FG002|Overall Study|Lack of Qualifying Event|2
6363875|NCT00687531|10153678|FG000|Overall Study|Did not meet protocol eligibility|104
6363876|NCT00687531|10153678|FG000|Overall Study|Adverse Event|5
6363877|NCT00687531|10153678|FG000|Overall Study|Lost to Follow-up|26
6363878|NCT00654628|10153682|FG000|6-week Active Treatment Period|Adverse Event|9
6363879|NCT00654628|10153682|FG000|6-week Active Treatment Period|Lost to Follow-up|10
6363880|NCT00654628|10153682|FG000|6-week Active Treatment Period|Transferred to branch hospital|1
6363881|NCT00654628|10153682|FG000|6-week Active Treatment Period|Out of window period|1
6363882|NCT00654628|10153682|FG000|6 -Week Extension Period (Single Site)|Adverse Event|4
6363883|NCT00654628|10153682|FG000|6 -Week Extension Period (Single Site)|Lost to Follow-up|1
6363884|NCT00536380|10153708|FG000|Overall Study|Adverse Event|0
6363885|NCT00536380|10153709|FG001|Overall Study|Adverse Event|2
6363886|NCT00536380|10153710|FG002|Overall Study|Adverse Event|2
6363887|NCT00536380|10153708|FG000|Overall Study|Lost to Follow-up|0
6363888|NCT00536380|10153709|FG001|Overall Study|Lost to Follow-up|0
6363889|NCT00536380|10153710|FG002|Overall Study|Lost to Follow-up|1
6363890|NCT00536380|10153708|FG000|Overall Study|Withdrawal unrelated to study drug|2
6363891|NCT00536380|10153709|FG001|Overall Study|Withdrawal unrelated to study drug|0
6363892|NCT00536380|10153710|FG002|Overall Study|Withdrawal unrelated to study drug|1
6363893|NCT00536380|10153708|FG000|Overall Study|Withdrawal related to study drug|7
6363894|NCT00536380|10153709|FG001|Overall Study|Withdrawal related to study drug|5
6363895|NCT00536380|10153710|FG002|Overall Study|Withdrawal related to study drug|2
6363896|NCT00536380|10153708|FG000|Overall Study|Noncompliance with protocol|3
6363897|NCT00536380|10153709|FG001|Overall Study|Noncompliance with protocol|2
6363898|NCT00536380|10153710|FG002|Overall Study|Noncompliance with protocol|2
6363899|NCT00536380|10153708|FG000|Overall Study|Did not meet protocol eligibility|0
6363900|NCT00536380|10153709|FG001|Overall Study|Did not meet protocol eligibility|0
6363901|NCT00536380|10153710|FG002|Overall Study|Did not meet protocol eligibility|1
6363902|NCT00536380|10153708|FG000|Overall Study|Administrative|0
6363903|NCT00536380|10153709|FG001|Overall Study|Administrative|0
6363904|NCT00536380|10153710|FG002|Overall Study|Administrative|1
6363905|NCT00521599|10153721|FG000|Overall Study|Adverse Event|5
6363906|NCT00521599|10153722|FG001|Overall Study|Adverse Event|7
6363907|NCT00521599|10153723|FG002|Overall Study|Adverse Event|6
6363908|NCT00521599|10153721|FG000|Overall Study|Treatment Failure|8
6363909|NCT00521599|10153722|FG001|Overall Study|Treatment Failure|9
6363910|NCT00521599|10153723|FG002|Overall Study|Treatment Failure|22
6363911|NCT00521599|10153721|FG000|Overall Study|Lost to Follow-up|2
6363912|NCT00521599|10153722|FG001|Overall Study|Lost to Follow-up|1
6363913|NCT00521599|10153723|FG002|Overall Study|Lost to Follow-up|2
6363914|NCT00521599|10153721|FG000|Overall Study|Withdrawal by Subject|3
6363915|NCT00521599|10153722|FG001|Overall Study|Withdrawal by Subject|5
6363916|NCT00521599|10153723|FG002|Overall Study|Withdrawal by Subject|1
6363917|NCT00521599|10153721|FG000|Overall Study|Withdrawal by subject treatment related|3
6363918|NCT00521599|10153722|FG001|Overall Study|Withdrawal by subject treatment related|1
6363919|NCT00521599|10153723|FG002|Overall Study|Withdrawal by subject treatment related|2
6363920|NCT00521599|10153721|FG000|Overall Study|Protocol Violation|2
6363921|NCT00521599|10153722|FG001|Overall Study|Protocol Violation|4
6363922|NCT00521599|10153723|FG002|Overall Study|Protocol Violation|2
6363923|NCT00521599|10153721|FG000|Overall Study|Did not meet protocol eligibility|2
6363924|NCT00521599|10153722|FG001|Overall Study|Did not meet protocol eligibility|2
6363925|NCT00521599|10153723|FG002|Overall Study|Did not meet protocol eligibility|1
6363926|NCT00496834|10153734|FG000|Overall Study|Withdrawal by Subject|4
6363927|NCT00496834|10153735|FG001|Overall Study|Withdrawal by Subject|6
6363928|NCT00496834|10153734|FG000|Overall Study|Contraindicated medication administered|0
6363929|NCT00496834|10153735|FG001|Overall Study|Contraindicated medication administered|1
6363930|NCT00496834|10153734|FG000|Overall Study|Inclusion/exclusion criteria not met|3
6363931|NCT00496834|10153735|FG001|Overall Study|Inclusion/exclusion criteria not met|2
6363932|NCT00496834|10153734|FG000|Overall Study|Adverse Event|5
6363933|NCT00496834|10153735|FG001|Overall Study|Adverse Event|3
6363934|NCT00496834|10153734|FG000|Overall Study|IP administration violation|2
6363935|NCT00496834|10153735|FG001|Overall Study|IP administration violation|0
6363936|NCT00496834|10153734|FG000|Overall Study|Lost to Follow-up|2
6363937|NCT00496834|10153735|FG001|Overall Study|Lost to Follow-up|0
6363938|NCT00496834|10153734|FG000|Overall Study|Blood Pressure control failure|2
6363939|NCT00496834|10153735|FG001|Overall Study|Blood Pressure control failure|1
6363940|NCT00442897|10153745|FG000|Base Study (12 Week Follow-up)|Adverse Event|1
6363941|NCT00442897|10153746|FG001|Base Study (12 Week Follow-up)|Adverse Event|0
6363942|NCT00442897|10153745|FG000|Base Study (12 Week Follow-up)|Death|0
6363943|NCT00442897|10153746|FG001|Base Study (12 Week Follow-up)|Death|1
6363944|NCT00442897|10153745|FG000|Base Study (12 Week Follow-up)|Protocol Violation|7
6363945|NCT00442897|10153746|FG001|Base Study (12 Week Follow-up)|Protocol Violation|3
6363946|NCT00442897|10153745|FG000|Base Study (12 Week Follow-up)|Withdrawal by Subject|9
6363947|NCT00442897|10153746|FG001|Base Study (12 Week Follow-up)|Withdrawal by Subject|8
6363948|NCT00442897|10153745|FG000|24 Weeks Follow-up (3 Centers)|Adverse Event|1
6363949|NCT00442897|10153746|FG001|24 Weeks Follow-up (3 Centers)|Adverse Event|0
6363950|NCT00442897|10153745|FG000|24 Weeks Follow-up (3 Centers)|Lost to Follow-up|2
6363951|NCT00442897|10153746|FG001|24 Weeks Follow-up (3 Centers)|Lost to Follow-up|2
6363952|NCT00442897|10153745|FG000|24 Weeks Follow-up (3 Centers)|Protocol Violation|2
6363953|NCT00442897|10153746|FG001|24 Weeks Follow-up (3 Centers)|Protocol Violation|1
6363954|NCT00442897|10153745|FG000|24 Weeks Follow-up (3 Centers)|Withdrawal by Subject|1
6363955|NCT00442897|10153746|FG001|24 Weeks Follow-up (3 Centers)|Withdrawal by Subject|3
6363956|NCT00423579|10153754|FG000|Overall Study|Lost to Follow-up|3
6363957|NCT00423579|10153755|FG001|Overall Study|Lost to Follow-up|0
6363958|NCT00423579|10153754|FG000|Overall Study|Protocol Violation|1
6363959|NCT00423579|10153755|FG001|Overall Study|Protocol Violation|3
6363960|NCT00423579|10153754|FG000|Overall Study|Diagnosis of diabetes|0
6363961|NCT00423579|10153755|FG001|Overall Study|Diagnosis of diabetes|1
6363962|NCT00394355|10153765|FG000|Overall Study|Adverse Event|10
6363963|NCT00394355|10153766|FG001|Overall Study|Adverse Event|6
6363964|NCT00394355|10153767|FG002|Overall Study|Adverse Event|7
6363965|NCT00394355|10153768|FG003|Overall Study|Adverse Event|8
6363966|NCT00394355|10153765|FG000|Overall Study|Did not meet protocol eligibility|1
6363967|NCT00394355|10153766|FG001|Overall Study|Did not meet protocol eligibility|5
6363968|NCT00394355|10153767|FG002|Overall Study|Did not meet protocol eligibility|4
6363969|NCT00394355|10153768|FG003|Overall Study|Did not meet protocol eligibility|2
6363970|NCT00394355|10153765|FG000|Overall Study|Subject withdrawal - unrelated to drug|12
6363971|NCT00394355|10153766|FG001|Overall Study|Subject withdrawal - unrelated to drug|14
6363972|NCT00394355|10153767|FG002|Overall Study|Subject withdrawal - unrelated to drug|10
6363973|NCT00394355|10153768|FG003|Overall Study|Subject withdrawal - unrelated to drug|6
6363974|NCT00394355|10153765|FG000|Overall Study|Subject withdrawal - related to drug|1
6363975|NCT00394355|10153766|FG001|Overall Study|Subject withdrawal - related to drug|0
6363976|NCT00394355|10153767|FG002|Overall Study|Subject withdrawal - related to drug|0
6363977|NCT00394355|10153768|FG003|Overall Study|Subject withdrawal - related to drug|0
6363978|NCT00394355|10153765|FG000|Overall Study|Lost to Follow-up|7
6363979|NCT00394355|10153766|FG001|Overall Study|Lost to Follow-up|5
6363980|NCT00394355|10153767|FG002|Overall Study|Lost to Follow-up|4
6363981|NCT00394355|10153768|FG003|Overall Study|Lost to Follow-up|3
6363982|NCT00394355|10153765|FG000|Overall Study|Noncompliance with protocol|4
6363983|NCT00394355|10153766|FG001|Overall Study|Noncompliance with protocol|3
6363984|NCT00394355|10153767|FG002|Overall Study|Noncompliance with protocol|10
6363985|NCT00394355|10153768|FG003|Overall Study|Noncompliance with protocol|8
6363986|NCT00394355|10153765|FG000|Overall Study|Administrative|0
6363987|NCT00394355|10153766|FG001|Overall Study|Administrative|1
6363988|NCT00394355|10153767|FG002|Overall Study|Administrative|1
6363989|NCT00394355|10153768|FG003|Overall Study|Administrative|1
6363990|NCT00394355|10153765|FG000|Overall Study|Lack of Efficacy|0
6363991|NCT00394355|10153766|FG001|Overall Study|Lack of Efficacy|0
6363992|NCT00394355|10153767|FG002|Overall Study|Lack of Efficacy|2
6363993|NCT00394355|10153768|FG003|Overall Study|Lack of Efficacy|3
6363994|NCT00166504|10153789|FG000|Overall Study|Adverse Event|3
6363995|NCT00166504|10153790|FG001|Overall Study|Adverse Event|3
6363996|NCT00166504|10153789|FG000|Overall Study|Lost to Follow-up|1
6363997|NCT00166504|10153790|FG001|Overall Study|Lost to Follow-up|1
6363998|NCT00166504|10153789|FG000|Overall Study|Withdrawal by Subject|1
6363999|NCT00166504|10153790|FG001|Overall Study|Withdrawal by Subject|0
6364000|NCT01345240|10153801|FG000|Overall Study|Adverse Event|3
6364001|NCT01345240|10153802|FG001|Overall Study|Adverse Event|5
6364002|NCT01345240|10153803|FG002|Overall Study|Adverse Event|4
6364003|NCT01345240|10153804|FG003|Overall Study|Adverse Event|2
6364004|NCT01345240|10153805|FG004|Overall Study|Adverse Event|1
6364005|NCT01345240|10153801|FG000|Overall Study|Lost to Follow-up|8
6364006|NCT01345240|10153802|FG001|Overall Study|Lost to Follow-up|9
6364007|NCT01345240|10153803|FG002|Overall Study|Lost to Follow-up|14
6364008|NCT01345240|10153804|FG003|Overall Study|Lost to Follow-up|7
6364009|NCT01345240|10153805|FG004|Overall Study|Lost to Follow-up|9
6364010|NCT01371305|10153832|FG000|Overall Study|Adverse Event|0
6364011|NCT01371305|10153833|FG001|Overall Study|Adverse Event|0
6364012|NCT01371305|10153834|FG002|Overall Study|Adverse Event|0
6364013|NCT01371305|10153835|FG003|Overall Study|Adverse Event|2
6364014|NCT01371305|10153836|FG004|Overall Study|Adverse Event|1
6364015|NCT01371305|10153837|FG005|Overall Study|Adverse Event|0
6364016|NCT01371305|10153832|FG000|Overall Study|Study terminated by sponsor|0
6364017|NCT01371305|10153833|FG001|Overall Study|Study terminated by sponsor|0
6364018|NCT01371305|10153834|FG002|Overall Study|Study terminated by sponsor|0
6364019|NCT01371305|10153835|FG003|Overall Study|Study terminated by sponsor|0
6364020|NCT01371305|10153836|FG004|Overall Study|Study terminated by sponsor|3
6364021|NCT01371305|10153837|FG005|Overall Study|Study terminated by sponsor|1
6364022|NCT01371305|10153832|FG000|Overall Study|Subject request|0
6364023|NCT01371305|10153833|FG001|Overall Study|Subject request|0
6364024|NCT01371305|10153834|FG002|Overall Study|Subject request|0
6364025|NCT01371305|10153835|FG003|Overall Study|Subject request|0
6364026|NCT01371305|10153836|FG004|Overall Study|Subject request|0
6364027|NCT01371305|10153837|FG005|Overall Study|Subject request|1
6364028|NCT01376323|10153857|FG000|Overall Study|Adverse Event|1
6364029|NCT01376323|10153858|FG001|Overall Study|Adverse Event|0
6364030|NCT01376323|10153859|FG002|Overall Study|Adverse Event|0
6364031|NCT01376323|10153860|FG003|Overall Study|Adverse Event|2
6364032|NCT01376323|10153861|FG004|Overall Study|Adverse Event|0
6364033|NCT01376323|10153857|FG000|Overall Study|Lost to Follow-up|0
6364034|NCT01376323|10153858|FG001|Overall Study|Lost to Follow-up|0
6364035|NCT01376323|10153859|FG002|Overall Study|Lost to Follow-up|0
6364036|NCT01376323|10153860|FG003|Overall Study|Lost to Follow-up|2
6364037|NCT01376323|10153861|FG004|Overall Study|Lost to Follow-up|0
6364038|NCT01376323|10153857|FG000|Overall Study|Physician Decision|1
6364039|NCT01376323|10153858|FG001|Overall Study|Physician Decision|0
6364040|NCT01376323|10153859|FG002|Overall Study|Physician Decision|2
6364041|NCT01376323|10153860|FG003|Overall Study|Physician Decision|1
6364042|NCT01376323|10153861|FG004|Overall Study|Physician Decision|1
6364043|NCT01376323|10153857|FG000|Overall Study|Withdrawal by Subject|0
6364044|NCT01376323|10153858|FG001|Overall Study|Withdrawal by Subject|1
6364045|NCT01376323|10153859|FG002|Overall Study|Withdrawal by Subject|1
6364046|NCT01376323|10153860|FG003|Overall Study|Withdrawal by Subject|0
6364047|NCT01376323|10153861|FG004|Overall Study|Withdrawal by Subject|0
6364048|NCT01386658|10153885|FG000|Initial Icatibant Exposure|Withdrawal by Subject|0
6364049|NCT01386658|10153886|FG001|Initial Icatibant Exposure|Withdrawal by Subject|9
6364050|NCT01386658|10153885|FG000|Initial Icatibant Exposure|Lack of adherence and poor compliance|0
6364051|NCT01386658|10153886|FG001|Initial Icatibant Exposure|Lack of adherence and poor compliance|3
6364052|NCT01386684|10153896|FG000|Overall Study|Lost to Follow-up|51
6364053|NCT01386684|10153896|FG000|Overall Study|Other|51
6364054|NCT01386684|10153896|FG000|Overall Study|Death|47
6364055|NCT01386684|10153896|FG000|Overall Study|Withdrawal of Consent|44
6364056|NCT01386684|10153896|FG000|Overall Study|Alternative Therapy Required|37
6364057|NCT01386684|10153896|FG000|Overall Study|Disease Progression|28
6364058|NCT01386684|10153896|FG000|Overall Study|Adverse Event|20
6364059|NCT01386684|10153896|FG000|Overall Study|Noncompliance|8
6364060|NCT01386684|10153896|FG000|Overall Study|Protocol Violation|4
6364061|NCT01386684|10153896|FG000|Overall Study|Missing|3
6364062|NCT04980014|10153900|FG000|Overall Study|Participants who are Duplicated|1
6364063|NCT04980014|10153900|FG000|Overall Study|Follow-up Failure|13
6364064|NCT04980014|10153900|FG000|Overall Study|Participants who did not Receive NesinaAct® Tablet|2
6364065|NCT04980014|10153900|FG000|Overall Study|Participants who Have Been Administered NesinaAct® Tablet prior to the consent|2
6364066|NCT04980014|10153900|FG000|Overall Study|Participants who Violated Inclusion/Exclusion Criteria|57
6364067|NCT04427501|10153931|FG000|Overall Study|Death|0
6364068|NCT04427501|10153932|FG001|Overall Study|Death|0
6364069|NCT04427501|10153933|FG002|Overall Study|Death|0
6364070|NCT04427501|10153934|FG003|Overall Study|Death|0
6364071|NCT04427501|10153935|FG004|Overall Study|Death|0
6364072|NCT04427501|10153936|FG005|Overall Study|Death|15
6364073|NCT04427501|10153937|FG006|Overall Study|Death|0
6364074|NCT04427501|10153938|FG007|Overall Study|Death|0
6364075|NCT04427501|10153939|FG008|Overall Study|Death|0
6364076|NCT04427501|10153940|FG009|Overall Study|Death|0
6364077|NCT04427501|10153931|FG000|Overall Study|Lost to Follow-up|5
6364078|NCT04427501|10153932|FG001|Overall Study|Lost to Follow-up|1
6364079|NCT04427501|10153933|FG002|Overall Study|Lost to Follow-up|2
6364080|NCT04427501|10153934|FG003|Overall Study|Lost to Follow-up|0
6364081|NCT04427501|10153935|FG004|Overall Study|Lost to Follow-up|2
6364082|NCT04427501|10153936|FG005|Overall Study|Lost to Follow-up|11
6364083|NCT04427501|10153937|FG006|Overall Study|Lost to Follow-up|10
6364084|NCT04427501|10153938|FG007|Overall Study|Lost to Follow-up|10
6364085|NCT04427501|10153939|FG008|Overall Study|Lost to Follow-up|2
6364086|NCT04427501|10153940|FG009|Overall Study|Lost to Follow-up|5
6364087|NCT04427501|10153931|FG000|Overall Study|Physician Decision|0
6364088|NCT04427501|10153932|FG001|Overall Study|Physician Decision|3
6364089|NCT04427501|10153933|FG002|Overall Study|Physician Decision|0
6364090|NCT04427501|10153934|FG003|Overall Study|Physician Decision|0
6364091|NCT04427501|10153935|FG004|Overall Study|Physician Decision|0
6364092|NCT04427501|10153936|FG005|Overall Study|Physician Decision|0
6364093|NCT04427501|10153937|FG006|Overall Study|Physician Decision|2
6364094|NCT04427501|10153938|FG007|Overall Study|Physician Decision|0
6364095|NCT04427501|10153939|FG008|Overall Study|Physician Decision|0
6364096|NCT04427501|10153940|FG009|Overall Study|Physician Decision|0
6364097|NCT04427501|10153931|FG000|Overall Study|Withdrawal by Subject|9
6364098|NCT04427501|10153932|FG001|Overall Study|Withdrawal by Subject|2
6364099|NCT04427501|10153933|FG002|Overall Study|Withdrawal by Subject|2
6364100|NCT04427501|10153934|FG003|Overall Study|Withdrawal by Subject|3
6364101|NCT04427501|10153935|FG004|Overall Study|Withdrawal by Subject|7
6364102|NCT04427501|10153936|FG005|Overall Study|Withdrawal by Subject|25
6364103|NCT04427501|10153937|FG006|Overall Study|Withdrawal by Subject|15
6364104|NCT04427501|10153938|FG007|Overall Study|Withdrawal by Subject|7
6364105|NCT04427501|10153939|FG008|Overall Study|Withdrawal by Subject|4
6364106|NCT04427501|10153940|FG009|Overall Study|Withdrawal by Subject|1
6364107|NCT04427501|10153931|FG000|Overall Study|Other - as reported by the investigator|1
6364108|NCT04427501|10153932|FG001|Overall Study|Other - as reported by the investigator|0
6364109|NCT04427501|10153933|FG002|Overall Study|Other - as reported by the investigator|0
6364110|NCT04427501|10153934|FG003|Overall Study|Other - as reported by the investigator|0
6364111|NCT04427501|10153935|FG004|Overall Study|Other - as reported by the investigator|0
6364112|NCT04427501|10153936|FG005|Overall Study|Other - as reported by the investigator|6
6364113|NCT04427501|10153937|FG006|Overall Study|Other - as reported by the investigator|6
6364114|NCT04427501|10153938|FG007|Overall Study|Other - as reported by the investigator|0
6364115|NCT04427501|10153939|FG008|Overall Study|Other - as reported by the investigator|0
6364116|NCT04427501|10153940|FG009|Overall Study|Other - as reported by the investigator|0
6364117|NCT03735849|10153976|FG000|Overall Study|Lost to Follow-up|1
6364118|NCT03735849|10153977|FG001|Overall Study|Lost to Follow-up|0
6364119|NCT03735849|10153978|FG002|Overall Study|Lost to Follow-up|0
6364120|NCT03735849|10153976|FG000|Overall Study|Participant unable to adhere to visit|1
6364121|NCT03735849|10153977|FG001|Overall Study|Participant unable to adhere to visit|0
6364122|NCT03735849|10153978|FG002|Overall Study|Participant unable to adhere to visit|0
6364123|NCT03735849|10153976|FG000|Overall Study|Not Randomized|0
6364124|NCT03735849|10153977|FG001|Overall Study|Not Randomized|0
6364125|NCT03735849|10153978|FG002|Overall Study|Not Randomized|4
6364126|NCT03552393|10153994|FG000|Core Period|Kidney Transplant|1
6364127|NCT03552393|10153994|FG000|Core Period|Prohibited Medication|1
6364128|NCT03552393|10153994|FG000|Safety Extension Period|Kidney Transplant|4
6364129|NCT03412747|10154001|FG000|Initial Treatment Period: Wk0-Wk16|Adverse Event|2
6364130|NCT03412747|10154002|FG001|Initial Treatment Period: Wk0-Wk16|Adverse Event|2
6364131|NCT03412747|10154003|FG002|Initial Treatment Period: Wk0-Wk16|Adverse Event|3
6364132|NCT03412747|10154001|FG000|Initial Treatment Period: Wk0-Wk16|Death|0
6364133|NCT03412747|10154002|FG001|Initial Treatment Period: Wk0-Wk16|Death|0
6364134|NCT03412747|10154003|FG002|Initial Treatment Period: Wk0-Wk16|Death|1
6364135|NCT03412747|10154001|FG000|Initial Treatment Period: Wk0-Wk16|Lack of Efficacy|0
6364136|NCT03412747|10154002|FG001|Initial Treatment Period: Wk0-Wk16|Lack of Efficacy|0
6364137|NCT03412747|10154003|FG002|Initial Treatment Period: Wk0-Wk16|Lack of Efficacy|1
6364138|NCT03412747|10154001|FG000|Initial Treatment Period: Wk0-Wk16|Protocol Violation|0
6364139|NCT03412747|10154002|FG001|Initial Treatment Period: Wk0-Wk16|Protocol Violation|0
6364140|NCT03412747|10154003|FG002|Initial Treatment Period: Wk0-Wk16|Protocol Violation|2
6364141|NCT03412747|10154001|FG000|Initial Treatment Period: Wk0-Wk16|Lost to Follow-up|0
6364142|NCT03412747|10154002|FG001|Initial Treatment Period: Wk0-Wk16|Lost to Follow-up|2
6364143|NCT03412747|10154003|FG002|Initial Treatment Period: Wk0-Wk16|Lost to Follow-up|1
6364144|NCT03412747|10154001|FG000|Initial Treatment Period: Wk0-Wk16|Withdrawal by Subject|4
6364145|NCT03412747|10154002|FG001|Initial Treatment Period: Wk0-Wk16|Withdrawal by Subject|1
6364146|NCT03412747|10154003|FG002|Initial Treatment Period: Wk0-Wk16|Withdrawal by Subject|1
6364147|NCT03412747|10154001|FG000|Initial Treatment Period: Wk0-Wk16|Participant moved out of state|1
6364148|NCT03412747|10154002|FG001|Initial Treatment Period: Wk0-Wk16|Participant moved out of state|0
6364149|NCT03412747|10154003|FG002|Initial Treatment Period: Wk0-Wk16|Participant moved out of state|0
6364150|NCT03412747|10154001|FG000|Maintenance Treatment Period: Wk16-Wk24|Adverse Event|3
6364151|NCT03412747|10154002|FG001|Maintenance Treatment Period: Wk16-Wk24|Adverse Event|1
6364152|NCT03412747|10154003|FG002|Maintenance Treatment Period: Wk16-Wk24|Adverse Event|0
6364153|NCT03412747|10154001|FG000|Maintenance Treatment Period: Wk16-Wk24|Lack of Efficacy|1
6364154|NCT03412747|10154002|FG001|Maintenance Treatment Period: Wk16-Wk24|Lack of Efficacy|0
6364155|NCT03412747|10154003|FG002|Maintenance Treatment Period: Wk16-Wk24|Lack of Efficacy|0
6364156|NCT03412747|10154001|FG000|Maintenance Treatment Period: Wk16-Wk24|Lost to Follow-up|0
6364157|NCT03412747|10154002|FG001|Maintenance Treatment Period: Wk16-Wk24|Lost to Follow-up|0
6364158|NCT03412747|10154003|FG002|Maintenance Treatment Period: Wk16-Wk24|Lost to Follow-up|1
6364159|NCT03412747|10154001|FG000|Maintenance Treatment Period: Wk16-Wk24|Withdrawal by Subject|1
6364160|NCT03412747|10154002|FG001|Maintenance Treatment Period: Wk16-Wk24|Withdrawal by Subject|0
6364161|NCT03412747|10154003|FG002|Maintenance Treatment Period: Wk16-Wk24|Withdrawal by Subject|0
6364162|NCT03412747|10154001|FG000|Maintenance Treatment Period: Wk24-Wk56|Adverse Event|3
6364163|NCT03412747|10154002|FG001|Maintenance Treatment Period: Wk24-Wk56|Adverse Event|4
6364164|NCT03412747|10154003|FG002|Maintenance Treatment Period: Wk24-Wk56|Adverse Event|6
6364165|NCT03412747|10154001|FG000|Maintenance Treatment Period: Wk24-Wk56|Lack of Efficacy|0
6364166|NCT03412747|10154002|FG001|Maintenance Treatment Period: Wk24-Wk56|Lack of Efficacy|1
6364167|NCT03412747|10154003|FG002|Maintenance Treatment Period: Wk24-Wk56|Lack of Efficacy|1
6364168|NCT03412747|10154001|FG000|Maintenance Treatment Period: Wk24-Wk56|Lost to Follow-up|0
6364169|NCT03412747|10154002|FG001|Maintenance Treatment Period: Wk24-Wk56|Lost to Follow-up|2
6364170|NCT03412747|10154003|FG002|Maintenance Treatment Period: Wk24-Wk56|Lost to Follow-up|5
6364171|NCT03412747|10154001|FG000|Maintenance Treatment Period: Wk24-Wk56|Withdrawal by Subject|3
6364172|NCT03412747|10154002|FG001|Maintenance Treatment Period: Wk24-Wk56|Withdrawal by Subject|1
6364173|NCT03412747|10154003|FG002|Maintenance Treatment Period: Wk24-Wk56|Withdrawal by Subject|4
6364174|NCT03412747|10154001|FG000|Maintenance Treatment Period: Wk24-Wk56|Moving out of town|0
6364175|NCT03412747|10154002|FG001|Maintenance Treatment Period: Wk24-Wk56|Moving out of town|1
6364176|NCT03412747|10154003|FG002|Maintenance Treatment Period: Wk24-Wk56|Moving out of town|0
6364177|NCT03333382|10154023|FG000|Overall Study|Lost to Follow-up|1
6364178|NCT03333382|10154024|FG001|Overall Study|Lost to Follow-up|0
6364179|NCT03107611|10154048|FG000|Overall Study|Adverse Event|1
6364180|NCT03107611|10154049|FG001|Overall Study|Adverse Event|0
6364181|NCT03107611|10154050|FG002|Overall Study|Adverse Event|2
6364182|NCT03107611|10154048|FG000|Overall Study|Lost to Follow-up|3
6364183|NCT03107611|10154049|FG001|Overall Study|Lost to Follow-up|3
6364184|NCT03107611|10154050|FG002|Overall Study|Lost to Follow-up|3
6084414|NCT00642902|9693366|FG000|Overall Study|Lost to Follow-up|1
6364185|NCT03107611|10154048|FG000|Overall Study|Protocol Violation|0
6364186|NCT03107611|10154049|FG001|Overall Study|Protocol Violation|0
6364187|NCT03107611|10154050|FG002|Overall Study|Protocol Violation|1
6364188|NCT03107611|10154048|FG000|Overall Study|Withdrawal by Subject|1
6364189|NCT03107611|10154049|FG001|Overall Study|Withdrawal by Subject|0
6364190|NCT03107611|10154050|FG002|Overall Study|Withdrawal by Subject|1
6364191|NCT03107611|10154048|FG000|Overall Study|Worsening signs/symptoms|2
6364192|NCT03107611|10154049|FG001|Overall Study|Worsening signs/symptoms|1
6364193|NCT03107611|10154050|FG002|Overall Study|Worsening signs/symptoms|2
6364194|NCT02720016|10154061|FG000|Overall Study|Separation of couple|6
6364195|NCT02720016|10154062|FG001|Overall Study|Separation of couple|8
6364196|NCT02720016|10154063|FG002|Overall Study|Separation of couple|2
6364197|NCT02720016|10154061|FG000|Overall Study|Withdrawal by Subject|6
6364198|NCT02720016|10154062|FG001|Overall Study|Withdrawal by Subject|6
6364199|NCT02720016|10154063|FG002|Overall Study|Withdrawal by Subject|4
6364200|NCT02720016|10154061|FG000|Overall Study|Scheduling issues|2
6364201|NCT02720016|10154062|FG001|Overall Study|Scheduling issues|4
6364202|NCT02720016|10154063|FG002|Overall Study|Scheduling issues|7
6364203|NCT02720016|10154061|FG000|Overall Study|Childcare|2
6364204|NCT02720016|10154062|FG001|Overall Study|Childcare|0
6364205|NCT02720016|10154063|FG002|Overall Study|Childcare|2
6364206|NCT02720016|10154061|FG000|Overall Study|Withdrawal by PI|2
6364207|NCT02720016|10154062|FG001|Overall Study|Withdrawal by PI|2
6364208|NCT02720016|10154063|FG002|Overall Study|Withdrawal by PI|0
6364209|NCT02720016|10154061|FG000|Overall Study|Moved away|2
6364210|NCT02720016|10154062|FG001|Overall Study|Moved away|0
6364211|NCT02720016|10154063|FG002|Overall Study|Moved away|0
6364212|NCT02720016|10154061|FG000|Overall Study|Not Primary Health Concern|0
6364213|NCT02720016|10154062|FG001|Overall Study|Not Primary Health Concern|0
6364214|NCT02720016|10154063|FG002|Overall Study|Not Primary Health Concern|2
6364215|NCT02720016|10154061|FG000|Overall Study|Transportation issues|0
6364216|NCT02720016|10154062|FG001|Overall Study|Transportation issues|0
6364217|NCT02720016|10154063|FG002|Overall Study|Transportation issues|1
6364218|NCT02720016|10154061|FG000|Overall Study|Other|0
6364219|NCT02720016|10154062|FG001|Overall Study|Other|0
6364220|NCT02720016|10154063|FG002|Overall Study|Other|2
6364221|NCT02607956|10154074|FG000|Double-Blinded Phase|Withdrew Consent|17
6364222|NCT02607956|10154075|FG001|Double-Blinded Phase|Withdrew Consent|19
6364223|NCT02607956|10154076|FG002|Double-Blinded Phase|Withdrew Consent|0
6364224|NCT02607956|10154077|FG003|Double-Blinded Phase|Withdrew Consent|0
6364225|NCT02607956|10154074|FG000|Double-Blinded Phase|Lost to Follow-up|19
6364226|NCT02607956|10154075|FG001|Double-Blinded Phase|Lost to Follow-up|16
6364227|NCT02607956|10154076|FG002|Double-Blinded Phase|Lost to Follow-up|0
6364228|NCT02607956|10154077|FG003|Double-Blinded Phase|Lost to Follow-up|0
6364229|NCT02607956|10154074|FG000|Double-Blinded Phase|Randomized but never treated|7
6364230|NCT02607956|10154075|FG001|Double-Blinded Phase|Randomized but never treated|5
6364231|NCT02607956|10154076|FG002|Double-Blinded Phase|Randomized but never treated|0
6364232|NCT02607956|10154077|FG003|Double-Blinded Phase|Randomized but never treated|0
6364233|NCT02607956|10154074|FG000|Double-Blinded Phase|Investigator's Discretion|7
6364234|NCT02607956|10154075|FG001|Double-Blinded Phase|Investigator's Discretion|2
6364235|NCT02607956|10154076|FG002|Double-Blinded Phase|Investigator's Discretion|0
6364236|NCT02607956|10154077|FG003|Double-Blinded Phase|Investigator's Discretion|0
6364237|NCT02607956|10154074|FG000|Double-Blinded Phase|Death|4
6364238|NCT02607956|10154075|FG001|Double-Blinded Phase|Death|4
6364239|NCT02607956|10154076|FG002|Double-Blinded Phase|Death|0
6364240|NCT02607956|10154077|FG003|Double-Blinded Phase|Death|0
6364241|NCT02607956|10154074|FG000|Double-Blinded Phase|Adverse Event|4
6364242|NCT02607956|10154075|FG001|Double-Blinded Phase|Adverse Event|3
6364243|NCT02607956|10154076|FG002|Double-Blinded Phase|Adverse Event|0
6364244|NCT02607956|10154077|FG003|Double-Blinded Phase|Adverse Event|0
6364245|NCT02607956|10154074|FG000|Double-Blinded Phase|Protocol Violation|3
6364246|NCT02607956|10154075|FG001|Double-Blinded Phase|Protocol Violation|1
6364247|NCT02607956|10154076|FG002|Double-Blinded Phase|Protocol Violation|0
6364248|NCT02607956|10154077|FG003|Double-Blinded Phase|Protocol Violation|0
6364249|NCT02607956|10154074|FG000|Double-Blinded Phase|Non-Compliance with Study Drug|0
6364250|NCT02607956|10154075|FG001|Double-Blinded Phase|Non-Compliance with Study Drug|3
6364251|NCT02607956|10154076|FG002|Double-Blinded Phase|Non-Compliance with Study Drug|0
6364252|NCT02607956|10154077|FG003|Double-Blinded Phase|Non-Compliance with Study Drug|0
6364253|NCT02607956|10154074|FG000|Open-Label Extension Phase|Withdrew Consent|0
6364254|NCT02607956|10154075|FG001|Open-Label Extension Phase|Withdrew Consent|0
6364255|NCT02607956|10154076|FG002|Open-Label Extension Phase|Withdrew Consent|10
6364256|NCT02607956|10154077|FG003|Open-Label Extension Phase|Withdrew Consent|16
6364257|NCT02607956|10154074|FG000|Open-Label Extension Phase|Lost to Follow-up|0
6364258|NCT02607956|10154075|FG001|Open-Label Extension Phase|Lost to Follow-up|0
6364259|NCT02607956|10154076|FG002|Open-Label Extension Phase|Lost to Follow-up|14
6364260|NCT02607956|10154077|FG003|Open-Label Extension Phase|Lost to Follow-up|6
6364261|NCT02607956|10154074|FG000|Open-Label Extension Phase|Death|0
6364262|NCT02607956|10154075|FG001|Open-Label Extension Phase|Death|0
6364263|NCT02607956|10154076|FG002|Open-Label Extension Phase|Death|1
6364264|NCT02607956|10154077|FG003|Open-Label Extension Phase|Death|3
6364265|NCT02607956|10154074|FG000|Open-Label Extension Phase|Investigator's Discretion|0
6364266|NCT02607956|10154075|FG001|Open-Label Extension Phase|Investigator's Discretion|0
6364267|NCT02607956|10154076|FG002|Open-Label Extension Phase|Investigator's Discretion|2
6364268|NCT02607956|10154077|FG003|Open-Label Extension Phase|Investigator's Discretion|2
6364269|NCT02607956|10154074|FG000|Open-Label Extension Phase|Non Compliance with Study Drug|0
6364270|NCT02607956|10154075|FG001|Open-Label Extension Phase|Non Compliance with Study Drug|0
6364271|NCT02607956|10154076|FG002|Open-Label Extension Phase|Non Compliance with Study Drug|2
6364272|NCT02607956|10154077|FG003|Open-Label Extension Phase|Non Compliance with Study Drug|0
6364273|NCT02607956|10154074|FG000|Open-Label Extension Phase|Protocol Violation|0
6364274|NCT02607956|10154075|FG001|Open-Label Extension Phase|Protocol Violation|0
6364275|NCT02607956|10154076|FG002|Open-Label Extension Phase|Protocol Violation|0
6364276|NCT02607956|10154077|FG003|Open-Label Extension Phase|Protocol Violation|2
6364277|NCT02607956|10154074|FG000|Open-Label Extension Phase|Pregnancy|0
6364278|NCT02607956|10154075|FG001|Open-Label Extension Phase|Pregnancy|0
6364279|NCT02607956|10154076|FG002|Open-Label Extension Phase|Pregnancy|0
6364280|NCT02607956|10154077|FG003|Open-Label Extension Phase|Pregnancy|1
6364281|NCT02564523|10154107|FG000|Overall Study|Withdrawal by Subject|3
6364282|NCT02564523|10154108|FG001|Overall Study|Withdrawal by Subject|0
6084415|NCT00642902|9693367|FG001|Overall Study|Lost to Follow-up|1
6364283|NCT02564523|10154109|FG002|Overall Study|Withdrawal by Subject|1
6364284|NCT02564523|10154110|FG003|Overall Study|Withdrawal by Subject|0
6364285|NCT02564523|10154111|FG004|Overall Study|Withdrawal by Subject|1
6364286|NCT02564523|10154112|FG005|Overall Study|Withdrawal by Subject|0
6364287|NCT02564523|10154113|FG006|Overall Study|Withdrawal by Subject|1
6364288|NCT02564523|10154114|FG007|Overall Study|Withdrawal by Subject|0
6364289|NCT02564523|10154115|FG008|Overall Study|Withdrawal by Subject|0
6364290|NCT02564523|10154116|FG009|Overall Study|Withdrawal by Subject|0
6364291|NCT02564523|10154117|FG010|Overall Study|Withdrawal by Subject|1
6364292|NCT02564523|10154118|FG011|Overall Study|Withdrawal by Subject|0
6364293|NCT02564523|10154119|FG012|Overall Study|Withdrawal by Subject|1
6364294|NCT02564523|10154120|FG013|Overall Study|Withdrawal by Subject|0
6364295|NCT02564523|10154121|FG014|Overall Study|Withdrawal by Subject|0
6364296|NCT02564523|10154122|FG015|Overall Study|Withdrawal by Subject|0
6364297|NCT02564523|10154123|FG016|Overall Study|Withdrawal by Subject|0
6364298|NCT02564523|10154124|FG017|Overall Study|Withdrawal by Subject|0
6364299|NCT02564523|10154107|FG000|Overall Study|Adverse Event|0
6364300|NCT02564523|10154108|FG001|Overall Study|Adverse Event|0
6364301|NCT02564523|10154109|FG002|Overall Study|Adverse Event|0
6364302|NCT02564523|10154110|FG003|Overall Study|Adverse Event|0
6364303|NCT02564523|10154111|FG004|Overall Study|Adverse Event|0
6364304|NCT02564523|10154112|FG005|Overall Study|Adverse Event|0
6364305|NCT02564523|10154113|FG006|Overall Study|Adverse Event|0
6364306|NCT02564523|10154114|FG007|Overall Study|Adverse Event|0
6364307|NCT02564523|10154115|FG008|Overall Study|Adverse Event|0
6364308|NCT02564523|10154116|FG009|Overall Study|Adverse Event|0
6364309|NCT02564523|10154117|FG010|Overall Study|Adverse Event|0
6364310|NCT02564523|10154118|FG011|Overall Study|Adverse Event|0
6364311|NCT02564523|10154119|FG012|Overall Study|Adverse Event|0
6364312|NCT02564523|10154120|FG013|Overall Study|Adverse Event|0
6364313|NCT02564523|10154121|FG014|Overall Study|Adverse Event|0
6364314|NCT02564523|10154122|FG015|Overall Study|Adverse Event|0
6364315|NCT02564523|10154123|FG016|Overall Study|Adverse Event|0
6364316|NCT02564523|10154124|FG017|Overall Study|Adverse Event|1
6364317|NCT02564523|10154107|FG000|Overall Study|Death|0
6364318|NCT02564523|10154108|FG001|Overall Study|Death|0
6364319|NCT02564523|10154109|FG002|Overall Study|Death|0
6364320|NCT02564523|10154110|FG003|Overall Study|Death|0
6364321|NCT02564523|10154111|FG004|Overall Study|Death|0
6364322|NCT02564523|10154112|FG005|Overall Study|Death|0
6364323|NCT02564523|10154113|FG006|Overall Study|Death|1
6364324|NCT02564523|10154114|FG007|Overall Study|Death|0
6084416|NCT00642902|9693368|FG002|Overall Study|Lost to Follow-up|0
6084417|NCT00642902|9693369|FG003|Overall Study|Lost to Follow-up|0
6084418|NCT00642902|9693366|FG000|Overall Study|Lack of Efficacy|0
6084419|NCT00642902|9693367|FG001|Overall Study|Lack of Efficacy|3
6084420|NCT00642902|9693368|FG002|Overall Study|Lack of Efficacy|3
6364325|NCT02564523|10154115|FG008|Overall Study|Death|0
6364326|NCT02564523|10154116|FG009|Overall Study|Death|0
6364327|NCT02564523|10154117|FG010|Overall Study|Death|1
6364328|NCT02564523|10154118|FG011|Overall Study|Death|0
6364329|NCT02564523|10154119|FG012|Overall Study|Death|0
6364330|NCT02564523|10154120|FG013|Overall Study|Death|0
6364331|NCT02564523|10154121|FG014|Overall Study|Death|0
6364332|NCT02564523|10154122|FG015|Overall Study|Death|0
6364333|NCT02564523|10154123|FG016|Overall Study|Death|0
6364334|NCT02564523|10154124|FG017|Overall Study|Death|0
6364335|NCT02564523|10154107|FG000|Overall Study|Lost to Follow-up|2
6364336|NCT02564523|10154108|FG001|Overall Study|Lost to Follow-up|1
6364337|NCT02564523|10154109|FG002|Overall Study|Lost to Follow-up|4
6364338|NCT02564523|10154110|FG003|Overall Study|Lost to Follow-up|0
6364339|NCT02564523|10154111|FG004|Overall Study|Lost to Follow-up|1
6364340|NCT02564523|10154112|FG005|Overall Study|Lost to Follow-up|0
6364341|NCT02564523|10154113|FG006|Overall Study|Lost to Follow-up|1
6364342|NCT02564523|10154114|FG007|Overall Study|Lost to Follow-up|0
6364343|NCT02564523|10154115|FG008|Overall Study|Lost to Follow-up|0
6084421|NCT00642902|9693369|FG003|Overall Study|Lack of Efficacy|0
6364344|NCT02564523|10154116|FG009|Overall Study|Lost to Follow-up|0
6364345|NCT02564523|10154117|FG010|Overall Study|Lost to Follow-up|0
6364346|NCT02564523|10154118|FG011|Overall Study|Lost to Follow-up|1
6364347|NCT02564523|10154119|FG012|Overall Study|Lost to Follow-up|1
6364348|NCT02564523|10154120|FG013|Overall Study|Lost to Follow-up|0
6364349|NCT02564523|10154121|FG014|Overall Study|Lost to Follow-up|0
6364350|NCT02564523|10154122|FG015|Overall Study|Lost to Follow-up|0
6364351|NCT02564523|10154123|FG016|Overall Study|Lost to Follow-up|0
6364352|NCT02564523|10154124|FG017|Overall Study|Lost to Follow-up|0
6364353|NCT02564523|10154107|FG000|Overall Study|Physician Decision|0
6364354|NCT02564523|10154108|FG001|Overall Study|Physician Decision|0
6364355|NCT02564523|10154109|FG002|Overall Study|Physician Decision|0
6364356|NCT02564523|10154110|FG003|Overall Study|Physician Decision|0
6364357|NCT02564523|10154111|FG004|Overall Study|Physician Decision|1
6364358|NCT02564523|10154112|FG005|Overall Study|Physician Decision|0
6364359|NCT02564523|10154113|FG006|Overall Study|Physician Decision|0
6364360|NCT02564523|10154114|FG007|Overall Study|Physician Decision|0
6364361|NCT02564523|10154115|FG008|Overall Study|Physician Decision|0
6364362|NCT02564523|10154116|FG009|Overall Study|Physician Decision|0
6364363|NCT02564523|10154117|FG010|Overall Study|Physician Decision|1
6364364|NCT02564523|10154118|FG011|Overall Study|Physician Decision|0
6364365|NCT02564523|10154119|FG012|Overall Study|Physician Decision|0
6364366|NCT02564523|10154120|FG013|Overall Study|Physician Decision|0
6364367|NCT02564523|10154121|FG014|Overall Study|Physician Decision|0
6364368|NCT02564523|10154122|FG015|Overall Study|Physician Decision|0
6364369|NCT02564523|10154123|FG016|Overall Study|Physician Decision|0
6364370|NCT02564523|10154124|FG017|Overall Study|Physician Decision|0
6364371|NCT02564523|10154107|FG000|Overall Study|Protocol Violation|2
6364372|NCT02564523|10154108|FG001|Overall Study|Protocol Violation|2
6364373|NCT02564523|10154109|FG002|Overall Study|Protocol Violation|5
6364374|NCT02564523|10154110|FG003|Overall Study|Protocol Violation|0
6364375|NCT02564523|10154111|FG004|Overall Study|Protocol Violation|1
6364376|NCT02564523|10154112|FG005|Overall Study|Protocol Violation|0
6364377|NCT02564523|10154113|FG006|Overall Study|Protocol Violation|0
6364378|NCT02564523|10154114|FG007|Overall Study|Protocol Violation|0
6364379|NCT02564523|10154115|FG008|Overall Study|Protocol Violation|0
6364380|NCT02564523|10154116|FG009|Overall Study|Protocol Violation|0
6364381|NCT02564523|10154117|FG010|Overall Study|Protocol Violation|0
6364382|NCT02564523|10154118|FG011|Overall Study|Protocol Violation|0
6364383|NCT02564523|10154119|FG012|Overall Study|Protocol Violation|0
6364384|NCT02564523|10154120|FG013|Overall Study|Protocol Violation|0
6364385|NCT02564523|10154121|FG014|Overall Study|Protocol Violation|0
6364386|NCT02564523|10154122|FG015|Overall Study|Protocol Violation|0
6364387|NCT02564523|10154123|FG016|Overall Study|Protocol Violation|0
6364388|NCT02564523|10154124|FG017|Overall Study|Protocol Violation|0
6364389|NCT02564523|10154107|FG000|Overall Study|Other|3
6364390|NCT02564523|10154108|FG001|Overall Study|Other|0
6364391|NCT02564523|10154109|FG002|Overall Study|Other|0
6364392|NCT02564523|10154110|FG003|Overall Study|Other|1
6364393|NCT02564523|10154111|FG004|Overall Study|Other|0
6364394|NCT02564523|10154112|FG005|Overall Study|Other|0
6364395|NCT02564523|10154113|FG006|Overall Study|Other|0
6364396|NCT02564523|10154114|FG007|Overall Study|Other|0
6364397|NCT02564523|10154115|FG008|Overall Study|Other|0
6364398|NCT02564523|10154116|FG009|Overall Study|Other|0
6364399|NCT02564523|10154117|FG010|Overall Study|Other|0
6364400|NCT02564523|10154118|FG011|Overall Study|Other|0
6364401|NCT02564523|10154119|FG012|Overall Study|Other|0
6364402|NCT02564523|10154120|FG013|Overall Study|Other|0
6364403|NCT02564523|10154121|FG014|Overall Study|Other|0
6364404|NCT02564523|10154122|FG015|Overall Study|Other|0
6364405|NCT02564523|10154123|FG016|Overall Study|Other|0
6364406|NCT02564523|10154124|FG017|Overall Study|Other|0
6364407|NCT02094261|10154203|FG000|Overall Study|Death|24
6364408|NCT02094261|10154203|FG000|Overall Study|Lost to Follow-up|1
6364409|NCT02094261|10154203|FG000|Overall Study|Withdrawal by Subject|4
6364410|NCT02094261|10154203|FG000|Overall Study|Ongoing Study at Data Cut-off|181
6364411|NCT01988493|10154212|FG000|Overall Study|Randomized but not treated|0
6364412|NCT01988493|10154213|FG001|Overall Study|Randomized but not treated|0
6364413|NCT01988493|10154214|FG002|Overall Study|Randomized but not treated|0
6364414|NCT01988493|10154215|FG003|Overall Study|Randomized but not treated|0
6364415|NCT01988493|10154216|FG004|Overall Study|Randomized but not treated|1
6364416|NCT01798004|10154233|FG000|Overall Study|Death|2
6364417|NCT01798004|10154233|FG000|Overall Study|Lack of Efficacy|8
6364418|NCT01798004|10154233|FG000|Overall Study|Physician Decision|25
6364419|NCT01798004|10154233|FG000|Overall Study|Withdrawal by Subject|4
6364420|NCT01798004|10154233|FG000|Overall Study|Ineligible|4
6364421|NCT01798004|10154233|FG000|Overall Study|Patient/parent refusal|7
6364422|NCT01798004|10154233|FG000|Overall Study|Initiation of other non-protocol therapy|5
6364423|NCT01798004|10154233|FG000|Overall Study|Enrollment another COG therapeutic trial|32
6364424|NCT01447628|10154260|FG000|Week 0 to Week 12 (1st Intervention)|Adverse Event|0
6364425|NCT01447628|10154261|FG001|Week 0 to Week 12 (1st Intervention)|Adverse Event|0
6364426|NCT01447628|10154262|FG002|Week 0 to Week 12 (1st Intervention)|Adverse Event|0
6364427|NCT01447628|10154263|FG003|Week 0 to Week 12 (1st Intervention)|Adverse Event|1
6364428|NCT01175356|10154283|FG000|Overall Study|Death|1
6364429|NCT01175356|10154283|FG000|Overall Study|Lack of Efficacy|12
6364430|NCT01175356|10154283|FG000|Overall Study|Lost to Follow-up|1
6364431|NCT01175356|10154283|FG000|Overall Study|Physician Decision|23
6364432|NCT01175356|10154283|FG000|Overall Study|Ineligible|1
6364433|NCT01175356|10154283|FG000|Overall Study|Treatment Slot Not Available|18
6364434|NCT01175356|10154283|FG000|Overall Study|Refusal by patient/parent/guardian|6
6364435|NCT01175356|10154283|FG000|Overall Study|Pts MIBG non-avid after enrollment|2
6364436|NCT01175356|10154283|FG000|Overall Study|On other COG study w/tumor tx intent|7
6364437|NCT01175356|10154283|FG000|Overall Study|Inadequate stem cell for transplant|1
6364438|NCT01175356|10154283|FG000|Overall Study|Initiation other tx prior to completion|9
6364439|NCT00515853|10154289|FG000|Overall Study|Lost to Follow-up|9
6364440|NCT00515853|10154290|FG001|Overall Study|Lost to Follow-up|13
6364441|NCT00515853|10154289|FG000|Overall Study|Withdrawal by Subject|6
6364442|NCT00515853|10154290|FG001|Overall Study|Withdrawal by Subject|4
6364443|NCT00003458|10154296|FG000|Overall Study|Not evaluable|4
6364444|NCT04613739|10154321|FG000|Overall Study|Lost to Follow-up|6
6364445|NCT04613739|10154322|FG001|Overall Study|Lost to Follow-up|9
6364446|NCT04613739|10154321|FG000|Overall Study|potentially duplicative/fraudulent|1
6364447|NCT04613739|10154322|FG001|Overall Study|potentially duplicative/fraudulent|3
6364450|NCT04407806|10154349|FG000|Overall Study|Withdrawal by Subject|1
6364451|NCT04407806|10154350|FG001|Overall Study|Withdrawal by Subject|2
6364452|NCT04324021|10154359|FG000|Overall Study|Adverse Event|1
6364453|NCT04324021|10154360|FG001|Overall Study|Adverse Event|0
6364454|NCT04324021|10154361|FG002|Overall Study|Adverse Event|0
6364455|NCT04324021|10154359|FG000|Overall Study|Lack of Efficacy|0
6364456|NCT04324021|10154360|FG001|Overall Study|Lack of Efficacy|0
6364457|NCT04324021|10154361|FG002|Overall Study|Lack of Efficacy|1
6364458|NCT04324021|10154359|FG000|Overall Study|Death|1
6364459|NCT04324021|10154360|FG001|Overall Study|Death|1
6364460|NCT04324021|10154361|FG002|Overall Study|Death|0
6364461|NCT04209621|10154372|FG000|Overall Study|Death|1
6364462|NCT04209621|10154372|FG000|Overall Study|Study Terminated Early|2
6364463|NCT04186663|10154377|FG000|Overall Study|Lost to Follow-up|1
6364464|NCT04186663|10154377|FG000|Overall Study|Unable to complete blood draw|3
6364465|NCT04158219|10154381|FG000|Overall Study|Lost to Follow-up|1
6364466|NCT04056299|10154401|FG000|Overall Study|Sponsor discontinued study|3
6364467|NCT04056299|10154402|FG001|Overall Study|Sponsor discontinued study|3
6364468|NCT03954743|10154450|FG000|Overall Study|Adverse Event|1
6364469|NCT03954743|10154451|FG001|Overall Study|Adverse Event|0
6364470|NCT03954743|10154450|FG000|Overall Study|Lost to Follow-up|6
6364471|NCT03954743|10154451|FG001|Overall Study|Lost to Follow-up|4
6364472|NCT03954743|10154450|FG000|Overall Study|Protocol Violation|1
6364473|NCT03954743|10154451|FG001|Overall Study|Protocol Violation|0
6364474|NCT03954743|10154450|FG000|Overall Study|CONSENT WITHDRAWAL NOT DUE TO ADV. EVENT|13
6364475|NCT03954743|10154451|FG001|Overall Study|CONSENT WITHDRAWAL NOT DUE TO ADV. EVENT|12
6364476|NCT03954743|10154450|FG000|Overall Study|MIGRATED / MOVED FROM THE STUDY AREA|3
6364477|NCT03954743|10154451|FG001|Overall Study|MIGRATED / MOVED FROM THE STUDY AREA|1
6364478|NCT03880565|10154459|FG000|Overall Study|Withdrawal by Subject|1
6364479|NCT03880565|10154460|FG001|Overall Study|Withdrawal by Subject|0
6364480|NCT03833661|10154466|FG000|Overall Study|Treatment ongoing|9
6364481|NCT03809663|10154474|FG000|Overall Study|Decision by sponsor|24
6364482|NCT03809663|10154475|FG001|Overall Study|Decision by sponsor|18
6364483|NCT03809663|10154476|FG002|Overall Study|Decision by sponsor|20
6364484|NCT03809663|10154477|FG003|Overall Study|Decision by sponsor|20
6364485|NCT03809663|10154478|FG004|Overall Study|Decision by sponsor|0
6364486|NCT03809663|10154479|FG005|Overall Study|Decision by sponsor|0
6364487|NCT03809663|10154474|FG000|Overall Study|Withdrawal by Subject|26
6364488|NCT03809663|10154475|FG001|Overall Study|Withdrawal by Subject|22
6364489|NCT03809663|10154476|FG002|Overall Study|Withdrawal by Subject|27
6364490|NCT03809663|10154477|FG003|Overall Study|Withdrawal by Subject|26
6364491|NCT03809663|10154478|FG004|Overall Study|Withdrawal by Subject|0
6364492|NCT03809663|10154479|FG005|Overall Study|Withdrawal by Subject|0
6364493|NCT03809663|10154474|FG000|Overall Study|Lost to Follow-up|1
6364494|NCT03809663|10154475|FG001|Overall Study|Lost to Follow-up|4
6364495|NCT03809663|10154476|FG002|Overall Study|Lost to Follow-up|1
6364496|NCT03809663|10154477|FG003|Overall Study|Lost to Follow-up|1
6364497|NCT03809663|10154478|FG004|Overall Study|Lost to Follow-up|0
6364498|NCT03809663|10154479|FG005|Overall Study|Lost to Follow-up|0
6364499|NCT03782792|10154506|FG000|Overall Study|Patient left the country|0
6364500|NCT03782792|10154507|FG001|Overall Study|Patient left the country|1
6364501|NCT03782792|10154506|FG000|Overall Study|Withdrawal by Subject|1
6364502|NCT03782792|10154507|FG001|Overall Study|Withdrawal by Subject|2
6364503|NCT03733119|10154526|FG000|Overall Study|Physician Decision|2
6364504|NCT03733119|10154527|FG001|Overall Study|Physician Decision|1
6364505|NCT03733119|10154526|FG000|Overall Study|ineligible to treat per protocol|0
6364506|NCT03733119|10154527|FG001|Overall Study|ineligible to treat per protocol|1
6364507|NCT03661996|10154538|FG000|Overall Study|Adverse Event|0
6364508|NCT03661996|10154539|FG001|Overall Study|Adverse Event|0
6364509|NCT03661996|10154540|FG002|Overall Study|Adverse Event|1
6364510|NCT03661996|10154541|FG003|Overall Study|Adverse Event|1
6364511|NCT03661996|10154542|FG004|Overall Study|Adverse Event|0
6364512|NCT03661996|10154538|FG000|Overall Study|Lost to Follow-up|5
6364513|NCT03661996|10154539|FG001|Overall Study|Lost to Follow-up|1
6364514|NCT03661996|10154540|FG002|Overall Study|Lost to Follow-up|2
6364515|NCT03661996|10154541|FG003|Overall Study|Lost to Follow-up|2
6364516|NCT03661996|10154542|FG004|Overall Study|Lost to Follow-up|6
6364517|NCT03661996|10154538|FG000|Overall Study|Physician Decision|1
6364518|NCT03661996|10154539|FG001|Overall Study|Physician Decision|1
6364519|NCT03661996|10154540|FG002|Overall Study|Physician Decision|1
6364520|NCT03661996|10154541|FG003|Overall Study|Physician Decision|2
6364521|NCT03661996|10154542|FG004|Overall Study|Physician Decision|0
6364522|NCT03661996|10154538|FG000|Overall Study|Protocol Violation|0
6364523|NCT03661996|10154539|FG001|Overall Study|Protocol Violation|0
6364524|NCT03661996|10154540|FG002|Overall Study|Protocol Violation|0
6364525|NCT03661996|10154541|FG003|Overall Study|Protocol Violation|0
6364526|NCT03661996|10154542|FG004|Overall Study|Protocol Violation|1
6364527|NCT03661996|10154538|FG000|Overall Study|Withdrawal by Subject|3
6364528|NCT03661996|10154539|FG001|Overall Study|Withdrawal by Subject|5
6364448|NCT04573972|10154330|FG000|Overall Study|Dyad partner did not join study or did not walk >0 steps|32
6364449|NCT04573972|10154331|FG001|Overall Study|Dyad partner did not join study or did not walk >0 steps|14
6364529|NCT03661996|10154540|FG002|Overall Study|Withdrawal by Subject|1
6364530|NCT03661996|10154541|FG003|Overall Study|Withdrawal by Subject|7
6364531|NCT03661996|10154542|FG004|Overall Study|Withdrawal by Subject|7
6364532|NCT03661996|10154538|FG000|Overall Study|Sponsors Decision|2
6364533|NCT03661996|10154539|FG001|Overall Study|Sponsors Decision|0
6364534|NCT03661996|10154540|FG002|Overall Study|Sponsors Decision|0
6364535|NCT03661996|10154541|FG003|Overall Study|Sponsors Decision|0
6364536|NCT03661996|10154542|FG004|Overall Study|Sponsors Decision|0
6364537|NCT03661996|10154538|FG000|Overall Study|Other|1
6364538|NCT03661996|10154539|FG001|Overall Study|Other|1
6364539|NCT03661996|10154540|FG002|Overall Study|Other|1
6364540|NCT03661996|10154541|FG003|Overall Study|Other|1
6364541|NCT03661996|10154542|FG004|Overall Study|Other|0
6364542|NCT03633461|10154559|FG000|Overall Study|Lost to Follow-up|0
6364543|NCT03633461|10154560|FG001|Overall Study|Lost to Follow-up|1
6364544|NCT03517722|10154588|FG000|Double Blind Period: Week 0-52|Adverse Event|9
6364545|NCT03517722|10154589|FG001|Double Blind Period: Week 0-52|Adverse Event|11
6364546|NCT03517722|10154588|FG000|Double Blind Period: Week 0-52|Death|0
6364547|NCT03517722|10154589|FG001|Double Blind Period: Week 0-52|Death|4
6364548|NCT03517722|10154588|FG000|Double Blind Period: Week 0-52|Lack of Efficacy|2
6364549|NCT03517722|10154589|FG001|Double Blind Period: Week 0-52|Lack of Efficacy|3
6364550|NCT03517722|10154588|FG000|Double Blind Period: Week 0-52|Pregnancy|0
6364551|NCT03517722|10154589|FG001|Double Blind Period: Week 0-52|Pregnancy|1
6364552|NCT03517722|10154588|FG000|Double Blind Period: Week 0-52|Protocol Violation|1
6364553|NCT03517722|10154589|FG001|Double Blind Period: Week 0-52|Protocol Violation|0
6364554|NCT03517722|10154588|FG000|Double Blind Period: Week 0-52|Withdrawal by Subject|11
6364555|NCT03517722|10154589|FG001|Double Blind Period: Week 0-52|Withdrawal by Subject|11
6364556|NCT03517722|10154588|FG000|Double Blind Period: Week 0-52|Study Terminated by Sponsor|76
6364557|NCT03517722|10154589|FG001|Double Blind Period: Week 0-52|Study Terminated by Sponsor|120
6364558|NCT03517722|10154588|FG000|Double Blind Period: Week 0-52|Other|4
6364559|NCT03517722|10154589|FG001|Double Blind Period: Week 0-52|Other|3
6364560|NCT03517722|10154588|FG000|Double Blind Period: Week 0-52|Initiated prohibited medication|0
6364561|NCT03517722|10154589|FG001|Double Blind Period: Week 0-52|Initiated prohibited medication|2
6364562|NCT03517722|10154588|FG000|Open-label Extension Period: Week 52-113|Adverse Event|0
6364563|NCT03517722|10154589|FG001|Open-label Extension Period: Week 52-113|Adverse Event|1
6364564|NCT03517722|10154588|FG000|Open-label Extension Period: Week 52-113|Lack of Efficacy|0
6364565|NCT03517722|10154589|FG001|Open-label Extension Period: Week 52-113|Lack of Efficacy|1
6364566|NCT03517722|10154588|FG000|Open-label Extension Period: Week 52-113|Withdrawal by Subject|1
6364567|NCT03517722|10154589|FG001|Open-label Extension Period: Week 52-113|Withdrawal by Subject|1
6364568|NCT03517722|10154588|FG000|Open-label Extension Period: Week 52-113|Study Terminated by Sponsor|87
6364569|NCT03517722|10154589|FG001|Open-label Extension Period: Week 52-113|Study Terminated by Sponsor|134
6364570|NCT03499314|10154598|FG000|Overall Study|Time Commitment|1
6364571|NCT03499314|10154599|FG001|Overall Study|Time Commitment|2
6364572|NCT03499314|10154598|FG000|Overall Study|Medical issue unrelated to research study|1
6364573|NCT03499314|10154599|FG001|Overall Study|Medical issue unrelated to research study|1
6364574|NCT03439124|10154607|FG000|Overall Study|Adverse Event|2
6364575|NCT03439124|10154608|FG001|Overall Study|Adverse Event|0
6364576|NCT03439124|10154607|FG000|Overall Study|Lost to Follow-up|1
6364577|NCT03439124|10154608|FG001|Overall Study|Lost to Follow-up|0
6364578|NCT03439124|10154607|FG000|Overall Study|Other reasons|1
6364579|NCT03439124|10154608|FG001|Overall Study|Other reasons|0
6364580|NCT03369431|10154616|FG000|Overall Study|Lost to Follow-up|1
6364581|NCT03369431|10154617|FG001|Overall Study|Lost to Follow-up|3
6364582|NCT03369431|10154616|FG000|Overall Study|Withdrawal by Subject|2
6364583|NCT03369431|10154617|FG001|Overall Study|Withdrawal by Subject|3
6364584|NCT03369431|10154616|FG000|Overall Study|Protocol Violation|1
6364585|NCT03369431|10154617|FG001|Overall Study|Protocol Violation|1
6364586|NCT03343054|10154626|FG000|Dose Escalation Period (Up to 286 Days)|Progressive Disease|2
6364587|NCT03343054|10154627|FG001|Dose Escalation Period (Up to 286 Days)|Progressive Disease|6
6364588|NCT03343054|10154628|FG002|Dose Escalation Period (Up to 286 Days)|Progressive Disease|0
6364589|NCT03343054|10154626|FG000|Dose Escalation Period (Up to 286 Days)|Global Deterioration of Health Status|1
6364590|NCT03343054|10154627|FG001|Dose Escalation Period (Up to 286 Days)|Global Deterioration of Health Status|0
6364591|NCT03343054|10154628|FG002|Dose Escalation Period (Up to 286 Days)|Global Deterioration of Health Status|0
6364592|NCT03343054|10154626|FG000|Dose Expansion Period (Up to 502 Days)|Progressive Disease|0
6364593|NCT03343054|10154627|FG001|Dose Expansion Period (Up to 502 Days)|Progressive Disease|0
6364594|NCT03343054|10154628|FG002|Dose Expansion Period (Up to 502 Days)|Progressive Disease|11
6364595|NCT03343054|10154626|FG000|Dose Expansion Period (Up to 502 Days)|Ongoing|0
6364596|NCT03343054|10154627|FG001|Dose Expansion Period (Up to 502 Days)|Ongoing|0
6364597|NCT03343054|10154628|FG002|Dose Expansion Period (Up to 502 Days)|Ongoing|8
6364598|NCT03336866|10154640|FG000|Overall Study|Lost to Follow-up|2
6364599|NCT03336866|10154641|FG001|Overall Study|Lost to Follow-up|0
6364600|NCT03336866|10154642|FG002|Overall Study|Lost to Follow-up|3
6364601|NCT03336866|10154640|FG000|Overall Study|Withdrawal by Subject|1
6364602|NCT03336866|10154641|FG001|Overall Study|Withdrawal by Subject|1
6364603|NCT03336866|10154642|FG002|Overall Study|Withdrawal by Subject|0
6364604|NCT03336866|10154640|FG000|Overall Study|Noncompliance with clinic house rules|0
6364605|NCT03336866|10154641|FG001|Overall Study|Noncompliance with clinic house rules|0
6364606|NCT03336866|10154642|FG002|Overall Study|Noncompliance with clinic house rules|1
6364607|NCT03332173|10154655|FG000|Overall Study|Death|7
6364608|NCT03332173|10154655|FG000|Overall Study|Withdrawal by Subject|6
6364609|NCT03332173|10154655|FG000|Overall Study|Lost to Follow-up|2
6364610|NCT03332173|10154655|FG000|Overall Study|Transferred to long-term extension study|29
6364611|NCT03322293|10154662|FG000|Overall Study|Lost to Follow-up|0
6364612|NCT03322293|10154663|FG001|Overall Study|Lost to Follow-up|0
6364613|NCT03322293|10154664|FG002|Overall Study|Lost to Follow-up|1
6364614|NCT03254394|10154686|FG000|Overall Study|Withdrawal by Subject|0
6364615|NCT03254394|10154687|FG001|Overall Study|Withdrawal by Subject|2
6364616|NCT03253809|10154693|FG000|Overall Study|Unable to obtain study related data|14
6364617|NCT03151408|10154713|FG000|Overall Study|Adverse Event|24
6364618|NCT03151408|10154714|FG001|Overall Study|Adverse Event|23
6364619|NCT03151408|10154713|FG000|Overall Study|Death|46
6364620|NCT03151408|10154714|FG001|Overall Study|Death|26
6364621|NCT03151408|10154713|FG000|Overall Study|Physician Decision|13
6364622|NCT03151408|10154714|FG001|Overall Study|Physician Decision|19
6364623|NCT03151408|10154713|FG000|Overall Study|Withdrawal by Subject|16
6364624|NCT03151408|10154714|FG001|Overall Study|Withdrawal by Subject|20
6364625|NCT03151408|10154713|FG000|Overall Study|Progressive disease|45
6364626|NCT03151408|10154714|FG001|Overall Study|Progressive disease|61
6364627|NCT03151408|10154713|FG000|Overall Study|non-compliance by patient|1
6364628|NCT03151408|10154714|FG001|Overall Study|non-compliance by patient|0
6364629|NCT03151408|10154713|FG000|Overall Study|other reasons|56
6364630|NCT03151408|10154714|FG001|Overall Study|other reasons|52
6364631|NCT03151408|10154713|FG000|Overall Study|randomized and not treated|2
6364632|NCT03151408|10154714|FG001|Overall Study|randomized and not treated|2
6364633|NCT03137173|10154722|FG000|Overall Study|Withdrawal by Subject|8
6364634|NCT03137173|10154723|FG001|Overall Study|Withdrawal by Subject|13
6364635|NCT03137173|10154722|FG000|Overall Study|Death|1
6364636|NCT03137173|10154723|FG001|Overall Study|Death|3
6364637|NCT03137173|10154722|FG000|Overall Study|Physician Decision|1
6364638|NCT03137173|10154723|FG001|Overall Study|Physician Decision|0
6364639|NCT03137173|10154722|FG000|Overall Study|Lost to Follow-up|13
6364640|NCT03137173|10154723|FG001|Overall Study|Lost to Follow-up|18
6364641|NCT03137173|10154722|FG000|Overall Study|Other reasons|3
6364642|NCT03137173|10154723|FG001|Overall Study|Other reasons|2
6364643|NCT03100149|10154742|FG000|Overall Study|Adverse Event|0
6364644|NCT03100149|10154743|FG001|Overall Study|Adverse Event|1
6364645|NCT03100149|10154744|FG002|Overall Study|Adverse Event|0
6364646|NCT03100149|10154742|FG000|Overall Study|Participant Moved out of Country|0
6364647|NCT03100149|10154743|FG001|Overall Study|Participant Moved out of Country|0
6364648|NCT03100149|10154744|FG002|Overall Study|Participant Moved out of Country|1
6364649|NCT03100149|10154742|FG000|Overall Study|Withdrawal by Subject|0
6364650|NCT03100149|10154743|FG001|Overall Study|Withdrawal by Subject|3
6364651|NCT03100149|10154744|FG002|Overall Study|Withdrawal by Subject|1
6364652|NCT03028740|10154775|FG000|Overall Study|Did not Receive Study Drug|4
6364653|NCT03028740|10154776|FG001|Overall Study|Did not Receive Study Drug|5
6364654|NCT03028740|10154775|FG000|Overall Study|Adverse Event|8
6364655|NCT03028740|10154776|FG001|Overall Study|Adverse Event|26
6364656|NCT03028740|10154775|FG000|Overall Study|Lack of Efficacy|0
6364657|NCT03028740|10154776|FG001|Overall Study|Lack of Efficacy|1
6364658|NCT03028740|10154775|FG000|Overall Study|Withdrawal by Subject|48
6364659|NCT03028740|10154776|FG001|Overall Study|Withdrawal by Subject|101
6364660|NCT03028740|10154775|FG000|Overall Study|Lost to Follow-up|30
6364661|NCT03028740|10154776|FG001|Overall Study|Lost to Follow-up|54
6364662|NCT03028740|10154775|FG000|Overall Study|Physician Decision|4
6364663|NCT03028740|10154776|FG001|Overall Study|Physician Decision|11
6364664|NCT03028740|10154775|FG000|Overall Study|Protocol Violation|4
6364665|NCT03028740|10154776|FG001|Overall Study|Protocol Violation|8
6364666|NCT03028740|10154775|FG000|Overall Study|Non-compliance with Study Drug|0
6364667|NCT03028740|10154776|FG001|Overall Study|Non-compliance with Study Drug|2
6364668|NCT03028740|10154775|FG000|Overall Study|Study Terminated by Sponsor|467
6364669|NCT03028740|10154776|FG001|Overall Study|Study Terminated by Sponsor|917
6364670|NCT03028740|10154775|FG000|Overall Study|Protocol-specified Withdrawal Criteria Met|27
6364671|NCT03028740|10154776|FG001|Overall Study|Protocol-specified Withdrawal Criteria Met|55
6364672|NCT03028740|10154775|FG000|Overall Study|Reason not Specified|1
6364673|NCT03028740|10154776|FG001|Overall Study|Reason not Specified|5
6364674|NCT02998476|10154828|FG000|Overall Study|Lost to Follow-up|1
6364675|NCT02998476|10154829|FG001|Overall Study|Lost to Follow-up|0
6364676|NCT02998476|10154828|FG000|Overall Study|Participants transferred to rollover study INCB50465-801|2
6364677|NCT02998476|10154829|FG001|Overall Study|Participants transferred to rollover study INCB50465-801|0
6364678|NCT02998476|10154828|FG000|Overall Study|Withdrawal by Subject|1
6364679|NCT02998476|10154829|FG001|Overall Study|Withdrawal by Subject|2
6364680|NCT02998476|10154828|FG000|Overall Study|Death|45
6364681|NCT02998476|10154829|FG001|Overall Study|Death|2
6364682|NCT02998476|10154828|FG000|Overall Study|Other|6
6364683|NCT02998476|10154829|FG001|Overall Study|Other|1
6364684|NCT02949128|10154845|FG000|Initial Evaluation Period|Failed to Meet Eligibility Criteria|2
6364685|NCT02949128|10154845|FG000|Initial Evaluation Period|Adverse Event|3
6364686|NCT02949128|10154845|FG000|Initial Evaluation Period|Death|2
6364687|NCT02949128|10154845|FG000|Initial Evaluation Period|Physician Decision|1
6364688|NCT02949128|10154845|FG000|Initial Evaluation Period|Protocol Violation|1
6364689|NCT02949128|10154845|FG000|Extension Period|Physician Decision|1
6364690|NCT02949128|10154845|FG000|Extension Period|Withdrawal by Subject|1
6364691|NCT02924064|10154855|FG000|Overall Study|Adverse Event|2
6364692|NCT02924064|10154856|FG001|Overall Study|Adverse Event|2
6364693|NCT02924064|10154855|FG000|Overall Study|Lost to Follow-up|0
6364694|NCT02924064|10154856|FG001|Overall Study|Lost to Follow-up|2
6364695|NCT02924064|10154855|FG000|Overall Study|Physician Decision|0
6364696|NCT02924064|10154856|FG001|Overall Study|Physician Decision|2
6364697|NCT02924064|10154855|FG000|Overall Study|Protocol Violation|1
6364698|NCT02924064|10154856|FG001|Overall Study|Protocol Violation|3
6364699|NCT02924064|10154855|FG000|Overall Study|Withdrawal by Subject|4
6364700|NCT02924064|10154856|FG001|Overall Study|Withdrawal by Subject|5
6364701|NCT02924064|10154855|FG000|Overall Study|Other|17
6364702|NCT02924064|10154856|FG001|Overall Study|Other|29
6364703|NCT02916706|10154864|FG000|Overall Study|Adverse Event|0
6364704|NCT02916706|10154865|FG001|Overall Study|Adverse Event|1
6364705|NCT02916706|10154864|FG000|Overall Study|Lost to Follow-up|0
6364706|NCT02916706|10154865|FG001|Overall Study|Lost to Follow-up|1
6364707|NCT02916706|10154864|FG000|Overall Study|Physician Decision|1
6364708|NCT02916706|10154865|FG001|Overall Study|Physician Decision|0
6364709|NCT02916706|10154864|FG000|Overall Study|Protocol Violation|3
6364710|NCT02916706|10154865|FG001|Overall Study|Protocol Violation|1
6364711|NCT02916706|10154864|FG000|Overall Study|Withdrawal by Subject|6
6364712|NCT02916706|10154865|FG001|Overall Study|Withdrawal by Subject|9
6364713|NCT02916706|10154864|FG000|Overall Study|Other|5
6364714|NCT02916706|10154865|FG001|Overall Study|Other|19
6364715|NCT02889900|10154871|FG000|Overall Study|Adverse Event|11
6364716|NCT02889900|10154871|FG000|Overall Study|Condition under investigation worsened|32
6364717|NCT02889900|10154871|FG000|Overall Study|Other|5
6364718|NCT02889900|10154871|FG000|Overall Study|Withdrawal by Subject|7
6364719|NCT02889900|10154871|FG000|Overall Study|Not treated|2
6171635|NCT01261338|9818537|FG001|Overall Study|Withdrawal by Subject|2
6364720|NCT02866695|10154875|FG000|Overall Study|Adverse Event|1
6364721|NCT02866695|10154875|FG000|Overall Study|Lost to Follow-up|1
6364722|NCT02854436|10154879|FG000|Overall Study|Adverse Event|1
6364723|NCT02854436|10154879|FG000|Overall Study|Death|208
6171636|NCT01261390|9818547|FG000|Overall Study|Significant Concurrent Illness|1
6171637|NCT01261390|9818548|FG001|Overall Study|Significant Concurrent Illness|0
6171638|NCT01261390|9818549|FG002|Overall Study|Significant Concurrent Illness|1
6171639|NCT01261390|9818550|FG003|Overall Study|Significant Concurrent Illness|0
6171640|NCT01261390|9818547|FG000|Overall Study|Dissatisfaction with Treatment|2
6171641|NCT01261390|9818548|FG001|Overall Study|Dissatisfaction with Treatment|1
6171642|NCT01261390|9818549|FG002|Overall Study|Dissatisfaction with Treatment|1
6171643|NCT01261390|9818550|FG003|Overall Study|Dissatisfaction with Treatment|2
6171644|NCT01261390|9818547|FG000|Overall Study|Relocation|0
6171645|NCT01261390|9818548|FG001|Overall Study|Relocation|1
6171646|NCT01261390|9818549|FG002|Overall Study|Relocation|0
6171647|NCT01261390|9818550|FG003|Overall Study|Relocation|0
6171648|NCT01261390|9818547|FG000|Overall Study|Loss of Interest in the Study|3
6171649|NCT01261390|9818548|FG001|Overall Study|Loss of Interest in the Study|1
6171650|NCT01261390|9818549|FG002|Overall Study|Loss of Interest in the Study|0
6171651|NCT01261390|9818550|FG003|Overall Study|Loss of Interest in the Study|0
6171652|NCT01261390|9818547|FG000|Overall Study|Lost to Follow-up|1
6171653|NCT01261390|9818548|FG001|Overall Study|Lost to Follow-up|6
6171654|NCT01261390|9818549|FG002|Overall Study|Lost to Follow-up|5
6171655|NCT01261390|9818550|FG003|Overall Study|Lost to Follow-up|6
6171656|NCT01261611|9818585|FG000|Treatment Cycle 1|Withdrawal by Subject|3
6171657|NCT01261611|9818586|FG001|Treatment Cycle 1|Withdrawal by Subject|2
6364724|NCT02854436|10154879|FG000|Overall Study|Lost to Follow-up|5
6364725|NCT02854436|10154879|FG000|Overall Study|Withdrawal by Subject|12
6364726|NCT02854436|10154879|FG000|Overall Study|Other|45
6364727|NCT02854436|10154879|FG000|Overall Study|Ongoing|18
6364728|NCT02834793|10154885|FG000|Core Study (Up to 18 Weeks)|Withdrawal by Subject|2
6364729|NCT02834793|10154886|FG001|Core Study (Up to 18 Weeks)|Withdrawal by Subject|1
6364730|NCT02834793|10154887|FG002|Core Study (Up to 18 Weeks)|Withdrawal by Subject|0
6364731|NCT02834793|10154888|FG003|Core Study (Up to 18 Weeks)|Withdrawal by Subject|0
6364732|NCT02834793|10154885|FG000|Core Study (Up to 18 Weeks)|Lack of Efficacy|1
6364733|NCT02834793|10154886|FG001|Core Study (Up to 18 Weeks)|Lack of Efficacy|0
6364734|NCT02834793|10154887|FG002|Core Study (Up to 18 Weeks)|Lack of Efficacy|0
6364735|NCT02834793|10154888|FG003|Core Study (Up to 18 Weeks)|Lack of Efficacy|0
6364736|NCT02834793|10154885|FG000|Core Study (Up to 18 Weeks)|Lost to Follow-up|1
6364737|NCT02834793|10154886|FG001|Core Study (Up to 18 Weeks)|Lost to Follow-up|0
6364738|NCT02834793|10154887|FG002|Core Study (Up to 18 Weeks)|Lost to Follow-up|0
6364739|NCT02834793|10154888|FG003|Core Study (Up to 18 Weeks)|Lost to Follow-up|0
6364740|NCT02834793|10154885|FG000|Core Study (Up to 18 Weeks)|Adverse Event|0
6364741|NCT02834793|10154886|FG001|Core Study (Up to 18 Weeks)|Adverse Event|3
6364742|NCT02834793|10154887|FG002|Core Study (Up to 18 Weeks)|Adverse Event|0
6364743|NCT02834793|10154888|FG003|Core Study (Up to 18 Weeks)|Adverse Event|0
6043209|NCT00387725|9641725|FG003|Overall Study|Adverse Event|1
6043210|NCT00387725|9641722|FG000|Overall Study|Protocol Violation|0
6043211|NCT00387725|9641723|FG001|Overall Study|Protocol Violation|1
6043212|NCT00387725|9641724|FG002|Overall Study|Protocol Violation|0
6043213|NCT00387725|9641725|FG003|Overall Study|Protocol Violation|0
6043214|NCT00387725|9641722|FG000|Overall Study|Withdrawal by Subject|1
6043215|NCT00387725|9641723|FG001|Overall Study|Withdrawal by Subject|0
6043216|NCT00387725|9641724|FG002|Overall Study|Withdrawal by Subject|1
6043217|NCT00387725|9641725|FG003|Overall Study|Withdrawal by Subject|0
6043218|NCT00387725|9641722|FG000|Overall Study|Parent/legal guardian request|0
6043219|NCT00387725|9641723|FG001|Overall Study|Parent/legal guardian request|0
6043220|NCT00387725|9641724|FG002|Overall Study|Parent/legal guardian request|1
6043221|NCT00387725|9641725|FG003|Overall Study|Parent/legal guardian request|1
6043222|NCT00387764|9641741|FG000|Overall Study|Adverse Event|12
6043223|NCT00387764|9641741|FG000|Overall Study|Withdrawal by Subject|8
6043224|NCT00387764|9641741|FG000|Overall Study|Sponsor Terminated Study|1
6043225|NCT00387764|9641741|FG000|Overall Study|Physician Decision|1
6043226|NCT00387764|9641741|FG000|Overall Study|Other|2
6043227|NCT00387764|9641741|FG000|Overall Study|Death|7
6043228|NCT00387790|9641745|FG000|Overall Study|Adverse Event|5
6043229|NCT00387790|9641745|FG000|Overall Study|Lack of Efficacy|2
6043230|NCT00387790|9641745|FG000|Overall Study|Physician Decision|2
6043231|NCT00387790|9641745|FG000|Overall Study|Withdrawal by Subject|3
6043232|NCT00387790|9641745|FG000|Overall Study|Ineligible for study|2
6043233|NCT00387881|9641760|FG000|Overall Study|Lost to Follow-up|23
6043234|NCT00387881|9641761|FG001|Overall Study|Lost to Follow-up|23
6043235|NCT00387881|9641760|FG000|Overall Study|Protocol Violation|2
6043236|NCT00387881|9641761|FG001|Overall Study|Protocol Violation|12
6043237|NCT00387881|9641760|FG000|Overall Study|Withdrawal by Subject|15
6043238|NCT00387881|9641761|FG001|Overall Study|Withdrawal by Subject|18
6043239|NCT00387881|9641760|FG000|Overall Study|Sponsor terminated Study|0
6043240|NCT00387881|9641761|FG001|Overall Study|Sponsor terminated Study|1
6043241|NCT00387881|9641760|FG000|Overall Study|Not eligible|6
6043242|NCT00387881|9641761|FG001|Overall Study|Not eligible|7
6043243|NCT00387881|9641760|FG000|Overall Study|No opportunity to treat headache|32
6043244|NCT00387881|9641761|FG001|Overall Study|No opportunity to treat headache|34
6364744|NCT02834793|10154885|FG000|Core Study (Up to 18 Weeks)|Study terminated by sponsor|0
6364745|NCT02834793|10154886|FG001|Core Study (Up to 18 Weeks)|Study terminated by sponsor|1
6364746|NCT02834793|10154887|FG002|Core Study (Up to 18 Weeks)|Study terminated by sponsor|0
6364747|NCT02834793|10154888|FG003|Core Study (Up to 18 Weeks)|Study terminated by sponsor|0
6364748|NCT02834793|10154885|FG000|Extension Phase A (up to 52 Weeks)|Withdrawal by Subject|0
6364749|NCT02834793|10154886|FG001|Extension Phase A (up to 52 Weeks)|Withdrawal by Subject|0
6364750|NCT02834793|10154887|FG002|Extension Phase A (up to 52 Weeks)|Withdrawal by Subject|7
6364751|NCT02834793|10154888|FG003|Extension Phase A (up to 52 Weeks)|Withdrawal by Subject|0
6364752|NCT02834793|10154885|FG000|Extension Phase A (up to 52 Weeks)|Lack of Efficacy|0
6364753|NCT02834793|10154886|FG001|Extension Phase A (up to 52 Weeks)|Lack of Efficacy|0
6364754|NCT02834793|10154887|FG002|Extension Phase A (up to 52 Weeks)|Lack of Efficacy|4
6364755|NCT02834793|10154888|FG003|Extension Phase A (up to 52 Weeks)|Lack of Efficacy|0
6364756|NCT02834793|10154885|FG000|Extension Phase A (up to 52 Weeks)|Adverse Event|0
6364757|NCT02834793|10154886|FG001|Extension Phase A (up to 52 Weeks)|Adverse Event|0
6364758|NCT02834793|10154887|FG002|Extension Phase A (up to 52 Weeks)|Adverse Event|5
6364759|NCT02834793|10154888|FG003|Extension Phase A (up to 52 Weeks)|Adverse Event|0
6364760|NCT02834793|10154885|FG000|Extension Phase A (up to 52 Weeks)|Study terminated by sponsor|0
6364761|NCT02834793|10154886|FG001|Extension Phase A (up to 52 Weeks)|Study terminated by sponsor|0
6364762|NCT02834793|10154887|FG002|Extension Phase A (up to 52 Weeks)|Study terminated by sponsor|9
6364763|NCT02834793|10154888|FG003|Extension Phase A (up to 52 Weeks)|Study terminated by sponsor|0
6364764|NCT02834793|10154885|FG000|Extension Phase A (up to 52 Weeks)|Other|0
6364765|NCT02834793|10154886|FG001|Extension Phase A (up to 52 Weeks)|Other|0
6364766|NCT02834793|10154887|FG002|Extension Phase A (up to 52 Weeks)|Other|1
6364767|NCT02834793|10154888|FG003|Extension Phase A (up to 52 Weeks)|Other|0
6364768|NCT02834793|10154885|FG000|Extension Phase B (up to 188 Weeks)|Lack of Efficacy|0
6364769|NCT02834793|10154886|FG001|Extension Phase B (up to 188 Weeks)|Lack of Efficacy|0
6364770|NCT02834793|10154887|FG002|Extension Phase B (up to 188 Weeks)|Lack of Efficacy|0
6364771|NCT02834793|10154888|FG003|Extension Phase B (up to 188 Weeks)|Lack of Efficacy|1
6364772|NCT02834793|10154885|FG000|Extension Phase B (up to 188 Weeks)|Adverse Event|0
6364773|NCT02834793|10154886|FG001|Extension Phase B (up to 188 Weeks)|Adverse Event|0
6364774|NCT02834793|10154887|FG002|Extension Phase B (up to 188 Weeks)|Adverse Event|0
6364775|NCT02834793|10154888|FG003|Extension Phase B (up to 188 Weeks)|Adverse Event|1
6364776|NCT02834793|10154885|FG000|Extension Phase B (up to 188 Weeks)|Study terminated by sponsor|0
6364777|NCT02834793|10154886|FG001|Extension Phase B (up to 188 Weeks)|Study terminated by sponsor|0
6364778|NCT02834793|10154887|FG002|Extension Phase B (up to 188 Weeks)|Study terminated by sponsor|0
6364779|NCT02834793|10154888|FG003|Extension Phase B (up to 188 Weeks)|Study terminated by sponsor|8
6364780|NCT02834793|10154885|FG000|Extension Phase B (up to 188 Weeks)|Other|0
6364781|NCT02834793|10154886|FG001|Extension Phase B (up to 188 Weeks)|Other|0
6364782|NCT02834793|10154887|FG002|Extension Phase B (up to 188 Weeks)|Other|0
6364783|NCT02834793|10154888|FG003|Extension Phase B (up to 188 Weeks)|Other|1
6364784|NCT02834793|10154885|FG000|Extension Phase B (up to 188 Weeks)|Withdrawal by Subject|0
6364785|NCT02834793|10154886|FG001|Extension Phase B (up to 188 Weeks)|Withdrawal by Subject|0
6364786|NCT02834793|10154887|FG002|Extension Phase B (up to 188 Weeks)|Withdrawal by Subject|0
6364787|NCT02834793|10154888|FG003|Extension Phase B (up to 188 Weeks)|Withdrawal by Subject|1
6364788|NCT02810457|10154898|FG000|Overall Study|Randomised but no treatment received|2
6364789|NCT02810457|10154899|FG001|Overall Study|Randomised but no treatment received|1
6364790|NCT02810457|10154898|FG000|Overall Study|Objective PD assessed by RECIST v1.1|191
6364791|NCT02810457|10154899|FG001|Overall Study|Objective PD assessed by RECIST v1.1|199
6364792|NCT02810457|10154898|FG000|Overall Study|Adverse Event|37
6364793|NCT02810457|10154899|FG001|Overall Study|Adverse Event|43
6364794|NCT02810457|10154898|FG000|Overall Study|Patient decision|31
6364795|NCT02810457|10154899|FG001|Overall Study|Patient decision|35
6364796|NCT02810457|10154898|FG000|Overall Study|Patient lost to follow-up|2
6364797|NCT02810457|10154899|FG001|Overall Study|Patient lost to follow-up|2
6364798|NCT02810457|10154898|FG000|Overall Study|Death|39
6364799|NCT02810457|10154899|FG001|Overall Study|Death|28
6364800|NCT02810457|10154898|FG000|Overall Study|Ongoing at data cutoff and discontinued|3
6364801|NCT02810457|10154899|FG001|Overall Study|Ongoing at data cutoff and discontinued|2
6364802|NCT02810457|10154898|FG000|Overall Study|Clinical progression|15
6364803|NCT02810457|10154899|FG001|Overall Study|Clinical progression|16
6364804|NCT02810457|10154898|FG000|Overall Study|Investigator decision|3
6364805|NCT02810457|10154899|FG001|Overall Study|Investigator decision|2
6364806|NCT02810457|10154898|FG000|Overall Study|Patient ineligibility|3
6364807|NCT02810457|10154899|FG001|Overall Study|Patient ineligibility|0
6364808|NCT02810457|10154898|FG000|Overall Study|Miscalculated PD|1
6364809|NCT02810457|10154899|FG001|Overall Study|Miscalculated PD|0
6364810|NCT02810457|10154898|FG000|Overall Study|Physician Decision|0
6364811|NCT02810457|10154899|FG001|Overall Study|Physician Decision|1
6364812|NCT02745535|10154935|FG000|Overall Study|Death|1
6364813|NCT02745535|10154935|FG000|Overall Study|Adverse Event|3
6364814|NCT02745535|10154935|FG000|Overall Study|Lost to Follow-up|2
6364815|NCT02625090|10154973|FG000|Overall Study|Participant wants to be pregnant|2
6364816|NCT02625090|10154973|FG000|Overall Study|For the Promoter|1
6364817|NCT02625090|10154973|FG000|Overall Study|Sponsor's Decision|9
6364818|NCT02625090|10154973|FG000|Overall Study|Somnolence|1
6084422|NCT00642902|9693366|FG000|Overall Study|Death|1
6364819|NCT02625090|10154973|FG000|Overall Study|Study terminated by Sponsor|7
6364820|NCT02625090|10154973|FG000|Overall Study|Negative Benefit/Risk|1
6364821|NCT02625090|10154973|FG000|Overall Study|Protocol Deviation|2
6364822|NCT02625090|10154973|FG000|Overall Study|Lack of Efficacy|16
6364823|NCT02625090|10154973|FG000|Overall Study|Adverse Event|3
6364824|NCT02539225|10154980|FG000|Part A|Adverse Event|13
6364825|NCT02539225|10154981|FG001|Part A|Adverse Event|4
6364826|NCT02539225|10154980|FG000|Part A|Withdrawal by Subject|2
6364827|NCT02539225|10154981|FG001|Part A|Withdrawal by Subject|4
6364828|NCT02539225|10154980|FG000|Part A|Physician Decision|4
6364829|NCT02539225|10154981|FG001|Part A|Physician Decision|7
6364830|NCT02539225|10154980|FG000|Part A|Did Not Receive study Drug|1
6364831|NCT02539225|10154981|FG001|Part A|Did Not Receive study Drug|1
6364832|NCT02539225|10154980|FG000|Pre Treatment for Part B|Progressive disease|1
6364833|NCT02539225|10154981|FG001|Pre Treatment for Part B|Progressive disease|1
6364834|NCT02539225|10154980|FG000|Pre Treatment for Part B|Adverse Event|1
6364835|NCT02539225|10154981|FG001|Pre Treatment for Part B|Adverse Event|1
6364836|NCT02539225|10154980|FG000|Pre Treatment for Part B|Withdrawal by Subject|1
6364837|NCT02539225|10154981|FG001|Pre Treatment for Part B|Withdrawal by Subject|0
6364838|NCT02539225|10154980|FG000|Pre Treatment for Part B|Physician Decision|2
6364839|NCT02539225|10154981|FG001|Pre Treatment for Part B|Physician Decision|0
6364840|NCT02539225|10154980|FG000|Part B|Adverse Event|4
6364841|NCT02539225|10154981|FG001|Part B|Adverse Event|4
6364842|NCT02539225|10154980|FG000|Part B|Withdrawal by Subject|0
6364843|NCT02539225|10154981|FG001|Part B|Withdrawal by Subject|3
6364844|NCT02539225|10154980|FG000|Part B|Physician Decision|0
6364845|NCT02539225|10154981|FG001|Part B|Physician Decision|9
6364846|NCT02526017|10155009|FG000|Overall Study|Withdrew Consent Before Receiving Study Treatment|0
6364847|NCT02526017|10155010|FG001|Overall Study|Withdrew Consent Before Receiving Study Treatment|0
6364848|NCT02526017|10155011|FG002|Overall Study|Withdrew Consent Before Receiving Study Treatment|0
6364849|NCT02526017|10155012|FG003|Overall Study|Withdrew Consent Before Receiving Study Treatment|0
6364850|NCT02526017|10155013|FG004|Overall Study|Withdrew Consent Before Receiving Study Treatment|1
6364851|NCT02526017|10155014|FG005|Overall Study|Withdrew Consent Before Receiving Study Treatment|0
6364852|NCT02526017|10155015|FG006|Overall Study|Withdrew Consent Before Receiving Study Treatment|0
6364853|NCT02526017|10155016|FG007|Overall Study|Withdrew Consent Before Receiving Study Treatment|0
6364854|NCT02526017|10155017|FG008|Overall Study|Withdrew Consent Before Receiving Study Treatment|0
6364855|NCT02482233|10155079|FG000|Overall Study|Lost to Follow-up|1
6364856|NCT02482233|10155080|FG001|Overall Study|Lost to Follow-up|1
6084423|NCT00642902|9693367|FG001|Overall Study|Death|0
6364857|NCT02450331|10155090|FG000|Overall Study|Death|120
6364858|NCT02450331|10155091|FG001|Overall Study|Death|114
6364859|NCT02450331|10155090|FG000|Overall Study|Lost to Follow-up|9
6364860|NCT02450331|10155091|FG001|Overall Study|Lost to Follow-up|7
6364861|NCT02450331|10155090|FG000|Overall Study|Withdrawal by Subject|50
6364862|NCT02450331|10155091|FG001|Overall Study|Withdrawal by Subject|39
6364863|NCT02450331|10155090|FG000|Overall Study|On-Study Status: In Disease recurrence follow-up|179
6364864|NCT02450331|10155091|FG001|Overall Study|On-Study Status: In Disease recurrence follow-up|208
6364865|NCT02450331|10155090|FG000|Overall Study|On-Study Status: In Survival follow-up|45
6364866|NCT02450331|10155091|FG001|Overall Study|On-Study Status: In Survival follow-up|38
6084424|NCT00642902|9693368|FG002|Overall Study|Death|0
6084425|NCT00642902|9693369|FG003|Overall Study|Death|0
6084426|NCT00642902|9693366|FG000|Overall Study|Premature termination of clinical trial|37
6364867|NCT02400736|10155107|FG000|Overall Study|Lost to Follow-up|6
6364868|NCT02400736|10155108|FG001|Overall Study|Lost to Follow-up|6
6364869|NCT02400736|10155107|FG000|Overall Study|Withdrawal by Subject|2
6364870|NCT02400736|10155108|FG001|Overall Study|Withdrawal by Subject|1
6364871|NCT02400736|10155107|FG000|Overall Study|Moved from the area|3
6364872|NCT02400736|10155108|FG001|Overall Study|Moved from the area|1
6364873|NCT02369653|10155120|FG000|Overall Study|Lost to Follow-up|0
6364874|NCT02369653|10155121|FG001|Overall Study|Lost to Follow-up|1
6364875|NCT02369653|10155120|FG000|Overall Study|Administrative reason by sponsor|0
6364876|NCT02369653|10155121|FG001|Overall Study|Administrative reason by sponsor|1
6364877|NCT02369653|10155120|FG000|Overall Study|Death|1
6364878|NCT02369653|10155121|FG001|Overall Study|Death|2
6364879|NCT02369653|10155120|FG000|Overall Study|Participant withdrew consent|13
6364880|NCT02369653|10155121|FG001|Overall Study|Participant withdrew consent|3
6364881|NCT02335424|10155131|FG000|Overall Study|Withdrawal by Subject|12
6364882|NCT02335424|10155131|FG000|Overall Study|Ongoing In Study|89
6364883|NCT02335424|10155131|FG000|Overall Study|Adverse Event|25
6364884|NCT02335424|10155131|FG000|Overall Study|Death|239
6364885|NCT02335424|10155131|FG000|Overall Study|Lost to Follow-up|2
6364886|NCT02335424|10155131|FG000|Overall Study|Physician Decision|3
6364887|NCT02335424|10155131|FG000|Overall Study|Not treated|4
6364888|NCT02326974|10155135|FG000|Overall Study|Withdrawal by Subject|2
6364889|NCT02326974|10155135|FG000|Overall Study|failed heterogenity evaluation|5
6364890|NCT02284568|10155146|FG000|Overall Study|Adverse Event|2
6364891|NCT02284568|10155147|FG001|Overall Study|Adverse Event|9
6364892|NCT02284568|10155148|FG002|Overall Study|Adverse Event|4
6364893|NCT02284568|10155146|FG000|Overall Study|Withdrawal by Subject|22
6364894|NCT02284568|10155147|FG001|Overall Study|Withdrawal by Subject|21
6364895|NCT02284568|10155148|FG002|Overall Study|Withdrawal by Subject|1
6364896|NCT02284568|10155146|FG000|Overall Study|Noncompliance with study drug admin|1
6364897|NCT02284568|10155147|FG001|Overall Study|Noncompliance with study drug admin|2
6364898|NCT02284568|10155148|FG002|Overall Study|Noncompliance with study drug admin|0
6364899|NCT02284568|10155146|FG000|Overall Study|Noncompliance|1
6364900|NCT02284568|10155147|FG001|Overall Study|Noncompliance|0
6364901|NCT02284568|10155148|FG002|Overall Study|Noncompliance|0
6364902|NCT02284568|10155146|FG000|Overall Study|Protocol Violation|0
6364903|NCT02284568|10155147|FG001|Overall Study|Protocol Violation|1
6364904|NCT02284568|10155148|FG002|Overall Study|Protocol Violation|0
6364905|NCT02284568|10155146|FG000|Overall Study|Sponsor requested patient stop treatment|0
6364906|NCT02284568|10155147|FG001|Overall Study|Sponsor requested patient stop treatment|0
6364907|NCT02284568|10155148|FG002|Overall Study|Sponsor requested patient stop treatment|90
6364908|NCT02284568|10155146|FG000|Overall Study|Lost to Follow-up|0
6364909|NCT02284568|10155147|FG001|Overall Study|Lost to Follow-up|3
6364910|NCT02284568|10155148|FG002|Overall Study|Lost to Follow-up|0
6364911|NCT02284568|10155146|FG000|Overall Study|Lack of Efficacy|4
6364912|NCT02284568|10155147|FG001|Overall Study|Lack of Efficacy|7
6364913|NCT02284568|10155148|FG002|Overall Study|Lack of Efficacy|0
6364914|NCT02284568|10155146|FG000|Overall Study|Other|1
6364915|NCT02284568|10155147|FG001|Overall Study|Other|2
6364916|NCT02284568|10155148|FG002|Overall Study|Other|0
6364917|NCT02284568|10155146|FG000|Overall Study|Withdrew before taking study drug|0
6364918|NCT02284568|10155147|FG001|Overall Study|Withdrew before taking study drug|1
6364919|NCT02284568|10155148|FG002|Overall Study|Withdrew before taking study drug|0
6364920|NCT02227238|10155162|FG000|Overall Study|Other: Reached stopping criteria|0
6364921|NCT02227238|10155163|FG001|Overall Study|Other: Reached stopping criteria|1
6364922|NCT02227238|10155162|FG000|Overall Study|Adverse Event|8
6364923|NCT02227238|10155163|FG001|Overall Study|Adverse Event|18
6364924|NCT02227238|10155162|FG000|Overall Study|Lack of Efficacy|10
6364925|NCT02227238|10155163|FG001|Overall Study|Lack of Efficacy|22
6364926|NCT02227238|10155162|FG000|Overall Study|Protocol Violation|7
6364927|NCT02227238|10155163|FG001|Overall Study|Protocol Violation|8
6364928|NCT02227238|10155162|FG000|Overall Study|Withdrawal by Subject|5
6364929|NCT02227238|10155163|FG001|Overall Study|Withdrawal by Subject|4
6364930|NCT02227238|10155162|FG000|Overall Study|Physician Decision|0
6364931|NCT02227238|10155163|FG001|Overall Study|Physician Decision|9
6364932|NCT02227238|10155162|FG000|Overall Study|Lost to Follow-up|7
6364933|NCT02227238|10155163|FG001|Overall Study|Lost to Follow-up|5
6364934|NCT02195986|10155172|FG000|Overall Study|Adverse Event|3
6364935|NCT02195986|10155173|FG001|Overall Study|Adverse Event|0
6364936|NCT02195986|10155174|FG002|Overall Study|Adverse Event|0
6364937|NCT02195986|10155172|FG000|Overall Study|Withdrawal by Subject|0
6364938|NCT02195986|10155173|FG001|Overall Study|Withdrawal by Subject|3
6364939|NCT02195986|10155174|FG002|Overall Study|Withdrawal by Subject|0
6364940|NCT02195986|10155172|FG000|Overall Study|Family Emergency|0
6364941|NCT02195986|10155173|FG001|Overall Study|Family Emergency|0
6364942|NCT02195986|10155174|FG002|Overall Study|Family Emergency|1
6364943|NCT02195986|10155172|FG000|Overall Study|Protocol Violation|0
6364944|NCT02195986|10155173|FG001|Overall Study|Protocol Violation|1
6364945|NCT02195986|10155174|FG002|Overall Study|Protocol Violation|1
6364946|NCT02195986|10155172|FG000|Overall Study|Non-compliance|0
6364947|NCT02195986|10155173|FG001|Overall Study|Non-compliance|1
6364948|NCT02195986|10155174|FG002|Overall Study|Non-compliance|0
6364949|NCT02086448|10155195|FG000|Overall Study|Withdrawal by Subject|1
6364950|NCT02086448|10155196|FG001|Overall Study|Withdrawal by Subject|0
6364951|NCT02086448|10155197|FG002|Overall Study|Withdrawal by Subject|0
6364952|NCT02086448|10155198|FG003|Overall Study|Withdrawal by Subject|2
6364953|NCT01982630|10155216|FG000|Overall Study|Adverse Event|2
6364954|NCT01982630|10155217|FG001|Overall Study|Adverse Event|0
6364955|NCT01982630|10155218|FG002|Overall Study|Adverse Event|1
6364956|NCT01982630|10155219|FG003|Overall Study|Adverse Event|0
6364957|NCT01982630|10155220|FG004|Overall Study|Adverse Event|1
6364958|NCT01982630|10155221|FG005|Overall Study|Adverse Event|2
6364959|NCT01982630|10155222|FG006|Overall Study|Adverse Event|1
6364960|NCT01982630|10155223|FG007|Overall Study|Adverse Event|0
6364961|NCT01982630|10155216|FG000|Overall Study|Physician Decision|1
6364962|NCT01982630|10155217|FG001|Overall Study|Physician Decision|0
6364963|NCT01982630|10155218|FG002|Overall Study|Physician Decision|2
6364964|NCT01982630|10155219|FG003|Overall Study|Physician Decision|1
6364965|NCT01982630|10155220|FG004|Overall Study|Physician Decision|2
6364966|NCT01982630|10155221|FG005|Overall Study|Physician Decision|0
6364967|NCT01982630|10155222|FG006|Overall Study|Physician Decision|0
6364968|NCT01982630|10155223|FG007|Overall Study|Physician Decision|0
6364969|NCT01982630|10155216|FG000|Overall Study|Did Not Receive Drug-Technical Issues|0
6364970|NCT01982630|10155217|FG001|Overall Study|Did Not Receive Drug-Technical Issues|0
6364971|NCT01982630|10155218|FG002|Overall Study|Did Not Receive Drug-Technical Issues|2
6364972|NCT01982630|10155219|FG003|Overall Study|Did Not Receive Drug-Technical Issues|0
6364973|NCT01982630|10155220|FG004|Overall Study|Did Not Receive Drug-Technical Issues|0
6364974|NCT01982630|10155221|FG005|Overall Study|Did Not Receive Drug-Technical Issues|0
6364975|NCT01982630|10155222|FG006|Overall Study|Did Not Receive Drug-Technical Issues|0
6364976|NCT01982630|10155223|FG007|Overall Study|Did Not Receive Drug-Technical Issues|0
6364977|NCT01982630|10155216|FG000|Overall Study|Withdrawal by Subject|0
6364978|NCT01982630|10155217|FG001|Overall Study|Withdrawal by Subject|0
6364979|NCT01982630|10155218|FG002|Overall Study|Withdrawal by Subject|0
6364980|NCT01982630|10155219|FG003|Overall Study|Withdrawal by Subject|0
6364981|NCT01982630|10155220|FG004|Overall Study|Withdrawal by Subject|0
6364982|NCT01982630|10155221|FG005|Overall Study|Withdrawal by Subject|1
6364983|NCT01982630|10155222|FG006|Overall Study|Withdrawal by Subject|0
6364984|NCT01982630|10155223|FG007|Overall Study|Withdrawal by Subject|0
6364985|NCT01982448|10155278|FG000|Preoperative Chemotherapy|Withdrawal by Subject|2
6364986|NCT01982448|10155279|FG001|Preoperative Chemotherapy|Withdrawal by Subject|2
6364987|NCT01982448|10155278|FG000|Preoperative Chemotherapy|Ineligible Prior to Starting Therapy|1
6364988|NCT01982448|10155279|FG001|Preoperative Chemotherapy|Ineligible Prior to Starting Therapy|0
6364989|NCT01982448|10155278|FG000|Preoperative Chemotherapy|Hypersensitivity during cycle 1 so therapy stopped|0
6364990|NCT01982448|10155279|FG001|Preoperative Chemotherapy|Hypersensitivity during cycle 1 so therapy stopped|2
6364991|NCT01982448|10155278|FG000|Preoperative Chemotherapy|Lost to Follow-up|0
6364992|NCT01982448|10155279|FG001|Preoperative Chemotherapy|Lost to Follow-up|1
6171658|NCT01261611|9818587|FG002|Treatment Cycle 1|Withdrawal by Subject|0
6364993|NCT01752920|10155311|FG000|Overall Study|Adverse Event|1
6364994|NCT01752920|10155312|FG001|Overall Study|Adverse Event|0
6364995|NCT01752920|10155313|FG002|Overall Study|Adverse Event|5
6364996|NCT01752920|10155314|FG003|Overall Study|Adverse Event|10
6364997|NCT01752920|10155311|FG000|Overall Study|Clinical Disease Progression|6
6364998|NCT01752920|10155312|FG001|Overall Study|Clinical Disease Progression|4
6364999|NCT01752920|10155313|FG002|Overall Study|Clinical Disease Progression|1
6365000|NCT01752920|10155314|FG003|Overall Study|Clinical Disease Progression|13
6365001|NCT01752920|10155311|FG000|Overall Study|Physician Decision|1
6365002|NCT01752920|10155312|FG001|Overall Study|Physician Decision|0
6365003|NCT01752920|10155313|FG002|Overall Study|Physician Decision|0
6365004|NCT01752920|10155314|FG003|Overall Study|Physician Decision|3
6365005|NCT01752920|10155311|FG000|Overall Study|Radiographic Disease Progression|20
6365006|NCT01752920|10155312|FG001|Overall Study|Radiographic Disease Progression|7
6365007|NCT01752920|10155313|FG002|Overall Study|Radiographic Disease Progression|12
6365008|NCT01752920|10155314|FG003|Overall Study|Radiographic Disease Progression|29
6365009|NCT01752920|10155311|FG000|Overall Study|Study Terminated by Sponsor|0
6365010|NCT01752920|10155312|FG001|Overall Study|Study Terminated by Sponsor|0
6365011|NCT01752920|10155313|FG002|Overall Study|Study Terminated by Sponsor|0
6365012|NCT01752920|10155314|FG003|Overall Study|Study Terminated by Sponsor|1
6365013|NCT01752920|10155311|FG000|Overall Study|Withdrawal by Subject|0
6365014|NCT01752920|10155312|FG001|Overall Study|Withdrawal by Subject|1
6365015|NCT01752920|10155313|FG002|Overall Study|Withdrawal by Subject|0
6365016|NCT01752920|10155314|FG003|Overall Study|Withdrawal by Subject|1
6365017|NCT01752920|10155311|FG000|Overall Study|Lack of clinical benefit|1
6365018|NCT01752920|10155312|FG001|Overall Study|Lack of clinical benefit|1
6365019|NCT01752920|10155313|FG002|Overall Study|Lack of clinical benefit|1
6365020|NCT01752920|10155314|FG003|Overall Study|Lack of clinical benefit|1
6365021|NCT01744093|10155328|FG000|Overall Study|Withdrawal by Subject|6
6365022|NCT01744093|10155329|FG001|Overall Study|Withdrawal by Subject|1
6365023|NCT01740297|10155346|FG000|Overall Study|Withdrawal by Subject|4
6365024|NCT01740297|10155347|FG001|Overall Study|Withdrawal by Subject|16
6365025|NCT01740297|10155348|FG002|Overall Study|Withdrawal by Subject|17
6365026|NCT01740297|10155346|FG000|Overall Study|Death|8
6365027|NCT01740297|10155347|FG001|Overall Study|Death|46
6365028|NCT01740297|10155348|FG002|Overall Study|Death|40
6365029|NCT01740297|10155346|FG000|Overall Study|Lost to Follow-up|1
6365030|NCT01740297|10155347|FG001|Overall Study|Lost to Follow-up|2
6365031|NCT01740297|10155348|FG002|Overall Study|Lost to Follow-up|4
6365032|NCT01729754|10155362|FG000|Part 1|Adverse Event|2
6365033|NCT01729754|10155363|FG001|Part 1|Adverse Event|0
6365034|NCT01729754|10155364|FG002|Part 1|Adverse Event|0
6365035|NCT01729754|10155365|FG003|Part 1|Adverse Event|1
6365036|NCT01729754|10155366|FG004|Part 1|Adverse Event|0
6365037|NCT01729754|10155367|FG005|Part 1|Adverse Event|0
6365038|NCT01729754|10155368|FG006|Part 1|Adverse Event|2
6365039|NCT01729754|10155369|FG007|Part 1|Adverse Event|0
6365040|NCT01729754|10155370|FG008|Part 1|Adverse Event|0
6365041|NCT01729754|10155371|FG009|Part 1|Adverse Event|5
6365042|NCT01729754|10155362|FG000|Part 1|Lack of Efficacy|1
6365043|NCT01729754|10155363|FG001|Part 1|Lack of Efficacy|0
6365044|NCT01729754|10155364|FG002|Part 1|Lack of Efficacy|0
6365045|NCT01729754|10155365|FG003|Part 1|Lack of Efficacy|0
6365046|NCT01729754|10155366|FG004|Part 1|Lack of Efficacy|0
6365047|NCT01729754|10155367|FG005|Part 1|Lack of Efficacy|0
6365048|NCT01729754|10155368|FG006|Part 1|Lack of Efficacy|2
6365049|NCT01729754|10155369|FG007|Part 1|Lack of Efficacy|0
6365050|NCT01729754|10155370|FG008|Part 1|Lack of Efficacy|0
6365051|NCT01729754|10155371|FG009|Part 1|Lack of Efficacy|0
6365052|NCT01729754|10155362|FG000|Part 1|Lost to Follow-up|1
6365053|NCT01729754|10155363|FG001|Part 1|Lost to Follow-up|0
6365054|NCT01729754|10155364|FG002|Part 1|Lost to Follow-up|0
6365055|NCT01729754|10155365|FG003|Part 1|Lost to Follow-up|2
6365056|NCT01729754|10155366|FG004|Part 1|Lost to Follow-up|0
6365057|NCT01729754|10155367|FG005|Part 1|Lost to Follow-up|0
6365058|NCT01729754|10155368|FG006|Part 1|Lost to Follow-up|3
6365059|NCT01729754|10155369|FG007|Part 1|Lost to Follow-up|0
6365060|NCT01729754|10155370|FG008|Part 1|Lost to Follow-up|0
6365061|NCT01729754|10155371|FG009|Part 1|Lost to Follow-up|3
6365062|NCT01729754|10155362|FG000|Part 1|Non-compliance with Study Drug|1
6365063|NCT01729754|10155363|FG001|Part 1|Non-compliance with Study Drug|0
6365064|NCT01729754|10155364|FG002|Part 1|Non-compliance with Study Drug|0
6365065|NCT01729754|10155365|FG003|Part 1|Non-compliance with Study Drug|0
6365066|NCT01729754|10155366|FG004|Part 1|Non-compliance with Study Drug|0
6365067|NCT01729754|10155367|FG005|Part 1|Non-compliance with Study Drug|0
6365068|NCT01729754|10155368|FG006|Part 1|Non-compliance with Study Drug|0
6365069|NCT01729754|10155369|FG007|Part 1|Non-compliance with Study Drug|0
6365070|NCT01729754|10155370|FG008|Part 1|Non-compliance with Study Drug|0
6365071|NCT01729754|10155371|FG009|Part 1|Non-compliance with Study Drug|0
6365072|NCT01729754|10155362|FG000|Part 1|Physician Decision|0
6365073|NCT01729754|10155363|FG001|Part 1|Physician Decision|0
6365074|NCT01729754|10155364|FG002|Part 1|Physician Decision|0
6365075|NCT01729754|10155365|FG003|Part 1|Physician Decision|0
6365076|NCT01729754|10155366|FG004|Part 1|Physician Decision|0
6365077|NCT01729754|10155367|FG005|Part 1|Physician Decision|0
6365078|NCT01729754|10155368|FG006|Part 1|Physician Decision|0
6365079|NCT01729754|10155369|FG007|Part 1|Physician Decision|0
6365080|NCT01729754|10155370|FG008|Part 1|Physician Decision|0
6365081|NCT01729754|10155371|FG009|Part 1|Physician Decision|4
6365082|NCT01729754|10155362|FG000|Part 1|Pregnancy|0
6365083|NCT01729754|10155363|FG001|Part 1|Pregnancy|0
6365084|NCT01729754|10155364|FG002|Part 1|Pregnancy|0
6365085|NCT01729754|10155365|FG003|Part 1|Pregnancy|1
6365086|NCT01729754|10155366|FG004|Part 1|Pregnancy|0
6365087|NCT01729754|10155367|FG005|Part 1|Pregnancy|0
6365088|NCT01729754|10155368|FG006|Part 1|Pregnancy|0
6365089|NCT01729754|10155369|FG007|Part 1|Pregnancy|0
6365090|NCT01729754|10155370|FG008|Part 1|Pregnancy|0
6365091|NCT01729754|10155371|FG009|Part 1|Pregnancy|1
6365092|NCT01729754|10155362|FG000|Part 1|Progressive Disease|0
6365093|NCT01729754|10155363|FG001|Part 1|Progressive Disease|0
6365094|NCT01729754|10155364|FG002|Part 1|Progressive Disease|0
6365095|NCT01729754|10155365|FG003|Part 1|Progressive Disease|0
6365096|NCT01729754|10155366|FG004|Part 1|Progressive Disease|0
6365097|NCT01729754|10155367|FG005|Part 1|Progressive Disease|0
6365098|NCT01729754|10155368|FG006|Part 1|Progressive Disease|0
6365099|NCT01729754|10155369|FG007|Part 1|Progressive Disease|0
6365100|NCT01729754|10155370|FG008|Part 1|Progressive Disease|0
6365101|NCT01729754|10155371|FG009|Part 1|Progressive Disease|1
6365102|NCT01729754|10155362|FG000|Part 1|Protocol Violation|2
6365103|NCT01729754|10155363|FG001|Part 1|Protocol Violation|0
6365104|NCT01729754|10155364|FG002|Part 1|Protocol Violation|0
6365105|NCT01729754|10155365|FG003|Part 1|Protocol Violation|1
6365106|NCT01729754|10155366|FG004|Part 1|Protocol Violation|0
6365107|NCT01729754|10155367|FG005|Part 1|Protocol Violation|0
6365108|NCT01729754|10155368|FG006|Part 1|Protocol Violation|1
6365109|NCT01729754|10155369|FG007|Part 1|Protocol Violation|0
6365110|NCT01729754|10155370|FG008|Part 1|Protocol Violation|0
6365111|NCT01729754|10155371|FG009|Part 1|Protocol Violation|0
6365112|NCT01729754|10155362|FG000|Part 1|Withdrawal by Subject|5
6365113|NCT01729754|10155363|FG001|Part 1|Withdrawal by Subject|0
6365114|NCT01729754|10155364|FG002|Part 1|Withdrawal by Subject|0
6365115|NCT01729754|10155365|FG003|Part 1|Withdrawal by Subject|7
6365116|NCT01729754|10155366|FG004|Part 1|Withdrawal by Subject|0
6365117|NCT01729754|10155367|FG005|Part 1|Withdrawal by Subject|0
6365118|NCT01729754|10155368|FG006|Part 1|Withdrawal by Subject|5
6365119|NCT01729754|10155369|FG007|Part 1|Withdrawal by Subject|0
6365120|NCT01729754|10155370|FG008|Part 1|Withdrawal by Subject|0
6365121|NCT01729754|10155371|FG009|Part 1|Withdrawal by Subject|6
6365122|NCT01729754|10155362|FG000|Part 1|Other Protocol Specified Criteria|2
6365123|NCT01729754|10155363|FG001|Part 1|Other Protocol Specified Criteria|0
6365124|NCT01729754|10155364|FG002|Part 1|Other Protocol Specified Criteria|0
6365125|NCT01729754|10155365|FG003|Part 1|Other Protocol Specified Criteria|0
6365126|NCT01729754|10155366|FG004|Part 1|Other Protocol Specified Criteria|0
6365127|NCT01729754|10155367|FG005|Part 1|Other Protocol Specified Criteria|0
6365128|NCT01729754|10155368|FG006|Part 1|Other Protocol Specified Criteria|1
6365129|NCT01729754|10155369|FG007|Part 1|Other Protocol Specified Criteria|0
6365130|NCT01729754|10155370|FG008|Part 1|Other Protocol Specified Criteria|0
6365131|NCT01729754|10155371|FG009|Part 1|Other Protocol Specified Criteria|4
6365132|NCT01729754|10155362|FG000|Part 2|Adverse Event|2
6365133|NCT01729754|10155363|FG001|Part 2|Adverse Event|0
6365134|NCT01729754|10155364|FG002|Part 2|Adverse Event|0
6365135|NCT01729754|10155365|FG003|Part 2|Adverse Event|0
6365136|NCT01729754|10155366|FG004|Part 2|Adverse Event|0
6365137|NCT01729754|10155367|FG005|Part 2|Adverse Event|0
6365138|NCT01729754|10155368|FG006|Part 2|Adverse Event|0
6365139|NCT01729754|10155369|FG007|Part 2|Adverse Event|0
6365140|NCT01729754|10155370|FG008|Part 2|Adverse Event|1
6365141|NCT01729754|10155371|FG009|Part 2|Adverse Event|2
6365142|NCT01729754|10155362|FG000|Part 2|Lack of Efficacy|0
6365143|NCT01729754|10155363|FG001|Part 2|Lack of Efficacy|0
6365144|NCT01729754|10155364|FG002|Part 2|Lack of Efficacy|0
6365145|NCT01729754|10155365|FG003|Part 2|Lack of Efficacy|0
6365146|NCT01729754|10155366|FG004|Part 2|Lack of Efficacy|0
6365147|NCT01729754|10155367|FG005|Part 2|Lack of Efficacy|0
6365148|NCT01729754|10155368|FG006|Part 2|Lack of Efficacy|0
6365149|NCT01729754|10155369|FG007|Part 2|Lack of Efficacy|0
6365150|NCT01729754|10155370|FG008|Part 2|Lack of Efficacy|2
6365151|NCT01729754|10155371|FG009|Part 2|Lack of Efficacy|2
6365152|NCT01729754|10155362|FG000|Part 2|Lost to Follow-up|0
6365153|NCT01729754|10155363|FG001|Part 2|Lost to Follow-up|0
6365154|NCT01729754|10155364|FG002|Part 2|Lost to Follow-up|0
6365155|NCT01729754|10155365|FG003|Part 2|Lost to Follow-up|2
6365156|NCT01729754|10155366|FG004|Part 2|Lost to Follow-up|0
6365157|NCT01729754|10155367|FG005|Part 2|Lost to Follow-up|0
6365158|NCT01729754|10155368|FG006|Part 2|Lost to Follow-up|0
6365159|NCT01729754|10155369|FG007|Part 2|Lost to Follow-up|1
6365160|NCT01729754|10155370|FG008|Part 2|Lost to Follow-up|0
6365161|NCT01729754|10155371|FG009|Part 2|Lost to Follow-up|2
6365162|NCT01729754|10155362|FG000|Part 2|Non-Compliance with Study Drug|0
6365163|NCT01729754|10155363|FG001|Part 2|Non-Compliance with Study Drug|0
6365164|NCT01729754|10155364|FG002|Part 2|Non-Compliance with Study Drug|0
6365165|NCT01729754|10155365|FG003|Part 2|Non-Compliance with Study Drug|0
6365166|NCT01729754|10155366|FG004|Part 2|Non-Compliance with Study Drug|0
6365167|NCT01729754|10155367|FG005|Part 2|Non-Compliance with Study Drug|0
6365168|NCT01729754|10155368|FG006|Part 2|Non-Compliance with Study Drug|0
6365169|NCT01729754|10155369|FG007|Part 2|Non-Compliance with Study Drug|0
6365170|NCT01729754|10155370|FG008|Part 2|Non-Compliance with Study Drug|0
6365171|NCT01729754|10155371|FG009|Part 2|Non-Compliance with Study Drug|1
6365172|NCT01729754|10155362|FG000|Part 2|Pregnancy|0
6365173|NCT01729754|10155363|FG001|Part 2|Pregnancy|0
6365174|NCT01729754|10155364|FG002|Part 2|Pregnancy|0
6365175|NCT01729754|10155365|FG003|Part 2|Pregnancy|1
6365176|NCT01729754|10155366|FG004|Part 2|Pregnancy|0
6365177|NCT01729754|10155367|FG005|Part 2|Pregnancy|0
6365178|NCT01729754|10155368|FG006|Part 2|Pregnancy|0
6365179|NCT01729754|10155369|FG007|Part 2|Pregnancy|0
6365180|NCT01729754|10155370|FG008|Part 2|Pregnancy|0
6365181|NCT01729754|10155371|FG009|Part 2|Pregnancy|1
6365182|NCT01729754|10155362|FG000|Part 2|Withdrawal by Subject|3
6365183|NCT01729754|10155363|FG001|Part 2|Withdrawal by Subject|0
6365184|NCT01729754|10155364|FG002|Part 2|Withdrawal by Subject|0
6365185|NCT01729754|10155365|FG003|Part 2|Withdrawal by Subject|2
6365186|NCT01729754|10155366|FG004|Part 2|Withdrawal by Subject|0
6365187|NCT01729754|10155367|FG005|Part 2|Withdrawal by Subject|0
6365188|NCT01729754|10155368|FG006|Part 2|Withdrawal by Subject|0
6365189|NCT01729754|10155369|FG007|Part 2|Withdrawal by Subject|1
6365190|NCT01729754|10155370|FG008|Part 2|Withdrawal by Subject|1
6365191|NCT01729754|10155371|FG009|Part 2|Withdrawal by Subject|4
6365192|NCT01729754|10155362|FG000|Part 2|Other Protocol Specified Criteria|1
6365193|NCT01729754|10155363|FG001|Part 2|Other Protocol Specified Criteria|0
6365194|NCT01729754|10155364|FG002|Part 2|Other Protocol Specified Criteria|0
6365195|NCT01729754|10155365|FG003|Part 2|Other Protocol Specified Criteria|0
6365196|NCT01729754|10155366|FG004|Part 2|Other Protocol Specified Criteria|0
6365197|NCT01729754|10155367|FG005|Part 2|Other Protocol Specified Criteria|0
6365198|NCT01729754|10155368|FG006|Part 2|Other Protocol Specified Criteria|0
6365199|NCT01729754|10155369|FG007|Part 2|Other Protocol Specified Criteria|1
6365200|NCT01729754|10155370|FG008|Part 2|Other Protocol Specified Criteria|0
6365201|NCT01729754|10155371|FG009|Part 2|Other Protocol Specified Criteria|0
6365202|NCT01729754|10155362|FG000|Part 3|Adverse Event|0
6365203|NCT01729754|10155363|FG001|Part 3|Adverse Event|0
6365204|NCT01729754|10155364|FG002|Part 3|Adverse Event|1
6365205|NCT01729754|10155365|FG003|Part 3|Adverse Event|0
6365206|NCT01729754|10155366|FG004|Part 3|Adverse Event|0
6365207|NCT01729754|10155367|FG005|Part 3|Adverse Event|5
6365208|NCT01729754|10155368|FG006|Part 3|Adverse Event|0
6365209|NCT01729754|10155369|FG007|Part 3|Adverse Event|0
6365210|NCT01729754|10155370|FG008|Part 3|Adverse Event|0
6365211|NCT01729754|10155371|FG009|Part 3|Adverse Event|3
6365212|NCT01729754|10155362|FG000|Part 3|Death|0
6365213|NCT01729754|10155363|FG001|Part 3|Death|0
6365214|NCT01729754|10155364|FG002|Part 3|Death|0
6365215|NCT01729754|10155365|FG003|Part 3|Death|0
6365216|NCT01729754|10155366|FG004|Part 3|Death|0
6365217|NCT01729754|10155367|FG005|Part 3|Death|2
6365218|NCT01729754|10155368|FG006|Part 3|Death|0
6365219|NCT01729754|10155369|FG007|Part 3|Death|0
6365220|NCT01729754|10155370|FG008|Part 3|Death|0
6365221|NCT01729754|10155371|FG009|Part 3|Death|0
6365222|NCT01729754|10155362|FG000|Part 3|Lack of Efficacy|0
6365223|NCT01729754|10155363|FG001|Part 3|Lack of Efficacy|0
6365224|NCT01729754|10155364|FG002|Part 3|Lack of Efficacy|0
6365225|NCT01729754|10155365|FG003|Part 3|Lack of Efficacy|0
6365226|NCT01729754|10155366|FG004|Part 3|Lack of Efficacy|2
6365227|NCT01729754|10155367|FG005|Part 3|Lack of Efficacy|0
6365228|NCT01729754|10155368|FG006|Part 3|Lack of Efficacy|0
6365229|NCT01729754|10155369|FG007|Part 3|Lack of Efficacy|0
6365230|NCT01729754|10155370|FG008|Part 3|Lack of Efficacy|0
6365231|NCT01729754|10155371|FG009|Part 3|Lack of Efficacy|4
6365232|NCT01729754|10155362|FG000|Part 3|Lost to Follow-up|0
6365233|NCT01729754|10155363|FG001|Part 3|Lost to Follow-up|1
6365234|NCT01729754|10155364|FG002|Part 3|Lost to Follow-up|2
6365235|NCT01729754|10155365|FG003|Part 3|Lost to Follow-up|0
6365236|NCT01729754|10155366|FG004|Part 3|Lost to Follow-up|0
6365237|NCT01729754|10155367|FG005|Part 3|Lost to Follow-up|3
6365238|NCT01729754|10155368|FG006|Part 3|Lost to Follow-up|0
6365239|NCT01729754|10155369|FG007|Part 3|Lost to Follow-up|0
6365240|NCT01729754|10155370|FG008|Part 3|Lost to Follow-up|1
6365241|NCT01729754|10155371|FG009|Part 3|Lost to Follow-up|0
6365242|NCT01729754|10155362|FG000|Part 3|Physician Decision|0
6365243|NCT01729754|10155363|FG001|Part 3|Physician Decision|0
6365244|NCT01729754|10155364|FG002|Part 3|Physician Decision|1
6365245|NCT01729754|10155365|FG003|Part 3|Physician Decision|0
6365246|NCT01729754|10155366|FG004|Part 3|Physician Decision|0
6365247|NCT01729754|10155367|FG005|Part 3|Physician Decision|0
6365248|NCT01729754|10155368|FG006|Part 3|Physician Decision|0
6365249|NCT01729754|10155369|FG007|Part 3|Physician Decision|0
6365250|NCT01729754|10155370|FG008|Part 3|Physician Decision|0
6365251|NCT01729754|10155371|FG009|Part 3|Physician Decision|0
6365252|NCT01729754|10155362|FG000|Part 3|Withdrawal by Subject|0
6365253|NCT01729754|10155363|FG001|Part 3|Withdrawal by Subject|4
6365254|NCT01729754|10155364|FG002|Part 3|Withdrawal by Subject|1
6365255|NCT01729754|10155365|FG003|Part 3|Withdrawal by Subject|0
6365256|NCT01729754|10155366|FG004|Part 3|Withdrawal by Subject|2
6365257|NCT01729754|10155367|FG005|Part 3|Withdrawal by Subject|1
6365258|NCT01729754|10155368|FG006|Part 3|Withdrawal by Subject|0
6365259|NCT01729754|10155369|FG007|Part 3|Withdrawal by Subject|2
6365260|NCT01729754|10155370|FG008|Part 3|Withdrawal by Subject|0
6365261|NCT01729754|10155371|FG009|Part 3|Withdrawal by Subject|0
6365262|NCT01729754|10155362|FG000|Part 3|Other Protocol Specified Criteria|0
6365263|NCT01729754|10155363|FG001|Part 3|Other Protocol Specified Criteria|0
6365264|NCT01729754|10155364|FG002|Part 3|Other Protocol Specified Criteria|0
6365265|NCT01729754|10155365|FG003|Part 3|Other Protocol Specified Criteria|0
6365266|NCT01729754|10155366|FG004|Part 3|Other Protocol Specified Criteria|0
6365267|NCT01729754|10155367|FG005|Part 3|Other Protocol Specified Criteria|2
6365268|NCT01729754|10155368|FG006|Part 3|Other Protocol Specified Criteria|0
6365269|NCT01729754|10155369|FG007|Part 3|Other Protocol Specified Criteria|1
6365270|NCT01729754|10155370|FG008|Part 3|Other Protocol Specified Criteria|0
6365271|NCT01729754|10155371|FG009|Part 3|Other Protocol Specified Criteria|0
6365272|NCT01668784|10155414|FG000|Randomized (Pre-treatment)|Disease Progression|0
6365273|NCT01668784|10155415|FG001|Randomized (Pre-treatment)|Disease Progression|1
6365274|NCT01668784|10155414|FG000|Randomized (Pre-treatment)|Request to Discontinue Study Treatment|0
6365275|NCT01668784|10155415|FG001|Randomized (Pre-treatment)|Request to Discontinue Study Treatment|3
6365276|NCT01668784|10155414|FG000|Randomized (Pre-treatment)|Withdrawal by Subject|1
6365277|NCT01668784|10155415|FG001|Randomized (Pre-treatment)|Withdrawal by Subject|8
6365278|NCT01668784|10155414|FG000|Randomized (Pre-treatment)|Poor/Non-Compliance|1
6365279|NCT01668784|10155415|FG001|Randomized (Pre-treatment)|Poor/Non-Compliance|0
6365280|NCT01668784|10155414|FG000|Randomized (Pre-treatment)|No Longer Meets Study Criteria|2
6365281|NCT01668784|10155415|FG001|Randomized (Pre-treatment)|No Longer Meets Study Criteria|1
6365282|NCT01668784|10155414|FG000|Randomized (Pre-treatment)|Other|0
6365283|NCT01668784|10155415|FG001|Randomized (Pre-treatment)|Other|1
6365284|NCT01668784|10155414|FG000|Treated (Overall)|Disease Progression|285
6365285|NCT01668784|10155415|FG001|Treated (Overall)|Disease Progression|273
6365286|NCT01668784|10155414|FG000|Treated (Overall)|Study Drug Toxicity|35
6365287|NCT01668784|10155415|FG001|Treated (Overall)|Study Drug Toxicity|53
6365288|NCT01668784|10155414|FG000|Treated (Overall)|Death|1
6365289|NCT01668784|10155415|FG001|Treated (Overall)|Death|1
6365290|NCT01668784|10155414|FG000|Treated (Overall)|Adverse Event Unrelated to Study Drug|9
6365291|NCT01668784|10155415|FG001|Treated (Overall)|Adverse Event Unrelated to Study Drug|14
6365292|NCT01668784|10155414|FG000|Treated (Overall)|Request to Discontinue Study Treatment|5
6365293|NCT01668784|10155415|FG001|Treated (Overall)|Request to Discontinue Study Treatment|18
6365294|NCT01668784|10155414|FG000|Treated (Overall)|Withdrawal by Subject|2
6365295|NCT01668784|10155415|FG001|Treated (Overall)|Withdrawal by Subject|3
6365296|NCT01668784|10155414|FG000|Treated (Overall)|Maximal Clinical Benefit|2
6365297|NCT01668784|10155415|FG001|Treated (Overall)|Maximal Clinical Benefit|3
6365298|NCT01668784|10155414|FG000|Treated (Overall)|Other|0
6365299|NCT01668784|10155415|FG001|Treated (Overall)|Other|4
6365300|NCT01564537|10155436|FG000|Overall Study|Withdrawal by Participant|4
6365301|NCT01564537|10155437|FG001|Overall Study|Withdrawal by Participant|4
6365302|NCT01564537|10155436|FG000|Overall Study|Lost to Follow-up|1
6365303|NCT01564537|10155437|FG001|Overall Study|Lost to Follow-up|0
6365304|NCT01564537|10155436|FG000|Overall Study|Other Miscellaneous Reasons|1
6365305|NCT01564537|10155437|FG001|Overall Study|Other Miscellaneous Reasons|2
6365306|NCT01515306|10155446|FG000|Overall Study|Adverse Event|3
6365307|NCT01515306|10155447|FG001|Overall Study|Adverse Event|2
6365308|NCT01515306|10155446|FG000|Overall Study|Progressive Disease|19
6365309|NCT01515306|10155447|FG001|Overall Study|Progressive Disease|9
6365310|NCT01515306|10155446|FG000|Overall Study|Withdrawal by Subject|1
6365311|NCT01515306|10155447|FG001|Overall Study|Withdrawal by Subject|2
6365312|NCT01515306|10155446|FG000|Overall Study|Physician Decision|1
6365313|NCT01515306|10155447|FG001|Overall Study|Physician Decision|1
6365314|NCT01423851|10155468|FG000|Whole Study|Disease progression|2
6365315|NCT01423851|10155469|FG001|Whole Study|Disease progression|1
6365316|NCT01423851|10155470|FG002|Whole Study|Disease progression|1
6365317|NCT01423851|10155471|FG003|Whole Study|Disease progression|4
6365318|NCT01423851|10155472|FG004|Whole Study|Disease progression|1
6365319|NCT01423851|10155473|FG005|Whole Study|Disease progression|3
6365320|NCT01423851|10155474|FG006|Whole Study|Disease progression|1
6365321|NCT01423851|10155475|FG007|Whole Study|Disease progression|4
6365322|NCT01423851|10155476|FG008|Whole Study|Disease progression|0
6365323|NCT01423851|10155477|FG009|Whole Study|Disease progression|2
6365324|NCT01423851|10155478|FG010|Whole Study|Disease progression|10
6365325|NCT01423851|10155468|FG000|Whole Study|Physician Decision|0
6365326|NCT01423851|10155469|FG001|Whole Study|Physician Decision|1
6365327|NCT01423851|10155470|FG002|Whole Study|Physician Decision|2
6365328|NCT01423851|10155471|FG003|Whole Study|Physician Decision|0
6365329|NCT01423851|10155472|FG004|Whole Study|Physician Decision|2
6365330|NCT01423851|10155473|FG005|Whole Study|Physician Decision|0
6365331|NCT01423851|10155474|FG006|Whole Study|Physician Decision|2
6365332|NCT01423851|10155475|FG007|Whole Study|Physician Decision|1
6365333|NCT01423851|10155476|FG008|Whole Study|Physician Decision|3
6365334|NCT01423851|10155477|FG009|Whole Study|Physician Decision|4
6043245|NCT00387881|9641760|FG000|Overall Study|Not otherwise specified|11
6043246|NCT00387881|9641761|FG001|Overall Study|Not otherwise specified|7
6043247|NCT00387894|9641767|FG000|Overall Study|Withdrawal by Subject|1
6043248|NCT00388037|9641775|FG000|Overall Study|Protocol Violation|1
6043249|NCT00388154|9641779|FG000|Overall Study|Withdrawal by Subject|1
6043250|NCT00388297|9641787|FG000|Overall Study|Lost to Follow-up|16
6365335|NCT01423851|10155478|FG010|Whole Study|Physician Decision|12
6365336|NCT01423851|10155468|FG000|Whole Study|Withdrawal by Subject|1
6365337|NCT01423851|10155469|FG001|Whole Study|Withdrawal by Subject|1
6365338|NCT01423851|10155470|FG002|Whole Study|Withdrawal by Subject|0
6365339|NCT01423851|10155471|FG003|Whole Study|Withdrawal by Subject|0
6365340|NCT01423851|10155472|FG004|Whole Study|Withdrawal by Subject|0
6043251|NCT00388297|9641788|FG001|Overall Study|Lost to Follow-up|12
6365341|NCT01423851|10155473|FG005|Whole Study|Withdrawal by Subject|0
6365342|NCT01423851|10155474|FG006|Whole Study|Withdrawal by Subject|0
6365343|NCT01423851|10155475|FG007|Whole Study|Withdrawal by Subject|0
6365344|NCT01423851|10155476|FG008|Whole Study|Withdrawal by Subject|2
6365345|NCT01423851|10155477|FG009|Whole Study|Withdrawal by Subject|0
6365346|NCT01423851|10155478|FG010|Whole Study|Withdrawal by Subject|4
6365347|NCT01423851|10155468|FG000|Whole Study|Adverse Event|0
6365348|NCT01423851|10155469|FG001|Whole Study|Adverse Event|0
6365349|NCT01423851|10155470|FG002|Whole Study|Adverse Event|0
6365350|NCT01423851|10155471|FG003|Whole Study|Adverse Event|2
6365351|NCT01423851|10155472|FG004|Whole Study|Adverse Event|0
6365352|NCT01423851|10155473|FG005|Whole Study|Adverse Event|0
6365353|NCT01423851|10155474|FG006|Whole Study|Adverse Event|0
6365354|NCT01423851|10155475|FG007|Whole Study|Adverse Event|3
6365355|NCT01423851|10155476|FG008|Whole Study|Adverse Event|3
6365356|NCT01423851|10155477|FG009|Whole Study|Adverse Event|2
6365357|NCT01423851|10155478|FG010|Whole Study|Adverse Event|3
6365358|NCT01385176|10155509|FG000|Randomization Phase|Death|1
6365359|NCT01385176|10155510|FG001|Randomization Phase|Death|2
6365360|NCT01385176|10155509|FG000|6-18 Month All VNS Active|Death|1
6365361|NCT01385176|10155510|FG001|6-18 Month All VNS Active|Death|2
6365362|NCT01385176|10155509|FG000|6-18 Month All VNS Active|Physician Decision|0
6365363|NCT01385176|10155510|FG001|6-18 Month All VNS Active|Physician Decision|1
6365364|NCT01385176|10155509|FG000|6-18 Month All VNS Active|Withdrawal by Subject|2
6365365|NCT01385176|10155510|FG001|6-18 Month All VNS Active|Withdrawal by Subject|0
6365366|NCT01385176|10155509|FG000|6-18 Month All VNS Active|Heart Transplant|1
6365367|NCT01385176|10155510|FG001|6-18 Month All VNS Active|Heart Transplant|0
6084427|NCT00642902|9693367|FG001|Overall Study|Premature termination of clinical trial|32
6084428|NCT00642902|9693368|FG002|Overall Study|Premature termination of clinical trial|35
6084429|NCT00642902|9693369|FG003|Overall Study|Premature termination of clinical trial|35
6084430|NCT00642902|9693366|FG000|Overall Study|Randomized, but not treated|0
6084431|NCT00642902|9693367|FG001|Overall Study|Randomized, but not treated|0
6084432|NCT00642902|9693368|FG002|Overall Study|Randomized, but not treated|1
6084433|NCT00642902|9693369|FG003|Overall Study|Randomized, but not treated|0
6084434|NCT00642902|9693366|FG000|Overall Study|Other|1
6084435|NCT00642902|9693367|FG001|Overall Study|Other|5
6084436|NCT00642902|9693368|FG002|Overall Study|Other|1
6084437|NCT00642902|9693369|FG003|Overall Study|Other|4
6084438|NCT00642941|9693391|FG000|Overall Study|Physician Decision|3
6084439|NCT00642941|9693392|FG001|Overall Study|Physician Decision|1
6084440|NCT00642941|9693393|FG002|Overall Study|Physician Decision|0
6084441|NCT00642941|9693394|FG003|Overall Study|Physician Decision|0
6084442|NCT00642941|9693395|FG004|Overall Study|Physician Decision|0
6084443|NCT00642941|9693396|FG005|Overall Study|Physician Decision|0
6084444|NCT00642941|9693397|FG006|Overall Study|Physician Decision|1
6084445|NCT00642941|9693398|FG007|Overall Study|Physician Decision|0
6084446|NCT00642941|9693399|FG008|Overall Study|Physician Decision|0
6084447|NCT00642941|9693400|FG009|Overall Study|Physician Decision|1
6084448|NCT00642941|9693401|FG010|Overall Study|Physician Decision|0
6084449|NCT00642941|9693402|FG011|Overall Study|Physician Decision|1
6365368|NCT01334606|10155534|FG000|Overall Study|Study Terminated due to slow enrolment|18
6365369|NCT01317875|10155550|FG000|Overall Study|Other|0
6365370|NCT01317875|10155551|FG001|Overall Study|Other|0
6365371|NCT01317875|10155552|FG002|Overall Study|Other|1
6365372|NCT01317875|10155553|FG003|Overall Study|Other|0
6365373|NCT01317875|10155554|FG004|Overall Study|Other|0
6365374|NCT01317875|10155555|FG005|Overall Study|Other|0
6365375|NCT01317875|10155556|FG006|Overall Study|Other|0
6365376|NCT01317875|10155557|FG007|Overall Study|Other|0
6365377|NCT01317875|10155558|FG008|Overall Study|Other|0
6365378|NCT01317875|10155559|FG009|Overall Study|Other|0
6365379|NCT01317875|10155550|FG000|Overall Study|Noncompliance with study drug|0
6365380|NCT01317875|10155551|FG001|Overall Study|Noncompliance with study drug|0
6365381|NCT01317875|10155552|FG002|Overall Study|Noncompliance with study drug|1
6365382|NCT01317875|10155553|FG003|Overall Study|Noncompliance with study drug|0
6365383|NCT01317875|10155554|FG004|Overall Study|Noncompliance with study drug|0
6365384|NCT01317875|10155555|FG005|Overall Study|Noncompliance with study drug|0
6365385|NCT01317875|10155556|FG006|Overall Study|Noncompliance with study drug|0
6365386|NCT01317875|10155557|FG007|Overall Study|Noncompliance with study drug|0
6365387|NCT01317875|10155558|FG008|Overall Study|Noncompliance with study drug|0
6365388|NCT01317875|10155559|FG009|Overall Study|Noncompliance with study drug|0
6365389|NCT01317875|10155550|FG000|Overall Study|Progressive Disease|1
6365390|NCT01317875|10155551|FG001|Overall Study|Progressive Disease|0
6365391|NCT01317875|10155552|FG002|Overall Study|Progressive Disease|2
6365392|NCT01317875|10155553|FG003|Overall Study|Progressive Disease|0
6365393|NCT01317875|10155554|FG004|Overall Study|Progressive Disease|1
6365394|NCT01317875|10155555|FG005|Overall Study|Progressive Disease|0
6365395|NCT01317875|10155556|FG006|Overall Study|Progressive Disease|0
6365396|NCT01317875|10155557|FG007|Overall Study|Progressive Disease|1
6365397|NCT01317875|10155558|FG008|Overall Study|Progressive Disease|0
6365398|NCT01317875|10155559|FG009|Overall Study|Progressive Disease|0
6365399|NCT01317875|10155550|FG000|Overall Study|Withdrawal by Subject|0
6365400|NCT01317875|10155551|FG001|Overall Study|Withdrawal by Subject|0
6365401|NCT01317875|10155552|FG002|Overall Study|Withdrawal by Subject|0
6365402|NCT01317875|10155553|FG003|Overall Study|Withdrawal by Subject|0
6365403|NCT01317875|10155554|FG004|Overall Study|Withdrawal by Subject|1
6365404|NCT01317875|10155555|FG005|Overall Study|Withdrawal by Subject|0
6365405|NCT01317875|10155556|FG006|Overall Study|Withdrawal by Subject|0
6365406|NCT01317875|10155557|FG007|Overall Study|Withdrawal by Subject|3
6365407|NCT01317875|10155558|FG008|Overall Study|Withdrawal by Subject|0
6365408|NCT01317875|10155559|FG009|Overall Study|Withdrawal by Subject|0
6365409|NCT01317875|10155550|FG000|Overall Study|Physician Decision|0
6365410|NCT01317875|10155551|FG001|Overall Study|Physician Decision|1
6365411|NCT01317875|10155552|FG002|Overall Study|Physician Decision|1
6365412|NCT01317875|10155553|FG003|Overall Study|Physician Decision|0
6365413|NCT01317875|10155554|FG004|Overall Study|Physician Decision|2
6365414|NCT01317875|10155555|FG005|Overall Study|Physician Decision|0
6365415|NCT01317875|10155556|FG006|Overall Study|Physician Decision|0
6365416|NCT01317875|10155557|FG007|Overall Study|Physician Decision|2
6365417|NCT01317875|10155558|FG008|Overall Study|Physician Decision|0
6365418|NCT01317875|10155559|FG009|Overall Study|Physician Decision|0
6365419|NCT01317875|10155550|FG000|Overall Study|Death|0
6365420|NCT01317875|10155551|FG001|Overall Study|Death|0
6365421|NCT01317875|10155552|FG002|Overall Study|Death|2
6365422|NCT01317875|10155553|FG003|Overall Study|Death|1
6365423|NCT01317875|10155554|FG004|Overall Study|Death|0
6365424|NCT01317875|10155555|FG005|Overall Study|Death|1
6365425|NCT01317875|10155556|FG006|Overall Study|Death|0
6365426|NCT01317875|10155557|FG007|Overall Study|Death|4
6365427|NCT01317875|10155558|FG008|Overall Study|Death|0
6365428|NCT01317875|10155559|FG009|Overall Study|Death|0
6365429|NCT01317875|10155550|FG000|Overall Study|Adverse Event|2
6365430|NCT01317875|10155551|FG001|Overall Study|Adverse Event|1
6365431|NCT01317875|10155552|FG002|Overall Study|Adverse Event|2
6365432|NCT01317875|10155553|FG003|Overall Study|Adverse Event|1
6365433|NCT01317875|10155554|FG004|Overall Study|Adverse Event|5
6365434|NCT01317875|10155555|FG005|Overall Study|Adverse Event|1
6365435|NCT01317875|10155556|FG006|Overall Study|Adverse Event|2
6365436|NCT01317875|10155557|FG007|Overall Study|Adverse Event|5
6365437|NCT01317875|10155558|FG008|Overall Study|Adverse Event|0
6365438|NCT01317875|10155559|FG009|Overall Study|Adverse Event|0
6365439|NCT01216683|10155624|FG000|Induction|Never started treatment|0
6365440|NCT01216683|10155625|FG001|Induction|Never started treatment|6
6365441|NCT01216683|10155626|FG002|Induction|Never started treatment|3
6365442|NCT01216683|10155624|FG000|Induction|Lack of Efficacy|4
6365443|NCT01216683|10155625|FG001|Induction|Lack of Efficacy|3
6365444|NCT01216683|10155626|FG002|Induction|Lack of Efficacy|7
6365445|NCT01216683|10155624|FG000|Induction|Adverse Event|0
6365446|NCT01216683|10155625|FG001|Induction|Adverse Event|5
6365447|NCT01216683|10155626|FG002|Induction|Adverse Event|5
6365448|NCT01216683|10155624|FG000|Induction|Death|0
6365449|NCT01216683|10155625|FG001|Induction|Death|0
6365450|NCT01216683|10155626|FG002|Induction|Death|2
6365451|NCT01216683|10155624|FG000|Induction|Withdrawal by Subject|0
6365452|NCT01216683|10155625|FG001|Induction|Withdrawal by Subject|4
6365453|NCT01216683|10155626|FG002|Induction|Withdrawal by Subject|2
6365454|NCT01216683|10155624|FG000|Induction|Other disease|0
6365455|NCT01216683|10155625|FG001|Induction|Other disease|1
6171659|NCT01261611|9818585|FG000|Treatment Cycle 1|Lost to Follow-up|1
6084450|NCT00642941|9693391|FG000|Overall Study|Death|4
6084451|NCT00642941|9693392|FG001|Overall Study|Death|0
6084452|NCT00642941|9693393|FG002|Overall Study|Death|1
6365456|NCT01216683|10155626|FG002|Induction|Other disease|2
6365457|NCT01216683|10155624|FG000|Continuation|Lack of Efficacy|3
6365458|NCT01216683|10155625|FG001|Continuation|Lack of Efficacy|2
6365459|NCT01216683|10155626|FG002|Continuation|Lack of Efficacy|7
6365460|NCT01216683|10155624|FG000|Continuation|Adverse Event|5
6365461|NCT01216683|10155625|FG001|Continuation|Adverse Event|3
6365462|NCT01216683|10155626|FG002|Continuation|Adverse Event|16
6365463|NCT01216683|10155624|FG000|Continuation|Death|1
6365464|NCT01216683|10155625|FG001|Continuation|Death|0
6365465|NCT01216683|10155626|FG002|Continuation|Death|2
6365466|NCT01216683|10155624|FG000|Continuation|Withdrawal by Subject|4
6365467|NCT01216683|10155625|FG001|Continuation|Withdrawal by Subject|5
6365468|NCT01216683|10155626|FG002|Continuation|Withdrawal by Subject|9
6365469|NCT01216683|10155624|FG000|Continuation|Other diseases|0
6365470|NCT01216683|10155625|FG001|Continuation|Other diseases|2
6365471|NCT01216683|10155626|FG002|Continuation|Other diseases|1
6365472|NCT01216683|10155624|FG000|Continuation|Physician Decision|1
6365473|NCT01216683|10155625|FG001|Continuation|Physician Decision|0
6365474|NCT01216683|10155626|FG002|Continuation|Physician Decision|1
6365475|NCT01216683|10155624|FG000|Continuation|Non-compliance|1
6365476|NCT01216683|10155625|FG001|Continuation|Non-compliance|0
6365477|NCT01216683|10155626|FG002|Continuation|Non-compliance|1
6365478|NCT01216683|10155624|FG000|Continuation|Insurance change|0
6365479|NCT01216683|10155625|FG001|Continuation|Insurance change|1
6365480|NCT01216683|10155626|FG002|Continuation|Insurance change|0
6365481|NCT01216683|10155624|FG000|Continuation|Mistakenly stayed on treatment for longer than expected|0
6365482|NCT01216683|10155625|FG001|Continuation|Mistakenly stayed on treatment for longer than expected|1
6365483|NCT01216683|10155626|FG002|Continuation|Mistakenly stayed on treatment for longer than expected|0
6365484|NCT01216683|10155624|FG000|Continuation|Not reported|0
6365485|NCT01216683|10155625|FG001|Continuation|Not reported|0
6365486|NCT01216683|10155626|FG002|Continuation|Not reported|1
6365487|NCT01216683|10155624|FG000|Continuation|Never started treatment|0
6365488|NCT01216683|10155625|FG001|Continuation|Never started treatment|1
6365489|NCT01216683|10155626|FG002|Continuation|Never started treatment|5
6365490|NCT01085097|10155650|FG000|Overall Study|Adverse Event|0
6365491|NCT01085097|10155651|FG001|Overall Study|Adverse Event|0
6365492|NCT01085097|10155652|FG002|Overall Study|Adverse Event|2
6365493|NCT01085097|10155650|FG000|Overall Study|Treatment failure|2
6365494|NCT01085097|10155651|FG001|Overall Study|Treatment failure|0
6365495|NCT01085097|10155652|FG002|Overall Study|Treatment failure|0
6365496|NCT00920621|10155664|FG000|Overall Study|Lost to Follow-up|16
6365497|NCT00920621|10155665|FG001|Overall Study|Lost to Follow-up|17
6365498|NCT00920621|10155666|FG002|Overall Study|Lost to Follow-up|19
6365499|NCT00920621|10155667|FG003|Overall Study|Lost to Follow-up|21
6365500|NCT00920621|10155664|FG000|Overall Study|Fetal/neonatal deaths|16
6365501|NCT00920621|10155665|FG001|Overall Study|Fetal/neonatal deaths|14
6365502|NCT00920621|10155666|FG002|Overall Study|Fetal/neonatal deaths|16
6365503|NCT00920621|10155667|FG003|Overall Study|Fetal/neonatal deaths|14
6365504|NCT00920621|10155664|FG000|Overall Study|Blood sample not collected|22
6365505|NCT00920621|10155665|FG001|Overall Study|Blood sample not collected|14
6365506|NCT00920621|10155666|FG002|Overall Study|Blood sample not collected|0
6365507|NCT00920621|10155667|FG003|Overall Study|Blood sample not collected|0
6365508|NCT00680901|10155684|FG000|Overall Study|Lost to Follow-up|8
6365509|NCT00680901|10155685|FG001|Overall Study|Lost to Follow-up|8
6365510|NCT00680901|10155684|FG000|Overall Study|Withdrawal by Subject|4
6365511|NCT00680901|10155685|FG001|Overall Study|Withdrawal by Subject|13
6365512|NCT00680901|10155684|FG000|Overall Study|Physician Decision|0
6365513|NCT00680901|10155685|FG001|Overall Study|Physician Decision|1
6365514|NCT00680901|10155684|FG000|Overall Study|Ongoing: On Study Treatment|16
6365515|NCT00680901|10155685|FG001|Overall Study|Ongoing: On Study Treatment|13
6365516|NCT00680901|10155684|FG000|Overall Study|Ongoing: In Follow Up|45
6365517|NCT00680901|10155685|FG001|Overall Study|Ongoing: In Follow Up|41
6365518|NCT00667251|10155693|FG000|Overall Study|Adverse Event|13
6365519|NCT00667251|10155694|FG001|Overall Study|Adverse Event|4
6171660|NCT01261611|9818586|FG001|Treatment Cycle 1|Lost to Follow-up|0
6365520|NCT00667251|10155693|FG000|Overall Study|Withdrawal by Subject|6
6365521|NCT00667251|10155694|FG001|Overall Study|Withdrawal by Subject|2
6365522|NCT00667251|10155693|FG000|Overall Study|Other/missing|46
6365523|NCT00667251|10155694|FG001|Overall Study|Other/missing|84
6365524|NCT00667251|10155693|FG000|Overall Study|Intercurrent Illness|4
6365525|NCT00667251|10155694|FG001|Overall Study|Intercurrent Illness|3
6365526|NCT00667251|10155693|FG000|Overall Study|Symptomatic progression|1
6365527|NCT00667251|10155694|FG001|Overall Study|Symptomatic progression|2
6365528|NCT00500071|10155710|FG000|Screening and Washout Phase|Protocol Violation|1
6365529|NCT00500071|10155710|FG000|Dose-optimization and Maintenance Phase|Adverse Event|13
6084453|NCT00642941|9693394|FG003|Overall Study|Death|1
6365530|NCT00500071|10155710|FG000|Dose-optimization and Maintenance Phase|Protocol Violation|2
6365531|NCT00500071|10155710|FG000|Dose-optimization and Maintenance Phase|Lack of Efficacy|2
6365532|NCT00500071|10155710|FG000|Dose-optimization and Maintenance Phase|Withdrawal by Subject|1
6365533|NCT00500071|10155710|FG000|Dose-optimization and Maintenance Phase|Lack of protocol compliance|4
6365534|NCT00500071|10155710|FG000|30-day Safety Follow-up|Lost to Follow-up|17
6365535|NCT00447122|10155718|FG000|Overall Study|worsening medical condition -came off|0
6365536|NCT00447122|10155719|FG001|Overall Study|worsening medical condition -came off|1
6365537|NCT00447122|10155720|FG002|Overall Study|worsening medical condition -came off|0
6365538|NCT00447122|10155721|FG003|Overall Study|worsening medical condition -came off|0
6365539|NCT00382252|10155731|FG000|Overall Study|Death|4
6365540|NCT00382252|10155731|FG000|Overall Study|Protocol Violation|8
6365541|NCT00382252|10155731|FG000|Overall Study|Not treated by RFA|1
6365542|NCT00324805|10155737|FG000|Overall Study|Adverse Event|62
6365543|NCT00324805|10155738|FG001|Overall Study|Adverse Event|203
6365544|NCT00324805|10155737|FG000|Overall Study|Progression|7
6365545|NCT00324805|10155738|FG001|Overall Study|Progression|35
6365546|NCT00324805|10155737|FG000|Overall Study|Withdrawal by Subject|51
6365547|NCT00324805|10155738|FG001|Overall Study|Withdrawal by Subject|174
6365548|NCT00324805|10155737|FG000|Overall Study|Death|6
6365549|NCT00324805|10155738|FG001|Overall Study|Death|9
6365550|NCT00324805|10155737|FG000|Overall Study|Alternative therapy|4
6365551|NCT00324805|10155738|FG001|Overall Study|Alternative therapy|8
6365552|NCT00324805|10155737|FG000|Overall Study|Other complicating disease|1
6365553|NCT00324805|10155738|FG001|Overall Study|Other complicating disease|9
6365554|NCT00324805|10155737|FG000|Overall Study|Other reasons|7
6365555|NCT00324805|10155738|FG001|Overall Study|Other reasons|26
6365556|NCT00324805|10155737|FG000|Overall Study|Other|0
6365557|NCT00324805|10155738|FG001|Overall Study|Other|2
6365558|NCT00324805|10155737|FG000|Overall Study|Did not start therapy|12
6365559|NCT00324805|10155738|FG001|Overall Study|Did not start therapy|17
6365560|NCT00309985|10155763|FG000|Overall Study|Disease progression|12
6365561|NCT00309985|10155764|FG001|Overall Study|Disease progression|0
6365562|NCT00309985|10155763|FG000|Overall Study|Adverse Event|30
6365563|NCT00309985|10155764|FG001|Overall Study|Adverse Event|0
6365564|NCT00309985|10155763|FG000|Overall Study|Death|2
6365565|NCT00309985|10155764|FG001|Overall Study|Death|0
6365566|NCT00309985|10155763|FG000|Overall Study|Withdrawal by Subject|5
6365567|NCT00309985|10155764|FG001|Overall Study|Withdrawal by Subject|1
6365568|NCT00309985|10155763|FG000|Overall Study|Physician Decision|3
6365569|NCT00309985|10155764|FG001|Overall Study|Physician Decision|0
6365570|NCT00309985|10155763|FG000|Overall Study|Never started treatment|7
6365571|NCT00309985|10155764|FG001|Overall Study|Never started treatment|0
6365572|NCT00309985|10155763|FG000|Overall Study|Complicating disease|1
6365573|NCT00309985|10155764|FG001|Overall Study|Complicating disease|0
6365574|NCT00309985|10155763|FG000|Overall Study|Non-compliance|1
6365575|NCT00309985|10155764|FG001|Overall Study|Non-compliance|0
6365576|NCT00309985|10155763|FG000|Overall Study|Chemotherapy discontinued only|1
6365577|NCT00309985|10155764|FG001|Overall Study|Chemotherapy discontinued only|0
6365578|NCT00290251|10155773|FG000|Treatment 1 (Months 2-4)|Withdrawal by Subject|0
6365579|NCT00290251|10155774|FG001|Treatment 1 (Months 2-4)|Withdrawal by Subject|0
6365580|NCT00290251|10155775|FG002|Treatment 1 (Months 2-4)|Withdrawal by Subject|0
6365581|NCT00290251|10155776|FG003|Treatment 1 (Months 2-4)|Withdrawal by Subject|0
6365582|NCT00290251|10155777|FG004|Treatment 1 (Months 2-4)|Withdrawal by Subject|0
6365583|NCT00290251|10155778|FG005|Treatment 1 (Months 2-4)|Withdrawal by Subject|2
6365584|NCT00290251|10155773|FG000|Treatment 1 (Months 2-4)|headache|0
6365585|NCT00290251|10155774|FG001|Treatment 1 (Months 2-4)|headache|0
6365586|NCT00290251|10155775|FG002|Treatment 1 (Months 2-4)|headache|0
6365587|NCT00290251|10155776|FG003|Treatment 1 (Months 2-4)|headache|0
6365588|NCT00290251|10155777|FG004|Treatment 1 (Months 2-4)|headache|1
6365589|NCT00290251|10155778|FG005|Treatment 1 (Months 2-4)|headache|0
6365590|NCT00290251|10155773|FG000|Treatment 1 (Months 2-4)|Out of body experience|0
6365591|NCT00290251|10155774|FG001|Treatment 1 (Months 2-4)|Out of body experience|0
6365592|NCT00290251|10155775|FG002|Treatment 1 (Months 2-4)|Out of body experience|0
6365593|NCT00290251|10155776|FG003|Treatment 1 (Months 2-4)|Out of body experience|1
6084454|NCT00642941|9693395|FG004|Overall Study|Death|2
6084455|NCT00642941|9693396|FG005|Overall Study|Death|1
6084456|NCT00642941|9693397|FG006|Overall Study|Death|0
6084457|NCT00642941|9693398|FG007|Overall Study|Death|0
6084458|NCT00642941|9693399|FG008|Overall Study|Death|0
6084459|NCT00642941|9693400|FG009|Overall Study|Death|0
6084460|NCT00642941|9693401|FG010|Overall Study|Death|0
6365594|NCT00290251|10155777|FG004|Treatment 1 (Months 2-4)|Out of body experience|0
6365595|NCT00290251|10155778|FG005|Treatment 1 (Months 2-4)|Out of body experience|0
6084461|NCT00642941|9693402|FG011|Overall Study|Death|1
6084462|NCT00642941|9693391|FG000|Overall Study|Study closed by Sponsor|0
6084463|NCT00642941|9693392|FG001|Overall Study|Study closed by Sponsor|1
6084464|NCT00642941|9693393|FG002|Overall Study|Study closed by Sponsor|0
6084465|NCT00642941|9693394|FG003|Overall Study|Study closed by Sponsor|0
6084466|NCT00642941|9693395|FG004|Overall Study|Study closed by Sponsor|0
6084467|NCT00642941|9693396|FG005|Overall Study|Study closed by Sponsor|0
6084468|NCT00642941|9693397|FG006|Overall Study|Study closed by Sponsor|0
6084469|NCT00642941|9693398|FG007|Overall Study|Study closed by Sponsor|0
6084470|NCT00642941|9693399|FG008|Overall Study|Study closed by Sponsor|0
6084471|NCT00642941|9693400|FG009|Overall Study|Study closed by Sponsor|0
6084472|NCT00642941|9693401|FG010|Overall Study|Study closed by Sponsor|0
6084473|NCT00642941|9693402|FG011|Overall Study|Study closed by Sponsor|0
6365596|NCT01403948|10155814|FG000|Overall Study|Progressive disease|0
6365597|NCT01403948|10155815|FG001|Overall Study|Progressive disease|2
6365598|NCT01403948|10155816|FG002|Overall Study|Progressive disease|2
6365599|NCT01403948|10155817|FG003|Overall Study|Progressive disease|4
6365600|NCT01403948|10155818|FG004|Overall Study|Progressive disease|2
6365601|NCT01403948|10155819|FG005|Overall Study|Progressive disease|6
6365602|NCT01403948|10155820|FG006|Overall Study|Progressive disease|2
6365603|NCT01403948|10155821|FG007|Overall Study|Progressive disease|4
6365604|NCT01403948|10155822|FG008|Overall Study|Progressive disease|5
6365605|NCT01403948|10155823|FG009|Overall Study|Progressive disease|5
6365606|NCT01403948|10155814|FG000|Overall Study|Other Adverse Event (Other than DLT)|0
6365607|NCT01403948|10155815|FG001|Overall Study|Other Adverse Event (Other than DLT)|0
6365608|NCT01403948|10155816|FG002|Overall Study|Other Adverse Event (Other than DLT)|0
6365609|NCT01403948|10155817|FG003|Overall Study|Other Adverse Event (Other than DLT)|0
6365610|NCT01403948|10155818|FG004|Overall Study|Other Adverse Event (Other than DLT)|2
6365611|NCT01403948|10155819|FG005|Overall Study|Other Adverse Event (Other than DLT)|0
6365612|NCT01403948|10155820|FG006|Overall Study|Other Adverse Event (Other than DLT)|2
6365613|NCT01403948|10155821|FG007|Overall Study|Other Adverse Event (Other than DLT)|0
6365614|NCT01403948|10155822|FG008|Overall Study|Other Adverse Event (Other than DLT)|1
6365615|NCT01403948|10155823|FG009|Overall Study|Other Adverse Event (Other than DLT)|0
6365616|NCT01403948|10155814|FG000|Overall Study|Lost to Follow-up|0
6365617|NCT01403948|10155815|FG001|Overall Study|Lost to Follow-up|0
6365618|NCT01403948|10155816|FG002|Overall Study|Lost to Follow-up|0
6365619|NCT01403948|10155817|FG003|Overall Study|Lost to Follow-up|0
6365620|NCT01403948|10155818|FG004|Overall Study|Lost to Follow-up|0
6365621|NCT01403948|10155819|FG005|Overall Study|Lost to Follow-up|0
6365622|NCT01403948|10155820|FG006|Overall Study|Lost to Follow-up|0
6365623|NCT01403948|10155821|FG007|Overall Study|Lost to Follow-up|0
6365624|NCT01403948|10155822|FG008|Overall Study|Lost to Follow-up|0
6365625|NCT01403948|10155823|FG009|Overall Study|Lost to Follow-up|1
6365626|NCT01403948|10155814|FG000|Overall Study|Refused cont. medication|0
6365627|NCT01403948|10155815|FG001|Overall Study|Refused cont. medication|0
6365628|NCT01403948|10155816|FG002|Overall Study|Refused cont. medication|0
6365629|NCT01403948|10155817|FG003|Overall Study|Refused cont. medication|0
6365630|NCT01403948|10155818|FG004|Overall Study|Refused cont. medication|1
6365631|NCT01403948|10155819|FG005|Overall Study|Refused cont. medication|0
6365632|NCT01403948|10155820|FG006|Overall Study|Refused cont. medication|0
6365633|NCT01403948|10155821|FG007|Overall Study|Refused cont. medication|0
6365634|NCT01403948|10155822|FG008|Overall Study|Refused cont. medication|0
6365635|NCT01403948|10155823|FG009|Overall Study|Refused cont. medication|1
6365636|NCT01403948|10155814|FG000|Overall Study|other than above|1
6365637|NCT01403948|10155815|FG001|Overall Study|other than above|2
6365638|NCT01403948|10155816|FG002|Overall Study|other than above|1
6365639|NCT01403948|10155817|FG003|Overall Study|other than above|0
6365640|NCT01403948|10155818|FG004|Overall Study|other than above|1
6365641|NCT01403948|10155819|FG005|Overall Study|other than above|1
6365642|NCT01403948|10155820|FG006|Overall Study|other than above|2
6365643|NCT01403948|10155821|FG007|Overall Study|other than above|0
6365644|NCT01403948|10155822|FG008|Overall Study|other than above|0
6365645|NCT01403948|10155823|FG009|Overall Study|other than above|0
6365646|NCT01404312|10155851|FG000|Overall Study|Death|21
6365647|NCT01404312|10155852|FG001|Overall Study|Death|27
6365648|NCT01404312|10155851|FG000|Overall Study|Withdrawal by Subject|15
6365649|NCT01404312|10155852|FG001|Overall Study|Withdrawal by Subject|18
6365650|NCT01404312|10155851|FG000|Overall Study|Participant Unable to get to clinic|93
6365651|NCT01404312|10155852|FG001|Overall Study|Participant Unable to get to clinic|103
6365652|NCT01404312|10155851|FG000|Overall Study|Lost to Follow-up|115
6365653|NCT01404312|10155852|FG001|Overall Study|Lost to Follow-up|111
6365654|NCT01404312|10155851|FG000|Overall Study|Site closed|22
6365655|NCT01404312|10155852|FG001|Overall Study|Site closed|21
6365656|NCT01404312|10155851|FG000|Overall Study|Participant not willing to adhere to req|31
6365657|NCT01404312|10155852|FG001|Overall Study|Participant not willing to adhere to req|29
6084474|NCT00642941|9693391|FG000|Overall Study|Withdrawal by Subject|1
6365658|NCT01404312|10155851|FG000|Overall Study|Severe debilitation, unable to continue|1
6365659|NCT01404312|10155852|FG001|Overall Study|Severe debilitation, unable to continue|2
6365660|NCT01425008|10155878|FG000|Dose Escalation Phase|Progressive Disease|2
6365661|NCT01425008|10155879|FG001|Dose Escalation Phase|Progressive Disease|3
6365662|NCT01425008|10155880|FG002|Dose Escalation Phase|Progressive Disease|2
6365663|NCT01425008|10155881|FG003|Dose Escalation Phase|Progressive Disease|3
6365664|NCT01425008|10155882|FG004|Dose Escalation Phase|Progressive Disease|5
6365665|NCT01425008|10155883|FG005|Dose Escalation Phase|Progressive Disease|4
6365666|NCT01425008|10155884|FG006|Dose Escalation Phase|Progressive Disease|0
6365667|NCT01425008|10155885|FG007|Dose Escalation Phase|Progressive Disease|2
6365668|NCT01425008|10155886|FG008|Dose Escalation Phase|Progressive Disease|6
6365669|NCT01425008|10155887|FG009|Dose Escalation Phase|Progressive Disease|2
6365670|NCT01425008|10155888|FG010|Dose Escalation Phase|Progressive Disease|0
6365671|NCT01425008|10155889|FG011|Dose Escalation Phase|Progressive Disease|0
6365672|NCT01425008|10155890|FG012|Dose Escalation Phase|Progressive Disease|0
6365673|NCT01425008|10155891|FG013|Dose Escalation Phase|Progressive Disease|0
6365674|NCT01425008|10155892|FG014|Dose Escalation Phase|Progressive Disease|0
6365675|NCT01425008|10155893|FG015|Dose Escalation Phase|Progressive Disease|0
6365676|NCT01425008|10155894|FG016|Dose Escalation Phase|Progressive Disease|0
6365677|NCT01425008|10155895|FG017|Dose Escalation Phase|Progressive Disease|0
6365678|NCT01425008|10155896|FG018|Dose Escalation Phase|Progressive Disease|0
6365679|NCT01425008|10155878|FG000|Dose Escalation Phase|Adverse Event|2
6365680|NCT01425008|10155879|FG001|Dose Escalation Phase|Adverse Event|0
6365681|NCT01425008|10155880|FG002|Dose Escalation Phase|Adverse Event|0
6365682|NCT01425008|10155881|FG003|Dose Escalation Phase|Adverse Event|0
6365683|NCT01425008|10155882|FG004|Dose Escalation Phase|Adverse Event|0
6365684|NCT01425008|10155883|FG005|Dose Escalation Phase|Adverse Event|2
6365685|NCT01425008|10155884|FG006|Dose Escalation Phase|Adverse Event|0
6365686|NCT01425008|10155885|FG007|Dose Escalation Phase|Adverse Event|0
6365687|NCT01425008|10155886|FG008|Dose Escalation Phase|Adverse Event|2
6365688|NCT01425008|10155887|FG009|Dose Escalation Phase|Adverse Event|0
6365689|NCT01425008|10155888|FG010|Dose Escalation Phase|Adverse Event|0
6365690|NCT01425008|10155889|FG011|Dose Escalation Phase|Adverse Event|0
6365691|NCT01425008|10155890|FG012|Dose Escalation Phase|Adverse Event|0
6365692|NCT01425008|10155891|FG013|Dose Escalation Phase|Adverse Event|0
6365693|NCT01425008|10155892|FG014|Dose Escalation Phase|Adverse Event|0
6365694|NCT01425008|10155893|FG015|Dose Escalation Phase|Adverse Event|0
6365695|NCT01425008|10155894|FG016|Dose Escalation Phase|Adverse Event|0
6365696|NCT01425008|10155895|FG017|Dose Escalation Phase|Adverse Event|0
6365697|NCT01425008|10155896|FG018|Dose Escalation Phase|Adverse Event|0
6365698|NCT01425008|10155878|FG000|Dose Escalation Phase|Unsatisfactory Therapeutic Response|0
6365699|NCT01425008|10155879|FG001|Dose Escalation Phase|Unsatisfactory Therapeutic Response|0
6365700|NCT01425008|10155880|FG002|Dose Escalation Phase|Unsatisfactory Therapeutic Response|0
6365701|NCT01425008|10155881|FG003|Dose Escalation Phase|Unsatisfactory Therapeutic Response|0
6365702|NCT01425008|10155882|FG004|Dose Escalation Phase|Unsatisfactory Therapeutic Response|1
6365703|NCT01425008|10155883|FG005|Dose Escalation Phase|Unsatisfactory Therapeutic Response|0
6365704|NCT01425008|10155884|FG006|Dose Escalation Phase|Unsatisfactory Therapeutic Response|2
6365705|NCT01425008|10155885|FG007|Dose Escalation Phase|Unsatisfactory Therapeutic Response|1
6365706|NCT01425008|10155886|FG008|Dose Escalation Phase|Unsatisfactory Therapeutic Response|1
6365707|NCT01425008|10155887|FG009|Dose Escalation Phase|Unsatisfactory Therapeutic Response|0
6365708|NCT01425008|10155888|FG010|Dose Escalation Phase|Unsatisfactory Therapeutic Response|0
6365709|NCT01425008|10155889|FG011|Dose Escalation Phase|Unsatisfactory Therapeutic Response|0
6365710|NCT01425008|10155890|FG012|Dose Escalation Phase|Unsatisfactory Therapeutic Response|0
6365711|NCT01425008|10155891|FG013|Dose Escalation Phase|Unsatisfactory Therapeutic Response|0
6365712|NCT01425008|10155892|FG014|Dose Escalation Phase|Unsatisfactory Therapeutic Response|0
6365713|NCT01425008|10155893|FG015|Dose Escalation Phase|Unsatisfactory Therapeutic Response|0
6365714|NCT01425008|10155894|FG016|Dose Escalation Phase|Unsatisfactory Therapeutic Response|0
6365715|NCT01425008|10155895|FG017|Dose Escalation Phase|Unsatisfactory Therapeutic Response|0
6365716|NCT01425008|10155896|FG018|Dose Escalation Phase|Unsatisfactory Therapeutic Response|0
6365717|NCT01425008|10155878|FG000|Dose Escalation Phase|Withdrawal by Subject|0
6365718|NCT01425008|10155879|FG001|Dose Escalation Phase|Withdrawal by Subject|0
6365719|NCT01425008|10155880|FG002|Dose Escalation Phase|Withdrawal by Subject|0
6365720|NCT01425008|10155881|FG003|Dose Escalation Phase|Withdrawal by Subject|0
6365721|NCT01425008|10155882|FG004|Dose Escalation Phase|Withdrawal by Subject|1
6365722|NCT01425008|10155883|FG005|Dose Escalation Phase|Withdrawal by Subject|1
6365723|NCT01425008|10155884|FG006|Dose Escalation Phase|Withdrawal by Subject|1
6365724|NCT01425008|10155885|FG007|Dose Escalation Phase|Withdrawal by Subject|0
6365725|NCT01425008|10155886|FG008|Dose Escalation Phase|Withdrawal by Subject|1
6365726|NCT01425008|10155887|FG009|Dose Escalation Phase|Withdrawal by Subject|0
6365727|NCT01425008|10155888|FG010|Dose Escalation Phase|Withdrawal by Subject|0
6365728|NCT01425008|10155889|FG011|Dose Escalation Phase|Withdrawal by Subject|0
6365729|NCT01425008|10155890|FG012|Dose Escalation Phase|Withdrawal by Subject|0
6365730|NCT01425008|10155891|FG013|Dose Escalation Phase|Withdrawal by Subject|0
6365731|NCT01425008|10155892|FG014|Dose Escalation Phase|Withdrawal by Subject|0
6365732|NCT01425008|10155893|FG015|Dose Escalation Phase|Withdrawal by Subject|0
6365733|NCT01425008|10155894|FG016|Dose Escalation Phase|Withdrawal by Subject|0
6365734|NCT01425008|10155895|FG017|Dose Escalation Phase|Withdrawal by Subject|0
6365735|NCT01425008|10155896|FG018|Dose Escalation Phase|Withdrawal by Subject|0
6365736|NCT01425008|10155878|FG000|Dose Escalation Phase|Symptomatic Deterioration|0
6365737|NCT01425008|10155879|FG001|Dose Escalation Phase|Symptomatic Deterioration|0
6365738|NCT01425008|10155880|FG002|Dose Escalation Phase|Symptomatic Deterioration|1
6365739|NCT01425008|10155881|FG003|Dose Escalation Phase|Symptomatic Deterioration|0
6365740|NCT01425008|10155882|FG004|Dose Escalation Phase|Symptomatic Deterioration|0
6365741|NCT01425008|10155883|FG005|Dose Escalation Phase|Symptomatic Deterioration|0
6365742|NCT01425008|10155884|FG006|Dose Escalation Phase|Symptomatic Deterioration|0
6365743|NCT01425008|10155885|FG007|Dose Escalation Phase|Symptomatic Deterioration|0
6365744|NCT01425008|10155886|FG008|Dose Escalation Phase|Symptomatic Deterioration|2
6365745|NCT01425008|10155887|FG009|Dose Escalation Phase|Symptomatic Deterioration|2
6365746|NCT01425008|10155888|FG010|Dose Escalation Phase|Symptomatic Deterioration|0
6365747|NCT01425008|10155889|FG011|Dose Escalation Phase|Symptomatic Deterioration|0
6365748|NCT01425008|10155890|FG012|Dose Escalation Phase|Symptomatic Deterioration|0
6365749|NCT01425008|10155891|FG013|Dose Escalation Phase|Symptomatic Deterioration|0
6365750|NCT01425008|10155892|FG014|Dose Escalation Phase|Symptomatic Deterioration|0
6365751|NCT01425008|10155893|FG015|Dose Escalation Phase|Symptomatic Deterioration|0
6365752|NCT01425008|10155894|FG016|Dose Escalation Phase|Symptomatic Deterioration|0
6365753|NCT01425008|10155895|FG017|Dose Escalation Phase|Symptomatic Deterioration|0
6365754|NCT01425008|10155896|FG018|Dose Escalation Phase|Symptomatic Deterioration|0
6365755|NCT01425008|10155878|FG000|Dose Escalation Phase|Other|0
6365756|NCT01425008|10155879|FG001|Dose Escalation Phase|Other|0
6365757|NCT01425008|10155880|FG002|Dose Escalation Phase|Other|0
6365758|NCT01425008|10155881|FG003|Dose Escalation Phase|Other|0
6365759|NCT01425008|10155882|FG004|Dose Escalation Phase|Other|0
6365760|NCT01425008|10155883|FG005|Dose Escalation Phase|Other|0
6365761|NCT01425008|10155884|FG006|Dose Escalation Phase|Other|0
6365762|NCT01425008|10155885|FG007|Dose Escalation Phase|Other|0
6365763|NCT01425008|10155886|FG008|Dose Escalation Phase|Other|1
6365764|NCT01425008|10155887|FG009|Dose Escalation Phase|Other|0
6365765|NCT01425008|10155888|FG010|Dose Escalation Phase|Other|0
6365766|NCT01425008|10155889|FG011|Dose Escalation Phase|Other|0
6365767|NCT01425008|10155890|FG012|Dose Escalation Phase|Other|0
6365768|NCT01425008|10155891|FG013|Dose Escalation Phase|Other|0
6365769|NCT01425008|10155892|FG014|Dose Escalation Phase|Other|0
6365770|NCT01425008|10155893|FG015|Dose Escalation Phase|Other|0
6365771|NCT01425008|10155894|FG016|Dose Escalation Phase|Other|0
6365772|NCT01425008|10155895|FG017|Dose Escalation Phase|Other|0
6365773|NCT01425008|10155896|FG018|Dose Escalation Phase|Other|0
6365774|NCT01425008|10155878|FG000|Dose Expansion Phase|Progressive Disease|0
6365775|NCT01425008|10155879|FG001|Dose Expansion Phase|Progressive Disease|0
6365776|NCT01425008|10155880|FG002|Dose Expansion Phase|Progressive Disease|0
6365777|NCT01425008|10155881|FG003|Dose Expansion Phase|Progressive Disease|0
6365778|NCT01425008|10155882|FG004|Dose Expansion Phase|Progressive Disease|0
6365779|NCT01425008|10155883|FG005|Dose Expansion Phase|Progressive Disease|0
6365780|NCT01425008|10155884|FG006|Dose Expansion Phase|Progressive Disease|0
6365781|NCT01425008|10155885|FG007|Dose Expansion Phase|Progressive Disease|0
6365782|NCT01425008|10155886|FG008|Dose Expansion Phase|Progressive Disease|0
6365783|NCT01425008|10155887|FG009|Dose Expansion Phase|Progressive Disease|0
6365784|NCT01425008|10155888|FG010|Dose Expansion Phase|Progressive Disease|10
6365785|NCT01425008|10155889|FG011|Dose Expansion Phase|Progressive Disease|4
6365786|NCT01425008|10155890|FG012|Dose Expansion Phase|Progressive Disease|12
6365787|NCT01425008|10155891|FG013|Dose Expansion Phase|Progressive Disease|1
6365788|NCT01425008|10155892|FG014|Dose Expansion Phase|Progressive Disease|5
6365789|NCT01425008|10155893|FG015|Dose Expansion Phase|Progressive Disease|8
6365790|NCT01425008|10155894|FG016|Dose Expansion Phase|Progressive Disease|9
6365791|NCT01425008|10155895|FG017|Dose Expansion Phase|Progressive Disease|2
6365792|NCT01425008|10155896|FG018|Dose Expansion Phase|Progressive Disease|10
6365793|NCT01425008|10155878|FG000|Dose Expansion Phase|Withdrawal by Subject|0
6365794|NCT01425008|10155879|FG001|Dose Expansion Phase|Withdrawal by Subject|0
6365795|NCT01425008|10155880|FG002|Dose Expansion Phase|Withdrawal by Subject|0
6365796|NCT01425008|10155881|FG003|Dose Expansion Phase|Withdrawal by Subject|0
6365797|NCT01425008|10155882|FG004|Dose Expansion Phase|Withdrawal by Subject|0
6365798|NCT01425008|10155883|FG005|Dose Expansion Phase|Withdrawal by Subject|0
6365799|NCT01425008|10155884|FG006|Dose Expansion Phase|Withdrawal by Subject|0
6365800|NCT01425008|10155885|FG007|Dose Expansion Phase|Withdrawal by Subject|0
6365801|NCT01425008|10155886|FG008|Dose Expansion Phase|Withdrawal by Subject|0
6365802|NCT01425008|10155887|FG009|Dose Expansion Phase|Withdrawal by Subject|0
6365803|NCT01425008|10155888|FG010|Dose Expansion Phase|Withdrawal by Subject|1
6365804|NCT01425008|10155889|FG011|Dose Expansion Phase|Withdrawal by Subject|0
6365805|NCT01425008|10155890|FG012|Dose Expansion Phase|Withdrawal by Subject|0
6365806|NCT01425008|10155891|FG013|Dose Expansion Phase|Withdrawal by Subject|0
6365807|NCT01425008|10155892|FG014|Dose Expansion Phase|Withdrawal by Subject|0
6365808|NCT01425008|10155893|FG015|Dose Expansion Phase|Withdrawal by Subject|1
6365809|NCT01425008|10155894|FG016|Dose Expansion Phase|Withdrawal by Subject|1
6365810|NCT01425008|10155895|FG017|Dose Expansion Phase|Withdrawal by Subject|0
6365811|NCT01425008|10155896|FG018|Dose Expansion Phase|Withdrawal by Subject|0
6365812|NCT01425008|10155878|FG000|Dose Expansion Phase|Other|0
6365813|NCT01425008|10155879|FG001|Dose Expansion Phase|Other|0
6365814|NCT01425008|10155880|FG002|Dose Expansion Phase|Other|0
6365815|NCT01425008|10155881|FG003|Dose Expansion Phase|Other|0
6365816|NCT01425008|10155882|FG004|Dose Expansion Phase|Other|0
6365817|NCT01425008|10155883|FG005|Dose Expansion Phase|Other|0
6365818|NCT01425008|10155884|FG006|Dose Expansion Phase|Other|0
6365819|NCT01425008|10155885|FG007|Dose Expansion Phase|Other|0
6365820|NCT01425008|10155886|FG008|Dose Expansion Phase|Other|0
6365821|NCT01425008|10155887|FG009|Dose Expansion Phase|Other|0
6365822|NCT01425008|10155888|FG010|Dose Expansion Phase|Other|0
6365823|NCT01425008|10155889|FG011|Dose Expansion Phase|Other|0
6365824|NCT01425008|10155890|FG012|Dose Expansion Phase|Other|1
6365825|NCT01425008|10155891|FG013|Dose Expansion Phase|Other|0
6365826|NCT01425008|10155892|FG014|Dose Expansion Phase|Other|0
6365827|NCT01425008|10155893|FG015|Dose Expansion Phase|Other|0
6365828|NCT01425008|10155894|FG016|Dose Expansion Phase|Other|2
6365829|NCT01425008|10155895|FG017|Dose Expansion Phase|Other|0
6365830|NCT01425008|10155896|FG018|Dose Expansion Phase|Other|4
6365831|NCT01425008|10155878|FG000|Dose Expansion Phase|Symptomatic Deterioration|0
6365832|NCT01425008|10155879|FG001|Dose Expansion Phase|Symptomatic Deterioration|0
6365833|NCT01425008|10155880|FG002|Dose Expansion Phase|Symptomatic Deterioration|0
6365834|NCT01425008|10155881|FG003|Dose Expansion Phase|Symptomatic Deterioration|0
6365835|NCT01425008|10155882|FG004|Dose Expansion Phase|Symptomatic Deterioration|0
6365836|NCT01425008|10155883|FG005|Dose Expansion Phase|Symptomatic Deterioration|0
6365837|NCT01425008|10155884|FG006|Dose Expansion Phase|Symptomatic Deterioration|0
6365838|NCT01425008|10155885|FG007|Dose Expansion Phase|Symptomatic Deterioration|0
6365839|NCT01425008|10155886|FG008|Dose Expansion Phase|Symptomatic Deterioration|0
6365840|NCT01425008|10155887|FG009|Dose Expansion Phase|Symptomatic Deterioration|0
6365841|NCT01425008|10155888|FG010|Dose Expansion Phase|Symptomatic Deterioration|2
6365842|NCT01425008|10155889|FG011|Dose Expansion Phase|Symptomatic Deterioration|1
6365843|NCT01425008|10155890|FG012|Dose Expansion Phase|Symptomatic Deterioration|0
6365844|NCT01425008|10155891|FG013|Dose Expansion Phase|Symptomatic Deterioration|0
6365845|NCT01425008|10155892|FG014|Dose Expansion Phase|Symptomatic Deterioration|0
6365846|NCT01425008|10155893|FG015|Dose Expansion Phase|Symptomatic Deterioration|1
6365847|NCT01425008|10155894|FG016|Dose Expansion Phase|Symptomatic Deterioration|2
6365848|NCT01425008|10155895|FG017|Dose Expansion Phase|Symptomatic Deterioration|0
6365849|NCT01425008|10155896|FG018|Dose Expansion Phase|Symptomatic Deterioration|1
6365850|NCT01425008|10155878|FG000|Dose Expansion Phase|Adverse Event|0
6365851|NCT01425008|10155879|FG001|Dose Expansion Phase|Adverse Event|0
6365852|NCT01425008|10155880|FG002|Dose Expansion Phase|Adverse Event|0
6365853|NCT01425008|10155881|FG003|Dose Expansion Phase|Adverse Event|0
6365854|NCT01425008|10155882|FG004|Dose Expansion Phase|Adverse Event|0
6365855|NCT01425008|10155883|FG005|Dose Expansion Phase|Adverse Event|0
6365856|NCT01425008|10155884|FG006|Dose Expansion Phase|Adverse Event|0
6365857|NCT01425008|10155885|FG007|Dose Expansion Phase|Adverse Event|0
6365858|NCT01425008|10155886|FG008|Dose Expansion Phase|Adverse Event|0
6365859|NCT01425008|10155887|FG009|Dose Expansion Phase|Adverse Event|0
6365860|NCT01425008|10155888|FG010|Dose Expansion Phase|Adverse Event|2
6365861|NCT01425008|10155889|FG011|Dose Expansion Phase|Adverse Event|3
6365862|NCT01425008|10155890|FG012|Dose Expansion Phase|Adverse Event|3
6365863|NCT01425008|10155891|FG013|Dose Expansion Phase|Adverse Event|0
6365864|NCT01425008|10155892|FG014|Dose Expansion Phase|Adverse Event|1
6365865|NCT01425008|10155893|FG015|Dose Expansion Phase|Adverse Event|1
6365866|NCT01425008|10155894|FG016|Dose Expansion Phase|Adverse Event|5
6365867|NCT01425008|10155895|FG017|Dose Expansion Phase|Adverse Event|0
6365868|NCT01425008|10155896|FG018|Dose Expansion Phase|Adverse Event|3
6365869|NCT01425008|10155878|FG000|Dose Expansion Phase|Lost to Follow-up|0
6365870|NCT01425008|10155879|FG001|Dose Expansion Phase|Lost to Follow-up|0
6365871|NCT01425008|10155880|FG002|Dose Expansion Phase|Lost to Follow-up|0
6365872|NCT01425008|10155881|FG003|Dose Expansion Phase|Lost to Follow-up|0
6365873|NCT01425008|10155882|FG004|Dose Expansion Phase|Lost to Follow-up|0
6365874|NCT01425008|10155883|FG005|Dose Expansion Phase|Lost to Follow-up|0
6365875|NCT01425008|10155884|FG006|Dose Expansion Phase|Lost to Follow-up|0
6365876|NCT01425008|10155885|FG007|Dose Expansion Phase|Lost to Follow-up|0
6365877|NCT01425008|10155886|FG008|Dose Expansion Phase|Lost to Follow-up|0
6365878|NCT01425008|10155887|FG009|Dose Expansion Phase|Lost to Follow-up|0
6365879|NCT01425008|10155888|FG010|Dose Expansion Phase|Lost to Follow-up|0
6365880|NCT01425008|10155889|FG011|Dose Expansion Phase|Lost to Follow-up|0
6365881|NCT01425008|10155890|FG012|Dose Expansion Phase|Lost to Follow-up|0
6365882|NCT01425008|10155891|FG013|Dose Expansion Phase|Lost to Follow-up|0
6365883|NCT01425008|10155892|FG014|Dose Expansion Phase|Lost to Follow-up|0
6365884|NCT01425008|10155893|FG015|Dose Expansion Phase|Lost to Follow-up|0
6365885|NCT01425008|10155894|FG016|Dose Expansion Phase|Lost to Follow-up|1
6365886|NCT01425008|10155895|FG017|Dose Expansion Phase|Lost to Follow-up|0
6365887|NCT01425008|10155896|FG018|Dose Expansion Phase|Lost to Follow-up|0
6365888|NCT01425008|10155878|FG000|Dose Expansion Phase|Unsatisfactory Therapeutic Response|0
6365889|NCT01425008|10155879|FG001|Dose Expansion Phase|Unsatisfactory Therapeutic Response|0
6365890|NCT01425008|10155880|FG002|Dose Expansion Phase|Unsatisfactory Therapeutic Response|0
6365891|NCT01425008|10155881|FG003|Dose Expansion Phase|Unsatisfactory Therapeutic Response|0
6365892|NCT01425008|10155882|FG004|Dose Expansion Phase|Unsatisfactory Therapeutic Response|0
6365893|NCT01425008|10155883|FG005|Dose Expansion Phase|Unsatisfactory Therapeutic Response|0
6365894|NCT01425008|10155884|FG006|Dose Expansion Phase|Unsatisfactory Therapeutic Response|0
6365895|NCT01425008|10155885|FG007|Dose Expansion Phase|Unsatisfactory Therapeutic Response|0
6365896|NCT01425008|10155886|FG008|Dose Expansion Phase|Unsatisfactory Therapeutic Response|0
6365897|NCT01425008|10155887|FG009|Dose Expansion Phase|Unsatisfactory Therapeutic Response|0
6365898|NCT01425008|10155888|FG010|Dose Expansion Phase|Unsatisfactory Therapeutic Response|0
6365899|NCT01425008|10155889|FG011|Dose Expansion Phase|Unsatisfactory Therapeutic Response|0
6365900|NCT01425008|10155890|FG012|Dose Expansion Phase|Unsatisfactory Therapeutic Response|0
6365901|NCT01425008|10155891|FG013|Dose Expansion Phase|Unsatisfactory Therapeutic Response|0
6365902|NCT01425008|10155892|FG014|Dose Expansion Phase|Unsatisfactory Therapeutic Response|0
6365903|NCT01425008|10155893|FG015|Dose Expansion Phase|Unsatisfactory Therapeutic Response|0
6365904|NCT01425008|10155894|FG016|Dose Expansion Phase|Unsatisfactory Therapeutic Response|0
6365905|NCT01425008|10155895|FG017|Dose Expansion Phase|Unsatisfactory Therapeutic Response|0
6365906|NCT01425008|10155896|FG018|Dose Expansion Phase|Unsatisfactory Therapeutic Response|1
6365907|NCT04425902|10155949|FG000|Treatment Period 2 (Days 11 to 20)|Adverse Event|1
6365908|NCT04072146|10155962|FG000|Overall Study|Adverse Event|0
6365909|NCT04072146|10155963|FG001|Overall Study|Adverse Event|1
6365910|NCT03861481|10155977|FG000|Overall Study|COVID-19 pandemic circumstances|0
6365911|NCT03861481|10155978|FG001|Overall Study|COVID-19 pandemic circumstances|1
6365912|NCT03861481|10155977|FG000|Overall Study|Participant not plan to participate in the study CIDP04|1
6365913|NCT03861481|10155978|FG001|Overall Study|Participant not plan to participate in the study CIDP04|0
6365914|NCT03861481|10155977|FG000|Overall Study|Relapse|1
6365915|NCT03861481|10155978|FG001|Overall Study|Relapse|0
6365916|NCT03861481|10155977|FG000|Overall Study|Withdrawal by Subject|0
6365917|NCT03861481|10155978|FG001|Overall Study|Withdrawal by Subject|1
6365918|NCT03861481|10155977|FG000|Overall Study|Lack of Efficacy|4
6365919|NCT03861481|10155978|FG001|Overall Study|Lack of Efficacy|5
6365920|NCT03692052|10155988|FG000|Core Period (Day 1 to Week 24)|Adverse Event|1
6365921|NCT03692052|10155988|FG000|Extension Period (Week 25 to 10 Years)|Withdrawal of Consent|1
6365922|NCT03692052|10155988|FG000|Extension Period (Week 25 to 10 Years)|Physician Decision|1
6365923|NCT03692052|10155988|FG000|Extension Period (Week 25 to 10 Years)|Ongoing|17
6365924|NCT03648476|10155994|FG000|Overall Study|Withdrawal by Subject|2
6365925|NCT03648476|10155995|FG001|Overall Study|Withdrawal by Subject|1
6365926|NCT03375203|10156007|FG000|Overall Study|Protocol Violation|0
6365927|NCT03375203|10156008|FG001|Overall Study|Protocol Violation|0
6365928|NCT03375203|10156009|FG002|Overall Study|Protocol Violation|1
6365929|NCT03375203|10156010|FG003|Overall Study|Protocol Violation|0
6365930|NCT03375203|10156011|FG004|Overall Study|Protocol Violation|0
6365931|NCT03375203|10156007|FG000|Overall Study|Adverse Event|2
6365932|NCT03375203|10156008|FG001|Overall Study|Adverse Event|3
6365933|NCT03375203|10156009|FG002|Overall Study|Adverse Event|0
6365934|NCT03375203|10156010|FG003|Overall Study|Adverse Event|2
6365935|NCT03375203|10156011|FG004|Overall Study|Adverse Event|2
6365936|NCT03375203|10156007|FG000|Overall Study|Withdrawal by Subject|3
6365937|NCT03375203|10156008|FG001|Overall Study|Withdrawal by Subject|0
6365938|NCT03375203|10156009|FG002|Overall Study|Withdrawal by Subject|1
6365939|NCT03375203|10156010|FG003|Overall Study|Withdrawal by Subject|0
6365940|NCT03375203|10156011|FG004|Overall Study|Withdrawal by Subject|2
6365941|NCT03375203|10156007|FG000|Overall Study|Non-compliance with study drug|1
6365942|NCT03375203|10156008|FG001|Overall Study|Non-compliance with study drug|0
6365943|NCT03375203|10156009|FG002|Overall Study|Non-compliance with study drug|0
6365944|NCT03375203|10156010|FG003|Overall Study|Non-compliance with study drug|0
6365945|NCT03375203|10156011|FG004|Overall Study|Non-compliance with study drug|0
6365946|NCT03375203|10156007|FG000|Overall Study|Randomized, not treated.|0
6365947|NCT03375203|10156008|FG001|Overall Study|Randomized, not treated.|1
6365948|NCT03375203|10156009|FG002|Overall Study|Randomized, not treated.|0
6365949|NCT03375203|10156010|FG003|Overall Study|Randomized, not treated.|0
6365950|NCT03375203|10156011|FG004|Overall Study|Randomized, not treated.|0
6365951|NCT02926833|10156028|FG000|Overall Study|Full Consent Withdrawal|0
6365952|NCT02926833|10156029|FG001|Overall Study|Full Consent Withdrawal|0
6365953|NCT02926833|10156030|FG002|Overall Study|Full Consent Withdrawal|0
6365954|NCT02926833|10156031|FG003|Overall Study|Full Consent Withdrawal|2
6365955|NCT02926833|10156028|FG000|Overall Study|Death|1
6365956|NCT02926833|10156029|FG001|Overall Study|Death|1
6365957|NCT02926833|10156030|FG002|Overall Study|Death|1
6365958|NCT02926833|10156031|FG003|Overall Study|Death|7
6365959|NCT02926833|10156028|FG000|Overall Study|Still on study|2
6365960|NCT02926833|10156029|FG001|Overall Study|Still on study|3
6365961|NCT02926833|10156030|FG002|Overall Study|Still on study|5
6365962|NCT02926833|10156031|FG003|Overall Study|Still on study|14
6365963|NCT02926833|10156028|FG000|Overall Study|Adverse Event|0
6365964|NCT02926833|10156029|FG001|Overall Study|Adverse Event|0
6365965|NCT02926833|10156030|FG002|Overall Study|Adverse Event|1
6365966|NCT02926833|10156031|FG003|Overall Study|Adverse Event|0
6365967|NCT02899299|10156044|FG000|Pre-treatment|Participant request to discontinue study treatment|0
6365968|NCT02899299|10156045|FG001|Pre-treatment|Participant request to discontinue study treatment|3
6365969|NCT02899299|10156044|FG000|Pre-treatment|Participant withdrew consent|1
6365970|NCT02899299|10156045|FG001|Pre-treatment|Participant withdrew consent|11
6365971|NCT02899299|10156044|FG000|Pre-treatment|Participant no longer meets study criteria|2
6365972|NCT02899299|10156045|FG001|Pre-treatment|Participant no longer meets study criteria|3
6365973|NCT02899299|10156044|FG000|Pre-treatment|Not reported|0
6365974|NCT02899299|10156045|FG001|Pre-treatment|Not reported|1
6365975|NCT02899299|10156044|FG000|Treatment|Disease Progression|182
6365976|NCT02899299|10156045|FG001|Treatment|Disease Progression|44
6365977|NCT02899299|10156044|FG000|Treatment|Study Drug Toxicity|59
6365978|NCT02899299|10156045|FG001|Treatment|Study Drug Toxicity|24
6365979|NCT02899299|10156044|FG000|Treatment|Adverse Event unrelated to Study Drug|12
6365980|NCT02899299|10156045|FG001|Treatment|Adverse Event unrelated to Study Drug|9
6365981|NCT02899299|10156044|FG000|Treatment|Participant request to discontinue Study treatment|4
6365982|NCT02899299|10156045|FG001|Treatment|Participant request to discontinue Study treatment|10
6365983|NCT02899299|10156044|FG000|Treatment|Participant withdrew consent|6
6365984|NCT02899299|10156045|FG001|Treatment|Participant withdrew consent|3
6365985|NCT02899299|10156044|FG000|Treatment|Lost to Follow-up|0
6365986|NCT02899299|10156045|FG001|Treatment|Lost to Follow-up|1
6365987|NCT02899299|10156044|FG000|Treatment|Maximum Clinical Benefit|10
6365988|NCT02899299|10156045|FG001|Treatment|Maximum Clinical Benefit|2
6365989|NCT02899299|10156044|FG000|Treatment|Poor/Non-compliance|1
6365990|NCT02899299|10156045|FG001|Treatment|Poor/Non-compliance|0
6365991|NCT02899299|10156044|FG000|Treatment|Participant no longer meets Study criteria|4
6365992|NCT02899299|10156045|FG001|Treatment|Participant no longer meets Study criteria|0
6365993|NCT02899299|10156044|FG000|Treatment|Administrative reason by Sponsor|2
6365994|NCT02899299|10156045|FG001|Treatment|Administrative reason by Sponsor|0
6365995|NCT02899299|10156044|FG000|Treatment|Other reasons|11
6365996|NCT02899299|10156045|FG001|Treatment|Other reasons|2
6365997|NCT02899299|10156044|FG000|Treatment|Not reported: Includes participants who achieved max duration of treatment|4
6365998|NCT02899299|10156045|FG001|Treatment|Not reported: Includes participants who achieved max duration of treatment|189
6365999|NCT02879448|10156053|FG000|Overall Study|No implant attempt|17
6366000|NCT02879448|10156054|FG001|Overall Study|No implant attempt|28
6366001|NCT02879448|10156053|FG000|Overall Study|Withdrawal by Subject|20
6366002|NCT02879448|10156054|FG001|Overall Study|Withdrawal by Subject|46
6366003|NCT02879448|10156053|FG000|Overall Study|Death|63
6366004|NCT02879448|10156054|FG001|Overall Study|Death|85
6366005|NCT02879448|10156053|FG000|Overall Study|Lost to Follow-up|3
6366006|NCT02879448|10156054|FG001|Overall Study|Lost to Follow-up|4
6366007|NCT02879448|10156053|FG000|Overall Study|Missing visit|34
6366008|NCT02879448|10156054|FG001|Overall Study|Missing visit|39
6366009|NCT02879448|10156053|FG000|Overall Study|Pending evaluation|1
6366010|NCT02879448|10156054|FG001|Overall Study|Pending evaluation|0
6366011|NCT02348216|10156071|FG000|Overall Study|Death|4
6366012|NCT02348216|10156072|FG001|Overall Study|Death|27
6366013|NCT02348216|10156073|FG002|Overall Study|Death|3
6366014|NCT02348216|10156074|FG003|Overall Study|Death|18
6366015|NCT02348216|10156075|FG004|Overall Study|Death|9
6366016|NCT02348216|10156076|FG005|Overall Study|Death|23
6366017|NCT02348216|10156077|FG006|Overall Study|Death|6
6366018|NCT02348216|10156071|FG000|Overall Study|Full consent withdrawal|0
6366019|NCT02348216|10156072|FG001|Overall Study|Full consent withdrawal|0
6366020|NCT02348216|10156073|FG002|Overall Study|Full consent withdrawal|0
6366021|NCT02348216|10156074|FG003|Overall Study|Full consent withdrawal|1
6366022|NCT02348216|10156075|FG004|Overall Study|Full consent withdrawal|0
6366023|NCT02348216|10156076|FG005|Overall Study|Full consent withdrawal|0
6366024|NCT02348216|10156077|FG006|Overall Study|Full consent withdrawal|1
6366025|NCT02348216|10156071|FG000|Overall Study|Lost to Follow-up|0
6366026|NCT02348216|10156072|FG001|Overall Study|Lost to Follow-up|0
6366027|NCT02348216|10156073|FG002|Overall Study|Lost to Follow-up|0
6366028|NCT02348216|10156074|FG003|Overall Study|Lost to Follow-up|0
6366029|NCT02348216|10156075|FG004|Overall Study|Lost to Follow-up|0
6366030|NCT02348216|10156076|FG005|Overall Study|Lost to Follow-up|0
6366031|NCT02348216|10156077|FG006|Overall Study|Lost to Follow-up|1
6366032|NCT02348216|10156071|FG000|Overall Study|Still on study|3
6366033|NCT02348216|10156072|FG001|Overall Study|Still on study|50
6366034|NCT02348216|10156073|FG002|Overall Study|Still on study|21
6366035|NCT02348216|10156074|FG003|Overall Study|Still on study|19
6366036|NCT02348216|10156075|FG004|Overall Study|Still on study|32
6366037|NCT02348216|10156076|FG005|Overall Study|Still on study|27
6366038|NCT02348216|10156077|FG006|Overall Study|Still on study|32
6366039|NCT02348216|10156071|FG000|Overall Study|Enrolled but did not initiate axicabtagene ciloleucel|1
6366040|NCT02348216|10156072|FG001|Overall Study|Enrolled but did not initiate axicabtagene ciloleucel|4
6366041|NCT02348216|10156073|FG002|Overall Study|Enrolled but did not initiate axicabtagene ciloleucel|6
6366042|NCT02348216|10156074|FG003|Overall Study|Enrolled but did not initiate axicabtagene ciloleucel|4
6366043|NCT02348216|10156075|FG004|Overall Study|Enrolled but did not initiate axicabtagene ciloleucel|5
6366044|NCT02348216|10156076|FG005|Overall Study|Enrolled but did not initiate axicabtagene ciloleucel|8
6366045|NCT02348216|10156077|FG006|Overall Study|Enrolled but did not initiate axicabtagene ciloleucel|2
6366046|NCT01451515|10156133|FG000|Overall Study|Death|0
6366047|NCT01451515|10156134|FG001|Overall Study|Death|1
6366048|NCT01451515|10156135|FG002|Overall Study|Death|0
6366049|NCT01451515|10156133|FG000|Overall Study|Withdrawal by Subject|0
6366050|NCT01451515|10156134|FG001|Overall Study|Withdrawal by Subject|1
6366051|NCT01451515|10156135|FG002|Overall Study|Withdrawal by Subject|0
6366052|NCT01451515|10156133|FG000|Overall Study|Development of unacceptable toxicity during treatment|0
6366053|NCT01451515|10156134|FG001|Overall Study|Development of unacceptable toxicity during treatment|0
6366054|NCT01451515|10156135|FG002|Overall Study|Development of unacceptable toxicity during treatment|1
6366055|NCT01451515|10156133|FG000|Overall Study|Relapse (except CNS)|1
6366056|NCT01451515|10156134|FG001|Overall Study|Relapse (except CNS)|1
6366057|NCT01451515|10156135|FG002|Overall Study|Relapse (except CNS)|0
6366058|NCT01332968|10156148|FG000|Induction Period|Withdrawal by Subject|3
6366059|NCT01332968|10156149|FG001|Induction Period|Withdrawal by Subject|5
6366060|NCT01332968|10156150|FG002|Induction Period|Withdrawal by Subject|0
6366061|NCT01332968|10156151|FG003|Induction Period|Withdrawal by Subject|0
6366062|NCT01332968|10156152|FG004|Induction Period|Withdrawal by Subject|0
6366063|NCT01332968|10156153|FG005|Induction Period|Withdrawal by Subject|0
6366064|NCT01332968|10156154|FG006|Induction Period|Withdrawal by Subject|0
6366065|NCT01332968|10156155|FG007|Induction Period|Withdrawal by Subject|0
6366066|NCT01332968|10156148|FG000|Induction Period|Protocol Violation|3
6366067|NCT01332968|10156149|FG001|Induction Period|Protocol Violation|4
6366068|NCT01332968|10156150|FG002|Induction Period|Protocol Violation|0
6366069|NCT01332968|10156151|FG003|Induction Period|Protocol Violation|0
6366070|NCT01332968|10156152|FG004|Induction Period|Protocol Violation|0
6366071|NCT01332968|10156153|FG005|Induction Period|Protocol Violation|0
6366072|NCT01332968|10156154|FG006|Induction Period|Protocol Violation|0
6366073|NCT01332968|10156155|FG007|Induction Period|Protocol Violation|0
6366074|NCT01332968|10156148|FG000|Induction Period|Progressive disease|15
6366075|NCT01332968|10156149|FG001|Induction Period|Progressive disease|7
6366076|NCT01332968|10156150|FG002|Induction Period|Progressive disease|0
6366077|NCT01332968|10156151|FG003|Induction Period|Progressive disease|0
6366078|NCT01332968|10156152|FG004|Induction Period|Progressive disease|0
6366079|NCT01332968|10156153|FG005|Induction Period|Progressive disease|0
6366080|NCT01332968|10156154|FG006|Induction Period|Progressive disease|0
6366081|NCT01332968|10156155|FG007|Induction Period|Progressive disease|0
6366082|NCT01332968|10156148|FG000|Induction Period|Physician Decision|6
6366083|NCT01332968|10156149|FG001|Induction Period|Physician Decision|1
6366084|NCT01332968|10156150|FG002|Induction Period|Physician Decision|0
6366085|NCT01332968|10156151|FG003|Induction Period|Physician Decision|0
6366086|NCT01332968|10156152|FG004|Induction Period|Physician Decision|0
6366087|NCT01332968|10156153|FG005|Induction Period|Physician Decision|0
6366088|NCT01332968|10156154|FG006|Induction Period|Physician Decision|0
6366089|NCT01332968|10156155|FG007|Induction Period|Physician Decision|0
6366090|NCT01332968|10156148|FG000|Induction Period|Other|2
6366091|NCT01332968|10156149|FG001|Induction Period|Other|2
6366092|NCT01332968|10156150|FG002|Induction Period|Other|0
6366093|NCT01332968|10156151|FG003|Induction Period|Other|0
6366094|NCT01332968|10156152|FG004|Induction Period|Other|0
6366095|NCT01332968|10156153|FG005|Induction Period|Other|0
6366096|NCT01332968|10156154|FG006|Induction Period|Other|0
6366097|NCT01332968|10156155|FG007|Induction Period|Other|0
6366098|NCT01332968|10156148|FG000|Induction Period|Non-compliance|1
6366099|NCT01332968|10156149|FG001|Induction Period|Non-compliance|0
6366100|NCT01332968|10156150|FG002|Induction Period|Non-compliance|0
6366101|NCT01332968|10156151|FG003|Induction Period|Non-compliance|0
6366102|NCT01332968|10156152|FG004|Induction Period|Non-compliance|0
6366103|NCT01332968|10156153|FG005|Induction Period|Non-compliance|0
6366104|NCT01332968|10156154|FG006|Induction Period|Non-compliance|0
6366105|NCT01332968|10156155|FG007|Induction Period|Non-compliance|0
6366106|NCT01332968|10156148|FG000|Induction Period|Death|1
6366107|NCT01332968|10156149|FG001|Induction Period|Death|4
6366108|NCT01332968|10156150|FG002|Induction Period|Death|0
6366109|NCT01332968|10156151|FG003|Induction Period|Death|0
6366110|NCT01332968|10156152|FG004|Induction Period|Death|0
6366111|NCT01332968|10156153|FG005|Induction Period|Death|0
6366112|NCT01332968|10156154|FG006|Induction Period|Death|0
6366113|NCT01332968|10156155|FG007|Induction Period|Death|0
6366114|NCT01332968|10156148|FG000|Induction Period|Adverse Event|23
6366115|NCT01332968|10156149|FG001|Induction Period|Adverse Event|26
6366116|NCT01332968|10156150|FG002|Induction Period|Adverse Event|0
6366117|NCT01332968|10156151|FG003|Induction Period|Adverse Event|0
6366118|NCT01332968|10156152|FG004|Induction Period|Adverse Event|0
6366119|NCT01332968|10156153|FG005|Induction Period|Adverse Event|0
6366120|NCT01332968|10156154|FG006|Induction Period|Adverse Event|0
6366121|NCT01332968|10156155|FG007|Induction Period|Adverse Event|0
6366122|NCT01332968|10156148|FG000|Induction Period|Randomized, but not treated|4
6366123|NCT01332968|10156149|FG001|Induction Period|Randomized, but not treated|7
6366124|NCT01332968|10156150|FG002|Induction Period|Randomized, but not treated|0
6366125|NCT01332968|10156151|FG003|Induction Period|Randomized, but not treated|0
6366126|NCT01332968|10156152|FG004|Induction Period|Randomized, but not treated|0
6366127|NCT01332968|10156153|FG005|Induction Period|Randomized, but not treated|0
6366128|NCT01332968|10156154|FG006|Induction Period|Randomized, but not treated|0
6366129|NCT01332968|10156155|FG007|Induction Period|Randomized, but not treated|0
6366130|NCT01332968|10156148|FG000|Maintenance/Observation Period|Withdrawal by Subject|0
6366131|NCT01332968|10156149|FG001|Maintenance/Observation Period|Withdrawal by Subject|0
6366132|NCT01332968|10156150|FG002|Maintenance/Observation Period|Withdrawal by Subject|10
6366133|NCT01332968|10156151|FG003|Maintenance/Observation Period|Withdrawal by Subject|5
6366134|NCT01332968|10156152|FG004|Maintenance/Observation Period|Withdrawal by Subject|0
6366135|NCT01332968|10156153|FG005|Maintenance/Observation Period|Withdrawal by Subject|0
6366136|NCT01332968|10156154|FG006|Maintenance/Observation Period|Withdrawal by Subject|0
6366137|NCT01332968|10156155|FG007|Maintenance/Observation Period|Withdrawal by Subject|0
6366138|NCT01332968|10156148|FG000|Maintenance/Observation Period|Protocol Violation|0
6366139|NCT01332968|10156149|FG001|Maintenance/Observation Period|Protocol Violation|0
6366140|NCT01332968|10156150|FG002|Maintenance/Observation Period|Protocol Violation|1
6366141|NCT01332968|10156151|FG003|Maintenance/Observation Period|Protocol Violation|1
6366142|NCT01332968|10156152|FG004|Maintenance/Observation Period|Protocol Violation|0
6366143|NCT01332968|10156153|FG005|Maintenance/Observation Period|Protocol Violation|0
6366144|NCT01332968|10156154|FG006|Maintenance/Observation Period|Protocol Violation|0
6366145|NCT01332968|10156155|FG007|Maintenance/Observation Period|Protocol Violation|0
6366146|NCT01332968|10156148|FG000|Maintenance/Observation Period|Progressive disease|0
6366147|NCT01332968|10156149|FG001|Maintenance/Observation Period|Progressive disease|0
6366148|NCT01332968|10156150|FG002|Maintenance/Observation Period|Progressive disease|72
6366149|NCT01332968|10156151|FG003|Maintenance/Observation Period|Progressive disease|39
6366150|NCT01332968|10156152|FG004|Maintenance/Observation Period|Progressive disease|0
6366151|NCT01332968|10156153|FG005|Maintenance/Observation Period|Progressive disease|0
6366152|NCT01332968|10156154|FG006|Maintenance/Observation Period|Progressive disease|0
6366153|NCT01332968|10156155|FG007|Maintenance/Observation Period|Progressive disease|0
6366154|NCT01332968|10156148|FG000|Maintenance/Observation Period|Physician Decision|0
6366155|NCT01332968|10156149|FG001|Maintenance/Observation Period|Physician Decision|0
6366156|NCT01332968|10156150|FG002|Maintenance/Observation Period|Physician Decision|14
6366157|NCT01332968|10156151|FG003|Maintenance/Observation Period|Physician Decision|19
6366158|NCT01332968|10156152|FG004|Maintenance/Observation Period|Physician Decision|0
6366159|NCT01332968|10156153|FG005|Maintenance/Observation Period|Physician Decision|0
6366160|NCT01332968|10156154|FG006|Maintenance/Observation Period|Physician Decision|0
6366161|NCT01332968|10156155|FG007|Maintenance/Observation Period|Physician Decision|0
6366162|NCT01332968|10156148|FG000|Maintenance/Observation Period|Other|0
6366163|NCT01332968|10156149|FG001|Maintenance/Observation Period|Other|0
6366164|NCT01332968|10156150|FG002|Maintenance/Observation Period|Other|4
6366165|NCT01332968|10156151|FG003|Maintenance/Observation Period|Other|5
6366166|NCT01332968|10156152|FG004|Maintenance/Observation Period|Other|0
6366167|NCT01332968|10156153|FG005|Maintenance/Observation Period|Other|0
6366168|NCT01332968|10156154|FG006|Maintenance/Observation Period|Other|0
6366169|NCT01332968|10156155|FG007|Maintenance/Observation Period|Other|0
6366170|NCT01332968|10156148|FG000|Maintenance/Observation Period|Non-compliance|0
6366171|NCT01332968|10156149|FG001|Maintenance/Observation Period|Non-compliance|0
6366172|NCT01332968|10156150|FG002|Maintenance/Observation Period|Non-compliance|2
6366173|NCT01332968|10156151|FG003|Maintenance/Observation Period|Non-compliance|3
6366174|NCT01332968|10156152|FG004|Maintenance/Observation Period|Non-compliance|0
6366175|NCT01332968|10156153|FG005|Maintenance/Observation Period|Non-compliance|1
6366176|NCT01332968|10156154|FG006|Maintenance/Observation Period|Non-compliance|0
6366177|NCT01332968|10156155|FG007|Maintenance/Observation Period|Non-compliance|0
6366178|NCT01332968|10156148|FG000|Maintenance/Observation Period|Lost to Follow-up|0
6366179|NCT01332968|10156149|FG001|Maintenance/Observation Period|Lost to Follow-up|0
6366180|NCT01332968|10156150|FG002|Maintenance/Observation Period|Lost to Follow-up|1
6366181|NCT01332968|10156151|FG003|Maintenance/Observation Period|Lost to Follow-up|2
6366182|NCT01332968|10156152|FG004|Maintenance/Observation Period|Lost to Follow-up|0
6366183|NCT01332968|10156153|FG005|Maintenance/Observation Period|Lost to Follow-up|0
6366184|NCT01332968|10156154|FG006|Maintenance/Observation Period|Lost to Follow-up|0
6366185|NCT01332968|10156155|FG007|Maintenance/Observation Period|Lost to Follow-up|0
6366186|NCT01332968|10156148|FG000|Maintenance/Observation Period|Death|0
6366187|NCT01332968|10156149|FG001|Maintenance/Observation Period|Death|0
6366188|NCT01332968|10156150|FG002|Maintenance/Observation Period|Death|5
6366189|NCT01332968|10156151|FG003|Maintenance/Observation Period|Death|6
6366190|NCT01332968|10156152|FG004|Maintenance/Observation Period|Death|0
6366191|NCT01332968|10156153|FG005|Maintenance/Observation Period|Death|0
6366192|NCT01332968|10156154|FG006|Maintenance/Observation Period|Death|0
6366193|NCT01332968|10156155|FG007|Maintenance/Observation Period|Death|0
6366194|NCT01332968|10156148|FG000|Maintenance/Observation Period|Adverse Event|0
6366195|NCT01332968|10156149|FG001|Maintenance/Observation Period|Adverse Event|0
6366196|NCT01332968|10156150|FG002|Maintenance/Observation Period|Adverse Event|50
6366197|NCT01332968|10156151|FG003|Maintenance/Observation Period|Adverse Event|65
6366198|NCT01332968|10156152|FG004|Maintenance/Observation Period|Adverse Event|0
6366199|NCT01332968|10156153|FG005|Maintenance/Observation Period|Adverse Event|0
6366200|NCT01332968|10156154|FG006|Maintenance/Observation Period|Adverse Event|0
6366201|NCT01332968|10156155|FG007|Maintenance/Observation Period|Adverse Event|0
6366202|NCT01332968|10156148|FG000|Maintenance/Observation Period|Treatment ongoing|0
6366203|NCT01332968|10156149|FG001|Maintenance/Observation Period|Treatment ongoing|0
6366204|NCT01332968|10156150|FG002|Maintenance/Observation Period|Treatment ongoing|54
6366205|NCT01332968|10156151|FG003|Maintenance/Observation Period|Treatment ongoing|62
6366206|NCT01332968|10156152|FG004|Maintenance/Observation Period|Treatment ongoing|10
6366207|NCT01332968|10156153|FG005|Maintenance/Observation Period|Treatment ongoing|8
6366208|NCT01332968|10156154|FG006|Maintenance/Observation Period|Treatment ongoing|0
6366209|NCT01332968|10156155|FG007|Maintenance/Observation Period|Treatment ongoing|0
6366210|NCT01332968|10156148|FG000|Follow-Up Period|Death|0
6366211|NCT01332968|10156149|FG001|Follow-Up Period|Death|0
6366212|NCT01332968|10156150|FG002|Follow-Up Period|Death|0
6366213|NCT01332968|10156151|FG003|Follow-Up Period|Death|0
6366214|NCT01332968|10156152|FG004|Follow-Up Period|Death|0
6366215|NCT01332968|10156153|FG005|Follow-Up Period|Death|0
6366216|NCT01332968|10156154|FG006|Follow-Up Period|Death|38
6366217|NCT01332968|10156155|FG007|Follow-Up Period|Death|22
6366218|NCT01332968|10156148|FG000|Follow-Up Period|Follow-up ongoing|0
6366219|NCT01332968|10156149|FG001|Follow-Up Period|Follow-up ongoing|0
6366220|NCT01332968|10156150|FG002|Follow-Up Period|Follow-up ongoing|0
6366221|NCT01332968|10156151|FG003|Follow-Up Period|Follow-up ongoing|0
6366222|NCT01332968|10156152|FG004|Follow-Up Period|Follow-up ongoing|0
6366223|NCT01332968|10156153|FG005|Follow-Up Period|Follow-up ongoing|0
6366224|NCT01332968|10156154|FG006|Follow-Up Period|Follow-up ongoing|502
6366225|NCT01332968|10156155|FG007|Follow-Up Period|Follow-up ongoing|505
6366226|NCT01332968|10156148|FG000|Follow-Up Period|Withdrawal by Subject|0
6366227|NCT01332968|10156149|FG001|Follow-Up Period|Withdrawal by Subject|0
6366228|NCT01332968|10156150|FG002|Follow-Up Period|Withdrawal by Subject|0
6366229|NCT01332968|10156151|FG003|Follow-Up Period|Withdrawal by Subject|0
6366230|NCT01332968|10156152|FG004|Follow-Up Period|Withdrawal by Subject|0
6366231|NCT01332968|10156153|FG005|Follow-Up Period|Withdrawal by Subject|0
6366232|NCT01332968|10156154|FG006|Follow-Up Period|Withdrawal by Subject|1
6366233|NCT01332968|10156155|FG007|Follow-Up Period|Withdrawal by Subject|2
6366234|NCT01332968|10156148|FG000|Follow-Up Period|Lost to Follow-up|0
6366235|NCT01332968|10156149|FG001|Follow-Up Period|Lost to Follow-up|0
6366236|NCT01332968|10156150|FG002|Follow-Up Period|Lost to Follow-up|0
6366237|NCT01332968|10156151|FG003|Follow-Up Period|Lost to Follow-up|0
6366238|NCT01332968|10156152|FG004|Follow-Up Period|Lost to Follow-up|0
6366239|NCT01332968|10156153|FG005|Follow-Up Period|Lost to Follow-up|0
6366240|NCT01332968|10156154|FG006|Follow-Up Period|Lost to Follow-up|1
6366241|NCT01332968|10156155|FG007|Follow-Up Period|Lost to Follow-up|2
6366242|NCT01231906|10156165|FG000|Overall Study|Lack of Efficacy|75
6366243|NCT01231906|10156166|FG001|Overall Study|Lack of Efficacy|68
6366244|NCT01231906|10156165|FG000|Overall Study|Lost to Follow-up|1
6366245|NCT01231906|10156166|FG001|Overall Study|Lost to Follow-up|0
6366246|NCT01231906|10156165|FG000|Overall Study|Physician Decision|34
6366247|NCT01231906|10156166|FG001|Overall Study|Physician Decision|24
6366248|NCT01231906|10156165|FG000|Overall Study|Withdrawal by Subject|0
6366249|NCT01231906|10156166|FG001|Overall Study|Withdrawal by Subject|4
6366250|NCT01231906|10156165|FG000|Overall Study|Ineligible|10
6366251|NCT01231906|10156166|FG001|Overall Study|Ineligible|3
6366252|NCT01231906|10156165|FG000|Overall Study|No treatment|1
6366253|NCT01231906|10156166|FG001|Overall Study|No treatment|2
6366254|NCT01470326|10156172|FG000|Overall Study|Protocol Violation|32
6366255|NCT01470326|10156172|FG000|Overall Study|No Drug Administration Information|2
6366256|NCT01470326|10156172|FG000|Overall Study|No Visit After 1st Day of Treatment|119
6366257|NCT01480180|10156178|FG000|Main Phase|Withdrawal criteria|12
6366258|NCT01480180|10156179|FG001|Main Phase|Withdrawal criteria|1
6366259|NCT01480180|10156180|FG002|Main Phase|Withdrawal criteria|0
6366260|NCT01480180|10156181|FG003|Main Phase|Withdrawal criteria|0
6366261|NCT01480180|10156182|FG004|Main Phase|Withdrawal criteria|0
6366262|NCT01480180|10156183|FG005|Main Phase|Withdrawal criteria|0
6366263|NCT01480180|10156178|FG000|Main Phase|Lack of Efficacy|1
6366264|NCT01480180|10156179|FG001|Main Phase|Lack of Efficacy|0
6366265|NCT01480180|10156180|FG002|Main Phase|Lack of Efficacy|0
6366266|NCT01480180|10156181|FG003|Main Phase|Lack of Efficacy|0
6366267|NCT01480180|10156182|FG004|Main Phase|Lack of Efficacy|0
6366268|NCT01480180|10156183|FG005|Main Phase|Lack of Efficacy|0
6366269|NCT01480180|10156178|FG000|Main Phase|Non-compliance|3
6366270|NCT01480180|10156179|FG001|Main Phase|Non-compliance|0
6366271|NCT01480180|10156180|FG002|Main Phase|Non-compliance|0
6366272|NCT01480180|10156181|FG003|Main Phase|Non-compliance|0
6366273|NCT01480180|10156182|FG004|Main Phase|Non-compliance|0
6366274|NCT01480180|10156183|FG005|Main Phase|Non-compliance|0
6366275|NCT01480180|10156178|FG000|Main Phase|Unclassified|3
6366276|NCT01480180|10156179|FG001|Main Phase|Unclassified|0
6366277|NCT01480180|10156180|FG002|Main Phase|Unclassified|0
6366278|NCT01480180|10156181|FG003|Main Phase|Unclassified|0
6366279|NCT01480180|10156182|FG004|Main Phase|Unclassified|0
6366280|NCT01480180|10156183|FG005|Main Phase|Unclassified|0
6366281|NCT01480180|10156178|FG000|Extension Phase, Part 1|Withdrawal criteria|0
6366282|NCT01480180|10156179|FG001|Extension Phase, Part 1|Withdrawal criteria|0
6366283|NCT01480180|10156180|FG002|Extension Phase, Part 1|Withdrawal criteria|5
6366284|NCT01480180|10156181|FG003|Extension Phase, Part 1|Withdrawal criteria|0
6366285|NCT01480180|10156182|FG004|Extension Phase, Part 1|Withdrawal criteria|0
6366286|NCT01480180|10156183|FG005|Extension Phase, Part 1|Withdrawal criteria|0
6366287|NCT01480180|10156178|FG000|Extension Phase, Part 1|Unclassified|0
6366288|NCT01480180|10156179|FG001|Extension Phase, Part 1|Unclassified|0
6366289|NCT01480180|10156180|FG002|Extension Phase, Part 1|Unclassified|1
6366290|NCT01480180|10156181|FG003|Extension Phase, Part 1|Unclassified|0
6366291|NCT01480180|10156182|FG004|Extension Phase, Part 1|Unclassified|0
6366292|NCT01480180|10156183|FG005|Extension Phase, Part 1|Unclassified|0
6366293|NCT01480180|10156178|FG000|Extension Phase, Part 1|Adverse Event|0
6366294|NCT01480180|10156179|FG001|Extension Phase, Part 1|Adverse Event|0
6366295|NCT01480180|10156180|FG002|Extension Phase, Part 1|Adverse Event|4
6366296|NCT01480180|10156181|FG003|Extension Phase, Part 1|Adverse Event|1
6366297|NCT01480180|10156182|FG004|Extension Phase, Part 1|Adverse Event|0
6366298|NCT01480180|10156183|FG005|Extension Phase, Part 1|Adverse Event|0
6366299|NCT01480180|10156178|FG000|Extension Phase, Part 1|Change of treatment|0
6366300|NCT01480180|10156179|FG001|Extension Phase, Part 1|Change of treatment|0
6366301|NCT01480180|10156180|FG002|Extension Phase, Part 1|Change of treatment|0
6366302|NCT01480180|10156181|FG003|Extension Phase, Part 1|Change of treatment|9
6366303|NCT01480180|10156182|FG004|Extension Phase, Part 1|Change of treatment|0
6366304|NCT01480180|10156183|FG005|Extension Phase, Part 1|Change of treatment|0
6366305|NCT01480180|10156178|FG000|Extension Phase, Part 2|Withdrawal criteria|0
6366306|NCT01480180|10156179|FG001|Extension Phase, Part 2|Withdrawal criteria|0
6366307|NCT01480180|10156180|FG002|Extension Phase, Part 2|Withdrawal criteria|10
6366308|NCT01480180|10156181|FG003|Extension Phase, Part 2|Withdrawal criteria|6
6366309|NCT01480180|10156182|FG004|Extension Phase, Part 2|Withdrawal criteria|1
6366310|NCT01480180|10156183|FG005|Extension Phase, Part 2|Withdrawal criteria|0
6366311|NCT01480180|10156178|FG000|Extension Phase, Part 2|Lack of Efficacy|0
6366312|NCT01480180|10156179|FG001|Extension Phase, Part 2|Lack of Efficacy|0
6366313|NCT01480180|10156180|FG002|Extension Phase, Part 2|Lack of Efficacy|4
6366314|NCT01480180|10156181|FG003|Extension Phase, Part 2|Lack of Efficacy|0
6366315|NCT01480180|10156182|FG004|Extension Phase, Part 2|Lack of Efficacy|0
6366316|NCT01480180|10156183|FG005|Extension Phase, Part 2|Lack of Efficacy|0
6366317|NCT01480180|10156178|FG000|Extension Phase, Part 2|Unclassified|0
6366318|NCT01480180|10156179|FG001|Extension Phase, Part 2|Unclassified|0
6366319|NCT01480180|10156180|FG002|Extension Phase, Part 2|Unclassified|3
6366320|NCT01480180|10156181|FG003|Extension Phase, Part 2|Unclassified|1
6366321|NCT01480180|10156182|FG004|Extension Phase, Part 2|Unclassified|1
6366322|NCT01480180|10156183|FG005|Extension Phase, Part 2|Unclassified|0
6366323|NCT01545050|10156219|FG000|Overall Study|Lack of Efficacy|0
6366324|NCT01545050|10156220|FG001|Overall Study|Lack of Efficacy|0
6366325|NCT01545050|10156221|FG002|Overall Study|Lack of Efficacy|0
6366326|NCT01545050|10156222|FG003|Overall Study|Lack of Efficacy|3
6366327|NCT01545050|10156223|FG004|Overall Study|Lack of Efficacy|2
6366328|NCT01545050|10156219|FG000|Overall Study|Adverse Event|1
6366329|NCT01545050|10156220|FG001|Overall Study|Adverse Event|1
6366330|NCT01545050|10156221|FG002|Overall Study|Adverse Event|2
6366331|NCT01545050|10156222|FG003|Overall Study|Adverse Event|2
6366332|NCT01545050|10156223|FG004|Overall Study|Adverse Event|0
6366333|NCT01545050|10156219|FG000|Overall Study|Discontinued study treatment|1
6366334|NCT01545050|10156220|FG001|Overall Study|Discontinued study treatment|0
6366335|NCT01545050|10156221|FG002|Overall Study|Discontinued study treatment|0
6366336|NCT01545050|10156222|FG003|Overall Study|Discontinued study treatment|0
6366337|NCT01545050|10156223|FG004|Overall Study|Discontinued study treatment|0
6366338|NCT01545050|10156219|FG000|Overall Study|Withdrawal by Subject|1
6366339|NCT01545050|10156220|FG001|Overall Study|Withdrawal by Subject|0
6366340|NCT01545050|10156221|FG002|Overall Study|Withdrawal by Subject|0
6366341|NCT01545050|10156222|FG003|Overall Study|Withdrawal by Subject|2
6366342|NCT01545050|10156223|FG004|Overall Study|Withdrawal by Subject|1
6366343|NCT01545050|10156219|FG000|Overall Study|Participant no longer meets study criteria|0
6366344|NCT01545050|10156220|FG001|Overall Study|Participant no longer meets study criteria|2
6366345|NCT01545050|10156221|FG002|Overall Study|Participant no longer meets study criteria|0
6366346|NCT01545050|10156222|FG003|Overall Study|Participant no longer meets study criteria|0
6366347|NCT01545050|10156223|FG004|Overall Study|Participant no longer meets study criteria|1
6366348|NCT01545050|10156219|FG000|Overall Study|Administrative reason by sponsor|4
6366349|NCT01545050|10156220|FG001|Overall Study|Administrative reason by sponsor|2
6366350|NCT01545050|10156221|FG002|Overall Study|Administrative reason by sponsor|3
6366351|NCT01545050|10156222|FG003|Overall Study|Administrative reason by sponsor|5
6366352|NCT01545050|10156223|FG004|Overall Study|Administrative reason by sponsor|5
6084475|NCT00642941|9693392|FG001|Overall Study|Withdrawal by Subject|0
6084476|NCT00642941|9693393|FG002|Overall Study|Withdrawal by Subject|0
6084477|NCT00642941|9693394|FG003|Overall Study|Withdrawal by Subject|2
6084478|NCT00642941|9693395|FG004|Overall Study|Withdrawal by Subject|0
6084479|NCT00642941|9693396|FG005|Overall Study|Withdrawal by Subject|0
6084480|NCT00642941|9693397|FG006|Overall Study|Withdrawal by Subject|2
6084481|NCT00642941|9693398|FG007|Overall Study|Withdrawal by Subject|0
6084482|NCT00642941|9693399|FG008|Overall Study|Withdrawal by Subject|1
6084483|NCT00642941|9693400|FG009|Overall Study|Withdrawal by Subject|0
6366353|NCT01555021|10156250|FG000|Overall Study|Lost to Follow-up|1
6366354|NCT01555021|10156251|FG001|Overall Study|Lost to Follow-up|2
6366355|NCT01561430|10156267|FG000|Overall Study|Adverse Event|0
6366356|NCT01561430|10156268|FG001|Overall Study|Adverse Event|0
6366357|NCT01561430|10156269|FG002|Overall Study|Adverse Event|3
6366358|NCT01561430|10156270|FG003|Overall Study|Adverse Event|1
6366359|NCT01561430|10156267|FG000|Overall Study|Withdrawal by Subject|0
6366360|NCT01561430|10156268|FG001|Overall Study|Withdrawal by Subject|0
6366361|NCT01561430|10156269|FG002|Overall Study|Withdrawal by Subject|1
6366362|NCT01561430|10156270|FG003|Overall Study|Withdrawal by Subject|0
6366363|NCT01561430|10156267|FG000|Overall Study|Physician Decision|0
6366364|NCT01561430|10156268|FG001|Overall Study|Physician Decision|1
6366365|NCT01561430|10156269|FG002|Overall Study|Physician Decision|0
6366366|NCT01561430|10156270|FG003|Overall Study|Physician Decision|0
6366367|NCT01561430|10156267|FG000|Overall Study|Sponsor Decision|1
6366368|NCT01561430|10156268|FG001|Overall Study|Sponsor Decision|14
6366369|NCT01561430|10156269|FG002|Overall Study|Sponsor Decision|13
6366370|NCT01561430|10156270|FG003|Overall Study|Sponsor Decision|12
6366371|NCT01595009|10156290|FG000|Core|Patients completed per protocol|85
6366372|NCT01595009|10156291|FG001|Core|Patients completed per protocol|44
6366373|NCT01595009|10156292|FG002|Core|Patients completed per protocol|0
6366374|NCT01595009|10156293|FG003|Core|Patients completed per protocol|0
6366375|NCT01595009|10156290|FG000|Core|Adverse Event|19
6366376|NCT01595009|10156291|FG001|Core|Adverse Event|23
6366377|NCT01595009|10156292|FG002|Core|Adverse Event|0
6366378|NCT01595009|10156293|FG003|Core|Adverse Event|0
6366379|NCT01595009|10156290|FG000|Core|Disease progression|14
6366380|NCT01595009|10156291|FG001|Core|Disease progression|26
6366381|NCT01595009|10156292|FG002|Core|Disease progression|0
6366382|NCT01595009|10156293|FG003|Core|Disease progression|0
6366383|NCT01595009|10156290|FG000|Core|Withdrawal by Subject|4
6366384|NCT01595009|10156291|FG001|Core|Withdrawal by Subject|17
6366385|NCT01595009|10156292|FG002|Core|Withdrawal by Subject|0
6366386|NCT01595009|10156293|FG003|Core|Withdrawal by Subject|0
6366387|NCT01595009|10156290|FG000|Core|Death|3
6366388|NCT01595009|10156291|FG001|Core|Death|6
6366389|NCT01595009|10156292|FG002|Core|Death|0
6366390|NCT01595009|10156293|FG003|Core|Death|0
6366391|NCT01595009|10156290|FG000|Core|Lost to Follow-up|1
6366392|NCT01595009|10156291|FG001|Core|Lost to Follow-up|2
6366393|NCT01595009|10156292|FG002|Core|Lost to Follow-up|0
6366394|NCT01595009|10156293|FG003|Core|Lost to Follow-up|0
6366395|NCT01595009|10156290|FG000|Core|Protocol deviation|0
6366396|NCT01595009|10156291|FG001|Core|Protocol deviation|1
6366397|NCT01595009|10156292|FG002|Core|Protocol deviation|0
6366398|NCT01595009|10156293|FG003|Core|Protocol deviation|0
6366399|NCT01595009|10156290|FG000|Core|Administrative problems|0
6366400|NCT01595009|10156291|FG001|Core|Administrative problems|1
6366401|NCT01595009|10156292|FG002|Core|Administrative problems|0
6366402|NCT01595009|10156293|FG003|Core|Administrative problems|0
6366403|NCT01595009|10156290|FG000|Extension|Administrative problems|0
6366404|NCT01595009|10156291|FG001|Extension|Administrative problems|0
6366405|NCT01595009|10156292|FG002|Extension|Administrative problems|0
6366406|NCT01595009|10156293|FG003|Extension|Administrative problems|1
6366407|NCT01595009|10156290|FG000|Extension|Patients completed per protocol|0
6366408|NCT01595009|10156291|FG001|Extension|Patients completed per protocol|0
6366409|NCT01595009|10156292|FG002|Extension|Patients completed per protocol|0
6366410|NCT01595009|10156293|FG003|Extension|Patients completed per protocol|2
6366411|NCT01595009|10156290|FG000|Extension|Disease progression|0
6366412|NCT01595009|10156291|FG001|Extension|Disease progression|0
6366413|NCT01595009|10156292|FG002|Extension|Disease progression|4
6366414|NCT01595009|10156293|FG003|Extension|Disease progression|7
6366415|NCT01595009|10156290|FG000|Extension|Adverse Event|0
6366416|NCT01595009|10156291|FG001|Extension|Adverse Event|0
6366417|NCT01595009|10156292|FG002|Extension|Adverse Event|0
6366418|NCT01595009|10156293|FG003|Extension|Adverse Event|1
6366419|NCT01620944|10156310|FG000|Overall Study|Early termination of Study|2
6366420|NCT01620944|10156311|FG001|Overall Study|Early termination of Study|1
6366421|NCT01627561|10156319|FG000|Overall Study|Lost to Follow-up|1
6366422|NCT01627561|10156320|FG001|Overall Study|Lost to Follow-up|0
6366423|NCT01627561|10156319|FG000|Overall Study|Withdrawal by Subject|0
6366424|NCT01627561|10156320|FG001|Overall Study|Withdrawal by Subject|1
6366425|NCT01627561|10156319|FG000|Overall Study|Migrated/moved from study area|0
6366426|NCT01627561|10156320|FG001|Overall Study|Migrated/moved from study area|2
6366427|NCT01652534|10156345|FG000|Overall Study|Lack of Efficacy|1
6366428|NCT01652534|10156346|FG001|Overall Study|Lack of Efficacy|0
6366429|NCT04799405|10156372|FG000|Phase 1 - Acute Stimulation, Daily tDCS|Withdrawal by Subject|2
6366430|NCT04537949|10156388|FG000|Overall Study|personal reasons not related to the IMP|1
6366431|NCT04537949|10156389|FG001|Overall Study|personal reasons not related to the IMP|0
6366432|NCT04537949|10156390|FG002|Overall Study|personal reasons not related to the IMP|0
6366433|NCT04537949|10156391|FG003|Overall Study|personal reasons not related to the IMP|0
6366434|NCT04537949|10156392|FG004|Overall Study|personal reasons not related to the IMP|0
6366435|NCT04537949|10156393|FG005|Overall Study|personal reasons not related to the IMP|0
6366436|NCT04537949|10156394|FG006|Overall Study|personal reasons not related to the IMP|0
6366437|NCT04537949|10156395|FG007|Overall Study|personal reasons not related to the IMP|0
6366438|NCT04529499|10156415|FG000|Overall Study|Withdrawal by Subject|9
6366439|NCT04529499|10156416|FG001|Overall Study|Withdrawal by Subject|11
6366440|NCT04529499|10156415|FG000|Overall Study|Physician Decision|1
6366441|NCT04529499|10156416|FG001|Overall Study|Physician Decision|2
6366442|NCT04529499|10156415|FG000|Overall Study|Adverse Event|4
6366443|NCT04529499|10156416|FG001|Overall Study|Adverse Event|4
6366444|NCT04529499|10156415|FG000|Overall Study|Death|14
6366445|NCT04529499|10156416|FG001|Overall Study|Death|11
6366446|NCT04529499|10156415|FG000|Overall Study|Lost to Follow-up|1
6366447|NCT04529499|10156416|FG001|Overall Study|Lost to Follow-up|1
6366448|NCT04529499|10156415|FG000|Overall Study|Others|7
6171661|NCT01261611|9818587|FG002|Treatment Cycle 1|Lost to Follow-up|0
6171662|NCT01261611|9818585|FG000|Treatment Cycle 1|Adverse Event|0
6171663|NCT01261611|9818586|FG001|Treatment Cycle 1|Adverse Event|1
6171664|NCT01261611|9818587|FG002|Treatment Cycle 1|Adverse Event|0
6171665|NCT01261611|9818585|FG000|Treatment Cycle 1|Protocol Violation|0
6171666|NCT01261611|9818586|FG001|Treatment Cycle 1|Protocol Violation|0
6171667|NCT01261611|9818587|FG002|Treatment Cycle 1|Protocol Violation|2
6171668|NCT01261611|9818585|FG000|Treatment Cycle 2|Completed study|4
6171669|NCT01261611|9818586|FG001|Treatment Cycle 2|Completed study|0
6366449|NCT04529499|10156416|FG001|Overall Study|Others|11
6366450|NCT04501094|10156424|FG000|Overall Study|Death (unrelated to research)|1
6171670|NCT01261611|9818587|FG002|Treatment Cycle 2|Completed study|0
6366451|NCT04501094|10156425|FG001|Overall Study|Death (unrelated to research)|0
6366452|NCT04421027|10156433|FG000|Overall Study|Adverse Event|5
6366453|NCT04421027|10156434|FG001|Overall Study|Adverse Event|3
6366454|NCT04421027|10156433|FG000|Overall Study|Death|98
6366455|NCT04421027|10156434|FG001|Overall Study|Death|61
6366456|NCT04421027|10156433|FG000|Overall Study|Lost to Follow-up|22
6366457|NCT04421027|10156434|FG001|Overall Study|Lost to Follow-up|20
6366458|NCT04421027|10156433|FG000|Overall Study|Other-Unknown|15
6366459|NCT04421027|10156434|FG001|Overall Study|Other-Unknown|9
6366460|NCT04421027|10156433|FG000|Overall Study|Physician Decision|1
6366461|NCT04421027|10156434|FG001|Overall Study|Physician Decision|1
6366462|NCT04421027|10156433|FG000|Overall Study|Withdrawal by Subject|7
6366463|NCT04421027|10156434|FG001|Overall Study|Withdrawal by Subject|12
6366464|NCT04421027|10156433|FG000|Overall Study|Randomized Not Dosed|9
6366465|NCT04421027|10156434|FG001|Overall Study|Randomized Not Dosed|14
6366466|NCT04414618|10156444|FG000|Overall Study|Death|3
6366467|NCT04414618|10156445|FG001|Overall Study|Death|3
6366468|NCT04414618|10156444|FG000|Overall Study|Withdrawal by Subject|2
6366469|NCT04414618|10156445|FG001|Overall Study|Withdrawal by Subject|1
6366470|NCT04414618|10156444|FG000|Overall Study|Lost to Follow-up|2
6366471|NCT04414618|10156445|FG001|Overall Study|Lost to Follow-up|3
6366472|NCT04414618|10156444|FG000|Overall Study|Physician Decision|1
6366473|NCT04414618|10156445|FG001|Overall Study|Physician Decision|0
6366474|NCT04412057|10156454|FG000|Overall Study|Death|3
6366475|NCT04412057|10156455|FG001|Overall Study|Death|7
6366476|NCT04412057|10156454|FG000|Overall Study|Discharged prior to receiving study treatment|1
6366477|NCT04412057|10156455|FG001|Overall Study|Discharged prior to receiving study treatment|0
6366478|NCT04402060|10156464|FG000|Overall Study|Death|1
6366479|NCT04402060|10156465|FG001|Overall Study|Death|12
6366480|NCT04402060|10156466|FG002|Overall Study|Death|7
6366481|NCT04402060|10156464|FG000|Overall Study|Adverse Event|0
6366482|NCT04402060|10156465|FG001|Overall Study|Adverse Event|0
6366483|NCT04402060|10156466|FG002|Overall Study|Adverse Event|1
6366484|NCT04402060|10156464|FG000|Overall Study|Withdrawal by Subject|0
6366485|NCT04402060|10156465|FG001|Overall Study|Withdrawal by Subject|1
6366486|NCT04402060|10156466|FG002|Overall Study|Withdrawal by Subject|2
6366487|NCT04402060|10156464|FG000|Overall Study|Sponsor Request|0
6366488|NCT04402060|10156465|FG001|Overall Study|Sponsor Request|2
6366489|NCT04402060|10156466|FG002|Overall Study|Sponsor Request|0
6366490|NCT04402060|10156464|FG000|Overall Study|Physician Decision|0
6366491|NCT04402060|10156465|FG001|Overall Study|Physician Decision|0
6366492|NCT04402060|10156466|FG002|Overall Study|Physician Decision|1
6366493|NCT04402060|10156464|FG000|Overall Study|Other|0
6366494|NCT04402060|10156465|FG001|Overall Study|Other|1
6366495|NCT04402060|10156466|FG002|Overall Study|Other|0
6366496|NCT04396626|10156479|FG000|Overall Study|Premature termination of study|975
6366497|NCT04376684|10156505|FG000|Part 1 (Up to Day 60)|Withdrawal by Subject|7
6366498|NCT04376684|10156506|FG001|Part 1 (Up to Day 60)|Withdrawal by Subject|8
6366499|NCT04376684|10156507|FG002|Part 1 (Up to Day 60)|Withdrawal by Subject|0
6366500|NCT04376684|10156508|FG003|Part 1 (Up to Day 60)|Withdrawal by Subject|0
6366501|NCT04376684|10156505|FG000|Part 1 (Up to Day 60)|Protocol Violation|2
6366502|NCT04376684|10156506|FG001|Part 1 (Up to Day 60)|Protocol Violation|3
6366503|NCT04376684|10156507|FG002|Part 1 (Up to Day 60)|Protocol Violation|0
6366504|NCT04376684|10156508|FG003|Part 1 (Up to Day 60)|Protocol Violation|0
6366505|NCT04376684|10156505|FG000|Part 1 (Up to Day 60)|Physician Decision|2
6366506|NCT04376684|10156506|FG001|Part 1 (Up to Day 60)|Physician Decision|5
6366507|NCT04376684|10156507|FG002|Part 1 (Up to Day 60)|Physician Decision|0
6366508|NCT04376684|10156508|FG003|Part 1 (Up to Day 60)|Physician Decision|0
6366509|NCT04376684|10156505|FG000|Part 1 (Up to Day 60)|Lost to Follow-up|4
6366510|NCT04376684|10156506|FG001|Part 1 (Up to Day 60)|Lost to Follow-up|8
6366511|NCT04376684|10156507|FG002|Part 1 (Up to Day 60)|Lost to Follow-up|0
6366512|NCT04376684|10156508|FG003|Part 1 (Up to Day 60)|Lost to Follow-up|0
6366513|NCT04376684|10156505|FG000|Part 2 (Up to Day 60)|Withdrawal by Subject|0
6366514|NCT04376684|10156506|FG001|Part 2 (Up to Day 60)|Withdrawal by Subject|0
6366515|NCT04376684|10156507|FG002|Part 2 (Up to Day 60)|Withdrawal by Subject|1
6366516|NCT04376684|10156508|FG003|Part 2 (Up to Day 60)|Withdrawal by Subject|1
6084484|NCT00642941|9693401|FG010|Overall Study|Withdrawal by Subject|0
6084485|NCT00642941|9693402|FG011|Overall Study|Withdrawal by Subject|1
6084486|NCT00642941|9693391|FG000|Overall Study|Protocol Violation|0
6084487|NCT00642941|9693392|FG001|Overall Study|Protocol Violation|0
6366517|NCT04376684|10156505|FG000|Part 2 (Up to Day 60)|Physician Decision|0
6366518|NCT04376684|10156506|FG001|Part 2 (Up to Day 60)|Physician Decision|0
6366519|NCT04376684|10156507|FG002|Part 2 (Up to Day 60)|Physician Decision|1
6366520|NCT04376684|10156508|FG003|Part 2 (Up to Day 60)|Physician Decision|1
6366521|NCT04376684|10156505|FG000|Part 2 (Up to Day 60)|Lost to Follow-up|0
6366522|NCT04376684|10156506|FG001|Part 2 (Up to Day 60)|Lost to Follow-up|0
6084488|NCT00642941|9693393|FG002|Overall Study|Protocol Violation|0
6366523|NCT04376684|10156507|FG002|Part 2 (Up to Day 60)|Lost to Follow-up|3
6366524|NCT04376684|10156508|FG003|Part 2 (Up to Day 60)|Lost to Follow-up|2
6366525|NCT04353284|10156520|FG000|Overall Study|Adverse Event|1
6366526|NCT04353284|10156521|FG001|Overall Study|Adverse Event|1
6366527|NCT04353284|10156520|FG000|Overall Study|Lost to Follow-up|1
6366528|NCT04353284|10156521|FG001|Overall Study|Lost to Follow-up|0
6366529|NCT04294147|10156529|FG000|Overall Study|Protocol Violation|2
6366530|NCT04294147|10156530|FG001|Overall Study|Protocol Violation|0
6366531|NCT04231825|10156542|FG000|Overall Study|Protocol Violation|3
6366532|NCT04231825|10156543|FG001|Overall Study|Protocol Violation|3
6366533|NCT04231825|10156542|FG000|Overall Study|Lost to Follow-up|0
6366534|NCT04231825|10156543|FG001|Overall Study|Lost to Follow-up|1
6366535|NCT04196686|10156549|FG000|First Treatment (4 Minutes)|Withdrawal by Subject|0
6366536|NCT04196686|10156550|FG001|First Treatment (4 Minutes)|Withdrawal by Subject|3
6366537|NCT04178772|10156556|FG000|Overall Study|Unsatisfacotry VIsual Response|1
6366538|NCT04178772|10156556|FG000|Overall Study|study terminated early due to COVID-19|7
6366539|NCT04148651|10156560|FG000|Overall Study|Lost to Follow-up|2
6084489|NCT00642941|9693394|FG003|Overall Study|Protocol Violation|0
6084490|NCT00642941|9693395|FG004|Overall Study|Protocol Violation|0
6366540|NCT03893448|10156575|FG000|Overall Study|Withdrawal by Parent/Guardian|59
6366541|NCT03893448|10156576|FG001|Overall Study|Withdrawal by Parent/Guardian|85
6366542|NCT03893448|10156575|FG000|Overall Study|Physician Decision|8
6366543|NCT03893448|10156576|FG001|Overall Study|Physician Decision|14
6366544|NCT03893448|10156575|FG000|Overall Study|Lost to Follow-up|34
6366545|NCT03893448|10156576|FG001|Overall Study|Lost to Follow-up|27
6366546|NCT03893448|10156575|FG000|Overall Study|Death|1
6366547|NCT03893448|10156576|FG001|Overall Study|Death|0
6366548|NCT03850444|10156615|FG000|Overall Study|Adverse Event|12
6366549|NCT03850444|10156616|FG001|Overall Study|Adverse Event|9
6366550|NCT03850444|10156615|FG000|Overall Study|Death|38
6366551|NCT03850444|10156616|FG001|Overall Study|Death|64
6366552|NCT03850444|10156615|FG000|Overall Study|Lost to Follow-up|0
6366553|NCT03850444|10156616|FG001|Overall Study|Lost to Follow-up|1
6366554|NCT03850444|10156615|FG000|Overall Study|Withdrawal by Subject|0
6366555|NCT03850444|10156616|FG001|Overall Study|Withdrawal by Subject|1
6366556|NCT03850444|10156615|FG000|Overall Study|Ongoing in Study|78
6366557|NCT03850444|10156616|FG001|Overall Study|Ongoing in Study|59
6366558|NCT03814590|10156640|FG000|Overall Study|Adverse Event|0
6366559|NCT03814590|10156641|FG001|Overall Study|Adverse Event|0
6366560|NCT03814590|10156642|FG002|Overall Study|Adverse Event|0
6366561|NCT03814590|10156643|FG003|Overall Study|Adverse Event|0
6366562|NCT03814590|10156644|FG004|Overall Study|Adverse Event|0
6366563|NCT03814590|10156645|FG005|Overall Study|Adverse Event|1
6366564|NCT03814590|10156646|FG006|Overall Study|Adverse Event|1
6366565|NCT03814590|10156647|FG007|Overall Study|Adverse Event|1
6366566|NCT03814590|10156648|FG008|Overall Study|Adverse Event|0
6366567|NCT03814590|10156649|FG009|Overall Study|Adverse Event|0
6366568|NCT03814590|10156650|FG010|Overall Study|Adverse Event|1
6366569|NCT03814590|10156651|FG011|Overall Study|Adverse Event|0
6366570|NCT03814590|10156652|FG012|Overall Study|Adverse Event|3
6366571|NCT03814590|10156653|FG013|Overall Study|Adverse Event|0
6366572|NCT03814590|10156640|FG000|Overall Study|Lost to Follow-up|0
6366573|NCT03814590|10156641|FG001|Overall Study|Lost to Follow-up|2
6366574|NCT03814590|10156642|FG002|Overall Study|Lost to Follow-up|1
6366575|NCT03814590|10156643|FG003|Overall Study|Lost to Follow-up|0
6366576|NCT03814590|10156644|FG004|Overall Study|Lost to Follow-up|1
6366577|NCT03814590|10156645|FG005|Overall Study|Lost to Follow-up|1
6366578|NCT03814590|10156646|FG006|Overall Study|Lost to Follow-up|1
6366579|NCT03814590|10156647|FG007|Overall Study|Lost to Follow-up|1
6366580|NCT03814590|10156648|FG008|Overall Study|Lost to Follow-up|0
6366581|NCT03814590|10156649|FG009|Overall Study|Lost to Follow-up|0
6366582|NCT03814590|10156650|FG010|Overall Study|Lost to Follow-up|1
6366583|NCT03814590|10156651|FG011|Overall Study|Lost to Follow-up|0
6366584|NCT03814590|10156652|FG012|Overall Study|Lost to Follow-up|0
6366585|NCT03814590|10156653|FG013|Overall Study|Lost to Follow-up|1
6366586|NCT03814590|10156640|FG000|Overall Study|CONSENT WITHDRAWAL, DUE TO COVID-19 BUT NOT DUE TO AN ADVERSE EVENT|0
6366587|NCT03814590|10156641|FG001|Overall Study|CONSENT WITHDRAWAL, DUE TO COVID-19 BUT NOT DUE TO AN ADVERSE EVENT|0
6366588|NCT03814590|10156642|FG002|Overall Study|CONSENT WITHDRAWAL, DUE TO COVID-19 BUT NOT DUE TO AN ADVERSE EVENT|0
6366589|NCT03814590|10156643|FG003|Overall Study|CONSENT WITHDRAWAL, DUE TO COVID-19 BUT NOT DUE TO AN ADVERSE EVENT|0
6366590|NCT03814590|10156644|FG004|Overall Study|CONSENT WITHDRAWAL, DUE TO COVID-19 BUT NOT DUE TO AN ADVERSE EVENT|0
6366591|NCT03814590|10156645|FG005|Overall Study|CONSENT WITHDRAWAL, DUE TO COVID-19 BUT NOT DUE TO AN ADVERSE EVENT|0
6366592|NCT03814590|10156646|FG006|Overall Study|CONSENT WITHDRAWAL, DUE TO COVID-19 BUT NOT DUE TO AN ADVERSE EVENT|0
6366593|NCT03814590|10156647|FG007|Overall Study|CONSENT WITHDRAWAL, DUE TO COVID-19 BUT NOT DUE TO AN ADVERSE EVENT|0
6366594|NCT03814590|10156648|FG008|Overall Study|CONSENT WITHDRAWAL, DUE TO COVID-19 BUT NOT DUE TO AN ADVERSE EVENT|0
6366595|NCT03814590|10156649|FG009|Overall Study|CONSENT WITHDRAWAL, DUE TO COVID-19 BUT NOT DUE TO AN ADVERSE EVENT|1
6366596|NCT03814590|10156650|FG010|Overall Study|CONSENT WITHDRAWAL, DUE TO COVID-19 BUT NOT DUE TO AN ADVERSE EVENT|0
6366597|NCT03814590|10156651|FG011|Overall Study|CONSENT WITHDRAWAL, DUE TO COVID-19 BUT NOT DUE TO AN ADVERSE EVENT|0
6366598|NCT03814590|10156652|FG012|Overall Study|CONSENT WITHDRAWAL, DUE TO COVID-19 BUT NOT DUE TO AN ADVERSE EVENT|0
6366599|NCT03814590|10156653|FG013|Overall Study|CONSENT WITHDRAWAL, DUE TO COVID-19 BUT NOT DUE TO AN ADVERSE EVENT|0
6366600|NCT03814590|10156640|FG000|Overall Study|CONSENT WITHDRAWAL, NOT DUE TO COVID-19 AND NOT DUE TO AN ADVERSE EVENT|0
6366601|NCT03814590|10156641|FG001|Overall Study|CONSENT WITHDRAWAL, NOT DUE TO COVID-19 AND NOT DUE TO AN ADVERSE EVENT|0
6366602|NCT03814590|10156642|FG002|Overall Study|CONSENT WITHDRAWAL, NOT DUE TO COVID-19 AND NOT DUE TO AN ADVERSE EVENT|0
6366603|NCT03814590|10156643|FG003|Overall Study|CONSENT WITHDRAWAL, NOT DUE TO COVID-19 AND NOT DUE TO AN ADVERSE EVENT|0
6366604|NCT03814590|10156644|FG004|Overall Study|CONSENT WITHDRAWAL, NOT DUE TO COVID-19 AND NOT DUE TO AN ADVERSE EVENT|0
6366605|NCT03814590|10156645|FG005|Overall Study|CONSENT WITHDRAWAL, NOT DUE TO COVID-19 AND NOT DUE TO AN ADVERSE EVENT|3
6366606|NCT03814590|10156646|FG006|Overall Study|CONSENT WITHDRAWAL, NOT DUE TO COVID-19 AND NOT DUE TO AN ADVERSE EVENT|1
6366607|NCT03814590|10156647|FG007|Overall Study|CONSENT WITHDRAWAL, NOT DUE TO COVID-19 AND NOT DUE TO AN ADVERSE EVENT|2
6366608|NCT03814590|10156648|FG008|Overall Study|CONSENT WITHDRAWAL, NOT DUE TO COVID-19 AND NOT DUE TO AN ADVERSE EVENT|0
6366609|NCT03814590|10156649|FG009|Overall Study|CONSENT WITHDRAWAL, NOT DUE TO COVID-19 AND NOT DUE TO AN ADVERSE EVENT|3
6366610|NCT03814590|10156650|FG010|Overall Study|CONSENT WITHDRAWAL, NOT DUE TO COVID-19 AND NOT DUE TO AN ADVERSE EVENT|1
6366611|NCT03814590|10156651|FG011|Overall Study|CONSENT WITHDRAWAL, NOT DUE TO COVID-19 AND NOT DUE TO AN ADVERSE EVENT|0
6366612|NCT03814590|10156652|FG012|Overall Study|CONSENT WITHDRAWAL, NOT DUE TO COVID-19 AND NOT DUE TO AN ADVERSE EVENT|1
6366613|NCT03814590|10156653|FG013|Overall Study|CONSENT WITHDRAWAL, NOT DUE TO COVID-19 AND NOT DUE TO AN ADVERSE EVENT|2
6366614|NCT03814590|10156640|FG000|Overall Study|MIGRATED / MOVED FROM THE STUDY AREA|0
6366615|NCT03814590|10156641|FG001|Overall Study|MIGRATED / MOVED FROM THE STUDY AREA|0
6366616|NCT03814590|10156642|FG002|Overall Study|MIGRATED / MOVED FROM THE STUDY AREA|0
6366617|NCT03814590|10156643|FG003|Overall Study|MIGRATED / MOVED FROM THE STUDY AREA|0
6366618|NCT03814590|10156644|FG004|Overall Study|MIGRATED / MOVED FROM THE STUDY AREA|0
6366619|NCT03814590|10156645|FG005|Overall Study|MIGRATED / MOVED FROM THE STUDY AREA|0
6366620|NCT03814590|10156646|FG006|Overall Study|MIGRATED / MOVED FROM THE STUDY AREA|0
6366621|NCT03814590|10156647|FG007|Overall Study|MIGRATED / MOVED FROM THE STUDY AREA|1
6366622|NCT03814590|10156648|FG008|Overall Study|MIGRATED / MOVED FROM THE STUDY AREA|0
6366623|NCT03814590|10156649|FG009|Overall Study|MIGRATED / MOVED FROM THE STUDY AREA|1
6366624|NCT03814590|10156650|FG010|Overall Study|MIGRATED / MOVED FROM THE STUDY AREA|0
6366625|NCT03814590|10156651|FG011|Overall Study|MIGRATED / MOVED FROM THE STUDY AREA|0
6366626|NCT03814590|10156652|FG012|Overall Study|MIGRATED / MOVED FROM THE STUDY AREA|0
6366627|NCT03814590|10156653|FG013|Overall Study|MIGRATED / MOVED FROM THE STUDY AREA|0
6366628|NCT03814590|10156640|FG000|Overall Study|UNKNOWN REASON|0
6366629|NCT03814590|10156641|FG001|Overall Study|UNKNOWN REASON|0
6366630|NCT03814590|10156642|FG002|Overall Study|UNKNOWN REASON|0
6366631|NCT03814590|10156643|FG003|Overall Study|UNKNOWN REASON|0
6366632|NCT03814590|10156644|FG004|Overall Study|UNKNOWN REASON|0
6366633|NCT03814590|10156645|FG005|Overall Study|UNKNOWN REASON|0
6366634|NCT03814590|10156646|FG006|Overall Study|UNKNOWN REASON|0
6366635|NCT03814590|10156647|FG007|Overall Study|UNKNOWN REASON|1
6366636|NCT03814590|10156648|FG008|Overall Study|UNKNOWN REASON|0
6366637|NCT03814590|10156649|FG009|Overall Study|UNKNOWN REASON|0
6366638|NCT03814590|10156650|FG010|Overall Study|UNKNOWN REASON|0
6366639|NCT03814590|10156651|FG011|Overall Study|UNKNOWN REASON|0
6366640|NCT03814590|10156652|FG012|Overall Study|UNKNOWN REASON|0
6366641|NCT03814590|10156653|FG013|Overall Study|UNKNOWN REASON|0
6366642|NCT03811574|10156696|FG000|Overall Study|Withdrawal by Subject|2
6366643|NCT03811574|10156697|FG001|Overall Study|Withdrawal by Subject|4
6366644|NCT03811574|10156698|FG002|Overall Study|Withdrawal by Subject|0
6084491|NCT00642941|9693396|FG005|Overall Study|Protocol Violation|0
6084492|NCT00642941|9693397|FG006|Overall Study|Protocol Violation|1
6084493|NCT00642941|9693398|FG007|Overall Study|Protocol Violation|0
6084494|NCT00642941|9693399|FG008|Overall Study|Protocol Violation|0
6084495|NCT00642941|9693400|FG009|Overall Study|Protocol Violation|0
6084496|NCT00642941|9693401|FG010|Overall Study|Protocol Violation|0
6084497|NCT00642941|9693402|FG011|Overall Study|Protocol Violation|0
6084498|NCT00642941|9693391|FG000|Overall Study|Adverse Event|1
6084499|NCT00642941|9693392|FG001|Overall Study|Adverse Event|1
6084500|NCT00642941|9693393|FG002|Overall Study|Adverse Event|0
6084501|NCT00642941|9693394|FG003|Overall Study|Adverse Event|0
6084502|NCT00642941|9693395|FG004|Overall Study|Adverse Event|0
6171671|NCT01261611|9818585|FG000|Treatment Cycle 2|Withdrawal by Subject|4
6084503|NCT00642941|9693396|FG005|Overall Study|Adverse Event|0
6084504|NCT00642941|9693397|FG006|Overall Study|Adverse Event|1
6084505|NCT00642941|9693398|FG007|Overall Study|Adverse Event|1
6084506|NCT00642941|9693399|FG008|Overall Study|Adverse Event|0
6366645|NCT03727750|10156734|FG000|Overall Study|Death|45
6366646|NCT03727750|10156734|FG000|Overall Study|Withdrawal by Subject|2
6366647|NCT03727750|10156734|FG000|Overall Study|Lost to Follow-up|1
6366648|NCT03727750|10156734|FG000|Overall Study|Other|1
6366649|NCT03726879|10156740|FG000|Overall Study|Death|6
6366650|NCT03726879|10156741|FG001|Overall Study|Death|4
6366651|NCT03726879|10156740|FG000|Overall Study|Physician Decision|0
6366652|NCT03726879|10156741|FG001|Overall Study|Physician Decision|2
6366653|NCT03726879|10156740|FG000|Overall Study|Protocol Violation|0
6366654|NCT03726879|10156741|FG001|Overall Study|Protocol Violation|1
6366655|NCT03726879|10156740|FG000|Overall Study|Withdrawal by Subject|5
6366656|NCT03726879|10156741|FG001|Overall Study|Withdrawal by Subject|5
6366657|NCT03726879|10156740|FG000|Overall Study|TSH result is unstable|0
6366658|NCT03726879|10156741|FG001|Overall Study|TSH result is unstable|1
6366659|NCT03726879|10156740|FG000|Overall Study|Continuing on Study|215
6366660|NCT03726879|10156741|FG001|Overall Study|Continuing on Study|215
6366661|NCT03715829|10156753|FG000|Dose Ranging Period|Adverse Event|2
6366662|NCT03715829|10156754|FG001|Dose Ranging Period|Adverse Event|4
6366663|NCT03715829|10156755|FG002|Dose Ranging Period|Adverse Event|5
6366664|NCT03715829|10156756|FG003|Dose Ranging Period|Adverse Event|2
6366665|NCT03715829|10156757|FG004|Dose Ranging Period|Adverse Event|3
6366666|NCT03715829|10156758|FG005|Dose Ranging Period|Adverse Event|3
6366667|NCT03715829|10156759|FG006|Dose Ranging Period|Adverse Event|0
6366668|NCT03715829|10156760|FG007|Dose Ranging Period|Adverse Event|0
6366669|NCT03715829|10156761|FG008|Dose Ranging Period|Adverse Event|0
6366670|NCT03715829|10156762|FG009|Dose Ranging Period|Adverse Event|0
6366671|NCT03715829|10156763|FG010|Dose Ranging Period|Adverse Event|0
6366672|NCT03715829|10156753|FG000|Dose Ranging Period|Lack of Efficacy|0
6366673|NCT03715829|10156754|FG001|Dose Ranging Period|Lack of Efficacy|1
6366674|NCT03715829|10156755|FG002|Dose Ranging Period|Lack of Efficacy|0
6366675|NCT03715829|10156756|FG003|Dose Ranging Period|Lack of Efficacy|1
6366676|NCT03715829|10156757|FG004|Dose Ranging Period|Lack of Efficacy|0
6366677|NCT03715829|10156758|FG005|Dose Ranging Period|Lack of Efficacy|0
6366678|NCT03715829|10156759|FG006|Dose Ranging Period|Lack of Efficacy|0
6366679|NCT03715829|10156760|FG007|Dose Ranging Period|Lack of Efficacy|0
6366680|NCT03715829|10156761|FG008|Dose Ranging Period|Lack of Efficacy|0
6366681|NCT03715829|10156762|FG009|Dose Ranging Period|Lack of Efficacy|0
6366682|NCT03715829|10156763|FG010|Dose Ranging Period|Lack of Efficacy|0
6366683|NCT03715829|10156753|FG000|Dose Ranging Period|Lost to Follow-up|2
6366684|NCT03715829|10156754|FG001|Dose Ranging Period|Lost to Follow-up|0
6366685|NCT03715829|10156755|FG002|Dose Ranging Period|Lost to Follow-up|1
6366686|NCT03715829|10156756|FG003|Dose Ranging Period|Lost to Follow-up|1
6366687|NCT03715829|10156757|FG004|Dose Ranging Period|Lost to Follow-up|1
6366688|NCT03715829|10156758|FG005|Dose Ranging Period|Lost to Follow-up|2
6366689|NCT03715829|10156759|FG006|Dose Ranging Period|Lost to Follow-up|0
6366690|NCT03715829|10156760|FG007|Dose Ranging Period|Lost to Follow-up|0
6366691|NCT03715829|10156761|FG008|Dose Ranging Period|Lost to Follow-up|0
6366692|NCT03715829|10156762|FG009|Dose Ranging Period|Lost to Follow-up|0
6366693|NCT03715829|10156763|FG010|Dose Ranging Period|Lost to Follow-up|0
6366694|NCT03715829|10156753|FG000|Dose Ranging Period|Protocol Violation|0
6366695|NCT03715829|10156754|FG001|Dose Ranging Period|Protocol Violation|0
6366696|NCT03715829|10156755|FG002|Dose Ranging Period|Protocol Violation|0
6366697|NCT03715829|10156756|FG003|Dose Ranging Period|Protocol Violation|1
6366698|NCT03715829|10156757|FG004|Dose Ranging Period|Protocol Violation|0
6366699|NCT03715829|10156758|FG005|Dose Ranging Period|Protocol Violation|0
6366700|NCT03715829|10156759|FG006|Dose Ranging Period|Protocol Violation|0
6366701|NCT03715829|10156760|FG007|Dose Ranging Period|Protocol Violation|0
6366702|NCT03715829|10156761|FG008|Dose Ranging Period|Protocol Violation|0
6366703|NCT03715829|10156762|FG009|Dose Ranging Period|Protocol Violation|0
6366704|NCT03715829|10156763|FG010|Dose Ranging Period|Protocol Violation|0
6366705|NCT03715829|10156753|FG000|Dose Ranging Period|Withdrawal by Subject|8
6366706|NCT03715829|10156754|FG001|Dose Ranging Period|Withdrawal by Subject|4
6366707|NCT03715829|10156755|FG002|Dose Ranging Period|Withdrawal by Subject|3
6366708|NCT03715829|10156756|FG003|Dose Ranging Period|Withdrawal by Subject|9
6366709|NCT03715829|10156757|FG004|Dose Ranging Period|Withdrawal by Subject|2
6366710|NCT03715829|10156758|FG005|Dose Ranging Period|Withdrawal by Subject|3
6366711|NCT03715829|10156759|FG006|Dose Ranging Period|Withdrawal by Subject|0
6366712|NCT03715829|10156760|FG007|Dose Ranging Period|Withdrawal by Subject|0
6366713|NCT03715829|10156761|FG008|Dose Ranging Period|Withdrawal by Subject|0
6366714|NCT03715829|10156762|FG009|Dose Ranging Period|Withdrawal by Subject|0
6366715|NCT03715829|10156763|FG010|Dose Ranging Period|Withdrawal by Subject|0
6366716|NCT03715829|10156753|FG000|Dose Ranging Period|Medication Error Without Associated Adverse Event|0
6366717|NCT03715829|10156754|FG001|Dose Ranging Period|Medication Error Without Associated Adverse Event|0
6366718|NCT03715829|10156755|FG002|Dose Ranging Period|Medication Error Without Associated Adverse Event|1
6366719|NCT03715829|10156756|FG003|Dose Ranging Period|Medication Error Without Associated Adverse Event|0
6366720|NCT03715829|10156757|FG004|Dose Ranging Period|Medication Error Without Associated Adverse Event|0
6366721|NCT03715829|10156758|FG005|Dose Ranging Period|Medication Error Without Associated Adverse Event|0
6366722|NCT03715829|10156759|FG006|Dose Ranging Period|Medication Error Without Associated Adverse Event|0
6366723|NCT03715829|10156760|FG007|Dose Ranging Period|Medication Error Without Associated Adverse Event|0
6366724|NCT03715829|10156761|FG008|Dose Ranging Period|Medication Error Without Associated Adverse Event|0
6366725|NCT03715829|10156762|FG009|Dose Ranging Period|Medication Error Without Associated Adverse Event|0
6366726|NCT03715829|10156763|FG010|Dose Ranging Period|Medication Error Without Associated Adverse Event|0
6366727|NCT03715829|10156753|FG000|Dose Ranging Period|No Longer Meets Eligibility Criteria|0
6366728|NCT03715829|10156754|FG001|Dose Ranging Period|No Longer Meets Eligibility Criteria|0
6366729|NCT03715829|10156755|FG002|Dose Ranging Period|No Longer Meets Eligibility Criteria|1
6366730|NCT03715829|10156756|FG003|Dose Ranging Period|No Longer Meets Eligibility Criteria|0
6366731|NCT03715829|10156757|FG004|Dose Ranging Period|No Longer Meets Eligibility Criteria|1
6366732|NCT03715829|10156758|FG005|Dose Ranging Period|No Longer Meets Eligibility Criteria|0
6366733|NCT03715829|10156759|FG006|Dose Ranging Period|No Longer Meets Eligibility Criteria|0
6366734|NCT03715829|10156760|FG007|Dose Ranging Period|No Longer Meets Eligibility Criteria|0
6366735|NCT03715829|10156761|FG008|Dose Ranging Period|No Longer Meets Eligibility Criteria|0
6366736|NCT03715829|10156762|FG009|Dose Ranging Period|No Longer Meets Eligibility Criteria|0
6366737|NCT03715829|10156763|FG010|Dose Ranging Period|No Longer Meets Eligibility Criteria|0
6366738|NCT03715829|10156753|FG000|Dose Ranging Period|Other|0
6366739|NCT03715829|10156754|FG001|Dose Ranging Period|Other|0
6366740|NCT03715829|10156755|FG002|Dose Ranging Period|Other|2
6366741|NCT03715829|10156756|FG003|Dose Ranging Period|Other|0
6366742|NCT03715829|10156757|FG004|Dose Ranging Period|Other|0
6366743|NCT03715829|10156758|FG005|Dose Ranging Period|Other|3
6366744|NCT03715829|10156759|FG006|Dose Ranging Period|Other|0
6366745|NCT03715829|10156760|FG007|Dose Ranging Period|Other|0
6366746|NCT03715829|10156761|FG008|Dose Ranging Period|Other|0
6366747|NCT03715829|10156762|FG009|Dose Ranging Period|Other|0
6366748|NCT03715829|10156763|FG010|Dose Ranging Period|Other|0
6366749|NCT03715829|10156753|FG000|Extension Period|Adverse Event|0
6366750|NCT03715829|10156754|FG001|Extension Period|Adverse Event|0
6366751|NCT03715829|10156755|FG002|Extension Period|Adverse Event|0
6366752|NCT03715829|10156756|FG003|Extension Period|Adverse Event|0
6366753|NCT03715829|10156757|FG004|Extension Period|Adverse Event|0
6366754|NCT03715829|10156758|FG005|Extension Period|Adverse Event|0
6366755|NCT03715829|10156759|FG006|Extension Period|Adverse Event|3
6366756|NCT03715829|10156760|FG007|Extension Period|Adverse Event|1
6366757|NCT03715829|10156761|FG008|Extension Period|Adverse Event|6
6366758|NCT03715829|10156762|FG009|Extension Period|Adverse Event|0
6366759|NCT03715829|10156763|FG010|Extension Period|Adverse Event|0
6366760|NCT03715829|10156753|FG000|Extension Period|Lack of Efficacy|0
6366761|NCT03715829|10156754|FG001|Extension Period|Lack of Efficacy|0
6366762|NCT03715829|10156755|FG002|Extension Period|Lack of Efficacy|0
6366763|NCT03715829|10156756|FG003|Extension Period|Lack of Efficacy|0
6366764|NCT03715829|10156757|FG004|Extension Period|Lack of Efficacy|0
6366765|NCT03715829|10156758|FG005|Extension Period|Lack of Efficacy|0
6366766|NCT03715829|10156759|FG006|Extension Period|Lack of Efficacy|1
6366767|NCT03715829|10156760|FG007|Extension Period|Lack of Efficacy|9
6366768|NCT03715829|10156761|FG008|Extension Period|Lack of Efficacy|2
6366769|NCT03715829|10156762|FG009|Extension Period|Lack of Efficacy|0
6366770|NCT03715829|10156763|FG010|Extension Period|Lack of Efficacy|0
6366771|NCT03715829|10156753|FG000|Extension Period|Lost to Follow-up|0
6366772|NCT03715829|10156754|FG001|Extension Period|Lost to Follow-up|0
6366773|NCT03715829|10156755|FG002|Extension Period|Lost to Follow-up|0
6366774|NCT03715829|10156756|FG003|Extension Period|Lost to Follow-up|0
6366775|NCT03715829|10156757|FG004|Extension Period|Lost to Follow-up|0
6366776|NCT03715829|10156758|FG005|Extension Period|Lost to Follow-up|0
6366777|NCT03715829|10156759|FG006|Extension Period|Lost to Follow-up|0
6366778|NCT03715829|10156760|FG007|Extension Period|Lost to Follow-up|0
6084507|NCT00642941|9693400|FG009|Overall Study|Adverse Event|1
6084508|NCT00642941|9693401|FG010|Overall Study|Adverse Event|0
6084509|NCT00642941|9693402|FG011|Overall Study|Adverse Event|0
6084510|NCT00642941|9693391|FG000|Overall Study|Other|1
6366779|NCT03715829|10156761|FG008|Extension Period|Lost to Follow-up|2
6366780|NCT03715829|10156762|FG009|Extension Period|Lost to Follow-up|0
6366781|NCT03715829|10156763|FG010|Extension Period|Lost to Follow-up|0
6366782|NCT03715829|10156753|FG000|Extension Period|Protocol Violation|0
6366783|NCT03715829|10156754|FG001|Extension Period|Protocol Violation|0
6366784|NCT03715829|10156755|FG002|Extension Period|Protocol Violation|0
6366785|NCT03715829|10156756|FG003|Extension Period|Protocol Violation|0
6366786|NCT03715829|10156757|FG004|Extension Period|Protocol Violation|0
6366787|NCT03715829|10156758|FG005|Extension Period|Protocol Violation|0
6366788|NCT03715829|10156759|FG006|Extension Period|Protocol Violation|0
6366789|NCT03715829|10156760|FG007|Extension Period|Protocol Violation|0
6366790|NCT03715829|10156761|FG008|Extension Period|Protocol Violation|1
6366791|NCT03715829|10156762|FG009|Extension Period|Protocol Violation|0
6366792|NCT03715829|10156763|FG010|Extension Period|Protocol Violation|0
6366793|NCT03715829|10156753|FG000|Extension Period|Withdrawal by Subject|0
6366794|NCT03715829|10156754|FG001|Extension Period|Withdrawal by Subject|0
6366795|NCT03715829|10156755|FG002|Extension Period|Withdrawal by Subject|0
6366796|NCT03715829|10156756|FG003|Extension Period|Withdrawal by Subject|0
6366797|NCT03715829|10156757|FG004|Extension Period|Withdrawal by Subject|0
6366798|NCT03715829|10156758|FG005|Extension Period|Withdrawal by Subject|0
6366799|NCT03715829|10156759|FG006|Extension Period|Withdrawal by Subject|3
6366800|NCT03715829|10156760|FG007|Extension Period|Withdrawal by Subject|3
6084511|NCT00642941|9693392|FG001|Overall Study|Other|1
6366801|NCT03715829|10156761|FG008|Extension Period|Withdrawal by Subject|12
6366802|NCT03715829|10156762|FG009|Extension Period|Withdrawal by Subject|3
6366803|NCT03715829|10156763|FG010|Extension Period|Withdrawal by Subject|0
6366804|NCT03715829|10156753|FG000|Extension Period|Medication Error Without Associated Adverse Event|0
6366805|NCT03715829|10156754|FG001|Extension Period|Medication Error Without Associated Adverse Event|0
6366806|NCT03715829|10156755|FG002|Extension Period|Medication Error Without Associated Adverse Event|0
6366807|NCT03715829|10156756|FG003|Extension Period|Medication Error Without Associated Adverse Event|0
6366808|NCT03715829|10156757|FG004|Extension Period|Medication Error Without Associated Adverse Event|0
6366809|NCT03715829|10156758|FG005|Extension Period|Medication Error Without Associated Adverse Event|0
6366810|NCT03715829|10156759|FG006|Extension Period|Medication Error Without Associated Adverse Event|0
6366811|NCT03715829|10156760|FG007|Extension Period|Medication Error Without Associated Adverse Event|1
6084512|NCT00642941|9693393|FG002|Overall Study|Other|1
6084513|NCT00642941|9693394|FG003|Overall Study|Other|1
6084514|NCT00642941|9693395|FG004|Overall Study|Other|0
6366812|NCT03715829|10156761|FG008|Extension Period|Medication Error Without Associated Adverse Event|1
6366813|NCT03715829|10156762|FG009|Extension Period|Medication Error Without Associated Adverse Event|0
6366814|NCT03715829|10156763|FG010|Extension Period|Medication Error Without Associated Adverse Event|0
6366815|NCT03715829|10156753|FG000|Extension Period|No Longer Meets Eligibility Criteria|0
6366816|NCT03715829|10156754|FG001|Extension Period|No Longer Meets Eligibility Criteria|0
6366817|NCT03715829|10156755|FG002|Extension Period|No Longer Meets Eligibility Criteria|0
6366818|NCT03715829|10156756|FG003|Extension Period|No Longer Meets Eligibility Criteria|0
6366819|NCT03715829|10156757|FG004|Extension Period|No Longer Meets Eligibility Criteria|0
6366820|NCT03715829|10156758|FG005|Extension Period|No Longer Meets Eligibility Criteria|0
6366821|NCT03715829|10156759|FG006|Extension Period|No Longer Meets Eligibility Criteria|0
6366822|NCT03715829|10156760|FG007|Extension Period|No Longer Meets Eligibility Criteria|0
6366823|NCT03715829|10156761|FG008|Extension Period|No Longer Meets Eligibility Criteria|1
6366824|NCT03715829|10156762|FG009|Extension Period|No Longer Meets Eligibility Criteria|0
6366825|NCT03715829|10156763|FG010|Extension Period|No Longer Meets Eligibility Criteria|0
6366826|NCT03715829|10156753|FG000|Extension Period|Other|0
6366827|NCT03715829|10156754|FG001|Extension Period|Other|0
6366828|NCT03715829|10156755|FG002|Extension Period|Other|0
6366829|NCT03715829|10156756|FG003|Extension Period|Other|0
6366830|NCT03715829|10156757|FG004|Extension Period|Other|0
6366831|NCT03715829|10156758|FG005|Extension Period|Other|0
6366832|NCT03715829|10156759|FG006|Extension Period|Other|1
6366833|NCT03715829|10156760|FG007|Extension Period|Other|2
6366834|NCT03715829|10156761|FG008|Extension Period|Other|4
6366835|NCT03715829|10156762|FG009|Extension Period|Other|0
6366836|NCT03715829|10156763|FG010|Extension Period|Other|0
6366837|NCT03693430|10156791|FG000|Overall Study|Lost to Follow-up|3
6366838|NCT03693430|10156792|FG001|Overall Study|Lost to Follow-up|14
6366839|NCT03693430|10156791|FG000|Overall Study|Death|1
6366840|NCT03693430|10156792|FG001|Overall Study|Death|0
6366841|NCT03693430|10156791|FG000|Overall Study|Withdrawal by Subject|0
6366842|NCT03693430|10156792|FG001|Overall Study|Withdrawal by Subject|4
6366843|NCT03677934|10156800|FG000|Overall Study|Study is ongoing|240
6366844|NCT03677934|10156801|FG001|Overall Study|Study is ongoing|161
6366845|NCT03677934|10156800|FG000|Overall Study|Adverse Event|5
6366846|NCT03677934|10156801|FG001|Overall Study|Adverse Event|0
6366847|NCT03677934|10156800|FG000|Overall Study|Death|2
6366848|NCT03677934|10156801|FG001|Overall Study|Death|0
6366849|NCT03677934|10156800|FG000|Overall Study|Withdrawal by Subject|0
6366850|NCT03677934|10156801|FG001|Overall Study|Withdrawal by Subject|5
6366851|NCT03677934|10156800|FG000|Overall Study|Physician Decision|0
6366852|NCT03677934|10156801|FG001|Overall Study|Physician Decision|1
6366853|NCT03677934|10156800|FG000|Overall Study|Damaged implant (no associated AE reported)|1
6366854|NCT03677934|10156801|FG001|Overall Study|Damaged implant (no associated AE reported)|0
6084515|NCT00642941|9693396|FG005|Overall Study|Other|1
6084516|NCT00642941|9693397|FG006|Overall Study|Other|0
6366855|NCT03575104|10156843|FG000|Overall Study|Adverse Event|4
6366856|NCT03575104|10156844|FG001|Overall Study|Adverse Event|3
6366857|NCT03575104|10156845|FG002|Overall Study|Adverse Event|4
6366858|NCT03575104|10156843|FG000|Overall Study|Withdrawal by Subject|13
6366859|NCT03575104|10156844|FG001|Overall Study|Withdrawal by Subject|16
6366860|NCT03575104|10156845|FG002|Overall Study|Withdrawal by Subject|11
6366861|NCT03575104|10156843|FG000|Overall Study|Other reasons|6
6366862|NCT03575104|10156844|FG001|Overall Study|Other reasons|8
6366863|NCT03575104|10156845|FG002|Overall Study|Other reasons|6
6366864|NCT03575104|10156843|FG000|Overall Study|Lost to Follow-up|1
6366865|NCT03575104|10156844|FG001|Overall Study|Lost to Follow-up|2
6366866|NCT03575104|10156845|FG002|Overall Study|Lost to Follow-up|1
6366867|NCT03569475|10156856|FG000|Double-blind Treatment Period (8 Weeks)|Adverse Event|1
6366868|NCT03569475|10156857|FG001|Double-blind Treatment Period (8 Weeks)|Adverse Event|2
6366869|NCT03569475|10156858|FG002|Double-blind Treatment Period (8 Weeks)|Adverse Event|5
6366870|NCT03569475|10156856|FG000|Double-blind Treatment Period (8 Weeks)|Lack of Efficacy|0
6366871|NCT03569475|10156857|FG001|Double-blind Treatment Period (8 Weeks)|Lack of Efficacy|1
6366872|NCT03569475|10156858|FG002|Double-blind Treatment Period (8 Weeks)|Lack of Efficacy|0
6366873|NCT03569475|10156856|FG000|Double-blind Treatment Period (8 Weeks)|Withdrawal by Subject|7
6366874|NCT03569475|10156857|FG001|Double-blind Treatment Period (8 Weeks)|Withdrawal by Subject|10
6366875|NCT03569475|10156858|FG002|Double-blind Treatment Period (8 Weeks)|Withdrawal by Subject|9
6366876|NCT03569475|10156856|FG000|Double-blind Treatment Period (8 Weeks)|Lost to Follow-up|7
6366877|NCT03569475|10156857|FG001|Double-blind Treatment Period (8 Weeks)|Lost to Follow-up|7
6366878|NCT03569475|10156858|FG002|Double-blind Treatment Period (8 Weeks)|Lost to Follow-up|6
6366879|NCT03569475|10156856|FG000|Double-blind Treatment Period (8 Weeks)|Protocol Deviation|1
6366880|NCT03569475|10156857|FG001|Double-blind Treatment Period (8 Weeks)|Protocol Deviation|1
6366881|NCT03569475|10156858|FG002|Double-blind Treatment Period (8 Weeks)|Protocol Deviation|1
6366882|NCT03569475|10156856|FG000|Double-blind Treatment Period (8 Weeks)|Non-compliance with Study Drug|1
6366883|NCT03569475|10156857|FG001|Double-blind Treatment Period (8 Weeks)|Non-compliance with Study Drug|1
6366884|NCT03569475|10156858|FG002|Double-blind Treatment Period (8 Weeks)|Non-compliance with Study Drug|1
6366885|NCT03569475|10156856|FG000|Double-blind Treatment Period (8 Weeks)|Reason not Specified|1
6366886|NCT03569475|10156857|FG001|Double-blind Treatment Period (8 Weeks)|Reason not Specified|1
6366887|NCT03569475|10156858|FG002|Double-blind Treatment Period (8 Weeks)|Reason not Specified|2
6366888|NCT03569475|10156856|FG000|Double-blind Down-taper Period (1 Week)|Lost to Follow-up|0
6366889|NCT03569475|10156857|FG001|Double-blind Down-taper Period (1 Week)|Lost to Follow-up|1
6366890|NCT03569475|10156858|FG002|Double-blind Down-taper Period (1 Week)|Lost to Follow-up|1
6366891|NCT03569475|10156856|FG000|Double-blind Down-taper Period (1 Week)|Withdrawal by Subject|0
6366892|NCT03569475|10156857|FG001|Double-blind Down-taper Period (1 Week)|Withdrawal by Subject|1
6366893|NCT03569475|10156858|FG002|Double-blind Down-taper Period (1 Week)|Withdrawal by Subject|1
6366894|NCT03545191|10156912|FG000|Overall Study|Death|1
6366895|NCT03545191|10156913|FG001|Overall Study|Death|0
6366896|NCT03545191|10156914|FG002|Overall Study|Death|0
6366897|NCT03545191|10156912|FG000|Overall Study|Adverse Event|4
6366898|NCT03545191|10156913|FG001|Overall Study|Adverse Event|2
6366899|NCT03545191|10156914|FG002|Overall Study|Adverse Event|7
6366900|NCT03545191|10156912|FG000|Overall Study|Other reasons|3
6366901|NCT03545191|10156913|FG001|Overall Study|Other reasons|11
6366902|NCT03545191|10156914|FG002|Overall Study|Other reasons|8
6366903|NCT03545191|10156912|FG000|Overall Study|Withdrawal by Subject|13
6366904|NCT03545191|10156913|FG001|Overall Study|Withdrawal by Subject|10
6366905|NCT03545191|10156914|FG002|Overall Study|Withdrawal by Subject|12
6366906|NCT03545191|10156912|FG000|Overall Study|Lost to Follow-up|1
6366907|NCT03545191|10156913|FG001|Overall Study|Lost to Follow-up|2
6366908|NCT03545191|10156914|FG002|Overall Study|Lost to Follow-up|3
6366909|NCT03500549|10156924|FG000|RCP (Day 1 - Week 16)|Adverse Event|3
6366910|NCT03500549|10156925|FG001|RCP (Day 1 - Week 16)|Adverse Event|0
6366911|NCT03500549|10156924|FG000|Open-label Period (Week 17 to Week 48)|Adverse Event|3
6366912|NCT03500549|10156925|FG001|Open-label Period (Week 17 to Week 48)|Adverse Event|7
6366913|NCT03456700|10156936|FG000|Overall Study|Withdrawal by Subject|1
6366914|NCT03427411|10156951|FG000|Overall Study|Screen failure - platelets too low|0
6366915|NCT03427411|10156952|FG001|Overall Study|Screen failure - platelets too low|1
6366916|NCT03387150|10156965|FG000|Overall Study|Withdrawal by Subject|3
6366917|NCT03387150|10156966|FG001|Overall Study|Withdrawal by Subject|0
6366918|NCT03387150|10156967|FG002|Overall Study|Withdrawal by Subject|3
6366919|NCT03387150|10156968|FG003|Overall Study|Withdrawal by Subject|4
6366920|NCT03387150|10156969|FG004|Overall Study|Withdrawal by Subject|1
6366921|NCT03387150|10156970|FG005|Overall Study|Withdrawal by Subject|2
6366922|NCT03387150|10156971|FG006|Overall Study|Withdrawal by Subject|0
6366923|NCT03387150|10156965|FG000|Overall Study|Lost to Follow-up|3
6366924|NCT03387150|10156966|FG001|Overall Study|Lost to Follow-up|2
6366925|NCT03387150|10156967|FG002|Overall Study|Lost to Follow-up|2
6366926|NCT03387150|10156968|FG003|Overall Study|Lost to Follow-up|3
6366927|NCT03387150|10156969|FG004|Overall Study|Lost to Follow-up|3
6366928|NCT03387150|10156970|FG005|Overall Study|Lost to Follow-up|3
6366929|NCT03387150|10156971|FG006|Overall Study|Lost to Follow-up|0
6366930|NCT03387150|10156965|FG000|Overall Study|Participant unable to adhere to visit|0
6366931|NCT03387150|10156966|FG001|Overall Study|Participant unable to adhere to visit|1
6366932|NCT03387150|10156967|FG002|Overall Study|Participant unable to adhere to visit|0
6366933|NCT03387150|10156968|FG003|Overall Study|Participant unable to adhere to visit|0
6366934|NCT03387150|10156969|FG004|Overall Study|Participant unable to adhere to visit|2
6366935|NCT03387150|10156970|FG005|Overall Study|Participant unable to adhere to visit|2
6366936|NCT03387150|10156971|FG006|Overall Study|Participant unable to adhere to visit|0
6366937|NCT03370133|10156990|FG000|Initial Treatment Period (WK 16)|Adverse Event|5
6366938|NCT03370133|10156991|FG001|Initial Treatment Period (WK 16)|Adverse Event|5
6366939|NCT03370133|10156992|FG002|Initial Treatment Period (WK 16)|Adverse Event|2
6366940|NCT03370133|10156993|FG003|Initial Treatment Period (WK 16)|Adverse Event|0
6366941|NCT03370133|10156994|FG004|Initial Treatment Period (WK 16)|Adverse Event|0
6366942|NCT03370133|10156995|FG005|Initial Treatment Period (WK 16)|Adverse Event|0
6366943|NCT03370133|10156990|FG000|Initial Treatment Period (WK 16)|Death|1
6366944|NCT03370133|10156991|FG001|Initial Treatment Period (WK 16)|Death|1
6366945|NCT03370133|10156992|FG002|Initial Treatment Period (WK 16)|Death|1
6366946|NCT03370133|10156993|FG003|Initial Treatment Period (WK 16)|Death|0
6366947|NCT03370133|10156994|FG004|Initial Treatment Period (WK 16)|Death|0
6366948|NCT03370133|10156995|FG005|Initial Treatment Period (WK 16)|Death|0
6366949|NCT03370133|10156990|FG000|Initial Treatment Period (WK 16)|Lack of Efficacy|2
6366950|NCT03370133|10156991|FG001|Initial Treatment Period (WK 16)|Lack of Efficacy|1
6366951|NCT03370133|10156992|FG002|Initial Treatment Period (WK 16)|Lack of Efficacy|0
6366952|NCT03370133|10156993|FG003|Initial Treatment Period (WK 16)|Lack of Efficacy|0
6366953|NCT03370133|10156994|FG004|Initial Treatment Period (WK 16)|Lack of Efficacy|0
6366954|NCT03370133|10156995|FG005|Initial Treatment Period (WK 16)|Lack of Efficacy|0
6366955|NCT03370133|10156990|FG000|Initial Treatment Period (WK 16)|Protocol Violation|0
6366956|NCT03370133|10156991|FG001|Initial Treatment Period (WK 16)|Protocol Violation|0
6366957|NCT03370133|10156992|FG002|Initial Treatment Period (WK 16)|Protocol Violation|2
6366958|NCT03370133|10156993|FG003|Initial Treatment Period (WK 16)|Protocol Violation|0
6366959|NCT03370133|10156994|FG004|Initial Treatment Period (WK 16)|Protocol Violation|0
6366960|NCT03370133|10156995|FG005|Initial Treatment Period (WK 16)|Protocol Violation|0
6366961|NCT03370133|10156990|FG000|Initial Treatment Period (WK 16)|Lost to Follow-up|0
6366962|NCT03370133|10156991|FG001|Initial Treatment Period (WK 16)|Lost to Follow-up|3
6366963|NCT03370133|10156992|FG002|Initial Treatment Period (WK 16)|Lost to Follow-up|0
6366964|NCT03370133|10156993|FG003|Initial Treatment Period (WK 16)|Lost to Follow-up|0
6366965|NCT03370133|10156994|FG004|Initial Treatment Period (WK 16)|Lost to Follow-up|0
6366966|NCT03370133|10156995|FG005|Initial Treatment Period (WK 16)|Lost to Follow-up|0
6366967|NCT03370133|10156990|FG000|Initial Treatment Period (WK 16)|Withdrawal by Subject|1
6366968|NCT03370133|10156991|FG001|Initial Treatment Period (WK 16)|Withdrawal by Subject|2
6366969|NCT03370133|10156992|FG002|Initial Treatment Period (WK 16)|Withdrawal by Subject|1
6366970|NCT03370133|10156993|FG003|Initial Treatment Period (WK 16)|Withdrawal by Subject|0
6366971|NCT03370133|10156994|FG004|Initial Treatment Period (WK 16)|Withdrawal by Subject|0
6366972|NCT03370133|10156995|FG005|Initial Treatment Period (WK 16)|Withdrawal by Subject|0
6366973|NCT03370133|10156990|FG000|Initial Treatment Period (WK 16)|Non-compliance|0
6366974|NCT03370133|10156991|FG001|Initial Treatment Period (WK 16)|Non-compliance|1
6366975|NCT03370133|10156992|FG002|Initial Treatment Period (WK 16)|Non-compliance|0
6366976|NCT03370133|10156993|FG003|Initial Treatment Period (WK 16)|Non-compliance|0
6366977|NCT03370133|10156994|FG004|Initial Treatment Period (WK 16)|Non-compliance|0
6366978|NCT03370133|10156995|FG005|Initial Treatment Period (WK 16)|Non-compliance|0
6366979|NCT03370133|10156990|FG000|Initial Treatment Period (WK 16)|Site closed|0
6366980|NCT03370133|10156991|FG001|Initial Treatment Period (WK 16)|Site closed|2
6366981|NCT03370133|10156992|FG002|Initial Treatment Period (WK 16)|Site closed|0
6366982|NCT03370133|10156993|FG003|Initial Treatment Period (WK 16)|Site closed|0
6366983|NCT03370133|10156994|FG004|Initial Treatment Period (WK 16)|Site closed|0
6366984|NCT03370133|10156995|FG005|Initial Treatment Period (WK 16)|Site closed|0
6366985|NCT03370133|10156990|FG000|Maintenance Treatment Period (WK 52)|Adverse Event|0
6366986|NCT03370133|10156991|FG001|Maintenance Treatment Period (WK 52)|Adverse Event|0
6366987|NCT03370133|10156992|FG002|Maintenance Treatment Period (WK 52)|Adverse Event|0
6366988|NCT03370133|10156993|FG003|Maintenance Treatment Period (WK 52)|Adverse Event|3
6366989|NCT03370133|10156994|FG004|Maintenance Treatment Period (WK 52)|Adverse Event|12
6366990|NCT03370133|10156995|FG005|Maintenance Treatment Period (WK 52)|Adverse Event|4
6366991|NCT03370133|10156990|FG000|Maintenance Treatment Period (WK 52)|Lack of Efficacy|0
6366992|NCT03370133|10156991|FG001|Maintenance Treatment Period (WK 52)|Lack of Efficacy|0
6366993|NCT03370133|10156992|FG002|Maintenance Treatment Period (WK 52)|Lack of Efficacy|0
6366994|NCT03370133|10156993|FG003|Maintenance Treatment Period (WK 52)|Lack of Efficacy|0
6366995|NCT03370133|10156994|FG004|Maintenance Treatment Period (WK 52)|Lack of Efficacy|1
6366996|NCT03370133|10156995|FG005|Maintenance Treatment Period (WK 52)|Lack of Efficacy|4
6366997|NCT03370133|10156990|FG000|Maintenance Treatment Period (WK 52)|Protocol Violation|0
6366998|NCT03370133|10156991|FG001|Maintenance Treatment Period (WK 52)|Protocol Violation|0
6366999|NCT03370133|10156992|FG002|Maintenance Treatment Period (WK 52)|Protocol Violation|0
6367000|NCT03370133|10156993|FG003|Maintenance Treatment Period (WK 52)|Protocol Violation|1
6367001|NCT03370133|10156994|FG004|Maintenance Treatment Period (WK 52)|Protocol Violation|1
6367002|NCT03370133|10156995|FG005|Maintenance Treatment Period (WK 52)|Protocol Violation|0
6367003|NCT03370133|10156990|FG000|Maintenance Treatment Period (WK 52)|Lost to Follow-up|0
6367004|NCT03370133|10156991|FG001|Maintenance Treatment Period (WK 52)|Lost to Follow-up|0
6367005|NCT03370133|10156992|FG002|Maintenance Treatment Period (WK 52)|Lost to Follow-up|0
6367006|NCT03370133|10156993|FG003|Maintenance Treatment Period (WK 52)|Lost to Follow-up|0
6367007|NCT03370133|10156994|FG004|Maintenance Treatment Period (WK 52)|Lost to Follow-up|4
6367008|NCT03370133|10156995|FG005|Maintenance Treatment Period (WK 52)|Lost to Follow-up|3
6367009|NCT03370133|10156990|FG000|Maintenance Treatment Period (WK 52)|Withdrawal by Subject|0
6367010|NCT03370133|10156991|FG001|Maintenance Treatment Period (WK 52)|Withdrawal by Subject|0
6367011|NCT03370133|10156992|FG002|Maintenance Treatment Period (WK 52)|Withdrawal by Subject|0
6367012|NCT03370133|10156993|FG003|Maintenance Treatment Period (WK 52)|Withdrawal by Subject|1
6367013|NCT03370133|10156994|FG004|Maintenance Treatment Period (WK 52)|Withdrawal by Subject|4
6367014|NCT03370133|10156995|FG005|Maintenance Treatment Period (WK 52)|Withdrawal by Subject|4
6367015|NCT03370133|10156990|FG000|Maintenance Treatment Period (WK 52)|Non-compliance|0
6367016|NCT03370133|10156991|FG001|Maintenance Treatment Period (WK 52)|Non-compliance|0
6367017|NCT03370133|10156992|FG002|Maintenance Treatment Period (WK 52)|Non-compliance|0
6367018|NCT03370133|10156993|FG003|Maintenance Treatment Period (WK 52)|Non-compliance|0
6367019|NCT03370133|10156994|FG004|Maintenance Treatment Period (WK 52)|Non-compliance|1
6367020|NCT03370133|10156995|FG005|Maintenance Treatment Period (WK 52)|Non-compliance|0
6367021|NCT03370133|10156990|FG000|Maintenance Treatment Period (WK 52)|Consent Withdrawn for IMP Not Procedures|0
6367022|NCT03370133|10156991|FG001|Maintenance Treatment Period (WK 52)|Consent Withdrawn for IMP Not Procedures|0
6367023|NCT03370133|10156992|FG002|Maintenance Treatment Period (WK 52)|Consent Withdrawn for IMP Not Procedures|0
6367024|NCT03370133|10156993|FG003|Maintenance Treatment Period (WK 52)|Consent Withdrawn for IMP Not Procedures|0
6367025|NCT03370133|10156994|FG004|Maintenance Treatment Period (WK 52)|Consent Withdrawn for IMP Not Procedures|0
6367026|NCT03370133|10156995|FG005|Maintenance Treatment Period (WK 52)|Consent Withdrawn for IMP Not Procedures|1
6367027|NCT03366792|10157013|FG000|Overall Study|Withdrawal by Subject|7
6367028|NCT03366792|10157013|FG000|Overall Study|Lost to Follow-up|2
6367029|NCT03366792|10157013|FG000|Overall Study|Ineligible (could not reach perinium)|2
6367030|NCT03366792|10157013|FG000|Overall Study|Study Closure (interim analysis showed no significant results)|4
6367031|NCT03366337|10157021|FG000|Overall Study|Lost to Follow-up|1
6367032|NCT03366337|10157022|FG001|Overall Study|Lost to Follow-up|0
6367033|NCT03366337|10157023|FG002|Overall Study|Lost to Follow-up|1
6367034|NCT03366337|10157024|FG003|Overall Study|Lost to Follow-up|0
6367035|NCT03366337|10157021|FG000|Overall Study|Withdrawal by Subject|2
6367036|NCT03366337|10157022|FG001|Overall Study|Withdrawal by Subject|0
6367037|NCT03366337|10157023|FG002|Overall Study|Withdrawal by Subject|1
6367038|NCT03366337|10157024|FG003|Overall Study|Withdrawal by Subject|1
6367039|NCT03342053|10157036|FG000|Overall Study|Adverse Event|2
6367040|NCT03342053|10157037|FG001|Overall Study|Adverse Event|0
6367041|NCT03342053|10157036|FG000|Overall Study|Withdrawal by Subject|0
6367042|NCT03342053|10157037|FG001|Overall Study|Withdrawal by Subject|1
6367043|NCT03330847|10157046|FG000|Overall Study|Patients ongoing study|62
6367044|NCT03330847|10157047|FG001|Overall Study|Patients ongoing study|65
6367045|NCT03330847|10157048|FG002|Overall Study|Patients ongoing study|15
6367046|NCT03283241|10157060|FG000|Overall Study|Adverse Event|4
6367047|NCT03283241|10157061|FG001|Overall Study|Adverse Event|1
6367048|NCT03283241|10157060|FG000|Overall Study|Withdrawal by Subject|0
6367049|NCT03283241|10157061|FG001|Overall Study|Withdrawal by Subject|1
6367050|NCT03283241|10157060|FG000|Overall Study|Subject relocated to Finland|0
6367051|NCT03283241|10157061|FG001|Overall Study|Subject relocated to Finland|1
6367052|NCT03242772|10157069|FG000|Overall Study|Lost to Follow-up|2
6367053|NCT03242772|10157070|FG001|Overall Study|Lost to Follow-up|0
6367054|NCT03242772|10157069|FG000|Overall Study|Physician Decision|0
6367055|NCT03242772|10157070|FG001|Overall Study|Physician Decision|1
6367056|NCT03242772|10157069|FG000|Overall Study|Withdrawal by Subject|1
6367057|NCT03242772|10157070|FG001|Overall Study|Withdrawal by Subject|0
6367058|NCT03236311|10157078|FG000|Overall Study|Study terminated by sponsor|0
6367059|NCT03236311|10157079|FG001|Overall Study|Study terminated by sponsor|2
6367060|NCT03236311|10157078|FG000|Overall Study|Adverse Event|0
6367061|NCT03236311|10157079|FG001|Overall Study|Adverse Event|1
6367062|NCT03192046|10157096|FG000|Overall Study|Withdrawal by Subject|1
6367063|NCT03192046|10157097|FG001|Overall Study|Withdrawal by Subject|1
6367064|NCT03190369|10157105|FG000|Overall Study|Poor compliance to protocol|0
6367065|NCT03190369|10157106|FG001|Overall Study|Poor compliance to protocol|1
6367066|NCT03190369|10157105|FG000|Overall Study|Withdraw before treatment|1
6367067|NCT03190369|10157106|FG001|Overall Study|Withdraw before treatment|5
6367068|NCT03190369|10157105|FG000|Overall Study|Randomized but not treated|0
6367069|NCT03190369|10157106|FG001|Overall Study|Randomized but not treated|2
6367070|NCT03178487|10157114|FG000|Overall Study|Adverse Event|1
6367071|NCT03178487|10157115|FG001|Overall Study|Adverse Event|1
6367072|NCT03178487|10157114|FG000|Overall Study|Withdrawal by Subject|2
6367073|NCT03178487|10157115|FG001|Overall Study|Withdrawal by Subject|1
6367074|NCT03178487|10157114|FG000|Overall Study|Lost to Follow-up|1
6367075|NCT03178487|10157115|FG001|Overall Study|Lost to Follow-up|0
6367076|NCT03178487|10157114|FG000|Overall Study|Other|0
6367077|NCT03178487|10157115|FG001|Overall Study|Other|2
6367078|NCT03106779|10157128|FG000|Overall Study|Lack of Efficacy|33
6367079|NCT03106779|10157129|FG001|Overall Study|Lack of Efficacy|24
6367080|NCT03106779|10157128|FG000|Overall Study|Adverse Event|8
6367081|NCT03106779|10157129|FG001|Overall Study|Adverse Event|16
6367082|NCT03106779|10157128|FG000|Overall Study|Physician Decision|10
6367083|NCT03106779|10157129|FG001|Overall Study|Physician Decision|6
6367084|NCT03106779|10157128|FG000|Overall Study|Patient/guardian decision|4
6367085|NCT03106779|10157129|FG001|Overall Study|Patient/guardian decision|3
6367086|NCT03106779|10157128|FG000|Overall Study|Progressive disease|1
6367087|NCT03106779|10157129|FG001|Overall Study|Progressive disease|3
6367088|NCT03106779|10157128|FG000|Overall Study|Lost to Follow-up|1
6367089|NCT03106779|10157129|FG001|Overall Study|Lost to Follow-up|2
6367090|NCT03106779|10157128|FG000|Overall Study|Death|1
6367091|NCT03106779|10157129|FG001|Overall Study|Death|0
6367092|NCT03106779|10157128|FG000|Overall Study|Protocol Violation|1
6367093|NCT03106779|10157129|FG001|Overall Study|Protocol Violation|0
6367094|NCT03106779|10157128|FG000|Overall Study|Not treated|1
6367095|NCT03106779|10157129|FG001|Overall Study|Not treated|0
6367096|NCT03096834|10157137|FG000|Double-Blind Treatment Epoch|Protocol deviation|2
6367097|NCT03096834|10157138|FG001|Double-Blind Treatment Epoch|Protocol deviation|1
6367098|NCT03096834|10157139|FG002|Double-Blind Treatment Epoch|Protocol deviation|0
6367099|NCT03096834|10157140|FG003|Double-Blind Treatment Epoch|Protocol deviation|0
6367100|NCT03096834|10157137|FG000|Double-Blind Treatment Epoch|Pregnancy|0
6367101|NCT03096834|10157138|FG001|Double-Blind Treatment Epoch|Pregnancy|1
6367102|NCT03096834|10157139|FG002|Double-Blind Treatment Epoch|Pregnancy|0
6367103|NCT03096834|10157140|FG003|Double-Blind Treatment Epoch|Pregnancy|0
6367104|NCT03096834|10157137|FG000|Double-Blind Treatment Epoch|Subject/guardian decision|1
6367105|NCT03096834|10157138|FG001|Double-Blind Treatment Epoch|Subject/guardian decision|1
6367106|NCT03096834|10157139|FG002|Double-Blind Treatment Epoch|Subject/guardian decision|0
6367107|NCT03096834|10157140|FG003|Double-Blind Treatment Epoch|Subject/guardian decision|0
6367108|NCT03096834|10157137|FG000|Open-Label Treatment Epoch|Lack of Efficacy|0
6367109|NCT03096834|10157138|FG001|Open-Label Treatment Epoch|Lack of Efficacy|0
6367110|NCT03096834|10157139|FG002|Open-Label Treatment Epoch|Lack of Efficacy|15
6367111|NCT03096834|10157140|FG003|Open-Label Treatment Epoch|Lack of Efficacy|15
6367112|NCT03096834|10157137|FG000|Open-Label Treatment Epoch|Adverse Event|0
6367113|NCT03096834|10157138|FG001|Open-Label Treatment Epoch|Adverse Event|0
6367114|NCT03096834|10157139|FG002|Open-Label Treatment Epoch|Adverse Event|5
6367115|NCT03096834|10157140|FG003|Open-Label Treatment Epoch|Adverse Event|6
6367116|NCT03096834|10157137|FG000|Open-Label Treatment Epoch|New therapy for study indication|0
6367117|NCT03096834|10157138|FG001|Open-Label Treatment Epoch|New therapy for study indication|0
6367118|NCT03096834|10157139|FG002|Open-Label Treatment Epoch|New therapy for study indication|1
6367119|NCT03096834|10157140|FG003|Open-Label Treatment Epoch|New therapy for study indication|1
6367120|NCT03096834|10157137|FG000|Open-Label Treatment Epoch|Physician Decision|0
6367121|NCT03096834|10157138|FG001|Open-Label Treatment Epoch|Physician Decision|0
6367122|NCT03096834|10157139|FG002|Open-Label Treatment Epoch|Physician Decision|1
6367123|NCT03096834|10157140|FG003|Open-Label Treatment Epoch|Physician Decision|0
6367124|NCT03096834|10157137|FG000|Open-Label Treatment Epoch|Pregnancy|0
6367125|NCT03096834|10157138|FG001|Open-Label Treatment Epoch|Pregnancy|0
6367126|NCT03096834|10157139|FG002|Open-Label Treatment Epoch|Pregnancy|1
6367127|NCT03096834|10157140|FG003|Open-Label Treatment Epoch|Pregnancy|0
6367128|NCT03096834|10157137|FG000|Open-Label Treatment Epoch|Subject/guardian decision|0
6367129|NCT03096834|10157138|FG001|Open-Label Treatment Epoch|Subject/guardian decision|0
6367130|NCT03096834|10157139|FG002|Open-Label Treatment Epoch|Subject/guardian decision|9
6367131|NCT03096834|10157140|FG003|Open-Label Treatment Epoch|Subject/guardian decision|17
6367132|NCT03096834|10157137|FG000|Safety Follow-Up Epoch|New therapy for study indication|0
6367133|NCT03096834|10157138|FG001|Safety Follow-Up Epoch|New therapy for study indication|0
6367134|NCT03096834|10157139|FG002|Safety Follow-Up Epoch|New therapy for study indication|0
6367135|NCT03096834|10157140|FG003|Safety Follow-Up Epoch|New therapy for study indication|1
6367136|NCT03096834|10157137|FG000|Safety Follow-Up Epoch|Protocol deviation|0
6367137|NCT03096834|10157138|FG001|Safety Follow-Up Epoch|Protocol deviation|0
6367138|NCT03096834|10157139|FG002|Safety Follow-Up Epoch|Protocol deviation|0
6367139|NCT03096834|10157140|FG003|Safety Follow-Up Epoch|Protocol deviation|1
6367140|NCT03096834|10157137|FG000|Safety Follow-Up Epoch|Lost to Follow-up|0
6367141|NCT03096834|10157138|FG001|Safety Follow-Up Epoch|Lost to Follow-up|0
6367142|NCT03096834|10157139|FG002|Safety Follow-Up Epoch|Lost to Follow-up|1
6367143|NCT03096834|10157140|FG003|Safety Follow-Up Epoch|Lost to Follow-up|0
6367144|NCT03089853|10157151|FG000|Overall Study|Lost to Follow-up|2
6367145|NCT03089853|10157152|FG001|Overall Study|Lost to Follow-up|1
6367146|NCT03070392|10157160|FG000|Overall Study|Not Treated|7
6367147|NCT03070392|10157161|FG001|Overall Study|Not Treated|0
6367148|NCT03070392|10157162|FG002|Overall Study|Not Treated|3
6367149|NCT03070392|10157163|FG003|Overall Study|Not Treated|12
6367150|NCT03070392|10157160|FG000|Overall Study|Death|3
6367151|NCT03070392|10157161|FG001|Overall Study|Death|0
6367152|NCT03070392|10157162|FG002|Overall Study|Death|0
6367153|NCT03070392|10157163|FG003|Overall Study|Death|1
6367154|NCT03070392|10157160|FG000|Overall Study|Withdrawal by Subject|7
6367155|NCT03070392|10157161|FG001|Overall Study|Withdrawal by Subject|0
6367156|NCT03070392|10157162|FG002|Overall Study|Withdrawal by Subject|0
6367157|NCT03070392|10157163|FG003|Overall Study|Withdrawal by Subject|3
6367158|NCT03070392|10157160|FG000|Overall Study|Physician Decision|1
6367159|NCT03070392|10157161|FG001|Overall Study|Physician Decision|0
6367160|NCT03070392|10157162|FG002|Overall Study|Physician Decision|0
6367161|NCT03070392|10157163|FG003|Overall Study|Physician Decision|2
6367162|NCT03070392|10157160|FG000|Overall Study|Progressive Disease|154
6367163|NCT03070392|10157161|FG001|Overall Study|Progressive Disease|6
6367164|NCT03070392|10157162|FG002|Overall Study|Progressive Disease|2
6367165|NCT03070392|10157163|FG003|Overall Study|Progressive Disease|70
6367166|NCT03070392|10157160|FG000|Overall Study|Adverse Event|6
6367167|NCT03070392|10157161|FG001|Overall Study|Adverse Event|1
6367168|NCT03070392|10157162|FG002|Overall Study|Adverse Event|1
6367169|NCT03070392|10157163|FG003|Overall Study|Adverse Event|3
6367170|NCT03070392|10157160|FG000|Overall Study|Alternate anticancer treatment|1
6367171|NCT03070392|10157161|FG001|Overall Study|Alternate anticancer treatment|0
6367172|NCT03070392|10157162|FG002|Overall Study|Alternate anticancer treatment|0
6367173|NCT03070392|10157163|FG003|Overall Study|Alternate anticancer treatment|1
6367174|NCT03070392|10157160|FG000|Overall Study|Ongoing|73
6367175|NCT03070392|10157161|FG001|Overall Study|Ongoing|0
6367176|NCT03070392|10157162|FG002|Overall Study|Ongoing|0
6367177|NCT03070392|10157163|FG003|Overall Study|Ongoing|11
6367178|NCT03048578|10157171|FG000|Overall Study|Withdrawal by Subject|5
6367179|NCT03048578|10157172|FG001|Overall Study|Withdrawal by Subject|6
6367180|NCT03048578|10157171|FG000|Overall Study|Lost to Follow-up|22
6367181|NCT03048578|10157172|FG001|Overall Study|Lost to Follow-up|10
6367182|NCT03048578|10157171|FG000|Overall Study|Adverse Event|1
6367183|NCT03048578|10157172|FG001|Overall Study|Adverse Event|2
6367184|NCT03048578|10157171|FG000|Overall Study|Terminated|3
6367185|NCT03048578|10157172|FG001|Overall Study|Terminated|2
6367186|NCT03015194|10157178|FG000|Overall Study|Death|10
6367187|NCT03015194|10157178|FG000|Overall Study|Withdrawal by Subject|2
6367188|NCT03012815|10157185|FG000|Overall Study|Lost to Follow-up|1
6367189|NCT03012815|10157186|FG001|Overall Study|Lost to Follow-up|0
6367190|NCT03012815|10157185|FG000|Overall Study|Physician Decision|3
6367191|NCT03012815|10157186|FG001|Overall Study|Physician Decision|2
6367192|NCT03012815|10157185|FG000|Overall Study|Adverse Event|1
6367193|NCT03012815|10157186|FG001|Overall Study|Adverse Event|0
6367194|NCT03001011|10157195|FG000|Overall Study|Adverse Event|9
6367195|NCT03001011|10157196|FG001|Overall Study|Adverse Event|3
6367196|NCT03001011|10157195|FG000|Overall Study|Chronic kidney disease lead to dialysis|15
6367197|NCT03001011|10157196|FG001|Overall Study|Chronic kidney disease lead to dialysis|10
6367198|NCT03001011|10157195|FG000|Overall Study|Other than specified above|3
6367199|NCT03001011|10157196|FG001|Overall Study|Other than specified above|8
6367200|NCT02999633|10157203|FG000|Overall Study|Adverse Event|2
6367201|NCT02999633|10157203|FG000|Overall Study|Progressive disease|12
6367202|NCT02993757|10157209|FG000|Overall Study|Non compliance with the protocol|155
6367203|NCT02993757|10157210|FG001|Overall Study|Non compliance with the protocol|170
6367204|NCT02993757|10157209|FG000|Overall Study|Lost to Follow-up|1
6367205|NCT02993757|10157210|FG001|Overall Study|Lost to Follow-up|0
6367206|NCT02993757|10157209|FG000|Overall Study|Voluntary withdraw not due adverse event|8
6367207|NCT02993757|10157210|FG001|Overall Study|Voluntary withdraw not due adverse event|8
6367208|NCT02992418|10157218|FG000|Overall Study|Withdrawal by Subject|11
6367209|NCT02992418|10157219|FG001|Overall Study|Withdrawal by Subject|12
6367210|NCT02992418|10157218|FG000|Overall Study|Non-compliance with the protocol|308
6367211|NCT02992418|10157219|FG001|Overall Study|Non-compliance with the protocol|308
6367212|NCT02992418|10157218|FG000|Overall Study|Lost to Follow-up|27
6367213|NCT02992418|10157219|FG001|Overall Study|Lost to Follow-up|22
6367214|NCT02979535|10157227|FG000|Overall Study|Non compliance with the protocol|78
6367215|NCT02979535|10157228|FG001|Overall Study|Non compliance with the protocol|82
6367216|NCT02979535|10157227|FG000|Overall Study|Consent withdrawn by participant|11
6367217|NCT02979535|10157228|FG001|Overall Study|Consent withdrawn by participant|18
6367218|NCT02979535|10157227|FG000|Overall Study|Lost to Follow-up|6
6367219|NCT02979535|10157228|FG001|Overall Study|Lost to Follow-up|1
6367220|NCT02978716|10157237|FG000|Overall Study|Death|25
6367221|NCT02978716|10157238|FG001|Overall Study|Death|13
6367222|NCT02978716|10157239|FG002|Overall Study|Death|20
6367223|NCT02978716|10157237|FG000|Overall Study|Lost to Follow-up|0
6367224|NCT02978716|10157238|FG001|Overall Study|Lost to Follow-up|0
6367225|NCT02978716|10157239|FG002|Overall Study|Lost to Follow-up|1
6367226|NCT02978716|10157237|FG000|Overall Study|Withdrawal by Subject|6
6367227|NCT02978716|10157238|FG001|Overall Study|Withdrawal by Subject|4
6367228|NCT02978716|10157239|FG002|Overall Study|Withdrawal by Subject|5
6367229|NCT02978716|10157237|FG000|Overall Study|Sponsor terminated|2
6367230|NCT02978716|10157238|FG001|Overall Study|Sponsor terminated|13
6367231|NCT02978716|10157239|FG002|Overall Study|Sponsor terminated|9
6367232|NCT02978716|10157237|FG000|Overall Study|Other|1
6367233|NCT02978716|10157238|FG001|Overall Study|Other|3
6367234|NCT02978716|10157239|FG002|Overall Study|Other|0
6367235|NCT02973321|10157254|FG000|Overall Study|Other than specified|0
6367236|NCT02973321|10157255|FG001|Overall Study|Other than specified|5
6367237|NCT02973321|10157256|FG002|Overall Study|Other than specified|3
6367238|NCT02973321|10157257|FG003|Overall Study|Other than specified|3
6367239|NCT02973321|10157258|FG004|Overall Study|Other than specified|1
6367240|NCT02973321|10157254|FG000|Overall Study|Lack of Efficacy|0
6367241|NCT02973321|10157255|FG001|Overall Study|Lack of Efficacy|0
6367242|NCT02973321|10157256|FG002|Overall Study|Lack of Efficacy|0
6367243|NCT02973321|10157257|FG003|Overall Study|Lack of Efficacy|0
6367244|NCT02973321|10157258|FG004|Overall Study|Lack of Efficacy|1
6367245|NCT02973321|10157254|FG000|Overall Study|Adverse Event|1
6367246|NCT02973321|10157255|FG001|Overall Study|Adverse Event|10
6367247|NCT02973321|10157256|FG002|Overall Study|Adverse Event|11
6367248|NCT02973321|10157257|FG003|Overall Study|Adverse Event|13
6367249|NCT02973321|10157258|FG004|Overall Study|Adverse Event|3
6084517|NCT00642941|9693398|FG007|Overall Study|Other|1
6084518|NCT00642941|9693399|FG008|Overall Study|Other|0
6084519|NCT00642941|9693400|FG009|Overall Study|Other|0
6084520|NCT00642941|9693401|FG010|Overall Study|Other|0
6084521|NCT00642941|9693402|FG011|Overall Study|Other|1
6084522|NCT00642941|9693391|FG000|Overall Study|Disease progression|60
6084523|NCT00642941|9693392|FG001|Overall Study|Disease progression|50
6084524|NCT00642941|9693393|FG002|Overall Study|Disease progression|5
6084525|NCT00642941|9693394|FG003|Overall Study|Disease progression|36
6084526|NCT00642941|9693395|FG004|Overall Study|Disease progression|23
6084527|NCT00642941|9693396|FG005|Overall Study|Disease progression|39
6171672|NCT01261611|9818586|FG001|Treatment Cycle 2|Withdrawal by Subject|0
6171673|NCT01261611|9818587|FG002|Treatment Cycle 2|Withdrawal by Subject|0
6171674|NCT01261611|9818585|FG000|Treatment Cycle 2|Adverse Event|1
6171675|NCT01261611|9818586|FG001|Treatment Cycle 2|Adverse Event|0
6171676|NCT01261611|9818587|FG002|Treatment Cycle 2|Adverse Event|0
6171677|NCT01261611|9818585|FG000|Treatment Cycle 2|Protocol Violation|2
6171678|NCT01261611|9818586|FG001|Treatment Cycle 2|Protocol Violation|0
6171679|NCT01261611|9818587|FG002|Treatment Cycle 2|Protocol Violation|0
6171680|NCT01261611|9818585|FG000|Treatment Cycle 2|Not otherwise specified|2
6171681|NCT01261611|9818586|FG001|Treatment Cycle 2|Not otherwise specified|0
6171682|NCT01261611|9818587|FG002|Treatment Cycle 2|Not otherwise specified|0
6084528|NCT00642941|9693397|FG006|Overall Study|Disease progression|18
6367250|NCT02943785|10157273|FG000|Overall Study|Adverse Event|112
6367251|NCT02943785|10157274|FG001|Overall Study|Adverse Event|97
6367252|NCT02943785|10157273|FG000|Overall Study|Withdrawal by Subject|63
6367253|NCT02943785|10157274|FG001|Overall Study|Withdrawal by Subject|126
6367254|NCT02943785|10157273|FG000|Overall Study|Physician Decision|23
6367255|NCT02943785|10157274|FG001|Overall Study|Physician Decision|47
6367256|NCT02943785|10157273|FG000|Overall Study|Death|46
6367257|NCT02943785|10157274|FG001|Overall Study|Death|46
6367258|NCT02943785|10157273|FG000|Overall Study|Lost to Follow-up|1
6367259|NCT02943785|10157274|FG001|Overall Study|Lost to Follow-up|0
6367260|NCT02943785|10157273|FG000|Overall Study|Other|16
6367261|NCT02943785|10157274|FG001|Overall Study|Other|19
6367262|NCT02943785|10157273|FG000|Overall Study|Did not receive any study medication|21
6367263|NCT02943785|10157274|FG001|Overall Study|Did not receive any study medication|28
6367264|NCT02937818|10157284|FG000|Overall Study|Participants decision|1
6367265|NCT02937818|10157285|FG001|Overall Study|Participants decision|0
6367266|NCT02937818|10157286|FG002|Overall Study|Participants decision|1
6367267|NCT02937818|10157287|FG003|Overall Study|Participants decision|1
6367268|NCT02937818|10157284|FG000|Overall Study|Adverse Event|2
6367269|NCT02937818|10157285|FG001|Overall Study|Adverse Event|4
6367270|NCT02937818|10157286|FG002|Overall Study|Adverse Event|1
6367271|NCT02937818|10157287|FG003|Overall Study|Adverse Event|1
6367272|NCT02937818|10157284|FG000|Overall Study|Disease progression|17
6367273|NCT02937818|10157285|FG001|Overall Study|Disease progression|14
6367274|NCT02937818|10157286|FG002|Overall Study|Disease progression|7
6367275|NCT02937818|10157287|FG003|Overall Study|Disease progression|18
6367276|NCT02937818|10157284|FG000|Overall Study|Participants ongoing durvalumab at Data cut off (DCO)|1
6367277|NCT02937818|10157285|FG001|Overall Study|Participants ongoing durvalumab at Data cut off (DCO)|2
6367278|NCT02937818|10157286|FG002|Overall Study|Participants ongoing durvalumab at Data cut off (DCO)|0
6367279|NCT02937818|10157287|FG003|Overall Study|Participants ongoing durvalumab at Data cut off (DCO)|0
6367280|NCT02937818|10157284|FG000|Overall Study|Condition under investigation worsened|0
6367281|NCT02937818|10157285|FG001|Overall Study|Condition under investigation worsened|0
6367282|NCT02937818|10157286|FG002|Overall Study|Condition under investigation worsened|1
6367283|NCT02937818|10157287|FG003|Overall Study|Condition under investigation worsened|0
6367284|NCT02937818|10157284|FG000|Overall Study|Participants ongoing ceralasertib and olaparib at DCO|0
6367285|NCT02937818|10157285|FG001|Overall Study|Participants ongoing ceralasertib and olaparib at DCO|0
6367286|NCT02937818|10157286|FG002|Overall Study|Participants ongoing ceralasertib and olaparib at DCO|0
6367287|NCT02937818|10157287|FG003|Overall Study|Participants ongoing ceralasertib and olaparib at DCO|1
6367288|NCT02923674|10157303|FG000|Overall Study|Clinic Closed Due to COVID-19|14
6367289|NCT02923674|10157304|FG001|Overall Study|Clinic Closed Due to COVID-19|11
6367290|NCT02923674|10157305|FG002|Overall Study|Clinic Closed Due to COVID-19|14
6367291|NCT02923674|10157303|FG000|Overall Study|Lost to Follow-up|7
6367292|NCT02923674|10157304|FG001|Overall Study|Lost to Follow-up|12
6367293|NCT02923674|10157305|FG002|Overall Study|Lost to Follow-up|7
6367294|NCT02923674|10157303|FG000|Overall Study|Problem with intervention|2
6367295|NCT02923674|10157304|FG001|Overall Study|Problem with intervention|2
6367296|NCT02923674|10157305|FG002|Overall Study|Problem with intervention|1
6367297|NCT02923674|10157303|FG000|Overall Study|Adverse Event|3
6367298|NCT02923674|10157304|FG001|Overall Study|Adverse Event|1
6367299|NCT02923674|10157305|FG002|Overall Study|Adverse Event|1
6367300|NCT02923674|10157303|FG000|Overall Study|Withdrawal by Subject|2
6367301|NCT02923674|10157304|FG001|Overall Study|Withdrawal by Subject|2
6367302|NCT02923674|10157305|FG002|Overall Study|Withdrawal by Subject|2
6367303|NCT02921971|10157315|FG000|Overall Study|Adverse Event|1
6367304|NCT02921971|10157316|FG001|Overall Study|Adverse Event|2
6367305|NCT02921971|10157315|FG000|Overall Study|Lack of Efficacy|3
6367306|NCT02921971|10157316|FG001|Overall Study|Lack of Efficacy|1
6367307|NCT02921971|10157315|FG000|Overall Study|Other than specified above|2
6367308|NCT02921971|10157316|FG001|Overall Study|Other than specified above|1
6367309|NCT02908685|10157334|FG000|Part 1 Exploratory|Withdrawal by Subject|0
6367310|NCT02908685|10157335|FG001|Part 1 Exploratory|Withdrawal by Subject|1
6367311|NCT02908685|10157336|FG002|Part 1 Exploratory|Withdrawal by Subject|0
6367312|NCT02908685|10157337|FG003|Part 1 Exploratory|Withdrawal by Subject|0
6367313|NCT02908685|10157338|FG004|Part 1 Exploratory|Withdrawal by Subject|0
6367314|NCT02908685|10157339|FG005|Part 1 Exploratory|Withdrawal by Subject|0
6367315|NCT02908685|10157340|FG006|Part 1 Exploratory|Withdrawal by Subject|0
6367316|NCT02908685|10157341|FG007|Part 1 Exploratory|Withdrawal by Subject|0
6367317|NCT02908685|10157342|FG008|Part 1 Exploratory|Withdrawal by Subject|0
6367318|NCT02908685|10157343|FG009|Part 1 Exploratory|Withdrawal by Subject|0
6367319|NCT02908685|10157344|FG010|Part 1 Exploratory|Withdrawal by Subject|0
6367320|NCT02908685|10157345|FG011|Part 1 Exploratory|Withdrawal by Subject|0
6367321|NCT02908685|10157334|FG000|Part 2 Confirmatory|Changed to Spinraza|0
6367322|NCT02908685|10157335|FG001|Part 2 Confirmatory|Changed to Spinraza|0
6227446|NCT01717313|9900162|FG001|Phase B (Weeks 24 to 54)|Study Terminated by Sponsor|4
6227447|NCT01717313|9900161|FG000|Phase B (Weeks 24 to 54)|Withdrawal by Subject|7
6227448|NCT01717313|9900162|FG001|Phase B (Weeks 24 to 54)|Withdrawal by Subject|9
6227449|NCT01717313|9900161|FG000|Phase B (Weeks 24 to 54)|Lost to Follow-up|1
6227450|NCT01717313|9900162|FG001|Phase B (Weeks 24 to 54)|Lost to Follow-up|3
6227451|NCT01717326|9900188|FG000|Overall Study|Death|0
6227452|NCT01717326|9900189|FG001|Overall Study|Death|0
6227453|NCT01717326|9900190|FG002|Overall Study|Death|0
6227454|NCT01717326|9900191|FG003|Overall Study|Death|0
6227455|NCT01717326|9900192|FG004|Overall Study|Death|0
6227456|NCT01717326|9900193|FG005|Overall Study|Death|0
6227457|NCT01717326|9900194|FG006|Overall Study|Death|0
6227458|NCT01717326|9900195|FG007|Overall Study|Death|0
6227459|NCT01717326|9900196|FG008|Overall Study|Death|0
6227460|NCT01717326|9900197|FG009|Overall Study|Death|0
6227461|NCT01717326|9900198|FG010|Overall Study|Death|1
6227462|NCT01717326|9900199|FG011|Overall Study|Death|0
6227463|NCT01717326|9900200|FG012|Overall Study|Death|0
6227464|NCT01717326|9900201|FG013|Overall Study|Death|0
6227465|NCT01717326|9900202|FG014|Overall Study|Death|0
6227466|NCT01717326|9900203|FG015|Overall Study|Death|0
6227467|NCT01717326|9900204|FG016|Overall Study|Death|0
6227468|NCT01717326|9900205|FG017|Overall Study|Death|0
6227469|NCT01717326|9900206|FG018|Overall Study|Death|0
6227470|NCT01717326|9900207|FG019|Overall Study|Death|0
6367323|NCT02908685|10157336|FG002|Part 2 Confirmatory|Changed to Spinraza|0
6367324|NCT02908685|10157337|FG003|Part 2 Confirmatory|Changed to Spinraza|0
6367325|NCT02908685|10157338|FG004|Part 2 Confirmatory|Changed to Spinraza|0
6367326|NCT02908685|10157339|FG005|Part 2 Confirmatory|Changed to Spinraza|0
6367327|NCT02908685|10157340|FG006|Part 2 Confirmatory|Changed to Spinraza|0
6367328|NCT02908685|10157341|FG007|Part 2 Confirmatory|Changed to Spinraza|0
6367329|NCT02908685|10157342|FG008|Part 2 Confirmatory|Changed to Spinraza|0
6367330|NCT02908685|10157343|FG009|Part 2 Confirmatory|Changed to Spinraza|0
6367331|NCT02908685|10157344|FG010|Part 2 Confirmatory|Changed to Spinraza|2
6367332|NCT02908685|10157345|FG011|Part 2 Confirmatory|Changed to Spinraza|1
6367333|NCT02908685|10157334|FG000|Part 2 Confirmatory|Changed to other treatment|0
6367334|NCT02908685|10157335|FG001|Part 2 Confirmatory|Changed to other treatment|0
6367335|NCT02908685|10157336|FG002|Part 2 Confirmatory|Changed to other treatment|0
6367336|NCT02908685|10157337|FG003|Part 2 Confirmatory|Changed to other treatment|0
6367337|NCT02908685|10157338|FG004|Part 2 Confirmatory|Changed to other treatment|0
6367338|NCT02908685|10157339|FG005|Part 2 Confirmatory|Changed to other treatment|0
6367339|NCT02908685|10157340|FG006|Part 2 Confirmatory|Changed to other treatment|0
6367340|NCT02908685|10157341|FG007|Part 2 Confirmatory|Changed to other treatment|0
6367341|NCT02908685|10157342|FG008|Part 2 Confirmatory|Changed to other treatment|0
6367342|NCT02908685|10157343|FG009|Part 2 Confirmatory|Changed to other treatment|0
6367343|NCT02908685|10157344|FG010|Part 2 Confirmatory|Changed to other treatment|1
6367344|NCT02908685|10157345|FG011|Part 2 Confirmatory|Changed to other treatment|0
6367345|NCT02886286|10157364|FG000|Overall Study|pump motor stall|0
6084529|NCT00642941|9693398|FG007|Overall Study|Disease progression|12
6084530|NCT00642941|9693399|FG008|Overall Study|Disease progression|10
6084531|NCT00642941|9693400|FG009|Overall Study|Disease progression|7
6084532|NCT00642941|9693401|FG010|Overall Study|Disease progression|12
6367346|NCT02886286|10157365|FG001|Overall Study|pump motor stall|1
6367347|NCT02874742|10157374|FG000|Overall Study|Death|3
6367348|NCT02874742|10157375|FG001|Overall Study|Death|1
6367349|NCT02874742|10157376|FG002|Overall Study|Death|1
6367350|NCT02874742|10157374|FG000|Overall Study|Lost to Follow-up|2
6367351|NCT02874742|10157375|FG001|Overall Study|Lost to Follow-up|0
6367352|NCT02874742|10157376|FG002|Overall Study|Lost to Follow-up|0
6367353|NCT02874742|10157374|FG000|Overall Study|Withdrawal by Subject|8
6367354|NCT02874742|10157375|FG001|Overall Study|Withdrawal by Subject|4
6367355|NCT02874742|10157376|FG002|Overall Study|Withdrawal by Subject|0
6367356|NCT02874742|10157374|FG000|Overall Study|Other|3
6367357|NCT02874742|10157375|FG001|Overall Study|Other|1
6367358|NCT02874742|10157376|FG002|Overall Study|Other|0
6043252|NCT00388297|9641789|FG002|Overall Study|Lost to Follow-up|11
6367359|NCT02874742|10157374|FG000|Overall Study|Ongoing|87
6367360|NCT02874742|10157375|FG001|Overall Study|Ongoing|98
6367361|NCT02874742|10157376|FG002|Overall Study|Ongoing|15
6043253|NCT00388297|9641790|FG003|Overall Study|Lost to Follow-up|8
6043254|NCT00388349|9641800|FG000|Phase I Dose Escalation|Dose reduction due to DLT|0
6043255|NCT00388349|9641801|FG001|Phase I Dose Escalation|Dose reduction due to DLT|3
6049025|NCT00420927|9648202|FG003|Period 2|Methotrexate intolerance|0
6049026|NCT00420927|9648203|FG004|Period 2|Methotrexate intolerance|0
6049027|NCT00420927|9648204|FG005|Period 2|Methotrexate intolerance|0
6049028|NCT00420927|9648205|FG006|Period 2|Methotrexate intolerance|1
6049029|NCT00420927|9648199|FG000|Period 2|Took prohibited medication|0
6049030|NCT00420927|9648200|FG001|Period 2|Took prohibited medication|0
6049031|NCT00420927|9648201|FG002|Period 2|Took prohibited medication|0
6049032|NCT00420927|9648202|FG003|Period 2|Took prohibited medication|0
6084533|NCT00642941|9693402|FG011|Overall Study|Disease progression|7
6367362|NCT02865187|10157386|FG000|Overall Study|Lost to Follow-up|12
6084534|NCT00642954|9693454|FG000|Overall Study|Progressive Disease|3
6227471|NCT01717326|9900188|FG000|Overall Study|Lost to Follow-up|3
6227472|NCT01717326|9900189|FG001|Overall Study|Lost to Follow-up|0
6227473|NCT01717326|9900190|FG002|Overall Study|Lost to Follow-up|0
6227474|NCT01717326|9900191|FG003|Overall Study|Lost to Follow-up|2
6227475|NCT01717326|9900192|FG004|Overall Study|Lost to Follow-up|1
6084535|NCT00642954|9693455|FG001|Overall Study|Progressive Disease|3
6227476|NCT01717326|9900193|FG005|Overall Study|Lost to Follow-up|0
6227477|NCT01717326|9900194|FG006|Overall Study|Lost to Follow-up|1
6227478|NCT01717326|9900195|FG007|Overall Study|Lost to Follow-up|0
6367363|NCT02865187|10157387|FG001|Overall Study|Lost to Follow-up|7
6367364|NCT02865187|10157386|FG000|Overall Study|Adverse Event|1
6367365|NCT02865187|10157387|FG001|Overall Study|Adverse Event|0
6367366|NCT02836249|10157395|FG000|Overall Study|Randomized but Never Treated|0
6367367|NCT02836249|10157396|FG001|Overall Study|Randomized but Never Treated|1
6367368|NCT02836249|10157395|FG000|Overall Study|Pregnancy|2
6367369|NCT02836249|10157396|FG001|Overall Study|Pregnancy|0
6367370|NCT02836249|10157395|FG000|Overall Study|Withdrew Consent|0
6367371|NCT02836249|10157396|FG001|Overall Study|Withdrew Consent|1
6367372|NCT02836249|10157395|FG000|Overall Study|Lost to Follow-up|0
6367373|NCT02836249|10157396|FG001|Overall Study|Lost to Follow-up|1
6367374|NCT02836249|10157395|FG000|Overall Study|Still on Study|121
6367375|NCT02836249|10157396|FG001|Overall Study|Still on Study|55
6367376|NCT02829918|10157402|FG000|Overall Study|Death|2
6367377|NCT02829918|10157402|FG000|Overall Study|Withdrawal by Subject|4
6367378|NCT02829918|10157402|FG000|Overall Study|Adverse Event|1
6367379|NCT02829918|10157402|FG000|Overall Study|Progression|1
6367380|NCT02824198|10157408|FG000|Overall Study|Non-compliance with the protocol|5
6367381|NCT02824198|10157409|FG001|Overall Study|Non-compliance with the protocol|1
6367382|NCT02824198|10157408|FG000|Overall Study|Lost to Follow-up|5
6084536|NCT00642954|9693456|FG002|Overall Study|Progressive Disease|3
6084537|NCT00642954|9693457|FG003|Overall Study|Progressive Disease|3
6367383|NCT02824198|10157409|FG001|Overall Study|Lost to Follow-up|2
6367384|NCT02824198|10157408|FG000|Overall Study|Withdrawal by Subject|5
6367385|NCT02824198|10157409|FG001|Overall Study|Withdrawal by Subject|0
6367386|NCT02821754|10157420|FG000|Overall Study|Procedure not required prior to amendment change|13
6367387|NCT02821754|10157421|FG001|Overall Study|Procedure not required prior to amendment change|11
6367388|NCT02821754|10157422|FG002|Overall Study|Procedure not required prior to amendment change|0
6367389|NCT02821754|10157420|FG000|Overall Study|Participant's Clinical status|2
6367390|NCT02821754|10157421|FG001|Overall Study|Participant's Clinical status|0
6367391|NCT02821754|10157422|FG002|Overall Study|Participant's Clinical status|0
6367392|NCT02821754|10157420|FG000|Overall Study|Participant removed for noncompliance|1
6367393|NCT02821754|10157421|FG001|Overall Study|Participant removed for noncompliance|0
6367394|NCT02821754|10157422|FG002|Overall Study|Participant removed for noncompliance|0
6367395|NCT02821754|10157420|FG000|Overall Study|Drug not available.|0
6367396|NCT02821754|10157421|FG001|Overall Study|Drug not available.|0
6367397|NCT02821754|10157422|FG002|Overall Study|Drug not available.|1
6367398|NCT02821754|10157420|FG000|Overall Study|Participant declined to participate (before treatment started.)|0
6367399|NCT02821754|10157421|FG001|Overall Study|Participant declined to participate (before treatment started.)|1
6367400|NCT02821754|10157422|FG002|Overall Study|Participant declined to participate (before treatment started.)|1
6367401|NCT02787551|10157430|FG000|Core Period: 26 Weeks|Adverse Event|10
6367402|NCT02787551|10157431|FG001|Core Period: 26 Weeks|Adverse Event|0
6367403|NCT02787551|10157430|FG000|Core Period: 26 Weeks|Lack of Efficacy|1
6367404|NCT02787551|10157431|FG001|Core Period: 26 Weeks|Lack of Efficacy|0
6367405|NCT02787551|10157430|FG000|Core Period: 26 Weeks|Poor compliance to protocol|2
6367406|NCT02787551|10157431|FG001|Core Period: 26 Weeks|Poor compliance to protocol|0
6367407|NCT02787551|10157430|FG000|Core Period: 26 Weeks|Withdrawal by Subject|9
6367408|NCT02787551|10157431|FG001|Core Period: 26 Weeks|Withdrawal by Subject|9
6367409|NCT02787551|10157430|FG000|Core Period: 26 Weeks|Randomized but not treated|2
6367410|NCT02787551|10157431|FG001|Core Period: 26 Weeks|Randomized but not treated|1
6367411|NCT02787551|10157430|FG000|Core Period: 26 Weeks|Other than specified|3
6367412|NCT02787551|10157431|FG001|Core Period: 26 Weeks|Other than specified|1
6367413|NCT02787551|10157430|FG000|Extension Period:26 Weeks(Upto 52 Weeks)|Adverse Event|1
6367414|NCT02787551|10157431|FG001|Extension Period:26 Weeks(Upto 52 Weeks)|Adverse Event|0
6367415|NCT02787551|10157430|FG000|Extension Period:26 Weeks(Upto 52 Weeks)|Poor compliance to protocol|3
6367416|NCT02787551|10157431|FG001|Extension Period:26 Weeks(Upto 52 Weeks)|Poor compliance to protocol|0
6367417|NCT02787551|10157430|FG000|Extension Period:26 Weeks(Upto 52 Weeks)|Other than specified|5
6367418|NCT02787551|10157431|FG001|Extension Period:26 Weeks(Upto 52 Weeks)|Other than specified|0
6367419|NCT02735044|10157451|FG000|Overall Study|Adverse Event|3
6367420|NCT02735044|10157452|FG001|Overall Study|Adverse Event|3
6367421|NCT02735044|10157451|FG000|Overall Study|Lack of Efficacy|1
6367422|NCT02735044|10157452|FG001|Overall Study|Lack of Efficacy|0
6367423|NCT02735044|10157451|FG000|Overall Study|Poor compliance to protocol|7
6367424|NCT02735044|10157452|FG001|Overall Study|Poor compliance to protocol|7
6367425|NCT02735044|10157451|FG000|Overall Study|Randomized and not treated|0
6367426|NCT02735044|10157452|FG001|Overall Study|Randomized and not treated|2
6367427|NCT02735044|10157451|FG000|Overall Study|Other, not specified above|5
6084538|NCT00642954|9693458|FG004|Overall Study|Progressive Disease|9
6084539|NCT00642954|9693454|FG000|Overall Study|Withdrawal by Subject|0
6367428|NCT02735044|10157452|FG001|Overall Study|Other, not specified above|11
6084540|NCT00642954|9693455|FG001|Overall Study|Withdrawal by Subject|0
6367429|NCT02720744|10157460|FG000|Overall Study|Protocol Violation|0
6367430|NCT02720744|10157461|FG001|Overall Study|Protocol Violation|2
6367431|NCT02720744|10157460|FG000|Overall Study|Pregnancy|2
6367432|NCT02720744|10157461|FG001|Overall Study|Pregnancy|0
6367433|NCT02720744|10157460|FG000|Overall Study|Lack of Efficacy|2
6367434|NCT02720744|10157461|FG001|Overall Study|Lack of Efficacy|8
6367435|NCT02720744|10157460|FG000|Overall Study|Adverse Event|21
6367436|NCT02720744|10157461|FG001|Overall Study|Adverse Event|3
6367437|NCT02720744|10157460|FG000|Overall Study|Withdrawal by Subject|11
6367438|NCT02720744|10157461|FG001|Overall Study|Withdrawal by Subject|11
6367439|NCT02720744|10157460|FG000|Overall Study|Lost to follow up|2
6367440|NCT02720744|10157461|FG001|Overall Study|Lost to follow up|0
6367441|NCT02720744|10157460|FG000|Overall Study|Non Compliance with Investigational Product|0
6367442|NCT02720744|10157461|FG001|Overall Study|Non Compliance with Investigational Product|1
6367443|NCT02720744|10157460|FG000|Overall Study|Excluded Concomitant Medication|0
6367444|NCT02720744|10157461|FG001|Overall Study|Excluded Concomitant Medication|1
6367445|NCT02713867|10157469|FG000|Randomization|Other Reason|2
6367446|NCT02713867|10157470|FG001|Randomization|Other Reason|1
6367447|NCT02713867|10157469|FG000|Randomization|Participant Withdrew consent|0
6367448|NCT02713867|10157470|FG001|Randomization|Participant Withdrew consent|2
6367449|NCT02713867|10157469|FG000|Treatment Period|Not Reported|1
6367450|NCT02713867|10157470|FG001|Treatment Period|Not Reported|0
6367451|NCT02713867|10157469|FG000|Treatment Period|Other Reasons|12
6367452|NCT02713867|10157470|FG001|Treatment Period|Other Reasons|18
6367453|NCT02713867|10157469|FG000|Treatment Period|Administrative reason by sponsor|9
6367454|NCT02713867|10157470|FG001|Treatment Period|Administrative reason by sponsor|4
6367455|NCT02713867|10157469|FG000|Treatment Period|No longer meets study criteria|2
6367456|NCT02713867|10157470|FG001|Treatment Period|No longer meets study criteria|1
6367457|NCT02713867|10157469|FG000|Treatment Period|Poor/Non Compliance|1
6367458|NCT02713867|10157470|FG001|Treatment Period|Poor/Non Compliance|0
6367459|NCT02713867|10157469|FG000|Treatment Period|Maximum Clinical Benefit|3
6367460|NCT02713867|10157470|FG001|Treatment Period|Maximum Clinical Benefit|4
6367461|NCT02713867|10157469|FG000|Treatment Period|Withdrew consent|1
6367462|NCT02713867|10157470|FG001|Treatment Period|Withdrew consent|6
6367463|NCT02713867|10157469|FG000|Treatment Period|Requested to Discontinue|8
6367464|NCT02713867|10157470|FG001|Treatment Period|Requested to Discontinue|7
6367465|NCT02713867|10157469|FG000|Treatment Period|AE unrelated to Study Drug|8
6367466|NCT02713867|10157470|FG001|Treatment Period|AE unrelated to Study Drug|9
6367467|NCT02713867|10157469|FG000|Treatment Period|Death|7
6367468|NCT02713867|10157470|FG001|Treatment Period|Death|3
6367469|NCT02713867|10157469|FG000|Treatment Period|Study Drug Toxicity|16
6367470|NCT02713867|10157470|FG001|Treatment Period|Study Drug Toxicity|20
6367471|NCT02713867|10157469|FG000|Treatment Period|Disease Progression|79
6367472|NCT02713867|10157470|FG001|Treatment Period|Disease Progression|78
6367473|NCT02704403|10157478|FG000|Overall Study|Randomized and not treated (due to non-compliance with protocol)|4
6367474|NCT02704403|10157479|FG001|Overall Study|Randomized and not treated (due to non-compliance with protocol)|3
6367475|NCT02704403|10157478|FG000|Overall Study|Administrative reasons by sponsor|1251
6367476|NCT02704403|10157479|FG001|Overall Study|Administrative reasons by sponsor|616
6367477|NCT02704403|10157478|FG000|Overall Study|Death|4
6367478|NCT02704403|10157479|FG001|Overall Study|Death|3
6367479|NCT02704403|10157478|FG000|Overall Study|Endpoint event|52
6367480|NCT02704403|10157479|FG001|Overall Study|Endpoint event|24
6367481|NCT02704403|10157478|FG000|Overall Study|Lost to Follow-up|22
6367482|NCT02704403|10157479|FG001|Overall Study|Lost to Follow-up|11
6367483|NCT02704403|10157478|FG000|Overall Study|Protocol Violation|15
6367484|NCT02704403|10157479|FG001|Overall Study|Protocol Violation|15
6367485|NCT02704403|10157478|FG000|Overall Study|Adverse Event|2
6367486|NCT02704403|10157479|FG001|Overall Study|Adverse Event|0
6367487|NCT02704403|10157478|FG000|Overall Study|Withdrawal by Subject|85
6367488|NCT02704403|10157479|FG001|Overall Study|Withdrawal by Subject|45
6367489|NCT02704403|10157478|FG000|Overall Study|Investigator decision|1
6367490|NCT02704403|10157479|FG001|Overall Study|Investigator decision|1
6367491|NCT02704403|10157478|FG000|Overall Study|Follow-up not possible|1
6367492|NCT02704403|10157479|FG001|Overall Study|Follow-up not possible|2
6367493|NCT02694185|10157487|FG000|Overall Study|Withdrawal by Subject|45
6367494|NCT02694185|10157488|FG001|Overall Study|Withdrawal by Subject|0
6367495|NCT02692651|10157496|FG000|Study Treatment|Death|7
6367496|NCT02692651|10157497|FG001|Study Treatment|Death|3
6367497|NCT02692651|10157496|FG000|Study Treatment|comfort care|1
6367498|NCT02692651|10157497|FG001|Study Treatment|comfort care|1
6367499|NCT02692651|10157496|FG000|Study Treatment|Protocol violation per treating team preference|8
6367500|NCT02692651|10157497|FG001|Study Treatment|Protocol violation per treating team preference|6
6367501|NCT02692651|10157496|FG000|Post Study Treatment Follow-up|Death|4
6367502|NCT02692651|10157497|FG001|Post Study Treatment Follow-up|Death|4
6367503|NCT02674061|10157505|FG000|Overall Study|Death|229
6367504|NCT02674061|10157506|FG001|Overall Study|Death|77
6367505|NCT02674061|10157505|FG000|Overall Study|Lost to Follow-up|3
6367506|NCT02674061|10157506|FG001|Overall Study|Lost to Follow-up|3
6367507|NCT02674061|10157505|FG000|Overall Study|Withdrawal by Subject|9
6367508|NCT02674061|10157506|FG001|Overall Study|Withdrawal by Subject|1
6367509|NCT02674061|10157505|FG000|Overall Study|Participation in Study Discontinued by Sponsor|44
6367510|NCT02674061|10157506|FG001|Overall Study|Participation in Study Discontinued by Sponsor|10
6367511|NCT02656706|10157514|FG000|Overall Study|Insurance Denial|1
6367512|NCT02642042|10157527|FG000|Overall Study|Adverse Event|22
6367513|NCT02642042|10157527|FG000|Overall Study|Refusal Unrelated to Adverse Event|1
6367514|NCT02642042|10157527|FG000|Overall Study|Progression/Relapse|28
6367515|NCT02642042|10157527|FG000|Overall Study|Death|1
6367516|NCT02642042|10157527|FG000|Overall Study|Not Protocol Specified|2
6367517|NCT02628444|10157534|FG000|Stage-I(24M:12M Treatment+12M Follow-up)|Adverse event (AE) intensity less than (<) Grade 1|1
6367518|NCT02628444|10157535|FG001|Stage-I(24M:12M Treatment+12M Follow-up)|Adverse event (AE) intensity less than (<) Grade 1|0
6367519|NCT02628444|10157536|FG002|Stage-I(24M:12M Treatment+12M Follow-up)|Adverse event (AE) intensity less than (<) Grade 1|0
6367520|NCT02628444|10157537|FG003|Stage-I(24M:12M Treatment+12M Follow-up)|Adverse event (AE) intensity less than (<) Grade 1|0
6367521|NCT02628444|10157538|FG004|Stage-I(24M:12M Treatment+12M Follow-up)|Adverse event (AE) intensity less than (<) Grade 1|0
6367522|NCT02628444|10157539|FG005|Stage-I(24M:12M Treatment+12M Follow-up)|Adverse event (AE) intensity less than (<) Grade 1|0
6367523|NCT02628444|10157540|FG006|Stage-I(24M:12M Treatment+12M Follow-up)|Adverse event (AE) intensity less than (<) Grade 1|0
6367524|NCT02628444|10157541|FG007|Stage-I(24M:12M Treatment+12M Follow-up)|Adverse event (AE) intensity less than (<) Grade 1|0
6367525|NCT02628444|10157542|FG008|Stage-I(24M:12M Treatment+12M Follow-up)|Adverse event (AE) intensity less than (<) Grade 1|0
6367526|NCT02628444|10157534|FG000|Stage-I(24M:12M Treatment+12M Follow-up)|Serious AE (SAE)|0
6367527|NCT02628444|10157535|FG001|Stage-I(24M:12M Treatment+12M Follow-up)|Serious AE (SAE)|4
6367528|NCT02628444|10157536|FG002|Stage-I(24M:12M Treatment+12M Follow-up)|Serious AE (SAE)|3
6367529|NCT02628444|10157537|FG003|Stage-I(24M:12M Treatment+12M Follow-up)|Serious AE (SAE)|0
6367530|NCT02628444|10157538|FG004|Stage-I(24M:12M Treatment+12M Follow-up)|Serious AE (SAE)|0
6367531|NCT02628444|10157539|FG005|Stage-I(24M:12M Treatment+12M Follow-up)|Serious AE (SAE)|0
6367532|NCT02628444|10157540|FG006|Stage-I(24M:12M Treatment+12M Follow-up)|Serious AE (SAE)|0
6043256|NCT00388362|9641809|FG000|Enrolled|Ineligible|1
6367533|NCT02628444|10157541|FG007|Stage-I(24M:12M Treatment+12M Follow-up)|Serious AE (SAE)|0
6367534|NCT02628444|10157542|FG008|Stage-I(24M:12M Treatment+12M Follow-up)|Serious AE (SAE)|0
6367535|NCT02628444|10157534|FG000|Stage-I(24M:12M Treatment+12M Follow-up)|Voluntary withdrawal not due to AE|21
6367536|NCT02628444|10157535|FG001|Stage-I(24M:12M Treatment+12M Follow-up)|Voluntary withdrawal not due to AE|16
6367537|NCT02628444|10157536|FG002|Stage-I(24M:12M Treatment+12M Follow-up)|Voluntary withdrawal not due to AE|25
6367538|NCT02628444|10157537|FG003|Stage-I(24M:12M Treatment+12M Follow-up)|Voluntary withdrawal not due to AE|0
6367539|NCT02628444|10157538|FG004|Stage-I(24M:12M Treatment+12M Follow-up)|Voluntary withdrawal not due to AE|0
6367540|NCT02628444|10157539|FG005|Stage-I(24M:12M Treatment+12M Follow-up)|Voluntary withdrawal not due to AE|0
6367541|NCT02628444|10157540|FG006|Stage-I(24M:12M Treatment+12M Follow-up)|Voluntary withdrawal not due to AE|0
6367542|NCT02628444|10157541|FG007|Stage-I(24M:12M Treatment+12M Follow-up)|Voluntary withdrawal not due to AE|0
6367543|NCT02628444|10157542|FG008|Stage-I(24M:12M Treatment+12M Follow-up)|Voluntary withdrawal not due to AE|0
6367544|NCT02628444|10157534|FG000|Stage-I(24M:12M Treatment+12M Follow-up)|Non-compliance with protocol|9
6367545|NCT02628444|10157535|FG001|Stage-I(24M:12M Treatment+12M Follow-up)|Non-compliance with protocol|16
6367546|NCT02628444|10157536|FG002|Stage-I(24M:12M Treatment+12M Follow-up)|Non-compliance with protocol|9
6367547|NCT02628444|10157537|FG003|Stage-I(24M:12M Treatment+12M Follow-up)|Non-compliance with protocol|0
6367548|NCT02628444|10157538|FG004|Stage-I(24M:12M Treatment+12M Follow-up)|Non-compliance with protocol|0
6367549|NCT02628444|10157539|FG005|Stage-I(24M:12M Treatment+12M Follow-up)|Non-compliance with protocol|0
6367550|NCT02628444|10157540|FG006|Stage-I(24M:12M Treatment+12M Follow-up)|Non-compliance with protocol|0
6367551|NCT02628444|10157541|FG007|Stage-I(24M:12M Treatment+12M Follow-up)|Non-compliance with protocol|0
6367552|NCT02628444|10157542|FG008|Stage-I(24M:12M Treatment+12M Follow-up)|Non-compliance with protocol|0
6367553|NCT02628444|10157534|FG000|Stage-I(24M:12M Treatment+12M Follow-up)|Lost to Follow-up|5
6367554|NCT02628444|10157535|FG001|Stage-I(24M:12M Treatment+12M Follow-up)|Lost to Follow-up|3
6367555|NCT02628444|10157536|FG002|Stage-I(24M:12M Treatment+12M Follow-up)|Lost to Follow-up|5
6367556|NCT02628444|10157537|FG003|Stage-I(24M:12M Treatment+12M Follow-up)|Lost to Follow-up|0
6367557|NCT02628444|10157538|FG004|Stage-I(24M:12M Treatment+12M Follow-up)|Lost to Follow-up|0
6367558|NCT02628444|10157539|FG005|Stage-I(24M:12M Treatment+12M Follow-up)|Lost to Follow-up|0
6367559|NCT02628444|10157540|FG006|Stage-I(24M:12M Treatment+12M Follow-up)|Lost to Follow-up|0
6367560|NCT02628444|10157541|FG007|Stage-I(24M:12M Treatment+12M Follow-up)|Lost to Follow-up|0
6367561|NCT02628444|10157542|FG008|Stage-I(24M:12M Treatment+12M Follow-up)|Lost to Follow-up|0
6367562|NCT02628444|10157534|FG000|STAGE-II(18M:12M Treatment+6M Follow-up)|Other AE|0
6367563|NCT02628444|10157535|FG001|STAGE-II(18M:12M Treatment+6M Follow-up)|Other AE|0
6367564|NCT02628444|10157536|FG002|STAGE-II(18M:12M Treatment+6M Follow-up)|Other AE|0
6367565|NCT02628444|10157537|FG003|STAGE-II(18M:12M Treatment+6M Follow-up)|Other AE|1
6367566|NCT02628444|10157538|FG004|STAGE-II(18M:12M Treatment+6M Follow-up)|Other AE|0
6367567|NCT02628444|10157539|FG005|STAGE-II(18M:12M Treatment+6M Follow-up)|Other AE|0
6367568|NCT02628444|10157540|FG006|STAGE-II(18M:12M Treatment+6M Follow-up)|Other AE|0
6367569|NCT02628444|10157541|FG007|STAGE-II(18M:12M Treatment+6M Follow-up)|Other AE|0
6367570|NCT02628444|10157542|FG008|STAGE-II(18M:12M Treatment+6M Follow-up)|Other AE|0
6367571|NCT02628444|10157534|FG000|STAGE-II(18M:12M Treatment+6M Follow-up)|Non-compliance with protocol|0
6367572|NCT02628444|10157535|FG001|STAGE-II(18M:12M Treatment+6M Follow-up)|Non-compliance with protocol|0
6367573|NCT02628444|10157536|FG002|STAGE-II(18M:12M Treatment+6M Follow-up)|Non-compliance with protocol|0
6367574|NCT02628444|10157537|FG003|STAGE-II(18M:12M Treatment+6M Follow-up)|Non-compliance with protocol|83
6367575|NCT02628444|10157538|FG004|STAGE-II(18M:12M Treatment+6M Follow-up)|Non-compliance with protocol|83
6367576|NCT02628444|10157539|FG005|STAGE-II(18M:12M Treatment+6M Follow-up)|Non-compliance with protocol|83
6367577|NCT02628444|10157540|FG006|STAGE-II(18M:12M Treatment+6M Follow-up)|Non-compliance with protocol|81
6367578|NCT02628444|10157541|FG007|STAGE-II(18M:12M Treatment+6M Follow-up)|Non-compliance with protocol|84
6367579|NCT02628444|10157542|FG008|STAGE-II(18M:12M Treatment+6M Follow-up)|Non-compliance with protocol|85
6367580|NCT02628444|10157534|FG000|STAGE-II(18M:12M Treatment+6M Follow-up)|Voluntary withdrawal not due to AE|0
6367581|NCT02628444|10157535|FG001|STAGE-II(18M:12M Treatment+6M Follow-up)|Voluntary withdrawal not due to AE|0
6367582|NCT02628444|10157536|FG002|STAGE-II(18M:12M Treatment+6M Follow-up)|Voluntary withdrawal not due to AE|0
6367583|NCT02628444|10157537|FG003|STAGE-II(18M:12M Treatment+6M Follow-up)|Voluntary withdrawal not due to AE|5
6367584|NCT02628444|10157538|FG004|STAGE-II(18M:12M Treatment+6M Follow-up)|Voluntary withdrawal not due to AE|6
6367585|NCT02628444|10157539|FG005|STAGE-II(18M:12M Treatment+6M Follow-up)|Voluntary withdrawal not due to AE|10
6367586|NCT02628444|10157540|FG006|STAGE-II(18M:12M Treatment+6M Follow-up)|Voluntary withdrawal not due to AE|12
6367587|NCT02628444|10157541|FG007|STAGE-II(18M:12M Treatment+6M Follow-up)|Voluntary withdrawal not due to AE|11
6367588|NCT02628444|10157542|FG008|STAGE-II(18M:12M Treatment+6M Follow-up)|Voluntary withdrawal not due to AE|9
6367589|NCT02628444|10157534|FG000|STAGE-II(18M:12M Treatment+6M Follow-up)|SAE|0
6367590|NCT02628444|10157535|FG001|STAGE-II(18M:12M Treatment+6M Follow-up)|SAE|0
6367591|NCT02628444|10157536|FG002|STAGE-II(18M:12M Treatment+6M Follow-up)|SAE|0
6367592|NCT02628444|10157537|FG003|STAGE-II(18M:12M Treatment+6M Follow-up)|SAE|0
6367593|NCT02628444|10157538|FG004|STAGE-II(18M:12M Treatment+6M Follow-up)|SAE|3
6367594|NCT02628444|10157539|FG005|STAGE-II(18M:12M Treatment+6M Follow-up)|SAE|0
6367595|NCT02628444|10157540|FG006|STAGE-II(18M:12M Treatment+6M Follow-up)|SAE|0
6367596|NCT02628444|10157541|FG007|STAGE-II(18M:12M Treatment+6M Follow-up)|SAE|2
6367597|NCT02628444|10157542|FG008|STAGE-II(18M:12M Treatment+6M Follow-up)|SAE|3
6367598|NCT02628444|10157534|FG000|STAGE-II(18M:12M Treatment+6M Follow-up)|Lost to Follow-up|0
6367599|NCT02628444|10157535|FG001|STAGE-II(18M:12M Treatment+6M Follow-up)|Lost to Follow-up|0
6367600|NCT02628444|10157536|FG002|STAGE-II(18M:12M Treatment+6M Follow-up)|Lost to Follow-up|0
6367601|NCT02628444|10157537|FG003|STAGE-II(18M:12M Treatment+6M Follow-up)|Lost to Follow-up|1
6367602|NCT02628444|10157538|FG004|STAGE-II(18M:12M Treatment+6M Follow-up)|Lost to Follow-up|1
6367603|NCT02628444|10157539|FG005|STAGE-II(18M:12M Treatment+6M Follow-up)|Lost to Follow-up|2
6367604|NCT02628444|10157540|FG006|STAGE-II(18M:12M Treatment+6M Follow-up)|Lost to Follow-up|3
6367605|NCT02628444|10157541|FG007|STAGE-II(18M:12M Treatment+6M Follow-up)|Lost to Follow-up|1
6367606|NCT02628444|10157542|FG008|STAGE-II(18M:12M Treatment+6M Follow-up)|Lost to Follow-up|2
6367607|NCT02623725|10157578|FG000|Overall Study|Non compliance with protocol|9
6367608|NCT02623725|10157579|FG001|Overall Study|Non compliance with protocol|3
6367609|NCT02623725|10157578|FG000|Overall Study|Serious adverse event|0
6367610|NCT02623725|10157579|FG001|Overall Study|Serious adverse event|2
6367611|NCT02623725|10157578|FG000|Overall Study|Withdrawal by Subject|7
6367612|NCT02623725|10157579|FG001|Overall Study|Withdrawal by Subject|1
6367613|NCT02608684|10157587|FG000|Overall Study|Physician Decision|2
6367614|NCT02608684|10157587|FG000|Overall Study|Withdrawal by Subject|1
6367615|NCT02603887|10157591|FG000|Stage 1|Adverse Event|4
6367616|NCT02603887|10157591|FG000|Stage 1|Disease progression|1
6367617|NCT02603887|10157591|FG000|Stage 2|FDA guidance|1
6367618|NCT02601209|10157602|FG000|Initial Treatment (Up to 4 Months)|Did not meet eligibility criteria|1
6367619|NCT02601209|10157603|FG001|Initial Treatment (Up to 4 Months)|Did not meet eligibility criteria|1
6367620|NCT02601209|10157604|FG002|Initial Treatment (Up to 4 Months)|Did not meet eligibility criteria|1
6367621|NCT02601209|10157605|FG003|Initial Treatment (Up to 4 Months)|Did not meet eligibility criteria|0
6367622|NCT02601209|10157606|FG004|Initial Treatment (Up to 4 Months)|Did not meet eligibility criteria|0
6367623|NCT02601209|10157607|FG005|Initial Treatment (Up to 4 Months)|Did not meet eligibility criteria|0
6367624|NCT02601209|10157608|FG006|Initial Treatment (Up to 4 Months)|Did not meet eligibility criteria|0
6367625|NCT02601209|10157609|FG007|Initial Treatment (Up to 4 Months)|Did not meet eligibility criteria|0
6367626|NCT02601209|10157610|FG008|Initial Treatment (Up to 4 Months)|Did not meet eligibility criteria|0
6367627|NCT02601209|10157602|FG000|Initial Treatment (Up to 4 Months)|Withdrew before initiation of regimen|0
6367628|NCT02601209|10157603|FG001|Initial Treatment (Up to 4 Months)|Withdrew before initiation of regimen|0
6367629|NCT02601209|10157604|FG002|Initial Treatment (Up to 4 Months)|Withdrew before initiation of regimen|0
6367630|NCT02601209|10157605|FG003|Initial Treatment (Up to 4 Months)|Withdrew before initiation of regimen|0
6367631|NCT02601209|10157606|FG004|Initial Treatment (Up to 4 Months)|Withdrew before initiation of regimen|1
6367632|NCT02601209|10157607|FG005|Initial Treatment (Up to 4 Months)|Withdrew before initiation of regimen|2
6367633|NCT02601209|10157608|FG006|Initial Treatment (Up to 4 Months)|Withdrew before initiation of regimen|1
6367634|NCT02601209|10157609|FG007|Initial Treatment (Up to 4 Months)|Withdrew before initiation of regimen|0
6367635|NCT02601209|10157610|FG008|Initial Treatment (Up to 4 Months)|Withdrew before initiation of regimen|0
6367636|NCT02587520|10157642|FG000|Overall Study|Protocol Violation|2
6367637|NCT02587520|10157643|FG001|Overall Study|Protocol Violation|0
6367638|NCT02587520|10157644|FG002|Overall Study|Protocol Violation|0
6367639|NCT02587520|10157645|FG003|Overall Study|Protocol Violation|2
6367640|NCT02587520|10157646|FG004|Overall Study|Protocol Violation|0
6367641|NCT02587520|10157647|FG005|Overall Study|Protocol Violation|1
6367642|NCT02587520|10157648|FG006|Overall Study|Protocol Violation|1
6367643|NCT02587520|10157649|FG007|Overall Study|Protocol Violation|1
6367644|NCT02587520|10157650|FG008|Overall Study|Protocol Violation|3
6367645|NCT02587520|10157651|FG009|Overall Study|Protocol Violation|3
6367646|NCT02587520|10157652|FG010|Overall Study|Protocol Violation|1
6367647|NCT02587520|10157653|FG011|Overall Study|Protocol Violation|2
6367648|NCT02587520|10157654|FG012|Overall Study|Protocol Violation|0
6367649|NCT02587520|10157655|FG013|Overall Study|Protocol Violation|0
6367650|NCT02587520|10157656|FG014|Overall Study|Protocol Violation|0
6367651|NCT02587520|10157657|FG015|Overall Study|Protocol Violation|0
6367652|NCT02587520|10157658|FG016|Overall Study|Protocol Violation|0
6367653|NCT02587520|10157659|FG017|Overall Study|Protocol Violation|0
6367654|NCT02587520|10157642|FG000|Overall Study|Adverse Event|0
6367655|NCT02587520|10157643|FG001|Overall Study|Adverse Event|0
6367656|NCT02587520|10157644|FG002|Overall Study|Adverse Event|0
6367657|NCT02587520|10157645|FG003|Overall Study|Adverse Event|0
6367658|NCT02587520|10157646|FG004|Overall Study|Adverse Event|0
6367659|NCT02587520|10157647|FG005|Overall Study|Adverse Event|0
6367660|NCT02587520|10157648|FG006|Overall Study|Adverse Event|0
6367661|NCT02587520|10157649|FG007|Overall Study|Adverse Event|0
6367662|NCT02587520|10157650|FG008|Overall Study|Adverse Event|0
6367663|NCT02587520|10157651|FG009|Overall Study|Adverse Event|0
6367664|NCT02587520|10157652|FG010|Overall Study|Adverse Event|0
6367665|NCT02587520|10157653|FG011|Overall Study|Adverse Event|1
6367666|NCT02587520|10157654|FG012|Overall Study|Adverse Event|0
6367667|NCT02587520|10157655|FG013|Overall Study|Adverse Event|0
6367668|NCT02587520|10157656|FG014|Overall Study|Adverse Event|0
6367669|NCT02587520|10157657|FG015|Overall Study|Adverse Event|0
6367670|NCT02587520|10157658|FG016|Overall Study|Adverse Event|0
6367671|NCT02587520|10157659|FG017|Overall Study|Adverse Event|0
6367672|NCT02587520|10157642|FG000|Overall Study|Withdrawal by Subject|0
6367673|NCT02587520|10157643|FG001|Overall Study|Withdrawal by Subject|0
6367674|NCT02587520|10157644|FG002|Overall Study|Withdrawal by Subject|1
6367675|NCT02587520|10157645|FG003|Overall Study|Withdrawal by Subject|1
6367676|NCT02587520|10157646|FG004|Overall Study|Withdrawal by Subject|0
6367677|NCT02587520|10157647|FG005|Overall Study|Withdrawal by Subject|1
6367678|NCT02587520|10157648|FG006|Overall Study|Withdrawal by Subject|1
6367679|NCT02587520|10157649|FG007|Overall Study|Withdrawal by Subject|0
6367680|NCT02587520|10157650|FG008|Overall Study|Withdrawal by Subject|0
6367681|NCT02587520|10157651|FG009|Overall Study|Withdrawal by Subject|0
6367682|NCT02587520|10157652|FG010|Overall Study|Withdrawal by Subject|0
6367683|NCT02587520|10157653|FG011|Overall Study|Withdrawal by Subject|0
6367684|NCT02587520|10157654|FG012|Overall Study|Withdrawal by Subject|0
6367685|NCT02587520|10157655|FG013|Overall Study|Withdrawal by Subject|1
6367686|NCT02587520|10157656|FG014|Overall Study|Withdrawal by Subject|0
6367687|NCT02587520|10157657|FG015|Overall Study|Withdrawal by Subject|0
6367688|NCT02587520|10157658|FG016|Overall Study|Withdrawal by Subject|0
6367689|NCT02587520|10157659|FG017|Overall Study|Withdrawal by Subject|0
6367690|NCT02587520|10157642|FG000|Overall Study|Lost to Follow-up|0
6367691|NCT02587520|10157643|FG001|Overall Study|Lost to Follow-up|2
6367692|NCT02587520|10157644|FG002|Overall Study|Lost to Follow-up|0
6367693|NCT02587520|10157645|FG003|Overall Study|Lost to Follow-up|2
6367694|NCT02587520|10157646|FG004|Overall Study|Lost to Follow-up|0
6367695|NCT02587520|10157647|FG005|Overall Study|Lost to Follow-up|1
6367696|NCT02587520|10157648|FG006|Overall Study|Lost to Follow-up|1
6367697|NCT02587520|10157649|FG007|Overall Study|Lost to Follow-up|1
6367698|NCT02587520|10157650|FG008|Overall Study|Lost to Follow-up|0
6367699|NCT02587520|10157651|FG009|Overall Study|Lost to Follow-up|2
6367700|NCT02587520|10157652|FG010|Overall Study|Lost to Follow-up|2
6367701|NCT02587520|10157653|FG011|Overall Study|Lost to Follow-up|1
6367702|NCT02587520|10157654|FG012|Overall Study|Lost to Follow-up|0
6367703|NCT02587520|10157655|FG013|Overall Study|Lost to Follow-up|0
6367704|NCT02587520|10157656|FG014|Overall Study|Lost to Follow-up|0
6367705|NCT02587520|10157657|FG015|Overall Study|Lost to Follow-up|0
6367706|NCT02587520|10157658|FG016|Overall Study|Lost to Follow-up|0
6367707|NCT02587520|10157659|FG017|Overall Study|Lost to Follow-up|0
6367708|NCT02584829|10157699|FG000|Overall Study|Physician Decision|1
6367709|NCT02584829|10157700|FG001|Overall Study|Physician Decision|0
6367710|NCT02584829|10157699|FG000|Overall Study|Withdrawal by Subject|0
6367711|NCT02584829|10157700|FG001|Overall Study|Withdrawal by Subject|1
6367712|NCT02584829|10157699|FG000|Overall Study|Progressive Disease|0
6367713|NCT02584829|10157700|FG001|Overall Study|Progressive Disease|3
6367714|NCT02570308|10157713|FG000|Overall Study|Death|1
6367715|NCT02570308|10157714|FG001|Overall Study|Death|5
6367716|NCT02570308|10157715|FG002|Overall Study|Death|4
6367717|NCT02570308|10157716|FG003|Overall Study|Death|4
6367718|NCT02570308|10157717|FG004|Overall Study|Death|69
6367719|NCT02570308|10157713|FG000|Overall Study|Lost to Follow-up|0
6367720|NCT02570308|10157714|FG001|Overall Study|Lost to Follow-up|0
6367721|NCT02570308|10157715|FG002|Overall Study|Lost to Follow-up|0
6367722|NCT02570308|10157716|FG003|Overall Study|Lost to Follow-up|0
6367723|NCT02570308|10157717|FG004|Overall Study|Lost to Follow-up|2
6367724|NCT02570308|10157713|FG000|Overall Study|Withdrawal by Subject|0
6367725|NCT02570308|10157714|FG001|Overall Study|Withdrawal by Subject|0
6367726|NCT02570308|10157715|FG002|Overall Study|Withdrawal by Subject|0
6367727|NCT02570308|10157716|FG003|Overall Study|Withdrawal by Subject|0
6367728|NCT02570308|10157717|FG004|Overall Study|Withdrawal by Subject|1
6367729|NCT02570308|10157713|FG000|Overall Study|Other|0
6367730|NCT02570308|10157714|FG001|Overall Study|Other|0
6367731|NCT02570308|10157715|FG002|Overall Study|Other|0
6367732|NCT02570308|10157716|FG003|Overall Study|Other|0
6367733|NCT02570308|10157717|FG004|Overall Study|Other|2
6367734|NCT02516241|10157738|FG000|Overall Study|Death|255
6367735|NCT02516241|10157739|FG001|Overall Study|Death|262
6367736|NCT02516241|10157740|FG002|Overall Study|Death|270
6367737|NCT02516241|10157738|FG000|Overall Study|Lost to Follow-up|1
6367738|NCT02516241|10157739|FG001|Overall Study|Lost to Follow-up|1
6367739|NCT02516241|10157740|FG002|Overall Study|Lost to Follow-up|3
6367740|NCT02516241|10157738|FG000|Overall Study|Withdrawal by Subject|2
6367741|NCT02516241|10157739|FG001|Overall Study|Withdrawal by Subject|7
6367742|NCT02516241|10157740|FG002|Overall Study|Withdrawal by Subject|12
6367743|NCT02516241|10157738|FG000|Overall Study|participants ongoing at data cut-off|84
6367744|NCT02516241|10157739|FG001|Overall Study|participants ongoing at data cut-off|76
6367745|NCT02516241|10157740|FG002|Overall Study|participants ongoing at data cut-off|59
6043257|NCT00388362|9641809|FG000|Enrolled|Adverse Event|9
6367746|NCT02514083|10157753|FG000|Overall Study|Adverse Event|1
6367747|NCT02497612|10157761|FG000|Overall Study|Met >=1 anti-malarial treatment criteria|57
6367748|NCT02497612|10157762|FG001|Overall Study|Met >=1 anti-malarial treatment criteria|51
6367749|NCT02497612|10157763|FG002|Overall Study|Met >=1 anti-malarial treatment criteria|39
6367750|NCT02497612|10157764|FG003|Overall Study|Met >=1 anti-malarial treatment criteria|41
6367751|NCT02497612|10157761|FG000|Overall Study|Participant's request|2
6367752|NCT02497612|10157762|FG001|Overall Study|Participant's request|3
6367753|NCT02497612|10157763|FG002|Overall Study|Participant's request|4
6367754|NCT02497612|10157764|FG003|Overall Study|Participant's request|1
6367755|NCT02497612|10157761|FG000|Overall Study|Investigator's judgement|1
6367756|NCT02497612|10157762|FG001|Overall Study|Investigator's judgement|0
6367757|NCT02497612|10157763|FG002|Overall Study|Investigator's judgement|0
6367758|NCT02497612|10157764|FG003|Overall Study|Investigator's judgement|2
6367759|NCT02497612|10157761|FG000|Overall Study|Adverse Event|3
6367760|NCT02497612|10157762|FG001|Overall Study|Adverse Event|1
6367761|NCT02497612|10157763|FG002|Overall Study|Adverse Event|4
6367762|NCT02497612|10157764|FG003|Overall Study|Adverse Event|1
6367763|NCT02497612|10157761|FG000|Overall Study|Lost to Follow-up|1
6367764|NCT02497612|10157762|FG001|Overall Study|Lost to Follow-up|1
6367765|NCT02497612|10157763|FG002|Overall Study|Lost to Follow-up|0
6367766|NCT02497612|10157764|FG003|Overall Study|Lost to Follow-up|1
6367767|NCT02497612|10157761|FG000|Overall Study|Other unspecified|1
6367768|NCT02497612|10157762|FG001|Overall Study|Other unspecified|1
6367769|NCT02497612|10157763|FG002|Overall Study|Other unspecified|2
6367770|NCT02497612|10157764|FG003|Overall Study|Other unspecified|0
6367771|NCT02497612|10157761|FG000|Overall Study|Not eligible|1
6367772|NCT02497612|10157762|FG001|Overall Study|Not eligible|0
6367773|NCT02497612|10157763|FG002|Overall Study|Not eligible|0
6367774|NCT02497612|10157764|FG003|Overall Study|Not eligible|1
6367775|NCT02460458|10157774|FG000|Confirmatory Phase|Patients excluded basing on phenotype central analyses|47
6084541|NCT00642954|9693456|FG002|Overall Study|Withdrawal by Subject|0
6084542|NCT00642954|9693457|FG003|Overall Study|Withdrawal by Subject|0
6084543|NCT00642954|9693458|FG004|Overall Study|Withdrawal by Subject|1
6084544|NCT00642954|9693454|FG000|Overall Study|Adverse Event|1
6367776|NCT02460458|10157774|FG000|Confirmatory Phase|Patients excluded due to lack of samples for central analyses|27
6367777|NCT02460458|10157774|FG000|Confirmatory Phase|Patients excluded due to lack of central characterized VWD mutations|14
6367778|NCT02460458|10157774|FG000|First Prospective Phase|Lost to Follow-up|16
6367779|NCT02460458|10157774|FG000|Confirmation of Clinical Phase Data|Lost to Follow-up|9
6367780|NCT02457559|10157789|FG000|Overall Study|Progressive Disease|1
6367781|NCT02457559|10157790|FG001|Overall Study|Progressive Disease|2
6367782|NCT02457559|10157791|FG002|Overall Study|Progressive Disease|3
6367783|NCT02457559|10157792|FG003|Overall Study|Progressive Disease|0
6367784|NCT02457559|10157793|FG004|Overall Study|Progressive Disease|0
6084545|NCT00642954|9693455|FG001|Overall Study|Adverse Event|1
6084546|NCT00642954|9693456|FG002|Overall Study|Adverse Event|0
6084547|NCT00642954|9693457|FG003|Overall Study|Adverse Event|0
6084548|NCT00642954|9693458|FG004|Overall Study|Adverse Event|6
6084549|NCT00642993|9693472|FG000|Overall Study|Adverse Event|85
6084550|NCT00642993|9693473|FG001|Overall Study|Adverse Event|4
6084551|NCT00642993|9693472|FG000|Overall Study|Lost to Follow-up|8
6084552|NCT00642993|9693473|FG001|Overall Study|Lost to Follow-up|4
6084553|NCT00642993|9693472|FG000|Overall Study|Withdrew - reason unrelated to treatment|11
6084554|NCT00642993|9693473|FG001|Overall Study|Withdrew - reason unrelated to treatment|3
6367785|NCT02457559|10157794|FG005|Overall Study|Progressive Disease|2
6367786|NCT02457559|10157795|FG006|Overall Study|Progressive Disease|1
6367787|NCT02457559|10157796|FG007|Overall Study|Progressive Disease|0
6367788|NCT02457559|10157797|FG008|Overall Study|Progressive Disease|1
6367789|NCT02457559|10157798|FG009|Overall Study|Progressive Disease|1
6367790|NCT02457559|10157799|FG010|Overall Study|Progressive Disease|1
6367791|NCT02457559|10157789|FG000|Overall Study|Investigator's Discretion|0
6367792|NCT02457559|10157790|FG001|Overall Study|Investigator's Discretion|0
6367793|NCT02457559|10157791|FG002|Overall Study|Investigator's Discretion|2
6367794|NCT02457559|10157792|FG003|Overall Study|Investigator's Discretion|0
6367795|NCT02457559|10157793|FG004|Overall Study|Investigator's Discretion|1
6367796|NCT02457559|10157794|FG005|Overall Study|Investigator's Discretion|0
6367797|NCT02457559|10157795|FG006|Overall Study|Investigator's Discretion|1
6367798|NCT02457559|10157796|FG007|Overall Study|Investigator's Discretion|0
6367799|NCT02457559|10157797|FG008|Overall Study|Investigator's Discretion|1
6367800|NCT02457559|10157798|FG009|Overall Study|Investigator's Discretion|0
6367801|NCT02457559|10157799|FG010|Overall Study|Investigator's Discretion|1
6367802|NCT02457559|10157789|FG000|Overall Study|Adverse Event|0
6367803|NCT02457559|10157790|FG001|Overall Study|Adverse Event|1
6367804|NCT02457559|10157791|FG002|Overall Study|Adverse Event|2
6367805|NCT02457559|10157792|FG003|Overall Study|Adverse Event|0
6367806|NCT02457559|10157793|FG004|Overall Study|Adverse Event|0
6367807|NCT02457559|10157794|FG005|Overall Study|Adverse Event|0
6367808|NCT02457559|10157795|FG006|Overall Study|Adverse Event|0
6367809|NCT02457559|10157796|FG007|Overall Study|Adverse Event|0
6367810|NCT02457559|10157797|FG008|Overall Study|Adverse Event|0
6367811|NCT02457559|10157798|FG009|Overall Study|Adverse Event|0
6367812|NCT02457559|10157799|FG010|Overall Study|Adverse Event|0
6367813|NCT02457559|10157789|FG000|Overall Study|Reason not Specified|1
6367814|NCT02457559|10157790|FG001|Overall Study|Reason not Specified|0
6367815|NCT02457559|10157791|FG002|Overall Study|Reason not Specified|0
6367816|NCT02457559|10157792|FG003|Overall Study|Reason not Specified|0
6367817|NCT02457559|10157793|FG004|Overall Study|Reason not Specified|0
6367818|NCT02457559|10157794|FG005|Overall Study|Reason not Specified|0
6367819|NCT02457559|10157795|FG006|Overall Study|Reason not Specified|0
6367820|NCT02457559|10157796|FG007|Overall Study|Reason not Specified|0
6367821|NCT02457559|10157797|FG008|Overall Study|Reason not Specified|0
6367822|NCT02457559|10157798|FG009|Overall Study|Reason not Specified|2
6084555|NCT00642993|9693472|FG000|Overall Study|Protocol Violation|1
6084556|NCT00642993|9693473|FG001|Overall Study|Protocol Violation|4
6087761|NCT00670449|9698234|FG003|Overall Study|Administrative Problems|1
6367823|NCT02457559|10157799|FG010|Overall Study|Reason not Specified|0
6367824|NCT02457559|10157789|FG000|Overall Study|Death|0
6367825|NCT02457559|10157790|FG001|Overall Study|Death|0
6367826|NCT02457559|10157791|FG002|Overall Study|Death|0
6367827|NCT02457559|10157792|FG003|Overall Study|Death|0
6367828|NCT02457559|10157793|FG004|Overall Study|Death|0
6367829|NCT02457559|10157794|FG005|Overall Study|Death|0
6367830|NCT02457559|10157795|FG006|Overall Study|Death|0
6367831|NCT02457559|10157796|FG007|Overall Study|Death|0
6367832|NCT02457559|10157797|FG008|Overall Study|Death|1
6367833|NCT02457559|10157798|FG009|Overall Study|Death|1
6367834|NCT02457559|10157799|FG010|Overall Study|Death|0
6367835|NCT02442349|10157837|FG000|Overall Study|Death|14
6367836|NCT02442349|10157837|FG000|Overall Study|Withdrawal by Subject|8
6367837|NCT02442349|10157837|FG000|Overall Study|On-going Study at Data Cut-off|149
6367838|NCT02434354|10157841|FG000|Overall Study|screen fail|3
6367839|NCT02381652|10157857|FG000|Overall Study|Withdrawal by Subject|0
6367840|NCT02381652|10157858|FG001|Overall Study|Withdrawal by Subject|0
6367841|NCT02381652|10157859|FG002|Overall Study|Withdrawal by Subject|1
6367842|NCT02367794|10157868|FG000|Overall Study|Death|252
6367843|NCT02367794|10157869|FG001|Overall Study|Death|245
6367844|NCT02367794|10157870|FG002|Overall Study|Death|243
6367845|NCT02367794|10157868|FG000|Overall Study|Lost to Follow-up|1
6367846|NCT02367794|10157869|FG001|Overall Study|Lost to Follow-up|2
6367847|NCT02367794|10157870|FG002|Overall Study|Lost to Follow-up|2
6367848|NCT02367794|10157868|FG000|Overall Study|Physician Decision|0
6367849|NCT02367794|10157869|FG001|Overall Study|Physician Decision|5
6367850|NCT02367794|10157870|FG002|Overall Study|Physician Decision|3
6367851|NCT02367794|10157868|FG000|Overall Study|Protocol Violation|1
6367852|NCT02367794|10157869|FG001|Overall Study|Protocol Violation|0
6367853|NCT02367794|10157870|FG002|Overall Study|Protocol Violation|1
6367854|NCT02367794|10157868|FG000|Overall Study|Withdrawal by Subject|25
6367855|NCT02367794|10157869|FG001|Overall Study|Withdrawal by Subject|12
6367856|NCT02367794|10157870|FG002|Overall Study|Withdrawal by Subject|20
6367857|NCT02367794|10157868|FG000|Overall Study|Brain metastasis|1
6367858|NCT02367794|10157869|FG001|Overall Study|Brain metastasis|0
6367859|NCT02367794|10157870|FG002|Overall Study|Brain metastasis|0
6367860|NCT02367794|10157868|FG000|Overall Study|Randomized in error|0
6367861|NCT02367794|10157869|FG001|Overall Study|Randomized in error|0
6367862|NCT02367794|10157870|FG002|Overall Study|Randomized in error|1
6367863|NCT02367794|10157868|FG000|Overall Study|Patient unable to receive carboplatin|0
6367864|NCT02367794|10157869|FG001|Overall Study|Patient unable to receive carboplatin|0
6367865|NCT02367794|10157870|FG002|Overall Study|Patient unable to receive carboplatin|1
6367866|NCT02367794|10157868|FG000|Overall Study|Hypercalcemia prior to C1D1|0
6367867|NCT02367794|10157869|FG001|Overall Study|Hypercalcemia prior to C1D1|0
6367868|NCT02367794|10157870|FG002|Overall Study|Hypercalcemia prior to C1D1|1
6367869|NCT02367794|10157868|FG000|Overall Study|Adverse Event|0
6367870|NCT02367794|10157869|FG001|Overall Study|Adverse Event|0
6367871|NCT02367794|10157870|FG002|Overall Study|Adverse Event|2
6367872|NCT02367794|10157868|FG000|Overall Study|Study Terminated By Sponsor|0
6367873|NCT02367794|10157869|FG001|Overall Study|Study Terminated By Sponsor|1
6367874|NCT02367794|10157870|FG002|Overall Study|Study Terminated By Sponsor|1
6367875|NCT02367794|10157868|FG000|Overall Study|Moved to Roll-Over Study|0
6367876|NCT02367794|10157869|FG001|Overall Study|Moved to Roll-Over Study|15
6367877|NCT02367794|10157870|FG002|Overall Study|Moved to Roll-Over Study|13
6367878|NCT02367794|10157868|FG000|Overall Study|Sponsor Request|60
6367879|NCT02367794|10157869|FG001|Overall Study|Sponsor Request|57
6367880|NCT02367794|10157870|FG002|Overall Study|Sponsor Request|45
6367881|NCT02367794|10157868|FG000|Overall Study|Moved into PTAP Study|0
6367882|NCT02367794|10157869|FG001|Overall Study|Moved into PTAP Study|2
6367883|NCT02367794|10157870|FG002|Overall Study|Moved into PTAP Study|3
6367884|NCT02367794|10157868|FG000|Overall Study|Moved to Commercial Atezolizumab Use|0
6367885|NCT02367794|10157869|FG001|Overall Study|Moved to Commercial Atezolizumab Use|2
6367886|NCT02367794|10157870|FG002|Overall Study|Moved to Commercial Atezolizumab Use|1
6367887|NCT02367794|10157868|FG000|Overall Study|Investigational Product Availability in Commercial Stock|0
6367888|NCT02367794|10157869|FG001|Overall Study|Investigational Product Availability in Commercial Stock|1
6367889|NCT02367794|10157870|FG002|Overall Study|Investigational Product Availability in Commercial Stock|0
6367890|NCT02367794|10157868|FG000|Overall Study|Participant Enrolled in Extended Protocol|0
6367891|NCT02367794|10157869|FG001|Overall Study|Participant Enrolled in Extended Protocol|1
6367892|NCT02367794|10157870|FG002|Overall Study|Participant Enrolled in Extended Protocol|0
6367893|NCT02367794|10157868|FG000|Overall Study|Discontinuation Matched Treatment Discontinuation|0
6367894|NCT02367794|10157869|FG001|Overall Study|Discontinuation Matched Treatment Discontinuation|0
6367895|NCT02367794|10157870|FG002|Overall Study|Discontinuation Matched Treatment Discontinuation|1
6367908|NCT02358031|10157924|FG000|Overall Study|Death|226
6367909|NCT02358031|10157925|FG001|Overall Study|Death|204
6367910|NCT02358031|10157926|FG002|Overall Study|Death|249
6367911|NCT02358031|10157924|FG000|Overall Study|Lost to Follow-up|0
6367912|NCT02358031|10157925|FG001|Overall Study|Lost to Follow-up|1
6367913|NCT02358031|10157926|FG002|Overall Study|Lost to Follow-up|1
6367914|NCT02358031|10157924|FG000|Overall Study|Withdrawal by Subject|14
6367915|NCT02358031|10157925|FG001|Overall Study|Withdrawal by Subject|12
6367916|NCT02358031|10157926|FG002|Overall Study|Withdrawal by Subject|17
6367917|NCT02358031|10157924|FG000|Overall Study|Ongoing in Study|61
6367918|NCT02358031|10157925|FG001|Overall Study|Ongoing in Study|64
6367919|NCT02358031|10157926|FG002|Overall Study|Ongoing in Study|33
6367920|NCT02353832|10157934|FG000|Overall Study|Ineligible after enrollment|1
6367921|NCT02353832|10157934|FG000|Overall Study|Lost to Follow-up|1
6367922|NCT02353728|10157938|FG000|Overall Study|Subject non-compliance|1
6367923|NCT02345070|10157945|FG000|Overall Study|Adverse Event|12
6367924|NCT02345070|10157946|FG001|Overall Study|Adverse Event|8
6367925|NCT02345070|10157947|FG002|Overall Study|Adverse Event|16
6367926|NCT02345070|10157945|FG000|Overall Study|Poor compliance to protocol|2
6367927|NCT02345070|10157946|FG001|Overall Study|Poor compliance to protocol|0
6367928|NCT02345070|10157947|FG002|Overall Study|Poor compliance to protocol|0
6367929|NCT02345070|10157945|FG000|Overall Study|Other than specified above|6
6367930|NCT02345070|10157946|FG001|Overall Study|Other than specified above|3
6367931|NCT02345070|10157947|FG002|Overall Study|Other than specified above|7
6367932|NCT02325466|10157955|FG000|Period 1 Timeframe - Baseline to Week 4|Adverse Event|0
6367933|NCT02325466|10157956|FG001|Period 1 Timeframe - Baseline to Week 4|Adverse Event|0
6367934|NCT02325466|10157957|FG002|Period 1 Timeframe - Baseline to Week 4|Adverse Event|1
6367935|NCT02325466|10157955|FG000|Period 1 Timeframe - Baseline to Week 4|Withdrawal by Subject|0
6367936|NCT02325466|10157956|FG001|Period 1 Timeframe - Baseline to Week 4|Withdrawal by Subject|2
6367937|NCT02325466|10157957|FG002|Period 1 Timeframe - Baseline to Week 4|Withdrawal by Subject|0
6367938|NCT02325466|10157955|FG000|Period 1 Timeframe - Baseline to Week 4|urgent vascularization|1
6367939|NCT02325466|10157956|FG001|Period 1 Timeframe - Baseline to Week 4|urgent vascularization|0
6367940|NCT02325466|10157957|FG002|Period 1 Timeframe - Baseline to Week 4|urgent vascularization|2
6367941|NCT02325466|10157955|FG000|Period 2 - Timeframe Week 4 to Week 10|Protocol Violation|1
6367942|NCT02325466|10157956|FG001|Period 2 - Timeframe Week 4 to Week 10|Protocol Violation|0
6367943|NCT02325466|10157957|FG002|Period 2 - Timeframe Week 4 to Week 10|Protocol Violation|0
6367944|NCT02325466|10157955|FG000|Period 2 - Timeframe Week 4 to Week 10|Withdrawal by Subject|1
6367945|NCT02325466|10157956|FG001|Period 2 - Timeframe Week 4 to Week 10|Withdrawal by Subject|1
6367946|NCT02325466|10157957|FG002|Period 2 - Timeframe Week 4 to Week 10|Withdrawal by Subject|0
6367947|NCT02325466|10157955|FG000|Period 2 - Timeframe Week 4 to Week 10|urgent vascularization|1
6367948|NCT02325466|10157956|FG001|Period 2 - Timeframe Week 4 to Week 10|urgent vascularization|0
6367949|NCT02325466|10157957|FG002|Period 2 - Timeframe Week 4 to Week 10|urgent vascularization|0
6367950|NCT02325466|10157955|FG000|3rd Crossover - Week 10 to Week 16|Adverse Event|1
6367951|NCT02325466|10157956|FG001|3rd Crossover - Week 10 to Week 16|Adverse Event|0
6367952|NCT02325466|10157957|FG002|3rd Crossover - Week 10 to Week 16|Adverse Event|0
6367953|NCT02325466|10157955|FG000|3rd Crossover - Week 10 to Week 16|Protocol Violation|0
6367954|NCT02325466|10157956|FG001|3rd Crossover - Week 10 to Week 16|Protocol Violation|1
6367955|NCT02325466|10157957|FG002|3rd Crossover - Week 10 to Week 16|Protocol Violation|0
6367956|NCT02325466|10157955|FG000|3rd Crossover - Week 10 to Week 16|urgent vascularization|0
6367957|NCT02325466|10157956|FG001|3rd Crossover - Week 10 to Week 16|urgent vascularization|1
6367958|NCT02325466|10157957|FG002|3rd Crossover - Week 10 to Week 16|urgent vascularization|0
6367959|NCT02322710|10157968|FG000|Overall Study|No efficacy assessment post-baseline|0
6367960|NCT02322710|10157969|FG001|Overall Study|No efficacy assessment post-baseline|1
6367961|NCT02322710|10157968|FG000|Overall Study|Protocol Violation|20
6367962|NCT02322710|10157969|FG001|Overall Study|Protocol Violation|25
6367963|NCT02234310|10158017|FG000|Overall Study|Physician Decision|1
6367964|NCT02234310|10158017|FG000|Overall Study|Adverse Event|1
6367965|NCT02234310|10158017|FG000|Overall Study|Eligibility Criteria not fulfilled|2
6367966|NCT02234310|10158017|FG000|Overall Study|Withdrawal by Subject|2
6367967|NCT02158091|10158031|FG000|Overall Study|DLT|2
6367968|NCT02158091|10158032|FG001|Overall Study|DLT|1
6367969|NCT02158091|10158033|FG002|Overall Study|DLT|0
6367970|NCT02106195|10158079|FG000|Overall Study|Adverse Event|2
6367971|NCT02106195|10158079|FG000|Overall Study|Protocol Violation|1
6367972|NCT02104180|10158091|FG000|Overall Study|Protocol Violation|1
6367973|NCT02104180|10158092|FG001|Overall Study|Protocol Violation|0
6367974|NCT02075840|10158100|FG000|Overall Study|Withdrawal by Subject|13
6367975|NCT02075840|10158101|FG001|Overall Study|Withdrawal by Subject|22
6367976|NCT02075840|10158100|FG000|Overall Study|Reason not specified|1
6367977|NCT02075840|10158101|FG001|Overall Study|Reason not specified|0
6367978|NCT02075840|10158100|FG000|Overall Study|Adverse Event|0
6367979|NCT02075840|10158101|FG001|Overall Study|Adverse Event|2
6367980|NCT02075840|10158100|FG000|Overall Study|Death|35
6367981|NCT02075840|10158101|FG001|Overall Study|Death|40
6367982|NCT02075840|10158100|FG000|Overall Study|Lost to Follow-up|3
6367983|NCT02075840|10158101|FG001|Overall Study|Lost to Follow-up|2
6367984|NCT02075840|10158100|FG000|Overall Study|Physician Decision|1
6367985|NCT02075840|10158101|FG001|Overall Study|Physician Decision|3
6367986|NCT02075840|10158100|FG000|Overall Study|Ongoing at CCOD|99
6367987|NCT02075840|10158101|FG001|Overall Study|Ongoing at CCOD|82
6367988|NCT02066181|10158109|FG000|Overall Study|Withdrawal by Subject|1
6367989|NCT02066181|10158110|FG001|Overall Study|Withdrawal by Subject|1
6367990|NCT02040857|10158123|FG000|Overall Study|Adverse Event|14
6367991|NCT02040857|10158123|FG000|Overall Study|Physician Decision|5
6367992|NCT02040857|10158123|FG000|Overall Study|Withdrawal by Subject|31
6367993|NCT02040857|10158123|FG000|Overall Study|patient non-compliance|3
6367994|NCT02040857|10158123|FG000|Overall Study|Lost to Follow-up|2
6367995|NCT02040857|10158123|FG000|Overall Study|recurrence|4
6367996|NCT02040857|10158123|FG000|Overall Study|ineligible|1
6367997|NCT01943825|10158143|FG000|Overall Study|Lost to Follow-up|9
6367998|NCT01943825|10158144|FG001|Overall Study|Lost to Follow-up|3
6367999|NCT01943825|10158145|FG002|Overall Study|Lost to Follow-up|12
6368000|NCT01943825|10158146|FG003|Overall Study|Lost to Follow-up|8
6368001|NCT01943825|10158143|FG000|Overall Study|Withdrawal by Subject|1
6368002|NCT01943825|10158144|FG001|Overall Study|Withdrawal by Subject|0
6368003|NCT01943825|10158145|FG002|Overall Study|Withdrawal by Subject|3
6368004|NCT01943825|10158146|FG003|Overall Study|Withdrawal by Subject|2
6368005|NCT01943825|10158143|FG000|Overall Study|Other than specified above|0
6368006|NCT01943825|10158144|FG001|Overall Study|Other than specified above|1
6368007|NCT01943825|10158145|FG002|Overall Study|Other than specified above|0
6368008|NCT01943825|10158146|FG003|Overall Study|Other than specified above|1
6368009|NCT01940471|10158162|FG000|Double-Blind Phase|Randomized but Never Treated|1
6368010|NCT01940471|10158163|FG001|Double-Blind Phase|Randomized but Never Treated|1
6368011|NCT01940471|10158162|FG000|Double-Blind Phase|Withdrew Consent|13
6368012|NCT01940471|10158163|FG001|Double-Blind Phase|Withdrew Consent|7
6368013|NCT01940471|10158162|FG000|Double-Blind Phase|Adverse Event|1
6368014|NCT01940471|10158163|FG001|Double-Blind Phase|Adverse Event|2
6368015|NCT01940471|10158162|FG000|Double-Blind Phase|Lost to Follow-up|3
6368016|NCT01940471|10158163|FG001|Double-Blind Phase|Lost to Follow-up|2
6368017|NCT01940471|10158162|FG000|Double-Blind Phase|Pregnancy|2
6368018|NCT01940471|10158163|FG001|Double-Blind Phase|Pregnancy|1
6368019|NCT01940471|10158162|FG000|Double-Blind Phase|Investigator's Discretion|5
6368020|NCT01940471|10158163|FG001|Double-Blind Phase|Investigator's Discretion|0
6368021|NCT01940471|10158162|FG000|Double-Blind Phase|Non-Compliance with Study Drug|1
6368022|NCT01940471|10158163|FG001|Double-Blind Phase|Non-Compliance with Study Drug|1
6368023|NCT01940471|10158162|FG000|Double-Blind Phase|Protocol-Specified Criteria|1
6368024|NCT01940471|10158163|FG001|Double-Blind Phase|Protocol-Specified Criteria|0
6368025|NCT01940471|10158162|FG000|Double-Blind Phase|Death|1
6368026|NCT01940471|10158163|FG001|Double-Blind Phase|Death|0
6368027|NCT01940471|10158162|FG000|Double-Blind Phase|Lack of Efficacy|1
6368028|NCT01940471|10158163|FG001|Double-Blind Phase|Lack of Efficacy|0
6368029|NCT01940471|10158162|FG000|Double-Blind Phase|Protocol Violation|0
6368030|NCT01940471|10158163|FG001|Double-Blind Phase|Protocol Violation|1
6368031|NCT01940471|10158162|FG000|Double-Blind Phase|Still in Double-Blind Phase|539
6368032|NCT01940471|10158163|FG001|Double-Blind Phase|Still in Double-Blind Phase|270
6368033|NCT01940471|10158162|FG000|Open-Label Extension|Still in Open-Label Extension Phase|14
6368034|NCT01940471|10158163|FG001|Open-Label Extension|Still in Open-Label Extension Phase|8
6368035|NCT01874353|10158172|FG000|Overall Study|One patient was unblinded and one patient was randomised in error|2
6368036|NCT01874353|10158173|FG001|Overall Study|One patient was unblinded and one patient was randomised in error|0
6368037|NCT01874353|10158174|FG002|Overall Study|One patient was unblinded and one patient was randomised in error|0
6368038|NCT01874353|10158175|FG003|Overall Study|One patient was unblinded and one patient was randomised in error|0
6368039|NCT01874353|10158172|FG000|Overall Study|Lost to Follow-up|2
6368040|NCT01874353|10158173|FG001|Overall Study|Lost to Follow-up|2
6368041|NCT01874353|10158174|FG002|Overall Study|Lost to Follow-up|2
6368042|NCT01874353|10158175|FG003|Overall Study|Lost to Follow-up|0
6368043|NCT01874353|10158172|FG000|Overall Study|Death|110
6368044|NCT01874353|10158173|FG001|Overall Study|Death|60
6368045|NCT01874353|10158174|FG002|Overall Study|Death|13
6368046|NCT01874353|10158175|FG003|Overall Study|Death|7
6368047|NCT01874353|10158172|FG000|Overall Study|Withdrawal by Subject|13
6368048|NCT01874353|10158173|FG001|Overall Study|Withdrawal by Subject|11
6368049|NCT01874353|10158174|FG002|Overall Study|Withdrawal by Subject|0
6368050|NCT01874353|10158175|FG003|Overall Study|Withdrawal by Subject|0
6368051|NCT01853748|10158204|FG000|Allocation|Withdrawal by Subject|1
6368052|NCT01853748|10158205|FG001|Allocation|Withdrawal by Subject|13
6368053|NCT01853748|10158204|FG000|Allocation|not sufficient to receive intervention|0
6368054|NCT01853748|10158205|FG001|Allocation|not sufficient to receive intervention|1
6368055|NCT01853748|10158204|FG000|Follow-Up|Withdrawal by Subject|7
6368056|NCT01853748|10158205|FG001|Follow-Up|Withdrawal by Subject|6
6368057|NCT01853748|10158204|FG000|Follow-Up|Adverse Event|67
6368058|NCT01853748|10158205|FG001|Follow-Up|Adverse Event|7
6368059|NCT01853748|10158204|FG000|Follow-Up|not available for data collection|16
6368060|NCT01853748|10158205|FG001|Follow-Up|not available for data collection|4
6368061|NCT01843374|10158222|FG000|Overall Study|Death|155
6368062|NCT01843374|10158223|FG001|Overall Study|Death|313
6368063|NCT01843374|10158222|FG000|Overall Study|Withdrawal by Subject|14
6368064|NCT01843374|10158223|FG001|Overall Study|Withdrawal by Subject|20
6368065|NCT01843374|10158222|FG000|Overall Study|Withdrawing due to Other reason|20
6368066|NCT01843374|10158223|FG001|Overall Study|Withdrawing due to Other reason|46
6368067|NCT01817751|10158242|FG000|Overall Study|Physician Decision|1
6368068|NCT01722331|10158249|FG000|Part 1|Adverse Event|5
6368069|NCT01722331|10158250|FG001|Part 1|Adverse Event|0
6368070|NCT01722331|10158251|FG002|Part 1|Adverse Event|0
6368071|NCT01722331|10158252|FG003|Part 1|Adverse Event|0
6368072|NCT01722331|10158253|FG004|Part 1|Adverse Event|0
6368073|NCT01722331|10158254|FG005|Part 1|Adverse Event|0
6368074|NCT01722331|10158255|FG006|Part 1|Adverse Event|0
6368075|NCT01722331|10158249|FG000|Part 1|Lack of Efficacy|0
6368076|NCT01722331|10158250|FG001|Part 1|Lack of Efficacy|0
6368077|NCT01722331|10158251|FG002|Part 1|Lack of Efficacy|1
6368078|NCT01722331|10158252|FG003|Part 1|Lack of Efficacy|0
6368079|NCT01722331|10158253|FG004|Part 1|Lack of Efficacy|2
6368080|NCT01722331|10158254|FG005|Part 1|Lack of Efficacy|0
6368081|NCT01722331|10158255|FG006|Part 1|Lack of Efficacy|0
6368082|NCT01722331|10158249|FG000|Part 1|Lost to Follow-up|1
6368083|NCT01722331|10158250|FG001|Part 1|Lost to Follow-up|0
6368084|NCT01722331|10158251|FG002|Part 1|Lost to Follow-up|2
6368085|NCT01722331|10158252|FG003|Part 1|Lost to Follow-up|0
6368086|NCT01722331|10158253|FG004|Part 1|Lost to Follow-up|1
6368087|NCT01722331|10158254|FG005|Part 1|Lost to Follow-up|0
6368088|NCT01722331|10158255|FG006|Part 1|Lost to Follow-up|0
6368089|NCT01722331|10158249|FG000|Part 1|Physician Decision|0
6368090|NCT01722331|10158250|FG001|Part 1|Physician Decision|0
6368091|NCT01722331|10158251|FG002|Part 1|Physician Decision|3
6368092|NCT01722331|10158252|FG003|Part 1|Physician Decision|0
6368093|NCT01722331|10158253|FG004|Part 1|Physician Decision|1
6368094|NCT01722331|10158254|FG005|Part 1|Physician Decision|0
6368095|NCT01722331|10158255|FG006|Part 1|Physician Decision|0
6368096|NCT01722331|10158249|FG000|Part 1|Pregnancy|1
6368097|NCT01722331|10158250|FG001|Part 1|Pregnancy|0
6368098|NCT01722331|10158251|FG002|Part 1|Pregnancy|0
6368099|NCT01722331|10158252|FG003|Part 1|Pregnancy|0
6368100|NCT01722331|10158253|FG004|Part 1|Pregnancy|0
6368101|NCT01722331|10158254|FG005|Part 1|Pregnancy|0
6368102|NCT01722331|10158255|FG006|Part 1|Pregnancy|0
6368103|NCT01722331|10158249|FG000|Part 1|Progressive Disease|0
6368104|NCT01722331|10158250|FG001|Part 1|Progressive Disease|0
6368105|NCT01722331|10158251|FG002|Part 1|Progressive Disease|0
6368106|NCT01722331|10158252|FG003|Part 1|Progressive Disease|0
6368107|NCT01722331|10158253|FG004|Part 1|Progressive Disease|1
6368108|NCT01722331|10158254|FG005|Part 1|Progressive Disease|0
6368109|NCT01722331|10158255|FG006|Part 1|Progressive Disease|0
6368110|NCT01722331|10158249|FG000|Part 1|Protocol Violation|1
6368111|NCT01722331|10158250|FG001|Part 1|Protocol Violation|0
6368112|NCT01722331|10158251|FG002|Part 1|Protocol Violation|0
6368113|NCT01722331|10158252|FG003|Part 1|Protocol Violation|0
6368114|NCT01722331|10158253|FG004|Part 1|Protocol Violation|1
6368115|NCT01722331|10158254|FG005|Part 1|Protocol Violation|0
6368116|NCT01722331|10158255|FG006|Part 1|Protocol Violation|0
6368117|NCT01722331|10158249|FG000|Part 1|Withdrawal by Subject|2
6368118|NCT01722331|10158250|FG001|Part 1|Withdrawal by Subject|0
6368119|NCT01722331|10158251|FG002|Part 1|Withdrawal by Subject|3
6368120|NCT01722331|10158252|FG003|Part 1|Withdrawal by Subject|0
6368121|NCT01722331|10158253|FG004|Part 1|Withdrawal by Subject|3
6368122|NCT01722331|10158254|FG005|Part 1|Withdrawal by Subject|0
6368123|NCT01722331|10158255|FG006|Part 1|Withdrawal by Subject|0
6368124|NCT01722331|10158249|FG000|Part 2|Adverse Event|3
6368125|NCT01722331|10158250|FG001|Part 2|Adverse Event|0
6368126|NCT01722331|10158251|FG002|Part 2|Adverse Event|0
6368127|NCT01722331|10158252|FG003|Part 2|Adverse Event|0
6368128|NCT01722331|10158253|FG004|Part 2|Adverse Event|0
6368129|NCT01722331|10158254|FG005|Part 2|Adverse Event|1
6368130|NCT01722331|10158255|FG006|Part 2|Adverse Event|0
6368131|NCT01722331|10158249|FG000|Part 2|Lack of Efficacy|3
6368132|NCT01722331|10158250|FG001|Part 2|Lack of Efficacy|0
6368133|NCT01722331|10158251|FG002|Part 2|Lack of Efficacy|11
6368134|NCT01722331|10158252|FG003|Part 2|Lack of Efficacy|0
6368135|NCT01722331|10158253|FG004|Part 2|Lack of Efficacy|0
6368136|NCT01722331|10158254|FG005|Part 2|Lack of Efficacy|3
6368137|NCT01722331|10158255|FG006|Part 2|Lack of Efficacy|3
6368138|NCT01722331|10158249|FG000|Part 2|Lost to Follow-up|0
6368139|NCT01722331|10158250|FG001|Part 2|Lost to Follow-up|0
6368140|NCT01722331|10158251|FG002|Part 2|Lost to Follow-up|3
6368141|NCT01722331|10158252|FG003|Part 2|Lost to Follow-up|0
6368142|NCT01722331|10158253|FG004|Part 2|Lost to Follow-up|0
6368143|NCT01722331|10158254|FG005|Part 2|Lost to Follow-up|1
6368144|NCT01722331|10158255|FG006|Part 2|Lost to Follow-up|1
6368145|NCT01722331|10158249|FG000|Part 2|Non-Compliance with Study Drug|1
6368146|NCT01722331|10158250|FG001|Part 2|Non-Compliance with Study Drug|0
6368147|NCT01722331|10158251|FG002|Part 2|Non-Compliance with Study Drug|1
6368148|NCT01722331|10158252|FG003|Part 2|Non-Compliance with Study Drug|0
6368149|NCT01722331|10158253|FG004|Part 2|Non-Compliance with Study Drug|0
6368150|NCT01722331|10158254|FG005|Part 2|Non-Compliance with Study Drug|0
6368151|NCT01722331|10158255|FG006|Part 2|Non-Compliance with Study Drug|0
6368152|NCT01722331|10158249|FG000|Part 2|Physician Decision|0
6368153|NCT01722331|10158250|FG001|Part 2|Physician Decision|0
6368154|NCT01722331|10158251|FG002|Part 2|Physician Decision|2
6368155|NCT01722331|10158252|FG003|Part 2|Physician Decision|0
6368156|NCT01722331|10158253|FG004|Part 2|Physician Decision|0
6368157|NCT01722331|10158254|FG005|Part 2|Physician Decision|0
6368158|NCT01722331|10158255|FG006|Part 2|Physician Decision|0
6368159|NCT01722331|10158249|FG000|Part 2|Pregnancy|0
6368160|NCT01722331|10158250|FG001|Part 2|Pregnancy|0
6368161|NCT01722331|10158251|FG002|Part 2|Pregnancy|0
6368162|NCT01722331|10158252|FG003|Part 2|Pregnancy|0
6368163|NCT01722331|10158253|FG004|Part 2|Pregnancy|0
6368164|NCT01722331|10158254|FG005|Part 2|Pregnancy|1
6368165|NCT01722331|10158255|FG006|Part 2|Pregnancy|0
6368166|NCT01722331|10158249|FG000|Part 2|Progressive Disease|0
6368167|NCT01722331|10158250|FG001|Part 2|Progressive Disease|0
6368168|NCT01722331|10158251|FG002|Part 2|Progressive Disease|1
6368169|NCT01722331|10158252|FG003|Part 2|Progressive Disease|0
6368170|NCT01722331|10158253|FG004|Part 2|Progressive Disease|0
6368171|NCT01722331|10158254|FG005|Part 2|Progressive Disease|0
6368172|NCT01722331|10158255|FG006|Part 2|Progressive Disease|0
6368173|NCT01722331|10158249|FG000|Part 2|Protocol Violation|1
6368174|NCT01722331|10158250|FG001|Part 2|Protocol Violation|0
6368175|NCT01722331|10158251|FG002|Part 2|Protocol Violation|0
6368176|NCT01722331|10158252|FG003|Part 2|Protocol Violation|0
6043258|NCT00388362|9641809|FG000|Enrolled|Death|1
6043259|NCT00388362|9641809|FG000|Enrolled|Loss insurance|1
6043260|NCT00388362|9641809|FG000|Enrolled|Withdrawal by Subject|1
6043261|NCT00388362|9641809|FG000|Remained on Study Median of 514 Days|Death|2
6043262|NCT00388505|9641839|FG000|Overall Study|Adverse Event or Death|43
6043263|NCT00388505|9641840|FG001|Overall Study|Adverse Event or Death|17
6043264|NCT00388505|9641839|FG000|Overall Study|Withdrawal by Subject|24
6043265|NCT00388505|9641840|FG001|Overall Study|Withdrawal by Subject|9
6043266|NCT00388505|9641839|FG000|Overall Study|Lost to Follow-up|5
6043267|NCT00388505|9641840|FG001|Overall Study|Lost to Follow-up|3
6043268|NCT00388505|9641839|FG000|Overall Study|Inappropriate Enrollment|0
6043269|NCT00388505|9641840|FG001|Overall Study|Inappropriate Enrollment|1
6043270|NCT00388505|9641839|FG000|Overall Study|Administrative Reason|1
6043271|NCT00388505|9641840|FG001|Overall Study|Administrative Reason|0
6043272|NCT00388505|9641839|FG000|Overall Study|Protocol Violation|6
6043273|NCT00388505|9641840|FG001|Overall Study|Protocol Violation|5
6043274|NCT00388505|9641839|FG000|Overall Study|Unable to classify|4
6043275|NCT00388505|9641840|FG001|Overall Study|Unable to classify|3
6043276|NCT00388583|9641848|FG000|Overall Study|Protocol Violation|1
6043277|NCT00388583|9641849|FG001|Overall Study|Protocol Violation|0
6043278|NCT00388583|9641848|FG000|Overall Study|Withdrawal by Subject|3
6043279|NCT00388583|9641849|FG001|Overall Study|Withdrawal by Subject|3
6043280|NCT00388583|9641848|FG000|Overall Study|Serious Adverse Event|2
6043281|NCT00388583|9641849|FG001|Overall Study|Serious Adverse Event|0
6043282|NCT00388583|9641848|FG000|Overall Study|Did not receive vaccine|0
6043283|NCT00388583|9641849|FG001|Overall Study|Did not receive vaccine|1
6043284|NCT00388674|9641857|FG000|Initial Treatment|Administrative Reason by Sponsor|241
6043285|NCT00388674|9641858|FG001|Initial Treatment|Administrative Reason by Sponsor|158
6043286|NCT00388674|9641857|FG000|Initial Treatment|Adverse Event|22
6043287|NCT00388674|9641858|FG001|Initial Treatment|Adverse Event|87
6043288|NCT00388674|9641857|FG000|Initial Treatment|Death|215
6043289|NCT00388674|9641858|FG001|Initial Treatment|Death|216
6043290|NCT00388674|9641857|FG000|Initial Treatment|Non-HCC HBV Disease Progression|11
6043291|NCT00388674|9641858|FG001|Initial Treatment|Non-HCC HBV Disease Progression|17
6368177|NCT01722331|10158253|FG004|Part 2|Protocol Violation|0
6368178|NCT01722331|10158254|FG005|Part 2|Protocol Violation|0
6368179|NCT01722331|10158255|FG006|Part 2|Protocol Violation|0
6368180|NCT01722331|10158249|FG000|Part 2|Withdrawal by Subject|5
6368181|NCT01722331|10158250|FG001|Part 2|Withdrawal by Subject|0
6043292|NCT00388674|9641857|FG000|Initial Treatment|HCC|12
6043293|NCT00388674|9641858|FG001|Initial Treatment|HCC|20
6043294|NCT00388674|9641857|FG000|Initial Treatment|Lost to Follow-up|526
6368182|NCT01722331|10158251|FG002|Part 2|Withdrawal by Subject|3
6368183|NCT01722331|10158252|FG003|Part 2|Withdrawal by Subject|0
6368184|NCT01722331|10158253|FG004|Part 2|Withdrawal by Subject|0
6368185|NCT01722331|10158254|FG005|Part 2|Withdrawal by Subject|2
6368186|NCT01722331|10158255|FG006|Part 2|Withdrawal by Subject|2
6368187|NCT01722331|10158249|FG000|Part 2|Other Protocol Specified Criteria|6
6368188|NCT01722331|10158250|FG001|Part 2|Other Protocol Specified Criteria|0
6368189|NCT01722331|10158251|FG002|Part 2|Other Protocol Specified Criteria|10
6368190|NCT01722331|10158252|FG003|Part 2|Other Protocol Specified Criteria|0
6368191|NCT01722331|10158253|FG004|Part 2|Other Protocol Specified Criteria|0
6368192|NCT01722331|10158254|FG005|Part 2|Other Protocol Specified Criteria|2
6368193|NCT01722331|10158255|FG006|Part 2|Other Protocol Specified Criteria|1
6368194|NCT01722331|10158249|FG000|Part 3|Adverse Event|2
6368195|NCT01722331|10158250|FG001|Part 3|Adverse Event|2
6368196|NCT01722331|10158251|FG002|Part 3|Adverse Event|0
6368197|NCT01722331|10158252|FG003|Part 3|Adverse Event|1
6368198|NCT01722331|10158253|FG004|Part 3|Adverse Event|0
6368199|NCT01722331|10158254|FG005|Part 3|Adverse Event|0
6368200|NCT01722331|10158255|FG006|Part 3|Adverse Event|0
6368201|NCT01722331|10158249|FG000|Part 3|Death|1
6368202|NCT01722331|10158250|FG001|Part 3|Death|0
6368203|NCT01722331|10158251|FG002|Part 3|Death|0
6368204|NCT01722331|10158252|FG003|Part 3|Death|0
6368205|NCT01722331|10158253|FG004|Part 3|Death|0
6368206|NCT01722331|10158254|FG005|Part 3|Death|0
6368207|NCT01722331|10158255|FG006|Part 3|Death|0
6368208|NCT01722331|10158249|FG000|Part 3|Lack of Efficacy|1
6368209|NCT01722331|10158250|FG001|Part 3|Lack of Efficacy|0
6368210|NCT01722331|10158251|FG002|Part 3|Lack of Efficacy|0
6368211|NCT01722331|10158252|FG003|Part 3|Lack of Efficacy|0
6368212|NCT01722331|10158253|FG004|Part 3|Lack of Efficacy|0
6368213|NCT01722331|10158254|FG005|Part 3|Lack of Efficacy|0
6368214|NCT01722331|10158255|FG006|Part 3|Lack of Efficacy|0
6368215|NCT01722331|10158249|FG000|Part 3|Lost to Follow-up|3
6368216|NCT01722331|10158250|FG001|Part 3|Lost to Follow-up|4
6368217|NCT01722331|10158251|FG002|Part 3|Lost to Follow-up|0
6368218|NCT01722331|10158252|FG003|Part 3|Lost to Follow-up|0
6368219|NCT01722331|10158253|FG004|Part 3|Lost to Follow-up|0
6368220|NCT01722331|10158254|FG005|Part 3|Lost to Follow-up|1
6368221|NCT01722331|10158255|FG006|Part 3|Lost to Follow-up|0
6368222|NCT01722331|10158249|FG000|Part 3|Non-Compliance with Study Drug|0
6368223|NCT01722331|10158250|FG001|Part 3|Non-Compliance with Study Drug|1
6368224|NCT01722331|10158251|FG002|Part 3|Non-Compliance with Study Drug|0
6368225|NCT01722331|10158252|FG003|Part 3|Non-Compliance with Study Drug|0
6368226|NCT01722331|10158253|FG004|Part 3|Non-Compliance with Study Drug|0
6368227|NCT01722331|10158254|FG005|Part 3|Non-Compliance with Study Drug|0
6368228|NCT01722331|10158255|FG006|Part 3|Non-Compliance with Study Drug|0
6368229|NCT01722331|10158249|FG000|Part 3|Physician Decision|1
6368230|NCT01722331|10158250|FG001|Part 3|Physician Decision|1
6368231|NCT01722331|10158251|FG002|Part 3|Physician Decision|0
6368232|NCT01722331|10158252|FG003|Part 3|Physician Decision|0
6368233|NCT01722331|10158253|FG004|Part 3|Physician Decision|0
6368234|NCT01722331|10158254|FG005|Part 3|Physician Decision|0
6368235|NCT01722331|10158255|FG006|Part 3|Physician Decision|1
6368236|NCT01722331|10158249|FG000|Part 3|Protocol Violation|2
6368237|NCT01722331|10158250|FG001|Part 3|Protocol Violation|1
6368238|NCT01722331|10158251|FG002|Part 3|Protocol Violation|0
6368239|NCT01722331|10158252|FG003|Part 3|Protocol Violation|0
6368240|NCT01722331|10158253|FG004|Part 3|Protocol Violation|0
6368241|NCT01722331|10158254|FG005|Part 3|Protocol Violation|0
6368242|NCT01722331|10158255|FG006|Part 3|Protocol Violation|0
6368243|NCT01722331|10158249|FG000|Part 3|Withdrawal by Subject|4
6368244|NCT01722331|10158250|FG001|Part 3|Withdrawal by Subject|7
6368245|NCT01722331|10158251|FG002|Part 3|Withdrawal by Subject|0
6368246|NCT01722331|10158252|FG003|Part 3|Withdrawal by Subject|0
6368247|NCT01722331|10158253|FG004|Part 3|Withdrawal by Subject|0
6368248|NCT01722331|10158254|FG005|Part 3|Withdrawal by Subject|2
6368249|NCT01722331|10158255|FG006|Part 3|Withdrawal by Subject|1
6368250|NCT01722331|10158249|FG000|Part 3|Other Protocol Specified Criteria|1
6368251|NCT01722331|10158250|FG001|Part 3|Other Protocol Specified Criteria|1
6368252|NCT01722331|10158251|FG002|Part 3|Other Protocol Specified Criteria|0
6368253|NCT01722331|10158252|FG003|Part 3|Other Protocol Specified Criteria|0
6368254|NCT01722331|10158253|FG004|Part 3|Other Protocol Specified Criteria|0
6368255|NCT01722331|10158254|FG005|Part 3|Other Protocol Specified Criteria|0
6368256|NCT01722331|10158255|FG006|Part 3|Other Protocol Specified Criteria|0
6368257|NCT01716117|10158269|FG000|Overall Study|Death|5
6368258|NCT01716117|10158270|FG001|Overall Study|Death|2
6368259|NCT01716117|10158269|FG000|Overall Study|Withdrawal by Subject|2
6368260|NCT01716117|10158270|FG001|Overall Study|Withdrawal by Subject|0
6368261|NCT01698905|10158284|FG000|Overall Study|Adverse Event|4
6368262|NCT01698905|10158284|FG000|Overall Study|Physician Decision|2
6368263|NCT01698905|10158284|FG000|Overall Study|Pregnancy|1
6368264|NCT01698905|10158284|FG000|Overall Study|Protocol Violation|1
6368265|NCT01698905|10158284|FG000|Overall Study|Subject/guardian decision|2
6368266|NCT01698905|10158284|FG000|Overall Study|Death|1
6368267|NCT01630590|10158305|FG000|Overall Study|Adverse Event|9
6368268|NCT01630590|10158305|FG000|Overall Study|Lack of Efficacy|37
6368269|NCT01630590|10158305|FG000|Overall Study|Withdrawal by Subject|4
6368270|NCT01630590|10158305|FG000|Overall Study|2nd primary tumor|2
6368271|NCT01630590|10158305|FG000|Overall Study|Automobile accident|1
6368272|NCT01630590|10158305|FG000|Overall Study|Maximum benefit|4
6368273|NCT01619085|10158309|FG000|Overall Study|Adverse Event|231
6368274|NCT01619085|10158309|FG000|Overall Study|Protocol Violation|4
6368275|NCT01619085|10158309|FG000|Overall Study|Lost to Follow-up|3
6368276|NCT01619085|10158309|FG000|Overall Study|Withdrawal by Subject|45
6368277|NCT01619085|10158309|FG000|Overall Study|Other than specified|96
6368278|NCT01619085|10158309|FG000|Overall Study|Not treated|1
6368279|NCT01619085|10158309|FG000|Overall Study|Death|145
6368280|NCT01499095|10158322|FG000|Overall Study|Randomized But Not Treated|1
6368281|NCT01499095|10158323|FG001|Overall Study|Randomized But Not Treated|1
6368282|NCT01499095|10158322|FG000|Overall Study|Adverse Event|12
6368283|NCT01499095|10158323|FG001|Overall Study|Adverse Event|7
6368284|NCT01499095|10158322|FG000|Overall Study|Lack of Efficacy|2
6368285|NCT01499095|10158323|FG001|Overall Study|Lack of Efficacy|1
6368286|NCT01499095|10158322|FG000|Overall Study|Protocol Violation|6
6368287|NCT01499095|10158323|FG001|Overall Study|Protocol Violation|7
6368288|NCT01499095|10158322|FG000|Overall Study|Received Rescue Therapy|32
6368289|NCT01499095|10158323|FG001|Overall Study|Received Rescue Therapy|40
6368290|NCT01499095|10158322|FG000|Overall Study|Diverse Reasons|22
6368291|NCT01499095|10158323|FG001|Overall Study|Diverse Reasons|25
6368292|NCT01499095|10158322|FG000|Overall Study|Lost to Follow-up|6
6368293|NCT01499095|10158323|FG001|Overall Study|Lost to Follow-up|4
6368294|NCT01499095|10158322|FG000|Overall Study|Insulin Dropped Below Authorized Dose|0
6368295|NCT01499095|10158323|FG001|Overall Study|Insulin Dropped Below Authorized Dose|5
6368296|NCT01499095|10158322|FG000|Overall Study|Hypoglycemia|3
6368297|NCT01499095|10158323|FG001|Overall Study|Hypoglycemia|1
6368298|NCT01499095|10158322|FG000|Overall Study|Diagnosed With Type 1 Diabetes Mellitus|2
6368299|NCT01499095|10158323|FG001|Overall Study|Diagnosed With Type 1 Diabetes Mellitus|1
6368300|NCT01499095|10158322|FG000|Overall Study|Change in Injection Schedule|2
6368301|NCT01499095|10158323|FG001|Overall Study|Change in Injection Schedule|0
6368302|NCT01499095|10158322|FG000|Overall Study|Perceived Lack of Efficacy|1
6368303|NCT01499095|10158323|FG001|Overall Study|Perceived Lack of Efficacy|1
6368304|NCT01499082|10158334|FG000|Overall Study|Randomized but not Treated|0
6368305|NCT01499082|10158335|FG001|Overall Study|Randomized but not Treated|1
6368306|NCT01499082|10158334|FG000|Overall Study|Adverse Event|12
6368307|NCT01499082|10158335|FG001|Overall Study|Adverse Event|16
6368308|NCT01499082|10158334|FG000|Overall Study|Lack of Efficacy|1
6368309|NCT01499082|10158335|FG001|Overall Study|Lack of Efficacy|1
6368310|NCT01499082|10158334|FG000|Overall Study|Protocol Violation|6
6368311|NCT01499082|10158335|FG001|Overall Study|Protocol Violation|8
6368312|NCT01499082|10158334|FG000|Overall Study|Diverse Reasons|18
6368313|NCT01499082|10158335|FG001|Overall Study|Diverse Reasons|14
6368314|NCT01499082|10158334|FG000|Overall Study|Site Closure for Noncompliance|5
6368315|NCT01499082|10158335|FG001|Overall Study|Site Closure for Noncompliance|2
6368316|NCT01499082|10158334|FG000|Overall Study|Hypoglycemia|2
6368317|NCT01499082|10158335|FG001|Overall Study|Hypoglycemia|3
6368318|NCT01499082|10158334|FG000|Overall Study|Lost to Follow-up|1
6368319|NCT01499082|10158335|FG001|Overall Study|Lost to Follow-up|3
6368320|NCT01496976|10158343|FG000|Overall Study|Withdrew - received stem cell transplant|1
6368321|NCT01488890|10158351|FG000|Overall Study|Serious adverse event|2
6368322|NCT01488890|10158352|FG001|Overall Study|Serious adverse event|0
6368323|NCT01488890|10158353|FG002|Overall Study|Serious adverse event|0
6368324|NCT01488890|10158354|FG003|Overall Study|Serious adverse event|0
6368325|NCT01488890|10158351|FG000|Overall Study|Protocol Violation|3
6368326|NCT01488890|10158352|FG001|Overall Study|Protocol Violation|0
6368327|NCT01488890|10158353|FG002|Overall Study|Protocol Violation|4
6368328|NCT01488890|10158354|FG003|Overall Study|Protocol Violation|0
6368329|NCT01488890|10158351|FG000|Overall Study|Lost to Follow-up|13
6368330|NCT01488890|10158352|FG001|Overall Study|Lost to Follow-up|10
6368331|NCT01488890|10158353|FG002|Overall Study|Lost to Follow-up|20
6368332|NCT01488890|10158354|FG003|Overall Study|Lost to Follow-up|3
6368333|NCT01488890|10158351|FG000|Overall Study|Withdrawal by Subject|14
6368334|NCT01488890|10158352|FG001|Overall Study|Withdrawal by Subject|10
6368335|NCT01488890|10158353|FG002|Overall Study|Withdrawal by Subject|11
6368336|NCT01488890|10158354|FG003|Overall Study|Withdrawal by Subject|2
6368337|NCT01436396|10158370|FG000|Overall Study|Protocol Violation|7
6368338|NCT01436396|10158371|FG001|Overall Study|Protocol Violation|5
6368339|NCT01436396|10158370|FG000|Overall Study|Adverse Event|1
6368340|NCT01436396|10158371|FG001|Overall Study|Adverse Event|2
6368341|NCT01436396|10158370|FG000|Overall Study|Withdrawal by Subject|19
6368342|NCT01436396|10158371|FG001|Overall Study|Withdrawal by Subject|29
6368343|NCT01436396|10158370|FG000|Overall Study|Serious adverse event|2
6368344|NCT01436396|10158371|FG001|Overall Study|Serious adverse event|3
6368345|NCT01436396|10158370|FG000|Overall Study|Lost to Follow-up|3
6368346|NCT01436396|10158371|FG001|Overall Study|Lost to Follow-up|3
6368347|NCT01411241|10158379|FG000|Overall Study|Protocol Violation|0
6368348|NCT01411241|10158380|FG001|Overall Study|Protocol Violation|5
6368349|NCT01411241|10158379|FG000|Overall Study|Withdrawal by Subject|9
6368350|NCT01411241|10158380|FG001|Overall Study|Withdrawal by Subject|10
6368351|NCT01411241|10158379|FG000|Overall Study|Serious Adverse Event|0
6368352|NCT01411241|10158380|FG001|Overall Study|Serious Adverse Event|3
6368353|NCT01411241|10158379|FG000|Overall Study|Lost to Follow-up|2
6368354|NCT01411241|10158380|FG001|Overall Study|Lost to Follow-up|4
6368355|NCT01374516|10158388|FG000|Vaccination Phase (Up to 25 Months)|Protocol Violation|43
6368356|NCT01374516|10158389|FG001|Vaccination Phase (Up to 25 Months)|Protocol Violation|14
6368357|NCT01374516|10158388|FG000|Vaccination Phase (Up to 25 Months)|Adverse Event|3
6368358|NCT01374516|10158389|FG001|Vaccination Phase (Up to 25 Months)|Adverse Event|0
6368359|NCT01374516|10158388|FG000|Vaccination Phase (Up to 25 Months)|Withdrawal by Subject|480
6368360|NCT01374516|10158389|FG001|Vaccination Phase (Up to 25 Months)|Withdrawal by Subject|240
6368361|NCT01374516|10158388|FG000|Vaccination Phase (Up to 25 Months)|Lost to Follow-up|106
6368362|NCT01374516|10158389|FG001|Vaccination Phase (Up to 25 Months)|Lost to Follow-up|46
6368363|NCT01374516|10158388|FG000|Vaccination Phase (Up to 25 Months)|Serious adverse event|7
6368364|NCT01374516|10158389|FG001|Vaccination Phase (Up to 25 Months)|Serious adverse event|9
6368365|NCT01374516|10158388|FG000|Surveillance Expansion Period|Protocol Violation|386
6368366|NCT01374516|10158389|FG001|Surveillance Expansion Period|Protocol Violation|217
6368367|NCT01374516|10158388|FG000|Surveillance Expansion Period|Withdrawal by Subject|1870
6368368|NCT01374516|10158389|FG001|Surveillance Expansion Period|Withdrawal by Subject|986
6368369|NCT01374516|10158388|FG000|Surveillance Expansion Period|Lost to Follow-up|73
6368370|NCT01374516|10158389|FG001|Surveillance Expansion Period|Lost to Follow-up|45
6368371|NCT01374516|10158388|FG000|Surveillance Expansion Period|Serious adverse event|20
6368372|NCT01374516|10158389|FG001|Surveillance Expansion Period|Serious adverse event|5
6368373|NCT01373281|10158404|FG000|Vaccination Phase (Up to 25 Months)|Withdrawal by Subject|40
6368374|NCT01373281|10158405|FG001|Vaccination Phase (Up to 25 Months)|Withdrawal by Subject|23
6368375|NCT01373281|10158404|FG000|Vaccination Phase (Up to 25 Months)|Protocol Violation|5
6368376|NCT01373281|10158405|FG001|Vaccination Phase (Up to 25 Months)|Protocol Violation|2
6368377|NCT01373281|10158404|FG000|Vaccination Phase (Up to 25 Months)|Lost to Follow-up|5
6368378|NCT01373281|10158405|FG001|Vaccination Phase (Up to 25 Months)|Lost to Follow-up|1
6368379|NCT01373281|10158404|FG000|Vaccination Phase (Up to 25 Months)|Serious adverse event|4
6368380|NCT01373281|10158405|FG001|Vaccination Phase (Up to 25 Months)|Serious adverse event|1
6368381|NCT01373281|10158404|FG000|Surveillance Expansion Period|Withdrawal by Subject|180
6368382|NCT01373281|10158405|FG001|Surveillance Expansion Period|Withdrawal by Subject|105
6368383|NCT01373281|10158404|FG000|Surveillance Expansion Period|Protocol Violation|9
6368384|NCT01373281|10158405|FG001|Surveillance Expansion Period|Protocol Violation|1
6368385|NCT01373281|10158404|FG000|Surveillance Expansion Period|Lost to Follow-up|10
6368386|NCT01373281|10158405|FG001|Surveillance Expansion Period|Lost to Follow-up|8
6368387|NCT01373281|10158404|FG000|Surveillance Expansion Period|Serious adverse event|3
6368388|NCT01373281|10158405|FG001|Surveillance Expansion Period|Serious adverse event|4
6368389|NCT01302847|10158426|FG000|Overall Study|Ongoing|0
6368390|NCT01302847|10158427|FG001|Overall Study|Ongoing|0
6368391|NCT01302847|10158428|FG002|Overall Study|Ongoing|0
6368392|NCT01302847|10158429|FG003|Overall Study|Ongoing|0
6368393|NCT01302847|10158430|FG004|Overall Study|Ongoing|0
6368394|NCT01302847|10158431|FG005|Overall Study|Ongoing|27
6368395|NCT01302847|10158432|FG006|Overall Study|Ongoing|22
6368396|NCT01302847|10158433|FG007|Overall Study|Ongoing|17
6368397|NCT01302847|10158426|FG000|Overall Study|Death|0
6368398|NCT01302847|10158427|FG001|Overall Study|Death|1
6368399|NCT01302847|10158428|FG002|Overall Study|Death|0
6368400|NCT01302847|10158429|FG003|Overall Study|Death|0
6368401|NCT01302847|10158430|FG004|Overall Study|Death|0
6368402|NCT01302847|10158431|FG005|Overall Study|Death|1
6368403|NCT01302847|10158432|FG006|Overall Study|Death|1
6368404|NCT01302847|10158433|FG007|Overall Study|Death|0
6368405|NCT01302847|10158426|FG000|Overall Study|Pregnancy|2
6368406|NCT01302847|10158427|FG001|Overall Study|Pregnancy|0
6368407|NCT01302847|10158428|FG002|Overall Study|Pregnancy|0
6368408|NCT01302847|10158429|FG003|Overall Study|Pregnancy|0
6368409|NCT01302847|10158430|FG004|Overall Study|Pregnancy|0
6368410|NCT01302847|10158431|FG005|Overall Study|Pregnancy|0
6368411|NCT01302847|10158432|FG006|Overall Study|Pregnancy|0
6368412|NCT01302847|10158433|FG007|Overall Study|Pregnancy|0
6368413|NCT01302847|10158426|FG000|Overall Study|Virologic failure|0
6368414|NCT01302847|10158427|FG001|Overall Study|Virologic failure|2
6368415|NCT01302847|10158428|FG002|Overall Study|Virologic failure|2
6368416|NCT01302847|10158429|FG003|Overall Study|Virologic failure|0
6368417|NCT01302847|10158430|FG004|Overall Study|Virologic failure|1
6368418|NCT01302847|10158431|FG005|Overall Study|Virologic failure|1
6368419|NCT01302847|10158432|FG006|Overall Study|Virologic failure|0
6368420|NCT01302847|10158433|FG007|Overall Study|Virologic failure|2
6368421|NCT01302847|10158426|FG000|Overall Study|Severe debilitation, unable to continue|0
6368422|NCT01302847|10158427|FG001|Overall Study|Severe debilitation, unable to continue|0
6368423|NCT01302847|10158428|FG002|Overall Study|Severe debilitation, unable to continue|0
6368424|NCT01302847|10158429|FG003|Overall Study|Severe debilitation, unable to continue|0
6368425|NCT01302847|10158430|FG004|Overall Study|Severe debilitation, unable to continue|0
6368426|NCT01302847|10158431|FG005|Overall Study|Severe debilitation, unable to continue|1
6368427|NCT01302847|10158432|FG006|Overall Study|Severe debilitation, unable to continue|1
6368428|NCT01302847|10158433|FG007|Overall Study|Severe debilitation, unable to continue|0
6368429|NCT01302847|10158426|FG000|Overall Study|Not able to get to clinic|1
6368430|NCT01302847|10158427|FG001|Overall Study|Not able to get to clinic|1
6368431|NCT01302847|10158428|FG002|Overall Study|Not able to get to clinic|0
6368432|NCT01302847|10158429|FG003|Overall Study|Not able to get to clinic|0
6368433|NCT01302847|10158430|FG004|Overall Study|Not able to get to clinic|0
6368434|NCT01302847|10158431|FG005|Overall Study|Not able to get to clinic|0
6368435|NCT01302847|10158432|FG006|Overall Study|Not able to get to clinic|0
6368436|NCT01302847|10158433|FG007|Overall Study|Not able to get to clinic|0
6368437|NCT01302847|10158426|FG000|Overall Study|Site closing|2
6368438|NCT01302847|10158427|FG001|Overall Study|Site closing|2
6368439|NCT01302847|10158428|FG002|Overall Study|Site closing|0
6368440|NCT01302847|10158429|FG003|Overall Study|Site closing|0
6368441|NCT01302847|10158430|FG004|Overall Study|Site closing|0
6368442|NCT01302847|10158431|FG005|Overall Study|Site closing|0
6368443|NCT01302847|10158432|FG006|Overall Study|Site closing|0
6368444|NCT01302847|10158433|FG007|Overall Study|Site closing|0
6368445|NCT01302847|10158426|FG000|Overall Study|Withdrawal by Subject|1
6368446|NCT01302847|10158427|FG001|Overall Study|Withdrawal by Subject|0
6368447|NCT01302847|10158428|FG002|Overall Study|Withdrawal by Subject|0
6368448|NCT01302847|10158429|FG003|Overall Study|Withdrawal by Subject|0
6368449|NCT01302847|10158430|FG004|Overall Study|Withdrawal by Subject|1
6368450|NCT01302847|10158431|FG005|Overall Study|Withdrawal by Subject|0
6368451|NCT01302847|10158432|FG006|Overall Study|Withdrawal by Subject|0
6368452|NCT01302847|10158433|FG007|Overall Study|Withdrawal by Subject|1
6368453|NCT01302847|10158426|FG000|Overall Study|Not willing to adhere to requirements|5
6368454|NCT01302847|10158427|FG001|Overall Study|Not willing to adhere to requirements|0
6368455|NCT01302847|10158428|FG002|Overall Study|Not willing to adhere to requirements|0
6368456|NCT01302847|10158429|FG003|Overall Study|Not willing to adhere to requirements|1
6368457|NCT01302847|10158430|FG004|Overall Study|Not willing to adhere to requirements|0
6368458|NCT01302847|10158431|FG005|Overall Study|Not willing to adhere to requirements|0
6368459|NCT01302847|10158432|FG006|Overall Study|Not willing to adhere to requirements|0
6368460|NCT01302847|10158433|FG007|Overall Study|Not willing to adhere to requirements|2
6368461|NCT01302847|10158426|FG000|Overall Study|Site unable to contact participant|2
6368462|NCT01302847|10158427|FG001|Overall Study|Site unable to contact participant|1
6368463|NCT01302847|10158428|FG002|Overall Study|Site unable to contact participant|0
6368464|NCT01302847|10158429|FG003|Overall Study|Site unable to contact participant|0
6368465|NCT01302847|10158430|FG004|Overall Study|Site unable to contact participant|0
6368466|NCT01302847|10158431|FG005|Overall Study|Site unable to contact participant|0
6368467|NCT01302847|10158432|FG006|Overall Study|Site unable to contact participant|2
6368468|NCT01302847|10158433|FG007|Overall Study|Site unable to contact participant|0
6368469|NCT01287611|10158462|FG000|Overall Study|Lost to Follow-up|29
6368470|NCT01287611|10158463|FG001|Overall Study|Lost to Follow-up|16
6368471|NCT01287611|10158462|FG000|Overall Study|Exclusion due to expanded Kerr incision|4
6368472|NCT01287611|10158463|FG001|Overall Study|Exclusion due to expanded Kerr incision|3
6368479|NCT01254422|10158482|FG000|Overall Study|Protocol Violation|1
6368480|NCT01254422|10158483|FG001|Overall Study|Protocol Violation|0
6368481|NCT01254422|10158482|FG000|Overall Study|Adverse Event|1
6368482|NCT01254422|10158483|FG001|Overall Study|Adverse Event|0
6368483|NCT01254422|10158482|FG000|Overall Study|Serious adverse event|0
6368484|NCT01254422|10158483|FG001|Overall Study|Serious adverse event|1
6368485|NCT01254422|10158482|FG000|Overall Study|Lost to Follow-up|1
6368486|NCT01254422|10158483|FG001|Overall Study|Lost to Follow-up|0
6368487|NCT01187433|10158491|FG000|Overall Study|Protocol Violation|6
6368488|NCT01187433|10158492|FG001|Overall Study|Protocol Violation|2
6368489|NCT01187433|10158491|FG000|Overall Study|Withdrawal by Subject|5
6368490|NCT01187433|10158492|FG001|Overall Study|Withdrawal by Subject|2
6368491|NCT01150045|10158502|FG000|Overall Study|Protocol Violation|0
6368492|NCT01150045|10158503|FG001|Overall Study|Protocol Violation|1
6368493|NCT01150045|10158504|FG002|Overall Study|Protocol Violation|0
6368494|NCT01150045|10158505|FG003|Overall Study|Protocol Violation|1
6368495|NCT01098032|10158515|FG000|Overall Study|Withdrawal by Subject|1
6368496|NCT01098032|10158516|FG001|Overall Study|Withdrawal by Subject|1
6368497|NCT01034306|10158524|FG000|Overall Study|Adverse Event|1
6368498|NCT01034306|10158525|FG001|Overall Study|Adverse Event|0
6368499|NCT01034306|10158524|FG000|Overall Study|Lost to Follow-up|0
6368500|NCT01034306|10158525|FG001|Overall Study|Lost to Follow-up|1
6368501|NCT01034306|10158524|FG000|Overall Study|Withdrawal by Subject|2
6368502|NCT01034306|10158525|FG001|Overall Study|Withdrawal by Subject|2
6368503|NCT01034306|10158524|FG000|Overall Study|hospitalized and decided to stop|1
6368504|NCT01034306|10158525|FG001|Overall Study|hospitalized and decided to stop|0
6368505|NCT01034306|10158524|FG000|Overall Study|Noncomplience|1
6368506|NCT01034306|10158525|FG001|Overall Study|Noncomplience|0
6368507|NCT01005745|10158531|FG000|Overall Study|No TIL growth|1
6368508|NCT01005745|10158531|FG000|Overall Study|Disease progressed during TIL growth|3
6368509|NCT01005745|10158531|FG000|Overall Study|Death prior to treatment|1
6368510|NCT01005745|10158531|FG000|Overall Study|Inappropriate antidiuretic hormone|1
6368511|NCT00993447|10158537|FG000|Overall Study|Withdrawal by Subject|23
6368512|NCT00993447|10158538|FG001|Overall Study|Withdrawal by Subject|8
6368513|NCT00993447|10158537|FG000|Overall Study|Protocol Violation|12
6368514|NCT00993447|10158538|FG001|Overall Study|Protocol Violation|8
6368515|NCT00993447|10158537|FG000|Overall Study|Lost to Follow-up|1
6368516|NCT00993447|10158538|FG001|Overall Study|Lost to Follow-up|3
6368517|NCT00993447|10158537|FG000|Overall Study|Adverse Event|1
6368518|NCT00993447|10158538|FG001|Overall Study|Adverse Event|0
6368519|NCT00945009|10158547|FG000|Overall Study|Lack of Efficacy|10
6368520|NCT00945009|10158548|FG001|Overall Study|Lack of Efficacy|0
6368521|NCT00945009|10158549|FG002|Overall Study|Lack of Efficacy|0
6368522|NCT00945009|10158547|FG000|Overall Study|Physician Decision|21
6368523|NCT00945009|10158548|FG001|Overall Study|Physician Decision|4
6368524|NCT00945009|10158549|FG002|Overall Study|Physician Decision|3
6368525|NCT00945009|10158547|FG000|Overall Study|Protocol Violation|6
6368526|NCT00945009|10158548|FG001|Overall Study|Protocol Violation|1
6368527|NCT00945009|10158549|FG002|Overall Study|Protocol Violation|0
6368528|NCT00945009|10158547|FG000|Overall Study|Withdrawal by Subject|1
6368529|NCT00945009|10158548|FG001|Overall Study|Withdrawal by Subject|0
6368530|NCT00945009|10158549|FG002|Overall Study|Withdrawal by Subject|0
6368531|NCT00945009|10158547|FG000|Overall Study|Ineligible|6
6368532|NCT00945009|10158548|FG001|Overall Study|Ineligible|1
6368533|NCT00945009|10158549|FG002|Overall Study|Ineligible|0
6368534|NCT00945009|10158547|FG000|Overall Study|Inevaluable|0
6368535|NCT00945009|10158548|FG001|Overall Study|Inevaluable|1
6368536|NCT00945009|10158549|FG002|Overall Study|Inevaluable|0
6368537|NCT00945009|10158547|FG000|Overall Study|Refusal of further protocol|1
6368538|NCT00945009|10158548|FG001|Overall Study|Refusal of further protocol|0
6368539|NCT00945009|10158549|FG002|Overall Study|Refusal of further protocol|0
6368540|NCT00942877|10158559|FG000|Overall Study|Refused further treatment|1
6368541|NCT00942877|10158560|FG001|Overall Study|Refused further treatment|1
6368542|NCT00942877|10158559|FG000|Overall Study|Patient was not treated|1
6368543|NCT00942877|10158560|FG001|Overall Study|Patient was not treated|0
6368544|NCT00942877|10158559|FG000|Overall Study|Adverse Event|1
6368545|NCT00942877|10158560|FG001|Overall Study|Adverse Event|0
6368546|NCT00942877|10158559|FG000|Overall Study|Progressive disease|42
6368547|NCT00942877|10158560|FG001|Overall Study|Progressive disease|3
6368548|NCT00880893|10158575|FG000|Overall Study|Protocol Violation|13
6368549|NCT00880893|10158576|FG001|Overall Study|Protocol Violation|1
6368550|NCT00880893|10158575|FG000|Overall Study|Withdrawal by Subject|15
6368551|NCT00880893|10158576|FG001|Overall Study|Withdrawal by Subject|11
6368552|NCT00880893|10158575|FG000|Overall Study|Lost to Follow-up|76
6368553|NCT00880893|10158576|FG001|Overall Study|Lost to Follow-up|33
6368554|NCT00880893|10158575|FG000|Overall Study|Serious adverse event|3
6368555|NCT00880893|10158576|FG001|Overall Study|Serious adverse event|0
6368556|NCT00866918|10158584|FG000|Overall Study|Death|1
6368557|NCT00866918|10158585|FG001|Overall Study|Death|5
6368558|NCT00866918|10158584|FG000|Overall Study|Lack of Efficacy|1
6368559|NCT00866918|10158585|FG001|Overall Study|Lack of Efficacy|1
6368560|NCT00866918|10158584|FG000|Overall Study|Physician Decision|10
6368561|NCT00866918|10158585|FG001|Overall Study|Physician Decision|2
6368562|NCT00866918|10158584|FG000|Overall Study|Ineligible|2
6368563|NCT00866918|10158585|FG001|Overall Study|Ineligible|4
6368564|NCT00866918|10158584|FG000|Overall Study|Inevaluable- RQPCR negative at diagnosi|1
6368565|NCT00866918|10158585|FG001|Overall Study|Inevaluable- RQPCR negative at diagnosi|0
6368566|NCT00866918|10158584|FG000|Overall Study|Secondary malignancy|1
6368567|NCT00866918|10158585|FG001|Overall Study|Secondary malignancy|0
6368568|NCT00753545|10158593|FG000|Overall Study|Death|98
6368569|NCT00753545|10158594|FG001|Overall Study|Death|112
6368570|NCT00753545|10158593|FG000|Overall Study|Lost to Follow-up|2
6368571|NCT00753545|10158594|FG001|Overall Study|Lost to Follow-up|3
6368572|NCT00753545|10158593|FG000|Overall Study|Protocol Violation|1
6368573|NCT00753545|10158594|FG001|Overall Study|Protocol Violation|0
6368574|NCT00753545|10158593|FG000|Overall Study|Voluntary Discontinuation of Patient|7
6368575|NCT00753545|10158594|FG001|Overall Study|Voluntary Discontinuation of Patient|3
6368596|NCT00587301|10158609|FG000|Overall Study|Screen Failure|9
6368597|NCT00587301|10158609|FG000|Overall Study|Lost to Follow-up|22
6368598|NCT00587301|10158609|FG000|Overall Study|Withdrawal by Subject|7
6368599|NCT00587301|10158609|FG000|Overall Study|Protocol Violation|7
6368600|NCT00579527|10158613|FG000|Overall Study|Death|4
6368601|NCT00576836|10158618|FG000|Overall Study|Death|0
6368602|NCT00576836|10158619|FG001|Overall Study|Death|1
6368603|NCT00576836|10158618|FG000|Overall Study|Physician Decision|0
6368604|NCT00576836|10158619|FG001|Overall Study|Physician Decision|1
6368605|NCT00576407|10158623|FG000|Overall Study|Death|7
6368606|NCT00576407|10158623|FG000|Overall Study|Physician Decision|1
6368607|NCT00557193|10158628|FG000|Induction|Adverse Event|2
6368608|NCT00557193|10158629|FG001|Induction|Adverse Event|0
6368609|NCT00557193|10158630|FG002|Induction|Adverse Event|0
6368610|NCT00557193|10158631|FG003|Induction|Adverse Event|0
6368611|NCT00557193|10158632|FG004|Induction|Adverse Event|0
6368612|NCT00557193|10158633|FG005|Induction|Adverse Event|0
6368613|NCT00557193|10158628|FG000|Induction|Death|6
6368614|NCT00557193|10158629|FG001|Induction|Death|0
6368615|NCT00557193|10158630|FG002|Induction|Death|0
6368616|NCT00557193|10158631|FG003|Induction|Death|0
6368617|NCT00557193|10158632|FG004|Induction|Death|0
6368618|NCT00557193|10158633|FG005|Induction|Death|0
6368619|NCT00557193|10158628|FG000|Induction|Physician Decision|3
6368620|NCT00557193|10158629|FG001|Induction|Physician Decision|0
6368621|NCT00557193|10158630|FG002|Induction|Physician Decision|0
6368622|NCT00557193|10158631|FG003|Induction|Physician Decision|0
6368623|NCT00557193|10158632|FG004|Induction|Physician Decision|0
6368624|NCT00557193|10158633|FG005|Induction|Physician Decision|0
6368625|NCT00557193|10158628|FG000|Induction|Withdrawal by Subject|1
6368626|NCT00557193|10158629|FG001|Induction|Withdrawal by Subject|0
6368627|NCT00557193|10158630|FG002|Induction|Withdrawal by Subject|0
6368628|NCT00557193|10158631|FG003|Induction|Withdrawal by Subject|0
6368629|NCT00557193|10158632|FG004|Induction|Withdrawal by Subject|0
6368630|NCT00557193|10158633|FG005|Induction|Withdrawal by Subject|0
6368631|NCT00557193|10158628|FG000|Induction|Refusal of Further Protocol Therapy|2
6368632|NCT00557193|10158629|FG001|Induction|Refusal of Further Protocol Therapy|0
6368633|NCT00557193|10158630|FG002|Induction|Refusal of Further Protocol Therapy|0
6368634|NCT00557193|10158631|FG003|Induction|Refusal of Further Protocol Therapy|0
6368635|NCT00557193|10158632|FG004|Induction|Refusal of Further Protocol Therapy|0
6368636|NCT00557193|10158633|FG005|Induction|Refusal of Further Protocol Therapy|0
6368637|NCT00557193|10158628|FG000|Induction|Ineligible|8
6368638|NCT00557193|10158629|FG001|Induction|Ineligible|0
6368639|NCT00557193|10158630|FG002|Induction|Ineligible|0
6368640|NCT00557193|10158631|FG003|Induction|Ineligible|0
6368641|NCT00557193|10158632|FG004|Induction|Ineligible|0
6368642|NCT00557193|10158633|FG005|Induction|Ineligible|0
6368643|NCT00557193|10158628|FG000|Induction|Inevaluable for post Induction|2
6368644|NCT00557193|10158629|FG001|Induction|Inevaluable for post Induction|0
6368645|NCT00557193|10158630|FG002|Induction|Inevaluable for post Induction|0
6368646|NCT00557193|10158631|FG003|Induction|Inevaluable for post Induction|0
6368647|NCT00557193|10158632|FG004|Induction|Inevaluable for post Induction|0
6368648|NCT00557193|10158633|FG005|Induction|Inevaluable for post Induction|0
6368649|NCT00557193|10158628|FG000|Induction|Unable to receive Lestaurtinib-Not in US|2
6368650|NCT00557193|10158629|FG001|Induction|Unable to receive Lestaurtinib-Not in US|0
6368651|NCT00557193|10158630|FG002|Induction|Unable to receive Lestaurtinib-Not in US|0
6368652|NCT00557193|10158631|FG003|Induction|Unable to receive Lestaurtinib-Not in US|0
6368653|NCT00557193|10158632|FG004|Induction|Unable to receive Lestaurtinib-Not in US|0
6368654|NCT00557193|10158633|FG005|Induction|Unable to receive Lestaurtinib-Not in US|0
6368655|NCT00557193|10158628|FG000|Post Induction Therapy by Tx Assignment|Adverse Event|0
6368656|NCT00557193|10158629|FG001|Post Induction Therapy by Tx Assignment|Adverse Event|1
6368657|NCT00557193|10158630|FG002|Post Induction Therapy by Tx Assignment|Adverse Event|2
6368658|NCT00557193|10158631|FG003|Post Induction Therapy by Tx Assignment|Adverse Event|1
6368659|NCT00557193|10158632|FG004|Post Induction Therapy by Tx Assignment|Adverse Event|0
6368660|NCT00557193|10158633|FG005|Post Induction Therapy by Tx Assignment|Adverse Event|3
6368661|NCT00557193|10158628|FG000|Post Induction Therapy by Tx Assignment|Death|0
6368662|NCT00557193|10158629|FG001|Post Induction Therapy by Tx Assignment|Death|0
6368663|NCT00557193|10158630|FG002|Post Induction Therapy by Tx Assignment|Death|2
6368664|NCT00557193|10158631|FG003|Post Induction Therapy by Tx Assignment|Death|0
6368665|NCT00557193|10158632|FG004|Post Induction Therapy by Tx Assignment|Death|2
6368666|NCT00557193|10158633|FG005|Post Induction Therapy by Tx Assignment|Death|2
6368667|NCT00557193|10158628|FG000|Post Induction Therapy by Tx Assignment|Physician Decision|0
6368668|NCT00557193|10158629|FG001|Post Induction Therapy by Tx Assignment|Physician Decision|3
6368669|NCT00557193|10158630|FG002|Post Induction Therapy by Tx Assignment|Physician Decision|5
6368670|NCT00557193|10158631|FG003|Post Induction Therapy by Tx Assignment|Physician Decision|1
6368671|NCT00557193|10158632|FG004|Post Induction Therapy by Tx Assignment|Physician Decision|2
6368672|NCT00557193|10158633|FG005|Post Induction Therapy by Tx Assignment|Physician Decision|2
6368673|NCT00557193|10158628|FG000|Post Induction Therapy by Tx Assignment|Refusal of Further Protocol|0
6368674|NCT00557193|10158629|FG001|Post Induction Therapy by Tx Assignment|Refusal of Further Protocol|1
6368675|NCT00557193|10158630|FG002|Post Induction Therapy by Tx Assignment|Refusal of Further Protocol|0
6368676|NCT00557193|10158631|FG003|Post Induction Therapy by Tx Assignment|Refusal of Further Protocol|2
6368677|NCT00557193|10158632|FG004|Post Induction Therapy by Tx Assignment|Refusal of Further Protocol|2
6368678|NCT00557193|10158633|FG005|Post Induction Therapy by Tx Assignment|Refusal of Further Protocol|5
6368679|NCT00557193|10158628|FG000|Post Induction Therapy by Tx Assignment|Relapse|0
6368680|NCT00557193|10158629|FG001|Post Induction Therapy by Tx Assignment|Relapse|5
6368681|NCT00557193|10158630|FG002|Post Induction Therapy by Tx Assignment|Relapse|16
6368682|NCT00557193|10158631|FG003|Post Induction Therapy by Tx Assignment|Relapse|3
6368683|NCT00557193|10158632|FG004|Post Induction Therapy by Tx Assignment|Relapse|1
6368684|NCT00557193|10158633|FG005|Post Induction Therapy by Tx Assignment|Relapse|20
6368685|NCT00557193|10158628|FG000|Post Induction Therapy by Tx Assignment|Developed second malignant neoplasm|0
6368686|NCT00557193|10158629|FG001|Post Induction Therapy by Tx Assignment|Developed second malignant neoplasm|0
6368687|NCT00557193|10158630|FG002|Post Induction Therapy by Tx Assignment|Developed second malignant neoplasm|1
6368688|NCT00557193|10158631|FG003|Post Induction Therapy by Tx Assignment|Developed second malignant neoplasm|0
6368689|NCT00557193|10158632|FG004|Post Induction Therapy by Tx Assignment|Developed second malignant neoplasm|0
6368690|NCT00557193|10158633|FG005|Post Induction Therapy by Tx Assignment|Developed second malignant neoplasm|0
6368691|NCT00557193|10158628|FG000|Post Induction Therapy by Tx Assignment|Patient Moved to Another Institution|0
6368692|NCT00557193|10158629|FG001|Post Induction Therapy by Tx Assignment|Patient Moved to Another Institution|0
6368693|NCT00557193|10158630|FG002|Post Induction Therapy by Tx Assignment|Patient Moved to Another Institution|2
6368694|NCT00557193|10158631|FG003|Post Induction Therapy by Tx Assignment|Patient Moved to Another Institution|0
6368695|NCT00557193|10158632|FG004|Post Induction Therapy by Tx Assignment|Patient Moved to Another Institution|0
6368696|NCT00557193|10158633|FG005|Post Induction Therapy by Tx Assignment|Patient Moved to Another Institution|0
6368697|NCT00557193|10158628|FG000|Post Induction Therapy by Tx Assignment|Induction Failure|0
6368698|NCT00557193|10158629|FG001|Post Induction Therapy by Tx Assignment|Induction Failure|0
6368699|NCT00557193|10158630|FG002|Post Induction Therapy by Tx Assignment|Induction Failure|4
6368700|NCT00557193|10158631|FG003|Post Induction Therapy by Tx Assignment|Induction Failure|0
6368701|NCT00557193|10158632|FG004|Post Induction Therapy by Tx Assignment|Induction Failure|0
6368702|NCT00557193|10158633|FG005|Post Induction Therapy by Tx Assignment|Induction Failure|5
6368703|NCT00547339|10158662|FG000|Overall Study|Physician Decision|0
6368704|NCT00547339|10158663|FG001|Overall Study|Physician Decision|0
6368705|NCT00547339|10158664|FG002|Overall Study|Physician Decision|1
6368706|NCT00547339|10158665|FG003|Overall Study|Physician Decision|0
6368707|NCT00531232|10158687|FG000|Overall Study|Investigator decision|0
6368708|NCT00531232|10158688|FG001|Overall Study|Investigator decision|0
6368709|NCT00531232|10158689|FG002|Overall Study|Investigator decision|4
6368710|NCT00531232|10158687|FG000|Overall Study|Participants refused further treatment|0
6368711|NCT00531232|10158688|FG001|Overall Study|Participants refused further treatment|1
6368712|NCT00531232|10158689|FG002|Overall Study|Participants refused further treatment|2
6368713|NCT00531232|10158687|FG000|Overall Study|Adverse events (AEs)|1
6368714|NCT00531232|10158688|FG001|Overall Study|Adverse events (AEs)|2
6368715|NCT00531232|10158689|FG002|Overall Study|Adverse events (AEs)|2
6368716|NCT00531232|10158687|FG000|Overall Study|Treatment failure|1
6368717|NCT00531232|10158688|FG001|Overall Study|Treatment failure|3
6368718|NCT00531232|10158689|FG002|Overall Study|Treatment failure|7
6368719|NCT00531232|10158687|FG000|Overall Study|Disease recurrence|0
6368720|NCT00531232|10158688|FG001|Overall Study|Disease recurrence|0
6368721|NCT00531232|10158689|FG002|Overall Study|Disease recurrence|1
6368722|NCT00531232|10158687|FG000|Overall Study|Deceased|2
6368723|NCT00531232|10158688|FG001|Overall Study|Deceased|2
6368724|NCT00531232|10158689|FG002|Overall Study|Deceased|2
6368725|NCT00531232|10158687|FG000|Overall Study|Withdrawal by Subject|0
6368726|NCT00531232|10158688|FG001|Overall Study|Withdrawal by Subject|1
6368727|NCT00531232|10158689|FG002|Overall Study|Withdrawal by Subject|2
6368728|NCT00531232|10158687|FG000|Overall Study|Other|0
6368729|NCT00531232|10158688|FG001|Overall Study|Other|0
6368730|NCT00531232|10158689|FG002|Overall Study|Other|5
6368731|NCT00379340|10158705|FG000|Overall Study|Death|0
6368732|NCT00379340|10158706|FG001|Overall Study|Death|0
6368733|NCT00379340|10158707|FG002|Overall Study|Death|0
6368734|NCT00379340|10158708|FG003|Overall Study|Death|2
6368735|NCT00379340|10158709|FG004|Overall Study|Death|0
6368736|NCT00379340|10158705|FG000|Overall Study|Lack of Efficacy|6
6368737|NCT00379340|10158706|FG001|Overall Study|Lack of Efficacy|1
6368738|NCT00379340|10158707|FG002|Overall Study|Lack of Efficacy|0
6368739|NCT00379340|10158708|FG003|Overall Study|Lack of Efficacy|4
6368740|NCT00379340|10158709|FG004|Overall Study|Lack of Efficacy|3
6368741|NCT00379340|10158705|FG000|Overall Study|Physician Decision|6
6368742|NCT00379340|10158706|FG001|Overall Study|Physician Decision|2
6368743|NCT00379340|10158707|FG002|Overall Study|Physician Decision|1
6368744|NCT00379340|10158708|FG003|Overall Study|Physician Decision|2
6368745|NCT00379340|10158709|FG004|Overall Study|Physician Decision|3
6368746|NCT00379340|10158705|FG000|Overall Study|Withdrawal by Subject|0
6368747|NCT00379340|10158706|FG001|Overall Study|Withdrawal by Subject|0
6368748|NCT00379340|10158707|FG002|Overall Study|Withdrawal by Subject|0
6368749|NCT00379340|10158708|FG003|Overall Study|Withdrawal by Subject|1
6368750|NCT00379340|10158709|FG004|Overall Study|Withdrawal by Subject|0
6368751|NCT00379340|10158705|FG000|Overall Study|Refusal of further protocol therapy|1
6368752|NCT00379340|10158706|FG001|Overall Study|Refusal of further protocol therapy|0
6368753|NCT00379340|10158707|FG002|Overall Study|Refusal of further protocol therapy|1
6368754|NCT00379340|10158708|FG003|Overall Study|Refusal of further protocol therapy|1
6368755|NCT00379340|10158709|FG004|Overall Study|Refusal of further protocol therapy|7
6368756|NCT00379340|10158705|FG000|Overall Study|On more than 1 tumor therapeutic study|0
6368757|NCT00379340|10158706|FG001|Overall Study|On more than 1 tumor therapeutic study|0
6368758|NCT00379340|10158707|FG002|Overall Study|On more than 1 tumor therapeutic study|0
6368759|NCT00379340|10158708|FG003|Overall Study|On more than 1 tumor therapeutic study|2
6368760|NCT00379340|10158709|FG004|Overall Study|On more than 1 tumor therapeutic study|0
6368761|NCT00379340|10158705|FG000|Overall Study|Delayed nephrectomy and anaplasia|0
6368762|NCT00379340|10158706|FG001|Overall Study|Delayed nephrectomy and anaplasia|0
6368763|NCT00379340|10158707|FG002|Overall Study|Delayed nephrectomy and anaplasia|0
6368764|NCT00379340|10158708|FG003|Overall Study|Delayed nephrectomy and anaplasia|1
6368765|NCT00379340|10158709|FG004|Overall Study|Delayed nephrectomy and anaplasia|1
6368766|NCT00304070|10158725|FG000|Overall Study|Death|0
6368767|NCT00304070|10158726|FG001|Overall Study|Death|0
6368768|NCT00304070|10158727|FG002|Overall Study|Death|3
6368769|NCT00304070|10158725|FG000|Overall Study|Lost to Follow-up|0
6368770|NCT00304070|10158726|FG001|Overall Study|Lost to Follow-up|0
6368771|NCT00304070|10158727|FG002|Overall Study|Lost to Follow-up|1
6368772|NCT00304070|10158725|FG000|Overall Study|Physician Decision|0
6368773|NCT00304070|10158726|FG001|Overall Study|Physician Decision|0
6368774|NCT00304070|10158727|FG002|Overall Study|Physician Decision|3
6368775|NCT00304070|10158725|FG000|Overall Study|Withdrawal by Subject|0
6368776|NCT00304070|10158726|FG001|Overall Study|Withdrawal by Subject|0
6368777|NCT00304070|10158727|FG002|Overall Study|Withdrawal by Subject|1
6368778|NCT00304070|10158725|FG000|Overall Study|Progressive Disease|3
6368779|NCT00304070|10158726|FG001|Overall Study|Progressive Disease|7
6368780|NCT00304070|10158727|FG002|Overall Study|Progressive Disease|4
6368781|NCT01701583|10158751|FG000|Overall Study|Withdrawal by Subject|2
6368782|NCT01701583|10158752|FG001|Overall Study|Withdrawal by Subject|0
6368783|NCT01714817|10158761|FG000|Year 1 Period|Lack of Efficacy|11
6368784|NCT01714817|10158762|FG001|Year 1 Period|Lack of Efficacy|9
6368785|NCT01714817|10158761|FG000|Year 1 Period|Adverse Event|20
6368786|NCT01714817|10158762|FG001|Year 1 Period|Adverse Event|17
6368787|NCT01714817|10158761|FG000|Year 1 Period|Withdrawal by Subject|6
6368788|NCT01714817|10158762|FG001|Year 1 Period|Withdrawal by Subject|7
6368789|NCT01714817|10158761|FG000|Year 1 Period|Death|1
6368790|NCT01714817|10158762|FG001|Year 1 Period|Death|1
6368791|NCT01714817|10158761|FG000|Year 1 Period|Lost to Follow-up|0
6368792|NCT01714817|10158762|FG001|Year 1 Period|Lost to Follow-up|2
6368793|NCT01714817|10158761|FG000|Year 1 Period|Poor / non-compliance|0
6368794|NCT01714817|10158762|FG001|Year 1 Period|Poor / non-compliance|1
6368795|NCT01714817|10158761|FG000|Year 1 Period|Pregnancy|2
6368796|NCT01714817|10158762|FG001|Year 1 Period|Pregnancy|0
6368797|NCT01714817|10158761|FG000|Year 1 Period|Participant no longer meets criteria|6
6368798|NCT01714817|10158762|FG001|Year 1 Period|Participant no longer meets criteria|2
6368799|NCT01714817|10158761|FG000|Year 1 Period|Not treated- received ACE inhibition|1
6368800|NCT01714817|10158762|FG001|Year 1 Period|Not treated- received ACE inhibition|0
6368801|NCT01714817|10158761|FG000|Year 1 Period|Change in Concomitant Medication|0
6368802|NCT01714817|10158762|FG001|Year 1 Period|Change in Concomitant Medication|1
6368803|NCT01714817|10158761|FG000|Year 1 Period|Need of use of Prohibited Medications|1
6368804|NCT01714817|10158762|FG001|Year 1 Period|Need of use of Prohibited Medications|0
6368805|NCT01714817|10158761|FG000|Year 1 Period|Antiproteinuric changed/dose increased|0
6368806|NCT01714817|10158762|FG001|Year 1 Period|Antiproteinuric changed/dose increased|1
6368807|NCT01714817|10158761|FG000|Year 1 Period|Hypersensitivity to the medication|0
6368808|NCT01714817|10158762|FG001|Year 1 Period|Hypersensitivity to the medication|1
6368809|NCT01714817|10158761|FG000|Year 2 Period|Lack of Efficacy|4
6368810|NCT01714817|10158762|FG001|Year 2 Period|Lack of Efficacy|12
6368811|NCT01714817|10158761|FG000|Year 2 Period|Adverse Event|7
6368812|NCT01714817|10158762|FG001|Year 2 Period|Adverse Event|6
6368813|NCT01714817|10158761|FG000|Year 2 Period|Participant request to stop treatment|4
6368814|NCT01714817|10158762|FG001|Year 2 Period|Participant request to stop treatment|4
6368815|NCT01714817|10158761|FG000|Year 2 Period|Administrative reason by Sponsor|4
6368816|NCT01714817|10158762|FG001|Year 2 Period|Administrative reason by Sponsor|3
6368817|NCT01714817|10158761|FG000|Year 2 Period|Participant withdrew consent|1
6368818|NCT01714817|10158762|FG001|Year 2 Period|Participant withdrew consent|5
6368819|NCT01714817|10158761|FG000|Year 2 Period|Participant no longer meets criteria|1
6368820|NCT01714817|10158762|FG001|Year 2 Period|Participant no longer meets criteria|4
6368821|NCT01714817|10158761|FG000|Year 2 Period|Lost to Follow-up|2
6368822|NCT01714817|10158762|FG001|Year 2 Period|Lost to Follow-up|0
6368823|NCT01714817|10158761|FG000|Year 2 Period|Participant went to US stopped treatment|0
6368824|NCT01714817|10158762|FG001|Year 2 Period|Participant went to US stopped treatment|1
6368825|NCT01714817|10158761|FG000|Year 2 Period|Pregnancy|1
6368826|NCT01714817|10158762|FG001|Year 2 Period|Pregnancy|1
6368827|NCT01714817|10158761|FG000|Year 2 Period|Completed Year 1, did not enter Year 2|2
6368828|NCT01714817|10158762|FG001|Year 2 Period|Completed Year 1, did not enter Year 2|1
6368829|NCT01714817|10158761|FG000|Year 2 Period|Given cyclophosphamide, corticosteroids|0
6368830|NCT01714817|10158762|FG001|Year 2 Period|Given cyclophosphamide, corticosteroids|1
6368831|NCT01714817|10158761|FG000|Long-Term Extension (LTE) Period|Administrative reason by Sponsor|27
6368832|NCT01714817|10158762|FG001|Long-Term Extension (LTE) Period|Administrative reason by Sponsor|21
6368833|NCT01714817|10158761|FG000|Long-Term Extension (LTE) Period|Disease progression|1
6368834|NCT01714817|10158762|FG001|Long-Term Extension (LTE) Period|Disease progression|4
6368835|NCT01714817|10158761|FG000|Long-Term Extension (LTE) Period|Not effective|0
6368836|NCT01714817|10158762|FG001|Long-Term Extension (LTE) Period|Not effective|1
6368837|NCT01714817|10158761|FG000|Long-Term Extension (LTE) Period|Participant request to stop treatment|1
6368838|NCT01714817|10158762|FG001|Long-Term Extension (LTE) Period|Participant request to stop treatment|1
6368839|NCT01714817|10158761|FG000|Long-Term Extension (LTE) Period|Participant withdrew consent|1
6368840|NCT01714817|10158762|FG001|Long-Term Extension (LTE) Period|Participant withdrew consent|1
6368841|NCT01714817|10158761|FG000|Long-Term Extension (LTE) Period|Adverse Event unrelated to study drug|1
6368842|NCT01714817|10158762|FG001|Long-Term Extension (LTE) Period|Adverse Event unrelated to study drug|0
6368843|NCT01714817|10158761|FG000|Long-Term Extension (LTE) Period|Lost to Follow-up|0
6368844|NCT01714817|10158762|FG001|Long-Term Extension (LTE) Period|Lost to Follow-up|1
6368845|NCT01714817|10158761|FG000|Long-Term Extension (LTE) Period|Pregnancy|1
6368846|NCT01714817|10158762|FG001|Long-Term Extension (LTE) Period|Pregnancy|0
6368847|NCT01714817|10158761|FG000|Long-Term Extension (LTE) Period|Study drug toxicity|1
6368848|NCT01714817|10158762|FG001|Long-Term Extension (LTE) Period|Study drug toxicity|0
6368849|NCT01714817|10158761|FG000|Long-Term Extension (LTE) Period|Participant no longer meets criteria|1
6368850|NCT01714817|10158762|FG001|Long-Term Extension (LTE) Period|Participant no longer meets criteria|0
6368851|NCT01714817|10158761|FG000|Long-Term Extension (LTE) Period|Completed Year 2, did not enter LTE|33
6368852|NCT01714817|10158762|FG001|Long-Term Extension (LTE) Period|Completed Year 2, did not enter LTE|38
6368853|NCT01714817|10158761|FG000|Long-Term Extension (LTE) Period|Absence of renal response|0
6368854|NCT01714817|10158762|FG001|Long-Term Extension (LTE) Period|Absence of renal response|1
6368855|NCT01714817|10158761|FG000|Long-Term Extension (LTE) Period|Investigator decision, study termination|0
6368856|NCT01714817|10158762|FG001|Long-Term Extension (LTE) Period|Investigator decision, study termination|1
6368857|NCT01714817|10158761|FG000|Long-Term Extension (LTE) Period|Study was terminated|0
6368858|NCT01714817|10158762|FG001|Long-Term Extension (LTE) Period|Study was terminated|1
6368859|NCT01755689|10158775|FG000|Overall Study|Withdrawal by Subject|1
6368860|NCT01755689|10158776|FG001|Overall Study|Withdrawal by Subject|3
6368861|NCT01755689|10158777|FG002|Overall Study|Withdrawal by Subject|2
6368862|NCT01755689|10158778|FG003|Overall Study|Withdrawal by Subject|1
6368863|NCT01755689|10158779|FG004|Overall Study|Withdrawal by Subject|1
6368864|NCT01755689|10158775|FG000|Overall Study|Migrated/moved from study area|0
6368865|NCT01755689|10158776|FG001|Overall Study|Migrated/moved from study area|1
6368866|NCT01755689|10158777|FG002|Overall Study|Migrated/moved from study area|1
6368867|NCT01755689|10158778|FG003|Overall Study|Migrated/moved from study area|1
6368868|NCT01755689|10158779|FG004|Overall Study|Migrated/moved from study area|1
6368869|NCT01755689|10158775|FG000|Overall Study|Lost to Follow-up|1
6368870|NCT01755689|10158776|FG001|Overall Study|Lost to Follow-up|0
6368871|NCT01755689|10158777|FG002|Overall Study|Lost to Follow-up|1
6368872|NCT01755689|10158778|FG003|Overall Study|Lost to Follow-up|0
6368873|NCT01755689|10158779|FG004|Overall Study|Lost to Follow-up|2
6368874|NCT01755689|10158775|FG000|Overall Study|Pregnancy|1
6368875|NCT01755689|10158776|FG001|Overall Study|Pregnancy|1
6368876|NCT01755689|10158777|FG002|Overall Study|Pregnancy|2
6368877|NCT01755689|10158778|FG003|Overall Study|Pregnancy|4
6368878|NCT01755689|10158779|FG004|Overall Study|Pregnancy|2
6368879|NCT01762761|10158801|FG000|Overall Study|Adverse Event|15
6368880|NCT01762761|10158802|FG001|Overall Study|Adverse Event|17
6368881|NCT01762761|10158801|FG000|Overall Study|Lack of Efficacy|9
6368882|NCT01762761|10158802|FG001|Overall Study|Lack of Efficacy|25
6368883|NCT01762761|10158801|FG000|Overall Study|Protocol Violation|1
6368884|NCT01762761|10158802|FG001|Overall Study|Protocol Violation|1
6368885|NCT01762761|10158801|FG000|Overall Study|Study closed/terminated|0
6368886|NCT01762761|10158802|FG001|Overall Study|Study closed/terminated|2
6368887|NCT01762761|10158801|FG000|Overall Study|Lost to Follow-up|3
6368888|NCT01762761|10158802|FG001|Overall Study|Lost to Follow-up|6
6368889|NCT01762761|10158801|FG000|Overall Study|Physician Decision|4
6368890|NCT01762761|10158802|FG001|Overall Study|Physician Decision|6
6368891|NCT01762761|10158801|FG000|Overall Study|Withdrawal by Subject|7
6368892|NCT01762761|10158802|FG001|Overall Study|Withdrawal by Subject|8
6368897|NCT01774370|10158826|FG000|Overall Study|Never taken the PRADAXA during the study|4
6368898|NCT01774370|10158826|FG000|Overall Study|Administered prior to the contract date|4
6368899|NCT01774370|10158826|FG000|Overall Study|Subjects of contraindications|34
6368900|NCT01774370|10158826|FG000|Overall Study|Violated inclusion/exclusion criteria|53
6368901|NCT01774370|10158826|FG000|Overall Study|Follow-up failure|34
6368902|NCT01777295|10158832|FG000|Overall Study|Withdrawal by Subject|2
6368903|NCT01777295|10158833|FG001|Overall Study|Withdrawal by Subject|2
6368904|NCT01777295|10158832|FG000|Overall Study|Pregnancy|0
6368905|NCT01777295|10158833|FG001|Overall Study|Pregnancy|1
6368906|NCT01777295|10158832|FG000|Overall Study|Personal problem|1
6368907|NCT01777295|10158833|FG001|Overall Study|Personal problem|0
6368908|NCT01777295|10158832|FG000|Overall Study|Investigator call for AEs check|1
6368909|NCT01777295|10158833|FG001|Overall Study|Investigator call for AEs check|0
6368910|NCT01787552|10158853|FG000|Overall Study|Withdrawal by Subject|2
6368911|NCT01787552|10158854|FG001|Overall Study|Withdrawal by Subject|0
6368912|NCT01787552|10158855|FG002|Overall Study|Withdrawal by Subject|0
6368913|NCT01787552|10158856|FG003|Overall Study|Withdrawal by Subject|4
6368914|NCT01787552|10158853|FG000|Overall Study|Physician Decision|2
6368915|NCT01787552|10158854|FG001|Overall Study|Physician Decision|2
6368916|NCT01787552|10158855|FG002|Overall Study|Physician Decision|1
6368917|NCT01787552|10158856|FG003|Overall Study|Physician Decision|2
6368918|NCT01787552|10158853|FG000|Overall Study|Death|0
6368919|NCT01787552|10158854|FG001|Overall Study|Death|0
6368920|NCT01787552|10158855|FG002|Overall Study|Death|0
6368921|NCT01787552|10158856|FG003|Overall Study|Death|1
6368922|NCT01787552|10158853|FG000|Overall Study|Adverse Event|2
6368923|NCT01787552|10158854|FG001|Overall Study|Adverse Event|5
6368924|NCT01787552|10158855|FG002|Overall Study|Adverse Event|2
6368925|NCT01787552|10158856|FG003|Overall Study|Adverse Event|16
6368926|NCT01787552|10158853|FG000|Overall Study|Study terminated by Sponsor|0
6368927|NCT01787552|10158854|FG001|Overall Study|Study terminated by Sponsor|0
6368928|NCT01787552|10158855|FG002|Overall Study|Study terminated by Sponsor|1
6368929|NCT01787552|10158856|FG003|Overall Study|Study terminated by Sponsor|3
6368930|NCT01787552|10158853|FG000|Overall Study|Progressive Disease|2
6368931|NCT01787552|10158854|FG001|Overall Study|Progressive Disease|2
6368932|NCT01787552|10158855|FG002|Overall Study|Progressive Disease|1
6368933|NCT01787552|10158856|FG003|Overall Study|Progressive Disease|1
6368934|NCT01807117|10158871|FG000|Overall Study|Physician Decision|2
6368935|NCT01807117|10158871|FG000|Overall Study|Disease diagnosis not a study disease|1
6368946|NCT01814826|10158899|FG000|Overall Study|Other|3
6368947|NCT01814826|10158900|FG001|Overall Study|Other|5
6368948|NCT01814826|10158901|FG002|Overall Study|Other|0
6368949|NCT01814826|10158899|FG000|Overall Study|Death|29
6368950|NCT01814826|10158900|FG001|Overall Study|Death|24
6368951|NCT01814826|10158901|FG002|Overall Study|Death|3
6368952|NCT01829711|10158910|FG000|Overall Study|Lost to Follow-up|2
6368953|NCT01829711|10158910|FG000|Overall Study|Withdrawal by Subject|3
6368954|NCT01829711|10158910|FG000|Overall Study|Death|4
6368955|NCT01829711|10158910|FG000|Overall Study|Started new therapies|17
6368956|NCT01829711|10158910|FG000|Overall Study|Adverse Event|3
6368957|NCT01829711|10158910|FG000|Overall Study|Due to progression of disease|13
6368893|NCT01763788|10158813|FG000|Overall Study|Lost to Follow-up|0
6368894|NCT01763788|10158814|FG001|Overall Study|Lost to Follow-up|0
6368895|NCT01763788|10158815|FG002|Overall Study|Lost to Follow-up|1
6368896|NCT01763788|10158816|FG003|Overall Study|Lost to Follow-up|0
6368936|NCT01808261|10158879|FG000|Overall Study|Physician Decision|0
6368937|NCT01808261|10158880|FG001|Overall Study|Physician Decision|2
6368938|NCT01808261|10158879|FG000|Overall Study|Study Closed/Terminated|25
6368939|NCT01808261|10158880|FG001|Overall Study|Study Closed/Terminated|23
6368940|NCT01808261|10158879|FG000|Overall Study|Adverse event, non-fatal|2
6368941|NCT01808261|10158880|FG001|Overall Study|Adverse event, non-fatal|0
6368942|NCT01808261|10158879|FG000|Overall Study|Consent withdrawn by subject|6
6368943|NCT01808261|10158880|FG001|Overall Study|Consent withdrawn by subject|7
6368944|NCT01808261|10158879|FG000|Overall Study|Lost to Follow-up|3
6368945|NCT01808261|10158880|FG001|Overall Study|Lost to Follow-up|1
6368958|NCT01829711|10158910|FG000|Overall Study|Due to lack of response|1
6368959|NCT01846273|10158917|FG000|Overall Study|Adverse Event|9
6368960|NCT01846273|10158918|FG001|Overall Study|Adverse Event|7
6368961|NCT01846273|10158919|FG002|Overall Study|Adverse Event|0
6368962|NCT01846273|10158917|FG000|Overall Study|Subject withdrew consent|5
6368963|NCT01846273|10158918|FG001|Overall Study|Subject withdrew consent|8
6368964|NCT01846273|10158919|FG002|Overall Study|Subject withdrew consent|0
6368965|NCT01846273|10158917|FG000|Overall Study|Lost to Follow-up|2
6368966|NCT01846273|10158918|FG001|Overall Study|Lost to Follow-up|1
6368967|NCT01846273|10158919|FG002|Overall Study|Lost to Follow-up|0
6368968|NCT01846273|10158917|FG000|Overall Study|Administrative problems|1
6368969|NCT01846273|10158918|FG001|Overall Study|Administrative problems|0
6368970|NCT01846273|10158919|FG002|Overall Study|Administrative problems|0
6368971|NCT01846273|10158917|FG000|Overall Study|Death|2
6368972|NCT01846273|10158918|FG001|Overall Study|Death|1
6368973|NCT01846273|10158919|FG002|Overall Study|Death|0
6368974|NCT01846273|10158917|FG000|Overall Study|Disease Progression|0
6368975|NCT01846273|10158918|FG001|Overall Study|Disease Progression|4
6368976|NCT01846273|10158919|FG002|Overall Study|Disease Progression|0
6368977|NCT01846273|10158917|FG000|Overall Study|Protocol Deviation|2
6368978|NCT01846273|10158918|FG001|Overall Study|Protocol Deviation|3
6368979|NCT01846273|10158919|FG002|Overall Study|Protocol Deviation|0
6368980|NCT01846273|10158917|FG000|Overall Study|Physician Decision|1
6368981|NCT01846273|10158918|FG001|Overall Study|Physician Decision|2
6368982|NCT01846273|10158919|FG002|Overall Study|Physician Decision|0
6368983|NCT01875185|10158929|FG000|Overall Study|study was terminated|52
6368984|NCT01875185|10158930|FG001|Overall Study|study was terminated|48
6368985|NCT01891643|10158956|FG000|Overall Study|Adverse event unrelated to study drug|2
6368986|NCT01891643|10158957|FG001|Overall Study|Adverse event unrelated to study drug|5
6368987|NCT01891643|10158956|FG000|Overall Study|Disease Progression|4
6368988|NCT01891643|10158957|FG001|Overall Study|Disease Progression|3
6368989|NCT01891643|10158956|FG000|Overall Study|Study Drug Toxicity|3
6368990|NCT01891643|10158957|FG001|Overall Study|Study Drug Toxicity|0
6368991|NCT01891643|10158956|FG000|Overall Study|Maximum Clinical Benefit|0
6368992|NCT01891643|10158957|FG001|Overall Study|Maximum Clinical Benefit|1
6368993|NCT01891643|10158956|FG000|Overall Study|Poor/Non-compliance|0
6368994|NCT01891643|10158957|FG001|Overall Study|Poor/Non-compliance|1
6368995|NCT01891643|10158956|FG000|Overall Study|Participant request to discontinue|1
6368996|NCT01891643|10158957|FG001|Overall Study|Participant request to discontinue|0
6368997|NCT01900691|10158963|FG000|Overall Study|Death|7
6368998|NCT01900691|10158963|FG000|Overall Study|Lost to Follow-up|4
6368999|NCT01900691|10158963|FG000|Overall Study|Study Device Not Placed|3
6369000|NCT01900691|10158963|FG000|Overall Study|Non Study stent inside study stent|1
6369001|NCT01900691|10158963|FG000|Overall Study|Six month Follow up completed, stent not removed|2
6369002|NCT01900691|10158963|FG000|Overall Study|Miscellaneous|2
6369003|NCT01901432|10158973|FG000|Overall Study|Adverse Event|0
6369004|NCT01901432|10158974|FG001|Overall Study|Adverse Event|1
6369005|NCT01901432|10158975|FG002|Overall Study|Adverse Event|1
6369006|NCT01901432|10158976|FG003|Overall Study|Adverse Event|0
6369007|NCT01901432|10158977|FG004|Overall Study|Adverse Event|1
6369008|NCT01901432|10158973|FG000|Overall Study|Withdrawal by Subject|0
6369009|NCT01901432|10158974|FG001|Overall Study|Withdrawal by Subject|0
6369010|NCT01901432|10158975|FG002|Overall Study|Withdrawal by Subject|1
6369011|NCT01901432|10158976|FG003|Overall Study|Withdrawal by Subject|0
6369012|NCT01901432|10158977|FG004|Overall Study|Withdrawal by Subject|5
6369013|NCT01901432|10158973|FG000|Overall Study|Physician Decision|0
6369014|NCT01901432|10158974|FG001|Overall Study|Physician Decision|0
6369015|NCT01901432|10158975|FG002|Overall Study|Physician Decision|0
6369016|NCT01901432|10158976|FG003|Overall Study|Physician Decision|0
6369017|NCT01901432|10158977|FG004|Overall Study|Physician Decision|2
6369018|NCT01901432|10158973|FG000|Overall Study|Patient decision to stop study drug|0
6369019|NCT01901432|10158974|FG001|Overall Study|Patient decision to stop study drug|0
6369020|NCT01901432|10158975|FG002|Overall Study|Patient decision to stop study drug|0
6369021|NCT01901432|10158976|FG003|Overall Study|Patient decision to stop study drug|0
6369022|NCT01901432|10158977|FG004|Overall Study|Patient decision to stop study drug|1
6171683|NCT01261611|9818585|FG000|Treatment Cycle 3|Completed study|24
6171684|NCT01261611|9818586|FG001|Treatment Cycle 3|Completed study|0
6171685|NCT01261611|9818587|FG002|Treatment Cycle 3|Completed study|0
6171686|NCT01261611|9818585|FG000|Treatment Cycle 3|Withdrawal by Subject|4
6171687|NCT01261611|9818586|FG001|Treatment Cycle 3|Withdrawal by Subject|0
6369023|NCT01904279|10158998|FG000|Overall Study|Lack of Efficacy|2
6369024|NCT01904279|10158999|FG001|Overall Study|Lack of Efficacy|3
6369025|NCT01904279|10158998|FG000|Overall Study|Withdrawal by Subject|1
6369026|NCT01904279|10158999|FG001|Overall Study|Withdrawal by Subject|0
6369027|NCT01917318|10159008|FG000|First Treatment|Withdrawal by Subject|0
6369028|NCT01917318|10159009|FG001|First Treatment|Withdrawal by Subject|1
6369029|NCT01921218|10159017|FG000|Overall Study|Death|2
6369030|NCT01921218|10159018|FG001|Overall Study|Death|1
6369031|NCT01921218|10159017|FG000|Overall Study|Withdrawal by Subject|0
6369032|NCT01921218|10159018|FG001|Overall Study|Withdrawal by Subject|2
6369033|NCT01921218|10159017|FG000|Overall Study|Kidney transplant|1
6369034|NCT01921218|10159018|FG001|Overall Study|Kidney transplant|1
6369053|NCT01931098|10159059|FG000|Overall Study|Withdrawal by Subject|0
6369054|NCT01931098|10159060|FG001|Overall Study|Withdrawal by Subject|1
6369055|NCT01931098|10159059|FG000|Overall Study|Enrolled in different protocol|0
6369056|NCT01931098|10159060|FG001|Overall Study|Enrolled in different protocol|1
6369057|NCT01931098|10159059|FG000|Overall Study|Unable to begin trmt:active infection|0
6369058|NCT01931098|10159060|FG001|Overall Study|Unable to begin trmt:active infection|1
6369059|NCT01931098|10159059|FG000|Overall Study|Refused further treatment|0
6369060|NCT01931098|10159060|FG001|Overall Study|Refused further treatment|1
6369061|NCT01945021|10159068|FG000|Overall Study|Adverse Event|1
6369062|NCT01945021|10159068|FG000|Overall Study|Withdrawal of consent|12
6369063|NCT01945021|10159068|FG000|Overall Study|Lost to Follow-up|5
6369064|NCT01945021|10159068|FG000|Overall Study|Death|65
6369065|NCT01956669|10159079|FG000|Overall Study|Disease Progression|12
6369066|NCT01956669|10159080|FG001|Overall Study|Disease Progression|7
6369067|NCT01956669|10159081|FG002|Overall Study|Disease Progression|7
6369068|NCT01956669|10159082|FG003|Overall Study|Disease Progression|8
6369069|NCT01956669|10159083|FG004|Overall Study|Disease Progression|4
6369070|NCT01956669|10159084|FG005|Overall Study|Disease Progression|3
6369071|NCT01956669|10159085|FG006|Overall Study|Disease Progression|5
6369072|NCT01956669|10159079|FG000|Overall Study|Adverse Event|0
6369073|NCT01956669|10159080|FG001|Overall Study|Adverse Event|2
6369074|NCT01956669|10159081|FG002|Overall Study|Adverse Event|2
6369075|NCT01956669|10159082|FG003|Overall Study|Adverse Event|1
6369076|NCT01956669|10159083|FG004|Overall Study|Adverse Event|0
6369077|NCT01956669|10159084|FG005|Overall Study|Adverse Event|0
6369078|NCT01956669|10159085|FG006|Overall Study|Adverse Event|0
6369079|NCT01956669|10159079|FG000|Overall Study|Physician Decision|0
6369080|NCT01956669|10159080|FG001|Overall Study|Physician Decision|2
6369081|NCT01956669|10159081|FG002|Overall Study|Physician Decision|0
6369082|NCT01956669|10159082|FG003|Overall Study|Physician Decision|0
6369083|NCT01956669|10159083|FG004|Overall Study|Physician Decision|0
6369084|NCT01956669|10159084|FG005|Overall Study|Physician Decision|1
6369085|NCT01956669|10159085|FG006|Overall Study|Physician Decision|0
6369086|NCT01956669|10159079|FG000|Overall Study|Withdrawal by Subject|0
6369087|NCT01956669|10159080|FG001|Overall Study|Withdrawal by Subject|0
6369088|NCT01956669|10159081|FG002|Overall Study|Withdrawal by Subject|1
6369089|NCT01956669|10159082|FG003|Overall Study|Withdrawal by Subject|1
6369090|NCT01956669|10159083|FG004|Overall Study|Withdrawal by Subject|0
6369091|NCT01956669|10159084|FG005|Overall Study|Withdrawal by Subject|0
6369092|NCT01956669|10159085|FG006|Overall Study|Withdrawal by Subject|1
6369093|NCT01967823|10159110|FG000|Overall Study|Died prior to completing therapy (before the six-week mark).|1
6369094|NCT01989676|10159120|FG000|Overall Study|Death|52
6369095|NCT01989676|10159121|FG001|Overall Study|Death|60
6369096|NCT01989676|10159120|FG000|Overall Study|Protocol Violation|2
6369097|NCT01989676|10159121|FG001|Overall Study|Protocol Violation|1
6369098|NCT01989676|10159120|FG000|Overall Study|Lost to Follow-up|8
6369099|NCT01989676|10159121|FG001|Overall Study|Lost to Follow-up|18
6369100|NCT01989676|10159120|FG000|Overall Study|No longer willing to participate in study|26
6369101|NCT01989676|10159121|FG001|Overall Study|No longer willing to participate in study|26
6369102|NCT01989676|10159120|FG000|Overall Study|Participants terminated from study by Sponsor|26
6369103|NCT01989676|10159121|FG001|Overall Study|Participants terminated from study by Sponsor|30
6369104|NCT01989676|10159120|FG000|Overall Study|Other|4
6369105|NCT01989676|10159121|FG001|Overall Study|Other|3
6369106|NCT01992653|10159136|FG000|Overall Study|Death|0
6369107|NCT01992653|10159137|FG001|Overall Study|Death|0
6369108|NCT01992653|10159138|FG002|Overall Study|Death|1
6369109|NCT01992653|10159139|FG003|Overall Study|Death|0
6369110|NCT01992653|10159140|FG004|Overall Study|Death|1
6369111|NCT01992653|10159141|FG005|Overall Study|Death|0
6369112|NCT01992653|10159142|FG006|Overall Study|Death|4
6369113|NCT01992653|10159143|FG007|Overall Study|Death|2
6369114|NCT01992653|10159136|FG000|Overall Study|Lost to Follow-up|0
6369115|NCT01992653|10159137|FG001|Overall Study|Lost to Follow-up|0
6369116|NCT01992653|10159138|FG002|Overall Study|Lost to Follow-up|0
6369117|NCT01992653|10159139|FG003|Overall Study|Lost to Follow-up|0
6369118|NCT01992653|10159140|FG004|Overall Study|Lost to Follow-up|0
6369119|NCT01992653|10159141|FG005|Overall Study|Lost to Follow-up|0
6369120|NCT01992653|10159142|FG006|Overall Study|Lost to Follow-up|0
6369121|NCT01992653|10159143|FG007|Overall Study|Lost to Follow-up|1
6369122|NCT01992653|10159136|FG000|Overall Study|Study Completed|0
6369123|NCT01992653|10159137|FG001|Overall Study|Study Completed|0
6369124|NCT01992653|10159138|FG002|Overall Study|Study Completed|0
6369035|NCT01923168|10159027|FG000|Overall Study|Protocol Violation|1
6369036|NCT01923168|10159028|FG001|Overall Study|Protocol Violation|1
6369037|NCT01923168|10159029|FG002|Overall Study|Protocol Violation|0
6369038|NCT01923168|10159027|FG000|Overall Study|Subject/guardian decision|14
6369039|NCT01923168|10159028|FG001|Overall Study|Subject/guardian decision|14
6369040|NCT01923168|10159029|FG002|Overall Study|Subject/guardian decision|4
6369041|NCT01923168|10159027|FG000|Overall Study|Adverse Event|12
6369042|NCT01923168|10159028|FG001|Overall Study|Adverse Event|12
6369043|NCT01923168|10159029|FG002|Overall Study|Adverse Event|0
6369044|NCT01923168|10159027|FG000|Overall Study|Physician Decision|6
6369045|NCT01923168|10159028|FG001|Overall Study|Physician Decision|9
6369046|NCT01923168|10159029|FG002|Overall Study|Physician Decision|5
6369047|NCT01923168|10159027|FG000|Overall Study|Progressive disease|4
6369048|NCT01923168|10159028|FG001|Overall Study|Progressive disease|3
6369049|NCT01923168|10159029|FG002|Overall Study|Progressive disease|7
6369050|NCT01923168|10159027|FG000|Overall Study|Death|0
6369051|NCT01923168|10159028|FG001|Overall Study|Death|0
6369052|NCT01923168|10159029|FG002|Overall Study|Death|1
6369125|NCT01992653|10159139|FG003|Overall Study|Study Completed|0
6369126|NCT01992653|10159140|FG004|Overall Study|Study Completed|0
6369127|NCT01992653|10159141|FG005|Overall Study|Study Completed|0
6369128|NCT01992653|10159142|FG006|Overall Study|Study Completed|0
6369129|NCT01992653|10159143|FG007|Overall Study|Study Completed|1
6369130|NCT01992653|10159136|FG000|Overall Study|Disease Progression|0
6369131|NCT01992653|10159137|FG001|Overall Study|Disease Progression|0
6369132|NCT01992653|10159138|FG002|Overall Study|Disease Progression|0
6369133|NCT01992653|10159139|FG003|Overall Study|Disease Progression|0
6369134|NCT01992653|10159140|FG004|Overall Study|Disease Progression|0
6369135|NCT01992653|10159141|FG005|Overall Study|Disease Progression|0
6369136|NCT01992653|10159142|FG006|Overall Study|Disease Progression|4
6369137|NCT01992653|10159143|FG007|Overall Study|Disease Progression|0
6171688|NCT01261611|9818587|FG002|Treatment Cycle 3|Withdrawal by Subject|0
6171689|NCT01261611|9818585|FG000|Treatment Cycle 3|Adverse Event|1
6171690|NCT01261611|9818586|FG001|Treatment Cycle 3|Adverse Event|0
6171691|NCT01261611|9818587|FG002|Treatment Cycle 3|Adverse Event|0
6171692|NCT01261611|9818585|FG000|Treatment Cycle 3|Lost to Follow-up|1
6369138|NCT02001974|10159164|FG000|Reparixin + Paclitaxel (28-day Cycles)|Disease progression|2
6369139|NCT02001974|10159165|FG001|Reparixin + Paclitaxel (28-day Cycles)|Disease progression|3
6369140|NCT02001974|10159166|FG002|Reparixin + Paclitaxel (28-day Cycles)|Disease progression|14
6369141|NCT02001974|10159164|FG000|Reparixin + Paclitaxel (28-day Cycles)|Adverse Event|1
6369142|NCT02001974|10159165|FG001|Reparixin + Paclitaxel (28-day Cycles)|Adverse Event|0
6369143|NCT02001974|10159166|FG002|Reparixin + Paclitaxel (28-day Cycles)|Adverse Event|4
6369144|NCT02001974|10159164|FG000|Reparixin + Paclitaxel (28-day Cycles)|Withdrawal by Subject|1
6369145|NCT02001974|10159165|FG001|Reparixin + Paclitaxel (28-day Cycles)|Withdrawal by Subject|0
6369146|NCT02001974|10159166|FG002|Reparixin + Paclitaxel (28-day Cycles)|Withdrawal by Subject|6
6369147|NCT02001974|10159164|FG000|Reparixin + Paclitaxel (28-day Cycles)|Physician Decision|0
6369148|NCT02001974|10159165|FG001|Reparixin + Paclitaxel (28-day Cycles)|Physician Decision|0
6369149|NCT02001974|10159166|FG002|Reparixin + Paclitaxel (28-day Cycles)|Physician Decision|2
6369150|NCT02014558|10159187|FG000|Overall Study|Never Received Study Drug|0
6369151|NCT02014558|10159188|FG001|Overall Study|Never Received Study Drug|0
6369152|NCT02014558|10159189|FG002|Overall Study|Never Received Study Drug|0
6369153|NCT02014558|10159190|FG003|Overall Study|Never Received Study Drug|0
6369154|NCT02014558|10159191|FG004|Overall Study|Never Received Study Drug|1
6369155|NCT02014558|10159192|FG005|Overall Study|Never Received Study Drug|0
6369156|NCT02014558|10159193|FG006|Overall Study|Never Received Study Drug|1
6369157|NCT02014558|10159194|FG007|Overall Study|Never Received Study Drug|0
6369158|NCT02014558|10159195|FG008|Overall Study|Never Received Study Drug|2
6369159|NCT02014558|10159196|FG009|Overall Study|Never Received Study Drug|0
6369160|NCT02014558|10159197|FG010|Overall Study|Never Received Study Drug|2
6369161|NCT02014558|10159198|FG011|Overall Study|Never Received Study Drug|2
6369162|NCT02014558|10159199|FG012|Overall Study|Never Received Study Drug|0
6369163|NCT02014558|10159187|FG000|Overall Study|Adverse Event|0
6369164|NCT02014558|10159188|FG001|Overall Study|Adverse Event|0
6369165|NCT02014558|10159189|FG002|Overall Study|Adverse Event|0
6369166|NCT02014558|10159190|FG003|Overall Study|Adverse Event|0
6369167|NCT02014558|10159191|FG004|Overall Study|Adverse Event|1
6369168|NCT02014558|10159192|FG005|Overall Study|Adverse Event|0
6369169|NCT02014558|10159193|FG006|Overall Study|Adverse Event|0
6369170|NCT02014558|10159194|FG007|Overall Study|Adverse Event|0
6369171|NCT02014558|10159195|FG008|Overall Study|Adverse Event|2
6369172|NCT02014558|10159196|FG009|Overall Study|Adverse Event|2
6369173|NCT02014558|10159197|FG010|Overall Study|Adverse Event|5
6369174|NCT02014558|10159198|FG011|Overall Study|Adverse Event|21
6369175|NCT02014558|10159199|FG012|Overall Study|Adverse Event|3
6369176|NCT02014558|10159187|FG000|Overall Study|Death|1
6369177|NCT02014558|10159188|FG001|Overall Study|Death|0
6369178|NCT02014558|10159189|FG002|Overall Study|Death|0
6369179|NCT02014558|10159190|FG003|Overall Study|Death|0
6369180|NCT02014558|10159191|FG004|Overall Study|Death|0
6369181|NCT02014558|10159192|FG005|Overall Study|Death|0
6369182|NCT02014558|10159193|FG006|Overall Study|Death|1
6369183|NCT02014558|10159194|FG007|Overall Study|Death|1
6369184|NCT02014558|10159195|FG008|Overall Study|Death|2
6369185|NCT02014558|10159196|FG009|Overall Study|Death|5
6369186|NCT02014558|10159197|FG010|Overall Study|Death|5
6369187|NCT02014558|10159198|FG011|Overall Study|Death|19
6369188|NCT02014558|10159199|FG012|Overall Study|Death|2
6369189|NCT02014558|10159187|FG000|Overall Study|Lack of Efficacy|1
6369190|NCT02014558|10159188|FG001|Overall Study|Lack of Efficacy|2
6369191|NCT02014558|10159189|FG002|Overall Study|Lack of Efficacy|1
6369192|NCT02014558|10159190|FG003|Overall Study|Lack of Efficacy|1
6369193|NCT02014558|10159191|FG004|Overall Study|Lack of Efficacy|0
6369194|NCT02014558|10159192|FG005|Overall Study|Lack of Efficacy|0
6369195|NCT02014558|10159193|FG006|Overall Study|Lack of Efficacy|1
6369196|NCT02014558|10159194|FG007|Overall Study|Lack of Efficacy|3
6369197|NCT02014558|10159195|FG008|Overall Study|Lack of Efficacy|3
6369198|NCT02014558|10159196|FG009|Overall Study|Lack of Efficacy|3
6369199|NCT02014558|10159197|FG010|Overall Study|Lack of Efficacy|16
6369200|NCT02014558|10159198|FG011|Overall Study|Lack of Efficacy|8
6369201|NCT02014558|10159199|FG012|Overall Study|Lack of Efficacy|5
6369202|NCT02014558|10159187|FG000|Overall Study|Lost to Follow-up|0
6369203|NCT02014558|10159188|FG001|Overall Study|Lost to Follow-up|0
6369204|NCT02014558|10159189|FG002|Overall Study|Lost to Follow-up|0
6369205|NCT02014558|10159190|FG003|Overall Study|Lost to Follow-up|0
6369206|NCT02014558|10159191|FG004|Overall Study|Lost to Follow-up|0
6171693|NCT01261611|9818586|FG001|Treatment Cycle 3|Lost to Follow-up|0
6369207|NCT02014558|10159192|FG005|Overall Study|Lost to Follow-up|0
6369208|NCT02014558|10159193|FG006|Overall Study|Lost to Follow-up|0
6369209|NCT02014558|10159194|FG007|Overall Study|Lost to Follow-up|0
6369210|NCT02014558|10159195|FG008|Overall Study|Lost to Follow-up|0
6369211|NCT02014558|10159196|FG009|Overall Study|Lost to Follow-up|0
6369212|NCT02014558|10159197|FG010|Overall Study|Lost to Follow-up|1
6369213|NCT02014558|10159198|FG011|Overall Study|Lost to Follow-up|0
6369214|NCT02014558|10159199|FG012|Overall Study|Lost to Follow-up|0
6369215|NCT02014558|10159187|FG000|Overall Study|Progressive Disease|1
6369216|NCT02014558|10159188|FG001|Overall Study|Progressive Disease|0
6369217|NCT02014558|10159189|FG002|Overall Study|Progressive Disease|1
6369218|NCT02014558|10159190|FG003|Overall Study|Progressive Disease|1
6369219|NCT02014558|10159191|FG004|Overall Study|Progressive Disease|1
6369220|NCT02014558|10159192|FG005|Overall Study|Progressive Disease|2
6369221|NCT02014558|10159193|FG006|Overall Study|Progressive Disease|1
6369222|NCT02014558|10159194|FG007|Overall Study|Progressive Disease|6
6369223|NCT02014558|10159195|FG008|Overall Study|Progressive Disease|5
6369224|NCT02014558|10159196|FG009|Overall Study|Progressive Disease|6
6369225|NCT02014558|10159197|FG010|Overall Study|Progressive Disease|22
6369226|NCT02014558|10159198|FG011|Overall Study|Progressive Disease|31
6369227|NCT02014558|10159199|FG012|Overall Study|Progressive Disease|6
6369228|NCT02014558|10159187|FG000|Overall Study|Withdrawal by Subject|0
6369229|NCT02014558|10159188|FG001|Overall Study|Withdrawal by Subject|0
6369230|NCT02014558|10159189|FG002|Overall Study|Withdrawal by Subject|0
6369231|NCT02014558|10159190|FG003|Overall Study|Withdrawal by Subject|0
6369232|NCT02014558|10159191|FG004|Overall Study|Withdrawal by Subject|1
6369233|NCT02014558|10159192|FG005|Overall Study|Withdrawal by Subject|0
6369234|NCT02014558|10159193|FG006|Overall Study|Withdrawal by Subject|0
6369235|NCT02014558|10159194|FG007|Overall Study|Withdrawal by Subject|0
6369236|NCT02014558|10159195|FG008|Overall Study|Withdrawal by Subject|0
6369237|NCT02014558|10159196|FG009|Overall Study|Withdrawal by Subject|2
6369238|NCT02014558|10159197|FG010|Overall Study|Withdrawal by Subject|6
6369239|NCT02014558|10159198|FG011|Overall Study|Withdrawal by Subject|10
6369240|NCT02014558|10159199|FG012|Overall Study|Withdrawal by Subject|0
6369241|NCT02014558|10159187|FG000|Overall Study|Miscellaneous|2
6369242|NCT02014558|10159188|FG001|Overall Study|Miscellaneous|1
6369243|NCT02014558|10159189|FG002|Overall Study|Miscellaneous|1
6369244|NCT02014558|10159190|FG003|Overall Study|Miscellaneous|1
6369245|NCT02014558|10159191|FG004|Overall Study|Miscellaneous|0
6369246|NCT02014558|10159192|FG005|Overall Study|Miscellaneous|1
6369247|NCT02014558|10159193|FG006|Overall Study|Miscellaneous|0
6369248|NCT02014558|10159194|FG007|Overall Study|Miscellaneous|1
6369249|NCT02014558|10159195|FG008|Overall Study|Miscellaneous|1
6369250|NCT02014558|10159196|FG009|Overall Study|Miscellaneous|3
6369251|NCT02014558|10159197|FG010|Overall Study|Miscellaneous|12
6369252|NCT02014558|10159198|FG011|Overall Study|Miscellaneous|11
6369253|NCT02014558|10159199|FG012|Overall Study|Miscellaneous|1
6369254|NCT02024555|10159254|FG000|Overall Study|Lost to Follow-up|1
6369255|NCT02024555|10159255|FG001|Overall Study|Lost to Follow-up|1
6369256|NCT02024555|10159254|FG000|Overall Study|Withdrawal by Subject|5
6369257|NCT02024555|10159255|FG001|Overall Study|Withdrawal by Subject|1
6369258|NCT02034123|10159279|FG000|Part1(Median of 7.286 Weeks of Exposure)|Adverse Event|0
6369259|NCT02034123|10159280|FG001|Part1(Median of 7.286 Weeks of Exposure)|Adverse Event|0
6369260|NCT02034123|10159281|FG002|Part1(Median of 7.286 Weeks of Exposure)|Adverse Event|0
6369261|NCT02034123|10159282|FG003|Part1(Median of 7.286 Weeks of Exposure)|Adverse Event|0
6369262|NCT02034123|10159283|FG004|Part1(Median of 7.286 Weeks of Exposure)|Adverse Event|1
6369263|NCT02034123|10159284|FG005|Part1(Median of 7.286 Weeks of Exposure)|Adverse Event|0
6369264|NCT02034123|10159285|FG006|Part1(Median of 7.286 Weeks of Exposure)|Adverse Event|0
6369265|NCT02034123|10159286|FG007|Part1(Median of 7.286 Weeks of Exposure)|Adverse Event|1
6369266|NCT02034123|10159287|FG008|Part1(Median of 7.286 Weeks of Exposure)|Adverse Event|1
6369267|NCT02034123|10159288|FG009|Part1(Median of 7.286 Weeks of Exposure)|Adverse Event|0
6369268|NCT02034123|10159289|FG010|Part1(Median of 7.286 Weeks of Exposure)|Adverse Event|0
6369269|NCT02034123|10159290|FG011|Part1(Median of 7.286 Weeks of Exposure)|Adverse Event|0
6369270|NCT02034123|10159291|FG012|Part1(Median of 7.286 Weeks of Exposure)|Adverse Event|0
6369271|NCT02034123|10159292|FG013|Part1(Median of 7.286 Weeks of Exposure)|Adverse Event|0
6369272|NCT02034123|10159293|FG014|Part1(Median of 7.286 Weeks of Exposure)|Adverse Event|0
6369273|NCT02034123|10159294|FG015|Part1(Median of 7.286 Weeks of Exposure)|Adverse Event|0
6369274|NCT02034123|10159295|FG016|Part1(Median of 7.286 Weeks of Exposure)|Adverse Event|0
6369275|NCT02034123|10159296|FG017|Part1(Median of 7.286 Weeks of Exposure)|Adverse Event|0
6369276|NCT02034123|10159279|FG000|Part1(Median of 7.286 Weeks of Exposure)|Lack of Efficacy|0
6369277|NCT02034123|10159280|FG001|Part1(Median of 7.286 Weeks of Exposure)|Lack of Efficacy|0
6369278|NCT02034123|10159281|FG002|Part1(Median of 7.286 Weeks of Exposure)|Lack of Efficacy|0
6369279|NCT02034123|10159282|FG003|Part1(Median of 7.286 Weeks of Exposure)|Lack of Efficacy|1
6369280|NCT02034123|10159283|FG004|Part1(Median of 7.286 Weeks of Exposure)|Lack of Efficacy|0
6369281|NCT02034123|10159284|FG005|Part1(Median of 7.286 Weeks of Exposure)|Lack of Efficacy|0
6369282|NCT02034123|10159285|FG006|Part1(Median of 7.286 Weeks of Exposure)|Lack of Efficacy|0
6369283|NCT02034123|10159286|FG007|Part1(Median of 7.286 Weeks of Exposure)|Lack of Efficacy|0
6369284|NCT02034123|10159287|FG008|Part1(Median of 7.286 Weeks of Exposure)|Lack of Efficacy|0
6369285|NCT02034123|10159288|FG009|Part1(Median of 7.286 Weeks of Exposure)|Lack of Efficacy|0
6369286|NCT02034123|10159289|FG010|Part1(Median of 7.286 Weeks of Exposure)|Lack of Efficacy|0
6369287|NCT02034123|10159290|FG011|Part1(Median of 7.286 Weeks of Exposure)|Lack of Efficacy|0
6369288|NCT02034123|10159291|FG012|Part1(Median of 7.286 Weeks of Exposure)|Lack of Efficacy|0
6369289|NCT02034123|10159292|FG013|Part1(Median of 7.286 Weeks of Exposure)|Lack of Efficacy|0
6369290|NCT02034123|10159293|FG014|Part1(Median of 7.286 Weeks of Exposure)|Lack of Efficacy|0
6369291|NCT02034123|10159294|FG015|Part1(Median of 7.286 Weeks of Exposure)|Lack of Efficacy|0
6369292|NCT02034123|10159295|FG016|Part1(Median of 7.286 Weeks of Exposure)|Lack of Efficacy|0
6369293|NCT02034123|10159296|FG017|Part1(Median of 7.286 Weeks of Exposure)|Lack of Efficacy|0
6369294|NCT02034123|10159279|FG000|Part1(Median of 7.286 Weeks of Exposure)|Other-Study closed/terminated|0
6369295|NCT02034123|10159280|FG001|Part1(Median of 7.286 Weeks of Exposure)|Other-Study closed/terminated|0
6369296|NCT02034123|10159281|FG002|Part1(Median of 7.286 Weeks of Exposure)|Other-Study closed/terminated|0
6369297|NCT02034123|10159282|FG003|Part1(Median of 7.286 Weeks of Exposure)|Other-Study closed/terminated|0
6369298|NCT02034123|10159283|FG004|Part1(Median of 7.286 Weeks of Exposure)|Other-Study closed/terminated|0
6369299|NCT02034123|10159284|FG005|Part1(Median of 7.286 Weeks of Exposure)|Other-Study closed/terminated|0
6369300|NCT02034123|10159285|FG006|Part1(Median of 7.286 Weeks of Exposure)|Other-Study closed/terminated|0
6369301|NCT02034123|10159286|FG007|Part1(Median of 7.286 Weeks of Exposure)|Other-Study closed/terminated|0
6369302|NCT02034123|10159287|FG008|Part1(Median of 7.286 Weeks of Exposure)|Other-Study closed/terminated|1
6369303|NCT02034123|10159288|FG009|Part1(Median of 7.286 Weeks of Exposure)|Other-Study closed/terminated|0
6369304|NCT02034123|10159289|FG010|Part1(Median of 7.286 Weeks of Exposure)|Other-Study closed/terminated|0
6369305|NCT02034123|10159290|FG011|Part1(Median of 7.286 Weeks of Exposure)|Other-Study closed/terminated|0
6369306|NCT02034123|10159291|FG012|Part1(Median of 7.286 Weeks of Exposure)|Other-Study closed/terminated|0
6369307|NCT02034123|10159292|FG013|Part1(Median of 7.286 Weeks of Exposure)|Other-Study closed/terminated|0
6369308|NCT02034123|10159293|FG014|Part1(Median of 7.286 Weeks of Exposure)|Other-Study closed/terminated|0
6369309|NCT02034123|10159294|FG015|Part1(Median of 7.286 Weeks of Exposure)|Other-Study closed/terminated|0
6369310|NCT02034123|10159295|FG016|Part1(Median of 7.286 Weeks of Exposure)|Other-Study closed/terminated|0
6369311|NCT02034123|10159296|FG017|Part1(Median of 7.286 Weeks of Exposure)|Other-Study closed/terminated|0
6369312|NCT02034123|10159279|FG000|Part1(Median of 7.286 Weeks of Exposure)|Withdrawal by Subject|0
6369313|NCT02034123|10159280|FG001|Part1(Median of 7.286 Weeks of Exposure)|Withdrawal by Subject|0
6369314|NCT02034123|10159281|FG002|Part1(Median of 7.286 Weeks of Exposure)|Withdrawal by Subject|0
6369315|NCT02034123|10159282|FG003|Part1(Median of 7.286 Weeks of Exposure)|Withdrawal by Subject|1
6369316|NCT02034123|10159283|FG004|Part1(Median of 7.286 Weeks of Exposure)|Withdrawal by Subject|1
6369317|NCT02034123|10159284|FG005|Part1(Median of 7.286 Weeks of Exposure)|Withdrawal by Subject|0
6369318|NCT02034123|10159285|FG006|Part1(Median of 7.286 Weeks of Exposure)|Withdrawal by Subject|0
6369319|NCT02034123|10159286|FG007|Part1(Median of 7.286 Weeks of Exposure)|Withdrawal by Subject|0
6084557|NCT00642993|9693472|FG000|Overall Study|Did not meet protocol eligibility|0
6369320|NCT02034123|10159287|FG008|Part1(Median of 7.286 Weeks of Exposure)|Withdrawal by Subject|0
6369321|NCT02034123|10159288|FG009|Part1(Median of 7.286 Weeks of Exposure)|Withdrawal by Subject|0
6369322|NCT02034123|10159289|FG010|Part1(Median of 7.286 Weeks of Exposure)|Withdrawal by Subject|0
6369323|NCT02034123|10159290|FG011|Part1(Median of 7.286 Weeks of Exposure)|Withdrawal by Subject|0
6369324|NCT02034123|10159291|FG012|Part1(Median of 7.286 Weeks of Exposure)|Withdrawal by Subject|0
6369325|NCT02034123|10159292|FG013|Part1(Median of 7.286 Weeks of Exposure)|Withdrawal by Subject|0
6369326|NCT02034123|10159293|FG014|Part1(Median of 7.286 Weeks of Exposure)|Withdrawal by Subject|0
6369327|NCT02034123|10159294|FG015|Part1(Median of 7.286 Weeks of Exposure)|Withdrawal by Subject|0
6369328|NCT02034123|10159295|FG016|Part1(Median of 7.286 Weeks of Exposure)|Withdrawal by Subject|0
6369329|NCT02034123|10159296|FG017|Part1(Median of 7.286 Weeks of Exposure)|Withdrawal by Subject|0
6369330|NCT02040584|10159341|FG000|Overall Study|Adverse Event|13
6369331|NCT02040584|10159342|FG001|Overall Study|Adverse Event|6
6369332|NCT02040584|10159341|FG000|Overall Study|Protocol Violation|9
6369333|NCT02040584|10159342|FG001|Overall Study|Protocol Violation|11
6369334|NCT02040584|10159341|FG000|Overall Study|Unsatisfactory therapeutic effect|0
6369335|NCT02040584|10159342|FG001|Overall Study|Unsatisfactory therapeutic effect|1
6369336|NCT02040584|10159341|FG000|Overall Study|Death|6
6369337|NCT02040584|10159342|FG001|Overall Study|Death|3
6369338|NCT02040584|10159341|FG000|Overall Study|Transplant rejection/retransplant|0
6369339|NCT02040584|10159342|FG001|Overall Study|Transplant rejection/retransplant|1
6369340|NCT02040584|10159341|FG000|Overall Study|Immunosuppressant/prohibited med use|7
6369341|NCT02040584|10159342|FG001|Overall Study|Immunosuppressant/prohibited med use|10
6369342|NCT02045797|10159361|FG000|Overall Study|Adverse Event|3
6369343|NCT02045797|10159362|FG001|Overall Study|Adverse Event|1
6369344|NCT02045797|10159363|FG002|Overall Study|Adverse Event|0
6369345|NCT02045797|10159361|FG000|Overall Study|Lack of Efficacy|1
6369346|NCT02045797|10159362|FG001|Overall Study|Lack of Efficacy|0
6369347|NCT02045797|10159363|FG002|Overall Study|Lack of Efficacy|0
6369348|NCT02045797|10159361|FG000|Overall Study|Lost to Follow-up|2
6369349|NCT02045797|10159362|FG001|Overall Study|Lost to Follow-up|3
6369350|NCT02045797|10159363|FG002|Overall Study|Lost to Follow-up|1
6369351|NCT02045797|10159361|FG000|Overall Study|Physician Decision|0
6369352|NCT02045797|10159362|FG001|Overall Study|Physician Decision|1
6369353|NCT02045797|10159363|FG002|Overall Study|Physician Decision|0
6369354|NCT02045797|10159361|FG000|Overall Study|Withdrawal by Subject|1
6369355|NCT02045797|10159362|FG001|Overall Study|Withdrawal by Subject|2
6369356|NCT02045797|10159363|FG002|Overall Study|Withdrawal by Subject|0
6369357|NCT02049710|10159373|FG000|Overall Study|Lost to Follow-up|319
6369358|NCT02049710|10159374|FG001|Overall Study|Lost to Follow-up|324
6369359|NCT02055547|10159380|FG000|Overall Study|Protocol Violation|0
6369360|NCT02055547|10159381|FG001|Overall Study|Protocol Violation|0
6369361|NCT02055547|10159382|FG002|Overall Study|Protocol Violation|1
6369362|NCT02055547|10159383|FG003|Overall Study|Protocol Violation|0
6369363|NCT02055547|10159384|FG004|Overall Study|Protocol Violation|0
6369364|NCT02055547|10159385|FG005|Overall Study|Protocol Violation|0
6369365|NCT02055547|10159386|FG006|Overall Study|Protocol Violation|1
6369366|NCT02055547|10159387|FG007|Overall Study|Protocol Violation|0
6369367|NCT02055547|10159388|FG008|Overall Study|Protocol Violation|0
6369368|NCT02055547|10159389|FG009|Overall Study|Protocol Violation|0
6369369|NCT02055547|10159390|FG010|Overall Study|Protocol Violation|0
6369370|NCT02055547|10159391|FG011|Overall Study|Protocol Violation|0
6369371|NCT02055547|10159392|FG012|Overall Study|Protocol Violation|0
6369372|NCT02055547|10159393|FG013|Overall Study|Protocol Violation|0
6369373|NCT02055547|10159394|FG014|Overall Study|Protocol Violation|0
6369374|NCT02055547|10159395|FG015|Overall Study|Protocol Violation|0
6369375|NCT02055547|10159396|FG016|Overall Study|Protocol Violation|0
6369376|NCT02055547|10159397|FG017|Overall Study|Protocol Violation|0
6369377|NCT02055547|10159398|FG018|Overall Study|Protocol Violation|0
6369378|NCT02055547|10159380|FG000|Overall Study|Physician Decision|0
6369379|NCT02055547|10159381|FG001|Overall Study|Physician Decision|1
6369380|NCT02055547|10159382|FG002|Overall Study|Physician Decision|1
6369381|NCT02055547|10159383|FG003|Overall Study|Physician Decision|0
6369382|NCT02055547|10159384|FG004|Overall Study|Physician Decision|1
6369383|NCT02055547|10159385|FG005|Overall Study|Physician Decision|0
6369384|NCT02055547|10159386|FG006|Overall Study|Physician Decision|0
6369385|NCT02055547|10159387|FG007|Overall Study|Physician Decision|0
6369386|NCT02055547|10159388|FG008|Overall Study|Physician Decision|0
6369387|NCT02055547|10159389|FG009|Overall Study|Physician Decision|1
6369388|NCT02055547|10159390|FG010|Overall Study|Physician Decision|1
6369389|NCT02055547|10159391|FG011|Overall Study|Physician Decision|0
6369390|NCT02055547|10159392|FG012|Overall Study|Physician Decision|0
6369391|NCT02055547|10159393|FG013|Overall Study|Physician Decision|0
6369392|NCT02055547|10159394|FG014|Overall Study|Physician Decision|0
6369393|NCT02055547|10159395|FG015|Overall Study|Physician Decision|0
6369394|NCT02055547|10159396|FG016|Overall Study|Physician Decision|0
6369395|NCT02055547|10159397|FG017|Overall Study|Physician Decision|0
6369396|NCT02055547|10159398|FG018|Overall Study|Physician Decision|0
6369397|NCT02055547|10159380|FG000|Overall Study|Adverse Event|0
6369398|NCT02055547|10159381|FG001|Overall Study|Adverse Event|0
6369399|NCT02055547|10159382|FG002|Overall Study|Adverse Event|0
6369400|NCT02055547|10159383|FG003|Overall Study|Adverse Event|0
6369401|NCT02055547|10159384|FG004|Overall Study|Adverse Event|0
6369402|NCT02055547|10159385|FG005|Overall Study|Adverse Event|0
6369403|NCT02055547|10159386|FG006|Overall Study|Adverse Event|1
6369404|NCT02055547|10159387|FG007|Overall Study|Adverse Event|0
6369405|NCT02055547|10159388|FG008|Overall Study|Adverse Event|1
6369406|NCT02055547|10159389|FG009|Overall Study|Adverse Event|0
6369407|NCT02055547|10159390|FG010|Overall Study|Adverse Event|0
6369408|NCT02055547|10159391|FG011|Overall Study|Adverse Event|0
6369409|NCT02055547|10159392|FG012|Overall Study|Adverse Event|0
6369410|NCT02055547|10159393|FG013|Overall Study|Adverse Event|0
6369411|NCT02055547|10159394|FG014|Overall Study|Adverse Event|0
6369412|NCT02055547|10159395|FG015|Overall Study|Adverse Event|0
6369413|NCT02055547|10159396|FG016|Overall Study|Adverse Event|0
6369414|NCT02055547|10159397|FG017|Overall Study|Adverse Event|0
6369415|NCT02055547|10159398|FG018|Overall Study|Adverse Event|0
6369416|NCT02055547|10159380|FG000|Overall Study|Withdrawal by Subject|0
6369417|NCT02055547|10159381|FG001|Overall Study|Withdrawal by Subject|0
6369418|NCT02055547|10159382|FG002|Overall Study|Withdrawal by Subject|0
6369419|NCT02055547|10159383|FG003|Overall Study|Withdrawal by Subject|0
6369420|NCT02055547|10159384|FG004|Overall Study|Withdrawal by Subject|0
6369421|NCT02055547|10159385|FG005|Overall Study|Withdrawal by Subject|1
6369422|NCT02055547|10159386|FG006|Overall Study|Withdrawal by Subject|0
6369423|NCT02055547|10159387|FG007|Overall Study|Withdrawal by Subject|0
6369424|NCT02055547|10159388|FG008|Overall Study|Withdrawal by Subject|1
6369425|NCT02055547|10159389|FG009|Overall Study|Withdrawal by Subject|0
6369426|NCT02055547|10159390|FG010|Overall Study|Withdrawal by Subject|0
6369427|NCT02055547|10159391|FG011|Overall Study|Withdrawal by Subject|0
6369428|NCT02055547|10159392|FG012|Overall Study|Withdrawal by Subject|0
6369429|NCT02055547|10159393|FG013|Overall Study|Withdrawal by Subject|1
6369430|NCT02055547|10159394|FG014|Overall Study|Withdrawal by Subject|0
6369431|NCT02055547|10159395|FG015|Overall Study|Withdrawal by Subject|1
6369432|NCT02055547|10159396|FG016|Overall Study|Withdrawal by Subject|0
6369433|NCT02055547|10159397|FG017|Overall Study|Withdrawal by Subject|0
6369434|NCT02055547|10159398|FG018|Overall Study|Withdrawal by Subject|0
6369435|NCT02055547|10159380|FG000|Overall Study|Lost to Follow-up|0
6369436|NCT02055547|10159381|FG001|Overall Study|Lost to Follow-up|0
6369437|NCT02055547|10159382|FG002|Overall Study|Lost to Follow-up|1
6369438|NCT02055547|10159383|FG003|Overall Study|Lost to Follow-up|0
6369439|NCT02055547|10159384|FG004|Overall Study|Lost to Follow-up|0
6369440|NCT02055547|10159385|FG005|Overall Study|Lost to Follow-up|0
6369441|NCT02055547|10159386|FG006|Overall Study|Lost to Follow-up|0
6369442|NCT02055547|10159387|FG007|Overall Study|Lost to Follow-up|0
6369443|NCT02055547|10159388|FG008|Overall Study|Lost to Follow-up|0
6369444|NCT02055547|10159389|FG009|Overall Study|Lost to Follow-up|0
6369445|NCT02055547|10159390|FG010|Overall Study|Lost to Follow-up|0
6369446|NCT02055547|10159391|FG011|Overall Study|Lost to Follow-up|0
6369447|NCT02055547|10159392|FG012|Overall Study|Lost to Follow-up|0
6369448|NCT02055547|10159393|FG013|Overall Study|Lost to Follow-up|0
6369449|NCT02055547|10159394|FG014|Overall Study|Lost to Follow-up|0
6369450|NCT02055547|10159395|FG015|Overall Study|Lost to Follow-up|0
6369451|NCT02055547|10159396|FG016|Overall Study|Lost to Follow-up|0
6369452|NCT02055547|10159397|FG017|Overall Study|Lost to Follow-up|0
6369453|NCT02055547|10159398|FG018|Overall Study|Lost to Follow-up|0
6369454|NCT02064387|10159444|FG000|Part 1 Max 23.5 Months Followup Duration|Death|0
6369455|NCT02064387|10159445|FG001|Part 1 Max 23.5 Months Followup Duration|Death|0
6369456|NCT02064387|10159446|FG002|Part 1 Max 23.5 Months Followup Duration|Death|0
6369457|NCT02064387|10159447|FG003|Part 1 Max 23.5 Months Followup Duration|Death|0
6369458|NCT02064387|10159448|FG004|Part 1 Max 23.5 Months Followup Duration|Death|0
6369459|NCT02064387|10159449|FG005|Part 1 Max 23.5 Months Followup Duration|Death|0
6369460|NCT02064387|10159450|FG006|Part 1 Max 23.5 Months Followup Duration|Death|0
6369461|NCT02064387|10159451|FG007|Part 1 Max 23.5 Months Followup Duration|Death|1
6369462|NCT02064387|10159452|FG008|Part 1 Max 23.5 Months Followup Duration|Death|0
6369463|NCT02064387|10159453|FG009|Part 1 Max 23.5 Months Followup Duration|Death|1
6369464|NCT02064387|10159454|FG010|Part 1 Max 23.5 Months Followup Duration|Death|0
6369465|NCT02064387|10159455|FG011|Part 1 Max 23.5 Months Followup Duration|Death|0
6369466|NCT02064387|10159444|FG000|Part 1 Max 23.5 Months Followup Duration|Lost to Follow-up|0
6369467|NCT02064387|10159445|FG001|Part 1 Max 23.5 Months Followup Duration|Lost to Follow-up|0
6369468|NCT02064387|10159446|FG002|Part 1 Max 23.5 Months Followup Duration|Lost to Follow-up|0
6369469|NCT02064387|10159447|FG003|Part 1 Max 23.5 Months Followup Duration|Lost to Follow-up|0
6369470|NCT02064387|10159448|FG004|Part 1 Max 23.5 Months Followup Duration|Lost to Follow-up|0
6369471|NCT02064387|10159449|FG005|Part 1 Max 23.5 Months Followup Duration|Lost to Follow-up|0
6369472|NCT02064387|10159450|FG006|Part 1 Max 23.5 Months Followup Duration|Lost to Follow-up|0
6369473|NCT02064387|10159451|FG007|Part 1 Max 23.5 Months Followup Duration|Lost to Follow-up|1
6369474|NCT02064387|10159452|FG008|Part 1 Max 23.5 Months Followup Duration|Lost to Follow-up|0
6369475|NCT02064387|10159453|FG009|Part 1 Max 23.5 Months Followup Duration|Lost to Follow-up|0
6369476|NCT02064387|10159454|FG010|Part 1 Max 23.5 Months Followup Duration|Lost to Follow-up|0
6369477|NCT02064387|10159455|FG011|Part 1 Max 23.5 Months Followup Duration|Lost to Follow-up|0
6369478|NCT02064387|10159444|FG000|Part 1 Max 23.5 Months Followup Duration|Withdrawal by Subject|0
6369479|NCT02064387|10159445|FG001|Part 1 Max 23.5 Months Followup Duration|Withdrawal by Subject|0
6369480|NCT02064387|10159446|FG002|Part 1 Max 23.5 Months Followup Duration|Withdrawal by Subject|0
6369481|NCT02064387|10159447|FG003|Part 1 Max 23.5 Months Followup Duration|Withdrawal by Subject|0
6369482|NCT02064387|10159448|FG004|Part 1 Max 23.5 Months Followup Duration|Withdrawal by Subject|0
6369483|NCT02064387|10159449|FG005|Part 1 Max 23.5 Months Followup Duration|Withdrawal by Subject|0
6369484|NCT02064387|10159450|FG006|Part 1 Max 23.5 Months Followup Duration|Withdrawal by Subject|0
6369485|NCT02064387|10159451|FG007|Part 1 Max 23.5 Months Followup Duration|Withdrawal by Subject|0
6369486|NCT02064387|10159452|FG008|Part 1 Max 23.5 Months Followup Duration|Withdrawal by Subject|1
6369487|NCT02064387|10159453|FG009|Part 1 Max 23.5 Months Followup Duration|Withdrawal by Subject|0
6369488|NCT02064387|10159454|FG010|Part 1 Max 23.5 Months Followup Duration|Withdrawal by Subject|0
6369489|NCT02064387|10159455|FG011|Part 1 Max 23.5 Months Followup Duration|Withdrawal by Subject|0
6369490|NCT02064387|10159444|FG000|Part 2 Max 35 Months Followup Duration|Death|0
6369491|NCT02064387|10159445|FG001|Part 2 Max 35 Months Followup Duration|Death|0
6369492|NCT02064387|10159446|FG002|Part 2 Max 35 Months Followup Duration|Death|0
6369493|NCT02064387|10159447|FG003|Part 2 Max 35 Months Followup Duration|Death|0
6369494|NCT02064387|10159448|FG004|Part 2 Max 35 Months Followup Duration|Death|0
6369495|NCT02064387|10159449|FG005|Part 2 Max 35 Months Followup Duration|Death|0
6369496|NCT02064387|10159450|FG006|Part 2 Max 35 Months Followup Duration|Death|0
6369497|NCT02064387|10159451|FG007|Part 2 Max 35 Months Followup Duration|Death|0
6369498|NCT02064387|10159452|FG008|Part 2 Max 35 Months Followup Duration|Death|0
6369499|NCT02064387|10159453|FG009|Part 2 Max 35 Months Followup Duration|Death|0
6369500|NCT02064387|10159454|FG010|Part 2 Max 35 Months Followup Duration|Death|5
6369501|NCT02064387|10159455|FG011|Part 2 Max 35 Months Followup Duration|Death|3
6369502|NCT02064387|10159444|FG000|Part 2 Max 35 Months Followup Duration|Withdrawal by Subject|0
6369503|NCT02064387|10159445|FG001|Part 2 Max 35 Months Followup Duration|Withdrawal by Subject|0
6369504|NCT02064387|10159446|FG002|Part 2 Max 35 Months Followup Duration|Withdrawal by Subject|0
6369505|NCT02064387|10159447|FG003|Part 2 Max 35 Months Followup Duration|Withdrawal by Subject|0
6369506|NCT02064387|10159448|FG004|Part 2 Max 35 Months Followup Duration|Withdrawal by Subject|0
6369507|NCT02064387|10159449|FG005|Part 2 Max 35 Months Followup Duration|Withdrawal by Subject|0
6369508|NCT02064387|10159450|FG006|Part 2 Max 35 Months Followup Duration|Withdrawal by Subject|0
6369509|NCT02064387|10159451|FG007|Part 2 Max 35 Months Followup Duration|Withdrawal by Subject|0
6369510|NCT02064387|10159452|FG008|Part 2 Max 35 Months Followup Duration|Withdrawal by Subject|0
6369511|NCT02064387|10159453|FG009|Part 2 Max 35 Months Followup Duration|Withdrawal by Subject|0
6369512|NCT02064387|10159454|FG010|Part 2 Max 35 Months Followup Duration|Withdrawal by Subject|1
6369513|NCT02064387|10159455|FG011|Part 2 Max 35 Months Followup Duration|Withdrawal by Subject|0
6369514|NCT02076178|10159496|FG000|Oral Phase|Adverse Event|0
6369515|NCT02076178|10159497|FG001|Oral Phase|Adverse Event|7
6369516|NCT02076178|10159496|FG000|Oral Phase|Withdrawal by Subject|0
6369517|NCT02076178|10159497|FG001|Oral Phase|Withdrawal by Subject|4
6369518|NCT02076178|10159496|FG000|Oral Phase|Physician Decision|0
6369519|NCT02076178|10159497|FG001|Oral Phase|Physician Decision|1
6369520|NCT02076178|10159496|FG000|Injection Phase|Protocol defined stopping criteria|1
6369521|NCT02076178|10159497|FG001|Injection Phase|Protocol defined stopping criteria|0
6369522|NCT02076178|10159496|FG000|Injection Phase|Withdrawal by Subject|0
6369523|NCT02076178|10159497|FG001|Injection Phase|Withdrawal by Subject|3
6171694|NCT01261611|9818587|FG002|Treatment Cycle 3|Lost to Follow-up|0
6171695|NCT01261611|9818585|FG000|Treatment Cycle 4|Completed study|87
6369524|NCT02076178|10159496|FG000|Injection Phase|Physician Decision|0
6369525|NCT02076178|10159497|FG001|Injection Phase|Physician Decision|3
6369526|NCT02076178|10159496|FG000|Injection Phase|Lost to Follow-up|0
6369527|NCT02076178|10159497|FG001|Injection Phase|Lost to Follow-up|1
6171696|NCT01261611|9818586|FG001|Treatment Cycle 4|Completed study|0
6369528|NCT02079766|10159507|FG000|Overall Study|Physician Decision|1
6369529|NCT02079766|10159508|FG001|Overall Study|Physician Decision|0
6369530|NCT02079766|10159507|FG000|Overall Study|Withdrawal by Subject|1
6369531|NCT02079766|10159508|FG001|Overall Study|Withdrawal by Subject|0
6369580|NCT02087189|10159541|FG000|Overall Study|enrolled but did not receive a TD01 as implant|2
6369581|NCT02112916|10159566|FG000|Overall Study|Adverse Event|6
6369582|NCT02112916|10159567|FG001|Overall Study|Adverse Event|9
6369583|NCT02112916|10159568|FG002|Overall Study|Adverse Event|3
6369584|NCT02112916|10159569|FG003|Overall Study|Adverse Event|2
6369585|NCT02112916|10159566|FG000|Overall Study|Death|9
6369586|NCT02112916|10159567|FG001|Overall Study|Death|9
6369587|NCT02112916|10159568|FG002|Overall Study|Death|3
6369588|NCT02112916|10159569|FG003|Overall Study|Death|4
6369589|NCT02112916|10159566|FG000|Overall Study|Lost to Follow-up|1
6369590|NCT02112916|10159567|FG001|Overall Study|Lost to Follow-up|0
6369591|NCT02112916|10159568|FG002|Overall Study|Lost to Follow-up|0
6369592|NCT02112916|10159569|FG003|Overall Study|Lost to Follow-up|0
6369593|NCT02112916|10159566|FG000|Overall Study|Physician Decision|94
6369594|NCT02112916|10159567|FG001|Overall Study|Physician Decision|72
6369595|NCT02112916|10159568|FG002|Overall Study|Physician Decision|24
6369596|NCT02112916|10159569|FG003|Overall Study|Physician Decision|15
6369597|NCT02112916|10159566|FG000|Overall Study|Withdrawal by Subject|5
6369598|NCT02112916|10159567|FG001|Overall Study|Withdrawal by Subject|3
6369599|NCT02112916|10159568|FG002|Overall Study|Withdrawal by Subject|1
6369600|NCT02112916|10159569|FG003|Overall Study|Withdrawal by Subject|1
6369601|NCT02112916|10159566|FG000|Overall Study|Ineligible|4
6369602|NCT02112916|10159567|FG001|Overall Study|Ineligible|8
6369603|NCT02112916|10159568|FG002|Overall Study|Ineligible|3
6369604|NCT02112916|10159569|FG003|Overall Study|Ineligible|8
6369605|NCT02112916|10159566|FG000|Overall Study|Inevaluable|6
6369606|NCT02112916|10159567|FG001|Overall Study|Inevaluable|4
6369607|NCT02112916|10159568|FG002|Overall Study|Inevaluable|5
6369608|NCT02112916|10159569|FG003|Overall Study|Inevaluable|5
6369609|NCT02112916|10159566|FG000|Overall Study|Refusal of further protocol therapy|19
6369610|NCT02112916|10159567|FG001|Overall Study|Refusal of further protocol therapy|16
6369611|NCT02112916|10159568|FG002|Overall Study|Refusal of further protocol therapy|1
6369612|NCT02112916|10159569|FG003|Overall Study|Refusal of further protocol therapy|7
6369613|NCT02112916|10159566|FG000|Overall Study|Development of SMN|1
6369614|NCT02112916|10159567|FG001|Overall Study|Development of SMN|0
6369615|NCT02112916|10159568|FG002|Overall Study|Development of SMN|0
6369616|NCT02112916|10159569|FG003|Overall Study|Development of SMN|1
6369617|NCT02112916|10159566|FG000|Overall Study|Relapse/Progression|10
6369618|NCT02112916|10159567|FG001|Overall Study|Relapse/Progression|18
6369619|NCT02112916|10159568|FG002|Overall Study|Relapse/Progression|15
6369620|NCT02112916|10159569|FG003|Overall Study|Relapse/Progression|2
6369621|NCT02112916|10159566|FG000|Overall Study|VHR T-ALL who have an M2/M3 marrow and/or detectable MRD by end of the 3 HR Intensification Blocks|5
6369622|NCT02112916|10159567|FG001|Overall Study|VHR T-ALL who have an M2/M3 marrow and/or detectable MRD by end of the 3 HR Intensification Blocks|5
6369623|NCT02112916|10159568|FG002|Overall Study|VHR T-ALL who have an M2/M3 marrow and/or detectable MRD by end of the 3 HR Intensification Blocks|0
6369624|NCT02112916|10159569|FG003|Overall Study|VHR T-ALL who have an M2/M3 marrow and/or detectable MRD by end of the 3 HR Intensification Blocks|0
6369625|NCT02112916|10159566|FG000|Overall Study|Still on Therapy|44
6369626|NCT02112916|10159567|FG001|Overall Study|Still on Therapy|47
6369627|NCT02112916|10159568|FG002|Overall Study|Still on Therapy|3
6369628|NCT02112916|10159569|FG003|Overall Study|Still on Therapy|2
6369629|NCT02112916|10159566|FG000|Overall Study|Identified to have Ph+ T-ALL|0
6369630|NCT02112916|10159567|FG001|Overall Study|Identified to have Ph+ T-ALL|1
6369631|NCT02112916|10159568|FG002|Overall Study|Identified to have Ph+ T-ALL|0
6369632|NCT02112916|10159569|FG003|Overall Study|Identified to have Ph+ T-ALL|0
6369633|NCT02112916|10159566|FG000|Overall Study|Identified to have Ph+ T-Lly|0
6369634|NCT02112916|10159567|FG001|Overall Study|Identified to have Ph+ T-Lly|0
6369635|NCT02112916|10159568|FG002|Overall Study|Identified to have Ph+ T-Lly|1
6369636|NCT02112916|10159569|FG003|Overall Study|Identified to have Ph+ T-Lly|0
6369639|NCT02135029|10159600|FG000|Overall Study|Adverse Event|2
6369640|NCT02135029|10159601|FG001|Overall Study|Adverse Event|2
6369641|NCT02135029|10159602|FG002|Overall Study|Adverse Event|2
6369642|NCT02135029|10159600|FG000|Overall Study|Lost to Follow-up|0
6369643|NCT02135029|10159601|FG001|Overall Study|Lost to Follow-up|1
6369644|NCT02135029|10159602|FG002|Overall Study|Lost to Follow-up|0
6369645|NCT02135029|10159600|FG000|Overall Study|Withdrawal by Subject|2
6369646|NCT02135029|10159601|FG001|Overall Study|Withdrawal by Subject|0
6369647|NCT02135029|10159602|FG002|Overall Study|Withdrawal by Subject|1
6369648|NCT02135029|10159600|FG000|Overall Study|Other|0
6369649|NCT02135029|10159601|FG001|Overall Study|Other|1
6369650|NCT02135029|10159602|FG002|Overall Study|Other|0
6369651|NCT02135029|10159600|FG000|Overall Study|Death|0
6369652|NCT02135029|10159601|FG001|Overall Study|Death|1
6369653|NCT02135029|10159602|FG002|Overall Study|Death|0
6369660|NCT02148133|10159620|FG000|Overall Study|Investigator discretion|1
6369661|NCT02148133|10159620|FG000|Overall Study|Lack of Efficacy|1
6369662|NCT02148133|10159620|FG000|Overall Study|Protocol deviation|1
6369663|NCT02148133|10159620|FG000|Overall Study|Protocol-defined stopping criteria|2
6369664|NCT02165215|10159640|FG000|Induction Phase|Adverse Event|1
6369665|NCT02165215|10159641|FG001|Induction Phase|Adverse Event|0
6369532|NCT02081391|10159518|FG000|12-hour Treatment|Withdrawal by Subject|3
6369533|NCT02081391|10159519|FG001|12-hour Treatment|Withdrawal by Subject|2
6369534|NCT02081391|10159520|FG002|12-hour Treatment|Withdrawal by Subject|0
6369535|NCT02081391|10159521|FG003|12-hour Treatment|Withdrawal by Subject|0
6369536|NCT02081391|10159518|FG000|12-hour Treatment|Physician Decision|4
6369537|NCT02081391|10159519|FG001|12-hour Treatment|Physician Decision|1
6369538|NCT02081391|10159520|FG002|12-hour Treatment|Physician Decision|0
6369539|NCT02081391|10159521|FG003|12-hour Treatment|Physician Decision|0
6369540|NCT02081391|10159518|FG000|12-hour Treatment|Lack of Efficacy|3
6369541|NCT02081391|10159519|FG001|12-hour Treatment|Lack of Efficacy|0
6369542|NCT02081391|10159520|FG002|12-hour Treatment|Lack of Efficacy|0
6369543|NCT02081391|10159521|FG003|12-hour Treatment|Lack of Efficacy|0
6369544|NCT02081391|10159518|FG000|12-hour Treatment|Adverse Event|4
6369545|NCT02081391|10159519|FG001|12-hour Treatment|Adverse Event|2
6369546|NCT02081391|10159520|FG002|12-hour Treatment|Adverse Event|0
6369547|NCT02081391|10159521|FG003|12-hour Treatment|Adverse Event|0
6369548|NCT02081391|10159518|FG000|12-hour Treatment|Recovery (opioid no longer needed)|2
6369549|NCT02081391|10159519|FG001|12-hour Treatment|Recovery (opioid no longer needed)|0
6369550|NCT02081391|10159520|FG002|12-hour Treatment|Recovery (opioid no longer needed)|1
6369551|NCT02081391|10159521|FG003|12-hour Treatment|Recovery (opioid no longer needed)|0
6369552|NCT02081391|10159518|FG000|12-hour Treatment|Further reasons|2
6369553|NCT02081391|10159519|FG001|12-hour Treatment|Further reasons|1
6369554|NCT02081391|10159520|FG002|12-hour Treatment|Further reasons|0
6369555|NCT02081391|10159521|FG003|12-hour Treatment|Further reasons|0
6369556|NCT02081391|10159518|FG000|24-hour Treatment and Trial Completion|Physician Decision|10
6369557|NCT02081391|10159519|FG001|24-hour Treatment and Trial Completion|Physician Decision|5
6369558|NCT02081391|10159520|FG002|24-hour Treatment and Trial Completion|Physician Decision|0
6369559|NCT02081391|10159521|FG003|24-hour Treatment and Trial Completion|Physician Decision|0
6369560|NCT02081391|10159518|FG000|24-hour Treatment and Trial Completion|Lack of Efficacy|1
6369561|NCT02081391|10159519|FG001|24-hour Treatment and Trial Completion|Lack of Efficacy|3
6369562|NCT02081391|10159520|FG002|24-hour Treatment and Trial Completion|Lack of Efficacy|0
6369563|NCT02081391|10159521|FG003|24-hour Treatment and Trial Completion|Lack of Efficacy|0
6369564|NCT02081391|10159518|FG000|24-hour Treatment and Trial Completion|Adverse Event|1
6369565|NCT02081391|10159519|FG001|24-hour Treatment and Trial Completion|Adverse Event|0
6369566|NCT02081391|10159520|FG002|24-hour Treatment and Trial Completion|Adverse Event|0
6369567|NCT02081391|10159521|FG003|24-hour Treatment and Trial Completion|Adverse Event|0
6369568|NCT02081391|10159518|FG000|24-hour Treatment and Trial Completion|Recovery (opioid no longer needed)|11
6369569|NCT02081391|10159519|FG001|24-hour Treatment and Trial Completion|Recovery (opioid no longer needed)|5
6369570|NCT02081391|10159520|FG002|24-hour Treatment and Trial Completion|Recovery (opioid no longer needed)|1
6369571|NCT02081391|10159521|FG003|24-hour Treatment and Trial Completion|Recovery (opioid no longer needed)|0
6369572|NCT02081391|10159518|FG000|24-hour Treatment and Trial Completion|Technical Problems|1
6369573|NCT02081391|10159519|FG001|24-hour Treatment and Trial Completion|Technical Problems|1
6369574|NCT02081391|10159520|FG002|24-hour Treatment and Trial Completion|Technical Problems|0
6369575|NCT02081391|10159521|FG003|24-hour Treatment and Trial Completion|Technical Problems|0
6369576|NCT02081391|10159518|FG000|24-hour Treatment and Trial Completion|Further reasons|3
6369577|NCT02081391|10159519|FG001|24-hour Treatment and Trial Completion|Further reasons|4
6369578|NCT02081391|10159520|FG002|24-hour Treatment and Trial Completion|Further reasons|0
6369579|NCT02081391|10159521|FG003|24-hour Treatment and Trial Completion|Further reasons|0
6369637|NCT02114697|10159586|FG000|Overall Study|Study terminated|5
6369638|NCT02114697|10159587|FG001|Overall Study|Study terminated|4
6369654|NCT02137239|10159613|FG000|Overall Study|Discontinued Study Treatment|0
6369655|NCT02137239|10159614|FG001|Overall Study|Discontinued Study Treatment|3
6369656|NCT02137239|10159613|FG000|Overall Study|Withdrew Consent|1
6369657|NCT02137239|10159614|FG001|Overall Study|Withdrew Consent|1
6369658|NCT02137239|10159613|FG000|Overall Study|Adverse Event|2
6369659|NCT02137239|10159614|FG001|Overall Study|Adverse Event|2
6369666|NCT02165215|10159642|FG002|Induction Phase|Adverse Event|0
6369667|NCT02165215|10159640|FG000|Induction Phase|Withdrawal by Subject|10
6369668|NCT02165215|10159641|FG001|Induction Phase|Withdrawal by Subject|0
6369669|NCT02165215|10159642|FG002|Induction Phase|Withdrawal by Subject|0
6369670|NCT02165215|10159640|FG000|Induction Phase|Protocol Violation|1
6369671|NCT02165215|10159641|FG001|Induction Phase|Protocol Violation|0
6369672|NCT02165215|10159642|FG002|Induction Phase|Protocol Violation|0
6369673|NCT02165215|10159640|FG000|Induction Phase|Physician Decision|1
6369674|NCT02165215|10159641|FG001|Induction Phase|Physician Decision|0
6369675|NCT02165215|10159642|FG002|Induction Phase|Physician Decision|0
6369676|NCT02165215|10159640|FG000|Induction Phase|Lack of Efficacy|2
6369677|NCT02165215|10159641|FG001|Induction Phase|Lack of Efficacy|0
6369678|NCT02165215|10159642|FG002|Induction Phase|Lack of Efficacy|0
6369679|NCT02165215|10159640|FG000|Induction Phase|Non-Compliance|2
6369680|NCT02165215|10159641|FG001|Induction Phase|Non-Compliance|0
6369681|NCT02165215|10159642|FG002|Induction Phase|Non-Compliance|0
6369682|NCT02165215|10159640|FG000|Induction Phase|Lost to Follow-up|6
6369683|NCT02165215|10159641|FG001|Induction Phase|Lost to Follow-up|0
6369684|NCT02165215|10159642|FG002|Induction Phase|Lost to Follow-up|0
6369685|NCT02165215|10159640|FG000|Maintenance Phase|Withdrawal by Subject|0
6369686|NCT02165215|10159641|FG001|Maintenance Phase|Withdrawal by Subject|7
6369687|NCT02165215|10159642|FG002|Maintenance Phase|Withdrawal by Subject|3
6369688|NCT02165215|10159640|FG000|Maintenance Phase|Multiple reasons|0
6369689|NCT02165215|10159641|FG001|Maintenance Phase|Multiple reasons|2
6369690|NCT02165215|10159642|FG002|Maintenance Phase|Multiple reasons|1
6369691|NCT02165215|10159640|FG000|Maintenance Phase|Lost to Follow-up|0
6369692|NCT02165215|10159641|FG001|Maintenance Phase|Lost to Follow-up|2
6369693|NCT02165215|10159642|FG002|Maintenance Phase|Lost to Follow-up|0
6369694|NCT02165215|10159640|FG000|Maintenance Phase|Adverse Event|0
6369695|NCT02165215|10159641|FG001|Maintenance Phase|Adverse Event|1
6369696|NCT02165215|10159642|FG002|Maintenance Phase|Adverse Event|1
6369697|NCT02180217|10159656|FG000|Overall Study|Adverse Event|3
6369698|NCT02180217|10159657|FG001|Overall Study|Adverse Event|2
6369699|NCT02180217|10159658|FG002|Overall Study|Adverse Event|22
6369700|NCT02180217|10159656|FG000|Overall Study|Death|1
6369701|NCT02180217|10159657|FG001|Overall Study|Death|1
6369702|NCT02180217|10159658|FG002|Overall Study|Death|0
6369703|NCT02180217|10159656|FG000|Overall Study|Withdrawal by Subject|1
6369704|NCT02180217|10159657|FG001|Overall Study|Withdrawal by Subject|1
6369705|NCT02180217|10159658|FG002|Overall Study|Withdrawal by Subject|4
6369706|NCT02180217|10159656|FG000|Overall Study|Subject/Guardian decision|5
6369707|NCT02180217|10159657|FG001|Overall Study|Subject/Guardian decision|3
6369708|NCT02180217|10159658|FG002|Overall Study|Subject/Guardian decision|6
6369709|NCT02180217|10159656|FG000|Overall Study|Physician Decision|1
6369710|NCT02180217|10159657|FG001|Overall Study|Physician Decision|1
6369711|NCT02180217|10159658|FG002|Overall Study|Physician Decision|6
6369712|NCT02180217|10159656|FG000|Overall Study|Unsatisfactory therapeutic effect|1
6369713|NCT02180217|10159657|FG001|Overall Study|Unsatisfactory therapeutic effect|0
6369714|NCT02180217|10159658|FG002|Overall Study|Unsatisfactory therapeutic effect|0
6369715|NCT02193867|10159682|FG000|Overall Study|Death|2
6369716|NCT02193867|10159682|FG000|Overall Study|Sponsor Study Termination|2
6369717|NCT02215096|10159689|FG000|Run-In Period (Up to Week 2)|Adverse Event|1
6369718|NCT02215096|10159690|FG001|Run-In Period (Up to Week 2)|Adverse Event|0
6369719|NCT02215096|10159691|FG002|Run-In Period (Up to Week 2)|Adverse Event|0
6369720|NCT02215096|10159692|FG003|Run-In Period (Up to Week 2)|Adverse Event|0
6369721|NCT02215096|10159693|FG004|Run-In Period (Up to Week 2)|Adverse Event|0
6369722|NCT02215096|10159689|FG000|Combination TP (Up to Maximum 654 Days)|Physician Decision|0
6369723|NCT02215096|10159690|FG001|Combination TP (Up to Maximum 654 Days)|Physician Decision|0
6369724|NCT02215096|10159691|FG002|Combination TP (Up to Maximum 654 Days)|Physician Decision|0
6369725|NCT02215096|10159692|FG003|Combination TP (Up to Maximum 654 Days)|Physician Decision|0
6369726|NCT02215096|10159693|FG004|Combination TP (Up to Maximum 654 Days)|Physician Decision|1
6369727|NCT02215096|10159689|FG000|Combination TP (Up to Maximum 654 Days)|Lost to Follow-up|0
6369728|NCT02215096|10159690|FG001|Combination TP (Up to Maximum 654 Days)|Lost to Follow-up|0
6369729|NCT02215096|10159691|FG002|Combination TP (Up to Maximum 654 Days)|Lost to Follow-up|0
6369730|NCT02215096|10159692|FG003|Combination TP (Up to Maximum 654 Days)|Lost to Follow-up|1
6369731|NCT02215096|10159693|FG004|Combination TP (Up to Maximum 654 Days)|Lost to Follow-up|0
6369732|NCT02215096|10159689|FG000|Combination TP (Up to Maximum 654 Days)|Withdrawal by Subject|0
6369733|NCT02215096|10159690|FG001|Combination TP (Up to Maximum 654 Days)|Withdrawal by Subject|2
6369734|NCT02215096|10159691|FG002|Combination TP (Up to Maximum 654 Days)|Withdrawal by Subject|1
6369735|NCT02215096|10159692|FG003|Combination TP (Up to Maximum 654 Days)|Withdrawal by Subject|1
6369736|NCT02215096|10159693|FG004|Combination TP (Up to Maximum 654 Days)|Withdrawal by Subject|0
6369737|NCT02218697|10159711|FG000|Overall Study|Adverse Event|0
6369738|NCT02218697|10159712|FG001|Overall Study|Adverse Event|2
6369739|NCT02218697|10159711|FG000|Overall Study|Unwilling to be vaccinated in left arm|0
6369740|NCT02218697|10159712|FG001|Overall Study|Unwilling to be vaccinated in left arm|1
6369741|NCT02218697|10159711|FG000|Overall Study|Withdrawal by Subject|2
6369742|NCT02218697|10159712|FG001|Overall Study|Withdrawal by Subject|3
6369747|NCT02224456|10159739|FG000|Overall Study|Lack of Efficacy|1
6369748|NCT02224456|10159739|FG000|Overall Study|Lost to Follow-up|15
6369749|NCT02224456|10159739|FG000|Overall Study|Withdrawal by Subject|9
6369750|NCT02224456|10159739|FG000|Overall Study|Physician Decision|3
6369751|NCT02224456|10159739|FG000|Overall Study|Death|2
6369752|NCT02224456|10159739|FG000|Overall Study|Pregnancy|4
6369753|NCT02224456|10159739|FG000|Overall Study|Protocol Violation|1
6369754|NCT02224456|10159739|FG000|Overall Study|Treatment Interruptions of ≥28 days|1
6369755|NCT02231762|10159743|FG000|Combination Phase|Adverse Event|10
6369756|NCT02231762|10159744|FG001|Combination Phase|Adverse Event|0
6369757|NCT02231762|10159745|FG002|Combination Phase|Adverse Event|0
6369758|NCT02231762|10159746|FG003|Combination Phase|Adverse Event|0
6369759|NCT02231762|10159743|FG000|Combination Phase|Withdrawal by Subject|2
6369760|NCT02231762|10159744|FG001|Combination Phase|Withdrawal by Subject|0
6369761|NCT02231762|10159745|FG002|Combination Phase|Withdrawal by Subject|0
6369762|NCT02231762|10159746|FG003|Combination Phase|Withdrawal by Subject|0
6369763|NCT02231762|10159743|FG000|Combination Phase|Disease Progression|6
6369764|NCT02231762|10159744|FG001|Combination Phase|Disease Progression|0
6369765|NCT02231762|10159745|FG002|Combination Phase|Disease Progression|0
6369766|NCT02231762|10159746|FG003|Combination Phase|Disease Progression|0
6369767|NCT02231762|10159743|FG000|Combination Phase|Did not meet inclusion criteria|1
6369768|NCT02231762|10159744|FG001|Combination Phase|Did not meet inclusion criteria|0
6369769|NCT02231762|10159745|FG002|Combination Phase|Did not meet inclusion criteria|0
6369770|NCT02231762|10159746|FG003|Combination Phase|Did not meet inclusion criteria|0
6369771|NCT02231762|10159743|FG000|Combination Phase|Protocol Violation|1
6369772|NCT02231762|10159744|FG001|Combination Phase|Protocol Violation|0
6369773|NCT02231762|10159745|FG002|Combination Phase|Protocol Violation|0
6369774|NCT02231762|10159746|FG003|Combination Phase|Protocol Violation|0
6369775|NCT02231762|10159743|FG000|Maintenance Phase|Disease progression|0
6369776|NCT02231762|10159744|FG001|Maintenance Phase|Disease progression|3
6369777|NCT02231762|10159745|FG002|Maintenance Phase|Disease progression|4
6369778|NCT02231762|10159746|FG003|Maintenance Phase|Disease progression|3
6369743|NCT02221037|10159722|FG000|Overall Study|Physician Decision|0
6369744|NCT02221037|10159723|FG001|Overall Study|Physician Decision|0
6369745|NCT02221037|10159724|FG002|Overall Study|Physician Decision|1
6369746|NCT02221037|10159725|FG003|Overall Study|Physician Decision|0
6369779|NCT02231762|10159743|FG000|Maintenance Phase|Adverse Event|0
6369780|NCT02231762|10159744|FG001|Maintenance Phase|Adverse Event|0
6369781|NCT02231762|10159745|FG002|Maintenance Phase|Adverse Event|1
6369782|NCT02231762|10159746|FG003|Maintenance Phase|Adverse Event|2
6171697|NCT01261611|9818587|FG002|Treatment Cycle 4|Completed study|0
6171698|NCT01261611|9818585|FG000|Treatment Cycle 4|Withdrawal by Subject|3
6171699|NCT01261611|9818586|FG001|Treatment Cycle 4|Withdrawal by Subject|0
6171700|NCT01261611|9818587|FG002|Treatment Cycle 4|Withdrawal by Subject|0
6171701|NCT01261611|9818585|FG000|Treatment Cycle 4|Adverse Event|1
6171702|NCT01261611|9818586|FG001|Treatment Cycle 4|Adverse Event|0
6171703|NCT01261611|9818587|FG002|Treatment Cycle 4|Adverse Event|0
6369783|NCT02234843|10159770|FG000|Overall Study|Death|1
6369784|NCT02234843|10159771|FG001|Overall Study|Death|0
6369785|NCT02234843|10159772|FG002|Overall Study|Death|0
6369786|NCT02234843|10159773|FG003|Overall Study|Death|0
6369787|NCT02234843|10159774|FG004|Overall Study|Death|0
6369788|NCT02234843|10159775|FG005|Overall Study|Death|0
6369789|NCT02234843|10159776|FG006|Overall Study|Death|0
6369790|NCT02234843|10159777|FG007|Overall Study|Death|0
6369791|NCT02234843|10159778|FG008|Overall Study|Death|0
6369792|NCT02234843|10159779|FG009|Overall Study|Death|0
6369793|NCT02234843|10159770|FG000|Overall Study|Protocol Violation|1
6369794|NCT02234843|10159771|FG001|Overall Study|Protocol Violation|0
6369795|NCT02234843|10159772|FG002|Overall Study|Protocol Violation|1
6369796|NCT02234843|10159773|FG003|Overall Study|Protocol Violation|0
6369797|NCT02234843|10159774|FG004|Overall Study|Protocol Violation|0
6369798|NCT02234843|10159775|FG005|Overall Study|Protocol Violation|0
6369799|NCT02234843|10159776|FG006|Overall Study|Protocol Violation|0
6369800|NCT02234843|10159777|FG007|Overall Study|Protocol Violation|0
6369801|NCT02234843|10159778|FG008|Overall Study|Protocol Violation|0
6369802|NCT02234843|10159779|FG009|Overall Study|Protocol Violation|0
6084558|NCT00642993|9693473|FG001|Overall Study|Did not meet protocol eligibility|1
6084559|NCT00642993|9693472|FG000|Overall Study|Administrative|1
6084560|NCT00642993|9693473|FG001|Overall Study|Administrative|0
6084561|NCT00643006|9693481|FG000|Overall Study|Lost to Follow-up|5
6084562|NCT00643006|9693482|FG001|Overall Study|Lost to Follow-up|4
6084563|NCT00643123|9693505|FG000|Overall Study|Lost to Follow-up|4
6084564|NCT00643123|9693506|FG001|Overall Study|Lost to Follow-up|0
6369803|NCT02234843|10159770|FG000|Overall Study|Efficacy outcome reached|2
6369804|NCT02234843|10159771|FG001|Overall Study|Efficacy outcome reached|0
6084565|NCT00643123|9693505|FG000|Overall Study|Withdrawal by Subject|1
6084566|NCT00643123|9693506|FG001|Overall Study|Withdrawal by Subject|1
6369805|NCT02234843|10159772|FG002|Overall Study|Efficacy outcome reached|0
6369806|NCT02234843|10159773|FG003|Overall Study|Efficacy outcome reached|0
6369807|NCT02234843|10159774|FG004|Overall Study|Efficacy outcome reached|0
6369808|NCT02234843|10159775|FG005|Overall Study|Efficacy outcome reached|2
6369809|NCT02234843|10159776|FG006|Overall Study|Efficacy outcome reached|0
6369810|NCT02234843|10159777|FG007|Overall Study|Efficacy outcome reached|0
6369811|NCT02234843|10159778|FG008|Overall Study|Efficacy outcome reached|0
6369812|NCT02234843|10159779|FG009|Overall Study|Efficacy outcome reached|0
6369813|NCT02234843|10159770|FG000|Overall Study|Patient convenience|2
6369814|NCT02234843|10159771|FG001|Overall Study|Patient convenience|0
6369815|NCT02234843|10159772|FG002|Overall Study|Patient convenience|0
6369816|NCT02234843|10159773|FG003|Overall Study|Patient convenience|0
6369817|NCT02234843|10159774|FG004|Overall Study|Patient convenience|0
6369818|NCT02234843|10159775|FG005|Overall Study|Patient convenience|1
6369819|NCT02234843|10159776|FG006|Overall Study|Patient convenience|0
6369820|NCT02234843|10159777|FG007|Overall Study|Patient convenience|0
6369821|NCT02234843|10159778|FG008|Overall Study|Patient convenience|0
6369822|NCT02234843|10159779|FG009|Overall Study|Patient convenience|0
6369823|NCT02234843|10159770|FG000|Overall Study|Withdrawal by Subject|5
6369824|NCT02234843|10159771|FG001|Overall Study|Withdrawal by Subject|1
6369825|NCT02234843|10159772|FG002|Overall Study|Withdrawal by Subject|1
6369826|NCT02234843|10159773|FG003|Overall Study|Withdrawal by Subject|0
6369827|NCT02234843|10159774|FG004|Overall Study|Withdrawal by Subject|0
6369828|NCT02234843|10159775|FG005|Overall Study|Withdrawal by Subject|7
6369829|NCT02234843|10159776|FG006|Overall Study|Withdrawal by Subject|0
6369830|NCT02234843|10159777|FG007|Overall Study|Withdrawal by Subject|0
6369831|NCT02234843|10159778|FG008|Overall Study|Withdrawal by Subject|0
6369832|NCT02234843|10159779|FG009|Overall Study|Withdrawal by Subject|0
6369833|NCT02234843|10159770|FG000|Overall Study|Recovery|1
6369834|NCT02234843|10159771|FG001|Overall Study|Recovery|0
6369835|NCT02234843|10159772|FG002|Overall Study|Recovery|0
6369836|NCT02234843|10159773|FG003|Overall Study|Recovery|0
6369837|NCT02234843|10159774|FG004|Overall Study|Recovery|0
6369838|NCT02234843|10159775|FG005|Overall Study|Recovery|0
6369839|NCT02234843|10159776|FG006|Overall Study|Recovery|0
6369840|NCT02234843|10159777|FG007|Overall Study|Recovery|0
6369841|NCT02234843|10159778|FG008|Overall Study|Recovery|0
6369842|NCT02234843|10159779|FG009|Overall Study|Recovery|0
6369843|NCT02234843|10159770|FG000|Overall Study|Other|0
6369844|NCT02234843|10159771|FG001|Overall Study|Other|2
6369845|NCT02234843|10159772|FG002|Overall Study|Other|0
6369846|NCT02234843|10159773|FG003|Overall Study|Other|1
6369847|NCT02234843|10159774|FG004|Overall Study|Other|0
6369848|NCT02234843|10159775|FG005|Overall Study|Other|1
6369849|NCT02234843|10159776|FG006|Overall Study|Other|0
6369850|NCT02234843|10159777|FG007|Overall Study|Other|1
6369851|NCT02234843|10159778|FG008|Overall Study|Other|0
6369852|NCT02234843|10159779|FG009|Overall Study|Other|0
6369853|NCT02234843|10159770|FG000|Overall Study|Physician Decision|4
6369854|NCT02234843|10159771|FG001|Overall Study|Physician Decision|1
6369855|NCT02234843|10159772|FG002|Overall Study|Physician Decision|0
6369856|NCT02234843|10159773|FG003|Overall Study|Physician Decision|1
6369857|NCT02234843|10159774|FG004|Overall Study|Physician Decision|0
6369858|NCT02234843|10159775|FG005|Overall Study|Physician Decision|0
6369859|NCT02234843|10159776|FG006|Overall Study|Physician Decision|0
6369860|NCT02234843|10159777|FG007|Overall Study|Physician Decision|1
6369861|NCT02234843|10159778|FG008|Overall Study|Physician Decision|0
6369862|NCT02234843|10159779|FG009|Overall Study|Physician Decision|0
6369863|NCT02234843|10159770|FG000|Overall Study|Adverse Event|5
6369864|NCT02234843|10159771|FG001|Overall Study|Adverse Event|1
6369865|NCT02234843|10159772|FG002|Overall Study|Adverse Event|1
6369866|NCT02234843|10159773|FG003|Overall Study|Adverse Event|3
6369867|NCT02234843|10159774|FG004|Overall Study|Adverse Event|2
6369868|NCT02234843|10159775|FG005|Overall Study|Adverse Event|1
6369869|NCT02234843|10159776|FG006|Overall Study|Adverse Event|0
6369870|NCT02234843|10159777|FG007|Overall Study|Adverse Event|0
6369871|NCT02234843|10159778|FG008|Overall Study|Adverse Event|1
6369872|NCT02234843|10159779|FG009|Overall Study|Adverse Event|0
6369873|NCT02234843|10159770|FG000|Overall Study|Non-compliance with study drug|1
6369874|NCT02234843|10159771|FG001|Overall Study|Non-compliance with study drug|0
6369875|NCT02234843|10159772|FG002|Overall Study|Non-compliance with study drug|0
6369876|NCT02234843|10159773|FG003|Overall Study|Non-compliance with study drug|0
6369877|NCT02234843|10159774|FG004|Overall Study|Non-compliance with study drug|0
6369878|NCT02234843|10159775|FG005|Overall Study|Non-compliance with study drug|1
6369879|NCT02234843|10159776|FG006|Overall Study|Non-compliance with study drug|1
6369880|NCT02234843|10159777|FG007|Overall Study|Non-compliance with study drug|0
6369881|NCT02234843|10159778|FG008|Overall Study|Non-compliance with study drug|0
6369882|NCT02234843|10159779|FG009|Overall Study|Non-compliance with study drug|0
6369883|NCT02234843|10159770|FG000|Overall Study|Lost to Follow-up|0
6369884|NCT02234843|10159771|FG001|Overall Study|Lost to Follow-up|1
6369885|NCT02234843|10159772|FG002|Overall Study|Lost to Follow-up|0
6369886|NCT02234843|10159773|FG003|Overall Study|Lost to Follow-up|0
6369887|NCT02234843|10159774|FG004|Overall Study|Lost to Follow-up|0
6369888|NCT02234843|10159775|FG005|Overall Study|Lost to Follow-up|0
6369889|NCT02234843|10159776|FG006|Overall Study|Lost to Follow-up|1
6369890|NCT02234843|10159777|FG007|Overall Study|Lost to Follow-up|0
6369891|NCT02234843|10159778|FG008|Overall Study|Lost to Follow-up|0
6369892|NCT02234843|10159779|FG009|Overall Study|Lost to Follow-up|0
6369893|NCT02243306|10159814|FG000|Overall Study|Adverse Event|0
6369894|NCT02243306|10159815|FG001|Overall Study|Adverse Event|1
6369895|NCT02243306|10159814|FG000|Overall Study|Other: Reached stopping criteria|0
6369896|NCT02243306|10159815|FG001|Overall Study|Other: Reached stopping criteria|1
6369897|NCT02243306|10159814|FG000|Overall Study|Physician Decision|0
6369898|NCT02243306|10159815|FG001|Overall Study|Physician Decision|1
6369899|NCT02246621|10159824|FG000|Overall Study|Withdrawal by Subject|28
6369900|NCT02246621|10159825|FG001|Overall Study|Withdrawal by Subject|16
6369901|NCT02246621|10159824|FG000|Overall Study|Lost to Follow-up|1
6369902|NCT02246621|10159825|FG001|Overall Study|Lost to Follow-up|0
6369903|NCT02246621|10159824|FG000|Overall Study|On Study Treatment/ Follow Up|236
6369904|NCT02246621|10159825|FG001|Overall Study|On Study Treatment/ Follow Up|119
6369905|NCT03926611|10159851|FG000|Overall Study|Adverse Event|0
6369906|NCT03926611|10159852|FG001|Overall Study|Adverse Event|0
6369907|NCT03926611|10159853|FG002|Overall Study|Adverse Event|0
6369908|NCT03926611|10159854|FG003|Overall Study|Adverse Event|3
6369909|NCT03926611|10159855|FG004|Overall Study|Adverse Event|1
6369910|NCT03926611|10159856|FG005|Overall Study|Adverse Event|3
6369911|NCT03926611|10159857|FG006|Overall Study|Adverse Event|0
6369912|NCT03926611|10159851|FG000|Overall Study|Lack of Efficacy|1
6369913|NCT03926611|10159852|FG001|Overall Study|Lack of Efficacy|2
6369914|NCT03926611|10159853|FG002|Overall Study|Lack of Efficacy|0
6369915|NCT03926611|10159854|FG003|Overall Study|Lack of Efficacy|0
6369916|NCT03926611|10159855|FG004|Overall Study|Lack of Efficacy|1
6369917|NCT03926611|10159856|FG005|Overall Study|Lack of Efficacy|0
6369918|NCT03926611|10159857|FG006|Overall Study|Lack of Efficacy|1
6369919|NCT03926611|10159851|FG000|Overall Study|Physician Decision|0
6369920|NCT03926611|10159852|FG001|Overall Study|Physician Decision|0
6369921|NCT03926611|10159853|FG002|Overall Study|Physician Decision|0
6369922|NCT03926611|10159854|FG003|Overall Study|Physician Decision|0
6369923|NCT03926611|10159855|FG004|Overall Study|Physician Decision|0
6369924|NCT03926611|10159856|FG005|Overall Study|Physician Decision|1
6369925|NCT03926611|10159857|FG006|Overall Study|Physician Decision|0
6369926|NCT03926611|10159851|FG000|Overall Study|Protocol Violation|1
6369927|NCT03926611|10159852|FG001|Overall Study|Protocol Violation|0
6369928|NCT03926611|10159853|FG002|Overall Study|Protocol Violation|0
6369929|NCT03926611|10159854|FG003|Overall Study|Protocol Violation|1
6369930|NCT03926611|10159855|FG004|Overall Study|Protocol Violation|1
6369931|NCT03926611|10159856|FG005|Overall Study|Protocol Violation|1
6369932|NCT03926611|10159857|FG006|Overall Study|Protocol Violation|1
6369933|NCT03926611|10159851|FG000|Overall Study|Technical problems|0
6369934|NCT03926611|10159852|FG001|Overall Study|Technical problems|0
6369935|NCT03926611|10159853|FG002|Overall Study|Technical problems|0
6369936|NCT03926611|10159854|FG003|Overall Study|Technical problems|0
6369937|NCT03926611|10159855|FG004|Overall Study|Technical problems|0
6369938|NCT03926611|10159856|FG005|Overall Study|Technical problems|1
6369939|NCT03926611|10159857|FG006|Overall Study|Technical problems|0
6369940|NCT03926611|10159851|FG000|Overall Study|Withdrawal by Subject|1
6369941|NCT03926611|10159852|FG001|Overall Study|Withdrawal by Subject|1
6369942|NCT03926611|10159853|FG002|Overall Study|Withdrawal by Subject|1
6369943|NCT03926611|10159854|FG003|Overall Study|Withdrawal by Subject|0
6369944|NCT03926611|10159855|FG004|Overall Study|Withdrawal by Subject|0
6369945|NCT03926611|10159856|FG005|Overall Study|Withdrawal by Subject|1
6369946|NCT03926611|10159857|FG006|Overall Study|Withdrawal by Subject|3
6369947|NCT03926611|10159851|FG000|Overall Study|Covid-19 pandemic|0
6369948|NCT03926611|10159852|FG001|Overall Study|Covid-19 pandemic|0
6369949|NCT03926611|10159853|FG002|Overall Study|Covid-19 pandemic|1
6369950|NCT03926611|10159854|FG003|Overall Study|Covid-19 pandemic|0
6369951|NCT03926611|10159855|FG004|Overall Study|Covid-19 pandemic|1
6369952|NCT03926611|10159856|FG005|Overall Study|Covid-19 pandemic|2
6369953|NCT03926611|10159857|FG006|Overall Study|Covid-19 pandemic|0
6369954|NCT03838484|10159881|FG000|Overall Study|Lost to Follow-up|0
6369955|NCT03838484|10159882|FG001|Overall Study|Lost to Follow-up|1
6369956|NCT03838484|10159883|FG002|Overall Study|Lost to Follow-up|0
6369957|NCT03838484|10159884|FG003|Overall Study|Lost to Follow-up|0
6369958|NCT03814720|10159905|FG000|Overall Study|Lost to Follow-up|0
6369959|NCT03814720|10159906|FG001|Overall Study|Lost to Follow-up|1
6369960|NCT03814720|10159907|FG002|Overall Study|Lost to Follow-up|0
6369961|NCT03814720|10159908|FG003|Overall Study|Lost to Follow-up|0
6369962|NCT03814720|10159909|FG004|Overall Study|Lost to Follow-up|0
6369963|NCT03635424|10159923|FG000|Overall Study|Adverse Event|1
6369964|NCT03635424|10159923|FG000|Overall Study|Death|1
6369965|NCT03635424|10159923|FG000|Overall Study|Device not implanted|1
6369966|NCT03529110|10159929|FG000|Overall Study|Progressive Disease|66
6369967|NCT03529110|10159930|FG001|Overall Study|Progressive Disease|158
6369968|NCT03529110|10159929|FG000|Overall Study|Clinical Progression|4
6369969|NCT03529110|10159930|FG001|Overall Study|Clinical Progression|12
6369970|NCT03529110|10159929|FG000|Overall Study|Adverse Event|35
6369971|NCT03529110|10159930|FG001|Overall Study|Adverse Event|17
6369972|NCT03529110|10159929|FG000|Overall Study|Withdrawal by Subject (from treatment only)|13
6369973|NCT03529110|10159930|FG001|Overall Study|Withdrawal by Subject (from treatment only)|11
6369974|NCT03529110|10159929|FG000|Overall Study|Lack of Efficacy|3
6369975|NCT03529110|10159930|FG001|Overall Study|Lack of Efficacy|3
6369976|NCT03529110|10159929|FG000|Overall Study|Physician Decision|2
6369977|NCT03529110|10159930|FG001|Overall Study|Physician Decision|8
6369978|NCT03529110|10159929|FG000|Overall Study|Miscellaneous|2
6369979|NCT03529110|10159930|FG001|Overall Study|Miscellaneous|5
6369980|NCT03517540|10159940|FG000|Overall Study|Protocol Violation|2
6369981|NCT03517540|10159941|FG001|Overall Study|Protocol Violation|0
6369982|NCT03517540|10159942|FG002|Overall Study|Protocol Violation|0
6369983|NCT03517540|10159943|FG003|Overall Study|Protocol Violation|1
6369984|NCT03517540|10159940|FG000|Overall Study|Adverse Event|9
6369985|NCT03517540|10159941|FG001|Overall Study|Adverse Event|3
6369986|NCT03517540|10159942|FG002|Overall Study|Adverse Event|8
6369987|NCT03517540|10159943|FG003|Overall Study|Adverse Event|1
6369988|NCT03517540|10159940|FG000|Overall Study|Withdrawal by Subject|3
6369989|NCT03517540|10159941|FG001|Overall Study|Withdrawal by Subject|4
6369990|NCT03517540|10159942|FG002|Overall Study|Withdrawal by Subject|1
6369991|NCT03517540|10159943|FG003|Overall Study|Withdrawal by Subject|3
6084567|NCT00643162|9693514|FG000|Overall Study|Withdrawal by Subject|1
6369992|NCT03437278|10159965|FG000|Overall Study|Adverse Event|0
6369993|NCT03437278|10159966|FG001|Overall Study|Adverse Event|0
6369994|NCT03437278|10159967|FG002|Overall Study|Adverse Event|1
6369995|NCT03437278|10159965|FG000|Overall Study|Progressive disease|1
6369996|NCT03437278|10159966|FG001|Overall Study|Progressive disease|0
6369997|NCT03437278|10159967|FG002|Overall Study|Progressive disease|0
6369998|NCT03437278|10159965|FG000|Overall Study|Physician Decision|1
6369999|NCT03437278|10159966|FG001|Overall Study|Physician Decision|0
6370000|NCT03437278|10159967|FG002|Overall Study|Physician Decision|1
6370001|NCT03350815|10159977|FG000|Period 1|Adverse Event|10
6370002|NCT03350815|10159978|FG001|Period 1|Adverse Event|0
6370003|NCT03350815|10159979|FG002|Period 1|Adverse Event|0
6370004|NCT03350815|10159980|FG003|Period 1|Adverse Event|0
6370005|NCT03350815|10159977|FG000|Period 1|Technical problems|1
6370006|NCT03350815|10159978|FG001|Period 1|Technical problems|0
6370007|NCT03350815|10159979|FG002|Period 1|Technical problems|0
6370008|NCT03350815|10159980|FG003|Period 1|Technical problems|0
6370009|NCT03350815|10159977|FG000|Period 1|Lost to Follow-up|3
6370010|NCT03350815|10159978|FG001|Period 1|Lost to Follow-up|0
6370011|NCT03350815|10159979|FG002|Period 1|Lost to Follow-up|0
6370012|NCT03350815|10159980|FG003|Period 1|Lost to Follow-up|0
6370013|NCT03350815|10159977|FG000|Period 1|Physician Decision|1
6370014|NCT03350815|10159978|FG001|Period 1|Physician Decision|0
6370015|NCT03350815|10159979|FG002|Period 1|Physician Decision|0
6370016|NCT03350815|10159980|FG003|Period 1|Physician Decision|0
6370017|NCT03350815|10159977|FG000|Period 1|Withdrawal by Subject|8
6370018|NCT03350815|10159978|FG001|Period 1|Withdrawal by Subject|0
6370019|NCT03350815|10159979|FG002|Period 1|Withdrawal by Subject|0
6370020|NCT03350815|10159980|FG003|Period 1|Withdrawal by Subject|0
6370021|NCT03350815|10159977|FG000|Period 1|Lack of Efficacy|15
6370022|NCT03350815|10159978|FG001|Period 1|Lack of Efficacy|0
6370023|NCT03350815|10159979|FG002|Period 1|Lack of Efficacy|0
6370024|NCT03350815|10159980|FG003|Period 1|Lack of Efficacy|0
6370025|NCT03350815|10159977|FG000|Period 1|Non-compliance with study treatment|2
6370026|NCT03350815|10159978|FG001|Period 1|Non-compliance with study treatment|0
6370027|NCT03350815|10159979|FG002|Period 1|Non-compliance with study treatment|0
6370028|NCT03350815|10159980|FG003|Period 1|Non-compliance with study treatment|0
6370029|NCT03350815|10159977|FG000|Period 1|Protocol Violation|3
6370030|NCT03350815|10159978|FG001|Period 1|Protocol Violation|0
6370031|NCT03350815|10159979|FG002|Period 1|Protocol Violation|0
6370032|NCT03350815|10159980|FG003|Period 1|Protocol Violation|0
6370033|NCT03350815|10159977|FG000|Period 2|Adverse Event|0
6370034|NCT03350815|10159978|FG001|Period 2|Adverse Event|3
6370035|NCT03350815|10159979|FG002|Period 2|Adverse Event|5
6370036|NCT03350815|10159980|FG003|Period 2|Adverse Event|0
6370037|NCT03350815|10159977|FG000|Period 2|Technical problem|0
6370038|NCT03350815|10159978|FG001|Period 2|Technical problem|1
6171704|NCT01261611|9818585|FG000|Treatment Cycle 4|Lost to Follow-up|2
6171705|NCT01261611|9818586|FG001|Treatment Cycle 4|Lost to Follow-up|0
6171706|NCT01261611|9818587|FG002|Treatment Cycle 4|Lost to Follow-up|0
6171707|NCT01261611|9818585|FG000|Treatment Cycle 4|Not otherwise specified|3
6171708|NCT01261611|9818586|FG001|Treatment Cycle 4|Not otherwise specified|0
6171709|NCT01261611|9818587|FG002|Treatment Cycle 4|Not otherwise specified|0
6171710|NCT01261611|9818585|FG000|Treatment Cycle 5|Withdrawal by Subject|1
6171711|NCT01261611|9818586|FG001|Treatment Cycle 5|Withdrawal by Subject|0
6171712|NCT01261611|9818587|FG002|Treatment Cycle 5|Withdrawal by Subject|0
6171713|NCT01261611|9818585|FG000|Treatment Cycle 5|Adverse Event|1
6171714|NCT01261611|9818586|FG001|Treatment Cycle 5|Adverse Event|0
6171715|NCT01261611|9818587|FG002|Treatment Cycle 5|Adverse Event|0
6171716|NCT01261611|9818585|FG000|Treatment Cycle 5|Lost to Follow-up|1
6171717|NCT01261611|9818586|FG001|Treatment Cycle 5|Lost to Follow-up|0
6171718|NCT01261611|9818587|FG002|Treatment Cycle 5|Lost to Follow-up|0
6171719|NCT01261624|9818601|FG000|Week 0 to Week 12|Disease Progression|1
6171720|NCT01261624|9818602|FG001|Week 0 to Week 12|Disease Progression|1
6171721|NCT01261624|9818601|FG000|Week 0 to Week 12|Insufficient Response|0
6171722|NCT01261624|9818602|FG001|Week 0 to Week 12|Insufficient Response|2
6171723|NCT01261624|9818601|FG000|Week 13 to Week 24|Insufficient Response|0
6171724|NCT01261624|9818602|FG001|Week 13 to Week 24|Insufficient Response|1
6171725|NCT01261780|9818616|FG000|Overall Study|Withdrawal by Subject|1
6171726|NCT01261780|9818617|FG001|Overall Study|Withdrawal by Subject|0
6171727|NCT01261780|9818616|FG000|Overall Study|Event not related to subject|1
6171728|NCT01261780|9818617|FG001|Overall Study|Event not related to subject|2
6370039|NCT03350815|10159979|FG002|Period 2|Technical problem|0
6370040|NCT03350815|10159980|FG003|Period 2|Technical problem|0
6370041|NCT03350815|10159977|FG000|Period 2|Lost to Follow-up|0
6370042|NCT03350815|10159978|FG001|Period 2|Lost to Follow-up|3
6370043|NCT03350815|10159979|FG002|Period 2|Lost to Follow-up|3
6370044|NCT03350815|10159980|FG003|Period 2|Lost to Follow-up|0
6370045|NCT03350815|10159977|FG000|Period 2|Physician Decision|0
6370046|NCT03350815|10159978|FG001|Period 2|Physician Decision|0
6370047|NCT03350815|10159979|FG002|Period 2|Physician Decision|1
6370048|NCT03350815|10159980|FG003|Period 2|Physician Decision|0
6370049|NCT03350815|10159977|FG000|Period 2|Withdrawal by Subject|0
6370050|NCT03350815|10159978|FG001|Period 2|Withdrawal by Subject|3
6370051|NCT03350815|10159979|FG002|Period 2|Withdrawal by Subject|4
6370052|NCT03350815|10159980|FG003|Period 2|Withdrawal by Subject|0
6370053|NCT03350815|10159977|FG000|Period 2|Lack of Efficacy|0
6370054|NCT03350815|10159978|FG001|Period 2|Lack of Efficacy|6
6370055|NCT03350815|10159979|FG002|Period 2|Lack of Efficacy|2
6370056|NCT03350815|10159980|FG003|Period 2|Lack of Efficacy|0
6370057|NCT03350815|10159977|FG000|Period 2|Protocol Violation|0
6370058|NCT03350815|10159978|FG001|Period 2|Protocol Violation|0
6370059|NCT03350815|10159979|FG002|Period 2|Protocol Violation|1
6370060|NCT03350815|10159980|FG003|Period 2|Protocol Violation|0
6370061|NCT03350815|10159977|FG000|Period 2|New therapy for study indication|0
6370062|NCT03350815|10159978|FG001|Period 2|New therapy for study indication|0
6370063|NCT03350815|10159979|FG002|Period 2|New therapy for study indication|1
6370064|NCT03350815|10159980|FG003|Period 2|New therapy for study indication|0
6370065|NCT03249714|10159993|FG000|Double-blind Treatment (Core Part)|Lack of Efficacy|1
6370066|NCT03249714|10159994|FG001|Double-blind Treatment (Core Part)|Lack of Efficacy|1
6370067|NCT03249714|10159993|FG000|Double-blind Treatment (Core Part)|Subject/guardian decision|1
6370068|NCT03249714|10159994|FG001|Double-blind Treatment (Core Part)|Subject/guardian decision|1
6370069|NCT03249714|10159993|FG000|Double-blind Treatment (Core Part)|Lost to Follow-up|1
6370070|NCT03249714|10159994|FG001|Double-blind Treatment (Core Part)|Lost to Follow-up|0
6370071|NCT03249714|10159993|FG000|Open-label Treatment (Extension Part)|Adverse Event|2
6370072|NCT03249714|10159994|FG001|Open-label Treatment (Extension Part)|Adverse Event|0
6370073|NCT03170882|10160018|FG000|Overall Study|Ongoing|10
6370074|NCT03170882|10160019|FG001|Overall Study|Ongoing|14
6370075|NCT03170882|10160018|FG000|Overall Study|Death|15
6370076|NCT03170882|10160019|FG001|Overall Study|Death|29
6370077|NCT03170882|10160018|FG000|Overall Study|Lost to Follow-up|0
6370078|NCT03170882|10160019|FG001|Overall Study|Lost to Follow-up|1
6370079|NCT03170882|10160018|FG000|Overall Study|Withdrawal by Subject|4
6370080|NCT03170882|10160019|FG001|Overall Study|Withdrawal by Subject|6
6370081|NCT03170882|10160018|FG000|Overall Study|Reason not Specified|0
6370082|NCT03170882|10160019|FG001|Overall Study|Reason not Specified|1
6370083|NCT03074318|10160029|FG000|Overall Study|Adverse Event|0
6370084|NCT03074318|10160030|FG001|Overall Study|Adverse Event|1
6370085|NCT03074318|10160031|FG002|Overall Study|Adverse Event|1
6370086|NCT03074318|10160032|FG003|Overall Study|Adverse Event|1
6370087|NCT03074318|10160029|FG000|Overall Study|Death|1
6370088|NCT03074318|10160030|FG001|Overall Study|Death|0
6370089|NCT03074318|10160031|FG002|Overall Study|Death|0
6370090|NCT03074318|10160032|FG003|Overall Study|Death|0
6370091|NCT03074318|10160029|FG000|Overall Study|Withdrawal by Subject|1
6370092|NCT03074318|10160030|FG001|Overall Study|Withdrawal by Subject|2
6370093|NCT03074318|10160031|FG002|Overall Study|Withdrawal by Subject|2
6043295|NCT00388674|9641858|FG001|Initial Treatment|Lost to Follow-up|624
6043296|NCT00388674|9641857|FG000|Initial Treatment|Malignancy (Non-HCC)|7
6043297|NCT00388674|9641858|FG001|Initial Treatment|Malignancy (Non-HCC)|3
6043298|NCT00388674|9641857|FG000|Initial Treatment|Never Treated with Study Medication|1
6043299|NCT00388674|9641858|FG001|Initial Treatment|Never Treated with Study Medication|7
6043300|NCT00388674|9641857|FG000|Initial Treatment|Non-Study related Comorbidities|3
6043301|NCT00388674|9641858|FG001|Initial Treatment|Non-Study related Comorbidities|4
6043302|NCT00388674|9641857|FG000|Initial Treatment|Not Defined|125
6043303|NCT00388674|9641858|FG001|Initial Treatment|Not Defined|172
6043304|NCT00388674|9641857|FG000|Initial Treatment|Partial or inadequate Treatment|112
6043305|NCT00388674|9641858|FG001|Initial Treatment|Partial or inadequate Treatment|472
6043306|NCT00388674|9641857|FG000|Initial Treatment|Pregnancy|26
6043307|NCT00388674|9641858|FG001|Initial Treatment|Pregnancy|16
6043308|NCT00388674|9641857|FG000|Initial Treatment|Study Drug Toxicity|5
6043309|NCT00388674|9641858|FG001|Initial Treatment|Study Drug Toxicity|92
6043310|NCT00388674|9641857|FG000|Initial Treatment|Participant Request|501
6043311|NCT00388674|9641858|FG001|Initial Treatment|Participant Request|673
6043312|NCT00388674|9641857|FG000|Initial Treatment|No Off-Treatment Status Data|11
6370094|NCT03074318|10160032|FG003|Overall Study|Withdrawal by Subject|4
6370095|NCT03074318|10160029|FG000|Overall Study|Trial Closure|2
6370096|NCT03074318|10160030|FG001|Overall Study|Trial Closure|2
6370097|NCT03074318|10160031|FG002|Overall Study|Trial Closure|3
6370098|NCT03074318|10160032|FG003|Overall Study|Trial Closure|11
6370121|NCT03010319|10160062|FG000|Overall Study|Adverse Event|15
6370122|NCT03010319|10160063|FG001|Overall Study|Adverse Event|9
6370123|NCT03010319|10160062|FG000|Overall Study|Withdrawal by Subject|1
6370124|NCT03010319|10160063|FG001|Overall Study|Withdrawal by Subject|6
6370125|NCT03010319|10160062|FG000|Overall Study|Physician Decision|2
6370126|NCT03010319|10160063|FG001|Overall Study|Physician Decision|4
6370127|NCT03010319|10160062|FG000|Overall Study|Sponsor requested withdrawal|2
6370128|NCT03010319|10160063|FG001|Overall Study|Sponsor requested withdrawal|2
6370129|NCT03010319|10160062|FG000|Overall Study|Death|1
6370130|NCT03010319|10160063|FG001|Overall Study|Death|0
6370131|NCT03010319|10160062|FG000|Overall Study|Lost to Follow-up|0
6370132|NCT03010319|10160063|FG001|Overall Study|Lost to Follow-up|1
6370133|NCT03010319|10160062|FG000|Overall Study|Other Reason|5
6370134|NCT03010319|10160063|FG001|Overall Study|Other Reason|7
6370135|NCT02915016|10160077|FG000|Overall Study|Lost to Follow-up|4
6370136|NCT02915016|10160078|FG001|Overall Study|Lost to Follow-up|2
6370137|NCT02915016|10160079|FG002|Overall Study|Lost to Follow-up|5
6370138|NCT02915016|10160080|FG003|Overall Study|Lost to Follow-up|3
6370139|NCT02915016|10160081|FG004|Overall Study|Lost to Follow-up|5
6370140|NCT02915016|10160082|FG005|Overall Study|Lost to Follow-up|2
6370141|NCT02915016|10160083|FG006|Overall Study|Lost to Follow-up|8
6370142|NCT02915016|10160084|FG007|Overall Study|Lost to Follow-up|2
6370143|NCT02915016|10160077|FG000|Overall Study|Physician Decision|0
6370144|NCT02915016|10160078|FG001|Overall Study|Physician Decision|0
6370145|NCT02915016|10160079|FG002|Overall Study|Physician Decision|1
6370146|NCT02915016|10160080|FG003|Overall Study|Physician Decision|0
6370147|NCT02915016|10160081|FG004|Overall Study|Physician Decision|0
6370148|NCT02915016|10160082|FG005|Overall Study|Physician Decision|1
6370149|NCT02915016|10160083|FG006|Overall Study|Physician Decision|2
6370150|NCT02915016|10160084|FG007|Overall Study|Physician Decision|0
6370151|NCT02915016|10160077|FG000|Overall Study|Withdrawal by Subject|2
6370152|NCT02915016|10160078|FG001|Overall Study|Withdrawal by Subject|0
6370153|NCT02915016|10160079|FG002|Overall Study|Withdrawal by Subject|1
6370154|NCT02915016|10160080|FG003|Overall Study|Withdrawal by Subject|0
6370155|NCT02915016|10160081|FG004|Overall Study|Withdrawal by Subject|1
6370156|NCT02915016|10160082|FG005|Overall Study|Withdrawal by Subject|3
6370157|NCT02915016|10160083|FG006|Overall Study|Withdrawal by Subject|1
6370158|NCT02915016|10160084|FG007|Overall Study|Withdrawal by Subject|1
6370159|NCT02915016|10160077|FG000|Overall Study|Elected not to continue|0
6370160|NCT02915016|10160078|FG001|Overall Study|Elected not to continue|0
6370161|NCT02915016|10160079|FG002|Overall Study|Elected not to continue|0
6370162|NCT02915016|10160080|FG003|Overall Study|Elected not to continue|1
6370163|NCT02915016|10160081|FG004|Overall Study|Elected not to continue|0
6370164|NCT02915016|10160082|FG005|Overall Study|Elected not to continue|0
6370165|NCT02915016|10160083|FG006|Overall Study|Elected not to continue|1
6370166|NCT02915016|10160084|FG007|Overall Study|Elected not to continue|0
6370167|NCT02915016|10160077|FG000|Overall Study|HIV infection|1
6370168|NCT02915016|10160078|FG001|Overall Study|HIV infection|1
6370169|NCT02915016|10160079|FG002|Overall Study|HIV infection|1
6370170|NCT02915016|10160080|FG003|Overall Study|HIV infection|0
6370171|NCT02915016|10160081|FG004|Overall Study|HIV infection|1
6370172|NCT02915016|10160082|FG005|Overall Study|HIV infection|0
6370173|NCT02915016|10160083|FG006|Overall Study|HIV infection|0
6370174|NCT02915016|10160084|FG007|Overall Study|HIV infection|0
6370175|NCT02915016|10160077|FG000|Overall Study|Participant unable to adhere|0
6370176|NCT02915016|10160078|FG001|Overall Study|Participant unable to adhere|0
6370177|NCT02915016|10160079|FG002|Overall Study|Participant unable to adhere|0
6370178|NCT02915016|10160080|FG003|Overall Study|Participant unable to adhere|0
6370179|NCT02915016|10160081|FG004|Overall Study|Participant unable to adhere|0
6370180|NCT02915016|10160082|FG005|Overall Study|Participant unable to adhere|0
6370181|NCT02915016|10160083|FG006|Overall Study|Participant unable to adhere|0
6370182|NCT02915016|10160084|FG007|Overall Study|Participant unable to adhere|1
6370183|NCT02871401|10160104|FG000|Overall Study|Adverse Event|1
6370184|NCT02871401|10160105|FG001|Overall Study|Adverse Event|0
6370185|NCT02701283|10160123|FG000|Overall Study|Death|25
6370186|NCT02701283|10160124|FG001|Overall Study|Death|29
6370187|NCT02701283|10160125|FG002|Overall Study|Death|19
6370188|NCT02701283|10160123|FG000|Overall Study|Lost to Follow-up|3
6370189|NCT02701283|10160124|FG001|Overall Study|Lost to Follow-up|8
6370190|NCT02701283|10160125|FG002|Overall Study|Lost to Follow-up|1
6370191|NCT02701283|10160123|FG000|Overall Study|Withdrawal by Subject|12
6370192|NCT02701283|10160124|FG001|Overall Study|Withdrawal by Subject|41
6370193|NCT02701283|10160125|FG002|Overall Study|Withdrawal by Subject|1
6370194|NCT02701283|10160123|FG000|Overall Study|Missed 2-year visit|22
6370195|NCT02701283|10160124|FG001|Overall Study|Missed 2-year visit|27
6370196|NCT02701283|10160125|FG002|Overall Study|Missed 2-year visit|0
6370197|NCT02701283|10160123|FG000|Overall Study|Exited prior to procedure (3 subjects crossed over from SAVR to TAVR)|7
6370198|NCT02701283|10160124|FG001|Overall Study|Exited prior to procedure (3 subjects crossed over from SAVR to TAVR)|57
6370199|NCT02701283|10160125|FG002|Overall Study|Exited prior to procedure (3 subjects crossed over from SAVR to TAVR)|0
6370200|NCT02696031|10160139|FG000|Up to Week 24|Adverse Event|2
6370201|NCT02696031|10160140|FG001|Up to Week 24|Adverse Event|4
6370202|NCT02696031|10160141|FG002|Up to Week 24|Adverse Event|2
6370203|NCT02696031|10160142|FG003|Up to Week 24|Adverse Event|0
6370204|NCT02696031|10160143|FG004|Up to Week 24|Adverse Event|0
6370205|NCT02696031|10160144|FG005|Up to Week 24|Adverse Event|0
6370206|NCT02696031|10160139|FG000|Up to Week 24|Lack of Efficacy|2
6370207|NCT02696031|10160140|FG001|Up to Week 24|Lack of Efficacy|1
6370208|NCT02696031|10160141|FG002|Up to Week 24|Lack of Efficacy|2
6370209|NCT02696031|10160142|FG003|Up to Week 24|Lack of Efficacy|0
6370210|NCT02696031|10160143|FG004|Up to Week 24|Lack of Efficacy|0
6370211|NCT02696031|10160144|FG005|Up to Week 24|Lack of Efficacy|0
6370212|NCT02696031|10160139|FG000|Up to Week 24|Lost to Follow-up|0
6370213|NCT02696031|10160140|FG001|Up to Week 24|Lost to Follow-up|1
6370214|NCT02696031|10160141|FG002|Up to Week 24|Lost to Follow-up|1
6370215|NCT02696031|10160142|FG003|Up to Week 24|Lost to Follow-up|0
6370216|NCT02696031|10160143|FG004|Up to Week 24|Lost to Follow-up|0
6370217|NCT02696031|10160144|FG005|Up to Week 24|Lost to Follow-up|0
6370218|NCT02696031|10160139|FG000|Up to Week 24|Physician Decision|1
6370219|NCT02696031|10160140|FG001|Up to Week 24|Physician Decision|0
6370220|NCT02696031|10160141|FG002|Up to Week 24|Physician Decision|1
6370221|NCT02696031|10160142|FG003|Up to Week 24|Physician Decision|0
6370222|NCT02696031|10160143|FG004|Up to Week 24|Physician Decision|0
6370223|NCT02696031|10160144|FG005|Up to Week 24|Physician Decision|0
6370224|NCT02696031|10160139|FG000|Up to Week 24|Protocol Violation|1
6370225|NCT02696031|10160140|FG001|Up to Week 24|Protocol Violation|0
6370226|NCT02696031|10160141|FG002|Up to Week 24|Protocol Violation|0
6370227|NCT02696031|10160142|FG003|Up to Week 24|Protocol Violation|0
6370228|NCT02696031|10160143|FG004|Up to Week 24|Protocol Violation|0
6370229|NCT02696031|10160144|FG005|Up to Week 24|Protocol Violation|0
6370230|NCT02696031|10160139|FG000|Up to Week 24|Withdrawal by Subject|4
6370231|NCT02696031|10160140|FG001|Up to Week 24|Withdrawal by Subject|1
6370232|NCT02696031|10160141|FG002|Up to Week 24|Withdrawal by Subject|5
6370233|NCT02696031|10160142|FG003|Up to Week 24|Withdrawal by Subject|0
6370234|NCT02696031|10160143|FG004|Up to Week 24|Withdrawal by Subject|0
6370235|NCT02696031|10160144|FG005|Up to Week 24|Withdrawal by Subject|0
6370236|NCT02696031|10160139|FG000|Up to Week 52|Adverse Event|4
6370237|NCT02696031|10160140|FG001|Up to Week 52|Adverse Event|5
6370238|NCT02696031|10160141|FG002|Up to Week 52|Adverse Event|3
6370239|NCT02696031|10160142|FG003|Up to Week 52|Adverse Event|0
6370240|NCT02696031|10160143|FG004|Up to Week 52|Adverse Event|0
6370241|NCT02696031|10160144|FG005|Up to Week 52|Adverse Event|0
6370242|NCT02696031|10160139|FG000|Up to Week 52|Lack of Efficacy|10
6370243|NCT02696031|10160140|FG001|Up to Week 52|Lack of Efficacy|7
6370244|NCT02696031|10160141|FG002|Up to Week 52|Lack of Efficacy|11
6370245|NCT02696031|10160142|FG003|Up to Week 52|Lack of Efficacy|0
6370246|NCT02696031|10160143|FG004|Up to Week 52|Lack of Efficacy|0
6370247|NCT02696031|10160144|FG005|Up to Week 52|Lack of Efficacy|0
6370248|NCT02696031|10160139|FG000|Up to Week 52|Lost to Follow-up|1
6370249|NCT02696031|10160140|FG001|Up to Week 52|Lost to Follow-up|1
6370250|NCT02696031|10160141|FG002|Up to Week 52|Lost to Follow-up|1
6370251|NCT02696031|10160142|FG003|Up to Week 52|Lost to Follow-up|0
6370252|NCT02696031|10160143|FG004|Up to Week 52|Lost to Follow-up|0
6370253|NCT02696031|10160144|FG005|Up to Week 52|Lost to Follow-up|0
6370254|NCT02696031|10160139|FG000|Up to Week 52|Physician Decision|1
6370255|NCT02696031|10160140|FG001|Up to Week 52|Physician Decision|1
6370256|NCT02696031|10160141|FG002|Up to Week 52|Physician Decision|2
6370257|NCT02696031|10160142|FG003|Up to Week 52|Physician Decision|0
6171729|NCT01261793|9818626|FG000|Overall Study|Lack of Efficacy|44
6171730|NCT01261793|9818627|FG001|Overall Study|Lack of Efficacy|37
6171731|NCT01261793|9818628|FG002|Overall Study|Lack of Efficacy|32
6171732|NCT01261793|9818626|FG000|Overall Study|Protocol Violation|3
6171733|NCT01261793|9818627|FG001|Overall Study|Protocol Violation|5
6171734|NCT01261793|9818628|FG002|Overall Study|Protocol Violation|6
6171735|NCT01261793|9818626|FG000|Overall Study|Lost to Follow-up|10
6171736|NCT01261793|9818627|FG001|Overall Study|Lost to Follow-up|3
6171737|NCT01261793|9818628|FG002|Overall Study|Lost to Follow-up|7
6171738|NCT01261793|9818626|FG000|Overall Study|Withdrawal by Subject|12
6370258|NCT02696031|10160143|FG004|Up to Week 52|Physician Decision|0
6370259|NCT02696031|10160144|FG005|Up to Week 52|Physician Decision|0
6370260|NCT02696031|10160139|FG000|Up to Week 52|Pregnancy|0
6370261|NCT02696031|10160140|FG001|Up to Week 52|Pregnancy|2
6370262|NCT02696031|10160141|FG002|Up to Week 52|Pregnancy|0
6370263|NCT02696031|10160142|FG003|Up to Week 52|Pregnancy|0
6370264|NCT02696031|10160143|FG004|Up to Week 52|Pregnancy|0
6370265|NCT02696031|10160144|FG005|Up to Week 52|Pregnancy|0
6370266|NCT02696031|10160139|FG000|Up to Week 52|Protocol Violation|1
6370267|NCT02696031|10160140|FG001|Up to Week 52|Protocol Violation|0
6370268|NCT02696031|10160141|FG002|Up to Week 52|Protocol Violation|0
6370269|NCT02696031|10160142|FG003|Up to Week 52|Protocol Violation|0
6370270|NCT02696031|10160143|FG004|Up to Week 52|Protocol Violation|0
6370271|NCT02696031|10160144|FG005|Up to Week 52|Protocol Violation|0
6370272|NCT02696031|10160139|FG000|Up to Week 52|Withdrawal by Subject|12
6370273|NCT02696031|10160140|FG001|Up to Week 52|Withdrawal by Subject|3
6370274|NCT02696031|10160141|FG002|Up to Week 52|Withdrawal by Subject|9
6370275|NCT02696031|10160142|FG003|Up to Week 52|Withdrawal by Subject|0
6370276|NCT02696031|10160143|FG004|Up to Week 52|Withdrawal by Subject|0
6370277|NCT02696031|10160144|FG005|Up to Week 52|Withdrawal by Subject|0
6171739|NCT01261793|9818627|FG001|Overall Study|Withdrawal by Subject|14
6171740|NCT01261793|9818628|FG002|Overall Study|Withdrawal by Subject|14
6171741|NCT01261793|9818626|FG000|Overall Study|Death|3
6370278|NCT02696031|10160139|FG000|Up to Week 104|Pregnancy|0
6370279|NCT02696031|10160140|FG001|Up to Week 104|Pregnancy|2
6370280|NCT02696031|10160141|FG002|Up to Week 104|Pregnancy|1
6370281|NCT02696031|10160142|FG003|Up to Week 104|Pregnancy|0
6370282|NCT02696031|10160143|FG004|Up to Week 104|Pregnancy|0
6370283|NCT02696031|10160144|FG005|Up to Week 104|Pregnancy|0
6370284|NCT02696031|10160139|FG000|Up to Week 104|Withdrawal by Subject|15
6370285|NCT02696031|10160140|FG001|Up to Week 104|Withdrawal by Subject|10
6370286|NCT02696031|10160141|FG002|Up to Week 104|Withdrawal by Subject|16
6370287|NCT02696031|10160142|FG003|Up to Week 104|Withdrawal by Subject|0
6370288|NCT02696031|10160143|FG004|Up to Week 104|Withdrawal by Subject|0
6370289|NCT02696031|10160144|FG005|Up to Week 104|Withdrawal by Subject|0
6370290|NCT02696031|10160139|FG000|Up to Week 104|Protocol Violation|1
6370291|NCT02696031|10160140|FG001|Up to Week 104|Protocol Violation|0
6370292|NCT02696031|10160141|FG002|Up to Week 104|Protocol Violation|0
6370293|NCT02696031|10160142|FG003|Up to Week 104|Protocol Violation|0
6370294|NCT02696031|10160143|FG004|Up to Week 104|Protocol Violation|0
6370295|NCT02696031|10160144|FG005|Up to Week 104|Protocol Violation|0
6370296|NCT02696031|10160139|FG000|Up to Week 104|Physician Decision|1
6370297|NCT02696031|10160140|FG001|Up to Week 104|Physician Decision|2
6370298|NCT02696031|10160141|FG002|Up to Week 104|Physician Decision|3
6370299|NCT02696031|10160142|FG003|Up to Week 104|Physician Decision|0
6370300|NCT02696031|10160143|FG004|Up to Week 104|Physician Decision|0
6370301|NCT02696031|10160144|FG005|Up to Week 104|Physician Decision|0
6370302|NCT02696031|10160139|FG000|Up to Week 104|Lost to Follow-up|2
6370303|NCT02696031|10160140|FG001|Up to Week 104|Lost to Follow-up|3
6370304|NCT02696031|10160141|FG002|Up to Week 104|Lost to Follow-up|1
6370305|NCT02696031|10160142|FG003|Up to Week 104|Lost to Follow-up|0
6370306|NCT02696031|10160143|FG004|Up to Week 104|Lost to Follow-up|0
6370307|NCT02696031|10160144|FG005|Up to Week 104|Lost to Follow-up|0
6370308|NCT02696031|10160139|FG000|Up to Week 104|Lack of Efficacy|13
6370309|NCT02696031|10160140|FG001|Up to Week 104|Lack of Efficacy|12
6370310|NCT02696031|10160141|FG002|Up to Week 104|Lack of Efficacy|11
6370311|NCT02696031|10160142|FG003|Up to Week 104|Lack of Efficacy|0
6370312|NCT02696031|10160143|FG004|Up to Week 104|Lack of Efficacy|0
6370313|NCT02696031|10160144|FG005|Up to Week 104|Lack of Efficacy|0
6370314|NCT02696031|10160139|FG000|Up to Week 104|Adverse Event|7
6370315|NCT02696031|10160140|FG001|Up to Week 104|Adverse Event|11
6370316|NCT02696031|10160141|FG002|Up to Week 104|Adverse Event|5
6370317|NCT02696031|10160142|FG003|Up to Week 104|Adverse Event|0
6370318|NCT02696031|10160143|FG004|Up to Week 104|Adverse Event|0
6370319|NCT02696031|10160144|FG005|Up to Week 104|Adverse Event|0
6370320|NCT02696031|10160139|FG000|Up to Week 104|Pt completed wk 52. Withdrawal by subject at wk 52.|0
6370321|NCT02696031|10160140|FG001|Up to Week 104|Pt completed wk 52. Withdrawal by subject at wk 52.|1
6370322|NCT02696031|10160141|FG002|Up to Week 104|Pt completed wk 52. Withdrawal by subject at wk 52.|0
6370323|NCT02696031|10160142|FG003|Up to Week 104|Pt completed wk 52. Withdrawal by subject at wk 52.|0
6370324|NCT02696031|10160143|FG004|Up to Week 104|Pt completed wk 52. Withdrawal by subject at wk 52.|0
6370325|NCT02696031|10160144|FG005|Up to Week 104|Pt completed wk 52. Withdrawal by subject at wk 52.|0
6370326|NCT02696031|10160139|FG000|Extension Phase From wk 104 to wk 208|Withdrawal by Subject|0
6370327|NCT02696031|10160140|FG001|Extension Phase From wk 104 to wk 208|Withdrawal by Subject|0
6370328|NCT02696031|10160141|FG002|Extension Phase From wk 104 to wk 208|Withdrawal by Subject|0
6370329|NCT02696031|10160142|FG003|Extension Phase From wk 104 to wk 208|Withdrawal by Subject|6
6370330|NCT02696031|10160143|FG004|Extension Phase From wk 104 to wk 208|Withdrawal by Subject|8
6370331|NCT02696031|10160144|FG005|Extension Phase From wk 104 to wk 208|Withdrawal by Subject|2
6370332|NCT02696031|10160139|FG000|Extension Phase From wk 104 to wk 208|Physician Decision|0
6370333|NCT02696031|10160140|FG001|Extension Phase From wk 104 to wk 208|Physician Decision|0
6370334|NCT02696031|10160141|FG002|Extension Phase From wk 104 to wk 208|Physician Decision|0
6370335|NCT02696031|10160142|FG003|Extension Phase From wk 104 to wk 208|Physician Decision|1
6370336|NCT02696031|10160143|FG004|Extension Phase From wk 104 to wk 208|Physician Decision|1
6370337|NCT02696031|10160144|FG005|Extension Phase From wk 104 to wk 208|Physician Decision|0
6370338|NCT02696031|10160139|FG000|Extension Phase From wk 104 to wk 208|Non-compliance with study treatment|0
6370339|NCT02696031|10160140|FG001|Extension Phase From wk 104 to wk 208|Non-compliance with study treatment|0
6370340|NCT02696031|10160141|FG002|Extension Phase From wk 104 to wk 208|Non-compliance with study treatment|0
6370341|NCT02696031|10160142|FG003|Extension Phase From wk 104 to wk 208|Non-compliance with study treatment|1
6370342|NCT02696031|10160143|FG004|Extension Phase From wk 104 to wk 208|Non-compliance with study treatment|0
6370343|NCT02696031|10160144|FG005|Extension Phase From wk 104 to wk 208|Non-compliance with study treatment|0
6370344|NCT02696031|10160139|FG000|Extension Phase From wk 104 to wk 208|Lost to Follow-up|0
6370345|NCT02696031|10160140|FG001|Extension Phase From wk 104 to wk 208|Lost to Follow-up|0
6370346|NCT02696031|10160141|FG002|Extension Phase From wk 104 to wk 208|Lost to Follow-up|0
6370347|NCT02696031|10160142|FG003|Extension Phase From wk 104 to wk 208|Lost to Follow-up|0
6370348|NCT02696031|10160143|FG004|Extension Phase From wk 104 to wk 208|Lost to Follow-up|1
6370349|NCT02696031|10160144|FG005|Extension Phase From wk 104 to wk 208|Lost to Follow-up|0
6370350|NCT02696031|10160139|FG000|Extension Phase From wk 104 to wk 208|Lack of Efficacy|0
6370351|NCT02696031|10160140|FG001|Extension Phase From wk 104 to wk 208|Lack of Efficacy|0
6370352|NCT02696031|10160141|FG002|Extension Phase From wk 104 to wk 208|Lack of Efficacy|0
6370353|NCT02696031|10160142|FG003|Extension Phase From wk 104 to wk 208|Lack of Efficacy|1
6370354|NCT02696031|10160143|FG004|Extension Phase From wk 104 to wk 208|Lack of Efficacy|1
6370355|NCT02696031|10160144|FG005|Extension Phase From wk 104 to wk 208|Lack of Efficacy|3
6370356|NCT02696031|10160139|FG000|Extension Phase From wk 104 to wk 208|Adverse Event|0
6370357|NCT02696031|10160140|FG001|Extension Phase From wk 104 to wk 208|Adverse Event|0
6370358|NCT02696031|10160141|FG002|Extension Phase From wk 104 to wk 208|Adverse Event|0
6370359|NCT02696031|10160142|FG003|Extension Phase From wk 104 to wk 208|Adverse Event|1
6370360|NCT02696031|10160143|FG004|Extension Phase From wk 104 to wk 208|Adverse Event|4
6370361|NCT02696031|10160144|FG005|Extension Phase From wk 104 to wk 208|Adverse Event|1
6370362|NCT02689453|10160156|FG000|Overall Study|Progressive disease|0
6370363|NCT02689453|10160157|FG001|Overall Study|Progressive disease|1
6370364|NCT02689453|10160158|FG002|Overall Study|Progressive disease|1
6370365|NCT02476851|10160170|FG000|Overall Study|Protocol Violation|1
6370366|NCT02476851|10160171|FG001|Overall Study|Protocol Violation|1
6370367|NCT02208024|10160196|FG000|Overall Study|Withdrawal by Subject|1
6370368|NCT02180867|10160207|FG000|Overall Study|Adverse Event|3
6370369|NCT02180867|10160208|FG001|Overall Study|Adverse Event|4
6370370|NCT02180867|10160209|FG002|Overall Study|Adverse Event|1
6370371|NCT02180867|10160210|FG003|Overall Study|Adverse Event|5
6370372|NCT02180867|10160211|FG004|Overall Study|Adverse Event|0
6370373|NCT02180867|10160212|FG005|Overall Study|Adverse Event|0
6370374|NCT02180867|10160213|FG006|Overall Study|Adverse Event|0
6370375|NCT02180867|10160207|FG000|Overall Study|Death|0
6370376|NCT02180867|10160208|FG001|Overall Study|Death|0
6370377|NCT02180867|10160209|FG002|Overall Study|Death|0
6370378|NCT02180867|10160210|FG003|Overall Study|Death|0
6370379|NCT02180867|10160211|FG004|Overall Study|Death|1
6370380|NCT02180867|10160212|FG005|Overall Study|Death|0
6370381|NCT02180867|10160213|FG006|Overall Study|Death|0
6370382|NCT02180867|10160207|FG000|Overall Study|Lack of Efficacy|0
6370383|NCT02180867|10160208|FG001|Overall Study|Lack of Efficacy|2
6370384|NCT02180867|10160209|FG002|Overall Study|Lack of Efficacy|0
6370385|NCT02180867|10160210|FG003|Overall Study|Lack of Efficacy|1
6370386|NCT02180867|10160211|FG004|Overall Study|Lack of Efficacy|6
6370387|NCT02180867|10160212|FG005|Overall Study|Lack of Efficacy|0
6370388|NCT02180867|10160213|FG006|Overall Study|Lack of Efficacy|1
6370389|NCT02180867|10160207|FG000|Overall Study|Physician Decision|1
6370390|NCT02180867|10160208|FG001|Overall Study|Physician Decision|3
6370391|NCT02180867|10160209|FG002|Overall Study|Physician Decision|1
6370392|NCT02180867|10160210|FG003|Overall Study|Physician Decision|10
6370393|NCT02180867|10160211|FG004|Overall Study|Physician Decision|9
6370394|NCT02180867|10160212|FG005|Overall Study|Physician Decision|3
6370395|NCT02180867|10160213|FG006|Overall Study|Physician Decision|4
6370396|NCT02180867|10160207|FG000|Overall Study|Withdrawal by Subject|0
6370397|NCT02180867|10160208|FG001|Overall Study|Withdrawal by Subject|0
6370398|NCT02180867|10160209|FG002|Overall Study|Withdrawal by Subject|0
6370399|NCT02180867|10160210|FG003|Overall Study|Withdrawal by Subject|1
6370400|NCT02180867|10160211|FG004|Overall Study|Withdrawal by Subject|1
6370401|NCT02180867|10160212|FG005|Overall Study|Withdrawal by Subject|0
6370402|NCT02180867|10160213|FG006|Overall Study|Withdrawal by Subject|0
6370403|NCT02180867|10160207|FG000|Overall Study|Ineligible|1
6370404|NCT02180867|10160208|FG001|Overall Study|Ineligible|2
6084568|NCT00643162|9693515|FG001|Overall Study|Withdrawal by Subject|1
6084569|NCT00643201|9693523|FG000|Randomized, Completed 6 Months of Study|Death|20
6084570|NCT00643201|9693524|FG001|Randomized, Completed 6 Months of Study|Death|26
6084571|NCT00643201|9693523|FG000|Randomized, Completed 6 Months of Study|Adverse Event|150
6084572|NCT00643201|9693524|FG001|Randomized, Completed 6 Months of Study|Adverse Event|182
6084573|NCT00643201|9693523|FG000|Randomized, Completed 6 Months of Study|Withdrawal by Subject|49
6370405|NCT02180867|10160209|FG002|Overall Study|Ineligible|0
6370406|NCT02180867|10160210|FG003|Overall Study|Ineligible|3
6370407|NCT02180867|10160211|FG004|Overall Study|Ineligible|5
6370408|NCT02180867|10160212|FG005|Overall Study|Ineligible|0
6370409|NCT02180867|10160213|FG006|Overall Study|Ineligible|0
6370410|NCT02180867|10160207|FG000|Overall Study|Repeat Eligibility Studies|0
6370411|NCT02180867|10160208|FG001|Overall Study|Repeat Eligibility Studies|0
6370412|NCT02180867|10160209|FG002|Overall Study|Repeat Eligibility Studies|0
6370413|NCT02180867|10160210|FG003|Overall Study|Repeat Eligibility Studies|0
6370414|NCT02180867|10160211|FG004|Overall Study|Repeat Eligibility Studies|1
6370415|NCT02180867|10160212|FG005|Overall Study|Repeat Eligibility Studies|0
6370416|NCT02180867|10160213|FG006|Overall Study|Repeat Eligibility Studies|0
6370417|NCT02180867|10160207|FG000|Overall Study|Refusal of further protocol therapy|1
6370418|NCT02180867|10160208|FG001|Overall Study|Refusal of further protocol therapy|0
6370419|NCT02180867|10160209|FG002|Overall Study|Refusal of further protocol therapy|2
6370420|NCT02180867|10160210|FG003|Overall Study|Refusal of further protocol therapy|6
6370421|NCT02180867|10160211|FG004|Overall Study|Refusal of further protocol therapy|4
6370422|NCT02180867|10160212|FG005|Overall Study|Refusal of further protocol therapy|0
6370423|NCT02180867|10160213|FG006|Overall Study|Refusal of further protocol therapy|0
6370424|NCT01866111|10160245|FG000|Double-blind Period of Study YKP3089C017|Not all subjects from double-blind rolled over to open-label|14
6370425|NCT01866111|10160246|FG001|Double-blind Period of Study YKP3089C017|Not all subjects from double-blind rolled over to open-label|13
6370426|NCT01866111|10160247|FG002|Double-blind Period of Study YKP3089C017|Not all subjects from double-blind rolled over to open-label|20
6084574|NCT00643201|9693524|FG001|Randomized, Completed 6 Months of Study|Withdrawal by Subject|49
6084575|NCT00643201|9693523|FG000|Randomized, Completed 6 Months of Study|Lost to Follow-up|14
6084576|NCT00643201|9693524|FG001|Randomized, Completed 6 Months of Study|Lost to Follow-up|14
6084577|NCT00643201|9693523|FG000|Randomized, Completed 6 Months of Study|Poor or non-compliance|20
6084578|NCT00643201|9693524|FG001|Randomized, Completed 6 Months of Study|Poor or non-compliance|23
6370427|NCT01866111|10160248|FG003|Double-blind Period of Study YKP3089C017|Not all subjects from double-blind rolled over to open-label|30
6084579|NCT00643201|9693523|FG000|Randomized, Completed 6 Months of Study|Pregnancy|3
6370428|NCT01866111|10160245|FG000|Open-label Extension Study YKP3089C017|Not all subjects completed open-label|65
6370429|NCT01866111|10160246|FG001|Open-label Extension Study YKP3089C017|Not all subjects completed open-label|67
6370430|NCT01866111|10160247|FG002|Open-label Extension Study YKP3089C017|Not all subjects completed open-label|63
6370431|NCT01866111|10160248|FG003|Open-label Extension Study YKP3089C017|Not all subjects completed open-label|52
6370432|NCT01767194|10160260|FG000|Overall Study|Adverse Event|1
6370433|NCT01767194|10160261|FG001|Overall Study|Adverse Event|1
6370434|NCT01767194|10160260|FG000|Overall Study|Death|0
6370435|NCT01767194|10160261|FG001|Overall Study|Death|1
6370436|NCT01767194|10160260|FG000|Overall Study|Lack of Efficacy|12
6370437|NCT01767194|10160261|FG001|Overall Study|Lack of Efficacy|11
6370438|NCT01767194|10160260|FG000|Overall Study|Physician Decision|2
6370439|NCT01767194|10160261|FG001|Overall Study|Physician Decision|23
6370440|NCT01767194|10160260|FG000|Overall Study|Withdrawal by Subject|0
6370441|NCT01767194|10160261|FG001|Overall Study|Withdrawal by Subject|1
6370442|NCT01767194|10160260|FG000|Overall Study|Ineligible|1
6370443|NCT01767194|10160261|FG001|Overall Study|Ineligible|1
6370444|NCT01767194|10160260|FG000|Overall Study|Refusal by patient/parent|2
6370445|NCT01767194|10160261|FG001|Overall Study|Refusal by patient/parent|4
6370446|NCT01767194|10160260|FG000|Overall Study|Criteria not met on time for next cycle|0
6370447|NCT01767194|10160261|FG001|Overall Study|Criteria not met on time for next cycle|1
6370448|NCT01767129|10160268|FG000|Treatment Period 1 (14 Days)|Adverse Event|1
6370449|NCT01767129|10160269|FG001|Treatment Period 1 (14 Days)|Adverse Event|0
6370450|NCT01708954|10160279|FG000|Step 1|Disease progression|26
6370451|NCT01708954|10160280|FG001|Step 1|Disease progression|17
6370452|NCT01708954|10160281|FG002|Step 1|Disease progression|14
6370453|NCT01708954|10160279|FG000|Step 1|Adverse Event|3
6370454|NCT01708954|10160280|FG001|Step 1|Adverse Event|11
6370455|NCT01708954|10160281|FG002|Step 1|Adverse Event|13
6370456|NCT01708954|10160279|FG000|Step 1|Death|3
6370457|NCT01708954|10160280|FG001|Step 1|Death|2
6370458|NCT01708954|10160281|FG002|Step 1|Death|3
6370459|NCT01708954|10160279|FG000|Step 1|Withdrawal by Subject|2
6370460|NCT01708954|10160280|FG001|Step 1|Withdrawal by Subject|5
6370461|NCT01708954|10160281|FG002|Step 1|Withdrawal by Subject|3
6370462|NCT01708954|10160279|FG000|Step 1|Other complicating disease|0
6370463|NCT01708954|10160280|FG001|Step 1|Other complicating disease|2
6370464|NCT01708954|10160281|FG002|Step 1|Other complicating disease|0
6370465|NCT01708954|10160279|FG000|Step 1|Crossed over to Step 2|2
6370466|NCT01708954|10160280|FG001|Step 1|Crossed over to Step 2|0
6370467|NCT01708954|10160281|FG002|Step 1|Crossed over to Step 2|0
6370468|NCT01708954|10160279|FG000|Step 1|Symptomatic deterioration|1
6370469|NCT01708954|10160280|FG001|Step 1|Symptomatic deterioration|0
6370470|NCT01708954|10160281|FG002|Step 1|Symptomatic deterioration|1
6370471|NCT01708954|10160279|FG000|Step 1|Off-treatment reason not submitted|1
6370472|NCT01708954|10160280|FG001|Step 1|Off-treatment reason not submitted|1
6370473|NCT01708954|10160281|FG002|Step 1|Off-treatment reason not submitted|1
6370474|NCT01708954|10160279|FG000|Step 1|Ineligible or never received treatment|4
6370475|NCT01708954|10160280|FG001|Step 1|Ineligible or never received treatment|2
6370476|NCT01708954|10160281|FG002|Step 1|Ineligible or never received treatment|8
6370477|NCT01708954|10160279|FG000|Step 2|Disease progression|9
6370478|NCT01708954|10160280|FG001|Step 2|Disease progression|4
6370479|NCT01708954|10160281|FG002|Step 2|Disease progression|0
6370480|NCT01708954|10160279|FG000|Step 2|Adverse Event|3
6370481|NCT01708954|10160280|FG001|Step 2|Adverse Event|2
6370482|NCT01708954|10160281|FG002|Step 2|Adverse Event|0
6370483|NCT01708954|10160279|FG000|Step 2|Withdrawal by Subject|1
6370484|NCT01708954|10160280|FG001|Step 2|Withdrawal by Subject|1
6370485|NCT01708954|10160281|FG002|Step 2|Withdrawal by Subject|0
6370486|NCT01708941|10160294|FG000|Overall Study|Adverse Event|4
6370487|NCT01708941|10160295|FG001|Overall Study|Adverse Event|6
6370488|NCT01708941|10160296|FG002|Overall Study|Adverse Event|1
6370489|NCT01708941|10160297|FG003|Overall Study|Adverse Event|0
6370490|NCT01708941|10160294|FG000|Overall Study|Death|1
6370491|NCT01708941|10160295|FG001|Overall Study|Death|1
6370492|NCT01708941|10160296|FG002|Overall Study|Death|2
6370493|NCT01708941|10160297|FG003|Overall Study|Death|14
6370494|NCT01708941|10160294|FG000|Overall Study|Withdrawal by Subject|1
6370495|NCT01708941|10160295|FG001|Overall Study|Withdrawal by Subject|0
6370496|NCT01708941|10160296|FG002|Overall Study|Withdrawal by Subject|3
6370497|NCT01708941|10160297|FG003|Overall Study|Withdrawal by Subject|4
6370498|NCT01708941|10160294|FG000|Overall Study|Disease progression|9
6370499|NCT01708941|10160295|FG001|Overall Study|Disease progression|10
6370500|NCT01708941|10160296|FG002|Overall Study|Disease progression|8
6370501|NCT01708941|10160297|FG003|Overall Study|Disease progression|0
6370502|NCT01708941|10160294|FG000|Overall Study|Alternative therapy|0
6370503|NCT01708941|10160295|FG001|Overall Study|Alternative therapy|0
6370504|NCT01708941|10160296|FG002|Overall Study|Alternative therapy|2
6370505|NCT01708941|10160297|FG003|Overall Study|Alternative therapy|0
6370506|NCT01708941|10160294|FG000|Overall Study|Ineligible and never started treatment|1
6370507|NCT01708941|10160295|FG001|Overall Study|Ineligible and never started treatment|0
6370508|NCT01708941|10160296|FG002|Overall Study|Ineligible and never started treatment|1
6370509|NCT01708941|10160297|FG003|Overall Study|Ineligible and never started treatment|0
6370510|NCT01708941|10160294|FG000|Overall Study|Never started treatment|2
6370511|NCT01708941|10160295|FG001|Overall Study|Never started treatment|1
6370512|NCT01708941|10160296|FG002|Overall Study|Never started treatment|0
6370513|NCT01708941|10160297|FG003|Overall Study|Never started treatment|0
6370514|NCT01708941|10160294|FG000|Overall Study|Ineligible|0
6370515|NCT01708941|10160295|FG001|Overall Study|Ineligible|0
6370516|NCT01708941|10160296|FG002|Overall Study|Ineligible|2
6370517|NCT01708941|10160297|FG003|Overall Study|Ineligible|0
6370518|NCT01622868|10160309|FG000|Overall Study|Protocol Violation|7
6370519|NCT01622868|10160310|FG001|Overall Study|Protocol Violation|0
6370520|NCT01609790|10160319|FG000|Overall Study|Protocol Violation|1
6370521|NCT01609790|10160320|FG001|Overall Study|Protocol Violation|7
6370522|NCT01609790|10160321|FG002|Overall Study|Protocol Violation|8
6370523|NCT01586910|10160331|FG000|Overall Study|Death|4
6370524|NCT01586910|10160332|FG001|Overall Study|Death|4
6370525|NCT01586910|10160331|FG000|Overall Study|Withdrawal by Subject|6
6370526|NCT01586910|10160332|FG001|Overall Study|Withdrawal by Subject|43
6370527|NCT01586910|10160331|FG000|Overall Study|Physician withdrew Subject|5
6370528|NCT01586910|10160332|FG001|Overall Study|Physician withdrew Subject|24
6370529|NCT01553149|10160342|FG000|Overall Study|Adverse Event|0
6370530|NCT01553149|10160343|FG001|Overall Study|Adverse Event|9
6370531|NCT01553149|10160342|FG000|Overall Study|Physician Decision|5
6370532|NCT01553149|10160343|FG001|Overall Study|Physician Decision|10
6370533|NCT01553149|10160342|FG000|Overall Study|Ineligible|0
6370534|NCT01553149|10160343|FG001|Overall Study|Ineligible|1
6370535|NCT01371981|10160370|FG000|Overall Study|Adverse Event|12
6370536|NCT01371981|10160371|FG001|Overall Study|Adverse Event|17
6370537|NCT01371981|10160372|FG002|Overall Study|Adverse Event|0
6370538|NCT01371981|10160373|FG003|Overall Study|Adverse Event|4
6370539|NCT01371981|10160374|FG004|Overall Study|Adverse Event|1
6370540|NCT01371981|10160375|FG005|Overall Study|Adverse Event|0
6370541|NCT01371981|10160370|FG000|Overall Study|Death|22
6171742|NCT01261793|9818627|FG001|Overall Study|Death|1
6171743|NCT01261793|9818628|FG002|Overall Study|Death|0
6370542|NCT01371981|10160371|FG001|Overall Study|Death|16
6370543|NCT01371981|10160372|FG002|Overall Study|Death|0
6370544|NCT01371981|10160373|FG003|Overall Study|Death|0
6370545|NCT01371981|10160374|FG004|Overall Study|Death|2
6370546|NCT01371981|10160375|FG005|Overall Study|Death|2
6370547|NCT01371981|10160370|FG000|Overall Study|Lack of Efficacy|69
6370548|NCT01371981|10160371|FG001|Overall Study|Lack of Efficacy|61
6370549|NCT01371981|10160372|FG002|Overall Study|Lack of Efficacy|4
6370550|NCT01371981|10160373|FG003|Overall Study|Lack of Efficacy|8
6370551|NCT01371981|10160374|FG004|Overall Study|Lack of Efficacy|5
6370552|NCT01371981|10160375|FG005|Overall Study|Lack of Efficacy|0
6370553|NCT01371981|10160370|FG000|Overall Study|Physician Decision|48
6370554|NCT01371981|10160371|FG001|Overall Study|Physician Decision|63
6370555|NCT01371981|10160372|FG002|Overall Study|Physician Decision|1
6370556|NCT01371981|10160373|FG003|Overall Study|Physician Decision|7
6370557|NCT01371981|10160374|FG004|Overall Study|Physician Decision|14
6370558|NCT01371981|10160375|FG005|Overall Study|Physician Decision|3
6370559|NCT01371981|10160370|FG000|Overall Study|Withdrawal by Subject|12
6370560|NCT01371981|10160371|FG001|Overall Study|Withdrawal by Subject|19
6370561|NCT01371981|10160372|FG002|Overall Study|Withdrawal by Subject|1
6370562|NCT01371981|10160373|FG003|Overall Study|Withdrawal by Subject|2
6370563|NCT01371981|10160374|FG004|Overall Study|Withdrawal by Subject|10
6370564|NCT01371981|10160375|FG005|Overall Study|Withdrawal by Subject|3
6370565|NCT01371981|10160370|FG000|Overall Study|Ineligible|19
6370566|NCT01371981|10160371|FG001|Overall Study|Ineligible|13
6370567|NCT01371981|10160372|FG002|Overall Study|Ineligible|0
6370568|NCT01371981|10160373|FG003|Overall Study|Ineligible|0
6370569|NCT01371981|10160374|FG004|Overall Study|Ineligible|0
6370570|NCT01371981|10160375|FG005|Overall Study|Ineligible|4
6370571|NCT01371981|10160370|FG000|Overall Study|Did not start treatment|2
6370572|NCT01371981|10160371|FG001|Overall Study|Did not start treatment|3
6370573|NCT01371981|10160372|FG002|Overall Study|Did not start treatment|0
6370574|NCT01371981|10160373|FG003|Overall Study|Did not start treatment|0
6370575|NCT01371981|10160374|FG004|Overall Study|Did not start treatment|0
6370576|NCT01371981|10160375|FG005|Overall Study|Did not start treatment|2
6370577|NCT01236560|10160417|FG000|Overall Study|Adverse Event|0
6370578|NCT01236560|10160418|FG001|Overall Study|Adverse Event|2
6370579|NCT01236560|10160419|FG002|Overall Study|Adverse Event|1
6370580|NCT01236560|10160420|FG003|Overall Study|Adverse Event|3
6370581|NCT01236560|10160421|FG004|Overall Study|Adverse Event|0
6370582|NCT01236560|10160422|FG005|Overall Study|Adverse Event|0
6370583|NCT01236560|10160417|FG000|Overall Study|Death|0
6370584|NCT01236560|10160418|FG001|Overall Study|Death|1
6370585|NCT01236560|10160419|FG002|Overall Study|Death|0
6370586|NCT01236560|10160420|FG003|Overall Study|Death|1
6370587|NCT01236560|10160421|FG004|Overall Study|Death|0
6171744|NCT01261793|9818626|FG000|Overall Study|Adverse Event|9
6171745|NCT01261793|9818627|FG001|Overall Study|Adverse Event|24
6370588|NCT01236560|10160422|FG005|Overall Study|Death|0
6370589|NCT01236560|10160417|FG000|Overall Study|Lost to Follow-up|0
6370590|NCT01236560|10160418|FG001|Overall Study|Lost to Follow-up|1
6370591|NCT01236560|10160419|FG002|Overall Study|Lost to Follow-up|1
6370592|NCT01236560|10160420|FG003|Overall Study|Lost to Follow-up|0
6370593|NCT01236560|10160421|FG004|Overall Study|Lost to Follow-up|0
6370594|NCT01236560|10160422|FG005|Overall Study|Lost to Follow-up|0
6370595|NCT01236560|10160417|FG000|Overall Study|Physician Decision|0
6370596|NCT01236560|10160418|FG001|Overall Study|Physician Decision|1
6370597|NCT01236560|10160419|FG002|Overall Study|Physician Decision|8
6370598|NCT01236560|10160420|FG003|Overall Study|Physician Decision|0
6370599|NCT01236560|10160421|FG004|Overall Study|Physician Decision|0
6370600|NCT01236560|10160422|FG005|Overall Study|Physician Decision|0
6370601|NCT01236560|10160417|FG000|Overall Study|Withdrawal by Subject|0
6370602|NCT01236560|10160418|FG001|Overall Study|Withdrawal by Subject|0
6370603|NCT01236560|10160419|FG002|Overall Study|Withdrawal by Subject|1
6370604|NCT01236560|10160420|FG003|Overall Study|Withdrawal by Subject|2
6370605|NCT01236560|10160421|FG004|Overall Study|Withdrawal by Subject|0
6370606|NCT01236560|10160422|FG005|Overall Study|Withdrawal by Subject|0
6370607|NCT01236560|10160417|FG000|Overall Study|Progressive disease|5
6370608|NCT01236560|10160418|FG001|Overall Study|Progressive disease|19
6370609|NCT01236560|10160419|FG002|Overall Study|Progressive disease|9
6370610|NCT01236560|10160420|FG003|Overall Study|Progressive disease|16
6370611|NCT01236560|10160421|FG004|Overall Study|Progressive disease|0
6370612|NCT01236560|10160422|FG005|Overall Study|Progressive disease|0
6370613|NCT01236547|10160437|FG000|Overall Study|Protocol Violation|0
6370614|NCT01236547|10160438|FG001|Overall Study|Protocol Violation|1
6370615|NCT01236547|10160439|FG002|Overall Study|Protocol Violation|1
6370616|NCT01236547|10160440|FG003|Overall Study|Protocol Violation|6
6370617|NCT01236547|10160441|FG004|Overall Study|Protocol Violation|12
6370618|NCT01142388|10160456|FG000|Overall Study|Lack of Efficacy|21
6370619|NCT01142388|10160457|FG001|Overall Study|Lack of Efficacy|31
6084580|NCT00643201|9693524|FG001|Randomized, Completed 6 Months of Study|Pregnancy|2
6084581|NCT00643201|9693523|FG000|Randomized, Completed 6 Months of Study|Fails to meet inclusion/exclusion|13
6084582|NCT00643201|9693524|FG001|Randomized, Completed 6 Months of Study|Fails to meet inclusion/exclusion|9
6084583|NCT00643201|9693523|FG000|Randomized, Completed 6 Months of Study|Administrative reason|1
6084584|NCT00643201|9693524|FG001|Randomized, Completed 6 Months of Study|Administrative reason|1
6084585|NCT00643201|9693523|FG000|Randomized, Completed 6 Months of Study|Other|107
6084586|NCT00643201|9693524|FG001|Randomized, Completed 6 Months of Study|Other|107
6084587|NCT00643201|9693523|FG000|Completed Study Follow Up|Death|28
6084588|NCT00643201|9693524|FG001|Completed Study Follow Up|Death|34
6084589|NCT00643201|9693523|FG000|Completed Study Follow Up|Withdrawal by Subject|23
6084590|NCT00643201|9693524|FG001|Completed Study Follow Up|Withdrawal by Subject|29
6084591|NCT00643201|9693523|FG000|Completed Study Follow Up|Lost to Follow-up|18
6084592|NCT00643201|9693524|FG001|Completed Study Follow Up|Lost to Follow-up|16
6084593|NCT00643201|9693523|FG000|Completed Study Follow Up|non-specified|1
6084594|NCT00643201|9693524|FG001|Completed Study Follow Up|non-specified|0
6084595|NCT00643279|9693534|FG000|Overall Study|Death|13
6084596|NCT00643279|9693535|FG001|Overall Study|Death|11
6084597|NCT00643279|9693534|FG000|Overall Study|Withdrawal by Subject|3
6084598|NCT00643279|9693535|FG001|Overall Study|Withdrawal by Subject|0
6084599|NCT00643279|9693534|FG000|Overall Study|Lost to Follow-up|0
6084600|NCT00643279|9693535|FG001|Overall Study|Lost to Follow-up|1
6084601|NCT00643279|9693534|FG000|Overall Study|Physician Decision|0
6084602|NCT00643279|9693535|FG001|Overall Study|Physician Decision|1
6084603|NCT00643448|9693546|FG000|Overall Study|Lack of Efficacy|2
6370620|NCT01142388|10160456|FG000|Overall Study|Adverse Event|9
6370621|NCT01142388|10160457|FG001|Overall Study|Adverse Event|5
6370622|NCT01142388|10160456|FG000|Overall Study|Death|3
6370623|NCT01142388|10160457|FG001|Overall Study|Death|2
6370624|NCT01142388|10160456|FG000|Overall Study|Withdrawal by Subject|5
6370625|NCT01142388|10160457|FG001|Overall Study|Withdrawal by Subject|3
6370626|NCT01142388|10160456|FG000|Overall Study|Alternative therapy|1
6370627|NCT01142388|10160457|FG001|Overall Study|Alternative therapy|0
6370628|NCT01142388|10160456|FG000|Overall Study|Other complications|0
6370629|NCT01142388|10160457|FG001|Overall Study|Other complications|2
6370630|NCT01142388|10160456|FG000|Overall Study|Other|1
6370631|NCT01142388|10160457|FG001|Overall Study|Other|1
6370632|NCT01142388|10160456|FG000|Overall Study|Never started therapy|7
6370633|NCT01142388|10160457|FG001|Overall Study|Never started therapy|3
6370634|NCT01062425|10160465|FG000|Overall Study|Protocol Violation|3
6370635|NCT01062425|10160466|FG001|Overall Study|Protocol Violation|6
6370636|NCT00980460|10160477|FG000|Overall Study|Death|0
6370637|NCT00980460|10160478|FG001|Overall Study|Death|0
6370638|NCT00980460|10160479|FG002|Overall Study|Death|1
6370639|NCT00980460|10160480|FG003|Overall Study|Death|2
6370640|NCT00980460|10160481|FG004|Overall Study|Death|1
6370641|NCT00980460|10160477|FG000|Overall Study|Lack of Efficacy|0
6370642|NCT00980460|10160478|FG001|Overall Study|Lack of Efficacy|0
6370643|NCT00980460|10160479|FG002|Overall Study|Lack of Efficacy|10
6370644|NCT00980460|10160480|FG003|Overall Study|Lack of Efficacy|6
6370645|NCT00980460|10160481|FG004|Overall Study|Lack of Efficacy|8
6370646|NCT00980460|10160477|FG000|Overall Study|Lost to Follow-up|0
6370647|NCT00980460|10160478|FG001|Overall Study|Lost to Follow-up|0
6370648|NCT00980460|10160479|FG002|Overall Study|Lost to Follow-up|0
6084604|NCT00643448|9693547|FG001|Overall Study|Lack of Efficacy|0
6370649|NCT00980460|10160480|FG003|Overall Study|Lost to Follow-up|1
6370650|NCT00980460|10160481|FG004|Overall Study|Lost to Follow-up|0
6370651|NCT00980460|10160477|FG000|Overall Study|Physician Decision|0
6370652|NCT00980460|10160478|FG001|Overall Study|Physician Decision|0
6370653|NCT00980460|10160479|FG002|Overall Study|Physician Decision|11
6370654|NCT00980460|10160480|FG003|Overall Study|Physician Decision|5
6370655|NCT00980460|10160481|FG004|Overall Study|Physician Decision|3
6370656|NCT00980460|10160477|FG000|Overall Study|Withdrawal by Subject|0
6370657|NCT00980460|10160478|FG001|Overall Study|Withdrawal by Subject|0
6370658|NCT00980460|10160479|FG002|Overall Study|Withdrawal by Subject|1
6370659|NCT00980460|10160480|FG003|Overall Study|Withdrawal by Subject|0
6370660|NCT00980460|10160481|FG004|Overall Study|Withdrawal by Subject|0
6370661|NCT00980460|10160477|FG000|Overall Study|Ineligible|0
6370662|NCT00980460|10160478|FG001|Overall Study|Ineligible|2
6370663|NCT00980460|10160479|FG002|Overall Study|Ineligible|3
6370664|NCT00980460|10160480|FG003|Overall Study|Ineligible|1
6370665|NCT00980460|10160481|FG004|Overall Study|Ineligible|4
6370666|NCT00980460|10160477|FG000|Overall Study|Refusal of further therapy|0
6370667|NCT00980460|10160478|FG001|Overall Study|Refusal of further therapy|2
6370668|NCT00980460|10160479|FG002|Overall Study|Refusal of further therapy|3
6370669|NCT00980460|10160480|FG003|Overall Study|Refusal of further therapy|2
6370670|NCT00980460|10160481|FG004|Overall Study|Refusal of further therapy|0
6370671|NCT00980460|10160477|FG000|Overall Study|No therapy within 42 days of resection|0
6370672|NCT00980460|10160478|FG001|Overall Study|No therapy within 42 days of resection|0
6370673|NCT00980460|10160479|FG002|Overall Study|No therapy within 42 days of resection|3
6370674|NCT00980460|10160480|FG003|Overall Study|No therapy within 42 days of resection|1
6370675|NCT00980460|10160481|FG004|Overall Study|No therapy within 42 days of resection|0
6370676|NCT00980460|10160477|FG000|Overall Study|No transplant by protocol timepoints|0
6370677|NCT00980460|10160478|FG001|Overall Study|No transplant by protocol timepoints|0
6370678|NCT00980460|10160479|FG002|Overall Study|No transplant by protocol timepoints|3
6370679|NCT00980460|10160480|FG003|Overall Study|No transplant by protocol timepoints|0
6370680|NCT00980460|10160481|FG004|Overall Study|No transplant by protocol timepoints|0
6370681|NCT00843882|10160503|FG000|Step 1|Lack of Efficacy|14
6370682|NCT00843882|10160504|FG001|Step 1|Lack of Efficacy|10
6370683|NCT00843882|10160505|FG002|Step 1|Lack of Efficacy|21
6370684|NCT00843882|10160503|FG000|Step 1|Adverse Event|8
6370685|NCT00843882|10160504|FG001|Step 1|Adverse Event|17
6370686|NCT00843882|10160505|FG002|Step 1|Adverse Event|20
6370687|NCT00843882|10160503|FG000|Step 1|Death|1
6370688|NCT00843882|10160504|FG001|Step 1|Death|2
6370689|NCT00843882|10160505|FG002|Step 1|Death|4
6370690|NCT00843882|10160503|FG000|Step 1|Withdrawal by Subject|6
6370691|NCT00843882|10160504|FG001|Step 1|Withdrawal by Subject|12
6370692|NCT00843882|10160505|FG002|Step 1|Withdrawal by Subject|9
6370693|NCT00843882|10160503|FG000|Step 1|Physician Decision|0
6370694|NCT00843882|10160504|FG001|Step 1|Physician Decision|5
6370695|NCT00843882|10160505|FG002|Step 1|Physician Decision|1
6370696|NCT00843882|10160503|FG000|Step 1|Patient and physician's decision|0
6370697|NCT00843882|10160504|FG001|Step 1|Patient and physician's decision|0
6370698|NCT00843882|10160505|FG002|Step 1|Patient and physician's decision|1
6370699|NCT00843882|10160503|FG000|Step 1|Other complicating disease|1
6370700|NCT00843882|10160504|FG001|Step 1|Other complicating disease|3
6370701|NCT00843882|10160505|FG002|Step 1|Other complicating disease|4
6370702|NCT00843882|10160503|FG000|Step 1|Alternative therapy|0
6370703|NCT00843882|10160504|FG001|Step 1|Alternative therapy|1
6370704|NCT00843882|10160505|FG002|Step 1|Alternative therapy|1
6370705|NCT00843882|10160503|FG000|Step 1|Patient switched treatment early due to DSMC announcement|0
6370706|NCT00843882|10160504|FG001|Step 1|Patient switched treatment early due to DSMC announcement|4
6370707|NCT00843882|10160505|FG002|Step 1|Patient switched treatment early due to DSMC announcement|0
6370708|NCT00843882|10160503|FG000|Step 1|Off treatment reason unknown|0
6370709|NCT00843882|10160504|FG001|Step 1|Off treatment reason unknown|1
6370710|NCT00843882|10160505|FG002|Step 1|Off treatment reason unknown|4
6370711|NCT00843882|10160503|FG000|Step 1|Never started treatment|2
6370712|NCT00843882|10160504|FG001|Step 1|Never started treatment|0
6370713|NCT00843882|10160505|FG002|Step 1|Never started treatment|0
6370714|NCT00843882|10160503|FG000|Step 2 (Cross-over to Arm B)|Lack of Efficacy|1
6370715|NCT00843882|10160504|FG001|Step 2 (Cross-over to Arm B)|Lack of Efficacy|9
6370716|NCT00843882|10160505|FG002|Step 2 (Cross-over to Arm B)|Lack of Efficacy|0
6370717|NCT00843882|10160503|FG000|Step 2 (Cross-over to Arm B)|Adverse Event|0
6370718|NCT00843882|10160504|FG001|Step 2 (Cross-over to Arm B)|Adverse Event|6
6370719|NCT00843882|10160505|FG002|Step 2 (Cross-over to Arm B)|Adverse Event|0
6370720|NCT00843882|10160503|FG000|Step 2 (Cross-over to Arm B)|Death|0
6370721|NCT00843882|10160504|FG001|Step 2 (Cross-over to Arm B)|Death|3
6370722|NCT00843882|10160505|FG002|Step 2 (Cross-over to Arm B)|Death|0
6370723|NCT00843882|10160503|FG000|Step 2 (Cross-over to Arm B)|Withdrawal by Subject|2
6370724|NCT00843882|10160504|FG001|Step 2 (Cross-over to Arm B)|Withdrawal by Subject|5
6370725|NCT00843882|10160505|FG002|Step 2 (Cross-over to Arm B)|Withdrawal by Subject|0
6370726|NCT00843882|10160503|FG000|Step 2 (Cross-over to Arm B)|Physician Decision|1
6370727|NCT00843882|10160504|FG001|Step 2 (Cross-over to Arm B)|Physician Decision|1
6370728|NCT00843882|10160505|FG002|Step 2 (Cross-over to Arm B)|Physician Decision|0
6370729|NCT00843882|10160503|FG000|Step 2 (Cross-over to Arm B)|Alternative treatment|0
6370730|NCT00843882|10160504|FG001|Step 2 (Cross-over to Arm B)|Alternative treatment|1
6370731|NCT00843882|10160505|FG002|Step 2 (Cross-over to Arm B)|Alternative treatment|0
6370732|NCT00843882|10160503|FG000|Step 2 (Cross-over to Arm B)|Prolonged wound healing|0
6370733|NCT00843882|10160504|FG001|Step 2 (Cross-over to Arm B)|Prolonged wound healing|1
6370734|NCT00843882|10160505|FG002|Step 2 (Cross-over to Arm B)|Prolonged wound healing|0
6370735|NCT00644228|10160520|FG000|Randomization & Eligibility|Ineligible|31
6370736|NCT00644228|10160521|FG001|Randomization & Eligibility|Ineligible|21
6370737|NCT00644228|10160520|FG000|Randomization & Eligibility|Withdrew Consent prior to therapy start|1
6370738|NCT00644228|10160521|FG001|Randomization & Eligibility|Withdrew Consent prior to therapy start|0
6370739|NCT00644228|10160520|FG000|Randomization & Eligibility|Invalid Consent|0
6370740|NCT00644228|10160521|FG001|Randomization & Eligibility|Invalid Consent|1
6370741|NCT00644228|10160520|FG000|Induction Therapy|Adverse Event|22
6370742|NCT00644228|10160521|FG001|Induction Therapy|Adverse Event|55
6370743|NCT00644228|10160520|FG000|Induction Therapy|Withdrawal by Subject|10
6370744|NCT00644228|10160521|FG001|Induction Therapy|Withdrawal by Subject|3
6370745|NCT00644228|10160520|FG000|Induction Therapy|Progression/Relapse|24
6370746|NCT00644228|10160521|FG001|Induction Therapy|Progression/Relapse|12
6370747|NCT00644228|10160520|FG000|Induction Therapy|Death|3
6370748|NCT00644228|10160521|FG001|Induction Therapy|Death|7
6370749|NCT00644228|10160520|FG000|Induction Therapy|Not Protocol-Specified|24
6370750|NCT00644228|10160521|FG001|Induction Therapy|Not Protocol-Specified|28
6370751|NCT00644228|10160520|FG000|Maintenance|Adverse Event|27
6370752|NCT00644228|10160521|FG001|Maintenance|Adverse Event|31
6370753|NCT00644228|10160520|FG000|Maintenance|Withdrawal by Subject|6
6370754|NCT00644228|10160521|FG001|Maintenance|Withdrawal by Subject|4
6370755|NCT00644228|10160520|FG000|Maintenance|Progression/Relapse|67
6370756|NCT00644228|10160521|FG001|Maintenance|Progression/Relapse|42
6370757|NCT00644228|10160520|FG000|Maintenance|Death|3
6370758|NCT00644228|10160521|FG001|Maintenance|Death|3
6370759|NCT00644228|10160520|FG000|Maintenance|Not Protocol-Specified|14
6370760|NCT00644228|10160521|FG001|Maintenance|Not Protocol-Specified|15
6370761|NCT00644228|10160520|FG000|Maintenance|On Treatment|26
6370762|NCT00644228|10160521|FG001|Maintenance|On Treatment|40
6370763|NCT00602641|10160529|FG000|Overall Study|Never started protocol therapy|6
6370764|NCT00602641|10160530|FG001|Overall Study|Never started protocol therapy|2
6370765|NCT00602641|10160529|FG000|Overall Study|Still on treatment at time of analysis|8
6370766|NCT00602641|10160530|FG001|Overall Study|Still on treatment at time of analysis|15
6370767|NCT00602641|10160529|FG000|Overall Study|Adverse Event|62
6370768|NCT00602641|10160530|FG001|Overall Study|Adverse Event|53
6370769|NCT00602641|10160529|FG000|Overall Study|Disease progression|38
6370770|NCT00602641|10160530|FG001|Overall Study|Disease progression|55
6370771|NCT00602641|10160529|FG000|Overall Study|Death|6
6370772|NCT00602641|10160530|FG001|Overall Study|Death|5
6370773|NCT00602641|10160529|FG000|Overall Study|Withdrawal by Subject|15
6370774|NCT00602641|10160530|FG001|Overall Study|Withdrawal by Subject|12
6370775|NCT00602641|10160529|FG000|Overall Study|Alternative therapy|5
6370776|NCT00602641|10160530|FG001|Overall Study|Alternative therapy|2
6370777|NCT00602641|10160529|FG000|Overall Study|Other Complicating Disease|5
6370778|NCT00602641|10160530|FG001|Overall Study|Other Complicating Disease|2
6370779|NCT00602641|10160529|FG000|Overall Study|Physician Decision|5
6370780|NCT00602641|10160530|FG001|Overall Study|Physician Decision|4
6370781|NCT00602641|10160529|FG000|Overall Study|Administrative Closure|1
6370782|NCT00602641|10160530|FG001|Overall Study|Administrative Closure|1
6370783|NCT00602641|10160529|FG000|Overall Study|Other|3
6370784|NCT00602641|10160530|FG001|Overall Study|Other|1
6370785|NCT00504582|10160543|FG000|Overall Study|Lost to Follow-up|1
6370786|NCT00504582|10160544|FG001|Overall Study|Lost to Follow-up|0
6370787|NCT00504582|10160545|FG002|Overall Study|Lost to Follow-up|0
6370788|NCT00408005|10160555|FG000|Induction|Adverse Event|19
6370789|NCT00408005|10160556|FG001|Induction|Adverse Event|3
6370790|NCT00408005|10160557|FG002|Induction|Adverse Event|0
6370791|NCT00408005|10160558|FG003|Induction|Adverse Event|0
6370792|NCT00408005|10160559|FG004|Induction|Adverse Event|0
6370793|NCT00408005|10160560|FG005|Induction|Adverse Event|0
6370794|NCT00408005|10160561|FG006|Induction|Adverse Event|0
6370795|NCT00408005|10160562|FG007|Induction|Adverse Event|0
6370796|NCT00408005|10160555|FG000|Induction|Death|6
6370797|NCT00408005|10160556|FG001|Induction|Death|0
6370798|NCT00408005|10160557|FG002|Induction|Death|0
6370799|NCT00408005|10160558|FG003|Induction|Death|0
6370800|NCT00408005|10160559|FG004|Induction|Death|0
6370801|NCT00408005|10160560|FG005|Induction|Death|0
6370802|NCT00408005|10160561|FG006|Induction|Death|0
6370803|NCT00408005|10160562|FG007|Induction|Death|0
6084605|NCT00643448|9693548|FG002|Overall Study|Lack of Efficacy|4
6084606|NCT00643448|9693546|FG000|Overall Study|Adverse Event|2
6084607|NCT00643448|9693547|FG001|Overall Study|Adverse Event|2
6084608|NCT00643448|9693548|FG002|Overall Study|Adverse Event|2
6084609|NCT00643448|9693546|FG000|Overall Study|QTcF>550 ms|0
6084610|NCT00643448|9693547|FG001|Overall Study|QTcF>550 ms|3
6084611|NCT00643448|9693548|FG002|Overall Study|QTcF>550 ms|0
6370804|NCT00408005|10160555|FG000|Induction|Physician Decision|83
6370805|NCT00408005|10160556|FG001|Induction|Physician Decision|9
6370806|NCT00408005|10160557|FG002|Induction|Physician Decision|0
6084612|NCT00643487|9693558|FG000|Overall Study|Technical difficulty|3
6370807|NCT00408005|10160558|FG003|Induction|Physician Decision|0
6370808|NCT00408005|10160559|FG004|Induction|Physician Decision|0
6370809|NCT00408005|10160560|FG005|Induction|Physician Decision|0
6370810|NCT00408005|10160561|FG006|Induction|Physician Decision|0
6370811|NCT00408005|10160562|FG007|Induction|Physician Decision|0
6370812|NCT00408005|10160555|FG000|Induction|Withdrawal by Subject|2
6084613|NCT00643565|9693564|FG000|Overall Study|Death|12
6084614|NCT00643565|9693565|FG001|Overall Study|Death|11
6084615|NCT00643565|9693564|FG000|Overall Study|Withdrawal by Subject|4
6084616|NCT00643565|9693565|FG001|Overall Study|Withdrawal by Subject|1
6370813|NCT00408005|10160556|FG001|Induction|Withdrawal by Subject|4
6370814|NCT00408005|10160557|FG002|Induction|Withdrawal by Subject|0
6370815|NCT00408005|10160558|FG003|Induction|Withdrawal by Subject|0
6370816|NCT00408005|10160559|FG004|Induction|Withdrawal by Subject|0
6370817|NCT00408005|10160560|FG005|Induction|Withdrawal by Subject|0
6370818|NCT00408005|10160561|FG006|Induction|Withdrawal by Subject|0
6370819|NCT00408005|10160562|FG007|Induction|Withdrawal by Subject|0
6370820|NCT00408005|10160555|FG000|Induction|Ineligible|33
6370821|NCT00408005|10160556|FG001|Induction|Ineligible|14
6370822|NCT00408005|10160557|FG002|Induction|Ineligible|0
6370823|NCT00408005|10160558|FG003|Induction|Ineligible|0
6370824|NCT00408005|10160559|FG004|Induction|Ineligible|0
6370825|NCT00408005|10160560|FG005|Induction|Ineligible|0
6370826|NCT00408005|10160561|FG006|Induction|Ineligible|0
6370827|NCT00408005|10160562|FG007|Induction|Ineligible|0
6370828|NCT00408005|10160555|FG000|Induction|Refusal of Further Protocol Therapy|225
6370829|NCT00408005|10160556|FG001|Induction|Refusal of Further Protocol Therapy|44
6370830|NCT00408005|10160557|FG002|Induction|Refusal of Further Protocol Therapy|0
6370831|NCT00408005|10160558|FG003|Induction|Refusal of Further Protocol Therapy|0
6370832|NCT00408005|10160559|FG004|Induction|Refusal of Further Protocol Therapy|0
6370833|NCT00408005|10160560|FG005|Induction|Refusal of Further Protocol Therapy|0
6370834|NCT00408005|10160561|FG006|Induction|Refusal of Further Protocol Therapy|0
6370835|NCT00408005|10160562|FG007|Induction|Refusal of Further Protocol Therapy|0
6370836|NCT00408005|10160555|FG000|Induction|Entered another COG therapeutic protocol|4
6370837|NCT00408005|10160556|FG001|Induction|Entered another COG therapeutic protocol|0
6370838|NCT00408005|10160557|FG002|Induction|Entered another COG therapeutic protocol|0
6370839|NCT00408005|10160558|FG003|Induction|Entered another COG therapeutic protocol|0
6370840|NCT00408005|10160559|FG004|Induction|Entered another COG therapeutic protocol|0
6370841|NCT00408005|10160560|FG005|Induction|Entered another COG therapeutic protocol|0
6370842|NCT00408005|10160561|FG006|Induction|Entered another COG therapeutic protocol|0
6370843|NCT00408005|10160562|FG007|Induction|Entered another COG therapeutic protocol|0
6370844|NCT00408005|10160555|FG000|Induction|Patient transferred Tx to Non-COG Site|3
6370845|NCT00408005|10160556|FG001|Induction|Patient transferred Tx to Non-COG Site|2
6370846|NCT00408005|10160557|FG002|Induction|Patient transferred Tx to Non-COG Site|0
6370847|NCT00408005|10160558|FG003|Induction|Patient transferred Tx to Non-COG Site|0
6370848|NCT00408005|10160559|FG004|Induction|Patient transferred Tx to Non-COG Site|0
6370849|NCT00408005|10160560|FG005|Induction|Patient transferred Tx to Non-COG Site|0
6370850|NCT00408005|10160561|FG006|Induction|Patient transferred Tx to Non-COG Site|0
6370851|NCT00408005|10160562|FG007|Induction|Patient transferred Tx to Non-COG Site|0
6370852|NCT00408005|10160555|FG000|Induction|Identified as Philadelphia Chr. Positive|6
6370853|NCT00408005|10160556|FG001|Induction|Identified as Philadelphia Chr. Positive|0
6370854|NCT00408005|10160557|FG002|Induction|Identified as Philadelphia Chr. Positive|0
6370855|NCT00408005|10160558|FG003|Induction|Identified as Philadelphia Chr. Positive|0
6370856|NCT00408005|10160559|FG004|Induction|Identified as Philadelphia Chr. Positive|0
6370857|NCT00408005|10160560|FG005|Induction|Identified as Philadelphia Chr. Positive|0
6370858|NCT00408005|10160561|FG006|Induction|Identified as Philadelphia Chr. Positive|0
6370859|NCT00408005|10160562|FG007|Induction|Identified as Philadelphia Chr. Positive|0
6370860|NCT00408005|10160555|FG000|Induction|Progressive Disease|0
6370861|NCT00408005|10160556|FG001|Induction|Progressive Disease|1
6370862|NCT00408005|10160557|FG002|Induction|Progressive Disease|0
6370863|NCT00408005|10160558|FG003|Induction|Progressive Disease|0
6370864|NCT00408005|10160559|FG004|Induction|Progressive Disease|0
6370865|NCT00408005|10160560|FG005|Induction|Progressive Disease|0
6370866|NCT00408005|10160561|FG006|Induction|Progressive Disease|0
6370867|NCT00408005|10160562|FG007|Induction|Progressive Disease|0
6370868|NCT00408005|10160555|FG000|Induction|Inevaluable|18
6370869|NCT00408005|10160556|FG001|Induction|Inevaluable|14
6370870|NCT00408005|10160557|FG002|Induction|Inevaluable|0
6370871|NCT00408005|10160558|FG003|Induction|Inevaluable|0
6370872|NCT00408005|10160559|FG004|Induction|Inevaluable|0
6370873|NCT00408005|10160560|FG005|Induction|Inevaluable|0
6370874|NCT00408005|10160561|FG006|Induction|Inevaluable|0
6370875|NCT00408005|10160562|FG007|Induction|Inevaluable|0
6370876|NCT00408005|10160555|FG000|Induction|Failed to Complete Randomization|3
6370877|NCT00408005|10160556|FG001|Induction|Failed to Complete Randomization|2
6370878|NCT00408005|10160557|FG002|Induction|Failed to Complete Randomization|0
6370879|NCT00408005|10160558|FG003|Induction|Failed to Complete Randomization|0
6370880|NCT00408005|10160559|FG004|Induction|Failed to Complete Randomization|0
6370881|NCT00408005|10160560|FG005|Induction|Failed to Complete Randomization|0
6370882|NCT00408005|10160561|FG006|Induction|Failed to Complete Randomization|0
6370883|NCT00408005|10160562|FG007|Induction|Failed to Complete Randomization|0
6370884|NCT00408005|10160555|FG000|Induction|Protocol Deviation|3
6370885|NCT00408005|10160556|FG001|Induction|Protocol Deviation|1
6370886|NCT00408005|10160557|FG002|Induction|Protocol Deviation|0
6370887|NCT00408005|10160558|FG003|Induction|Protocol Deviation|0
6370888|NCT00408005|10160559|FG004|Induction|Protocol Deviation|0
6370889|NCT00408005|10160560|FG005|Induction|Protocol Deviation|0
6370890|NCT00408005|10160561|FG006|Induction|Protocol Deviation|0
6370891|NCT00408005|10160562|FG007|Induction|Protocol Deviation|0
6370892|NCT00408005|10160555|FG000|Induction|Hematopoietic Stem Cell Transplantation|1
6370893|NCT00408005|10160556|FG001|Induction|Hematopoietic Stem Cell Transplantation|0
6370894|NCT00408005|10160557|FG002|Induction|Hematopoietic Stem Cell Transplantation|0
6370895|NCT00408005|10160558|FG003|Induction|Hematopoietic Stem Cell Transplantation|0
6370896|NCT00408005|10160559|FG004|Induction|Hematopoietic Stem Cell Transplantation|0
6370897|NCT00408005|10160560|FG005|Induction|Hematopoietic Stem Cell Transplantation|0
6370898|NCT00408005|10160561|FG006|Induction|Hematopoietic Stem Cell Transplantation|0
6370899|NCT00408005|10160562|FG007|Induction|Hematopoietic Stem Cell Transplantation|0
6370900|NCT00408005|10160555|FG000|Induction|Recurrent leukemia|1
6370901|NCT00408005|10160556|FG001|Induction|Recurrent leukemia|0
6370902|NCT00408005|10160557|FG002|Induction|Recurrent leukemia|0
6370903|NCT00408005|10160558|FG003|Induction|Recurrent leukemia|0
6370904|NCT00408005|10160559|FG004|Induction|Recurrent leukemia|0
6370905|NCT00408005|10160560|FG005|Induction|Recurrent leukemia|0
6370906|NCT00408005|10160561|FG006|Induction|Recurrent leukemia|0
6370907|NCT00408005|10160562|FG007|Induction|Recurrent leukemia|0
6370908|NCT00408005|10160555|FG000|Post Induction Therapy by Tx Assignment|Adverse Event|0
6370909|NCT00408005|10160556|FG001|Post Induction Therapy by Tx Assignment|Adverse Event|0
6370910|NCT00408005|10160557|FG002|Post Induction Therapy by Tx Assignment|Adverse Event|7
6370911|NCT00408005|10160558|FG003|Post Induction Therapy by Tx Assignment|Adverse Event|4
6370912|NCT00408005|10160559|FG004|Post Induction Therapy by Tx Assignment|Adverse Event|8
6370913|NCT00408005|10160560|FG005|Post Induction Therapy by Tx Assignment|Adverse Event|12
6370914|NCT00408005|10160561|FG006|Post Induction Therapy by Tx Assignment|Adverse Event|2
6370915|NCT00408005|10160562|FG007|Post Induction Therapy by Tx Assignment|Adverse Event|0
6370916|NCT00408005|10160555|FG000|Post Induction Therapy by Tx Assignment|Death|0
6370917|NCT00408005|10160556|FG001|Post Induction Therapy by Tx Assignment|Death|0
6370918|NCT00408005|10160557|FG002|Post Induction Therapy by Tx Assignment|Death|3
6370919|NCT00408005|10160558|FG003|Post Induction Therapy by Tx Assignment|Death|0
6370920|NCT00408005|10160559|FG004|Post Induction Therapy by Tx Assignment|Death|5
6370921|NCT00408005|10160560|FG005|Post Induction Therapy by Tx Assignment|Death|5
6370922|NCT00408005|10160561|FG006|Post Induction Therapy by Tx Assignment|Death|3
6370923|NCT00408005|10160562|FG007|Post Induction Therapy by Tx Assignment|Death|1
6370924|NCT00408005|10160555|FG000|Post Induction Therapy by Tx Assignment|Lost to Follow-up|0
6370925|NCT00408005|10160556|FG001|Post Induction Therapy by Tx Assignment|Lost to Follow-up|0
6370926|NCT00408005|10160557|FG002|Post Induction Therapy by Tx Assignment|Lost to Follow-up|2
6370927|NCT00408005|10160558|FG003|Post Induction Therapy by Tx Assignment|Lost to Follow-up|0
6370928|NCT00408005|10160559|FG004|Post Induction Therapy by Tx Assignment|Lost to Follow-up|1
6370929|NCT00408005|10160560|FG005|Post Induction Therapy by Tx Assignment|Lost to Follow-up|0
6370930|NCT00408005|10160561|FG006|Post Induction Therapy by Tx Assignment|Lost to Follow-up|0
6370931|NCT00408005|10160562|FG007|Post Induction Therapy by Tx Assignment|Lost to Follow-up|0
6370932|NCT00408005|10160555|FG000|Post Induction Therapy by Tx Assignment|Physician Decision|0
6370933|NCT00408005|10160556|FG001|Post Induction Therapy by Tx Assignment|Physician Decision|0
6370934|NCT00408005|10160557|FG002|Post Induction Therapy by Tx Assignment|Physician Decision|24
6370935|NCT00408005|10160558|FG003|Post Induction Therapy by Tx Assignment|Physician Decision|19
6370936|NCT00408005|10160559|FG004|Post Induction Therapy by Tx Assignment|Physician Decision|27
6370937|NCT00408005|10160560|FG005|Post Induction Therapy by Tx Assignment|Physician Decision|45
6370938|NCT00408005|10160561|FG006|Post Induction Therapy by Tx Assignment|Physician Decision|10
6370939|NCT00408005|10160562|FG007|Post Induction Therapy by Tx Assignment|Physician Decision|4
6370940|NCT00408005|10160555|FG000|Post Induction Therapy by Tx Assignment|Withdrawal by Subject|0
6370941|NCT00408005|10160556|FG001|Post Induction Therapy by Tx Assignment|Withdrawal by Subject|0
6370942|NCT00408005|10160557|FG002|Post Induction Therapy by Tx Assignment|Withdrawal by Subject|1
6370943|NCT00408005|10160558|FG003|Post Induction Therapy by Tx Assignment|Withdrawal by Subject|1
6370944|NCT00408005|10160559|FG004|Post Induction Therapy by Tx Assignment|Withdrawal by Subject|0
6370945|NCT00408005|10160560|FG005|Post Induction Therapy by Tx Assignment|Withdrawal by Subject|2
6370946|NCT00408005|10160561|FG006|Post Induction Therapy by Tx Assignment|Withdrawal by Subject|0
6370947|NCT00408005|10160562|FG007|Post Induction Therapy by Tx Assignment|Withdrawal by Subject|0
6370948|NCT00408005|10160555|FG000|Post Induction Therapy by Tx Assignment|Refusal of Further Protocol Therapy|0
6370949|NCT00408005|10160556|FG001|Post Induction Therapy by Tx Assignment|Refusal of Further Protocol Therapy|0
6370950|NCT00408005|10160557|FG002|Post Induction Therapy by Tx Assignment|Refusal of Further Protocol Therapy|27
6370951|NCT00408005|10160558|FG003|Post Induction Therapy by Tx Assignment|Refusal of Further Protocol Therapy|10
6370952|NCT00408005|10160559|FG004|Post Induction Therapy by Tx Assignment|Refusal of Further Protocol Therapy|36
6370953|NCT00408005|10160560|FG005|Post Induction Therapy by Tx Assignment|Refusal of Further Protocol Therapy|16
6370954|NCT00408005|10160561|FG006|Post Induction Therapy by Tx Assignment|Refusal of Further Protocol Therapy|4
6370955|NCT00408005|10160562|FG007|Post Induction Therapy by Tx Assignment|Refusal of Further Protocol Therapy|2
6370956|NCT00408005|10160555|FG000|Post Induction Therapy by Tx Assignment|Entered another COG therapeutic protocol|0
6370957|NCT00408005|10160556|FG001|Post Induction Therapy by Tx Assignment|Entered another COG therapeutic protocol|0
6370958|NCT00408005|10160557|FG002|Post Induction Therapy by Tx Assignment|Entered another COG therapeutic protocol|0
6370959|NCT00408005|10160558|FG003|Post Induction Therapy by Tx Assignment|Entered another COG therapeutic protocol|0
6370960|NCT00408005|10160559|FG004|Post Induction Therapy by Tx Assignment|Entered another COG therapeutic protocol|1
6370961|NCT00408005|10160560|FG005|Post Induction Therapy by Tx Assignment|Entered another COG therapeutic protocol|0
6370962|NCT00408005|10160561|FG006|Post Induction Therapy by Tx Assignment|Entered another COG therapeutic protocol|0
6370963|NCT00408005|10160562|FG007|Post Induction Therapy by Tx Assignment|Entered another COG therapeutic protocol|0
6370964|NCT00408005|10160555|FG000|Post Induction Therapy by Tx Assignment|Patient transferred Tx to Non-COG Site|0
6370965|NCT00408005|10160556|FG001|Post Induction Therapy by Tx Assignment|Patient transferred Tx to Non-COG Site|0
6370966|NCT00408005|10160557|FG002|Post Induction Therapy by Tx Assignment|Patient transferred Tx to Non-COG Site|3
6370967|NCT00408005|10160558|FG003|Post Induction Therapy by Tx Assignment|Patient transferred Tx to Non-COG Site|1
6370968|NCT00408005|10160559|FG004|Post Induction Therapy by Tx Assignment|Patient transferred Tx to Non-COG Site|1
6370969|NCT00408005|10160560|FG005|Post Induction Therapy by Tx Assignment|Patient transferred Tx to Non-COG Site|0
6370970|NCT00408005|10160561|FG006|Post Induction Therapy by Tx Assignment|Patient transferred Tx to Non-COG Site|1
6370971|NCT00408005|10160562|FG007|Post Induction Therapy by Tx Assignment|Patient transferred Tx to Non-COG Site|0
6370972|NCT00408005|10160555|FG000|Post Induction Therapy by Tx Assignment|Progressive Disease|0
6370973|NCT00408005|10160556|FG001|Post Induction Therapy by Tx Assignment|Progressive Disease|0
6370974|NCT00408005|10160557|FG002|Post Induction Therapy by Tx Assignment|Progressive Disease|0
6370975|NCT00408005|10160558|FG003|Post Induction Therapy by Tx Assignment|Progressive Disease|0
6370976|NCT00408005|10160559|FG004|Post Induction Therapy by Tx Assignment|Progressive Disease|1
6370977|NCT00408005|10160560|FG005|Post Induction Therapy by Tx Assignment|Progressive Disease|0
6370978|NCT00408005|10160561|FG006|Post Induction Therapy by Tx Assignment|Progressive Disease|7
6370979|NCT00408005|10160562|FG007|Post Induction Therapy by Tx Assignment|Progressive Disease|7
6370980|NCT00408005|10160555|FG000|Post Induction Therapy by Tx Assignment|Inevaluable|0
6370981|NCT00408005|10160556|FG001|Post Induction Therapy by Tx Assignment|Inevaluable|0
6370982|NCT00408005|10160557|FG002|Post Induction Therapy by Tx Assignment|Inevaluable|0
6370983|NCT00408005|10160558|FG003|Post Induction Therapy by Tx Assignment|Inevaluable|0
6370984|NCT00408005|10160559|FG004|Post Induction Therapy by Tx Assignment|Inevaluable|0
6370985|NCT00408005|10160560|FG005|Post Induction Therapy by Tx Assignment|Inevaluable|1
6370986|NCT00408005|10160561|FG006|Post Induction Therapy by Tx Assignment|Inevaluable|0
6370987|NCT00408005|10160562|FG007|Post Induction Therapy by Tx Assignment|Inevaluable|0
6370988|NCT00408005|10160555|FG000|Post Induction Therapy by Tx Assignment|Protocol Deviation|0
6370989|NCT00408005|10160556|FG001|Post Induction Therapy by Tx Assignment|Protocol Deviation|0
6370990|NCT00408005|10160557|FG002|Post Induction Therapy by Tx Assignment|Protocol Deviation|2
6370991|NCT00408005|10160558|FG003|Post Induction Therapy by Tx Assignment|Protocol Deviation|1
6370992|NCT00408005|10160559|FG004|Post Induction Therapy by Tx Assignment|Protocol Deviation|1
6370993|NCT00408005|10160560|FG005|Post Induction Therapy by Tx Assignment|Protocol Deviation|2
6370994|NCT00408005|10160561|FG006|Post Induction Therapy by Tx Assignment|Protocol Deviation|0
6370995|NCT00408005|10160562|FG007|Post Induction Therapy by Tx Assignment|Protocol Deviation|0
6370996|NCT00408005|10160555|FG000|Post Induction Therapy by Tx Assignment|Hematopoietic Stem Cell Transplantation|0
6370997|NCT00408005|10160556|FG001|Post Induction Therapy by Tx Assignment|Hematopoietic Stem Cell Transplantation|0
6370998|NCT00408005|10160557|FG002|Post Induction Therapy by Tx Assignment|Hematopoietic Stem Cell Transplantation|0
6370999|NCT00408005|10160558|FG003|Post Induction Therapy by Tx Assignment|Hematopoietic Stem Cell Transplantation|0
6371000|NCT00408005|10160559|FG004|Post Induction Therapy by Tx Assignment|Hematopoietic Stem Cell Transplantation|1
6371001|NCT00408005|10160560|FG005|Post Induction Therapy by Tx Assignment|Hematopoietic Stem Cell Transplantation|2
6371002|NCT00408005|10160561|FG006|Post Induction Therapy by Tx Assignment|Hematopoietic Stem Cell Transplantation|0
6371003|NCT00408005|10160562|FG007|Post Induction Therapy by Tx Assignment|Hematopoietic Stem Cell Transplantation|0
6371004|NCT00408005|10160555|FG000|Post Induction Therapy by Tx Assignment|Recurrent Leukemia After Total Remission|0
6371005|NCT00408005|10160556|FG001|Post Induction Therapy by Tx Assignment|Recurrent Leukemia After Total Remission|0
6371006|NCT00408005|10160557|FG002|Post Induction Therapy by Tx Assignment|Recurrent Leukemia After Total Remission|13
6371007|NCT00408005|10160558|FG003|Post Induction Therapy by Tx Assignment|Recurrent Leukemia After Total Remission|7
6371008|NCT00408005|10160559|FG004|Post Induction Therapy by Tx Assignment|Recurrent Leukemia After Total Remission|49
6371009|NCT00408005|10160560|FG005|Post Induction Therapy by Tx Assignment|Recurrent Leukemia After Total Remission|15
6371010|NCT00408005|10160561|FG006|Post Induction Therapy by Tx Assignment|Recurrent Leukemia After Total Remission|1
6371011|NCT00408005|10160562|FG007|Post Induction Therapy by Tx Assignment|Recurrent Leukemia After Total Remission|0
6371012|NCT00408005|10160555|FG000|Post Induction Therapy by Tx Assignment|Development of SMN|0
6371013|NCT00408005|10160556|FG001|Post Induction Therapy by Tx Assignment|Development of SMN|0
6371014|NCT00408005|10160557|FG002|Post Induction Therapy by Tx Assignment|Development of SMN|3
6371015|NCT00408005|10160558|FG003|Post Induction Therapy by Tx Assignment|Development of SMN|1
6371016|NCT00408005|10160559|FG004|Post Induction Therapy by Tx Assignment|Development of SMN|1
6371017|NCT00408005|10160560|FG005|Post Induction Therapy by Tx Assignment|Development of SMN|1
6371018|NCT00408005|10160561|FG006|Post Induction Therapy by Tx Assignment|Development of SMN|0
6371019|NCT00408005|10160562|FG007|Post Induction Therapy by Tx Assignment|Development of SMN|0
6371020|NCT00026312|10160584|FG000|Overall Study|Adverse Event|0
6371021|NCT00026312|10160585|FG001|Overall Study|Adverse Event|32
6371022|NCT00026312|10160584|FG000|Overall Study|Death|1
6371023|NCT00026312|10160585|FG001|Overall Study|Death|7
6371024|NCT00026312|10160584|FG000|Overall Study|Lack of Efficacy|19
6371025|NCT00026312|10160585|FG001|Overall Study|Lack of Efficacy|114
6371026|NCT00026312|10160584|FG000|Overall Study|Lost to Follow-up|0
6371027|NCT00026312|10160585|FG001|Overall Study|Lost to Follow-up|5
6371028|NCT00026312|10160584|FG000|Overall Study|Physician Decision|1
6371029|NCT00026312|10160585|FG001|Overall Study|Physician Decision|37
6371030|NCT00026312|10160584|FG000|Overall Study|Protocol Violation|0
6371031|NCT00026312|10160585|FG001|Overall Study|Protocol Violation|3
6371032|NCT00026312|10160584|FG000|Overall Study|Withdrawal by Subject|1
6371033|NCT00026312|10160585|FG001|Overall Study|Withdrawal by Subject|6
6371034|NCT00026312|10160584|FG000|Overall Study|Ineligible|4
6371035|NCT00026312|10160585|FG001|Overall Study|Ineligible|5
6371036|NCT00026312|10160584|FG000|Overall Study|Entry onto another COG study|0
6371037|NCT00026312|10160585|FG001|Overall Study|Entry onto another COG study|1
6371038|NCT00026312|10160584|FG000|Overall Study|Refusal by patient/parent/guardian|8
6371039|NCT00026312|10160585|FG001|Overall Study|Refusal by patient/parent/guardian|59
6371040|NCT02257918|10160608|FG000|Overall Study|Lost to Follow-up|4
6371041|NCT02257918|10160609|FG001|Overall Study|Lost to Follow-up|1
6371042|NCT02257918|10160610|FG002|Overall Study|Lost to Follow-up|0
6371043|NCT02257918|10160608|FG000|Overall Study|Withdrawal by Subject|0
6371044|NCT02257918|10160609|FG001|Overall Study|Withdrawal by Subject|0
6371045|NCT02257918|10160610|FG002|Overall Study|Withdrawal by Subject|1
6371046|NCT02257918|10160608|FG000|Overall Study|Pregnancy|0
6371047|NCT02257918|10160609|FG001|Overall Study|Pregnancy|0
6371048|NCT02257918|10160610|FG002|Overall Study|Pregnancy|1
6371049|NCT02258542|10160622|FG000|Overall Study|eg. not made to the visit|7
6371050|NCT02258542|10160623|FG001|Overall Study|eg. not made to the visit|4
6371051|NCT02258542|10160624|FG002|Overall Study|eg. not made to the visit|0
6371052|NCT02258542|10160625|FG003|Overall Study|eg. not made to the visit|1
6371053|NCT02258542|10160622|FG000|Overall Study|study specific discount. criteria|1
6371054|NCT02258542|10160623|FG001|Overall Study|study specific discount. criteria|1
6371055|NCT02258542|10160624|FG002|Overall Study|study specific discount. criteria|0
6371056|NCT02258542|10160625|FG003|Overall Study|study specific discount. criteria|0
6371057|NCT02258542|10160622|FG000|Overall Study|Withdrawal by Subject|20
6371058|NCT02258542|10160623|FG001|Overall Study|Withdrawal by Subject|20
6371059|NCT02258542|10160624|FG002|Overall Study|Withdrawal by Subject|7
6371060|NCT02258542|10160625|FG003|Overall Study|Withdrawal by Subject|1
6371061|NCT02258542|10160622|FG000|Overall Study|Lost to Follow-up|5
6371062|NCT02258542|10160623|FG001|Overall Study|Lost to Follow-up|12
6371063|NCT02258542|10160624|FG002|Overall Study|Lost to Follow-up|1
6371064|NCT02258542|10160625|FG003|Overall Study|Lost to Follow-up|2
6371065|NCT02258542|10160622|FG000|Overall Study|Death|5
6371066|NCT02258542|10160623|FG001|Overall Study|Death|4
6371067|NCT02258542|10160624|FG002|Overall Study|Death|0
6371068|NCT02258542|10160625|FG003|Overall Study|Death|1
6371069|NCT02258542|10160622|FG000|Overall Study|Adverse Event|3
6371070|NCT02258542|10160623|FG001|Overall Study|Adverse Event|4
6371071|NCT02258542|10160624|FG002|Overall Study|Adverse Event|0
6371072|NCT02258542|10160625|FG003|Overall Study|Adverse Event|0
6371073|NCT02258542|10160622|FG000|Overall Study|Protocol Violation|1
6371074|NCT02258542|10160623|FG001|Overall Study|Protocol Violation|2
6371075|NCT02258542|10160624|FG002|Overall Study|Protocol Violation|0
6371076|NCT02258542|10160625|FG003|Overall Study|Protocol Violation|0
6371077|NCT02258542|10160622|FG000|Overall Study|Eligibility criteria not fulfilled|0
6371078|NCT02258542|10160623|FG001|Overall Study|Eligibility criteria not fulfilled|2
6171746|NCT01261793|9818628|FG002|Overall Study|Adverse Event|19
6227479|NCT01717326|9900196|FG008|Overall Study|Lost to Follow-up|0
6227480|NCT01717326|9900197|FG009|Overall Study|Lost to Follow-up|0
6227481|NCT01717326|9900198|FG010|Overall Study|Lost to Follow-up|1
6227482|NCT01717326|9900199|FG011|Overall Study|Lost to Follow-up|0
6371079|NCT02258542|10160624|FG002|Overall Study|Eligibility criteria not fulfilled|0
6371080|NCT02258542|10160625|FG003|Overall Study|Eligibility criteria not fulfilled|0
6371081|NCT02290431|10160653|FG000|Overall Study|Adverse Event|20
6371082|NCT02290431|10160653|FG000|Overall Study|Progressive disease|4
6371083|NCT02290431|10160653|FG000|Overall Study|Study terminated by Sponsor|1
6371084|NCT02290431|10160653|FG000|Overall Study|Physician Decision|2
6371085|NCT02314923|10160667|FG000|Overall Study|Death|0
6371086|NCT02314923|10160668|FG001|Overall Study|Death|0
6371087|NCT02314923|10160669|FG002|Overall Study|Death|0
6371088|NCT02314923|10160670|FG003|Overall Study|Death|1
6371089|NCT02314923|10160671|FG004|Overall Study|Death|0
6371090|NCT02314923|10160672|FG005|Overall Study|Death|0
6371091|NCT02314923|10160673|FG006|Overall Study|Death|0
6371092|NCT02314923|10160674|FG007|Overall Study|Death|0
6371093|NCT02314923|10160675|FG008|Overall Study|Death|0
6371094|NCT02314923|10160676|FG009|Overall Study|Death|0
6371095|NCT02314923|10160667|FG000|Overall Study|Lost to Follow-up|2
6371096|NCT02314923|10160668|FG001|Overall Study|Lost to Follow-up|3
6371097|NCT02314923|10160669|FG002|Overall Study|Lost to Follow-up|1
6227483|NCT01717326|9900200|FG012|Overall Study|Lost to Follow-up|0
6371098|NCT02314923|10160670|FG003|Overall Study|Lost to Follow-up|0
6371099|NCT02314923|10160671|FG004|Overall Study|Lost to Follow-up|0
6371100|NCT02314923|10160672|FG005|Overall Study|Lost to Follow-up|0
6171747|NCT01261793|9818626|FG000|Overall Study|Patient non-availability|1
6171748|NCT01261793|9818627|FG001|Overall Study|Patient non-availability|1
6171749|NCT01261793|9818628|FG002|Overall Study|Patient non-availability|1
6171750|NCT01261793|9818626|FG000|Overall Study|Suspected pregnancy|1
6171751|NCT01261793|9818627|FG001|Overall Study|Suspected pregnancy|1
6171752|NCT01261793|9818628|FG002|Overall Study|Suspected pregnancy|0
6171753|NCT01261793|9818626|FG000|Overall Study|Patient non-compliance|1
6171754|NCT01261793|9818627|FG001|Overall Study|Patient non-compliance|0
6171755|NCT01261793|9818628|FG002|Overall Study|Patient non-compliance|1
6171756|NCT01261793|9818626|FG000|Overall Study|Patient pregnant|1
6171757|NCT01261793|9818627|FG001|Overall Study|Patient pregnant|0
6171758|NCT01261793|9818628|FG002|Overall Study|Patient pregnant|0
6171759|NCT01261793|9818626|FG000|Overall Study|Outside the study area|0
6371101|NCT02314923|10160673|FG006|Overall Study|Lost to Follow-up|3
6371102|NCT02314923|10160674|FG007|Overall Study|Lost to Follow-up|4
6371103|NCT02314923|10160675|FG008|Overall Study|Lost to Follow-up|2
6371104|NCT02314923|10160676|FG009|Overall Study|Lost to Follow-up|0
6371105|NCT02314923|10160667|FG000|Overall Study|Withdrawal by Subject|0
6371106|NCT02314923|10160668|FG001|Overall Study|Withdrawal by Subject|0
6371107|NCT02314923|10160669|FG002|Overall Study|Withdrawal by Subject|1
6371108|NCT02314923|10160670|FG003|Overall Study|Withdrawal by Subject|0
6371109|NCT02314923|10160671|FG004|Overall Study|Withdrawal by Subject|1
6371110|NCT02314923|10160672|FG005|Overall Study|Withdrawal by Subject|0
6371111|NCT02314923|10160673|FG006|Overall Study|Withdrawal by Subject|1
6371112|NCT02314923|10160674|FG007|Overall Study|Withdrawal by Subject|0
6371113|NCT02314923|10160675|FG008|Overall Study|Withdrawal by Subject|0
6371114|NCT02314923|10160676|FG009|Overall Study|Withdrawal by Subject|0
6371115|NCT02314923|10160667|FG000|Overall Study|Physician Decision|0
6371116|NCT02314923|10160668|FG001|Overall Study|Physician Decision|1
6371117|NCT02314923|10160669|FG002|Overall Study|Physician Decision|0
6371118|NCT02314923|10160670|FG003|Overall Study|Physician Decision|0
6371119|NCT02314923|10160671|FG004|Overall Study|Physician Decision|0
6371120|NCT02314923|10160672|FG005|Overall Study|Physician Decision|0
6371121|NCT02314923|10160673|FG006|Overall Study|Physician Decision|0
6371122|NCT02314923|10160674|FG007|Overall Study|Physician Decision|0
6371123|NCT02314923|10160675|FG008|Overall Study|Physician Decision|0
6371124|NCT02314923|10160676|FG009|Overall Study|Physician Decision|0
6371125|NCT02314923|10160667|FG000|Overall Study|Participant unavailable|0
6371126|NCT02314923|10160668|FG001|Overall Study|Participant unavailable|0
6371127|NCT02314923|10160669|FG002|Overall Study|Participant unavailable|0
6371128|NCT02314923|10160670|FG003|Overall Study|Participant unavailable|0
6371129|NCT02314923|10160671|FG004|Overall Study|Participant unavailable|0
6371130|NCT02314923|10160672|FG005|Overall Study|Participant unavailable|1
6371131|NCT02314923|10160673|FG006|Overall Study|Participant unavailable|0
6371132|NCT02314923|10160674|FG007|Overall Study|Participant unavailable|0
6371133|NCT02314923|10160675|FG008|Overall Study|Participant unavailable|0
6371134|NCT02314923|10160676|FG009|Overall Study|Participant unavailable|0
6371135|NCT02314923|10160667|FG000|Overall Study|Screen failure|0
6371136|NCT02314923|10160668|FG001|Overall Study|Screen failure|0
6371137|NCT02314923|10160669|FG002|Overall Study|Screen failure|0
6371138|NCT02314923|10160670|FG003|Overall Study|Screen failure|0
6371139|NCT02314923|10160671|FG004|Overall Study|Screen failure|0
6371140|NCT02314923|10160672|FG005|Overall Study|Screen failure|0
6371141|NCT02314923|10160673|FG006|Overall Study|Screen failure|1
6371142|NCT02314923|10160674|FG007|Overall Study|Screen failure|0
6371143|NCT02314923|10160675|FG008|Overall Study|Screen failure|0
6371144|NCT02314923|10160676|FG009|Overall Study|Screen failure|0
6371145|NCT02314923|10160667|FG000|Overall Study|Participant relocation|1
6371146|NCT02314923|10160668|FG001|Overall Study|Participant relocation|0
6371147|NCT02314923|10160669|FG002|Overall Study|Participant relocation|0
6371148|NCT02314923|10160670|FG003|Overall Study|Participant relocation|0
6371149|NCT02314923|10160671|FG004|Overall Study|Participant relocation|0
6371150|NCT02314923|10160672|FG005|Overall Study|Participant relocation|0
6371151|NCT02314923|10160673|FG006|Overall Study|Participant relocation|0
6371152|NCT02314923|10160674|FG007|Overall Study|Participant relocation|1
6371153|NCT02314923|10160675|FG008|Overall Study|Participant relocation|0
6371154|NCT02314923|10160676|FG009|Overall Study|Participant relocation|0
6371155|NCT04524507|10160717|FG000|Overall Study|Lost to Follow-up|2
6371156|NCT04524507|10160718|FG001|Overall Study|Lost to Follow-up|4
6371157|NCT04524507|10160717|FG000|Overall Study|Withdrawal by Subject|2
6371158|NCT04524507|10160718|FG001|Overall Study|Withdrawal by Subject|9
6371159|NCT04524507|10160717|FG000|Overall Study|Death|2
6371160|NCT04524507|10160718|FG001|Overall Study|Death|10
6371161|NCT04382924|10160727|FG000|Overall Study|Death|2
6371162|NCT04382924|10160728|FG001|Overall Study|Death|5
6371163|NCT04382924|10160729|FG002|Overall Study|Death|4
6371164|NCT04382924|10160727|FG000|Overall Study|Protocol Violation|0
6371165|NCT04382924|10160728|FG001|Overall Study|Protocol Violation|1
6371166|NCT04382924|10160729|FG002|Overall Study|Protocol Violation|1
6371167|NCT04382924|10160727|FG000|Overall Study|Transferred to other hospital/declined in person visits|0
6371168|NCT04382924|10160728|FG001|Overall Study|Transferred to other hospital/declined in person visits|1
6371169|NCT04382924|10160729|FG002|Overall Study|Transferred to other hospital/declined in person visits|1
6371170|NCT04382924|10160727|FG000|Overall Study|Withdrawal by Subject|6
6371171|NCT04382924|10160728|FG001|Overall Study|Withdrawal by Subject|3
6371172|NCT04382924|10160729|FG002|Overall Study|Withdrawal by Subject|6
6371173|NCT03842436|10160760|FG000|Overall Study|Lost to Follow-up|1
6371174|NCT03462030|10160781|FG000|Overall Study|Withdrawal by Subject|1
6371175|NCT03462030|10160782|FG001|Overall Study|Withdrawal by Subject|1
6371176|NCT03446768|10160790|FG000|Overall Study|Withdrawal by Subject|0
6371177|NCT03446768|10160791|FG001|Overall Study|Withdrawal by Subject|1
6371178|NCT03253393|10160836|FG000|Washout (Minimum 48 Hours)|13 participants exited study after first two visits/interventions|6
6371179|NCT03253393|10160837|FG001|Washout (Minimum 48 Hours)|13 participants exited study after first two visits/interventions|7
6371180|NCT03253393|10160838|FG002|Washout (Minimum 48 Hours)|13 participants exited study after first two visits/interventions|0
6371181|NCT03188822|10160852|FG000|Overall Study|Subjects chose not to attend the SOC 12 month follow up visit|6
6371182|NCT03188822|10160852|FG000|Overall Study|Clinic was closed due to COVID-19 for 12 month follow up visit|1
6371183|NCT03128671|10160858|FG000|Allocation|ICU discharge prior to intervention initiation|4
6371184|NCT03128671|10160859|FG001|Allocation|ICU discharge prior to intervention initiation|0
6371185|NCT03128671|10160858|FG000|Allocation|Death|1
6371186|NCT03128671|10160859|FG001|Allocation|Death|0
6371187|NCT03128671|10160858|FG000|Allocation|Withdrawal by Subject|4
6371188|NCT03128671|10160859|FG001|Allocation|Withdrawal by Subject|0
6371189|NCT03128671|10160858|FG000|Intervention|Withdrawal by Subject|11
6371190|NCT03128671|10160859|FG001|Intervention|Withdrawal by Subject|10
6371191|NCT03128671|10160858|FG000|Intervention|Palliative/hospice care initiated|9
6371192|NCT03128671|10160859|FG001|Intervention|Palliative/hospice care initiated|10
6371193|NCT03128671|10160858|FG000|Intervention|Death|13
6371194|NCT03128671|10160859|FG001|Intervention|Death|11
6371195|NCT03128671|10160858|FG000|Intervention|Interrupted by hurricane|1
6371196|NCT03128671|10160859|FG001|Intervention|Interrupted by hurricane|0
6371197|NCT03128671|10160858|FG000|Intervention|Physician Decision|2
6371198|NCT03128671|10160859|FG001|Intervention|Physician Decision|3
6371199|NCT03111732|10160865|FG000|Overall Study|Enrolled in different study|1
6371200|NCT03111732|10160865|FG000|Overall Study|Progressive disease|3
6371201|NCT03111732|10160865|FG000|Overall Study|Withdrawal by Subject|1
6371202|NCT03065244|10160876|FG000|Overall Study|Lost to Follow-up|1
6371203|NCT03065244|10160877|FG001|Overall Study|Lost to Follow-up|1
6371204|NCT03065244|10160876|FG000|Overall Study|Diagnosed with a different disease|1
6371205|NCT03065244|10160877|FG001|Overall Study|Diagnosed with a different disease|1
6371206|NCT03065244|10160876|FG000|Overall Study|Protocol Violation|0
6371207|NCT03065244|10160877|FG001|Overall Study|Protocol Violation|1
6371208|NCT03065244|10160876|FG000|Overall Study|Withdrawal by Subject|1
6371209|NCT03065244|10160877|FG001|Overall Study|Withdrawal by Subject|1
6371210|NCT02879305|10160885|FG000|Overall Study|Investigator Site Closed|55
6371211|NCT02879305|10160886|FG001|Overall Study|Investigator Site Closed|57
6371212|NCT02879305|10160885|FG000|Overall Study|Withdrawal by Subject|44
6371213|NCT02879305|10160886|FG001|Overall Study|Withdrawal by Subject|42
6371214|NCT02879305|10160885|FG000|Overall Study|Lost to Follow-up|17
6371215|NCT02879305|10160886|FG001|Overall Study|Lost to Follow-up|12
6371216|NCT02879305|10160885|FG000|Overall Study|Other|1
6371217|NCT02879305|10160886|FG001|Overall Study|Other|0
6371218|NCT02787850|10160903|FG000|Overall Study|Withdrawal by Subject|0
6371219|NCT02787850|10160904|FG001|Overall Study|Withdrawal by Subject|1
6371220|NCT02676284|10160923|FG000|Overall Study|Withdrawal by Subject|1
6371221|NCT02431702|10160927|FG000|Part 1: 2-Month Oral Run-in Phase|Adverse Event|7
6371222|NCT02431702|10160928|FG001|Part 1: 2-Month Oral Run-in Phase|Adverse Event|0
6371223|NCT02431702|10160929|FG002|Part 1: 2-Month Oral Run-in Phase|Adverse Event|0
6371224|NCT02431702|10160930|FG003|Part 1: 2-Month Oral Run-in Phase|Adverse Event|0
6371225|NCT02431702|10160931|FG004|Part 1: 2-Month Oral Run-in Phase|Adverse Event|0
6371226|NCT02431702|10160932|FG005|Part 1: 2-Month Oral Run-in Phase|Adverse Event|0
6371227|NCT02431702|10160933|FG006|Part 1: 2-Month Oral Run-in Phase|Adverse Event|0
6371228|NCT02431702|10160927|FG000|Part 1: 2-Month Oral Run-in Phase|Lost to Follow-up|11
6371229|NCT02431702|10160928|FG001|Part 1: 2-Month Oral Run-in Phase|Lost to Follow-up|0
6371230|NCT02431702|10160929|FG002|Part 1: 2-Month Oral Run-in Phase|Lost to Follow-up|0
6371231|NCT02431702|10160930|FG003|Part 1: 2-Month Oral Run-in Phase|Lost to Follow-up|0
6371232|NCT02431702|10160931|FG004|Part 1: 2-Month Oral Run-in Phase|Lost to Follow-up|0
6371233|NCT02431702|10160932|FG005|Part 1: 2-Month Oral Run-in Phase|Lost to Follow-up|0
6371234|NCT02431702|10160933|FG006|Part 1: 2-Month Oral Run-in Phase|Lost to Follow-up|23
6371235|NCT02431702|10160927|FG000|Part 1: 2-Month Oral Run-in Phase|Withdrawal of Consent|9
6371236|NCT02431702|10160928|FG001|Part 1: 2-Month Oral Run-in Phase|Withdrawal of Consent|0
6371237|NCT02431702|10160929|FG002|Part 1: 2-Month Oral Run-in Phase|Withdrawal of Consent|0
6371238|NCT02431702|10160930|FG003|Part 1: 2-Month Oral Run-in Phase|Withdrawal of Consent|0
6371239|NCT02431702|10160931|FG004|Part 1: 2-Month Oral Run-in Phase|Withdrawal of Consent|0
6371240|NCT02431702|10160932|FG005|Part 1: 2-Month Oral Run-in Phase|Withdrawal of Consent|0
6371241|NCT02431702|10160933|FG006|Part 1: 2-Month Oral Run-in Phase|Withdrawal of Consent|6
6371242|NCT02431702|10160927|FG000|Part 1: 2-Month Oral Run-in Phase|Other|5
6371243|NCT02431702|10160928|FG001|Part 1: 2-Month Oral Run-in Phase|Other|0
6371244|NCT02431702|10160929|FG002|Part 1: 2-Month Oral Run-in Phase|Other|0
6371245|NCT02431702|10160930|FG003|Part 1: 2-Month Oral Run-in Phase|Other|0
6371246|NCT02431702|10160931|FG004|Part 1: 2-Month Oral Run-in Phase|Other|0
6371247|NCT02431702|10160932|FG005|Part 1: 2-Month Oral Run-in Phase|Other|0
6371248|NCT02431702|10160933|FG006|Part 1: 2-Month Oral Run-in Phase|Other|3
6371249|NCT02431702|10160927|FG000|Part 1: 2-Month Oral Run-in Phase|Does not Tolerate Paliperidone ER|2
6371250|NCT02431702|10160928|FG001|Part 1: 2-Month Oral Run-in Phase|Does not Tolerate Paliperidone ER|0
6371251|NCT02431702|10160929|FG002|Part 1: 2-Month Oral Run-in Phase|Does not Tolerate Paliperidone ER|0
6371252|NCT02431702|10160930|FG003|Part 1: 2-Month Oral Run-in Phase|Does not Tolerate Paliperidone ER|0
6371253|NCT02431702|10160931|FG004|Part 1: 2-Month Oral Run-in Phase|Does not Tolerate Paliperidone ER|0
6371254|NCT02431702|10160932|FG005|Part 1: 2-Month Oral Run-in Phase|Does not Tolerate Paliperidone ER|0
6371255|NCT02431702|10160933|FG006|Part 1: 2-Month Oral Run-in Phase|Does not Tolerate Paliperidone ER|0
6371256|NCT02431702|10160927|FG000|Part 2: 9Month Disease Progression Phase|Adverse Event|0
6371257|NCT02431702|10160928|FG001|Part 2: 9Month Disease Progression Phase|Adverse Event|5
6371258|NCT02431702|10160929|FG002|Part 2: 9Month Disease Progression Phase|Adverse Event|1
6371259|NCT02431702|10160930|FG003|Part 2: 9Month Disease Progression Phase|Adverse Event|0
6371260|NCT02431702|10160931|FG004|Part 2: 9Month Disease Progression Phase|Adverse Event|0
6371261|NCT02431702|10160932|FG005|Part 2: 9Month Disease Progression Phase|Adverse Event|0
6371262|NCT02431702|10160933|FG006|Part 2: 9Month Disease Progression Phase|Adverse Event|0
6371263|NCT02431702|10160927|FG000|Part 2: 9Month Disease Progression Phase|Lost to Follow-up|0
6371264|NCT02431702|10160928|FG001|Part 2: 9Month Disease Progression Phase|Lost to Follow-up|6
6371265|NCT02431702|10160929|FG002|Part 2: 9Month Disease Progression Phase|Lost to Follow-up|13
6371266|NCT02431702|10160930|FG003|Part 2: 9Month Disease Progression Phase|Lost to Follow-up|0
6371267|NCT02431702|10160931|FG004|Part 2: 9Month Disease Progression Phase|Lost to Follow-up|0
6371268|NCT02431702|10160932|FG005|Part 2: 9Month Disease Progression Phase|Lost to Follow-up|0
6371269|NCT02431702|10160933|FG006|Part 2: 9Month Disease Progression Phase|Lost to Follow-up|0
6371270|NCT02431702|10160927|FG000|Part 2: 9Month Disease Progression Phase|Withdrawal by Subject|0
6371271|NCT02431702|10160928|FG001|Part 2: 9Month Disease Progression Phase|Withdrawal by Subject|11
6371272|NCT02431702|10160929|FG002|Part 2: 9Month Disease Progression Phase|Withdrawal by Subject|8
6371273|NCT02431702|10160930|FG003|Part 2: 9Month Disease Progression Phase|Withdrawal by Subject|0
6371274|NCT02431702|10160931|FG004|Part 2: 9Month Disease Progression Phase|Withdrawal by Subject|0
6371275|NCT02431702|10160932|FG005|Part 2: 9Month Disease Progression Phase|Withdrawal by Subject|0
6371276|NCT02431702|10160933|FG006|Part 2: 9Month Disease Progression Phase|Withdrawal by Subject|0
6371277|NCT02431702|10160927|FG000|Part 2: 9Month Disease Progression Phase|Assigned PP, but required OAP|0
6371278|NCT02431702|10160928|FG001|Part 2: 9Month Disease Progression Phase|Assigned PP, but required OAP|2
6371279|NCT02431702|10160929|FG002|Part 2: 9Month Disease Progression Phase|Assigned PP, but required OAP|0
6371280|NCT02431702|10160930|FG003|Part 2: 9Month Disease Progression Phase|Assigned PP, but required OAP|0
6371281|NCT02431702|10160931|FG004|Part 2: 9Month Disease Progression Phase|Assigned PP, but required OAP|0
6371282|NCT02431702|10160932|FG005|Part 2: 9Month Disease Progression Phase|Assigned PP, but required OAP|0
6371283|NCT02431702|10160933|FG006|Part 2: 9Month Disease Progression Phase|Assigned PP, but required OAP|0
6371284|NCT02431702|10160927|FG000|Part 2: 9Month Disease Progression Phase|Other|0
6371285|NCT02431702|10160928|FG001|Part 2: 9Month Disease Progression Phase|Other|2
6371286|NCT02431702|10160929|FG002|Part 2: 9Month Disease Progression Phase|Other|2
6371287|NCT02431702|10160930|FG003|Part 2: 9Month Disease Progression Phase|Other|0
6371288|NCT02431702|10160931|FG004|Part 2: 9Month Disease Progression Phase|Other|0
6371289|NCT02431702|10160932|FG005|Part 2: 9Month Disease Progression Phase|Other|0
6371290|NCT02431702|10160933|FG006|Part 2: 9Month Disease Progression Phase|Other|0
6371291|NCT02431702|10160927|FG000|Part 2: 9Month Disease Progression Phase|Assigned OAP, but required PP|0
6371292|NCT02431702|10160928|FG001|Part 2: 9Month Disease Progression Phase|Assigned OAP, but required PP|0
6371293|NCT02431702|10160929|FG002|Part 2: 9Month Disease Progression Phase|Assigned OAP, but required PP|5
6084617|NCT00643565|9693564|FG000|Overall Study|Lost to Follow-up|0
6084618|NCT00643565|9693565|FG001|Overall Study|Lost to Follow-up|6
6084619|NCT00643565|9693564|FG000|Overall Study|Other|7
6084620|NCT00643565|9693565|FG001|Overall Study|Other|8
6084621|NCT00643565|9693564|FG000|Overall Study|Refused Treatment / Did Not Cooperate|0
6084622|NCT00643565|9693565|FG001|Overall Study|Refused Treatment / Did Not Cooperate|1
6084623|NCT00643565|9693564|FG000|Overall Study|Recurrence of Disease|2
6084624|NCT00643565|9693565|FG001|Overall Study|Recurrence of Disease|1
6171760|NCT01261793|9818627|FG001|Overall Study|Outside the study area|2
6171761|NCT01261793|9818628|FG002|Overall Study|Outside the study area|1
6171762|NCT01261793|9818626|FG000|Overall Study|Lack of efficacy & patient not available|0
6171763|NCT01261793|9818627|FG001|Overall Study|Lack of efficacy & patient not available|1
6171764|NCT01261793|9818628|FG002|Overall Study|Lack of efficacy & patient not available|0
6171765|NCT01261793|9818626|FG000|Overall Study|Patient withdrew after cardiology visit|0
6171766|NCT01261793|9818627|FG001|Overall Study|Patient withdrew after cardiology visit|1
6171767|NCT01261793|9818628|FG002|Overall Study|Patient withdrew after cardiology visit|0
6171768|NCT01261793|9818626|FG000|Overall Study|Randomization error|0
6171769|NCT01261793|9818627|FG001|Overall Study|Randomization error|1
6171770|NCT01261793|9818628|FG002|Overall Study|Randomization error|0
6171771|NCT01261793|9818626|FG000|Overall Study|Patient unable to start IV line|0
6171772|NCT01261793|9818627|FG001|Overall Study|Patient unable to start IV line|0
6171773|NCT01261793|9818628|FG002|Overall Study|Patient unable to start IV line|1
6171774|NCT01261975|9818645|FG000|Overall Study|Surgical complication|1
6171775|NCT01262027|9818652|FG000|Overall Study|Adverse Event|1
6171776|NCT01262027|9818652|FG000|Overall Study|Withdrawal by Subject|3
6171777|NCT01262027|9818652|FG000|Overall Study|Protocol Violation|1
6171778|NCT01262092|9818658|FG000|Buprenorphine+Gabapentin/Plac Induction|Lost to Follow-up|2
6171779|NCT01262092|9818659|FG001|Buprenorphine+Gabapentin/Plac Induction|Lost to Follow-up|1
6171780|NCT01262092|9818658|FG000|Buprenorphine+Gabapentin/Plac Induction|Physician Decision|1
6171781|NCT01262092|9818659|FG001|Buprenorphine+Gabapentin/Plac Induction|Physician Decision|0
6171782|NCT01262092|9818658|FG000|Buprenorphine Taper|noncompliance - missed medication|1
6171783|NCT01262092|9818659|FG001|Buprenorphine Taper|noncompliance - missed medication|1
6171784|NCT01262092|9818658|FG000|Gabapentin Taper|noncompliance - missed medications|1
6171785|NCT01262092|9818659|FG001|Gabapentin Taper|noncompliance - missed medications|0
6171786|NCT01262287|9818698|FG000|Overall Study|Lost to Follow-up|2
6171787|NCT01262287|9818699|FG001|Overall Study|Lost to Follow-up|1
6171788|NCT01262352|9818711|FG000|Period 1|Illness after randomization|1
6171789|NCT01262352|9818712|FG001|Period 1|Illness after randomization|0
6171790|NCT01262352|9818711|FG000|Washout|Adverse Event|1
6171791|NCT01262352|9818712|FG001|Washout|Adverse Event|1
6371294|NCT02431702|10160930|FG003|Part 2: 9Month Disease Progression Phase|Assigned OAP, but required PP|0
6371295|NCT02431702|10160931|FG004|Part 2: 9Month Disease Progression Phase|Assigned OAP, but required PP|0
6371296|NCT02431702|10160932|FG005|Part 2: 9Month Disease Progression Phase|Assigned OAP, but required PP|0
6371297|NCT02431702|10160933|FG006|Part 2: 9Month Disease Progression Phase|Assigned OAP, but required PP|0
6371298|NCT02431702|10160927|FG000|Part 3: 9 Month of Additional Treatment|Adverse Event|0
6371299|NCT02431702|10160928|FG001|Part 3: 9 Month of Additional Treatment|Adverse Event|0
6371300|NCT02431702|10160929|FG002|Part 3: 9 Month of Additional Treatment|Adverse Event|0
6371301|NCT02431702|10160930|FG003|Part 3: 9 Month of Additional Treatment|Adverse Event|2
6371302|NCT02431702|10160931|FG004|Part 3: 9 Month of Additional Treatment|Adverse Event|3
6371303|NCT02431702|10160932|FG005|Part 3: 9 Month of Additional Treatment|Adverse Event|0
6371304|NCT02431702|10160933|FG006|Part 3: 9 Month of Additional Treatment|Adverse Event|0
6371305|NCT02431702|10160927|FG000|Part 3: 9 Month of Additional Treatment|Lost to Follow-up|0
6371306|NCT02431702|10160928|FG001|Part 3: 9 Month of Additional Treatment|Lost to Follow-up|0
6371307|NCT02431702|10160929|FG002|Part 3: 9 Month of Additional Treatment|Lost to Follow-up|0
6371308|NCT02431702|10160930|FG003|Part 3: 9 Month of Additional Treatment|Lost to Follow-up|1
6371309|NCT02431702|10160931|FG004|Part 3: 9 Month of Additional Treatment|Lost to Follow-up|0
6371310|NCT02431702|10160932|FG005|Part 3: 9 Month of Additional Treatment|Lost to Follow-up|5
6371311|NCT02431702|10160933|FG006|Part 3: 9 Month of Additional Treatment|Lost to Follow-up|0
6371312|NCT02431702|10160927|FG000|Part 3: 9 Month of Additional Treatment|Withdrawal by Subject|0
6371313|NCT02431702|10160928|FG001|Part 3: 9 Month of Additional Treatment|Withdrawal by Subject|0
6371314|NCT02431702|10160929|FG002|Part 3: 9 Month of Additional Treatment|Withdrawal by Subject|0
6371315|NCT02431702|10160930|FG003|Part 3: 9 Month of Additional Treatment|Withdrawal by Subject|5
6371316|NCT02431702|10160931|FG004|Part 3: 9 Month of Additional Treatment|Withdrawal by Subject|6
6371317|NCT02431702|10160932|FG005|Part 3: 9 Month of Additional Treatment|Withdrawal by Subject|6
6371318|NCT02431702|10160933|FG006|Part 3: 9 Month of Additional Treatment|Withdrawal by Subject|0
6371319|NCT02431702|10160927|FG000|Part 3: 9 Month of Additional Treatment|Other|0
6371320|NCT02431702|10160928|FG001|Part 3: 9 Month of Additional Treatment|Other|0
6371321|NCT02431702|10160929|FG002|Part 3: 9 Month of Additional Treatment|Other|0
6371322|NCT02431702|10160930|FG003|Part 3: 9 Month of Additional Treatment|Other|1
6371323|NCT02431702|10160931|FG004|Part 3: 9 Month of Additional Treatment|Other|1
6371324|NCT02431702|10160932|FG005|Part 3: 9 Month of Additional Treatment|Other|6
6371325|NCT02431702|10160933|FG006|Part 3: 9 Month of Additional Treatment|Other|0
6371326|NCT02200770|10160970|FG000|Randomized-controlled Period (RCP)|Adverse Event|0
6371327|NCT02200770|10160971|FG001|Randomized-controlled Period (RCP)|Adverse Event|2
6371328|NCT02200770|10160970|FG000|Randomized-controlled Period (RCP)|Withdrawal by Subject|1
6371329|NCT02200770|10160971|FG001|Randomized-controlled Period (RCP)|Withdrawal by Subject|1
6371330|NCT02200770|10160970|FG000|Randomized-controlled Period (RCP)|Participants randomized, but not treated|0
6371331|NCT02200770|10160971|FG001|Randomized-controlled Period (RCP)|Participants randomized, but not treated|1
6371332|NCT02200770|10160970|FG000|Randomized-controlled Period (RCP)|Other|1
6371333|NCT02200770|10160971|FG001|Randomized-controlled Period (RCP)|Other|2
6171792|NCT01262352|9818711|FG000|Washout|Extended Washout|0
6371334|NCT02200770|10160970|FG000|Open-label Period (OLP)|Adverse Event|1
6371335|NCT02200770|10160971|FG001|Open-label Period (OLP)|Adverse Event|2
6371336|NCT02200770|10160970|FG000|Open-label Period (OLP)|Death|1
6371337|NCT02200770|10160971|FG001|Open-label Period (OLP)|Death|2
6371338|NCT02200770|10160970|FG000|Open-label Period (OLP)|Lost to Follow-up|0
6371339|NCT02200770|10160971|FG001|Open-label Period (OLP)|Lost to Follow-up|1
6371340|NCT02200770|10160970|FG000|Open-label Period (OLP)|Withdrawal by Subject|0
6371341|NCT02200770|10160971|FG001|Open-label Period (OLP)|Withdrawal by Subject|14
6371342|NCT02200770|10160970|FG000|Open-label Period (OLP)|Other|6
6371343|NCT02200770|10160971|FG001|Open-label Period (OLP)|Other|15
6371344|NCT02136069|10160981|FG000|Overall Study|UC flare-up|1
6371345|NCT02136069|10160982|FG001|Overall Study|UC flare-up|0
6371346|NCT02136069|10160981|FG000|Overall Study|Adverse Event|6
6371347|NCT02136069|10160982|FG001|Overall Study|Adverse Event|8
6371348|NCT02136069|10160981|FG000|Overall Study|Death|0
6371349|NCT02136069|10160982|FG001|Overall Study|Death|1
6371350|NCT02136069|10160981|FG000|Overall Study|Lack of Efficacy|10
6371351|NCT02136069|10160982|FG001|Overall Study|Lack of Efficacy|4
6371352|NCT02136069|10160981|FG000|Overall Study|Lost to Follow-up|1
6371353|NCT02136069|10160982|FG001|Overall Study|Lost to Follow-up|0
6371354|NCT02136069|10160981|FG000|Overall Study|Non-Compliance|1
6371355|NCT02136069|10160982|FG001|Overall Study|Non-Compliance|0
6371356|NCT02136069|10160981|FG000|Overall Study|Physician Decision|5
6371357|NCT02136069|10160982|FG001|Overall Study|Physician Decision|4
6371358|NCT02136069|10160981|FG000|Overall Study|Withdrawal by Subject|10
6371359|NCT02136069|10160982|FG001|Overall Study|Withdrawal by Subject|11
6371360|NCT02086552|10160988|FG000|Overall Study|Withdrawal by Subject|1
6371361|NCT01209767|10160997|FG000|Overall Study|Withdrawal by Subject|1
6371362|NCT01209767|10160997|FG000|Overall Study|Lost to Follow-up|3
6371363|NCT01186848|10161005|FG000|Overall Study|Lost to Follow-up|4
6371364|NCT01186848|10161005|FG000|Overall Study|Withdrawal by Subject|2
6371365|NCT01186848|10161005|FG000|Overall Study|Adverse Event|2
6371366|NCT01024608|10161022|FG000|Overall Study|Adverse Event|1
6371367|NCT01024608|10161023|FG001|Overall Study|Adverse Event|0
6371368|NCT01024608|10161022|FG000|Overall Study|Withdrawal by Subject|1
6371369|NCT01024608|10161023|FG001|Overall Study|Withdrawal by Subject|0
6371370|NCT01024608|10161022|FG000|Overall Study|Lost to Follow-up|0
6371371|NCT01024608|10161023|FG001|Overall Study|Lost to Follow-up|1
6371372|NCT01024608|10161022|FG000|Overall Study|Protocol Violation|0
6371373|NCT01024608|10161023|FG001|Overall Study|Protocol Violation|3
6371374|NCT01024608|10161022|FG000|Overall Study|Never received study treatment|2
6371375|NCT01024608|10161023|FG001|Overall Study|Never received study treatment|0
6371376|NCT00988247|10161031|FG000|Overall Study|Adverse Event|17
6371377|NCT00988247|10161032|FG001|Overall Study|Adverse Event|3
6371378|NCT00988247|10161031|FG000|Overall Study|Withdrawal by Subject|44
6371379|NCT00988247|10161032|FG001|Overall Study|Withdrawal by Subject|13
6371380|NCT00988247|10161031|FG000|Overall Study|Pregnancy|1
6371381|NCT00988247|10161032|FG001|Overall Study|Pregnancy|2
6371382|NCT00988247|10161031|FG000|Overall Study|Lost to Follow-up|11
6371383|NCT00988247|10161032|FG001|Overall Study|Lost to Follow-up|2
6371384|NCT00988247|10161031|FG000|Overall Study|Protocol Violation|4
6371385|NCT00988247|10161032|FG001|Overall Study|Protocol Violation|5
6371386|NCT00988247|10161031|FG000|Overall Study|Sponsor requested withdrawal|3
6371387|NCT00988247|10161032|FG001|Overall Study|Sponsor requested withdrawal|1
6371388|NCT00988247|10161031|FG000|Overall Study|Other|3
6371389|NCT00988247|10161032|FG001|Overall Study|Other|0
6371390|NCT00730639|10161064|FG000|Overall Study|Adverse Event|3
6371391|NCT00730639|10161065|FG001|Overall Study|Adverse Event|0
6371392|NCT00730639|10161066|FG002|Overall Study|Adverse Event|9
6371393|NCT00730639|10161067|FG003|Overall Study|Adverse Event|8
6371394|NCT00730639|10161068|FG004|Overall Study|Adverse Event|23
6371395|NCT00730639|10161064|FG000|Overall Study|Complete Response|0
6371396|NCT00730639|10161065|FG001|Overall Study|Complete Response|0
6371397|NCT00730639|10161066|FG002|Overall Study|Complete Response|2
6371398|NCT00730639|10161067|FG003|Overall Study|Complete Response|2
6371399|NCT00730639|10161068|FG004|Overall Study|Complete Response|1
6084625|NCT00643565|9693564|FG000|Overall Study|Progression of Disease|18
6084626|NCT00643565|9693565|FG001|Overall Study|Progression of Disease|14
6084627|NCT00643565|9693564|FG000|Overall Study|Protocol Violation|3
6084628|NCT00643565|9693565|FG001|Overall Study|Protocol Violation|0
6371400|NCT00730639|10161064|FG000|Overall Study|Completed Maximum Cycles|0
6371401|NCT00730639|10161065|FG001|Overall Study|Completed Maximum Cycles|0
6371402|NCT00730639|10161066|FG002|Overall Study|Completed Maximum Cycles|11
6371403|NCT00730639|10161067|FG003|Overall Study|Completed Maximum Cycles|3
6371404|NCT00730639|10161068|FG004|Overall Study|Completed Maximum Cycles|6
6371405|NCT00730639|10161064|FG000|Overall Study|Death|0
6371406|NCT00730639|10161065|FG001|Overall Study|Death|0
6371407|NCT00730639|10161066|FG002|Overall Study|Death|0
6371408|NCT00730639|10161067|FG003|Overall Study|Death|0
6371409|NCT00730639|10161068|FG004|Overall Study|Death|2
6371410|NCT00730639|10161064|FG000|Overall Study|Disease Progression|12
6371411|NCT00730639|10161065|FG001|Overall Study|Disease Progression|13
6371412|NCT00730639|10161066|FG002|Overall Study|Disease Progression|48
6371413|NCT00730639|10161067|FG003|Overall Study|Disease Progression|32
6371414|NCT00730639|10161068|FG004|Overall Study|Disease Progression|88
6371415|NCT00730639|10161064|FG000|Overall Study|non-specified|0
6371416|NCT00730639|10161065|FG001|Overall Study|non-specified|0
6371417|NCT00730639|10161066|FG002|Overall Study|non-specified|4
6371418|NCT00730639|10161067|FG003|Overall Study|non-specified|2
6371419|NCT00730639|10161068|FG004|Overall Study|non-specified|3
6371420|NCT00730639|10161064|FG000|Overall Study|Protocol Violation|0
6371421|NCT00730639|10161065|FG001|Overall Study|Protocol Violation|0
6371422|NCT00730639|10161066|FG002|Overall Study|Protocol Violation|1
6371423|NCT00730639|10161067|FG003|Overall Study|Protocol Violation|0
6371424|NCT00730639|10161068|FG004|Overall Study|Protocol Violation|0
6371425|NCT00730639|10161064|FG000|Overall Study|Withdrawal by Subject|0
6371426|NCT00730639|10161065|FG001|Overall Study|Withdrawal by Subject|0
6371427|NCT00730639|10161066|FG002|Overall Study|Withdrawal by Subject|6
6371428|NCT00730639|10161067|FG003|Overall Study|Withdrawal by Subject|3
6371429|NCT00730639|10161068|FG004|Overall Study|Withdrawal by Subject|4
6371430|NCT00730639|10161064|FG000|Overall Study|Treatment on-going|2
6371431|NCT00730639|10161065|FG001|Overall Study|Treatment on-going|5
6371432|NCT00730639|10161066|FG002|Overall Study|Treatment on-going|5
6371433|NCT00730639|10161067|FG003|Overall Study|Treatment on-going|4
6371434|NCT00730639|10161068|FG004|Overall Study|Treatment on-going|4
6084629|NCT00643565|9693564|FG000|Overall Study|Did Not Cooperate|0
6084630|NCT00643565|9693565|FG001|Overall Study|Did Not Cooperate|1
6084631|NCT00643565|9693564|FG000|Overall Study|Administrative|22
6084632|NCT00643565|9693565|FG001|Overall Study|Administrative|16
6084633|NCT00643565|9693564|FG000|Overall Study|Adverse Event|5
6371435|NCT04834362|10161106|FG000|Overall Study|Death|1
6371436|NCT04834362|10161107|FG001|Overall Study|Death|2
6371437|NCT04611789|10161133|FG000|Overall Study|Lost to Follow-up|1
6371438|NCT04611789|10161134|FG001|Overall Study|Lost to Follow-up|0
6371439|NCT04611789|10161135|FG002|Overall Study|Lost to Follow-up|0
6371440|NCT04254809|10161198|FG000|Overall Study|Lost to Follow-up|5
6371441|NCT04254809|10161199|FG001|Overall Study|Lost to Follow-up|10
6371442|NCT04230122|10161207|FG000|Overall Study|Lost to Follow-up|1
6371443|NCT04230122|10161208|FG001|Overall Study|Lost to Follow-up|0
6371444|NCT04033068|10161237|FG000|Overall Study|Withdrawal by Subject|0
6371445|NCT04033068|10161238|FG001|Overall Study|Withdrawal by Subject|0
6371446|NCT04033068|10161239|FG002|Overall Study|Withdrawal by Subject|1
6371447|NCT04033068|10161240|FG003|Overall Study|Withdrawal by Subject|0
6371448|NCT04033068|10161237|FG000|Overall Study|Lost to Follow-up|0
6371449|NCT04033068|10161238|FG001|Overall Study|Lost to Follow-up|1
6371450|NCT04033068|10161239|FG002|Overall Study|Lost to Follow-up|0
6371451|NCT04033068|10161240|FG003|Overall Study|Lost to Follow-up|0
6371452|NCT04033068|10161237|FG000|Overall Study|Inclusion / exclusion criteria not fulfilled|0
6371453|NCT04033068|10161238|FG001|Overall Study|Inclusion / exclusion criteria not fulfilled|0
6371454|NCT04033068|10161239|FG002|Overall Study|Inclusion / exclusion criteria not fulfilled|0
6371455|NCT04033068|10161240|FG003|Overall Study|Inclusion / exclusion criteria not fulfilled|1
6371456|NCT03561597|10161250|FG000|Overall Study|Lost to Follow-up|20
6371457|NCT03350984|10161265|FG000|Overall Study|Death|1
6371458|NCT03350984|10161266|FG001|Overall Study|Death|0
6371459|NCT03350984|10161265|FG000|Overall Study|Lost to Follow-up|5
6371460|NCT03350984|10161266|FG001|Overall Study|Lost to Follow-up|6
6371461|NCT03350984|10161265|FG000|Overall Study|Protocol Violation|1
6371462|NCT03350984|10161266|FG001|Overall Study|Protocol Violation|2
6371463|NCT03350984|10161265|FG000|Overall Study|Physician Decision|1
6371464|NCT03350984|10161266|FG001|Overall Study|Physician Decision|0
6371465|NCT03277261|10161274|FG000|Overall Study|Adverse Event|17
6371466|NCT03277261|10161275|FG001|Overall Study|Adverse Event|1
6371467|NCT03277261|10161274|FG000|Overall Study|Participant Withdrawal of Consent|6
6371468|NCT03277261|10161275|FG001|Overall Study|Participant Withdrawal of Consent|15
6371469|NCT03277261|10161274|FG000|Overall Study|Investigator / Sponsor Decision|4
6371470|NCT03277261|10161275|FG001|Overall Study|Investigator / Sponsor Decision|2
6371471|NCT03277261|10161274|FG000|Overall Study|Pregnancy|2
6371472|NCT03277261|10161275|FG001|Overall Study|Pregnancy|0
6371473|NCT03277261|10161274|FG000|Overall Study|Lost to Follow-up|2
6371474|NCT03277261|10161275|FG001|Overall Study|Lost to Follow-up|2
6371475|NCT03277261|10161274|FG000|Overall Study|Lack of Efficacy|2
6371476|NCT03277261|10161275|FG001|Overall Study|Lack of Efficacy|2
6371477|NCT03277261|10161274|FG000|Overall Study|Other-Alternative Treatment/Unspecified Reasons|1
6371478|NCT03277261|10161275|FG001|Overall Study|Other-Alternative Treatment/Unspecified Reasons|1
6371479|NCT03277248|10161284|FG000|Overall Study|Adverse Event|3
6371480|NCT03277248|10161285|FG001|Overall Study|Adverse Event|1
6371481|NCT03277248|10161284|FG000|Overall Study|Subject Withdrawal of Consent|6
6371482|NCT03277248|10161285|FG001|Overall Study|Subject Withdrawal of Consent|23
6371483|NCT03277248|10161284|FG000|Overall Study|Investigator/Sponsor Decision|2
6371484|NCT03277248|10161285|FG001|Overall Study|Investigator/Sponsor Decision|2
6371485|NCT03277248|10161284|FG000|Overall Study|Pregnancy|4
6371486|NCT03277248|10161285|FG001|Overall Study|Pregnancy|1
6371487|NCT03277248|10161284|FG000|Overall Study|Lost to Follow-up|0
6371488|NCT03277248|10161285|FG001|Overall Study|Lost to Follow-up|2
6371489|NCT03277248|10161284|FG000|Overall Study|Lack of Efficacy|0
6084634|NCT00643565|9693565|FG001|Overall Study|Adverse Event|8
6371490|NCT03277248|10161285|FG001|Overall Study|Lack of Efficacy|2
6371491|NCT03277248|10161284|FG000|Overall Study|Other-Alternative Treatment//COVID-19 related/Unspecified Reasons|3
6371492|NCT03277248|10161285|FG001|Overall Study|Other-Alternative Treatment//COVID-19 related/Unspecified Reasons|3
6171793|NCT01262352|9818712|FG001|Washout|Extended Washout|1
6171794|NCT01262365|9818721|FG000|Overall Study|Lack of Efficacy|35
6171795|NCT01262365|9818722|FG001|Overall Study|Lack of Efficacy|30
6171796|NCT01262365|9818723|FG002|Overall Study|Lack of Efficacy|47
6171797|NCT01262365|9818721|FG000|Overall Study|Protocol Violation|3
6171798|NCT01262365|9818722|FG001|Overall Study|Protocol Violation|1
6171799|NCT01262365|9818723|FG002|Overall Study|Protocol Violation|1
6171800|NCT01262365|9818721|FG000|Overall Study|Lost to Follow-up|3
6171801|NCT01262365|9818722|FG001|Overall Study|Lost to Follow-up|7
6171802|NCT01262365|9818723|FG002|Overall Study|Lost to Follow-up|6
6171803|NCT01262365|9818721|FG000|Overall Study|Withdrawal by Subject|17
6171804|NCT01262365|9818722|FG001|Overall Study|Withdrawal by Subject|22
6171805|NCT01262365|9818723|FG002|Overall Study|Withdrawal by Subject|22
6171806|NCT01262365|9818721|FG000|Overall Study|Death|1
6171807|NCT01262365|9818722|FG001|Overall Study|Death|2
6171808|NCT01262365|9818723|FG002|Overall Study|Death|1
6171809|NCT01262365|9818721|FG000|Overall Study|Adverse Event|26
6171810|NCT01262365|9818722|FG001|Overall Study|Adverse Event|16
6171811|NCT01262365|9818723|FG002|Overall Study|Adverse Event|11
6171812|NCT01262365|9818721|FG000|Overall Study|sponsor decision|1
6171813|NCT01262365|9818722|FG001|Overall Study|sponsor decision|1
6371493|NCT03179462|10161294|FG000|Overall Study|screening failure|1
6371494|NCT03179462|10161295|FG001|Overall Study|screening failure|2
6371495|NCT03179462|10161296|FG002|Overall Study|screening failure|0
6371496|NCT03099707|10161306|FG000|Overall Study|Withdrawal by Subject|0
6371497|NCT03099707|10161307|FG001|Overall Study|Withdrawal by Subject|3
6371498|NCT03099707|10161306|FG000|Overall Study|Lost to Follow-up|0
6371499|NCT03099707|10161307|FG001|Overall Study|Lost to Follow-up|1
6371500|NCT03064763|10161313|FG000|Overall Study|Ongoing in study|10
6371501|NCT03064763|10161313|FG000|Overall Study|Death|8
6371502|NCT02906033|10161338|FG000|Baseline|Protocol Violation|37
6371503|NCT02906033|10161339|FG001|Baseline|Protocol Violation|33
6371504|NCT02906033|10161338|FG000|Follow-up|Lost to Follow-up|46
6371505|NCT02906033|10161339|FG001|Follow-up|Lost to Follow-up|62
6371506|NCT02837783|10161347|FG000|Overall Study|Adverse Event|1
6371507|NCT02837783|10161348|FG001|Overall Study|Adverse Event|0
6371508|NCT02837783|10161347|FG000|Overall Study|Other, Not Specified|1
6171814|NCT01262365|9818723|FG002|Overall Study|sponsor decision|0
6171815|NCT01262365|9818721|FG000|Overall Study|Randomization error|1
6171816|NCT01262365|9818722|FG001|Overall Study|Randomization error|0
6371509|NCT02837783|10161348|FG001|Overall Study|Other, Not Specified|2
6371510|NCT02786537|10161360|FG000|As Randomized|Adverse Event|0
6371511|NCT02786537|10161361|FG001|As Randomized|Adverse Event|11
6371512|NCT02786537|10161362|FG002|As Randomized|Adverse Event|0
6171817|NCT01262365|9818723|FG002|Overall Study|Randomization error|2
6171818|NCT01262365|9818721|FG000|Overall Study|Non-compliance|1
6371513|NCT02786537|10161363|FG003|As Randomized|Adverse Event|4
6171819|NCT01262365|9818722|FG001|Overall Study|Non-compliance|0
6171820|NCT01262365|9818723|FG002|Overall Study|Non-compliance|2
6171821|NCT01262365|9818721|FG000|Overall Study|Suspected pregnancy|1
6171822|NCT01262365|9818722|FG001|Overall Study|Suspected pregnancy|0
6171823|NCT01262365|9818723|FG002|Overall Study|Suspected pregnancy|0
6171824|NCT01262365|9818721|FG000|Overall Study|Patient pregnant|1
6171825|NCT01262365|9818722|FG001|Overall Study|Patient pregnant|0
6171826|NCT01262365|9818723|FG002|Overall Study|Patient pregnant|1
6171827|NCT01262365|9818721|FG000|Overall Study|Toxicity related to study drug|0
6171828|NCT01262365|9818722|FG001|Overall Study|Toxicity related to study drug|1
6171829|NCT01262365|9818723|FG002|Overall Study|Toxicity related to study drug|0
6171830|NCT01262365|9818721|FG000|Overall Study|Cannot tolerate the protocol|0
6171831|NCT01262365|9818722|FG001|Overall Study|Cannot tolerate the protocol|1
6171832|NCT01262365|9818723|FG002|Overall Study|Cannot tolerate the protocol|0
6171833|NCT01262365|9818721|FG000|Overall Study|Patient unavailable|0
6171834|NCT01262365|9818722|FG001|Overall Study|Patient unavailable|0
6171835|NCT01262365|9818723|FG002|Overall Study|Patient unavailable|1
6171836|NCT01262456|9818734|FG000|3-Month Double-Blind Period|Withdrawal by Subject|6
6171837|NCT01262456|9818735|FG001|3-Month Double-Blind Period|Withdrawal by Subject|8
6171838|NCT01262456|9818736|FG002|3-Month Double-Blind Period|Withdrawal by Subject|9
6171839|NCT01262456|9818734|FG000|3-Month Double-Blind Period|Lost to Follow-up|4
6171840|NCT01262456|9818735|FG001|3-Month Double-Blind Period|Lost to Follow-up|5
6171841|NCT01262456|9818736|FG002|3-Month Double-Blind Period|Lost to Follow-up|3
6171842|NCT01262456|9818734|FG000|3-Month Double-Blind Period|Adverse Event|6
6171843|NCT01262456|9818735|FG001|3-Month Double-Blind Period|Adverse Event|4
6171844|NCT01262456|9818736|FG002|3-Month Double-Blind Period|Adverse Event|8
6171845|NCT01262456|9818734|FG000|3-Month Double-Blind Period|Protocol Violation|3
6171846|NCT01262456|9818735|FG001|3-Month Double-Blind Period|Protocol Violation|6
6171847|NCT01262456|9818736|FG002|3-Month Double-Blind Period|Protocol Violation|6
6171848|NCT01262456|9818734|FG000|1-Month Open-Label Extension Period|Withdrawal by Subject|1
6171849|NCT01262456|9818735|FG001|1-Month Open-Label Extension Period|Withdrawal by Subject|1
6171850|NCT01262456|9818736|FG002|1-Month Open-Label Extension Period|Withdrawal by Subject|1
6171851|NCT01262456|9818734|FG000|1-Month Open-Label Extension Period|Lost to Follow-up|0
6371514|NCT02786537|10161364|FG004|As Randomized|Adverse Event|6
6371515|NCT02786537|10161365|FG005|As Randomized|Adverse Event|2
6371516|NCT02786537|10161360|FG000|As Randomized|Lack of Efficacy|0
6371517|NCT02786537|10161361|FG001|As Randomized|Lack of Efficacy|0
6371518|NCT02786537|10161362|FG002|As Randomized|Lack of Efficacy|0
6371519|NCT02786537|10161363|FG003|As Randomized|Lack of Efficacy|1
6371520|NCT02786537|10161364|FG004|As Randomized|Lack of Efficacy|0
6371521|NCT02786537|10161365|FG005|As Randomized|Lack of Efficacy|0
6371522|NCT02786537|10161360|FG000|As Randomized|Withdrawal by Subject|1
6371523|NCT02786537|10161361|FG001|As Randomized|Withdrawal by Subject|2
6371524|NCT02786537|10161362|FG002|As Randomized|Withdrawal by Subject|0
6371525|NCT02786537|10161363|FG003|As Randomized|Withdrawal by Subject|1
6371526|NCT02786537|10161364|FG004|As Randomized|Withdrawal by Subject|1
6371527|NCT02786537|10161365|FG005|As Randomized|Withdrawal by Subject|0
6371528|NCT02786537|10161360|FG000|As Randomized|Death|0
6371529|NCT02786537|10161361|FG001|As Randomized|Death|2
6371530|NCT02786537|10161362|FG002|As Randomized|Death|0
6371531|NCT02786537|10161363|FG003|As Randomized|Death|3
6371532|NCT02786537|10161364|FG004|As Randomized|Death|1
6371533|NCT02786537|10161365|FG005|As Randomized|Death|0
6371534|NCT02786537|10161360|FG000|As Randomized|Non-compliance with study drug|1
6371535|NCT02786537|10161361|FG001|As Randomized|Non-compliance with study drug|11
6371536|NCT02786537|10161362|FG002|As Randomized|Non-compliance with study drug|0
6371537|NCT02786537|10161363|FG003|As Randomized|Non-compliance with study drug|1
6371538|NCT02786537|10161364|FG004|As Randomized|Non-compliance with study drug|0
6371539|NCT02786537|10161365|FG005|As Randomized|Non-compliance with study drug|1
6371540|NCT02786537|10161360|FG000|As Randomized|Lost to treatment follow-up|4
6371541|NCT02786537|10161361|FG001|As Randomized|Lost to treatment follow-up|32
6371542|NCT02786537|10161362|FG002|As Randomized|Lost to treatment follow-up|0
6371543|NCT02786537|10161363|FG003|As Randomized|Lost to treatment follow-up|24
6371544|NCT02786537|10161364|FG004|As Randomized|Lost to treatment follow-up|4
6371545|NCT02786537|10161365|FG005|As Randomized|Lost to treatment follow-up|4
6371546|NCT02786537|10161360|FG000|As Randomized|Incarceration|0
6371547|NCT02786537|10161361|FG001|As Randomized|Incarceration|1
6171852|NCT01262456|9818735|FG001|1-Month Open-Label Extension Period|Lost to Follow-up|1
6171853|NCT01262456|9818736|FG002|1-Month Open-Label Extension Period|Lost to Follow-up|0
6171854|NCT01262456|9818734|FG000|1-Month Open-Label Extension Period|Adverse Event|2
6171855|NCT01262456|9818735|FG001|1-Month Open-Label Extension Period|Adverse Event|0
6171856|NCT01262456|9818736|FG002|1-Month Open-Label Extension Period|Adverse Event|2
6171857|NCT01262456|9818734|FG000|1-Month Open-Label Extension Period|Protocol Violation|1
6371548|NCT02786537|10161362|FG002|As Randomized|Incarceration|0
6371549|NCT02786537|10161363|FG003|As Randomized|Incarceration|0
6371550|NCT02786537|10161364|FG004|As Randomized|Incarceration|0
6371551|NCT02786537|10161365|FG005|As Randomized|Incarceration|0
6371552|NCT02786537|10161360|FG000|As Randomized|Opiate Dependency Relapse|0
6371553|NCT02786537|10161361|FG001|As Randomized|Opiate Dependency Relapse|1
6371554|NCT02786537|10161362|FG002|As Randomized|Opiate Dependency Relapse|0
6371555|NCT02786537|10161363|FG003|As Randomized|Opiate Dependency Relapse|0
6371556|NCT02786537|10161364|FG004|As Randomized|Opiate Dependency Relapse|0
6371557|NCT02786537|10161365|FG005|As Randomized|Opiate Dependency Relapse|0
6371558|NCT02786537|10161360|FG000|As Randomized|HCV drugs stolen from pt|0
6371559|NCT02786537|10161361|FG001|As Randomized|HCV drugs stolen from pt|1
6371560|NCT02786537|10161362|FG002|As Randomized|HCV drugs stolen from pt|0
6371561|NCT02786537|10161363|FG003|As Randomized|HCV drugs stolen from pt|0
6371562|NCT02786537|10161364|FG004|As Randomized|HCV drugs stolen from pt|0
6371563|NCT02786537|10161365|FG005|As Randomized|HCV drugs stolen from pt|0
6371564|NCT02786537|10161360|FG000|As Randomized|Advised to stop after lapse in dosing|0
6371565|NCT02786537|10161361|FG001|As Randomized|Advised to stop after lapse in dosing|1
6371566|NCT02786537|10161362|FG002|As Randomized|Advised to stop after lapse in dosing|0
6371567|NCT02786537|10161363|FG003|As Randomized|Advised to stop after lapse in dosing|0
6371568|NCT02786537|10161364|FG004|As Randomized|Advised to stop after lapse in dosing|0
6371569|NCT02786537|10161365|FG005|As Randomized|Advised to stop after lapse in dosing|0
6371570|NCT02786537|10161360|FG000|As Randomized|Subject lost insurance|0
6371571|NCT02786537|10161361|FG001|As Randomized|Subject lost insurance|0
6371572|NCT02786537|10161362|FG002|As Randomized|Subject lost insurance|0
6371573|NCT02786537|10161363|FG003|As Randomized|Subject lost insurance|1
6371574|NCT02786537|10161364|FG004|As Randomized|Subject lost insurance|0
6371575|NCT02786537|10161365|FG005|As Randomized|Subject lost insurance|0
6371576|NCT02786537|10161360|FG000|As Treated|Adverse Event|0
6371577|NCT02786537|10161361|FG001|As Treated|Adverse Event|11
6371578|NCT02786537|10161362|FG002|As Treated|Adverse Event|0
6371579|NCT02786537|10161363|FG003|As Treated|Adverse Event|4
6371580|NCT02786537|10161364|FG004|As Treated|Adverse Event|6
6371581|NCT02786537|10161365|FG005|As Treated|Adverse Event|2
6371582|NCT02786537|10161360|FG000|As Treated|Death|0
6371583|NCT02786537|10161361|FG001|As Treated|Death|2
6371584|NCT02786537|10161362|FG002|As Treated|Death|0
6371585|NCT02786537|10161363|FG003|As Treated|Death|3
6371586|NCT02786537|10161364|FG004|As Treated|Death|1
6371587|NCT02786537|10161365|FG005|As Treated|Death|0
6371588|NCT02786537|10161360|FG000|As Treated|Lack of Efficacy|0
6371589|NCT02786537|10161361|FG001|As Treated|Lack of Efficacy|0
6371590|NCT02786537|10161362|FG002|As Treated|Lack of Efficacy|0
6371591|NCT02786537|10161363|FG003|As Treated|Lack of Efficacy|1
6371592|NCT02786537|10161364|FG004|As Treated|Lack of Efficacy|0
6371593|NCT02786537|10161365|FG005|As Treated|Lack of Efficacy|0
6371594|NCT02786537|10161360|FG000|As Treated|Lost to Follow-up|4
6371595|NCT02786537|10161361|FG001|As Treated|Lost to Follow-up|32
6371596|NCT02786537|10161362|FG002|As Treated|Lost to Follow-up|0
6371597|NCT02786537|10161363|FG003|As Treated|Lost to Follow-up|25
6371598|NCT02786537|10161364|FG004|As Treated|Lost to Follow-up|4
6371599|NCT02786537|10161365|FG005|As Treated|Lost to Follow-up|4
6371600|NCT02786537|10161360|FG000|As Treated|Non-compliance with study drug|1
6371601|NCT02786537|10161361|FG001|As Treated|Non-compliance with study drug|11
6371602|NCT02786537|10161362|FG002|As Treated|Non-compliance with study drug|0
6371603|NCT02786537|10161363|FG003|As Treated|Non-compliance with study drug|1
6371604|NCT02786537|10161364|FG004|As Treated|Non-compliance with study drug|0
6371605|NCT02786537|10161365|FG005|As Treated|Non-compliance with study drug|1
6371606|NCT02786537|10161360|FG000|As Treated|Lost insurance|0
6371607|NCT02786537|10161361|FG001|As Treated|Lost insurance|0
6371608|NCT02786537|10161362|FG002|As Treated|Lost insurance|0
6371609|NCT02786537|10161363|FG003|As Treated|Lost insurance|1
6371610|NCT02786537|10161364|FG004|As Treated|Lost insurance|0
6371611|NCT02786537|10161365|FG005|As Treated|Lost insurance|0
6371612|NCT02786537|10161360|FG000|As Treated|Withdrawal by Subject|1
6371613|NCT02786537|10161361|FG001|As Treated|Withdrawal by Subject|2
6371614|NCT02786537|10161362|FG002|As Treated|Withdrawal by Subject|0
6371615|NCT02786537|10161363|FG003|As Treated|Withdrawal by Subject|0
6371616|NCT02786537|10161364|FG004|As Treated|Withdrawal by Subject|1
6371617|NCT02786537|10161365|FG005|As Treated|Withdrawal by Subject|0
6371618|NCT02786537|10161360|FG000|As Treated|Incarceration|0
6371619|NCT02786537|10161361|FG001|As Treated|Incarceration|1
6371620|NCT02786537|10161362|FG002|As Treated|Incarceration|0
6371621|NCT02786537|10161363|FG003|As Treated|Incarceration|0
6371622|NCT02786537|10161364|FG004|As Treated|Incarceration|0
6371623|NCT02786537|10161365|FG005|As Treated|Incarceration|0
6371624|NCT02786537|10161360|FG000|As Treated|Opiate dependency relapse|0
6371625|NCT02786537|10161361|FG001|As Treated|Opiate dependency relapse|1
6371626|NCT02786537|10161362|FG002|As Treated|Opiate dependency relapse|0
6371627|NCT02786537|10161363|FG003|As Treated|Opiate dependency relapse|0
6371628|NCT02786537|10161364|FG004|As Treated|Opiate dependency relapse|0
6371629|NCT02786537|10161365|FG005|As Treated|Opiate dependency relapse|0
6371630|NCT02786537|10161360|FG000|As Treated|Drugs stolen from patient|0
6371631|NCT02786537|10161361|FG001|As Treated|Drugs stolen from patient|1
6371632|NCT02786537|10161362|FG002|As Treated|Drugs stolen from patient|0
6371633|NCT02786537|10161363|FG003|As Treated|Drugs stolen from patient|0
6371634|NCT02786537|10161364|FG004|As Treated|Drugs stolen from patient|0
6371635|NCT02786537|10161365|FG005|As Treated|Drugs stolen from patient|0
6371636|NCT02786537|10161360|FG000|As Treated|Advised to stop tx after loss of meds|0
6371637|NCT02786537|10161361|FG001|As Treated|Advised to stop tx after loss of meds|1
6371638|NCT02786537|10161362|FG002|As Treated|Advised to stop tx after loss of meds|0
6371639|NCT02786537|10161363|FG003|As Treated|Advised to stop tx after loss of meds|0
6371640|NCT02786537|10161364|FG004|As Treated|Advised to stop tx after loss of meds|0
6371641|NCT02786537|10161365|FG005|As Treated|Advised to stop tx after loss of meds|0
6371642|NCT02740231|10161475|FG000|Overall Study|Withdrawal by Subject|1
6371643|NCT02740231|10161476|FG001|Overall Study|Withdrawal by Subject|1
6371644|NCT02740231|10161477|FG002|Overall Study|Withdrawal by Subject|1
6371645|NCT02740231|10161478|FG003|Overall Study|Withdrawal by Subject|0
6371646|NCT02740231|10161475|FG000|Overall Study|Lack of Efficacy|0
6371647|NCT02740231|10161476|FG001|Overall Study|Lack of Efficacy|1
6371648|NCT02740231|10161477|FG002|Overall Study|Lack of Efficacy|0
6371649|NCT02740231|10161478|FG003|Overall Study|Lack of Efficacy|4
6371650|NCT02740231|10161475|FG000|Overall Study|Lost to Follow-up|1
6371651|NCT02740231|10161476|FG001|Overall Study|Lost to Follow-up|3
6371652|NCT02740231|10161477|FG002|Overall Study|Lost to Follow-up|0
6371653|NCT02740231|10161478|FG003|Overall Study|Lost to Follow-up|3
6371654|NCT02740231|10161475|FG000|Overall Study|Adverse Event|0
6371655|NCT02740231|10161476|FG001|Overall Study|Adverse Event|1
6371656|NCT02740231|10161477|FG002|Overall Study|Adverse Event|0
6371657|NCT02740231|10161478|FG003|Overall Study|Adverse Event|1
6371658|NCT02710084|10161490|FG000|First Phase - 12 Weeks|Withdrawal by Subject|3
6371659|NCT02710084|10161491|FG001|First Phase - 12 Weeks|Withdrawal by Subject|1
6371660|NCT02660034|10161512|FG000|Overall Study|Progressive Disease (Radiographic)|3
6371661|NCT02660034|10161513|FG001|Overall Study|Progressive Disease (Radiographic)|1
6371662|NCT02660034|10161514|FG002|Overall Study|Progressive Disease (Radiographic)|0
6371663|NCT02660034|10161515|FG003|Overall Study|Progressive Disease (Radiographic)|1
6371664|NCT02660034|10161516|FG004|Overall Study|Progressive Disease (Radiographic)|0
6371665|NCT02660034|10161517|FG005|Overall Study|Progressive Disease (Radiographic)|0
6371666|NCT02660034|10161518|FG006|Overall Study|Progressive Disease (Radiographic)|0
6371667|NCT02660034|10161519|FG007|Overall Study|Progressive Disease (Radiographic)|0
6371668|NCT02660034|10161520|FG008|Overall Study|Progressive Disease (Radiographic)|0
6371669|NCT02660034|10161521|FG009|Overall Study|Progressive Disease (Radiographic)|0
6371670|NCT02660034|10161522|FG010|Overall Study|Progressive Disease (Radiographic)|0
6371671|NCT02660034|10161523|FG011|Overall Study|Progressive Disease (Radiographic)|0
6371672|NCT02660034|10161524|FG012|Overall Study|Progressive Disease (Radiographic)|0
6371673|NCT02660034|10161525|FG013|Overall Study|Progressive Disease (Radiographic)|0
6371674|NCT02660034|10161512|FG000|Overall Study|Progressive Disease (Clinical)|7
6371675|NCT02660034|10161513|FG001|Overall Study|Progressive Disease (Clinical)|8
6371676|NCT02660034|10161514|FG002|Overall Study|Progressive Disease (Clinical)|3
6371677|NCT02660034|10161515|FG003|Overall Study|Progressive Disease (Clinical)|9
6371678|NCT02660034|10161516|FG004|Overall Study|Progressive Disease (Clinical)|3
6371679|NCT02660034|10161517|FG005|Overall Study|Progressive Disease (Clinical)|0
6371680|NCT02660034|10161518|FG006|Overall Study|Progressive Disease (Clinical)|0
6371681|NCT02660034|10161519|FG007|Overall Study|Progressive Disease (Clinical)|0
6371682|NCT02660034|10161520|FG008|Overall Study|Progressive Disease (Clinical)|0
6371683|NCT02660034|10161521|FG009|Overall Study|Progressive Disease (Clinical)|0
6371684|NCT02660034|10161522|FG010|Overall Study|Progressive Disease (Clinical)|0
6371685|NCT02660034|10161523|FG011|Overall Study|Progressive Disease (Clinical)|0
6371686|NCT02660034|10161524|FG012|Overall Study|Progressive Disease (Clinical)|0
6371687|NCT02660034|10161525|FG013|Overall Study|Progressive Disease (Clinical)|0
6371688|NCT02660034|10161512|FG000|Overall Study|Lost to Follow-up|0
6371689|NCT02660034|10161513|FG001|Overall Study|Lost to Follow-up|0
6371690|NCT02660034|10161514|FG002|Overall Study|Lost to Follow-up|1
6371691|NCT02660034|10161515|FG003|Overall Study|Lost to Follow-up|1
6371692|NCT02660034|10161516|FG004|Overall Study|Lost to Follow-up|0
6371693|NCT02660034|10161517|FG005|Overall Study|Lost to Follow-up|0
6371694|NCT02660034|10161518|FG006|Overall Study|Lost to Follow-up|0
6371695|NCT02660034|10161519|FG007|Overall Study|Lost to Follow-up|0
6371696|NCT02660034|10161520|FG008|Overall Study|Lost to Follow-up|0
6371697|NCT02660034|10161521|FG009|Overall Study|Lost to Follow-up|1
6371698|NCT02660034|10161522|FG010|Overall Study|Lost to Follow-up|1
6371699|NCT02660034|10161523|FG011|Overall Study|Lost to Follow-up|1
6371700|NCT02660034|10161524|FG012|Overall Study|Lost to Follow-up|0
6371701|NCT02660034|10161525|FG013|Overall Study|Lost to Follow-up|0
6371702|NCT02660034|10161512|FG000|Overall Study|Participant moved into special access scheme|1
6371703|NCT02660034|10161513|FG001|Overall Study|Participant moved into special access scheme|2
6371704|NCT02660034|10161514|FG002|Overall Study|Participant moved into special access scheme|0
6371705|NCT02660034|10161515|FG003|Overall Study|Participant moved into special access scheme|0
6371706|NCT02660034|10161516|FG004|Overall Study|Participant moved into special access scheme|0
6371707|NCT02660034|10161517|FG005|Overall Study|Participant moved into special access scheme|0
6371708|NCT02660034|10161518|FG006|Overall Study|Participant moved into special access scheme|0
6371709|NCT02660034|10161519|FG007|Overall Study|Participant moved into special access scheme|0
6371710|NCT02660034|10161520|FG008|Overall Study|Participant moved into special access scheme|0
6371711|NCT02660034|10161521|FG009|Overall Study|Participant moved into special access scheme|0
6371712|NCT02660034|10161522|FG010|Overall Study|Participant moved into special access scheme|0
6371713|NCT02660034|10161523|FG011|Overall Study|Participant moved into special access scheme|0
6371714|NCT02660034|10161524|FG012|Overall Study|Participant moved into special access scheme|0
6371715|NCT02660034|10161525|FG013|Overall Study|Participant moved into special access scheme|0
6371716|NCT02660034|10161512|FG000|Overall Study|Adverse Event|1
6371717|NCT02660034|10161513|FG001|Overall Study|Adverse Event|0
6371718|NCT02660034|10161514|FG002|Overall Study|Adverse Event|0
6371719|NCT02660034|10161515|FG003|Overall Study|Adverse Event|0
6371720|NCT02660034|10161516|FG004|Overall Study|Adverse Event|0
6371721|NCT02660034|10161517|FG005|Overall Study|Adverse Event|0
6371722|NCT02660034|10161518|FG006|Overall Study|Adverse Event|0
6371723|NCT02660034|10161519|FG007|Overall Study|Adverse Event|0
6371724|NCT02660034|10161520|FG008|Overall Study|Adverse Event|0
6371725|NCT02660034|10161521|FG009|Overall Study|Adverse Event|0
6371726|NCT02660034|10161522|FG010|Overall Study|Adverse Event|0
6371727|NCT02660034|10161523|FG011|Overall Study|Adverse Event|0
6371728|NCT02660034|10161524|FG012|Overall Study|Adverse Event|0
6371729|NCT02660034|10161525|FG013|Overall Study|Adverse Event|0
6371730|NCT02660034|10161512|FG000|Overall Study|Sponsor Decision|0
6371731|NCT02660034|10161513|FG001|Overall Study|Sponsor Decision|1
6371732|NCT02660034|10161514|FG002|Overall Study|Sponsor Decision|2
6371733|NCT02660034|10161515|FG003|Overall Study|Sponsor Decision|2
6371734|NCT02660034|10161516|FG004|Overall Study|Sponsor Decision|3
6371735|NCT02660034|10161517|FG005|Overall Study|Sponsor Decision|0
6371736|NCT02660034|10161518|FG006|Overall Study|Sponsor Decision|0
6371737|NCT02660034|10161519|FG007|Overall Study|Sponsor Decision|0
6371738|NCT02660034|10161520|FG008|Overall Study|Sponsor Decision|0
6371739|NCT02660034|10161521|FG009|Overall Study|Sponsor Decision|0
6371740|NCT02660034|10161522|FG010|Overall Study|Sponsor Decision|0
6371741|NCT02660034|10161523|FG011|Overall Study|Sponsor Decision|0
6371742|NCT02660034|10161524|FG012|Overall Study|Sponsor Decision|0
6371743|NCT02660034|10161525|FG013|Overall Study|Sponsor Decision|1
6371744|NCT02660034|10161512|FG000|Overall Study|Withdrawal by Subject|0
6371745|NCT02660034|10161513|FG001|Overall Study|Withdrawal by Subject|0
6371746|NCT02660034|10161514|FG002|Overall Study|Withdrawal by Subject|0
6371747|NCT02660034|10161515|FG003|Overall Study|Withdrawal by Subject|0
6371748|NCT02660034|10161516|FG004|Overall Study|Withdrawal by Subject|0
6371749|NCT02660034|10161517|FG005|Overall Study|Withdrawal by Subject|0
6371750|NCT02660034|10161518|FG006|Overall Study|Withdrawal by Subject|1
6371751|NCT02660034|10161519|FG007|Overall Study|Withdrawal by Subject|1
6371752|NCT02660034|10161520|FG008|Overall Study|Withdrawal by Subject|1
6371753|NCT02660034|10161521|FG009|Overall Study|Withdrawal by Subject|0
6371754|NCT02660034|10161522|FG010|Overall Study|Withdrawal by Subject|0
6371755|NCT02660034|10161523|FG011|Overall Study|Withdrawal by Subject|1
6371756|NCT02660034|10161524|FG012|Overall Study|Withdrawal by Subject|2
6371757|NCT02660034|10161525|FG013|Overall Study|Withdrawal by Subject|0
6371758|NCT02660034|10161512|FG000|Overall Study|Death|0
6371759|NCT02660034|10161513|FG001|Overall Study|Death|0
6371760|NCT02660034|10161514|FG002|Overall Study|Death|0
6371761|NCT02660034|10161515|FG003|Overall Study|Death|0
6371762|NCT02660034|10161516|FG004|Overall Study|Death|0
6371763|NCT02660034|10161517|FG005|Overall Study|Death|13
6371764|NCT02660034|10161518|FG006|Overall Study|Death|14
6371765|NCT02660034|10161519|FG007|Overall Study|Death|10
6371766|NCT02660034|10161520|FG008|Overall Study|Death|9
6371767|NCT02660034|10161521|FG009|Overall Study|Death|21
6371768|NCT02660034|10161522|FG010|Overall Study|Death|17
6371769|NCT02660034|10161523|FG011|Overall Study|Death|15
6371770|NCT02660034|10161524|FG012|Overall Study|Death|18
6371771|NCT02660034|10161525|FG013|Overall Study|Death|7
6371772|NCT02660034|10161512|FG000|Overall Study|Physician Decision|0
6371773|NCT02660034|10161513|FG001|Overall Study|Physician Decision|0
6371774|NCT02660034|10161514|FG002|Overall Study|Physician Decision|0
6371775|NCT02660034|10161515|FG003|Overall Study|Physician Decision|0
6371776|NCT02660034|10161516|FG004|Overall Study|Physician Decision|0
6371777|NCT02660034|10161517|FG005|Overall Study|Physician Decision|0
6371778|NCT02660034|10161518|FG006|Overall Study|Physician Decision|0
6371779|NCT02660034|10161519|FG007|Overall Study|Physician Decision|0
6371780|NCT02660034|10161520|FG008|Overall Study|Physician Decision|0
6371781|NCT02660034|10161521|FG009|Overall Study|Physician Decision|0
6371782|NCT02660034|10161522|FG010|Overall Study|Physician Decision|0
6371783|NCT02660034|10161523|FG011|Overall Study|Physician Decision|0
6371784|NCT02660034|10161524|FG012|Overall Study|Physician Decision|0
6371785|NCT02660034|10161525|FG013|Overall Study|Physician Decision|1
6371786|NCT02660034|10161512|FG000|Overall Study|Participants transferred to LTE|0
6371787|NCT02660034|10161513|FG001|Overall Study|Participants transferred to LTE|0
6371788|NCT02660034|10161514|FG002|Overall Study|Participants transferred to LTE|0
6371789|NCT02660034|10161515|FG003|Overall Study|Participants transferred to LTE|0
6371790|NCT02660034|10161516|FG004|Overall Study|Participants transferred to LTE|0
6371791|NCT02660034|10161517|FG005|Overall Study|Participants transferred to LTE|10
6371792|NCT02660034|10161518|FG006|Overall Study|Participants transferred to LTE|8
6371793|NCT02660034|10161519|FG007|Overall Study|Participants transferred to LTE|8
6371794|NCT02660034|10161520|FG008|Overall Study|Participants transferred to LTE|10
6371795|NCT02660034|10161521|FG009|Overall Study|Participants transferred to LTE|1
6371796|NCT02660034|10161522|FG010|Overall Study|Participants transferred to LTE|2
6371797|NCT02660034|10161523|FG011|Overall Study|Participants transferred to LTE|4
6371798|NCT02660034|10161524|FG012|Overall Study|Participants transferred to LTE|1
6371799|NCT02660034|10161525|FG013|Overall Study|Participants transferred to LTE|1
6371800|NCT02640625|10161559|FG000|Overall Study|Adverse Event|1
6371801|NCT02561962|10161573|FG000|Overall Study|Ongoing in study|1
6371802|NCT02561962|10161574|FG001|Overall Study|Ongoing in study|0
6371803|NCT02561962|10161575|FG002|Overall Study|Ongoing in study|0
6371804|NCT02561962|10161576|FG003|Overall Study|Ongoing in study|1
6371805|NCT02561962|10161577|FG004|Overall Study|Ongoing in study|0
6371806|NCT02561962|10161578|FG005|Overall Study|Ongoing in study|1
6371807|NCT02561962|10161579|FG006|Overall Study|Ongoing in study|0
6371808|NCT02561962|10161580|FG007|Overall Study|Ongoing in study|4
6371809|NCT02561962|10161581|FG008|Overall Study|Ongoing in study|1
6371810|NCT02561962|10161573|FG000|Overall Study|Withdrawal by Subject|1
6371811|NCT02561962|10161574|FG001|Overall Study|Withdrawal by Subject|0
6371812|NCT02561962|10161575|FG002|Overall Study|Withdrawal by Subject|0
6371813|NCT02561962|10161576|FG003|Overall Study|Withdrawal by Subject|0
6371814|NCT02561962|10161577|FG004|Overall Study|Withdrawal by Subject|1
6371815|NCT02561962|10161578|FG005|Overall Study|Withdrawal by Subject|1
6371816|NCT02561962|10161579|FG006|Overall Study|Withdrawal by Subject|2
6371817|NCT02561962|10161580|FG007|Overall Study|Withdrawal by Subject|1
6371818|NCT02561962|10161581|FG008|Overall Study|Withdrawal by Subject|0
6371819|NCT02561962|10161573|FG000|Overall Study|Decision by sponsor|0
6371820|NCT02561962|10161574|FG001|Overall Study|Decision by sponsor|0
6371821|NCT02561962|10161575|FG002|Overall Study|Decision by sponsor|0
6371822|NCT02561962|10161576|FG003|Overall Study|Decision by sponsor|0
6371823|NCT02561962|10161577|FG004|Overall Study|Decision by sponsor|1
6371824|NCT02561962|10161578|FG005|Overall Study|Decision by sponsor|1
6371825|NCT02561962|10161579|FG006|Overall Study|Decision by sponsor|0
6371826|NCT02561962|10161580|FG007|Overall Study|Decision by sponsor|3
6371827|NCT02561962|10161581|FG008|Overall Study|Decision by sponsor|0
6371828|NCT02561962|10161573|FG000|Overall Study|Lost to Follow-up|0
6371829|NCT02561962|10161574|FG001|Overall Study|Lost to Follow-up|0
6371830|NCT02561962|10161575|FG002|Overall Study|Lost to Follow-up|0
6371831|NCT02561962|10161576|FG003|Overall Study|Lost to Follow-up|0
6371832|NCT02561962|10161577|FG004|Overall Study|Lost to Follow-up|0
6371833|NCT02561962|10161578|FG005|Overall Study|Lost to Follow-up|1
6371834|NCT02561962|10161579|FG006|Overall Study|Lost to Follow-up|0
6371835|NCT02561962|10161580|FG007|Overall Study|Lost to Follow-up|0
6371836|NCT02561962|10161581|FG008|Overall Study|Lost to Follow-up|0
6371837|NCT02500589|10161603|FG000|Overall Study|Withdrawal by Subject|11
6371838|NCT02500589|10161604|FG001|Overall Study|Withdrawal by Subject|14
6371839|NCT02500589|10161603|FG000|Overall Study|Lost to Follow-up|10
6371840|NCT02500589|10161604|FG001|Overall Study|Lost to Follow-up|12
6371841|NCT02500589|10161603|FG000|Overall Study|Excluded post rand: cognitive impairment|0
6371842|NCT02500589|10161604|FG001|Overall Study|Excluded post rand: cognitive impairment|1
6371843|NCT02500589|10161603|FG000|Overall Study|Death|7
6371844|NCT02500589|10161604|FG001|Overall Study|Death|5
6371845|NCT02474329|10161614|FG000|Overall Study|Withdraw or did not contribute data.|13
6371846|NCT02471339|10161621|FG000|Overall Study|Did not provide follow-up data|2
6371847|NCT02471339|10161622|FG001|Overall Study|Did not provide follow-up data|0
6371848|NCT01388491|10161653|FG000|Overall Study|Adverse Event|10
6371849|NCT01388491|10161654|FG001|Overall Study|Adverse Event|9
6371850|NCT01388491|10161653|FG000|Overall Study|Sponsor Request|9
6371851|NCT01388491|10161654|FG001|Overall Study|Sponsor Request|7
6371852|NCT01388491|10161653|FG000|Overall Study|Withdrawal by Subject|6
6371853|NCT01388491|10161654|FG001|Overall Study|Withdrawal by Subject|10
6371854|NCT01388491|10161653|FG000|Overall Study|Lost to Follow-up|4
6371855|NCT01388491|10161654|FG001|Overall Study|Lost to Follow-up|3
6371856|NCT01388491|10161653|FG000|Overall Study|Protocol Violation|2
6371857|NCT01388491|10161654|FG001|Overall Study|Protocol Violation|0
6371858|NCT01388491|10161653|FG000|Overall Study|Noncompliance|2
6371859|NCT01388491|10161654|FG001|Overall Study|Noncompliance|0
6371860|NCT01388491|10161653|FG000|Overall Study|Pregnancy|1
6371861|NCT01388491|10161654|FG001|Overall Study|Pregnancy|0
6371862|NCT01373151|10161667|FG000|Period 1|Lack of Efficacy|3
6371863|NCT01373151|10161668|FG001|Period 1|Lack of Efficacy|0
6371864|NCT01373151|10161669|FG002|Period 1|Lack of Efficacy|0
6371865|NCT01373151|10161670|FG003|Period 1|Lack of Efficacy|0
6371866|NCT01373151|10161671|FG004|Period 1|Lack of Efficacy|1
6371867|NCT01373151|10161672|FG005|Period 1|Lack of Efficacy|0
6371868|NCT01373151|10161673|FG006|Period 1|Lack of Efficacy|0
6371869|NCT01373151|10161667|FG000|Period 1|Adverse Event|0
6371870|NCT01373151|10161668|FG001|Period 1|Adverse Event|0
6371871|NCT01373151|10161669|FG002|Period 1|Adverse Event|1
6371872|NCT01373151|10161670|FG003|Period 1|Adverse Event|0
6371873|NCT01373151|10161671|FG004|Period 1|Adverse Event|4
6371874|NCT01373151|10161672|FG005|Period 1|Adverse Event|3
6371875|NCT01373151|10161673|FG006|Period 1|Adverse Event|0
6371876|NCT01373151|10161667|FG000|Period 1|Withdrawal by Subject|2
6371877|NCT01373151|10161668|FG001|Period 1|Withdrawal by Subject|0
6371878|NCT01373151|10161669|FG002|Period 1|Withdrawal by Subject|3
6371879|NCT01373151|10161670|FG003|Period 1|Withdrawal by Subject|1
6371880|NCT01373151|10161671|FG004|Period 1|Withdrawal by Subject|0
6371881|NCT01373151|10161672|FG005|Period 1|Withdrawal by Subject|1
6371882|NCT01373151|10161673|FG006|Period 1|Withdrawal by Subject|0
6371883|NCT01373151|10161667|FG000|Period 2|Lack of Efficacy|9
6371884|NCT01373151|10161668|FG001|Period 2|Lack of Efficacy|0
6371885|NCT01373151|10161669|FG002|Period 2|Lack of Efficacy|0
6371886|NCT01373151|10161670|FG003|Period 2|Lack of Efficacy|1
6371887|NCT01373151|10161671|FG004|Period 2|Lack of Efficacy|2
6371888|NCT01373151|10161672|FG005|Period 2|Lack of Efficacy|0
6371889|NCT01373151|10161673|FG006|Period 2|Lack of Efficacy|3
6371890|NCT01373151|10161667|FG000|Period 2|Adverse Event|0
6371891|NCT01373151|10161668|FG001|Period 2|Adverse Event|0
6371892|NCT01373151|10161669|FG002|Period 2|Adverse Event|3
6371893|NCT01373151|10161670|FG003|Period 2|Adverse Event|3
6371894|NCT01373151|10161671|FG004|Period 2|Adverse Event|0
6371895|NCT01373151|10161672|FG005|Period 2|Adverse Event|0
6371896|NCT01373151|10161673|FG006|Period 2|Adverse Event|1
6371897|NCT01373151|10161667|FG000|Period 2|subject request to discontinue|0
6371898|NCT01373151|10161668|FG001|Period 2|subject request to discontinue|1
6371899|NCT01373151|10161669|FG002|Period 2|subject request to discontinue|0
6371900|NCT01373151|10161670|FG003|Period 2|subject request to discontinue|0
6371901|NCT01373151|10161671|FG004|Period 2|subject request to discontinue|0
6371902|NCT01373151|10161672|FG005|Period 2|subject request to discontinue|0
6371903|NCT01373151|10161673|FG006|Period 2|subject request to discontinue|0
6371904|NCT01373151|10161667|FG000|Period 2|Withdrawal by Subject|0
6371905|NCT01373151|10161668|FG001|Period 2|Withdrawal by Subject|0
6371906|NCT01373151|10161669|FG002|Period 2|Withdrawal by Subject|0
6371907|NCT01373151|10161670|FG003|Period 2|Withdrawal by Subject|1
6371908|NCT01373151|10161671|FG004|Period 2|Withdrawal by Subject|0
6371909|NCT01373151|10161672|FG005|Period 2|Withdrawal by Subject|0
6371910|NCT01373151|10161673|FG006|Period 2|Withdrawal by Subject|0
6371911|NCT01373151|10161667|FG000|Period 2|Other|0
6371912|NCT01373151|10161668|FG001|Period 2|Other|0
6371913|NCT01373151|10161669|FG002|Period 2|Other|1
6371914|NCT01373151|10161670|FG003|Period 2|Other|0
6371915|NCT01373151|10161671|FG004|Period 2|Other|0
6371916|NCT01373151|10161672|FG005|Period 2|Other|0
6371917|NCT01373151|10161673|FG006|Period 2|Other|1
6371918|NCT01281644|10161702|FG000|Overall Study|Lost to Follow-up|3
6371919|NCT01281644|10161702|FG000|Overall Study|Withdrawal by Subject|2
6371920|NCT00960297|10161714|FG000|Overall Study|Physician Decision|1
6371921|NCT00960297|10161714|FG000|Overall Study|Venous port infection|1
6371922|NCT00960297|10161714|FG000|Overall Study|Disease progression|1
6371923|NCT00910650|10161718|FG000|Overall Study|Death|2
6371924|NCT00703326|10161728|FG000|Overall Study|Lost to Follow-up|47
6371925|NCT00703326|10161729|FG001|Overall Study|Lost to Follow-up|18
6371926|NCT00703326|10161728|FG000|Overall Study|Withdrawal by Subject|54
6371927|NCT00703326|10161729|FG001|Overall Study|Withdrawal by Subject|20
6371928|NCT00703326|10161728|FG000|Overall Study|Adverse Event|1
6371929|NCT00703326|10161729|FG001|Overall Study|Adverse Event|0
6371930|NCT00602667|10161739|FG000|Overall Study|Still on Therapy|0
6371931|NCT00602667|10161740|FG001|Overall Study|Still on Therapy|2
6371932|NCT00602667|10161741|FG002|Overall Study|Still on Therapy|2
6371933|NCT00602667|10161739|FG000|Overall Study|Death|0
6371934|NCT00602667|10161740|FG001|Overall Study|Death|1
6371935|NCT00602667|10161741|FG002|Overall Study|Death|1
6371936|NCT00602667|10161739|FG000|Overall Study|Family request|3
6371937|NCT00602667|10161740|FG001|Overall Study|Family request|25
6371938|NCT00602667|10161741|FG002|Overall Study|Family request|6
6371939|NCT00602667|10161739|FG000|Overall Study|Excessive toxicity|1
6371940|NCT00602667|10161740|FG001|Overall Study|Excessive toxicity|1
6371941|NCT00602667|10161741|FG002|Overall Study|Excessive toxicity|0
6371942|NCT00602667|10161739|FG000|Overall Study|Second malignancy|0
6371943|NCT00602667|10161740|FG001|Overall Study|Second malignancy|1
6371944|NCT00602667|10161741|FG002|Overall Study|Second malignancy|0
6371945|NCT00602667|10161739|FG000|Overall Study|Physician Decision|2
6371946|NCT00602667|10161740|FG001|Overall Study|Physician Decision|3
6371947|NCT00602667|10161741|FG002|Overall Study|Physician Decision|8
6371948|NCT00602667|10161739|FG000|Overall Study|Progressive disease|13
6371949|NCT00602667|10161740|FG001|Overall Study|Progressive disease|48
6371950|NCT00602667|10161741|FG002|Overall Study|Progressive disease|45
6371951|NCT00602667|10161739|FG000|Overall Study|Progressive disease prior to therapy|0
6371952|NCT00602667|10161740|FG001|Overall Study|Progressive disease prior to therapy|0
6371953|NCT00602667|10161741|FG002|Overall Study|Progressive disease prior to therapy|1
6371954|NCT00472186|10161782|FG000|Overall Study|Study was terminated due to poor compliance with returning logbooks by families.|1
6371955|NCT00472186|10161783|FG001|Overall Study|Study was terminated due to poor compliance with returning logbooks by families.|0
6084635|NCT00643604|9693581|FG000|Overall Study|Death|1
6084636|NCT00643682|9693587|FG000|Overall Study|did not keep appointment|522
6084637|NCT00643682|9693588|FG001|Overall Study|did not keep appointment|509
6084638|NCT00643760|9693599|FG000|Overall Study|Adverse Event|11
6084639|NCT00643760|9693600|FG001|Overall Study|Adverse Event|5
6371956|NCT03996876|10161793|FG000|Overall Study|Incomplete Data|2
6371957|NCT03996876|10161794|FG001|Overall Study|Incomplete Data|4
6371958|NCT03589976|10161803|FG000|Overall Study|Death|5
6371959|NCT03589976|10161804|FG001|Overall Study|Death|1
6371960|NCT03589976|10161803|FG000|Overall Study|Adverse Event|5
6371961|NCT03589976|10161804|FG001|Overall Study|Adverse Event|1
6371962|NCT03589976|10161803|FG000|Overall Study|Withdrawal by Subject|4
6371963|NCT03589976|10161804|FG001|Overall Study|Withdrawal by Subject|1
6371964|NCT03589976|10161803|FG000|Overall Study|Lost to Follow-up|1
6371965|NCT03589976|10161804|FG001|Overall Study|Lost to Follow-up|0
6371966|NCT03589976|10161803|FG000|Overall Study|Other|4
6371967|NCT03589976|10161804|FG001|Overall Study|Other|3
6371968|NCT03135262|10161851|FG000|Overall Study|discontinued due to worsening of pre-existing medical condition|1
6371969|NCT03135262|10161852|FG001|Overall Study|discontinued due to worsening of pre-existing medical condition|0
6371970|NCT03135262|10161853|FG002|Overall Study|discontinued due to worsening of pre-existing medical condition|0
6371971|NCT03135262|10161854|FG003|Overall Study|discontinued due to worsening of pre-existing medical condition|0
5972131|NCT04498247|9557786|FG002|Overall Study|Lost to Follow-up|0
6371972|NCT03135262|10161855|FG004|Overall Study|discontinued due to worsening of pre-existing medical condition|0
6371973|NCT03135262|10161851|FG000|Overall Study|Progression of disease|0
6371974|NCT03135262|10161852|FG001|Overall Study|Progression of disease|0
6371975|NCT03135262|10161853|FG002|Overall Study|Progression of disease|0
6371976|NCT03135262|10161854|FG003|Overall Study|Progression of disease|1
6371977|NCT03135262|10161855|FG004|Overall Study|Progression of disease|0
6371978|NCT03135262|10161851|FG000|Overall Study|Death|6
6371979|NCT03135262|10161852|FG001|Overall Study|Death|2
6371980|NCT03135262|10161853|FG002|Overall Study|Death|2
6371981|NCT03135262|10161854|FG003|Overall Study|Death|2
6371982|NCT03135262|10161855|FG004|Overall Study|Death|0
6371983|NCT03135262|10161851|FG000|Overall Study|Withdrawal by Subject|0
6371984|NCT03135262|10161852|FG001|Overall Study|Withdrawal by Subject|0
6371985|NCT03135262|10161853|FG002|Overall Study|Withdrawal by Subject|1
6371986|NCT03135262|10161854|FG003|Overall Study|Withdrawal by Subject|0
6371987|NCT03135262|10161855|FG004|Overall Study|Withdrawal by Subject|1
6371988|NCT03135262|10161851|FG000|Overall Study|Study terminated by sponsor|2
6371989|NCT03135262|10161852|FG001|Overall Study|Study terminated by sponsor|4
6371990|NCT03135262|10161853|FG002|Overall Study|Study terminated by sponsor|4
6371991|NCT03135262|10161854|FG003|Overall Study|Study terminated by sponsor|3
6371992|NCT03135262|10161855|FG004|Overall Study|Study terminated by sponsor|0
6371993|NCT03104075|10161887|FG000|Overall Study|Participant did not complete the last study visit due to hospitalization unrelated to the vaccine|1
6371994|NCT03104075|10161888|FG001|Overall Study|Participant did not complete the last study visit due to hospitalization unrelated to the vaccine|0
6371995|NCT03038087|10161895|FG000|Overall Study|lost data|1
6371996|NCT02662985|10161935|FG000|Treatment Period 1|Adverse Event|0
6371997|NCT02662985|10161936|FG001|Treatment Period 1|Adverse Event|2
6371998|NCT02662985|10161935|FG000|Treatment Period 1|Protocol Violation|0
6371999|NCT02662985|10161936|FG001|Treatment Period 1|Protocol Violation|1
6372000|NCT02662985|10161935|FG000|Treatment Period 1|Physician Decision|1
6372001|NCT02662985|10161936|FG001|Treatment Period 1|Physician Decision|0
6372002|NCT02662985|10161935|FG000|Treatment Period 1|Withdrawal by Subject|0
6372003|NCT02662985|10161936|FG001|Treatment Period 1|Withdrawal by Subject|1
6372004|NCT02662985|10161935|FG000|Treatment Period 2|Lack of Efficacy|0
6372005|NCT02662985|10161936|FG001|Treatment Period 2|Lack of Efficacy|1
6372006|NCT02662985|10161935|FG000|Treatment Period 2|Lost to Follow-up|1
6372007|NCT02662985|10161936|FG001|Treatment Period 2|Lost to Follow-up|0
6372008|NCT02662985|10161935|FG000|Treatment Period 3 (Extension Period)|Withdrew before entering period|4
6372009|NCT02662985|10161936|FG001|Treatment Period 3 (Extension Period)|Withdrew before entering period|4
6372010|NCT02662985|10161935|FG000|Treatment Period 3 (Extension Period)|Adverse Event|1
6372011|NCT02662985|10161936|FG001|Treatment Period 3 (Extension Period)|Adverse Event|1
6372012|NCT02662985|10161935|FG000|Treatment Period 3 (Extension Period)|Lack of Efficacy|0
6372013|NCT02662985|10161936|FG001|Treatment Period 3 (Extension Period)|Lack of Efficacy|1
6372014|NCT02662985|10161935|FG000|Treatment Period 3 (Extension Period)|Withdrawal by Subject|1
6372015|NCT02662985|10161936|FG001|Treatment Period 3 (Extension Period)|Withdrawal by Subject|2
6372016|NCT02662985|10161935|FG000|Treatment Period 3 (Extension Period)|Death|0
6372017|NCT02662985|10161936|FG001|Treatment Period 3 (Extension Period)|Death|1
6372018|NCT02606461|10161946|FG000|Overall Study|Withdrawal by Subject|3
6372019|NCT02606461|10161947|FG001|Overall Study|Withdrawal by Subject|2
6372020|NCT02606461|10161948|FG002|Overall Study|Withdrawal by Subject|14
6372021|NCT02606461|10161949|FG003|Overall Study|Withdrawal by Subject|11
6372022|NCT02606461|10161946|FG000|Overall Study|Death|16
6372023|NCT02606461|10161947|FG001|Overall Study|Death|25
6372024|NCT02606461|10161948|FG002|Overall Study|Death|105
6372025|NCT02606461|10161949|FG003|Overall Study|Death|58
6372026|NCT02606461|10161946|FG000|Overall Study|Lost to Follow-up|2
6372027|NCT02606461|10161947|FG001|Overall Study|Lost to Follow-up|2
6372028|NCT02606461|10161948|FG002|Overall Study|Lost to Follow-up|4
6372029|NCT02606461|10161949|FG003|Overall Study|Lost to Follow-up|1
6372030|NCT02606461|10161946|FG000|Overall Study|Physician Decision|0
6372031|NCT02606461|10161947|FG001|Overall Study|Physician Decision|0
6372032|NCT02606461|10161948|FG002|Overall Study|Physician Decision|1
6372033|NCT02606461|10161949|FG003|Overall Study|Physician Decision|1
6372034|NCT02606461|10161946|FG000|Overall Study|Disease Progression|1
6372035|NCT02606461|10161947|FG001|Overall Study|Disease Progression|0
6372036|NCT02606461|10161948|FG002|Overall Study|Disease Progression|0
6372037|NCT02606461|10161949|FG003|Overall Study|Disease Progression|0
6372038|NCT02606461|10161946|FG000|Overall Study|No treatment|0
6372039|NCT02606461|10161947|FG001|Overall Study|No treatment|0
6372040|NCT02606461|10161948|FG002|Overall Study|No treatment|1
6372041|NCT02606461|10161949|FG003|Overall Study|No treatment|0
6372042|NCT02606461|10161946|FG000|Overall Study|Ongoing|5
6372043|NCT02606461|10161947|FG001|Overall Study|Ongoing|1
6372044|NCT02606461|10161948|FG002|Overall Study|Ongoing|63
6372045|NCT02606461|10161949|FG003|Overall Study|Ongoing|26
6372046|NCT02536339|10161962|FG000|Overall Study|Death|20
6372047|NCT02536339|10161962|FG000|Overall Study|Withdrawal by Subject|3
6372048|NCT02536339|10161962|FG000|Overall Study|Lost to Follow-up|2
6372049|NCT02536339|10161962|FG000|Overall Study|Treatment discontinued|2
6372050|NCT02536339|10161962|FG000|Overall Study|Physician Decision|1
6372051|NCT02323295|10161968|FG000|Overall Study|Adverse Event|0
6372052|NCT02323295|10161969|FG001|Overall Study|Adverse Event|1
6372053|NCT02323295|10161968|FG000|Overall Study|Withdrawal by Subject|0
6372054|NCT02323295|10161969|FG001|Overall Study|Withdrawal by Subject|1
6372055|NCT02323295|10161968|FG000|Overall Study|Patient did not have surgery as planned.|0
6372056|NCT02323295|10161969|FG001|Overall Study|Patient did not have surgery as planned.|1
6372057|NCT02036970|10161999|FG000|Part 1: Day 1 Through Week 16|Adverse Event|0
6372058|NCT02036970|10162000|FG001|Part 1: Day 1 Through Week 16|Adverse Event|0
6372059|NCT02036970|10162001|FG002|Part 1: Day 1 Through Week 16|Adverse Event|3
6372060|NCT02036970|10162002|FG003|Part 1: Day 1 Through Week 16|Adverse Event|2
6372061|NCT02036970|10162003|FG004|Part 1: Day 1 Through Week 16|Adverse Event|0
6372062|NCT02036970|10162004|FG005|Part 1: Day 1 Through Week 16|Adverse Event|1
6372063|NCT02036970|10162005|FG006|Part 1: Day 1 Through Week 16|Adverse Event|0
6372064|NCT02036970|10162006|FG007|Part 1: Day 1 Through Week 16|Adverse Event|1
6372065|NCT02036970|10162007|FG008|Part 1: Day 1 Through Week 16|Adverse Event|3
6372066|NCT02036970|10162008|FG009|Part 1: Day 1 Through Week 16|Adverse Event|1
6372067|NCT02036970|10161999|FG000|Part 1: Day 1 Through Week 16|Death|0
6372068|NCT02036970|10162000|FG001|Part 1: Day 1 Through Week 16|Death|0
6372069|NCT02036970|10162001|FG002|Part 1: Day 1 Through Week 16|Death|0
6372070|NCT02036970|10162002|FG003|Part 1: Day 1 Through Week 16|Death|0
6372071|NCT02036970|10162003|FG004|Part 1: Day 1 Through Week 16|Death|0
6372072|NCT02036970|10162004|FG005|Part 1: Day 1 Through Week 16|Death|0
6372073|NCT02036970|10162005|FG006|Part 1: Day 1 Through Week 16|Death|0
6372074|NCT02036970|10162006|FG007|Part 1: Day 1 Through Week 16|Death|0
6372075|NCT02036970|10162007|FG008|Part 1: Day 1 Through Week 16|Death|1
6372076|NCT02036970|10162008|FG009|Part 1: Day 1 Through Week 16|Death|0
6372077|NCT02036970|10161999|FG000|Part 1: Day 1 Through Week 16|Protocol Violation|1
6372078|NCT02036970|10162000|FG001|Part 1: Day 1 Through Week 16|Protocol Violation|0
6372079|NCT02036970|10162001|FG002|Part 1: Day 1 Through Week 16|Protocol Violation|1
6372080|NCT02036970|10162002|FG003|Part 1: Day 1 Through Week 16|Protocol Violation|0
6372081|NCT02036970|10162003|FG004|Part 1: Day 1 Through Week 16|Protocol Violation|0
6372082|NCT02036970|10162004|FG005|Part 1: Day 1 Through Week 16|Protocol Violation|0
6372083|NCT02036970|10162005|FG006|Part 1: Day 1 Through Week 16|Protocol Violation|0
6372084|NCT02036970|10162006|FG007|Part 1: Day 1 Through Week 16|Protocol Violation|0
6372085|NCT02036970|10162007|FG008|Part 1: Day 1 Through Week 16|Protocol Violation|2
6372086|NCT02036970|10162008|FG009|Part 1: Day 1 Through Week 16|Protocol Violation|0
6372087|NCT02036970|10161999|FG000|Part 1: Day 1 Through Week 16|Withdrawal by Subject|0
6372088|NCT02036970|10162000|FG001|Part 1: Day 1 Through Week 16|Withdrawal by Subject|0
6372089|NCT02036970|10162001|FG002|Part 1: Day 1 Through Week 16|Withdrawal by Subject|0
6372090|NCT02036970|10162002|FG003|Part 1: Day 1 Through Week 16|Withdrawal by Subject|0
6372091|NCT02036970|10162003|FG004|Part 1: Day 1 Through Week 16|Withdrawal by Subject|1
6372092|NCT02036970|10162004|FG005|Part 1: Day 1 Through Week 16|Withdrawal by Subject|0
6372093|NCT02036970|10162005|FG006|Part 1: Day 1 Through Week 16|Withdrawal by Subject|0
6372094|NCT02036970|10162006|FG007|Part 1: Day 1 Through Week 16|Withdrawal by Subject|0
6372095|NCT02036970|10162007|FG008|Part 1: Day 1 Through Week 16|Withdrawal by Subject|2
6372096|NCT02036970|10162008|FG009|Part 1: Day 1 Through Week 16|Withdrawal by Subject|4
6372097|NCT02036970|10161999|FG000|Part 1: Day 1 Through Week 16|Progressive Disease|0
6372098|NCT02036970|10162000|FG001|Part 1: Day 1 Through Week 16|Progressive Disease|0
6372099|NCT02036970|10162001|FG002|Part 1: Day 1 Through Week 16|Progressive Disease|0
6372100|NCT02036970|10162002|FG003|Part 1: Day 1 Through Week 16|Progressive Disease|1
6372101|NCT02036970|10162003|FG004|Part 1: Day 1 Through Week 16|Progressive Disease|0
6372102|NCT02036970|10162004|FG005|Part 1: Day 1 Through Week 16|Progressive Disease|0
6372103|NCT02036970|10162005|FG006|Part 1: Day 1 Through Week 16|Progressive Disease|0
6372104|NCT02036970|10162006|FG007|Part 1: Day 1 Through Week 16|Progressive Disease|0
6372105|NCT02036970|10162007|FG008|Part 1: Day 1 Through Week 16|Progressive Disease|0
6372106|NCT02036970|10162008|FG009|Part 1: Day 1 Through Week 16|Progressive Disease|0
6372107|NCT02036970|10161999|FG000|Part 2: Week 16 Onwards|Adverse Event|0
6372108|NCT02036970|10162000|FG001|Part 2: Week 16 Onwards|Adverse Event|2
6372109|NCT02036970|10162001|FG002|Part 2: Week 16 Onwards|Adverse Event|1
6372110|NCT02036970|10162002|FG003|Part 2: Week 16 Onwards|Adverse Event|1
6372111|NCT02036970|10162003|FG004|Part 2: Week 16 Onwards|Adverse Event|1
6372112|NCT02036970|10162004|FG005|Part 2: Week 16 Onwards|Adverse Event|0
6372113|NCT02036970|10162005|FG006|Part 2: Week 16 Onwards|Adverse Event|1
6372114|NCT02036970|10162006|FG007|Part 2: Week 16 Onwards|Adverse Event|0
6372115|NCT02036970|10162007|FG008|Part 2: Week 16 Onwards|Adverse Event|6
6372116|NCT02036970|10162008|FG009|Part 2: Week 16 Onwards|Adverse Event|3
6372117|NCT02036970|10161999|FG000|Part 2: Week 16 Onwards|Protocol Violation|0
6372118|NCT02036970|10162000|FG001|Part 2: Week 16 Onwards|Protocol Violation|0
6372119|NCT02036970|10162001|FG002|Part 2: Week 16 Onwards|Protocol Violation|0
6372120|NCT02036970|10162002|FG003|Part 2: Week 16 Onwards|Protocol Violation|0
6372121|NCT02036970|10162003|FG004|Part 2: Week 16 Onwards|Protocol Violation|0
6372122|NCT02036970|10162004|FG005|Part 2: Week 16 Onwards|Protocol Violation|0
6372123|NCT02036970|10162005|FG006|Part 2: Week 16 Onwards|Protocol Violation|0
6372124|NCT02036970|10162006|FG007|Part 2: Week 16 Onwards|Protocol Violation|1
6372125|NCT02036970|10162007|FG008|Part 2: Week 16 Onwards|Protocol Violation|0
6372126|NCT02036970|10162008|FG009|Part 2: Week 16 Onwards|Protocol Violation|0
6372127|NCT02036970|10161999|FG000|Part 2: Week 16 Onwards|Withdrawal by Subject|0
6372128|NCT02036970|10162000|FG001|Part 2: Week 16 Onwards|Withdrawal by Subject|1
6372129|NCT02036970|10162001|FG002|Part 2: Week 16 Onwards|Withdrawal by Subject|1
6372130|NCT02036970|10162002|FG003|Part 2: Week 16 Onwards|Withdrawal by Subject|0
6372131|NCT02036970|10162003|FG004|Part 2: Week 16 Onwards|Withdrawal by Subject|0
6372132|NCT02036970|10162004|FG005|Part 2: Week 16 Onwards|Withdrawal by Subject|0
6372133|NCT02036970|10162005|FG006|Part 2: Week 16 Onwards|Withdrawal by Subject|0
6372134|NCT02036970|10162006|FG007|Part 2: Week 16 Onwards|Withdrawal by Subject|0
6372135|NCT02036970|10162007|FG008|Part 2: Week 16 Onwards|Withdrawal by Subject|3
6372136|NCT02036970|10162008|FG009|Part 2: Week 16 Onwards|Withdrawal by Subject|0
6372137|NCT02036970|10161999|FG000|Part 2: Week 16 Onwards|Progressive Disease|0
6372138|NCT02036970|10162000|FG001|Part 2: Week 16 Onwards|Progressive Disease|2
6372139|NCT02036970|10162001|FG002|Part 2: Week 16 Onwards|Progressive Disease|1
6372140|NCT02036970|10162002|FG003|Part 2: Week 16 Onwards|Progressive Disease|1
6372141|NCT02036970|10162003|FG004|Part 2: Week 16 Onwards|Progressive Disease|0
6372142|NCT02036970|10162004|FG005|Part 2: Week 16 Onwards|Progressive Disease|0
6372143|NCT02036970|10162005|FG006|Part 2: Week 16 Onwards|Progressive Disease|0
6372144|NCT02036970|10162006|FG007|Part 2: Week 16 Onwards|Progressive Disease|0
6372145|NCT02036970|10162007|FG008|Part 2: Week 16 Onwards|Progressive Disease|0
6372146|NCT02036970|10162008|FG009|Part 2: Week 16 Onwards|Progressive Disease|2
6372147|NCT01941719|10162042|FG000|Overall Study|Lost to Follow-up|20
6372148|NCT01941719|10162043|FG001|Overall Study|Lost to Follow-up|19
6372149|NCT01828099|10162052|FG000|Overall Study|Adverse Event|15
6372150|NCT01828099|10162053|FG001|Overall Study|Adverse Event|18
6372151|NCT01828099|10162052|FG000|Overall Study|Death|9
6372152|NCT01828099|10162053|FG001|Overall Study|Death|11
6372153|NCT01828099|10162052|FG000|Overall Study|Lost to Follow-up|2
6372154|NCT01828099|10162053|FG001|Overall Study|Lost to Follow-up|0
6372155|NCT01828099|10162052|FG000|Overall Study|Non-compliance with study treatment|2
6372156|NCT01828099|10162053|FG001|Overall Study|Non-compliance with study treatment|0
6372157|NCT01828099|10162052|FG000|Overall Study|Physician Decision|7
6372158|NCT01828099|10162053|FG001|Overall Study|Physician Decision|11
6372159|NCT01828099|10162052|FG000|Overall Study|Progressive disease|51
6372160|NCT01828099|10162053|FG001|Overall Study|Progressive disease|94
6372161|NCT01828099|10162052|FG000|Overall Study|Protocol Violation|1
6372162|NCT01828099|10162053|FG001|Overall Study|Protocol Violation|0
6372163|NCT01828099|10162052|FG000|Overall Study|Subject/guardian decision|7
6372164|NCT01828099|10162053|FG001|Overall Study|Subject/guardian decision|23
6372165|NCT00943618|10162078|FG000|Overall Study|Lost to Follow-up|38
6372166|NCT00943618|10162079|FG001|Overall Study|Lost to Follow-up|48
6372167|NCT00943618|10162080|FG002|Overall Study|Lost to Follow-up|20
6372168|NCT00943618|10162078|FG000|Overall Study|Discontinued Medication|17
6372169|NCT00943618|10162079|FG001|Overall Study|Discontinued Medication|29
6372170|NCT00943618|10162080|FG002|Overall Study|Discontinued Medication|11
6372171|NCT03938272|10162090|FG000|Overall Study|Withdrawal by Subject|1
6372172|NCT03938272|10162091|FG001|Overall Study|Withdrawal by Subject|0
6372173|NCT03938272|10162090|FG000|Overall Study|Physician Decision|0
6372174|NCT03938272|10162091|FG001|Overall Study|Physician Decision|2
6372175|NCT03938272|10162090|FG000|Overall Study|Study termination by sponsor|10
6372176|NCT03938272|10162091|FG001|Overall Study|Study termination by sponsor|8
6372177|NCT03641339|10162103|FG000|Overall Study|Physician Decision|1
6372178|NCT03641339|10162104|FG001|Overall Study|Physician Decision|0
6372179|NCT03641339|10162105|FG002|Overall Study|Physician Decision|0
6372180|NCT03641339|10162106|FG003|Overall Study|Physician Decision|0
6372181|NCT03641339|10162107|FG004|Overall Study|Physician Decision|0
6372182|NCT03641339|10162108|FG005|Overall Study|Physician Decision|0
6372183|NCT03641339|10162103|FG000|Overall Study|Withdrawal by Subject|0
6372184|NCT03641339|10162104|FG001|Overall Study|Withdrawal by Subject|2
6372185|NCT03641339|10162105|FG002|Overall Study|Withdrawal by Subject|0
6372186|NCT03641339|10162106|FG003|Overall Study|Withdrawal by Subject|2
6372187|NCT03641339|10162107|FG004|Overall Study|Withdrawal by Subject|0
6372188|NCT03641339|10162108|FG005|Overall Study|Withdrawal by Subject|1
6372189|NCT03625466|10162124|FG000|Overall Study|Adverse Event|0
6372190|NCT03625466|10162125|FG001|Overall Study|Adverse Event|1
6372191|NCT03625466|10162124|FG000|Overall Study|Withdrawal of Consent (not due to AE)|0
6372192|NCT03625466|10162125|FG001|Overall Study|Withdrawal of Consent (not due to AE)|1
6372193|NCT03317795|10162133|FG000|Overall Study|IUD Expulsion|1
6372194|NCT03317795|10162134|FG001|Overall Study|IUD Expulsion|0
6372195|NCT03317795|10162133|FG000|Overall Study|Lost to Follow-up|1
6372196|NCT03317795|10162134|FG001|Overall Study|Lost to Follow-up|3
6372197|NCT03317795|10162133|FG000|Overall Study|Treatment change|0
6372198|NCT03317795|10162134|FG001|Overall Study|Treatment change|3
6372199|NCT03317795|10162133|FG000|Overall Study|Intolerance of medication|0
6372200|NCT03317795|10162134|FG001|Overall Study|Intolerance of medication|1
6372201|NCT03287245|10162144|FG000|Overall Study|Study terminated by sponsor|3
6372202|NCT03287245|10162145|FG001|Overall Study|Study terminated by sponsor|0
6372203|NCT03287245|10162146|FG002|Overall Study|Study terminated by sponsor|3
6372204|NCT03287245|10162147|FG003|Overall Study|Study terminated by sponsor|1
6372205|NCT03287245|10162144|FG000|Overall Study|Adverse Event|1
6372206|NCT03287245|10162145|FG001|Overall Study|Adverse Event|0
6372207|NCT03287245|10162146|FG002|Overall Study|Adverse Event|0
6372208|NCT03287245|10162147|FG003|Overall Study|Adverse Event|0
6372209|NCT03287245|10162144|FG000|Overall Study|Withdrawal by Subject|8
6372210|NCT03287245|10162145|FG001|Overall Study|Withdrawal by Subject|3
6372211|NCT03287245|10162146|FG002|Overall Study|Withdrawal by Subject|3
6372212|NCT03287245|10162147|FG003|Overall Study|Withdrawal by Subject|0
6372213|NCT03287245|10162144|FG000|Overall Study|Physician Decision|3
6372214|NCT03287245|10162145|FG001|Overall Study|Physician Decision|2
6372215|NCT03287245|10162146|FG002|Overall Study|Physician Decision|0
6372216|NCT03287245|10162147|FG003|Overall Study|Physician Decision|0
6372217|NCT03092219|10162188|FG000|Overall Study|Protocol Violation|7
6372218|NCT03092219|10162189|FG001|Overall Study|Protocol Violation|4
6372219|NCT03033069|10162202|FG000|Overall Study|Adverse Event|6
6372220|NCT03033069|10162203|FG001|Overall Study|Adverse Event|7
6372221|NCT03033069|10162204|FG002|Overall Study|Adverse Event|4
6372222|NCT03033069|10162205|FG003|Overall Study|Adverse Event|6
6372223|NCT03033069|10162202|FG000|Overall Study|Lack of Efficacy|0
6372224|NCT03033069|10162203|FG001|Overall Study|Lack of Efficacy|0
6372225|NCT03033069|10162204|FG002|Overall Study|Lack of Efficacy|1
6372226|NCT03033069|10162205|FG003|Overall Study|Lack of Efficacy|0
6372227|NCT03033069|10162202|FG000|Overall Study|Lost to Follow-up|6
6372228|NCT03033069|10162203|FG001|Overall Study|Lost to Follow-up|5
6372229|NCT03033069|10162204|FG002|Overall Study|Lost to Follow-up|5
6372230|NCT03033069|10162205|FG003|Overall Study|Lost to Follow-up|6
6372231|NCT03033069|10162202|FG000|Overall Study|Non-Compliance With Study Drug|1
6372232|NCT03033069|10162203|FG001|Overall Study|Non-Compliance With Study Drug|1
6372233|NCT03033069|10162204|FG002|Overall Study|Non-Compliance With Study Drug|1
6372234|NCT03033069|10162205|FG003|Overall Study|Non-Compliance With Study Drug|0
6372235|NCT03033069|10162202|FG000|Overall Study|Protocol Deviation|0
6372236|NCT03033069|10162203|FG001|Overall Study|Protocol Deviation|1
6372237|NCT03033069|10162204|FG002|Overall Study|Protocol Deviation|0
6372238|NCT03033069|10162205|FG003|Overall Study|Protocol Deviation|0
6372239|NCT03033069|10162202|FG000|Overall Study|Withdrawal by Subject|10
6372240|NCT03033069|10162203|FG001|Overall Study|Withdrawal by Subject|10
6372241|NCT03033069|10162204|FG002|Overall Study|Withdrawal by Subject|11
6372242|NCT03033069|10162205|FG003|Overall Study|Withdrawal by Subject|6
6372243|NCT03033069|10162202|FG000|Overall Study|Withdrawal By Caregiver|1
6372244|NCT03033069|10162203|FG001|Overall Study|Withdrawal By Caregiver|0
6372245|NCT03033069|10162204|FG002|Overall Study|Withdrawal By Caregiver|0
6372246|NCT03033069|10162205|FG003|Overall Study|Withdrawal By Caregiver|0
6372247|NCT03033069|10162202|FG000|Overall Study|Reason not Specified|0
6372248|NCT03033069|10162203|FG001|Overall Study|Reason not Specified|1
6372249|NCT03033069|10162204|FG002|Overall Study|Reason not Specified|0
6372250|NCT03033069|10162205|FG003|Overall Study|Reason not Specified|1
6372251|NCT02663622|10162234|FG000|Overall Study|Ongoing in study|0
6372252|NCT02663622|10162235|FG001|Overall Study|Ongoing in study|0
6372253|NCT02663622|10162236|FG002|Overall Study|Ongoing in study|0
6372254|NCT02663622|10162237|FG003|Overall Study|Ongoing in study|6
6372255|NCT02663622|10162234|FG000|Overall Study|Death|3
6372256|NCT02663622|10162235|FG001|Overall Study|Death|1
6372257|NCT02663622|10162236|FG002|Overall Study|Death|1
6372258|NCT02663622|10162237|FG003|Overall Study|Death|8
6372259|NCT02663622|10162234|FG000|Overall Study|Protocol Violation|0
6372260|NCT02663622|10162235|FG001|Overall Study|Protocol Violation|0
6372261|NCT02663622|10162236|FG002|Overall Study|Protocol Violation|0
6372262|NCT02663622|10162237|FG003|Overall Study|Protocol Violation|1
6372263|NCT02609503|10162248|FG000|Overall Study|Adverse Event|1
6372264|NCT02609503|10162248|FG000|Overall Study|Death|1
6372265|NCT02609503|10162248|FG000|Overall Study|Withdrawal by Subject|1
6372266|NCT02609503|10162248|FG000|Overall Study|Disease progression|1
6372267|NCT02587598|10162266|FG000|Overall Study|Death|4
6372268|NCT02587598|10162267|FG001|Overall Study|Death|8
6372269|NCT02587598|10162268|FG002|Overall Study|Death|4
6372270|NCT02587598|10162269|FG003|Overall Study|Death|16
6372271|NCT02587598|10162270|FG004|Overall Study|Death|9
6372272|NCT02587598|10162271|FG005|Overall Study|Death|4
6372273|NCT02587598|10162272|FG006|Overall Study|Death|6
6372274|NCT02587598|10162273|FG007|Overall Study|Death|7
6372275|NCT02587598|10162274|FG008|Overall Study|Death|9
6372276|NCT02587598|10162275|FG009|Overall Study|Death|1
6372277|NCT02587598|10162276|FG010|Overall Study|Death|3
6372278|NCT02587598|10162266|FG000|Overall Study|Study Terminated by the Sponsor|0
6372279|NCT02587598|10162267|FG001|Overall Study|Study Terminated by the Sponsor|1
6372280|NCT02587598|10162268|FG002|Overall Study|Study Terminated by the Sponsor|0
6372281|NCT02587598|10162269|FG003|Overall Study|Study Terminated by the Sponsor|3
6372282|NCT02587598|10162270|FG004|Overall Study|Study Terminated by the Sponsor|0
6372283|NCT02587598|10162271|FG005|Overall Study|Study Terminated by the Sponsor|1
6372284|NCT02587598|10162272|FG006|Overall Study|Study Terminated by the Sponsor|0
6372285|NCT02587598|10162273|FG007|Overall Study|Study Terminated by the Sponsor|0
6372286|NCT02587598|10162274|FG008|Overall Study|Study Terminated by the Sponsor|0
6372287|NCT02587598|10162275|FG009|Overall Study|Study Terminated by the Sponsor|1
6372288|NCT02587598|10162276|FG010|Overall Study|Study Terminated by the Sponsor|6
6372289|NCT02587598|10162266|FG000|Overall Study|Reason for study withdrawal not specified|0
6372290|NCT02587598|10162267|FG001|Overall Study|Reason for study withdrawal not specified|1
6372291|NCT02587598|10162268|FG002|Overall Study|Reason for study withdrawal not specified|0
6372292|NCT02587598|10162269|FG003|Overall Study|Reason for study withdrawal not specified|0
6372293|NCT02587598|10162270|FG004|Overall Study|Reason for study withdrawal not specified|0
6372294|NCT02587598|10162271|FG005|Overall Study|Reason for study withdrawal not specified|0
6372295|NCT02587598|10162272|FG006|Overall Study|Reason for study withdrawal not specified|0
6372296|NCT02587598|10162273|FG007|Overall Study|Reason for study withdrawal not specified|0
6372297|NCT02587598|10162274|FG008|Overall Study|Reason for study withdrawal not specified|0
6372298|NCT02587598|10162275|FG009|Overall Study|Reason for study withdrawal not specified|0
6372299|NCT02587598|10162276|FG010|Overall Study|Reason for study withdrawal not specified|0
6372300|NCT02587598|10162266|FG000|Overall Study|Withdrawal by Subject|0
6372301|NCT02587598|10162267|FG001|Overall Study|Withdrawal by Subject|1
6372302|NCT02587598|10162268|FG002|Overall Study|Withdrawal by Subject|0
6372303|NCT02587598|10162269|FG003|Overall Study|Withdrawal by Subject|2
6372304|NCT02587598|10162270|FG004|Overall Study|Withdrawal by Subject|3
6372305|NCT02587598|10162271|FG005|Overall Study|Withdrawal by Subject|1
6372306|NCT02587598|10162272|FG006|Overall Study|Withdrawal by Subject|0
6372307|NCT02587598|10162273|FG007|Overall Study|Withdrawal by Subject|0
6372308|NCT02587598|10162274|FG008|Overall Study|Withdrawal by Subject|0
6372309|NCT02587598|10162275|FG009|Overall Study|Withdrawal by Subject|1
6372310|NCT02587598|10162276|FG010|Overall Study|Withdrawal by Subject|2
6372311|NCT02587598|10162266|FG000|Overall Study|Physician Decision|0
6372312|NCT02587598|10162267|FG001|Overall Study|Physician Decision|0
6372313|NCT02587598|10162268|FG002|Overall Study|Physician Decision|0
6372314|NCT02587598|10162269|FG003|Overall Study|Physician Decision|0
6372315|NCT02587598|10162270|FG004|Overall Study|Physician Decision|0
6372316|NCT02587598|10162271|FG005|Overall Study|Physician Decision|0
6372317|NCT02587598|10162272|FG006|Overall Study|Physician Decision|0
6372318|NCT02587598|10162273|FG007|Overall Study|Physician Decision|0
6372319|NCT02587598|10162274|FG008|Overall Study|Physician Decision|0
6372320|NCT02587598|10162275|FG009|Overall Study|Physician Decision|0
6372321|NCT02587598|10162276|FG010|Overall Study|Physician Decision|3
6372322|NCT02485574|10162312|FG000|Overall Study|dropped out because they failed to undergo CT scan at postoperative 12 months|4
6372323|NCT02214160|10162324|FG000|Overall Study|Withdrawal by Subject|1
6372324|NCT02214160|10162325|FG001|Overall Study|Withdrawal by Subject|0
6372325|NCT02214160|10162326|FG002|Overall Study|Withdrawal by Subject|6
6372326|NCT02214160|10162324|FG000|Overall Study|Death|2
6372327|NCT02214160|10162325|FG001|Overall Study|Death|2
6372328|NCT02214160|10162326|FG002|Overall Study|Death|1
6372329|NCT02214160|10162324|FG000|Overall Study|Subject Non-Compliance|0
6372330|NCT02214160|10162325|FG001|Overall Study|Subject Non-Compliance|3
6372331|NCT02214160|10162326|FG002|Overall Study|Subject Non-Compliance|1
6372332|NCT02214160|10162324|FG000|Overall Study|Adverse Event|0
6372333|NCT02214160|10162325|FG001|Overall Study|Adverse Event|1
6372334|NCT02214160|10162326|FG002|Overall Study|Adverse Event|1
6372335|NCT02214160|10162324|FG000|Overall Study|Sponsor Decision|0
6372336|NCT02214160|10162325|FG001|Overall Study|Sponsor Decision|2
6372337|NCT02214160|10162326|FG002|Overall Study|Sponsor Decision|0
6372338|NCT02214160|10162324|FG000|Overall Study|Protocol Violation|1
6372339|NCT02214160|10162325|FG001|Overall Study|Protocol Violation|0
6372340|NCT02214160|10162326|FG002|Overall Study|Protocol Violation|0
6372341|NCT02214160|10162324|FG000|Overall Study|Physician Decision|0
6372342|NCT02214160|10162325|FG001|Overall Study|Physician Decision|0
6372343|NCT02214160|10162326|FG002|Overall Study|Physician Decision|1
6372344|NCT01460160|10162346|FG000|Treatment Phase|Lack of Efficacy|3
6372345|NCT01460160|10162346|FG000|Treatment Phase|Study Drug Toxicity|2
6372346|NCT01460160|10162346|FG000|Treatment Phase|Adverse Event|8
6372347|NCT01460160|10162346|FG000|Treatment Phase|Withdrawal by Subject|4
6372348|NCT01460160|10162346|FG000|Treatment Phase|Death|2
6372349|NCT01460160|10162346|FG000|Treatment Phase|Other reasons|9
6372350|NCT01460160|10162346|FG000|Follow-up Phase|Withdrawal by Subject|4
6372351|NCT01460160|10162346|FG000|Follow-up Phase|Death|14
6372352|NCT01460160|10162346|FG000|Follow-up Phase|Lost to Follow-up|7
6372353|NCT01460160|10162346|FG000|Follow-up Phase|Follow-up no longer required per protocol|70
6372354|NCT01460160|10162346|FG000|Follow-up Phase|Other and not reported reasons|5
6372355|NCT01170702|10162363|FG000|Overall Study|Exclusion criteria met after consent|1
6372356|NCT01170702|10162364|FG001|Overall Study|Exclusion criteria met after consent|2
6372357|NCT01170702|10162365|FG002|Overall Study|Exclusion criteria met after consent|0
6372358|NCT01170702|10162366|FG003|Overall Study|Exclusion criteria met after consent|2
6372359|NCT01018563|10162376|FG000|Overall Study|Termination of the study by Sponsor|2
6372360|NCT01018563|10162377|FG001|Overall Study|Termination of the study by Sponsor|1
6372361|NCT00805961|10162387|FG000|Modality Therapy|Withdrawal by Subject|1
6372362|NCT00805961|10162387|FG000|Modality Therapy|Adverse Event|1
6372363|NCT00805961|10162387|FG000|Modality Therapy|Disease Progression|2
6372364|NCT00805961|10162387|FG000|Treatment-Free Interval|Adverse Event|3
6372365|NCT00805961|10162387|FG000|Treatment-Free Interval|Intercurrent Illness|2
6372366|NCT00805961|10162387|FG000|Treatment-Free Interval|Physician Decision|1
6372367|NCT00805961|10162387|FG000|Treatment-Free Interval|Lack of Efficacy|1
6372368|NCT00805961|10162387|FG000|Maintenance Treatment|Lack of Efficacy|13
6372369|NCT00805961|10162387|FG000|Maintenance Treatment|Intercurrent Illness|7
6372370|NCT00805961|10162387|FG000|Maintenance Treatment|Adverse Event|6
6372371|NCT00805961|10162387|FG000|Maintenance Treatment|Withdrawal by Subject|5
6372372|NCT00805961|10162387|FG000|Maintenance Treatment|Symptomatic Deterioration|2
6372373|NCT00805961|10162387|FG000|Maintenance Treatment|Withdrawn Consent|1
6372374|NCT03921424|10162408|FG000|Overall Study|Lost to Follow-up|0
6372375|NCT03921424|10162409|FG001|Overall Study|Lost to Follow-up|1
6372376|NCT03921424|10162408|FG000|Overall Study|Withdrawal By Parent/Guardian|0
6372377|NCT03921424|10162409|FG001|Overall Study|Withdrawal By Parent/Guardian|2
6372378|NCT03598777|10162422|FG000|Overall Study|Study Terminated by Sponsor|3
6372379|NCT03598777|10162423|FG001|Overall Study|Study Terminated by Sponsor|0
6372380|NCT03598777|10162424|FG002|Overall Study|Study Terminated by Sponsor|0
6372381|NCT03598777|10162425|FG003|Overall Study|Study Terminated by Sponsor|0
6372382|NCT03598777|10162426|FG004|Overall Study|Study Terminated by Sponsor|15
6372383|NCT03598777|10162422|FG000|Overall Study|Withdrawal by Subject|1
6372384|NCT03598777|10162423|FG001|Overall Study|Withdrawal by Subject|1
6372385|NCT03598777|10162424|FG002|Overall Study|Withdrawal by Subject|0
6372386|NCT03598777|10162425|FG003|Overall Study|Withdrawal by Subject|0
6372387|NCT03598777|10162426|FG004|Overall Study|Withdrawal by Subject|0
6372388|NCT03598777|10162422|FG000|Overall Study|Adverse Event|1
6372389|NCT03598777|10162423|FG001|Overall Study|Adverse Event|0
6372390|NCT03598777|10162424|FG002|Overall Study|Adverse Event|0
6372391|NCT03598777|10162425|FG003|Overall Study|Adverse Event|0
6372392|NCT03598777|10162426|FG004|Overall Study|Adverse Event|0
6372393|NCT03598777|10162422|FG000|Overall Study|Lost to Follow-up|1
6372394|NCT03598777|10162423|FG001|Overall Study|Lost to Follow-up|0
6372395|NCT03598777|10162424|FG002|Overall Study|Lost to Follow-up|0
6372396|NCT03598777|10162425|FG003|Overall Study|Lost to Follow-up|0
6372397|NCT03598777|10162426|FG004|Overall Study|Lost to Follow-up|0
6372398|NCT03406078|10162443|FG000|Overall Study|Death|1
6372399|NCT03406078|10162444|FG001|Overall Study|Death|0
6372400|NCT03406078|10162443|FG000|Overall Study|Lost to Follow-up|0
6372401|NCT03406078|10162444|FG001|Overall Study|Lost to Follow-up|1
6372402|NCT03406078|10162443|FG000|Overall Study|Withdrawal by Subject|5
6372403|NCT03406078|10162444|FG001|Overall Study|Withdrawal by Subject|2
6372404|NCT03345342|10162466|FG000|Open-Label Phase|Adverse Event|30
6372405|NCT03345342|10162467|FG001|Open-Label Phase|Adverse Event|0
6372406|NCT03345342|10162468|FG002|Open-Label Phase|Adverse Event|0
6372407|NCT03345342|10162469|FG003|Open-Label Phase|Adverse Event|0
6372408|NCT03345342|10162470|FG004|Open-Label Phase|Adverse Event|0
6372409|NCT03345342|10162466|FG000|Open-Label Phase|Death|1
6372410|NCT03345342|10162467|FG001|Open-Label Phase|Death|0
6372411|NCT03345342|10162468|FG002|Open-Label Phase|Death|0
6372412|NCT03345342|10162469|FG003|Open-Label Phase|Death|0
6372413|NCT03345342|10162470|FG004|Open-Label Phase|Death|0
6372414|NCT03345342|10162466|FG000|Open-Label Phase|Initiated Prohibited Medication|2
6372415|NCT03345342|10162467|FG001|Open-Label Phase|Initiated Prohibited Medication|0
6372416|NCT03345342|10162468|FG002|Open-Label Phase|Initiated Prohibited Medication|0
6372417|NCT03345342|10162469|FG003|Open-Label Phase|Initiated Prohibited Medication|0
6372418|NCT03345342|10162470|FG004|Open-Label Phase|Initiated Prohibited Medication|0
6372419|NCT03345342|10162466|FG000|Open-Label Phase|Lack of Efficacy|6
6372420|NCT03345342|10162467|FG001|Open-Label Phase|Lack of Efficacy|0
6372421|NCT03345342|10162468|FG002|Open-Label Phase|Lack of Efficacy|0
6372422|NCT03345342|10162469|FG003|Open-Label Phase|Lack of Efficacy|0
6372423|NCT03345342|10162470|FG004|Open-Label Phase|Lack of Efficacy|0
6372424|NCT03345342|10162466|FG000|Open-Label Phase|Lost to Follow-up|9
6372425|NCT03345342|10162467|FG001|Open-Label Phase|Lost to Follow-up|0
6372426|NCT03345342|10162468|FG002|Open-Label Phase|Lost to Follow-up|0
6372427|NCT03345342|10162469|FG003|Open-Label Phase|Lost to Follow-up|0
6043313|NCT00388674|9641858|FG001|Initial Treatment|No Off-Treatment Status Data|13
6043314|NCT00388674|9641857|FG000|Initial Treatment|Not Reported|10
6043315|NCT00388674|9641858|FG001|Initial Treatment|Not Reported|12
6043316|NCT00388674|9641857|FG000|End of Study|Administrative Reason By Sponsor|299
6372428|NCT03345342|10162470|FG004|Open-Label Phase|Lost to Follow-up|0
6372429|NCT03345342|10162466|FG000|Open-Label Phase|Non-Compliance with Study Drug|4
6372430|NCT03345342|10162467|FG001|Open-Label Phase|Non-Compliance with Study Drug|0
6372431|NCT03345342|10162468|FG002|Open-Label Phase|Non-Compliance with Study Drug|0
6372432|NCT03345342|10162469|FG003|Open-Label Phase|Non-Compliance with Study Drug|0
6372433|NCT03345342|10162470|FG004|Open-Label Phase|Non-Compliance with Study Drug|0
6372434|NCT03345342|10162466|FG000|Open-Label Phase|Physician Decision|4
6372435|NCT03345342|10162467|FG001|Open-Label Phase|Physician Decision|0
6372436|NCT03345342|10162468|FG002|Open-Label Phase|Physician Decision|0
6372437|NCT03345342|10162469|FG003|Open-Label Phase|Physician Decision|0
6372438|NCT03345342|10162470|FG004|Open-Label Phase|Physician Decision|0
6372439|NCT03345342|10162466|FG000|Open-Label Phase|Protocol Violation|8
6372440|NCT03345342|10162467|FG001|Open-Label Phase|Protocol Violation|0
6372441|NCT03345342|10162468|FG002|Open-Label Phase|Protocol Violation|0
6372442|NCT03345342|10162469|FG003|Open-Label Phase|Protocol Violation|0
6372443|NCT03345342|10162470|FG004|Open-Label Phase|Protocol Violation|0
6043317|NCT00388674|9641858|FG001|End of Study|Administrative Reason By Sponsor|253
6043318|NCT00388674|9641857|FG000|End of Study|Death|239
6372444|NCT03345342|10162466|FG000|Open-Label Phase|Withdrawal by Subject|57
6372445|NCT03345342|10162467|FG001|Open-Label Phase|Withdrawal by Subject|0
6372446|NCT03345342|10162468|FG002|Open-Label Phase|Withdrawal by Subject|0
6372447|NCT03345342|10162469|FG003|Open-Label Phase|Withdrawal by Subject|0
6372448|NCT03345342|10162470|FG004|Open-Label Phase|Withdrawal by Subject|0
6372449|NCT03345342|10162466|FG000|Open-Label Phase|Other|15
6372450|NCT03345342|10162467|FG001|Open-Label Phase|Other|0
6372451|NCT03345342|10162468|FG002|Open-Label Phase|Other|0
6372452|NCT03345342|10162469|FG003|Open-Label Phase|Other|0
6372453|NCT03345342|10162470|FG004|Open-Label Phase|Other|0
6372454|NCT03345342|10162466|FG000|Double-Blind Phase|Adverse Event|0
6372455|NCT03345342|10162467|FG001|Double-Blind Phase|Adverse Event|1
6372456|NCT03345342|10162468|FG002|Double-Blind Phase|Adverse Event|6
6372457|NCT03345342|10162469|FG003|Double-Blind Phase|Adverse Event|0
6372458|NCT03345342|10162470|FG004|Double-Blind Phase|Adverse Event|0
6372459|NCT03345342|10162466|FG000|Double-Blind Phase|Death|0
6372460|NCT03345342|10162467|FG001|Double-Blind Phase|Death|2
6372461|NCT03345342|10162468|FG002|Double-Blind Phase|Death|1
6372462|NCT03345342|10162469|FG003|Double-Blind Phase|Death|0
6372463|NCT03345342|10162470|FG004|Double-Blind Phase|Death|0
6372464|NCT03345342|10162466|FG000|Double-Blind Phase|Initiated Prohibited Medication|0
6372465|NCT03345342|10162467|FG001|Double-Blind Phase|Initiated Prohibited Medication|0
6372466|NCT03345342|10162468|FG002|Double-Blind Phase|Initiated Prohibited Medication|2
6372467|NCT03345342|10162469|FG003|Double-Blind Phase|Initiated Prohibited Medication|0
6372468|NCT03345342|10162470|FG004|Double-Blind Phase|Initiated Prohibited Medication|0
6372469|NCT03345342|10162466|FG000|Double-Blind Phase|Lost to Follow-up|0
6372470|NCT03345342|10162467|FG001|Double-Blind Phase|Lost to Follow-up|1
6372471|NCT03345342|10162468|FG002|Double-Blind Phase|Lost to Follow-up|7
6372472|NCT03345342|10162469|FG003|Double-Blind Phase|Lost to Follow-up|0
6372473|NCT03345342|10162470|FG004|Double-Blind Phase|Lost to Follow-up|0
6372474|NCT03345342|10162466|FG000|Double-Blind Phase|Physician Decision|0
6372475|NCT03345342|10162467|FG001|Double-Blind Phase|Physician Decision|1
6372476|NCT03345342|10162468|FG002|Double-Blind Phase|Physician Decision|4
6372477|NCT03345342|10162469|FG003|Double-Blind Phase|Physician Decision|0
6372478|NCT03345342|10162470|FG004|Double-Blind Phase|Physician Decision|0
6372479|NCT03345342|10162466|FG000|Double-Blind Phase|Protocol Violation|0
6372480|NCT03345342|10162467|FG001|Double-Blind Phase|Protocol Violation|0
6372481|NCT03345342|10162468|FG002|Double-Blind Phase|Protocol Violation|1
6372482|NCT03345342|10162469|FG003|Double-Blind Phase|Protocol Violation|0
6372483|NCT03345342|10162470|FG004|Double-Blind Phase|Protocol Violation|0
6372484|NCT03345342|10162466|FG000|Double-Blind Phase|Withdrawal by Subject|0
6372485|NCT03345342|10162467|FG001|Double-Blind Phase|Withdrawal by Subject|16
6372486|NCT03345342|10162468|FG002|Double-Blind Phase|Withdrawal by Subject|38
6372487|NCT03345342|10162469|FG003|Double-Blind Phase|Withdrawal by Subject|0
6372488|NCT03345342|10162470|FG004|Double-Blind Phase|Withdrawal by Subject|0
6372489|NCT03345342|10162466|FG000|Double-Blind Phase|Other|0
6372490|NCT03345342|10162467|FG001|Double-Blind Phase|Other|1
6372491|NCT03345342|10162468|FG002|Double-Blind Phase|Other|3
6372492|NCT03345342|10162469|FG003|Double-Blind Phase|Other|0
6372493|NCT03345342|10162470|FG004|Double-Blind Phase|Other|0
6372494|NCT03345342|10162466|FG000|Follow-Up Phase|Adverse Event|0
6372495|NCT03345342|10162467|FG001|Follow-Up Phase|Adverse Event|0
6372496|NCT03345342|10162468|FG002|Follow-Up Phase|Adverse Event|0
6372497|NCT03345342|10162469|FG003|Follow-Up Phase|Adverse Event|0
6372498|NCT03345342|10162470|FG004|Follow-Up Phase|Adverse Event|4
6372499|NCT03345342|10162466|FG000|Follow-Up Phase|Lost to Follow-up|0
6372500|NCT03345342|10162467|FG001|Follow-Up Phase|Lost to Follow-up|0
6372501|NCT03345342|10162468|FG002|Follow-Up Phase|Lost to Follow-up|0
6372502|NCT03345342|10162469|FG003|Follow-Up Phase|Lost to Follow-up|0
6372503|NCT03345342|10162470|FG004|Follow-Up Phase|Lost to Follow-up|6
6372504|NCT03345342|10162466|FG000|Follow-Up Phase|Physician Decision|0
6372505|NCT03345342|10162467|FG001|Follow-Up Phase|Physician Decision|0
6372506|NCT03345342|10162468|FG002|Follow-Up Phase|Physician Decision|0
6372507|NCT03345342|10162469|FG003|Follow-Up Phase|Physician Decision|0
6372508|NCT03345342|10162470|FG004|Follow-Up Phase|Physician Decision|5
6372509|NCT03345342|10162466|FG000|Follow-Up Phase|Withdrawal by Subject|0
6372510|NCT03345342|10162467|FG001|Follow-Up Phase|Withdrawal by Subject|0
6372511|NCT03345342|10162468|FG002|Follow-Up Phase|Withdrawal by Subject|0
6372512|NCT03345342|10162469|FG003|Follow-Up Phase|Withdrawal by Subject|5
6372513|NCT03345342|10162470|FG004|Follow-Up Phase|Withdrawal by Subject|15
6372514|NCT03345342|10162466|FG000|Follow-Up Phase|Other|0
6372515|NCT03345342|10162467|FG001|Follow-Up Phase|Other|0
6372516|NCT03345342|10162468|FG002|Follow-Up Phase|Other|0
6372517|NCT03345342|10162469|FG003|Follow-Up Phase|Other|3
6372518|NCT03345342|10162470|FG004|Follow-Up Phase|Other|1
6372519|NCT03265145|10162484|FG000|Overall Study|Protocol Violation|2
6372520|NCT03265145|10162485|FG001|Overall Study|Protocol Violation|0
6372521|NCT03265145|10162484|FG000|Overall Study|Adverse Event|1
6372522|NCT03265145|10162485|FG001|Overall Study|Adverse Event|0
6372523|NCT03265145|10162484|FG000|Overall Study|Withdrawal by Subject|23
6372524|NCT03265145|10162485|FG001|Overall Study|Withdrawal by Subject|19
6372525|NCT03265145|10162484|FG000|Overall Study|Death|12
6372526|NCT03265145|10162485|FG001|Overall Study|Death|12
6372527|NCT03265145|10162484|FG000|Overall Study|Lost to Follow-up|13
6372528|NCT03265145|10162485|FG001|Overall Study|Lost to Follow-up|9
6372529|NCT03265145|10162484|FG000|Overall Study|missing end of study form, could not definitely count as completion or discontinuation|0
6372530|NCT03265145|10162485|FG001|Overall Study|missing end of study form, could not definitely count as completion or discontinuation|1
6372531|NCT03265145|10162484|FG000|Overall Study|Switched back to previous medication|1
6372532|NCT03265145|10162485|FG001|Overall Study|Switched back to previous medication|0
6372533|NCT03265145|10162484|FG000|Overall Study|Did not want to take medication|1
6372534|NCT03265145|10162485|FG001|Overall Study|Did not want to take medication|0
6372535|NCT03265145|10162484|FG000|Overall Study|Subject could not afford medication|0
6372536|NCT03265145|10162485|FG001|Overall Study|Subject could not afford medication|1
6372537|NCT03265145|10162484|FG000|Overall Study|Site closed|2
6372538|NCT03265145|10162485|FG001|Overall Study|Site closed|3
6372539|NCT03265145|10162484|FG000|Overall Study|Incorrectly randomized|16
6372540|NCT03265145|10162485|FG001|Overall Study|Incorrectly randomized|6
6372541|NCT03265145|10162484|FG000|Overall Study|Entered into Electronic Data Capture in error|0
6372542|NCT03265145|10162485|FG001|Overall Study|Entered into Electronic Data Capture in error|1
6372543|NCT03265145|10162484|FG000|Overall Study|Physician Decision|0
6372544|NCT03265145|10162485|FG001|Overall Study|Physician Decision|3
6372545|NCT03265145|10162484|FG000|Overall Study|Subject transferred to another facility|0
6372546|NCT03265145|10162485|FG001|Overall Study|Subject transferred to another facility|1
6372547|NCT02880241|10162513|FG000|Overall Study|Lack of Efficacy|1
6372548|NCT02880241|10162514|FG001|Overall Study|Lack of Efficacy|0
6372549|NCT02880241|10162515|FG002|Overall Study|Lack of Efficacy|0
6372550|NCT02880241|10162516|FG003|Overall Study|Lack of Efficacy|0
6372551|NCT02880241|10162517|FG004|Overall Study|Lack of Efficacy|0
6372552|NCT02880241|10162518|FG005|Overall Study|Lack of Efficacy|0
6372553|NCT02832687|10162536|FG000|Overall Study|Adverse Event|0
6372554|NCT02832687|10162537|FG001|Overall Study|Adverse Event|2
6372555|NCT02499900|10162549|FG000|Core Study Period|Other|1
6372556|NCT02499900|10162550|FG001|Core Study Period|Other|4
6372557|NCT02499900|10162549|FG000|Core Study Period|Lost to Follow-up|1
6372558|NCT02499900|10162550|FG001|Core Study Period|Lost to Follow-up|2
6372559|NCT02499900|10162549|FG000|Core Study Period|Per sponsor request|0
6372560|NCT02499900|10162550|FG001|Core Study Period|Per sponsor request|1
6372561|NCT02499900|10162549|FG000|Core Study Period|Pregnancy|1
6372562|NCT02499900|10162550|FG001|Core Study Period|Pregnancy|0
6372563|NCT02499900|10162549|FG000|Core Study Period|Protocol Violation|3
6372564|NCT02499900|10162550|FG001|Core Study Period|Protocol Violation|0
6372565|NCT02499900|10162549|FG000|Core Study Period|Withdrawal by Subject|11
6372566|NCT02499900|10162550|FG001|Core Study Period|Withdrawal by Subject|10
6372567|NCT02499900|10162549|FG000|Core Study Period|Adverse Event|18
6372568|NCT02499900|10162550|FG001|Core Study Period|Adverse Event|14
6372569|NCT02499900|10162549|FG000|Core Study Period|Death|0
6372570|NCT02499900|10162550|FG001|Core Study Period|Death|1
6372571|NCT02499900|10162549|FG000|Completed Core, Continued Into Extension|Physician Decision|1
6372572|NCT02499900|10162550|FG001|Completed Core, Continued Into Extension|Physician Decision|0
6372573|NCT02499900|10162549|FG000|Completed Core, Continued Into Extension|Withdrawal by Subject|0
6372574|NCT02499900|10162550|FG001|Completed Core, Continued Into Extension|Withdrawal by Subject|2
6372575|NCT02499900|10162549|FG000|Completed Core, Continued Into Extension|Did not wish to take injectables drugs|1
6372576|NCT02499900|10162550|FG001|Completed Core, Continued Into Extension|Did not wish to take injectables drugs|0
6372577|NCT02499900|10162549|FG000|Completed Core, Continued Into Extension|Personal motivation|1
6372578|NCT02499900|10162550|FG001|Completed Core, Continued Into Extension|Personal motivation|0
6372579|NCT02499900|10162549|FG000|Extension Study Period|Adverse Event|2
6372580|NCT02499900|10162550|FG001|Extension Study Period|Adverse Event|4
6372581|NCT02499900|10162549|FG000|Extension Study Period|Withdrawal by Subject|5
6372582|NCT02499900|10162550|FG001|Extension Study Period|Withdrawal by Subject|2
6372583|NCT02499900|10162549|FG000|Extension Study Period|Physician Decision|2
6372584|NCT02499900|10162550|FG001|Extension Study Period|Physician Decision|5
6372585|NCT02499900|10162549|FG000|Extension Study Period|Pregnancy|1
6372586|NCT02499900|10162550|FG001|Extension Study Period|Pregnancy|2
6372587|NCT02499900|10162549|FG000|Extension Study Period|Lost to Follow-up|2
6372588|NCT02499900|10162550|FG001|Extension Study Period|Lost to Follow-up|5
6372589|NCT02499900|10162549|FG000|Extension Study Period|Other|0
6372590|NCT02499900|10162550|FG001|Extension Study Period|Other|2
6372591|NCT02269917|10162577|FG000|BL to EOE-Test and BL to Switch-Control|Lost to Follow-up|25
6372592|NCT02269917|10162578|FG001|BL to EOE-Test and BL to Switch-Control|Lost to Follow-up|7
6372593|NCT02269917|10162579|FG002|BL to EOE-Test and BL to Switch-Control|Lost to Follow-up|0
6084640|NCT00643760|9693601|FG002|Overall Study|Adverse Event|12
6084641|NCT00643760|9693602|FG003|Overall Study|Adverse Event|21
6084642|NCT00643760|9693603|FG004|Overall Study|Adverse Event|6
6084643|NCT00643760|9693599|FG000|Overall Study|Lack of Efficacy|3
6372594|NCT02269917|10162577|FG000|BL to EOE-Test and BL to Switch-Control|Other|19
6372595|NCT02269917|10162578|FG001|BL to EOE-Test and BL to Switch-Control|Other|4
6372596|NCT02269917|10162579|FG002|BL to EOE-Test and BL to Switch-Control|Other|0
6372597|NCT02269917|10162577|FG000|BL to EOE-Test and BL to Switch-Control|Withdrawal by Subject|32
6372598|NCT02269917|10162578|FG001|BL to EOE-Test and BL to Switch-Control|Withdrawal by Subject|10
6372599|NCT02269917|10162579|FG002|BL to EOE-Test and BL to Switch-Control|Withdrawal by Subject|0
6372600|NCT02269917|10162577|FG000|BL to EOE-Test and BL to Switch-Control|Adverse Event|24
6372601|NCT02269917|10162578|FG001|BL to EOE-Test and BL to Switch-Control|Adverse Event|4
6372602|NCT02269917|10162579|FG002|BL to EOE-Test and BL to Switch-Control|Adverse Event|0
6372603|NCT02269917|10162577|FG000|BL to EOE-Test and BL to Switch-Control|Non-compliance with study drug|4
6372604|NCT02269917|10162578|FG001|BL to EOE-Test and BL to Switch-Control|Non-compliance with study drug|0
6372605|NCT02269917|10162579|FG002|BL to EOE-Test and BL to Switch-Control|Non-compliance with study drug|0
6372606|NCT02269917|10162577|FG000|BL to EOE-Test and BL to Switch-Control|Physician Decision|4
6372607|NCT02269917|10162578|FG001|BL to EOE-Test and BL to Switch-Control|Physician Decision|0
6372608|NCT02269917|10162579|FG002|BL to EOE-Test and BL to Switch-Control|Physician Decision|0
6372609|NCT02269917|10162577|FG000|BL to EOE-Test and BL to Switch-Control|Protocol Violation|2
6372610|NCT02269917|10162578|FG001|BL to EOE-Test and BL to Switch-Control|Protocol Violation|1
6372611|NCT02269917|10162579|FG002|BL to EOE-Test and BL to Switch-Control|Protocol Violation|0
6372612|NCT02269917|10162577|FG000|BL to EOE-Test and BL to Switch-Control|Death|4
6372613|NCT02269917|10162578|FG001|BL to EOE-Test and BL to Switch-Control|Death|0
6372614|NCT02269917|10162579|FG002|BL to EOE-Test and BL to Switch-Control|Death|0
6372615|NCT02269917|10162577|FG000|BL to EOE-Test and BL to Switch-Control|Randomized but not treated|3
6372616|NCT02269917|10162578|FG001|BL to EOE-Test and BL to Switch-Control|Randomized but not treated|5
6372617|NCT02269917|10162579|FG002|BL to EOE-Test and BL to Switch-Control|Randomized but not treated|0
6372618|NCT02269917|10162577|FG000|Switch to D/C/F/TAF (Until EOE)|Death|0
6372619|NCT02269917|10162578|FG001|Switch to D/C/F/TAF (Until EOE)|Death|0
6372620|NCT02269917|10162579|FG002|Switch to D/C/F/TAF (Until EOE)|Death|1
6372621|NCT02269917|10162577|FG000|Switch to D/C/F/TAF (Until EOE)|Lost to Follow-up|0
6372622|NCT02269917|10162578|FG001|Switch to D/C/F/TAF (Until EOE)|Lost to Follow-up|0
6372623|NCT02269917|10162579|FG002|Switch to D/C/F/TAF (Until EOE)|Lost to Follow-up|10
6372624|NCT02269917|10162577|FG000|Switch to D/C/F/TAF (Until EOE)|Adverse Event|0
6372625|NCT02269917|10162578|FG001|Switch to D/C/F/TAF (Until EOE)|Adverse Event|0
6372626|NCT02269917|10162579|FG002|Switch to D/C/F/TAF (Until EOE)|Adverse Event|11
6372627|NCT02269917|10162577|FG000|Switch to D/C/F/TAF (Until EOE)|Physician Decision|0
6372628|NCT02269917|10162578|FG001|Switch to D/C/F/TAF (Until EOE)|Physician Decision|0
6372629|NCT02269917|10162579|FG002|Switch to D/C/F/TAF (Until EOE)|Physician Decision|1
6372630|NCT02269917|10162577|FG000|Switch to D/C/F/TAF (Until EOE)|Pregnancy|0
6372631|NCT02269917|10162578|FG001|Switch to D/C/F/TAF (Until EOE)|Pregnancy|0
6372632|NCT02269917|10162579|FG002|Switch to D/C/F/TAF (Until EOE)|Pregnancy|2
6372633|NCT02269917|10162577|FG000|Switch to D/C/F/TAF (Until EOE)|Withdrawal by Subject|0
6372634|NCT02269917|10162578|FG001|Switch to D/C/F/TAF (Until EOE)|Withdrawal by Subject|0
6372635|NCT02269917|10162579|FG002|Switch to D/C/F/TAF (Until EOE)|Withdrawal by Subject|5
6372636|NCT02269917|10162577|FG000|Switch to D/C/F/TAF (Until EOE)|Other|0
6372637|NCT02269917|10162578|FG001|Switch to D/C/F/TAF (Until EOE)|Other|0
6372638|NCT02269917|10162579|FG002|Switch to D/C/F/TAF (Until EOE)|Other|8
6372639|NCT02225366|10162590|FG000|Overall Study|Lack of Efficacy|1
6372640|NCT02225366|10162591|FG001|Overall Study|Lack of Efficacy|0
6372641|NCT01530997|10162597|FG000|Overall Study|Physician Decision|1
6372642|NCT01530997|10162597|FG000|Overall Study|Withdrawal by Subject|1
6372643|NCT01067521|10162623|FG000|Double-Blind Placebo-Controlled Period|Death|0
6372644|NCT01067521|10162624|FG001|Double-Blind Placebo-Controlled Period|Death|1
6372645|NCT01067521|10162623|FG000|Double-Blind Placebo-Controlled Period|Adverse Event|29
6372646|NCT01067521|10162624|FG001|Double-Blind Placebo-Controlled Period|Adverse Event|6
6372647|NCT01067521|10162623|FG000|Double-Blind Placebo-Controlled Period|Withdrawal by Subject|34
6372648|NCT01067521|10162624|FG001|Double-Blind Placebo-Controlled Period|Withdrawal by Subject|17
6372649|NCT01067521|10162623|FG000|Double-Blind Placebo-Controlled Period|Physician Decision|1
6372650|NCT01067521|10162624|FG001|Double-Blind Placebo-Controlled Period|Physician Decision|1
6084644|NCT00643760|9693600|FG001|Overall Study|Lack of Efficacy|1
6372651|NCT01067521|10162623|FG000|Double-Blind Placebo-Controlled Period|Refused to sign informed consent|4
6372652|NCT01067521|10162624|FG001|Double-Blind Placebo-Controlled Period|Refused to sign informed consent|1
6372653|NCT01067521|10162623|FG000|Double-Blind Placebo-Controlled Period|Noncompliance with study drug|2
6372654|NCT01067521|10162624|FG001|Double-Blind Placebo-Controlled Period|Noncompliance with study drug|0
6372655|NCT01067521|10162623|FG000|Double-Blind Placebo-Controlled Period|Protocol Violation|2
6372656|NCT01067521|10162624|FG001|Double-Blind Placebo-Controlled Period|Protocol Violation|0
6372657|NCT01067521|10162623|FG000|Double-Blind Placebo-Controlled Period|Pregnancy|7
6372658|NCT01067521|10162624|FG001|Double-Blind Placebo-Controlled Period|Pregnancy|4
6372659|NCT01067521|10162623|FG000|Double-Blind Placebo-Controlled Period|Lost to Follow-up|5
6372660|NCT01067521|10162624|FG001|Double-Blind Placebo-Controlled Period|Lost to Follow-up|1
6372661|NCT01067521|10162623|FG000|Open-Label Period|Death|3
6372662|NCT01067521|10162624|FG001|Open-Label Period|Death|1
6372663|NCT01067521|10162623|FG000|Open-Label Period|Adverse Event|30
6372664|NCT01067521|10162624|FG001|Open-Label Period|Adverse Event|28
6372665|NCT01067521|10162623|FG000|Open-Label Period|Withdrawal by Subject|160
6372666|NCT01067521|10162624|FG001|Open-Label Period|Withdrawal by Subject|88
6372667|NCT01067521|10162623|FG000|Open-Label Period|Physician Decision|13
6372668|NCT01067521|10162624|FG001|Open-Label Period|Physician Decision|11
6372669|NCT01067521|10162623|FG000|Open-Label Period|Non-compliance with study drug|5
6372670|NCT01067521|10162624|FG001|Open-Label Period|Non-compliance with study drug|0
6372671|NCT01067521|10162623|FG000|Open-Label Period|Protocol Violation|3
6372672|NCT01067521|10162624|FG001|Open-Label Period|Protocol Violation|0
6372673|NCT01067521|10162623|FG000|Open-Label Period|Pregnancy|14
6372674|NCT01067521|10162624|FG001|Open-Label Period|Pregnancy|8
6372675|NCT01067521|10162623|FG000|Open-Label Period|Teva requested subject to be withdrawn|5
6372676|NCT01067521|10162624|FG001|Open-Label Period|Teva requested subject to be withdrawn|2
6372677|NCT01067521|10162623|FG000|Open-Label Period|Lost to Follow-up|21
6372678|NCT01067521|10162624|FG001|Open-Label Period|Lost to Follow-up|20
6372679|NCT01047319|10162638|FG000|Overall Study|Teva requested participant withdrawal|3
6372680|NCT01047319|10162639|FG001|Overall Study|Teva requested participant withdrawal|0
6372681|NCT01047319|10162640|FG002|Overall Study|Teva requested participant withdrawal|1
6372682|NCT01047319|10162638|FG000|Overall Study|Protocol Violation|3
6372683|NCT01047319|10162639|FG001|Overall Study|Protocol Violation|2
6372684|NCT01047319|10162640|FG002|Overall Study|Protocol Violation|4
6372685|NCT01047319|10162638|FG000|Overall Study|Lack of Efficacy|4
6372686|NCT01047319|10162639|FG001|Overall Study|Lack of Efficacy|3
6372687|NCT01047319|10162640|FG002|Overall Study|Lack of Efficacy|3
6372688|NCT01047319|10162638|FG000|Overall Study|Death|5
6372689|NCT01047319|10162639|FG001|Overall Study|Death|1
6372690|NCT01047319|10162640|FG002|Overall Study|Death|5
6372691|NCT01047319|10162638|FG000|Overall Study|Pregnancy|13
6372692|NCT01047319|10162639|FG001|Overall Study|Pregnancy|8
6372693|NCT01047319|10162640|FG002|Overall Study|Pregnancy|8
6372694|NCT01047319|10162638|FG000|Overall Study|Physician Decision|12
6372695|NCT01047319|10162639|FG001|Overall Study|Physician Decision|9
6372696|NCT01047319|10162640|FG002|Overall Study|Physician Decision|10
6372697|NCT01047319|10162638|FG000|Overall Study|Lost to Follow-up|14
6372698|NCT01047319|10162639|FG001|Overall Study|Lost to Follow-up|10
6372699|NCT01047319|10162640|FG002|Overall Study|Lost to Follow-up|10
6372700|NCT01047319|10162638|FG000|Overall Study|Adverse Event|16
6372701|NCT01047319|10162639|FG001|Overall Study|Adverse Event|27
6372702|NCT01047319|10162640|FG002|Overall Study|Adverse Event|21
6372703|NCT01047319|10162638|FG000|Overall Study|Withdrawal by Subject|77
6372704|NCT01047319|10162639|FG001|Overall Study|Withdrawal by Subject|75
6372705|NCT01047319|10162640|FG002|Overall Study|Withdrawal by Subject|87
6372706|NCT01047319|10162638|FG000|Overall Study|Study terminated by Sponsor|198
6372707|NCT01047319|10162639|FG001|Overall Study|Study terminated by Sponsor|215
6372708|NCT01047319|10162640|FG002|Overall Study|Study terminated by Sponsor|203
6372709|NCT00988052|10162650|FG000|Overall Study|Missing|1
6372710|NCT00988052|10162651|FG001|Overall Study|Missing|0
6372711|NCT00988052|10162650|FG000|Overall Study|Teva requested subject withdrawal|3
6372712|NCT00988052|10162651|FG001|Overall Study|Teva requested subject withdrawal|1
6372713|NCT00988052|10162650|FG000|Overall Study|Death|1
6372714|NCT00988052|10162651|FG001|Overall Study|Death|3
6372715|NCT00988052|10162650|FG000|Overall Study|Protocol Violation|6
6372716|NCT00988052|10162651|FG001|Overall Study|Protocol Violation|5
6372717|NCT00988052|10162650|FG000|Overall Study|Pregnancy|6
6372718|NCT00988052|10162651|FG001|Overall Study|Pregnancy|6
6372719|NCT00988052|10162650|FG000|Overall Study|Lack of Efficacy|8
6372720|NCT00988052|10162651|FG001|Overall Study|Lack of Efficacy|7
6372721|NCT00988052|10162650|FG000|Overall Study|Lost to Follow-up|6
6372722|NCT00988052|10162651|FG001|Overall Study|Lost to Follow-up|11
6372723|NCT00988052|10162650|FG000|Overall Study|Physician Decision|27
6372724|NCT00988052|10162651|FG001|Overall Study|Physician Decision|28
6372725|NCT00988052|10162650|FG000|Overall Study|Adverse Event|35
6372726|NCT00988052|10162651|FG001|Overall Study|Adverse Event|28
6372727|NCT00988052|10162650|FG000|Overall Study|Withdrawal by Subject|90
6372728|NCT00988052|10162651|FG001|Overall Study|Withdrawal by Subject|91
6372729|NCT00988052|10162650|FG000|Overall Study|Study terminated by sponsor|240
6372730|NCT00988052|10162651|FG001|Overall Study|Study terminated by sponsor|236
6372731|NCT02021773|10162660|FG000|Overall Study|Adverse Event|1
6372732|NCT02021773|10162661|FG001|Overall Study|Adverse Event|4
6372733|NCT02021773|10162662|FG002|Overall Study|Adverse Event|3
6372734|NCT02021773|10162660|FG000|Overall Study|Lack of Efficacy|2
6372735|NCT02021773|10162661|FG001|Overall Study|Lack of Efficacy|2
6372736|NCT02021773|10162662|FG002|Overall Study|Lack of Efficacy|2
6372737|NCT02021773|10162660|FG000|Overall Study|Protocol Violation|2
6372738|NCT02021773|10162661|FG001|Overall Study|Protocol Violation|3
6372739|NCT02021773|10162662|FG002|Overall Study|Protocol Violation|1
6372740|NCT02021773|10162660|FG000|Overall Study|Withdrawal by Subject|3
6372741|NCT02021773|10162661|FG001|Overall Study|Withdrawal by Subject|4
6084645|NCT00643760|9693601|FG002|Overall Study|Lack of Efficacy|0
6084646|NCT00643760|9693602|FG003|Overall Study|Lack of Efficacy|4
6084647|NCT00643760|9693603|FG004|Overall Study|Lack of Efficacy|3
6084648|NCT00643760|9693599|FG000|Overall Study|Protocol Violation|7
6084649|NCT00643760|9693600|FG001|Overall Study|Protocol Violation|6
6372742|NCT02021773|10162662|FG002|Overall Study|Withdrawal by Subject|5
6372743|NCT02021773|10162660|FG000|Overall Study|Lost to Follow-up|1
6372744|NCT02021773|10162661|FG001|Overall Study|Lost to Follow-up|3
6372745|NCT02021773|10162662|FG002|Overall Study|Lost to Follow-up|0
6372746|NCT02021773|10162660|FG000|Overall Study|Reason not specified|3
6372747|NCT02021773|10162661|FG001|Overall Study|Reason not specified|0
6372748|NCT02021773|10162662|FG002|Overall Study|Reason not specified|0
6084650|NCT00643760|9693601|FG002|Overall Study|Protocol Violation|4
6084651|NCT00643760|9693602|FG003|Overall Study|Protocol Violation|4
6084652|NCT00643760|9693603|FG004|Overall Study|Protocol Violation|6
6372749|NCT04553406|10162686|FG000|Overall Study|Study Discontinuation|0
6372750|NCT04553406|10162687|FG001|Overall Study|Study Discontinuation|1
6372751|NCT03792750|10162693|FG000|Overall Study|Death|3
6372752|NCT03739138|10162714|FG000|Overall Study|Death|0
6372753|NCT03739138|10162715|FG001|Overall Study|Death|7
6372754|NCT03739138|10162716|FG002|Overall Study|Death|4
6372755|NCT03739138|10162717|FG003|Overall Study|Death|13
6372756|NCT03739138|10162718|FG004|Overall Study|Death|0
6372757|NCT03739138|10162714|FG000|Overall Study|Lost to Follow-up|0
6372758|NCT03739138|10162715|FG001|Overall Study|Lost to Follow-up|0
6372759|NCT03739138|10162716|FG002|Overall Study|Lost to Follow-up|1
6372760|NCT03739138|10162717|FG003|Overall Study|Lost to Follow-up|0
6372761|NCT03739138|10162718|FG004|Overall Study|Lost to Follow-up|0
6372762|NCT03739138|10162714|FG000|Overall Study|Study Terminated By Sponsor|0
6372763|NCT03739138|10162715|FG001|Overall Study|Study Terminated By Sponsor|0
6372764|NCT03739138|10162716|FG002|Overall Study|Study Terminated By Sponsor|0
6372765|NCT03739138|10162717|FG003|Overall Study|Study Terminated By Sponsor|4
6372766|NCT03739138|10162718|FG004|Overall Study|Study Terminated By Sponsor|0
6372767|NCT03739138|10162714|FG000|Overall Study|Withdrawal by Subject|0
6372768|NCT03739138|10162715|FG001|Overall Study|Withdrawal by Subject|0
6372769|NCT03739138|10162716|FG002|Overall Study|Withdrawal by Subject|0
6372770|NCT03739138|10162717|FG003|Overall Study|Withdrawal by Subject|1
6372771|NCT03739138|10162718|FG004|Overall Study|Withdrawal by Subject|0
6372772|NCT03518086|10162728|FG000|Overall Study|Adverse Event|23
6372773|NCT03518086|10162729|FG001|Overall Study|Adverse Event|15
6372774|NCT03518086|10162730|FG002|Overall Study|Adverse Event|0
6372775|NCT03518086|10162731|FG003|Overall Study|Adverse Event|0
6372776|NCT03518086|10162728|FG000|Overall Study|Withdrawal by Subject|8
6372777|NCT03518086|10162729|FG001|Overall Study|Withdrawal by Subject|5
6372778|NCT03518086|10162730|FG002|Overall Study|Withdrawal by Subject|0
6372779|NCT03518086|10162731|FG003|Overall Study|Withdrawal by Subject|0
6372780|NCT03518086|10162728|FG000|Overall Study|Lack of Efficacy|5
6372781|NCT03518086|10162729|FG001|Overall Study|Lack of Efficacy|5
6372782|NCT03518086|10162730|FG002|Overall Study|Lack of Efficacy|0
6372783|NCT03518086|10162731|FG003|Overall Study|Lack of Efficacy|0
6372784|NCT03518086|10162728|FG000|Overall Study|Protocol Violation|1
6372785|NCT03518086|10162729|FG001|Overall Study|Protocol Violation|5
6372786|NCT03518086|10162730|FG002|Overall Study|Protocol Violation|0
6372787|NCT03518086|10162731|FG003|Overall Study|Protocol Violation|0
6372788|NCT03518086|10162728|FG000|Overall Study|Lost to Follow-up|0
6372789|NCT03518086|10162729|FG001|Overall Study|Lost to Follow-up|3
6372790|NCT03518086|10162730|FG002|Overall Study|Lost to Follow-up|0
6372791|NCT03518086|10162731|FG003|Overall Study|Lost to Follow-up|0
6372792|NCT03518086|10162728|FG000|Overall Study|Insufficient Diary Data|0
6372793|NCT03518086|10162729|FG001|Overall Study|Insufficient Diary Data|2
6372794|NCT03518086|10162730|FG002|Overall Study|Insufficient Diary Data|0
6372795|NCT03518086|10162731|FG003|Overall Study|Insufficient Diary Data|0
6372796|NCT03518086|10162728|FG000|Overall Study|Non- compliance to Protocol|0
6372797|NCT03518086|10162729|FG001|Overall Study|Non- compliance to Protocol|1
6372798|NCT03518086|10162730|FG002|Overall Study|Non- compliance to Protocol|0
6372799|NCT03518086|10162731|FG003|Overall Study|Non- compliance to Protocol|0
6372800|NCT03518086|10162728|FG000|Overall Study|COVID-19 Related Study Disruption|0
6372801|NCT03518086|10162729|FG001|Overall Study|COVID-19 Related Study Disruption|2
6372802|NCT03518086|10162730|FG002|Overall Study|COVID-19 Related Study Disruption|0
6372803|NCT03518086|10162731|FG003|Overall Study|COVID-19 Related Study Disruption|0
6372804|NCT03518086|10162728|FG000|Overall Study|Site Terminated by Sponsor|0
6372805|NCT03518086|10162729|FG001|Overall Study|Site Terminated by Sponsor|1
6372806|NCT03518086|10162730|FG002|Overall Study|Site Terminated by Sponsor|0
6372807|NCT03518086|10162731|FG003|Overall Study|Site Terminated by Sponsor|0
6372808|NCT03468309|10162738|FG000|Overall Study|Lost to Follow-up|4
6372809|NCT03468309|10162738|FG000|Overall Study|Withdrawal by Subject|2
6372810|NCT03347123|10162744|FG000|Overall Study|Death|1
6372811|NCT03347123|10162745|FG001|Overall Study|Death|2
6372812|NCT03347123|10162746|FG002|Overall Study|Death|0
6372813|NCT03347123|10162747|FG003|Overall Study|Death|0
6372814|NCT03347123|10162748|FG004|Overall Study|Death|0
6372815|NCT03347123|10162749|FG005|Overall Study|Death|0
6372816|NCT03347123|10162750|FG006|Overall Study|Death|0
6372817|NCT03347123|10162744|FG000|Overall Study|Withdrawal by Subject|1
6372818|NCT03347123|10162745|FG001|Overall Study|Withdrawal by Subject|0
6372819|NCT03347123|10162746|FG002|Overall Study|Withdrawal by Subject|0
6372820|NCT03347123|10162747|FG003|Overall Study|Withdrawal by Subject|0
6372821|NCT03347123|10162748|FG004|Overall Study|Withdrawal by Subject|0
6372822|NCT03347123|10162749|FG005|Overall Study|Withdrawal by Subject|0
6372823|NCT03347123|10162750|FG006|Overall Study|Withdrawal by Subject|0
6372824|NCT03347123|10162744|FG000|Overall Study|Reason not Specified|3
6372825|NCT03347123|10162745|FG001|Overall Study|Reason not Specified|4
6372826|NCT03347123|10162746|FG002|Overall Study|Reason not Specified|0
6372827|NCT03347123|10162747|FG003|Overall Study|Reason not Specified|0
6372828|NCT03347123|10162748|FG004|Overall Study|Reason not Specified|0
6372829|NCT03347123|10162749|FG005|Overall Study|Reason not Specified|0
6372830|NCT03347123|10162750|FG006|Overall Study|Reason not Specified|0
6372831|NCT03318523|10162765|FG000|PC Period: Up to Year 1|Adverse Event|1
6372832|NCT03318523|10162766|FG001|PC Period: Up to Year 1|Adverse Event|0
6372833|NCT03318523|10162767|FG002|PC Period: Up to Year 1|Adverse Event|2
6372834|NCT03318523|10162768|FG003|PC Period: Up to Year 1|Adverse Event|0
6372835|NCT03318523|10162769|FG004|PC Period: Up to Year 1|Adverse Event|0
6372836|NCT03318523|10162770|FG005|PC Period: Up to Year 1|Adverse Event|0
6372837|NCT03318523|10162771|FG006|PC Period: Up to Year 1|Adverse Event|0
6372838|NCT03318523|10162772|FG007|PC Period: Up to Year 1|Adverse Event|0
6372839|NCT03318523|10162773|FG008|PC Period: Up to Year 1|Adverse Event|0
6372840|NCT03318523|10162774|FG009|PC Period: Up to Year 1|Adverse Event|0
6372841|NCT03318523|10162765|FG000|PC Period: Up to Year 1|Consent Withdrawn|3
6372842|NCT03318523|10162766|FG001|PC Period: Up to Year 1|Consent Withdrawn|2
6372843|NCT03318523|10162767|FG002|PC Period: Up to Year 1|Consent Withdrawn|0
6372844|NCT03318523|10162768|FG003|PC Period: Up to Year 1|Consent Withdrawn|4
6372845|NCT03318523|10162769|FG004|PC Period: Up to Year 1|Consent Withdrawn|0
6372846|NCT03318523|10162770|FG005|PC Period: Up to Year 1|Consent Withdrawn|0
6372847|NCT03318523|10162771|FG006|PC Period: Up to Year 1|Consent Withdrawn|0
6372848|NCT03318523|10162772|FG007|PC Period: Up to Year 1|Consent Withdrawn|0
6372849|NCT03318523|10162773|FG008|PC Period: Up to Year 1|Consent Withdrawn|0
6372850|NCT03318523|10162774|FG009|PC Period: Up to Year 1|Consent Withdrawn|0
6372851|NCT03318523|10162765|FG000|DBE Period:Year 2 to EOS (Up to 3 Years)|Adverse Event|0
6372852|NCT03318523|10162766|FG001|DBE Period:Year 2 to EOS (Up to 3 Years)|Adverse Event|0
6372853|NCT03318523|10162767|FG002|DBE Period:Year 2 to EOS (Up to 3 Years)|Adverse Event|0
6372854|NCT03318523|10162768|FG003|DBE Period:Year 2 to EOS (Up to 3 Years)|Adverse Event|0
6372855|NCT03318523|10162769|FG004|DBE Period:Year 2 to EOS (Up to 3 Years)|Adverse Event|1
6372856|NCT03318523|10162770|FG005|DBE Period:Year 2 to EOS (Up to 3 Years)|Adverse Event|0
6372857|NCT03318523|10162771|FG006|DBE Period:Year 2 to EOS (Up to 3 Years)|Adverse Event|0
6372858|NCT03318523|10162772|FG007|DBE Period:Year 2 to EOS (Up to 3 Years)|Adverse Event|1
6372859|NCT03318523|10162773|FG008|DBE Period:Year 2 to EOS (Up to 3 Years)|Adverse Event|0
6372860|NCT03318523|10162774|FG009|DBE Period:Year 2 to EOS (Up to 3 Years)|Adverse Event|2
6372861|NCT03318523|10162765|FG000|DBE Period:Year 2 to EOS (Up to 3 Years)|Consent Withdrawn|0
6372862|NCT03318523|10162766|FG001|DBE Period:Year 2 to EOS (Up to 3 Years)|Consent Withdrawn|0
6372863|NCT03318523|10162767|FG002|DBE Period:Year 2 to EOS (Up to 3 Years)|Consent Withdrawn|0
6372864|NCT03318523|10162768|FG003|DBE Period:Year 2 to EOS (Up to 3 Years)|Consent Withdrawn|0
6372865|NCT03318523|10162769|FG004|DBE Period:Year 2 to EOS (Up to 3 Years)|Consent Withdrawn|1
6372866|NCT03318523|10162770|FG005|DBE Period:Year 2 to EOS (Up to 3 Years)|Consent Withdrawn|0
6372867|NCT03318523|10162771|FG006|DBE Period:Year 2 to EOS (Up to 3 Years)|Consent Withdrawn|0
6372868|NCT03318523|10162772|FG007|DBE Period:Year 2 to EOS (Up to 3 Years)|Consent Withdrawn|1
6372869|NCT03318523|10162773|FG008|DBE Period:Year 2 to EOS (Up to 3 Years)|Consent Withdrawn|3
6372870|NCT03318523|10162774|FG009|DBE Period:Year 2 to EOS (Up to 3 Years)|Consent Withdrawn|2
6372871|NCT03318523|10162765|FG000|DBE Period:Year 2 to EOS (Up to 3 Years)|Investigator Decision|0
6372872|NCT03318523|10162766|FG001|DBE Period:Year 2 to EOS (Up to 3 Years)|Investigator Decision|0
6372873|NCT03318523|10162767|FG002|DBE Period:Year 2 to EOS (Up to 3 Years)|Investigator Decision|0
6372874|NCT03318523|10162768|FG003|DBE Period:Year 2 to EOS (Up to 3 Years)|Investigator Decision|0
6372875|NCT03318523|10162769|FG004|DBE Period:Year 2 to EOS (Up to 3 Years)|Investigator Decision|0
6372876|NCT03318523|10162770|FG005|DBE Period:Year 2 to EOS (Up to 3 Years)|Investigator Decision|1
6372877|NCT03318523|10162771|FG006|DBE Period:Year 2 to EOS (Up to 3 Years)|Investigator Decision|0
6372878|NCT03318523|10162772|FG007|DBE Period:Year 2 to EOS (Up to 3 Years)|Investigator Decision|0
6372879|NCT03318523|10162773|FG008|DBE Period:Year 2 to EOS (Up to 3 Years)|Investigator Decision|0
6372880|NCT03318523|10162774|FG009|DBE Period:Year 2 to EOS (Up to 3 Years)|Investigator Decision|0
6372881|NCT03318523|10162765|FG000|DBE Period:Year 2 to EOS (Up to 3 Years)|Death|0
6372882|NCT03318523|10162766|FG001|DBE Period:Year 2 to EOS (Up to 3 Years)|Death|0
6372883|NCT03318523|10162767|FG002|DBE Period:Year 2 to EOS (Up to 3 Years)|Death|0
6372884|NCT03318523|10162768|FG003|DBE Period:Year 2 to EOS (Up to 3 Years)|Death|0
6372885|NCT03318523|10162769|FG004|DBE Period:Year 2 to EOS (Up to 3 Years)|Death|0
6372886|NCT03318523|10162770|FG005|DBE Period:Year 2 to EOS (Up to 3 Years)|Death|0
6372887|NCT03318523|10162771|FG006|DBE Period:Year 2 to EOS (Up to 3 Years)|Death|0
6372888|NCT03318523|10162772|FG007|DBE Period:Year 2 to EOS (Up to 3 Years)|Death|0
6372889|NCT03318523|10162773|FG008|DBE Period:Year 2 to EOS (Up to 3 Years)|Death|0
6372890|NCT03318523|10162774|FG009|DBE Period:Year 2 to EOS (Up to 3 Years)|Death|1
6372891|NCT03318523|10162765|FG000|DBE Period:Year 2 to EOS (Up to 3 Years)|Study Terminated by Sponsor|0
6372892|NCT03318523|10162766|FG001|DBE Period:Year 2 to EOS (Up to 3 Years)|Study Terminated by Sponsor|0
6372893|NCT03318523|10162767|FG002|DBE Period:Year 2 to EOS (Up to 3 Years)|Study Terminated by Sponsor|0
6372894|NCT03318523|10162768|FG003|DBE Period:Year 2 to EOS (Up to 3 Years)|Study Terminated by Sponsor|0
6372895|NCT03318523|10162769|FG004|DBE Period:Year 2 to EOS (Up to 3 Years)|Study Terminated by Sponsor|17
6372896|NCT03318523|10162770|FG005|DBE Period:Year 2 to EOS (Up to 3 Years)|Study Terminated by Sponsor|36
6372897|NCT03318523|10162771|FG006|DBE Period:Year 2 to EOS (Up to 3 Years)|Study Terminated by Sponsor|39
6372898|NCT03318523|10162772|FG007|DBE Period:Year 2 to EOS (Up to 3 Years)|Study Terminated by Sponsor|48
6372899|NCT03318523|10162773|FG008|DBE Period:Year 2 to EOS (Up to 3 Years)|Study Terminated by Sponsor|94
6372900|NCT03318523|10162774|FG009|DBE Period:Year 2 to EOS (Up to 3 Years)|Study Terminated by Sponsor|91
6372901|NCT03318523|10162765|FG000|DBE Period:Year 2 to EOS (Up to 3 Years)|Other|0
6372902|NCT03318523|10162766|FG001|DBE Period:Year 2 to EOS (Up to 3 Years)|Other|0
6084653|NCT00643760|9693599|FG000|Overall Study|Lost to Follow-up|6
6372903|NCT03318523|10162767|FG002|DBE Period:Year 2 to EOS (Up to 3 Years)|Other|0
6372904|NCT03318523|10162768|FG003|DBE Period:Year 2 to EOS (Up to 3 Years)|Other|0
6372905|NCT03318523|10162769|FG004|DBE Period:Year 2 to EOS (Up to 3 Years)|Other|1
6372906|NCT03318523|10162770|FG005|DBE Period:Year 2 to EOS (Up to 3 Years)|Other|0
6372907|NCT03318523|10162771|FG006|DBE Period:Year 2 to EOS (Up to 3 Years)|Other|0
6372908|NCT03318523|10162772|FG007|DBE Period:Year 2 to EOS (Up to 3 Years)|Other|2
6372909|NCT03318523|10162773|FG008|DBE Period:Year 2 to EOS (Up to 3 Years)|Other|3
6372910|NCT03318523|10162774|FG009|DBE Period:Year 2 to EOS (Up to 3 Years)|Other|0
6372911|NCT03260894|10162800|FG000|Overall Study|Death|6
6372912|NCT03260894|10162801|FG001|Overall Study|Death|8
6372913|NCT03260894|10162800|FG000|Overall Study|Withdrawal by Subject|4
6372914|NCT03260894|10162801|FG001|Overall Study|Withdrawal by Subject|11
6372915|NCT03260894|10162800|FG000|Overall Study|On-going at clinical cut off date|36
6372916|NCT03260894|10162801|FG001|Overall Study|On-going at clinical cut off date|31
6372917|NCT02906020|10162817|FG000|Part 1: Dose Escalation Period|Adverse Event|0
6372918|NCT02906020|10162818|FG001|Part 1: Dose Escalation Period|Adverse Event|1
6372919|NCT02906020|10162819|FG002|Part 1: Dose Escalation Period|Adverse Event|0
6372920|NCT02906020|10162820|FG003|Part 1: Dose Escalation Period|Adverse Event|1
6372921|NCT02906020|10162821|FG004|Part 1: Dose Escalation Period|Adverse Event|0
6372922|NCT02906020|10162822|FG005|Part 1: Dose Escalation Period|Adverse Event|0
6372923|NCT02906020|10162823|FG006|Part 1: Dose Escalation Period|Adverse Event|0
6372924|NCT02906020|10162824|FG007|Part 1: Dose Escalation Period|Adverse Event|0
6372925|NCT02906020|10162825|FG008|Part 1: Dose Escalation Period|Adverse Event|0
6372926|NCT02906020|10162826|FG009|Part 1: Dose Escalation Period|Adverse Event|0
6372927|NCT02906020|10162827|FG010|Part 1: Dose Escalation Period|Adverse Event|0
6372928|NCT02906020|10162828|FG011|Part 1: Dose Escalation Period|Adverse Event|0
6372929|NCT02906020|10162829|FG012|Part 1: Dose Escalation Period|Adverse Event|0
6372930|NCT02906020|10162830|FG013|Part 1: Dose Escalation Period|Adverse Event|0
6372931|NCT02906020|10162831|FG014|Part 1: Dose Escalation Period|Adverse Event|0
6372932|NCT02906020|10162832|FG015|Part 1: Dose Escalation Period|Adverse Event|0
6372933|NCT02906020|10162817|FG000|Part 2: Double-blind Treatment Period|Adverse Event|0
6372934|NCT02906020|10162818|FG001|Part 2: Double-blind Treatment Period|Adverse Event|0
6372935|NCT02906020|10162819|FG002|Part 2: Double-blind Treatment Period|Adverse Event|0
6372936|NCT02906020|10162820|FG003|Part 2: Double-blind Treatment Period|Adverse Event|0
6372937|NCT02906020|10162821|FG004|Part 2: Double-blind Treatment Period|Adverse Event|0
6372938|NCT02906020|10162822|FG005|Part 2: Double-blind Treatment Period|Adverse Event|0
6372939|NCT02906020|10162823|FG006|Part 2: Double-blind Treatment Period|Adverse Event|0
6372940|NCT02906020|10162824|FG007|Part 2: Double-blind Treatment Period|Adverse Event|0
6372941|NCT02906020|10162825|FG008|Part 2: Double-blind Treatment Period|Adverse Event|6
6372942|NCT02906020|10162826|FG009|Part 2: Double-blind Treatment Period|Adverse Event|15
6372943|NCT02906020|10162827|FG010|Part 2: Double-blind Treatment Period|Adverse Event|0
6372944|NCT02906020|10162828|FG011|Part 2: Double-blind Treatment Period|Adverse Event|0
6372945|NCT02906020|10162829|FG012|Part 2: Double-blind Treatment Period|Adverse Event|0
6372946|NCT02906020|10162830|FG013|Part 2: Double-blind Treatment Period|Adverse Event|0
6372947|NCT02906020|10162831|FG014|Part 2: Double-blind Treatment Period|Adverse Event|0
6372948|NCT02906020|10162832|FG015|Part 2: Double-blind Treatment Period|Adverse Event|0
6372949|NCT02906020|10162817|FG000|Part 2: Double-blind Treatment Period|Other|0
6372950|NCT02906020|10162818|FG001|Part 2: Double-blind Treatment Period|Other|0
6372951|NCT02906020|10162819|FG002|Part 2: Double-blind Treatment Period|Other|0
6171858|NCT01262456|9818735|FG001|1-Month Open-Label Extension Period|Protocol Violation|0
6171859|NCT01262456|9818736|FG002|1-Month Open-Label Extension Period|Protocol Violation|2
6171860|NCT01262456|9818734|FG000|1-Month Open-Label Extension Period|Other Reason|0
6171861|NCT01262456|9818735|FG001|1-Month Open-Label Extension Period|Other Reason|1
6171862|NCT01262456|9818736|FG002|1-Month Open-Label Extension Period|Other Reason|0
6171863|NCT01262560|9818764|FG000|Overall Study|Protocol Violation|0
6171864|NCT01262560|9818765|FG001|Overall Study|Protocol Violation|1
6171865|NCT01262560|9818766|FG002|Overall Study|Protocol Violation|2
6171866|NCT01262573|9818776|FG000|Overall Study|Withdrawal by Subject|0
6171867|NCT01262573|9818777|FG001|Overall Study|Withdrawal by Subject|1
6171868|NCT01262638|9818798|FG000|Overall Study|Adverse Event|3
6171869|NCT01262638|9818799|FG001|Overall Study|Adverse Event|4
6171870|NCT01262638|9818800|FG002|Overall Study|Adverse Event|3
6171871|NCT01262638|9818801|FG003|Overall Study|Adverse Event|4
6372952|NCT02906020|10162820|FG003|Part 2: Double-blind Treatment Period|Other|0
6372953|NCT02906020|10162821|FG004|Part 2: Double-blind Treatment Period|Other|0
6372954|NCT02906020|10162822|FG005|Part 2: Double-blind Treatment Period|Other|0
6372955|NCT02906020|10162823|FG006|Part 2: Double-blind Treatment Period|Other|0
6372956|NCT02906020|10162824|FG007|Part 2: Double-blind Treatment Period|Other|0
6372957|NCT02906020|10162825|FG008|Part 2: Double-blind Treatment Period|Other|6
6372958|NCT02906020|10162826|FG009|Part 2: Double-blind Treatment Period|Other|10
6372959|NCT02906020|10162827|FG010|Part 2: Double-blind Treatment Period|Other|0
6372960|NCT02906020|10162828|FG011|Part 2: Double-blind Treatment Period|Other|0
6372961|NCT02906020|10162829|FG012|Part 2: Double-blind Treatment Period|Other|0
6372962|NCT02906020|10162830|FG013|Part 2: Double-blind Treatment Period|Other|0
6372963|NCT02906020|10162831|FG014|Part 2: Double-blind Treatment Period|Other|0
6372964|NCT02906020|10162832|FG015|Part 2: Double-blind Treatment Period|Other|0
6372965|NCT02906020|10162817|FG000|Part 2: Long-term Follow-up Period|Adverse Event|0
6372966|NCT02906020|10162818|FG001|Part 2: Long-term Follow-up Period|Adverse Event|0
6372967|NCT02906020|10162819|FG002|Part 2: Long-term Follow-up Period|Adverse Event|0
6372968|NCT02906020|10162820|FG003|Part 2: Long-term Follow-up Period|Adverse Event|0
6171872|NCT01262638|9818798|FG000|Overall Study|Protocol Violation|1
6171873|NCT01262638|9818799|FG001|Overall Study|Protocol Violation|0
6171874|NCT01262638|9818800|FG002|Overall Study|Protocol Violation|0
6372969|NCT02906020|10162821|FG004|Part 2: Long-term Follow-up Period|Adverse Event|0
6372970|NCT02906020|10162822|FG005|Part 2: Long-term Follow-up Period|Adverse Event|0
6372971|NCT02906020|10162823|FG006|Part 2: Long-term Follow-up Period|Adverse Event|0
6372972|NCT02906020|10162824|FG007|Part 2: Long-term Follow-up Period|Adverse Event|0
6372973|NCT02906020|10162825|FG008|Part 2: Long-term Follow-up Period|Adverse Event|0
6372974|NCT02906020|10162826|FG009|Part 2: Long-term Follow-up Period|Adverse Event|0
6372975|NCT02906020|10162827|FG010|Part 2: Long-term Follow-up Period|Adverse Event|0
6372976|NCT02906020|10162828|FG011|Part 2: Long-term Follow-up Period|Adverse Event|0
6372977|NCT02906020|10162829|FG012|Part 2: Long-term Follow-up Period|Adverse Event|10
6372978|NCT02906020|10162830|FG013|Part 2: Long-term Follow-up Period|Adverse Event|4
6372979|NCT02906020|10162831|FG014|Part 2: Long-term Follow-up Period|Adverse Event|0
6372980|NCT02906020|10162832|FG015|Part 2: Long-term Follow-up Period|Adverse Event|0
6372981|NCT02906020|10162817|FG000|Part 2: Long-term Follow-up Period|Progressive Disease|0
6372982|NCT02906020|10162818|FG001|Part 2: Long-term Follow-up Period|Progressive Disease|0
6372983|NCT02906020|10162819|FG002|Part 2: Long-term Follow-up Period|Progressive Disease|0
6372984|NCT02906020|10162820|FG003|Part 2: Long-term Follow-up Period|Progressive Disease|0
6372985|NCT02906020|10162821|FG004|Part 2: Long-term Follow-up Period|Progressive Disease|0
6372986|NCT02906020|10162822|FG005|Part 2: Long-term Follow-up Period|Progressive Disease|0
6372987|NCT02906020|10162823|FG006|Part 2: Long-term Follow-up Period|Progressive Disease|0
6372988|NCT02906020|10162824|FG007|Part 2: Long-term Follow-up Period|Progressive Disease|0
6372989|NCT02906020|10162825|FG008|Part 2: Long-term Follow-up Period|Progressive Disease|0
6372990|NCT02906020|10162826|FG009|Part 2: Long-term Follow-up Period|Progressive Disease|0
6372991|NCT02906020|10162827|FG010|Part 2: Long-term Follow-up Period|Progressive Disease|0
6372992|NCT02906020|10162828|FG011|Part 2: Long-term Follow-up Period|Progressive Disease|0
6372993|NCT02906020|10162829|FG012|Part 2: Long-term Follow-up Period|Progressive Disease|7
6372994|NCT02906020|10162830|FG013|Part 2: Long-term Follow-up Period|Progressive Disease|4
6372995|NCT02906020|10162831|FG014|Part 2: Long-term Follow-up Period|Progressive Disease|0
6372996|NCT02906020|10162832|FG015|Part 2: Long-term Follow-up Period|Progressive Disease|1
6372997|NCT02906020|10162817|FG000|Part 2: Long-term Follow-up Period|Lack of Efficacy|0
6372998|NCT02906020|10162818|FG001|Part 2: Long-term Follow-up Period|Lack of Efficacy|0
6372999|NCT02906020|10162819|FG002|Part 2: Long-term Follow-up Period|Lack of Efficacy|0
6373000|NCT02906020|10162820|FG003|Part 2: Long-term Follow-up Period|Lack of Efficacy|0
6373001|NCT02906020|10162821|FG004|Part 2: Long-term Follow-up Period|Lack of Efficacy|0
6373002|NCT02906020|10162822|FG005|Part 2: Long-term Follow-up Period|Lack of Efficacy|0
6373003|NCT02906020|10162823|FG006|Part 2: Long-term Follow-up Period|Lack of Efficacy|0
6373004|NCT02906020|10162824|FG007|Part 2: Long-term Follow-up Period|Lack of Efficacy|0
6373005|NCT02906020|10162825|FG008|Part 2: Long-term Follow-up Period|Lack of Efficacy|0
6171875|NCT01262638|9818801|FG003|Overall Study|Protocol Violation|1
6171876|NCT01262638|9818798|FG000|Overall Study|Withdrawal by Subject|2
6084654|NCT00643760|9693600|FG001|Overall Study|Lost to Follow-up|2
6084655|NCT00643760|9693601|FG002|Overall Study|Lost to Follow-up|1
6084656|NCT00643760|9693602|FG003|Overall Study|Lost to Follow-up|3
6084657|NCT00643760|9693603|FG004|Overall Study|Lost to Follow-up|3
6084658|NCT00643760|9693599|FG000|Overall Study|Investigator Discretion|0
6084659|NCT00643760|9693600|FG001|Overall Study|Investigator Discretion|0
6084660|NCT00643760|9693601|FG002|Overall Study|Investigator Discretion|0
6084661|NCT00643760|9693602|FG003|Overall Study|Investigator Discretion|2
6084662|NCT00643760|9693603|FG004|Overall Study|Investigator Discretion|0
6084663|NCT00643760|9693599|FG000|Overall Study|Withdrawal by Subject|3
6084664|NCT00643760|9693600|FG001|Overall Study|Withdrawal by Subject|1
6084665|NCT00643760|9693601|FG002|Overall Study|Withdrawal by Subject|2
6084666|NCT00643760|9693602|FG003|Overall Study|Withdrawal by Subject|4
6084667|NCT00643760|9693603|FG004|Overall Study|Withdrawal by Subject|1
6084668|NCT00643851|9693618|FG000|Overall Study|Death|0
6084669|NCT00643851|9693619|FG001|Overall Study|Death|1
6084670|NCT00643851|9693620|FG002|Overall Study|Death|0
6084671|NCT00643851|9693618|FG000|Overall Study|Lack of Efficacy|0
6084672|NCT00643851|9693619|FG001|Overall Study|Lack of Efficacy|1
6084673|NCT00643851|9693620|FG002|Overall Study|Lack of Efficacy|0
6084674|NCT00643851|9693618|FG000|Overall Study|Adverse Event|2
6084675|NCT00643851|9693619|FG001|Overall Study|Adverse Event|6
6084676|NCT00643851|9693620|FG002|Overall Study|Adverse Event|6
6084677|NCT00643851|9693618|FG000|Overall Study|Lost to Follow-up|4
6084678|NCT00643851|9693619|FG001|Overall Study|Lost to Follow-up|6
6084679|NCT00643851|9693620|FG002|Overall Study|Lost to Follow-up|9
6084680|NCT00643851|9693618|FG000|Overall Study|Withdrawal by Subject|8
6084681|NCT00643851|9693619|FG001|Overall Study|Withdrawal by Subject|15
6171877|NCT01262638|9818799|FG001|Overall Study|Withdrawal by Subject|1
6171878|NCT01262638|9818800|FG002|Overall Study|Withdrawal by Subject|0
6171879|NCT01262638|9818801|FG003|Overall Study|Withdrawal by Subject|1
6171880|NCT01262638|9818798|FG000|Overall Study|Per Investigator/Sponsor/Regulatory Body|0
6171881|NCT01262638|9818799|FG001|Overall Study|Per Investigator/Sponsor/Regulatory Body|0
6084682|NCT00643851|9693620|FG002|Overall Study|Withdrawal by Subject|9
6084683|NCT00643851|9693618|FG000|Overall Study|Non-compl., not met criteria, etc.|3
6084684|NCT00643851|9693619|FG001|Overall Study|Non-compl., not met criteria, etc.|4
6084685|NCT00643851|9693620|FG002|Overall Study|Non-compl., not met criteria, etc.|6
6373006|NCT02906020|10162826|FG009|Part 2: Long-term Follow-up Period|Lack of Efficacy|0
6373007|NCT02906020|10162827|FG010|Part 2: Long-term Follow-up Period|Lack of Efficacy|0
6373008|NCT02906020|10162828|FG011|Part 2: Long-term Follow-up Period|Lack of Efficacy|0
6373009|NCT02906020|10162829|FG012|Part 2: Long-term Follow-up Period|Lack of Efficacy|1
6373010|NCT02906020|10162830|FG013|Part 2: Long-term Follow-up Period|Lack of Efficacy|1
6373011|NCT02906020|10162831|FG014|Part 2: Long-term Follow-up Period|Lack of Efficacy|0
6373012|NCT02906020|10162832|FG015|Part 2: Long-term Follow-up Period|Lack of Efficacy|0
6373013|NCT02906020|10162817|FG000|Part 2: Long-term Follow-up Period|Poor Compliance to Protocol|0
6373014|NCT02906020|10162818|FG001|Part 2: Long-term Follow-up Period|Poor Compliance to Protocol|0
6373015|NCT02906020|10162819|FG002|Part 2: Long-term Follow-up Period|Poor Compliance to Protocol|0
6373016|NCT02906020|10162820|FG003|Part 2: Long-term Follow-up Period|Poor Compliance to Protocol|0
6373017|NCT02906020|10162821|FG004|Part 2: Long-term Follow-up Period|Poor Compliance to Protocol|0
6373018|NCT02906020|10162822|FG005|Part 2: Long-term Follow-up Period|Poor Compliance to Protocol|0
6373019|NCT02906020|10162823|FG006|Part 2: Long-term Follow-up Period|Poor Compliance to Protocol|0
6373020|NCT02906020|10162824|FG007|Part 2: Long-term Follow-up Period|Poor Compliance to Protocol|0
6373021|NCT02906020|10162825|FG008|Part 2: Long-term Follow-up Period|Poor Compliance to Protocol|0
6373022|NCT02906020|10162826|FG009|Part 2: Long-term Follow-up Period|Poor Compliance to Protocol|0
6373023|NCT02906020|10162827|FG010|Part 2: Long-term Follow-up Period|Poor Compliance to Protocol|0
6373024|NCT02906020|10162828|FG011|Part 2: Long-term Follow-up Period|Poor Compliance to Protocol|0
6373025|NCT02906020|10162829|FG012|Part 2: Long-term Follow-up Period|Poor Compliance to Protocol|1
6373026|NCT02906020|10162830|FG013|Part 2: Long-term Follow-up Period|Poor Compliance to Protocol|4
6373027|NCT02906020|10162831|FG014|Part 2: Long-term Follow-up Period|Poor Compliance to Protocol|0
6373028|NCT02906020|10162832|FG015|Part 2: Long-term Follow-up Period|Poor Compliance to Protocol|0
6373029|NCT02906020|10162817|FG000|Part 2: Long-term Follow-up Period|Study terminated by sponsor|0
6373030|NCT02906020|10162818|FG001|Part 2: Long-term Follow-up Period|Study terminated by sponsor|0
6373031|NCT02906020|10162819|FG002|Part 2: Long-term Follow-up Period|Study terminated by sponsor|0
6373032|NCT02906020|10162820|FG003|Part 2: Long-term Follow-up Period|Study terminated by sponsor|0
6373033|NCT02906020|10162821|FG004|Part 2: Long-term Follow-up Period|Study terminated by sponsor|0
6373034|NCT02906020|10162822|FG005|Part 2: Long-term Follow-up Period|Study terminated by sponsor|0
6373035|NCT02906020|10162823|FG006|Part 2: Long-term Follow-up Period|Study terminated by sponsor|0
6373036|NCT02906020|10162824|FG007|Part 2: Long-term Follow-up Period|Study terminated by sponsor|0
6373037|NCT02906020|10162825|FG008|Part 2: Long-term Follow-up Period|Study terminated by sponsor|0
6373038|NCT02906020|10162826|FG009|Part 2: Long-term Follow-up Period|Study terminated by sponsor|0
6373039|NCT02906020|10162827|FG010|Part 2: Long-term Follow-up Period|Study terminated by sponsor|0
6373040|NCT02906020|10162828|FG011|Part 2: Long-term Follow-up Period|Study terminated by sponsor|0
6373041|NCT02906020|10162829|FG012|Part 2: Long-term Follow-up Period|Study terminated by sponsor|67
6373042|NCT02906020|10162830|FG013|Part 2: Long-term Follow-up Period|Study terminated by sponsor|64
6373043|NCT02906020|10162831|FG014|Part 2: Long-term Follow-up Period|Study terminated by sponsor|7
6373044|NCT02906020|10162832|FG015|Part 2: Long-term Follow-up Period|Study terminated by sponsor|8
6373045|NCT02906020|10162817|FG000|Part 2: Long-term Follow-up Period|Other|0
6373046|NCT02906020|10162818|FG001|Part 2: Long-term Follow-up Period|Other|0
6373047|NCT02906020|10162819|FG002|Part 2: Long-term Follow-up Period|Other|0
6373048|NCT02906020|10162820|FG003|Part 2: Long-term Follow-up Period|Other|0
6373049|NCT02906020|10162821|FG004|Part 2: Long-term Follow-up Period|Other|0
6373050|NCT02906020|10162822|FG005|Part 2: Long-term Follow-up Period|Other|0
6373051|NCT02906020|10162823|FG006|Part 2: Long-term Follow-up Period|Other|0
6373052|NCT02906020|10162824|FG007|Part 2: Long-term Follow-up Period|Other|0
6373053|NCT02906020|10162825|FG008|Part 2: Long-term Follow-up Period|Other|0
6373054|NCT02906020|10162826|FG009|Part 2: Long-term Follow-up Period|Other|0
6373055|NCT02906020|10162827|FG010|Part 2: Long-term Follow-up Period|Other|0
6373056|NCT02906020|10162828|FG011|Part 2: Long-term Follow-up Period|Other|0
6373057|NCT02906020|10162829|FG012|Part 2: Long-term Follow-up Period|Other|13
6373058|NCT02906020|10162830|FG013|Part 2: Long-term Follow-up Period|Other|8
6373059|NCT02906020|10162831|FG014|Part 2: Long-term Follow-up Period|Other|3
6373060|NCT02906020|10162832|FG015|Part 2: Long-term Follow-up Period|Other|2
6373061|NCT02891226|10162864|FG000|Period 1 (Weeks 0 to 12)|Adverse Event|4
6373062|NCT02891226|10162865|FG001|Period 1 (Weeks 0 to 12)|Adverse Event|1
6373063|NCT02891226|10162866|FG002|Period 1 (Weeks 0 to 12)|Adverse Event|3
6373064|NCT02891226|10162867|FG003|Period 1 (Weeks 0 to 12)|Adverse Event|0
6373065|NCT02891226|10162868|FG004|Period 1 (Weeks 0 to 12)|Adverse Event|0
6373066|NCT02891226|10162869|FG005|Period 1 (Weeks 0 to 12)|Adverse Event|0
6373067|NCT02891226|10162870|FG006|Period 1 (Weeks 0 to 12)|Adverse Event|0
6373068|NCT02891226|10162871|FG007|Period 1 (Weeks 0 to 12)|Adverse Event|0
6373069|NCT02891226|10162872|FG008|Period 1 (Weeks 0 to 12)|Adverse Event|0
6373070|NCT02891226|10162873|FG009|Period 1 (Weeks 0 to 12)|Adverse Event|0
6373071|NCT02891226|10162874|FG010|Period 1 (Weeks 0 to 12)|Adverse Event|0
6373072|NCT02891226|10162875|FG011|Period 1 (Weeks 0 to 12)|Adverse Event|0
6373073|NCT02891226|10162876|FG012|Period 1 (Weeks 0 to 12)|Adverse Event|0
6373074|NCT02891226|10162877|FG013|Period 1 (Weeks 0 to 12)|Adverse Event|0
6373075|NCT02891226|10162878|FG014|Period 1 (Weeks 0 to 12)|Adverse Event|0
6373076|NCT02891226|10162879|FG015|Period 1 (Weeks 0 to 12)|Adverse Event|0
6373077|NCT02891226|10162864|FG000|Period 1 (Weeks 0 to 12)|Lost to Follow-up|1
6373078|NCT02891226|10162865|FG001|Period 1 (Weeks 0 to 12)|Lost to Follow-up|1
6373079|NCT02891226|10162866|FG002|Period 1 (Weeks 0 to 12)|Lost to Follow-up|0
6373080|NCT02891226|10162867|FG003|Period 1 (Weeks 0 to 12)|Lost to Follow-up|0
6373081|NCT02891226|10162868|FG004|Period 1 (Weeks 0 to 12)|Lost to Follow-up|0
6373082|NCT02891226|10162869|FG005|Period 1 (Weeks 0 to 12)|Lost to Follow-up|0
6373083|NCT02891226|10162870|FG006|Period 1 (Weeks 0 to 12)|Lost to Follow-up|0
6373084|NCT02891226|10162871|FG007|Period 1 (Weeks 0 to 12)|Lost to Follow-up|0
6373085|NCT02891226|10162872|FG008|Period 1 (Weeks 0 to 12)|Lost to Follow-up|0
6373086|NCT02891226|10162873|FG009|Period 1 (Weeks 0 to 12)|Lost to Follow-up|0
6373087|NCT02891226|10162874|FG010|Period 1 (Weeks 0 to 12)|Lost to Follow-up|0
6373088|NCT02891226|10162875|FG011|Period 1 (Weeks 0 to 12)|Lost to Follow-up|0
6373089|NCT02891226|10162876|FG012|Period 1 (Weeks 0 to 12)|Lost to Follow-up|0
6373090|NCT02891226|10162877|FG013|Period 1 (Weeks 0 to 12)|Lost to Follow-up|0
6373091|NCT02891226|10162878|FG014|Period 1 (Weeks 0 to 12)|Lost to Follow-up|0
6373092|NCT02891226|10162879|FG015|Period 1 (Weeks 0 to 12)|Lost to Follow-up|0
6373093|NCT02891226|10162864|FG000|Period 1 (Weeks 0 to 12)|Withdrawal by Subject|0
6373094|NCT02891226|10162865|FG001|Period 1 (Weeks 0 to 12)|Withdrawal by Subject|0
6373095|NCT02891226|10162866|FG002|Period 1 (Weeks 0 to 12)|Withdrawal by Subject|0
6373096|NCT02891226|10162867|FG003|Period 1 (Weeks 0 to 12)|Withdrawal by Subject|2
6373097|NCT02891226|10162868|FG004|Period 1 (Weeks 0 to 12)|Withdrawal by Subject|0
6373098|NCT02891226|10162869|FG005|Period 1 (Weeks 0 to 12)|Withdrawal by Subject|0
6373099|NCT02891226|10162870|FG006|Period 1 (Weeks 0 to 12)|Withdrawal by Subject|0
6373100|NCT02891226|10162871|FG007|Period 1 (Weeks 0 to 12)|Withdrawal by Subject|0
6373101|NCT02891226|10162872|FG008|Period 1 (Weeks 0 to 12)|Withdrawal by Subject|0
6373102|NCT02891226|10162873|FG009|Period 1 (Weeks 0 to 12)|Withdrawal by Subject|0
6373103|NCT02891226|10162874|FG010|Period 1 (Weeks 0 to 12)|Withdrawal by Subject|0
6373104|NCT02891226|10162875|FG011|Period 1 (Weeks 0 to 12)|Withdrawal by Subject|0
6373105|NCT02891226|10162876|FG012|Period 1 (Weeks 0 to 12)|Withdrawal by Subject|0
6373106|NCT02891226|10162877|FG013|Period 1 (Weeks 0 to 12)|Withdrawal by Subject|0
6373107|NCT02891226|10162878|FG014|Period 1 (Weeks 0 to 12)|Withdrawal by Subject|0
6373108|NCT02891226|10162879|FG015|Period 1 (Weeks 0 to 12)|Withdrawal by Subject|0
6373109|NCT02891226|10162864|FG000|Period 1 (Weeks 0 to 12)|Enrollment Failure|0
6373110|NCT02891226|10162865|FG001|Period 1 (Weeks 0 to 12)|Enrollment Failure|0
6373111|NCT02891226|10162866|FG002|Period 1 (Weeks 0 to 12)|Enrollment Failure|1
6373112|NCT02891226|10162867|FG003|Period 1 (Weeks 0 to 12)|Enrollment Failure|0
6373113|NCT02891226|10162868|FG004|Period 1 (Weeks 0 to 12)|Enrollment Failure|0
6373114|NCT02891226|10162869|FG005|Period 1 (Weeks 0 to 12)|Enrollment Failure|0
6373115|NCT02891226|10162870|FG006|Period 1 (Weeks 0 to 12)|Enrollment Failure|0
6373116|NCT02891226|10162871|FG007|Period 1 (Weeks 0 to 12)|Enrollment Failure|0
6373117|NCT02891226|10162872|FG008|Period 1 (Weeks 0 to 12)|Enrollment Failure|0
6373118|NCT02891226|10162873|FG009|Period 1 (Weeks 0 to 12)|Enrollment Failure|0
6373119|NCT02891226|10162874|FG010|Period 1 (Weeks 0 to 12)|Enrollment Failure|0
6373120|NCT02891226|10162875|FG011|Period 1 (Weeks 0 to 12)|Enrollment Failure|0
6373121|NCT02891226|10162876|FG012|Period 1 (Weeks 0 to 12)|Enrollment Failure|0
6373122|NCT02891226|10162877|FG013|Period 1 (Weeks 0 to 12)|Enrollment Failure|0
6373123|NCT02891226|10162878|FG014|Period 1 (Weeks 0 to 12)|Enrollment Failure|0
6373124|NCT02891226|10162879|FG015|Period 1 (Weeks 0 to 12)|Enrollment Failure|0
6373125|NCT02891226|10162864|FG000|Period 1 (Weeks 0 to 12)|Sponsor Decision|0
6373126|NCT02891226|10162865|FG001|Period 1 (Weeks 0 to 12)|Sponsor Decision|0
6373127|NCT02891226|10162866|FG002|Period 1 (Weeks 0 to 12)|Sponsor Decision|0
6373128|NCT02891226|10162867|FG003|Period 1 (Weeks 0 to 12)|Sponsor Decision|1
6373129|NCT02891226|10162868|FG004|Period 1 (Weeks 0 to 12)|Sponsor Decision|0
6373130|NCT02891226|10162869|FG005|Period 1 (Weeks 0 to 12)|Sponsor Decision|0
6373131|NCT02891226|10162870|FG006|Period 1 (Weeks 0 to 12)|Sponsor Decision|0
6373132|NCT02891226|10162871|FG007|Period 1 (Weeks 0 to 12)|Sponsor Decision|0
6373133|NCT02891226|10162872|FG008|Period 1 (Weeks 0 to 12)|Sponsor Decision|0
6373134|NCT02891226|10162873|FG009|Period 1 (Weeks 0 to 12)|Sponsor Decision|0
6373135|NCT02891226|10162874|FG010|Period 1 (Weeks 0 to 12)|Sponsor Decision|0
6373136|NCT02891226|10162875|FG011|Period 1 (Weeks 0 to 12)|Sponsor Decision|0
6373137|NCT02891226|10162876|FG012|Period 1 (Weeks 0 to 12)|Sponsor Decision|0
6373138|NCT02891226|10162877|FG013|Period 1 (Weeks 0 to 12)|Sponsor Decision|0
6373139|NCT02891226|10162878|FG014|Period 1 (Weeks 0 to 12)|Sponsor Decision|0
6373140|NCT02891226|10162879|FG015|Period 1 (Weeks 0 to 12)|Sponsor Decision|0
6373141|NCT02891226|10162864|FG000|Period 1 (Weeks 0 to 12)|Lack of Efficacy|0
6373142|NCT02891226|10162865|FG001|Period 1 (Weeks 0 to 12)|Lack of Efficacy|0
6373143|NCT02891226|10162866|FG002|Period 1 (Weeks 0 to 12)|Lack of Efficacy|0
6373144|NCT02891226|10162867|FG003|Period 1 (Weeks 0 to 12)|Lack of Efficacy|1
6373145|NCT02891226|10162868|FG004|Period 1 (Weeks 0 to 12)|Lack of Efficacy|0
6373146|NCT02891226|10162869|FG005|Period 1 (Weeks 0 to 12)|Lack of Efficacy|0
6373147|NCT02891226|10162870|FG006|Period 1 (Weeks 0 to 12)|Lack of Efficacy|0
6373148|NCT02891226|10162871|FG007|Period 1 (Weeks 0 to 12)|Lack of Efficacy|0
6373149|NCT02891226|10162872|FG008|Period 1 (Weeks 0 to 12)|Lack of Efficacy|0
6373150|NCT02891226|10162873|FG009|Period 1 (Weeks 0 to 12)|Lack of Efficacy|0
6373151|NCT02891226|10162874|FG010|Period 1 (Weeks 0 to 12)|Lack of Efficacy|0
6373152|NCT02891226|10162875|FG011|Period 1 (Weeks 0 to 12)|Lack of Efficacy|0
6373153|NCT02891226|10162876|FG012|Period 1 (Weeks 0 to 12)|Lack of Efficacy|0
6373154|NCT02891226|10162877|FG013|Period 1 (Weeks 0 to 12)|Lack of Efficacy|0
6373155|NCT02891226|10162878|FG014|Period 1 (Weeks 0 to 12)|Lack of Efficacy|0
6373156|NCT02891226|10162879|FG015|Period 1 (Weeks 0 to 12)|Lack of Efficacy|0
6373157|NCT02891226|10162864|FG000|Period 2 (Weeks 12 to 52)|Adverse Event|0
6373158|NCT02891226|10162865|FG001|Period 2 (Weeks 12 to 52)|Adverse Event|0
6373159|NCT02891226|10162866|FG002|Period 2 (Weeks 12 to 52)|Adverse Event|0
6373160|NCT02891226|10162867|FG003|Period 2 (Weeks 12 to 52)|Adverse Event|0
6373161|NCT02891226|10162868|FG004|Period 2 (Weeks 12 to 52)|Adverse Event|0
6373162|NCT02891226|10162869|FG005|Period 2 (Weeks 12 to 52)|Adverse Event|0
6373163|NCT02891226|10162870|FG006|Period 2 (Weeks 12 to 52)|Adverse Event|1
6373164|NCT02891226|10162871|FG007|Period 2 (Weeks 12 to 52)|Adverse Event|1
6373165|NCT02891226|10162872|FG008|Period 2 (Weeks 12 to 52)|Adverse Event|3
6373166|NCT02891226|10162873|FG009|Period 2 (Weeks 12 to 52)|Adverse Event|7
6373167|NCT02891226|10162874|FG010|Period 2 (Weeks 12 to 52)|Adverse Event|0
6373168|NCT02891226|10162875|FG011|Period 2 (Weeks 12 to 52)|Adverse Event|0
6373169|NCT02891226|10162876|FG012|Period 2 (Weeks 12 to 52)|Adverse Event|0
6373170|NCT02891226|10162877|FG013|Period 2 (Weeks 12 to 52)|Adverse Event|0
6373171|NCT02891226|10162878|FG014|Period 2 (Weeks 12 to 52)|Adverse Event|0
6373172|NCT02891226|10162879|FG015|Period 2 (Weeks 12 to 52)|Adverse Event|0
6373173|NCT02891226|10162864|FG000|Period 2 (Weeks 12 to 52)|Lost to Follow-up|0
6373174|NCT02891226|10162865|FG001|Period 2 (Weeks 12 to 52)|Lost to Follow-up|0
6373175|NCT02891226|10162866|FG002|Period 2 (Weeks 12 to 52)|Lost to Follow-up|0
6373176|NCT02891226|10162867|FG003|Period 2 (Weeks 12 to 52)|Lost to Follow-up|0
6373177|NCT02891226|10162868|FG004|Period 2 (Weeks 12 to 52)|Lost to Follow-up|0
6373178|NCT02891226|10162869|FG005|Period 2 (Weeks 12 to 52)|Lost to Follow-up|1
6373179|NCT02891226|10162870|FG006|Period 2 (Weeks 12 to 52)|Lost to Follow-up|0
6373180|NCT02891226|10162871|FG007|Period 2 (Weeks 12 to 52)|Lost to Follow-up|0
6373181|NCT02891226|10162872|FG008|Period 2 (Weeks 12 to 52)|Lost to Follow-up|0
6373182|NCT02891226|10162873|FG009|Period 2 (Weeks 12 to 52)|Lost to Follow-up|1
6373183|NCT02891226|10162874|FG010|Period 2 (Weeks 12 to 52)|Lost to Follow-up|0
6373184|NCT02891226|10162875|FG011|Period 2 (Weeks 12 to 52)|Lost to Follow-up|0
6373185|NCT02891226|10162876|FG012|Period 2 (Weeks 12 to 52)|Lost to Follow-up|0
6373186|NCT02891226|10162877|FG013|Period 2 (Weeks 12 to 52)|Lost to Follow-up|0
6373187|NCT02891226|10162878|FG014|Period 2 (Weeks 12 to 52)|Lost to Follow-up|0
6373188|NCT02891226|10162879|FG015|Period 2 (Weeks 12 to 52)|Lost to Follow-up|0
6373189|NCT02891226|10162864|FG000|Period 2 (Weeks 12 to 52)|Withdrawal by Subject|0
6373190|NCT02891226|10162865|FG001|Period 2 (Weeks 12 to 52)|Withdrawal by Subject|0
6373191|NCT02891226|10162866|FG002|Period 2 (Weeks 12 to 52)|Withdrawal by Subject|0
6373192|NCT02891226|10162867|FG003|Period 2 (Weeks 12 to 52)|Withdrawal by Subject|0
6373193|NCT02891226|10162868|FG004|Period 2 (Weeks 12 to 52)|Withdrawal by Subject|0
6373194|NCT02891226|10162869|FG005|Period 2 (Weeks 12 to 52)|Withdrawal by Subject|0
6373195|NCT02891226|10162870|FG006|Period 2 (Weeks 12 to 52)|Withdrawal by Subject|1
6373196|NCT02891226|10162871|FG007|Period 2 (Weeks 12 to 52)|Withdrawal by Subject|2
6373197|NCT02891226|10162872|FG008|Period 2 (Weeks 12 to 52)|Withdrawal by Subject|1
6373198|NCT02891226|10162873|FG009|Period 2 (Weeks 12 to 52)|Withdrawal by Subject|6
6373199|NCT02891226|10162874|FG010|Period 2 (Weeks 12 to 52)|Withdrawal by Subject|0
6373200|NCT02891226|10162875|FG011|Period 2 (Weeks 12 to 52)|Withdrawal by Subject|0
6373201|NCT02891226|10162876|FG012|Period 2 (Weeks 12 to 52)|Withdrawal by Subject|0
6373202|NCT02891226|10162877|FG013|Period 2 (Weeks 12 to 52)|Withdrawal by Subject|0
6373203|NCT02891226|10162878|FG014|Period 2 (Weeks 12 to 52)|Withdrawal by Subject|0
6373204|NCT02891226|10162879|FG015|Period 2 (Weeks 12 to 52)|Withdrawal by Subject|0
6373205|NCT02891226|10162864|FG000|Period 2 (Weeks 12 to 52)|PI decision due to Lack of Efficacy|0
6373206|NCT02891226|10162865|FG001|Period 2 (Weeks 12 to 52)|PI decision due to Lack of Efficacy|0
6373207|NCT02891226|10162866|FG002|Period 2 (Weeks 12 to 52)|PI decision due to Lack of Efficacy|0
6373208|NCT02891226|10162867|FG003|Period 2 (Weeks 12 to 52)|PI decision due to Lack of Efficacy|0
6373209|NCT02891226|10162868|FG004|Period 2 (Weeks 12 to 52)|PI decision due to Lack of Efficacy|1
6373210|NCT02891226|10162869|FG005|Period 2 (Weeks 12 to 52)|PI decision due to Lack of Efficacy|0
6373211|NCT02891226|10162870|FG006|Period 2 (Weeks 12 to 52)|PI decision due to Lack of Efficacy|0
6373212|NCT02891226|10162871|FG007|Period 2 (Weeks 12 to 52)|PI decision due to Lack of Efficacy|0
6373213|NCT02891226|10162872|FG008|Period 2 (Weeks 12 to 52)|PI decision due to Lack of Efficacy|0
6373214|NCT02891226|10162873|FG009|Period 2 (Weeks 12 to 52)|PI decision due to Lack of Efficacy|0
6373215|NCT02891226|10162874|FG010|Period 2 (Weeks 12 to 52)|PI decision due to Lack of Efficacy|0
6373216|NCT02891226|10162875|FG011|Period 2 (Weeks 12 to 52)|PI decision due to Lack of Efficacy|0
6373217|NCT02891226|10162876|FG012|Period 2 (Weeks 12 to 52)|PI decision due to Lack of Efficacy|0
6373218|NCT02891226|10162877|FG013|Period 2 (Weeks 12 to 52)|PI decision due to Lack of Efficacy|0
6373219|NCT02891226|10162878|FG014|Period 2 (Weeks 12 to 52)|PI decision due to Lack of Efficacy|0
6373220|NCT02891226|10162879|FG015|Period 2 (Weeks 12 to 52)|PI decision due to Lack of Efficacy|0
6373221|NCT02891226|10162864|FG000|Period 2 (Weeks 12 to 52)|PI and Sponsor Decision due to Subject Safety|0
6084686|NCT00643916|9693634|FG000|Overall Study|Protocol Violation|0
6373222|NCT02891226|10162865|FG001|Period 2 (Weeks 12 to 52)|PI and Sponsor Decision due to Subject Safety|0
6084687|NCT00643916|9693635|FG001|Overall Study|Protocol Violation|1
6373223|NCT02891226|10162866|FG002|Period 2 (Weeks 12 to 52)|PI and Sponsor Decision due to Subject Safety|0
6373224|NCT02891226|10162867|FG003|Period 2 (Weeks 12 to 52)|PI and Sponsor Decision due to Subject Safety|0
6373225|NCT02891226|10162868|FG004|Period 2 (Weeks 12 to 52)|PI and Sponsor Decision due to Subject Safety|0
6373226|NCT02891226|10162869|FG005|Period 2 (Weeks 12 to 52)|PI and Sponsor Decision due to Subject Safety|0
6373227|NCT02891226|10162870|FG006|Period 2 (Weeks 12 to 52)|PI and Sponsor Decision due to Subject Safety|1
6373228|NCT02891226|10162871|FG007|Period 2 (Weeks 12 to 52)|PI and Sponsor Decision due to Subject Safety|0
6373229|NCT02891226|10162872|FG008|Period 2 (Weeks 12 to 52)|PI and Sponsor Decision due to Subject Safety|0
6373230|NCT02891226|10162873|FG009|Period 2 (Weeks 12 to 52)|PI and Sponsor Decision due to Subject Safety|0
6373231|NCT02891226|10162874|FG010|Period 2 (Weeks 12 to 52)|PI and Sponsor Decision due to Subject Safety|0
6373232|NCT02891226|10162875|FG011|Period 2 (Weeks 12 to 52)|PI and Sponsor Decision due to Subject Safety|0
6373233|NCT02891226|10162876|FG012|Period 2 (Weeks 12 to 52)|PI and Sponsor Decision due to Subject Safety|0
6373234|NCT02891226|10162877|FG013|Period 2 (Weeks 12 to 52)|PI and Sponsor Decision due to Subject Safety|0
6373235|NCT02891226|10162878|FG014|Period 2 (Weeks 12 to 52)|PI and Sponsor Decision due to Subject Safety|0
6373236|NCT02891226|10162879|FG015|Period 2 (Weeks 12 to 52)|PI and Sponsor Decision due to Subject Safety|0
6373237|NCT02891226|10162864|FG000|Period 2 (Weeks 12 to 52)|Lack of Efficacy|0
6373238|NCT02891226|10162865|FG001|Period 2 (Weeks 12 to 52)|Lack of Efficacy|0
6373239|NCT02891226|10162866|FG002|Period 2 (Weeks 12 to 52)|Lack of Efficacy|0
6373240|NCT02891226|10162867|FG003|Period 2 (Weeks 12 to 52)|Lack of Efficacy|0
6373241|NCT02891226|10162868|FG004|Period 2 (Weeks 12 to 52)|Lack of Efficacy|0
6373242|NCT02891226|10162869|FG005|Period 2 (Weeks 12 to 52)|Lack of Efficacy|0
6373243|NCT02891226|10162870|FG006|Period 2 (Weeks 12 to 52)|Lack of Efficacy|0
6373244|NCT02891226|10162871|FG007|Period 2 (Weeks 12 to 52)|Lack of Efficacy|1
6373245|NCT02891226|10162872|FG008|Period 2 (Weeks 12 to 52)|Lack of Efficacy|1
6373246|NCT02891226|10162873|FG009|Period 2 (Weeks 12 to 52)|Lack of Efficacy|1
6373247|NCT02891226|10162874|FG010|Period 2 (Weeks 12 to 52)|Lack of Efficacy|0
6373248|NCT02891226|10162875|FG011|Period 2 (Weeks 12 to 52)|Lack of Efficacy|0
6373249|NCT02891226|10162876|FG012|Period 2 (Weeks 12 to 52)|Lack of Efficacy|0
6373250|NCT02891226|10162877|FG013|Period 2 (Weeks 12 to 52)|Lack of Efficacy|0
6373251|NCT02891226|10162878|FG014|Period 2 (Weeks 12 to 52)|Lack of Efficacy|0
6373252|NCT02891226|10162879|FG015|Period 2 (Weeks 12 to 52)|Lack of Efficacy|0
6373253|NCT02891226|10162864|FG000|Period 2 (Weeks 12 to 52)|PI Decision due to Lack of Efficacy|0
6373254|NCT02891226|10162865|FG001|Period 2 (Weeks 12 to 52)|PI Decision due to Lack of Efficacy|0
6373255|NCT02891226|10162866|FG002|Period 2 (Weeks 12 to 52)|PI Decision due to Lack of Efficacy|0
6373256|NCT02891226|10162867|FG003|Period 2 (Weeks 12 to 52)|PI Decision due to Lack of Efficacy|0
6373257|NCT02891226|10162868|FG004|Period 2 (Weeks 12 to 52)|PI Decision due to Lack of Efficacy|0
6373258|NCT02891226|10162869|FG005|Period 2 (Weeks 12 to 52)|PI Decision due to Lack of Efficacy|0
6373259|NCT02891226|10162870|FG006|Period 2 (Weeks 12 to 52)|PI Decision due to Lack of Efficacy|0
6373260|NCT02891226|10162871|FG007|Period 2 (Weeks 12 to 52)|PI Decision due to Lack of Efficacy|1
6373261|NCT02891226|10162872|FG008|Period 2 (Weeks 12 to 52)|PI Decision due to Lack of Efficacy|0
6373262|NCT02891226|10162873|FG009|Period 2 (Weeks 12 to 52)|PI Decision due to Lack of Efficacy|0
6373263|NCT02891226|10162874|FG010|Period 2 (Weeks 12 to 52)|PI Decision due to Lack of Efficacy|0
6373264|NCT02891226|10162875|FG011|Period 2 (Weeks 12 to 52)|PI Decision due to Lack of Efficacy|0
6373265|NCT02891226|10162876|FG012|Period 2 (Weeks 12 to 52)|PI Decision due to Lack of Efficacy|0
6373266|NCT02891226|10162877|FG013|Period 2 (Weeks 12 to 52)|PI Decision due to Lack of Efficacy|0
6373267|NCT02891226|10162878|FG014|Period 2 (Weeks 12 to 52)|PI Decision due to Lack of Efficacy|0
6373268|NCT02891226|10162879|FG015|Period 2 (Weeks 12 to 52)|PI Decision due to Lack of Efficacy|0
6373269|NCT02891226|10162864|FG000|Period 2 (Weeks 12 to 52)|Endoscopic Procedure was not Evaluated|0
6373270|NCT02891226|10162865|FG001|Period 2 (Weeks 12 to 52)|Endoscopic Procedure was not Evaluated|0
6373271|NCT02891226|10162866|FG002|Period 2 (Weeks 12 to 52)|Endoscopic Procedure was not Evaluated|0
6084688|NCT00643916|9693636|FG002|Overall Study|Protocol Violation|1
6084689|NCT00643916|9693637|FG003|Overall Study|Protocol Violation|1
6084690|NCT00643916|9693638|FG004|Overall Study|Protocol Violation|0
6373272|NCT02891226|10162867|FG003|Period 2 (Weeks 12 to 52)|Endoscopic Procedure was not Evaluated|0
6373273|NCT02891226|10162868|FG004|Period 2 (Weeks 12 to 52)|Endoscopic Procedure was not Evaluated|0
6373274|NCT02891226|10162869|FG005|Period 2 (Weeks 12 to 52)|Endoscopic Procedure was not Evaluated|0
6373275|NCT02891226|10162870|FG006|Period 2 (Weeks 12 to 52)|Endoscopic Procedure was not Evaluated|0
6373276|NCT02891226|10162871|FG007|Period 2 (Weeks 12 to 52)|Endoscopic Procedure was not Evaluated|0
6373277|NCT02891226|10162872|FG008|Period 2 (Weeks 12 to 52)|Endoscopic Procedure was not Evaluated|1
6373278|NCT02891226|10162873|FG009|Period 2 (Weeks 12 to 52)|Endoscopic Procedure was not Evaluated|0
6373279|NCT02891226|10162874|FG010|Period 2 (Weeks 12 to 52)|Endoscopic Procedure was not Evaluated|0
6373280|NCT02891226|10162875|FG011|Period 2 (Weeks 12 to 52)|Endoscopic Procedure was not Evaluated|0
6373281|NCT02891226|10162876|FG012|Period 2 (Weeks 12 to 52)|Endoscopic Procedure was not Evaluated|0
6084691|NCT00643916|9693639|FG005|Overall Study|Protocol Violation|0
6084692|NCT00643916|9693634|FG000|Overall Study|Lost to Follow-up|0
6084693|NCT00643916|9693635|FG001|Overall Study|Lost to Follow-up|1
6084694|NCT00643916|9693636|FG002|Overall Study|Lost to Follow-up|0
6084695|NCT00643916|9693637|FG003|Overall Study|Lost to Follow-up|0
6373282|NCT02891226|10162877|FG013|Period 2 (Weeks 12 to 52)|Endoscopic Procedure was not Evaluated|0
6373283|NCT02891226|10162878|FG014|Period 2 (Weeks 12 to 52)|Endoscopic Procedure was not Evaluated|0
6373284|NCT02891226|10162879|FG015|Period 2 (Weeks 12 to 52)|Endoscopic Procedure was not Evaluated|0
6373285|NCT02891226|10162864|FG000|Period 2 (Weeks 12 to 52)|Lack of Efficacy and Withdrew from Study|0
6373286|NCT02891226|10162865|FG001|Period 2 (Weeks 12 to 52)|Lack of Efficacy and Withdrew from Study|0
6373287|NCT02891226|10162866|FG002|Period 2 (Weeks 12 to 52)|Lack of Efficacy and Withdrew from Study|0
6373288|NCT02891226|10162867|FG003|Period 2 (Weeks 12 to 52)|Lack of Efficacy and Withdrew from Study|0
6373289|NCT02891226|10162868|FG004|Period 2 (Weeks 12 to 52)|Lack of Efficacy and Withdrew from Study|0
6373290|NCT02891226|10162869|FG005|Period 2 (Weeks 12 to 52)|Lack of Efficacy and Withdrew from Study|0
6373291|NCT02891226|10162870|FG006|Period 2 (Weeks 12 to 52)|Lack of Efficacy and Withdrew from Study|0
6373292|NCT02891226|10162871|FG007|Period 2 (Weeks 12 to 52)|Lack of Efficacy and Withdrew from Study|0
6373293|NCT02891226|10162872|FG008|Period 2 (Weeks 12 to 52)|Lack of Efficacy and Withdrew from Study|0
6373294|NCT02891226|10162873|FG009|Period 2 (Weeks 12 to 52)|Lack of Efficacy and Withdrew from Study|1
6373295|NCT02891226|10162874|FG010|Period 2 (Weeks 12 to 52)|Lack of Efficacy and Withdrew from Study|0
6373296|NCT02891226|10162875|FG011|Period 2 (Weeks 12 to 52)|Lack of Efficacy and Withdrew from Study|0
6373297|NCT02891226|10162876|FG012|Period 2 (Weeks 12 to 52)|Lack of Efficacy and Withdrew from Study|0
6373298|NCT02891226|10162877|FG013|Period 2 (Weeks 12 to 52)|Lack of Efficacy and Withdrew from Study|0
6373299|NCT02891226|10162878|FG014|Period 2 (Weeks 12 to 52)|Lack of Efficacy and Withdrew from Study|0
6373300|NCT02891226|10162879|FG015|Period 2 (Weeks 12 to 52)|Lack of Efficacy and Withdrew from Study|0
6373301|NCT02891226|10162864|FG000|Period 2 (Weeks 12 to 52)|Sponsor Decision|0
6373302|NCT02891226|10162865|FG001|Period 2 (Weeks 12 to 52)|Sponsor Decision|0
6373303|NCT02891226|10162866|FG002|Period 2 (Weeks 12 to 52)|Sponsor Decision|0
6373304|NCT02891226|10162867|FG003|Period 2 (Weeks 12 to 52)|Sponsor Decision|0
6373305|NCT02891226|10162868|FG004|Period 2 (Weeks 12 to 52)|Sponsor Decision|0
6373306|NCT02891226|10162869|FG005|Period 2 (Weeks 12 to 52)|Sponsor Decision|0
6373307|NCT02891226|10162870|FG006|Period 2 (Weeks 12 to 52)|Sponsor Decision|0
6373308|NCT02891226|10162871|FG007|Period 2 (Weeks 12 to 52)|Sponsor Decision|0
6373309|NCT02891226|10162872|FG008|Period 2 (Weeks 12 to 52)|Sponsor Decision|0
6373310|NCT02891226|10162873|FG009|Period 2 (Weeks 12 to 52)|Sponsor Decision|1
6373311|NCT02891226|10162874|FG010|Period 2 (Weeks 12 to 52)|Sponsor Decision|0
6373312|NCT02891226|10162875|FG011|Period 2 (Weeks 12 to 52)|Sponsor Decision|0
6373313|NCT02891226|10162876|FG012|Period 2 (Weeks 12 to 52)|Sponsor Decision|0
6373314|NCT02891226|10162877|FG013|Period 2 (Weeks 12 to 52)|Sponsor Decision|0
6373315|NCT02891226|10162878|FG014|Period 2 (Weeks 12 to 52)|Sponsor Decision|0
6373316|NCT02891226|10162879|FG015|Period 2 (Weeks 12 to 52)|Sponsor Decision|0
6373317|NCT02891226|10162864|FG000|Period 3 (Weeks 52 to 208)|Adverse Event|0
6373318|NCT02891226|10162865|FG001|Period 3 (Weeks 52 to 208)|Adverse Event|0
6373319|NCT02891226|10162866|FG002|Period 3 (Weeks 52 to 208)|Adverse Event|0
6373320|NCT02891226|10162867|FG003|Period 3 (Weeks 52 to 208)|Adverse Event|0
6373321|NCT02891226|10162868|FG004|Period 3 (Weeks 52 to 208)|Adverse Event|0
6373322|NCT02891226|10162869|FG005|Period 3 (Weeks 52 to 208)|Adverse Event|0
6373323|NCT02891226|10162870|FG006|Period 3 (Weeks 52 to 208)|Adverse Event|0
6373324|NCT02891226|10162871|FG007|Period 3 (Weeks 52 to 208)|Adverse Event|0
6373325|NCT02891226|10162872|FG008|Period 3 (Weeks 52 to 208)|Adverse Event|0
6373326|NCT02891226|10162873|FG009|Period 3 (Weeks 52 to 208)|Adverse Event|0
6373327|NCT02891226|10162874|FG010|Period 3 (Weeks 52 to 208)|Adverse Event|5
6373328|NCT02891226|10162875|FG011|Period 3 (Weeks 52 to 208)|Adverse Event|0
6373329|NCT02891226|10162876|FG012|Period 3 (Weeks 52 to 208)|Adverse Event|0
6373330|NCT02891226|10162877|FG013|Period 3 (Weeks 52 to 208)|Adverse Event|0
6373331|NCT02891226|10162878|FG014|Period 3 (Weeks 52 to 208)|Adverse Event|0
6373332|NCT02891226|10162879|FG015|Period 3 (Weeks 52 to 208)|Adverse Event|0
6373333|NCT02891226|10162864|FG000|Period 3 (Weeks 52 to 208)|Lost to Follow-up|0
6373334|NCT02891226|10162865|FG001|Period 3 (Weeks 52 to 208)|Lost to Follow-up|0
6373335|NCT02891226|10162866|FG002|Period 3 (Weeks 52 to 208)|Lost to Follow-up|0
6373336|NCT02891226|10162867|FG003|Period 3 (Weeks 52 to 208)|Lost to Follow-up|0
6373337|NCT02891226|10162868|FG004|Period 3 (Weeks 52 to 208)|Lost to Follow-up|0
6373338|NCT02891226|10162869|FG005|Period 3 (Weeks 52 to 208)|Lost to Follow-up|0
6373339|NCT02891226|10162870|FG006|Period 3 (Weeks 52 to 208)|Lost to Follow-up|0
6373340|NCT02891226|10162871|FG007|Period 3 (Weeks 52 to 208)|Lost to Follow-up|0
6373341|NCT02891226|10162872|FG008|Period 3 (Weeks 52 to 208)|Lost to Follow-up|0
6373342|NCT02891226|10162873|FG009|Period 3 (Weeks 52 to 208)|Lost to Follow-up|0
6373343|NCT02891226|10162874|FG010|Period 3 (Weeks 52 to 208)|Lost to Follow-up|1
6373344|NCT02891226|10162875|FG011|Period 3 (Weeks 52 to 208)|Lost to Follow-up|0
6373345|NCT02891226|10162876|FG012|Period 3 (Weeks 52 to 208)|Lost to Follow-up|0
6373346|NCT02891226|10162877|FG013|Period 3 (Weeks 52 to 208)|Lost to Follow-up|0
6373347|NCT02891226|10162878|FG014|Period 3 (Weeks 52 to 208)|Lost to Follow-up|0
6373348|NCT02891226|10162879|FG015|Period 3 (Weeks 52 to 208)|Lost to Follow-up|0
6373349|NCT02891226|10162864|FG000|Period 3 (Weeks 52 to 208)|Withdrawal by Subject|0
6373350|NCT02891226|10162865|FG001|Period 3 (Weeks 52 to 208)|Withdrawal by Subject|0
6373351|NCT02891226|10162866|FG002|Period 3 (Weeks 52 to 208)|Withdrawal by Subject|0
6373352|NCT02891226|10162867|FG003|Period 3 (Weeks 52 to 208)|Withdrawal by Subject|0
6373353|NCT02891226|10162868|FG004|Period 3 (Weeks 52 to 208)|Withdrawal by Subject|0
6373354|NCT02891226|10162869|FG005|Period 3 (Weeks 52 to 208)|Withdrawal by Subject|0
6373355|NCT02891226|10162870|FG006|Period 3 (Weeks 52 to 208)|Withdrawal by Subject|0
6373356|NCT02891226|10162871|FG007|Period 3 (Weeks 52 to 208)|Withdrawal by Subject|0
6373357|NCT02891226|10162872|FG008|Period 3 (Weeks 52 to 208)|Withdrawal by Subject|0
6373358|NCT02891226|10162873|FG009|Period 3 (Weeks 52 to 208)|Withdrawal by Subject|0
6373359|NCT02891226|10162874|FG010|Period 3 (Weeks 52 to 208)|Withdrawal by Subject|14
6373360|NCT02891226|10162875|FG011|Period 3 (Weeks 52 to 208)|Withdrawal by Subject|0
6373361|NCT02891226|10162876|FG012|Period 3 (Weeks 52 to 208)|Withdrawal by Subject|0
6373362|NCT02891226|10162877|FG013|Period 3 (Weeks 52 to 208)|Withdrawal by Subject|0
6373363|NCT02891226|10162878|FG014|Period 3 (Weeks 52 to 208)|Withdrawal by Subject|0
6373364|NCT02891226|10162879|FG015|Period 3 (Weeks 52 to 208)|Withdrawal by Subject|0
6373365|NCT02891226|10162864|FG000|Period 3 (Weeks 52 to 208)|Roll over to AMAX|0
6373366|NCT02891226|10162865|FG001|Period 3 (Weeks 52 to 208)|Roll over to AMAX|0
6373367|NCT02891226|10162866|FG002|Period 3 (Weeks 52 to 208)|Roll over to AMAX|0
6373368|NCT02891226|10162867|FG003|Period 3 (Weeks 52 to 208)|Roll over to AMAX|0
6373369|NCT02891226|10162868|FG004|Period 3 (Weeks 52 to 208)|Roll over to AMAX|0
6373370|NCT02891226|10162869|FG005|Period 3 (Weeks 52 to 208)|Roll over to AMAX|0
6373371|NCT02891226|10162870|FG006|Period 3 (Weeks 52 to 208)|Roll over to AMAX|0
6373372|NCT02891226|10162871|FG007|Period 3 (Weeks 52 to 208)|Roll over to AMAX|0
6373373|NCT02891226|10162872|FG008|Period 3 (Weeks 52 to 208)|Roll over to AMAX|0
6373374|NCT02891226|10162873|FG009|Period 3 (Weeks 52 to 208)|Roll over to AMAX|0
6373375|NCT02891226|10162874|FG010|Period 3 (Weeks 52 to 208)|Roll over to AMAX|108
6373376|NCT02891226|10162875|FG011|Period 3 (Weeks 52 to 208)|Roll over to AMAX|0
6373377|NCT02891226|10162876|FG012|Period 3 (Weeks 52 to 208)|Roll over to AMAX|0
6373378|NCT02891226|10162877|FG013|Period 3 (Weeks 52 to 208)|Roll over to AMAX|0
6373379|NCT02891226|10162878|FG014|Period 3 (Weeks 52 to 208)|Roll over to AMAX|0
6373380|NCT02891226|10162879|FG015|Period 3 (Weeks 52 to 208)|Roll over to AMAX|0
6373381|NCT02891226|10162864|FG000|Period 3 (Weeks 52 to 208)|Decided to not Participate in Extension Period (Week 104-208)|0
6373382|NCT02891226|10162865|FG001|Period 3 (Weeks 52 to 208)|Decided to not Participate in Extension Period (Week 104-208)|0
6373383|NCT02891226|10162866|FG002|Period 3 (Weeks 52 to 208)|Decided to not Participate in Extension Period (Week 104-208)|0
6373384|NCT02891226|10162867|FG003|Period 3 (Weeks 52 to 208)|Decided to not Participate in Extension Period (Week 104-208)|0
6373385|NCT02891226|10162868|FG004|Period 3 (Weeks 52 to 208)|Decided to not Participate in Extension Period (Week 104-208)|0
6373386|NCT02891226|10162869|FG005|Period 3 (Weeks 52 to 208)|Decided to not Participate in Extension Period (Week 104-208)|0
6373387|NCT02891226|10162870|FG006|Period 3 (Weeks 52 to 208)|Decided to not Participate in Extension Period (Week 104-208)|0
6373388|NCT02891226|10162871|FG007|Period 3 (Weeks 52 to 208)|Decided to not Participate in Extension Period (Week 104-208)|0
6373389|NCT02891226|10162872|FG008|Period 3 (Weeks 52 to 208)|Decided to not Participate in Extension Period (Week 104-208)|0
6373390|NCT02891226|10162873|FG009|Period 3 (Weeks 52 to 208)|Decided to not Participate in Extension Period (Week 104-208)|0
6373391|NCT02891226|10162874|FG010|Period 3 (Weeks 52 to 208)|Decided to not Participate in Extension Period (Week 104-208)|2
6373392|NCT02891226|10162875|FG011|Period 3 (Weeks 52 to 208)|Decided to not Participate in Extension Period (Week 104-208)|0
6373393|NCT02891226|10162876|FG012|Period 3 (Weeks 52 to 208)|Decided to not Participate in Extension Period (Week 104-208)|0
6373394|NCT02891226|10162877|FG013|Period 3 (Weeks 52 to 208)|Decided to not Participate in Extension Period (Week 104-208)|0
6373395|NCT02891226|10162878|FG014|Period 3 (Weeks 52 to 208)|Decided to not Participate in Extension Period (Week 104-208)|0
6373396|NCT02891226|10162879|FG015|Period 3 (Weeks 52 to 208)|Decided to not Participate in Extension Period (Week 104-208)|0
6373397|NCT02891226|10162864|FG000|Period 3 (Weeks 52 to 208)|Lack of Efficacy|0
6373398|NCT02891226|10162865|FG001|Period 3 (Weeks 52 to 208)|Lack of Efficacy|0
6373399|NCT02891226|10162866|FG002|Period 3 (Weeks 52 to 208)|Lack of Efficacy|0
6373400|NCT02891226|10162867|FG003|Period 3 (Weeks 52 to 208)|Lack of Efficacy|0
6373401|NCT02891226|10162868|FG004|Period 3 (Weeks 52 to 208)|Lack of Efficacy|0
6373402|NCT02891226|10162869|FG005|Period 3 (Weeks 52 to 208)|Lack of Efficacy|0
6373403|NCT02891226|10162870|FG006|Period 3 (Weeks 52 to 208)|Lack of Efficacy|0
6373404|NCT02891226|10162871|FG007|Period 3 (Weeks 52 to 208)|Lack of Efficacy|0
6373405|NCT02891226|10162872|FG008|Period 3 (Weeks 52 to 208)|Lack of Efficacy|0
6373406|NCT02891226|10162873|FG009|Period 3 (Weeks 52 to 208)|Lack of Efficacy|0
6373407|NCT02891226|10162874|FG010|Period 3 (Weeks 52 to 208)|Lack of Efficacy|3
6373408|NCT02891226|10162875|FG011|Period 3 (Weeks 52 to 208)|Lack of Efficacy|0
6373409|NCT02891226|10162876|FG012|Period 3 (Weeks 52 to 208)|Lack of Efficacy|0
6373410|NCT02891226|10162877|FG013|Period 3 (Weeks 52 to 208)|Lack of Efficacy|0
6373411|NCT02891226|10162878|FG014|Period 3 (Weeks 52 to 208)|Lack of Efficacy|0
6373412|NCT02891226|10162879|FG015|Period 3 (Weeks 52 to 208)|Lack of Efficacy|0
6373413|NCT02891226|10162864|FG000|Period 3 (Weeks 52 to 208)|PI Decision as Subject Not Responding to Study Drug|0
6373414|NCT02891226|10162865|FG001|Period 3 (Weeks 52 to 208)|PI Decision as Subject Not Responding to Study Drug|0
6373415|NCT02891226|10162866|FG002|Period 3 (Weeks 52 to 208)|PI Decision as Subject Not Responding to Study Drug|0
6373416|NCT02891226|10162867|FG003|Period 3 (Weeks 52 to 208)|PI Decision as Subject Not Responding to Study Drug|0
6373417|NCT02891226|10162868|FG004|Period 3 (Weeks 52 to 208)|PI Decision as Subject Not Responding to Study Drug|0
6373418|NCT02891226|10162869|FG005|Period 3 (Weeks 52 to 208)|PI Decision as Subject Not Responding to Study Drug|0
6373419|NCT02891226|10162870|FG006|Period 3 (Weeks 52 to 208)|PI Decision as Subject Not Responding to Study Drug|0
6373420|NCT02891226|10162871|FG007|Period 3 (Weeks 52 to 208)|PI Decision as Subject Not Responding to Study Drug|0
6373421|NCT02891226|10162872|FG008|Period 3 (Weeks 52 to 208)|PI Decision as Subject Not Responding to Study Drug|0
6373422|NCT02891226|10162873|FG009|Period 3 (Weeks 52 to 208)|PI Decision as Subject Not Responding to Study Drug|0
6373423|NCT02891226|10162874|FG010|Period 3 (Weeks 52 to 208)|PI Decision as Subject Not Responding to Study Drug|2
6373424|NCT02891226|10162875|FG011|Period 3 (Weeks 52 to 208)|PI Decision as Subject Not Responding to Study Drug|0
6373425|NCT02891226|10162876|FG012|Period 3 (Weeks 52 to 208)|PI Decision as Subject Not Responding to Study Drug|0
6373426|NCT02891226|10162877|FG013|Period 3 (Weeks 52 to 208)|PI Decision as Subject Not Responding to Study Drug|0
6373427|NCT02891226|10162878|FG014|Period 3 (Weeks 52 to 208)|PI Decision as Subject Not Responding to Study Drug|0
6373428|NCT02891226|10162879|FG015|Period 3 (Weeks 52 to 208)|PI Decision as Subject Not Responding to Study Drug|0
6373429|NCT02891226|10162864|FG000|Period 3 (Weeks 52 to 208)|Non-Compliance With Study Visit Schedule|0
6373430|NCT02891226|10162865|FG001|Period 3 (Weeks 52 to 208)|Non-Compliance With Study Visit Schedule|0
6373431|NCT02891226|10162866|FG002|Period 3 (Weeks 52 to 208)|Non-Compliance With Study Visit Schedule|0
6373432|NCT02891226|10162867|FG003|Period 3 (Weeks 52 to 208)|Non-Compliance With Study Visit Schedule|0
6373433|NCT02891226|10162868|FG004|Period 3 (Weeks 52 to 208)|Non-Compliance With Study Visit Schedule|0
6373434|NCT02891226|10162869|FG005|Period 3 (Weeks 52 to 208)|Non-Compliance With Study Visit Schedule|0
6373435|NCT02891226|10162870|FG006|Period 3 (Weeks 52 to 208)|Non-Compliance With Study Visit Schedule|0
6373436|NCT02891226|10162871|FG007|Period 3 (Weeks 52 to 208)|Non-Compliance With Study Visit Schedule|0
6373437|NCT02891226|10162872|FG008|Period 3 (Weeks 52 to 208)|Non-Compliance With Study Visit Schedule|0
6084696|NCT00643916|9693638|FG004|Overall Study|Lost to Follow-up|0
6084697|NCT00643916|9693639|FG005|Overall Study|Lost to Follow-up|0
6084698|NCT00643916|9693634|FG000|Overall Study|Withdrawal by Subject|2
6373438|NCT02891226|10162873|FG009|Period 3 (Weeks 52 to 208)|Non-Compliance With Study Visit Schedule|0
6373439|NCT02891226|10162874|FG010|Period 3 (Weeks 52 to 208)|Non-Compliance With Study Visit Schedule|2
6373440|NCT02891226|10162875|FG011|Period 3 (Weeks 52 to 208)|Non-Compliance With Study Visit Schedule|0
6373441|NCT02891226|10162876|FG012|Period 3 (Weeks 52 to 208)|Non-Compliance With Study Visit Schedule|0
6373442|NCT02891226|10162877|FG013|Period 3 (Weeks 52 to 208)|Non-Compliance With Study Visit Schedule|0
6373443|NCT02891226|10162878|FG014|Period 3 (Weeks 52 to 208)|Non-Compliance With Study Visit Schedule|0
6171882|NCT01262638|9818800|FG002|Overall Study|Per Investigator/Sponsor/Regulatory Body|1
6171883|NCT01262638|9818801|FG003|Overall Study|Per Investigator/Sponsor/Regulatory Body|0
6373444|NCT02891226|10162879|FG015|Period 3 (Weeks 52 to 208)|Non-Compliance With Study Visit Schedule|0
6373445|NCT02891226|10162864|FG000|Follow-up Period|Withdrawal by Subject|0
6373446|NCT02891226|10162865|FG001|Follow-up Period|Withdrawal by Subject|0
6373447|NCT02891226|10162866|FG002|Follow-up Period|Withdrawal by Subject|0
6373448|NCT02891226|10162867|FG003|Follow-up Period|Withdrawal by Subject|0
6373449|NCT02891226|10162868|FG004|Follow-up Period|Withdrawal by Subject|0
6373450|NCT02891226|10162869|FG005|Follow-up Period|Withdrawal by Subject|0
6373451|NCT02891226|10162870|FG006|Follow-up Period|Withdrawal by Subject|0
6373452|NCT02891226|10162871|FG007|Follow-up Period|Withdrawal by Subject|0
6373453|NCT02891226|10162872|FG008|Follow-up Period|Withdrawal by Subject|0
6373454|NCT02891226|10162873|FG009|Follow-up Period|Withdrawal by Subject|0
6373455|NCT02891226|10162874|FG010|Follow-up Period|Withdrawal by Subject|0
6373456|NCT02891226|10162875|FG011|Follow-up Period|Withdrawal by Subject|1
6373457|NCT02891226|10162876|FG012|Follow-up Period|Withdrawal by Subject|0
6373458|NCT02891226|10162877|FG013|Follow-up Period|Withdrawal by Subject|0
6373459|NCT02891226|10162878|FG014|Follow-up Period|Withdrawal by Subject|1
6373460|NCT02891226|10162879|FG015|Follow-up Period|Withdrawal by Subject|1
6373461|NCT02549092|10162912|FG000|Treatment Period|Adverse Event|2
6373462|NCT02549092|10162913|FG001|Treatment Period|Adverse Event|2
6373463|NCT02549092|10162912|FG000|Treatment Period|Withdrawal by Subject|1
6373464|NCT02549092|10162913|FG001|Treatment Period|Withdrawal by Subject|3
6373465|NCT02549092|10162912|FG000|Treatment Period|Lack of Efficacy|0
6373466|NCT02549092|10162913|FG001|Treatment Period|Lack of Efficacy|2
6373467|NCT02549092|10162912|FG000|Extension/Transition Period|Still in Extension/Transition Period|4
6373468|NCT02549092|10162913|FG001|Extension/Transition Period|Still in Extension/Transition Period|8
6373469|NCT02549092|10162912|FG000|Extension/Transition Period|Premature Discontinuation for Unspecified Reason|1
6373470|NCT02549092|10162913|FG001|Extension/Transition Period|Premature Discontinuation for Unspecified Reason|1
6373471|NCT02323126|10162934|FG000|Overall Study|Patient / guardian decision|0
6373472|NCT02323126|10162935|FG001|Overall Study|Patient / guardian decision|1
6373473|NCT02323126|10162936|FG002|Overall Study|Patient / guardian decision|2
6373474|NCT02323126|10162934|FG000|Overall Study|Progressive disease|14
6373475|NCT02323126|10162935|FG001|Overall Study|Progressive disease|8
6373476|NCT02323126|10162936|FG002|Overall Study|Progressive disease|14
6373477|NCT02323126|10162934|FG000|Overall Study|Physician Decision|0
6084699|NCT00643916|9693635|FG001|Overall Study|Withdrawal by Subject|2
6373478|NCT02323126|10162935|FG001|Overall Study|Physician Decision|1
6373479|NCT02323126|10162936|FG002|Overall Study|Physician Decision|3
6373480|NCT02323126|10162934|FG000|Overall Study|Death|1
6373481|NCT02323126|10162935|FG001|Overall Study|Death|1
6373482|NCT02323126|10162936|FG002|Overall Study|Death|4
6373483|NCT02323126|10162934|FG000|Overall Study|Adverse Event|3
6373484|NCT02323126|10162935|FG001|Overall Study|Adverse Event|5
6373485|NCT02323126|10162936|FG002|Overall Study|Adverse Event|7
6084700|NCT00643916|9693636|FG002|Overall Study|Withdrawal by Subject|2
6084701|NCT00643916|9693637|FG003|Overall Study|Withdrawal by Subject|1
6084702|NCT00643916|9693638|FG004|Overall Study|Withdrawal by Subject|0
6084703|NCT00643916|9693639|FG005|Overall Study|Withdrawal by Subject|1
6084704|NCT00643916|9693634|FG000|Overall Study|Not Vaccinated|2
6084705|NCT00643916|9693635|FG001|Overall Study|Not Vaccinated|2
6084706|NCT00643916|9693636|FG002|Overall Study|Not Vaccinated|3
6084707|NCT00643916|9693637|FG003|Overall Study|Not Vaccinated|0
6084708|NCT00643916|9693638|FG004|Overall Study|Not Vaccinated|2
6084709|NCT00643916|9693639|FG005|Overall Study|Not Vaccinated|0
6084710|NCT00644059|9693656|FG000|Overall Study|Lost to Follow-up|37
6084711|NCT00644059|9693657|FG001|Overall Study|Lost to Follow-up|34
6373486|NCT01902290|10162949|FG000|Overall Study|Withdrawal by Subject|19
6373487|NCT01902290|10162950|FG001|Overall Study|Withdrawal by Subject|27
6373488|NCT01902290|10162949|FG000|Overall Study|Lost to Follow-up|2
6373489|NCT01902290|10162950|FG001|Overall Study|Lost to Follow-up|2
6373490|NCT01902290|10162949|FG000|Overall Study|Death|1
6373491|NCT01902290|10162950|FG001|Overall Study|Death|0
6373492|NCT01902290|10162949|FG000|Overall Study|Sponsor Decision|26
6373493|NCT01902290|10162950|FG001|Overall Study|Sponsor Decision|24
6373494|NCT01126749|10162961|FG000|Phase 1b|Other|0
6373495|NCT01126749|10162962|FG001|Phase 1b|Other|1
6373496|NCT01126749|10162963|FG002|Phase 1b|Other|0
6373497|NCT01126749|10162964|FG003|Phase 1b|Other|0
6373498|NCT01126749|10162961|FG000|Phase 1b|Withdrawal by Subject|0
6373499|NCT01126749|10162962|FG001|Phase 1b|Withdrawal by Subject|1
6373500|NCT01126749|10162963|FG002|Phase 1b|Withdrawal by Subject|0
6373501|NCT01126749|10162964|FG003|Phase 1b|Withdrawal by Subject|0
6373502|NCT01126749|10162961|FG000|Phase 1b|Death|3
6373503|NCT01126749|10162962|FG001|Phase 1b|Death|4
6373504|NCT01126749|10162963|FG002|Phase 1b|Death|0
6373505|NCT01126749|10162964|FG003|Phase 1b|Death|0
6373506|NCT01126749|10162961|FG000|Phase 2|Completed 1 Year Follow-Up Per Protocol|0
6373507|NCT01126749|10162962|FG001|Phase 2|Completed 1 Year Follow-Up Per Protocol|0
6373508|NCT01126749|10162963|FG002|Phase 2|Completed 1 Year Follow-Up Per Protocol|4
6373509|NCT01126749|10162964|FG003|Phase 2|Completed 1 Year Follow-Up Per Protocol|7
6373510|NCT01126749|10162961|FG000|Phase 2|Study Termination by Sponsor|0
6373511|NCT01126749|10162962|FG001|Phase 2|Study Termination by Sponsor|0
6373512|NCT01126749|10162963|FG002|Phase 2|Study Termination by Sponsor|12
6373513|NCT01126749|10162964|FG003|Phase 2|Study Termination by Sponsor|6
6373514|NCT01126749|10162961|FG000|Phase 2|Other|0
6373515|NCT01126749|10162962|FG001|Phase 2|Other|0
6373516|NCT01126749|10162963|FG002|Phase 2|Other|4
6373517|NCT01126749|10162964|FG003|Phase 2|Other|2
6373518|NCT01126749|10162961|FG000|Phase 2|Withdrawal by Subject|0
6373519|NCT01126749|10162962|FG001|Phase 2|Withdrawal by Subject|0
6373520|NCT01126749|10162963|FG002|Phase 2|Withdrawal by Subject|0
6373521|NCT01126749|10162964|FG003|Phase 2|Withdrawal by Subject|2
6373522|NCT01126749|10162961|FG000|Phase 2|Lost to Follow-up|0
6373523|NCT01126749|10162962|FG001|Phase 2|Lost to Follow-up|0
6373524|NCT01126749|10162963|FG002|Phase 2|Lost to Follow-up|0
6373525|NCT01126749|10162964|FG003|Phase 2|Lost to Follow-up|1
6373526|NCT01126749|10162961|FG000|Phase 2|Death|0
6373527|NCT01126749|10162962|FG001|Phase 2|Death|0
6373528|NCT01126749|10162963|FG002|Phase 2|Death|22
6373529|NCT01126749|10162964|FG003|Phase 2|Death|22
6373530|NCT01126749|10162961|FG000|Phase 2|Adverse Event|0
6373531|NCT01126749|10162962|FG001|Phase 2|Adverse Event|0
6373532|NCT01126749|10162963|FG002|Phase 2|Adverse Event|0
6373533|NCT01126749|10162964|FG003|Phase 2|Adverse Event|1
6373534|NCT01059448|10162987|FG000|Overall Study|Adverse Event|1
6373535|NCT01059448|10162988|FG001|Overall Study|Adverse Event|3
6373536|NCT01059448|10162989|FG002|Overall Study|Adverse Event|0
6373537|NCT01059448|10162990|FG003|Overall Study|Adverse Event|1
6373538|NCT01059448|10162987|FG000|Overall Study|Withdrawal by Subject|2
6373539|NCT01059448|10162988|FG001|Overall Study|Withdrawal by Subject|0
6084712|NCT00644059|9693658|FG002|Overall Study|Lost to Follow-up|16
6373540|NCT01059448|10162989|FG002|Overall Study|Withdrawal by Subject|2
6373541|NCT01059448|10162990|FG003|Overall Study|Withdrawal by Subject|4
6373542|NCT01059448|10162987|FG000|Overall Study|Disease Progression|2
6373543|NCT01059448|10162988|FG001|Overall Study|Disease Progression|1
6373544|NCT01059448|10162989|FG002|Overall Study|Disease Progression|4
6084713|NCT00644059|9693656|FG000|Overall Study|Withdrawal by Subject|52
6373545|NCT01059448|10162990|FG003|Overall Study|Disease Progression|2
6373546|NCT01059448|10162987|FG000|Overall Study|Administrative Decision|43
6373547|NCT01059448|10162988|FG001|Overall Study|Administrative Decision|49
6373548|NCT01059448|10162989|FG002|Overall Study|Administrative Decision|45
6373549|NCT01059448|10162990|FG003|Overall Study|Administrative Decision|46
6373550|NCT01059448|10162987|FG000|Overall Study|Lost to Follow-up|0
6373551|NCT01059448|10162988|FG001|Overall Study|Lost to Follow-up|0
6373552|NCT01059448|10162989|FG002|Overall Study|Lost to Follow-up|2
6373553|NCT01059448|10162990|FG003|Overall Study|Lost to Follow-up|0
6373554|NCT01059448|10162987|FG000|Overall Study|Death|0
6373555|NCT01059448|10162988|FG001|Overall Study|Death|1
6373556|NCT01059448|10162989|FG002|Overall Study|Death|0
6373557|NCT01059448|10162990|FG003|Overall Study|Death|0
6373558|NCT01059448|10162987|FG000|Overall Study|Other|1
6373559|NCT01059448|10162988|FG001|Overall Study|Other|1
6373560|NCT01059448|10162989|FG002|Overall Study|Other|0
6373561|NCT01059448|10162990|FG003|Overall Study|Other|1
6373562|NCT00821587|10163002|FG000|Overall Study|Physician Decision|0
6373563|NCT00821587|10163003|FG001|Overall Study|Physician Decision|1
6373564|NCT00585195|10163030|FG000|Overall Study|Adverse Event|0
6373565|NCT00585195|10163031|FG001|Overall Study|Adverse Event|0
6373566|NCT00585195|10163032|FG002|Overall Study|Adverse Event|0
6373567|NCT00585195|10163033|FG003|Overall Study|Adverse Event|0
6373568|NCT00585195|10163034|FG004|Overall Study|Adverse Event|2
6373569|NCT00585195|10163035|FG005|Overall Study|Adverse Event|1
6373570|NCT00585195|10163036|FG006|Overall Study|Adverse Event|0
6373571|NCT00585195|10163037|FG007|Overall Study|Adverse Event|1
6373572|NCT00585195|10163038|FG008|Overall Study|Adverse Event|0
6373573|NCT00585195|10163039|FG009|Overall Study|Adverse Event|0
6373574|NCT00585195|10163040|FG010|Overall Study|Adverse Event|3
6373575|NCT00585195|10163041|FG011|Overall Study|Adverse Event|0
6373576|NCT00585195|10163042|FG012|Overall Study|Adverse Event|8
6373577|NCT00585195|10163043|FG013|Overall Study|Adverse Event|6
6373578|NCT00585195|10163044|FG014|Overall Study|Adverse Event|4
6373579|NCT00585195|10163045|FG015|Overall Study|Adverse Event|1
6373580|NCT00585195|10163046|FG016|Overall Study|Adverse Event|14
6373581|NCT00585195|10163047|FG017|Overall Study|Adverse Event|9
6373582|NCT00585195|10163048|FG018|Overall Study|Adverse Event|2
6373583|NCT00585195|10163049|FG019|Overall Study|Adverse Event|3
6373584|NCT00585195|10163050|FG020|Overall Study|Adverse Event|1
6373585|NCT00585195|10163030|FG000|Overall Study|Progressive Disease|2
6373586|NCT00585195|10163031|FG001|Overall Study|Progressive Disease|2
6373587|NCT00585195|10163032|FG002|Overall Study|Progressive Disease|5
6373588|NCT00585195|10163033|FG003|Overall Study|Progressive Disease|4
6373589|NCT00585195|10163034|FG004|Overall Study|Progressive Disease|6
6373590|NCT00585195|10163035|FG005|Overall Study|Progressive Disease|4
6373591|NCT00585195|10163036|FG006|Overall Study|Progressive Disease|6
6373592|NCT00585195|10163037|FG007|Overall Study|Progressive Disease|3
6373593|NCT00585195|10163038|FG008|Overall Study|Progressive Disease|0
6373594|NCT00585195|10163039|FG009|Overall Study|Progressive Disease|5
6373595|NCT00585195|10163040|FG010|Overall Study|Progressive Disease|2
6373596|NCT00585195|10163041|FG011|Overall Study|Progressive Disease|25
6373597|NCT00585195|10163042|FG012|Overall Study|Progressive Disease|29
6373598|NCT00585195|10163043|FG013|Overall Study|Progressive Disease|26
6373599|NCT00585195|10163044|FG014|Overall Study|Progressive Disease|21
6373600|NCT00585195|10163045|FG015|Overall Study|Progressive Disease|12
6373601|NCT00585195|10163046|FG016|Overall Study|Progressive Disease|94
6373602|NCT00585195|10163047|FG017|Overall Study|Progressive Disease|42
6373603|NCT00585195|10163048|FG018|Overall Study|Progressive Disease|4
6373604|NCT00585195|10163049|FG019|Overall Study|Progressive Disease|9
6373605|NCT00585195|10163050|FG020|Overall Study|Progressive Disease|8
6373606|NCT00585195|10163030|FG000|Overall Study|Withdrawal by Subject|1
6373607|NCT00585195|10163031|FG001|Overall Study|Withdrawal by Subject|1
6373608|NCT00585195|10163032|FG002|Overall Study|Withdrawal by Subject|2
6373609|NCT00585195|10163033|FG003|Overall Study|Withdrawal by Subject|2
6373610|NCT00585195|10163034|FG004|Overall Study|Withdrawal by Subject|0
6373611|NCT00585195|10163035|FG005|Overall Study|Withdrawal by Subject|0
6373612|NCT00585195|10163036|FG006|Overall Study|Withdrawal by Subject|0
6373613|NCT00585195|10163037|FG007|Overall Study|Withdrawal by Subject|1
6373614|NCT00585195|10163038|FG008|Overall Study|Withdrawal by Subject|0
6373615|NCT00585195|10163039|FG009|Overall Study|Withdrawal by Subject|0
6373616|NCT00585195|10163040|FG010|Overall Study|Withdrawal by Subject|3
6373617|NCT00585195|10163041|FG011|Overall Study|Withdrawal by Subject|8
6373618|NCT00585195|10163042|FG012|Overall Study|Withdrawal by Subject|15
6373619|NCT00585195|10163043|FG013|Overall Study|Withdrawal by Subject|0
6373620|NCT00585195|10163044|FG014|Overall Study|Withdrawal by Subject|3
6373621|NCT00585195|10163045|FG015|Overall Study|Withdrawal by Subject|0
6373622|NCT00585195|10163046|FG016|Overall Study|Withdrawal by Subject|7
6373623|NCT00585195|10163047|FG017|Overall Study|Withdrawal by Subject|1
6373624|NCT00585195|10163048|FG018|Overall Study|Withdrawal by Subject|2
6373625|NCT00585195|10163049|FG019|Overall Study|Withdrawal by Subject|2
6373626|NCT00585195|10163050|FG020|Overall Study|Withdrawal by Subject|0
6373627|NCT00585195|10163030|FG000|Overall Study|Other|0
6373628|NCT00585195|10163031|FG001|Overall Study|Other|1
6373629|NCT00585195|10163032|FG002|Overall Study|Other|1
6373630|NCT00585195|10163033|FG003|Overall Study|Other|1
6373631|NCT00585195|10163034|FG004|Overall Study|Other|0
6373632|NCT00585195|10163035|FG005|Overall Study|Other|1
6373633|NCT00585195|10163036|FG006|Overall Study|Other|0
6373634|NCT00585195|10163037|FG007|Overall Study|Other|0
6373635|NCT00585195|10163038|FG008|Overall Study|Other|2
6373636|NCT00585195|10163039|FG009|Overall Study|Other|1
6373637|NCT00585195|10163040|FG010|Overall Study|Other|0
6373638|NCT00585195|10163041|FG011|Overall Study|Other|19
6373639|NCT00585195|10163042|FG012|Overall Study|Other|23
6373640|NCT00585195|10163043|FG013|Overall Study|Other|7
6373641|NCT00585195|10163044|FG014|Overall Study|Other|11
6373642|NCT00585195|10163045|FG015|Overall Study|Other|3
6373643|NCT00585195|10163046|FG016|Overall Study|Other|28
6373644|NCT00585195|10163047|FG017|Overall Study|Other|12
6373645|NCT00585195|10163048|FG018|Overall Study|Other|10
6373646|NCT00585195|10163049|FG019|Overall Study|Other|4
6373647|NCT00585195|10163050|FG020|Overall Study|Other|2
6373648|NCT00585195|10163030|FG000|Overall Study|Randomized not treated|0
6373649|NCT00585195|10163031|FG001|Overall Study|Randomized not treated|0
6373650|NCT00585195|10163032|FG002|Overall Study|Randomized not treated|1
6373651|NCT00585195|10163033|FG003|Overall Study|Randomized not treated|0
6373652|NCT00585195|10163034|FG004|Overall Study|Randomized not treated|1
6373653|NCT00585195|10163035|FG005|Overall Study|Randomized not treated|0
6373654|NCT00585195|10163036|FG006|Overall Study|Randomized not treated|1
6373655|NCT00585195|10163037|FG007|Overall Study|Randomized not treated|0
6373656|NCT00585195|10163038|FG008|Overall Study|Randomized not treated|0
6373657|NCT00585195|10163039|FG009|Overall Study|Randomized not treated|0
6373658|NCT00585195|10163040|FG010|Overall Study|Randomized not treated|2
6373659|NCT00585195|10163041|FG011|Overall Study|Randomized not treated|0
6373660|NCT00585195|10163042|FG012|Overall Study|Randomized not treated|0
6373661|NCT00585195|10163043|FG013|Overall Study|Randomized not treated|0
6373662|NCT00585195|10163044|FG014|Overall Study|Randomized not treated|0
6373663|NCT00585195|10163045|FG015|Overall Study|Randomized not treated|1
6373664|NCT00585195|10163046|FG016|Overall Study|Randomized not treated|0
6373665|NCT00585195|10163047|FG017|Overall Study|Randomized not treated|1
6373666|NCT00585195|10163048|FG018|Overall Study|Randomized not treated|3
6373667|NCT00585195|10163049|FG019|Overall Study|Randomized not treated|0
6373668|NCT00585195|10163050|FG020|Overall Study|Randomized not treated|2
6373669|NCT00585195|10163030|FG000|Overall Study|Death|0
6373670|NCT00585195|10163031|FG001|Overall Study|Death|0
6373671|NCT00585195|10163032|FG002|Overall Study|Death|0
6373672|NCT00585195|10163033|FG003|Overall Study|Death|0
6373673|NCT00585195|10163034|FG004|Overall Study|Death|0
6373674|NCT00585195|10163035|FG005|Overall Study|Death|0
6373675|NCT00585195|10163036|FG006|Overall Study|Death|0
6373676|NCT00585195|10163037|FG007|Overall Study|Death|0
6373677|NCT00585195|10163038|FG008|Overall Study|Death|1
6373678|NCT00585195|10163039|FG009|Overall Study|Death|0
6373679|NCT00585195|10163040|FG010|Overall Study|Death|1
6373680|NCT00585195|10163041|FG011|Overall Study|Death|1
6373681|NCT00585195|10163042|FG012|Overall Study|Death|7
6373682|NCT00585195|10163043|FG013|Overall Study|Death|2
6373683|NCT00585195|10163044|FG014|Overall Study|Death|8
6373684|NCT00585195|10163045|FG015|Overall Study|Death|2
6373685|NCT00585195|10163046|FG016|Overall Study|Death|11
6373686|NCT00585195|10163047|FG017|Overall Study|Death|0
6373687|NCT00585195|10163048|FG018|Overall Study|Death|0
6373688|NCT00585195|10163049|FG019|Overall Study|Death|0
6373689|NCT00585195|10163050|FG020|Overall Study|Death|1
6373690|NCT00585195|10163030|FG000|Overall Study|Lost to Follow-up|0
6373691|NCT00585195|10163031|FG001|Overall Study|Lost to Follow-up|0
6373692|NCT00585195|10163032|FG002|Overall Study|Lost to Follow-up|0
6373693|NCT00585195|10163033|FG003|Overall Study|Lost to Follow-up|0
6373694|NCT00585195|10163034|FG004|Overall Study|Lost to Follow-up|0
6373695|NCT00585195|10163035|FG005|Overall Study|Lost to Follow-up|0
6373696|NCT00585195|10163036|FG006|Overall Study|Lost to Follow-up|0
6373697|NCT00585195|10163037|FG007|Overall Study|Lost to Follow-up|0
6373698|NCT00585195|10163038|FG008|Overall Study|Lost to Follow-up|0
6373699|NCT00585195|10163039|FG009|Overall Study|Lost to Follow-up|0
6373700|NCT00585195|10163040|FG010|Overall Study|Lost to Follow-up|0
6373701|NCT00585195|10163041|FG011|Overall Study|Lost to Follow-up|0
6373702|NCT00585195|10163042|FG012|Overall Study|Lost to Follow-up|1
6373703|NCT00585195|10163043|FG013|Overall Study|Lost to Follow-up|0
6373704|NCT00585195|10163044|FG014|Overall Study|Lost to Follow-up|0
6373705|NCT00585195|10163045|FG015|Overall Study|Lost to Follow-up|0
6373706|NCT00585195|10163046|FG016|Overall Study|Lost to Follow-up|0
6373707|NCT00585195|10163047|FG017|Overall Study|Lost to Follow-up|2
6373708|NCT00585195|10163048|FG018|Overall Study|Lost to Follow-up|0
6373709|NCT00585195|10163049|FG019|Overall Study|Lost to Follow-up|0
6373710|NCT00585195|10163050|FG020|Overall Study|Lost to Follow-up|0
6373711|NCT00585195|10163030|FG000|Overall Study|Ongoing|0
6373712|NCT00585195|10163031|FG001|Overall Study|Ongoing|0
6373713|NCT00585195|10163032|FG002|Overall Study|Ongoing|0
6373714|NCT00585195|10163033|FG003|Overall Study|Ongoing|0
6043319|NCT00388674|9641858|FG001|End of Study|Death|262
6373715|NCT00585195|10163034|FG004|Overall Study|Ongoing|0
6043320|NCT00388674|9641857|FG000|End of Study|HBV Disease Progression (Non-HCC)|3
6373716|NCT00585195|10163035|FG005|Overall Study|Ongoing|0
6373717|NCT00585195|10163036|FG006|Overall Study|Ongoing|0
6373718|NCT00585195|10163037|FG007|Overall Study|Ongoing|0
6373719|NCT00585195|10163038|FG008|Overall Study|Ongoing|0
6373720|NCT00585195|10163039|FG009|Overall Study|Ongoing|0
6373721|NCT00585195|10163040|FG010|Overall Study|Ongoing|0
6373722|NCT00585195|10163041|FG011|Overall Study|Ongoing|0
6373723|NCT00585195|10163042|FG012|Overall Study|Ongoing|2
6373724|NCT00585195|10163043|FG013|Overall Study|Ongoing|0
6373725|NCT00585195|10163044|FG014|Overall Study|Ongoing|0
6373726|NCT00585195|10163045|FG015|Overall Study|Ongoing|0
6373727|NCT00585195|10163046|FG016|Overall Study|Ongoing|0
6373728|NCT00585195|10163047|FG017|Overall Study|Ongoing|0
6373729|NCT00585195|10163048|FG018|Overall Study|Ongoing|0
6373730|NCT00585195|10163049|FG019|Overall Study|Ongoing|0
6373731|NCT00585195|10163050|FG020|Overall Study|Ongoing|0
6373732|NCT00585195|10163030|FG000|Overall Study|Withdrawn Due to Pregnancy|0
6373733|NCT00585195|10163031|FG001|Overall Study|Withdrawn Due to Pregnancy|0
6373734|NCT00585195|10163032|FG002|Overall Study|Withdrawn Due to Pregnancy|0
6373735|NCT00585195|10163033|FG003|Overall Study|Withdrawn Due to Pregnancy|0
6373736|NCT00585195|10163034|FG004|Overall Study|Withdrawn Due to Pregnancy|0
6373737|NCT00585195|10163035|FG005|Overall Study|Withdrawn Due to Pregnancy|0
6373738|NCT00585195|10163036|FG006|Overall Study|Withdrawn Due to Pregnancy|0
6373739|NCT00585195|10163037|FG007|Overall Study|Withdrawn Due to Pregnancy|0
6373740|NCT00585195|10163038|FG008|Overall Study|Withdrawn Due to Pregnancy|0
6373741|NCT00585195|10163039|FG009|Overall Study|Withdrawn Due to Pregnancy|0
6373742|NCT00585195|10163040|FG010|Overall Study|Withdrawn Due to Pregnancy|0
6373743|NCT00585195|10163041|FG011|Overall Study|Withdrawn Due to Pregnancy|0
6373744|NCT00585195|10163042|FG012|Overall Study|Withdrawn Due to Pregnancy|0
6373745|NCT00585195|10163043|FG013|Overall Study|Withdrawn Due to Pregnancy|0
6373746|NCT00585195|10163044|FG014|Overall Study|Withdrawn Due to Pregnancy|1
6373747|NCT00585195|10163045|FG015|Overall Study|Withdrawn Due to Pregnancy|0
6373748|NCT00585195|10163046|FG016|Overall Study|Withdrawn Due to Pregnancy|0
6373749|NCT00585195|10163047|FG017|Overall Study|Withdrawn Due to Pregnancy|0
6373750|NCT00585195|10163048|FG018|Overall Study|Withdrawn Due to Pregnancy|0
6373751|NCT00585195|10163049|FG019|Overall Study|Withdrawn Due to Pregnancy|0
6373752|NCT00585195|10163050|FG020|Overall Study|Withdrawn Due to Pregnancy|0
6373753|NCT00278915|10163133|FG000|Overall Study|Lack of Efficacy|1
6084714|NCT00644059|9693657|FG001|Overall Study|Withdrawal by Subject|60
6084715|NCT00644059|9693658|FG002|Overall Study|Withdrawal by Subject|30
6084716|NCT00644059|9693656|FG000|Overall Study|Adverse Event|8
6084717|NCT00644059|9693657|FG001|Overall Study|Adverse Event|5
6084718|NCT00644059|9693658|FG002|Overall Study|Adverse Event|1
6084719|NCT00644059|9693656|FG000|Overall Study|Inappropriate Enrollment|1
6084720|NCT00644059|9693657|FG001|Overall Study|Inappropriate Enrollment|3
6084721|NCT00644059|9693658|FG002|Overall Study|Inappropriate Enrollment|0
6084722|NCT00644059|9693656|FG000|Overall Study|Protocol Deviation/violation|20
6084723|NCT00644059|9693657|FG001|Overall Study|Protocol Deviation/violation|19
6084724|NCT00644059|9693658|FG002|Overall Study|Protocol Deviation/violation|15
6084725|NCT00644059|9693656|FG000|Overall Study|Unable to classify|6
6084726|NCT00644059|9693657|FG001|Overall Study|Unable to classify|2
6084727|NCT00644059|9693658|FG002|Overall Study|Unable to classify|3
6084728|NCT00644332|9693725|FG000|Overall Study|Adverse Event|11
6084729|NCT00644332|9693725|FG000|Overall Study|Withdrawal by Subject|6
6084730|NCT00644332|9693725|FG000|Overall Study|Completion Status Unknown|2
6084731|NCT00644332|9693725|FG000|Overall Study|Did Not Meet Eligibility Requirements|1
6084732|NCT00644332|9693725|FG000|Overall Study|Could Not Attend Scheduled Visits|1
6084733|NCT00644358|9693729|FG000|Overall Study|Adverse Event|124
6084734|NCT00644358|9693729|FG000|Overall Study|Lost to Follow-up|105
6084735|NCT00644358|9693729|FG000|Overall Study|Consent Withdrawal|64
6084736|NCT00644358|9693729|FG000|Overall Study|Lack of Effectiveness|39
6084737|NCT00644358|9693729|FG000|Overall Study|Protocol Violation|5
6084738|NCT00644358|9693729|FG000|Overall Study|Noncompliance|14
6084739|NCT00644358|9693729|FG000|Overall Study|Other Unspecified|11
6084740|NCT00644423|9693735|FG000|Overall Study|Lost to Follow-up|1
6084741|NCT00644423|9693736|FG001|Overall Study|Lost to Follow-up|1
6084742|NCT00644787|9693755|FG000|Period 1: Titration Phase|Adverse Event|11
6084743|NCT00644787|9693756|FG001|Period 1: Titration Phase|Adverse Event|0
6084744|NCT00644787|9693757|FG002|Period 1: Titration Phase|Adverse Event|0
6084745|NCT00644787|9693755|FG000|Period 1: Titration Phase|Withdrawal by Subject|2
6084746|NCT00644787|9693756|FG001|Period 1: Titration Phase|Withdrawal by Subject|0
6084747|NCT00644787|9693757|FG002|Period 1: Titration Phase|Withdrawal by Subject|0
6084748|NCT00644787|9693755|FG000|Period 1: Titration Phase|Physician Decision|1
6084749|NCT00644787|9693756|FG001|Period 1: Titration Phase|Physician Decision|0
6084750|NCT00644787|9693757|FG002|Period 1: Titration Phase|Physician Decision|0
6084751|NCT00644787|9693755|FG000|Period 1: Titration Phase|Worsening of underlying disease|5
6084752|NCT00644787|9693756|FG001|Period 1: Titration Phase|Worsening of underlying disease|0
6373754|NCT04446429|10163139|FG000|Overall Study|Lost to Follow-up|6
6373755|NCT04446429|10163140|FG001|Overall Study|Lost to Follow-up|0
6373756|NCT04194528|10163163|FG000|Overall Study|Adverse Event|1
6084753|NCT00644787|9693757|FG002|Period 1: Titration Phase|Worsening of underlying disease|0
6373757|NCT03116685|10163195|FG000|Overall Study|Physician Decision|0
6373758|NCT03116685|10163196|FG001|Overall Study|Physician Decision|1
6373759|NCT03099304|10163207|FG000|DB Period Day 1 to Week 24|Adverse Event|1
6373760|NCT03099304|10163208|FG001|DB Period Day 1 to Week 24|Adverse Event|1
6373761|NCT03099304|10163209|FG002|DB Period Day 1 to Week 24|Adverse Event|0
6373762|NCT03099304|10163210|FG003|DB Period Day 1 to Week 24|Adverse Event|0
6373763|NCT03099304|10163211|FG004|DB Period Day 1 to Week 24|Adverse Event|1
6373764|NCT03099304|10163207|FG000|DB Period Day 1 to Week 24|Lost to Follow-up|1
6373765|NCT03099304|10163208|FG001|DB Period Day 1 to Week 24|Lost to Follow-up|1
6373766|NCT03099304|10163209|FG002|DB Period Day 1 to Week 24|Lost to Follow-up|0
6373767|NCT03099304|10163210|FG003|DB Period Day 1 to Week 24|Lost to Follow-up|0
6373768|NCT03099304|10163211|FG004|DB Period Day 1 to Week 24|Lost to Follow-up|0
6373769|NCT03099304|10163207|FG000|DB Period Day 1 to Week 24|Reason not specified|0
6373770|NCT03099304|10163208|FG001|DB Period Day 1 to Week 24|Reason not specified|0
6373771|NCT03099304|10163209|FG002|DB Period Day 1 to Week 24|Reason not specified|0
6373772|NCT03099304|10163210|FG003|DB Period Day 1 to Week 24|Reason not specified|1
6373773|NCT03099304|10163211|FG004|DB Period Day 1 to Week 24|Reason not specified|0
6373774|NCT03099304|10163207|FG000|DB Period Day 1 to Week 24|Withdrawal by Subject|3
6373775|NCT03099304|10163208|FG001|DB Period Day 1 to Week 24|Withdrawal by Subject|3
6373776|NCT03099304|10163209|FG002|DB Period Day 1 to Week 24|Withdrawal by Subject|0
6084754|NCT00644787|9693755|FG000|Period 1: Titration Phase|Worsening of complications|1
6084755|NCT00644787|9693756|FG001|Period 1: Titration Phase|Worsening of complications|0
6084756|NCT00644787|9693757|FG002|Period 1: Titration Phase|Worsening of complications|0
6084757|NCT00644787|9693755|FG000|Period 1: Titration Phase|Worsening of symptoms|1
6084758|NCT00644787|9693756|FG001|Period 1: Titration Phase|Worsening of symptoms|0
6084759|NCT00644787|9693757|FG002|Period 1: Titration Phase|Worsening of symptoms|0
6084760|NCT00644787|9693755|FG000|Period 1: Titration Phase|Dose adjustment required on Day 12 or 13|3
6084761|NCT00644787|9693756|FG001|Period 1: Titration Phase|Dose adjustment required on Day 12 or 13|0
6084762|NCT00644787|9693757|FG002|Period 1: Titration Phase|Dose adjustment required on Day 12 or 13|0
6373777|NCT03099304|10163210|FG003|DB Period Day 1 to Week 24|Withdrawal by Subject|2
6373778|NCT03099304|10163211|FG004|DB Period Day 1 to Week 24|Withdrawal by Subject|2
6373779|NCT03099304|10163207|FG000|DB Period Day 1 to Week 24|Protocol Violation|0
6373780|NCT03099304|10163208|FG001|DB Period Day 1 to Week 24|Protocol Violation|0
6373781|NCT03099304|10163209|FG002|DB Period Day 1 to Week 24|Protocol Violation|1
6373782|NCT03099304|10163210|FG003|DB Period Day 1 to Week 24|Protocol Violation|1
6373783|NCT03099304|10163211|FG004|DB Period Day 1 to Week 24|Protocol Violation|0
6373784|NCT03099304|10163207|FG000|DB Period Weeks 24 to 52|Protocol Violation|0
6373785|NCT03099304|10163208|FG001|DB Period Weeks 24 to 52|Protocol Violation|0
6373786|NCT03099304|10163209|FG002|DB Period Weeks 24 to 52|Protocol Violation|1
6373787|NCT03099304|10163210|FG003|DB Period Weeks 24 to 52|Protocol Violation|0
6373788|NCT03099304|10163211|FG004|DB Period Weeks 24 to 52|Protocol Violation|0
6373789|NCT03099304|10163207|FG000|DB Period Weeks 24 to 52|Lost to Follow-up|0
6373790|NCT03099304|10163208|FG001|DB Period Weeks 24 to 52|Lost to Follow-up|1
6373791|NCT03099304|10163209|FG002|DB Period Weeks 24 to 52|Lost to Follow-up|1
6373792|NCT03099304|10163210|FG003|DB Period Weeks 24 to 52|Lost to Follow-up|1
6373793|NCT03099304|10163211|FG004|DB Period Weeks 24 to 52|Lost to Follow-up|0
6373794|NCT03099304|10163207|FG000|DB Period Weeks 24 to 52|Adverse Event|0
6373795|NCT03099304|10163208|FG001|DB Period Weeks 24 to 52|Adverse Event|0
6373796|NCT03099304|10163209|FG002|DB Period Weeks 24 to 52|Adverse Event|0
6373797|NCT03099304|10163210|FG003|DB Period Weeks 24 to 52|Adverse Event|1
6373798|NCT03099304|10163211|FG004|DB Period Weeks 24 to 52|Adverse Event|1
6373799|NCT03099304|10163207|FG000|DB Period Weeks 24 to 52|Withdrawal by Subject|0
6373800|NCT03099304|10163208|FG001|DB Period Weeks 24 to 52|Withdrawal by Subject|0
6373801|NCT03099304|10163209|FG002|DB Period Weeks 24 to 52|Withdrawal by Subject|0
6373802|NCT03099304|10163210|FG003|DB Period Weeks 24 to 52|Withdrawal by Subject|4
6373803|NCT03099304|10163211|FG004|DB Period Weeks 24 to 52|Withdrawal by Subject|1
6373804|NCT03099304|10163207|FG000|DB Period Weeks 24 to 52|Reason not specified|0
6373805|NCT03099304|10163208|FG001|DB Period Weeks 24 to 52|Reason not specified|0
6373806|NCT03099304|10163209|FG002|DB Period Weeks 24 to 52|Reason not specified|0
6373807|NCT03099304|10163210|FG003|DB Period Weeks 24 to 52|Reason not specified|1
6373808|NCT03099304|10163211|FG004|DB Period Weeks 24 to 52|Reason not specified|0
6373809|NCT02682901|10163257|FG000|Overall Study|Adverse Event|10
6373810|NCT02682901|10163258|FG001|Overall Study|Adverse Event|3
6373811|NCT02682901|10163257|FG000|Overall Study|Lack of Efficacy|0
6373812|NCT02682901|10163258|FG001|Overall Study|Lack of Efficacy|1
6373813|NCT02567825|10163266|FG000|Overall Study|No follow-up post-randomization|5
6373814|NCT02567825|10163267|FG001|Overall Study|No follow-up post-randomization|1
6373815|NCT02567825|10163266|FG000|Overall Study|Follow-up less than 23 months|16
6373816|NCT02567825|10163267|FG001|Overall Study|Follow-up less than 23 months|20
6373817|NCT02555657|10163275|FG000|Overall Study|Death|274
6373818|NCT02555657|10163276|FG001|Overall Study|Death|262
6373819|NCT02555657|10163275|FG000|Overall Study|Physician Decision|0
6373820|NCT02555657|10163276|FG001|Overall Study|Physician Decision|1
6373821|NCT02555657|10163275|FG000|Overall Study|Sponsor Decision|27
6373822|NCT02555657|10163276|FG001|Overall Study|Sponsor Decision|15
6373823|NCT02555657|10163275|FG000|Overall Study|Withdrawal by Subject|11
6373824|NCT02555657|10163276|FG001|Overall Study|Withdrawal by Subject|32
6373825|NCT02190721|10163286|FG000|Overall Study|Patient was out of the city|0
6373826|NCT02190721|10163287|FG001|Overall Study|Patient was out of the city|1
6373827|NCT02190721|10163288|FG002|Overall Study|Patient was out of the city|0
6373828|NCT00739401|10163321|FG000|Overall Study|patients were not due for the 2 year follow-up|34
6373829|NCT00739401|10163321|FG000|Overall Study|Death|3
6373830|NCT00739401|10163321|FG000|Overall Study|Withdrawal by Subject|4
6373831|NCT00651742|10163325|FG000|Overall Study|Objective Disease Progression|22
6373832|NCT00651742|10163325|FG000|Overall Study|Toxicity|3
6373833|NCT00651742|10163325|FG000|Overall Study|Investigator Judgment|1
6373834|NCT00651742|10163325|FG000|Overall Study|Withdrawal of Consent|1
6373835|NCT00651742|10163325|FG000|Overall Study|Enrolled but not treated|1
6373836|NCT04930263|10163344|FG000|Overall Study|Withdrawal by Subject|3
6373837|NCT04930263|10163345|FG001|Overall Study|Withdrawal by Subject|5
6373838|NCT04321252|10163360|FG000|Overall Study|Withdrawal by Subject|0
6373839|NCT04321252|10163361|FG001|Overall Study|Withdrawal by Subject|0
6373840|NCT04321252|10163362|FG002|Overall Study|Withdrawal by Subject|0
6373841|NCT04321252|10163363|FG003|Overall Study|Withdrawal by Subject|0
6373842|NCT04321252|10163364|FG004|Overall Study|Withdrawal by Subject|0
6373843|NCT04321252|10163365|FG005|Overall Study|Withdrawal by Subject|1
6373844|NCT04321252|10163366|FG006|Overall Study|Withdrawal by Subject|0
6373845|NCT04321252|10163367|FG007|Overall Study|Withdrawal by Subject|0
6373846|NCT04321252|10163368|FG008|Overall Study|Withdrawal by Subject|0
6373847|NCT04176445|10163398|FG000|Overall Study|Adverse Event|0
6373848|NCT04176445|10163399|FG001|Overall Study|Adverse Event|1
6373849|NCT04176445|10163398|FG000|Overall Study|change plans weaning after first intervention|0
6084763|NCT00644787|9693755|FG000|Period 1: Titration Phase|Participant was judged as ineligible|3
6084764|NCT00644787|9693756|FG001|Period 1: Titration Phase|Participant was judged as ineligible|0
6084765|NCT00644787|9693757|FG002|Period 1: Titration Phase|Participant was judged as ineligible|0
6084766|NCT00644787|9693755|FG000|Period 2: Double Blind Phase|Adverse Event|0
6084767|NCT00644787|9693756|FG001|Period 2: Double Blind Phase|Adverse Event|2
6084768|NCT00644787|9693757|FG002|Period 2: Double Blind Phase|Adverse Event|4
6084769|NCT00644787|9693755|FG000|Period 2: Double Blind Phase|Withdrawal by Subject|0
6084770|NCT00644787|9693756|FG001|Period 2: Double Blind Phase|Withdrawal by Subject|1
6084771|NCT00644787|9693757|FG002|Period 2: Double Blind Phase|Withdrawal by Subject|0
6084772|NCT00644787|9693755|FG000|Period 2: Double Blind Phase|Worsening of underlying disease|0
6084773|NCT00644787|9693756|FG001|Period 2: Double Blind Phase|Worsening of underlying disease|6
6084774|NCT00644787|9693757|FG002|Period 2: Double Blind Phase|Worsening of underlying disease|2
6084775|NCT00644787|9693755|FG000|Period 2: Double Blind Phase|Worsening of symptoms|0
6084776|NCT00644787|9693756|FG001|Period 2: Double Blind Phase|Worsening of symptoms|0
6084777|NCT00644787|9693757|FG002|Period 2: Double Blind Phase|Worsening of symptoms|1
6084778|NCT00644878|9693765|FG000|Overall Study|Adverse Event|2
6084779|NCT00644878|9693765|FG000|Overall Study|Abnormal laboratory value|3
6084780|NCT00644878|9693765|FG000|Overall Study|Protocol deviation|2
6084781|NCT00644878|9693765|FG000|Overall Study|Treatment duration completed as per protocol|11
6084782|NCT00644917|9693769|FG000|Overall Study|Withdrawal by Subject|2
6084783|NCT00644969|9693779|FG000|Treatment Phase|Randomized, not treated|1
6171884|NCT01262638|9818798|FG000|Overall Study|Lost to Follow-up|1
6373850|NCT04176445|10163399|FG001|Overall Study|change plans weaning after first intervention|1
6373851|NCT04126213|10163411|FG000|Overall Study|Lost to Follow-up|9
6373852|NCT04126213|10163412|FG001|Overall Study|Lost to Follow-up|1
6373853|NCT04126213|10163413|FG002|Overall Study|Lost to Follow-up|5
6373854|NCT04126213|10163414|FG003|Overall Study|Lost to Follow-up|10
6373855|NCT04126213|10163415|FG004|Overall Study|Lost to Follow-up|4
6373856|NCT04126213|10163416|FG005|Overall Study|Lost to Follow-up|7
6373857|NCT04126213|10163411|FG000|Overall Study|Withdrawal by Subject|3
6373858|NCT04126213|10163412|FG001|Overall Study|Withdrawal by Subject|2
6373859|NCT04126213|10163413|FG002|Overall Study|Withdrawal by Subject|1
6373860|NCT04126213|10163414|FG003|Overall Study|Withdrawal by Subject|1
6373861|NCT04126213|10163415|FG004|Overall Study|Withdrawal by Subject|1
6373862|NCT04126213|10163416|FG005|Overall Study|Withdrawal by Subject|1
6373863|NCT04126213|10163411|FG000|Overall Study|Other|0
6373864|NCT04126213|10163412|FG001|Overall Study|Other|0
6373865|NCT04126213|10163413|FG002|Overall Study|Other|2
6373866|NCT04126213|10163414|FG003|Overall Study|Other|2
6373867|NCT04126213|10163415|FG004|Overall Study|Other|0
6373868|NCT04126213|10163416|FG005|Overall Study|Other|1
6373869|NCT04126213|10163411|FG000|Overall Study|MIGRATED / MOVED FROM THE STUDY AREA|0
6373870|NCT04126213|10163412|FG001|Overall Study|MIGRATED / MOVED FROM THE STUDY AREA|2
6373871|NCT04126213|10163413|FG002|Overall Study|MIGRATED / MOVED FROM THE STUDY AREA|1
6373872|NCT04126213|10163414|FG003|Overall Study|MIGRATED / MOVED FROM THE STUDY AREA|0
6373873|NCT04126213|10163415|FG004|Overall Study|MIGRATED / MOVED FROM THE STUDY AREA|1
6373874|NCT04126213|10163416|FG005|Overall Study|MIGRATED / MOVED FROM THE STUDY AREA|2
6373875|NCT03672188|10163452|FG000|Overall Study|Withdrawal by Subject|0
6373876|NCT03672188|10163453|FG001|Overall Study|Withdrawal by Subject|0
6373877|NCT03672188|10163454|FG002|Overall Study|Withdrawal by Subject|0
6373878|NCT03672188|10163455|FG003|Overall Study|Withdrawal by Subject|3
6373879|NCT03672188|10163456|FG004|Overall Study|Withdrawal by Subject|0
6373880|NCT03672188|10163457|FG005|Overall Study|Withdrawal by Subject|0
6373881|NCT03672188|10163458|FG006|Overall Study|Withdrawal by Subject|0
6373882|NCT03672188|10163459|FG007|Overall Study|Withdrawal by Subject|0
6373883|NCT03672188|10163460|FG008|Overall Study|Withdrawal by Subject|0
6373884|NCT03672188|10163461|FG009|Overall Study|Withdrawal by Subject|0
6373885|NCT03672188|10163462|FG010|Overall Study|Withdrawal by Subject|0
6373886|NCT03672188|10163463|FG011|Overall Study|Withdrawal by Subject|0
6373887|NCT03672188|10163464|FG012|Overall Study|Withdrawal by Subject|0
6373888|NCT03672188|10163465|FG013|Overall Study|Withdrawal by Subject|0
6373889|NCT03672188|10163466|FG014|Overall Study|Withdrawal by Subject|0
6373890|NCT03672188|10163452|FG000|Overall Study|Death|0
6373891|NCT03672188|10163453|FG001|Overall Study|Death|0
6373892|NCT03672188|10163454|FG002|Overall Study|Death|0
6373893|NCT03672188|10163455|FG003|Overall Study|Death|0
6373894|NCT03672188|10163456|FG004|Overall Study|Death|0
6373895|NCT03672188|10163457|FG005|Overall Study|Death|0
6373896|NCT03672188|10163458|FG006|Overall Study|Death|0
6373897|NCT03672188|10163459|FG007|Overall Study|Death|0
6373898|NCT03672188|10163460|FG008|Overall Study|Death|0
6373899|NCT03672188|10163461|FG009|Overall Study|Death|0
6373900|NCT03672188|10163462|FG010|Overall Study|Death|0
6373901|NCT03672188|10163463|FG011|Overall Study|Death|0
6373902|NCT03672188|10163464|FG012|Overall Study|Death|1
6373903|NCT03672188|10163465|FG013|Overall Study|Death|0
6373904|NCT03672188|10163466|FG014|Overall Study|Death|0
6373905|NCT03672188|10163452|FG000|Overall Study|Lost to Follow-up|0
6373906|NCT03672188|10163453|FG001|Overall Study|Lost to Follow-up|0
6373907|NCT03672188|10163454|FG002|Overall Study|Lost to Follow-up|1
6373908|NCT03672188|10163455|FG003|Overall Study|Lost to Follow-up|0
6373909|NCT03672188|10163456|FG004|Overall Study|Lost to Follow-up|0
6373910|NCT03672188|10163457|FG005|Overall Study|Lost to Follow-up|0
6373911|NCT03672188|10163458|FG006|Overall Study|Lost to Follow-up|0
6373912|NCT03672188|10163459|FG007|Overall Study|Lost to Follow-up|0
6373913|NCT03672188|10163460|FG008|Overall Study|Lost to Follow-up|0
6373914|NCT03672188|10163461|FG009|Overall Study|Lost to Follow-up|0
6373915|NCT03672188|10163462|FG010|Overall Study|Lost to Follow-up|0
6373916|NCT03672188|10163463|FG011|Overall Study|Lost to Follow-up|0
6373917|NCT03672188|10163464|FG012|Overall Study|Lost to Follow-up|0
6373918|NCT03672188|10163465|FG013|Overall Study|Lost to Follow-up|0
6373919|NCT03672188|10163466|FG014|Overall Study|Lost to Follow-up|0
6373920|NCT03230916|10163547|FG000|Overall Study|Withdrawal by Subject|0
6373921|NCT03230916|10163548|FG001|Overall Study|Withdrawal by Subject|0
6373922|NCT03230916|10163549|FG002|Overall Study|Withdrawal by Subject|0
6373923|NCT03230916|10163550|FG003|Overall Study|Withdrawal by Subject|0
6373924|NCT03230916|10163551|FG004|Overall Study|Withdrawal by Subject|0
6373925|NCT03230916|10163552|FG005|Overall Study|Withdrawal by Subject|1
6373926|NCT03230916|10163553|FG006|Overall Study|Withdrawal by Subject|0
6373927|NCT03230916|10163554|FG007|Overall Study|Withdrawal by Subject|0
6373928|NCT03230916|10163555|FG008|Overall Study|Withdrawal by Subject|0
6373929|NCT03230916|10163556|FG009|Overall Study|Withdrawal by Subject|0
6373930|NCT03230916|10163557|FG010|Overall Study|Withdrawal by Subject|0
6373931|NCT03195894|10163600|FG000|Overall Study|"An example is Started other treatment."|4
6373932|NCT03195894|10163601|FG001|Overall Study|"An example is Started other treatment."|5
6373933|NCT03195894|10163600|FG000|Overall Study|Withdrawal by Subject|15
6373934|NCT03195894|10163601|FG001|Overall Study|Withdrawal by Subject|4
6373935|NCT03195894|10163600|FG000|Overall Study|Lost to Follow-up|14
6373936|NCT03195894|10163601|FG001|Overall Study|Lost to Follow-up|19
6373937|NCT03032705|10163612|FG000|Overall Study|Lost to Follow-up|16
6373938|NCT03032705|10163613|FG001|Overall Study|Lost to Follow-up|17
6373939|NCT03032705|10163612|FG000|Overall Study|did not quality|6
6373940|NCT03032705|10163613|FG001|Overall Study|did not quality|6
6373941|NCT02573259|10163626|FG000|Overall Study|Death|1
6373942|NCT02573259|10163627|FG001|Overall Study|Death|6
6373943|NCT02573259|10163628|FG002|Overall Study|Death|5
6373944|NCT02573259|10163629|FG003|Overall Study|Death|6
6373945|NCT02573259|10163630|FG004|Overall Study|Death|9
6373946|NCT02573259|10163631|FG005|Overall Study|Death|32
6373947|NCT02573259|10163632|FG006|Overall Study|Death|21
6373948|NCT02573259|10163626|FG000|Overall Study|Lost to Follow-up|0
6373949|NCT02573259|10163627|FG001|Overall Study|Lost to Follow-up|0
6373950|NCT02573259|10163628|FG002|Overall Study|Lost to Follow-up|0
6373951|NCT02573259|10163629|FG003|Overall Study|Lost to Follow-up|0
6373952|NCT02573259|10163630|FG004|Overall Study|Lost to Follow-up|0
6373953|NCT02573259|10163631|FG005|Overall Study|Lost to Follow-up|2
6373954|NCT02573259|10163632|FG006|Overall Study|Lost to Follow-up|1
6373955|NCT02573259|10163626|FG000|Overall Study|Participant refused further follow-up|0
6373956|NCT02573259|10163627|FG001|Overall Study|Participant refused further follow-up|2
6373957|NCT02573259|10163628|FG002|Overall Study|Participant refused further follow-up|1
6373958|NCT02573259|10163629|FG003|Overall Study|Participant refused further follow-up|0
6373959|NCT02573259|10163630|FG004|Overall Study|Participant refused further follow-up|3
6373960|NCT02573259|10163631|FG005|Overall Study|Participant refused further follow-up|20
6373961|NCT02573259|10163632|FG006|Overall Study|Participant refused further follow-up|7
6373962|NCT02573259|10163626|FG000|Overall Study|Other|0
6373963|NCT02573259|10163627|FG001|Overall Study|Other|0
6373964|NCT02573259|10163628|FG002|Overall Study|Other|0
6373965|NCT02573259|10163629|FG003|Overall Study|Other|0
6373966|NCT02573259|10163630|FG004|Overall Study|Other|1
6373967|NCT02573259|10163631|FG005|Overall Study|Other|4
6373968|NCT02573259|10163632|FG006|Overall Study|Other|5
6373969|NCT02318329|10163674|FG000|Overall Study|Progressive Disease|2
6373970|NCT02318329|10163675|FG001|Overall Study|Progressive Disease|3
6373971|NCT02318329|10163676|FG002|Overall Study|Progressive Disease|2
6373972|NCT02318329|10163677|FG003|Overall Study|Progressive Disease|3
6373973|NCT02318329|10163678|FG004|Overall Study|Progressive Disease|3
6373974|NCT02318329|10163679|FG005|Overall Study|Progressive Disease|3
6373975|NCT02318329|10163680|FG006|Overall Study|Progressive Disease|1
6373976|NCT02318329|10163681|FG007|Overall Study|Progressive Disease|1
6373977|NCT02318329|10163682|FG008|Overall Study|Progressive Disease|5
6373978|NCT02318329|10163683|FG009|Overall Study|Progressive Disease|39
6373979|NCT02318329|10163674|FG000|Overall Study|Death|0
6373980|NCT02318329|10163675|FG001|Overall Study|Death|0
6373981|NCT02318329|10163676|FG002|Overall Study|Death|0
6373982|NCT02318329|10163677|FG003|Overall Study|Death|0
6373983|NCT02318329|10163678|FG004|Overall Study|Death|0
6373984|NCT02318329|10163679|FG005|Overall Study|Death|0
6373985|NCT02318329|10163680|FG006|Overall Study|Death|0
6373986|NCT02318329|10163681|FG007|Overall Study|Death|0
6373987|NCT02318329|10163682|FG008|Overall Study|Death|0
6373988|NCT02318329|10163683|FG009|Overall Study|Death|5
6373989|NCT02318329|10163674|FG000|Overall Study|Lost to Follow-up|0
6373990|NCT02318329|10163675|FG001|Overall Study|Lost to Follow-up|0
6373991|NCT02318329|10163676|FG002|Overall Study|Lost to Follow-up|0
6373992|NCT02318329|10163677|FG003|Overall Study|Lost to Follow-up|0
6373993|NCT02318329|10163678|FG004|Overall Study|Lost to Follow-up|0
6373994|NCT02318329|10163679|FG005|Overall Study|Lost to Follow-up|0
6373995|NCT02318329|10163680|FG006|Overall Study|Lost to Follow-up|0
6373996|NCT02318329|10163681|FG007|Overall Study|Lost to Follow-up|0
6373997|NCT02318329|10163682|FG008|Overall Study|Lost to Follow-up|0
6373998|NCT02318329|10163683|FG009|Overall Study|Lost to Follow-up|1
6373999|NCT02318329|10163674|FG000|Overall Study|Withdrawal by Subject|0
6374000|NCT02318329|10163675|FG001|Overall Study|Withdrawal by Subject|0
6374001|NCT02318329|10163676|FG002|Overall Study|Withdrawal by Subject|0
6374002|NCT02318329|10163677|FG003|Overall Study|Withdrawal by Subject|0
6374003|NCT02318329|10163678|FG004|Overall Study|Withdrawal by Subject|0
6374004|NCT02318329|10163679|FG005|Overall Study|Withdrawal by Subject|0
6374005|NCT02318329|10163680|FG006|Overall Study|Withdrawal by Subject|0
6374006|NCT02318329|10163681|FG007|Overall Study|Withdrawal by Subject|0
6374007|NCT02318329|10163682|FG008|Overall Study|Withdrawal by Subject|0
6374008|NCT02318329|10163683|FG009|Overall Study|Withdrawal by Subject|6
6374009|NCT02318329|10163674|FG000|Overall Study|Other|1
6374010|NCT02318329|10163675|FG001|Overall Study|Other|1
6374011|NCT02318329|10163676|FG002|Overall Study|Other|1
6374012|NCT02318329|10163677|FG003|Overall Study|Other|0
6374013|NCT02318329|10163678|FG004|Overall Study|Other|0
6374014|NCT02318329|10163679|FG005|Overall Study|Other|0
6374015|NCT02318329|10163680|FG006|Overall Study|Other|0
6374016|NCT02318329|10163681|FG007|Overall Study|Other|0
6374017|NCT02318329|10163682|FG008|Overall Study|Other|1
6374018|NCT02318329|10163683|FG009|Overall Study|Other|1
6374019|NCT01602666|10163726|FG000|Induction Chemotherapy|Death|2
6374020|NCT01602666|10163727|FG001|Induction Chemotherapy|Death|1
6374021|NCT01602666|10163726|FG000|Induction Chemotherapy|Lack of Efficacy|16
6374022|NCT01602666|10163727|FG001|Induction Chemotherapy|Lack of Efficacy|7
6374023|NCT01602666|10163726|FG000|Induction Chemotherapy|Physician Decision|12
6374024|NCT01602666|10163727|FG001|Induction Chemotherapy|Physician Decision|5
6374025|NCT01602666|10163726|FG000|Induction Chemotherapy|Withdrawal by Subject|0
6374026|NCT01602666|10163727|FG001|Induction Chemotherapy|Withdrawal by Subject|2
6374027|NCT01602666|10163726|FG000|Induction Chemotherapy|Refusal of further protocol therapy|5
6374028|NCT01602666|10163727|FG001|Induction Chemotherapy|Refusal of further protocol therapy|6
6374029|NCT01602666|10163726|FG000|Induction Chemotherapy|Radiotherapy can't be initiated in 6 wks|2
6374030|NCT01602666|10163727|FG001|Induction Chemotherapy|Radiotherapy can't be initiated in 6 wks|3
6374031|NCT01602666|10163726|FG000|Radiation Therapy on Protocol|Lost to Follow-up|4
6374032|NCT01602666|10163727|FG001|Radiation Therapy on Protocol|Lost to Follow-up|5
6374033|NCT01602666|10163726|FG000|Radiation Therapy on Protocol|Withdrawal by Subject|2
6374034|NCT01602666|10163727|FG001|Radiation Therapy on Protocol|Withdrawal by Subject|3
6374035|NCT01602666|10163726|FG000|Radiation Therapy on Protocol|In-evaluable for reduced dose(30.6 Gy)|4
6374036|NCT01602666|10163727|FG001|Radiation Therapy on Protocol|In-evaluable for reduced dose(30.6 Gy)|0
6374037|NCT01602666|10163726|FG000|Radiation Therapy on Protocol|In-evaluable for reduced dose(18 Gy)|0
6374038|NCT01602666|10163727|FG001|Radiation Therapy on Protocol|In-evaluable for reduced dose(18 Gy)|14
6374039|NCT01602666|10163726|FG000|Radiation Therapy on Protocol|In-evaluable for RT dose (24Gy)|0
6374040|NCT01602666|10163727|FG001|Radiation Therapy on Protocol|In-evaluable for RT dose (24Gy)|9
6374041|NCT01375959|10163737|FG000|First Intervention (6 Weeks)|Adverse Event|2
6374042|NCT01375959|10163738|FG001|First Intervention (6 Weeks)|Adverse Event|3
6374043|NCT01375959|10163737|FG000|Second Intervention (6 Weeks)|Withdrawal by Subject|0
6374044|NCT01375959|10163738|FG001|Second Intervention (6 Weeks)|Withdrawal by Subject|1
6374045|NCT01375959|10163737|FG000|Second Intervention (6 Weeks)|Adverse Event|0
6374046|NCT01375959|10163738|FG001|Second Intervention (6 Weeks)|Adverse Event|2
6374047|NCT01224106|10163749|FG000|Double-Blind Treatment Phase|Death|3
6374048|NCT01224106|10163750|FG001|Double-Blind Treatment Phase|Death|0
6374049|NCT01224106|10163751|FG002|Double-Blind Treatment Phase|Death|0
6374050|NCT01224106|10163752|FG003|Double-Blind Treatment Phase|Death|0
6374051|NCT01224106|10163753|FG004|Double-Blind Treatment Phase|Death|0
6374052|NCT01224106|10163749|FG000|Double-Blind Treatment Phase|Physician Decision|6
6374053|NCT01224106|10163750|FG001|Double-Blind Treatment Phase|Physician Decision|5
6374054|NCT01224106|10163751|FG002|Double-Blind Treatment Phase|Physician Decision|4
6374055|NCT01224106|10163752|FG003|Double-Blind Treatment Phase|Physician Decision|0
6374056|NCT01224106|10163753|FG004|Double-Blind Treatment Phase|Physician Decision|0
6374057|NCT01224106|10163749|FG000|Double-Blind Treatment Phase|Adverse Event|0
6374058|NCT01224106|10163750|FG001|Double-Blind Treatment Phase|Adverse Event|5
6374059|NCT01224106|10163751|FG002|Double-Blind Treatment Phase|Adverse Event|3
6374060|NCT01224106|10163752|FG003|Double-Blind Treatment Phase|Adverse Event|0
6374061|NCT01224106|10163753|FG004|Double-Blind Treatment Phase|Adverse Event|0
6374062|NCT01224106|10163749|FG000|Double-Blind Treatment Phase|Other|0
6374063|NCT01224106|10163750|FG001|Double-Blind Treatment Phase|Other|0
6374064|NCT01224106|10163751|FG002|Double-Blind Treatment Phase|Other|1
6374065|NCT01224106|10163752|FG003|Double-Blind Treatment Phase|Other|0
6374066|NCT01224106|10163753|FG004|Double-Blind Treatment Phase|Other|0
6374067|NCT01224106|10163749|FG000|Double-Blind Treatment Phase|Participant/legal guardian decision|7
6374068|NCT01224106|10163750|FG001|Double-Blind Treatment Phase|Participant/legal guardian decision|8
6374069|NCT01224106|10163751|FG002|Double-Blind Treatment Phase|Participant/legal guardian decision|8
6374070|NCT01224106|10163752|FG003|Double-Blind Treatment Phase|Participant/legal guardian decision|0
6374071|NCT01224106|10163753|FG004|Double-Blind Treatment Phase|Participant/legal guardian decision|0
6374072|NCT01224106|10163749|FG000|Double-Blind Treatment Phase|Parts 1 and 2 Termination by Sponsor|62
6374073|NCT01224106|10163750|FG001|Double-Blind Treatment Phase|Parts 1 and 2 Termination by Sponsor|68
6374074|NCT01224106|10163751|FG002|Double-Blind Treatment Phase|Parts 1 and 2 Termination by Sponsor|63
6374075|NCT01224106|10163752|FG003|Double-Blind Treatment Phase|Parts 1 and 2 Termination by Sponsor|0
6374076|NCT01224106|10163753|FG004|Double-Blind Treatment Phase|Parts 1 and 2 Termination by Sponsor|0
6374077|NCT01224106|10163749|FG000|Double-Blind Treatment Phase|Lost to Follow-up|1
6374078|NCT01224106|10163750|FG001|Double-Blind Treatment Phase|Lost to Follow-up|0
6374079|NCT01224106|10163751|FG002|Double-Blind Treatment Phase|Lost to Follow-up|1
6374080|NCT01224106|10163752|FG003|Double-Blind Treatment Phase|Lost to Follow-up|0
6374081|NCT01224106|10163753|FG004|Double-Blind Treatment Phase|Lost to Follow-up|0
6374082|NCT01224106|10163749|FG000|Open-Label Extension (OLE) Phase|Death|0
6374083|NCT01224106|10163750|FG001|Open-Label Extension (OLE) Phase|Death|0
6374084|NCT01224106|10163751|FG002|Open-Label Extension (OLE) Phase|Death|0
6374085|NCT01224106|10163752|FG003|Open-Label Extension (OLE) Phase|Death|1
6374086|NCT01224106|10163753|FG004|Open-Label Extension (OLE) Phase|Death|3
6374087|NCT01224106|10163749|FG000|Open-Label Extension (OLE) Phase|Adverse Event|0
6374088|NCT01224106|10163750|FG001|Open-Label Extension (OLE) Phase|Adverse Event|0
6374089|NCT01224106|10163751|FG002|Open-Label Extension (OLE) Phase|Adverse Event|0
6084784|NCT00644969|9693780|FG001|Treatment Phase|Randomized, not treated|0
6084785|NCT00644969|9693779|FG000|Treatment Phase|Adverse Event|3
6374090|NCT01224106|10163752|FG003|Open-Label Extension (OLE) Phase|Adverse Event|2
6374091|NCT01224106|10163753|FG004|Open-Label Extension (OLE) Phase|Adverse Event|6
6374092|NCT01224106|10163749|FG000|Open-Label Extension (OLE) Phase|Physician Decision|0
6374093|NCT01224106|10163750|FG001|Open-Label Extension (OLE) Phase|Physician Decision|0
6374094|NCT01224106|10163751|FG002|Open-Label Extension (OLE) Phase|Physician Decision|0
6374095|NCT01224106|10163752|FG003|Open-Label Extension (OLE) Phase|Physician Decision|2
6374096|NCT01224106|10163753|FG004|Open-Label Extension (OLE) Phase|Physician Decision|7
6374097|NCT01224106|10163749|FG000|Open-Label Extension (OLE) Phase|Withdrawal by Subject|0
6374098|NCT01224106|10163750|FG001|Open-Label Extension (OLE) Phase|Withdrawal by Subject|0
6374099|NCT01224106|10163751|FG002|Open-Label Extension (OLE) Phase|Withdrawal by Subject|0
6374100|NCT01224106|10163752|FG003|Open-Label Extension (OLE) Phase|Withdrawal by Subject|6
6374101|NCT01224106|10163753|FG004|Open-Label Extension (OLE) Phase|Withdrawal by Subject|15
6374102|NCT01224106|10163749|FG000|Open-Label Extension (OLE) Phase|Other|0
6374103|NCT01224106|10163750|FG001|Open-Label Extension (OLE) Phase|Other|0
6374104|NCT01224106|10163751|FG002|Open-Label Extension (OLE) Phase|Other|0
6374105|NCT01224106|10163752|FG003|Open-Label Extension (OLE) Phase|Other|5
6374106|NCT01224106|10163753|FG004|Open-Label Extension (OLE) Phase|Other|3
6374107|NCT00354835|10163782|FG000|Overall Study|Death|1
6374108|NCT00354835|10163783|FG001|Overall Study|Death|1
6374109|NCT00354835|10163782|FG000|Overall Study|Physician Decision|8
6374110|NCT00354835|10163783|FG001|Overall Study|Physician Decision|13
6374111|NCT00354835|10163782|FG000|Overall Study|Withdrawal by Subject|2
6374112|NCT00354835|10163783|FG001|Overall Study|Withdrawal by Subject|1
6374113|NCT00354835|10163782|FG000|Overall Study|Ineligible|17
6374114|NCT00354835|10163783|FG001|Overall Study|Ineligible|16
6374115|NCT00354835|10163782|FG000|Overall Study|Disease progression or relapse|15
6374116|NCT00354835|10163783|FG001|Overall Study|Disease progression or relapse|22
6374117|NCT00354835|10163782|FG000|Overall Study|Adverse Event|6
6374118|NCT00354835|10163783|FG001|Overall Study|Adverse Event|0
6374119|NCT00354835|10163782|FG000|Overall Study|Refusal of further therapy|3
6374120|NCT00354835|10163783|FG001|Overall Study|Refusal of further therapy|8
6374121|NCT04531241|10163804|FG000|Period 1|Withdrawal by Subject|2
6374122|NCT04531241|10163805|FG001|Period 1|Withdrawal by Subject|0
6374123|NCT04531241|10163804|FG000|Period 1|Dispesed incorrect lens power|1
6374124|NCT04531241|10163805|FG001|Period 1|Dispesed incorrect lens power|0
6374125|NCT04531241|10163804|FG000|Period 1|Protocol Violation|1
6374126|NCT04531241|10163805|FG001|Period 1|Protocol Violation|0
6374127|NCT04531241|10163804|FG000|Period 1|No longer eligible|0
6374128|NCT04531241|10163805|FG001|Period 1|No longer eligible|1
6374129|NCT04531241|10163804|FG000|Period 1|Lens Discomfort|0
6374130|NCT04531241|10163805|FG001|Period 1|Lens Discomfort|1
6374131|NCT04531241|10163804|FG000|Period 2|Covid-19 Related|1
6374132|NCT04531241|10163805|FG001|Period 2|Covid-19 Related|1
6374133|NCT04185220|10163850|FG000|Dose Escalation|Stopped treatment early due to progressive disease, dose limiting toxicity and acute renal failure|0
6374134|NCT04185220|10163851|FG001|Dose Escalation|Stopped treatment early due to progressive disease, dose limiting toxicity and acute renal failure|1
6374135|NCT04185220|10163850|FG000|Dose Escalation|Stopped treatment early on cycle 1/day 2 due to Gr 2 infusion reaction & resulting Gr 3 hip fracture|0
6374136|NCT04185220|10163851|FG001|Dose Escalation|Stopped treatment early on cycle 1/day 2 due to Gr 2 infusion reaction & resulting Gr 3 hip fracture|1
6374137|NCT03600714|10163868|FG000|Overall Study|Out of country and could not return for post-treatment visits|1
6374138|NCT03470441|10163889|FG000|Overall Study|Death|0
6374139|NCT03470441|10163890|FG001|Overall Study|Death|1
6374140|NCT03470441|10163891|FG002|Overall Study|Death|1
6374141|NCT03470441|10163892|FG003|Overall Study|Death|0
6374142|NCT03470441|10163889|FG000|Overall Study|Adverse Event|0
6374143|NCT03470441|10163890|FG001|Overall Study|Adverse Event|0
6374144|NCT03470441|10163891|FG002|Overall Study|Adverse Event|0
6374145|NCT03470441|10163892|FG003|Overall Study|Adverse Event|1
6374146|NCT03470441|10163889|FG000|Overall Study|Withdrawal by Subject|1
6374147|NCT03470441|10163890|FG001|Overall Study|Withdrawal by Subject|4
6374148|NCT03470441|10163891|FG002|Overall Study|Withdrawal by Subject|1
6374149|NCT03470441|10163892|FG003|Overall Study|Withdrawal by Subject|3
6374150|NCT03452397|10163906|FG000|Overall Study|Adverse Event|1
6374151|NCT03452397|10163907|FG001|Overall Study|Adverse Event|0
6374152|NCT03452397|10163908|FG002|Overall Study|Adverse Event|0
6374153|NCT03452397|10163909|FG003|Overall Study|Adverse Event|0
6374154|NCT03452397|10163906|FG000|Overall Study|Administrative reason|0
6374155|NCT03452397|10163907|FG001|Overall Study|Administrative reason|0
6374156|NCT03452397|10163908|FG002|Overall Study|Administrative reason|1
6374157|NCT03452397|10163909|FG003|Overall Study|Administrative reason|1
6374158|NCT03452397|10163906|FG000|Overall Study|Withdrawal by Subject|0
6374159|NCT03452397|10163907|FG001|Overall Study|Withdrawal by Subject|0
6374160|NCT03452397|10163908|FG002|Overall Study|Withdrawal by Subject|1
6374161|NCT03452397|10163909|FG003|Overall Study|Withdrawal by Subject|0
6374162|NCT03448939|10163923|FG000|Overall Study|Adverse Event|5
6374163|NCT03448939|10163924|FG001|Overall Study|Adverse Event|1
6374164|NCT03448939|10163923|FG000|Overall Study|Lost to Follow-up|6
6374165|NCT03448939|10163924|FG001|Overall Study|Lost to Follow-up|6
6374166|NCT03448939|10163923|FG000|Overall Study|Pregnancy|1
6374167|NCT03448939|10163924|FG001|Overall Study|Pregnancy|1
6374168|NCT03448939|10163923|FG000|Overall Study|Withdrawal by Subject|9
6374169|NCT03448939|10163924|FG001|Overall Study|Withdrawal by Subject|3
6374170|NCT03410108|10163930|FG000|Overall Study|Ongoing|41
6374171|NCT03410108|10163930|FG000|Overall Study|Adverse Event|4
6374172|NCT03410108|10163930|FG000|Overall Study|Progressive Disease|58
6374173|NCT03410108|10163930|FG000|Overall Study|Withdrawal by Subject|1
6374174|NCT03283371|10163948|FG000|Placebo-controlled|Adverse Event|1
6374175|NCT03283371|10163949|FG001|Placebo-controlled|Adverse Event|1
6374176|NCT03283371|10163950|FG002|Placebo-controlled|Adverse Event|0
6374177|NCT03283371|10163951|FG003|Placebo-controlled|Adverse Event|0
6374178|NCT03283371|10163948|FG000|Placebo-controlled|Lack of Efficacy|1
6374179|NCT03283371|10163949|FG001|Placebo-controlled|Lack of Efficacy|0
6374180|NCT03283371|10163950|FG002|Placebo-controlled|Lack of Efficacy|0
6374181|NCT03283371|10163951|FG003|Placebo-controlled|Lack of Efficacy|0
6374182|NCT03283371|10163948|FG000|Placebo-controlled|Withdrawal by Subject|1
6374183|NCT03283371|10163949|FG001|Placebo-controlled|Withdrawal by Subject|1
6374184|NCT03283371|10163950|FG002|Placebo-controlled|Withdrawal by Subject|0
6374185|NCT03283371|10163951|FG003|Placebo-controlled|Withdrawal by Subject|0
6374186|NCT03283371|10163948|FG000|Placebo-controlled|Participants Did Not Receive Study Drug|0
6374187|NCT03283371|10163949|FG001|Placebo-controlled|Participants Did Not Receive Study Drug|1
6374188|NCT03283371|10163950|FG002|Placebo-controlled|Participants Did Not Receive Study Drug|0
6374189|NCT03283371|10163951|FG003|Placebo-controlled|Participants Did Not Receive Study Drug|0
6374190|NCT03283371|10163948|FG000|Open-label Phase|Adverse Event|0
6374191|NCT03283371|10163949|FG001|Open-label Phase|Adverse Event|0
6374192|NCT03283371|10163950|FG002|Open-label Phase|Adverse Event|2
6374193|NCT03283371|10163951|FG003|Open-label Phase|Adverse Event|0
6374194|NCT03283371|10163948|FG000|Open-label Phase|Withdrawal by Subject|0
6374195|NCT03283371|10163949|FG001|Open-label Phase|Withdrawal by Subject|0
6374196|NCT03283371|10163950|FG002|Open-label Phase|Withdrawal by Subject|1
6374197|NCT03283371|10163951|FG003|Open-label Phase|Withdrawal by Subject|0
6374198|NCT03283371|10163948|FG000|Open-label Phase|Other|0
6374199|NCT03283371|10163949|FG001|Open-label Phase|Other|0
6374200|NCT03283371|10163950|FG002|Open-label Phase|Other|1
6374201|NCT03283371|10163951|FG003|Open-label Phase|Other|1
6374202|NCT03257254|10163961|FG000|Overall Study|Withdrawal by Subject|7
6374203|NCT03257254|10163961|FG000|Overall Study|Lost to Follow-up|9
6374204|NCT03257254|10163961|FG000|Overall Study|Study discontinued by sponsor|5
6374205|NCT03084718|10163970|FG000|Overall Study|Withdrawal by Subject|4
6374206|NCT03084718|10163971|FG001|Overall Study|Withdrawal by Subject|3
6374207|NCT03084718|10163972|FG002|Overall Study|Withdrawal by Subject|4
6374208|NCT03084718|10163973|FG003|Overall Study|Withdrawal by Subject|0
6374209|NCT03084718|10163974|FG004|Overall Study|Withdrawal by Subject|0
6374210|NCT03084718|10163970|FG000|Overall Study|Physician Decision|1
6374211|NCT03084718|10163971|FG001|Overall Study|Physician Decision|0
6374212|NCT03084718|10163972|FG002|Overall Study|Physician Decision|0
6374213|NCT03084718|10163973|FG003|Overall Study|Physician Decision|0
6374214|NCT03084718|10163974|FG004|Overall Study|Physician Decision|0
6374215|NCT03084718|10163970|FG000|Overall Study|Adverse Event|3
6374216|NCT03084718|10163971|FG001|Overall Study|Adverse Event|5
6374217|NCT03084718|10163972|FG002|Overall Study|Adverse Event|5
6374218|NCT03084718|10163973|FG003|Overall Study|Adverse Event|8
6374219|NCT03084718|10163974|FG004|Overall Study|Adverse Event|2
6374220|NCT03084718|10163970|FG000|Overall Study|Lack of Efficacy|2
6374221|NCT03084718|10163971|FG001|Overall Study|Lack of Efficacy|0
6374222|NCT03084718|10163972|FG002|Overall Study|Lack of Efficacy|1
6374223|NCT03084718|10163973|FG003|Overall Study|Lack of Efficacy|4
6374224|NCT03084718|10163974|FG004|Overall Study|Lack of Efficacy|0
6374225|NCT03084718|10163970|FG000|Overall Study|Lost to Follow-up|0
6374226|NCT03084718|10163971|FG001|Overall Study|Lost to Follow-up|1
6374227|NCT03084718|10163972|FG002|Overall Study|Lost to Follow-up|0
6374228|NCT03084718|10163973|FG003|Overall Study|Lost to Follow-up|0
6374229|NCT03084718|10163974|FG004|Overall Study|Lost to Follow-up|2
6374230|NCT03084718|10163970|FG000|Overall Study|Protocol Violation|0
6374231|NCT03084718|10163971|FG001|Overall Study|Protocol Violation|0
6374232|NCT03084718|10163972|FG002|Overall Study|Protocol Violation|1
6374233|NCT03084718|10163973|FG003|Overall Study|Protocol Violation|0
6374234|NCT03084718|10163974|FG004|Overall Study|Protocol Violation|0
6374235|NCT03084718|10163970|FG000|Overall Study|Death|0
6374236|NCT03084718|10163971|FG001|Overall Study|Death|1
6374237|NCT03084718|10163972|FG002|Overall Study|Death|0
6374238|NCT03084718|10163973|FG003|Overall Study|Death|0
6374239|NCT03084718|10163974|FG004|Overall Study|Death|0
6374240|NCT03084718|10163970|FG000|Overall Study|Randomization error; E-diary non-compliance; Complications with device use|1
6374241|NCT03084718|10163971|FG001|Overall Study|Randomization error; E-diary non-compliance; Complications with device use|0
6374242|NCT03084718|10163972|FG002|Overall Study|Randomization error; E-diary non-compliance; Complications with device use|1
6374243|NCT03084718|10163973|FG003|Overall Study|Randomization error; E-diary non-compliance; Complications with device use|2
6374244|NCT03084718|10163974|FG004|Overall Study|Randomization error; E-diary non-compliance; Complications with device use|0
6374245|NCT03069417|10163991|FG000|Overall Study|Lost to Follow-up|2
6374246|NCT03069417|10163992|FG001|Overall Study|Lost to Follow-up|0
6374247|NCT03069417|10163991|FG000|Overall Study|Reason Unknown|4
6374248|NCT03069417|10163992|FG001|Overall Study|Reason Unknown|7
5972132|NCT04498247|9557787|FG003|Overall Study|Lost to Follow-up|1
6374249|NCT02936323|10164021|FG000|Phase 1 Dose Escalation|Informed Consent Withdrawn|0
6374250|NCT02936323|10164022|FG001|Phase 1 Dose Escalation|Informed Consent Withdrawn|1
6374251|NCT02936323|10164023|FG002|Phase 1 Dose Escalation|Informed Consent Withdrawn|0
6374252|NCT02936323|10164024|FG003|Phase 1 Dose Escalation|Informed Consent Withdrawn|1
6374253|NCT02936323|10164025|FG004|Phase 1 Dose Escalation|Informed Consent Withdrawn|1
6374254|NCT02936323|10164026|FG005|Phase 1 Dose Escalation|Informed Consent Withdrawn|1
6374255|NCT02936323|10164027|FG006|Phase 1 Dose Escalation|Informed Consent Withdrawn|0
6374256|NCT02936323|10164028|FG007|Phase 1 Dose Escalation|Informed Consent Withdrawn|0
6374257|NCT02936323|10164029|FG008|Phase 1 Dose Escalation|Informed Consent Withdrawn|0
6374258|NCT02936323|10164030|FG009|Phase 1 Dose Escalation|Informed Consent Withdrawn|0
6374259|NCT02936323|10164021|FG000|Phase 1 Dose Escalation|Death|2
6374260|NCT02936323|10164022|FG001|Phase 1 Dose Escalation|Death|1
6374261|NCT02936323|10164023|FG002|Phase 1 Dose Escalation|Death|3
6374262|NCT02936323|10164024|FG003|Phase 1 Dose Escalation|Death|1
6374263|NCT02936323|10164025|FG004|Phase 1 Dose Escalation|Death|2
6374264|NCT02936323|10164026|FG005|Phase 1 Dose Escalation|Death|3
6374265|NCT02936323|10164027|FG006|Phase 1 Dose Escalation|Death|3
6374266|NCT02936323|10164028|FG007|Phase 1 Dose Escalation|Death|0
6374267|NCT02936323|10164029|FG008|Phase 1 Dose Escalation|Death|0
6374268|NCT02936323|10164030|FG009|Phase 1 Dose Escalation|Death|0
6374269|NCT02936323|10164021|FG000|Phase 1 Dose Escalation|Study Discontinued at Site|0
6171885|NCT01262638|9818799|FG001|Overall Study|Lost to Follow-up|1
6171886|NCT01262638|9818800|FG002|Overall Study|Lost to Follow-up|1
6171887|NCT01262638|9818801|FG003|Overall Study|Lost to Follow-up|1
6171888|NCT01262638|9818798|FG000|Overall Study|Participant Went Out of Town|0
6171889|NCT01262638|9818799|FG001|Overall Study|Participant Went Out of Town|0
6171890|NCT01262638|9818800|FG002|Overall Study|Participant Went Out of Town|1
6171891|NCT01262638|9818801|FG003|Overall Study|Participant Went Out of Town|0
6171892|NCT01262651|9818816|FG000|Overall Study|Adverse Event|40
6171893|NCT01262651|9818817|FG001|Overall Study|Adverse Event|35
6171894|NCT01262651|9818816|FG000|Overall Study|Withdrawal by Subject|15
6171895|NCT01262651|9818817|FG001|Overall Study|Withdrawal by Subject|11
6171896|NCT01262651|9818816|FG000|Overall Study|Withdrawal by Investigator|2
6171897|NCT01262651|9818817|FG001|Overall Study|Withdrawal by Investigator|2
6171898|NCT01262651|9818816|FG000|Overall Study|Met Withdrawal Criteria|1
6171899|NCT01262651|9818817|FG001|Overall Study|Met Withdrawal Criteria|0
6374270|NCT02936323|10164022|FG001|Phase 1 Dose Escalation|Study Discontinued at Site|0
6374271|NCT02936323|10164023|FG002|Phase 1 Dose Escalation|Study Discontinued at Site|0
6374272|NCT02936323|10164024|FG003|Phase 1 Dose Escalation|Study Discontinued at Site|0
6374273|NCT02936323|10164025|FG004|Phase 1 Dose Escalation|Study Discontinued at Site|0
6374274|NCT02936323|10164026|FG005|Phase 1 Dose Escalation|Study Discontinued at Site|1
6374275|NCT02936323|10164027|FG006|Phase 1 Dose Escalation|Study Discontinued at Site|0
6374276|NCT02936323|10164028|FG007|Phase 1 Dose Escalation|Study Discontinued at Site|0
6374277|NCT02936323|10164029|FG008|Phase 1 Dose Escalation|Study Discontinued at Site|0
6374278|NCT02936323|10164030|FG009|Phase 1 Dose Escalation|Study Discontinued at Site|0
6374279|NCT02936323|10164021|FG000|Phase 2a Dose Expansion|Informed Consent Withdrawn|0
6374280|NCT02936323|10164022|FG001|Phase 2a Dose Expansion|Informed Consent Withdrawn|0
6374281|NCT02936323|10164023|FG002|Phase 2a Dose Expansion|Informed Consent Withdrawn|0
6374282|NCT02936323|10164024|FG003|Phase 2a Dose Expansion|Informed Consent Withdrawn|0
6374283|NCT02936323|10164025|FG004|Phase 2a Dose Expansion|Informed Consent Withdrawn|0
6374284|NCT02936323|10164026|FG005|Phase 2a Dose Expansion|Informed Consent Withdrawn|0
6374285|NCT02936323|10164027|FG006|Phase 2a Dose Expansion|Informed Consent Withdrawn|0
6374286|NCT02936323|10164028|FG007|Phase 2a Dose Expansion|Informed Consent Withdrawn|11
6374287|NCT02936323|10164029|FG008|Phase 2a Dose Expansion|Informed Consent Withdrawn|4
6374288|NCT02936323|10164030|FG009|Phase 2a Dose Expansion|Informed Consent Withdrawn|2
6374289|NCT02936323|10164021|FG000|Phase 2a Dose Expansion|Physician Decision|0
6374290|NCT02936323|10164022|FG001|Phase 2a Dose Expansion|Physician Decision|0
6374291|NCT02936323|10164023|FG002|Phase 2a Dose Expansion|Physician Decision|0
6374292|NCT02936323|10164024|FG003|Phase 2a Dose Expansion|Physician Decision|0
6374293|NCT02936323|10164025|FG004|Phase 2a Dose Expansion|Physician Decision|0
6374294|NCT02936323|10164026|FG005|Phase 2a Dose Expansion|Physician Decision|0
6374295|NCT02936323|10164027|FG006|Phase 2a Dose Expansion|Physician Decision|0
6374296|NCT02936323|10164028|FG007|Phase 2a Dose Expansion|Physician Decision|0
6374297|NCT02936323|10164029|FG008|Phase 2a Dose Expansion|Physician Decision|0
6374298|NCT02936323|10164030|FG009|Phase 2a Dose Expansion|Physician Decision|1
6374299|NCT02936323|10164021|FG000|Phase 2a Dose Expansion|Lost to Follow-up|0
6374300|NCT02936323|10164022|FG001|Phase 2a Dose Expansion|Lost to Follow-up|0
6374301|NCT02936323|10164023|FG002|Phase 2a Dose Expansion|Lost to Follow-up|0
6374302|NCT02936323|10164024|FG003|Phase 2a Dose Expansion|Lost to Follow-up|0
6374303|NCT02936323|10164025|FG004|Phase 2a Dose Expansion|Lost to Follow-up|0
6374304|NCT02936323|10164026|FG005|Phase 2a Dose Expansion|Lost to Follow-up|0
6374305|NCT02936323|10164027|FG006|Phase 2a Dose Expansion|Lost to Follow-up|0
6374306|NCT02936323|10164028|FG007|Phase 2a Dose Expansion|Lost to Follow-up|2
6374307|NCT02936323|10164029|FG008|Phase 2a Dose Expansion|Lost to Follow-up|1
6374308|NCT02936323|10164030|FG009|Phase 2a Dose Expansion|Lost to Follow-up|0
6374309|NCT02936323|10164021|FG000|Phase 2a Dose Expansion|Change(s) to patient's condition|0
6374310|NCT02936323|10164022|FG001|Phase 2a Dose Expansion|Change(s) to patient's condition|0
6374311|NCT02936323|10164023|FG002|Phase 2a Dose Expansion|Change(s) to patient's condition|0
6374312|NCT02936323|10164024|FG003|Phase 2a Dose Expansion|Change(s) to patient's condition|0
6374313|NCT02936323|10164025|FG004|Phase 2a Dose Expansion|Change(s) to patient's condition|0
6374314|NCT02936323|10164026|FG005|Phase 2a Dose Expansion|Change(s) to patient's condition|0
6374315|NCT02936323|10164027|FG006|Phase 2a Dose Expansion|Change(s) to patient's condition|0
6374316|NCT02936323|10164028|FG007|Phase 2a Dose Expansion|Change(s) to patient's condition|0
6374317|NCT02936323|10164029|FG008|Phase 2a Dose Expansion|Change(s) to patient's condition|0
6374318|NCT02936323|10164030|FG009|Phase 2a Dose Expansion|Change(s) to patient's condition|1
6374319|NCT02936323|10164021|FG000|Phase 2a Dose Expansion|Death|0
6374320|NCT02936323|10164022|FG001|Phase 2a Dose Expansion|Death|0
6374321|NCT02936323|10164023|FG002|Phase 2a Dose Expansion|Death|0
6374322|NCT02936323|10164024|FG003|Phase 2a Dose Expansion|Death|0
6374323|NCT02936323|10164025|FG004|Phase 2a Dose Expansion|Death|0
6374324|NCT02936323|10164026|FG005|Phase 2a Dose Expansion|Death|0
6374325|NCT02936323|10164027|FG006|Phase 2a Dose Expansion|Death|0
6374326|NCT02936323|10164028|FG007|Phase 2a Dose Expansion|Death|4
6374327|NCT02936323|10164029|FG008|Phase 2a Dose Expansion|Death|8
6374328|NCT02936323|10164030|FG009|Phase 2a Dose Expansion|Death|10
6374329|NCT02437318|10164073|FG000|Overall Study|Progressive disease|173
6374330|NCT02437318|10164074|FG001|Overall Study|Progressive disease|208
6374331|NCT02437318|10164073|FG000|Overall Study|Subject/guardian decision|22
6374332|NCT02437318|10164074|FG001|Overall Study|Subject/guardian decision|10
6374333|NCT02437318|10164073|FG000|Overall Study|Physician Decision|11
6374334|NCT02437318|10164074|FG001|Overall Study|Physician Decision|10
6374335|NCT02437318|10164073|FG000|Overall Study|Adverse Event|14
6374336|NCT02437318|10164074|FG001|Overall Study|Adverse Event|3
6374337|NCT02437318|10164073|FG000|Overall Study|Death|4
6374338|NCT02437318|10164074|FG001|Overall Study|Death|4
6374339|NCT02437318|10164073|FG000|Overall Study|Protocol Violation|5
6374340|NCT02437318|10164074|FG001|Overall Study|Protocol Violation|6
6374341|NCT02437318|10164073|FG000|Overall Study|Untreated|0
6374342|NCT02437318|10164074|FG001|Overall Study|Untreated|1
6374343|NCT02429791|10164082|FG000|Early Switch Phase (Up to Week 52)|Adverse Event|6
6374344|NCT02429791|10164083|FG001|Early Switch Phase (Up to Week 52)|Adverse Event|2
6374345|NCT02429791|10164082|FG000|Early Switch Phase (Up to Week 52)|Physician Decision|0
6374346|NCT02429791|10164083|FG001|Early Switch Phase (Up to Week 52)|Physician Decision|2
6374347|NCT02429791|10164082|FG000|Early Switch Phase (Up to Week 52)|Lack of Efficacy|2
6374348|NCT02429791|10164083|FG001|Early Switch Phase (Up to Week 52)|Lack of Efficacy|1
6374349|NCT02429791|10164082|FG000|Early Switch Phase (Up to Week 52)|Lost to Follow-up|1
6374350|NCT02429791|10164083|FG001|Early Switch Phase (Up to Week 52)|Lost to Follow-up|2
6374351|NCT02429791|10164082|FG000|Early Switch Phase (Up to Week 52)|Protocol Violation|1
6374352|NCT02429791|10164083|FG001|Early Switch Phase (Up to Week 52)|Protocol Violation|4
6374353|NCT02429791|10164082|FG000|Early Switch Phase (Up to Week 52)|Withdrawal by Subject|3
6374354|NCT02429791|10164083|FG001|Early Switch Phase (Up to Week 52)|Withdrawal by Subject|7
6374355|NCT02429791|10164082|FG000|Late Switch Phase (Week 52 to Week 148)|Adverse Event|11
6374356|NCT02429791|10164083|FG001|Late Switch Phase (Week 52 to Week 148)|Adverse Event|12
6374357|NCT02429791|10164082|FG000|Late Switch Phase (Week 52 to Week 148)|Physician Decision|0
6374358|NCT02429791|10164083|FG001|Late Switch Phase (Week 52 to Week 148)|Physician Decision|4
6374359|NCT02429791|10164082|FG000|Late Switch Phase (Week 52 to Week 148)|Lack of Efficacy|4
6374360|NCT02429791|10164083|FG001|Late Switch Phase (Week 52 to Week 148)|Lack of Efficacy|3
6374361|NCT02429791|10164082|FG000|Late Switch Phase (Week 52 to Week 148)|Lost to Follow-up|0
6374362|NCT02429791|10164083|FG001|Late Switch Phase (Week 52 to Week 148)|Lost to Follow-up|1
6374363|NCT02429791|10164082|FG000|Late Switch Phase (Week 52 to Week 148)|Protocol Violation|3
6374364|NCT02429791|10164083|FG001|Late Switch Phase (Week 52 to Week 148)|Protocol Violation|3
6374365|NCT02429791|10164082|FG000|Late Switch Phase (Week 52 to Week 148)|Withdrawal by Subject|7
6374366|NCT02429791|10164083|FG001|Late Switch Phase (Week 52 to Week 148)|Withdrawal by Subject|5
6374367|NCT02422797|10164098|FG000|Early Switch Phase (Up to Week 52)|Adverse Event|11
6374368|NCT02422797|10164099|FG001|Early Switch Phase (Up to Week 52)|Adverse Event|1
6374369|NCT02422797|10164098|FG000|Early Switch Phase (Up to Week 52)|Physician Decision|0
6374370|NCT02422797|10164099|FG001|Early Switch Phase (Up to Week 52)|Physician Decision|1
6374371|NCT02422797|10164098|FG000|Early Switch Phase (Up to Week 52)|Lack of Efficacy|1
6374372|NCT02422797|10164099|FG001|Early Switch Phase (Up to Week 52)|Lack of Efficacy|2
6374373|NCT02422797|10164098|FG000|Early Switch Phase (Up to Week 52)|Lost to Follow-up|1
6374374|NCT02422797|10164099|FG001|Early Switch Phase (Up to Week 52)|Lost to Follow-up|1
6374375|NCT02422797|10164098|FG000|Early Switch Phase (Up to Week 52)|Protocol Violation|0
6374376|NCT02422797|10164099|FG001|Early Switch Phase (Up to Week 52)|Protocol Violation|3
6374377|NCT02422797|10164098|FG000|Early Switch Phase (Up to Week 52)|Reached stopping criteria|1
6374378|NCT02422797|10164099|FG001|Early Switch Phase (Up to Week 52)|Reached stopping criteria|1
6374379|NCT02422797|10164098|FG000|Early Switch Phase (Up to Week 52)|Withdrawal by Subject|2
6374380|NCT02422797|10164099|FG001|Early Switch Phase (Up to Week 52)|Withdrawal by Subject|7
6374381|NCT02422797|10164098|FG000|Late Switch Phase (Week 52 to Week 148)|Physician Decision|0
6374382|NCT02422797|10164099|FG001|Late Switch Phase (Week 52 to Week 148)|Physician Decision|1
6374383|NCT02422797|10164098|FG000|Late Switch Phase (Week 52 to Week 148)|Adverse Event|10
6374384|NCT02422797|10164099|FG001|Late Switch Phase (Week 52 to Week 148)|Adverse Event|6
6374385|NCT02422797|10164098|FG000|Late Switch Phase (Week 52 to Week 148)|Lack of Efficacy|5
6374386|NCT02422797|10164099|FG001|Late Switch Phase (Week 52 to Week 148)|Lack of Efficacy|3
6374387|NCT02422797|10164098|FG000|Late Switch Phase (Week 52 to Week 148)|Lost to Follow-up|2
6374388|NCT02422797|10164099|FG001|Late Switch Phase (Week 52 to Week 148)|Lost to Follow-up|2
6374389|NCT02422797|10164098|FG000|Late Switch Phase (Week 52 to Week 148)|Withdrawal by Subject|2
6374390|NCT02422797|10164099|FG001|Late Switch Phase (Week 52 to Week 148)|Withdrawal by Subject|6
6374391|NCT02422797|10164098|FG000|Late Switch Phase (Week 52 to Week 148)|Reached stopping criteria|1
6374392|NCT02422797|10164099|FG001|Late Switch Phase (Week 52 to Week 148)|Reached stopping criteria|0
6374393|NCT02422797|10164098|FG000|Late Switch Phase (Week 52 to Week 148)|Protocol Violation|3
6374394|NCT02422797|10164099|FG001|Late Switch Phase (Week 52 to Week 148)|Protocol Violation|0
6374395|NCT02132611|10164128|FG000|Overall Study|Death|2
6374396|NCT01147822|10164134|FG000|Overall Study|Death|66
6374397|NCT01147822|10164135|FG001|Overall Study|Death|59
6374398|NCT01147822|10164134|FG000|Overall Study|Protocol Violation|0
6374399|NCT01147822|10164135|FG001|Overall Study|Protocol Violation|1
6374400|NCT01147822|10164134|FG000|Overall Study|Lost to Follow-up|3
6374401|NCT01147822|10164135|FG001|Overall Study|Lost to Follow-up|2
6374402|NCT01147822|10164134|FG000|Overall Study|Physician Decision|0
6374403|NCT01147822|10164135|FG001|Overall Study|Physician Decision|2
6374404|NCT01147822|10164134|FG000|Overall Study|Withdrawal by Subject|8
6374405|NCT01147822|10164135|FG001|Overall Study|Withdrawal by Subject|13
6374406|NCT01147822|10164134|FG000|Overall Study|Not Completed/Ongoing|111
6374407|NCT01147822|10164135|FG001|Overall Study|Not Completed/Ongoing|102
6374408|NCT04476251|10164156|FG000|Overall Study|Not treated|1
6374409|NCT03915860|10164164|FG000|Overall Study|Adverse Event|3
6374410|NCT03915860|10164164|FG000|Overall Study|Withdrawal by Subject|6
6374411|NCT03915860|10164164|FG000|Overall Study|Lost to Follow-up|2
6374412|NCT03915860|10164164|FG000|Overall Study|Other than specified|3
6374413|NCT03795233|10164183|FG000|Overall Study|Withdrawal by Subject|2
6374414|NCT03795233|10164184|FG001|Overall Study|Withdrawal by Subject|1
6374415|NCT03795233|10164183|FG000|Overall Study|Lost to Follow-up|1
6374416|NCT03795233|10164184|FG001|Overall Study|Lost to Follow-up|0
6374417|NCT03795233|10164183|FG000|Overall Study|Death|1
6374418|NCT03795233|10164184|FG001|Overall Study|Death|0
6374419|NCT03786380|10164195|FG000|Overall Study|Adverse Event|1
6374420|NCT03786380|10164196|FG001|Overall Study|Adverse Event|0
6374421|NCT03786380|10164197|FG002|Overall Study|Adverse Event|0
6374422|NCT03786380|10164198|FG003|Overall Study|Adverse Event|3
6374423|NCT03786380|10164199|FG004|Overall Study|Adverse Event|1
6374424|NCT03786380|10164195|FG000|Overall Study|Lack of Efficacy|0
6374425|NCT03786380|10164196|FG001|Overall Study|Lack of Efficacy|0
6374426|NCT03786380|10164197|FG002|Overall Study|Lack of Efficacy|0
6374427|NCT03786380|10164198|FG003|Overall Study|Lack of Efficacy|0
6374428|NCT03786380|10164199|FG004|Overall Study|Lack of Efficacy|1
6374429|NCT03786380|10164195|FG000|Overall Study|Withdrawal by Subject|1
6374430|NCT03786380|10164196|FG001|Overall Study|Withdrawal by Subject|2
6374431|NCT03786380|10164197|FG002|Overall Study|Withdrawal by Subject|2
6374432|NCT03786380|10164198|FG003|Overall Study|Withdrawal by Subject|1
6374433|NCT03786380|10164199|FG004|Overall Study|Withdrawal by Subject|2
6374434|NCT03786380|10164195|FG000|Overall Study|Lost to Follow-up|3
6374435|NCT03786380|10164196|FG001|Overall Study|Lost to Follow-up|0
6374436|NCT03786380|10164197|FG002|Overall Study|Lost to Follow-up|1
6374437|NCT03786380|10164198|FG003|Overall Study|Lost to Follow-up|2
6374438|NCT03786380|10164199|FG004|Overall Study|Lost to Follow-up|0
6374439|NCT03786380|10164195|FG000|Overall Study|Physician Decision|0
6374440|NCT03786380|10164196|FG001|Overall Study|Physician Decision|0
6374441|NCT03786380|10164197|FG002|Overall Study|Physician Decision|1
6374442|NCT03786380|10164198|FG003|Overall Study|Physician Decision|0
6374443|NCT03786380|10164199|FG004|Overall Study|Physician Decision|0
6374444|NCT03786380|10164195|FG000|Overall Study|Study Terminated by the Sponsor|30
6374445|NCT03786380|10164196|FG001|Overall Study|Study Terminated by the Sponsor|20
6374446|NCT03786380|10164197|FG002|Overall Study|Study Terminated by the Sponsor|50
6374447|NCT03786380|10164198|FG003|Overall Study|Study Terminated by the Sponsor|57
6374448|NCT03786380|10164199|FG004|Overall Study|Study Terminated by the Sponsor|23
6374449|NCT03786380|10164195|FG000|Overall Study|Reason Not Specified|0
6374450|NCT03786380|10164196|FG001|Overall Study|Reason Not Specified|0
6374451|NCT03786380|10164197|FG002|Overall Study|Reason Not Specified|0
6374452|NCT03786380|10164198|FG003|Overall Study|Reason Not Specified|0
6374453|NCT03786380|10164199|FG004|Overall Study|Reason Not Specified|1
6374454|NCT03645863|10164223|FG000|Overall Study|Withdrawal by Subject|1
6374455|NCT03645863|10164224|FG001|Overall Study|Withdrawal by Subject|0
6374456|NCT03645863|10164225|FG002|Overall Study|Withdrawal by Subject|0
6374457|NCT03564145|10164233|FG000|Overall Study|Adverse Event|4
6374458|NCT03564145|10164233|FG000|Overall Study|Lost to Follow-up|21
6374459|NCT03564145|10164233|FG000|Overall Study|Protocol Violation|2
6374460|NCT03564145|10164233|FG000|Overall Study|Withdrawal by Subject|48
6374461|NCT03564145|10164233|FG000|Overall Study|Study Terminated by Sponsor|146
6171900|NCT01262677|9818826|FG000|Overall Study|Does not meet entrance criteria|0
6171901|NCT01262677|9818827|FG001|Overall Study|Does not meet entrance criteria|2
6171902|NCT01262677|9818828|FG002|Overall Study|Does not meet entrance criteria|0
6171903|NCT01262677|9818826|FG000|Overall Study|Insufficient clinical response|0
6171904|NCT01262677|9818827|FG001|Overall Study|Insufficient clinical response|0
6171905|NCT01262677|9818828|FG002|Overall Study|Insufficient clinical response|1
6171906|NCT01262677|9818826|FG000|Overall Study|Lost to Follow-up|1
6171907|NCT01262677|9818827|FG001|Overall Study|Lost to Follow-up|0
6171908|NCT01262677|9818828|FG002|Overall Study|Lost to Follow-up|2
6374462|NCT03564145|10164233|FG000|Overall Study|Physician Decision|1
6374463|NCT03564145|10164233|FG000|Overall Study|Other Than Specified|1
6374464|NCT03564145|10164233|FG000|Overall Study|Pregnancy|1
6374465|NCT03564119|10164239|FG000|Overall Study|Adverse Event|4
6171909|NCT01262677|9818826|FG000|Overall Study|No longer willing to participate|3
6171910|NCT01262677|9818827|FG001|Overall Study|No longer willing to participate|3
6171911|NCT01262677|9818828|FG002|Overall Study|No longer willing to participate|2
6171912|NCT01262677|9818826|FG000|Overall Study|Reason not provided|2
6171913|NCT01262677|9818827|FG001|Overall Study|Reason not provided|1
6171914|NCT01262677|9818828|FG002|Overall Study|Reason not provided|3
6171915|NCT01262677|9818826|FG000|Overall Study|Protocol Violation|0
6171916|NCT01262677|9818827|FG001|Overall Study|Protocol Violation|1
6374466|NCT03564119|10164240|FG001|Overall Study|Adverse Event|0
6374467|NCT03564119|10164239|FG000|Overall Study|Lost to Follow-up|1
6374468|NCT03564119|10164240|FG001|Overall Study|Lost to Follow-up|4
6171917|NCT01262677|9818828|FG002|Overall Study|Protocol Violation|1
6374469|NCT03564119|10164239|FG000|Overall Study|Protocol Violation|1
6374470|NCT03564119|10164240|FG001|Overall Study|Protocol Violation|0
6374471|NCT03564119|10164239|FG000|Overall Study|Withdrawal by Subject|9
6374472|NCT03564119|10164240|FG001|Overall Study|Withdrawal by Subject|4
6374473|NCT03564119|10164239|FG000|Overall Study|Other Than Specified|0
6374474|NCT03564119|10164240|FG001|Overall Study|Other Than Specified|1
6171918|NCT01262677|9818826|FG000|Overall Study|Adverse Event (AE) related to study drug|3
6171919|NCT01262677|9818827|FG001|Overall Study|Adverse Event (AE) related to study drug|8
6171920|NCT01262677|9818828|FG002|Overall Study|Adverse Event (AE) related to study drug|3
6171921|NCT01262820|9818840|FG000|Overall Study|Adverse Event|5
6043321|NCT00388674|9641858|FG001|End of Study|HBV Disease Progression (Non-HCC)|9
6084786|NCT00644969|9693780|FG001|Treatment Phase|Adverse Event|0
6084787|NCT00644969|9693779|FG000|Treatment Phase|Withdrawal by Subject|4
6084788|NCT00644969|9693780|FG001|Treatment Phase|Withdrawal by Subject|0
6084789|NCT00644969|9693779|FG000|Treatment Phase|Lost to Follow-up|2
6084790|NCT00644969|9693780|FG001|Treatment Phase|Lost to Follow-up|2
6084791|NCT00644969|9693779|FG000|Treatment Phase|Other|4
6084792|NCT00644969|9693780|FG001|Treatment Phase|Other|1
6084793|NCT00644969|9693779|FG000|Post Treatment Phase|Death|1
6171922|NCT01262820|9818840|FG000|Overall Study|Lack of Efficacy|9
6171923|NCT01262820|9818840|FG000|Overall Study|Drug held for 21+ days|1
6171924|NCT01262872|9818861|FG000|Step 2|Death|0
6171925|NCT01262872|9818862|FG001|Step 2|Death|0
6171926|NCT01262872|9818863|FG002|Step 2|Death|0
6171927|NCT01262872|9818864|FG003|Step 2|Death|1
6171928|NCT01262872|9818865|FG004|Step 2|Death|0
6043322|NCT00388674|9641857|FG000|End of Study|HCC|8
6043323|NCT00388674|9641858|FG001|End of Study|HCC|7
6043324|NCT00388674|9641857|FG000|End of Study|Lost to Follow-up|587
6043325|NCT00388674|9641858|FG001|End of Study|Lost to Follow-up|715
6043326|NCT00388674|9641857|FG000|End of Study|Malignancy (Non-HCC)|1
6043327|NCT00388674|9641858|FG001|End of Study|Malignancy (Non-HCC)|1
6043328|NCT00388674|9641857|FG000|End of Study|Non-Study Related Comorbidities|3
6043329|NCT00388674|9641858|FG001|End of Study|Non-Study Related Comorbidities|4
6171929|NCT01262872|9818866|FG005|Step 2|Death|2
6043330|NCT00388674|9641857|FG000|End of Study|Not Defined|135
6043331|NCT00388674|9641858|FG001|End of Study|Not Defined|214
6084794|NCT00644969|9693780|FG001|Post Treatment Phase|Death|0
6084795|NCT00644969|9693779|FG000|Post Treatment Phase|Withdrawal by Subject|4
6171930|NCT01262872|9818867|FG006|Step 2|Death|2
6374475|NCT03181529|10164295|FG000|Overall Study|Withdrawal by Subject|1
6374476|NCT03181529|10164296|FG001|Overall Study|Withdrawal by Subject|1
6374477|NCT03181529|10164295|FG000|Overall Study|Dropped out of study due to sleep difficulties. Sleep difficulties were also reported at screening|1
6374478|NCT03181529|10164296|FG001|Overall Study|Dropped out of study due to sleep difficulties. Sleep difficulties were also reported at screening|0
6374479|NCT02946931|10164302|FG000|Overall Study|Did not require collection of CRFs|573
6374480|NCT02946931|10164302|FG000|Overall Study|Other than listed|38
6374481|NCT02946931|10164302|FG000|Overall Study|Discharge from hospital|117
6374482|NCT02946931|10164302|FG000|Overall Study|Adverse Event|81
6374483|NCT02946931|10164302|FG000|Overall Study|CRFs not fixed|2
6374484|NCT02946931|10164302|FG000|Overall Study|CRFs not valid|1
6374485|NCT02946931|10164302|FG000|Overall Study|CRFs with missing information on the date of termination of PMS|6
6374486|NCT02779556|10164308|FG000|Baseline|Partial baseline interview completed|1
6374487|NCT02779556|10164309|FG001|Baseline|Partial baseline interview completed|0
6374488|NCT02779556|10164308|FG000|3 Months|Lost to Follow-up|40
6374489|NCT02779556|10164309|FG001|3 Months|Lost to Follow-up|29
6374490|NCT02779556|10164308|FG000|3 Months|Missed 3 month clinic visit|27
6374491|NCT02779556|10164309|FG001|3 Months|Missed 3 month clinic visit|19
6374492|NCT02779556|10164308|FG000|6 Month|Lost to Follow-up|33
6374493|NCT02779556|10164309|FG001|6 Month|Lost to Follow-up|39
6374494|NCT02779556|10164308|FG000|6 Month HbA1c|No value collected during window|69
6374495|NCT02779556|10164309|FG001|6 Month HbA1c|No value collected during window|50
6374496|NCT02779556|10164308|FG000|12 Month HbA1c|No value collected during window|138
6374497|NCT02779556|10164309|FG001|12 Month HbA1c|No value collected during window|102
6374498|NCT02675751|10164333|FG000|Overall Study|Lost to Follow-up|16
6374499|NCT02621424|10164348|FG000|Overall Study|Withdrawal by Subject|1
6374500|NCT02621424|10164349|FG001|Overall Study|Withdrawal by Subject|2
6374501|NCT02595372|10164355|FG000|Overall Study|Adverse Event|6
6374502|NCT02595372|10164355|FG000|Overall Study|Physician Decision|2
6374503|NCT02595372|10164355|FG000|Overall Study|Disease Progression|1
6374504|NCT02334722|10164367|FG000|Overall Study|Lost to Follow-up|4
6374505|NCT02334722|10164368|FG001|Overall Study|Lost to Follow-up|0
6374506|NCT02334722|10164367|FG000|Overall Study|6 week questionnaire not completed|2
6374507|NCT02334722|10164368|FG001|Overall Study|6 week questionnaire not completed|0
6374508|NCT02334722|10164367|FG000|Overall Study|Unable to obtain medication|1
6374509|NCT02334722|10164368|FG001|Overall Study|Unable to obtain medication|1
6374510|NCT02334722|10164367|FG000|Overall Study|Withdrawal by Subject|0
6374511|NCT02334722|10164368|FG001|Overall Study|Withdrawal by Subject|3
6374512|NCT02334722|10164367|FG000|Overall Study|Adverse Event|0
6374513|NCT02334722|10164368|FG001|Overall Study|Adverse Event|2
6374514|NCT02334722|10164367|FG000|Overall Study|Physician Decision|0
6374515|NCT02334722|10164368|FG001|Overall Study|Physician Decision|1
6374516|NCT01966731|10164378|FG000|Overall Study|Death|2
6374517|NCT01966731|10164378|FG000|Overall Study|Lost to Follow-up|1
6374518|NCT01966731|10164378|FG000|Overall Study|Physician Decision|2
6374519|NCT01966731|10164378|FG000|Overall Study|Follow up is not complete|600
6374520|NCT01966731|10164378|FG000|Overall Study|Screening Failure|29
6374521|NCT01966731|10164378|FG000|Overall Study|Found to be ineligible|1
6374522|NCT01844518|10164402|FG000|Overall Study|Adverse Event|7
6374523|NCT01844518|10164403|FG001|Overall Study|Adverse Event|1
6374524|NCT01844518|10164402|FG000|Overall Study|Lack of Efficacy|17
6374525|NCT01844518|10164403|FG001|Overall Study|Lack of Efficacy|5
6374526|NCT01844518|10164402|FG000|Overall Study|Participant's request to discontinue|4
6374527|NCT01844518|10164403|FG001|Overall Study|Participant's request to discontinue|1
6374528|NCT01844518|10164402|FG000|Overall Study|Poor/Non-compliance|1
6374529|NCT01844518|10164403|FG001|Overall Study|Poor/Non-compliance|0
6374530|NCT01844518|10164402|FG000|Overall Study|No Longer Met Study Criteria|2
6374531|NCT01844518|10164403|FG001|Overall Study|No Longer Met Study Criteria|0
6374532|NCT01844518|10164402|FG000|Overall Study|Withdrawal by Subject|9
6374533|NCT01844518|10164403|FG001|Overall Study|Withdrawal by Subject|0
6374534|NCT01844518|10164402|FG000|Overall Study|Pregnancy|1
6374535|NCT01844518|10164403|FG001|Overall Study|Pregnancy|0
6374536|NCT01675479|10164412|FG000|Overall Study|Lost to Follow-up|11
6374537|NCT01349959|10164425|FG000|Overall Study|Adverse Event|7
6374538|NCT01168219|10164429|FG000|Overall Study|off study before starting treatment|2
6374539|NCT01168219|10164429|FG000|Overall Study|withdrew before transplant|1
6374540|NCT01168219|10164429|FG000|Overall Study|ineligible due to CML|2
6374541|NCT00812708|10164433|FG000|Overall Study|Device could not be implanted|2
6374542|NCT00812708|10164433|FG000|Overall Study|Lack of medical insurance|1
6374543|NCT00812708|10164433|FG000|Overall Study|Switched to another study|1
6374544|NCT00812708|10164433|FG000|Overall Study|Surgery cancelled due to uveitis|1
6374545|NCT00812708|10164433|FG000|Overall Study|Signed consent but later withdrew|3
6374546|NCT00792259|10164441|FG000|Overall Study|Poor Quality Scans|1
6374547|NCT00792259|10164442|FG001|Overall Study|Poor Quality Scans|0
6374548|NCT00792259|10164443|FG002|Overall Study|Poor Quality Scans|0
6374549|NCT00741988|10164453|FG000|Overall Study|Adverse Event|2
6374550|NCT00741988|10164454|FG001|Overall Study|Adverse Event|4
6374551|NCT00741988|10164453|FG000|Overall Study|Lack of Efficacy|2
6374552|NCT00741988|10164454|FG001|Overall Study|Lack of Efficacy|0
6374553|NCT00515671|10164471|FG000|Overall Study|Lost to Follow-up|13
6374554|NCT00515671|10164472|FG001|Overall Study|Lost to Follow-up|10
6374555|NCT00515671|10164471|FG000|Overall Study|Withdrawal by Subject|3
6374556|NCT00515671|10164472|FG001|Overall Study|Withdrawal by Subject|5
6374557|NCT00515671|10164471|FG000|Overall Study|incarcerated|1
6374558|NCT00515671|10164472|FG001|Overall Study|incarcerated|2
6374559|NCT00455403|10164480|FG000|Overall Study|Lost to Follow-up|2
6374560|NCT00455403|10164481|FG001|Overall Study|Lost to Follow-up|1
6374561|NCT00455403|10164480|FG000|Overall Study|Withdrawal by Subject|1
6374562|NCT00455403|10164481|FG001|Overall Study|Withdrawal by Subject|3
6374563|NCT00455403|10164480|FG000|Overall Study|Protocol Violation|0
6374564|NCT00455403|10164481|FG001|Overall Study|Protocol Violation|2
6374565|NCT00238420|10164489|FG000|Overall Study|Protocol Violation|1
6374566|NCT00238420|10164490|FG001|Overall Study|Protocol Violation|1
6374567|NCT04128319|10164505|FG000|Overall Study|Death|3
6374568|NCT03761810|10164511|FG000|Overall Study|Adverse Event|12
6374569|NCT03761810|10164512|FG001|Overall Study|Adverse Event|0
6374570|NCT03761810|10164511|FG000|Overall Study|Lost to Follow-up|15
6374571|NCT03761810|10164512|FG001|Overall Study|Lost to Follow-up|7
6374572|NCT03761810|10164511|FG000|Overall Study|Pregnancy|1
6374573|NCT03761810|10164512|FG001|Overall Study|Pregnancy|0
6374574|NCT03761810|10164511|FG000|Overall Study|Withdrawal by Subject|14
6374575|NCT03761810|10164512|FG001|Overall Study|Withdrawal by Subject|5
6374576|NCT03761810|10164511|FG000|Overall Study|Physician Decision|1
6374577|NCT03761810|10164512|FG001|Overall Study|Physician Decision|0
6374578|NCT03761810|10164511|FG000|Overall Study|Withdrawal by Parent/Guardian|4
6374579|NCT03761810|10164512|FG001|Overall Study|Withdrawal by Parent/Guardian|0
6374580|NCT03761810|10164511|FG000|Overall Study|Other Than Specified|1
6374581|NCT03761810|10164512|FG001|Overall Study|Other Than Specified|0
6374582|NCT03761784|10164520|FG000|Overall Study|Adverse Event|4
6374583|NCT03761784|10164521|FG001|Overall Study|Adverse Event|0
6374584|NCT03761784|10164520|FG000|Overall Study|Lost to Follow-up|10
6374585|NCT03761784|10164521|FG001|Overall Study|Lost to Follow-up|7
6374586|NCT03761784|10164520|FG000|Overall Study|Pregnancy|1
6374587|NCT03761784|10164521|FG001|Overall Study|Pregnancy|0
6374588|NCT03761784|10164520|FG000|Overall Study|Protocol Violation|2
6374589|NCT03761784|10164521|FG001|Overall Study|Protocol Violation|0
6374590|NCT03761784|10164520|FG000|Overall Study|Withdrawal by Parent or Guardian|4
6374591|NCT03761784|10164521|FG001|Overall Study|Withdrawal by Parent or Guardian|1
6374592|NCT03761784|10164520|FG000|Overall Study|Withdrawal by Subject|9
6374593|NCT03761784|10164521|FG001|Overall Study|Withdrawal by Subject|4
6374594|NCT03761784|10164520|FG000|Overall Study|Physician Decision|1
6374595|NCT03761784|10164521|FG001|Overall Study|Physician Decision|0
6374596|NCT03761784|10164520|FG000|Overall Study|Other Than Specified|1
6374597|NCT03761784|10164521|FG001|Overall Study|Other Than Specified|0
6374672|NCT02871778|10164613|FG006|Part A: Treatment Period 2|Lost to Follow-up|0
6374673|NCT02871778|10164614|FG007|Part A: Treatment Period 2|Lost to Follow-up|0
6374674|NCT02871778|10164607|FG000|Part A: Treatment Period 2|Non-Compliant with Study Drug|1
6374675|NCT02871778|10164608|FG001|Part A: Treatment Period 2|Non-Compliant with Study Drug|0
6374676|NCT02871778|10164609|FG002|Part A: Treatment Period 2|Non-Compliant with Study Drug|1
6374677|NCT02871778|10164610|FG003|Part A: Treatment Period 2|Non-Compliant with Study Drug|0
6374678|NCT02871778|10164611|FG004|Part A: Treatment Period 2|Non-Compliant with Study Drug|0
6374679|NCT02871778|10164612|FG005|Part A: Treatment Period 2|Non-Compliant with Study Drug|0
6374680|NCT02871778|10164613|FG006|Part A: Treatment Period 2|Non-Compliant with Study Drug|0
6374681|NCT02871778|10164614|FG007|Part A: Treatment Period 2|Non-Compliant with Study Drug|0
6374682|NCT02871778|10164607|FG000|Part B: Treatment Period 3|Adverse Event|0
6374683|NCT02871778|10164608|FG001|Part B: Treatment Period 3|Adverse Event|0
6374684|NCT02871778|10164609|FG002|Part B: Treatment Period 3|Adverse Event|0
6374685|NCT02871778|10164610|FG003|Part B: Treatment Period 3|Adverse Event|0
6374686|NCT02871778|10164611|FG004|Part B: Treatment Period 3|Adverse Event|1
6374687|NCT02871778|10164612|FG005|Part B: Treatment Period 3|Adverse Event|1
6374688|NCT02871778|10164613|FG006|Part B: Treatment Period 3|Adverse Event|1
6374689|NCT02871778|10164614|FG007|Part B: Treatment Period 3|Adverse Event|0
6374690|NCT02756208|10164647|FG000|Overall Study|Withdrawal by Subject|1
6374691|NCT02756208|10164648|FG001|Overall Study|Withdrawal by Subject|0
6374692|NCT02756208|10164649|FG002|Overall Study|Withdrawal by Subject|1
6374693|NCT02756208|10164650|FG003|Overall Study|Withdrawal by Subject|3
6374694|NCT02756208|10164647|FG000|Overall Study|Lost to Follow-up|3
6374695|NCT02756208|10164648|FG001|Overall Study|Lost to Follow-up|1
6374696|NCT02756208|10164649|FG002|Overall Study|Lost to Follow-up|1
6374697|NCT02756208|10164650|FG003|Overall Study|Lost to Follow-up|1
6374698|NCT02756208|10164647|FG000|Overall Study|Physician Decision|1
6374699|NCT02756208|10164648|FG001|Overall Study|Physician Decision|0
6374700|NCT02756208|10164649|FG002|Overall Study|Physician Decision|0
6374701|NCT02756208|10164650|FG003|Overall Study|Physician Decision|0
6374702|NCT02756208|10164647|FG000|Overall Study|Protocol Violation|0
6374703|NCT02756208|10164648|FG001|Overall Study|Protocol Violation|1
6374704|NCT02756208|10164649|FG002|Overall Study|Protocol Violation|0
6374705|NCT02756208|10164650|FG003|Overall Study|Protocol Violation|0
6374706|NCT02714218|10164663|FG000|Overall Study|Disease Progression|56
6374707|NCT02714218|10164664|FG001|Overall Study|Disease Progression|51
6374708|NCT02714218|10164665|FG002|Overall Study|Disease Progression|14
6374709|NCT02714218|10164663|FG000|Overall Study|Adverse Event Unrelated to Study Drug|10
6374710|NCT02714218|10164664|FG001|Overall Study|Adverse Event Unrelated to Study Drug|6
6374711|NCT02714218|10164665|FG002|Overall Study|Adverse Event Unrelated to Study Drug|0
6374712|NCT02714218|10164663|FG000|Overall Study|Study Drug Toxicity|46
6374713|NCT02714218|10164664|FG001|Overall Study|Study Drug Toxicity|69
6374714|NCT02714218|10164665|FG002|Overall Study|Study Drug Toxicity|4
6374715|NCT02714218|10164663|FG000|Overall Study|Request to Discontinue Treatment|1
6374716|NCT02714218|10164664|FG001|Overall Study|Request to Discontinue Treatment|5
6374717|NCT02714218|10164665|FG002|Overall Study|Request to Discontinue Treatment|1
6374718|NCT02714218|10164663|FG000|Overall Study|Participant Withdrew Consent|2
6374719|NCT02714218|10164664|FG001|Overall Study|Participant Withdrew Consent|3
6374720|NCT02714218|10164665|FG002|Overall Study|Participant Withdrew Consent|0
6374721|NCT02714218|10164663|FG000|Overall Study|Maximum Clinical Benefit|2
6374722|NCT02714218|10164664|FG001|Overall Study|Maximum Clinical Benefit|2
6374598|NCT03541317|10164529|FG000|Stage 2 of the Implementation|Withdrawal by Subject|1
6374599|NCT03541317|10164530|FG001|Stage 2 of the Implementation|Withdrawal by Subject|0
6374600|NCT03541317|10164531|FG002|Stage 2 of the Implementation|Withdrawal by Subject|0
6374601|NCT03541317|10164532|FG003|Stage 2 of the Implementation|Withdrawal by Subject|0
6374602|NCT03541317|10164533|FG004|Stage 2 of the Implementation|Withdrawal by Subject|0
6374603|NCT03541317|10164534|FG005|Stage 2 of the Implementation|Withdrawal by Subject|0
6374604|NCT03361865|10164557|FG000|Overall Study|Death|17
6374605|NCT03361865|10164558|FG001|Overall Study|Death|18
6374606|NCT03361865|10164557|FG000|Overall Study|Physician Decision|1
6374607|NCT03361865|10164558|FG001|Overall Study|Physician Decision|9
6374608|NCT03361865|10164557|FG000|Overall Study|Withdrawal by Subject|1
6374609|NCT03361865|10164558|FG001|Overall Study|Withdrawal by Subject|0
6374610|NCT02929056|10164584|FG000|Overall Study|Lost to Follow-up|0
6374611|NCT02929056|10164585|FG001|Overall Study|Lost to Follow-up|1
6374612|NCT02896855|10164593|FG000|Overall Study|Death|50
6374613|NCT02896855|10164594|FG001|Overall Study|Death|40
6374614|NCT02896855|10164593|FG000|Overall Study|Lost to Follow-up|15
6374615|NCT02896855|10164594|FG001|Overall Study|Lost to Follow-up|9
6374616|NCT02896855|10164593|FG000|Overall Study|Withdrawal by Subject|7
6374617|NCT02896855|10164594|FG001|Overall Study|Withdrawal by Subject|4
6374618|NCT02871778|10164607|FG000|Part A: Treatment Period 1|Adverse Event|1
6374619|NCT02871778|10164608|FG001|Part A: Treatment Period 1|Adverse Event|1
6374620|NCT02871778|10164609|FG002|Part A: Treatment Period 1|Adverse Event|1
6374621|NCT02871778|10164610|FG003|Part A: Treatment Period 1|Adverse Event|0
6374622|NCT02871778|10164611|FG004|Part A: Treatment Period 1|Adverse Event|0
6374623|NCT02871778|10164612|FG005|Part A: Treatment Period 1|Adverse Event|0
6374624|NCT02871778|10164613|FG006|Part A: Treatment Period 1|Adverse Event|0
6374625|NCT02871778|10164614|FG007|Part A: Treatment Period 1|Adverse Event|0
6374626|NCT02871778|10164607|FG000|Part A: Treatment Period 1|Withdrawal of consent (not due to adverse event)|2
6374627|NCT02871778|10164608|FG001|Part A: Treatment Period 1|Withdrawal of consent (not due to adverse event)|2
6374628|NCT02871778|10164609|FG002|Part A: Treatment Period 1|Withdrawal of consent (not due to adverse event)|0
6374629|NCT02871778|10164610|FG003|Part A: Treatment Period 1|Withdrawal of consent (not due to adverse event)|2
6374630|NCT02871778|10164611|FG004|Part A: Treatment Period 1|Withdrawal of consent (not due to adverse event)|0
6374631|NCT02871778|10164612|FG005|Part A: Treatment Period 1|Withdrawal of consent (not due to adverse event)|0
6374632|NCT02871778|10164613|FG006|Part A: Treatment Period 1|Withdrawal of consent (not due to adverse event)|0
6374633|NCT02871778|10164614|FG007|Part A: Treatment Period 1|Withdrawal of consent (not due to adverse event)|0
6374634|NCT02871778|10164607|FG000|Part A: Treatment Period 1|Noncompliant with study drug|0
6374635|NCT02871778|10164608|FG001|Part A: Treatment Period 1|Noncompliant with study drug|0
6374636|NCT02871778|10164609|FG002|Part A: Treatment Period 1|Noncompliant with study drug|1
6374637|NCT02871778|10164610|FG003|Part A: Treatment Period 1|Noncompliant with study drug|0
6374638|NCT02871778|10164611|FG004|Part A: Treatment Period 1|Noncompliant with study drug|0
6374639|NCT02871778|10164612|FG005|Part A: Treatment Period 1|Noncompliant with study drug|0
6374640|NCT02871778|10164613|FG006|Part A: Treatment Period 1|Noncompliant with study drug|0
6374641|NCT02871778|10164614|FG007|Part A: Treatment Period 1|Noncompliant with study drug|0
6374642|NCT02871778|10164607|FG000|Part A: Treatment Period 1|Other withdrawal criteria met|0
6374643|NCT02871778|10164608|FG001|Part A: Treatment Period 1|Other withdrawal criteria met|0
6374644|NCT02871778|10164609|FG002|Part A: Treatment Period 1|Other withdrawal criteria met|1
6374645|NCT02871778|10164610|FG003|Part A: Treatment Period 1|Other withdrawal criteria met|0
6374646|NCT02871778|10164611|FG004|Part A: Treatment Period 1|Other withdrawal criteria met|0
6374647|NCT02871778|10164612|FG005|Part A: Treatment Period 1|Other withdrawal criteria met|0
6374648|NCT02871778|10164613|FG006|Part A: Treatment Period 1|Other withdrawal criteria met|0
6374649|NCT02871778|10164614|FG007|Part A: Treatment Period 1|Other withdrawal criteria met|0
6374650|NCT02871778|10164607|FG000|Part A: Treatment Period 1|Wrong drug shipment|0
6374651|NCT02871778|10164608|FG001|Part A: Treatment Period 1|Wrong drug shipment|1
6374652|NCT02871778|10164609|FG002|Part A: Treatment Period 1|Wrong drug shipment|0
6374653|NCT02871778|10164610|FG003|Part A: Treatment Period 1|Wrong drug shipment|0
6374654|NCT02871778|10164611|FG004|Part A: Treatment Period 1|Wrong drug shipment|0
6374655|NCT02871778|10164612|FG005|Part A: Treatment Period 1|Wrong drug shipment|0
6374656|NCT02871778|10164613|FG006|Part A: Treatment Period 1|Wrong drug shipment|0
6374657|NCT02871778|10164614|FG007|Part A: Treatment Period 1|Wrong drug shipment|0
6374658|NCT02871778|10164607|FG000|Part A: Treatment Period 2|Adverse Event|2
6374659|NCT02871778|10164608|FG001|Part A: Treatment Period 2|Adverse Event|2
6374660|NCT02871778|10164609|FG002|Part A: Treatment Period 2|Adverse Event|0
6374661|NCT02871778|10164610|FG003|Part A: Treatment Period 2|Adverse Event|0
6374662|NCT02871778|10164611|FG004|Part A: Treatment Period 2|Adverse Event|0
6374663|NCT02871778|10164612|FG005|Part A: Treatment Period 2|Adverse Event|0
6374664|NCT02871778|10164613|FG006|Part A: Treatment Period 2|Adverse Event|0
6374665|NCT02871778|10164614|FG007|Part A: Treatment Period 2|Adverse Event|0
6374666|NCT02871778|10164607|FG000|Part A: Treatment Period 2|Lost to Follow-up|0
6374667|NCT02871778|10164608|FG001|Part A: Treatment Period 2|Lost to Follow-up|0
6374668|NCT02871778|10164609|FG002|Part A: Treatment Period 2|Lost to Follow-up|0
6374669|NCT02871778|10164610|FG003|Part A: Treatment Period 2|Lost to Follow-up|1
6374670|NCT02871778|10164611|FG004|Part A: Treatment Period 2|Lost to Follow-up|0
6374671|NCT02871778|10164612|FG005|Part A: Treatment Period 2|Lost to Follow-up|0
6374723|NCT02714218|10164665|FG002|Overall Study|Maximum Clinical Benefit|0
6374724|NCT02714218|10164663|FG000|Overall Study|Medical Decision|0
6374725|NCT02714218|10164664|FG001|Overall Study|Medical Decision|1
6374726|NCT02714218|10164665|FG002|Overall Study|Medical Decision|0
6374727|NCT02714218|10164663|FG000|Overall Study|Not Reported|9
6374728|NCT02714218|10164664|FG001|Overall Study|Not Reported|5
6374729|NCT02714218|10164665|FG002|Overall Study|Not Reported|0
6374730|NCT02714218|10164663|FG000|Overall Study|Completed|2
6374731|NCT02714218|10164664|FG001|Overall Study|Completed|0
6374732|NCT02714218|10164665|FG002|Overall Study|Completed|0
6374733|NCT02714218|10164663|FG000|Overall Study|Dose Delayed > 6 weeks|1
6374734|NCT02714218|10164664|FG001|Overall Study|Dose Delayed > 6 weeks|0
6374735|NCT02714218|10164665|FG002|Overall Study|Dose Delayed > 6 weeks|0
6374736|NCT02714218|10164663|FG000|Overall Study|Complete Response|1
6374737|NCT02714218|10164664|FG001|Overall Study|Complete Response|0
6374738|NCT02714218|10164665|FG002|Overall Study|Complete Response|0
6374739|NCT02714218|10164663|FG000|Overall Study|Stop treatment, but will do follow up|0
6374740|NCT02714218|10164664|FG001|Overall Study|Stop treatment, but will do follow up|1
6374741|NCT02714218|10164665|FG002|Overall Study|Stop treatment, but will do follow up|0
6374742|NCT02564263|10164674|FG000|Overall Study|Adverse Event|31
6374743|NCT02564263|10164675|FG001|Overall Study|Adverse Event|29
6374744|NCT02564263|10164674|FG000|Overall Study|Death|236
6374745|NCT02564263|10164675|FG001|Overall Study|Death|242
6374746|NCT02564263|10164674|FG000|Overall Study|Withdrawal by Subject|5
6374747|NCT02564263|10164675|FG001|Overall Study|Withdrawal by Subject|18
6374748|NCT02564263|10164674|FG000|Overall Study|Ongoing in Study|42
6374749|NCT02564263|10164675|FG001|Overall Study|Ongoing in Study|25
6374750|NCT02149121|10164688|FG000|Main Study Period|Lack of Efficacy|2
6374751|NCT02149121|10164689|FG001|Main Study Period|Lack of Efficacy|2
6374752|NCT02149121|10164690|FG002|Main Study Period|Lack of Efficacy|1
6374753|NCT02149121|10164691|FG003|Main Study Period|Lack of Efficacy|0
6374754|NCT02149121|10164692|FG004|Main Study Period|Lack of Efficacy|0
6374755|NCT02149121|10164693|FG005|Main Study Period|Lack of Efficacy|0
6374756|NCT02149121|10164694|FG006|Main Study Period|Lack of Efficacy|0
6374757|NCT02149121|10164688|FG000|Main Study Period|Withdrawal by Subject|9
6374758|NCT02149121|10164689|FG001|Main Study Period|Withdrawal by Subject|5
6374759|NCT02149121|10164690|FG002|Main Study Period|Withdrawal by Subject|1
6374760|NCT02149121|10164691|FG003|Main Study Period|Withdrawal by Subject|0
6374761|NCT02149121|10164692|FG004|Main Study Period|Withdrawal by Subject|0
6374762|NCT02149121|10164693|FG005|Main Study Period|Withdrawal by Subject|0
6374763|NCT02149121|10164694|FG006|Main Study Period|Withdrawal by Subject|0
6374764|NCT02149121|10164688|FG000|Main Study Period|Adverse Event|2
6374765|NCT02149121|10164689|FG001|Main Study Period|Adverse Event|5
6374766|NCT02149121|10164690|FG002|Main Study Period|Adverse Event|1
6374767|NCT02149121|10164691|FG003|Main Study Period|Adverse Event|0
6374768|NCT02149121|10164692|FG004|Main Study Period|Adverse Event|0
6374769|NCT02149121|10164693|FG005|Main Study Period|Adverse Event|0
6374770|NCT02149121|10164694|FG006|Main Study Period|Adverse Event|0
6374771|NCT02149121|10164688|FG000|Main Study Period|Protocol Violation|2
6374772|NCT02149121|10164689|FG001|Main Study Period|Protocol Violation|0
6374773|NCT02149121|10164690|FG002|Main Study Period|Protocol Violation|0
6374774|NCT02149121|10164691|FG003|Main Study Period|Protocol Violation|0
6374775|NCT02149121|10164692|FG004|Main Study Period|Protocol Violation|0
6374776|NCT02149121|10164693|FG005|Main Study Period|Protocol Violation|0
6374777|NCT02149121|10164694|FG006|Main Study Period|Protocol Violation|0
6374778|NCT02149121|10164688|FG000|Main Study Period|Lost to Follow-up|2
6374779|NCT02149121|10164689|FG001|Main Study Period|Lost to Follow-up|1
6374780|NCT02149121|10164690|FG002|Main Study Period|Lost to Follow-up|0
6374781|NCT02149121|10164691|FG003|Main Study Period|Lost to Follow-up|0
6374782|NCT02149121|10164692|FG004|Main Study Period|Lost to Follow-up|0
6374783|NCT02149121|10164693|FG005|Main Study Period|Lost to Follow-up|0
6374784|NCT02149121|10164694|FG006|Main Study Period|Lost to Follow-up|0
6374785|NCT02149121|10164688|FG000|Main Study Period|Death|1
6374786|NCT02149121|10164689|FG001|Main Study Period|Death|0
6374787|NCT02149121|10164690|FG002|Main Study Period|Death|0
6374788|NCT02149121|10164691|FG003|Main Study Period|Death|0
6374789|NCT02149121|10164692|FG004|Main Study Period|Death|0
6374790|NCT02149121|10164693|FG005|Main Study Period|Death|0
6374791|NCT02149121|10164694|FG006|Main Study Period|Death|0
6374792|NCT02149121|10164688|FG000|Main Study Period|Physician Decision|1
6374793|NCT02149121|10164689|FG001|Main Study Period|Physician Decision|0
6374794|NCT02149121|10164690|FG002|Main Study Period|Physician Decision|0
6374795|NCT02149121|10164691|FG003|Main Study Period|Physician Decision|0
6374796|NCT02149121|10164692|FG004|Main Study Period|Physician Decision|0
6374797|NCT02149121|10164693|FG005|Main Study Period|Physician Decision|0
6374798|NCT02149121|10164694|FG006|Main Study Period|Physician Decision|0
6374799|NCT02149121|10164688|FG000|Main Study Period|Developed any malignancy|0
6374800|NCT02149121|10164689|FG001|Main Study Period|Developed any malignancy|1
6374801|NCT02149121|10164690|FG002|Main Study Period|Developed any malignancy|1
6374802|NCT02149121|10164691|FG003|Main Study Period|Developed any malignancy|0
6374803|NCT02149121|10164692|FG004|Main Study Period|Developed any malignancy|0
6374804|NCT02149121|10164693|FG005|Main Study Period|Developed any malignancy|0
6374805|NCT02149121|10164694|FG006|Main Study Period|Developed any malignancy|0
6374806|NCT02149121|10164688|FG000|Main Study Period|Unmet predefined eligibility criteria|2
6374807|NCT02149121|10164689|FG001|Main Study Period|Unmet predefined eligibility criteria|2
6374808|NCT02149121|10164690|FG002|Main Study Period|Unmet predefined eligibility criteria|0
6374809|NCT02149121|10164691|FG003|Main Study Period|Unmet predefined eligibility criteria|0
6374810|NCT02149121|10164692|FG004|Main Study Period|Unmet predefined eligibility criteria|0
6374811|NCT02149121|10164693|FG005|Main Study Period|Unmet predefined eligibility criteria|0
6374812|NCT02149121|10164694|FG006|Main Study Period|Unmet predefined eligibility criteria|0
6374813|NCT02149121|10164688|FG000|Main Study Period|Disease progression|0
6374814|NCT02149121|10164689|FG001|Main Study Period|Disease progression|1
6374815|NCT02149121|10164690|FG002|Main Study Period|Disease progression|0
6374816|NCT02149121|10164691|FG003|Main Study Period|Disease progression|0
6374817|NCT02149121|10164692|FG004|Main Study Period|Disease progression|0
6374818|NCT02149121|10164693|FG005|Main Study Period|Disease progression|0
6374819|NCT02149121|10164694|FG006|Main Study Period|Disease progression|0
6374820|NCT02149121|10164688|FG000|Extension Study Period|Withdrawal by Subject|0
6374821|NCT02149121|10164689|FG001|Extension Study Period|Withdrawal by Subject|0
6374822|NCT02149121|10164690|FG002|Extension Study Period|Withdrawal by Subject|0
6374823|NCT02149121|10164691|FG003|Extension Study Period|Withdrawal by Subject|1
6374824|NCT02149121|10164692|FG004|Extension Study Period|Withdrawal by Subject|0
6374825|NCT02149121|10164693|FG005|Extension Study Period|Withdrawal by Subject|2
6374826|NCT02149121|10164694|FG006|Extension Study Period|Withdrawal by Subject|0
6374827|NCT01889186|10164717|FG000|Overall Study|Adverse event- not related to progression|18
6374828|NCT01889186|10164718|FG001|Overall Study|Adverse event- not related to progression|5
6374829|NCT01889186|10164717|FG000|Overall Study|Adverse event- related to progression|7
6374830|NCT01889186|10164718|FG001|Overall Study|Adverse event- related to progression|2
6374831|NCT01889186|10164717|FG000|Overall Study|COVID-19 logistical restrictions|1
6374832|NCT01889186|10164718|FG001|Overall Study|COVID-19 logistical restrictions|0
6374833|NCT01889186|10164717|FG000|Overall Study|Investigator request|1
6374834|NCT01889186|10164718|FG001|Overall Study|Investigator request|1
6374835|NCT01889186|10164717|FG000|Overall Study|Progressive disease- Richter's|12
6374836|NCT01889186|10164718|FG001|Overall Study|Progressive disease- Richter's|7
6374837|NCT01889186|10164717|FG000|Overall Study|Progressive disease per protocol|46
6374838|NCT01889186|10164718|FG001|Overall Study|Progressive disease per protocol|17
6374839|NCT01889186|10164717|FG000|Overall Study|Stem cell transplant|2
6374840|NCT01889186|10164718|FG001|Overall Study|Stem cell transplant|1
6374841|NCT01889186|10164717|FG000|Overall Study|Withdrew consent|2
6374842|NCT01889186|10164718|FG001|Overall Study|Withdrew consent|3
6374843|NCT01889186|10164717|FG000|Overall Study|Other, not specified|18
6374844|NCT01889186|10164718|FG001|Overall Study|Other, not specified|15
6374845|NCT01850004|10164726|FG000|Overall Study|Subject Moved|1
6374846|NCT01850004|10164726|FG000|Overall Study|Poor/Non-compliance|1
6374847|NCT01850004|10164726|FG000|Overall Study|Subject Withdrew Consent|4
6374848|NCT01850004|10164726|FG000|Overall Study|Subject Request to Discontinue Treatment|1
6374849|NCT01850004|10164726|FG000|Overall Study|AE Unrelated to Study Drug|1
6374850|NCT01757535|10164733|FG000|Overall Study|Disease Relapse|143
6374851|NCT01757535|10164734|FG001|Overall Study|Disease Relapse|180
6374852|NCT01757535|10164733|FG000|Overall Study|Adverse Event|29
6374853|NCT01757535|10164734|FG001|Overall Study|Adverse Event|11
6374854|NCT01757535|10164733|FG000|Overall Study|Withdrawal by Subject|9
6374855|NCT01757535|10164734|FG001|Overall Study|Withdrawal by Subject|13
6374856|NCT01757535|10164733|FG000|Overall Study|Miscellaneous|5
6374857|NCT01757535|10164734|FG001|Overall Study|Miscellaneous|2
6374858|NCT01757535|10164733|FG000|Overall Study|Physician Decision|6
6374859|NCT01757535|10164734|FG001|Overall Study|Physician Decision|0
6374860|NCT01757535|10164733|FG000|Overall Study|Death|1
6374861|NCT01757535|10164734|FG001|Overall Study|Death|2
6374862|NCT01510184|10164742|FG000|Overall Study|Sponsor discretion|28
6374863|NCT01510184|10164743|FG001|Overall Study|Sponsor discretion|28
6374864|NCT01510184|10164742|FG000|Overall Study|Death|1
6374865|NCT01510184|10164743|FG001|Overall Study|Death|2
6374866|NCT01510184|10164742|FG000|Overall Study|Withdrawal by Subject|1
6374867|NCT01510184|10164743|FG001|Overall Study|Withdrawal by Subject|4
6374868|NCT01510184|10164742|FG000|Overall Study|Other|0
6374869|NCT01510184|10164743|FG001|Overall Study|Other|1
6374870|NCT01471444|10164751|FG000|Overall Study|Physician Decision|3
6374871|NCT01471444|10164752|FG001|Overall Study|Physician Decision|2
6374872|NCT01471444|10164751|FG000|Overall Study|Withdrawal by Subject|0
6374873|NCT01471444|10164752|FG001|Overall Study|Withdrawal by Subject|1
6374874|NCT01238211|10164759|FG000|Overall Study|Continues active treatment|31
6374875|NCT01238211|10164759|FG000|Overall Study|Adverse Event|7
6374876|NCT01238211|10164759|FG000|Overall Study|Death|4
6374877|NCT01238211|10164759|FG000|Overall Study|Relapse/Progression|2
6374878|NCT01238211|10164759|FG000|Overall Study|Withdrawal by Subject|7
6374879|NCT01238211|10164759|FG000|Overall Study|Non-protocol treatment|4
6374880|NCT01238211|10164759|FG000|Overall Study|Investigator/Patient Decision|3
6084796|NCT00644969|9693780|FG001|Post Treatment Phase|Withdrawal by Subject|2
6084797|NCT00644969|9693779|FG000|Post Treatment Phase|Lost to Follow-up|4
6084798|NCT00644969|9693780|FG001|Post Treatment Phase|Lost to Follow-up|1
6084799|NCT00644969|9693779|FG000|Post Treatment Phase|Other|1
6084800|NCT00644969|9693780|FG001|Post Treatment Phase|Other|0
6084801|NCT00644995|9693788|FG000|Overall Study|Lost to Follow-up|1
6084802|NCT00644995|9693789|FG001|Overall Study|Lost to Follow-up|4
6084803|NCT00644995|9693788|FG000|Overall Study|Refused|1
6084804|NCT00644995|9693789|FG001|Overall Study|Refused|0
6084805|NCT00645099|9693808|FG000|Overall Study|Lack of Efficacy|15
6374881|NCT03745651|10164807|FG000|Vehicle Control Period (Day 1 to Week 8)|Adverse Event|1
6374882|NCT03745651|10164808|FG001|Vehicle Control Period (Day 1 to Week 8)|Adverse Event|1
6374883|NCT03745651|10164809|FG002|Vehicle Control Period (Day 1 to Week 8)|Adverse Event|0
6374884|NCT03745651|10164810|FG003|Vehicle Control Period (Day 1 to Week 8)|Adverse Event|0
6374885|NCT03745651|10164811|FG004|Vehicle Control Period (Day 1 to Week 8)|Adverse Event|0
6374886|NCT03745651|10164812|FG005|Vehicle Control Period (Day 1 to Week 8)|Adverse Event|0
6374887|NCT03745651|10164813|FG006|Vehicle Control Period (Day 1 to Week 8)|Adverse Event|0
6374888|NCT03745651|10164807|FG000|Vehicle Control Period (Day 1 to Week 8)|Lost to Follow-up|3
6374889|NCT03745651|10164808|FG001|Vehicle Control Period (Day 1 to Week 8)|Lost to Follow-up|13
6374890|NCT03745651|10164809|FG002|Vehicle Control Period (Day 1 to Week 8)|Lost to Follow-up|4
6374891|NCT03745651|10164810|FG003|Vehicle Control Period (Day 1 to Week 8)|Lost to Follow-up|0
6374892|NCT03745651|10164811|FG004|Vehicle Control Period (Day 1 to Week 8)|Lost to Follow-up|0
6374893|NCT03745651|10164812|FG005|Vehicle Control Period (Day 1 to Week 8)|Lost to Follow-up|0
6374894|NCT03745651|10164813|FG006|Vehicle Control Period (Day 1 to Week 8)|Lost to Follow-up|0
6374895|NCT03745651|10164807|FG000|Vehicle Control Period (Day 1 to Week 8)|Physician Decision|3
6374896|NCT03745651|10164808|FG001|Vehicle Control Period (Day 1 to Week 8)|Physician Decision|0
6374897|NCT03745651|10164809|FG002|Vehicle Control Period (Day 1 to Week 8)|Physician Decision|1
6374898|NCT03745651|10164810|FG003|Vehicle Control Period (Day 1 to Week 8)|Physician Decision|0
6374899|NCT03745651|10164811|FG004|Vehicle Control Period (Day 1 to Week 8)|Physician Decision|0
6374900|NCT03745651|10164812|FG005|Vehicle Control Period (Day 1 to Week 8)|Physician Decision|0
6374901|NCT03745651|10164813|FG006|Vehicle Control Period (Day 1 to Week 8)|Physician Decision|0
6374902|NCT03745651|10164807|FG000|Vehicle Control Period (Day 1 to Week 8)|Protocol Violation|0
6374903|NCT03745651|10164808|FG001|Vehicle Control Period (Day 1 to Week 8)|Protocol Violation|2
6374904|NCT03745651|10164809|FG002|Vehicle Control Period (Day 1 to Week 8)|Protocol Violation|0
6374905|NCT03745651|10164810|FG003|Vehicle Control Period (Day 1 to Week 8)|Protocol Violation|0
6374906|NCT03745651|10164811|FG004|Vehicle Control Period (Day 1 to Week 8)|Protocol Violation|0
6374907|NCT03745651|10164812|FG005|Vehicle Control Period (Day 1 to Week 8)|Protocol Violation|0
6374908|NCT03745651|10164813|FG006|Vehicle Control Period (Day 1 to Week 8)|Protocol Violation|0
6374909|NCT03745651|10164807|FG000|Vehicle Control Period (Day 1 to Week 8)|Withdrawal by Subject|11
6374910|NCT03745651|10164808|FG001|Vehicle Control Period (Day 1 to Week 8)|Withdrawal by Subject|21
6374911|NCT03745651|10164809|FG002|Vehicle Control Period (Day 1 to Week 8)|Withdrawal by Subject|15
6374912|NCT03745651|10164810|FG003|Vehicle Control Period (Day 1 to Week 8)|Withdrawal by Subject|0
6374913|NCT03745651|10164811|FG004|Vehicle Control Period (Day 1 to Week 8)|Withdrawal by Subject|0
6374914|NCT03745651|10164812|FG005|Vehicle Control Period (Day 1 to Week 8)|Withdrawal by Subject|0
6374915|NCT03745651|10164813|FG006|Vehicle Control Period (Day 1 to Week 8)|Withdrawal by Subject|0
6374916|NCT03745651|10164807|FG000|Vehicle Control Period (Day 1 to Week 8)|Reason not Specified|1
6374917|NCT03745651|10164808|FG001|Vehicle Control Period (Day 1 to Week 8)|Reason not Specified|2
6374918|NCT03745651|10164809|FG002|Vehicle Control Period (Day 1 to Week 8)|Reason not Specified|2
6374919|NCT03745651|10164810|FG003|Vehicle Control Period (Day 1 to Week 8)|Reason not Specified|0
6374920|NCT03745651|10164811|FG004|Vehicle Control Period (Day 1 to Week 8)|Reason not Specified|0
6374921|NCT03745651|10164812|FG005|Vehicle Control Period (Day 1 to Week 8)|Reason not Specified|0
6374922|NCT03745651|10164813|FG006|Vehicle Control Period (Day 1 to Week 8)|Reason not Specified|0
6374923|NCT03745651|10164807|FG000|Long-Term Safety Period (Weeks 8 to 52)|Adverse Event|0
6374924|NCT03745651|10164808|FG001|Long-Term Safety Period (Weeks 8 to 52)|Adverse Event|0
6374925|NCT03745651|10164809|FG002|Long-Term Safety Period (Weeks 8 to 52)|Adverse Event|0
6374926|NCT03745651|10164810|FG003|Long-Term Safety Period (Weeks 8 to 52)|Adverse Event|0
6374927|NCT03745651|10164811|FG004|Long-Term Safety Period (Weeks 8 to 52)|Adverse Event|0
6374928|NCT03745651|10164812|FG005|Long-Term Safety Period (Weeks 8 to 52)|Adverse Event|4
6374929|NCT03745651|10164813|FG006|Long-Term Safety Period (Weeks 8 to 52)|Adverse Event|0
6374930|NCT03745651|10164807|FG000|Long-Term Safety Period (Weeks 8 to 52)|Lack of Efficacy|0
6374931|NCT03745651|10164808|FG001|Long-Term Safety Period (Weeks 8 to 52)|Lack of Efficacy|0
6374932|NCT03745651|10164809|FG002|Long-Term Safety Period (Weeks 8 to 52)|Lack of Efficacy|0
6374933|NCT03745651|10164810|FG003|Long-Term Safety Period (Weeks 8 to 52)|Lack of Efficacy|1
6374934|NCT03745651|10164811|FG004|Long-Term Safety Period (Weeks 8 to 52)|Lack of Efficacy|0
6374935|NCT03745651|10164812|FG005|Long-Term Safety Period (Weeks 8 to 52)|Lack of Efficacy|4
6374936|NCT03745651|10164813|FG006|Long-Term Safety Period (Weeks 8 to 52)|Lack of Efficacy|4
6374937|NCT03745651|10164807|FG000|Long-Term Safety Period (Weeks 8 to 52)|Lost to Follow-up|0
6374938|NCT03745651|10164808|FG001|Long-Term Safety Period (Weeks 8 to 52)|Lost to Follow-up|0
6374939|NCT03745651|10164809|FG002|Long-Term Safety Period (Weeks 8 to 52)|Lost to Follow-up|0
6374940|NCT03745651|10164810|FG003|Long-Term Safety Period (Weeks 8 to 52)|Lost to Follow-up|4
6374941|NCT03745651|10164811|FG004|Long-Term Safety Period (Weeks 8 to 52)|Lost to Follow-up|2
6374942|NCT03745651|10164812|FG005|Long-Term Safety Period (Weeks 8 to 52)|Lost to Follow-up|13
6374943|NCT03745651|10164813|FG006|Long-Term Safety Period (Weeks 8 to 52)|Lost to Follow-up|10
6374944|NCT03745651|10164807|FG000|Long-Term Safety Period (Weeks 8 to 52)|Physician Decision|0
6374945|NCT03745651|10164808|FG001|Long-Term Safety Period (Weeks 8 to 52)|Physician Decision|0
6374946|NCT03745651|10164809|FG002|Long-Term Safety Period (Weeks 8 to 52)|Physician Decision|0
6374947|NCT03745651|10164810|FG003|Long-Term Safety Period (Weeks 8 to 52)|Physician Decision|1
6374948|NCT03745651|10164811|FG004|Long-Term Safety Period (Weeks 8 to 52)|Physician Decision|0
6374949|NCT03745651|10164812|FG005|Long-Term Safety Period (Weeks 8 to 52)|Physician Decision|4
6374950|NCT03745651|10164813|FG006|Long-Term Safety Period (Weeks 8 to 52)|Physician Decision|2
6374951|NCT03745651|10164807|FG000|Long-Term Safety Period (Weeks 8 to 52)|Pregnancy|0
6374952|NCT03745651|10164808|FG001|Long-Term Safety Period (Weeks 8 to 52)|Pregnancy|0
6374953|NCT03745651|10164809|FG002|Long-Term Safety Period (Weeks 8 to 52)|Pregnancy|0
6374954|NCT03745651|10164810|FG003|Long-Term Safety Period (Weeks 8 to 52)|Pregnancy|1
6374955|NCT03745651|10164811|FG004|Long-Term Safety Period (Weeks 8 to 52)|Pregnancy|0
6374956|NCT03745651|10164812|FG005|Long-Term Safety Period (Weeks 8 to 52)|Pregnancy|0
6374957|NCT03745651|10164813|FG006|Long-Term Safety Period (Weeks 8 to 52)|Pregnancy|1
6374958|NCT03745651|10164807|FG000|Long-Term Safety Period (Weeks 8 to 52)|Protocol Violation|0
6374959|NCT03745651|10164808|FG001|Long-Term Safety Period (Weeks 8 to 52)|Protocol Violation|0
6374960|NCT03745651|10164809|FG002|Long-Term Safety Period (Weeks 8 to 52)|Protocol Violation|0
6374961|NCT03745651|10164810|FG003|Long-Term Safety Period (Weeks 8 to 52)|Protocol Violation|0
6374962|NCT03745651|10164811|FG004|Long-Term Safety Period (Weeks 8 to 52)|Protocol Violation|0
6374963|NCT03745651|10164812|FG005|Long-Term Safety Period (Weeks 8 to 52)|Protocol Violation|1
6374964|NCT03745651|10164813|FG006|Long-Term Safety Period (Weeks 8 to 52)|Protocol Violation|0
6374965|NCT03745651|10164807|FG000|Long-Term Safety Period (Weeks 8 to 52)|Withdrawal by Subject|0
6374966|NCT03745651|10164808|FG001|Long-Term Safety Period (Weeks 8 to 52)|Withdrawal by Subject|0
6374967|NCT03745651|10164809|FG002|Long-Term Safety Period (Weeks 8 to 52)|Withdrawal by Subject|0
6374968|NCT03745651|10164810|FG003|Long-Term Safety Period (Weeks 8 to 52)|Withdrawal by Subject|12
6374969|NCT03745651|10164811|FG004|Long-Term Safety Period (Weeks 8 to 52)|Withdrawal by Subject|8
6374970|NCT03745651|10164812|FG005|Long-Term Safety Period (Weeks 8 to 52)|Withdrawal by Subject|26
6374971|NCT03745651|10164813|FG006|Long-Term Safety Period (Weeks 8 to 52)|Withdrawal by Subject|34
6374972|NCT03745651|10164807|FG000|Long-Term Safety Period (Weeks 8 to 52)|Reason not Specified|0
6374973|NCT03745651|10164808|FG001|Long-Term Safety Period (Weeks 8 to 52)|Reason not Specified|0
6374974|NCT03745651|10164809|FG002|Long-Term Safety Period (Weeks 8 to 52)|Reason not Specified|0
6374975|NCT03745651|10164810|FG003|Long-Term Safety Period (Weeks 8 to 52)|Reason not Specified|1
6374976|NCT03745651|10164811|FG004|Long-Term Safety Period (Weeks 8 to 52)|Reason not Specified|1
6374977|NCT03745651|10164812|FG005|Long-Term Safety Period (Weeks 8 to 52)|Reason not Specified|1
6084806|NCT00645099|9693809|FG001|Overall Study|Lack of Efficacy|6
6084807|NCT00645099|9693808|FG000|Overall Study|Withdrawal by Subject|30
6084808|NCT00645099|9693809|FG001|Overall Study|Withdrawal by Subject|22
6084809|NCT00645099|9693808|FG000|Overall Study|Lost to Follow-up|6
6084810|NCT00645099|9693809|FG001|Overall Study|Lost to Follow-up|4
6084811|NCT00645099|9693808|FG000|Overall Study|Adverse Event|11
6084812|NCT00645099|9693809|FG001|Overall Study|Adverse Event|5
6084813|NCT00645099|9693808|FG000|Overall Study|Other|9
6084814|NCT00645099|9693809|FG001|Overall Study|Other|5
6084815|NCT00645164|9693815|FG000|Overall Study|Lost to Follow-up|2
6084816|NCT00645164|9693815|FG000|Overall Study|Withdrawal by Subject|4
6084817|NCT00645164|9693815|FG000|Overall Study|Protocol Violation|1
6084818|NCT00645411|9693827|FG000|Overall Study|Adverse Event|0
6084819|NCT00645411|9693828|FG001|Overall Study|Adverse Event|0
6084820|NCT00645411|9693829|FG002|Overall Study|Adverse Event|0
6084821|NCT00645411|9693830|FG003|Overall Study|Adverse Event|2
6084822|NCT00645411|9693827|FG000|Overall Study|Withdrawal by Subject|2
6084823|NCT00645411|9693828|FG001|Overall Study|Withdrawal by Subject|1
6084824|NCT00645411|9693829|FG002|Overall Study|Withdrawal by Subject|19
6084825|NCT00645411|9693830|FG003|Overall Study|Withdrawal by Subject|21
6043332|NCT00388674|9641857|FG000|End of Study|Participant Withdrew Consent|437
6043333|NCT00388674|9641858|FG001|End of Study|Participant Withdrew Consent|673
6043334|NCT00388674|9641857|FG000|End of Study|No Off-Treatment Status Data|22
6043335|NCT00388674|9641858|FG001|End of Study|No Off-Treatment Status Data|30
6043336|NCT00388674|9641857|FG000|End of Study|Not Reported|0
6043337|NCT00388674|9641858|FG001|End of Study|Not Reported|1
6043338|NCT00388726|9641866|FG000|Overall Study|Adverse Event|50
6043339|NCT00388726|9641867|FG001|Overall Study|Adverse Event|24
6043340|NCT00388726|9641866|FG000|Overall Study|Progressive Disease|336
6043341|NCT00388726|9641867|FG001|Overall Study|Progressive Disease|153
6043342|NCT00388726|9641866|FG000|Overall Study|Clinical Progression|61
6043343|NCT00388726|9641867|FG001|Overall Study|Clinical Progression|36
6043344|NCT00388726|9641866|FG000|Overall Study|Withdrawal by Subject|10
6043345|NCT00388726|9641867|FG001|Overall Study|Withdrawal by Subject|7
6043346|NCT00388726|9641866|FG000|Overall Study|Administrative|6
6043347|NCT00388726|9641867|FG001|Overall Study|Administrative|9
6043348|NCT00388726|9641866|FG000|Overall Study|Physician Decision|18
6043349|NCT00388726|9641867|FG001|Overall Study|Physician Decision|13
6043350|NCT00388726|9641866|FG000|Overall Study|Death|3
6043351|NCT00388726|9641867|FG001|Overall Study|Death|2
6043352|NCT00388947|9641882|FG000|Overall Study|Protocol Violation|47
6043353|NCT00388973|9641888|FG000|Overall Study|Adverse Event|16
6043354|NCT00388973|9641889|FG001|Overall Study|Adverse Event|6
6043355|NCT00388973|9641888|FG000|Overall Study|Lack of Efficacy|1
6043356|NCT00388973|9641889|FG001|Overall Study|Lack of Efficacy|12
6043357|NCT00388973|9641888|FG000|Overall Study|Protocol Violation|3
6043358|NCT00388973|9641889|FG001|Overall Study|Protocol Violation|0
6043359|NCT00388973|9641888|FG000|Overall Study|Withdrawal by Subject|14
6043360|NCT00388973|9641889|FG001|Overall Study|Withdrawal by Subject|17
6043361|NCT00388973|9641888|FG000|Overall Study|Study specific Discontinuation Criteria|0
6084826|NCT00645411|9693827|FG000|Overall Study|Lost to Follow-up|10
6084827|NCT00645411|9693828|FG001|Overall Study|Lost to Follow-up|5
6084828|NCT00645411|9693829|FG002|Overall Study|Lost to Follow-up|124
6084829|NCT00645411|9693830|FG003|Overall Study|Lost to Follow-up|75
6084830|NCT00645411|9693827|FG000|Overall Study|Protocol Violation|1
6084831|NCT00645411|9693828|FG001|Overall Study|Protocol Violation|0
6084832|NCT00645411|9693829|FG002|Overall Study|Protocol Violation|1
6084833|NCT00645411|9693830|FG003|Overall Study|Protocol Violation|0
6084834|NCT00645411|9693827|FG000|Overall Study|Inappropriate enrollment|0
6084835|NCT00645411|9693828|FG001|Overall Study|Inappropriate enrollment|0
5972133|NCT04498247|9557788|FG004|Overall Study|Lost to Follow-up|0
5972134|NCT04498247|9557789|FG005|Overall Study|Lost to Follow-up|0
5972135|NCT04498247|9557790|FG006|Overall Study|Lost to Follow-up|0
5972136|NCT04498247|9557791|FG007|Overall Study|Lost to Follow-up|0
5972137|NCT04498247|9557784|FG000|Overall Study|Mistakenly Randomized; Not Treated|1
5972138|NCT04498247|9557785|FG001|Overall Study|Mistakenly Randomized; Not Treated|0
5972139|NCT04498247|9557786|FG002|Overall Study|Mistakenly Randomized; Not Treated|0
5972140|NCT04498247|9557787|FG003|Overall Study|Mistakenly Randomized; Not Treated|0
5972141|NCT04498247|9557788|FG004|Overall Study|Mistakenly Randomized; Not Treated|0
5972142|NCT04498247|9557789|FG005|Overall Study|Mistakenly Randomized; Not Treated|0
5972143|NCT04498247|9557790|FG006|Overall Study|Mistakenly Randomized; Not Treated|0
5972144|NCT04498247|9557791|FG007|Overall Study|Mistakenly Randomized; Not Treated|0
5972145|NCT04498247|9557784|FG000|Overall Study|Withdrawal by Subject|0
5972146|NCT04498247|9557785|FG001|Overall Study|Withdrawal by Subject|8
5972147|NCT04498247|9557786|FG002|Overall Study|Withdrawal by Subject|0
5972148|NCT04498247|9557787|FG003|Overall Study|Withdrawal by Subject|7
5972149|NCT04498247|9557788|FG004|Overall Study|Withdrawal by Subject|0
5972150|NCT04498247|9557789|FG005|Overall Study|Withdrawal by Subject|0
5972151|NCT04498247|9557790|FG006|Overall Study|Withdrawal by Subject|1
5972152|NCT04498247|9557791|FG007|Overall Study|Withdrawal by Subject|0
5972153|NCT04498247|9557784|FG000|Overall Study|Received a non-study COVID-19 vaccine.|0
5972154|NCT04498247|9557785|FG001|Overall Study|Received a non-study COVID-19 vaccine.|4
5972155|NCT04498247|9557786|FG002|Overall Study|Received a non-study COVID-19 vaccine.|0
6043362|NCT00388973|9641889|FG001|Overall Study|Study specific Discontinuation Criteria|1
6043363|NCT00388973|9641888|FG000|Overall Study|Did not complete 61 days of treatment|5
6043364|NCT00388973|9641889|FG001|Overall Study|Did not complete 61 days of treatment|4
6043365|NCT00388973|9641888|FG000|Overall Study|Left region|0
6084836|NCT00645411|9693829|FG002|Overall Study|Inappropriate enrollment|4
6084837|NCT00645411|9693830|FG003|Overall Study|Inappropriate enrollment|1
6084838|NCT00645411|9693827|FG000|Overall Study|Unable to classify|0
6084839|NCT00645411|9693828|FG001|Overall Study|Unable to classify|0
6084840|NCT00645411|9693829|FG002|Overall Study|Unable to classify|3
6084841|NCT00645411|9693830|FG003|Overall Study|Unable to classify|4
6084842|NCT00645528|9693856|FG000|Overall Study|Did not show up for Visit 2|7
6084843|NCT00645593|9693862|FG000|Overall Study|Later found to be ineligible|1
6084844|NCT00645593|9693863|FG001|Overall Study|Later found to be ineligible|0
6084845|NCT00645671|9693871|FG000|Overall Study|Protocol Violation|1
6043366|NCT00388973|9641889|FG001|Overall Study|Left region|1
6043367|NCT00388973|9641888|FG000|Overall Study|Did not complete 2-week follow-up visit|17
6171931|NCT01262872|9818868|FG007|Step 2|Death|1
6171932|NCT01262872|9818861|FG000|Step 2|Protocol Violation|0
6171933|NCT01262872|9818862|FG001|Step 2|Protocol Violation|0
6043368|NCT00388973|9641889|FG001|Overall Study|Did not complete 2-week follow-up visit|17
6084846|NCT00645671|9693872|FG001|Overall Study|Protocol Violation|0
6084847|NCT00645671|9693871|FG000|Overall Study|Withdrawal by Subject|0
6084848|NCT00645671|9693872|FG001|Overall Study|Withdrawal by Subject|4
6171934|NCT01262872|9818863|FG002|Step 2|Protocol Violation|1
6171935|NCT01262872|9818864|FG003|Step 2|Protocol Violation|0
6043369|NCT00389064|9641897|FG000|Overall Study|Adverse Event|11
6043370|NCT00389064|9641898|FG001|Overall Study|Adverse Event|3
6084849|NCT00645671|9693871|FG000|Overall Study|Adverse Event|0
6084850|NCT00645671|9693872|FG001|Overall Study|Adverse Event|1
6084851|NCT00645671|9693871|FG000|Overall Study|Physician Decision|0
6171936|NCT01262872|9818865|FG004|Step 2|Protocol Violation|0
6171937|NCT01262872|9818866|FG005|Step 2|Protocol Violation|0
6084852|NCT00645671|9693872|FG001|Overall Study|Physician Decision|1
6084853|NCT00645788|9693902|FG000|Overall Study|Did not receive study drug|1
6084854|NCT00645788|9693903|FG001|Overall Study|Did not receive study drug|1
6084855|NCT00645788|9693904|FG002|Overall Study|Did not receive study drug|0
6084856|NCT00645788|9693905|FG003|Overall Study|Did not receive study drug|0
6084857|NCT00645788|9693902|FG000|Overall Study|Adverse Event|4
6084858|NCT00645788|9693903|FG001|Overall Study|Adverse Event|9
6084859|NCT00645788|9693904|FG002|Overall Study|Adverse Event|5
6084860|NCT00645788|9693905|FG003|Overall Study|Adverse Event|3
6084861|NCT00645788|9693902|FG000|Overall Study|Lost to Follow-up|1
6084862|NCT00645788|9693903|FG001|Overall Study|Lost to Follow-up|0
6084863|NCT00645788|9693904|FG002|Overall Study|Lost to Follow-up|0
6084864|NCT00645788|9693905|FG003|Overall Study|Lost to Follow-up|0
6084865|NCT00645788|9693902|FG000|Overall Study|Protocol Violation|1
6084866|NCT00645788|9693903|FG001|Overall Study|Protocol Violation|0
6084867|NCT00645788|9693904|FG002|Overall Study|Protocol Violation|2
6084868|NCT00645788|9693905|FG003|Overall Study|Protocol Violation|0
6084869|NCT00645788|9693902|FG000|Overall Study|Withdrawal by Subject|0
6084870|NCT00645788|9693903|FG001|Overall Study|Withdrawal by Subject|1
6084871|NCT00645788|9693904|FG002|Overall Study|Withdrawal by Subject|0
6084872|NCT00645788|9693905|FG003|Overall Study|Withdrawal by Subject|2
6171938|NCT01262872|9818867|FG006|Step 2|Protocol Violation|3
6171939|NCT01262872|9818868|FG007|Step 2|Protocol Violation|1
6171940|NCT01262872|9818861|FG000|Step 2|Withdrawal by Subject|0
6171941|NCT01262872|9818862|FG001|Step 2|Withdrawal by Subject|0
6171942|NCT01262872|9818863|FG002|Step 2|Withdrawal by Subject|4
6171943|NCT01262872|9818864|FG003|Step 2|Withdrawal by Subject|6
6171944|NCT01262872|9818865|FG004|Step 2|Withdrawal by Subject|3
6171945|NCT01262872|9818866|FG005|Step 2|Withdrawal by Subject|1
6171946|NCT01262872|9818867|FG006|Step 2|Withdrawal by Subject|2
6171947|NCT01262872|9818868|FG007|Step 2|Withdrawal by Subject|1
6171948|NCT01262872|9818861|FG000|Step 2|Migrated/moved from study area|0
6171949|NCT01262872|9818862|FG001|Step 2|Migrated/moved from study area|0
6171950|NCT01262872|9818863|FG002|Step 2|Migrated/moved from study area|4
6171951|NCT01262872|9818864|FG003|Step 2|Migrated/moved from study area|3
6084873|NCT00645788|9693902|FG000|Overall Study|Pulmonary exacerbation|13
6084874|NCT00645788|9693903|FG001|Overall Study|Pulmonary exacerbation|16
6084875|NCT00645788|9693904|FG002|Overall Study|Pulmonary exacerbation|11
6084876|NCT00645788|9693905|FG003|Overall Study|Pulmonary exacerbation|9
6084877|NCT00645840|9693924|FG000|Overall Study|Protocol Violation|3
6084878|NCT00645853|9693930|FG000|Overall Study|Adverse Event|18
6084879|NCT00645853|9693931|FG001|Overall Study|Adverse Event|7
6171952|NCT01262872|9818865|FG004|Step 2|Migrated/moved from study area|2
6171953|NCT01262872|9818866|FG005|Step 2|Migrated/moved from study area|6
6171954|NCT01262872|9818867|FG006|Step 2|Migrated/moved from study area|2
6171955|NCT01262872|9818868|FG007|Step 2|Migrated/moved from study area|3
6171956|NCT01262898|9818906|FG000|Overall Study|Protocol Violation|1
6171957|NCT01262898|9818907|FG001|Overall Study|Protocol Violation|1
6171958|NCT01262898|9818908|FG002|Overall Study|Protocol Violation|0
6171959|NCT01262898|9818909|FG003|Overall Study|Protocol Violation|0
6171960|NCT01262898|9818906|FG000|Overall Study|Lost to Follow-up|1
6171961|NCT01262898|9818907|FG001|Overall Study|Lost to Follow-up|0
6171962|NCT01262898|9818908|FG002|Overall Study|Lost to Follow-up|0
6171963|NCT01262898|9818909|FG003|Overall Study|Lost to Follow-up|0
6171964|NCT01262898|9818906|FG000|Overall Study|Withdrawal by Subject|1
6171965|NCT01262898|9818907|FG001|Overall Study|Withdrawal by Subject|1
6171966|NCT01262898|9818908|FG002|Overall Study|Withdrawal by Subject|0
6171967|NCT01262898|9818909|FG003|Overall Study|Withdrawal by Subject|0
6171968|NCT01262976|9818928|FG000|Up to Month 2|Serious Adverse Event|0
6171969|NCT01262976|9818929|FG001|Up to Month 2|Serious Adverse Event|0
6171970|NCT01262976|9818930|FG002|Up to Month 2|Serious Adverse Event|1
6171971|NCT01262976|9818931|FG003|Up to Month 2|Serious Adverse Event|0
6084880|NCT00645853|9693930|FG000|Overall Study|AZ study closure in Hungary|60
6171972|NCT01262976|9818932|FG004|Up to Month 2|Serious Adverse Event|0
6171973|NCT01262976|9818933|FG005|Up to Month 2|Serious Adverse Event|0
6227484|NCT01717326|9900201|FG013|Overall Study|Lost to Follow-up|0
6084881|NCT00645853|9693931|FG001|Overall Study|AZ study closure in Hungary|40
6084882|NCT00645853|9693930|FG000|Overall Study|Withdrawal by Subject|5
6084883|NCT00645853|9693931|FG001|Overall Study|Withdrawal by Subject|2
6084884|NCT00645853|9693930|FG000|Overall Study|Protocol Violation|0
6084885|NCT00645853|9693931|FG001|Overall Study|Protocol Violation|2
6084886|NCT00645853|9693930|FG000|Overall Study|Discontinuation criteria|2
6084887|NCT00645853|9693931|FG001|Overall Study|Discontinuation criteria|2
6171974|NCT01262976|9818928|FG000|Up to Month 2|Withdrawal by Subject|1
6171975|NCT01262976|9818929|FG001|Up to Month 2|Withdrawal by Subject|0
6171976|NCT01262976|9818930|FG002|Up to Month 2|Withdrawal by Subject|0
6171977|NCT01262976|9818931|FG003|Up to Month 2|Withdrawal by Subject|0
6171978|NCT01262976|9818932|FG004|Up to Month 2|Withdrawal by Subject|0
6171979|NCT01262976|9818933|FG005|Up to Month 2|Withdrawal by Subject|0
6171980|NCT01262976|9818928|FG000|Up to Month 2|Migrated/moved from study area|0
6171981|NCT01262976|9818929|FG001|Up to Month 2|Migrated/moved from study area|1
6171982|NCT01262976|9818930|FG002|Up to Month 2|Migrated/moved from study area|0
6171983|NCT01262976|9818931|FG003|Up to Month 2|Migrated/moved from study area|0
6171984|NCT01262976|9818932|FG004|Up to Month 2|Migrated/moved from study area|1
6171985|NCT01262976|9818933|FG005|Up to Month 2|Migrated/moved from study area|1
6171986|NCT01262976|9818928|FG000|Up to Month 2|Lost to Follow-up|1
6171987|NCT01262976|9818929|FG001|Up to Month 2|Lost to Follow-up|0
6171988|NCT01262976|9818930|FG002|Up to Month 2|Lost to Follow-up|0
6171989|NCT01262976|9818931|FG003|Up to Month 2|Lost to Follow-up|1
6171990|NCT01262976|9818932|FG004|Up to Month 2|Lost to Follow-up|1
6171991|NCT01262976|9818933|FG005|Up to Month 2|Lost to Follow-up|1
6171992|NCT01262976|9818928|FG000|Up to Month 2|Other|1
6171993|NCT01262976|9818929|FG001|Up to Month 2|Other|0
6171994|NCT01262976|9818930|FG002|Up to Month 2|Other|0
6171995|NCT01262976|9818931|FG003|Up to Month 2|Other|1
6171996|NCT01262976|9818932|FG004|Up to Month 2|Other|0
6171997|NCT01262976|9818933|FG005|Up to Month 2|Other|2
6171998|NCT01262976|9818928|FG000|Up to Month 7|Serious Adverse Event|0
6171999|NCT01262976|9818929|FG001|Up to Month 7|Serious Adverse Event|0
6172000|NCT01262976|9818930|FG002|Up to Month 7|Serious Adverse Event|2
6172001|NCT01262976|9818931|FG003|Up to Month 7|Serious Adverse Event|0
6172002|NCT01262976|9818932|FG004|Up to Month 7|Serious Adverse Event|0
6172003|NCT01262976|9818933|FG005|Up to Month 7|Serious Adverse Event|0
6172004|NCT01262976|9818928|FG000|Up to Month 7|Withdrawal by Subject|1
6172005|NCT01262976|9818929|FG001|Up to Month 7|Withdrawal by Subject|0
6172006|NCT01262976|9818930|FG002|Up to Month 7|Withdrawal by Subject|0
6172007|NCT01262976|9818931|FG003|Up to Month 7|Withdrawal by Subject|0
6172008|NCT01262976|9818932|FG004|Up to Month 7|Withdrawal by Subject|0
6172009|NCT01262976|9818933|FG005|Up to Month 7|Withdrawal by Subject|0
6172010|NCT01262976|9818928|FG000|Up to Month 7|Migrated/moved from study area|0
6172011|NCT01262976|9818929|FG001|Up to Month 7|Migrated/moved from study area|0
6172012|NCT01262976|9818930|FG002|Up to Month 7|Migrated/moved from study area|1
6374978|NCT03745651|10164813|FG006|Long-Term Safety Period (Weeks 8 to 52)|Reason not Specified|0
6374979|NCT03745638|10164832|FG000|Vehicle Control Period (Day 1 to Week 8)|Adverse Event|4
6374980|NCT03745638|10164833|FG001|Vehicle Control Period (Day 1 to Week 8)|Adverse Event|2
6374981|NCT03745638|10164834|FG002|Vehicle Control Period (Day 1 to Week 8)|Adverse Event|1
6374982|NCT03745638|10164835|FG003|Vehicle Control Period (Day 1 to Week 8)|Adverse Event|0
6374983|NCT03745638|10164836|FG004|Vehicle Control Period (Day 1 to Week 8)|Adverse Event|0
6374984|NCT03745638|10164837|FG005|Vehicle Control Period (Day 1 to Week 8)|Adverse Event|0
6374985|NCT03745638|10164838|FG006|Vehicle Control Period (Day 1 to Week 8)|Adverse Event|0
6374986|NCT03745638|10164832|FG000|Vehicle Control Period (Day 1 to Week 8)|Lack of Efficacy|1
6374987|NCT03745638|10164833|FG001|Vehicle Control Period (Day 1 to Week 8)|Lack of Efficacy|0
6374988|NCT03745638|10164834|FG002|Vehicle Control Period (Day 1 to Week 8)|Lack of Efficacy|0
6374989|NCT03745638|10164835|FG003|Vehicle Control Period (Day 1 to Week 8)|Lack of Efficacy|0
6374990|NCT03745638|10164836|FG004|Vehicle Control Period (Day 1 to Week 8)|Lack of Efficacy|0
6374991|NCT03745638|10164837|FG005|Vehicle Control Period (Day 1 to Week 8)|Lack of Efficacy|0
6374992|NCT03745638|10164838|FG006|Vehicle Control Period (Day 1 to Week 8)|Lack of Efficacy|0
6374993|NCT03745638|10164832|FG000|Vehicle Control Period (Day 1 to Week 8)|Lost to Follow-up|5
6374994|NCT03745638|10164833|FG001|Vehicle Control Period (Day 1 to Week 8)|Lost to Follow-up|12
6374995|NCT03745638|10164834|FG002|Vehicle Control Period (Day 1 to Week 8)|Lost to Follow-up|8
6374996|NCT03745638|10164835|FG003|Vehicle Control Period (Day 1 to Week 8)|Lost to Follow-up|0
6374997|NCT03745638|10164836|FG004|Vehicle Control Period (Day 1 to Week 8)|Lost to Follow-up|0
6374998|NCT03745638|10164837|FG005|Vehicle Control Period (Day 1 to Week 8)|Lost to Follow-up|0
6374999|NCT03745638|10164838|FG006|Vehicle Control Period (Day 1 to Week 8)|Lost to Follow-up|0
6375000|NCT03745638|10164832|FG000|Vehicle Control Period (Day 1 to Week 8)|Physician Decision|1
6375001|NCT03745638|10164833|FG001|Vehicle Control Period (Day 1 to Week 8)|Physician Decision|1
6375002|NCT03745638|10164834|FG002|Vehicle Control Period (Day 1 to Week 8)|Physician Decision|0
6375003|NCT03745638|10164835|FG003|Vehicle Control Period (Day 1 to Week 8)|Physician Decision|0
6375004|NCT03745638|10164836|FG004|Vehicle Control Period (Day 1 to Week 8)|Physician Decision|0
6375005|NCT03745638|10164837|FG005|Vehicle Control Period (Day 1 to Week 8)|Physician Decision|0
6375006|NCT03745638|10164838|FG006|Vehicle Control Period (Day 1 to Week 8)|Physician Decision|0
6375007|NCT03745638|10164832|FG000|Vehicle Control Period (Day 1 to Week 8)|Pregnancy|1
6375008|NCT03745638|10164833|FG001|Vehicle Control Period (Day 1 to Week 8)|Pregnancy|0
6375009|NCT03745638|10164834|FG002|Vehicle Control Period (Day 1 to Week 8)|Pregnancy|0
6375010|NCT03745638|10164835|FG003|Vehicle Control Period (Day 1 to Week 8)|Pregnancy|0
6375011|NCT03745638|10164836|FG004|Vehicle Control Period (Day 1 to Week 8)|Pregnancy|0
6375012|NCT03745638|10164837|FG005|Vehicle Control Period (Day 1 to Week 8)|Pregnancy|0
6375013|NCT03745638|10164838|FG006|Vehicle Control Period (Day 1 to Week 8)|Pregnancy|0
6375014|NCT03745638|10164832|FG000|Vehicle Control Period (Day 1 to Week 8)|Protocol Violation|0
6375015|NCT03745638|10164833|FG001|Vehicle Control Period (Day 1 to Week 8)|Protocol Violation|3
6375016|NCT03745638|10164834|FG002|Vehicle Control Period (Day 1 to Week 8)|Protocol Violation|0
6172013|NCT01262976|9818931|FG003|Up to Month 7|Migrated/moved from study area|3
6172014|NCT01262976|9818932|FG004|Up to Month 7|Migrated/moved from study area|1
6172015|NCT01262976|9818933|FG005|Up to Month 7|Migrated/moved from study area|1
6172016|NCT01262976|9818928|FG000|Up to Month 7|Lost to Follow-up|1
6172017|NCT01262976|9818929|FG001|Up to Month 7|Lost to Follow-up|0
6172018|NCT01262976|9818930|FG002|Up to Month 7|Lost to Follow-up|1
6172019|NCT01262976|9818931|FG003|Up to Month 7|Lost to Follow-up|3
6172020|NCT01262976|9818932|FG004|Up to Month 7|Lost to Follow-up|1
6172021|NCT01262976|9818933|FG005|Up to Month 7|Lost to Follow-up|3
6172022|NCT01262976|9818928|FG000|Up to Month 7|Other|3
6172023|NCT01262976|9818929|FG001|Up to Month 7|Other|0
6172024|NCT01262976|9818930|FG002|Up to Month 7|Other|2
6172025|NCT01262976|9818931|FG003|Up to Month 7|Other|0
6172026|NCT01262976|9818932|FG004|Up to Month 7|Other|0
6172027|NCT01262976|9818933|FG005|Up to Month 7|Other|0
6172028|NCT01262976|9818928|FG000|Up to Year 1|Serious Adverse Event|0
6172029|NCT01262976|9818929|FG001|Up to Year 1|Serious Adverse Event|0
6172030|NCT01262976|9818930|FG002|Up to Year 1|Serious Adverse Event|2
6172031|NCT01262976|9818931|FG003|Up to Year 1|Serious Adverse Event|0
6172032|NCT01262976|9818932|FG004|Up to Year 1|Serious Adverse Event|0
6172033|NCT01262976|9818933|FG005|Up to Year 1|Serious Adverse Event|0
6172034|NCT01262976|9818928|FG000|Up to Year 1|Withdrawal by Subject|1
6172035|NCT01262976|9818929|FG001|Up to Year 1|Withdrawal by Subject|0
6172036|NCT01262976|9818930|FG002|Up to Year 1|Withdrawal by Subject|0
6172037|NCT01262976|9818931|FG003|Up to Year 1|Withdrawal by Subject|0
6172038|NCT01262976|9818932|FG004|Up to Year 1|Withdrawal by Subject|0
6172039|NCT01262976|9818933|FG005|Up to Year 1|Withdrawal by Subject|0
6172040|NCT01262976|9818928|FG000|Up to Year 1|Migrated/moved from study area|1
6172041|NCT01262976|9818929|FG001|Up to Year 1|Migrated/moved from study area|0
6172042|NCT01262976|9818930|FG002|Up to Year 1|Migrated/moved from study area|0
6172043|NCT01262976|9818931|FG003|Up to Year 1|Migrated/moved from study area|3
6172044|NCT01262976|9818932|FG004|Up to Year 1|Migrated/moved from study area|3
6172045|NCT01262976|9818933|FG005|Up to Year 1|Migrated/moved from study area|2
6172046|NCT01262976|9818928|FG000|Up to Year 1|Lost to Follow-up|4
6172047|NCT01262976|9818929|FG001|Up to Year 1|Lost to Follow-up|0
6172048|NCT01262976|9818930|FG002|Up to Year 1|Lost to Follow-up|0
6172049|NCT01262976|9818931|FG003|Up to Year 1|Lost to Follow-up|1
6172050|NCT01262976|9818932|FG004|Up to Year 1|Lost to Follow-up|6
6172051|NCT01262976|9818933|FG005|Up to Year 1|Lost to Follow-up|5
6172052|NCT01262976|9818928|FG000|Up to Year 1|Other|3
6172053|NCT01262976|9818929|FG001|Up to Year 1|Other|1
6172054|NCT01262976|9818930|FG002|Up to Year 1|Other|0
6172055|NCT01262976|9818931|FG003|Up to Year 1|Other|0
6172056|NCT01262976|9818932|FG004|Up to Year 1|Other|2
6172057|NCT01262976|9818933|FG005|Up to Year 1|Other|1
6172058|NCT01262976|9818928|FG000|Up to Year 1|Subjects with unknown completion status|0
6172059|NCT01262976|9818929|FG001|Up to Year 1|Subjects with unknown completion status|0
6172060|NCT01262976|9818930|FG002|Up to Year 1|Subjects with unknown completion status|1
6172061|NCT01262976|9818931|FG003|Up to Year 1|Subjects with unknown completion status|0
6172062|NCT01262976|9818932|FG004|Up to Year 1|Subjects with unknown completion status|0
6172063|NCT01262976|9818933|FG005|Up to Year 1|Subjects with unknown completion status|1
6172064|NCT01262976|9818928|FG000|Up to Year 2|Serious Adverse Event|0
6172065|NCT01262976|9818929|FG001|Up to Year 2|Serious Adverse Event|0
6172066|NCT01262976|9818930|FG002|Up to Year 2|Serious Adverse Event|2
6172067|NCT01262976|9818931|FG003|Up to Year 2|Serious Adverse Event|0
6172068|NCT01262976|9818932|FG004|Up to Year 2|Serious Adverse Event|0
6172069|NCT01262976|9818933|FG005|Up to Year 2|Serious Adverse Event|0
6172070|NCT01262976|9818928|FG000|Up to Year 2|Withdrawal by Subject|1
6172071|NCT01262976|9818929|FG001|Up to Year 2|Withdrawal by Subject|0
6172072|NCT01262976|9818930|FG002|Up to Year 2|Withdrawal by Subject|0
6172073|NCT01262976|9818931|FG003|Up to Year 2|Withdrawal by Subject|0
6172074|NCT01262976|9818932|FG004|Up to Year 2|Withdrawal by Subject|0
6172075|NCT01262976|9818933|FG005|Up to Year 2|Withdrawal by Subject|0
6172076|NCT01262976|9818928|FG000|Up to Year 2|Migrated/moved from study area|0
6172077|NCT01262976|9818929|FG001|Up to Year 2|Migrated/moved from study area|0
6172078|NCT01262976|9818930|FG002|Up to Year 2|Migrated/moved from study area|0
6172079|NCT01262976|9818931|FG003|Up to Year 2|Migrated/moved from study area|2
6172080|NCT01262976|9818932|FG004|Up to Year 2|Migrated/moved from study area|1
6172081|NCT01262976|9818933|FG005|Up to Year 2|Migrated/moved from study area|2
6172082|NCT01262976|9818928|FG000|Up to Year 2|Lost to Follow-up|1
6172083|NCT01262976|9818929|FG001|Up to Year 2|Lost to Follow-up|1
6172084|NCT01262976|9818930|FG002|Up to Year 2|Lost to Follow-up|2
6084888|NCT00645853|9693930|FG000|Overall Study|recall of ICF, planned operation, death|7
6084889|NCT00645853|9693931|FG001|Overall Study|recall of ICF, planned operation, death|4
6172085|NCT01262976|9818931|FG003|Up to Year 2|Lost to Follow-up|2
6172086|NCT01262976|9818932|FG004|Up to Year 2|Lost to Follow-up|3
6172087|NCT01262976|9818933|FG005|Up to Year 2|Lost to Follow-up|3
6172088|NCT01262976|9818928|FG000|Up to Year 2|Subjects with unknown completion status|0
6172089|NCT01262976|9818929|FG001|Up to Year 2|Subjects with unknown completion status|0
6172090|NCT01262976|9818930|FG002|Up to Year 2|Subjects with unknown completion status|1
6172091|NCT01262976|9818931|FG003|Up to Year 2|Subjects with unknown completion status|0
6172092|NCT01262976|9818932|FG004|Up to Year 2|Subjects with unknown completion status|0
6172093|NCT01262976|9818933|FG005|Up to Year 2|Subjects with unknown completion status|0
6172094|NCT01262976|9818928|FG000|Up to Year 2|Other|3
6172095|NCT01262976|9818929|FG001|Up to Year 2|Other|0
6172096|NCT01262976|9818930|FG002|Up to Year 2|Other|0
6172097|NCT01262976|9818931|FG003|Up to Year 2|Other|0
6172098|NCT01262976|9818932|FG004|Up to Year 2|Other|0
6172099|NCT01262976|9818933|FG005|Up to Year 2|Other|0
6172100|NCT01262976|9818928|FG000|Up to Year 3|Serious Adverse Event|0
6172101|NCT01262976|9818929|FG001|Up to Year 3|Serious Adverse Event|0
6172102|NCT01262976|9818930|FG002|Up to Year 3|Serious Adverse Event|2
6172103|NCT01262976|9818931|FG003|Up to Year 3|Serious Adverse Event|0
6172104|NCT01262976|9818932|FG004|Up to Year 3|Serious Adverse Event|0
6172105|NCT01262976|9818933|FG005|Up to Year 3|Serious Adverse Event|0
6375017|NCT03745638|10164835|FG003|Vehicle Control Period (Day 1 to Week 8)|Protocol Violation|0
6375018|NCT03745638|10164836|FG004|Vehicle Control Period (Day 1 to Week 8)|Protocol Violation|0
6375019|NCT03745638|10164837|FG005|Vehicle Control Period (Day 1 to Week 8)|Protocol Violation|0
6375020|NCT03745638|10164838|FG006|Vehicle Control Period (Day 1 to Week 8)|Protocol Violation|0
6375021|NCT03745638|10164832|FG000|Vehicle Control Period (Day 1 to Week 8)|Withdrawal by Subject|17
6375022|NCT03745638|10164833|FG001|Vehicle Control Period (Day 1 to Week 8)|Withdrawal by Subject|11
6172106|NCT01262976|9818928|FG000|Up to Year 3|Withdrawal by Subject|1
6172107|NCT01262976|9818929|FG001|Up to Year 3|Withdrawal by Subject|0
6172108|NCT01262976|9818930|FG002|Up to Year 3|Withdrawal by Subject|0
6172109|NCT01262976|9818931|FG003|Up to Year 3|Withdrawal by Subject|0
6172110|NCT01262976|9818932|FG004|Up to Year 3|Withdrawal by Subject|0
6172111|NCT01262976|9818933|FG005|Up to Year 3|Withdrawal by Subject|0
6172112|NCT01262976|9818928|FG000|Up to Year 3|Migrated/moved from study area|0
6172113|NCT01262976|9818929|FG001|Up to Year 3|Migrated/moved from study area|0
6172114|NCT01262976|9818930|FG002|Up to Year 3|Migrated/moved from study area|0
6172115|NCT01262976|9818931|FG003|Up to Year 3|Migrated/moved from study area|2
6172116|NCT01262976|9818932|FG004|Up to Year 3|Migrated/moved from study area|1
6172117|NCT01262976|9818933|FG005|Up to Year 3|Migrated/moved from study area|1
6172118|NCT01262976|9818928|FG000|Up to Year 3|Lost to Follow-up|2
6172119|NCT01262976|9818929|FG001|Up to Year 3|Lost to Follow-up|2
6172120|NCT01262976|9818930|FG002|Up to Year 3|Lost to Follow-up|4
6172121|NCT01262976|9818931|FG003|Up to Year 3|Lost to Follow-up|3
6172122|NCT01262976|9818932|FG004|Up to Year 3|Lost to Follow-up|1
6172123|NCT01262976|9818933|FG005|Up to Year 3|Lost to Follow-up|3
6172124|NCT01262976|9818928|FG000|Up to Year 3|Subjects with unknown completion status|0
6172125|NCT01262976|9818929|FG001|Up to Year 3|Subjects with unknown completion status|0
6172126|NCT01262976|9818930|FG002|Up to Year 3|Subjects with unknown completion status|1
6172127|NCT01262976|9818931|FG003|Up to Year 3|Subjects with unknown completion status|0
6172128|NCT01262976|9818932|FG004|Up to Year 3|Subjects with unknown completion status|0
6172129|NCT01262976|9818933|FG005|Up to Year 3|Subjects with unknown completion status|0
6172130|NCT01262976|9818928|FG000|Up to Year 3|Other|3
6172131|NCT01262976|9818929|FG001|Up to Year 3|Other|0
6172132|NCT01262976|9818930|FG002|Up to Year 3|Other|0
6172133|NCT01262976|9818931|FG003|Up to Year 3|Other|0
6172134|NCT01262976|9818932|FG004|Up to Year 3|Other|0
6172135|NCT01262976|9818933|FG005|Up to Year 3|Other|0
6172136|NCT01262989|9818948|FG000|Period 1|Lost to Follow-up|1
6172137|NCT01262989|9818949|FG001|Period 1|Lost to Follow-up|1
6172138|NCT01262989|9818948|FG000|Period 1|Intercurrent disease|0
6172139|NCT01262989|9818949|FG001|Period 1|Intercurrent disease|1
6172140|NCT01262989|9818948|FG000|Period 1|Positive answer for exclusion criteria|0
6375023|NCT03745638|10164834|FG002|Vehicle Control Period (Day 1 to Week 8)|Withdrawal by Subject|19
6375024|NCT03745638|10164835|FG003|Vehicle Control Period (Day 1 to Week 8)|Withdrawal by Subject|0
6172141|NCT01262989|9818949|FG001|Period 1|Positive answer for exclusion criteria|1
6172142|NCT01262989|9818948|FG000|Period 2|Intercurrent disease|0
6172143|NCT01262989|9818949|FG001|Period 2|Intercurrent disease|1
6172144|NCT01263015|9818957|FG000|Double-blind Phase: 96 Weeks Duration|Adverse Event|13
6172145|NCT01263015|9818958|FG001|Double-blind Phase: 96 Weeks Duration|Adverse Event|48
6172146|NCT01263015|9818957|FG000|Double-blind Phase: 96 Weeks Duration|Lack of Efficacy|18
6172147|NCT01263015|9818958|FG001|Double-blind Phase: 96 Weeks Duration|Lack of Efficacy|14
6172148|NCT01263015|9818957|FG000|Double-blind Phase: 96 Weeks Duration|Protocol Violation|14
6172149|NCT01263015|9818958|FG001|Double-blind Phase: 96 Weeks Duration|Protocol Violation|12
6172150|NCT01263015|9818957|FG000|Double-blind Phase: 96 Weeks Duration|Lost to Follow-up|17
6172151|NCT01263015|9818958|FG001|Double-blind Phase: 96 Weeks Duration|Lost to Follow-up|18
6172152|NCT01263015|9818957|FG000|Double-blind Phase: 96 Weeks Duration|Withdrawal by Subject|9
6172153|NCT01263015|9818958|FG001|Double-blind Phase: 96 Weeks Duration|Withdrawal by Subject|15
6172154|NCT01263015|9818957|FG000|Double-blind Phase: 96 Weeks Duration|Physician Decision|1
6172155|NCT01263015|9818958|FG001|Double-blind Phase: 96 Weeks Duration|Physician Decision|2
6172156|NCT01263015|9818957|FG000|Open-label Phase: 48 Weeks Duration|Adverse Event|3
6172157|NCT01263015|9818958|FG001|Open-label Phase: 48 Weeks Duration|Adverse Event|10
6172158|NCT01263015|9818957|FG000|Open-label Phase: 48 Weeks Duration|Lack of Efficacy|7
6172159|NCT01263015|9818958|FG001|Open-label Phase: 48 Weeks Duration|Lack of Efficacy|2
6172160|NCT01263015|9818957|FG000|Open-label Phase: 48 Weeks Duration|Protocol Violation|3
6172161|NCT01263015|9818958|FG001|Open-label Phase: 48 Weeks Duration|Protocol Violation|2
6172162|NCT01263015|9818957|FG000|Open-label Phase: 48 Weeks Duration|Lost to Follow-up|8
6172163|NCT01263015|9818958|FG001|Open-label Phase: 48 Weeks Duration|Lost to Follow-up|8
6172164|NCT01263015|9818957|FG000|Open-label Phase: 48 Weeks Duration|Physician Decision|0
6172165|NCT01263015|9818958|FG001|Open-label Phase: 48 Weeks Duration|Physician Decision|2
6172166|NCT01263015|9818957|FG000|Open-label Phase: 48 Weeks Duration|Withdrawal by Subject|3
6172167|NCT01263015|9818958|FG001|Open-label Phase: 48 Weeks Duration|Withdrawal by Subject|7
6172168|NCT01263054|9818966|FG000|Overall Study|Death|1
6172169|NCT01263054|9818967|FG001|Overall Study|Death|0
6172170|NCT01263054|9818966|FG000|Overall Study|Lost to Follow-up|2
6172171|NCT01263054|9818967|FG001|Overall Study|Lost to Follow-up|2
6172172|NCT01263054|9818966|FG000|Overall Study|Withdrawal by Subject|1
6172173|NCT01263054|9818967|FG001|Overall Study|Withdrawal by Subject|3
6172174|NCT01263054|9818966|FG000|Overall Study|Qualification Violation|1
6172175|NCT01263054|9818967|FG001|Overall Study|Qualification Violation|0
6172176|NCT01263054|9818966|FG000|Overall Study|Other|0
6172177|NCT01263054|9818967|FG001|Overall Study|Other|1
6172178|NCT01263093|9818975|FG000|Washout|Physician Decision|1
6172179|NCT01263093|9818976|FG001|Washout|Physician Decision|0
6172180|NCT01263093|9818975|FG000|Period 2|Adverse Event|1
6172181|NCT01263093|9818976|FG001|Period 2|Adverse Event|0
6172182|NCT01263106|9818983|FG000|Washout (at Least 7 Days)|Lost to Follow-up|1
6172183|NCT01263106|9818984|FG001|Washout (at Least 7 Days)|Lost to Follow-up|1
6172184|NCT01263119|9818993|FG000|Period 1|Protocol Violation|2
6172185|NCT01263119|9818993|FG000|Period 2|Adverse Event|2
6084890|NCT00645944|9693939|FG000|Randomized|Withdrawal by Subject|1
6084891|NCT00645944|9693940|FG001|Randomized|Withdrawal by Subject|2
6084892|NCT00645944|9693939|FG000|Received Medication|Adverse Event|2
6172186|NCT01263197|9819012|FG000|First Intervention (Period 1)|Adverse Event|0
6172187|NCT01263197|9819013|FG001|First Intervention (Period 1)|Adverse Event|0
6172188|NCT01263197|9819014|FG002|First Intervention (Period 1)|Adverse Event|0
6172189|NCT01263197|9819015|FG003|First Intervention (Period 1)|Adverse Event|0
6172190|NCT01263197|9819016|FG004|First Intervention (Period 1)|Adverse Event|0
6172191|NCT01263197|9819017|FG005|First Intervention (Period 1)|Adverse Event|1
6172192|NCT01263197|9819012|FG000|Washout Period 1|Protocol Violation|0
6172193|NCT01263197|9819013|FG001|Washout Period 1|Protocol Violation|0
6172194|NCT01263197|9819014|FG002|Washout Period 1|Protocol Violation|0
6172195|NCT01263197|9819015|FG003|Washout Period 1|Protocol Violation|0
6172196|NCT01263197|9819016|FG004|Washout Period 1|Protocol Violation|1
6172197|NCT01263197|9819017|FG005|Washout Period 1|Protocol Violation|0
6172198|NCT01263197|9819012|FG000|Washout Period 2|Physician Decision|0
6172199|NCT01263197|9819013|FG001|Washout Period 2|Physician Decision|0
6172200|NCT01263197|9819014|FG002|Washout Period 2|Physician Decision|0
6172201|NCT01263197|9819015|FG003|Washout Period 2|Physician Decision|0
6172202|NCT01263197|9819016|FG004|Washout Period 2|Physician Decision|0
6172203|NCT01263197|9819017|FG005|Washout Period 2|Physician Decision|1
6172204|NCT01263197|9819012|FG000|Washout Period 2|Protocol Violation|0
6172205|NCT01263197|9819013|FG001|Washout Period 2|Protocol Violation|0
6172206|NCT01263197|9819014|FG002|Washout Period 2|Protocol Violation|0
6172207|NCT01263197|9819015|FG003|Washout Period 2|Protocol Violation|1
6172208|NCT01263197|9819016|FG004|Washout Period 2|Protocol Violation|0
6172209|NCT01263197|9819017|FG005|Washout Period 2|Protocol Violation|0
6172210|NCT01263197|9819012|FG000|Third Intervention (Period 3)|Adverse Event|0
6172211|NCT01263197|9819013|FG001|Third Intervention (Period 3)|Adverse Event|1
6172212|NCT01263197|9819014|FG002|Third Intervention (Period 3)|Adverse Event|0
6172213|NCT01263197|9819015|FG003|Third Intervention (Period 3)|Adverse Event|0
6172214|NCT01263197|9819016|FG004|Third Intervention (Period 3)|Adverse Event|0
6172215|NCT01263197|9819017|FG005|Third Intervention (Period 3)|Adverse Event|0
6172216|NCT01263223|9819031|FG000|Period 2|Withdrawal by Subject|0
6172217|NCT01263223|9819032|FG001|Period 2|Withdrawal by Subject|1
6172218|NCT01263223|9819031|FG000|7-day Follow-up|Withdrawal by Subject|0
6172219|NCT01263223|9819032|FG001|7-day Follow-up|Withdrawal by Subject|1
6172220|NCT01263223|9819031|FG000|7-day Follow-up|Lost to Follow-up|1
6172221|NCT01263223|9819032|FG001|7-day Follow-up|Lost to Follow-up|0
6172222|NCT01263444|9819089|FG000|Overall Study|Adverse Event|8
6172223|NCT01263444|9819089|FG000|Overall Study|Withdrawal by Subject|1
6172224|NCT01263444|9819089|FG000|Overall Study|Protocol Violation|1
6172225|NCT01263470|9819099|FG000|Overall Study|Adverse Event|2
6172226|NCT01263470|9819100|FG001|Overall Study|Adverse Event|2
6172227|NCT01263470|9819101|FG002|Overall Study|Adverse Event|1
6172228|NCT01263470|9819102|FG003|Overall Study|Adverse Event|1
6172229|NCT01263470|9819103|FG004|Overall Study|Adverse Event|2
6172230|NCT01263470|9819104|FG005|Overall Study|Adverse Event|2
6172231|NCT01263470|9819099|FG000|Overall Study|Protocol Violation|0
6172232|NCT01263470|9819100|FG001|Overall Study|Protocol Violation|1
6172233|NCT01263470|9819101|FG002|Overall Study|Protocol Violation|0
6172234|NCT01263470|9819102|FG003|Overall Study|Protocol Violation|0
6172235|NCT01263470|9819103|FG004|Overall Study|Protocol Violation|0
6172236|NCT01263470|9819104|FG005|Overall Study|Protocol Violation|1
6172237|NCT01263470|9819099|FG000|Overall Study|Withdrawal by Subject|0
6172238|NCT01263470|9819100|FG001|Overall Study|Withdrawal by Subject|1
6172239|NCT01263470|9819101|FG002|Overall Study|Withdrawal by Subject|1
6172240|NCT01263470|9819102|FG003|Overall Study|Withdrawal by Subject|2
6172241|NCT01263470|9819103|FG004|Overall Study|Withdrawal by Subject|0
6172242|NCT01263470|9819104|FG005|Overall Study|Withdrawal by Subject|2
6172243|NCT01263470|9819099|FG000|Overall Study|Lack of Efficacy|0
6172244|NCT01263470|9819100|FG001|Overall Study|Lack of Efficacy|0
6172245|NCT01263470|9819101|FG002|Overall Study|Lack of Efficacy|2
6172246|NCT01263470|9819102|FG003|Overall Study|Lack of Efficacy|0
6172247|NCT01263470|9819103|FG004|Overall Study|Lack of Efficacy|0
6172248|NCT01263470|9819104|FG005|Overall Study|Lack of Efficacy|0
6172249|NCT01263470|9819099|FG000|Overall Study|Participant Unavailability|0
6172250|NCT01263470|9819100|FG001|Overall Study|Participant Unavailability|1
6172251|NCT01263470|9819101|FG002|Overall Study|Participant Unavailability|0
6172252|NCT01263470|9819102|FG003|Overall Study|Participant Unavailability|0
6172253|NCT01263470|9819103|FG004|Overall Study|Participant Unavailability|0
6172254|NCT01263470|9819104|FG005|Overall Study|Participant Unavailability|0
6172255|NCT01263470|9819099|FG000|Overall Study|Study Drug Non-compliance|0
6172256|NCT01263470|9819100|FG001|Overall Study|Study Drug Non-compliance|0
6172257|NCT01263470|9819101|FG002|Overall Study|Study Drug Non-compliance|0
6172258|NCT01263470|9819102|FG003|Overall Study|Study Drug Non-compliance|0
6172259|NCT01263470|9819103|FG004|Overall Study|Study Drug Non-compliance|1
6172260|NCT01263470|9819104|FG005|Overall Study|Study Drug Non-compliance|0
6172261|NCT01263483|9819121|FG000|Overall Study|Adverse Event|4
6172262|NCT01263483|9819122|FG001|Overall Study|Adverse Event|0
6172263|NCT01263483|9819123|FG002|Overall Study|Adverse Event|3
6172264|NCT01263483|9819121|FG000|Overall Study|Withdrawal by Subject|1
6172265|NCT01263483|9819122|FG001|Overall Study|Withdrawal by Subject|0
6172266|NCT01263483|9819123|FG002|Overall Study|Withdrawal by Subject|0
6172267|NCT01263483|9819121|FG000|Overall Study|Lack of Efficacy|2
6172268|NCT01263483|9819122|FG001|Overall Study|Lack of Efficacy|0
6172269|NCT01263483|9819123|FG002|Overall Study|Lack of Efficacy|0
6172270|NCT01263483|9819121|FG000|Overall Study|Protocol Violation|0
6172271|NCT01263483|9819122|FG001|Overall Study|Protocol Violation|1
6172272|NCT01263483|9819123|FG002|Overall Study|Protocol Violation|1
6172273|NCT01263483|9819121|FG000|Overall Study|Participant Unavailability|0
6172274|NCT01263483|9819122|FG001|Overall Study|Participant Unavailability|1
6172275|NCT01263483|9819123|FG002|Overall Study|Participant Unavailability|1
6172276|NCT01263496|9819136|FG000|Enrolled - Long-Term Extension Study|Protocol Violation|1
6172277|NCT01263496|9819137|FG001|Enrolled - Long-Term Extension Study|Protocol Violation|0
6172278|NCT01263496|9819138|FG002|Enrolled - Long-Term Extension Study|Protocol Violation|0
6172279|NCT01263496|9819139|FG003|Enrolled - Long-Term Extension Study|Protocol Violation|0
6172280|NCT01263496|9819140|FG004|Enrolled - Long-Term Extension Study|Protocol Violation|0
6172281|NCT01263496|9819141|FG005|Enrolled - Long-Term Extension Study|Protocol Violation|0
6172282|NCT01263496|9819142|FG006|Enrolled - Long-Term Extension Study|Protocol Violation|0
6172283|NCT01263496|9819143|FG007|Enrolled - Long-Term Extension Study|Protocol Violation|0
6172284|NCT01263496|9819144|FG008|Enrolled - Long-Term Extension Study|Protocol Violation|0
6172285|NCT01263496|9819136|FG000|Enrolled - Long-Term Extension Study|Adverse Event|0
6172286|NCT01263496|9819137|FG001|Enrolled - Long-Term Extension Study|Adverse Event|0
6172287|NCT01263496|9819138|FG002|Enrolled - Long-Term Extension Study|Adverse Event|0
6172288|NCT01263496|9819139|FG003|Enrolled - Long-Term Extension Study|Adverse Event|1
6172289|NCT01263496|9819140|FG004|Enrolled - Long-Term Extension Study|Adverse Event|2
6172290|NCT01263496|9819141|FG005|Enrolled - Long-Term Extension Study|Adverse Event|0
6172291|NCT01263496|9819142|FG006|Enrolled - Long-Term Extension Study|Adverse Event|0
6172292|NCT01263496|9819143|FG007|Enrolled - Long-Term Extension Study|Adverse Event|0
6172293|NCT01263496|9819144|FG008|Enrolled - Long-Term Extension Study|Adverse Event|0
6172294|NCT01263496|9819136|FG000|Entered - Long-Term Extension Study|Adverse Event|0
6172295|NCT01263496|9819137|FG001|Entered - Long-Term Extension Study|Adverse Event|5
6172296|NCT01263496|9819138|FG002|Entered - Long-Term Extension Study|Adverse Event|6
6172297|NCT01263496|9819139|FG003|Entered - Long-Term Extension Study|Adverse Event|3
6172298|NCT01263496|9819140|FG004|Entered - Long-Term Extension Study|Adverse Event|1
6172299|NCT01263496|9819141|FG005|Entered - Long-Term Extension Study|Adverse Event|0
6172300|NCT01263496|9819142|FG006|Entered - Long-Term Extension Study|Adverse Event|0
6172301|NCT01263496|9819143|FG007|Entered - Long-Term Extension Study|Adverse Event|0
6172302|NCT01263496|9819144|FG008|Entered - Long-Term Extension Study|Adverse Event|1
6172303|NCT01263496|9819136|FG000|Entered - Long-Term Extension Study|Lost to Follow-up|0
6172304|NCT01263496|9819137|FG001|Entered - Long-Term Extension Study|Lost to Follow-up|2
6172305|NCT01263496|9819138|FG002|Entered - Long-Term Extension Study|Lost to Follow-up|0
6172306|NCT01263496|9819139|FG003|Entered - Long-Term Extension Study|Lost to Follow-up|0
6172307|NCT01263496|9819140|FG004|Entered - Long-Term Extension Study|Lost to Follow-up|0
6172308|NCT01263496|9819141|FG005|Entered - Long-Term Extension Study|Lost to Follow-up|0
6172309|NCT01263496|9819142|FG006|Entered - Long-Term Extension Study|Lost to Follow-up|0
6172310|NCT01263496|9819143|FG007|Entered - Long-Term Extension Study|Lost to Follow-up|0
6172311|NCT01263496|9819144|FG008|Entered - Long-Term Extension Study|Lost to Follow-up|0
6172312|NCT01263496|9819136|FG000|Entered - Long-Term Extension Study|Withdrawal by Subject|1
6172313|NCT01263496|9819137|FG001|Entered - Long-Term Extension Study|Withdrawal by Subject|2
6172314|NCT01263496|9819138|FG002|Entered - Long-Term Extension Study|Withdrawal by Subject|0
6172315|NCT01263496|9819139|FG003|Entered - Long-Term Extension Study|Withdrawal by Subject|2
6172316|NCT01263496|9819140|FG004|Entered - Long-Term Extension Study|Withdrawal by Subject|4
6172317|NCT01263496|9819141|FG005|Entered - Long-Term Extension Study|Withdrawal by Subject|1
6172318|NCT01263496|9819142|FG006|Entered - Long-Term Extension Study|Withdrawal by Subject|1
6172319|NCT01263496|9819143|FG007|Entered - Long-Term Extension Study|Withdrawal by Subject|0
6172320|NCT01263496|9819144|FG008|Entered - Long-Term Extension Study|Withdrawal by Subject|1
6172321|NCT01263496|9819136|FG000|Entered - Long-Term Extension Study|Lack of Efficacy|8
6172322|NCT01263496|9819137|FG001|Entered - Long-Term Extension Study|Lack of Efficacy|4
6084893|NCT00645944|9693940|FG001|Received Medication|Adverse Event|1
6172323|NCT01263496|9819138|FG002|Entered - Long-Term Extension Study|Lack of Efficacy|4
6172324|NCT01263496|9819139|FG003|Entered - Long-Term Extension Study|Lack of Efficacy|1
6172325|NCT01263496|9819140|FG004|Entered - Long-Term Extension Study|Lack of Efficacy|5
6172326|NCT01263496|9819141|FG005|Entered - Long-Term Extension Study|Lack of Efficacy|0
6172327|NCT01263496|9819142|FG006|Entered - Long-Term Extension Study|Lack of Efficacy|0
6172328|NCT01263496|9819143|FG007|Entered - Long-Term Extension Study|Lack of Efficacy|0
6172329|NCT01263496|9819144|FG008|Entered - Long-Term Extension Study|Lack of Efficacy|1
6172330|NCT01263496|9819136|FG000|Entered - Long-Term Extension Study|Participant Unavailability|0
6172331|NCT01263496|9819137|FG001|Entered - Long-Term Extension Study|Participant Unavailability|0
6172332|NCT01263496|9819138|FG002|Entered - Long-Term Extension Study|Participant Unavailability|0
6172333|NCT01263496|9819139|FG003|Entered - Long-Term Extension Study|Participant Unavailability|0
6172334|NCT01263496|9819140|FG004|Entered - Long-Term Extension Study|Participant Unavailability|0
6172335|NCT01263496|9819141|FG005|Entered - Long-Term Extension Study|Participant Unavailability|0
6172336|NCT01263496|9819142|FG006|Entered - Long-Term Extension Study|Participant Unavailability|0
6172337|NCT01263496|9819143|FG007|Entered - Long-Term Extension Study|Participant Unavailability|1
6172338|NCT01263496|9819144|FG008|Entered - Long-Term Extension Study|Participant Unavailability|0
6172339|NCT01263509|9819158|FG000|Entered - Long-Term Extension Study|Adverse Event|5
6172340|NCT01263509|9819159|FG001|Entered - Long-Term Extension Study|Adverse Event|5
6172341|NCT01263509|9819160|FG002|Entered - Long-Term Extension Study|Adverse Event|4
6172342|NCT01263509|9819161|FG003|Entered - Long-Term Extension Study|Adverse Event|1
6172343|NCT01263509|9819158|FG000|Entered - Long-Term Extension Study|Lack of Efficacy|1
6172344|NCT01263509|9819159|FG001|Entered - Long-Term Extension Study|Lack of Efficacy|4
6172345|NCT01263509|9819160|FG002|Entered - Long-Term Extension Study|Lack of Efficacy|1
6172346|NCT01263509|9819161|FG003|Entered - Long-Term Extension Study|Lack of Efficacy|0
6172347|NCT01263509|9819158|FG000|Entered - Long-Term Extension Study|Withdrawal by Subject|1
6172348|NCT01263509|9819159|FG001|Entered - Long-Term Extension Study|Withdrawal by Subject|2
6172349|NCT01263509|9819160|FG002|Entered - Long-Term Extension Study|Withdrawal by Subject|0
6172350|NCT01263509|9819161|FG003|Entered - Long-Term Extension Study|Withdrawal by Subject|0
6172351|NCT01263509|9819158|FG000|Entered - Long-Term Extension Study|Participant Unavailability|1
6172352|NCT01263509|9819159|FG001|Entered - Long-Term Extension Study|Participant Unavailability|1
6172353|NCT01263509|9819160|FG002|Entered - Long-Term Extension Study|Participant Unavailability|0
6172354|NCT01263509|9819161|FG003|Entered - Long-Term Extension Study|Participant Unavailability|0
6172355|NCT01263509|9819158|FG000|Entered - Long-Term Extension Study|Poor Glycosylated Hemoglobin Control|0
6172356|NCT01263509|9819159|FG001|Entered - Long-Term Extension Study|Poor Glycosylated Hemoglobin Control|0
6172357|NCT01263509|9819160|FG002|Entered - Long-Term Extension Study|Poor Glycosylated Hemoglobin Control|0
6172358|NCT01263509|9819161|FG003|Entered - Long-Term Extension Study|Poor Glycosylated Hemoglobin Control|1
6172359|NCT01263561|9819169|FG000|Overall Study|Death|1
6172360|NCT01263561|9819170|FG001|Overall Study|Death|2
6172361|NCT01263639|9819178|FG000|Overall Study|Lost to Follow-up|66
6172362|NCT01263639|9819179|FG001|Overall Study|Lost to Follow-up|70
6172363|NCT01263639|9819178|FG000|Overall Study|Exclusion =Admission greater than 7 days|7
6172364|NCT01263639|9819179|FG001|Overall Study|Exclusion =Admission greater than 7 days|9
6172365|NCT01263665|9819185|FG000|Overall Study|Withdrew Consent|1
6172366|NCT01263665|9819185|FG000|Overall Study|Lost to Follow-up|3
6172367|NCT01263665|9819185|FG000|Overall Study|Death|2
6172368|NCT01263665|9819185|FG000|Overall Study|Amputation above the ankle|1
6172369|NCT01263665|9819185|FG000|Overall Study|Surgical Bypass|2
6172370|NCT01263691|9819195|FG000|Overall Study|Lost to Follow-up|1
6172371|NCT01263691|9819196|FG001|Overall Study|Lost to Follow-up|0
6172372|NCT01263691|9819197|FG002|Overall Study|Lost to Follow-up|1
6172373|NCT01263691|9819198|FG003|Overall Study|Lost to Follow-up|1
6172374|NCT01263691|9819199|FG004|Overall Study|Lost to Follow-up|0
6172375|NCT01263691|9819200|FG005|Overall Study|Lost to Follow-up|0
6172376|NCT01263691|9819195|FG000|Overall Study|Withdrawal by Subject|1
6172377|NCT01263691|9819196|FG001|Overall Study|Withdrawal by Subject|0
6172378|NCT01263691|9819197|FG002|Overall Study|Withdrawal by Subject|0
6172379|NCT01263691|9819198|FG003|Overall Study|Withdrawal by Subject|0
6172380|NCT01263691|9819199|FG004|Overall Study|Withdrawal by Subject|0
6172381|NCT01263691|9819200|FG005|Overall Study|Withdrawal by Subject|0
6172382|NCT01263691|9819195|FG000|Overall Study|Adverse Event|1
6172383|NCT01263691|9819196|FG001|Overall Study|Adverse Event|0
6172384|NCT01263691|9819197|FG002|Overall Study|Adverse Event|0
6172385|NCT01263691|9819198|FG003|Overall Study|Adverse Event|0
6172386|NCT01263691|9819199|FG004|Overall Study|Adverse Event|0
6172387|NCT01263691|9819200|FG005|Overall Study|Adverse Event|0
6172388|NCT01263704|9819235|FG000|Overall Study|Progressive disease|18
6043371|NCT00389064|9641897|FG000|Overall Study|Lack of Efficacy|3
6172389|NCT01263704|9819235|FG000|Overall Study|Adverse Event|3
6172390|NCT01263704|9819235|FG000|Overall Study|Death|2
6172391|NCT01263704|9819235|FG000|Overall Study|Patient withdrew consent|2
6172392|NCT01263704|9819235|FG000|Overall Study|Eligibility criteria not fulfilled|1
6172393|NCT01263704|9819235|FG000|Overall Study|Lost to Follow-up|1
6172394|NCT01263704|9819235|FG000|Overall Study|Colon metastases|1
6172395|NCT01263704|9819235|FG000|Overall Study|Principal Investigator (PI) decision|1
6172396|NCT01263782|9819252|FG000|Overall Study|Death|0
6172397|NCT01263782|9819253|FG001|Overall Study|Death|0
6172398|NCT01263782|9819254|FG002|Overall Study|Death|1
6172399|NCT01263782|9819255|FG003|Overall Study|Death|0
6172400|NCT01263782|9819252|FG000|Overall Study|Progressive disease|0
6172401|NCT01263782|9819253|FG001|Overall Study|Progressive disease|0
6172402|NCT01263782|9819254|FG002|Overall Study|Progressive disease|0
6172403|NCT01263782|9819255|FG003|Overall Study|Progressive disease|1
6172404|NCT01263782|9819252|FG000|Overall Study|Too early|0
6172405|NCT01263782|9819253|FG001|Overall Study|Too early|0
6172406|NCT01263782|9819254|FG002|Overall Study|Too early|1
6172407|NCT01263782|9819255|FG003|Overall Study|Too early|0
6172408|NCT01263782|9819252|FG000|Overall Study|Inevaluable|0
6172409|NCT01263782|9819253|FG001|Overall Study|Inevaluable|0
6172410|NCT01263782|9819254|FG002|Overall Study|Inevaluable|1
6172411|NCT01263782|9819255|FG003|Overall Study|Inevaluable|0
6172412|NCT01263873|9819267|FG000|Overall Study|One provider unable to complete numbers|1
6172413|NCT01263873|9819268|FG001|Overall Study|One provider unable to complete numbers|1
6172414|NCT01263925|9819276|FG000|Overall Study|Protocol Violation|1
6172415|NCT01263925|9819277|FG001|Overall Study|Protocol Violation|0
6172416|NCT01263925|9819276|FG000|Overall Study|Lack of Efficacy|0
6172417|NCT01263925|9819277|FG001|Overall Study|Lack of Efficacy|1
6172418|NCT01263925|9819276|FG000|Overall Study|Adverse Event|23
6172419|NCT01263925|9819277|FG001|Overall Study|Adverse Event|22
6043372|NCT00389064|9641898|FG001|Overall Study|Lack of Efficacy|14
6043373|NCT00389064|9641897|FG000|Overall Study|Withdrawal by Subject|17
6172420|NCT01263925|9819276|FG000|Overall Study|Unsatisfactory Compliance of Subject|8
6172421|NCT01263925|9819277|FG001|Overall Study|Unsatisfactory Compliance of Subject|5
6172422|NCT01263925|9819276|FG000|Overall Study|Withdrawal by Subject|6
6172423|NCT01263925|9819277|FG001|Overall Study|Withdrawal by Subject|8
6172424|NCT01263925|9819276|FG000|Overall Study|Other|4
6172425|NCT01263925|9819277|FG001|Overall Study|Other|4
6172426|NCT01263925|9819276|FG000|Overall Study|Lost to Follow-up|3
6172427|NCT01263925|9819277|FG001|Overall Study|Lost to Follow-up|1
6172428|NCT01263925|9819276|FG000|Overall Study|Lack of Efficacy/ Adverse Event (AE)|1
6172429|NCT01263925|9819277|FG001|Overall Study|Lack of Efficacy/ Adverse Event (AE)|1
6172430|NCT01263925|9819276|FG000|Overall Study|AE/ Unsatisfactory Compliance|2
6172431|NCT01263925|9819277|FG001|Overall Study|AE/ Unsatisfactory Compliance|2
6172432|NCT01263925|9819276|FG000|Overall Study|AE/ Withdrawal|1
6172433|NCT01263925|9819277|FG001|Overall Study|AE/ Withdrawal|4
6172434|NCT01263925|9819276|FG000|Overall Study|Unsatisfactory Compliance/ Withdrawal|1
6172435|NCT01263925|9819277|FG001|Overall Study|Unsatisfactory Compliance/ Withdrawal|1
6172436|NCT01263925|9819276|FG000|Overall Study|Unsatisfactory Compl./ Lost to Follow up|1
6172437|NCT01263925|9819277|FG001|Overall Study|Unsatisfactory Compl./ Lost to Follow up|2
6172438|NCT01263925|9819276|FG000|Overall Study|Withdrawal/ Not specified|0
6172439|NCT01263925|9819277|FG001|Overall Study|Withdrawal/ Not specified|1
6172440|NCT01264016|9819288|FG000|Overall Study|Withdrawal by Subject|1
6172441|NCT01264016|9819288|FG000|Overall Study|Felt faint at sight of blood|1
6172442|NCT01264081|9819293|FG000|Participants Screened|Screening failures|30
6172443|NCT01264081|9819293|FG000|Started Treatment|Withdrawal by Subject|1
6172444|NCT01264081|9819293|FG000|Started Treatment|Not complete cycle 1 due to death|1
6172445|NCT01264380|9819297|FG000|Period C|Disease Progression|0
6172446|NCT01264380|9819298|FG001|Period C|Disease Progression|0
6172447|NCT01264380|9819299|FG002|Period C|Disease Progression|4
6172448|NCT01264380|9819297|FG000|Period C|Death|0
6172449|NCT01264380|9819298|FG001|Period C|Death|0
6172450|NCT01264380|9819299|FG002|Period C|Death|2
6043374|NCT00389064|9641898|FG001|Overall Study|Withdrawal by Subject|27
6043375|NCT00389064|9641897|FG000|Overall Study|Physician Decision|2
6172451|NCT01264380|9819297|FG000|Period C|Follow-up for survival status|0
6172452|NCT01264380|9819298|FG001|Period C|Follow-up for survival status|0
6172453|NCT01264380|9819299|FG002|Period C|Follow-up for survival status|6
6172454|NCT01264380|9819297|FG000|Period C|Withdrawal by Subject|0
6172455|NCT01264380|9819298|FG001|Period C|Withdrawal by Subject|0
6172456|NCT01264380|9819299|FG002|Period C|Withdrawal by Subject|1
6172457|NCT01264380|9819297|FG000|Period C|Adverse Event|0
6172458|NCT01264380|9819298|FG001|Period C|Adverse Event|0
6172459|NCT01264380|9819299|FG002|Period C|Adverse Event|1
6172460|NCT01264419|9819307|FG000|Overall Study|Lost to Follow-up|3
6172461|NCT01264718|9819347|FG000|Overall Study|Lost to Follow-up|3
6172462|NCT01264718|9819348|FG001|Overall Study|Lost to Follow-up|2
6172463|NCT01264718|9819347|FG000|Overall Study|Withdrawal by Subject|9
6172464|NCT01264718|9819348|FG001|Overall Study|Withdrawal by Subject|15
6172465|NCT01264718|9819347|FG000|Overall Study|Loss of Medicaid/CHIP eligibility|37
6172466|NCT01264718|9819348|FG001|Overall Study|Loss of Medicaid/CHIP eligibility|26
6172467|NCT01264770|9819360|FG000|Overall Study|Not reported|0
6172468|NCT01264770|9819361|FG001|Overall Study|Not reported|0
6172469|NCT01264770|9819362|FG002|Overall Study|Not reported|1
6172470|NCT01264770|9819363|FG003|Overall Study|Not reported|0
6172471|NCT01264770|9819364|FG004|Overall Study|Not reported|0
6172472|NCT01264770|9819365|FG005|Overall Study|Not reported|0
6172473|NCT01264770|9819360|FG000|Overall Study|e.g., change in circumstances|8
6172474|NCT01264770|9819361|FG001|Overall Study|e.g., change in circumstances|3
6172475|NCT01264770|9819362|FG002|Overall Study|e.g., change in circumstances|3
6172476|NCT01264770|9819363|FG003|Overall Study|e.g., change in circumstances|3
6172477|NCT01264770|9819364|FG004|Overall Study|e.g., change in circumstances|4
6172478|NCT01264770|9819365|FG005|Overall Study|e.g., change in circumstances|4
6172479|NCT01264770|9819360|FG000|Overall Study|Severe non-compliance to protocol|0
6172480|NCT01264770|9819361|FG001|Overall Study|Severe non-compliance to protocol|0
6172481|NCT01264770|9819362|FG002|Overall Study|Severe non-compliance to protocol|1
6172482|NCT01264770|9819363|FG003|Overall Study|Severe non-compliance to protocol|1
6172483|NCT01264770|9819364|FG004|Overall Study|Severe non-compliance to protocol|0
6172484|NCT01264770|9819365|FG005|Overall Study|Severe non-compliance to protocol|0
6172485|NCT01264770|9819360|FG000|Overall Study|Lack of therapeutic response|1
6172486|NCT01264770|9819361|FG001|Overall Study|Lack of therapeutic response|0
6172487|NCT01264770|9819362|FG002|Overall Study|Lack of therapeutic response|2
6172488|NCT01264770|9819363|FG003|Overall Study|Lack of therapeutic response|1
6172489|NCT01264770|9819364|FG004|Overall Study|Lack of therapeutic response|1
6172490|NCT01264770|9819365|FG005|Overall Study|Lack of therapeutic response|0
6172491|NCT01264770|9819360|FG000|Overall Study|Dev. of study specific discont. criteria|2
6172492|NCT01264770|9819361|FG001|Overall Study|Dev. of study specific discont. criteria|0
6172493|NCT01264770|9819362|FG002|Overall Study|Dev. of study specific discont. criteria|0
6172494|NCT01264770|9819363|FG003|Overall Study|Dev. of study specific discont. criteria|0
6172495|NCT01264770|9819364|FG004|Overall Study|Dev. of study specific discont. criteria|1
6172496|NCT01264770|9819365|FG005|Overall Study|Dev. of study specific discont. criteria|1
6172497|NCT01264770|9819360|FG000|Overall Study|Lost to Follow-up|0
6172498|NCT01264770|9819361|FG001|Overall Study|Lost to Follow-up|0
6172499|NCT01264770|9819362|FG002|Overall Study|Lost to Follow-up|1
6172500|NCT01264770|9819363|FG003|Overall Study|Lost to Follow-up|1
6172501|NCT01264770|9819364|FG004|Overall Study|Lost to Follow-up|0
6172502|NCT01264770|9819365|FG005|Overall Study|Lost to Follow-up|0
6172503|NCT01264770|9819360|FG000|Overall Study|Adverse Event|7
6172504|NCT01264770|9819361|FG001|Overall Study|Adverse Event|7
6172505|NCT01264770|9819362|FG002|Overall Study|Adverse Event|8
6172506|NCT01264770|9819363|FG003|Overall Study|Adverse Event|0
6172507|NCT01264770|9819364|FG004|Overall Study|Adverse Event|2
6172508|NCT01264770|9819365|FG005|Overall Study|Adverse Event|1
6172509|NCT01264887|9819385|FG000|Overall Study|Adverse Event|5
6172510|NCT01264887|9819385|FG000|Overall Study|Death|7
6172511|NCT01264887|9819385|FG000|Overall Study|Lack of Efficacy|5
6172512|NCT01264887|9819385|FG000|Overall Study|Physician Decision|4
6172513|NCT01264887|9819385|FG000|Overall Study|Withdrawal by Subject|6
6172514|NCT01264887|9819385|FG000|Overall Study|Sponsor Decision Administrative Reasons|2
6172515|NCT01264887|9819385|FG000|Overall Study|Other|2
6172516|NCT01264939|9819393|FG000|Overall Study|Adverse Event|1
6172517|NCT01264939|9819394|FG001|Overall Study|Adverse Event|3
6172518|NCT01264939|9819393|FG000|Overall Study|Lost to Follow-up|0
6172519|NCT01264939|9819394|FG001|Overall Study|Lost to Follow-up|3
6172520|NCT01264939|9819393|FG000|Overall Study|Physician Decision|1
6172521|NCT01264939|9819394|FG001|Overall Study|Physician Decision|1
6172522|NCT01264939|9819393|FG000|Overall Study|Patient/Guardian Decision|8
6172523|NCT01264939|9819394|FG001|Overall Study|Patient/Guardian Decision|10
6172524|NCT01264939|9819393|FG000|Overall Study|Disease Progression|8
6172525|NCT01264939|9819394|FG001|Overall Study|Disease Progression|11
6172526|NCT01265056|9819415|FG000|Initial Study Period|Withdrawal by Subject|1
6172527|NCT01265056|9819416|FG001|Initial Study Period|Withdrawal by Subject|1
6172528|NCT01265056|9819415|FG000|Initial Study Period|Withdrawal by Subject|1
6172529|NCT01265056|9819416|FG001|Initial Study Period|Withdrawal by Subject|1
6172530|NCT01265056|9819415|FG000|Follow up|Lost to Follow-up|7
6172531|NCT01265056|9819416|FG001|Follow up|Lost to Follow-up|3
6172532|NCT01265394|9819422|FG000|Overall Study|Subjects withdrawn|37
5972156|NCT04498247|9557787|FG003|Overall Study|Received a non-study COVID-19 vaccine.|3
5972157|NCT04498247|9557788|FG004|Overall Study|Received a non-study COVID-19 vaccine.|0
5972158|NCT04498247|9557789|FG005|Overall Study|Received a non-study COVID-19 vaccine.|0
5972159|NCT04498247|9557790|FG006|Overall Study|Received a non-study COVID-19 vaccine.|7
5972160|NCT04498247|9557791|FG007|Overall Study|Received a non-study COVID-19 vaccine.|0
5972161|NCT04472650|9557808|FG000|Washout Period (Minimum 14 Days)|Adverse Event|1
5972162|NCT04472650|9557809|FG001|Washout Period (Minimum 14 Days)|Adverse Event|0
5972232|NCT03987919|9557983|FG000|Overall Study|Adverse Event|1
5972233|NCT03987919|9557984|FG001|Overall Study|Adverse Event|4
5972234|NCT03987919|9557985|FG002|Overall Study|Adverse Event|1
5972235|NCT03987919|9557986|FG003|Overall Study|Adverse Event|3
5972236|NCT03987919|9557983|FG000|Overall Study|Death|4
5972237|NCT03987919|9557984|FG001|Overall Study|Death|4
5972238|NCT03987919|9557985|FG002|Overall Study|Death|4
5972239|NCT03987919|9557986|FG003|Overall Study|Death|1
5972240|NCT03987919|9557983|FG000|Overall Study|Lost to Follow-up|5
5972241|NCT03987919|9557984|FG001|Overall Study|Lost to Follow-up|6
5972242|NCT03987919|9557985|FG002|Overall Study|Lost to Follow-up|8
5972243|NCT03987919|9557986|FG003|Overall Study|Lost to Follow-up|12
5972244|NCT03987919|9557983|FG000|Overall Study|Physician Decision|0
5972245|NCT03987919|9557984|FG001|Overall Study|Physician Decision|2
5972246|NCT03987919|9557985|FG002|Overall Study|Physician Decision|0
5972247|NCT03987919|9557986|FG003|Overall Study|Physician Decision|4
5972248|NCT03987919|9557983|FG000|Overall Study|Pregnancy|1
5972249|NCT03987919|9557984|FG001|Overall Study|Pregnancy|0
5972250|NCT03987919|9557985|FG002|Overall Study|Pregnancy|1
5972251|NCT03987919|9557986|FG003|Overall Study|Pregnancy|1
5972252|NCT03987919|9557983|FG000|Overall Study|Protocol Violation|0
5972253|NCT03987919|9557984|FG001|Overall Study|Protocol Violation|1
5972254|NCT03987919|9557985|FG002|Overall Study|Protocol Violation|0
5972255|NCT03987919|9557986|FG003|Overall Study|Protocol Violation|0
5972256|NCT03987919|9557983|FG000|Overall Study|Site terminated by Sponsor|0
5972257|NCT03987919|9557984|FG001|Overall Study|Site terminated by Sponsor|0
5972258|NCT03987919|9557985|FG002|Overall Study|Site terminated by Sponsor|0
5972259|NCT03987919|9557986|FG003|Overall Study|Site terminated by Sponsor|1
5972260|NCT03987919|9557983|FG000|Overall Study|Withdrawal by Subject|7
5972261|NCT03987919|9557984|FG001|Overall Study|Withdrawal by Subject|7
5972262|NCT03987919|9557985|FG002|Overall Study|Withdrawal by Subject|8
5972263|NCT03987919|9557986|FG003|Overall Study|Withdrawal by Subject|4
5972264|NCT03987919|9557983|FG000|Overall Study|Other - as reported by the investigator|1
5972265|NCT03987919|9557984|FG001|Overall Study|Other - as reported by the investigator|3
6172533|NCT01265420|9819427|FG000|Overall Study|Lost to Follow-up|1
6172534|NCT01265498|9819467|FG000|Overall Study|Protocol modified to eliminate wk72 bx|31
6172535|NCT01265498|9819468|FG001|Overall Study|Protocol modified to eliminate wk72 bx|33
6172536|NCT01265511|9819476|FG000|Overall Study|Lack of Efficacy|2
6172537|NCT01265511|9819477|FG001|Overall Study|Lack of Efficacy|1
6172538|NCT01265511|9819476|FG000|Overall Study|Met stopping rules|0
6172539|NCT01265511|9819477|FG001|Overall Study|Met stopping rules|2
6192296|NCT01430130|9849520|FG000|Overall Study|Lost to Follow-up|1
6192297|NCT01430130|9849520|FG000|Overall Study|Infection on Control Side of Incision|1
6192298|NCT01430403|9849568|FG000|Overall Study|Lost to Follow-up|5
6192299|NCT01430403|9849569|FG001|Overall Study|Lost to Follow-up|5
6192300|NCT01430403|9849570|FG002|Overall Study|Lost to Follow-up|3
6192301|NCT01430403|9849568|FG000|Overall Study|Physician Decision|1
6192302|NCT01430403|9849569|FG001|Overall Study|Physician Decision|0
6192303|NCT01430403|9849570|FG002|Overall Study|Physician Decision|0
6192304|NCT01430403|9849568|FG000|Overall Study|Protocol Violation|2
6192305|NCT01430403|9849569|FG001|Overall Study|Protocol Violation|3
6192306|NCT01430403|9849570|FG002|Overall Study|Protocol Violation|2
6192307|NCT01430403|9849568|FG000|Overall Study|Withdrawal by Subject|9
6192308|NCT01430403|9849569|FG001|Overall Study|Withdrawal by Subject|1
6192309|NCT01430403|9849570|FG002|Overall Study|Withdrawal by Subject|3
6192310|NCT01430442|9849591|FG000|Overall Study|Subject Withdrew Consent|3
6192311|NCT01430442|9849592|FG001|Overall Study|Subject Withdrew Consent|0
6192312|NCT01430442|9849593|FG002|Overall Study|Subject Withdrew Consent|1
6192313|NCT01430442|9849594|FG003|Overall Study|Subject Withdrew Consent|0
6192314|NCT01430442|9849595|FG004|Overall Study|Subject Withdrew Consent|2
6192315|NCT01430442|9849596|FG005|Overall Study|Subject Withdrew Consent|1
6192316|NCT01430442|9849597|FG006|Overall Study|Subject Withdrew Consent|5
6192317|NCT01430442|9849598|FG007|Overall Study|Subject Withdrew Consent|2
6192318|NCT01430442|9849591|FG000|Overall Study|Lost to Follow-up|2
6192319|NCT01430442|9849592|FG001|Overall Study|Lost to Follow-up|0
6192320|NCT01430442|9849593|FG002|Overall Study|Lost to Follow-up|1
6192321|NCT01430442|9849594|FG003|Overall Study|Lost to Follow-up|2
6192322|NCT01430442|9849595|FG004|Overall Study|Lost to Follow-up|2
6192323|NCT01430442|9849596|FG005|Overall Study|Lost to Follow-up|1
6192324|NCT01430442|9849597|FG006|Overall Study|Lost to Follow-up|5
6192325|NCT01430442|9849598|FG007|Overall Study|Lost to Follow-up|1
6172540|NCT01265537|9819494|FG000|Overall Study|Adverse Event|2
6172541|NCT01265537|9819495|FG001|Overall Study|Adverse Event|1
6172542|NCT01265537|9819494|FG000|Overall Study|Physician Decision|0
6172543|NCT01265537|9819495|FG001|Overall Study|Physician Decision|1
6172544|NCT01265550|9819505|FG000|Pre Randomization|Withdrawal by Subject|0
6172545|NCT01265550|9819506|FG001|Pre Randomization|Withdrawal by Subject|0
6172546|NCT01265550|9819507|FG002|Pre Randomization|Withdrawal by Subject|0
6172547|NCT01265550|9819508|FG003|Pre Randomization|Withdrawal by Subject|70
6172548|NCT01265550|9819505|FG000|Pre Randomization|Technical Exclusions|0
6172549|NCT01265550|9819506|FG001|Pre Randomization|Technical Exclusions|0
6172550|NCT01265550|9819507|FG002|Pre Randomization|Technical Exclusions|0
6172551|NCT01265550|9819508|FG003|Pre Randomization|Technical Exclusions|54
6172552|NCT01265550|9819505|FG000|Pre Randomization|GERD, PPI-Responsive|0
6172553|NCT01265550|9819506|FG001|Pre Randomization|GERD, PPI-Responsive|0
6172554|NCT01265550|9819507|FG002|Pre Randomization|GERD, PPI-Responsive|0
6172555|NCT01265550|9819508|FG003|Pre Randomization|GERD, PPI-Responsive|42
6172556|NCT01265550|9819505|FG000|Pre Randomization|Non-GERD organic disorders|0
6172557|NCT01265550|9819506|FG001|Pre Randomization|Non-GERD organic disorders|0
6172558|NCT01265550|9819507|FG002|Pre Randomization|Non-GERD organic disorders|0
6172559|NCT01265550|9819508|FG003|Pre Randomization|Non-GERD organic disorders|23
6172560|NCT01265550|9819505|FG000|Pre Randomization|Functional heartburn|0
6172561|NCT01265550|9819506|FG001|Pre Randomization|Functional heartburn|0
6172562|NCT01265550|9819507|FG002|Pre Randomization|Functional heartburn|0
6172563|NCT01265550|9819508|FG003|Pre Randomization|Functional heartburn|99
6172564|NCT01265563|9819527|FG000|Overall Study|Withdrawal by Subject|0
6172565|NCT01265563|9819528|FG001|Overall Study|Withdrawal by Subject|1
6172566|NCT01265563|9819529|FG002|Overall Study|Withdrawal by Subject|1
6172567|NCT01265563|9819530|FG003|Overall Study|Withdrawal by Subject|0
6172568|NCT01265563|9819531|FG004|Overall Study|Withdrawal by Subject|2
6172569|NCT01265615|9819552|FG000|Overall Study|Protocol Violation|2
6172570|NCT01265615|9819553|FG001|Overall Study|Protocol Violation|2
6172571|NCT01265615|9819554|FG002|Overall Study|Protocol Violation|4
6172572|NCT01265615|9819555|FG003|Overall Study|Protocol Violation|3
6172573|NCT01265719|9819576|FG000|Overall Study|Does not meet entrance criteria|0
6172574|NCT01265719|9819577|FG001|Overall Study|Does not meet entrance criteria|3
6172575|NCT01265719|9819576|FG000|Overall Study|Other reasons|2
6172576|NCT01265719|9819577|FG001|Overall Study|Other reasons|0
6172577|NCT01265719|9819576|FG000|Overall Study|Withdrawal by Subject|8
6172578|NCT01265719|9819577|FG001|Overall Study|Withdrawal by Subject|3
6172579|NCT01265719|9819576|FG000|Overall Study|Lost to Follow-up|2
6172580|NCT01265719|9819577|FG001|Overall Study|Lost to Follow-up|7
6172581|NCT01265719|9819576|FG000|Overall Study|Adverse Event|2
6172582|NCT01265719|9819577|FG001|Overall Study|Adverse Event|0
6172583|NCT01265797|9819585|FG000|Run-in Month|Withdrawal by Subject|0
6172584|NCT01265797|9819586|FG001|Run-in Month|Withdrawal by Subject|4
6172585|NCT01265797|9819585|FG000|Run-in Month|1st seizure during run-in month|0
6172586|NCT01265797|9819586|FG001|Run-in Month|1st seizure during run-in month|1
6172587|NCT01265797|9819585|FG000|Blinded Month|Lack of Efficacy|5
6172588|NCT01265797|9819586|FG001|Blinded Month|Lack of Efficacy|0
6172589|NCT01265797|9819585|FG000|Blinded Month|Lost to Follow-up|1
6172590|NCT01265797|9819586|FG001|Blinded Month|Lost to Follow-up|0
6172591|NCT01265797|9819585|FG000|Blinded Month|Protocol Violation|2
6172592|NCT01265797|9819586|FG001|Blinded Month|Protocol Violation|1
6172593|NCT01265797|9819585|FG000|Blinded Month|Adverse Event|2
6172594|NCT01265797|9819586|FG001|Blinded Month|Adverse Event|0
6172595|NCT01265797|9819585|FG000|Blinded Month|Diary data incomplete|0
6172596|NCT01265797|9819586|FG001|Blinded Month|Diary data incomplete|1
6172597|NCT01265797|9819585|FG000|Open Label Month|Lost to Follow-up|0
6172598|NCT01265797|9819586|FG001|Open Label Month|Lost to Follow-up|1
6172599|NCT01265823|9819594|FG000|Overall Study|Unsatisfactory Response Efficacy|1
6172600|NCT01265823|9819594|FG000|Overall Study|Failure to Return|4
6172601|NCT01265823|9819594|FG000|Overall Study|Protocol Violation|1
6172602|NCT01265823|9819594|FG000|Overall Study|Participant Request|1
6172603|NCT01265875|9819602|FG000|Overall Study|Uncooperative/unreliable|1
6172604|NCT01265953|9819609|FG000|Overall Study|Non compliance|5
6172605|NCT01265953|9819610|FG001|Overall Study|Non compliance|3
6172606|NCT01265992|9819629|FG000|Overall Study|Lost to Follow-up|1
6172607|NCT01265992|9819629|FG000|Overall Study|Withdrawal by Subject|1
6172608|NCT01265992|9819629|FG000|Overall Study|Adverse Event|1
6172609|NCT01265992|9819629|FG000|Overall Study|Administrative reasons|2
6172610|NCT01265992|9819629|FG000|Overall Study|Stopped treatment|3
6172611|NCT01265992|9819629|FG000|Overall Study|Did not receive treatment|1
6172612|NCT01266018|9819633|FG000|Overall Study|Physician Decision|1
6172613|NCT01266018|9819634|FG001|Overall Study|Physician Decision|0
6172614|NCT01266018|9819633|FG000|Overall Study|Progressive disease|0
6172615|NCT01266018|9819634|FG001|Overall Study|Progressive disease|1
6172616|NCT01266070|9819640|FG000|Overall Study|Adverse Event|3
6172617|NCT01266070|9819640|FG000|Overall Study|Protocol Violation|1
6172618|NCT01266122|9819646|FG000|Overall Study|Lost to Follow-up|6
6172619|NCT01266122|9819647|FG001|Overall Study|Lost to Follow-up|6
6172620|NCT01266148|9819655|FG000|Overall Study|Adverse Event|2
6172621|NCT01266148|9819656|FG001|Overall Study|Adverse Event|0
6172622|NCT01266148|9819655|FG000|Overall Study|Ongoing rejection|1
6172623|NCT01266148|9819656|FG001|Overall Study|Ongoing rejection|0
6172624|NCT01266148|9819655|FG000|Overall Study|2 2R rejections|1
6172625|NCT01266148|9819656|FG001|Overall Study|2 2R rejections|0
6172626|NCT01266148|9819655|FG000|Overall Study|Death|2
6172627|NCT01266148|9819656|FG001|Overall Study|Death|3
6172628|NCT01266148|9819655|FG000|Overall Study|missing mGFR value + AE|1
6172629|NCT01266148|9819656|FG001|Overall Study|missing mGFR value + AE|0
6172630|NCT01266161|9819664|FG000|Overall Study|Ineligible|1
6172631|NCT01266161|9819665|FG001|Overall Study|Ineligible|0
6172632|NCT01266161|9819664|FG000|Overall Study|Lack of Efficacy|0
6172633|NCT01266161|9819665|FG001|Overall Study|Lack of Efficacy|1
6172634|NCT01266161|9819664|FG000|Overall Study|Vomited within 4 hours of dosing|3
6172635|NCT01266161|9819665|FG001|Overall Study|Vomited within 4 hours of dosing|0
6172636|NCT01266265|9819673|FG000|Overall Study|Death|95
6172637|NCT01266265|9819674|FG001|Overall Study|Death|73
6172638|NCT01266265|9819673|FG000|Overall Study|Lost to Follow-up|23
6172639|NCT01266265|9819674|FG001|Overall Study|Lost to Follow-up|28
6172640|NCT01266265|9819673|FG000|Overall Study|Withdrawal by Subject|13
6172641|NCT01266265|9819674|FG001|Overall Study|Withdrawal by Subject|11
6172642|NCT01266265|9819673|FG000|Overall Study|Respiratory-related adverse event|2
6172643|NCT01266265|9819674|FG001|Overall Study|Respiratory-related adverse event|1
6172644|NCT01266265|9819673|FG000|Overall Study|Transferred care to another provider|22
6172645|NCT01266265|9819674|FG001|Overall Study|Transferred care to another provider|28
6172646|NCT01266265|9819673|FG000|Overall Study|Stopped/changed PAH medication(s)|16
6172647|NCT01266265|9819674|FG001|Overall Study|Stopped/changed PAH medication(s)|9
6172648|NCT01266265|9819673|FG000|Overall Study|Enrolled in another clinical study|15
6172649|NCT01266265|9819674|FG001|Overall Study|Enrolled in another clinical study|26
6172650|NCT01266265|9819673|FG000|Overall Study|Non-compliance|8
6172651|NCT01266265|9819674|FG001|Overall Study|Non-compliance|5
6172652|NCT01266265|9819673|FG000|Overall Study|Lung transplant|6
6172653|NCT01266265|9819674|FG001|Overall Study|Lung transplant|5
6172654|NCT01266265|9819673|FG000|Overall Study|Site closed early|4
6172655|NCT01266265|9819674|FG001|Overall Study|Site closed early|3
6172656|NCT01266265|9819673|FG000|Overall Study|Clinical worsening|1
6172657|NCT01266265|9819674|FG001|Overall Study|Clinical worsening|1
6172658|NCT01266291|9819680|FG000|Overall Study|Adverse Event|1
6172659|NCT01266317|9819684|FG000|Overall Study|Withdrawal by Subject|2
6172660|NCT01266460|9819692|FG000|Overall Study|Adverse Event|3
6172661|NCT01266460|9819692|FG000|Overall Study|Withdrawal by Subject|5
6172662|NCT01266460|9819692|FG000|Overall Study|Disease Progression|18
6172663|NCT01266460|9819692|FG000|Overall Study|Not otherwise specified|8
6172664|NCT01266590|9819696|FG000|Overall Study|Adverse Event|3
6172665|NCT01266590|9819696|FG000|Overall Study|Lost to Follow-up|1
6172666|NCT01266590|9819696|FG000|Overall Study|Withdrawal by Subject|1
6172667|NCT01266590|9819696|FG000|Overall Study|Physician Decision|1
6172668|NCT01266603|9819703|FG000|Overall Study|Adverse Event|1
6172669|NCT01266603|9819703|FG000|Overall Study|Lack of Efficacy|14
6172670|NCT01266603|9819703|FG000|Overall Study|Withdrawal by Subject|1
6172671|NCT01266603|9819703|FG000|Overall Study|Failed screening; MAGE-A3 negative|26
6172672|NCT01266642|9819709|FG000|Overall Study|Protocol Violation|0
6172673|NCT01266642|9819710|FG001|Overall Study|Protocol Violation|1
6172674|NCT01266850|9819721|FG000|Overall Study|Lost to Follow-up|19
6172675|NCT01266850|9819722|FG001|Overall Study|Lost to Follow-up|19
6172676|NCT01266850|9819723|FG002|Overall Study|Lost to Follow-up|13
6172677|NCT01266850|9819724|FG003|Overall Study|Lost to Follow-up|13
6172678|NCT01266850|9819725|FG004|Overall Study|Lost to Follow-up|12
6172679|NCT01266850|9819721|FG000|Overall Study|Withdrawal by Subject|8
6172680|NCT01266850|9819722|FG001|Overall Study|Withdrawal by Subject|9
6172681|NCT01266850|9819723|FG002|Overall Study|Withdrawal by Subject|6
6172682|NCT01266850|9819724|FG003|Overall Study|Withdrawal by Subject|9
6172683|NCT01266850|9819725|FG004|Overall Study|Withdrawal by Subject|12
6172684|NCT01266850|9819721|FG000|Overall Study|Physician Decision|3
6172685|NCT01266850|9819722|FG001|Overall Study|Physician Decision|6
6172686|NCT01266850|9819723|FG002|Overall Study|Physician Decision|4
6172687|NCT01266850|9819724|FG003|Overall Study|Physician Decision|4
6172688|NCT01266850|9819725|FG004|Overall Study|Physician Decision|3
6084894|NCT00645944|9693939|FG000|Received Medication|Withdrawal by Subject|1
6084895|NCT00645944|9693940|FG001|Received Medication|Withdrawal by Subject|1
6084896|NCT00645944|9693939|FG000|Received Medication|Lost to Follow-up|1
6084897|NCT00645944|9693940|FG001|Received Medication|Lost to Follow-up|0
6172689|NCT01266850|9819721|FG000|Overall Study|Protocol Violation|0
6172690|NCT01266850|9819722|FG001|Overall Study|Protocol Violation|1
6172691|NCT01266850|9819723|FG002|Overall Study|Protocol Violation|0
6172692|NCT01266850|9819724|FG003|Overall Study|Protocol Violation|1
6172693|NCT01266850|9819725|FG004|Overall Study|Protocol Violation|2
6172694|NCT01266850|9819721|FG000|Overall Study|Adverse Event|0
6172695|NCT01266850|9819722|FG001|Overall Study|Adverse Event|0
6172696|NCT01266850|9819723|FG002|Overall Study|Adverse Event|0
6172697|NCT01266850|9819724|FG003|Overall Study|Adverse Event|0
6172698|NCT01266850|9819725|FG004|Overall Study|Adverse Event|1
6172699|NCT01266850|9819721|FG000|Overall Study|Site Closure|0
6172700|NCT01266850|9819722|FG001|Overall Study|Site Closure|1
6172701|NCT01266850|9819723|FG002|Overall Study|Site Closure|1
6172702|NCT01266850|9819724|FG003|Overall Study|Site Closure|1
6172703|NCT01266850|9819725|FG004|Overall Study|Site Closure|0
6172704|NCT01266876|9819742|FG000|Overall Study|Adverse Event|0
6172705|NCT01266876|9819743|FG001|Overall Study|Adverse Event|0
6172706|NCT01266876|9819744|FG002|Overall Study|Adverse Event|0
6172707|NCT01266876|9819745|FG003|Overall Study|Adverse Event|1
6172708|NCT01266876|9819746|FG004|Overall Study|Adverse Event|0
6172709|NCT01266902|9819760|FG000|Period 1 (Main Study)|Investigator's decision/Participant's decision|2
6172710|NCT01266902|9819761|FG001|Period 1 (Main Study)|Investigator's decision/Participant's decision|3
6172711|NCT01266902|9819762|FG002|Period 1 (Main Study)|Investigator's decision/Participant's decision|0
6172712|NCT01266902|9819760|FG000|Period 1 (Main Study)|Lost to Follow-up|5
6172713|NCT01266902|9819761|FG001|Period 1 (Main Study)|Lost to Follow-up|12
6172714|NCT01266902|9819762|FG002|Period 1 (Main Study)|Lost to Follow-up|0
6172715|NCT01266902|9819760|FG000|Period 1 (Main Study)|Lack of Efficacy|4
6172716|NCT01266902|9819761|FG001|Period 1 (Main Study)|Lack of Efficacy|2
6172717|NCT01266902|9819762|FG002|Period 1 (Main Study)|Lack of Efficacy|0
6172718|NCT01266902|9819760|FG000|Period 1 (Main Study)|Adverse Event|3
6172719|NCT01266902|9819761|FG001|Period 1 (Main Study)|Adverse Event|11
6172720|NCT01266902|9819762|FG002|Period 1 (Main Study)|Adverse Event|0
6172721|NCT01266902|9819760|FG000|Period 1 (Main Study)|Withdrawal by Subject|2
6172722|NCT01266902|9819761|FG001|Period 1 (Main Study)|Withdrawal by Subject|12
6172723|NCT01266902|9819762|FG002|Period 1 (Main Study)|Withdrawal by Subject|0
6172724|NCT01266902|9819760|FG000|Period 1 (Main Study)|Subject non-compliant|3
6172725|NCT01266902|9819761|FG001|Period 1 (Main Study)|Subject non-compliant|7
6172726|NCT01266902|9819762|FG002|Period 1 (Main Study)|Subject non-compliant|0
6172727|NCT01266902|9819760|FG000|Period 1 (Main Study)|Continued RPV treatment|11
6172728|NCT01266902|9819761|FG001|Period 1 (Main Study)|Continued RPV treatment|34
6172729|NCT01266902|9819762|FG002|Period 1 (Main Study)|Continued RPV treatment|0
6172730|NCT01266902|9819760|FG000|Period 2 (After Protocol Amendment 3)|Withdrawal by Subject|0
6172731|NCT01266902|9819761|FG001|Period 2 (After Protocol Amendment 3)|Withdrawal by Subject|0
6172732|NCT01266902|9819762|FG002|Period 2 (After Protocol Amendment 3)|Withdrawal by Subject|1
6172733|NCT01266902|9819760|FG000|Period 2 (After Protocol Amendment 3)|Adverse Event|0
6172734|NCT01266902|9819761|FG001|Period 2 (After Protocol Amendment 3)|Adverse Event|0
6172735|NCT01266902|9819762|FG002|Period 2 (After Protocol Amendment 3)|Adverse Event|1
6084898|NCT00645944|9693939|FG000|Received Medication|Protocol Violation|2
6172736|NCT01266902|9819760|FG000|Period 2 (After Protocol Amendment 3)|Lost to Follow-up|0
6172737|NCT01266902|9819761|FG001|Period 2 (After Protocol Amendment 3)|Lost to Follow-up|0
6172738|NCT01266902|9819762|FG002|Period 2 (After Protocol Amendment 3)|Lost to Follow-up|6
6172739|NCT01266967|9819772|FG000|Overall Study|Death|69
6172740|NCT01266967|9819773|FG001|Overall Study|Death|61
6172741|NCT01266967|9819772|FG000|Overall Study|Study Closed/Terminated|15
6172742|NCT01266967|9819773|FG001|Overall Study|Study Closed/Terminated|17
6172743|NCT01266967|9819772|FG000|Overall Study|Lost to Follow-up|2
6172744|NCT01266967|9819773|FG001|Overall Study|Lost to Follow-up|1
6172745|NCT01266967|9819772|FG000|Overall Study|Physician Decision|0
6172746|NCT01266967|9819773|FG001|Overall Study|Physician Decision|1
6172747|NCT01266967|9819772|FG000|Overall Study|Withdrawal by Subject|3
6172748|NCT01266967|9819773|FG001|Overall Study|Withdrawal by Subject|3
6172749|NCT01266993|9819784|FG000|Booster Phase (Month 68-69)|Lost to Follow-up|5
6172750|NCT01266993|9819785|FG001|Booster Phase (Month 68-69)|Lost to Follow-up|1
6172751|NCT01266993|9819784|FG000|Booster Phase (Month 68-69)|Withdrawal by Subject|0
6172752|NCT01266993|9819785|FG001|Booster Phase (Month 68-69)|Withdrawal by Subject|1
6172753|NCT01267175|9819825|FG000|Overall Study|Withdrawal by Subject|1
6172754|NCT01267175|9819825|FG000|Overall Study|Lost to Follow-up|1
6172755|NCT01267201|9819829|FG000|First Intervention Period|Withdrawal by Subject|1
6172756|NCT01267201|9819830|FG001|First Intervention Period|Withdrawal by Subject|0
6172757|NCT01267201|9819831|FG002|First Intervention Period|Withdrawal by Subject|0
6172758|NCT01267201|9819832|FG003|First Intervention Period|Withdrawal by Subject|0
6172759|NCT01267201|9819833|FG004|First Intervention Period|Withdrawal by Subject|0
6172760|NCT01267201|9819834|FG005|First Intervention Period|Withdrawal by Subject|0
6172761|NCT01267201|9819829|FG000|Second Intervention Period|Withdrawal by Subject|0
6172762|NCT01267201|9819830|FG001|Second Intervention Period|Withdrawal by Subject|1
6172763|NCT01267201|9819831|FG002|Second Intervention Period|Withdrawal by Subject|0
6172764|NCT01267201|9819832|FG003|Second Intervention Period|Withdrawal by Subject|0
6172765|NCT01267201|9819833|FG004|Second Intervention Period|Withdrawal by Subject|0
6172766|NCT01267201|9819834|FG005|Second Intervention Period|Withdrawal by Subject|0
6172767|NCT01267253|9819867|FG000|Overall Study|Ineligible - required test not done|1
6172768|NCT01267253|9819867|FG000|Overall Study|Inevaluable-never received study treatme|2
6172769|NCT01267266|9819871|FG000|Enrollment Phase|Withdrawal by Subject|2
6172770|NCT01267266|9819872|FG001|Enrollment Phase|Withdrawal by Subject|0
6172771|NCT01267266|9819871|FG000|Lead-in Phase|Lack of Efficacy|20
6172772|NCT01267266|9819872|FG001|Lead-in Phase|Lack of Efficacy|0
6172773|NCT01267266|9819871|FG000|Lead-in Phase|Adverse Event|2
6172774|NCT01267266|9819872|FG001|Lead-in Phase|Adverse Event|0
6172775|NCT01267266|9819871|FG000|Lead-in Phase|Withdrawal by Subject|1
6172776|NCT01267266|9819872|FG001|Lead-in Phase|Withdrawal by Subject|0
6172777|NCT01267994|9819947|FG000|Overall Study|Adverse Event|2
6172778|NCT01268046|9819956|FG000|Overall Study|Withdrawal by Subject|1
6172779|NCT01268046|9819957|FG001|Overall Study|Withdrawal by Subject|0
6172780|NCT01268046|9819958|FG002|Overall Study|Withdrawal by Subject|0
6172781|NCT01268046|9819959|FG003|Overall Study|Withdrawal by Subject|1
6172782|NCT01268046|9819956|FG000|Overall Study|Lost to Follow-up|0
6172783|NCT01268046|9819957|FG001|Overall Study|Lost to Follow-up|0
6172784|NCT01268046|9819958|FG002|Overall Study|Lost to Follow-up|1
6172785|NCT01268046|9819959|FG003|Overall Study|Lost to Follow-up|0
6172786|NCT01268059|9819973|FG000|Overall Study|Lost to Follow-up|0
6172787|NCT01268059|9819974|FG001|Overall Study|Lost to Follow-up|1
6172788|NCT01268059|9819975|FG002|Overall Study|Lost to Follow-up|0
6172789|NCT01268059|9819976|FG003|Overall Study|Lost to Follow-up|0
6172790|NCT01268059|9819973|FG000|Overall Study|Withdrawal by Subject|7
6172791|NCT01268059|9819974|FG001|Overall Study|Withdrawal by Subject|4
6172792|NCT01268059|9819975|FG002|Overall Study|Withdrawal by Subject|0
6172793|NCT01268059|9819976|FG003|Overall Study|Withdrawal by Subject|0
6172794|NCT01268059|9819973|FG000|Overall Study|Death|20
6172795|NCT01268059|9819974|FG001|Overall Study|Death|30
6172796|NCT01268059|9819975|FG002|Overall Study|Death|3
6172797|NCT01268059|9819976|FG003|Overall Study|Death|5
6172798|NCT01268059|9819973|FG000|Overall Study|Progression of disease|1
6172799|NCT01268059|9819974|FG001|Overall Study|Progression of disease|0
6172800|NCT01268059|9819975|FG002|Overall Study|Progression of disease|0
6172801|NCT01268059|9819976|FG003|Overall Study|Progression of disease|0
6172802|NCT01268098|9819991|FG000|Overall Study|Adverse Event|1
6172803|NCT01268098|9819992|FG001|Overall Study|Adverse Event|0
6172804|NCT01268150|9820007|FG000|Treatment Phase|Progression of disease|18
6172805|NCT01268150|9820007|FG000|Treatment Phase|Adverse Event|3
6172806|NCT01268150|9820007|FG000|Treatment Phase|Withdrawal by Subject|3
6172807|NCT01268150|9820007|FG000|Treatment Phase|Other|4
6172808|NCT01268150|9820007|FG000|Extension Phase|Adverse Event|3
6172809|NCT01268150|9820007|FG000|Extension Phase|Disease progression|18
6172810|NCT01268150|9820007|FG000|Extension Phase|Other|6
6172811|NCT01268267|9820017|FG000|Overall Study|Protocol Violation|1
6172812|NCT01268293|9820022|FG000|Overall Study|Disease progression|7
6172813|NCT01268293|9820022|FG000|Overall Study|Adverse Event|1
6172814|NCT01268293|9820022|FG000|Overall Study|Subject choice|1
6172815|NCT01268306|9820026|FG000|Overall Study|Lost to Follow-up|1
6172816|NCT01268488|9820030|FG000|Overall Study|Adverse Event|3
6172817|NCT01268488|9820030|FG000|Overall Study|Physician Decision|2
6172818|NCT01268501|9820035|FG000|Overall Study|Lost to Follow-up|1
6172819|NCT01268501|9820035|FG000|Overall Study|Withdrawal by Subject|3
6172820|NCT01268501|9820035|FG000|Overall Study|Unacceptable Subjective Vision|3
6172821|NCT01268501|9820035|FG000|Overall Study|Handling Difficulties|2
6172822|NCT01268514|9820039|FG000|Overall Study|Adverse Event|20
6172823|NCT01268514|9820039|FG000|Overall Study|Death|8
6172824|NCT01268514|9820039|FG000|Overall Study|Lost to Follow-up|5
6172825|NCT01268514|9820039|FG000|Overall Study|Withdrawal by Subject|3
6172826|NCT01268514|9820039|FG000|Overall Study|Withdrawal by Surgeon|5
6172827|NCT01268566|9820071|FG000|Overall Study|Lost to Follow-up|1
6172828|NCT01268566|9820071|FG000|Overall Study|Withdrawal by Subject|12
6172829|NCT01268566|9820071|FG000|Overall Study|Death|30
6172830|NCT01268683|9820082|FG000|Overall Study|Lost to Follow-up|1
6172831|NCT01268683|9820082|FG000|Overall Study|Death|1
6172832|NCT01268891|9820088|FG000|Overall Study|Adverse Event|3
6172833|NCT01268891|9820089|FG001|Overall Study|Adverse Event|7
6172834|NCT01268891|9820088|FG000|Overall Study|Lack of Efficacy|1
6172835|NCT01268891|9820089|FG001|Overall Study|Lack of Efficacy|0
6172836|NCT01268891|9820088|FG000|Overall Study|Withdrawal of Consent|3
6172837|NCT01268891|9820089|FG001|Overall Study|Withdrawal of Consent|1
6172838|NCT01268891|9820088|FG000|Overall Study|Administrative or other reason(s)|1
6172839|NCT01268891|9820089|FG001|Overall Study|Administrative or other reason(s)|0
6172840|NCT01269125|9820130|FG000|Overall Study|Adverse Event|3
6172841|NCT01269125|9820131|FG001|Overall Study|Adverse Event|5
6172842|NCT01269125|9820132|FG002|Overall Study|Adverse Event|0
6172843|NCT01269125|9820130|FG000|Overall Study|Lost to Follow-up|4
6172844|NCT01269125|9820131|FG001|Overall Study|Lost to Follow-up|0
6172845|NCT01269125|9820132|FG002|Overall Study|Lost to Follow-up|0
6172846|NCT01269346|9820140|FG000|Treatment Phase|Disease progression|3
6172847|NCT01269346|9820140|FG000|Treatment Phase|Adverse Event|3
6172848|NCT01269346|9820140|FG000|Treatment Phase|Withdrawal by Subject|1
6172849|NCT01269346|9820140|FG000|Treatment Phase|Other|2
6172850|NCT01269346|9820140|FG000|Extension Phase|Adverse Event|6
6172851|NCT01269346|9820140|FG000|Extension Phase|Withdrawal by Subject|4
6172852|NCT01269346|9820140|FG000|Extension Phase|Disease progression|22
6172853|NCT01269346|9820140|FG000|Extension Phase|Physician decision or participant choice|9
6172854|NCT01269346|9820140|FG000|Extension Phase|Clinical progression|1
6172855|NCT01269346|9820140|FG000|Extension Phase|Started a prohibited con med|1
6172856|NCT01269385|9820154|FG000|Overall Study|Adverse Event|1
6172857|NCT01269385|9820155|FG001|Overall Study|Adverse Event|1
6172858|NCT01269385|9820156|FG002|Overall Study|Adverse Event|0
6172859|NCT01269385|9820157|FG003|Overall Study|Adverse Event|0
6172860|NCT01269918|9820193|FG000|Overall Study|Did not receive study drug|0
6172861|NCT01269918|9820194|FG001|Overall Study|Did not receive study drug|3
6172862|NCT01270139|9820212|FG000|Overall Study|Adverse Event|8
6172863|NCT01270139|9820213|FG001|Overall Study|Adverse Event|17
6172864|NCT01270139|9820214|FG002|Overall Study|Adverse Event|18
6172865|NCT01270139|9820212|FG000|Overall Study|Lost to Follow-up|10
6172866|NCT01270139|9820213|FG001|Overall Study|Lost to Follow-up|9
6172867|NCT01270139|9820214|FG002|Overall Study|Lost to Follow-up|2
6172868|NCT01270256|9820231|FG000|Overall Study|Withdrawal by Subject|1
6172869|NCT01270256|9820232|FG001|Overall Study|Withdrawal by Subject|0
6172870|NCT01270321|9820241|FG000|Overall Study|Death|3
6172871|NCT01270321|9820242|FG001|Overall Study|Death|1
6172872|NCT01270321|9820243|FG002|Overall Study|Death|4
6172873|NCT01270321|9820241|FG000|Overall Study|Adverse Event|7
6172874|NCT01270321|9820242|FG001|Overall Study|Adverse Event|9
6172875|NCT01270321|9820243|FG002|Overall Study|Adverse Event|5
6172876|NCT01270464|9820254|FG000|Overall Study|Protocol Violation|4
6172877|NCT01270464|9820255|FG001|Overall Study|Protocol Violation|3
6172878|NCT01270464|9820256|FG002|Overall Study|Protocol Violation|2
6172879|NCT01270464|9820254|FG000|Overall Study|Lack of Efficacy|2
6172880|NCT01270464|9820255|FG001|Overall Study|Lack of Efficacy|3
6172881|NCT01270464|9820256|FG002|Overall Study|Lack of Efficacy|1
6172882|NCT01270464|9820254|FG000|Overall Study|Adverse Event|9
6172883|NCT01270464|9820255|FG001|Overall Study|Adverse Event|1
6172884|NCT01270464|9820256|FG002|Overall Study|Adverse Event|7
6172885|NCT01270464|9820254|FG000|Overall Study|Withdrawal by Subject|2
6172886|NCT01270464|9820255|FG001|Overall Study|Withdrawal by Subject|1
6172887|NCT01270464|9820256|FG002|Overall Study|Withdrawal by Subject|4
6172888|NCT01270464|9820254|FG000|Overall Study|Lost to Follow-up|2
6172889|NCT01270464|9820255|FG001|Overall Study|Lost to Follow-up|3
6172890|NCT01270464|9820256|FG002|Overall Study|Lost to Follow-up|1
6172891|NCT01270464|9820254|FG000|Overall Study|Other|1
6172892|NCT01270464|9820255|FG001|Overall Study|Other|1
6172893|NCT01270464|9820256|FG002|Overall Study|Other|3
6172894|NCT01270503|9820264|FG000|Overall Study|Lost to Follow-up|1
6172895|NCT01270620|9820314|FG000|Overall Study|Withdrawal by Subject|1
6172896|NCT01270620|9820315|FG001|Overall Study|Withdrawal by Subject|3
6172897|NCT01270802|9820380|FG000|Overall Study|Withdrawal by Subject|1
6172898|NCT01270802|9820381|FG001|Overall Study|Withdrawal by Subject|0
6172899|NCT01270802|9820380|FG000|Overall Study|Adverse Event|1
6172900|NCT01270802|9820381|FG001|Overall Study|Adverse Event|0
6172901|NCT01270802|9820380|FG000|Overall Study|Lost to Follow-up|0
6172902|NCT01270802|9820381|FG001|Overall Study|Lost to Follow-up|1
6172903|NCT01270828|9820390|FG000|Pregabalin CR SB|Reason Unspecified|0
6172904|NCT01270828|9820391|FG001|Pregabalin CR SB|Reason Unspecified|0
6172905|NCT01270828|9820392|FG002|Pregabalin CR SB|Reason Unspecified|8
6172906|NCT01270828|9820390|FG000|Pregabalin CR SB|Enrolled but not treated|0
6172907|NCT01270828|9820391|FG001|Pregabalin CR SB|Enrolled but not treated|0
6172908|NCT01270828|9820392|FG002|Pregabalin CR SB|Enrolled but not treated|5
6172909|NCT01270828|9820390|FG000|Pregabalin CR SB|Related adverse event|0
6172910|NCT01270828|9820391|FG001|Pregabalin CR SB|Related adverse event|0
6172911|NCT01270828|9820392|FG002|Pregabalin CR SB|Related adverse event|46
6172912|NCT01270828|9820390|FG000|Pregabalin CR SB|Lack of Efficacy|0
6172913|NCT01270828|9820391|FG001|Pregabalin CR SB|Lack of Efficacy|0
6172914|NCT01270828|9820392|FG002|Pregabalin CR SB|Lack of Efficacy|32
6172915|NCT01270828|9820390|FG000|Pregabalin CR SB|Withdrawal by Subject|0
6172916|NCT01270828|9820391|FG001|Pregabalin CR SB|Withdrawal by Subject|0
6172917|NCT01270828|9820392|FG002|Pregabalin CR SB|Withdrawal by Subject|29
6172918|NCT01270828|9820390|FG000|Pregabalin CR SB|Lost to Follow-up|0
6172919|NCT01270828|9820391|FG001|Pregabalin CR SB|Lost to Follow-up|0
6172920|NCT01270828|9820392|FG002|Pregabalin CR SB|Lost to Follow-up|10
6172921|NCT01270828|9820390|FG000|Pregabalin CR SB|Unrelated AE|0
6172922|NCT01270828|9820391|FG001|Pregabalin CR SB|Unrelated AE|0
6172923|NCT01270828|9820392|FG002|Pregabalin CR SB|Unrelated AE|8
6172924|NCT01270828|9820390|FG000|Pregabalin CR SB|Protocol Violation|0
6172925|NCT01270828|9820391|FG001|Pregabalin CR SB|Protocol Violation|0
6172926|NCT01270828|9820392|FG002|Pregabalin CR SB|Protocol Violation|8
6172927|NCT01270828|9820390|FG000|Double Blind Phase|Death|0
6172928|NCT01270828|9820391|FG001|Double Blind Phase|Death|1
6172929|NCT01270828|9820392|FG002|Double Blind Phase|Death|0
6172930|NCT01270828|9820390|FG000|Double Blind Phase|Protocol Violation|0
6172931|NCT01270828|9820391|FG001|Double Blind Phase|Protocol Violation|1
6172932|NCT01270828|9820392|FG002|Double Blind Phase|Protocol Violation|0
6172933|NCT01270828|9820390|FG000|Double Blind Phase|Protocol and GCP non-compliance|4
6172934|NCT01270828|9820391|FG001|Double Blind Phase|Protocol and GCP non-compliance|3
6172935|NCT01270828|9820392|FG002|Double Blind Phase|Protocol and GCP non-compliance|0
6172936|NCT01270828|9820390|FG000|Double Blind Phase|Reason Unspecified|7
6172937|NCT01270828|9820391|FG001|Double Blind Phase|Reason Unspecified|4
6172938|NCT01270828|9820392|FG002|Double Blind Phase|Reason Unspecified|0
6172939|NCT01270828|9820390|FG000|Double Blind Phase|Withdrawal by Subject|6
6172940|NCT01270828|9820391|FG001|Double Blind Phase|Withdrawal by Subject|15
6172941|NCT01270828|9820392|FG002|Double Blind Phase|Withdrawal by Subject|0
6172942|NCT01270828|9820390|FG000|Double Blind Phase|Lost to Follow-up|1
6172943|NCT01270828|9820391|FG001|Double Blind Phase|Lost to Follow-up|2
6172944|NCT01270828|9820392|FG002|Double Blind Phase|Lost to Follow-up|0
6172945|NCT01270828|9820390|FG000|Double Blind Phase|Lack of Efficacy|2
6172946|NCT01270828|9820391|FG001|Double Blind Phase|Lack of Efficacy|11
6172947|NCT01270828|9820392|FG002|Double Blind Phase|Lack of Efficacy|0
6172948|NCT01270828|9820390|FG000|Double Blind Phase|Adverse event not related to study drug|1
6172949|NCT01270828|9820391|FG001|Double Blind Phase|Adverse event not related to study drug|1
6172950|NCT01270828|9820392|FG002|Double Blind Phase|Adverse event not related to study drug|0
6172951|NCT01270828|9820390|FG000|Double Blind Phase|Adverse event related to study drug|5
6172952|NCT01270828|9820391|FG001|Double Blind Phase|Adverse event related to study drug|7
6172953|NCT01270828|9820392|FG002|Double Blind Phase|Adverse event related to study drug|0
6172954|NCT01270841|9820404|FG000|Overall Study|Adverse Event|0
6172955|NCT01270841|9820405|FG001|Overall Study|Adverse Event|1
6172956|NCT01270841|9820406|FG002|Overall Study|Adverse Event|0
6172957|NCT01270841|9820407|FG003|Overall Study|Adverse Event|3
6172958|NCT01270841|9820404|FG000|Overall Study|Withdrawal by Subject|3
6172959|NCT01270841|9820405|FG001|Overall Study|Withdrawal by Subject|2
6172960|NCT01270841|9820406|FG002|Overall Study|Withdrawal by Subject|3
6172961|NCT01270841|9820407|FG003|Overall Study|Withdrawal by Subject|3
6172962|NCT01270841|9820404|FG000|Overall Study|Lost to Follow-up|3
6172963|NCT01270841|9820405|FG001|Overall Study|Lost to Follow-up|1
6172964|NCT01270841|9820406|FG002|Overall Study|Lost to Follow-up|4
6172965|NCT01270841|9820407|FG003|Overall Study|Lost to Follow-up|2
6172966|NCT01270841|9820404|FG000|Overall Study|Physician Decision|0
6172967|NCT01270841|9820405|FG001|Overall Study|Physician Decision|1
6172968|NCT01270841|9820406|FG002|Overall Study|Physician Decision|0
6172969|NCT01270841|9820407|FG003|Overall Study|Physician Decision|0
6172970|NCT01270841|9820404|FG000|Overall Study|Did not qualify|6
6172971|NCT01270841|9820405|FG001|Overall Study|Did not qualify|3
6172972|NCT01270841|9820406|FG002|Overall Study|Did not qualify|4
6172973|NCT01270841|9820407|FG003|Overall Study|Did not qualify|5
6172974|NCT01270841|9820404|FG000|Overall Study|Protocol Violation|1
6172975|NCT01270841|9820405|FG001|Overall Study|Protocol Violation|5
6172976|NCT01270841|9820406|FG002|Overall Study|Protocol Violation|0
6172977|NCT01270841|9820407|FG003|Overall Study|Protocol Violation|0
6172978|NCT01270841|9820404|FG000|Overall Study|Enrolled in error|0
6172979|NCT01270841|9820405|FG001|Overall Study|Enrolled in error|1
6172980|NCT01270841|9820406|FG002|Overall Study|Enrolled in error|0
6172981|NCT01270841|9820407|FG003|Overall Study|Enrolled in error|0
6172982|NCT01270880|9820426|FG000|Overall Study|Never rec'd treatment, but registered.|1
6172983|NCT01270958|9820430|FG000|Overall Study|Lost to Follow-up|2
6172984|NCT01270958|9820430|FG000|Overall Study|Did not meet inclusion criteria for age|2
6172985|NCT01270971|9820436|FG000|Overall Study|Withdrawal by Subject|24
6172986|NCT01270971|9820437|FG001|Overall Study|Withdrawal by Subject|11
6172987|NCT01270971|9820436|FG000|Overall Study|Lost to Follow-up|18
6172988|NCT01270971|9820437|FG001|Overall Study|Lost to Follow-up|5
6172989|NCT01270971|9820436|FG000|Overall Study|Adverse Event|1
6172990|NCT01270971|9820437|FG001|Overall Study|Adverse Event|2
6172991|NCT01270971|9820436|FG000|Overall Study|Non compliance|2
6172992|NCT01270971|9820437|FG001|Overall Study|Non compliance|2
6172993|NCT01270971|9820436|FG000|Overall Study|Non-specific|7
6172994|NCT01270971|9820437|FG001|Overall Study|Non-specific|3
6172995|NCT01271010|9820443|FG000|Overall Study|Reason not specified|11
6172996|NCT01271010|9820443|FG000|Overall Study|Start of new CLL therapy|1
6172997|NCT01271010|9820443|FG000|Overall Study|Protocol Violation|1
6172998|NCT01271010|9820443|FG000|Overall Study|Death|2
6172999|NCT01271010|9820443|FG000|Overall Study|Progression and relapse of disease|1
6173000|NCT01271010|9820443|FG000|Overall Study|Withdrawal by Subject|18
6173001|NCT01271010|9820443|FG000|Overall Study|Disease progression|27
6173002|NCT01271504|9820487|FG000|Overall Study|Death|7
6173003|NCT01271504|9820488|FG001|Overall Study|Death|6
6173004|NCT01271504|9820489|FG002|Overall Study|Death|32
6173005|NCT01271504|9820490|FG003|Overall Study|Death|32
6173006|NCT01271504|9820487|FG000|Overall Study|Lost to Follow-up|0
6173007|NCT01271504|9820488|FG001|Overall Study|Lost to Follow-up|1
6173008|NCT01271504|9820489|FG002|Overall Study|Lost to Follow-up|3
6173009|NCT01271504|9820490|FG003|Overall Study|Lost to Follow-up|1
6173010|NCT01271504|9820487|FG000|Overall Study|Protocol Violation|0
6173011|NCT01271504|9820488|FG001|Overall Study|Protocol Violation|0
6173012|NCT01271504|9820489|FG002|Overall Study|Protocol Violation|0
6173013|NCT01271504|9820490|FG003|Overall Study|Protocol Violation|2
6173014|NCT01271504|9820487|FG000|Overall Study|Administrative Reasons|0
6173015|NCT01271504|9820488|FG001|Overall Study|Administrative Reasons|0
6173016|NCT01271504|9820489|FG002|Overall Study|Administrative Reasons|6
6173017|NCT01271504|9820490|FG003|Overall Study|Administrative Reasons|5
6173018|NCT01271504|9820487|FG000|Overall Study|Withdrawal by Subject|0
6173019|NCT01271504|9820488|FG001|Overall Study|Withdrawal by Subject|0
6173020|NCT01271504|9820489|FG002|Overall Study|Withdrawal by Subject|1
6173021|NCT01271504|9820490|FG003|Overall Study|Withdrawal by Subject|3
6173022|NCT01271504|9820487|FG000|Overall Study|Other|0
6173023|NCT01271504|9820488|FG001|Overall Study|Other|1
6173024|NCT01271504|9820489|FG002|Overall Study|Other|2
6173025|NCT01271504|9820490|FG003|Overall Study|Other|0
6192326|NCT01430442|9849591|FG000|Overall Study|Pregnancy|1
6192327|NCT01430442|9849592|FG001|Overall Study|Pregnancy|0
6192328|NCT01430442|9849593|FG002|Overall Study|Pregnancy|0
6192329|NCT01430442|9849594|FG003|Overall Study|Pregnancy|0
6192330|NCT01430442|9849595|FG004|Overall Study|Pregnancy|0
6192331|NCT01430442|9849596|FG005|Overall Study|Pregnancy|1
6192332|NCT01430442|9849597|FG006|Overall Study|Pregnancy|0
6192333|NCT01430442|9849598|FG007|Overall Study|Pregnancy|0
6192334|NCT01430442|9849591|FG000|Overall Study|Patient No Longer Meets Study Criteria|7
6192335|NCT01430442|9849592|FG001|Overall Study|Patient No Longer Meets Study Criteria|6
6192336|NCT01430442|9849593|FG002|Overall Study|Patient No Longer Meets Study Criteria|3
6192337|NCT01430442|9849594|FG003|Overall Study|Patient No Longer Meets Study Criteria|2
6192338|NCT01430442|9849595|FG004|Overall Study|Patient No Longer Meets Study Criteria|5
6173026|NCT01271712|9820526|FG000|Double Blind Treatment|Death|2
6173027|NCT01271712|9820527|FG001|Double Blind Treatment|Death|0
6173028|NCT01271712|9820526|FG000|Double Blind Treatment|Lack of Efficacy|1
6173029|NCT01271712|9820527|FG001|Double Blind Treatment|Lack of Efficacy|0
6173030|NCT01271712|9820526|FG000|Double Blind Treatment|Adverse Event|9
6173031|NCT01271712|9820527|FG001|Double Blind Treatment|Adverse Event|4
6173032|NCT01271712|9820526|FG000|Double Blind Treatment|Progressive disease|23
6173033|NCT01271712|9820527|FG001|Double Blind Treatment|Progressive disease|3
6173034|NCT01271712|9820526|FG000|Double Blind Treatment|Withdrawal by Subject|4
6173035|NCT01271712|9820527|FG001|Double Blind Treatment|Withdrawal by Subject|1
6173036|NCT01271712|9820526|FG000|Double Blind Treatment|Non compliance with study drug|2
6173037|NCT01271712|9820527|FG001|Double Blind Treatment|Non compliance with study drug|0
6173038|NCT01271712|9820526|FG000|Double Blind Treatment|receive no study drug|1
6173039|NCT01271712|9820527|FG001|Double Blind Treatment|receive no study drug|0
6173040|NCT01271712|9820526|FG000|Open Label Treatment|Death|6
6173041|NCT01271712|9820527|FG001|Open Label Treatment|Death|5
6173042|NCT01271712|9820526|FG000|Open Label Treatment|Withdrawal by Subject|6
6173043|NCT01271712|9820527|FG001|Open Label Treatment|Withdrawal by Subject|11
6173044|NCT01271712|9820526|FG000|Open Label Treatment|Physician Decision|2
6173045|NCT01271712|9820527|FG001|Open Label Treatment|Physician Decision|0
6173046|NCT01271712|9820526|FG000|Open Label Treatment|Adverse Event|14
6173047|NCT01271712|9820527|FG001|Open Label Treatment|Adverse Event|8
6173048|NCT01271712|9820526|FG000|Open Label Treatment|Progressive disease|59
6173049|NCT01271712|9820527|FG001|Open Label Treatment|Progressive disease|32
6173050|NCT01271712|9820526|FG000|Open Label Treatment|transferred to rollover study|1
6173051|NCT01271712|9820527|FG001|Open Label Treatment|transferred to rollover study|0
6173052|NCT01271712|9820526|FG000|Open Label Treatment|Non-compliance with study drug|1
6173053|NCT01271712|9820527|FG001|Open Label Treatment|Non-compliance with study drug|0
6173054|NCT01271712|9820526|FG000|Open Label Treatment|Protocol Violation|0
6173055|NCT01271712|9820527|FG001|Open Label Treatment|Protocol Violation|1
6173056|NCT01271712|9820526|FG000|Open Label Treatment|Switching to other therapy|2
6173057|NCT01271712|9820527|FG001|Open Label Treatment|Switching to other therapy|1
6173058|NCT01271712|9820526|FG000|Safety Follow-up|Death|11
6173059|NCT01271712|9820527|FG001|Safety Follow-up|Death|7
6173060|NCT01271712|9820526|FG000|Safety Follow-up|Withdrawal by Subject|4
6173061|NCT01271712|9820527|FG001|Safety Follow-up|Withdrawal by Subject|2
6173062|NCT01271712|9820526|FG000|Safety Follow-up|Protocol Violation|1
6173063|NCT01271712|9820527|FG001|Safety Follow-up|Protocol Violation|1
6173064|NCT01271712|9820526|FG000|Safety Follow-up|Not analyzed after cutoff 08Jun2015|3
6173065|NCT01271712|9820527|FG001|Safety Follow-up|Not analyzed after cutoff 08Jun2015|4
6173066|NCT01271712|9820526|FG000|Safety Follow-up|No follow-up|1
6173067|NCT01271712|9820527|FG001|Safety Follow-up|No follow-up|1
6173068|NCT01271712|9820526|FG000|Safety Follow-up|Progressive disease|1
6173069|NCT01271712|9820527|FG001|Safety Follow-up|Progressive disease|0
6173070|NCT01271712|9820526|FG000|Survival Follow-up|Not analyzed after cutoff 08Jun2015|15
6173071|NCT01271712|9820527|FG001|Survival Follow-up|Not analyzed after cutoff 08Jun2015|6
6173072|NCT01271725|9820536|FG000|Part A|Progressive disease according to RECIST|8
6173073|NCT01271725|9820537|FG001|Part A|Progressive disease according to RECIST|0
6173074|NCT01271725|9820536|FG000|Part A|Clinical signs/symptoms of progression|2
6173075|NCT01271725|9820537|FG001|Part A|Clinical signs/symptoms of progression|0
6173076|NCT01271725|9820536|FG000|Part A|Other Adverse Event|8
6173077|NCT01271725|9820537|FG001|Part A|Other Adverse Event|0
6173078|NCT01271725|9820536|FG000|Part A|Lost to Follow-up|1
6173079|NCT01271725|9820537|FG001|Part A|Lost to Follow-up|0
6173080|NCT01271725|9820536|FG000|Part A|Withdrawal by Subject|12
6173081|NCT01271725|9820537|FG001|Part A|Withdrawal by Subject|0
6173082|NCT01271725|9820536|FG000|Part A|Other than specified|3
6173083|NCT01271725|9820537|FG001|Part A|Other than specified|0
6173084|NCT01271725|9820536|FG000|Part A|Protocol Violation|1
6173085|NCT01271725|9820537|FG001|Part A|Protocol Violation|0
6173086|NCT01271725|9820536|FG000|Part B|Other than specified|0
6173087|NCT01271725|9820537|FG001|Part B|Other than specified|2
6173088|NCT01271725|9820536|FG000|Part B|Clinical signs/symptoms of progression|0
6173089|NCT01271725|9820537|FG001|Part B|Clinical signs/symptoms of progression|2
6173090|NCT01271725|9820536|FG000|Part B|Other Adverse Event|0
6173091|NCT01271725|9820537|FG001|Part B|Other Adverse Event|1
6173092|NCT01271725|9820536|FG000|Part B|Protocol Violation|0
6173093|NCT01271725|9820537|FG001|Part B|Protocol Violation|1
6173094|NCT01271725|9820536|FG000|Part B|Withdrawal by Subject|0
6173095|NCT01271725|9820537|FG001|Part B|Withdrawal by Subject|6
6173096|NCT01271803|9820549|FG000|Overall Study|Progressive disease|0
6173097|NCT01271803|9820550|FG001|Overall Study|Progressive disease|0
6173098|NCT01271803|9820551|FG002|Overall Study|Progressive disease|2
6173099|NCT01271803|9820549|FG000|Overall Study|Death|53
6173100|NCT01271803|9820550|FG001|Overall Study|Death|34
6173101|NCT01271803|9820551|FG002|Overall Study|Death|0
6173102|NCT01271803|9820549|FG000|Overall Study|Withdrawal by Subject|1
6173103|NCT01271803|9820550|FG001|Overall Study|Withdrawal by Subject|5
6173104|NCT01271803|9820551|FG002|Overall Study|Withdrawal by Subject|0
6173105|NCT01271803|9820549|FG000|Overall Study|Lost to Follow-up|1
6173106|NCT01271803|9820550|FG001|Overall Study|Lost to Follow-up|0
6173107|NCT01271803|9820551|FG002|Overall Study|Lost to Follow-up|0
6173108|NCT01271933|9820624|FG000|Single-Blind Phase|Lack of Efficacy|37
6173109|NCT01271933|9820625|FG001|Single-Blind Phase|Lack of Efficacy|0
6173110|NCT01271933|9820626|FG002|Single-Blind Phase|Lack of Efficacy|0
6173111|NCT01271933|9820624|FG000|Single-Blind Phase|Lost to Follow-up|10
6173112|NCT01271933|9820625|FG001|Single-Blind Phase|Lost to Follow-up|0
6173113|NCT01271933|9820626|FG002|Single-Blind Phase|Lost to Follow-up|0
6173114|NCT01271933|9820624|FG000|Single-Blind Phase|Withdrawal by Subject|15
6173115|NCT01271933|9820625|FG001|Single-Blind Phase|Withdrawal by Subject|0
6173116|NCT01271933|9820626|FG002|Single-Blind Phase|Withdrawal by Subject|0
6173117|NCT01271933|9820624|FG000|Single-Blind Phase|Protocol Violation|3
6173118|NCT01271933|9820625|FG001|Single-Blind Phase|Protocol Violation|0
6173119|NCT01271933|9820626|FG002|Single-Blind Phase|Protocol Violation|0
6043376|NCT00389064|9641898|FG001|Overall Study|Physician Decision|2
6043377|NCT00389064|9641897|FG000|Overall Study|Lost to Follow-up|1
6043378|NCT00389064|9641898|FG001|Overall Study|Lost to Follow-up|2
6043379|NCT00389064|9641897|FG000|Overall Study|Protocol Violation|2
6043380|NCT00389064|9641898|FG001|Overall Study|Protocol Violation|0
6043381|NCT00389064|9641897|FG000|Overall Study|Multiple Reasons|9
6043382|NCT00389064|9641898|FG001|Overall Study|Multiple Reasons|11
6043383|NCT00389207|9641916|FG000|Overall Study|Adverse Event|26
6043384|NCT00389207|9641917|FG001|Overall Study|Adverse Event|32
6043385|NCT00389207|9641918|FG002|Overall Study|Adverse Event|10
6043386|NCT00389207|9641916|FG000|Overall Study|Protocol Violation|3
6043387|NCT00389207|9641917|FG001|Overall Study|Protocol Violation|1
6043388|NCT00389207|9641918|FG002|Overall Study|Protocol Violation|4
6043389|NCT00389207|9641916|FG000|Overall Study|Lost to Follow-up|12
6043390|NCT00389207|9641917|FG001|Overall Study|Lost to Follow-up|9
6043391|NCT00389207|9641918|FG002|Overall Study|Lost to Follow-up|7
6043392|NCT00389207|9641916|FG000|Overall Study|Withdrawal by Subject|5
6043393|NCT00389207|9641917|FG001|Overall Study|Withdrawal by Subject|7
6043394|NCT00389207|9641918|FG002|Overall Study|Withdrawal by Subject|11
6043395|NCT00389207|9641916|FG000|Overall Study|Other|17
6043396|NCT00389207|9641917|FG001|Overall Study|Other|23
6043397|NCT00389207|9641918|FG002|Overall Study|Other|9
6043398|NCT00389324|9641931|FG000|Run-In Phase|Adverse Event|1
6043399|NCT00389324|9641931|FG000|Run-In Phase|Lost to Follow-up|1
6043400|NCT00389324|9641931|FG000|Run-In Phase|Withdrawal by Subject|1
6043401|NCT00389324|9641931|FG000|Subcutaneous Phase|Adverse Event|2
6043402|NCT00389324|9641931|FG000|Subcutaneous Phase|Non-compliance with study medication|2
6043403|NCT00389324|9641931|FG000|Subcutaneous Phase|Withdrawal by Subject|2
6043404|NCT00389324|9641931|FG000|Subcutaneous Phase|Lost to Follow-up|1
6043405|NCT00389441|9641938|FG000|Overall Study|Adverse Event|7
6043406|NCT00389441|9641938|FG000|Overall Study|Death|4
6043407|NCT00389441|9641938|FG000|Overall Study|Lost to Follow-up|2
6043408|NCT00389441|9641938|FG000|Overall Study|Withdrawal by Subject|4
6043409|NCT00389441|9641938|FG000|Overall Study|Physician Decision|1
6043410|NCT00389441|9641938|FG000|Overall Study|Protocol Violation|1
6043411|NCT00389441|9641938|FG000|Overall Study|Global deterioration of health status|4
6043412|NCT00389441|9641938|FG000|Overall Study|Objective progression or relapse|26
6043413|NCT00389441|9641938|FG000|Overall Study|Ongoing in study A4061008 (NCT00828919)|2
6043414|NCT00389441|9641938|FG000|Overall Study|Clinical progression|1
6043415|NCT00389519|9641980|FG000|Placebo Run-In|Did not meet blood pressure criteria|119
6043416|NCT00389519|9641981|FG001|Placebo Run-In|Did not meet blood pressure criteria|0
6043417|NCT00389519|9641982|FG002|Placebo Run-In|Did not meet blood pressure criteria|0
6043418|NCT00389519|9641983|FG003|Placebo Run-In|Did not meet blood pressure criteria|0
6043419|NCT00389519|9641980|FG000|Placebo Run-In|Withdrawal by Subject|19
6043420|NCT00389519|9641981|FG001|Placebo Run-In|Withdrawal by Subject|0
6043421|NCT00389519|9641982|FG002|Placebo Run-In|Withdrawal by Subject|0
6043422|NCT00389519|9641983|FG003|Placebo Run-In|Withdrawal by Subject|0
6043423|NCT00389519|9641980|FG000|Placebo Run-In|Reason not specified|40
6043424|NCT00389519|9641981|FG001|Placebo Run-In|Reason not specified|0
6043425|NCT00389519|9641982|FG002|Placebo Run-In|Reason not specified|0
6043426|NCT00389519|9641983|FG003|Placebo Run-In|Reason not specified|0
6043427|NCT00389519|9641980|FG000|Randomized|Did not receive study drug|2
6043428|NCT00389519|9641981|FG001|Randomized|Did not receive study drug|0
6043429|NCT00389519|9641982|FG002|Randomized|Did not receive study drug|0
6043430|NCT00389519|9641983|FG003|Randomized|Did not receive study drug|0
6043431|NCT00389519|9641980|FG000|Treated|Adverse Event|1
6043432|NCT00389519|9641981|FG001|Treated|Adverse Event|0
6043433|NCT00389519|9641982|FG002|Treated|Adverse Event|0
6043434|NCT00389519|9641983|FG003|Treated|Adverse Event|2
6043435|NCT00389519|9641980|FG000|Treated|Reason not specified|1
6043436|NCT00389519|9641981|FG001|Treated|Reason not specified|1
6043437|NCT00389519|9641982|FG002|Treated|Reason not specified|0
6043438|NCT00389519|9641983|FG003|Treated|Reason not specified|2
6043439|NCT00389597|9642006|FG000|Overall Study|Lost to Follow-up|8
6043440|NCT00389597|9642007|FG001|Overall Study|Lost to Follow-up|6
6043441|NCT00389597|9642008|FG002|Overall Study|Lost to Follow-up|4
6043442|NCT00389597|9642009|FG003|Overall Study|Lost to Follow-up|6
6043443|NCT00389831|9642034|FG000|Overall Study|Lack of Efficacy|0
6043444|NCT00389831|9642035|FG001|Overall Study|Lack of Efficacy|2
6043445|NCT00389831|9642034|FG000|Overall Study|Did not receive treatment.|0
6043446|NCT00389831|9642035|FG001|Overall Study|Did not receive treatment.|2
6043447|NCT00389831|9642034|FG000|Overall Study|Other reasons|0
6043448|NCT00389831|9642035|FG001|Overall Study|Other reasons|2
6043449|NCT00389831|9642034|FG000|Overall Study|Lost to Follow-up|0
6043450|NCT00389831|9642035|FG001|Overall Study|Lost to Follow-up|1
6043451|NCT00390013|9642069|FG000|Phase 1|tired|0
6043452|NCT00390013|9642070|FG001|Phase 1|tired|0
6043453|NCT00390013|9642071|FG002|Phase 1|tired|0
6043454|NCT00390013|9642072|FG003|Phase 1|tired|1
6043455|NCT00390013|9642069|FG000|Phase 2 First Treatment|tired|1
6043456|NCT00390013|9642070|FG001|Phase 2 First Treatment|tired|0
6043457|NCT00390013|9642071|FG002|Phase 2 First Treatment|tired|0
6043458|NCT00390013|9642072|FG003|Phase 2 First Treatment|tired|0
6043459|NCT00390013|9642069|FG000|Phase 2 First Treatment|Withdrawal by Subject|0
6043460|NCT00390013|9642070|FG001|Phase 2 First Treatment|Withdrawal by Subject|1
6043461|NCT00390013|9642071|FG002|Phase 2 First Treatment|Withdrawal by Subject|0
6043462|NCT00390013|9642072|FG003|Phase 2 First Treatment|Withdrawal by Subject|0
6043463|NCT00390221|9642085|FG000|Overall Study|Lost to Follow-up|0
6043464|NCT00390221|9642086|FG001|Overall Study|Lost to Follow-up|3
6043465|NCT00390221|9642087|FG002|Overall Study|Lost to Follow-up|0
6043466|NCT00390221|9642085|FG000|Overall Study|Adverse Event|1
6043467|NCT00390221|9642086|FG001|Overall Study|Adverse Event|4
6043468|NCT00390221|9642087|FG002|Overall Study|Adverse Event|3
6043469|NCT00390221|9642085|FG000|Overall Study|Investigator Decision|0
6084899|NCT00645944|9693940|FG001|Received Medication|Protocol Violation|1
6084900|NCT00646113|9693959|FG000|Overall Study|Lost to Follow-up|5
6084901|NCT00646113|9693959|FG000|Overall Study|Adverse Event|3
6084902|NCT00646399|9693965|FG000|Overall Study|Death|63
6084903|NCT00646399|9693966|FG001|Overall Study|Death|53
6084904|NCT00646399|9693965|FG000|Overall Study|Withdrawal by Subject|9
6084905|NCT00646399|9693966|FG001|Overall Study|Withdrawal by Subject|10
6084906|NCT00646399|9693965|FG000|Overall Study|Other Reason|11
6084907|NCT00646399|9693966|FG001|Overall Study|Other Reason|11
6084908|NCT00646451|9693972|FG000|Overall Study|Adverse Event|3
6084909|NCT00646451|9693973|FG001|Overall Study|Adverse Event|0
6084910|NCT00646451|9693972|FG000|Overall Study|Exacerbation of pre-existing condition|1
6084911|NCT00646451|9693973|FG001|Overall Study|Exacerbation of pre-existing condition|0
6084912|NCT00646776|9694018|FG000|Overall Study|Adverse Event|1
6084913|NCT00646776|9694019|FG001|Overall Study|Adverse Event|9
6084914|NCT00646776|9694018|FG000|Overall Study|Investigator discretion|0
6084915|NCT00646776|9694019|FG001|Overall Study|Investigator discretion|4
6084916|NCT00646906|9694032|FG000|Crossover Period 1|Withdrawal by Subject|1
6084917|NCT00646906|9694033|FG001|Crossover Period 1|Withdrawal by Subject|0
6084918|NCT00646906|9694034|FG002|Crossover Period 1|Withdrawal by Subject|0
6084919|NCT00646906|9694035|FG003|Crossover Period 1|Withdrawal by Subject|0
6084920|NCT00646906|9694036|FG004|Crossover Period 1|Withdrawal by Subject|0
6084921|NCT00646906|9694037|FG005|Crossover Period 1|Withdrawal by Subject|1
6084922|NCT00646906|9694038|FG006|Crossover Period 1|Withdrawal by Subject|0
6084923|NCT00646906|9694032|FG000|Crossover Period 2|Withdrawal by Subject|0
6084924|NCT00646906|9694033|FG001|Crossover Period 2|Withdrawal by Subject|1
6084925|NCT00646906|9694034|FG002|Crossover Period 2|Withdrawal by Subject|2
6084926|NCT00646906|9694035|FG003|Crossover Period 2|Withdrawal by Subject|1
6084927|NCT00646906|9694036|FG004|Crossover Period 2|Withdrawal by Subject|0
6084928|NCT00646906|9694037|FG005|Crossover Period 2|Withdrawal by Subject|0
6084929|NCT00646906|9694038|FG006|Crossover Period 2|Withdrawal by Subject|0
6084930|NCT00646906|9694032|FG000|Crossover Period 2|Physician Decision|0
6084931|NCT00646906|9694033|FG001|Crossover Period 2|Physician Decision|0
6084932|NCT00646906|9694034|FG002|Crossover Period 2|Physician Decision|0
6084933|NCT00646906|9694035|FG003|Crossover Period 2|Physician Decision|0
6084934|NCT00646906|9694036|FG004|Crossover Period 2|Physician Decision|0
6084935|NCT00646906|9694037|FG005|Crossover Period 2|Physician Decision|0
6084936|NCT00646906|9694038|FG006|Crossover Period 2|Physician Decision|1
6084937|NCT00646958|9694054|FG000|Overall Study|Lack of Efficacy|1
6084938|NCT00646958|9694055|FG001|Overall Study|Lack of Efficacy|0
6084939|NCT00646958|9694056|FG002|Overall Study|Lack of Efficacy|0
6084940|NCT00646958|9694054|FG000|Overall Study|Adverse Event|4
6084941|NCT00646958|9694055|FG001|Overall Study|Adverse Event|0
6084942|NCT00646958|9694056|FG002|Overall Study|Adverse Event|0
6084943|NCT00646958|9694054|FG000|Overall Study|Lost to Follow-up|1
6084944|NCT00646958|9694055|FG001|Overall Study|Lost to Follow-up|5
6084945|NCT00646958|9694056|FG002|Overall Study|Lost to Follow-up|7
6084946|NCT00646958|9694054|FG000|Overall Study|Protocol Violation|1
6084947|NCT00646958|9694055|FG001|Overall Study|Protocol Violation|1
6084948|NCT00646958|9694056|FG002|Overall Study|Protocol Violation|0
6084949|NCT00646958|9694054|FG000|Overall Study|Abnormal screening lab tests|1
6084950|NCT00646958|9694055|FG001|Overall Study|Abnormal screening lab tests|1
6084951|NCT00646958|9694056|FG002|Overall Study|Abnormal screening lab tests|0
6084952|NCT00646958|9694054|FG000|Overall Study|Withdrawal by Subject|1
6084953|NCT00646958|9694055|FG001|Overall Study|Withdrawal by Subject|2
6084954|NCT00646958|9694056|FG002|Overall Study|Withdrawal by Subject|0
6084955|NCT00646958|9694054|FG000|Overall Study|Did not receive study drug|2
6084956|NCT00646958|9694055|FG001|Overall Study|Did not receive study drug|0
6084957|NCT00646958|9694056|FG002|Overall Study|Did not receive study drug|2
6084958|NCT00647270|9694067|FG000|Period 1, Placebo-control (12 Weeks)|Adverse Event|2
6084959|NCT00647270|9694068|FG001|Period 1, Placebo-control (12 Weeks)|Adverse Event|7
6084960|NCT00647270|9694069|FG002|Period 1, Placebo-control (12 Weeks)|Adverse Event|7
6084961|NCT00647270|9694067|FG000|Period 1, Placebo-control (12 Weeks)|Lost to Follow-up|0
6084962|NCT00647270|9694068|FG001|Period 1, Placebo-control (12 Weeks)|Lost to Follow-up|1
6084963|NCT00647270|9694069|FG002|Period 1, Placebo-control (12 Weeks)|Lost to Follow-up|1
6084964|NCT00647270|9694067|FG000|Period 1, Placebo-control (12 Weeks)|Withdrawal by Subject|2
6084965|NCT00647270|9694068|FG001|Period 1, Placebo-control (12 Weeks)|Withdrawal by Subject|1
6084966|NCT00647270|9694069|FG002|Period 1, Placebo-control (12 Weeks)|Withdrawal by Subject|7
6084967|NCT00647270|9694067|FG000|Period 1, Placebo-control (12 Weeks)|Other|4
6084968|NCT00647270|9694068|FG001|Period 1, Placebo-control (12 Weeks)|Other|4
6084969|NCT00647270|9694069|FG002|Period 1, Placebo-control (12 Weeks)|Other|8
6084970|NCT00647270|9694067|FG000|Period 2, Placebo Switched to Adalimumab|Adverse Event|1
6084971|NCT00647270|9694068|FG001|Period 2, Placebo Switched to Adalimumab|Adverse Event|3
6084972|NCT00647270|9694069|FG002|Period 2, Placebo Switched to Adalimumab|Adverse Event|3
6084973|NCT00647270|9694067|FG000|Period 2, Placebo Switched to Adalimumab|Withdrawal by Subject|0
6087762|NCT00670449|9698231|FG000|Overall Study|Subject Withdrew Consent|0
6043470|NCT00390221|9642086|FG001|Overall Study|Investigator Decision|0
6043471|NCT00390221|9642087|FG002|Overall Study|Investigator Decision|1
6043472|NCT00390221|9642085|FG000|Overall Study|Withdrawal by Subject|13
6043473|NCT00390221|9642086|FG001|Overall Study|Withdrawal by Subject|9
6043474|NCT00390221|9642087|FG002|Overall Study|Withdrawal by Subject|7
6043475|NCT00390221|9642085|FG000|Overall Study|Subject Non-compliance|1
6043476|NCT00390221|9642086|FG001|Overall Study|Subject Non-compliance|0
6043477|NCT00390221|9642087|FG002|Overall Study|Subject Non-compliance|2
6043478|NCT00390221|9642085|FG000|Overall Study|Other|3
6043479|NCT00390221|9642086|FG001|Overall Study|Other|4
6043480|NCT00390221|9642087|FG002|Overall Study|Other|2
6043481|NCT00390299|9642106|FG000|Overall Study|Cancellation|1
6043482|NCT00390299|9642107|FG001|Overall Study|Cancellation|0
6043483|NCT00390299|9642108|FG002|Overall Study|Cancellation|0
6043484|NCT00390299|9642109|FG003|Overall Study|Cancellation|0
6043485|NCT00390299|9642110|FG004|Overall Study|Cancellation|0
6043486|NCT00390416|9642128|FG000|Overall Study|Withdrawal by Subject|1
6043487|NCT00390416|9642128|FG000|Overall Study|Not treated|3
6043488|NCT00390455|9642151|FG000|Overall Study|Adverse Event|17
6043489|NCT00390455|9642152|FG001|Overall Study|Adverse Event|3
6043490|NCT00390455|9642151|FG000|Overall Study|Withdrawal by Subject|8
6043491|NCT00390455|9642152|FG001|Overall Study|Withdrawal by Subject|8
6043492|NCT00390455|9642151|FG000|Overall Study|Alternate Treatment|0
6043493|NCT00390455|9642152|FG001|Overall Study|Alternate Treatment|1
6043494|NCT00390455|9642151|FG000|Overall Study|Other Medical Reasons|7
6043495|NCT00390455|9642152|FG001|Overall Study|Other Medical Reasons|11
6043496|NCT00390468|9642158|FG000|Overall Study|Protocol Violation|2
6043497|NCT00390468|9642158|FG000|Overall Study|Lack of Efficacy|1
6043498|NCT00390546|9642164|FG000|Overall Study|Renal impairment|1
6043499|NCT00390546|9642165|FG001|Overall Study|Renal impairment|0
6043500|NCT00390546|9642164|FG000|Overall Study|Physician Decision|5
6043501|NCT00390546|9642165|FG001|Overall Study|Physician Decision|5
6043502|NCT00390572|9642184|FG000|Overall Study|Lost to Follow-up|8
6043503|NCT00390572|9642185|FG001|Overall Study|Lost to Follow-up|4
6043504|NCT00390572|9642184|FG000|Overall Study|health condition|0
6043505|NCT00390572|9642185|FG001|Overall Study|health condition|1
6043506|NCT00390689|9642205|FG000|Overall Study|Adverse Event|2
6043507|NCT00390689|9642206|FG001|Overall Study|Adverse Event|5
6043508|NCT00390689|9642207|FG002|Overall Study|Adverse Event|2
6043509|NCT00390689|9642205|FG000|Overall Study|Lack of Efficacy|0
6043510|NCT00390689|9642206|FG001|Overall Study|Lack of Efficacy|0
6043511|NCT00390689|9642207|FG002|Overall Study|Lack of Efficacy|1
6043512|NCT00390689|9642205|FG000|Overall Study|Protocol Violation|1
6043513|NCT00390689|9642206|FG001|Overall Study|Protocol Violation|0
6043514|NCT00390689|9642207|FG002|Overall Study|Protocol Violation|0
6043515|NCT00390689|9642205|FG000|Overall Study|Investigator's judgement|2
6043516|NCT00390689|9642206|FG001|Overall Study|Investigator's judgement|0
6043517|NCT00390689|9642207|FG002|Overall Study|Investigator's judgement|0
6043518|NCT00390780|9642226|FG000|Overall Study|Not completed|10
6043519|NCT00390780|9642227|FG001|Overall Study|Not completed|4
6043520|NCT00390780|9642226|FG000|Overall Study|Protocol Violation|6
6043521|NCT00390780|9642227|FG001|Overall Study|Protocol Violation|4
6043522|NCT00390780|9642226|FG000|Overall Study|Lost to Follow-up|3
6043523|NCT00390780|9642227|FG001|Overall Study|Lost to Follow-up|6
6043524|NCT00390780|9642226|FG000|Overall Study|Adverse Event|2
6043525|NCT00390780|9642227|FG001|Overall Study|Adverse Event|3
6043526|NCT00390780|9642226|FG000|Overall Study|Death|1
6043527|NCT00390780|9642227|FG001|Overall Study|Death|3
6043528|NCT00390780|9642226|FG000|Overall Study|Withdrawal by Subject|1
6043529|NCT00390780|9642227|FG001|Overall Study|Withdrawal by Subject|2
6043530|NCT00390780|9642226|FG000|Overall Study|Inclusion criteria not satisfied|0
6043531|NCT00390780|9642227|FG001|Overall Study|Inclusion criteria not satisfied|2
6043532|NCT00390780|9642226|FG000|Overall Study|Lost to follow up and other reasons|0
6043533|NCT00390780|9642227|FG001|Overall Study|Lost to follow up and other reasons|1
6043534|NCT00390780|9642226|FG000|Overall Study|Investigator decision, SAE, other reason|0
6043535|NCT00390780|9642227|FG001|Overall Study|Investigator decision, SAE, other reason|1
6043536|NCT00390780|9642226|FG000|Overall Study|SAE, death|0
6043537|NCT00390780|9642227|FG001|Overall Study|SAE, death|1
6043538|NCT00390806|9642235|FG000|Overall Study|Lost to Follow-up|7
6043539|NCT00390806|9642236|FG001|Overall Study|Lost to Follow-up|6
6043540|NCT00390806|9642235|FG000|Overall Study|Protocol Violation|2
6043541|NCT00390806|9642236|FG001|Overall Study|Protocol Violation|2
6043542|NCT00390806|9642235|FG000|Overall Study|Withdrawal by Subject|12
6043543|NCT00390806|9642236|FG001|Overall Study|Withdrawal by Subject|15
6043544|NCT00390806|9642235|FG000|Overall Study|Investigator Decision|4
6043545|NCT00390806|9642236|FG001|Overall Study|Investigator Decision|6
6043546|NCT00390806|9642235|FG000|Overall Study|Death|1
6043547|NCT00390806|9642236|FG001|Overall Study|Death|0
6043548|NCT00390806|9642235|FG000|Overall Study|Physician Decision|0
6043549|NCT00390806|9642236|FG001|Overall Study|Physician Decision|1
6043550|NCT00390806|9642235|FG000|Overall Study|Ongoing|4
6043551|NCT00390806|9642236|FG001|Overall Study|Ongoing|2
6043552|NCT00390858|9642244|FG000|Overall Study|Adverse Event|6
6043553|NCT00390858|9642245|FG001|Overall Study|Adverse Event|2
6084974|NCT00647270|9694068|FG001|Period 2, Placebo Switched to Adalimumab|Withdrawal by Subject|0
6084975|NCT00647270|9694069|FG002|Period 2, Placebo Switched to Adalimumab|Withdrawal by Subject|4
6084976|NCT00647270|9694067|FG000|Period 2, Placebo Switched to Adalimumab|Other|2
6084977|NCT00647270|9694068|FG001|Period 2, Placebo Switched to Adalimumab|Other|6
6084978|NCT00647270|9694069|FG002|Period 2, Placebo Switched to Adalimumab|Other|0
6173120|NCT01271933|9820624|FG000|Single-Blind Phase|Adverse Event|52
6173121|NCT01271933|9820625|FG001|Single-Blind Phase|Adverse Event|0
6173122|NCT01271933|9820626|FG002|Single-Blind Phase|Adverse Event|0
6173123|NCT01271933|9820624|FG000|Single-Blind Phase|(Failed to meet dosing requirement)|1
6173124|NCT01271933|9820625|FG001|Single-Blind Phase|(Failed to meet dosing requirement)|0
6173125|NCT01271933|9820626|FG002|Single-Blind Phase|(Failed to meet dosing requirement)|0
6173126|NCT01271933|9820624|FG000|Single-Blind Phase|(Protocol non-compliance)|2
6173127|NCT01271933|9820625|FG001|Single-Blind Phase|(Protocol non-compliance)|0
6173128|NCT01271933|9820626|FG002|Single-Blind Phase|(Protocol non-compliance)|0
6173129|NCT01271933|9820624|FG000|Single-Blind Phase|(Participant request-personal reason)|1
6173130|NCT01271933|9820625|FG001|Single-Blind Phase|(Participant request-personal reason)|0
6173131|NCT01271933|9820626|FG002|Single-Blind Phase|(Participant request-personal reason)|0
6173132|NCT01271933|9820624|FG000|Double-Blind Phase|Randomized but not treated|0
6173133|NCT01271933|9820625|FG001|Double-Blind Phase|Randomized but not treated|0
6173134|NCT01271933|9820626|FG002|Double-Blind Phase|Randomized but not treated|1
6173135|NCT01271933|9820624|FG000|Double-Blind Phase|Lack of Efficacy|0
6173136|NCT01271933|9820625|FG001|Double-Blind Phase|Lack of Efficacy|6
6173137|NCT01271933|9820626|FG002|Double-Blind Phase|Lack of Efficacy|9
6173138|NCT01271933|9820624|FG000|Double-Blind Phase|Lost to Follow-up|0
6173139|NCT01271933|9820625|FG001|Double-Blind Phase|Lost to Follow-up|1
6173140|NCT01271933|9820626|FG002|Double-Blind Phase|Lost to Follow-up|1
6173141|NCT01271933|9820624|FG000|Double-Blind Phase|Withdrawal by Subject|0
6173142|NCT01271933|9820625|FG001|Double-Blind Phase|Withdrawal by Subject|6
6173143|NCT01271933|9820626|FG002|Double-Blind Phase|Withdrawal by Subject|1
6173144|NCT01271933|9820624|FG000|Double-Blind Phase|Adverse Event|0
6173145|NCT01271933|9820625|FG001|Double-Blind Phase|Adverse Event|3
6173146|NCT01271933|9820626|FG002|Double-Blind Phase|Adverse Event|0
6173147|NCT01271933|9820624|FG000|Double-Blind Phase|Participant request-personal reason|0
6173148|NCT01271933|9820625|FG001|Double-Blind Phase|Participant request-personal reason|1
6173149|NCT01271933|9820626|FG002|Double-Blind Phase|Participant request-personal reason|0
6173150|NCT01272011|9820662|FG000|Overall Study|Withdrawal By Subject or Failed Screen|0
6173151|NCT01272011|9820663|FG001|Overall Study|Withdrawal By Subject or Failed Screen|2
6173152|NCT01272011|9820664|FG002|Overall Study|Withdrawal By Subject or Failed Screen|0
6173153|NCT01272180|9820680|FG000|Overall Study|Adverse Event|0
6173154|NCT01272180|9820681|FG001|Overall Study|Adverse Event|0
6173155|NCT01272180|9820682|FG002|Overall Study|Adverse Event|1
6173156|NCT01272180|9820683|FG003|Overall Study|Adverse Event|0
6173157|NCT01272180|9820680|FG000|Overall Study|Withdrawal by Subject|2
6173158|NCT01272180|9820681|FG001|Overall Study|Withdrawal by Subject|6
6173159|NCT01272180|9820682|FG002|Overall Study|Withdrawal by Subject|3
6173160|NCT01272180|9820683|FG003|Overall Study|Withdrawal by Subject|2
6173161|NCT01272180|9820680|FG000|Overall Study|Lost to Follow-up|15
6173162|NCT01272180|9820681|FG001|Overall Study|Lost to Follow-up|14
6173163|NCT01272180|9820682|FG002|Overall Study|Lost to Follow-up|8
6173164|NCT01272180|9820683|FG003|Overall Study|Lost to Follow-up|10
6173165|NCT01272180|9820680|FG000|Overall Study|Inappropriate enrollment|0
6173166|NCT01272180|9820681|FG001|Overall Study|Inappropriate enrollment|0
6173167|NCT01272180|9820682|FG002|Overall Study|Inappropriate enrollment|1
6173168|NCT01272180|9820683|FG003|Overall Study|Inappropriate enrollment|1
6173169|NCT01272180|9820680|FG000|Overall Study|Protocol Violation|0
6173170|NCT01272180|9820681|FG001|Overall Study|Protocol Violation|1
6173171|NCT01272180|9820682|FG002|Overall Study|Protocol Violation|0
6173172|NCT01272180|9820683|FG003|Overall Study|Protocol Violation|1
6173173|NCT01272193|9820699|FG000|Overall Study|Adverse Event|1
6173174|NCT01272193|9820700|FG001|Overall Study|Adverse Event|1
6173175|NCT01272193|9820699|FG000|Overall Study|Lack of Efficacy|0
6375025|NCT03745638|10164836|FG004|Vehicle Control Period (Day 1 to Week 8)|Withdrawal by Subject|0
6375026|NCT03745638|10164837|FG005|Vehicle Control Period (Day 1 to Week 8)|Withdrawal by Subject|0
6375027|NCT03745638|10164838|FG006|Vehicle Control Period (Day 1 to Week 8)|Withdrawal by Subject|0
6375028|NCT03745638|10164832|FG000|Vehicle Control Period (Day 1 to Week 8)|Reason Not Specified|2
6375029|NCT03745638|10164833|FG001|Vehicle Control Period (Day 1 to Week 8)|Reason Not Specified|1
6375030|NCT03745638|10164834|FG002|Vehicle Control Period (Day 1 to Week 8)|Reason Not Specified|0
6173176|NCT01272193|9820700|FG001|Overall Study|Lack of Efficacy|3
6173177|NCT01272193|9820699|FG000|Overall Study|Withdrawal Criteria|1
6173178|NCT01272193|9820700|FG001|Overall Study|Withdrawal Criteria|1
6173179|NCT01272193|9820699|FG000|Overall Study|Unclassified|8
6173180|NCT01272193|9820700|FG001|Overall Study|Unclassified|7
6173181|NCT01272219|9820710|FG000|Main Period: Week 0 to Week 56|Adverse Event|86
6173182|NCT01272219|9820711|FG001|Main Period: Week 0 to Week 56|Adverse Event|0
6173183|NCT01272219|9820712|FG002|Main Period: Week 0 to Week 56|Adverse Event|0
6173184|NCT01272219|9820713|FG003|Main Period: Week 0 to Week 56|Adverse Event|16
6173185|NCT01272219|9820714|FG004|Main Period: Week 0 to Week 56|Adverse Event|152
6173186|NCT01272219|9820715|FG005|Main Period: Week 0 to Week 56|Adverse Event|29
6173187|NCT01272219|9820710|FG000|Main Period: Week 0 to Week 56|Lack of Efficacy|11
6173188|NCT01272219|9820711|FG001|Main Period: Week 0 to Week 56|Lack of Efficacy|0
6173189|NCT01272219|9820712|FG002|Main Period: Week 0 to Week 56|Lack of Efficacy|0
6173190|NCT01272219|9820713|FG003|Main Period: Week 0 to Week 56|Lack of Efficacy|14
6173191|NCT01272219|9820714|FG004|Main Period: Week 0 to Week 56|Lack of Efficacy|12
6173192|NCT01272219|9820715|FG005|Main Period: Week 0 to Week 56|Lack of Efficacy|22
6173193|NCT01272219|9820710|FG000|Main Period: Week 0 to Week 56|Protocol Violation|25
6173194|NCT01272219|9820711|FG001|Main Period: Week 0 to Week 56|Protocol Violation|0
6173195|NCT01272219|9820712|FG002|Main Period: Week 0 to Week 56|Protocol Violation|0
6173196|NCT01272219|9820713|FG003|Main Period: Week 0 to Week 56|Protocol Violation|18
6173197|NCT01272219|9820714|FG004|Main Period: Week 0 to Week 56|Protocol Violation|40
6173198|NCT01272219|9820715|FG005|Main Period: Week 0 to Week 56|Protocol Violation|20
6173199|NCT01272219|9820710|FG000|Main Period: Week 0 to Week 56|Withdrawal criteria|122
6173200|NCT01272219|9820711|FG001|Main Period: Week 0 to Week 56|Withdrawal criteria|0
6173201|NCT01272219|9820712|FG002|Main Period: Week 0 to Week 56|Withdrawal criteria|0
6173202|NCT01272219|9820713|FG003|Main Period: Week 0 to Week 56|Withdrawal criteria|114
6173203|NCT01272219|9820714|FG004|Main Period: Week 0 to Week 56|Withdrawal criteria|172
6173204|NCT01272219|9820715|FG005|Main Period: Week 0 to Week 56|Withdrawal criteria|147
6173205|NCT01272219|9820710|FG000|Main Period: Week 0 to Week 56|Unclassified|36
6173206|NCT01272219|9820711|FG001|Main Period: Week 0 to Week 56|Unclassified|0
6173207|NCT01272219|9820712|FG002|Main Period: Week 0 to Week 56|Unclassified|0
6173208|NCT01272219|9820713|FG003|Main Period: Week 0 to Week 56|Unclassified|29
6173209|NCT01272219|9820714|FG004|Main Period: Week 0 to Week 56|Unclassified|42
6173210|NCT01272219|9820715|FG005|Main Period: Week 0 to Week 56|Unclassified|34
6173211|NCT01272219|9820710|FG000|Re-randomised Period: Week 56 to Week 68|Adverse Event|0
6173212|NCT01272219|9820711|FG001|Re-randomised Period: Week 56 to Week 68|Adverse Event|1
6173213|NCT01272219|9820712|FG002|Re-randomised Period: Week 56 to Week 68|Adverse Event|1
6173214|NCT01272219|9820713|FG003|Re-randomised Period: Week 56 to Week 68|Adverse Event|2
6173215|NCT01272219|9820714|FG004|Re-randomised Period: Week 56 to Week 68|Adverse Event|0
6173216|NCT01272219|9820715|FG005|Re-randomised Period: Week 56 to Week 68|Adverse Event|0
6173217|NCT01272219|9820710|FG000|Re-randomised Period: Week 56 to Week 68|Lack of Efficacy|0
6375031|NCT03745638|10164835|FG003|Vehicle Control Period (Day 1 to Week 8)|Reason Not Specified|0
6375032|NCT03745638|10164836|FG004|Vehicle Control Period (Day 1 to Week 8)|Reason Not Specified|0
6375033|NCT03745638|10164837|FG005|Vehicle Control Period (Day 1 to Week 8)|Reason Not Specified|0
6375034|NCT03745638|10164838|FG006|Vehicle Control Period (Day 1 to Week 8)|Reason Not Specified|0
6375035|NCT03745638|10164832|FG000|Long-Term Safety Period (Weeks 8 to 52)|Adverse Event|0
6375036|NCT03745638|10164833|FG001|Long-Term Safety Period (Weeks 8 to 52)|Adverse Event|0
6375037|NCT03745638|10164834|FG002|Long-Term Safety Period (Weeks 8 to 52)|Adverse Event|0
6375038|NCT03745638|10164835|FG003|Long-Term Safety Period (Weeks 8 to 52)|Adverse Event|0
6375039|NCT03745638|10164836|FG004|Long-Term Safety Period (Weeks 8 to 52)|Adverse Event|0
6375040|NCT03745638|10164837|FG005|Long-Term Safety Period (Weeks 8 to 52)|Adverse Event|6
6375041|NCT03745638|10164838|FG006|Long-Term Safety Period (Weeks 8 to 52)|Adverse Event|1
6375042|NCT03745638|10164832|FG000|Long-Term Safety Period (Weeks 8 to 52)|Lack of Efficacy|0
6375043|NCT03745638|10164833|FG001|Long-Term Safety Period (Weeks 8 to 52)|Lack of Efficacy|0
6375044|NCT03745638|10164834|FG002|Long-Term Safety Period (Weeks 8 to 52)|Lack of Efficacy|0
6375045|NCT03745638|10164835|FG003|Long-Term Safety Period (Weeks 8 to 52)|Lack of Efficacy|1
6375046|NCT03745638|10164836|FG004|Long-Term Safety Period (Weeks 8 to 52)|Lack of Efficacy|0
6375047|NCT03745638|10164837|FG005|Long-Term Safety Period (Weeks 8 to 52)|Lack of Efficacy|2
6084979|NCT00647296|9694084|FG000|Part 1: 12-week Double-Blind Treatment|Withdrawal by Subject|0
6084980|NCT00647296|9694085|FG001|Part 1: 12-week Double-Blind Treatment|Withdrawal by Subject|0
6084981|NCT00647296|9694086|FG002|Part 1: 12-week Double-Blind Treatment|Withdrawal by Subject|0
6084982|NCT00647296|9694087|FG003|Part 1: 12-week Double-Blind Treatment|Withdrawal by Subject|1
6084983|NCT00647296|9694084|FG000|Part 1: 12-week Double-Blind Treatment|Adverse Event|1
6173218|NCT01272219|9820711|FG001|Re-randomised Period: Week 56 to Week 68|Lack of Efficacy|0
6173219|NCT01272219|9820712|FG002|Re-randomised Period: Week 56 to Week 68|Lack of Efficacy|0
6173220|NCT01272219|9820713|FG003|Re-randomised Period: Week 56 to Week 68|Lack of Efficacy|1
6173221|NCT01272219|9820714|FG004|Re-randomised Period: Week 56 to Week 68|Lack of Efficacy|0
6173222|NCT01272219|9820715|FG005|Re-randomised Period: Week 56 to Week 68|Lack of Efficacy|0
6173223|NCT01272219|9820710|FG000|Re-randomised Period: Week 56 to Week 68|Protocol Violation|0
6173224|NCT01272219|9820711|FG001|Re-randomised Period: Week 56 to Week 68|Protocol Violation|1
6173225|NCT01272219|9820712|FG002|Re-randomised Period: Week 56 to Week 68|Protocol Violation|0
6173226|NCT01272219|9820713|FG003|Re-randomised Period: Week 56 to Week 68|Protocol Violation|3
6173227|NCT01272219|9820714|FG004|Re-randomised Period: Week 56 to Week 68|Protocol Violation|0
6173228|NCT01272219|9820715|FG005|Re-randomised Period: Week 56 to Week 68|Protocol Violation|0
6173229|NCT01272219|9820710|FG000|Re-randomised Period: Week 56 to Week 68|Withdrawal criteria|0
6173230|NCT01272219|9820711|FG001|Re-randomised Period: Week 56 to Week 68|Withdrawal criteria|6
6173231|NCT01272219|9820712|FG002|Re-randomised Period: Week 56 to Week 68|Withdrawal criteria|4
6173232|NCT01272219|9820713|FG003|Re-randomised Period: Week 56 to Week 68|Withdrawal criteria|7
6173233|NCT01272219|9820714|FG004|Re-randomised Period: Week 56 to Week 68|Withdrawal criteria|0
6173234|NCT01272219|9820715|FG005|Re-randomised Period: Week 56 to Week 68|Withdrawal criteria|0
6173235|NCT01272219|9820710|FG000|Re-randomised Period: Week 56 to Week 68|Unclassified|0
6173236|NCT01272219|9820711|FG001|Re-randomised Period: Week 56 to Week 68|Unclassified|1
6173237|NCT01272219|9820712|FG002|Re-randomised Period: Week 56 to Week 68|Unclassified|2
6173238|NCT01272219|9820713|FG003|Re-randomised Period: Week 56 to Week 68|Unclassified|2
6173239|NCT01272219|9820714|FG004|Re-randomised Period: Week 56 to Week 68|Unclassified|0
6173240|NCT01272219|9820715|FG005|Re-randomised Period: Week 56 to Week 68|Unclassified|0
6173241|NCT01272219|9820710|FG000|Main + Extension Period: Week 0-172|Adverse Event|0
6173242|NCT01272219|9820711|FG001|Main + Extension Period: Week 0-172|Adverse Event|0
6173243|NCT01272219|9820712|FG002|Main + Extension Period: Week 0-172|Adverse Event|0
6173244|NCT01272219|9820713|FG003|Main + Extension Period: Week 0-172|Adverse Event|0
6173245|NCT01272219|9820714|FG004|Main + Extension Period: Week 0-172|Adverse Event|191
6173246|NCT01272219|9820715|FG005|Main + Extension Period: Week 0-172|Adverse Event|43
6173247|NCT01272219|9820710|FG000|Main + Extension Period: Week 0-172|Lack of Efficacy|0
6173248|NCT01272219|9820711|FG001|Main + Extension Period: Week 0-172|Lack of Efficacy|0
6173249|NCT01272219|9820712|FG002|Main + Extension Period: Week 0-172|Lack of Efficacy|0
6173250|NCT01272219|9820713|FG003|Main + Extension Period: Week 0-172|Lack of Efficacy|0
6173251|NCT01272219|9820714|FG004|Main + Extension Period: Week 0-172|Lack of Efficacy|29
6173252|NCT01272219|9820715|FG005|Main + Extension Period: Week 0-172|Lack of Efficacy|36
6173253|NCT01272219|9820710|FG000|Main + Extension Period: Week 0-172|Protocol Violation|0
6173254|NCT01272219|9820711|FG001|Main + Extension Period: Week 0-172|Protocol Violation|0
6173255|NCT01272219|9820712|FG002|Main + Extension Period: Week 0-172|Protocol Violation|0
6173256|NCT01272219|9820713|FG003|Main + Extension Period: Week 0-172|Protocol Violation|0
6173257|NCT01272219|9820714|FG004|Main + Extension Period: Week 0-172|Protocol Violation|76
6173258|NCT01272219|9820715|FG005|Main + Extension Period: Week 0-172|Protocol Violation|36
6173259|NCT01272219|9820710|FG000|Main + Extension Period: Week 0-172|Withdrawal criteria|0
6173260|NCT01272219|9820711|FG001|Main + Extension Period: Week 0-172|Withdrawal criteria|0
6173261|NCT01272219|9820712|FG002|Main + Extension Period: Week 0-172|Withdrawal criteria|0
6173262|NCT01272219|9820713|FG003|Main + Extension Period: Week 0-172|Withdrawal criteria|0
6173263|NCT01272219|9820714|FG004|Main + Extension Period: Week 0-172|Withdrawal criteria|364
6173264|NCT01272219|9820715|FG005|Main + Extension Period: Week 0-172|Withdrawal criteria|256
6173265|NCT01272219|9820710|FG000|Main + Extension Period: Week 0-172|Missing reason|0
6173266|NCT01272219|9820711|FG001|Main + Extension Period: Week 0-172|Missing reason|0
6173267|NCT01272219|9820712|FG002|Main + Extension Period: Week 0-172|Missing reason|0
6173268|NCT01272219|9820713|FG003|Main + Extension Period: Week 0-172|Missing reason|0
6173269|NCT01272219|9820714|FG004|Main + Extension Period: Week 0-172|Missing reason|1
6173270|NCT01272219|9820715|FG005|Main + Extension Period: Week 0-172|Missing reason|0
6173271|NCT01272219|9820710|FG000|Main + Extension Period: Week 0-172|Unclassified|0
6173272|NCT01272219|9820711|FG001|Main + Extension Period: Week 0-172|Unclassified|0
6173273|NCT01272219|9820712|FG002|Main + Extension Period: Week 0-172|Unclassified|0
6173274|NCT01272219|9820713|FG003|Main + Extension Period: Week 0-172|Unclassified|0
6173275|NCT01272219|9820714|FG004|Main + Extension Period: Week 0-172|Unclassified|61
6173276|NCT01272219|9820715|FG005|Main + Extension Period: Week 0-172|Unclassified|51
6192339|NCT01430442|9849596|FG005|Overall Study|Patient No Longer Meets Study Criteria|5
6192340|NCT01430442|9849597|FG006|Overall Study|Patient No Longer Meets Study Criteria|9
6192341|NCT01430442|9849598|FG007|Overall Study|Patient No Longer Meets Study Criteria|6
6192342|NCT01430455|9849616|FG000|Overall Study|Withdrawal by Subject|1
6192343|NCT01430455|9849616|FG000|Overall Study|Switched to follow-up phase|1
6192344|NCT01430468|9849622|FG000|Overall Study|Physician Decision|2
6192345|NCT01430468|9849623|FG001|Overall Study|Physician Decision|1
6192346|NCT01430468|9849622|FG000|Overall Study|Withdrawal by Subject|5
6192347|NCT01430468|9849623|FG001|Overall Study|Withdrawal by Subject|5
6192348|NCT01430559|9849631|FG000|Overall Study|Adverse Event|7
6192349|NCT01430559|9849632|FG001|Overall Study|Adverse Event|3
6192350|NCT01430559|9849631|FG000|Overall Study|Entry criteria not met|1
6192351|NCT01430559|9849632|FG001|Overall Study|Entry criteria not met|1
6192352|NCT01430559|9849631|FG000|Overall Study|Lost to Follow-up|1
6192353|NCT01430559|9849632|FG001|Overall Study|Lost to Follow-up|0
6192354|NCT01430559|9849631|FG000|Overall Study|Medication error|1
6192355|NCT01430559|9849632|FG001|Overall Study|Medication error|0
6192356|NCT01430559|9849631|FG000|Overall Study|Withdrawal by Subject|3
6192357|NCT01430559|9849632|FG001|Overall Study|Withdrawal by Subject|2
6192358|NCT01430559|9849631|FG000|Overall Study|Protocol Violation|1
6192359|NCT01430559|9849632|FG001|Overall Study|Protocol Violation|0
6192360|NCT01430559|9849631|FG000|Overall Study|Other|3
6192361|NCT01430559|9849632|FG001|Overall Study|Other|3
6192362|NCT01430559|9849631|FG000|Overall Study|Randomized, Not Treated|3
6192363|NCT01430559|9849632|FG001|Overall Study|Randomized, Not Treated|3
6192364|NCT01430585|9849643|FG000|Overall Study|Death|1
6192365|NCT01430585|9849643|FG000|Overall Study|Objective Progression or Relapse|3
6192366|NCT01430585|9849643|FG000|Overall Study|Study Terminated by Sponsor|3
6192367|NCT01430585|9849643|FG000|Overall Study|Other|7
6192368|NCT01430611|9849655|FG000|Overall Study|Adverse Event|0
6192369|NCT01430611|9849656|FG001|Overall Study|Adverse Event|1
6192370|NCT01430611|9849655|FG000|Overall Study|Protocol Violation|1
6192371|NCT01430611|9849656|FG001|Overall Study|Protocol Violation|0
6173277|NCT01272232|9820731|FG000|Weeks 0-56|Adverse Event|39
6173278|NCT01272232|9820732|FG001|Weeks 0-56|Adverse Event|18
6173279|NCT01272232|9820733|FG002|Weeks 0-56|Adverse Event|7
6173280|NCT01272232|9820731|FG000|Weeks 0-56|Lack of Efficacy|0
6173281|NCT01272232|9820732|FG001|Weeks 0-56|Lack of Efficacy|0
6173282|NCT01272232|9820733|FG002|Weeks 0-56|Lack of Efficacy|3
6173283|NCT01272232|9820731|FG000|Weeks 0-56|Protocol Violation|12
6173284|NCT01272232|9820732|FG001|Weeks 0-56|Protocol Violation|8
6173285|NCT01272232|9820733|FG002|Weeks 0-56|Protocol Violation|13
6173286|NCT01272232|9820731|FG000|Weeks 0-56|Withdrawal criteria|32
6173287|NCT01272232|9820732|FG001|Weeks 0-56|Withdrawal criteria|14
6173288|NCT01272232|9820733|FG002|Weeks 0-56|Withdrawal criteria|37
6173289|NCT01272232|9820731|FG000|Weeks 0-56|Unclassified|16
6173290|NCT01272232|9820732|FG001|Weeks 0-56|Unclassified|7
6173291|NCT01272232|9820733|FG002|Weeks 0-56|Unclassified|12
6173292|NCT01272232|9820731|FG000|Off Drug Follow-up Period (Weeks 56-68)|Adverse Event|1
6173293|NCT01272232|9820732|FG001|Off Drug Follow-up Period (Weeks 56-68)|Adverse Event|1
6173294|NCT01272232|9820733|FG002|Off Drug Follow-up Period (Weeks 56-68)|Adverse Event|0
6173295|NCT01272232|9820731|FG000|Off Drug Follow-up Period (Weeks 56-68)|Lack of Efficacy|1
6173296|NCT01272232|9820732|FG001|Off Drug Follow-up Period (Weeks 56-68)|Lack of Efficacy|0
6173297|NCT01272232|9820733|FG002|Off Drug Follow-up Period (Weeks 56-68)|Lack of Efficacy|0
6173298|NCT01272232|9820731|FG000|Off Drug Follow-up Period (Weeks 56-68)|Protocol Violation|1
6173299|NCT01272232|9820732|FG001|Off Drug Follow-up Period (Weeks 56-68)|Protocol Violation|0
6173300|NCT01272232|9820733|FG002|Off Drug Follow-up Period (Weeks 56-68)|Protocol Violation|1
6173301|NCT01272232|9820731|FG000|Off Drug Follow-up Period (Weeks 56-68)|Withdrawal criteria|9
6173302|NCT01272232|9820732|FG001|Off Drug Follow-up Period (Weeks 56-68)|Withdrawal criteria|7
6173303|NCT01272232|9820733|FG002|Off Drug Follow-up Period (Weeks 56-68)|Withdrawal criteria|4
6173304|NCT01272232|9820731|FG000|Off Drug Follow-up Period (Weeks 56-68)|Unclassified|2
6173305|NCT01272232|9820732|FG001|Off Drug Follow-up Period (Weeks 56-68)|Unclassified|2
6173306|NCT01272232|9820733|FG002|Off Drug Follow-up Period (Weeks 56-68)|Unclassified|0
6173307|NCT01272635|9820772|FG000|Overall Study|Lost to Follow-up|31
6173308|NCT01272635|9820773|FG001|Overall Study|Lost to Follow-up|20
6173309|NCT01272635|9820774|FG002|Overall Study|Lost to Follow-up|31
6173310|NCT01272635|9820775|FG003|Overall Study|Lost to Follow-up|23
6173311|NCT01272661|9820786|FG000|Overall Study|lost to followup/case closed/ no birth|126
6173312|NCT01272661|9820787|FG001|Overall Study|lost to followup/case closed/ no birth|209
6173313|NCT01272661|9820788|FG002|Overall Study|lost to followup/case closed/ no birth|72
6173314|NCT01272804|9820802|FG000|Overall Study|Adverse Event|1
6173315|NCT01272804|9820803|FG001|Overall Study|Adverse Event|0
6173316|NCT01272804|9820804|FG002|Overall Study|Adverse Event|0
6173317|NCT01272804|9820805|FG003|Overall Study|Adverse Event|0
6173318|NCT01272804|9820806|FG004|Overall Study|Adverse Event|2
6173319|NCT01272804|9820807|FG005|Overall Study|Adverse Event|1
6173320|NCT01272869|9820832|FG000|Period 2 (14 Days)|Adverse Event|1
6173321|NCT01272869|9820833|FG001|Period 2 (14 Days)|Adverse Event|0
6173322|NCT01272908|9820843|FG000|Initial Treatment Period|Adverse Event|1
6173323|NCT01272908|9820843|FG000|Initial Treatment Period|Lack of Efficacy|5
6173324|NCT01272908|9820843|FG000|Initial Treatment Period|Protocol Violation|1
6173325|NCT01272908|9820843|FG000|Initial Treatment Period|Withdrawal by Subject|1
6173326|NCT01272908|9820843|FG000|Re-Treatment Period|Adverse Event|2
6173327|NCT01272908|9820843|FG000|Re-Treatment Period|Lack of Efficacy|3
6173328|NCT01272908|9820843|FG000|Re-Treatment Period|Withdrawal by Subject|1
6173329|NCT01272921|9820851|FG000|Overall Study|Protocol Violation|2
6173330|NCT01272921|9820852|FG001|Overall Study|Protocol Violation|1
6173331|NCT01272934|9820862|FG000|Overall Study|Adverse Event|0
6173332|NCT01272934|9820863|FG001|Overall Study|Adverse Event|1
6173333|NCT01272934|9820862|FG000|Overall Study|Abnormal Laboratory Value|0
6173334|NCT01272934|9820863|FG001|Overall Study|Abnormal Laboratory Value|1
6173335|NCT01272947|9820872|FG000|Overall Study|Abnormal Laboratory Value|2
6173336|NCT01272947|9820873|FG001|Overall Study|Abnormal Laboratory Value|2
6173337|NCT01273038|9820902|FG000|Second Intervention (14 Days)|Adverse Event|0
6173338|NCT01273038|9820903|FG001|Second Intervention (14 Days)|Adverse Event|1
6173339|NCT01273038|9820902|FG000|Second Intervention (14 Days)|Withdrawal by Subject|0
6173340|NCT01273038|9820903|FG001|Second Intervention (14 Days)|Withdrawal by Subject|1
6173341|NCT01273155|9820913|FG000|Overall Study|Off study trmt prior to end of C1/PD|2
6173342|NCT01273155|9820914|FG001|Overall Study|Off study trmt prior to end of C1/PD|3
6173343|NCT01273155|9820915|FG002|Overall Study|Off study trmt prior to end of C1/PD|8
6173344|NCT01273155|9820916|FG003|Overall Study|Off study trmt prior to end of C1/PD|0
6173345|NCT01273155|9820917|FG004|Overall Study|Off study trmt prior to end of C1/PD|0
6173346|NCT01273155|9820918|FG005|Overall Study|Off study trmt prior to end of C1/PD|2
6173347|NCT01273155|9820919|FG006|Overall Study|Off study trmt prior to end of C1/PD|3
6173348|NCT01273155|9820913|FG000|Overall Study|Change in liver function/no longer eval.|0
6173349|NCT01273155|9820914|FG001|Overall Study|Change in liver function/no longer eval.|1
6173350|NCT01273155|9820915|FG002|Overall Study|Change in liver function/no longer eval.|0
6173351|NCT01273155|9820916|FG003|Overall Study|Change in liver function/no longer eval.|0
6173352|NCT01273155|9820917|FG004|Overall Study|Change in liver function/no longer eval.|1
6173353|NCT01273155|9820918|FG005|Overall Study|Change in liver function/no longer eval.|0
6173354|NCT01273155|9820919|FG006|Overall Study|Change in liver function/no longer eval.|0
6173355|NCT01273155|9820913|FG000|Overall Study|Off study prior to C1/due to toxicity|0
6173356|NCT01273155|9820914|FG001|Overall Study|Off study prior to C1/due to toxicity|0
6173357|NCT01273155|9820915|FG002|Overall Study|Off study prior to C1/due to toxicity|2
6173358|NCT01273155|9820916|FG003|Overall Study|Off study prior to C1/due to toxicity|0
6173359|NCT01273155|9820917|FG004|Overall Study|Off study prior to C1/due to toxicity|0
6173360|NCT01273155|9820918|FG005|Overall Study|Off study prior to C1/due to toxicity|0
6173361|NCT01273155|9820919|FG006|Overall Study|Off study prior to C1/due to toxicity|1
6173362|NCT01273155|9820913|FG000|Overall Study|Died during Cycle 1|0
6173363|NCT01273155|9820914|FG001|Overall Study|Died during Cycle 1|0
6173364|NCT01273155|9820915|FG002|Overall Study|Died during Cycle 1|1
6173365|NCT01273155|9820916|FG003|Overall Study|Died during Cycle 1|1
6173366|NCT01273155|9820917|FG004|Overall Study|Died during Cycle 1|0
6173367|NCT01273155|9820918|FG005|Overall Study|Died during Cycle 1|2
6173368|NCT01273155|9820919|FG006|Overall Study|Died during Cycle 1|2
6173369|NCT01273155|9820913|FG000|Overall Study|Withdrew during C1/refused further trmt|0
6173370|NCT01273155|9820914|FG001|Overall Study|Withdrew during C1/refused further trmt|0
6173371|NCT01273155|9820915|FG002|Overall Study|Withdrew during C1/refused further trmt|1
6173372|NCT01273155|9820916|FG003|Overall Study|Withdrew during C1/refused further trmt|0
6173373|NCT01273155|9820917|FG004|Overall Study|Withdrew during C1/refused further trmt|1
6173374|NCT01273155|9820918|FG005|Overall Study|Withdrew during C1/refused further trmt|1
6173375|NCT01273155|9820919|FG006|Overall Study|Withdrew during C1/refused further trmt|0
6173376|NCT01273181|9820946|FG000|Phase I, Dose 1|Study termination|1
6173377|NCT01273181|9820947|FG001|Phase I, Dose 1|Study termination|0
6173378|NCT01273181|9820948|FG002|Phase I, Dose 1|Study termination|0
6173379|NCT01273181|9820949|FG003|Phase I, Dose 1|Study termination|0
6173380|NCT01273181|9820946|FG000|Phase I, Dose 2|Death during treatment|0
6173381|NCT01273181|9820947|FG001|Phase I, Dose 2|Death during treatment|1
6173382|NCT01273181|9820948|FG002|Phase I, Dose 2|Death during treatment|0
6173383|NCT01273181|9820949|FG003|Phase I, Dose 2|Death during treatment|0
6173384|NCT01273181|9820946|FG000|Phase 2, Dose 1|Study termination|0
6173385|NCT01273181|9820947|FG001|Phase 2, Dose 1|Study termination|0
6173386|NCT01273181|9820948|FG002|Phase 2, Dose 1|Study termination|1
6173387|NCT01273181|9820949|FG003|Phase 2, Dose 1|Study termination|0
6173388|NCT01273181|9820946|FG000|Phase 2, Dose 2|Death during treatment|0
6173389|NCT01273181|9820947|FG001|Phase 2, Dose 2|Death during treatment|0
6173390|NCT01273181|9820948|FG002|Phase 2, Dose 2|Death during treatment|0
6173391|NCT01273181|9820949|FG003|Phase 2, Dose 2|Death during treatment|1
6173392|NCT01273519|9820970|FG000|Overall Study|Adverse Event|3
6173393|NCT01273519|9820971|FG001|Overall Study|Adverse Event|0
6173394|NCT01273519|9820972|FG002|Overall Study|Adverse Event|0
6173395|NCT01273519|9820970|FG000|Overall Study|Lost to Follow-up|2
6173396|NCT01273519|9820971|FG001|Overall Study|Lost to Follow-up|1
6173397|NCT01273519|9820972|FG002|Overall Study|Lost to Follow-up|3
6173398|NCT01273519|9820970|FG000|Overall Study|Lack of Efficacy|8
6173399|NCT01273519|9820971|FG001|Overall Study|Lack of Efficacy|3
6173400|NCT01273519|9820972|FG002|Overall Study|Lack of Efficacy|4
6173401|NCT01273519|9820970|FG000|Overall Study|Other|6
6173402|NCT01273519|9820971|FG001|Overall Study|Other|1
6173403|NCT01273519|9820972|FG002|Overall Study|Other|1
6173404|NCT01273597|9820983|FG000|Overall Study|Adverse Event|5
6173405|NCT01273597|9820983|FG000|Overall Study|Underwent Kidney Transplantation|2
6173406|NCT01273597|9820983|FG000|Overall Study|Reason Not Reported|1
6173407|NCT01273623|9820987|FG000|Overall Study|did not meet IVUS criteria|29
6173408|NCT01273805|9821007|FG000|Overall Study|Radiologic PD or Symptom Deterioration|10
6173409|NCT01273805|9821008|FG001|Overall Study|Radiologic PD or Symptom Deterioration|10
6173410|NCT01273818|9821017|FG000|Overall Study|Physician Decision|13
6173411|NCT01273818|9821018|FG001|Overall Study|Physician Decision|2
6173412|NCT01273818|9821019|FG002|Overall Study|Physician Decision|9
6173413|NCT01273883|9821036|FG000|First Intervention|Adverse Event|2
6173414|NCT01273883|9821037|FG001|First Intervention|Adverse Event|1
6173415|NCT01273883|9821036|FG000|Second Intervention|Lost to Follow-up|1
6173416|NCT01273883|9821037|FG001|Second Intervention|Lost to Follow-up|1
6173417|NCT01273883|9821036|FG000|Second Intervention|Lack of Efficacy|1
6173418|NCT01273883|9821037|FG001|Second Intervention|Lack of Efficacy|0
6173419|NCT01274182|9821050|FG000|Overall Study|Unsatisfactory therapeutic effect|6
6173420|NCT01274182|9821051|FG001|Overall Study|Unsatisfactory therapeutic effect|3
6173421|NCT01274182|9821052|FG002|Overall Study|Unsatisfactory therapeutic effect|4
6173422|NCT01274182|9821050|FG000|Overall Study|Adverse Event|4
6173423|NCT01274182|9821051|FG001|Overall Study|Adverse Event|5
6173424|NCT01274182|9821052|FG002|Overall Study|Adverse Event|3
6173425|NCT01274182|9821050|FG000|Overall Study|Withdrawal by Subject|5
6173426|NCT01274182|9821051|FG001|Overall Study|Withdrawal by Subject|5
6173427|NCT01274182|9821052|FG002|Overall Study|Withdrawal by Subject|3
6173428|NCT01274182|9821050|FG000|Overall Study|Lost to Follow-up|2
6173429|NCT01274182|9821051|FG001|Overall Study|Lost to Follow-up|3
6173430|NCT01274182|9821052|FG002|Overall Study|Lost to Follow-up|1
6173431|NCT01274182|9821050|FG000|Overall Study|Protocol Violation|3
6173432|NCT01274182|9821051|FG001|Overall Study|Protocol Violation|2
6173433|NCT01274182|9821052|FG002|Overall Study|Protocol Violation|0
6173434|NCT01274182|9821050|FG000|Overall Study|Death|1
6173435|NCT01274182|9821051|FG001|Overall Study|Death|0
6173436|NCT01274182|9821052|FG002|Overall Study|Death|1
6173437|NCT01274338|9821070|FG000|Overall Study|Lack of Efficacy|72
6173438|NCT01274338|9821071|FG001|Overall Study|Lack of Efficacy|108
6173439|NCT01274338|9821072|FG002|Overall Study|Lack of Efficacy|116
6173440|NCT01274338|9821073|FG003|Overall Study|Lack of Efficacy|0
6173441|NCT01274338|9821074|FG004|Overall Study|Lack of Efficacy|0
6173442|NCT01274338|9821075|FG005|Overall Study|Lack of Efficacy|0
6173443|NCT01274338|9821070|FG000|Overall Study|Adverse Event|272
6173444|NCT01274338|9821071|FG001|Overall Study|Adverse Event|105
6173445|NCT01274338|9821072|FG002|Overall Study|Adverse Event|180
6173446|NCT01274338|9821073|FG003|Overall Study|Adverse Event|1
6173447|NCT01274338|9821074|FG004|Overall Study|Adverse Event|0
6173448|NCT01274338|9821075|FG005|Overall Study|Adverse Event|0
6173449|NCT01274338|9821070|FG000|Overall Study|Death|8
6173450|NCT01274338|9821071|FG001|Overall Study|Death|1
6173451|NCT01274338|9821072|FG002|Overall Study|Death|0
6173452|NCT01274338|9821073|FG003|Overall Study|Death|0
6173453|NCT01274338|9821074|FG004|Overall Study|Death|0
6173454|NCT01274338|9821075|FG005|Overall Study|Death|0
6173455|NCT01274338|9821070|FG000|Overall Study|Withdrawal by Subject|27
6173456|NCT01274338|9821071|FG001|Overall Study|Withdrawal by Subject|99
6173457|NCT01274338|9821072|FG002|Overall Study|Withdrawal by Subject|17
6173458|NCT01274338|9821073|FG003|Overall Study|Withdrawal by Subject|0
6173459|NCT01274338|9821074|FG004|Overall Study|Withdrawal by Subject|0
6173460|NCT01274338|9821075|FG005|Overall Study|Withdrawal by Subject|0
6173461|NCT01274338|9821070|FG000|Overall Study|Did not start treatment|8
6173462|NCT01274338|9821071|FG001|Overall Study|Did not start treatment|116
6173463|NCT01274338|9821072|FG002|Overall Study|Did not start treatment|7
6173464|NCT01274338|9821073|FG003|Overall Study|Did not start treatment|0
6173465|NCT01274338|9821074|FG004|Overall Study|Did not start treatment|0
6173466|NCT01274338|9821075|FG005|Overall Study|Did not start treatment|0
6173467|NCT01274338|9821070|FG000|Overall Study|Alternative therapy|0
6173468|NCT01274338|9821071|FG001|Overall Study|Alternative therapy|1
6173469|NCT01274338|9821072|FG002|Overall Study|Alternative therapy|0
6173470|NCT01274338|9821073|FG003|Overall Study|Alternative therapy|0
6173471|NCT01274338|9821074|FG004|Overall Study|Alternative therapy|0
6173472|NCT01274338|9821075|FG005|Overall Study|Alternative therapy|0
6173473|NCT01274338|9821070|FG000|Overall Study|Other complicating diseases|0
6173474|NCT01274338|9821071|FG001|Overall Study|Other complicating diseases|3
6173475|NCT01274338|9821072|FG002|Overall Study|Other complicating diseases|1
6173476|NCT01274338|9821073|FG003|Overall Study|Other complicating diseases|0
6173477|NCT01274338|9821074|FG004|Overall Study|Other complicating diseases|0
6173478|NCT01274338|9821075|FG005|Overall Study|Other complicating diseases|0
6173479|NCT01274338|9821070|FG000|Overall Study|Treatment arm was suspended due to toxicity|4
6173480|NCT01274338|9821071|FG001|Overall Study|Treatment arm was suspended due to toxicity|0
6173481|NCT01274338|9821072|FG002|Overall Study|Treatment arm was suspended due to toxicity|0
6173482|NCT01274338|9821073|FG003|Overall Study|Treatment arm was suspended due to toxicity|0
6173483|NCT01274338|9821074|FG004|Overall Study|Treatment arm was suspended due to toxicity|0
6173484|NCT01274338|9821075|FG005|Overall Study|Treatment arm was suspended due to toxicity|0
6173485|NCT01274338|9821070|FG000|Overall Study|Pregnancy|0
6173486|NCT01274338|9821071|FG001|Overall Study|Pregnancy|0
6173487|NCT01274338|9821072|FG002|Overall Study|Pregnancy|1
6173488|NCT01274338|9821073|FG003|Overall Study|Pregnancy|0
6173489|NCT01274338|9821074|FG004|Overall Study|Pregnancy|0
6173490|NCT01274338|9821075|FG005|Overall Study|Pregnancy|0
6173491|NCT01274338|9821070|FG000|Overall Study|Reason not reported|12
6173492|NCT01274338|9821071|FG001|Overall Study|Reason not reported|21
6173493|NCT01274338|9821072|FG002|Overall Study|Reason not reported|3
6173494|NCT01274338|9821073|FG003|Overall Study|Reason not reported|0
6173495|NCT01274338|9821074|FG004|Overall Study|Reason not reported|1
6173496|NCT01274338|9821075|FG005|Overall Study|Reason not reported|0
6173497|NCT01274351|9821088|FG000|Overall Study|Lost to Follow-up|1
6173498|NCT01274351|9821088|FG000|Overall Study|patient not compliant with the protocol|1
6173499|NCT01274351|9821088|FG000|Overall Study|Pregnancy|1
6173500|NCT01274351|9821088|FG000|Overall Study|Death|2
6173501|NCT01274351|9821088|FG000|Overall Study|Withdrawal by Subject|3
6173502|NCT01274351|9821088|FG000|Overall Study|Adverse Event|8
6173503|NCT01274351|9821088|FG000|Overall Study|progression of disease|3
6173504|NCT01274351|9821088|FG000|Overall Study|hospitalization|1
6173505|NCT01274637|9821115|FG000|Overall Study|Withdrawal by Subject|0
6173506|NCT01274637|9821116|FG001|Overall Study|Withdrawal by Subject|1
6173507|NCT01274637|9821115|FG000|Overall Study|Lost to Follow-up|0
6173508|NCT01274637|9821116|FG001|Overall Study|Lost to Follow-up|1
6173509|NCT01274715|9821122|FG000|Overall Study|Lost to Follow-up|1
6173510|NCT01274715|9821122|FG000|Overall Study|After consent, met exclusion criteria.|1
6173511|NCT01274715|9821122|FG000|Overall Study|After consent, met exclusion criteria.|1
6173512|NCT01274715|9821122|FG000|Overall Study|After consent, met exclusion criteria.|1
6227485|NCT01717326|9900202|FG014|Overall Study|Lost to Follow-up|0
6173513|NCT01275066|9821142|FG000|Overall Study|Withdrawal by Subject|0
6173514|NCT01275066|9821143|FG001|Overall Study|Withdrawal by Subject|0
6173515|NCT01275066|9821144|FG002|Overall Study|Withdrawal by Subject|1
6173516|NCT01275066|9821142|FG000|Overall Study|Not Diagnosed w/ Disease|1
6173517|NCT01275066|9821143|FG001|Overall Study|Not Diagnosed w/ Disease|0
6173518|NCT01275066|9821144|FG002|Overall Study|Not Diagnosed w/ Disease|0
6173519|NCT01275131|9821160|FG000|Period 1|Withdrawal by Subject|1
6173520|NCT01275131|9821161|FG001|Period 1|Withdrawal by Subject|0
6173521|NCT01275131|9821162|FG002|Period 1|Withdrawal by Subject|3
6173522|NCT01275131|9821163|FG003|Period 1|Withdrawal by Subject|2
6173523|NCT01275131|9821160|FG000|Period 1|Physician Decision|1
6173524|NCT01275131|9821161|FG001|Period 1|Physician Decision|0
6173525|NCT01275131|9821162|FG002|Period 1|Physician Decision|0
6173526|NCT01275131|9821163|FG003|Period 1|Physician Decision|0
6173527|NCT01275131|9821160|FG000|Period 2 (Crossover)|Adverse Event|0
6173528|NCT01275131|9821161|FG001|Period 2 (Crossover)|Adverse Event|1
6173529|NCT01275131|9821162|FG002|Period 2 (Crossover)|Adverse Event|0
6173530|NCT01275131|9821163|FG003|Period 2 (Crossover)|Adverse Event|0
6173531|NCT01275131|9821160|FG000|Period 2 (Crossover)|Withdrawal by Subject|1
6173532|NCT01275131|9821161|FG001|Period 2 (Crossover)|Withdrawal by Subject|0
6173533|NCT01275131|9821162|FG002|Period 2 (Crossover)|Withdrawal by Subject|1
6173534|NCT01275131|9821163|FG003|Period 2 (Crossover)|Withdrawal by Subject|2
6173535|NCT01275144|9821181|FG000|Second Intervention (6 Days)|Withdrawal by Subject|1
6173536|NCT01275144|9821182|FG001|Second Intervention (6 Days)|Withdrawal by Subject|0
6173537|NCT01275170|9821198|FG000|Part 1: Period 1|Equipment malfunction before study drug|1
6173538|NCT01275170|9821199|FG001|Part 1: Period 1|Equipment malfunction before study drug|0
6173539|NCT01275170|9821200|FG002|Part 1: Period 1|Equipment malfunction before study drug|0
6173540|NCT01275170|9821201|FG003|Part 1: Period 1|Equipment malfunction before study drug|0
6173541|NCT01275170|9821202|FG004|Part 1: Period 1|Equipment malfunction before study drug|0
6173542|NCT01275170|9821203|FG005|Part 1: Period 1|Equipment malfunction before study drug|0
6173543|NCT01275170|9821204|FG006|Part 1: Period 1|Equipment malfunction before study drug|0
6173544|NCT01275170|9821205|FG007|Part 1: Period 1|Equipment malfunction before study drug|0
6173545|NCT01275196|9821240|FG000|Overall Study|Adverse Event|3
6173546|NCT01275196|9821241|FG001|Overall Study|Adverse Event|5
6173547|NCT01275196|9821240|FG000|Overall Study|Withdrawal by Subject|4
6173548|NCT01275196|9821241|FG001|Overall Study|Withdrawal by Subject|5
6173549|NCT01275196|9821240|FG000|Overall Study|Lost to Follow-up|1
6173550|NCT01275196|9821241|FG001|Overall Study|Lost to Follow-up|0
6173551|NCT01275196|9821240|FG000|Overall Study|Disease Progression|6
6173552|NCT01275196|9821241|FG001|Overall Study|Disease Progression|5
6173553|NCT01275196|9821240|FG000|Overall Study|Protocol Violation|1
6173554|NCT01275196|9821241|FG001|Overall Study|Protocol Violation|0
6173555|NCT01275196|9821240|FG000|Overall Study|Suboptimal response/treatment failure|5
6227486|NCT01717326|9900203|FG015|Overall Study|Lost to Follow-up|2
6227487|NCT01717326|9900204|FG016|Overall Study|Lost to Follow-up|1
6227488|NCT01717326|9900205|FG017|Overall Study|Lost to Follow-up|0
6227489|NCT01717326|9900206|FG018|Overall Study|Lost to Follow-up|2
6227490|NCT01717326|9900207|FG019|Overall Study|Lost to Follow-up|3
6227491|NCT01717326|9900188|FG000|Overall Study|Physician Decision|0
6227492|NCT01717326|9900189|FG001|Overall Study|Physician Decision|0
6227493|NCT01717326|9900190|FG002|Overall Study|Physician Decision|0
6227494|NCT01717326|9900191|FG003|Overall Study|Physician Decision|0
6227495|NCT01717326|9900192|FG004|Overall Study|Physician Decision|0
6227496|NCT01717326|9900193|FG005|Overall Study|Physician Decision|0
6227497|NCT01717326|9900194|FG006|Overall Study|Physician Decision|0
6227498|NCT01717326|9900195|FG007|Overall Study|Physician Decision|0
6227499|NCT01717326|9900196|FG008|Overall Study|Physician Decision|0
6227500|NCT01717326|9900197|FG009|Overall Study|Physician Decision|1
6227501|NCT01717326|9900198|FG010|Overall Study|Physician Decision|0
6227502|NCT01717326|9900199|FG011|Overall Study|Physician Decision|0
6227503|NCT01717326|9900200|FG012|Overall Study|Physician Decision|0
6227504|NCT01717326|9900201|FG013|Overall Study|Physician Decision|0
6227505|NCT01717326|9900202|FG014|Overall Study|Physician Decision|0
6227506|NCT01717326|9900203|FG015|Overall Study|Physician Decision|0
6227507|NCT01717326|9900204|FG016|Overall Study|Physician Decision|0
6227508|NCT01717326|9900205|FG017|Overall Study|Physician Decision|0
6227509|NCT01717326|9900206|FG018|Overall Study|Physician Decision|0
6227510|NCT01717326|9900207|FG019|Overall Study|Physician Decision|0
6227511|NCT01717326|9900188|FG000|Overall Study|Protocol Violation|0
6227512|NCT01717326|9900189|FG001|Overall Study|Protocol Violation|0
6227513|NCT01717326|9900190|FG002|Overall Study|Protocol Violation|0
6227514|NCT01717326|9900191|FG003|Overall Study|Protocol Violation|0
6227515|NCT01717326|9900192|FG004|Overall Study|Protocol Violation|1
6227516|NCT01717326|9900193|FG005|Overall Study|Protocol Violation|0
6227517|NCT01717326|9900194|FG006|Overall Study|Protocol Violation|0
6227518|NCT01717326|9900195|FG007|Overall Study|Protocol Violation|0
6227519|NCT01717326|9900196|FG008|Overall Study|Protocol Violation|0
6227520|NCT01717326|9900197|FG009|Overall Study|Protocol Violation|0
6227521|NCT01717326|9900198|FG010|Overall Study|Protocol Violation|0
6227522|NCT01717326|9900199|FG011|Overall Study|Protocol Violation|0
6173556|NCT01275196|9821241|FG001|Overall Study|Suboptimal response/treatment failure|6
6173557|NCT01275222|9821255|FG000|Phase l by Treatment|Adverse Event|1
6173558|NCT01275222|9821256|FG001|Phase l by Treatment|Adverse Event|4
6173559|NCT01275222|9821257|FG002|Phase l by Treatment|Adverse Event|2
6173560|NCT01275222|9821258|FG003|Phase l by Treatment|Adverse Event|3
6227523|NCT01717326|9900200|FG012|Overall Study|Protocol Violation|0
6227524|NCT01717326|9900201|FG013|Overall Study|Protocol Violation|0
6227525|NCT01717326|9900202|FG014|Overall Study|Protocol Violation|0
6227526|NCT01717326|9900203|FG015|Overall Study|Protocol Violation|0
6173561|NCT01275222|9821259|FG004|Phase l by Treatment|Adverse Event|0
6173562|NCT01275222|9821260|FG005|Phase l by Treatment|Adverse Event|0
6173563|NCT01275222|9821255|FG000|Phase l by Treatment|Abnormal laboratory value(s)|0
6173564|NCT01275222|9821256|FG001|Phase l by Treatment|Abnormal laboratory value(s)|0
6173565|NCT01275222|9821257|FG002|Phase l by Treatment|Abnormal laboratory value(s)|1
6173566|NCT01275222|9821258|FG003|Phase l by Treatment|Abnormal laboratory value(s)|0
6173567|NCT01275222|9821259|FG004|Phase l by Treatment|Abnormal laboratory value(s)|0
6173568|NCT01275222|9821260|FG005|Phase l by Treatment|Abnormal laboratory value(s)|0
6173569|NCT01275222|9821255|FG000|Phase l by Treatment|Abnormal test procedure result(s)|0
6173570|NCT01275222|9821256|FG001|Phase l by Treatment|Abnormal test procedure result(s)|0
6173571|NCT01275222|9821257|FG002|Phase l by Treatment|Abnormal test procedure result(s)|0
6173572|NCT01275222|9821258|FG003|Phase l by Treatment|Abnormal test procedure result(s)|1
6173573|NCT01275222|9821259|FG004|Phase l by Treatment|Abnormal test procedure result(s)|0
6173574|NCT01275222|9821260|FG005|Phase l by Treatment|Abnormal test procedure result(s)|0
6173575|NCT01275222|9821255|FG000|Phase l by Treatment|Disease progression|12
6173576|NCT01275222|9821256|FG001|Phase l by Treatment|Disease progression|8
6173577|NCT01275222|9821257|FG002|Phase l by Treatment|Disease progression|2
6173578|NCT01275222|9821258|FG003|Phase l by Treatment|Disease progression|5
6173579|NCT01275222|9821259|FG004|Phase l by Treatment|Disease progression|0
6173580|NCT01275222|9821260|FG005|Phase l by Treatment|Disease progression|0
6173581|NCT01275222|9821255|FG000|Phase l by Treatment|Withdrawal by Subject|0
6173582|NCT01275222|9821256|FG001|Phase l by Treatment|Withdrawal by Subject|0
6173583|NCT01275222|9821257|FG002|Phase l by Treatment|Withdrawal by Subject|0
6173584|NCT01275222|9821258|FG003|Phase l by Treatment|Withdrawal by Subject|1
6173585|NCT01275222|9821259|FG004|Phase l by Treatment|Withdrawal by Subject|0
6173586|NCT01275222|9821260|FG005|Phase l by Treatment|Withdrawal by Subject|0
6173587|NCT01275222|9821255|FG000|Phase l by Treatment|Death|0
6173588|NCT01275222|9821256|FG001|Phase l by Treatment|Death|1
6173589|NCT01275222|9821257|FG002|Phase l by Treatment|Death|0
6173590|NCT01275222|9821258|FG003|Phase l by Treatment|Death|1
6173591|NCT01275222|9821259|FG004|Phase l by Treatment|Death|0
6173592|NCT01275222|9821260|FG005|Phase l by Treatment|Death|0
6173593|NCT01275222|9821255|FG000|Phase ll by Stratum|Adverse Event|0
6173594|NCT01275222|9821256|FG001|Phase ll by Stratum|Adverse Event|0
6173595|NCT01275222|9821257|FG002|Phase ll by Stratum|Adverse Event|0
6173596|NCT01275222|9821258|FG003|Phase ll by Stratum|Adverse Event|0
6173597|NCT01275222|9821259|FG004|Phase ll by Stratum|Adverse Event|2
6173598|NCT01275222|9821260|FG005|Phase ll by Stratum|Adverse Event|10
6173599|NCT01275222|9821255|FG000|Phase ll by Stratum|Abnormal laboratory values|0
6173600|NCT01275222|9821256|FG001|Phase ll by Stratum|Abnormal laboratory values|0
6173601|NCT01275222|9821257|FG002|Phase ll by Stratum|Abnormal laboratory values|0
6173602|NCT01275222|9821258|FG003|Phase ll by Stratum|Abnormal laboratory values|0
6173603|NCT01275222|9821259|FG004|Phase ll by Stratum|Abnormal laboratory values|0
6173604|NCT01275222|9821260|FG005|Phase ll by Stratum|Abnormal laboratory values|1
6173605|NCT01275222|9821255|FG000|Phase ll by Stratum|Disease progression|0
6173606|NCT01275222|9821256|FG001|Phase ll by Stratum|Disease progression|0
6173607|NCT01275222|9821257|FG002|Phase ll by Stratum|Disease progression|0
6173608|NCT01275222|9821258|FG003|Phase ll by Stratum|Disease progression|0
6173609|NCT01275222|9821259|FG004|Phase ll by Stratum|Disease progression|23
6173610|NCT01275222|9821260|FG005|Phase ll by Stratum|Disease progression|31
6173611|NCT01275222|9821255|FG000|Phase ll by Stratum|Withdrawal by Subject|0
6173612|NCT01275222|9821256|FG001|Phase ll by Stratum|Withdrawal by Subject|0
6173613|NCT01275222|9821257|FG002|Phase ll by Stratum|Withdrawal by Subject|0
6173614|NCT01275222|9821258|FG003|Phase ll by Stratum|Withdrawal by Subject|0
6173615|NCT01275222|9821259|FG004|Phase ll by Stratum|Withdrawal by Subject|2
6173616|NCT01275222|9821260|FG005|Phase ll by Stratum|Withdrawal by Subject|3
6173617|NCT01275222|9821255|FG000|Phase ll by Stratum|Death|0
6173618|NCT01275222|9821256|FG001|Phase ll by Stratum|Death|0
6173619|NCT01275222|9821257|FG002|Phase ll by Stratum|Death|0
6173620|NCT01275222|9821258|FG003|Phase ll by Stratum|Death|0
6173621|NCT01275222|9821259|FG004|Phase ll by Stratum|Death|1
6173622|NCT01275222|9821260|FG005|Phase ll by Stratum|Death|1
6173623|NCT01275339|9821298|FG000|Overall Study|Referred for surgery for AS symptoms|1
6173624|NCT01275339|9821299|FG001|Overall Study|Referred for surgery for AS symptoms|0
6173625|NCT01275339|9821300|FG002|Overall Study|Referred for surgery for AS symptoms|0
6173626|NCT01275339|9821301|FG003|Overall Study|Referred for surgery for AS symptoms|0
6173627|NCT01275339|9821298|FG000|Overall Study|Withdrawal by Subject|0
6173628|NCT01275339|9821299|FG001|Overall Study|Withdrawal by Subject|0
6173629|NCT01275339|9821300|FG002|Overall Study|Withdrawal by Subject|1
6173630|NCT01275339|9821301|FG003|Overall Study|Withdrawal by Subject|0
6173631|NCT01275430|9821328|FG000|Overall Study|Adverse Event|1
6173632|NCT01275430|9821328|FG000|Overall Study|No Contrast Injection|6
6173633|NCT01275430|9821328|FG000|Overall Study|Device Malfunction|1
6173634|NCT01275430|9821328|FG000|Overall Study|Inability to achieve maximum p-wave|1
6173635|NCT01275625|9821337|FG000|Overall Study|Death|1
6173636|NCT01275625|9821337|FG000|Overall Study|Lack of Efficacy|2
6173637|NCT01275625|9821337|FG000|Overall Study|Lost to Follow-up|1
6173638|NCT01275625|9821337|FG000|Overall Study|Withdrawal by Subject|3
6173639|NCT01275625|9821337|FG000|Overall Study|Protocol Violation|1
6173640|NCT01275625|9821337|FG000|Overall Study|Adverse Event|4
6173641|NCT01275625|9821337|FG000|Overall Study|Other|1
6173642|NCT01275755|9821347|FG000|Double-blind Treatment Period|Adverse Event|0
6173643|NCT01275755|9821348|FG001|Double-blind Treatment Period|Adverse Event|2
6173644|NCT01275755|9821347|FG000|Double-blind Treatment Period|Lost to Follow-up|1
6173645|NCT01275755|9821348|FG001|Double-blind Treatment Period|Lost to Follow-up|1
6084984|NCT00647296|9694085|FG001|Part 1: 12-week Double-Blind Treatment|Adverse Event|0
6084985|NCT00647296|9694086|FG002|Part 1: 12-week Double-Blind Treatment|Adverse Event|0
6084986|NCT00647296|9694087|FG003|Part 1: 12-week Double-Blind Treatment|Adverse Event|1
6084987|NCT00647296|9694084|FG000|Part 1: 12-week Double-Blind Treatment|Physician Decision|0
6084988|NCT00647296|9694085|FG001|Part 1: 12-week Double-Blind Treatment|Physician Decision|1
6084989|NCT00647296|9694086|FG002|Part 1: 12-week Double-Blind Treatment|Physician Decision|0
6084990|NCT00647296|9694087|FG003|Part 1: 12-week Double-Blind Treatment|Physician Decision|0
6084991|NCT00647296|9694084|FG000|Part 2: 4-week Placebo Washout|Withdrawal by Subject|1
6084992|NCT00647296|9694085|FG001|Part 2: 4-week Placebo Washout|Withdrawal by Subject|0
6084993|NCT00647296|9694086|FG002|Part 2: 4-week Placebo Washout|Withdrawal by Subject|0
6084994|NCT00647296|9694087|FG003|Part 2: 4-week Placebo Washout|Withdrawal by Subject|0
6084995|NCT00647296|9694084|FG000|Part 2: 4-week Placebo Washout|Lost to Follow-up|1
6084996|NCT00647296|9694085|FG001|Part 2: 4-week Placebo Washout|Lost to Follow-up|0
6084997|NCT00647296|9694086|FG002|Part 2: 4-week Placebo Washout|Lost to Follow-up|0
6173646|NCT01275755|9821347|FG000|Double-blind Treatment Period|Withdrawal by Subject|1
6173647|NCT01275755|9821348|FG001|Double-blind Treatment Period|Withdrawal by Subject|0
6173648|NCT01275755|9821347|FG000|Run-out Placebo Period|Lost to Follow-up|1
6173649|NCT01275755|9821348|FG001|Run-out Placebo Period|Lost to Follow-up|0
6173650|NCT01275833|9821356|FG000|Overall Study|Study terminated|1
6173651|NCT01275833|9821357|FG001|Overall Study|Study terminated|1
6173652|NCT01276041|9821363|FG000|Overall Study|Adverse Event|2
6173653|NCT01276041|9821363|FG000|Overall Study|Protocol Violation|1
6173654|NCT01276106|9821371|FG000|Overall Study|Adverse Event|3
6173655|NCT01276106|9821372|FG001|Overall Study|Adverse Event|3
6173656|NCT01276106|9821373|FG002|Overall Study|Adverse Event|11
6173657|NCT01276106|9821374|FG003|Overall Study|Adverse Event|3
6173658|NCT01276106|9821371|FG000|Overall Study|Withdrawal by Subject|6
6173659|NCT01276106|9821372|FG001|Overall Study|Withdrawal by Subject|3
6173660|NCT01276106|9821373|FG002|Overall Study|Withdrawal by Subject|1
6173661|NCT01276106|9821374|FG003|Overall Study|Withdrawal by Subject|6
6173662|NCT01276106|9821371|FG000|Overall Study|Lack of Efficacy|0
6173663|NCT01276106|9821372|FG001|Overall Study|Lack of Efficacy|1
6173664|NCT01276106|9821373|FG002|Overall Study|Lack of Efficacy|0
6173665|NCT01276106|9821374|FG003|Overall Study|Lack of Efficacy|1
6173666|NCT01276106|9821371|FG000|Overall Study|Lost to Follow-up|2
6173667|NCT01276106|9821372|FG001|Overall Study|Lost to Follow-up|1
6173668|NCT01276106|9821373|FG002|Overall Study|Lost to Follow-up|1
6173669|NCT01276106|9821374|FG003|Overall Study|Lost to Follow-up|0
6173670|NCT01276106|9821371|FG000|Overall Study|Physician Decision|0
6173671|NCT01276106|9821372|FG001|Overall Study|Physician Decision|0
6173672|NCT01276106|9821373|FG002|Overall Study|Physician Decision|1
6173673|NCT01276106|9821374|FG003|Overall Study|Physician Decision|1
6173674|NCT01276106|9821371|FG000|Overall Study|Protocol Violation|1
6173675|NCT01276106|9821372|FG001|Overall Study|Protocol Violation|1
6173676|NCT01276106|9821373|FG002|Overall Study|Protocol Violation|0
6173677|NCT01276106|9821374|FG003|Overall Study|Protocol Violation|2
6173678|NCT01276106|9821371|FG000|Overall Study|Insufficient therapeutic effects|0
6173679|NCT01276106|9821372|FG001|Overall Study|Insufficient therapeutic effects|0
6173680|NCT01276106|9821373|FG002|Overall Study|Insufficient therapeutic effects|2
6173681|NCT01276106|9821374|FG003|Overall Study|Insufficient therapeutic effects|0
6173682|NCT01276223|9821418|FG000|Overall Study|Adverse Event|7
6173683|NCT01276223|9821419|FG001|Overall Study|Adverse Event|4
6173684|NCT01276223|9821420|FG002|Overall Study|Adverse Event|1
6173685|NCT01276223|9821418|FG000|Overall Study|Lost to Follow-up|0
6173686|NCT01276223|9821419|FG001|Overall Study|Lost to Follow-up|0
6173687|NCT01276223|9821420|FG002|Overall Study|Lost to Follow-up|1
6173688|NCT01276223|9821418|FG000|Overall Study|Other|0
6173689|NCT01276223|9821419|FG001|Overall Study|Other|0
6173690|NCT01276223|9821420|FG002|Overall Study|Other|1
6173691|NCT01276223|9821418|FG000|Overall Study|Pt Decision Unrelated to Adverse Event|3
6173692|NCT01276223|9821419|FG001|Overall Study|Pt Decision Unrelated to Adverse Event|0
6173693|NCT01276223|9821420|FG002|Overall Study|Pt Decision Unrelated to Adverse Event|0
6173694|NCT01276223|9821418|FG000|Overall Study|Protocol Violation|1
6173695|NCT01276223|9821419|FG001|Overall Study|Protocol Violation|0
6173696|NCT01276223|9821420|FG002|Overall Study|Protocol Violation|0
6173697|NCT01276236|9821427|FG000|Overall Study|Lack of Efficacy|2
6173698|NCT01276236|9821427|FG000|Overall Study|Withdrawal by Subject|4
6173699|NCT01276288|9821431|FG000|Overall Study|Adverse Event|1
6173700|NCT01276288|9821432|FG001|Overall Study|Adverse Event|1
6173701|NCT01276288|9821433|FG002|Overall Study|Adverse Event|0
6173702|NCT01276288|9821434|FG003|Overall Study|Adverse Event|0
6173703|NCT01276288|9821431|FG000|Overall Study|not treated|1
6173704|NCT01276288|9821432|FG001|Overall Study|not treated|0
6173705|NCT01276288|9821433|FG002|Overall Study|not treated|0
6173706|NCT01276288|9821434|FG003|Overall Study|not treated|0
6173707|NCT01276327|9821483|FG000|Overall Study|Adverse Event|1
6173708|NCT01276327|9821484|FG001|Overall Study|Adverse Event|3
6173709|NCT01276327|9821483|FG000|Overall Study|Withdrawal by Subject|1
6173710|NCT01276327|9821484|FG001|Overall Study|Withdrawal by Subject|0
6173711|NCT01276353|9821492|FG000|Double-blind|Adverse Event|2
6173712|NCT01276353|9821493|FG001|Double-blind|Adverse Event|0
6173713|NCT01276353|9821492|FG000|Double-blind|Withdrawal by Subject|1
6173714|NCT01276353|9821493|FG001|Double-blind|Withdrawal by Subject|0
6173715|NCT01276353|9821492|FG000|Extension|Adverse Event|2
6173716|NCT01276353|9821493|FG001|Extension|Adverse Event|5
6173717|NCT01276353|9821492|FG000|Extension|Withdrawal by Subject|1
6173718|NCT01276353|9821493|FG001|Extension|Withdrawal by Subject|2
6173719|NCT01276353|9821492|FG000|Extension|Withdrawal of study drug 4 days in a row|3
6173720|NCT01276353|9821493|FG001|Extension|Withdrawal of study drug 4 days in a row|1
6173721|NCT01276353|9821492|FG000|Extension|Physician Decision|1
6173722|NCT01276353|9821493|FG001|Extension|Physician Decision|0
6173723|NCT01276353|9821492|FG000|Extension|Prohibited concomitant medications|0
6173724|NCT01276353|9821493|FG001|Extension|Prohibited concomitant medications|1
6173725|NCT01276379|9821505|FG000|Overall Study|Screening failure|40
6173726|NCT01276457|9821513|FG000|Core Study|Adverse Event|6
6173727|NCT01276457|9821514|FG001|Core Study|Adverse Event|3
6173728|NCT01276457|9821513|FG000|Core Study|Lost to Follow-up|1
6173729|NCT01276457|9821514|FG001|Core Study|Lost to Follow-up|2
6173730|NCT01276457|9821513|FG000|Core Study|Administrative problems|1
6173731|NCT01276457|9821514|FG001|Core Study|Administrative problems|1
6173732|NCT01276457|9821513|FG000|Core Study|Death|2
6173733|NCT01276457|9821514|FG001|Core Study|Death|2
6173734|NCT01276457|9821513|FG000|Core Study|Lack of Efficacy|3
6173735|NCT01276457|9821514|FG001|Core Study|Lack of Efficacy|12
6173736|NCT01276457|9821513|FG000|Extension Study|Lost to Follow-up|3
6173737|NCT01276457|9821514|FG001|Extension Study|Lost to Follow-up|0
6173738|NCT01276457|9821513|FG000|Extension Study|Death|0
6173739|NCT01276457|9821514|FG001|Extension Study|Death|1
6173740|NCT01276457|9821513|FG000|Extension Study|Lack of Efficacy|3
6173741|NCT01276457|9821514|FG001|Extension Study|Lack of Efficacy|1
6173742|NCT01276509|9821524|FG000|Overall Study|Adverse Event|9
6173743|NCT01276509|9821525|FG001|Overall Study|Adverse Event|8
6173744|NCT01276509|9821526|FG002|Overall Study|Adverse Event|4
6173745|NCT01276509|9821527|FG003|Overall Study|Adverse Event|3
6173746|NCT01276509|9821524|FG000|Overall Study|Lack of Efficacy|2
6173747|NCT01276509|9821525|FG001|Overall Study|Lack of Efficacy|1
6173748|NCT01276509|9821526|FG002|Overall Study|Lack of Efficacy|1
6173749|NCT01276509|9821527|FG003|Overall Study|Lack of Efficacy|2
6173750|NCT01276509|9821524|FG000|Overall Study|Pregnancy|1
6173751|NCT01276509|9821525|FG001|Overall Study|Pregnancy|0
6173752|NCT01276509|9821526|FG002|Overall Study|Pregnancy|0
6173753|NCT01276509|9821527|FG003|Overall Study|Pregnancy|0
6173754|NCT01276509|9821524|FG000|Overall Study|Withdrawal by Subject|1
6173755|NCT01276509|9821525|FG001|Overall Study|Withdrawal by Subject|2
6173756|NCT01276509|9821526|FG002|Overall Study|Withdrawal by Subject|0
6173757|NCT01276509|9821527|FG003|Overall Study|Withdrawal by Subject|0
6173758|NCT01276509|9821524|FG000|Overall Study|Other|0
6173759|NCT01276509|9821525|FG001|Overall Study|Other|1
6173760|NCT01276509|9821526|FG002|Overall Study|Other|0
6173761|NCT01276509|9821527|FG003|Overall Study|Other|0
6173762|NCT01276639|9821544|FG000|Week 0 to 16|Death|1
6173763|NCT01276639|9821545|FG001|Week 0 to 16|Death|0
6173764|NCT01276639|9821546|FG002|Week 0 to 16|Death|0
6173765|NCT01276639|9821547|FG003|Week 0 to 16|Death|0
6173766|NCT01276639|9821548|FG004|Week 0 to 16|Death|0
6173767|NCT01276639|9821544|FG000|Week 0 to 16|Adverse Event|11
6173768|NCT01276639|9821545|FG001|Week 0 to 16|Adverse Event|8
6173769|NCT01276639|9821546|FG002|Week 0 to 16|Adverse Event|11
6173770|NCT01276639|9821547|FG003|Week 0 to 16|Adverse Event|0
6173771|NCT01276639|9821548|FG004|Week 0 to 16|Adverse Event|0
6173772|NCT01276639|9821544|FG000|Week 0 to 16|Lack of Efficacy|20
6173773|NCT01276639|9821545|FG001|Week 0 to 16|Lack of Efficacy|15
6173774|NCT01276639|9821546|FG002|Week 0 to 16|Lack of Efficacy|25
6173775|NCT01276639|9821547|FG003|Week 0 to 16|Lack of Efficacy|0
6173776|NCT01276639|9821548|FG004|Week 0 to 16|Lack of Efficacy|0
6173777|NCT01276639|9821544|FG000|Week 0 to 16|Lost to Follow-up|3
6173778|NCT01276639|9821545|FG001|Week 0 to 16|Lost to Follow-up|5
6084998|NCT00647296|9694087|FG003|Part 2: 4-week Placebo Washout|Lost to Follow-up|0
6173779|NCT01276639|9821546|FG002|Week 0 to 16|Lost to Follow-up|3
6173780|NCT01276639|9821547|FG003|Week 0 to 16|Lost to Follow-up|0
6173781|NCT01276639|9821548|FG004|Week 0 to 16|Lost to Follow-up|0
6173782|NCT01276639|9821544|FG000|Week 0 to 16|Withdrawal by Subject|8
6173783|NCT01276639|9821545|FG001|Week 0 to 16|Withdrawal by Subject|5
6173784|NCT01276639|9821546|FG002|Week 0 to 16|Withdrawal by Subject|4
6173785|NCT01276639|9821547|FG003|Week 0 to 16|Withdrawal by Subject|0
6173786|NCT01276639|9821548|FG004|Week 0 to 16|Withdrawal by Subject|0
6173787|NCT01276639|9821544|FG000|Week 0 to 16|Other|7
6173788|NCT01276639|9821545|FG001|Week 0 to 16|Other|7
6173789|NCT01276639|9821546|FG002|Week 0 to 16|Other|2
6173790|NCT01276639|9821547|FG003|Week 0 to 16|Other|0
6173791|NCT01276639|9821548|FG004|Week 0 to 16|Other|0
6173792|NCT01276639|9821544|FG000|Week 0 to 16|Randomized, But Not Treated|0
6173793|NCT01276639|9821545|FG001|Week 0 to 16|Randomized, But Not Treated|1
6173794|NCT01276639|9821546|FG002|Week 0 to 16|Randomized, But Not Treated|0
6173795|NCT01276639|9821547|FG003|Week 0 to 16|Randomized, But Not Treated|0
6173796|NCT01276639|9821548|FG004|Week 0 to 16|Randomized, But Not Treated|0
6173797|NCT01276639|9821544|FG000|Week 16 to 52|Death|1
6173798|NCT01276639|9821545|FG001|Week 16 to 52|Death|0
6173799|NCT01276639|9821546|FG002|Week 16 to 52|Death|0
6173800|NCT01276639|9821547|FG003|Week 16 to 52|Death|0
6173801|NCT01276639|9821548|FG004|Week 16 to 52|Death|0
6173802|NCT01276639|9821544|FG000|Week 16 to 52|Adverse Event|10
6173803|NCT01276639|9821545|FG001|Week 16 to 52|Adverse Event|13
6173804|NCT01276639|9821546|FG002|Week 16 to 52|Adverse Event|0
6173805|NCT01276639|9821547|FG003|Week 16 to 52|Adverse Event|1
6173806|NCT01276639|9821548|FG004|Week 16 to 52|Adverse Event|3
6173807|NCT01276639|9821544|FG000|Week 16 to 52|Lack of Efficacy|99
6173808|NCT01276639|9821545|FG001|Week 16 to 52|Lack of Efficacy|71
6173809|NCT01276639|9821546|FG002|Week 16 to 52|Lack of Efficacy|0
6173810|NCT01276639|9821547|FG003|Week 16 to 52|Lack of Efficacy|14
6173811|NCT01276639|9821548|FG004|Week 16 to 52|Lack of Efficacy|13
6173812|NCT01276639|9821544|FG000|Week 16 to 52|Lost to Follow-up|3
6173813|NCT01276639|9821545|FG001|Week 16 to 52|Lost to Follow-up|1
6173814|NCT01276639|9821546|FG002|Week 16 to 52|Lost to Follow-up|0
6173815|NCT01276639|9821547|FG003|Week 16 to 52|Lost to Follow-up|0
6173816|NCT01276639|9821548|FG004|Week 16 to 52|Lost to Follow-up|1
6173817|NCT01276639|9821544|FG000|Week 16 to 52|Withdrawal by Subject|4
6173818|NCT01276639|9821545|FG001|Week 16 to 52|Withdrawal by Subject|4
6173819|NCT01276639|9821546|FG002|Week 16 to 52|Withdrawal by Subject|0
6173820|NCT01276639|9821547|FG003|Week 16 to 52|Withdrawal by Subject|0
6173821|NCT01276639|9821548|FG004|Week 16 to 52|Withdrawal by Subject|1
6173822|NCT01276639|9821544|FG000|Week 16 to 52|Other|10
6173823|NCT01276639|9821545|FG001|Week 16 to 52|Other|12
6173824|NCT01276639|9821546|FG002|Week 16 to 52|Other|0
6173825|NCT01276639|9821547|FG003|Week 16 to 52|Other|1
6173826|NCT01276639|9821548|FG004|Week 16 to 52|Other|3
6173827|NCT01276756|9821583|FG000|Overall Study|Lost to Follow-up|2
6173828|NCT01276756|9821584|FG001|Overall Study|Lost to Follow-up|0
6173829|NCT01276756|9821583|FG000|Overall Study|Adverse Event|3
6173830|NCT01276756|9821584|FG001|Overall Study|Adverse Event|2
6173831|NCT01276821|9821592|FG000|Overall Study|Protocol Violation|0
6173832|NCT01276821|9821593|FG001|Overall Study|Protocol Violation|1
6173833|NCT01276847|9821602|FG000|Overall Study|Withdrawal by Subject|1
6173834|NCT01276847|9821603|FG001|Overall Study|Withdrawal by Subject|0
6173835|NCT01276847|9821604|FG002|Overall Study|Withdrawal by Subject|0
6173836|NCT01277042|9821622|FG000|Overall Study|Adverse Event|4
6173837|NCT01277042|9821623|FG001|Overall Study|Adverse Event|3
6173838|NCT01277042|9821622|FG000|Overall Study|Lost to Follow-up|2
6173839|NCT01277042|9821623|FG001|Overall Study|Lost to Follow-up|2
6173840|NCT01277042|9821622|FG000|Overall Study|Withdrawal by Subject|2
6173841|NCT01277042|9821623|FG001|Overall Study|Withdrawal by Subject|0
6173842|NCT01277302|9821663|FG000|7-Month Fixed Treatment Period|Subject Decision to Withdraw|0
6173843|NCT01277302|9821664|FG001|7-Month Fixed Treatment Period|Subject Decision to Withdraw|0
6173844|NCT01277302|9821665|FG002|7-Month Fixed Treatment Period|Subject Decision to Withdraw|8
6173845|NCT01277302|9821663|FG000|7-Month Fixed Treatment Period|Lost to Follow-up|0
6173846|NCT01277302|9821664|FG001|7-Month Fixed Treatment Period|Lost to Follow-up|0
6173847|NCT01277302|9821665|FG002|7-Month Fixed Treatment Period|Lost to Follow-up|2
6173848|NCT01277302|9821663|FG000|7-Month Fixed Treatment Period|Subject Required Other Drug Therapy|0
6173849|NCT01277302|9821664|FG001|7-Month Fixed Treatment Period|Subject Required Other Drug Therapy|0
6173850|NCT01277302|9821665|FG002|7-Month Fixed Treatment Period|Subject Required Other Drug Therapy|1
6173851|NCT01277302|9821663|FG000|7-Month Fixed Treatment Period|Subject Non-compliance|0
6173852|NCT01277302|9821664|FG001|7-Month Fixed Treatment Period|Subject Non-compliance|0
6173853|NCT01277302|9821665|FG002|7-Month Fixed Treatment Period|Subject Non-compliance|1
6173854|NCT01277302|9821663|FG000|8-Month Alternate Dose Regimen Period|Death|0
6173855|NCT01277302|9821664|FG001|8-Month Alternate Dose Regimen Period|Death|1
6173856|NCT01277302|9821665|FG002|8-Month Alternate Dose Regimen Period|Death|0
6173857|NCT01277302|9821663|FG000|8-Month Alternate Dose Regimen Period|Lost to Follow-up|1
6173858|NCT01277302|9821664|FG001|8-Month Alternate Dose Regimen Period|Lost to Follow-up|1
6173859|NCT01277302|9821665|FG002|8-Month Alternate Dose Regimen Period|Lost to Follow-up|3
6173860|NCT01277302|9821663|FG000|8-Month Alternate Dose Regimen Period|Subject Decision to Withdraw|3
6173861|NCT01277302|9821664|FG001|8-Month Alternate Dose Regimen Period|Subject Decision to Withdraw|0
6173862|NCT01277302|9821665|FG002|8-Month Alternate Dose Regimen Period|Subject Decision to Withdraw|1
6173863|NCT01277302|9821663|FG000|8-Month Alternate Dose Regimen Period|Subject Non-compliance|0
6173864|NCT01277302|9821664|FG001|8-Month Alternate Dose Regimen Period|Subject Non-compliance|2
6173865|NCT01277302|9821665|FG002|8-Month Alternate Dose Regimen Period|Subject Non-compliance|1
6173866|NCT01277302|9821663|FG000|8-Month Alternate Dose Regimen Period|Relocation|1
6173867|NCT01277302|9821664|FG001|8-Month Alternate Dose Regimen Period|Relocation|0
6173868|NCT01277302|9821665|FG002|8-Month Alternate Dose Regimen Period|Relocation|1
6173869|NCT01277510|9821701|FG000|Double-blind Phase|Non-compliance|0
6173870|NCT01277510|9821702|FG001|Double-blind Phase|Non-compliance|1
6173871|NCT01277510|9821701|FG000|Double-blind Phase|Adverse Event|1
6173872|NCT01277510|9821702|FG001|Double-blind Phase|Adverse Event|0
6173873|NCT01277510|9821701|FG000|Double-blind Phase|Withdrawal by Subject|2
6173874|NCT01277510|9821702|FG001|Double-blind Phase|Withdrawal by Subject|0
6192372|NCT01430611|9849655|FG000|Overall Study|Lost to Follow-up|1
6173875|NCT01277510|9821701|FG000|Double-blind Phase|Administrative decision|7
6173876|NCT01277510|9821702|FG001|Double-blind Phase|Administrative decision|9
6173877|NCT01277510|9821701|FG000|Double-blind Phase|Death|0
6173878|NCT01277510|9821702|FG001|Double-blind Phase|Death|1
6173879|NCT01277510|9821701|FG000|Double-blind Phase|Protocol-specified criteria|2
6173880|NCT01277510|9821702|FG001|Double-blind Phase|Protocol-specified criteria|6
6173881|NCT01277510|9821701|FG000|Double-blind Phase|Other|1
6173882|NCT01277510|9821702|FG001|Double-blind Phase|Other|1
6173883|NCT01277510|9821701|FG000|Open-label Phase|Administrative decision|4
6173884|NCT01277510|9821702|FG001|Open-label Phase|Administrative decision|3
6173885|NCT01277510|9821701|FG000|Open-label Phase|Protocol-specified criteria|1
6173886|NCT01277510|9821702|FG001|Open-label Phase|Protocol-specified criteria|0
6173887|NCT01277510|9821701|FG000|Open-label Phase|Never received investigational product|2
6173888|NCT01277510|9821702|FG001|Open-label Phase|Never received investigational product|0
6192373|NCT01430611|9849656|FG001|Overall Study|Lost to Follow-up|0
6192374|NCT01430611|9849655|FG000|Overall Study|Withdrawal by Subject|15
6192375|NCT01430611|9849656|FG001|Overall Study|Withdrawal by Subject|14
6375048|NCT03745638|10164838|FG006|Long-Term Safety Period (Weeks 8 to 52)|Lack of Efficacy|2
6375049|NCT03745638|10164832|FG000|Long-Term Safety Period (Weeks 8 to 52)|Lost to Follow-up|0
6192376|NCT01430624|9849665|FG000|Overall Study|Lost to Follow-up|23
6192377|NCT01430624|9849666|FG001|Overall Study|Lost to Follow-up|29
6192378|NCT01430624|9849667|FG002|Overall Study|Lost to Follow-up|27
6192379|NCT01430624|9849665|FG000|Overall Study|technical or eligibility|5
6192380|NCT01430624|9849666|FG001|Overall Study|technical or eligibility|5
6192381|NCT01430624|9849667|FG002|Overall Study|technical or eligibility|2
6192382|NCT01430754|9849699|FG000|Run-In Phase|Circadian Period Ineligible|24
6192383|NCT01430754|9849700|FG001|Run-In Phase|Circadian Period Ineligible|0
6192384|NCT01430754|9849699|FG000|Run-In Phase|Protocol Violation|6
6192385|NCT01430754|9849700|FG001|Run-In Phase|Protocol Violation|0
6192386|NCT01430754|9849699|FG000|Run-In Phase|Adverse Event|2
6192387|NCT01430754|9849700|FG001|Run-In Phase|Adverse Event|0
6192388|NCT01430754|9849699|FG000|Run-In Phase|Other|2
6192389|NCT01430754|9849700|FG001|Run-In Phase|Other|0
6192390|NCT01430754|9849699|FG000|Run-In Phase|Withdrawal by Subject|2
6192391|NCT01430754|9849700|FG001|Run-In Phase|Withdrawal by Subject|0
6192392|NCT01430754|9849699|FG000|Run-In Phase|Lost to Follow-up|1
6192393|NCT01430754|9849700|FG001|Run-In Phase|Lost to Follow-up|0
6192394|NCT01431079|9849728|FG000|Overall Study|Lost to Follow-up|35
6192395|NCT01431079|9849729|FG001|Overall Study|Lost to Follow-up|39
6192396|NCT01431144|9849774|FG000|Overall Study|Implant mobility and removal|2
6192397|NCT01431144|9849775|FG001|Overall Study|Implant mobility and removal|0
6192398|NCT01431274|9849814|FG000|Overall Study|Adverse Event|51
6192399|NCT01431274|9849815|FG001|Overall Study|Adverse Event|37
6192400|NCT01431274|9849816|FG002|Overall Study|Adverse Event|43
6192401|NCT01431274|9849817|FG003|Overall Study|Adverse Event|30
6192402|NCT01431274|9849818|FG004|Overall Study|Adverse Event|37
6192403|NCT01431274|9849814|FG000|Overall Study|Consent withdrawn not due to AE|29
6192404|NCT01431274|9849815|FG001|Overall Study|Consent withdrawn not due to AE|20
6192405|NCT01431274|9849816|FG002|Overall Study|Consent withdrawn not due to AE|17
6192406|NCT01431274|9849817|FG003|Overall Study|Consent withdrawn not due to AE|20
6192407|NCT01431274|9849818|FG004|Overall Study|Consent withdrawn not due to AE|11
6192408|NCT01431274|9849814|FG000|Overall Study|Non compliant with protocol|5
6192409|NCT01431274|9849815|FG001|Overall Study|Non compliant with protocol|8
6192410|NCT01431274|9849816|FG002|Overall Study|Non compliant with protocol|4
6192411|NCT01431274|9849817|FG003|Overall Study|Non compliant with protocol|4
6192412|NCT01431274|9849818|FG004|Overall Study|Non compliant with protocol|4
6192413|NCT01431274|9849814|FG000|Overall Study|Lost to Follow-up|6
6192414|NCT01431274|9849815|FG001|Overall Study|Lost to Follow-up|7
6192415|NCT01431274|9849816|FG002|Overall Study|Lost to Follow-up|1
6192416|NCT01431274|9849817|FG003|Overall Study|Lost to Follow-up|4
6192417|NCT01431274|9849818|FG004|Overall Study|Lost to Follow-up|0
6192418|NCT01431274|9849814|FG000|Overall Study|Other reason not stated above|6
6192419|NCT01431274|9849815|FG001|Overall Study|Other reason not stated above|5
6192420|NCT01431274|9849816|FG002|Overall Study|Other reason not stated above|7
6192421|NCT01431274|9849817|FG003|Overall Study|Other reason not stated above|2
6192422|NCT01431274|9849818|FG004|Overall Study|Other reason not stated above|4
6192423|NCT01431287|9849835|FG000|Overall Study|not treated|0
6192424|NCT01431287|9849836|FG001|Overall Study|not treated|0
6192425|NCT01431287|9849837|FG002|Overall Study|not treated|1
6192426|NCT01431287|9849838|FG003|Overall Study|not treated|0
6192427|NCT01431287|9849839|FG004|Overall Study|not treated|0
6192428|NCT01431287|9849835|FG000|Overall Study|Adverse Event|59
6192429|NCT01431287|9849836|FG001|Overall Study|Adverse Event|57
6192430|NCT01431287|9849837|FG002|Overall Study|Adverse Event|53
6192431|NCT01431287|9849838|FG003|Overall Study|Adverse Event|33
6192432|NCT01431287|9849839|FG004|Overall Study|Adverse Event|41
6192433|NCT01431287|9849835|FG000|Overall Study|Non compliant with protocol|6
6192434|NCT01431287|9849836|FG001|Overall Study|Non compliant with protocol|6
6375050|NCT03745638|10164833|FG001|Long-Term Safety Period (Weeks 8 to 52)|Lost to Follow-up|0
6192435|NCT01431287|9849837|FG002|Overall Study|Non compliant with protocol|5
6192436|NCT01431287|9849838|FG003|Overall Study|Non compliant with protocol|6
6192437|NCT01431287|9849839|FG004|Overall Study|Non compliant with protocol|5
6192438|NCT01431287|9849835|FG000|Overall Study|Lost to Follow-up|0
6173889|NCT01277523|9821713|FG000|Overall Study|Adverse Event|1
6173890|NCT01277523|9821714|FG001|Overall Study|Adverse Event|0
6173891|NCT01277523|9821715|FG002|Overall Study|Adverse Event|0
6173892|NCT01277523|9821713|FG000|Overall Study|Protocol Violation|2
6173893|NCT01277523|9821714|FG001|Overall Study|Protocol Violation|0
6173894|NCT01277523|9821715|FG002|Overall Study|Protocol Violation|0
6173895|NCT01277523|9821713|FG000|Overall Study|Other Reason not Defined|0
6173896|NCT01277523|9821714|FG001|Overall Study|Other Reason not Defined|1
6173897|NCT01277523|9821715|FG002|Overall Study|Other Reason not Defined|0
6173898|NCT01277549|9821725|FG000|Overall Study|Failed to meet eligibility criteria|13
6173899|NCT01277549|9821726|FG001|Overall Study|Failed to meet eligibility criteria|9
6173900|NCT01277549|9821725|FG000|Overall Study|Withdrawal by Subject|1
6173901|NCT01277549|9821726|FG001|Overall Study|Withdrawal by Subject|3
6173902|NCT01277549|9821725|FG000|Overall Study|Protocol Violation|10
6173903|NCT01277549|9821726|FG001|Overall Study|Protocol Violation|1
6173904|NCT01277549|9821725|FG000|Overall Study|Physician Decision|2
6173905|NCT01277549|9821726|FG001|Overall Study|Physician Decision|1
6173906|NCT01277601|9821739|FG000|Overall Study|Adverse Event|5
6173907|NCT01277601|9821740|FG001|Overall Study|Adverse Event|3
6173908|NCT01277601|9821741|FG002|Overall Study|Adverse Event|0
6173909|NCT01277601|9821742|FG003|Overall Study|Adverse Event|7
6173910|NCT01277601|9821739|FG000|Overall Study|Withdrawal by Subject|18
6173911|NCT01277601|9821740|FG001|Overall Study|Withdrawal by Subject|21
6173912|NCT01277601|9821741|FG002|Overall Study|Withdrawal by Subject|8
6173913|NCT01277601|9821742|FG003|Overall Study|Withdrawal by Subject|17
6173914|NCT01277601|9821739|FG000|Overall Study|Lost to Follow-up|7
6173915|NCT01277601|9821740|FG001|Overall Study|Lost to Follow-up|9
6173916|NCT01277601|9821741|FG002|Overall Study|Lost to Follow-up|4
6173917|NCT01277601|9821742|FG003|Overall Study|Lost to Follow-up|2
6173918|NCT01277601|9821739|FG000|Overall Study|Physician Decision|3
6173919|NCT01277601|9821740|FG001|Overall Study|Physician Decision|5
6173920|NCT01277601|9821741|FG002|Overall Study|Physician Decision|1
6173921|NCT01277601|9821742|FG003|Overall Study|Physician Decision|6
6173922|NCT01277601|9821739|FG000|Overall Study|Pregnancy|2
6173923|NCT01277601|9821740|FG001|Overall Study|Pregnancy|2
6173924|NCT01277601|9821741|FG002|Overall Study|Pregnancy|4
6173925|NCT01277601|9821742|FG003|Overall Study|Pregnancy|1
6173926|NCT01277601|9821739|FG000|Overall Study|Noncompliance with Study Drug|1
6173927|NCT01277601|9821740|FG001|Overall Study|Noncompliance with Study Drug|3
6173928|NCT01277601|9821741|FG002|Overall Study|Noncompliance with Study Drug|2
6173929|NCT01277601|9821742|FG003|Overall Study|Noncompliance with Study Drug|0
6173930|NCT01277601|9821739|FG000|Overall Study|Subject Never Dosed with Study Drug|1
6173931|NCT01277601|9821740|FG001|Overall Study|Subject Never Dosed with Study Drug|2
6173932|NCT01277601|9821741|FG002|Overall Study|Subject Never Dosed with Study Drug|3
6173933|NCT01277601|9821742|FG003|Overall Study|Subject Never Dosed with Study Drug|1
6173934|NCT01277601|9821739|FG000|Overall Study|Protocol Violation|0
6173935|NCT01277601|9821740|FG001|Overall Study|Protocol Violation|2
6173936|NCT01277601|9821741|FG002|Overall Study|Protocol Violation|5
6173937|NCT01277601|9821742|FG003|Overall Study|Protocol Violation|0
6173938|NCT01277601|9821739|FG000|Overall Study|Subject Terminated from Study by Sponsor|0
6173939|NCT01277601|9821740|FG001|Overall Study|Subject Terminated from Study by Sponsor|1
6173940|NCT01277601|9821741|FG002|Overall Study|Subject Terminated from Study by Sponsor|0
6173941|NCT01277601|9821742|FG003|Overall Study|Subject Terminated from Study by Sponsor|2
6173942|NCT01277666|9821772|FG000|Overall Study|Adverse Event|26
6173943|NCT01277666|9821773|FG001|Overall Study|Adverse Event|25
6173944|NCT01277666|9821774|FG002|Overall Study|Adverse Event|20
6173945|NCT01277666|9821772|FG000|Overall Study|Lack of Efficacy|8
6173946|NCT01277666|9821773|FG001|Overall Study|Lack of Efficacy|20
6173947|NCT01277666|9821774|FG002|Overall Study|Lack of Efficacy|12
6173948|NCT01277666|9821772|FG000|Overall Study|Protocol Violation|2
6173949|NCT01277666|9821773|FG001|Overall Study|Protocol Violation|3
6173950|NCT01277666|9821774|FG002|Overall Study|Protocol Violation|2
6173951|NCT01277666|9821772|FG000|Overall Study|Protocol Defined Stopping criteria|1
6173952|NCT01277666|9821773|FG001|Overall Study|Protocol Defined Stopping criteria|2
6173953|NCT01277666|9821774|FG002|Overall Study|Protocol Defined Stopping criteria|6
6173954|NCT01277666|9821772|FG000|Overall Study|Lost to Follow-up|1
6173955|NCT01277666|9821773|FG001|Overall Study|Lost to Follow-up|1
6173956|NCT01277666|9821774|FG002|Overall Study|Lost to Follow-up|2
6173957|NCT01277666|9821772|FG000|Overall Study|Withdrawal by Subject|7
6173958|NCT01277666|9821773|FG001|Overall Study|Withdrawal by Subject|8
6173959|NCT01277666|9821774|FG002|Overall Study|Withdrawal by Subject|6
6173960|NCT01277666|9821772|FG000|Overall Study|Death|0
6173961|NCT01277666|9821773|FG001|Overall Study|Death|0
6173962|NCT01277666|9821774|FG002|Overall Study|Death|1
6173963|NCT01277718|9821782|FG000|Period 2 - Second Intervention|Protocol Violation|0
6173964|NCT01277718|9821783|FG001|Period 2 - Second Intervention|Protocol Violation|1
6173965|NCT01277718|9821782|FG000|Period 2 - Second Intervention|Physician Decision|0
6173966|NCT01277718|9821783|FG001|Period 2 - Second Intervention|Physician Decision|2
6375051|NCT03745638|10164834|FG002|Long-Term Safety Period (Weeks 8 to 52)|Lost to Follow-up|0
6173967|NCT01277744|9821791|FG000|Overall Study|Physician Decision|2
6173968|NCT01277757|9821795|FG000|Overall Study|Disease Progression|1
6173969|NCT01277757|9821795|FG000|Overall Study|Withdrawal by Subject|1
6173970|NCT01277861|9821806|FG000|Overall Study|Physician Decision|2
6173971|NCT01277861|9821807|FG001|Overall Study|Physician Decision|2
6173972|NCT01277887|9821817|FG000|Pre-Quit Treatment Phase|No longer interested in treatment|1
6173973|NCT01277887|9821818|FG001|Pre-Quit Treatment Phase|No longer interested in treatment|0
6173974|NCT01277887|9821817|FG000|Pre-Quit Treatment Phase|Withdrawal by Subject|2
6173975|NCT01277887|9821818|FG001|Pre-Quit Treatment Phase|Withdrawal by Subject|0
6173976|NCT01277887|9821817|FG000|Post-Quit Treatment Phase|No longer interested in treatment|3
6173977|NCT01277887|9821818|FG001|Post-Quit Treatment Phase|No longer interested in treatment|5
6173978|NCT01278030|9821826|FG000|Overall Study|Withdrawal by Subject|8
6173979|NCT01278030|9821827|FG001|Overall Study|Withdrawal by Subject|4
6173980|NCT01278160|9821835|FG000|Overall Study|Adverse Event|1
6173981|NCT01278160|9821836|FG001|Overall Study|Adverse Event|1
6173982|NCT01278160|9821835|FG000|Overall Study|Lost to Follow-up|0
6173983|NCT01278160|9821836|FG001|Overall Study|Lost to Follow-up|1
6173984|NCT01278160|9821835|FG000|Overall Study|Withdrawal by Subject|3
6173985|NCT01278160|9821836|FG001|Overall Study|Withdrawal by Subject|2
6173986|NCT01278160|9821835|FG000|Overall Study|Unclassified|1
6173987|NCT01278160|9821836|FG001|Overall Study|Unclassified|2
6173988|NCT01278173|9821842|FG000|Overall Study|Lack of Efficacy|13
6173989|NCT01278173|9821842|FG000|Overall Study|Adverse Event|8
6173990|NCT01278173|9821842|FG000|Overall Study|Administrative or other reason|4
6173991|NCT01278173|9821842|FG000|Overall Study|Protocol Violation|1
6173992|NCT01278173|9821842|FG000|Overall Study|Withdrawal by Subject|1
6173993|NCT01278342|9821853|FG000|Overall Study|Physician Decision|0
6173994|NCT01278342|9821854|FG001|Overall Study|Physician Decision|1
6173995|NCT01278342|9821855|FG002|Overall Study|Physician Decision|0
6173996|NCT01278342|9821853|FG000|Overall Study|Lost to Follow-up|1
6173997|NCT01278342|9821854|FG001|Overall Study|Lost to Follow-up|0
6173998|NCT01278342|9821855|FG002|Overall Study|Lost to Follow-up|0
6173999|NCT01278342|9821853|FG000|Overall Study|Administrative problems|2
6174000|NCT01278342|9821854|FG001|Overall Study|Administrative problems|0
6174001|NCT01278342|9821855|FG002|Overall Study|Administrative problems|0
6174002|NCT01278342|9821853|FG000|Overall Study|Other|1
6174003|NCT01278342|9821854|FG001|Overall Study|Other|0
6174004|NCT01278342|9821855|FG002|Overall Study|Other|0
6174005|NCT01278394|9821863|FG000|Overall Study|Lost to Follow-up|1
6174006|NCT01278407|9821870|FG000|Confirmatory Phase|Adverse Event|5
6174007|NCT01278407|9821871|FG001|Confirmatory Phase|Adverse Event|10
6174008|NCT01278407|9821872|FG002|Confirmatory Phase|Adverse Event|1
6174009|NCT01278407|9821873|FG003|Confirmatory Phase|Adverse Event|0
6174010|NCT01278407|9821874|FG004|Confirmatory Phase|Adverse Event|0
6174011|NCT01278407|9821870|FG000|Confirmatory Phase|Participant's Choice|3
6174012|NCT01278407|9821871|FG001|Confirmatory Phase|Participant's Choice|5
6174013|NCT01278407|9821872|FG002|Confirmatory Phase|Participant's Choice|3
6174014|NCT01278407|9821873|FG003|Confirmatory Phase|Participant's Choice|0
6174015|NCT01278407|9821874|FG004|Confirmatory Phase|Participant's Choice|0
6174016|NCT01278407|9821870|FG000|Confirmatory Phase|Other|1
6174017|NCT01278407|9821871|FG001|Confirmatory Phase|Other|1
6174018|NCT01278407|9821872|FG002|Confirmatory Phase|Other|2
6174019|NCT01278407|9821873|FG003|Confirmatory Phase|Other|0
6174020|NCT01278407|9821874|FG004|Confirmatory Phase|Other|0
6174021|NCT01278407|9821870|FG000|Extension Phase|Adverse Event|0
6174022|NCT01278407|9821871|FG001|Extension Phase|Adverse Event|0
6174023|NCT01278407|9821872|FG002|Extension Phase|Adverse Event|0
6174024|NCT01278407|9821873|FG003|Extension Phase|Adverse Event|7
6174025|NCT01278407|9821874|FG004|Extension Phase|Adverse Event|16
6174026|NCT01278407|9821870|FG000|Extension Phase|Participant's Choice|0
6174027|NCT01278407|9821871|FG001|Extension Phase|Participant's Choice|0
6174028|NCT01278407|9821872|FG002|Extension Phase|Participant's Choice|0
6174029|NCT01278407|9821873|FG003|Extension Phase|Participant's Choice|4
6174030|NCT01278407|9821874|FG004|Extension Phase|Participant's Choice|11
6174031|NCT01278407|9821870|FG000|Extension Phase|Other|0
6174032|NCT01278407|9821871|FG001|Extension Phase|Other|0
6174033|NCT01278407|9821872|FG002|Extension Phase|Other|0
6174034|NCT01278407|9821873|FG003|Extension Phase|Other|1
6174035|NCT01278407|9821874|FG004|Extension Phase|Other|3
6174036|NCT01278615|9821888|FG000|Overall Study|Withdrawal by Subject|2
6174037|NCT01278745|9821894|FG000|Overall Study|Death|2
6174038|NCT01278745|9821895|FG001|Overall Study|Death|5
6174039|NCT01278745|9821896|FG002|Overall Study|Death|7
6174040|NCT01278745|9821897|FG003|Overall Study|Death|0
6174041|NCT01278745|9821894|FG000|Overall Study|Physician Decision|1
6174042|NCT01278745|9821895|FG001|Overall Study|Physician Decision|0
6174043|NCT01278745|9821896|FG002|Overall Study|Physician Decision|0
6174044|NCT01278745|9821897|FG003|Overall Study|Physician Decision|9
6174045|NCT01278745|9821894|FG000|Overall Study|Withdrawal by Subject|1
6174046|NCT01278745|9821895|FG001|Overall Study|Withdrawal by Subject|1
6174047|NCT01278745|9821896|FG002|Overall Study|Withdrawal by Subject|5
6174048|NCT01278745|9821897|FG003|Overall Study|Withdrawal by Subject|1
6174049|NCT01278745|9821894|FG000|Overall Study|Sponsor Decision|1
6174050|NCT01278745|9821895|FG001|Overall Study|Sponsor Decision|0
6174051|NCT01278745|9821896|FG002|Overall Study|Sponsor Decision|62
6174052|NCT01278745|9821897|FG003|Overall Study|Sponsor Decision|6
6174053|NCT01278745|9821894|FG000|Overall Study|Ineligible|0
6174054|NCT01278745|9821895|FG001|Overall Study|Ineligible|0
6174055|NCT01278745|9821896|FG002|Overall Study|Ineligible|42
6174056|NCT01278745|9821897|FG003|Overall Study|Ineligible|61
6174057|NCT01278745|9821894|FG000|Overall Study|Moves,enrollment in mx studies, et al.|0
6174058|NCT01278745|9821895|FG001|Overall Study|Moves,enrollment in mx studies, et al.|0
6174059|NCT01278745|9821896|FG002|Overall Study|Moves,enrollment in mx studies, et al.|5
6174060|NCT01278745|9821897|FG003|Overall Study|Moves,enrollment in mx studies, et al.|1
6174061|NCT01278797|9821905|FG000|Period 1|Adverse Event|0
6174062|NCT01278797|9821906|FG001|Period 1|Adverse Event|1
6174063|NCT01278797|9821905|FG000|Period 1|Protocol Violation|1
6174064|NCT01278797|9821906|FG001|Period 1|Protocol Violation|0
6174065|NCT01278862|9821914|FG000|Overall Study|Lost to Follow-up|1
6174066|NCT01278862|9821915|FG001|Overall Study|Lost to Follow-up|1
6174067|NCT01279044|9821951|FG000|PHASE 2 - Randmonized Controlled Trial|Withdrawal by Subject|0
6174068|NCT01279044|9821952|FG001|PHASE 2 - Randmonized Controlled Trial|Withdrawal by Subject|3
6174069|NCT01279044|9821953|FG002|PHASE 2 - Randmonized Controlled Trial|Withdrawal by Subject|2
6174070|NCT01279044|9821951|FG000|PHASE 2 - Randmonized Controlled Trial|Lost to Follow-up|0
6174071|NCT01279044|9821952|FG001|PHASE 2 - Randmonized Controlled Trial|Lost to Follow-up|8
6174072|NCT01279044|9821953|FG002|PHASE 2 - Randmonized Controlled Trial|Lost to Follow-up|0
6174073|NCT01279044|9821951|FG000|PHASE 2 - Randmonized Controlled Trial|Death|0
6174074|NCT01279044|9821952|FG001|PHASE 2 - Randmonized Controlled Trial|Death|0
6174075|NCT01279044|9821953|FG002|PHASE 2 - Randmonized Controlled Trial|Death|1
6174076|NCT01279057|9821962|FG000|Overall Study|Adverse Event|1
6174077|NCT01279057|9821963|FG001|Overall Study|Adverse Event|0
6174078|NCT01279057|9821964|FG002|Overall Study|Adverse Event|1
6174079|NCT01279057|9821962|FG000|Overall Study|Insufficient therapeutic response|0
6174080|NCT01279057|9821963|FG001|Overall Study|Insufficient therapeutic response|0
6174081|NCT01279057|9821964|FG002|Overall Study|Insufficient therapeutic response|1
6174082|NCT01279057|9821962|FG000|Overall Study|Restricted medication for seasonal allergic rhinitis|0
6174083|NCT01279057|9821963|FG001|Overall Study|Restricted medication for seasonal allergic rhinitis|1
6174084|NCT01279057|9821964|FG002|Overall Study|Restricted medication for seasonal allergic rhinitis|0
6174085|NCT01279057|9821962|FG000|Overall Study|Withdrew consent|2
6174086|NCT01279057|9821963|FG001|Overall Study|Withdrew consent|0
6174087|NCT01279057|9821964|FG002|Overall Study|Withdrew consent|1
6174088|NCT01279057|9821962|FG000|Overall Study|Pregnancy|0
6174089|NCT01279057|9821963|FG001|Overall Study|Pregnancy|1
6174090|NCT01279057|9821964|FG002|Overall Study|Pregnancy|0
6174091|NCT01279057|9821962|FG000|Overall Study|Other|3
6174092|NCT01279057|9821963|FG001|Overall Study|Other|3
6174093|NCT01279057|9821964|FG002|Overall Study|Other|0
6174094|NCT01279070|9821974|FG000|Overall Study|Withdrawal by Subject|2
6174095|NCT01279070|9821975|FG001|Overall Study|Withdrawal by Subject|3
6174096|NCT01279070|9821974|FG000|Overall Study|Acute exacerbation|3
6174097|NCT01279070|9821975|FG001|Overall Study|Acute exacerbation|1
6174098|NCT01279200|9822005|FG000|Overall Study|Withdrawal by Subject|1
6174099|NCT01279200|9822006|FG001|Overall Study|Withdrawal by Subject|3
6174100|NCT01279200|9822005|FG000|Overall Study|Patient withdrawal due to high cost|0
6174101|NCT01279200|9822006|FG001|Overall Study|Patient withdrawal due to high cost|1
6174102|NCT01279200|9822005|FG000|Overall Study|Inconvenience of ultrasound visit|0
6174103|NCT01279200|9822006|FG001|Overall Study|Inconvenience of ultrasound visit|1
6174104|NCT01279200|9822005|FG000|Overall Study|ultrasound screening failure|0
6174105|NCT01279200|9822006|FG001|Overall Study|ultrasound screening failure|1
6174106|NCT01279200|9822005|FG000|Overall Study|Lost to Follow-up|0
6174107|NCT01279200|9822006|FG001|Overall Study|Lost to Follow-up|1
6174108|NCT01279200|9822005|FG000|Overall Study|Adverse Event|1
6174109|NCT01279200|9822006|FG001|Overall Study|Adverse Event|0
6174110|NCT01279343|9822031|FG000|Overall Study|Did not receive treatment|2
6174111|NCT01279343|9822032|FG001|Overall Study|Did not receive treatment|6
6174112|NCT01279447|9822040|FG000|Overall Study|Lost to Follow-up|3
6174113|NCT01279447|9822041|FG001|Overall Study|Lost to Follow-up|1
6174114|NCT01279486|9822047|FG000|Overall Study|Lost to Follow-up|1
6174115|NCT01279681|9822062|FG000|Overall Study|Disease Progression|9
6174116|NCT01279681|9822063|FG001|Overall Study|Disease Progression|6
6174117|NCT01279681|9822062|FG000|Overall Study|Withdrawal by Subject|3
6174118|NCT01279681|9822063|FG001|Overall Study|Withdrawal by Subject|4
6174119|NCT01279681|9822062|FG000|Overall Study|Adverse Event|2
6174120|NCT01279681|9822063|FG001|Overall Study|Adverse Event|3
6174121|NCT01279681|9822062|FG000|Overall Study|Death|0
6174122|NCT01279681|9822063|FG001|Overall Study|Death|1
6174123|NCT01279681|9822062|FG000|Overall Study|Withdrawal Prior to Beginning Treatment|0
6174124|NCT01279681|9822063|FG001|Overall Study|Withdrawal Prior to Beginning Treatment|1
6174125|NCT01279681|9822062|FG000|Overall Study|Physician Decision|1
6174126|NCT01279681|9822063|FG001|Overall Study|Physician Decision|0
6174127|NCT01279681|9822062|FG000|Overall Study|Other Reason|0
6174128|NCT01279681|9822063|FG001|Overall Study|Other Reason|2
6174129|NCT01279850|9822069|FG000|Overall Study|Protocol Violation|50
6174130|NCT01279850|9822069|FG000|Overall Study|No Drug Administration Information|7
6174131|NCT01279850|9822069|FG000|Overall Study|No Visit After Treatment|34
6174132|NCT01279954|9822075|FG000|Overall Study|Lack of Efficacy|3
6174133|NCT01279954|9822076|FG001|Overall Study|Lack of Efficacy|4
6174134|NCT01280266|9822126|FG000|First Intervention (Week 1-4)|Adverse Event|1
6174135|NCT01280266|9822127|FG001|First Intervention (Week 1-4)|Adverse Event|0
6174136|NCT01280266|9822126|FG000|First Intervention (Week 1-4)|Withdrawal by Subject|0
6174137|NCT01280266|9822127|FG001|First Intervention (Week 1-4)|Withdrawal by Subject|2
6174138|NCT01280357|9822137|FG000|Overall Study|Excluded no internal monitoring|14
6174139|NCT01280357|9822137|FG000|Overall Study|IInsufficient data/No data supplied|12
6174140|NCT01280591|9822169|FG000|Overall Study|Withdrawal by Subject|0
6174141|NCT01280591|9822170|FG001|Overall Study|Withdrawal by Subject|0
6174142|NCT01280591|9822171|FG002|Overall Study|Withdrawal by Subject|0
6174143|NCT01280591|9822172|FG003|Overall Study|Withdrawal by Subject|2
6174144|NCT01280591|9822169|FG000|Overall Study|Does not meet exclusion #27 criteria|0
6174145|NCT01280591|9822170|FG001|Overall Study|Does not meet exclusion #27 criteria|0
6174146|NCT01280591|9822171|FG002|Overall Study|Does not meet exclusion #27 criteria|0
6174147|NCT01280591|9822172|FG003|Overall Study|Does not meet exclusion #27 criteria|1
6174148|NCT01280617|9822193|FG000|Overall Study|Adverse Event|0
6174149|NCT01280617|9822194|FG001|Overall Study|Adverse Event|1
6043554|NCT00390858|9642244|FG000|Overall Study|Lack of Efficacy|0
6043555|NCT00390858|9642245|FG001|Overall Study|Lack of Efficacy|1
6174150|NCT01280656|9822203|FG000|Overall Study|Adverse Event|1
6174151|NCT01280656|9822204|FG001|Overall Study|Adverse Event|14
6174152|NCT01280656|9822205|FG002|Overall Study|Adverse Event|13
6174153|NCT01280656|9822203|FG000|Overall Study|Lack of Efficacy|1
6174154|NCT01280656|9822204|FG001|Overall Study|Lack of Efficacy|22
6174155|NCT01280656|9822205|FG002|Overall Study|Lack of Efficacy|38
6174156|NCT01280656|9822203|FG000|Overall Study|Treatment shortening (RGT)|0
6174157|NCT01280656|9822204|FG001|Overall Study|Treatment shortening (RGT)|4
6174158|NCT01280656|9822205|FG002|Overall Study|Treatment shortening (RGT)|5
6174159|NCT01280656|9822203|FG000|Overall Study|Other|1
6174160|NCT01280656|9822204|FG001|Overall Study|Other|7
6174161|NCT01280656|9822205|FG002|Overall Study|Other|7
6174162|NCT01280721|9822234|FG000|Overall Study|Adverse Event|4
6174163|NCT01280721|9822234|FG000|Overall Study|Physician Decision|3
6174164|NCT01280721|9822234|FG000|Overall Study|Withdrawal by Subject|6
6174165|NCT01280721|9822234|FG000|Overall Study|eGFR under the withdrawal criteria|7
6174166|NCT01280721|9822234|FG000|Overall Study|No tolerability for the lowest dose|2
6174167|NCT01280812|9822252|FG000|Overall Study|Withdrawal by Subject|2
6174168|NCT01280812|9822253|FG001|Overall Study|Withdrawal by Subject|1
6174169|NCT01280812|9822254|FG002|Overall Study|Withdrawal by Subject|0
6174170|NCT01280812|9822252|FG000|Overall Study|Lost to Follow-up|1
6174171|NCT01280812|9822253|FG001|Overall Study|Lost to Follow-up|1
6174172|NCT01280812|9822254|FG002|Overall Study|Lost to Follow-up|1
6174173|NCT01280903|9822265|FG000|Overall Study|Lost to Follow-up|23
6174174|NCT01280903|9822266|FG001|Overall Study|Lost to Follow-up|16
6174175|NCT01280955|9822281|FG000|Overall Study|Death|2
6174176|NCT01280955|9822281|FG000|Overall Study|Withdrawal by Subject|1
6174177|NCT01280968|9822289|FG000|Overall Study|Lost to Follow-up|8
6174178|NCT01280968|9822290|FG001|Overall Study|Lost to Follow-up|2
6174179|NCT01280968|9822289|FG000|Overall Study|Unable to Follow Experimental Protocol|2
6174180|NCT01280968|9822290|FG001|Overall Study|Unable to Follow Experimental Protocol|0
6174181|NCT01280968|9822289|FG000|Overall Study|Commuting Problems|2
6174182|NCT01280968|9822290|FG001|Overall Study|Commuting Problems|0
6174183|NCT01280968|9822289|FG000|Overall Study|Anxiety|2
6174184|NCT01280968|9822290|FG001|Overall Study|Anxiety|0
6174185|NCT01280968|9822289|FG000|Overall Study|Adverse Event|1
6174186|NCT01280968|9822290|FG001|Overall Study|Adverse Event|0
6174187|NCT01280968|9822289|FG000|Overall Study|Scheduling Conflicts|1
6174188|NCT01280968|9822290|FG001|Overall Study|Scheduling Conflicts|1
6174189|NCT01280968|9822289|FG000|Overall Study|Pre-existing Neurological Condition|1
6174190|NCT01280968|9822290|FG001|Overall Study|Pre-existing Neurological Condition|0
6174191|NCT01280968|9822289|FG000|Overall Study|Unable to Smoke in Supine Position|1
6174192|NCT01280968|9822290|FG001|Overall Study|Unable to Smoke in Supine Position|0
6174193|NCT01280981|9822297|FG000|Overall Study|Withdrawal by Subject|11
6174194|NCT01280981|9822297|FG000|Overall Study|Protocol Violation|2
6174195|NCT01280981|9822297|FG000|Overall Study|Lack of Efficacy|13
6174196|NCT01280981|9822297|FG000|Overall Study|Lost to Follow-up|3
6174197|NCT01280981|9822297|FG000|Overall Study|Adverse Event|6
6174198|NCT01280981|9822297|FG000|Overall Study|Irregular or discontinued menses|3
6174199|NCT01280981|9822297|FG000|Overall Study|Failed to return|45
6174200|NCT01280981|9822297|FG000|Overall Study|Non-compliance with protocol|3
6174201|NCT01280981|9822297|FG000|Overall Study|Withdrawal of consent|3
6174202|NCT01280981|9822297|FG000|Overall Study|Elective surgery|2
6174203|NCT01280981|9822297|FG000|Overall Study|Study site closure|1
6174204|NCT01281137|9822312|FG000|Baseline Population|No samples assayed (excluded from all analyses)|0
6174205|NCT01281137|9822313|FG001|Baseline Population|No samples assayed (excluded from all analyses)|1
6043556|NCT00390858|9642244|FG000|Overall Study|Withdrawal by Subject|3
6043557|NCT00390858|9642245|FG001|Overall Study|Withdrawal by Subject|4
6043558|NCT00390884|9642253|FG000|Overall Study|Withdrawal by Subject|2
6043559|NCT00390884|9642254|FG001|Overall Study|Withdrawal by Subject|2
6043560|NCT00390910|9642263|FG000|Overall Study|Adverse Event|1
6174206|NCT01281137|9822312|FG000|Analysis Population (Baseline)|baseline sample only so excluded from longitudinal analysis|4
6174207|NCT01281137|9822313|FG001|Analysis Population (Baseline)|baseline sample only so excluded from longitudinal analysis|9
6174208|NCT01281137|9822312|FG000|Analysis Population (9 Months)|5 from the baseline analysis population did not have samples assayed for the analysis at month 9.|0
6192439|NCT01431287|9849836|FG001|Overall Study|Lost to Follow-up|3
6174209|NCT01281137|9822313|FG001|Analysis Population (9 Months)|5 from the baseline analysis population did not have samples assayed for the analysis at month 9.|5
6174210|NCT01281137|9822312|FG000|Analysis Population (10.5 Months)|1 from the baseline analysis population did not have a sample assayed for analysis at month 10.5|1
6174211|NCT01281137|9822313|FG001|Analysis Population (10.5 Months)|1 from the baseline analysis population did not have a sample assayed for analysis at month 10.5|0
6174212|NCT01281137|9822312|FG000|Analysis Population (12 Months)|3 from the baseline analysis population did not have a sample assayed for analysis at month 12|1
6174213|NCT01281137|9822313|FG001|Analysis Population (12 Months)|3 from the baseline analysis population did not have a sample assayed for analysis at month 12|2
6174214|NCT01281189|9822339|FG000|Overall Study|Adverse Event|7
6174215|NCT01281189|9822340|FG001|Overall Study|Adverse Event|9
6174216|NCT01281189|9822339|FG000|Overall Study|Lost to Follow-up|6
6174217|NCT01281189|9822340|FG001|Overall Study|Lost to Follow-up|4
6174218|NCT01281189|9822339|FG000|Overall Study|Withdrawal by Subject|21
6174219|NCT01281189|9822340|FG001|Overall Study|Withdrawal by Subject|24
6174220|NCT01281189|9822339|FG000|Overall Study|Physician Decision|2
6174221|NCT01281189|9822340|FG001|Overall Study|Physician Decision|3
6174222|NCT01281189|9822339|FG000|Overall Study|Death|103
6174223|NCT01281189|9822340|FG001|Overall Study|Death|91
6174224|NCT01281189|9822339|FG000|Overall Study|Other|8
6174225|NCT01281189|9822340|FG001|Overall Study|Other|12
6174226|NCT01281202|9822348|FG000|Overall Study|Adverse Event|2
6174227|NCT01281202|9822349|FG001|Overall Study|Adverse Event|0
6174228|NCT01281202|9822348|FG000|Overall Study|Withdrawal by Subject|2
6174229|NCT01281202|9822349|FG001|Overall Study|Withdrawal by Subject|2
6174230|NCT01281202|9822348|FG000|Overall Study|Protocol Violation|11
6174231|NCT01281202|9822349|FG001|Overall Study|Protocol Violation|10
6174232|NCT01281202|9822348|FG000|Overall Study|Administrative|2
6174233|NCT01281202|9822349|FG001|Overall Study|Administrative|8
6174234|NCT01281202|9822348|FG000|Overall Study|Lost to Follow-up|11
6174235|NCT01281202|9822349|FG001|Overall Study|Lost to Follow-up|13
6174236|NCT01281202|9822348|FG000|Overall Study|Incarceration|0
6174237|NCT01281202|9822349|FG001|Overall Study|Incarceration|3
6174238|NCT01281306|9822364|FG000|Overall Study|Lack of Efficacy|0
6174239|NCT01281306|9822365|FG001|Overall Study|Lack of Efficacy|1
6174240|NCT01281306|9822366|FG002|Overall Study|Lack of Efficacy|3
6174241|NCT01281306|9822367|FG003|Overall Study|Lack of Efficacy|0
6174242|NCT01281306|9822368|FG004|Overall Study|Lack of Efficacy|2
6174243|NCT01281306|9822369|FG005|Overall Study|Lack of Efficacy|0
6174244|NCT01281306|9822370|FG006|Overall Study|Lack of Efficacy|1
6174245|NCT01281306|9822364|FG000|Overall Study|Withdrawal by Subject|1
6174246|NCT01281306|9822365|FG001|Overall Study|Withdrawal by Subject|0
6174247|NCT01281306|9822366|FG002|Overall Study|Withdrawal by Subject|2
6174248|NCT01281306|9822367|FG003|Overall Study|Withdrawal by Subject|4
6174249|NCT01281306|9822368|FG004|Overall Study|Withdrawal by Subject|1
6174250|NCT01281306|9822369|FG005|Overall Study|Withdrawal by Subject|3
6174251|NCT01281306|9822370|FG006|Overall Study|Withdrawal by Subject|1
6174252|NCT01281306|9822364|FG000|Overall Study|Protocol deviation|0
6174253|NCT01281306|9822365|FG001|Overall Study|Protocol deviation|1
6174254|NCT01281306|9822366|FG002|Overall Study|Protocol deviation|1
6174255|NCT01281306|9822367|FG003|Overall Study|Protocol deviation|1
6174256|NCT01281306|9822368|FG004|Overall Study|Protocol deviation|1
6174257|NCT01281306|9822369|FG005|Overall Study|Protocol deviation|0
6174258|NCT01281306|9822370|FG006|Overall Study|Protocol deviation|0
6174259|NCT01281306|9822364|FG000|Overall Study|Condition no longer requires study drug|1
6174260|NCT01281306|9822365|FG001|Overall Study|Condition no longer requires study drug|0
6174261|NCT01281306|9822366|FG002|Overall Study|Condition no longer requires study drug|0
6174262|NCT01281306|9822367|FG003|Overall Study|Condition no longer requires study drug|0
6174263|NCT01281306|9822368|FG004|Overall Study|Condition no longer requires study drug|0
6174264|NCT01281306|9822369|FG005|Overall Study|Condition no longer requires study drug|1
6174265|NCT01281306|9822370|FG006|Overall Study|Condition no longer requires study drug|1
6174266|NCT01281306|9822364|FG000|Overall Study|Lost to Follow-up|1
6174267|NCT01281306|9822365|FG001|Overall Study|Lost to Follow-up|0
6174268|NCT01281306|9822366|FG002|Overall Study|Lost to Follow-up|0
6174269|NCT01281306|9822367|FG003|Overall Study|Lost to Follow-up|2
6174270|NCT01281306|9822368|FG004|Overall Study|Lost to Follow-up|0
6174271|NCT01281306|9822369|FG005|Overall Study|Lost to Follow-up|0
6174272|NCT01281306|9822370|FG006|Overall Study|Lost to Follow-up|1
6174273|NCT01281306|9822364|FG000|Overall Study|Death|1
6174274|NCT01281306|9822365|FG001|Overall Study|Death|0
6174275|NCT01281306|9822366|FG002|Overall Study|Death|0
6174276|NCT01281306|9822367|FG003|Overall Study|Death|0
6174277|NCT01281306|9822368|FG004|Overall Study|Death|0
6174278|NCT01281306|9822369|FG005|Overall Study|Death|0
6174279|NCT01281306|9822370|FG006|Overall Study|Death|0
6174280|NCT01281306|9822364|FG000|Overall Study|Adverse Event|3
6174281|NCT01281306|9822365|FG001|Overall Study|Adverse Event|2
6174282|NCT01281306|9822366|FG002|Overall Study|Adverse Event|2
6174283|NCT01281306|9822367|FG003|Overall Study|Adverse Event|3
6174284|NCT01281306|9822368|FG004|Overall Study|Adverse Event|5
6174285|NCT01281306|9822369|FG005|Overall Study|Adverse Event|3
6174286|NCT01281306|9822370|FG006|Overall Study|Adverse Event|3
6174287|NCT01281306|9822364|FG000|Overall Study|Randomized in error|1
6174288|NCT01281306|9822365|FG001|Overall Study|Randomized in error|0
6174289|NCT01281306|9822366|FG002|Overall Study|Randomized in error|0
6174290|NCT01281306|9822367|FG003|Overall Study|Randomized in error|1
6174291|NCT01281306|9822368|FG004|Overall Study|Randomized in error|0
6174292|NCT01281306|9822369|FG005|Overall Study|Randomized in error|0
6174293|NCT01281306|9822370|FG006|Overall Study|Randomized in error|0
6174294|NCT01281839|9822408|FG000|Overall Study|Lost to Follow-up|6
6174295|NCT01281839|9822409|FG001|Overall Study|Lost to Follow-up|3
6174296|NCT01281839|9822408|FG000|Overall Study|Withdrawal by Subject|4
6174297|NCT01281839|9822409|FG001|Overall Study|Withdrawal by Subject|10
6174298|NCT01281839|9822408|FG000|Overall Study|Reason not specified|0
6174299|NCT01281839|9822409|FG001|Overall Study|Reason not specified|1
6174300|NCT01281865|9822417|FG000|Overall Study|Adverse Event|1
6174301|NCT01281865|9822418|FG001|Overall Study|Adverse Event|1
6174302|NCT01281865|9822417|FG000|Overall Study|Withdrawal by Subject|1
6174303|NCT01281865|9822418|FG001|Overall Study|Withdrawal by Subject|0
6174304|NCT01281865|9822417|FG000|Overall Study|Lack of Efficacy|1
6174305|NCT01281865|9822418|FG001|Overall Study|Lack of Efficacy|0
6174306|NCT01281917|9822424|FG000|Overall Study|Withdrawal by Subject|1
6174307|NCT01281956|9822428|FG000|2nd Intervention (3 Months)|Withdrawal by Subject|1
6174308|NCT01281956|9822429|FG001|2nd Intervention (3 Months)|Withdrawal by Subject|0
6174309|NCT01281969|9822440|FG000|Overall Study|not randomized didn't meet criteria|0
6174310|NCT01281969|9822441|FG001|Overall Study|not randomized didn't meet criteria|0
6174311|NCT01281969|9822442|FG002|Overall Study|not randomized didn't meet criteria|7
6174312|NCT01281969|9822440|FG000|Overall Study|AE during LP prior to IVIG admin|1
6174313|NCT01281969|9822441|FG001|Overall Study|AE during LP prior to IVIG admin|0
6174314|NCT01281969|9822442|FG002|Overall Study|AE during LP prior to IVIG admin|3
6174315|NCT01281969|9822440|FG000|Overall Study|not randomized, child consent not given|0
6174316|NCT01281969|9822441|FG001|Overall Study|not randomized, child consent not given|0
6174317|NCT01281969|9822442|FG002|Overall Study|not randomized, child consent not given|2
6174318|NCT01282164|9822466|FG000|Overall Study|Lack of hypoglycemia during ITT|1
6174319|NCT01282164|9822467|FG001|Overall Study|Lack of hypoglycemia during ITT|0
6174320|NCT01282203|9822481|FG000|Overall Study|Adverse Event|1
6174321|NCT01282229|9822488|FG000|Overall Study|Protocol Violation|2
6174322|NCT01282294|9822515|FG000|Overall Study|Lost to Follow-up|14
6174323|NCT01282294|9822515|FG000|Overall Study|Screening failure|1
6174324|NCT01282294|9822515|FG000|Overall Study|Adverse Event|1
6174325|NCT01282294|9822515|FG000|Overall Study|Patient non-compliance|2
6174326|NCT01282294|9822515|FG000|Overall Study|Physician Decision|1
6174327|NCT01282372|9822519|FG000|Overall Study|Lack of Efficacy / Exacerbation|25
6174328|NCT01282372|9822519|FG000|Overall Study|Lost to Follow-up|23
6174329|NCT01282372|9822519|FG000|Overall Study|Withdrawal by Subject|11
6174330|NCT01282372|9822519|FG000|Overall Study|Refer Pre-Assignment Detail for Reason 1|4
6174331|NCT01282372|9822519|FG000|Overall Study|Death|1
6174332|NCT01282372|9822519|FG000|Overall Study|Presence of AE, Lack of Efficacy|1
6174333|NCT01282372|9822519|FG000|Overall Study|Presence of AE, Regression of Symptoms|1
6174334|NCT01282372|9822519|FG000|Overall Study|Refer Pre-Assignment Detail for Reason 2|1
6174335|NCT01282372|9822519|FG000|Overall Study|Adverse Event|12
6174336|NCT01282424|9822530|FG000|Treatment Period (TP) (81 Months)|Adverse Event|30
6174337|NCT01282424|9822530|FG000|Treatment Period (TP) (81 Months)|Withdrew Consent|6
6174338|NCT01282424|9822530|FG000|Treatment Period (TP) (81 Months)|Investigator Request|7
6174339|NCT01282424|9822530|FG000|Treatment Period (TP) (81 Months)|Other (Unknown)|3
6174340|NCT01282424|9822530|FG000|Long-term Follow-up Period (5 Years)|Withdrew Consent|2
6174341|NCT01282424|9822530|FG000|Long-term Follow-up Period (5 Years)|Death|40
6174342|NCT01282424|9822530|FG000|Long-term Follow-up Period (5 Years)|Lost to Follow-up|1
6174343|NCT01282424|9822530|FG000|Long-term Follow-up Period (5 Years)|Other (Unknown)|21
6174344|NCT01282463|9822537|FG000|Overall Study|Lost to Follow-up|1
6174345|NCT01282463|9822538|FG001|Overall Study|Lost to Follow-up|0
6174346|NCT01282463|9822539|FG002|Overall Study|Lost to Follow-up|0
6174347|NCT01282463|9822537|FG000|Overall Study|Withdrawal by Subject|6
6174348|NCT01282463|9822538|FG001|Overall Study|Withdrawal by Subject|2
6174349|NCT01282463|9822539|FG002|Overall Study|Withdrawal by Subject|3
6174350|NCT01282463|9822537|FG000|Overall Study|"Never Treated Death"|0
6174351|NCT01282463|9822538|FG001|Overall Study|"Never Treated Death"|1
6174352|NCT01282463|9822539|FG002|Overall Study|"Never Treated Death"|0
6174353|NCT01282463|9822537|FG000|Overall Study|"Never Treated PD"|0
6174354|NCT01282463|9822538|FG001|Overall Study|"Never Treated PD"|1
6174355|NCT01282463|9822539|FG002|Overall Study|"Never Treated PD"|0
6174356|NCT01282463|9822537|FG000|Overall Study|Protocol Violation|0
6174357|NCT01282463|9822538|FG001|Overall Study|Protocol Violation|0
6174358|NCT01282463|9822539|FG002|Overall Study|Protocol Violation|1
6174359|NCT01282463|9822537|FG000|Overall Study|Physician Decision|1
6174360|NCT01282463|9822538|FG001|Overall Study|Physician Decision|0
6174361|NCT01282463|9822539|FG002|Overall Study|Physician Decision|0
6174362|NCT01282476|9822555|FG000|Overall Study|Death|11
6174363|NCT01282801|9822569|FG000|Second Intervention|Emesis During Critical Breakfast|0
6174364|NCT01282801|9822570|FG001|Second Intervention|Emesis During Critical Breakfast|1
6174365|NCT01282814|9822578|FG000|First Intervention|Emesis During Dosing Interval|0
6174366|NCT01282814|9822579|FG001|First Intervention|Emesis During Dosing Interval|3
6174367|NCT01282814|9822578|FG000|Washout of 7 Days|Withdrawal by Subject|2
6174368|NCT01282814|9822579|FG001|Washout of 7 Days|Withdrawal by Subject|0
6174369|NCT01282866|9822585|FG000|Overall Study|Adverse Event|1
6174370|NCT01283009|9822591|FG000|Overall Study|Death|83
6174371|NCT01283009|9822592|FG001|Overall Study|Death|78
6174372|NCT01283009|9822591|FG000|Overall Study|Study ended early|23
6174373|NCT01283009|9822592|FG001|Overall Study|Study ended early|26
6174374|NCT01283009|9822591|FG000|Overall Study|Withdrawal by Subject|10
6174375|NCT01283009|9822592|FG001|Overall Study|Withdrawal by Subject|8
6174376|NCT01283009|9822591|FG000|Overall Study|Physician Decision|1
6174377|NCT01283009|9822592|FG001|Overall Study|Physician Decision|1
6174378|NCT01283009|9822591|FG000|Overall Study|Lost to Follow-up|1
6174379|NCT01283009|9822592|FG001|Overall Study|Lost to Follow-up|0
6174380|NCT01283009|9822591|FG000|Overall Study|Patient Withdrawn by LAR/DPOA|0
6174381|NCT01283009|9822592|FG001|Overall Study|Patient Withdrawn by LAR/DPOA|4
6174382|NCT01283035|9822603|FG000|Overall Study|Subject later found ineligible|1
6174383|NCT01283139|9822611|FG000|Overall Study|Lost to Follow-up|5
6174384|NCT01283139|9822612|FG001|Overall Study|Lost to Follow-up|2
6174385|NCT01283139|9822613|FG002|Overall Study|Lost to Follow-up|3
6174386|NCT01283139|9822614|FG003|Overall Study|Lost to Follow-up|1
6174387|NCT01283139|9822611|FG000|Overall Study|Withdrawal by Subject|8
6174388|NCT01283139|9822612|FG001|Overall Study|Withdrawal by Subject|8
6174389|NCT01283139|9822613|FG002|Overall Study|Withdrawal by Subject|6
6174390|NCT01283139|9822614|FG003|Overall Study|Withdrawal by Subject|8
6174391|NCT01283139|9822611|FG000|Overall Study|Death|2
6174392|NCT01283139|9822612|FG001|Overall Study|Death|0
6174393|NCT01283139|9822613|FG002|Overall Study|Death|2
6174394|NCT01283139|9822614|FG003|Overall Study|Death|2
6174395|NCT01283139|9822611|FG000|Overall Study|Lack of Efficacy|1
6174396|NCT01283139|9822612|FG001|Overall Study|Lack of Efficacy|2
6174397|NCT01283139|9822613|FG002|Overall Study|Lack of Efficacy|2
6174398|NCT01283139|9822614|FG003|Overall Study|Lack of Efficacy|1
6174399|NCT01283139|9822611|FG000|Overall Study|Early termination due to AE/SAE|1
6174400|NCT01283139|9822612|FG001|Overall Study|Early termination due to AE/SAE|1
6174401|NCT01283139|9822613|FG002|Overall Study|Early termination due to AE/SAE|0
6174402|NCT01283139|9822614|FG003|Overall Study|Early termination due to AE/SAE|0
6174403|NCT01283139|9822611|FG000|Overall Study|Participant's refusal to continue|0
6174404|NCT01283139|9822612|FG001|Overall Study|Participant's refusal to continue|3
6174405|NCT01283139|9822613|FG002|Overall Study|Participant's refusal to continue|1
6174406|NCT01283139|9822614|FG003|Overall Study|Participant's refusal to continue|1
6174407|NCT01283139|9822611|FG000|Overall Study|Pregnancy|0
6174408|NCT01283139|9822612|FG001|Overall Study|Pregnancy|1
6174409|NCT01283139|9822613|FG002|Overall Study|Pregnancy|1
6174410|NCT01283139|9822614|FG003|Overall Study|Pregnancy|0
6174411|NCT01283139|9822611|FG000|Overall Study|Missed follow-up visit|0
6174412|NCT01283139|9822612|FG001|Overall Study|Missed follow-up visit|1
6174413|NCT01283139|9822613|FG002|Overall Study|Missed follow-up visit|2
6174414|NCT01283139|9822614|FG003|Overall Study|Missed follow-up visit|2
6174415|NCT01283139|9822611|FG000|Overall Study|Participant randomized in error|0
6174416|NCT01283139|9822612|FG001|Overall Study|Participant randomized in error|0
6174417|NCT01283139|9822613|FG002|Overall Study|Participant randomized in error|1
6174418|NCT01283139|9822614|FG003|Overall Study|Participant randomized in error|0
6174419|NCT01283152|9822626|FG000|Overall Study|Discharged prior to 24 hr assessment|1
6174420|NCT01283152|9822627|FG001|Overall Study|Discharged prior to 24 hr assessment|0
6174421|NCT01283152|9822626|FG000|Overall Study|Refused HESA|1
6174422|NCT01283152|9822627|FG001|Overall Study|Refused HESA|0
6174423|NCT01283282|9822633|FG000|First Intervention (6 Weeks)|Physician Decision|0
6174424|NCT01283282|9822634|FG001|First Intervention (6 Weeks)|Physician Decision|1
6174425|NCT01283282|9822633|FG000|First Intervention (6 Weeks)|Withdrawal by Subject|2
6174426|NCT01283282|9822634|FG001|First Intervention (6 Weeks)|Withdrawal by Subject|3
6174427|NCT01283282|9822633|FG000|First Intervention (6 Weeks)|Lost to Follow-up|1
6174428|NCT01283282|9822634|FG001|First Intervention (6 Weeks)|Lost to Follow-up|0
6174429|NCT01283334|9822652|FG000|Overall Study|Withdrawal by Subject|1
6174430|NCT01283334|9822652|FG000|Overall Study|Inability to Swallow Everolimus Pills|1
6174431|NCT01283334|9822652|FG000|Overall Study|Adverse Event|4
6174432|NCT01283334|9822652|FG000|Overall Study|Physician Decision|1
6174433|NCT01283386|9822660|FG000|Overall Study|Death|2
6174434|NCT01283386|9822661|FG001|Overall Study|Death|0
6174435|NCT01283386|9822660|FG000|Overall Study|Withdrawal by Subject|2
6174436|NCT01283386|9822661|FG001|Overall Study|Withdrawal by Subject|1
6174437|NCT01283386|9822660|FG000|Overall Study|Relapse of underlying disease|1
6174438|NCT01283386|9822661|FG001|Overall Study|Relapse of underlying disease|3
6174439|NCT01283386|9822660|FG000|Overall Study|Progression of underlying disease|2
6174440|NCT01283386|9822661|FG001|Overall Study|Progression of underlying disease|7
6174441|NCT01283386|9822660|FG000|Overall Study|Reason not specified|1
6174442|NCT01283386|9822661|FG001|Overall Study|Reason not specified|0
6174443|NCT01283386|9822660|FG000|Overall Study|Protocol Violation|0
6174444|NCT01283386|9822661|FG001|Overall Study|Protocol Violation|1
6174445|NCT01283464|9822669|FG000|Overall Study|Lost to Follow-up|0
6174446|NCT01283464|9822670|FG001|Overall Study|Lost to Follow-up|1
6174447|NCT01283464|9822669|FG000|Overall Study|Withdrawal by Subject|1
6174448|NCT01283464|9822670|FG001|Overall Study|Withdrawal by Subject|0
6174449|NCT01283464|9822669|FG000|Overall Study|Physician Decision|1
6174450|NCT01283464|9822670|FG001|Overall Study|Physician Decision|0
6174451|NCT01283516|9822685|FG000|Overall Study|Adverse Event|0
6174452|NCT01283516|9822686|FG001|Overall Study|Adverse Event|0
6174453|NCT01283516|9822687|FG002|Overall Study|Adverse Event|0
6174454|NCT01283516|9822688|FG003|Overall Study|Adverse Event|0
6174455|NCT01283516|9822689|FG004|Overall Study|Adverse Event|0
6174456|NCT01283516|9822690|FG005|Overall Study|Adverse Event|0
6174457|NCT01283516|9822691|FG006|Overall Study|Adverse Event|2
6174458|NCT01283516|9822692|FG007|Overall Study|Adverse Event|0
6174459|NCT01283516|9822693|FG008|Overall Study|Adverse Event|28
6174460|NCT01283516|9822685|FG000|Overall Study|Death|0
6174461|NCT01283516|9822686|FG001|Overall Study|Death|0
6174462|NCT01283516|9822687|FG002|Overall Study|Death|0
6174463|NCT01283516|9822688|FG003|Overall Study|Death|0
6174464|NCT01283516|9822689|FG004|Overall Study|Death|0
6174465|NCT01283516|9822690|FG005|Overall Study|Death|1
6174466|NCT01283516|9822691|FG006|Overall Study|Death|0
6174467|NCT01283516|9822692|FG007|Overall Study|Death|1
6174468|NCT01283516|9822693|FG008|Overall Study|Death|12
6174469|NCT01283516|9822685|FG000|Overall Study|Disease Progression|2
6174470|NCT01283516|9822686|FG001|Overall Study|Disease Progression|2
6174471|NCT01283516|9822687|FG002|Overall Study|Disease Progression|3
6174472|NCT01283516|9822688|FG003|Overall Study|Disease Progression|3
6174473|NCT01283516|9822689|FG004|Overall Study|Disease Progression|13
6174474|NCT01283516|9822690|FG005|Overall Study|Disease Progression|8
6084999|NCT00647296|9694084|FG000|Part 2: 4-week Placebo Washout|Death|3
6085000|NCT00647296|9694085|FG001|Part 2: 4-week Placebo Washout|Death|0
6174475|NCT01283516|9822691|FG006|Overall Study|Disease Progression|6
6174476|NCT01283516|9822692|FG007|Overall Study|Disease Progression|3
6174477|NCT01283516|9822693|FG008|Overall Study|Disease Progression|139
6174478|NCT01283516|9822685|FG000|Overall Study|Withdrawal by Subject|0
6174479|NCT01283516|9822686|FG001|Overall Study|Withdrawal by Subject|0
6174480|NCT01283516|9822687|FG002|Overall Study|Withdrawal by Subject|0
6174481|NCT01283516|9822688|FG003|Overall Study|Withdrawal by Subject|0
6174482|NCT01283516|9822689|FG004|Overall Study|Withdrawal by Subject|1
6174483|NCT01283516|9822690|FG005|Overall Study|Withdrawal by Subject|0
6174484|NCT01283516|9822691|FG006|Overall Study|Withdrawal by Subject|1
6174485|NCT01283516|9822692|FG007|Overall Study|Withdrawal by Subject|0
6174486|NCT01283516|9822693|FG008|Overall Study|Withdrawal by Subject|36
6174487|NCT01283516|9822685|FG000|Overall Study|Administrative problems|0
6174488|NCT01283516|9822686|FG001|Overall Study|Administrative problems|0
6174489|NCT01283516|9822687|FG002|Overall Study|Administrative problems|0
6174490|NCT01283516|9822688|FG003|Overall Study|Administrative problems|0
6174491|NCT01283516|9822689|FG004|Overall Study|Administrative problems|0
6174492|NCT01283516|9822690|FG005|Overall Study|Administrative problems|1
6174493|NCT01283516|9822691|FG006|Overall Study|Administrative problems|1
6174494|NCT01283516|9822692|FG007|Overall Study|Administrative problems|1
6174495|NCT01283516|9822693|FG008|Overall Study|Administrative problems|39
6174496|NCT01283516|9822685|FG000|Overall Study|Lost to Follow-up|0
6174497|NCT01283516|9822686|FG001|Overall Study|Lost to Follow-up|0
6174498|NCT01283516|9822687|FG002|Overall Study|Lost to Follow-up|0
6174499|NCT01283516|9822688|FG003|Overall Study|Lost to Follow-up|0
6174500|NCT01283516|9822689|FG004|Overall Study|Lost to Follow-up|0
6174501|NCT01283516|9822690|FG005|Overall Study|Lost to Follow-up|0
6174502|NCT01283516|9822691|FG006|Overall Study|Lost to Follow-up|0
6174503|NCT01283516|9822692|FG007|Overall Study|Lost to Follow-up|0
6174504|NCT01283516|9822693|FG008|Overall Study|Lost to Follow-up|1
6174505|NCT01283542|9822721|FG000|Main Phase|Acute or progressive vision loss|1
6174506|NCT01283542|9822721|FG000|Main Phase|Uncontrolled diabetes mellitus|1
6174507|NCT01283542|9822721|FG000|Main Phase|abnormal laboratory values|5
6174508|NCT01283542|9822721|FG000|Extension Phase|Physician Decision|1
6174509|NCT01283542|9822721|FG000|Extension Phase|Adverse Event|1
6174510|NCT01283542|9822721|FG000|Extension Phase|Administrative problems|1
6192440|NCT01431287|9849837|FG002|Overall Study|Lost to Follow-up|2
6192441|NCT01431287|9849838|FG003|Overall Study|Lost to Follow-up|3
6192442|NCT01431287|9849839|FG004|Overall Study|Lost to Follow-up|1
6192443|NCT01431287|9849835|FG000|Overall Study|Consent withdrawn not due to AE|29
6192444|NCT01431287|9849836|FG001|Overall Study|Consent withdrawn not due to AE|30
6192445|NCT01431287|9849837|FG002|Overall Study|Consent withdrawn not due to AE|34
6192446|NCT01431287|9849838|FG003|Overall Study|Consent withdrawn not due to AE|19
6192447|NCT01431287|9849839|FG004|Overall Study|Consent withdrawn not due to AE|29
6192448|NCT01431287|9849835|FG000|Overall Study|not stated above|4
6192449|NCT01431287|9849836|FG001|Overall Study|not stated above|2
6192450|NCT01431287|9849837|FG002|Overall Study|not stated above|2
6192451|NCT01431287|9849838|FG003|Overall Study|not stated above|2
6192452|NCT01431287|9849839|FG004|Overall Study|not stated above|1
6193365|NCT01437540|9851007|FG001|Overall Study|Withdrawal by Subject|15
6193366|NCT01437878|9851029|FG000|Overall Study|Withdrawal by Subject|1
6193367|NCT01437878|9851030|FG001|Overall Study|Withdrawal by Subject|0
6193368|NCT01437943|9851038|FG000|Overall Study|Aliskiren trials terminated by Novartis|4
6193369|NCT01437943|9851039|FG001|Overall Study|Aliskiren trials terminated by Novartis|2
6193370|NCT01437943|9851038|FG000|Overall Study|Subject expressed pregnancy plans|1
6193371|NCT01437943|9851039|FG001|Overall Study|Subject expressed pregnancy plans|0
6085001|NCT00647296|9694086|FG002|Part 2: 4-week Placebo Washout|Death|0
6193372|NCT01437943|9851038|FG000|Overall Study|Adverse Event|2
6193373|NCT01437943|9851039|FG001|Overall Study|Adverse Event|0
6193374|NCT01437995|9851048|FG000|Overall Study|Lost to Follow-up|11
6193375|NCT01437995|9851049|FG001|Overall Study|Lost to Follow-up|18
6174511|NCT01283581|9822757|FG000|Overall Study|Lost to Follow-up|8
6174512|NCT01283581|9822758|FG001|Overall Study|Lost to Follow-up|6
6174513|NCT01283581|9822759|FG002|Overall Study|Lost to Follow-up|8
6174514|NCT01283581|9822757|FG000|Overall Study|Withdrawal by Subject|2
6174515|NCT01283581|9822758|FG001|Overall Study|Withdrawal by Subject|5
6174516|NCT01283581|9822759|FG002|Overall Study|Withdrawal by Subject|2
6174517|NCT01283581|9822757|FG000|Overall Study|Adverse Event|1
6174518|NCT01283581|9822758|FG001|Overall Study|Adverse Event|1
6174519|NCT01283581|9822759|FG002|Overall Study|Adverse Event|4
6174520|NCT01283581|9822757|FG000|Overall Study|Physician Decision|0
6174521|NCT01283581|9822758|FG001|Overall Study|Physician Decision|1
6174522|NCT01283581|9822759|FG002|Overall Study|Physician Decision|2
6174523|NCT01283581|9822757|FG000|Overall Study|Protocol Violation|0
6174524|NCT01283581|9822758|FG001|Overall Study|Protocol Violation|1
6174525|NCT01283581|9822759|FG002|Overall Study|Protocol Violation|2
6174526|NCT01283581|9822757|FG000|Overall Study|Noncompliance|1
6174527|NCT01283581|9822758|FG001|Overall Study|Noncompliance|0
6174528|NCT01283581|9822759|FG002|Overall Study|Noncompliance|0
6174529|NCT01283581|9822757|FG000|Overall Study|Investigator unblinded|0
6174530|NCT01283581|9822758|FG001|Overall Study|Investigator unblinded|0
6174531|NCT01283581|9822759|FG002|Overall Study|Investigator unblinded|1
6174532|NCT01283581|9822757|FG000|Overall Study|"Early termination"|0
6174533|NCT01283581|9822758|FG001|Overall Study|"Early termination"|0
6174534|NCT01283581|9822759|FG002|Overall Study|"Early termination"|1
6174535|NCT01283971|9822772|FG000|Overall Study|Adverse Event|3
6174536|NCT01283971|9822773|FG001|Overall Study|Adverse Event|5
6174537|NCT01283971|9822772|FG000|Overall Study|Insufficient therapeutic responses|3
6174538|NCT01283971|9822773|FG001|Overall Study|Insufficient therapeutic responses|3
6174539|NCT01283971|9822772|FG000|Overall Study|Protocol Violation|5
6174540|NCT01283971|9822773|FG001|Overall Study|Protocol Violation|1
6174541|NCT01283971|9822772|FG000|Overall Study|Refused treatment|3
6174542|NCT01283971|9822773|FG001|Overall Study|Refused treatment|1
6174543|NCT01283971|9822772|FG000|Overall Study|Failure to return|0
6174544|NCT01283971|9822773|FG001|Overall Study|Failure to return|1
6174545|NCT01283971|9822772|FG000|Overall Study|Administrative reasons|1
6174546|NCT01283971|9822773|FG001|Overall Study|Administrative reasons|1
6174547|NCT01284062|9822783|FG000|Overall Study|Adverse Event|4
6174548|NCT01284062|9822784|FG001|Overall Study|Adverse Event|5
6174549|NCT01284062|9822785|FG002|Overall Study|Adverse Event|0
6174550|NCT01284062|9822786|FG003|Overall Study|Adverse Event|5
6174551|NCT01284062|9822783|FG000|Overall Study|Lack of Efficacy|3
6174552|NCT01284062|9822784|FG001|Overall Study|Lack of Efficacy|2
6174553|NCT01284062|9822785|FG002|Overall Study|Lack of Efficacy|2
6174554|NCT01284062|9822786|FG003|Overall Study|Lack of Efficacy|1
6174555|NCT01284062|9822783|FG000|Overall Study|Medication error without adverse event|0
6174556|NCT01284062|9822784|FG001|Overall Study|Medication error without adverse event|0
6174557|NCT01284062|9822785|FG002|Overall Study|Medication error without adverse event|1
6174558|NCT01284062|9822786|FG003|Overall Study|Medication error without adverse event|0
6174559|NCT01284062|9822783|FG000|Overall Study|Protocol Violation|1
6174560|NCT01284062|9822784|FG001|Overall Study|Protocol Violation|0
6174561|NCT01284062|9822785|FG002|Overall Study|Protocol Violation|0
6174562|NCT01284062|9822786|FG003|Overall Study|Protocol Violation|2
6174563|NCT01284062|9822783|FG000|Overall Study|Withdrawal by Subject|3
6174564|NCT01284062|9822784|FG001|Overall Study|Withdrawal by Subject|1
6174565|NCT01284062|9822785|FG002|Overall Study|Withdrawal by Subject|2
6174566|NCT01284062|9822786|FG003|Overall Study|Withdrawal by Subject|5
6174567|NCT01284062|9822783|FG000|Overall Study|Other|0
6174568|NCT01284062|9822784|FG001|Overall Study|Other|0
6174569|NCT01284062|9822785|FG002|Overall Study|Other|0
6174570|NCT01284062|9822786|FG003|Overall Study|Other|1
6174571|NCT01284062|9822783|FG000|Overall Study|Site Closed|0
6174572|NCT01284062|9822784|FG001|Overall Study|Site Closed|0
6174573|NCT01284062|9822785|FG002|Overall Study|Site Closed|1
6174574|NCT01284062|9822786|FG003|Overall Study|Site Closed|0
6174575|NCT01284114|9822799|FG000|Overall Study|viral infection|1
6174576|NCT01284114|9822799|FG000|Overall Study|From the results of ALLTITUDE study|1
6174577|NCT01284114|9822799|FG000|Overall Study|Symptomatic hypotension|1
6174578|NCT01284114|9822799|FG000|Overall Study|dizziness|1
6174579|NCT01284127|9822804|FG000|Overall Study|Adverse Event|2
6174580|NCT01284127|9822804|FG000|Overall Study|Withdrawal by Subject|4
6174581|NCT01284127|9822804|FG000|Overall Study|Physician Decision|1
6174582|NCT01284140|9822810|FG000|Subjects With Paired 24hr Collections|Day 3 urinary profile not available|5
6174583|NCT01284140|9822811|FG001|Subjects With Paired 24hr Collections|Day 3 urinary profile not available|5
6174584|NCT01284140|9822810|FG000|Subjects With Paired 24hr Collections|Day 1 urinary profile incomplete|0
6174585|NCT01284140|9822811|FG001|Subjects With Paired 24hr Collections|Day 1 urinary profile incomplete|1
6174586|NCT01284361|9822896|FG000|Overall Study|Withdrawal by Subject|1
6174587|NCT01284361|9822896|FG000|Overall Study|Protocol Violation|5
6174588|NCT01284361|9822896|FG000|Overall Study|Adverse Event|1
6174589|NCT01284361|9822896|FG000|Overall Study|Lost to Follow-up|2
6174590|NCT01284621|9822916|FG000|Washout Period 1 (7 Days)|Required unexpected medical treatment|0
6174591|NCT01284621|9822917|FG001|Washout Period 1 (7 Days)|Required unexpected medical treatment|0
6174592|NCT01284621|9822918|FG002|Washout Period 1 (7 Days)|Required unexpected medical treatment|0
6174593|NCT01284621|9822919|FG003|Washout Period 1 (7 Days)|Required unexpected medical treatment|0
6174594|NCT01284621|9822920|FG004|Washout Period 1 (7 Days)|Required unexpected medical treatment|1
6174595|NCT01284621|9822921|FG005|Washout Period 1 (7 Days)|Required unexpected medical treatment|0
6174596|NCT01284634|9822935|FG000|Overall Study|Adverse Event|1
6174597|NCT01284634|9822936|FG001|Overall Study|Adverse Event|0
6174598|NCT01284634|9822937|FG002|Overall Study|Adverse Event|2
6174599|NCT01284634|9822938|FG003|Overall Study|Adverse Event|1
6174600|NCT01284959|9822951|FG000|Overall Study|Withdrawal by Subject|1
6174601|NCT01284959|9822952|FG001|Overall Study|Withdrawal by Subject|0
6174602|NCT01284959|9822953|FG002|Overall Study|Withdrawal by Subject|0
6174603|NCT01284959|9822951|FG000|Overall Study|Adverse Event|0
6174604|NCT01284959|9822952|FG001|Overall Study|Adverse Event|0
6174605|NCT01284959|9822953|FG002|Overall Study|Adverse Event|1
6174606|NCT01285310|9822982|FG000|Placebo Controlled Phase: Weeks 0-24|Adverse Event|3
6174607|NCT01285310|9822983|FG001|Placebo Controlled Phase: Weeks 0-24|Adverse Event|4
6174608|NCT01285310|9822984|FG002|Placebo Controlled Phase: Weeks 0-24|Adverse Event|6
6085002|NCT00647296|9694087|FG003|Part 2: 4-week Placebo Washout|Death|0
6085003|NCT00647296|9694084|FG000|Part 2: 76-week Double-Blind Treatment|Withdrawal by Subject|0
6174609|NCT01285310|9822985|FG003|Placebo Controlled Phase: Weeks 0-24|Adverse Event|0
6174610|NCT01285310|9822986|FG004|Placebo Controlled Phase: Weeks 0-24|Adverse Event|0
6174611|NCT01285310|9822982|FG000|Placebo Controlled Phase: Weeks 0-24|Lack of Efficacy|1
6174612|NCT01285310|9822983|FG001|Placebo Controlled Phase: Weeks 0-24|Lack of Efficacy|7
6174613|NCT01285310|9822984|FG002|Placebo Controlled Phase: Weeks 0-24|Lack of Efficacy|3
6174614|NCT01285310|9822985|FG003|Placebo Controlled Phase: Weeks 0-24|Lack of Efficacy|0
6174615|NCT01285310|9822986|FG004|Placebo Controlled Phase: Weeks 0-24|Lack of Efficacy|0
6174616|NCT01285310|9822982|FG000|Placebo Controlled Phase: Weeks 0-24|Non-compliance|1
6174617|NCT01285310|9822983|FG001|Placebo Controlled Phase: Weeks 0-24|Non-compliance|0
6174618|NCT01285310|9822984|FG002|Placebo Controlled Phase: Weeks 0-24|Non-compliance|2
6174619|NCT01285310|9822985|FG003|Placebo Controlled Phase: Weeks 0-24|Non-compliance|0
6174620|NCT01285310|9822986|FG004|Placebo Controlled Phase: Weeks 0-24|Non-compliance|0
6174621|NCT01285310|9822982|FG000|Placebo Controlled Phase: Weeks 0-24|Withdrawal by Subject|3
6174622|NCT01285310|9822983|FG001|Placebo Controlled Phase: Weeks 0-24|Withdrawal by Subject|3
6174623|NCT01285310|9822984|FG002|Placebo Controlled Phase: Weeks 0-24|Withdrawal by Subject|2
6174624|NCT01285310|9822985|FG003|Placebo Controlled Phase: Weeks 0-24|Withdrawal by Subject|0
6174625|NCT01285310|9822986|FG004|Placebo Controlled Phase: Weeks 0-24|Withdrawal by Subject|0
6174626|NCT01285310|9822982|FG000|Placebo Controlled Phase: Weeks 0-24|Lost to Follow-up|0
6174627|NCT01285310|9822983|FG001|Placebo Controlled Phase: Weeks 0-24|Lost to Follow-up|1
6174628|NCT01285310|9822984|FG002|Placebo Controlled Phase: Weeks 0-24|Lost to Follow-up|1
6174629|NCT01285310|9822985|FG003|Placebo Controlled Phase: Weeks 0-24|Lost to Follow-up|0
6174630|NCT01285310|9822986|FG004|Placebo Controlled Phase: Weeks 0-24|Lost to Follow-up|0
6174631|NCT01285310|9822982|FG000|Placebo Controlled Phase: Weeks 0-24|Other|1
6174632|NCT01285310|9822983|FG001|Placebo Controlled Phase: Weeks 0-24|Other|0
6174633|NCT01285310|9822984|FG002|Placebo Controlled Phase: Weeks 0-24|Other|1
6174634|NCT01285310|9822985|FG003|Placebo Controlled Phase: Weeks 0-24|Other|0
6174635|NCT01285310|9822986|FG004|Placebo Controlled Phase: Weeks 0-24|Other|0
6174636|NCT01285310|9822982|FG000|Active Treatment Phase: Weeks 25-52|Adverse Event|0
6174637|NCT01285310|9822983|FG001|Active Treatment Phase: Weeks 25-52|Adverse Event|2
6174638|NCT01285310|9822984|FG002|Active Treatment Phase: Weeks 25-52|Adverse Event|3
6174639|NCT01285310|9822985|FG003|Active Treatment Phase: Weeks 25-52|Adverse Event|0
6174640|NCT01285310|9822986|FG004|Active Treatment Phase: Weeks 25-52|Adverse Event|2
6174641|NCT01285310|9822982|FG000|Active Treatment Phase: Weeks 25-52|Lack of Efficacy|0
6174642|NCT01285310|9822983|FG001|Active Treatment Phase: Weeks 25-52|Lack of Efficacy|4
6174643|NCT01285310|9822984|FG002|Active Treatment Phase: Weeks 25-52|Lack of Efficacy|3
6174644|NCT01285310|9822985|FG003|Active Treatment Phase: Weeks 25-52|Lack of Efficacy|1
6174645|NCT01285310|9822986|FG004|Active Treatment Phase: Weeks 25-52|Lack of Efficacy|0
6174646|NCT01285310|9822982|FG000|Active Treatment Phase: Weeks 25-52|Withdrawal by Subject|0
6174647|NCT01285310|9822983|FG001|Active Treatment Phase: Weeks 25-52|Withdrawal by Subject|3
6174648|NCT01285310|9822984|FG002|Active Treatment Phase: Weeks 25-52|Withdrawal by Subject|0
6174649|NCT01285310|9822985|FG003|Active Treatment Phase: Weeks 25-52|Withdrawal by Subject|2
6174650|NCT01285310|9822986|FG004|Active Treatment Phase: Weeks 25-52|Withdrawal by Subject|2
6174651|NCT01285310|9822982|FG000|Active Treatment Phase: Weeks 25-52|Study Termination by sponsor|0
6174652|NCT01285310|9822983|FG001|Active Treatment Phase: Weeks 25-52|Study Termination by sponsor|21
6085004|NCT00647296|9694085|FG001|Part 2: 76-week Double-Blind Treatment|Withdrawal by Subject|5
6085005|NCT00647296|9694086|FG002|Part 2: 76-week Double-Blind Treatment|Withdrawal by Subject|0
6085006|NCT00647296|9694087|FG003|Part 2: 76-week Double-Blind Treatment|Withdrawal by Subject|4
6085007|NCT00647296|9694084|FG000|Part 2: 76-week Double-Blind Treatment|Adverse Event|0
6085008|NCT00647296|9694085|FG001|Part 2: 76-week Double-Blind Treatment|Adverse Event|1
6085009|NCT00647296|9694086|FG002|Part 2: 76-week Double-Blind Treatment|Adverse Event|0
6085010|NCT00647296|9694087|FG003|Part 2: 76-week Double-Blind Treatment|Adverse Event|4
6085011|NCT00647296|9694084|FG000|Part 2: 76-week Double-Blind Treatment|Lost to Follow-up|0
6085012|NCT00647296|9694085|FG001|Part 2: 76-week Double-Blind Treatment|Lost to Follow-up|1
6085013|NCT00647296|9694086|FG002|Part 2: 76-week Double-Blind Treatment|Lost to Follow-up|0
6174653|NCT01285310|9822984|FG002|Active Treatment Phase: Weeks 25-52|Study Termination by sponsor|19
6174654|NCT01285310|9822985|FG003|Active Treatment Phase: Weeks 25-52|Study Termination by sponsor|6
6174655|NCT01285310|9822986|FG004|Active Treatment Phase: Weeks 25-52|Study Termination by sponsor|15
6174656|NCT01285310|9822982|FG000|Active Treatment Phase: Weeks 25-52|Other|0
6174657|NCT01285310|9822983|FG001|Active Treatment Phase: Weeks 25-52|Other|1
6174658|NCT01285310|9822984|FG002|Active Treatment Phase: Weeks 25-52|Other|0
6174659|NCT01285310|9822985|FG003|Active Treatment Phase: Weeks 25-52|Other|0
6174660|NCT01285310|9822986|FG004|Active Treatment Phase: Weeks 25-52|Other|0
6174661|NCT01285310|9822982|FG000|Active Treatment Phase: Weeks 25-52|Non-compliance|0
6174662|NCT01285310|9822983|FG001|Active Treatment Phase: Weeks 25-52|Non-compliance|1
6174663|NCT01285310|9822984|FG002|Active Treatment Phase: Weeks 25-52|Non-compliance|1
6174664|NCT01285310|9822985|FG003|Active Treatment Phase: Weeks 25-52|Non-compliance|1
6174665|NCT01285310|9822986|FG004|Active Treatment Phase: Weeks 25-52|Non-compliance|0
6174666|NCT01285323|9823026|FG000|Overall Study|Adverse Event|9
6174667|NCT01285323|9823027|FG001|Overall Study|Adverse Event|8
6174668|NCT01285323|9823026|FG000|Overall Study|Lack of Efficacy|4
6174669|NCT01285323|9823027|FG001|Overall Study|Lack of Efficacy|2
6174670|NCT01285323|9823026|FG000|Overall Study|Withdrawal by Subject|15
6174671|NCT01285323|9823027|FG001|Overall Study|Withdrawal by Subject|11
6174672|NCT01285323|9823026|FG000|Overall Study|Protocol Violation|1
6174673|NCT01285323|9823027|FG001|Overall Study|Protocol Violation|2
6174674|NCT01285323|9823026|FG000|Overall Study|Non-compliance with study procedures|2
6174675|NCT01285323|9823027|FG001|Overall Study|Non-compliance with study procedures|3
6174676|NCT01285323|9823026|FG000|Overall Study|Lost to Follow-up|1
6174677|NCT01285323|9823027|FG001|Overall Study|Lost to Follow-up|1
6174678|NCT01285323|9823026|FG000|Overall Study|Other|1
6174679|NCT01285323|9823027|FG001|Overall Study|Other|3
6174680|NCT01285349|9823036|FG000|Overall Study|Lost to Follow-up|27
6174681|NCT01285349|9823037|FG001|Overall Study|Lost to Follow-up|20
6174682|NCT01285349|9823038|FG002|Overall Study|Lost to Follow-up|27
6174683|NCT01285401|9823049|FG000|Overall Study|Prematurely withdrawn from the study|17
6174684|NCT01285401|9823050|FG001|Overall Study|Prematurely withdrawn from the study|29
6174685|NCT01285492|9823070|FG000|Overall Study|Adverse Event|11
6174686|NCT01285492|9823071|FG001|Overall Study|Adverse Event|0
6174687|NCT01285492|9823070|FG000|Overall Study|Protocol Violation|3
6174688|NCT01285492|9823071|FG001|Overall Study|Protocol Violation|0
6174689|NCT01285492|9823070|FG000|Overall Study|Withdrawal by Subject|2
6174690|NCT01285492|9823071|FG001|Overall Study|Withdrawal by Subject|1
6174691|NCT01285492|9823070|FG000|Overall Study|Death|1
6174692|NCT01285492|9823071|FG001|Overall Study|Death|0
6174693|NCT01285518|9823085|FG000|Overall Study|Lost to Follow-up|0
6174694|NCT01285518|9823086|FG001|Overall Study|Lost to Follow-up|0
6174695|NCT01285518|9823087|FG002|Overall Study|Lost to Follow-up|0
6174696|NCT01285518|9823088|FG003|Overall Study|Lost to Follow-up|0
6174697|NCT01285518|9823089|FG004|Overall Study|Lost to Follow-up|0
6174698|NCT01285518|9823090|FG005|Overall Study|Lost to Follow-up|1
6174699|NCT01285518|9823091|FG006|Overall Study|Lost to Follow-up|0
6174700|NCT01285518|9823092|FG007|Overall Study|Lost to Follow-up|0
6174701|NCT01285609|9823113|FG000|Randomized|Progressive Disease|41
6174702|NCT01285609|9823114|FG001|Randomized|Progressive Disease|61
6174703|NCT01285609|9823113|FG000|Randomized|Adverse Event Unrelated to Study Drug|18
6174704|NCT01285609|9823114|FG001|Randomized|Adverse Event Unrelated to Study Drug|18
6174705|NCT01285609|9823113|FG000|Randomized|Study Drug Toxicity|13
6174706|NCT01285609|9823114|FG001|Randomized|Study Drug Toxicity|14
6174707|NCT01285609|9823113|FG000|Randomized|Death|5
6174708|NCT01285609|9823114|FG001|Randomized|Death|7
6174709|NCT01285609|9823113|FG000|Randomized|Withdrawal by Subject|8
6174710|NCT01285609|9823114|FG001|Randomized|Withdrawal by Subject|11
6174711|NCT01285609|9823113|FG000|Randomized|Subject No Longer Met Study Criteria|1
6174712|NCT01285609|9823114|FG001|Randomized|Subject No Longer Met Study Criteria|1
6174713|NCT01285609|9823113|FG000|Randomized|Undisclosed Reasons|1
6174714|NCT01285609|9823114|FG001|Randomized|Undisclosed Reasons|0
6174715|NCT01285609|9823113|FG000|Randomized|Randomized but not Treated|4
6174716|NCT01285609|9823114|FG001|Randomized|Randomized but not Treated|4
6174717|NCT01285609|9823113|FG000|Treated With Blinded Therapy|Progressive Disease|223
6174718|NCT01285609|9823114|FG001|Treated With Blinded Therapy|Progressive Disease|305
6174719|NCT01285609|9823113|FG000|Treated With Blinded Therapy|Study Drug Toxicity|87
6174720|NCT01285609|9823114|FG001|Treated With Blinded Therapy|Study Drug Toxicity|14
6174721|NCT01285609|9823113|FG000|Treated With Blinded Therapy|Adverse Event Unrelated to Study Drug|36
6174722|NCT01285609|9823114|FG001|Treated With Blinded Therapy|Adverse Event Unrelated to Study Drug|14
6174723|NCT01285609|9823113|FG000|Treated With Blinded Therapy|Withdrawal by Subject|20
6174724|NCT01285609|9823114|FG001|Treated With Blinded Therapy|Withdrawal by Subject|7
6174725|NCT01285609|9823113|FG000|Treated With Blinded Therapy|Death|11
6174726|NCT01285609|9823114|FG001|Treated With Blinded Therapy|Death|3
6174727|NCT01285609|9823113|FG000|Treated With Blinded Therapy|Maximum Clinical Benefit|2
6174728|NCT01285609|9823114|FG001|Treated With Blinded Therapy|Maximum Clinical Benefit|4
6174729|NCT01285609|9823113|FG000|Treated With Blinded Therapy|Not Reported|0
6174730|NCT01285609|9823114|FG001|Treated With Blinded Therapy|Not Reported|2
6174731|NCT01285609|9823113|FG000|Treated With Blinded Therapy|Poor/Non-Compliance|1
6174732|NCT01285609|9823114|FG001|Treated With Blinded Therapy|Poor/Non-Compliance|2
6174733|NCT01285609|9823113|FG000|Treated With Blinded Therapy|Subject No Longer Met Study Criteria|1
6174734|NCT01285609|9823114|FG001|Treated With Blinded Therapy|Subject No Longer Met Study Criteria|0
6174735|NCT01285609|9823113|FG000|Treated With Blinded Therapy|Administrative Reason by Sponsor|1
6174736|NCT01285609|9823114|FG001|Treated With Blinded Therapy|Administrative Reason by Sponsor|3
6174737|NCT01285609|9823113|FG000|Treated With Blinded Therapy|Physician and Patient decision|1
6174738|NCT01285609|9823114|FG001|Treated With Blinded Therapy|Physician and Patient decision|3
6174739|NCT01285609|9823113|FG000|Treated With Blinded Therapy|Participant refused participation|1
6174740|NCT01285609|9823114|FG001|Treated With Blinded Therapy|Participant refused participation|0
6174741|NCT01285609|9823113|FG000|Treated With Blinded Therapy|Participant started radiotherapy|1
6174742|NCT01285609|9823114|FG001|Treated With Blinded Therapy|Participant started radiotherapy|0
6174743|NCT01285609|9823113|FG000|Treated With Blinded Therapy|Participant hospitalized|1
6174744|NCT01285609|9823114|FG001|Treated With Blinded Therapy|Participant hospitalized|0
6174745|NCT01285609|9823113|FG000|Treated With Blinded Therapy|Investigator's assessment|1
6174746|NCT01285609|9823114|FG001|Treated With Blinded Therapy|Investigator's assessment|0
6174747|NCT01285609|9823113|FG000|Treated With Blinded Therapy|PI decision to discontinue|0
6174748|NCT01285609|9823114|FG001|Treated With Blinded Therapy|PI decision to discontinue|1
6174749|NCT01285609|9823113|FG000|Treated With Blinded Therapy|Worsening of general condition|0
6174750|NCT01285609|9823114|FG001|Treated With Blinded Therapy|Worsening of general condition|1
6174751|NCT01285908|9823169|FG000|Baseline Measurement|unable to insert catheter|1
6174752|NCT01285908|9823170|FG001|Baseline Measurement|unable to insert catheter|0
6174753|NCT01285908|9823171|FG002|Baseline Measurement|unable to insert catheter|0
6174754|NCT01285908|9823169|FG000|Baseline Measurement|History of stroke, exclusion criteria|1
6174755|NCT01285908|9823170|FG001|Baseline Measurement|History of stroke, exclusion criteria|0
6174756|NCT01285908|9823171|FG002|Baseline Measurement|History of stroke, exclusion criteria|0
6174757|NCT01285908|9823169|FG000|Baseline Measurement|unable to tolerate procedure|1
6174758|NCT01285908|9823170|FG001|Baseline Measurement|unable to tolerate procedure|0
6174759|NCT01285908|9823171|FG002|Baseline Measurement|unable to tolerate procedure|0
6174760|NCT01285960|9823201|FG000|Overall Study|Withdrawal by Subject|2
6174761|NCT01285960|9823201|FG000|Overall Study|Lost to Follow-up|2
6174762|NCT01285960|9823201|FG000|Overall Study|2 subjects received less 10 sonications|2
6174763|NCT01286012|9823207|FG000|Overall Study|Adverse Event|3
6174764|NCT01286012|9823208|FG001|Overall Study|Adverse Event|3
6174765|NCT01286012|9823207|FG000|Overall Study|Death|2
6174766|NCT01286012|9823208|FG001|Overall Study|Death|3
6174767|NCT01286012|9823207|FG000|Overall Study|Protocol Violation|1
6174768|NCT01286012|9823208|FG001|Overall Study|Protocol Violation|1
6174769|NCT01286012|9823207|FG000|Overall Study|Withdrawal by Subject|4
6174770|NCT01286012|9823208|FG001|Overall Study|Withdrawal by Subject|4
6174771|NCT01286012|9823207|FG000|Overall Study|Physician Decision|2
6174772|NCT01286012|9823208|FG001|Overall Study|Physician Decision|0
6174773|NCT01286012|9823207|FG000|Overall Study|peritoneal dialysis, randomized in error|1
6174774|NCT01286012|9823208|FG001|Overall Study|peritoneal dialysis, randomized in error|3
6174775|NCT01286077|9823217|FG000|Overall Study|Adverse Event|2
6174776|NCT01286077|9823218|FG001|Overall Study|Adverse Event|0
6174777|NCT01286077|9823217|FG000|Overall Study|Death|1
6174778|NCT01286077|9823218|FG001|Overall Study|Death|0
6174779|NCT01286077|9823217|FG000|Overall Study|Protocol Violation|1
6174780|NCT01286077|9823218|FG001|Overall Study|Protocol Violation|1
6174781|NCT01286077|9823217|FG000|Overall Study|Withdrawal by Subject|0
6174782|NCT01286077|9823218|FG001|Overall Study|Withdrawal by Subject|2
6174783|NCT01286077|9823217|FG000|Overall Study|Intercurrent illness|1
6174784|NCT01286077|9823218|FG001|Overall Study|Intercurrent illness|0
6174785|NCT01286077|9823217|FG000|Overall Study|Non-compliance|1
6174786|NCT01286077|9823218|FG001|Overall Study|Non-compliance|0
6174787|NCT01286077|9823217|FG000|Overall Study|The subject starts with alternative MMY|0
6174788|NCT01286077|9823218|FG001|Overall Study|The subject starts with alternative MMY|3
6174789|NCT01286077|9823217|FG000|Overall Study|Patient's decision to stop treatment|3
6174790|NCT01286077|9823218|FG001|Overall Study|Patient's decision to stop treatment|0
6174791|NCT01286077|9823217|FG000|Overall Study|Progression of disease|0
6174792|NCT01286077|9823218|FG001|Overall Study|Progression of disease|1
6174793|NCT01286077|9823217|FG000|Overall Study|refill medication not received in time|1
6174794|NCT01286077|9823218|FG001|Overall Study|refill medication not received in time|0
6174795|NCT01286129|9823226|FG000|Overall Study|Withdrawal by Subject|4
6174796|NCT01286129|9823227|FG001|Overall Study|Withdrawal by Subject|1
6174797|NCT01286129|9823226|FG000|Overall Study|Could not comply with study requirements|4
6174798|NCT01286129|9823227|FG001|Overall Study|Could not comply with study requirements|4
6174799|NCT01286168|9823235|FG000|Overall Study|Withdrawal by Subject|1
6174800|NCT01286168|9823235|FG000|Overall Study|Surgical Drains Fell Out at Home|2
6174801|NCT01286311|9823246|FG000|Overall Study|Physician did not want outreach sent|14
6174802|NCT01286311|9823247|FG001|Overall Study|Physician did not want outreach sent|0
6174803|NCT01286480|9823314|FG000|Overall Study|Withdrawal by Subject|5
6174804|NCT01286480|9823315|FG001|Overall Study|Withdrawal by Subject|3
6174805|NCT01286558|9823327|FG000|Overall Study|Adverse Event|1
6174806|NCT01286558|9823328|FG001|Overall Study|Adverse Event|1
6174807|NCT01286558|9823327|FG000|Overall Study|Withdrawal by Subject|0
6085014|NCT00647296|9694087|FG003|Part 2: 76-week Double-Blind Treatment|Lost to Follow-up|0
6174808|NCT01286558|9823328|FG001|Overall Study|Withdrawal by Subject|1
6174809|NCT01286740|9823334|FG000|Overall Study|Enrolled but not treated|1
6174810|NCT01286740|9823334|FG000|Overall Study|Protocol Violation|1
6174811|NCT01286753|9823340|FG000|Overall Study|Adverse Event|7
6174812|NCT01286753|9823341|FG001|Overall Study|Adverse Event|6
6174813|NCT01286753|9823340|FG000|Overall Study|Progression|11
6174814|NCT01286753|9823341|FG001|Overall Study|Progression|13
6174815|NCT01286753|9823340|FG000|Overall Study|Refused Treatment|1
6174816|NCT01286753|9823341|FG001|Overall Study|Refused Treatment|0
6174817|NCT01286753|9823340|FG000|Overall Study|Withdrawal of Consent|0
6174818|NCT01286753|9823341|FG001|Overall Study|Withdrawal of Consent|2
6174819|NCT01286753|9823340|FG000|Overall Study|Discontinued to Join Extension Study|6
6174820|NCT01286753|9823341|FG001|Overall Study|Discontinued to Join Extension Study|4
6174821|NCT01286753|9823340|FG000|Overall Study|Participant to Receive Radiotherapy|1
6174822|NCT01286753|9823341|FG001|Overall Study|Participant to Receive Radiotherapy|0
6174823|NCT01286779|9823348|FG000|Overall Study|Withdrawal by Subject|9
6174824|NCT01286779|9823348|FG000|Overall Study|Protocol Violation|5
6174825|NCT01286779|9823348|FG000|Overall Study|Physician Decision|2
6174826|NCT01286779|9823348|FG000|Overall Study|Participant had scheduled surgery|1
6174827|NCT01286779|9823348|FG000|Overall Study|Participant moved to another country|1
6174828|NCT01286779|9823348|FG000|Overall Study|Discontinued by sponsor|1
6174829|NCT01286987|9823394|FG000|Part 1: Dose Escalation|Clinical Progression|1
6174830|NCT01286987|9823395|FG001|Part 1: Dose Escalation|Clinical Progression|1
6174831|NCT01286987|9823396|FG002|Part 1: Dose Escalation|Clinical Progression|0
6174832|NCT01286987|9823397|FG003|Part 1: Dose Escalation|Clinical Progression|1
6174833|NCT01286987|9823398|FG004|Part 1: Dose Escalation|Clinical Progression|1
6174834|NCT01286987|9823399|FG005|Part 1: Dose Escalation|Clinical Progression|1
6174835|NCT01286987|9823400|FG006|Part 1: Dose Escalation|Clinical Progression|0
6174836|NCT01286987|9823401|FG007|Part 1: Dose Escalation|Clinical Progression|2
6174837|NCT01286987|9823402|FG008|Part 1: Dose Escalation|Clinical Progression|1
6174838|NCT01286987|9823403|FG009|Part 1: Dose Escalation|Clinical Progression|0
6174839|NCT01286987|9823404|FG010|Part 1: Dose Escalation|Clinical Progression|0
6174840|NCT01286987|9823405|FG011|Part 1: Dose Escalation|Clinical Progression|0
6174841|NCT01286987|9823406|FG012|Part 1: Dose Escalation|Clinical Progression|0
6174842|NCT01286987|9823407|FG013|Part 1: Dose Escalation|Clinical Progression|0
6174843|NCT01286987|9823408|FG014|Part 1: Dose Escalation|Clinical Progression|0
6174844|NCT01286987|9823394|FG000|Part 1: Dose Escalation|Progressive Disease|2
6174845|NCT01286987|9823395|FG001|Part 1: Dose Escalation|Progressive Disease|2
6174846|NCT01286987|9823396|FG002|Part 1: Dose Escalation|Progressive Disease|3
6174847|NCT01286987|9823397|FG003|Part 1: Dose Escalation|Progressive Disease|2
6174848|NCT01286987|9823398|FG004|Part 1: Dose Escalation|Progressive Disease|1
6174849|NCT01286987|9823399|FG005|Part 1: Dose Escalation|Progressive Disease|5
6174850|NCT01286987|9823400|FG006|Part 1: Dose Escalation|Progressive Disease|5
6174851|NCT01286987|9823401|FG007|Part 1: Dose Escalation|Progressive Disease|3
6174852|NCT01286987|9823402|FG008|Part 1: Dose Escalation|Progressive Disease|5
6174853|NCT01286987|9823403|FG009|Part 1: Dose Escalation|Progressive Disease|0
6174854|NCT01286987|9823404|FG010|Part 1: Dose Escalation|Progressive Disease|0
6174855|NCT01286987|9823405|FG011|Part 1: Dose Escalation|Progressive Disease|0
6174856|NCT01286987|9823406|FG012|Part 1: Dose Escalation|Progressive Disease|0
6174857|NCT01286987|9823407|FG013|Part 1: Dose Escalation|Progressive Disease|0
6174858|NCT01286987|9823408|FG014|Part 1: Dose Escalation|Progressive Disease|0
6174859|NCT01286987|9823394|FG000|Part 1: Dose Escalation|Physician Decision|0
6174860|NCT01286987|9823395|FG001|Part 1: Dose Escalation|Physician Decision|0
6174861|NCT01286987|9823396|FG002|Part 1: Dose Escalation|Physician Decision|0
6174862|NCT01286987|9823397|FG003|Part 1: Dose Escalation|Physician Decision|0
6174863|NCT01286987|9823398|FG004|Part 1: Dose Escalation|Physician Decision|1
6174864|NCT01286987|9823399|FG005|Part 1: Dose Escalation|Physician Decision|0
6174865|NCT01286987|9823400|FG006|Part 1: Dose Escalation|Physician Decision|0
6174866|NCT01286987|9823401|FG007|Part 1: Dose Escalation|Physician Decision|0
6174867|NCT01286987|9823402|FG008|Part 1: Dose Escalation|Physician Decision|0
6174868|NCT01286987|9823403|FG009|Part 1: Dose Escalation|Physician Decision|0
6174869|NCT01286987|9823404|FG010|Part 1: Dose Escalation|Physician Decision|0
6174870|NCT01286987|9823405|FG011|Part 1: Dose Escalation|Physician Decision|0
6174871|NCT01286987|9823406|FG012|Part 1: Dose Escalation|Physician Decision|0
6174872|NCT01286987|9823407|FG013|Part 1: Dose Escalation|Physician Decision|0
6174873|NCT01286987|9823408|FG014|Part 1: Dose Escalation|Physician Decision|0
6174874|NCT01286987|9823394|FG000|Part 2: Dose Expansion|Death|0
6174875|NCT01286987|9823395|FG001|Part 2: Dose Expansion|Death|0
6174876|NCT01286987|9823396|FG002|Part 2: Dose Expansion|Death|0
6174877|NCT01286987|9823397|FG003|Part 2: Dose Expansion|Death|0
6174878|NCT01286987|9823398|FG004|Part 2: Dose Expansion|Death|0
6174879|NCT01286987|9823399|FG005|Part 2: Dose Expansion|Death|0
6174880|NCT01286987|9823400|FG006|Part 2: Dose Expansion|Death|0
6174881|NCT01286987|9823401|FG007|Part 2: Dose Expansion|Death|0
6174882|NCT01286987|9823402|FG008|Part 2: Dose Expansion|Death|0
6174883|NCT01286987|9823403|FG009|Part 2: Dose Expansion|Death|0
6174884|NCT01286987|9823404|FG010|Part 2: Dose Expansion|Death|0
6174885|NCT01286987|9823405|FG011|Part 2: Dose Expansion|Death|0
6174886|NCT01286987|9823406|FG012|Part 2: Dose Expansion|Death|1
6174887|NCT01286987|9823407|FG013|Part 2: Dose Expansion|Death|1
6174888|NCT01286987|9823408|FG014|Part 2: Dose Expansion|Death|0
6174889|NCT01286987|9823394|FG000|Part 2: Dose Expansion|Physician Decision|0
6174890|NCT01286987|9823395|FG001|Part 2: Dose Expansion|Physician Decision|0
6174891|NCT01286987|9823396|FG002|Part 2: Dose Expansion|Physician Decision|0
6174892|NCT01286987|9823397|FG003|Part 2: Dose Expansion|Physician Decision|0
6174893|NCT01286987|9823398|FG004|Part 2: Dose Expansion|Physician Decision|0
6174894|NCT01286987|9823399|FG005|Part 2: Dose Expansion|Physician Decision|0
6174895|NCT01286987|9823400|FG006|Part 2: Dose Expansion|Physician Decision|0
6174896|NCT01286987|9823401|FG007|Part 2: Dose Expansion|Physician Decision|0
6174897|NCT01286987|9823402|FG008|Part 2: Dose Expansion|Physician Decision|0
6174898|NCT01286987|9823403|FG009|Part 2: Dose Expansion|Physician Decision|0
6174899|NCT01286987|9823404|FG010|Part 2: Dose Expansion|Physician Decision|1
6174900|NCT01286987|9823405|FG011|Part 2: Dose Expansion|Physician Decision|1
6174901|NCT01286987|9823406|FG012|Part 2: Dose Expansion|Physician Decision|0
6174902|NCT01286987|9823407|FG013|Part 2: Dose Expansion|Physician Decision|1
6174903|NCT01286987|9823408|FG014|Part 2: Dose Expansion|Physician Decision|0
6174904|NCT01286987|9823394|FG000|Part 2: Dose Expansion|Other|0
6174905|NCT01286987|9823395|FG001|Part 2: Dose Expansion|Other|0
6174906|NCT01286987|9823396|FG002|Part 2: Dose Expansion|Other|0
6174907|NCT01286987|9823397|FG003|Part 2: Dose Expansion|Other|0
6174908|NCT01286987|9823398|FG004|Part 2: Dose Expansion|Other|0
6174909|NCT01286987|9823399|FG005|Part 2: Dose Expansion|Other|0
6174910|NCT01286987|9823400|FG006|Part 2: Dose Expansion|Other|0
6174911|NCT01286987|9823401|FG007|Part 2: Dose Expansion|Other|0
6174912|NCT01286987|9823402|FG008|Part 2: Dose Expansion|Other|0
6174913|NCT01286987|9823403|FG009|Part 2: Dose Expansion|Other|0
6174914|NCT01286987|9823404|FG010|Part 2: Dose Expansion|Other|0
6174915|NCT01286987|9823405|FG011|Part 2: Dose Expansion|Other|0
6174916|NCT01286987|9823406|FG012|Part 2: Dose Expansion|Other|0
6174917|NCT01286987|9823407|FG013|Part 2: Dose Expansion|Other|1
6174918|NCT01286987|9823408|FG014|Part 2: Dose Expansion|Other|0
6174919|NCT01286987|9823394|FG000|Part 2: Dose Expansion|Progressive Disease|0
6174920|NCT01286987|9823395|FG001|Part 2: Dose Expansion|Progressive Disease|0
6174921|NCT01286987|9823396|FG002|Part 2: Dose Expansion|Progressive Disease|0
6174922|NCT01286987|9823397|FG003|Part 2: Dose Expansion|Progressive Disease|0
6174923|NCT01286987|9823398|FG004|Part 2: Dose Expansion|Progressive Disease|0
6174924|NCT01286987|9823399|FG005|Part 2: Dose Expansion|Progressive Disease|0
6174925|NCT01286987|9823400|FG006|Part 2: Dose Expansion|Progressive Disease|0
6174926|NCT01286987|9823401|FG007|Part 2: Dose Expansion|Progressive Disease|0
6174927|NCT01286987|9823402|FG008|Part 2: Dose Expansion|Progressive Disease|0
6174928|NCT01286987|9823403|FG009|Part 2: Dose Expansion|Progressive Disease|11
6174929|NCT01286987|9823404|FG010|Part 2: Dose Expansion|Progressive Disease|6
6174930|NCT01286987|9823405|FG011|Part 2: Dose Expansion|Progressive Disease|7
6174931|NCT01286987|9823406|FG012|Part 2: Dose Expansion|Progressive Disease|11
6174932|NCT01286987|9823407|FG013|Part 2: Dose Expansion|Progressive Disease|19
6174933|NCT01286987|9823408|FG014|Part 2: Dose Expansion|Progressive Disease|2
6174934|NCT01286987|9823394|FG000|Part 2: Dose Expansion|Clinical Progression|0
6174935|NCT01286987|9823395|FG001|Part 2: Dose Expansion|Clinical Progression|0
6174936|NCT01286987|9823396|FG002|Part 2: Dose Expansion|Clinical Progression|0
6174937|NCT01286987|9823397|FG003|Part 2: Dose Expansion|Clinical Progression|0
6174938|NCT01286987|9823398|FG004|Part 2: Dose Expansion|Clinical Progression|0
6174939|NCT01286987|9823399|FG005|Part 2: Dose Expansion|Clinical Progression|0
6174940|NCT01286987|9823400|FG006|Part 2: Dose Expansion|Clinical Progression|0
6174941|NCT01286987|9823401|FG007|Part 2: Dose Expansion|Clinical Progression|0
6174942|NCT01286987|9823402|FG008|Part 2: Dose Expansion|Clinical Progression|0
6174943|NCT01286987|9823403|FG009|Part 2: Dose Expansion|Clinical Progression|0
6174944|NCT01286987|9823404|FG010|Part 2: Dose Expansion|Clinical Progression|2
6174945|NCT01286987|9823405|FG011|Part 2: Dose Expansion|Clinical Progression|2
6174946|NCT01286987|9823406|FG012|Part 2: Dose Expansion|Clinical Progression|0
6174947|NCT01286987|9823407|FG013|Part 2: Dose Expansion|Clinical Progression|2
6174948|NCT01286987|9823408|FG014|Part 2: Dose Expansion|Clinical Progression|0
6174949|NCT01286987|9823394|FG000|Part 2: Dose Expansion|Withdrawal by Subject|0
6174950|NCT01286987|9823395|FG001|Part 2: Dose Expansion|Withdrawal by Subject|0
6174951|NCT01286987|9823396|FG002|Part 2: Dose Expansion|Withdrawal by Subject|0
6174952|NCT01286987|9823397|FG003|Part 2: Dose Expansion|Withdrawal by Subject|0
6174953|NCT01286987|9823398|FG004|Part 2: Dose Expansion|Withdrawal by Subject|0
6174954|NCT01286987|9823399|FG005|Part 2: Dose Expansion|Withdrawal by Subject|0
6174955|NCT01286987|9823400|FG006|Part 2: Dose Expansion|Withdrawal by Subject|0
6174956|NCT01286987|9823401|FG007|Part 2: Dose Expansion|Withdrawal by Subject|0
6174957|NCT01286987|9823402|FG008|Part 2: Dose Expansion|Withdrawal by Subject|0
6174958|NCT01286987|9823403|FG009|Part 2: Dose Expansion|Withdrawal by Subject|0
6174959|NCT01286987|9823404|FG010|Part 2: Dose Expansion|Withdrawal by Subject|1
6174960|NCT01286987|9823405|FG011|Part 2: Dose Expansion|Withdrawal by Subject|0
6174961|NCT01286987|9823406|FG012|Part 2: Dose Expansion|Withdrawal by Subject|0
6174962|NCT01286987|9823407|FG013|Part 2: Dose Expansion|Withdrawal by Subject|0
6174963|NCT01286987|9823408|FG014|Part 2: Dose Expansion|Withdrawal by Subject|0
6174964|NCT01287013|9823452|FG000|Overall Study|Non-evaluable|3
6174965|NCT01287013|9823453|FG001|Overall Study|Non-evaluable|5
6174966|NCT01287013|9823454|FG002|Overall Study|Non-evaluable|21
6174967|NCT01287039|9823464|FG000|Overall Study|Noncompliance with study procedures|0
6174968|NCT01287039|9823465|FG001|Overall Study|Noncompliance with study procedures|1
6174969|NCT01287039|9823464|FG000|Overall Study|Change of location/residence|0
6174970|NCT01287039|9823465|FG001|Overall Study|Change of location/residence|3
6174971|NCT01287039|9823464|FG000|Overall Study|Elective surgery|0
6174972|NCT01287039|9823465|FG001|Overall Study|Elective surgery|1
6174973|NCT01287039|9823464|FG000|Overall Study|Protocol Violation|2
6174974|NCT01287039|9823465|FG001|Overall Study|Protocol Violation|3
6174975|NCT01287039|9823464|FG000|Overall Study|Excluded medication taken|1
6174976|NCT01287039|9823465|FG001|Overall Study|Excluded medication taken|0
6174977|NCT01287039|9823464|FG000|Overall Study|Noncompliance with study medication|0
6174978|NCT01287039|9823465|FG001|Overall Study|Noncompliance with study medication|1
6174979|NCT01287039|9823464|FG000|Overall Study|Problem with travel|0
6174980|NCT01287039|9823465|FG001|Overall Study|Problem with travel|1
6174981|NCT01287039|9823464|FG000|Overall Study|Death|1
6174982|NCT01287039|9823465|FG001|Overall Study|Death|0
6174983|NCT01287039|9823464|FG000|Overall Study|Change of residence|1
6174984|NCT01287039|9823465|FG001|Overall Study|Change of residence|0
6174985|NCT01287039|9823464|FG000|Overall Study|Adverse Event|7
6174986|NCT01287039|9823465|FG001|Overall Study|Adverse Event|4
6174987|NCT01287039|9823464|FG000|Overall Study|Withdrawal by Subject|14
6174988|NCT01287039|9823465|FG001|Overall Study|Withdrawal by Subject|11
6174989|NCT01287039|9823464|FG000|Overall Study|Lost to Follow-up|3
6174990|NCT01287039|9823465|FG001|Overall Study|Lost to Follow-up|2
6174991|NCT01287065|9823471|FG000|Treatment Period 1|Adverse Event|0
6174992|NCT01287065|9823472|FG001|Treatment Period 1|Adverse Event|0
6174993|NCT01287065|9823473|FG002|Treatment Period 1|Adverse Event|0
6174994|NCT01287065|9823474|FG003|Treatment Period 1|Adverse Event|0
6174995|NCT01287065|9823475|FG004|Treatment Period 1|Adverse Event|1
6174996|NCT01287065|9823476|FG005|Treatment Period 1|Adverse Event|0
6174997|NCT01287065|9823471|FG000|Treatment Period 1|Withdrawal by Subject|0
6174998|NCT01287065|9823472|FG001|Treatment Period 1|Withdrawal by Subject|0
6174999|NCT01287065|9823473|FG002|Treatment Period 1|Withdrawal by Subject|0
6175000|NCT01287065|9823474|FG003|Treatment Period 1|Withdrawal by Subject|0
6175001|NCT01287065|9823475|FG004|Treatment Period 1|Withdrawal by Subject|0
6175002|NCT01287065|9823476|FG005|Treatment Period 1|Withdrawal by Subject|1
6175003|NCT01287104|9823497|FG000|Overall Study|Patient developed progressive disease|1
6175004|NCT01287104|9823498|FG001|Overall Study|Patient developed progressive disease|1
6175005|NCT01287104|9823499|FG002|Overall Study|Patient developed progressive disease|3
6175006|NCT01287104|9823500|FG003|Overall Study|Patient developed progressive disease|2
6175007|NCT01287104|9823497|FG000|Overall Study|Donor anaphylaxis|0
6175008|NCT01287104|9823498|FG001|Overall Study|Donor anaphylaxis|1
6175009|NCT01287104|9823499|FG002|Overall Study|Donor anaphylaxis|0
6175010|NCT01287104|9823500|FG003|Overall Study|Donor anaphylaxis|1
6175011|NCT01287104|9823497|FG000|Overall Study|Developed GVHD or complications of BMT|0
6175012|NCT01287104|9823498|FG001|Overall Study|Developed GVHD or complications of BMT|1
6175013|NCT01287104|9823499|FG002|Overall Study|Developed GVHD or complications of BMT|4
6175014|NCT01287104|9823500|FG003|Overall Study|Developed GVHD or complications of BMT|0
6175015|NCT01287104|9823497|FG000|Overall Study|Low donor chimerism|0
6175016|NCT01287104|9823498|FG001|Overall Study|Low donor chimerism|1
6175017|NCT01287104|9823499|FG002|Overall Study|Low donor chimerism|0
6175018|NCT01287104|9823500|FG003|Overall Study|Low donor chimerism|0
6175019|NCT01287104|9823497|FG000|Overall Study|NK cells did not meet release criteria|0
6175020|NCT01287104|9823498|FG001|Overall Study|NK cells did not meet release criteria|1
6175021|NCT01287104|9823499|FG002|Overall Study|NK cells did not meet release criteria|0
6175022|NCT01287104|9823500|FG003|Overall Study|NK cells did not meet release criteria|0
6175023|NCT01287117|9823521|FG000|Overall Study|Adverse Event|2
6175024|NCT01287117|9823522|FG001|Overall Study|Adverse Event|1
6175025|NCT01287117|9823523|FG002|Overall Study|Adverse Event|1
6175026|NCT01287117|9823524|FG003|Overall Study|Adverse Event|1
6175027|NCT01287117|9823521|FG000|Overall Study|Lost to Follow-up|1
6175028|NCT01287117|9823522|FG001|Overall Study|Lost to Follow-up|1
6175029|NCT01287117|9823523|FG002|Overall Study|Lost to Follow-up|0
6175030|NCT01287117|9823524|FG003|Overall Study|Lost to Follow-up|0
6175031|NCT01287117|9823521|FG000|Overall Study|Physician Decision|0
6175032|NCT01287117|9823522|FG001|Overall Study|Physician Decision|1
6175033|NCT01287117|9823523|FG002|Overall Study|Physician Decision|1
6175034|NCT01287117|9823524|FG003|Overall Study|Physician Decision|1
6175035|NCT01287117|9823521|FG000|Overall Study|Patient/Legal Guardian's Decision|2
6175036|NCT01287117|9823522|FG001|Overall Study|Patient/Legal Guardian's Decision|6
6175037|NCT01287117|9823523|FG002|Overall Study|Patient/Legal Guardian's Decision|8
6175038|NCT01287117|9823524|FG003|Overall Study|Patient/Legal Guardian's Decision|5
6175039|NCT01287117|9823521|FG000|Overall Study|Disease Progression|10
6175040|NCT01287117|9823522|FG001|Overall Study|Disease Progression|5
6175041|NCT01287117|9823523|FG002|Overall Study|Disease Progression|6
6175042|NCT01287117|9823524|FG003|Overall Study|Disease Progression|5
6175043|NCT01287195|9823534|FG000|Overall Study|Withdrawal by Subject|2
6175044|NCT01287221|9823551|FG000|Overall Study|Lack of Perceived Benefit|1
6175045|NCT01287221|9823552|FG001|Overall Study|Lack of Perceived Benefit|1
6175046|NCT01287221|9823551|FG000|Overall Study|Adverse Event|3
6175047|NCT01287221|9823552|FG001|Overall Study|Adverse Event|3
6175048|NCT01287221|9823551|FG000|Overall Study|Withdrawal by Subject|0
6175049|NCT01287221|9823552|FG001|Overall Study|Withdrawal by Subject|1
6175050|NCT01287364|9823560|FG000|Overall Study|Adverse Event|0
6175051|NCT01287364|9823561|FG001|Overall Study|Adverse Event|3
6175052|NCT01287364|9823560|FG000|Overall Study|Protocol Violation|5
6175053|NCT01287364|9823561|FG001|Overall Study|Protocol Violation|5
6175054|NCT01287364|9823560|FG000|Overall Study|Other Reason|4
6175055|NCT01287364|9823561|FG001|Overall Study|Other Reason|2
6175056|NCT01287403|9823593|FG000|1st Intervention (1 Day)|Adverse Event|1
6175057|NCT01287416|9823609|FG000|Pre-post Training|Withdrawal by Subject|17
6175058|NCT01287416|9823610|FG001|Pre-post Training|Withdrawal by Subject|24
6175059|NCT01287416|9823609|FG000|Pre-post Training|Lost to Follow-up|5
6175060|NCT01287416|9823610|FG001|Pre-post Training|Lost to Follow-up|1
6175061|NCT01287416|9823609|FG000|6 Month Follow-up|Lost to Follow-up|3
6175062|NCT01287416|9823610|FG001|6 Month Follow-up|Lost to Follow-up|2
6175063|NCT01287520|9823625|FG000|Overall Study|Adverse Event|2
6175064|NCT01287520|9823626|FG001|Overall Study|Adverse Event|2
6175065|NCT01287520|9823627|FG002|Overall Study|Adverse Event|2
6175066|NCT01287520|9823628|FG003|Overall Study|Adverse Event|1
6175067|NCT01287520|9823629|FG004|Overall Study|Adverse Event|1
6175068|NCT01287520|9823630|FG005|Overall Study|Adverse Event|2
6175069|NCT01287520|9823631|FG006|Overall Study|Adverse Event|0
6175070|NCT01287520|9823632|FG007|Overall Study|Adverse Event|2
6175071|NCT01287520|9823633|FG008|Overall Study|Adverse Event|0
6175072|NCT01287520|9823625|FG000|Overall Study|Physician Decision|1
6175073|NCT01287520|9823626|FG001|Overall Study|Physician Decision|1
6175074|NCT01287520|9823627|FG002|Overall Study|Physician Decision|2
6175075|NCT01287520|9823628|FG003|Overall Study|Physician Decision|0
6175076|NCT01287520|9823629|FG004|Overall Study|Physician Decision|1
6175077|NCT01287520|9823630|FG005|Overall Study|Physician Decision|1
6175078|NCT01287520|9823631|FG006|Overall Study|Physician Decision|0
6175079|NCT01287520|9823632|FG007|Overall Study|Physician Decision|1
6175080|NCT01287520|9823633|FG008|Overall Study|Physician Decision|0
6175081|NCT01287520|9823625|FG000|Overall Study|Progressive disease|0
6175082|NCT01287520|9823626|FG001|Overall Study|Progressive disease|4
6175083|NCT01287520|9823627|FG002|Overall Study|Progressive disease|1
6175084|NCT01287520|9823628|FG003|Overall Study|Progressive disease|6
6175085|NCT01287520|9823629|FG004|Overall Study|Progressive disease|1
6175086|NCT01287520|9823630|FG005|Overall Study|Progressive disease|0
6175087|NCT01287520|9823631|FG006|Overall Study|Progressive disease|2
6175088|NCT01287520|9823632|FG007|Overall Study|Progressive disease|2
6175089|NCT01287520|9823633|FG008|Overall Study|Progressive disease|4
6175090|NCT01287520|9823625|FG000|Overall Study|Withdrawal by Subject|0
6175091|NCT01287520|9823626|FG001|Overall Study|Withdrawal by Subject|0
6175092|NCT01287520|9823627|FG002|Overall Study|Withdrawal by Subject|0
6175093|NCT01287520|9823628|FG003|Overall Study|Withdrawal by Subject|0
6175094|NCT01287520|9823629|FG004|Overall Study|Withdrawal by Subject|0
6175095|NCT01287520|9823630|FG005|Overall Study|Withdrawal by Subject|1
6175096|NCT01287520|9823631|FG006|Overall Study|Withdrawal by Subject|0
6175097|NCT01287520|9823632|FG007|Overall Study|Withdrawal by Subject|0
6175098|NCT01287520|9823633|FG008|Overall Study|Withdrawal by Subject|1
6175099|NCT01287754|9823684|FG000|Overall Study|Death|2
6175100|NCT01287754|9823685|FG001|Overall Study|Death|12
6175101|NCT01287754|9823684|FG000|Overall Study|Lost to Follow-up|1
6175102|NCT01287754|9823685|FG001|Overall Study|Lost to Follow-up|6
6175103|NCT01287754|9823684|FG000|Overall Study|Protocol Violation|0
6175104|NCT01287754|9823685|FG001|Overall Study|Protocol Violation|3
6175105|NCT01287832|9823693|FG000|Overall Study|Adverse Event|1
6175106|NCT01287832|9823694|FG001|Overall Study|Adverse Event|0
6175107|NCT01287832|9823693|FG000|Overall Study|Death|0
6175108|NCT01287832|9823694|FG001|Overall Study|Death|1
6175109|NCT01287897|9823704|FG000|Overall Study|Adverse Event|5
6175110|NCT01287897|9823705|FG001|Overall Study|Adverse Event|3
6175111|NCT01287897|9823706|FG002|Overall Study|Adverse Event|6
6175112|NCT01287897|9823707|FG003|Overall Study|Adverse Event|4
6175113|NCT01287897|9823704|FG000|Overall Study|Lack of Efficacy|2
6175114|NCT01287897|9823705|FG001|Overall Study|Lack of Efficacy|0
6175115|NCT01287897|9823706|FG002|Overall Study|Lack of Efficacy|0
6175116|NCT01287897|9823707|FG003|Overall Study|Lack of Efficacy|0
6175117|NCT01287897|9823704|FG000|Overall Study|Protocol Violation|1
6175118|NCT01287897|9823705|FG001|Overall Study|Protocol Violation|1
6175119|NCT01287897|9823706|FG002|Overall Study|Protocol Violation|0
6175120|NCT01287897|9823707|FG003|Overall Study|Protocol Violation|1
6175121|NCT01287897|9823704|FG000|Overall Study|Lost to Follow-up|0
6175122|NCT01287897|9823705|FG001|Overall Study|Lost to Follow-up|0
6175123|NCT01287897|9823706|FG002|Overall Study|Lost to Follow-up|2
6175124|NCT01287897|9823707|FG003|Overall Study|Lost to Follow-up|0
6175125|NCT01287897|9823704|FG000|Overall Study|Withdrawal by Subject|1
6175126|NCT01287897|9823705|FG001|Overall Study|Withdrawal by Subject|5
6175127|NCT01287897|9823706|FG002|Overall Study|Withdrawal by Subject|3
6175128|NCT01287897|9823707|FG003|Overall Study|Withdrawal by Subject|2
6175129|NCT01287897|9823704|FG000|Overall Study|Not consented properly|0
6175130|NCT01287897|9823705|FG001|Overall Study|Not consented properly|1
6175131|NCT01287897|9823706|FG002|Overall Study|Not consented properly|0
6175132|NCT01287897|9823707|FG003|Overall Study|Not consented properly|0
6175133|NCT01287897|9823704|FG000|Overall Study|Not meeting entrance criteria|1
6175134|NCT01287897|9823705|FG001|Overall Study|Not meeting entrance criteria|1
6175135|NCT01287897|9823706|FG002|Overall Study|Not meeting entrance criteria|0
6175136|NCT01287897|9823707|FG003|Overall Study|Not meeting entrance criteria|0
6175137|NCT01287897|9823704|FG000|Overall Study|Other|1
6175138|NCT01287897|9823705|FG001|Overall Study|Other|0
6175139|NCT01287897|9823706|FG002|Overall Study|Other|1
6175140|NCT01287897|9823707|FG003|Overall Study|Other|0
6175141|NCT01288053|9823725|FG000|Overall Study|Death|1
6175142|NCT01288079|9823733|FG000|Overall Study|Withdrawal by Subject|2
6175143|NCT01288079|9823734|FG001|Overall Study|Withdrawal by Subject|4
6175144|NCT01288079|9823735|FG002|Overall Study|Withdrawal by Subject|1
6175145|NCT01288079|9823736|FG003|Overall Study|Withdrawal by Subject|0
6175146|NCT01288079|9823733|FG000|Overall Study|Adverse Event|2
6175147|NCT01288079|9823734|FG001|Overall Study|Adverse Event|1
6175148|NCT01288079|9823735|FG002|Overall Study|Adverse Event|2
6175149|NCT01288079|9823736|FG003|Overall Study|Adverse Event|3
6175150|NCT01288079|9823733|FG000|Overall Study|Severe Non-Compliance to Protocol|1
6175151|NCT01288079|9823734|FG001|Overall Study|Severe Non-Compliance to Protocol|3
6175152|NCT01288079|9823735|FG002|Overall Study|Severe Non-Compliance to Protocol|1
6175153|NCT01288079|9823736|FG003|Overall Study|Severe Non-Compliance to Protocol|3
6175154|NCT01288079|9823733|FG000|Overall Study|Condition under Investigation Worsened|0
6175155|NCT01288079|9823734|FG001|Overall Study|Condition under Investigation Worsened|0
6175156|NCT01288079|9823735|FG002|Overall Study|Condition under Investigation Worsened|0
6175157|NCT01288079|9823736|FG003|Overall Study|Condition under Investigation Worsened|1
6175158|NCT01288079|9823733|FG000|Overall Study|Lack of Efficacy|2
6175159|NCT01288079|9823734|FG001|Overall Study|Lack of Efficacy|2
6175160|NCT01288079|9823735|FG002|Overall Study|Lack of Efficacy|0
6175161|NCT01288079|9823736|FG003|Overall Study|Lack of Efficacy|2
6175162|NCT01288079|9823733|FG000|Overall Study|Study-Specific Withdrawal Criteria|1
6175163|NCT01288079|9823734|FG001|Overall Study|Study-Specific Withdrawal Criteria|1
6175164|NCT01288079|9823735|FG002|Overall Study|Study-Specific Withdrawal Criteria|0
6175165|NCT01288079|9823736|FG003|Overall Study|Study-Specific Withdrawal Criteria|0
6175166|NCT01288079|9823733|FG000|Overall Study|Lost to Follow-up|1
6175167|NCT01288079|9823734|FG001|Overall Study|Lost to Follow-up|1
6175168|NCT01288079|9823735|FG002|Overall Study|Lost to Follow-up|1
6175169|NCT01288079|9823736|FG003|Overall Study|Lost to Follow-up|0
6175170|NCT01288079|9823733|FG000|Overall Study|Other or Study Termination|11
6175171|NCT01288079|9823734|FG001|Overall Study|Other or Study Termination|15
6175172|NCT01288079|9823735|FG002|Overall Study|Other or Study Termination|14
6175173|NCT01288079|9823736|FG003|Overall Study|Other or Study Termination|8
6175174|NCT01288209|9823748|FG000|Overall Study|Withdrawal by Subject|1
6175175|NCT01288209|9823749|FG001|Overall Study|Withdrawal by Subject|3
6175176|NCT01288209|9823748|FG000|Overall Study|Other|1
6175177|NCT01288209|9823749|FG001|Overall Study|Other|0
6175178|NCT01288287|9823755|FG000|Overall Study|Lost to Follow-up|8
6175179|NCT01288287|9823755|FG000|Overall Study|Withdrawal by Subject|4
6175180|NCT01288287|9823755|FG000|Overall Study|Lack of Efficacy|13
6175181|NCT01288287|9823755|FG000|Overall Study|Other Reason|13
6175182|NCT01288287|9823755|FG000|Overall Study|Unknown Reason|1
6175183|NCT01288287|9823755|FG000|Overall Study|Unknown Status|7
6175184|NCT01288430|9823770|FG000|Part 1|Progressive disease|2
6175185|NCT01288430|9823771|FG001|Part 1|Progressive disease|1
6175186|NCT01288430|9823772|FG002|Part 1|Progressive disease|1
6175187|NCT01288430|9823773|FG003|Part 1|Progressive disease|6
6175188|NCT01288430|9823774|FG004|Part 1|Progressive disease|2
6175189|NCT01288430|9823775|FG005|Part 1|Progressive disease|4
6175190|NCT01288430|9823776|FG006|Part 1|Progressive disease|2
6175191|NCT01288430|9823777|FG007|Part 1|Progressive disease|0
6175192|NCT01288430|9823778|FG008|Part 1|Progressive disease|0
6175193|NCT01288430|9823779|FG009|Part 1|Progressive disease|0
6175194|NCT01288430|9823770|FG000|Part 1|Clinical disease progression|0
6175195|NCT01288430|9823771|FG001|Part 1|Clinical disease progression|0
6175196|NCT01288430|9823772|FG002|Part 1|Clinical disease progression|1
6175197|NCT01288430|9823773|FG003|Part 1|Clinical disease progression|0
6175198|NCT01288430|9823774|FG004|Part 1|Clinical disease progression|0
6175199|NCT01288430|9823775|FG005|Part 1|Clinical disease progression|2
6175200|NCT01288430|9823776|FG006|Part 1|Clinical disease progression|2
6175201|NCT01288430|9823777|FG007|Part 1|Clinical disease progression|0
6175202|NCT01288430|9823778|FG008|Part 1|Clinical disease progression|0
6175203|NCT01288430|9823779|FG009|Part 1|Clinical disease progression|0
6175204|NCT01288430|9823770|FG000|Part 1|Death due to disease progression|0
6175205|NCT01288430|9823771|FG001|Part 1|Death due to disease progression|0
6175206|NCT01288430|9823772|FG002|Part 1|Death due to disease progression|0
6175207|NCT01288430|9823773|FG003|Part 1|Death due to disease progression|0
6175208|NCT01288430|9823774|FG004|Part 1|Death due to disease progression|1
6175209|NCT01288430|9823775|FG005|Part 1|Death due to disease progression|0
6175210|NCT01288430|9823776|FG006|Part 1|Death due to disease progression|0
6175211|NCT01288430|9823777|FG007|Part 1|Death due to disease progression|0
6175212|NCT01288430|9823778|FG008|Part 1|Death due to disease progression|0
6175213|NCT01288430|9823779|FG009|Part 1|Death due to disease progression|0
6175214|NCT01288430|9823770|FG000|Part 1|Adverse Event|0
6175215|NCT01288430|9823771|FG001|Part 1|Adverse Event|0
6175216|NCT01288430|9823772|FG002|Part 1|Adverse Event|3
6175217|NCT01288430|9823773|FG003|Part 1|Adverse Event|1
6175218|NCT01288430|9823774|FG004|Part 1|Adverse Event|0
6175219|NCT01288430|9823775|FG005|Part 1|Adverse Event|0
6175220|NCT01288430|9823776|FG006|Part 1|Adverse Event|2
6175221|NCT01288430|9823777|FG007|Part 1|Adverse Event|0
6175222|NCT01288430|9823778|FG008|Part 1|Adverse Event|0
6175223|NCT01288430|9823779|FG009|Part 1|Adverse Event|0
6175224|NCT01288430|9823770|FG000|Part 1|Other|0
6175225|NCT01288430|9823771|FG001|Part 1|Other|2
6175226|NCT01288430|9823772|FG002|Part 1|Other|0
6175227|NCT01288430|9823773|FG003|Part 1|Other|0
6175228|NCT01288430|9823774|FG004|Part 1|Other|0
6175229|NCT01288430|9823775|FG005|Part 1|Other|0
6175230|NCT01288430|9823776|FG006|Part 1|Other|1
6175231|NCT01288430|9823777|FG007|Part 1|Other|0
6175232|NCT01288430|9823778|FG008|Part 1|Other|0
6175233|NCT01288430|9823779|FG009|Part 1|Other|0
6175234|NCT01288430|9823770|FG000|Part 2|Progressive disease|0
6175235|NCT01288430|9823771|FG001|Part 2|Progressive disease|0
6175236|NCT01288430|9823772|FG002|Part 2|Progressive disease|0
6175237|NCT01288430|9823773|FG003|Part 2|Progressive disease|0
6175238|NCT01288430|9823774|FG004|Part 2|Progressive disease|0
6175239|NCT01288430|9823775|FG005|Part 2|Progressive disease|0
6175240|NCT01288430|9823776|FG006|Part 2|Progressive disease|0
6175241|NCT01288430|9823777|FG007|Part 2|Progressive disease|8
6175242|NCT01288430|9823778|FG008|Part 2|Progressive disease|7
6175243|NCT01288430|9823779|FG009|Part 2|Progressive disease|2
6175244|NCT01288430|9823770|FG000|Part 2|Clinical disease progression|0
6175245|NCT01288430|9823771|FG001|Part 2|Clinical disease progression|0
6175246|NCT01288430|9823772|FG002|Part 2|Clinical disease progression|0
6175247|NCT01288430|9823773|FG003|Part 2|Clinical disease progression|0
6175248|NCT01288430|9823774|FG004|Part 2|Clinical disease progression|0
6175249|NCT01288430|9823775|FG005|Part 2|Clinical disease progression|0
6175250|NCT01288430|9823776|FG006|Part 2|Clinical disease progression|0
6175251|NCT01288430|9823777|FG007|Part 2|Clinical disease progression|2
6175252|NCT01288430|9823778|FG008|Part 2|Clinical disease progression|0
6175253|NCT01288430|9823779|FG009|Part 2|Clinical disease progression|0
6175254|NCT01288430|9823770|FG000|Part 2|Withdrawal by Subject|0
6175255|NCT01288430|9823771|FG001|Part 2|Withdrawal by Subject|0
6175256|NCT01288430|9823772|FG002|Part 2|Withdrawal by Subject|0
6175257|NCT01288430|9823773|FG003|Part 2|Withdrawal by Subject|0
6175258|NCT01288430|9823774|FG004|Part 2|Withdrawal by Subject|0
6175259|NCT01288430|9823775|FG005|Part 2|Withdrawal by Subject|0
6175260|NCT01288430|9823776|FG006|Part 2|Withdrawal by Subject|0
6175261|NCT01288430|9823777|FG007|Part 2|Withdrawal by Subject|1
6175262|NCT01288430|9823778|FG008|Part 2|Withdrawal by Subject|4
6175263|NCT01288430|9823779|FG009|Part 2|Withdrawal by Subject|0
6175264|NCT01288430|9823770|FG000|Part 2|Adverse Event|0
6175265|NCT01288430|9823771|FG001|Part 2|Adverse Event|0
6175266|NCT01288430|9823772|FG002|Part 2|Adverse Event|0
6175267|NCT01288430|9823773|FG003|Part 2|Adverse Event|0
6175268|NCT01288430|9823774|FG004|Part 2|Adverse Event|0
6175269|NCT01288430|9823775|FG005|Part 2|Adverse Event|0
6175270|NCT01288430|9823776|FG006|Part 2|Adverse Event|0
6175271|NCT01288430|9823777|FG007|Part 2|Adverse Event|1
6175272|NCT01288430|9823778|FG008|Part 2|Adverse Event|1
6175273|NCT01288430|9823779|FG009|Part 2|Adverse Event|0
6175274|NCT01288430|9823770|FG000|Part 2|Other|0
6175275|NCT01288430|9823771|FG001|Part 2|Other|0
6175276|NCT01288430|9823772|FG002|Part 2|Other|0
6175277|NCT01288430|9823773|FG003|Part 2|Other|0
6175278|NCT01288430|9823774|FG004|Part 2|Other|0
6175279|NCT01288430|9823775|FG005|Part 2|Other|0
6175280|NCT01288430|9823776|FG006|Part 2|Other|0
6175281|NCT01288430|9823777|FG007|Part 2|Other|0
6175282|NCT01288430|9823778|FG008|Part 2|Other|0
6175283|NCT01288430|9823779|FG009|Part 2|Other|1
6175284|NCT01288443|9823812|FG000|Overall Study|Adverse Event|0
6175285|NCT01288443|9823813|FG001|Overall Study|Adverse Event|0
6175286|NCT01288443|9823814|FG002|Overall Study|Adverse Event|1
6175287|NCT01288443|9823815|FG003|Overall Study|Adverse Event|1
6175288|NCT01288443|9823816|FG004|Overall Study|Adverse Event|3
6175289|NCT01288443|9823817|FG005|Overall Study|Adverse Event|1
6175290|NCT01288443|9823812|FG000|Overall Study|Poor compliance to protocol|0
6175291|NCT01288443|9823813|FG001|Overall Study|Poor compliance to protocol|0
6175292|NCT01288443|9823814|FG002|Overall Study|Poor compliance to protocol|0
6175293|NCT01288443|9823815|FG003|Overall Study|Poor compliance to protocol|0
6175294|NCT01288443|9823816|FG004|Overall Study|Poor compliance to protocol|0
6175295|NCT01288443|9823817|FG005|Overall Study|Poor compliance to protocol|1
6175296|NCT01288443|9823812|FG000|Overall Study|Participant Moved|0
6175297|NCT01288443|9823813|FG001|Overall Study|Participant Moved|0
6175298|NCT01288443|9823814|FG002|Overall Study|Participant Moved|0
6175299|NCT01288443|9823815|FG003|Overall Study|Participant Moved|1
6175300|NCT01288443|9823816|FG004|Overall Study|Participant Moved|2
6175301|NCT01288443|9823817|FG005|Overall Study|Participant Moved|1
6175302|NCT01288443|9823812|FG000|Overall Study|Consent withdrawn by Participant|0
6175303|NCT01288443|9823813|FG001|Overall Study|Consent withdrawn by Participant|0
6175304|NCT01288443|9823814|FG002|Overall Study|Consent withdrawn by Participant|0
6175305|NCT01288443|9823815|FG003|Overall Study|Consent withdrawn by Participant|0
6175306|NCT01288443|9823816|FG004|Overall Study|Consent withdrawn by Participant|0
6175307|NCT01288443|9823817|FG005|Overall Study|Consent withdrawn by Participant|1
6175308|NCT01288443|9823812|FG000|Overall Study|Lost to Follow-up|0
6175309|NCT01288443|9823813|FG001|Overall Study|Lost to Follow-up|1
6175310|NCT01288443|9823814|FG002|Overall Study|Lost to Follow-up|0
6175311|NCT01288443|9823815|FG003|Overall Study|Lost to Follow-up|0
6175312|NCT01288443|9823816|FG004|Overall Study|Lost to Follow-up|0
6175313|NCT01288443|9823817|FG005|Overall Study|Lost to Follow-up|0
6175314|NCT01288443|9823812|FG000|Overall Study|Study drug auto-injector administration|0
6175315|NCT01288443|9823813|FG001|Overall Study|Study drug auto-injector administration|0
6175316|NCT01288443|9823814|FG002|Overall Study|Study drug auto-injector administration|0
6175317|NCT01288443|9823815|FG003|Overall Study|Study drug auto-injector administration|0
6175318|NCT01288443|9823816|FG004|Overall Study|Study drug auto-injector administration|1
6175319|NCT01288443|9823817|FG005|Overall Study|Study drug auto-injector administration|1
6175320|NCT01288443|9823812|FG000|Overall Study|Other than above|0
6175321|NCT01288443|9823813|FG001|Overall Study|Other than above|0
6175322|NCT01288443|9823814|FG002|Overall Study|Other than above|0
6175323|NCT01288443|9823815|FG003|Overall Study|Other than above|2
6175324|NCT01288443|9823816|FG004|Overall Study|Other than above|1
6175325|NCT01288443|9823817|FG005|Overall Study|Other than above|0
6175326|NCT01288469|9823834|FG000|Overall Study|Adverse Event|4
6175327|NCT01288469|9823835|FG001|Overall Study|Adverse Event|1
6175328|NCT01288469|9823836|FG002|Overall Study|Adverse Event|1
6175329|NCT01288469|9823834|FG000|Overall Study|Poor compliance to protocol|0
6175330|NCT01288469|9823835|FG001|Overall Study|Poor compliance to protocol|1
6175331|NCT01288469|9823836|FG002|Overall Study|Poor compliance to protocol|0
6175332|NCT01288469|9823834|FG000|Overall Study|Participant Moved|1
6175333|NCT01288469|9823835|FG001|Overall Study|Participant Moved|0
6175334|NCT01288469|9823836|FG002|Overall Study|Participant Moved|0
6175335|NCT01288469|9823834|FG000|Overall Study|Consent withdrawn by subject|1
6175336|NCT01288469|9823835|FG001|Overall Study|Consent withdrawn by subject|1
6175337|NCT01288469|9823836|FG002|Overall Study|Consent withdrawn by subject|1
6175338|NCT01288469|9823834|FG000|Overall Study|Exclusion criteria finally met|1
6175339|NCT01288469|9823835|FG001|Overall Study|Exclusion criteria finally met|0
6175340|NCT01288469|9823836|FG002|Overall Study|Exclusion criteria finally met|0
6175341|NCT01288612|9823860|FG000|Overall Study|Unable to contact|11
6175342|NCT01288612|9823861|FG001|Overall Study|Unable to contact|16
6175343|NCT01288612|9823862|FG002|Overall Study|Unable to contact|20
6175344|NCT01288612|9823860|FG000|Overall Study|Declined|78
6175345|NCT01288612|9823861|FG001|Overall Study|Declined|63
6175346|NCT01288612|9823862|FG002|Overall Study|Declined|62
6175347|NCT01288612|9823860|FG000|Overall Study|Unable to intubate|0
6175348|NCT01288612|9823861|FG001|Overall Study|Unable to intubate|3
6175349|NCT01288612|9823862|FG002|Overall Study|Unable to intubate|0
6175350|NCT01288729|9823872|FG000|Overall Study|Withdrawal by Subject|1
6175351|NCT01288729|9823873|FG001|Overall Study|Withdrawal by Subject|0
6175352|NCT01288911|9823928|FG000|Double-blind Period|Death|11
6175353|NCT01288911|9823929|FG001|Double-blind Period|Death|7
6175354|NCT01288911|9823928|FG000|Double-blind Period|Lost to Follow-up|0
6175355|NCT01288911|9823929|FG001|Double-blind Period|Lost to Follow-up|2
6175356|NCT01288911|9823928|FG000|Double-blind Period|Progressive Disease|75
6175357|NCT01288911|9823929|FG001|Double-blind Period|Progressive Disease|103
6175358|NCT01288911|9823928|FG000|Double-blind Period|Protocol Violation|1
6175359|NCT01288911|9823929|FG001|Double-blind Period|Protocol Violation|0
6175360|NCT01288911|9823928|FG000|Double-blind Period|Withdrawal by Subject|25
6175361|NCT01288911|9823929|FG001|Double-blind Period|Withdrawal by Subject|26
6175362|NCT01288911|9823928|FG000|Double-blind Period|Miscellaneous Reason|29
6175363|NCT01288911|9823929|FG001|Double-blind Period|Miscellaneous Reason|42
6175364|NCT01288911|9823928|FG000|Double-blind Period|Randomized but never received study drug|1
6175365|NCT01288911|9823929|FG001|Double-blind Period|Randomized but never received study drug|2
6175366|NCT01288911|9823928|FG000|Open-label Period (All Enzalutamide)|Death|0
6175367|NCT01288911|9823929|FG001|Open-label Period (All Enzalutamide)|Death|1
6175368|NCT01288911|9823928|FG000|Open-label Period (All Enzalutamide)|Lost to Follow-up|1
6175369|NCT01288911|9823929|FG001|Open-label Period (All Enzalutamide)|Lost to Follow-up|0
6175370|NCT01288911|9823928|FG000|Open-label Period (All Enzalutamide)|Progressive disease|18
6175371|NCT01288911|9823929|FG001|Open-label Period (All Enzalutamide)|Progressive disease|3
6175372|NCT01288911|9823928|FG000|Open-label Period (All Enzalutamide)|Withdrawal by Subject|1
6175373|NCT01288911|9823929|FG001|Open-label Period (All Enzalutamide)|Withdrawal by Subject|0
6175374|NCT01288911|9823928|FG000|Open-label Period (All Enzalutamide)|Miscellaneous Reason|5
6175375|NCT01288911|9823929|FG001|Open-label Period (All Enzalutamide)|Miscellaneous Reason|0
6175376|NCT01288911|9823928|FG000|Open-label Period (All Enzalutamide)|Transitioned to 9785-CL-0123 NCT02960022|17
6175377|NCT01288911|9823929|FG001|Open-label Period (All Enzalutamide)|Transitioned to 9785-CL-0123 NCT02960022|5
6175378|NCT01288937|9823940|FG000|Overall Study|Adverse Event|1
6175379|NCT01288937|9823941|FG001|Overall Study|Adverse Event|0
6175380|NCT01288976|9823950|FG000|Overall Study|Withdrawal by Subject|58
6175381|NCT01288976|9823951|FG001|Overall Study|Withdrawal by Subject|12
6175382|NCT01288976|9823952|FG002|Overall Study|Withdrawal by Subject|9
6175383|NCT01288976|9823950|FG000|Overall Study|Death|98
6175384|NCT01288976|9823951|FG001|Overall Study|Death|6
6175385|NCT01288976|9823952|FG002|Overall Study|Death|4
6175386|NCT01288976|9823950|FG000|Overall Study|Data unavailable|22
6175387|NCT01288976|9823951|FG001|Overall Study|Data unavailable|9
6175388|NCT01288976|9823952|FG002|Overall Study|Data unavailable|7
6175389|NCT01288989|9823963|FG000|Overall Study|Death|0
6175390|NCT01288989|9823964|FG001|Overall Study|Death|0
6175391|NCT01288989|9823965|FG002|Overall Study|Death|0
6175392|NCT01288989|9823966|FG003|Overall Study|Death|1
6175393|NCT01288989|9823967|FG004|Overall Study|Death|0
6175394|NCT01288989|9823963|FG000|Overall Study|Dose limiting toxicity|1
6175395|NCT01288989|9823964|FG001|Overall Study|Dose limiting toxicity|0
6175396|NCT01288989|9823965|FG002|Overall Study|Dose limiting toxicity|0
6175397|NCT01288989|9823966|FG003|Overall Study|Dose limiting toxicity|0
6175398|NCT01288989|9823967|FG004|Overall Study|Dose limiting toxicity|0
6175399|NCT01288989|9823963|FG000|Overall Study|Adverse Event|0
6175400|NCT01288989|9823964|FG001|Overall Study|Adverse Event|0
6175401|NCT01288989|9823965|FG002|Overall Study|Adverse Event|0
6175402|NCT01288989|9823966|FG003|Overall Study|Adverse Event|0
6175403|NCT01288989|9823967|FG004|Overall Study|Adverse Event|2
6175404|NCT01288989|9823963|FG000|Overall Study|Physician Decision|0
6175405|NCT01288989|9823964|FG001|Overall Study|Physician Decision|0
6175406|NCT01288989|9823965|FG002|Overall Study|Physician Decision|0
6175407|NCT01288989|9823966|FG003|Overall Study|Physician Decision|0
6175408|NCT01288989|9823967|FG004|Overall Study|Physician Decision|1
6175409|NCT01288989|9823963|FG000|Overall Study|Withdrawal by Subject|0
6175410|NCT01288989|9823964|FG001|Overall Study|Withdrawal by Subject|0
6175411|NCT01288989|9823965|FG002|Overall Study|Withdrawal by Subject|0
6175412|NCT01288989|9823966|FG003|Overall Study|Withdrawal by Subject|0
6175413|NCT01288989|9823967|FG004|Overall Study|Withdrawal by Subject|3
6175414|NCT01289015|9823987|FG000|Overall Study|Protocol Violation|12
6175415|NCT01289015|9823988|FG001|Overall Study|Protocol Violation|9
6175416|NCT01289015|9823987|FG000|Overall Study|Adverse Event|3
6175417|NCT01289015|9823988|FG001|Overall Study|Adverse Event|0
6175418|NCT01289015|9823987|FG000|Overall Study|Lost to Follow-up|33
6175419|NCT01289015|9823988|FG001|Overall Study|Lost to Follow-up|17
6175420|NCT01289015|9823987|FG000|Overall Study|Withdrawal by Subject|17
6175421|NCT01289015|9823988|FG001|Overall Study|Withdrawal by Subject|8
6175422|NCT01289015|9823987|FG000|Overall Study|Disease progression|1
6175423|NCT01289015|9823988|FG001|Overall Study|Disease progression|0
6175424|NCT01289015|9823987|FG000|Overall Study|Negative baseline culture and others|33
6175425|NCT01289015|9823988|FG001|Overall Study|Negative baseline culture and others|20
6175426|NCT01289028|9823994|FG000|Overall Study|Progressive Disease|49
6175427|NCT01289028|9823994|FG000|Overall Study|Adverse Event|14
6175428|NCT01289028|9823994|FG000|Overall Study|Withdrawal by Subject|6
6175429|NCT01289028|9823994|FG000|Overall Study|Death|4
6175430|NCT01289028|9823994|FG000|Overall Study|Lack of Efficacy|2
6175431|NCT01289028|9823994|FG000|Overall Study|No longer required|2
6175432|NCT01289028|9823994|FG000|Overall Study|Lost to Follow-up|2
6175433|NCT01289028|9823994|FG000|Overall Study|New Cancer Therapy|2
6175434|NCT01289028|9823994|FG000|Overall Study|Abnormal Lab Value|1
6175435|NCT01289028|9823994|FG000|Overall Study|Missing reason for discon|1
6175436|NCT01289041|9824000|FG000|Overall Study|Adverse Event|24
6175437|NCT01289041|9824000|FG000|Overall Study|Physician Decision|1
6175438|NCT01289041|9824000|FG000|Overall Study|Progressive Disease|41
6175439|NCT01289041|9824000|FG000|Overall Study|Withdrawal by Subject|3
6175440|NCT01289041|9824000|FG000|Overall Study|Death|1
6175441|NCT01289119|9824026|FG000|Overall Study|Adverse Event|2
6175442|NCT01289119|9824027|FG001|Overall Study|Adverse Event|1
6175443|NCT01289119|9824028|FG002|Overall Study|Adverse Event|0
6175444|NCT01289119|9824029|FG003|Overall Study|Adverse Event|2
6175445|NCT01289119|9824030|FG004|Overall Study|Adverse Event|1
6175446|NCT01289119|9824031|FG005|Overall Study|Adverse Event|0
6175447|NCT01289119|9824026|FG000|Overall Study|Major Protocol Deviation|2
6175448|NCT01289119|9824027|FG001|Overall Study|Major Protocol Deviation|1
6175449|NCT01289119|9824028|FG002|Overall Study|Major Protocol Deviation|3
6175450|NCT01289119|9824029|FG003|Overall Study|Major Protocol Deviation|0
6175451|NCT01289119|9824030|FG004|Overall Study|Major Protocol Deviation|2
6175452|NCT01289119|9824031|FG005|Overall Study|Major Protocol Deviation|1
6175453|NCT01289119|9824026|FG000|Overall Study|Lost to Follow-up|0
6175454|NCT01289119|9824027|FG001|Overall Study|Lost to Follow-up|3
6175455|NCT01289119|9824028|FG002|Overall Study|Lost to Follow-up|0
6175456|NCT01289119|9824029|FG003|Overall Study|Lost to Follow-up|0
6227527|NCT01717326|9900204|FG016|Overall Study|Protocol Violation|0
6175457|NCT01289119|9824030|FG004|Overall Study|Lost to Follow-up|0
6175458|NCT01289119|9824031|FG005|Overall Study|Lost to Follow-up|1
6175459|NCT01289119|9824026|FG000|Overall Study|Withdrawal by Subject|4
6175460|NCT01289119|9824027|FG001|Overall Study|Withdrawal by Subject|2
6175461|NCT01289119|9824028|FG002|Overall Study|Withdrawal by Subject|4
6175462|NCT01289119|9824029|FG003|Overall Study|Withdrawal by Subject|3
6175463|NCT01289119|9824030|FG004|Overall Study|Withdrawal by Subject|1
6175464|NCT01289119|9824031|FG005|Overall Study|Withdrawal by Subject|1
6175465|NCT01289119|9824026|FG000|Overall Study|Pregnancy|0
6175466|NCT01289119|9824027|FG001|Overall Study|Pregnancy|1
6175467|NCT01289119|9824028|FG002|Overall Study|Pregnancy|0
6175468|NCT01289119|9824029|FG003|Overall Study|Pregnancy|0
6175469|NCT01289119|9824030|FG004|Overall Study|Pregnancy|0
6175470|NCT01289119|9824031|FG005|Overall Study|Pregnancy|0
6175471|NCT01289119|9824026|FG000|Overall Study|Lack of Efficacy|0
6175472|NCT01289119|9824027|FG001|Overall Study|Lack of Efficacy|1
6175473|NCT01289119|9824028|FG002|Overall Study|Lack of Efficacy|1
6175474|NCT01289119|9824029|FG003|Overall Study|Lack of Efficacy|1
6175475|NCT01289119|9824030|FG004|Overall Study|Lack of Efficacy|1
6175476|NCT01289119|9824031|FG005|Overall Study|Lack of Efficacy|1
6175477|NCT01289119|9824026|FG000|Overall Study|Other|1
6175478|NCT01289119|9824027|FG001|Overall Study|Other|0
6175479|NCT01289119|9824028|FG002|Overall Study|Other|1
6175480|NCT01289119|9824029|FG003|Overall Study|Other|0
6175481|NCT01289119|9824030|FG004|Overall Study|Other|0
6175482|NCT01289119|9824031|FG005|Overall Study|Other|0
6175483|NCT01289210|9824045|FG000|Overall Study|Adverse Event|1
6175484|NCT01289353|9824070|FG000|Overall Study|Lost to Follow-up|2
6175485|NCT01289418|9824090|FG000|Day 8 Survey|email address invalid|283
6175486|NCT01289418|9824090|FG000|Day 8 Survey|participants did not complete the survey|1935
6175487|NCT01289418|9824090|FG000|Day 29 Survey|email address invalid|283
6175488|NCT01289418|9824090|FG000|Day 29 Survey|participants did not complete the survey|2185
6192453|NCT01431521|9849901|FG000|Overall Study|Withdrawal by Subject|0
6192454|NCT01431521|9849902|FG001|Overall Study|Withdrawal by Subject|0
6192455|NCT01431521|9849903|FG002|Overall Study|Withdrawal by Subject|1
6192456|NCT01431521|9849904|FG003|Overall Study|Withdrawal by Subject|0
6192457|NCT01431534|9849916|FG000|Treatment Phase|Adverse Event|0
6192458|NCT01431534|9849917|FG001|Treatment Phase|Adverse Event|0
6192459|NCT01431534|9849918|FG002|Treatment Phase|Adverse Event|1
6192460|NCT01431534|9849916|FG000|Treatment Phase|Progressive Disease|4
6192461|NCT01431534|9849917|FG001|Treatment Phase|Progressive Disease|3
6192462|NCT01431534|9849918|FG002|Treatment Phase|Progressive Disease|10
6192463|NCT01431638|9849933|FG000|Overall Study|Adverse Event|1
6192464|NCT01431638|9849934|FG001|Overall Study|Adverse Event|3
6192465|NCT01431638|9849935|FG002|Overall Study|Adverse Event|1
6192466|NCT01431638|9849933|FG000|Overall Study|Unsatisfactory therapeutic effect|2
6192467|NCT01431638|9849934|FG001|Overall Study|Unsatisfactory therapeutic effect|2
6192468|NCT01431638|9849935|FG002|Overall Study|Unsatisfactory therapeutic effect|4
6192469|NCT01431638|9849933|FG000|Overall Study|Participants condition no longer requires study drug|0
6192470|NCT01431638|9849934|FG001|Overall Study|Participants condition no longer requires study drug|1
6192471|NCT01431638|9849935|FG002|Overall Study|Participants condition no longer requires study drug|0
6192472|NCT01431638|9849933|FG000|Overall Study|Participant withdrew consent|14
6192473|NCT01431638|9849934|FG001|Overall Study|Participant withdrew consent|5
6192474|NCT01431638|9849935|FG002|Overall Study|Participant withdrew consent|8
6192475|NCT01431638|9849933|FG000|Overall Study|Lost to Follow-up|7
6192476|NCT01431638|9849934|FG001|Overall Study|Lost to Follow-up|9
6192477|NCT01431638|9849935|FG002|Overall Study|Lost to Follow-up|7
6192478|NCT01431638|9849933|FG000|Overall Study|Administrative problems|1
6192479|NCT01431638|9849934|FG001|Overall Study|Administrative problems|4
6192480|NCT01431638|9849935|FG002|Overall Study|Administrative problems|6
6192481|NCT01431638|9849933|FG000|Overall Study|Death|1
6192482|NCT01431638|9849934|FG001|Overall Study|Death|0
6192483|NCT01431638|9849935|FG002|Overall Study|Death|0
6192484|NCT01431638|9849933|FG000|Overall Study|Protocol deviation|1
6192485|NCT01431638|9849934|FG001|Overall Study|Protocol deviation|1
6192486|NCT01431638|9849935|FG002|Overall Study|Protocol deviation|4
6192487|NCT01431638|9849933|FG000|Overall Study|Participants Did not enter extension study from core study|39
6192488|NCT01431638|9849934|FG001|Overall Study|Participants Did not enter extension study from core study|46
6192489|NCT01431638|9849935|FG002|Overall Study|Participants Did not enter extension study from core study|32
6192490|NCT01431716|9849947|FG000|Overall Study|Withdrawal of consent|1
6192491|NCT01431950|9849993|FG000|Overall Study|Study Site Closed/Terminated|7
6192492|NCT01431950|9849994|FG001|Overall Study|Study Site Closed/Terminated|3
6192493|NCT01431950|9849993|FG000|Overall Study|Withdrawal by Subject|4
6192494|NCT01431950|9849994|FG001|Overall Study|Withdrawal by Subject|3
6192495|NCT01431950|9849993|FG000|Overall Study|Protocol Violation|2
6192496|NCT01431950|9849994|FG001|Overall Study|Protocol Violation|3
6192497|NCT01431950|9849993|FG000|Overall Study|Adverse Event|2
6192498|NCT01431950|9849994|FG001|Overall Study|Adverse Event|2
6227528|NCT01717326|9900205|FG017|Overall Study|Protocol Violation|0
6192499|NCT01431950|9849993|FG000|Overall Study|Physician Decision|2
6192500|NCT01431950|9849994|FG001|Overall Study|Physician Decision|1
6192501|NCT01431950|9849993|FG000|Overall Study|Lack of Efficacy|2
6192502|NCT01431950|9849994|FG001|Overall Study|Lack of Efficacy|1
6192503|NCT01431950|9849993|FG000|Overall Study|Lost to Follow-up|0
6192504|NCT01431950|9849994|FG001|Overall Study|Lost to Follow-up|1
6192505|NCT01431950|9849993|FG000|Overall Study|Met Protocol-defined Stopping Criteria|0
6192506|NCT01431950|9849994|FG001|Overall Study|Met Protocol-defined Stopping Criteria|1
6192507|NCT01431963|9850000|FG000|Overall Study|Adverse Event|18
6192508|NCT01431963|9850000|FG000|Overall Study|Lack of Efficacy|7
6192509|NCT01431963|9850000|FG000|Overall Study|Protocol Violation|1
6192510|NCT01431963|9850000|FG000|Overall Study|Protocol-defined Stopping Criteria|2
6192511|NCT01431963|9850000|FG000|Overall Study|Physician Decision|4
6192512|NCT01431963|9850000|FG000|Overall Study|Withdrawal by Subject|3
6192513|NCT01431976|9850004|FG000|Overall Study|Adverse Event|6
6192514|NCT01431976|9850004|FG000|Overall Study|Lack of Efficacy|2
6192515|NCT01431976|9850004|FG000|Overall Study|Met Protocol-defined Stopping Criteria|4
6175489|NCT01289574|9824158|FG000|Overall Study|Lack of Efficacy|4
6175490|NCT01289574|9824159|FG001|Overall Study|Lack of Efficacy|0
6175491|NCT01289574|9824160|FG002|Overall Study|Lack of Efficacy|1
6175492|NCT01289574|9824158|FG000|Overall Study|Lost to Follow-up|2
6175493|NCT01289574|9824159|FG001|Overall Study|Lost to Follow-up|0
6175494|NCT01289574|9824160|FG002|Overall Study|Lost to Follow-up|1
6175495|NCT01289574|9824158|FG000|Overall Study|Withdrawal by Subject|1
6175496|NCT01289574|9824159|FG001|Overall Study|Withdrawal by Subject|1
6175497|NCT01289574|9824160|FG002|Overall Study|Withdrawal by Subject|1
6175498|NCT01289574|9824158|FG000|Overall Study|Adverse Event|0
6175499|NCT01289574|9824159|FG001|Overall Study|Adverse Event|1
6175500|NCT01289574|9824160|FG002|Overall Study|Adverse Event|0
6175501|NCT01289574|9824158|FG000|Overall Study|Subject wanted alternate treatment|0
6175502|NCT01289574|9824159|FG001|Overall Study|Subject wanted alternate treatment|1
6175503|NCT01289574|9824160|FG002|Overall Study|Subject wanted alternate treatment|0
6175504|NCT01289639|9824172|FG000|Overall Study|Lost to Follow-up|1
6175505|NCT01289639|9824173|FG001|Overall Study|Lost to Follow-up|0
6175506|NCT01289639|9824174|FG002|Overall Study|Lost to Follow-up|0
6175507|NCT01289678|9824191|FG000|Overall Study|Physician Decision|6
6175508|NCT01289782|9824197|FG000|Overall Study|Lost to Follow-up|14
6175509|NCT01289782|9824198|FG001|Overall Study|Lost to Follow-up|7
6175510|NCT01289782|9824197|FG000|Overall Study|Protocol Violation|1
6175511|NCT01289782|9824198|FG001|Overall Study|Protocol Violation|1
6175512|NCT01289782|9824197|FG000|Overall Study|Withdrawal by Subject|8
6175513|NCT01289782|9824198|FG001|Overall Study|Withdrawal by Subject|2
6175514|NCT01289782|9824197|FG000|Overall Study|Sponsor's Decision|1
6175515|NCT01289782|9824198|FG001|Overall Study|Sponsor's Decision|0
6175516|NCT01289782|9824197|FG000|Overall Study|Reason not specified|1
6175517|NCT01289782|9824198|FG001|Overall Study|Reason not specified|2
6175518|NCT01289821|9824204|FG000|Treatment Period|Withdrawal by Subject|1
6175519|NCT01289821|9824204|FG000|Treatment Period|Physician Decision|3
6175520|NCT01289821|9824204|FG000|Treatment Period|Adverse Event|4
6175521|NCT01289821|9824204|FG000|Treatment Period|Radiological Progression|43
6175522|NCT01289821|9824204|FG000|Treatment Period|Clinical Progression|2
6175523|NCT01289821|9824204|FG000|Treatment Period|Therapeutic procedure required|1
6175524|NCT01289821|9824204|FG000|Safety Follow-up Period|Withdrawal by Subject|1
6175525|NCT01289821|9824204|FG000|Safety Follow-up Period|Protocol Violation|3
6175526|NCT01289821|9824204|FG000|Safety Follow-up Period|Unspecified reason|1
6175527|NCT01289821|9824204|FG000|Survival Follow-up Period|Protocol Violation|1
6175528|NCT01289821|9824204|FG000|Survival Follow-up Period|Lost to Follow-up|1
6175529|NCT01289821|9824204|FG000|Survival Follow-up Period|Clinical endpoint reached|16
6175530|NCT01289847|9824208|FG000|Overall Study|Patient could not comply with visits|1
6175531|NCT01289990|9824244|FG000|Overall Study|Death|0
6175532|NCT01289990|9824245|FG001|Overall Study|Death|0
6175533|NCT01289990|9824246|FG002|Overall Study|Death|0
6175534|NCT01289990|9824247|FG003|Overall Study|Death|1
6175535|NCT01289990|9824248|FG004|Overall Study|Death|2
6175536|NCT01289990|9824249|FG005|Overall Study|Death|1
6175537|NCT01289990|9824250|FG006|Overall Study|Death|0
6175538|NCT01289990|9824251|FG007|Overall Study|Death|0
6175539|NCT01289990|9824252|FG008|Overall Study|Death|0
6175540|NCT01289990|9824253|FG009|Overall Study|Death|0
6175541|NCT01289990|9824254|FG010|Overall Study|Death|0
6175542|NCT01289990|9824255|FG011|Overall Study|Death|1
6175543|NCT01289990|9824256|FG012|Overall Study|Death|0
6175544|NCT01289990|9824244|FG000|Overall Study|Lost to Follow-up|3
6175545|NCT01289990|9824245|FG001|Overall Study|Lost to Follow-up|2
6175546|NCT01289990|9824246|FG002|Overall Study|Lost to Follow-up|5
6175547|NCT01289990|9824247|FG003|Overall Study|Lost to Follow-up|5
6175548|NCT01289990|9824248|FG004|Overall Study|Lost to Follow-up|3
6175549|NCT01289990|9824249|FG005|Overall Study|Lost to Follow-up|4
6175550|NCT01289990|9824250|FG006|Overall Study|Lost to Follow-up|2
6175551|NCT01289990|9824251|FG007|Overall Study|Lost to Follow-up|2
6175552|NCT01289990|9824252|FG008|Overall Study|Lost to Follow-up|1
6175553|NCT01289990|9824253|FG009|Overall Study|Lost to Follow-up|4
6175554|NCT01289990|9824254|FG010|Overall Study|Lost to Follow-up|2
6175555|NCT01289990|9824255|FG011|Overall Study|Lost to Follow-up|1
6175556|NCT01289990|9824256|FG012|Overall Study|Lost to Follow-up|2
6175557|NCT01289990|9824244|FG000|Overall Study|Withdrawal by Subject|15
6175558|NCT01289990|9824245|FG001|Overall Study|Withdrawal by Subject|14
6175559|NCT01289990|9824246|FG002|Overall Study|Withdrawal by Subject|12
6175560|NCT01289990|9824247|FG003|Overall Study|Withdrawal by Subject|13
6175561|NCT01289990|9824248|FG004|Overall Study|Withdrawal by Subject|8
6175562|NCT01289990|9824249|FG005|Overall Study|Withdrawal by Subject|7
6175563|NCT01289990|9824250|FG006|Overall Study|Withdrawal by Subject|13
6175564|NCT01289990|9824251|FG007|Overall Study|Withdrawal by Subject|9
6175565|NCT01289990|9824252|FG008|Overall Study|Withdrawal by Subject|12
6175566|NCT01289990|9824253|FG009|Overall Study|Withdrawal by Subject|13
6175567|NCT01289990|9824254|FG010|Overall Study|Withdrawal by Subject|11
6175568|NCT01289990|9824255|FG011|Overall Study|Withdrawal by Subject|13
6175569|NCT01289990|9824256|FG012|Overall Study|Withdrawal by Subject|16
6175570|NCT01289990|9824244|FG000|Overall Study|discontinued in preceding trial|18
6175571|NCT01289990|9824245|FG001|Overall Study|discontinued in preceding trial|20
6175572|NCT01289990|9824246|FG002|Overall Study|discontinued in preceding trial|41
6175573|NCT01289990|9824247|FG003|Overall Study|discontinued in preceding trial|17
6175574|NCT01289990|9824248|FG004|Overall Study|discontinued in preceding trial|11
6175575|NCT01289990|9824249|FG005|Overall Study|discontinued in preceding trial|12
6175576|NCT01289990|9824250|FG006|Overall Study|discontinued in preceding trial|18
6175577|NCT01289990|9824251|FG007|Overall Study|discontinued in preceding trial|8
6175578|NCT01289990|9824252|FG008|Overall Study|discontinued in preceding trial|17
6175579|NCT01289990|9824253|FG009|Overall Study|discontinued in preceding trial|21
6175580|NCT01289990|9824254|FG010|Overall Study|discontinued in preceding trial|17
6175581|NCT01289990|9824255|FG011|Overall Study|discontinued in preceding trial|17
6175582|NCT01289990|9824256|FG012|Overall Study|discontinued in preceding trial|24
6175583|NCT01289990|9824244|FG000|Overall Study|did not continue in extension|41
6175584|NCT01289990|9824245|FG001|Overall Study|did not continue in extension|45
6175585|NCT01289990|9824246|FG002|Overall Study|did not continue in extension|51
6175586|NCT01289990|9824247|FG003|Overall Study|did not continue in extension|51
6175587|NCT01289990|9824248|FG004|Overall Study|did not continue in extension|48
6175588|NCT01289990|9824249|FG005|Overall Study|did not continue in extension|50
6175589|NCT01289990|9824250|FG006|Overall Study|did not continue in extension|54
6175590|NCT01289990|9824251|FG007|Overall Study|did not continue in extension|36
6175591|NCT01289990|9824252|FG008|Overall Study|did not continue in extension|44
6175592|NCT01289990|9824253|FG009|Overall Study|did not continue in extension|48
6175593|NCT01289990|9824254|FG010|Overall Study|did not continue in extension|45
6175594|NCT01289990|9824255|FG011|Overall Study|did not continue in extension|34
6175595|NCT01289990|9824256|FG012|Overall Study|did not continue in extension|56
6175596|NCT01289990|9824244|FG000|Overall Study|Not treated|0
6175597|NCT01289990|9824245|FG001|Overall Study|Not treated|0
6175598|NCT01289990|9824246|FG002|Overall Study|Not treated|0
6175599|NCT01289990|9824247|FG003|Overall Study|Not treated|0
6175600|NCT01289990|9824248|FG004|Overall Study|Not treated|0
6175601|NCT01289990|9824249|FG005|Overall Study|Not treated|0
6175602|NCT01289990|9824250|FG006|Overall Study|Not treated|1
6175603|NCT01289990|9824251|FG007|Overall Study|Not treated|0
6175604|NCT01289990|9824252|FG008|Overall Study|Not treated|1
6175605|NCT01289990|9824253|FG009|Overall Study|Not treated|0
6175606|NCT01289990|9824254|FG010|Overall Study|Not treated|1
6175607|NCT01289990|9824255|FG011|Overall Study|Not treated|2
6175608|NCT01289990|9824256|FG012|Overall Study|Not treated|0
6175609|NCT01290029|9824284|FG000|Overall Study|Other|2
6175610|NCT01290068|9824290|FG000|Overall Study|Adverse Event|1
6085015|NCT00647296|9694084|FG000|Part 2: 76-week Double-Blind Treatment|Death|0
6085016|NCT00647296|9694085|FG001|Part 2: 76-week Double-Blind Treatment|Death|7
6085017|NCT00647296|9694086|FG002|Part 2: 76-week Double-Blind Treatment|Death|0
6085018|NCT00647296|9694087|FG003|Part 2: 76-week Double-Blind Treatment|Death|5
6085019|NCT00647296|9694084|FG000|Part 2: 76-week Double-Blind Treatment|Inability to attend study visits in person|0
6085020|NCT00647296|9694085|FG001|Part 2: 76-week Double-Blind Treatment|Inability to attend study visits in person|1
6085021|NCT00647296|9694086|FG002|Part 2: 76-week Double-Blind Treatment|Inability to attend study visits in person|0
6085022|NCT00647296|9694087|FG003|Part 2: 76-week Double-Blind Treatment|Inability to attend study visits in person|1
6085023|NCT00647348|9694111|FG000|Overall Study|Lost to Follow-up|3
6175611|NCT01290068|9824291|FG001|Overall Study|Adverse Event|3
6175612|NCT01290068|9824290|FG000|Overall Study|Lost to Follow-up|3
6175613|NCT01290068|9824291|FG001|Overall Study|Lost to Follow-up|0
6175614|NCT01290068|9824290|FG000|Overall Study|Withdrawal by subject prior to implant|0
6175615|NCT01290068|9824291|FG001|Overall Study|Withdrawal by subject prior to implant|2
6175616|NCT01290068|9824290|FG000|Overall Study|Other|3
6175617|NCT01290068|9824291|FG001|Overall Study|Other|1
6175618|NCT01290094|9824297|FG000|Overall Study|Withdrawal by Subject|1
6175619|NCT01290094|9824297|FG000|Overall Study|Lost to Follow-up|5
6175620|NCT01290224|9824301|FG000|Overall Study|Adverse Event|1
6175621|NCT01290224|9824301|FG000|Overall Study|Refused Further Treatment|4
6175622|NCT01290263|9824320|FG000|Overall Study|Adverse Event|0
6175623|NCT01290263|9824321|FG001|Overall Study|Adverse Event|0
6175624|NCT01290263|9824322|FG002|Overall Study|Adverse Event|0
6175625|NCT01290263|9824323|FG003|Overall Study|Adverse Event|1
6175626|NCT01290263|9824324|FG004|Overall Study|Adverse Event|1
6175627|NCT01290263|9824320|FG000|Overall Study|Lack of Efficacy|8
6175628|NCT01290263|9824321|FG001|Overall Study|Lack of Efficacy|2
6175629|NCT01290263|9824322|FG002|Overall Study|Lack of Efficacy|7
6175630|NCT01290263|9824323|FG003|Overall Study|Lack of Efficacy|24
6175631|NCT01290263|9824324|FG004|Overall Study|Lack of Efficacy|33
6175632|NCT01290263|9824320|FG000|Overall Study|Withdrawal by Subject|3
6175633|NCT01290263|9824321|FG001|Overall Study|Withdrawal by Subject|1
6175634|NCT01290263|9824322|FG002|Overall Study|Withdrawal by Subject|0
6227529|NCT01717326|9900206|FG018|Overall Study|Protocol Violation|0
6175635|NCT01290263|9824323|FG003|Overall Study|Withdrawal by Subject|1
6175636|NCT01290263|9824324|FG004|Overall Study|Withdrawal by Subject|2
6175637|NCT01290263|9824320|FG000|Overall Study|Participant Non-Compliance|0
6175638|NCT01290263|9824321|FG001|Overall Study|Participant Non-Compliance|0
6175639|NCT01290263|9824322|FG002|Overall Study|Participant Non-Compliance|0
6175640|NCT01290263|9824323|FG003|Overall Study|Participant Non-Compliance|1
6175641|NCT01290263|9824324|FG004|Overall Study|Participant Non-Compliance|1
6175642|NCT01290315|9824336|FG000|Overall Study|Adverse Event|0
6175643|NCT01290315|9824337|FG001|Overall Study|Adverse Event|0
6175644|NCT01290315|9824338|FG002|Overall Study|Adverse Event|0
6175645|NCT01290315|9824339|FG003|Overall Study|Adverse Event|3
6175646|NCT01290315|9824336|FG000|Overall Study|Selection criteria/compliance|2
6175647|NCT01290315|9824337|FG001|Overall Study|Selection criteria/compliance|1
6175648|NCT01290315|9824338|FG002|Overall Study|Selection criteria/compliance|0
6175649|NCT01290315|9824339|FG003|Overall Study|Selection criteria/compliance|2
6175650|NCT01290315|9824336|FG000|Overall Study|Lost to Follow-up|0
6175651|NCT01290315|9824337|FG001|Overall Study|Lost to Follow-up|1
6175652|NCT01290315|9824338|FG002|Overall Study|Lost to Follow-up|0
6175653|NCT01290315|9824339|FG003|Overall Study|Lost to Follow-up|0
6175654|NCT01290315|9824336|FG000|Overall Study|Withdrawal by Subject|1
6175655|NCT01290315|9824337|FG001|Overall Study|Withdrawal by Subject|1
6175656|NCT01290315|9824338|FG002|Overall Study|Withdrawal by Subject|0
6175657|NCT01290315|9824339|FG003|Overall Study|Withdrawal by Subject|0
6175658|NCT01290341|9824350|FG000|Overall Study|Protocol Violation|7
6175659|NCT01290341|9824351|FG001|Overall Study|Protocol Violation|3
6175660|NCT01290341|9824350|FG000|Overall Study|Adverse Event|1
6175661|NCT01290341|9824351|FG001|Overall Study|Adverse Event|0
6175662|NCT01290341|9824350|FG000|Overall Study|Lost to Follow-up|21
6175663|NCT01290341|9824351|FG001|Overall Study|Lost to Follow-up|10
6175664|NCT01290341|9824350|FG000|Overall Study|Withdrawal by Subject|19
6175665|NCT01290341|9824351|FG001|Overall Study|Withdrawal by Subject|5
6175666|NCT01290341|9824350|FG000|Overall Study|Negative baseline culture and others|44
6175667|NCT01290341|9824351|FG001|Overall Study|Negative baseline culture and others|11
6175668|NCT01290523|9824374|FG000|Overall Study|Death|3
6175669|NCT01290601|9824387|FG000|Overall Study|Adverse Event|0
6175670|NCT01290601|9824388|FG001|Overall Study|Adverse Event|2
6175671|NCT01290601|9824389|FG002|Overall Study|Adverse Event|0
6175672|NCT01290601|9824390|FG003|Overall Study|Adverse Event|0
6175673|NCT01290601|9824387|FG000|Overall Study|Lack of Efficacy|2
6175674|NCT01290601|9824388|FG001|Overall Study|Lack of Efficacy|1
6175675|NCT01290601|9824389|FG002|Overall Study|Lack of Efficacy|0
6175676|NCT01290601|9824390|FG003|Overall Study|Lack of Efficacy|0
6175677|NCT01290601|9824387|FG000|Overall Study|Lost to Follow-up|7
6175678|NCT01290601|9824388|FG001|Overall Study|Lost to Follow-up|2
6175679|NCT01290601|9824389|FG002|Overall Study|Lost to Follow-up|0
6175680|NCT01290601|9824390|FG003|Overall Study|Lost to Follow-up|0
6175681|NCT01290601|9824387|FG000|Overall Study|Other|1
6175682|NCT01290601|9824388|FG001|Overall Study|Other|0
6175683|NCT01290601|9824389|FG002|Overall Study|Other|0
6175684|NCT01290601|9824390|FG003|Overall Study|Other|0
6175685|NCT01290601|9824387|FG000|Overall Study|Protocol Violation|1
6175686|NCT01290601|9824388|FG001|Overall Study|Protocol Violation|0
6175687|NCT01290601|9824389|FG002|Overall Study|Protocol Violation|0
6175688|NCT01290601|9824390|FG003|Overall Study|Protocol Violation|0
6175689|NCT01290666|9824427|FG000|Overall Study|Lost to Follow-up|11
6175690|NCT01290666|9824427|FG000|Overall Study|Withdrawal by Subject|23
6175691|NCT01290666|9824427|FG000|Overall Study|Early Termination of Study|4
6175692|NCT01290679|9824433|FG000|Overall Study|Adverse Event|2
6175693|NCT01290679|9824434|FG001|Overall Study|Adverse Event|0
6175694|NCT01290679|9824433|FG000|Overall Study|Lost to Follow-up|8
6175695|NCT01290679|9824434|FG001|Overall Study|Lost to Follow-up|10
6175696|NCT01290679|9824433|FG000|Overall Study|Protocol Violation|0
6175697|NCT01290679|9824434|FG001|Overall Study|Protocol Violation|1
6175698|NCT01290679|9824433|FG000|Overall Study|Withdrawal by Subject|6
6175699|NCT01290679|9824434|FG001|Overall Study|Withdrawal by Subject|5
6175700|NCT01290679|9824433|FG000|Overall Study|Subject Entered Another Trial|0
6175701|NCT01290679|9824434|FG001|Overall Study|Subject Entered Another Trial|5
6175702|NCT01290731|9824440|FG000|Overall Study|Withdrawal by Subject|1
6175703|NCT01290757|9824446|FG000|Overall Study|Adverse Event|1
6175704|NCT01290757|9824447|FG001|Overall Study|Adverse Event|0
6175705|NCT01290757|9824446|FG000|Overall Study|Protocol Violation|1
6175706|NCT01290757|9824447|FG001|Overall Study|Protocol Violation|1
6175707|NCT01290757|9824446|FG000|Overall Study|Other|0
6175708|NCT01290757|9824447|FG001|Overall Study|Other|1
6175709|NCT01290796|9824453|FG000|Overall Study|Lost to Follow-up|21
6175710|NCT01290796|9824453|FG000|Overall Study|Withdrawal by Subject|4
6175711|NCT01290796|9824453|FG000|Overall Study|Physician Decision|2
6175712|NCT01290796|9824453|FG000|Overall Study|Secondary Surgical Intervention|2
6175713|NCT01290796|9824453|FG000|Overall Study|Withdrawal by Sponsor|1
6175714|NCT01290887|9824469|FG000|Overall Study|Adverse Event|6
6175715|NCT01290887|9824470|FG001|Overall Study|Adverse Event|11
6175716|NCT01290887|9824469|FG000|Overall Study|Lack of Efficacy|4
6175717|NCT01290887|9824470|FG001|Overall Study|Lack of Efficacy|5
6175718|NCT01290887|9824469|FG000|Overall Study|Withdrawal by Subject|26
6175719|NCT01290887|9824470|FG001|Overall Study|Withdrawal by Subject|32
6175720|NCT01290887|9824469|FG000|Overall Study|Protocol Violation|2
6175721|NCT01290887|9824470|FG001|Overall Study|Protocol Violation|1
6175722|NCT01290887|9824469|FG000|Overall Study|Lost to Follow-up|4
6175723|NCT01290887|9824470|FG001|Overall Study|Lost to Follow-up|4
6175724|NCT01290887|9824469|FG000|Overall Study|Non-compliance to study procedures|0
6175725|NCT01290887|9824470|FG001|Overall Study|Non-compliance to study procedures|1
6175726|NCT01290887|9824469|FG000|Overall Study|Non-compliance to study medications|1
6175727|NCT01290887|9824470|FG001|Overall Study|Non-compliance to study medications|0
6175728|NCT01290887|9824469|FG000|Overall Study|Sponsor closure of study|420
6175729|NCT01290887|9824470|FG001|Overall Study|Sponsor closure of study|476
6175730|NCT01290887|9824469|FG000|Overall Study|Other|3
6175731|NCT01290887|9824470|FG001|Overall Study|Other|6
6175732|NCT01291017|9824496|FG000|Overall Study|Lost to Follow-up|2
6175733|NCT01291017|9824496|FG000|Overall Study|Withdrawal by Subject|3
6175734|NCT01291173|9824542|FG000|Overall Study|Adverse Event|0
6085024|NCT00647348|9694112|FG001|Overall Study|Lost to Follow-up|6
6085025|NCT00647556|9694129|FG000|Overall Study|Adverse Event|0
6085026|NCT00647556|9694130|FG001|Overall Study|Adverse Event|1
6085027|NCT00647556|9694129|FG000|Overall Study|Lost to Follow-up|1
6085028|NCT00647556|9694130|FG001|Overall Study|Lost to Follow-up|0
6085029|NCT00647556|9694129|FG000|Overall Study|Protocol Violation|0
6085030|NCT00647556|9694130|FG001|Overall Study|Protocol Violation|1
6085031|NCT00647556|9694129|FG000|Overall Study|Withdrawal by Subject|1
6085032|NCT00647556|9694130|FG001|Overall Study|Withdrawal by Subject|0
6085033|NCT00647556|9694129|FG000|Overall Study|Surgery for pre-existing neck pain|1
6085034|NCT00647556|9694130|FG001|Overall Study|Surgery for pre-existing neck pain|0
6085035|NCT00647699|9694138|FG000|Overall Study|Lost to Follow-up|5
6085036|NCT00647699|9694139|FG001|Overall Study|Lost to Follow-up|4
6085037|NCT00647699|9694138|FG000|Overall Study|Withdrawal by Subject|3
6085038|NCT00647699|9694139|FG001|Overall Study|Withdrawal by Subject|8
6085039|NCT00648037|9694156|FG000|Overall Study|Not Treated|1
6085040|NCT00648037|9694156|FG000|Overall Study|Withdrawal by Subject|1
6085041|NCT00648037|9694156|FG000|Overall Study|Adverse Event|11
6085042|NCT00648037|9694156|FG000|Overall Study|Relapse|2
6085043|NCT00648037|9694156|FG000|Overall Study|Other|1
6085044|NCT00648167|9694173|FG000|Overall Study|Adverse Event|6
6175735|NCT01291173|9824543|FG001|Overall Study|Adverse Event|3
6175736|NCT01291173|9824544|FG002|Overall Study|Adverse Event|1
6175737|NCT01291173|9824545|FG003|Overall Study|Adverse Event|3
6175738|NCT01291173|9824542|FG000|Overall Study|Protocol Violation|7
6175739|NCT01291173|9824543|FG001|Overall Study|Protocol Violation|2
6175740|NCT01291173|9824544|FG002|Overall Study|Protocol Violation|2
6175741|NCT01291173|9824545|FG003|Overall Study|Protocol Violation|5
6175742|NCT01291173|9824542|FG000|Overall Study|Withdrawal by Subject|6
6175743|NCT01291173|9824543|FG001|Overall Study|Withdrawal by Subject|4
6175744|NCT01291173|9824544|FG002|Overall Study|Withdrawal by Subject|4
6175745|NCT01291173|9824545|FG003|Overall Study|Withdrawal by Subject|2
6175746|NCT01291173|9824542|FG000|Overall Study|Lost to Follow-up|4
6175747|NCT01291173|9824543|FG001|Overall Study|Lost to Follow-up|6
6175748|NCT01291173|9824544|FG002|Overall Study|Lost to Follow-up|3
6175749|NCT01291173|9824545|FG003|Overall Study|Lost to Follow-up|2
6175750|NCT01291173|9824542|FG000|Overall Study|Unable to meet visit schedule|0
6175751|NCT01291173|9824543|FG001|Overall Study|Unable to meet visit schedule|0
6175752|NCT01291173|9824544|FG002|Overall Study|Unable to meet visit schedule|1
6175753|NCT01291173|9824545|FG003|Overall Study|Unable to meet visit schedule|0
6175754|NCT01291173|9824542|FG000|Overall Study|Lack of compliance|0
6175755|NCT01291173|9824543|FG001|Overall Study|Lack of compliance|0
6175756|NCT01291173|9824544|FG002|Overall Study|Lack of compliance|0
6175757|NCT01291173|9824545|FG003|Overall Study|Lack of compliance|1
6175758|NCT01291173|9824542|FG000|Overall Study|Subject was unblinded|0
6175759|NCT01291173|9824543|FG001|Overall Study|Subject was unblinded|0
6175760|NCT01291173|9824544|FG002|Overall Study|Subject was unblinded|1
6175761|NCT01291173|9824545|FG003|Overall Study|Subject was unblinded|0
6175762|NCT01291173|9824542|FG000|Overall Study|Excluded therapy|0
6175763|NCT01291173|9824543|FG001|Overall Study|Excluded therapy|0
6175764|NCT01291173|9824544|FG002|Overall Study|Excluded therapy|1
6175765|NCT01291173|9824545|FG003|Overall Study|Excluded therapy|0
6175766|NCT01291225|9824557|FG000|Overall Study|Lost to Follow-up|85
6175767|NCT01291225|9824558|FG001|Overall Study|Lost to Follow-up|39
6175768|NCT01291277|9824574|FG000|Overall Study|Death|2
6175769|NCT01291277|9824575|FG001|Overall Study|Death|2
6175770|NCT01291277|9824574|FG000|Overall Study|Lost to Follow-up|3
6175771|NCT01291277|9824575|FG001|Overall Study|Lost to Follow-up|1
6175772|NCT01292057|9824615|FG000|Overall Study|Protocol Violation|1
6175773|NCT01292057|9824616|FG001|Overall Study|Protocol Violation|1
6175774|NCT01292057|9824615|FG000|Overall Study|Lost to Follow-up|1
6175775|NCT01292057|9824616|FG001|Overall Study|Lost to Follow-up|1
6175776|NCT01292187|9824635|FG000|Overall Study|Adverse Event|10
6227530|NCT01717326|9900207|FG019|Overall Study|Protocol Violation|0
6085045|NCT00648167|9694173|FG000|Overall Study|unable to swallow tablets|1
6085046|NCT00648739|9694299|FG000|Overall Study|Adverse Event|1
6085047|NCT00648739|9694300|FG001|Overall Study|Adverse Event|0
6085048|NCT00648739|9694301|FG002|Overall Study|Adverse Event|1
6085049|NCT00648739|9694302|FG003|Overall Study|Adverse Event|2
6085050|NCT00648739|9694303|FG004|Overall Study|Adverse Event|1
6175777|NCT01292187|9824636|FG001|Overall Study|Adverse Event|5
6175778|NCT01292187|9824635|FG000|Overall Study|Withdrawal by Subject|6
6085051|NCT00648739|9694304|FG005|Overall Study|Adverse Event|0
6085052|NCT00648739|9694305|FG006|Overall Study|Adverse Event|0
6175779|NCT01292187|9824636|FG001|Overall Study|Withdrawal by Subject|5
6175780|NCT01292187|9824635|FG000|Overall Study|All other reasons|1
6175781|NCT01292187|9824636|FG001|Overall Study|All other reasons|3
6175782|NCT01292226|9824643|FG000|Overall Study|Adverse Event|5
6175783|NCT01292226|9824643|FG000|Overall Study|Death|1
6175784|NCT01292226|9824643|FG000|Overall Study|Graft loss|1
6175785|NCT01292226|9824643|FG000|Overall Study|Protocol Violation|3
6175786|NCT01292226|9824643|FG000|Overall Study|Withdrawal by Subject|1
6175787|NCT01292226|9824643|FG000|Overall Study|Other|2
6175788|NCT01292239|9824649|FG000|Overall Study|Other|1
6175789|NCT01292239|9824650|FG001|Overall Study|Other|1
6175790|NCT01292239|9824649|FG000|Overall Study|Withdrawal by Subject|3
6175791|NCT01292239|9824650|FG001|Overall Study|Withdrawal by Subject|6
6175792|NCT01292473|9824682|FG000|Overall Study|Adverse Event|1
6175793|NCT01292473|9824683|FG001|Overall Study|Adverse Event|0
6175794|NCT01292473|9824684|FG002|Overall Study|Adverse Event|1
6175795|NCT01292473|9824685|FG003|Overall Study|Adverse Event|1
6175796|NCT01292473|9824682|FG000|Overall Study|Lost to Follow-up|1
6175797|NCT01292473|9824683|FG001|Overall Study|Lost to Follow-up|1
6175798|NCT01292473|9824684|FG002|Overall Study|Lost to Follow-up|2
6175799|NCT01292473|9824685|FG003|Overall Study|Lost to Follow-up|2
6175800|NCT01292473|9824682|FG000|Overall Study|Withdrawal by Subject|3
6175801|NCT01292473|9824683|FG001|Overall Study|Withdrawal by Subject|4
6175802|NCT01292473|9824684|FG002|Overall Study|Withdrawal by Subject|3
6175803|NCT01292473|9824685|FG003|Overall Study|Withdrawal by Subject|3
6175804|NCT01292473|9824682|FG000|Overall Study|Physician Decision|0
6175805|NCT01292473|9824683|FG001|Overall Study|Physician Decision|1
6175806|NCT01292473|9824684|FG002|Overall Study|Physician Decision|0
6175807|NCT01292473|9824685|FG003|Overall Study|Physician Decision|0
6175808|NCT01292473|9824682|FG000|Overall Study|Disease Progression|0
6175809|NCT01292473|9824683|FG001|Overall Study|Disease Progression|1
6175810|NCT01292473|9824684|FG002|Overall Study|Disease Progression|3
6175811|NCT01292473|9824685|FG003|Overall Study|Disease Progression|6
6175812|NCT01292486|9824699|FG000|Overall Study|Protocol Violation|2
6175813|NCT01292486|9824699|FG000|Overall Study|Did not meet screening criteria|2
6175814|NCT01292486|9824699|FG000|Overall Study|Adverse Event|1
6175815|NCT01292486|9824699|FG000|Overall Study|Physician Decision|1
6175816|NCT01292603|9824718|FG000|Part 1: Pilot Dose Selection Period|Adverse Event|0
6175817|NCT01292603|9824719|FG001|Part 1: Pilot Dose Selection Period|Adverse Event|0
6175818|NCT01292603|9824720|FG002|Part 1: Pilot Dose Selection Period|Adverse Event|0
6175819|NCT01292603|9824721|FG003|Part 1: Pilot Dose Selection Period|Adverse Event|4
6175820|NCT01292603|9824722|FG004|Part 1: Pilot Dose Selection Period|Adverse Event|0
6175821|NCT01292603|9824723|FG005|Part 1: Pilot Dose Selection Period|Adverse Event|0
6175822|NCT01292603|9824718|FG000|Part 1: Pilot Dose Selection Period|Death|0
6175823|NCT01292603|9824719|FG001|Part 1: Pilot Dose Selection Period|Death|0
6175824|NCT01292603|9824720|FG002|Part 1: Pilot Dose Selection Period|Death|0
6175825|NCT01292603|9824721|FG003|Part 1: Pilot Dose Selection Period|Death|1
6175826|NCT01292603|9824722|FG004|Part 1: Pilot Dose Selection Period|Death|0
6175827|NCT01292603|9824723|FG005|Part 1: Pilot Dose Selection Period|Death|0
6175828|NCT01292603|9824718|FG000|Part 1: Pilot Dose Selection Period|Protocol Violation|0
6175829|NCT01292603|9824719|FG001|Part 1: Pilot Dose Selection Period|Protocol Violation|0
6175830|NCT01292603|9824720|FG002|Part 1: Pilot Dose Selection Period|Protocol Violation|0
6175831|NCT01292603|9824721|FG003|Part 1: Pilot Dose Selection Period|Protocol Violation|2
6175832|NCT01292603|9824722|FG004|Part 1: Pilot Dose Selection Period|Protocol Violation|0
6175833|NCT01292603|9824723|FG005|Part 1: Pilot Dose Selection Period|Protocol Violation|0
6175834|NCT01292603|9824718|FG000|Part 1: Pilot Dose Selection Period|Withdrawal by Subject|0
6175835|NCT01292603|9824719|FG001|Part 1: Pilot Dose Selection Period|Withdrawal by Subject|0
6175836|NCT01292603|9824720|FG002|Part 1: Pilot Dose Selection Period|Withdrawal by Subject|0
6175837|NCT01292603|9824721|FG003|Part 1: Pilot Dose Selection Period|Withdrawal by Subject|1
6175838|NCT01292603|9824722|FG004|Part 1: Pilot Dose Selection Period|Withdrawal by Subject|0
6175839|NCT01292603|9824723|FG005|Part 1: Pilot Dose Selection Period|Withdrawal by Subject|0
6175840|NCT01292603|9824718|FG000|Part 1: Regular Follow-Up Period|Death|3
6175841|NCT01292603|9824719|FG001|Part 1: Regular Follow-Up Period|Death|1
6175842|NCT01292603|9824720|FG002|Part 1: Regular Follow-Up Period|Death|3
6175843|NCT01292603|9824721|FG003|Part 1: Regular Follow-Up Period|Death|1
6175844|NCT01292603|9824722|FG004|Part 1: Regular Follow-Up Period|Death|0
6175845|NCT01292603|9824723|FG005|Part 1: Regular Follow-Up Period|Death|0
6175846|NCT01292603|9824718|FG000|Part 1: Regular Follow-Up Period|Disease Progression|3
6175847|NCT01292603|9824719|FG001|Part 1: Regular Follow-Up Period|Disease Progression|6
6175848|NCT01292603|9824720|FG002|Part 1: Regular Follow-Up Period|Disease Progression|3
6175849|NCT01292603|9824721|FG003|Part 1: Regular Follow-Up Period|Disease Progression|0
6175850|NCT01292603|9824722|FG004|Part 1: Regular Follow-Up Period|Disease Progression|0
6175851|NCT01292603|9824723|FG005|Part 1: Regular Follow-Up Period|Disease Progression|0
6175852|NCT01292603|9824718|FG000|Part 2: Dose Confirmation Period|Death|0
6175853|NCT01292603|9824719|FG001|Part 2: Dose Confirmation Period|Death|0
6175854|NCT01292603|9824720|FG002|Part 2: Dose Confirmation Period|Death|0
6175855|NCT01292603|9824721|FG003|Part 2: Dose Confirmation Period|Death|0
6175856|NCT01292603|9824722|FG004|Part 2: Dose Confirmation Period|Death|1
6175857|NCT01292603|9824723|FG005|Part 2: Dose Confirmation Period|Death|0
6175858|NCT01292603|9824718|FG000|Part 2: Dose Confirmation Period|Physician Decision|0
6175859|NCT01292603|9824719|FG001|Part 2: Dose Confirmation Period|Physician Decision|0
6175860|NCT01292603|9824720|FG002|Part 2: Dose Confirmation Period|Physician Decision|0
6175861|NCT01292603|9824721|FG003|Part 2: Dose Confirmation Period|Physician Decision|0
6175862|NCT01292603|9824722|FG004|Part 2: Dose Confirmation Period|Physician Decision|2
6192516|NCT01431976|9850004|FG000|Overall Study|Physician Decision|1
6175863|NCT01292603|9824723|FG005|Part 2: Dose Confirmation Period|Physician Decision|0
6175864|NCT01292603|9824718|FG000|Part 2: Dose Confirmation Period|Withdrawn Prior to Treatment|0
6175865|NCT01292603|9824719|FG001|Part 2: Dose Confirmation Period|Withdrawn Prior to Treatment|0
6175866|NCT01292603|9824720|FG002|Part 2: Dose Confirmation Period|Withdrawn Prior to Treatment|0
6175867|NCT01292603|9824721|FG003|Part 2: Dose Confirmation Period|Withdrawn Prior to Treatment|0
6175868|NCT01292603|9824722|FG004|Part 2: Dose Confirmation Period|Withdrawn Prior to Treatment|1
6175869|NCT01292603|9824723|FG005|Part 2: Dose Confirmation Period|Withdrawn Prior to Treatment|1
6175870|NCT01292603|9824718|FG000|Part 2: Dose Confirmation Period|Adverse Event|0
6175871|NCT01292603|9824719|FG001|Part 2: Dose Confirmation Period|Adverse Event|0
6175872|NCT01292603|9824720|FG002|Part 2: Dose Confirmation Period|Adverse Event|0
6175873|NCT01292603|9824721|FG003|Part 2: Dose Confirmation Period|Adverse Event|0
6175874|NCT01292603|9824722|FG004|Part 2: Dose Confirmation Period|Adverse Event|7
6175875|NCT01292603|9824723|FG005|Part 2: Dose Confirmation Period|Adverse Event|9
6175876|NCT01292603|9824718|FG000|Part 2: Dose Confirmation Period|Protocol Violation|0
6175877|NCT01292603|9824719|FG001|Part 2: Dose Confirmation Period|Protocol Violation|0
6175878|NCT01292603|9824720|FG002|Part 2: Dose Confirmation Period|Protocol Violation|0
6175879|NCT01292603|9824721|FG003|Part 2: Dose Confirmation Period|Protocol Violation|0
6175880|NCT01292603|9824722|FG004|Part 2: Dose Confirmation Period|Protocol Violation|5
6175881|NCT01292603|9824723|FG005|Part 2: Dose Confirmation Period|Protocol Violation|3
6175882|NCT01292603|9824718|FG000|Part 2: Dose Confirmation Period|Withdrawal by Subject|0
6175883|NCT01292603|9824719|FG001|Part 2: Dose Confirmation Period|Withdrawal by Subject|0
6175884|NCT01292603|9824720|FG002|Part 2: Dose Confirmation Period|Withdrawal by Subject|0
6175885|NCT01292603|9824721|FG003|Part 2: Dose Confirmation Period|Withdrawal by Subject|0
6175886|NCT01292603|9824722|FG004|Part 2: Dose Confirmation Period|Withdrawal by Subject|0
6175887|NCT01292603|9824723|FG005|Part 2: Dose Confirmation Period|Withdrawal by Subject|2
6175888|NCT01292603|9824718|FG000|Part 2: Regular Follow-Up|Death|0
6175889|NCT01292603|9824719|FG001|Part 2: Regular Follow-Up|Death|0
6175890|NCT01292603|9824720|FG002|Part 2: Regular Follow-Up|Death|0
6175891|NCT01292603|9824721|FG003|Part 2: Regular Follow-Up|Death|0
6175892|NCT01292603|9824722|FG004|Part 2: Regular Follow-Up|Death|6
6175893|NCT01292603|9824723|FG005|Part 2: Regular Follow-Up|Death|3
6175894|NCT01292603|9824718|FG000|Part 2: Regular Follow-Up|Disease Progression|0
6175895|NCT01292603|9824719|FG001|Part 2: Regular Follow-Up|Disease Progression|0
6175896|NCT01292603|9824720|FG002|Part 2: Regular Follow-Up|Disease Progression|0
6175897|NCT01292603|9824721|FG003|Part 2: Regular Follow-Up|Disease Progression|0
6175898|NCT01292603|9824722|FG004|Part 2: Regular Follow-Up|Disease Progression|5
6175899|NCT01292603|9824723|FG005|Part 2: Regular Follow-Up|Disease Progression|5
6175900|NCT01292603|9824718|FG000|Part 2: Regular Follow-Up|Noncompliance|0
6175901|NCT01292603|9824719|FG001|Part 2: Regular Follow-Up|Noncompliance|0
6175902|NCT01292603|9824720|FG002|Part 2: Regular Follow-Up|Noncompliance|0
6175903|NCT01292603|9824721|FG003|Part 2: Regular Follow-Up|Noncompliance|0
6175904|NCT01292603|9824722|FG004|Part 2: Regular Follow-Up|Noncompliance|1
6175905|NCT01292603|9824723|FG005|Part 2: Regular Follow-Up|Noncompliance|0
6175906|NCT01292603|9824718|FG000|Part 2: Regular Follow-Up|Withdrawal by Subject|0
6175907|NCT01292603|9824719|FG001|Part 2: Regular Follow-Up|Withdrawal by Subject|0
6175908|NCT01292603|9824720|FG002|Part 2: Regular Follow-Up|Withdrawal by Subject|0
6175909|NCT01292603|9824721|FG003|Part 2: Regular Follow-Up|Withdrawal by Subject|0
6175910|NCT01292603|9824722|FG004|Part 2: Regular Follow-Up|Withdrawal by Subject|0
6175911|NCT01292603|9824723|FG005|Part 2: Regular Follow-Up|Withdrawal by Subject|1
6175912|NCT01292603|9824718|FG000|Part 2: Regular Follow-Up|Protocol Violation|0
6175913|NCT01292603|9824719|FG001|Part 2: Regular Follow-Up|Protocol Violation|0
6175914|NCT01292603|9824720|FG002|Part 2: Regular Follow-Up|Protocol Violation|0
6175915|NCT01292603|9824721|FG003|Part 2: Regular Follow-Up|Protocol Violation|0
6175916|NCT01292603|9824722|FG004|Part 2: Regular Follow-Up|Protocol Violation|2
6175917|NCT01292603|9824723|FG005|Part 2: Regular Follow-Up|Protocol Violation|0
6175918|NCT01292603|9824718|FG000|Part 2: Regular Follow-Up|Physician Decision|0
6175919|NCT01292603|9824719|FG001|Part 2: Regular Follow-Up|Physician Decision|0
6175920|NCT01292603|9824720|FG002|Part 2: Regular Follow-Up|Physician Decision|0
6175921|NCT01292603|9824721|FG003|Part 2: Regular Follow-Up|Physician Decision|0
6175922|NCT01292603|9824722|FG004|Part 2: Regular Follow-Up|Physician Decision|2
6175923|NCT01292603|9824723|FG005|Part 2: Regular Follow-Up|Physician Decision|0
6175924|NCT01292603|9824718|FG000|Part 2: Regular Follow-Up|Lost to Follow-up|0
6175925|NCT01292603|9824719|FG001|Part 2: Regular Follow-Up|Lost to Follow-up|0
6175926|NCT01292603|9824720|FG002|Part 2: Regular Follow-Up|Lost to Follow-up|0
6175927|NCT01292603|9824721|FG003|Part 2: Regular Follow-Up|Lost to Follow-up|0
6227531|NCT01717326|9900188|FG000|Overall Study|Withdrawal by Subject|0
6227532|NCT01717326|9900189|FG001|Overall Study|Withdrawal by Subject|1
6175928|NCT01292603|9824722|FG004|Part 2: Regular Follow-Up|Lost to Follow-up|1
6175929|NCT01292603|9824723|FG005|Part 2: Regular Follow-Up|Lost to Follow-up|1
6175930|NCT01292603|9824718|FG000|Part 2: Regular Follow-Up|Adverse Event|0
6175931|NCT01292603|9824719|FG001|Part 2: Regular Follow-Up|Adverse Event|0
6175932|NCT01292603|9824720|FG002|Part 2: Regular Follow-Up|Adverse Event|0
6175933|NCT01292603|9824721|FG003|Part 2: Regular Follow-Up|Adverse Event|0
6175934|NCT01292603|9824722|FG004|Part 2: Regular Follow-Up|Adverse Event|2
6175935|NCT01292603|9824723|FG005|Part 2: Regular Follow-Up|Adverse Event|2
6175936|NCT01292603|9824718|FG000|Overall Survival Status|Death|3
6175937|NCT01292603|9824719|FG001|Overall Survival Status|Death|1
6175938|NCT01292603|9824720|FG002|Overall Survival Status|Death|3
6175939|NCT01292603|9824721|FG003|Overall Survival Status|Death|1
6175940|NCT01292603|9824722|FG004|Overall Survival Status|Death|16
6175941|NCT01292603|9824723|FG005|Overall Survival Status|Death|10
6175942|NCT01292837|9824765|FG000|Overall Study|Adverse Event|1
6175943|NCT01292837|9824765|FG000|Overall Study|Further treatment determined|1
6175944|NCT01292876|9824769|FG000|Overall Study|Physician Decision|4
6175945|NCT01292928|9824775|FG000|Overall Study|Death|8
6175946|NCT01292928|9824775|FG000|Overall Study|Withdrawal by Subject|8
6085053|NCT00648739|9694299|FG000|Overall Study|Withdrawal by Subject|1
6175947|NCT01292928|9824775|FG000|Overall Study|Lost to Follow-up|6
6175948|NCT01292928|9824775|FG000|Overall Study|Physician Decision|2
6175949|NCT01293006|9824785|FG000|Period 2|Lost to Follow-up|1
6175950|NCT01293006|9824786|FG001|Period 2|Lost to Follow-up|0
6175951|NCT01293006|9824787|FG002|Period 2|Lost to Follow-up|0
6175952|NCT01293006|9824788|FG003|Period 2|Lost to Follow-up|0
6175953|NCT01293032|9824807|FG000|Recurrence Score(RS)Assigned/Randomized|Refused Assigned Arm|0
6175954|NCT01293032|9824808|FG001|Recurrence Score(RS)Assigned/Randomized|Refused Assigned Arm|0
6175955|NCT01293032|9824809|FG002|Recurrence Score(RS)Assigned/Randomized|Refused Assigned Arm|5
6175956|NCT01293032|9824810|FG003|Recurrence Score(RS)Assigned/Randomized|Refused Assigned Arm|0
6175957|NCT01293032|9824807|FG000|Treatment|Adverse Event|0
6175958|NCT01293032|9824808|FG001|Treatment|Adverse Event|0
6175959|NCT01293032|9824809|FG002|Treatment|Adverse Event|1
6175960|NCT01293032|9824810|FG003|Treatment|Adverse Event|1
6175961|NCT01293032|9824807|FG000|Treatment|Withdrawal by Subject|2
6175962|NCT01293032|9824808|FG001|Treatment|Withdrawal by Subject|4
6175963|NCT01293032|9824809|FG002|Treatment|Withdrawal by Subject|0
6175964|NCT01293032|9824810|FG003|Treatment|Withdrawal by Subject|0
6175965|NCT01293032|9824807|FG000|Treatment|Disease Progression, relapse|0
6175966|NCT01293032|9824808|FG001|Treatment|Disease Progression, relapse|1
6175967|NCT01293032|9824809|FG002|Treatment|Disease Progression, relapse|0
6175968|NCT01293032|9824810|FG003|Treatment|Disease Progression, relapse|0
6175969|NCT01293084|9824817|FG000|Overall Study|Physician Decision|3
6175970|NCT01293084|9824817|FG000|Overall Study|Withdrawal by Subject|2
6175971|NCT01293240|9824823|FG000|Overall Study|Noncompliance|2
6175972|NCT01293539|9824837|FG000|Overall Study|Physician Decision|1
6175973|NCT01293695|9824843|FG000|Overall Study|Withdrawal by Subject|7
6175974|NCT01293695|9824844|FG001|Overall Study|Withdrawal by Subject|1
6175975|NCT01293695|9824843|FG000|Overall Study|Lost to Follow-up|8
6175976|NCT01293695|9824844|FG001|Overall Study|Lost to Follow-up|6
6175977|NCT01293968|9824859|FG000|Overall Study|non-cooperation|3
6175978|NCT01293968|9824860|FG001|Overall Study|non-cooperation|3
6175979|NCT01294150|9824881|FG000|Overall Study|Physician Decision|2
6175980|NCT01294150|9824882|FG001|Overall Study|Physician Decision|2
6175981|NCT01294358|9824947|FG000|Cohort 2: 6/9/11-9/17/12|Disease progression|0
6175982|NCT01294358|9824948|FG001|Cohort 2: 6/9/11-9/17/12|Disease progression|2
6175983|NCT01294358|9824949|FG002|Cohort 2: 6/9/11-9/17/12|Disease progression|0
6175984|NCT01294358|9824950|FG003|Cohort 2: 6/9/11-9/17/12|Disease progression|0
6175985|NCT01294358|9824951|FG004|Cohort 2: 6/9/11-9/17/12|Disease progression|0
6175986|NCT01294358|9824947|FG000|Cohort 3: 12/1/11-10/6/12|Disease progression|0
6175987|NCT01294358|9824948|FG001|Cohort 3: 12/1/11-10/6/12|Disease progression|0
6175988|NCT01294358|9824949|FG002|Cohort 3: 12/1/11-10/6/12|Disease progression|2
6175989|NCT01294358|9824950|FG003|Cohort 3: 12/1/11-10/6/12|Disease progression|0
6175990|NCT01294358|9824951|FG004|Cohort 3: 12/1/11-10/6/12|Disease progression|0
6175991|NCT01294358|9824947|FG000|Cohort 4: 12/30/11-2/17/17|pt rec'd surgical resection of pancreas|0
6175992|NCT01294358|9824948|FG001|Cohort 4: 12/30/11-2/17/17|pt rec'd surgical resection of pancreas|0
6175993|NCT01294358|9824949|FG002|Cohort 4: 12/30/11-2/17/17|pt rec'd surgical resection of pancreas|0
6175994|NCT01294358|9824950|FG003|Cohort 4: 12/30/11-2/17/17|pt rec'd surgical resection of pancreas|1
6175995|NCT01294358|9824951|FG004|Cohort 4: 12/30/11-2/17/17|pt rec'd surgical resection of pancreas|0
6175996|NCT01294358|9824947|FG000|Cohort 5: 3/8/12-3/9/12|dose limiting toxicity grade 4|0
6175997|NCT01294358|9824948|FG001|Cohort 5: 3/8/12-3/9/12|dose limiting toxicity grade 4|0
6175998|NCT01294358|9824949|FG002|Cohort 5: 3/8/12-3/9/12|dose limiting toxicity grade 4|0
6175999|NCT01294358|9824950|FG003|Cohort 5: 3/8/12-3/9/12|dose limiting toxicity grade 4|0
6176000|NCT01294358|9824951|FG004|Cohort 5: 3/8/12-3/9/12|dose limiting toxicity grade 4|1
6176001|NCT01294371|9824968|FG000|Overall Study|Adverse Event|1
6176002|NCT01294371|9824968|FG000|Overall Study|Withdrawal by Subject|12
6176003|NCT01294371|9824968|FG000|Overall Study|Lost to Follow-up|6
6176004|NCT01294371|9824968|FG000|Overall Study|Administrative Reason|1
6085054|NCT00648739|9694300|FG001|Overall Study|Withdrawal by Subject|0
6176005|NCT01294371|9824968|FG000|Overall Study|Other|14
6176006|NCT01294397|9824988|FG000|Overall Study|Withdrawal by Subject|1
6176007|NCT01294397|9824988|FG000|Overall Study|Administrative Decision|1
6176008|NCT01294423|9824997|FG000|Overall Study|Adverse Event|1
6176009|NCT01294423|9824998|FG001|Overall Study|Adverse Event|2
6176010|NCT01294423|9824999|FG002|Overall Study|Adverse Event|3
6176011|NCT01294423|9824997|FG000|Overall Study|Withdrawal by Subject|1
6176012|NCT01294423|9824998|FG001|Overall Study|Withdrawal by Subject|2
6176013|NCT01294423|9824999|FG002|Overall Study|Withdrawal by Subject|2
6176014|NCT01294423|9824997|FG000|Overall Study|subject no longer meets study criteria|2
6176015|NCT01294423|9824998|FG001|Overall Study|subject no longer meets study criteria|5
6176016|NCT01294423|9824999|FG002|Overall Study|subject no longer meets study criteria|2
6176017|NCT01294423|9824997|FG000|Overall Study|poor/non-compliance|1
6176018|NCT01294423|9824998|FG001|Overall Study|poor/non-compliance|0
6176019|NCT01294423|9824999|FG002|Overall Study|poor/non-compliance|1
6176020|NCT01294436|9825009|FG000|Overall Study|Adverse Event|10
6176021|NCT01294436|9825010|FG001|Overall Study|Adverse Event|17
6176022|NCT01294436|9825009|FG000|Overall Study|Withdrawal by Subject|11
6176023|NCT01294436|9825010|FG001|Overall Study|Withdrawal by Subject|28
6176024|NCT01294436|9825009|FG000|Overall Study|subject no longer meets study criteria|5
6176025|NCT01294436|9825010|FG001|Overall Study|subject no longer meets study criteria|20
6176026|NCT01294436|9825009|FG000|Overall Study|poor/non-compliance|2
6176027|NCT01294436|9825010|FG001|Overall Study|poor/non-compliance|5
6176028|NCT01294449|9825018|FG000|Overall Study|Death|11
6176029|NCT01294449|9825019|FG001|Overall Study|Death|12
6176030|NCT01294449|9825018|FG000|Overall Study|Withdrawal by Subject|1
6176031|NCT01294449|9825019|FG001|Overall Study|Withdrawal by Subject|3
6176032|NCT01294462|9825027|FG000|Overall Study|Lost to Follow-up|1
6176033|NCT01294462|9825028|FG001|Overall Study|Lost to Follow-up|0
6176034|NCT01294462|9825027|FG000|Overall Study|Withdrawal by Subject|65
6176035|NCT01294462|9825028|FG001|Overall Study|Withdrawal by Subject|63
6176036|NCT01294514|9825034|FG000|Overall Study|Excluded due to Arrhythmia|1
6176037|NCT01294553|9825042|FG000|Overall Study|Duplicated Participants|1
6176038|NCT01294553|9825042|FG000|Overall Study|Protocol Violation|268
6176039|NCT01294579|9825047|FG000|Overall Study|Disease progression|12
6176040|NCT01294579|9825047|FG000|Overall Study|Adverse Event|11
6176041|NCT01294579|9825047|FG000|Overall Study|Study closed/terminated|3
6176042|NCT01294579|9825047|FG000|Overall Study|Lost to Follow-up|1
6176043|NCT01294579|9825047|FG000|Overall Study|Physician Decision|3
6176044|NCT01294579|9825047|FG000|Overall Study|Withdrawal by Subject|5
6176045|NCT01294592|9825053|FG000|Overall Study|Adverse Event|28
6176046|NCT01294592|9825054|FG001|Overall Study|Adverse Event|13
6176047|NCT01294592|9825053|FG000|Overall Study|Lack of Efficacy|7
6176048|NCT01294592|9825054|FG001|Overall Study|Lack of Efficacy|5
6176049|NCT01294592|9825053|FG000|Overall Study|Protocol Violation|1
6176050|NCT01294592|9825054|FG001|Overall Study|Protocol Violation|7
6176051|NCT01294592|9825053|FG000|Overall Study|Lost to Follow-up|7
6176052|NCT01294592|9825054|FG001|Overall Study|Lost to Follow-up|9
6176053|NCT01294592|9825053|FG000|Overall Study|Physician Decision|6
6176054|NCT01294592|9825054|FG001|Overall Study|Physician Decision|11
6176055|NCT01294592|9825053|FG000|Overall Study|Withdrawal by Subject|28
6176056|NCT01294592|9825054|FG001|Overall Study|Withdrawal by Subject|28
6176057|NCT01294644|9825066|FG000|Overall Study|Adverse Event|2
6176058|NCT01294644|9825067|FG001|Overall Study|Adverse Event|0
6176059|NCT01294644|9825068|FG002|Overall Study|Adverse Event|1
6176060|NCT01294644|9825066|FG000|Overall Study|Withdrawal by Subject|3
6176061|NCT01294644|9825067|FG001|Overall Study|Withdrawal by Subject|7
6176062|NCT01294644|9825068|FG002|Overall Study|Withdrawal by Subject|4
6176063|NCT01294644|9825066|FG000|Overall Study|Lost to Follow-up|3
6176064|NCT01294644|9825067|FG001|Overall Study|Lost to Follow-up|2
6176065|NCT01294644|9825068|FG002|Overall Study|Lost to Follow-up|5
6176066|NCT01294644|9825066|FG000|Overall Study|Miscellaneous Reason|2
6176067|NCT01294644|9825067|FG001|Overall Study|Miscellaneous Reason|1
6176068|NCT01294644|9825068|FG002|Overall Study|Miscellaneous Reason|4
6192517|NCT01431976|9850004|FG000|Overall Study|Withdrawal by Subject|1
6192518|NCT01432171|9850030|FG000|Overall Study|Death|1
6192519|NCT01432171|9850031|FG001|Overall Study|Death|2
6192520|NCT01432171|9850030|FG000|Overall Study|Lost to Follow-up|6
6192521|NCT01432171|9850031|FG001|Overall Study|Lost to Follow-up|5
6085055|NCT00648739|9694301|FG002|Overall Study|Withdrawal by Subject|1
6085056|NCT00648739|9694302|FG003|Overall Study|Withdrawal by Subject|0
6085057|NCT00648739|9694303|FG004|Overall Study|Withdrawal by Subject|0
6192522|NCT01432171|9850030|FG000|Overall Study|Withdrawal by Subject|3
6192523|NCT01432171|9850031|FG001|Overall Study|Withdrawal by Subject|1
6192524|NCT01432171|9850030|FG000|Overall Study|Noncompliance|2
6192525|NCT01432171|9850031|FG001|Overall Study|Noncompliance|3
6192526|NCT01432171|9850030|FG000|Overall Study|Insurance denial trial coverage|1
6192527|NCT01432171|9850031|FG001|Overall Study|Insurance denial trial coverage|0
6192528|NCT01432171|9850030|FG000|Overall Study|Patient moved to palliative care|1
6192529|NCT01432171|9850031|FG001|Overall Study|Patient moved to palliative care|0
6192530|NCT01432262|9850055|FG000|Overall Study|Withdrawal by Subject|2
6192531|NCT01432262|9850056|FG001|Overall Study|Withdrawal by Subject|1
6192532|NCT01432275|9850062|FG000|First BG Meter System (7 Days)|Adverse Event|0
6192533|NCT01432275|9850063|FG001|First BG Meter System (7 Days)|Adverse Event|2
6192534|NCT01432275|9850062|FG000|First BG Meter System (7 Days)|Withdrawal by Subject|0
6192535|NCT01432275|9850063|FG001|First BG Meter System (7 Days)|Withdrawal by Subject|1
6192536|NCT01432275|9850062|FG000|Second BG Meter System (7 Days)|Adverse Event|1
6192537|NCT01432275|9850063|FG001|Second BG Meter System (7 Days)|Adverse Event|1
6192538|NCT01432275|9850062|FG000|Second BG Meter System (7 Days)|Lost to Follow-up|1
6192539|NCT01432275|9850063|FG001|Second BG Meter System (7 Days)|Lost to Follow-up|0
6192540|NCT01432275|9850062|FG000|Second BG Meter System (7 Days)|Physician Decision|0
6176069|NCT01294683|9825078|FG000|Precrossover (Periods I/II)|Adverse Event|49
6176070|NCT01294683|9825079|FG001|Precrossover (Periods I/II)|Adverse Event|52
6176071|NCT01294683|9825078|FG000|Precrossover (Periods I/II)|Lost to Follow-up|3
6176072|NCT01294683|9825079|FG001|Precrossover (Periods I/II)|Lost to Follow-up|6
6176073|NCT01294683|9825078|FG000|Precrossover (Periods I/II)|Non-compliance with Study Drug|1
6176074|NCT01294683|9825079|FG001|Precrossover (Periods I/II)|Non-compliance with Study Drug|1
6176075|NCT01294683|9825078|FG000|Precrossover (Periods I/II)|Physician Decision|1
6176076|NCT01294683|9825079|FG001|Precrossover (Periods I/II)|Physician Decision|0
6176077|NCT01294683|9825078|FG000|Precrossover (Periods I/II)|Protocol Violation|5
6176078|NCT01294683|9825079|FG001|Precrossover (Periods I/II)|Protocol Violation|5
6176079|NCT01294683|9825078|FG000|Precrossover (Periods I/II)|Study Terminated by Sponsor|187
6176080|NCT01294683|9825079|FG001|Precrossover (Periods I/II)|Study Terminated by Sponsor|192
6176081|NCT01294683|9825078|FG000|Precrossover (Periods I/II)|Technical Problems|0
6176082|NCT01294683|9825079|FG001|Precrossover (Periods I/II)|Technical Problems|1
6176083|NCT01294683|9825078|FG000|Precrossover (Periods I/II)|Withdrawal by Subject|11
6176084|NCT01294683|9825079|FG001|Precrossover (Periods I/II)|Withdrawal by Subject|9
6176085|NCT01294683|9825078|FG000|Post Crossover (Period III)|Adverse Event|6
6176086|NCT01294683|9825079|FG001|Post Crossover (Period III)|Adverse Event|6
6176087|NCT01294683|9825078|FG000|Post Crossover (Period III)|Lost to Follow-up|1
6176088|NCT01294683|9825079|FG001|Post Crossover (Period III)|Lost to Follow-up|3
6176089|NCT01294683|9825078|FG000|Post Crossover (Period III)|Study Terminated by Sponsor|23
6176090|NCT01294683|9825079|FG001|Post Crossover (Period III)|Study Terminated by Sponsor|21
6176091|NCT01294683|9825078|FG000|Post Crossover (Period III)|Withdrawal by Subject|3
6176092|NCT01294683|9825079|FG001|Post Crossover (Period III)|Withdrawal by Subject|2
6176093|NCT01294787|9825112|FG000|Period 1|Adverse Event|0
6176094|NCT01294787|9825113|FG001|Period 1|Adverse Event|0
6176095|NCT01294787|9825114|FG002|Period 1|Adverse Event|0
6176096|NCT01294787|9825115|FG003|Period 1|Adverse Event|0
6176097|NCT01294787|9825116|FG004|Period 1|Adverse Event|1
6176098|NCT01294787|9825117|FG005|Period 1|Adverse Event|0
6176099|NCT01294787|9825112|FG000|Period 1|Withdrawal by Subject|0
6176100|NCT01294787|9825113|FG001|Period 1|Withdrawal by Subject|0
6176101|NCT01294787|9825114|FG002|Period 1|Withdrawal by Subject|0
6176102|NCT01294787|9825115|FG003|Period 1|Withdrawal by Subject|1
6176103|NCT01294787|9825116|FG004|Period 1|Withdrawal by Subject|1
6176104|NCT01294787|9825117|FG005|Period 1|Withdrawal by Subject|1
6176105|NCT01294787|9825112|FG000|Period 1|Administrative problem|0
6176106|NCT01294787|9825113|FG001|Period 1|Administrative problem|0
6176107|NCT01294787|9825114|FG002|Period 1|Administrative problem|1
6176108|NCT01294787|9825115|FG003|Period 1|Administrative problem|0
6176109|NCT01294787|9825116|FG004|Period 1|Administrative problem|0
6176110|NCT01294787|9825117|FG005|Period 1|Administrative problem|1
6176111|NCT01294787|9825112|FG000|Period 2|Adverse Event|0
6176112|NCT01294787|9825113|FG001|Period 2|Adverse Event|3
6176113|NCT01294787|9825114|FG002|Period 2|Adverse Event|0
6176114|NCT01294787|9825115|FG003|Period 2|Adverse Event|1
6176115|NCT01294787|9825116|FG004|Period 2|Adverse Event|0
6176116|NCT01294787|9825117|FG005|Period 2|Adverse Event|0
6176117|NCT01294787|9825112|FG000|Period 2|No longer needs study drug|0
6176118|NCT01294787|9825113|FG001|Period 2|No longer needs study drug|0
6176119|NCT01294787|9825114|FG002|Period 2|No longer needs study drug|0
6176120|NCT01294787|9825115|FG003|Period 2|No longer needs study drug|1
6176121|NCT01294787|9825116|FG004|Period 2|No longer needs study drug|0
6176122|NCT01294787|9825117|FG005|Period 2|No longer needs study drug|0
6176123|NCT01294787|9825112|FG000|Period 3|Adverse Event|0
6176124|NCT01294787|9825113|FG001|Period 3|Adverse Event|0
6176125|NCT01294787|9825114|FG002|Period 3|Adverse Event|0
6176126|NCT01294787|9825115|FG003|Period 3|Adverse Event|0
6176127|NCT01294787|9825116|FG004|Period 3|Adverse Event|1
6176128|NCT01294787|9825117|FG005|Period 3|Adverse Event|0
6176129|NCT01294800|9825132|FG000|Overall Study|Adverse Event|7
6176130|NCT01294800|9825133|FG001|Overall Study|Adverse Event|6
6176131|NCT01294800|9825134|FG002|Overall Study|Adverse Event|12
6176132|NCT01294800|9825135|FG003|Overall Study|Adverse Event|5
6176133|NCT01294800|9825132|FG000|Overall Study|Subject Withdrew Consent|2
6176134|NCT01294800|9825133|FG001|Overall Study|Subject Withdrew Consent|2
6176135|NCT01294800|9825134|FG002|Overall Study|Subject Withdrew Consent|2
6176136|NCT01294800|9825135|FG003|Overall Study|Subject Withdrew Consent|11
6176137|NCT01294800|9825132|FG000|Overall Study|Lost to Follow-up|0
6176138|NCT01294800|9825133|FG001|Overall Study|Lost to Follow-up|0
6176139|NCT01294800|9825134|FG002|Overall Study|Lost to Follow-up|1
6176140|NCT01294800|9825135|FG003|Overall Study|Lost to Follow-up|0
6176141|NCT01294800|9825132|FG000|Overall Study|Non-compliance With Protocol|0
6176142|NCT01294800|9825133|FG001|Overall Study|Non-compliance With Protocol|1
6176143|NCT01294800|9825134|FG002|Overall Study|Non-compliance With Protocol|1
6176144|NCT01294800|9825135|FG003|Overall Study|Non-compliance With Protocol|0
6176145|NCT01294800|9825132|FG000|Overall Study|Did Not Meet Protocol Eligibility|2
6176146|NCT01294800|9825133|FG001|Overall Study|Did Not Meet Protocol Eligibility|1
6176147|NCT01294800|9825134|FG002|Overall Study|Did Not Meet Protocol Eligibility|1
6176148|NCT01294800|9825135|FG003|Overall Study|Did Not Meet Protocol Eligibility|0
6176149|NCT01294917|9825145|FG000|Overall Study|Relocation|5
6176150|NCT01294917|9825145|FG000|Overall Study|Inconvenience|1
6176151|NCT01295034|9825153|FG000|Overall Study|Lost to Follow-up|5
6176152|NCT01295034|9825154|FG001|Overall Study|Lost to Follow-up|5
6176153|NCT01295281|9825181|FG000|First Intervention (7 Days)|Death|0
6176154|NCT01295281|9825182|FG001|First Intervention (7 Days)|Death|1
6176155|NCT01295320|9825188|FG000|Overall Study|Adverse Event|2
6176156|NCT01295320|9825188|FG000|Overall Study|Lost to Follow-up|4
6176157|NCT01295320|9825188|FG000|Overall Study|Withdrawal by Subject|2
6176158|NCT01295320|9825188|FG000|Overall Study|Subject was bedridden|1
6176159|NCT01295320|9825188|FG000|Overall Study|Unable to travel|1
6176160|NCT01295580|9825198|FG000|Overall Study|Protocol Violation|4
6176161|NCT01295580|9825199|FG001|Overall Study|Protocol Violation|2
6176162|NCT01295580|9825198|FG000|Overall Study|Withdrawal by Subject|1
6176163|NCT01295580|9825199|FG001|Overall Study|Withdrawal by Subject|4
6176164|NCT01295580|9825198|FG000|Overall Study|Adverse Event|2
6176165|NCT01295580|9825199|FG001|Overall Study|Adverse Event|1
6176166|NCT01295580|9825198|FG000|Overall Study|Lost to Follow-up|1
6176167|NCT01295580|9825199|FG001|Overall Study|Lost to Follow-up|0
6176168|NCT01295580|9825198|FG000|Overall Study|Lack of Efficacy|1
6176169|NCT01295580|9825199|FG001|Overall Study|Lack of Efficacy|0
6176170|NCT01295580|9825198|FG000|Overall Study|Other: inconvenience|1
6176171|NCT01295580|9825199|FG001|Overall Study|Other: inconvenience|0
6176172|NCT01295580|9825198|FG000|Overall Study|Other: family objection|0
6176173|NCT01295580|9825199|FG001|Overall Study|Other: family objection|1
6176174|NCT01295671|9825208|FG000|Overall Study|Lost to Follow-up|4
6176175|NCT01295671|9825209|FG001|Overall Study|Lost to Follow-up|6
6176176|NCT01295671|9825210|FG002|Overall Study|Lost to Follow-up|3
6176177|NCT01295671|9825208|FG000|Overall Study|Withdrawal by Subject|3
6176178|NCT01295671|9825209|FG001|Overall Study|Withdrawal by Subject|1
6176179|NCT01295671|9825210|FG002|Overall Study|Withdrawal by Subject|0
6176180|NCT01295814|9825229|FG000|Overall Study|Lack of Efficacy|0
6176181|NCT01295814|9825230|FG001|Overall Study|Lack of Efficacy|2
6176182|NCT01295814|9825229|FG000|Overall Study|Withdrawal by Subject|2
6176183|NCT01295814|9825230|FG001|Overall Study|Withdrawal by Subject|0
6176184|NCT01295827|9825248|FG000|Overall Study|Adverse Event|1
6176185|NCT01295827|9825249|FG001|Overall Study|Adverse Event|2
6176186|NCT01295827|9825250|FG002|Overall Study|Adverse Event|2
6176187|NCT01295827|9825251|FG003|Overall Study|Adverse Event|1
6176188|NCT01295827|9825252|FG004|Overall Study|Adverse Event|1
6176189|NCT01295827|9825253|FG005|Overall Study|Adverse Event|4
6176190|NCT01295827|9825254|FG006|Overall Study|Adverse Event|15
6176191|NCT01295827|9825255|FG007|Overall Study|Adverse Event|49
6176192|NCT01295827|9825256|FG008|Overall Study|Adverse Event|22
6176193|NCT01295827|9825257|FG009|Overall Study|Adverse Event|7
6176194|NCT01295827|9825258|FG010|Overall Study|Adverse Event|50
6176195|NCT01295827|9825259|FG011|Overall Study|Adverse Event|21
6176196|NCT01295827|9825260|FG012|Overall Study|Adverse Event|0
6176197|NCT01295827|9825261|FG013|Overall Study|Adverse Event|0
6176198|NCT01295827|9825262|FG014|Overall Study|Adverse Event|0
6176199|NCT01295827|9825248|FG000|Overall Study|Lost to Follow-up|0
6176200|NCT01295827|9825249|FG001|Overall Study|Lost to Follow-up|0
6176201|NCT01295827|9825250|FG002|Overall Study|Lost to Follow-up|3
6176202|NCT01295827|9825251|FG003|Overall Study|Lost to Follow-up|0
6176203|NCT01295827|9825252|FG004|Overall Study|Lost to Follow-up|1
6176204|NCT01295827|9825253|FG005|Overall Study|Lost to Follow-up|0
6176205|NCT01295827|9825254|FG006|Overall Study|Lost to Follow-up|4
6176206|NCT01295827|9825255|FG007|Overall Study|Lost to Follow-up|8
6176207|NCT01295827|9825256|FG008|Overall Study|Lost to Follow-up|7
6176208|NCT01295827|9825257|FG009|Overall Study|Lost to Follow-up|4
6176209|NCT01295827|9825258|FG010|Overall Study|Lost to Follow-up|7
6176210|NCT01295827|9825259|FG011|Overall Study|Lost to Follow-up|3
6176211|NCT01295827|9825260|FG012|Overall Study|Lost to Follow-up|0
6176212|NCT01295827|9825261|FG013|Overall Study|Lost to Follow-up|0
6176213|NCT01295827|9825262|FG014|Overall Study|Lost to Follow-up|0
6176214|NCT01295827|9825248|FG000|Overall Study|Not Reported|0
6176215|NCT01295827|9825249|FG001|Overall Study|Not Reported|0
6176216|NCT01295827|9825250|FG002|Overall Study|Not Reported|0
6176217|NCT01295827|9825251|FG003|Overall Study|Not Reported|1
6176218|NCT01295827|9825252|FG004|Overall Study|Not Reported|0
6176219|NCT01295827|9825253|FG005|Overall Study|Not Reported|0
6176220|NCT01295827|9825254|FG006|Overall Study|Not Reported|24
6176221|NCT01295827|9825255|FG007|Overall Study|Not Reported|58
6176222|NCT01295827|9825256|FG008|Overall Study|Not Reported|41
6176223|NCT01295827|9825257|FG009|Overall Study|Not Reported|2
6176224|NCT01295827|9825258|FG010|Overall Study|Not Reported|23
6176225|NCT01295827|9825259|FG011|Overall Study|Not Reported|13
6176226|NCT01295827|9825260|FG012|Overall Study|Not Reported|0
6176227|NCT01295827|9825261|FG013|Overall Study|Not Reported|0
6176228|NCT01295827|9825262|FG014|Overall Study|Not Reported|0
6176229|NCT01295827|9825248|FG000|Overall Study|Progressive Disease|2
6176230|NCT01295827|9825249|FG001|Overall Study|Progressive Disease|1
6176231|NCT01295827|9825250|FG002|Overall Study|Progressive Disease|5
6176232|NCT01295827|9825251|FG003|Overall Study|Progressive Disease|2
6176233|NCT01295827|9825252|FG004|Overall Study|Progressive Disease|0
6176234|NCT01295827|9825253|FG005|Overall Study|Progressive Disease|1
6176235|NCT01295827|9825254|FG006|Overall Study|Progressive Disease|87
6176236|NCT01295827|9825255|FG007|Overall Study|Progressive Disease|144
6176237|NCT01295827|9825256|FG008|Overall Study|Progressive Disease|85
6176238|NCT01295827|9825257|FG009|Overall Study|Progressive Disease|40
6176239|NCT01295827|9825258|FG010|Overall Study|Progressive Disease|175
6176240|NCT01295827|9825259|FG011|Overall Study|Progressive Disease|136
6176241|NCT01295827|9825260|FG012|Overall Study|Progressive Disease|0
6176242|NCT01295827|9825261|FG013|Overall Study|Progressive Disease|0
6176243|NCT01295827|9825262|FG014|Overall Study|Progressive Disease|0
6176244|NCT01295827|9825248|FG000|Overall Study|Screen Failure|0
6176245|NCT01295827|9825249|FG001|Overall Study|Screen Failure|0
6176246|NCT01295827|9825250|FG002|Overall Study|Screen Failure|0
6176247|NCT01295827|9825251|FG003|Overall Study|Screen Failure|0
6176248|NCT01295827|9825252|FG004|Overall Study|Screen Failure|0
6176249|NCT01295827|9825253|FG005|Overall Study|Screen Failure|0
6176250|NCT01295827|9825254|FG006|Overall Study|Screen Failure|2
6176251|NCT01295827|9825255|FG007|Overall Study|Screen Failure|2
6176252|NCT01295827|9825256|FG008|Overall Study|Screen Failure|2
6176253|NCT01295827|9825257|FG009|Overall Study|Screen Failure|0
6176254|NCT01295827|9825258|FG010|Overall Study|Screen Failure|1
6176255|NCT01295827|9825259|FG011|Overall Study|Screen Failure|0
6176256|NCT01295827|9825260|FG012|Overall Study|Screen Failure|0
6176257|NCT01295827|9825261|FG013|Overall Study|Screen Failure|0
6176258|NCT01295827|9825262|FG014|Overall Study|Screen Failure|0
6176259|NCT01295827|9825248|FG000|Overall Study|Withdrawal by Subject|1
6176260|NCT01295827|9825249|FG001|Overall Study|Withdrawal by Subject|0
6176261|NCT01295827|9825250|FG002|Overall Study|Withdrawal by Subject|2
6176262|NCT01295827|9825251|FG003|Overall Study|Withdrawal by Subject|0
6176263|NCT01295827|9825252|FG004|Overall Study|Withdrawal by Subject|0
6176264|NCT01295827|9825253|FG005|Overall Study|Withdrawal by Subject|1
6176265|NCT01295827|9825254|FG006|Overall Study|Withdrawal by Subject|13
6176266|NCT01295827|9825255|FG007|Overall Study|Withdrawal by Subject|35
6176267|NCT01295827|9825256|FG008|Overall Study|Withdrawal by Subject|11
6176268|NCT01295827|9825257|FG009|Overall Study|Withdrawal by Subject|2
6176269|NCT01295827|9825258|FG010|Overall Study|Withdrawal by Subject|18
6176270|NCT01295827|9825259|FG011|Overall Study|Withdrawal by Subject|13
6176271|NCT01295827|9825260|FG012|Overall Study|Withdrawal by Subject|0
6176272|NCT01295827|9825261|FG013|Overall Study|Withdrawal by Subject|0
6176273|NCT01295827|9825262|FG014|Overall Study|Withdrawal by Subject|0
6176274|NCT01295827|9825248|FG000|Overall Study|Other|0
6176275|NCT01295827|9825249|FG001|Overall Study|Other|0
6176276|NCT01295827|9825250|FG002|Overall Study|Other|0
6176277|NCT01295827|9825251|FG003|Overall Study|Other|0
6176278|NCT01295827|9825252|FG004|Overall Study|Other|0
6176279|NCT01295827|9825253|FG005|Overall Study|Other|0
6176280|NCT01295827|9825254|FG006|Overall Study|Other|1
6176281|NCT01295827|9825255|FG007|Overall Study|Other|1
6176282|NCT01295827|9825256|FG008|Overall Study|Other|1
6176283|NCT01295827|9825257|FG009|Overall Study|Other|0
6085058|NCT00648739|9694304|FG005|Overall Study|Withdrawal by Subject|2
6085059|NCT00648739|9694305|FG006|Overall Study|Withdrawal by Subject|0
6176284|NCT01295827|9825258|FG010|Overall Study|Other|2
6176285|NCT01295827|9825259|FG011|Overall Study|Other|0
6176286|NCT01295827|9825260|FG012|Overall Study|Other|0
6176287|NCT01295827|9825261|FG013|Overall Study|Other|0
6176288|NCT01295827|9825262|FG014|Overall Study|Other|0
6176289|NCT01295905|9825327|FG000|Overall Study|Did not meet inclusion criteria|1
6176290|NCT01295905|9825328|FG001|Overall Study|Did not meet inclusion criteria|0
6176291|NCT01295905|9825327|FG000|Overall Study|Met exclusion criteria|1
6176292|NCT01295905|9825328|FG001|Overall Study|Met exclusion criteria|0
6176293|NCT01296035|9825334|FG000|Overall Study|Withdrawal by Subject|1
6176294|NCT01296152|9825338|FG000|Overall Study|Unwilling to adhere to study requirement|1
6176295|NCT01296347|9825353|FG000|Allocation|Withdrawal by Subject|1
6176296|NCT01296347|9825354|FG001|Allocation|Withdrawal by Subject|2
6176297|NCT01296347|9825353|FG000|Allocation|Lack of Efficacy|1
6176298|NCT01296347|9825354|FG001|Allocation|Lack of Efficacy|2
6176299|NCT01296347|9825353|FG000|Allocation|not received infusion|1
6176300|NCT01296347|9825354|FG001|Allocation|not received infusion|0
6176301|NCT01296347|9825353|FG000|6 Week Follow up|Death|0
6176302|NCT01296347|9825354|FG001|6 Week Follow up|Death|1
6176303|NCT01296347|9825353|FG000|3 Month Follow up|Death|1
6176304|NCT01296347|9825354|FG001|3 Month Follow up|Death|0
6176305|NCT01296347|9825353|FG000|3 Month Follow up|Lost to Follow-up|0
6176306|NCT01296347|9825354|FG001|3 Month Follow up|Lost to Follow-up|1
6176307|NCT01296347|9825353|FG000|6 Month Follow up|Death|2
6176308|NCT01296347|9825354|FG001|6 Month Follow up|Death|1
6176309|NCT01296347|9825353|FG000|6 Month Follow up|Lost to Follow-up|0
6176310|NCT01296347|9825354|FG001|6 Month Follow up|Lost to Follow-up|1
6176311|NCT01296347|9825353|FG000|12 Month Follow up|Lost to Follow-up|3
6176312|NCT01296347|9825354|FG001|12 Month Follow up|Lost to Follow-up|1
6176313|NCT01296347|9825353|FG000|12 Month Follow up|Death|1
6176314|NCT01296347|9825354|FG001|12 Month Follow up|Death|1
6176315|NCT01296347|9825353|FG000|12 Month Follow up|Withdrawal by Subject|0
6176316|NCT01296347|9825354|FG001|12 Month Follow up|Withdrawal by Subject|1
6176317|NCT01296412|9825374|FG000|Overall Study|Adverse Event|8
6176318|NCT01296412|9825375|FG001|Overall Study|Adverse Event|29
6176319|NCT01296412|9825374|FG000|Overall Study|Lack of Efficacy|1
6176320|NCT01296412|9825375|FG001|Overall Study|Lack of Efficacy|0
6176321|NCT01296412|9825374|FG000|Overall Study|Lost to Follow-up|10
6176322|NCT01296412|9825375|FG001|Overall Study|Lost to Follow-up|7
6176323|NCT01296412|9825374|FG000|Overall Study|Non-compliance with study drug|1
6176324|NCT01296412|9825375|FG001|Overall Study|Non-compliance with study drug|2
6176325|NCT01296412|9825374|FG000|Overall Study|Other reason not specified|20
6176326|NCT01296412|9825375|FG001|Overall Study|Other reason not specified|15
6176327|NCT01296412|9825374|FG000|Overall Study|Physician Decision|1
6176328|NCT01296412|9825375|FG001|Overall Study|Physician Decision|3
6176329|NCT01296412|9825374|FG000|Overall Study|Pregnancy|0
6176330|NCT01296412|9825375|FG001|Overall Study|Pregnancy|1
6176331|NCT01296412|9825374|FG000|Overall Study|Withdrawal by Subject|10
6176332|NCT01296412|9825375|FG001|Overall Study|Withdrawal by Subject|13
6176333|NCT01296568|9825390|FG000|Continued Access Phase|Lost to Follow-up|1
6176334|NCT01296568|9825390|FG000|Continued Access Phase|Withdrawal by Subject|1
6176335|NCT01296568|9825390|FG000|Continued Access Phase|Disease Progression|1
6176336|NCT01296672|9825407|FG000|Overall Study|Lost to Follow-up|73
6176337|NCT01296672|9825408|FG001|Overall Study|Lost to Follow-up|18
6176338|NCT01296698|9825418|FG000|Overall Study|Adverse Event|1
6176339|NCT01296698|9825419|FG001|Overall Study|Adverse Event|0
6176340|NCT01296698|9825418|FG000|Overall Study|Death|1
6176341|NCT01296698|9825419|FG001|Overall Study|Death|0
6176342|NCT01296698|9825418|FG000|Overall Study|Lost to Follow-up|19
6176343|NCT01296698|9825419|FG001|Overall Study|Lost to Follow-up|1
6176344|NCT01296698|9825418|FG000|Overall Study|Withdrawal by Subject|12
6176345|NCT01296698|9825419|FG001|Overall Study|Withdrawal by Subject|0
6176346|NCT01296698|9825418|FG000|Overall Study|Difficulty Contacting Subject|2
6176347|NCT01296698|9825419|FG001|Overall Study|Difficulty Contacting Subject|0
6176348|NCT01296698|9825418|FG000|Overall Study|Study Terminated by Sponsor|209
6176349|NCT01296698|9825419|FG001|Overall Study|Study Terminated by Sponsor|12
6176350|NCT01296932|9825467|FG000|Overall Study|Dose limiting toxicity|0
6176351|NCT01296932|9825468|FG001|Overall Study|Dose limiting toxicity|0
6176352|NCT01296932|9825469|FG002|Overall Study|Dose limiting toxicity|0
6176353|NCT01296932|9825470|FG003|Overall Study|Dose limiting toxicity|0
6176354|NCT01296932|9825471|FG004|Overall Study|Dose limiting toxicity|0
6176355|NCT01296932|9825472|FG005|Overall Study|Dose limiting toxicity|0
6176356|NCT01296932|9825473|FG006|Overall Study|Dose limiting toxicity|1
6176357|NCT01296932|9825474|FG007|Overall Study|Dose limiting toxicity|0
6176358|NCT01296932|9825475|FG008|Overall Study|Dose limiting toxicity|1
6176359|NCT01296932|9825467|FG000|Overall Study|Progressive disease|2
6176360|NCT01296932|9825468|FG001|Overall Study|Progressive disease|0
6176361|NCT01296932|9825469|FG002|Overall Study|Progressive disease|1
6176362|NCT01296932|9825470|FG003|Overall Study|Progressive disease|1
6176363|NCT01296932|9825471|FG004|Overall Study|Progressive disease|2
6176364|NCT01296932|9825472|FG005|Overall Study|Progressive disease|3
6176365|NCT01296932|9825473|FG006|Overall Study|Progressive disease|1
6176366|NCT01296932|9825474|FG007|Overall Study|Progressive disease|0
6176367|NCT01296932|9825475|FG008|Overall Study|Progressive disease|0
6176368|NCT01296932|9825467|FG000|Overall Study|Withdrawal by Subject|0
6176369|NCT01296932|9825468|FG001|Overall Study|Withdrawal by Subject|0
6176370|NCT01296932|9825469|FG002|Overall Study|Withdrawal by Subject|1
6176371|NCT01296932|9825470|FG003|Overall Study|Withdrawal by Subject|1
6176372|NCT01296932|9825471|FG004|Overall Study|Withdrawal by Subject|0
6176373|NCT01296932|9825472|FG005|Overall Study|Withdrawal by Subject|0
6176374|NCT01296932|9825473|FG006|Overall Study|Withdrawal by Subject|3
6176375|NCT01296932|9825474|FG007|Overall Study|Withdrawal by Subject|0
6176376|NCT01296932|9825475|FG008|Overall Study|Withdrawal by Subject|0
6176377|NCT01296932|9825467|FG000|Overall Study|Adverse Event|1
6176378|NCT01296932|9825468|FG001|Overall Study|Adverse Event|1
6176379|NCT01296932|9825469|FG002|Overall Study|Adverse Event|1
6176380|NCT01296932|9825470|FG003|Overall Study|Adverse Event|2
6085060|NCT00648739|9694299|FG000|Overall Study|Lack of Efficacy|0
6176381|NCT01296932|9825471|FG004|Overall Study|Adverse Event|1
6176382|NCT01296932|9825472|FG005|Overall Study|Adverse Event|0
6176383|NCT01296932|9825473|FG006|Overall Study|Adverse Event|0
6375052|NCT03745638|10164835|FG003|Long-Term Safety Period (Weeks 8 to 52)|Lost to Follow-up|3
6375053|NCT03745638|10164836|FG004|Long-Term Safety Period (Weeks 8 to 52)|Lost to Follow-up|5
6375054|NCT03745638|10164837|FG005|Long-Term Safety Period (Weeks 8 to 52)|Lost to Follow-up|13
6375055|NCT03745638|10164838|FG006|Long-Term Safety Period (Weeks 8 to 52)|Lost to Follow-up|24
6375056|NCT03745638|10164832|FG000|Long-Term Safety Period (Weeks 8 to 52)|Physician Decision|0
6176384|NCT01296932|9825474|FG007|Overall Study|Adverse Event|0
6176385|NCT01296932|9825475|FG008|Overall Study|Adverse Event|1
6176386|NCT01296932|9825467|FG000|Overall Study|Investigator decision|0
6176387|NCT01296932|9825468|FG001|Overall Study|Investigator decision|1
6176388|NCT01296932|9825469|FG002|Overall Study|Investigator decision|0
6176389|NCT01296932|9825470|FG003|Overall Study|Investigator decision|1
6176390|NCT01296932|9825471|FG004|Overall Study|Investigator decision|0
6176391|NCT01296932|9825472|FG005|Overall Study|Investigator decision|0
6176392|NCT01296932|9825473|FG006|Overall Study|Investigator decision|1
6176393|NCT01296932|9825474|FG007|Overall Study|Investigator decision|0
6176394|NCT01296932|9825475|FG008|Overall Study|Investigator decision|1
6176395|NCT01296932|9825467|FG000|Overall Study|No clinical benefit anymore|0
6176396|NCT01296932|9825468|FG001|Overall Study|No clinical benefit anymore|1
6176397|NCT01296932|9825469|FG002|Overall Study|No clinical benefit anymore|0
6176398|NCT01296932|9825470|FG003|Overall Study|No clinical benefit anymore|0
6176399|NCT01296932|9825471|FG004|Overall Study|No clinical benefit anymore|0
6176400|NCT01296932|9825472|FG005|Overall Study|No clinical benefit anymore|0
6176401|NCT01296932|9825473|FG006|Overall Study|No clinical benefit anymore|0
6176402|NCT01296932|9825474|FG007|Overall Study|No clinical benefit anymore|0
6176403|NCT01296932|9825475|FG008|Overall Study|No clinical benefit anymore|0
6176404|NCT01296932|9825467|FG000|Overall Study|Physician Decision|0
6176405|NCT01296932|9825468|FG001|Overall Study|Physician Decision|0
6176406|NCT01296932|9825469|FG002|Overall Study|Physician Decision|1
6176407|NCT01296932|9825470|FG003|Overall Study|Physician Decision|0
6176408|NCT01296932|9825471|FG004|Overall Study|Physician Decision|0
6176409|NCT01296932|9825472|FG005|Overall Study|Physician Decision|0
6176410|NCT01296932|9825473|FG006|Overall Study|Physician Decision|0
6176411|NCT01296932|9825474|FG007|Overall Study|Physician Decision|0
6176412|NCT01296932|9825475|FG008|Overall Study|Physician Decision|0
6176413|NCT01296932|9825467|FG000|Overall Study|IV problems, administration not possible|0
6176414|NCT01296932|9825468|FG001|Overall Study|IV problems, administration not possible|0
6176415|NCT01296932|9825469|FG002|Overall Study|IV problems, administration not possible|1
6176416|NCT01296932|9825470|FG003|Overall Study|IV problems, administration not possible|0
6176417|NCT01296932|9825471|FG004|Overall Study|IV problems, administration not possible|0
6176418|NCT01296932|9825472|FG005|Overall Study|IV problems, administration not possible|0
6176419|NCT01296932|9825473|FG006|Overall Study|IV problems, administration not possible|0
6176420|NCT01296932|9825474|FG007|Overall Study|IV problems, administration not possible|0
6176421|NCT01296932|9825475|FG008|Overall Study|IV problems, administration not possible|0
6176422|NCT01296932|9825467|FG000|Overall Study|per protocol|0
6176423|NCT01296932|9825468|FG001|Overall Study|per protocol|0
6176424|NCT01296932|9825469|FG002|Overall Study|per protocol|1
6176425|NCT01296932|9825470|FG003|Overall Study|per protocol|1
6176426|NCT01296932|9825471|FG004|Overall Study|per protocol|0
6176427|NCT01296932|9825472|FG005|Overall Study|per protocol|0
6176428|NCT01296932|9825473|FG006|Overall Study|per protocol|0
6176429|NCT01296932|9825474|FG007|Overall Study|per protocol|0
6176430|NCT01296932|9825475|FG008|Overall Study|per protocol|0
6176431|NCT01296932|9825467|FG000|Overall Study|Low benefit and too many side effects|0
6176432|NCT01296932|9825468|FG001|Overall Study|Low benefit and too many side effects|0
6176433|NCT01296932|9825469|FG002|Overall Study|Low benefit and too many side effects|0
6176434|NCT01296932|9825470|FG003|Overall Study|Low benefit and too many side effects|0
6176435|NCT01296932|9825471|FG004|Overall Study|Low benefit and too many side effects|0
6176436|NCT01296932|9825472|FG005|Overall Study|Low benefit and too many side effects|0
6176437|NCT01296932|9825473|FG006|Overall Study|Low benefit and too many side effects|0
6176438|NCT01296932|9825474|FG007|Overall Study|Low benefit and too many side effects|1
6176439|NCT01296932|9825475|FG008|Overall Study|Low benefit and too many side effects|0
6176440|NCT01296932|9825467|FG000|Overall Study|No adequate treatment response|0
6176441|NCT01296932|9825468|FG001|Overall Study|No adequate treatment response|0
6176442|NCT01296932|9825469|FG002|Overall Study|No adequate treatment response|0
6176443|NCT01296932|9825470|FG003|Overall Study|No adequate treatment response|0
6176444|NCT01296932|9825471|FG004|Overall Study|No adequate treatment response|0
6176445|NCT01296932|9825472|FG005|Overall Study|No adequate treatment response|0
6176446|NCT01296932|9825473|FG006|Overall Study|No adequate treatment response|0
6176447|NCT01296932|9825474|FG007|Overall Study|No adequate treatment response|1
6176448|NCT01296932|9825475|FG008|Overall Study|No adequate treatment response|0
6176449|NCT01296932|9825467|FG000|Overall Study|Dosage already reduced, AE still present|0
6176450|NCT01296932|9825468|FG001|Overall Study|Dosage already reduced, AE still present|0
6176451|NCT01296932|9825469|FG002|Overall Study|Dosage already reduced, AE still present|0
6176452|NCT01296932|9825470|FG003|Overall Study|Dosage already reduced, AE still present|0
6176453|NCT01296932|9825471|FG004|Overall Study|Dosage already reduced, AE still present|0
6176454|NCT01296932|9825472|FG005|Overall Study|Dosage already reduced, AE still present|0
6176455|NCT01296932|9825473|FG006|Overall Study|Dosage already reduced, AE still present|0
6176456|NCT01296932|9825474|FG007|Overall Study|Dosage already reduced, AE still present|0
6176457|NCT01296932|9825475|FG008|Overall Study|Dosage already reduced, AE still present|1
6176458|NCT01297062|9825502|FG000|Overall Study|Adverse Event|2
6176459|NCT01297062|9825503|FG001|Overall Study|Adverse Event|0
6176460|NCT01297062|9825504|FG002|Overall Study|Adverse Event|1
6176461|NCT01297062|9825505|FG003|Overall Study|Adverse Event|0
6176462|NCT01297062|9825506|FG004|Overall Study|Adverse Event|0
6176463|NCT01297062|9825507|FG005|Overall Study|Adverse Event|0
6176464|NCT01297062|9825508|FG006|Overall Study|Adverse Event|0
6176465|NCT01297062|9825502|FG000|Overall Study|Physician Decision|1
6176466|NCT01297062|9825503|FG001|Overall Study|Physician Decision|0
6176467|NCT01297062|9825504|FG002|Overall Study|Physician Decision|1
6176468|NCT01297062|9825505|FG003|Overall Study|Physician Decision|0
6176469|NCT01297062|9825506|FG004|Overall Study|Physician Decision|0
6176470|NCT01297062|9825507|FG005|Overall Study|Physician Decision|0
6176471|NCT01297062|9825508|FG006|Overall Study|Physician Decision|6
6176472|NCT01297062|9825502|FG000|Overall Study|Protocol Violation|0
6176473|NCT01297062|9825503|FG001|Overall Study|Protocol Violation|0
6176474|NCT01297062|9825504|FG002|Overall Study|Protocol Violation|0
6176475|NCT01297062|9825505|FG003|Overall Study|Protocol Violation|0
6176476|NCT01297062|9825506|FG004|Overall Study|Protocol Violation|1
6176477|NCT01297062|9825507|FG005|Overall Study|Protocol Violation|0
6176478|NCT01297062|9825508|FG006|Overall Study|Protocol Violation|0
6176479|NCT01297062|9825502|FG000|Overall Study|Subject Decision|1
6176480|NCT01297062|9825503|FG001|Overall Study|Subject Decision|1
6176481|NCT01297062|9825504|FG002|Overall Study|Subject Decision|0
6176482|NCT01297062|9825505|FG003|Overall Study|Subject Decision|1
6176483|NCT01297062|9825506|FG004|Overall Study|Subject Decision|1
6176484|NCT01297062|9825507|FG005|Overall Study|Subject Decision|1
6176485|NCT01297062|9825508|FG006|Overall Study|Subject Decision|2
6176486|NCT01297244|9825518|FG000|Overall Study|Progressive disease|22
6176487|NCT01297244|9825519|FG001|Overall Study|Progressive disease|3
6176488|NCT01297244|9825518|FG000|Overall Study|Adverse Event|9
6176489|NCT01297244|9825519|FG001|Overall Study|Adverse Event|1
6176490|NCT01297244|9825518|FG000|Overall Study|Death|1
6176491|NCT01297244|9825519|FG001|Overall Study|Death|1
6176492|NCT01297244|9825518|FG000|Overall Study|Clinical progression|1
6176493|NCT01297244|9825519|FG001|Overall Study|Clinical progression|1
6176494|NCT01297244|9825518|FG000|Overall Study|Withdrawal by Subject|2
6176495|NCT01297244|9825519|FG001|Overall Study|Withdrawal by Subject|0
6176496|NCT01297270|9825534|FG000|Overall Study|Adverse Event|19
6176497|NCT01297270|9825535|FG001|Overall Study|Adverse Event|32
6176498|NCT01297270|9825536|FG002|Overall Study|Adverse Event|5
6176499|NCT01297270|9825534|FG000|Overall Study|Lack of Efficacy|15
6176500|NCT01297270|9825535|FG001|Overall Study|Lack of Efficacy|17
6176501|NCT01297270|9825536|FG002|Overall Study|Lack of Efficacy|15
6176502|NCT01297270|9825534|FG000|Overall Study|Lost to Follow-up|1
6176503|NCT01297270|9825535|FG001|Overall Study|Lost to Follow-up|2
6176504|NCT01297270|9825536|FG002|Overall Study|Lost to Follow-up|1
6176505|NCT01297270|9825534|FG000|Overall Study|Protocol Violation|0
6176506|NCT01297270|9825535|FG001|Overall Study|Protocol Violation|2
6227533|NCT01717326|9900190|FG002|Overall Study|Withdrawal by Subject|0
6227534|NCT01717326|9900191|FG003|Overall Study|Withdrawal by Subject|0
6227535|NCT01717326|9900192|FG004|Overall Study|Withdrawal by Subject|0
6227536|NCT01717326|9900193|FG005|Overall Study|Withdrawal by Subject|0
6227537|NCT01717326|9900194|FG006|Overall Study|Withdrawal by Subject|0
6227538|NCT01717326|9900195|FG007|Overall Study|Withdrawal by Subject|0
6227539|NCT01717326|9900196|FG008|Overall Study|Withdrawal by Subject|0
6227540|NCT01717326|9900197|FG009|Overall Study|Withdrawal by Subject|1
6227541|NCT01717326|9900198|FG010|Overall Study|Withdrawal by Subject|0
6227542|NCT01717326|9900199|FG011|Overall Study|Withdrawal by Subject|0
6227543|NCT01717326|9900200|FG012|Overall Study|Withdrawal by Subject|1
6227544|NCT01717326|9900201|FG013|Overall Study|Withdrawal by Subject|0
6227545|NCT01717326|9900202|FG014|Overall Study|Withdrawal by Subject|0
6227546|NCT01717326|9900203|FG015|Overall Study|Withdrawal by Subject|1
6227547|NCT01717326|9900204|FG016|Overall Study|Withdrawal by Subject|0
6227548|NCT01717326|9900205|FG017|Overall Study|Withdrawal by Subject|0
6227549|NCT01717326|9900206|FG018|Overall Study|Withdrawal by Subject|2
6227550|NCT01717326|9900207|FG019|Overall Study|Withdrawal by Subject|3
6227551|NCT01717391|9900249|FG000|Overall Study|Withdrawal by Subject|5
6227552|NCT01717391|9900249|FG000|Overall Study|Physician Decision|1
6227553|NCT01717391|9900249|FG000|Overall Study|FLT technical failure|3
6227554|NCT01717456|9900257|FG000|End of Treatment|Physician Decision|0
6227555|NCT01717456|9900258|FG001|End of Treatment|Physician Decision|1
6227556|NCT01717456|9900257|FG000|End of Treatment|Lost to Follow-up|0
6227557|NCT01717456|9900258|FG001|End of Treatment|Lost to Follow-up|1
6227558|NCT01717456|9900257|FG000|Follow-Up 6 Months After End of Tx|Lost to Follow-up|4
6227559|NCT01717456|9900258|FG001|Follow-Up 6 Months After End of Tx|Lost to Follow-up|4
6227560|NCT01717638|9900282|FG000|Overall Study|Lost to Follow-up|0
6227561|NCT01717638|9900283|FG001|Overall Study|Lost to Follow-up|0
6227562|NCT01717638|9900284|FG002|Overall Study|Lost to Follow-up|0
6227563|NCT01717638|9900285|FG003|Overall Study|Lost to Follow-up|0
6227564|NCT01717638|9900286|FG004|Overall Study|Lost to Follow-up|0
6227565|NCT01717638|9900287|FG005|Overall Study|Lost to Follow-up|1
6227566|NCT01717638|9900288|FG006|Overall Study|Lost to Follow-up|0
6085061|NCT00648739|9694300|FG001|Overall Study|Lack of Efficacy|0
6227567|NCT01717638|9900289|FG007|Overall Study|Lost to Follow-up|0
6227568|NCT01717638|9900290|FG008|Overall Study|Lost to Follow-up|0
6227569|NCT01717638|9900291|FG009|Overall Study|Lost to Follow-up|0
6227570|NCT01717638|9900292|FG010|Overall Study|Lost to Follow-up|0
6227571|NCT01717638|9900293|FG011|Overall Study|Lost to Follow-up|0
6227572|NCT01717638|9900294|FG012|Overall Study|Lost to Follow-up|0
6227573|NCT01717638|9900282|FG000|Overall Study|Father in hospital|0
6227574|NCT01717638|9900283|FG001|Overall Study|Father in hospital|0
6227575|NCT01717638|9900284|FG002|Overall Study|Father in hospital|0
6227576|NCT01717638|9900285|FG003|Overall Study|Father in hospital|0
6227577|NCT01717638|9900286|FG004|Overall Study|Father in hospital|0
6085062|NCT00648739|9694301|FG002|Overall Study|Lack of Efficacy|0
6227578|NCT01717638|9900287|FG005|Overall Study|Father in hospital|0
6227579|NCT01717638|9900288|FG006|Overall Study|Father in hospital|0
6227580|NCT01717638|9900289|FG007|Overall Study|Father in hospital|0
6227581|NCT01717638|9900290|FG008|Overall Study|Father in hospital|0
6227582|NCT01717638|9900291|FG009|Overall Study|Father in hospital|0
6176507|NCT01297270|9825536|FG002|Overall Study|Protocol Violation|0
6176508|NCT01297270|9825534|FG000|Overall Study|Withdrawal by Subject|7
6176509|NCT01297270|9825535|FG001|Overall Study|Withdrawal by Subject|15
6176510|NCT01297270|9825536|FG002|Overall Study|Withdrawal by Subject|7
6176511|NCT01297270|9825534|FG000|Overall Study|Other reason not defined above|3
6176512|NCT01297270|9825535|FG001|Overall Study|Other reason not defined above|3
6176513|NCT01297270|9825536|FG002|Overall Study|Other reason not defined above|1
6176514|NCT01297270|9825534|FG000|Overall Study|Not treated|0
6176515|NCT01297270|9825535|FG001|Overall Study|Not treated|1
6176516|NCT01297270|9825536|FG002|Overall Study|Not treated|0
6176517|NCT01297309|9825548|FG000|Overall Study|Eligibility failure|2
6176518|NCT01297309|9825548|FG000|Overall Study|Screen failure|2
6176519|NCT01297309|9825548|FG000|Overall Study|Withdrawal by Subject|5
6176520|NCT01297309|9825548|FG000|Overall Study|Adverse Event|1
6176521|NCT01297309|9825548|FG000|Overall Study|Investigator Decision|2
6176522|NCT01297309|9825548|FG000|Overall Study|Death|1
6176523|NCT01297309|9825548|FG000|Overall Study|Participant not entering extensionperiod|1
6176524|NCT01297322|9825554|FG000|Overall Study|Lost to Follow-up|1
6176525|NCT01297322|9825555|FG001|Overall Study|Lost to Follow-up|0
6176526|NCT01297322|9825554|FG000|Overall Study|Withdrawal by Subject|0
6176527|NCT01297322|9825555|FG001|Overall Study|Withdrawal by Subject|1
6176528|NCT01297322|9825554|FG000|Overall Study|Protocol Violation|0
6176529|NCT01297322|9825555|FG001|Overall Study|Protocol Violation|3
6176530|NCT01297465|9825580|FG000|Overall Study|Lack of Ovarian Response|1
6176531|NCT01297465|9825581|FG001|Overall Study|Lack of Ovarian Response|1
6176532|NCT01297465|9825580|FG000|Overall Study|Ovarian hyperstimulation syndrome risk|0
6176533|NCT01297465|9825581|FG001|Overall Study|Ovarian hyperstimulation syndrome risk|1
6176534|NCT01297465|9825580|FG000|Overall Study|No Oocytes Retrieved|1
6176535|NCT01297465|9825581|FG001|Overall Study|No Oocytes Retrieved|1
6176536|NCT01297465|9825580|FG000|Overall Study|Poor oocyte quality|0
6176537|NCT01297465|9825581|FG001|Overall Study|Poor oocyte quality|1
6176538|NCT01297465|9825580|FG000|Overall Study|No Fertilization|6
6176539|NCT01297465|9825581|FG001|Overall Study|No Fertilization|4
6176540|NCT01297465|9825580|FG000|Overall Study|All Embryos Discarded|0
6176541|NCT01297465|9825581|FG001|Overall Study|All Embryos Discarded|1
6176542|NCT01297465|9825580|FG000|Overall Study|Intention to Freeze all Embryos|0
6176543|NCT01297465|9825581|FG001|Overall Study|Intention to Freeze all Embryos|1
6176544|NCT01297491|9825589|FG000|Overall Study|Adverse Event|11
6176545|NCT01297491|9825590|FG001|Overall Study|Adverse Event|6
6176546|NCT01297491|9825589|FG000|Overall Study|Physician Decision|3
6176547|NCT01297491|9825590|FG001|Overall Study|Physician Decision|2
6176548|NCT01297491|9825589|FG000|Overall Study|Progressive disease|11
6176549|NCT01297491|9825590|FG001|Overall Study|Progressive disease|20
6176550|NCT01297491|9825589|FG000|Overall Study|Patient/Guardian decision|3
6176551|NCT01297491|9825590|FG001|Overall Study|Patient/Guardian decision|4
6176552|NCT01297491|9825589|FG000|Overall Study|Death|2
6176553|NCT01297491|9825590|FG001|Overall Study|Death|1
6176554|NCT01297504|9825596|FG000|Overall Study|Invalid Consent|1
6176555|NCT01297504|9825596|FG000|Overall Study|Received Palivizumab in Previous Season|1
6176556|NCT01297504|9825596|FG000|Overall Study|No Study Visits|4
6176557|NCT01297504|9825596|FG000|Overall Study|Death|3
6176558|NCT01297504|9825596|FG000|Overall Study|Lost to Follow-up|43
6176559|NCT01297504|9825596|FG000|Overall Study|Withdrawal by Subject|9
6176560|NCT01297504|9825596|FG000|Overall Study|Site Closure|3
6176561|NCT01297504|9825596|FG000|Overall Study|Protocol Violation|3
6176562|NCT01297517|9825607|FG000|Overall Study|Adverse Event|21
6176563|NCT01297517|9825608|FG001|Overall Study|Adverse Event|7
6176564|NCT01297517|9825609|FG002|Overall Study|Adverse Event|16
6176565|NCT01297517|9825607|FG000|Overall Study|Lost to Follow-up|1
6176566|NCT01297517|9825608|FG001|Overall Study|Lost to Follow-up|0
6176567|NCT01297517|9825609|FG002|Overall Study|Lost to Follow-up|1
6176568|NCT01297517|9825607|FG000|Overall Study|Patient Decision Unrelated to AE|2
6176569|NCT01297517|9825608|FG001|Overall Study|Patient Decision Unrelated to AE|3
6176570|NCT01297517|9825609|FG002|Overall Study|Patient Decision Unrelated to AE|7
6176571|NCT01297517|9825607|FG000|Overall Study|Noncompliance|1
6176572|NCT01297517|9825608|FG001|Overall Study|Noncompliance|0
6176573|NCT01297517|9825609|FG002|Overall Study|Noncompliance|0
6176574|NCT01297517|9825607|FG000|Overall Study|Protocol Violation|1
6176575|NCT01297517|9825608|FG001|Overall Study|Protocol Violation|1
6176576|NCT01297517|9825609|FG002|Overall Study|Protocol Violation|1
6176577|NCT01297517|9825607|FG000|Overall Study|Inadequate Control of IOP|1
6176578|NCT01297517|9825608|FG001|Overall Study|Inadequate Control of IOP|1
6176579|NCT01297517|9825609|FG002|Overall Study|Inadequate Control of IOP|2
6176580|NCT01297920|9825627|FG000|Overall Study|Adverse Event|42
6176581|NCT01297920|9825628|FG001|Overall Study|Adverse Event|10
6176582|NCT01297920|9825629|FG002|Overall Study|Adverse Event|38
6176583|NCT01297920|9825627|FG000|Overall Study|Patient Decision Unrelated to AE|6
6176584|NCT01297920|9825628|FG001|Overall Study|Patient Decision Unrelated to AE|5
6176585|NCT01297920|9825629|FG002|Overall Study|Patient Decision Unrelated to AE|2
6176586|NCT01297920|9825627|FG000|Overall Study|Noncompliance|1
6176587|NCT01297920|9825628|FG001|Overall Study|Noncompliance|0
6176588|NCT01297920|9825629|FG002|Overall Study|Noncompliance|0
6176589|NCT01297920|9825627|FG000|Overall Study|Protocol Violation|1
6176590|NCT01297920|9825628|FG001|Overall Study|Protocol Violation|3
6176591|NCT01297920|9825629|FG002|Overall Study|Protocol Violation|0
6176592|NCT01297920|9825627|FG000|Overall Study|Inadequate Control of IOP|7
6176593|NCT01297920|9825628|FG001|Overall Study|Inadequate Control of IOP|9
6176594|NCT01297920|9825629|FG002|Overall Study|Inadequate Control of IOP|17
6176595|NCT01297920|9825627|FG000|Overall Study|Patient Did Not Meet Entrance Criteria|1
6176596|NCT01297920|9825628|FG001|Overall Study|Patient Did Not Meet Entrance Criteria|0
6176597|NCT01297920|9825629|FG002|Overall Study|Patient Did Not Meet Entrance Criteria|0
6176598|NCT01297959|9825639|FG000|Overall Study|Adverse Event|0
6176599|NCT01297959|9825640|FG001|Overall Study|Adverse Event|1
6176600|NCT01297959|9825639|FG000|Overall Study|Protocol Violation|2
6176601|NCT01297959|9825640|FG001|Overall Study|Protocol Violation|1
6176602|NCT01297959|9825639|FG000|Overall Study|Withdrawal by Subject|5
6176603|NCT01297959|9825640|FG001|Overall Study|Withdrawal by Subject|4
6176604|NCT01297959|9825639|FG000|Overall Study|Physician Decision|0
6176605|NCT01297959|9825640|FG001|Overall Study|Physician Decision|1
6176606|NCT01297959|9825639|FG000|Overall Study|Unrelated medical illness / complication|0
6176607|NCT01297959|9825640|FG001|Overall Study|Unrelated medical illness / complication|2
6176608|NCT01297959|9825639|FG000|Overall Study|Other|13
6176609|NCT01297959|9825640|FG001|Overall Study|Other|7
6176610|NCT01298141|9825686|FG000|Overall Study|Adverse Event|3
6176611|NCT01298141|9825686|FG000|Overall Study|Refusal of Required Study Procedures|1
6176612|NCT01298141|9825686|FG000|Overall Study|Withdrawal by Subject|6
6176613|NCT01298141|9825686|FG000|Overall Study|Termination of Study by the Investigator|5
6176614|NCT01298141|9825686|FG000|Overall Study|Other|5
6085063|NCT00648739|9694302|FG003|Overall Study|Lack of Efficacy|0
6085064|NCT00648739|9694303|FG004|Overall Study|Lack of Efficacy|1
6085065|NCT00648739|9694304|FG005|Overall Study|Lack of Efficacy|2
6085066|NCT00648739|9694305|FG006|Overall Study|Lack of Efficacy|0
6085067|NCT00648739|9694299|FG000|Overall Study|Investigator Considered it Advisable|0
6176615|NCT01298141|9825686|FG000|Overall Study|Lost to Follow-up|1
6176616|NCT01298141|9825686|FG000|Overall Study|Death|6
6176617|NCT01298141|9825686|FG000|Overall Study|Not treated|4
6176618|NCT01298193|9825699|FG000|Observational Phase (First Cycle)|Withdrawal by Subject|2
6176619|NCT01298193|9825699|FG000|Observational Phase (First Cycle)|Received TC at a different dose|16
6176620|NCT01298193|9825699|FG000|Observational Phase (First Cycle)|previous emetogenic chemotherapy|9
6176621|NCT01298193|9825699|FG000|Efficacy Phase (Second Cycle)|Death|1
6176622|NCT01298323|9825717|FG000|Overall Study|Adverse Event|2
6176623|NCT01298323|9825718|FG001|Overall Study|Adverse Event|4
6176624|NCT01298323|9825717|FG000|Overall Study|Death|11
6176625|NCT01298323|9825718|FG001|Overall Study|Death|16
6176626|NCT01298323|9825717|FG000|Overall Study|Lost to Follow-up|1
6176627|NCT01298323|9825718|FG001|Overall Study|Lost to Follow-up|0
6176628|NCT01298323|9825717|FG000|Overall Study|Withdrawal by Subject|6
6176629|NCT01298323|9825718|FG001|Overall Study|Withdrawal by Subject|3
6176630|NCT01298323|9825717|FG000|Overall Study|Protocol Violation|1
6176631|NCT01298323|9825718|FG001|Overall Study|Protocol Violation|0
6176632|NCT01298323|9825717|FG000|Overall Study|Other|10
6176633|NCT01298323|9825718|FG001|Overall Study|Other|9
6176634|NCT01298323|9825717|FG000|Overall Study|Ongoing|55
6176635|NCT01298323|9825718|FG001|Overall Study|Ongoing|55
6176636|NCT01298323|9825717|FG000|Overall Study|Eligibility criteria not fulfilled|0
6176637|NCT01298323|9825718|FG001|Overall Study|Eligibility criteria not fulfilled|1
6176638|NCT01298362|9825726|FG000|Overall Study|Did not provide 12month BMD measurements|38
6176639|NCT01298362|9825727|FG001|Overall Study|Did not provide 12month BMD measurements|43
6176640|NCT01298492|9825735|FG000|Overall Study|Death|2
6176641|NCT01298492|9825735|FG000|Overall Study|Insufficient Clinical Response|22
6176642|NCT01298492|9825735|FG000|Overall Study|Lost to Follow-up|12
6176643|NCT01298492|9825735|FG000|Overall Study|Withdrawal by Subject|47
6176644|NCT01298492|9825735|FG000|Overall Study|Other (Unspecified)|7
6176645|NCT01298492|9825735|FG000|Overall Study|Withdrawn Due to Pregnancy|1
6176646|NCT01298492|9825735|FG000|Overall Study|Protocol Violation|2
6176647|NCT01298492|9825735|FG000|Overall Study|Adverse Event(Related to Study Drug)|8
6176648|NCT01298492|9825735|FG000|Overall Study|Adverse Event(Not Related to Study Drug)|18
6176649|NCT01298518|9825742|FG000|Overall Study|Withdrawal by Subject|0
6176650|NCT01298518|9825743|FG001|Overall Study|Withdrawal by Subject|0
6176651|NCT01298518|9825744|FG002|Overall Study|Withdrawal by Subject|1
6176652|NCT01298531|9825754|FG000|Overall Study|Lack of Efficacy|0
6176653|NCT01298531|9825755|FG001|Overall Study|Lack of Efficacy|1
6176654|NCT01298531|9825754|FG000|Overall Study|Lost to Follow-up|2
6176655|NCT01298531|9825755|FG001|Overall Study|Lost to Follow-up|0
6176656|NCT01298531|9825754|FG000|Overall Study|Protocol Violation|1
6176657|NCT01298531|9825755|FG001|Overall Study|Protocol Violation|1
6176658|NCT01298531|9825754|FG000|Overall Study|Adverse Event|4
6176659|NCT01298531|9825755|FG001|Overall Study|Adverse Event|3
6176660|NCT01298531|9825754|FG000|Overall Study|Does not meet entrance criteria|0
6176661|NCT01298531|9825755|FG001|Overall Study|Does not meet entrance criteria|1
6176662|NCT01298531|9825754|FG000|Overall Study|Other|2
6176663|NCT01298531|9825755|FG001|Overall Study|Other|1
6176664|NCT01298570|9825770|FG000|Overall Study|Disease progression, relapse during acti|64
6176665|NCT01298570|9825771|FG001|Overall Study|Disease progression, relapse during acti|40
6176666|NCT01298570|9825770|FG000|Overall Study|Adverse Event|20
6176667|NCT01298570|9825771|FG001|Overall Study|Adverse Event|2
6176668|NCT01298570|9825770|FG000|Overall Study|Withdrawal by Subject|21
6176669|NCT01298570|9825771|FG001|Overall Study|Withdrawal by Subject|6
6085068|NCT00648739|9694300|FG001|Overall Study|Investigator Considered it Advisable|0
6176670|NCT01298570|9825770|FG000|Overall Study|Treatment delay > 4 weeks|4
6176671|NCT01298570|9825771|FG001|Overall Study|Treatment delay > 4 weeks|5
6176672|NCT01298570|9825770|FG000|Overall Study|Physician Decision|4
6176673|NCT01298570|9825771|FG001|Overall Study|Physician Decision|2
6176674|NCT01298570|9825770|FG000|Overall Study|Other complicating disease|2
6176675|NCT01298570|9825771|FG001|Overall Study|Other complicating disease|1
6176676|NCT01298570|9825770|FG000|Overall Study|Surgery|2
6176677|NCT01298570|9825771|FG001|Overall Study|Surgery|1
6176678|NCT01298570|9825770|FG000|Overall Study|Symptomatic progression/deterioration|3
6176679|NCT01298570|9825771|FG001|Overall Study|Symptomatic progression/deterioration|2
6176680|NCT01298570|9825770|FG000|Overall Study|Death|0
6176681|NCT01298570|9825771|FG001|Overall Study|Death|1
6176682|NCT01298570|9825770|FG000|Overall Study|Ineligibility|0
6176683|NCT01298570|9825771|FG001|Overall Study|Ineligibility|1
6176684|NCT01298596|9825779|FG000|Overall Study|Withdrawal by Subject|1
6176685|NCT01298596|9825780|FG001|Overall Study|Withdrawal by Subject|1
6176686|NCT01298596|9825779|FG000|Overall Study|Death|5
6176687|NCT01298596|9825780|FG001|Overall Study|Death|3
6176688|NCT01298596|9825779|FG000|Overall Study|Lost to Follow-up|6
6176689|NCT01298596|9825780|FG001|Overall Study|Lost to Follow-up|14
6176690|NCT01298596|9825779|FG000|Overall Study|Referred for further management|16
6176691|NCT01298596|9825780|FG001|Overall Study|Referred for further management|15
6176692|NCT01298648|9825786|FG000|Overall Study|Withdrawal by Subject|2
6176693|NCT01298648|9825786|FG000|Overall Study|Lost to Follow-up|21
6176694|NCT01298661|9825793|FG000|Overall Study|Withdrawal by Subject|2
6176695|NCT01298661|9825794|FG001|Overall Study|Withdrawal by Subject|0
6176696|NCT01298661|9825795|FG002|Overall Study|Withdrawal by Subject|2
6176697|NCT01298700|9825806|FG000|Overall Study|Adverse Event|50
6176698|NCT01298700|9825807|FG001|Overall Study|Adverse Event|51
6176699|NCT01298700|9825806|FG000|Overall Study|Lack of Efficacy|9
6176700|NCT01298700|9825807|FG001|Overall Study|Lack of Efficacy|14
6176701|NCT01298700|9825806|FG000|Overall Study|Lost to Follow-up|5
6176702|NCT01298700|9825807|FG001|Overall Study|Lost to Follow-up|2
6176703|NCT01298700|9825806|FG000|Overall Study|Withdrawal by Subject|12
6176704|NCT01298700|9825807|FG001|Overall Study|Withdrawal by Subject|9
6176705|NCT01298700|9825806|FG000|Overall Study|Protocol Violation|6
6176706|NCT01298700|9825807|FG001|Overall Study|Protocol Violation|4
6176707|NCT01298700|9825806|FG000|Overall Study|Other Miscellaneous Reasons|16
6176708|NCT01298700|9825807|FG001|Overall Study|Other Miscellaneous Reasons|15
6176709|NCT01298700|9825806|FG000|Overall Study|Did not Receive Study Drug|3
6176710|NCT01298700|9825807|FG001|Overall Study|Did not Receive Study Drug|5
6176711|NCT01298765|9825822|FG000|Titration Period|Adverse Event|26
6176712|NCT01298765|9825822|FG000|Titration Period|Death|1
6176713|NCT01298765|9825822|FG000|Titration Period|Lack of Efficacy|21
6176714|NCT01298765|9825822|FG000|Titration Period|Lost to Follow-up|9
6176715|NCT01298765|9825822|FG000|Titration Period|Physician Decision|1
6176716|NCT01298765|9825822|FG000|Titration Period|Withdrawal by Subject|10
6176717|NCT01298765|9825822|FG000|Titration Period|Other: Not Lack of Analgesic Effect|8
6176718|NCT01298765|9825822|FG000|Long-Term Treatment Period|Adverse Event|19
6176719|NCT01298765|9825822|FG000|Long-Term Treatment Period|Lack of Efficacy|6
6176720|NCT01298765|9825822|FG000|Long-Term Treatment Period|Lost to Follow-up|8
6176721|NCT01298765|9825822|FG000|Long-Term Treatment Period|Withdrawal by Subject|19
6176722|NCT01298765|9825822|FG000|Long-Term Treatment Period|Physician Decision|1
6176723|NCT01298765|9825822|FG000|Long-Term Treatment Period|Other: Not Lack of Analgesic Effect|46
6176724|NCT01298778|9825828|FG000|Overall Study|Lost to Follow-up|2
6176725|NCT01298778|9825829|FG001|Overall Study|Lost to Follow-up|3
6176726|NCT01298778|9825828|FG000|Overall Study|Incorrect use of VAS|1
6176727|NCT01298778|9825829|FG001|Overall Study|Incorrect use of VAS|0
6176728|NCT01298778|9825828|FG000|Overall Study|Withdrawal by Subject|0
6176729|NCT01298778|9825829|FG001|Overall Study|Withdrawal by Subject|1
6176730|NCT01298778|9825828|FG000|Overall Study|Protocol Violation|0
6176731|NCT01298778|9825829|FG001|Overall Study|Protocol Violation|1
6176732|NCT01298778|9825828|FG000|Overall Study|not meet inclusion/exclusion criteria|0
6176733|NCT01298778|9825829|FG001|Overall Study|not meet inclusion/exclusion criteria|1
6176734|NCT01298999|9825839|FG000|Overall Study|Physician Decision|0
6176735|NCT01298999|9825840|FG001|Overall Study|Physician Decision|1
6176736|NCT01298999|9825839|FG000|Overall Study|Baseline Endoscopy showed low grade dysplasia or indefinite for dysplasia|3
6176737|NCT01298999|9825840|FG001|Overall Study|Baseline Endoscopy showed low grade dysplasia or indefinite for dysplasia|0
6176738|NCT01299025|9825848|FG000|Overall Study|Withdrawal by Subject|2
6176739|NCT01299025|9825849|FG001|Overall Study|Withdrawal by Subject|1
6176740|NCT01299025|9825848|FG000|Overall Study|Lost to Follow-up|1
6176741|NCT01299025|9825849|FG001|Overall Study|Lost to Follow-up|0
6176742|NCT01299038|9825857|FG000|Overall Study|Withdrawal by Subject|1
6176743|NCT01299038|9825858|FG001|Overall Study|Withdrawal by Subject|0
6176744|NCT01299116|9825888|FG000|Overall Study|Lost to Follow-up|65
6176745|NCT01299116|9825889|FG001|Overall Study|Lost to Follow-up|9
6176746|NCT01299116|9825890|FG002|Overall Study|Lost to Follow-up|11
6176747|NCT01299272|9825901|FG000|Acute Open-label (OL) Period|Remission Criteria Not Met|140
6176748|NCT01299272|9825902|FG001|Acute Open-label (OL) Period|Remission Criteria Not Met|0
6176749|NCT01299272|9825903|FG002|Acute Open-label (OL) Period|Remission Criteria Not Met|0
6176750|NCT01299272|9825904|FG003|Acute Open-label (OL) Period|Remission Criteria Not Met|0
6176751|NCT01299272|9825901|FG000|Acute Open-label (OL) Period|Adverse Event|140
6176752|NCT01299272|9825902|FG001|Acute Open-label (OL) Period|Adverse Event|0
6176753|NCT01299272|9825903|FG002|Acute Open-label (OL) Period|Adverse Event|0
6176754|NCT01299272|9825904|FG003|Acute Open-label (OL) Period|Adverse Event|0
6176755|NCT01299272|9825901|FG000|Acute Open-label (OL) Period|Withdrawal by Subject|56
6176756|NCT01299272|9825902|FG001|Acute Open-label (OL) Period|Withdrawal by Subject|0
6176757|NCT01299272|9825903|FG002|Acute Open-label (OL) Period|Withdrawal by Subject|0
6176758|NCT01299272|9825904|FG003|Acute Open-label (OL) Period|Withdrawal by Subject|0
6176759|NCT01299272|9825901|FG000|Acute Open-label (OL) Period|Protocol Violation|36
6176760|NCT01299272|9825902|FG001|Acute Open-label (OL) Period|Protocol Violation|0
6176761|NCT01299272|9825903|FG002|Acute Open-label (OL) Period|Protocol Violation|0
6176762|NCT01299272|9825904|FG003|Acute Open-label (OL) Period|Protocol Violation|0
6176763|NCT01299272|9825901|FG000|Acute Open-label (OL) Period|Lost to Follow-up|14
6176764|NCT01299272|9825902|FG001|Acute Open-label (OL) Period|Lost to Follow-up|0
6176765|NCT01299272|9825903|FG002|Acute Open-label (OL) Period|Lost to Follow-up|0
6176766|NCT01299272|9825904|FG003|Acute Open-label (OL) Period|Lost to Follow-up|0
6176767|NCT01299272|9825901|FG000|Acute Open-label (OL) Period|Sponsor Decision|13
6176768|NCT01299272|9825902|FG001|Acute Open-label (OL) Period|Sponsor Decision|0
6176769|NCT01299272|9825903|FG002|Acute Open-label (OL) Period|Sponsor Decision|0
6176770|NCT01299272|9825904|FG003|Acute Open-label (OL) Period|Sponsor Decision|0
6176771|NCT01299272|9825901|FG000|Acute Open-label (OL) Period|Lack of Efficacy|10
6176772|NCT01299272|9825902|FG001|Acute Open-label (OL) Period|Lack of Efficacy|0
6176773|NCT01299272|9825903|FG002|Acute Open-label (OL) Period|Lack of Efficacy|0
6176774|NCT01299272|9825904|FG003|Acute Open-label (OL) Period|Lack of Efficacy|0
6176775|NCT01299272|9825901|FG000|Acute Open-label (OL) Period|Physician Decision|5
6176776|NCT01299272|9825902|FG001|Acute Open-label (OL) Period|Physician Decision|0
6176777|NCT01299272|9825903|FG002|Acute Open-label (OL) Period|Physician Decision|0
6176778|NCT01299272|9825904|FG003|Acute Open-label (OL) Period|Physician Decision|0
6176779|NCT01299272|9825901|FG000|Stabilization Open-label (OL) Period|Randomization Criteria Not Met|0
6176780|NCT01299272|9825902|FG001|Stabilization Open-label (OL) Period|Randomization Criteria Not Met|80
6176781|NCT01299272|9825903|FG002|Stabilization Open-label (OL) Period|Randomization Criteria Not Met|0
6176782|NCT01299272|9825904|FG003|Stabilization Open-label (OL) Period|Randomization Criteria Not Met|0
6176783|NCT01299272|9825901|FG000|Stabilization Open-label (OL) Period|Protocol Violation|0
6176784|NCT01299272|9825902|FG001|Stabilization Open-label (OL) Period|Protocol Violation|44
6176785|NCT01299272|9825903|FG002|Stabilization Open-label (OL) Period|Protocol Violation|0
6176786|NCT01299272|9825904|FG003|Stabilization Open-label (OL) Period|Protocol Violation|0
6176787|NCT01299272|9825901|FG000|Stabilization Open-label (OL) Period|Adverse Event|0
6176788|NCT01299272|9825902|FG001|Stabilization Open-label (OL) Period|Adverse Event|42
6176789|NCT01299272|9825903|FG002|Stabilization Open-label (OL) Period|Adverse Event|0
6176790|NCT01299272|9825904|FG003|Stabilization Open-label (OL) Period|Adverse Event|0
6176791|NCT01299272|9825901|FG000|Stabilization Open-label (OL) Period|Withdrawal by Subject|0
6176792|NCT01299272|9825902|FG001|Stabilization Open-label (OL) Period|Withdrawal by Subject|42
6176793|NCT01299272|9825903|FG002|Stabilization Open-label (OL) Period|Withdrawal by Subject|0
6176794|NCT01299272|9825904|FG003|Stabilization Open-label (OL) Period|Withdrawal by Subject|0
6176795|NCT01299272|9825901|FG000|Stabilization Open-label (OL) Period|Sponsor Decision|0
6176796|NCT01299272|9825902|FG001|Stabilization Open-label (OL) Period|Sponsor Decision|12
6176797|NCT01299272|9825903|FG002|Stabilization Open-label (OL) Period|Sponsor Decision|0
6176798|NCT01299272|9825904|FG003|Stabilization Open-label (OL) Period|Sponsor Decision|0
6176799|NCT01299272|9825901|FG000|Stabilization Open-label (OL) Period|Lack of Efficacy|0
6176800|NCT01299272|9825902|FG001|Stabilization Open-label (OL) Period|Lack of Efficacy|11
6176801|NCT01299272|9825903|FG002|Stabilization Open-label (OL) Period|Lack of Efficacy|0
6176802|NCT01299272|9825904|FG003|Stabilization Open-label (OL) Period|Lack of Efficacy|0
6176803|NCT01299272|9825901|FG000|Stabilization Open-label (OL) Period|Lost to Follow-up|0
6176804|NCT01299272|9825902|FG001|Stabilization Open-label (OL) Period|Lost to Follow-up|9
6176805|NCT01299272|9825903|FG002|Stabilization Open-label (OL) Period|Lost to Follow-up|0
6176806|NCT01299272|9825904|FG003|Stabilization Open-label (OL) Period|Lost to Follow-up|0
6176807|NCT01299272|9825901|FG000|Stabilization Open-label (OL) Period|Reemergence of Study Condition Symptoms|0
6176808|NCT01299272|9825902|FG001|Stabilization Open-label (OL) Period|Reemergence of Study Condition Symptoms|6
6176809|NCT01299272|9825903|FG002|Stabilization Open-label (OL) Period|Reemergence of Study Condition Symptoms|0
6176810|NCT01299272|9825904|FG003|Stabilization Open-label (OL) Period|Reemergence of Study Condition Symptoms|0
6176811|NCT01299272|9825901|FG000|Stabilization Open-label (OL) Period|Physician Decision|0
6176812|NCT01299272|9825902|FG001|Stabilization Open-label (OL) Period|Physician Decision|3
6176813|NCT01299272|9825903|FG002|Stabilization Open-label (OL) Period|Physician Decision|0
6176814|NCT01299272|9825904|FG003|Stabilization Open-label (OL) Period|Physician Decision|0
6176815|NCT01299272|9825901|FG000|Double-blind (DB) Randomized Period|Withdrawal by Subject|0
6176816|NCT01299272|9825902|FG001|Double-blind (DB) Randomized Period|Withdrawal by Subject|0
6176817|NCT01299272|9825903|FG002|Double-blind (DB) Randomized Period|Withdrawal by Subject|22
6176818|NCT01299272|9825904|FG003|Double-blind (DB) Randomized Period|Withdrawal by Subject|15
6176819|NCT01299272|9825901|FG000|Double-blind (DB) Randomized Period|Lack of Efficacy|0
6176820|NCT01299272|9825902|FG001|Double-blind (DB) Randomized Period|Lack of Efficacy|0
6176821|NCT01299272|9825903|FG002|Double-blind (DB) Randomized Period|Lack of Efficacy|20
6176822|NCT01299272|9825904|FG003|Double-blind (DB) Randomized Period|Lack of Efficacy|10
6176823|NCT01299272|9825901|FG000|Double-blind (DB) Randomized Period|Adverse Event|0
6176824|NCT01299272|9825902|FG001|Double-blind (DB) Randomized Period|Adverse Event|0
6176825|NCT01299272|9825903|FG002|Double-blind (DB) Randomized Period|Adverse Event|8
6176826|NCT01299272|9825904|FG003|Double-blind (DB) Randomized Period|Adverse Event|9
6176827|NCT01299272|9825901|FG000|Double-blind (DB) Randomized Period|Protocol Violation|0
6375057|NCT03745638|10164833|FG001|Long-Term Safety Period (Weeks 8 to 52)|Physician Decision|0
6375058|NCT03745638|10164834|FG002|Long-Term Safety Period (Weeks 8 to 52)|Physician Decision|0
6375059|NCT03745638|10164835|FG003|Long-Term Safety Period (Weeks 8 to 52)|Physician Decision|0
6375060|NCT03745638|10164836|FG004|Long-Term Safety Period (Weeks 8 to 52)|Physician Decision|1
6375061|NCT03745638|10164837|FG005|Long-Term Safety Period (Weeks 8 to 52)|Physician Decision|3
6375062|NCT03745638|10164838|FG006|Long-Term Safety Period (Weeks 8 to 52)|Physician Decision|0
6375063|NCT03745638|10164832|FG000|Long-Term Safety Period (Weeks 8 to 52)|Protocol Violation|0
6375064|NCT03745638|10164833|FG001|Long-Term Safety Period (Weeks 8 to 52)|Protocol Violation|0
6375065|NCT03745638|10164834|FG002|Long-Term Safety Period (Weeks 8 to 52)|Protocol Violation|0
6375066|NCT03745638|10164835|FG003|Long-Term Safety Period (Weeks 8 to 52)|Protocol Violation|0
6375067|NCT03745638|10164836|FG004|Long-Term Safety Period (Weeks 8 to 52)|Protocol Violation|0
6375068|NCT03745638|10164837|FG005|Long-Term Safety Period (Weeks 8 to 52)|Protocol Violation|1
6375069|NCT03745638|10164838|FG006|Long-Term Safety Period (Weeks 8 to 52)|Protocol Violation|0
6375070|NCT03745638|10164832|FG000|Long-Term Safety Period (Weeks 8 to 52)|Withdrawal by Subject|0
6375071|NCT03745638|10164833|FG001|Long-Term Safety Period (Weeks 8 to 52)|Withdrawal by Subject|0
6375072|NCT03745638|10164834|FG002|Long-Term Safety Period (Weeks 8 to 52)|Withdrawal by Subject|0
6375073|NCT03745638|10164835|FG003|Long-Term Safety Period (Weeks 8 to 52)|Withdrawal by Subject|7
6375074|NCT03745638|10164836|FG004|Long-Term Safety Period (Weeks 8 to 52)|Withdrawal by Subject|3
6375075|NCT03745638|10164837|FG005|Long-Term Safety Period (Weeks 8 to 52)|Withdrawal by Subject|17
6375076|NCT03745638|10164838|FG006|Long-Term Safety Period (Weeks 8 to 52)|Withdrawal by Subject|21
6375077|NCT03745638|10164832|FG000|Long-Term Safety Period (Weeks 8 to 52)|Reason Not Specified|0
6375078|NCT03745638|10164833|FG001|Long-Term Safety Period (Weeks 8 to 52)|Reason Not Specified|0
6375079|NCT03745638|10164834|FG002|Long-Term Safety Period (Weeks 8 to 52)|Reason Not Specified|0
6375080|NCT03745638|10164835|FG003|Long-Term Safety Period (Weeks 8 to 52)|Reason Not Specified|0
6375081|NCT03745638|10164836|FG004|Long-Term Safety Period (Weeks 8 to 52)|Reason Not Specified|0
6375082|NCT03745638|10164837|FG005|Long-Term Safety Period (Weeks 8 to 52)|Reason Not Specified|4
6375083|NCT03745638|10164838|FG006|Long-Term Safety Period (Weeks 8 to 52)|Reason Not Specified|3
6375084|NCT03715764|10164857|FG000|Baseline (Randomized (n=69)|Withdrawal by Subject|2
6375085|NCT03715764|10164858|FG001|Baseline (Randomized (n=69)|Withdrawal by Subject|3
6375086|NCT03715764|10164857|FG000|3 Month Follow-up|Lost to Follow-up|2
6375087|NCT03715764|10164858|FG001|3 Month Follow-up|Lost to Follow-up|2
6375088|NCT03715764|10164857|FG000|3 Month Follow-up|Withdrawal by Subject|1
6375089|NCT03715764|10164858|FG001|3 Month Follow-up|Withdrawal by Subject|1
6375090|NCT03715764|10164857|FG000|6 Month Follow-up|Lost to Follow-up|3
6375091|NCT03715764|10164858|FG001|6 Month Follow-up|Lost to Follow-up|0
6375092|NCT03715764|10164857|FG000|12 Month Follow-up|Lost to Follow-up|2
6375093|NCT03715764|10164858|FG001|12 Month Follow-up|Lost to Follow-up|3
6375094|NCT03715764|10164857|FG000|12 Month Follow-up|Pregnancy|0
6375095|NCT03715764|10164858|FG001|12 Month Follow-up|Pregnancy|1
6375096|NCT03715764|10164857|FG000|12 Month Follow-up|Surgery|2
6375097|NCT03715764|10164858|FG001|12 Month Follow-up|Surgery|0
6375098|NCT03715764|10164857|FG000|12 Month Follow-up|Wrong address|1
6375099|NCT03715764|10164858|FG001|12 Month Follow-up|Wrong address|0
6375100|NCT03715764|10164857|FG000|12 Month Follow-up|No symptoms|1
6375101|NCT03715764|10164858|FG001|12 Month Follow-up|No symptoms|0
6375102|NCT03715764|10164857|FG000|12 Month Follow-up|Changed primary care centre|0
6375103|NCT03715764|10164858|FG001|12 Month Follow-up|Changed primary care centre|1
6375104|NCT03654729|10164871|FG000|Overall Study|Death|9
6375105|NCT03654729|10164872|FG001|Overall Study|Death|9
6375106|NCT03654729|10164873|FG002|Overall Study|Death|16
6375107|NCT03654729|10164871|FG000|Overall Study|Withdrawal by Subject|8
6375108|NCT03654729|10164872|FG001|Overall Study|Withdrawal by Subject|6
6375109|NCT03654729|10164873|FG002|Overall Study|Withdrawal by Subject|4
6375110|NCT03654729|10164871|FG000|Overall Study|Study terminated by Sponsor|3
6375111|NCT03654729|10164872|FG001|Overall Study|Study terminated by Sponsor|5
6375112|NCT03654729|10164873|FG002|Overall Study|Study terminated by Sponsor|4
6375113|NCT03654729|10164871|FG000|Overall Study|Not reported|2
6375114|NCT03654729|10164872|FG001|Overall Study|Not reported|4
6375115|NCT03654729|10164873|FG002|Overall Study|Not reported|5
6176828|NCT01299272|9825902|FG001|Double-blind (DB) Randomized Period|Protocol Violation|0
6375116|NCT03654729|10164871|FG000|Overall Study|Progressive disease|3
6375117|NCT03654729|10164872|FG001|Overall Study|Progressive disease|0
6375118|NCT03654729|10164873|FG002|Overall Study|Progressive disease|0
6375119|NCT03654729|10164871|FG000|Overall Study|Lost to Follow-up|2
6375120|NCT03654729|10164872|FG001|Overall Study|Lost to Follow-up|0
6375121|NCT03654729|10164873|FG002|Overall Study|Lost to Follow-up|0
6375122|NCT03654729|10164871|FG000|Overall Study|Physician Decision|2
6375123|NCT03654729|10164872|FG001|Overall Study|Physician Decision|0
6375124|NCT03654729|10164873|FG002|Overall Study|Physician Decision|0
6375125|NCT03654729|10164871|FG000|Overall Study|Protocol Violation|1
6375126|NCT03654729|10164872|FG001|Overall Study|Protocol Violation|1
6375127|NCT03654729|10164873|FG002|Overall Study|Protocol Violation|0
6375128|NCT03654729|10164871|FG000|Overall Study|Non-compliance with study drug|0
6375129|NCT03654729|10164872|FG001|Overall Study|Non-compliance with study drug|1
6375130|NCT03654729|10164873|FG002|Overall Study|Non-compliance with study drug|0
6375131|NCT03654729|10164871|FG000|Overall Study|Site terminated by Sponsor|1
6375132|NCT03654729|10164872|FG001|Overall Study|Site terminated by Sponsor|0
6375133|NCT03654729|10164873|FG002|Overall Study|Site terminated by Sponsor|0
6085069|NCT00648739|9694301|FG002|Overall Study|Investigator Considered it Advisable|0
6085070|NCT00648739|9694302|FG003|Overall Study|Investigator Considered it Advisable|0
6085071|NCT00648739|9694303|FG004|Overall Study|Investigator Considered it Advisable|0
6085072|NCT00648739|9694304|FG005|Overall Study|Investigator Considered it Advisable|1
6085073|NCT00648739|9694305|FG006|Overall Study|Investigator Considered it Advisable|1
6085074|NCT00648739|9694299|FG000|Overall Study|Death|0
6176829|NCT01299272|9825903|FG002|Double-blind (DB) Randomized Period|Protocol Violation|8
6085075|NCT00648739|9694300|FG001|Overall Study|Death|1
6176830|NCT01299272|9825904|FG003|Double-blind (DB) Randomized Period|Protocol Violation|7
6176831|NCT01299272|9825901|FG000|Double-blind (DB) Randomized Period|Lost to Follow-up|0
6176832|NCT01299272|9825902|FG001|Double-blind (DB) Randomized Period|Lost to Follow-up|0
6176833|NCT01299272|9825903|FG002|Double-blind (DB) Randomized Period|Lost to Follow-up|5
6176834|NCT01299272|9825904|FG003|Double-blind (DB) Randomized Period|Lost to Follow-up|5
6176835|NCT01299272|9825901|FG000|Double-blind (DB) Randomized Period|Reemergence of Study Condition Symptoms|0
6176836|NCT01299272|9825902|FG001|Double-blind (DB) Randomized Period|Reemergence of Study Condition Symptoms|0
6176837|NCT01299272|9825903|FG002|Double-blind (DB) Randomized Period|Reemergence of Study Condition Symptoms|4
6176838|NCT01299272|9825904|FG003|Double-blind (DB) Randomized Period|Reemergence of Study Condition Symptoms|10
6176839|NCT01299272|9825901|FG000|Double-blind (DB) Randomized Period|Physician Decision|0
6176840|NCT01299272|9825902|FG001|Double-blind (DB) Randomized Period|Physician Decision|0
6176841|NCT01299272|9825903|FG002|Double-blind (DB) Randomized Period|Physician Decision|2
6176842|NCT01299272|9825904|FG003|Double-blind (DB) Randomized Period|Physician Decision|1
6176843|NCT01299272|9825901|FG000|Double-blind (DB) Randomized Period|Sponsor Decision|0
6375134|NCT02976038|10164925|FG000|Overall Study|Physician Decision|22
6375135|NCT02976038|10164925|FG000|Overall Study|Withdrawal by Subject|3
6375136|NCT02976038|10164925|FG000|Overall Study|Lost to Follow-up|2
6375137|NCT02976038|10164925|FG000|Overall Study|Adverse Event|1
6375138|NCT02631070|10164941|FG000|Overall Study|Withdrawal by Subject|35
6375139|NCT02631070|10164942|FG001|Overall Study|Withdrawal by Subject|13
6375140|NCT02631070|10164941|FG000|Overall Study|Death|45
6375141|NCT02631070|10164942|FG001|Overall Study|Death|24
6375142|NCT02631070|10164941|FG000|Overall Study|Lost to Follow-up|5
6375143|NCT02631070|10164942|FG001|Overall Study|Lost to Follow-up|1
6375144|NCT02631070|10164941|FG000|Overall Study|Transition to rollover protocol|52
6375145|NCT02631070|10164942|FG001|Overall Study|Transition to rollover protocol|21
6375146|NCT02631070|10164941|FG000|Overall Study|Other reasons|12
6375147|NCT02631070|10164942|FG001|Overall Study|Other reasons|5
6375148|NCT02281955|10164948|FG000|Overall Study|Death|1
6375149|NCT02202434|10164956|FG000|Overall Study|Death|70
6375150|NCT02202434|10164957|FG001|Overall Study|Death|39
6375151|NCT02202434|10164958|FG002|Overall Study|Death|13
6375152|NCT02202434|10164959|FG003|Overall Study|Death|27
6375153|NCT02202434|10164956|FG000|Overall Study|Lost to Follow-up|1
6375154|NCT02202434|10164957|FG001|Overall Study|Lost to Follow-up|1
6375155|NCT02202434|10164958|FG002|Overall Study|Lost to Follow-up|1
6375156|NCT02202434|10164959|FG003|Overall Study|Lost to Follow-up|0
6375157|NCT02202434|10164956|FG000|Overall Study|Physician Decision|2
6375158|NCT02202434|10164957|FG001|Overall Study|Physician Decision|3
6375159|NCT02202434|10164958|FG002|Overall Study|Physician Decision|0
6375160|NCT02202434|10164959|FG003|Overall Study|Physician Decision|0
6375161|NCT02202434|10164956|FG000|Overall Study|Withdrawal by Subject|13
6375162|NCT02202434|10164957|FG001|Overall Study|Withdrawal by Subject|14
6375163|NCT02202434|10164958|FG002|Overall Study|Withdrawal by Subject|1
6375164|NCT02202434|10164959|FG003|Overall Study|Withdrawal by Subject|4
6375165|NCT02202434|10164956|FG000|Overall Study|Completed Study|1
6375166|NCT02202434|10164957|FG001|Overall Study|Completed Study|0
6375167|NCT02202434|10164958|FG002|Overall Study|Completed Study|0
6375168|NCT02202434|10164959|FG003|Overall Study|Completed Study|0
6375169|NCT02202434|10164956|FG000|Overall Study|Visit Missed|21
6375170|NCT02202434|10164957|FG001|Overall Study|Visit Missed|12
6375171|NCT02202434|10164958|FG002|Overall Study|Visit Missed|0
6375172|NCT02202434|10164959|FG003|Overall Study|Visit Missed|5
6375173|NCT02202434|10164956|FG000|Overall Study|Other|1
6375174|NCT02202434|10164957|FG001|Overall Study|Other|0
6375175|NCT02202434|10164958|FG002|Overall Study|Other|0
6375176|NCT02202434|10164959|FG003|Overall Study|Other|1
6375177|NCT02097134|10164969|FG000|Overall Study|Physician Decision|4
6375178|NCT02097134|10164969|FG000|Overall Study|Non-Protocol Therapy|1
6375179|NCT02097134|10164969|FG000|Overall Study|Progressive Disease|3
6375180|NCT02097134|10164969|FG000|Overall Study|Refusal of Further Protocol Therapy|1
6375181|NCT01230242|10164978|FG000|Overall Study|Physician Decision|2
6375182|NCT01230242|10164978|FG000|Overall Study|Withdrawal by Subject|1
6375183|NCT00983437|10164982|FG000|Overall Study|Adverse Event|9
6375184|NCT00983437|10164982|FG000|Overall Study|Lack of Efficacy|1
6375185|NCT00983437|10164982|FG000|Overall Study|Withdrawal by Subject|8
6375186|NCT00983437|10164982|FG000|Overall Study|Noncompliance to Study Procedures|1
6375187|NCT00983437|10164982|FG000|Overall Study|Lost to Follow-up|2
6375188|NCT00983437|10164982|FG000|Overall Study|Other Reason|26
6375189|NCT00965757|10164988|FG000|Double-blind Phase|Progression of concomitant disease|1
6375190|NCT00965757|10164989|FG001|Double-blind Phase|Progression of concomitant disease|2
6375191|NCT00965757|10164990|FG002|Double-blind Phase|Progression of concomitant disease|0
6375192|NCT00965757|10164991|FG003|Double-blind Phase|Progression of concomitant disease|0
6375193|NCT00965757|10164988|FG000|Double-blind Phase|Adverse drug reaction|2
6375194|NCT00965757|10164989|FG001|Double-blind Phase|Adverse drug reaction|1
6375195|NCT00965757|10164990|FG002|Double-blind Phase|Adverse drug reaction|0
6375196|NCT00965757|10164991|FG003|Double-blind Phase|Adverse drug reaction|0
6375197|NCT00965757|10164988|FG000|Double-blind Phase|Abnormal Laboratory Value|2
6375198|NCT00965757|10164989|FG001|Double-blind Phase|Abnormal Laboratory Value|0
6375199|NCT00965757|10164990|FG002|Double-blind Phase|Abnormal Laboratory Value|0
6375200|NCT00965757|10164991|FG003|Double-blind Phase|Abnormal Laboratory Value|0
6375201|NCT00965757|10164988|FG000|Double-blind Phase|Lack of Efficacy|7
6375202|NCT00965757|10164989|FG001|Double-blind Phase|Lack of Efficacy|11
6375203|NCT00965757|10164990|FG002|Double-blind Phase|Lack of Efficacy|0
6375204|NCT00965757|10164991|FG003|Double-blind Phase|Lack of Efficacy|0
6375205|NCT00965757|10164988|FG000|Double-blind Phase|Drug Refusal Due to Adverse Event|2
6375206|NCT00965757|10164989|FG001|Double-blind Phase|Drug Refusal Due to Adverse Event|0
6375207|NCT00965757|10164990|FG002|Double-blind Phase|Drug Refusal Due to Adverse Event|0
6375208|NCT00965757|10164991|FG003|Double-blind Phase|Drug Refusal Due to Adverse Event|0
6375209|NCT00965757|10164988|FG000|Double-blind Phase|Lost to Follow-up|0
6375210|NCT00965757|10164989|FG001|Double-blind Phase|Lost to Follow-up|1
6375211|NCT00965757|10164990|FG002|Double-blind Phase|Lost to Follow-up|0
6375212|NCT00965757|10164991|FG003|Double-blind Phase|Lost to Follow-up|0
6375213|NCT00965757|10164988|FG000|Double-blind Phase|Ineligible after Taking Study Drug|2
6375214|NCT00965757|10164989|FG001|Double-blind Phase|Ineligible after Taking Study Drug|3
6375215|NCT00965757|10164990|FG002|Double-blind Phase|Ineligible after Taking Study Drug|0
6375216|NCT00965757|10164991|FG003|Double-blind Phase|Ineligible after Taking Study Drug|0
6375217|NCT00965757|10164988|FG000|Double-blind Phase|Other|1
6375218|NCT00965757|10164989|FG001|Double-blind Phase|Other|0
6375219|NCT00965757|10164990|FG002|Double-blind Phase|Other|0
6375220|NCT00965757|10164991|FG003|Double-blind Phase|Other|0
6176844|NCT01299272|9825902|FG001|Double-blind (DB) Randomized Period|Sponsor Decision|0
6176845|NCT01299272|9825903|FG002|Double-blind (DB) Randomized Period|Sponsor Decision|1
6176846|NCT01299272|9825904|FG003|Double-blind (DB) Randomized Period|Sponsor Decision|1
6176847|NCT01299376|9825926|FG000|Double-blind Treatment (Weeks 1 to 8)|Adverse Event|1
6176848|NCT01299376|9825927|FG001|Double-blind Treatment (Weeks 1 to 8)|Adverse Event|2
6085076|NCT00648739|9694301|FG002|Overall Study|Death|0
6085077|NCT00648739|9694302|FG003|Overall Study|Death|0
6375221|NCT00965757|10164988|FG000|Extension Phase|Progression of concomitant disease|0
6085078|NCT00648739|9694303|FG004|Overall Study|Death|0
6176849|NCT01299376|9825926|FG000|Double-blind Treatment (Weeks 1 to 8)|Lack of Efficacy|0
6176850|NCT01299376|9825927|FG001|Double-blind Treatment (Weeks 1 to 8)|Lack of Efficacy|1
6176851|NCT01299376|9825926|FG000|Double-blind Treatment (Weeks 1 to 8)|Lost to Follow-up|0
6176852|NCT01299376|9825927|FG001|Double-blind Treatment (Weeks 1 to 8)|Lost to Follow-up|1
6176853|NCT01299376|9825926|FG000|Double-blind Treatment (Weeks 1 to 8)|Blood Pressure/Potassium Criteria Met|4
6176854|NCT01299376|9825927|FG001|Double-blind Treatment (Weeks 1 to 8)|Blood Pressure/Potassium Criteria Met|7
6176855|NCT01299376|9825926|FG000|Double-blind Treatment (Weeks 1 to 8)|Protocol Violation|1
6176856|NCT01299376|9825927|FG001|Double-blind Treatment (Weeks 1 to 8)|Protocol Violation|0
6176857|NCT01299376|9825926|FG000|Double-blind Treatment (Weeks 1 to 8)|Withdrawal by Subject|1
6176858|NCT01299376|9825927|FG001|Double-blind Treatment (Weeks 1 to 8)|Withdrawal by Subject|1
6176859|NCT01299376|9825926|FG000|Extension (Weeks 9 to 52)|Withdrawal by Subject|2
6176860|NCT01299376|9825927|FG001|Extension (Weeks 9 to 52)|Withdrawal by Subject|1
6176861|NCT01299376|9825926|FG000|Extension (Weeks 9 to 52)|Adverse Event|2
6176862|NCT01299376|9825927|FG001|Extension (Weeks 9 to 52)|Adverse Event|3
6176863|NCT01299376|9825926|FG000|Extension (Weeks 9 to 52)|Lost to Follow-up|1
6176864|NCT01299376|9825927|FG001|Extension (Weeks 9 to 52)|Lost to Follow-up|2
6176865|NCT01299376|9825926|FG000|Extension (Weeks 9 to 52)|Blood Pressure/Potassium Criteria Met|4
6176866|NCT01299376|9825927|FG001|Extension (Weeks 9 to 52)|Blood Pressure/Potassium Criteria Met|9
6176867|NCT01299376|9825926|FG000|Extension (Weeks 9 to 52)|Physician Decision|1
6176868|NCT01299376|9825927|FG001|Extension (Weeks 9 to 52)|Physician Decision|0
6176869|NCT01299389|9825939|FG000|Double-blind|Adverse Event|45
6176870|NCT01299389|9825940|FG001|Double-blind|Adverse Event|27
6176871|NCT01299389|9825941|FG002|Double-blind|Adverse Event|0
6176872|NCT01299389|9825942|FG003|Double-blind|Adverse Event|0
6176873|NCT01299389|9825939|FG000|Double-blind|Lack of Efficacy|45
6176874|NCT01299389|9825940|FG001|Double-blind|Lack of Efficacy|21
6176875|NCT01299389|9825941|FG002|Double-blind|Lack of Efficacy|0
6176876|NCT01299389|9825942|FG003|Double-blind|Lack of Efficacy|0
6176877|NCT01299389|9825939|FG000|Double-blind|Lost to Follow-up|2
6176878|NCT01299389|9825940|FG001|Double-blind|Lost to Follow-up|1
6176879|NCT01299389|9825941|FG002|Double-blind|Lost to Follow-up|0
6176880|NCT01299389|9825942|FG003|Double-blind|Lost to Follow-up|0
6176881|NCT01299389|9825939|FG000|Double-blind|Withdrawal by Subject|16
6176882|NCT01299389|9825940|FG001|Double-blind|Withdrawal by Subject|13
6176883|NCT01299389|9825941|FG002|Double-blind|Withdrawal by Subject|0
6176884|NCT01299389|9825942|FG003|Double-blind|Withdrawal by Subject|0
6176885|NCT01299389|9825939|FG000|Double-blind|Other|1
6176886|NCT01299389|9825940|FG001|Double-blind|Other|1
6176887|NCT01299389|9825941|FG002|Double-blind|Other|0
6176888|NCT01299389|9825942|FG003|Double-blind|Other|0
6176889|NCT01299389|9825939|FG000|Double-blind|"fail to meet study population criteria"|0
6176890|NCT01299389|9825940|FG001|Double-blind|"fail to meet study population criteria"|1
6176891|NCT01299389|9825941|FG002|Double-blind|"fail to meet study population criteria"|0
6176892|NCT01299389|9825942|FG003|Double-blind|"fail to meet study population criteria"|0
6176893|NCT01299389|9825939|FG000|Post-observational|Other|0
6176894|NCT01299389|9825940|FG001|Post-observational|Other|0
6176895|NCT01299389|9825941|FG002|Post-observational|Other|12
6176896|NCT01299389|9825942|FG003|Post-observational|Other|6
6176897|NCT01299480|9825999|FG000|Overall Study|No longer willing to participate|19
6176898|NCT01299480|9826000|FG001|Overall Study|No longer willing to participate|17
6176899|NCT01299480|9826001|FG002|Overall Study|No longer willing to participate|14
6176900|NCT01299480|9826002|FG003|Overall Study|No longer willing to participate|13
6176901|NCT01299480|9826003|FG004|Overall Study|No longer willing to participate|10
6176902|NCT01299480|9825999|FG000|Overall Study|Protocol Violation|7
6176903|NCT01299480|9826000|FG001|Overall Study|Protocol Violation|5
6176904|NCT01299480|9826001|FG002|Overall Study|Protocol Violation|8
6176905|NCT01299480|9826002|FG003|Overall Study|Protocol Violation|1
6176906|NCT01299480|9826003|FG004|Overall Study|Protocol Violation|1
6176907|NCT01299480|9825999|FG000|Overall Study|Withdrawal by Subject|3
6176908|NCT01299480|9826000|FG001|Overall Study|Withdrawal by Subject|4
6375222|NCT00965757|10164989|FG001|Extension Phase|Progression of concomitant disease|0
6375223|NCT00965757|10164990|FG002|Extension Phase|Progression of concomitant disease|4
6176909|NCT01299480|9826001|FG002|Overall Study|Withdrawal by Subject|7
6176910|NCT01299480|9826002|FG003|Overall Study|Withdrawal by Subject|3
6176911|NCT01299480|9826003|FG004|Overall Study|Withdrawal by Subject|4
6176912|NCT01299480|9825999|FG000|Overall Study|Adverse Event|6
6176913|NCT01299480|9826000|FG001|Overall Study|Adverse Event|4
6176914|NCT01299480|9826001|FG002|Overall Study|Adverse Event|5
6176915|NCT01299480|9826002|FG003|Overall Study|Adverse Event|4
6176916|NCT01299480|9826003|FG004|Overall Study|Adverse Event|0
6176917|NCT01299480|9825999|FG000|Overall Study|Withdrawal due to pregnancy|0
6176918|NCT01299480|9826000|FG001|Overall Study|Withdrawal due to pregnancy|1
6176919|NCT01299480|9826001|FG002|Overall Study|Withdrawal due to pregnancy|1
6176920|NCT01299480|9826002|FG003|Overall Study|Withdrawal due to pregnancy|0
6176921|NCT01299480|9826003|FG004|Overall Study|Withdrawal due to pregnancy|0
6176922|NCT01299480|9825999|FG000|Overall Study|Physician Decision|1
6176923|NCT01299480|9826000|FG001|Overall Study|Physician Decision|1
6176924|NCT01299480|9826001|FG002|Overall Study|Physician Decision|0
6176925|NCT01299480|9826002|FG003|Overall Study|Physician Decision|2
6176926|NCT01299480|9826003|FG004|Overall Study|Physician Decision|0
6176927|NCT01299480|9825999|FG000|Overall Study|Lost to Follow-up|3
6176928|NCT01299480|9826000|FG001|Overall Study|Lost to Follow-up|1
6176929|NCT01299480|9826001|FG002|Overall Study|Lost to Follow-up|2
6176930|NCT01299480|9826002|FG003|Overall Study|Lost to Follow-up|1
6176931|NCT01299480|9826003|FG004|Overall Study|Lost to Follow-up|2
6176932|NCT01299480|9825999|FG000|Overall Study|Other|3
6176933|NCT01299480|9826000|FG001|Overall Study|Other|2
6176934|NCT01299480|9826001|FG002|Overall Study|Other|3
6176935|NCT01299480|9826002|FG003|Overall Study|Other|0
6176936|NCT01299480|9826003|FG004|Overall Study|Other|3
6176937|NCT01299480|9825999|FG000|Overall Study|Started, but not vaccinated|0
6176938|NCT01299480|9826000|FG001|Overall Study|Started, but not vaccinated|0
6176939|NCT01299480|9826001|FG002|Overall Study|Started, but not vaccinated|1
6176940|NCT01299480|9826002|FG003|Overall Study|Started, but not vaccinated|1
6176941|NCT01299480|9826003|FG004|Overall Study|Started, but not vaccinated|0
6176942|NCT01299571|9826016|FG000|Overall Study|Protocol Violation|107
6176943|NCT01299584|9826021|FG000|Overall Study|Protocol Violation|9
6176944|NCT01299727|9826045|FG000|Overall Study|Withdrawal by Subject|1
6176945|NCT01299727|9826046|FG001|Overall Study|Withdrawal by Subject|0
6176946|NCT01299727|9826047|FG002|Overall Study|Withdrawal by Subject|0
6176947|NCT01299727|9826045|FG000|Overall Study|Adverse Event|0
6176948|NCT01299727|9826046|FG001|Overall Study|Adverse Event|0
6176949|NCT01299727|9826047|FG002|Overall Study|Adverse Event|1
6176950|NCT01299727|9826045|FG000|Overall Study|Completed the Treatment Period|3
6176951|NCT01299727|9826046|FG001|Overall Study|Completed the Treatment Period|4
6176952|NCT01299727|9826047|FG002|Overall Study|Completed the Treatment Period|3
6176953|NCT01299766|9826057|FG000|Overall Study|Death|5
6176954|NCT01299766|9826058|FG001|Overall Study|Death|4
6176955|NCT01299766|9826057|FG000|Overall Study|Withdrawal by Subject|29
6176956|NCT01299766|9826058|FG001|Overall Study|Withdrawal by Subject|19
6176957|NCT01299805|9826066|FG000|Overall Study|Adverse Event|2
6176958|NCT01299805|9826067|FG001|Overall Study|Adverse Event|0
6176959|NCT01299896|9826075|FG000|Overall Study|Withdrawal by Subject|1
6176960|NCT01299896|9826076|FG001|Overall Study|Withdrawal by Subject|7
6176961|NCT01299896|9826075|FG000|Overall Study|Lost to Follow-up|0
6176962|NCT01299896|9826076|FG001|Overall Study|Lost to Follow-up|11
6176963|NCT01299909|9826085|FG000|Overall Study|Lost to Follow-up|22
6176964|NCT01299909|9826086|FG001|Overall Study|Lost to Follow-up|18
6176965|NCT01299909|9826087|FG002|Overall Study|Lost to Follow-up|17
6176966|NCT01299961|9826094|FG000|Overall Study|Adverse Event|3
6176967|NCT01299961|9826094|FG000|Overall Study|Lack of Efficacy|2
6176968|NCT01299961|9826094|FG000|Overall Study|Lost to Follow-up|1
6176969|NCT01300052|9826100|FG000|Overall Study|Adverse Event|3
6176970|NCT01300052|9826101|FG001|Overall Study|Adverse Event|0
6176971|NCT01300052|9826100|FG000|Overall Study|Withdrawal by Subject|2
6176972|NCT01300052|9826101|FG001|Overall Study|Withdrawal by Subject|2
6176973|NCT01300052|9826100|FG000|Overall Study|Protocol Violation|1
6176974|NCT01300052|9826101|FG001|Overall Study|Protocol Violation|1
6176975|NCT01300234|9826118|FG000|Overall Study|Adverse Event|1
6176976|NCT01300234|9826119|FG001|Overall Study|Adverse Event|1
6176977|NCT01300234|9826118|FG000|Overall Study|Protocol Violation|2
6176978|NCT01300234|9826119|FG001|Overall Study|Protocol Violation|3
6176979|NCT01300234|9826118|FG000|Overall Study|Withdrawal by Subject|5
6176980|NCT01300234|9826119|FG001|Overall Study|Withdrawal by Subject|9
6176981|NCT01300234|9826118|FG000|Overall Study|Lost to Follow-up|14
6176982|NCT01300234|9826119|FG001|Overall Study|Lost to Follow-up|12
6176983|NCT01300234|9826118|FG000|Overall Study|Pregnancy|2
6176984|NCT01300234|9826119|FG001|Overall Study|Pregnancy|1
6176985|NCT01300234|9826118|FG000|Overall Study|Participant reached stopping critera|2
6176986|NCT01300234|9826119|FG001|Overall Study|Participant reached stopping critera|0
6176987|NCT01300234|9826118|FG000|Overall Study|Participant stopped medication|1
6176988|NCT01300234|9826119|FG001|Overall Study|Participant stopped medication|1
6176989|NCT01300234|9826118|FG000|Overall Study|Participant refused return to hospital|1
6176990|NCT01300234|9826119|FG001|Overall Study|Participant refused return to hospital|0
6176991|NCT01300247|9826138|FG000|Overall Study|Death|1
6176992|NCT01300247|9826139|FG001|Overall Study|Death|1
6176993|NCT01300247|9826138|FG000|Overall Study|Lost to Follow-up|2
6176994|NCT01300247|9826139|FG001|Overall Study|Lost to Follow-up|0
6176995|NCT01300247|9826138|FG000|Overall Study|Withdrawal by Subject|1
6176996|NCT01300247|9826139|FG001|Overall Study|Withdrawal by Subject|0
6176997|NCT01300247|9826138|FG000|Overall Study|Non-Compliance|0
6176998|NCT01300247|9826139|FG001|Overall Study|Non-Compliance|1
6176999|NCT01300260|9826147|FG000|Period 1 of Study: First Intervention|Adverse Event|0
6177000|NCT01300260|9826148|FG001|Period 1 of Study: First Intervention|Adverse Event|1
6177001|NCT01300260|9826147|FG000|Period 1 of Study: First Intervention|Withdrawal by Subject|1
6177002|NCT01300260|9826148|FG001|Period 1 of Study: First Intervention|Withdrawal by Subject|0
6177003|NCT01300260|9826147|FG000|Period 2 of Study: Second Intervention|Adverse Event|0
6177004|NCT01300260|9826148|FG001|Period 2 of Study: Second Intervention|Adverse Event|1
6177005|NCT01300286|9826165|FG000|Overall Study|did not get dosed|1
6192541|NCT01432275|9850063|FG001|Second BG Meter System (7 Days)|Physician Decision|1
6192542|NCT01432275|9850062|FG000|Second BG Meter System (7 Days)|Withdrawal by Subject|0
6192543|NCT01432275|9850063|FG001|Second BG Meter System (7 Days)|Withdrawal by Subject|1
6192544|NCT01432275|9850062|FG000|ADC With Calculator (10 Days)|Physician Decision|1
6192545|NCT01432275|9850063|FG001|ADC With Calculator (10 Days)|Physician Decision|1
6192546|NCT01432275|9850062|FG000|ADC With Calculator (10 Days)|Withdrawal by Subject|2
6192547|NCT01432275|9850063|FG001|ADC With Calculator (10 Days)|Withdrawal by Subject|0
6192548|NCT01432275|9850062|FG000|ADC With Calculator (10 Days)|Protocol Violation|0
6192549|NCT01432275|9850063|FG001|ADC With Calculator (10 Days)|Protocol Violation|1
6192550|NCT01432327|9850073|FG000|Posttest 3 Months|depression|3
6192551|NCT01432327|9850074|FG001|Posttest 3 Months|depression|0
6192552|NCT01432327|9850075|FG002|Posttest 3 Months|depression|0
6192553|NCT01432327|9850076|FG003|Posttest 3 Months|depression|0
6192554|NCT01432327|9850073|FG000|Posttest 3 Months|Lost to Follow-up|1
6192555|NCT01432327|9850074|FG001|Posttest 3 Months|Lost to Follow-up|0
6192556|NCT01432327|9850075|FG002|Posttest 3 Months|Lost to Follow-up|2
6192557|NCT01432327|9850076|FG003|Posttest 3 Months|Lost to Follow-up|1
6192558|NCT01432327|9850073|FG000|Posttest 3 Months|Allergic reaction|0
6192559|NCT01432327|9850074|FG001|Posttest 3 Months|Allergic reaction|2
6192560|NCT01432327|9850075|FG002|Posttest 3 Months|Allergic reaction|0
6192561|NCT01432327|9850076|FG003|Posttest 3 Months|Allergic reaction|0
6192562|NCT01432327|9850073|FG000|Posttest 6 Months|Lost to Follow-up|0
6192563|NCT01432327|9850074|FG001|Posttest 6 Months|Lost to Follow-up|0
6192564|NCT01432327|9850075|FG002|Posttest 6 Months|Lost to Follow-up|3
6192565|NCT01432327|9850076|FG003|Posttest 6 Months|Lost to Follow-up|2
6192566|NCT01432327|9850073|FG000|Posttest 6 Months|Allergic reaction|0
6192567|NCT01432327|9850074|FG001|Posttest 6 Months|Allergic reaction|0
6192568|NCT01432327|9850075|FG002|Posttest 6 Months|Allergic reaction|1
6192569|NCT01432327|9850076|FG003|Posttest 6 Months|Allergic reaction|0
6192570|NCT01432327|9850073|FG000|Posttest 6 Months|Withdrawal by Subject|0
6192571|NCT01432327|9850074|FG001|Posttest 6 Months|Withdrawal by Subject|0
6192572|NCT01432327|9850075|FG002|Posttest 6 Months|Withdrawal by Subject|1
6192573|NCT01432327|9850076|FG003|Posttest 6 Months|Withdrawal by Subject|0
6192574|NCT01432327|9850073|FG000|Posttest 1 Year|Measurement have to take place in future|24
6192575|NCT01432327|9850074|FG001|Posttest 1 Year|Measurement have to take place in future|28
6192576|NCT01432327|9850075|FG002|Posttest 1 Year|Measurement have to take place in future|15
6192577|NCT01432327|9850076|FG003|Posttest 1 Year|Measurement have to take place in future|20
6192578|NCT01432327|9850073|FG000|Posttest 1 Year|Lost to Follow-up|0
6192579|NCT01432327|9850074|FG001|Posttest 1 Year|Lost to Follow-up|0
6192580|NCT01432327|9850075|FG002|Posttest 1 Year|Lost to Follow-up|4
6192581|NCT01432327|9850076|FG003|Posttest 1 Year|Lost to Follow-up|2
6192582|NCT01432327|9850073|FG000|Posttest 1 Year|Allergic reaction|0
6192583|NCT01432327|9850074|FG001|Posttest 1 Year|Allergic reaction|0
6192584|NCT01432327|9850075|FG002|Posttest 1 Year|Allergic reaction|1
6192585|NCT01432327|9850076|FG003|Posttest 1 Year|Allergic reaction|1
6192586|NCT01432366|9850086|FG000|Overall Study|Non-Responder|7
6192587|NCT01432366|9850086|FG000|Overall Study|Adverse Event|8
6192588|NCT01432366|9850086|FG000|Overall Study|Withdrawal Due to Non-Compliance|3
6192589|NCT01432366|9850086|FG000|Overall Study|Pregnancy|1
6192590|NCT01432366|9850086|FG000|Overall Study|Lost to Follow-up|13
6192591|NCT01432366|9850086|FG000|Overall Study|Lack of Efficacy|1
6192592|NCT01432366|9850086|FG000|Overall Study|Site Closed|20
6192593|NCT01432366|9850086|FG000|Overall Study|Investigator Forget to Complete Visits|1
6192594|NCT01432366|9850086|FG000|Overall Study|Other|14
6192595|NCT01432444|9850103|FG000|Tolerability/Cross-titration Phase|Lost to Follow-up|10
6192596|NCT01432444|9850104|FG001|Tolerability/Cross-titration Phase|Lost to Follow-up|0
6192597|NCT01432444|9850105|FG002|Tolerability/Cross-titration Phase|Lost to Follow-up|0
6192598|NCT01432444|9850103|FG000|Tolerability/Cross-titration Phase|Adverse Event|16
6192599|NCT01432444|9850104|FG001|Tolerability/Cross-titration Phase|Adverse Event|0
6192600|NCT01432444|9850105|FG002|Tolerability/Cross-titration Phase|Adverse Event|0
6192601|NCT01432444|9850103|FG000|Tolerability/Cross-titration Phase|Met Withdrawal Criteria|5
6192602|NCT01432444|9850104|FG001|Tolerability/Cross-titration Phase|Met Withdrawal Criteria|0
6192603|NCT01432444|9850105|FG002|Tolerability/Cross-titration Phase|Met Withdrawal Criteria|0
6192604|NCT01432444|9850103|FG000|Tolerability/Cross-titration Phase|Physician Decision|8
6192605|NCT01432444|9850104|FG001|Tolerability/Cross-titration Phase|Physician Decision|0
6192606|NCT01432444|9850105|FG002|Tolerability/Cross-titration Phase|Physician Decision|0
6375224|NCT00965757|10164991|FG003|Extension Phase|Progression of concomitant disease|2
6375225|NCT00965757|10164988|FG000|Extension Phase|Adverse drug reaction|0
6375226|NCT00965757|10164989|FG001|Extension Phase|Adverse drug reaction|0
6375227|NCT00965757|10164990|FG002|Extension Phase|Adverse drug reaction|6
6375228|NCT00965757|10164991|FG003|Extension Phase|Adverse drug reaction|3
6375229|NCT00965757|10164988|FG000|Extension Phase|Abnormal Laboratory Value|0
6375230|NCT00965757|10164989|FG001|Extension Phase|Abnormal Laboratory Value|0
6375231|NCT00965757|10164990|FG002|Extension Phase|Abnormal Laboratory Value|6
6375232|NCT00965757|10164991|FG003|Extension Phase|Abnormal Laboratory Value|1
6375233|NCT00965757|10164988|FG000|Extension Phase|Lack of Efficacy|0
6375234|NCT00965757|10164989|FG001|Extension Phase|Lack of Efficacy|0
6375235|NCT00965757|10164990|FG002|Extension Phase|Lack of Efficacy|8
6375236|NCT00965757|10164991|FG003|Extension Phase|Lack of Efficacy|12
6375237|NCT00965757|10164988|FG000|Extension Phase|Drug Refusal Due to Adverse Event|0
6375238|NCT00965757|10164989|FG001|Extension Phase|Drug Refusal Due to Adverse Event|0
6375239|NCT00965757|10164990|FG002|Extension Phase|Drug Refusal Due to Adverse Event|4
6375240|NCT00965757|10164991|FG003|Extension Phase|Drug Refusal Due to Adverse Event|0
6375241|NCT00965757|10164988|FG000|Extension Phase|Lost to Follow-up|0
6375242|NCT00965757|10164989|FG001|Extension Phase|Lost to Follow-up|0
6375243|NCT00965757|10164990|FG002|Extension Phase|Lost to Follow-up|0
6375244|NCT00965757|10164991|FG003|Extension Phase|Lost to Follow-up|1
6375245|NCT00965757|10164988|FG000|Extension Phase|Ineligible after Taking Study Drug|0
6375246|NCT00965757|10164989|FG001|Extension Phase|Ineligible after Taking Study Drug|0
6375247|NCT00965757|10164990|FG002|Extension Phase|Ineligible after Taking Study Drug|3
6375248|NCT00965757|10164991|FG003|Extension Phase|Ineligible after Taking Study Drug|3
6375249|NCT00965757|10164988|FG000|Extension Phase|Protocol Violation|0
6375250|NCT00965757|10164989|FG001|Extension Phase|Protocol Violation|0
6375251|NCT00965757|10164990|FG002|Extension Phase|Protocol Violation|0
6375252|NCT00965757|10164991|FG003|Extension Phase|Protocol Violation|1
6375253|NCT00965757|10164988|FG000|Extension Phase|Other|0
6375254|NCT00965757|10164989|FG001|Extension Phase|Other|0
6375255|NCT00965757|10164990|FG002|Extension Phase|Other|2
6375256|NCT00965757|10164991|FG003|Extension Phase|Other|1
6375257|NCT00928447|10164999|FG000|Overall Study|Withdrawal by Subject|1
6375258|NCT00928447|10164999|FG000|Overall Study|Investigator's decision|1
6375259|NCT00893789|10165007|FG000|Overall Study|Withdrawal by Subject|3
6375260|NCT00893789|10165008|FG001|Overall Study|Withdrawal by Subject|1
6375261|NCT00893789|10165009|FG002|Overall Study|Withdrawal by Subject|3
6375262|NCT00893789|10165010|FG003|Overall Study|Withdrawal by Subject|1
6375263|NCT00893789|10165007|FG000|Overall Study|Noncompliance With Study Drug|1
6375264|NCT00893789|10165008|FG001|Overall Study|Noncompliance With Study Drug|0
6375265|NCT00893789|10165009|FG002|Overall Study|Noncompliance With Study Drug|1
6375266|NCT00893789|10165010|FG003|Overall Study|Noncompliance With Study Drug|2
6375267|NCT00893789|10165007|FG000|Overall Study|Noncompliance With Study Procedures|1
6375268|NCT00893789|10165008|FG001|Overall Study|Noncompliance With Study Procedures|0
6375269|NCT00893789|10165009|FG002|Overall Study|Noncompliance With Study Procedures|0
6375270|NCT00893789|10165010|FG003|Overall Study|Noncompliance With Study Procedures|0
6375271|NCT00893789|10165007|FG000|Overall Study|Taking Excluded Concomitant Medication|1
6375272|NCT00893789|10165008|FG001|Overall Study|Taking Excluded Concomitant Medication|0
6375273|NCT00893789|10165009|FG002|Overall Study|Taking Excluded Concomitant Medication|1
6375274|NCT00893789|10165010|FG003|Overall Study|Taking Excluded Concomitant Medication|0
6375275|NCT00893789|10165007|FG000|Overall Study|Adverse Event|0
6375276|NCT00893789|10165008|FG001|Overall Study|Adverse Event|2
6375277|NCT00893789|10165009|FG002|Overall Study|Adverse Event|1
6375278|NCT00893789|10165010|FG003|Overall Study|Adverse Event|5
6375279|NCT00893789|10165007|FG000|Overall Study|Protocol Violation|0
6375280|NCT00893789|10165008|FG001|Overall Study|Protocol Violation|1
6375281|NCT00893789|10165009|FG002|Overall Study|Protocol Violation|1
6375282|NCT00893789|10165010|FG003|Overall Study|Protocol Violation|4
6375283|NCT00893789|10165007|FG000|Overall Study|Lost to Follow-up|0
6375284|NCT00893789|10165008|FG001|Overall Study|Lost to Follow-up|0
6375285|NCT00893789|10165009|FG002|Overall Study|Lost to Follow-up|0
6375286|NCT00893789|10165010|FG003|Overall Study|Lost to Follow-up|1
6085079|NCT00648739|9694304|FG005|Overall Study|Death|0
6085080|NCT00648739|9694305|FG006|Overall Study|Death|0
6085081|NCT00648739|9694299|FG000|Overall Study|Positive Human Anti-human Antibody|0
6177006|NCT01300338|9826172|FG000|Overall Study|Lost to Follow-up|5
6177007|NCT01300338|9826173|FG001|Overall Study|Lost to Follow-up|0
6177008|NCT01300351|9826181|FG000|Overall Study|Did not receive treatment|2
6177009|NCT01300351|9826182|FG001|Overall Study|Did not receive treatment|0
6177010|NCT01300351|9826181|FG000|Overall Study|Ongoing treatment at data cut-off|27
6177011|NCT01300351|9826182|FG001|Overall Study|Ongoing treatment at data cut-off|23
6177012|NCT01300351|9826181|FG000|Overall Study|Lost to Follow-up|0
6177013|NCT01300351|9826182|FG001|Overall Study|Lost to Follow-up|1
6177014|NCT01300351|9826181|FG000|Overall Study|Adverse Event|0
6177015|NCT01300351|9826182|FG001|Overall Study|Adverse Event|4
6177016|NCT01300351|9826181|FG000|Overall Study|Withdrawal by Subject|7
6177017|NCT01300351|9826182|FG001|Overall Study|Withdrawal by Subject|10
6177018|NCT01300455|9826190|FG000|Washout|Withdrawal by Subject|1
6177019|NCT01300455|9826191|FG001|Washout|Withdrawal by Subject|0
6177020|NCT01300546|9826199|FG000|Overall Study|Withdrawal by Subject|1
6177021|NCT01300546|9826200|FG001|Overall Study|Withdrawal by Subject|0
6177022|NCT01300546|9826199|FG000|Overall Study|Lost to Follow-up|0
6177023|NCT01300546|9826200|FG001|Overall Study|Lost to Follow-up|2
6177024|NCT01300546|9826199|FG000|Overall Study|Lack of Efficacy|0
6177025|NCT01300546|9826200|FG001|Overall Study|Lack of Efficacy|3
6177026|NCT01300546|9826199|FG000|Overall Study|Adverse Event|0
6177027|NCT01300546|9826200|FG001|Overall Study|Adverse Event|1
6177028|NCT01300572|9826215|FG000|Overall Study|HAMA + post dosimetry|1
6177029|NCT01300650|9826225|FG000|Overall Study|Adverse Event|1
6177030|NCT01300728|9826232|FG000|Overall Study|Withdrawal by Subject|1
6177031|NCT01300728|9826233|FG001|Overall Study|Withdrawal by Subject|1
6177032|NCT01300728|9826232|FG000|Overall Study|Physician Decision|1
6177033|NCT01300728|9826233|FG001|Overall Study|Physician Decision|0
6177034|NCT01300741|9826239|FG000|Overall Study|Lens deposits|1
6177035|NCT01300741|9826239|FG000|Overall Study|Lost to Follow-up|1
6177036|NCT01300741|9826239|FG000|Overall Study|Discomfort|1
6177037|NCT01300767|9826245|FG000|Overall Study|Discomfort|2
6177038|NCT01300767|9826245|FG000|Overall Study|Biomicroscopy|1
6177039|NCT01300767|9826245|FG000|Overall Study|Unacceptable fit|1
6177040|NCT01300819|9826253|FG000|Overall Study|Adverse Event|9
6177041|NCT01300819|9826254|FG001|Overall Study|Adverse Event|27
6177042|NCT01300819|9826253|FG000|Overall Study|Lack of Efficacy|2
6177043|NCT01300819|9826254|FG001|Overall Study|Lack of Efficacy|1
6177044|NCT01300819|9826253|FG000|Overall Study|Withdrawal by Subject|10
6177045|NCT01300819|9826254|FG001|Overall Study|Withdrawal by Subject|12
6177046|NCT01300819|9826253|FG000|Overall Study|Patient was 1 month late for Visit 10|0
6177047|NCT01300819|9826254|FG001|Overall Study|Patient was 1 month late for Visit 10|1
6177048|NCT01300819|9826253|FG000|Overall Study|Refusal to down titrate study drug|0
6177049|NCT01300819|9826254|FG001|Overall Study|Refusal to down titrate study drug|1
6177050|NCT01300819|9826253|FG000|Overall Study|Administrative reason|0
6177051|NCT01300819|9826254|FG001|Overall Study|Administrative reason|1
6177052|NCT01300819|9826253|FG000|Overall Study|Safety follow up not done by mistake|0
6177053|NCT01300819|9826254|FG001|Overall Study|Safety follow up not done by mistake|1
6177054|NCT01300819|9826253|FG000|Overall Study|Follow up call was not done|1
6177055|NCT01300819|9826254|FG001|Overall Study|Follow up call was not done|0
6177056|NCT01300923|9826260|FG000|Overall Study|Physician Decision|0
6177057|NCT01300923|9826261|FG001|Overall Study|Physician Decision|2
6177058|NCT01301001|9826279|FG000|First Intervention|Lost to Follow-up|4
6177059|NCT01301001|9826280|FG001|First Intervention|Lost to Follow-up|4
6177060|NCT01301001|9826279|FG000|First Intervention|Withdrawal by Subject|1
6177061|NCT01301001|9826280|FG001|First Intervention|Withdrawal by Subject|4
6177062|NCT01301001|9826279|FG000|First Intervention|Adverse Event|5
6177063|NCT01301001|9826280|FG001|First Intervention|Adverse Event|0
6177064|NCT01301001|9826279|FG000|First Intervention|Protocol Violation|0
6177065|NCT01301001|9826280|FG001|First Intervention|Protocol Violation|1
6177066|NCT01301001|9826279|FG000|Second Intervention|Adverse Event|2
6177067|NCT01301001|9826280|FG001|Second Intervention|Adverse Event|0
6177068|NCT01301001|9826279|FG000|Second Intervention|Withdrawal by Subject|2
6177069|NCT01301001|9826280|FG001|Second Intervention|Withdrawal by Subject|0
6177070|NCT01301027|9826289|FG000|Overall Study|Physician Decision|2
6177071|NCT01301027|9826290|FG001|Overall Study|Physician Decision|0
6177072|NCT01301027|9826289|FG000|Overall Study|Withdrawal by Subject|2
6177073|NCT01301027|9826290|FG001|Overall Study|Withdrawal by Subject|3
6177074|NCT01301027|9826289|FG000|Overall Study|Adverse Event|0
6177075|NCT01301027|9826290|FG001|Overall Study|Adverse Event|2
6177076|NCT01301027|9826289|FG000|Overall Study|Fracture|1
6177077|NCT01301027|9826290|FG001|Overall Study|Fracture|3
6177078|NCT01301027|9826289|FG000|Overall Study|Transplant|0
6177079|NCT01301027|9826290|FG001|Overall Study|Transplant|2
6177080|NCT01301027|9826289|FG000|Overall Study|Volume Overload|3
6177081|NCT01301027|9826290|FG001|Overall Study|Volume Overload|0
6177082|NCT01301066|9826298|FG000|Overall Study|Lost to Follow-up|5
6177083|NCT01301066|9826299|FG001|Overall Study|Lost to Follow-up|11
6177084|NCT01301066|9826298|FG000|Overall Study|Protocol Violation|8
6177085|NCT01301066|9826299|FG001|Overall Study|Protocol Violation|7
6177086|NCT01301066|9826298|FG000|Overall Study|Withdrawal by Subject|4
6177087|NCT01301066|9826299|FG001|Overall Study|Withdrawal by Subject|9
6177088|NCT01301066|9826298|FG000|Overall Study|Adverse Event|6
6177089|NCT01301066|9826299|FG001|Overall Study|Adverse Event|6
6177090|NCT01301066|9826298|FG000|Overall Study|Sponsor Decision|2
6177091|NCT01301066|9826299|FG001|Overall Study|Sponsor Decision|1
6177092|NCT01301066|9826298|FG000|Overall Study|Physician Decision|0
6177093|NCT01301066|9826299|FG001|Overall Study|Physician Decision|1
6177094|NCT01301066|9826298|FG000|Overall Study|Other|2
6177095|NCT01301066|9826299|FG001|Overall Study|Other|0
6177096|NCT01301079|9826307|FG000|Overall Study|Lost to Follow-up|2
6177097|NCT01301079|9826308|FG001|Overall Study|Lost to Follow-up|2
6177098|NCT01301092|9826321|FG000|Overall Study|Lost to Follow-up|0
6177099|NCT01301092|9826322|FG001|Overall Study|Lost to Follow-up|0
6227583|NCT01717638|9900292|FG010|Overall Study|Father in hospital|0
6227584|NCT01717638|9900293|FG011|Overall Study|Father in hospital|0
6227585|NCT01717638|9900294|FG012|Overall Study|Father in hospital|1
6227586|NCT01717638|9900282|FG000|Overall Study|Withdrawal by Subject|0
6227587|NCT01717638|9900283|FG001|Overall Study|Withdrawal by Subject|1
6227588|NCT01717638|9900284|FG002|Overall Study|Withdrawal by Subject|1
6227589|NCT01717638|9900285|FG003|Overall Study|Withdrawal by Subject|0
6227590|NCT01717638|9900286|FG004|Overall Study|Withdrawal by Subject|1
6227591|NCT01717638|9900287|FG005|Overall Study|Withdrawal by Subject|0
6227592|NCT01717638|9900288|FG006|Overall Study|Withdrawal by Subject|2
6227593|NCT01717638|9900289|FG007|Overall Study|Withdrawal by Subject|1
6227594|NCT01717638|9900290|FG008|Overall Study|Withdrawal by Subject|2
6227595|NCT01717638|9900291|FG009|Overall Study|Withdrawal by Subject|1
6227596|NCT01717638|9900292|FG010|Overall Study|Withdrawal by Subject|0
6227597|NCT01717638|9900293|FG011|Overall Study|Withdrawal by Subject|0
6227598|NCT01717638|9900294|FG012|Overall Study|Withdrawal by Subject|18
6227599|NCT01717768|9900347|FG000|Part 1 (Duration of 15 Days)|Lost to Follow-up|0
6227600|NCT01717768|9900348|FG001|Part 1 (Duration of 15 Days)|Lost to Follow-up|1
6227601|NCT01717768|9900349|FG002|Part 1 (Duration of 15 Days)|Lost to Follow-up|0
6227602|NCT01717768|9900350|FG003|Part 1 (Duration of 15 Days)|Lost to Follow-up|0
6227603|NCT01717768|9900351|FG004|Part 1 (Duration of 15 Days)|Lost to Follow-up|0
6227604|NCT01717768|9900352|FG005|Part 1 (Duration of 15 Days)|Lost to Follow-up|0
6227605|NCT01717768|9900353|FG006|Part 1 (Duration of 15 Days)|Lost to Follow-up|0
6227606|NCT01717768|9900354|FG007|Part 1 (Duration of 15 Days)|Lost to Follow-up|0
6227607|NCT01717768|9900355|FG008|Part 1 (Duration of 15 Days)|Lost to Follow-up|0
6227608|NCT01717768|9900356|FG009|Part 1 (Duration of 15 Days)|Lost to Follow-up|0
6227609|NCT01717768|9900357|FG010|Part 1 (Duration of 15 Days)|Lost to Follow-up|0
6227610|NCT01717768|9900358|FG011|Part 1 (Duration of 15 Days)|Lost to Follow-up|0
6227611|NCT01717768|9900347|FG000|Part 4-Treatment 1 (Duration of 15 Days)|Protocol Violation|0
6227612|NCT01717768|9900348|FG001|Part 4-Treatment 1 (Duration of 15 Days)|Protocol Violation|0
6227613|NCT01717768|9900349|FG002|Part 4-Treatment 1 (Duration of 15 Days)|Protocol Violation|0
6227614|NCT01717768|9900350|FG003|Part 4-Treatment 1 (Duration of 15 Days)|Protocol Violation|0
6227615|NCT01717768|9900351|FG004|Part 4-Treatment 1 (Duration of 15 Days)|Protocol Violation|0
6227616|NCT01717768|9900352|FG005|Part 4-Treatment 1 (Duration of 15 Days)|Protocol Violation|0
6227617|NCT01717768|9900353|FG006|Part 4-Treatment 1 (Duration of 15 Days)|Protocol Violation|0
6227618|NCT01717768|9900354|FG007|Part 4-Treatment 1 (Duration of 15 Days)|Protocol Violation|0
6227619|NCT01717768|9900355|FG008|Part 4-Treatment 1 (Duration of 15 Days)|Protocol Violation|0
6227620|NCT01717768|9900356|FG009|Part 4-Treatment 1 (Duration of 15 Days)|Protocol Violation|0
6227621|NCT01717768|9900357|FG010|Part 4-Treatment 1 (Duration of 15 Days)|Protocol Violation|0
6227622|NCT01717768|9900358|FG011|Part 4-Treatment 1 (Duration of 15 Days)|Protocol Violation|1
6227623|NCT01717768|9900347|FG000|Part 4-Treatment 2 (Duration of 15 Days)|Withdrawal by Subject|0
6227624|NCT01717768|9900348|FG001|Part 4-Treatment 2 (Duration of 15 Days)|Withdrawal by Subject|0
6227625|NCT01717768|9900349|FG002|Part 4-Treatment 2 (Duration of 15 Days)|Withdrawal by Subject|0
6227626|NCT01717768|9900350|FG003|Part 4-Treatment 2 (Duration of 15 Days)|Withdrawal by Subject|0
6227627|NCT01717768|9900351|FG004|Part 4-Treatment 2 (Duration of 15 Days)|Withdrawal by Subject|0
6227628|NCT01717768|9900352|FG005|Part 4-Treatment 2 (Duration of 15 Days)|Withdrawal by Subject|0
6227629|NCT01717768|9900353|FG006|Part 4-Treatment 2 (Duration of 15 Days)|Withdrawal by Subject|0
6227630|NCT01717768|9900354|FG007|Part 4-Treatment 2 (Duration of 15 Days)|Withdrawal by Subject|2
6227631|NCT01717768|9900355|FG008|Part 4-Treatment 2 (Duration of 15 Days)|Withdrawal by Subject|0
6227632|NCT01717768|9900356|FG009|Part 4-Treatment 2 (Duration of 15 Days)|Withdrawal by Subject|0
6227633|NCT01717768|9900357|FG010|Part 4-Treatment 2 (Duration of 15 Days)|Withdrawal by Subject|0
6227634|NCT01717768|9900358|FG011|Part 4-Treatment 2 (Duration of 15 Days)|Withdrawal by Subject|0
6227635|NCT01717768|9900347|FG000|Part 4-Treatment 2 (Duration of 15 Days)|Lost to Follow-up|0
6227636|NCT01717768|9900348|FG001|Part 4-Treatment 2 (Duration of 15 Days)|Lost to Follow-up|0
6227637|NCT01717768|9900349|FG002|Part 4-Treatment 2 (Duration of 15 Days)|Lost to Follow-up|0
6227638|NCT01717768|9900350|FG003|Part 4-Treatment 2 (Duration of 15 Days)|Lost to Follow-up|0
6227639|NCT01717768|9900351|FG004|Part 4-Treatment 2 (Duration of 15 Days)|Lost to Follow-up|0
6227640|NCT01717768|9900352|FG005|Part 4-Treatment 2 (Duration of 15 Days)|Lost to Follow-up|0
6227641|NCT01717768|9900353|FG006|Part 4-Treatment 2 (Duration of 15 Days)|Lost to Follow-up|0
6227642|NCT01717768|9900354|FG007|Part 4-Treatment 2 (Duration of 15 Days)|Lost to Follow-up|0
6227643|NCT01717768|9900355|FG008|Part 4-Treatment 2 (Duration of 15 Days)|Lost to Follow-up|0
6177100|NCT01301092|9826323|FG002|Overall Study|Lost to Follow-up|1
6177101|NCT01301274|9826347|FG000|Overall Study|Physician Decision|2
6177102|NCT01301274|9826348|FG001|Overall Study|Physician Decision|1
6177103|NCT01301391|9826359|FG000|Overall Study|Death|13
6177104|NCT01301391|9826359|FG000|Overall Study|Lost to Follow-up|3
6177105|NCT01301391|9826359|FG000|Overall Study|Physician Decision|2
6177106|NCT01301391|9826359|FG000|Overall Study|Sponsor's decision|8
6177107|NCT01301456|9826375|FG000|Stage 1|Withdrawal by Subject|0
6177108|NCT01301456|9826376|FG001|Stage 1|Withdrawal by Subject|0
6177109|NCT01301456|9826377|FG002|Stage 1|Withdrawal by Subject|1
6177110|NCT01301456|9826378|FG003|Stage 1|Withdrawal by Subject|0
6177111|NCT01301456|9826379|FG004|Stage 1|Withdrawal by Subject|1
6177112|NCT01301456|9826380|FG005|Stage 1|Withdrawal by Subject|0
6177113|NCT01301456|9826381|FG006|Stage 1|Withdrawal by Subject|0
6177114|NCT01301456|9826382|FG007|Stage 1|Withdrawal by Subject|0
6177115|NCT01301456|9826383|FG008|Stage 1|Withdrawal by Subject|0
6177116|NCT01301456|9826384|FG009|Stage 1|Withdrawal by Subject|0
6177117|NCT01301456|9826385|FG010|Stage 1|Withdrawal by Subject|0
6177118|NCT01301456|9826386|FG011|Stage 1|Withdrawal by Subject|0
6177119|NCT01301456|9826375|FG000|Stage 1|Randomized but not treated|0
6177120|NCT01301456|9826376|FG001|Stage 1|Randomized but not treated|0
6177121|NCT01301456|9826377|FG002|Stage 1|Randomized but not treated|0
6177122|NCT01301456|9826378|FG003|Stage 1|Randomized but not treated|0
6177123|NCT01301456|9826379|FG004|Stage 1|Randomized but not treated|0
6177124|NCT01301456|9826380|FG005|Stage 1|Randomized but not treated|0
6177125|NCT01301456|9826381|FG006|Stage 1|Randomized but not treated|1
6177126|NCT01301456|9826382|FG007|Stage 1|Randomized but not treated|0
6177127|NCT01301456|9826383|FG008|Stage 1|Randomized but not treated|0
6177128|NCT01301456|9826384|FG009|Stage 1|Randomized but not treated|0
6177129|NCT01301456|9826385|FG010|Stage 1|Randomized but not treated|0
6177130|NCT01301456|9826386|FG011|Stage 1|Randomized but not treated|0
6177131|NCT01301456|9826375|FG000|Stage 2|Adverse Event|0
6177132|NCT01301456|9826376|FG001|Stage 2|Adverse Event|0
6177133|NCT01301456|9826377|FG002|Stage 2|Adverse Event|0
6177134|NCT01301456|9826378|FG003|Stage 2|Adverse Event|0
6177135|NCT01301456|9826379|FG004|Stage 2|Adverse Event|0
6177136|NCT01301456|9826380|FG005|Stage 2|Adverse Event|0
6177137|NCT01301456|9826381|FG006|Stage 2|Adverse Event|0
6085082|NCT00648739|9694300|FG001|Overall Study|Positive Human Anti-human Antibody|0
6085083|NCT00648739|9694301|FG002|Overall Study|Positive Human Anti-human Antibody|1
6177138|NCT01301456|9826382|FG007|Stage 2|Adverse Event|0
6177139|NCT01301456|9826383|FG008|Stage 2|Adverse Event|0
6177140|NCT01301456|9826384|FG009|Stage 2|Adverse Event|0
6177141|NCT01301456|9826385|FG010|Stage 2|Adverse Event|1
6177142|NCT01301456|9826386|FG011|Stage 2|Adverse Event|0
6177143|NCT01301508|9826432|FG000|Overall Study|Withdrawal by Subject|1
6177144|NCT01301508|9826433|FG001|Overall Study|Withdrawal by Subject|2
6177145|NCT01301508|9826432|FG000|Overall Study|Lost to Follow-up|0
6177146|NCT01301508|9826433|FG001|Overall Study|Lost to Follow-up|1
6177147|NCT01301625|9826439|FG000|Overall Study|Death|5
6177148|NCT01301625|9826439|FG000|Overall Study|Not Due|21
6177149|NCT01301625|9826439|FG000|Overall Study|Expected|8
6177150|NCT01301625|9826439|FG000|Overall Study|Lost to Follow-up|1
6177151|NCT01301729|9826443|FG000|Overall Study|Withdrawal by Subject|2
6177152|NCT01301729|9826443|FG000|Overall Study|Participant did not Return for Treatment|1
6177153|NCT01301729|9826443|FG000|Overall Study|Violated Selection Criteria|1
6177154|NCT01301833|9826460|FG000|Overall Study|Adverse Event|7
6177155|NCT01301833|9826461|FG001|Overall Study|Adverse Event|5
6177156|NCT01301833|9826462|FG002|Overall Study|Adverse Event|5
6177157|NCT01301833|9826463|FG003|Overall Study|Adverse Event|5
6177158|NCT01301833|9826460|FG000|Overall Study|Lack of Efficacy|1
6177159|NCT01301833|9826461|FG001|Overall Study|Lack of Efficacy|1
6177160|NCT01301833|9826462|FG002|Overall Study|Lack of Efficacy|0
6177161|NCT01301833|9826463|FG003|Overall Study|Lack of Efficacy|0
6177162|NCT01301833|9826460|FG000|Overall Study|Physician Decision|3
6177163|NCT01301833|9826461|FG001|Overall Study|Physician Decision|1
6177164|NCT01301833|9826462|FG002|Overall Study|Physician Decision|1
6177165|NCT01301833|9826463|FG003|Overall Study|Physician Decision|0
6177166|NCT01301833|9826460|FG000|Overall Study|Withdrawal by Subject|3
6177167|NCT01301833|9826461|FG001|Overall Study|Withdrawal by Subject|1
6177168|NCT01301833|9826462|FG002|Overall Study|Withdrawal by Subject|1
6177169|NCT01301833|9826463|FG003|Overall Study|Withdrawal by Subject|2
6085084|NCT00648739|9694302|FG003|Overall Study|Positive Human Anti-human Antibody|0
6085085|NCT00648739|9694303|FG004|Overall Study|Positive Human Anti-human Antibody|0
6177170|NCT01301833|9826460|FG000|Overall Study|Personal matter|1
6177171|NCT01301833|9826461|FG001|Overall Study|Personal matter|0
6177172|NCT01301833|9826462|FG002|Overall Study|Personal matter|0
6177173|NCT01301833|9826463|FG003|Overall Study|Personal matter|0
6177174|NCT01301950|9826475|FG000|Overall Study|Surgery was cancelled by patient|0
6177175|NCT01301950|9826476|FG001|Overall Study|Surgery was cancelled by patient|1
6177176|NCT01302041|9826482|FG000|Overall Study|Death|5
6177177|NCT01302041|9826482|FG000|Overall Study|Withdrawal by Subject|4
6177178|NCT01302041|9826482|FG000|Overall Study|Other-Transitioned to 9785-CL-0123|29
6177179|NCT01302041|9826482|FG000|Overall Study|Other-Miscellaneous Reason|2
6177180|NCT01302054|9826487|FG000|Tolterodine Open-Label Run-In Phase|Lack of Efficacy|4
6177181|NCT01302054|9826488|FG001|Tolterodine Open-Label Run-In Phase|Lack of Efficacy|0
6177182|NCT01302054|9826489|FG002|Tolterodine Open-Label Run-In Phase|Lack of Efficacy|0
6177183|NCT01302054|9826487|FG000|Tolterodine Open-Label Run-In Phase|Lost to Follow-up|17
6177184|NCT01302054|9826488|FG001|Tolterodine Open-Label Run-In Phase|Lost to Follow-up|0
6177185|NCT01302054|9826489|FG002|Tolterodine Open-Label Run-In Phase|Lost to Follow-up|0
6177186|NCT01302054|9826487|FG000|Tolterodine Open-Label Run-In Phase|Withdrawal by Subject|16
6177187|NCT01302054|9826488|FG001|Tolterodine Open-Label Run-In Phase|Withdrawal by Subject|0
6177188|NCT01302054|9826489|FG002|Tolterodine Open-Label Run-In Phase|Withdrawal by Subject|0
6177189|NCT01302054|9826487|FG000|Tolterodine Open-Label Run-In Phase|Protocol Violation|8
6177190|NCT01302054|9826488|FG001|Tolterodine Open-Label Run-In Phase|Protocol Violation|0
6177191|NCT01302054|9826489|FG002|Tolterodine Open-Label Run-In Phase|Protocol Violation|0
6177192|NCT01302054|9826487|FG000|Tolterodine Open-Label Run-In Phase|Adverse Event|13
6177193|NCT01302054|9826488|FG001|Tolterodine Open-Label Run-In Phase|Adverse Event|0
6177194|NCT01302054|9826489|FG002|Tolterodine Open-Label Run-In Phase|Adverse Event|0
6177195|NCT01302054|9826487|FG000|Tolterodine Open-Label Run-In Phase|Did Not Meet Entrance Criteria|314
6177196|NCT01302054|9826488|FG001|Tolterodine Open-Label Run-In Phase|Did Not Meet Entrance Criteria|0
6177197|NCT01302054|9826489|FG002|Tolterodine Open-Label Run-In Phase|Did Not Meet Entrance Criteria|0
6177198|NCT01302054|9826487|FG000|Tolterodine Open-Label Run-In Phase|Other|7
6177199|NCT01302054|9826488|FG001|Tolterodine Open-Label Run-In Phase|Other|0
6177200|NCT01302054|9826489|FG002|Tolterodine Open-Label Run-In Phase|Other|0
6177201|NCT01302054|9826487|FG000|Between Open-Label and Double Blind|Did Not Enter Double-Blind Phase|2
6177202|NCT01302054|9826488|FG001|Between Open-Label and Double Blind|Did Not Enter Double-Blind Phase|0
6177203|NCT01302054|9826489|FG002|Between Open-Label and Double Blind|Did Not Enter Double-Blind Phase|0
6177204|NCT01302054|9826487|FG000|Double-Blind Treatment Phase|Lack of Efficacy|0
6177205|NCT01302054|9826488|FG001|Double-Blind Treatment Phase|Lack of Efficacy|2
6177206|NCT01302054|9826489|FG002|Double-Blind Treatment Phase|Lack of Efficacy|4
6177207|NCT01302054|9826487|FG000|Double-Blind Treatment Phase|Lost to Follow-up|0
6177208|NCT01302054|9826488|FG001|Double-Blind Treatment Phase|Lost to Follow-up|2
6177209|NCT01302054|9826489|FG002|Double-Blind Treatment Phase|Lost to Follow-up|1
6177210|NCT01302054|9826487|FG000|Double-Blind Treatment Phase|Withdrawal by Subject|0
6177211|NCT01302054|9826488|FG001|Double-Blind Treatment Phase|Withdrawal by Subject|6
6177212|NCT01302054|9826489|FG002|Double-Blind Treatment Phase|Withdrawal by Subject|14
6177213|NCT01302054|9826487|FG000|Double-Blind Treatment Phase|Protocol Violation|0
6177214|NCT01302054|9826488|FG001|Double-Blind Treatment Phase|Protocol Violation|3
6177215|NCT01302054|9826489|FG002|Double-Blind Treatment Phase|Protocol Violation|6
6177216|NCT01302054|9826487|FG000|Double-Blind Treatment Phase|Adverse Event|0
6177217|NCT01302054|9826488|FG001|Double-Blind Treatment Phase|Adverse Event|10
6177218|NCT01302054|9826489|FG002|Double-Blind Treatment Phase|Adverse Event|10
6177219|NCT01302054|9826487|FG000|Double-Blind Treatment Phase|Did Not Meet Entrance Criteria|0
6177220|NCT01302054|9826488|FG001|Double-Blind Treatment Phase|Did Not Meet Entrance Criteria|0
6177221|NCT01302054|9826489|FG002|Double-Blind Treatment Phase|Did Not Meet Entrance Criteria|2
6177222|NCT01302054|9826487|FG000|Double-Blind Treatment Phase|Other|0
6177223|NCT01302054|9826488|FG001|Double-Blind Treatment Phase|Other|4
6177224|NCT01302054|9826489|FG002|Double-Blind Treatment Phase|Other|9
6177225|NCT01302067|9826501|FG000|Overall Study|Death|0
6177226|NCT01302067|9826502|FG001|Overall Study|Death|0
6177227|NCT01302067|9826503|FG002|Overall Study|Death|1
6177228|NCT01302067|9826501|FG000|Overall Study|Physician Decision|9
6177229|NCT01302067|9826502|FG001|Overall Study|Physician Decision|5
6177230|NCT01302067|9826503|FG002|Overall Study|Physician Decision|14
6177231|NCT01302067|9826501|FG000|Overall Study|Lack of Efficacy|8
6177232|NCT01302067|9826502|FG001|Overall Study|Lack of Efficacy|4
6177233|NCT01302067|9826503|FG002|Overall Study|Lack of Efficacy|2
6177234|NCT01302067|9826501|FG000|Overall Study|Lost to Follow-up|9
6177235|NCT01302067|9826502|FG001|Overall Study|Lost to Follow-up|4
6177236|NCT01302067|9826503|FG002|Overall Study|Lost to Follow-up|15
6177237|NCT01302067|9826501|FG000|Overall Study|Withdrawal by Subject|13
6177238|NCT01302067|9826502|FG001|Overall Study|Withdrawal by Subject|6
6177239|NCT01302067|9826503|FG002|Overall Study|Withdrawal by Subject|10
6177240|NCT01302067|9826501|FG000|Overall Study|Other|1
6177241|NCT01302067|9826502|FG001|Overall Study|Other|1
6177242|NCT01302067|9826503|FG002|Overall Study|Other|3
6177243|NCT01302067|9826501|FG000|Overall Study|Protocol Violation|11
6177244|NCT01302067|9826502|FG001|Overall Study|Protocol Violation|0
6177245|NCT01302067|9826503|FG002|Overall Study|Protocol Violation|8
6177246|NCT01302067|9826501|FG000|Overall Study|Adverse Event|27
6177247|NCT01302067|9826502|FG001|Overall Study|Adverse Event|14
6177248|NCT01302067|9826503|FG002|Overall Study|Adverse Event|45
6177249|NCT01302080|9826514|FG000|Overall Study|Withdrew Consent|92
6177250|NCT01302080|9826515|FG001|Overall Study|Withdrew Consent|39
6177251|NCT01302080|9826514|FG000|Overall Study|Patient/Family Moved|28
6177252|NCT01302080|9826515|FG001|Overall Study|Patient/Family Moved|3
6177253|NCT01302080|9826514|FG000|Overall Study|Lost to Follow-up|192
6177254|NCT01302080|9826515|FG001|Overall Study|Lost to Follow-up|93
6177255|NCT01302080|9826514|FG000|Overall Study|Death|1
6177256|NCT01302080|9826515|FG001|Overall Study|Death|0
6177257|NCT01302080|9826514|FG000|Overall Study|Other|52
6177258|NCT01302080|9826515|FG001|Overall Study|Other|8
6177259|NCT01302080|9826514|FG000|Overall Study|Reason Missing For Discontinuation|1
6177260|NCT01302080|9826515|FG001|Overall Study|Reason Missing For Discontinuation|0
6177261|NCT01302119|9826547|FG000|Overall Study|Withdrawal by Subject|30
6177262|NCT01302119|9826548|FG001|Overall Study|Withdrawal by Subject|20
6177263|NCT01302119|9826547|FG000|Overall Study|Lost to Follow-up|10
6177264|NCT01302119|9826548|FG001|Overall Study|Lost to Follow-up|4
6177265|NCT01302119|9826547|FG000|Overall Study|Adverse Event|2
6177266|NCT01302119|9826548|FG001|Overall Study|Adverse Event|1
6177267|NCT01302119|9826547|FG000|Overall Study|Non-compliance|4
6177268|NCT01302119|9826548|FG001|Overall Study|Non-compliance|2
6177269|NCT01302119|9826547|FG000|Overall Study|Non-specific|4
6177270|NCT01302119|9826548|FG001|Overall Study|Non-specific|1
6177271|NCT01302366|9826554|FG000|Overall Study|patient choice or noncompliance|5
6177272|NCT01302392|9826575|FG000|Overall Study|Lost to Follow-up|1
6177273|NCT01302392|9826576|FG001|Overall Study|Lost to Follow-up|0
6177274|NCT01302392|9826575|FG000|Overall Study|Withdrawal by Subject|6
6177275|NCT01302392|9826576|FG001|Overall Study|Withdrawal by Subject|1
6177276|NCT01302418|9826582|FG000|Overall Study|Protocol Violation|9
6085086|NCT00648739|9694304|FG005|Overall Study|Positive Human Anti-human Antibody|0
6177277|NCT01302418|9826582|FG000|Overall Study|Non-evaluable|9
6177278|NCT01302548|9826603|FG000|Overall Study|Lost to Follow-up|2
6177279|NCT01302548|9826604|FG001|Overall Study|Lost to Follow-up|1
6177280|NCT01302691|9826612|FG000|Overall Study|Adverse Event|2
6177281|NCT01302691|9826613|FG001|Overall Study|Adverse Event|0
6177282|NCT01302691|9826612|FG000|Overall Study|Death|0
6177283|NCT01302691|9826613|FG001|Overall Study|Death|1
6177284|NCT01302691|9826612|FG000|Overall Study|Lost to Follow-up|1
6177285|NCT01302691|9826613|FG001|Overall Study|Lost to Follow-up|0
6177286|NCT01302691|9826612|FG000|Overall Study|Blood Pressure/Potassium Criteria Met|6
6177287|NCT01302691|9826613|FG001|Overall Study|Blood Pressure/Potassium Criteria Met|4
6085087|NCT00648739|9694305|FG006|Overall Study|Positive Human Anti-human Antibody|0
6085088|NCT00648739|9694299|FG000|Overall Study|Follow-up Visits Not Completed|0
6177288|NCT01302691|9826612|FG000|Overall Study|Physician Decision|0
6177289|NCT01302691|9826613|FG001|Overall Study|Physician Decision|1
6177290|NCT01302691|9826612|FG000|Overall Study|Protocol Violation|1
6177291|NCT01302691|9826613|FG001|Overall Study|Protocol Violation|0
6177292|NCT01302834|9826653|FG000|Overall Study|Protocol Violation|17
6177293|NCT01302834|9826654|FG001|Overall Study|Protocol Violation|23
6177294|NCT01302834|9826653|FG000|Overall Study|HIV positive|1
6177295|NCT01302834|9826654|FG001|Overall Study|HIV positive|3
6177296|NCT01302899|9826666|FG000|Period 2 (Weeks 7 to 12)|Protocol Deviation|1
6177297|NCT01302899|9826667|FG001|Period 2 (Weeks 7 to 12)|Protocol Deviation|0
6177298|NCT01302899|9826666|FG000|Period 2 (Weeks 7 to 12)|Abnormal laboratory value(s)|0
6177299|NCT01302899|9826667|FG001|Period 2 (Weeks 7 to 12)|Abnormal laboratory value(s)|1
6177300|NCT01302938|9826679|FG000|Overall Study|Withdrawal by Subject|1
6177301|NCT01302938|9826680|FG001|Overall Study|Withdrawal by Subject|0
6177302|NCT01302938|9826679|FG000|Overall Study|Adverse Event|1
6177303|NCT01302938|9826680|FG001|Overall Study|Adverse Event|0
6177304|NCT01302964|9826689|FG000|Overall Study|Adverse Event|1
6177305|NCT01302964|9826690|FG001|Overall Study|Adverse Event|0
6177306|NCT01303159|9826705|FG000|Overall Study|Death|16
6177307|NCT01303159|9826705|FG000|Overall Study|Study Termination|7
6177308|NCT01303172|9826711|FG000|Overall Study|Physician Decision|9
6177309|NCT01303172|9826712|FG001|Overall Study|Physician Decision|6
6177310|NCT01303172|9826711|FG000|Overall Study|Adverse Event|5
6177311|NCT01303172|9826712|FG001|Overall Study|Adverse Event|2
6177312|NCT01303172|9826711|FG000|Overall Study|Withdrawal by Subject|4
6177313|NCT01303172|9826712|FG001|Overall Study|Withdrawal by Subject|2
6177314|NCT01303172|9826711|FG000|Overall Study|Death|20
6177315|NCT01303172|9826712|FG001|Overall Study|Death|7
6177316|NCT01303172|9826711|FG000|Overall Study|Lack of Efficacy|25
6177317|NCT01303172|9826712|FG001|Overall Study|Lack of Efficacy|17
6177318|NCT01303380|9826736|FG000|Overall Study|Lack of compliance to study procedures|1
6177319|NCT01303419|9826749|FG000|Overall Study|Discontinuation of study|60
6177320|NCT01303419|9826749|FG000|Overall Study|Did not complete both imaging methods|5
6177321|NCT01303419|9826749|FG000|Overall Study|Did not meet all I/E after screening|31
6177322|NCT01303445|9826753|FG000|First Intervention (7 Days)|Withdrawal by Subject|1
6177323|NCT01303445|9826754|FG001|First Intervention (7 Days)|Withdrawal by Subject|0
6177324|NCT01303445|9826753|FG000|Second Intervention (7 Days)|Adverse Event|0
6177325|NCT01303445|9826754|FG001|Second Intervention (7 Days)|Adverse Event|2
6177326|NCT01303445|9826753|FG000|Second Intervention (7 Days)|Withdrawal by Subject|1
6177327|NCT01303445|9826754|FG001|Second Intervention (7 Days)|Withdrawal by Subject|0
6177328|NCT01303445|9826753|FG000|Washout (14 Days)|Protocol Violation|1
6177329|NCT01303445|9826754|FG001|Washout (14 Days)|Protocol Violation|0
6177330|NCT01303445|9826753|FG000|Washout (14 Days)|Lost to Follow-up|0
6177331|NCT01303445|9826754|FG001|Washout (14 Days)|Lost to Follow-up|2
6177332|NCT01303445|9826753|FG000|Fourth Intervention (7 Days)|Withdrawal by Subject|1
6177333|NCT01303445|9826754|FG001|Fourth Intervention (7 Days)|Withdrawal by Subject|0
6177334|NCT01303445|9826753|FG000|Follow-up Period (14 Days)|Withdrawal by Subject|0
6177335|NCT01303445|9826754|FG001|Follow-up Period (14 Days)|Withdrawal by Subject|1
6177336|NCT01303510|9826766|FG000|Overall Study|Lost to Follow-up|1
6177337|NCT01303510|9826767|FG001|Overall Study|Lost to Follow-up|0
6177338|NCT01303627|9826775|FG000|Overall Study|the failure while performing URS|0
6193376|NCT01437995|9851050|FG002|Overall Study|Lost to Follow-up|20
6177339|NCT01303627|9826776|FG001|Overall Study|the failure while performing URS|1
6177340|NCT01303861|9826813|FG000|Overall Study|Lost to Follow-up|34
6177341|NCT01303861|9826814|FG001|Overall Study|Lost to Follow-up|14
6177342|NCT01303861|9826815|FG002|Overall Study|Lost to Follow-up|27
6177343|NCT01303861|9826816|FG003|Overall Study|Lost to Follow-up|31
6177344|NCT01303861|9826813|FG000|Overall Study|Lack of Efficacy|3
6177345|NCT01303861|9826814|FG001|Overall Study|Lack of Efficacy|2
6177346|NCT01303861|9826815|FG002|Overall Study|Lack of Efficacy|1
6177347|NCT01303861|9826816|FG003|Overall Study|Lack of Efficacy|0
6177348|NCT01303861|9826813|FG000|Overall Study|Withdrawal by Subject|16
6177349|NCT01303861|9826814|FG001|Overall Study|Withdrawal by Subject|8
6177350|NCT01303861|9826815|FG002|Overall Study|Withdrawal by Subject|8
6177351|NCT01303861|9826816|FG003|Overall Study|Withdrawal by Subject|23
6177352|NCT01303861|9826813|FG000|Overall Study|Adverse Event|4
6177353|NCT01303861|9826814|FG001|Overall Study|Adverse Event|1
6177354|NCT01303861|9826815|FG002|Overall Study|Adverse Event|0
6177355|NCT01303861|9826816|FG003|Overall Study|Adverse Event|5
6177356|NCT01303861|9826813|FG000|Overall Study|Pregnancy|1
6177357|NCT01303861|9826814|FG001|Overall Study|Pregnancy|0
6177358|NCT01303861|9826815|FG002|Overall Study|Pregnancy|0
6177359|NCT01303861|9826816|FG003|Overall Study|Pregnancy|0
6177360|NCT01303965|9826840|FG000|Overall Study|Adverse Event|1
6177361|NCT01303965|9826841|FG001|Overall Study|Adverse Event|1
6177362|NCT01303965|9826840|FG000|Overall Study|Death|0
6177363|NCT01303965|9826841|FG001|Overall Study|Death|3
6177364|NCT01303965|9826840|FG000|Overall Study|Withdrawal by Subject|1
6177365|NCT01303965|9826841|FG001|Overall Study|Withdrawal by Subject|0
6177366|NCT01303965|9826840|FG000|Overall Study|Disease Progression|1
6177367|NCT01303965|9826841|FG001|Overall Study|Disease Progression|6
6177368|NCT01304147|9826859|FG000|Second Intervention (7days)|Withdrawal by Subject|1
6177369|NCT01304147|9826860|FG001|Second Intervention (7days)|Withdrawal by Subject|1
6177370|NCT01304329|9826914|FG000|Third Intervention (3 Days)|Adverse Event|0
6177371|NCT01304329|9826915|FG001|Third Intervention (3 Days)|Adverse Event|1
6177372|NCT01304329|9826916|FG002|Third Intervention (3 Days)|Adverse Event|0
6177373|NCT01304329|9826917|FG003|Third Intervention (3 Days)|Adverse Event|0
6177374|NCT01304329|9826918|FG004|Third Intervention (3 Days)|Adverse Event|0
6177375|NCT01304329|9826919|FG005|Third Intervention (3 Days)|Adverse Event|0
6177376|NCT01304498|9826933|FG000|Overall Study|Adverse Event|1
6177377|NCT01304498|9826934|FG001|Overall Study|Adverse Event|1
6177378|NCT01304498|9826933|FG000|Overall Study|Withdrawal by Subject|2
6177379|NCT01304498|9826934|FG001|Overall Study|Withdrawal by Subject|3
6177380|NCT01304498|9826933|FG000|Overall Study|Protocol Violation|1
6177381|NCT01304498|9826934|FG001|Overall Study|Protocol Violation|0
6085089|NCT00648739|9694300|FG001|Overall Study|Follow-up Visits Not Completed|1
6085090|NCT00648739|9694301|FG002|Overall Study|Follow-up Visits Not Completed|0
6085091|NCT00648739|9694302|FG003|Overall Study|Follow-up Visits Not Completed|0
6085092|NCT00648739|9694303|FG004|Overall Study|Follow-up Visits Not Completed|0
6085093|NCT00648739|9694304|FG005|Overall Study|Follow-up Visits Not Completed|0
6085094|NCT00648739|9694305|FG006|Overall Study|Follow-up Visits Not Completed|0
6085095|NCT00649220|9694331|FG000|Overall Study|Adverse Event|2
6085096|NCT00649220|9694331|FG000|Overall Study|Withdrawal by Subject|1
6085097|NCT00649389|9694339|FG000|Overall Study|Adverse Event|22
6085098|NCT00649389|9694340|FG001|Overall Study|Adverse Event|46
6085099|NCT00649389|9694341|FG002|Overall Study|Adverse Event|38
6085100|NCT00649389|9694342|FG003|Overall Study|Adverse Event|48
6085101|NCT00649389|9694339|FG000|Overall Study|Lost to Follow-up|15
6085102|NCT00649389|9694340|FG001|Overall Study|Lost to Follow-up|17
6085103|NCT00649389|9694341|FG002|Overall Study|Lost to Follow-up|21
6085104|NCT00649389|9694342|FG003|Overall Study|Lost to Follow-up|26
6085105|NCT00649389|9694339|FG000|Overall Study|Protocol Violation|11
6085106|NCT00649389|9694340|FG001|Overall Study|Protocol Violation|13
6085107|NCT00649389|9694341|FG002|Overall Study|Protocol Violation|9
6085108|NCT00649389|9694342|FG003|Overall Study|Protocol Violation|8
6085109|NCT00649389|9694339|FG000|Overall Study|Withdrawal by Subject|20
6085110|NCT00649389|9694340|FG001|Overall Study|Withdrawal by Subject|21
6085111|NCT00649389|9694341|FG002|Overall Study|Withdrawal by Subject|19
6085112|NCT00649389|9694342|FG003|Overall Study|Withdrawal by Subject|23
6085113|NCT00649389|9694339|FG000|Overall Study|Other|3
6085114|NCT00649389|9694340|FG001|Overall Study|Other|9
6085115|NCT00649389|9694341|FG002|Overall Study|Other|1
6177382|NCT01304498|9826933|FG000|Overall Study|Lost to Follow-up|2
6177383|NCT01304498|9826934|FG001|Overall Study|Lost to Follow-up|1
6177384|NCT01304693|9826959|FG000|Overall Study|Adverse Event|0
6177385|NCT01304693|9826960|FG001|Overall Study|Adverse Event|0
6177386|NCT01304693|9826961|FG002|Overall Study|Adverse Event|0
6177387|NCT01304693|9826962|FG003|Overall Study|Adverse Event|0
6177388|NCT01304693|9826963|FG004|Overall Study|Adverse Event|1
6085116|NCT00649389|9694342|FG003|Overall Study|Other|6
6085117|NCT00649428|9694354|FG000|Overall Study|Adverse Event|2
6085118|NCT00649428|9694355|FG001|Overall Study|Adverse Event|2
6177389|NCT01304693|9826959|FG000|Overall Study|Decision Unrelated to an Adverse Event|0
6177390|NCT01304693|9826960|FG001|Overall Study|Decision Unrelated to an Adverse Event|0
6177391|NCT01304693|9826961|FG002|Overall Study|Decision Unrelated to an Adverse Event|1
6177392|NCT01304693|9826962|FG003|Overall Study|Decision Unrelated to an Adverse Event|1
6177393|NCT01304693|9826963|FG004|Overall Study|Decision Unrelated to an Adverse Event|0
6177394|NCT01304706|9826975|FG000|Overall Study|Adverse Event|2
6177395|NCT01304706|9826975|FG000|Overall Study|Lack of Efficacy|1
6177396|NCT01304706|9826975|FG000|Overall Study|Death|3
6177397|NCT01304706|9826975|FG000|Overall Study|Withdrawal by Subject|3
6177398|NCT01304706|9826975|FG000|Overall Study|Lost to Follow-up|7
6177399|NCT01304706|9826975|FG000|Overall Study|Discontinued due to failed drug admin.|1
6177400|NCT01304940|9826981|FG000|Overall Study|not meet symptom severity requirement|3
6177401|NCT01304940|9826982|FG001|Overall Study|not meet symptom severity requirement|0
6177402|NCT01305044|9826996|FG000|Overall Study|Withdrawal by Subject|3
6177403|NCT01305044|9826997|FG001|Overall Study|Withdrawal by Subject|6
6177404|NCT01305200|9827006|FG000|Overall Study|Physician Decision|4
6177405|NCT01305200|9827007|FG001|Overall Study|Physician Decision|6
6177406|NCT01305200|9827008|FG002|Overall Study|Physician Decision|1
6177407|NCT01305200|9827006|FG000|Overall Study|Withdrawal by Subject|24
6177408|NCT01305200|9827007|FG001|Overall Study|Withdrawal by Subject|21
6177409|NCT01305200|9827008|FG002|Overall Study|Withdrawal by Subject|1
6177410|NCT01305200|9827006|FG000|Overall Study|Ineligible|1
6177411|NCT01305200|9827007|FG001|Overall Study|Ineligible|2
6177412|NCT01305200|9827008|FG002|Overall Study|Ineligible|1
6177413|NCT01305200|9827006|FG000|Overall Study|Death|0
6177414|NCT01305200|9827007|FG001|Overall Study|Death|2
6177415|NCT01305200|9827008|FG002|Overall Study|Death|0
6177416|NCT01305239|9827026|FG000|Overall Study|Adverse Event|22
6177417|NCT01305239|9827026|FG000|Overall Study|Exemestane taken prior to inclusion only|1
6177418|NCT01305408|9827063|FG000|Overall Study|Adverse Event|10
6177419|NCT01305408|9827064|FG001|Overall Study|Adverse Event|7
6177420|NCT01305408|9827063|FG000|Overall Study|Lack of Efficacy|3
6177421|NCT01305408|9827064|FG001|Overall Study|Lack of Efficacy|4
6177422|NCT01305408|9827063|FG000|Overall Study|Withdrawal by Subject|9
6177423|NCT01305408|9827064|FG001|Overall Study|Withdrawal by Subject|9
6177424|NCT01305408|9827063|FG000|Overall Study|Protocol Violation|4
6177425|NCT01305408|9827064|FG001|Overall Study|Protocol Violation|6
6177426|NCT01305408|9827063|FG000|Overall Study|Lost to Follow-up|5
6177427|NCT01305408|9827064|FG001|Overall Study|Lost to Follow-up|3
6177428|NCT01305408|9827063|FG000|Overall Study|Noncompliance with study medication|0
6177429|NCT01305408|9827064|FG001|Overall Study|Noncompliance with study medication|1
6177430|NCT01305408|9827063|FG000|Overall Study|Noncompliance with study procedures|0
6177431|NCT01305408|9827064|FG001|Overall Study|Noncompliance with study procedures|1
6177432|NCT01305408|9827063|FG000|Overall Study|Other|1
6177433|NCT01305408|9827064|FG001|Overall Study|Other|0
6177434|NCT01305564|9827074|FG000|Overall Study|Death|21
6177435|NCT01305564|9827074|FG000|Overall Study|Lost to Follow-up|12
6177436|NCT01305564|9827074|FG000|Overall Study|Withdrawal by Subject|1
6177437|NCT01305564|9827074|FG000|Overall Study|Physician Decision|3
6177438|NCT01305577|9827092|FG000|Overall Study|Adverse Event|2
6177439|NCT01305577|9827093|FG001|Overall Study|Adverse Event|2
6177440|NCT01305577|9827094|FG002|Overall Study|Adverse Event|1
6177441|NCT01305577|9827092|FG000|Overall Study|Withdrawal by Subject|7
6177442|NCT01305577|9827093|FG001|Overall Study|Withdrawal by Subject|5
6177443|NCT01305577|9827094|FG002|Overall Study|Withdrawal by Subject|6
6177444|NCT01305577|9827092|FG000|Overall Study|Lost to Follow-up|4
6177445|NCT01305577|9827093|FG001|Overall Study|Lost to Follow-up|3
6177446|NCT01305577|9827094|FG002|Overall Study|Lost to Follow-up|2
6177447|NCT01305577|9827092|FG000|Overall Study|Protocol Deviation|0
6177448|NCT01305577|9827093|FG001|Overall Study|Protocol Deviation|1
6177449|NCT01305577|9827094|FG002|Overall Study|Protocol Deviation|1
6177450|NCT01305941|9827125|FG000|Overall Study|Adverse Event|6
6177451|NCT01305941|9827125|FG000|Overall Study|Clinical decline|2
6177452|NCT01305941|9827125|FG000|Overall Study|Withdrawal by Subject|1
6177453|NCT01305941|9827125|FG000|Overall Study|Death|1
6177454|NCT01306032|9827135|FG000|First Intervention|Adverse Event|1
6177455|NCT01306032|9827136|FG001|First Intervention|Adverse Event|0
6177456|NCT01306032|9827137|FG002|First Intervention|Adverse Event|1
6177457|NCT01306032|9827138|FG003|First Intervention|Adverse Event|0
6177458|NCT01306032|9827139|FG004|First Intervention|Adverse Event|0
6177459|NCT01306032|9827140|FG005|First Intervention|Adverse Event|1
6177460|NCT01306032|9827135|FG000|First Intervention|Withdrawal by Subject|0
6177461|NCT01306032|9827136|FG001|First Intervention|Withdrawal by Subject|2
6177462|NCT01306032|9827137|FG002|First Intervention|Withdrawal by Subject|0
6177463|NCT01306032|9827138|FG003|First Intervention|Withdrawal by Subject|1
6177464|NCT01306032|9827139|FG004|First Intervention|Withdrawal by Subject|0
6177465|NCT01306032|9827140|FG005|First Intervention|Withdrawal by Subject|0
6177466|NCT01306032|9827135|FG000|First Intervention|Death|0
6177467|NCT01306032|9827136|FG001|First Intervention|Death|0
6271924|NCT02169336|9974036|FG002|Overall Study|Physician Decision|1
6177468|NCT01306032|9827137|FG002|First Intervention|Death|1
6177469|NCT01306032|9827138|FG003|First Intervention|Death|0
6177470|NCT01306032|9827139|FG004|First Intervention|Death|0
6177471|NCT01306032|9827140|FG005|First Intervention|Death|0
6177472|NCT01306032|9827135|FG000|First Intervention|Ineligible|0
6177473|NCT01306032|9827136|FG001|First Intervention|Ineligible|0
6177474|NCT01306032|9827137|FG002|First Intervention|Ineligible|0
6177475|NCT01306032|9827138|FG003|First Intervention|Ineligible|0
6177476|NCT01306032|9827139|FG004|First Intervention|Ineligible|0
6177477|NCT01306032|9827140|FG005|First Intervention|Ineligible|1
6177478|NCT01306032|9827135|FG000|First Intervention|Progressive disease|0
6177479|NCT01306032|9827136|FG001|First Intervention|Progressive disease|0
6177480|NCT01306032|9827137|FG002|First Intervention|Progressive disease|0
6177481|NCT01306032|9827138|FG003|First Intervention|Progressive disease|0
6177482|NCT01306032|9827139|FG004|First Intervention|Progressive disease|2
6177483|NCT01306032|9827140|FG005|First Intervention|Progressive disease|0
6177484|NCT01306032|9827135|FG000|Disease Progression/Crossover|Withdrawal by Subject|0
6177485|NCT01306032|9827136|FG001|Disease Progression/Crossover|Withdrawal by Subject|0
6177486|NCT01306032|9827137|FG002|Disease Progression/Crossover|Withdrawal by Subject|0
6177487|NCT01306032|9827138|FG003|Disease Progression/Crossover|Withdrawal by Subject|1
6177488|NCT01306032|9827139|FG004|Disease Progression/Crossover|Withdrawal by Subject|0
6177489|NCT01306032|9827140|FG005|Disease Progression/Crossover|Withdrawal by Subject|0
6177490|NCT01306032|9827135|FG000|Disease Progression/Crossover|other/symptomatic progression|0
6177491|NCT01306032|9827136|FG001|Disease Progression/Crossover|other/symptomatic progression|2
6177492|NCT01306032|9827137|FG002|Disease Progression/Crossover|other/symptomatic progression|0
6177493|NCT01306032|9827138|FG003|Disease Progression/Crossover|other/symptomatic progression|2
6177494|NCT01306032|9827139|FG004|Disease Progression/Crossover|other/symptomatic progression|0
6177495|NCT01306032|9827140|FG005|Disease Progression/Crossover|other/symptomatic progression|0
6177496|NCT01306058|9827166|FG000|Overall Study|Death|1
6177497|NCT01306058|9827166|FG000|Overall Study|Enrolled but did not get treatment|1
6177498|NCT01306162|9827174|FG000|Period 1|Adverse Event|0
6177499|NCT01306162|9827175|FG001|Period 1|Adverse Event|0
6177500|NCT01306162|9827176|FG002|Period 1|Adverse Event|0
6177501|NCT01306162|9827177|FG003|Period 1|Adverse Event|1
6177502|NCT01306162|9827174|FG000|Washout 1|Non-compliance to protocol|0
6177503|NCT01306162|9827175|FG001|Washout 1|Non-compliance to protocol|1
6177504|NCT01306162|9827176|FG002|Washout 1|Non-compliance to protocol|0
6177505|NCT01306162|9827177|FG003|Washout 1|Non-compliance to protocol|0
6177506|NCT01306201|9827196|FG000|Overall Study|Arrhythmia|4
6177507|NCT01306201|9827196|FG000|Overall Study|Files could not be processed|3
6177508|NCT01306201|9827196|FG000|Overall Study|Files unreadable|3
6177509|NCT01306214|9827207|FG000|Overall Study|Death|0
6177510|NCT01306214|9827208|FG001|Overall Study|Death|0
6177511|NCT01306214|9827209|FG002|Overall Study|Death|1
6177512|NCT01306214|9827207|FG000|Overall Study|Lost to Follow-up|3
6177513|NCT01306214|9827208|FG001|Overall Study|Lost to Follow-up|5
6177514|NCT01306214|9827209|FG002|Overall Study|Lost to Follow-up|4
6177515|NCT01306214|9827207|FG000|Overall Study|Withdrawal by Subject|24
6177516|NCT01306214|9827208|FG001|Overall Study|Withdrawal by Subject|22
6177517|NCT01306214|9827209|FG002|Overall Study|Withdrawal by Subject|16
6177518|NCT01306214|9827207|FG000|Overall Study|Not treated|1
6177519|NCT01306214|9827208|FG001|Overall Study|Not treated|1
6177520|NCT01306214|9827209|FG002|Overall Study|Not treated|1
6177521|NCT01306253|9827219|FG000|Overall Study|Lost to Follow-up|1
6177522|NCT01306253|9827220|FG001|Overall Study|Lost to Follow-up|1
6177523|NCT01306305|9827241|FG000|Overall Study|Lost to Follow-up|1
6177524|NCT01306305|9827242|FG001|Overall Study|Lost to Follow-up|0
6177525|NCT01306305|9827241|FG000|Overall Study|Withdrew consent|1
6177526|NCT01306305|9827242|FG001|Overall Study|Withdrew consent|0
6192607|NCT01432444|9850103|FG000|Tolerability/Cross-titration Phase|Withdrawal by Subject|15
6192608|NCT01432444|9850104|FG001|Tolerability/Cross-titration Phase|Withdrawal by Subject|0
6192609|NCT01432444|9850105|FG002|Tolerability/Cross-titration Phase|Withdrawal by Subject|0
6192610|NCT01432444|9850103|FG000|Tolerability/Cross-titration Phase|Protocol Deviation|1
6192611|NCT01432444|9850104|FG001|Tolerability/Cross-titration Phase|Protocol Deviation|0
6192612|NCT01432444|9850105|FG002|Tolerability/Cross-titration Phase|Protocol Deviation|0
6192613|NCT01432444|9850103|FG000|Tolerability/Cross-titration Phase|Lack of Efficacy|5
6192614|NCT01432444|9850104|FG001|Tolerability/Cross-titration Phase|Lack of Efficacy|0
6192615|NCT01432444|9850105|FG002|Tolerability/Cross-titration Phase|Lack of Efficacy|0
6192616|NCT01432444|9850103|FG000|Treatment Phase|Lost to Follow-up|0
6192617|NCT01432444|9850104|FG001|Treatment Phase|Lost to Follow-up|33
6192618|NCT01432444|9850105|FG002|Treatment Phase|Lost to Follow-up|0
6192619|NCT01432444|9850103|FG000|Treatment Phase|Adverse Event|0
6192620|NCT01432444|9850104|FG001|Treatment Phase|Adverse Event|37
6192621|NCT01432444|9850105|FG002|Treatment Phase|Adverse Event|0
6192622|NCT01432444|9850103|FG000|Treatment Phase|Met Withdrawal Criteria|0
6192623|NCT01432444|9850104|FG001|Treatment Phase|Met Withdrawal Criteria|11
6192624|NCT01432444|9850105|FG002|Treatment Phase|Met Withdrawal Criteria|0
6192625|NCT01432444|9850103|FG000|Treatment Phase|Physician Decision|0
6192626|NCT01432444|9850104|FG001|Treatment Phase|Physician Decision|5
6192627|NCT01432444|9850105|FG002|Treatment Phase|Physician Decision|0
6192628|NCT01432444|9850103|FG000|Treatment Phase|Withdrawal by Subject|0
6192629|NCT01432444|9850104|FG001|Treatment Phase|Withdrawal by Subject|41
6192630|NCT01432444|9850105|FG002|Treatment Phase|Withdrawal by Subject|0
6192631|NCT01432444|9850103|FG000|Treatment Phase|Protocol Deviation|0
6192632|NCT01432444|9850104|FG001|Treatment Phase|Protocol Deviation|3
6192633|NCT01432444|9850105|FG002|Treatment Phase|Protocol Deviation|0
6192634|NCT01432444|9850103|FG000|Treatment Phase|Lack of Efficacy|0
6192635|NCT01432444|9850104|FG001|Treatment Phase|Lack of Efficacy|10
6192636|NCT01432444|9850105|FG002|Treatment Phase|Lack of Efficacy|0
6192637|NCT01432444|9850103|FG000|Extension Phase|Lost to Follow-up|0
6192638|NCT01432444|9850104|FG001|Extension Phase|Lost to Follow-up|0
6177527|NCT01306331|9827250|FG000|Overall Study|Adverse Event|28
6177528|NCT01306331|9827251|FG001|Overall Study|Adverse Event|25
6177529|NCT01306331|9827250|FG000|Overall Study|Lost to Follow-up|321
6177530|NCT01306331|9827251|FG001|Overall Study|Lost to Follow-up|323
6177531|NCT01306331|9827250|FG000|Overall Study|Physician Decision|26
6177532|NCT01306331|9827251|FG001|Overall Study|Physician Decision|22
6177533|NCT01306331|9827250|FG000|Overall Study|Pregnancy|136
6177534|NCT01306331|9827251|FG001|Overall Study|Pregnancy|151
6177535|NCT01306331|9827250|FG000|Overall Study|Protocol Violation|154
6177536|NCT01306331|9827251|FG001|Overall Study|Protocol Violation|124
6177537|NCT01306331|9827250|FG000|Overall Study|Withdrawal by Subject|163
6177538|NCT01306331|9827251|FG001|Overall Study|Withdrawal by Subject|152
6177539|NCT01306331|9827250|FG000|Overall Study|Not sexually active|29
6177540|NCT01306331|9827251|FG001|Overall Study|Not sexually active|28
6177541|NCT01306331|9827250|FG000|Overall Study|Meth. no longer prim. meth. birth cntrl|10
6177542|NCT01306331|9827251|FG001|Overall Study|Meth. no longer prim. meth. birth cntrl|20
6177543|NCT01306331|9827250|FG000|Overall Study|Other|34
6177544|NCT01306331|9827251|FG001|Overall Study|Other|32
6177545|NCT01306617|9827260|FG000|Overall Study|Adverse Event|1
6177546|NCT01306617|9827261|FG001|Overall Study|Adverse Event|0
6177547|NCT01306617|9827262|FG002|Overall Study|Adverse Event|0
6177548|NCT01306617|9827260|FG000|Overall Study|Virologic Failure|0
6177549|NCT01306617|9827261|FG001|Overall Study|Virologic Failure|0
6177550|NCT01306617|9827262|FG002|Overall Study|Virologic Failure|5
6177551|NCT01306617|9827260|FG000|Overall Study|Non-compliance|0
6177552|NCT01306617|9827261|FG001|Overall Study|Non-compliance|1
6177553|NCT01306617|9827262|FG002|Overall Study|Non-compliance|0
6177554|NCT01306643|9827270|FG000|Overall Study|Adverse Event|5
6177555|NCT01306643|9827270|FG000|Overall Study|Disease Progression|7
6177556|NCT01306643|9827270|FG000|Overall Study|Other: Change in Eligibility Status|1
6177557|NCT01306656|9827276|FG000|Overall Study|Lost to Follow-up|1
6177558|NCT01306656|9827277|FG001|Overall Study|Lost to Follow-up|0
6177559|NCT01306877|9827287|FG000|Overall Study|Lost to Follow-up|3
6177560|NCT01306877|9827288|FG001|Overall Study|Lost to Follow-up|3
6177561|NCT01306877|9827287|FG000|Overall Study|Physician Decision|0
6177562|NCT01306877|9827288|FG001|Overall Study|Physician Decision|1
6177563|NCT01306890|9827294|FG000|Overall Study|Adverse Event|2
6177564|NCT01306890|9827294|FG000|Overall Study|Death|1223
6177565|NCT01306890|9827294|FG000|Overall Study|Lost to Follow-up|58
6177566|NCT01306890|9827294|FG000|Overall Study|Withdrawal by Subject|88
6177567|NCT01306890|9827294|FG000|Overall Study|Unspecified reasons|104
6177568|NCT01306890|9827294|FG000|Overall Study|Study Termination|3
6177569|NCT01306890|9827294|FG000|Overall Study|No discontinuation documentation|41
6177570|NCT01306942|9827301|FG000|Phase I|Adverse Event|2
6177571|NCT01306942|9827302|FG001|Phase I|Adverse Event|2
6177572|NCT01306942|9827303|FG002|Phase I|Adverse Event|0
6177573|NCT01306942|9827304|FG003|Phase I|Adverse Event|0
6177574|NCT01306942|9827301|FG000|Phase I|Physician Decision|3
6177575|NCT01306942|9827302|FG001|Phase I|Physician Decision|1
6177576|NCT01306942|9827303|FG002|Phase I|Physician Decision|0
6177577|NCT01306942|9827304|FG003|Phase I|Physician Decision|0
6177578|NCT01306942|9827301|FG000|Phase II|Adverse Event|0
6177579|NCT01306942|9827302|FG001|Phase II|Adverse Event|0
6177580|NCT01306942|9827303|FG002|Phase II|Adverse Event|0
6177581|NCT01306942|9827304|FG003|Phase II|Adverse Event|6
6177582|NCT01306942|9827301|FG000|Phase II|Physician Decision|2
6177583|NCT01306942|9827302|FG001|Phase II|Physician Decision|0
6177584|NCT01306942|9827303|FG002|Phase II|Physician Decision|0
6177585|NCT01306942|9827304|FG003|Phase II|Physician Decision|5
6177586|NCT01306942|9827301|FG000|Phase II|Withdrawal by Subject|0
6177587|NCT01306942|9827302|FG001|Phase II|Withdrawal by Subject|0
6177588|NCT01306942|9827303|FG002|Phase II|Withdrawal by Subject|0
6177589|NCT01306942|9827304|FG003|Phase II|Withdrawal by Subject|2
6085119|NCT00649428|9694354|FG000|Overall Study|Withdrawal by Subject|6
6085120|NCT00649428|9694355|FG001|Overall Study|Withdrawal by Subject|6
6375287|NCT03901144|10165028|FG000|Overall Study|Lost to Follow-up|1
6375288|NCT03901144|10165029|FG001|Overall Study|Lost to Follow-up|1
6375289|NCT03901144|10165030|FG002|Overall Study|Lost to Follow-up|1
6375290|NCT03901144|10165031|FG003|Overall Study|Lost to Follow-up|1
6375291|NCT03461211|10165056|FG000|Overall Study|Adverse Event|1
6375292|NCT03461211|10165057|FG001|Overall Study|Adverse Event|1
6375293|NCT03461211|10165056|FG000|Overall Study|Lack of Efficacy|0
6375294|NCT03461211|10165057|FG001|Overall Study|Lack of Efficacy|1
6375295|NCT03282123|10165065|FG000|Overall Study|Withdrawal by Subject|5
6375296|NCT03276780|10165072|FG000|Overall Study|Withdrawal by Subject|5
6375297|NCT03276780|10165073|FG001|Overall Study|Withdrawal by Subject|3
6177590|NCT01306942|9827301|FG000|Phase II|Death|0
6085121|NCT00649428|9694354|FG000|Overall Study|Lost to Follow-up|1
6177591|NCT01306942|9827302|FG001|Phase II|Death|0
6177592|NCT01306942|9827303|FG002|Phase II|Death|0
6177593|NCT01306942|9827304|FG003|Phase II|Death|1
6085122|NCT00649428|9694355|FG001|Overall Study|Lost to Follow-up|3
6177594|NCT01306942|9827301|FG000|Phase II|Not finished treatment|0
6177595|NCT01306942|9827302|FG001|Phase II|Not finished treatment|0
6177596|NCT01306942|9827303|FG002|Phase II|Not finished treatment|0
6177597|NCT01306942|9827304|FG003|Phase II|Not finished treatment|1
6177598|NCT01306942|9827301|FG000|Phase II|Protocol Violation|0
6375298|NCT03276780|10165072|FG000|Overall Study|Lost to Follow-up|3
6177599|NCT01306942|9827302|FG001|Phase II|Protocol Violation|0
6177600|NCT01306942|9827303|FG002|Phase II|Protocol Violation|0
6177601|NCT01306942|9827304|FG003|Phase II|Protocol Violation|1
6177602|NCT01306968|9827320|FG000|Overall Study|Lost to Follow-up|1
6177603|NCT01306968|9827321|FG001|Overall Study|Lost to Follow-up|1
6177604|NCT01306968|9827322|FG002|Overall Study|Lost to Follow-up|0
6177605|NCT01306968|9827323|FG003|Overall Study|Lost to Follow-up|0
6177606|NCT01306968|9827320|FG000|Overall Study|Physician Decision|0
6177607|NCT01306968|9827321|FG001|Overall Study|Physician Decision|1
6177608|NCT01306968|9827322|FG002|Overall Study|Physician Decision|0
6177609|NCT01306968|9827323|FG003|Overall Study|Physician Decision|0
6177610|NCT01306968|9827320|FG000|Overall Study|Relocated and left active duty|0
6177611|NCT01306968|9827321|FG001|Overall Study|Relocated and left active duty|1
6177612|NCT01306968|9827322|FG002|Overall Study|Relocated and left active duty|1
6177613|NCT01306968|9827323|FG003|Overall Study|Relocated and left active duty|1
6177614|NCT01306968|9827320|FG000|Overall Study|Withdrew - time commitment|0
6177615|NCT01306968|9827321|FG001|Overall Study|Withdrew - time commitment|0
6177616|NCT01306968|9827322|FG002|Overall Study|Withdrew - time commitment|0
6177617|NCT01306968|9827323|FG003|Overall Study|Withdrew - time commitment|2
6177618|NCT01306968|9827320|FG000|Overall Study|Withdrew over privacy concerns|0
6177619|NCT01306968|9827321|FG001|Overall Study|Withdrew over privacy concerns|0
6177620|NCT01306968|9827322|FG002|Overall Study|Withdrew over privacy concerns|0
6177621|NCT01306968|9827323|FG003|Overall Study|Withdrew over privacy concerns|1
6177622|NCT01307020|9827354|FG000|Overall Study|Lost to Follow-up|0
6177623|NCT01307020|9827355|FG001|Overall Study|Lost to Follow-up|0
6177624|NCT01307020|9827356|FG002|Overall Study|Lost to Follow-up|1
6177625|NCT01307020|9827357|FG003|Overall Study|Lost to Follow-up|1
6177626|NCT01307020|9827358|FG004|Overall Study|Lost to Follow-up|0
6177627|NCT01307020|9827359|FG005|Overall Study|Lost to Follow-up|0
6177628|NCT01307020|9827360|FG006|Overall Study|Lost to Follow-up|1
6177629|NCT01307020|9827361|FG007|Overall Study|Lost to Follow-up|0
6177630|NCT01307020|9827362|FG008|Overall Study|Lost to Follow-up|0
6177631|NCT01307020|9827363|FG009|Overall Study|Lost to Follow-up|0
6177632|NCT01307020|9827354|FG000|Overall Study|Electronic data capture failure|0
6177633|NCT01307020|9827355|FG001|Overall Study|Electronic data capture failure|1
6177634|NCT01307020|9827356|FG002|Overall Study|Electronic data capture failure|0
6177635|NCT01307020|9827357|FG003|Overall Study|Electronic data capture failure|0
6177636|NCT01307020|9827358|FG004|Overall Study|Electronic data capture failure|0
6177637|NCT01307020|9827359|FG005|Overall Study|Electronic data capture failure|0
6177638|NCT01307020|9827360|FG006|Overall Study|Electronic data capture failure|0
6177639|NCT01307020|9827361|FG007|Overall Study|Electronic data capture failure|0
6177640|NCT01307020|9827362|FG008|Overall Study|Electronic data capture failure|0
6177641|NCT01307020|9827363|FG009|Overall Study|Electronic data capture failure|0
6177642|NCT01307111|9827401|FG000|IUD Insertion|Lost to Follow-up|2
6177643|NCT01307111|9827402|FG001|IUD Insertion|Lost to Follow-up|0
6177644|NCT01307111|9827401|FG000|1-2 Week IUD Check up|IUD expulsion/removal|2
6177645|NCT01307111|9827402|FG001|1-2 Week IUD Check up|IUD expulsion/removal|2
6177646|NCT01307267|9827431|FG000|Overall Study|Death|4
6177647|NCT01307267|9827432|FG001|Overall Study|Death|3
6177648|NCT01307267|9827433|FG002|Overall Study|Death|5
6177649|NCT01307267|9827434|FG003|Overall Study|Death|3
6177650|NCT01307267|9827435|FG004|Overall Study|Death|1
6177651|NCT01307267|9827436|FG005|Overall Study|Death|26
6177652|NCT01307267|9827437|FG006|Overall Study|Death|2
6177653|NCT01307267|9827438|FG007|Overall Study|Death|2
6177654|NCT01307267|9827439|FG008|Overall Study|Death|21
6177655|NCT01307267|9827440|FG009|Overall Study|Death|2
6177656|NCT01307267|9827441|FG010|Overall Study|Death|3
6177657|NCT01307267|9827442|FG011|Overall Study|Death|9
6177658|NCT01307267|9827443|FG012|Overall Study|Death|0
6177659|NCT01307267|9827444|FG013|Overall Study|Death|0
6177660|NCT01307267|9827445|FG014|Overall Study|Death|0
6177661|NCT01307267|9827446|FG015|Overall Study|Death|0
6177662|NCT01307267|9827447|FG016|Overall Study|Death|1
6177663|NCT01307267|9827448|FG017|Overall Study|Death|1
6177664|NCT01307267|9827449|FG018|Overall Study|Death|2
6177665|NCT01307267|9827450|FG019|Overall Study|Death|8
6177666|NCT01307267|9827451|FG020|Overall Study|Death|1
6177667|NCT01307267|9827452|FG021|Overall Study|Death|2
6177668|NCT01307267|9827453|FG022|Overall Study|Death|2
6177669|NCT01307267|9827431|FG000|Overall Study|Lost to Follow-up|0
6177670|NCT01307267|9827432|FG001|Overall Study|Lost to Follow-up|0
6177671|NCT01307267|9827433|FG002|Overall Study|Lost to Follow-up|0
6177672|NCT01307267|9827434|FG003|Overall Study|Lost to Follow-up|0
6177673|NCT01307267|9827435|FG004|Overall Study|Lost to Follow-up|0
6177674|NCT01307267|9827436|FG005|Overall Study|Lost to Follow-up|7
6177675|NCT01307267|9827437|FG006|Overall Study|Lost to Follow-up|0
6177676|NCT01307267|9827438|FG007|Overall Study|Lost to Follow-up|0
6177677|NCT01307267|9827439|FG008|Overall Study|Lost to Follow-up|1
6177678|NCT01307267|9827440|FG009|Overall Study|Lost to Follow-up|2
6177679|NCT01307267|9827441|FG010|Overall Study|Lost to Follow-up|1
6177680|NCT01307267|9827442|FG011|Overall Study|Lost to Follow-up|0
6177681|NCT01307267|9827443|FG012|Overall Study|Lost to Follow-up|0
6177682|NCT01307267|9827444|FG013|Overall Study|Lost to Follow-up|0
6177683|NCT01307267|9827445|FG014|Overall Study|Lost to Follow-up|0
6177684|NCT01307267|9827446|FG015|Overall Study|Lost to Follow-up|0
6177685|NCT01307267|9827447|FG016|Overall Study|Lost to Follow-up|0
6177686|NCT01307267|9827448|FG017|Overall Study|Lost to Follow-up|0
6177687|NCT01307267|9827449|FG018|Overall Study|Lost to Follow-up|0
6177688|NCT01307267|9827450|FG019|Overall Study|Lost to Follow-up|2
6177689|NCT01307267|9827451|FG020|Overall Study|Lost to Follow-up|0
6177690|NCT01307267|9827452|FG021|Overall Study|Lost to Follow-up|0
6177691|NCT01307267|9827453|FG022|Overall Study|Lost to Follow-up|0
6177692|NCT01307267|9827431|FG000|Overall Study|Withdrawal by Subject|0
6177693|NCT01307267|9827432|FG001|Overall Study|Withdrawal by Subject|0
6177694|NCT01307267|9827433|FG002|Overall Study|Withdrawal by Subject|0
6177695|NCT01307267|9827434|FG003|Overall Study|Withdrawal by Subject|0
6177696|NCT01307267|9827435|FG004|Overall Study|Withdrawal by Subject|0
6177697|NCT01307267|9827436|FG005|Overall Study|Withdrawal by Subject|1
6177698|NCT01307267|9827437|FG006|Overall Study|Withdrawal by Subject|0
6177699|NCT01307267|9827438|FG007|Overall Study|Withdrawal by Subject|1
6177700|NCT01307267|9827439|FG008|Overall Study|Withdrawal by Subject|5
6177701|NCT01307267|9827440|FG009|Overall Study|Withdrawal by Subject|1
6177702|NCT01307267|9827441|FG010|Overall Study|Withdrawal by Subject|1
6177703|NCT01307267|9827442|FG011|Overall Study|Withdrawal by Subject|1
6177704|NCT01307267|9827443|FG012|Overall Study|Withdrawal by Subject|0
6177705|NCT01307267|9827444|FG013|Overall Study|Withdrawal by Subject|0
6177706|NCT01307267|9827445|FG014|Overall Study|Withdrawal by Subject|0
6177707|NCT01307267|9827446|FG015|Overall Study|Withdrawal by Subject|0
6177708|NCT01307267|9827447|FG016|Overall Study|Withdrawal by Subject|0
6177709|NCT01307267|9827448|FG017|Overall Study|Withdrawal by Subject|0
6177710|NCT01307267|9827449|FG018|Overall Study|Withdrawal by Subject|0
6177711|NCT01307267|9827450|FG019|Overall Study|Withdrawal by Subject|3
6177712|NCT01307267|9827451|FG020|Overall Study|Withdrawal by Subject|0
6177713|NCT01307267|9827452|FG021|Overall Study|Withdrawal by Subject|0
6177714|NCT01307267|9827453|FG022|Overall Study|Withdrawal by Subject|0
6177715|NCT01307267|9827431|FG000|Overall Study|Other|0
6177716|NCT01307267|9827432|FG001|Overall Study|Other|0
6177717|NCT01307267|9827433|FG002|Overall Study|Other|0
6177718|NCT01307267|9827434|FG003|Overall Study|Other|0
6177719|NCT01307267|9827435|FG004|Overall Study|Other|0
6177720|NCT01307267|9827436|FG005|Overall Study|Other|7
6177721|NCT01307267|9827437|FG006|Overall Study|Other|0
6177722|NCT01307267|9827438|FG007|Overall Study|Other|1
6177723|NCT01307267|9827439|FG008|Overall Study|Other|3
6177724|NCT01307267|9827440|FG009|Overall Study|Other|0
6177725|NCT01307267|9827441|FG010|Overall Study|Other|1
6177726|NCT01307267|9827442|FG011|Overall Study|Other|1
6177727|NCT01307267|9827443|FG012|Overall Study|Other|1
6177728|NCT01307267|9827444|FG013|Overall Study|Other|0
6177729|NCT01307267|9827445|FG014|Overall Study|Other|2
6177730|NCT01307267|9827446|FG015|Overall Study|Other|1
6177731|NCT01307267|9827447|FG016|Overall Study|Other|0
6177732|NCT01307267|9827448|FG017|Overall Study|Other|0
6177733|NCT01307267|9827449|FG018|Overall Study|Other|0
6177734|NCT01307267|9827450|FG019|Overall Study|Other|19
6177735|NCT01307267|9827451|FG020|Overall Study|Other|2
6177736|NCT01307267|9827452|FG021|Overall Study|Other|3
6177737|NCT01307267|9827453|FG022|Overall Study|Other|2
6177738|NCT01307319|9827515|FG000|Overall Study|Adverse Event|2
6177739|NCT01307319|9827516|FG001|Overall Study|Adverse Event|2
6177740|NCT01307319|9827517|FG002|Overall Study|Adverse Event|1
6177741|NCT01307319|9827515|FG000|Overall Study|Lost to Follow-up|1
6177742|NCT01307319|9827516|FG001|Overall Study|Lost to Follow-up|0
6177743|NCT01307319|9827517|FG002|Overall Study|Lost to Follow-up|1
6177744|NCT01307319|9827515|FG000|Overall Study|Protocol Violation|1
6177745|NCT01307319|9827516|FG001|Overall Study|Protocol Violation|1
6177746|NCT01307319|9827517|FG002|Overall Study|Protocol Violation|0
6177747|NCT01307319|9827515|FG000|Overall Study|Withdrawal by Subject|0
6177748|NCT01307319|9827516|FG001|Overall Study|Withdrawal by Subject|1
6177749|NCT01307319|9827517|FG002|Overall Study|Withdrawal by Subject|2
6177750|NCT01307319|9827515|FG000|Overall Study|Other|0
6177751|NCT01307319|9827516|FG001|Overall Study|Other|4
6177752|NCT01307319|9827517|FG002|Overall Study|Other|3
6177753|NCT01307423|9827532|FG000|Placebo-controlled Phase (Week 0 - 24)|Adverse Event|4
6177754|NCT01307423|9827533|FG001|Placebo-controlled Phase (Week 0 - 24)|Adverse Event|4
6177755|NCT01307423|9827534|FG002|Placebo-controlled Phase (Week 0 - 24)|Adverse Event|6
6177756|NCT01307423|9827535|FG003|Placebo-controlled Phase (Week 0 - 24)|Adverse Event|0
6177757|NCT01307423|9827536|FG004|Placebo-controlled Phase (Week 0 - 24)|Adverse Event|0
6177758|NCT01307423|9827537|FG005|Placebo-controlled Phase (Week 0 - 24)|Adverse Event|0
6177759|NCT01307423|9827538|FG006|Placebo-controlled Phase (Week 0 - 24)|Adverse Event|0
6177760|NCT01307423|9827539|FG007|Placebo-controlled Phase (Week 0 - 24)|Adverse Event|0
6177761|NCT01307423|9827540|FG008|Placebo-controlled Phase (Week 0 - 24)|Adverse Event|0
6177762|NCT01307423|9827532|FG000|Placebo-controlled Phase (Week 0 - 24)|Lack of Efficacy|1
6177763|NCT01307423|9827533|FG001|Placebo-controlled Phase (Week 0 - 24)|Lack of Efficacy|3
6177764|NCT01307423|9827534|FG002|Placebo-controlled Phase (Week 0 - 24)|Lack of Efficacy|2
6177765|NCT01307423|9827535|FG003|Placebo-controlled Phase (Week 0 - 24)|Lack of Efficacy|0
6177766|NCT01307423|9827536|FG004|Placebo-controlled Phase (Week 0 - 24)|Lack of Efficacy|0
6177767|NCT01307423|9827537|FG005|Placebo-controlled Phase (Week 0 - 24)|Lack of Efficacy|0
6177768|NCT01307423|9827538|FG006|Placebo-controlled Phase (Week 0 - 24)|Lack of Efficacy|0
6177769|NCT01307423|9827539|FG007|Placebo-controlled Phase (Week 0 - 24)|Lack of Efficacy|0
6177770|NCT01307423|9827540|FG008|Placebo-controlled Phase (Week 0 - 24)|Lack of Efficacy|0
6177771|NCT01307423|9827532|FG000|Placebo-controlled Phase (Week 0 - 24)|Withdrawal by Subject|8
6177772|NCT01307423|9827533|FG001|Placebo-controlled Phase (Week 0 - 24)|Withdrawal by Subject|4
6177773|NCT01307423|9827534|FG002|Placebo-controlled Phase (Week 0 - 24)|Withdrawal by Subject|10
6177774|NCT01307423|9827535|FG003|Placebo-controlled Phase (Week 0 - 24)|Withdrawal by Subject|0
6177775|NCT01307423|9827536|FG004|Placebo-controlled Phase (Week 0 - 24)|Withdrawal by Subject|0
6177776|NCT01307423|9827537|FG005|Placebo-controlled Phase (Week 0 - 24)|Withdrawal by Subject|0
6177777|NCT01307423|9827538|FG006|Placebo-controlled Phase (Week 0 - 24)|Withdrawal by Subject|0
6177778|NCT01307423|9827539|FG007|Placebo-controlled Phase (Week 0 - 24)|Withdrawal by Subject|0
6177779|NCT01307423|9827540|FG008|Placebo-controlled Phase (Week 0 - 24)|Withdrawal by Subject|0
6177780|NCT01307423|9827532|FG000|Placebo-controlled Phase (Week 0 - 24)|Randomization Error|0
6177781|NCT01307423|9827533|FG001|Placebo-controlled Phase (Week 0 - 24)|Randomization Error|0
6177782|NCT01307423|9827534|FG002|Placebo-controlled Phase (Week 0 - 24)|Randomization Error|1
6177783|NCT01307423|9827535|FG003|Placebo-controlled Phase (Week 0 - 24)|Randomization Error|0
6177784|NCT01307423|9827536|FG004|Placebo-controlled Phase (Week 0 - 24)|Randomization Error|0
6177785|NCT01307423|9827537|FG005|Placebo-controlled Phase (Week 0 - 24)|Randomization Error|0
6177786|NCT01307423|9827538|FG006|Placebo-controlled Phase (Week 0 - 24)|Randomization Error|0
6177787|NCT01307423|9827539|FG007|Placebo-controlled Phase (Week 0 - 24)|Randomization Error|0
6177788|NCT01307423|9827540|FG008|Placebo-controlled Phase (Week 0 - 24)|Randomization Error|0
6177789|NCT01307423|9827532|FG000|Placebo-controlled Phase (Week 0 - 24)|Lost to Follow-up|5
6177790|NCT01307423|9827533|FG001|Placebo-controlled Phase (Week 0 - 24)|Lost to Follow-up|1
6177791|NCT01307423|9827534|FG002|Placebo-controlled Phase (Week 0 - 24)|Lost to Follow-up|2
6177792|NCT01307423|9827535|FG003|Placebo-controlled Phase (Week 0 - 24)|Lost to Follow-up|0
6177793|NCT01307423|9827536|FG004|Placebo-controlled Phase (Week 0 - 24)|Lost to Follow-up|0
6192639|NCT01432444|9850105|FG002|Extension Phase|Lost to Follow-up|17
6227644|NCT01717768|9900356|FG009|Part 4-Treatment 2 (Duration of 15 Days)|Lost to Follow-up|1
6227645|NCT01717768|9900357|FG010|Part 4-Treatment 2 (Duration of 15 Days)|Lost to Follow-up|0
6227646|NCT01717768|9900358|FG011|Part 4-Treatment 2 (Duration of 15 Days)|Lost to Follow-up|0
6227647|NCT01717859|9900384|FG000|Overall Study|Adverse Event|5
6227648|NCT01717859|9900384|FG000|Overall Study|Moved out of state|1
6227649|NCT01717859|9900384|FG000|Overall Study|Patient concerned about mental health|1
6227650|NCT01717859|9900384|FG000|Overall Study|Lost to Follow-up|1
6227651|NCT01717859|9900384|FG000|Overall Study|Withdrawal by Subject|2
6227652|NCT01717976|9900423|FG000|Overall Study|Protocol Violation|0
6227653|NCT01717976|9900424|FG001|Overall Study|Protocol Violation|1
6227654|NCT01717989|9900430|FG000|Overall Study|Ineligibility determined|6
6227655|NCT01717989|9900430|FG000|Overall Study|Protocol deviation|6
6227656|NCT01717989|9900430|FG000|Overall Study|Withdrawal by Subject|11
6227657|NCT01717989|9900430|FG000|Overall Study|Physician Decision|2
6227658|NCT01717989|9900430|FG000|Overall Study|Lost to Follow-up|11
6227659|NCT01717989|9900430|FG000|Overall Study|Death|439
6227660|NCT01717989|9900430|FG000|Overall Study|Protocol-specified criteria|551
6227661|NCT01717989|9900430|FG000|Overall Study|Other|40
6227662|NCT01718353|9900460|FG000|Overall Study|Lost to Follow-up|0
6227663|NCT01718353|9900461|FG001|Overall Study|Lost to Follow-up|1
6227664|NCT01718353|9900460|FG000|Overall Study|Principal Investigator's Decision|10
6227665|NCT01718353|9900461|FG001|Overall Study|Principal Investigator's Decision|4
6227666|NCT01718353|9900460|FG000|Overall Study|Randomized but not treated|2
6227667|NCT01718353|9900461|FG001|Overall Study|Randomized but not treated|0
6227668|NCT01718483|9900471|FG000|Overall Study|Withdrawal by Subject|14
6227669|NCT01718483|9900472|FG001|Overall Study|Withdrawal by Subject|12
6227670|NCT01718483|9900471|FG000|Overall Study|Adverse Event|5
6227671|NCT01718483|9900472|FG001|Overall Study|Adverse Event|12
6227672|NCT01718483|9900471|FG000|Overall Study|Lost to Follow-up|8
6227673|NCT01718483|9900472|FG001|Overall Study|Lost to Follow-up|3
6227674|NCT01718483|9900471|FG000|Overall Study|Protocol Violation|4
6227675|NCT01718483|9900472|FG001|Overall Study|Protocol Violation|2
6227676|NCT01718483|9900471|FG000|Overall Study|Other|1
6227677|NCT01718483|9900472|FG001|Overall Study|Other|4
6227678|NCT01718483|9900471|FG000|Overall Study|Pregnancy|1
6227679|NCT01718483|9900472|FG001|Overall Study|Pregnancy|1
6227680|NCT01718483|9900471|FG000|Overall Study|Lack of Efficacy|1
6227681|NCT01718483|9900472|FG001|Overall Study|Lack of Efficacy|0
6227682|NCT01718509|9900480|FG000|Overall Study|Lost to Follow-up|18
6227683|NCT01718509|9900481|FG001|Overall Study|Lost to Follow-up|15
6227684|NCT01718509|9900480|FG000|Overall Study|Withdrawal by Subject|7
6227685|NCT01718509|9900481|FG001|Overall Study|Withdrawal by Subject|13
6227686|NCT01718509|9900480|FG000|Overall Study|Adverse Event|5
6227687|NCT01718509|9900481|FG001|Overall Study|Adverse Event|7
6227688|NCT01718509|9900480|FG000|Overall Study|Other|13
6227689|NCT01718509|9900481|FG001|Overall Study|Other|11
6227690|NCT01718509|9900480|FG000|Overall Study|Protocol Violation|4
6227691|NCT01718509|9900481|FG001|Overall Study|Protocol Violation|2
6227692|NCT01718509|9900480|FG000|Overall Study|Lack of Efficacy|1
6227693|NCT01718509|9900481|FG001|Overall Study|Lack of Efficacy|0
6227694|NCT01718535|9900504|FG000|Overall Study|Bidirectional Sequencing not possible|1
6375299|NCT03276780|10165073|FG001|Overall Study|Lost to Follow-up|5
6177794|NCT01307423|9827537|FG005|Placebo-controlled Phase (Week 0 - 24)|Lost to Follow-up|0
6177795|NCT01307423|9827538|FG006|Placebo-controlled Phase (Week 0 - 24)|Lost to Follow-up|0
6177796|NCT01307423|9827539|FG007|Placebo-controlled Phase (Week 0 - 24)|Lost to Follow-up|0
6177797|NCT01307423|9827540|FG008|Placebo-controlled Phase (Week 0 - 24)|Lost to Follow-up|0
6177798|NCT01307423|9827532|FG000|Placebo-controlled Phase (Week 0 - 24)|Protocol Violation|1
6177799|NCT01307423|9827533|FG001|Placebo-controlled Phase (Week 0 - 24)|Protocol Violation|0
6177800|NCT01307423|9827534|FG002|Placebo-controlled Phase (Week 0 - 24)|Protocol Violation|0
6177801|NCT01307423|9827535|FG003|Placebo-controlled Phase (Week 0 - 24)|Protocol Violation|0
6177802|NCT01307423|9827536|FG004|Placebo-controlled Phase (Week 0 - 24)|Protocol Violation|0
6177803|NCT01307423|9827537|FG005|Placebo-controlled Phase (Week 0 - 24)|Protocol Violation|0
6177804|NCT01307423|9827538|FG006|Placebo-controlled Phase (Week 0 - 24)|Protocol Violation|0
6177805|NCT01307423|9827539|FG007|Placebo-controlled Phase (Week 0 - 24)|Protocol Violation|0
6177806|NCT01307423|9827540|FG008|Placebo-controlled Phase (Week 0 - 24)|Protocol Violation|0
6177807|NCT01307423|9827532|FG000|Placebo-controlled Phase (Week 0 - 24)|Other|1
6177808|NCT01307423|9827533|FG001|Placebo-controlled Phase (Week 0 - 24)|Other|2
6177809|NCT01307423|9827534|FG002|Placebo-controlled Phase (Week 0 - 24)|Other|0
6177810|NCT01307423|9827535|FG003|Placebo-controlled Phase (Week 0 - 24)|Other|0
6177811|NCT01307423|9827536|FG004|Placebo-controlled Phase (Week 0 - 24)|Other|0
6177812|NCT01307423|9827537|FG005|Placebo-controlled Phase (Week 0 - 24)|Other|0
6177813|NCT01307423|9827538|FG006|Placebo-controlled Phase (Week 0 - 24)|Other|0
6177814|NCT01307423|9827539|FG007|Placebo-controlled Phase (Week 0 - 24)|Other|0
6177815|NCT01307423|9827540|FG008|Placebo-controlled Phase (Week 0 - 24)|Other|0
6177816|NCT01307423|9827532|FG000|Placebo-controlled Phase (Week 0 - 24)|Non-compliance with Study Drug|0
6177817|NCT01307423|9827533|FG001|Placebo-controlled Phase (Week 0 - 24)|Non-compliance with Study Drug|1
6177818|NCT01307423|9827534|FG002|Placebo-controlled Phase (Week 0 - 24)|Non-compliance with Study Drug|1
6177819|NCT01307423|9827535|FG003|Placebo-controlled Phase (Week 0 - 24)|Non-compliance with Study Drug|0
6177820|NCT01307423|9827536|FG004|Placebo-controlled Phase (Week 0 - 24)|Non-compliance with Study Drug|0
6177821|NCT01307423|9827537|FG005|Placebo-controlled Phase (Week 0 - 24)|Non-compliance with Study Drug|0
6177822|NCT01307423|9827538|FG006|Placebo-controlled Phase (Week 0 - 24)|Non-compliance with Study Drug|0
6177823|NCT01307423|9827539|FG007|Placebo-controlled Phase (Week 0 - 24)|Non-compliance with Study Drug|0
6177824|NCT01307423|9827540|FG008|Placebo-controlled Phase (Week 0 - 24)|Non-compliance with Study Drug|0
6177825|NCT01307423|9827532|FG000|Active Treatment Phase (Week 25-52)|Adverse Event|0
6177826|NCT01307423|9827533|FG001|Active Treatment Phase (Week 25-52)|Adverse Event|3
6177827|NCT01307423|9827534|FG002|Active Treatment Phase (Week 25-52)|Adverse Event|2
6177828|NCT01307423|9827535|FG003|Active Treatment Phase (Week 25-52)|Adverse Event|2
6177829|NCT01307423|9827536|FG004|Active Treatment Phase (Week 25-52)|Adverse Event|2
6177830|NCT01307423|9827537|FG005|Active Treatment Phase (Week 25-52)|Adverse Event|0
6177831|NCT01307423|9827538|FG006|Active Treatment Phase (Week 25-52)|Adverse Event|0
6177832|NCT01307423|9827539|FG007|Active Treatment Phase (Week 25-52)|Adverse Event|0
6177833|NCT01307423|9827540|FG008|Active Treatment Phase (Week 25-52)|Adverse Event|0
6177834|NCT01307423|9827532|FG000|Active Treatment Phase (Week 25-52)|Lack of Efficacy|0
6177835|NCT01307423|9827533|FG001|Active Treatment Phase (Week 25-52)|Lack of Efficacy|5
6177836|NCT01307423|9827534|FG002|Active Treatment Phase (Week 25-52)|Lack of Efficacy|5
6177837|NCT01307423|9827535|FG003|Active Treatment Phase (Week 25-52)|Lack of Efficacy|3
6177838|NCT01307423|9827536|FG004|Active Treatment Phase (Week 25-52)|Lack of Efficacy|1
6177839|NCT01307423|9827537|FG005|Active Treatment Phase (Week 25-52)|Lack of Efficacy|0
6177840|NCT01307423|9827538|FG006|Active Treatment Phase (Week 25-52)|Lack of Efficacy|0
6177841|NCT01307423|9827539|FG007|Active Treatment Phase (Week 25-52)|Lack of Efficacy|0
6177842|NCT01307423|9827540|FG008|Active Treatment Phase (Week 25-52)|Lack of Efficacy|0
6177843|NCT01307423|9827532|FG000|Active Treatment Phase (Week 25-52)|Non-compliance with Study Drug|0
6177844|NCT01307423|9827533|FG001|Active Treatment Phase (Week 25-52)|Non-compliance with Study Drug|0
6177845|NCT01307423|9827534|FG002|Active Treatment Phase (Week 25-52)|Non-compliance with Study Drug|0
6177846|NCT01307423|9827535|FG003|Active Treatment Phase (Week 25-52)|Non-compliance with Study Drug|0
6177847|NCT01307423|9827536|FG004|Active Treatment Phase (Week 25-52)|Non-compliance with Study Drug|0
6177848|NCT01307423|9827537|FG005|Active Treatment Phase (Week 25-52)|Non-compliance with Study Drug|1
6177849|NCT01307423|9827538|FG006|Active Treatment Phase (Week 25-52)|Non-compliance with Study Drug|0
6177850|NCT01307423|9827539|FG007|Active Treatment Phase (Week 25-52)|Non-compliance with Study Drug|0
6177851|NCT01307423|9827540|FG008|Active Treatment Phase (Week 25-52)|Non-compliance with Study Drug|0
6177852|NCT01307423|9827532|FG000|Active Treatment Phase (Week 25-52)|Withdrawal by Subject|0
6177853|NCT01307423|9827533|FG001|Active Treatment Phase (Week 25-52)|Withdrawal by Subject|11
6177854|NCT01307423|9827534|FG002|Active Treatment Phase (Week 25-52)|Withdrawal by Subject|2
6177855|NCT01307423|9827535|FG003|Active Treatment Phase (Week 25-52)|Withdrawal by Subject|0
6177856|NCT01307423|9827536|FG004|Active Treatment Phase (Week 25-52)|Withdrawal by Subject|0
6177857|NCT01307423|9827537|FG005|Active Treatment Phase (Week 25-52)|Withdrawal by Subject|1
6177858|NCT01307423|9827538|FG006|Active Treatment Phase (Week 25-52)|Withdrawal by Subject|1
6177859|NCT01307423|9827539|FG007|Active Treatment Phase (Week 25-52)|Withdrawal by Subject|0
6177860|NCT01307423|9827540|FG008|Active Treatment Phase (Week 25-52)|Withdrawal by Subject|0
6177861|NCT01307423|9827532|FG000|Active Treatment Phase (Week 25-52)|Lost to Follow-up|0
6177862|NCT01307423|9827533|FG001|Active Treatment Phase (Week 25-52)|Lost to Follow-up|0
6177863|NCT01307423|9827534|FG002|Active Treatment Phase (Week 25-52)|Lost to Follow-up|0
6177864|NCT01307423|9827535|FG003|Active Treatment Phase (Week 25-52)|Lost to Follow-up|2
6177865|NCT01307423|9827536|FG004|Active Treatment Phase (Week 25-52)|Lost to Follow-up|0
6177866|NCT01307423|9827537|FG005|Active Treatment Phase (Week 25-52)|Lost to Follow-up|0
6177867|NCT01307423|9827538|FG006|Active Treatment Phase (Week 25-52)|Lost to Follow-up|0
6177868|NCT01307423|9827539|FG007|Active Treatment Phase (Week 25-52)|Lost to Follow-up|0
6177869|NCT01307423|9827540|FG008|Active Treatment Phase (Week 25-52)|Lost to Follow-up|0
6177870|NCT01307423|9827532|FG000|Active Treatment Phase (Week 25-52)|Other|0
6177871|NCT01307423|9827533|FG001|Active Treatment Phase (Week 25-52)|Other|0
6177872|NCT01307423|9827534|FG002|Active Treatment Phase (Week 25-52)|Other|0
6177873|NCT01307423|9827535|FG003|Active Treatment Phase (Week 25-52)|Other|1
6177874|NCT01307423|9827536|FG004|Active Treatment Phase (Week 25-52)|Other|0
6177875|NCT01307423|9827537|FG005|Active Treatment Phase (Week 25-52)|Other|0
6177876|NCT01307423|9827538|FG006|Active Treatment Phase (Week 25-52)|Other|0
6177877|NCT01307423|9827539|FG007|Active Treatment Phase (Week 25-52)|Other|0
6177878|NCT01307423|9827540|FG008|Active Treatment Phase (Week 25-52)|Other|0
6177879|NCT01307423|9827532|FG000|Active Treatment Phase (Week 25-52)|Protocol Violation|0
6177880|NCT01307423|9827533|FG001|Active Treatment Phase (Week 25-52)|Protocol Violation|0
6177881|NCT01307423|9827534|FG002|Active Treatment Phase (Week 25-52)|Protocol Violation|0
6177882|NCT01307423|9827535|FG003|Active Treatment Phase (Week 25-52)|Protocol Violation|0
6177883|NCT01307423|9827536|FG004|Active Treatment Phase (Week 25-52)|Protocol Violation|0
6177884|NCT01307423|9827537|FG005|Active Treatment Phase (Week 25-52)|Protocol Violation|1
6177885|NCT01307423|9827538|FG006|Active Treatment Phase (Week 25-52)|Protocol Violation|0
6177886|NCT01307423|9827539|FG007|Active Treatment Phase (Week 25-52)|Protocol Violation|0
6177887|NCT01307423|9827540|FG008|Active Treatment Phase (Week 25-52)|Protocol Violation|0
6177888|NCT01307423|9827532|FG000|Long-term Safety Phase (Year 2)|Adverse Event|0
6177889|NCT01307423|9827533|FG001|Long-term Safety Phase (Year 2)|Adverse Event|2
6177890|NCT01307423|9827534|FG002|Long-term Safety Phase (Year 2)|Adverse Event|7
6177891|NCT01307423|9827535|FG003|Long-term Safety Phase (Year 2)|Adverse Event|0
6177892|NCT01307423|9827536|FG004|Long-term Safety Phase (Year 2)|Adverse Event|0
6177893|NCT01307423|9827537|FG005|Long-term Safety Phase (Year 2)|Adverse Event|0
6177894|NCT01307423|9827538|FG006|Long-term Safety Phase (Year 2)|Adverse Event|0
6177895|NCT01307423|9827539|FG007|Long-term Safety Phase (Year 2)|Adverse Event|1
6177896|NCT01307423|9827540|FG008|Long-term Safety Phase (Year 2)|Adverse Event|1
6177897|NCT01307423|9827532|FG000|Long-term Safety Phase (Year 2)|Lack of Efficacy|0
6177898|NCT01307423|9827533|FG001|Long-term Safety Phase (Year 2)|Lack of Efficacy|7
6177899|NCT01307423|9827534|FG002|Long-term Safety Phase (Year 2)|Lack of Efficacy|5
6177900|NCT01307423|9827535|FG003|Long-term Safety Phase (Year 2)|Lack of Efficacy|0
6177901|NCT01307423|9827536|FG004|Long-term Safety Phase (Year 2)|Lack of Efficacy|0
6177902|NCT01307423|9827537|FG005|Long-term Safety Phase (Year 2)|Lack of Efficacy|0
6177903|NCT01307423|9827538|FG006|Long-term Safety Phase (Year 2)|Lack of Efficacy|0
6177904|NCT01307423|9827539|FG007|Long-term Safety Phase (Year 2)|Lack of Efficacy|4
6177905|NCT01307423|9827540|FG008|Long-term Safety Phase (Year 2)|Lack of Efficacy|3
6177906|NCT01307423|9827532|FG000|Long-term Safety Phase (Year 2)|Noncompliance with study drug|0
6177907|NCT01307423|9827533|FG001|Long-term Safety Phase (Year 2)|Noncompliance with study drug|0
6177908|NCT01307423|9827534|FG002|Long-term Safety Phase (Year 2)|Noncompliance with study drug|1
6177909|NCT01307423|9827535|FG003|Long-term Safety Phase (Year 2)|Noncompliance with study drug|0
6177910|NCT01307423|9827536|FG004|Long-term Safety Phase (Year 2)|Noncompliance with study drug|0
6177911|NCT01307423|9827537|FG005|Long-term Safety Phase (Year 2)|Noncompliance with study drug|0
6177912|NCT01307423|9827538|FG006|Long-term Safety Phase (Year 2)|Noncompliance with study drug|0
6177913|NCT01307423|9827539|FG007|Long-term Safety Phase (Year 2)|Noncompliance with study drug|0
6177914|NCT01307423|9827540|FG008|Long-term Safety Phase (Year 2)|Noncompliance with study drug|0
6177915|NCT01307423|9827532|FG000|Long-term Safety Phase (Year 2)|Withdrawal by Subject|0
6177916|NCT01307423|9827533|FG001|Long-term Safety Phase (Year 2)|Withdrawal by Subject|13
6177917|NCT01307423|9827534|FG002|Long-term Safety Phase (Year 2)|Withdrawal by Subject|12
6177918|NCT01307423|9827535|FG003|Long-term Safety Phase (Year 2)|Withdrawal by Subject|0
6177919|NCT01307423|9827536|FG004|Long-term Safety Phase (Year 2)|Withdrawal by Subject|0
6177920|NCT01307423|9827537|FG005|Long-term Safety Phase (Year 2)|Withdrawal by Subject|0
6177921|NCT01307423|9827538|FG006|Long-term Safety Phase (Year 2)|Withdrawal by Subject|0
6177922|NCT01307423|9827539|FG007|Long-term Safety Phase (Year 2)|Withdrawal by Subject|3
6177923|NCT01307423|9827540|FG008|Long-term Safety Phase (Year 2)|Withdrawal by Subject|2
6177924|NCT01307423|9827532|FG000|Long-term Safety Phase (Year 2)|Miscellaneous|0
6177925|NCT01307423|9827533|FG001|Long-term Safety Phase (Year 2)|Miscellaneous|1
6177926|NCT01307423|9827534|FG002|Long-term Safety Phase (Year 2)|Miscellaneous|0
6177927|NCT01307423|9827535|FG003|Long-term Safety Phase (Year 2)|Miscellaneous|0
6177928|NCT01307423|9827536|FG004|Long-term Safety Phase (Year 2)|Miscellaneous|0
6177929|NCT01307423|9827537|FG005|Long-term Safety Phase (Year 2)|Miscellaneous|0
6177930|NCT01307423|9827538|FG006|Long-term Safety Phase (Year 2)|Miscellaneous|0
6177931|NCT01307423|9827539|FG007|Long-term Safety Phase (Year 2)|Miscellaneous|1
6177932|NCT01307423|9827540|FG008|Long-term Safety Phase (Year 2)|Miscellaneous|1
6177933|NCT01307423|9827532|FG000|Long-term Safety Phase (Year 3)|Adverse Event|0
6177934|NCT01307423|9827533|FG001|Long-term Safety Phase (Year 3)|Adverse Event|1
6177935|NCT01307423|9827534|FG002|Long-term Safety Phase (Year 3)|Adverse Event|2
6177936|NCT01307423|9827535|FG003|Long-term Safety Phase (Year 3)|Adverse Event|0
6177937|NCT01307423|9827536|FG004|Long-term Safety Phase (Year 3)|Adverse Event|0
6177938|NCT01307423|9827537|FG005|Long-term Safety Phase (Year 3)|Adverse Event|0
6177939|NCT01307423|9827538|FG006|Long-term Safety Phase (Year 3)|Adverse Event|0
6177940|NCT01307423|9827539|FG007|Long-term Safety Phase (Year 3)|Adverse Event|3
6177941|NCT01307423|9827540|FG008|Long-term Safety Phase (Year 3)|Adverse Event|4
6177942|NCT01307423|9827532|FG000|Long-term Safety Phase (Year 3)|Lack of Efficacy|0
6177943|NCT01307423|9827533|FG001|Long-term Safety Phase (Year 3)|Lack of Efficacy|2
6177944|NCT01307423|9827534|FG002|Long-term Safety Phase (Year 3)|Lack of Efficacy|4
6177945|NCT01307423|9827535|FG003|Long-term Safety Phase (Year 3)|Lack of Efficacy|0
6177946|NCT01307423|9827536|FG004|Long-term Safety Phase (Year 3)|Lack of Efficacy|0
6177947|NCT01307423|9827537|FG005|Long-term Safety Phase (Year 3)|Lack of Efficacy|0
6177948|NCT01307423|9827538|FG006|Long-term Safety Phase (Year 3)|Lack of Efficacy|0
6177949|NCT01307423|9827539|FG007|Long-term Safety Phase (Year 3)|Lack of Efficacy|1
6177950|NCT01307423|9827540|FG008|Long-term Safety Phase (Year 3)|Lack of Efficacy|2
6177951|NCT01307423|9827532|FG000|Long-term Safety Phase (Year 3)|Noncompliance with Study Drug|0
6177952|NCT01307423|9827533|FG001|Long-term Safety Phase (Year 3)|Noncompliance with Study Drug|1
6177953|NCT01307423|9827534|FG002|Long-term Safety Phase (Year 3)|Noncompliance with Study Drug|1
6177954|NCT01307423|9827535|FG003|Long-term Safety Phase (Year 3)|Noncompliance with Study Drug|0
6177955|NCT01307423|9827536|FG004|Long-term Safety Phase (Year 3)|Noncompliance with Study Drug|0
6177956|NCT01307423|9827537|FG005|Long-term Safety Phase (Year 3)|Noncompliance with Study Drug|0
6177957|NCT01307423|9827538|FG006|Long-term Safety Phase (Year 3)|Noncompliance with Study Drug|0
6177958|NCT01307423|9827539|FG007|Long-term Safety Phase (Year 3)|Noncompliance with Study Drug|0
6177959|NCT01307423|9827540|FG008|Long-term Safety Phase (Year 3)|Noncompliance with Study Drug|0
6177960|NCT01307423|9827532|FG000|Long-term Safety Phase (Year 3)|Withdrawal by Subject|0
6177961|NCT01307423|9827533|FG001|Long-term Safety Phase (Year 3)|Withdrawal by Subject|2
6177962|NCT01307423|9827534|FG002|Long-term Safety Phase (Year 3)|Withdrawal by Subject|8
6177963|NCT01307423|9827535|FG003|Long-term Safety Phase (Year 3)|Withdrawal by Subject|0
6177964|NCT01307423|9827536|FG004|Long-term Safety Phase (Year 3)|Withdrawal by Subject|0
6177965|NCT01307423|9827537|FG005|Long-term Safety Phase (Year 3)|Withdrawal by Subject|0
6177966|NCT01307423|9827538|FG006|Long-term Safety Phase (Year 3)|Withdrawal by Subject|0
6177967|NCT01307423|9827539|FG007|Long-term Safety Phase (Year 3)|Withdrawal by Subject|2
6177968|NCT01307423|9827540|FG008|Long-term Safety Phase (Year 3)|Withdrawal by Subject|4
6177969|NCT01307423|9827532|FG000|Long-term Safety Phase (Year 3)|Lost to Follow-up|0
6177970|NCT01307423|9827533|FG001|Long-term Safety Phase (Year 3)|Lost to Follow-up|2
6177971|NCT01307423|9827534|FG002|Long-term Safety Phase (Year 3)|Lost to Follow-up|3
6177972|NCT01307423|9827535|FG003|Long-term Safety Phase (Year 3)|Lost to Follow-up|0
6177973|NCT01307423|9827536|FG004|Long-term Safety Phase (Year 3)|Lost to Follow-up|0
6177974|NCT01307423|9827537|FG005|Long-term Safety Phase (Year 3)|Lost to Follow-up|0
6177975|NCT01307423|9827538|FG006|Long-term Safety Phase (Year 3)|Lost to Follow-up|0
6177976|NCT01307423|9827539|FG007|Long-term Safety Phase (Year 3)|Lost to Follow-up|1
6177977|NCT01307423|9827540|FG008|Long-term Safety Phase (Year 3)|Lost to Follow-up|1
6177978|NCT01307423|9827532|FG000|Long-term Safety Phase (Year 3)|Miscellaneous|0
6177979|NCT01307423|9827533|FG001|Long-term Safety Phase (Year 3)|Miscellaneous|1
6177980|NCT01307423|9827534|FG002|Long-term Safety Phase (Year 3)|Miscellaneous|0
6177981|NCT01307423|9827535|FG003|Long-term Safety Phase (Year 3)|Miscellaneous|0
6177982|NCT01307423|9827536|FG004|Long-term Safety Phase (Year 3)|Miscellaneous|0
6177983|NCT01307423|9827537|FG005|Long-term Safety Phase (Year 3)|Miscellaneous|0
6177984|NCT01307423|9827538|FG006|Long-term Safety Phase (Year 3)|Miscellaneous|0
6177985|NCT01307423|9827539|FG007|Long-term Safety Phase (Year 3)|Miscellaneous|1
6177986|NCT01307423|9827540|FG008|Long-term Safety Phase (Year 3)|Miscellaneous|0
6177987|NCT01307423|9827532|FG000|Long-term Safety Phase (Year 4)|Adverse Event|0
6177988|NCT01307423|9827533|FG001|Long-term Safety Phase (Year 4)|Adverse Event|2
6177989|NCT01307423|9827534|FG002|Long-term Safety Phase (Year 4)|Adverse Event|0
6177990|NCT01307423|9827535|FG003|Long-term Safety Phase (Year 4)|Adverse Event|0
6177991|NCT01307423|9827536|FG004|Long-term Safety Phase (Year 4)|Adverse Event|0
6177992|NCT01307423|9827537|FG005|Long-term Safety Phase (Year 4)|Adverse Event|0
6177993|NCT01307423|9827538|FG006|Long-term Safety Phase (Year 4)|Adverse Event|0
6177994|NCT01307423|9827539|FG007|Long-term Safety Phase (Year 4)|Adverse Event|0
6177995|NCT01307423|9827540|FG008|Long-term Safety Phase (Year 4)|Adverse Event|0
6177996|NCT01307423|9827532|FG000|Long-term Safety Phase (Year 4)|Lack of Efficacy|0
6177997|NCT01307423|9827533|FG001|Long-term Safety Phase (Year 4)|Lack of Efficacy|1
6375300|NCT03276780|10165072|FG000|Overall Study|Moved out of state|1
6375301|NCT03276780|10165073|FG001|Overall Study|Moved out of state|1
6177998|NCT01307423|9827534|FG002|Long-term Safety Phase (Year 4)|Lack of Efficacy|0
6177999|NCT01307423|9827535|FG003|Long-term Safety Phase (Year 4)|Lack of Efficacy|0
6178000|NCT01307423|9827536|FG004|Long-term Safety Phase (Year 4)|Lack of Efficacy|0
6178001|NCT01307423|9827537|FG005|Long-term Safety Phase (Year 4)|Lack of Efficacy|0
6178002|NCT01307423|9827538|FG006|Long-term Safety Phase (Year 4)|Lack of Efficacy|0
6178003|NCT01307423|9827539|FG007|Long-term Safety Phase (Year 4)|Lack of Efficacy|0
6178004|NCT01307423|9827540|FG008|Long-term Safety Phase (Year 4)|Lack of Efficacy|1
6178005|NCT01307423|9827532|FG000|Long-term Safety Phase (Year 4)|Withdrawal by Subject|0
6178006|NCT01307423|9827533|FG001|Long-term Safety Phase (Year 4)|Withdrawal by Subject|5
6178007|NCT01307423|9827534|FG002|Long-term Safety Phase (Year 4)|Withdrawal by Subject|4
6178008|NCT01307423|9827535|FG003|Long-term Safety Phase (Year 4)|Withdrawal by Subject|0
6178009|NCT01307423|9827536|FG004|Long-term Safety Phase (Year 4)|Withdrawal by Subject|0
6178010|NCT01307423|9827537|FG005|Long-term Safety Phase (Year 4)|Withdrawal by Subject|0
6178011|NCT01307423|9827538|FG006|Long-term Safety Phase (Year 4)|Withdrawal by Subject|0
6178012|NCT01307423|9827539|FG007|Long-term Safety Phase (Year 4)|Withdrawal by Subject|1
6178013|NCT01307423|9827540|FG008|Long-term Safety Phase (Year 4)|Withdrawal by Subject|4
6178014|NCT01307423|9827532|FG000|Long-term Safety Phase (Year 4)|Lost to Follow-up|0
6178015|NCT01307423|9827533|FG001|Long-term Safety Phase (Year 4)|Lost to Follow-up|0
6178016|NCT01307423|9827534|FG002|Long-term Safety Phase (Year 4)|Lost to Follow-up|1
6178017|NCT01307423|9827535|FG003|Long-term Safety Phase (Year 4)|Lost to Follow-up|0
6178018|NCT01307423|9827536|FG004|Long-term Safety Phase (Year 4)|Lost to Follow-up|0
6178019|NCT01307423|9827537|FG005|Long-term Safety Phase (Year 4)|Lost to Follow-up|0
6178020|NCT01307423|9827538|FG006|Long-term Safety Phase (Year 4)|Lost to Follow-up|0
6178021|NCT01307423|9827539|FG007|Long-term Safety Phase (Year 4)|Lost to Follow-up|0
6178022|NCT01307423|9827540|FG008|Long-term Safety Phase (Year 4)|Lost to Follow-up|0
6178023|NCT01307423|9827532|FG000|Long-term Safety Phase (Year 4)|Miscellaneous|0
6178024|NCT01307423|9827533|FG001|Long-term Safety Phase (Year 4)|Miscellaneous|0
6178025|NCT01307423|9827534|FG002|Long-term Safety Phase (Year 4)|Miscellaneous|0
6178026|NCT01307423|9827535|FG003|Long-term Safety Phase (Year 4)|Miscellaneous|0
6178027|NCT01307423|9827536|FG004|Long-term Safety Phase (Year 4)|Miscellaneous|0
6178028|NCT01307423|9827537|FG005|Long-term Safety Phase (Year 4)|Miscellaneous|0
6178029|NCT01307423|9827538|FG006|Long-term Safety Phase (Year 4)|Miscellaneous|0
6178030|NCT01307423|9827539|FG007|Long-term Safety Phase (Year 4)|Miscellaneous|1
6178031|NCT01307423|9827540|FG008|Long-term Safety Phase (Year 4)|Miscellaneous|0
6178032|NCT01307423|9827532|FG000|Long-term Safety Phase (Year 5)|Adverse Event|0
6178033|NCT01307423|9827533|FG001|Long-term Safety Phase (Year 5)|Adverse Event|1
6178034|NCT01307423|9827534|FG002|Long-term Safety Phase (Year 5)|Adverse Event|1
6178035|NCT01307423|9827535|FG003|Long-term Safety Phase (Year 5)|Adverse Event|0
6178036|NCT01307423|9827536|FG004|Long-term Safety Phase (Year 5)|Adverse Event|0
6375302|NCT03276780|10165072|FG000|Overall Study|Already enrolled in another smoking cessation study providing NRT|1
6375303|NCT03276780|10165073|FG001|Overall Study|Already enrolled in another smoking cessation study providing NRT|0
6375304|NCT03276780|10165072|FG000|Overall Study|No show to appointments after baseline through Week 5|8
6375305|NCT03276780|10165073|FG001|Overall Study|No show to appointments after baseline through Week 5|1
6375306|NCT03050814|10165097|FG000|Overall Study|Screen failures|0
6375307|NCT03050814|10165098|FG001|Overall Study|Screen failures|0
6375308|NCT03050814|10165099|FG002|Overall Study|Screen failures|4
6375309|NCT02797262|10165107|FG000|Overall Study|Withdrawal by Subject|5
6375310|NCT02797262|10165108|FG001|Overall Study|Withdrawal by Subject|1
6375311|NCT02797262|10165107|FG000|Overall Study|Lost to Follow-up|10
6375312|NCT02797262|10165108|FG001|Overall Study|Lost to Follow-up|7
6375313|NCT02797262|10165107|FG000|Overall Study|Death|1
6375314|NCT02797262|10165108|FG001|Overall Study|Death|2
6375315|NCT02797262|10165107|FG000|Overall Study|Adverse Event|1
6375316|NCT02797262|10165108|FG001|Overall Study|Adverse Event|0
6085123|NCT00649428|9694354|FG000|Overall Study|Insufficient manufacturing yield|5
6085124|NCT00649428|9694355|FG001|Overall Study|Insufficient manufacturing yield|1
6085125|NCT00649428|9694354|FG000|Overall Study|Protocol Violation|6
6085126|NCT00649428|9694355|FG001|Overall Study|Protocol Violation|2
6085127|NCT00649428|9694354|FG000|Overall Study|Physician Decision|0
6085128|NCT00649428|9694355|FG001|Overall Study|Physician Decision|1
6085129|NCT00650091|9694381|FG000|Amended Study Design|Withdrawal by Subject|12
6085130|NCT00650091|9694382|FG001|Amended Study Design|Withdrawal by Subject|11
6375317|NCT02797262|10165107|FG000|Overall Study|COVID-19|2
6375318|NCT02797262|10165108|FG001|Overall Study|COVID-19|1
6375319|NCT02797262|10165107|FG000|Overall Study|Out-of-country|1
6375320|NCT02797262|10165108|FG001|Overall Study|Out-of-country|0
6085131|NCT00650091|9694383|FG002|Amended Study Design|Withdrawal by Subject|0
6085132|NCT00650091|9694381|FG000|Amended Study Design|Physician Decision|5
6178037|NCT01307423|9827537|FG005|Long-term Safety Phase (Year 5)|Adverse Event|0
6178038|NCT01307423|9827538|FG006|Long-term Safety Phase (Year 5)|Adverse Event|0
6178039|NCT01307423|9827539|FG007|Long-term Safety Phase (Year 5)|Adverse Event|0
6178040|NCT01307423|9827540|FG008|Long-term Safety Phase (Year 5)|Adverse Event|1
6178041|NCT01307423|9827532|FG000|Long-term Safety Phase (Year 5)|Lack of Efficacy|0
6178042|NCT01307423|9827533|FG001|Long-term Safety Phase (Year 5)|Lack of Efficacy|2
6178043|NCT01307423|9827534|FG002|Long-term Safety Phase (Year 5)|Lack of Efficacy|1
6178044|NCT01307423|9827535|FG003|Long-term Safety Phase (Year 5)|Lack of Efficacy|0
6178045|NCT01307423|9827536|FG004|Long-term Safety Phase (Year 5)|Lack of Efficacy|0
6178046|NCT01307423|9827537|FG005|Long-term Safety Phase (Year 5)|Lack of Efficacy|0
6178047|NCT01307423|9827538|FG006|Long-term Safety Phase (Year 5)|Lack of Efficacy|0
6178048|NCT01307423|9827539|FG007|Long-term Safety Phase (Year 5)|Lack of Efficacy|0
6178049|NCT01307423|9827540|FG008|Long-term Safety Phase (Year 5)|Lack of Efficacy|0
6178050|NCT01307423|9827532|FG000|Long-term Safety Phase (Year 5)|Withdrawal by Subject|0
6178051|NCT01307423|9827533|FG001|Long-term Safety Phase (Year 5)|Withdrawal by Subject|6
6178052|NCT01307423|9827534|FG002|Long-term Safety Phase (Year 5)|Withdrawal by Subject|2
6178053|NCT01307423|9827535|FG003|Long-term Safety Phase (Year 5)|Withdrawal by Subject|0
6178054|NCT01307423|9827536|FG004|Long-term Safety Phase (Year 5)|Withdrawal by Subject|0
6178055|NCT01307423|9827537|FG005|Long-term Safety Phase (Year 5)|Withdrawal by Subject|0
6178056|NCT01307423|9827538|FG006|Long-term Safety Phase (Year 5)|Withdrawal by Subject|0
6178057|NCT01307423|9827539|FG007|Long-term Safety Phase (Year 5)|Withdrawal by Subject|0
6178058|NCT01307423|9827540|FG008|Long-term Safety Phase (Year 5)|Withdrawal by Subject|1
6178059|NCT01307423|9827532|FG000|Long-term Safety Phase (Year 5)|Lost to Follow-up|0
6178060|NCT01307423|9827533|FG001|Long-term Safety Phase (Year 5)|Lost to Follow-up|1
6178061|NCT01307423|9827534|FG002|Long-term Safety Phase (Year 5)|Lost to Follow-up|0
6178062|NCT01307423|9827535|FG003|Long-term Safety Phase (Year 5)|Lost to Follow-up|0
6178063|NCT01307423|9827536|FG004|Long-term Safety Phase (Year 5)|Lost to Follow-up|0
6178064|NCT01307423|9827537|FG005|Long-term Safety Phase (Year 5)|Lost to Follow-up|0
6178065|NCT01307423|9827538|FG006|Long-term Safety Phase (Year 5)|Lost to Follow-up|0
6178066|NCT01307423|9827539|FG007|Long-term Safety Phase (Year 5)|Lost to Follow-up|0
6178067|NCT01307423|9827540|FG008|Long-term Safety Phase (Year 5)|Lost to Follow-up|0
6178068|NCT01307423|9827532|FG000|Long-term Safety Phase (Year 5)|Miscellaneous|0
6178069|NCT01307423|9827533|FG001|Long-term Safety Phase (Year 5)|Miscellaneous|0
6178070|NCT01307423|9827534|FG002|Long-term Safety Phase (Year 5)|Miscellaneous|2
6178071|NCT01307423|9827535|FG003|Long-term Safety Phase (Year 5)|Miscellaneous|0
6178072|NCT01307423|9827536|FG004|Long-term Safety Phase (Year 5)|Miscellaneous|0
6178073|NCT01307423|9827537|FG005|Long-term Safety Phase (Year 5)|Miscellaneous|0
6178074|NCT01307423|9827538|FG006|Long-term Safety Phase (Year 5)|Miscellaneous|0
6178075|NCT01307423|9827539|FG007|Long-term Safety Phase (Year 5)|Miscellaneous|1
6178076|NCT01307423|9827540|FG008|Long-term Safety Phase (Year 5)|Miscellaneous|1
6178077|NCT01307449|9827576|FG000|Overall Study|Adverse Event|1
6178078|NCT01307449|9827577|FG001|Overall Study|Adverse Event|0
6178079|NCT01307449|9827578|FG002|Overall Study|Adverse Event|0
6178080|NCT01307449|9827579|FG003|Overall Study|Adverse Event|0
6178081|NCT01307501|9827593|FG000|Overall Study|Treatment Failure|1
6178082|NCT01307501|9827593|FG000|Overall Study|Death|20
6178083|NCT01307501|9827593|FG000|Overall Study|Lost to Follow-up|1
6178084|NCT01307501|9827593|FG000|Overall Study|Starting Hospice|1
6178085|NCT01307579|9827599|FG000|Overall Study|Death|3
6178086|NCT01307579|9827600|FG001|Overall Study|Death|6
6178087|NCT01307579|9827599|FG000|Overall Study|Physician Decision|26
6178088|NCT01307579|9827600|FG001|Overall Study|Physician Decision|29
6178089|NCT01307579|9827599|FG000|Overall Study|Withdrawal by Subject|7
6178090|NCT01307579|9827600|FG001|Overall Study|Withdrawal by Subject|3
6178091|NCT01307579|9827599|FG000|Overall Study|Institutional diagnosis of IFD|21
6178092|NCT01307579|9827600|FG001|Overall Study|Institutional diagnosis of IFD|36
6178093|NCT01307579|9827599|FG000|Overall Study|Begin conditioning for HSCT|42
6178094|NCT01307579|9827600|FG001|Overall Study|Begin conditioning for HSCT|44
6178095|NCT01307579|9827599|FG000|Overall Study|Refractory or relapsed AML|38
6178096|NCT01307579|9827600|FG001|Overall Study|Refractory or relapsed AML|23
6178097|NCT01307579|9827599|FG000|Overall Study|Ineligible|3
6178098|NCT01307579|9827600|FG001|Overall Study|Ineligible|4
6178099|NCT01307891|9827636|FG000|Overall Study|Progressive Disease|3
6178100|NCT01307891|9827637|FG001|Overall Study|Progressive Disease|1
6178101|NCT01308008|9827653|FG000|4 Weeks|Illness, disinterest, time|9
6178102|NCT01308008|9827654|FG001|4 Weeks|Illness, disinterest, time|2
6178103|NCT01308424|9827688|FG000|Baseline Eligibility|Screen Failures|71
6178104|NCT01308424|9827689|FG001|Baseline Eligibility|Screen Failures|0
6178105|NCT01308424|9827690|FG002|Baseline Eligibility|Screen Failures|0
6178106|NCT01308424|9827688|FG000|Randomization|Adverse Event|0
6178107|NCT01308424|9827689|FG001|Randomization|Adverse Event|1
6178108|NCT01308424|9827690|FG002|Randomization|Adverse Event|1
6178109|NCT01308424|9827688|FG000|Randomization|Lost to Follow-up|0
6178110|NCT01308424|9827689|FG001|Randomization|Lost to Follow-up|1
6178111|NCT01308424|9827690|FG002|Randomization|Lost to Follow-up|0
6178112|NCT01308424|9827688|FG000|Randomization|Physician Decision|0
6178113|NCT01308424|9827689|FG001|Randomization|Physician Decision|1
6178114|NCT01308424|9827690|FG002|Randomization|Physician Decision|1
6178115|NCT01308463|9827701|FG000|Overall Study|Study Discontinued|23
6043561|NCT00390910|9642264|FG001|Overall Study|Adverse Event|0
6043562|NCT00390910|9642265|FG002|Overall Study|Adverse Event|0
6178116|NCT01308463|9827701|FG000|Overall Study|Death|4
6178117|NCT01308463|9827701|FG000|Overall Study|Revision|2
6178118|NCT01308476|9827707|FG000|Overall Study|Lost to Follow-up|2
6178119|NCT01308476|9827708|FG001|Overall Study|Lost to Follow-up|2
6178120|NCT01308476|9827707|FG000|Overall Study|Other|1
6178121|NCT01308476|9827708|FG001|Overall Study|Other|0
6178122|NCT01308567|9827717|FG000|Overall Study|Lost to Follow-up|2
6178123|NCT01308567|9827718|FG001|Overall Study|Lost to Follow-up|4
6178124|NCT01308567|9827719|FG002|Overall Study|Lost to Follow-up|4
6178125|NCT01308580|9827729|FG000|Overall Study|Lost to Follow-up|12
6178126|NCT01308580|9827730|FG001|Overall Study|Lost to Follow-up|7
6178127|NCT01308736|9827750|FG000|Overall Study|Did not attend a single session|6
6178128|NCT01308736|9827751|FG001|Overall Study|Did not attend a single session|5
6178129|NCT01308749|9827759|FG000|Period 1: Double Blind Treatment|Adverse Event|1
6178130|NCT01308749|9827760|FG001|Period 1: Double Blind Treatment|Adverse Event|0
6178131|NCT01308749|9827759|FG000|Period 2: Open Label Treatment|Adverse Event|0
6178132|NCT01308749|9827760|FG001|Period 2: Open Label Treatment|Adverse Event|1
6178133|NCT01308749|9827759|FG000|Period 2: Open Label Treatment|Lost to Follow-up|0
6178134|NCT01308749|9827760|FG001|Period 2: Open Label Treatment|Lost to Follow-up|1
6178135|NCT01308762|9827783|FG000|Overall Study|Protocol Violation|0
6178136|NCT01308762|9827784|FG001|Overall Study|Protocol Violation|1
6178137|NCT01308762|9827785|FG002|Overall Study|Protocol Violation|0
6178138|NCT01308788|9827798|FG000|2-year Treatment|medication change by treating physician|4
6178139|NCT01308788|9827799|FG001|2-year Treatment|medication change by treating physician|11
6178140|NCT01308853|9827818|FG000|Overall Study|Adverse Event|1
6178141|NCT01308853|9827818|FG000|Overall Study|Lost to Follow-up|2
6178142|NCT01308853|9827818|FG000|Overall Study|Insertion of permanent implants|1
6178143|NCT01309100|9827826|FG000|Overall Study|Protocol Violation|1
6178144|NCT01309100|9827826|FG000|Overall Study|Positive Slit lamp finding|1
6178145|NCT01309165|9827835|FG000|Overall Study|Lost to Follow-up|4
6178146|NCT01309165|9827836|FG001|Overall Study|Lost to Follow-up|3
6178147|NCT01309165|9827835|FG000|Overall Study|Return to work|1
6178148|NCT01309165|9827836|FG001|Overall Study|Return to work|2
6178149|NCT01309165|9827835|FG000|Overall Study|Left country|0
6178150|NCT01309165|9827836|FG001|Overall Study|Left country|1
6178151|NCT01309165|9827835|FG000|Overall Study|No transportation|0
6178152|NCT01309165|9827836|FG001|Overall Study|No transportation|1
6178153|NCT01309165|9827835|FG000|Overall Study|Admitted to hospital for second stroke|1
6178154|NCT01309165|9827836|FG001|Overall Study|Admitted to hospital for second stroke|0
6178155|NCT01309204|9827845|FG000|Overall Study|Adverse Event|48
6178156|NCT01309204|9827846|FG001|Overall Study|Adverse Event|58
6178157|NCT01309204|9827845|FG000|Overall Study|Lost to Follow-up|2
6178158|NCT01309204|9827846|FG001|Overall Study|Lost to Follow-up|2
6178159|NCT01309204|9827845|FG000|Overall Study|Subject's decision unrelated to an AE|9
6178160|NCT01309204|9827846|FG001|Overall Study|Subject's decision unrelated to an AE|10
6178161|NCT01309204|9827845|FG000|Overall Study|Inadequate control of IOP|4
6178162|NCT01309204|9827846|FG001|Overall Study|Inadequate control of IOP|4
6178163|NCT01309204|9827845|FG000|Overall Study|Other|4
6178164|NCT01309204|9827846|FG001|Overall Study|Other|1
6178165|NCT01309243|9827854|FG000|Randomized Phase Through Week 96|Randomized but not treated|6
6178166|NCT01309243|9827855|FG001|Randomized Phase Through Week 96|Randomized but not treated|7
6178167|NCT01309243|9827854|FG000|Randomized Phase Through Week 96|Adverse Event|12
6178168|NCT01309243|9827855|FG001|Randomized Phase Through Week 96|Adverse Event|43
6178169|NCT01309243|9827854|FG000|Randomized Phase Through Week 96|Death|0
6178170|NCT01309243|9827855|FG001|Randomized Phase Through Week 96|Death|1
6178171|NCT01309243|9827854|FG000|Randomized Phase Through Week 96|Pregnancy|2
6178172|NCT01309243|9827855|FG001|Randomized Phase Through Week 96|Pregnancy|0
6178173|NCT01309243|9827854|FG000|Randomized Phase Through Week 96|Lack of Efficacy|16
6178174|NCT01309243|9827855|FG001|Randomized Phase Through Week 96|Lack of Efficacy|4
6178175|NCT01309243|9827854|FG000|Randomized Phase Through Week 96|Investigators Discretion|3
6178176|NCT01309243|9827855|FG001|Randomized Phase Through Week 96|Investigators Discretion|6
6178177|NCT01309243|9827854|FG000|Randomized Phase Through Week 96|Withdrew Consent|12
6178178|NCT01309243|9827855|FG001|Randomized Phase Through Week 96|Withdrew Consent|18
6178179|NCT01309243|9827854|FG000|Randomized Phase Through Week 96|Lost to Follow-up|23
6178180|NCT01309243|9827855|FG001|Randomized Phase Through Week 96|Lost to Follow-up|22
6178181|NCT01309243|9827854|FG000|Randomized Phase Through Week 96|Subject Non-Compliance|9
6178182|NCT01309243|9827855|FG001|Randomized Phase Through Week 96|Subject Non-Compliance|7
6178183|NCT01309243|9827854|FG000|Randomized Phase Through Week 96|Protocol Violation|1
6178184|NCT01309243|9827855|FG001|Randomized Phase Through Week 96|Protocol Violation|1
6178185|NCT01309243|9827854|FG000|Extension Phase|Lost to Follow-up|6
6178186|NCT01309243|9827855|FG001|Extension Phase|Lost to Follow-up|0
6178187|NCT01309269|9827861|FG000|Overall Study|Adverse Event|56
6178188|NCT01309269|9827861|FG000|Overall Study|Withdrawal by Subject|25
6178189|NCT01309269|9827861|FG000|Overall Study|Lack of Acceptance|15
6178190|NCT01309269|9827861|FG000|Overall Study|Other Erythropoiesis-stimulating Agents|119
6178191|NCT01309269|9827861|FG000|Overall Study|Kidney Transplant|25
6178192|NCT01309269|9827861|FG000|Overall Study|Administrative Problems|141
6178193|NCT01309269|9827861|FG000|Overall Study|Other|256
6178194|NCT01309269|9827861|FG000|Overall Study|Other|1
6178195|NCT01309269|9827861|FG000|Overall Study|Study Completion Data Not Recorded|95
6178196|NCT01309269|9827861|FG000|Overall Study|Enrolled but not Treated|107
6178197|NCT01309282|9827865|FG000|Overall Study|Lost to Follow-up|1
6178198|NCT01309308|9827871|FG000|Overall Study|Lost to Follow-up|6
6178199|NCT01309308|9827872|FG001|Overall Study|Lost to Follow-up|4
6178200|NCT01309386|9827893|FG000|Overall Study|Other|2
6178201|NCT01309386|9827894|FG001|Overall Study|Other|0
6178202|NCT01309386|9827893|FG000|Overall Study|Withdrawal by Subject|2
6178203|NCT01309386|9827894|FG001|Overall Study|Withdrawal by Subject|0
6178204|NCT01309386|9827893|FG000|Overall Study|Progressive disease|9
6178205|NCT01309386|9827894|FG001|Overall Study|Progressive disease|11
6178206|NCT01309386|9827893|FG000|Overall Study|Physician Decision|1
6178207|NCT01309386|9827894|FG001|Overall Study|Physician Decision|1
6178208|NCT01309386|9827893|FG000|Overall Study|Lack of Efficacy|3
6178209|NCT01309386|9827894|FG001|Overall Study|Lack of Efficacy|1
6178210|NCT01309386|9827893|FG000|Overall Study|Adverse Event|5
6178211|NCT01309386|9827894|FG001|Overall Study|Adverse Event|8
6178212|NCT01309659|9827922|FG000|Overall Study|Protocol Violation|0
6178213|NCT01309659|9827923|FG001|Overall Study|Protocol Violation|1
6178214|NCT01309737|9827932|FG000|Week 0 to 16|Death|1
6178215|NCT01309737|9827933|FG001|Week 0 to 16|Death|0
6178216|NCT01309737|9827934|FG002|Week 0 to 16|Death|1
6178217|NCT01309737|9827935|FG003|Week 0 to 16|Death|0
6178218|NCT01309737|9827936|FG004|Week 0 to 16|Death|0
6178219|NCT01309737|9827932|FG000|Week 0 to 16|Adverse Event|11
6178220|NCT01309737|9827933|FG001|Week 0 to 16|Adverse Event|10
6178221|NCT01309737|9827934|FG002|Week 0 to 16|Adverse Event|5
6178222|NCT01309737|9827935|FG003|Week 0 to 16|Adverse Event|0
6178223|NCT01309737|9827936|FG004|Week 0 to 16|Adverse Event|0
6178224|NCT01309737|9827932|FG000|Week 0 to 16|Lack of Efficacy|15
6178225|NCT01309737|9827933|FG001|Week 0 to 16|Lack of Efficacy|2
6178226|NCT01309737|9827934|FG002|Week 0 to 16|Lack of Efficacy|24
6178227|NCT01309737|9827935|FG003|Week 0 to 16|Lack of Efficacy|0
6178228|NCT01309737|9827936|FG004|Week 0 to 16|Lack of Efficacy|0
6178229|NCT01309737|9827932|FG000|Week 0 to 16|Lost to Follow-up|7
6178230|NCT01309737|9827933|FG001|Week 0 to 16|Lost to Follow-up|8
6178231|NCT01309737|9827934|FG002|Week 0 to 16|Lost to Follow-up|3
6178232|NCT01309737|9827935|FG003|Week 0 to 16|Lost to Follow-up|0
6178233|NCT01309737|9827936|FG004|Week 0 to 16|Lost to Follow-up|0
6178234|NCT01309737|9827932|FG000|Week 0 to 16|Withdrawal by Subject|7
6178235|NCT01309737|9827933|FG001|Week 0 to 16|Withdrawal by Subject|6
6178236|NCT01309737|9827934|FG002|Week 0 to 16|Withdrawal by Subject|7
6178237|NCT01309737|9827935|FG003|Week 0 to 16|Withdrawal by Subject|0
6178238|NCT01309737|9827936|FG004|Week 0 to 16|Withdrawal by Subject|0
6178239|NCT01309737|9827932|FG000|Week 0 to 16|Other|10
6178240|NCT01309737|9827933|FG001|Week 0 to 16|Other|14
6178241|NCT01309737|9827934|FG002|Week 0 to 16|Other|4
6178242|NCT01309737|9827935|FG003|Week 0 to 16|Other|0
6178243|NCT01309737|9827936|FG004|Week 0 to 16|Other|0
6178244|NCT01309737|9827932|FG000|Week 0 to 16|Randomized, but not treated|1
6178245|NCT01309737|9827933|FG001|Week 0 to 16|Randomized, but not treated|0
6178246|NCT01309737|9827934|FG002|Week 0 to 16|Randomized, but not treated|0
6178247|NCT01309737|9827935|FG003|Week 0 to 16|Randomized, but not treated|0
6178248|NCT01309737|9827936|FG004|Week 0 to 16|Randomized, but not treated|0
6178249|NCT01309737|9827932|FG000|Week 16 to 52|Death|0
6178250|NCT01309737|9827933|FG001|Week 16 to 52|Death|0
6178251|NCT01309737|9827934|FG002|Week 16 to 52|Death|0
6178252|NCT01309737|9827935|FG003|Week 16 to 52|Death|0
6178253|NCT01309737|9827936|FG004|Week 16 to 52|Death|1
6178254|NCT01309737|9827932|FG000|Week 16 to 52|Adverse Event|7
6178255|NCT01309737|9827933|FG001|Week 16 to 52|Adverse Event|7
6178256|NCT01309737|9827934|FG002|Week 16 to 52|Adverse Event|0
6178257|NCT01309737|9827935|FG003|Week 16 to 52|Adverse Event|6
6178258|NCT01309737|9827936|FG004|Week 16 to 52|Adverse Event|5
6227695|NCT01718535|9900505|FG001|Overall Study|Bidirectional Sequencing not possible|0
6227696|NCT01718535|9900506|FG002|Overall Study|Bidirectional Sequencing not possible|0
6227697|NCT01718535|9900507|FG003|Overall Study|Bidirectional Sequencing not possible|1
6227698|NCT01718535|9900508|FG004|Overall Study|Bidirectional Sequencing not possible|0
6227699|NCT01718535|9900509|FG005|Overall Study|Bidirectional Sequencing not possible|0
6227700|NCT01718535|9900510|FG006|Overall Study|Bidirectional Sequencing not possible|0
6227701|NCT01718535|9900511|FG007|Overall Study|Bidirectional Sequencing not possible|0
6227702|NCT01718535|9900512|FG008|Overall Study|Bidirectional Sequencing not possible|0
6178259|NCT01309737|9827932|FG000|Week 16 to 52|Lack of Efficacy|107
6178260|NCT01309737|9827933|FG001|Week 16 to 52|Lack of Efficacy|76
6178261|NCT01309737|9827934|FG002|Week 16 to 52|Lack of Efficacy|0
6178262|NCT01309737|9827935|FG003|Week 16 to 52|Lack of Efficacy|25
6178263|NCT01309737|9827936|FG004|Week 16 to 52|Lack of Efficacy|21
6178264|NCT01309737|9827932|FG000|Week 16 to 52|Lost to Follow-up|4
6178265|NCT01309737|9827933|FG001|Week 16 to 52|Lost to Follow-up|2
6178266|NCT01309737|9827934|FG002|Week 16 to 52|Lost to Follow-up|0
6178267|NCT01309737|9827935|FG003|Week 16 to 52|Lost to Follow-up|1
6178268|NCT01309737|9827936|FG004|Week 16 to 52|Lost to Follow-up|4
6178269|NCT01309737|9827932|FG000|Week 16 to 52|Withdrawal by Subject|5
6178270|NCT01309737|9827933|FG001|Week 16 to 52|Withdrawal by Subject|6
6178271|NCT01309737|9827934|FG002|Week 16 to 52|Withdrawal by Subject|0
6178272|NCT01309737|9827935|FG003|Week 16 to 52|Withdrawal by Subject|0
6178273|NCT01309737|9827936|FG004|Week 16 to 52|Withdrawal by Subject|2
6178274|NCT01309737|9827932|FG000|Week 16 to 52|Other|10
6178275|NCT01309737|9827933|FG001|Week 16 to 52|Other|12
6178276|NCT01309737|9827934|FG002|Week 16 to 52|Other|0
6178277|NCT01309737|9827935|FG003|Week 16 to 52|Other|2
6178278|NCT01309737|9827936|FG004|Week 16 to 52|Other|0
6178279|NCT01309828|9827970|FG000|Overall Study|Adverse Event|10
6178280|NCT01309828|9827971|FG001|Overall Study|Adverse Event|11
6178281|NCT01309828|9827970|FG000|Overall Study|Voluntary Withdrawal|5
6178282|NCT01309828|9827971|FG001|Overall Study|Voluntary Withdrawal|4
6178283|NCT01309828|9827970|FG000|Overall Study|Major Protocol Deviation|0
6178284|NCT01309828|9827971|FG001|Overall Study|Major Protocol Deviation|1
6178285|NCT01309828|9827970|FG000|Overall Study|Other|1
6178286|NCT01309828|9827971|FG001|Overall Study|Other|0
6178287|NCT01309841|9827980|FG000|Overall Study|Other|0
6178288|NCT01309841|9827981|FG001|Overall Study|Other|1
6178289|NCT01309841|9827982|FG002|Overall Study|Other|1
6178290|NCT01309841|9827980|FG000|Overall Study|Lost to Follow-up|7
6178291|NCT01309841|9827981|FG001|Overall Study|Lost to Follow-up|6
6178292|NCT01309841|9827982|FG002|Overall Study|Lost to Follow-up|4
6178293|NCT01309841|9827980|FG000|Overall Study|Study-Specific Withdrawal Criteria|3
6178294|NCT01309841|9827981|FG001|Overall Study|Study-Specific Withdrawal Criteria|1
6178295|NCT01309841|9827982|FG002|Overall Study|Study-Specific Withdrawal Criteria|2
6178296|NCT01309841|9827980|FG000|Overall Study|Lack of Efficacy|0
6178297|NCT01309841|9827981|FG001|Overall Study|Lack of Efficacy|0
6178298|NCT01309841|9827982|FG002|Overall Study|Lack of Efficacy|2
6178299|NCT01309841|9827980|FG000|Overall Study|Adverse Event|9
6178300|NCT01309841|9827981|FG001|Overall Study|Adverse Event|22
6178301|NCT01309841|9827982|FG002|Overall Study|Adverse Event|11
6178302|NCT01309841|9827980|FG000|Overall Study|Death|1
6178303|NCT01309841|9827981|FG001|Overall Study|Death|0
6178304|NCT01309841|9827982|FG002|Overall Study|Death|0
6178305|NCT01309841|9827980|FG000|Overall Study|Eligibility Criteria Not Fulfilled|0
6178306|NCT01309841|9827981|FG001|Overall Study|Eligibility Criteria Not Fulfilled|0
6178307|NCT01309841|9827982|FG002|Overall Study|Eligibility Criteria Not Fulfilled|1
6178308|NCT01309841|9827980|FG000|Overall Study|Withdrawal by Subject|17
6178309|NCT01309841|9827981|FG001|Overall Study|Withdrawal by Subject|6
6178310|NCT01309841|9827982|FG002|Overall Study|Withdrawal by Subject|13
6178311|NCT01309841|9827980|FG000|Overall Study|Did Not Receive Treatment|2
6178312|NCT01309841|9827981|FG001|Overall Study|Did Not Receive Treatment|0
6178313|NCT01309841|9827982|FG002|Overall Study|Did Not Receive Treatment|1
6178314|NCT01309841|9827980|FG000|Overall Study|Severe non-compliance with protocol|0
6178315|NCT01309841|9827981|FG001|Overall Study|Severe non-compliance with protocol|5
6178316|NCT01309841|9827982|FG002|Overall Study|Severe non-compliance with protocol|2
6178317|NCT01309893|9828004|FG000|Week 2 - Crossover Intervention|Lost to Follow-up|1
6178318|NCT01309893|9828005|FG001|Week 2 - Crossover Intervention|Lost to Follow-up|0
6178319|NCT01309893|9828004|FG000|Week 2 - Crossover Intervention|Missed crossover visit|0
6178320|NCT01309893|9828005|FG001|Week 2 - Crossover Intervention|Missed crossover visit|1
6178321|NCT01309919|9828020|FG000|Overall Study|Did not receive a postpartum IUD|17
6178322|NCT01309919|9828021|FG001|Overall Study|Did not receive a postpartum IUD|48
6178323|NCT01309997|9828029|FG000|Overall Study|Adverse Event|1
6178324|NCT01309997|9828030|FG001|Overall Study|Adverse Event|0
6085133|NCT00650091|9694382|FG001|Amended Study Design|Physician Decision|0
6085134|NCT00650091|9694383|FG002|Amended Study Design|Physician Decision|0
6085135|NCT00650091|9694381|FG000|Amended Study Design|Adverse Event|1
6085136|NCT00650091|9694382|FG001|Amended Study Design|Adverse Event|4
6085137|NCT00650091|9694383|FG002|Amended Study Design|Adverse Event|0
6085138|NCT00650091|9694381|FG000|Amended Study Design|Lung transplantation|4
6178325|NCT01309997|9828029|FG000|Overall Study|Death|1
6178326|NCT01309997|9828030|FG001|Overall Study|Death|3
6178327|NCT01309997|9828029|FG000|Overall Study|Lack of Efficacy|2
6178328|NCT01309997|9828030|FG001|Overall Study|Lack of Efficacy|2
6178329|NCT01309997|9828029|FG000|Overall Study|Withdrawal by Subject|1
6178330|NCT01309997|9828030|FG001|Overall Study|Withdrawal by Subject|1
6178331|NCT01310036|9828047|FG000|Overall Study|Administrative/other|10
6178332|NCT01310036|9828047|FG000|Overall Study|Withdrew Consent|11
6178333|NCT01310036|9828047|FG000|Overall Study|Refused Treatment/Did not Cooperate|4
6178334|NCT01310036|9828047|FG000|Overall Study|Progression of Disease|164
6178335|NCT01310036|9828047|FG000|Overall Study|Death|1
6178336|NCT01310036|9828047|FG000|Overall Study|Adverse event or intercurrent illness|12
6178337|NCT01310075|9828053|FG000|Overall Study|Lost to Follow-up|1
6178338|NCT01310075|9828054|FG001|Overall Study|Lost to Follow-up|0
6178339|NCT01310075|9828053|FG000|Overall Study|Physician Decision|10
6085139|NCT00650091|9694382|FG001|Amended Study Design|Lung transplantation|2
6085140|NCT00650091|9694383|FG002|Amended Study Design|Lung transplantation|0
6178340|NCT01310075|9828054|FG001|Overall Study|Physician Decision|7
6178341|NCT01310075|9828053|FG000|Overall Study|Protocol Violation|2
6178342|NCT01310075|9828054|FG001|Overall Study|Protocol Violation|2
6178343|NCT01310075|9828053|FG000|Overall Study|Withdrawal by Subject|1
6178344|NCT01310075|9828054|FG001|Overall Study|Withdrawal by Subject|1
6178345|NCT01310127|9828062|FG000|Overall Study|Protocol Violation|1
6178346|NCT01310127|9828063|FG001|Overall Study|Protocol Violation|1
6178347|NCT01310127|9828062|FG000|Overall Study|advanced psc cataract outlier|1
6178348|NCT01310127|9828063|FG001|Overall Study|advanced psc cataract outlier|0
6178349|NCT01310413|9828104|FG000|Day 0 to Day 385|Withdrawal by Subject|5
6178350|NCT01310413|9828105|FG001|Day 0 to Day 385|Withdrawal by Subject|2
6178351|NCT01310413|9828106|FG002|Day 0 to Day 385|Withdrawal by Subject|0
6178352|NCT01310413|9828107|FG003|Day 0 to Day 385|Withdrawal by Subject|2
6178353|NCT01310413|9828108|FG004|Day 0 to Day 385|Withdrawal by Subject|1
6178354|NCT01310413|9828109|FG005|Day 0 to Day 385|Withdrawal by Subject|1
6178355|NCT01310413|9828110|FG006|Day 0 to Day 385|Withdrawal by Subject|0
6178356|NCT01310413|9828104|FG000|Day 0 to Day 385|Lost to Follow-up|18
6178357|NCT01310413|9828105|FG001|Day 0 to Day 385|Lost to Follow-up|3
6178358|NCT01310413|9828106|FG002|Day 0 to Day 385|Lost to Follow-up|3
6178359|NCT01310413|9828107|FG003|Day 0 to Day 385|Lost to Follow-up|5
6178360|NCT01310413|9828108|FG004|Day 0 to Day 385|Lost to Follow-up|1
6178361|NCT01310413|9828109|FG005|Day 0 to Day 385|Lost to Follow-up|2
6178362|NCT01310413|9828110|FG006|Day 0 to Day 385|Lost to Follow-up|0
6178363|NCT01310413|9828104|FG000|Day 0 to Day 385|Migrated/moved from study area|3
6178364|NCT01310413|9828105|FG001|Day 0 to Day 385|Migrated/moved from study area|3
6178365|NCT01310413|9828106|FG002|Day 0 to Day 385|Migrated/moved from study area|1
6178366|NCT01310413|9828107|FG003|Day 0 to Day 385|Migrated/moved from study area|1
6178367|NCT01310413|9828108|FG004|Day 0 to Day 385|Migrated/moved from study area|1
6178368|NCT01310413|9828109|FG005|Day 0 to Day 385|Migrated/moved from study area|0
6178369|NCT01310413|9828110|FG006|Day 0 to Day 385|Migrated/moved from study area|0
6178370|NCT01310413|9828104|FG000|Day 0 to Day 385|Other|1
6178371|NCT01310413|9828105|FG001|Day 0 to Day 385|Other|0
6178372|NCT01310413|9828106|FG002|Day 0 to Day 385|Other|3
6178373|NCT01310413|9828107|FG003|Day 0 to Day 385|Other|0
6178374|NCT01310413|9828108|FG004|Day 0 to Day 385|Other|0
6178375|NCT01310413|9828109|FG005|Day 0 to Day 385|Other|0
6178376|NCT01310413|9828110|FG006|Day 0 to Day 385|Other|0
6178377|NCT01310413|9828104|FG000|From Day U0 to Day U385|Withdrawal by Subject|0
6178378|NCT01310413|9828105|FG001|From Day U0 to Day U385|Withdrawal by Subject|0
6178379|NCT01310413|9828106|FG002|From Day U0 to Day U385|Withdrawal by Subject|0
6178380|NCT01310413|9828107|FG003|From Day U0 to Day U385|Withdrawal by Subject|0
6178381|NCT01310413|9828108|FG004|From Day U0 to Day U385|Withdrawal by Subject|0
6178382|NCT01310413|9828109|FG005|From Day U0 to Day U385|Withdrawal by Subject|0
6178383|NCT01310413|9828110|FG006|From Day U0 to Day U385|Withdrawal by Subject|1
6178384|NCT01310413|9828104|FG000|From Day U0 to Day U385|Lost to Follow-up|0
6178385|NCT01310413|9828105|FG001|From Day U0 to Day U385|Lost to Follow-up|0
6178386|NCT01310413|9828106|FG002|From Day U0 to Day U385|Lost to Follow-up|0
6178387|NCT01310413|9828107|FG003|From Day U0 to Day U385|Lost to Follow-up|0
6178388|NCT01310413|9828108|FG004|From Day U0 to Day U385|Lost to Follow-up|0
6178389|NCT01310413|9828109|FG005|From Day U0 to Day U385|Lost to Follow-up|0
6178390|NCT01310413|9828110|FG006|From Day U0 to Day U385|Lost to Follow-up|2
6178391|NCT01310699|9828150|FG000|Overall Study|Patients did not complete tandem.|4
6178392|NCT01310699|9828151|FG001|Overall Study|Patients did not complete tandem.|6
6178393|NCT01310777|9828162|FG000|Overall Study|Adverse Event|23
6178394|NCT01310777|9828163|FG001|Overall Study|Adverse Event|1
6178395|NCT01310777|9828164|FG002|Overall Study|Adverse Event|15
6178396|NCT01310777|9828162|FG000|Overall Study|Lost to Follow-up|0
6178397|NCT01310777|9828163|FG001|Overall Study|Lost to Follow-up|4
6178398|NCT01310777|9828164|FG002|Overall Study|Lost to Follow-up|1
6178399|NCT01310777|9828162|FG000|Overall Study|Patient's Decision Unrelated to AE|1
6178400|NCT01310777|9828163|FG001|Overall Study|Patient's Decision Unrelated to AE|1
6178401|NCT01310777|9828164|FG002|Overall Study|Patient's Decision Unrelated to AE|2
6178402|NCT01310777|9828162|FG000|Overall Study|Inadequate Control of IOP|5
6178403|NCT01310777|9828163|FG001|Overall Study|Inadequate Control of IOP|7
6178404|NCT01310777|9828164|FG002|Overall Study|Inadequate Control of IOP|10
6178405|NCT01310777|9828162|FG000|Overall Study|Other|4
6178406|NCT01310777|9828163|FG001|Overall Study|Other|1
6178407|NCT01310777|9828164|FG002|Overall Study|Other|2
6178408|NCT01310868|9828181|FG000|Overall Study|Do not have histologically confirmed GBM|13
6178409|NCT01311024|9828187|FG000|Overall Study|Protocol Violation|35
6178410|NCT01311024|9828188|FG001|Overall Study|Protocol Violation|22
6178411|NCT01311505|9828214|FG000|First Intervention Period|Protocol Violation|0
6178412|NCT01311505|9828215|FG001|First Intervention Period|Protocol Violation|1
6178413|NCT01311557|9828226|FG000|Overall Study|Serious adverse event|0
6178414|NCT01311557|9828227|FG001|Overall Study|Serious adverse event|1
6178415|NCT01311557|9828226|FG000|Overall Study|Protocol Violation|4
6178416|NCT01311557|9828227|FG001|Overall Study|Protocol Violation|2
6178417|NCT01311557|9828226|FG000|Overall Study|Lost to Follow-up|0
6178418|NCT01311557|9828227|FG001|Overall Study|Lost to Follow-up|1
6178419|NCT01311557|9828226|FG000|Overall Study|Withdrawal by Subject|1
6178420|NCT01311557|9828227|FG001|Overall Study|Withdrawal by Subject|2
6178421|NCT01311648|9828236|FG000|Main Study|Protocol Violation|0
6178422|NCT01311648|9828237|FG001|Main Study|Protocol Violation|1
6178423|NCT01311648|9828236|FG000|Main Study|Adverse Event|0
6178424|NCT01311648|9828237|FG001|Main Study|Adverse Event|1
6178425|NCT01311648|9828236|FG000|Main Study|Inhibitor management|0
6178426|NCT01311648|9828237|FG001|Main Study|Inhibitor management|17
6178427|NCT01311648|9828236|FG000|Main Study|Withdrawal by Subject|0
6178428|NCT01311648|9828237|FG001|Main Study|Withdrawal by Subject|2
6178429|NCT01311648|9828236|FG000|Extension Study|Physician Decision|0
6178430|NCT01311648|9828237|FG001|Extension Study|Physician Decision|1
6178431|NCT01311648|9828236|FG000|Extension Study|ITI therapy with marketed product|0
6178432|NCT01311648|9828237|FG001|Extension Study|ITI therapy with marketed product|1
6178433|NCT01311648|9828236|FG000|Extension Study|Incorrect visit planning|0
6178434|NCT01311648|9828237|FG001|Extension Study|Incorrect visit planning|1
6178435|NCT01311648|9828236|FG000|Extension Study|Family's decision|0
6178436|NCT01311648|9828237|FG001|Extension Study|Family's decision|1
6178437|NCT01311648|9828236|FG000|Extension Study|Failure of ITI therapy|0
6178438|NCT01311648|9828237|FG001|Extension Study|Failure of ITI therapy|3
6178439|NCT01311648|9828236|FG000|Extension Study|Long travel|0
6178440|NCT01311648|9828237|FG001|Extension Study|Long travel|1
6178441|NCT01311648|9828236|FG000|Extension Study|Diagnosed with von Willebrand disease|1
6178442|NCT01311648|9828237|FG001|Extension Study|Diagnosed with von Willebrand disease|0
6178443|NCT01311648|9828236|FG000|Extension Study|Withdrawal by Subject|0
6178444|NCT01311648|9828237|FG001|Extension Study|Withdrawal by Subject|1
6178445|NCT01311648|9828236|FG000|Extension Study|Inhibitor management|0
6178446|NCT01311648|9828237|FG001|Extension Study|Inhibitor management|2
6178447|NCT01311661|9828250|FG000|Overall Study|Adverse Event|2
6178448|NCT01311661|9828250|FG000|Overall Study|Protocol Violation|3
6178449|NCT01311661|9828250|FG000|Overall Study|Withdrawal by Subject|2
6178450|NCT01312129|9828304|FG000|Second Intervention (24 Hours)|Lost to Follow-up|0
6178451|NCT01312129|9828305|FG001|Second Intervention (24 Hours)|Lost to Follow-up|1
6178452|NCT01312467|9828359|FG000|Overall Study|Adverse Event|4
6178453|NCT01312467|9828359|FG000|Overall Study|Lost to Follow-up|1
6178454|NCT01312467|9828359|FG000|Overall Study|Withdrawal by Subject|2
6178455|NCT01312467|9828359|FG000|Overall Study|Deported to country of origin|1
6178456|NCT01312467|9828359|FG000|Overall Study|Another medical condition|1
6178457|NCT01312467|9828359|FG000|Overall Study|Ineligible|4
6178458|NCT01312779|9828391|FG000|Overall Study|Withdrawal by Subject|2
6178459|NCT01312779|9828391|FG000|Overall Study|Death|3
6178460|NCT01312779|9828391|FG000|Overall Study|Not Implanted with Device|27
6192640|NCT01432444|9850103|FG000|Extension Phase|Adverse Event|0
6192641|NCT01432444|9850104|FG001|Extension Phase|Adverse Event|0
6192642|NCT01432444|9850105|FG002|Extension Phase|Adverse Event|10
6192643|NCT01432444|9850103|FG000|Extension Phase|Sponsor Discontinued Trial|0
6192644|NCT01432444|9850104|FG001|Extension Phase|Sponsor Discontinued Trial|0
6192645|NCT01432444|9850105|FG002|Extension Phase|Sponsor Discontinued Trial|7
6192646|NCT01432444|9850103|FG000|Extension Phase|Met Withdrawal Criteria|0
6192647|NCT01432444|9850104|FG001|Extension Phase|Met Withdrawal Criteria|0
6192648|NCT01432444|9850105|FG002|Extension Phase|Met Withdrawal Criteria|144
6192649|NCT01432444|9850103|FG000|Extension Phase|Physician Decision|0
6192650|NCT01432444|9850104|FG001|Extension Phase|Physician Decision|0
6192651|NCT01432444|9850105|FG002|Extension Phase|Physician Decision|1
6192652|NCT01432444|9850103|FG000|Extension Phase|Withdrawal by Subject|0
6192653|NCT01432444|9850104|FG001|Extension Phase|Withdrawal by Subject|0
6192654|NCT01432444|9850105|FG002|Extension Phase|Withdrawal by Subject|13
6192655|NCT01432457|9850113|FG000|Overall Study|Adverse Event|7
6192656|NCT01432457|9850114|FG001|Overall Study|Adverse Event|10
6192657|NCT01432457|9850115|FG002|Overall Study|Adverse Event|16
6192658|NCT01432457|9850113|FG000|Overall Study|Lack of Efficacy|2
6192659|NCT01432457|9850114|FG001|Overall Study|Lack of Efficacy|1
6192660|NCT01432457|9850115|FG002|Overall Study|Lack of Efficacy|1
6192661|NCT01432457|9850113|FG000|Overall Study|Lost to Follow-up|11
6192662|NCT01432457|9850114|FG001|Overall Study|Lost to Follow-up|15
6192663|NCT01432457|9850115|FG002|Overall Study|Lost to Follow-up|20
6192664|NCT01432457|9850113|FG000|Overall Study|Protocol Violation|3
6192665|NCT01432457|9850114|FG001|Overall Study|Protocol Violation|2
6192666|NCT01432457|9850115|FG002|Overall Study|Protocol Violation|6
6192667|NCT01432457|9850113|FG000|Overall Study|Withdrawal by Subject|6
6192668|NCT01432457|9850114|FG001|Overall Study|Withdrawal by Subject|11
6192669|NCT01432457|9850115|FG002|Overall Study|Withdrawal by Subject|9
6192670|NCT01432457|9850113|FG000|Overall Study|Reasons not defined|2
6192671|NCT01432457|9850114|FG001|Overall Study|Reasons not defined|3
6192672|NCT01432457|9850115|FG002|Overall Study|Reasons not defined|4
6192673|NCT01432457|9850113|FG000|Overall Study|Did not take study drug|6
6192674|NCT01432457|9850114|FG001|Overall Study|Did not take study drug|6
6192675|NCT01432457|9850115|FG002|Overall Study|Did not take study drug|3
6192676|NCT01432574|9850140|FG000|Overall Study|Moved|2
6192677|NCT01432574|9850140|FG000|Overall Study|Not interested|1
6192678|NCT01432600|9850149|FG000|Overall Study|Rapid PD, allocated intv. not rec'd|0
6192679|NCT01432600|9850150|FG001|Overall Study|Rapid PD, allocated intv. not rec'd|1
6192680|NCT01432600|9850151|FG002|Overall Study|Rapid PD, allocated intv. not rec'd|1
6192681|NCT01432626|9850161|FG000|Overall Study|LV function recovered|2
6192682|NCT01432626|9850161|FG000|Overall Study|Withdrawal by Subject|2
6192683|NCT01432626|9850161|FG000|Overall Study|Only 1 image competed|2
6192684|NCT01432626|9850161|FG000|Overall Study|Imaging agent not available|1
6192685|NCT01432730|9850165|FG000|Period 1|Adverse Event|2
6192686|NCT01432730|9850166|FG001|Period 1|Adverse Event|0
6192687|NCT01432730|9850165|FG000|Period 2|Adverse Event|0
6192688|NCT01432730|9850166|FG001|Period 2|Adverse Event|4
6192689|NCT01432756|9850176|FG000|Overall Study|Lost to Follow-up|1
6192690|NCT01432756|9850177|FG001|Overall Study|Lost to Follow-up|0
6192691|NCT01432756|9850178|FG002|Overall Study|Lost to Follow-up|2
6192692|NCT01432756|9850179|FG003|Overall Study|Lost to Follow-up|1
6192693|NCT01432938|9850197|FG000|First Intervention|Protocol Violation|1
6192694|NCT01432938|9850198|FG001|First Intervention|Protocol Violation|0
6178461|NCT01312909|9828431|FG000|Overall Study|Randomized but not treated|1
6178462|NCT01312909|9828432|FG001|Overall Study|Randomized but not treated|3
6178463|NCT01312909|9828433|FG002|Overall Study|Randomized but not treated|1
6178464|NCT01312909|9828431|FG000|Overall Study|Adverse Event|1
6178465|NCT01312909|9828432|FG001|Overall Study|Adverse Event|0
6178466|NCT01312909|9828433|FG002|Overall Study|Adverse Event|3
6178467|NCT01312909|9828431|FG000|Overall Study|Protocol Violation|2
6178468|NCT01312909|9828432|FG001|Overall Study|Protocol Violation|0
6178469|NCT01312909|9828433|FG002|Overall Study|Protocol Violation|2
6178470|NCT01312909|9828431|FG000|Overall Study|Other|9
6178471|NCT01312909|9828432|FG001|Overall Study|Other|6
6178472|NCT01312909|9828433|FG002|Overall Study|Other|11
6178473|NCT01312909|9828431|FG000|Overall Study|Withdrawal by Subject|8
6178474|NCT01312909|9828432|FG001|Overall Study|Withdrawal by Subject|10
6178475|NCT01312909|9828433|FG002|Overall Study|Withdrawal by Subject|7
6178476|NCT01312909|9828431|FG000|Overall Study|Lost to Follow-up|21
6178477|NCT01312909|9828432|FG001|Overall Study|Lost to Follow-up|17
6178478|NCT01312909|9828433|FG002|Overall Study|Lost to Follow-up|20
6178479|NCT01312909|9828431|FG000|Overall Study|Insufficient clinical response|0
6178480|NCT01312909|9828432|FG001|Overall Study|Insufficient clinical response|0
6178481|NCT01312909|9828433|FG002|Overall Study|Insufficient clinical response|1
6178482|NCT01312909|9828431|FG000|Overall Study|Entrance criteria not met|0
6178483|NCT01312909|9828432|FG001|Overall Study|Entrance criteria not met|0
6178484|NCT01312909|9828433|FG002|Overall Study|Entrance criteria not met|2
6178485|NCT01312961|9828450|FG000|Overall Study|Adverse Event|3
6178486|NCT01312961|9828451|FG001|Overall Study|Adverse Event|3
6178487|NCT01312961|9828450|FG000|Overall Study|Lack of Efficacy|11
6178488|NCT01312961|9828451|FG001|Overall Study|Lack of Efficacy|1
6178489|NCT01312961|9828450|FG000|Overall Study|Poor compliance to protocol|1
6178490|NCT01312961|9828451|FG001|Overall Study|Poor compliance to protocol|0
6178491|NCT01312961|9828450|FG000|Overall Study|Other than specified above|2
6178492|NCT01312961|9828451|FG001|Overall Study|Other than specified above|3
6178493|NCT01313039|9828458|FG000|Overall Study|Physician Decision|1
6178494|NCT01313039|9828458|FG000|Overall Study|Adverse Event|1
6178495|NCT01313078|9828462|FG000|Overall Study|Death|1
6178496|NCT01313078|9828462|FG000|Overall Study|Discontinued study drug|1
6178497|NCT01313078|9828462|FG000|Overall Study|Withdrawal by Subject|1
6178498|NCT01313117|9828466|FG000|Cohort 2: Dose Level 2 (ALA 600mg Daily)|Adverse Event|1
6178499|NCT01313117|9828466|FG000|Cohort 5: Dose Level 2 (ALA 600mg Daily)|Adverse Event|1
6178500|NCT01313182|9828473|FG000|Overall Study|Protocol Violation|66
6178501|NCT01313182|9828474|FG001|Overall Study|Protocol Violation|92
6178502|NCT01313208|9828482|FG000|Double-blind Phase (Weeks 1 - 12)|Withdrawal by Subject|3
6178503|NCT01313208|9828483|FG001|Double-blind Phase (Weeks 1 - 12)|Withdrawal by Subject|2
6178504|NCT01313208|9828482|FG000|Double-blind Phase (Weeks 1 - 12)|Adverse Event|1
6178505|NCT01313208|9828483|FG001|Double-blind Phase (Weeks 1 - 12)|Adverse Event|2
6178506|NCT01313208|9828482|FG000|Double-blind Phase (Weeks 1 - 12)|Ineligibility determined|0
6178507|NCT01313208|9828483|FG001|Double-blind Phase (Weeks 1 - 12)|Ineligibility determined|1
6178508|NCT01313208|9828482|FG000|Double-blind Phase (Weeks 1 - 12)|Lost to Follow-up|1
6178509|NCT01313208|9828483|FG001|Double-blind Phase (Weeks 1 - 12)|Lost to Follow-up|0
6178510|NCT01313208|9828482|FG000|Double-blind Phase (Weeks 1 - 12)|Noncompliance|1
6178511|NCT01313208|9828483|FG001|Double-blind Phase (Weeks 1 - 12)|Noncompliance|0
6178512|NCT01313208|9828482|FG000|Open-label Phase (Weeks 13 - 24)|Withdrawal by Subject|3
6178513|NCT01313208|9828483|FG001|Open-label Phase (Weeks 13 - 24)|Withdrawal by Subject|1
6178514|NCT01313208|9828482|FG000|Open-label Phase (Weeks 13 - 24)|Noncompliance|0
6178515|NCT01313208|9828483|FG001|Open-label Phase (Weeks 13 - 24)|Noncompliance|2
6178516|NCT01313208|9828482|FG000|Open-label Phase (Weeks 13 - 24)|Adverse Event|1
6178517|NCT01313208|9828483|FG001|Open-label Phase (Weeks 13 - 24)|Adverse Event|0
6178518|NCT01313208|9828482|FG000|Open-label Phase (Weeks 13 - 24)|Other|2
6178519|NCT01313208|9828483|FG001|Open-label Phase (Weeks 13 - 24)|Other|0
6178520|NCT01313221|9828494|FG000|Overall Study|Protocol Violation|0
6178521|NCT01313221|9828495|FG001|Overall Study|Protocol Violation|1
6178522|NCT01313221|9828496|FG002|Overall Study|Protocol Violation|1
6178523|NCT01313221|9828494|FG000|Overall Study|Non-compliance|3
6178524|NCT01313221|9828495|FG001|Overall Study|Non-compliance|0
6178525|NCT01313221|9828496|FG002|Overall Study|Non-compliance|2
6178526|NCT01313221|9828494|FG000|Overall Study|Withdrawal by Subject|2
6178527|NCT01313221|9828495|FG001|Overall Study|Withdrawal by Subject|3
6178528|NCT01313221|9828496|FG002|Overall Study|Withdrawal by Subject|5
6178529|NCT01313221|9828494|FG000|Overall Study|Requirement for alternative therapy|0
6178530|NCT01313221|9828495|FG001|Overall Study|Requirement for alternative therapy|1
6178531|NCT01313221|9828496|FG002|Overall Study|Requirement for alternative therapy|1
6178532|NCT01313221|9828494|FG000|Overall Study|Lost to Follow-up|6
6178533|NCT01313221|9828495|FG001|Overall Study|Lost to Follow-up|3
6178534|NCT01313221|9828496|FG002|Overall Study|Lost to Follow-up|1
6178535|NCT01313221|9828494|FG000|Overall Study|Other|1
6178536|NCT01313221|9828495|FG001|Overall Study|Other|0
6178537|NCT01313221|9828496|FG002|Overall Study|Other|0
6178538|NCT01313221|9828494|FG000|Overall Study|Adverse Event|0
6178539|NCT01313221|9828495|FG001|Overall Study|Adverse Event|0
6178540|NCT01313221|9828496|FG002|Overall Study|Adverse Event|7
6178541|NCT01313221|9828494|FG000|Overall Study|Disease progression|0
6178542|NCT01313221|9828495|FG001|Overall Study|Disease progression|0
6178543|NCT01313221|9828496|FG002|Overall Study|Disease progression|2
6178544|NCT01313221|9828494|FG000|Overall Study|Physician Decision|0
6178545|NCT01313221|9828495|FG001|Overall Study|Physician Decision|0
6178546|NCT01313221|9828496|FG002|Overall Study|Physician Decision|2
6178547|NCT01313221|9828494|FG000|Overall Study|Pregnancy|0
6178548|NCT01313221|9828495|FG001|Overall Study|Pregnancy|0
6178549|NCT01313221|9828496|FG002|Overall Study|Pregnancy|2
6178550|NCT01313286|9828504|FG000|Period 1|Withdrawal by Subject|2
6178551|NCT01313286|9828505|FG001|Period 1|Withdrawal by Subject|0
6178552|NCT01313299|9828514|FG000|Overall Study|Adverse Event|3
6178553|NCT01313299|9828515|FG001|Overall Study|Adverse Event|1
6178554|NCT01313299|9828516|FG002|Overall Study|Adverse Event|1
6178555|NCT01313299|9828514|FG000|Overall Study|Lost to Follow-up|1
6178556|NCT01313299|9828515|FG001|Overall Study|Lost to Follow-up|0
6178557|NCT01313299|9828516|FG002|Overall Study|Lost to Follow-up|0
6178558|NCT01313299|9828514|FG000|Overall Study|Protocol Violation|2
6178559|NCT01313299|9828515|FG001|Overall Study|Protocol Violation|0
6178560|NCT01313299|9828516|FG002|Overall Study|Protocol Violation|0
6178561|NCT01313299|9828514|FG000|Overall Study|Withdrawal by Subject|1
6178562|NCT01313299|9828515|FG001|Overall Study|Withdrawal by Subject|0
6178563|NCT01313299|9828516|FG002|Overall Study|Withdrawal by Subject|2
6178564|NCT01313299|9828514|FG000|Overall Study|Family reason and moved out of state|0
6178565|NCT01313299|9828515|FG001|Overall Study|Family reason and moved out of state|2
6178566|NCT01313299|9828516|FG002|Overall Study|Family reason and moved out of state|0
6178567|NCT01313299|9828514|FG000|Overall Study|Lack of subject compliance|0
6178568|NCT01313299|9828515|FG001|Overall Study|Lack of subject compliance|0
6178569|NCT01313299|9828516|FG002|Overall Study|Lack of subject compliance|1
6375321|NCT02409368|10165126|FG000|Overall Study|Adverse event unrelated to study drug|16
6375322|NCT02409368|10165127|FG001|Overall Study|Adverse event unrelated to study drug|42
6375323|NCT02409368|10165128|FG002|Overall Study|Adverse event unrelated to study drug|10
6375324|NCT02409368|10165126|FG000|Overall Study|Death|5
6375325|NCT02409368|10165127|FG001|Overall Study|Death|17
6375326|NCT02409368|10165128|FG002|Overall Study|Death|5
6375327|NCT02409368|10165126|FG000|Overall Study|Disease Progression|101
6375328|NCT02409368|10165127|FG001|Overall Study|Disease Progression|346
6375329|NCT02409368|10165128|FG002|Overall Study|Disease Progression|63
6375330|NCT02409368|10165126|FG000|Overall Study|Lost to Follow-up|1
6178570|NCT01313312|9828524|FG000|Overall Study|Adverse Event|5
6178571|NCT01313312|9828524|FG000|Overall Study|Withdrawal by Subject|18
6178572|NCT01313312|9828524|FG000|Overall Study|Lack of Efficacy|3
6178573|NCT01313312|9828524|FG000|Overall Study|Investigator Decision|1
6178574|NCT01313312|9828524|FG000|Overall Study|Observational Phase|1
6178575|NCT01313312|9828524|FG000|Overall Study|Subject Withdrawn Early in Error|4
6178576|NCT01313312|9828524|FG000|Overall Study|Did Not Receive Treatment with Dysport®|4
6178577|NCT01313559|9828554|FG000|Overall Study|Withdrawal by Subject|1
6178578|NCT01313559|9828555|FG001|Overall Study|Withdrawal by Subject|2
6178579|NCT01313559|9828554|FG000|Overall Study|Disease progression|1
6178580|NCT01313559|9828555|FG001|Overall Study|Disease progression|0
6178581|NCT01313559|9828554|FG000|Overall Study|Rising PSA|2
6178582|NCT01313559|9828555|FG001|Overall Study|Rising PSA|0
6178583|NCT01313624|9828563|FG000|Double-Blind Phase|Adverse Event|27
6178584|NCT01313624|9828564|FG001|Double-Blind Phase|Adverse Event|4
6178585|NCT01313624|9828563|FG000|Double-Blind Phase|Withdrawal by Subject|9
6178586|NCT01313624|9828564|FG001|Double-Blind Phase|Withdrawal by Subject|4
6178587|NCT01313624|9828563|FG000|Double-Blind Phase|Lost to Follow-up|0
6178588|NCT01313624|9828564|FG001|Double-Blind Phase|Lost to Follow-up|2
6178589|NCT01313624|9828563|FG000|Double-Blind Phase|Physician Decision|1
6178590|NCT01313624|9828564|FG001|Double-Blind Phase|Physician Decision|0
6178591|NCT01313624|9828563|FG000|Double-Blind Phase|Lack of Efficacy|1
6178592|NCT01313624|9828564|FG001|Double-Blind Phase|Lack of Efficacy|0
6178593|NCT01313624|9828563|FG000|Open-Label Phase|Adverse Event|1
6178594|NCT01313624|9828564|FG001|Open-Label Phase|Adverse Event|10
6178595|NCT01313624|9828563|FG000|Open-Label Phase|Withdrawal by Subject|2
6178596|NCT01313624|9828564|FG001|Open-Label Phase|Withdrawal by Subject|2
6178597|NCT01313624|9828563|FG000|Open-Label Phase|Lost to Follow-up|1
6178598|NCT01313624|9828564|FG001|Open-Label Phase|Lost to Follow-up|1
6178599|NCT01313637|9828576|FG000|Overall Study|Adverse Event|17
6178600|NCT01313637|9828577|FG001|Overall Study|Adverse Event|24
6178601|NCT01313637|9828578|FG002|Overall Study|Adverse Event|25
6178602|NCT01313637|9828579|FG003|Overall Study|Adverse Event|18
6178603|NCT01313637|9828576|FG000|Overall Study|Lack of Efficacy|44
6178604|NCT01313637|9828577|FG001|Overall Study|Lack of Efficacy|38
6178605|NCT01313637|9828578|FG002|Overall Study|Lack of Efficacy|37
6178606|NCT01313637|9828579|FG003|Overall Study|Lack of Efficacy|24
6178607|NCT01313637|9828576|FG000|Overall Study|Protocol Violation|4
6178608|NCT01313637|9828577|FG001|Overall Study|Protocol Violation|3
6178609|NCT01313637|9828578|FG002|Overall Study|Protocol Violation|11
6375331|NCT02409368|10165127|FG001|Overall Study|Lost to Follow-up|5
6178610|NCT01313637|9828579|FG003|Overall Study|Protocol Violation|5
6178611|NCT01313637|9828576|FG000|Overall Study|Met Protocol- Defined Stopping Criteria|16
6178612|NCT01313637|9828577|FG001|Overall Study|Met Protocol- Defined Stopping Criteria|15
6178613|NCT01313637|9828578|FG002|Overall Study|Met Protocol- Defined Stopping Criteria|14
6178614|NCT01313637|9828579|FG003|Overall Study|Met Protocol- Defined Stopping Criteria|13
6178615|NCT01313637|9828576|FG000|Overall Study|Lost to Follow-up|0
6178616|NCT01313637|9828577|FG001|Overall Study|Lost to Follow-up|2
6178617|NCT01313637|9828578|FG002|Overall Study|Lost to Follow-up|1
6178618|NCT01313637|9828579|FG003|Overall Study|Lost to Follow-up|3
6178619|NCT01313637|9828576|FG000|Overall Study|Withdrawal by Subject|11
6178620|NCT01313637|9828577|FG001|Overall Study|Withdrawal by Subject|13
6178621|NCT01313637|9828578|FG002|Overall Study|Withdrawal by Subject|18
6178622|NCT01313637|9828579|FG003|Overall Study|Withdrawal by Subject|15
6178623|NCT01313650|9828593|FG000|Overall Study|Adverse Event|9
6178624|NCT01313650|9828594|FG001|Overall Study|Adverse Event|34
6178625|NCT01313650|9828595|FG002|Overall Study|Adverse Event|24
6178626|NCT01313650|9828596|FG003|Overall Study|Adverse Event|23
6178627|NCT01313650|9828593|FG000|Overall Study|Lack of Efficacy|37
6178628|NCT01313650|9828594|FG001|Overall Study|Lack of Efficacy|20
6178629|NCT01313650|9828595|FG002|Overall Study|Lack of Efficacy|32
6178630|NCT01313650|9828596|FG003|Overall Study|Lack of Efficacy|20
6178631|NCT01313650|9828593|FG000|Overall Study|Lost to Follow-up|1
6178632|NCT01313650|9828594|FG001|Overall Study|Lost to Follow-up|0
6178633|NCT01313650|9828595|FG002|Overall Study|Lost to Follow-up|3
6178634|NCT01313650|9828596|FG003|Overall Study|Lost to Follow-up|2
6178635|NCT01313650|9828593|FG000|Overall Study|Withdrawal by Subject|16
6178636|NCT01313650|9828594|FG001|Overall Study|Withdrawal by Subject|20
6178637|NCT01313650|9828595|FG002|Overall Study|Withdrawal by Subject|15
6178638|NCT01313650|9828596|FG003|Overall Study|Withdrawal by Subject|15
6178639|NCT01313650|9828593|FG000|Overall Study|Protocol Violation|4
6178640|NCT01313650|9828594|FG001|Overall Study|Protocol Violation|7
6178641|NCT01313650|9828595|FG002|Overall Study|Protocol Violation|5
6375332|NCT02409368|10165128|FG002|Overall Study|Lost to Follow-up|0
6375333|NCT02409368|10165126|FG000|Overall Study|maximum clinical benefit|3
6375334|NCT02409368|10165127|FG001|Overall Study|maximum clinical benefit|8
6375335|NCT02409368|10165128|FG002|Overall Study|maximum clinical benefit|1
6375336|NCT02409368|10165126|FG000|Overall Study|poor/non compliant|0
6375337|NCT02409368|10165127|FG001|Overall Study|poor/non compliant|2
6375338|NCT02409368|10165128|FG002|Overall Study|poor/non compliant|2
6085141|NCT00650091|9694381|FG000|Amended Study Design|Other|1
6178642|NCT01313650|9828596|FG003|Overall Study|Protocol Violation|6
6178643|NCT01313650|9828593|FG000|Overall Study|Met Protocol-defined Stopping Criteria|9
6178644|NCT01313650|9828594|FG001|Overall Study|Met Protocol-defined Stopping Criteria|13
6178645|NCT01313650|9828595|FG002|Overall Study|Met Protocol-defined Stopping Criteria|24
6178646|NCT01313650|9828596|FG003|Overall Study|Met Protocol-defined Stopping Criteria|15
6178647|NCT01313663|9828608|FG000|Overall Study|Study Closed/Terminated|2
6178648|NCT01313663|9828609|FG001|Overall Study|Study Closed/Terminated|4
6178649|NCT01313663|9828608|FG000|Overall Study|Lost to Follow-up|0
6178650|NCT01313663|9828609|FG001|Overall Study|Lost to Follow-up|1
6178651|NCT01313663|9828608|FG000|Overall Study|Physician Decision|0
6178652|NCT01313663|9828609|FG001|Overall Study|Physician Decision|2
6178653|NCT01313663|9828608|FG000|Overall Study|Withdrawal by Subject|2
6178654|NCT01313663|9828609|FG001|Overall Study|Withdrawal by Subject|1
6178655|NCT01313676|9828619|FG000|Overall Study|Adverse Event|395
6178656|NCT01313676|9828620|FG001|Overall Study|Adverse Event|365
6178657|NCT01313676|9828621|FG002|Overall Study|Adverse Event|372
6178658|NCT01313676|9828622|FG003|Overall Study|Adverse Event|333
6178659|NCT01313676|9828619|FG000|Overall Study|Lack of Efficacy|98
6178660|NCT01313676|9828620|FG001|Overall Study|Lack of Efficacy|90
6178661|NCT01313676|9828621|FG002|Overall Study|Lack of Efficacy|65
6178662|NCT01313676|9828622|FG003|Overall Study|Lack of Efficacy|46
6178663|NCT01313676|9828619|FG000|Overall Study|Protocol Violation|37
6178664|NCT01313676|9828620|FG001|Overall Study|Protocol Violation|44
6178665|NCT01313676|9828621|FG002|Overall Study|Protocol Violation|46
6178666|NCT01313676|9828622|FG003|Overall Study|Protocol Violation|44
6178667|NCT01313676|9828619|FG000|Overall Study|Met Protocol-Defined Stopping Critera|3
6178668|NCT01313676|9828620|FG001|Overall Study|Met Protocol-Defined Stopping Critera|4
6178669|NCT01313676|9828621|FG002|Overall Study|Met Protocol-Defined Stopping Critera|2
6178670|NCT01313676|9828622|FG003|Overall Study|Met Protocol-Defined Stopping Critera|11
6178671|NCT01313676|9828619|FG000|Overall Study|Study Closed/terminated|7
6178672|NCT01313676|9828620|FG001|Overall Study|Study Closed/terminated|6
6178673|NCT01313676|9828621|FG002|Overall Study|Study Closed/terminated|9
6178674|NCT01313676|9828622|FG003|Overall Study|Study Closed/terminated|9
6178675|NCT01313676|9828619|FG000|Overall Study|Lost to Follow-up|0
6178676|NCT01313676|9828620|FG001|Overall Study|Lost to Follow-up|0
6178677|NCT01313676|9828621|FG002|Overall Study|Lost to Follow-up|1
6178678|NCT01313676|9828622|FG003|Overall Study|Lost to Follow-up|0
6085142|NCT00650091|9694382|FG001|Amended Study Design|Other|3
6178679|NCT01313676|9828619|FG000|Overall Study|Physician Decision|53
6178680|NCT01313676|9828620|FG001|Overall Study|Physician Decision|64
6178681|NCT01313676|9828621|FG002|Overall Study|Physician Decision|62
6178682|NCT01313676|9828622|FG003|Overall Study|Physician Decision|48
6178683|NCT01313676|9828619|FG000|Overall Study|Decision by Participant or Proxy|643
6178684|NCT01313676|9828620|FG001|Overall Study|Decision by Participant or Proxy|527
6178685|NCT01313676|9828621|FG002|Overall Study|Decision by Participant or Proxy|515
6178686|NCT01313676|9828622|FG003|Overall Study|Decision by Participant or Proxy|492
6178687|NCT01313676|9828619|FG000|Overall Study|Sponsor Terminated Study Treatment|1
6178688|NCT01313676|9828620|FG001|Overall Study|Sponsor Terminated Study Treatment|1
6178689|NCT01313676|9828621|FG002|Overall Study|Sponsor Terminated Study Treatment|0
6178690|NCT01313676|9828622|FG003|Overall Study|Sponsor Terminated Study Treatment|1
6178691|NCT01313676|9828619|FG000|Overall Study|Investigator Site Closed|12
6178692|NCT01313676|9828620|FG001|Overall Study|Investigator Site Closed|11
6178693|NCT01313676|9828621|FG002|Overall Study|Investigator Site Closed|15
6178694|NCT01313676|9828622|FG003|Overall Study|Investigator Site Closed|10
6178695|NCT01313676|9828619|FG000|Overall Study|Missing|1
6178696|NCT01313676|9828620|FG001|Overall Study|Missing|1
6178697|NCT01313676|9828621|FG002|Overall Study|Missing|1
6178698|NCT01313676|9828622|FG003|Overall Study|Missing|0
6178699|NCT01313728|9828633|FG000|Informed Consent to Baseline|Withdrawal by Subject|1
6178700|NCT01313767|9828640|FG000|Overall Study|Adverse Event|1
6178701|NCT01313767|9828641|FG001|Overall Study|Adverse Event|0
6178702|NCT01313767|9828640|FG000|Overall Study|Lost to Follow-up|1
6178703|NCT01313767|9828641|FG001|Overall Study|Lost to Follow-up|0
6178704|NCT01313767|9828640|FG000|Overall Study|Withdrawal by Subject|2
6178705|NCT01313767|9828641|FG001|Overall Study|Withdrawal by Subject|1
6178706|NCT01313767|9828640|FG000|Overall Study|Protocol Violation|3
6178707|NCT01313767|9828641|FG001|Overall Study|Protocol Violation|1
6178708|NCT01313780|9828649|FG000|Overall Study|Lack of Efficacy|4
6178709|NCT01313780|9828650|FG001|Overall Study|Lack of Efficacy|2
6178710|NCT01313780|9828649|FG000|Overall Study|Adverse Event|6
6178711|NCT01313780|9828650|FG001|Overall Study|Adverse Event|11
6178712|NCT01313780|9828649|FG000|Overall Study|Withdrawal by Subject|2
6178713|NCT01313780|9828650|FG001|Overall Study|Withdrawal by Subject|8
6178714|NCT01313780|9828649|FG000|Overall Study|Protocol Violation|10
6178715|NCT01313780|9828650|FG001|Overall Study|Protocol Violation|4
6178716|NCT01313780|9828649|FG000|Overall Study|missing data|3
6085143|NCT00650091|9694383|FG002|Amended Study Design|Other|0
6085144|NCT00650104|9694391|FG000|Overall Study|Adverse Event|17
6178717|NCT01313780|9828650|FG001|Overall Study|missing data|3
6178718|NCT01313858|9828659|FG000|Overall Study|Premature Treatment Termination|251
6178719|NCT01313858|9828660|FG001|Overall Study|Premature Treatment Termination|219
6178720|NCT01313858|9828661|FG002|Overall Study|Premature Treatment Termination|191
6178721|NCT01313858|9828659|FG000|Overall Study|Lost to Follow-up|35
6178722|NCT01313858|9828660|FG001|Overall Study|Lost to Follow-up|51
6178723|NCT01313858|9828661|FG002|Overall Study|Lost to Follow-up|47
6178724|NCT01313884|9828667|FG000|Overall Study|Per insurance pvdr, pt can't be on cl tr|1
6178725|NCT01314105|9828722|FG000|Overall Study|Progressive Disease|6
6178726|NCT01314105|9828723|FG001|Overall Study|Progressive Disease|10
6178727|NCT01314105|9828722|FG000|Overall Study|Refused to continue taking medication|0
6178728|NCT01314105|9828723|FG001|Overall Study|Refused to continue taking medication|1
6178729|NCT01314105|9828722|FG000|Overall Study|Other Adverse Event|1
6178730|NCT01314105|9828723|FG001|Overall Study|Other Adverse Event|1
6178731|NCT01314261|9828735|FG000|Overall Study|Adverse Event|1
6178732|NCT01314261|9828736|FG001|Overall Study|Adverse Event|0
6178733|NCT01314261|9828737|FG002|Overall Study|Adverse Event|0
6178734|NCT01314261|9828738|FG003|Overall Study|Adverse Event|0
6178735|NCT01314261|9828735|FG000|Overall Study|Withdrawal by Subject|0
6178736|NCT01314261|9828736|FG001|Overall Study|Withdrawal by Subject|3
6178737|NCT01314261|9828737|FG002|Overall Study|Withdrawal by Subject|1
6178738|NCT01314261|9828738|FG003|Overall Study|Withdrawal by Subject|0
6178739|NCT01314261|9828735|FG000|Overall Study|Lost to Follow-up|1
6178740|NCT01314261|9828736|FG001|Overall Study|Lost to Follow-up|0
6178741|NCT01314261|9828737|FG002|Overall Study|Lost to Follow-up|2
6178742|NCT01314261|9828738|FG003|Overall Study|Lost to Follow-up|2
6178743|NCT01314261|9828735|FG000|Overall Study|Virologic Failure|0
6178744|NCT01314261|9828736|FG001|Overall Study|Virologic Failure|1
6178745|NCT01314261|9828737|FG002|Overall Study|Virologic Failure|0
6178746|NCT01314261|9828738|FG003|Overall Study|Virologic Failure|1
6178747|NCT01314443|9828767|FG000|Overall Study|Withdrawal by Subject|2
6178748|NCT01314443|9828768|FG001|Overall Study|Withdrawal by Subject|1
6178749|NCT01314443|9828769|FG002|Overall Study|Withdrawal by Subject|1
6178750|NCT01314443|9828770|FG003|Overall Study|Withdrawal by Subject|1
6178751|NCT01314443|9828767|FG000|Overall Study|Protocol Violation|2
6178752|NCT01314443|9828768|FG001|Overall Study|Protocol Violation|2
6178753|NCT01314443|9828769|FG002|Overall Study|Protocol Violation|1
6178754|NCT01314443|9828770|FG003|Overall Study|Protocol Violation|1
6178755|NCT01314703|9828780|FG000|Overall Study|screen failure and closed enrollment|8
6178756|NCT01314716|9828787|FG000|Double-Blind Phase|Randomized but not treated|1
6178757|NCT01314716|9828788|FG001|Double-Blind Phase|Randomized but not treated|1
6178758|NCT01314716|9828787|FG000|Double-Blind Phase|Adverse Event|10
6178759|NCT01314716|9828788|FG001|Double-Blind Phase|Adverse Event|4
6178760|NCT01314716|9828787|FG000|Double-Blind Phase|Withdrawal by Subject|5
6178761|NCT01314716|9828788|FG001|Double-Blind Phase|Withdrawal by Subject|6
6178762|NCT01314716|9828787|FG000|Double-Blind Phase|Lost to Follow-up|0
6178763|NCT01314716|9828788|FG001|Double-Blind Phase|Lost to Follow-up|1
6178764|NCT01314716|9828787|FG000|Double-Blind Phase|Sponsor request|1
6178765|NCT01314716|9828788|FG001|Double-Blind Phase|Sponsor request|2
6178766|NCT01314716|9828787|FG000|Double-Blind Phase|Physician Decision|0
6178767|NCT01314716|9828788|FG001|Double-Blind Phase|Physician Decision|1
6178768|NCT01314716|9828787|FG000|Open-Label Phase|Adverse Event|4
6178769|NCT01314716|9828788|FG001|Open-Label Phase|Adverse Event|6
6178770|NCT01314716|9828787|FG000|Open-Label Phase|Withdrawal by Subject|1
6178771|NCT01314716|9828788|FG001|Open-Label Phase|Withdrawal by Subject|2
6178772|NCT01314716|9828787|FG000|Open-Label Phase|Physician Decision|5
6178773|NCT01314716|9828788|FG001|Open-Label Phase|Physician Decision|4
6178774|NCT01314872|9828818|FG000|Treatment Period 1|Protocol Violation|2
6178775|NCT01314872|9828819|FG001|Treatment Period 1|Protocol Violation|1
6375339|NCT02409368|10165126|FG000|Overall Study|study drug toxicity|12
6375340|NCT02409368|10165127|FG001|Overall Study|study drug toxicity|35
6375341|NCT02409368|10165128|FG002|Overall Study|study drug toxicity|6
6375342|NCT02409368|10165126|FG000|Overall Study|no longer meets study criteria|3
6375343|NCT02409368|10165127|FG001|Overall Study|no longer meets study criteria|9
6375344|NCT02409368|10165128|FG002|Overall Study|no longer meets study criteria|3
6375345|NCT02409368|10165126|FG000|Overall Study|Participant request to discontinue|3
6375346|NCT02409368|10165127|FG001|Overall Study|Participant request to discontinue|3
6375347|NCT02409368|10165128|FG002|Overall Study|Participant request to discontinue|3
6375348|NCT02409368|10165126|FG000|Overall Study|Participant withdrew consent|2
6375349|NCT02409368|10165127|FG001|Overall Study|Participant withdrew consent|4
6375350|NCT02409368|10165128|FG002|Overall Study|Participant withdrew consent|3
6178776|NCT01314872|9828820|FG002|Treatment Period 1|Protocol Violation|1
6178777|NCT01314872|9828821|FG003|Treatment Period 1|Protocol Violation|0
6178778|NCT01314872|9828822|FG004|Treatment Period 1|Protocol Violation|1
6178779|NCT01314872|9828823|FG005|Treatment Period 1|Protocol Violation|0
6178780|NCT01314872|9828824|FG006|Treatment Period 1|Protocol Violation|0
6178781|NCT01314872|9828825|FG007|Treatment Period 1|Protocol Violation|0
6178782|NCT01314872|9828826|FG008|Treatment Period 1|Protocol Violation|0
6178783|NCT01314872|9828827|FG009|Treatment Period 1|Protocol Violation|1
6178784|NCT01314872|9828828|FG010|Treatment Period 1|Protocol Violation|1
6178785|NCT01314872|9828829|FG011|Treatment Period 1|Protocol Violation|0
6178786|NCT01314872|9828830|FG012|Treatment Period 1|Protocol Violation|0
6178787|NCT01314872|9828831|FG013|Treatment Period 1|Protocol Violation|0
6178788|NCT01314872|9828832|FG014|Treatment Period 1|Protocol Violation|0
6178789|NCT01314872|9828818|FG000|Treatment Period 1|Physician Decision|0
6178790|NCT01314872|9828819|FG001|Treatment Period 1|Physician Decision|1
6178791|NCT01314872|9828820|FG002|Treatment Period 1|Physician Decision|0
6178792|NCT01314872|9828821|FG003|Treatment Period 1|Physician Decision|1
6178793|NCT01314872|9828822|FG004|Treatment Period 1|Physician Decision|0
6178794|NCT01314872|9828823|FG005|Treatment Period 1|Physician Decision|0
6178795|NCT01314872|9828824|FG006|Treatment Period 1|Physician Decision|0
6178796|NCT01314872|9828825|FG007|Treatment Period 1|Physician Decision|0
6178797|NCT01314872|9828826|FG008|Treatment Period 1|Physician Decision|0
6178798|NCT01314872|9828827|FG009|Treatment Period 1|Physician Decision|1
6178799|NCT01314872|9828828|FG010|Treatment Period 1|Physician Decision|0
6178800|NCT01314872|9828829|FG011|Treatment Period 1|Physician Decision|0
6178801|NCT01314872|9828830|FG012|Treatment Period 1|Physician Decision|0
6178802|NCT01314872|9828831|FG013|Treatment Period 1|Physician Decision|0
6178803|NCT01314872|9828832|FG014|Treatment Period 1|Physician Decision|0
6178804|NCT01314872|9828818|FG000|Treatment Period 1|Lack of Efficacy|1
6178805|NCT01314872|9828819|FG001|Treatment Period 1|Lack of Efficacy|0
6178806|NCT01314872|9828820|FG002|Treatment Period 1|Lack of Efficacy|0
6178807|NCT01314872|9828821|FG003|Treatment Period 1|Lack of Efficacy|0
6178808|NCT01314872|9828822|FG004|Treatment Period 1|Lack of Efficacy|0
6178809|NCT01314872|9828823|FG005|Treatment Period 1|Lack of Efficacy|1
6178810|NCT01314872|9828824|FG006|Treatment Period 1|Lack of Efficacy|0
6178811|NCT01314872|9828825|FG007|Treatment Period 1|Lack of Efficacy|2
6178812|NCT01314872|9828826|FG008|Treatment Period 1|Lack of Efficacy|0
6178813|NCT01314872|9828827|FG009|Treatment Period 1|Lack of Efficacy|0
6178814|NCT01314872|9828828|FG010|Treatment Period 1|Lack of Efficacy|0
6178815|NCT01314872|9828829|FG011|Treatment Period 1|Lack of Efficacy|0
6178816|NCT01314872|9828830|FG012|Treatment Period 1|Lack of Efficacy|0
6178817|NCT01314872|9828831|FG013|Treatment Period 1|Lack of Efficacy|0
6178818|NCT01314872|9828832|FG014|Treatment Period 1|Lack of Efficacy|0
6178819|NCT01314872|9828818|FG000|Treatment Period 1|Adverse event, non-fatal|4
6178820|NCT01314872|9828819|FG001|Treatment Period 1|Adverse event, non-fatal|2
6178821|NCT01314872|9828820|FG002|Treatment Period 1|Adverse event, non-fatal|3
6178822|NCT01314872|9828821|FG003|Treatment Period 1|Adverse event, non-fatal|2
6178823|NCT01314872|9828822|FG004|Treatment Period 1|Adverse event, non-fatal|2
6178824|NCT01314872|9828823|FG005|Treatment Period 1|Adverse event, non-fatal|4
6178825|NCT01314872|9828824|FG006|Treatment Period 1|Adverse event, non-fatal|4
6178826|NCT01314872|9828825|FG007|Treatment Period 1|Adverse event, non-fatal|2
6178827|NCT01314872|9828826|FG008|Treatment Period 1|Adverse event, non-fatal|3
6178828|NCT01314872|9828827|FG009|Treatment Period 1|Adverse event, non-fatal|0
6178829|NCT01314872|9828828|FG010|Treatment Period 1|Adverse event, non-fatal|1
6178830|NCT01314872|9828829|FG011|Treatment Period 1|Adverse event, non-fatal|0
6178831|NCT01314872|9828830|FG012|Treatment Period 1|Adverse event, non-fatal|0
6178832|NCT01314872|9828831|FG013|Treatment Period 1|Adverse event, non-fatal|0
6178833|NCT01314872|9828832|FG014|Treatment Period 1|Adverse event, non-fatal|0
6375351|NCT02409368|10165126|FG000|Overall Study|Other Reasons|2
6375352|NCT02409368|10165127|FG001|Overall Study|Other Reasons|17
6375353|NCT02409368|10165128|FG002|Overall Study|Other Reasons|3
6375354|NCT02409368|10165126|FG000|Overall Study|Not Reported|0
6178834|NCT01314872|9828818|FG000|Treatment Period 1|Withdrawal by Subject|3
6178835|NCT01314872|9828819|FG001|Treatment Period 1|Withdrawal by Subject|1
6178836|NCT01314872|9828820|FG002|Treatment Period 1|Withdrawal by Subject|0
6178837|NCT01314872|9828821|FG003|Treatment Period 1|Withdrawal by Subject|2
6178838|NCT01314872|9828822|FG004|Treatment Period 1|Withdrawal by Subject|3
6178839|NCT01314872|9828823|FG005|Treatment Period 1|Withdrawal by Subject|1
6178840|NCT01314872|9828824|FG006|Treatment Period 1|Withdrawal by Subject|3
6178841|NCT01314872|9828825|FG007|Treatment Period 1|Withdrawal by Subject|2
6178842|NCT01314872|9828826|FG008|Treatment Period 1|Withdrawal by Subject|2
6178843|NCT01314872|9828827|FG009|Treatment Period 1|Withdrawal by Subject|2
6178844|NCT01314872|9828828|FG010|Treatment Period 1|Withdrawal by Subject|1
6178845|NCT01314872|9828829|FG011|Treatment Period 1|Withdrawal by Subject|0
6178846|NCT01314872|9828830|FG012|Treatment Period 1|Withdrawal by Subject|0
6178847|NCT01314872|9828831|FG013|Treatment Period 1|Withdrawal by Subject|0
6178848|NCT01314872|9828832|FG014|Treatment Period 1|Withdrawal by Subject|0
6178849|NCT01314872|9828818|FG000|Treatment Period 1|Lost to Follow-up|0
6178850|NCT01314872|9828819|FG001|Treatment Period 1|Lost to Follow-up|1
6178851|NCT01314872|9828820|FG002|Treatment Period 1|Lost to Follow-up|2
6178852|NCT01314872|9828821|FG003|Treatment Period 1|Lost to Follow-up|2
6178853|NCT01314872|9828822|FG004|Treatment Period 1|Lost to Follow-up|1
6178854|NCT01314872|9828823|FG005|Treatment Period 1|Lost to Follow-up|1
6178855|NCT01314872|9828824|FG006|Treatment Period 1|Lost to Follow-up|1
6178856|NCT01314872|9828825|FG007|Treatment Period 1|Lost to Follow-up|1
6178857|NCT01314872|9828826|FG008|Treatment Period 1|Lost to Follow-up|1
6178858|NCT01314872|9828827|FG009|Treatment Period 1|Lost to Follow-up|0
6178859|NCT01314872|9828828|FG010|Treatment Period 1|Lost to Follow-up|0
6178860|NCT01314872|9828829|FG011|Treatment Period 1|Lost to Follow-up|0
6178861|NCT01314872|9828830|FG012|Treatment Period 1|Lost to Follow-up|0
6178862|NCT01314872|9828831|FG013|Treatment Period 1|Lost to Follow-up|0
6178863|NCT01314872|9828832|FG014|Treatment Period 1|Lost to Follow-up|0
6178864|NCT01314872|9828818|FG000|Period 2|Protocol Violation|0
6178865|NCT01314872|9828819|FG001|Period 2|Protocol Violation|0
6178866|NCT01314872|9828820|FG002|Period 2|Protocol Violation|0
6178867|NCT01314872|9828821|FG003|Period 2|Protocol Violation|0
6178868|NCT01314872|9828822|FG004|Period 2|Protocol Violation|0
6178869|NCT01314872|9828823|FG005|Period 2|Protocol Violation|0
6178870|NCT01314872|9828824|FG006|Period 2|Protocol Violation|0
6178871|NCT01314872|9828825|FG007|Period 2|Protocol Violation|0
6178872|NCT01314872|9828826|FG008|Period 2|Protocol Violation|0
6178873|NCT01314872|9828827|FG009|Period 2|Protocol Violation|0
6178874|NCT01314872|9828828|FG010|Period 2|Protocol Violation|0
6178875|NCT01314872|9828829|FG011|Period 2|Protocol Violation|3
6178876|NCT01314872|9828830|FG012|Period 2|Protocol Violation|3
6178877|NCT01314872|9828831|FG013|Period 2|Protocol Violation|2
6178878|NCT01314872|9828832|FG014|Period 2|Protocol Violation|0
6178879|NCT01314872|9828818|FG000|Period 2|Non-compliance with study drug|0
6178880|NCT01314872|9828819|FG001|Period 2|Non-compliance with study drug|0
6178881|NCT01314872|9828820|FG002|Period 2|Non-compliance with study drug|0
6178882|NCT01314872|9828821|FG003|Period 2|Non-compliance with study drug|0
6178883|NCT01314872|9828822|FG004|Period 2|Non-compliance with study drug|0
6178884|NCT01314872|9828823|FG005|Period 2|Non-compliance with study drug|0
6178885|NCT01314872|9828824|FG006|Period 2|Non-compliance with study drug|0
6178886|NCT01314872|9828825|FG007|Period 2|Non-compliance with study drug|0
6178887|NCT01314872|9828826|FG008|Period 2|Non-compliance with study drug|0
6178888|NCT01314872|9828827|FG009|Period 2|Non-compliance with study drug|0
6178889|NCT01314872|9828828|FG010|Period 2|Non-compliance with study drug|0
6178890|NCT01314872|9828829|FG011|Period 2|Non-compliance with study drug|3
6178891|NCT01314872|9828830|FG012|Period 2|Non-compliance with study drug|3
6178892|NCT01314872|9828831|FG013|Period 2|Non-compliance with study drug|1
6178893|NCT01314872|9828832|FG014|Period 2|Non-compliance with study drug|2
6178894|NCT01314872|9828818|FG000|Period 2|Lack of Efficacy|0
6178895|NCT01314872|9828819|FG001|Period 2|Lack of Efficacy|0
6178896|NCT01314872|9828820|FG002|Period 2|Lack of Efficacy|0
6178897|NCT01314872|9828821|FG003|Period 2|Lack of Efficacy|0
6178898|NCT01314872|9828822|FG004|Period 2|Lack of Efficacy|0
6178899|NCT01314872|9828823|FG005|Period 2|Lack of Efficacy|0
6178900|NCT01314872|9828824|FG006|Period 2|Lack of Efficacy|0
6178901|NCT01314872|9828825|FG007|Period 2|Lack of Efficacy|0
6178902|NCT01314872|9828826|FG008|Period 2|Lack of Efficacy|0
6178903|NCT01314872|9828827|FG009|Period 2|Lack of Efficacy|0
6178904|NCT01314872|9828828|FG010|Period 2|Lack of Efficacy|0
6178905|NCT01314872|9828829|FG011|Period 2|Lack of Efficacy|7
6178906|NCT01314872|9828830|FG012|Period 2|Lack of Efficacy|12
6178907|NCT01314872|9828831|FG013|Period 2|Lack of Efficacy|9
6178908|NCT01314872|9828832|FG014|Period 2|Lack of Efficacy|2
6178909|NCT01314872|9828818|FG000|Period 2|Pregnancy|0
6178910|NCT01314872|9828819|FG001|Period 2|Pregnancy|0
6178911|NCT01314872|9828820|FG002|Period 2|Pregnancy|0
6178912|NCT01314872|9828821|FG003|Period 2|Pregnancy|0
6178913|NCT01314872|9828822|FG004|Period 2|Pregnancy|0
6178914|NCT01314872|9828823|FG005|Period 2|Pregnancy|0
6178915|NCT01314872|9828824|FG006|Period 2|Pregnancy|0
6178916|NCT01314872|9828825|FG007|Period 2|Pregnancy|0
6178917|NCT01314872|9828826|FG008|Period 2|Pregnancy|0
6178918|NCT01314872|9828827|FG009|Period 2|Pregnancy|0
6178919|NCT01314872|9828828|FG010|Period 2|Pregnancy|0
6178920|NCT01314872|9828829|FG011|Period 2|Pregnancy|0
6178921|NCT01314872|9828830|FG012|Period 2|Pregnancy|0
6178922|NCT01314872|9828831|FG013|Period 2|Pregnancy|0
6178923|NCT01314872|9828832|FG014|Period 2|Pregnancy|1
6178924|NCT01314872|9828818|FG000|Period 2|Study terminated by Sponsor|0
6178925|NCT01314872|9828819|FG001|Period 2|Study terminated by Sponsor|0
6178926|NCT01314872|9828820|FG002|Period 2|Study terminated by Sponsor|0
6178927|NCT01314872|9828821|FG003|Period 2|Study terminated by Sponsor|0
6178928|NCT01314872|9828822|FG004|Period 2|Study terminated by Sponsor|0
6178929|NCT01314872|9828823|FG005|Period 2|Study terminated by Sponsor|0
6178930|NCT01314872|9828824|FG006|Period 2|Study terminated by Sponsor|0
6178931|NCT01314872|9828825|FG007|Period 2|Study terminated by Sponsor|0
6178932|NCT01314872|9828826|FG008|Period 2|Study terminated by Sponsor|0
6178933|NCT01314872|9828827|FG009|Period 2|Study terminated by Sponsor|0
6178934|NCT01314872|9828828|FG010|Period 2|Study terminated by Sponsor|0
6178935|NCT01314872|9828829|FG011|Period 2|Study terminated by Sponsor|2
6178936|NCT01314872|9828830|FG012|Period 2|Study terminated by Sponsor|2
6178937|NCT01314872|9828831|FG013|Period 2|Study terminated by Sponsor|3
6178938|NCT01314872|9828832|FG014|Period 2|Study terminated by Sponsor|0
6178939|NCT01314872|9828818|FG000|Period 2|Adverse event, non-fatal|0
6178940|NCT01314872|9828819|FG001|Period 2|Adverse event, non-fatal|0
6178941|NCT01314872|9828820|FG002|Period 2|Adverse event, non-fatal|0
6178942|NCT01314872|9828821|FG003|Period 2|Adverse event, non-fatal|0
6178943|NCT01314872|9828822|FG004|Period 2|Adverse event, non-fatal|0
6178944|NCT01314872|9828823|FG005|Period 2|Adverse event, non-fatal|0
6178945|NCT01314872|9828824|FG006|Period 2|Adverse event, non-fatal|0
6178946|NCT01314872|9828825|FG007|Period 2|Adverse event, non-fatal|0
6178947|NCT01314872|9828826|FG008|Period 2|Adverse event, non-fatal|0
6178948|NCT01314872|9828827|FG009|Period 2|Adverse event, non-fatal|0
6178949|NCT01314872|9828828|FG010|Period 2|Adverse event, non-fatal|0
6178950|NCT01314872|9828829|FG011|Period 2|Adverse event, non-fatal|13
6178951|NCT01314872|9828830|FG012|Period 2|Adverse event, non-fatal|16
6178952|NCT01314872|9828831|FG013|Period 2|Adverse event, non-fatal|24
6178953|NCT01314872|9828832|FG014|Period 2|Adverse event, non-fatal|9
6178954|NCT01314872|9828818|FG000|Period 2|Withdrawal by Subject|0
6178955|NCT01314872|9828819|FG001|Period 2|Withdrawal by Subject|0
6178956|NCT01314872|9828820|FG002|Period 2|Withdrawal by Subject|0
6178957|NCT01314872|9828821|FG003|Period 2|Withdrawal by Subject|0
6178958|NCT01314872|9828822|FG004|Period 2|Withdrawal by Subject|0
6178959|NCT01314872|9828823|FG005|Period 2|Withdrawal by Subject|0
6178960|NCT01314872|9828824|FG006|Period 2|Withdrawal by Subject|0
6178961|NCT01314872|9828825|FG007|Period 2|Withdrawal by Subject|0
6085145|NCT00650104|9694391|FG000|Overall Study|Death|2
6085146|NCT00650104|9694391|FG000|Overall Study|Withdrawal by Subject|11
6085147|NCT00650104|9694391|FG000|Overall Study|Physician Decision|7
6085148|NCT00650104|9694391|FG000|Overall Study|Lost to Follow-up|1
6085149|NCT00650104|9694391|FG000|Overall Study|Non-compliance|2
6178962|NCT01314872|9828826|FG008|Period 2|Withdrawal by Subject|0
6178963|NCT01314872|9828827|FG009|Period 2|Withdrawal by Subject|0
6178964|NCT01314872|9828828|FG010|Period 2|Withdrawal by Subject|0
6178965|NCT01314872|9828829|FG011|Period 2|Withdrawal by Subject|14
6178966|NCT01314872|9828830|FG012|Period 2|Withdrawal by Subject|17
6178967|NCT01314872|9828831|FG013|Period 2|Withdrawal by Subject|12
6178968|NCT01314872|9828832|FG014|Period 2|Withdrawal by Subject|4
6178969|NCT01314872|9828818|FG000|Period 2|Lost to Follow-up|0
6085150|NCT00650104|9694391|FG000|Overall Study|Sponsor Terminated Dosing|1
6178970|NCT01314872|9828819|FG001|Period 2|Lost to Follow-up|0
6178971|NCT01314872|9828820|FG002|Period 2|Lost to Follow-up|0
6178972|NCT01314872|9828821|FG003|Period 2|Lost to Follow-up|0
6178973|NCT01314872|9828822|FG004|Period 2|Lost to Follow-up|0
6178974|NCT01314872|9828823|FG005|Period 2|Lost to Follow-up|0
6178975|NCT01314872|9828824|FG006|Period 2|Lost to Follow-up|0
6178976|NCT01314872|9828825|FG007|Period 2|Lost to Follow-up|0
6085151|NCT00650585|9694411|FG000|Overall Study|Lost to Follow-up|505
6178977|NCT01314872|9828826|FG008|Period 2|Lost to Follow-up|0
6178978|NCT01314872|9828827|FG009|Period 2|Lost to Follow-up|0
6178979|NCT01314872|9828828|FG010|Period 2|Lost to Follow-up|0
6178980|NCT01314872|9828829|FG011|Period 2|Lost to Follow-up|6
6178981|NCT01314872|9828830|FG012|Period 2|Lost to Follow-up|7
6178982|NCT01314872|9828831|FG013|Period 2|Lost to Follow-up|2
6178983|NCT01314872|9828832|FG014|Period 2|Lost to Follow-up|6
6178984|NCT01314911|9828866|FG000|Overall Study|Lost to Follow-up|3
6178985|NCT01314911|9828867|FG001|Overall Study|Lost to Follow-up|2
6178986|NCT01314911|9828866|FG000|Overall Study|Withdrawal by Subject|1
6178987|NCT01314911|9828867|FG001|Overall Study|Withdrawal by Subject|3
6178988|NCT01314911|9828866|FG000|Overall Study|Received Non-randomized Study Drug|0
6178989|NCT01314911|9828867|FG001|Overall Study|Received Non-randomized Study Drug|1
6085152|NCT00650585|9694412|FG001|Overall Study|Lost to Follow-up|482
6178990|NCT01314911|9828866|FG000|Overall Study|Never Started Treatment|1
6178991|NCT01314911|9828867|FG001|Overall Study|Never Started Treatment|0
6178992|NCT01315028|9828888|FG000|Overall Study|Lost to Follow-up|1
6178993|NCT01315028|9828889|FG001|Overall Study|Lost to Follow-up|0
6178994|NCT01315028|9828888|FG000|Overall Study|Death|0
6178995|NCT01315028|9828889|FG001|Overall Study|Death|1
6178996|NCT01315132|9828895|FG000|Overall Study|not treated due to disease progression|1
6178997|NCT01315236|9828919|FG000|Double-blind Phase|Death|1
6178998|NCT01315236|9828920|FG001|Double-blind Phase|Death|0
6178999|NCT01315236|9828919|FG000|Double-blind Phase|Adverse Event|1
6179000|NCT01315236|9828920|FG001|Double-blind Phase|Adverse Event|0
6179001|NCT01315236|9828919|FG000|Double-blind Phase|Withdrawal of Consent|1
6179002|NCT01315236|9828920|FG001|Double-blind Phase|Withdrawal of Consent|0
6179003|NCT01315236|9828919|FG000|Double-blind Phase|Lost to Follow-up|1
6179004|NCT01315236|9828920|FG001|Double-blind Phase|Lost to Follow-up|0
6179005|NCT01315236|9828919|FG000|Open-label Phase|Death|1
6179006|NCT01315236|9828920|FG001|Open-label Phase|Death|0
6179007|NCT01315236|9828919|FG000|Open-label Phase|Adverse Event|0
6179008|NCT01315236|9828920|FG001|Open-label Phase|Adverse Event|1
6179009|NCT01315236|9828919|FG000|Open-label Phase|Other|0
6179010|NCT01315236|9828920|FG001|Open-label Phase|Other|1
6179011|NCT01315236|9828919|FG000|12-Month Follow-up Period|Death|0
6179012|NCT01315236|9828920|FG001|12-Month Follow-up Period|Death|1
6179013|NCT01315236|9828919|FG000|12-Month Follow-up Period|Did not return to the site for Month 12|1
6179014|NCT01315236|9828920|FG001|12-Month Follow-up Period|Did not return to the site for Month 12|0
6179015|NCT01315249|9828930|FG000|Overall Study|Adverse Event|22
6179016|NCT01315249|9828931|FG001|Overall Study|Adverse Event|26
6179017|NCT01315249|9828930|FG000|Overall Study|Withdrawal by Subject|11
6179018|NCT01315249|9828931|FG001|Overall Study|Withdrawal by Subject|10
6179019|NCT01315249|9828930|FG000|Overall Study|Protocol Violation|8
6179020|NCT01315249|9828931|FG001|Overall Study|Protocol Violation|5
6179021|NCT01315249|9828930|FG000|Overall Study|Abnormal test results|1
6179022|NCT01315249|9828931|FG001|Overall Study|Abnormal test results|2
6179023|NCT01315249|9828930|FG000|Overall Study|Administrative problems|1
6179024|NCT01315249|9828931|FG001|Overall Study|Administrative problems|0
6179025|NCT01315249|9828930|FG000|Overall Study|inability to use device|1
6179026|NCT01315249|9828931|FG001|Overall Study|inability to use device|0
6179027|NCT01315249|9828930|FG000|Overall Study|Lack of Efficacy|0
6179028|NCT01315249|9828931|FG001|Overall Study|Lack of Efficacy|1
6179029|NCT01315249|9828930|FG000|Overall Study|Lost to Follow-up|0
6179030|NCT01315249|9828931|FG001|Overall Study|Lost to Follow-up|2
6179031|NCT01315249|9828930|FG000|Overall Study|Death|0
6179032|NCT01315249|9828931|FG001|Overall Study|Death|1
6179033|NCT01315678|9828959|FG000|Overall Study|Withdrawal by Subject|7
6179034|NCT01315678|9828960|FG001|Overall Study|Withdrawal by Subject|3
6179035|NCT01315678|9828959|FG000|Overall Study|Adverse Event|3
6179036|NCT01315678|9828960|FG001|Overall Study|Adverse Event|1
6179037|NCT01315678|9828959|FG000|Overall Study|Lost to Follow-up|1
6179038|NCT01315678|9828960|FG001|Overall Study|Lost to Follow-up|0
6179039|NCT01315678|9828959|FG000|Overall Study|similar reason to those listed above|3
6179040|NCT01315678|9828960|FG001|Overall Study|similar reason to those listed above|2
6227703|NCT01718535|9900513|FG009|Overall Study|Bidirectional Sequencing not possible|0
6227704|NCT01719003|9900557|FG000|Overall Study|Non compliant with protocol|1
6227705|NCT01719003|9900558|FG001|Overall Study|Non compliant with protocol|1
6227706|NCT01719003|9900559|FG002|Overall Study|Non compliant with protocol|0
6227707|NCT01719003|9900560|FG003|Overall Study|Non compliant with protocol|1
6227708|NCT01719003|9900561|FG004|Overall Study|Non compliant with protocol|2
6227709|NCT01719003|9900562|FG005|Overall Study|Non compliant with protocol|1
6227710|NCT01719003|9900563|FG006|Overall Study|Non compliant with protocol|2
6227711|NCT01719003|9900564|FG007|Overall Study|Non compliant with protocol|3
6227712|NCT01719003|9900565|FG008|Overall Study|Non compliant with protocol|0
6227713|NCT01719003|9900557|FG000|Overall Study|Adverse Event|6
6375355|NCT02409368|10165127|FG001|Overall Study|Not Reported|1
6375356|NCT02409368|10165128|FG002|Overall Study|Not Reported|0
6375357|NCT02277119|10165149|FG000|Overall Study|Lack of Efficacy|1
6375358|NCT02277119|10165150|FG001|Overall Study|Lack of Efficacy|1
6227714|NCT01719003|9900558|FG001|Overall Study|Adverse Event|5
6227715|NCT01719003|9900559|FG002|Overall Study|Adverse Event|4
6227716|NCT01719003|9900560|FG003|Overall Study|Adverse Event|3
6179041|NCT01315847|9828970|FG000|Part I, Period 1|Reached maximum number of arterial lines|3
6179042|NCT01315847|9828971|FG001|Part I, Period 1|Reached maximum number of arterial lines|0
6179043|NCT01315847|9828970|FG000|Part III, Period 1|[11C]MK-4232 synthesis failure|0
6179044|NCT01315847|9828971|FG001|Part III, Period 1|[11C]MK-4232 synthesis failure|1
6227717|NCT01719003|9900561|FG004|Overall Study|Adverse Event|4
6227718|NCT01719003|9900562|FG005|Overall Study|Adverse Event|3
6227719|NCT01719003|9900563|FG006|Overall Study|Adverse Event|6
6227720|NCT01719003|9900564|FG007|Overall Study|Adverse Event|5
6227721|NCT01719003|9900565|FG008|Overall Study|Adverse Event|0
6227722|NCT01719003|9900557|FG000|Overall Study|Lost to Follow-up|0
6227723|NCT01719003|9900558|FG001|Overall Study|Lost to Follow-up|6
6227724|NCT01719003|9900559|FG002|Overall Study|Lost to Follow-up|7
6227725|NCT01719003|9900560|FG003|Overall Study|Lost to Follow-up|2
6227726|NCT01719003|9900561|FG004|Overall Study|Lost to Follow-up|3
6227727|NCT01719003|9900562|FG005|Overall Study|Lost to Follow-up|4
6179045|NCT01316055|9828989|FG000|Overall Study|Lost to Follow-up|1
6179046|NCT01316055|9828990|FG001|Overall Study|Lost to Follow-up|0
6179047|NCT01316055|9828991|FG002|Overall Study|Lost to Follow-up|0
6375359|NCT02277119|10165151|FG002|Overall Study|Lack of Efficacy|1
6179048|NCT01316224|9829011|FG000|Overall Study|Protocol Violation|3
6179049|NCT01316224|9829011|FG000|Overall Study|Adverse Event|3
6179050|NCT01316224|9829011|FG000|Overall Study|Lack of Efficacy|1
6179051|NCT01316224|9829011|FG000|Overall Study|Withdrawal by Subject|1
6375360|NCT02277119|10165149|FG000|Overall Study|Protocol Violation|2
6179052|NCT01316224|9829011|FG000|Overall Study|Adverse Event With Treatment Failure|1
6179053|NCT01316224|9829011|FG000|Overall Study|Other|1
6375361|NCT02277119|10165150|FG001|Overall Study|Protocol Violation|3
6375362|NCT02277119|10165151|FG002|Overall Study|Protocol Violation|7
6179054|NCT01316276|9829026|FG000|Overall Study|Death|1
6179055|NCT01316276|9829026|FG000|Overall Study|Adverse Event|19
6179056|NCT01316276|9829026|FG000|Overall Study|Withdrawal of consent|24
6179057|NCT01316276|9829026|FG000|Overall Study|Lost to Follow-up|1
6179058|NCT01316276|9829026|FG000|Overall Study|Other|22
6179059|NCT01316380|9829078|FG000|Overall Study|Adverse Event|0
6179060|NCT01316380|9829079|FG001|Overall Study|Adverse Event|2
6179061|NCT01316380|9829080|FG002|Overall Study|Adverse Event|1
6179062|NCT01316380|9829078|FG000|Overall Study|Protocol Violation|0
6179063|NCT01316380|9829079|FG001|Overall Study|Protocol Violation|0
6179064|NCT01316380|9829080|FG002|Overall Study|Protocol Violation|1
6179065|NCT01316380|9829078|FG000|Overall Study|Withdrawal by Subject|1
6179066|NCT01316380|9829079|FG001|Overall Study|Withdrawal by Subject|2
6179067|NCT01316380|9829080|FG002|Overall Study|Withdrawal by Subject|0
6179068|NCT01316380|9829078|FG000|Overall Study|Other|0
6179069|NCT01316380|9829079|FG001|Overall Study|Other|1
6179070|NCT01316380|9829080|FG002|Overall Study|Other|1
6179071|NCT01316380|9829078|FG000|Overall Study|Not treated|1
6179072|NCT01316380|9829079|FG001|Overall Study|Not treated|0
6179073|NCT01316380|9829080|FG002|Overall Study|Not treated|0
6179074|NCT01316419|9829088|FG000|Overall Study|Not treated|103
6179075|NCT01316419|9829088|FG000|Overall Study|Violated inclusion/exclusion criterion|143
6179076|NCT01316419|9829088|FG000|Overall Study|Lost to Follow-up|19
6179077|NCT01316575|9829103|FG000|Overall Study|Withdrawal by Subject|2
6179078|NCT01316575|9829104|FG001|Overall Study|Withdrawal by Subject|0
6179079|NCT01316575|9829103|FG000|Overall Study|Required alternate treatment|0
6179080|NCT01316575|9829104|FG001|Overall Study|Required alternate treatment|1
6179081|NCT01316614|9829110|FG000|Overall Study|No solid lesion and FNA not indicated|25
6179082|NCT01316614|9829110|FG000|Overall Study|Cytology slides not available for review|4
6179083|NCT01316614|9829110|FG000|Overall Study|Cystic lesion|5
6179084|NCT01316614|9829110|FG000|Overall Study|Inadequate number of passes|2
6179085|NCT01316614|9829110|FG000|Overall Study|Medically unstable|1
6179086|NCT01316692|9829115|FG000|Overall Study|Adverse Event|5
6179087|NCT01316692|9829115|FG000|Overall Study|Disease Progression|7
6179088|NCT01316887|9829133|FG000|Overall Study|Adverse Event|13
6179089|NCT01316887|9829134|FG001|Overall Study|Adverse Event|21
6179090|NCT01316887|9829135|FG002|Overall Study|Adverse Event|17
6179091|NCT01316887|9829133|FG000|Overall Study|Lack of Efficacy|9
6179092|NCT01316887|9829134|FG001|Overall Study|Lack of Efficacy|3
6179093|NCT01316887|9829135|FG002|Overall Study|Lack of Efficacy|1
6179094|NCT01316887|9829133|FG000|Overall Study|Protocol Violation|2
6179095|NCT01316887|9829134|FG001|Overall Study|Protocol Violation|6
6179096|NCT01316887|9829135|FG002|Overall Study|Protocol Violation|6
6179097|NCT01316887|9829133|FG000|Overall Study|Protocol-defined Stopping Criteria|8
6179098|NCT01316887|9829134|FG001|Overall Study|Protocol-defined Stopping Criteria|37
6179099|NCT01316887|9829135|FG002|Overall Study|Protocol-defined Stopping Criteria|36
6179100|NCT01316887|9829133|FG000|Overall Study|Study Closed/Terminated|2
6179101|NCT01316887|9829134|FG001|Overall Study|Study Closed/Terminated|4
6179102|NCT01316887|9829135|FG002|Overall Study|Study Closed/Terminated|3
6179103|NCT01316887|9829133|FG000|Overall Study|Lost to Follow-up|1
6179104|NCT01316887|9829134|FG001|Overall Study|Lost to Follow-up|7
6179105|NCT01316887|9829135|FG002|Overall Study|Lost to Follow-up|5
6179106|NCT01316887|9829133|FG000|Overall Study|Withdrawal by Subject|8
6179107|NCT01316887|9829134|FG001|Overall Study|Withdrawal by Subject|16
6179108|NCT01316887|9829135|FG002|Overall Study|Withdrawal by Subject|15
6179109|NCT01316900|9829148|FG000|Overall Study|Adverse Event|10
6179110|NCT01316900|9829149|FG001|Overall Study|Adverse Event|10
6179111|NCT01316900|9829150|FG002|Overall Study|Adverse Event|15
6179112|NCT01316900|9829151|FG003|Overall Study|Adverse Event|9
6179113|NCT01316900|9829148|FG000|Overall Study|Lack of Efficacy|17
6179114|NCT01316900|9829149|FG001|Overall Study|Lack of Efficacy|9
6179115|NCT01316900|9829150|FG002|Overall Study|Lack of Efficacy|5
6179116|NCT01316900|9829151|FG003|Overall Study|Lack of Efficacy|7
6179117|NCT01316900|9829148|FG000|Overall Study|Protocol Violation|7
6179118|NCT01316900|9829149|FG001|Overall Study|Protocol Violation|1
6179119|NCT01316900|9829150|FG002|Overall Study|Protocol Violation|4
6179120|NCT01316900|9829151|FG003|Overall Study|Protocol Violation|0
6179121|NCT01316900|9829148|FG000|Overall Study|Protocol-defined Stopping Criteria|2
6179122|NCT01316900|9829149|FG001|Overall Study|Protocol-defined Stopping Criteria|3
6179123|NCT01316900|9829150|FG002|Overall Study|Protocol-defined Stopping Criteria|10
6179124|NCT01316900|9829151|FG003|Overall Study|Protocol-defined Stopping Criteria|5
6179125|NCT01316900|9829148|FG000|Overall Study|Lost to Follow-up|1
6179126|NCT01316900|9829149|FG001|Overall Study|Lost to Follow-up|0
6179127|NCT01316900|9829150|FG002|Overall Study|Lost to Follow-up|1
6179128|NCT01316900|9829151|FG003|Overall Study|Lost to Follow-up|1
6179129|NCT01316900|9829148|FG000|Overall Study|Withdrawal by Subject|7
6179130|NCT01316900|9829149|FG001|Overall Study|Withdrawal by Subject|8
6179131|NCT01316900|9829150|FG002|Overall Study|Withdrawal by Subject|6
6179132|NCT01316900|9829151|FG003|Overall Study|Withdrawal by Subject|9
6179133|NCT01316913|9829165|FG000|Overall Study|Adverse Event|17
6375363|NCT02220894|10165161|FG000|Overall Study|Adverse Event|118
6179134|NCT01316913|9829166|FG001|Overall Study|Adverse Event|20
6179135|NCT01316913|9829167|FG002|Overall Study|Adverse Event|15
6179136|NCT01316913|9829168|FG003|Overall Study|Adverse Event|11
6179137|NCT01316913|9829165|FG000|Overall Study|Lack of Efficacy|22
6179138|NCT01316913|9829166|FG001|Overall Study|Lack of Efficacy|12
6179139|NCT01316913|9829167|FG002|Overall Study|Lack of Efficacy|9
6179140|NCT01316913|9829168|FG003|Overall Study|Lack of Efficacy|13
6179141|NCT01316913|9829165|FG000|Overall Study|Protocol Violation|1
6179142|NCT01316913|9829166|FG001|Overall Study|Protocol Violation|4
6179143|NCT01316913|9829167|FG002|Overall Study|Protocol Violation|4
6179144|NCT01316913|9829168|FG003|Overall Study|Protocol Violation|1
6179145|NCT01316913|9829165|FG000|Overall Study|Protocol-defined Stopping Criteria|7
6179146|NCT01316913|9829166|FG001|Overall Study|Protocol-defined Stopping Criteria|8
6179147|NCT01316913|9829167|FG002|Overall Study|Protocol-defined Stopping Criteria|11
6179148|NCT01316913|9829168|FG003|Overall Study|Protocol-defined Stopping Criteria|6
6179149|NCT01316913|9829165|FG000|Overall Study|Lost to Follow-up|0
6179150|NCT01316913|9829166|FG001|Overall Study|Lost to Follow-up|1
6179151|NCT01316913|9829167|FG002|Overall Study|Lost to Follow-up|0
6179152|NCT01316913|9829168|FG003|Overall Study|Lost to Follow-up|2
6179153|NCT01316913|9829165|FG000|Overall Study|Withdrawal by Subject|10
6179154|NCT01316913|9829166|FG001|Overall Study|Withdrawal by Subject|9
6179155|NCT01316913|9829167|FG002|Overall Study|Withdrawal by Subject|10
6179156|NCT01316913|9829168|FG003|Overall Study|Withdrawal by Subject|6
6179157|NCT01316939|9829190|FG000|Overall Study|Study closed/terminated|26
6179158|NCT01316939|9829191|FG001|Overall Study|Study closed/terminated|25
6179159|NCT01316939|9829192|FG002|Overall Study|Study closed/terminated|23
6179160|NCT01316939|9829190|FG000|Overall Study|Lack of Efficacy|24
6179161|NCT01316939|9829191|FG001|Overall Study|Lack of Efficacy|25
6179162|NCT01316939|9829192|FG002|Overall Study|Lack of Efficacy|25
6179163|NCT01316939|9829190|FG000|Overall Study|Adverse Event|9
6179164|NCT01316939|9829191|FG001|Overall Study|Adverse Event|12
6179165|NCT01316939|9829192|FG002|Overall Study|Adverse Event|11
6179166|NCT01316939|9829190|FG000|Overall Study|Withdrawal by Subject|1
6179167|NCT01316939|9829191|FG001|Overall Study|Withdrawal by Subject|3
6179168|NCT01316939|9829192|FG002|Overall Study|Withdrawal by Subject|6
6179169|NCT01316939|9829190|FG000|Overall Study|Physician Decision|2
6179170|NCT01316939|9829191|FG001|Overall Study|Physician Decision|2
6179171|NCT01316939|9829192|FG002|Overall Study|Physician Decision|1
6179172|NCT01316939|9829190|FG000|Overall Study|Lost to Follow-up|0
6179173|NCT01316939|9829191|FG001|Overall Study|Lost to Follow-up|0
6179174|NCT01316939|9829192|FG002|Overall Study|Lost to Follow-up|2
6179175|NCT01316939|9829190|FG000|Overall Study|Met Liver chemistry stopping criteria|1
6179176|NCT01316939|9829191|FG001|Overall Study|Met Liver chemistry stopping criteria|0
6179177|NCT01316939|9829192|FG002|Overall Study|Met Liver chemistry stopping criteria|1
6179178|NCT01316939|9829190|FG000|Overall Study|Protocol Violation|0
6179179|NCT01316939|9829191|FG001|Overall Study|Protocol Violation|1
6179180|NCT01316939|9829192|FG002|Overall Study|Protocol Violation|0
6179181|NCT01317004|9829202|FG000|Overall Study|Withdrawal by Subject|1
6179182|NCT01317004|9829203|FG001|Overall Study|Withdrawal by Subject|4
6179183|NCT01317004|9829202|FG000|Overall Study|Protocol Violation|0
6085153|NCT00650585|9694411|FG000|Overall Study|No parental consent|935
6085154|NCT00650585|9694412|FG001|Overall Study|No parental consent|866
6085155|NCT00650585|9694411|FG000|Overall Study|Excluded/ruled ineligible|357
6179184|NCT01317004|9829203|FG001|Overall Study|Protocol Violation|2
6179185|NCT01317004|9829202|FG000|Overall Study|Adverse Event|3
6179186|NCT01317004|9829203|FG001|Overall Study|Adverse Event|3
6179187|NCT01317199|9829231|FG000|Dose-escalation Phase 1|Physician Decision|5
6179188|NCT01317199|9829232|FG001|Dose-escalation Phase 1|Physician Decision|0
6179189|NCT01317199|9829233|FG002|Dose-escalation Phase 1|Physician Decision|0
6179190|NCT01317199|9829234|FG003|Dose-escalation Phase 1|Physician Decision|0
6179191|NCT01317199|9829231|FG000|Dose-escalation Phase 1|Disease progression|1
6179192|NCT01317199|9829232|FG001|Dose-escalation Phase 1|Disease progression|0
6179193|NCT01317199|9829233|FG002|Dose-escalation Phase 1|Disease progression|0
6179194|NCT01317199|9829234|FG003|Dose-escalation Phase 1|Disease progression|0
6179195|NCT01317199|9829231|FG000|Dose-escalation Phase 1|Comorbidities, myasthenia gravis|1
6179196|NCT01317199|9829232|FG001|Dose-escalation Phase 1|Comorbidities, myasthenia gravis|0
6179197|NCT01317199|9829233|FG002|Dose-escalation Phase 1|Comorbidities, myasthenia gravis|0
6179198|NCT01317199|9829234|FG003|Dose-escalation Phase 1|Comorbidities, myasthenia gravis|0
6179199|NCT01317199|9829231|FG000|Randomized Phase 2|Disease progression|0
6179200|NCT01317199|9829232|FG001|Randomized Phase 2|Disease progression|3
6179201|NCT01317199|9829233|FG002|Randomized Phase 2|Disease progression|7
6179202|NCT01317199|9829234|FG003|Randomized Phase 2|Disease progression|5
6179203|NCT01317199|9829231|FG000|Randomized Phase 2|Withdrawal by Subject|0
6179204|NCT01317199|9829232|FG001|Randomized Phase 2|Withdrawal by Subject|3
6179205|NCT01317199|9829233|FG002|Randomized Phase 2|Withdrawal by Subject|5
6179206|NCT01317199|9829234|FG003|Randomized Phase 2|Withdrawal by Subject|4
6179207|NCT01317199|9829231|FG000|Randomized Phase 2|Adverse Event|0
6179208|NCT01317199|9829232|FG001|Randomized Phase 2|Adverse Event|0
6179209|NCT01317199|9829233|FG002|Randomized Phase 2|Adverse Event|0
6179210|NCT01317199|9829234|FG003|Randomized Phase 2|Adverse Event|1
6179211|NCT01317199|9829231|FG000|Randomized Phase 2|Comorbidities|0
6179212|NCT01317199|9829232|FG001|Randomized Phase 2|Comorbidities|2
6375364|NCT02220894|10165162|FG001|Overall Study|Adverse Event|70
6375365|NCT02220894|10165161|FG000|Overall Study|Death|252
6375366|NCT02220894|10165162|FG001|Overall Study|Death|368
6375367|NCT02220894|10165161|FG000|Overall Study|Lost to Follow-up|0
6375368|NCT02220894|10165162|FG001|Overall Study|Lost to Follow-up|2
6375369|NCT02220894|10165161|FG000|Overall Study|Withdrawal by Parent/Guardian|0
6375370|NCT02220894|10165162|FG001|Overall Study|Withdrawal by Parent/Guardian|1
6375371|NCT02220894|10165161|FG000|Overall Study|Withdrawal by Subject|2
6375372|NCT02220894|10165162|FG001|Overall Study|Withdrawal by Subject|13
6375373|NCT02220894|10165161|FG000|Overall Study|Ongoing in Study|265
6375374|NCT02220894|10165162|FG001|Overall Study|Ongoing in Study|183
6375375|NCT01721759|10165317|FG000|Overall Study|Disease progression|78
6375376|NCT01721759|10165317|FG000|Overall Study|Study drug toxicity|14
6375377|NCT01721759|10165317|FG000|Overall Study|Adverse event unrelated to study drug|9
6375378|NCT01721759|10165317|FG000|Overall Study|Withdrawal by Subject|1
6375379|NCT01285102|10165330|FG000|Overall Study|Closed to accrual by sponsor due to poor accrual and challenge with dosing|4
6179213|NCT01317199|9829233|FG002|Randomized Phase 2|Comorbidities|2
6179214|NCT01317199|9829234|FG003|Randomized Phase 2|Comorbidities|2
6179215|NCT01317199|9829231|FG000|Randomized Phase 2|Rising PSA, not as defined by protocol|0
6179216|NCT01317199|9829232|FG001|Randomized Phase 2|Rising PSA, not as defined by protocol|2
6179217|NCT01317199|9829233|FG002|Randomized Phase 2|Rising PSA, not as defined by protocol|5
6179218|NCT01317199|9829234|FG003|Randomized Phase 2|Rising PSA, not as defined by protocol|2
6179219|NCT01317199|9829231|FG000|Randomized Phase 2|Disenrolled before treatment|0
6179220|NCT01317199|9829232|FG001|Randomized Phase 2|Disenrolled before treatment|1
6179221|NCT01317199|9829233|FG002|Randomized Phase 2|Disenrolled before treatment|1
6179222|NCT01317199|9829234|FG003|Randomized Phase 2|Disenrolled before treatment|2
6179223|NCT01317199|9829231|FG000|Randomized Phase 2|Patient stopped taking study drug|0
6179224|NCT01317199|9829232|FG001|Randomized Phase 2|Patient stopped taking study drug|0
6179225|NCT01317199|9829233|FG002|Randomized Phase 2|Patient stopped taking study drug|0
6179226|NCT01317199|9829234|FG003|Randomized Phase 2|Patient stopped taking study drug|1
6179227|NCT01317199|9829231|FG000|Randomized Phase 2|Patient transferred to other facility|0
6179228|NCT01317199|9829232|FG001|Randomized Phase 2|Patient transferred to other facility|0
6179229|NCT01317199|9829233|FG002|Randomized Phase 2|Patient transferred to other facility|1
6179230|NCT01317199|9829234|FG003|Randomized Phase 2|Patient transferred to other facility|0
6179231|NCT01317277|9829253|FG000|Overall Study|Lost to Follow-up|3
6179232|NCT01317277|9829254|FG001|Overall Study|Lost to Follow-up|1
6179233|NCT01317277|9829253|FG000|Overall Study|Lost MEMS|1
6179234|NCT01317277|9829254|FG001|Overall Study|Lost MEMS|1
6179235|NCT01317277|9829253|FG000|Overall Study|Unable to comply with intervention|1
6179236|NCT01317277|9829254|FG001|Overall Study|Unable to comply with intervention|0
6179237|NCT01317277|9829253|FG000|Overall Study|Withdrawal by Subject|1
6179238|NCT01317277|9829254|FG001|Overall Study|Withdrawal by Subject|0
6179239|NCT01317277|9829253|FG000|Overall Study|Adverse Event|1
6179240|NCT01317277|9829254|FG001|Overall Study|Adverse Event|0
6179241|NCT01317472|9829262|FG000|Overall Study|Withdrawal by Subject|1
6179242|NCT01317472|9829263|FG001|Overall Study|Withdrawal by Subject|0
6179243|NCT01317472|9829262|FG000|Overall Study|Unrelated hospitalization|1
6179244|NCT01317472|9829263|FG001|Overall Study|Unrelated hospitalization|0
6179245|NCT01317550|9829273|FG000|Overall Study|Withdrawal by Subject|1
6179246|NCT01317550|9829274|FG001|Overall Study|Withdrawal by Subject|0
6179247|NCT01317550|9829275|FG002|Overall Study|Withdrawal by Subject|0
6179248|NCT01317550|9829276|FG003|Overall Study|Withdrawal by Subject|0
6179249|NCT01317550|9829273|FG000|Overall Study|Lack of compliance study med|1
6179250|NCT01317550|9829274|FG001|Overall Study|Lack of compliance study med|0
6179251|NCT01317550|9829275|FG002|Overall Study|Lack of compliance study med|0
6179252|NCT01317550|9829276|FG003|Overall Study|Lack of compliance study med|0
6179253|NCT01317615|9829286|FG000|Overall Study|Disease progression|25
6179254|NCT01317615|9829286|FG000|Overall Study|New cancer therapy|5
6179255|NCT01317615|9829286|FG000|Overall Study|Death|6
6179256|NCT01317615|9829286|FG000|Overall Study|Withdrawal by Subject|5
6179257|NCT01317615|9829286|FG000|Overall Study|Abnormal laboratory value(s)|1
6179258|NCT01317615|9829286|FG000|Overall Study|Adverse Event|7
6179259|NCT01317641|9829299|FG000|Overall Study|Not treated|0
6179260|NCT01317641|9829300|FG001|Overall Study|Not treated|0
6179261|NCT01317641|9829301|FG002|Overall Study|Not treated|0
6179262|NCT01317641|9829302|FG003|Overall Study|Not treated|0
6179263|NCT01317641|9829303|FG004|Overall Study|Not treated|0
6179264|NCT01317641|9829304|FG005|Overall Study|Not treated|0
6179265|NCT01317641|9829305|FG006|Overall Study|Not treated|0
6179266|NCT01317641|9829306|FG007|Overall Study|Not treated|1
6179267|NCT01317641|9829307|FG008|Overall Study|Not treated|1
6179268|NCT01317641|9829299|FG000|Overall Study|Adverse Event|0
6179269|NCT01317641|9829300|FG001|Overall Study|Adverse Event|1
6179270|NCT01317641|9829301|FG002|Overall Study|Adverse Event|0
6179271|NCT01317641|9829302|FG003|Overall Study|Adverse Event|1
6179272|NCT01317641|9829303|FG004|Overall Study|Adverse Event|0
6179273|NCT01317641|9829304|FG005|Overall Study|Adverse Event|0
6179274|NCT01317641|9829305|FG006|Overall Study|Adverse Event|2
6179275|NCT01317641|9829306|FG007|Overall Study|Adverse Event|1
6179276|NCT01317641|9829307|FG008|Overall Study|Adverse Event|0
6179277|NCT01317641|9829299|FG000|Overall Study|Protocol Violation|1
6179278|NCT01317641|9829300|FG001|Overall Study|Protocol Violation|0
6179279|NCT01317641|9829301|FG002|Overall Study|Protocol Violation|0
6179280|NCT01317641|9829302|FG003|Overall Study|Protocol Violation|0
6179281|NCT01317641|9829303|FG004|Overall Study|Protocol Violation|0
6179282|NCT01317641|9829304|FG005|Overall Study|Protocol Violation|0
6179283|NCT01317641|9829305|FG006|Overall Study|Protocol Violation|0
6179284|NCT01317641|9829306|FG007|Overall Study|Protocol Violation|0
6179285|NCT01317641|9829307|FG008|Overall Study|Protocol Violation|0
6179286|NCT01317641|9829299|FG000|Overall Study|Disease progression|0
6179287|NCT01317641|9829300|FG001|Overall Study|Disease progression|0
6179288|NCT01317641|9829301|FG002|Overall Study|Disease progression|0
6179289|NCT01317641|9829302|FG003|Overall Study|Disease progression|0
6179290|NCT01317641|9829303|FG004|Overall Study|Disease progression|0
6179291|NCT01317641|9829304|FG005|Overall Study|Disease progression|0
6179292|NCT01317641|9829305|FG006|Overall Study|Disease progression|0
6179293|NCT01317641|9829306|FG007|Overall Study|Disease progression|3
6179294|NCT01317641|9829307|FG008|Overall Study|Disease progression|4
6179295|NCT01317641|9829299|FG000|Overall Study|Withdrawal by Subject|0
6179296|NCT01317641|9829300|FG001|Overall Study|Withdrawal by Subject|0
6179297|NCT01317641|9829301|FG002|Overall Study|Withdrawal by Subject|0
6179298|NCT01317641|9829302|FG003|Overall Study|Withdrawal by Subject|0
6179299|NCT01317641|9829303|FG004|Overall Study|Withdrawal by Subject|0
6179300|NCT01317641|9829304|FG005|Overall Study|Withdrawal by Subject|0
6179301|NCT01317641|9829305|FG006|Overall Study|Withdrawal by Subject|1
6179302|NCT01317641|9829306|FG007|Overall Study|Withdrawal by Subject|0
6179303|NCT01317641|9829307|FG008|Overall Study|Withdrawal by Subject|0
6179304|NCT01317797|9829359|FG000|Overall Study|Other|0
6179305|NCT01317797|9829360|FG001|Overall Study|Other|1
6179306|NCT01317797|9829361|FG002|Overall Study|Other|0
6179307|NCT01317797|9829359|FG000|Overall Study|Withdrawal of Patient|0
6179308|NCT01317797|9829360|FG001|Overall Study|Withdrawal of Patient|0
6179309|NCT01317797|9829361|FG002|Overall Study|Withdrawal of Patient|1
6179310|NCT01317940|9829384|FG000|Overall Study|Death|1
6179311|NCT01317940|9829385|FG001|Overall Study|Death|0
6179312|NCT01317940|9829386|FG002|Overall Study|Death|1
6179313|NCT01317940|9829387|FG003|Overall Study|Death|0
6179314|NCT01317940|9829388|FG004|Overall Study|Death|0
6179315|NCT01317940|9829389|FG005|Overall Study|Death|0
6179316|NCT01317940|9829384|FG000|Overall Study|Lost to Follow-up|0
6179317|NCT01317940|9829385|FG001|Overall Study|Lost to Follow-up|0
6179318|NCT01317940|9829386|FG002|Overall Study|Lost to Follow-up|1
6179319|NCT01317940|9829387|FG003|Overall Study|Lost to Follow-up|1
6179320|NCT01317940|9829388|FG004|Overall Study|Lost to Follow-up|1
6179321|NCT01317940|9829389|FG005|Overall Study|Lost to Follow-up|0
6179322|NCT01317940|9829384|FG000|Overall Study|Change in therapy plan|0
6179323|NCT01317940|9829385|FG001|Overall Study|Change in therapy plan|0
6179324|NCT01317940|9829386|FG002|Overall Study|Change in therapy plan|3
6179325|NCT01317940|9829387|FG003|Overall Study|Change in therapy plan|0
6179326|NCT01317940|9829388|FG004|Overall Study|Change in therapy plan|0
6179327|NCT01317940|9829389|FG005|Overall Study|Change in therapy plan|0
6179328|NCT01318070|9829416|FG000|Overall Study|Adverse Event|1
6179329|NCT01318070|9829417|FG001|Overall Study|Adverse Event|1
6179330|NCT01318070|9829418|FG002|Overall Study|Adverse Event|5
6179331|NCT01318070|9829416|FG000|Overall Study|Withdrawal by Subject|0
6179332|NCT01318070|9829417|FG001|Overall Study|Withdrawal by Subject|1
6179333|NCT01318070|9829418|FG002|Overall Study|Withdrawal by Subject|1
6179334|NCT01318070|9829416|FG000|Overall Study|Lack of Efficacy|0
6179335|NCT01318070|9829417|FG001|Overall Study|Lack of Efficacy|0
6179336|NCT01318070|9829418|FG002|Overall Study|Lack of Efficacy|1
6179337|NCT01318070|9829416|FG000|Overall Study|Principal Investigator Discretion|1
6179338|NCT01318070|9829417|FG001|Overall Study|Principal Investigator Discretion|0
6179339|NCT01318070|9829418|FG002|Overall Study|Principal Investigator Discretion|0
6179340|NCT01318083|9829429|FG000|Overall Study|Adverse Event|4
6179341|NCT01318083|9829430|FG001|Overall Study|Adverse Event|1
6179342|NCT01318083|9829431|FG002|Overall Study|Adverse Event|2
6179343|NCT01318083|9829429|FG000|Overall Study|Withdrawal by Subject|1
6179344|NCT01318083|9829430|FG001|Overall Study|Withdrawal by Subject|0
6179345|NCT01318083|9829431|FG002|Overall Study|Withdrawal by Subject|2
6179346|NCT01318083|9829429|FG000|Overall Study|Lack of Efficacy|0
6179347|NCT01318083|9829430|FG001|Overall Study|Lack of Efficacy|0
6179348|NCT01318083|9829431|FG002|Overall Study|Lack of Efficacy|1
6179349|NCT01318083|9829429|FG000|Overall Study|Treatment Complications|1
6179350|NCT01318083|9829430|FG001|Overall Study|Treatment Complications|0
6179351|NCT01318083|9829431|FG002|Overall Study|Treatment Complications|0
6179352|NCT01318083|9829429|FG000|Overall Study|Lack of Study Medication Compliance|0
6179353|NCT01318083|9829430|FG001|Overall Study|Lack of Study Medication Compliance|1
6179354|NCT01318083|9829431|FG002|Overall Study|Lack of Study Medication Compliance|0
6179355|NCT01318109|9829442|FG000|Overall Study|Adverse Event|0
6179356|NCT01318109|9829443|FG001|Overall Study|Adverse Event|2
6179357|NCT01318109|9829444|FG002|Overall Study|Adverse Event|0
6179358|NCT01318109|9829442|FG000|Overall Study|Withdrawal by Subject|1
6179359|NCT01318109|9829443|FG001|Overall Study|Withdrawal by Subject|0
6179360|NCT01318109|9829444|FG002|Overall Study|Withdrawal by Subject|0
6179361|NCT01318109|9829442|FG000|Overall Study|Schedule Conflict|0
6179362|NCT01318109|9829443|FG001|Overall Study|Schedule Conflict|1
6179363|NCT01318109|9829444|FG002|Overall Study|Schedule Conflict|0
6179364|NCT01318122|9829454|FG000|Enrolled - Long-Term Extension Study|Adverse Event|0
6179365|NCT01318122|9829455|FG001|Enrolled - Long-Term Extension Study|Adverse Event|0
6179366|NCT01318122|9829456|FG002|Enrolled - Long-Term Extension Study|Adverse Event|2
6179367|NCT01318122|9829457|FG003|Enrolled - Long-Term Extension Study|Adverse Event|1
6179368|NCT01318122|9829454|FG000|Enrolled - Long-Term Extension Study|Other|1
6179369|NCT01318122|9829455|FG001|Enrolled - Long-Term Extension Study|Other|0
6179370|NCT01318122|9829456|FG002|Enrolled - Long-Term Extension Study|Other|0
6179371|NCT01318122|9829457|FG003|Enrolled - Long-Term Extension Study|Other|0
6179372|NCT01318122|9829454|FG000|Entered - Long-Term Extension Study|Adverse Event|6
6179373|NCT01318122|9829455|FG001|Entered - Long-Term Extension Study|Adverse Event|6
6179374|NCT01318122|9829456|FG002|Entered - Long-Term Extension Study|Adverse Event|2
6179375|NCT01318122|9829457|FG003|Entered - Long-Term Extension Study|Adverse Event|4
6179376|NCT01318122|9829454|FG000|Entered - Long-Term Extension Study|Lost to Follow-up|1
6179377|NCT01318122|9829455|FG001|Entered - Long-Term Extension Study|Lost to Follow-up|0
6179378|NCT01318122|9829456|FG002|Entered - Long-Term Extension Study|Lost to Follow-up|0
6179379|NCT01318122|9829457|FG003|Entered - Long-Term Extension Study|Lost to Follow-up|0
6179380|NCT01318122|9829454|FG000|Entered - Long-Term Extension Study|Withdrawal by Subject|2
6179381|NCT01318122|9829455|FG001|Entered - Long-Term Extension Study|Withdrawal by Subject|3
6179382|NCT01318122|9829456|FG002|Entered - Long-Term Extension Study|Withdrawal by Subject|1
6179383|NCT01318122|9829457|FG003|Entered - Long-Term Extension Study|Withdrawal by Subject|0
6179384|NCT01318122|9829454|FG000|Entered - Long-Term Extension Study|Lack of Efficacy|0
6179385|NCT01318122|9829455|FG001|Entered - Long-Term Extension Study|Lack of Efficacy|2
6179386|NCT01318122|9829456|FG002|Entered - Long-Term Extension Study|Lack of Efficacy|3
6179387|NCT01318122|9829457|FG003|Entered - Long-Term Extension Study|Lack of Efficacy|0
6179388|NCT01318135|9829467|FG000|Enrolled - Long-Term Extension Study|Adverse Event|1
6179389|NCT01318135|9829468|FG001|Enrolled - Long-Term Extension Study|Adverse Event|0
6179390|NCT01318135|9829469|FG002|Enrolled - Long-Term Extension Study|Adverse Event|0
6179391|NCT01318135|9829470|FG003|Enrolled - Long-Term Extension Study|Adverse Event|0
6179392|NCT01318135|9829471|FG004|Enrolled - Long-Term Extension Study|Adverse Event|0
6179393|NCT01318135|9829472|FG005|Enrolled - Long-Term Extension Study|Adverse Event|0
6179394|NCT01318135|9829473|FG006|Enrolled - Long-Term Extension Study|Adverse Event|0
6179395|NCT01318135|9829474|FG007|Enrolled - Long-Term Extension Study|Adverse Event|0
6179396|NCT01318135|9829467|FG000|Enrolled - Long-Term Extension Study|Treatment Complications|1
6179397|NCT01318135|9829468|FG001|Enrolled - Long-Term Extension Study|Treatment Complications|0
6179398|NCT01318135|9829469|FG002|Enrolled - Long-Term Extension Study|Treatment Complications|0
6179399|NCT01318135|9829470|FG003|Enrolled - Long-Term Extension Study|Treatment Complications|0
6179400|NCT01318135|9829471|FG004|Enrolled - Long-Term Extension Study|Treatment Complications|0
6179401|NCT01318135|9829472|FG005|Enrolled - Long-Term Extension Study|Treatment Complications|0
6179402|NCT01318135|9829473|FG006|Enrolled - Long-Term Extension Study|Treatment Complications|0
6179403|NCT01318135|9829474|FG007|Enrolled - Long-Term Extension Study|Treatment Complications|0
6179404|NCT01318135|9829467|FG000|Entered - Long-Term Extension Study|Adverse Event|9
6085156|NCT00650585|9694412|FG001|Overall Study|Excluded/ruled ineligible|129
6085157|NCT00650767|9694422|FG000|Overall Study|Adverse Event|0
6085158|NCT00650767|9694423|FG001|Overall Study|Adverse Event|3
6179405|NCT01318135|9829468|FG001|Entered - Long-Term Extension Study|Adverse Event|3
6179406|NCT01318135|9829469|FG002|Entered - Long-Term Extension Study|Adverse Event|4
6179407|NCT01318135|9829470|FG003|Entered - Long-Term Extension Study|Adverse Event|3
6179408|NCT01318135|9829471|FG004|Entered - Long-Term Extension Study|Adverse Event|4
6179409|NCT01318135|9829472|FG005|Entered - Long-Term Extension Study|Adverse Event|2
6179410|NCT01318135|9829473|FG006|Entered - Long-Term Extension Study|Adverse Event|0
6179411|NCT01318135|9829474|FG007|Entered - Long-Term Extension Study|Adverse Event|0
6179412|NCT01318135|9829467|FG000|Entered - Long-Term Extension Study|Protocol Violation|1
6179413|NCT01318135|9829468|FG001|Entered - Long-Term Extension Study|Protocol Violation|1
6192695|NCT01432938|9850197|FG000|First Intervention|Physician Decision|1
6179414|NCT01318135|9829469|FG002|Entered - Long-Term Extension Study|Protocol Violation|0
6179415|NCT01318135|9829470|FG003|Entered - Long-Term Extension Study|Protocol Violation|0
6179416|NCT01318135|9829471|FG004|Entered - Long-Term Extension Study|Protocol Violation|1
6179417|NCT01318135|9829472|FG005|Entered - Long-Term Extension Study|Protocol Violation|0
6179418|NCT01318135|9829473|FG006|Entered - Long-Term Extension Study|Protocol Violation|0
6179419|NCT01318135|9829474|FG007|Entered - Long-Term Extension Study|Protocol Violation|0
6179420|NCT01318135|9829467|FG000|Entered - Long-Term Extension Study|Withdrawal by Subject|2
6179421|NCT01318135|9829468|FG001|Entered - Long-Term Extension Study|Withdrawal by Subject|2
6179422|NCT01318135|9829469|FG002|Entered - Long-Term Extension Study|Withdrawal by Subject|2
6179423|NCT01318135|9829470|FG003|Entered - Long-Term Extension Study|Withdrawal by Subject|1
6179424|NCT01318135|9829471|FG004|Entered - Long-Term Extension Study|Withdrawal by Subject|2
6179425|NCT01318135|9829472|FG005|Entered - Long-Term Extension Study|Withdrawal by Subject|0
6179426|NCT01318135|9829473|FG006|Entered - Long-Term Extension Study|Withdrawal by Subject|0
6179427|NCT01318135|9829474|FG007|Entered - Long-Term Extension Study|Withdrawal by Subject|1
6179428|NCT01318135|9829467|FG000|Entered - Long-Term Extension Study|Lack of Efficacy|5
6179429|NCT01318135|9829468|FG001|Entered - Long-Term Extension Study|Lack of Efficacy|7
6179430|NCT01318135|9829469|FG002|Entered - Long-Term Extension Study|Lack of Efficacy|2
6179431|NCT01318135|9829470|FG003|Entered - Long-Term Extension Study|Lack of Efficacy|3
6179432|NCT01318135|9829471|FG004|Entered - Long-Term Extension Study|Lack of Efficacy|2
6179433|NCT01318135|9829472|FG005|Entered - Long-Term Extension Study|Lack of Efficacy|2
6179434|NCT01318135|9829473|FG006|Entered - Long-Term Extension Study|Lack of Efficacy|1
6179435|NCT01318135|9829474|FG007|Entered - Long-Term Extension Study|Lack of Efficacy|1
6179436|NCT01318135|9829467|FG000|Entered - Long-Term Extension Study|Use of Excluded Medications|0
6179437|NCT01318135|9829468|FG001|Entered - Long-Term Extension Study|Use of Excluded Medications|0
6179438|NCT01318135|9829469|FG002|Entered - Long-Term Extension Study|Use of Excluded Medications|0
6179439|NCT01318135|9829470|FG003|Entered - Long-Term Extension Study|Use of Excluded Medications|0
6179440|NCT01318135|9829471|FG004|Entered - Long-Term Extension Study|Use of Excluded Medications|0
6179441|NCT01318135|9829472|FG005|Entered - Long-Term Extension Study|Use of Excluded Medications|0
6179442|NCT01318135|9829473|FG006|Entered - Long-Term Extension Study|Use of Excluded Medications|0
6179443|NCT01318135|9829474|FG007|Entered - Long-Term Extension Study|Use of Excluded Medications|1
6179444|NCT01318382|9829511|FG000|Overall Study|Physician Decision|2
6179445|NCT01318382|9829511|FG000|Overall Study|Device Malfunction|10
6179446|NCT01318382|9829511|FG000|Overall Study|Protocol Violation|1
6179447|NCT01318499|9829523|FG000|Overall Study|Adverse Event|16
6179448|NCT01318499|9829524|FG001|Overall Study|Adverse Event|11
6179449|NCT01318499|9829525|FG002|Overall Study|Adverse Event|6
6179450|NCT01318499|9829523|FG000|Overall Study|Pt Decision Unrelated to Adverse Event|1
6179451|NCT01318499|9829524|FG001|Overall Study|Pt Decision Unrelated to Adverse Event|1
6179452|NCT01318499|9829525|FG002|Overall Study|Pt Decision Unrelated to Adverse Event|2
6179453|NCT01318499|9829523|FG000|Overall Study|Noncompliance|2
6179454|NCT01318499|9829524|FG001|Overall Study|Noncompliance|3
6179455|NCT01318499|9829525|FG002|Overall Study|Noncompliance|0
6179456|NCT01318499|9829523|FG000|Overall Study|Treatment Failure|19
6179457|NCT01318499|9829524|FG001|Overall Study|Treatment Failure|19
6179458|NCT01318499|9829525|FG002|Overall Study|Treatment Failure|101
6179459|NCT01318499|9829523|FG000|Overall Study|Protocol Violation|2
6179460|NCT01318499|9829524|FG001|Overall Study|Protocol Violation|4
6179461|NCT01318499|9829525|FG002|Overall Study|Protocol Violation|2
6179462|NCT01318499|9829523|FG000|Overall Study|Patient Did Not Use Study Medication|18
6179463|NCT01318499|9829524|FG001|Overall Study|Patient Did Not Use Study Medication|28
6179464|NCT01318499|9829525|FG002|Overall Study|Patient Did Not Use Study Medication|14
6179465|NCT01318499|9829523|FG000|Overall Study|Other|7
6179466|NCT01318499|9829524|FG001|Overall Study|Other|10
6179467|NCT01318499|9829525|FG002|Overall Study|Other|22
6179468|NCT01318512|9829535|FG000|Maintenance Period (6 Months)|Death|2
6179469|NCT01318512|9829535|FG000|Maintenance Period (6 Months)|Protocol Violation|9
6192696|NCT01432938|9850198|FG001|First Intervention|Physician Decision|0
6192697|NCT01432938|9850197|FG000|Second Intervention|Adverse Event|1
6192698|NCT01432938|9850198|FG001|Second Intervention|Adverse Event|0
6227728|NCT01719003|9900563|FG006|Overall Study|Lost to Follow-up|3
6085159|NCT00650767|9694424|FG002|Overall Study|Adverse Event|10
6085160|NCT00650767|9694425|FG003|Overall Study|Adverse Event|8
6085161|NCT00650767|9694422|FG000|Overall Study|Death|1
6085162|NCT00650767|9694423|FG001|Overall Study|Death|0
6085163|NCT00650767|9694424|FG002|Overall Study|Death|0
6085164|NCT00650767|9694425|FG003|Overall Study|Death|0
6192699|NCT01432951|9850205|FG000|Treatment Phase (Day 1 to 30)|Never Treated|1
6192700|NCT01433055|9850220|FG000|Overall Study|Diagnosed with cancer unrelated to study|1
6192701|NCT01433055|9850221|FG001|Overall Study|Diagnosed with cancer unrelated to study|0
6192702|NCT01433055|9850220|FG000|Overall Study|Severely elevated triglycerides at entry|1
6192703|NCT01433055|9850221|FG001|Overall Study|Severely elevated triglycerides at entry|0
6192704|NCT01433159|9850248|FG000|Overall Study|Adverse Event|1
6192705|NCT01433159|9850249|FG001|Overall Study|Adverse Event|0
6192706|NCT01433159|9850248|FG000|Overall Study|Physician Decision|1
6192707|NCT01433159|9850249|FG001|Overall Study|Physician Decision|0
6192708|NCT01433159|9850248|FG000|Overall Study|Protocol Violation|0
6227729|NCT01719003|9900564|FG007|Overall Study|Lost to Follow-up|2
6179470|NCT01318811|9829585|FG000|Overall Study|Physician Decision|1
6179471|NCT01318811|9829586|FG001|Overall Study|Physician Decision|1
6179472|NCT01318811|9829585|FG000|Overall Study|CRRT stopped for head CT|0
6179473|NCT01318811|9829586|FG001|Overall Study|CRRT stopped for head CT|1
6179474|NCT01318811|9829585|FG000|Overall Study|Death|0
6179475|NCT01318811|9829586|FG001|Overall Study|Death|1
6179476|NCT01318811|9829585|FG000|Overall Study|CRRT stopped for head MRI|0
6179477|NCT01318811|9829586|FG001|Overall Study|CRRT stopped for head MRI|1
6179478|NCT01318876|9829592|FG000|Day 8 Survey|email address invalid|96
6179479|NCT01318876|9829592|FG000|Day 8 Survey|survey not completed-don't know why|1724
6179480|NCT01318876|9829592|FG000|Day 29 Survey|survey not completed-don't know why|1825
6179481|NCT01318902|9829600|FG000|Overall Study|Symptomatic Deterioration|0
6179482|NCT01318902|9829601|FG001|Overall Study|Symptomatic Deterioration|1
6179483|NCT01318902|9829602|FG002|Overall Study|Symptomatic Deterioration|1
6179484|NCT01318902|9829603|FG003|Overall Study|Symptomatic Deterioration|2
6179485|NCT01318902|9829600|FG000|Overall Study|Withdrawal by Patient|0
6179486|NCT01318902|9829601|FG001|Overall Study|Withdrawal by Patient|1
6179487|NCT01318902|9829602|FG002|Overall Study|Withdrawal by Patient|0
6179488|NCT01318902|9829603|FG003|Overall Study|Withdrawal by Patient|3
6179489|NCT01318902|9829600|FG000|Overall Study|Unsatisfactory Therapeutic Response|1
6179490|NCT01318902|9829601|FG001|Overall Study|Unsatisfactory Therapeutic Response|0
6179491|NCT01318902|9829602|FG002|Overall Study|Unsatisfactory Therapeutic Response|0
6179492|NCT01318902|9829603|FG003|Overall Study|Unsatisfactory Therapeutic Response|1
6179493|NCT01318902|9829600|FG000|Overall Study|Adverse Event|0
6179494|NCT01318902|9829601|FG001|Overall Study|Adverse Event|1
6179495|NCT01318902|9829602|FG002|Overall Study|Adverse Event|0
6179496|NCT01318902|9829603|FG003|Overall Study|Adverse Event|0
6179497|NCT01318902|9829600|FG000|Overall Study|Terminated by Sponsor|0
6179498|NCT01318902|9829601|FG001|Overall Study|Terminated by Sponsor|0
6179499|NCT01318902|9829602|FG002|Overall Study|Terminated by Sponsor|1
6179500|NCT01318902|9829603|FG003|Overall Study|Terminated by Sponsor|0
6179501|NCT01318915|9829615|FG000|Overall Study|Lost to Follow-up|1
6179502|NCT01319383|9829643|FG000|Overall Study|No ex vivo or in vivo response|4
6179503|NCT01319383|9829644|FG001|Overall Study|No ex vivo or in vivo response|0
6179504|NCT01319383|9829643|FG000|Overall Study|Physician Decision|3
6179505|NCT01319383|9829644|FG001|Overall Study|Physician Decision|0
6179506|NCT01319383|9829643|FG000|Overall Study|Lack of Efficacy|5
6179507|NCT01319383|9829644|FG001|Overall Study|Lack of Efficacy|9
6179508|NCT01319383|9829643|FG000|Overall Study|No in vivo response to interval doses|0
6179509|NCT01319383|9829644|FG001|Overall Study|No in vivo response to interval doses|1
6179510|NCT01319422|9829667|FG000|Overall Study|Withdrawal by Subject|1
6179511|NCT01319422|9829668|FG001|Overall Study|Withdrawal by Subject|0
6179512|NCT01319721|9829705|FG000|Overall Study|Lost to Follow-up|1
6179513|NCT01319721|9829706|FG001|Overall Study|Lost to Follow-up|6
6179514|NCT01319877|9829757|FG000|Overall Study|Lost to Follow-up|100
6179515|NCT01319877|9829758|FG001|Overall Study|Lost to Follow-up|37
6179516|NCT01319877|9829757|FG000|Overall Study|Physician Decision|2
6179517|NCT01319877|9829758|FG001|Overall Study|Physician Decision|0
6179518|NCT01319877|9829757|FG000|Overall Study|Disease Progression|2
6179519|NCT01319877|9829758|FG001|Overall Study|Disease Progression|2
6179520|NCT01319877|9829757|FG000|Overall Study|Withdrawal by Subject|0
6179521|NCT01319877|9829758|FG001|Overall Study|Withdrawal by Subject|1
6179522|NCT01319877|9829757|FG000|Overall Study|Reason Not Specified|4
6179523|NCT01319877|9829758|FG001|Overall Study|Reason Not Specified|5
6179524|NCT01319929|9829765|FG000|First Treatment Period (4 Weeks)|Adverse Event|2
6179525|NCT01319929|9829766|FG001|First Treatment Period (4 Weeks)|Adverse Event|0
6179526|NCT01319929|9829765|FG000|First Treatment Period (4 Weeks)|Withdrawal by Subject|1
6179527|NCT01319929|9829766|FG001|First Treatment Period (4 Weeks)|Withdrawal by Subject|1
6179528|NCT01319929|9829765|FG000|First Treatment Period (4 Weeks)|Protocol Violation|0
6179529|NCT01319929|9829766|FG001|First Treatment Period (4 Weeks)|Protocol Violation|1
6179530|NCT01319929|9829765|FG000|Second Treatment Period (4 Weeks)|Adverse Event|1
6179531|NCT01319929|9829766|FG001|Second Treatment Period (4 Weeks)|Adverse Event|0
6179532|NCT01319929|9829765|FG000|Second Treatment Period (4 Weeks)|Sponsor Decision|0
6179533|NCT01319929|9829766|FG001|Second Treatment Period (4 Weeks)|Sponsor Decision|1
6179534|NCT01319994|9829775|FG000|Overall Study|Protocol Violation|7
6179535|NCT01319994|9829776|FG001|Overall Study|Protocol Violation|6
6179536|NCT01320033|9829785|FG000|Overall Study|Lack of Efficacy|0
6179537|NCT01320033|9829786|FG001|Overall Study|Lack of Efficacy|0
6179538|NCT01320033|9829787|FG002|Overall Study|Lack of Efficacy|1
6179539|NCT01320033|9829785|FG000|Overall Study|Adverse Event|9
6179540|NCT01320033|9829786|FG001|Overall Study|Adverse Event|7
6179541|NCT01320033|9829787|FG002|Overall Study|Adverse Event|8
6179542|NCT01320033|9829785|FG000|Overall Study|Withdrawal by Subject|22
6179543|NCT01320033|9829786|FG001|Overall Study|Withdrawal by Subject|23
6179544|NCT01320033|9829787|FG002|Overall Study|Withdrawal by Subject|23
6179545|NCT01320033|9829785|FG000|Overall Study|Protocol Violation|3
6179546|NCT01320033|9829786|FG001|Overall Study|Protocol Violation|5
6179547|NCT01320033|9829787|FG002|Overall Study|Protocol Violation|3
6179548|NCT01320033|9829785|FG000|Overall Study|Lost to Follow-up|22
6179549|NCT01320033|9829786|FG001|Overall Study|Lost to Follow-up|26
6179550|NCT01320033|9829787|FG002|Overall Study|Lost to Follow-up|17
6179551|NCT01320033|9829785|FG000|Overall Study|Other|2
6179552|NCT01320033|9829786|FG001|Overall Study|Other|3
6179553|NCT01320033|9829787|FG002|Overall Study|Other|1
6179554|NCT01320085|9829798|FG000|Overall Study|Treatment Ongoing|0
6179555|NCT01320085|9829799|FG001|Overall Study|Treatment Ongoing|13
6179556|NCT01320085|9829800|FG002|Overall Study|Treatment Ongoing|2
6179557|NCT01320085|9829798|FG000|Overall Study|Disease Progression|26
6179558|NCT01320085|9829799|FG001|Overall Study|Disease Progression|86
6179559|NCT01320085|9829800|FG002|Overall Study|Disease Progression|16
6179560|NCT01320085|9829798|FG000|Overall Study|Adverse Event|12
6179561|NCT01320085|9829799|FG001|Overall Study|Adverse Event|14
6179562|NCT01320085|9829800|FG002|Overall Study|Adverse Event|5
6179563|NCT01320085|9829798|FG000|Overall Study|Withdrawal by Subject|2
6179564|NCT01320085|9829799|FG001|Overall Study|Withdrawal by Subject|4
6179565|NCT01320085|9829800|FG002|Overall Study|Withdrawal by Subject|1
6179566|NCT01320085|9829798|FG000|Overall Study|Protocol Deviation|1
6179567|NCT01320085|9829799|FG001|Overall Study|Protocol Deviation|0
6179568|NCT01320085|9829800|FG002|Overall Study|Protocol Deviation|1
6179569|NCT01320150|9829819|FG000|Overall Study|Protocol Violation|15
6179570|NCT01320150|9829819|FG000|Overall Study|Withdrawal by Subject|5
6179571|NCT01320150|9829819|FG000|Overall Study|Death|2
6179572|NCT01320150|9829819|FG000|Overall Study|Lost to Follow-up|44
6179573|NCT01320202|9829825|FG000|Overall Study|Adverse Event|5
6179574|NCT01320202|9829826|FG001|Overall Study|Adverse Event|5
6179575|NCT01320202|9829825|FG000|Overall Study|Death|5
6179576|NCT01320202|9829826|FG001|Overall Study|Death|3
6179577|NCT01320202|9829825|FG000|Overall Study|Lost to Follow-up|1
6179578|NCT01320202|9829826|FG001|Overall Study|Lost to Follow-up|0
6179579|NCT01320202|9829825|FG000|Overall Study|Physician Decision|3
6179580|NCT01320202|9829826|FG001|Overall Study|Physician Decision|1
6179581|NCT01320202|9829825|FG000|Overall Study|Protocol Violation|2
6179582|NCT01320202|9829826|FG001|Overall Study|Protocol Violation|1
6179583|NCT01320202|9829825|FG000|Overall Study|Withdrawal by Subject|10
6179584|NCT01320202|9829826|FG001|Overall Study|Withdrawal by Subject|3
6179585|NCT01320202|9829825|FG000|Overall Study|non-protocol change to ESA or IV iron|17
6179586|NCT01320202|9829826|FG001|Overall Study|non-protocol change to ESA or IV iron|20
6179587|NCT01320202|9829825|FG000|Overall Study|kidney transplant|1
6179588|NCT01320202|9829826|FG001|Overall Study|kidney transplant|2
6179589|NCT01320202|9829825|FG000|Overall Study|blood transfusion|1
6179590|NCT01320202|9829826|FG001|Overall Study|blood transfusion|7
6179591|NCT01320202|9829825|FG000|Overall Study|moved/changed dialysis|5
6085165|NCT00650767|9694422|FG000|Overall Study|Withdrawal by Subject|2
6085166|NCT00650767|9694423|FG001|Overall Study|Withdrawal by Subject|4
6179592|NCT01320202|9829826|FG001|Overall Study|moved/changed dialysis|2
6179593|NCT01320202|9829825|FG000|Overall Study|sponsor request|2
6179594|NCT01320202|9829826|FG001|Overall Study|sponsor request|0
6179595|NCT01320202|9829825|FG000|Overall Study|ineligible|3
6179596|NCT01320202|9829826|FG001|Overall Study|ineligible|0
6179597|NCT01320202|9829825|FG000|Overall Study|regained renal function|1
6179598|NCT01320202|9829826|FG001|Overall Study|regained renal function|0
6179599|NCT01320293|9829835|FG000|Overall Study|Lack of Efficacy|1
6179600|NCT01320293|9829835|FG000|Overall Study|Adverse Event|1
6179601|NCT01320722|9829861|FG000|Overall Study|Did not Receive Intervention|3
6179602|NCT01320722|9829862|FG001|Overall Study|Did not Receive Intervention|2
6179603|NCT01320722|9829863|FG002|Overall Study|Did not Receive Intervention|1
6179604|NCT01320722|9829864|FG003|Overall Study|Did not Receive Intervention|1
6179605|NCT01320722|9829865|FG004|Overall Study|Did not Receive Intervention|2
6179606|NCT01320722|9829861|FG000|Overall Study|Lost to Follow-up|0
6179607|NCT01320722|9829862|FG001|Overall Study|Lost to Follow-up|1
6179608|NCT01320722|9829863|FG002|Overall Study|Lost to Follow-up|0
6179609|NCT01320722|9829864|FG003|Overall Study|Lost to Follow-up|1
6179610|NCT01320722|9829865|FG004|Overall Study|Lost to Follow-up|3
6179611|NCT01320722|9829861|FG000|Overall Study|Not Available for the 8 Week Visit|0
6179612|NCT01320722|9829862|FG001|Overall Study|Not Available for the 8 Week Visit|3
6179613|NCT01320722|9829863|FG002|Overall Study|Not Available for the 8 Week Visit|0
6179614|NCT01320722|9829864|FG003|Overall Study|Not Available for the 8 Week Visit|0
6179615|NCT01320722|9829865|FG004|Overall Study|Not Available for the 8 Week Visit|0
6179616|NCT01320722|9829861|FG000|Overall Study|Participant Developed a Rash|0
6179617|NCT01320722|9829862|FG001|Overall Study|Participant Developed a Rash|0
6179618|NCT01320722|9829863|FG002|Overall Study|Participant Developed a Rash|2
6179619|NCT01320722|9829864|FG003|Overall Study|Participant Developed a Rash|1
6179620|NCT01320722|9829865|FG004|Overall Study|Participant Developed a Rash|1
6179621|NCT01320722|9829861|FG000|Overall Study|Non-compliant with Medication|0
6179622|NCT01320722|9829862|FG001|Overall Study|Non-compliant with Medication|0
6179623|NCT01320722|9829863|FG002|Overall Study|Non-compliant with Medication|1
6179624|NCT01320722|9829864|FG003|Overall Study|Non-compliant with Medication|0
6179625|NCT01320722|9829865|FG004|Overall Study|Non-compliant with Medication|0
6179626|NCT01320722|9829861|FG000|Overall Study|Adverse Event|0
6179627|NCT01320722|9829862|FG001|Overall Study|Adverse Event|0
6179628|NCT01320722|9829863|FG002|Overall Study|Adverse Event|3
6179629|NCT01320722|9829864|FG003|Overall Study|Adverse Event|6
6179630|NCT01320722|9829865|FG004|Overall Study|Adverse Event|0
6179631|NCT01320722|9829861|FG000|Overall Study|Not Compliant with Study Procedures|0
6085167|NCT00650767|9694424|FG002|Overall Study|Withdrawal by Subject|3
6085168|NCT00650767|9694425|FG003|Overall Study|Withdrawal by Subject|3
6085169|NCT00650767|9694422|FG000|Overall Study|Lost to Follow-up|1
6085170|NCT00650767|9694423|FG001|Overall Study|Lost to Follow-up|1
6085171|NCT00650767|9694424|FG002|Overall Study|Lost to Follow-up|1
6085172|NCT00650767|9694425|FG003|Overall Study|Lost to Follow-up|0
6085173|NCT00650767|9694422|FG000|Overall Study|Other|1
6085174|NCT00650767|9694423|FG001|Overall Study|Other|1
6085175|NCT00650767|9694424|FG002|Overall Study|Other|0
6085176|NCT00650767|9694425|FG003|Overall Study|Other|0
6085177|NCT00650806|9694439|FG000|Overall Study|Adverse Event|0
6085178|NCT00650806|9694440|FG001|Overall Study|Adverse Event|5
6085179|NCT00650806|9694441|FG002|Overall Study|Adverse Event|3
6085180|NCT00650806|9694442|FG003|Overall Study|Adverse Event|4
6085181|NCT00650806|9694439|FG000|Overall Study|Lost to Follow-up|7
6085182|NCT00650806|9694440|FG001|Overall Study|Lost to Follow-up|6
6085183|NCT00650806|9694441|FG002|Overall Study|Lost to Follow-up|11
6085184|NCT00650806|9694442|FG003|Overall Study|Lost to Follow-up|10
6085185|NCT00650806|9694439|FG000|Overall Study|Protocol Violation|0
6085186|NCT00650806|9694440|FG001|Overall Study|Protocol Violation|0
6085187|NCT00650806|9694441|FG002|Overall Study|Protocol Violation|0
6085188|NCT00650806|9694442|FG003|Overall Study|Protocol Violation|1
6085189|NCT00650806|9694439|FG000|Overall Study|Pregnancy|0
6085190|NCT00650806|9694440|FG001|Overall Study|Pregnancy|0
6085191|NCT00650806|9694441|FG002|Overall Study|Pregnancy|0
6085192|NCT00650806|9694442|FG003|Overall Study|Pregnancy|1
6085193|NCT00650806|9694439|FG000|Overall Study|Withdrawal by Subject|7
6085194|NCT00650806|9694440|FG001|Overall Study|Withdrawal by Subject|5
6085195|NCT00650806|9694441|FG002|Overall Study|Withdrawal by Subject|8
6085196|NCT00650806|9694442|FG003|Overall Study|Withdrawal by Subject|6
6085197|NCT00650806|9694439|FG000|Overall Study|Noncompliance with study drug regimen|1
6085198|NCT00650806|9694440|FG001|Overall Study|Noncompliance with study drug regimen|1
6085199|NCT00650806|9694441|FG002|Overall Study|Noncompliance with study drug regimen|0
6085200|NCT00650806|9694442|FG003|Overall Study|Noncompliance with study drug regimen|0
6085201|NCT00650806|9694439|FG000|Overall Study|Study terminated by sponsor|2
6085202|NCT00650806|9694440|FG001|Overall Study|Study terminated by sponsor|3
6085203|NCT00650806|9694441|FG002|Overall Study|Study terminated by sponsor|5
6085204|NCT00650806|9694442|FG003|Overall Study|Study terminated by sponsor|4
6085205|NCT00650806|9694439|FG000|Overall Study|Other|1
6085206|NCT00650806|9694440|FG001|Overall Study|Other|1
6085207|NCT00650806|9694441|FG002|Overall Study|Other|2
6085208|NCT00650806|9694442|FG003|Overall Study|Other|0
6085209|NCT00650845|9694456|FG000|Overall Study|Withdrawal by Subject|5
6085210|NCT00650845|9694457|FG001|Overall Study|Withdrawal by Subject|0
6085211|NCT00650845|9694456|FG000|Overall Study|Protocol Violation|0
6085212|NCT00650845|9694457|FG001|Overall Study|Protocol Violation|13
6179632|NCT01320722|9829862|FG001|Overall Study|Not Compliant with Study Procedures|0
6179633|NCT01320722|9829863|FG002|Overall Study|Not Compliant with Study Procedures|0
6179634|NCT01320722|9829864|FG003|Overall Study|Not Compliant with Study Procedures|4
6179635|NCT01320722|9829865|FG004|Overall Study|Not Compliant with Study Procedures|0
6179636|NCT01320722|9829861|FG000|Overall Study|Pregnancy|0
6179637|NCT01320722|9829862|FG001|Overall Study|Pregnancy|0
6179638|NCT01320722|9829863|FG002|Overall Study|Pregnancy|0
6179639|NCT01320722|9829864|FG003|Overall Study|Pregnancy|1
6179640|NCT01320722|9829865|FG004|Overall Study|Pregnancy|0
6179641|NCT01320722|9829861|FG000|Overall Study|Started an Exclusionary Medication|0
6179642|NCT01320722|9829862|FG001|Overall Study|Started an Exclusionary Medication|0
6179643|NCT01320722|9829863|FG002|Overall Study|Started an Exclusionary Medication|0
6179644|NCT01320722|9829864|FG003|Overall Study|Started an Exclusionary Medication|0
6179645|NCT01320722|9829865|FG004|Overall Study|Started an Exclusionary Medication|1
6179646|NCT01320722|9829861|FG000|Overall Study|Withdrew due to Health Condition|0
6179647|NCT01320722|9829862|FG001|Overall Study|Withdrew due to Health Condition|0
6179648|NCT01320722|9829863|FG002|Overall Study|Withdrew due to Health Condition|0
6179649|NCT01320722|9829864|FG003|Overall Study|Withdrew due to Health Condition|0
6179650|NCT01320722|9829865|FG004|Overall Study|Withdrew due to Health Condition|1
6179651|NCT01320735|9829880|FG000|Overall Study|Adverse Event|3
6179652|NCT01320735|9829880|FG000|Overall Study|Withdrawal by Subject|3
6179653|NCT01320735|9829880|FG000|Overall Study|Lost to Follow-up|13
6179654|NCT01320735|9829880|FG000|Overall Study|Administrative Reason|6
6179655|NCT01320735|9829880|FG000|Overall Study|Progression/Hormone-Refractory Pca|55
6179656|NCT01320735|9829880|FG000|Overall Study|Protocol Violation|1
6179657|NCT01320735|9829880|FG000|Overall Study|Other|1
6179658|NCT01320735|9829880|FG000|Overall Study|No Decrease of Prostate Specific Antigen|7
6179659|NCT01320735|9829880|FG000|Overall Study|Investigator Unable to be Contacted|17
6085213|NCT00651118|9694494|FG000|Overall Study|Adverse Event|4
6085214|NCT00651118|9694495|FG001|Overall Study|Adverse Event|0
6085215|NCT00651118|9694496|FG002|Overall Study|Adverse Event|1
6085216|NCT00651118|9694497|FG003|Overall Study|Adverse Event|1
6085217|NCT00651118|9694494|FG000|Overall Study|Protocol Violation|2
6085218|NCT00651118|9694495|FG001|Overall Study|Protocol Violation|2
6085219|NCT00651118|9694496|FG002|Overall Study|Protocol Violation|6
6085220|NCT00651118|9694497|FG003|Overall Study|Protocol Violation|2
6085221|NCT00651118|9694494|FG000|Overall Study|Lost to Follow-up|2
6085222|NCT00651118|9694495|FG001|Overall Study|Lost to Follow-up|0
6085223|NCT00651118|9694496|FG002|Overall Study|Lost to Follow-up|1
6085224|NCT00651118|9694497|FG003|Overall Study|Lost to Follow-up|2
6085225|NCT00651118|9694494|FG000|Overall Study|administrative|1
6085226|NCT00651118|9694495|FG001|Overall Study|administrative|4
6085227|NCT00651118|9694496|FG002|Overall Study|administrative|2
6085228|NCT00651118|9694497|FG003|Overall Study|administrative|1
6085229|NCT00651118|9694494|FG000|Overall Study|Withdrawal by Subject|0
6085230|NCT00651118|9694495|FG001|Overall Study|Withdrawal by Subject|1
6085231|NCT00651118|9694496|FG002|Overall Study|Withdrawal by Subject|1
6085232|NCT00651118|9694497|FG003|Overall Study|Withdrawal by Subject|1
6085233|NCT00651157|9694510|FG000|Overall Study|Death|1
6085234|NCT00651157|9694510|FG000|Overall Study|Protocol Violation|1
6085235|NCT00651183|9694516|FG000|Overall Study|Lack of Efficacy|1
6085236|NCT00651183|9694517|FG001|Overall Study|Lack of Efficacy|0
6085237|NCT00651183|9694516|FG000|Overall Study|Efficacy insufficient + patients wish|0
6085238|NCT00651183|9694517|FG001|Overall Study|Efficacy insufficient + patients wish|1
6085239|NCT00651183|9694516|FG000|Overall Study|Tolerability insufficient|5
6085240|NCT00651183|9694517|FG001|Overall Study|Tolerability insufficient|2
6085241|NCT00651183|9694516|FG000|Overall Study|Tolerability insufficient +Patients wish|0
6085242|NCT00651183|9694517|FG001|Overall Study|Tolerability insufficient +Patients wish|1
6085243|NCT00651183|9694516|FG000|Overall Study|Withdrawal by Subject|6
6085244|NCT00651183|9694517|FG001|Overall Study|Withdrawal by Subject|3
6085245|NCT00651183|9694516|FG000|Overall Study|Lost to Follow-up|3
6085246|NCT00651183|9694517|FG001|Overall Study|Lost to Follow-up|1
6085247|NCT00651183|9694516|FG000|Overall Study|Other reasons|4
6085248|NCT00651183|9694517|FG001|Overall Study|Other reasons|2
6085249|NCT00651183|9694516|FG000|Overall Study|missing|1
6085250|NCT00651183|9694517|FG001|Overall Study|missing|0
6085251|NCT00651261|9694525|FG000|Overall Study|Adverse Event|32
6085252|NCT00651261|9694526|FG001|Overall Study|Adverse Event|22
6085253|NCT00651261|9694525|FG000|Overall Study|Death|18
6179660|NCT01320943|9829901|FG000|Overall Study|Lost to Follow-up|1
6179661|NCT01320943|9829902|FG001|Overall Study|Lost to Follow-up|0
6179662|NCT01320943|9829901|FG000|Overall Study|Physician Decision|0
6179663|NCT01320943|9829902|FG001|Overall Study|Physician Decision|1
6179664|NCT01320943|9829901|FG000|Overall Study|Randomized but not Treated|0
6179665|NCT01320943|9829902|FG001|Overall Study|Randomized but not Treated|1
6179666|NCT01321073|9829915|FG000|Overall Study|Did not attempt implant|4
6179667|NCT01321073|9829915|FG000|Overall Study|Death|3
6179668|NCT01321606|9829965|FG000|Overall Study|Lost to Follow-up|0
6179669|NCT01321606|9829966|FG001|Overall Study|Lost to Follow-up|0
6179670|NCT01321606|9829967|FG002|Overall Study|Lost to Follow-up|0
6179671|NCT01321606|9829968|FG003|Overall Study|Lost to Follow-up|1
6179672|NCT01321710|9829981|FG000|Overall Study|Lost to Follow-up|4
6179673|NCT01321710|9829982|FG001|Overall Study|Lost to Follow-up|5
6179674|NCT01321710|9829983|FG002|Overall Study|Lost to Follow-up|0
6179675|NCT01321723|9829996|FG000|Overall Study|Adverse Event|3
6179676|NCT01321723|9829997|FG001|Overall Study|Adverse Event|5
6179677|NCT01321723|9829998|FG002|Overall Study|Adverse Event|2
6179678|NCT01321723|9829996|FG000|Overall Study|Withdrawal by Subject|2
6179679|NCT01321723|9829997|FG001|Overall Study|Withdrawal by Subject|0
6179680|NCT01321723|9829998|FG002|Overall Study|Withdrawal by Subject|2
6179681|NCT01321749|9830008|FG000|Overall Study|Lost to Follow-up|4
6179682|NCT01321749|9830009|FG001|Overall Study|Lost to Follow-up|11
6179683|NCT01321749|9830008|FG000|Overall Study|Protocol Violation|4
6179684|NCT01321749|9830009|FG001|Overall Study|Protocol Violation|7
6179685|NCT01321749|9830008|FG000|Overall Study|Withdrawal by Subject|5
6179686|NCT01321749|9830009|FG001|Overall Study|Withdrawal by Subject|4
6179687|NCT01321879|9830015|FG000|Overall Study|Lack of Efficacy|5
6179688|NCT01321879|9830015|FG000|Overall Study|Adverse Event|5
6179689|NCT01321879|9830015|FG000|Overall Study|Death|3
6179690|NCT01321879|9830015|FG000|Overall Study|Withdrawal by Subject|1
6179691|NCT01322009|9830021|FG000|Overall Study|Death|0
6179692|NCT01322009|9830022|FG001|Overall Study|Death|1
6179693|NCT01322009|9830021|FG000|Overall Study|Adverse Event|0
6179694|NCT01322009|9830022|FG001|Overall Study|Adverse Event|1
6179695|NCT01322009|9830021|FG000|Overall Study|ng tube discontinued|0
6179696|NCT01322009|9830022|FG001|Overall Study|ng tube discontinued|1
6179697|NCT01322347|9830048|FG000|Overall Study|Adverse Event|7
6179698|NCT01322347|9830049|FG001|Overall Study|Adverse Event|2
6179699|NCT01322347|9830048|FG000|Overall Study|Death|5
6179700|NCT01322347|9830049|FG001|Overall Study|Death|3
6179701|NCT01322347|9830048|FG000|Overall Study|Physician Decision|2
6179702|NCT01322347|9830049|FG001|Overall Study|Physician Decision|1
6085254|NCT00651261|9694526|FG001|Overall Study|Death|18
6085255|NCT00651261|9694525|FG000|Overall Study|Withdrawal by Subject|22
6085256|NCT00651261|9694526|FG001|Overall Study|Withdrawal by Subject|40
6085257|NCT00651261|9694525|FG000|Overall Study|Induction failure|24
6085258|NCT00651261|9694526|FG001|Overall Study|Induction failure|35
6085259|NCT00651261|9694525|FG000|Overall Study|Disease progression|58
6179703|NCT01322347|9830048|FG000|Overall Study|Protocol Violation|5
6085260|NCT00651261|9694526|FG001|Overall Study|Disease progression|58
6085261|NCT00651261|9694525|FG000|Overall Study|Alternative therapy|109
6085262|NCT00651261|9694526|FG001|Overall Study|Alternative therapy|107
6179704|NCT01322347|9830049|FG001|Overall Study|Protocol Violation|2
6179705|NCT01322347|9830048|FG000|Overall Study|Withdrawal by Subject|1
6179706|NCT01322347|9830049|FG001|Overall Study|Withdrawal by Subject|4
6179707|NCT01322347|9830048|FG000|Overall Study|non-protocol change to ESA or IV iron|14
6085263|NCT00651261|9694525|FG000|Overall Study|Other disease or participant decisions|23
6085264|NCT00651261|9694526|FG001|Overall Study|Other disease or participant decisions|23
6085265|NCT00651261|9694525|FG000|Overall Study|Never treated|5
6085266|NCT00651261|9694526|FG001|Overall Study|Never treated|3
6085267|NCT00651313|9694534|FG000|Overall Study|Adverse Event|0
6179708|NCT01322347|9830049|FG001|Overall Study|non-protocol change to ESA or IV iron|6
6179709|NCT01322347|9830048|FG000|Overall Study|blood transfusion|5
6179710|NCT01322347|9830049|FG001|Overall Study|blood transfusion|5
6179711|NCT01322347|9830048|FG000|Overall Study|sponsor decision|1
6179712|NCT01322347|9830049|FG001|Overall Study|sponsor decision|3
6179713|NCT01322347|9830048|FG000|Overall Study|ineligible|6
6179714|NCT01322347|9830049|FG001|Overall Study|ineligible|3
6179715|NCT01322347|9830048|FG000|Overall Study|kidney transplant|3
6179716|NCT01322347|9830049|FG001|Overall Study|kidney transplant|1
6179717|NCT01322347|9830048|FG000|Overall Study|study drug withheld > 12 wks|0
6179718|NCT01322347|9830049|FG001|Overall Study|study drug withheld > 12 wks|1
6179719|NCT01322347|9830048|FG000|Overall Study|moved/changed dialysis|2
6179720|NCT01322347|9830049|FG001|Overall Study|moved/changed dialysis|4
6179721|NCT01322386|9830063|FG000|Overall Study|Protocol Violation|0
6179722|NCT01322386|9830064|FG001|Overall Study|Protocol Violation|1
6179723|NCT01322386|9830063|FG000|Overall Study|Physician Decision|0
6179724|NCT01322386|9830064|FG001|Overall Study|Physician Decision|1
6179725|NCT01322490|9830075|FG000|Treatment Period|Adverse Event|12
6179726|NCT01322490|9830076|FG001|Treatment Period|Adverse Event|18
6179727|NCT01322490|9830077|FG002|Treatment Period|Adverse Event|15
6179728|NCT01322490|9830075|FG000|Treatment Period|Death|5
6179729|NCT01322490|9830076|FG001|Treatment Period|Death|7
6179730|NCT01322490|9830077|FG002|Treatment Period|Death|3
6179731|NCT01322490|9830075|FG000|Treatment Period|Lack of Efficacy|89
6179732|NCT01322490|9830076|FG001|Treatment Period|Lack of Efficacy|100
6179733|NCT01322490|9830077|FG002|Treatment Period|Lack of Efficacy|112
6179734|NCT01322490|9830075|FG000|Treatment Period|Physician Decision|0
6179735|NCT01322490|9830076|FG001|Treatment Period|Physician Decision|2
6179736|NCT01322490|9830077|FG002|Treatment Period|Physician Decision|1
6179737|NCT01322490|9830075|FG000|Treatment Period|Protocol Violation|7
6179738|NCT01322490|9830076|FG001|Treatment Period|Protocol Violation|5
6179739|NCT01322490|9830077|FG002|Treatment Period|Protocol Violation|4
6179740|NCT01322490|9830075|FG000|Treatment Period|Withdrawal by Subject|14
6179741|NCT01322490|9830076|FG001|Treatment Period|Withdrawal by Subject|16
6179742|NCT01322490|9830077|FG002|Treatment Period|Withdrawal by Subject|11
6179743|NCT01322490|9830075|FG000|Treatment Period|Non-compliance with study drug|0
6179744|NCT01322490|9830076|FG001|Treatment Period|Non-compliance with study drug|0
6179745|NCT01322490|9830077|FG002|Treatment Period|Non-compliance with study drug|1
6179746|NCT01322490|9830075|FG000|Treatment Period|Other per report|2
6179747|NCT01322490|9830076|FG001|Treatment Period|Other per report|2
6179748|NCT01322490|9830077|FG002|Treatment Period|Other per report|1
6179749|NCT01322490|9830075|FG000|Treatment Period|Randomized but Not Treated|3
6179750|NCT01322490|9830076|FG001|Treatment Period|Randomized but Not Treated|3
6179751|NCT01322490|9830077|FG002|Treatment Period|Randomized but Not Treated|5
6179752|NCT01322490|9830075|FG000|Long Term Follow-up Period|Death|235
6179753|NCT01322490|9830076|FG001|Long Term Follow-up Period|Death|239
6179754|NCT01322490|9830077|FG002|Long Term Follow-up Period|Death|236
6179755|NCT01322490|9830075|FG000|Long Term Follow-up Period|Lost to Follow-up|2
6179756|NCT01322490|9830076|FG001|Long Term Follow-up Period|Lost to Follow-up|2
6179757|NCT01322490|9830077|FG002|Long Term Follow-up Period|Lost to Follow-up|3
6179758|NCT01322490|9830075|FG000|Long Term Follow-up Period|Withdrawal by Subject|9
6179759|NCT01322490|9830076|FG001|Long Term Follow-up Period|Withdrawal by Subject|6
6179760|NCT01322490|9830077|FG002|Long Term Follow-up Period|Withdrawal by Subject|6
6179761|NCT01322490|9830075|FG000|Long Term Follow-up Period|Study Terminated by Sponsor|160
6179762|NCT01322490|9830076|FG001|Long Term Follow-up Period|Study Terminated by Sponsor|158
6179763|NCT01322490|9830077|FG002|Long Term Follow-up Period|Study Terminated by Sponsor|165
6179764|NCT01322490|9830075|FG000|Long Term Follow-up Period|Other per report|3
6179765|NCT01322490|9830076|FG001|Long Term Follow-up Period|Other per report|2
6179766|NCT01322490|9830077|FG002|Long Term Follow-up Period|Other per report|2
6179767|NCT01322490|9830075|FG000|Long Term Follow-up Period|Unknown/Missing|0
6179768|NCT01322490|9830076|FG001|Long Term Follow-up Period|Unknown/Missing|1
6179769|NCT01322490|9830077|FG002|Long Term Follow-up Period|Unknown/Missing|1
6179770|NCT01323192|9830193|FG000|Overall Study|Adverse Event|6
6179771|NCT01323192|9830194|FG001|Overall Study|Adverse Event|1
6179772|NCT01323192|9830193|FG000|Overall Study|Withdrawal by Subject|3
6085268|NCT00651313|9694535|FG001|Overall Study|Adverse Event|1
6179773|NCT01323192|9830194|FG001|Overall Study|Withdrawal by Subject|1
6179774|NCT01323192|9830193|FG000|Overall Study|Noncompliance with study medication|0
6179775|NCT01323192|9830194|FG001|Overall Study|Noncompliance with study medication|3
6179776|NCT01323192|9830193|FG000|Overall Study|Nonmedical reasons|0
6179777|NCT01323192|9830194|FG001|Overall Study|Nonmedical reasons|1
6179778|NCT01323270|9830202|FG000|Overall Study|Withdrawal by Subject|19
6179779|NCT01323270|9830203|FG001|Overall Study|Withdrawal by Subject|10
6179780|NCT01323270|9830202|FG000|Overall Study|Protocol Violation|9
6179781|NCT01323270|9830203|FG001|Overall Study|Protocol Violation|7
6179782|NCT01323270|9830202|FG000|Overall Study|Lost to Follow-up|4
6179783|NCT01323270|9830203|FG001|Overall Study|Lost to Follow-up|6
6179784|NCT01323270|9830202|FG000|Overall Study|Adverse Event|8
6179785|NCT01323270|9830203|FG001|Overall Study|Adverse Event|0
6179786|NCT01323270|9830202|FG000|Overall Study|Other|0
6179787|NCT01323270|9830203|FG001|Overall Study|Other|3
6179788|NCT01323270|9830202|FG000|Overall Study|Physician Decision|0
6179789|NCT01323270|9830203|FG001|Overall Study|Physician Decision|2
6179790|NCT01323270|9830202|FG000|Overall Study|Not eligible|1
6179791|NCT01323270|9830203|FG001|Overall Study|Not eligible|1
6179792|NCT01323270|9830202|FG000|Overall Study|Death|1
6179793|NCT01323270|9830203|FG001|Overall Study|Death|0
6179794|NCT01323270|9830202|FG000|Overall Study|Randomized, but not vaccinated|1
6179795|NCT01323270|9830203|FG001|Overall Study|Randomized, but not vaccinated|0
6179796|NCT01323387|9830210|FG000|Overall Study|Withdrawal by Subject|41
6179797|NCT01323387|9830210|FG000|Overall Study|Radiographic Data Unavailable|1
6179798|NCT01323387|9830210|FG000|Overall Study|Revision|14
6179799|NCT01323387|9830210|FG000|Overall Study|Protocol Violation|12
6179800|NCT01323387|9830210|FG000|Overall Study|Randomized but Never Treated|16
6179801|NCT01323478|9830216|FG000|Overall Study|Adverse Event|7
6179802|NCT01323478|9830216|FG000|Overall Study|Lack of Efficacy|4
6179803|NCT01323478|9830216|FG000|Overall Study|Non-compliance With Study Product|3
6179804|NCT01323478|9830216|FG000|Overall Study|Protocol Violation|1
6179805|NCT01323478|9830216|FG000|Overall Study|Withdrawal of Consent|1
6179806|NCT01323478|9830216|FG000|Overall Study|Administrative or Other Reasons|8
6179807|NCT01323530|9830231|FG000|Phase 1b (Dose Escalation Phase)|Adverse Event|2
6179808|NCT01323530|9830232|FG001|Phase 1b (Dose Escalation Phase)|Adverse Event|0
6179809|NCT01323530|9830233|FG002|Phase 1b (Dose Escalation Phase)|Adverse Event|0
6179810|NCT01323530|9830234|FG003|Phase 1b (Dose Escalation Phase)|Adverse Event|0
6179811|NCT01323530|9830235|FG004|Phase 1b (Dose Escalation Phase)|Adverse Event|0
6179812|NCT01323530|9830236|FG005|Phase 1b (Dose Escalation Phase)|Adverse Event|2
6179813|NCT01323530|9830237|FG006|Phase 1b (Dose Escalation Phase)|Adverse Event|0
6179814|NCT01323530|9830231|FG000|Phase 1b (Dose Escalation Phase)|Withdrawal by Subject|1
6179815|NCT01323530|9830232|FG001|Phase 1b (Dose Escalation Phase)|Withdrawal by Subject|1
6179816|NCT01323530|9830233|FG002|Phase 1b (Dose Escalation Phase)|Withdrawal by Subject|1
6179817|NCT01323530|9830234|FG003|Phase 1b (Dose Escalation Phase)|Withdrawal by Subject|0
6179818|NCT01323530|9830235|FG004|Phase 1b (Dose Escalation Phase)|Withdrawal by Subject|2
6179819|NCT01323530|9830236|FG005|Phase 1b (Dose Escalation Phase)|Withdrawal by Subject|0
6179820|NCT01323530|9830237|FG006|Phase 1b (Dose Escalation Phase)|Withdrawal by Subject|0
6179821|NCT01323530|9830231|FG000|Phase 1b (Dose Escalation Phase)|Clinical Progression|0
6179822|NCT01323530|9830232|FG001|Phase 1b (Dose Escalation Phase)|Clinical Progression|1
6179823|NCT01323530|9830233|FG002|Phase 1b (Dose Escalation Phase)|Clinical Progression|0
6227730|NCT01719003|9900565|FG008|Overall Study|Lost to Follow-up|2
6227731|NCT01719003|9900557|FG000|Overall Study|Refusal to continue, not due to AE|2
6227732|NCT01719003|9900558|FG001|Overall Study|Refusal to continue, not due to AE|5
6227733|NCT01719003|9900559|FG002|Overall Study|Refusal to continue, not due to AE|4
6227734|NCT01719003|9900560|FG003|Overall Study|Refusal to continue, not due to AE|4
6227735|NCT01719003|9900561|FG004|Overall Study|Refusal to continue, not due to AE|4
6227736|NCT01719003|9900562|FG005|Overall Study|Refusal to continue, not due to AE|3
6227737|NCT01719003|9900563|FG006|Overall Study|Refusal to continue, not due to AE|8
6227738|NCT01719003|9900564|FG007|Overall Study|Refusal to continue, not due to AE|7
6227739|NCT01719003|9900565|FG008|Overall Study|Refusal to continue, not due to AE|1
6227740|NCT01719003|9900557|FG000|Overall Study|Reason other than those specified|0
6227741|NCT01719003|9900558|FG001|Overall Study|Reason other than those specified|0
6227742|NCT01719003|9900559|FG002|Overall Study|Reason other than those specified|2
6227743|NCT01719003|9900560|FG003|Overall Study|Reason other than those specified|3
6227744|NCT01719003|9900561|FG004|Overall Study|Reason other than those specified|4
6227745|NCT01719003|9900562|FG005|Overall Study|Reason other than those specified|1
6227746|NCT01719003|9900563|FG006|Overall Study|Reason other than those specified|0
6227747|NCT01719003|9900564|FG007|Overall Study|Reason other than those specified|3
6227748|NCT01719003|9900565|FG008|Overall Study|Reason other than those specified|1
6227749|NCT01719003|9900557|FG000|Overall Study|Lack of Efficacy|0
6227750|NCT01719003|9900558|FG001|Overall Study|Lack of Efficacy|0
6227751|NCT01719003|9900559|FG002|Overall Study|Lack of Efficacy|0
6227752|NCT01719003|9900560|FG003|Overall Study|Lack of Efficacy|0
6227753|NCT01719003|9900561|FG004|Overall Study|Lack of Efficacy|0
6227754|NCT01719003|9900562|FG005|Overall Study|Lack of Efficacy|0
6227755|NCT01719003|9900563|FG006|Overall Study|Lack of Efficacy|1
6227756|NCT01719003|9900564|FG007|Overall Study|Lack of Efficacy|0
6227757|NCT01719003|9900565|FG008|Overall Study|Lack of Efficacy|0
6227758|NCT01719172|9900584|FG000|Overall Study|Lost to Follow-up|1
6227759|NCT01719172|9900584|FG000|Overall Study|Death|1
6227760|NCT01719224|9900588|FG000|Intervention 1: Sleeping Position 1|Withdrawal by Subject|4
6179824|NCT01323530|9830234|FG003|Phase 1b (Dose Escalation Phase)|Clinical Progression|0
6179825|NCT01323530|9830235|FG004|Phase 1b (Dose Escalation Phase)|Clinical Progression|1
6179826|NCT01323530|9830236|FG005|Phase 1b (Dose Escalation Phase)|Clinical Progression|1
6179827|NCT01323530|9830237|FG006|Phase 1b (Dose Escalation Phase)|Clinical Progression|0
6179828|NCT01323530|9830231|FG000|Phase 2 (Dose-confirmation Phase)|Adverse Event|0
6179829|NCT01323530|9830232|FG001|Phase 2 (Dose-confirmation Phase)|Adverse Event|0
6179830|NCT01323530|9830233|FG002|Phase 2 (Dose-confirmation Phase)|Adverse Event|0
6179831|NCT01323530|9830234|FG003|Phase 2 (Dose-confirmation Phase)|Adverse Event|0
6179832|NCT01323530|9830235|FG004|Phase 2 (Dose-confirmation Phase)|Adverse Event|0
6179833|NCT01323530|9830236|FG005|Phase 2 (Dose-confirmation Phase)|Adverse Event|0
6179834|NCT01323530|9830237|FG006|Phase 2 (Dose-confirmation Phase)|Adverse Event|2
6179835|NCT01323530|9830231|FG000|Phase 2 (Dose-confirmation Phase)|Clinical progression|0
6179836|NCT01323530|9830232|FG001|Phase 2 (Dose-confirmation Phase)|Clinical progression|0
6179837|NCT01323530|9830233|FG002|Phase 2 (Dose-confirmation Phase)|Clinical progression|0
6179838|NCT01323530|9830234|FG003|Phase 2 (Dose-confirmation Phase)|Clinical progression|0
6179839|NCT01323530|9830235|FG004|Phase 2 (Dose-confirmation Phase)|Clinical progression|0
6179840|NCT01323530|9830236|FG005|Phase 2 (Dose-confirmation Phase)|Clinical progression|0
6179841|NCT01323530|9830237|FG006|Phase 2 (Dose-confirmation Phase)|Clinical progression|3
6179842|NCT01323530|9830231|FG000|Phase 2 (Dose-confirmation Phase)|Withdrawal by Subject|0
6179843|NCT01323530|9830232|FG001|Phase 2 (Dose-confirmation Phase)|Withdrawal by Subject|0
6179844|NCT01323530|9830233|FG002|Phase 2 (Dose-confirmation Phase)|Withdrawal by Subject|0
6179845|NCT01323530|9830234|FG003|Phase 2 (Dose-confirmation Phase)|Withdrawal by Subject|0
6179846|NCT01323530|9830235|FG004|Phase 2 (Dose-confirmation Phase)|Withdrawal by Subject|0
6179847|NCT01323530|9830236|FG005|Phase 2 (Dose-confirmation Phase)|Withdrawal by Subject|0
6179848|NCT01323530|9830237|FG006|Phase 2 (Dose-confirmation Phase)|Withdrawal by Subject|8
6179849|NCT01323530|9830231|FG000|Phase 2 (Dose-confirmation Phase)|Investigators decision|0
6179850|NCT01323530|9830232|FG001|Phase 2 (Dose-confirmation Phase)|Investigators decision|0
6179851|NCT01323530|9830233|FG002|Phase 2 (Dose-confirmation Phase)|Investigators decision|0
6179852|NCT01323530|9830234|FG003|Phase 2 (Dose-confirmation Phase)|Investigators decision|0
6179853|NCT01323530|9830235|FG004|Phase 2 (Dose-confirmation Phase)|Investigators decision|0
6179854|NCT01323530|9830236|FG005|Phase 2 (Dose-confirmation Phase)|Investigators decision|0
6179855|NCT01323530|9830237|FG006|Phase 2 (Dose-confirmation Phase)|Investigators decision|3
6179856|NCT01323530|9830231|FG000|Phase 2 (Dose-confirmation Phase)|Development of bladder cancer|0
6179857|NCT01323530|9830232|FG001|Phase 2 (Dose-confirmation Phase)|Development of bladder cancer|0
6179858|NCT01323530|9830233|FG002|Phase 2 (Dose-confirmation Phase)|Development of bladder cancer|0
6179859|NCT01323530|9830234|FG003|Phase 2 (Dose-confirmation Phase)|Development of bladder cancer|0
6179860|NCT01323530|9830235|FG004|Phase 2 (Dose-confirmation Phase)|Development of bladder cancer|0
6179861|NCT01323530|9830236|FG005|Phase 2 (Dose-confirmation Phase)|Development of bladder cancer|0
6179862|NCT01323530|9830237|FG006|Phase 2 (Dose-confirmation Phase)|Development of bladder cancer|1
6179863|NCT01323582|9830256|FG000|Weeks 1-4 (First Period)|Withdrawal by Subject|2
6179864|NCT01323582|9830257|FG001|Weeks 1-4 (First Period)|Withdrawal by Subject|2
6179865|NCT01323582|9830256|FG000|Weeks 5-7 (Washout)|Withdrawal by Subject|0
6179866|NCT01323582|9830257|FG001|Weeks 5-7 (Washout)|Withdrawal by Subject|1
6179867|NCT01323582|9830256|FG000|Weeks 8-11 (Period 2)|Withdrawal by Subject|0
6179868|NCT01323582|9830257|FG001|Weeks 8-11 (Period 2)|Withdrawal by Subject|1
6179869|NCT01323621|9830278|FG000|2-week, Single-blind Run In Period|Not Met Inclusion/Exclusion Criteria|121
6179870|NCT01323621|9830279|FG001|2-week, Single-blind Run In Period|Not Met Inclusion/Exclusion Criteria|0
6179871|NCT01323621|9830280|FG002|2-week, Single-blind Run In Period|Not Met Inclusion/Exclusion Criteria|0
6179872|NCT01323621|9830278|FG000|2-week, Single-blind Run In Period|Physician Decision|7
6179873|NCT01323621|9830279|FG001|2-week, Single-blind Run In Period|Physician Decision|0
6179874|NCT01323621|9830280|FG002|2-week, Single-blind Run In Period|Physician Decision|0
6179875|NCT01323621|9830278|FG000|2-week, Single-blind Run In Period|Withdrawal by Subject|12
6179876|NCT01323621|9830279|FG001|2-week, Single-blind Run In Period|Withdrawal by Subject|0
6179877|NCT01323621|9830280|FG002|2-week, Single-blind Run In Period|Withdrawal by Subject|0
6179878|NCT01323621|9830278|FG000|2-week, Single-blind Run In Period|Protocol Violation|1
6179879|NCT01323621|9830279|FG001|2-week, Single-blind Run In Period|Protocol Violation|0
6179880|NCT01323621|9830280|FG002|2-week, Single-blind Run In Period|Protocol Violation|0
6179881|NCT01323621|9830278|FG000|2-week, Single-blind Run In Period|Lost to Follow-up|1
6179882|NCT01323621|9830279|FG001|2-week, Single-blind Run In Period|Lost to Follow-up|0
6179883|NCT01323621|9830280|FG002|2-week, Single-blind Run In Period|Lost to Follow-up|0
6179884|NCT01323621|9830278|FG000|2-week, Single-blind Run In Period|Did Not Meet Continuation Criteria|86
6179885|NCT01323621|9830279|FG001|2-week, Single-blind Run In Period|Did Not Meet Continuation Criteria|0
6179886|NCT01323621|9830280|FG002|2-week, Single-blind Run In Period|Did Not Meet Continuation Criteria|0
6179887|NCT01323621|9830278|FG000|12-week, Double-blind Treatment Period|Adverse Event|0
6179888|NCT01323621|9830279|FG001|12-week, Double-blind Treatment Period|Adverse Event|1
6179889|NCT01323621|9830280|FG002|12-week, Double-blind Treatment Period|Adverse Event|5
6179890|NCT01323621|9830278|FG000|12-week, Double-blind Treatment Period|Lack of Efficacy|0
6179891|NCT01323621|9830279|FG001|12-week, Double-blind Treatment Period|Lack of Efficacy|2
6179892|NCT01323621|9830280|FG002|12-week, Double-blind Treatment Period|Lack of Efficacy|6
6179893|NCT01323621|9830278|FG000|12-week, Double-blind Treatment Period|Protocol Violation|0
6179894|NCT01323621|9830279|FG001|12-week, Double-blind Treatment Period|Protocol Violation|4
6179895|NCT01323621|9830280|FG002|12-week, Double-blind Treatment Period|Protocol Violation|4
6179896|NCT01323621|9830278|FG000|12-week, Double-blind Treatment Period|Lost to Follow-up|0
6179897|NCT01323621|9830279|FG001|12-week, Double-blind Treatment Period|Lost to Follow-up|1
6179898|NCT01323621|9830280|FG002|12-week, Double-blind Treatment Period|Lost to Follow-up|0
6179899|NCT01323621|9830278|FG000|12-week, Double-blind Treatment Period|Physician Decision|0
6179900|NCT01323621|9830279|FG001|12-week, Double-blind Treatment Period|Physician Decision|2
6179901|NCT01323621|9830280|FG002|12-week, Double-blind Treatment Period|Physician Decision|1
6179902|NCT01323621|9830278|FG000|12-week, Double-blind Treatment Period|Withdrawal by Subject|0
6179903|NCT01323621|9830279|FG001|12-week, Double-blind Treatment Period|Withdrawal by Subject|5
6179904|NCT01323621|9830280|FG002|12-week, Double-blind Treatment Period|Withdrawal by Subject|4
6179905|NCT01323634|9830288|FG000|2-week Run-in Period|Inclusion/Exclusion Criteria not Met|125
6179906|NCT01323634|9830289|FG001|2-week Run-in Period|Inclusion/Exclusion Criteria not Met|0
6179907|NCT01323634|9830290|FG002|2-week Run-in Period|Inclusion/Exclusion Criteria not Met|0
6179908|NCT01323634|9830288|FG000|2-week Run-in Period|Continuation Criteria not Met|73
6179909|NCT01323634|9830289|FG001|2-week Run-in Period|Continuation Criteria not Met|0
6179910|NCT01323634|9830290|FG002|2-week Run-in Period|Continuation Criteria not Met|0
6179911|NCT01323634|9830288|FG000|2-week Run-in Period|Withdrawal by Subject|7
6179912|NCT01323634|9830289|FG001|2-week Run-in Period|Withdrawal by Subject|0
6179913|NCT01323634|9830290|FG002|2-week Run-in Period|Withdrawal by Subject|0
6179914|NCT01323634|9830288|FG000|2-week Run-in Period|Physician Decision|5
6179915|NCT01323634|9830289|FG001|2-week Run-in Period|Physician Decision|0
6179916|NCT01323634|9830290|FG002|2-week Run-in Period|Physician Decision|0
6179917|NCT01323634|9830288|FG000|2-week Run-in Period|Protocol Violation|1
6179918|NCT01323634|9830289|FG001|2-week Run-in Period|Protocol Violation|0
6179919|NCT01323634|9830290|FG002|2-week Run-in Period|Protocol Violation|0
6179920|NCT01323634|9830288|FG000|2-week Run-in Period|Adverse Event|1
6179921|NCT01323634|9830289|FG001|2-week Run-in Period|Adverse Event|0
6179922|NCT01323634|9830290|FG002|2-week Run-in Period|Adverse Event|0
6179923|NCT01323634|9830288|FG000|Double-Blind (DB) Treatment Period|Adverse Event|0
6179924|NCT01323634|9830289|FG001|Double-Blind (DB) Treatment Period|Adverse Event|8
6179925|NCT01323634|9830290|FG002|Double-Blind (DB) Treatment Period|Adverse Event|4
6179926|NCT01323634|9830288|FG000|Double-Blind (DB) Treatment Period|Lack of Efficacy|0
6179927|NCT01323634|9830289|FG001|Double-Blind (DB) Treatment Period|Lack of Efficacy|0
6179928|NCT01323634|9830290|FG002|Double-Blind (DB) Treatment Period|Lack of Efficacy|2
6085269|NCT00651313|9694534|FG000|Overall Study|Withdrawal by Subject|3
6085270|NCT00651313|9694535|FG001|Overall Study|Withdrawal by Subject|1
6085271|NCT00651313|9694534|FG000|Overall Study|Lost to Follow-up|1
6085272|NCT00651313|9694535|FG001|Overall Study|Lost to Follow-up|1
6179929|NCT01323634|9830288|FG000|Double-Blind (DB) Treatment Period|Protocol Violation|0
6179930|NCT01323634|9830289|FG001|Double-Blind (DB) Treatment Period|Protocol Violation|6
6179931|NCT01323634|9830290|FG002|Double-Blind (DB) Treatment Period|Protocol Violation|7
6179932|NCT01323634|9830288|FG000|Double-Blind (DB) Treatment Period|Lost to Follow-up|0
6179933|NCT01323634|9830289|FG001|Double-Blind (DB) Treatment Period|Lost to Follow-up|1
6179934|NCT01323634|9830290|FG002|Double-Blind (DB) Treatment Period|Lost to Follow-up|1
6179935|NCT01323634|9830288|FG000|Double-Blind (DB) Treatment Period|Physician Decision|0
6179936|NCT01323634|9830289|FG001|Double-Blind (DB) Treatment Period|Physician Decision|2
6179937|NCT01323634|9830290|FG002|Double-Blind (DB) Treatment Period|Physician Decision|3
6179938|NCT01323634|9830288|FG000|Double-Blind (DB) Treatment Period|Withdrawal by Subject|0
6179939|NCT01323634|9830289|FG001|Double-Blind (DB) Treatment Period|Withdrawal by Subject|7
6179940|NCT01323634|9830290|FG002|Double-Blind (DB) Treatment Period|Withdrawal by Subject|4
6179941|NCT01323634|9830288|FG000|Double-Blind (DB) Treatment Period|Did not Receive DB Study Medication|0
6179942|NCT01323634|9830289|FG001|Double-Blind (DB) Treatment Period|Did not Receive DB Study Medication|1
6179943|NCT01323634|9830290|FG002|Double-Blind (DB) Treatment Period|Did not Receive DB Study Medication|1
6179944|NCT01323647|9830298|FG000|Overall Study|Migrated/moved from study area|2
6179945|NCT01323647|9830299|FG001|Overall Study|Migrated/moved from study area|0
6179946|NCT01323647|9830298|FG000|Overall Study|Withdrawal by Subject|5
6179947|NCT01323647|9830299|FG001|Overall Study|Withdrawal by Subject|0
6179948|NCT01323647|9830298|FG000|Overall Study|Lost to Follow-up|2
6179949|NCT01323647|9830299|FG001|Overall Study|Lost to Follow-up|0
6179950|NCT01323660|9830305|FG000|Treatment Period 1 (12 Weeks)|Adverse Event|6
6179951|NCT01323660|9830306|FG001|Treatment Period 1 (12 Weeks)|Adverse Event|1
6179952|NCT01323660|9830307|FG002|Treatment Period 1 (12 Weeks)|Adverse Event|1
6179953|NCT01323660|9830308|FG003|Treatment Period 1 (12 Weeks)|Adverse Event|3
6179954|NCT01323660|9830309|FG004|Treatment Period 1 (12 Weeks)|Adverse Event|3
6179955|NCT01323660|9830310|FG005|Treatment Period 1 (12 Weeks)|Adverse Event|4
6179956|NCT01323660|9830305|FG000|Treatment Period 1 (12 Weeks)|Lack of Efficacy|6
6179957|NCT01323660|9830306|FG001|Treatment Period 1 (12 Weeks)|Lack of Efficacy|0
6179958|NCT01323660|9830307|FG002|Treatment Period 1 (12 Weeks)|Lack of Efficacy|2
6179959|NCT01323660|9830308|FG003|Treatment Period 1 (12 Weeks)|Lack of Efficacy|0
6179960|NCT01323660|9830309|FG004|Treatment Period 1 (12 Weeks)|Lack of Efficacy|1
6085273|NCT00651313|9694534|FG000|Overall Study|Adminstrative Discontinuation|2
6085274|NCT00651313|9694535|FG001|Overall Study|Adminstrative Discontinuation|3
6085275|NCT00651664|9694574|FG000|Overall Study|Occurrence of Adverse Event(s)|0
6085276|NCT00651664|9694575|FG001|Overall Study|Occurrence of Adverse Event(s)|0
6085277|NCT00651664|9694576|FG002|Overall Study|Occurrence of Adverse Event(s)|0
6085278|NCT00651664|9694577|FG003|Overall Study|Occurrence of Adverse Event(s)|0
6085279|NCT00651664|9694578|FG004|Overall Study|Occurrence of Adverse Event(s)|0
6085280|NCT00651664|9694579|FG005|Overall Study|Occurrence of Adverse Event(s)|0
6085281|NCT00651664|9694580|FG006|Overall Study|Occurrence of Adverse Event(s)|1
6085282|NCT00651664|9694581|FG007|Overall Study|Occurrence of Adverse Event(s)|0
6085283|NCT00651664|9694582|FG008|Overall Study|Occurrence of Adverse Event(s)|1
6085284|NCT00651664|9694583|FG009|Overall Study|Occurrence of Adverse Event(s)|0
6085285|NCT00651664|9694574|FG000|Overall Study|Unsatisfactory Therapeutic Response|0
6085286|NCT00651664|9694575|FG001|Overall Study|Unsatisfactory Therapeutic Response|0
6085287|NCT00651664|9694576|FG002|Overall Study|Unsatisfactory Therapeutic Response|0
6085288|NCT00651664|9694577|FG003|Overall Study|Unsatisfactory Therapeutic Response|0
6085289|NCT00651664|9694578|FG004|Overall Study|Unsatisfactory Therapeutic Response|1
6085290|NCT00651664|9694579|FG005|Overall Study|Unsatisfactory Therapeutic Response|1
6085291|NCT00651664|9694580|FG006|Overall Study|Unsatisfactory Therapeutic Response|0
6085292|NCT00651664|9694581|FG007|Overall Study|Unsatisfactory Therapeutic Response|1
6085293|NCT00651664|9694582|FG008|Overall Study|Unsatisfactory Therapeutic Response|0
6085294|NCT00651664|9694583|FG009|Overall Study|Unsatisfactory Therapeutic Response|1
6085295|NCT00651664|9694574|FG000|Overall Study|Progressive Disease|3
6085296|NCT00651664|9694575|FG001|Overall Study|Progressive Disease|3
6085297|NCT00651664|9694576|FG002|Overall Study|Progressive Disease|3
6085298|NCT00651664|9694577|FG003|Overall Study|Progressive Disease|12
6085299|NCT00651664|9694578|FG004|Overall Study|Progressive Disease|4
6085300|NCT00651664|9694579|FG005|Overall Study|Progressive Disease|1
6085301|NCT00651664|9694580|FG006|Overall Study|Progressive Disease|3
6085302|NCT00651664|9694581|FG007|Overall Study|Progressive Disease|6
6085303|NCT00651664|9694582|FG008|Overall Study|Progressive Disease|5
6085304|NCT00651664|9694583|FG009|Overall Study|Progressive Disease|5
6085305|NCT00651664|9694574|FG000|Overall Study|Patient Declined Further Treatment|0
6085306|NCT00651664|9694575|FG001|Overall Study|Patient Declined Further Treatment|0
6179961|NCT01323660|9830310|FG005|Treatment Period 1 (12 Weeks)|Lack of Efficacy|3
6179962|NCT01323660|9830305|FG000|Treatment Period 1 (12 Weeks)|Protocol Violation|2
6179963|NCT01323660|9830306|FG001|Treatment Period 1 (12 Weeks)|Protocol Violation|0
6179964|NCT01323660|9830307|FG002|Treatment Period 1 (12 Weeks)|Protocol Violation|1
6179965|NCT01323660|9830308|FG003|Treatment Period 1 (12 Weeks)|Protocol Violation|1
6179966|NCT01323660|9830309|FG004|Treatment Period 1 (12 Weeks)|Protocol Violation|1
6179967|NCT01323660|9830310|FG005|Treatment Period 1 (12 Weeks)|Protocol Violation|2
6179968|NCT01323660|9830305|FG000|Treatment Period 1 (12 Weeks)|Met Protocol-defined Stopping Criteria|0
6179969|NCT01323660|9830306|FG001|Treatment Period 1 (12 Weeks)|Met Protocol-defined Stopping Criteria|0
6179970|NCT01323660|9830307|FG002|Treatment Period 1 (12 Weeks)|Met Protocol-defined Stopping Criteria|0
6179971|NCT01323660|9830308|FG003|Treatment Period 1 (12 Weeks)|Met Protocol-defined Stopping Criteria|0
6179972|NCT01323660|9830309|FG004|Treatment Period 1 (12 Weeks)|Met Protocol-defined Stopping Criteria|1
6179973|NCT01323660|9830310|FG005|Treatment Period 1 (12 Weeks)|Met Protocol-defined Stopping Criteria|0
6179974|NCT01323660|9830305|FG000|Treatment Period 1 (12 Weeks)|Lost to Follow-up|0
6179975|NCT01323660|9830306|FG001|Treatment Period 1 (12 Weeks)|Lost to Follow-up|0
6179976|NCT01323660|9830307|FG002|Treatment Period 1 (12 Weeks)|Lost to Follow-up|0
6179977|NCT01323660|9830308|FG003|Treatment Period 1 (12 Weeks)|Lost to Follow-up|0
6179978|NCT01323660|9830309|FG004|Treatment Period 1 (12 Weeks)|Lost to Follow-up|1
6179979|NCT01323660|9830310|FG005|Treatment Period 1 (12 Weeks)|Lost to Follow-up|0
6179980|NCT01323660|9830305|FG000|Treatment Period 1 (12 Weeks)|Withdrawal by Subject|5
6179981|NCT01323660|9830306|FG001|Treatment Period 1 (12 Weeks)|Withdrawal by Subject|0
6179982|NCT01323660|9830307|FG002|Treatment Period 1 (12 Weeks)|Withdrawal by Subject|1
6179983|NCT01323660|9830308|FG003|Treatment Period 1 (12 Weeks)|Withdrawal by Subject|1
6179984|NCT01323660|9830309|FG004|Treatment Period 1 (12 Weeks)|Withdrawal by Subject|3
6179985|NCT01323660|9830310|FG005|Treatment Period 1 (12 Weeks)|Withdrawal by Subject|0
6179986|NCT01323660|9830305|FG000|Washout Period (14 Days)|Adverse Event|0
6179987|NCT01323660|9830306|FG001|Washout Period (14 Days)|Adverse Event|0
6179988|NCT01323660|9830307|FG002|Washout Period (14 Days)|Adverse Event|0
6179989|NCT01323660|9830308|FG003|Washout Period (14 Days)|Adverse Event|0
6179990|NCT01323660|9830309|FG004|Washout Period (14 Days)|Adverse Event|1
6179991|NCT01323660|9830310|FG005|Washout Period (14 Days)|Adverse Event|0
6179992|NCT01323660|9830305|FG000|Washout Period (14 Days)|Lack of Efficacy|0
6179993|NCT01323660|9830306|FG001|Washout Period (14 Days)|Lack of Efficacy|0
6179994|NCT01323660|9830307|FG002|Washout Period (14 Days)|Lack of Efficacy|1
6179995|NCT01323660|9830308|FG003|Washout Period (14 Days)|Lack of Efficacy|3
6179996|NCT01323660|9830309|FG004|Washout Period (14 Days)|Lack of Efficacy|2
6179997|NCT01323660|9830310|FG005|Washout Period (14 Days)|Lack of Efficacy|2
6179998|NCT01323660|9830305|FG000|Treatment Period 2 (12 Weeks)|Adverse Event|1
6085307|NCT00651664|9694576|FG002|Overall Study|Patient Declined Further Treatment|0
6085308|NCT00651664|9694577|FG003|Overall Study|Patient Declined Further Treatment|1
6085309|NCT00651664|9694578|FG004|Overall Study|Patient Declined Further Treatment|1
6085310|NCT00651664|9694579|FG005|Overall Study|Patient Declined Further Treatment|1
6179999|NCT01323660|9830306|FG001|Treatment Period 2 (12 Weeks)|Adverse Event|0
6180000|NCT01323660|9830307|FG002|Treatment Period 2 (12 Weeks)|Adverse Event|0
6180001|NCT01323660|9830308|FG003|Treatment Period 2 (12 Weeks)|Adverse Event|1
6180002|NCT01323660|9830309|FG004|Treatment Period 2 (12 Weeks)|Adverse Event|1
6180003|NCT01323660|9830310|FG005|Treatment Period 2 (12 Weeks)|Adverse Event|2
6180004|NCT01323660|9830305|FG000|Treatment Period 2 (12 Weeks)|Lack of Efficacy|9
6180005|NCT01323660|9830306|FG001|Treatment Period 2 (12 Weeks)|Lack of Efficacy|0
6180006|NCT01323660|9830307|FG002|Treatment Period 2 (12 Weeks)|Lack of Efficacy|2
6180007|NCT01323660|9830308|FG003|Treatment Period 2 (12 Weeks)|Lack of Efficacy|2
6180008|NCT01323660|9830309|FG004|Treatment Period 2 (12 Weeks)|Lack of Efficacy|1
6180009|NCT01323660|9830310|FG005|Treatment Period 2 (12 Weeks)|Lack of Efficacy|3
6180010|NCT01323660|9830305|FG000|Treatment Period 2 (12 Weeks)|Study Closed/Terminated|0
6180011|NCT01323660|9830306|FG001|Treatment Period 2 (12 Weeks)|Study Closed/Terminated|0
6180012|NCT01323660|9830307|FG002|Treatment Period 2 (12 Weeks)|Study Closed/Terminated|0
6180013|NCT01323660|9830308|FG003|Treatment Period 2 (12 Weeks)|Study Closed/Terminated|0
6180014|NCT01323660|9830309|FG004|Treatment Period 2 (12 Weeks)|Study Closed/Terminated|0
6180015|NCT01323660|9830310|FG005|Treatment Period 2 (12 Weeks)|Study Closed/Terminated|1
6180016|NCT01323660|9830305|FG000|Treatment Period 2 (12 Weeks)|Lost to Follow-up|1
6180017|NCT01323660|9830306|FG001|Treatment Period 2 (12 Weeks)|Lost to Follow-up|0
6180018|NCT01323660|9830307|FG002|Treatment Period 2 (12 Weeks)|Lost to Follow-up|0
6180019|NCT01323660|9830308|FG003|Treatment Period 2 (12 Weeks)|Lost to Follow-up|0
6180020|NCT01323660|9830309|FG004|Treatment Period 2 (12 Weeks)|Lost to Follow-up|0
6180021|NCT01323660|9830310|FG005|Treatment Period 2 (12 Weeks)|Lost to Follow-up|1
6180022|NCT01323660|9830305|FG000|Treatment Period 2 (12 Weeks)|Withdrawal by Subject|1
6180023|NCT01323660|9830306|FG001|Treatment Period 2 (12 Weeks)|Withdrawal by Subject|1
6180024|NCT01323660|9830307|FG002|Treatment Period 2 (12 Weeks)|Withdrawal by Subject|1
6180025|NCT01323660|9830308|FG003|Treatment Period 2 (12 Weeks)|Withdrawal by Subject|0
6180026|NCT01323660|9830309|FG004|Treatment Period 2 (12 Weeks)|Withdrawal by Subject|2
6180027|NCT01323660|9830310|FG005|Treatment Period 2 (12 Weeks)|Withdrawal by Subject|0
6180028|NCT01323673|9830326|FG000|Overall Study|Adverse Event|0
6180029|NCT01323673|9830327|FG001|Overall Study|Adverse Event|1
6180030|NCT01323673|9830326|FG000|Overall Study|Lost to Follow-up|0
6180031|NCT01323673|9830327|FG001|Overall Study|Lost to Follow-up|1
6180032|NCT01323673|9830326|FG000|Overall Study|Protocol Violation|1
6180033|NCT01323673|9830327|FG001|Overall Study|Protocol Violation|0
6180034|NCT01323673|9830326|FG000|Overall Study|Withdrawal by Subject|2
6180035|NCT01323673|9830327|FG001|Overall Study|Withdrawal by Subject|3
6180036|NCT01323790|9830347|FG000|Overall Study|Other|3
6180037|NCT01323790|9830348|FG001|Overall Study|Other|2
6180038|NCT01323790|9830349|FG002|Overall Study|Other|1
6180039|NCT01323790|9830347|FG000|Overall Study|Lost to Follow-up|11
6180040|NCT01323790|9830348|FG001|Overall Study|Lost to Follow-up|9
6180041|NCT01323790|9830349|FG002|Overall Study|Lost to Follow-up|9
6180042|NCT01323790|9830347|FG000|Overall Study|Study-Specific Withdrawal Criteria|0
6180043|NCT01323790|9830348|FG001|Overall Study|Study-Specific Withdrawal Criteria|3
6180044|NCT01323790|9830349|FG002|Overall Study|Study-Specific Withdrawal Criteria|3
6180045|NCT01323790|9830347|FG000|Overall Study|Lack of Efficacy|3
6180046|NCT01323790|9830348|FG001|Overall Study|Lack of Efficacy|0
6180047|NCT01323790|9830349|FG002|Overall Study|Lack of Efficacy|3
6180048|NCT01323790|9830347|FG000|Overall Study|Adverse Event|11
6180049|NCT01323790|9830348|FG001|Overall Study|Adverse Event|24
6180050|NCT01323790|9830349|FG002|Overall Study|Adverse Event|12
6180051|NCT01323790|9830347|FG000|Overall Study|Eligibility Criteria Not Fulfilled|0
6180052|NCT01323790|9830348|FG001|Overall Study|Eligibility Criteria Not Fulfilled|0
6180053|NCT01323790|9830349|FG002|Overall Study|Eligibility Criteria Not Fulfilled|1
6180054|NCT01323790|9830347|FG000|Overall Study|Withdrawal by Subject|23
6180055|NCT01323790|9830348|FG001|Overall Study|Withdrawal by Subject|20
6180056|NCT01323790|9830349|FG002|Overall Study|Withdrawal by Subject|13
6180057|NCT01323790|9830347|FG000|Overall Study|Did Not Receive Treatment|2
6180058|NCT01323790|9830348|FG001|Overall Study|Did Not Receive Treatment|0
6180059|NCT01323790|9830349|FG002|Overall Study|Did Not Receive Treatment|1
6180060|NCT01323790|9830347|FG000|Overall Study|Severe non-compliance with protocol|2
6180061|NCT01323790|9830348|FG001|Overall Study|Severe non-compliance with protocol|2
6180062|NCT01323790|9830349|FG002|Overall Study|Severe non-compliance with protocol|2
6180063|NCT01323920|9830378|FG000|Overall Study|Death|5
6180064|NCT01323920|9830378|FG000|Overall Study|Withdrawal by Subject|1
6180065|NCT01323946|9830385|FG000|Overall Study|Lost to Follow-up|0
6180066|NCT01323946|9830386|FG001|Overall Study|Lost to Follow-up|1
6180067|NCT01323946|9830387|FG002|Overall Study|Lost to Follow-up|0
6180068|NCT01323946|9830385|FG000|Overall Study|Parents refused the last blood draw|1
6180069|NCT01323946|9830386|FG001|Overall Study|Parents refused the last blood draw|0
6180070|NCT01323946|9830387|FG002|Overall Study|Parents refused the last blood draw|0
6180071|NCT01323946|9830385|FG000|Overall Study|Withdrawal by Subject|2
6180072|NCT01323946|9830386|FG001|Overall Study|Withdrawal by Subject|2
6180073|NCT01323946|9830387|FG002|Overall Study|Withdrawal by Subject|0
6180074|NCT01323972|9830414|FG000|Overall Study|Withdrawal by Subject|1
6180075|NCT01323972|9830415|FG001|Overall Study|Withdrawal by Subject|0
6180076|NCT01323972|9830416|FG002|Overall Study|Withdrawal by Subject|1
6180077|NCT01323972|9830417|FG003|Overall Study|Withdrawal by Subject|0
6180078|NCT01323972|9830414|FG000|Overall Study|Migrated/moved from study area|1
6180079|NCT01323972|9830415|FG001|Overall Study|Migrated/moved from study area|2
6180080|NCT01323972|9830416|FG002|Overall Study|Migrated/moved from study area|0
6180081|NCT01323972|9830417|FG003|Overall Study|Migrated/moved from study area|0
6180082|NCT01323972|9830414|FG000|Overall Study|Lost to Follow-up|0
6180083|NCT01323972|9830415|FG001|Overall Study|Lost to Follow-up|1
6180084|NCT01323972|9830416|FG002|Overall Study|Lost to Follow-up|1
6180085|NCT01323972|9830417|FG003|Overall Study|Lost to Follow-up|1
6180086|NCT01324024|9830450|FG000|Second Intervention (4 Weeks)|Withdrawal by Subject|2
6180087|NCT01324024|9830451|FG001|Second Intervention (4 Weeks)|Withdrawal by Subject|1
6180088|NCT01324102|9830463|FG000|Overall Study|illness|1
6180089|NCT01324102|9830464|FG001|Overall Study|illness|6
6180090|NCT01324141|9830486|FG000|Overall Study|Declined to participate before treatment started|1
6180091|NCT01324141|9830486|FG000|Overall Study|Disease progression on study|1
6180092|NCT01324232|9830504|FG000|Overall Study|Protocol Violation|0
6180093|NCT01324232|9830505|FG001|Overall Study|Protocol Violation|0
6180094|NCT01324232|9830506|FG002|Overall Study|Protocol Violation|0
6180095|NCT01324232|9830507|FG003|Overall Study|Protocol Violation|2
6180096|NCT01324232|9830504|FG000|Overall Study|Missing|0
6180097|NCT01324232|9830505|FG001|Overall Study|Missing|0
6180098|NCT01324232|9830506|FG002|Overall Study|Missing|1
6180099|NCT01324232|9830507|FG003|Overall Study|Missing|0
6180100|NCT01324232|9830504|FG000|Overall Study|Participant's Personal Reason/Decision|0
6180101|NCT01324232|9830505|FG001|Overall Study|Participant's Personal Reason/Decision|1
6180102|NCT01324232|9830506|FG002|Overall Study|Participant's Personal Reason/Decision|0
6180103|NCT01324232|9830507|FG003|Overall Study|Participant's Personal Reason/Decision|0
6180104|NCT01324232|9830504|FG000|Overall Study|Lack of Efficacy|2
6180105|NCT01324232|9830505|FG001|Overall Study|Lack of Efficacy|1
6180106|NCT01324232|9830506|FG002|Overall Study|Lack of Efficacy|2
6180107|NCT01324232|9830507|FG003|Overall Study|Lack of Efficacy|2
6180108|NCT01324232|9830504|FG000|Overall Study|Participant Refused Medication|0
6180109|NCT01324232|9830505|FG001|Overall Study|Participant Refused Medication|1
6180110|NCT01324232|9830506|FG002|Overall Study|Participant Refused Medication|0
6180111|NCT01324232|9830507|FG003|Overall Study|Participant Refused Medication|0
6180112|NCT01324232|9830504|FG000|Overall Study|Intercurrent illness|0
6180113|NCT01324232|9830505|FG001|Overall Study|Intercurrent illness|0
6180114|NCT01324232|9830506|FG002|Overall Study|Intercurrent illness|0
6180115|NCT01324232|9830507|FG003|Overall Study|Intercurrent illness|1
6180116|NCT01324232|9830504|FG000|Overall Study|Adverse Event|2
6180117|NCT01324232|9830505|FG001|Overall Study|Adverse Event|5
6180118|NCT01324232|9830506|FG002|Overall Study|Adverse Event|6
6180119|NCT01324232|9830507|FG003|Overall Study|Adverse Event|6
6180120|NCT01324232|9830504|FG000|Overall Study|Withdrawal by Subject|0
6180121|NCT01324232|9830505|FG001|Overall Study|Withdrawal by Subject|3
6180122|NCT01324232|9830506|FG002|Overall Study|Withdrawal by Subject|4
6180123|NCT01324232|9830507|FG003|Overall Study|Withdrawal by Subject|0
6180124|NCT01324232|9830504|FG000|Overall Study|Lost to Follow-up|1
6180125|NCT01324232|9830505|FG001|Overall Study|Lost to Follow-up|0
6180126|NCT01324232|9830506|FG002|Overall Study|Lost to Follow-up|0
6180127|NCT01324232|9830507|FG003|Overall Study|Lost to Follow-up|0
6180128|NCT01324271|9830522|FG000|Overall Study|Lost to Follow-up|3
6180129|NCT01324271|9830523|FG001|Overall Study|Lost to Follow-up|0
6180130|NCT01324271|9830522|FG000|Overall Study|Physician Decision|1
6180131|NCT01324271|9830523|FG001|Overall Study|Physician Decision|0
6180132|NCT01324310|9830529|FG000|Overall Study|Adverse Event|1
6180133|NCT01324310|9830529|FG000|Overall Study|Disease Progression|1
6180134|NCT01324323|9830535|FG000|Overall Study|Withdrawal by Subject|1
6180135|NCT01324349|9830549|FG000|Overall Study|Death|1
6180136|NCT01324349|9830550|FG001|Overall Study|Death|1
6180137|NCT01324349|9830549|FG000|Overall Study|Withdrawal by Subject|0
6180138|NCT01324349|9830550|FG001|Overall Study|Withdrawal by Subject|1
6180139|NCT01324388|9830559|FG000|Part 1 of Study|Adverse Event|2
6180140|NCT01324388|9830560|FG001|Part 1 of Study|Adverse Event|0
6180141|NCT01324388|9830561|FG002|Part 1 of Study|Adverse Event|0
6180142|NCT01324388|9830562|FG003|Part 1 of Study|Adverse Event|0
6180143|NCT01324388|9830559|FG000|Part 1 of Study|Protocol Violation|1
6180144|NCT01324388|9830560|FG001|Part 1 of Study|Protocol Violation|2
6180145|NCT01324388|9830561|FG002|Part 1 of Study|Protocol Violation|0
6180146|NCT01324388|9830562|FG003|Part 1 of Study|Protocol Violation|0
6180147|NCT01324388|9830559|FG000|Part 1 of Study|Physician Decision|1
6180148|NCT01324388|9830560|FG001|Part 1 of Study|Physician Decision|0
6180149|NCT01324388|9830561|FG002|Part 1 of Study|Physician Decision|0
6180150|NCT01324388|9830562|FG003|Part 1 of Study|Physician Decision|0
6180151|NCT01324388|9830559|FG000|Part 2 of Study: First Intervention|Protocol Violation|0
6180152|NCT01324388|9830560|FG001|Part 2 of Study: First Intervention|Protocol Violation|0
6180153|NCT01324388|9830561|FG002|Part 2 of Study: First Intervention|Protocol Violation|0
6180154|NCT01324388|9830562|FG003|Part 2 of Study: First Intervention|Protocol Violation|1
6180155|NCT01324388|9830559|FG000|Part 2 of Study: Second Intervention|Withdrawal by Subject|0
6180156|NCT01324388|9830560|FG001|Part 2 of Study: Second Intervention|Withdrawal by Subject|0
6180157|NCT01324388|9830561|FG002|Part 2 of Study: Second Intervention|Withdrawal by Subject|1
6180158|NCT01324388|9830562|FG003|Part 2 of Study: Second Intervention|Withdrawal by Subject|0
6085311|NCT00651664|9694580|FG006|Overall Study|Patient Declined Further Treatment|0
6085312|NCT00651664|9694581|FG007|Overall Study|Patient Declined Further Treatment|0
6180159|NCT01324401|9830576|FG000|Overall Study|Withdrawn before any treatment|0
6180160|NCT01324401|9830577|FG001|Overall Study|Withdrawn before any treatment|3
6180161|NCT01324401|9830576|FG000|Overall Study|Adverse Event|1
6180162|NCT01324401|9830577|FG001|Overall Study|Adverse Event|3
6180163|NCT01324440|9830585|FG000|Overall Study|Subject moved|0
6180164|NCT01324440|9830586|FG001|Overall Study|Subject moved|1
6192709|NCT01433159|9850249|FG001|Overall Study|Protocol Violation|1
6192710|NCT01433172|9850258|FG000|Overall Study|Withdrawal by Subject|0
6192711|NCT01433172|9850259|FG001|Overall Study|Withdrawal by Subject|1
6192712|NCT01433172|9850260|FG002|Overall Study|Withdrawal by Subject|0
6192713|NCT01433172|9850258|FG000|Overall Study|Disease Progression|0
6192714|NCT01433172|9850259|FG001|Overall Study|Disease Progression|0
6192715|NCT01433172|9850260|FG002|Overall Study|Disease Progression|1
6192716|NCT01433172|9850258|FG000|Overall Study|Death|0
6192717|NCT01433172|9850259|FG001|Overall Study|Death|2
6192718|NCT01433172|9850260|FG002|Overall Study|Death|0
6192719|NCT01433250|9850270|FG000|Overall Study|Protocol Violation|0
6192720|NCT01433250|9850271|FG001|Overall Study|Protocol Violation|1
6192721|NCT01433250|9850270|FG000|Overall Study|Withdrawal by Subject|3
6192722|NCT01433250|9850271|FG001|Overall Study|Withdrawal by Subject|2
6192723|NCT01433263|9850279|FG000|Overall Study|Adverse Event|3
6192724|NCT01433263|9850280|FG001|Overall Study|Adverse Event|1
6192725|NCT01433263|9850279|FG000|Overall Study|Death|5
6192726|NCT01433263|9850280|FG001|Overall Study|Death|3
6192727|NCT01433263|9850279|FG000|Overall Study|Lost to Follow-up|0
6192728|NCT01433263|9850280|FG001|Overall Study|Lost to Follow-up|1
6192729|NCT01433263|9850279|FG000|Overall Study|Protocol Deviation|1
6192730|NCT01433263|9850280|FG001|Overall Study|Protocol Deviation|0
6192731|NCT01433263|9850279|FG000|Overall Study|Withdrawal by Subject|10
6192732|NCT01433263|9850280|FG001|Overall Study|Withdrawal by Subject|7
6192733|NCT01433354|9850289|FG000|Overall Study|Adverse Event|6
6192734|NCT01433354|9850289|FG000|Overall Study|Lost to Follow-up|1
6192735|NCT01433354|9850289|FG000|Overall Study|Administrative problems|90
6192736|NCT01433354|9850289|FG000|Overall Study|Protocol Violation|2
6192737|NCT01433354|9850289|FG000|Overall Study|Lack of Efficacy|17
6192738|NCT01433354|9850289|FG000|Overall Study|Subject Withdrew Consent|3
6192739|NCT01433549|9850303|FG000|Phase 2: Second Study Product|Adverse Event|0
6192740|NCT01433549|9850304|FG001|Phase 2: Second Study Product|Adverse Event|1
6192741|NCT01433978|9850337|FG000|Core Study|Adverse Event, Non-Fatal|0
6192742|NCT01433978|9850338|FG001|Core Study|Adverse Event, Non-Fatal|1
6192743|NCT01433978|9850339|FG002|Core Study|Adverse Event, Non-Fatal|0
6227761|NCT01719224|9900589|FG001|Intervention 1: Sleeping Position 1|Withdrawal by Subject|2
6227762|NCT01719380|9900615|FG000|Overall Study|Adverse Event|0
6227763|NCT01719380|9900616|FG001|Overall Study|Adverse Event|0
6227764|NCT01719380|9900617|FG002|Overall Study|Adverse Event|1
6227765|NCT01719380|9900618|FG003|Overall Study|Adverse Event|2
6227766|NCT01719380|9900619|FG004|Overall Study|Adverse Event|0
6227767|NCT01719380|9900620|FG005|Overall Study|Adverse Event|1
6227768|NCT01719380|9900621|FG006|Overall Study|Adverse Event|0
6227769|NCT01719380|9900622|FG007|Overall Study|Adverse Event|1
6227770|NCT01719380|9900623|FG008|Overall Study|Adverse Event|4
6227771|NCT01719380|9900624|FG009|Overall Study|Adverse Event|3
6375380|NCT03877926|10165415|FG000|Overall Study|Adverse Event|1
6375381|NCT03877926|10165416|FG001|Overall Study|Adverse Event|0
6227772|NCT01719380|9900615|FG000|Overall Study|Death|0
6227773|NCT01719380|9900616|FG001|Overall Study|Death|1
6227774|NCT01719380|9900617|FG002|Overall Study|Death|0
6085313|NCT00651664|9694582|FG008|Overall Study|Patient Declined Further Treatment|0
6085314|NCT00651664|9694583|FG009|Overall Study|Patient Declined Further Treatment|1
6085315|NCT00651664|9694574|FG000|Overall Study|Symptomatic Deterioration|0
6085316|NCT00651664|9694575|FG001|Overall Study|Symptomatic Deterioration|0
6085317|NCT00651664|9694576|FG002|Overall Study|Symptomatic Deterioration|0
6085318|NCT00651664|9694577|FG003|Overall Study|Symptomatic Deterioration|1
6085319|NCT00651664|9694578|FG004|Overall Study|Symptomatic Deterioration|0
6085320|NCT00651664|9694579|FG005|Overall Study|Symptomatic Deterioration|0
6085321|NCT00651664|9694580|FG006|Overall Study|Symptomatic Deterioration|1
6227775|NCT01719380|9900618|FG003|Overall Study|Death|0
6227776|NCT01719380|9900619|FG004|Overall Study|Death|0
6227777|NCT01719380|9900620|FG005|Overall Study|Death|0
6227778|NCT01719380|9900621|FG006|Overall Study|Death|0
6227779|NCT01719380|9900622|FG007|Overall Study|Death|0
6227780|NCT01719380|9900623|FG008|Overall Study|Death|3
6227781|NCT01719380|9900624|FG009|Overall Study|Death|3
6227782|NCT01719380|9900615|FG000|Overall Study|Participant/Guardian Decision|0
6227783|NCT01719380|9900616|FG001|Overall Study|Participant/Guardian Decision|0
6227784|NCT01719380|9900617|FG002|Overall Study|Participant/Guardian Decision|1
6227785|NCT01719380|9900618|FG003|Overall Study|Participant/Guardian Decision|0
6227786|NCT01719380|9900619|FG004|Overall Study|Participant/Guardian Decision|0
6227787|NCT01719380|9900620|FG005|Overall Study|Participant/Guardian Decision|0
6227788|NCT01719380|9900621|FG006|Overall Study|Participant/Guardian Decision|0
6192744|NCT01433978|9850337|FG000|Core Study|Lack of Efficacy|5
6192745|NCT01433978|9850338|FG001|Core Study|Lack of Efficacy|1
6227789|NCT01719380|9900622|FG007|Overall Study|Participant/Guardian Decision|0
6180165|NCT01324570|9830616|FG000|Overall Study|Adverse Event|4
6180166|NCT01324570|9830617|FG001|Overall Study|Adverse Event|7
6180167|NCT01324570|9830616|FG000|Overall Study|Withdrawal by Subject|0
6180168|NCT01324570|9830617|FG001|Overall Study|Withdrawal by Subject|3
6180169|NCT01324570|9830616|FG000|Overall Study|Lack of Efficacy|0
6180170|NCT01324570|9830617|FG001|Overall Study|Lack of Efficacy|1
6180171|NCT01324570|9830616|FG000|Overall Study|Confirmed or suspected diversion|0
6180172|NCT01324570|9830617|FG001|Overall Study|Confirmed or suspected diversion|1
6180173|NCT01324570|9830616|FG000|Overall Study|Administrative|0
6180174|NCT01324570|9830617|FG001|Overall Study|Administrative|2
6180175|NCT01324622|9830627|FG000|Overall Study|Lost to Follow-up|7
6180176|NCT01324622|9830628|FG001|Overall Study|Lost to Follow-up|7
6180177|NCT01324622|9830627|FG000|Overall Study|Death|1
6180178|NCT01324622|9830628|FG001|Overall Study|Death|0
6180179|NCT01324622|9830627|FG000|Overall Study|Lack of Efficacy|1
6180180|NCT01324622|9830628|FG001|Overall Study|Lack of Efficacy|0
6180181|NCT01324830|9830680|FG000|Overall Study|Progressive Disease|3
6180182|NCT01324830|9830681|FG001|Overall Study|Progressive Disease|2
6180183|NCT01324830|9830682|FG002|Overall Study|Progressive Disease|3
6180184|NCT01324830|9830683|FG003|Overall Study|Progressive Disease|3
6180185|NCT01324830|9830684|FG004|Overall Study|Progressive Disease|6
6180186|NCT01324830|9830685|FG005|Overall Study|Progressive Disease|6
6180187|NCT01324830|9830686|FG006|Overall Study|Progressive Disease|3
6180188|NCT01324830|9830687|FG007|Overall Study|Progressive Disease|3
6180189|NCT01324830|9830688|FG008|Overall Study|Progressive Disease|3
6180190|NCT01324830|9830689|FG009|Overall Study|Progressive Disease|6
6180191|NCT01324830|9830690|FG010|Overall Study|Progressive Disease|2
6180192|NCT01324830|9830691|FG011|Overall Study|Progressive Disease|1
6180193|NCT01324830|9830692|FG012|Overall Study|Progressive Disease|1
6180194|NCT01324830|9830693|FG013|Overall Study|Progressive Disease|1
6180195|NCT01324830|9830694|FG014|Overall Study|Progressive Disease|1
6180196|NCT01324830|9830695|FG015|Overall Study|Progressive Disease|3
6180197|NCT01324830|9830696|FG016|Overall Study|Progressive Disease|2
6180198|NCT01324830|9830697|FG017|Overall Study|Progressive Disease|3
6180199|NCT01324830|9830698|FG018|Overall Study|Progressive Disease|4
6180200|NCT01324830|9830680|FG000|Overall Study|Dose limiting toxicity|0
6180201|NCT01324830|9830681|FG001|Overall Study|Dose limiting toxicity|0
6180202|NCT01324830|9830682|FG002|Overall Study|Dose limiting toxicity|0
6180203|NCT01324830|9830683|FG003|Overall Study|Dose limiting toxicity|0
6180204|NCT01324830|9830684|FG004|Overall Study|Dose limiting toxicity|1
6180205|NCT01324830|9830685|FG005|Overall Study|Dose limiting toxicity|0
6180206|NCT01324830|9830686|FG006|Overall Study|Dose limiting toxicity|0
6180207|NCT01324830|9830687|FG007|Overall Study|Dose limiting toxicity|0
6180208|NCT01324830|9830688|FG008|Overall Study|Dose limiting toxicity|0
6180209|NCT01324830|9830689|FG009|Overall Study|Dose limiting toxicity|0
6180210|NCT01324830|9830690|FG010|Overall Study|Dose limiting toxicity|0
6180211|NCT01324830|9830691|FG011|Overall Study|Dose limiting toxicity|0
6180212|NCT01324830|9830692|FG012|Overall Study|Dose limiting toxicity|0
6180213|NCT01324830|9830693|FG013|Overall Study|Dose limiting toxicity|0
6180214|NCT01324830|9830694|FG014|Overall Study|Dose limiting toxicity|0
6180215|NCT01324830|9830695|FG015|Overall Study|Dose limiting toxicity|0
6180216|NCT01324830|9830696|FG016|Overall Study|Dose limiting toxicity|1
6180217|NCT01324830|9830697|FG017|Overall Study|Dose limiting toxicity|1
6180218|NCT01324830|9830698|FG018|Overall Study|Dose limiting toxicity|1
6180219|NCT01324830|9830680|FG000|Overall Study|Reason not mentioned above|0
6180220|NCT01324830|9830681|FG001|Overall Study|Reason not mentioned above|0
6180221|NCT01324830|9830682|FG002|Overall Study|Reason not mentioned above|0
6180222|NCT01324830|9830683|FG003|Overall Study|Reason not mentioned above|0
6180223|NCT01324830|9830684|FG004|Overall Study|Reason not mentioned above|0
6180224|NCT01324830|9830685|FG005|Overall Study|Reason not mentioned above|0
6180225|NCT01324830|9830686|FG006|Overall Study|Reason not mentioned above|0
6180226|NCT01324830|9830687|FG007|Overall Study|Reason not mentioned above|0
6180227|NCT01324830|9830688|FG008|Overall Study|Reason not mentioned above|0
6180228|NCT01324830|9830689|FG009|Overall Study|Reason not mentioned above|0
6180229|NCT01324830|9830690|FG010|Overall Study|Reason not mentioned above|0
6180230|NCT01324830|9830691|FG011|Overall Study|Reason not mentioned above|0
6180231|NCT01324830|9830692|FG012|Overall Study|Reason not mentioned above|0
6180232|NCT01324830|9830693|FG013|Overall Study|Reason not mentioned above|0
6180233|NCT01324830|9830694|FG014|Overall Study|Reason not mentioned above|0
6180234|NCT01324830|9830695|FG015|Overall Study|Reason not mentioned above|0
6180235|NCT01324830|9830696|FG016|Overall Study|Reason not mentioned above|0
6180236|NCT01324830|9830697|FG017|Overall Study|Reason not mentioned above|1
6180237|NCT01324830|9830698|FG018|Overall Study|Reason not mentioned above|0
6180238|NCT01324830|9830680|FG000|Overall Study|Adverse Event, serious fatal|0
6180239|NCT01324830|9830681|FG001|Overall Study|Adverse Event, serious fatal|1
6180240|NCT01324830|9830682|FG002|Overall Study|Adverse Event, serious fatal|0
6180241|NCT01324830|9830683|FG003|Overall Study|Adverse Event, serious fatal|0
6180242|NCT01324830|9830684|FG004|Overall Study|Adverse Event, serious fatal|0
6180243|NCT01324830|9830685|FG005|Overall Study|Adverse Event, serious fatal|0
6180244|NCT01324830|9830686|FG006|Overall Study|Adverse Event, serious fatal|0
6180245|NCT01324830|9830687|FG007|Overall Study|Adverse Event, serious fatal|0
6180246|NCT01324830|9830688|FG008|Overall Study|Adverse Event, serious fatal|0
6192746|NCT01433978|9850339|FG002|Core Study|Lack of Efficacy|0
6180247|NCT01324830|9830689|FG009|Overall Study|Adverse Event, serious fatal|0
6180248|NCT01324830|9830690|FG010|Overall Study|Adverse Event, serious fatal|0
6180249|NCT01324830|9830691|FG011|Overall Study|Adverse Event, serious fatal|0
6180250|NCT01324830|9830692|FG012|Overall Study|Adverse Event, serious fatal|0
6180251|NCT01324830|9830693|FG013|Overall Study|Adverse Event, serious fatal|0
6180252|NCT01324830|9830694|FG014|Overall Study|Adverse Event, serious fatal|0
6180253|NCT01324830|9830695|FG015|Overall Study|Adverse Event, serious fatal|0
6180254|NCT01324830|9830696|FG016|Overall Study|Adverse Event, serious fatal|0
6180255|NCT01324830|9830697|FG017|Overall Study|Adverse Event, serious fatal|0
6180256|NCT01324830|9830698|FG018|Overall Study|Adverse Event, serious fatal|0
6180257|NCT01324830|9830680|FG000|Overall Study|Adverse Event, non-fatal|0
6180258|NCT01324830|9830681|FG001|Overall Study|Adverse Event, non-fatal|0
6180259|NCT01324830|9830682|FG002|Overall Study|Adverse Event, non-fatal|0
6180260|NCT01324830|9830683|FG003|Overall Study|Adverse Event, non-fatal|0
6180261|NCT01324830|9830684|FG004|Overall Study|Adverse Event, non-fatal|0
6180262|NCT01324830|9830685|FG005|Overall Study|Adverse Event, non-fatal|0
6180263|NCT01324830|9830686|FG006|Overall Study|Adverse Event, non-fatal|0
6180264|NCT01324830|9830687|FG007|Overall Study|Adverse Event, non-fatal|0
6180265|NCT01324830|9830688|FG008|Overall Study|Adverse Event, non-fatal|2
6180266|NCT01324830|9830689|FG009|Overall Study|Adverse Event, non-fatal|0
6180267|NCT01324830|9830690|FG010|Overall Study|Adverse Event, non-fatal|1
6180268|NCT01324830|9830691|FG011|Overall Study|Adverse Event, non-fatal|0
6180269|NCT01324830|9830692|FG012|Overall Study|Adverse Event, non-fatal|0
6180270|NCT01324830|9830693|FG013|Overall Study|Adverse Event, non-fatal|0
6180271|NCT01324830|9830694|FG014|Overall Study|Adverse Event, non-fatal|0
6180272|NCT01324830|9830695|FG015|Overall Study|Adverse Event, non-fatal|0
6180273|NCT01324830|9830696|FG016|Overall Study|Adverse Event, non-fatal|0
6180274|NCT01324830|9830697|FG017|Overall Study|Adverse Event, non-fatal|1
6180275|NCT01324830|9830698|FG018|Overall Study|Adverse Event, non-fatal|0
6180276|NCT01324830|9830680|FG000|Overall Study|Withdrawal by Subject|0
6180277|NCT01324830|9830681|FG001|Overall Study|Withdrawal by Subject|0
6180278|NCT01324830|9830682|FG002|Overall Study|Withdrawal by Subject|0
6180279|NCT01324830|9830683|FG003|Overall Study|Withdrawal by Subject|0
6180280|NCT01324830|9830684|FG004|Overall Study|Withdrawal by Subject|0
6180281|NCT01324830|9830685|FG005|Overall Study|Withdrawal by Subject|1
6180282|NCT01324830|9830686|FG006|Overall Study|Withdrawal by Subject|0
6180283|NCT01324830|9830687|FG007|Overall Study|Withdrawal by Subject|0
6180284|NCT01324830|9830688|FG008|Overall Study|Withdrawal by Subject|0
6180285|NCT01324830|9830689|FG009|Overall Study|Withdrawal by Subject|0
6180286|NCT01324830|9830690|FG010|Overall Study|Withdrawal by Subject|1
6180287|NCT01324830|9830691|FG011|Overall Study|Withdrawal by Subject|0
6180288|NCT01324830|9830692|FG012|Overall Study|Withdrawal by Subject|0
6180289|NCT01324830|9830693|FG013|Overall Study|Withdrawal by Subject|0
6180290|NCT01324830|9830694|FG014|Overall Study|Withdrawal by Subject|0
6180291|NCT01324830|9830695|FG015|Overall Study|Withdrawal by Subject|0
6180292|NCT01324830|9830696|FG016|Overall Study|Withdrawal by Subject|0
6180293|NCT01324830|9830697|FG017|Overall Study|Withdrawal by Subject|0
6180294|NCT01324830|9830698|FG018|Overall Study|Withdrawal by Subject|1
6180295|NCT01324947|9830755|FG000|Overall Study|Adverse Event|7
6180296|NCT01324947|9830755|FG000|Overall Study|Death|10
6180297|NCT01324947|9830755|FG000|Overall Study|Other|3
6180298|NCT01324947|9830755|FG000|Overall Study|Progressive Disease|50
6180299|NCT01324947|9830755|FG000|Overall Study|Withdrawal by Subject|3
6180300|NCT01324947|9830755|FG000|Overall Study|1 discontinued before starting drug|1
6180301|NCT01324999|9830761|FG000|Overall Study|Adverse Event|3
6180302|NCT01324999|9830761|FG000|Overall Study|Withdrawal by Subject|2
6180303|NCT01325207|9830780|FG000|Completed 4 Weeks/1 Cycle of Treatment|Adverse Event|0
6043563|NCT00390910|9642263|FG000|Overall Study|Lost to Follow-up|0
6043564|NCT00390910|9642264|FG001|Overall Study|Lost to Follow-up|1
6043565|NCT00390910|9642265|FG002|Overall Study|Lost to Follow-up|5
6043566|NCT00390910|9642263|FG000|Overall Study|Withdrawal by Subject|1
6043567|NCT00390910|9642264|FG001|Overall Study|Withdrawal by Subject|3
6043568|NCT00390910|9642265|FG002|Overall Study|Withdrawal by Subject|2
6085322|NCT00651664|9694581|FG007|Overall Study|Symptomatic Deterioration|0
6085323|NCT00651664|9694582|FG008|Overall Study|Symptomatic Deterioration|1
6043569|NCT00390910|9642263|FG000|Overall Study|Migrated/moved from study area|0
6043570|NCT00390910|9642264|FG001|Overall Study|Migrated/moved from study area|0
6043571|NCT00390910|9642265|FG002|Overall Study|Migrated/moved from study area|3
6043572|NCT00391027|9642286|FG000|Overall Study|Adverse Event|8
6043573|NCT00391027|9642287|FG001|Overall Study|Adverse Event|8
6043574|NCT00391027|9642286|FG000|Overall Study|Lack of Efficacy|3
6043575|NCT00391027|9642287|FG001|Overall Study|Lack of Efficacy|0
6085324|NCT00651664|9694583|FG009|Overall Study|Symptomatic Deterioration|0
6180304|NCT01325207|9830781|FG001|Completed 4 Weeks/1 Cycle of Treatment|Adverse Event|0
6180305|NCT01325207|9830782|FG002|Completed 4 Weeks/1 Cycle of Treatment|Adverse Event|0
6043576|NCT00391027|9642286|FG000|Overall Study|Withdrawal by Subject|10
6043577|NCT00391027|9642287|FG001|Overall Study|Withdrawal by Subject|1
6043578|NCT00391027|9642286|FG000|Overall Study|Other|4
6043579|NCT00391027|9642287|FG001|Overall Study|Other|3
6085325|NCT00651664|9694574|FG000|Overall Study|Reason not Specified|0
6085326|NCT00651664|9694575|FG001|Overall Study|Reason not Specified|0
6180306|NCT01325207|9830783|FG003|Completed 4 Weeks/1 Cycle of Treatment|Adverse Event|0
6180307|NCT01325207|9830784|FG004|Completed 4 Weeks/1 Cycle of Treatment|Adverse Event|2
6180308|NCT01325207|9830785|FG005|Completed 4 Weeks/1 Cycle of Treatment|Adverse Event|0
6180309|NCT01325207|9830780|FG000|Completed 8 Weeks/2 Cycles of Treatment|Progressive Disease|1
6180310|NCT01325207|9830781|FG001|Completed 8 Weeks/2 Cycles of Treatment|Progressive Disease|1
6180311|NCT01325207|9830782|FG002|Completed 8 Weeks/2 Cycles of Treatment|Progressive Disease|0
6180312|NCT01325207|9830783|FG003|Completed 8 Weeks/2 Cycles of Treatment|Progressive Disease|0
6180313|NCT01325207|9830784|FG004|Completed 8 Weeks/2 Cycles of Treatment|Progressive Disease|2
6180314|NCT01325207|9830785|FG005|Completed 8 Weeks/2 Cycles of Treatment|Progressive Disease|5
6180315|NCT01325207|9830780|FG000|Started 9th Week/Cycle 3 of Treatment|Progressive disease|1
6180316|NCT01325207|9830781|FG001|Started 9th Week/Cycle 3 of Treatment|Progressive disease|1
6180317|NCT01325207|9830782|FG002|Started 9th Week/Cycle 3 of Treatment|Progressive disease|1
6180318|NCT01325207|9830783|FG003|Started 9th Week/Cycle 3 of Treatment|Progressive disease|1
6180319|NCT01325207|9830784|FG004|Started 9th Week/Cycle 3 of Treatment|Progressive disease|0
6180320|NCT01325207|9830785|FG005|Started 9th Week/Cycle 3 of Treatment|Progressive disease|4
6180321|NCT01325207|9830780|FG000|Started 9th Week/Cycle 3 of Treatment|Withdrawal by Subject|0
6180322|NCT01325207|9830781|FG001|Started 9th Week/Cycle 3 of Treatment|Withdrawal by Subject|1
6180323|NCT01325207|9830782|FG002|Started 9th Week/Cycle 3 of Treatment|Withdrawal by Subject|0
6180324|NCT01325207|9830783|FG003|Started 9th Week/Cycle 3 of Treatment|Withdrawal by Subject|0
6180325|NCT01325207|9830784|FG004|Started 9th Week/Cycle 3 of Treatment|Withdrawal by Subject|0
6180326|NCT01325207|9830785|FG005|Started 9th Week/Cycle 3 of Treatment|Withdrawal by Subject|0
6180327|NCT01325207|9830780|FG000|Started 9th Week/Cycle 3 of Treatment|Adverse Event|0
6180328|NCT01325207|9830781|FG001|Started 9th Week/Cycle 3 of Treatment|Adverse Event|0
6180329|NCT01325207|9830782|FG002|Started 9th Week/Cycle 3 of Treatment|Adverse Event|0
6180330|NCT01325207|9830783|FG003|Started 9th Week/Cycle 3 of Treatment|Adverse Event|0
6180331|NCT01325207|9830784|FG004|Started 9th Week/Cycle 3 of Treatment|Adverse Event|0
6180332|NCT01325207|9830785|FG005|Started 9th Week/Cycle 3 of Treatment|Adverse Event|1
6180333|NCT01325207|9830780|FG000|Follow-up Every 3 Months Until Death|Lost to Follow-up|0
6180334|NCT01325207|9830781|FG001|Follow-up Every 3 Months Until Death|Lost to Follow-up|0
6180335|NCT01325207|9830782|FG002|Follow-up Every 3 Months Until Death|Lost to Follow-up|0
6180336|NCT01325207|9830783|FG003|Follow-up Every 3 Months Until Death|Lost to Follow-up|0
6180337|NCT01325207|9830784|FG004|Follow-up Every 3 Months Until Death|Lost to Follow-up|0
6180338|NCT01325207|9830785|FG005|Follow-up Every 3 Months Until Death|Lost to Follow-up|1
6180339|NCT01325207|9830780|FG000|Follow-up Every 3 Months Until Death|Follow-up Considered Complete|0
6180340|NCT01325207|9830781|FG001|Follow-up Every 3 Months Until Death|Follow-up Considered Complete|0
6180341|NCT01325207|9830782|FG002|Follow-up Every 3 Months Until Death|Follow-up Considered Complete|0
6180342|NCT01325207|9830783|FG003|Follow-up Every 3 Months Until Death|Follow-up Considered Complete|0
6180343|NCT01325207|9830784|FG004|Follow-up Every 3 Months Until Death|Follow-up Considered Complete|1
6180344|NCT01325207|9830785|FG005|Follow-up Every 3 Months Until Death|Follow-up Considered Complete|0
6180345|NCT01325337|9830814|FG000|Overall Study|Adverse Event|0
6180346|NCT01325337|9830815|FG001|Overall Study|Adverse Event|2
6180347|NCT01325337|9830816|FG002|Overall Study|Adverse Event|2
6180348|NCT01325337|9830817|FG003|Overall Study|Adverse Event|1
6180349|NCT01325337|9830818|FG004|Overall Study|Adverse Event|2
6180350|NCT01325337|9830814|FG000|Overall Study|Lost to Follow-up|2
6180351|NCT01325337|9830815|FG001|Overall Study|Lost to Follow-up|2
6180352|NCT01325337|9830816|FG002|Overall Study|Lost to Follow-up|2
6180353|NCT01325337|9830817|FG003|Overall Study|Lost to Follow-up|1
6180354|NCT01325337|9830818|FG004|Overall Study|Lost to Follow-up|2
6180355|NCT01325337|9830814|FG000|Overall Study|Personal Reasons|2
6180356|NCT01325337|9830815|FG001|Overall Study|Personal Reasons|5
6180357|NCT01325337|9830816|FG002|Overall Study|Personal Reasons|4
6180358|NCT01325337|9830817|FG003|Overall Study|Personal Reasons|8
6180359|NCT01325337|9830818|FG004|Overall Study|Personal Reasons|3
6180360|NCT01325337|9830814|FG000|Overall Study|Withdrawal by Subject|1
6180361|NCT01325337|9830815|FG001|Overall Study|Withdrawal by Subject|0
6180362|NCT01325337|9830816|FG002|Overall Study|Withdrawal by Subject|1
6180363|NCT01325337|9830817|FG003|Overall Study|Withdrawal by Subject|0
6180364|NCT01325337|9830818|FG004|Overall Study|Withdrawal by Subject|1
6180365|NCT01325350|9830835|FG000|Overall Study|Adverse Event|3
6180366|NCT01325350|9830836|FG001|Overall Study|Adverse Event|3
6180367|NCT01325350|9830837|FG002|Overall Study|Adverse Event|3
6180368|NCT01325350|9830838|FG003|Overall Study|Adverse Event|1
6180369|NCT01325350|9830839|FG004|Overall Study|Adverse Event|2
6180370|NCT01325350|9830835|FG000|Overall Study|Pregnancy|0
6180371|NCT01325350|9830836|FG001|Overall Study|Pregnancy|0
6180372|NCT01325350|9830837|FG002|Overall Study|Pregnancy|1
6180373|NCT01325350|9830838|FG003|Overall Study|Pregnancy|0
6180374|NCT01325350|9830839|FG004|Overall Study|Pregnancy|1
6180375|NCT01325350|9830835|FG000|Overall Study|Lost to Follow-up|1
6180376|NCT01325350|9830836|FG001|Overall Study|Lost to Follow-up|0
6180377|NCT01325350|9830837|FG002|Overall Study|Lost to Follow-up|5
6180378|NCT01325350|9830838|FG003|Overall Study|Lost to Follow-up|1
6180379|NCT01325350|9830839|FG004|Overall Study|Lost to Follow-up|5
6180380|NCT01325350|9830835|FG000|Overall Study|Personal Reasons|2
6180381|NCT01325350|9830836|FG001|Overall Study|Personal Reasons|1
6180382|NCT01325350|9830837|FG002|Overall Study|Personal Reasons|6
6180383|NCT01325350|9830838|FG003|Overall Study|Personal Reasons|5
6180384|NCT01325350|9830839|FG004|Overall Study|Personal Reasons|3
6180385|NCT01325350|9830835|FG000|Overall Study|Protocol Violation|0
6180386|NCT01325350|9830836|FG001|Overall Study|Protocol Violation|0
6180387|NCT01325350|9830837|FG002|Overall Study|Protocol Violation|0
6180388|NCT01325350|9830838|FG003|Overall Study|Protocol Violation|1
6180389|NCT01325350|9830839|FG004|Overall Study|Protocol Violation|0
6180390|NCT01325350|9830835|FG000|Overall Study|Withdrawal by Subject|0
6180391|NCT01325350|9830836|FG001|Overall Study|Withdrawal by Subject|0
6180392|NCT01325350|9830837|FG002|Overall Study|Withdrawal by Subject|1
6180393|NCT01325350|9830838|FG003|Overall Study|Withdrawal by Subject|1
6180394|NCT01325350|9830839|FG004|Overall Study|Withdrawal by Subject|0
6180395|NCT01325350|9830835|FG000|Overall Study|Did Not Receive Treatment|0
6180396|NCT01325350|9830836|FG001|Overall Study|Did Not Receive Treatment|1
6180397|NCT01325350|9830837|FG002|Overall Study|Did Not Receive Treatment|1
6180398|NCT01325350|9830838|FG003|Overall Study|Did Not Receive Treatment|0
6180399|NCT01325350|9830839|FG004|Overall Study|Did Not Receive Treatment|1
6180400|NCT01325428|9830851|FG000|Part A|Progressive disease according to RECIST|9
6180401|NCT01325428|9830851|FG000|Part A|Clinical signs, symptoms of progression|2
6180402|NCT01325428|9830851|FG000|Part A|Other adverse event|1
6180403|NCT01325428|9830851|FG000|Part A|Refused continue taking trial medication|2
6180404|NCT01325428|9830851|FG000|Part A|Other reason not defined above|2
6180405|NCT01325428|9830851|FG000|Part B|Refused continue taking trial medication|2
6180406|NCT01325428|9830851|FG000|Part B|Other reason not defined above|1
6180407|NCT01325493|9830862|FG000|Overall Study|Protocol Violation|0
6180408|NCT01325493|9830863|FG001|Overall Study|Protocol Violation|1
6180409|NCT01325493|9830862|FG000|Overall Study|loss of neuromonitoring signals|0
6180410|NCT01325493|9830863|FG001|Overall Study|loss of neuromonitoring signals|2
6180411|NCT01325493|9830862|FG000|Overall Study|Allergy|1
6180412|NCT01325493|9830863|FG001|Overall Study|Allergy|0
6180413|NCT01325532|9830871|FG000|Overall Study|Withdrawal by Subject|2
6180414|NCT01325532|9830872|FG001|Overall Study|Withdrawal by Subject|0
6180415|NCT01325584|9830878|FG000|Overall Study|Death|1
6180416|NCT01325623|9830882|FG000|Overall Study|Withdrawal by Subject|3
6180417|NCT01325701|9830921|FG000|Overall Study|Adverse Event|12
6180418|NCT01325701|9830922|FG001|Overall Study|Adverse Event|0
6180419|NCT01325701|9830921|FG000|Overall Study|Protocol Violation|1
6180420|NCT01325701|9830922|FG001|Overall Study|Protocol Violation|0
6180421|NCT01325701|9830921|FG000|Overall Study|Physician Decision|2
6180422|NCT01325701|9830922|FG001|Overall Study|Physician Decision|2
6180423|NCT01325701|9830921|FG000|Overall Study|Withdrawal by Subject|2
6180424|NCT01325701|9830922|FG001|Overall Study|Withdrawal by Subject|1
6180425|NCT01325701|9830921|FG000|Overall Study|Rollerover Extension Study|4
6180426|NCT01325701|9830922|FG001|Overall Study|Rollerover Extension Study|0
6180427|NCT01326026|9830959|FG000|Overall Study|Adverse Event|4
6180428|NCT01326026|9830960|FG001|Overall Study|Adverse Event|3
6180429|NCT01326026|9830959|FG000|Overall Study|Withdrawal Criteria|5
6180430|NCT01326026|9830960|FG001|Overall Study|Withdrawal Criteria|7
6180431|NCT01326026|9830959|FG000|Overall Study|Other|3
6180432|NCT01326026|9830960|FG001|Overall Study|Other|3
6180433|NCT01326481|9830966|FG000|7.5 mg/kg TRC105, 1000 mg/m2 Cape|Adverse Event|1
6180434|NCT01326533|9830974|FG000|Overall Study|Lost to Follow-up|2
6180435|NCT01326533|9830975|FG001|Overall Study|Lost to Follow-up|0
6180436|NCT01326533|9830974|FG000|Overall Study|Withdrawal by Subject|1
6180437|NCT01326533|9830975|FG001|Overall Study|Withdrawal by Subject|0
6227790|NCT01719380|9900623|FG008|Overall Study|Participant/Guardian Decision|2
6227791|NCT01719380|9900624|FG009|Overall Study|Participant/Guardian Decision|2
6227792|NCT01719380|9900615|FG000|Overall Study|Physician Decision|0
6180438|NCT01326533|9830974|FG000|Overall Study|Adverse Event|1
6180439|NCT01326533|9830975|FG001|Overall Study|Adverse Event|0
6180440|NCT01326546|9830983|FG000|Overall Study|Lost to Follow-up|8
6180441|NCT01326546|9830984|FG001|Overall Study|Lost to Follow-up|7
6180442|NCT01326546|9830983|FG000|Overall Study|Protocol Violation|3
6180443|NCT01326546|9830984|FG001|Overall Study|Protocol Violation|4
6180444|NCT01326546|9830983|FG000|Overall Study|Pregnancy|0
6180445|NCT01326546|9830984|FG001|Overall Study|Pregnancy|1
6180446|NCT01326546|9830983|FG000|Overall Study|Adverse Event|1
6180447|NCT01326546|9830984|FG001|Overall Study|Adverse Event|0
6180448|NCT01326546|9830983|FG000|Overall Study|Withdrawal by Subject|5
6085327|NCT00651664|9694576|FG002|Overall Study|Reason not Specified|0
6180449|NCT01326546|9830984|FG001|Overall Study|Withdrawal by Subject|1
6180450|NCT01326702|9830997|FG000|Overall Study|Other|1
6180451|NCT01326702|9830998|FG001|Overall Study|Other|0
6180452|NCT01326702|9830999|FG002|Overall Study|Other|0
6180453|NCT01326702|9831000|FG003|Overall Study|Other|0
6180454|NCT01326702|9831001|FG004|Overall Study|Other|0
6180455|NCT01326702|9831002|FG005|Overall Study|Other|1
6180456|NCT01326702|9831003|FG006|Overall Study|Other|0
6180457|NCT01326702|9830997|FG000|Overall Study|progressive disease|1
6180458|NCT01326702|9830998|FG001|Overall Study|progressive disease|1
6180459|NCT01326702|9830999|FG002|Overall Study|progressive disease|3
6180460|NCT01326702|9831000|FG003|Overall Study|progressive disease|1
6180461|NCT01326702|9831001|FG004|Overall Study|progressive disease|3
6180462|NCT01326702|9831002|FG005|Overall Study|progressive disease|2
6180463|NCT01326702|9831003|FG006|Overall Study|progressive disease|3
6180464|NCT01326702|9830997|FG000|Overall Study|Death|0
6180465|NCT01326702|9830998|FG001|Overall Study|Death|1
6180466|NCT01326702|9830999|FG002|Overall Study|Death|0
6180467|NCT01326702|9831000|FG003|Overall Study|Death|0
6180468|NCT01326702|9831001|FG004|Overall Study|Death|0
6180469|NCT01326702|9831002|FG005|Overall Study|Death|0
6180470|NCT01326702|9831003|FG006|Overall Study|Death|0
6180471|NCT01326702|9830997|FG000|Overall Study|Adverse Event|0
6180472|NCT01326702|9830998|FG001|Overall Study|Adverse Event|0
6180473|NCT01326702|9830999|FG002|Overall Study|Adverse Event|1
6180474|NCT01326702|9831000|FG003|Overall Study|Adverse Event|1
6180475|NCT01326702|9831001|FG004|Overall Study|Adverse Event|0
6180476|NCT01326702|9831002|FG005|Overall Study|Adverse Event|3
6180477|NCT01326702|9831003|FG006|Overall Study|Adverse Event|1
6180478|NCT01326702|9830997|FG000|Overall Study|Withdrawal by Subject|0
6180479|NCT01326702|9830998|FG001|Overall Study|Withdrawal by Subject|0
6180480|NCT01326702|9830999|FG002|Overall Study|Withdrawal by Subject|1
6180481|NCT01326702|9831000|FG003|Overall Study|Withdrawal by Subject|0
6180482|NCT01326702|9831001|FG004|Overall Study|Withdrawal by Subject|1
6180483|NCT01326702|9831002|FG005|Overall Study|Withdrawal by Subject|1
6180484|NCT01326702|9831003|FG006|Overall Study|Withdrawal by Subject|3
6180485|NCT01326702|9830997|FG000|Overall Study|Not Treated|0
6180486|NCT01326702|9830998|FG001|Overall Study|Not Treated|0
6180487|NCT01326702|9830999|FG002|Overall Study|Not Treated|0
6180488|NCT01326702|9831000|FG003|Overall Study|Not Treated|1
6180489|NCT01326702|9831001|FG004|Overall Study|Not Treated|0
6180490|NCT01326702|9831002|FG005|Overall Study|Not Treated|1
6180491|NCT01326702|9831003|FG006|Overall Study|Not Treated|0
6180492|NCT01326728|9831024|FG000|Overall Study|Death|13
6180493|NCT01326728|9831025|FG001|Overall Study|Death|0
6180494|NCT01326728|9831024|FG000|Overall Study|Early closure of study|34
6180495|NCT01326728|9831025|FG001|Overall Study|Early closure of study|9
6180496|NCT01326910|9831049|FG000|Overall Study|Withdrawal by Subject|3
6180497|NCT01326910|9831050|FG001|Overall Study|Withdrawal by Subject|2
6180498|NCT01326910|9831049|FG000|Overall Study|Protocol Violation|1
6180499|NCT01326910|9831050|FG001|Overall Study|Protocol Violation|1
6180500|NCT01326962|9831056|FG000|Overall Study|Adverse Event|1
6180501|NCT01326962|9831056|FG000|Overall Study|Withdrawal by Subject|1
6180502|NCT01326962|9831056|FG000|Overall Study|Lost to Follow-up|3
6180503|NCT01326962|9831056|FG000|Overall Study|Other|2
6180504|NCT01327053|9831062|FG000|Overall Study|Adverse Event|23
6180505|NCT01327053|9831063|FG001|Overall Study|Adverse Event|57
6180506|NCT01327053|9831062|FG000|Overall Study|Patient/guardian decision|11
6180507|NCT01327053|9831063|FG001|Overall Study|Patient/guardian decision|35
6180508|NCT01327053|9831062|FG000|Overall Study|Physician Decision|10
6180509|NCT01327053|9831063|FG001|Overall Study|Physician Decision|14
6180510|NCT01327053|9831062|FG000|Overall Study|Death|1
6180511|NCT01327053|9831063|FG001|Overall Study|Death|5
6180512|NCT01327053|9831062|FG000|Overall Study|Lost to Follow-up|2
6180513|NCT01327053|9831063|FG001|Overall Study|Lost to Follow-up|4
6180514|NCT01327053|9831062|FG000|Overall Study|Non-compliance with study treatment|0
6180515|NCT01327053|9831063|FG001|Overall Study|Non-compliance with study treatment|5
6180516|NCT01327053|9831062|FG000|Overall Study|Study terminated by Sponsor|1
6180517|NCT01327053|9831063|FG001|Overall Study|Study terminated by Sponsor|3
6180518|NCT01327053|9831062|FG000|Overall Study|Progressive disease|31
6180519|NCT01327053|9831063|FG001|Overall Study|Progressive disease|26
6180520|NCT01327053|9831062|FG000|Overall Study|Protocol Violation|0
6180521|NCT01327053|9831063|FG001|Overall Study|Protocol Violation|1
6180522|NCT01327053|9831062|FG000|Overall Study|Untreated|0
6180523|NCT01327053|9831063|FG001|Overall Study|Untreated|1
6180524|NCT01327300|9831092|FG000|Washout (3 Weeks)|Withdrawal by Subject|1
6180525|NCT01327300|9831093|FG001|Washout (3 Weeks)|Withdrawal by Subject|0
6180526|NCT01327339|9831126|FG000|Overall Study|Protocol Violation|8
6180527|NCT01327482|9831130|FG000|Overall Study|Adverse Event|1
6180528|NCT01327495|9831140|FG000|Overall Study|Adverse Event|2
6180529|NCT01327495|9831141|FG001|Overall Study|Adverse Event|1
6180530|NCT01327495|9831142|FG002|Overall Study|Adverse Event|1
6180531|NCT01327495|9831143|FG003|Overall Study|Adverse Event|0
6180532|NCT01327495|9831144|FG004|Overall Study|Adverse Event|0
6180533|NCT01327495|9831145|FG005|Overall Study|Adverse Event|2
6180534|NCT01327495|9831140|FG000|Overall Study|Withdrawal by Subject|0
6180535|NCT01327495|9831141|FG001|Overall Study|Withdrawal by Subject|1
6180536|NCT01327495|9831142|FG002|Overall Study|Withdrawal by Subject|1
6180537|NCT01327495|9831143|FG003|Overall Study|Withdrawal by Subject|0
6180538|NCT01327495|9831144|FG004|Overall Study|Withdrawal by Subject|1
6180539|NCT01327495|9831145|FG005|Overall Study|Withdrawal by Subject|0
6180540|NCT01327495|9831140|FG000|Overall Study|Physician Decision|0
6180541|NCT01327495|9831141|FG001|Overall Study|Physician Decision|0
6180542|NCT01327495|9831142|FG002|Overall Study|Physician Decision|0
6180543|NCT01327495|9831143|FG003|Overall Study|Physician Decision|0
6180544|NCT01327495|9831144|FG004|Overall Study|Physician Decision|2
6180545|NCT01327495|9831145|FG005|Overall Study|Physician Decision|0
6180546|NCT01327547|9831176|FG000|Overall Study|Adverse Event|4
6180547|NCT01327547|9831177|FG001|Overall Study|Adverse Event|1
6180548|NCT01327547|9831176|FG000|Overall Study|Death|1
6180549|NCT01327547|9831177|FG001|Overall Study|Death|2
6180550|NCT01327547|9831176|FG000|Overall Study|Lost to Follow-up|6
6180551|NCT01327547|9831177|FG001|Overall Study|Lost to Follow-up|6
6180552|NCT01327547|9831176|FG000|Overall Study|Non-Compliance With Study Treatment|0
6180553|NCT01327547|9831177|FG001|Overall Study|Non-Compliance With Study Treatment|2
6180554|NCT01327547|9831176|FG000|Overall Study|Withdrawal by Subject|3
6180555|NCT01327547|9831177|FG001|Overall Study|Withdrawal by Subject|7
6180556|NCT01327547|9831176|FG000|Overall Study|Does Not Meet Entrance Criteria|2
6180557|NCT01327547|9831177|FG001|Overall Study|Does Not Meet Entrance Criteria|2
6180558|NCT01327547|9831176|FG000|Overall Study|Protocol Violation|1
6180559|NCT01327547|9831177|FG001|Overall Study|Protocol Violation|0
6180560|NCT01327547|9831176|FG000|Overall Study|Non-compliance due to alcohol intake|0
6180561|NCT01327547|9831177|FG001|Overall Study|Non-compliance due to alcohol intake|1
6180562|NCT01327547|9831176|FG000|Overall Study|Required prohibited medication|2
6180563|NCT01327547|9831177|FG001|Overall Study|Required prohibited medication|0
6180564|NCT01327547|9831176|FG000|Overall Study|Non-compliance with study procedures|1
6180565|NCT01327547|9831177|FG001|Overall Study|Non-compliance with study procedures|0
6180566|NCT01327547|9831176|FG000|Overall Study|By investigator in subject's interest|0
6180567|NCT01327547|9831177|FG001|Overall Study|By investigator in subject's interest|1
6180568|NCT01327573|9831194|FG000|Overall Study|Physician Decision|3
6180569|NCT01327573|9831195|FG001|Overall Study|Physician Decision|1
6180570|NCT01327599|9831202|FG000|Overall Study|Adverse Event|1
6180571|NCT01327599|9831202|FG000|Overall Study|Could Not Attend Visit|1
6180572|NCT01327599|9831202|FG000|Overall Study|Withdrawal of Consent|1
6180573|NCT01327612|9831213|FG000|Overall Study|Withdrawal by Subject|0
6180574|NCT01327612|9831214|FG001|Overall Study|Withdrawal by Subject|0
6180575|NCT01327612|9831215|FG002|Overall Study|Withdrawal by Subject|0
6180576|NCT01327612|9831216|FG003|Overall Study|Withdrawal by Subject|0
6180577|NCT01327612|9831217|FG004|Overall Study|Withdrawal by Subject|0
6180578|NCT01327612|9831218|FG005|Overall Study|Withdrawal by Subject|1
6180579|NCT01327612|9831219|FG006|Overall Study|Withdrawal by Subject|0
6180580|NCT01327612|9831213|FG000|Overall Study|Disease Progression|1
6180581|NCT01327612|9831214|FG001|Overall Study|Disease Progression|1
6180582|NCT01327612|9831215|FG002|Overall Study|Disease Progression|1
6180583|NCT01327612|9831216|FG003|Overall Study|Disease Progression|0
6180584|NCT01327612|9831217|FG004|Overall Study|Disease Progression|1
6180585|NCT01327612|9831218|FG005|Overall Study|Disease Progression|2
6180586|NCT01327612|9831219|FG006|Overall Study|Disease Progression|2
6180587|NCT01327612|9831213|FG000|Overall Study|Administrative Decision|0
6180588|NCT01327612|9831214|FG001|Overall Study|Administrative Decision|0
6180589|NCT01327612|9831215|FG002|Overall Study|Administrative Decision|0
6180590|NCT01327612|9831216|FG003|Overall Study|Administrative Decision|1
6180591|NCT01327612|9831217|FG004|Overall Study|Administrative Decision|0
6180592|NCT01327612|9831218|FG005|Overall Study|Administrative Decision|0
6180593|NCT01327612|9831219|FG006|Overall Study|Administrative Decision|0
6180594|NCT01327612|9831213|FG000|Overall Study|Death|0
6180595|NCT01327612|9831214|FG001|Overall Study|Death|0
6180596|NCT01327612|9831215|FG002|Overall Study|Death|0
6180597|NCT01327612|9831216|FG003|Overall Study|Death|0
6180598|NCT01327612|9831217|FG004|Overall Study|Death|1
6180599|NCT01327612|9831218|FG005|Overall Study|Death|0
6180600|NCT01327612|9831219|FG006|Overall Study|Death|0
6180601|NCT01327651|9831245|FG000|Self-administered Dosing Period|Lost to Follow-up|3
6180602|NCT01327651|9831246|FG001|Self-administered Dosing Period|Lost to Follow-up|2
6180603|NCT01327651|9831247|FG002|Self-administered Dosing Period|Lost to Follow-up|4
6180604|NCT01327651|9831248|FG003|Self-administered Dosing Period|Lost to Follow-up|2
6180605|NCT01327651|9831249|FG004|Self-administered Dosing Period|Lost to Follow-up|3
6180606|NCT01327651|9831250|FG005|Self-administered Dosing Period|Lost to Follow-up|0
6180607|NCT01327651|9831251|FG006|Self-administered Dosing Period|Lost to Follow-up|8
6180608|NCT01327651|9831252|FG007|Self-administered Dosing Period|Lost to Follow-up|9
6180609|NCT01327651|9831253|FG008|Self-administered Dosing Period|Lost to Follow-up|10
6180610|NCT01327651|9831245|FG000|Self-administered Dosing Period|Ineligible (retrospective result)|1
6180611|NCT01327651|9831246|FG001|Self-administered Dosing Period|Ineligible (retrospective result)|0
6180612|NCT01327651|9831247|FG002|Self-administered Dosing Period|Ineligible (retrospective result)|0
6180613|NCT01327651|9831248|FG003|Self-administered Dosing Period|Ineligible (retrospective result)|0
6180614|NCT01327651|9831249|FG004|Self-administered Dosing Period|Ineligible (retrospective result)|0
6180615|NCT01327651|9831250|FG005|Self-administered Dosing Period|Ineligible (retrospective result)|0
6180616|NCT01327651|9831251|FG006|Self-administered Dosing Period|Ineligible (retrospective result)|0
6180617|NCT01327651|9831252|FG007|Self-administered Dosing Period|Ineligible (retrospective result)|0
6180618|NCT01327651|9831253|FG008|Self-administered Dosing Period|Ineligible (retrospective result)|0
6180619|NCT01327651|9831245|FG000|Self-administered Dosing Period|Withdrawal by Subject|0
6180620|NCT01327651|9831246|FG001|Self-administered Dosing Period|Withdrawal by Subject|1
6180621|NCT01327651|9831247|FG002|Self-administered Dosing Period|Withdrawal by Subject|0
6180622|NCT01327651|9831248|FG003|Self-administered Dosing Period|Withdrawal by Subject|1
6180623|NCT01327651|9831249|FG004|Self-administered Dosing Period|Withdrawal by Subject|0
6180624|NCT01327651|9831250|FG005|Self-administered Dosing Period|Withdrawal by Subject|0
6180625|NCT01327651|9831251|FG006|Self-administered Dosing Period|Withdrawal by Subject|2
6192747|NCT01433978|9850337|FG000|Core Study|Study Terminated by Sponsor|6
6180626|NCT01327651|9831252|FG007|Self-administered Dosing Period|Withdrawal by Subject|1
6180627|NCT01327651|9831253|FG008|Self-administered Dosing Period|Withdrawal by Subject|1
6180628|NCT01327651|9831245|FG000|Post Study Follow-up|Lost to Follow-up|0
6180629|NCT01327651|9831246|FG001|Post Study Follow-up|Lost to Follow-up|1
6180630|NCT01327651|9831247|FG002|Post Study Follow-up|Lost to Follow-up|1
6180631|NCT01327651|9831248|FG003|Post Study Follow-up|Lost to Follow-up|0
6180632|NCT01327651|9831249|FG004|Post Study Follow-up|Lost to Follow-up|0
6180633|NCT01327651|9831250|FG005|Post Study Follow-up|Lost to Follow-up|0
6180634|NCT01327651|9831251|FG006|Post Study Follow-up|Lost to Follow-up|4
6180635|NCT01327651|9831252|FG007|Post Study Follow-up|Lost to Follow-up|1
6180636|NCT01327651|9831253|FG008|Post Study Follow-up|Lost to Follow-up|2
6180637|NCT01327703|9831303|FG000|Second Treatment Period|Adverse Event|1
6180638|NCT01327703|9831304|FG001|Second Treatment Period|Adverse Event|1
6180639|NCT01327703|9831303|FG000|Second Treatment Period|Protocol Violation|0
6180640|NCT01327703|9831304|FG001|Second Treatment Period|Protocol Violation|1
6180641|NCT01327846|9831317|FG000|Core Phase|Subject decision (vital status: missing)|1
6180642|NCT01327846|9831318|FG001|Core Phase|Subject decision (vital status: missing)|2
6180643|NCT01327846|9831319|FG002|Core Phase|Subject decision (vital status: missing)|2
6180644|NCT01327846|9831320|FG003|Core Phase|Subject decision (vital status: missing)|1
6180645|NCT01327846|9831317|FG000|Core Phase|Subject decision (vital stat: unkn)|0
6180646|NCT01327846|9831318|FG001|Core Phase|Subject decision (vital stat: unkn)|0
6180647|NCT01327846|9831319|FG002|Core Phase|Subject decision (vital stat: unkn)|3
6180648|NCT01327846|9831320|FG003|Core Phase|Subject decision (vital stat: unkn)|3
6180649|NCT01327846|9831317|FG000|Core Phase|Subject decision (vital stat: dead)|1
6180650|NCT01327846|9831318|FG001|Core Phase|Subject decision (vital stat: dead)|3
6180651|NCT01327846|9831319|FG002|Core Phase|Subject decision (vital stat: dead)|4
6180652|NCT01327846|9831320|FG003|Core Phase|Subject decision (vital stat: dead)|4
6180653|NCT01327846|9831317|FG000|Core Phase|Subject decision (vital stat: alive)|23
6180654|NCT01327846|9831318|FG001|Core Phase|Subject decision (vital stat: alive)|24
6180655|NCT01327846|9831319|FG002|Core Phase|Subject decision (vital stat: alive)|13
6180656|NCT01327846|9831320|FG003|Core Phase|Subject decision (vital stat: alive)|20
6180657|NCT01327846|9831317|FG000|Core Phase|Lost to Follow-up|3
6180658|NCT01327846|9831318|FG001|Core Phase|Lost to Follow-up|3
6180659|NCT01327846|9831319|FG002|Core Phase|Lost to Follow-up|4
6180660|NCT01327846|9831320|FG003|Core Phase|Lost to Follow-up|5
6180661|NCT01327846|9831317|FG000|Extension Phase|Study terminated by sponsor|1073
6180662|NCT01327846|9831318|FG001|Extension Phase|Study terminated by sponsor|1124
6180663|NCT01327846|9831319|FG002|Extension Phase|Study terminated by sponsor|1067
6180664|NCT01327846|9831320|FG003|Extension Phase|Study terminated by sponsor|1660
6180665|NCT01327846|9831317|FG000|Extension Phase|Withdrawal by Subject|20
6180666|NCT01327846|9831318|FG001|Extension Phase|Withdrawal by Subject|13
6180667|NCT01327846|9831319|FG002|Extension Phase|Withdrawal by Subject|19
6180668|NCT01327846|9831320|FG003|Extension Phase|Withdrawal by Subject|37
6180669|NCT01327846|9831317|FG000|Extension Phase|Lost to Follow-up|4
6180670|NCT01327846|9831318|FG001|Extension Phase|Lost to Follow-up|3
6180671|NCT01327846|9831319|FG002|Extension Phase|Lost to Follow-up|4
6180672|NCT01327846|9831320|FG003|Extension Phase|Lost to Follow-up|7
6180673|NCT01327846|9831317|FG000|Extension Phase|Technical Problems|2
6180674|NCT01327846|9831318|FG001|Extension Phase|Technical Problems|4
6180675|NCT01327846|9831319|FG002|Extension Phase|Technical Problems|2
6085328|NCT00651664|9694577|FG003|Overall Study|Reason not Specified|0
6180676|NCT01327846|9831320|FG003|Extension Phase|Technical Problems|2
6180677|NCT01327885|9831333|FG000|Overall Study|Disease progression-according to RECIST|173
6180678|NCT01327885|9831334|FG001|Overall Study|Disease progression-according to RECIST|165
6180679|NCT01327885|9831333|FG000|Overall Study|Clinical progression|24
6180680|NCT01327885|9831334|FG001|Overall Study|Clinical progression|27
6180681|NCT01327885|9831333|FG000|Overall Study|Adverse Event|14
6180682|NCT01327885|9831334|FG001|Overall Study|Adverse Event|10
6180683|NCT01327885|9831333|FG000|Overall Study|Subject choice|5
6180684|NCT01327885|9831334|FG001|Overall Study|Subject choice|10
6180685|NCT01327885|9831333|FG000|Overall Study|Other|8
6180686|NCT01327885|9831334|FG001|Overall Study|Other|6
6180687|NCT01327885|9831333|FG000|Overall Study|Withdrawal of consent from study|3
6180688|NCT01327885|9831334|FG001|Overall Study|Withdrawal of consent from study|4
6180689|NCT01327885|9831333|FG000|Overall Study|Not treated|1
6180690|NCT01327885|9831334|FG001|Overall Study|Not treated|1
6180691|NCT01327885|9831333|FG000|Overall Study|Administrative decision|0
6180692|NCT01327885|9831334|FG001|Overall Study|Administrative decision|1
6180693|NCT01328002|9831362|FG000|Open-Label Period|Inclusion/exclusion criteria not met|66
6227793|NCT01719380|9900616|FG001|Overall Study|Physician Decision|0
6180694|NCT01328002|9831363|FG001|Open-Label Period|Inclusion/exclusion criteria not met|0
6180695|NCT01328002|9831362|FG000|Open-Label Period|Adverse Event|8
6180696|NCT01328002|9831363|FG001|Open-Label Period|Adverse Event|0
6180697|NCT01328002|9831362|FG000|Open-Label Period|Lack of Efficacy|3
6180698|NCT01328002|9831363|FG001|Open-Label Period|Lack of Efficacy|0
6180699|NCT01328002|9831362|FG000|Open-Label Period|Protocol Violation|2
6180700|NCT01328002|9831363|FG001|Open-Label Period|Protocol Violation|0
6180701|NCT01328002|9831362|FG000|Open-Label Period|Withdrawal by Subject|9
6180702|NCT01328002|9831363|FG001|Open-Label Period|Withdrawal by Subject|0
6227794|NCT01719380|9900617|FG002|Overall Study|Physician Decision|2
6180703|NCT01328002|9831362|FG000|Open-Label Period|Lost to Follow-up|6
6180704|NCT01328002|9831363|FG001|Open-Label Period|Lost to Follow-up|0
6180705|NCT01328002|9831362|FG000|Open-Label Period|Other Reason|2
6180706|NCT01328002|9831363|FG001|Open-Label Period|Other Reason|0
6180707|NCT01328002|9831362|FG000|Double-Blind Period|Adverse Event|1
6180708|NCT01328002|9831363|FG001|Double-Blind Period|Adverse Event|0
6180709|NCT01328002|9831362|FG000|Double-Blind Period|Lack of Efficacy|1
6180710|NCT01328002|9831363|FG001|Double-Blind Period|Lack of Efficacy|0
6180711|NCT01328041|9831370|FG000|Overall Study|Adverse Event|7
6180712|NCT01328041|9831370|FG000|Overall Study|Lack of Efficacy|27
6180713|NCT01328041|9831370|FG000|Overall Study|Protocol Violation|7
6180714|NCT01328041|9831370|FG000|Overall Study|Lost to Follow-up|7
6180715|NCT01328041|9831370|FG000|Overall Study|Physician Decision|2
6180716|NCT01328041|9831370|FG000|Overall Study|Withdrawal by Subject|7
6180717|NCT01328054|9831374|FG000|Lapatinib on Day 3 and Day 4 (2 Days)|Adverse Event|0
6180718|NCT01328054|9831375|FG001|Lapatinib on Day 3 and Day 4 (2 Days)|Adverse Event|2
6180719|NCT01328054|9831374|FG000|Lapatinib on Day 3 and Day 4 (2 Days)|Physician Decision|0
6180720|NCT01328054|9831375|FG001|Lapatinib on Day 3 and Day 4 (2 Days)|Physician Decision|1
6180721|NCT01328054|9831374|FG000|Lapatinib on Day 3 and Day 4 (2 Days)|Withdrawal by Subject|0
6180722|NCT01328054|9831375|FG001|Lapatinib on Day 3 and Day 4 (2 Days)|Withdrawal by Subject|2
6180723|NCT01328080|9831387|FG000|Overall Study|Lost to Follow-up|5
6180724|NCT01328249|9831406|FG000|Overall Study|Adverse Event|3
6180725|NCT01328249|9831407|FG001|Overall Study|Adverse Event|0
6180726|NCT01328249|9831406|FG000|Overall Study|Disease progression|1
6180727|NCT01328249|9831407|FG001|Overall Study|Disease progression|0
6180728|NCT01328249|9831406|FG000|Overall Study|Withdrawal by Subject|1
6180729|NCT01328249|9831407|FG001|Overall Study|Withdrawal by Subject|1
6180730|NCT01328249|9831406|FG000|Overall Study|Moved before end of treatment visit|1
6180731|NCT01328249|9831407|FG001|Overall Study|Moved before end of treatment visit|0
6180732|NCT01328249|9831406|FG000|Overall Study|Subject choice|1
6180733|NCT01328249|9831407|FG001|Overall Study|Subject choice|1
6180734|NCT01328249|9831406|FG000|Overall Study|Protocol Violation|0
6180735|NCT01328249|9831407|FG001|Overall Study|Protocol Violation|1
6180736|NCT01328366|9831415|FG000|Overall Study|Death|1
6180737|NCT01328366|9831415|FG000|Overall Study|Withdrawal by Subject|2
6180738|NCT01328366|9831415|FG000|Overall Study|Lost to Follow-up|7
6180739|NCT01328431|9831443|FG000|Baseline|Protocol Violation|0
6180740|NCT01328431|9831444|FG001|Baseline|Protocol Violation|2
6180741|NCT01328431|9831443|FG000|1 Month (1M)|Lost to Follow-up|55
6180742|NCT01328431|9831444|FG001|1 Month (1M)|Lost to Follow-up|58
6180743|NCT01328431|9831443|FG000|3 Month (3M)|Death|2
6180744|NCT01328431|9831444|FG001|3 Month (3M)|Death|2
6180745|NCT01328431|9831443|FG000|3 Month (3M)|Lost to Follow-up|75
6180746|NCT01328431|9831444|FG001|3 Month (3M)|Lost to Follow-up|70
6180747|NCT01328431|9831443|FG000|12 Month (12M)|Death|2
6180748|NCT01328431|9831444|FG001|12 Month (12M)|Death|6
6180749|NCT01328431|9831443|FG000|12 Month (12M)|Lost to Follow-up|82
6180750|NCT01328431|9831444|FG001|12 Month (12M)|Lost to Follow-up|91
6180751|NCT01328444|9831450|FG000|Treatment Period 1 (12 Weeks)|Adverse Event|3
6180752|NCT01328444|9831451|FG001|Treatment Period 1 (12 Weeks)|Adverse Event|1
6180753|NCT01328444|9831452|FG002|Treatment Period 1 (12 Weeks)|Adverse Event|1
6180754|NCT01328444|9831453|FG003|Treatment Period 1 (12 Weeks)|Adverse Event|3
6180755|NCT01328444|9831454|FG004|Treatment Period 1 (12 Weeks)|Adverse Event|5
6180756|NCT01328444|9831455|FG005|Treatment Period 1 (12 Weeks)|Adverse Event|2
6180757|NCT01328444|9831450|FG000|Treatment Period 1 (12 Weeks)|Lack of Efficacy|6
6180758|NCT01328444|9831451|FG001|Treatment Period 1 (12 Weeks)|Lack of Efficacy|1
6180759|NCT01328444|9831452|FG002|Treatment Period 1 (12 Weeks)|Lack of Efficacy|1
6180760|NCT01328444|9831453|FG003|Treatment Period 1 (12 Weeks)|Lack of Efficacy|1
6180761|NCT01328444|9831454|FG004|Treatment Period 1 (12 Weeks)|Lack of Efficacy|6
6180762|NCT01328444|9831455|FG005|Treatment Period 1 (12 Weeks)|Lack of Efficacy|2
6180763|NCT01328444|9831450|FG000|Treatment Period 1 (12 Weeks)|Protocol Violation|0
6180764|NCT01328444|9831451|FG001|Treatment Period 1 (12 Weeks)|Protocol Violation|0
6180765|NCT01328444|9831452|FG002|Treatment Period 1 (12 Weeks)|Protocol Violation|0
6180766|NCT01328444|9831453|FG003|Treatment Period 1 (12 Weeks)|Protocol Violation|1
6180767|NCT01328444|9831454|FG004|Treatment Period 1 (12 Weeks)|Protocol Violation|0
6180768|NCT01328444|9831455|FG005|Treatment Period 1 (12 Weeks)|Protocol Violation|1
6180769|NCT01328444|9831450|FG000|Treatment Period 1 (12 Weeks)|Met Protocol- Defined Stopping Criteria|0
6180770|NCT01328444|9831451|FG001|Treatment Period 1 (12 Weeks)|Met Protocol- Defined Stopping Criteria|1
6180771|NCT01328444|9831452|FG002|Treatment Period 1 (12 Weeks)|Met Protocol- Defined Stopping Criteria|0
6180772|NCT01328444|9831453|FG003|Treatment Period 1 (12 Weeks)|Met Protocol- Defined Stopping Criteria|0
6180773|NCT01328444|9831454|FG004|Treatment Period 1 (12 Weeks)|Met Protocol- Defined Stopping Criteria|2
6180774|NCT01328444|9831455|FG005|Treatment Period 1 (12 Weeks)|Met Protocol- Defined Stopping Criteria|0
6180775|NCT01328444|9831450|FG000|Treatment Period 1 (12 Weeks)|Lost to Follow-up|2
6180776|NCT01328444|9831451|FG001|Treatment Period 1 (12 Weeks)|Lost to Follow-up|0
6180777|NCT01328444|9831452|FG002|Treatment Period 1 (12 Weeks)|Lost to Follow-up|0
6180778|NCT01328444|9831453|FG003|Treatment Period 1 (12 Weeks)|Lost to Follow-up|1
6180779|NCT01328444|9831454|FG004|Treatment Period 1 (12 Weeks)|Lost to Follow-up|0
6180780|NCT01328444|9831455|FG005|Treatment Period 1 (12 Weeks)|Lost to Follow-up|1
6192748|NCT01433978|9850338|FG001|Core Study|Study Terminated by Sponsor|9
6180781|NCT01328444|9831450|FG000|Treatment Period 1 (12 Weeks)|Withdrawal by Subject|0
6180782|NCT01328444|9831451|FG001|Treatment Period 1 (12 Weeks)|Withdrawal by Subject|2
6180783|NCT01328444|9831452|FG002|Treatment Period 1 (12 Weeks)|Withdrawal by Subject|1
6180784|NCT01328444|9831453|FG003|Treatment Period 1 (12 Weeks)|Withdrawal by Subject|2
6180785|NCT01328444|9831454|FG004|Treatment Period 1 (12 Weeks)|Withdrawal by Subject|1
6180786|NCT01328444|9831455|FG005|Treatment Period 1 (12 Weeks)|Withdrawal by Subject|0
6180787|NCT01328444|9831450|FG000|Washout Period (14 Days)|Adverse Event|1
6180788|NCT01328444|9831451|FG001|Washout Period (14 Days)|Adverse Event|1
6180789|NCT01328444|9831452|FG002|Washout Period (14 Days)|Adverse Event|0
6180790|NCT01328444|9831453|FG003|Washout Period (14 Days)|Adverse Event|1
6180791|NCT01328444|9831454|FG004|Washout Period (14 Days)|Adverse Event|1
6180792|NCT01328444|9831455|FG005|Washout Period (14 Days)|Adverse Event|2
6180793|NCT01328444|9831450|FG000|Washout Period (14 Days)|Lack of Efficacy|0
6180794|NCT01328444|9831451|FG001|Washout Period (14 Days)|Lack of Efficacy|0
6180795|NCT01328444|9831452|FG002|Washout Period (14 Days)|Lack of Efficacy|0
6180796|NCT01328444|9831453|FG003|Washout Period (14 Days)|Lack of Efficacy|0
6180797|NCT01328444|9831454|FG004|Washout Period (14 Days)|Lack of Efficacy|0
6180798|NCT01328444|9831455|FG005|Washout Period (14 Days)|Lack of Efficacy|1
6180799|NCT01328444|9831450|FG000|Washout Period (14 Days)|Withdrawal by Subject|0
6180800|NCT01328444|9831451|FG001|Washout Period (14 Days)|Withdrawal by Subject|0
6180801|NCT01328444|9831452|FG002|Washout Period (14 Days)|Withdrawal by Subject|0
6180802|NCT01328444|9831453|FG003|Washout Period (14 Days)|Withdrawal by Subject|0
6180803|NCT01328444|9831454|FG004|Washout Period (14 Days)|Withdrawal by Subject|0
6180804|NCT01328444|9831455|FG005|Washout Period (14 Days)|Withdrawal by Subject|1
6180805|NCT01328444|9831450|FG000|Treatment Period 2 (12 Weeks)|Adverse Event|5
6180806|NCT01328444|9831451|FG001|Treatment Period 2 (12 Weeks)|Adverse Event|0
6180807|NCT01328444|9831452|FG002|Treatment Period 2 (12 Weeks)|Adverse Event|1
6180808|NCT01328444|9831453|FG003|Treatment Period 2 (12 Weeks)|Adverse Event|1
6180809|NCT01328444|9831454|FG004|Treatment Period 2 (12 Weeks)|Adverse Event|1
6180810|NCT01328444|9831455|FG005|Treatment Period 2 (12 Weeks)|Adverse Event|0
6180811|NCT01328444|9831450|FG000|Treatment Period 2 (12 Weeks)|Lack of Efficacy|5
6180812|NCT01328444|9831451|FG001|Treatment Period 2 (12 Weeks)|Lack of Efficacy|1
6180813|NCT01328444|9831452|FG002|Treatment Period 2 (12 Weeks)|Lack of Efficacy|1
6180814|NCT01328444|9831453|FG003|Treatment Period 2 (12 Weeks)|Lack of Efficacy|2
6180815|NCT01328444|9831454|FG004|Treatment Period 2 (12 Weeks)|Lack of Efficacy|3
6180816|NCT01328444|9831455|FG005|Treatment Period 2 (12 Weeks)|Lack of Efficacy|4
6180817|NCT01328444|9831450|FG000|Treatment Period 2 (12 Weeks)|Protocol Violation|1
6180818|NCT01328444|9831451|FG001|Treatment Period 2 (12 Weeks)|Protocol Violation|0
6180819|NCT01328444|9831452|FG002|Treatment Period 2 (12 Weeks)|Protocol Violation|0
6180820|NCT01328444|9831453|FG003|Treatment Period 2 (12 Weeks)|Protocol Violation|0
6180821|NCT01328444|9831454|FG004|Treatment Period 2 (12 Weeks)|Protocol Violation|1
6180822|NCT01328444|9831455|FG005|Treatment Period 2 (12 Weeks)|Protocol Violation|0
6180823|NCT01328444|9831450|FG000|Treatment Period 2 (12 Weeks)|Met Protocol Defined Stopping Criteria|0
6180824|NCT01328444|9831451|FG001|Treatment Period 2 (12 Weeks)|Met Protocol Defined Stopping Criteria|0
6180825|NCT01328444|9831452|FG002|Treatment Period 2 (12 Weeks)|Met Protocol Defined Stopping Criteria|0
6180826|NCT01328444|9831453|FG003|Treatment Period 2 (12 Weeks)|Met Protocol Defined Stopping Criteria|1
6180827|NCT01328444|9831454|FG004|Treatment Period 2 (12 Weeks)|Met Protocol Defined Stopping Criteria|1
6180828|NCT01328444|9831455|FG005|Treatment Period 2 (12 Weeks)|Met Protocol Defined Stopping Criteria|0
6180829|NCT01328444|9831450|FG000|Treatment Period 2 (12 Weeks)|Lost to Follow-up|0
6180830|NCT01328444|9831451|FG001|Treatment Period 2 (12 Weeks)|Lost to Follow-up|0
6180831|NCT01328444|9831452|FG002|Treatment Period 2 (12 Weeks)|Lost to Follow-up|1
6180832|NCT01328444|9831453|FG003|Treatment Period 2 (12 Weeks)|Lost to Follow-up|1
6180833|NCT01328444|9831454|FG004|Treatment Period 2 (12 Weeks)|Lost to Follow-up|1
6180834|NCT01328444|9831455|FG005|Treatment Period 2 (12 Weeks)|Lost to Follow-up|2
6180835|NCT01328444|9831450|FG000|Treatment Period 2 (12 Weeks)|Withdrawal by Subject|0
6180836|NCT01328444|9831451|FG001|Treatment Period 2 (12 Weeks)|Withdrawal by Subject|0
6180837|NCT01328444|9831452|FG002|Treatment Period 2 (12 Weeks)|Withdrawal by Subject|0
6180838|NCT01328444|9831453|FG003|Treatment Period 2 (12 Weeks)|Withdrawal by Subject|0
6180839|NCT01328444|9831454|FG004|Treatment Period 2 (12 Weeks)|Withdrawal by Subject|1
6180840|NCT01328444|9831455|FG005|Treatment Period 2 (12 Weeks)|Withdrawal by Subject|1
6180841|NCT01328496|9831471|FG000|Overall Study|Significant Change in Health Status|1
6180842|NCT01328496|9831472|FG001|Overall Study|Significant Change in Health Status|0
6180843|NCT01328535|9831481|FG000|Overall Study|Ineligible|1
6180844|NCT01328548|9831489|FG000|Overall Study|Death|3
6180845|NCT01328548|9831490|FG001|Overall Study|Death|0
6180846|NCT01328548|9831489|FG000|Overall Study|Protocol Violation|1
6180847|NCT01328548|9831490|FG001|Overall Study|Protocol Violation|0
6180848|NCT01328574|9831496|FG000|Overall Study|Refused further treatment|1
6180849|NCT01328717|9831505|FG000|Overall Study|Adverse Event|1
6180850|NCT01328756|9831518|FG000|Overall Study|Protocol Violation|4
6180851|NCT01328756|9831518|FG000|Overall Study|Adverse Event|39
6180852|NCT01328756|9831518|FG000|Overall Study|Lack of Efficacy|5
6180853|NCT01328756|9831518|FG000|Overall Study|Withdrawal by Subject|41
6180854|NCT01328756|9831518|FG000|Overall Study|Lost to Follow-up|5
6180855|NCT01328756|9831518|FG000|Overall Study|Other|29
6180856|NCT01328951|9831552|FG000|Overall Study|Disease Progression|17
6180857|NCT01328951|9831553|FG001|Overall Study|Disease Progression|14
6180858|NCT01328951|9831552|FG000|Overall Study|Adverse Event|2
6180859|NCT01328951|9831553|FG001|Overall Study|Adverse Event|0
6180860|NCT01328951|9831552|FG000|Overall Study|Death|243
6180861|NCT01328951|9831553|FG001|Overall Study|Death|258
6180862|NCT01328951|9831552|FG000|Overall Study|Lost to Follow-up|6
6180863|NCT01328951|9831553|FG001|Overall Study|Lost to Follow-up|7
6180864|NCT01328951|9831552|FG000|Overall Study|Withdrawal by Subject|6
6180865|NCT01328951|9831553|FG001|Overall Study|Withdrawal by Subject|6
6180866|NCT01328951|9831552|FG000|Overall Study|Study Closed by the Sponsor|36
6180867|NCT01328951|9831553|FG001|Overall Study|Study Closed by the Sponsor|31
6180868|NCT01328951|9831552|FG000|Overall Study|Other|11
6180869|NCT01328951|9831553|FG001|Overall Study|Other|6
6180870|NCT01329029|9831578|FG000|Overall Study|Withdrawal by Subject|117
6180871|NCT01329029|9831579|FG001|Overall Study|Withdrawal by Subject|87
6180872|NCT01329029|9831578|FG000|Overall Study|Adverse Event|82
6180873|NCT01329029|9831579|FG001|Overall Study|Adverse Event|29
6180874|NCT01329029|9831578|FG000|Overall Study|Death|16
6180875|NCT01329029|9831579|FG001|Overall Study|Death|19
6180876|NCT01329029|9831578|FG000|Overall Study|Other|14
6180877|NCT01329029|9831579|FG001|Overall Study|Other|20
6180878|NCT01329029|9831578|FG000|Overall Study|COPD Exacerbation|11
6180879|NCT01329029|9831579|FG001|Overall Study|COPD Exacerbation|18
6227795|NCT01719380|9900618|FG003|Overall Study|Physician Decision|0
6227796|NCT01719380|9900619|FG004|Overall Study|Physician Decision|0
6227797|NCT01719380|9900620|FG005|Overall Study|Physician Decision|0
6227798|NCT01719380|9900621|FG006|Overall Study|Physician Decision|0
6227799|NCT01719380|9900622|FG007|Overall Study|Physician Decision|0
6227800|NCT01719380|9900623|FG008|Overall Study|Physician Decision|1
6227801|NCT01719380|9900624|FG009|Overall Study|Physician Decision|1
6227802|NCT01719380|9900615|FG000|Overall Study|Lack of Efficacy|2
6227803|NCT01719380|9900616|FG001|Overall Study|Lack of Efficacy|6
6227804|NCT01719380|9900617|FG002|Overall Study|Lack of Efficacy|5
6227805|NCT01719380|9900618|FG003|Overall Study|Lack of Efficacy|6
6227806|NCT01719380|9900619|FG004|Overall Study|Lack of Efficacy|3
6227807|NCT01719380|9900620|FG005|Overall Study|Lack of Efficacy|7
6227808|NCT01719380|9900621|FG006|Overall Study|Lack of Efficacy|10
6227809|NCT01719380|9900622|FG007|Overall Study|Lack of Efficacy|6
6227810|NCT01719380|9900623|FG008|Overall Study|Lack of Efficacy|39
6227811|NCT01719380|9900624|FG009|Overall Study|Lack of Efficacy|42
6227812|NCT01719380|9900615|FG000|Overall Study|Progressive Disease|0
6227813|NCT01719380|9900616|FG001|Overall Study|Progressive Disease|0
6227814|NCT01719380|9900617|FG002|Overall Study|Progressive Disease|0
6227815|NCT01719380|9900618|FG003|Overall Study|Progressive Disease|0
6227816|NCT01719380|9900619|FG004|Overall Study|Progressive Disease|0
6227817|NCT01719380|9900620|FG005|Overall Study|Progressive Disease|0
6227818|NCT01719380|9900621|FG006|Overall Study|Progressive Disease|0
6227819|NCT01719380|9900622|FG007|Overall Study|Progressive Disease|0
6227820|NCT01719380|9900623|FG008|Overall Study|Progressive Disease|1
6227821|NCT01719380|9900624|FG009|Overall Study|Progressive Disease|0
6227822|NCT01719757|9900678|FG000|Overall Study|Adverse Event|38
6227823|NCT01719757|9900678|FG000|Overall Study|Withdrawal by Subject|15
6227824|NCT01719757|9900678|FG000|Overall Study|Lost to Follow-up|20
6227825|NCT01719757|9900678|FG000|Overall Study|Protocol Violation|1
6227826|NCT01719757|9900678|FG000|Overall Study|well controlled pain|27
6227827|NCT01719783|9900686|FG000|Dose 2|Physician Decision|1
6227828|NCT01719783|9900687|FG001|Dose 2|Physician Decision|0
6227829|NCT01719861|9900713|FG000|Cycle 1|Death|4
6227830|NCT01719861|9900713|FG000|Cycle 2|Death|1
6227831|NCT01720043|9900727|FG000|Overall Study|Withdrawal by Subject|1
6227832|NCT01720069|9900734|FG000|Overall Study|Could not use e-diary correctly|0
6227833|NCT01720069|9900735|FG001|Overall Study|Could not use e-diary correctly|1
6227834|NCT01720069|9900736|FG002|Overall Study|Could not use e-diary correctly|1
6227835|NCT01720069|9900734|FG000|Overall Study|Randomised without baseline values|0
6227836|NCT01720069|9900735|FG001|Overall Study|Randomised without baseline values|0
6227837|NCT01720069|9900736|FG002|Overall Study|Randomised without baseline values|1
6227838|NCT01720069|9900734|FG000|Overall Study|Adverse Event|0
6227839|NCT01720069|9900735|FG001|Overall Study|Adverse Event|0
6227840|NCT01720069|9900736|FG002|Overall Study|Adverse Event|1
6227841|NCT01720069|9900734|FG000|Overall Study|Lack of Efficacy|0
6227842|NCT01720069|9900735|FG001|Overall Study|Lack of Efficacy|4
6227843|NCT01720069|9900736|FG002|Overall Study|Lack of Efficacy|0
6227844|NCT01720069|9900734|FG000|Overall Study|Treatment period withdrawal criteria met|4
6227845|NCT01720069|9900735|FG001|Overall Study|Treatment period withdrawal criteria met|8
6227846|NCT01720069|9900736|FG002|Overall Study|Treatment period withdrawal criteria met|9
6227847|NCT01720069|9900734|FG000|Overall Study|Withdrawal by Subject|0
6227848|NCT01720069|9900735|FG001|Overall Study|Withdrawal by Subject|2
6227849|NCT01720069|9900736|FG002|Overall Study|Withdrawal by Subject|1
6227850|NCT01720069|9900734|FG000|Overall Study|OCS bursts occured, discontinued in line|1
6227851|NCT01720069|9900735|FG001|Overall Study|OCS bursts occured, discontinued in line|0
6227852|NCT01720069|9900736|FG002|Overall Study|OCS bursts occured, discontinued in line|0
6227853|NCT01720069|9900734|FG000|Overall Study|Non-compliance on using e-diary|0
6180880|NCT01329029|9831578|FG000|Overall Study|Physician Decision|16
6180881|NCT01329029|9831579|FG001|Overall Study|Physician Decision|13
6227854|NCT01720069|9900735|FG001|Overall Study|Non-compliance on using e-diary|0
6180882|NCT01329029|9831578|FG000|Overall Study|Lost to Follow-up|8
6180883|NCT01329029|9831579|FG001|Overall Study|Lost to Follow-up|5
6180884|NCT01329029|9831578|FG000|Overall Study|Met Pre-defined Discontinuation Criteria|5
6180885|NCT01329029|9831579|FG001|Overall Study|Met Pre-defined Discontinuation Criteria|1
6180886|NCT01329263|9831610|FG000|Overall Study|Lost to Follow-up|4
6180887|NCT01329263|9831611|FG001|Overall Study|Lost to Follow-up|21
6180888|NCT01329263|9831610|FG000|Overall Study|Withdrawal by Subject|1
6180889|NCT01329263|9831611|FG001|Overall Study|Withdrawal by Subject|2
6180890|NCT01329328|9831622|FG000|Overall Study|Withdrawal by Subject|2
6180891|NCT01329328|9831623|FG001|Overall Study|Withdrawal by Subject|4
6180892|NCT01329328|9831624|FG002|Overall Study|Withdrawal by Subject|3
6180893|NCT01329419|9831636|FG000|Overall Study|Protocol Violation|235
6180894|NCT01329562|9831643|FG000|Overall Study|Protocol Violation|5
6180895|NCT01329562|9831644|FG001|Overall Study|Protocol Violation|3
6180896|NCT01329562|9831643|FG000|Overall Study|Lost to Follow-up|1
6180897|NCT01329562|9831644|FG001|Overall Study|Lost to Follow-up|1
6180898|NCT01329562|9831643|FG000|Overall Study|Subject withdrew due to personal issues.|3
6180899|NCT01329562|9831644|FG001|Overall Study|Subject withdrew due to personal issues.|2
6180900|NCT01329562|9831643|FG000|Overall Study|Physician Decision|0
6180901|NCT01329562|9831644|FG001|Overall Study|Physician Decision|1
6180902|NCT01329900|9831665|FG000|Overall Study|Elevated creatinine/renal function|1
6180903|NCT01329939|9831673|FG000|Overall Study|Lost to Follow-up|3
6180904|NCT01329939|9831674|FG001|Overall Study|Lost to Follow-up|0
6180905|NCT01329939|9831675|FG002|Overall Study|Lost to Follow-up|1
6180906|NCT01329939|9831676|FG003|Overall Study|Lost to Follow-up|2
6180907|NCT01329939|9831673|FG000|Overall Study|Withdrawal by Subject|0
6180908|NCT01329939|9831674|FG001|Overall Study|Withdrawal by Subject|1
6180909|NCT01329939|9831675|FG002|Overall Study|Withdrawal by Subject|0
6180910|NCT01329939|9831676|FG003|Overall Study|Withdrawal by Subject|0
6180911|NCT01329939|9831673|FG000|Overall Study|Adverse Event|0
6180912|NCT01329939|9831674|FG001|Overall Study|Adverse Event|0
6180913|NCT01329939|9831675|FG002|Overall Study|Adverse Event|0
6180914|NCT01329939|9831676|FG003|Overall Study|Adverse Event|3
6180915|NCT01329978|9831689|FG000|Sofosbuvir+PEG+RBV Treatment Period|Adverse Event|1
6180916|NCT01329978|9831690|FG001|Sofosbuvir+PEG+RBV Treatment Period|Adverse Event|2
6180917|NCT01329978|9831691|FG002|Sofosbuvir+PEG+RBV Treatment Period|Adverse Event|0
6180918|NCT01329978|9831692|FG003|Sofosbuvir+PEG+RBV Treatment Period|Adverse Event|0
6180919|NCT01329978|9831693|FG004|Sofosbuvir+PEG+RBV Treatment Period|Adverse Event|0
6180920|NCT01329978|9831689|FG000|Sofosbuvir+PEG+RBV Treatment Period|Lost to Follow-up|2
6180921|NCT01329978|9831690|FG001|Sofosbuvir+PEG+RBV Treatment Period|Lost to Follow-up|8
6180922|NCT01329978|9831691|FG002|Sofosbuvir+PEG+RBV Treatment Period|Lost to Follow-up|2
6180923|NCT01329978|9831692|FG003|Sofosbuvir+PEG+RBV Treatment Period|Lost to Follow-up|0
6180924|NCT01329978|9831693|FG004|Sofosbuvir+PEG+RBV Treatment Period|Lost to Follow-up|0
6180925|NCT01329978|9831689|FG000|Sofosbuvir+PEG+RBV Treatment Period|Withdrawal by Subject|1
6180926|NCT01329978|9831690|FG001|Sofosbuvir+PEG+RBV Treatment Period|Withdrawal by Subject|1
6180927|NCT01329978|9831691|FG002|Sofosbuvir+PEG+RBV Treatment Period|Withdrawal by Subject|3
6180928|NCT01329978|9831692|FG003|Sofosbuvir+PEG+RBV Treatment Period|Withdrawal by Subject|0
6180929|NCT01329978|9831693|FG004|Sofosbuvir+PEG+RBV Treatment Period|Withdrawal by Subject|0
6180930|NCT01329978|9831689|FG000|Sofosbuvir+PEG+RBV Treatment Period|Subject Was Incarcerated|0
6180931|NCT01329978|9831690|FG001|Sofosbuvir+PEG+RBV Treatment Period|Subject Was Incarcerated|1
6180932|NCT01329978|9831691|FG002|Sofosbuvir+PEG+RBV Treatment Period|Subject Was Incarcerated|0
6180933|NCT01329978|9831692|FG003|Sofosbuvir+PEG+RBV Treatment Period|Subject Was Incarcerated|0
6180934|NCT01329978|9831693|FG004|Sofosbuvir+PEG+RBV Treatment Period|Subject Was Incarcerated|0
6180935|NCT01329978|9831689|FG000|Sofosbuvir+PEG+RBV Treatment Period|Subject Moved Out of State|0
6180936|NCT01329978|9831690|FG001|Sofosbuvir+PEG+RBV Treatment Period|Subject Moved Out of State|1
6180937|NCT01329978|9831691|FG002|Sofosbuvir+PEG+RBV Treatment Period|Subject Moved Out of State|0
6180938|NCT01329978|9831692|FG003|Sofosbuvir+PEG+RBV Treatment Period|Subject Moved Out of State|0
6180939|NCT01329978|9831693|FG004|Sofosbuvir+PEG+RBV Treatment Period|Subject Moved Out of State|0
6180940|NCT01329978|9831689|FG000|Rerandomization Treatment Period|Lost to Follow-up|0
6180941|NCT01329978|9831690|FG001|Rerandomization Treatment Period|Lost to Follow-up|0
6180942|NCT01329978|9831691|FG002|Rerandomization Treatment Period|Lost to Follow-up|0
6180943|NCT01329978|9831692|FG003|Rerandomization Treatment Period|Lost to Follow-up|5
6180944|NCT01329978|9831693|FG004|Rerandomization Treatment Period|Lost to Follow-up|3
6180945|NCT01329978|9831689|FG000|Rerandomization Treatment Period|Withdrawal by Subject|0
6180946|NCT01329978|9831690|FG001|Rerandomization Treatment Period|Withdrawal by Subject|0
6180947|NCT01329978|9831691|FG002|Rerandomization Treatment Period|Withdrawal by Subject|0
6180948|NCT01329978|9831692|FG003|Rerandomization Treatment Period|Withdrawal by Subject|0
6180949|NCT01329978|9831693|FG004|Rerandomization Treatment Period|Withdrawal by Subject|1
6180950|NCT01330017|9831710|FG000|Overall Study|Adverse Event|0
6180951|NCT01330017|9831711|FG001|Overall Study|Adverse Event|1
6180952|NCT01330017|9831712|FG002|Overall Study|Adverse Event|1
6180953|NCT01330017|9831713|FG003|Overall Study|Adverse Event|4
6180954|NCT01330017|9831714|FG004|Overall Study|Adverse Event|0
6180955|NCT01330017|9831710|FG000|Overall Study|Withdrawal by Subject|0
6180956|NCT01330017|9831711|FG001|Overall Study|Withdrawal by Subject|0
6180957|NCT01330017|9831712|FG002|Overall Study|Withdrawal by Subject|1
6180958|NCT01330017|9831713|FG003|Overall Study|Withdrawal by Subject|0
6180959|NCT01330017|9831714|FG004|Overall Study|Withdrawal by Subject|1
6180960|NCT01330017|9831710|FG000|Overall Study|Lost to Follow-up|0
6180961|NCT01330017|9831711|FG001|Overall Study|Lost to Follow-up|0
6180962|NCT01330017|9831712|FG002|Overall Study|Lost to Follow-up|1
6180963|NCT01330017|9831713|FG003|Overall Study|Lost to Follow-up|0
6180964|NCT01330017|9831714|FG004|Overall Study|Lost to Follow-up|0
6180965|NCT01330017|9831710|FG000|Overall Study|Protocol Violation|0
6180966|NCT01330017|9831711|FG001|Overall Study|Protocol Violation|0
6180967|NCT01330017|9831712|FG002|Overall Study|Protocol Violation|0
6180968|NCT01330017|9831713|FG003|Overall Study|Protocol Violation|1
6180969|NCT01330017|9831714|FG004|Overall Study|Protocol Violation|0
6180970|NCT01330017|9831710|FG000|Overall Study|Unknown Reason|5
6180971|NCT01330017|9831711|FG001|Overall Study|Unknown Reason|3
6180972|NCT01330017|9831712|FG002|Overall Study|Unknown Reason|5
6180973|NCT01330017|9831713|FG003|Overall Study|Unknown Reason|7
6180974|NCT01330017|9831714|FG004|Overall Study|Unknown Reason|2
6180975|NCT01330030|9831728|FG000|Overall Study|Lost to Follow-up|16
6180976|NCT01330030|9831729|FG001|Overall Study|Lost to Follow-up|17
6180977|NCT01330108|9831744|FG000|Overall Study|Withdrawal by Subject|4
6180978|NCT01330303|9831761|FG000|Period 1|Adverse Event|1
6180979|NCT01330303|9831762|FG001|Period 1|Adverse Event|0
6180980|NCT01330303|9831761|FG000|Period 1|Protocol Violation|0
6180981|NCT01330303|9831762|FG001|Period 1|Protocol Violation|1
6180982|NCT01330303|9831761|FG000|Period 1|Withdrawal by Subject|0
6180983|NCT01330303|9831762|FG001|Period 1|Withdrawal by Subject|1
6180984|NCT01330316|9831771|FG000|Overall Study|Adverse Event|2
6180985|NCT01330316|9831772|FG001|Overall Study|Adverse Event|2
6180986|NCT01330316|9831771|FG000|Overall Study|Lack of Efficacy|0
6180987|NCT01330316|9831772|FG001|Overall Study|Lack of Efficacy|10
6180988|NCT01330316|9831771|FG000|Overall Study|Lost to Follow-up|0
6180989|NCT01330316|9831772|FG001|Overall Study|Lost to Follow-up|1
6180990|NCT01330316|9831771|FG000|Overall Study|Withdrawal by Subject|0
6180991|NCT01330316|9831772|FG001|Overall Study|Withdrawal by Subject|1
6180992|NCT01330316|9831771|FG000|Overall Study|other than above|0
6180993|NCT01330316|9831772|FG001|Overall Study|other than above|1
6180994|NCT01330381|9831789|FG000|Double-blind Treatment Period (8 Weeks)|Withdrawal by Subject|5
6180995|NCT01330381|9831790|FG001|Double-blind Treatment Period (8 Weeks)|Withdrawal by Subject|4
6180996|NCT01330381|9831791|FG002|Double-blind Treatment Period (8 Weeks)|Withdrawal by Subject|0
6180997|NCT01330381|9831789|FG000|Double-blind Treatment Period (8 Weeks)|Non-compliance|2
6180998|NCT01330381|9831790|FG001|Double-blind Treatment Period (8 Weeks)|Non-compliance|1
6180999|NCT01330381|9831791|FG002|Double-blind Treatment Period (8 Weeks)|Non-compliance|0
6181000|NCT01330381|9831789|FG000|Double-blind Treatment Period (8 Weeks)|Adverse Event|1
6181001|NCT01330381|9831790|FG001|Double-blind Treatment Period (8 Weeks)|Adverse Event|1
6181002|NCT01330381|9831791|FG002|Double-blind Treatment Period (8 Weeks)|Adverse Event|0
6181003|NCT01330381|9831789|FG000|Double-blind Treatment Period (8 Weeks)|Lost to Follow-up|1
6181004|NCT01330381|9831790|FG001|Double-blind Treatment Period (8 Weeks)|Lost to Follow-up|0
6181005|NCT01330381|9831791|FG002|Double-blind Treatment Period (8 Weeks)|Lost to Follow-up|0
6181006|NCT01330381|9831789|FG000|Double-blind Treatment Period (8 Weeks)|Did not fulfill inclusion/exclusion|1
6181007|NCT01330381|9831790|FG001|Double-blind Treatment Period (8 Weeks)|Did not fulfill inclusion/exclusion|0
6181008|NCT01330381|9831791|FG002|Double-blind Treatment Period (8 Weeks)|Did not fulfill inclusion/exclusion|0
6181009|NCT01330381|9831789|FG000|Double-blind Treatment Period (8 Weeks)|Lack of Efficacy|1
6181010|NCT01330381|9831790|FG001|Double-blind Treatment Period (8 Weeks)|Lack of Efficacy|1
6181011|NCT01330381|9831791|FG002|Double-blind Treatment Period (8 Weeks)|Lack of Efficacy|0
6181012|NCT01330381|9831789|FG000|Open-label Treatment Period (16 Weeks)|Withdrawal by Subject|7
6181013|NCT01330381|9831790|FG001|Open-label Treatment Period (16 Weeks)|Withdrawal by Subject|0
6181014|NCT01330381|9831791|FG002|Open-label Treatment Period (16 Weeks)|Withdrawal by Subject|16
6181015|NCT01330381|9831789|FG000|Open-label Treatment Period (16 Weeks)|Adverse Event|2
6181016|NCT01330381|9831790|FG001|Open-label Treatment Period (16 Weeks)|Adverse Event|0
6181017|NCT01330381|9831791|FG002|Open-label Treatment Period (16 Weeks)|Adverse Event|0
6181018|NCT01330381|9831789|FG000|Open-label Treatment Period (16 Weeks)|Sponsor's decision|1
6181019|NCT01330381|9831790|FG001|Open-label Treatment Period (16 Weeks)|Sponsor's decision|0
6181020|NCT01330381|9831791|FG002|Open-label Treatment Period (16 Weeks)|Sponsor's decision|1
6181021|NCT01330381|9831789|FG000|Open-label Treatment Period (16 Weeks)|Non-compliance|0
6181022|NCT01330381|9831790|FG001|Open-label Treatment Period (16 Weeks)|Non-compliance|0
6181023|NCT01330381|9831791|FG002|Open-label Treatment Period (16 Weeks)|Non-compliance|1
6192749|NCT01433978|9850339|FG002|Core Study|Study Terminated by Sponsor|0
6192750|NCT01433978|9850337|FG000|Extension Phase|Adverse Event, Non-Fatal|0
6192751|NCT01433978|9850338|FG001|Extension Phase|Adverse Event, Non-Fatal|0
6192752|NCT01433978|9850339|FG002|Extension Phase|Adverse Event, Non-Fatal|1
6192753|NCT01433978|9850337|FG000|Extension Phase|Lack of Efficacy|0
6192754|NCT01433978|9850338|FG001|Extension Phase|Lack of Efficacy|0
6192755|NCT01433978|9850339|FG002|Extension Phase|Lack of Efficacy|1
6192756|NCT01433978|9850337|FG000|Extension Phase|Study Terminated by Sponsor|0
6192757|NCT01433978|9850338|FG001|Extension Phase|Study Terminated by Sponsor|0
6192758|NCT01433978|9850339|FG002|Extension Phase|Study Terminated by Sponsor|4
6192759|NCT01433991|9850350|FG000|Pretreatment Phase (Single Agent Run-in)|Did not enter into treatment phase|2
6181024|NCT01330433|9831815|FG000|Overall Study|Death|1
6181025|NCT01330433|9831816|FG001|Overall Study|Death|3
6181026|NCT01330433|9831815|FG000|Overall Study|Lost to Follow-up|1
6181027|NCT01330433|9831816|FG001|Overall Study|Lost to Follow-up|0
6181028|NCT01330459|9831824|FG000|Overall Study|Physician Decision|0
6181029|NCT01330459|9831825|FG001|Overall Study|Physician Decision|2
6181030|NCT01330628|9831835|FG000|Overall Study|Death|2
6181031|NCT01330628|9831836|FG001|Overall Study|Death|3
6181032|NCT01330628|9831835|FG000|Overall Study|Lost to Follow-up|5
6181033|NCT01330628|9831836|FG001|Overall Study|Lost to Follow-up|6
6181034|NCT01330628|9831835|FG000|Overall Study|Adverse Event|44
6181035|NCT01330628|9831836|FG001|Overall Study|Adverse Event|25
6181036|NCT01330628|9831835|FG000|Overall Study|Withdrawn|18
6181037|NCT01330628|9831836|FG001|Overall Study|Withdrawn|6
6181038|NCT01330628|9831835|FG000|Overall Study|Didn't receive study treatment|1
6181039|NCT01330628|9831836|FG001|Overall Study|Didn't receive study treatment|0
6181040|NCT01330914|9831842|FG000|Overall Study|Withdrawal by Subject|4
6181041|NCT01330914|9831842|FG000|Overall Study|No longer eligible (sleeve gastrectomy)|3
6181042|NCT01331005|9831878|FG000|Overall Study|Lost to Follow-up|2
6181043|NCT01331005|9831879|FG001|Overall Study|Lost to Follow-up|1
6181044|NCT01331005|9831878|FG000|Overall Study|Withdrawal by Subject|2
6181045|NCT01331005|9831879|FG001|Overall Study|Withdrawal by Subject|3
6181046|NCT01331109|9831894|FG000|Overall Study|Adverse Event|6
6181047|NCT01331109|9831894|FG000|Overall Study|Lack of Efficacy|2
6181048|NCT01331109|9831894|FG000|Overall Study|Protocol Violation|3
6181049|NCT01331109|9831894|FG000|Overall Study|Withdrawal by Subject|7
6181050|NCT01331109|9831894|FG000|Overall Study|Lost to Follow-up|1
6181051|NCT01331109|9831894|FG000|Overall Study|Study Terminated by Sponsor|38
6181052|NCT01331161|9831900|FG000|Overall Study|Physician Decision|1
6181053|NCT01331161|9831901|FG001|Overall Study|Physician Decision|0
6181054|NCT01331161|9831900|FG000|Overall Study|Lost to Follow-up|0
6181055|NCT01331161|9831901|FG001|Overall Study|Lost to Follow-up|1
6181056|NCT01331161|9831900|FG000|Overall Study|Pregnancy|0
6181057|NCT01331161|9831901|FG001|Overall Study|Pregnancy|1
6181058|NCT01331239|9831920|FG000|Part II: Core Study|Adverse Event|0
6181059|NCT01331239|9831921|FG001|Part II: Core Study|Adverse Event|3
6181060|NCT01331239|9831922|FG002|Part II: Core Study|Adverse Event|0
6181061|NCT01331239|9831920|FG000|Part II: Core Study|Subj's cond. no longer require treatment|0
6181062|NCT01331239|9831921|FG001|Part II: Core Study|Subj's cond. no longer require treatment|2
6181063|NCT01331239|9831922|FG002|Part II: Core Study|Subj's cond. no longer require treatment|1
6181064|NCT01331239|9831920|FG000|Part II: Core Study|Withdrawal by Subject|0
6181065|NCT01331239|9831921|FG001|Part II: Core Study|Withdrawal by Subject|2
6181066|NCT01331239|9831922|FG002|Part II: Core Study|Withdrawal by Subject|0
6375382|NCT03877926|10165417|FG002|Overall Study|Adverse Event|0
6375383|NCT03877926|10165418|FG003|Overall Study|Adverse Event|0
6181067|NCT01331239|9831920|FG000|Part II: Core Study|Administrative problems|0
6181068|NCT01331239|9831921|FG001|Part II: Core Study|Administrative problems|1
6181069|NCT01331239|9831922|FG002|Part II: Core Study|Administrative problems|0
6181070|NCT01331291|9831940|FG000|Overall Study|Lack of Efficacy|2
6181071|NCT01331291|9831941|FG001|Overall Study|Lack of Efficacy|8
6181072|NCT01331291|9831940|FG000|Overall Study|Death|0
6181073|NCT01331291|9831941|FG001|Overall Study|Death|1
6181074|NCT01331681|9831963|FG000|Overall Study|Adverse Event|10
6181075|NCT01331681|9831964|FG001|Overall Study|Adverse Event|13
6181076|NCT01331681|9831965|FG002|Overall Study|Adverse Event|10
6181077|NCT01331681|9831963|FG000|Overall Study|Death|6
6181078|NCT01331681|9831964|FG001|Overall Study|Death|6
6181079|NCT01331681|9831965|FG002|Overall Study|Death|2
6181080|NCT01331681|9831963|FG000|Overall Study|Lack of Efficacy|0
6181081|NCT01331681|9831964|FG001|Overall Study|Lack of Efficacy|1
6181082|NCT01331681|9831965|FG002|Overall Study|Lack of Efficacy|0
6181083|NCT01331681|9831963|FG000|Overall Study|Withdrawal by Subject|12
6181084|NCT01331681|9831964|FG001|Overall Study|Withdrawal by Subject|8
6181085|NCT01331681|9831965|FG002|Overall Study|Withdrawal by Subject|15
6181086|NCT01331681|9831963|FG000|Overall Study|Protocol Violation|1
6181087|NCT01331681|9831964|FG001|Overall Study|Protocol Violation|1
6181088|NCT01331681|9831965|FG002|Overall Study|Protocol Violation|0
6181089|NCT01331681|9831963|FG000|Overall Study|Lost to Follow-up|2
6181090|NCT01331681|9831964|FG001|Overall Study|Lost to Follow-up|4
6181091|NCT01331681|9831965|FG002|Overall Study|Lost to Follow-up|1
6181092|NCT01331681|9831963|FG000|Overall Study|Physician Decision|2
6181093|NCT01331681|9831964|FG001|Overall Study|Physician Decision|0
6181094|NCT01331681|9831965|FG002|Overall Study|Physician Decision|4
6181095|NCT01331681|9831963|FG000|Overall Study|Therapeutic procedure required|1
6181096|NCT01331681|9831964|FG001|Overall Study|Therapeutic procedure required|0
6181097|NCT01331681|9831965|FG002|Overall Study|Therapeutic procedure required|0
6181098|NCT01331681|9831963|FG000|Overall Study|Sponsor decision|1
6181099|NCT01331681|9831964|FG001|Overall Study|Sponsor decision|1
6181100|NCT01331681|9831965|FG002|Overall Study|Sponsor decision|0
6181101|NCT01331681|9831963|FG000|Overall Study|Switching to other therapy|0
6181102|NCT01331681|9831964|FG001|Overall Study|Switching to other therapy|0
6181103|NCT01331681|9831965|FG002|Overall Study|Switching to other therapy|1
6181104|NCT01331681|9831963|FG000|Overall Study|Not Received Study Treatment|0
6181105|NCT01331681|9831964|FG001|Overall Study|Not Received Study Treatment|0
6181106|NCT01331681|9831965|FG002|Overall Study|Not Received Study Treatment|2
6181107|NCT01331824|9831998|FG000|Overall Study|Adverse Event|2
6181108|NCT01331824|9831998|FG000|Overall Study|Death|1
6181109|NCT01331824|9831998|FG000|Overall Study|Disease Progression|9
6181110|NCT01331824|9831998|FG000|Overall Study|Withdrawal by Subject|1
6181111|NCT01331837|9832004|FG000|Overall Study|Death|30
6181112|NCT01331837|9832005|FG001|Overall Study|Death|34
6181113|NCT01331837|9832004|FG000|Overall Study|Lost to Follow-up|3
6181114|NCT01331837|9832005|FG001|Overall Study|Lost to Follow-up|1
6181115|NCT01331837|9832004|FG000|Overall Study|Info not recorded|10
6181116|NCT01331837|9832005|FG001|Overall Study|Info not recorded|16
6181117|NCT01331837|9832004|FG000|Overall Study|Withdrawal by Subject|13
6181118|NCT01331837|9832005|FG001|Overall Study|Withdrawal by Subject|16
6181119|NCT01332019|9832013|FG000|Overall Study|Was Not Dosed|1
6181120|NCT01332019|9832014|FG001|Overall Study|Was Not Dosed|0
6181121|NCT01332019|9832013|FG000|Overall Study|Other|16
6181122|NCT01332019|9832014|FG001|Overall Study|Other|18
6181123|NCT01332019|9832013|FG000|Overall Study|Death|2
6181124|NCT01332019|9832014|FG001|Overall Study|Death|1
6181125|NCT01332019|9832013|FG000|Overall Study|Physician Decision|4
6181126|NCT01332019|9832014|FG001|Overall Study|Physician Decision|3
6181127|NCT01332019|9832013|FG000|Overall Study|Withdrawal by Subject|73
6181128|NCT01332019|9832014|FG001|Overall Study|Withdrawal by Subject|71
6181129|NCT01332019|9832013|FG000|Overall Study|Lost to Follow-up|4
6181130|NCT01332019|9832014|FG001|Overall Study|Lost to Follow-up|7
6181131|NCT01332019|9832013|FG000|Overall Study|Adverse Event|13
6181132|NCT01332019|9832014|FG001|Overall Study|Adverse Event|22
6181133|NCT01332149|9832036|FG000|Overall Study|Adverse Event|11
6181134|NCT01332149|9832037|FG001|Overall Study|Adverse Event|9
6181135|NCT01332149|9832036|FG000|Overall Study|Other unspecified|5
6181136|NCT01332149|9832037|FG001|Overall Study|Other unspecified|7
6181137|NCT01332149|9832036|FG000|Overall Study|Protocol Violation|1
6181138|NCT01332149|9832037|FG001|Overall Study|Protocol Violation|3
6181139|NCT01332149|9832036|FG000|Overall Study|Withdrawal by Subject|4
6181140|NCT01332149|9832037|FG001|Overall Study|Withdrawal by Subject|5
6181141|NCT01332149|9832036|FG000|Overall Study|Lost to Follow-up|1
6181142|NCT01332149|9832037|FG001|Overall Study|Lost to Follow-up|1
6181143|NCT01332149|9832036|FG000|Overall Study|Insufficient clinical response|4
6181144|NCT01332149|9832037|FG001|Overall Study|Insufficient clinical response|7
6181145|NCT01332149|9832036|FG000|Overall Study|Did not meet entrance criteria|3
6181146|NCT01332149|9832037|FG001|Overall Study|Did not meet entrance criteria|4
6181147|NCT01332149|9832036|FG000|Overall Study|Randomized but not treated|1
6181148|NCT01332149|9832037|FG001|Overall Study|Randomized but not treated|2
6181149|NCT01332227|9832062|FG000|Overall Study|Adverse Event|4
6181150|NCT01332227|9832063|FG001|Overall Study|Adverse Event|1
6181151|NCT01332227|9832062|FG000|Overall Study|Withdrawal by Subject|5
6181152|NCT01332227|9832063|FG001|Overall Study|Withdrawal by Subject|1
6181153|NCT01332227|9832062|FG000|Overall Study|Lost to Follow-up|2
6181154|NCT01332227|9832063|FG001|Overall Study|Lost to Follow-up|0
6181155|NCT01332227|9832062|FG000|Overall Study|Lack of Efficacy|3
6181156|NCT01332227|9832063|FG001|Overall Study|Lack of Efficacy|1
6181157|NCT01332227|9832062|FG000|Overall Study|Poor compliance/noncompliance|1
6181158|NCT01332227|9832063|FG001|Overall Study|Poor compliance/noncompliance|1
6181159|NCT01332227|9832062|FG000|Overall Study|Patient moved from area|1
6181160|NCT01332227|9832063|FG001|Overall Study|Patient moved from area|0
6181161|NCT01332227|9832062|FG000|Overall Study|Patient began prohibited medication|0
6181162|NCT01332227|9832063|FG001|Overall Study|Patient began prohibited medication|1
6181163|NCT01332292|9832078|FG000|Treatment Period 1 (14 Days)|Adverse Event|1
6181164|NCT01332292|9832079|FG001|Treatment Period 1 (14 Days)|Adverse Event|0
6181165|NCT01332292|9832078|FG000|Treatment Period 1 (14 Days)|Protocol Violation|1
6181166|NCT01332292|9832079|FG001|Treatment Period 1 (14 Days)|Protocol Violation|1
6181167|NCT01332292|9832078|FG000|Treatment Period 2 (14 Days)|Physician Decision|1
6181168|NCT01332292|9832079|FG001|Treatment Period 2 (14 Days)|Physician Decision|1
6181169|NCT01332305|9832092|FG000|Overall Study|Adverse Event|1
6181170|NCT01332305|9832093|FG001|Overall Study|Adverse Event|4
6181171|NCT01332305|9832094|FG002|Overall Study|Adverse Event|6
6181172|NCT01332305|9832095|FG003|Overall Study|Adverse Event|3
6181173|NCT01332305|9832096|FG004|Overall Study|Adverse Event|5
6181174|NCT01332305|9832092|FG000|Overall Study|Withdrawal by Subject|6
6181175|NCT01332305|9832093|FG001|Overall Study|Withdrawal by Subject|5
6181176|NCT01332305|9832094|FG002|Overall Study|Withdrawal by Subject|4
6181177|NCT01332305|9832095|FG003|Overall Study|Withdrawal by Subject|1
6181178|NCT01332305|9832096|FG004|Overall Study|Withdrawal by Subject|0
6181179|NCT01332305|9832092|FG000|Overall Study|Lost to Follow-up|0
6181180|NCT01332305|9832093|FG001|Overall Study|Lost to Follow-up|2
6181181|NCT01332305|9832094|FG002|Overall Study|Lost to Follow-up|3
6181182|NCT01332305|9832095|FG003|Overall Study|Lost to Follow-up|2
6181183|NCT01332305|9832096|FG004|Overall Study|Lost to Follow-up|3
6181184|NCT01332305|9832092|FG000|Overall Study|Protocol Violation|1
6181185|NCT01332305|9832093|FG001|Overall Study|Protocol Violation|2
6181186|NCT01332305|9832094|FG002|Overall Study|Protocol Violation|1
6181187|NCT01332305|9832095|FG003|Overall Study|Protocol Violation|0
6181188|NCT01332305|9832096|FG004|Overall Study|Protocol Violation|3
6181189|NCT01332305|9832092|FG000|Overall Study|Withdrawal by Sponsor|1
6181190|NCT01332305|9832093|FG001|Overall Study|Withdrawal by Sponsor|0
6181191|NCT01332305|9832094|FG002|Overall Study|Withdrawal by Sponsor|0
6181192|NCT01332305|9832095|FG003|Overall Study|Withdrawal by Sponsor|1
6181193|NCT01332305|9832096|FG004|Overall Study|Withdrawal by Sponsor|1
6181194|NCT01332305|9832092|FG000|Overall Study|Treatment Failure|1
6181195|NCT01332305|9832093|FG001|Overall Study|Treatment Failure|1
6181196|NCT01332305|9832094|FG002|Overall Study|Treatment Failure|0
6181197|NCT01332305|9832095|FG003|Overall Study|Treatment Failure|0
6181198|NCT01332305|9832096|FG004|Overall Study|Treatment Failure|0
6181199|NCT01332305|9832092|FG000|Overall Study|Physician Decision|0
6181200|NCT01332305|9832093|FG001|Overall Study|Physician Decision|0
6181201|NCT01332305|9832094|FG002|Overall Study|Physician Decision|0
6181202|NCT01332305|9832095|FG003|Overall Study|Physician Decision|1
6181203|NCT01332305|9832096|FG004|Overall Study|Physician Decision|0
6181204|NCT01332318|9832112|FG000|Overall Study|Adverse Event|0
6181205|NCT01332318|9832113|FG001|Overall Study|Adverse Event|3
6181206|NCT01332318|9832114|FG002|Overall Study|Adverse Event|0
6181207|NCT01332318|9832115|FG003|Overall Study|Adverse Event|0
6181208|NCT01332318|9832112|FG000|Overall Study|Withdrawal by Subject|1
6181209|NCT01332318|9832113|FG001|Overall Study|Withdrawal by Subject|1
6181210|NCT01332318|9832114|FG002|Overall Study|Withdrawal by Subject|0
6181211|NCT01332318|9832115|FG003|Overall Study|Withdrawal by Subject|1
6181212|NCT01332318|9832112|FG000|Overall Study|Protocol Violation|1
6181213|NCT01332318|9832113|FG001|Overall Study|Protocol Violation|0
6181214|NCT01332318|9832114|FG002|Overall Study|Protocol Violation|1
6181215|NCT01332318|9832115|FG003|Overall Study|Protocol Violation|1
6181216|NCT01332331|9832128|FG000|Overall Study|Lost to Follow-up|0
6181217|NCT01332331|9832129|FG001|Overall Study|Lost to Follow-up|1
6181218|NCT01332331|9832128|FG000|Overall Study|Adverse Event|1
6181219|NCT01332331|9832129|FG001|Overall Study|Adverse Event|1
6181220|NCT01332331|9832128|FG000|Overall Study|Physician Decision|1
6181221|NCT01332331|9832129|FG001|Overall Study|Physician Decision|0
6181222|NCT01332630|9832201|FG000|Overall Study|Withdrawal by Subject|3
6181223|NCT01332851|9832211|FG000|Overall Study|Withdrawal by Subject|4
6181224|NCT01332851|9832212|FG001|Overall Study|Withdrawal by Subject|2
6181225|NCT01332851|9832211|FG000|Overall Study|Lost to Follow-up|7
6181226|NCT01332851|9832212|FG001|Overall Study|Lost to Follow-up|11
6181227|NCT01332994|9832229|FG000|Overall Study|Adverse Event|34
6181228|NCT01332994|9832229|FG000|Overall Study|Death|1
6181229|NCT01332994|9832229|FG000|Overall Study|Lack of Efficacy|1
6181230|NCT01332994|9832229|FG000|Overall Study|Lost to Follow-up|4
6181231|NCT01332994|9832229|FG000|Overall Study|Protocol Violation|6
6181232|NCT01332994|9832229|FG000|Overall Study|Withdrawal by Subject|15
6181233|NCT01332994|9832229|FG000|Overall Study|Administrative Problem|2
6181234|NCT01332994|9832229|FG000|Overall Study|Other|8
6181235|NCT01333033|9832235|FG000|Overall Study|Ineligible|0
6181236|NCT01333033|9832236|FG001|Overall Study|Ineligible|0
6181237|NCT01333033|9832237|FG002|Overall Study|Ineligible|0
6181238|NCT01333033|9832238|FG003|Overall Study|Ineligible|0
6181239|NCT01333033|9832239|FG004|Overall Study|Ineligible|6
6181240|NCT01333033|9832240|FG005|Overall Study|Ineligible|8
6181241|NCT01333033|9832235|FG000|Overall Study|Withdrawal by Subject|0
6181242|NCT01333033|9832236|FG001|Overall Study|Withdrawal by Subject|0
6181243|NCT01333033|9832237|FG002|Overall Study|Withdrawal by Subject|0
6181244|NCT01333033|9832238|FG003|Overall Study|Withdrawal by Subject|0
6181245|NCT01333033|9832239|FG004|Overall Study|Withdrawal by Subject|4
6181246|NCT01333033|9832240|FG005|Overall Study|Withdrawal by Subject|2
6181247|NCT01333033|9832235|FG000|Overall Study|PET inevaluable|0
6181248|NCT01333033|9832236|FG001|Overall Study|PET inevaluable|0
6181249|NCT01333033|9832237|FG002|Overall Study|PET inevaluable|0
6181250|NCT01333033|9832238|FG003|Overall Study|PET inevaluable|0
6181251|NCT01333033|9832239|FG004|Overall Study|PET inevaluable|2
6181252|NCT01333033|9832240|FG005|Overall Study|PET inevaluable|4
6181253|NCT01333033|9832235|FG000|Overall Study|Adverse Event|0
6181254|NCT01333033|9832236|FG001|Overall Study|Adverse Event|0
6181255|NCT01333033|9832237|FG002|Overall Study|Adverse Event|0
6181256|NCT01333033|9832238|FG003|Overall Study|Adverse Event|0
6181257|NCT01333033|9832239|FG004|Overall Study|Adverse Event|2
6181258|NCT01333033|9832240|FG005|Overall Study|Adverse Event|1
6181259|NCT01333033|9832235|FG000|Overall Study|Progression|0
6181260|NCT01333033|9832236|FG001|Overall Study|Progression|0
6181261|NCT01333033|9832237|FG002|Overall Study|Progression|0
6181262|NCT01333033|9832238|FG003|Overall Study|Progression|0
6181263|NCT01333033|9832239|FG004|Overall Study|Progression|0
6181264|NCT01333033|9832240|FG005|Overall Study|Progression|1
6181265|NCT01333033|9832235|FG000|Overall Study|MD Decision|0
6181266|NCT01333033|9832236|FG001|Overall Study|MD Decision|0
6181267|NCT01333033|9832237|FG002|Overall Study|MD Decision|0
6181268|NCT01333033|9832238|FG003|Overall Study|MD Decision|0
6181269|NCT01333033|9832239|FG004|Overall Study|MD Decision|0
6181270|NCT01333033|9832240|FG005|Overall Study|MD Decision|2
6181271|NCT01333059|9832260|FG000|Overall Study|Physician Decision|3
6181272|NCT01333059|9832261|FG001|Overall Study|Physician Decision|3
6181273|NCT01333059|9832260|FG000|Overall Study|Protocol Violation|3
6181274|NCT01333059|9832261|FG001|Overall Study|Protocol Violation|0
6181275|NCT01333072|9832271|FG000|Overall Study|Lost to Follow-up|3
6181276|NCT01333072|9832272|FG001|Overall Study|Lost to Follow-up|0
6181277|NCT01333072|9832271|FG000|Overall Study|Adverse Event|2
6181278|NCT01333072|9832272|FG001|Overall Study|Adverse Event|4
6181279|NCT01333072|9832271|FG000|Overall Study|Physician Decision|1
6181280|NCT01333072|9832272|FG001|Overall Study|Physician Decision|0
6181281|NCT01333111|9832287|FG000|Overall Study|patient undergoing major surgery|0
6181282|NCT01333111|9832288|FG001|Overall Study|patient undergoing major surgery|2
6181283|NCT01333111|9832289|FG002|Overall Study|patient undergoing major surgery|0
6181284|NCT01333111|9832287|FG000|Overall Study|personal reasons|0
6181285|NCT01333111|9832288|FG001|Overall Study|personal reasons|0
6181286|NCT01333111|9832289|FG002|Overall Study|personal reasons|1
6181287|NCT01333111|9832287|FG000|Overall Study|unclassified|1
6181288|NCT01333111|9832288|FG001|Overall Study|unclassified|0
6181289|NCT01333111|9832289|FG002|Overall Study|unclassified|0
6181290|NCT01333111|9832287|FG000|Overall Study|withdrawal criteria|0
6181291|NCT01333111|9832288|FG001|Overall Study|withdrawal criteria|1
6181292|NCT01333111|9832289|FG002|Overall Study|withdrawal criteria|0
6181293|NCT01333111|9832287|FG000|Overall Study|Non-compliance|1
6181294|NCT01333111|9832288|FG001|Overall Study|Non-compliance|0
6181295|NCT01333111|9832289|FG002|Overall Study|Non-compliance|0
6181296|NCT01333111|9832287|FG000|Overall Study|Ineffective therapy|0
6181297|NCT01333111|9832288|FG001|Overall Study|Ineffective therapy|0
6181298|NCT01333111|9832289|FG002|Overall Study|Ineffective therapy|1
6181299|NCT01333189|9832299|FG000|Overall Study|Time constraints|1
6181300|NCT01333189|9832300|FG001|Overall Study|Time constraints|0
6181301|NCT01333189|9832299|FG000|Overall Study|Adverse Event|1
6181302|NCT01333189|9832300|FG001|Overall Study|Adverse Event|0
6181303|NCT01333189|9832299|FG000|Overall Study|Transportation difficulties|0
6181304|NCT01333189|9832300|FG001|Overall Study|Transportation difficulties|1
6181305|NCT01333189|9832299|FG000|Overall Study|Moved from region|0
6181306|NCT01333189|9832300|FG001|Overall Study|Moved from region|1
6181307|NCT01333397|9832311|FG000|Overall Study|Lost to Follow-up|1
6181308|NCT01333397|9832312|FG001|Overall Study|Lost to Follow-up|0
6181309|NCT01333397|9832313|FG002|Overall Study|Lost to Follow-up|0
6181310|NCT01333397|9832314|FG003|Overall Study|Lost to Follow-up|1
6181311|NCT01333397|9832315|FG004|Overall Study|Lost to Follow-up|0
6181312|NCT01333475|9832338|FG000|Overall Study|pt withdrew-need emergent radiation trmt|1
6181313|NCT01333475|9832339|FG001|Overall Study|pt withdrew-need emergent radiation trmt|0
6181314|NCT01333475|9832338|FG000|Overall Study|Toxicity|1
6181315|NCT01333475|9832339|FG001|Overall Study|Toxicity|3
6181316|NCT01333501|9832362|FG000|Overall Study|Adverse Event|3
6181317|NCT01333501|9832363|FG001|Overall Study|Adverse Event|1
6181318|NCT01333501|9832362|FG000|Overall Study|Abnormal laboratory value|2
6181319|NCT01333501|9832363|FG001|Overall Study|Abnormal laboratory value|1
6181320|NCT01333501|9832362|FG000|Overall Study|Unsatisfactory therapeutic effect|1
6181321|NCT01333501|9832363|FG001|Overall Study|Unsatisfactory therapeutic effect|7
6181322|NCT01333501|9832362|FG000|Overall Study|Withdrawn consent|3
6181323|NCT01333501|9832363|FG001|Overall Study|Withdrawn consent|12
6181324|NCT01333722|9832389|FG000|Overall Study|Lack of Efficacy|0
6181325|NCT01333722|9832390|FG001|Overall Study|Lack of Efficacy|2
6181326|NCT01333722|9832389|FG000|Overall Study|Withdrawal by Subject|0
6181327|NCT01333722|9832390|FG001|Overall Study|Withdrawal by Subject|1
6181328|NCT01333865|9832402|FG000|Overall Study|Adverse Event|2
6181329|NCT01333956|9832410|FG000|Overall Study|Lost to Follow-up|1
6181330|NCT01333956|9832411|FG001|Overall Study|Lost to Follow-up|2
6181331|NCT01333956|9832412|FG002|Overall Study|Lost to Follow-up|0
6181332|NCT01333956|9832413|FG003|Overall Study|Lost to Follow-up|1
6181333|NCT01333956|9832410|FG000|Overall Study|Unable to complete study procedure|1
6181334|NCT01333956|9832411|FG001|Overall Study|Unable to complete study procedure|0
6181335|NCT01333956|9832412|FG002|Overall Study|Unable to complete study procedure|0
6181336|NCT01333956|9832413|FG003|Overall Study|Unable to complete study procedure|1
6181337|NCT01333956|9832410|FG000|Overall Study|Withdrawal by Subject|0
6181338|NCT01333956|9832411|FG001|Overall Study|Withdrawal by Subject|2
6181339|NCT01333956|9832412|FG002|Overall Study|Withdrawal by Subject|1
6181340|NCT01333956|9832413|FG003|Overall Study|Withdrawal by Subject|0
6181341|NCT01334125|9832430|FG000|Overall Study|Lost to Follow-up|3
6181342|NCT01334125|9832431|FG001|Overall Study|Lost to Follow-up|3
6181343|NCT01334515|9832458|FG000|Overall Study|Adverse Event|1
6181344|NCT01334515|9832459|FG001|Overall Study|Adverse Event|6
6181345|NCT01334515|9832458|FG000|Overall Study|Death|1
6181346|NCT01334515|9832459|FG001|Overall Study|Death|0
6181347|NCT01334515|9832458|FG000|Overall Study|Lack of Efficacy|8
6181348|NCT01334515|9832459|FG001|Overall Study|Lack of Efficacy|21
6181349|NCT01334515|9832458|FG000|Overall Study|Physician Decision|1
6181350|NCT01334515|9832459|FG001|Overall Study|Physician Decision|1
6181351|NCT01334515|9832458|FG000|Overall Study|Withdrawal by Subject|1
6181352|NCT01334515|9832459|FG001|Overall Study|Withdrawal by Subject|1
6181353|NCT01334554|9832467|FG000|Overall Study|Adverse Event|4
6181354|NCT01334554|9832468|FG001|Overall Study|Adverse Event|2
6181355|NCT01334710|9832476|FG000|Overall Study|Trial was terminated|3
6181356|NCT01334866|9832510|FG000|Overall Study|Withdrawal by Subject|10
6181357|NCT01334866|9832510|FG000|Overall Study|Lost to Follow-up|3
6181358|NCT01334866|9832510|FG000|Overall Study|Physician Decision|3
6181359|NCT01334866|9832510|FG000|Overall Study|medically necessary prior to procedure|2
6181360|NCT01334866|9832510|FG000|Overall Study|medically necessary post-procedure|1
6181361|NCT01334918|9832518|FG000|Overall Study|Did not receive study drug|6
6227855|NCT01720069|9900736|FG002|Overall Study|Non-compliance on using e-diary|1
6181362|NCT01334918|9832519|FG001|Overall Study|Did not receive study drug|0
6181363|NCT01334918|9832518|FG000|Overall Study|Adverse Event|2
6181364|NCT01334918|9832519|FG001|Overall Study|Adverse Event|0
6181365|NCT01334918|9832518|FG000|Overall Study|Withdrawal by Subject|0
6181366|NCT01334918|9832519|FG001|Overall Study|Withdrawal by Subject|1
6181367|NCT01335009|9832552|FG000|Overall Study|Too ill to travel to study sites|1
6181368|NCT01335009|9832553|FG001|Overall Study|Too ill to travel to study sites|0
6181369|NCT01335009|9832552|FG000|Overall Study|Death|28
6181370|NCT01335009|9832553|FG001|Overall Study|Death|32
6181371|NCT01335009|9832552|FG000|Overall Study|Withdrawal by Subject|1
6181372|NCT01335009|9832553|FG001|Overall Study|Withdrawal by Subject|1
6181373|NCT01335009|9832552|FG000|Overall Study|Lost to Follow-up|1
6181374|NCT01335009|9832553|FG001|Overall Study|Lost to Follow-up|0
6181375|NCT01335464|9832615|FG000|Overall Study|Adverse Event|15
6181376|NCT01335464|9832616|FG001|Overall Study|Adverse Event|25
6181377|NCT01335464|9832615|FG000|Overall Study|Non compliant with protocol|2
6181378|NCT01335464|9832616|FG001|Overall Study|Non compliant with protocol|0
6181379|NCT01335464|9832615|FG000|Overall Study|Consent withdrawn, not due to AE|12
6181380|NCT01335464|9832616|FG001|Overall Study|Consent withdrawn, not due to AE|23
6181381|NCT01335464|9832615|FG000|Overall Study|Not treated|2
6181382|NCT01335464|9832616|FG001|Overall Study|Not treated|0
6181383|NCT01335464|9832615|FG000|Overall Study|Reason other than those stated above|1
6181384|NCT01335464|9832616|FG001|Overall Study|Reason other than those stated above|1
6181385|NCT01335477|9832624|FG000|Overall Study|Adverse Event|30
6181386|NCT01335477|9832625|FG001|Overall Study|Adverse Event|42
6181387|NCT01335477|9832624|FG000|Overall Study|Non compliant with protocol|0
6181388|NCT01335477|9832625|FG001|Overall Study|Non compliant with protocol|2
6181389|NCT01335477|9832624|FG000|Overall Study|Lost to Follow-up|1
6181390|NCT01335477|9832625|FG001|Overall Study|Lost to Follow-up|2
6181391|NCT01335477|9832624|FG000|Overall Study|Consent withdrawn, not due to AE|7
6181392|NCT01335477|9832625|FG001|Overall Study|Consent withdrawn, not due to AE|9
6181393|NCT01335477|9832624|FG000|Overall Study|Not treated|1
6181394|NCT01335477|9832625|FG001|Overall Study|Not treated|2
6181395|NCT01335477|9832624|FG000|Overall Study|Reason other than those stated above|2
6181396|NCT01335477|9832625|FG001|Overall Study|Reason other than those stated above|2
6181397|NCT01335698|9832649|FG000|Treatment Stage 1|Lack of Efficacy|3
6181398|NCT01335698|9832650|FG001|Treatment Stage 1|Lack of Efficacy|1
6181399|NCT01335698|9832651|FG002|Treatment Stage 1|Lack of Efficacy|3
6181400|NCT01335698|9832652|FG003|Treatment Stage 1|Lack of Efficacy|3
6181401|NCT01335698|9832653|FG004|Treatment Stage 1|Lack of Efficacy|1
6181402|NCT01335698|9832649|FG000|Treatment Stage 1|Adverse Event|1
6181403|NCT01335698|9832650|FG001|Treatment Stage 1|Adverse Event|2
6181404|NCT01335698|9832651|FG002|Treatment Stage 1|Adverse Event|2
6181405|NCT01335698|9832652|FG003|Treatment Stage 1|Adverse Event|1
6181406|NCT01335698|9832653|FG004|Treatment Stage 1|Adverse Event|1
6181407|NCT01335698|9832649|FG000|Treatment Stage 1|Withdrawal by Subject|1
6181408|NCT01335698|9832650|FG001|Treatment Stage 1|Withdrawal by Subject|2
6181409|NCT01335698|9832651|FG002|Treatment Stage 1|Withdrawal by Subject|0
6181410|NCT01335698|9832652|FG003|Treatment Stage 1|Withdrawal by Subject|1
6181411|NCT01335698|9832653|FG004|Treatment Stage 1|Withdrawal by Subject|0
6181412|NCT01335698|9832649|FG000|Treatment Stage 1|Lost to Follow-up|1
6181413|NCT01335698|9832650|FG001|Treatment Stage 1|Lost to Follow-up|1
6181414|NCT01335698|9832651|FG002|Treatment Stage 1|Lost to Follow-up|0
6181415|NCT01335698|9832652|FG003|Treatment Stage 1|Lost to Follow-up|0
6181416|NCT01335698|9832653|FG004|Treatment Stage 1|Lost to Follow-up|0
6181417|NCT01335698|9832649|FG000|Treatment Stage 1|Poor compliance/noncompliance|0
6181418|NCT01335698|9832650|FG001|Treatment Stage 1|Poor compliance/noncompliance|1
6181419|NCT01335698|9832651|FG002|Treatment Stage 1|Poor compliance/noncompliance|0
6181420|NCT01335698|9832652|FG003|Treatment Stage 1|Poor compliance/noncompliance|2
6181421|NCT01335698|9832653|FG004|Treatment Stage 1|Poor compliance/noncompliance|0
6181422|NCT01335698|9832649|FG000|Treatment Stage 1|No longer meets study criteria|1
6181423|NCT01335698|9832650|FG001|Treatment Stage 1|No longer meets study criteria|1
6181424|NCT01335698|9832651|FG002|Treatment Stage 1|No longer meets study criteria|0
6181425|NCT01335698|9832652|FG003|Treatment Stage 1|No longer meets study criteria|1
6181426|NCT01335698|9832653|FG004|Treatment Stage 1|No longer meets study criteria|0
6181427|NCT01335698|9832649|FG000|Treatment Stage 1|Other|1
6181428|NCT01335698|9832650|FG001|Treatment Stage 1|Other|0
6181429|NCT01335698|9832651|FG002|Treatment Stage 1|Other|0
6181430|NCT01335698|9832652|FG003|Treatment Stage 1|Other|1
6181431|NCT01335698|9832653|FG004|Treatment Stage 1|Other|0
6181432|NCT01335698|9832649|FG000|Treatment Stage 2|Lack of Efficacy|2
6181433|NCT01335698|9832650|FG001|Treatment Stage 2|Lack of Efficacy|1
6181434|NCT01335698|9832651|FG002|Treatment Stage 2|Lack of Efficacy|3
6181435|NCT01335698|9832652|FG003|Treatment Stage 2|Lack of Efficacy|1
6181436|NCT01335698|9832653|FG004|Treatment Stage 2|Lack of Efficacy|0
6181437|NCT01335698|9832649|FG000|Treatment Stage 2|Adverse Event|2
6181438|NCT01335698|9832650|FG001|Treatment Stage 2|Adverse Event|0
6181439|NCT01335698|9832651|FG002|Treatment Stage 2|Adverse Event|0
6181440|NCT01335698|9832652|FG003|Treatment Stage 2|Adverse Event|3
6181441|NCT01335698|9832653|FG004|Treatment Stage 2|Adverse Event|0
6181442|NCT01335698|9832649|FG000|Treatment Stage 2|Withdrawal by Subject|3
6181443|NCT01335698|9832650|FG001|Treatment Stage 2|Withdrawal by Subject|1
6181444|NCT01335698|9832651|FG002|Treatment Stage 2|Withdrawal by Subject|1
6181445|NCT01335698|9832652|FG003|Treatment Stage 2|Withdrawal by Subject|0
6181446|NCT01335698|9832653|FG004|Treatment Stage 2|Withdrawal by Subject|0
6181447|NCT01335698|9832649|FG000|Treatment Stage 2|Poor compliance/noncompliance|1
6181448|NCT01335698|9832650|FG001|Treatment Stage 2|Poor compliance/noncompliance|0
6181449|NCT01335698|9832651|FG002|Treatment Stage 2|Poor compliance/noncompliance|1
6181450|NCT01335698|9832652|FG003|Treatment Stage 2|Poor compliance/noncompliance|3
6181451|NCT01335698|9832653|FG004|Treatment Stage 2|Poor compliance/noncompliance|1
6181452|NCT01335698|9832649|FG000|Treatment Stage 2|Lost to Follow-up|1
6181453|NCT01335698|9832650|FG001|Treatment Stage 2|Lost to Follow-up|0
6181454|NCT01335698|9832651|FG002|Treatment Stage 2|Lost to Follow-up|0
6181455|NCT01335698|9832652|FG003|Treatment Stage 2|Lost to Follow-up|0
6181456|NCT01335698|9832653|FG004|Treatment Stage 2|Lost to Follow-up|0
6181457|NCT01335698|9832649|FG000|Treatment Stage 2|Capsules received at state hospital|1
6181458|NCT01335698|9832650|FG001|Treatment Stage 2|Capsules received at state hospital|0
6181459|NCT01335698|9832651|FG002|Treatment Stage 2|Capsules received at state hospital|0
6181460|NCT01335698|9832652|FG003|Treatment Stage 2|Capsules received at state hospital|0
6181461|NCT01335698|9832653|FG004|Treatment Stage 2|Capsules received at state hospital|0
6181462|NCT01335698|9832649|FG000|Treatment Stage 2|Subject no longer meets study criteria|0
6181463|NCT01335698|9832650|FG001|Treatment Stage 2|Subject no longer meets study criteria|0
6181464|NCT01335698|9832651|FG002|Treatment Stage 2|Subject no longer meets study criteria|0
6181465|NCT01335698|9832652|FG003|Treatment Stage 2|Subject no longer meets study criteria|1
6181466|NCT01335698|9832653|FG004|Treatment Stage 2|Subject no longer meets study criteria|0
6181467|NCT01335698|9832649|FG000|Treatment Stage 2|Switched to another formulation|1
6181468|NCT01335698|9832650|FG001|Treatment Stage 2|Switched to another formulation|1
6181469|NCT01335698|9832651|FG002|Treatment Stage 2|Switched to another formulation|0
6181470|NCT01335698|9832652|FG003|Treatment Stage 2|Switched to another formulation|0
6181471|NCT01335698|9832653|FG004|Treatment Stage 2|Switched to another formulation|0
6181472|NCT01335971|9832725|FG000|Overall Study|Withdrawal by Subject|1
6181473|NCT01335971|9832726|FG001|Overall Study|Withdrawal by Subject|0
6181474|NCT01335971|9832727|FG002|Overall Study|Withdrawal by Subject|0
6181475|NCT01335971|9832725|FG000|Overall Study|Did not complete bronchoscopy|1
6181476|NCT01335971|9832726|FG001|Overall Study|Did not complete bronchoscopy|1
6181477|NCT01335971|9832727|FG002|Overall Study|Did not complete bronchoscopy|1
6181478|NCT01336023|9832738|FG000|Week 0 to Week 26|Adverse Event|8
6181479|NCT01336023|9832739|FG001|Week 0 to Week 26|Adverse Event|10
6181480|NCT01336023|9832740|FG002|Week 0 to Week 26|Adverse Event|24
6181481|NCT01336023|9832738|FG000|Week 0 to Week 26|Lack of Efficacy|0
6181482|NCT01336023|9832739|FG001|Week 0 to Week 26|Lack of Efficacy|1
6181483|NCT01336023|9832740|FG002|Week 0 to Week 26|Lack of Efficacy|0
6181484|NCT01336023|9832738|FG000|Week 0 to Week 26|Protocol Violation|1
6181485|NCT01336023|9832739|FG001|Week 0 to Week 26|Protocol Violation|2
6181486|NCT01336023|9832740|FG002|Week 0 to Week 26|Protocol Violation|0
6181487|NCT01336023|9832738|FG000|Week 0 to Week 26|Withdrawal Criteria|34
6085329|NCT00651664|9694578|FG004|Overall Study|Reason not Specified|0
6085330|NCT00651664|9694579|FG005|Overall Study|Reason not Specified|0
6181488|NCT01336023|9832739|FG001|Week 0 to Week 26|Withdrawal Criteria|69
6181489|NCT01336023|9832740|FG002|Week 0 to Week 26|Withdrawal Criteria|40
6181490|NCT01336023|9832738|FG000|Week 0 to Week 26|Unclassified|5
6181491|NCT01336023|9832739|FG001|Week 0 to Week 26|Unclassified|16
6181492|NCT01336023|9832740|FG002|Week 0 to Week 26|Unclassified|9
6181493|NCT01336023|9832738|FG000|Week 27 to 52|Adverse Event|1
6181494|NCT01336023|9832739|FG001|Week 27 to 52|Adverse Event|5
6181495|NCT01336023|9832740|FG002|Week 27 to 52|Adverse Event|2
6227856|NCT01720069|9900734|FG000|Overall Study|Lost to Follow-up|0
6227857|NCT01720069|9900735|FG001|Overall Study|Lost to Follow-up|0
6227858|NCT01720069|9900736|FG002|Overall Study|Lost to Follow-up|1
6227859|NCT01720225|9900750|FG000|Overall Study|Withdrawal by Subject|0
6227860|NCT01720225|9900751|FG001|Overall Study|Withdrawal by Subject|1
6227861|NCT01720225|9900750|FG000|Overall Study|Did not complete 2 cycles of therapy|3
6227862|NCT01720225|9900751|FG001|Overall Study|Did not complete 2 cycles of therapy|0
6227863|NCT01720264|9900770|FG000|Transplant With Sitagliptin for 15 Days|Adverse Event|1
6227864|NCT01720264|9900770|FG000|Post-transplant (Day 16) to 1 Year|Death|8
6227865|NCT01720264|9900770|FG000|Post-transplant (Day 16) to 1 Year|Disease Progression|4
6227866|NCT01720446|9900824|FG000|Overall Study|Lost to Follow-up|12
6227867|NCT01720446|9900825|FG001|Overall Study|Lost to Follow-up|6
6227868|NCT01720446|9900826|FG002|Overall Study|Lost to Follow-up|16
6227869|NCT01720446|9900827|FG003|Overall Study|Lost to Follow-up|16
6227870|NCT01720446|9900824|FG000|Overall Study|Withdrawal by Subject|2
6227871|NCT01720446|9900825|FG001|Overall Study|Withdrawal by Subject|5
6227872|NCT01720446|9900826|FG002|Overall Study|Withdrawal by Subject|4
6227873|NCT01720446|9900827|FG003|Overall Study|Withdrawal by Subject|4
6227874|NCT01720524|9900842|FG000|Part A|Insufficient Clinical Response|2
6227875|NCT01720524|9900843|FG001|Part A|Insufficient Clinical Response|4
6227876|NCT01720524|9900842|FG000|Part A|Adverse Event|2
6227877|NCT01720524|9900843|FG001|Part A|Adverse Event|2
6227878|NCT01720524|9900842|FG000|Part A|Death|2
6227879|NCT01720524|9900843|FG001|Part A|Death|1
6227880|NCT01720524|9900842|FG000|Part A|Lost to Follow-up|0
6227881|NCT01720524|9900843|FG001|Part A|Lost to Follow-up|1
6227882|NCT01720524|9900842|FG000|Part A|Missed 28 day follow-up visit|1
6227883|NCT01720524|9900843|FG001|Part A|Missed 28 day follow-up visit|1
6181496|NCT01336023|9832738|FG000|Week 27 to 52|Protocol Violation|0
6181497|NCT01336023|9832739|FG001|Week 27 to 52|Protocol Violation|2
6181498|NCT01336023|9832740|FG002|Week 27 to 52|Protocol Violation|1
6181499|NCT01336023|9832738|FG000|Week 27 to 52|Withdrawal Criteria|14
6181500|NCT01336023|9832739|FG001|Week 27 to 52|Withdrawal Criteria|19
6181501|NCT01336023|9832740|FG002|Week 27 to 52|Withdrawal Criteria|16
6181502|NCT01336023|9832738|FG000|Week 27 to 52|Unclassified|13
6181503|NCT01336023|9832739|FG001|Week 27 to 52|Unclassified|18
6181504|NCT01336023|9832740|FG002|Week 27 to 52|Unclassified|9
6181505|NCT01336205|9832759|FG000|Overall Study|Other|22
6181506|NCT01336205|9832760|FG001|Overall Study|Other|9
6181507|NCT01336205|9832759|FG000|Overall Study|Lost to Follow-up|40
6181508|NCT01336205|9832760|FG001|Overall Study|Lost to Follow-up|20
6181509|NCT01336205|9832759|FG000|Overall Study|Study-Specific Withdrawal Criteria|16
6181510|NCT01336205|9832760|FG001|Overall Study|Study-Specific Withdrawal Criteria|7
6181511|NCT01336205|9832759|FG000|Overall Study|Lack of Efficacy|4
6181512|NCT01336205|9832760|FG001|Overall Study|Lack of Efficacy|0
6181513|NCT01336205|9832759|FG000|Overall Study|Severe noncompliance with protocol|9
6181514|NCT01336205|9832760|FG001|Overall Study|Severe noncompliance with protocol|2
6181515|NCT01336205|9832759|FG000|Overall Study|Adverse Event|56
6181516|NCT01336205|9832760|FG001|Overall Study|Adverse Event|6
6181517|NCT01336205|9832759|FG000|Overall Study|Death|1
6181518|NCT01336205|9832760|FG001|Overall Study|Death|1
6181519|NCT01336205|9832759|FG000|Overall Study|Eligibility Criteria Not Fulfilled|9
6181520|NCT01336205|9832760|FG001|Overall Study|Eligibility Criteria Not Fulfilled|6
6181521|NCT01336205|9832759|FG000|Overall Study|Withdrawal by Subject|72
6181522|NCT01336205|9832760|FG001|Overall Study|Withdrawal by Subject|38
6181523|NCT01336205|9832759|FG000|Overall Study|Did not receive treatment|4
6181524|NCT01336205|9832760|FG001|Overall Study|Did not receive treatment|0
6181525|NCT01336569|9832786|FG000|Overall Study|Lost to Follow-up|4
6181526|NCT01336608|9832793|FG000|2-week, Single-blind Run-In Period|Did Not Meet Continuation Criteria|102
6181527|NCT01336608|9832794|FG001|2-week, Single-blind Run-In Period|Did Not Meet Continuation Criteria|0
6181528|NCT01336608|9832795|FG002|2-week, Single-blind Run-In Period|Did Not Meet Continuation Criteria|0
6181529|NCT01336608|9832796|FG003|2-week, Single-blind Run-In Period|Did Not Meet Continuation Criteria|0
6181530|NCT01336608|9832793|FG000|2-week, Single-blind Run-In Period|Withdrawal by Subject|9
6181531|NCT01336608|9832794|FG001|2-week, Single-blind Run-In Period|Withdrawal by Subject|0
6181532|NCT01336608|9832795|FG002|2-week, Single-blind Run-In Period|Withdrawal by Subject|0
6181533|NCT01336608|9832796|FG003|2-week, Single-blind Run-In Period|Withdrawal by Subject|0
6181534|NCT01336608|9832793|FG000|2-week, Single-blind Run-In Period|Adverse Event|1
6181535|NCT01336608|9832794|FG001|2-week, Single-blind Run-In Period|Adverse Event|0
6181536|NCT01336608|9832795|FG002|2-week, Single-blind Run-In Period|Adverse Event|0
6181537|NCT01336608|9832796|FG003|2-week, Single-blind Run-In Period|Adverse Event|0
6181538|NCT01336608|9832793|FG000|2-week, Single-blind Run-In Period|Physician Decision|1
6181539|NCT01336608|9832794|FG001|2-week, Single-blind Run-In Period|Physician Decision|0
6181540|NCT01336608|9832795|FG002|2-week, Single-blind Run-In Period|Physician Decision|0
6181541|NCT01336608|9832796|FG003|2-week, Single-blind Run-In Period|Physician Decision|0
6181542|NCT01336608|9832793|FG000|2-week, Single-blind Run-In Period|Lost to Follow-up|2
6181543|NCT01336608|9832794|FG001|2-week, Single-blind Run-In Period|Lost to Follow-up|0
6181544|NCT01336608|9832795|FG002|2-week, Single-blind Run-In Period|Lost to Follow-up|0
6181545|NCT01336608|9832796|FG003|2-week, Single-blind Run-In Period|Lost to Follow-up|0
6181546|NCT01336608|9832793|FG000|24-week, Double-blind Treatment Period|Adverse Event|0
6181547|NCT01336608|9832794|FG001|24-week, Double-blind Treatment Period|Adverse Event|8
6181548|NCT01336608|9832795|FG002|24-week, Double-blind Treatment Period|Adverse Event|6
6181549|NCT01336608|9832796|FG003|24-week, Double-blind Treatment Period|Adverse Event|7
6181550|NCT01336608|9832793|FG000|24-week, Double-blind Treatment Period|Lack of Efficacy-No Sub-Reason|0
6181551|NCT01336608|9832794|FG001|24-week, Double-blind Treatment Period|Lack of Efficacy-No Sub-Reason|2
6181552|NCT01336608|9832795|FG002|24-week, Double-blind Treatment Period|Lack of Efficacy-No Sub-Reason|0
6181553|NCT01336608|9832796|FG003|24-week, Double-blind Treatment Period|Lack of Efficacy-No Sub-Reason|0
6181554|NCT01336608|9832793|FG000|24-week, Double-blind Treatment Period|Lack of Efficacy-Sub-Reason Exacerbation|0
6181555|NCT01336608|9832794|FG001|24-week, Double-blind Treatment Period|Lack of Efficacy-Sub-Reason Exacerbation|13
6181556|NCT01336608|9832795|FG002|24-week, Double-blind Treatment Period|Lack of Efficacy-Sub-Reason Exacerbation|13
6181557|NCT01336608|9832796|FG003|24-week, Double-blind Treatment Period|Lack of Efficacy-Sub-Reason Exacerbation|6
6181558|NCT01336608|9832793|FG000|24-week, Double-blind Treatment Period|Protocol Violation|0
6181559|NCT01336608|9832794|FG001|24-week, Double-blind Treatment Period|Protocol Violation|4
6181560|NCT01336608|9832795|FG002|24-week, Double-blind Treatment Period|Protocol Violation|3
6181561|NCT01336608|9832796|FG003|24-week, Double-blind Treatment Period|Protocol Violation|3
6181562|NCT01336608|9832793|FG000|24-week, Double-blind Treatment Period|Protocol-defined Stopping Criteria|0
6181563|NCT01336608|9832794|FG001|24-week, Double-blind Treatment Period|Protocol-defined Stopping Criteria|4
6181564|NCT01336608|9832795|FG002|24-week, Double-blind Treatment Period|Protocol-defined Stopping Criteria|3
6181565|NCT01336608|9832796|FG003|24-week, Double-blind Treatment Period|Protocol-defined Stopping Criteria|6
6181566|NCT01336608|9832793|FG000|24-week, Double-blind Treatment Period|Lost to Follow-up|0
6181567|NCT01336608|9832794|FG001|24-week, Double-blind Treatment Period|Lost to Follow-up|3
6227884|NCT01720524|9900842|FG000|Part A|Withdrawal by Subject|0
6181568|NCT01336608|9832795|FG002|24-week, Double-blind Treatment Period|Lost to Follow-up|0
6181569|NCT01336608|9832796|FG003|24-week, Double-blind Treatment Period|Lost to Follow-up|0
6181570|NCT01336608|9832793|FG000|24-week, Double-blind Treatment Period|Physician Decision|0
6181571|NCT01336608|9832794|FG001|24-week, Double-blind Treatment Period|Physician Decision|3
6181572|NCT01336608|9832795|FG002|24-week, Double-blind Treatment Period|Physician Decision|1
6181573|NCT01336608|9832796|FG003|24-week, Double-blind Treatment Period|Physician Decision|1
6181574|NCT01336608|9832793|FG000|24-week, Double-blind Treatment Period|Withdrawal by Subject|0
6181575|NCT01336608|9832794|FG001|24-week, Double-blind Treatment Period|Withdrawal by Subject|7
6181576|NCT01336608|9832795|FG002|24-week, Double-blind Treatment Period|Withdrawal by Subject|4
6181577|NCT01336608|9832796|FG003|24-week, Double-blind Treatment Period|Withdrawal by Subject|1
6181578|NCT01336647|9832807|FG000|Overall Study|Lost to Follow-up|4
6181579|NCT01336647|9832808|FG001|Overall Study|Lost to Follow-up|1
6181580|NCT01336647|9832809|FG002|Overall Study|Lost to Follow-up|3
6181581|NCT01336712|9832819|FG000|Overall Study|Death|2
6181582|NCT01336712|9832819|FG000|Overall Study|Lack of Efficacy|1
6181583|NCT01336738|9832828|FG000|Overall Study|Adverse Event|0
6181584|NCT01336738|9832829|FG001|Overall Study|Adverse Event|3
6181585|NCT01336738|9832830|FG002|Overall Study|Adverse Event|2
6181586|NCT01336738|9832831|FG003|Overall Study|Adverse Event|1
6181587|NCT01336738|9832832|FG004|Overall Study|Adverse Event|3
6181588|NCT01336738|9832828|FG000|Overall Study|Lost to Follow-up|2
6181589|NCT01336738|9832829|FG001|Overall Study|Lost to Follow-up|1
6181590|NCT01336738|9832830|FG002|Overall Study|Lost to Follow-up|2
6181591|NCT01336738|9832831|FG003|Overall Study|Lost to Follow-up|2
6181592|NCT01336738|9832832|FG004|Overall Study|Lost to Follow-up|2
6181593|NCT01336738|9832828|FG000|Overall Study|Did not meet entrance criteria|0
6181594|NCT01336738|9832829|FG001|Overall Study|Did not meet entrance criteria|1
6181595|NCT01336738|9832830|FG002|Overall Study|Did not meet entrance criteria|0
6181596|NCT01336738|9832831|FG003|Overall Study|Did not meet entrance criteria|0
6181597|NCT01336738|9832832|FG004|Overall Study|Did not meet entrance criteria|0
6181598|NCT01336738|9832828|FG000|Overall Study|Protocol Violation|0
6181599|NCT01336738|9832829|FG001|Overall Study|Protocol Violation|1
6181600|NCT01336738|9832830|FG002|Overall Study|Protocol Violation|0
6181601|NCT01336738|9832831|FG003|Overall Study|Protocol Violation|0
6181602|NCT01336738|9832832|FG004|Overall Study|Protocol Violation|0
6181603|NCT01336738|9832828|FG000|Overall Study|Withdrawal by Subject|2
6181604|NCT01336738|9832829|FG001|Overall Study|Withdrawal by Subject|0
6181605|NCT01336738|9832830|FG002|Overall Study|Withdrawal by Subject|2
6181606|NCT01336738|9832831|FG003|Overall Study|Withdrawal by Subject|1
6181607|NCT01336738|9832832|FG004|Overall Study|Withdrawal by Subject|1
6181608|NCT01336738|9832828|FG000|Overall Study|Other|3
6181609|NCT01336738|9832829|FG001|Overall Study|Other|3
6181610|NCT01336738|9832830|FG002|Overall Study|Other|2
6181611|NCT01336738|9832831|FG003|Overall Study|Other|3
6181612|NCT01336738|9832832|FG004|Overall Study|Other|4
6181613|NCT01336764|9832846|FG000|Overall Study|Withdrawal by Subject|5
6181614|NCT01336764|9832847|FG001|Overall Study|Withdrawal by Subject|5
6192760|NCT01433991|9850351|FG001|Pretreatment Phase (Single Agent Run-in)|Did not enter into treatment phase|0
6192761|NCT01433991|9850352|FG002|Pretreatment Phase (Single Agent Run-in)|Did not enter into treatment phase|0
6192762|NCT01433991|9850353|FG003|Pretreatment Phase (Single Agent Run-in)|Did not enter into treatment phase|0
6192763|NCT01433991|9850350|FG000|Treatment Phase (Combination Agent)|Adverse Event|1
6192764|NCT01433991|9850351|FG001|Treatment Phase (Combination Agent)|Adverse Event|0
6192765|NCT01433991|9850352|FG002|Treatment Phase (Combination Agent)|Adverse Event|3
6192766|NCT01433991|9850353|FG003|Treatment Phase (Combination Agent)|Adverse Event|1
6192767|NCT01433991|9850350|FG000|Treatment Phase (Combination Agent)|Lost to Follow-up|0
6192768|NCT01433991|9850351|FG001|Treatment Phase (Combination Agent)|Lost to Follow-up|0
6192769|NCT01433991|9850352|FG002|Treatment Phase (Combination Agent)|Lost to Follow-up|0
6192770|NCT01433991|9850353|FG003|Treatment Phase (Combination Agent)|Lost to Follow-up|1
6192771|NCT01433991|9850350|FG000|Treatment Phase (Combination Agent)|Participant Choice|0
6192772|NCT01433991|9850351|FG001|Treatment Phase (Combination Agent)|Participant Choice|0
6192773|NCT01433991|9850352|FG002|Treatment Phase (Combination Agent)|Participant Choice|0
6192774|NCT01433991|9850353|FG003|Treatment Phase (Combination Agent)|Participant Choice|1
6192775|NCT01433991|9850350|FG000|Treatment Phase (Combination Agent)|Clinical progression|0
6192776|NCT01433991|9850351|FG001|Treatment Phase (Combination Agent)|Clinical progression|1
6192777|NCT01433991|9850352|FG002|Treatment Phase (Combination Agent)|Clinical progression|2
6192778|NCT01433991|9850353|FG003|Treatment Phase (Combination Agent)|Clinical progression|3
6192779|NCT01433991|9850350|FG000|Treatment Phase (Combination Agent)|Progressive disease|1
6192780|NCT01433991|9850351|FG001|Treatment Phase (Combination Agent)|Progressive disease|0
6192781|NCT01433991|9850352|FG002|Treatment Phase (Combination Agent)|Progressive disease|0
6192782|NCT01433991|9850353|FG003|Treatment Phase (Combination Agent)|Progressive disease|0
6192783|NCT01433991|9850350|FG000|Treatment Phase (Combination Agent)|Terminated by sponsor|0
6192784|NCT01433991|9850351|FG001|Treatment Phase (Combination Agent)|Terminated by sponsor|0
6192785|NCT01433991|9850352|FG002|Treatment Phase (Combination Agent)|Terminated by sponsor|1
6192786|NCT01433991|9850353|FG003|Treatment Phase (Combination Agent)|Terminated by sponsor|0
6192787|NCT01434290|9850401|FG000|Overall Study|Protocol Violation|6
6192788|NCT01434290|9850402|FG001|Overall Study|Protocol Violation|3
6181615|NCT01336894|9832867|FG000|Follow-up|Study terminated prematurely|2
6181616|NCT01336894|9832868|FG001|Follow-up|Study terminated prematurely|7
6181617|NCT01336972|9832898|FG000|Overall Study|Adverse Event|1
6181618|NCT01336972|9832899|FG001|Overall Study|Adverse Event|1
6181619|NCT01336972|9832900|FG002|Overall Study|Adverse Event|0
6181620|NCT01337050|9832912|FG000|Overall Study|Death|0
6181621|NCT01337050|9832913|FG001|Overall Study|Death|0
6181622|NCT01337050|9832914|FG002|Overall Study|Death|4
6181623|NCT01337050|9832912|FG000|Overall Study|Other|4
6181624|NCT01337050|9832913|FG001|Overall Study|Other|6
6181625|NCT01337050|9832914|FG002|Overall Study|Other|8
6181626|NCT01337050|9832912|FG000|Overall Study|Participants refused further follow-up|0
6181627|NCT01337050|9832913|FG001|Overall Study|Participants refused further follow-up|7
6181628|NCT01337050|9832914|FG002|Overall Study|Participants refused further follow-up|7
6181629|NCT01337089|9832927|FG000|Overall Study|Adverse Event|237
6181630|NCT01337089|9832927|FG000|Overall Study|Withdrawal by Subject|129
6181631|NCT01337089|9832927|FG000|Overall Study|Withdrawal by Investigator|33
6181632|NCT01337089|9832927|FG000|Overall Study|Met Withdrawal Criteria|3
6181633|NCT01337089|9832927|FG000|Overall Study|Lost to Follow-up|2
6181634|NCT01337115|9832933|FG000|Overall Study|Protocol Violation|2
6181635|NCT01337115|9832934|FG001|Overall Study|Protocol Violation|0
6181636|NCT01337167|9832944|FG000|Infant Series|Adverse Event|1
6181637|NCT01337167|9832945|FG001|Infant Series|Adverse Event|1
6181638|NCT01337167|9832944|FG000|Infant Series|Death|1
6181639|NCT01337167|9832945|FG001|Infant Series|Death|1
6181640|NCT01337167|9832944|FG000|Infant Series|Lost to Follow-up|13
6181641|NCT01337167|9832945|FG001|Infant Series|Lost to Follow-up|7
6181642|NCT01337167|9832944|FG000|Infant Series|Non-compliance with study drug|2
6181643|NCT01337167|9832945|FG001|Infant Series|Non-compliance with study drug|1
6181644|NCT01337167|9832944|FG000|Infant Series|Physician Decision|3
6181645|NCT01337167|9832945|FG001|Infant Series|Physician Decision|1
6181646|NCT01337167|9832944|FG000|Infant Series|Protocol Violation|22
6181647|NCT01337167|9832945|FG001|Infant Series|Protocol Violation|9
6181648|NCT01337167|9832944|FG000|Infant Series|Withdrawal by Subject|15
6181649|NCT01337167|9832945|FG001|Infant Series|Withdrawal by Subject|4
6181650|NCT01337167|9832944|FG000|Infant Series|Randomized but not vaccinated|5
6181651|NCT01337167|9832945|FG001|Infant Series|Randomized but not vaccinated|3
6181652|NCT01337167|9832944|FG000|Interim Period|Lost to Follow-up|51
6181653|NCT01337167|9832945|FG001|Interim Period|Lost to Follow-up|23
6181654|NCT01337167|9832944|FG000|Interim Period|Non-compliance with study drug|1
6181655|NCT01337167|9832945|FG001|Interim Period|Non-compliance with study drug|0
6181656|NCT01337167|9832944|FG000|Interim Period|Physician Decision|6
6181657|NCT01337167|9832945|FG001|Interim Period|Physician Decision|3
6181658|NCT01337167|9832944|FG000|Interim Period|Protocol Violation|5
6181659|NCT01337167|9832945|FG001|Interim Period|Protocol Violation|3
6181660|NCT01337167|9832944|FG000|Interim Period|Withdrawal by Subject|18
6181661|NCT01337167|9832945|FG001|Interim Period|Withdrawal by Subject|10
6181662|NCT01337167|9832944|FG000|Interim Period|Other protocol criterion not met|0
6181663|NCT01337167|9832945|FG001|Interim Period|Other protocol criterion not met|1
6181664|NCT01337167|9832944|FG000|Toddler Vaccinations|Lost to Follow-up|11
6181665|NCT01337167|9832945|FG001|Toddler Vaccinations|Lost to Follow-up|12
6181666|NCT01337167|9832944|FG000|Toddler Vaccinations|Protocol Violation|0
6181667|NCT01337167|9832945|FG001|Toddler Vaccinations|Protocol Violation|1
6181668|NCT01337167|9832944|FG000|Toddler Vaccinations|Withdrawal by Subject|3
6181669|NCT01337167|9832945|FG001|Toddler Vaccinations|Withdrawal by Subject|0
6181670|NCT01337297|9832953|FG000|Overall Study|They entered to single anodal tDCS|4
6181671|NCT01337297|9832954|FG001|Overall Study|They entered to single anodal tDCS|3
6181672|NCT01337297|9832953|FG000|Overall Study|Lost to Follow-up|1
6181673|NCT01337297|9832954|FG001|Overall Study|Lost to Follow-up|3
6181674|NCT01337596|9832978|FG000|Overall Study|Withdrawal by Subject|0
6181675|NCT01337596|9832979|FG001|Overall Study|Withdrawal by Subject|0
6181676|NCT01337596|9832980|FG002|Overall Study|Withdrawal by Subject|0
6181677|NCT01337596|9832981|FG003|Overall Study|Withdrawal by Subject|0
6181678|NCT01337596|9832982|FG004|Overall Study|Withdrawal by Subject|2
6181679|NCT01337596|9832983|FG005|Overall Study|Withdrawal by Subject|0
6181680|NCT01337596|9832984|FG006|Overall Study|Withdrawal by Subject|0
6181681|NCT01337596|9832985|FG007|Overall Study|Withdrawal by Subject|0
6181682|NCT01337596|9832986|FG008|Overall Study|Withdrawal by Subject|0
6181683|NCT01337635|9833011|FG000|Overall Study|Lost to Follow-up|0
6181684|NCT01337635|9833012|FG001|Overall Study|Lost to Follow-up|1
6181685|NCT01337674|9833020|FG000|Treatment Period 1|Adverse Event|0
6181686|NCT01337674|9833021|FG001|Treatment Period 1|Adverse Event|1
6181687|NCT01337674|9833022|FG002|Treatment Period 1|Adverse Event|0
6181688|NCT01337674|9833023|FG003|Treatment Period 1|Adverse Event|0
6181689|NCT01337674|9833020|FG000|Treatment Period 1|Discontinued due to blood draws|0
6181690|NCT01337674|9833021|FG001|Treatment Period 1|Discontinued due to blood draws|0
6181691|NCT01337674|9833022|FG002|Treatment Period 1|Discontinued due to blood draws|0
6181692|NCT01337674|9833023|FG003|Treatment Period 1|Discontinued due to blood draws|1
6181693|NCT01337674|9833020|FG000|Treatment Period 2|Withdrawal by Subject|0
6181694|NCT01337674|9833021|FG001|Treatment Period 2|Withdrawal by Subject|0
6181695|NCT01337674|9833022|FG002|Treatment Period 2|Withdrawal by Subject|1
6181696|NCT01337674|9833023|FG003|Treatment Period 2|Withdrawal by Subject|0
6181697|NCT01337960|9833066|FG000|Overall Study|Lost to Follow-up|1
6181698|NCT01337960|9833067|FG001|Overall Study|Lost to Follow-up|0
6181699|NCT01337960|9833068|FG002|Overall Study|Lost to Follow-up|0
6181700|NCT01337960|9833066|FG000|Overall Study|Withdrawal by Subject|1
6181701|NCT01337960|9833067|FG001|Overall Study|Withdrawal by Subject|0
6181702|NCT01337960|9833068|FG002|Overall Study|Withdrawal by Subject|0
6181703|NCT01337973|9833079|FG000|Overall Study|Lost to Follow-up|2
6181704|NCT01337973|9833080|FG001|Overall Study|Lost to Follow-up|4
6181705|NCT01337973|9833081|FG002|Overall Study|Lost to Follow-up|3
6181706|NCT01337973|9833079|FG000|Overall Study|Death|1
6181707|NCT01337973|9833080|FG001|Overall Study|Death|2
6181708|NCT01337973|9833081|FG002|Overall Study|Death|1
6181709|NCT01337973|9833079|FG000|Overall Study|Withdrawal by Subject|10
6181710|NCT01337973|9833080|FG001|Overall Study|Withdrawal by Subject|8
6181711|NCT01337973|9833081|FG002|Overall Study|Withdrawal by Subject|4
6181712|NCT01337973|9833079|FG000|Overall Study|missing data on primary outcome|3
6181713|NCT01337973|9833080|FG001|Overall Study|missing data on primary outcome|1
6181714|NCT01337973|9833081|FG002|Overall Study|missing data on primary outcome|3
6181715|NCT01337986|9833091|FG000|Overall Study|Adverse Event|2
6181716|NCT01337986|9833092|FG001|Overall Study|Adverse Event|2
6181717|NCT01337986|9833091|FG000|Overall Study|Lost to Follow-up|1
6181718|NCT01337986|9833092|FG001|Overall Study|Lost to Follow-up|0
6181719|NCT01337986|9833091|FG000|Overall Study|Protocol Violation|0
6181720|NCT01337986|9833092|FG001|Overall Study|Protocol Violation|3
6181721|NCT01338012|9833114|FG000|Overall Study|Death|4
6181722|NCT01338012|9833114|FG000|Overall Study|Study terminated|4
6181723|NCT01338025|9833120|FG000|Overall Study|Unexpected closure of study|10
6181724|NCT01338025|9833121|FG001|Overall Study|Unexpected closure of study|9
6181725|NCT01338025|9833120|FG000|Overall Study|Withdrawal by Subject|0
6181726|NCT01338025|9833121|FG001|Overall Study|Withdrawal by Subject|2
6181727|NCT01338025|9833120|FG000|Overall Study|Found ineligible after starting|1
6181728|NCT01338025|9833121|FG001|Overall Study|Found ineligible after starting|0
6181729|NCT01338298|9833129|FG000|Overall Study|Withdrawal by Subject|1
6181730|NCT01338298|9833130|FG001|Overall Study|Withdrawal by Subject|1
6181731|NCT01338298|9833129|FG000|Overall Study|Abdominal Pain and scheduled surgery|0
6181732|NCT01338298|9833130|FG001|Overall Study|Abdominal Pain and scheduled surgery|1
6181733|NCT01338298|9833129|FG000|Overall Study|Administrative error|0
6181734|NCT01338298|9833130|FG001|Overall Study|Administrative error|1
6181735|NCT01338298|9833129|FG000|Overall Study|Positive symptom worsening|1
6181736|NCT01338298|9833130|FG001|Overall Study|Positive symptom worsening|0
6181737|NCT01338298|9833129|FG000|Overall Study|Depressive symptoms and nausea|1
6181738|NCT01338298|9833130|FG001|Overall Study|Depressive symptoms and nausea|0
6181739|NCT01338298|9833129|FG000|Overall Study|Non-adherence|1
6181740|NCT01338298|9833130|FG001|Overall Study|Non-adherence|0
6181741|NCT01338415|9833138|FG000|Core + Extension|Adverse Event|8
6181742|NCT01338415|9833139|FG001|Core + Extension|Adverse Event|6
6181743|NCT01338415|9833140|FG002|Core + Extension|Adverse Event|0
6181744|NCT01338415|9833138|FG000|Core + Extension|Withdrawal by Subject|1
6181745|NCT01338415|9833139|FG001|Core + Extension|Withdrawal by Subject|1
6181746|NCT01338415|9833140|FG002|Core + Extension|Withdrawal by Subject|0
6181747|NCT01338415|9833138|FG000|Core + Extension|Other (PAH not the main etiology of PH)|0
6181748|NCT01338415|9833139|FG001|Core + Extension|Other (PAH not the main etiology of PH)|2
6181749|NCT01338415|9833140|FG002|Core + Extension|Other (PAH not the main etiology of PH)|0
6181750|NCT01338415|9833138|FG000|Core + Extension|Other (administrative reason)|1
6181751|NCT01338415|9833139|FG001|Core + Extension|Other (administrative reason)|0
6181752|NCT01338415|9833140|FG002|Core + Extension|Other (administrative reason)|0
6181753|NCT01338415|9833138|FG000|Exceptional Use Treatment Period|Administrative decision|0
6181754|NCT01338415|9833139|FG001|Exceptional Use Treatment Period|Administrative decision|0
6181755|NCT01338415|9833140|FG002|Exceptional Use Treatment Period|Administrative decision|1
6181756|NCT01338415|9833138|FG000|Exceptional Use Treatment Period|Ongoing at the cut-off date of 19 Nov 2019|0
6181757|NCT01338415|9833139|FG001|Exceptional Use Treatment Period|Ongoing at the cut-off date of 19 Nov 2019|0
6181758|NCT01338415|9833140|FG002|Exceptional Use Treatment Period|Ongoing at the cut-off date of 19 Nov 2019|3
6181759|NCT01338415|9833138|FG000|Exceptional Use Treatment Period|Withdrawal by Subject|0
6181760|NCT01338415|9833139|FG001|Exceptional Use Treatment Period|Withdrawal by Subject|0
6181761|NCT01338415|9833140|FG002|Exceptional Use Treatment Period|Withdrawal by Subject|1
6181762|NCT01338415|9833138|FG000|Exceptional Use Treatment Period|Death|0
6181763|NCT01338415|9833139|FG001|Exceptional Use Treatment Period|Death|0
6181764|NCT01338415|9833140|FG002|Exceptional Use Treatment Period|Death|1
6181765|NCT01338493|9833148|FG000|Enrolled|Withdrawal by Subject|1
6181766|NCT01338493|9833148|FG000|Enrolled|Patient not implanted|4
6181767|NCT01338493|9833148|FG000|Discharge|Death|1
6181768|NCT01338493|9833148|FG000|Discharge|Missed visit|1
6181769|NCT01338493|9833148|FG000|6 Months Follow up|Lost to Follow-up|11
6181770|NCT01338493|9833148|FG000|6 Months Follow up|Missed visit|8
6181771|NCT01338493|9833148|FG000|12 Months Follow up|Lost to Follow-up|9
6181772|NCT01338610|9833168|FG000|Overall Study|Patient Decision Unrelated to Advs Event|1
6181773|NCT01338610|9833169|FG001|Overall Study|Patient Decision Unrelated to Advs Event|1
6181774|NCT01338610|9833170|FG002|Overall Study|Patient Decision Unrelated to Advs Event|0
6181775|NCT01338610|9833168|FG000|Overall Study|Protocol Violation|1
6181776|NCT01338610|9833169|FG001|Overall Study|Protocol Violation|0
6181777|NCT01338610|9833170|FG002|Overall Study|Protocol Violation|1
6181778|NCT01338610|9833168|FG000|Overall Study|Adverse Event|3
6181779|NCT01338610|9833169|FG001|Overall Study|Adverse Event|0
6181780|NCT01338610|9833170|FG002|Overall Study|Adverse Event|0
6181781|NCT01338792|9833186|FG000|Overall Study|Adverse Event|2
6181782|NCT01338792|9833186|FG000|Overall Study|Death|1
6181783|NCT01338792|9833186|FG000|Overall Study|Withdrawal by Subject|1
6181784|NCT01338818|9833190|FG000|Overall Study|Adverse Event|8
6181785|NCT01338818|9833190|FG000|Overall Study|Lack of Efficacy|5
6181786|NCT01338818|9833190|FG000|Overall Study|no longer require study drug|1
6181787|NCT01338818|9833190|FG000|Overall Study|Withdrawal by Subject|11
6181788|NCT01338818|9833190|FG000|Overall Study|Lost to Follow-up|4
6181789|NCT01338818|9833190|FG000|Overall Study|Administrative problems|3
6181790|NCT01338818|9833190|FG000|Overall Study|Protocol Deviation|4
6181791|NCT01338870|9833204|FG000|Overall Study|Lost to Follow-up|0
6181792|NCT01338870|9833205|FG001|Overall Study|Lost to Follow-up|0
6181793|NCT01338870|9833206|FG002|Overall Study|Lost to Follow-up|1
6181794|NCT01338870|9833207|FG003|Overall Study|Lost to Follow-up|0
6181795|NCT01338870|9833208|FG004|Overall Study|Lost to Follow-up|1
6181796|NCT01338870|9833209|FG005|Overall Study|Lost to Follow-up|0
6181797|NCT01338870|9833204|FG000|Overall Study|Withdrawal by Subject|2
6181798|NCT01338870|9833205|FG001|Overall Study|Withdrawal by Subject|3
6181799|NCT01338870|9833206|FG002|Overall Study|Withdrawal by Subject|4
6181800|NCT01338870|9833207|FG003|Overall Study|Withdrawal by Subject|0
6181801|NCT01338870|9833208|FG004|Overall Study|Withdrawal by Subject|0
6181802|NCT01338870|9833209|FG005|Overall Study|Withdrawal by Subject|2
6181803|NCT01338870|9833204|FG000|Overall Study|Other|3
6181804|NCT01338870|9833205|FG001|Overall Study|Other|3
6181805|NCT01338870|9833206|FG002|Overall Study|Other|3
6181806|NCT01338870|9833207|FG003|Overall Study|Other|2
6181807|NCT01338870|9833208|FG004|Overall Study|Other|0
6181808|NCT01338870|9833209|FG005|Overall Study|Other|2
6181809|NCT01338870|9833204|FG000|Overall Study|Protocol Violation|0
6181810|NCT01338870|9833205|FG001|Overall Study|Protocol Violation|2
6181811|NCT01338870|9833206|FG002|Overall Study|Protocol Violation|2
6181812|NCT01338870|9833207|FG003|Overall Study|Protocol Violation|2
6181813|NCT01338870|9833208|FG004|Overall Study|Protocol Violation|1
6181814|NCT01338870|9833209|FG005|Overall Study|Protocol Violation|1
6181815|NCT01338870|9833204|FG000|Overall Study|Adverse Event|4
6181816|NCT01338870|9833205|FG001|Overall Study|Adverse Event|4
6181817|NCT01338870|9833206|FG002|Overall Study|Adverse Event|1
6181818|NCT01338870|9833207|FG003|Overall Study|Adverse Event|5
6181819|NCT01338870|9833208|FG004|Overall Study|Adverse Event|4
6181820|NCT01338870|9833209|FG005|Overall Study|Adverse Event|1
6181821|NCT01338987|9833228|FG000|Overall Study|enrolled on new protocol|0
6181822|NCT01338987|9833229|FG001|Overall Study|enrolled on new protocol|0
6181823|NCT01338987|9833230|FG002|Overall Study|enrolled on new protocol|1
6181824|NCT01338987|9833231|FG003|Overall Study|enrolled on new protocol|0
6181825|NCT01338987|9833232|FG004|Overall Study|enrolled on new protocol|0
6181826|NCT01338987|9833228|FG000|Overall Study|Disease progression on study|2
6181827|NCT01338987|9833229|FG001|Overall Study|Disease progression on study|1
6181828|NCT01338987|9833230|FG002|Overall Study|Disease progression on study|1
6181829|NCT01338987|9833231|FG003|Overall Study|Disease progression on study|0
6181830|NCT01338987|9833232|FG004|Overall Study|Disease progression on study|0
6181831|NCT01339000|9833248|FG000|Overall Study|study closed due to lack of drug supply|1
6181832|NCT01339000|9833249|FG001|Overall Study|study closed due to lack of drug supply|0
6181833|NCT01339052|9833264|FG000|Overall Study|Disease progression|13
6181834|NCT01339052|9833265|FG001|Overall Study|Disease progression|46
6181835|NCT01339052|9833264|FG000|Overall Study|Adverse Event|1
6181836|NCT01339052|9833265|FG001|Overall Study|Adverse Event|1
6181837|NCT01339052|9833264|FG000|Overall Study|Withdrawal by Subject|0
6181838|NCT01339052|9833265|FG001|Overall Study|Withdrawal by Subject|3
6181839|NCT01339052|9833264|FG000|Overall Study|Physician Decision|1
6181840|NCT01339052|9833265|FG001|Overall Study|Physician Decision|0
6181841|NCT01339273|9833303|FG000|Overall Study|Lost to Follow-up|8
6181842|NCT01339273|9833304|FG001|Overall Study|Lost to Follow-up|8
6181843|NCT01339390|9833321|FG000|Overall Study|Death|32
6181844|NCT01339390|9833322|FG001|Overall Study|Death|29
6181845|NCT01339390|9833321|FG000|Overall Study|Lost to Follow-up|125
6181846|NCT01339390|9833322|FG001|Overall Study|Lost to Follow-up|127
6181847|NCT01339429|9833341|FG000|Overall Study|Withdrawal by Subject|1
6181848|NCT01339429|9833341|FG000|Overall Study|Physician Decision|3
6181849|NCT01339559|9833345|FG000|Overall Study|Adverse Event|92
6181850|NCT01339559|9833345|FG000|Overall Study|Death|5
6181851|NCT01339559|9833345|FG000|Overall Study|Lack of Efficacy|164
6181852|NCT01339559|9833345|FG000|Overall Study|Lost to Follow-up|22
6181853|NCT01339559|9833345|FG000|Overall Study|Subject choice|89
6181854|NCT01339559|9833345|FG000|Overall Study|Protocol Violation|15
6181855|NCT01339559|9833345|FG000|Overall Study|Study closure at site|1
6181856|NCT01339559|9833345|FG000|Overall Study|Incarcerated|2
6181857|NCT01339559|9833345|FG000|Overall Study|Epilepsy surgery|1
6181858|NCT01339559|9833345|FG000|Overall Study|Pregnancy planned|2
6181859|NCT01339559|9833345|FG000|Overall Study|Left the country|1
6181860|NCT01339559|9833345|FG000|Overall Study|Investigator decision|2
6181861|NCT01339559|9833345|FG000|Overall Study|Patient didn't wish to continue|1
6181862|NCT01339559|9833345|FG000|Overall Study|PI decision|1
6181863|NCT01339832|9833350|FG000|Overall Study|Lost to Follow-up|3
6181864|NCT01339832|9833350|FG000|Overall Study|Death|11
6181865|NCT01339897|9833369|FG000|Overall Study|Adverse Event|1
6181866|NCT01339897|9833370|FG001|Overall Study|Adverse Event|0
6181867|NCT01339897|9833371|FG002|Overall Study|Adverse Event|0
6181868|NCT01339897|9833372|FG003|Overall Study|Adverse Event|1
6181869|NCT01339910|9833386|FG000|Overall Study|Withdrawal by Subject|1
6181870|NCT01339910|9833387|FG001|Overall Study|Withdrawal by Subject|0
6181871|NCT01339910|9833386|FG000|Overall Study|Physician Decision|1
6181872|NCT01339910|9833387|FG001|Overall Study|Physician Decision|0
6181873|NCT01339910|9833386|FG000|Overall Study|Disease relapse|1
6181874|NCT01339910|9833387|FG001|Overall Study|Disease relapse|4
6181875|NCT01339923|9833400|FG000|Overall Study|Adverse Event|1
6181876|NCT01339923|9833401|FG001|Overall Study|Adverse Event|1
6181877|NCT01339923|9833402|FG002|Overall Study|Adverse Event|1
6181878|NCT01339923|9833403|FG003|Overall Study|Adverse Event|0
6181879|NCT01339923|9833404|FG004|Overall Study|Adverse Event|0
6181880|NCT01339923|9833405|FG005|Overall Study|Adverse Event|0
6181881|NCT01339923|9833406|FG006|Overall Study|Adverse Event|1
6181882|NCT01339923|9833400|FG000|Overall Study|Inappropriate Enrollment|1
6181883|NCT01339923|9833401|FG001|Overall Study|Inappropriate Enrollment|0
6181884|NCT01339923|9833402|FG002|Overall Study|Inappropriate Enrollment|0
6181885|NCT01339923|9833403|FG003|Overall Study|Inappropriate Enrollment|0
6181886|NCT01339923|9833404|FG004|Overall Study|Inappropriate Enrollment|0
6181887|NCT01339923|9833405|FG005|Overall Study|Inappropriate Enrollment|1
6181888|NCT01339923|9833406|FG006|Overall Study|Inappropriate Enrollment|0
6181889|NCT01339923|9833400|FG000|Overall Study|Lost to Follow-up|4
6181890|NCT01339923|9833401|FG001|Overall Study|Lost to Follow-up|4
6181891|NCT01339923|9833402|FG002|Overall Study|Lost to Follow-up|0
6181892|NCT01339923|9833403|FG003|Overall Study|Lost to Follow-up|3
6181893|NCT01339923|9833404|FG004|Overall Study|Lost to Follow-up|1
6181894|NCT01339923|9833405|FG005|Overall Study|Lost to Follow-up|1
6181895|NCT01339923|9833406|FG006|Overall Study|Lost to Follow-up|5
6181896|NCT01339923|9833400|FG000|Overall Study|Protocol Violation|0
6181897|NCT01339923|9833401|FG001|Overall Study|Protocol Violation|0
6181898|NCT01339923|9833402|FG002|Overall Study|Protocol Violation|0
6181899|NCT01339923|9833403|FG003|Overall Study|Protocol Violation|0
6181900|NCT01339923|9833404|FG004|Overall Study|Protocol Violation|0
6181901|NCT01339923|9833405|FG005|Overall Study|Protocol Violation|3
6181902|NCT01339923|9833406|FG006|Overall Study|Protocol Violation|1
6181903|NCT01339923|9833400|FG000|Overall Study|Unable to Classify|1
6181904|NCT01339923|9833401|FG001|Overall Study|Unable to Classify|0
6181905|NCT01339923|9833402|FG002|Overall Study|Unable to Classify|1
6181906|NCT01339923|9833403|FG003|Overall Study|Unable to Classify|0
6181907|NCT01339923|9833404|FG004|Overall Study|Unable to Classify|0
6181908|NCT01339923|9833405|FG005|Overall Study|Unable to Classify|1
6181909|NCT01339923|9833406|FG006|Overall Study|Unable to Classify|5
6181910|NCT01339923|9833400|FG000|Overall Study|Withdrawal by Subject|7
6181911|NCT01339923|9833401|FG001|Overall Study|Withdrawal by Subject|11
6181912|NCT01339923|9833402|FG002|Overall Study|Withdrawal by Subject|6
6181913|NCT01339923|9833403|FG003|Overall Study|Withdrawal by Subject|1
6181914|NCT01339923|9833404|FG004|Overall Study|Withdrawal by Subject|4
6181915|NCT01339923|9833405|FG005|Overall Study|Withdrawal by Subject|3
6181916|NCT01339923|9833406|FG006|Overall Study|Withdrawal by Subject|2
6181917|NCT01340014|9833441|FG000|Period 1, First 7 Days|Adverse Event|1
6181918|NCT01340014|9833442|FG001|Period 1, First 7 Days|Adverse Event|0
6181919|NCT01340014|9833441|FG000|Period 1, First 7 Days|Personal Reasons|1
6181920|NCT01340014|9833442|FG001|Period 1, First 7 Days|Personal Reasons|0
6181921|NCT01340014|9833441|FG000|Period 2, Second 7 Days|Adverse Event|0
6181922|NCT01340014|9833442|FG001|Period 2, Second 7 Days|Adverse Event|1
6181923|NCT01340027|9833460|FG000|Overall Study|Randomized but Never Received Study Drug|0
6181924|NCT01340027|9833461|FG001|Overall Study|Randomized but Never Received Study Drug|0
6181925|NCT01340027|9833462|FG002|Overall Study|Randomized but Never Received Study Drug|1
6181926|NCT01340027|9833463|FG003|Overall Study|Randomized but Never Received Study Drug|0
6181927|NCT01340027|9833464|FG004|Overall Study|Randomized but Never Received Study Drug|0
6181928|NCT01340027|9833465|FG005|Overall Study|Randomized but Never Received Study Drug|0
6181929|NCT01340027|9833466|FG006|Overall Study|Randomized but Never Received Study Drug|0
6181930|NCT01340027|9833467|FG007|Overall Study|Randomized but Never Received Study Drug|0
6181931|NCT01340027|9833468|FG008|Overall Study|Randomized but Never Received Study Drug|0
6181932|NCT01340027|9833469|FG009|Overall Study|Randomized but Never Received Study Drug|0
6181933|NCT01340027|9833470|FG010|Overall Study|Randomized but Never Received Study Drug|0
6181934|NCT01340027|9833471|FG011|Overall Study|Randomized but Never Received Study Drug|0
6181935|NCT01340027|9833460|FG000|Overall Study|Adverse Event|0
6181936|NCT01340027|9833461|FG001|Overall Study|Adverse Event|1
6181937|NCT01340027|9833462|FG002|Overall Study|Adverse Event|2
6181938|NCT01340027|9833463|FG003|Overall Study|Adverse Event|0
6181939|NCT01340027|9833464|FG004|Overall Study|Adverse Event|1
6181940|NCT01340027|9833465|FG005|Overall Study|Adverse Event|2
6181941|NCT01340027|9833466|FG006|Overall Study|Adverse Event|2
6181942|NCT01340027|9833467|FG007|Overall Study|Adverse Event|1
6181943|NCT01340027|9833468|FG008|Overall Study|Adverse Event|4
6181944|NCT01340027|9833469|FG009|Overall Study|Adverse Event|1
6181945|NCT01340027|9833470|FG010|Overall Study|Adverse Event|1
6181946|NCT01340027|9833471|FG011|Overall Study|Adverse Event|3
6181947|NCT01340027|9833460|FG000|Overall Study|Lack of Efficacy|0
6181948|NCT01340027|9833461|FG001|Overall Study|Lack of Efficacy|0
6181949|NCT01340027|9833462|FG002|Overall Study|Lack of Efficacy|0
6181950|NCT01340027|9833463|FG003|Overall Study|Lack of Efficacy|0
6181951|NCT01340027|9833464|FG004|Overall Study|Lack of Efficacy|0
6181952|NCT01340027|9833465|FG005|Overall Study|Lack of Efficacy|0
6181953|NCT01340027|9833466|FG006|Overall Study|Lack of Efficacy|1
6181954|NCT01340027|9833467|FG007|Overall Study|Lack of Efficacy|1
6181955|NCT01340027|9833468|FG008|Overall Study|Lack of Efficacy|1
6181956|NCT01340027|9833469|FG009|Overall Study|Lack of Efficacy|0
6181957|NCT01340027|9833470|FG010|Overall Study|Lack of Efficacy|0
6181958|NCT01340027|9833471|FG011|Overall Study|Lack of Efficacy|0
6181959|NCT01340027|9833460|FG000|Overall Study|Lost to Follow-up|0
6181960|NCT01340027|9833461|FG001|Overall Study|Lost to Follow-up|1
6181961|NCT01340027|9833462|FG002|Overall Study|Lost to Follow-up|0
6181962|NCT01340027|9833463|FG003|Overall Study|Lost to Follow-up|0
6181963|NCT01340027|9833464|FG004|Overall Study|Lost to Follow-up|0
6181964|NCT01340027|9833465|FG005|Overall Study|Lost to Follow-up|0
6181965|NCT01340027|9833466|FG006|Overall Study|Lost to Follow-up|1
6181966|NCT01340027|9833467|FG007|Overall Study|Lost to Follow-up|0
6181967|NCT01340027|9833468|FG008|Overall Study|Lost to Follow-up|0
6181968|NCT01340027|9833469|FG009|Overall Study|Lost to Follow-up|1
6181969|NCT01340027|9833470|FG010|Overall Study|Lost to Follow-up|0
6181970|NCT01340027|9833471|FG011|Overall Study|Lost to Follow-up|0
6181971|NCT01340027|9833460|FG000|Overall Study|Protocol Violation|1
6181972|NCT01340027|9833461|FG001|Overall Study|Protocol Violation|2
6181973|NCT01340027|9833462|FG002|Overall Study|Protocol Violation|0
6181974|NCT01340027|9833463|FG003|Overall Study|Protocol Violation|0
6181975|NCT01340027|9833464|FG004|Overall Study|Protocol Violation|6
6181976|NCT01340027|9833465|FG005|Overall Study|Protocol Violation|0
6181977|NCT01340027|9833466|FG006|Overall Study|Protocol Violation|0
6181978|NCT01340027|9833467|FG007|Overall Study|Protocol Violation|1
6181979|NCT01340027|9833468|FG008|Overall Study|Protocol Violation|2
6181980|NCT01340027|9833469|FG009|Overall Study|Protocol Violation|2
6181981|NCT01340027|9833470|FG010|Overall Study|Protocol Violation|0
6181982|NCT01340027|9833471|FG011|Overall Study|Protocol Violation|0
6181983|NCT01340027|9833460|FG000|Overall Study|Withdrawal by Subject|4
6181984|NCT01340027|9833461|FG001|Overall Study|Withdrawal by Subject|3
6181985|NCT01340027|9833462|FG002|Overall Study|Withdrawal by Subject|1
6181986|NCT01340027|9833463|FG003|Overall Study|Withdrawal by Subject|3
6181987|NCT01340027|9833464|FG004|Overall Study|Withdrawal by Subject|3
6181988|NCT01340027|9833465|FG005|Overall Study|Withdrawal by Subject|2
6181989|NCT01340027|9833466|FG006|Overall Study|Withdrawal by Subject|3
6181990|NCT01340027|9833467|FG007|Overall Study|Withdrawal by Subject|4
6181991|NCT01340027|9833468|FG008|Overall Study|Withdrawal by Subject|1
6181992|NCT01340027|9833469|FG009|Overall Study|Withdrawal by Subject|2
6181993|NCT01340027|9833470|FG010|Overall Study|Withdrawal by Subject|0
6181994|NCT01340027|9833471|FG011|Overall Study|Withdrawal by Subject|1
6181995|NCT01340027|9833460|FG000|Overall Study|Miscellaneous|0
6181996|NCT01340027|9833461|FG001|Overall Study|Miscellaneous|0
6181997|NCT01340027|9833462|FG002|Overall Study|Miscellaneous|0
6181998|NCT01340027|9833463|FG003|Overall Study|Miscellaneous|1
6181999|NCT01340027|9833464|FG004|Overall Study|Miscellaneous|0
6182000|NCT01340027|9833465|FG005|Overall Study|Miscellaneous|0
6182001|NCT01340027|9833466|FG006|Overall Study|Miscellaneous|0
6182002|NCT01340027|9833467|FG007|Overall Study|Miscellaneous|0
6182003|NCT01340027|9833468|FG008|Overall Study|Miscellaneous|0
6182004|NCT01340027|9833469|FG009|Overall Study|Miscellaneous|0
6182005|NCT01340027|9833470|FG010|Overall Study|Miscellaneous|1
6182006|NCT01340027|9833471|FG011|Overall Study|Miscellaneous|0
6182007|NCT01340066|9833516|FG000|Placebo Run in Period|Screen Failures|27
6182008|NCT01340066|9833517|FG001|Placebo Run in Period|Screen Failures|0
6182009|NCT01340066|9833518|FG002|Placebo Run in Period|Screen Failures|0
6182010|NCT01340066|9833516|FG000|5 Week Double Blind Randomization Period|Adverse Event|0
6182011|NCT01340066|9833517|FG001|5 Week Double Blind Randomization Period|Adverse Event|2
6182012|NCT01340066|9833518|FG002|5 Week Double Blind Randomization Period|Adverse Event|2
6182013|NCT01340066|9833516|FG000|5 Week Double Blind Randomization Period|Physician Decision|0
6182014|NCT01340066|9833517|FG001|5 Week Double Blind Randomization Period|Physician Decision|1
6182015|NCT01340066|9833518|FG002|5 Week Double Blind Randomization Period|Physician Decision|0
6182016|NCT01340066|9833516|FG000|5 Week Double Blind Randomization Period|Withdrawal by Subject|0
6182017|NCT01340066|9833517|FG001|5 Week Double Blind Randomization Period|Withdrawal by Subject|2
6085331|NCT00651664|9694580|FG006|Overall Study|Reason not Specified|1
6085332|NCT00651664|9694581|FG007|Overall Study|Reason not Specified|0
6182018|NCT01340066|9833518|FG002|5 Week Double Blind Randomization Period|Withdrawal by Subject|1
6182019|NCT01340196|9833534|FG000|Treat. Period 3 (Faldaprevir)|Adverse Event|2
6182020|NCT01340209|9833546|FG000|Overall Study|Adverse Event|1
6182021|NCT01340209|9833547|FG001|Overall Study|Adverse Event|1
6182022|NCT01340209|9833548|FG002|Overall Study|Adverse Event|2
6182023|NCT01340209|9833546|FG000|Overall Study|Protocol Violation|1
6182024|NCT01340209|9833547|FG001|Overall Study|Protocol Violation|2
6085333|NCT00651664|9694582|FG008|Overall Study|Reason not Specified|0
6182025|NCT01340209|9833548|FG002|Overall Study|Protocol Violation|1
6182026|NCT01340209|9833546|FG000|Overall Study|Withdrawal by Subject|0
6182027|NCT01340209|9833547|FG001|Overall Study|Withdrawal by Subject|0
6182028|NCT01340209|9833548|FG002|Overall Study|Withdrawal by Subject|1
6182029|NCT01340209|9833546|FG000|Overall Study|Other reason not defined above|3
6182030|NCT01340209|9833547|FG001|Overall Study|Other reason not defined above|5
6182031|NCT01340209|9833548|FG002|Overall Study|Other reason not defined above|4
6182032|NCT01340300|9833560|FG000|Overall Study|Lost to Follow-up|3
6182033|NCT01340300|9833561|FG001|Overall Study|Lost to Follow-up|0
6182034|NCT01340300|9833562|FG002|Overall Study|Lost to Follow-up|5
6182035|NCT01340300|9833563|FG003|Overall Study|Lost to Follow-up|10
6182036|NCT01340300|9833560|FG000|Overall Study|Withdrawal by Subject|5
6182037|NCT01340300|9833561|FG001|Overall Study|Withdrawal by Subject|6
6182038|NCT01340300|9833562|FG002|Overall Study|Withdrawal by Subject|6
6182039|NCT01340300|9833563|FG003|Overall Study|Withdrawal by Subject|3
6182040|NCT01340300|9833560|FG000|Overall Study|Adverse Event|1
6182041|NCT01340300|9833561|FG001|Overall Study|Adverse Event|0
6182042|NCT01340300|9833562|FG002|Overall Study|Adverse Event|4
6182043|NCT01340300|9833563|FG003|Overall Study|Adverse Event|0
6182044|NCT01340300|9833560|FG000|Overall Study|Physician Decision|0
6182045|NCT01340300|9833561|FG001|Overall Study|Physician Decision|1
6182046|NCT01340300|9833562|FG002|Overall Study|Physician Decision|0
6182047|NCT01340300|9833563|FG003|Overall Study|Physician Decision|0
6182048|NCT01340300|9833560|FG000|Overall Study|Unrelated sickness|0
6182049|NCT01340300|9833561|FG001|Overall Study|Unrelated sickness|2
6182050|NCT01340300|9833562|FG002|Overall Study|Unrelated sickness|0
6182051|NCT01340300|9833563|FG003|Overall Study|Unrelated sickness|1
6182052|NCT01340482|9833576|FG000|Overall Study|Adverse Event|2
6182053|NCT01340482|9833577|FG001|Overall Study|Adverse Event|0
6182054|NCT01340482|9833578|FG002|Overall Study|Adverse Event|0
6182055|NCT01340495|9833588|FG000|Overall Study|Withdrawal by Subject|1
6182056|NCT01340625|9833608|FG000|First Intervention|Adverse Event|1
6182057|NCT01340625|9833609|FG001|First Intervention|Adverse Event|0
6182058|NCT01340625|9833608|FG000|Washout Period of 28 Days|Withdrawal by Subject|1
6182059|NCT01340625|9833609|FG001|Washout Period of 28 Days|Withdrawal by Subject|0
6182060|NCT01340651|9833615|FG000|Overall Study|Adverse Event|3
6182061|NCT01340651|9833615|FG000|Overall Study|Consent Withdrawn|2
6182062|NCT01340651|9833615|FG000|Overall Study|Commercial Supply per Sponsor|12
6182063|NCT01340664|9833624|FG000|Overall Study|Adverse Event|0
6182064|NCT01340664|9833625|FG001|Overall Study|Adverse Event|1
6182065|NCT01340664|9833626|FG002|Overall Study|Adverse Event|7
6182066|NCT01340664|9833624|FG000|Overall Study|Lost to Follow-up|2
6182067|NCT01340664|9833625|FG001|Overall Study|Lost to Follow-up|0
6182068|NCT01340664|9833626|FG002|Overall Study|Lost to Follow-up|2
6182069|NCT01340664|9833624|FG000|Overall Study|Withdrawal by Subject|2
6182070|NCT01340664|9833625|FG001|Overall Study|Withdrawal by Subject|4
6182071|NCT01340664|9833626|FG002|Overall Study|Withdrawal by Subject|0
6182072|NCT01340664|9833624|FG000|Overall Study|Glycemic withdrawal criteria|2
6182073|NCT01340664|9833625|FG001|Overall Study|Glycemic withdrawal criteria|0
6182074|NCT01340664|9833626|FG002|Overall Study|Glycemic withdrawal criteria|0
6182075|NCT01340664|9833624|FG000|Overall Study|Creatinine or eGFR withdrawal criteria|0
6182076|NCT01340664|9833625|FG001|Overall Study|Creatinine or eGFR withdrawal criteria|1
6182077|NCT01340664|9833626|FG002|Overall Study|Creatinine or eGFR withdrawal criteria|2
6182078|NCT01340664|9833624|FG000|Overall Study|Other|1
6182079|NCT01340664|9833625|FG001|Overall Study|Other|2
6182080|NCT01340664|9833626|FG002|Overall Study|Other|2
6182081|NCT01340768|9833636|FG000|Overall Study|Lost to Follow-up|10
6182082|NCT01340768|9833637|FG001|Overall Study|Lost to Follow-up|4
6182083|NCT01340768|9833636|FG000|Overall Study|Withdrawal by Subject|5
6182084|NCT01340768|9833637|FG001|Overall Study|Withdrawal by Subject|1
6182085|NCT01340768|9833636|FG000|Overall Study|Other|2
6182086|NCT01340768|9833637|FG001|Overall Study|Other|0
6182087|NCT01340794|9833645|FG000|Overall Study|Withdrawal by Subject|0
6182088|NCT01340794|9833646|FG001|Overall Study|Withdrawal by Subject|1
6182089|NCT01340872|9833656|FG000|Double-blind Phase|Adverse Event|6
6182090|NCT01340872|9833657|FG001|Double-blind Phase|Adverse Event|4
6182091|NCT01340872|9833658|FG002|Double-blind Phase|Adverse Event|0
6182092|NCT01340872|9833659|FG003|Double-blind Phase|Adverse Event|0
6182093|NCT01340872|9833656|FG000|Double-blind Phase|Withdrawal by Subject|3
6182094|NCT01340872|9833657|FG001|Double-blind Phase|Withdrawal by Subject|5
6182095|NCT01340872|9833658|FG002|Double-blind Phase|Withdrawal by Subject|0
6182096|NCT01340872|9833659|FG003|Double-blind Phase|Withdrawal by Subject|0
6182097|NCT01340872|9833656|FG000|Double-blind Phase|Lost to Follow-up|0
6182098|NCT01340872|9833657|FG001|Double-blind Phase|Lost to Follow-up|1
6182099|NCT01340872|9833658|FG002|Double-blind Phase|Lost to Follow-up|0
6182100|NCT01340872|9833659|FG003|Double-blind Phase|Lost to Follow-up|0
6182101|NCT01340872|9833656|FG000|Double-blind Phase|Protocol Violation|0
6182102|NCT01340872|9833657|FG001|Double-blind Phase|Protocol Violation|1
6182103|NCT01340872|9833658|FG002|Double-blind Phase|Protocol Violation|0
6182104|NCT01340872|9833659|FG003|Double-blind Phase|Protocol Violation|0
6182105|NCT01340872|9833656|FG000|Open-label Phase|Physician Decision|0
6182106|NCT01340872|9833657|FG001|Open-label Phase|Physician Decision|0
6182107|NCT01340872|9833658|FG002|Open-label Phase|Physician Decision|2
6182108|NCT01340872|9833659|FG003|Open-label Phase|Physician Decision|1
6182109|NCT01340872|9833656|FG000|Open-label Phase|Pregnancy|0
6182110|NCT01340872|9833657|FG001|Open-label Phase|Pregnancy|0
6182111|NCT01340872|9833658|FG002|Open-label Phase|Pregnancy|1
6182112|NCT01340872|9833659|FG003|Open-label Phase|Pregnancy|0
6182113|NCT01340872|9833656|FG000|Open-label Phase|Adverse Event|0
6182114|NCT01340872|9833657|FG001|Open-label Phase|Adverse Event|0
6182115|NCT01340872|9833658|FG002|Open-label Phase|Adverse Event|8
6182116|NCT01340872|9833659|FG003|Open-label Phase|Adverse Event|4
6182117|NCT01340872|9833656|FG000|Open-label Phase|Withdrawal by Subject|0
6182118|NCT01340872|9833657|FG001|Open-label Phase|Withdrawal by Subject|0
6182119|NCT01340872|9833658|FG002|Open-label Phase|Withdrawal by Subject|1
6182120|NCT01340872|9833659|FG003|Open-label Phase|Withdrawal by Subject|6
6182121|NCT01340872|9833656|FG000|Open-label Phase|Worsening of IBD|0
6182122|NCT01340872|9833657|FG001|Open-label Phase|Worsening of IBD|0
6182123|NCT01340872|9833658|FG002|Open-label Phase|Worsening of IBD|1
6182124|NCT01340872|9833659|FG003|Open-label Phase|Worsening of IBD|0
6182125|NCT01340898|9833674|FG000|Primary Phase|Serious Adverse Events|0
6182126|NCT01340898|9833675|FG001|Primary Phase|Serious Adverse Events|0
6182127|NCT01340898|9833676|FG002|Primary Phase|Serious Adverse Events|1
6182128|NCT01340898|9833674|FG000|Primary Phase|Withdrawal by Subject|8
6182129|NCT01340898|9833675|FG001|Primary Phase|Withdrawal by Subject|7
6182130|NCT01340898|9833676|FG002|Primary Phase|Withdrawal by Subject|5
6182131|NCT01340898|9833674|FG000|Primary Phase|Migrated/moved from study area|4
6182132|NCT01340898|9833675|FG001|Primary Phase|Migrated/moved from study area|1
6182133|NCT01340898|9833676|FG002|Primary Phase|Migrated/moved from study area|0
6182134|NCT01340898|9833674|FG000|Primary Phase|Lost to Follow-up|4
6182135|NCT01340898|9833675|FG001|Primary Phase|Lost to Follow-up|1
6182136|NCT01340898|9833676|FG002|Primary Phase|Lost to Follow-up|0
6182137|NCT01340898|9833674|FG000|Booster Phase|Withdrawal by Subject|3
6182138|NCT01340898|9833675|FG001|Booster Phase|Withdrawal by Subject|0
6182139|NCT01340898|9833676|FG002|Booster Phase|Withdrawal by Subject|4
6182140|NCT01340898|9833674|FG000|Booster Phase|Migrated/moved from study area|3
6182141|NCT01340898|9833675|FG001|Booster Phase|Migrated/moved from study area|0
6182142|NCT01340898|9833676|FG002|Booster Phase|Migrated/moved from study area|0
6182143|NCT01340898|9833674|FG000|Booster Phase|Lost to Follow-up|4
6182144|NCT01340898|9833675|FG001|Booster Phase|Lost to Follow-up|2
6182145|NCT01340898|9833676|FG002|Booster Phase|Lost to Follow-up|3
6182146|NCT01340937|9833690|FG000|Period 1: Infant Series|Other protocol criterion not met|0
6182147|NCT01340937|9833691|FG001|Period 1: Infant Series|Other protocol criterion not met|1
6182148|NCT01340937|9833692|FG002|Period 1: Infant Series|Other protocol criterion not met|1
6182149|NCT01340937|9833693|FG003|Period 1: Infant Series|Other protocol criterion not met|0
6182150|NCT01340937|9833690|FG000|Period 1: Infant Series|Adverse Event|0
6182151|NCT01340937|9833691|FG001|Period 1: Infant Series|Adverse Event|1
6182152|NCT01340937|9833692|FG002|Period 1: Infant Series|Adverse Event|4
6182153|NCT01340937|9833693|FG003|Period 1: Infant Series|Adverse Event|0
6182154|NCT01340937|9833690|FG000|Period 1: Infant Series|Death|2
6182155|NCT01340937|9833691|FG001|Period 1: Infant Series|Death|0
6182156|NCT01340937|9833692|FG002|Period 1: Infant Series|Death|2
6182157|NCT01340937|9833693|FG003|Period 1: Infant Series|Death|0
6182158|NCT01340937|9833690|FG000|Period 1: Infant Series|Lost to Follow-up|20
6182159|NCT01340937|9833691|FG001|Period 1: Infant Series|Lost to Follow-up|14
6182160|NCT01340937|9833692|FG002|Period 1: Infant Series|Lost to Follow-up|12
6182161|NCT01340937|9833693|FG003|Period 1: Infant Series|Lost to Follow-up|13
6227885|NCT01720524|9900843|FG001|Part A|Withdrawal by Subject|1
6227886|NCT01720524|9900842|FG000|Part A|Other|0
6227887|NCT01720524|9900843|FG001|Part A|Other|1
6227888|NCT01720524|9900842|FG000|Part A|Lost to Follow-up|0
6227889|NCT01720524|9900843|FG001|Part A|Lost to Follow-up|1
6227890|NCT01720524|9900842|FG000|Part B|No longer willing to participate in study|1
6227891|NCT01720524|9900843|FG001|Part B|No longer willing to participate in study|4
6227892|NCT01720524|9900842|FG000|Part B|Other|2
6227893|NCT01720524|9900843|FG001|Part B|Other|0
6227894|NCT01720524|9900842|FG000|Part B|Lost to Follow-up|2
6227895|NCT01720524|9900843|FG001|Part B|Lost to Follow-up|3
6227896|NCT01720524|9900842|FG000|Part B|Death|0
6227897|NCT01720524|9900843|FG001|Part B|Death|2
6227898|NCT01720602|9900851|FG000|Overall Study|Adverse Event|3
6227899|NCT01720602|9900851|FG000|Overall Study|Progressive disease on therapy|2
6227900|NCT01720667|9900857|FG000|Overall Study|Adverse Event|1
6227901|NCT01720667|9900858|FG001|Overall Study|Adverse Event|1
6227902|NCT01720667|9900857|FG000|Overall Study|Withdrawal by Subject|3
6227903|NCT01720667|9900858|FG001|Overall Study|Withdrawal by Subject|0
6227904|NCT01720797|9900868|FG000|Overall Study|Withdrawal by Subject|3
6227905|NCT01720797|9900869|FG001|Overall Study|Withdrawal by Subject|0
6227906|NCT01721044|9900878|FG000|Treatment Period|Adverse Event|7
6227907|NCT01721044|9900879|FG001|Treatment Period|Adverse Event|7
6227908|NCT01721044|9900880|FG002|Treatment Period|Adverse Event|10
6227909|NCT01721044|9900878|FG000|Treatment Period|Death|0
6227910|NCT01721044|9900879|FG001|Treatment Period|Death|0
6227911|NCT01721044|9900880|FG002|Treatment Period|Death|1
6182162|NCT01340937|9833690|FG000|Period 1: Infant Series|Physician Decision|2
6182163|NCT01340937|9833691|FG001|Period 1: Infant Series|Physician Decision|3
6227912|NCT01721044|9900878|FG000|Treatment Period|Lack of Efficacy|16
6227913|NCT01721044|9900879|FG001|Treatment Period|Lack of Efficacy|4
6227914|NCT01721044|9900880|FG002|Treatment Period|Lack of Efficacy|4
6227915|NCT01721044|9900878|FG000|Treatment Period|Lost to Follow-up|0
6182164|NCT01340937|9833692|FG002|Period 1: Infant Series|Physician Decision|1
6182165|NCT01340937|9833693|FG003|Period 1: Infant Series|Physician Decision|0
6182166|NCT01340937|9833690|FG000|Period 1: Infant Series|Protocol Violation|1
6182167|NCT01340937|9833691|FG001|Period 1: Infant Series|Protocol Violation|4
6182168|NCT01340937|9833692|FG002|Period 1: Infant Series|Protocol Violation|4
6182169|NCT01340937|9833693|FG003|Period 1: Infant Series|Protocol Violation|3
6182170|NCT01340937|9833690|FG000|Period 1: Infant Series|Withdrawal by Subject|33
6182171|NCT01340937|9833691|FG001|Period 1: Infant Series|Withdrawal by Subject|32
6182172|NCT01340937|9833692|FG002|Period 1: Infant Series|Withdrawal by Subject|30
6182173|NCT01340937|9833693|FG003|Period 1: Infant Series|Withdrawal by Subject|15
6182174|NCT01340937|9833690|FG000|Period 1: Infant Series|Randomized but not vaccinated|0
6182175|NCT01340937|9833691|FG001|Period 1: Infant Series|Randomized but not vaccinated|5
6182176|NCT01340937|9833692|FG002|Period 1: Infant Series|Randomized but not vaccinated|2
6182177|NCT01340937|9833693|FG003|Period 1: Infant Series|Randomized but not vaccinated|1
6182178|NCT01340937|9833690|FG000|Period 2: Interim Period|Withdrawal by Subject|28
6182179|NCT01340937|9833691|FG001|Period 2: Interim Period|Withdrawal by Subject|23
6182180|NCT01340937|9833692|FG002|Period 2: Interim Period|Withdrawal by Subject|17
6182181|NCT01340937|9833693|FG003|Period 2: Interim Period|Withdrawal by Subject|12
6182182|NCT01340937|9833690|FG000|Period 2: Interim Period|Adverse Event|1
6182183|NCT01340937|9833691|FG001|Period 2: Interim Period|Adverse Event|0
6182184|NCT01340937|9833692|FG002|Period 2: Interim Period|Adverse Event|1
6182185|NCT01340937|9833693|FG003|Period 2: Interim Period|Adverse Event|0
6182186|NCT01340937|9833690|FG000|Period 2: Interim Period|Lost to Follow-up|29
6182187|NCT01340937|9833691|FG001|Period 2: Interim Period|Lost to Follow-up|48
6182188|NCT01340937|9833692|FG002|Period 2: Interim Period|Lost to Follow-up|53
6182189|NCT01340937|9833693|FG003|Period 2: Interim Period|Lost to Follow-up|23
6182190|NCT01340937|9833690|FG000|Period 2: Interim Period|Physician Decision|0
6182191|NCT01340937|9833691|FG001|Period 2: Interim Period|Physician Decision|1
6182192|NCT01340937|9833692|FG002|Period 2: Interim Period|Physician Decision|1
6182193|NCT01340937|9833693|FG003|Period 2: Interim Period|Physician Decision|0
6182194|NCT01340937|9833690|FG000|Period 2: Interim Period|Protocol Violation|5
6182195|NCT01340937|9833691|FG001|Period 2: Interim Period|Protocol Violation|3
6182196|NCT01340937|9833692|FG002|Period 2: Interim Period|Protocol Violation|6
6182197|NCT01340937|9833693|FG003|Period 2: Interim Period|Protocol Violation|3
6182198|NCT01340937|9833690|FG000|Period 2: Interim Period|Technical problems|4
6182199|NCT01340937|9833691|FG001|Period 2: Interim Period|Technical problems|4
6182200|NCT01340937|9833692|FG002|Period 2: Interim Period|Technical problems|6
6182201|NCT01340937|9833693|FG003|Period 2: Interim Period|Technical problems|3
6182202|NCT01340937|9833690|FG000|Period 3: Toddler Vaccinations|Withdrawal by Subject|2
6182203|NCT01340937|9833691|FG001|Period 3: Toddler Vaccinations|Withdrawal by Subject|2
6182204|NCT01340937|9833692|FG002|Period 3: Toddler Vaccinations|Withdrawal by Subject|1
6182205|NCT01340937|9833693|FG003|Period 3: Toddler Vaccinations|Withdrawal by Subject|1
6182206|NCT01340937|9833690|FG000|Period 3: Toddler Vaccinations|Lost to Follow-up|6
6182207|NCT01340937|9833691|FG001|Period 3: Toddler Vaccinations|Lost to Follow-up|14
6182208|NCT01340937|9833692|FG002|Period 3: Toddler Vaccinations|Lost to Follow-up|7
6182209|NCT01340937|9833693|FG003|Period 3: Toddler Vaccinations|Lost to Follow-up|8
6182210|NCT01340937|9833690|FG000|Period 3: Toddler Vaccinations|Protocol Violation|0
6182211|NCT01340937|9833691|FG001|Period 3: Toddler Vaccinations|Protocol Violation|0
6182212|NCT01340937|9833692|FG002|Period 3: Toddler Vaccinations|Protocol Violation|0
6182213|NCT01340937|9833693|FG003|Period 3: Toddler Vaccinations|Protocol Violation|1
6182214|NCT01340937|9833690|FG000|Period 3: Toddler Vaccinations|Technical problem|1
6182215|NCT01340937|9833691|FG001|Period 3: Toddler Vaccinations|Technical problem|1
6182216|NCT01340937|9833692|FG002|Period 3: Toddler Vaccinations|Technical problem|1
6182217|NCT01340937|9833693|FG003|Period 3: Toddler Vaccinations|Technical problem|0
6182218|NCT01340976|9833715|FG000|Overall Study|Physician Decision|2
6182219|NCT01340976|9833716|FG001|Overall Study|Physician Decision|0
6182220|NCT01340976|9833717|FG002|Overall Study|Physician Decision|1
6182221|NCT01340976|9833718|FG003|Overall Study|Physician Decision|1
6182222|NCT01340976|9833719|FG004|Overall Study|Physician Decision|1
6182223|NCT01340976|9833720|FG005|Overall Study|Physician Decision|0
6182224|NCT01340976|9833715|FG000|Overall Study|Death|0
6182225|NCT01340976|9833716|FG001|Overall Study|Death|1
6182226|NCT01340976|9833717|FG002|Overall Study|Death|0
6182227|NCT01340976|9833718|FG003|Overall Study|Death|0
6182228|NCT01340976|9833719|FG004|Overall Study|Death|0
6182229|NCT01340976|9833720|FG005|Overall Study|Death|0
6182230|NCT01340976|9833715|FG000|Overall Study|Dose Limiting Toxicity Stopping Rule|1
6182231|NCT01340976|9833716|FG001|Overall Study|Dose Limiting Toxicity Stopping Rule|0
6182232|NCT01340976|9833717|FG002|Overall Study|Dose Limiting Toxicity Stopping Rule|0
6182233|NCT01340976|9833718|FG003|Overall Study|Dose Limiting Toxicity Stopping Rule|0
6182234|NCT01340976|9833719|FG004|Overall Study|Dose Limiting Toxicity Stopping Rule|0
6182235|NCT01340976|9833720|FG005|Overall Study|Dose Limiting Toxicity Stopping Rule|0
6182236|NCT01340976|9833715|FG000|Overall Study|Withdrawal by Subject|0
6182237|NCT01340976|9833716|FG001|Overall Study|Withdrawal by Subject|0
6182238|NCT01340976|9833717|FG002|Overall Study|Withdrawal by Subject|0
6182239|NCT01340976|9833718|FG003|Overall Study|Withdrawal by Subject|1
6182240|NCT01340976|9833719|FG004|Overall Study|Withdrawal by Subject|1
6043580|NCT00391053|9642297|FG000|Overall Study|Serious Adverse Events|1
6043581|NCT00391053|9642298|FG001|Overall Study|Serious Adverse Events|0
6043582|NCT00391053|9642299|FG002|Overall Study|Serious Adverse Events|1
6043583|NCT00391053|9642300|FG003|Overall Study|Serious Adverse Events|4
6043584|NCT00391053|9642297|FG000|Overall Study|Protocol Violation|2
6043585|NCT00391053|9642298|FG001|Overall Study|Protocol Violation|0
6182241|NCT01340976|9833720|FG005|Overall Study|Withdrawal by Subject|0
6182242|NCT01340976|9833715|FG000|Overall Study|Other anemia treatment|1
6182243|NCT01340976|9833716|FG001|Overall Study|Other anemia treatment|0
6182244|NCT01340976|9833717|FG002|Overall Study|Other anemia treatment|2
6182245|NCT01340976|9833718|FG003|Overall Study|Other anemia treatment|1
6182246|NCT01340976|9833719|FG004|Overall Study|Other anemia treatment|0
6182247|NCT01340976|9833720|FG005|Overall Study|Other anemia treatment|1
6182248|NCT01340976|9833715|FG000|Overall Study|Adverse Event|0
6182249|NCT01340976|9833716|FG001|Overall Study|Adverse Event|1
6182250|NCT01340976|9833717|FG002|Overall Study|Adverse Event|0
6182251|NCT01340976|9833718|FG003|Overall Study|Adverse Event|0
6182252|NCT01340976|9833719|FG004|Overall Study|Adverse Event|0
6182253|NCT01340976|9833720|FG005|Overall Study|Adverse Event|0
6182254|NCT01341457|9833761|FG000|Overall Study|Adverse Event|2
6182255|NCT01341457|9833762|FG001|Overall Study|Adverse Event|0
6182256|NCT01341470|9833775|FG000|Overall Study|Sponsor decision|0
6182257|NCT01341470|9833776|FG001|Overall Study|Sponsor decision|0
6182258|NCT01341470|9833777|FG002|Overall Study|Sponsor decision|1
6182259|NCT01341470|9833778|FG003|Overall Study|Sponsor decision|1
6182260|NCT01341470|9833779|FG004|Overall Study|Sponsor decision|0
6182261|NCT01341470|9833780|FG005|Overall Study|Sponsor decision|1
6182262|NCT01341639|9833798|FG000|Infant Series|Protocol Violation|1
6182263|NCT01341639|9833799|FG001|Infant Series|Protocol Violation|0
6182264|NCT01341639|9833798|FG000|Infant Series|Not Vaccinated|0
6182265|NCT01341639|9833799|FG001|Infant Series|Not Vaccinated|1
6182266|NCT01341639|9833798|FG000|Infant Series|Adverse Event|0
6182267|NCT01341639|9833799|FG001|Infant Series|Adverse Event|5
6182268|NCT01341639|9833798|FG000|Infant Series|Withdrawal by Subject|11
6182269|NCT01341639|9833799|FG001|Infant Series|Withdrawal by Subject|8
6182270|NCT01341639|9833798|FG000|Infant Series|Lost to Follow-up|0
6182271|NCT01341639|9833799|FG001|Infant Series|Lost to Follow-up|2
6182272|NCT01341639|9833798|FG000|Infant Series|Site 0048 Participants|17
6182273|NCT01341639|9833799|FG001|Infant Series|Site 0048 Participants|16
6182274|NCT01341639|9833798|FG000|Interim Period|Withdrawal by Subject|6
6182275|NCT01341639|9833799|FG001|Interim Period|Withdrawal by Subject|7
6182276|NCT01341639|9833798|FG000|Interim Period|Lost to Follow-up|2
6182277|NCT01341639|9833799|FG001|Interim Period|Lost to Follow-up|0
6182278|NCT01341639|9833798|FG000|Interim Period|Physician Decision|0
6182279|NCT01341639|9833799|FG001|Interim Period|Physician Decision|1
6182280|NCT01341639|9833798|FG000|Interim Period|Protocol Violation|0
6182281|NCT01341639|9833799|FG001|Interim Period|Protocol Violation|1
6182282|NCT01341639|9833798|FG000|Post-Treatment|Withdrawal by Subject|0
6182283|NCT01341639|9833799|FG001|Post-Treatment|Withdrawal by Subject|1
6182284|NCT01341639|9833798|FG000|Post-Treatment|Adverse Event|0
6182285|NCT01341639|9833799|FG001|Post-Treatment|Adverse Event|2
6182286|NCT01341652|9833807|FG000|Overall Study|Incorrect Random Assignment|0
6182287|NCT01341652|9833808|FG001|Overall Study|Incorrect Random Assignment|1
6182288|NCT01341652|9833807|FG000|Overall Study|ineligible; presence metastatic disease|0
6182289|NCT01341652|9833808|FG001|Overall Study|ineligible; presence metastatic disease|1
6182290|NCT01341782|9833827|FG000|Overall Study|Adverse Event|1
6182291|NCT01341782|9833828|FG001|Overall Study|Adverse Event|1
6182292|NCT01341782|9833827|FG000|Overall Study|Withdrawal by Subject|6
6182293|NCT01341782|9833828|FG001|Overall Study|Withdrawal by Subject|5
6182294|NCT01341782|9833827|FG000|Overall Study|Missed 3 consecutive doses|0
6182295|NCT01341782|9833828|FG001|Overall Study|Missed 3 consecutive doses|4
6182296|NCT01341782|9833827|FG000|Overall Study|2 consecutive calcium values >11.5 mg/dL|0
6182297|NCT01341782|9833828|FG001|Overall Study|2 consecutive calcium values >11.5 mg/dL|1
6182298|NCT01341782|9833827|FG000|Overall Study|2 consecutive calcium values < 8.4 mg/dL|3
6182299|NCT01341782|9833828|FG001|Overall Study|2 consecutive calcium values < 8.4 mg/dL|3
6182300|NCT01341782|9833827|FG000|Overall Study|Other|5
6182301|NCT01341782|9833828|FG001|Overall Study|Other|0
6182302|NCT01341990|9833849|FG000|Overall Study|Adverse Event|0
6182303|NCT01341990|9833850|FG001|Overall Study|Adverse Event|1
6182304|NCT01341990|9833849|FG000|Overall Study|Torn Study Lens|1
6182305|NCT01341990|9833850|FG001|Overall Study|Torn Study Lens|0
6182306|NCT01341990|9833849|FG000|Overall Study|Withdrawal by Subject|2
6182307|NCT01341990|9833850|FG001|Overall Study|Withdrawal by Subject|0
6182308|NCT01342081|9833868|FG000|Overall Study|Did not receive allocated intervention|0
6182309|NCT01342081|9833869|FG001|Overall Study|Did not receive allocated intervention|0
6182310|NCT01342081|9833870|FG002|Overall Study|Did not receive allocated intervention|1
6182311|NCT01342081|9833868|FG000|Overall Study|Adverse Event|1
6182312|NCT01342081|9833869|FG001|Overall Study|Adverse Event|0
6182313|NCT01342081|9833870|FG002|Overall Study|Adverse Event|0
6182314|NCT01342081|9833868|FG000|Overall Study|Physician Decision|0
6182315|NCT01342081|9833869|FG001|Overall Study|Physician Decision|1
6182316|NCT01342081|9833870|FG002|Overall Study|Physician Decision|0
6182317|NCT01342081|9833868|FG000|Overall Study|Withdrawal by Subject|1
6182318|NCT01342081|9833869|FG001|Overall Study|Withdrawal by Subject|1
6085334|NCT00651664|9694583|FG009|Overall Study|Reason not Specified|0
6085335|NCT00651755|9694609|FG000|Cycle 1 (First 21 Days)|Withdrawal by Subject|1
6182319|NCT01342081|9833870|FG002|Overall Study|Withdrawal by Subject|0
6182320|NCT01342094|9833880|FG000|Overall Study|Adverse Event|5
6182321|NCT01342094|9833881|FG001|Overall Study|Adverse Event|0
6182322|NCT01342094|9833880|FG000|Overall Study|Not meeting inclusion/exclusion criteria|0
6182323|NCT01342094|9833881|FG001|Overall Study|Not meeting inclusion/exclusion criteria|1
6182324|NCT01342094|9833880|FG000|Overall Study|Withdrawal by Subject|0
6182325|NCT01342094|9833881|FG001|Overall Study|Withdrawal by Subject|2
6182326|NCT01342211|9833906|FG000|Overall Study|Lost to Follow-up|0
6085336|NCT00651755|9694610|FG001|Cycle 1 (First 21 Days)|Withdrawal by Subject|0
6182327|NCT01342211|9833907|FG001|Overall Study|Lost to Follow-up|0
6182328|NCT01342211|9833908|FG002|Overall Study|Lost to Follow-up|0
6182329|NCT01342211|9833909|FG003|Overall Study|Lost to Follow-up|1
6182330|NCT01342211|9833910|FG004|Overall Study|Lost to Follow-up|0
6182331|NCT01342211|9833906|FG000|Overall Study|Adverse Event|0
6182332|NCT01342211|9833907|FG001|Overall Study|Adverse Event|0
6182333|NCT01342211|9833908|FG002|Overall Study|Adverse Event|0
6182334|NCT01342211|9833909|FG003|Overall Study|Adverse Event|0
6182335|NCT01342211|9833910|FG004|Overall Study|Adverse Event|1
6182336|NCT01342211|9833906|FG000|Overall Study|Withdrawal by Subject|0
6182337|NCT01342211|9833907|FG001|Overall Study|Withdrawal by Subject|0
6182338|NCT01342211|9833908|FG002|Overall Study|Withdrawal by Subject|0
6182339|NCT01342211|9833909|FG003|Overall Study|Withdrawal by Subject|1
6182340|NCT01342211|9833910|FG004|Overall Study|Withdrawal by Subject|0
6182341|NCT01342211|9833906|FG000|Overall Study|Randomized, but not Treated|0
6182342|NCT01342211|9833907|FG001|Overall Study|Randomized, but not Treated|2
6182343|NCT01342211|9833908|FG002|Overall Study|Randomized, but not Treated|0
6182344|NCT01342211|9833909|FG003|Overall Study|Randomized, but not Treated|0
6182345|NCT01342211|9833910|FG004|Overall Study|Randomized, but not Treated|1
6182346|NCT01342341|9833928|FG000|Overall Study|Lost to Follow-up|4
6182347|NCT01342341|9833929|FG001|Overall Study|Lost to Follow-up|4
6182348|NCT01342367|9833937|FG000|Overall Study|Death|1
6182349|NCT01342367|9833938|FG001|Overall Study|Death|0
6182350|NCT01342367|9833937|FG000|Overall Study|Withdrawal by Subject|1
6182351|NCT01342367|9833938|FG001|Overall Study|Withdrawal by Subject|2
6182352|NCT01342445|9833946|FG000|Overall Study|Experienced side effects|0
6182353|NCT01342445|9833947|FG001|Overall Study|Experienced side effects|2
6085337|NCT00651755|9694609|FG000|Cycle 2 (Second 21 Days)|Not Evaluable|0
6182354|NCT01342484|9833992|FG000|Overall Study|Other Reasons|1
6182355|NCT01342484|9833993|FG001|Overall Study|Other Reasons|0
6182356|NCT01342484|9833994|FG002|Overall Study|Other Reasons|0
6182357|NCT01342484|9833992|FG000|Overall Study|Protocol Violation|0
6182358|NCT01342484|9833993|FG001|Overall Study|Protocol Violation|0
6182359|NCT01342484|9833994|FG002|Overall Study|Protocol Violation|1
6182360|NCT01342484|9833992|FG000|Overall Study|Withdrawal by Subject|1
6182361|NCT01342484|9833993|FG001|Overall Study|Withdrawal by Subject|0
6182362|NCT01342484|9833994|FG002|Overall Study|Withdrawal by Subject|0
6182363|NCT01342510|9834006|FG000|Overall Study|Protocol Violation|12
6182364|NCT01342510|9834007|FG001|Overall Study|Protocol Violation|6
6182365|NCT01342510|9834008|FG002|Overall Study|Protocol Violation|13
6182366|NCT01342510|9834009|FG003|Overall Study|Protocol Violation|11
6182367|NCT01342640|9834108|FG000|Overall Study|Adverse Event|3
6182368|NCT01342640|9834108|FG000|Overall Study|Protocol Violation|16
6182369|NCT01342640|9834108|FG000|Overall Study|Lost to Follow-up|21
6182370|NCT01342640|9834108|FG000|Overall Study|Other|1
6192789|NCT01434290|9850401|FG000|Overall Study|No protocol treatment|2
6192790|NCT01434290|9850402|FG001|Overall Study|No protocol treatment|4
6192791|NCT01434654|9850428|FG000|Overall Study|Withdrawal by Subject|1
6192792|NCT01434654|9850429|FG001|Overall Study|Withdrawal by Subject|0
6192793|NCT01434654|9850428|FG000|Overall Study|Lost to Follow-up|1
6192794|NCT01434654|9850429|FG001|Overall Study|Lost to Follow-up|0
6192795|NCT01434667|9850439|FG000|Overall Study|Lost to Follow-up|5
6192796|NCT01434667|9850440|FG001|Overall Study|Lost to Follow-up|10
6192797|NCT01434680|9850450|FG000|Overall Study|Withdrawal by Subject|1
6192798|NCT01434680|9850451|FG001|Overall Study|Withdrawal by Subject|0
6192799|NCT01434680|9850452|FG002|Overall Study|Withdrawal by Subject|2
6192800|NCT01434680|9850453|FG003|Overall Study|Withdrawal by Subject|0
6192801|NCT01434680|9850450|FG000|Overall Study|Lost to Follow-up|1
6192802|NCT01434680|9850451|FG001|Overall Study|Lost to Follow-up|1
6192803|NCT01434680|9850452|FG002|Overall Study|Lost to Follow-up|0
6192804|NCT01434680|9850453|FG003|Overall Study|Lost to Follow-up|0
6192805|NCT01434680|9850450|FG000|Overall Study|Protocol Violation|1
6192806|NCT01434680|9850451|FG001|Overall Study|Protocol Violation|1
6192807|NCT01434680|9850452|FG002|Overall Study|Protocol Violation|0
6192808|NCT01434680|9850453|FG003|Overall Study|Protocol Violation|0
6192809|NCT01434693|9850467|FG000|Overall Study|Adverse Event|1
6085338|NCT00651755|9694610|FG001|Cycle 2 (Second 21 Days)|Not Evaluable|1
6192810|NCT01434693|9850468|FG001|Overall Study|Adverse Event|0
6192811|NCT01434693|9850469|FG002|Overall Study|Adverse Event|0
6182371|NCT01342796|9834131|FG000|Overall Study|Withdrawal by Subject|2
6182372|NCT01342796|9834132|FG001|Overall Study|Withdrawal by Subject|0
6182373|NCT01342796|9834131|FG000|Overall Study|Lost to Follow-up|0
6182374|NCT01342796|9834132|FG001|Overall Study|Lost to Follow-up|3
6182375|NCT01342796|9834131|FG000|Overall Study|Inappropriate enrollment|1
6182376|NCT01342796|9834132|FG001|Overall Study|Inappropriate enrollment|0
6182377|NCT01342887|9834138|FG000|Overall Study|Death|2
6182378|NCT01342913|9834144|FG000|2-week Run-in Period|Inclusion/Exclusion Criteria Not Met|66
6182379|NCT01342913|9834145|FG001|2-week Run-in Period|Inclusion/Exclusion Criteria Not Met|0
6182380|NCT01342913|9834146|FG002|2-week Run-in Period|Inclusion/Exclusion Criteria Not Met|0
6182381|NCT01342913|9834144|FG000|2-week Run-in Period|Physician Decision|6
6182382|NCT01342913|9834145|FG001|2-week Run-in Period|Physician Decision|0
6182383|NCT01342913|9834146|FG002|2-week Run-in Period|Physician Decision|0
6182384|NCT01342913|9834144|FG000|2-week Run-in Period|Withdrawal by Subject|7
6227916|NCT01721044|9900879|FG001|Treatment Period|Lost to Follow-up|0
6227917|NCT01721044|9900880|FG002|Treatment Period|Lost to Follow-up|1
6227918|NCT01721044|9900878|FG000|Treatment Period|Physician Decision|1
6227919|NCT01721044|9900879|FG001|Treatment Period|Physician Decision|0
6227920|NCT01721044|9900880|FG002|Treatment Period|Physician Decision|2
6227921|NCT01721044|9900878|FG000|Treatment Period|Protocol Violation|1
6227922|NCT01721044|9900879|FG001|Treatment Period|Protocol Violation|0
6227923|NCT01721044|9900880|FG002|Treatment Period|Protocol Violation|0
6227924|NCT01721044|9900878|FG000|Treatment Period|Withdrawal by Subject|7
6227925|NCT01721044|9900879|FG001|Treatment Period|Withdrawal by Subject|6
6227926|NCT01721044|9900880|FG002|Treatment Period|Withdrawal by Subject|1
6227927|NCT01721057|9900902|FG000|Treatment Period|Withdrawal by Subject|11
6227928|NCT01721057|9900903|FG001|Treatment Period|Withdrawal by Subject|5
6227929|NCT01721057|9900904|FG002|Treatment Period|Withdrawal by Subject|8
6227930|NCT01721057|9900905|FG003|Treatment Period|Withdrawal by Subject|0
6227931|NCT01721057|9900906|FG004|Treatment Period|Withdrawal by Subject|0
6227932|NCT01721057|9900907|FG005|Treatment Period|Withdrawal by Subject|0
6227933|NCT01721057|9900908|FG006|Treatment Period|Withdrawal by Subject|0
6227934|NCT01721057|9900902|FG000|Treatment Period|Adverse Event|7
6227935|NCT01721057|9900903|FG001|Treatment Period|Adverse Event|10
6227936|NCT01721057|9900904|FG002|Treatment Period|Adverse Event|12
6227937|NCT01721057|9900905|FG003|Treatment Period|Adverse Event|0
6227938|NCT01721057|9900906|FG004|Treatment Period|Adverse Event|0
6227939|NCT01721057|9900907|FG005|Treatment Period|Adverse Event|0
6227940|NCT01721057|9900908|FG006|Treatment Period|Adverse Event|0
6227941|NCT01721057|9900902|FG000|Treatment Period|Lack of Efficacy|7
6227942|NCT01721057|9900903|FG001|Treatment Period|Lack of Efficacy|3
6227943|NCT01721057|9900904|FG002|Treatment Period|Lack of Efficacy|0
6227944|NCT01721057|9900905|FG003|Treatment Period|Lack of Efficacy|0
6227945|NCT01721057|9900906|FG004|Treatment Period|Lack of Efficacy|0
6227946|NCT01721057|9900907|FG005|Treatment Period|Lack of Efficacy|0
6227947|NCT01721057|9900908|FG006|Treatment Period|Lack of Efficacy|0
6227948|NCT01721057|9900902|FG000|Treatment Period|Lost to Follow-up|1
6227949|NCT01721057|9900903|FG001|Treatment Period|Lost to Follow-up|0
6227950|NCT01721057|9900904|FG002|Treatment Period|Lost to Follow-up|0
6227951|NCT01721057|9900905|FG003|Treatment Period|Lost to Follow-up|0
6227952|NCT01721057|9900906|FG004|Treatment Period|Lost to Follow-up|0
6227953|NCT01721057|9900907|FG005|Treatment Period|Lost to Follow-up|0
6227954|NCT01721057|9900908|FG006|Treatment Period|Lost to Follow-up|0
6227955|NCT01721057|9900902|FG000|Treatment Period|Physician Decision|0
6227956|NCT01721057|9900903|FG001|Treatment Period|Physician Decision|1
6227957|NCT01721057|9900904|FG002|Treatment Period|Physician Decision|3
6227958|NCT01721057|9900905|FG003|Treatment Period|Physician Decision|0
6227959|NCT01721057|9900906|FG004|Treatment Period|Physician Decision|0
6227960|NCT01721057|9900907|FG005|Treatment Period|Physician Decision|0
6227961|NCT01721057|9900908|FG006|Treatment Period|Physician Decision|0
6227962|NCT01721057|9900902|FG000|Treatment Period|Death|2
6227963|NCT01721057|9900903|FG001|Treatment Period|Death|0
6227964|NCT01721057|9900904|FG002|Treatment Period|Death|0
6227965|NCT01721057|9900905|FG003|Treatment Period|Death|0
6227966|NCT01721057|9900906|FG004|Treatment Period|Death|0
6227967|NCT01721057|9900907|FG005|Treatment Period|Death|0
6227968|NCT01721057|9900908|FG006|Treatment Period|Death|0
6227969|NCT01721057|9900902|FG000|Rescue Period|Adverse Event|0
6227970|NCT01721057|9900903|FG001|Rescue Period|Adverse Event|0
6227971|NCT01721057|9900904|FG002|Rescue Period|Adverse Event|0
6227972|NCT01721057|9900905|FG003|Rescue Period|Adverse Event|1
6227973|NCT01721057|9900906|FG004|Rescue Period|Adverse Event|0
6227974|NCT01721057|9900907|FG005|Rescue Period|Adverse Event|0
6227975|NCT01721057|9900908|FG006|Rescue Period|Adverse Event|0
6227976|NCT01721057|9900902|FG000|Rescue Period|Lack of Efficacy|0
6227977|NCT01721057|9900903|FG001|Rescue Period|Lack of Efficacy|0
6227978|NCT01721057|9900904|FG002|Rescue Period|Lack of Efficacy|0
6227979|NCT01721057|9900905|FG003|Rescue Period|Lack of Efficacy|2
6227980|NCT01721057|9900906|FG004|Rescue Period|Lack of Efficacy|0
6227981|NCT01721057|9900907|FG005|Rescue Period|Lack of Efficacy|0
6227982|NCT01721057|9900908|FG006|Rescue Period|Lack of Efficacy|0
6227983|NCT01721070|9900935|FG000|Ketoconazole 400 mg and SUF NT 15 mcg|Withdrawal by Subject|1
6227984|NCT01721109|9900953|FG000|Overall Study|Lack of Efficacy|1
6227985|NCT01721109|9900953|FG000|Overall Study|Non- Compliance with Study Drug|3
6182385|NCT01342913|9834145|FG001|2-week Run-in Period|Withdrawal by Subject|0
6182386|NCT01342913|9834146|FG002|2-week Run-in Period|Withdrawal by Subject|0
6182387|NCT01342913|9834144|FG000|2-week Run-in Period|Adverse Event|2
6182388|NCT01342913|9834145|FG001|2-week Run-in Period|Adverse Event|0
6182389|NCT01342913|9834146|FG002|2-week Run-in Period|Adverse Event|0
6182390|NCT01342913|9834144|FG000|2-week Run-in Period|Protocol Violation|5
6182391|NCT01342913|9834145|FG001|2-week Run-in Period|Protocol Violation|0
6182392|NCT01342913|9834146|FG002|2-week Run-in Period|Protocol Violation|0
6182393|NCT01342913|9834144|FG000|2-week Run-in Period|Continuation Criteria Not Met|88
6182394|NCT01342913|9834145|FG001|2-week Run-in Period|Continuation Criteria Not Met|0
6182395|NCT01342913|9834146|FG002|2-week Run-in Period|Continuation Criteria Not Met|0
6182396|NCT01342913|9834144|FG000|Double-Blind Treatment Period|Adverse Event|0
6182397|NCT01342913|9834145|FG001|Double-Blind Treatment Period|Adverse Event|3
6182398|NCT01342913|9834146|FG002|Double-Blind Treatment Period|Adverse Event|6
6182399|NCT01342913|9834144|FG000|Double-Blind Treatment Period|Lack of Efficacy|0
6182400|NCT01342913|9834145|FG001|Double-Blind Treatment Period|Lack of Efficacy|2
6182401|NCT01342913|9834146|FG002|Double-Blind Treatment Period|Lack of Efficacy|3
6182402|NCT01342913|9834144|FG000|Double-Blind Treatment Period|Protocol Violation|0
6182403|NCT01342913|9834145|FG001|Double-Blind Treatment Period|Protocol Violation|6
6182404|NCT01342913|9834146|FG002|Double-Blind Treatment Period|Protocol Violation|9
6182405|NCT01342913|9834144|FG000|Double-Blind Treatment Period|Lost to Follow-up|0
6182406|NCT01342913|9834145|FG001|Double-Blind Treatment Period|Lost to Follow-up|1
6182407|NCT01342913|9834146|FG002|Double-Blind Treatment Period|Lost to Follow-up|3
6182408|NCT01342913|9834144|FG000|Double-Blind Treatment Period|Physician Decision|0
6182409|NCT01342913|9834145|FG001|Double-Blind Treatment Period|Physician Decision|2
6182410|NCT01342913|9834146|FG002|Double-Blind Treatment Period|Physician Decision|0
6182411|NCT01342913|9834144|FG000|Double-Blind Treatment Period|Withdrawal by Subject|0
6182412|NCT01342913|9834145|FG001|Double-Blind Treatment Period|Withdrawal by Subject|2
6182413|NCT01342913|9834146|FG002|Double-Blind Treatment Period|Withdrawal by Subject|2
6182414|NCT01342926|9834156|FG000|Overall Study|Adverse Event|5
6182415|NCT01342926|9834157|FG001|Overall Study|Adverse Event|8
6182416|NCT01342926|9834158|FG002|Overall Study|Adverse Event|10
6182417|NCT01342926|9834159|FG003|Overall Study|Adverse Event|7
6182418|NCT01342926|9834156|FG000|Overall Study|Lost to Follow-up|0
6182419|NCT01342926|9834157|FG001|Overall Study|Lost to Follow-up|1
6182420|NCT01342926|9834158|FG002|Overall Study|Lost to Follow-up|1
6182421|NCT01342926|9834159|FG003|Overall Study|Lost to Follow-up|0
6182422|NCT01342926|9834156|FG000|Overall Study|Investigator Discretion|2
6182423|NCT01342926|9834157|FG001|Overall Study|Investigator Discretion|2
6182424|NCT01342926|9834158|FG002|Overall Study|Investigator Discretion|0
6182425|NCT01342926|9834159|FG003|Overall Study|Investigator Discretion|0
6182426|NCT01342926|9834156|FG000|Overall Study|Withdrawal by Subject|2
6182427|NCT01342926|9834157|FG001|Overall Study|Withdrawal by Subject|4
6182428|NCT01342926|9834158|FG002|Overall Study|Withdrawal by Subject|3
6182429|NCT01342926|9834159|FG003|Overall Study|Withdrawal by Subject|5
6182430|NCT01342965|9834171|FG000|Overall Study|Death|58
6182431|NCT01342965|9834172|FG001|Overall Study|Death|57
6182432|NCT01342965|9834171|FG000|Overall Study|Lost to Follow-up|5
6182433|NCT01342965|9834172|FG001|Overall Study|Lost to Follow-up|3
6182434|NCT01342965|9834171|FG000|Overall Study|Other Reasons- Unspecified|44
6182435|NCT01342965|9834172|FG001|Overall Study|Other Reasons- Unspecified|38
6182436|NCT01342965|9834171|FG000|Overall Study|Withdrawal by Subject|2
6182437|NCT01342965|9834172|FG001|Overall Study|Withdrawal by Subject|9
6182438|NCT01343043|9834195|FG000|Overall Study|Disease progression before treatment|1
6182439|NCT01343043|9834196|FG001|Overall Study|Disease progression before treatment|0
6182440|NCT01343043|9834197|FG002|Overall Study|Disease progression before treatment|0
6182441|NCT01343043|9834198|FG003|Overall Study|Disease progression before treatment|0
6182442|NCT01343043|9834195|FG000|Overall Study|Withdrawal by Subject|1
6182443|NCT01343043|9834196|FG001|Overall Study|Withdrawal by Subject|0
6182444|NCT01343043|9834197|FG002|Overall Study|Withdrawal by Subject|0
6182445|NCT01343043|9834198|FG003|Overall Study|Withdrawal by Subject|0
6182446|NCT01343043|9834195|FG000|Overall Study|Death|1
6182447|NCT01343043|9834196|FG001|Overall Study|Death|1
6182448|NCT01343043|9834197|FG002|Overall Study|Death|0
6182449|NCT01343043|9834198|FG003|Overall Study|Death|1
6182450|NCT01343056|9834215|FG000|Overall Study|Lost to Follow-up|7
6182451|NCT01343056|9834216|FG001|Overall Study|Lost to Follow-up|5
6182452|NCT01343056|9834217|FG002|Overall Study|Lost to Follow-up|3
6182453|NCT01343056|9834218|FG003|Overall Study|Lost to Follow-up|9
6182454|NCT01343082|9834232|FG000|The run-in Period|Not meeting criteria|3
6182455|NCT01343082|9834233|FG001|The run-in Period|Not meeting criteria|4
6182456|NCT01343082|9834234|FG002|The run-in Period|Not meeting criteria|5
6182457|NCT01343082|9834232|FG000|Treatment Period , Switched to DE-111|Adverse Event|1
6182458|NCT01343082|9834233|FG001|Treatment Period , Switched to DE-111|Adverse Event|4
6182459|NCT01343082|9834234|FG002|Treatment Period , Switched to DE-111|Adverse Event|3
6182460|NCT01343082|9834232|FG000|Treatment Period , Switched to DE-111|Lack of Efficacy|0
6182461|NCT01343082|9834233|FG001|Treatment Period , Switched to DE-111|Lack of Efficacy|1
6182462|NCT01343082|9834234|FG002|Treatment Period , Switched to DE-111|Lack of Efficacy|2
6182463|NCT01343082|9834232|FG000|Treatment Period , Switched to DE-111|Physician Decision|0
6182464|NCT01343082|9834233|FG001|Treatment Period , Switched to DE-111|Physician Decision|2
6182465|NCT01343082|9834234|FG002|Treatment Period , Switched to DE-111|Physician Decision|2
6182466|NCT01343082|9834232|FG000|Treatment Period , Switched to DE-111|Withdrawal by Subject|4
6182467|NCT01343082|9834233|FG001|Treatment Period , Switched to DE-111|Withdrawal by Subject|2
6182468|NCT01343082|9834234|FG002|Treatment Period , Switched to DE-111|Withdrawal by Subject|5
6182469|NCT01343277|9834272|FG000|Overall Study|Other|3
6182470|NCT01343277|9834273|FG001|Overall Study|Other|3
6182471|NCT01343277|9834272|FG000|Overall Study|Withdrawal by Subject|18
6182472|NCT01343277|9834273|FG001|Overall Study|Withdrawal by Subject|13
6182473|NCT01343277|9834272|FG000|Overall Study|Physician Decision|1
6182474|NCT01343277|9834273|FG001|Overall Study|Physician Decision|2
6182475|NCT01343277|9834272|FG000|Overall Study|Death|10
6182476|NCT01343277|9834273|FG001|Overall Study|Death|1
6182477|NCT01343277|9834272|FG000|Overall Study|Adverse Event|67
6182478|NCT01343277|9834273|FG001|Overall Study|Adverse Event|13
6182479|NCT01343277|9834272|FG000|Overall Study|Disease progression|270
6182480|NCT01343277|9834273|FG001|Overall Study|Disease progression|138
6182481|NCT01343277|9834272|FG000|Overall Study|Randomized not treated|6
6182482|NCT01343277|9834273|FG001|Overall Study|Randomized not treated|21
6182483|NCT01343277|9834272|FG000|Overall Study|Treatment ongoing|8
6182484|NCT01343277|9834273|FG001|Overall Study|Treatment ongoing|2
6182485|NCT01343277|9834272|FG000|Overall Study|Subsequent anticancer therapy|1
6182486|NCT01343277|9834273|FG001|Overall Study|Subsequent anticancer therapy|0
6182487|NCT01343368|9834281|FG000|Overall Study|Death|1
6182488|NCT01343368|9834282|FG001|Overall Study|Death|0
6182489|NCT01343368|9834281|FG000|Overall Study|Lost to Follow-up|1
6182490|NCT01343368|9834282|FG001|Overall Study|Lost to Follow-up|0
6182491|NCT01343407|9834288|FG000|Second Treatment Period (Part 2)|Adverse Event|0
6182492|NCT01343407|9834289|FG001|Second Treatment Period (Part 2)|Adverse Event|0
6182493|NCT01343407|9834290|FG002|Second Treatment Period (Part 2)|Adverse Event|1
6182494|NCT01343407|9834291|FG003|Second Treatment Period (Part 2)|Adverse Event|0
6182495|NCT01343407|9834292|FG004|Second Treatment Period (Part 2)|Adverse Event|0
6182496|NCT01343407|9834293|FG005|Second Treatment Period (Part 2)|Adverse Event|0
6182497|NCT01343407|9834288|FG000|Second Washout (Part 2)|Withdrawal by Subject|0
6182498|NCT01343407|9834289|FG001|Second Washout (Part 2)|Withdrawal by Subject|0
6182499|NCT01343407|9834290|FG002|Second Washout (Part 2)|Withdrawal by Subject|1
6182500|NCT01343407|9834291|FG003|Second Washout (Part 2)|Withdrawal by Subject|0
6182501|NCT01343407|9834292|FG004|Second Washout (Part 2)|Withdrawal by Subject|0
6182502|NCT01343407|9834293|FG005|Second Washout (Part 2)|Withdrawal by Subject|0
6182503|NCT01343693|9834319|FG000|Overall Study|Lost to Follow-up|9
6182504|NCT01343823|9834327|FG000|Overall Study|Study Terminated|1
6182505|NCT01343823|9834328|FG001|Overall Study|Study Terminated|0
6182506|NCT01343823|9834329|FG002|Overall Study|Study Terminated|0
6182507|NCT01343823|9834330|FG003|Overall Study|Study Terminated|1
6182508|NCT01343823|9834327|FG000|Overall Study|Withdrawal by Subject|1
6182509|NCT01343823|9834328|FG001|Overall Study|Withdrawal by Subject|0
6182510|NCT01343823|9834329|FG002|Overall Study|Withdrawal by Subject|0
6182511|NCT01343823|9834330|FG003|Overall Study|Withdrawal by Subject|0
6182512|NCT01343888|9834343|FG000|Overall Study|Adverse Event|12
6182513|NCT01343888|9834344|FG001|Overall Study|Adverse Event|22
6182514|NCT01343888|9834345|FG002|Overall Study|Adverse Event|5
6182515|NCT01343888|9834343|FG000|Overall Study|Lack of Efficacy|9
6182516|NCT01343888|9834344|FG001|Overall Study|Lack of Efficacy|9
6182517|NCT01343888|9834345|FG002|Overall Study|Lack of Efficacy|13
6182518|NCT01343888|9834343|FG000|Overall Study|Lost to Follow-up|0
6182519|NCT01343888|9834344|FG001|Overall Study|Lost to Follow-up|2
6182520|NCT01343888|9834345|FG002|Overall Study|Lost to Follow-up|1
6182521|NCT01343888|9834343|FG000|Overall Study|Protocol Violation|0
6182522|NCT01343888|9834344|FG001|Overall Study|Protocol Violation|2
6182523|NCT01343888|9834345|FG002|Overall Study|Protocol Violation|0
6182524|NCT01343888|9834343|FG000|Overall Study|Withdrawal by Subject|4
6182525|NCT01343888|9834344|FG001|Overall Study|Withdrawal by Subject|4
6182526|NCT01343888|9834345|FG002|Overall Study|Withdrawal by Subject|2
6182527|NCT01343888|9834343|FG000|Overall Study|other than stated above|0
6182528|NCT01343888|9834344|FG001|Overall Study|other than stated above|0
6182529|NCT01343888|9834345|FG002|Overall Study|other than stated above|1
6182530|NCT01343901|9834353|FG000|Overall Study|Death|85
6182531|NCT01343901|9834353|FG000|Overall Study|Physician Decision|4
6182532|NCT01343901|9834353|FG000|Overall Study|Lost to Follow-up|12
6182533|NCT01343901|9834353|FG000|Overall Study|Management by another medical team|11
6182534|NCT01343901|9834353|FG000|Overall Study|Participant decision|1
6085339|NCT00651820|9694630|FG000|Overall Study|Lost to Follow-up|2
6182535|NCT01344057|9834357|FG000|Overall Study|Premature Withdrawal|1
6182536|NCT01344161|9834363|FG000|Overall Study|Lost to Follow-up|4
6182537|NCT01344161|9834364|FG001|Overall Study|Lost to Follow-up|1
6182538|NCT01344161|9834363|FG000|Overall Study|Pregnancy|0
6182539|NCT01344161|9834364|FG001|Overall Study|Pregnancy|1
6182540|NCT01344161|9834363|FG000|Overall Study|Protocol Violation|1
6182541|NCT01344161|9834364|FG001|Overall Study|Protocol Violation|1
6182542|NCT01344226|9834370|FG000|Overall Study|Protocol Violation|2
6227986|NCT01721109|9900953|FG000|Overall Study|Withdrew Consent|1
6227987|NCT01721109|9900953|FG000|Overall Study|Lost to Follow-up|2
6182543|NCT01344226|9834370|FG000|Overall Study|Withdrawal by Subject|3
6182544|NCT01344226|9834370|FG000|Overall Study|Lack of Efficacy|3
6182545|NCT01344356|9834376|FG000|Overall Study|Physician Decision|0
6182546|NCT01344356|9834377|FG001|Overall Study|Physician Decision|3
6182547|NCT01344356|9834376|FG000|Overall Study|Lost to Follow-up|0
6182548|NCT01344356|9834377|FG001|Overall Study|Lost to Follow-up|6
6182549|NCT01344369|9834387|FG000|Washout of 28 Days|Withdrawal by Subject|1
6182550|NCT01344369|9834388|FG001|Washout of 28 Days|Withdrawal by Subject|0
6182551|NCT01344369|9834387|FG000|Washout of 28 Days|Physician Decision|0
6182552|NCT01344369|9834388|FG001|Washout of 28 Days|Physician Decision|1
6182553|NCT01344369|9834387|FG000|Second Intervention|Emesis within 2 x Tmax|0
6182554|NCT01344369|9834388|FG001|Second Intervention|Emesis within 2 x Tmax|1
6182555|NCT01344447|9834394|FG000|Overall Study|Adverse Event|1
6182556|NCT01344447|9834394|FG000|Overall Study|Protocol Violation|1
6182557|NCT01344447|9834394|FG000|Overall Study|Withdrawal by Subject|1
6182558|NCT01344447|9834394|FG000|Overall Study|The contrast was not seen|1
6182559|NCT01344447|9834394|FG000|Overall Study|Physician Decision|1
6182560|NCT01344447|9834394|FG000|Overall Study|MRA unsuccessful|1
6182561|NCT01344447|9834394|FG000|Overall Study|Bolus tracking failed|1
6182562|NCT01344447|9834394|FG000|Overall Study|Error of power injector|1
6182563|NCT01344460|9834402|FG000|Overall Study|Withdrawal by Subject|1
6182564|NCT01344460|9834402|FG000|Overall Study|Lost to Follow-up|2
6182565|NCT01344538|9834412|FG000|Overall Study|Adverse Event|1
6182566|NCT01344538|9834413|FG001|Overall Study|Adverse Event|1
6182567|NCT01344538|9834412|FG000|Overall Study|Lost to Follow-up|1
6182568|NCT01344538|9834413|FG001|Overall Study|Lost to Follow-up|0
6182569|NCT01344629|9834430|FG000|Crossover Period 2|Withdrawal by Subject|0
6182570|NCT01344629|9834431|FG001|Crossover Period 2|Withdrawal by Subject|1
6182571|NCT01344759|9834439|FG000|Overall Study|Patients failed to reach sedation level|0
6182572|NCT01344759|9834440|FG001|Overall Study|Patients failed to reach sedation level|2
6182573|NCT01344824|9834452|FG000|Overall Study|Adverse Event|15
6182574|NCT01344824|9834452|FG000|Overall Study|Withdrawal by Subject|6
6182575|NCT01344824|9834452|FG000|Overall Study|Other complicating disease|1
6182576|NCT01344824|9834452|FG000|Overall Study|Progression|15
6182577|NCT01344876|9834457|FG000|Overall Study|Adverse Event|0
6182578|NCT01344876|9834458|FG001|Overall Study|Adverse Event|0
6182579|NCT01344876|9834459|FG002|Overall Study|Adverse Event|0
6182580|NCT01344876|9834460|FG003|Overall Study|Adverse Event|0
6182581|NCT01344876|9834461|FG004|Overall Study|Adverse Event|1
6182582|NCT01344876|9834457|FG000|Overall Study|Withdrawal by Subject|0
6182583|NCT01344876|9834458|FG001|Overall Study|Withdrawal by Subject|0
6182584|NCT01344876|9834459|FG002|Overall Study|Withdrawal by Subject|1
6182585|NCT01344876|9834460|FG003|Overall Study|Withdrawal by Subject|0
6182586|NCT01344876|9834461|FG004|Overall Study|Withdrawal by Subject|0
6182587|NCT01344876|9834457|FG000|Overall Study|Definite progression of primary disease|1
6182588|NCT01344876|9834458|FG001|Overall Study|Definite progression of primary disease|0
6182589|NCT01344876|9834459|FG002|Overall Study|Definite progression of primary disease|0
6182590|NCT01344876|9834460|FG003|Overall Study|Definite progression of primary disease|3
6182591|NCT01344876|9834461|FG004|Overall Study|Definite progression of primary disease|0
6182592|NCT01345019|9834476|FG000|Blinded Treatment Phase|Death|147
6182593|NCT01345019|9834477|FG001|Blinded Treatment Phase|Death|137
6182594|NCT01345019|9834476|FG000|Blinded Treatment Phase|Withdrawal by Subject|103
6182595|NCT01345019|9834477|FG001|Blinded Treatment Phase|Withdrawal by Subject|112
6182596|NCT01345019|9834476|FG000|Blinded Treatment Phase|Completed Survival Follow-up|21
6182597|NCT01345019|9834477|FG001|Blinded Treatment Phase|Completed Survival Follow-up|9
6182598|NCT01345019|9834476|FG000|Blinded Treatment Phase|Disease Progression|12
6182599|NCT01345019|9834477|FG001|Blinded Treatment Phase|Disease Progression|10
6182600|NCT01345019|9834476|FG000|Blinded Treatment Phase|Adverse Event|6
6182601|NCT01345019|9834477|FG001|Blinded Treatment Phase|Adverse Event|13
6182602|NCT01345019|9834476|FG000|Blinded Treatment Phase|Administrative Decision|10
6182603|NCT01345019|9834477|FG001|Blinded Treatment Phase|Administrative Decision|8
6182604|NCT01345019|9834476|FG000|Blinded Treatment Phase|Noncompliance|5
6182605|NCT01345019|9834477|FG001|Blinded Treatment Phase|Noncompliance|3
6182606|NCT01345019|9834476|FG000|Blinded Treatment Phase|Ineligibility Determined|1
6182607|NCT01345019|9834477|FG001|Blinded Treatment Phase|Ineligibility Determined|6
6182608|NCT01345019|9834476|FG000|Blinded Treatment Phase|Protocol Deviation|5
6182609|NCT01345019|9834477|FG001|Blinded Treatment Phase|Protocol Deviation|0
6182610|NCT01345019|9834476|FG000|Blinded Treatment Phase|Other, Not Specified|2
6182611|NCT01345019|9834477|FG001|Blinded Treatment Phase|Other, Not Specified|3
6182612|NCT01345019|9834476|FG000|Blinded Treatment Phase|Lost to Follow-up|6
6182613|NCT01345019|9834477|FG001|Blinded Treatment Phase|Lost to Follow-up|3
6182614|NCT01345019|9834476|FG000|Open Label Treatment Phase|Death|49
6182615|NCT01345019|9834477|FG001|Open Label Treatment Phase|Death|48
6182616|NCT01345019|9834476|FG000|Open Label Treatment Phase|Withdrawal by Subject|49
6182617|NCT01345019|9834477|FG001|Open Label Treatment Phase|Withdrawal by Subject|47
6182618|NCT01345019|9834476|FG000|Open Label Treatment Phase|Adverse Event|30
6182619|NCT01345019|9834477|FG001|Open Label Treatment Phase|Adverse Event|51
6182620|NCT01345019|9834476|FG000|Open Label Treatment Phase|Administrative Decision|30
6182621|NCT01345019|9834477|FG001|Open Label Treatment Phase|Administrative Decision|15
6182622|NCT01345019|9834476|FG000|Open Label Treatment Phase|Disease Progression|17
6182623|NCT01345019|9834477|FG001|Open Label Treatment Phase|Disease Progression|18
6375384|NCT03877926|10165415|FG000|Overall Study|Death|2
6375385|NCT03877926|10165416|FG001|Overall Study|Death|2
6182624|NCT01345019|9834476|FG000|Open Label Treatment Phase|Noncompliance|5
6182625|NCT01345019|9834477|FG001|Open Label Treatment Phase|Noncompliance|4
6182626|NCT01345019|9834476|FG000|Open Label Treatment Phase|Lost to Follow-up|1
6182627|NCT01345019|9834477|FG001|Open Label Treatment Phase|Lost to Follow-up|2
6182628|NCT01345019|9834476|FG000|Open Label Treatment Phase|Pregnancy|1
6182629|NCT01345019|9834477|FG001|Open Label Treatment Phase|Pregnancy|0
6182630|NCT01345019|9834476|FG000|Open Label Treatment Phase|Other, Not Specified|9
6182631|NCT01345019|9834477|FG001|Open Label Treatment Phase|Other, Not Specified|7
6182632|NCT01345019|9834476|FG000|Open Label Treatment Phase|Protocol Violation|0
6182633|NCT01345019|9834477|FG001|Open Label Treatment Phase|Protocol Violation|1
6182634|NCT01345058|9834487|FG000|Overall Study|Withdrawal by Subject|1
6182635|NCT01345058|9834488|FG001|Overall Study|Withdrawal by Subject|0
6182636|NCT01345058|9834487|FG000|Overall Study|Participant Reported Increase in Events|1
6182637|NCT01345058|9834488|FG001|Overall Study|Participant Reported Increase in Events|0
6182638|NCT01345058|9834487|FG000|Overall Study|Side Effects of Hair Loss and Itchiness|1
6182639|NCT01345058|9834488|FG001|Overall Study|Side Effects of Hair Loss and Itchiness|0
6182640|NCT01345058|9834487|FG000|Overall Study|Participant Stopped Taking Study Drug|1
6182641|NCT01345058|9834488|FG001|Overall Study|Participant Stopped Taking Study Drug|0
6182642|NCT01345058|9834487|FG000|Overall Study|Participant No-Show at Multiple Visits|1
6182643|NCT01345058|9834488|FG001|Overall Study|Participant No-Show at Multiple Visits|0
6182644|NCT01345123|9834497|FG000|Overall Study|participants no longer with health plan|79
6182645|NCT01345123|9834498|FG001|Overall Study|participants no longer with health plan|85
6182646|NCT01345123|9834499|FG002|Overall Study|participants no longer with health plan|88
6182647|NCT01345162|9834510|FG000|Overall Study|Protocol Violation|2
6182648|NCT01345162|9834511|FG001|Overall Study|Protocol Violation|4
6182649|NCT01345188|9834517|FG000|Randomization Ranolazine/Placebo 6 Weeks|Withdrawal by Subject|2
6182650|NCT01345188|9834517|FG000|Crossover Ranolazine/Placebo 6 Weeks|Lost to Follow-up|1
6182651|NCT01345253|9834526|FG000|Double-blind (DB) Phase (52 Weeks)|Adverse Event|22
6182652|NCT01345253|9834527|FG001|Double-blind (DB) Phase (52 Weeks)|Adverse Event|27
6182653|NCT01345253|9834526|FG000|Double-blind (DB) Phase (52 Weeks)|Lack of Efficacy|11
6182654|NCT01345253|9834527|FG001|Double-blind (DB) Phase (52 Weeks)|Lack of Efficacy|7
6182655|NCT01345253|9834526|FG000|Double-blind (DB) Phase (52 Weeks)|Protocol Violation|1
6182656|NCT01345253|9834527|FG001|Double-blind (DB) Phase (52 Weeks)|Protocol Violation|5
6182657|NCT01345253|9834526|FG000|Double-blind (DB) Phase (52 Weeks)|Met Protocol Defined Stopping Criteria|6
6182658|NCT01345253|9834527|FG001|Double-blind (DB) Phase (52 Weeks)|Met Protocol Defined Stopping Criteria|1
6182659|NCT01345253|9834526|FG000|Double-blind (DB) Phase (52 Weeks)|Lost to Follow-up|3
6182660|NCT01345253|9834527|FG001|Double-blind (DB) Phase (52 Weeks)|Lost to Follow-up|8
6182661|NCT01345253|9834526|FG000|Double-blind (DB) Phase (52 Weeks)|Physician Decision|4
6182662|NCT01345253|9834527|FG001|Double-blind (DB) Phase (52 Weeks)|Physician Decision|12
6182663|NCT01345253|9834526|FG000|Double-blind (DB) Phase (52 Weeks)|Withdrawal by Subject|9
6182664|NCT01345253|9834527|FG001|Double-blind (DB) Phase (52 Weeks)|Withdrawal by Subject|19
6182665|NCT01345253|9834526|FG000|Open-label Phase (Up to Year 5 Week 44)|Adverse Event|7
6182666|NCT01345253|9834527|FG001|Open-label Phase (Up to Year 5 Week 44)|Adverse Event|18
6182667|NCT01345253|9834526|FG000|Open-label Phase (Up to Year 5 Week 44)|Death|0
6182668|NCT01345253|9834527|FG001|Open-label Phase (Up to Year 5 Week 44)|Death|1
6182669|NCT01345253|9834526|FG000|Open-label Phase (Up to Year 5 Week 44)|Lack of Efficacy|3
6182670|NCT01345253|9834527|FG001|Open-label Phase (Up to Year 5 Week 44)|Lack of Efficacy|7
6182671|NCT01345253|9834526|FG000|Open-label Phase (Up to Year 5 Week 44)|Protocol Violation|2
6182672|NCT01345253|9834527|FG001|Open-label Phase (Up to Year 5 Week 44)|Protocol Violation|5
6182673|NCT01345253|9834526|FG000|Open-label Phase (Up to Year 5 Week 44)|Lost to Follow-up|4
6182674|NCT01345253|9834527|FG001|Open-label Phase (Up to Year 5 Week 44)|Lost to Follow-up|6
6182675|NCT01345253|9834526|FG000|Open-label Phase (Up to Year 5 Week 44)|Physician Decision|11
6182676|NCT01345253|9834527|FG001|Open-label Phase (Up to Year 5 Week 44)|Physician Decision|24
6182677|NCT01345253|9834526|FG000|Open-label Phase (Up to Year 5 Week 44)|Withdrawal by Subject|37
6182678|NCT01345253|9834527|FG001|Open-label Phase (Up to Year 5 Week 44)|Withdrawal by Subject|82
6182679|NCT01345253|9834526|FG000|Open-label Phase (Up to Year 5 Week 44)|Not Recorded|1
6182680|NCT01345253|9834527|FG001|Open-label Phase (Up to Year 5 Week 44)|Not Recorded|1
6182681|NCT01345292|9834538|FG000|Overall Study|Withdrawal by Subject|2
6182682|NCT01345292|9834539|FG001|Overall Study|Withdrawal by Subject|0
6182683|NCT01345292|9834540|FG002|Overall Study|Withdrawal by Subject|1
6182684|NCT01345318|9834548|FG000|Overall Study|Adverse Event|16
6182685|NCT01345318|9834548|FG000|Overall Study|Lack of Efficacy|17
6182686|NCT01345318|9834548|FG000|Overall Study|Lost to Follow-up|2
6182687|NCT01345318|9834548|FG000|Overall Study|Protocol Violation|1
6182688|NCT01345318|9834548|FG000|Overall Study|Withdrawal by Subject|41
6182689|NCT01345318|9834548|FG000|Overall Study|Other|3
6182690|NCT01345591|9834557|FG000|Overall Study|Lost to Follow-up|1
6182691|NCT01345630|9834568|FG000|Overall Study|Adverse Event|22
6182692|NCT01345630|9834569|FG001|Overall Study|Adverse Event|23
6182693|NCT01345630|9834568|FG000|Overall Study|Lost to Follow-up|17
6182694|NCT01345630|9834569|FG001|Overall Study|Lost to Follow-up|16
6375386|NCT03877926|10165417|FG002|Overall Study|Death|2
6182695|NCT01345630|9834568|FG000|Overall Study|Protocol Violation|4
6182696|NCT01345630|9834569|FG001|Overall Study|Protocol Violation|1
6182697|NCT01345630|9834568|FG000|Overall Study|Medication error without associated AE|0
6182698|NCT01345630|9834569|FG001|Overall Study|Medication error without associated AE|1
6182699|NCT01345630|9834568|FG000|Overall Study|Study terminated by sponsor|254
6182700|NCT01345630|9834569|FG001|Overall Study|Study terminated by sponsor|285
6182701|NCT01345630|9834568|FG000|Overall Study|Other reasons|6
6182702|NCT01345630|9834569|FG001|Overall Study|Other reasons|8
6182703|NCT01345630|9834568|FG000|Overall Study|Withdrawn due to pregnancy|1
6182704|NCT01345630|9834569|FG001|Overall Study|Withdrawn due to pregnancy|2
6182705|NCT01345630|9834568|FG000|Overall Study|No longer willing to participate|9
6182706|NCT01345630|9834569|FG001|Overall Study|No longer willing to participate|12
6182707|NCT01345630|9834568|FG000|Overall Study|Insufficient clinical response|48
6182708|NCT01345630|9834569|FG001|Overall Study|Insufficient clinical response|11
6182709|NCT01345669|9834581|FG000|Overall Study|Primary tumour recurrence|53
6182710|NCT01345669|9834582|FG001|Overall Study|Primary tumour recurrence|32
6182711|NCT01345669|9834581|FG000|Overall Study|Second primary tumour|4
6182712|NCT01345669|9834582|FG001|Overall Study|Second primary tumour|3
6182713|NCT01345669|9834581|FG000|Overall Study|Adverse Event|63
6182714|NCT01345669|9834582|FG001|Overall Study|Adverse Event|9
6182715|NCT01345669|9834581|FG000|Overall Study|Protocol Violation|3
6182716|NCT01345669|9834582|FG001|Overall Study|Protocol Violation|1
6182717|NCT01345669|9834581|FG000|Overall Study|Lost to Follow-up|1
6182718|NCT01345669|9834582|FG001|Overall Study|Lost to Follow-up|1
6182719|NCT01345669|9834581|FG000|Overall Study|Withdrawal by Subject|52
6182720|NCT01345669|9834582|FG001|Overall Study|Withdrawal by Subject|13
6182721|NCT01345669|9834581|FG000|Overall Study|Other Reasons|111
6182722|NCT01345669|9834582|FG001|Overall Study|Other Reasons|60
6182723|NCT01345682|9834590|FG000|Overall Study|Progressive disease per RECIST|226
6182724|NCT01345682|9834591|FG001|Overall Study|Progressive disease per RECIST|93
6182725|NCT01345682|9834590|FG000|Overall Study|Worsening of underlying cancer disease|23
6182726|NCT01345682|9834591|FG001|Overall Study|Worsening of underlying cancer disease|12
6182727|NCT01345682|9834590|FG000|Overall Study|Adverse Event|51
6182728|NCT01345682|9834591|FG001|Overall Study|Adverse Event|41
6182729|NCT01345682|9834590|FG000|Overall Study|Non-compliance with protocol|0
6182730|NCT01345682|9834591|FG001|Overall Study|Non-compliance with protocol|1
6182731|NCT01345682|9834590|FG000|Overall Study|Lost to Follow-up|0
6182732|NCT01345682|9834591|FG001|Overall Study|Lost to Follow-up|1
6182733|NCT01345682|9834590|FG000|Overall Study|Refused to continue trial medication|16
6182734|NCT01345682|9834591|FG001|Overall Study|Refused to continue trial medication|9
6182735|NCT01345682|9834590|FG000|Overall Study|Not treated|2
6182736|NCT01345682|9834591|FG001|Overall Study|Not treated|1
6182737|NCT01345682|9834590|FG000|Overall Study|Reason other than those specified above|4
6182738|NCT01345682|9834591|FG001|Overall Study|Reason other than those specified above|3
6182739|NCT01345929|9834616|FG000|Overall Study|Withdrawal by Subject|9
6182740|NCT01345929|9834617|FG001|Overall Study|Withdrawal by Subject|8
6182741|NCT01345929|9834616|FG000|Overall Study|Lost to Follow-up|9
6182742|NCT01345929|9834617|FG001|Overall Study|Lost to Follow-up|9
6182743|NCT01345929|9834616|FG000|Overall Study|Adverse Event|0
6182744|NCT01345929|9834617|FG001|Overall Study|Adverse Event|1
6182745|NCT01345929|9834616|FG000|Overall Study|Didn't meet eligibility criteria|2
6182746|NCT01345929|9834617|FG001|Overall Study|Didn't meet eligibility criteria|0
6182747|NCT01345929|9834616|FG000|Overall Study|40,000 CFU/ML|1
6182748|NCT01345929|9834617|FG001|Overall Study|40,000 CFU/ML|0
6182749|NCT01345929|9834616|FG000|Overall Study|Patient withdrawal|0
6182750|NCT01345929|9834617|FG001|Overall Study|Patient withdrawal|1
6182751|NCT01346059|9834625|FG000|Overall Study|Withdrawal by Subject|1
6182752|NCT01346059|9834626|FG001|Overall Study|Withdrawal by Subject|0
6182753|NCT01346176|9834648|FG000|Recruited|Protocol Violation|1
6182754|NCT01346176|9834649|FG001|Recruited|Protocol Violation|0
6182755|NCT01346176|9834650|FG002|Recruited|Protocol Violation|0
6182756|NCT01346176|9834648|FG000|Completed Advance Directive|Death|3
6182757|NCT01346176|9834649|FG001|Completed Advance Directive|Death|2
6182758|NCT01346176|9834650|FG002|Completed Advance Directive|Death|2
6182759|NCT01346176|9834648|FG000|Completed Advance Directive|Became Ineligible|3
6182760|NCT01346176|9834649|FG001|Completed Advance Directive|Became Ineligible|0
6182761|NCT01346176|9834650|FG002|Completed Advance Directive|Became Ineligible|1
6182762|NCT01346176|9834648|FG000|Completed Advance Directive|Other reason did not complete AD|7
6182763|NCT01346176|9834649|FG001|Completed Advance Directive|Other reason did not complete AD|12
6182764|NCT01346176|9834650|FG002|Completed Advance Directive|Other reason did not complete AD|7
6182765|NCT01346176|9834648|FG000|Completed Satisfaction Survey|Death|3
6182766|NCT01346176|9834649|FG001|Completed Satisfaction Survey|Death|0
6182767|NCT01346176|9834650|FG002|Completed Satisfaction Survey|Death|2
6182768|NCT01346176|9834648|FG000|Completed Satisfaction Survey|Lost to Follow-up|3
6182769|NCT01346176|9834649|FG001|Completed Satisfaction Survey|Lost to Follow-up|4
6182770|NCT01346176|9834650|FG002|Completed Satisfaction Survey|Lost to Follow-up|4
6182771|NCT01346189|9834662|FG000|Overall Study|Withdrawal by Subject|7
6182772|NCT01346189|9834663|FG001|Overall Study|Withdrawal by Subject|5
6182773|NCT01346189|9834664|FG002|Overall Study|Withdrawal by Subject|3
6182774|NCT01346189|9834665|FG003|Overall Study|Withdrawal by Subject|5
6182775|NCT01346189|9834662|FG000|Overall Study|Physician Decision|4
6182776|NCT01346189|9834663|FG001|Overall Study|Physician Decision|0
6182777|NCT01346189|9834664|FG002|Overall Study|Physician Decision|0
6182778|NCT01346189|9834665|FG003|Overall Study|Physician Decision|0
6182779|NCT01346189|9834662|FG000|Overall Study|Moved|3
6182780|NCT01346189|9834663|FG001|Overall Study|Moved|0
6182781|NCT01346189|9834664|FG002|Overall Study|Moved|4
6182782|NCT01346189|9834665|FG003|Overall Study|Moved|0
6182783|NCT01346189|9834662|FG000|Overall Study|Other|2
6182784|NCT01346189|9834663|FG001|Overall Study|Other|4
6182785|NCT01346189|9834664|FG002|Overall Study|Other|7
6182786|NCT01346189|9834665|FG003|Overall Study|Other|3
6182787|NCT01346189|9834662|FG000|Overall Study|Death|0
6182788|NCT01346189|9834663|FG001|Overall Study|Death|3
6182789|NCT01346189|9834664|FG002|Overall Study|Death|0
6182790|NCT01346189|9834665|FG003|Overall Study|Death|0
6182791|NCT01346189|9834662|FG000|Overall Study|Non-health system primary care physician|0
6182792|NCT01346189|9834663|FG001|Overall Study|Non-health system primary care physician|5
6182793|NCT01346189|9834664|FG002|Overall Study|Non-health system primary care physician|0
6182794|NCT01346189|9834665|FG003|Overall Study|Non-health system primary care physician|0
6182795|NCT01346189|9834662|FG000|Overall Study|Travel|0
6182796|NCT01346189|9834663|FG001|Overall Study|Travel|0
6182797|NCT01346189|9834664|FG002|Overall Study|Travel|0
6182798|NCT01346189|9834665|FG003|Overall Study|Travel|3
6182799|NCT01346293|9834686|FG000|Overall Study|Protocol Violation|30
6182800|NCT01346293|9834687|FG001|Overall Study|Protocol Violation|9
6182801|NCT01346293|9834686|FG000|Overall Study|Lost to Follow-up|21
6182802|NCT01346293|9834687|FG001|Overall Study|Lost to Follow-up|8
6182803|NCT01346293|9834686|FG000|Overall Study|Withdrawal by Subject|15
6182804|NCT01346293|9834687|FG001|Overall Study|Withdrawal by Subject|4
6182805|NCT01346293|9834686|FG000|Overall Study|Other|1
6182806|NCT01346293|9834687|FG001|Overall Study|Other|0
6182807|NCT01346371|9834697|FG000|Overall Study|Lost to Follow-up|2
6182808|NCT01346371|9834698|FG001|Overall Study|Lost to Follow-up|0
6182809|NCT01346410|9834713|FG000|Overall Study|Death|1
6182810|NCT01346475|9834719|FG000|First Intervention|Lost to Follow-up|4
6182811|NCT01346475|9834720|FG001|First Intervention|Lost to Follow-up|3
6182812|NCT01346501|9834732|FG000|Overall Study|Initiated Other Biological Agents|3
6182813|NCT01346501|9834733|FG001|Overall Study|Initiated Other Biological Agents|1
6182814|NCT01346501|9834732|FG000|Overall Study|Other|8
6182815|NCT01346501|9834733|FG001|Overall Study|Other|12
6182816|NCT01346514|9834743|FG000|Overall Study|Lost to Follow-up|19
6182817|NCT01346514|9834744|FG001|Overall Study|Lost to Follow-up|30
6182818|NCT01346514|9834743|FG000|Overall Study|Withdrawal by Subject|7
6182819|NCT01346514|9834744|FG001|Overall Study|Withdrawal by Subject|3
6182820|NCT01346514|9834743|FG000|Overall Study|Death|3
6182821|NCT01346514|9834744|FG001|Overall Study|Death|4
6182822|NCT01346540|9834754|FG000|Overall Study|Progressive disease-RECIST 1.1 criteria|3
6182823|NCT01346540|9834755|FG001|Overall Study|Progressive disease-RECIST 1.1 criteria|8
6182824|NCT01346540|9834754|FG000|Overall Study|Adverse Event|0
6182825|NCT01346540|9834755|FG001|Overall Study|Adverse Event|4
6182826|NCT01346592|9834765|FG000|Overall Study|Lost to Follow-up|62
6182827|NCT01346592|9834766|FG001|Overall Study|Lost to Follow-up|29
6182828|NCT01346592|9834767|FG002|Overall Study|Lost to Follow-up|29
6182829|NCT01346592|9834765|FG000|Overall Study|Protocol Violation|2
6182830|NCT01346592|9834766|FG001|Overall Study|Protocol Violation|1
6182831|NCT01346592|9834767|FG002|Overall Study|Protocol Violation|0
6182832|NCT01346592|9834765|FG000|Overall Study|Death|1
6182833|NCT01346592|9834766|FG001|Overall Study|Death|3
6182834|NCT01346592|9834767|FG002|Overall Study|Death|4
6182835|NCT01346592|9834765|FG000|Overall Study|Adverse Event|0
6182836|NCT01346592|9834766|FG001|Overall Study|Adverse Event|1
6182837|NCT01346592|9834767|FG002|Overall Study|Adverse Event|0
6182838|NCT01346592|9834765|FG000|Overall Study|Withdrawal by Subject|77
6182839|NCT01346592|9834766|FG001|Overall Study|Withdrawal by Subject|51
6182840|NCT01346592|9834767|FG002|Overall Study|Withdrawal by Subject|38
6182841|NCT01346592|9834765|FG000|Overall Study|Inappropriate enrollment|3
6182842|NCT01346592|9834766|FG001|Overall Study|Inappropriate enrollment|1
6182843|NCT01346592|9834767|FG002|Overall Study|Inappropriate enrollment|1
6182844|NCT01346592|9834765|FG000|Overall Study|Administrative reason|1
6182845|NCT01346592|9834766|FG001|Overall Study|Administrative reason|0
6182846|NCT01346592|9834767|FG002|Overall Study|Administrative reason|0
6182847|NCT01346592|9834765|FG000|Overall Study|Unable to Classify|7
6182848|NCT01346592|9834766|FG001|Overall Study|Unable to Classify|3
6182849|NCT01346592|9834767|FG002|Overall Study|Unable to Classify|6
6182850|NCT01346696|9834796|FG000|Overall Study|Death|1
6182851|NCT01346774|9834802|FG000|Overall Study|Did not take a single dose|6
6182852|NCT01346774|9834803|FG001|Overall Study|Did not take a single dose|4
6182853|NCT01346774|9834802|FG000|Overall Study|Lost to Follow-up|3
6182854|NCT01346774|9834803|FG001|Overall Study|Lost to Follow-up|4
6182855|NCT01346774|9834802|FG000|Overall Study|Withdrawal by Subject|1
6182856|NCT01346774|9834803|FG001|Overall Study|Withdrawal by Subject|4
6182857|NCT01346774|9834802|FG000|Overall Study|Protocol Violation|2
6182858|NCT01346774|9834803|FG001|Overall Study|Protocol Violation|3
6182859|NCT01346774|9834802|FG000|Overall Study|Adverse Event|1
6182860|NCT01346774|9834803|FG001|Overall Study|Adverse Event|2
6182861|NCT01346969|9834831|FG000|Overall Study|Withdrawal by Subject|0
6182862|NCT01346969|9834832|FG001|Overall Study|Withdrawal by Subject|0
6182863|NCT01346969|9834833|FG002|Overall Study|Withdrawal by Subject|1
6182864|NCT01346969|9834834|FG003|Overall Study|Withdrawal by Subject|0
6182865|NCT01346969|9834831|FG000|Overall Study|Lost to Follow-up|1
6182866|NCT01346969|9834832|FG001|Overall Study|Lost to Follow-up|0
6182867|NCT01346969|9834833|FG002|Overall Study|Lost to Follow-up|2
6182868|NCT01346969|9834834|FG003|Overall Study|Lost to Follow-up|0
6182869|NCT01346969|9834831|FG000|Overall Study|Physician Decision|0
6182870|NCT01346969|9834832|FG001|Overall Study|Physician Decision|0
6182871|NCT01346969|9834833|FG002|Overall Study|Physician Decision|0
6182872|NCT01346969|9834834|FG003|Overall Study|Physician Decision|1
6182873|NCT01346969|9834831|FG000|Overall Study|Randomized but not treated|1
6182874|NCT01346969|9834832|FG001|Overall Study|Randomized but not treated|0
6182875|NCT01346969|9834833|FG002|Overall Study|Randomized but not treated|0
6182876|NCT01346969|9834834|FG003|Overall Study|Randomized but not treated|0
6182877|NCT01347073|9834871|FG000|Overall Study|Adverse Event|1
6182878|NCT01347073|9834871|FG000|Overall Study|Liver Transplant|1
6182879|NCT01347086|9834891|FG000|Overall Study|failed screening visit|0
6182880|NCT01347086|9834892|FG001|Overall Study|failed screening visit|0
6182881|NCT01347086|9834893|FG002|Overall Study|failed screening visit|1
6182882|NCT01347086|9834894|FG003|Overall Study|failed screening visit|0
6182883|NCT01347086|9834895|FG004|Overall Study|failed screening visit|0
6182884|NCT01347086|9834896|FG005|Overall Study|failed screening visit|0
6182885|NCT01347086|9834897|FG006|Overall Study|failed screening visit|1
6182886|NCT01347086|9834898|FG007|Overall Study|failed screening visit|1
6182887|NCT01347086|9834899|FG008|Overall Study|failed screening visit|0
6182888|NCT01347086|9834900|FG009|Overall Study|failed screening visit|1
6182889|NCT01347112|9834934|FG000|Overall Study|Withdrawal by Subject|1
6182890|NCT01347112|9834935|FG001|Overall Study|Withdrawal by Subject|7
6182891|NCT01347112|9834934|FG000|Overall Study|Lost to Follow-up|3
6182892|NCT01347112|9834935|FG001|Overall Study|Lost to Follow-up|5
6182893|NCT01347307|9834951|FG000|Overall Study|Death|0
6182894|NCT01347307|9834952|FG001|Overall Study|Death|4
6182895|NCT01347307|9834951|FG000|Overall Study|Physician Decision|0
6182896|NCT01347307|9834952|FG001|Overall Study|Physician Decision|1
6182897|NCT01347554|9834978|FG000|Overall Study|Lack of Efficacy|7
6182898|NCT01347554|9834979|FG001|Overall Study|Lack of Efficacy|11
6182899|NCT01347580|9834987|FG000|Overall Study|Withdrawal by Subject|13
6182900|NCT01347580|9834988|FG001|Overall Study|Withdrawal by Subject|23
6182901|NCT01347580|9834987|FG000|Overall Study|Death|30
6182902|NCT01347580|9834988|FG001|Overall Study|Death|19
6182903|NCT01347580|9834987|FG000|Overall Study|Protocol Violation|10
6182904|NCT01347580|9834988|FG001|Overall Study|Protocol Violation|7
6182905|NCT01347580|9834987|FG000|Overall Study|Lost to Follow-up|3
6182906|NCT01347580|9834988|FG001|Overall Study|Lost to Follow-up|1
6182907|NCT01347580|9834987|FG000|Overall Study|Had other reason|9
6182908|NCT01347580|9834988|FG001|Overall Study|Had other reason|6
6182909|NCT01347710|9834994|FG000|Overall Study|Withdrawal by Subject|2
6182910|NCT01347710|9834994|FG000|Overall Study|Adverse Event|4
6182911|NCT01347710|9834994|FG000|Overall Study|Angio or SPECT not completed|18
6182912|NCT01347710|9834994|FG000|Overall Study|issue with vitals prior to dosing|1
6182913|NCT01347710|9834994|FG000|Overall Study|Lost to Follow-up|1
6182914|NCT01347710|9834994|FG000|Overall Study|Physician Decision|2
6182915|NCT01347710|9834994|FG000|Overall Study|Other|3
6182916|NCT01347762|9835006|FG000|Overall Study|Lost to Follow-up|0
6182917|NCT01347762|9835007|FG001|Overall Study|Lost to Follow-up|1
6182918|NCT01347762|9835008|FG002|Overall Study|Lost to Follow-up|6
6182919|NCT01347762|9835009|FG003|Overall Study|Lost to Follow-up|5
6182920|NCT01347762|9835006|FG000|Overall Study|Withdrawal by Subject|4
6182921|NCT01347762|9835007|FG001|Overall Study|Withdrawal by Subject|1
6182922|NCT01347762|9835008|FG002|Overall Study|Withdrawal by Subject|3
6182923|NCT01347762|9835009|FG003|Overall Study|Withdrawal by Subject|3
6182924|NCT01347866|9835046|FG000|Overall Study|Death|0
6182925|NCT01347866|9835047|FG001|Overall Study|Death|0
6182926|NCT01347866|9835048|FG002|Overall Study|Death|0
6182927|NCT01347866|9835049|FG003|Overall Study|Death|1
6182928|NCT01347866|9835050|FG004|Overall Study|Death|2
6182929|NCT01347866|9835051|FG005|Overall Study|Death|2
6182930|NCT01347866|9835052|FG006|Overall Study|Death|1
6182931|NCT01347866|9835053|FG007|Overall Study|Death|0
6182932|NCT01347866|9835054|FG008|Overall Study|Death|4
6182933|NCT01347866|9835055|FG009|Overall Study|Death|1
6182934|NCT01347866|9835056|FG010|Overall Study|Death|3
6182935|NCT01347866|9835057|FG011|Overall Study|Death|1
6182936|NCT01347866|9835058|FG012|Overall Study|Death|2
6182937|NCT01347866|9835059|FG013|Overall Study|Death|0
6182938|NCT01347866|9835060|FG014|Overall Study|Death|0
6182939|NCT01347866|9835061|FG015|Overall Study|Death|1
6182940|NCT01347866|9835062|FG016|Overall Study|Death|0
6182941|NCT01347866|9835046|FG000|Overall Study|Lost to Follow-up|0
6182942|NCT01347866|9835047|FG001|Overall Study|Lost to Follow-up|0
6182943|NCT01347866|9835048|FG002|Overall Study|Lost to Follow-up|0
6182944|NCT01347866|9835049|FG003|Overall Study|Lost to Follow-up|0
6182945|NCT01347866|9835050|FG004|Overall Study|Lost to Follow-up|0
6182946|NCT01347866|9835051|FG005|Overall Study|Lost to Follow-up|0
6182947|NCT01347866|9835052|FG006|Overall Study|Lost to Follow-up|0
6182948|NCT01347866|9835053|FG007|Overall Study|Lost to Follow-up|1
6182949|NCT01347866|9835054|FG008|Overall Study|Lost to Follow-up|1
6182950|NCT01347866|9835055|FG009|Overall Study|Lost to Follow-up|0
6182951|NCT01347866|9835056|FG010|Overall Study|Lost to Follow-up|0
6182952|NCT01347866|9835057|FG011|Overall Study|Lost to Follow-up|0
6182953|NCT01347866|9835058|FG012|Overall Study|Lost to Follow-up|0
6182954|NCT01347866|9835059|FG013|Overall Study|Lost to Follow-up|0
6182955|NCT01347866|9835060|FG014|Overall Study|Lost to Follow-up|0
6182956|NCT01347866|9835061|FG015|Overall Study|Lost to Follow-up|0
6182957|NCT01347866|9835062|FG016|Overall Study|Lost to Follow-up|0
6182958|NCT01347866|9835046|FG000|Overall Study|Other|3
6182959|NCT01347866|9835047|FG001|Overall Study|Other|1
6182960|NCT01347866|9835048|FG002|Overall Study|Other|1
6182961|NCT01347866|9835049|FG003|Overall Study|Other|4
6182962|NCT01347866|9835050|FG004|Overall Study|Other|5
6182963|NCT01347866|9835051|FG005|Overall Study|Other|0
6182964|NCT01347866|9835052|FG006|Overall Study|Other|5
6182965|NCT01347866|9835053|FG007|Overall Study|Other|3
6182966|NCT01347866|9835054|FG008|Overall Study|Other|22
6182967|NCT01347866|9835055|FG009|Overall Study|Other|5
6182968|NCT01347866|9835056|FG010|Overall Study|Other|0
6182969|NCT01347866|9835057|FG011|Overall Study|Other|3
6182970|NCT01347866|9835058|FG012|Overall Study|Other|4
6182971|NCT01347866|9835059|FG013|Overall Study|Other|4
6182972|NCT01347866|9835060|FG014|Overall Study|Other|2
6182973|NCT01347866|9835061|FG015|Overall Study|Other|3
6182974|NCT01347866|9835062|FG016|Overall Study|Other|0
6182975|NCT01347866|9835046|FG000|Overall Study|Subject refused further follow-up|2
6182976|NCT01347866|9835047|FG001|Overall Study|Subject refused further follow-up|0
6182977|NCT01347866|9835048|FG002|Overall Study|Subject refused further follow-up|0
6182978|NCT01347866|9835049|FG003|Overall Study|Subject refused further follow-up|2
6182979|NCT01347866|9835050|FG004|Overall Study|Subject refused further follow-up|0
6182980|NCT01347866|9835051|FG005|Overall Study|Subject refused further follow-up|1
6182981|NCT01347866|9835052|FG006|Overall Study|Subject refused further follow-up|0
6182982|NCT01347866|9835053|FG007|Overall Study|Subject refused further follow-up|0
6182983|NCT01347866|9835054|FG008|Overall Study|Subject refused further follow-up|4
6182984|NCT01347866|9835055|FG009|Overall Study|Subject refused further follow-up|1
6182985|NCT01347866|9835056|FG010|Overall Study|Subject refused further follow-up|0
6182986|NCT01347866|9835057|FG011|Overall Study|Subject refused further follow-up|0
6182987|NCT01347866|9835058|FG012|Overall Study|Subject refused further follow-up|1
6182988|NCT01347866|9835059|FG013|Overall Study|Subject refused further follow-up|3
6182989|NCT01347866|9835060|FG014|Overall Study|Subject refused further follow-up|1
6182990|NCT01347866|9835061|FG015|Overall Study|Subject refused further follow-up|0
6182991|NCT01347866|9835062|FG016|Overall Study|Subject refused further follow-up|2
6182992|NCT01347879|9835135|FG000|Overall Study|Adverse Event|0
6182993|NCT01347879|9835136|FG001|Overall Study|Adverse Event|12
6182994|NCT01347879|9835135|FG000|Overall Study|Lost to Follow-up|2
6182995|NCT01347879|9835136|FG001|Overall Study|Lost to Follow-up|0
6182996|NCT01347879|9835135|FG000|Overall Study|Withdrawal by Subject|3
6227988|NCT01721161|9900959|FG000|Overall Study|Adverse Event|2
6227989|NCT01721161|9900960|FG001|Overall Study|Adverse Event|3
6227990|NCT01721161|9900959|FG000|Overall Study|Lost to Follow-up|1
6227991|NCT01721161|9900960|FG001|Overall Study|Lost to Follow-up|2
6227992|NCT01721161|9900959|FG000|Overall Study|Withdrawal by Subject|1
6227993|NCT01721161|9900960|FG001|Overall Study|Withdrawal by Subject|1
6085340|NCT00651924|9694638|FG000|Overall Study|Withdrawal by PI|0
6227994|NCT01721161|9900959|FG000|Overall Study|Other|0
6227995|NCT01721161|9900960|FG001|Overall Study|Other|1
6227996|NCT01721200|9900969|FG000|Overall Study|Lost to Follow-up|3
6227997|NCT01721200|9900970|FG001|Overall Study|Lost to Follow-up|5
6227998|NCT01721317|9900992|FG000|Overall Study|Study Closed / Terminated|2
6227999|NCT01721317|9900993|FG001|Overall Study|Study Closed / Terminated|2
6228000|NCT01721317|9900992|FG000|Overall Study|Physician Decision|0
6228001|NCT01721317|9900993|FG001|Overall Study|Physician Decision|1
6228002|NCT01721317|9900992|FG000|Overall Study|Withdrawal by Subject|0
6228003|NCT01721317|9900993|FG001|Overall Study|Withdrawal by Subject|1
6228004|NCT01721330|9901001|FG000|Overall Study|Withdrawal by Subject|0
6228005|NCT01721330|9901002|FG001|Overall Study|Withdrawal by Subject|1
6228006|NCT01721369|9901008|FG000|Overall Study|Not initial etiological diagnosis|12
6228007|NCT01721408|9901014|FG000|Overall Study|Adverse Event|6
6228008|NCT01721408|9901015|FG001|Overall Study|Adverse Event|1
6228009|NCT01721408|9901014|FG000|Overall Study|Death|1
6228010|NCT01721408|9901015|FG001|Overall Study|Death|0
6228011|NCT01721408|9901014|FG000|Overall Study|Insufficient clinical response|15
6182997|NCT01347879|9835136|FG001|Overall Study|Withdrawal by Subject|2
6182998|NCT01347879|9835135|FG000|Overall Study|Other|2
6182999|NCT01347879|9835136|FG001|Overall Study|Other|3
6183000|NCT01347931|9835142|FG000|Standard Oxygen Therapy|Withdrawal by Subject|1
6183001|NCT01348087|9835148|FG000|Overall Study|Unsatisfactory therapeutic effect|35
6183002|NCT01348087|9835148|FG000|Overall Study|Administrative problems|79
6183003|NCT01348087|9835148|FG000|Overall Study|protocol deviation|1
6183004|NCT01348087|9835148|FG000|Overall Study|Lost to Follow-up|1
6183005|NCT01348087|9835148|FG000|Overall Study|Subject withdrew consent|7
6183006|NCT01348087|9835148|FG000|Overall Study|Adverse Event|25
6228012|NCT01721408|9901015|FG001|Overall Study|Insufficient clinical response|6
6228013|NCT01721408|9901014|FG000|Overall Study|No longer willing to participate study|9
6183007|NCT01348100|9835169|FG000|Overall Study|Subject Withdrew Consent|0
6183008|NCT01348100|9835170|FG001|Overall Study|Subject Withdrew Consent|0
6183009|NCT01348100|9835171|FG002|Overall Study|Subject Withdrew Consent|2
6183010|NCT01348100|9835172|FG003|Overall Study|Subject Withdrew Consent|0
6183011|NCT01348100|9835173|FG004|Overall Study|Subject Withdrew Consent|1
6183012|NCT01348100|9835174|FG005|Overall Study|Subject Withdrew Consent|0
6183013|NCT01348100|9835175|FG006|Overall Study|Subject Withdrew Consent|1
6183014|NCT01348100|9835169|FG000|Overall Study|Protocol Deviation|0
6183015|NCT01348100|9835170|FG001|Overall Study|Protocol Deviation|0
6183016|NCT01348100|9835171|FG002|Overall Study|Protocol Deviation|0
6183017|NCT01348100|9835172|FG003|Overall Study|Protocol Deviation|1
6183018|NCT01348100|9835173|FG004|Overall Study|Protocol Deviation|0
6183019|NCT01348100|9835174|FG005|Overall Study|Protocol Deviation|0
6183020|NCT01348100|9835175|FG006|Overall Study|Protocol Deviation|0
6183021|NCT01348100|9835169|FG000|Overall Study|Unsatisfactory Therapeutic Effect|0
6183022|NCT01348100|9835170|FG001|Overall Study|Unsatisfactory Therapeutic Effect|0
6183023|NCT01348100|9835171|FG002|Overall Study|Unsatisfactory Therapeutic Effect|0
6183024|NCT01348100|9835172|FG003|Overall Study|Unsatisfactory Therapeutic Effect|0
6183025|NCT01348100|9835173|FG004|Overall Study|Unsatisfactory Therapeutic Effect|0
6183026|NCT01348100|9835174|FG005|Overall Study|Unsatisfactory Therapeutic Effect|1
6183027|NCT01348100|9835175|FG006|Overall Study|Unsatisfactory Therapeutic Effect|0
6183028|NCT01348100|9835169|FG000|Overall Study|Lost to Follow-up|0
6183029|NCT01348100|9835170|FG001|Overall Study|Lost to Follow-up|0
6183030|NCT01348100|9835171|FG002|Overall Study|Lost to Follow-up|0
6183031|NCT01348100|9835172|FG003|Overall Study|Lost to Follow-up|0
6183032|NCT01348100|9835173|FG004|Overall Study|Lost to Follow-up|0
6183033|NCT01348100|9835174|FG005|Overall Study|Lost to Follow-up|0
6183034|NCT01348100|9835175|FG006|Overall Study|Lost to Follow-up|1
6183035|NCT01348100|9835169|FG000|Overall Study|Administrative Problems|0
6183036|NCT01348100|9835170|FG001|Overall Study|Administrative Problems|0
6183037|NCT01348100|9835171|FG002|Overall Study|Administrative Problems|0
6183038|NCT01348100|9835172|FG003|Overall Study|Administrative Problems|0
6183039|NCT01348100|9835173|FG004|Overall Study|Administrative Problems|0
6183040|NCT01348100|9835174|FG005|Overall Study|Administrative Problems|1
6183041|NCT01348100|9835175|FG006|Overall Study|Administrative Problems|1
6183042|NCT01348139|9835196|FG000|Period 1|Adverse Event|1
6183043|NCT01348139|9835197|FG001|Period 1|Adverse Event|0
6183044|NCT01348139|9835198|FG002|Period 1|Adverse Event|0
6183045|NCT01348139|9835199|FG003|Period 1|Adverse Event|0
6183046|NCT01348139|9835200|FG004|Period 1|Adverse Event|0
6183047|NCT01348139|9835201|FG005|Period 1|Adverse Event|0
6183048|NCT01348165|9835222|FG000|Overall Study|Adverse Event|0
6183049|NCT01348165|9835223|FG001|Overall Study|Adverse Event|0
6183050|NCT01348165|9835224|FG002|Overall Study|Adverse Event|0
6183051|NCT01348165|9835225|FG003|Overall Study|Adverse Event|0
6183052|NCT01348165|9835226|FG004|Overall Study|Adverse Event|0
6183053|NCT01348165|9835227|FG005|Overall Study|Adverse Event|0
6375387|NCT03877926|10165418|FG003|Overall Study|Death|0
6375388|NCT03877926|10165415|FG000|Overall Study|Lost to Follow-up|41
6375389|NCT03877926|10165416|FG001|Overall Study|Lost to Follow-up|52
6375390|NCT03877926|10165417|FG002|Overall Study|Lost to Follow-up|45
6375391|NCT03877926|10165418|FG003|Overall Study|Lost to Follow-up|17
6375392|NCT03877926|10165415|FG000|Overall Study|Physician Decision|2
6375393|NCT03877926|10165416|FG001|Overall Study|Physician Decision|0
6375394|NCT03877926|10165417|FG002|Overall Study|Physician Decision|2
6375395|NCT03877926|10165418|FG003|Overall Study|Physician Decision|0
6375396|NCT03877926|10165415|FG000|Overall Study|Withdrawal by Subject|18
6375397|NCT03877926|10165416|FG001|Overall Study|Withdrawal by Subject|21
6375398|NCT03877926|10165417|FG002|Overall Study|Withdrawal by Subject|12
6375399|NCT03877926|10165418|FG003|Overall Study|Withdrawal by Subject|4
6375400|NCT03877926|10165415|FG000|Overall Study|Other - Various|4
6375401|NCT03877926|10165416|FG001|Overall Study|Other - Various|1
6183054|NCT01348165|9835228|FG006|Overall Study|Adverse Event|1
6183055|NCT01348347|9835251|FG000|Overall Study|Withdrawal by Subject|1
6183056|NCT01348347|9835252|FG001|Overall Study|Withdrawal by Subject|1
6183057|NCT01348347|9835253|FG002|Overall Study|Withdrawal by Subject|1
6183058|NCT01348347|9835251|FG000|Overall Study|Progressive disease|2
6183059|NCT01348347|9835252|FG001|Overall Study|Progressive disease|5
6183060|NCT01348347|9835253|FG002|Overall Study|Progressive disease|5
6183061|NCT01348425|9835264|FG000|Overall Study|Imaging was not taken.|1
6183062|NCT01348425|9835265|FG001|Overall Study|Imaging was not taken.|1
6183063|NCT01348490|9835270|FG000|Overall Study|Death|1
6183064|NCT01348490|9835270|FG000|Overall Study|Adverse Event|3
6183065|NCT01348490|9835270|FG000|Overall Study|Consent withdrawn|7
6183066|NCT01348490|9835270|FG000|Overall Study|Disease progression|3
6183067|NCT01348490|9835270|FG000|Overall Study|Lost to Follow-up|1
6183068|NCT01348490|9835270|FG000|Overall Study|Termination of clinical trial by sponsor|1
6183069|NCT01348490|9835270|FG000|Overall Study|Other Unspecified|8
6183070|NCT01348542|9835293|FG000|Overall Study|Withdrawal by Subject|3
6183071|NCT01348542|9835294|FG001|Overall Study|Withdrawal by Subject|0
6375402|NCT03877926|10165417|FG002|Overall Study|Other - Various|1
6375403|NCT03877926|10165418|FG003|Overall Study|Other - Various|0
6375404|NCT03877926|10165415|FG000|Overall Study|Not Treated|3
6375405|NCT03877926|10165416|FG001|Overall Study|Not Treated|1
6375406|NCT03877926|10165417|FG002|Overall Study|Not Treated|1
6375407|NCT03877926|10165418|FG003|Overall Study|Not Treated|0
6183072|NCT01348698|9835313|FG000|Overall Study|Does not meet lesion size criteria|1
6183073|NCT01348698|9835313|FG000|Overall Study|Death|3
6183074|NCT01348698|9835313|FG000|Overall Study|PI decision to close study|68
6183075|NCT01348763|9835317|FG000|With Tenofovir/Emtricitabine (10 Days)|Withdrawal by Subject|1
6183076|NCT01348763|9835317|FG000|With Tenofovir/Emtricitabine (10 Days)|Physician Decision|1
6183077|NCT01348776|9835321|FG000|Overall Study|Lost to Follow-up|3
6183078|NCT01348789|9835334|FG000|Overall Study|Protocol Violation|2
6183079|NCT01348789|9835334|FG000|Overall Study|Withdrawal by Subject|2
6183080|NCT01348828|9835345|FG000|Overall Study|Death|20
6183081|NCT01348828|9835345|FG000|Overall Study|Withdrawals/Lost to Follow-up|10
6183082|NCT01348828|9835345|FG000|Overall Study|Conversion|2
6183083|NCT01348828|9835345|FG000|Overall Study|missed visit|1
6183084|NCT01348854|9835351|FG000|Overall Study|Lost to Follow-up|2
6183085|NCT01348854|9835352|FG001|Overall Study|Lost to Follow-up|1
6183086|NCT01348854|9835351|FG000|Overall Study|Withdrawal by Subject|1
6183087|NCT01348854|9835352|FG001|Overall Study|Withdrawal by Subject|0
6183088|NCT01349036|9835360|FG000|Overall Study|Disease progression|13
6183089|NCT01349036|9835361|FG001|Overall Study|Disease progression|22
6183090|NCT01349036|9835360|FG000|Overall Study|Other|1
6183091|NCT01349036|9835361|FG001|Overall Study|Other|0
6183092|NCT01349036|9835360|FG000|Overall Study|Withdrawal by Subject|0
6183093|NCT01349036|9835361|FG001|Overall Study|Withdrawal by Subject|2
6183094|NCT01349049|9835380|FG000|Overall Study|Disease progression|3
6183095|NCT01349049|9835381|FG001|Overall Study|Disease progression|5
6183096|NCT01349049|9835382|FG002|Overall Study|Disease progression|3
6183097|NCT01349049|9835383|FG003|Overall Study|Disease progression|2
6183098|NCT01349049|9835384|FG004|Overall Study|Disease progression|2
6183099|NCT01349049|9835385|FG005|Overall Study|Disease progression|2
6183100|NCT01349049|9835386|FG006|Overall Study|Disease progression|3
6183101|NCT01349049|9835387|FG007|Overall Study|Disease progression|2
6183102|NCT01349049|9835388|FG008|Overall Study|Disease progression|33
6183103|NCT01349049|9835380|FG000|Overall Study|Adverse Event|0
6183104|NCT01349049|9835381|FG001|Overall Study|Adverse Event|1
6183105|NCT01349049|9835382|FG002|Overall Study|Adverse Event|0
6183106|NCT01349049|9835383|FG003|Overall Study|Adverse Event|0
6183107|NCT01349049|9835384|FG004|Overall Study|Adverse Event|0
6183108|NCT01349049|9835385|FG005|Overall Study|Adverse Event|3
6183109|NCT01349049|9835386|FG006|Overall Study|Adverse Event|1
6183110|NCT01349049|9835387|FG007|Overall Study|Adverse Event|0
6183111|NCT01349049|9835388|FG008|Overall Study|Adverse Event|4
6183112|NCT01349049|9835380|FG000|Overall Study|Physician Decision|0
6183113|NCT01349049|9835381|FG001|Overall Study|Physician Decision|1
6183114|NCT01349049|9835382|FG002|Overall Study|Physician Decision|0
6183115|NCT01349049|9835383|FG003|Overall Study|Physician Decision|0
6183116|NCT01349049|9835384|FG004|Overall Study|Physician Decision|0
6183117|NCT01349049|9835385|FG005|Overall Study|Physician Decision|0
6183118|NCT01349049|9835386|FG006|Overall Study|Physician Decision|0
6183119|NCT01349049|9835387|FG007|Overall Study|Physician Decision|0
6183120|NCT01349049|9835388|FG008|Overall Study|Physician Decision|2
6183121|NCT01349049|9835380|FG000|Overall Study|Protocol Violation|0
6183122|NCT01349049|9835381|FG001|Overall Study|Protocol Violation|0
6183123|NCT01349049|9835382|FG002|Overall Study|Protocol Violation|0
6183124|NCT01349049|9835383|FG003|Overall Study|Protocol Violation|0
6183125|NCT01349049|9835384|FG004|Overall Study|Protocol Violation|0
6183126|NCT01349049|9835385|FG005|Overall Study|Protocol Violation|0
6183127|NCT01349049|9835386|FG006|Overall Study|Protocol Violation|0
6183128|NCT01349049|9835387|FG007|Overall Study|Protocol Violation|0
6183129|NCT01349049|9835388|FG008|Overall Study|Protocol Violation|1
6183130|NCT01349049|9835380|FG000|Overall Study|Hematopoietic stem cell transplant|0
6183131|NCT01349049|9835381|FG001|Overall Study|Hematopoietic stem cell transplant|0
6183132|NCT01349049|9835382|FG002|Overall Study|Hematopoietic stem cell transplant|0
6183133|NCT01349049|9835383|FG003|Overall Study|Hematopoietic stem cell transplant|0
6183134|NCT01349049|9835384|FG004|Overall Study|Hematopoietic stem cell transplant|1
6183135|NCT01349049|9835385|FG005|Overall Study|Hematopoietic stem cell transplant|0
6183136|NCT01349049|9835386|FG006|Overall Study|Hematopoietic stem cell transplant|1
6183137|NCT01349049|9835387|FG007|Overall Study|Hematopoietic stem cell transplant|1
6183138|NCT01349049|9835388|FG008|Overall Study|Hematopoietic stem cell transplant|0
6183139|NCT01349049|9835380|FG000|Overall Study|Other|0
6183140|NCT01349049|9835381|FG001|Overall Study|Other|0
6183141|NCT01349049|9835382|FG002|Overall Study|Other|0
6183142|NCT01349049|9835383|FG003|Overall Study|Other|0
6183143|NCT01349049|9835384|FG004|Overall Study|Other|0
6183144|NCT01349049|9835385|FG005|Overall Study|Other|1
6183145|NCT01349049|9835386|FG006|Overall Study|Other|0
6183146|NCT01349049|9835387|FG007|Overall Study|Other|0
6183147|NCT01349049|9835388|FG008|Overall Study|Other|4
6183148|NCT01349049|9835380|FG000|Overall Study|Death|0
6183149|NCT01349049|9835381|FG001|Overall Study|Death|0
6183150|NCT01349049|9835382|FG002|Overall Study|Death|0
6183151|NCT01349049|9835383|FG003|Overall Study|Death|0
6183152|NCT01349049|9835384|FG004|Overall Study|Death|0
6183153|NCT01349049|9835385|FG005|Overall Study|Death|0
6183154|NCT01349049|9835386|FG006|Overall Study|Death|0
6183155|NCT01349049|9835387|FG007|Overall Study|Death|1
6183156|NCT01349049|9835388|FG008|Overall Study|Death|5
6183157|NCT01349049|9835380|FG000|Overall Study|Non-compliance|0
6183158|NCT01349049|9835381|FG001|Overall Study|Non-compliance|0
6183159|NCT01349049|9835382|FG002|Overall Study|Non-compliance|0
6183160|NCT01349049|9835383|FG003|Overall Study|Non-compliance|1
6183161|NCT01349049|9835384|FG004|Overall Study|Non-compliance|0
6183162|NCT01349049|9835385|FG005|Overall Study|Non-compliance|0
6183163|NCT01349049|9835386|FG006|Overall Study|Non-compliance|0
6183164|NCT01349049|9835387|FG007|Overall Study|Non-compliance|0
6183165|NCT01349049|9835388|FG008|Overall Study|Non-compliance|0
6183166|NCT01349049|9835380|FG000|Overall Study|Withdrawal by Subject|0
6183167|NCT01349049|9835381|FG001|Overall Study|Withdrawal by Subject|0
6183168|NCT01349049|9835382|FG002|Overall Study|Withdrawal by Subject|0
6183169|NCT01349049|9835383|FG003|Overall Study|Withdrawal by Subject|0
6183170|NCT01349049|9835384|FG004|Overall Study|Withdrawal by Subject|0
6183171|NCT01349049|9835385|FG005|Overall Study|Withdrawal by Subject|0
6375408|NCT03862807|10165441|FG000|Overall Study|Not Treated Due to Eligibility Criteria Failure|1
6375409|NCT03857867|10165445|FG000|Overall Study|Physician Decision|1
6375410|NCT03691571|10165452|FG000|Overall Study|Withdrawal by Subject|9
6375411|NCT03691571|10165453|FG001|Overall Study|Withdrawal by Subject|2
6375412|NCT03436199|10165463|FG000|Overall Study|Adverse Event|15
6375413|NCT03436199|10165464|FG001|Overall Study|Adverse Event|40
6183172|NCT01349049|9835386|FG006|Overall Study|Withdrawal by Subject|0
6183173|NCT01349049|9835387|FG007|Overall Study|Withdrawal by Subject|0
6183174|NCT01349049|9835388|FG008|Overall Study|Withdrawal by Subject|6
6183175|NCT01349192|9835437|FG000|Overall Study|Protocol Violation|0
6183176|NCT01349192|9835438|FG001|Overall Study|Protocol Violation|1
6183177|NCT01349192|9835437|FG000|Overall Study|Withdrawal by Subject|0
6183178|NCT01349192|9835438|FG001|Overall Study|Withdrawal by Subject|2
6183179|NCT01349192|9835437|FG000|Overall Study|Lost to Follow-up|1
6183180|NCT01349192|9835438|FG001|Overall Study|Lost to Follow-up|3
6183181|NCT01349192|9835437|FG000|Overall Study|Failure to adhere to Protocol|2
6183182|NCT01349192|9835438|FG001|Overall Study|Failure to adhere to Protocol|0
6183183|NCT01349465|9835452|FG000|Overall Study|Adverse Event|1
6183184|NCT01349465|9835453|FG001|Overall Study|Adverse Event|0
6183185|NCT01349465|9835452|FG000|Overall Study|Death|3
6183186|NCT01349465|9835453|FG001|Overall Study|Death|0
6183187|NCT01349465|9835452|FG000|Overall Study|Lost to Follow-up|10
6183188|NCT01349465|9835453|FG001|Overall Study|Lost to Follow-up|1
6183189|NCT01349465|9835452|FG000|Overall Study|Withdrawal by Subject|4
6183190|NCT01349465|9835453|FG001|Overall Study|Withdrawal by Subject|2
6183191|NCT01349465|9835452|FG000|Overall Study|Subject Ineligible To Continue The Trial|0
6183192|NCT01349465|9835453|FG001|Overall Study|Subject Ineligible To Continue The Trial|19
6183193|NCT01349569|9835470|FG000|Overall Study|Lack of Efficacy|4
6183194|NCT01349660|9835480|FG000|Overall Study|Still Receiving Study Treatment|0
6183195|NCT01349660|9835481|FG001|Overall Study|Still Receiving Study Treatment|0
6183196|NCT01349660|9835482|FG002|Overall Study|Still Receiving Study Treatment|1
6183197|NCT01349660|9835480|FG000|Overall Study|Disease Progression|2
6183198|NCT01349660|9835481|FG001|Overall Study|Disease Progression|4
6183199|NCT01349660|9835482|FG002|Overall Study|Disease Progression|50
6183200|NCT01349660|9835480|FG000|Overall Study|Adverse Event|1
6183201|NCT01349660|9835481|FG001|Overall Study|Adverse Event|1
6183202|NCT01349660|9835482|FG002|Overall Study|Adverse Event|12
6183203|NCT01349660|9835480|FG000|Overall Study|Withdrawal by Subject|2
6183204|NCT01349660|9835481|FG001|Overall Study|Withdrawal by Subject|0
6183205|NCT01349660|9835482|FG002|Overall Study|Withdrawal by Subject|9
6183206|NCT01349660|9835480|FG000|Overall Study|Death|1
6183207|NCT01349660|9835481|FG001|Overall Study|Death|1
6183208|NCT01349660|9835482|FG002|Overall Study|Death|0
6183209|NCT01349660|9835480|FG000|Overall Study|Non-Permitted Interventions|0
6183210|NCT01349660|9835481|FG001|Overall Study|Non-Permitted Interventions|0
6183211|NCT01349660|9835482|FG002|Overall Study|Non-Permitted Interventions|2
6183212|NCT01349660|9835480|FG000|Overall Study|Study Compliance|0
6183213|NCT01349660|9835481|FG001|Overall Study|Study Compliance|0
6183214|NCT01349660|9835482|FG002|Overall Study|Study Compliance|1
6183215|NCT01349660|9835480|FG000|Overall Study|Declining Performance Status|0
6183216|NCT01349660|9835481|FG001|Overall Study|Declining Performance Status|0
6183217|NCT01349660|9835482|FG002|Overall Study|Declining Performance Status|1
6183218|NCT01349673|9835497|FG000|Overall Study|Progression Of Disease Past 40 cm|1
6183219|NCT01349673|9835497|FG000|Overall Study|No Longer Qualified For Study|1
6183220|NCT01349673|9835497|FG000|Overall Study|Site Closure|10
6183221|NCT01349673|9835497|FG000|Overall Study|Withdrawal by Subject|21
6183222|NCT01349673|9835497|FG000|Overall Study|Lost to Follow-up|6
6183223|NCT01349673|9835497|FG000|Overall Study|Adverse Event|17
6183224|NCT01349673|9835497|FG000|Overall Study|Study Terminated By Sponsor|50
6183225|NCT01349673|9835497|FG000|Overall Study|Lack of Efficacy|8
6183226|NCT01349790|9835501|FG000|Overall Study|Investigator Judgement|3
6183227|NCT01349790|9835501|FG000|Overall Study|Death|2
6183228|NCT01349790|9835501|FG000|Overall Study|Withdrawal by Patient|2
6183229|NCT01349790|9835501|FG000|Overall Study|Adverse Event|1
6183230|NCT01349790|9835501|FG000|Overall Study|Lost to Follow-up|1
6183231|NCT01349803|9835509|FG000|Overall Study|Adverse Event|0
6183232|NCT01349803|9835510|FG001|Overall Study|Adverse Event|0
6375414|NCT03436199|10165465|FG002|Overall Study|Adverse Event|7
6183233|NCT01349803|9835511|FG002|Overall Study|Adverse Event|0
6183234|NCT01349803|9835512|FG003|Overall Study|Adverse Event|2
6183235|NCT01349803|9835509|FG000|Overall Study|Withdrawal by Subject|1
6183236|NCT01349803|9835510|FG001|Overall Study|Withdrawal by Subject|0
6183237|NCT01349803|9835511|FG002|Overall Study|Withdrawal by Subject|0
6183238|NCT01349803|9835512|FG003|Overall Study|Withdrawal by Subject|0
6183239|NCT01349803|9835509|FG000|Overall Study|Protocol-specified criteria|0
6183240|NCT01349803|9835510|FG001|Overall Study|Protocol-specified criteria|1
6183241|NCT01349803|9835511|FG002|Overall Study|Protocol-specified criteria|3
6183242|NCT01349803|9835512|FG003|Overall Study|Protocol-specified criteria|0
6183243|NCT01349816|9835530|FG000|Overall Study|Withdrawal by Subject|4
6183244|NCT01349816|9835530|FG000|Overall Study|Physician Decision|1
6183245|NCT01349816|9835530|FG000|Overall Study|Adverse Event|14
6183246|NCT01349816|9835530|FG000|Overall Study|Lost to Follow-up|2
6183247|NCT01349816|9835530|FG000|Overall Study|Protocol Violation|1
6183248|NCT01349816|9835530|FG000|Overall Study|Protocol-specified criteria|8
6183249|NCT01349829|9835546|FG000|Overall Study|Lost to Follow-up|4
6183250|NCT01349829|9835547|FG001|Overall Study|Lost to Follow-up|8
6183251|NCT01349829|9835546|FG000|Overall Study|Consent withdrawal|3
6183252|NCT01349829|9835547|FG001|Overall Study|Consent withdrawal|8
6183253|NCT01349829|9835546|FG000|Overall Study|Migrated/moved|2
6183254|NCT01349829|9835547|FG001|Overall Study|Migrated/moved|7
6183255|NCT01350102|9835578|FG000|Overall Study|Adverse Event|0
6183256|NCT01350102|9835579|FG001|Overall Study|Adverse Event|0
6183257|NCT01350102|9835580|FG002|Overall Study|Adverse Event|1
6183258|NCT01350102|9835581|FG003|Overall Study|Adverse Event|0
6183259|NCT01350115|9835593|FG000|Long Term Follow-Up (All Patients)|Lost to Follow-up|0
6183260|NCT01350115|9835594|FG001|Long Term Follow-Up (All Patients)|Lost to Follow-up|1
6183261|NCT01350115|9835593|FG000|Long Term Follow-Up (All Patients)|Adverse Event|0
6183262|NCT01350115|9835594|FG001|Long Term Follow-Up (All Patients)|Adverse Event|1
6183263|NCT01350115|9835593|FG000|Long Term Follow-Up (All Patients)|Withdrawal by Subject|1
6183264|NCT01350115|9835594|FG001|Long Term Follow-Up (All Patients)|Withdrawal by Subject|0
6183265|NCT01350128|9835602|FG000|Overall Study|Withdrawal by Subject|3
6183266|NCT01350128|9835602|FG000|Overall Study|Protocol discontinuation criteria|8
6183267|NCT01350128|9835602|FG000|Overall Study|Physician Decision|1
6183268|NCT01350128|9835602|FG000|Overall Study|Lost to Follow-up|2
6183269|NCT01350141|9835619|FG000|Overall Study|Lost to Follow-up|1
6183270|NCT01350141|9835620|FG001|Overall Study|Lost to Follow-up|0
6183271|NCT01350141|9835621|FG002|Overall Study|Lost to Follow-up|1
6183272|NCT01350141|9835619|FG000|Overall Study|Withdrawal by Subject|1
6183273|NCT01350141|9835620|FG001|Overall Study|Withdrawal by Subject|0
6183274|NCT01350141|9835621|FG002|Overall Study|Withdrawal by Subject|0
6183275|NCT01350141|9835619|FG000|Overall Study|Randomized but not treated|1
6183276|NCT01350141|9835620|FG001|Overall Study|Randomized but not treated|0
6183277|NCT01350141|9835621|FG002|Overall Study|Randomized but not treated|0
6183278|NCT01350271|9835638|FG000|Overall Study|Lost to Follow-up|21
6183279|NCT01350271|9835639|FG001|Overall Study|Lost to Follow-up|17
6183280|NCT01350271|9835640|FG002|Overall Study|Lost to Follow-up|26
6183281|NCT01350336|9835651|FG000|Overall Study|Lost to Follow-up|31
6183282|NCT01350336|9835651|FG000|Overall Study|Withdrawal by Subject|14
6183283|NCT01350336|9835651|FG000|Overall Study|Physician Decision|8
6183284|NCT01350336|9835651|FG000|Overall Study|Death|4
6183285|NCT01350414|9835717|FG000|Overall Study|Lost to Follow-up|13
6183286|NCT01350414|9835717|FG000|Overall Study|Withdrawal by Subject|4
6183287|NCT01350414|9835717|FG000|Overall Study|Physician Decision|2
6183288|NCT01350492|9835749|FG000|Intervention|Lost to Follow-up|2
6183289|NCT01350492|9835750|FG001|Intervention|Lost to Follow-up|5
6183290|NCT01350492|9835749|FG000|Intervention|Withdrawal by Subject|3
6183291|NCT01350492|9835750|FG001|Intervention|Withdrawal by Subject|1
6183292|NCT01350492|9835749|FG000|Post Intervention Follow-Up|Lost to Follow-up|6
6183293|NCT01350492|9835750|FG001|Post Intervention Follow-Up|Lost to Follow-up|1
6183294|NCT01350492|9835749|FG000|Post Intervention Follow-Up|Withdrawal by Subject|0
6183295|NCT01350492|9835750|FG001|Post Intervention Follow-Up|Withdrawal by Subject|1
6183296|NCT01350505|9835756|FG000|Overall Study|Lost to Follow-up|4
6183297|NCT01350544|9835762|FG000|Overall Study|Administrative Withdrawal|0
6183298|NCT01350544|9835763|FG001|Overall Study|Administrative Withdrawal|1
6183299|NCT01350544|9835762|FG000|Overall Study|Death|1
6183300|NCT01350544|9835763|FG001|Overall Study|Death|2
6183301|NCT01350544|9835762|FG000|Overall Study|Moved out of LA County|2
6183302|NCT01350544|9835763|FG001|Overall Study|Moved out of LA County|2
6183303|NCT01350544|9835762|FG000|Overall Study|Medical Issues|1
6183304|NCT01350544|9835763|FG001|Overall Study|Medical Issues|1
6183305|NCT01350544|9835762|FG000|Overall Study|Withdrawal by Subject|0
6183306|NCT01350544|9835763|FG001|Overall Study|Withdrawal by Subject|1
6183307|NCT01350544|9835762|FG000|Overall Study|Incarceration|1
6183308|NCT01350544|9835763|FG001|Overall Study|Incarceration|0
6183309|NCT01350544|9835762|FG000|Overall Study|Lost to Follow-up|18
6183310|NCT01350544|9835763|FG001|Overall Study|Lost to Follow-up|15
6183311|NCT01350804|9835773|FG000|Core Study|Withdrawal by Subject|11
6183312|NCT01350804|9835774|FG001|Core Study|Withdrawal by Subject|17
6183313|NCT01350804|9835775|FG002|Core Study|Withdrawal by Subject|16
6183314|NCT01350804|9835776|FG003|Core Study|Withdrawal by Subject|7
6183315|NCT01350804|9835773|FG000|Core Study|Study terminated by Sponsor|0
6183316|NCT01350804|9835774|FG001|Core Study|Study terminated by Sponsor|0
6183317|NCT01350804|9835775|FG002|Core Study|Study terminated by Sponsor|0
6183318|NCT01350804|9835776|FG003|Core Study|Study terminated by Sponsor|2
6183319|NCT01350804|9835773|FG000|Core Study|Protocol deviation|1
6183320|NCT01350804|9835774|FG001|Core Study|Protocol deviation|0
6183321|NCT01350804|9835775|FG002|Core Study|Protocol deviation|1
6183322|NCT01350804|9835776|FG003|Core Study|Protocol deviation|0
6183323|NCT01350804|9835773|FG000|Core Study|Physician Decision|1
6183324|NCT01350804|9835774|FG001|Core Study|Physician Decision|0
6183325|NCT01350804|9835775|FG002|Core Study|Physician Decision|1
6183326|NCT01350804|9835776|FG003|Core Study|Physician Decision|3
6183327|NCT01350804|9835773|FG000|Core Study|Lost to Follow-up|3
6183328|NCT01350804|9835774|FG001|Core Study|Lost to Follow-up|0
6183329|NCT01350804|9835775|FG002|Core Study|Lost to Follow-up|2
6183330|NCT01350804|9835776|FG003|Core Study|Lost to Follow-up|1
6183331|NCT01350804|9835773|FG000|Core Study|Lack of Efficacy|16
6183332|NCT01350804|9835774|FG001|Core Study|Lack of Efficacy|19
6183333|NCT01350804|9835775|FG002|Core Study|Lack of Efficacy|18
6183334|NCT01350804|9835776|FG003|Core Study|Lack of Efficacy|5
6183335|NCT01350804|9835773|FG000|Core Study|Death|1
6183336|NCT01350804|9835774|FG001|Core Study|Death|1
6183337|NCT01350804|9835775|FG002|Core Study|Death|1
6183338|NCT01350804|9835776|FG003|Core Study|Death|0
6183339|NCT01350804|9835773|FG000|Core Study|Adverse Event|8
6183340|NCT01350804|9835774|FG001|Core Study|Adverse Event|10
6183341|NCT01350804|9835775|FG002|Core Study|Adverse Event|8
6183342|NCT01350804|9835776|FG003|Core Study|Adverse Event|8
6183343|NCT01350804|9835773|FG000|Extension Study, Weeks 52 - 260|Withdrawal by Subject|5
6183344|NCT01350804|9835774|FG001|Extension Study, Weeks 52 - 260|Withdrawal by Subject|6
6183345|NCT01350804|9835775|FG002|Extension Study, Weeks 52 - 260|Withdrawal by Subject|4
6183346|NCT01350804|9835776|FG003|Extension Study, Weeks 52 - 260|Withdrawal by Subject|3
6183347|NCT01350804|9835773|FG000|Extension Study, Weeks 52 - 260|Study terminated by Sponsor|67
6183348|NCT01350804|9835774|FG001|Extension Study, Weeks 52 - 260|Study terminated by Sponsor|67
6183349|NCT01350804|9835775|FG002|Extension Study, Weeks 52 - 260|Study terminated by Sponsor|64
6183350|NCT01350804|9835776|FG003|Extension Study, Weeks 52 - 260|Study terminated by Sponsor|16
6183351|NCT01350804|9835773|FG000|Extension Study, Weeks 52 - 260|Physician Decision|1
6183352|NCT01350804|9835774|FG001|Extension Study, Weeks 52 - 260|Physician Decision|0
6183353|NCT01350804|9835775|FG002|Extension Study, Weeks 52 - 260|Physician Decision|2
6183354|NCT01350804|9835776|FG003|Extension Study, Weeks 52 - 260|Physician Decision|0
6183355|NCT01350804|9835773|FG000|Extension Study, Weeks 52 - 260|Lost to Follow-up|0
6183356|NCT01350804|9835774|FG001|Extension Study, Weeks 52 - 260|Lost to Follow-up|1
6183357|NCT01350804|9835775|FG002|Extension Study, Weeks 52 - 260|Lost to Follow-up|0
6183358|NCT01350804|9835776|FG003|Extension Study, Weeks 52 - 260|Lost to Follow-up|0
6183359|NCT01350804|9835773|FG000|Extension Study, Weeks 52 - 260|Lack of Efficacy|4
6183360|NCT01350804|9835774|FG001|Extension Study, Weeks 52 - 260|Lack of Efficacy|4
6183361|NCT01350804|9835775|FG002|Extension Study, Weeks 52 - 260|Lack of Efficacy|0
6183362|NCT01350804|9835776|FG003|Extension Study, Weeks 52 - 260|Lack of Efficacy|1
6183363|NCT01350804|9835773|FG000|Extension Study, Weeks 52 - 260|Adverse Event|3
6183364|NCT01350804|9835774|FG001|Extension Study, Weeks 52 - 260|Adverse Event|1
6183365|NCT01350804|9835775|FG002|Extension Study, Weeks 52 - 260|Adverse Event|2
6183366|NCT01350804|9835776|FG003|Extension Study, Weeks 52 - 260|Adverse Event|3
6183367|NCT01350973|9835803|FG000|Overall Study|Adverse Event|4
6183368|NCT01350973|9835804|FG001|Overall Study|Adverse Event|7
6183369|NCT01350973|9835805|FG002|Overall Study|Adverse Event|7
6183370|NCT01350973|9835803|FG000|Overall Study|Voluntary Withdrawal|2
6183371|NCT01350973|9835804|FG001|Overall Study|Voluntary Withdrawal|1
6183372|NCT01350973|9835805|FG002|Overall Study|Voluntary Withdrawal|1
6183373|NCT01350999|9835816|FG000|Overall Study|Adverse Event|4
6183374|NCT01350999|9835817|FG001|Overall Study|Adverse Event|9
6183375|NCT01350999|9835818|FG002|Overall Study|Adverse Event|10
6183376|NCT01350999|9835816|FG000|Overall Study|Voluntary withdrawal|3
6183377|NCT01350999|9835817|FG001|Overall Study|Voluntary withdrawal|4
6183378|NCT01350999|9835818|FG002|Overall Study|Voluntary withdrawal|6
6183379|NCT01350999|9835816|FG000|Overall Study|Difficulty Making it to Study Visit|1
6183380|NCT01350999|9835817|FG001|Overall Study|Difficulty Making it to Study Visit|1
6183381|NCT01350999|9835818|FG002|Overall Study|Difficulty Making it to Study Visit|5
6183382|NCT01351025|9835828|FG000|Week 0 - 20|Lost to Follow-up|2
6183383|NCT01351025|9835829|FG001|Week 0 - 20|Lost to Follow-up|1
6183384|NCT01351025|9835828|FG000|Week 0 - 20|Withdrawal by Subject|1
6183385|NCT01351025|9835829|FG001|Week 0 - 20|Withdrawal by Subject|0
6183386|NCT01351025|9835828|FG000|Week 24 - 44|Lost to Follow-up|0
6183387|NCT01351025|9835829|FG001|Week 24 - 44|Lost to Follow-up|2
6183388|NCT01351025|9835828|FG000|Week 24 - 44|Site closed|0
6183389|NCT01351025|9835829|FG001|Week 24 - 44|Site closed|1
6183390|NCT01351025|9835828|FG000|Week 24 - 44|unable to get to clinic|1
6183391|NCT01351025|9835829|FG001|Week 24 - 44|unable to get to clinic|1
6183392|NCT01351350|9835882|FG000|Overall Study|Disease Progression|5
6183393|NCT01351350|9835883|FG001|Overall Study|Disease Progression|13
6183394|NCT01351350|9835884|FG002|Overall Study|Disease Progression|6
6183395|NCT01351350|9835885|FG003|Overall Study|Disease Progression|8
6183396|NCT01351350|9835886|FG004|Overall Study|Disease Progression|5
6183397|NCT01351350|9835882|FG000|Overall Study|Adverse Event|1
6183398|NCT01351350|9835883|FG001|Overall Study|Adverse Event|10
6183399|NCT01351350|9835884|FG002|Overall Study|Adverse Event|1
6183400|NCT01351350|9835885|FG003|Overall Study|Adverse Event|2
6183401|NCT01351350|9835886|FG004|Overall Study|Adverse Event|0
6183402|NCT01351350|9835882|FG000|Overall Study|Participant Decision|2
6183403|NCT01351350|9835883|FG001|Overall Study|Participant Decision|6
6183404|NCT01351350|9835884|FG002|Overall Study|Participant Decision|3
6183405|NCT01351350|9835885|FG003|Overall Study|Participant Decision|3
6183406|NCT01351350|9835886|FG004|Overall Study|Participant Decision|2
6183407|NCT01351350|9835882|FG000|Overall Study|Enrolled but not Treated|0
6183408|NCT01351350|9835883|FG001|Overall Study|Enrolled but not Treated|0
6183409|NCT01351350|9835884|FG002|Overall Study|Enrolled but not Treated|1
6183410|NCT01351350|9835885|FG003|Overall Study|Enrolled but not Treated|0
6183411|NCT01351350|9835886|FG004|Overall Study|Enrolled but not Treated|0
6183412|NCT01351415|9835922|FG000|Overall Study|Withdrawal by Subject|15
6183413|NCT01351415|9835923|FG001|Overall Study|Withdrawal by Subject|17
6183414|NCT01351415|9835922|FG000|Overall Study|Trial termination by the Sponsor|28
6183415|NCT01351415|9835923|FG001|Overall Study|Trial termination by the Sponsor|19
6183416|NCT01351415|9835922|FG000|Overall Study|Lost to Follow-up|5
6183417|NCT01351415|9835923|FG001|Overall Study|Lost to Follow-up|7
6183418|NCT01351415|9835922|FG000|Overall Study|Death|190
6183419|NCT01351415|9835923|FG001|Overall Study|Death|187
6183420|NCT01351415|9835922|FG000|Overall Study|Physician Decision|2
6183421|NCT01351415|9835923|FG001|Overall Study|Physician Decision|3
6183422|NCT01351415|9835922|FG000|Overall Study|Reason unknown|0
6183423|NCT01351415|9835923|FG001|Overall Study|Reason unknown|2
6183424|NCT01351415|9835922|FG000|Overall Study|Never Started|5
6183425|NCT01351415|9835923|FG001|Overall Study|Never Started|5
6183426|NCT01351623|9835941|FG000|Overall Study|Protocol Violation|2
6183427|NCT01351623|9835941|FG000|Overall Study|Adverse Event|4
6183428|NCT01351623|9835941|FG000|Overall Study|Withdrawal by Subject|1
6183429|NCT01351623|9835941|FG000|Overall Study|Death|2
6183430|NCT01352117|9836005|FG000|Overall Study|Death|15
6183431|NCT01352117|9836006|FG001|Overall Study|Death|16
6183432|NCT01352117|9836005|FG000|Overall Study|Withdrawal by Subject|1
6183433|NCT01352117|9836006|FG001|Overall Study|Withdrawal by Subject|0
6183434|NCT01352117|9836005|FG000|Overall Study|Lost to Follow-up|2
6183435|NCT01352117|9836006|FG001|Overall Study|Lost to Follow-up|7
6183436|NCT01352117|9836005|FG000|Overall Study|Non-adherent to study requirements|1
6183437|NCT01352117|9836006|FG001|Overall Study|Non-adherent to study requirements|1
6183438|NCT01352117|9836005|FG000|Overall Study|Did not initiate study treatment|1
6183439|NCT01352117|9836006|FG001|Overall Study|Did not initiate study treatment|0
6183440|NCT01352117|9836005|FG000|Overall Study|Ineligible (no KS diagnosis)|1
6183441|NCT01352117|9836006|FG001|Overall Study|Ineligible (no KS diagnosis)|0
6183442|NCT01352221|9836028|FG000|Double-blind Phase|Adverse Event|6
6183443|NCT01352221|9836029|FG001|Double-blind Phase|Adverse Event|4
6183444|NCT01352221|9836030|FG002|Double-blind Phase|Adverse Event|0
6183445|NCT01352221|9836031|FG003|Double-blind Phase|Adverse Event|0
6183446|NCT01352221|9836028|FG000|Double-blind Phase|Withdrawal by Subject|3
6183447|NCT01352221|9836029|FG001|Double-blind Phase|Withdrawal by Subject|5
6183448|NCT01352221|9836030|FG002|Double-blind Phase|Withdrawal by Subject|0
6183449|NCT01352221|9836031|FG003|Double-blind Phase|Withdrawal by Subject|0
6183450|NCT01352221|9836028|FG000|Double-blind Phase|Lost to Follow-up|0
6183451|NCT01352221|9836029|FG001|Double-blind Phase|Lost to Follow-up|1
6183452|NCT01352221|9836030|FG002|Double-blind Phase|Lost to Follow-up|0
6183453|NCT01352221|9836031|FG003|Double-blind Phase|Lost to Follow-up|0
6183454|NCT01352221|9836028|FG000|Double-blind Phase|Protocol Violation|0
6183455|NCT01352221|9836029|FG001|Double-blind Phase|Protocol Violation|1
6183456|NCT01352221|9836030|FG002|Double-blind Phase|Protocol Violation|0
6183457|NCT01352221|9836031|FG003|Double-blind Phase|Protocol Violation|0
6183458|NCT01352221|9836028|FG000|Open-label Phase|Physician Decision|0
6183459|NCT01352221|9836029|FG001|Open-label Phase|Physician Decision|0
6183460|NCT01352221|9836030|FG002|Open-label Phase|Physician Decision|2
6183461|NCT01352221|9836031|FG003|Open-label Phase|Physician Decision|1
6183462|NCT01352221|9836028|FG000|Open-label Phase|Pregnancy|0
6183463|NCT01352221|9836029|FG001|Open-label Phase|Pregnancy|0
6183464|NCT01352221|9836030|FG002|Open-label Phase|Pregnancy|1
6183465|NCT01352221|9836031|FG003|Open-label Phase|Pregnancy|0
6183466|NCT01352221|9836028|FG000|Open-label Phase|Adverse Event|0
6183467|NCT01352221|9836029|FG001|Open-label Phase|Adverse Event|0
6183468|NCT01352221|9836030|FG002|Open-label Phase|Adverse Event|8
6183469|NCT01352221|9836031|FG003|Open-label Phase|Adverse Event|4
6183470|NCT01352221|9836028|FG000|Open-label Phase|Withdrawal by Subject|0
6183471|NCT01352221|9836029|FG001|Open-label Phase|Withdrawal by Subject|0
6183472|NCT01352221|9836030|FG002|Open-label Phase|Withdrawal by Subject|1
6183473|NCT01352221|9836031|FG003|Open-label Phase|Withdrawal by Subject|6
6183474|NCT01352221|9836028|FG000|Open-label Phase|Worsening of IBD|0
6183475|NCT01352221|9836029|FG001|Open-label Phase|Worsening of IBD|0
6183476|NCT01352221|9836030|FG002|Open-label Phase|Worsening of IBD|1
6183477|NCT01352221|9836031|FG003|Open-label Phase|Worsening of IBD|0
6183478|NCT01352507|9836063|FG000|Treatment Period 1|Adverse Event|3
6183479|NCT01352507|9836064|FG001|Treatment Period 1|Adverse Event|0
6183480|NCT01352507|9836063|FG000|Treatment Period 1|Lost to Follow-up|3
6183481|NCT01352507|9836064|FG001|Treatment Period 1|Lost to Follow-up|4
6183482|NCT01352507|9836063|FG000|Treatment Period 1|Withdrawal by Subject|7
6183483|NCT01352507|9836064|FG001|Treatment Period 1|Withdrawal by Subject|5
6183484|NCT01352507|9836063|FG000|Treatment Period 1|Physician Decision|1
6183485|NCT01352507|9836064|FG001|Treatment Period 1|Physician Decision|0
6183486|NCT01352507|9836063|FG000|Washout Period|Withdrawal by Subject|0
6183487|NCT01352507|9836064|FG001|Washout Period|Withdrawal by Subject|1
6183488|NCT01352507|9836063|FG000|Treatment Period 2|Entry Criteria Not Met|1
6183489|NCT01352507|9836064|FG001|Treatment Period 2|Entry Criteria Not Met|0
6183490|NCT01352507|9836063|FG000|Treatment Period 2|Withdrawal by Subject|4
6183491|NCT01352507|9836064|FG001|Treatment Period 2|Withdrawal by Subject|3
6183492|NCT01352507|9836063|FG000|Treatment Period 2|Lack of Efficacy|1
6183493|NCT01352507|9836064|FG001|Treatment Period 2|Lack of Efficacy|0
6183494|NCT01352585|9836082|FG000|Overall Study|Adverse Event|2
6183495|NCT01352585|9836083|FG001|Overall Study|Adverse Event|1
6183496|NCT01352585|9836082|FG000|Overall Study|Lost to Follow-up|1
6183497|NCT01352585|9836083|FG001|Overall Study|Lost to Follow-up|0
6183498|NCT01352585|9836082|FG000|Overall Study|Other|5
6183499|NCT01352585|9836083|FG001|Overall Study|Other|2
6183500|NCT01352715|9836113|FG000|Overall Study|Death|3
6183501|NCT01352715|9836114|FG001|Overall Study|Death|3
6183502|NCT01352715|9836113|FG000|Overall Study|Lost to Follow-up|5
6183503|NCT01352715|9836114|FG001|Overall Study|Lost to Follow-up|7
6183504|NCT01352715|9836113|FG000|Overall Study|Withdrawal by Subject|4
6183505|NCT01352715|9836114|FG001|Overall Study|Withdrawal by Subject|8
6183506|NCT01352715|9836113|FG000|Overall Study|site closure|16
6183507|NCT01352715|9836114|FG001|Overall Study|site closure|15
6183508|NCT01352715|9836113|FG000|Overall Study|no final visit in closeout period|15
6183509|NCT01352715|9836114|FG001|Overall Study|no final visit in closeout period|12
6183510|NCT01352715|9836113|FG000|Overall Study|major ineligibility|2
6183511|NCT01352715|9836114|FG001|Overall Study|major ineligibility|1
6183512|NCT01352741|9836120|FG000|Open-label Tapentadol Titration Period|Protocol Violation|4
6183513|NCT01352741|9836121|FG001|Open-label Tapentadol Titration Period|Protocol Violation|0
6183514|NCT01352741|9836120|FG000|Open-label Tapentadol Titration Period|Lack of Efficacy|19
6183515|NCT01352741|9836121|FG001|Open-label Tapentadol Titration Period|Lack of Efficacy|0
6183516|NCT01352741|9836120|FG000|Open-label Tapentadol Titration Period|Adverse Event|34
6183517|NCT01352741|9836121|FG001|Open-label Tapentadol Titration Period|Adverse Event|0
6183518|NCT01352741|9836120|FG000|Open-label Tapentadol Titration Period|Withdrawal of consent|7
6183519|NCT01352741|9836121|FG001|Open-label Tapentadol Titration Period|Withdrawal of consent|0
6183520|NCT01352741|9836120|FG000|Open-label Tapentadol Titration Period|Non-compliance with Trial Requirements|5
6183521|NCT01352741|9836121|FG001|Open-label Tapentadol Titration Period|Non-compliance with Trial Requirements|0
6183522|NCT01352741|9836120|FG000|Open-label Tapentadol Titration Period|Other|4
6183523|NCT01352741|9836121|FG001|Open-label Tapentadol Titration Period|Other|0
6183524|NCT01352741|9836120|FG000|Double-blind Comparative Period|Protocol Violation|2
6183525|NCT01352741|9836121|FG001|Double-blind Comparative Period|Protocol Violation|0
6183526|NCT01352741|9836120|FG000|Double-blind Comparative Period|Lack of Efficacy|0
6183527|NCT01352741|9836121|FG001|Double-blind Comparative Period|Lack of Efficacy|3
6183528|NCT01352741|9836120|FG000|Double-blind Comparative Period|Adverse Event|16
6183529|NCT01352741|9836121|FG001|Double-blind Comparative Period|Adverse Event|17
6183530|NCT01352741|9836120|FG000|Double-blind Comparative Period|Lost to Follow-up|1
6183531|NCT01352741|9836121|FG001|Double-blind Comparative Period|Lost to Follow-up|0
6183532|NCT01352741|9836120|FG000|Double-blind Comparative Period|Death|0
6183533|NCT01352741|9836121|FG001|Double-blind Comparative Period|Death|1
6183534|NCT01352741|9836120|FG000|Double-blind Comparative Period|Withdrawal of consent|8
6183535|NCT01352741|9836121|FG001|Double-blind Comparative Period|Withdrawal of consent|3
6183536|NCT01352741|9836120|FG000|Double-blind Comparative Period|Other|1
6183537|NCT01352741|9836121|FG001|Double-blind Comparative Period|Other|2
6183538|NCT01352741|9836120|FG000|Open-Label Tapentadol Continuation Arm|Adverse Event|4
6183539|NCT01352741|9836121|FG001|Open-Label Tapentadol Continuation Arm|Adverse Event|0
6183540|NCT01352741|9836120|FG000|Open-Label Tapentadol Continuation Arm|Lack of Efficacy|1
6183541|NCT01352741|9836121|FG001|Open-Label Tapentadol Continuation Arm|Lack of Efficacy|0
6183542|NCT01352741|9836120|FG000|Open-Label Tapentadol Continuation Arm|Withdrawal by Subject|2
6183543|NCT01352741|9836121|FG001|Open-Label Tapentadol Continuation Arm|Withdrawal by Subject|0
6183544|NCT01352741|9836120|FG000|Open-Label Tapentadol Continuation Arm|Protocol Violation|1
6183545|NCT01352741|9836121|FG001|Open-Label Tapentadol Continuation Arm|Protocol Violation|0
6183546|NCT01352793|9836143|FG000|Overall Study|Lost to Follow-up|289
6183547|NCT01352793|9836144|FG001|Overall Study|Lost to Follow-up|125
6183548|NCT01352793|9836143|FG000|Overall Study|Withdrawal by Subject|120
6183549|NCT01352793|9836144|FG001|Overall Study|Withdrawal by Subject|55
6183550|NCT01352793|9836143|FG000|Overall Study|Protocol Violation|44
6183551|NCT01352793|9836144|FG001|Overall Study|Protocol Violation|23
6183552|NCT01352793|9836143|FG000|Overall Study|Adverse Event|44
6183553|NCT01352793|9836144|FG001|Overall Study|Adverse Event|10
6183554|NCT01352793|9836143|FG000|Overall Study|Physician Decision|1
6183555|NCT01352793|9836144|FG001|Overall Study|Physician Decision|0
6183556|NCT01352793|9836143|FG000|Overall Study|Pregnancy|26
6228014|NCT01721408|9901015|FG001|Overall Study|No longer willing to participate study|10
6183557|NCT01352793|9836144|FG001|Overall Study|Pregnancy|8
6183558|NCT01352793|9836143|FG000|Overall Study|Other|25
6183559|NCT01352793|9836144|FG001|Overall Study|Other|7
6183560|NCT01352793|9836143|FG000|Overall Study|Medication error|2
6183561|NCT01352793|9836144|FG001|Overall Study|Medication error|2
6228015|NCT01721408|9901014|FG000|Overall Study|Protocol Violation|0
6183562|NCT01352793|9836143|FG000|Overall Study|Death|1
6183563|NCT01352793|9836144|FG001|Overall Study|Death|0
6183564|NCT01352793|9836143|FG000|Overall Study|Randomized but not vaccinated|8
6183565|NCT01352793|9836144|FG001|Overall Study|Randomized but not vaccinated|0
6183566|NCT01352793|9836143|FG000|Overall Study|No longer meets eligibility criteria|25
6183567|NCT01352793|9836144|FG001|Overall Study|No longer meets eligibility criteria|15
6183568|NCT01352845|9836152|FG000|Overall Study|Lost to Follow-up|313
6183569|NCT01352845|9836153|FG001|Overall Study|Lost to Follow-up|92
6183570|NCT01352845|9836152|FG000|Overall Study|No Longer Willing to Participate|205
6183571|NCT01352845|9836153|FG001|Overall Study|No Longer Willing to Participate|58
6183572|NCT01352845|9836152|FG000|Overall Study|Withdrawal by Subject|48
6183573|NCT01352845|9836153|FG001|Overall Study|Withdrawal by Subject|16
6183574|NCT01352845|9836152|FG000|Overall Study|No Longer Meets Eligibility Criteria|24
6183575|NCT01352845|9836153|FG001|Overall Study|No Longer Meets Eligibility Criteria|11
6183576|NCT01352845|9836152|FG000|Overall Study|Pregnancy|27
6183577|NCT01352845|9836153|FG001|Overall Study|Pregnancy|7
6183578|NCT01352845|9836152|FG000|Overall Study|Adverse Event|22
6183579|NCT01352845|9836153|FG001|Overall Study|Adverse Event|6
6183580|NCT01352845|9836152|FG000|Overall Study|Other|17
6183581|NCT01352845|9836153|FG001|Overall Study|Other|7
6183582|NCT01352845|9836152|FG000|Overall Study|Protocol Violation|12
6183583|NCT01352845|9836153|FG001|Overall Study|Protocol Violation|6
6183584|NCT01352845|9836152|FG000|Overall Study|Death|3
6183585|NCT01352845|9836153|FG001|Overall Study|Death|0
6183586|NCT01353222|9836192|FG000|Overall Study|Death|30
6183587|NCT01353222|9836193|FG001|Overall Study|Death|30
6183588|NCT01353222|9836192|FG000|Overall Study|Withdrawal by Subject|8
6183589|NCT01353222|9836193|FG001|Overall Study|Withdrawal by Subject|5
6183590|NCT01353222|9836192|FG000|Overall Study|Study Terminated|31
6183591|NCT01353222|9836193|FG001|Overall Study|Study Terminated|37
6183592|NCT01353222|9836192|FG000|Overall Study|Site closed research department|1
6183593|NCT01353222|9836193|FG001|Overall Study|Site closed research department|0
6183594|NCT01353274|9836199|FG000|Overall Study|No case report form (CRF) collected|28
6183595|NCT01353508|9836216|FG000|Period 1 - First Intervention (7 Days)|Adverse Event|0
6183596|NCT01353508|9836217|FG001|Period 1 - First Intervention (7 Days)|Adverse Event|0
6183597|NCT01353508|9836218|FG002|Period 1 - First Intervention (7 Days)|Adverse Event|0
6183598|NCT01353508|9836219|FG003|Period 1 - First Intervention (7 Days)|Adverse Event|1
6183599|NCT01353508|9836216|FG000|Period 2 - Second Intervention (7 Days)|Withdrawal by Subject|1
6183600|NCT01353508|9836217|FG001|Period 2 - Second Intervention (7 Days)|Withdrawal by Subject|0
6183601|NCT01353508|9836218|FG002|Period 2 - Second Intervention (7 Days)|Withdrawal by Subject|0
6183602|NCT01353508|9836219|FG003|Period 2 - Second Intervention (7 Days)|Withdrawal by Subject|0
6183603|NCT01353586|9836231|FG000|Overall Study|Procedure terminated prior to ablation|3
6183604|NCT01353586|9836232|FG001|Overall Study|Procedure terminated prior to ablation|0
6183605|NCT01353586|9836231|FG000|Overall Study|Never had insertion of study catheter|4
6183606|NCT01353586|9836232|FG001|Overall Study|Never had insertion of study catheter|1
6183607|NCT01353586|9836231|FG000|Overall Study|Neurological exam not done|0
6183608|NCT01353586|9836232|FG001|Overall Study|Neurological exam not done|1
6183609|NCT01353664|9836241|FG000|Overall Study|Other|3
6183610|NCT01353664|9836241|FG000|Overall Study|Disease Progression|16
6183611|NCT01353703|9836247|FG000|Overall Study|Migrated/moved from study area|1
6183612|NCT01353703|9836248|FG001|Overall Study|Migrated/moved from study area|0
6183613|NCT01353859|9836256|FG000|Overall Study|Adverse Event|3
6183614|NCT01353859|9836256|FG000|Overall Study|Lack of Efficacy|1
6183615|NCT01353898|9836266|FG000|Overall Study|Study site terminated|0
6183616|NCT01353898|9836267|FG001|Overall Study|Study site terminated|0
6183617|NCT01353898|9836268|FG002|Overall Study|Study site terminated|0
6183618|NCT01353898|9836269|FG003|Overall Study|Study site terminated|0
6183619|NCT01353898|9836270|FG004|Overall Study|Study site terminated|0
6183620|NCT01353898|9836271|FG005|Overall Study|Study site terminated|1
6183621|NCT01353911|9836293|FG000|Overall Study|Lost to Follow-up|2
6183622|NCT01353911|9836294|FG001|Overall Study|Lost to Follow-up|6
6183623|NCT01353911|9836295|FG002|Overall Study|Lost to Follow-up|4
6183624|NCT01353911|9836296|FG003|Overall Study|Lost to Follow-up|0
6183625|NCT01353911|9836297|FG004|Overall Study|Lost to Follow-up|4
6183626|NCT01353911|9836298|FG005|Overall Study|Lost to Follow-up|4
6183627|NCT01353911|9836299|FG006|Overall Study|Lost to Follow-up|3
6183628|NCT01353911|9836300|FG007|Overall Study|Lost to Follow-up|6
6183629|NCT01353911|9836293|FG000|Overall Study|Withdrawal by Subject|2
6183630|NCT01353911|9836294|FG001|Overall Study|Withdrawal by Subject|3
6183631|NCT01353911|9836295|FG002|Overall Study|Withdrawal by Subject|4
6183632|NCT01353911|9836296|FG003|Overall Study|Withdrawal by Subject|2
6183633|NCT01353911|9836297|FG004|Overall Study|Withdrawal by Subject|2
6183634|NCT01353911|9836298|FG005|Overall Study|Withdrawal by Subject|3
6183635|NCT01353911|9836299|FG006|Overall Study|Withdrawal by Subject|3
6183636|NCT01353911|9836300|FG007|Overall Study|Withdrawal by Subject|9
6183637|NCT01353911|9836293|FG000|Overall Study|Status Not Recorded|4
6183638|NCT01353911|9836294|FG001|Overall Study|Status Not Recorded|0
6183639|NCT01353911|9836295|FG002|Overall Study|Status Not Recorded|1
6183640|NCT01353911|9836296|FG003|Overall Study|Status Not Recorded|0
6183641|NCT01353911|9836297|FG004|Overall Study|Status Not Recorded|0
6183642|NCT01353911|9836298|FG005|Overall Study|Status Not Recorded|0
6183643|NCT01353911|9836299|FG006|Overall Study|Status Not Recorded|0
6183644|NCT01353911|9836300|FG007|Overall Study|Status Not Recorded|0
6183645|NCT01353963|9836318|FG000|Overall Study|Adverse Event|2
6183646|NCT01354028|9836340|FG000|Overall Study|Physician Decision|0
6183647|NCT01354028|9836341|FG001|Overall Study|Physician Decision|2
6183648|NCT01354028|9836340|FG000|Overall Study|Discharged before study start|2
6183649|NCT01354028|9836341|FG001|Overall Study|Discharged before study start|2
6183650|NCT01354028|9836340|FG000|Overall Study|No quiet alert state|0
6183651|NCT01354028|9836341|FG001|Overall Study|No quiet alert state|1
6183652|NCT01354106|9836353|FG000|Overall Study|Withdrawal by Subject|2
6183653|NCT01354132|9836361|FG000|Randomization|Physician Decision|1
6183654|NCT01354132|9836362|FG001|Randomization|Physician Decision|0
6183655|NCT01354132|9836361|FG000|Randomization|Withdrawal by Subject|0
6183656|NCT01354132|9836362|FG001|Randomization|Withdrawal by Subject|1
6183657|NCT01354132|9836361|FG000|Double Blind (Visits 1-7)|Adverse Event|1
6183658|NCT01354132|9836362|FG001|Double Blind (Visits 1-7)|Adverse Event|0
6183659|NCT01354132|9836361|FG000|Double Blind (Visits 1-7)|Withdrawal by Subject|8
6183660|NCT01354132|9836362|FG001|Double Blind (Visits 1-7)|Withdrawal by Subject|11
6183661|NCT01354132|9836361|FG000|1 Month Post Study Medication|Withdrawal by Subject|1
6183662|NCT01354132|9836362|FG001|1 Month Post Study Medication|Withdrawal by Subject|3
6183663|NCT01354223|9836389|FG000|Overall Study|Withdrawal by Subject|3
6183664|NCT01354223|9836390|FG001|Overall Study|Withdrawal by Subject|1
6183665|NCT01354314|9836400|FG000|Overall Study|Lost to Follow-up|1
6183666|NCT01354314|9836401|FG001|Overall Study|Lost to Follow-up|0
6183667|NCT01354314|9836402|FG002|Overall Study|Lost to Follow-up|1
6183668|NCT01354314|9836403|FG003|Overall Study|Lost to Follow-up|1
6183669|NCT01354314|9836400|FG000|Overall Study|Withdrawal by Subject|0
6183670|NCT01354314|9836401|FG001|Overall Study|Withdrawal by Subject|0
6183671|NCT01354314|9836402|FG002|Overall Study|Withdrawal by Subject|1
6183672|NCT01354314|9836403|FG003|Overall Study|Withdrawal by Subject|0
6183673|NCT01354314|9836400|FG000|Overall Study|Adverse Event|0
6183674|NCT01354314|9836401|FG001|Overall Study|Adverse Event|0
6183675|NCT01354314|9836402|FG002|Overall Study|Adverse Event|0
6183676|NCT01354314|9836403|FG003|Overall Study|Adverse Event|1
6183677|NCT01354314|9836400|FG000|Overall Study|Protocol Violation|1
6183678|NCT01354314|9836401|FG001|Overall Study|Protocol Violation|1
6183679|NCT01354314|9836402|FG002|Overall Study|Protocol Violation|0
6183680|NCT01354314|9836403|FG003|Overall Study|Protocol Violation|0
6183681|NCT01354314|9836400|FG000|Overall Study|Less than 90% Adherence|4
6183682|NCT01354314|9836401|FG001|Overall Study|Less than 90% Adherence|2
6183683|NCT01354314|9836402|FG002|Overall Study|Less than 90% Adherence|6
6183684|NCT01354314|9836403|FG003|Overall Study|Less than 90% Adherence|4
6183685|NCT01354353|9836421|FG000|Overall Study|Adverse Event|1
6183686|NCT01354353|9836422|FG001|Overall Study|Adverse Event|0
6183687|NCT01354353|9836423|FG002|Overall Study|Adverse Event|0
6183688|NCT01354353|9836424|FG003|Overall Study|Adverse Event|4
6183689|NCT01354353|9836425|FG004|Overall Study|Adverse Event|0
6183690|NCT01354353|9836426|FG005|Overall Study|Adverse Event|5
6183691|NCT01354353|9836421|FG000|Overall Study|Entry Criteria Not Met|0
6183692|NCT01354353|9836422|FG001|Overall Study|Entry Criteria Not Met|0
6183693|NCT01354353|9836423|FG002|Overall Study|Entry Criteria Not Met|0
6183694|NCT01354353|9836424|FG003|Overall Study|Entry Criteria Not Met|1
6183695|NCT01354353|9836425|FG004|Overall Study|Entry Criteria Not Met|1
6183696|NCT01354353|9836426|FG005|Overall Study|Entry Criteria Not Met|0
6183697|NCT01354353|9836421|FG000|Overall Study|Physician Decision|0
6183698|NCT01354353|9836422|FG001|Overall Study|Physician Decision|1
6183699|NCT01354353|9836423|FG002|Overall Study|Physician Decision|1
6183700|NCT01354353|9836424|FG003|Overall Study|Physician Decision|0
6183701|NCT01354353|9836425|FG004|Overall Study|Physician Decision|0
6183702|NCT01354353|9836426|FG005|Overall Study|Physician Decision|0
6183703|NCT01354353|9836421|FG000|Overall Study|Withdrawal by Subject|2
6183704|NCT01354353|9836422|FG001|Overall Study|Withdrawal by Subject|0
6183705|NCT01354353|9836423|FG002|Overall Study|Withdrawal by Subject|1
6183706|NCT01354353|9836424|FG003|Overall Study|Withdrawal by Subject|0
6183707|NCT01354353|9836425|FG004|Overall Study|Withdrawal by Subject|0
6183708|NCT01354353|9836426|FG005|Overall Study|Withdrawal by Subject|1
6183709|NCT01354496|9836460|FG000|Period 1|Adverse Event|0
6183710|NCT01354496|9836461|FG001|Period 1|Adverse Event|0
6183711|NCT01354496|9836462|FG002|Period 1|Adverse Event|1
6183712|NCT01354496|9836463|FG003|Period 1|Adverse Event|0
6183713|NCT01354496|9836464|FG004|Period 1|Adverse Event|0
6183714|NCT01354496|9836465|FG005|Period 1|Adverse Event|0
6183715|NCT01354496|9836460|FG000|Period 1|Physician Decision|0
6183716|NCT01354496|9836461|FG001|Period 1|Physician Decision|0
6183717|NCT01354496|9836462|FG002|Period 1|Physician Decision|1
6183718|NCT01354496|9836463|FG003|Period 1|Physician Decision|0
6183719|NCT01354496|9836464|FG004|Period 1|Physician Decision|0
6183720|NCT01354496|9836465|FG005|Period 1|Physician Decision|0
6183721|NCT01354496|9836460|FG000|Period 2|Adverse Event|0
6183722|NCT01354496|9836461|FG001|Period 2|Adverse Event|0
6183723|NCT01354496|9836462|FG002|Period 2|Adverse Event|0
6183724|NCT01354496|9836463|FG003|Period 2|Adverse Event|1
6183725|NCT01354496|9836464|FG004|Period 2|Adverse Event|0
6183726|NCT01354496|9836465|FG005|Period 2|Adverse Event|0
6183727|NCT01354496|9836460|FG000|Washout (at Least 14 Days)|Scheduling Conflict|0
6183728|NCT01354496|9836461|FG001|Washout (at Least 14 Days)|Scheduling Conflict|1
6183729|NCT01354496|9836462|FG002|Washout (at Least 14 Days)|Scheduling Conflict|0
6183730|NCT01354496|9836463|FG003|Washout (at Least 14 Days)|Scheduling Conflict|1
6183731|NCT01354496|9836464|FG004|Washout (at Least 14 Days)|Scheduling Conflict|0
6183732|NCT01354496|9836465|FG005|Washout (at Least 14 Days)|Scheduling Conflict|0
6192812|NCT01434693|9850470|FG003|Overall Study|Adverse Event|0
6192813|NCT01434693|9850467|FG000|Overall Study|Withdrawal by Subject|1
6192814|NCT01434693|9850468|FG001|Overall Study|Withdrawal by Subject|0
6192815|NCT01434693|9850469|FG002|Overall Study|Withdrawal by Subject|1
6192816|NCT01434693|9850470|FG003|Overall Study|Withdrawal by Subject|1
6192817|NCT01434693|9850467|FG000|Overall Study|Lost to Follow-up|1
6192818|NCT01434693|9850468|FG001|Overall Study|Lost to Follow-up|0
6192819|NCT01434693|9850469|FG002|Overall Study|Lost to Follow-up|0
6192820|NCT01434693|9850470|FG003|Overall Study|Lost to Follow-up|0
6192821|NCT01434810|9850482|FG000|Overall Study|Did not receive treatment|11
6192822|NCT01434810|9850483|FG001|Overall Study|Did not receive treatment|3
6192823|NCT01434810|9850482|FG000|Overall Study|Missing data/received <5hr phototherapy|12
6192824|NCT01434810|9850483|FG001|Overall Study|Missing data/received <5hr phototherapy|7
6192825|NCT01434823|9850491|FG000|Overall Study|Incomplete data in medical record|4
6192826|NCT01434823|9850492|FG001|Overall Study|Incomplete data in medical record|7
6192827|NCT01435018|9850502|FG000|Overall Study|Death|37
6192828|NCT01435018|9850503|FG001|Overall Study|Death|18
6192829|NCT01435018|9850504|FG002|Overall Study|Death|25
6192830|NCT01435018|9850502|FG000|Overall Study|Site is closing|4
6192831|NCT01435018|9850503|FG001|Overall Study|Site is closing|9
6192832|NCT01435018|9850504|FG002|Overall Study|Site is closing|7
6192833|NCT01435018|9850502|FG000|Overall Study|Withdrew consent|0
6192834|NCT01435018|9850503|FG001|Overall Study|Withdrew consent|3
6192835|NCT01435018|9850504|FG002|Overall Study|Withdrew consent|1
6192836|NCT01435018|9850502|FG000|Overall Study|Not willing to adhere to requirements|0
6192837|NCT01435018|9850503|FG001|Overall Study|Not willing to adhere to requirements|2
6192838|NCT01435018|9850504|FG002|Overall Study|Not willing to adhere to requirements|3
6192839|NCT01435018|9850502|FG000|Overall Study|Not able to get to clinic|2
6192840|NCT01435018|9850503|FG001|Overall Study|Not able to get to clinic|0
6192841|NCT01435018|9850504|FG002|Overall Study|Not able to get to clinic|2
6192842|NCT01435018|9850502|FG000|Overall Study|Severe debilitation, unable to continue|0
6192843|NCT01435018|9850503|FG001|Overall Study|Severe debilitation, unable to continue|0
6192844|NCT01435018|9850504|FG002|Overall Study|Severe debilitation, unable to continue|1
6192845|NCT01435018|9850502|FG000|Overall Study|Unable to contact participant/parent|1
6192846|NCT01435018|9850503|FG001|Overall Study|Unable to contact participant/parent|1
6192847|NCT01435018|9850504|FG002|Overall Study|Unable to contact participant/parent|1
6192848|NCT01435018|9850502|FG000|Overall Study|Enrollment Violation|0
6192849|NCT01435018|9850503|FG001|Overall Study|Enrollment Violation|1
6192850|NCT01435018|9850504|FG002|Overall Study|Enrollment Violation|0
6192851|NCT01435018|9850502|FG000|Overall Study|Never started chemotherapy|3
6192852|NCT01435018|9850503|FG001|Overall Study|Never started chemotherapy|0
6192853|NCT01435018|9850504|FG002|Overall Study|Never started chemotherapy|1
6192854|NCT01435031|9850514|FG000|ITT at 1 Month|Withdrawal by Subject|1
6192855|NCT01435031|9850514|FG000|ITT at 1 Month|Death|1
6192856|NCT01435031|9850514|FG000|ITT at 1 Month|Lost to Follow-up|4
6192857|NCT01435031|9850514|FG000|ITT at 6 Months|Death|2
6192858|NCT01435031|9850514|FG000|ITT at 6 Months|Lost to Follow-up|3
6192859|NCT01435031|9850514|FG000|ITT at 1 Year|Death|1
6192860|NCT01435031|9850514|FG000|ITT at 1 Year|Withdrawal by Subject|2
6192861|NCT01435031|9850514|FG000|ITT at 1 Year|Lost to Follow-up|6
6192862|NCT01435031|9850514|FG000|ITT at 2 Years|Death|7
6192863|NCT01435031|9850514|FG000|ITT at 2 Years|Withdrawal by Subject|2
6192864|NCT01435031|9850514|FG000|ITT at 2 Years|Lost to Follow-up|4
6192865|NCT01435031|9850514|FG000|ITT at 3 Years|Death|5
6192866|NCT01435031|9850514|FG000|ITT at 3 Years|Withdrawal by Subject|2
6192867|NCT01435031|9850514|FG000|ITT at 3 Years|Lost to Follow-up|4
6192868|NCT01435031|9850514|FG000|ITT at 4 Years|Death|4
6192869|NCT01435031|9850514|FG000|ITT at 4 Years|Withdrawal by Subject|2
6192870|NCT01435031|9850514|FG000|ITT at 4 Years|Lost to Follow-up|1
6192871|NCT01435122|9850518|FG000|Overall Study|Early withdrawal due to toxicity|8
6192872|NCT01435265|9850528|FG000|Overall Study|Lost to Follow-up|0
6192873|NCT01435265|9850529|FG001|Overall Study|Lost to Follow-up|1
6192874|NCT01435356|9850546|FG000|Overall Study|Adverse Event|2
6192875|NCT01435356|9850547|FG001|Overall Study|Adverse Event|0
6192876|NCT01435356|9850546|FG000|Overall Study|Disease progression/recurrence|17
6192877|NCT01435356|9850547|FG001|Overall Study|Disease progression/recurrence|10
6192878|NCT01435356|9850546|FG000|Overall Study|Protocol Violation|0
6192879|NCT01435356|9850547|FG001|Overall Study|Protocol Violation|1
6192880|NCT01435356|9850546|FG000|Overall Study|Study Discontinuation, amendment 4|5
6192881|NCT01435356|9850547|FG001|Overall Study|Study Discontinuation, amendment 4|11
6192882|NCT01435356|9850546|FG000|Overall Study|Withdrawal by Subject|1
6192883|NCT01435356|9850547|FG001|Overall Study|Withdrawal by Subject|1
6192884|NCT01435356|9850546|FG000|Overall Study|Facial palsy|1
6192885|NCT01435356|9850547|FG001|Overall Study|Facial palsy|0
6192886|NCT01435356|9850546|FG000|Overall Study|IC withdrawal due to study cancellation|1
6192887|NCT01435356|9850547|FG001|Overall Study|IC withdrawal due to study cancellation|0
6183733|NCT01354899|9836509|FG000|Overall Study|discharge from the hospital|2
6183734|NCT01354899|9836509|FG000|Overall Study|Protocol Violation|1
6183735|NCT01354938|9836513|FG000|Overall Study|Lost to Follow-up|1
6183736|NCT01354964|9836519|FG000|Overall Study|Lost to Follow-up|2
6183737|NCT01354964|9836520|FG001|Overall Study|Lost to Follow-up|0
6183738|NCT01354964|9836519|FG000|Overall Study|IV access issues|1
6183739|NCT01354964|9836520|FG001|Overall Study|IV access issues|1
6183740|NCT01354964|9836519|FG000|Overall Study|Physician Decision|1
6183741|NCT01354964|9836520|FG001|Overall Study|Physician Decision|0
6183742|NCT01355068|9836532|FG000|First Intervention Period|Adverse Event|0
6183743|NCT01355068|9836533|FG001|First Intervention Period|Adverse Event|1
6183744|NCT01355068|9836532|FG000|First Intervention Period|Withdrawal by Subject|0
6183745|NCT01355068|9836533|FG001|First Intervention Period|Withdrawal by Subject|1
6183746|NCT01355081|9836542|FG000|Overall Study|Pretreatment Event or Adverse Event|3
6228016|NCT01721408|9901015|FG001|Overall Study|Protocol Violation|2
6228017|NCT01721408|9901014|FG000|Overall Study|Other|3
6228018|NCT01721408|9901015|FG001|Overall Study|Other|3
6228019|NCT01721408|9901014|FG000|Overall Study|Lost to Follow-up|1
6228020|NCT01721408|9901015|FG001|Overall Study|Lost to Follow-up|2
6228021|NCT01721408|9901014|FG000|Overall Study|Does not meet entrance criteria|1
6228022|NCT01721408|9901015|FG001|Overall Study|Does not meet entrance criteria|0
6228023|NCT01721486|9901054|FG000|Overall Study|Protocol Violation|1
6228024|NCT01721486|9901055|FG001|Overall Study|Protocol Violation|0
6228025|NCT01721486|9901054|FG000|Overall Study|Physician Decision|0
6228026|NCT01721486|9901055|FG001|Overall Study|Physician Decision|1
6228027|NCT01721772|9901075|FG000|Overall Study|Disease progression|96
6228028|NCT01721772|9901076|FG001|Overall Study|Disease progression|175
6228029|NCT01721772|9901075|FG000|Overall Study|Study drug toxicity|5
6228030|NCT01721772|9901076|FG001|Overall Study|Study drug toxicity|7
6228031|NCT01721772|9901075|FG000|Overall Study|Unrelated adverse event|2
6228032|NCT01721772|9901076|FG001|Overall Study|Unrelated adverse event|3
6228033|NCT01721772|9901075|FG000|Overall Study|Withdrawal by Subject|7
6228034|NCT01721772|9901076|FG001|Overall Study|Withdrawal by Subject|5
6228035|NCT01721772|9901075|FG000|Overall Study|Maximum clinical benefit|1
6228036|NCT01721772|9901076|FG001|Overall Study|Maximum clinical benefit|1
6228037|NCT01721772|9901075|FG000|Overall Study|Other|0
6228038|NCT01721772|9901076|FG001|Overall Study|Other|1
6228039|NCT01721876|9901088|FG000|Overall Study|Not treated|1
6228040|NCT01721876|9901089|FG001|Overall Study|Not treated|4
6228041|NCT01721876|9901088|FG000|Overall Study|Disease progression / relapse|123
6228042|NCT01721876|9901089|FG001|Overall Study|Disease progression / relapse|156
6228043|NCT01721876|9901088|FG000|Overall Study|Death|6
6228044|NCT01721876|9901089|FG001|Overall Study|Death|13
6228045|NCT01721876|9901088|FG000|Overall Study|Adverse Event|41
6228046|NCT01721876|9901089|FG001|Overall Study|Adverse Event|165
6228047|NCT01721876|9901088|FG000|Overall Study|Protocol Violation|2
6228048|NCT01721876|9901089|FG001|Overall Study|Protocol Violation|1
6228049|NCT01721876|9901088|FG000|Overall Study|Withdrawal by Subject|15
6228050|NCT01721876|9901089|FG001|Overall Study|Withdrawal by Subject|38
6228051|NCT01721876|9901088|FG000|Overall Study|Reason not listed|34
6228052|NCT01721876|9901089|FG001|Overall Study|Reason not listed|63
6228053|NCT01721876|9901088|FG000|Overall Study|Sponsor terminated trial|0
6228054|NCT01721876|9901089|FG001|Overall Study|Sponsor terminated trial|4
6228055|NCT01721954|9901097|FG000|Overall Study|Death|58
6228056|NCT01721954|9901098|FG001|Overall Study|Death|64
6228057|NCT01721954|9901097|FG000|Overall Study|Withdrawal by Subject|8
6228058|NCT01721954|9901098|FG001|Overall Study|Withdrawal by Subject|4
6228059|NCT01721954|9901097|FG000|Overall Study|Adverse Event|2
6228060|NCT01721954|9901098|FG001|Overall Study|Adverse Event|0
6228061|NCT01721954|9901097|FG000|Overall Study|Lost to Follow-up|2
6228062|NCT01721954|9901098|FG001|Overall Study|Lost to Follow-up|1
6228063|NCT01722045|9901108|FG000|Overall Study|Adverse Event|8
6228064|NCT01722045|9901108|FG000|Overall Study|Death|3
6228065|NCT01722045|9901108|FG000|Overall Study|Withdrawal by Subject|8
6228066|NCT01722045|9901108|FG000|Overall Study|Lost to Follow-up|4
6228067|NCT01722045|9901108|FG000|Overall Study|Protocol Deviation|1
6183747|NCT01355081|9836543|FG001|Overall Study|Pretreatment Event or Adverse Event|4
6183748|NCT01355081|9836544|FG002|Overall Study|Pretreatment Event or Adverse Event|6
6183749|NCT01355081|9836542|FG000|Overall Study|Major Protocol Deviation|0
6183750|NCT01355081|9836543|FG001|Overall Study|Major Protocol Deviation|1
6183751|NCT01355081|9836544|FG002|Overall Study|Major Protocol Deviation|0
6183752|NCT01355081|9836542|FG000|Overall Study|Lost to Follow-up|0
6183753|NCT01355081|9836543|FG001|Overall Study|Lost to Follow-up|0
6183754|NCT01355081|9836544|FG002|Overall Study|Lost to Follow-up|1
6228068|NCT01722045|9901108|FG000|Overall Study|Physician Decision|3
6228069|NCT01722045|9901108|FG000|Overall Study|Relocation (did not wish to transfer)|1
6228070|NCT01722071|9901112|FG000|Overall Study|Protocol Violation|1
6228071|NCT01722071|9901113|FG001|Overall Study|Protocol Violation|0
6228072|NCT01722097|9901121|FG000|Overall Study|Patient sheets not returned|6
6228073|NCT01722097|9901122|FG001|Overall Study|Patient sheets not returned|5
6228074|NCT01722162|9901130|FG000|Overall Study|Withdrawal by Subject|1
6228075|NCT01722162|9901131|FG001|Overall Study|Withdrawal by Subject|1
6228076|NCT01722162|9901130|FG000|Overall Study|Found ineligible|1
6228077|NCT01722162|9901131|FG001|Overall Study|Found ineligible|0
6228078|NCT01722162|9901130|FG000|Overall Study|Unrelated to study adverse event|2
6183755|NCT01355081|9836542|FG000|Overall Study|Withdrawal of Consent|2
6183756|NCT01355081|9836543|FG001|Overall Study|Withdrawal of Consent|3
6183757|NCT01355081|9836544|FG002|Overall Study|Withdrawal of Consent|3
6183758|NCT01355081|9836542|FG000|Overall Study|Lack of Efficacy|2
6183759|NCT01355081|9836543|FG001|Overall Study|Lack of Efficacy|1
6183760|NCT01355081|9836544|FG002|Overall Study|Lack of Efficacy|1
6183761|NCT01355081|9836542|FG000|Overall Study|Non Compliance with Study Medication|0
6183762|NCT01355081|9836543|FG001|Overall Study|Non Compliance with Study Medication|1
6183763|NCT01355081|9836544|FG002|Overall Study|Non Compliance with Study Medication|0
6183764|NCT01355159|9836554|FG000|Overall Study|Withdrew consent|39
6183765|NCT01355159|9836555|FG001|Overall Study|Withdrew consent|47
6183766|NCT01355159|9836554|FG000|Overall Study|No primary outcome data|17
6183767|NCT01355159|9836555|FG001|Overall Study|No primary outcome data|11
6183768|NCT01355159|9836554|FG000|Overall Study|Spontaneous abortion (<20 weeks)|22
6183769|NCT01355159|9836555|FG001|Overall Study|Spontaneous abortion (<20 weeks)|15
6183770|NCT01355159|9836554|FG000|Overall Study|Early intrauterine fetal death|6
6183771|NCT01355159|9836555|FG001|Overall Study|Early intrauterine fetal death|6
6183772|NCT01355289|9836590|FG000|Core Study|Adverse Event, Non-Fatal|1
6183773|NCT01355289|9836591|FG001|Core Study|Adverse Event, Non-Fatal|0
6183774|NCT01355289|9836592|FG002|Core Study|Adverse Event, Non-Fatal|0
6183775|NCT01355289|9836593|FG003|Core Study|Adverse Event, Non-Fatal|0
6183776|NCT01355289|9836594|FG004|Core Study|Adverse Event, Non-Fatal|0
6183777|NCT01355289|9836590|FG000|Core Study|Inadequate Therapeutic Effect|0
6183778|NCT01355289|9836591|FG001|Core Study|Inadequate Therapeutic Effect|0
6183779|NCT01355289|9836592|FG002|Core Study|Inadequate Therapeutic Effect|0
6183780|NCT01355289|9836593|FG003|Core Study|Inadequate Therapeutic Effect|1
6183781|NCT01355289|9836594|FG004|Core Study|Inadequate Therapeutic Effect|0
6183782|NCT01355289|9836590|FG000|Core Study|Other|0
6183783|NCT01355289|9836591|FG001|Core Study|Other|0
6183784|NCT01355289|9836592|FG002|Core Study|Other|0
6183785|NCT01355289|9836593|FG003|Core Study|Other|1
6183786|NCT01355289|9836594|FG004|Core Study|Other|0
6183787|NCT01355289|9836590|FG000|Open Label Extension|Adverse Event, Non-Fatal|0
6183788|NCT01355289|9836591|FG001|Open Label Extension|Adverse Event, Non-Fatal|0
6183789|NCT01355289|9836592|FG002|Open Label Extension|Adverse Event, Non-Fatal|0
6183790|NCT01355289|9836593|FG003|Open Label Extension|Adverse Event, Non-Fatal|0
6183791|NCT01355289|9836594|FG004|Open Label Extension|Adverse Event, Non-Fatal|1
6183792|NCT01355289|9836590|FG000|Open Label Extension|Lost to Follow-up|0
6183793|NCT01355289|9836591|FG001|Open Label Extension|Lost to Follow-up|0
6183794|NCT01355289|9836592|FG002|Open Label Extension|Lost to Follow-up|0
6183795|NCT01355289|9836593|FG003|Open Label Extension|Lost to Follow-up|0
6183796|NCT01355289|9836594|FG004|Open Label Extension|Lost to Follow-up|1
6183797|NCT01355289|9836590|FG000|Open Label Extension|Inadequate Therapeutic Effect|0
6183798|NCT01355289|9836591|FG001|Open Label Extension|Inadequate Therapeutic Effect|0
6183799|NCT01355289|9836592|FG002|Open Label Extension|Inadequate Therapeutic Effect|0
6183800|NCT01355289|9836593|FG003|Open Label Extension|Inadequate Therapeutic Effect|0
6183801|NCT01355289|9836594|FG004|Open Label Extension|Inadequate Therapeutic Effect|29
6183802|NCT01355289|9836590|FG000|Open Label Extension|Other|0
6183803|NCT01355289|9836591|FG001|Open Label Extension|Other|0
6183804|NCT01355289|9836592|FG002|Open Label Extension|Other|0
6183805|NCT01355289|9836593|FG003|Open Label Extension|Other|0
6183806|NCT01355289|9836594|FG004|Open Label Extension|Other|3
6183807|NCT01355302|9836607|FG000|Phase 1b|Death|4
6183808|NCT01355302|9836608|FG001|Phase 1b|Death|0
6183809|NCT01355302|9836609|FG002|Phase 1b|Death|0
6183810|NCT01355302|9836607|FG000|Phase 1b|Study terminated by sponsor|2
6183811|NCT01355302|9836608|FG001|Phase 1b|Study terminated by sponsor|0
6183812|NCT01355302|9836609|FG002|Phase 1b|Study terminated by sponsor|0
6183813|NCT01355497|9836650|FG000|Overall Study|Death|19
6183814|NCT01355497|9836651|FG001|Overall Study|Death|18
6183815|NCT01355497|9836650|FG000|Overall Study|Lost to Follow-up|3
6183816|NCT01355497|9836651|FG001|Overall Study|Lost to Follow-up|0
6183817|NCT01355497|9836650|FG000|Overall Study|Protocol Violation|0
6183818|NCT01355497|9836651|FG001|Overall Study|Protocol Violation|1
6183819|NCT01355497|9836650|FG000|Overall Study|other-not provided|9
6183820|NCT01355497|9836651|FG001|Overall Study|other-not provided|4
6183821|NCT01355497|9836650|FG000|Overall Study|Withdrawal by Subject|12
6183822|NCT01355497|9836651|FG001|Overall Study|Withdrawal by Subject|20
6183823|NCT01355497|9836650|FG000|Overall Study|noncompliance|1
6183824|NCT01355497|9836651|FG001|Overall Study|noncompliance|2
6183825|NCT01355497|9836650|FG000|Overall Study|progressive disease|11
6183826|NCT01355497|9836651|FG001|Overall Study|progressive disease|8
6183827|NCT01355497|9836650|FG000|Overall Study|Adverse Event|11
6183828|NCT01355497|9836651|FG001|Overall Study|Adverse Event|10
6183829|NCT01355523|9836659|FG000|Overall Study|Withdrawal by Subject|1
6183830|NCT01355523|9836660|FG001|Overall Study|Withdrawal by Subject|4
6183831|NCT01355523|9836659|FG000|Overall Study|Lost to Follow-up|0
6183832|NCT01355523|9836660|FG001|Overall Study|Lost to Follow-up|2
6183833|NCT01355523|9836659|FG000|Overall Study|Protocol Violation|0
6183834|NCT01355523|9836660|FG001|Overall Study|Protocol Violation|2
6183835|NCT01355523|9836659|FG000|Overall Study|Adverse Event|0
6183836|NCT01355523|9836660|FG001|Overall Study|Adverse Event|2
6183837|NCT01355575|9836666|FG000|Overall Study|Withdrawal by Subject|2
6183838|NCT01355627|9836693|FG000|Overall Study|Request By the Patient to Discontinue|5
6183839|NCT01355627|9836694|FG001|Overall Study|Request By the Patient to Discontinue|7
6183840|NCT01355627|9836693|FG000|Overall Study|Lost to Follow-up|8
6183841|NCT01355627|9836694|FG001|Overall Study|Lost to Follow-up|7
6183842|NCT01355627|9836693|FG000|Overall Study|Fatal Adverse Event|19
6183843|NCT01355627|9836694|FG001|Overall Study|Fatal Adverse Event|23
6183844|NCT01355627|9836693|FG000|Overall Study|Other|1
6183845|NCT01355627|9836694|FG001|Overall Study|Other|1
6183846|NCT01356407|9836738|FG000|Overall Study|Lost to Follow-up|2
6183847|NCT01356407|9836739|FG001|Overall Study|Lost to Follow-up|0
6183848|NCT01356407|9836738|FG000|Overall Study|Patient Withdrew Consent|2
6183849|NCT01356407|9836739|FG001|Overall Study|Patient Withdrew Consent|1
6183850|NCT01356407|9836738|FG000|Overall Study|Could not afford IMP administration|0
6183851|NCT01356407|9836739|FG001|Overall Study|Could not afford IMP administration|1
6183852|NCT01356407|9836738|FG000|Overall Study|Not complete Endoscopy|2
6183853|NCT01356407|9836739|FG001|Overall Study|Not complete Endoscopy|2
6183854|NCT01356589|9836776|FG000|Overall Study|Enrolled, but not treated|3
6183855|NCT01356589|9836776|FG000|Overall Study|Dose data not recorded|2
6183856|NCT01356602|9836783|FG000|Overall Study|Protocol Deviation|0
6183857|NCT01356602|9836784|FG001|Overall Study|Protocol Deviation|1
6183858|NCT01356602|9836785|FG002|Overall Study|Protocol Deviation|1
6183859|NCT01356602|9836783|FG000|Overall Study|Administrative Problems|1
6183860|NCT01356602|9836784|FG001|Overall Study|Administrative Problems|4
6183861|NCT01356602|9836785|FG002|Overall Study|Administrative Problems|5
6183862|NCT01356602|9836783|FG000|Overall Study|Lost to Follow-up|4
6183863|NCT01356602|9836784|FG001|Overall Study|Lost to Follow-up|5
6183864|NCT01356602|9836785|FG002|Overall Study|Lost to Follow-up|6
6183865|NCT01356602|9836783|FG000|Overall Study|Withdrawal by Subject|4
6183866|NCT01356602|9836784|FG001|Overall Study|Withdrawal by Subject|3
6183867|NCT01356602|9836785|FG002|Overall Study|Withdrawal by Subject|7
6183868|NCT01356602|9836783|FG000|Overall Study|Lack of Efficacy|0
6183869|NCT01356602|9836784|FG001|Overall Study|Lack of Efficacy|1
6183870|NCT01356602|9836785|FG002|Overall Study|Lack of Efficacy|4
6183871|NCT01356602|9836783|FG000|Overall Study|Adverse Event|0
6183872|NCT01356602|9836784|FG001|Overall Study|Adverse Event|1
6183873|NCT01356602|9836785|FG002|Overall Study|Adverse Event|1
6183874|NCT01356940|9836799|FG000|First Intervention (28 Days)|Adverse Event|1
6183875|NCT01356940|9836800|FG001|First Intervention (28 Days)|Adverse Event|0
6183876|NCT01356940|9836799|FG000|Second Intervention (28 Days)|Withdrawal by Subject|1
6183877|NCT01356940|9836800|FG001|Second Intervention (28 Days)|Withdrawal by Subject|0
6183878|NCT01356966|9836810|FG000|Overall Study|Withdrawal by Subject|1
6183879|NCT01356966|9836811|FG001|Overall Study|Withdrawal by Subject|2
6183880|NCT01356966|9836810|FG000|Overall Study|Physician Decision|1
6183881|NCT01356966|9836811|FG001|Overall Study|Physician Decision|0
6183882|NCT01357161|9836837|FG000|Part 1 (Open Label Run-in)|Death|5
6183883|NCT01357161|9836838|FG001|Part 1 (Open Label Run-in)|Death|0
6183884|NCT01357161|9836839|FG002|Part 1 (Open Label Run-in)|Death|0
6183885|NCT01357161|9836837|FG000|Part 1 (Open Label Run-in)|Lost to Follow-up|3
6183886|NCT01357161|9836838|FG001|Part 1 (Open Label Run-in)|Lost to Follow-up|0
6183887|NCT01357161|9836839|FG002|Part 1 (Open Label Run-in)|Lost to Follow-up|0
6183888|NCT01357161|9836837|FG000|Part 1 (Open Label Run-in)|Physician Decision|1
6183889|NCT01357161|9836838|FG001|Part 1 (Open Label Run-in)|Physician Decision|0
6183890|NCT01357161|9836839|FG002|Part 1 (Open Label Run-in)|Physician Decision|0
6183891|NCT01357161|9836837|FG000|Part 1 (Open Label Run-in)|Study Terminated By Sponsor|5
6183892|NCT01357161|9836838|FG001|Part 1 (Open Label Run-in)|Study Terminated By Sponsor|0
6183893|NCT01357161|9836839|FG002|Part 1 (Open Label Run-in)|Study Terminated By Sponsor|0
6183894|NCT01357161|9836837|FG000|Part 1 (Open Label Run-in)|Withdrawal by Subject|1
6183895|NCT01357161|9836838|FG001|Part 1 (Open Label Run-in)|Withdrawal by Subject|0
6183896|NCT01357161|9836839|FG002|Part 1 (Open Label Run-in)|Withdrawal by Subject|0
6183897|NCT01357161|9836837|FG000|Part 2 (Double-Blind Comparison)|Death|0
6183898|NCT01357161|9836838|FG001|Part 2 (Double-Blind Comparison)|Death|22
6183899|NCT01357161|9836839|FG002|Part 2 (Double-Blind Comparison)|Death|19
6183900|NCT01357161|9836837|FG000|Part 2 (Double-Blind Comparison)|Lost to Follow-up|0
6183901|NCT01357161|9836838|FG001|Part 2 (Double-Blind Comparison)|Lost to Follow-up|1
6183902|NCT01357161|9836839|FG002|Part 2 (Double-Blind Comparison)|Lost to Follow-up|6
6183903|NCT01357161|9836837|FG000|Part 2 (Double-Blind Comparison)|Physician Decision|0
6183904|NCT01357161|9836838|FG001|Part 2 (Double-Blind Comparison)|Physician Decision|1
6183905|NCT01357161|9836839|FG002|Part 2 (Double-Blind Comparison)|Physician Decision|4
6183906|NCT01357161|9836837|FG000|Part 2 (Double-Blind Comparison)|Progressive Disease|0
6183907|NCT01357161|9836838|FG001|Part 2 (Double-Blind Comparison)|Progressive Disease|1
6183908|NCT01357161|9836839|FG002|Part 2 (Double-Blind Comparison)|Progressive Disease|3
6183909|NCT01357161|9836837|FG000|Part 2 (Double-Blind Comparison)|Study Terminated By Sponsor|0
6183910|NCT01357161|9836838|FG001|Part 2 (Double-Blind Comparison)|Study Terminated By Sponsor|29
6183911|NCT01357161|9836839|FG002|Part 2 (Double-Blind Comparison)|Study Terminated By Sponsor|26
6183912|NCT01357161|9836837|FG000|Part 2 (Double-Blind Comparison)|Withdrawal by Subject|0
6183913|NCT01357161|9836838|FG001|Part 2 (Double-Blind Comparison)|Withdrawal by Subject|5
6183914|NCT01357161|9836839|FG002|Part 2 (Double-Blind Comparison)|Withdrawal by Subject|4
6183915|NCT01357239|9836851|FG000|Stratum: All Patients|Adverse Event|0
6183916|NCT01357239|9836852|FG001|Stratum: All Patients|Adverse Event|0
6183917|NCT01357239|9836853|FG002|Stratum: All Patients|Adverse Event|1
6183918|NCT01357239|9836854|FG003|Stratum: All Patients|Adverse Event|1
6183919|NCT01357239|9836851|FG000|Stratum: All Patients|Subject withdrew consent|0
6183920|NCT01357239|9836852|FG001|Stratum: All Patients|Subject withdrew consent|0
6183921|NCT01357239|9836853|FG002|Stratum: All Patients|Subject withdrew consent|1
6183922|NCT01357239|9836854|FG003|Stratum: All Patients|Subject withdrew consent|1
6183923|NCT01357239|9836851|FG000|Stratum I: Fully-Methylated|Adverse Event|0
6183924|NCT01357239|9836852|FG001|Stratum I: Fully-Methylated|Adverse Event|0
6183925|NCT01357239|9836853|FG002|Stratum I: Fully-Methylated|Adverse Event|1
6183926|NCT01357239|9836854|FG003|Stratum I: Fully-Methylated|Adverse Event|0
6183927|NCT01357239|9836851|FG000|Stratum II: Partially-Methylated|Adverse Event|0
6183928|NCT01357239|9836852|FG001|Stratum II: Partially-Methylated|Adverse Event|0
6183929|NCT01357239|9836853|FG002|Stratum II: Partially-Methylated|Adverse Event|0
6183930|NCT01357239|9836854|FG003|Stratum II: Partially-Methylated|Adverse Event|1
6183931|NCT01357239|9836851|FG000|Stratum II: Partially-Methylated|Subject withdrew consent|0
6183932|NCT01357239|9836852|FG001|Stratum II: Partially-Methylated|Subject withdrew consent|0
6183933|NCT01357239|9836853|FG002|Stratum II: Partially-Methylated|Subject withdrew consent|1
6183934|NCT01357239|9836854|FG003|Stratum II: Partially-Methylated|Subject withdrew consent|1
6183935|NCT01357551|9836901|FG000|Overall Study|Withdrawal by Subject|6
6183936|NCT01357551|9836902|FG001|Overall Study|Withdrawal by Subject|4
6183937|NCT01357551|9836901|FG000|Overall Study|Death|0
6183938|NCT01357551|9836902|FG001|Overall Study|Death|1
6183939|NCT01357551|9836901|FG000|Overall Study|Lost to Follow-up|16
6183940|NCT01357551|9836902|FG001|Overall Study|Lost to Follow-up|6
6183941|NCT01357577|9836924|FG000|Overall Study|Lost to Follow-up|20
6183942|NCT01357577|9836925|FG001|Overall Study|Lost to Follow-up|16
6183943|NCT01357577|9836924|FG000|Overall Study|Withdrawal by Subject|16
6183944|NCT01357577|9836925|FG001|Overall Study|Withdrawal by Subject|8
6183945|NCT01357577|9836924|FG000|Overall Study|look at data in database?|1
6183946|NCT01357577|9836925|FG001|Overall Study|look at data in database?|2
6183947|NCT01357616|9836934|FG000|Overall Study|Adverse Event|1
6183948|NCT01357616|9836935|FG001|Overall Study|Adverse Event|1
6183949|NCT01357616|9836934|FG000|Overall Study|Lost to Follow-up|4
6183950|NCT01357616|9836935|FG001|Overall Study|Lost to Follow-up|3
6183951|NCT01357616|9836934|FG000|Overall Study|Protocol Violation|0
6183952|NCT01357616|9836935|FG001|Overall Study|Protocol Violation|2
6183953|NCT01357616|9836934|FG000|Overall Study|Inadequate Control of IOP|1
6183954|NCT01357616|9836935|FG001|Overall Study|Inadequate Control of IOP|2
6183955|NCT01357616|9836934|FG000|Overall Study|Decision Unrelated to Adverse Event|3
6183956|NCT01357616|9836935|FG001|Overall Study|Decision Unrelated to Adverse Event|1
6183957|NCT01357616|9836934|FG000|Overall Study|Withdrawal by Subject|1
6183958|NCT01357616|9836935|FG001|Overall Study|Withdrawal by Subject|0
6183959|NCT01357655|9836943|FG000|Overall Study|Administrative Reason by Sponsor|45
6183960|NCT01357655|9836944|FG001|Overall Study|Administrative Reason by Sponsor|0
6183961|NCT01357655|9836943|FG000|Overall Study|Adverse Event Unrelated to Study Drug|3
6183962|NCT01357655|9836944|FG001|Overall Study|Adverse Event Unrelated to Study Drug|0
6183963|NCT01357655|9836943|FG000|Overall Study|Disease Progression|1
6183964|NCT01357655|9836944|FG001|Overall Study|Disease Progression|0
6183965|NCT01357655|9836943|FG000|Overall Study|Lost to Follow-up|2
6183966|NCT01357655|9836944|FG001|Overall Study|Lost to Follow-up|0
6183967|NCT01357655|9836943|FG000|Overall Study|Maximum Clinical Benefit|2
6183968|NCT01357655|9836944|FG001|Overall Study|Maximum Clinical Benefit|0
6183969|NCT01357655|9836943|FG000|Overall Study|Reason Unspecified|1
6183970|NCT01357655|9836944|FG001|Overall Study|Reason Unspecified|0
6183971|NCT01357655|9836943|FG000|Overall Study|Study Drug Toxicity|11
6183972|NCT01357655|9836944|FG001|Overall Study|Study Drug Toxicity|0
6183973|NCT01357655|9836943|FG000|Overall Study|Subject Withdrew Consent|1
6183974|NCT01357655|9836944|FG001|Overall Study|Subject Withdrew Consent|0
6183975|NCT01357850|9836962|FG000|Overall Study|Lost to Follow-up|1
6183976|NCT01357850|9836963|FG001|Overall Study|Lost to Follow-up|0
6183977|NCT01357850|9836964|FG002|Overall Study|Lost to Follow-up|0
6183978|NCT01357850|9836965|FG003|Overall Study|Lost to Follow-up|0
6183979|NCT01357889|9836978|FG000|Single-dose Phase (BE Phase: 28 Days)|Withdrawal by Subject|2
6183980|NCT01357889|9836979|FG001|Single-dose Phase (BE Phase: 28 Days)|Withdrawal by Subject|1
6183981|NCT01357889|9836978|FG000|Single-dose Phase (BE Phase: 28 Days)|Persistent Hyperglycemia|1
6183982|NCT01357889|9836979|FG001|Single-dose Phase (BE Phase: 28 Days)|Persistent Hyperglycemia|1
6183983|NCT01357889|9836978|FG000|Single-dose Phase (BE Phase: 28 Days)|Physician Decision|1
6183984|NCT01357889|9836979|FG001|Single-dose Phase (BE Phase: 28 Days)|Physician Decision|0
6085341|NCT00651924|9694639|FG001|Overall Study|Withdrawal by PI|2
6085342|NCT00651924|9694638|FG000|Overall Study|Withdrawal by Subject|0
6183985|NCT01357889|9836978|FG000|Multiple-dose Phase (MDP) (Overall)|Adverse Event|2
6183986|NCT01357889|9836979|FG001|Multiple-dose Phase (MDP) (Overall)|Adverse Event|2
6183987|NCT01357889|9836978|FG000|Multiple-dose Phase (MDP) (Overall)|Noncompliance|0
6183988|NCT01357889|9836979|FG001|Multiple-dose Phase (MDP) (Overall)|Noncompliance|2
6183989|NCT01357889|9836978|FG000|Multiple-dose Phase (MDP) (Overall)|Lost to Follow-up|0
6183990|NCT01357889|9836979|FG001|Multiple-dose Phase (MDP) (Overall)|Lost to Follow-up|2
6183991|NCT01357889|9836978|FG000|Multiple-dose Phase (MDP) (Overall)|Withdrawal by Subject|5
6183992|NCT01357889|9836979|FG001|Multiple-dose Phase (MDP) (Overall)|Withdrawal by Subject|2
6183993|NCT01357889|9836978|FG000|Multiple-dose Phase (MDP) (Overall)|Physician Decision|2
6183994|NCT01357889|9836979|FG001|Multiple-dose Phase (MDP) (Overall)|Physician Decision|1
6183995|NCT01357889|9836978|FG000|Multiple-dose Phase (MDP) (Overall)|Withdrawn Due to Hyperglycemia|7
6183996|NCT01357889|9836979|FG001|Multiple-dose Phase (MDP) (Overall)|Withdrawn Due to Hyperglycemia|7
6183997|NCT01357889|9836978|FG000|Follow-up Phase (FUP) (8 Weeks)|Noncompliance|1
6183998|NCT01357889|9836979|FG001|Follow-up Phase (FUP) (8 Weeks)|Noncompliance|0
6183999|NCT01357889|9836978|FG000|Follow-up Phase (FUP) (8 Weeks)|Lost to Follow-up|0
6184000|NCT01357889|9836979|FG001|Follow-up Phase (FUP) (8 Weeks)|Lost to Follow-up|4
6184001|NCT01357889|9836978|FG000|Follow-up Phase (FUP) (8 Weeks)|Withdrawal by Subject|1
6184002|NCT01357889|9836979|FG001|Follow-up Phase (FUP) (8 Weeks)|Withdrawal by Subject|0
6184003|NCT01357889|9836978|FG000|Follow-up Phase (FUP) (8 Weeks)|Hyperglycemia|1
6184004|NCT01357889|9836979|FG001|Follow-up Phase (FUP) (8 Weeks)|Hyperglycemia|0
6184005|NCT01357915|9836989|FG000|Overall Study|Lost to Follow-up|3
6184006|NCT01357915|9836990|FG001|Overall Study|Lost to Follow-up|0
6184007|NCT01357980|9837000|FG000|Overall Study|Lack of Efficacy|0
6184008|NCT01357980|9837001|FG001|Overall Study|Lack of Efficacy|1
6184009|NCT01357980|9837002|FG002|Overall Study|Lack of Efficacy|0
6184010|NCT01357980|9837003|FG003|Overall Study|Lack of Efficacy|0
6184011|NCT01357980|9837000|FG000|Overall Study|Consent withdrawn|0
6184012|NCT01357980|9837001|FG001|Overall Study|Consent withdrawn|0
6184013|NCT01357980|9837002|FG002|Overall Study|Consent withdrawn|1
6184014|NCT01357980|9837003|FG003|Overall Study|Consent withdrawn|0
6184015|NCT01358175|9837016|FG000|Overall Study|Death|1
6184016|NCT01358175|9837017|FG001|Overall Study|Death|0
6184017|NCT01358175|9837018|FG002|Overall Study|Death|1
6184018|NCT01358175|9837016|FG000|Overall Study|Withdrawal by Subject|9
6184019|NCT01358175|9837017|FG001|Overall Study|Withdrawal by Subject|5
6184020|NCT01358175|9837018|FG002|Overall Study|Withdrawal by Subject|10
6184021|NCT01358175|9837016|FG000|Overall Study|Technical issues|0
6184022|NCT01358175|9837017|FG001|Overall Study|Technical issues|1
6184023|NCT01358175|9837018|FG002|Overall Study|Technical issues|0
6184024|NCT01358175|9837016|FG000|Overall Study|Pregnancy|0
6184025|NCT01358175|9837017|FG001|Overall Study|Pregnancy|1
6184026|NCT01358175|9837018|FG002|Overall Study|Pregnancy|0
6184027|NCT01358175|9837016|FG000|Overall Study|Physician Decision|1
6184028|NCT01358175|9837017|FG001|Overall Study|Physician Decision|0
6184029|NCT01358175|9837018|FG002|Overall Study|Physician Decision|0
6184030|NCT01358175|9837016|FG000|Overall Study|Non Compliance with Study Treatment|0
6184031|NCT01358175|9837017|FG001|Overall Study|Non Compliance with Study Treatment|1
6184032|NCT01358175|9837018|FG002|Overall Study|Non Compliance with Study Treatment|1
6184033|NCT01358175|9837016|FG000|Overall Study|Lost to Follow-up|1
6184034|NCT01358175|9837017|FG001|Overall Study|Lost to Follow-up|1
6184035|NCT01358175|9837018|FG002|Overall Study|Lost to Follow-up|3
6184036|NCT01358175|9837016|FG000|Overall Study|Lack of Efficacy|3
6184037|NCT01358175|9837017|FG001|Overall Study|Lack of Efficacy|8
6184038|NCT01358175|9837018|FG002|Overall Study|Lack of Efficacy|6
6184039|NCT01358175|9837016|FG000|Overall Study|Adverse Event|6
6184040|NCT01358175|9837017|FG001|Overall Study|Adverse Event|11
6184041|NCT01358175|9837018|FG002|Overall Study|Adverse Event|11
6184042|NCT01358331|9837050|FG000|Overall Study|Lost to Follow-up|0
6184043|NCT01358331|9837051|FG001|Overall Study|Lost to Follow-up|0
6184044|NCT01358331|9837052|FG002|Overall Study|Lost to Follow-up|0
6184045|NCT01358331|9837053|FG003|Overall Study|Lost to Follow-up|1
6184046|NCT01358331|9837054|FG004|Overall Study|Lost to Follow-up|0
6184047|NCT01358331|9837055|FG005|Overall Study|Lost to Follow-up|0
6184048|NCT01358331|9837050|FG000|Overall Study|Withdrawal by Subject|0
6184049|NCT01358331|9837051|FG001|Overall Study|Withdrawal by Subject|0
6184050|NCT01358331|9837052|FG002|Overall Study|Withdrawal by Subject|0
6184051|NCT01358331|9837053|FG003|Overall Study|Withdrawal by Subject|1
6184052|NCT01358331|9837054|FG004|Overall Study|Withdrawal by Subject|1
6184053|NCT01358331|9837055|FG005|Overall Study|Withdrawal by Subject|1
6184054|NCT01358331|9837050|FG000|Overall Study|Adverse Events|1
6184055|NCT01358331|9837051|FG001|Overall Study|Adverse Events|1
6184056|NCT01358331|9837052|FG002|Overall Study|Adverse Events|1
6184057|NCT01358331|9837053|FG003|Overall Study|Adverse Events|0
6184058|NCT01358331|9837054|FG004|Overall Study|Adverse Events|1
6184059|NCT01358331|9837055|FG005|Overall Study|Adverse Events|5
6184060|NCT01358331|9837050|FG000|Overall Study|Symptomatic Deterioration|0
6184061|NCT01358331|9837051|FG001|Overall Study|Symptomatic Deterioration|0
6184062|NCT01358331|9837052|FG002|Overall Study|Symptomatic Deterioration|0
6184063|NCT01358331|9837053|FG003|Overall Study|Symptomatic Deterioration|0
6184064|NCT01358331|9837054|FG004|Overall Study|Symptomatic Deterioration|1
6184065|NCT01358331|9837055|FG005|Overall Study|Symptomatic Deterioration|0
6184066|NCT01358331|9837050|FG000|Overall Study|Participants did not wish to continue|0
6184067|NCT01358331|9837051|FG001|Overall Study|Participants did not wish to continue|0
6184068|NCT01358331|9837052|FG002|Overall Study|Participants did not wish to continue|0
6228079|NCT01722162|9901131|FG001|Overall Study|Unrelated to study adverse event|2
6184069|NCT01358331|9837053|FG003|Overall Study|Participants did not wish to continue|0
6184070|NCT01358331|9837054|FG004|Overall Study|Participants did not wish to continue|1
6184071|NCT01358331|9837055|FG005|Overall Study|Participants did not wish to continue|0
6228080|NCT01722162|9901130|FG000|Overall Study|Adverse Event|1
6184072|NCT01358331|9837050|FG000|Overall Study|Progress of disease under investigation|1
6184073|NCT01358331|9837051|FG001|Overall Study|Progress of disease under investigation|2
6184074|NCT01358331|9837052|FG002|Overall Study|Progress of disease under investigation|3
6184075|NCT01358331|9837053|FG003|Overall Study|Progress of disease under investigation|1
6184076|NCT01358331|9837054|FG004|Overall Study|Progress of disease under investigation|3
6184077|NCT01358331|9837055|FG005|Overall Study|Progress of disease under investigation|0
6184078|NCT01358357|9837071|FG000|Open Label Phase|Adverse Event|0
6184079|NCT01358357|9837072|FG001|Open Label Phase|Adverse Event|0
6184080|NCT01358357|9837073|FG002|Open Label Phase|Adverse Event|59
6184081|NCT01358357|9837071|FG000|Open Label Phase|Lack of Efficacy|0
6184082|NCT01358357|9837072|FG001|Open Label Phase|Lack of Efficacy|0
6184083|NCT01358357|9837073|FG002|Open Label Phase|Lack of Efficacy|107
6184084|NCT01358357|9837071|FG000|Open Label Phase|Lost to Follow-up|0
6184085|NCT01358357|9837072|FG001|Open Label Phase|Lost to Follow-up|0
6184086|NCT01358357|9837073|FG002|Open Label Phase|Lost to Follow-up|76
6184087|NCT01358357|9837071|FG000|Open Label Phase|Protocol Violation|0
6184088|NCT01358357|9837072|FG001|Open Label Phase|Protocol Violation|0
6184089|NCT01358357|9837073|FG002|Open Label Phase|Protocol Violation|45
6184090|NCT01358357|9837071|FG000|Open Label Phase|Withdrawal by Subject|0
6184091|NCT01358357|9837072|FG001|Open Label Phase|Withdrawal by Subject|0
6184092|NCT01358357|9837073|FG002|Open Label Phase|Withdrawal by Subject|112
6184093|NCT01358357|9837071|FG000|Open Label Phase|Did not meet criteria for DB phase|0
6184094|NCT01358357|9837072|FG001|Open Label Phase|Did not meet criteria for DB phase|0
6184095|NCT01358357|9837073|FG002|Open Label Phase|Did not meet criteria for DB phase|16
6184096|NCT01358357|9837071|FG000|Open Label Phase|Terminated at study completion|0
6184097|NCT01358357|9837072|FG001|Open Label Phase|Terminated at study completion|0
6184098|NCT01358357|9837073|FG002|Open Label Phase|Terminated at study completion|5
6184099|NCT01358357|9837071|FG000|Open Label Phase|Mood episode|0
6184100|NCT01358357|9837072|FG001|Open Label Phase|Mood episode|0
6184101|NCT01358357|9837073|FG002|Open Label Phase|Mood episode|42
6184102|NCT01358357|9837071|FG000|Double-Blind Phase|Adverse Event|8
6184103|NCT01358357|9837072|FG001|Double-Blind Phase|Adverse Event|5
6184104|NCT01358357|9837073|FG002|Double-Blind Phase|Adverse Event|0
6184105|NCT01358357|9837071|FG000|Double-Blind Phase|Lost to Follow-up|5
6184106|NCT01358357|9837072|FG001|Double-Blind Phase|Lost to Follow-up|7
6184107|NCT01358357|9837073|FG002|Double-Blind Phase|Lost to Follow-up|0
6184108|NCT01358357|9837071|FG000|Double-Blind Phase|Protocol Violation|1
6184109|NCT01358357|9837072|FG001|Double-Blind Phase|Protocol Violation|11
6184110|NCT01358357|9837073|FG002|Double-Blind Phase|Protocol Violation|0
6184111|NCT01358357|9837071|FG000|Double-Blind Phase|Protocol Violation|16
6184112|NCT01358357|9837072|FG001|Double-Blind Phase|Protocol Violation|12
6184113|NCT01358357|9837073|FG002|Double-Blind Phase|Protocol Violation|0
6184114|NCT01358357|9837071|FG000|Double-Blind Phase|Terminated at study completion|2
6184115|NCT01358357|9837072|FG001|Double-Blind Phase|Terminated at study completion|0
6184116|NCT01358357|9837073|FG002|Double-Blind Phase|Terminated at study completion|0
6184117|NCT01358357|9837071|FG000|Double-Blind Phase|Recurrence of mood event|48
6184118|NCT01358357|9837072|FG001|Double-Blind Phase|Recurrence of mood event|64
6184119|NCT01358357|9837073|FG002|Double-Blind Phase|Recurrence of mood event|0
6184120|NCT01358357|9837071|FG000|Double-Blind Phase|Administrative|0
6184121|NCT01358357|9837072|FG001|Double-Blind Phase|Administrative|1
6184122|NCT01358357|9837073|FG002|Double-Blind Phase|Administrative|0
6184123|NCT01358526|9837082|FG000|Open-label Titration Period|Adverse Event|95
6184124|NCT01358526|9837083|FG001|Open-label Titration Period|Adverse Event|0
6184125|NCT01358526|9837084|FG002|Open-label Titration Period|Adverse Event|0
6184126|NCT01358526|9837082|FG000|Open-label Titration Period|Withdrawal by Subject|65
6184127|NCT01358526|9837083|FG001|Open-label Titration Period|Withdrawal by Subject|0
6184128|NCT01358526|9837084|FG002|Open-label Titration Period|Withdrawal by Subject|0
6184129|NCT01358526|9837082|FG000|Open-label Titration Period|Lost to Follow-up|25
6184130|NCT01358526|9837083|FG001|Open-label Titration Period|Lost to Follow-up|0
6184131|NCT01358526|9837084|FG002|Open-label Titration Period|Lost to Follow-up|0
6184132|NCT01358526|9837082|FG000|Open-label Titration Period|Lack of Efficacy|107
6184133|NCT01358526|9837083|FG001|Open-label Titration Period|Lack of Efficacy|0
6184134|NCT01358526|9837084|FG002|Open-label Titration Period|Lack of Efficacy|0
6184135|NCT01358526|9837082|FG000|Open-label Titration Period|Confirmed or suspected diversion|16
6184136|NCT01358526|9837083|FG001|Open-label Titration Period|Confirmed or suspected diversion|0
6184137|NCT01358526|9837084|FG002|Open-label Titration Period|Confirmed or suspected diversion|0
6184138|NCT01358526|9837082|FG000|Open-label Titration Period|Administrative|8
6184139|NCT01358526|9837083|FG001|Open-label Titration Period|Administrative|0
6184140|NCT01358526|9837084|FG002|Open-label Titration Period|Administrative|0
6184141|NCT01358526|9837082|FG000|Open-label Titration Period|Did not qualify|178
6184142|NCT01358526|9837083|FG001|Open-label Titration Period|Did not qualify|0
6184143|NCT01358526|9837084|FG002|Open-label Titration Period|Did not qualify|0
6184144|NCT01358526|9837082|FG000|Double-blind Phase|Adverse Event|0
6184145|NCT01358526|9837083|FG001|Double-blind Phase|Adverse Event|24
6184146|NCT01358526|9837084|FG002|Double-blind Phase|Adverse Event|23
6184147|NCT01358526|9837082|FG000|Double-blind Phase|Withdrawal by Subject|0
6184148|NCT01358526|9837083|FG001|Double-blind Phase|Withdrawal by Subject|10
6184149|NCT01358526|9837084|FG002|Double-blind Phase|Withdrawal by Subject|8
6184150|NCT01358526|9837082|FG000|Double-blind Phase|Lost to Follow-up|0
6184151|NCT01358526|9837083|FG001|Double-blind Phase|Lost to Follow-up|4
6184152|NCT01358526|9837084|FG002|Double-blind Phase|Lost to Follow-up|1
6184153|NCT01358526|9837082|FG000|Double-blind Phase|Lack of Efficacy|0
6184154|NCT01358526|9837083|FG001|Double-blind Phase|Lack of Efficacy|31
6184155|NCT01358526|9837084|FG002|Double-blind Phase|Lack of Efficacy|73
6184156|NCT01358526|9837082|FG000|Double-blind Phase|Confirmed or suspected diversion|0
6184157|NCT01358526|9837083|FG001|Double-blind Phase|Confirmed or suspected diversion|5
6184158|NCT01358526|9837084|FG002|Double-blind Phase|Confirmed or suspected diversion|6
6184159|NCT01358526|9837082|FG000|Double-blind Phase|Administrative|0
6184160|NCT01358526|9837083|FG001|Double-blind Phase|Administrative|6
6184161|NCT01358526|9837084|FG002|Double-blind Phase|Administrative|10
6184162|NCT01358578|9837095|FG000|Induction Period|Adverse Event|2
6184163|NCT01358578|9837096|FG001|Induction Period|Adverse Event|4
6184164|NCT01358578|9837097|FG002|Induction Period|Adverse Event|2
6184165|NCT01358578|9837098|FG003|Induction Period|Adverse Event|6
6184166|NCT01358578|9837099|FG004|Induction Period|Adverse Event|0
6184167|NCT01358578|9837100|FG005|Induction Period|Adverse Event|0
6184168|NCT01358578|9837095|FG000|Induction Period|Lack of Efficacy|0
6184169|NCT01358578|9837096|FG001|Induction Period|Lack of Efficacy|0
6184170|NCT01358578|9837097|FG002|Induction Period|Lack of Efficacy|9
6184171|NCT01358578|9837098|FG003|Induction Period|Lack of Efficacy|1
6184172|NCT01358578|9837099|FG004|Induction Period|Lack of Efficacy|0
6184173|NCT01358578|9837100|FG005|Induction Period|Lack of Efficacy|0
6184174|NCT01358578|9837095|FG000|Induction Period|Lost to Follow-up|0
6184175|NCT01358578|9837096|FG001|Induction Period|Lost to Follow-up|0
6184176|NCT01358578|9837097|FG002|Induction Period|Lost to Follow-up|1
6184177|NCT01358578|9837098|FG003|Induction Period|Lost to Follow-up|4
6184178|NCT01358578|9837099|FG004|Induction Period|Lost to Follow-up|0
6184179|NCT01358578|9837100|FG005|Induction Period|Lost to Follow-up|0
6184180|NCT01358578|9837095|FG000|Induction Period|Physician Decision|2
6184181|NCT01358578|9837096|FG001|Induction Period|Physician Decision|1
6184182|NCT01358578|9837097|FG002|Induction Period|Physician Decision|2
6184183|NCT01358578|9837098|FG003|Induction Period|Physician Decision|0
6184184|NCT01358578|9837099|FG004|Induction Period|Physician Decision|0
6184185|NCT01358578|9837100|FG005|Induction Period|Physician Decision|0
6184186|NCT01358578|9837095|FG000|Induction Period|Protocol Deviation|3
6184187|NCT01358578|9837096|FG001|Induction Period|Protocol Deviation|5
6184188|NCT01358578|9837097|FG002|Induction Period|Protocol Deviation|0
6184189|NCT01358578|9837098|FG003|Induction Period|Protocol Deviation|3
6184190|NCT01358578|9837099|FG004|Induction Period|Protocol Deviation|0
6184191|NCT01358578|9837100|FG005|Induction Period|Protocol Deviation|0
6184192|NCT01358578|9837095|FG000|Induction Period|technical problems|0
6184193|NCT01358578|9837096|FG001|Induction Period|technical problems|0
6184194|NCT01358578|9837097|FG002|Induction Period|technical problems|1
6184195|NCT01358578|9837098|FG003|Induction Period|technical problems|1
6184196|NCT01358578|9837099|FG004|Induction Period|technical problems|0
6184197|NCT01358578|9837100|FG005|Induction Period|technical problems|0
6184198|NCT01358578|9837095|FG000|Induction Period|Withdrawal by Subject|5
6184199|NCT01358578|9837096|FG001|Induction Period|Withdrawal by Subject|5
6184200|NCT01358578|9837097|FG002|Induction Period|Withdrawal by Subject|10
6184201|NCT01358578|9837098|FG003|Induction Period|Withdrawal by Subject|6
6184202|NCT01358578|9837099|FG004|Induction Period|Withdrawal by Subject|0
6184203|NCT01358578|9837100|FG005|Induction Period|Withdrawal by Subject|0
6184204|NCT01358578|9837095|FG000|Maintenance Period|Adverse Event|2
6184205|NCT01358578|9837096|FG001|Maintenance Period|Adverse Event|7
6184206|NCT01358578|9837097|FG002|Maintenance Period|Adverse Event|0
6184207|NCT01358578|9837098|FG003|Maintenance Period|Adverse Event|6
6184208|NCT01358578|9837099|FG004|Maintenance Period|Adverse Event|4
6184209|NCT01358578|9837100|FG005|Maintenance Period|Adverse Event|3
6184210|NCT01358578|9837095|FG000|Maintenance Period|Lack of Efficacy|10
6184211|NCT01358578|9837096|FG001|Maintenance Period|Lack of Efficacy|2
6184212|NCT01358578|9837097|FG002|Maintenance Period|Lack of Efficacy|0
6184213|NCT01358578|9837098|FG003|Maintenance Period|Lack of Efficacy|11
6184214|NCT01358578|9837099|FG004|Maintenance Period|Lack of Efficacy|3
6184215|NCT01358578|9837100|FG005|Maintenance Period|Lack of Efficacy|0
6184216|NCT01358578|9837095|FG000|Maintenance Period|Lost to Follow-up|4
6184217|NCT01358578|9837096|FG001|Maintenance Period|Lost to Follow-up|0
6184218|NCT01358578|9837097|FG002|Maintenance Period|Lost to Follow-up|0
6184219|NCT01358578|9837098|FG003|Maintenance Period|Lost to Follow-up|5
6184220|NCT01358578|9837099|FG004|Maintenance Period|Lost to Follow-up|1
6184221|NCT01358578|9837100|FG005|Maintenance Period|Lost to Follow-up|1
6184222|NCT01358578|9837095|FG000|Maintenance Period|Non-compliance with study treatment|3
6184223|NCT01358578|9837096|FG001|Maintenance Period|Non-compliance with study treatment|1
6184224|NCT01358578|9837097|FG002|Maintenance Period|Non-compliance with study treatment|0
6184225|NCT01358578|9837098|FG003|Maintenance Period|Non-compliance with study treatment|2
6184226|NCT01358578|9837099|FG004|Maintenance Period|Non-compliance with study treatment|1
6184227|NCT01358578|9837100|FG005|Maintenance Period|Non-compliance with study treatment|2
6184228|NCT01358578|9837095|FG000|Maintenance Period|Physician Decision|0
6184229|NCT01358578|9837096|FG001|Maintenance Period|Physician Decision|1
6184230|NCT01358578|9837097|FG002|Maintenance Period|Physician Decision|0
6184231|NCT01358578|9837098|FG003|Maintenance Period|Physician Decision|1
6184232|NCT01358578|9837099|FG004|Maintenance Period|Physician Decision|0
6184233|NCT01358578|9837100|FG005|Maintenance Period|Physician Decision|0
6184234|NCT01358578|9837095|FG000|Maintenance Period|Pregnancy|1
6184235|NCT01358578|9837096|FG001|Maintenance Period|Pregnancy|0
6184236|NCT01358578|9837097|FG002|Maintenance Period|Pregnancy|0
6184237|NCT01358578|9837098|FG003|Maintenance Period|Pregnancy|0
6184238|NCT01358578|9837099|FG004|Maintenance Period|Pregnancy|0
6184239|NCT01358578|9837100|FG005|Maintenance Period|Pregnancy|0
6184240|NCT01358578|9837095|FG000|Maintenance Period|Protocol deviation|7
6184241|NCT01358578|9837096|FG001|Maintenance Period|Protocol deviation|4
6184242|NCT01358578|9837097|FG002|Maintenance Period|Protocol deviation|0
6184243|NCT01358578|9837098|FG003|Maintenance Period|Protocol deviation|2
6184244|NCT01358578|9837099|FG004|Maintenance Period|Protocol deviation|2
6184245|NCT01358578|9837100|FG005|Maintenance Period|Protocol deviation|2
6184246|NCT01358578|9837095|FG000|Maintenance Period|Withdrawal by Subject|12
6184247|NCT01358578|9837096|FG001|Maintenance Period|Withdrawal by Subject|7
6184248|NCT01358578|9837097|FG002|Maintenance Period|Withdrawal by Subject|2
6184249|NCT01358578|9837098|FG003|Maintenance Period|Withdrawal by Subject|15
6184250|NCT01358578|9837099|FG004|Maintenance Period|Withdrawal by Subject|6
6184251|NCT01358578|9837100|FG005|Maintenance Period|Withdrawal by Subject|3
6184252|NCT01358578|9837095|FG000|Follow-up Period|Adverse Event|1
6184253|NCT01358578|9837096|FG001|Follow-up Period|Adverse Event|1
6184254|NCT01358578|9837097|FG002|Follow-up Period|Adverse Event|0
6184255|NCT01358578|9837098|FG003|Follow-up Period|Adverse Event|0
6184256|NCT01358578|9837099|FG004|Follow-up Period|Adverse Event|0
6184257|NCT01358578|9837100|FG005|Follow-up Period|Adverse Event|0
6184258|NCT01358578|9837095|FG000|Follow-up Period|Lack of Efficacy|3
6184259|NCT01358578|9837096|FG001|Follow-up Period|Lack of Efficacy|0
6184260|NCT01358578|9837097|FG002|Follow-up Period|Lack of Efficacy|4
6184261|NCT01358578|9837098|FG003|Follow-up Period|Lack of Efficacy|1
6184262|NCT01358578|9837099|FG004|Follow-up Period|Lack of Efficacy|0
6184263|NCT01358578|9837100|FG005|Follow-up Period|Lack of Efficacy|0
6184264|NCT01358578|9837095|FG000|Follow-up Period|Lost to Follow-up|0
6184265|NCT01358578|9837096|FG001|Follow-up Period|Lost to Follow-up|1
6184266|NCT01358578|9837097|FG002|Follow-up Period|Lost to Follow-up|0
6184267|NCT01358578|9837098|FG003|Follow-up Period|Lost to Follow-up|4
6184268|NCT01358578|9837099|FG004|Follow-up Period|Lost to Follow-up|0
6184269|NCT01358578|9837100|FG005|Follow-up Period|Lost to Follow-up|0
6184270|NCT01358578|9837095|FG000|Follow-up Period|non- compliance with study treatment|1
6184271|NCT01358578|9837096|FG001|Follow-up Period|non- compliance with study treatment|0
6184272|NCT01358578|9837097|FG002|Follow-up Period|non- compliance with study treatment|0
6184273|NCT01358578|9837098|FG003|Follow-up Period|non- compliance with study treatment|0
6184274|NCT01358578|9837099|FG004|Follow-up Period|non- compliance with study treatment|0
6184275|NCT01358578|9837100|FG005|Follow-up Period|non- compliance with study treatment|0
6184276|NCT01358578|9837095|FG000|Follow-up Period|Pregnancy|1
6184277|NCT01358578|9837096|FG001|Follow-up Period|Pregnancy|0
6184278|NCT01358578|9837097|FG002|Follow-up Period|Pregnancy|0
6184279|NCT01358578|9837098|FG003|Follow-up Period|Pregnancy|0
6184280|NCT01358578|9837099|FG004|Follow-up Period|Pregnancy|0
6184281|NCT01358578|9837100|FG005|Follow-up Period|Pregnancy|0
6184282|NCT01358578|9837095|FG000|Follow-up Period|Withdrawal by Subject|3
6184283|NCT01358578|9837096|FG001|Follow-up Period|Withdrawal by Subject|3
6184284|NCT01358578|9837097|FG002|Follow-up Period|Withdrawal by Subject|1
6184285|NCT01358578|9837098|FG003|Follow-up Period|Withdrawal by Subject|12
6184286|NCT01358578|9837099|FG004|Follow-up Period|Withdrawal by Subject|0
6184287|NCT01358578|9837100|FG005|Follow-up Period|Withdrawal by Subject|0
6184288|NCT01358578|9837095|FG000|Follow-up Period|Physician Decision|1
6184289|NCT01358578|9837096|FG001|Follow-up Period|Physician Decision|1
6184290|NCT01358578|9837097|FG002|Follow-up Period|Physician Decision|0
6184291|NCT01358578|9837098|FG003|Follow-up Period|Physician Decision|2
6184292|NCT01358578|9837099|FG004|Follow-up Period|Physician Decision|0
6184293|NCT01358578|9837100|FG005|Follow-up Period|Physician Decision|0
6184294|NCT01358708|9837130|FG000|Double-Blind Treatment Phase|Lost to Follow-up|2
6184295|NCT01358708|9837131|FG001|Double-Blind Treatment Phase|Lost to Follow-up|0
6184296|NCT01358708|9837130|FG000|Double-Blind Treatment Phase|Protocol Violation|1
6184297|NCT01358708|9837131|FG001|Double-Blind Treatment Phase|Protocol Violation|0
6184298|NCT01358721|9837145|FG000|Overall Study|Withdrawal by Subject|0
6184299|NCT01358721|9837146|FG001|Overall Study|Withdrawal by Subject|0
6184300|NCT01358721|9837147|FG002|Overall Study|Withdrawal by Subject|0
6184301|NCT01358721|9837148|FG003|Overall Study|Withdrawal by Subject|1
6184302|NCT01358721|9837145|FG000|Overall Study|Death|0
6184303|NCT01358721|9837146|FG001|Overall Study|Death|2
6184304|NCT01358721|9837147|FG002|Overall Study|Death|0
6184305|NCT01358721|9837148|FG003|Overall Study|Death|0
6184306|NCT01358721|9837145|FG000|Overall Study|Study Drug Toxicity|1
6184307|NCT01358721|9837146|FG001|Overall Study|Study Drug Toxicity|3
6184308|NCT01358721|9837147|FG002|Overall Study|Study Drug Toxicity|4
6184309|NCT01358721|9837148|FG003|Overall Study|Study Drug Toxicity|5
6184310|NCT01358721|9837145|FG000|Overall Study|SUBJ request to discontinue study TRT|0
6184311|NCT01358721|9837146|FG001|Overall Study|SUBJ request to discontinue study TRT|0
6184312|NCT01358721|9837147|FG002|Overall Study|SUBJ request to discontinue study TRT|0
6184313|NCT01358721|9837148|FG003|Overall Study|SUBJ request to discontinue study TRT|1
6184314|NCT01358721|9837145|FG000|Overall Study|Subject No Longer Meets Study Criteria|0
6184315|NCT01358721|9837146|FG001|Overall Study|Subject No Longer Meets Study Criteria|2
6184316|NCT01358721|9837147|FG002|Overall Study|Subject No Longer Meets Study Criteria|0
6184317|NCT01358721|9837148|FG003|Overall Study|Subject No Longer Meets Study Criteria|1
6184318|NCT01358721|9837145|FG000|Overall Study|Adverse Event related to study drug|1
6184319|NCT01358721|9837146|FG001|Overall Study|Adverse Event related to study drug|0
6184320|NCT01358721|9837147|FG002|Overall Study|Adverse Event related to study drug|0
6184321|NCT01358721|9837148|FG003|Overall Study|Adverse Event related to study drug|1
6184322|NCT01358721|9837145|FG000|Overall Study|Disease Progression|19
6184323|NCT01358721|9837146|FG001|Overall Study|Disease Progression|15
6184324|NCT01358721|9837147|FG002|Overall Study|Disease Progression|17
6184325|NCT01358721|9837148|FG003|Overall Study|Disease Progression|15
6184326|NCT01358721|9837145|FG000|Overall Study|Out of State/Unmet Criteria|0
6184327|NCT01358721|9837146|FG001|Overall Study|Out of State/Unmet Criteria|0
6184328|NCT01358721|9837147|FG002|Overall Study|Out of State/Unmet Criteria|1
6184329|NCT01358721|9837148|FG003|Overall Study|Out of State/Unmet Criteria|0
6184330|NCT01358734|9837161|FG000|Overall Study|Adverse Event|4
6184331|NCT01358734|9837162|FG001|Overall Study|Adverse Event|7
6184332|NCT01358734|9837163|FG002|Overall Study|Adverse Event|3
6184333|NCT01358734|9837161|FG000|Overall Study|Lack of Efficacy|0
6184334|NCT01358734|9837162|FG001|Overall Study|Lack of Efficacy|1
6184335|NCT01358734|9837163|FG002|Overall Study|Lack of Efficacy|3
6184336|NCT01358734|9837161|FG000|Overall Study|Withdrawal by Subject|1
6184337|NCT01358734|9837162|FG001|Overall Study|Withdrawal by Subject|6
6184338|NCT01358734|9837163|FG002|Overall Study|Withdrawal by Subject|3
6184339|NCT01358734|9837161|FG000|Overall Study|Death|3
6184340|NCT01358734|9837162|FG001|Overall Study|Death|7
6184341|NCT01358734|9837163|FG002|Overall Study|Death|2
6184342|NCT01358734|9837161|FG000|Overall Study|Progressive Disease|5
6184343|NCT01358734|9837162|FG001|Overall Study|Progressive Disease|13
6184344|NCT01358734|9837163|FG002|Overall Study|Progressive Disease|16
6184345|NCT01358734|9837161|FG000|Overall Study|Non-compliance with study drug|0
6184346|NCT01358734|9837162|FG001|Overall Study|Non-compliance with study drug|0
6184347|NCT01358734|9837163|FG002|Overall Study|Non-compliance with study drug|1
6184348|NCT01358734|9837161|FG000|Overall Study|Other|2
6184349|NCT01358734|9837162|FG001|Overall Study|Other|5
6184350|NCT01358734|9837163|FG002|Overall Study|Other|4
6184351|NCT01358734|9837161|FG000|Overall Study|Protocol Violation|0
6228081|NCT01722162|9901131|FG001|Overall Study|Adverse Event|1
6228082|NCT01722162|9901130|FG000|Overall Study|Insurance denial post enrollment|0
6228083|NCT01722162|9901131|FG001|Overall Study|Insurance denial post enrollment|1
6228084|NCT01722162|9901130|FG000|Overall Study|Noncompliance|0
6228085|NCT01722162|9901131|FG001|Overall Study|Noncompliance|1
6228086|NCT01722266|9901141|FG000|Overall Study|Withdrawal by Subject|1
6228087|NCT01722266|9901142|FG001|Overall Study|Withdrawal by Subject|2
6228088|NCT01722266|9901143|FG002|Overall Study|Withdrawal by Subject|0
6228089|NCT01722266|9901144|FG003|Overall Study|Withdrawal by Subject|0
6228090|NCT01722266|9901141|FG000|Overall Study|Tolerated only 0.6 mg liraglutide|0
6228091|NCT01722266|9901142|FG001|Overall Study|Tolerated only 0.6 mg liraglutide|1
6228092|NCT01722266|9901143|FG002|Overall Study|Tolerated only 0.6 mg liraglutide|3
6228093|NCT01722266|9901144|FG003|Overall Study|Tolerated only 0.6 mg liraglutide|0
6228094|NCT01722266|9901141|FG000|Overall Study|Dropped out due to Nausea|0
6228095|NCT01722266|9901142|FG001|Overall Study|Dropped out due to Nausea|0
6228096|NCT01722266|9901143|FG002|Overall Study|Dropped out due to Nausea|2
6228097|NCT01722266|9901144|FG003|Overall Study|Dropped out due to Nausea|0
6228098|NCT01722669|9901253|FG000|Overall Study|Withdrawal by Subject|0
6228099|NCT01722669|9901254|FG001|Overall Study|Withdrawal by Subject|0
6228100|NCT01722669|9901255|FG002|Overall Study|Withdrawal by Subject|0
6228101|NCT01722669|9901256|FG003|Overall Study|Withdrawal by Subject|0
6228102|NCT01722669|9901257|FG004|Overall Study|Withdrawal by Subject|0
6228103|NCT01722669|9901258|FG005|Overall Study|Withdrawal by Subject|2
6228104|NCT01722877|9901291|FG000|Overall Study|Death|1
6228105|NCT01722877|9901291|FG000|Overall Study|Lost to Follow-up|1
6228106|NCT01722994|9901299|FG000|Overall Study|Missing data|25
6228107|NCT01722994|9901300|FG001|Overall Study|Missing data|17
6228108|NCT01723072|9901310|FG000|Overall Study|Withdrawal by Subject|7
6228109|NCT01723072|9901311|FG001|Overall Study|Withdrawal by Subject|13
6228110|NCT01723072|9901310|FG000|Overall Study|Discon for rescue medication after wk 24|0
6228111|NCT01723072|9901311|FG001|Overall Study|Discon for rescue medication after wk 24|5
6228112|NCT01723072|9901310|FG000|Overall Study|Other|4
6228113|NCT01723072|9901311|FG001|Overall Study|Other|3
6228114|NCT01723163|9901319|FG000|Treatment Phase|Withdrawal by Subject|14
6228115|NCT01723163|9901320|FG001|Treatment Phase|Withdrawal by Subject|6
6228116|NCT01723163|9901319|FG000|Treatment Phase|Withdrawal by PI|5
6184352|NCT01358734|9837162|FG001|Overall Study|Protocol Violation|0
6184353|NCT01358734|9837163|FG002|Overall Study|Protocol Violation|2
6184354|NCT01358760|9837174|FG000|Overall Study|Adverse Event|3
6184355|NCT01358760|9837175|FG001|Overall Study|Adverse Event|4
6184356|NCT01358760|9837176|FG002|Overall Study|Adverse Event|3
6184357|NCT01358760|9837174|FG000|Overall Study|Lost to Follow-up|1
6184358|NCT01358760|9837175|FG001|Overall Study|Lost to Follow-up|1
6184359|NCT01358760|9837176|FG002|Overall Study|Lost to Follow-up|3
6184360|NCT01358760|9837174|FG000|Overall Study|Withdrawal by Subject|5
6184361|NCT01358760|9837175|FG001|Overall Study|Withdrawal by Subject|3
6184362|NCT01358760|9837176|FG002|Overall Study|Withdrawal by Subject|2
6184363|NCT01358760|9837174|FG000|Overall Study|Physician Decision|1
6184364|NCT01358760|9837175|FG001|Overall Study|Physician Decision|0
6184365|NCT01358760|9837176|FG002|Overall Study|Physician Decision|1
6184366|NCT01358760|9837174|FG000|Overall Study|Entry criteria not met/Non-compliance|12
6184367|NCT01358760|9837175|FG001|Overall Study|Entry criteria not met/Non-compliance|12
6184368|NCT01358760|9837176|FG002|Overall Study|Entry criteria not met/Non-compliance|16
6184369|NCT01358825|9837186|FG000|Overall Study|Blood sample not drawn|0
6184370|NCT01358825|9837187|FG001|Overall Study|Blood sample not drawn|1
6184371|NCT01358864|9837201|FG000|Overall Study|Adverse Event|0
6184372|NCT01358864|9837202|FG001|Overall Study|Adverse Event|6
6184373|NCT01358864|9837203|FG002|Overall Study|Adverse Event|9
6184374|NCT01358864|9837204|FG003|Overall Study|Adverse Event|0
6184375|NCT01358864|9837205|FG004|Overall Study|Adverse Event|4
6184376|NCT01358864|9837206|FG005|Overall Study|Adverse Event|8
6184377|NCT01358864|9837207|FG006|Overall Study|Adverse Event|12
6184378|NCT01358864|9837208|FG007|Overall Study|Adverse Event|7
6184379|NCT01358864|9837201|FG000|Overall Study|Lack of Efficacy|26
6184380|NCT01358864|9837202|FG001|Overall Study|Lack of Efficacy|3
6184381|NCT01358864|9837203|FG002|Overall Study|Lack of Efficacy|4
6184382|NCT01358864|9837204|FG003|Overall Study|Lack of Efficacy|19
6184383|NCT01358864|9837205|FG004|Overall Study|Lack of Efficacy|7
6184384|NCT01358864|9837206|FG005|Overall Study|Lack of Efficacy|4
6184385|NCT01358864|9837207|FG006|Overall Study|Lack of Efficacy|49
6184386|NCT01358864|9837208|FG007|Overall Study|Lack of Efficacy|44
6184387|NCT01358864|9837201|FG000|Overall Study|Lost to Follow-up|0
6184388|NCT01358864|9837202|FG001|Overall Study|Lost to Follow-up|0
6184389|NCT01358864|9837203|FG002|Overall Study|Lost to Follow-up|1
6184390|NCT01358864|9837204|FG003|Overall Study|Lost to Follow-up|0
6184391|NCT01358864|9837205|FG004|Overall Study|Lost to Follow-up|0
6184392|NCT01358864|9837206|FG005|Overall Study|Lost to Follow-up|0
6184393|NCT01358864|9837207|FG006|Overall Study|Lost to Follow-up|0
6184394|NCT01358864|9837208|FG007|Overall Study|Lost to Follow-up|1
6184395|NCT01358864|9837201|FG000|Overall Study|Withdrawal by Subject|3
6184396|NCT01358864|9837202|FG001|Overall Study|Withdrawal by Subject|4
6184397|NCT01358864|9837203|FG002|Overall Study|Withdrawal by Subject|2
6184398|NCT01358864|9837204|FG003|Overall Study|Withdrawal by Subject|0
6184399|NCT01358864|9837205|FG004|Overall Study|Withdrawal by Subject|0
6184400|NCT01358864|9837206|FG005|Overall Study|Withdrawal by Subject|1
6184401|NCT01358864|9837207|FG006|Overall Study|Withdrawal by Subject|1
6184402|NCT01358864|9837208|FG007|Overall Study|Withdrawal by Subject|3
6184403|NCT01358864|9837201|FG000|Overall Study|Other reason not defined above|2
6184404|NCT01358864|9837202|FG001|Overall Study|Other reason not defined above|0
6184405|NCT01358864|9837203|FG002|Overall Study|Other reason not defined above|0
6184406|NCT01358864|9837204|FG003|Overall Study|Other reason not defined above|0
6184407|NCT01358864|9837205|FG004|Overall Study|Other reason not defined above|0
6184408|NCT01358864|9837206|FG005|Overall Study|Other reason not defined above|0
6184409|NCT01358864|9837207|FG006|Overall Study|Other reason not defined above|2
6184410|NCT01358864|9837208|FG007|Overall Study|Other reason not defined above|0
6184411|NCT01358864|9837201|FG000|Overall Study|Not treated|0
6184412|NCT01358864|9837202|FG001|Overall Study|Not treated|0
6184413|NCT01358864|9837203|FG002|Overall Study|Not treated|0
6184414|NCT01358864|9837204|FG003|Overall Study|Not treated|0
6184415|NCT01358864|9837205|FG004|Overall Study|Not treated|0
6184416|NCT01358864|9837206|FG005|Overall Study|Not treated|0
6184417|NCT01358864|9837207|FG006|Overall Study|Not treated|1
6184418|NCT01358864|9837208|FG007|Overall Study|Not treated|0
6184419|NCT01358968|9837228|FG000|Period 2|Adverse Event|0
6184420|NCT01358968|9837229|FG001|Period 2|Adverse Event|1
6184421|NCT01358968|9837230|FG002|Period 2|Adverse Event|0
6184422|NCT01358968|9837231|FG003|Period 2|Adverse Event|0
6184423|NCT01358968|9837228|FG000|Continued Access Phase|Progression of Disease|0
6184424|NCT01358968|9837229|FG001|Continued Access Phase|Progression of Disease|0
6184425|NCT01358968|9837230|FG002|Continued Access Phase|Progression of Disease|8
6184426|NCT01358968|9837231|FG003|Continued Access Phase|Progression of Disease|4
6184427|NCT01358968|9837228|FG000|Continued Access Phase|Protocol Violation|0
6184428|NCT01358968|9837229|FG001|Continued Access Phase|Protocol Violation|0
6184429|NCT01358968|9837230|FG002|Continued Access Phase|Protocol Violation|0
6184430|NCT01358968|9837231|FG003|Continued Access Phase|Protocol Violation|2
6184431|NCT01358968|9837228|FG000|Continued Access Phase|Withdrawal by Subject|0
6184432|NCT01358968|9837229|FG001|Continued Access Phase|Withdrawal by Subject|0
6184433|NCT01358968|9837230|FG002|Continued Access Phase|Withdrawal by Subject|3
6184434|NCT01358968|9837231|FG003|Continued Access Phase|Withdrawal by Subject|0
6184435|NCT01358968|9837228|FG000|Continued Access Phase|Death|0
6184436|NCT01358968|9837229|FG001|Continued Access Phase|Death|0
6184437|NCT01358968|9837230|FG002|Continued Access Phase|Death|1
6184438|NCT01358968|9837231|FG003|Continued Access Phase|Death|1
6184439|NCT01358981|9837248|FG000|Period 1|Withdrawal by Subject|0
6184440|NCT01358981|9837249|FG001|Period 1|Withdrawal by Subject|0
6184441|NCT01358981|9837250|FG002|Period 1|Withdrawal by Subject|0
6184442|NCT01358981|9837251|FG003|Period 1|Withdrawal by Subject|1
6184443|NCT01358981|9837252|FG004|Period 1|Withdrawal by Subject|0
6184444|NCT01358981|9837253|FG005|Period 1|Withdrawal by Subject|0
6184445|NCT01358981|9837254|FG006|Period 1|Withdrawal by Subject|0
6184446|NCT01359046|9837286|FG000|Overall Study|Did not receive allocated intervention|6
6184447|NCT01359046|9837287|FG001|Overall Study|Did not receive allocated intervention|6
6184448|NCT01359046|9837286|FG000|Overall Study|Physician Decision|1
6184449|NCT01359046|9837287|FG001|Overall Study|Physician Decision|11
6184450|NCT01359150|9837301|FG000|Overall Study|Lack of Efficacy|1
6184451|NCT01359150|9837302|FG001|Overall Study|Lack of Efficacy|1
6184452|NCT01359150|9837301|FG000|Overall Study|Withdrawal by Subject|1
6184453|NCT01359150|9837302|FG001|Overall Study|Withdrawal by Subject|1
6184454|NCT01359150|9837301|FG000|Overall Study|Adverse Event|4
6184455|NCT01359150|9837302|FG001|Overall Study|Adverse Event|3
6184456|NCT01359150|9837301|FG000|Overall Study|Other|1
6184457|NCT01359150|9837302|FG001|Overall Study|Other|0
6184458|NCT01359449|9837328|FG000|Overall Study|Lost to Follow-up|1
6184459|NCT01359449|9837329|FG001|Overall Study|Lost to Follow-up|0
6184460|NCT01359449|9837328|FG000|Overall Study|Protocol Violation|0
6184461|NCT01359449|9837329|FG001|Overall Study|Protocol Violation|2
6184462|NCT01359449|9837328|FG000|Overall Study|Withdrawal by Subject|3
6184463|NCT01359449|9837329|FG001|Overall Study|Withdrawal by Subject|2
6184464|NCT01359592|9837335|FG000|Initial Registration|Adverse Event|1
6184465|NCT01359592|9837336|FG001|Initial Registration|Adverse Event|0
6184466|NCT01359592|9837337|FG002|Initial Registration|Adverse Event|0
6184467|NCT01359592|9837338|FG003|Initial Registration|Adverse Event|0
6184468|NCT01359592|9837335|FG000|Initial Registration|Death|1
6184469|NCT01359592|9837336|FG001|Initial Registration|Death|0
6184470|NCT01359592|9837337|FG002|Initial Registration|Death|0
6184471|NCT01359592|9837338|FG003|Initial Registration|Death|0
6184472|NCT01359592|9837335|FG000|Initial Registration|Other reason not protocol specified|1
6184473|NCT01359592|9837336|FG001|Initial Registration|Other reason not protocol specified|0
6184474|NCT01359592|9837337|FG002|Initial Registration|Other reason not protocol specified|0
6184475|NCT01359592|9837338|FG003|Initial Registration|Other reason not protocol specified|0
6184476|NCT01359592|9837335|FG000|Initial Registration|Ineligible|26
6184477|NCT01359592|9837336|FG001|Initial Registration|Ineligible|0
6184478|NCT01359592|9837337|FG002|Initial Registration|Ineligible|0
6184479|NCT01359592|9837338|FG003|Initial Registration|Ineligible|0
6184480|NCT01359592|9837335|FG000|PET-Directed Therapy|Adverse Event|0
6184481|NCT01359592|9837336|FG001|PET-Directed Therapy|Adverse Event|0
6184482|NCT01359592|9837337|FG002|PET-Directed Therapy|Adverse Event|1
6184483|NCT01359592|9837338|FG003|PET-Directed Therapy|Adverse Event|0
6085343|NCT00651924|9694639|FG001|Overall Study|Withdrawal by Subject|5
6085344|NCT00651937|9694647|FG000|Overall Study|Withdrawal by Subject|4
6184484|NCT01359592|9837335|FG000|PET-Directed Therapy|Refusal unrelated to adverse event|0
6184485|NCT01359592|9837336|FG001|PET-Directed Therapy|Refusal unrelated to adverse event|0
6184486|NCT01359592|9837337|FG002|PET-Directed Therapy|Refusal unrelated to adverse event|1
6184487|NCT01359592|9837338|FG003|PET-Directed Therapy|Refusal unrelated to adverse event|0
6085345|NCT00651937|9694648|FG001|Overall Study|Withdrawal by Subject|1
6085346|NCT00652028|9694658|FG000|Overall Study|Adverse Event|1
6085347|NCT00652028|9694659|FG001|Overall Study|Adverse Event|0
6085348|NCT00652028|9694660|FG002|Overall Study|Adverse Event|0
6085349|NCT00652028|9694661|FG003|Overall Study|Adverse Event|0
6085350|NCT00652028|9694658|FG000|Overall Study|No Longer Meets Entry Criteria|0
6085351|NCT00652028|9694659|FG001|Overall Study|No Longer Meets Entry Criteria|1
6085352|NCT00652028|9694660|FG002|Overall Study|No Longer Meets Entry Criteria|0
6085353|NCT00652028|9694661|FG003|Overall Study|No Longer Meets Entry Criteria|0
6085354|NCT00652028|9694658|FG000|Overall Study|Physician Decision|0
6085355|NCT00652028|9694659|FG001|Overall Study|Physician Decision|0
6184488|NCT01359592|9837335|FG000|PET-Directed Therapy|Ineligible|0
6184489|NCT01359592|9837336|FG001|PET-Directed Therapy|Ineligible|0
6184490|NCT01359592|9837337|FG002|PET-Directed Therapy|Ineligible|24
6184491|NCT01359592|9837338|FG003|PET-Directed Therapy|Ineligible|0
6184492|NCT01359644|9837363|FG000|Treatment Period|Lack of Efficacy|0
6184493|NCT01359644|9837364|FG001|Treatment Period|Lack of Efficacy|1
6184494|NCT01359644|9837365|FG002|Treatment Period|Lack of Efficacy|0
6184495|NCT01359644|9837366|FG003|Treatment Period|Lack of Efficacy|0
6184496|NCT01359644|9837367|FG004|Treatment Period|Lack of Efficacy|0
6184497|NCT01359644|9837368|FG005|Treatment Period|Lack of Efficacy|0
6184498|NCT01359644|9837369|FG006|Treatment Period|Lack of Efficacy|0
6184499|NCT01359644|9837370|FG007|Treatment Period|Lack of Efficacy|0
6184500|NCT01359644|9837371|FG008|Treatment Period|Lack of Efficacy|0
6184501|NCT01359644|9837372|FG009|Treatment Period|Lack of Efficacy|0
6184502|NCT01359644|9837363|FG000|Treatment Period|Adverse Event|0
6184503|NCT01359644|9837364|FG001|Treatment Period|Adverse Event|0
6184504|NCT01359644|9837365|FG002|Treatment Period|Adverse Event|1
6184505|NCT01359644|9837366|FG003|Treatment Period|Adverse Event|0
6085356|NCT00652028|9694660|FG002|Overall Study|Physician Decision|1
6085357|NCT00652028|9694661|FG003|Overall Study|Physician Decision|0
6184506|NCT01359644|9837367|FG004|Treatment Period|Adverse Event|0
6184507|NCT01359644|9837368|FG005|Treatment Period|Adverse Event|1
6184508|NCT01359644|9837369|FG006|Treatment Period|Adverse Event|0
6184509|NCT01359644|9837370|FG007|Treatment Period|Adverse Event|0
6184510|NCT01359644|9837371|FG008|Treatment Period|Adverse Event|0
6184511|NCT01359644|9837372|FG009|Treatment Period|Adverse Event|0
6184512|NCT01359644|9837363|FG000|Treatment Period|Lost to Follow-up|0
6184513|NCT01359644|9837364|FG001|Treatment Period|Lost to Follow-up|0
6184514|NCT01359644|9837365|FG002|Treatment Period|Lost to Follow-up|0
6184515|NCT01359644|9837366|FG003|Treatment Period|Lost to Follow-up|0
6184516|NCT01359644|9837367|FG004|Treatment Period|Lost to Follow-up|0
6184517|NCT01359644|9837368|FG005|Treatment Period|Lost to Follow-up|1
6184518|NCT01359644|9837369|FG006|Treatment Period|Lost to Follow-up|0
6184519|NCT01359644|9837370|FG007|Treatment Period|Lost to Follow-up|0
6184520|NCT01359644|9837371|FG008|Treatment Period|Lost to Follow-up|0
6184521|NCT01359644|9837372|FG009|Treatment Period|Lost to Follow-up|0
6184522|NCT01359644|9837363|FG000|Follow-up Period|Withdrawal by Subject|0
6184523|NCT01359644|9837364|FG001|Follow-up Period|Withdrawal by Subject|0
6184524|NCT01359644|9837365|FG002|Follow-up Period|Withdrawal by Subject|0
6184525|NCT01359644|9837366|FG003|Follow-up Period|Withdrawal by Subject|0
6184526|NCT01359644|9837367|FG004|Follow-up Period|Withdrawal by Subject|0
6184527|NCT01359644|9837368|FG005|Follow-up Period|Withdrawal by Subject|1
6184528|NCT01359644|9837369|FG006|Follow-up Period|Withdrawal by Subject|0
6184529|NCT01359644|9837370|FG007|Follow-up Period|Withdrawal by Subject|0
6184530|NCT01359644|9837371|FG008|Follow-up Period|Withdrawal by Subject|0
6184531|NCT01359644|9837372|FG009|Follow-up Period|Withdrawal by Subject|0
6184532|NCT01359644|9837363|FG000|Follow-up Period|Lost to Follow-up|0
6184533|NCT01359644|9837364|FG001|Follow-up Period|Lost to Follow-up|0
6184534|NCT01359644|9837365|FG002|Follow-up Period|Lost to Follow-up|0
6184535|NCT01359644|9837366|FG003|Follow-up Period|Lost to Follow-up|0
6184536|NCT01359644|9837367|FG004|Follow-up Period|Lost to Follow-up|0
6184537|NCT01359644|9837368|FG005|Follow-up Period|Lost to Follow-up|0
6184538|NCT01359644|9837369|FG006|Follow-up Period|Lost to Follow-up|1
6184539|NCT01359644|9837370|FG007|Follow-up Period|Lost to Follow-up|2
6184540|NCT01359644|9837371|FG008|Follow-up Period|Lost to Follow-up|0
6184541|NCT01359644|9837372|FG009|Follow-up Period|Lost to Follow-up|0
6184542|NCT01359904|9837431|FG000|Overall Study|Withdrawal by Subject|1
6184543|NCT01359904|9837432|FG001|Overall Study|Withdrawal by Subject|0
6184544|NCT01359943|9837441|FG000|Double-blind (Weeks 0 - 16)|Abnormal laboratory values|1
6184545|NCT01359943|9837442|FG001|Double-blind (Weeks 0 - 16)|Abnormal laboratory values|0
6184546|NCT01359943|9837443|FG002|Double-blind (Weeks 0 - 16)|Abnormal laboratory values|0
6184547|NCT01359943|9837441|FG000|Double-blind (Weeks 0 - 16)|Adverse Event|1
6184548|NCT01359943|9837442|FG001|Double-blind (Weeks 0 - 16)|Adverse Event|2
6184549|NCT01359943|9837443|FG002|Double-blind (Weeks 0 - 16)|Adverse Event|0
6184550|NCT01359943|9837441|FG000|Double-blind (Weeks 0 - 16)|Withdrawal by Subject|0
6184551|NCT01359943|9837442|FG001|Double-blind (Weeks 0 - 16)|Withdrawal by Subject|2
6184552|NCT01359943|9837443|FG002|Double-blind (Weeks 0 - 16)|Withdrawal by Subject|0
6184553|NCT01359943|9837441|FG000|Open Label 150 mg s.c. (Weeks 16 - 52)|Administrative problems|1
6184554|NCT01359943|9837442|FG001|Open Label 150 mg s.c. (Weeks 16 - 52)|Administrative problems|0
6184555|NCT01359943|9837443|FG002|Open Label 150 mg s.c. (Weeks 16 - 52)|Administrative problems|0
6184556|NCT01359943|9837441|FG000|Open Label 150 mg s.c. (Weeks 16 - 52)|Withdrawal by Subject|1
6184557|NCT01359943|9837442|FG001|Open Label 150 mg s.c. (Weeks 16 - 52)|Withdrawal by Subject|3
6085358|NCT00652093|9694683|FG000|Overall Study|Withdrawal by Subject|0
6085359|NCT00652093|9694684|FG001|Overall Study|Withdrawal by Subject|0
6085360|NCT00652093|9694685|FG002|Overall Study|Withdrawal by Subject|1
6085361|NCT00652093|9694686|FG003|Overall Study|Withdrawal by Subject|0
6085362|NCT00652093|9694687|FG004|Overall Study|Withdrawal by Subject|1
6184558|NCT01359943|9837443|FG002|Open Label 150 mg s.c. (Weeks 16 - 52)|Withdrawal by Subject|4
6184559|NCT01359943|9837441|FG000|Open Label 150 mg s.c. (Weeks 16 - 52)|Protocol deviation|0
6184560|NCT01359943|9837442|FG001|Open Label 150 mg s.c. (Weeks 16 - 52)|Protocol deviation|1
6184561|NCT01359943|9837443|FG002|Open Label 150 mg s.c. (Weeks 16 - 52)|Protocol deviation|0
6184562|NCT01359943|9837441|FG000|Open Label 150 mg s.c. (Weeks 16 - 52)|Lack of Efficacy|3
6184563|NCT01359943|9837442|FG001|Open Label 150 mg s.c. (Weeks 16 - 52)|Lack of Efficacy|3
6184564|NCT01359943|9837443|FG002|Open Label 150 mg s.c. (Weeks 16 - 52)|Lack of Efficacy|3
6184565|NCT01359943|9837441|FG000|Open Label 150 mg s.c. (Weeks 16 - 52)|Abnormal laboratory values|0
6184566|NCT01359943|9837442|FG001|Open Label 150 mg s.c. (Weeks 16 - 52)|Abnormal laboratory values|1
6184567|NCT01359943|9837443|FG002|Open Label 150 mg s.c. (Weeks 16 - 52)|Abnormal laboratory values|0
6184568|NCT01359943|9837441|FG000|Open Label 150 mg s.c. (Weeks 16 - 52)|Adverse Event|3
6184569|NCT01359943|9837442|FG001|Open Label 150 mg s.c. (Weeks 16 - 52)|Adverse Event|5
6184570|NCT01359943|9837443|FG002|Open Label 150 mg s.c. (Weeks 16 - 52)|Adverse Event|1
6184571|NCT01359943|9837441|FG000|Follow-up (Weeks 52 - 60)|Withdrawal by Subject|1
6184572|NCT01359943|9837442|FG001|Follow-up (Weeks 52 - 60)|Withdrawal by Subject|5
6184573|NCT01359943|9837443|FG002|Follow-up (Weeks 52 - 60)|Withdrawal by Subject|4
6184574|NCT01359943|9837441|FG000|Follow-up (Weeks 52 - 60)|Administrative problems|1
6184575|NCT01359943|9837442|FG001|Follow-up (Weeks 52 - 60)|Administrative problems|0
6184576|NCT01359943|9837443|FG002|Follow-up (Weeks 52 - 60)|Administrative problems|0
6184577|NCT01359943|9837441|FG000|Follow-up (Weeks 52 - 60)|Protocol deviation|0
6184578|NCT01359943|9837442|FG001|Follow-up (Weeks 52 - 60)|Protocol deviation|1
6184579|NCT01359943|9837443|FG002|Follow-up (Weeks 52 - 60)|Protocol deviation|0
6228117|NCT01723163|9901320|FG001|Treatment Phase|Withdrawal by PI|1
6228118|NCT01723163|9901319|FG000|3-Month Follow-up|Withdrawal by Subject|1
6184580|NCT01359943|9837441|FG000|Follow-up (Weeks 52 - 60)|Lack of Efficacy|3
6184581|NCT01359943|9837442|FG001|Follow-up (Weeks 52 - 60)|Lack of Efficacy|3
6184582|NCT01359943|9837443|FG002|Follow-up (Weeks 52 - 60)|Lack of Efficacy|3
6184583|NCT01359943|9837441|FG000|Follow-up (Weeks 52 - 60)|Abnormal laboratory value|0
6184584|NCT01359943|9837442|FG001|Follow-up (Weeks 52 - 60)|Abnormal laboratory value|1
6184585|NCT01359943|9837443|FG002|Follow-up (Weeks 52 - 60)|Abnormal laboratory value|0
6184586|NCT01359943|9837441|FG000|Follow-up (Weeks 52 - 60)|Adverse Event|3
6184587|NCT01359943|9837442|FG001|Follow-up (Weeks 52 - 60)|Adverse Event|5
6184588|NCT01359943|9837443|FG002|Follow-up (Weeks 52 - 60)|Adverse Event|1
6184589|NCT01359956|9837457|FG000|Overall Study|Death|61
6184590|NCT01359956|9837458|FG001|Overall Study|Death|64
6184591|NCT01359956|9837459|FG002|Overall Study|Death|67
6184592|NCT01359956|9837460|FG003|Overall Study|Death|58
6184593|NCT01360021|9837473|FG000|Overall Study|Eligibility criteria + other|2
6184594|NCT01360021|9837474|FG001|Overall Study|Eligibility criteria + other|1
6184595|NCT01360021|9837475|FG002|Overall Study|Eligibility criteria + other|1
6184596|NCT01360021|9837473|FG000|Overall Study|Protocol Violation|0
6184597|NCT01360021|9837474|FG001|Overall Study|Protocol Violation|0
6184598|NCT01360021|9837475|FG002|Overall Study|Protocol Violation|1
6184599|NCT01360021|9837473|FG000|Overall Study|Withdrawal by Subject|4
6184600|NCT01360021|9837474|FG001|Overall Study|Withdrawal by Subject|0
6184601|NCT01360021|9837475|FG002|Overall Study|Withdrawal by Subject|2
6184602|NCT01360021|9837473|FG000|Overall Study|Adverse Event|2
6184603|NCT01360021|9837474|FG001|Overall Study|Adverse Event|3
6184604|NCT01360021|9837475|FG002|Overall Study|Adverse Event|3
6184605|NCT01360398|9837492|FG000|Overall Study|Withdrawal by Subject|14
6184606|NCT01360398|9837492|FG000|Overall Study|Other|7
6184607|NCT01360398|9837492|FG000|Overall Study|Migrated/moved from study area|1
6184608|NCT01360554|9837508|FG000|Overall Study|Death|359
6184609|NCT01360554|9837509|FG001|Overall Study|Death|371
6184610|NCT01360554|9837508|FG000|Overall Study|Lost to Follow-up|4
6184611|NCT01360554|9837509|FG001|Overall Study|Lost to Follow-up|4
6184612|NCT01360554|9837508|FG000|Overall Study|Withdrawal by Subject|23
6184613|NCT01360554|9837509|FG001|Overall Study|Withdrawal by Subject|24
6184614|NCT01360554|9837508|FG000|Overall Study|Study terminated by sponsor|49
6184615|NCT01360554|9837509|FG001|Overall Study|Study terminated by sponsor|37
6184616|NCT01360554|9837508|FG000|Overall Study|Other, not specified|1
6184617|NCT01360554|9837509|FG001|Overall Study|Other, not specified|0
6184618|NCT01360554|9837508|FG000|Overall Study|Randomized but not treated.|3
6184619|NCT01360554|9837509|FG001|Overall Study|Randomized but not treated.|3
6184620|NCT01360632|9837518|FG000|Phase A (8 Weeks)|Lost to Follow-up|27
6184621|NCT01360632|9837519|FG001|Phase A (8 Weeks)|Lost to Follow-up|0
6184622|NCT01360632|9837520|FG002|Phase A (8 Weeks)|Lost to Follow-up|0
6184623|NCT01360632|9837521|FG003|Phase A (8 Weeks)|Lost to Follow-up|0
6184624|NCT01360632|9837522|FG004|Phase A (8 Weeks)|Lost to Follow-up|0
6184625|NCT01360632|9837518|FG000|Phase A (8 Weeks)|Adverse Event|60
6184626|NCT01360632|9837519|FG001|Phase A (8 Weeks)|Adverse Event|0
6184627|NCT01360632|9837520|FG002|Phase A (8 Weeks)|Adverse Event|0
6184628|NCT01360632|9837521|FG003|Phase A (8 Weeks)|Adverse Event|0
6184629|NCT01360632|9837522|FG004|Phase A (8 Weeks)|Adverse Event|0
6184630|NCT01360632|9837518|FG000|Phase A (8 Weeks)|Met Withdrawal Criteria|45
6184631|NCT01360632|9837519|FG001|Phase A (8 Weeks)|Met Withdrawal Criteria|0
6184632|NCT01360632|9837520|FG002|Phase A (8 Weeks)|Met Withdrawal Criteria|0
6184633|NCT01360632|9837521|FG003|Phase A (8 Weeks)|Met Withdrawal Criteria|0
6184634|NCT01360632|9837522|FG004|Phase A (8 Weeks)|Met Withdrawal Criteria|0
6184635|NCT01360632|9837518|FG000|Phase A (8 Weeks)|Physician Decision|10
6184636|NCT01360632|9837519|FG001|Phase A (8 Weeks)|Physician Decision|0
6184637|NCT01360632|9837520|FG002|Phase A (8 Weeks)|Physician Decision|0
6184638|NCT01360632|9837521|FG003|Phase A (8 Weeks)|Physician Decision|0
6184639|NCT01360632|9837522|FG004|Phase A (8 Weeks)|Physician Decision|0
6184640|NCT01360632|9837518|FG000|Phase A (8 Weeks)|Withdrawal by Subject|74
6184641|NCT01360632|9837519|FG001|Phase A (8 Weeks)|Withdrawal by Subject|0
6184642|NCT01360632|9837520|FG002|Phase A (8 Weeks)|Withdrawal by Subject|0
6184643|NCT01360632|9837521|FG003|Phase A (8 Weeks)|Withdrawal by Subject|0
6184644|NCT01360632|9837522|FG004|Phase A (8 Weeks)|Withdrawal by Subject|0
6184645|NCT01360632|9837518|FG000|Phase A (8 Weeks)|Protocol Deviation|39
6184646|NCT01360632|9837519|FG001|Phase A (8 Weeks)|Protocol Deviation|0
6184647|NCT01360632|9837520|FG002|Phase A (8 Weeks)|Protocol Deviation|0
6184648|NCT01360632|9837521|FG003|Phase A (8 Weeks)|Protocol Deviation|0
6184649|NCT01360632|9837522|FG004|Phase A (8 Weeks)|Protocol Deviation|0
6184650|NCT01360632|9837518|FG000|Phase B (6 Weeks)|Lost to Follow-up|0
6184651|NCT01360632|9837519|FG001|Phase B (6 Weeks)|Lost to Follow-up|1
6184652|NCT01360632|9837520|FG002|Phase B (6 Weeks)|Lost to Follow-up|1
6184653|NCT01360632|9837521|FG003|Phase B (6 Weeks)|Lost to Follow-up|0
6184654|NCT01360632|9837522|FG004|Phase B (6 Weeks)|Lost to Follow-up|0
6184655|NCT01360632|9837518|FG000|Phase B (6 Weeks)|Adverse Event|0
6184656|NCT01360632|9837519|FG001|Phase B (6 Weeks)|Adverse Event|3
6184657|NCT01360632|9837520|FG002|Phase B (6 Weeks)|Adverse Event|9
6184658|NCT01360632|9837521|FG003|Phase B (6 Weeks)|Adverse Event|3
6184659|NCT01360632|9837522|FG004|Phase B (6 Weeks)|Adverse Event|0
6184660|NCT01360632|9837518|FG000|Phase B (6 Weeks)|Met Withdrawal Criteria|0
6184661|NCT01360632|9837519|FG001|Phase B (6 Weeks)|Met Withdrawal Criteria|0
6184662|NCT01360632|9837520|FG002|Phase B (6 Weeks)|Met Withdrawal Criteria|2
6184663|NCT01360632|9837521|FG003|Phase B (6 Weeks)|Met Withdrawal Criteria|1
6184664|NCT01360632|9837522|FG004|Phase B (6 Weeks)|Met Withdrawal Criteria|0
6184665|NCT01360632|9837518|FG000|Phase B (6 Weeks)|Physician Decision|0
6184666|NCT01360632|9837519|FG001|Phase B (6 Weeks)|Physician Decision|0
6184667|NCT01360632|9837520|FG002|Phase B (6 Weeks)|Physician Decision|0
6184668|NCT01360632|9837521|FG003|Phase B (6 Weeks)|Physician Decision|1
6184669|NCT01360632|9837522|FG004|Phase B (6 Weeks)|Physician Decision|0
6184670|NCT01360632|9837518|FG000|Phase B (6 Weeks)|Withdrawal by Subject|0
6085363|NCT00652093|9694688|FG005|Overall Study|Withdrawal by Subject|0
6085364|NCT00652093|9694683|FG000|Overall Study|Physician Decision|0
6085365|NCT00652093|9694684|FG001|Overall Study|Physician Decision|0
6085366|NCT00652093|9694685|FG002|Overall Study|Physician Decision|0
6085367|NCT00652093|9694686|FG003|Overall Study|Physician Decision|0
6085368|NCT00652093|9694687|FG004|Overall Study|Physician Decision|1
6085369|NCT00652093|9694688|FG005|Overall Study|Physician Decision|0
6085370|NCT00652340|9694724|FG000|Overall Study|Had not progressed.|4
6184671|NCT01360632|9837519|FG001|Phase B (6 Weeks)|Withdrawal by Subject|4
6184672|NCT01360632|9837520|FG002|Phase B (6 Weeks)|Withdrawal by Subject|4
6184673|NCT01360632|9837521|FG003|Phase B (6 Weeks)|Withdrawal by Subject|7
6184674|NCT01360632|9837522|FG004|Phase B (6 Weeks)|Withdrawal by Subject|0
6184675|NCT01360632|9837518|FG000|Phase B (6 Weeks)|Protocol Deviation|0
6184676|NCT01360632|9837519|FG001|Phase B (6 Weeks)|Protocol Deviation|1
6184677|NCT01360632|9837520|FG002|Phase B (6 Weeks)|Protocol Deviation|4
6184678|NCT01360632|9837521|FG003|Phase B (6 Weeks)|Protocol Deviation|1
6184679|NCT01360632|9837522|FG004|Phase B (6 Weeks)|Protocol Deviation|0
6184680|NCT01360632|9837518|FG000|Phase B (6 Weeks)|Lack of Efficacy|0
6184681|NCT01360632|9837519|FG001|Phase B (6 Weeks)|Lack of Efficacy|1
6184682|NCT01360632|9837520|FG002|Phase B (6 Weeks)|Lack of Efficacy|0
6184683|NCT01360632|9837521|FG003|Phase B (6 Weeks)|Lack of Efficacy|0
6184684|NCT01360632|9837522|FG004|Phase B (6 Weeks)|Lack of Efficacy|0
6184685|NCT01360632|9837518|FG000|Phase A+|Lost to Follow-up|0
6184686|NCT01360632|9837519|FG001|Phase A+|Lost to Follow-up|0
6184687|NCT01360632|9837520|FG002|Phase A+|Lost to Follow-up|0
6184688|NCT01360632|9837521|FG003|Phase A+|Lost to Follow-up|0
6184689|NCT01360632|9837522|FG004|Phase A+|Lost to Follow-up|2
6184690|NCT01360632|9837518|FG000|Phase A+|Adverse Event|0
6184691|NCT01360632|9837519|FG001|Phase A+|Adverse Event|0
6184692|NCT01360632|9837520|FG002|Phase A+|Adverse Event|0
6184693|NCT01360632|9837521|FG003|Phase A+|Adverse Event|0
6184694|NCT01360632|9837522|FG004|Phase A+|Adverse Event|2
6184695|NCT01360632|9837518|FG000|Phase A+|Met Withdrawal Criteria|0
6184696|NCT01360632|9837519|FG001|Phase A+|Met Withdrawal Criteria|0
6184697|NCT01360632|9837520|FG002|Phase A+|Met Withdrawal Criteria|0
6184698|NCT01360632|9837521|FG003|Phase A+|Met Withdrawal Criteria|0
6184699|NCT01360632|9837522|FG004|Phase A+|Met Withdrawal Criteria|7
6184700|NCT01360632|9837518|FG000|Phase A+|Physician Decision|0
6184701|NCT01360632|9837519|FG001|Phase A+|Physician Decision|0
6184702|NCT01360632|9837520|FG002|Phase A+|Physician Decision|0
6184703|NCT01360632|9837521|FG003|Phase A+|Physician Decision|0
6184704|NCT01360632|9837522|FG004|Phase A+|Physician Decision|3
6184705|NCT01360632|9837518|FG000|Phase A+|Withdrawal by Subject|0
6184706|NCT01360632|9837519|FG001|Phase A+|Withdrawal by Subject|0
6184707|NCT01360632|9837520|FG002|Phase A+|Withdrawal by Subject|0
6184708|NCT01360632|9837521|FG003|Phase A+|Withdrawal by Subject|0
6184709|NCT01360632|9837522|FG004|Phase A+|Withdrawal by Subject|8
6184710|NCT01360632|9837518|FG000|Phase A+|Protocol Deviation|0
6184711|NCT01360632|9837519|FG001|Phase A+|Protocol Deviation|0
6184712|NCT01360632|9837520|FG002|Phase A+|Protocol Deviation|0
6184713|NCT01360632|9837521|FG003|Phase A+|Protocol Deviation|0
6184714|NCT01360632|9837522|FG004|Phase A+|Protocol Deviation|3
6184715|NCT01360645|9837532|FG000|Placebo+ADT Prospective Phase-A(8 Weeks)|Lost to Follow-up|16
6184716|NCT01360645|9837533|FG001|Placebo+ADT Prospective Phase-A(8 Weeks)|Lost to Follow-up|0
6184717|NCT01360645|9837534|FG002|Placebo+ADT Prospective Phase-A(8 Weeks)|Lost to Follow-up|0
6184718|NCT01360645|9837535|FG003|Placebo+ADT Prospective Phase-A(8 Weeks)|Lost to Follow-up|0
6184719|NCT01360645|9837532|FG000|Placebo+ADT Prospective Phase-A(8 Weeks)|Adverse Event|19
6184720|NCT01360645|9837533|FG001|Placebo+ADT Prospective Phase-A(8 Weeks)|Adverse Event|0
6085371|NCT00652340|9694725|FG001|Overall Study|Had not progressed.|3
6085372|NCT00652366|9694736|FG000|Overall Study|Adverse Event|8
6085373|NCT00652366|9694737|FG001|Overall Study|Adverse Event|4
6085374|NCT00652366|9694738|FG002|Overall Study|Adverse Event|7
6184721|NCT01360645|9837534|FG002|Placebo+ADT Prospective Phase-A(8 Weeks)|Adverse Event|0
6184722|NCT01360645|9837535|FG003|Placebo+ADT Prospective Phase-A(8 Weeks)|Adverse Event|0
6184723|NCT01360645|9837532|FG000|Placebo+ADT Prospective Phase-A(8 Weeks)|Met Withdrawal Criteria|16
6184724|NCT01360645|9837533|FG001|Placebo+ADT Prospective Phase-A(8 Weeks)|Met Withdrawal Criteria|0
6228119|NCT01723163|9901320|FG001|3-Month Follow-up|Withdrawal by Subject|0
6184725|NCT01360645|9837534|FG002|Placebo+ADT Prospective Phase-A(8 Weeks)|Met Withdrawal Criteria|0
6184726|NCT01360645|9837535|FG003|Placebo+ADT Prospective Phase-A(8 Weeks)|Met Withdrawal Criteria|0
6184727|NCT01360645|9837532|FG000|Placebo+ADT Prospective Phase-A(8 Weeks)|Withdrawal by Subject|34
6228120|NCT01723163|9901319|FG000|3-Month Follow-up|Unable to Contact|12
6085375|NCT00652366|9694739|FG003|Overall Study|Adverse Event|17
6085376|NCT00652366|9694740|FG004|Overall Study|Adverse Event|13
6184728|NCT01360645|9837533|FG001|Placebo+ADT Prospective Phase-A(8 Weeks)|Withdrawal by Subject|0
6184729|NCT01360645|9837534|FG002|Placebo+ADT Prospective Phase-A(8 Weeks)|Withdrawal by Subject|0
6184730|NCT01360645|9837535|FG003|Placebo+ADT Prospective Phase-A(8 Weeks)|Withdrawal by Subject|0
6184731|NCT01360645|9837532|FG000|Placebo+ADT Prospective Phase-A(8 Weeks)|Protocol Deviation|24
6184732|NCT01360645|9837533|FG001|Placebo+ADT Prospective Phase-A(8 Weeks)|Protocol Deviation|0
6184733|NCT01360645|9837534|FG002|Placebo+ADT Prospective Phase-A(8 Weeks)|Protocol Deviation|0
6184734|NCT01360645|9837535|FG003|Placebo+ADT Prospective Phase-A(8 Weeks)|Protocol Deviation|0
6184735|NCT01360645|9837532|FG000|Placebo+ADT Prospective Phase-A(8 Weeks)|Physician Decision|5
6184736|NCT01360645|9837533|FG001|Placebo+ADT Prospective Phase-A(8 Weeks)|Physician Decision|0
6184737|NCT01360645|9837534|FG002|Placebo+ADT Prospective Phase-A(8 Weeks)|Physician Decision|0
6184738|NCT01360645|9837535|FG003|Placebo+ADT Prospective Phase-A(8 Weeks)|Physician Decision|0
6184739|NCT01360645|9837532|FG000|Phase B (6 Weeks)|Lost to Follow-up|0
6085377|NCT00652366|9694736|FG000|Overall Study|Death|5
6085378|NCT00652366|9694737|FG001|Overall Study|Death|4
6085379|NCT00652366|9694738|FG002|Overall Study|Death|1
6085380|NCT00652366|9694739|FG003|Overall Study|Death|8
6085381|NCT00652366|9694740|FG004|Overall Study|Death|5
6184740|NCT01360645|9837533|FG001|Phase B (6 Weeks)|Lost to Follow-up|1
6184741|NCT01360645|9837534|FG002|Phase B (6 Weeks)|Lost to Follow-up|0
6184742|NCT01360645|9837535|FG003|Phase B (6 Weeks)|Lost to Follow-up|0
6184743|NCT01360645|9837532|FG000|Phase B (6 Weeks)|Adverse Event|0
6184744|NCT01360645|9837533|FG001|Phase B (6 Weeks)|Adverse Event|6
6184745|NCT01360645|9837534|FG002|Phase B (6 Weeks)|Adverse Event|0
6184746|NCT01360645|9837535|FG003|Phase B (6 Weeks)|Adverse Event|0
6184747|NCT01360645|9837532|FG000|Phase B (6 Weeks)|Met Withdrawal Criteria|0
6184748|NCT01360645|9837533|FG001|Phase B (6 Weeks)|Met Withdrawal Criteria|3
6184749|NCT01360645|9837534|FG002|Phase B (6 Weeks)|Met Withdrawal Criteria|2
6184750|NCT01360645|9837535|FG003|Phase B (6 Weeks)|Met Withdrawal Criteria|0
6184751|NCT01360645|9837532|FG000|Phase B (6 Weeks)|Withdrawal by Subject|0
6184752|NCT01360645|9837533|FG001|Phase B (6 Weeks)|Withdrawal by Subject|3
6184753|NCT01360645|9837534|FG002|Phase B (6 Weeks)|Withdrawal by Subject|8
6184754|NCT01360645|9837535|FG003|Phase B (6 Weeks)|Withdrawal by Subject|0
6184755|NCT01360645|9837532|FG000|Phase B (6 Weeks)|Protocol Deviation|0
6184756|NCT01360645|9837533|FG001|Phase B (6 Weeks)|Protocol Deviation|1
6184757|NCT01360645|9837534|FG002|Phase B (6 Weeks)|Protocol Deviation|3
6184758|NCT01360645|9837535|FG003|Phase B (6 Weeks)|Protocol Deviation|0
6184759|NCT01360645|9837532|FG000|Phase A+|Lost to Follow-up|0
6184760|NCT01360645|9837533|FG001|Phase A+|Lost to Follow-up|0
6184761|NCT01360645|9837534|FG002|Phase A+|Lost to Follow-up|0
6184762|NCT01360645|9837535|FG003|Phase A+|Lost to Follow-up|7
6184763|NCT01360645|9837532|FG000|Phase A+|Adverse Event|0
6184764|NCT01360645|9837533|FG001|Phase A+|Adverse Event|0
6184765|NCT01360645|9837534|FG002|Phase A+|Adverse Event|0
6184766|NCT01360645|9837535|FG003|Phase A+|Adverse Event|2
6184767|NCT01360645|9837532|FG000|Phase A+|Met Withdrawal Criteria|0
6184768|NCT01360645|9837533|FG001|Phase A+|Met Withdrawal Criteria|0
6184769|NCT01360645|9837534|FG002|Phase A+|Met Withdrawal Criteria|0
6184770|NCT01360645|9837535|FG003|Phase A+|Met Withdrawal Criteria|4
6184771|NCT01360645|9837532|FG000|Phase A+|Physician Decision|0
6184772|NCT01360645|9837533|FG001|Phase A+|Physician Decision|0
6184773|NCT01360645|9837534|FG002|Phase A+|Physician Decision|0
6184774|NCT01360645|9837535|FG003|Phase A+|Physician Decision|2
6184775|NCT01360645|9837532|FG000|Phase A+|Withdrawal by Subject|0
6184776|NCT01360645|9837533|FG001|Phase A+|Withdrawal by Subject|0
6184777|NCT01360645|9837534|FG002|Phase A+|Withdrawal by Subject|0
6184778|NCT01360645|9837535|FG003|Phase A+|Withdrawal by Subject|5
6184779|NCT01360645|9837532|FG000|Phase A+|Protocol Deviation|0
6184780|NCT01360645|9837533|FG001|Phase A+|Protocol Deviation|0
6184781|NCT01360645|9837534|FG002|Phase A+|Protocol Deviation|0
6184782|NCT01360645|9837535|FG003|Phase A+|Protocol Deviation|4
6184783|NCT01360762|9837541|FG000|Main Study Period (12-month Treatment)|Lost to Follow-up|7
6184784|NCT01360762|9837541|FG000|Main Study Period (12-month Treatment)|Death|5
6184785|NCT01360762|9837541|FG000|Main Study Period (12-month Treatment)|Discontinuation of study drug for safety|1
6184786|NCT01360762|9837541|FG000|Main Study Period (12-month Treatment)|Patient relapsed|15
6184787|NCT01360762|9837541|FG000|Main Study Period (12-month Treatment)|Discontinuation|1
6184788|NCT01360762|9837541|FG000|Whole Study Period|Lost to Follow-up|10
6184789|NCT01360762|9837541|FG000|Whole Study Period|Death|7
6184790|NCT01360762|9837541|FG000|Whole Study Period|Patient relapsed|18
6184791|NCT01360762|9837541|FG000|Whole Study Period|Discontinuation of study drug for safety|1
6085382|NCT00652366|9694736|FG000|Overall Study|Lack of Efficacy|84
6085383|NCT00652366|9694737|FG001|Overall Study|Lack of Efficacy|58
6184792|NCT01360840|9837548|FG000|Overall Study|Ongoing at data cut-off|10
6184793|NCT01360840|9837549|FG001|Overall Study|Ongoing at data cut-off|10
6184794|NCT01360840|9837550|FG002|Overall Study|Ongoing at data cut-off|9
6184795|NCT01360866|9837564|FG000|Overall Study|Lost to Follow-up|11
6184796|NCT01360866|9837565|FG001|Overall Study|Lost to Follow-up|28
6184797|NCT01360866|9837566|FG002|Overall Study|Lost to Follow-up|41
6184798|NCT01360866|9837567|FG003|Overall Study|Lost to Follow-up|0
6184799|NCT01360866|9837564|FG000|Overall Study|Adverse Event|56
6184800|NCT01360866|9837565|FG001|Overall Study|Adverse Event|61
6184801|NCT01360866|9837566|FG002|Overall Study|Adverse Event|134
6184802|NCT01360866|9837567|FG003|Overall Study|Adverse Event|6
6184803|NCT01360866|9837564|FG000|Overall Study|Paticipant met withdrawal criteria|11
6184804|NCT01360866|9837565|FG001|Overall Study|Paticipant met withdrawal criteria|28
6184805|NCT01360866|9837566|FG002|Overall Study|Paticipant met withdrawal criteria|54
6184806|NCT01360866|9837567|FG003|Overall Study|Paticipant met withdrawal criteria|0
6184807|NCT01360866|9837564|FG000|Overall Study|Withdrawn by Investigator|9
6184808|NCT01360866|9837565|FG001|Overall Study|Withdrawn by Investigator|8
6184809|NCT01360866|9837566|FG002|Overall Study|Withdrawn by Investigator|31
6184810|NCT01360866|9837567|FG003|Overall Study|Withdrawn by Investigator|2
6184811|NCT01360866|9837564|FG000|Overall Study|Withdrawal by participant|79
6184812|NCT01360866|9837565|FG001|Overall Study|Withdrawal by participant|89
6184813|NCT01360866|9837566|FG002|Overall Study|Withdrawal by participant|168
6184814|NCT01360866|9837567|FG003|Overall Study|Withdrawal by participant|8
6184815|NCT01360866|9837564|FG000|Overall Study|Protocol Deviation|25
6184816|NCT01360866|9837565|FG001|Overall Study|Protocol Deviation|33
6184817|NCT01360866|9837566|FG002|Overall Study|Protocol Deviation|61
6184818|NCT01360866|9837567|FG003|Overall Study|Protocol Deviation|2
6184819|NCT01360866|9837564|FG000|Overall Study|Lack of Efficacy|30
6184820|NCT01360866|9837565|FG001|Overall Study|Lack of Efficacy|40
6184821|NCT01360866|9837566|FG002|Overall Study|Lack of Efficacy|30
6184822|NCT01360866|9837567|FG003|Overall Study|Lack of Efficacy|4
6184823|NCT01360996|9837580|FG000|Overall Study|Withdrawal by Subject|4
6184824|NCT01360996|9837581|FG001|Overall Study|Withdrawal by Subject|3
6184825|NCT01360996|9837582|FG002|Overall Study|Withdrawal by Subject|2
6184826|NCT01360996|9837580|FG000|Overall Study|Noncompliant|2
6184827|NCT01360996|9837581|FG001|Overall Study|Noncompliant|0
6184828|NCT01360996|9837582|FG002|Overall Study|Noncompliant|0
6184829|NCT01361009|9837589|FG000|Overall Study|Protocol Violation|116
6184830|NCT01361126|9837617|FG000|Overall Study|Sponsor decision|0
6184831|NCT01361126|9837618|FG001|Overall Study|Sponsor decision|2
6184832|NCT01361178|9837627|FG000|Overall Study|Death|13
6184833|NCT01361178|9837628|FG001|Overall Study|Death|0
6184834|NCT01361308|9837642|FG000|Overall Study|Withdrawal by Subject|9
6184835|NCT01361308|9837643|FG001|Overall Study|Withdrawal by Subject|13
6184836|NCT01361308|9837642|FG000|Overall Study|Physician Decision|3
6184837|NCT01361308|9837643|FG001|Overall Study|Physician Decision|3
6184838|NCT01361308|9837642|FG000|Overall Study|Lack of Efficacy|2
6184839|NCT01361308|9837643|FG001|Overall Study|Lack of Efficacy|0
6184840|NCT01361308|9837642|FG000|Overall Study|Protocol Violation|1
6184841|NCT01361308|9837643|FG001|Overall Study|Protocol Violation|0
6184842|NCT01361308|9837642|FG000|Overall Study|Lost to Follow-up|5
6184843|NCT01361308|9837643|FG001|Overall Study|Lost to Follow-up|4
6184844|NCT01361308|9837642|FG000|Overall Study|Adverse Event|8
6184845|NCT01361308|9837643|FG001|Overall Study|Adverse Event|4
6184846|NCT01361308|9837642|FG000|Overall Study|Eligibility Criteria Not Met|2
6184847|NCT01361308|9837643|FG001|Overall Study|Eligibility Criteria Not Met|3
6184848|NCT01361308|9837642|FG000|Overall Study|Failed C-SSRS|5
6184849|NCT01361308|9837643|FG001|Overall Study|Failed C-SSRS|2
6184850|NCT01361308|9837642|FG000|Overall Study|Other|0
6184851|NCT01361308|9837643|FG001|Overall Study|Other|1
6184852|NCT01361464|9837649|FG000|Overall Study|Death|1
6184853|NCT01361464|9837649|FG000|Overall Study|Withdrawal by Subject|2
6184854|NCT01361568|9837659|FG000|Overall Study|Adverse Event|0
6184855|NCT01361568|9837660|FG001|Overall Study|Adverse Event|0
6184856|NCT01361568|9837661|FG002|Overall Study|Adverse Event|0
6184857|NCT01361568|9837662|FG003|Overall Study|Adverse Event|0
6184858|NCT01361568|9837663|FG004|Overall Study|Adverse Event|1
6184859|NCT01361568|9837664|FG005|Overall Study|Adverse Event|0
6184860|NCT01361568|9837659|FG000|Overall Study|Physician Decision|0
6184861|NCT01361568|9837660|FG001|Overall Study|Physician Decision|0
6184862|NCT01361568|9837661|FG002|Overall Study|Physician Decision|0
6184863|NCT01361568|9837662|FG003|Overall Study|Physician Decision|0
6184864|NCT01361568|9837663|FG004|Overall Study|Physician Decision|0
6184865|NCT01361568|9837664|FG005|Overall Study|Physician Decision|1
6184866|NCT01361568|9837659|FG000|Overall Study|Withdrawal by Subject|2
6184867|NCT01361568|9837660|FG001|Overall Study|Withdrawal by Subject|1
6184868|NCT01361568|9837661|FG002|Overall Study|Withdrawal by Subject|0
6184869|NCT01361568|9837662|FG003|Overall Study|Withdrawal by Subject|0
6184870|NCT01361568|9837663|FG004|Overall Study|Withdrawal by Subject|0
6184871|NCT01361568|9837664|FG005|Overall Study|Withdrawal by Subject|1
6184872|NCT01361594|9837681|FG000|Overall Study|Withdrawal by Subject|1
6184873|NCT01361594|9837682|FG001|Overall Study|Withdrawal by Subject|2
6184874|NCT01361607|9837690|FG000|Overall Study|Adverse Event|38
6184875|NCT01361607|9837691|FG001|Overall Study|Adverse Event|29
6184876|NCT01361607|9837690|FG000|Overall Study|Withdrawal by Subject|19
6184877|NCT01361607|9837691|FG001|Overall Study|Withdrawal by Subject|8
6184878|NCT01361607|9837690|FG000|Overall Study|Withdrawal by Investigator|5
6184879|NCT01361607|9837691|FG001|Overall Study|Withdrawal by Investigator|3
6184880|NCT01361607|9837690|FG000|Overall Study|Lost to Follow-up|1
6184881|NCT01361607|9837691|FG001|Overall Study|Lost to Follow-up|0
6184882|NCT01361607|9837690|FG000|Overall Study|Met Withdrawal Criteria|1
6184883|NCT01361607|9837691|FG001|Overall Study|Met Withdrawal Criteria|1
6192888|NCT01435356|9850546|FG000|Overall Study|Physician Decision|1
6192889|NCT01435356|9850547|FG001|Overall Study|Physician Decision|0
6192890|NCT01435356|9850546|FG000|Overall Study|Patient decision|3
6192891|NCT01435356|9850547|FG001|Overall Study|Patient decision|0
6192892|NCT01435356|9850546|FG000|Overall Study|Patient moved to another city|1
6192893|NCT01435356|9850547|FG001|Overall Study|Patient moved to another city|1
6192894|NCT01435382|9850557|FG000|Overall Study|Lost to Follow-up|1
6192895|NCT01435382|9850558|FG001|Overall Study|Lost to Follow-up|0
6192896|NCT01435382|9850559|FG002|Overall Study|Lost to Follow-up|1
6192897|NCT01435382|9850560|FG003|Overall Study|Lost to Follow-up|0
6192898|NCT01435382|9850557|FG000|Overall Study|Withdrawal by Subject|0
6192899|NCT01435382|9850558|FG001|Overall Study|Withdrawal by Subject|2
6192900|NCT01435382|9850559|FG002|Overall Study|Withdrawal by Subject|0
6192901|NCT01435382|9850560|FG003|Overall Study|Withdrawal by Subject|1
6192902|NCT01435460|9850578|FG000|Overall Study|Adverse Event|2
6192903|NCT01435460|9850579|FG001|Overall Study|Adverse Event|1
6192904|NCT01435460|9850578|FG000|Overall Study|Lost to Follow-up|6
6192905|NCT01435460|9850579|FG001|Overall Study|Lost to Follow-up|1
6192906|NCT01435460|9850578|FG000|Overall Study|Withdrawal by Subject|1
6192907|NCT01435460|9850579|FG001|Overall Study|Withdrawal by Subject|3
6192908|NCT01435460|9850578|FG000|Overall Study|Protocol Violation|0
6192909|NCT01435460|9850579|FG001|Overall Study|Protocol Violation|1
6192910|NCT01435460|9850578|FG000|Overall Study|Did not meet eligibility criteria|2
6192911|NCT01435460|9850579|FG001|Overall Study|Did not meet eligibility criteria|0
6192912|NCT01435577|9850596|FG000|Overall Study|Adverse Event|10
6192913|NCT01435577|9850597|FG001|Overall Study|Adverse Event|0
6192914|NCT01435577|9850596|FG000|Overall Study|Lack of Efficacy|7
6192915|NCT01435577|9850597|FG001|Overall Study|Lack of Efficacy|51
6192916|NCT01435577|9850596|FG000|Overall Study|Alternative treatment started|0
6192917|NCT01435577|9850597|FG001|Overall Study|Alternative treatment started|1
6192918|NCT01435616|9850618|FG000|Overall Study|Adverse Event|39
6192919|NCT01435616|9850619|FG001|Overall Study|Adverse Event|21
6192920|NCT01435616|9850618|FG000|Overall Study|Death|7
6192921|NCT01435616|9850619|FG001|Overall Study|Death|2
6192922|NCT01435616|9850618|FG000|Overall Study|Lost to Follow-up|22
6192923|NCT01435616|9850619|FG001|Overall Study|Lost to Follow-up|13
6192924|NCT01435616|9850618|FG000|Overall Study|Protocol Violation|16
6192925|NCT01435616|9850619|FG001|Overall Study|Protocol Violation|13
6192926|NCT01435616|9850618|FG000|Overall Study|Withdrawal by Subject|66
6192927|NCT01435616|9850619|FG001|Overall Study|Withdrawal by Subject|24
6192928|NCT01435616|9850618|FG000|Overall Study|Physician Decision|20
6192929|NCT01435616|9850619|FG001|Overall Study|Physician Decision|7
6192930|NCT01435616|9850618|FG000|Overall Study|Sponsor Decision|1
6192931|NCT01435616|9850619|FG001|Overall Study|Sponsor Decision|0
6192932|NCT01435655|9850627|FG000|Overall Study|Death|2
6192933|NCT01435655|9850627|FG000|Overall Study|Other|1
6192934|NCT01435759|9850636|FG000|Antidepressant Lead-in Phase|Adverse Event|40
6192935|NCT01435759|9850637|FG001|Antidepressant Lead-in Phase|Adverse Event|0
6192936|NCT01435759|9850638|FG002|Antidepressant Lead-in Phase|Adverse Event|0
6192937|NCT01435759|9850639|FG003|Antidepressant Lead-in Phase|Adverse Event|0
6192938|NCT01435759|9850640|FG004|Antidepressant Lead-in Phase|Adverse Event|0
6192939|NCT01435759|9850641|FG005|Antidepressant Lead-in Phase|Adverse Event|0
6192940|NCT01435759|9850636|FG000|Antidepressant Lead-in Phase|Protocol Violation|16
6192941|NCT01435759|9850637|FG001|Antidepressant Lead-in Phase|Protocol Violation|0
6192942|NCT01435759|9850638|FG002|Antidepressant Lead-in Phase|Protocol Violation|0
6192943|NCT01435759|9850639|FG003|Antidepressant Lead-in Phase|Protocol Violation|0
6192944|NCT01435759|9850640|FG004|Antidepressant Lead-in Phase|Protocol Violation|0
6192945|NCT01435759|9850641|FG005|Antidepressant Lead-in Phase|Protocol Violation|0
6192946|NCT01435759|9850636|FG000|Antidepressant Lead-in Phase|Withdrawal by Subject|74
6192947|NCT01435759|9850637|FG001|Antidepressant Lead-in Phase|Withdrawal by Subject|0
6192948|NCT01435759|9850638|FG002|Antidepressant Lead-in Phase|Withdrawal by Subject|0
6192949|NCT01435759|9850639|FG003|Antidepressant Lead-in Phase|Withdrawal by Subject|0
6192950|NCT01435759|9850640|FG004|Antidepressant Lead-in Phase|Withdrawal by Subject|0
6192951|NCT01435759|9850641|FG005|Antidepressant Lead-in Phase|Withdrawal by Subject|0
6192952|NCT01435759|9850636|FG000|Antidepressant Lead-in Phase|Lost to Follow-up|83
6192953|NCT01435759|9850637|FG001|Antidepressant Lead-in Phase|Lost to Follow-up|0
6192954|NCT01435759|9850638|FG002|Antidepressant Lead-in Phase|Lost to Follow-up|0
6192955|NCT01435759|9850639|FG003|Antidepressant Lead-in Phase|Lost to Follow-up|0
6192956|NCT01435759|9850640|FG004|Antidepressant Lead-in Phase|Lost to Follow-up|0
6192957|NCT01435759|9850641|FG005|Antidepressant Lead-in Phase|Lost to Follow-up|0
6192958|NCT01435759|9850636|FG000|Antidepressant Lead-in Phase|Met BP or Pulse Withdrawal Criteria|10
6192959|NCT01435759|9850637|FG001|Antidepressant Lead-in Phase|Met BP or Pulse Withdrawal Criteria|0
6192960|NCT01435759|9850638|FG002|Antidepressant Lead-in Phase|Met BP or Pulse Withdrawal Criteria|0
6184884|NCT01361711|9837713|FG000|Trial Entry (Registration)|Patient did not meet Protocol criteria for trial entry|1
6184885|NCT01361711|9837713|FG000|Week 9 Bone Marrow Response Assessment|Complete Remission in Week 8|1
6184886|NCT01361711|9837713|FG000|Continued Treatment After 9 Weeks|Complete Remission in Week 9|7
6184887|NCT01361711|9837713|FG000|Continued Treatment After 12 Weeks|Complete Remission in Week 12|2
6184888|NCT01361711|9837713|FG000|Continued Treatment After 12 Weeks|Progressive Disease at Week 11|1
6184889|NCT01361711|9837713|FG000|Completed Week 18 of Treatment|Complete Remission|2
6184890|NCT01361711|9837713|FG000|Completed Week 18 of Treatment|Other|9
6184891|NCT01361711|9837713|FG000|10 Year Follow-up|Still in follow-up|22
6184892|NCT01361711|9837713|FG000|10 Year Follow-up|Death|7
6184893|NCT01361711|9837713|FG000|10 Year Follow-up|Developed new cancer|1
6184894|NCT01361711|9837713|FG000|10 Year Follow-up|Lost to Follow-up|2
6184895|NCT01361711|9837713|FG000|10 Year Follow-up|New treatment started|6
6184896|NCT01361711|9837713|FG000|10 Year Follow-up|Progressive Disease and New treatment started|11
6184897|NCT01361711|9837713|FG000|10 Year Follow-up|Progressive Disease|1
6184898|NCT01361919|9837731|FG000|Overall Study|technical issues|10
6184899|NCT01361919|9837732|FG001|Overall Study|technical issues|12
6184900|NCT01361919|9837733|FG002|Overall Study|technical issues|10
6184901|NCT01362049|9837745|FG000|Follow-Up at 7 Weeks|Lost to Follow-up|3
6184902|NCT01362049|9837746|FG001|Follow-Up at 7 Weeks|Lost to Follow-up|3
6184903|NCT01362049|9837747|FG002|Follow-Up at 7 Weeks|Lost to Follow-up|2
6184904|NCT01362049|9837748|FG003|Follow-Up at 7 Weeks|Lost to Follow-up|1
6184905|NCT01362049|9837745|FG000|Follow-Up at 52 Weeks (12 Months)|Lost to Follow-up|5
6184906|NCT01362049|9837746|FG001|Follow-Up at 52 Weeks (12 Months)|Lost to Follow-up|3
6184907|NCT01362049|9837747|FG002|Follow-Up at 52 Weeks (12 Months)|Lost to Follow-up|2
6184908|NCT01362049|9837748|FG003|Follow-Up at 52 Weeks (12 Months)|Lost to Follow-up|3
6184909|NCT01362062|9837764|FG000|Overall Study|Adverse Event|1
6184910|NCT01362062|9837765|FG001|Overall Study|Adverse Event|0
6184911|NCT01362062|9837764|FG000|Overall Study|Lost to Follow-up|11
6184912|NCT01362062|9837765|FG001|Overall Study|Lost to Follow-up|0
6184913|NCT01362062|9837764|FG000|Overall Study|Withdrawal by Subject|2
6184914|NCT01362062|9837765|FG001|Overall Study|Withdrawal by Subject|0
6184915|NCT01362062|9837764|FG000|Overall Study|Non-compliant participant|2
6184916|NCT01362062|9837765|FG001|Overall Study|Non-compliant participant|0
6184917|NCT01362062|9837764|FG000|Overall Study|Detected with Spondylo-arthritis|1
6184918|NCT01362062|9837765|FG001|Overall Study|Detected with Spondylo-arthritis|0
6184919|NCT01362062|9837764|FG000|Overall Study|Had significant improvement|9
6184920|NCT01362062|9837765|FG001|Overall Study|Had significant improvement|0
6184921|NCT01362140|9837781|FG000|Overall Study|Noncompliance|1
6184922|NCT01362140|9837782|FG001|Overall Study|Noncompliance|0
6184923|NCT01362140|9837781|FG000|Overall Study|Adverse Event|2
6184924|NCT01362140|9837782|FG001|Overall Study|Adverse Event|2
6184925|NCT01362140|9837781|FG000|Overall Study|Withdrawal by Subject|3
6184926|NCT01362140|9837782|FG001|Overall Study|Withdrawal by Subject|3
6184927|NCT01362140|9837781|FG000|Overall Study|Administrative Decision|0
6184928|NCT01362140|9837782|FG001|Overall Study|Administrative Decision|1
6184929|NCT01362140|9837781|FG000|Overall Study|Death|2
6184930|NCT01362140|9837782|FG001|Overall Study|Death|1
6184931|NCT01362140|9837781|FG000|Overall Study|Other|1
6184932|NCT01362140|9837782|FG001|Overall Study|Other|1
6184933|NCT01362140|9837781|FG000|Overall Study|Protocol-specified Criteria|1
6184934|NCT01362140|9837782|FG001|Overall Study|Protocol-specified Criteria|2
6184935|NCT01362140|9837781|FG000|Overall Study|Discontinued Without Receiving Treatment|0
6184936|NCT01362140|9837782|FG001|Overall Study|Discontinued Without Receiving Treatment|1
6184937|NCT01362244|9837803|FG000|Overall Study|Adverse Event|3
6184938|NCT01362244|9837804|FG001|Overall Study|Adverse Event|5
6184939|NCT01362244|9837803|FG000|Overall Study|Lack of Efficacy|5
6184940|NCT01362244|9837804|FG001|Overall Study|Lack of Efficacy|11
6184941|NCT01362244|9837803|FG000|Overall Study|Lost to Follow-up|0
6184942|NCT01362244|9837804|FG001|Overall Study|Lost to Follow-up|2
6184943|NCT01362244|9837803|FG000|Overall Study|Protocol Violation|5
6184944|NCT01362244|9837804|FG001|Overall Study|Protocol Violation|1
6184945|NCT01362244|9837803|FG000|Overall Study|Withdrawal by Subject|2
6184946|NCT01362244|9837804|FG001|Overall Study|Withdrawal by Subject|1
6184947|NCT01362244|9837803|FG000|Overall Study|Did not Meet Continuation Criteria|17
6184948|NCT01362244|9837804|FG001|Overall Study|Did not Meet Continuation Criteria|11
6184949|NCT01362244|9837803|FG000|Overall Study|Protocol Defined Stopping Criteria|0
6184950|NCT01362244|9837804|FG001|Overall Study|Protocol Defined Stopping Criteria|1
6184951|NCT01362270|9837812|FG000|Overall Study|Withdrawal by Subject|1
6184952|NCT01362270|9837813|FG001|Overall Study|Withdrawal by Subject|0
6184953|NCT01362270|9837812|FG000|Overall Study|Met exclusion criteria after 1st session|0
6184954|NCT01362270|9837813|FG001|Overall Study|Met exclusion criteria after 1st session|1
6184955|NCT01362270|9837812|FG000|Overall Study|Met excl. criteria before 1st session|1
6184956|NCT01362270|9837813|FG001|Overall Study|Met excl. criteria before 1st session|1
6184957|NCT01362296|9837821|FG000|Randomized Phase (RP)|PD including Death due to PD|56
6184958|NCT01362296|9837822|FG001|Randomized Phase (RP)|PD including Death due to PD|28
6184959|NCT01362296|9837823|FG002|Randomized Phase (RP)|PD including Death due to PD|0
6184960|NCT01362296|9837824|FG003|Randomized Phase (RP)|PD including Death due to PD|0
6184961|NCT01362296|9837821|FG000|Randomized Phase (RP)|Physician Decision|1
6184962|NCT01362296|9837822|FG001|Randomized Phase (RP)|Physician Decision|9
6184963|NCT01362296|9837823|FG002|Randomized Phase (RP)|Physician Decision|0
6184964|NCT01362296|9837824|FG003|Randomized Phase (RP)|Physician Decision|0
6184965|NCT01362296|9837821|FG000|Randomized Phase (RP)|Withdrawal by Subject|2
6184966|NCT01362296|9837822|FG001|Randomized Phase (RP)|Withdrawal by Subject|1
6184967|NCT01362296|9837823|FG002|Randomized Phase (RP)|Withdrawal by Subject|0
6184968|NCT01362296|9837824|FG003|Randomized Phase (RP)|Withdrawal by Subject|0
6184969|NCT01362296|9837821|FG000|Randomized Phase (RP)|Adverse Event|20
6184970|NCT01362296|9837822|FG001|Randomized Phase (RP)|Adverse Event|4
6184971|NCT01362296|9837823|FG002|Randomized Phase (RP)|Adverse Event|0
6184972|NCT01362296|9837824|FG003|Randomized Phase (RP)|Adverse Event|0
6184973|NCT01362296|9837821|FG000|Randomized Phase (RP)|Study Closed/Terminated|8
6184974|NCT01362296|9837822|FG001|Randomized Phase (RP)|Study Closed/Terminated|1
6184975|NCT01362296|9837823|FG002|Randomized Phase (RP)|Study Closed/Terminated|0
6184976|NCT01362296|9837824|FG003|Randomized Phase (RP)|Study Closed/Terminated|0
6184977|NCT01362296|9837821|FG000|Crossover Phase|PD including Death due to PD|0
6184978|NCT01362296|9837822|FG001|Crossover Phase|PD including Death due to PD|0
6184979|NCT01362296|9837823|FG002|Crossover Phase|PD including Death due to PD|16
6184980|NCT01362296|9837824|FG003|Crossover Phase|PD including Death due to PD|1
6184981|NCT01362296|9837821|FG000|Crossover Phase|Withdrawal by Subject|0
6184982|NCT01362296|9837822|FG001|Crossover Phase|Withdrawal by Subject|0
6184983|NCT01362296|9837823|FG002|Crossover Phase|Withdrawal by Subject|2
6184984|NCT01362296|9837824|FG003|Crossover Phase|Withdrawal by Subject|1
6184985|NCT01362296|9837821|FG000|Crossover Phase|Adverse Event|0
6184986|NCT01362296|9837822|FG001|Crossover Phase|Adverse Event|0
6184987|NCT01362296|9837823|FG002|Crossover Phase|Adverse Event|4
6184988|NCT01362296|9837824|FG003|Crossover Phase|Adverse Event|0
6184989|NCT01362296|9837821|FG000|Crossover Phase|Study Closed/Terminated|0
6184990|NCT01362296|9837822|FG001|Crossover Phase|Study Closed/Terminated|0
6184991|NCT01362296|9837823|FG002|Crossover Phase|Study Closed/Terminated|1
6184992|NCT01362296|9837824|FG003|Crossover Phase|Study Closed/Terminated|0
6184993|NCT01362322|9837836|FG000|Overall Study|Withdrawal by Subject|3
6184994|NCT01362322|9837837|FG001|Overall Study|Withdrawal by Subject|1
6184995|NCT01362322|9837836|FG000|Overall Study|Lost to Follow-up|2
6184996|NCT01362322|9837837|FG001|Overall Study|Lost to Follow-up|6
6184997|NCT01362348|9837843|FG000|Overall Study|Protocol-defined stopping criteria|9
6184998|NCT01362348|9837843|FG000|Overall Study|Study closed/terminated|5
6184999|NCT01362439|9837847|FG000|Overall Study|Adverse Event|1
6185000|NCT01362439|9837847|FG000|Overall Study|Lack of Efficacy|3
6185001|NCT01362439|9837847|FG000|Overall Study|Lost to Follow-up|2
6185002|NCT01362439|9837847|FG000|Overall Study|Study medication non-compliant|1
6185003|NCT01362439|9837847|FG000|Overall Study|Participant who withdrew consent|8
6185004|NCT01362491|9837855|FG000|Overall Study|Ineligible|1
6185005|NCT01362491|9837856|FG001|Overall Study|Ineligible|0
6185006|NCT01362491|9837857|FG002|Overall Study|Ineligible|0
6185007|NCT01362517|9837866|FG000|Overall Study|Protocol Violation|1
6185008|NCT01362517|9837866|FG000|Overall Study|Lost to Follow-up|1
6185009|NCT01362530|9837875|FG000|Base Study (Cycle 1)|Adverse Event|2
6185010|NCT01362530|9837876|FG001|Base Study (Cycle 1)|Adverse Event|0
6185011|NCT01362530|9837875|FG000|Base Study (Cycle 1)|Physician Decision|0
6185012|NCT01362530|9837876|FG001|Base Study (Cycle 1)|Physician Decision|1
6185013|NCT01362530|9837875|FG000|Base Study (Cycle 1)|Protocol Violation|2
6185014|NCT01362530|9837876|FG001|Base Study (Cycle 1)|Protocol Violation|0
6185015|NCT01362530|9837875|FG000|Base Study (Cycle 1)|Withdrawal by Subject|1
6185016|NCT01362530|9837876|FG001|Base Study (Cycle 1)|Withdrawal by Subject|2
6185017|NCT01362530|9837875|FG000|Optional Extension (Cycles 2-6)|Adverse Event|2
6185018|NCT01362530|9837876|FG001|Optional Extension (Cycles 2-6)|Adverse Event|0
6185019|NCT01362530|9837875|FG000|Optional Extension (Cycles 2-6)|Completed Chemotherapy Regimen|51
6185020|NCT01362530|9837876|FG001|Optional Extension (Cycles 2-6)|Completed Chemotherapy Regimen|0
6185021|NCT01362530|9837875|FG000|Optional Extension (Cycles 2-6)|Did Not Meet Additional Criteria|25
6185022|NCT01362530|9837876|FG001|Optional Extension (Cycles 2-6)|Did Not Meet Additional Criteria|0
6185023|NCT01362530|9837875|FG000|Optional Extension (Cycles 2-6)|Did Not Respond To Chemotherapy Regimen|4
6185024|NCT01362530|9837876|FG001|Optional Extension (Cycles 2-6)|Did Not Respond To Chemotherapy Regimen|0
6185025|NCT01362530|9837875|FG000|Optional Extension (Cycles 2-6)|Lack of Efficacy|1
6185026|NCT01362530|9837876|FG001|Optional Extension (Cycles 2-6)|Lack of Efficacy|0
6185027|NCT01362530|9837875|FG000|Optional Extension (Cycles 2-6)|Lost to Follow-up|1
6185028|NCT01362530|9837876|FG001|Optional Extension (Cycles 2-6)|Lost to Follow-up|0
6185029|NCT01362530|9837875|FG000|Optional Extension (Cycles 2-6)|Physician Decision|19
6185030|NCT01362530|9837876|FG001|Optional Extension (Cycles 2-6)|Physician Decision|0
6185031|NCT01362530|9837875|FG000|Optional Extension (Cycles 2-6)|Protocol Violation|4
6185032|NCT01362530|9837876|FG001|Optional Extension (Cycles 2-6)|Protocol Violation|0
6185033|NCT01362530|9837875|FG000|Optional Extension (Cycles 2-6)|Withdrawal by Subject|18
6185034|NCT01362530|9837876|FG001|Optional Extension (Cycles 2-6)|Withdrawal by Subject|0
6185035|NCT01362608|9837885|FG000|Overall Study|Protocol Violation|0
6185036|NCT01362608|9837886|FG001|Overall Study|Protocol Violation|1
6185037|NCT01362608|9837885|FG000|Overall Study|Lost to Follow-up|3
6185038|NCT01362608|9837886|FG001|Overall Study|Lost to Follow-up|1
6185039|NCT01362608|9837885|FG000|Overall Study|Withdrawal by Subject|1
6185040|NCT01362608|9837886|FG001|Overall Study|Withdrawal by Subject|2
6185041|NCT01362608|9837885|FG000|Overall Study|Lack of Efficacy|0
6185042|NCT01362608|9837886|FG001|Overall Study|Lack of Efficacy|2
6185043|NCT01362608|9837885|FG000|Overall Study|Adverse Event|0
6185044|NCT01362608|9837886|FG001|Overall Study|Adverse Event|2
6185045|NCT01362790|9837911|FG000|Pilot Phase & Phase 2|Changed treatment, too early to assess|1
6185046|NCT01362790|9837912|FG001|Pilot Phase & Phase 2|Changed treatment, too early to assess|0
6185047|NCT01362790|9837913|FG002|Pilot Phase & Phase 2|Changed treatment, too early to assess|0
6185048|NCT01362790|9837914|FG003|Pilot Phase & Phase 2|Changed treatment, too early to assess|0
6185049|NCT01362790|9837915|FG004|Pilot Phase & Phase 2|Changed treatment, too early to assess|0
6185050|NCT01362790|9837916|FG005|Pilot Phase & Phase 2|Changed treatment, too early to assess|0
6185051|NCT01362790|9837917|FG006|Pilot Phase & Phase 2|Changed treatment, too early to assess|0
6185052|NCT01362790|9837911|FG000|Pilot Phase & Phase 2|Adverse Event|0
6185053|NCT01362790|9837912|FG001|Pilot Phase & Phase 2|Adverse Event|1
6185054|NCT01362790|9837913|FG002|Pilot Phase & Phase 2|Adverse Event|0
6185055|NCT01362790|9837914|FG003|Pilot Phase & Phase 2|Adverse Event|1
6185056|NCT01362790|9837915|FG004|Pilot Phase & Phase 2|Adverse Event|0
6185057|NCT01362790|9837916|FG005|Pilot Phase & Phase 2|Adverse Event|2
6185058|NCT01362790|9837917|FG006|Pilot Phase & Phase 2|Adverse Event|0
6185059|NCT01362790|9837911|FG000|Pilot Phase & Phase 2|Physician Decision|0
6185060|NCT01362790|9837912|FG001|Pilot Phase & Phase 2|Physician Decision|0
6185061|NCT01362790|9837913|FG002|Pilot Phase & Phase 2|Physician Decision|0
6185062|NCT01362790|9837914|FG003|Pilot Phase & Phase 2|Physician Decision|1
6185063|NCT01362790|9837915|FG004|Pilot Phase & Phase 2|Physician Decision|0
6185064|NCT01362790|9837916|FG005|Pilot Phase & Phase 2|Physician Decision|0
6185065|NCT01362790|9837917|FG006|Pilot Phase & Phase 2|Physician Decision|0
6185066|NCT01362790|9837911|FG000|Pilot Phase & Phase 2|Developed antibodies|7
6185067|NCT01362790|9837912|FG001|Pilot Phase & Phase 2|Developed antibodies|2
6185068|NCT01362790|9837913|FG002|Pilot Phase & Phase 2|Developed antibodies|3
6185069|NCT01362790|9837914|FG003|Pilot Phase & Phase 2|Developed antibodies|8
6185070|NCT01362790|9837915|FG004|Pilot Phase & Phase 2|Developed antibodies|0
6185071|NCT01362790|9837916|FG005|Pilot Phase & Phase 2|Developed antibodies|0
6185072|NCT01362790|9837917|FG006|Pilot Phase & Phase 2|Developed antibodies|0
6185073|NCT01362790|9837911|FG000|Pilot Phase & Phase 2|Refused further treatment|0
6185074|NCT01362790|9837912|FG001|Pilot Phase & Phase 2|Refused further treatment|1
6185075|NCT01362790|9837913|FG002|Pilot Phase & Phase 2|Refused further treatment|0
6185076|NCT01362790|9837914|FG003|Pilot Phase & Phase 2|Refused further treatment|0
6185077|NCT01362790|9837915|FG004|Pilot Phase & Phase 2|Refused further treatment|0
6185078|NCT01362790|9837916|FG005|Pilot Phase & Phase 2|Refused further treatment|0
6185079|NCT01362790|9837917|FG006|Pilot Phase & Phase 2|Refused further treatment|0
6185080|NCT01362790|9837911|FG000|Pilot Phase & Phase 2|Progressive disease|1
6185081|NCT01362790|9837912|FG001|Pilot Phase & Phase 2|Progressive disease|2
6185082|NCT01362790|9837913|FG002|Pilot Phase & Phase 2|Progressive disease|2
6185083|NCT01362790|9837914|FG003|Pilot Phase & Phase 2|Progressive disease|3
6185084|NCT01362790|9837915|FG004|Pilot Phase & Phase 2|Progressive disease|0
6185085|NCT01362790|9837916|FG005|Pilot Phase & Phase 2|Progressive disease|2
6185086|NCT01362790|9837917|FG006|Pilot Phase & Phase 2|Progressive disease|0
6185087|NCT01362790|9837911|FG000|Pilot Phase & Phase 2|Treatment delay >3 weeks|1
6185088|NCT01362790|9837912|FG001|Pilot Phase & Phase 2|Treatment delay >3 weeks|0
6185089|NCT01362790|9837913|FG002|Pilot Phase & Phase 2|Treatment delay >3 weeks|0
6185090|NCT01362790|9837914|FG003|Pilot Phase & Phase 2|Treatment delay >3 weeks|0
6185091|NCT01362790|9837915|FG004|Pilot Phase & Phase 2|Treatment delay >3 weeks|0
6185092|NCT01362790|9837916|FG005|Pilot Phase & Phase 2|Treatment delay >3 weeks|0
6185093|NCT01362790|9837917|FG006|Pilot Phase & Phase 2|Treatment delay >3 weeks|0
6185094|NCT01362790|9837911|FG000|Pilot Phase & Phase 2|Complicating disease/intercurr. illness|0
6185095|NCT01362790|9837912|FG001|Pilot Phase & Phase 2|Complicating disease/intercurr. illness|2
6185096|NCT01362790|9837913|FG002|Pilot Phase & Phase 2|Complicating disease/intercurr. illness|0
6185097|NCT01362790|9837914|FG003|Pilot Phase & Phase 2|Complicating disease/intercurr. illness|0
6185098|NCT01362790|9837915|FG004|Pilot Phase & Phase 2|Complicating disease/intercurr. illness|0
6185099|NCT01362790|9837916|FG005|Pilot Phase & Phase 2|Complicating disease/intercurr. illness|0
6185100|NCT01362790|9837917|FG006|Pilot Phase & Phase 2|Complicating disease/intercurr. illness|0
6185101|NCT01362790|9837911|FG000|Pilot Phase & Phase 2|Death on study|0
6185102|NCT01362790|9837912|FG001|Pilot Phase & Phase 2|Death on study|0
6185103|NCT01362790|9837913|FG002|Pilot Phase & Phase 2|Death on study|0
6185104|NCT01362790|9837914|FG003|Pilot Phase & Phase 2|Death on study|1
6185105|NCT01362790|9837915|FG004|Pilot Phase & Phase 2|Death on study|0
6185106|NCT01362790|9837916|FG005|Pilot Phase & Phase 2|Death on study|0
6185107|NCT01362790|9837917|FG006|Pilot Phase & Phase 2|Death on study|0
6185108|NCT01362790|9837911|FG000|Dose De-escalation of Regimen A|Adverse Event|0
6185109|NCT01362790|9837912|FG001|Dose De-escalation of Regimen A|Adverse Event|0
6185110|NCT01362790|9837913|FG002|Dose De-escalation of Regimen A|Adverse Event|0
6185111|NCT01362790|9837914|FG003|Dose De-escalation of Regimen A|Adverse Event|0
6185112|NCT01362790|9837915|FG004|Dose De-escalation of Regimen A|Adverse Event|1
6185113|NCT01362790|9837916|FG005|Dose De-escalation of Regimen A|Adverse Event|0
6185114|NCT01362790|9837917|FG006|Dose De-escalation of Regimen A|Adverse Event|0
6185115|NCT01362790|9837911|FG000|Dose De-escalation of Regimen A|Deveoped antibodies|0
6185116|NCT01362790|9837912|FG001|Dose De-escalation of Regimen A|Deveoped antibodies|0
6185117|NCT01362790|9837913|FG002|Dose De-escalation of Regimen A|Deveoped antibodies|0
6185118|NCT01362790|9837914|FG003|Dose De-escalation of Regimen A|Deveoped antibodies|0
6185119|NCT01362790|9837915|FG004|Dose De-escalation of Regimen A|Deveoped antibodies|3
6185120|NCT01362790|9837916|FG005|Dose De-escalation of Regimen A|Deveoped antibodies|0
6185121|NCT01362790|9837917|FG006|Dose De-escalation of Regimen A|Deveoped antibodies|0
6185122|NCT01362790|9837911|FG000|Dose De-escalation of Regimen A|Progressive disease|0
6185123|NCT01362790|9837912|FG001|Dose De-escalation of Regimen A|Progressive disease|0
6185124|NCT01362790|9837913|FG002|Dose De-escalation of Regimen A|Progressive disease|0
6185125|NCT01362790|9837914|FG003|Dose De-escalation of Regimen A|Progressive disease|0
6185126|NCT01362790|9837915|FG004|Dose De-escalation of Regimen A|Progressive disease|2
6185127|NCT01362790|9837916|FG005|Dose De-escalation of Regimen A|Progressive disease|0
6185128|NCT01362790|9837917|FG006|Dose De-escalation of Regimen A|Progressive disease|0
6185129|NCT01363011|9837969|FG000|Main Study|Adverse Event|2
6185130|NCT01363011|9837970|FG001|Main Study|Adverse Event|3
6185131|NCT01363011|9837969|FG000|Main Study|Investigator's Discretion|1
6185132|NCT01363011|9837970|FG001|Main Study|Investigator's Discretion|1
6185133|NCT01363011|9837969|FG000|Main Study|Withdrew Consent|1
6185134|NCT01363011|9837970|FG001|Main Study|Withdrew Consent|4
6185135|NCT01363011|9837969|FG000|Main Study|Protocol Violation|0
6185136|NCT01363011|9837970|FG001|Main Study|Protocol Violation|1
6185137|NCT01363011|9837969|FG000|Extension Phase|Adverse Event|1
6185138|NCT01363011|9837970|FG001|Extension Phase|Adverse Event|1
6185139|NCT01363011|9837969|FG000|Extension Phase|Lack of Efficacy|0
6185140|NCT01363011|9837970|FG001|Extension Phase|Lack of Efficacy|1
6185141|NCT01363011|9837969|FG000|Extension Phase|Investigator's Discretion|2
6185142|NCT01363011|9837970|FG001|Extension Phase|Investigator's Discretion|2
6185143|NCT01363011|9837969|FG000|Extension Phase|Withdrew Consent|0
6185144|NCT01363011|9837970|FG001|Extension Phase|Withdrew Consent|1
6185145|NCT01363011|9837969|FG000|Extension Phase|Lost to Follow-up|0
6185146|NCT01363011|9837970|FG001|Extension Phase|Lost to Follow-up|2
6185147|NCT01363011|9837969|FG000|Extension Phase|Rolled Over to Another Gilead Study|2
6185148|NCT01363011|9837970|FG001|Extension Phase|Rolled Over to Another Gilead Study|1
6185149|NCT01363076|9837984|FG000|Overall Study|Withdrawal by Subject|0
6185150|NCT01363076|9837985|FG001|Overall Study|Withdrawal by Subject|1
6185151|NCT01363297|9838009|FG000|Overall Study|Other|0
6185152|NCT01363297|9838010|FG001|Overall Study|Other|0
6185153|NCT01363297|9838011|FG002|Overall Study|Other|0
6185154|NCT01363297|9838012|FG003|Overall Study|Other|0
6185155|NCT01363297|9838013|FG004|Overall Study|Other|1
6185156|NCT01363297|9838009|FG000|Overall Study|Death|3
6185157|NCT01363297|9838010|FG001|Overall Study|Death|6
6185158|NCT01363297|9838011|FG002|Overall Study|Death|6
6185159|NCT01363297|9838012|FG003|Overall Study|Death|10
6185160|NCT01363297|9838013|FG004|Overall Study|Death|30
6185161|NCT01363349|9838032|FG000|Overall Study|Adverse Event|6
6185162|NCT01363349|9838033|FG001|Overall Study|Adverse Event|7
6185163|NCT01363349|9838032|FG000|Overall Study|Lack of Efficacy|3
6185164|NCT01363349|9838033|FG001|Overall Study|Lack of Efficacy|10
6185165|NCT01363349|9838032|FG000|Overall Study|Non compliance/Protocol deviations|2
6185166|NCT01363349|9838033|FG001|Overall Study|Non compliance/Protocol deviations|2
6185167|NCT01363349|9838032|FG000|Overall Study|Withdrawal by Subject|14
6185168|NCT01363349|9838033|FG001|Overall Study|Withdrawal by Subject|6
6185169|NCT01363349|9838032|FG000|Overall Study|Lost to Follow-up|5
6185170|NCT01363349|9838033|FG001|Overall Study|Lost to Follow-up|6
6185171|NCT01363349|9838032|FG000|Overall Study|Not reported|36
6185172|NCT01363349|9838033|FG001|Overall Study|Not reported|37
6185173|NCT01363349|9838032|FG000|Overall Study|missing|1
6185174|NCT01363349|9838033|FG001|Overall Study|missing|2
6185175|NCT01363440|9838055|FG000|Overall Study|Adverse Event|5
6185176|NCT01363440|9838056|FG001|Overall Study|Adverse Event|4
6185177|NCT01363440|9838057|FG002|Overall Study|Adverse Event|4
6185178|NCT01363440|9838055|FG000|Overall Study|Death|3
6185179|NCT01363440|9838056|FG001|Overall Study|Death|7
6185180|NCT01363440|9838057|FG002|Overall Study|Death|5
6185181|NCT01363440|9838055|FG000|Overall Study|Withdrawal by Subject|9
6185182|NCT01363440|9838056|FG001|Overall Study|Withdrawal by Subject|11
6185183|NCT01363440|9838057|FG002|Overall Study|Withdrawal by Subject|11
6185184|NCT01363440|9838055|FG000|Overall Study|Lost to Follow-up|2
6185185|NCT01363440|9838056|FG001|Overall Study|Lost to Follow-up|4
6185186|NCT01363440|9838057|FG002|Overall Study|Lost to Follow-up|5
6185187|NCT01363440|9838055|FG000|Overall Study|Other|4
6185188|NCT01363440|9838056|FG001|Overall Study|Other|5
6185189|NCT01363440|9838057|FG002|Overall Study|Other|2
6185190|NCT01363661|9838085|FG000|Overall Study|Adverse Event|9
6185191|NCT01363661|9838086|FG001|Overall Study|Adverse Event|2
6185192|NCT01363661|9838085|FG000|Overall Study|Withdrawal by Subject|1
6185193|NCT01363661|9838086|FG001|Overall Study|Withdrawal by Subject|1
6185194|NCT01363661|9838085|FG000|Overall Study|Protocol Violation|1
6185195|NCT01363661|9838086|FG001|Overall Study|Protocol Violation|0
6185196|NCT01363661|9838085|FG000|Overall Study|Lost to Follow-up|3
6185197|NCT01363661|9838086|FG001|Overall Study|Lost to Follow-up|1
6185198|NCT01363700|9838095|FG000|Epinastine vs Placebo Period1|Withdrawal by Subject|0
6185199|NCT01363700|9838096|FG001|Epinastine vs Placebo Period1|Withdrawal by Subject|1
6185200|NCT01363700|9838097|FG002|Epinastine vs Placebo Period1|Withdrawal by Subject|0
6185201|NCT01363700|9838098|FG003|Epinastine vs Placebo Period1|Withdrawal by Subject|0
6185202|NCT01363700|9838099|FG004|Epinastine vs Placebo Period1|Withdrawal by Subject|0
6185203|NCT01363713|9838110|FG000|Overall Study|Adverse Event|1
6185204|NCT01363713|9838110|FG000|Overall Study|Protocol Violation|3
6185205|NCT01363713|9838110|FG000|Overall Study|Withdrawal by Subject|2
6185206|NCT01363765|9838116|FG000|Overall Study|non-diagnostic|2621
6185207|NCT01363765|9838117|FG001|Overall Study|non-diagnostic|1124
6185208|NCT01363765|9838116|FG000|Overall Study|duplicate records|736
6185209|NCT01363765|9838117|FG001|Overall Study|duplicate records|3177
6185210|NCT01363765|9838116|FG000|Overall Study|non-resident|156
6185211|NCT01363765|9838117|FG001|Overall Study|non-resident|76
6185212|NCT01363765|9838116|FG000|Overall Study|age not recorded (used for cross-linkage|117
6185213|NCT01363765|9838117|FG001|Overall Study|age not recorded (used for cross-linkage|354
6185214|NCT01363765|9838116|FG000|Overall Study|smear during intervention|2170
6185215|NCT01363765|9838117|FG001|Overall Study|smear during intervention|0
6185216|NCT01363908|9838132|FG000|Chronic Dosing (CD) Phase|Adverse Event|1
6185217|NCT01363908|9838133|FG001|Chronic Dosing (CD) Phase|Adverse Event|1
6185218|NCT01363908|9838132|FG000|Chronic Dosing (CD) Phase|Patient decision|0
6185219|NCT01363908|9838133|FG001|Chronic Dosing (CD) Phase|Patient decision|1
6185220|NCT01363908|9838132|FG000|Chronic Dosing (CD) Phase|Physician Decision|0
6185221|NCT01363908|9838133|FG001|Chronic Dosing (CD) Phase|Physician Decision|1
6185222|NCT01363908|9838132|FG000|Chronic Dosing (CD) Phase|Early study termination|9
6185223|NCT01363908|9838133|FG001|Chronic Dosing (CD) Phase|Early study termination|3
6185224|NCT01363986|9838139|FG000|Overall Study|Disease progression|1
6185225|NCT01364233|9838170|FG000|Overall Study|Lost to Follow-up|1
6185226|NCT01364298|9838185|FG000|Overall Study|Adverse Event|3
6185227|NCT01364298|9838186|FG001|Overall Study|Adverse Event|4
6185228|NCT01364298|9838185|FG000|Overall Study|Lack of adherence to treatment|1
6185229|NCT01364298|9838186|FG001|Overall Study|Lack of adherence to treatment|3
6185230|NCT01364298|9838185|FG000|Overall Study|Lack of Efficacy|1
6185231|NCT01364298|9838186|FG001|Overall Study|Lack of Efficacy|0
6185232|NCT01364298|9838185|FG000|Overall Study|Lost to Follow-up|5
6185233|NCT01364298|9838186|FG001|Overall Study|Lost to Follow-up|10
6185234|NCT01364298|9838185|FG000|Overall Study|Withdrawal by Subject|3
6185235|NCT01364298|9838186|FG001|Overall Study|Withdrawal by Subject|3
6185236|NCT01364298|9838185|FG000|Overall Study|Other|1
6185237|NCT01364298|9838186|FG001|Overall Study|Other|3
6185238|NCT01364389|9838195|FG000|Overall Study|Withdrawal by Subject|0
6185239|NCT01364389|9838196|FG001|Overall Study|Withdrawal by Subject|1
6185240|NCT01364389|9838197|FG002|Overall Study|Withdrawal by Subject|0
6228121|NCT01723163|9901320|FG001|3-Month Follow-up|Unable to Contact|19
6228122|NCT01723163|9901319|FG000|6-Month Follow-up|Death|1
6228123|NCT01723163|9901320|FG001|6-Month Follow-up|Death|0
6228124|NCT01723163|9901319|FG000|6-Month Follow-up|Unable to Contact|17
6228125|NCT01723163|9901320|FG001|6-Month Follow-up|Unable to Contact|15
6228126|NCT01723163|9901319|FG000|12-Month Follow-up|Death|1
6228127|NCT01723163|9901320|FG001|12-Month Follow-up|Death|0
6228128|NCT01723163|9901319|FG000|12-Month Follow-up|Unable to Contact|23
6228129|NCT01723163|9901320|FG001|12-Month Follow-up|Unable to Contact|28
6228130|NCT01723228|9901328|FG000|Overall Study|Adverse Event|2
6228131|NCT01723228|9901329|FG001|Overall Study|Adverse Event|6
6228132|NCT01723228|9901328|FG000|Overall Study|Withdrawal by Subject|2
6228133|NCT01723228|9901329|FG001|Overall Study|Withdrawal by Subject|1
6228134|NCT01723228|9901328|FG000|Overall Study|Protocol Violation|0
6228135|NCT01723228|9901329|FG001|Overall Study|Protocol Violation|2
6228136|NCT01723228|9901328|FG000|Overall Study|Lost to Follow-up|2
6228137|NCT01723228|9901329|FG001|Overall Study|Lost to Follow-up|1
6228138|NCT01723228|9901328|FG000|Overall Study|Other|2
6228139|NCT01723228|9901329|FG001|Overall Study|Other|1
6228140|NCT01723254|9901343|FG000|Overall Study|Conflict with work schedule|0
6228141|NCT01723254|9901344|FG001|Overall Study|Conflict with work schedule|0
6228142|NCT01723254|9901345|FG002|Overall Study|Conflict with work schedule|0
6228143|NCT01723254|9901346|FG003|Overall Study|Conflict with work schedule|0
6228144|NCT01723254|9901347|FG004|Overall Study|Conflict with work schedule|0
6228145|NCT01723254|9901348|FG005|Overall Study|Conflict with work schedule|0
6228146|NCT01723254|9901349|FG006|Overall Study|Conflict with work schedule|0
6228147|NCT01723254|9901350|FG007|Overall Study|Conflict with work schedule|1
6228148|NCT01723254|9901343|FG000|Overall Study|Personal issues|0
6228149|NCT01723254|9901344|FG001|Overall Study|Personal issues|0
6228150|NCT01723254|9901345|FG002|Overall Study|Personal issues|0
6228151|NCT01723254|9901346|FG003|Overall Study|Personal issues|0
6228152|NCT01723254|9901347|FG004|Overall Study|Personal issues|0
6228153|NCT01723254|9901348|FG005|Overall Study|Personal issues|1
6185241|NCT01364389|9838195|FG000|Overall Study|Protocol deviation|0
6228154|NCT01723254|9901349|FG006|Overall Study|Personal issues|0
6228155|NCT01723254|9901350|FG007|Overall Study|Personal issues|0
6228156|NCT01723254|9901343|FG000|Overall Study|No longer have time to participate|0
6228157|NCT01723254|9901344|FG001|Overall Study|No longer have time to participate|0
6228158|NCT01723254|9901345|FG002|Overall Study|No longer have time to participate|0
6228159|NCT01723254|9901346|FG003|Overall Study|No longer have time to participate|1
6185242|NCT01364389|9838196|FG001|Overall Study|Protocol deviation|0
6185243|NCT01364389|9838197|FG002|Overall Study|Protocol deviation|1
6185244|NCT01364389|9838195|FG000|Overall Study|Administrative problems|1
6185245|NCT01364389|9838196|FG001|Overall Study|Administrative problems|0
6185246|NCT01364389|9838197|FG002|Overall Study|Administrative problems|0
6185247|NCT01364389|9838195|FG000|Overall Study|Adverse Event|1
6185248|NCT01364389|9838196|FG001|Overall Study|Adverse Event|0
6185249|NCT01364389|9838197|FG002|Overall Study|Adverse Event|0
6185250|NCT01364428|9838207|FG000|Overall Study|Adverse Event|1
6185251|NCT01364428|9838208|FG001|Overall Study|Adverse Event|2
6185252|NCT01364428|9838207|FG000|Overall Study|Protocol Violation|2
6185253|NCT01364428|9838208|FG001|Overall Study|Protocol Violation|0
6185254|NCT01364428|9838207|FG000|Overall Study|Withdrawal Criteria|14
6185255|NCT01364428|9838208|FG001|Overall Study|Withdrawal Criteria|10
6185256|NCT01364428|9838207|FG000|Overall Study|Other|3
6185257|NCT01364428|9838208|FG001|Overall Study|Other|3
6185258|NCT01364467|9838216|FG000|Overall Study|Lost to Follow-up|1
6185259|NCT01364467|9838217|FG001|Overall Study|Lost to Follow-up|2
6185260|NCT01364649|9838267|FG000|Overall Study|Pretreatment Event or Adverse Event|20
6185261|NCT01364649|9838268|FG001|Overall Study|Pretreatment Event or Adverse Event|14
6185262|NCT01364649|9838267|FG000|Overall Study|Lack of Efficacy|6
6185263|NCT01364649|9838268|FG001|Overall Study|Lack of Efficacy|0
6185264|NCT01364649|9838267|FG000|Overall Study|Non-compliance with Investigational Drug|1
6185265|NCT01364649|9838268|FG001|Overall Study|Non-compliance with Investigational Drug|0
6185266|NCT01364649|9838267|FG000|Overall Study|Protocol Deviations|4
6185267|NCT01364649|9838268|FG001|Overall Study|Protocol Deviations|8
6185268|NCT01364649|9838267|FG000|Overall Study|Withdrawal of Consent|9
6185269|NCT01364649|9838268|FG001|Overall Study|Withdrawal of Consent|7
6185270|NCT01364649|9838267|FG000|Overall Study|Lost to Follow-up|12
6185271|NCT01364649|9838268|FG001|Overall Study|Lost to Follow-up|13
6185272|NCT01364649|9838267|FG000|Overall Study|Other|4
6185273|NCT01364649|9838268|FG001|Overall Study|Other|1
6185274|NCT01364727|9838274|FG000|Overall Study|Not Eligible|2
6185275|NCT01364870|9838288|FG000|Overall Study|Withdrawal by Subject|13
6185276|NCT01364870|9838289|FG001|Overall Study|Withdrawal by Subject|24
6185277|NCT01364870|9838290|FG002|Overall Study|Withdrawal by Subject|10
6185278|NCT01364870|9838288|FG000|Overall Study|Adverse Event|8
6185279|NCT01364870|9838289|FG001|Overall Study|Adverse Event|6
6185280|NCT01364870|9838290|FG002|Overall Study|Adverse Event|4
6185281|NCT01364870|9838288|FG000|Overall Study|Protocol Violation|1
6185282|NCT01364870|9838289|FG001|Overall Study|Protocol Violation|0
6185283|NCT01364870|9838290|FG002|Overall Study|Protocol Violation|0
6185284|NCT01364922|9838305|FG000|Open-label (OL) Period|Adverse Event|7
6185285|NCT01364922|9838306|FG001|Open-label (OL) Period|Adverse Event|0
6185286|NCT01364922|9838307|FG002|Open-label (OL) Period|Adverse Event|0
6185287|NCT01364922|9838305|FG000|Open-label (OL) Period|Did Not Meet Randomization Criteria|6
6185288|NCT01364922|9838306|FG001|Open-label (OL) Period|Did Not Meet Randomization Criteria|0
6185289|NCT01364922|9838307|FG002|Open-label (OL) Period|Did Not Meet Randomization Criteria|0
6185290|NCT01364922|9838305|FG000|Open-label (OL) Period|Withdrawal by Subject|4
6185291|NCT01364922|9838306|FG001|Open-label (OL) Period|Withdrawal by Subject|0
6185292|NCT01364922|9838307|FG002|Open-label (OL) Period|Withdrawal by Subject|0
6185293|NCT01364922|9838305|FG000|Open-label (OL) Period|Lack of Efficacy|3
6185294|NCT01364922|9838306|FG001|Open-label (OL) Period|Lack of Efficacy|0
6185295|NCT01364922|9838307|FG002|Open-label (OL) Period|Lack of Efficacy|0
6185296|NCT01364922|9838305|FG000|Open-label (OL) Period|Lost to Follow-up|1
6185297|NCT01364922|9838306|FG001|Open-label (OL) Period|Lost to Follow-up|0
6185298|NCT01364922|9838307|FG002|Open-label (OL) Period|Lost to Follow-up|0
6185299|NCT01364922|9838305|FG000|Open-label (OL) Period|Other, Unspecified|1
6185300|NCT01364922|9838306|FG001|Open-label (OL) Period|Other, Unspecified|0
6185301|NCT01364922|9838307|FG002|Open-label (OL) Period|Other, Unspecified|0
6185302|NCT01364922|9838305|FG000|Double-Blind (DB) Period|Lack of Efficacy|0
6185303|NCT01364922|9838306|FG001|Double-Blind (DB) Period|Lack of Efficacy|3
6185304|NCT01364922|9838307|FG002|Double-Blind (DB) Period|Lack of Efficacy|4
6185305|NCT01364922|9838305|FG000|Double-Blind (DB) Period|Subject Noncompliant|0
6185306|NCT01364922|9838306|FG001|Double-Blind (DB) Period|Subject Noncompliant|1
6185307|NCT01364922|9838307|FG002|Double-Blind (DB) Period|Subject Noncompliant|0
6185308|NCT01364922|9838305|FG000|Double-Blind (DB) Period|Adverse Event|0
6185309|NCT01364922|9838306|FG001|Double-Blind (DB) Period|Adverse Event|0
6185310|NCT01364922|9838307|FG002|Double-Blind (DB) Period|Adverse Event|1
6185311|NCT01364922|9838305|FG000|Double-Blind (DB) Period|Other, Unspecified|0
6185312|NCT01364922|9838306|FG001|Double-Blind (DB) Period|Other, Unspecified|1
6185313|NCT01364922|9838307|FG002|Double-Blind (DB) Period|Other, Unspecified|0
6185314|NCT01365039|9838316|FG000|Overall Study|Study related symptoms and complaints|1
6185315|NCT01365039|9838317|FG001|Overall Study|Study related symptoms and complaints|0
6185316|NCT01365052|9838326|FG000|Overall Study|Adverse Event|4
6185317|NCT01365052|9838327|FG001|Overall Study|Adverse Event|4
6185318|NCT01365091|9838337|FG000|Period 1|Adverse Event|1
6185319|NCT01365091|9838338|FG001|Period 1|Adverse Event|0
6185320|NCT01365091|9838339|FG002|Period 1|Adverse Event|2
6185321|NCT01365091|9838340|FG003|Period 1|Adverse Event|3
6185322|NCT01365091|9838337|FG000|Period 1|Positive test result for drugs of abuse|1
6185323|NCT01365091|9838338|FG001|Period 1|Positive test result for drugs of abuse|0
6185324|NCT01365091|9838339|FG002|Period 1|Positive test result for drugs of abuse|0
6185325|NCT01365091|9838340|FG003|Period 1|Positive test result for drugs of abuse|0
6185326|NCT01365091|9838337|FG000|Period 1|No longer met study criteria|0
6185327|NCT01365091|9838338|FG001|Period 1|No longer met study criteria|1
6185328|NCT01365091|9838339|FG002|Period 1|No longer met study criteria|0
6185329|NCT01365091|9838340|FG003|Period 1|No longer met study criteria|0
6185330|NCT01365091|9838337|FG000|Period 1|Withdrawal by Subject|0
6185331|NCT01365091|9838338|FG001|Period 1|Withdrawal by Subject|1
6185332|NCT01365091|9838339|FG002|Period 1|Withdrawal by Subject|0
6185333|NCT01365091|9838340|FG003|Period 1|Withdrawal by Subject|0
6185334|NCT01365091|9838337|FG000|Period 1|Personal reasons|0
6185335|NCT01365091|9838338|FG001|Period 1|Personal reasons|0
6185336|NCT01365091|9838339|FG002|Period 1|Personal reasons|1
6185337|NCT01365091|9838340|FG003|Period 1|Personal reasons|0
6185338|NCT01365091|9838337|FG000|Period 2|Withdrawal by Subject|1
6185339|NCT01365091|9838338|FG001|Period 2|Withdrawal by Subject|0
6185340|NCT01365091|9838339|FG002|Period 2|Withdrawal by Subject|0
6185341|NCT01365091|9838340|FG003|Period 2|Withdrawal by Subject|0
6185342|NCT01365091|9838337|FG000|Period 2|Adverse Event|0
6185343|NCT01365091|9838338|FG001|Period 2|Adverse Event|0
6185344|NCT01365091|9838339|FG002|Period 2|Adverse Event|1
6185345|NCT01365091|9838340|FG003|Period 2|Adverse Event|0
6185346|NCT01365130|9838364|FG000|Overall Study|Progression/worsening of Dx prior to txt|2
6185347|NCT01365273|9838370|FG000|Overall Study|Lost to Follow-up|1
6185348|NCT01365273|9838371|FG001|Overall Study|Lost to Follow-up|0
6185349|NCT01365273|9838370|FG000|Overall Study|Protocol Violation|0
6185350|NCT01365273|9838371|FG001|Overall Study|Protocol Violation|1
6185351|NCT01365273|9838370|FG000|Overall Study|Physician Decision|1
6185352|NCT01365273|9838371|FG001|Overall Study|Physician Decision|0
6185353|NCT01365455|9838380|FG000|Induction Period|Adverse Event|5
6185354|NCT01365455|9838381|FG001|Induction Period|Adverse Event|3
6185355|NCT01365455|9838382|FG002|Induction Period|Adverse Event|4
6185356|NCT01365455|9838383|FG003|Induction Period|Adverse Event|0
6185357|NCT01365455|9838384|FG004|Induction Period|Adverse Event|0
6185358|NCT01365455|9838380|FG000|Induction Period|Lack of Efficacy|1
6185359|NCT01365455|9838381|FG001|Induction Period|Lack of Efficacy|1
6185360|NCT01365455|9838382|FG002|Induction Period|Lack of Efficacy|0
6185361|NCT01365455|9838383|FG003|Induction Period|Lack of Efficacy|0
6185362|NCT01365455|9838384|FG004|Induction Period|Lack of Efficacy|0
6185363|NCT01365455|9838380|FG000|Induction Period|Pregnancy|0
6185364|NCT01365455|9838381|FG001|Induction Period|Pregnancy|1
6185365|NCT01365455|9838382|FG002|Induction Period|Pregnancy|0
6185366|NCT01365455|9838383|FG003|Induction Period|Pregnancy|0
6185367|NCT01365455|9838384|FG004|Induction Period|Pregnancy|0
6185368|NCT01365455|9838380|FG000|Induction Period|Protocol deviation|0
6185369|NCT01365455|9838381|FG001|Induction Period|Protocol deviation|1
6185370|NCT01365455|9838382|FG002|Induction Period|Protocol deviation|1
6185371|NCT01365455|9838383|FG003|Induction Period|Protocol deviation|0
6185372|NCT01365455|9838384|FG004|Induction Period|Protocol deviation|0
6185373|NCT01365455|9838380|FG000|Induction Period|Subject/guardian decision|9
6185374|NCT01365455|9838381|FG001|Induction Period|Subject/guardian decision|1
6185375|NCT01365455|9838382|FG002|Induction Period|Subject/guardian decision|8
6185376|NCT01365455|9838383|FG003|Induction Period|Subject/guardian decision|0
6185377|NCT01365455|9838384|FG004|Induction Period|Subject/guardian decision|0
6185378|NCT01365455|9838380|FG000|Induction Period|Lost to Follow-up|0
6185379|NCT01365455|9838381|FG001|Induction Period|Lost to Follow-up|0
6185380|NCT01365455|9838382|FG002|Induction Period|Lost to Follow-up|3
6185381|NCT01365455|9838383|FG003|Induction Period|Lost to Follow-up|0
6185382|NCT01365455|9838384|FG004|Induction Period|Lost to Follow-up|0
6185383|NCT01365455|9838380|FG000|Maintenance Period|Adverse Event|12
6185384|NCT01365455|9838381|FG001|Maintenance Period|Adverse Event|5
6185385|NCT01365455|9838382|FG002|Maintenance Period|Adverse Event|1
6185386|NCT01365455|9838383|FG003|Maintenance Period|Adverse Event|2
6185387|NCT01365455|9838384|FG004|Maintenance Period|Adverse Event|4
6185388|NCT01365455|9838380|FG000|Maintenance Period|Lack of Efficacy|10
6185389|NCT01365455|9838381|FG001|Maintenance Period|Lack of Efficacy|2
6185390|NCT01365455|9838382|FG002|Maintenance Period|Lack of Efficacy|0
6185391|NCT01365455|9838383|FG003|Maintenance Period|Lack of Efficacy|2
6185392|NCT01365455|9838384|FG004|Maintenance Period|Lack of Efficacy|2
6185393|NCT01365455|9838380|FG000|Maintenance Period|Lost to Follow-up|2
6185394|NCT01365455|9838381|FG001|Maintenance Period|Lost to Follow-up|4
6185395|NCT01365455|9838382|FG002|Maintenance Period|Lost to Follow-up|0
6185396|NCT01365455|9838383|FG003|Maintenance Period|Lost to Follow-up|0
6185397|NCT01365455|9838384|FG004|Maintenance Period|Lost to Follow-up|3
6185398|NCT01365455|9838380|FG000|Maintenance Period|Non-compliance with study treatment|0
6185399|NCT01365455|9838381|FG001|Maintenance Period|Non-compliance with study treatment|0
6185400|NCT01365455|9838382|FG002|Maintenance Period|Non-compliance with study treatment|0
6185401|NCT01365455|9838383|FG003|Maintenance Period|Non-compliance with study treatment|1
6185402|NCT01365455|9838384|FG004|Maintenance Period|Non-compliance with study treatment|0
6185403|NCT01365455|9838380|FG000|Maintenance Period|Physician Decision|0
6185404|NCT01365455|9838381|FG001|Maintenance Period|Physician Decision|1
6185405|NCT01365455|9838382|FG002|Maintenance Period|Physician Decision|0
6185406|NCT01365455|9838383|FG003|Maintenance Period|Physician Decision|0
6185407|NCT01365455|9838384|FG004|Maintenance Period|Physician Decision|1
6185408|NCT01365455|9838380|FG000|Maintenance Period|Pregnancy|0
6185409|NCT01365455|9838381|FG001|Maintenance Period|Pregnancy|4
6185410|NCT01365455|9838382|FG002|Maintenance Period|Pregnancy|0
6185411|NCT01365455|9838383|FG003|Maintenance Period|Pregnancy|0
6185412|NCT01365455|9838384|FG004|Maintenance Period|Pregnancy|2
6185413|NCT01365455|9838380|FG000|Maintenance Period|Protocol deviation|1
6185414|NCT01365455|9838381|FG001|Maintenance Period|Protocol deviation|1
6185415|NCT01365455|9838382|FG002|Maintenance Period|Protocol deviation|0
6185416|NCT01365455|9838383|FG003|Maintenance Period|Protocol deviation|0
6185417|NCT01365455|9838384|FG004|Maintenance Period|Protocol deviation|0
6185418|NCT01365455|9838380|FG000|Maintenance Period|Subject/guardian decision|4
6185419|NCT01365455|9838381|FG001|Maintenance Period|Subject/guardian decision|6
6043586|NCT00391053|9642299|FG002|Overall Study|Protocol Violation|0
6043587|NCT00391053|9642300|FG003|Overall Study|Protocol Violation|0
6043588|NCT00391053|9642297|FG000|Overall Study|Lost to Follow-up|1
6185420|NCT01365455|9838382|FG002|Maintenance Period|Subject/guardian decision|2
6185421|NCT01365455|9838383|FG003|Maintenance Period|Subject/guardian decision|4
6185422|NCT01365455|9838384|FG004|Maintenance Period|Subject/guardian decision|1
6185423|NCT01365468|9838404|FG000|Overall Study|Physician Decision|1
6185424|NCT01365468|9838405|FG001|Overall Study|Physician Decision|0
6185425|NCT01365468|9838404|FG000|Overall Study|Disease progression|1
6185426|NCT01365468|9838405|FG001|Overall Study|Disease progression|0
6185427|NCT01365468|9838404|FG000|Overall Study|Lost to Follow-up|2
6185428|NCT01365468|9838405|FG001|Overall Study|Lost to Follow-up|0
6185429|NCT01365481|9838416|FG000|Overall Study|Adverse Event|6
6185430|NCT01365481|9838417|FG001|Overall Study|Adverse Event|9
6185431|NCT01365481|9838418|FG002|Overall Study|Adverse Event|0
6185432|NCT01365481|9838419|FG003|Overall Study|Adverse Event|2
6185433|NCT01365481|9838416|FG000|Overall Study|Withdrawal by Subject|0
6185434|NCT01365481|9838417|FG001|Overall Study|Withdrawal by Subject|2
6185435|NCT01365481|9838418|FG002|Overall Study|Withdrawal by Subject|1
6185436|NCT01365481|9838419|FG003|Overall Study|Withdrawal by Subject|1
6185437|NCT01365481|9838416|FG000|Overall Study|Lost to Follow-up|1
6185438|NCT01365481|9838417|FG001|Overall Study|Lost to Follow-up|1
6185439|NCT01365481|9838418|FG002|Overall Study|Lost to Follow-up|2
6185440|NCT01365481|9838419|FG003|Overall Study|Lost to Follow-up|3
6185441|NCT01365481|9838416|FG000|Overall Study|Abnormal laboratory value(s)|0
6185442|NCT01365481|9838417|FG001|Overall Study|Abnormal laboratory value(s)|1
6185443|NCT01365481|9838418|FG002|Overall Study|Abnormal laboratory value(s)|0
6185444|NCT01365481|9838419|FG003|Overall Study|Abnormal laboratory value(s)|0
6185445|NCT01365481|9838416|FG000|Overall Study|Administrative problems|0
6185446|NCT01365481|9838417|FG001|Overall Study|Administrative problems|1
6185447|NCT01365481|9838418|FG002|Overall Study|Administrative problems|0
6185448|NCT01365481|9838419|FG003|Overall Study|Administrative problems|0
6185449|NCT01365481|9838416|FG000|Overall Study|Protocol deviation|0
6185450|NCT01365481|9838417|FG001|Overall Study|Protocol deviation|1
6185451|NCT01365481|9838418|FG002|Overall Study|Protocol deviation|0
6185452|NCT01365481|9838419|FG003|Overall Study|Protocol deviation|1
6185453|NCT01365481|9838416|FG000|Overall Study|Unsatisfactory therapeutic effect|0
6185454|NCT01365481|9838417|FG001|Overall Study|Unsatisfactory therapeutic effect|0
6185455|NCT01365481|9838418|FG002|Overall Study|Unsatisfactory therapeutic effect|1
6185456|NCT01365481|9838419|FG003|Overall Study|Unsatisfactory therapeutic effect|0
6185457|NCT01365494|9838431|FG000|Overall Study|Adverse Event|1
6185458|NCT01365494|9838432|FG001|Overall Study|Adverse Event|0
6185459|NCT01365494|9838431|FG000|Overall Study|Withdrawal by Subject|0
6185460|NCT01365494|9838432|FG001|Overall Study|Withdrawal by Subject|1
6185461|NCT01365494|9838431|FG000|Overall Study|Lost to Follow-up|1
6185462|NCT01365494|9838432|FG001|Overall Study|Lost to Follow-up|2
6185463|NCT01365507|9838441|FG000|Overall Study|Withdrawal Criteria|8
6185464|NCT01365507|9838442|FG001|Overall Study|Withdrawal Criteria|5
6185465|NCT01365507|9838441|FG000|Overall Study|Unclassified|1
6185466|NCT01365507|9838442|FG001|Overall Study|Unclassified|4
6185467|NCT01365546|9838448|FG000|Overall Study|Withdrawal by Subject|1
6185468|NCT01365546|9838448|FG000|Overall Study|Screen failure|9
6185469|NCT01365546|9838448|FG000|Overall Study|Study termination|1
6185470|NCT01365910|9838516|FG000|Overall Study|Withdrawal by Subject|7
6185471|NCT01365910|9838516|FG000|Overall Study|disease progression|18
6185472|NCT01365910|9838516|FG000|Overall Study|Adverse Event|3
6185473|NCT01365910|9838516|FG000|Overall Study|other complicating disease|1
6185474|NCT01365910|9838516|FG000|Overall Study|pt did not get tx, nausea/vomiting|1
6185475|NCT01366209|9838531|FG000|Overall Study|Adverse Event|6
6185476|NCT01366209|9838532|FG001|Overall Study|Adverse Event|7
6185477|NCT01366209|9838531|FG000|Overall Study|Withdrawal by Subject|4
6185478|NCT01366209|9838532|FG001|Overall Study|Withdrawal by Subject|4
6185479|NCT01366209|9838531|FG000|Overall Study|Death|12
6185480|NCT01366209|9838532|FG001|Overall Study|Death|19
6185481|NCT01366209|9838531|FG000|Overall Study|Lung transplantation|6
6185482|NCT01366209|9838532|FG001|Overall Study|Lung transplantation|1
6043589|NCT00391053|9642298|FG001|Overall Study|Lost to Follow-up|0
6185483|NCT01366209|9838531|FG000|Overall Study|Lost to Follow-up|2
6185484|NCT01366209|9838532|FG001|Overall Study|Lost to Follow-up|1
6185485|NCT01366209|9838531|FG000|Overall Study|Physician Decision|1
6185486|NCT01366209|9838532|FG001|Overall Study|Physician Decision|0
6185487|NCT01366209|9838531|FG000|Overall Study|Sponsors decision|0
6185488|NCT01366209|9838532|FG001|Overall Study|Sponsors decision|1
6185489|NCT01366209|9838531|FG000|Overall Study|Withdrew consent|4
6185490|NCT01366209|9838532|FG001|Overall Study|Withdrew consent|3
6185491|NCT01366443|9838543|FG000|Overall Study|Lost to Follow-up|2
6185492|NCT01366443|9838543|FG000|Overall Study|Under 18 yo|1
6185493|NCT01366521|9838569|FG000|Overall Study|Adverse Event|1
6185494|NCT01366521|9838570|FG001|Overall Study|Adverse Event|0
6185495|NCT01366521|9838571|FG002|Overall Study|Adverse Event|0
6185496|NCT01366521|9838572|FG003|Overall Study|Adverse Event|0
6185497|NCT01366521|9838569|FG000|Overall Study|Protocol Violation|0
6185498|NCT01366521|9838570|FG001|Overall Study|Protocol Violation|0
6185499|NCT01366521|9838571|FG002|Overall Study|Protocol Violation|1
6185500|NCT01366521|9838572|FG003|Overall Study|Protocol Violation|0
6185501|NCT01366521|9838569|FG000|Overall Study|Physician Decision|0
6185502|NCT01366521|9838570|FG001|Overall Study|Physician Decision|0
6185503|NCT01366521|9838571|FG002|Overall Study|Physician Decision|1
6185504|NCT01366521|9838572|FG003|Overall Study|Physician Decision|0
6185505|NCT01366521|9838569|FG000|Overall Study|Withdrawal by Subject|0
6185506|NCT01366521|9838570|FG001|Overall Study|Withdrawal by Subject|1
6185507|NCT01366521|9838571|FG002|Overall Study|Withdrawal by Subject|0
6185508|NCT01366521|9838572|FG003|Overall Study|Withdrawal by Subject|0
6185509|NCT01366534|9838587|FG000|Overall Study|Lost to Follow-up|1
6185510|NCT01366534|9838588|FG001|Overall Study|Lost to Follow-up|0
6185511|NCT01366534|9838589|FG002|Overall Study|Lost to Follow-up|0
6185512|NCT01366534|9838587|FG000|Overall Study|Migrated|1
6185513|NCT01366534|9838588|FG001|Overall Study|Migrated|1
6185514|NCT01366534|9838589|FG002|Overall Study|Migrated|0
6185515|NCT01366534|9838587|FG000|Overall Study|Declined challenged|0
6185516|NCT01366534|9838588|FG001|Overall Study|Declined challenged|1
6185517|NCT01366534|9838589|FG002|Overall Study|Declined challenged|0
6185518|NCT01366638|9838600|FG000|Overall Study|Withdrawal by Subject|0
6185519|NCT01366638|9838601|FG001|Overall Study|Withdrawal by Subject|0
6185520|NCT01366638|9838602|FG002|Overall Study|Withdrawal by Subject|6
6185521|NCT01366638|9838600|FG000|Overall Study|Other|1
6185522|NCT01366638|9838601|FG001|Overall Study|Other|0
6185523|NCT01366638|9838602|FG002|Overall Study|Other|0
6185524|NCT01366846|9838614|FG000|Overall Study|Withdrawal by Subject|2
6185525|NCT01366846|9838615|FG001|Overall Study|Withdrawal by Subject|0
6185526|NCT01366846|9838616|FG002|Overall Study|Withdrawal by Subject|0
6185527|NCT01366846|9838617|FG003|Overall Study|Withdrawal by Subject|0
6185528|NCT01366846|9838614|FG000|Overall Study|Communication Difficulties|1
6185529|NCT01366846|9838615|FG001|Overall Study|Communication Difficulties|4
6185530|NCT01366846|9838616|FG002|Overall Study|Communication Difficulties|0
6185531|NCT01366846|9838617|FG003|Overall Study|Communication Difficulties|1
6185532|NCT01366846|9838614|FG000|Overall Study|Scheduling Conflicts|0
6185533|NCT01366846|9838615|FG001|Overall Study|Scheduling Conflicts|0
6185534|NCT01366846|9838616|FG002|Overall Study|Scheduling Conflicts|1
6185535|NCT01366846|9838617|FG003|Overall Study|Scheduling Conflicts|0
6185536|NCT01367119|9838660|FG000|Overall Study|Adverse Event|1
6185537|NCT01367119|9838661|FG001|Overall Study|Adverse Event|0
6185538|NCT01367119|9838660|FG000|Overall Study|Withdrawal by Subject|1
6185539|NCT01367119|9838661|FG001|Overall Study|Withdrawal by Subject|1
6185540|NCT01367158|9838678|FG000|Overall Study|Withdrew consent|0
6185541|NCT01367158|9838679|FG001|Overall Study|Withdrew consent|2
6185542|NCT01367158|9838680|FG002|Overall Study|Withdrew consent|1
6185543|NCT01367158|9838681|FG003|Overall Study|Withdrew consent|0
6185544|NCT01367158|9838682|FG004|Overall Study|Withdrew consent|2
6185545|NCT01367158|9838683|FG005|Overall Study|Withdrew consent|0
6185546|NCT01367158|9838684|FG006|Overall Study|Withdrew consent|0
6185547|NCT01367158|9838685|FG007|Overall Study|Withdrew consent|1
6185548|NCT01367158|9838686|FG008|Overall Study|Withdrew consent|0
6185549|NCT01367158|9838687|FG009|Overall Study|Withdrew consent|0
6185550|NCT01367158|9838688|FG010|Overall Study|Withdrew consent|0
6185551|NCT01367158|9838678|FG000|Overall Study|Lost to Follow-up|0
6185552|NCT01367158|9838679|FG001|Overall Study|Lost to Follow-up|0
6185553|NCT01367158|9838680|FG002|Overall Study|Lost to Follow-up|0
6185554|NCT01367158|9838681|FG003|Overall Study|Lost to Follow-up|1
6185555|NCT01367158|9838682|FG004|Overall Study|Lost to Follow-up|0
6185556|NCT01367158|9838683|FG005|Overall Study|Lost to Follow-up|2
6185557|NCT01367158|9838684|FG006|Overall Study|Lost to Follow-up|0
6185558|NCT01367158|9838685|FG007|Overall Study|Lost to Follow-up|1
6185559|NCT01367158|9838686|FG008|Overall Study|Lost to Follow-up|0
6185560|NCT01367158|9838687|FG009|Overall Study|Lost to Follow-up|0
6185561|NCT01367158|9838688|FG010|Overall Study|Lost to Follow-up|1
6185562|NCT01367158|9838678|FG000|Overall Study|Protocol Violation|0
6185563|NCT01367158|9838679|FG001|Overall Study|Protocol Violation|1
6185564|NCT01367158|9838680|FG002|Overall Study|Protocol Violation|0
6185565|NCT01367158|9838681|FG003|Overall Study|Protocol Violation|0
6185566|NCT01367158|9838682|FG004|Overall Study|Protocol Violation|0
6185567|NCT01367158|9838683|FG005|Overall Study|Protocol Violation|0
6185568|NCT01367158|9838684|FG006|Overall Study|Protocol Violation|0
6185569|NCT01367158|9838685|FG007|Overall Study|Protocol Violation|0
6185570|NCT01367158|9838686|FG008|Overall Study|Protocol Violation|0
6185571|NCT01367158|9838687|FG009|Overall Study|Protocol Violation|0
6185572|NCT01367158|9838688|FG010|Overall Study|Protocol Violation|0
6185573|NCT01367236|9838725|FG000|Overall Study|Withdrawal by Subject|3
6185574|NCT01367236|9838726|FG001|Overall Study|Withdrawal by Subject|1
6185575|NCT01367249|9838734|FG000|Overall Study|Withdrawal by Subject|6
6185576|NCT01367249|9838735|FG001|Overall Study|Withdrawal by Subject|6
6185577|NCT01367249|9838734|FG000|Overall Study|Other|3
6185578|NCT01367249|9838735|FG001|Overall Study|Other|10
6192961|NCT01435759|9850639|FG003|Antidepressant Lead-in Phase|Met BP or Pulse Withdrawal Criteria|0
6192962|NCT01435759|9850640|FG004|Antidepressant Lead-in Phase|Met BP or Pulse Withdrawal Criteria|0
6192963|NCT01435759|9850641|FG005|Antidepressant Lead-in Phase|Met BP or Pulse Withdrawal Criteria|0
6192964|NCT01435759|9850636|FG000|Antidepressant Lead-in Phase|Other|119
6192965|NCT01435759|9850637|FG001|Antidepressant Lead-in Phase|Other|0
6192966|NCT01435759|9850638|FG002|Antidepressant Lead-in Phase|Other|0
6192967|NCT01435759|9850639|FG003|Antidepressant Lead-in Phase|Other|0
6192968|NCT01435759|9850640|FG004|Antidepressant Lead-in Phase|Other|0
6192969|NCT01435759|9850641|FG005|Antidepressant Lead-in Phase|Other|0
6192970|NCT01435759|9850636|FG000|Double-blind Phase|Adverse Event|7
6192971|NCT01435759|9850637|FG001|Double-blind Phase|Adverse Event|0
6192972|NCT01435759|9850638|FG002|Double-blind Phase|Adverse Event|1
6192973|NCT01435759|9850639|FG003|Double-blind Phase|Adverse Event|1
6192974|NCT01435759|9850640|FG004|Double-blind Phase|Adverse Event|1
6192975|NCT01435759|9850641|FG005|Double-blind Phase|Adverse Event|3
6192976|NCT01435759|9850636|FG000|Double-blind Phase|Protocol Violation|2
6192977|NCT01435759|9850637|FG001|Double-blind Phase|Protocol Violation|0
6192978|NCT01435759|9850638|FG002|Double-blind Phase|Protocol Violation|1
6192979|NCT01435759|9850639|FG003|Double-blind Phase|Protocol Violation|2
6192980|NCT01435759|9850640|FG004|Double-blind Phase|Protocol Violation|0
6192981|NCT01435759|9850641|FG005|Double-blind Phase|Protocol Violation|1
6192982|NCT01435759|9850636|FG000|Double-blind Phase|Withdrawal by Subject|17
6192983|NCT01435759|9850637|FG001|Double-blind Phase|Withdrawal by Subject|4
6192984|NCT01435759|9850638|FG002|Double-blind Phase|Withdrawal by Subject|3
6192985|NCT01435759|9850639|FG003|Double-blind Phase|Withdrawal by Subject|4
6192986|NCT01435759|9850640|FG004|Double-blind Phase|Withdrawal by Subject|2
6192987|NCT01435759|9850641|FG005|Double-blind Phase|Withdrawal by Subject|2
6192988|NCT01435759|9850636|FG000|Double-blind Phase|Lost to Follow-up|31
6192989|NCT01435759|9850637|FG001|Double-blind Phase|Lost to Follow-up|1
6192990|NCT01435759|9850638|FG002|Double-blind Phase|Lost to Follow-up|2
6192991|NCT01435759|9850639|FG003|Double-blind Phase|Lost to Follow-up|0
6192992|NCT01435759|9850640|FG004|Double-blind Phase|Lost to Follow-up|3
6192993|NCT01435759|9850641|FG005|Double-blind Phase|Lost to Follow-up|3
6192994|NCT01435759|9850636|FG000|Double-blind Phase|Met BP or Pulse Withdrawal Criteria|1
6192995|NCT01435759|9850637|FG001|Double-blind Phase|Met BP or Pulse Withdrawal Criteria|0
6192996|NCT01435759|9850638|FG002|Double-blind Phase|Met BP or Pulse Withdrawal Criteria|0
6192997|NCT01435759|9850639|FG003|Double-blind Phase|Met BP or Pulse Withdrawal Criteria|0
6192998|NCT01435759|9850640|FG004|Double-blind Phase|Met BP or Pulse Withdrawal Criteria|3
6192999|NCT01435759|9850641|FG005|Double-blind Phase|Met BP or Pulse Withdrawal Criteria|0
6193000|NCT01435759|9850636|FG000|Double-blind Phase|Other|8
6193001|NCT01435759|9850637|FG001|Double-blind Phase|Other|2
6193002|NCT01435759|9850638|FG002|Double-blind Phase|Other|0
6193003|NCT01435759|9850639|FG003|Double-blind Phase|Other|2
6193004|NCT01435759|9850640|FG004|Double-blind Phase|Other|0
6193005|NCT01435759|9850641|FG005|Double-blind Phase|Other|0
6193006|NCT01435772|9850656|FG000|Overall Study|Adverse Event|1
6193007|NCT01435772|9850657|FG001|Overall Study|Adverse Event|0
6193008|NCT01435772|9850658|FG002|Overall Study|Adverse Event|2
6193009|NCT01435772|9850656|FG000|Overall Study|Withdrawal by Subject|0
6193010|NCT01435772|9850657|FG001|Overall Study|Withdrawal by Subject|1
6193011|NCT01435772|9850658|FG002|Overall Study|Withdrawal by Subject|3
6193012|NCT01435772|9850656|FG000|Overall Study|Other - study termination|2
6193013|NCT01435772|9850657|FG001|Overall Study|Other - study termination|2
6193014|NCT01435772|9850658|FG002|Overall Study|Other - study termination|10
6193015|NCT01435798|9850667|FG000|Overall Study|Withdrawal by Subject|1
6193016|NCT01435928|9850686|FG000|Open Label Phase - up to 24 Weeks|Adverse Event|83
6193017|NCT01435928|9850687|FG001|Open Label Phase - up to 24 Weeks|Adverse Event|0
6193018|NCT01435928|9850688|FG002|Open Label Phase - up to 24 Weeks|Adverse Event|0
6193019|NCT01435928|9850686|FG000|Open Label Phase - up to 24 Weeks|Death|1
6193020|NCT01435928|9850687|FG001|Open Label Phase - up to 24 Weeks|Death|0
6193021|NCT01435928|9850688|FG002|Open Label Phase - up to 24 Weeks|Death|0
6193022|NCT01435928|9850686|FG000|Open Label Phase - up to 24 Weeks|Lack of Efficacy|46
6193023|NCT01435928|9850687|FG001|Open Label Phase - up to 24 Weeks|Lack of Efficacy|0
6193024|NCT01435928|9850688|FG002|Open Label Phase - up to 24 Weeks|Lack of Efficacy|0
6193025|NCT01435928|9850686|FG000|Open Label Phase - up to 24 Weeks|Lost to Follow-up|60
6193026|NCT01435928|9850687|FG001|Open Label Phase - up to 24 Weeks|Lost to Follow-up|0
6193027|NCT01435928|9850688|FG002|Open Label Phase - up to 24 Weeks|Lost to Follow-up|0
6193028|NCT01435928|9850686|FG000|Open Label Phase - up to 24 Weeks|Protocol Violation|39
6193029|NCT01435928|9850687|FG001|Open Label Phase - up to 24 Weeks|Protocol Violation|0
6193030|NCT01435928|9850688|FG002|Open Label Phase - up to 24 Weeks|Protocol Violation|0
6193031|NCT01435928|9850686|FG000|Open Label Phase - up to 24 Weeks|Withdrawal by Subject|96
6193032|NCT01435928|9850687|FG001|Open Label Phase - up to 24 Weeks|Withdrawal by Subject|0
6193033|NCT01435928|9850688|FG002|Open Label Phase - up to 24 Weeks|Withdrawal by Subject|0
6193034|NCT01435928|9850686|FG000|Open Label Phase - up to 24 Weeks|did not meet stabilization criteria|44
6185579|NCT01367275|9838745|FG000|Overall Study|Ineligible|1
6185580|NCT01367275|9838745|FG000|Overall Study|Disease Progression|2
6185581|NCT01367457|9838781|FG000|Overall Study|Death|2
6185582|NCT01367457|9838782|FG001|Overall Study|Death|0
6185583|NCT01367457|9838783|FG002|Overall Study|Death|0
6185584|NCT01367457|9838781|FG000|Overall Study|Investigator's decision|2
6185585|NCT01367457|9838782|FG001|Overall Study|Investigator's decision|0
6185586|NCT01367457|9838783|FG002|Overall Study|Investigator's decision|0
6185587|NCT01367457|9838781|FG000|Overall Study|Clinical decline (CD)|2
6185588|NCT01367457|9838782|FG001|Overall Study|Clinical decline (CD)|0
6185589|NCT01367457|9838783|FG002|Overall Study|Clinical decline (CD)|0
6185590|NCT01367457|9838781|FG000|Overall Study|Progression and death|8
6185591|NCT01367457|9838782|FG001|Overall Study|Progression and death|0
6185592|NCT01367457|9838783|FG002|Overall Study|Progression and death|0
6185593|NCT01367457|9838781|FG000|Overall Study|Toxicity|16
6185594|NCT01367457|9838782|FG001|Overall Study|Toxicity|0
6185595|NCT01367457|9838783|FG002|Overall Study|Toxicity|0
6185596|NCT01367457|9838781|FG000|Overall Study|Progression|137
6185597|NCT01367457|9838782|FG001|Overall Study|Progression|0
6185598|NCT01367457|9838783|FG002|Overall Study|Progression|0
6185599|NCT01367457|9838781|FG000|Overall Study|Patient asks for rest + slow progression|1
6185600|NCT01367457|9838782|FG001|Overall Study|Patient asks for rest + slow progression|0
6185601|NCT01367457|9838783|FG002|Overall Study|Patient asks for rest + slow progression|0
6185602|NCT01367457|9838781|FG000|Overall Study|Investigator's opinion, stable disease|1
6185603|NCT01367457|9838782|FG001|Overall Study|Investigator's opinion, stable disease|0
6185604|NCT01367457|9838783|FG002|Overall Study|Investigator's opinion, stable disease|0
6185605|NCT01367457|9838781|FG000|Overall Study|Bleeding from cavernous haemangioma|1
6185606|NCT01367457|9838782|FG001|Overall Study|Bleeding from cavernous haemangioma|0
6375415|NCT03436199|10165463|FG000|Overall Study|Withdrawal by Subject|4
6375416|NCT03436199|10165464|FG001|Overall Study|Withdrawal by Subject|10
6375417|NCT03436199|10165465|FG002|Overall Study|Withdrawal by Subject|3
6375418|NCT03436199|10165463|FG000|Overall Study|Lost to Follow-up|1
6375419|NCT03436199|10165464|FG001|Overall Study|Lost to Follow-up|0
6375420|NCT03436199|10165465|FG002|Overall Study|Lost to Follow-up|2
6185607|NCT01367457|9838783|FG002|Overall Study|Bleeding from cavernous haemangioma|0
6185608|NCT01367457|9838781|FG000|Overall Study|3 yr Temsirolimus treatment (no disease)|1
6185609|NCT01367457|9838782|FG001|Overall Study|3 yr Temsirolimus treatment (no disease)|0
6185610|NCT01367457|9838783|FG002|Overall Study|3 yr Temsirolimus treatment (no disease)|0
6185611|NCT01367457|9838781|FG000|Overall Study|low grade toxicities + stable disease|1
6185612|NCT01367457|9838782|FG001|Overall Study|low grade toxicities + stable disease|0
6185613|NCT01367457|9838783|FG002|Overall Study|low grade toxicities + stable disease|0
6185614|NCT01367457|9838781|FG000|Overall Study|Choledocolithiasis and pancreatitis|1
6185615|NCT01367457|9838782|FG001|Overall Study|Choledocolithiasis and pancreatitis|0
6185616|NCT01367457|9838783|FG002|Overall Study|Choledocolithiasis and pancreatitis|0
6185617|NCT01367457|9838781|FG000|Overall Study|Withdrawal by Subject|1
6185618|NCT01367457|9838782|FG001|Overall Study|Withdrawal by Subject|0
6185619|NCT01367457|9838783|FG002|Overall Study|Withdrawal by Subject|0
6185620|NCT01367457|9838781|FG000|Overall Study|CD, associated leukaemia|1
6185621|NCT01367457|9838782|FG001|Overall Study|CD, associated leukaemia|0
6185622|NCT01367457|9838783|FG002|Overall Study|CD, associated leukaemia|0
6185623|NCT01367457|9838781|FG000|Overall Study|Uncontrolled pain|1
6185624|NCT01367457|9838782|FG001|Overall Study|Uncontrolled pain|0
6185625|NCT01367457|9838783|FG002|Overall Study|Uncontrolled pain|0
6185626|NCT01367457|9838781|FG000|Overall Study|Overall status worsens to grade 4|1
6185627|NCT01367457|9838782|FG001|Overall Study|Overall status worsens to grade 4|0
6185628|NCT01367457|9838783|FG002|Overall Study|Overall status worsens to grade 4|0
6185629|NCT01367457|9838781|FG000|Overall Study|Stabilisation + frequent infections|1
6185630|NCT01367457|9838782|FG001|Overall Study|Stabilisation + frequent infections|0
6185631|NCT01367457|9838783|FG002|Overall Study|Stabilisation + frequent infections|0
6185632|NCT01367457|9838781|FG000|Overall Study|No clinical benefit|1
6185633|NCT01367457|9838782|FG001|Overall Study|No clinical benefit|0
6185634|NCT01367457|9838783|FG002|Overall Study|No clinical benefit|0
6185635|NCT01367457|9838781|FG000|Overall Study|Intestinal obstruction with necrosis|1
6185636|NCT01367457|9838782|FG001|Overall Study|Intestinal obstruction with necrosis|0
6185637|NCT01367457|9838783|FG002|Overall Study|Intestinal obstruction with necrosis|0
6185638|NCT01367457|9838781|FG000|Overall Study|Overall decline|1
6185639|NCT01367457|9838782|FG001|Overall Study|Overall decline|0
6185640|NCT01367457|9838783|FG002|Overall Study|Overall decline|0
6185641|NCT01367457|9838781|FG000|Overall Study|Rejection of treatment|1
6185642|NCT01367457|9838782|FG001|Overall Study|Rejection of treatment|0
6185643|NCT01367457|9838783|FG002|Overall Study|Rejection of treatment|0
6185644|NCT01367457|9838781|FG000|Overall Study|Lost to Follow-up|1
6185645|NCT01367457|9838782|FG001|Overall Study|Lost to Follow-up|0
6185646|NCT01367457|9838783|FG002|Overall Study|Lost to Follow-up|0
6185647|NCT01367457|9838781|FG000|Overall Study|Death from septic shock|1
6185648|NCT01367457|9838782|FG001|Overall Study|Death from septic shock|0
6185649|NCT01367457|9838783|FG002|Overall Study|Death from septic shock|0
6185650|NCT01367457|9838781|FG000|Overall Study|CD, Suspected disease progression (DP)|1
6185651|NCT01367457|9838782|FG001|Overall Study|CD, Suspected disease progression (DP)|0
6375421|NCT03436199|10165463|FG000|Overall Study|Protocol Violation|1
6185652|NCT01367457|9838783|FG002|Overall Study|CD, Suspected disease progression (DP)|0
6185653|NCT01367457|9838781|FG000|Overall Study|Patient's Wish|1
6185654|NCT01367457|9838782|FG001|Overall Study|Patient's Wish|0
6185655|NCT01367457|9838783|FG002|Overall Study|Patient's Wish|0
6185656|NCT01367457|9838781|FG000|Overall Study|Palliative. Overall decline|1
6185657|NCT01367457|9838782|FG001|Overall Study|Palliative. Overall decline|0
6185658|NCT01367457|9838783|FG002|Overall Study|Palliative. Overall decline|0
6185659|NCT01367457|9838781|FG000|Overall Study|Suspected DP/suspected active infection|1
6185660|NCT01367457|9838782|FG001|Overall Study|Suspected DP/suspected active infection|0
6185661|NCT01367457|9838783|FG002|Overall Study|Suspected DP/suspected active infection|0
6185662|NCT01367665|9838793|FG000|Overall Study|Death|102
6185663|NCT01367665|9838794|FG001|Overall Study|Death|19
6185664|NCT01367665|9838793|FG000|Overall Study|Lost to Follow-up|222
6185665|NCT01367665|9838794|FG001|Overall Study|Lost to Follow-up|22
6185666|NCT01367665|9838793|FG000|Overall Study|Not Done|118
6185667|NCT01367665|9838794|FG001|Overall Study|Not Done|14
6185668|NCT01367704|9838803|FG000|Overall Study|Lost to Follow-up|47
6185669|NCT01367704|9838804|FG001|Overall Study|Lost to Follow-up|161
6185670|NCT01367834|9838812|FG000|Overall Study|Withdrawal by Subject|2
6185671|NCT01367834|9838813|FG001|Overall Study|Withdrawal by Subject|2
6185672|NCT01367834|9838812|FG000|Overall Study|Study was ended.|0
6185673|NCT01367834|9838813|FG001|Overall Study|Study was ended.|1
6185674|NCT01367847|9838821|FG000|Overall Study|Withdrawal by Subject|2
6185675|NCT01367847|9838822|FG001|Overall Study|Withdrawal by Subject|2
6185676|NCT01367886|9838838|FG000|Overall Study|Lost to Follow-up|4
6185677|NCT01367886|9838838|FG000|Overall Study|Lack of Efficacy|2
6185678|NCT01367886|9838838|FG000|Overall Study|Death|1
6185679|NCT01368042|9838843|FG000|Overall Study|Death|14
6185680|NCT01368042|9838843|FG000|Overall Study|Protocol Violation|11
6185681|NCT01368042|9838843|FG000|Overall Study|Lost to Follow-up|4
6185682|NCT01368042|9838843|FG000|Overall Study|Transplanted|1
6185683|NCT01368081|9838860|FG000|Overall Study|Adverse Event|4
6185684|NCT01368081|9838861|FG001|Overall Study|Adverse Event|4
6185685|NCT01368081|9838862|FG002|Overall Study|Adverse Event|3
6185686|NCT01368081|9838863|FG003|Overall Study|Adverse Event|2
6185687|NCT01368081|9838864|FG004|Overall Study|Adverse Event|2
6185688|NCT01368081|9838865|FG005|Overall Study|Adverse Event|5
6185689|NCT01368081|9838866|FG006|Overall Study|Adverse Event|6
6185690|NCT01368081|9838867|FG007|Overall Study|Adverse Event|2
6185691|NCT01368081|9838868|FG008|Overall Study|Adverse Event|3
6185692|NCT01368081|9838869|FG009|Overall Study|Adverse Event|5
6185693|NCT01368081|9838870|FG010|Overall Study|Adverse Event|6
6185694|NCT01368081|9838871|FG011|Overall Study|Adverse Event|1
6185695|NCT01368081|9838872|FG012|Overall Study|Adverse Event|3
6185696|NCT01368081|9838860|FG000|Overall Study|Lack of Efficacy|0
6185697|NCT01368081|9838861|FG001|Overall Study|Lack of Efficacy|1
6185698|NCT01368081|9838862|FG002|Overall Study|Lack of Efficacy|0
6185699|NCT01368081|9838863|FG003|Overall Study|Lack of Efficacy|1
6185700|NCT01368081|9838864|FG004|Overall Study|Lack of Efficacy|0
6185701|NCT01368081|9838865|FG005|Overall Study|Lack of Efficacy|0
6185702|NCT01368081|9838866|FG006|Overall Study|Lack of Efficacy|0
6185703|NCT01368081|9838867|FG007|Overall Study|Lack of Efficacy|2
6185704|NCT01368081|9838868|FG008|Overall Study|Lack of Efficacy|0
6185705|NCT01368081|9838869|FG009|Overall Study|Lack of Efficacy|0
6185706|NCT01368081|9838870|FG010|Overall Study|Lack of Efficacy|0
6185707|NCT01368081|9838871|FG011|Overall Study|Lack of Efficacy|0
6185708|NCT01368081|9838872|FG012|Overall Study|Lack of Efficacy|0
6185709|NCT01368081|9838860|FG000|Overall Study|Protocol Violation|0
6185710|NCT01368081|9838861|FG001|Overall Study|Protocol Violation|0
6185711|NCT01368081|9838862|FG002|Overall Study|Protocol Violation|0
6185712|NCT01368081|9838863|FG003|Overall Study|Protocol Violation|0
6185713|NCT01368081|9838864|FG004|Overall Study|Protocol Violation|0
6185714|NCT01368081|9838865|FG005|Overall Study|Protocol Violation|1
6185715|NCT01368081|9838866|FG006|Overall Study|Protocol Violation|0
6185716|NCT01368081|9838867|FG007|Overall Study|Protocol Violation|1
6185717|NCT01368081|9838868|FG008|Overall Study|Protocol Violation|0
6185718|NCT01368081|9838869|FG009|Overall Study|Protocol Violation|0
6185719|NCT01368081|9838870|FG010|Overall Study|Protocol Violation|0
6185720|NCT01368081|9838871|FG011|Overall Study|Protocol Violation|0
6185721|NCT01368081|9838872|FG012|Overall Study|Protocol Violation|0
6185722|NCT01368081|9838860|FG000|Overall Study|Lost to Follow-up|0
6185723|NCT01368081|9838861|FG001|Overall Study|Lost to Follow-up|0
6185724|NCT01368081|9838862|FG002|Overall Study|Lost to Follow-up|0
6185725|NCT01368081|9838863|FG003|Overall Study|Lost to Follow-up|0
6185726|NCT01368081|9838864|FG004|Overall Study|Lost to Follow-up|0
6185727|NCT01368081|9838865|FG005|Overall Study|Lost to Follow-up|0
6185728|NCT01368081|9838866|FG006|Overall Study|Lost to Follow-up|0
6185729|NCT01368081|9838867|FG007|Overall Study|Lost to Follow-up|0
6185730|NCT01368081|9838868|FG008|Overall Study|Lost to Follow-up|0
6185731|NCT01368081|9838869|FG009|Overall Study|Lost to Follow-up|0
6185732|NCT01368081|9838870|FG010|Overall Study|Lost to Follow-up|0
6185733|NCT01368081|9838871|FG011|Overall Study|Lost to Follow-up|0
6185734|NCT01368081|9838872|FG012|Overall Study|Lost to Follow-up|1
6185735|NCT01368081|9838860|FG000|Overall Study|Withdrawal by Subject|4
6185736|NCT01368081|9838861|FG001|Overall Study|Withdrawal by Subject|4
6185737|NCT01368081|9838862|FG002|Overall Study|Withdrawal by Subject|1
6185738|NCT01368081|9838863|FG003|Overall Study|Withdrawal by Subject|1
6185739|NCT01368081|9838864|FG004|Overall Study|Withdrawal by Subject|0
6185740|NCT01368081|9838865|FG005|Overall Study|Withdrawal by Subject|3
6185741|NCT01368081|9838866|FG006|Overall Study|Withdrawal by Subject|4
6185742|NCT01368081|9838867|FG007|Overall Study|Withdrawal by Subject|2
6185743|NCT01368081|9838868|FG008|Overall Study|Withdrawal by Subject|5
6185744|NCT01368081|9838869|FG009|Overall Study|Withdrawal by Subject|4
6185745|NCT01368081|9838870|FG010|Overall Study|Withdrawal by Subject|3
6185746|NCT01368081|9838871|FG011|Overall Study|Withdrawal by Subject|2
6185747|NCT01368081|9838872|FG012|Overall Study|Withdrawal by Subject|0
6185748|NCT01368081|9838860|FG000|Overall Study|Other reason not defined above|2
6185749|NCT01368081|9838861|FG001|Overall Study|Other reason not defined above|0
6185750|NCT01368081|9838862|FG002|Overall Study|Other reason not defined above|0
6185751|NCT01368081|9838863|FG003|Overall Study|Other reason not defined above|1
6185752|NCT01368081|9838864|FG004|Overall Study|Other reason not defined above|0
6185753|NCT01368081|9838865|FG005|Overall Study|Other reason not defined above|1
6185754|NCT01368081|9838866|FG006|Overall Study|Other reason not defined above|2
6185755|NCT01368081|9838867|FG007|Overall Study|Other reason not defined above|0
6185756|NCT01368081|9838868|FG008|Overall Study|Other reason not defined above|0
6185757|NCT01368081|9838869|FG009|Overall Study|Other reason not defined above|1
6185758|NCT01368081|9838870|FG010|Overall Study|Other reason not defined above|0
6185759|NCT01368081|9838871|FG011|Overall Study|Other reason not defined above|0
6185760|NCT01368081|9838872|FG012|Overall Study|Other reason not defined above|3
6185761|NCT01368211|9838902|FG000|Second Platelets Transfusion|No need for additional transfusion|1
6185762|NCT01368211|9838903|FG001|Second Platelets Transfusion|No need for additional transfusion|2
6185763|NCT01368276|9838924|FG000|Overall Study|Death|1
6185764|NCT01368276|9838925|FG001|Overall Study|Death|10
6185765|NCT01368406|9838933|FG000|Overall Study|Lost to Follow-up|8
6185766|NCT01368406|9838934|FG001|Overall Study|Lost to Follow-up|4
6185767|NCT01368406|9838933|FG000|Overall Study|Withdrawal by Subject|8
6185768|NCT01368406|9838934|FG001|Overall Study|Withdrawal by Subject|4
6185769|NCT01368406|9838933|FG000|Overall Study|relapse of the disease|3
6185770|NCT01368406|9838934|FG001|Overall Study|relapse of the disease|2
6185771|NCT01368406|9838933|FG000|Overall Study|started working|2
6185772|NCT01368406|9838934|FG001|Overall Study|started working|3
6185773|NCT01368432|9838942|FG000|Overall Study|Lost to Follow-up|0
6185774|NCT01368432|9838943|FG001|Overall Study|Lost to Follow-up|1
6185775|NCT01368536|9838966|FG000|Overall Study|Adverse Event|5
6185776|NCT01368536|9838967|FG001|Overall Study|Adverse Event|6
6185777|NCT01368536|9838968|FG002|Overall Study|Adverse Event|8
6185778|NCT01368536|9838966|FG000|Overall Study|Abnormal laboratory value(s)|0
6185779|NCT01368536|9838967|FG001|Overall Study|Abnormal laboratory value(s)|1
6185780|NCT01368536|9838968|FG002|Overall Study|Abnormal laboratory value(s)|2
6185781|NCT01368536|9838966|FG000|Overall Study|Abnormal test procedure result(s)|0
6185782|NCT01368536|9838967|FG001|Overall Study|Abnormal test procedure result(s)|0
6185783|NCT01368536|9838968|FG002|Overall Study|Abnormal test procedure result(s)|1
6185784|NCT01368536|9838966|FG000|Overall Study|Unsatisfactory therapeutic effect|7
6185785|NCT01368536|9838967|FG001|Overall Study|Unsatisfactory therapeutic effect|2
6185786|NCT01368536|9838968|FG002|Overall Study|Unsatisfactory therapeutic effect|2
6185787|NCT01368536|9838966|FG000|Overall Study|No longer required study medication|0
6185788|NCT01368536|9838967|FG001|Overall Study|No longer required study medication|0
6185789|NCT01368536|9838968|FG002|Overall Study|No longer required study medication|1
6185790|NCT01368536|9838966|FG000|Overall Study|Withdrawal by Subject|2
6185791|NCT01368536|9838967|FG001|Overall Study|Withdrawal by Subject|5
6185792|NCT01368536|9838968|FG002|Overall Study|Withdrawal by Subject|4
6185793|NCT01368536|9838966|FG000|Overall Study|Lost to Follow-up|3
6185794|NCT01368536|9838967|FG001|Overall Study|Lost to Follow-up|3
6185795|NCT01368536|9838968|FG002|Overall Study|Lost to Follow-up|5
6185796|NCT01368536|9838966|FG000|Overall Study|Administrative problems|34
6185797|NCT01368536|9838967|FG001|Overall Study|Administrative problems|39
6185798|NCT01368536|9838968|FG002|Overall Study|Administrative problems|35
6185799|NCT01368536|9838966|FG000|Overall Study|Protocol deviation|0
6185800|NCT01368536|9838967|FG001|Overall Study|Protocol deviation|3
6185801|NCT01368536|9838968|FG002|Overall Study|Protocol deviation|1
6185802|NCT01368562|9838977|FG000|Overall Study|Adverse Event|1
6185803|NCT01368562|9838977|FG000|Overall Study|Disease progression|1
6185804|NCT01368562|9838977|FG000|Overall Study|Lost to Follow-up|1
6185805|NCT01368562|9838977|FG000|Overall Study|Death|6
6185806|NCT01368562|9838977|FG000|Overall Study|Unresponsive to treatment|5
6185807|NCT01368562|9838977|FG000|Overall Study|Other|3
6185808|NCT01368562|9838977|FG000|Overall Study|Other than specified|2
6185809|NCT01368614|9838981|FG000|Screening Period|Screen Failure|58
6185810|NCT01368614|9838982|FG001|Screening Period|Screen Failure|0
6185811|NCT01368614|9838983|FG002|Screening Period|Screen Failure|0
6185812|NCT01368614|9838984|FG003|Screening Period|Screen Failure|0
6185813|NCT01368614|9838981|FG000|Study Period|Withdrawal by Subject|0
6185814|NCT01368614|9838982|FG001|Study Period|Withdrawal by Subject|1
6185815|NCT01368614|9838983|FG002|Study Period|Withdrawal by Subject|1
6185816|NCT01368614|9838984|FG003|Study Period|Withdrawal by Subject|3
6185817|NCT01368614|9838981|FG000|Study Period|Lost to Follow-up|0
6185818|NCT01368614|9838982|FG001|Study Period|Lost to Follow-up|0
6185819|NCT01368614|9838983|FG002|Study Period|Lost to Follow-up|1
6185820|NCT01368614|9838984|FG003|Study Period|Lost to Follow-up|0
6185821|NCT01368835|9839019|FG000|Overall Study|Inclusion criteria/photography quality|22
6185822|NCT01368835|9839019|FG000|Overall Study|Lost to Follow-up|11
6185823|NCT01368900|9839071|FG000|Overall Study|Lost to Follow-up|7
6185824|NCT01368965|9839077|FG000|Overall Study|Lost to Follow-up|12
6185825|NCT01369069|9839089|FG000|Overall Study|Lost to Follow-up|8
6228160|NCT01723254|9901347|FG004|Overall Study|No longer have time to participate|0
6228161|NCT01723254|9901348|FG005|Overall Study|No longer have time to participate|0
6228162|NCT01723254|9901349|FG006|Overall Study|No longer have time to participate|0
6228163|NCT01723254|9901350|FG007|Overall Study|No longer have time to participate|0
6228164|NCT01723254|9901343|FG000|Overall Study|Move/Left to another country/city|0
6228165|NCT01723254|9901344|FG001|Overall Study|Move/Left to another country/city|0
6228166|NCT01723254|9901345|FG002|Overall Study|Move/Left to another country/city|2
6228167|NCT01723254|9901346|FG003|Overall Study|Move/Left to another country/city|1
6228168|NCT01723254|9901347|FG004|Overall Study|Move/Left to another country/city|1
6228169|NCT01723254|9901348|FG005|Overall Study|Move/Left to another country/city|0
6228170|NCT01723254|9901349|FG006|Overall Study|Move/Left to another country/city|0
6228171|NCT01723254|9901350|FG007|Overall Study|Move/Left to another country/city|0
6228172|NCT01723254|9901343|FG000|Overall Study|Protocol Violation|0
6228173|NCT01723254|9901344|FG001|Overall Study|Protocol Violation|1
6228174|NCT01723254|9901345|FG002|Overall Study|Protocol Violation|0
6228175|NCT01723254|9901346|FG003|Overall Study|Protocol Violation|0
6228176|NCT01723254|9901347|FG004|Overall Study|Protocol Violation|0
6228177|NCT01723254|9901348|FG005|Overall Study|Protocol Violation|0
6228178|NCT01723254|9901349|FG006|Overall Study|Protocol Violation|0
6228179|NCT01723254|9901350|FG007|Overall Study|Protocol Violation|0
6228180|NCT01723254|9901343|FG000|Overall Study|Withdrawal by Subject|1
6228181|NCT01723254|9901344|FG001|Overall Study|Withdrawal by Subject|2
6228182|NCT01723254|9901345|FG002|Overall Study|Withdrawal by Subject|1
6228183|NCT01723254|9901346|FG003|Overall Study|Withdrawal by Subject|0
6228184|NCT01723254|9901347|FG004|Overall Study|Withdrawal by Subject|1
6228185|NCT01723254|9901348|FG005|Overall Study|Withdrawal by Subject|1
6228186|NCT01723254|9901349|FG006|Overall Study|Withdrawal by Subject|1
6228187|NCT01723254|9901350|FG007|Overall Study|Withdrawal by Subject|2
6228188|NCT01723397|9901379|FG000|Study Period 1|Protocol Violation|0
6228189|NCT01723397|9901380|FG001|Study Period 1|Protocol Violation|1
6228190|NCT01723397|9901379|FG000|Study Period 2|Protocol Violation|0
6228191|NCT01723397|9901380|FG001|Study Period 2|Protocol Violation|1
6228192|NCT01723826|9901443|FG000|Overall Study|Adverse Event|4
6228193|NCT01723826|9901444|FG001|Overall Study|Adverse Event|1
6228194|NCT01723826|9901445|FG002|Overall Study|Adverse Event|4
6228195|NCT01723826|9901446|FG003|Overall Study|Adverse Event|5
6228196|NCT01723826|9901443|FG000|Overall Study|Death according to AE eCRF|2
6228197|NCT01723826|9901444|FG001|Overall Study|Death according to AE eCRF|3
6228198|NCT01723826|9901445|FG002|Overall Study|Death according to AE eCRF|3
6228199|NCT01723826|9901446|FG003|Overall Study|Death according to AE eCRF|7
6228200|NCT01723826|9901443|FG000|Overall Study|Lost to Follow-up|1
6228201|NCT01723826|9901444|FG001|Overall Study|Lost to Follow-up|3
6228202|NCT01723826|9901445|FG002|Overall Study|Lost to Follow-up|1
6228203|NCT01723826|9901446|FG003|Overall Study|Lost to Follow-up|1
6228204|NCT01723826|9901443|FG000|Overall Study|Non-compliance|0
6228205|NCT01723826|9901444|FG001|Overall Study|Non-compliance|1
6228206|NCT01723826|9901445|FG002|Overall Study|Non-compliance|3
6228207|NCT01723826|9901446|FG003|Overall Study|Non-compliance|3
6228208|NCT01723826|9901443|FG000|Overall Study|Non-compliance With Study Drug|0
6228209|NCT01723826|9901444|FG001|Overall Study|Non-compliance With Study Drug|1
6228210|NCT01723826|9901445|FG002|Overall Study|Non-compliance With Study Drug|0
6228211|NCT01723826|9901446|FG003|Overall Study|Non-compliance With Study Drug|0
6228212|NCT01723826|9901443|FG000|Overall Study|Other Reason|8
6228213|NCT01723826|9901444|FG001|Overall Study|Other Reason|6
6228214|NCT01723826|9901445|FG002|Overall Study|Other Reason|12
6228215|NCT01723826|9901446|FG003|Overall Study|Other Reason|14
6228216|NCT01723826|9901443|FG000|Overall Study|Physician Decision|1
6228217|NCT01723826|9901444|FG001|Overall Study|Physician Decision|3
6228218|NCT01723826|9901445|FG002|Overall Study|Physician Decision|4
6228219|NCT01723826|9901446|FG003|Overall Study|Physician Decision|11
6228220|NCT01723826|9901443|FG000|Overall Study|Protocol Violation|1
6228221|NCT01723826|9901444|FG001|Overall Study|Protocol Violation|1
6185826|NCT01369069|9839090|FG001|Overall Study|Lost to Follow-up|9
6185827|NCT01369069|9839089|FG000|Overall Study|Withdrawal by Subject|9
6185828|NCT01369069|9839090|FG001|Overall Study|Withdrawal by Subject|7
6185829|NCT01369225|9839107|FG000|Overall Study|Withdrawal by Subject|1
6185830|NCT01369225|9839108|FG001|Overall Study|Withdrawal by Subject|0
6185831|NCT01369225|9839109|FG002|Overall Study|Withdrawal by Subject|2
6185832|NCT01369225|9839110|FG003|Overall Study|Withdrawal by Subject|1
6185833|NCT01369225|9839111|FG004|Overall Study|Withdrawal by Subject|0
6185834|NCT01369225|9839112|FG005|Overall Study|Withdrawal by Subject|0
6185835|NCT01369225|9839107|FG000|Overall Study|Does Not Meet Entrance Criteria|0
6228222|NCT01723826|9901445|FG002|Overall Study|Protocol Violation|3
6228223|NCT01723826|9901446|FG003|Overall Study|Protocol Violation|1
6228224|NCT01723826|9901443|FG000|Overall Study|Withdrawal by Subject|10
6228225|NCT01723826|9901444|FG001|Overall Study|Withdrawal by Subject|17
6228226|NCT01723826|9901445|FG002|Overall Study|Withdrawal by Subject|27
6185836|NCT01369225|9839108|FG001|Overall Study|Does Not Meet Entrance Criteria|0
6185837|NCT01369225|9839109|FG002|Overall Study|Does Not Meet Entrance Criteria|1
6185838|NCT01369225|9839110|FG003|Overall Study|Does Not Meet Entrance Criteria|0
6185839|NCT01369225|9839111|FG004|Overall Study|Does Not Meet Entrance Criteria|0
6185840|NCT01369225|9839112|FG005|Overall Study|Does Not Meet Entrance Criteria|0
6185841|NCT01369225|9839107|FG000|Overall Study|Other|1
6185842|NCT01369225|9839108|FG001|Overall Study|Other|0
6185843|NCT01369225|9839109|FG002|Overall Study|Other|0
6185844|NCT01369225|9839110|FG003|Overall Study|Other|0
6185845|NCT01369225|9839111|FG004|Overall Study|Other|1
6185846|NCT01369225|9839112|FG005|Overall Study|Other|0
6185847|NCT01369225|9839107|FG000|Overall Study|Adverse Event|0
6185848|NCT01369225|9839108|FG001|Overall Study|Adverse Event|0
6185849|NCT01369225|9839109|FG002|Overall Study|Adverse Event|0
6185850|NCT01369225|9839110|FG003|Overall Study|Adverse Event|1
6185851|NCT01369225|9839111|FG004|Overall Study|Adverse Event|1
6185852|NCT01369225|9839112|FG005|Overall Study|Adverse Event|0
6185853|NCT01369329|9839129|FG000|Overall Study|Withdrawal by Subject|8
6185854|NCT01369329|9839130|FG001|Overall Study|Withdrawal by Subject|6
6185855|NCT01369329|9839131|FG002|Overall Study|Withdrawal by Subject|10
6185856|NCT01369329|9839129|FG000|Overall Study|Lost to Follow-up|2
6185857|NCT01369329|9839130|FG001|Overall Study|Lost to Follow-up|2
6185858|NCT01369329|9839131|FG002|Overall Study|Lost to Follow-up|2
6185859|NCT01369329|9839129|FG000|Overall Study|Other|2
6185860|NCT01369329|9839130|FG001|Overall Study|Other|3
6185861|NCT01369329|9839131|FG002|Overall Study|Other|2
6185862|NCT01369342|9839142|FG000|Overall Study|Withdrawal by Subject|7
6185863|NCT01369342|9839143|FG001|Overall Study|Withdrawal by Subject|7
6185864|NCT01369342|9839144|FG002|Overall Study|Withdrawal by Subject|2
6185865|NCT01369342|9839142|FG000|Overall Study|Lost to Follow-up|5
6185866|NCT01369342|9839143|FG001|Overall Study|Lost to Follow-up|2
6185867|NCT01369342|9839144|FG002|Overall Study|Lost to Follow-up|1
6185868|NCT01369342|9839142|FG000|Overall Study|Not Treated|1
6185869|NCT01369342|9839143|FG001|Overall Study|Not Treated|0
6185870|NCT01369342|9839144|FG002|Overall Study|Not Treated|0
6185871|NCT01369355|9839158|FG000|Week 0 - Week 44 (Maintenance)|Adverse Event|9
6185872|NCT01369355|9839159|FG001|Week 0 - Week 44 (Maintenance)|Adverse Event|12
6185873|NCT01369355|9839160|FG002|Week 0 - Week 44 (Maintenance)|Adverse Event|6
6185874|NCT01369355|9839161|FG003|Week 0 - Week 44 (Maintenance)|Adverse Event|7
6185875|NCT01369355|9839162|FG004|Week 0 - Week 44 (Maintenance)|Adverse Event|14
6185876|NCT01369355|9839163|FG005|Week 0 - Week 44 (Maintenance)|Adverse Event|25
6185877|NCT01369355|9839164|FG006|Week 0 - Week 44 (Maintenance)|Adverse Event|0
6185878|NCT01369355|9839165|FG007|Week 0 - Week 44 (Maintenance)|Adverse Event|0
6185879|NCT01369355|9839166|FG008|Week 0 - Week 44 (Maintenance)|Adverse Event|0
6185880|NCT01369355|9839158|FG000|Week 0 - Week 44 (Maintenance)|Lack of Efficacy|15
6185881|NCT01369355|9839159|FG001|Week 0 - Week 44 (Maintenance)|Lack of Efficacy|14
6185882|NCT01369355|9839160|FG002|Week 0 - Week 44 (Maintenance)|Lack of Efficacy|15
6185883|NCT01369355|9839161|FG003|Week 0 - Week 44 (Maintenance)|Lack of Efficacy|15
6185884|NCT01369355|9839162|FG004|Week 0 - Week 44 (Maintenance)|Lack of Efficacy|126
6185885|NCT01369355|9839163|FG005|Week 0 - Week 44 (Maintenance)|Lack of Efficacy|217
6185886|NCT01369355|9839164|FG006|Week 0 - Week 44 (Maintenance)|Lack of Efficacy|0
6185887|NCT01369355|9839165|FG007|Week 0 - Week 44 (Maintenance)|Lack of Efficacy|0
6185888|NCT01369355|9839166|FG008|Week 0 - Week 44 (Maintenance)|Lack of Efficacy|0
6185889|NCT01369355|9839158|FG000|Week 0 - Week 44 (Maintenance)|Protocol Violation|0
6185890|NCT01369355|9839159|FG001|Week 0 - Week 44 (Maintenance)|Protocol Violation|1
6185891|NCT01369355|9839160|FG002|Week 0 - Week 44 (Maintenance)|Protocol Violation|1
6185892|NCT01369355|9839161|FG003|Week 0 - Week 44 (Maintenance)|Protocol Violation|0
6185893|NCT01369355|9839162|FG004|Week 0 - Week 44 (Maintenance)|Protocol Violation|0
6185894|NCT01369355|9839163|FG005|Week 0 - Week 44 (Maintenance)|Protocol Violation|2
6185895|NCT01369355|9839164|FG006|Week 0 - Week 44 (Maintenance)|Protocol Violation|0
6185896|NCT01369355|9839165|FG007|Week 0 - Week 44 (Maintenance)|Protocol Violation|0
6185897|NCT01369355|9839166|FG008|Week 0 - Week 44 (Maintenance)|Protocol Violation|0
6185898|NCT01369355|9839158|FG000|Week 0 - Week 44 (Maintenance)|Lost to Follow-up|1
6185899|NCT01369355|9839159|FG001|Week 0 - Week 44 (Maintenance)|Lost to Follow-up|0
6185900|NCT01369355|9839160|FG002|Week 0 - Week 44 (Maintenance)|Lost to Follow-up|1
6185901|NCT01369355|9839161|FG003|Week 0 - Week 44 (Maintenance)|Lost to Follow-up|2
6185902|NCT01369355|9839162|FG004|Week 0 - Week 44 (Maintenance)|Lost to Follow-up|5
6185903|NCT01369355|9839163|FG005|Week 0 - Week 44 (Maintenance)|Lost to Follow-up|6
6185904|NCT01369355|9839164|FG006|Week 0 - Week 44 (Maintenance)|Lost to Follow-up|0
6185905|NCT01369355|9839165|FG007|Week 0 - Week 44 (Maintenance)|Lost to Follow-up|0
6185906|NCT01369355|9839166|FG008|Week 0 - Week 44 (Maintenance)|Lost to Follow-up|0
6185907|NCT01369355|9839158|FG000|Week 0 - Week 44 (Maintenance)|Withdrawal by Subject|6
6185908|NCT01369355|9839159|FG001|Week 0 - Week 44 (Maintenance)|Withdrawal by Subject|2
6185909|NCT01369355|9839160|FG002|Week 0 - Week 44 (Maintenance)|Withdrawal by Subject|7
6185910|NCT01369355|9839161|FG003|Week 0 - Week 44 (Maintenance)|Withdrawal by Subject|6
6185911|NCT01369355|9839162|FG004|Week 0 - Week 44 (Maintenance)|Withdrawal by Subject|8
6185912|NCT01369355|9839163|FG005|Week 0 - Week 44 (Maintenance)|Withdrawal by Subject|22
6185913|NCT01369355|9839164|FG006|Week 0 - Week 44 (Maintenance)|Withdrawal by Subject|0
6185914|NCT01369355|9839165|FG007|Week 0 - Week 44 (Maintenance)|Withdrawal by Subject|0
6185915|NCT01369355|9839166|FG008|Week 0 - Week 44 (Maintenance)|Withdrawal by Subject|0
6185916|NCT01369355|9839158|FG000|Week 0 - Week 44 (Maintenance)|Other|0
6185917|NCT01369355|9839159|FG001|Week 0 - Week 44 (Maintenance)|Other|0
6185918|NCT01369355|9839160|FG002|Week 0 - Week 44 (Maintenance)|Other|1
6185919|NCT01369355|9839161|FG003|Week 0 - Week 44 (Maintenance)|Other|0
6185920|NCT01369355|9839162|FG004|Week 0 - Week 44 (Maintenance)|Other|1
6185921|NCT01369355|9839163|FG005|Week 0 - Week 44 (Maintenance)|Other|0
6185922|NCT01369355|9839164|FG006|Week 0 - Week 44 (Maintenance)|Other|0
6185923|NCT01369355|9839165|FG007|Week 0 - Week 44 (Maintenance)|Other|0
6185924|NCT01369355|9839166|FG008|Week 0 - Week 44 (Maintenance)|Other|0
6185925|NCT01369355|9839158|FG000|Long-term Extension (Week 44-272)|Adverse Event|0
6185926|NCT01369355|9839159|FG001|Long-term Extension (Week 44-272)|Adverse Event|0
6185927|NCT01369355|9839160|FG002|Long-term Extension (Week 44-272)|Adverse Event|0
6185928|NCT01369355|9839161|FG003|Long-term Extension (Week 44-272)|Adverse Event|0
6185929|NCT01369355|9839162|FG004|Long-term Extension (Week 44-272)|Adverse Event|0
6185930|NCT01369355|9839163|FG005|Long-term Extension (Week 44-272)|Adverse Event|0
6185931|NCT01369355|9839164|FG006|Long-term Extension (Week 44-272)|Adverse Event|15
6185932|NCT01369355|9839165|FG007|Long-term Extension (Week 44-272)|Adverse Event|29
6185933|NCT01369355|9839166|FG008|Long-term Extension (Week 44-272)|Adverse Event|53
6375422|NCT03436199|10165464|FG001|Overall Study|Protocol Violation|1
6375423|NCT03436199|10165465|FG002|Overall Study|Protocol Violation|0
6375424|NCT03436199|10165463|FG000|Overall Study|Physician Decision|0
6375425|NCT03436199|10165464|FG001|Overall Study|Physician Decision|1
6185934|NCT01369355|9839158|FG000|Long-term Extension (Week 44-272)|Death|0
6185935|NCT01369355|9839159|FG001|Long-term Extension (Week 44-272)|Death|0
6185936|NCT01369355|9839160|FG002|Long-term Extension (Week 44-272)|Death|0
6185937|NCT01369355|9839161|FG003|Long-term Extension (Week 44-272)|Death|0
6185938|NCT01369355|9839162|FG004|Long-term Extension (Week 44-272)|Death|0
6185939|NCT01369355|9839163|FG005|Long-term Extension (Week 44-272)|Death|0
6185940|NCT01369355|9839164|FG006|Long-term Extension (Week 44-272)|Death|0
6185941|NCT01369355|9839165|FG007|Long-term Extension (Week 44-272)|Death|1
6185942|NCT01369355|9839166|FG008|Long-term Extension (Week 44-272)|Death|3
6185943|NCT01369355|9839158|FG000|Long-term Extension (Week 44-272)|Lack of Efficacy|0
6185944|NCT01369355|9839159|FG001|Long-term Extension (Week 44-272)|Lack of Efficacy|0
6185945|NCT01369355|9839160|FG002|Long-term Extension (Week 44-272)|Lack of Efficacy|0
6185946|NCT01369355|9839161|FG003|Long-term Extension (Week 44-272)|Lack of Efficacy|0
6185947|NCT01369355|9839162|FG004|Long-term Extension (Week 44-272)|Lack of Efficacy|0
6185948|NCT01369355|9839163|FG005|Long-term Extension (Week 44-272)|Lack of Efficacy|0
6185949|NCT01369355|9839164|FG006|Long-term Extension (Week 44-272)|Lack of Efficacy|12
6185950|NCT01369355|9839165|FG007|Long-term Extension (Week 44-272)|Lack of Efficacy|26
6185951|NCT01369355|9839166|FG008|Long-term Extension (Week 44-272)|Lack of Efficacy|29
6185952|NCT01369355|9839158|FG000|Long-term Extension (Week 44-272)|Protocol Violation|0
6185953|NCT01369355|9839159|FG001|Long-term Extension (Week 44-272)|Protocol Violation|0
6185954|NCT01369355|9839160|FG002|Long-term Extension (Week 44-272)|Protocol Violation|0
6185955|NCT01369355|9839161|FG003|Long-term Extension (Week 44-272)|Protocol Violation|0
6185956|NCT01369355|9839162|FG004|Long-term Extension (Week 44-272)|Protocol Violation|0
6185957|NCT01369355|9839163|FG005|Long-term Extension (Week 44-272)|Protocol Violation|0
6185958|NCT01369355|9839164|FG006|Long-term Extension (Week 44-272)|Protocol Violation|0
6185959|NCT01369355|9839165|FG007|Long-term Extension (Week 44-272)|Protocol Violation|1
6185960|NCT01369355|9839166|FG008|Long-term Extension (Week 44-272)|Protocol Violation|2
6185961|NCT01369355|9839158|FG000|Long-term Extension (Week 44-272)|Physician Decision|0
6185962|NCT01369355|9839159|FG001|Long-term Extension (Week 44-272)|Physician Decision|0
6185963|NCT01369355|9839160|FG002|Long-term Extension (Week 44-272)|Physician Decision|0
6185964|NCT01369355|9839161|FG003|Long-term Extension (Week 44-272)|Physician Decision|0
6185965|NCT01369355|9839162|FG004|Long-term Extension (Week 44-272)|Physician Decision|0
6185966|NCT01369355|9839163|FG005|Long-term Extension (Week 44-272)|Physician Decision|0
6185967|NCT01369355|9839164|FG006|Long-term Extension (Week 44-272)|Physician Decision|1
6185968|NCT01369355|9839165|FG007|Long-term Extension (Week 44-272)|Physician Decision|5
6185969|NCT01369355|9839166|FG008|Long-term Extension (Week 44-272)|Physician Decision|11
6185970|NCT01369355|9839158|FG000|Long-term Extension (Week 44-272)|Lost to Follow-up|0
6185971|NCT01369355|9839159|FG001|Long-term Extension (Week 44-272)|Lost to Follow-up|0
6185972|NCT01369355|9839160|FG002|Long-term Extension (Week 44-272)|Lost to Follow-up|0
6185973|NCT01369355|9839161|FG003|Long-term Extension (Week 44-272)|Lost to Follow-up|0
6185974|NCT01369355|9839162|FG004|Long-term Extension (Week 44-272)|Lost to Follow-up|0
6185975|NCT01369355|9839163|FG005|Long-term Extension (Week 44-272)|Lost to Follow-up|0
6185976|NCT01369355|9839164|FG006|Long-term Extension (Week 44-272)|Lost to Follow-up|1
6185977|NCT01369355|9839165|FG007|Long-term Extension (Week 44-272)|Lost to Follow-up|5
6185978|NCT01369355|9839166|FG008|Long-term Extension (Week 44-272)|Lost to Follow-up|9
6185979|NCT01369355|9839158|FG000|Long-term Extension (Week 44-272)|Withdrawal by Subject|0
6185980|NCT01369355|9839159|FG001|Long-term Extension (Week 44-272)|Withdrawal by Subject|0
6185981|NCT01369355|9839160|FG002|Long-term Extension (Week 44-272)|Withdrawal by Subject|0
6185982|NCT01369355|9839161|FG003|Long-term Extension (Week 44-272)|Withdrawal by Subject|0
6185983|NCT01369355|9839162|FG004|Long-term Extension (Week 44-272)|Withdrawal by Subject|0
6375426|NCT03436199|10165465|FG002|Overall Study|Physician Decision|0
6185984|NCT01369355|9839163|FG005|Long-term Extension (Week 44-272)|Withdrawal by Subject|0
6185985|NCT01369355|9839164|FG006|Long-term Extension (Week 44-272)|Withdrawal by Subject|12
6185986|NCT01369355|9839165|FG007|Long-term Extension (Week 44-272)|Withdrawal by Subject|30
6185987|NCT01369355|9839166|FG008|Long-term Extension (Week 44-272)|Withdrawal by Subject|47
6185988|NCT01369355|9839158|FG000|Long-term Extension (Week 44-272)|Other|0
6185989|NCT01369355|9839159|FG001|Long-term Extension (Week 44-272)|Other|0
6185990|NCT01369355|9839160|FG002|Long-term Extension (Week 44-272)|Other|0
6185991|NCT01369355|9839161|FG003|Long-term Extension (Week 44-272)|Other|0
6185992|NCT01369355|9839162|FG004|Long-term Extension (Week 44-272)|Other|0
6185993|NCT01369355|9839163|FG005|Long-term Extension (Week 44-272)|Other|0
6185994|NCT01369355|9839164|FG006|Long-term Extension (Week 44-272)|Other|110
6185995|NCT01369355|9839165|FG007|Long-term Extension (Week 44-272)|Other|9
6185996|NCT01369355|9839166|FG008|Long-term Extension (Week 44-272)|Other|17
6185997|NCT01369433|9839185|FG000|Overall Study|Adverse Event|31
6185998|NCT01369433|9839186|FG001|Overall Study|Adverse Event|1
6185999|NCT01369433|9839185|FG000|Overall Study|Required significant surgical procedure|1
6186000|NCT01369433|9839186|FG001|Overall Study|Required significant surgical procedure|0
6186001|NCT01369433|9839185|FG000|Overall Study|Non-compliance|1
6186002|NCT01369433|9839186|FG001|Overall Study|Non-compliance|0
6186003|NCT01369433|9839185|FG000|Overall Study|Withdrawal by Subject|5
6186004|NCT01369433|9839186|FG001|Overall Study|Withdrawal by Subject|2
6186005|NCT01369433|9839185|FG000|Overall Study|Study terminated by Sponsor|67
6186006|NCT01369433|9839186|FG001|Overall Study|Study terminated by Sponsor|0
6186007|NCT01369433|9839185|FG000|Overall Study|Lost to Follow-up|1
6186008|NCT01369433|9839186|FG001|Overall Study|Lost to Follow-up|0
6186009|NCT01369433|9839185|FG000|Overall Study|Death|5
6186010|NCT01369433|9839186|FG001|Overall Study|Death|0
6186011|NCT01369433|9839185|FG000|Overall Study|Investigator discretion|6
6186012|NCT01369433|9839186|FG001|Overall Study|Investigator discretion|1
6186013|NCT01369433|9839185|FG000|Overall Study|Progressive Disease|92
6186014|NCT01369433|9839186|FG001|Overall Study|Progressive Disease|12
6186015|NCT01369485|9839194|FG000|Randomized Phase (Day 0 to Week 12)|Adverse Event|7
6186016|NCT01369485|9839195|FG001|Randomized Phase (Day 0 to Week 12)|Adverse Event|5
6186017|NCT01369485|9839194|FG000|Randomized Phase (Day 0 to Week 12)|Withdrawal by Subject|12
6186018|NCT01369485|9839195|FG001|Randomized Phase (Day 0 to Week 12)|Withdrawal by Subject|8
6186019|NCT01369485|9839194|FG000|Randomized Phase (Day 0 to Week 12)|Lost to Follow-up|2
6186020|NCT01369485|9839195|FG001|Randomized Phase (Day 0 to Week 12)|Lost to Follow-up|4
6186021|NCT01369485|9839194|FG000|Randomized Phase (Day 0 to Week 12)|expired patches|2
6186022|NCT01369485|9839195|FG001|Randomized Phase (Day 0 to Week 12)|expired patches|0
6186023|NCT01369485|9839194|FG000|Open Label Phase (Week 12 to Month 12)|Adverse Event|11
6186024|NCT01369485|9839195|FG001|Open Label Phase (Week 12 to Month 12)|Adverse Event|9
6186025|NCT01369485|9839194|FG000|Open Label Phase (Week 12 to Month 12)|Lost to Follow-up|2
6186026|NCT01369485|9839195|FG001|Open Label Phase (Week 12 to Month 12)|Lost to Follow-up|3
6186027|NCT01369485|9839194|FG000|Open Label Phase (Week 12 to Month 12)|Physician Decision|3
6186028|NCT01369485|9839195|FG001|Open Label Phase (Week 12 to Month 12)|Physician Decision|4
6186029|NCT01369485|9839194|FG000|Open Label Phase (Week 12 to Month 12)|Withdrawal by Subject|17
6186030|NCT01369485|9839195|FG001|Open Label Phase (Week 12 to Month 12)|Withdrawal by Subject|20
6186031|NCT01369485|9839194|FG000|Open Label Phase (Week 12 to Month 12)|Death|0
6186032|NCT01369485|9839195|FG001|Open Label Phase (Week 12 to Month 12)|Death|1
6186033|NCT01369485|9839194|FG000|Open Label Phase (Week 12 to Month 12)|1 pacemaker, 1 noncompliance, 1 hospice|0
6186034|NCT01369485|9839195|FG001|Open Label Phase (Week 12 to Month 12)|1 pacemaker, 1 noncompliance, 1 hospice|3
6186035|NCT01369498|9839213|FG000|Overall Study|Lack of Efficacy|9
6186036|NCT01369498|9839214|FG001|Overall Study|Lack of Efficacy|9
6186037|NCT01369498|9839215|FG002|Overall Study|Lack of Efficacy|1
6186038|NCT01369498|9839216|FG003|Overall Study|Lack of Efficacy|3
6186039|NCT01369498|9839213|FG000|Overall Study|Adverse Event|1
6186040|NCT01369498|9839214|FG001|Overall Study|Adverse Event|2
6186041|NCT01369498|9839215|FG002|Overall Study|Adverse Event|0
6186042|NCT01369498|9839216|FG003|Overall Study|Adverse Event|1
6186043|NCT01369498|9839213|FG000|Overall Study|Withdrawal of Consent|0
6186044|NCT01369498|9839214|FG001|Overall Study|Withdrawal of Consent|1
6186045|NCT01369498|9839215|FG002|Overall Study|Withdrawal of Consent|1
6186046|NCT01369498|9839216|FG003|Overall Study|Withdrawal of Consent|1
6186047|NCT01369498|9839213|FG000|Overall Study|Death|0
6186048|NCT01369498|9839214|FG001|Overall Study|Death|0
6186049|NCT01369498|9839215|FG002|Overall Study|Death|1
6186050|NCT01369498|9839216|FG003|Overall Study|Death|0
6186051|NCT01369498|9839213|FG000|Overall Study|Investigator's Discretion|1
6186052|NCT01369498|9839214|FG001|Overall Study|Investigator's Discretion|0
6186053|NCT01369498|9839215|FG002|Overall Study|Investigator's Discretion|1
6186054|NCT01369498|9839216|FG003|Overall Study|Investigator's Discretion|3
6186055|NCT01369498|9839213|FG000|Overall Study|Unknown Reason|1
6186056|NCT01369498|9839214|FG001|Overall Study|Unknown Reason|0
6186057|NCT01369498|9839215|FG002|Overall Study|Unknown Reason|11
6186058|NCT01369498|9839216|FG003|Overall Study|Unknown Reason|6
6186059|NCT01369498|9839213|FG000|Overall Study|Disease Progression|0
6186060|NCT01369498|9839214|FG001|Overall Study|Disease Progression|0
6186061|NCT01369498|9839215|FG002|Overall Study|Disease Progression|0
6186062|NCT01369498|9839216|FG003|Overall Study|Disease Progression|1
6186063|NCT01369511|9839231|FG000|Overall Study|Adverse Event|1
6186064|NCT01369511|9839232|FG001|Overall Study|Adverse Event|1
6186065|NCT01369511|9839233|FG002|Overall Study|Adverse Event|5
6186066|NCT01369511|9839234|FG003|Overall Study|Adverse Event|0
6186067|NCT01369511|9839231|FG000|Overall Study|Entry criteria not met|2
6186068|NCT01369511|9839232|FG001|Overall Study|Entry criteria not met|0
6186069|NCT01369511|9839233|FG002|Overall Study|Entry criteria not met|0
6186070|NCT01369511|9839234|FG003|Overall Study|Entry criteria not met|1
6186071|NCT01369511|9839231|FG000|Overall Study|Lost to Follow-up|0
6186072|NCT01369511|9839232|FG001|Overall Study|Lost to Follow-up|1
6186073|NCT01369511|9839233|FG002|Overall Study|Lost to Follow-up|1
6186074|NCT01369511|9839234|FG003|Overall Study|Lost to Follow-up|2
6186075|NCT01369511|9839231|FG000|Overall Study|Protocol Violation|0
6186076|NCT01369511|9839232|FG001|Overall Study|Protocol Violation|1
6186077|NCT01369511|9839233|FG002|Overall Study|Protocol Violation|0
6186078|NCT01369511|9839234|FG003|Overall Study|Protocol Violation|2
6186079|NCT01369511|9839231|FG000|Overall Study|Physician Decision|3
6186080|NCT01369511|9839232|FG001|Overall Study|Physician Decision|4
6186081|NCT01369511|9839233|FG002|Overall Study|Physician Decision|0
6186082|NCT01369511|9839234|FG003|Overall Study|Physician Decision|0
6186083|NCT01369511|9839231|FG000|Overall Study|Sponsor decision|2
6186084|NCT01369511|9839232|FG001|Overall Study|Sponsor decision|0
6186085|NCT01369511|9839233|FG002|Overall Study|Sponsor decision|1
6186086|NCT01369511|9839234|FG003|Overall Study|Sponsor decision|0
6186087|NCT01369511|9839231|FG000|Overall Study|Withdrawal by Subject|5
6186088|NCT01369511|9839232|FG001|Overall Study|Withdrawal by Subject|6
6186089|NCT01369511|9839233|FG002|Overall Study|Withdrawal by Subject|4
6186090|NCT01369511|9839234|FG003|Overall Study|Withdrawal by Subject|6
6186091|NCT01369615|9839246|FG000|Overall Study|Withdrawal by Subject|0
6186092|NCT01369615|9839247|FG001|Overall Study|Withdrawal by Subject|1
6186093|NCT01369615|9839246|FG000|Overall Study|Lost to Follow-up|0
6186094|NCT01369615|9839247|FG001|Overall Study|Lost to Follow-up|1
6186095|NCT01369680|9839257|FG000|Overall Study|Lost to Follow-up|0
6186096|NCT01369680|9839258|FG001|Overall Study|Lost to Follow-up|0
6186097|NCT01369680|9839259|FG002|Overall Study|Lost to Follow-up|1
6186098|NCT01369680|9839260|FG003|Overall Study|Lost to Follow-up|2
6186099|NCT01369784|9839319|FG000|Overall Study|Protocol Violation|12
6186100|NCT01369849|9839326|FG000|Overall Study|Ineligible prior to treatment|0
6186101|NCT01369849|9839327|FG001|Overall Study|Ineligible prior to treatment|0
6186102|NCT01369849|9839328|FG002|Overall Study|Ineligible prior to treatment|1
6186103|NCT01369849|9839326|FG000|Overall Study|Ineligible after receiving treatment|0
6186104|NCT01369849|9839327|FG001|Overall Study|Ineligible after receiving treatment|1
6186105|NCT01369849|9839328|FG002|Overall Study|Ineligible after receiving treatment|0
6186106|NCT01370005|9839363|FG000|Overall Study|Not treated|1
6186107|NCT01370005|9839364|FG001|Overall Study|Not treated|0
6186108|NCT01370005|9839365|FG002|Overall Study|Not treated|0
6186109|NCT01370005|9839363|FG000|Overall Study|Adverse Event|5
6186110|NCT01370005|9839364|FG001|Overall Study|Adverse Event|5
6186111|NCT01370005|9839365|FG002|Overall Study|Adverse Event|6
6186112|NCT01370005|9839363|FG000|Overall Study|Lack of Efficacy|1
6186113|NCT01370005|9839364|FG001|Overall Study|Lack of Efficacy|0
6186114|NCT01370005|9839365|FG002|Overall Study|Lack of Efficacy|0
6186115|NCT01370005|9839363|FG000|Overall Study|Non compliant with protocol|0
6186116|NCT01370005|9839364|FG001|Overall Study|Non compliant with protocol|1
6186117|NCT01370005|9839365|FG002|Overall Study|Non compliant with protocol|2
6186118|NCT01370005|9839363|FG000|Overall Study|Lost to Follow-up|1
6186119|NCT01370005|9839364|FG001|Overall Study|Lost to Follow-up|1
6186120|NCT01370005|9839365|FG002|Overall Study|Lost to Follow-up|1
6186121|NCT01370005|9839363|FG000|Overall Study|Patient refusal to continue,not due toAE|5
6186122|NCT01370005|9839364|FG001|Overall Study|Patient refusal to continue,not due toAE|4
6186123|NCT01370005|9839365|FG002|Overall Study|Patient refusal to continue,not due toAE|0
6186124|NCT01370005|9839363|FG000|Overall Study|Other reason not defined above|3
6186125|NCT01370005|9839364|FG001|Overall Study|Other reason not defined above|0
6186126|NCT01370005|9839365|FG002|Overall Study|Other reason not defined above|2
6186127|NCT01370018|9839373|FG000|Overall Study|Did not meet criteria for analysis|1
6186128|NCT01370083|9839379|FG000|Overall Study|Lost to Follow-up|2
6186129|NCT01370083|9839380|FG001|Overall Study|Lost to Follow-up|0
6186130|NCT01370083|9839379|FG000|Overall Study|Adverse Event|0
6186131|NCT01370083|9839380|FG001|Overall Study|Adverse Event|1
6186132|NCT01370213|9839406|FG000|Overall Study|Early Death|1
6186133|NCT01370213|9839407|FG001|Overall Study|Early Death|0
6186134|NCT01370213|9839408|FG002|Overall Study|Early Death|0
6186135|NCT01370213|9839406|FG000|Overall Study|Not evaluable|0
6186136|NCT01370213|9839407|FG001|Overall Study|Not evaluable|2
6186137|NCT01370213|9839408|FG002|Overall Study|Not evaluable|0
6186138|NCT01370265|9839415|FG000|First Intervention|Adverse Event|1
6186139|NCT01370265|9839416|FG001|First Intervention|Adverse Event|1
6186140|NCT01370317|9839425|FG000|Overall Study|Participant withdrew consent|1
6186141|NCT01370317|9839426|FG001|Overall Study|Participant withdrew consent|0
6186142|NCT01370317|9839425|FG000|Overall Study|Protocol deviation|0
6186143|NCT01370317|9839426|FG001|Overall Study|Protocol deviation|1
6186144|NCT01370356|9839434|FG000|Overall Study|Death|1
6186145|NCT01370356|9839435|FG001|Overall Study|Death|0
6186146|NCT01370356|9839434|FG000|Overall Study|Lack of Efficacy|6
6186147|NCT01370356|9839435|FG001|Overall Study|Lack of Efficacy|28
6186148|NCT01370356|9839434|FG000|Overall Study|Lost to Follow-up|76
6186149|NCT01370356|9839435|FG001|Overall Study|Lost to Follow-up|81
6186150|NCT01370356|9839434|FG000|Overall Study|Withdrawal by Subject|54
6186151|NCT01370356|9839435|FG001|Overall Study|Withdrawal by Subject|59
6186152|NCT01370356|9839434|FG000|Overall Study|Reason not specified|39
6186153|NCT01370356|9839435|FG001|Overall Study|Reason not specified|43
6186154|NCT01370356|9839434|FG000|Overall Study|Protocol Violation|3
6186155|NCT01370356|9839435|FG001|Overall Study|Protocol Violation|3
6186156|NCT01370356|9839434|FG000|Overall Study|Adverse event (AE) Related to Study Drug|12
6186157|NCT01370356|9839435|FG001|Overall Study|Adverse event (AE) Related to Study Drug|9
6186158|NCT01370356|9839434|FG000|Overall Study|AE Not Related to Study Drug|1
6186159|NCT01370356|9839435|FG001|Overall Study|AE Not Related to Study Drug|4
6186160|NCT01370408|9839454|FG000|Overall Study|treatment failure|9
6186161|NCT01370499|9839470|FG000|Overall Study|Adverse Event|38
6186162|NCT01370499|9839471|FG001|Overall Study|Adverse Event|12
6186163|NCT01370499|9839470|FG000|Overall Study|Lack of Efficacy|4
6186164|NCT01370499|9839471|FG001|Overall Study|Lack of Efficacy|2
6186165|NCT01370499|9839470|FG000|Overall Study|Lost to Follow-up|2
6186166|NCT01370499|9839471|FG001|Overall Study|Lost to Follow-up|1
6186167|NCT01370499|9839470|FG000|Overall Study|Physician Decision|3
6186168|NCT01370499|9839471|FG001|Overall Study|Physician Decision|3
6186169|NCT01370499|9839470|FG000|Overall Study|Protocol Violation|5
6186170|NCT01370499|9839471|FG001|Overall Study|Protocol Violation|4
6186171|NCT01370499|9839470|FG000|Overall Study|Withdrawal by Subject|18
6186172|NCT01370499|9839471|FG001|Overall Study|Withdrawal by Subject|7
6186173|NCT01370499|9839470|FG000|Overall Study|Sponsor Decision|41
6186174|NCT01370499|9839471|FG001|Overall Study|Sponsor Decision|15
6186175|NCT01370525|9839481|FG000|Overall Study|Voluntary Discontinuation by Subject|2
6186176|NCT01370525|9839482|FG001|Overall Study|Voluntary Discontinuation by Subject|3
6186177|NCT01370525|9839481|FG000|Overall Study|Eligibility criteria not fulfilled|2
6186178|NCT01370525|9839482|FG001|Overall Study|Eligibility criteria not fulfilled|0
6186179|NCT01370525|9839481|FG000|Overall Study|Adverse Event|0
6186180|NCT01370525|9839482|FG001|Overall Study|Adverse Event|1
6186181|NCT01370525|9839481|FG000|Overall Study|Protocol Violation|2
6186182|NCT01370525|9839482|FG001|Overall Study|Protocol Violation|1
6186183|NCT01370525|9839481|FG000|Overall Study|Lost to follow up|2
6186184|NCT01370525|9839482|FG001|Overall Study|Lost to follow up|6
6186185|NCT01370538|9839490|FG000|Overall Study|Voluntary Discontinuation by Subject|3
6186186|NCT01370538|9839491|FG001|Overall Study|Voluntary Discontinuation by Subject|2
6186187|NCT01370538|9839490|FG000|Overall Study|Eligibility criteria not fulfilled|0
6186188|NCT01370538|9839491|FG001|Overall Study|Eligibility criteria not fulfilled|1
6186189|NCT01370538|9839490|FG000|Overall Study|Adverse Event|1
6186190|NCT01370538|9839491|FG001|Overall Study|Adverse Event|0
6186191|NCT01370538|9839490|FG000|Overall Study|Protocol Violation|8
6186192|NCT01370538|9839491|FG001|Overall Study|Protocol Violation|5
6186193|NCT01370538|9839490|FG000|Overall Study|Development of study specific withdrawal|1
6186194|NCT01370538|9839491|FG001|Overall Study|Development of study specific withdrawal|1
6186195|NCT01370538|9839490|FG000|Overall Study|Lost to follow up|6
6186196|NCT01370538|9839491|FG001|Overall Study|Lost to follow up|10
6186197|NCT01370616|9839503|FG000|Overall Study|Adverse Event|11
6186198|NCT01370616|9839504|FG001|Overall Study|Adverse Event|16
6186199|NCT01370616|9839503|FG000|Overall Study|Death|1
6186200|NCT01370616|9839504|FG001|Overall Study|Death|0
6186201|NCT01370616|9839503|FG000|Overall Study|Lack of Efficacy|6
6186202|NCT01370616|9839504|FG001|Overall Study|Lack of Efficacy|2
6186203|NCT01370616|9839503|FG000|Overall Study|Lost to Follow-up|0
6186204|NCT01370616|9839504|FG001|Overall Study|Lost to Follow-up|3
6186205|NCT01370616|9839503|FG000|Overall Study|Physician Decision|6
6186206|NCT01370616|9839504|FG001|Overall Study|Physician Decision|6
6186207|NCT01370616|9839503|FG000|Overall Study|Progressive Disease|0
6186208|NCT01370616|9839504|FG001|Overall Study|Progressive Disease|1
6186209|NCT01370616|9839503|FG000|Overall Study|Recovery|1
6186210|NCT01370616|9839504|FG001|Overall Study|Recovery|0
6186211|NCT01370616|9839503|FG000|Overall Study|Technical Problems|3
6186212|NCT01370616|9839504|FG001|Overall Study|Technical Problems|5
6186213|NCT01370616|9839503|FG000|Overall Study|Withdrawal by Subject|34
6186214|NCT01370616|9839504|FG001|Overall Study|Withdrawal by Subject|34
6186215|NCT01370642|9839517|FG000|Overall Study|Adverse Event|2
6186216|NCT01370642|9839518|FG001|Overall Study|Adverse Event|1
6186217|NCT01370642|9839519|FG002|Overall Study|Adverse Event|1
6186218|NCT01370642|9839517|FG000|Overall Study|Detectable HCV RNA|0
6186219|NCT01370642|9839518|FG001|Overall Study|Detectable HCV RNA|0
6186220|NCT01370642|9839519|FG002|Overall Study|Detectable HCV RNA|22
6186221|NCT01370642|9839517|FG000|Overall Study|Lost to Follow-up|0
6186222|NCT01370642|9839518|FG001|Overall Study|Lost to Follow-up|0
6186223|NCT01370642|9839519|FG002|Overall Study|Lost to Follow-up|1
6186224|NCT01370642|9839517|FG000|Overall Study|Physician Decision|4
6186225|NCT01370642|9839518|FG001|Overall Study|Physician Decision|1
6186226|NCT01370642|9839519|FG002|Overall Study|Physician Decision|2
6186227|NCT01370642|9839517|FG000|Overall Study|Withdrawal by Subject|2
6186228|NCT01370642|9839518|FG001|Overall Study|Withdrawal by Subject|4
6186229|NCT01370642|9839519|FG002|Overall Study|Withdrawal by Subject|3
6186230|NCT01370655|9839539|FG000|Period 1|Adverse Event|2
6186231|NCT01370655|9839540|FG001|Period 1|Adverse Event|0
6186232|NCT01370655|9839541|FG002|Period 1|Adverse Event|0
6186233|NCT01370655|9839542|FG003|Period 1|Adverse Event|0
6186234|NCT01370655|9839543|FG004|Period 1|Adverse Event|0
6186235|NCT01370655|9839544|FG005|Period 1|Adverse Event|0
6186236|NCT01370655|9839545|FG006|Period 1|Adverse Event|1
6186237|NCT01370655|9839546|FG007|Period 1|Adverse Event|0
6186238|NCT01370655|9839547|FG008|Period 1|Adverse Event|0
6186239|NCT01370655|9839548|FG009|Period 1|Adverse Event|0
6186240|NCT01370655|9839549|FG010|Period 1|Adverse Event|0
6186241|NCT01370655|9839550|FG011|Period 1|Adverse Event|0
6186242|NCT01370655|9839539|FG000|Period 2|Adverse Event|0
6186243|NCT01370655|9839540|FG001|Period 2|Adverse Event|0
6186244|NCT01370655|9839541|FG002|Period 2|Adverse Event|1
6186245|NCT01370655|9839542|FG003|Period 2|Adverse Event|0
6186246|NCT01370655|9839543|FG004|Period 2|Adverse Event|1
6186247|NCT01370655|9839544|FG005|Period 2|Adverse Event|0
6186248|NCT01370655|9839545|FG006|Period 2|Adverse Event|0
6186249|NCT01370655|9839546|FG007|Period 2|Adverse Event|1
6186250|NCT01370655|9839547|FG008|Period 2|Adverse Event|0
6186251|NCT01370655|9839548|FG009|Period 2|Adverse Event|0
6186252|NCT01370655|9839549|FG010|Period 2|Adverse Event|0
6186253|NCT01370655|9839550|FG011|Period 2|Adverse Event|0
6186254|NCT01370655|9839539|FG000|Period 2|met protocol specified stopping criteria|0
6186255|NCT01370655|9839540|FG001|Period 2|met protocol specified stopping criteria|0
6186256|NCT01370655|9839541|FG002|Period 2|met protocol specified stopping criteria|1
6186257|NCT01370655|9839542|FG003|Period 2|met protocol specified stopping criteria|0
6186258|NCT01370655|9839543|FG004|Period 2|met protocol specified stopping criteria|0
6186259|NCT01370655|9839544|FG005|Period 2|met protocol specified stopping criteria|0
6186260|NCT01370655|9839545|FG006|Period 2|met protocol specified stopping criteria|1
6186261|NCT01370655|9839546|FG007|Period 2|met protocol specified stopping criteria|0
6186262|NCT01370655|9839547|FG008|Period 2|met protocol specified stopping criteria|1
6186263|NCT01370655|9839548|FG009|Period 2|met protocol specified stopping criteria|0
6186264|NCT01370655|9839549|FG010|Period 2|met protocol specified stopping criteria|1
6186265|NCT01370655|9839550|FG011|Period 2|met protocol specified stopping criteria|0
6186266|NCT01370655|9839539|FG000|Period 2|Withdrawal by Subject|0
6186267|NCT01370655|9839540|FG001|Period 2|Withdrawal by Subject|0
6186268|NCT01370655|9839541|FG002|Period 2|Withdrawal by Subject|0
6186269|NCT01370655|9839542|FG003|Period 2|Withdrawal by Subject|0
6186270|NCT01370655|9839543|FG004|Period 2|Withdrawal by Subject|0
6186271|NCT01370655|9839544|FG005|Period 2|Withdrawal by Subject|0
6186272|NCT01370655|9839545|FG006|Period 2|Withdrawal by Subject|0
6186273|NCT01370655|9839546|FG007|Period 2|Withdrawal by Subject|0
6186274|NCT01370655|9839547|FG008|Period 2|Withdrawal by Subject|1
6186275|NCT01370655|9839548|FG009|Period 2|Withdrawal by Subject|0
6186276|NCT01370655|9839549|FG010|Period 2|Withdrawal by Subject|0
6186277|NCT01370655|9839550|FG011|Period 2|Withdrawal by Subject|0
6186278|NCT01370694|9839560|FG000|Overall Study|Switched to rituximab|4
6186279|NCT01370694|9839560|FG000|Overall Study|Progressive disease|2
6186280|NCT01370733|9839566|FG000|Overall Study|Withdrawal by Subject|8
6186281|NCT01370733|9839567|FG001|Overall Study|Withdrawal by Subject|8
6186282|NCT01370733|9839566|FG000|Overall Study|Lost to Follow-up|3
6186283|NCT01370733|9839567|FG001|Overall Study|Lost to Follow-up|0
6186284|NCT01370733|9839566|FG000|Overall Study|Adverse Event|2
6186285|NCT01370733|9839567|FG001|Overall Study|Adverse Event|4
6186286|NCT01370733|9839566|FG000|Overall Study|Lack of Efficacy|3
6186287|NCT01370733|9839567|FG001|Overall Study|Lack of Efficacy|5
6186288|NCT01370733|9839566|FG000|Overall Study|Physician Decision|0
6186289|NCT01370733|9839567|FG001|Overall Study|Physician Decision|2
6186290|NCT01370733|9839566|FG000|Overall Study|Protocol Violation|1
6186291|NCT01370733|9839567|FG001|Overall Study|Protocol Violation|3
6186292|NCT01370863|9839588|FG000|Overall Study|Adverse Event|1
6186293|NCT01370863|9839589|FG001|Overall Study|Adverse Event|1
6186294|NCT01370863|9839588|FG000|Overall Study|Did not want second pH/MII monitoring|1
6186295|NCT01370863|9839589|FG001|Overall Study|Did not want second pH/MII monitoring|1
6186296|NCT01370863|9839588|FG000|Overall Study|Not meeting inclusion/exclusion criteria|0
6186297|NCT01370863|9839589|FG001|Overall Study|Not meeting inclusion/exclusion criteria|1
6186298|NCT01371006|9839597|FG000|Overall Study|Adverse Event|1
6186299|NCT01371006|9839598|FG001|Overall Study|Adverse Event|0
6186300|NCT01371539|9839644|FG000|Period One: One Week|Lost to Follow-up|0
6186301|NCT01371539|9839645|FG001|Period One: One Week|Lost to Follow-up|1
6186302|NCT01371539|9839644|FG000|Period Two: One Week|Lost to Follow-up|0
6186303|NCT01371539|9839645|FG001|Period Two: One Week|Lost to Follow-up|1
6186304|NCT01371539|9839644|FG000|Period Two: One Week|Unacceptable Objective Visual Acuity|0
6186305|NCT01371539|9839645|FG001|Period Two: One Week|Unacceptable Objective Visual Acuity|1
6186306|NCT01371539|9839644|FG000|Period Two: One Week|Time/job conflict|0
6186307|NCT01371539|9839645|FG001|Period Two: One Week|Time/job conflict|1
6186308|NCT01371552|9839651|FG000|Part 1, First 3 Days|Inconvenience|0
6186309|NCT01371552|9839652|FG001|Part 1, First 3 Days|Inconvenience|0
6186310|NCT01371552|9839653|FG002|Part 1, First 3 Days|Inconvenience|1
6186311|NCT01371552|9839654|FG003|Part 1, First 3 Days|Inconvenience|0
6186312|NCT01371552|9839655|FG004|Part 1, First 3 Days|Inconvenience|0
6186313|NCT01371552|9839656|FG005|Part 1, First 3 Days|Inconvenience|0
6186314|NCT01371565|9839665|FG000|Overall Study|Withdrawal by Subject|1
6228227|NCT01723826|9901446|FG003|Overall Study|Withdrawal by Subject|48
6269581|NCT02141854|9969901|FG002|Run-In Period (Pre-assignment)|Withdrawal by Subject|0
6186315|NCT01371565|9839665|FG000|Overall Study|Death|1
6186316|NCT01371565|9839665|FG000|Overall Study|Resection of neuroendocrine tumor|1
6186317|NCT01371643|9839671|FG000|Overall Study|Withdrawal by Subject|3
6186318|NCT01371643|9839672|FG001|Overall Study|Withdrawal by Subject|0
6186319|NCT01371656|9839680|FG000|Overall Study|Death|7
6186320|NCT01371656|9839681|FG001|Overall Study|Death|4
6186321|NCT01371656|9839680|FG000|Overall Study|Physician Decision|46
6186322|NCT01371656|9839681|FG001|Overall Study|Physician Decision|7
6186323|NCT01371656|9839680|FG000|Overall Study|Withdrawal by Subject|7
6186324|NCT01371656|9839681|FG001|Overall Study|Withdrawal by Subject|0
6186325|NCT01371656|9839680|FG000|Overall Study|Ineligible|4
6186326|NCT01371656|9839681|FG001|Overall Study|Ineligible|3
6186327|NCT01371708|9839690|FG000|Overall Study|Insufficient clinical response|3
6186328|NCT01371708|9839691|FG001|Overall Study|Insufficient clinical response|2
6186329|NCT01371708|9839692|FG002|Overall Study|Insufficient clinical response|0
6186330|NCT01371708|9839690|FG000|Overall Study|Lost to Follow-up|5
6186331|NCT01371708|9839691|FG001|Overall Study|Lost to Follow-up|9
6186332|NCT01371708|9839692|FG002|Overall Study|Lost to Follow-up|7
6186333|NCT01371708|9839690|FG000|Overall Study|Protocol Violation|2
6186334|NCT01371708|9839691|FG001|Overall Study|Protocol Violation|1
6186335|NCT01371708|9839692|FG002|Overall Study|Protocol Violation|2
6186336|NCT01371708|9839690|FG000|Overall Study|No longer willing to participate|7
6186337|NCT01371708|9839691|FG001|Overall Study|No longer willing to participate|7
6186338|NCT01371708|9839692|FG002|Overall Study|No longer willing to participate|13
6186339|NCT01371708|9839690|FG000|Overall Study|Medication error/not related to AE|0
6186340|NCT01371708|9839691|FG001|Overall Study|Medication error/not related to AE|1
6186341|NCT01371708|9839692|FG002|Overall Study|Medication error/not related to AE|0
6186342|NCT01371708|9839690|FG000|Overall Study|Other|3
6186343|NCT01371708|9839691|FG001|Overall Study|Other|2
6186344|NCT01371708|9839692|FG002|Overall Study|Other|4
6186345|NCT01371708|9839690|FG000|Overall Study|Adverse Event|5
6186346|NCT01371708|9839691|FG001|Overall Study|Adverse Event|8
6186347|NCT01371708|9839692|FG002|Overall Study|Adverse Event|12
6186348|NCT01371708|9839690|FG000|Overall Study|Started but did not receive treatment|1
6186349|NCT01371708|9839691|FG001|Overall Study|Started but did not receive treatment|0
6186350|NCT01371708|9839692|FG002|Overall Study|Started but did not receive treatment|1
6186351|NCT01371721|9839705|FG000|Overall Study|Adverse Event|5
6186352|NCT01371721|9839706|FG001|Overall Study|Adverse Event|4
6186353|NCT01371721|9839707|FG002|Overall Study|Adverse Event|5
6186354|NCT01371721|9839705|FG000|Overall Study|Protocol Violation|6
6186355|NCT01371721|9839706|FG001|Overall Study|Protocol Violation|4
6186356|NCT01371721|9839707|FG002|Overall Study|Protocol Violation|5
6186357|NCT01371721|9839705|FG000|Overall Study|Lost to Follow-up|8
6186358|NCT01371721|9839706|FG001|Overall Study|Lost to Follow-up|2
6186359|NCT01371721|9839707|FG002|Overall Study|Lost to Follow-up|6
6186360|NCT01371721|9839705|FG000|Overall Study|Withdrawal by Subject|5
6186361|NCT01371721|9839706|FG001|Overall Study|Withdrawal by Subject|7
6186362|NCT01371721|9839707|FG002|Overall Study|Withdrawal by Subject|11
6186363|NCT01371721|9839705|FG000|Overall Study|Other|2
6186364|NCT01371721|9839706|FG001|Overall Study|Other|3
6186365|NCT01371721|9839707|FG002|Overall Study|Other|0
6186366|NCT01371721|9839705|FG000|Overall Study|Lack of Efficacy|2
6186367|NCT01371721|9839706|FG001|Overall Study|Lack of Efficacy|4
6186368|NCT01371721|9839707|FG002|Overall Study|Lack of Efficacy|3
6186369|NCT01371721|9839705|FG000|Overall Study|Randomized but not treated|1
6186370|NCT01371721|9839706|FG001|Overall Study|Randomized but not treated|0
6186371|NCT01371721|9839707|FG002|Overall Study|Randomized but not treated|0
6186372|NCT01371734|9839720|FG000|Overall Study|Other|2
6186373|NCT01371734|9839721|FG001|Overall Study|Other|1
6186374|NCT01371734|9839722|FG002|Overall Study|Other|2
6186375|NCT01371734|9839720|FG000|Overall Study|Withdrawal by Subject|3
6186376|NCT01371734|9839721|FG001|Overall Study|Withdrawal by Subject|4
6186377|NCT01371734|9839722|FG002|Overall Study|Withdrawal by Subject|9
6186378|NCT01371734|9839720|FG000|Overall Study|Lost to Follow-up|5
6186379|NCT01371734|9839721|FG001|Overall Study|Lost to Follow-up|3
6186380|NCT01371734|9839722|FG002|Overall Study|Lost to Follow-up|1
6186381|NCT01371734|9839720|FG000|Overall Study|Protocol Violation|3
6186382|NCT01371734|9839721|FG001|Overall Study|Protocol Violation|1
6186383|NCT01371734|9839722|FG002|Overall Study|Protocol Violation|2
6186384|NCT01371734|9839720|FG000|Overall Study|Adverse Event|8
6186385|NCT01371734|9839721|FG001|Overall Study|Adverse Event|8
6186386|NCT01371734|9839722|FG002|Overall Study|Adverse Event|3
6186387|NCT01371734|9839720|FG000|Overall Study|Lack of Efficacy|2
6186388|NCT01371734|9839721|FG001|Overall Study|Lack of Efficacy|2
6186389|NCT01371734|9839722|FG002|Overall Study|Lack of Efficacy|0
6186390|NCT01371747|9839736|FG000|Overall Study|Adverse Event|4
6186391|NCT01371747|9839737|FG001|Overall Study|Adverse Event|2
6186392|NCT01371747|9839738|FG002|Overall Study|Adverse Event|7
6186393|NCT01371747|9839739|FG003|Overall Study|Adverse Event|2
6186394|NCT01371747|9839740|FG004|Overall Study|Adverse Event|2
6186395|NCT01371747|9839741|FG005|Overall Study|Adverse Event|2
6186396|NCT01371747|9839736|FG000|Overall Study|Death|1
6186397|NCT01371747|9839737|FG001|Overall Study|Death|0
6186398|NCT01371747|9839738|FG002|Overall Study|Death|4
6186399|NCT01371747|9839739|FG003|Overall Study|Death|1
6186400|NCT01371747|9839740|FG004|Overall Study|Death|2
6186401|NCT01371747|9839741|FG005|Overall Study|Death|0
6186402|NCT01371747|9839736|FG000|Overall Study|Abnormal Renal Function|0
6186403|NCT01371747|9839737|FG001|Overall Study|Abnormal Renal Function|2
6186404|NCT01371747|9839738|FG002|Overall Study|Abnormal Renal Function|0
6186405|NCT01371747|9839739|FG003|Overall Study|Abnormal Renal Function|1
6186406|NCT01371747|9839740|FG004|Overall Study|Abnormal Renal Function|0
6186407|NCT01371747|9839741|FG005|Overall Study|Abnormal Renal Function|1
6186408|NCT01371747|9839736|FG000|Overall Study|High Serum Potassium Results|1
6186409|NCT01371747|9839737|FG001|Overall Study|High Serum Potassium Results|1
6186410|NCT01371747|9839738|FG002|Overall Study|High Serum Potassium Results|1
6186411|NCT01371747|9839739|FG003|Overall Study|High Serum Potassium Results|2
6186412|NCT01371747|9839740|FG004|Overall Study|High Serum Potassium Results|0
6186413|NCT01371747|9839741|FG005|Overall Study|High Serum Potassium Results|2
6186414|NCT01371747|9839736|FG000|Overall Study|Low Serum Potassium Results|1
6186415|NCT01371747|9839737|FG001|Overall Study|Low Serum Potassium Results|1
6186416|NCT01371747|9839738|FG002|Overall Study|Low Serum Potassium Results|1
6186417|NCT01371747|9839739|FG003|Overall Study|Low Serum Potassium Results|1
6186418|NCT01371747|9839740|FG004|Overall Study|Low Serum Potassium Results|0
6186419|NCT01371747|9839741|FG005|Overall Study|Low Serum Potassium Results|3
6186420|NCT01371747|9839736|FG000|Overall Study|Protocol Violation|0
6186421|NCT01371747|9839737|FG001|Overall Study|Protocol Violation|0
6186422|NCT01371747|9839738|FG002|Overall Study|Protocol Violation|1
6186423|NCT01371747|9839739|FG003|Overall Study|Protocol Violation|0
6186424|NCT01371747|9839740|FG004|Overall Study|Protocol Violation|0
6186425|NCT01371747|9839741|FG005|Overall Study|Protocol Violation|0
6186426|NCT01371747|9839736|FG000|Overall Study|Non-Compliance|3
6186427|NCT01371747|9839737|FG001|Overall Study|Non-Compliance|4
6186428|NCT01371747|9839738|FG002|Overall Study|Non-Compliance|3
6186429|NCT01371747|9839739|FG003|Overall Study|Non-Compliance|0
6186430|NCT01371747|9839740|FG004|Overall Study|Non-Compliance|0
6186431|NCT01371747|9839741|FG005|Overall Study|Non-Compliance|1
6186432|NCT01371747|9839736|FG000|Overall Study|Physician Decision|0
6186433|NCT01371747|9839737|FG001|Overall Study|Physician Decision|0
6186434|NCT01371747|9839738|FG002|Overall Study|Physician Decision|0
6186435|NCT01371747|9839739|FG003|Overall Study|Physician Decision|0
6186436|NCT01371747|9839740|FG004|Overall Study|Physician Decision|1
6186437|NCT01371747|9839741|FG005|Overall Study|Physician Decision|0
6186438|NCT01371747|9839736|FG000|Overall Study|Withdrawal by Subject|6
6186439|NCT01371747|9839737|FG001|Overall Study|Withdrawal by Subject|12
6186440|NCT01371747|9839738|FG002|Overall Study|Withdrawal by Subject|5
6186441|NCT01371747|9839739|FG003|Overall Study|Withdrawal by Subject|2
6186442|NCT01371747|9839740|FG004|Overall Study|Withdrawal by Subject|2
6186443|NCT01371747|9839741|FG005|Overall Study|Withdrawal by Subject|4
6186444|NCT01371747|9839736|FG000|Overall Study|Other Reasons|2
6186445|NCT01371747|9839737|FG001|Overall Study|Other Reasons|1
6186446|NCT01371747|9839738|FG002|Overall Study|Other Reasons|2
6186447|NCT01371747|9839739|FG003|Overall Study|Other Reasons|0
6186448|NCT01371747|9839740|FG004|Overall Study|Other Reasons|0
6186449|NCT01371747|9839741|FG005|Overall Study|Other Reasons|1
6186450|NCT01371825|9839765|FG000|Overall Study|Death|4
6186451|NCT01371838|9839771|FG000|Overall Study|Withdrawal by Subject|27
6186452|NCT01371838|9839772|FG001|Overall Study|Withdrawal by Subject|33
6186453|NCT01371838|9839771|FG000|Overall Study|Lost to Follow-up|10
6186454|NCT01371838|9839772|FG001|Overall Study|Lost to Follow-up|20
6186455|NCT01371838|9839771|FG000|Overall Study|Death|3
6186456|NCT01371838|9839772|FG001|Overall Study|Death|4
6186457|NCT01371838|9839771|FG000|Overall Study|Protocol Violation|3
6186458|NCT01371838|9839772|FG001|Overall Study|Protocol Violation|0
6186459|NCT01371838|9839771|FG000|Overall Study|Investigator Decision|3
6186460|NCT01371838|9839772|FG001|Overall Study|Investigator Decision|8
6186461|NCT01371838|9839771|FG000|Overall Study|Last follow-up visit not conducted|2
6186462|NCT01371838|9839772|FG001|Overall Study|Last follow-up visit not conducted|0
6186463|NCT01371838|9839771|FG000|Overall Study|Lack of therapeutic response|0
6186464|NCT01371838|9839772|FG001|Overall Study|Lack of therapeutic response|1
6186465|NCT01371838|9839771|FG000|Overall Study|Surgery|1
6186466|NCT01371838|9839772|FG001|Overall Study|Surgery|0
6186467|NCT01371851|9839780|FG000|Overall Study|Lost to Follow-up|5
6186468|NCT01371851|9839781|FG001|Overall Study|Lost to Follow-up|8
6186469|NCT01371851|9839780|FG000|Overall Study|was arrested and put in jail|0
6186470|NCT01371851|9839781|FG001|Overall Study|was arrested and put in jail|1
6186471|NCT01371851|9839780|FG000|Overall Study|non study related adverse event|1
6186472|NCT01371851|9839781|FG001|Overall Study|non study related adverse event|0
6186473|NCT01371851|9839780|FG000|Overall Study|Blood Pressure outside study parameters|2
6186474|NCT01371851|9839781|FG001|Overall Study|Blood Pressure outside study parameters|0
6186475|NCT01371877|9839789|FG000|Overall Study|3 for unknown reasons and 1 pregnant|0
6186476|NCT01371877|9839790|FG001|Overall Study|3 for unknown reasons and 1 pregnant|4
6186477|NCT01371994|9839798|FG000|Overall Study|Adverse Event|3
6186478|NCT01371994|9839799|FG001|Overall Study|Adverse Event|6
6186479|NCT01371994|9839798|FG000|Overall Study|Lack of Efficacy|3
6186480|NCT01371994|9839799|FG001|Overall Study|Lack of Efficacy|0
6186481|NCT01371994|9839798|FG000|Overall Study|Withdrawal by Subject|13
6186482|NCT01371994|9839799|FG001|Overall Study|Withdrawal by Subject|7
6186483|NCT01371994|9839798|FG000|Overall Study|Lost to Follow-up|1
6186484|NCT01371994|9839799|FG001|Overall Study|Lost to Follow-up|1
6186485|NCT01371994|9839798|FG000|Overall Study|Protocol Violation|24
6186486|NCT01371994|9839799|FG001|Overall Study|Protocol Violation|17
6186487|NCT01371994|9839798|FG000|Overall Study|Randomized but Never Received Study Drug|6
6186488|NCT01371994|9839799|FG001|Overall Study|Randomized but Never Received Study Drug|6
6186489|NCT01371994|9839798|FG000|Overall Study|Physician Decision|1
6186490|NCT01371994|9839799|FG001|Overall Study|Physician Decision|1
6186491|NCT01371994|9839798|FG000|Overall Study|Miscellaneous Reasons|6
6186492|NCT01371994|9839799|FG001|Overall Study|Miscellaneous Reasons|4
6186493|NCT01372085|9839815|FG000|Washout Period 2|Physician Decision|0
6186494|NCT01372085|9839816|FG001|Washout Period 2|Physician Decision|0
6186495|NCT01372085|9839817|FG002|Washout Period 2|Physician Decision|0
6186496|NCT01372085|9839818|FG003|Washout Period 2|Physician Decision|0
6186497|NCT01372085|9839819|FG004|Washout Period 2|Physician Decision|1
6186498|NCT01372085|9839820|FG005|Washout Period 2|Physician Decision|0
6186499|NCT01372085|9839821|FG006|Washout Period 2|Physician Decision|0
6186500|NCT01372085|9839822|FG007|Washout Period 2|Physician Decision|0
6186501|NCT01372085|9839823|FG008|Washout Period 2|Physician Decision|0
6186502|NCT01372085|9839824|FG009|Washout Period 2|Physician Decision|0
6186503|NCT01372085|9839815|FG000|Washout Period 3|Withdrawal by Subject|0
6186504|NCT01372085|9839816|FG001|Washout Period 3|Withdrawal by Subject|0
6186505|NCT01372085|9839817|FG002|Washout Period 3|Withdrawal by Subject|0
6186506|NCT01372085|9839818|FG003|Washout Period 3|Withdrawal by Subject|0
6186507|NCT01372085|9839819|FG004|Washout Period 3|Withdrawal by Subject|0
6186508|NCT01372085|9839820|FG005|Washout Period 3|Withdrawal by Subject|2
6186509|NCT01372085|9839821|FG006|Washout Period 3|Withdrawal by Subject|0
6186510|NCT01372085|9839822|FG007|Washout Period 3|Withdrawal by Subject|0
6186511|NCT01372085|9839823|FG008|Washout Period 3|Withdrawal by Subject|0
6186512|NCT01372085|9839824|FG009|Washout Period 3|Withdrawal by Subject|0
6186513|NCT01372150|9839851|FG000|Overall Study|Lack of Efficacy|3
6186514|NCT01372150|9839852|FG001|Overall Study|Lack of Efficacy|0
6186515|NCT01372150|9839853|FG002|Overall Study|Lack of Efficacy|1
6186516|NCT01372150|9839851|FG000|Overall Study|Lost to Follow-up|4
6186517|NCT01372150|9839852|FG001|Overall Study|Lost to Follow-up|5
6186518|NCT01372150|9839853|FG002|Overall Study|Lost to Follow-up|6
6186519|NCT01372150|9839851|FG000|Overall Study|Protocol Violation|1
6186520|NCT01372150|9839852|FG001|Overall Study|Protocol Violation|0
6186521|NCT01372150|9839853|FG002|Overall Study|Protocol Violation|3
6186522|NCT01372150|9839851|FG000|Overall Study|Withdrawal by Subject|2
6186523|NCT01372150|9839852|FG001|Overall Study|Withdrawal by Subject|7
6186524|NCT01372150|9839853|FG002|Overall Study|Withdrawal by Subject|2
6186525|NCT01372150|9839851|FG000|Overall Study|Other|1
6186526|NCT01372150|9839852|FG001|Overall Study|Other|0
6186527|NCT01372150|9839853|FG002|Overall Study|Other|2
6186528|NCT01372150|9839851|FG000|Overall Study|Adverse Event|2
6186529|NCT01372150|9839852|FG001|Overall Study|Adverse Event|1
6186530|NCT01372150|9839853|FG002|Overall Study|Adverse Event|2
6186531|NCT01372150|9839851|FG000|Overall Study|Randomized but not treated|0
6186532|NCT01372150|9839852|FG001|Overall Study|Randomized but not treated|1
6186533|NCT01372150|9839853|FG002|Overall Study|Randomized but not treated|0
6186534|NCT01372384|9839879|FG000|Overall Study|Progression of disease|3
6186535|NCT01372410|9839883|FG000|Treatment Period 1 (7 Days)|Lack of Efficacy|1
6186536|NCT01372410|9839884|FG001|Treatment Period 1 (7 Days)|Lack of Efficacy|1
6186537|NCT01372410|9839885|FG002|Treatment Period 1 (7 Days)|Lack of Efficacy|0
6186538|NCT01372410|9839886|FG003|Treatment Period 1 (7 Days)|Lack of Efficacy|0
6186539|NCT01372410|9839887|FG004|Treatment Period 1 (7 Days)|Lack of Efficacy|1
6186540|NCT01372410|9839888|FG005|Treatment Period 1 (7 Days)|Lack of Efficacy|0
6186541|NCT01372410|9839889|FG006|Treatment Period 1 (7 Days)|Lack of Efficacy|0
6186542|NCT01372410|9839890|FG007|Treatment Period 1 (7 Days)|Lack of Efficacy|0
6186543|NCT01372410|9839883|FG000|Treatment Period 1 (7 Days)|Adverse Event|0
6186544|NCT01372410|9839884|FG001|Treatment Period 1 (7 Days)|Adverse Event|1
6186545|NCT01372410|9839885|FG002|Treatment Period 1 (7 Days)|Adverse Event|0
6186546|NCT01372410|9839886|FG003|Treatment Period 1 (7 Days)|Adverse Event|0
6186547|NCT01372410|9839887|FG004|Treatment Period 1 (7 Days)|Adverse Event|0
6186548|NCT01372410|9839888|FG005|Treatment Period 1 (7 Days)|Adverse Event|0
6186549|NCT01372410|9839889|FG006|Treatment Period 1 (7 Days)|Adverse Event|1
6186550|NCT01372410|9839890|FG007|Treatment Period 1 (7 Days)|Adverse Event|0
6186551|NCT01372410|9839883|FG000|Treatment Period 1 (7 Days)|Lost to Follow-up|0
6186552|NCT01372410|9839884|FG001|Treatment Period 1 (7 Days)|Lost to Follow-up|0
6186553|NCT01372410|9839885|FG002|Treatment Period 1 (7 Days)|Lost to Follow-up|0
6186554|NCT01372410|9839886|FG003|Treatment Period 1 (7 Days)|Lost to Follow-up|0
6186555|NCT01372410|9839887|FG004|Treatment Period 1 (7 Days)|Lost to Follow-up|1
6186556|NCT01372410|9839888|FG005|Treatment Period 1 (7 Days)|Lost to Follow-up|0
6186557|NCT01372410|9839889|FG006|Treatment Period 1 (7 Days)|Lost to Follow-up|0
6186558|NCT01372410|9839890|FG007|Treatment Period 1 (7 Days)|Lost to Follow-up|0
6186559|NCT01372410|9839883|FG000|Treatment Period 1 (7 Days)|Participant Withdrew Consent|0
6186560|NCT01372410|9839884|FG001|Treatment Period 1 (7 Days)|Participant Withdrew Consent|0
6186561|NCT01372410|9839885|FG002|Treatment Period 1 (7 Days)|Participant Withdrew Consent|0
6186562|NCT01372410|9839886|FG003|Treatment Period 1 (7 Days)|Participant Withdrew Consent|0
6228228|NCT01723904|9901456|FG000|Overall Study|Noncompliant|3
6228229|NCT01723904|9901456|FG000|Overall Study|Adverse Event|5
6375427|NCT03436199|10165463|FG000|Overall Study|Could not return to clinic|1
6186563|NCT01372410|9839887|FG004|Treatment Period 1 (7 Days)|Participant Withdrew Consent|0
6186564|NCT01372410|9839888|FG005|Treatment Period 1 (7 Days)|Participant Withdrew Consent|0
6186565|NCT01372410|9839889|FG006|Treatment Period 1 (7 Days)|Participant Withdrew Consent|1
6186566|NCT01372410|9839890|FG007|Treatment Period 1 (7 Days)|Participant Withdrew Consent|0
6186567|NCT01372410|9839883|FG000|Washout Period 1 (10-14 Days)|Participant Withdrew Consent|1
6186568|NCT01372410|9839884|FG001|Washout Period 1 (10-14 Days)|Participant Withdrew Consent|0
6186569|NCT01372410|9839885|FG002|Washout Period 1 (10-14 Days)|Participant Withdrew Consent|0
6186570|NCT01372410|9839886|FG003|Washout Period 1 (10-14 Days)|Participant Withdrew Consent|0
6186571|NCT01372410|9839887|FG004|Washout Period 1 (10-14 Days)|Participant Withdrew Consent|0
6186572|NCT01372410|9839888|FG005|Washout Period 1 (10-14 Days)|Participant Withdrew Consent|0
6186573|NCT01372410|9839889|FG006|Washout Period 1 (10-14 Days)|Participant Withdrew Consent|0
6186574|NCT01372410|9839890|FG007|Washout Period 1 (10-14 Days)|Participant Withdrew Consent|1
6186575|NCT01372410|9839883|FG000|Washout Period 2 (10-14 Days)|Adverse Event|0
6186576|NCT01372410|9839884|FG001|Washout Period 2 (10-14 Days)|Adverse Event|0
6186577|NCT01372410|9839885|FG002|Washout Period 2 (10-14 Days)|Adverse Event|0
6186578|NCT01372410|9839886|FG003|Washout Period 2 (10-14 Days)|Adverse Event|0
6186579|NCT01372410|9839887|FG004|Washout Period 2 (10-14 Days)|Adverse Event|1
6186580|NCT01372410|9839888|FG005|Washout Period 2 (10-14 Days)|Adverse Event|0
6186581|NCT01372410|9839889|FG006|Washout Period 2 (10-14 Days)|Adverse Event|0
6186582|NCT01372410|9839890|FG007|Washout Period 2 (10-14 Days)|Adverse Event|0
6186583|NCT01372410|9839883|FG000|Washout Period 2 (10-14 Days)|Participant Withdrew Consent|0
6186584|NCT01372410|9839884|FG001|Washout Period 2 (10-14 Days)|Participant Withdrew Consent|0
6186585|NCT01372410|9839885|FG002|Washout Period 2 (10-14 Days)|Participant Withdrew Consent|0
6186586|NCT01372410|9839886|FG003|Washout Period 2 (10-14 Days)|Participant Withdrew Consent|0
6186587|NCT01372410|9839887|FG004|Washout Period 2 (10-14 Days)|Participant Withdrew Consent|1
6186588|NCT01372410|9839888|FG005|Washout Period 2 (10-14 Days)|Participant Withdrew Consent|0
6186589|NCT01372410|9839889|FG006|Washout Period 2 (10-14 Days)|Participant Withdrew Consent|1
6186590|NCT01372410|9839890|FG007|Washout Period 2 (10-14 Days)|Participant Withdrew Consent|1
6186591|NCT01372410|9839883|FG000|Washout Period 2 (10-14 Days)|Lack of Efficacy|0
6186592|NCT01372410|9839884|FG001|Washout Period 2 (10-14 Days)|Lack of Efficacy|0
6186593|NCT01372410|9839885|FG002|Washout Period 2 (10-14 Days)|Lack of Efficacy|0
6186594|NCT01372410|9839886|FG003|Washout Period 2 (10-14 Days)|Lack of Efficacy|0
6186595|NCT01372410|9839887|FG004|Washout Period 2 (10-14 Days)|Lack of Efficacy|0
6186596|NCT01372410|9839888|FG005|Washout Period 2 (10-14 Days)|Lack of Efficacy|0
6186597|NCT01372410|9839889|FG006|Washout Period 2 (10-14 Days)|Lack of Efficacy|0
6186598|NCT01372410|9839890|FG007|Washout Period 2 (10-14 Days)|Lack of Efficacy|1
6186599|NCT01372410|9839883|FG000|Treatment Period 3 (7 Days)|Adverse Event|0
6186600|NCT01372410|9839884|FG001|Treatment Period 3 (7 Days)|Adverse Event|0
6186601|NCT01372410|9839885|FG002|Treatment Period 3 (7 Days)|Adverse Event|1
6186602|NCT01372410|9839886|FG003|Treatment Period 3 (7 Days)|Adverse Event|0
6186603|NCT01372410|9839887|FG004|Treatment Period 3 (7 Days)|Adverse Event|0
6186604|NCT01372410|9839888|FG005|Treatment Period 3 (7 Days)|Adverse Event|0
6186605|NCT01372410|9839889|FG006|Treatment Period 3 (7 Days)|Adverse Event|0
6186606|NCT01372410|9839890|FG007|Treatment Period 3 (7 Days)|Adverse Event|0
6186607|NCT01372410|9839883|FG000|Treatment Period 3 (7 Days)|Protocol Deviation|0
6186608|NCT01372410|9839884|FG001|Treatment Period 3 (7 Days)|Protocol Deviation|0
6186609|NCT01372410|9839885|FG002|Treatment Period 3 (7 Days)|Protocol Deviation|0
6186610|NCT01372410|9839886|FG003|Treatment Period 3 (7 Days)|Protocol Deviation|0
6186611|NCT01372410|9839887|FG004|Treatment Period 3 (7 Days)|Protocol Deviation|0
6186612|NCT01372410|9839888|FG005|Treatment Period 3 (7 Days)|Protocol Deviation|1
6186613|NCT01372410|9839889|FG006|Treatment Period 3 (7 Days)|Protocol Deviation|0
6186614|NCT01372410|9839890|FG007|Treatment Period 3 (7 Days)|Protocol Deviation|0
6186615|NCT01372501|9839919|FG000|Overall Study|Adverse Event|4
6186616|NCT01372501|9839919|FG000|Overall Study|Device migration|1
6186617|NCT01372605|9839926|FG000|Overall Study|Death|1
6186618|NCT01372605|9839927|FG001|Overall Study|Death|2
6186619|NCT01372605|9839926|FG000|Overall Study|Lost to Follow-up|2
6186620|NCT01372605|9839927|FG001|Overall Study|Lost to Follow-up|1
6186621|NCT01372605|9839926|FG000|Overall Study|Withdrawal by Subject|4
6186622|NCT01372605|9839927|FG001|Overall Study|Withdrawal by Subject|7
6186623|NCT01372605|9839926|FG000|Overall Study|Moved|3
6186624|NCT01372605|9839927|FG001|Overall Study|Moved|0
6186625|NCT01372605|9839926|FG000|Overall Study|Changed medical home|2
6186626|NCT01372605|9839927|FG001|Overall Study|Changed medical home|0
6186627|NCT01372748|9839935|FG000|Overall Study|Lost to Follow-up|16
6186628|NCT01372748|9839936|FG001|Overall Study|Lost to Follow-up|34
6186629|NCT01372748|9839935|FG000|Overall Study|Withdrawal by Subject|7
6186630|NCT01372748|9839936|FG001|Overall Study|Withdrawal by Subject|5
6186631|NCT01372774|9839944|FG000|Overall Study|Withdrawal prior to treatment|4
6186632|NCT01372774|9839945|FG001|Overall Study|Withdrawal prior to treatment|5
6186633|NCT01372878|9839957|FG000|Overall Study|Withdrawal by Subject|63
6186634|NCT01372878|9839957|FG000|Overall Study|Protocol Violation|17
6186635|NCT01372878|9839957|FG000|Overall Study|incomplete study procedure|104
6186636|NCT01372995|9839964|FG000|Overall Study|Spouse withdrew participant from study|0
6186637|NCT01372995|9839965|FG001|Overall Study|Spouse withdrew participant from study|1
6186638|NCT01372995|9839966|FG002|Overall Study|Spouse withdrew participant from study|0
6186639|NCT01372995|9839964|FG000|Overall Study|Physician Decision|0
6186640|NCT01372995|9839965|FG001|Overall Study|Physician Decision|0
6186641|NCT01372995|9839966|FG002|Overall Study|Physician Decision|1
6193035|NCT01435928|9850687|FG001|Open Label Phase - up to 24 Weeks|did not meet stabilization criteria|0
6193036|NCT01435928|9850688|FG002|Open Label Phase - up to 24 Weeks|did not meet stabilization criteria|0
6193037|NCT01435928|9850686|FG000|Open Label Phase - up to 24 Weeks|Terminated at study completion|6
6193038|NCT01435928|9850687|FG001|Open Label Phase - up to 24 Weeks|Terminated at study completion|0
6193039|NCT01435928|9850688|FG002|Open Label Phase - up to 24 Weeks|Terminated at study completion|0
6193040|NCT01435928|9850686|FG000|Open Label Phase - up to 24 Weeks|Administrative|14
6193041|NCT01435928|9850687|FG001|Open Label Phase - up to 24 Weeks|Administrative|0
6193042|NCT01435928|9850688|FG002|Open Label Phase - up to 24 Weeks|Administrative|0
6193043|NCT01435928|9850686|FG000|Double Blind Phase - 28 Weeks|Adverse Event|0
6193044|NCT01435928|9850687|FG001|Double Blind Phase - 28 Weeks|Adverse Event|3
6193045|NCT01435928|9850688|FG002|Double Blind Phase - 28 Weeks|Adverse Event|1
6193046|NCT01435928|9850686|FG000|Double Blind Phase - 28 Weeks|Lost to Follow-up|0
6193047|NCT01435928|9850687|FG001|Double Blind Phase - 28 Weeks|Lost to Follow-up|2
6193048|NCT01435928|9850688|FG002|Double Blind Phase - 28 Weeks|Lost to Follow-up|5
6193049|NCT01435928|9850686|FG000|Double Blind Phase - 28 Weeks|Protocol Violation|0
6193050|NCT01435928|9850687|FG001|Double Blind Phase - 28 Weeks|Protocol Violation|11
6193051|NCT01435928|9850688|FG002|Double Blind Phase - 28 Weeks|Protocol Violation|4
6193052|NCT01435928|9850686|FG000|Double Blind Phase - 28 Weeks|Withdrawal by Subject|0
6193053|NCT01435928|9850687|FG001|Double Blind Phase - 28 Weeks|Withdrawal by Subject|5
6193054|NCT01435928|9850688|FG002|Double Blind Phase - 28 Weeks|Withdrawal by Subject|12
6193055|NCT01435928|9850686|FG000|Double Blind Phase - 28 Weeks|Terminated at study completion|0
6193056|NCT01435928|9850687|FG001|Double Blind Phase - 28 Weeks|Terminated at study completion|47
6193057|NCT01435928|9850688|FG002|Double Blind Phase - 28 Weeks|Terminated at study completion|39
6193058|NCT01435928|9850686|FG000|Double Blind Phase - 28 Weeks|Relapse criteria met|0
6193059|NCT01435928|9850687|FG001|Double Blind Phase - 28 Weeks|Relapse criteria met|43
6193060|NCT01435928|9850688|FG002|Double Blind Phase - 28 Weeks|Relapse criteria met|58
6193061|NCT01435928|9850686|FG000|Double Blind Phase - 28 Weeks|Administrative|0
6193062|NCT01435928|9850687|FG001|Double Blind Phase - 28 Weeks|Administrative|5
6193063|NCT01435928|9850688|FG002|Double Blind Phase - 28 Weeks|Administrative|2
6193064|NCT01436071|9850716|FG000|Overall Study|Adverse Event|1
6193065|NCT01436071|9850717|FG001|Overall Study|Adverse Event|0
6085384|NCT00652366|9694738|FG002|Overall Study|Lack of Efficacy|53
6085385|NCT00652366|9694739|FG003|Overall Study|Lack of Efficacy|133
6085386|NCT00652366|9694740|FG004|Overall Study|Lack of Efficacy|13
6085387|NCT00652366|9694736|FG000|Overall Study|Violation of Selection Criteria|0
6085388|NCT00652366|9694737|FG001|Overall Study|Violation of Selection Criteria|0
6085389|NCT00652366|9694738|FG002|Overall Study|Violation of Selection Criteria|1
6085390|NCT00652366|9694739|FG003|Overall Study|Violation of Selection Criteria|0
6085391|NCT00652366|9694740|FG004|Overall Study|Violation of Selection Criteria|0
6085392|NCT00652366|9694736|FG000|Overall Study|Protocol Violation|1
6085393|NCT00652366|9694737|FG001|Overall Study|Protocol Violation|0
6085394|NCT00652366|9694738|FG002|Overall Study|Protocol Violation|0
6085395|NCT00652366|9694739|FG003|Overall Study|Protocol Violation|0
6193066|NCT01436071|9850716|FG000|Overall Study|Lack of Efficacy|16
6193067|NCT01436071|9850717|FG001|Overall Study|Lack of Efficacy|7
6193068|NCT01436071|9850716|FG000|Overall Study|Protocol Violation|0
6193069|NCT01436071|9850717|FG001|Overall Study|Protocol Violation|1
6193070|NCT01436071|9850716|FG000|Overall Study|Lost to Follow-up|3
6193071|NCT01436071|9850717|FG001|Overall Study|Lost to Follow-up|1
6193072|NCT01436071|9850716|FG000|Overall Study|Physician Decision|1
6193073|NCT01436071|9850717|FG001|Overall Study|Physician Decision|0
6193074|NCT01436071|9850716|FG000|Overall Study|Withdrawal by Subject|2
6193075|NCT01436071|9850717|FG001|Overall Study|Withdrawal by Subject|2
6193076|NCT01436071|9850716|FG000|Overall Study|Did Not Receive Trial Medication|3
6193077|NCT01436071|9850717|FG001|Overall Study|Did Not Receive Trial Medication|3
6193078|NCT01436110|9850726|FG000|Overall Study|Lack of Efficacy|23
6193079|NCT01436110|9850727|FG001|Overall Study|Lack of Efficacy|14
6193080|NCT01436110|9850728|FG002|Overall Study|Lack of Efficacy|9
6193081|NCT01436110|9850726|FG000|Overall Study|Withdrawal by Subject|6
6193082|NCT01436110|9850727|FG001|Overall Study|Withdrawal by Subject|8
6193083|NCT01436110|9850728|FG002|Overall Study|Withdrawal by Subject|4
6193084|NCT01436110|9850726|FG000|Overall Study|Adverse Event|2
6193085|NCT01436110|9850727|FG001|Overall Study|Adverse Event|1
6193086|NCT01436110|9850728|FG002|Overall Study|Adverse Event|2
6193087|NCT01436110|9850726|FG000|Overall Study|Physician Decision|3
6193088|NCT01436110|9850727|FG001|Overall Study|Physician Decision|1
6193089|NCT01436110|9850728|FG002|Overall Study|Physician Decision|1
6193090|NCT01436110|9850726|FG000|Overall Study|Lost to Follow-up|1
6193091|NCT01436110|9850727|FG001|Overall Study|Lost to Follow-up|1
6085396|NCT00652366|9694740|FG004|Overall Study|Protocol Violation|0
6193092|NCT01436110|9850728|FG002|Overall Study|Lost to Follow-up|3
6193093|NCT01436110|9850726|FG000|Overall Study|Protocol Violation|3
6085397|NCT00652366|9694736|FG000|Overall Study|Refused treatment|3
6085398|NCT00652366|9694737|FG001|Overall Study|Refused treatment|7
6085399|NCT00652366|9694738|FG002|Overall Study|Refused treatment|6
6186642|NCT01373164|9839979|FG000|Overall Study|Lost to Follow-up|0
6186643|NCT01373164|9839980|FG001|Overall Study|Lost to Follow-up|0
6186644|NCT01373164|9839981|FG002|Overall Study|Lost to Follow-up|1
6186645|NCT01373164|9839982|FG003|Overall Study|Lost to Follow-up|2
6186646|NCT01373164|9839983|FG004|Overall Study|Lost to Follow-up|0
6186647|NCT01373164|9839979|FG000|Overall Study|Withdrawal by Subject|0
6186648|NCT01373164|9839980|FG001|Overall Study|Withdrawal by Subject|1
6186649|NCT01373164|9839981|FG002|Overall Study|Withdrawal by Subject|0
6186650|NCT01373164|9839982|FG003|Overall Study|Withdrawal by Subject|10
6186651|NCT01373164|9839983|FG004|Overall Study|Withdrawal by Subject|2
6186652|NCT01373229|9839998|FG000|Overall Study|Death|3
6186653|NCT01373229|9839998|FG000|Overall Study|Physician Decision|3
6186654|NCT01373294|9840010|FG000|Overall Study|Adverse Event|1
6186655|NCT01373294|9840011|FG001|Overall Study|Adverse Event|0
6186656|NCT01373346|9840017|FG000|Overall Study|Death|1
6186657|NCT01373918|9840065|FG000|Overall Study|Physician Decision|0
6186658|NCT01373918|9840066|FG001|Overall Study|Physician Decision|1
6186659|NCT01373931|9840074|FG000|Lead-in Period|Adverse Event|2
6186660|NCT01373931|9840075|FG001|Lead-in Period|Adverse Event|0
6186661|NCT01373931|9840074|FG000|Period 1|Adverse Event|2
6186662|NCT01373931|9840075|FG001|Period 1|Adverse Event|0
6186663|NCT01373931|9840074|FG000|Period 1|Withdrawal by Subject|0
6186664|NCT01373931|9840075|FG001|Period 1|Withdrawal by Subject|2
6186665|NCT01374087|9840084|FG000|Overall Study|Adverse Event|1
6186666|NCT01374087|9840085|FG001|Overall Study|Adverse Event|0
6186667|NCT01374087|9840084|FG000|Overall Study|Disease progression|2
6186668|NCT01374087|9840085|FG001|Overall Study|Disease progression|2
6186669|NCT01374087|9840084|FG000|Overall Study|Study discontinued|13
6186670|NCT01374087|9840085|FG001|Overall Study|Study discontinued|13
6186671|NCT01374178|9840091|FG000|Washout Period of at Least 7 Days|Withdrawal by Subject|1
6186672|NCT01374178|9840092|FG001|Washout Period of at Least 7 Days|Withdrawal by Subject|0
6186673|NCT01374178|9840091|FG000|Period 2 (up to 24 Hours After Dosing)|Adverse Event|2
6186674|NCT01374178|9840092|FG001|Period 2 (up to 24 Hours After Dosing)|Adverse Event|0
6186675|NCT01374217|9840098|FG000|Overall Study|Lack of Efficacy|13
6186676|NCT01374269|9840104|FG000|Overall Study|Withdrawal by Subject|4
6186677|NCT01374269|9840105|FG001|Overall Study|Withdrawal by Subject|0
6186678|NCT01374269|9840104|FG000|Overall Study|Lost to Follow-up|1
6186679|NCT01374269|9840105|FG001|Overall Study|Lost to Follow-up|3
6186680|NCT01374269|9840104|FG000|Overall Study|closed research|1
6186681|NCT01374269|9840105|FG001|Overall Study|closed research|2
6186682|NCT01374425|9840113|FG000|Overall Study|Radiographic Disease Progression|86
6186683|NCT01374425|9840114|FG001|Overall Study|Radiographic Disease Progression|81
6186684|NCT01374425|9840113|FG000|Overall Study|Clinical Disease Progression|9
6186685|NCT01374425|9840114|FG001|Overall Study|Clinical Disease Progression|6
6186686|NCT01374425|9840113|FG000|Overall Study|Adverse Event|29
6186687|NCT01374425|9840114|FG001|Overall Study|Adverse Event|18
6186688|NCT01374425|9840113|FG000|Overall Study|Death (Progression of Disease)|1
6186689|NCT01374425|9840114|FG001|Overall Study|Death (Progression of Disease)|0
6186690|NCT01374425|9840113|FG000|Overall Study|Death (Adverse Event)|2
6186691|NCT01374425|9840114|FG001|Overall Study|Death (Adverse Event)|4
6186692|NCT01374425|9840113|FG000|Overall Study|Withdrawal by Subject|6
6186693|NCT01374425|9840114|FG001|Overall Study|Withdrawal by Subject|7
6186694|NCT01374425|9840113|FG000|Overall Study|Refused Treatment|10
6186695|NCT01374425|9840114|FG001|Overall Study|Refused Treatment|24
6186696|NCT01374425|9840113|FG000|Overall Study|Protocol Violation|2
6186697|NCT01374425|9840114|FG001|Overall Study|Protocol Violation|3
6186698|NCT01374425|9840113|FG000|Overall Study|Sponsor Decision|0
6186699|NCT01374425|9840114|FG001|Overall Study|Sponsor Decision|1
6186700|NCT01374425|9840113|FG000|Overall Study|Lost to Follow-up|2
6186701|NCT01374425|9840114|FG001|Overall Study|Lost to Follow-up|1
6186702|NCT01374425|9840113|FG000|Overall Study|Other|41
6186703|NCT01374425|9840114|FG001|Overall Study|Other|43
6186704|NCT01374451|9840152|FG000|Overall Study|Administrative problems|1
6186705|NCT01374451|9840153|FG001|Overall Study|Administrative problems|0
6186706|NCT01374568|9840165|FG000|Overall Study|Lab unable to analyze BTM|0
6186707|NCT01374568|9840166|FG001|Overall Study|Lab unable to analyze BTM|2
6186708|NCT01374906|9840180|FG000|Overall Study|Abnormal laboratory value(s)|0
6186709|NCT01374906|9840181|FG001|Overall Study|Abnormal laboratory value(s)|3
6186710|NCT01374906|9840180|FG000|Overall Study|Administrative problems|2
6186711|NCT01374906|9840181|FG001|Overall Study|Administrative problems|2
6186712|NCT01374906|9840180|FG000|Overall Study|Adverse Event|10
6186713|NCT01374906|9840181|FG001|Overall Study|Adverse Event|11
6186714|NCT01374906|9840180|FG000|Overall Study|Death|0
6186715|NCT01374906|9840181|FG001|Overall Study|Death|2
6186716|NCT01374906|9840180|FG000|Overall Study|Protocol Violation|2
6228230|NCT01723904|9901456|FG000|Overall Study|Unable to follow protocol/ judged by inv|3
6186717|NCT01374906|9840181|FG001|Overall Study|Protocol Violation|2
6186718|NCT01374906|9840180|FG000|Overall Study|Withdrawal by Subject|15
6186719|NCT01374906|9840181|FG001|Overall Study|Withdrawal by Subject|9
6186720|NCT01374906|9840180|FG000|Overall Study|Unsatisfactory therapeutic effect|11
6186721|NCT01374906|9840181|FG001|Overall Study|Unsatisfactory therapeutic effect|19
6186722|NCT01374919|9840191|FG000|Overall Study|Withdrawal by Subject|2
6186723|NCT01374971|9840195|FG000|Overall Study|Withdrawal by Subject|1
6186724|NCT01375010|9840201|FG000|Overall Study|Lost to Follow-up|8
6186725|NCT01375010|9840202|FG001|Overall Study|Lost to Follow-up|2
6186726|NCT01375010|9840201|FG000|Overall Study|Withdrawal by Subject|4
6186727|NCT01375010|9840202|FG001|Overall Study|Withdrawal by Subject|2
6186728|NCT01375049|9840208|FG000|Overall Study|Adverse Event|2
6186729|NCT01375049|9840208|FG000|Overall Study|Lost to Follow-up|1
6186730|NCT01375049|9840208|FG000|Overall Study|Withdrawal by Subject|2
6186731|NCT01375049|9840208|FG000|Overall Study|Protocol-Specified Withdrawal Criteria|45
6186732|NCT01375075|9840222|FG000|Overall Study|Adverse Event|0
6186733|NCT01375075|9840223|FG001|Overall Study|Adverse Event|0
6186734|NCT01375075|9840224|FG002|Overall Study|Adverse Event|3
6186735|NCT01375075|9840225|FG003|Overall Study|Adverse Event|1
6186736|NCT01375075|9840226|FG004|Overall Study|Adverse Event|0
6186737|NCT01375075|9840227|FG005|Overall Study|Adverse Event|1
6186738|NCT01375075|9840222|FG000|Overall Study|Entry Criterion Not Met|1
6186739|NCT01375075|9840223|FG001|Overall Study|Entry Criterion Not Met|0
6186740|NCT01375075|9840224|FG002|Overall Study|Entry Criterion Not Met|0
6186741|NCT01375075|9840225|FG003|Overall Study|Entry Criterion Not Met|0
6186742|NCT01375075|9840226|FG004|Overall Study|Entry Criterion Not Met|0
6186743|NCT01375075|9840227|FG005|Overall Study|Entry Criterion Not Met|1
6186744|NCT01375075|9840222|FG000|Overall Study|Withdrawal by Subject|0
6186745|NCT01375075|9840223|FG001|Overall Study|Withdrawal by Subject|1
6186746|NCT01375075|9840224|FG002|Overall Study|Withdrawal by Subject|0
6186747|NCT01375075|9840225|FG003|Overall Study|Withdrawal by Subject|0
6186748|NCT01375075|9840226|FG004|Overall Study|Withdrawal by Subject|0
6186749|NCT01375075|9840227|FG005|Overall Study|Withdrawal by Subject|1
6186750|NCT01375205|9840276|FG000|Overall Study|Lost to Follow-up|15
6186751|NCT01375205|9840277|FG001|Overall Study|Lost to Follow-up|12
6186752|NCT01375205|9840276|FG000|Overall Study|Withdrawal by Subject|6
6186753|NCT01375205|9840277|FG001|Overall Study|Withdrawal by Subject|1
6186754|NCT01375374|9840283|FG000|Overall Study|Adverse Event|1
6186755|NCT01375608|9840303|FG000|Overall Study|Withdrawal by Subject|2
6186756|NCT01375673|9840319|FG000|Overall Study|Withdrawal by Subject|0
6186757|NCT01375673|9840320|FG001|Overall Study|Withdrawal by Subject|1
6186758|NCT01375751|9840329|FG000|Overall Study|Other|0
6186759|NCT01375751|9840330|FG001|Overall Study|Other|1
6186760|NCT01375751|9840331|FG002|Overall Study|Other|0
6186761|NCT01375764|9840344|FG000|Overall Study|Lost to Follow-up|0
6186762|NCT01375764|9840345|FG001|Overall Study|Lost to Follow-up|1
6186763|NCT01375764|9840346|FG002|Overall Study|Lost to Follow-up|0
6186764|NCT01375764|9840347|FG003|Overall Study|Lost to Follow-up|0
6186765|NCT01375764|9840348|FG004|Overall Study|Lost to Follow-up|0
6186766|NCT01375764|9840344|FG000|Overall Study|Withdrawal by Subject|2
6186767|NCT01375764|9840345|FG001|Overall Study|Withdrawal by Subject|0
6186768|NCT01375764|9840346|FG002|Overall Study|Withdrawal by Subject|0
6186769|NCT01375764|9840347|FG003|Overall Study|Withdrawal by Subject|0
6186770|NCT01375764|9840348|FG004|Overall Study|Withdrawal by Subject|1
6186771|NCT01375764|9840344|FG000|Overall Study|Other|0
6186772|NCT01375764|9840345|FG001|Overall Study|Other|0
6186773|NCT01375764|9840346|FG002|Overall Study|Other|0
6186774|NCT01375764|9840347|FG003|Overall Study|Other|1
6186775|NCT01375764|9840348|FG004|Overall Study|Other|0
6186776|NCT01375777|9840369|FG000|Overall Study|Withdrawal by Subject|0
6186777|NCT01375777|9840370|FG001|Overall Study|Withdrawal by Subject|2
6186778|NCT01375777|9840371|FG002|Overall Study|Withdrawal by Subject|1
6186779|NCT01375777|9840372|FG003|Overall Study|Withdrawal by Subject|0
6186780|NCT01375777|9840373|FG004|Overall Study|Withdrawal by Subject|1
6186781|NCT01375777|9840374|FG005|Overall Study|Withdrawal by Subject|1
6186782|NCT01375777|9840375|FG006|Overall Study|Withdrawal by Subject|1
6186783|NCT01375777|9840376|FG007|Overall Study|Withdrawal by Subject|2
6186784|NCT01375777|9840377|FG008|Overall Study|Withdrawal by Subject|1
6186785|NCT01375777|9840369|FG000|Overall Study|Lost to Follow-up|1
6186786|NCT01375777|9840370|FG001|Overall Study|Lost to Follow-up|0
6186787|NCT01375777|9840371|FG002|Overall Study|Lost to Follow-up|0
6186788|NCT01375777|9840372|FG003|Overall Study|Lost to Follow-up|0
6186789|NCT01375777|9840373|FG004|Overall Study|Lost to Follow-up|0
6186790|NCT01375777|9840374|FG005|Overall Study|Lost to Follow-up|0
6186791|NCT01375777|9840375|FG006|Overall Study|Lost to Follow-up|1
6186792|NCT01375777|9840376|FG007|Overall Study|Lost to Follow-up|0
6186793|NCT01375777|9840377|FG008|Overall Study|Lost to Follow-up|0
6186794|NCT01375777|9840369|FG000|Overall Study|Other|1
6186795|NCT01375777|9840370|FG001|Overall Study|Other|1
6186796|NCT01375777|9840371|FG002|Overall Study|Other|0
6186797|NCT01375777|9840372|FG003|Overall Study|Other|0
6186798|NCT01375777|9840373|FG004|Overall Study|Other|0
6186799|NCT01375777|9840374|FG005|Overall Study|Other|0
6186800|NCT01375777|9840375|FG006|Overall Study|Other|0
6186801|NCT01375777|9840376|FG007|Overall Study|Other|0
6186802|NCT01375777|9840377|FG008|Overall Study|Other|1
6186803|NCT01376037|9840408|FG000|Overall Study|Lost to Follow-up|0
6186804|NCT01376037|9840409|FG001|Overall Study|Lost to Follow-up|2
6186805|NCT01376089|9840426|FG000|Overall Study|Patient received no contrast media|3
6186806|NCT01376089|9840427|FG001|Overall Study|Patient received no contrast media|4
6186807|NCT01376167|9840440|FG000|Overall Study|Lost to Follow-up|2
6186808|NCT01376167|9840441|FG001|Overall Study|Lost to Follow-up|4
6186809|NCT01376167|9840442|FG002|Overall Study|Lost to Follow-up|2
6186810|NCT01376167|9840440|FG000|Overall Study|Physician Decision|1
6186811|NCT01376167|9840441|FG001|Overall Study|Physician Decision|1
6186812|NCT01376167|9840442|FG002|Overall Study|Physician Decision|0
6186813|NCT01376167|9840440|FG000|Overall Study|Withdrawal by Subject|1
6186814|NCT01376167|9840441|FG001|Overall Study|Withdrawal by Subject|5
6186815|NCT01376167|9840442|FG002|Overall Study|Withdrawal by Subject|4
6186816|NCT01376245|9840457|FG000|2-wk Single-blind Placebo Run-in Period|Did Not Meet Continuation Criteria|66
6186817|NCT01376245|9840458|FG001|2-wk Single-blind Placebo Run-in Period|Did Not Meet Continuation Criteria|0
6186818|NCT01376245|9840459|FG002|2-wk Single-blind Placebo Run-in Period|Did Not Meet Continuation Criteria|0
6186819|NCT01376245|9840460|FG003|2-wk Single-blind Placebo Run-in Period|Did Not Meet Continuation Criteria|0
6186820|NCT01376245|9840461|FG004|2-wk Single-blind Placebo Run-in Period|Did Not Meet Continuation Criteria|0
6186821|NCT01376245|9840457|FG000|2-wk Single-blind Placebo Run-in Period|Adverse Event|4
6186822|NCT01376245|9840458|FG001|2-wk Single-blind Placebo Run-in Period|Adverse Event|0
6186823|NCT01376245|9840459|FG002|2-wk Single-blind Placebo Run-in Period|Adverse Event|0
6186824|NCT01376245|9840460|FG003|2-wk Single-blind Placebo Run-in Period|Adverse Event|0
6186825|NCT01376245|9840461|FG004|2-wk Single-blind Placebo Run-in Period|Adverse Event|0
6186826|NCT01376245|9840457|FG000|2-wk Single-blind Placebo Run-in Period|Lost to Follow-up|1
6186827|NCT01376245|9840458|FG001|2-wk Single-blind Placebo Run-in Period|Lost to Follow-up|0
6186828|NCT01376245|9840459|FG002|2-wk Single-blind Placebo Run-in Period|Lost to Follow-up|0
6186829|NCT01376245|9840460|FG003|2-wk Single-blind Placebo Run-in Period|Lost to Follow-up|0
6186830|NCT01376245|9840461|FG004|2-wk Single-blind Placebo Run-in Period|Lost to Follow-up|0
6186831|NCT01376245|9840457|FG000|2-wk Single-blind Placebo Run-in Period|Physician Decision|2
6186832|NCT01376245|9840458|FG001|2-wk Single-blind Placebo Run-in Period|Physician Decision|0
6186833|NCT01376245|9840459|FG002|2-wk Single-blind Placebo Run-in Period|Physician Decision|0
6186834|NCT01376245|9840460|FG003|2-wk Single-blind Placebo Run-in Period|Physician Decision|0
6186835|NCT01376245|9840461|FG004|2-wk Single-blind Placebo Run-in Period|Physician Decision|0
6186836|NCT01376245|9840457|FG000|2-wk Single-blind Placebo Run-in Period|Withdrawal by Subject|28
6186837|NCT01376245|9840458|FG001|2-wk Single-blind Placebo Run-in Period|Withdrawal by Subject|0
6186838|NCT01376245|9840459|FG002|2-wk Single-blind Placebo Run-in Period|Withdrawal by Subject|0
6186839|NCT01376245|9840460|FG003|2-wk Single-blind Placebo Run-in Period|Withdrawal by Subject|0
6186840|NCT01376245|9840461|FG004|2-wk Single-blind Placebo Run-in Period|Withdrawal by Subject|0
6186841|NCT01376245|9840457|FG000|24-week, Double-blind Treatment Period|Adverse Event|0
6186842|NCT01376245|9840458|FG001|24-week, Double-blind Treatment Period|Adverse Event|16
6186843|NCT01376245|9840459|FG002|24-week, Double-blind Treatment Period|Adverse Event|7
6186844|NCT01376245|9840460|FG003|24-week, Double-blind Treatment Period|Adverse Event|8
6186845|NCT01376245|9840461|FG004|24-week, Double-blind Treatment Period|Adverse Event|18
6186846|NCT01376245|9840457|FG000|24-week, Double-blind Treatment Period|Lack of Efficacy|0
6228231|NCT01724021|9901462|FG000|Overall Study|Adverse Event|11
6228232|NCT01724021|9901463|FG001|Overall Study|Adverse Event|6
6228233|NCT01724021|9901462|FG000|Overall Study|Death|46
6228234|NCT01724021|9901463|FG001|Overall Study|Death|58
6228235|NCT01724021|9901462|FG000|Overall Study|Participant request/ Withdrew consent|18
6228236|NCT01724021|9901463|FG001|Overall Study|Participant request/ Withdrew consent|14
6228237|NCT01724021|9901462|FG000|Overall Study|Lost to Follow-up|15
6228238|NCT01724021|9901463|FG001|Overall Study|Lost to Follow-up|15
6228239|NCT01724021|9901462|FG000|Overall Study|Reason Not Specified|36
6228240|NCT01724021|9901463|FG001|Overall Study|Reason Not Specified|39
6228241|NCT01724021|9901462|FG000|Overall Study|Missing|1
6228242|NCT01724021|9901463|FG001|Overall Study|Missing|1
6228243|NCT01724177|9901504|FG000|Overall Study|Adverse Event|8
6228244|NCT01724177|9901504|FG000|Overall Study|Progressive disease or Relapsed Disease|16
6228245|NCT01724177|9901504|FG000|Overall Study|Nervous participant|1
6228246|NCT01724177|9901504|FG000|Overall Study|Serious Adverse Event Related|1
6228247|NCT01724216|9901509|FG000|Overall Study|Scan was not completed|1
6228248|NCT01724359|9901513|FG000|Overall Study|Adverse Event|10
6228249|NCT01724359|9901513|FG000|Overall Study|Death|1
6228250|NCT01724359|9901513|FG000|Overall Study|Other|20
6228251|NCT01724489|9901521|FG000|Overall Study|Adverse Event|8
6228252|NCT01724489|9901522|FG001|Overall Study|Adverse Event|3
6228253|NCT01724489|9901521|FG000|Overall Study|Surgery, medication|1
6228254|NCT01724489|9901522|FG001|Overall Study|Surgery, medication|1
6228255|NCT01724489|9901521|FG000|Overall Study|Lost to Follow-up|1
6228256|NCT01724489|9901522|FG001|Overall Study|Lost to Follow-up|2
6228257|NCT01724489|9901521|FG000|Overall Study|Withdrawal by Subject|6
6228258|NCT01724489|9901522|FG001|Overall Study|Withdrawal by Subject|6
6228259|NCT01724528|9901530|FG000|Overall Study|Death|3
6228260|NCT01724528|9901531|FG001|Overall Study|Death|0
6228261|NCT01724528|9901530|FG000|Overall Study|Withdrawal by Subject|0
6228262|NCT01724528|9901531|FG001|Overall Study|Withdrawal by Subject|2
6228263|NCT01724528|9901530|FG000|Overall Study|Protocol Violation|0
6228264|NCT01724528|9901531|FG001|Overall Study|Protocol Violation|1
6228265|NCT01724528|9901530|FG000|Overall Study|Patient refused to attend last visit|1
6228266|NCT01724528|9901531|FG001|Overall Study|Patient refused to attend last visit|0
6228267|NCT01725126|9901543|FG000|Overall Study|Protocol Violation|0
6228268|NCT01725126|9901544|FG001|Overall Study|Protocol Violation|1
6228269|NCT01725126|9901545|FG002|Overall Study|Protocol Violation|0
6228270|NCT01725126|9901546|FG003|Overall Study|Protocol Violation|0
6228271|NCT01725126|9901547|FG004|Overall Study|Protocol Violation|0
6228272|NCT01725126|9901548|FG005|Overall Study|Protocol Violation|0
6228273|NCT01725126|9901543|FG000|Overall Study|Withdrawal by Subject|0
6228274|NCT01725126|9901544|FG001|Overall Study|Withdrawal by Subject|0
6228275|NCT01725126|9901545|FG002|Overall Study|Withdrawal by Subject|0
6228276|NCT01725126|9901546|FG003|Overall Study|Withdrawal by Subject|1
6228277|NCT01725126|9901547|FG004|Overall Study|Withdrawal by Subject|0
6228278|NCT01725126|9901548|FG005|Overall Study|Withdrawal by Subject|0
6228279|NCT01725217|9901574|FG000|Overall Study|Withdrawal by Subject|1
6228280|NCT01725217|9901575|FG001|Overall Study|Withdrawal by Subject|0
6228281|NCT01725217|9901576|FG002|Overall Study|Withdrawal by Subject|0
6228282|NCT01725282|9901597|FG000|Overall Study|Adverse Event|1
6228283|NCT01725282|9901598|FG001|Overall Study|Adverse Event|3
6228284|NCT01725282|9901599|FG002|Overall Study|Adverse Event|6
6228285|NCT01725282|9901600|FG003|Overall Study|Adverse Event|4
6228286|NCT01725282|9901597|FG000|Overall Study|Exacerbation of Target Disease|1
6228287|NCT01725282|9901598|FG001|Overall Study|Exacerbation of Target Disease|0
6228288|NCT01725282|9901599|FG002|Overall Study|Exacerbation of Target Disease|0
6228289|NCT01725282|9901600|FG003|Overall Study|Exacerbation of Target Disease|1
6228290|NCT01725282|9901597|FG000|Overall Study|Met Exclusion Criteria|0
6228291|NCT01725282|9901598|FG001|Overall Study|Met Exclusion Criteria|0
6228292|NCT01725282|9901599|FG002|Overall Study|Met Exclusion Criteria|1
6228293|NCT01725282|9901600|FG003|Overall Study|Met Exclusion Criteria|0
6228294|NCT01725282|9901597|FG000|Overall Study|Study Site Withdrawal|0
6228295|NCT01725282|9901598|FG001|Overall Study|Study Site Withdrawal|1
6228296|NCT01725282|9901599|FG002|Overall Study|Study Site Withdrawal|0
6228297|NCT01725282|9901600|FG003|Overall Study|Study Site Withdrawal|0
6228298|NCT01725282|9901597|FG000|Overall Study|Withdrawal by Subject|0
6228299|NCT01725282|9901598|FG001|Overall Study|Withdrawal by Subject|0
6228300|NCT01725282|9901599|FG002|Overall Study|Withdrawal by Subject|1
6228301|NCT01725282|9901600|FG003|Overall Study|Withdrawal by Subject|1
6228302|NCT01725282|9901597|FG000|Overall Study|Lack of Efficacy|0
6228303|NCT01725282|9901598|FG001|Overall Study|Lack of Efficacy|1
6228304|NCT01725282|9901599|FG002|Overall Study|Lack of Efficacy|0
6228305|NCT01725282|9901600|FG003|Overall Study|Lack of Efficacy|1
6228306|NCT01725308|9901613|FG000|Treatment Period I|Did Not Receive Drug|1
6228307|NCT01725308|9901614|FG001|Treatment Period I|Did Not Receive Drug|0
6228308|NCT01725308|9901615|FG002|Treatment Period I|Did Not Receive Drug|0
6228309|NCT01725308|9901613|FG000|Treatment Period I|Adverse Event|5
6228310|NCT01725308|9901614|FG001|Treatment Period I|Adverse Event|4
6228311|NCT01725308|9901615|FG002|Treatment Period I|Adverse Event|21
6228312|NCT01725308|9901613|FG000|Treatment Period I|Insufficient Response|7
6228313|NCT01725308|9901614|FG001|Treatment Period I|Insufficient Response|0
6228314|NCT01725308|9901615|FG002|Treatment Period I|Insufficient Response|5
6228315|NCT01725308|9901613|FG000|Treatment Period I|Worsening of the Target Disease|8
6228316|NCT01725308|9901614|FG001|Treatment Period I|Worsening of the Target Disease|0
6228317|NCT01725308|9901615|FG002|Treatment Period I|Worsening of the Target Disease|2
6228318|NCT01725308|9901613|FG000|Treatment Period I|Changes in the Episodes|3
6228319|NCT01725308|9901614|FG001|Treatment Period I|Changes in the Episodes|0
6228320|NCT01725308|9901615|FG002|Treatment Period I|Changes in the Episodes|2
6228321|NCT01725308|9901613|FG000|Treatment Period I|Withdrawal of Consent|12
6228322|NCT01725308|9901614|FG001|Treatment Period I|Withdrawal of Consent|7
6228323|NCT01725308|9901615|FG002|Treatment Period I|Withdrawal of Consent|5
6228324|NCT01725308|9901613|FG000|Treatment Period I|Lost to Follow-up|3
6228325|NCT01725308|9901614|FG001|Treatment Period I|Lost to Follow-up|2
6228326|NCT01725308|9901615|FG002|Treatment Period I|Lost to Follow-up|2
6228327|NCT01725308|9901613|FG000|Treatment Period I|Protocol Deviations|3
6228328|NCT01725308|9901614|FG001|Treatment Period I|Protocol Deviations|1
6228329|NCT01725308|9901615|FG002|Treatment Period I|Protocol Deviations|1
6228330|NCT01725308|9901613|FG000|Treatment Period I|Miscellaneous|2
6228331|NCT01725308|9901614|FG001|Treatment Period I|Miscellaneous|0
6228332|NCT01725308|9901615|FG002|Treatment Period I|Miscellaneous|3
6228333|NCT01725308|9901613|FG000|Treatment Period II|Did Not Meet Transition Criteria|0
6228334|NCT01725308|9901614|FG001|Treatment Period II|Did Not Meet Transition Criteria|3
6228335|NCT01725308|9901615|FG002|Treatment Period II|Did Not Meet Transition Criteria|4
6228336|NCT01725308|9901613|FG000|Treatment Period II|Did Not Receive Drug|4
6228337|NCT01725308|9901614|FG001|Treatment Period II|Did Not Receive Drug|0
6228338|NCT01725308|9901615|FG002|Treatment Period II|Did Not Receive Drug|0
6228339|NCT01725308|9901613|FG000|Treatment Period II|Adverse Event|13
6228340|NCT01725308|9901614|FG001|Treatment Period II|Adverse Event|8
6228341|NCT01725308|9901615|FG002|Treatment Period II|Adverse Event|20
6228342|NCT01725308|9901613|FG000|Treatment Period II|Insufficient Response|2
6228343|NCT01725308|9901614|FG001|Treatment Period II|Insufficient Response|4
6228344|NCT01725308|9901615|FG002|Treatment Period II|Insufficient Response|6
6228345|NCT01725308|9901613|FG000|Treatment Period II|Worsening of the Target Disease|1
6228346|NCT01725308|9901614|FG001|Treatment Period II|Worsening of the Target Disease|4
6228347|NCT01725308|9901615|FG002|Treatment Period II|Worsening of the Target Disease|2
6228348|NCT01725308|9901613|FG000|Treatment Period II|Changes in the Episodes|1
6228349|NCT01725308|9901614|FG001|Treatment Period II|Changes in the Episodes|0
6228350|NCT01725308|9901615|FG002|Treatment Period II|Changes in the Episodes|5
6228351|NCT01725308|9901613|FG000|Treatment Period II|Withdrawal of Consent|28
6228352|NCT01725308|9901614|FG001|Treatment Period II|Withdrawal of Consent|2
6228353|NCT01725308|9901615|FG002|Treatment Period II|Withdrawal of Consent|16
6228354|NCT01725308|9901613|FG000|Treatment Period II|Lost to Follow-up|1
6228355|NCT01725308|9901614|FG001|Treatment Period II|Lost to Follow-up|5
6228356|NCT01725308|9901615|FG002|Treatment Period II|Lost to Follow-up|3
6228357|NCT01725308|9901613|FG000|Treatment Period II|Protocol Deviations|0
6228358|NCT01725308|9901614|FG001|Treatment Period II|Protocol Deviations|0
6228359|NCT01725308|9901615|FG002|Treatment Period II|Protocol Deviations|1
6228360|NCT01725308|9901613|FG000|Treatment Period II|Miscellaneous|5
6228361|NCT01725308|9901614|FG001|Treatment Period II|Miscellaneous|3
6228362|NCT01725308|9901615|FG002|Treatment Period II|Miscellaneous|7
6228363|NCT01725386|9901632|FG000|Overall Study|Death|84
6228364|NCT01725386|9901633|FG001|Overall Study|Death|40
6228365|NCT01725386|9901632|FG000|Overall Study|Lost to Follow-up|81
6228366|NCT01725386|9901633|FG001|Overall Study|Lost to Follow-up|6
6228367|NCT01725386|9901632|FG000|Overall Study|Withdrawal by Subject|10
6228368|NCT01725386|9901633|FG001|Overall Study|Withdrawal by Subject|0
6228369|NCT01725451|9901639|FG000|Period 1|Withdrawal by Subject|1
6228370|NCT01725451|9901640|FG001|Period 1|Withdrawal by Subject|0
6228371|NCT01725451|9901641|FG002|Period 1|Withdrawal by Subject|0
6228372|NCT01725451|9901642|FG003|Period 1|Withdrawal by Subject|0
6228373|NCT01725451|9901639|FG000|Washout From Period 3|Protocol Violation|0
6228374|NCT01725451|9901640|FG001|Washout From Period 3|Protocol Violation|0
6228375|NCT01725451|9901641|FG002|Washout From Period 3|Protocol Violation|1
6228376|NCT01725451|9901642|FG003|Washout From Period 3|Protocol Violation|0
6228377|NCT01725451|9901639|FG000|Washout From Period 3|Adverse Event|0
6228378|NCT01725451|9901640|FG001|Washout From Period 3|Adverse Event|1
6228379|NCT01725451|9901641|FG002|Washout From Period 3|Adverse Event|0
6228380|NCT01725451|9901642|FG003|Washout From Period 3|Adverse Event|0
6228381|NCT01725451|9901639|FG000|Period 4|Adverse Event|0
6228382|NCT01725451|9901640|FG001|Period 4|Adverse Event|0
6228383|NCT01725451|9901641|FG002|Period 4|Adverse Event|1
6228384|NCT01725451|9901642|FG003|Period 4|Adverse Event|0
6228385|NCT01725529|9901660|FG000|Overall Study|Adverse Event|1
6228386|NCT01725529|9901661|FG001|Overall Study|Adverse Event|0
6228387|NCT01725529|9901662|FG002|Overall Study|Adverse Event|0
6228388|NCT01725529|9901660|FG000|Overall Study|Lost to Follow-up|2
6228389|NCT01725529|9901661|FG001|Overall Study|Lost to Follow-up|1
6228390|NCT01725529|9901662|FG002|Overall Study|Lost to Follow-up|1
6228391|NCT01725529|9901660|FG000|Overall Study|Protocol Violation|0
6228392|NCT01725529|9901661|FG001|Overall Study|Protocol Violation|1
6228393|NCT01725529|9901662|FG002|Overall Study|Protocol Violation|1
6228394|NCT01725529|9901660|FG000|Overall Study|Withdrawal by Subject|12
6228395|NCT01725529|9901661|FG001|Overall Study|Withdrawal by Subject|14
6228396|NCT01725529|9901662|FG002|Overall Study|Withdrawal by Subject|8
6228397|NCT01725750|9901672|FG000|Overall Study|Adverse Event|1
6228398|NCT01725750|9901673|FG001|Overall Study|Adverse Event|0
6228399|NCT01725750|9901672|FG000|Overall Study|Lost to Follow-up|1
6228400|NCT01725750|9901673|FG001|Overall Study|Lost to Follow-up|1
6228401|NCT01725750|9901672|FG000|Overall Study|Withdrawal by Subject|0
6228402|NCT01725750|9901673|FG001|Overall Study|Withdrawal by Subject|9
6228403|NCT01726023|9901701|FG000|Overall Study|Death|1
6228404|NCT01726023|9901702|FG001|Overall Study|Death|1
6228405|NCT01726023|9901701|FG000|Overall Study|Lost to Follow-up|5
6228406|NCT01726023|9901702|FG001|Overall Study|Lost to Follow-up|10
6228407|NCT01726023|9901701|FG000|Overall Study|Other Eligibility criteria|7
6228408|NCT01726023|9901702|FG001|Overall Study|Other Eligibility criteria|7
6228409|NCT01726023|9901701|FG000|Overall Study|Withdrawal by Subject|16
6228410|NCT01726023|9901702|FG001|Overall Study|Withdrawal by Subject|8
6228411|NCT01726049|9901726|FG000|Overall Study|Death|1
6228412|NCT01726049|9901727|FG001|Overall Study|Death|1
6228413|NCT01726049|9901726|FG000|Overall Study|Adverse Event|4
6228414|NCT01726049|9901727|FG001|Overall Study|Adverse Event|1
6228415|NCT01726049|9901726|FG000|Overall Study|refused second HC|0
6228416|NCT01726049|9901727|FG001|Overall Study|refused second HC|2
6228417|NCT01726270|9901733|FG000|Part 1, Self-Selection Phase|Withdrawal by Subject|10
6228418|NCT01726270|9901733|FG000|Eligibility for Part 2|Eligible but did not enter Part 2|20
6228419|NCT01726270|9901733|FG000|Part 2, Actual-Use Phase|Withdrawal by Subject|21
6228420|NCT01726270|9901733|FG000|Part 2, Actual-Use Phase|Adverse Event|6
6228421|NCT01726270|9901733|FG000|Part 2, Actual-Use Phase|Lost to Follow-up|5
6228422|NCT01726270|9901733|FG000|Part 2, Actual-Use Phase|Other than reason specified above|7
6228423|NCT01726335|9901739|FG000|Overall Study|Lost to Follow-up|2
6228424|NCT01726335|9901739|FG000|Overall Study|Withdrawal by Subject|15
6228425|NCT01726335|9901739|FG000|Overall Study|Adverse Event|4
6228426|NCT01726335|9901739|FG000|Overall Study|Lost to Follow-up|2
6228427|NCT01726335|9901739|FG000|Overall Study|Exacerbation of psychotic symptoms|1
6228428|NCT01726517|9901757|FG000|Overall Study|Withdrawal by Subject|0
6228429|NCT01726517|9901758|FG001|Overall Study|Withdrawal by Subject|0
6228430|NCT01726517|9901759|FG002|Overall Study|Withdrawal by Subject|1
6228431|NCT01726517|9901760|FG003|Overall Study|Withdrawal by Subject|0
6228432|NCT01726517|9901761|FG004|Overall Study|Withdrawal by Subject|0
6228433|NCT01726803|9901792|FG000|Overall Study|Lost to Follow-up|6
6228434|NCT01726803|9901793|FG001|Overall Study|Lost to Follow-up|1
6228435|NCT01726803|9901792|FG000|Overall Study|Withdrawal by Subject|1
6228436|NCT01726803|9901793|FG001|Overall Study|Withdrawal by Subject|0
6228437|NCT01727024|9901799|FG000|Period 1|Lost to Follow-up|1
6228438|NCT01727024|9901800|FG001|Period 1|Lost to Follow-up|1
6228439|NCT01727024|9901799|FG000|Period 1|Withdrawal by Subject|2
6228440|NCT01727024|9901800|FG001|Period 1|Withdrawal by Subject|3
6228441|NCT01727141|9901819|FG000|Overall Study|Physician Decision|0
6228442|NCT01727141|9901820|FG001|Overall Study|Physician Decision|1
6228443|NCT01727141|9901821|FG002|Overall Study|Physician Decision|0
6228444|NCT01727141|9901822|FG003|Overall Study|Physician Decision|2
6228445|NCT01727141|9901819|FG000|Overall Study|Lost to Follow-up|0
6228446|NCT01727141|9901820|FG001|Overall Study|Lost to Follow-up|2
6228447|NCT01727141|9901821|FG002|Overall Study|Lost to Follow-up|0
6228448|NCT01727141|9901822|FG003|Overall Study|Lost to Follow-up|0
6228449|NCT01727141|9901819|FG000|Overall Study|Death|0
6228450|NCT01727141|9901820|FG001|Overall Study|Death|1
6228451|NCT01727141|9901821|FG002|Overall Study|Death|1
6228452|NCT01727141|9901822|FG003|Overall Study|Death|1
6228453|NCT01727141|9901819|FG000|Overall Study|Protocol deviation|1
6228454|NCT01727141|9901820|FG001|Overall Study|Protocol deviation|1
6228455|NCT01727141|9901821|FG002|Overall Study|Protocol deviation|0
6228456|NCT01727141|9901822|FG003|Overall Study|Protocol deviation|1
6228457|NCT01727141|9901819|FG000|Overall Study|Withdrawal by Subject|4
6228458|NCT01727141|9901820|FG001|Overall Study|Withdrawal by Subject|4
6228459|NCT01727141|9901821|FG002|Overall Study|Withdrawal by Subject|2
6228460|NCT01727141|9901822|FG003|Overall Study|Withdrawal by Subject|11
6228461|NCT01727154|9901832|FG000|Overall Study|Death|17
6228462|NCT01727154|9901832|FG000|Overall Study|Withdrawal by Subject|14
6228463|NCT01727154|9901832|FG000|Overall Study|Subject Withdrew Consent|18
6228464|NCT01727154|9901832|FG000|Overall Study|Study Terminated|6
6228465|NCT01727154|9901832|FG000|Overall Study|No Discontinuation Documentation|4
6228466|NCT01727258|9901843|FG000|Overall Study|Adverse Event|0
6228467|NCT01727258|9901844|FG001|Overall Study|Adverse Event|2
6228468|NCT01727258|9901845|FG002|Overall Study|Adverse Event|0
6228469|NCT01727258|9901843|FG000|Overall Study|Noncompliance with Study Drug|0
6228470|NCT01727258|9901844|FG001|Overall Study|Noncompliance with Study Drug|0
6228471|NCT01727258|9901845|FG002|Overall Study|Noncompliance with Study Drug|1
6228472|NCT01727258|9901843|FG000|Overall Study|Withdrawal by Subject|1
6228473|NCT01727258|9901844|FG001|Overall Study|Withdrawal by Subject|1
6228474|NCT01727258|9901845|FG002|Overall Study|Withdrawal by Subject|0
6228475|NCT01727258|9901843|FG000|Overall Study|Lost to Follow-up|1
6228476|NCT01727258|9901844|FG001|Overall Study|Lost to Follow-up|0
6228477|NCT01727258|9901845|FG002|Overall Study|Lost to Follow-up|0
6228478|NCT01727297|9901853|FG000|Overall Study|Death|13
6228479|NCT01727297|9901854|FG001|Overall Study|Death|0
6228480|NCT01727297|9901853|FG000|Overall Study|Protocol Violation|1
6228481|NCT01727297|9901854|FG001|Overall Study|Protocol Violation|10
6228482|NCT01727297|9901853|FG000|Overall Study|Adverse Event|3
6228483|NCT01727297|9901854|FG001|Overall Study|Adverse Event|1
6228484|NCT01727297|9901853|FG000|Overall Study|Lost to Follow-up|11
6228485|NCT01727297|9901854|FG001|Overall Study|Lost to Follow-up|0
6228486|NCT01727297|9901853|FG000|Overall Study|Withdrawal by Subject|26
6228487|NCT01727297|9901854|FG001|Overall Study|Withdrawal by Subject|27
6228488|NCT01727297|9901853|FG000|Overall Study|Physician Decision|19
6228489|NCT01727297|9901854|FG001|Overall Study|Physician Decision|5
6228490|NCT01727297|9901853|FG000|Overall Study|Other (e.g. AF detection pre-implant)|29
6228491|NCT01727297|9901854|FG001|Overall Study|Other (e.g. AF detection pre-implant)|8
6228492|NCT01727336|9901873|FG000|Part 1 Dalantercept Dose Escalation|Adverse Event|0
6228493|NCT01727336|9901874|FG001|Part 1 Dalantercept Dose Escalation|Adverse Event|1
6228494|NCT01727336|9901875|FG002|Part 1 Dalantercept Dose Escalation|Adverse Event|5
6228495|NCT01727336|9901876|FG003|Part 1 Dalantercept Dose Escalation|Adverse Event|0
6228496|NCT01727336|9901877|FG004|Part 1 Dalantercept Dose Escalation|Adverse Event|0
6228497|NCT01727336|9901878|FG005|Part 1 Dalantercept Dose Escalation|Adverse Event|0
6228498|NCT01727336|9901873|FG000|Part 1 Dalantercept Dose Escalation|Lack of Efficacy|3
6228499|NCT01727336|9901874|FG001|Part 1 Dalantercept Dose Escalation|Lack of Efficacy|1
6228500|NCT01727336|9901875|FG002|Part 1 Dalantercept Dose Escalation|Lack of Efficacy|3
6228501|NCT01727336|9901876|FG003|Part 1 Dalantercept Dose Escalation|Lack of Efficacy|0
6228502|NCT01727336|9901877|FG004|Part 1 Dalantercept Dose Escalation|Lack of Efficacy|0
6228503|NCT01727336|9901878|FG005|Part 1 Dalantercept Dose Escalation|Lack of Efficacy|0
6228504|NCT01727336|9901873|FG000|Part 2 Blinded|Death|0
6228505|NCT01727336|9901874|FG001|Part 2 Blinded|Death|0
6228506|NCT01727336|9901875|FG002|Part 2 Blinded|Death|0
6228507|NCT01727336|9901876|FG003|Part 2 Blinded|Death|0
6228508|NCT01727336|9901877|FG004|Part 2 Blinded|Death|20
6228509|NCT01727336|9901878|FG005|Part 2 Blinded|Death|16
6228510|NCT01727336|9901873|FG000|Part 2 Blinded|Lack of Efficacy|0
6228511|NCT01727336|9901874|FG001|Part 2 Blinded|Lack of Efficacy|0
6228512|NCT01727336|9901875|FG002|Part 2 Blinded|Lack of Efficacy|0
6228513|NCT01727336|9901876|FG003|Part 2 Blinded|Lack of Efficacy|0
6228514|NCT01727336|9901877|FG004|Part 2 Blinded|Lack of Efficacy|42
6228515|NCT01727336|9901878|FG005|Part 2 Blinded|Lack of Efficacy|44
6228516|NCT01727336|9901873|FG000|Part 2 Blinded|Lost to Follow-up|0
6228517|NCT01727336|9901874|FG001|Part 2 Blinded|Lost to Follow-up|0
6228518|NCT01727336|9901875|FG002|Part 2 Blinded|Lost to Follow-up|0
6228519|NCT01727336|9901876|FG003|Part 2 Blinded|Lost to Follow-up|0
6228520|NCT01727336|9901877|FG004|Part 2 Blinded|Lost to Follow-up|0
6228521|NCT01727336|9901878|FG005|Part 2 Blinded|Lost to Follow-up|1
6228522|NCT01727336|9901873|FG000|Part 2 Blinded|Withdrawal by Subject|0
6228523|NCT01727336|9901874|FG001|Part 2 Blinded|Withdrawal by Subject|0
6228524|NCT01727336|9901875|FG002|Part 2 Blinded|Withdrawal by Subject|0
6228525|NCT01727336|9901876|FG003|Part 2 Blinded|Withdrawal by Subject|0
6228526|NCT01727336|9901877|FG004|Part 2 Blinded|Withdrawal by Subject|0
6228527|NCT01727336|9901878|FG005|Part 2 Blinded|Withdrawal by Subject|4
6228528|NCT01727336|9901873|FG000|Part 2 Blinded|use of prohibited medications|0
6228529|NCT01727336|9901874|FG001|Part 2 Blinded|use of prohibited medications|0
6228530|NCT01727336|9901875|FG002|Part 2 Blinded|use of prohibited medications|0
6228531|NCT01727336|9901876|FG003|Part 2 Blinded|use of prohibited medications|0
6228532|NCT01727336|9901877|FG004|Part 2 Blinded|use of prohibited medications|1
6228533|NCT01727336|9901878|FG005|Part 2 Blinded|use of prohibited medications|3
6228534|NCT01727505|9901907|FG000|First 24 Hours|Adverse Event|0
6228535|NCT01727505|9901908|FG001|First 24 Hours|Adverse Event|1
6228536|NCT01727505|9901907|FG000|Second 24 Hours|Missing data|0
6228537|NCT01727505|9901908|FG001|Second 24 Hours|Missing data|1
6228538|NCT01727700|9901917|FG000|Overall Study|Adverse Event|0
6228539|NCT01727700|9901918|FG001|Overall Study|Adverse Event|7
6228540|NCT01727700|9901919|FG002|Overall Study|Adverse Event|1
6228541|NCT01727700|9901917|FG000|Overall Study|Particpant withdrew consent|0
6228542|NCT01727700|9901918|FG001|Overall Study|Particpant withdrew consent|3
6228543|NCT01727700|9901919|FG002|Overall Study|Particpant withdrew consent|1
6228544|NCT01727700|9901917|FG000|Overall Study|Protocol Violation|2
6228545|NCT01727700|9901918|FG001|Overall Study|Protocol Violation|0
6228546|NCT01727700|9901919|FG002|Overall Study|Protocol Violation|0
6228547|NCT01727713|9901927|FG000|Overall Study|Lost to Follow-up|5
6228548|NCT01727713|9901927|FG000|Overall Study|Adverse Event|10
6375428|NCT03436199|10165464|FG001|Overall Study|Could not return to clinic|0
6375429|NCT03436199|10165465|FG002|Overall Study|Could not return to clinic|0
6375430|NCT03436199|10165463|FG000|Overall Study|Withdrawn per physician|0
6375431|NCT03436199|10165464|FG001|Overall Study|Withdrawn per physician|1
6375432|NCT03436199|10165465|FG002|Overall Study|Withdrawn per physician|0
6375433|NCT03250273|10165484|FG000|Overall Study|Disease Progression|2
6375434|NCT03250273|10165485|FG001|Overall Study|Disease Progression|9
6375435|NCT03250273|10165484|FG000|Overall Study|Adverse Event|0
6375436|NCT03250273|10165485|FG001|Overall Study|Adverse Event|1
6375437|NCT03250273|10165484|FG000|Overall Study|Death|0
6375438|NCT03250273|10165485|FG001|Overall Study|Death|1
6375439|NCT03250273|10165484|FG000|Overall Study|Failed to Maintain Eligibility|0
6228549|NCT01727713|9901927|FG000|Overall Study|Participant Met Withdrawal Criteria|5
6228550|NCT01727713|9901927|FG000|Overall Study|Withdrawal by Subject|13
6228551|NCT01727713|9901927|FG000|Overall Study|Protocol Deviation|2
6228552|NCT01728077|9901968|FG000|Overall Study|Lack of Efficacy|3
6228553|NCT01728077|9901969|FG001|Overall Study|Lack of Efficacy|1
6228554|NCT01728077|9901968|FG000|Overall Study|Lost to Follow-up|1
6228555|NCT01728077|9901969|FG001|Overall Study|Lost to Follow-up|0
6228556|NCT01728077|9901968|FG000|Overall Study|Subject choice|2
6228557|NCT01728077|9901969|FG001|Overall Study|Subject choice|3
6228558|NCT01728077|9901968|FG000|Overall Study|Death|0
6228559|NCT01728077|9901969|FG001|Overall Study|Death|1
6228560|NCT01728077|9901968|FG000|Overall Study|Patient moving|1
6228561|NCT01728077|9901969|FG001|Overall Study|Patient moving|0
6228562|NCT01728077|9901968|FG000|Overall Study|Non compliance|1
6228563|NCT01728077|9901969|FG001|Overall Study|Non compliance|0
6228564|NCT01728116|9901978|FG000|Overall Study|Sponsor Terminated Study|106
6228565|NCT01728116|9901979|FG001|Overall Study|Sponsor Terminated Study|35
6228566|NCT01728116|9901978|FG000|Overall Study|Withdrawal by Subject|16
6228567|NCT01728116|9901979|FG001|Overall Study|Withdrawal by Subject|9
6228568|NCT01728116|9901978|FG000|Overall Study|Adverse Event|13
6228569|NCT01728116|9901979|FG001|Overall Study|Adverse Event|0
6228570|NCT01728116|9901978|FG000|Overall Study|Procedure/device failure|7
6228571|NCT01728116|9901979|FG001|Overall Study|Procedure/device failure|0
6228572|NCT01728116|9901978|FG000|Overall Study|Lost to Follow-up|9
6228573|NCT01728116|9901979|FG001|Overall Study|Lost to Follow-up|2
6228574|NCT01728116|9901978|FG000|Overall Study|Physician Decision|2
6228575|NCT01728116|9901979|FG001|Overall Study|Physician Decision|0
6228576|NCT01728116|9901978|FG000|Overall Study|Subject Non-Compliance|2
6228577|NCT01728116|9901979|FG001|Overall Study|Subject Non-Compliance|0
6228578|NCT01728116|9901978|FG000|Overall Study|Inter-current finding at procedure|1
6228579|NCT01728116|9901979|FG001|Overall Study|Inter-current finding at procedure|0
6228580|NCT01728116|9901978|FG000|Overall Study|Incorrectly enrolled in Study|0
6228581|NCT01728116|9901979|FG001|Overall Study|Incorrectly enrolled in Study|1
6228582|NCT01728116|9901978|FG000|Overall Study|various not noted previously|5
6228583|NCT01728116|9901979|FG001|Overall Study|various not noted previously|0
6228584|NCT01728194|9901988|FG000|Overall Study|Lost to Follow-up|4
6228585|NCT01728194|9901989|FG001|Overall Study|Lost to Follow-up|3
6228586|NCT01728194|9901988|FG000|Overall Study|Physician Decision|4
6228587|NCT01728194|9901989|FG001|Overall Study|Physician Decision|0
6375440|NCT03250273|10165485|FG001|Overall Study|Failed to Maintain Eligibility|1
6228588|NCT01728194|9901988|FG000|Overall Study|Withdrawal by Subject|7
6375441|NCT03217136|10165493|FG000|Overall Study|Lost to Follow-up|2
6375442|NCT03217136|10165494|FG001|Overall Study|Lost to Follow-up|1
6375443|NCT03217136|10165493|FG000|Overall Study|Site Randomized Participant in Error|0
6375444|NCT03217136|10165494|FG001|Overall Study|Site Randomized Participant in Error|1
6375445|NCT03217136|10165493|FG000|Overall Study|Did Not Meet Criteria after Randomization|0
6375446|NCT03217136|10165494|FG001|Overall Study|Did Not Meet Criteria after Randomization|1
6375447|NCT03217136|10165493|FG000|Overall Study|Dispensing Error|1
6375448|NCT03217136|10165494|FG001|Overall Study|Dispensing Error|0
6375449|NCT03217136|10165493|FG000|Overall Study|Withdrawal by Parent/Guardian|1
6375450|NCT03217136|10165494|FG001|Overall Study|Withdrawal by Parent/Guardian|0
6375451|NCT03181542|10165502|FG000|Overall Study|Subject withdrawn because research physician could not make it in time to place IV|1
6375452|NCT03181542|10165503|FG001|Overall Study|Subject withdrawn because research physician could not make it in time to place IV|0
6228589|NCT01728194|9901989|FG001|Overall Study|Withdrawal by Subject|3
6228590|NCT01728194|9901988|FG000|Overall Study|Perceived Medication Side Effects|4
6228591|NCT01728194|9901989|FG001|Overall Study|Perceived Medication Side Effects|0
6228592|NCT01728194|9901988|FG000|Overall Study|Family Member Request|1
6228593|NCT01728194|9901989|FG001|Overall Study|Family Member Request|0
6228594|NCT01728246|9901997|FG000|Overall Study|Participant needed rescue medication|1
6228595|NCT01728246|9901998|FG001|Overall Study|Participant needed rescue medication|5
6228596|NCT01728246|9901997|FG000|Overall Study|Protocol Violation|1
6228597|NCT01728246|9901998|FG001|Overall Study|Protocol Violation|0
6228598|NCT01728246|9901997|FG000|Overall Study|Withdrawal by Subject|2
6228599|NCT01728246|9901998|FG001|Overall Study|Withdrawal by Subject|3
6228600|NCT01728246|9901997|FG000|Overall Study|Lost to Follow-up|23
6228601|NCT01728246|9901998|FG001|Overall Study|Lost to Follow-up|22
6228602|NCT01728246|9901997|FG000|Overall Study|Lack of Efficacy|1
6228603|NCT01728246|9901998|FG001|Overall Study|Lack of Efficacy|1
6228604|NCT01728246|9901997|FG000|Overall Study|Adverse Event|8
6228605|NCT01728246|9901998|FG001|Overall Study|Adverse Event|5
6228606|NCT01728324|9902007|FG000|Termination of DBV|Adverse Event|14
6228607|NCT01728324|9902008|FG001|Termination of DBV|Adverse Event|13
6228608|NCT01728324|9902009|FG002|Termination of DBV|Adverse Event|4
6228609|NCT01728324|9902007|FG000|Termination of DBV|Lack of Efficacy|14
6228610|NCT01728324|9902008|FG001|Termination of DBV|Lack of Efficacy|12
6228611|NCT01728324|9902009|FG002|Termination of DBV|Lack of Efficacy|8
6228612|NCT01728324|9902007|FG000|Termination of DBV|Withdrawal by Subject|9
6228613|NCT01728324|9902008|FG001|Termination of DBV|Withdrawal by Subject|6
6228614|NCT01728324|9902009|FG002|Termination of DBV|Withdrawal by Subject|2
6228615|NCT01728324|9902007|FG000|Termination of DBV|Other than stated|1
6228616|NCT01728324|9902008|FG001|Termination of DBV|Other than stated|3
6228617|NCT01728324|9902009|FG002|Termination of DBV|Other than stated|0
6228618|NCT01728324|9902007|FG000|Termination of DBV|Adverse Event (Placebo Period)|0
6228619|NCT01728324|9902008|FG001|Termination of DBV|Adverse Event (Placebo Period)|1
6228620|NCT01728324|9902009|FG002|Termination of DBV|Adverse Event (Placebo Period)|0
6228621|NCT01728324|9902007|FG000|Termination of DBV|Protocol Violation (Placebo Period)|0
6228622|NCT01728324|9902008|FG001|Termination of DBV|Protocol Violation (Placebo Period)|1
6228623|NCT01728324|9902009|FG002|Termination of DBV|Protocol Violation (Placebo Period)|0
6228624|NCT01728324|9902007|FG000|Termination of FDV|Adverse Event|14
6228625|NCT01728324|9902008|FG001|Termination of FDV|Adverse Event|13
6228626|NCT01728324|9902009|FG002|Termination of FDV|Adverse Event|4
6228627|NCT01728324|9902007|FG000|Termination of FDV|Lack of Efficacy|14
6228628|NCT01728324|9902008|FG001|Termination of FDV|Lack of Efficacy|12
6228629|NCT01728324|9902009|FG002|Termination of FDV|Lack of Efficacy|8
6228630|NCT01728324|9902007|FG000|Termination of FDV|Withdrawal by Subject|9
6228631|NCT01728324|9902008|FG001|Termination of FDV|Withdrawal by Subject|6
6228632|NCT01728324|9902009|FG002|Termination of FDV|Withdrawal by Subject|2
6228633|NCT01728324|9902007|FG000|Termination of FDV|Other than stated|1
6228634|NCT01728324|9902008|FG001|Termination of FDV|Other than stated|3
6228635|NCT01728324|9902009|FG002|Termination of FDV|Other than stated|0
6228636|NCT01728324|9902007|FG000|Termination of FDV|Adverse Event (Placebo Period)|0
6228637|NCT01728324|9902008|FG001|Termination of FDV|Adverse Event (Placebo Period)|1
6228638|NCT01728324|9902009|FG002|Termination of FDV|Adverse Event (Placebo Period)|0
6228639|NCT01728324|9902007|FG000|Termination of FDV|Protocol Violation (Placebo Period)|0
6228640|NCT01728324|9902008|FG001|Termination of FDV|Protocol Violation (Placebo Period)|1
6228641|NCT01728324|9902009|FG002|Termination of FDV|Protocol Violation (Placebo Period)|0
6228642|NCT01728324|9902007|FG000|Termination of RBV|Adverse Event|15
6228643|NCT01728324|9902008|FG001|Termination of RBV|Adverse Event|16
6186847|NCT01376245|9840458|FG001|24-week, Double-blind Treatment Period|Lack of Efficacy|4
6186848|NCT01376245|9840459|FG002|24-week, Double-blind Treatment Period|Lack of Efficacy|5
6186849|NCT01376245|9840460|FG003|24-week, Double-blind Treatment Period|Lack of Efficacy|4
6186850|NCT01376245|9840461|FG004|24-week, Double-blind Treatment Period|Lack of Efficacy|3
6186851|NCT01376245|9840457|FG000|24-week, Double-blind Treatment Period|Protocol Violation|0
6186852|NCT01376245|9840458|FG001|24-week, Double-blind Treatment Period|Protocol Violation|2
6186853|NCT01376245|9840459|FG002|24-week, Double-blind Treatment Period|Protocol Violation|0
6186854|NCT01376245|9840460|FG003|24-week, Double-blind Treatment Period|Protocol Violation|2
6186855|NCT01376245|9840461|FG004|24-week, Double-blind Treatment Period|Protocol Violation|1
6193094|NCT01436110|9850727|FG001|Overall Study|Protocol Violation|1
6228644|NCT01728324|9902009|FG002|Termination of RBV|Adverse Event|5
6228645|NCT01728324|9902007|FG000|Termination of RBV|Lack of Efficacy|14
6228646|NCT01728324|9902008|FG001|Termination of RBV|Lack of Efficacy|11
6228647|NCT01728324|9902009|FG002|Termination of RBV|Lack of Efficacy|7
6228648|NCT01728324|9902007|FG000|Termination of RBV|Withdrawal by Subject|9
6228649|NCT01728324|9902008|FG001|Termination of RBV|Withdrawal by Subject|5
6228650|NCT01728324|9902009|FG002|Termination of RBV|Withdrawal by Subject|2
6228651|NCT01728324|9902007|FG000|Termination of RBV|Other than stated|1
6228652|NCT01728324|9902008|FG001|Termination of RBV|Other than stated|3
6228653|NCT01728324|9902009|FG002|Termination of RBV|Other than stated|1
6228654|NCT01728324|9902007|FG000|Termination of RBV|Adverse Event (Placebo Period)|0
6228655|NCT01728324|9902008|FG001|Termination of RBV|Adverse Event (Placebo Period)|1
6228656|NCT01728324|9902009|FG002|Termination of RBV|Adverse Event (Placebo Period)|0
6228657|NCT01728324|9902007|FG000|Termination of RBV|Protocol Violation (Placebo Period)|0
6228658|NCT01728324|9902008|FG001|Termination of RBV|Protocol Violation (Placebo Period)|1
6228659|NCT01728324|9902009|FG002|Termination of RBV|Protocol Violation (Placebo Period)|0
6228660|NCT01728376|9902031|FG000|Overall Study|Adverse Event|1
6228661|NCT01728376|9902032|FG001|Overall Study|Adverse Event|1
6228662|NCT01728376|9902033|FG002|Overall Study|Adverse Event|1
6228663|NCT01728376|9902034|FG003|Overall Study|Adverse Event|1
6228664|NCT01728376|9902035|FG004|Overall Study|Adverse Event|1
6228665|NCT01728376|9902036|FG005|Overall Study|Adverse Event|0
6228666|NCT01728376|9902031|FG000|Overall Study|Persistent Positive Blood Cultures|1
6228667|NCT01728376|9902032|FG001|Overall Study|Persistent Positive Blood Cultures|0
6228668|NCT01728376|9902033|FG002|Overall Study|Persistent Positive Blood Cultures|1
6228669|NCT01728376|9902034|FG003|Overall Study|Persistent Positive Blood Cultures|0
6228670|NCT01728376|9902035|FG004|Overall Study|Persistent Positive Blood Cultures|0
6228671|NCT01728376|9902036|FG005|Overall Study|Persistent Positive Blood Cultures|0
6228672|NCT01728376|9902031|FG000|Overall Study|No relevant bacteria|2
6228673|NCT01728376|9902032|FG001|Overall Study|No relevant bacteria|0
6228674|NCT01728376|9902033|FG002|Overall Study|No relevant bacteria|0
6228675|NCT01728376|9902034|FG003|Overall Study|No relevant bacteria|0
6228676|NCT01728376|9902035|FG004|Overall Study|No relevant bacteria|1
6228677|NCT01728376|9902036|FG005|Overall Study|No relevant bacteria|1
6228678|NCT01728376|9902031|FG000|Overall Study|Did not receive treatment|0
6228679|NCT01728376|9902032|FG001|Overall Study|Did not receive treatment|1
6228680|NCT01728376|9902033|FG002|Overall Study|Did not receive treatment|0
6228681|NCT01728376|9902034|FG003|Overall Study|Did not receive treatment|0
6228682|NCT01728376|9902035|FG004|Overall Study|Did not receive treatment|0
6228683|NCT01728376|9902036|FG005|Overall Study|Did not receive treatment|0
6228684|NCT01728376|9902031|FG000|Overall Study|Subject/Parent/Legal Guardian Decision|0
6228685|NCT01728376|9902032|FG001|Overall Study|Subject/Parent/Legal Guardian Decision|0
6228686|NCT01728376|9902033|FG002|Overall Study|Subject/Parent/Legal Guardian Decision|0
6228687|NCT01728376|9902034|FG003|Overall Study|Subject/Parent/Legal Guardian Decision|1
6228688|NCT01728376|9902035|FG004|Overall Study|Subject/Parent/Legal Guardian Decision|0
6228689|NCT01728376|9902036|FG005|Overall Study|Subject/Parent/Legal Guardian Decision|1
6228690|NCT01728454|9902053|FG000|Stage 1 and 2|Pregnancy|1
6228691|NCT01728454|9902054|FG001|Stage 1 and 2|Pregnancy|0
6228692|NCT01728454|9902055|FG002|Stage 1 and 2|Pregnancy|0
6228693|NCT01728454|9902053|FG000|Stage 1 and 2|Non-compliance with Protocol|0
6228694|NCT01728454|9902054|FG001|Stage 1 and 2|Non-compliance with Protocol|0
6228695|NCT01728454|9902055|FG002|Stage 1 and 2|Non-compliance with Protocol|1
6228696|NCT01728454|9902053|FG000|Stage 1 and 2|Moved to Active Drug/ Lack of Efficacy|1
6228697|NCT01728454|9902054|FG001|Stage 1 and 2|Moved to Active Drug/ Lack of Efficacy|0
6228698|NCT01728454|9902055|FG002|Stage 1 and 2|Moved to Active Drug/ Lack of Efficacy|0
6228699|NCT01728454|9902053|FG000|Stage 1 and 2|Lost to Follow-up|1
6228700|NCT01728454|9902054|FG001|Stage 1 and 2|Lost to Follow-up|1
6228701|NCT01728454|9902055|FG002|Stage 1 and 2|Lost to Follow-up|0
6228702|NCT01728454|9902053|FG000|Stage 1 and 2|Withdrew due to Adverse Events/Toxicity|2
6228703|NCT01728454|9902054|FG001|Stage 1 and 2|Withdrew due to Adverse Events/Toxicity|3
6228704|NCT01728454|9902055|FG002|Stage 1 and 2|Withdrew due to Adverse Events/Toxicity|3
6228705|NCT01728454|9902053|FG000|Stage 3|Reason Missing|0
6228706|NCT01728454|9902054|FG001|Stage 3|Reason Missing|0
6228707|NCT01728454|9902055|FG002|Stage 3|Reason Missing|1
6228708|NCT01728454|9902053|FG000|Stage 3|Subject Required Other Treatment|0
6228709|NCT01728454|9902054|FG001|Stage 3|Subject Required Other Treatment|1
6228710|NCT01728454|9902055|FG002|Stage 3|Subject Required Other Treatment|0
6228711|NCT01728454|9902053|FG000|Stage 3|Pregnancy|1
6228712|NCT01728454|9902054|FG001|Stage 3|Pregnancy|0
6228713|NCT01728454|9902055|FG002|Stage 3|Pregnancy|0
6228714|NCT01728454|9902053|FG000|Stage 3|Withdrew Consent|1
6228715|NCT01728454|9902054|FG001|Stage 3|Withdrew Consent|0
6228716|NCT01728454|9902055|FG002|Stage 3|Withdrew Consent|1
6228717|NCT01728454|9902053|FG000|Stage 3|Non-compliance with Protocol|0
6228718|NCT01728454|9902054|FG001|Stage 3|Non-compliance with Protocol|0
6228719|NCT01728454|9902055|FG002|Stage 3|Non-compliance with Protocol|1
6228720|NCT01728454|9902053|FG000|Stage 3|Lost to Follow-up|0
6228721|NCT01728454|9902054|FG001|Stage 3|Lost to Follow-up|3
6228722|NCT01728454|9902055|FG002|Stage 3|Lost to Follow-up|1
6228723|NCT01728454|9902053|FG000|Stage 3|Withdrew due to Adverse Events/Toxicity|1
6228724|NCT01728454|9902054|FG001|Stage 3|Withdrew due to Adverse Events/Toxicity|0
6228725|NCT01728454|9902055|FG002|Stage 3|Withdrew due to Adverse Events/Toxicity|0
6228726|NCT01728584|9902070|FG000|Overall Study|Adverse Event|1
6228727|NCT01728584|9902071|FG001|Overall Study|Adverse Event|0
6228728|NCT01728584|9902072|FG002|Overall Study|Adverse Event|0
6228729|NCT01728584|9902073|FG003|Overall Study|Adverse Event|0
6228730|NCT01728584|9902070|FG000|Overall Study|Physician Decision|4
6228731|NCT01728584|9902071|FG001|Overall Study|Physician Decision|0
6228732|NCT01728584|9902072|FG002|Overall Study|Physician Decision|1
6228733|NCT01728584|9902073|FG003|Overall Study|Physician Decision|0
6228734|NCT01728584|9902070|FG000|Overall Study|Withdrawal by Subject|1
6228735|NCT01728584|9902071|FG001|Overall Study|Withdrawal by Subject|0
6228736|NCT01728584|9902072|FG002|Overall Study|Withdrawal by Subject|0
6228737|NCT01728584|9902073|FG003|Overall Study|Withdrawal by Subject|0
6228738|NCT01728584|9902070|FG000|Overall Study|Screen failure|1
6228739|NCT01728584|9902071|FG001|Overall Study|Screen failure|0
6228740|NCT01728584|9902072|FG002|Overall Study|Screen failure|0
6228741|NCT01728584|9902073|FG003|Overall Study|Screen failure|0
6228742|NCT01728584|9902070|FG000|Overall Study|Other reason (not specified)|1
6228743|NCT01728584|9902071|FG001|Overall Study|Other reason (not specified)|0
6228744|NCT01728584|9902072|FG002|Overall Study|Other reason (not specified)|0
6228745|NCT01728584|9902073|FG003|Overall Study|Other reason (not specified)|1
6228746|NCT01728623|9902090|FG000|Overall Study|Disease progression|26
6228747|NCT01728623|9902090|FG000|Overall Study|Adverse Event|1
6228748|NCT01728623|9902090|FG000|Overall Study|Withdrawal by Subject|1
6228749|NCT01728779|9902106|FG000|Overall Study|Withdrawal by Subject|1
6228750|NCT01728792|9902115|FG000|Overall Study|Withdrawal of Consent|1
6228751|NCT01728792|9902116|FG001|Overall Study|Withdrawal of Consent|1
6228752|NCT01728792|9902117|FG002|Overall Study|Withdrawal of Consent|0
6228753|NCT01728792|9902118|FG003|Overall Study|Withdrawal of Consent|1
6228754|NCT01728792|9902119|FG004|Overall Study|Withdrawal of Consent|0
6228755|NCT01728792|9902115|FG000|Overall Study|Lost to Follow-up|2
6228756|NCT01728792|9902116|FG001|Overall Study|Lost to Follow-up|1
6228757|NCT01728792|9902117|FG002|Overall Study|Lost to Follow-up|4
6228758|NCT01728792|9902118|FG003|Overall Study|Lost to Follow-up|2
6228759|NCT01728792|9902119|FG004|Overall Study|Lost to Follow-up|0
6228760|NCT01729026|9902161|FG000|Randomization to 3-month Follow-up|Lost to Follow-up|2
6228761|NCT01729026|9902162|FG001|Randomization to 3-month Follow-up|Lost to Follow-up|2
6228762|NCT01729026|9902161|FG000|3-month to 6-month (Final) Follow-up|Lost to Follow-up|1
6228763|NCT01729026|9902162|FG001|3-month to 6-month (Final) Follow-up|Lost to Follow-up|2
6228764|NCT01729039|9902173|FG000|Overall Study|disqualified|2
6228765|NCT01729039|9902174|FG001|Overall Study|disqualified|5
6228766|NCT01729039|9902173|FG000|Overall Study|Withdrawal by Subject|8
6228767|NCT01729039|9902174|FG001|Overall Study|Withdrawal by Subject|7
6228768|NCT01729156|9902186|FG000|Overall Study|Withdrawal by Subject|1
6228769|NCT01729156|9902187|FG001|Overall Study|Withdrawal by Subject|0
6228770|NCT01729156|9902188|FG002|Overall Study|Withdrawal by Subject|0
6228771|NCT01729208|9902199|FG000|Baseline|Physician Decision|5
6228772|NCT01729208|9902200|FG001|Baseline|Physician Decision|4
6228773|NCT01729208|9902199|FG000|12 Months Follow-up|Withdrawal by Subject|4
6228774|NCT01729208|9902200|FG001|12 Months Follow-up|Withdrawal by Subject|7
6228775|NCT01729208|9902199|FG000|12 Months Follow-up|Lost to Follow-up|3
6228776|NCT01729208|9902200|FG001|12 Months Follow-up|Lost to Follow-up|3
6228777|NCT01729208|9902199|FG000|24 Months Follow-up|Lost to Follow-up|3
6228778|NCT01729208|9902200|FG001|24 Months Follow-up|Lost to Follow-up|0
6228779|NCT01729208|9902199|FG000|36 Months Follow-up|Physician Decision|1
6228780|NCT01729208|9902200|FG001|36 Months Follow-up|Physician Decision|0
6228781|NCT01729208|9902199|FG000|36 Months Follow-up|Withdrawal by Subject|2
6228782|NCT01729208|9902200|FG001|36 Months Follow-up|Withdrawal by Subject|4
6228783|NCT01729559|9902236|FG000|Overall Study|Protocol Violation|31
6228784|NCT01729559|9902237|FG001|Overall Study|Protocol Violation|28
6228785|NCT01729728|9902255|FG000|Overall Study|Adverse Event|0
6228786|NCT01729728|9902256|FG001|Overall Study|Adverse Event|6
6228787|NCT01729728|9902257|FG002|Overall Study|Adverse Event|0
6228788|NCT01729728|9902255|FG000|Overall Study|Protocol Violation|1
6228789|NCT01729728|9902256|FG001|Overall Study|Protocol Violation|0
6228790|NCT01729728|9902257|FG002|Overall Study|Protocol Violation|1
6228791|NCT01729819|9902390|FG000|Overall Study|Adverse Event|2
6228792|NCT01729819|9902391|FG001|Overall Study|Adverse Event|4
6228793|NCT01729819|9902390|FG000|Overall Study|Lack of Efficacy|1
6228794|NCT01729819|9902391|FG001|Overall Study|Lack of Efficacy|0
6228795|NCT01729819|9902390|FG000|Overall Study|Lost to Follow-up|2
6228796|NCT01729819|9902391|FG001|Overall Study|Lost to Follow-up|0
6228797|NCT01729819|9902390|FG000|Overall Study|Other reason|1
6228798|NCT01729819|9902391|FG001|Overall Study|Other reason|0
6228799|NCT01729819|9902390|FG000|Overall Study|Protocol Violation|0
6228800|NCT01729819|9902391|FG001|Overall Study|Protocol Violation|1
6228801|NCT01729819|9902390|FG000|Overall Study|Withdrawal by Subject|0
6228802|NCT01729819|9902391|FG001|Overall Study|Withdrawal by Subject|2
6228803|NCT01729871|9902417|FG000|Overall Study|Adverse Event|7
6228804|NCT01729871|9902418|FG001|Overall Study|Adverse Event|7
6228805|NCT01729871|9902417|FG000|Overall Study|Death|0
6228806|NCT01729871|9902418|FG001|Overall Study|Death|1
6228807|NCT01729871|9902417|FG000|Overall Study|Lack of Efficacy|0
6228808|NCT01729871|9902418|FG001|Overall Study|Lack of Efficacy|1
6228809|NCT01729871|9902417|FG000|Overall Study|Physician Decision|0
6228810|NCT01729871|9902418|FG001|Overall Study|Physician Decision|2
6228811|NCT01729871|9902417|FG000|Overall Study|Protocol Violation|1
6228812|NCT01729871|9902418|FG001|Overall Study|Protocol Violation|0
6228813|NCT01729871|9902417|FG000|Overall Study|Withdrawal by Subject|0
6228814|NCT01729871|9902418|FG001|Overall Study|Withdrawal by Subject|3
6228815|NCT01729871|9902417|FG000|Overall Study|Other|4
6228816|NCT01729871|9902418|FG001|Overall Study|Other|9
6228817|NCT01730040|9902435|FG000|Overall Study|Randomized but not treated|0
6228818|NCT01730040|9902436|FG001|Overall Study|Randomized but not treated|0
6228819|NCT01730040|9902437|FG002|Overall Study|Randomized but not treated|0
6228820|NCT01730040|9902438|FG003|Overall Study|Randomized but not treated|0
6228821|NCT01730040|9902439|FG004|Overall Study|Randomized but not treated|0
6228822|NCT01730040|9902440|FG005|Overall Study|Randomized but not treated|1
6228823|NCT01730040|9902441|FG006|Overall Study|Randomized but not treated|0
6228824|NCT01730040|9902435|FG000|Overall Study|Subject moved|0
6228825|NCT01730040|9902436|FG001|Overall Study|Subject moved|0
6228826|NCT01730040|9902437|FG002|Overall Study|Subject moved|1
6228827|NCT01730040|9902438|FG003|Overall Study|Subject moved|0
6228828|NCT01730040|9902439|FG004|Overall Study|Subject moved|0
6228829|NCT01730040|9902440|FG005|Overall Study|Subject moved|0
6228830|NCT01730040|9902441|FG006|Overall Study|Subject moved|1
6228831|NCT01730040|9902435|FG000|Overall Study|Physician Decision|0
6228832|NCT01730040|9902436|FG001|Overall Study|Physician Decision|0
6228833|NCT01730040|9902437|FG002|Overall Study|Physician Decision|0
6228834|NCT01730040|9902438|FG003|Overall Study|Physician Decision|0
6228835|NCT01730040|9902439|FG004|Overall Study|Physician Decision|0
6228836|NCT01730040|9902440|FG005|Overall Study|Physician Decision|1
6228837|NCT01730040|9902441|FG006|Overall Study|Physician Decision|1
6228838|NCT01730040|9902435|FG000|Overall Study|Other than specified|7
6228839|NCT01730040|9902436|FG001|Overall Study|Other than specified|8
6228840|NCT01730040|9902437|FG002|Overall Study|Other than specified|5
6228841|NCT01730040|9902438|FG003|Overall Study|Other than specified|5
6228842|NCT01730040|9902439|FG004|Overall Study|Other than specified|5
6228843|NCT01730040|9902440|FG005|Overall Study|Other than specified|4
6228844|NCT01730040|9902441|FG006|Overall Study|Other than specified|4
6228845|NCT01730040|9902435|FG000|Overall Study|Adverse Event|4
6228846|NCT01730040|9902436|FG001|Overall Study|Adverse Event|3
6228847|NCT01730040|9902437|FG002|Overall Study|Adverse Event|5
6228848|NCT01730040|9902438|FG003|Overall Study|Adverse Event|3
6228849|NCT01730040|9902439|FG004|Overall Study|Adverse Event|1
6228850|NCT01730040|9902440|FG005|Overall Study|Adverse Event|1
6228851|NCT01730040|9902441|FG006|Overall Study|Adverse Event|2
6228852|NCT01730040|9902435|FG000|Overall Study|Poor compliance to protocol|2
6228853|NCT01730040|9902436|FG001|Overall Study|Poor compliance to protocol|4
6228854|NCT01730040|9902437|FG002|Overall Study|Poor compliance to protocol|0
6228855|NCT01730040|9902438|FG003|Overall Study|Poor compliance to protocol|0
6228856|NCT01730040|9902439|FG004|Overall Study|Poor compliance to protocol|0
6228857|NCT01730040|9902440|FG005|Overall Study|Poor compliance to protocol|0
6228858|NCT01730040|9902441|FG006|Overall Study|Poor compliance to protocol|1
6228859|NCT01730053|9902463|FG000|Overall Study|Participant moved|0
6228860|NCT01730053|9902464|FG001|Overall Study|Participant moved|0
6228861|NCT01730053|9902465|FG002|Overall Study|Participant moved|1
6228862|NCT01730053|9902466|FG003|Overall Study|Participant moved|0
6228863|NCT01730053|9902467|FG004|Overall Study|Participant moved|0
6228864|NCT01730053|9902468|FG005|Overall Study|Participant moved|0
6228865|NCT01730053|9902463|FG000|Overall Study|Physician Decision|0
6228866|NCT01730053|9902464|FG001|Overall Study|Physician Decision|0
6228867|NCT01730053|9902465|FG002|Overall Study|Physician Decision|0
6228868|NCT01730053|9902466|FG003|Overall Study|Physician Decision|1
6228869|NCT01730053|9902467|FG004|Overall Study|Physician Decision|0
6228870|NCT01730053|9902468|FG005|Overall Study|Physician Decision|0
6228871|NCT01730053|9902463|FG000|Overall Study|Adverse Event|2
6228872|NCT01730053|9902464|FG001|Overall Study|Adverse Event|6
6228873|NCT01730053|9902465|FG002|Overall Study|Adverse Event|3
6228874|NCT01730053|9902466|FG003|Overall Study|Adverse Event|3
6228875|NCT01730053|9902467|FG004|Overall Study|Adverse Event|2
6228876|NCT01730053|9902468|FG005|Overall Study|Adverse Event|2
6228877|NCT01730053|9902463|FG000|Overall Study|Poor compliance to protocol|1
6228878|NCT01730053|9902464|FG001|Overall Study|Poor compliance to protocol|2
6228879|NCT01730053|9902465|FG002|Overall Study|Poor compliance to protocol|2
6228880|NCT01730053|9902466|FG003|Overall Study|Poor compliance to protocol|0
6228881|NCT01730053|9902467|FG004|Overall Study|Poor compliance to protocol|0
6228882|NCT01730053|9902468|FG005|Overall Study|Poor compliance to protocol|2
6228883|NCT01730053|9902463|FG000|Overall Study|Other than specified|2
6228884|NCT01730053|9902464|FG001|Overall Study|Other than specified|6
6228885|NCT01730053|9902465|FG002|Overall Study|Other than specified|5
6228886|NCT01730053|9902466|FG003|Overall Study|Other than specified|4
6228887|NCT01730053|9902467|FG004|Overall Study|Other than specified|7
6228888|NCT01730053|9902468|FG005|Overall Study|Other than specified|9
6228889|NCT01730339|9902485|FG000|Overall Study|Withdrawal by Subject|3
6228890|NCT01730339|9902486|FG001|Overall Study|Withdrawal by Subject|2
6228891|NCT01730339|9902485|FG000|Overall Study|Lost to Follow-up|1
6228892|NCT01730339|9902486|FG001|Overall Study|Lost to Follow-up|1
6228893|NCT01730339|9902485|FG000|Overall Study|Un-specified|1
6228894|NCT01730339|9902486|FG001|Overall Study|Un-specified|0
6228895|NCT01730378|9902504|FG000|Overall Study|Lost to Follow-up|1
6228896|NCT01730378|9902505|FG001|Overall Study|Lost to Follow-up|0
6228897|NCT01730534|9902514|FG000|Overall Study|Withdrawal by Subject|97
6228898|NCT01730534|9902515|FG001|Overall Study|Withdrawal by Subject|127
6228899|NCT01730534|9902514|FG000|Overall Study|Lost to Follow-up|12
6228900|NCT01730534|9902515|FG001|Overall Study|Lost to Follow-up|18
6228901|NCT01730586|9902521|FG000|Overall Study|Progressive Disease|2
6228902|NCT01730586|9902521|FG000|Overall Study|Inadequate Trial|8
6228903|NCT01730586|9902521|FG000|Overall Study|Adverse Event|2
6228904|NCT01730586|9902521|FG000|Overall Study|Hospice|1
6228905|NCT01730729|9902527|FG000|Overall Study|Adverse Event|1
6228906|NCT01730729|9902527|FG000|Overall Study|Death|1
6228907|NCT01730729|9902527|FG000|Overall Study|Progressive Disease|12
6228908|NCT01730950|9902558|FG000|Overall Study|Protocol Violation|6
6085400|NCT00652366|9694739|FG003|Overall Study|Refused treatment|17
6085401|NCT00652366|9694740|FG004|Overall Study|Refused treatment|5
6186856|NCT01376245|9840457|FG000|24-week, Double-blind Treatment Period|Met Protocol-Defined Stopping Criteria|0
6186857|NCT01376245|9840458|FG001|24-week, Double-blind Treatment Period|Met Protocol-Defined Stopping Criteria|2
6186858|NCT01376245|9840459|FG002|24-week, Double-blind Treatment Period|Met Protocol-Defined Stopping Criteria|3
6186859|NCT01376245|9840460|FG003|24-week, Double-blind Treatment Period|Met Protocol-Defined Stopping Criteria|1
6186860|NCT01376245|9840461|FG004|24-week, Double-blind Treatment Period|Met Protocol-Defined Stopping Criteria|0
6186861|NCT01376245|9840457|FG000|24-week, Double-blind Treatment Period|Lost to Follow-up|0
6186862|NCT01376245|9840458|FG001|24-week, Double-blind Treatment Period|Lost to Follow-up|2
6186863|NCT01376245|9840459|FG002|24-week, Double-blind Treatment Period|Lost to Follow-up|0
6186864|NCT01376245|9840460|FG003|24-week, Double-blind Treatment Period|Lost to Follow-up|1
6186865|NCT01376245|9840461|FG004|24-week, Double-blind Treatment Period|Lost to Follow-up|1
6186866|NCT01376245|9840457|FG000|24-week, Double-blind Treatment Period|Physician Decision|0
6186867|NCT01376245|9840458|FG001|24-week, Double-blind Treatment Period|Physician Decision|0
6186868|NCT01376245|9840459|FG002|24-week, Double-blind Treatment Period|Physician Decision|1
6186869|NCT01376245|9840460|FG003|24-week, Double-blind Treatment Period|Physician Decision|1
6186870|NCT01376245|9840461|FG004|24-week, Double-blind Treatment Period|Physician Decision|0
6186871|NCT01376245|9840457|FG000|24-week, Double-blind Treatment Period|Withdrawal by Subject|0
6186872|NCT01376245|9840458|FG001|24-week, Double-blind Treatment Period|Withdrawal by Subject|6
6186873|NCT01376245|9840459|FG002|24-week, Double-blind Treatment Period|Withdrawal by Subject|9
6186874|NCT01376245|9840460|FG003|24-week, Double-blind Treatment Period|Withdrawal by Subject|6
6186875|NCT01376245|9840461|FG004|24-week, Double-blind Treatment Period|Withdrawal by Subject|3
6186876|NCT01376310|9840482|FG000|Overall Study|Study closed/terminated|1
6186877|NCT01376310|9840483|FG001|Overall Study|Study closed/terminated|2
6186878|NCT01376310|9840482|FG000|Overall Study|Withdrawal by Subject|8
6186879|NCT01376310|9840483|FG001|Overall Study|Withdrawal by Subject|2
6186880|NCT01376310|9840482|FG000|Overall Study|Physician Decision|26
6186881|NCT01376310|9840483|FG001|Overall Study|Physician Decision|7
6186882|NCT01376310|9840482|FG000|Overall Study|Lost to Follow-up|1
6186883|NCT01376310|9840483|FG001|Overall Study|Lost to Follow-up|0
6186884|NCT01376349|9840492|FG000|Raondomized Treatment|Withdrawal by Subject|10
6186885|NCT01376349|9840493|FG001|Raondomized Treatment|Withdrawal by Subject|16
6186886|NCT01376349|9840494|FG002|Raondomized Treatment|Withdrawal by Subject|13
6186887|NCT01376349|9840492|FG000|Raondomized Treatment|Adverse Event|13
6186888|NCT01376349|9840493|FG001|Raondomized Treatment|Adverse Event|17
6186889|NCT01376349|9840494|FG002|Raondomized Treatment|Adverse Event|14
6186890|NCT01376349|9840492|FG000|Raondomized Treatment|Unkown|1
6186891|NCT01376349|9840493|FG001|Raondomized Treatment|Unkown|2
6186892|NCT01376349|9840494|FG002|Raondomized Treatment|Unkown|1
6186893|NCT01376349|9840492|FG000|Raondomized Treatment|Alternative Treatment|0
6186894|NCT01376349|9840493|FG001|Raondomized Treatment|Alternative Treatment|0
6186895|NCT01376349|9840494|FG002|Raondomized Treatment|Alternative Treatment|1
6186896|NCT01376388|9840507|FG000|Overall Study|Adverse Event|13
6186897|NCT01376388|9840507|FG000|Overall Study|Lack of Efficacy|2
6186898|NCT01376388|9840507|FG000|Overall Study|Withdrawal by Subject|3
6186899|NCT01376700|9840532|FG000|Overall Study|Sponsor terminated study early|8
6186900|NCT01376700|9840532|FG000|Overall Study|Low or high titer inhibitor|8
6186901|NCT01376804|9840539|FG000|Treatment Period|Withdrawal by Subject|1
6186902|NCT01376804|9840539|FG000|Treatment Period|Adverse Event|6
6186903|NCT01376804|9840539|FG000|Treatment Period|Patient did not receive study drug|1
6186904|NCT01376908|9840545|FG000|Overall Study|Protocol Violation|1
6186905|NCT01376908|9840546|FG001|Overall Study|Protocol Violation|1
6186906|NCT01376908|9840545|FG000|Overall Study|Withdrawal by Subject|1
6186907|NCT01376908|9840546|FG001|Overall Study|Withdrawal by Subject|2
6186908|NCT01377012|9840562|FG000|Core Study|Study terminated by Sponsor|47
6186909|NCT01377012|9840563|FG001|Core Study|Study terminated by Sponsor|54
6186910|NCT01377012|9840564|FG002|Core Study|Study terminated by Sponsor|46
6186911|NCT01377012|9840562|FG000|Core Study|Technical problems|1
6186912|NCT01377012|9840563|FG001|Core Study|Technical problems|0
6186913|NCT01377012|9840564|FG002|Core Study|Technical problems|0
6186914|NCT01377012|9840562|FG000|Core Study|Withdrawal by Subject|15
6186915|NCT01377012|9840563|FG001|Core Study|Withdrawal by Subject|23
6186916|NCT01377012|9840564|FG002|Core Study|Withdrawal by Subject|18
6186917|NCT01377012|9840562|FG000|Core Study|Protocol Violation|7
6186918|NCT01377012|9840563|FG001|Core Study|Protocol Violation|3
6186919|NCT01377012|9840564|FG002|Core Study|Protocol Violation|2
6186920|NCT01377012|9840562|FG000|Core Study|Pregnancy|0
6186921|NCT01377012|9840563|FG001|Core Study|Pregnancy|0
6085402|NCT00652366|9694736|FG000|Overall Study|Other|5
6186922|NCT01377012|9840564|FG002|Core Study|Pregnancy|1
6186923|NCT01377012|9840562|FG000|Core Study|Physician Decision|5
6186924|NCT01377012|9840563|FG001|Core Study|Physician Decision|4
6186925|NCT01377012|9840564|FG002|Core Study|Physician Decision|10
6186926|NCT01377012|9840562|FG000|Core Study|Non-Compliant with study treatment|0
6085403|NCT00652366|9694737|FG001|Overall Study|Other|2
6228909|NCT01730950|9902559|FG001|Overall Study|Protocol Violation|6
6228910|NCT01731002|9902569|FG000|Overall Study|Adverse Event|0
6228911|NCT01731002|9902570|FG001|Overall Study|Adverse Event|2
6228912|NCT01731002|9902571|FG002|Overall Study|Adverse Event|2
6228913|NCT01731002|9902569|FG000|Overall Study|Non-Compliant|0
6228914|NCT01731002|9902570|FG001|Overall Study|Non-Compliant|1
6186927|NCT01377012|9840563|FG001|Core Study|Non-Compliant with study treatment|0
6186928|NCT01377012|9840564|FG002|Core Study|Non-Compliant with study treatment|1
6186929|NCT01377012|9840562|FG000|Core Study|No Longer require treatment|0
6186930|NCT01377012|9840563|FG001|Core Study|No Longer require treatment|0
6186931|NCT01377012|9840564|FG002|Core Study|No Longer require treatment|1
6186932|NCT01377012|9840562|FG000|Core Study|Lost to Follow-up|7
6186933|NCT01377012|9840563|FG001|Core Study|Lost to Follow-up|5
6186934|NCT01377012|9840564|FG002|Core Study|Lost to Follow-up|4
6186935|NCT01377012|9840562|FG000|Core Study|Lack of Efficacy|41
6186936|NCT01377012|9840563|FG001|Core Study|Lack of Efficacy|28
6186937|NCT01377012|9840564|FG002|Core Study|Lack of Efficacy|37
6186938|NCT01377012|9840562|FG000|Core Study|Death|1
6186939|NCT01377012|9840563|FG001|Core Study|Death|1
6186940|NCT01377012|9840564|FG002|Core Study|Death|1
6186941|NCT01377012|9840562|FG000|Core Study|Adverse Event|10
6186942|NCT01377012|9840563|FG001|Core Study|Adverse Event|14
6186943|NCT01377012|9840564|FG002|Core Study|Adverse Event|13
6186944|NCT01377012|9840562|FG000|Extension Study, Weeks 104-260|Lack of Efficacy|3
6186945|NCT01377012|9840563|FG001|Extension Study, Weeks 104-260|Lack of Efficacy|0
6186946|NCT01377012|9840564|FG002|Extension Study, Weeks 104-260|Lack of Efficacy|0
6228915|NCT01731002|9902571|FG002|Overall Study|Non-Compliant|0
6228916|NCT01731002|9902569|FG000|Overall Study|Lost to Follow-up|1
6228917|NCT01731002|9902570|FG001|Overall Study|Lost to Follow-up|0
6228918|NCT01731002|9902571|FG002|Overall Study|Lost to Follow-up|0
6228919|NCT01731002|9902569|FG000|Overall Study|Test Agent Discontinuation|0
6228920|NCT01731002|9902570|FG001|Overall Study|Test Agent Discontinuation|1
6228921|NCT01731002|9902571|FG002|Overall Study|Test Agent Discontinuation|0
6228922|NCT01731002|9902569|FG000|Overall Study|Uncontrolled Intraocular Pressure (IOP)|2
6228923|NCT01731002|9902570|FG001|Overall Study|Uncontrolled Intraocular Pressure (IOP)|0
6228924|NCT01731002|9902571|FG002|Overall Study|Uncontrolled Intraocular Pressure (IOP)|0
6228925|NCT01731002|9902569|FG000|Overall Study|Elevated IOP|1
6228926|NCT01731002|9902570|FG001|Overall Study|Elevated IOP|0
6228927|NCT01731002|9902571|FG002|Overall Study|Elevated IOP|0
6228928|NCT01731002|9902569|FG000|Overall Study|Inappropriate use of study medications|0
6228929|NCT01731002|9902570|FG001|Overall Study|Inappropriate use of study medications|0
6228930|NCT01731002|9902571|FG002|Overall Study|Inappropriate use of study medications|1
6228931|NCT01731171|9902594|FG000|Overall Study|Withdrawal by Subject|4
6228932|NCT01731171|9902595|FG001|Overall Study|Withdrawal by Subject|1
6228933|NCT01731171|9902594|FG000|Overall Study|Lost to Follow-up|3
6228934|NCT01731171|9902595|FG001|Overall Study|Lost to Follow-up|2
6228935|NCT01731171|9902594|FG000|Overall Study|Moved out of Area|0
6228936|NCT01731171|9902595|FG001|Overall Study|Moved out of Area|2
6228937|NCT01731171|9902594|FG000|Overall Study|Terminated for Lack of Adherence|0
6228938|NCT01731171|9902595|FG001|Overall Study|Terminated for Lack of Adherence|1
6228939|NCT01731171|9902594|FG000|Overall Study|Terminated for Safety Reasons|0
6228940|NCT01731171|9902595|FG001|Overall Study|Terminated for Safety Reasons|1
6228941|NCT01731470|9902601|FG000|Overall Study|Withdrawal by Subject|1
6228942|NCT01731470|9902601|FG000|Overall Study|Did not meet study criteria|1
6228943|NCT01731600|9902607|FG000|Overall Study|Adverse Event|2
6228944|NCT01731600|9902608|FG001|Overall Study|Adverse Event|0
6228945|NCT01731600|9902607|FG000|Overall Study|Withdrawal criteria|1
6228946|NCT01731600|9902608|FG001|Overall Study|Withdrawal criteria|0
6228947|NCT01731600|9902607|FG000|Overall Study|Other reasons|3
6228948|NCT01731600|9902608|FG001|Overall Study|Other reasons|0
6228949|NCT01731678|9902618|FG000|Overall Study|Withdrawal by Subject|3
6228950|NCT01731678|9902618|FG000|Overall Study|Did not meet inclusion criteria|1
6228951|NCT01731678|9902618|FG000|Overall Study|RMT too high, making TMS difficult|3
6228952|NCT01731886|9902640|FG000|Overall Study|Death|1
6228953|NCT01731886|9902641|FG001|Overall Study|Death|0
6228954|NCT01731886|9902640|FG000|Overall Study|Never started treatment|0
6228955|NCT01731886|9902641|FG001|Overall Study|Never started treatment|1
6228956|NCT01731886|9902640|FG000|Overall Study|Non-compliant|1
6228957|NCT01731886|9902641|FG001|Overall Study|Non-compliant|0
6228958|NCT01731912|9902648|FG000|Overall Study|noncompliance|2
6228959|NCT01731938|9902656|FG000|Preliminary Part I|Withdrawal by Subject|2
6228960|NCT01731938|9902657|FG001|Preliminary Part I|Withdrawal by Subject|2
6228961|NCT01731938|9902656|FG000|Preliminary Part I|Physician Decision|1
6228962|NCT01731938|9902657|FG001|Preliminary Part I|Physician Decision|0
6228963|NCT01731938|9902656|FG000|Preliminary Part I|Lost to Follow-up|0
6228964|NCT01731938|9902657|FG001|Preliminary Part I|Lost to Follow-up|3
6228965|NCT01731938|9902656|FG000|Preliminary Part I|Missed Week 6 visit|0
6186947|NCT01377012|9840562|FG000|Extension Study, Weeks 104-260|Study terminated by sponsor|52
6186948|NCT01377012|9840563|FG001|Extension Study, Weeks 104-260|Study terminated by sponsor|69
6186949|NCT01377012|9840564|FG002|Extension Study, Weeks 104-260|Study terminated by sponsor|63
6186950|NCT01377012|9840562|FG000|Extension Study, Weeks 104-260|Withdrawal by Subject|1
6228966|NCT01731938|9902657|FG001|Preliminary Part I|Missed Week 6 visit|3
6228967|NCT01731938|9902656|FG000|Primary Part II|Withdrawal by Subject|5
6228968|NCT01731938|9902657|FG001|Primary Part II|Withdrawal by Subject|4
6228969|NCT01731938|9902656|FG000|Primary Part II|Lost to Follow-up|4
6228970|NCT01731938|9902657|FG001|Primary Part II|Lost to Follow-up|5
6228971|NCT01731938|9902656|FG000|Primary Part II|Death|2
6228972|NCT01731938|9902657|FG001|Primary Part II|Death|1
6228973|NCT01731938|9902656|FG000|Primary Part II|Missed Week 6 visit|2
6228974|NCT01731938|9902657|FG001|Primary Part II|Missed Week 6 visit|3
6228975|NCT01731951|9902670|FG000|Overall Study|Documented Disease Progression|1
6228976|NCT01731951|9902671|FG001|Overall Study|Documented Disease Progression|0
6228977|NCT01731951|9902672|FG002|Overall Study|Documented Disease Progression|0
6228978|NCT01731951|9902673|FG003|Overall Study|Documented Disease Progression|0
6228979|NCT01731951|9902674|FG004|Overall Study|Documented Disease Progression|0
6228980|NCT01731951|9902675|FG005|Overall Study|Documented Disease Progression|0
6228981|NCT01731951|9902670|FG000|Overall Study|Lost to Follow-up|2
6228982|NCT01731951|9902671|FG001|Overall Study|Lost to Follow-up|0
6228983|NCT01731951|9902672|FG002|Overall Study|Lost to Follow-up|0
6228984|NCT01731951|9902673|FG003|Overall Study|Lost to Follow-up|1
6228985|NCT01731951|9902674|FG004|Overall Study|Lost to Follow-up|3
6228986|NCT01731951|9902675|FG005|Overall Study|Lost to Follow-up|1
6228987|NCT01731951|9902670|FG000|Overall Study|Withdrawal of Consent|1
6228988|NCT01731951|9902671|FG001|Overall Study|Withdrawal of Consent|0
6228989|NCT01731951|9902672|FG002|Overall Study|Withdrawal of Consent|0
6228990|NCT01731951|9902673|FG003|Overall Study|Withdrawal of Consent|0
6228991|NCT01731951|9902674|FG004|Overall Study|Withdrawal of Consent|0
6228992|NCT01731951|9902675|FG005|Overall Study|Withdrawal of Consent|2
6228993|NCT01731951|9902670|FG000|Overall Study|Death|13
6228994|NCT01731951|9902671|FG001|Overall Study|Death|15
6228995|NCT01731951|9902672|FG002|Overall Study|Death|9
6228996|NCT01731951|9902673|FG003|Overall Study|Death|8
6228997|NCT01731951|9902674|FG004|Overall Study|Death|9
6228998|NCT01731951|9902675|FG005|Overall Study|Death|6
6228999|NCT01731990|9902695|FG000|Overall Study|Adverse Event|1
6229000|NCT01731990|9902696|FG001|Overall Study|Adverse Event|5
6229001|NCT01731990|9902695|FG000|Overall Study|Withdrawal by Subject|1
6229002|NCT01731990|9902696|FG001|Overall Study|Withdrawal by Subject|1
6229003|NCT01731990|9902695|FG000|Overall Study|Protocol deviation|1
6229004|NCT01731990|9902696|FG001|Overall Study|Protocol deviation|2
6229005|NCT01731990|9902695|FG000|Overall Study|Death|1
6229006|NCT01731990|9902696|FG001|Overall Study|Death|0
6229007|NCT01732107|9902702|FG000|Overall Study|Adverse Event|2
6229008|NCT01732107|9902702|FG000|Overall Study|Disease Progression|8
6229009|NCT01732107|9902702|FG000|Overall Study|Physician Decision|1
6229010|NCT01732107|9902702|FG000|Overall Study|Withdrawal by Subject|2
6269582|NCT02141854|9969902|FG003|Run-In Period (Pre-assignment)|Withdrawal by Subject|0
6269583|NCT02141854|9969903|FG004|Run-In Period (Pre-assignment)|Withdrawal by Subject|0
6269584|NCT02141854|9969904|FG005|Run-In Period (Pre-assignment)|Withdrawal by Subject|0
6269585|NCT02141854|9969899|FG000|Run-In Period (Pre-assignment)|Lost to Follow-up|6
6269586|NCT02141854|9969900|FG001|Run-In Period (Pre-assignment)|Lost to Follow-up|0
6269587|NCT02141854|9969901|FG002|Run-In Period (Pre-assignment)|Lost to Follow-up|0
6269588|NCT02141854|9969902|FG003|Run-In Period (Pre-assignment)|Lost to Follow-up|0
6269589|NCT02141854|9969903|FG004|Run-In Period (Pre-assignment)|Lost to Follow-up|0
6269590|NCT02141854|9969904|FG005|Run-In Period (Pre-assignment)|Lost to Follow-up|0
6269591|NCT02141854|9969899|FG000|Treatment Period|Protocol Violation|0
6269592|NCT02141854|9969900|FG001|Treatment Period|Protocol Violation|1
6269593|NCT02141854|9969901|FG002|Treatment Period|Protocol Violation|0
6269594|NCT02141854|9969902|FG003|Treatment Period|Protocol Violation|2
6269595|NCT02141854|9969903|FG004|Treatment Period|Protocol Violation|2
6269596|NCT02141854|9969904|FG005|Treatment Period|Protocol Violation|1
6269597|NCT02141854|9969899|FG000|Treatment Period|Noncompliance|0
6269598|NCT02141854|9969900|FG001|Treatment Period|Noncompliance|0
6269599|NCT02141854|9969901|FG002|Treatment Period|Noncompliance|0
6269600|NCT02141854|9969902|FG003|Treatment Period|Noncompliance|1
6269601|NCT02141854|9969903|FG004|Treatment Period|Noncompliance|0
6269602|NCT02141854|9969904|FG005|Treatment Period|Noncompliance|0
6269603|NCT02141854|9969899|FG000|Treatment Period|Lack of Efficacy|0
6269604|NCT02141854|9969900|FG001|Treatment Period|Lack of Efficacy|0
6269605|NCT02141854|9969901|FG002|Treatment Period|Lack of Efficacy|0
6269606|NCT02141854|9969902|FG003|Treatment Period|Lack of Efficacy|1
6269607|NCT02141854|9969903|FG004|Treatment Period|Lack of Efficacy|1
6269608|NCT02141854|9969904|FG005|Treatment Period|Lack of Efficacy|7
6269609|NCT02141854|9969899|FG000|Treatment Period|Pregnancy|0
6269610|NCT02141854|9969900|FG001|Treatment Period|Pregnancy|1
6269611|NCT02141854|9969901|FG002|Treatment Period|Pregnancy|0
6269612|NCT02141854|9969902|FG003|Treatment Period|Pregnancy|0
6269613|NCT02141854|9969903|FG004|Treatment Period|Pregnancy|0
6269614|NCT02141854|9969904|FG005|Treatment Period|Pregnancy|0
6269615|NCT02141854|9969899|FG000|Treatment Period|Other|0
6269616|NCT02141854|9969900|FG001|Treatment Period|Other|1
6269617|NCT02141854|9969901|FG002|Treatment Period|Other|2
6269618|NCT02141854|9969902|FG003|Treatment Period|Other|0
6269619|NCT02141854|9969903|FG004|Treatment Period|Other|1
6269620|NCT02141854|9969904|FG005|Treatment Period|Other|2
6269621|NCT02141854|9969899|FG000|Treatment Period|Adverse Event|0
6269622|NCT02141854|9969900|FG001|Treatment Period|Adverse Event|2
6229011|NCT01732458|9902753|FG000|Overall Study|Lost to Follow-up|0
6229012|NCT01732458|9902754|FG001|Overall Study|Lost to Follow-up|2
6229013|NCT01732458|9902755|FG002|Overall Study|Lost to Follow-up|0
6229014|NCT01732458|9902756|FG003|Overall Study|Lost to Follow-up|0
6229015|NCT01732458|9902753|FG000|Overall Study|Non-Compliance With Study Drug|0
6229016|NCT01732458|9902754|FG001|Overall Study|Non-Compliance With Study Drug|0
6229017|NCT01732458|9902755|FG002|Overall Study|Non-Compliance With Study Drug|1
6229018|NCT01732458|9902756|FG003|Overall Study|Non-Compliance With Study Drug|0
6229019|NCT01732458|9902753|FG000|Overall Study|Physician Decision|1
6229020|NCT01732458|9902754|FG001|Overall Study|Physician Decision|2
6229021|NCT01732458|9902755|FG002|Overall Study|Physician Decision|2
6229022|NCT01732458|9902756|FG003|Overall Study|Physician Decision|0
6229023|NCT01732458|9902753|FG000|Overall Study|Protocol Violation|2
6229024|NCT01732458|9902754|FG001|Overall Study|Protocol Violation|0
6229025|NCT01732458|9902755|FG002|Overall Study|Protocol Violation|0
6229026|NCT01732458|9902756|FG003|Overall Study|Protocol Violation|2
6229027|NCT01732458|9902753|FG000|Overall Study|Screen Failure|0
6229028|NCT01732458|9902754|FG001|Overall Study|Screen Failure|1
6229029|NCT01732458|9902755|FG002|Overall Study|Screen Failure|0
6229030|NCT01732458|9902756|FG003|Overall Study|Screen Failure|0
6229031|NCT01732471|9902778|FG000|Overall Study|Withdrawal by Subject|1
6229032|NCT01732484|9902782|FG000|Overall Study|Death|7
6229033|NCT01732484|9902782|FG000|Overall Study|Lost to Follow-up|14
6229034|NCT01732484|9902782|FG000|Overall Study|chronical illness|5
6229035|NCT01732510|9902795|FG000|Overall Study|Adverse Event|0
6229036|NCT01732510|9902796|FG001|Overall Study|Adverse Event|1
6229037|NCT01732510|9902797|FG002|Overall Study|Adverse Event|1
6229038|NCT01732510|9902798|FG003|Overall Study|Adverse Event|0
6229039|NCT01732510|9902799|FG004|Overall Study|Adverse Event|0
6229040|NCT01732510|9902800|FG005|Overall Study|Adverse Event|0
6229041|NCT01732510|9902801|FG006|Overall Study|Adverse Event|1
6229042|NCT01732510|9902795|FG000|Overall Study|Protocol Violation|0
6229043|NCT01732510|9902796|FG001|Overall Study|Protocol Violation|0
6229044|NCT01732510|9902797|FG002|Overall Study|Protocol Violation|0
6229045|NCT01732510|9902798|FG003|Overall Study|Protocol Violation|1
6229046|NCT01732510|9902799|FG004|Overall Study|Protocol Violation|0
6229047|NCT01732510|9902800|FG005|Overall Study|Protocol Violation|0
6229048|NCT01732510|9902801|FG006|Overall Study|Protocol Violation|0
6229049|NCT01732510|9902795|FG000|Overall Study|Withdrawal by Subject|1
6229050|NCT01732510|9902796|FG001|Overall Study|Withdrawal by Subject|3
6229051|NCT01732510|9902797|FG002|Overall Study|Withdrawal by Subject|2
6229052|NCT01732510|9902798|FG003|Overall Study|Withdrawal by Subject|1
6229053|NCT01732510|9902799|FG004|Overall Study|Withdrawal by Subject|5
6229054|NCT01732510|9902800|FG005|Overall Study|Withdrawal by Subject|0
6229055|NCT01732510|9902801|FG006|Overall Study|Withdrawal by Subject|1
6229056|NCT01732510|9902795|FG000|Overall Study|Lost to Follow-up|0
6229057|NCT01732510|9902796|FG001|Overall Study|Lost to Follow-up|0
6229058|NCT01732510|9902797|FG002|Overall Study|Lost to Follow-up|1
6229059|NCT01732510|9902798|FG003|Overall Study|Lost to Follow-up|1
6229060|NCT01732510|9902799|FG004|Overall Study|Lost to Follow-up|0
6229061|NCT01732510|9902800|FG005|Overall Study|Lost to Follow-up|1
6229062|NCT01732510|9902801|FG006|Overall Study|Lost to Follow-up|0
6229063|NCT01732510|9902795|FG000|Overall Study|Physician Decision|0
6229064|NCT01732510|9902796|FG001|Overall Study|Physician Decision|1
6229065|NCT01732510|9902797|FG002|Overall Study|Physician Decision|0
6229066|NCT01732510|9902798|FG003|Overall Study|Physician Decision|0
6229067|NCT01732510|9902799|FG004|Overall Study|Physician Decision|0
6229068|NCT01732510|9902800|FG005|Overall Study|Physician Decision|0
6229069|NCT01732510|9902801|FG006|Overall Study|Physician Decision|0
6229070|NCT01732510|9902795|FG000|Overall Study|Pregnancy|0
6229071|NCT01732510|9902796|FG001|Overall Study|Pregnancy|0
6229072|NCT01732510|9902797|FG002|Overall Study|Pregnancy|0
6229073|NCT01732510|9902798|FG003|Overall Study|Pregnancy|1
6229074|NCT01732510|9902799|FG004|Overall Study|Pregnancy|0
6229075|NCT01732510|9902800|FG005|Overall Study|Pregnancy|0
6229076|NCT01732510|9902801|FG006|Overall Study|Pregnancy|0
6229077|NCT01732510|9902795|FG000|Overall Study|Study Terminated By Sponsor|0
6229078|NCT01732510|9902796|FG001|Overall Study|Study Terminated By Sponsor|0
6229079|NCT01732510|9902797|FG002|Overall Study|Study Terminated By Sponsor|0
6229080|NCT01732510|9902798|FG003|Overall Study|Study Terminated By Sponsor|1
6229081|NCT01732510|9902799|FG004|Overall Study|Study Terminated By Sponsor|0
6229082|NCT01732510|9902800|FG005|Overall Study|Study Terminated By Sponsor|12
6229083|NCT01732510|9902801|FG006|Overall Study|Study Terminated By Sponsor|6
6229084|NCT01732536|9902822|FG000|Overall Study|Withdrawal by Subject|1
6229085|NCT01732536|9902823|FG001|Overall Study|Withdrawal by Subject|1
6229086|NCT01732549|9902834|FG000|Overall Study|Adverse Event|13
6229087|NCT01732549|9902835|FG001|Overall Study|Adverse Event|3
6229088|NCT01732549|9902834|FG000|Overall Study|Consent withdrawn|13
6229089|NCT01732549|9902835|FG001|Overall Study|Consent withdrawn|6
6229090|NCT01732549|9902834|FG000|Overall Study|Disease progression|37
6229091|NCT01732549|9902835|FG001|Overall Study|Disease progression|50
6229092|NCT01732549|9902834|FG000|Overall Study|Other|8
6229093|NCT01732549|9902835|FG001|Overall Study|Other|14
6229094|NCT01732588|9902845|FG000|First Intervention (7 Days)|Adverse Event|0
6229095|NCT01732588|9902846|FG001|First Intervention (7 Days)|Adverse Event|1
6229096|NCT01732588|9902847|FG002|First Intervention (7 Days)|Adverse Event|0
6229097|NCT01732640|9902855|FG000|Overall Study|Adverse Event|0
6229098|NCT01732640|9902856|FG001|Overall Study|Adverse Event|1
6229099|NCT01732640|9902855|FG000|Overall Study|Death|0
6229100|NCT01732640|9902856|FG001|Overall Study|Death|1
6229101|NCT01732692|9902868|FG000|Overall Study|Adverse Event|0
6229102|NCT01732692|9902869|FG001|Overall Study|Adverse Event|1
6229103|NCT01732757|9902891|FG000|Overall Study|Lost to Follow-up|1
6229104|NCT01732757|9902892|FG001|Overall Study|Lost to Follow-up|0
6229105|NCT01732757|9902893|FG002|Overall Study|Lost to Follow-up|0
6229106|NCT01732770|9902903|FG000|Overall Study|Lost to Follow-up|2
6229107|NCT01732770|9902904|FG001|Overall Study|Lost to Follow-up|3
6229108|NCT01732770|9902903|FG000|Overall Study|Withdrawal by Subject|5
6229109|NCT01732770|9902904|FG001|Overall Study|Withdrawal by Subject|3
6229110|NCT01732770|9902903|FG000|Overall Study|Decision by Sponsor|2
6229111|NCT01732770|9902904|FG001|Overall Study|Decision by Sponsor|2
6229112|NCT01732770|9902903|FG000|Overall Study|Death|1
6229113|NCT01732770|9902904|FG001|Overall Study|Death|0
6229114|NCT01732783|9902913|FG000|Overall Study|Discontinued Panitumumab Treatment|106
6229115|NCT01732783|9902914|FG001|Overall Study|Discontinued Panitumumab Treatment|25
6229116|NCT01732783|9902915|FG002|Overall Study|Discontinued Panitumumab Treatment|7
6229117|NCT01732783|9902913|FG000|Overall Study|Death|13
6229118|NCT01732783|9902914|FG001|Overall Study|Death|4
6229119|NCT01732783|9902915|FG002|Overall Study|Death|1
6229120|NCT01732783|9902913|FG000|Overall Study|Lost to Follow-up|7
6229121|NCT01732783|9902914|FG001|Overall Study|Lost to Follow-up|1
6229122|NCT01732783|9902915|FG002|Overall Study|Lost to Follow-up|1
6229123|NCT01732783|9902913|FG000|Overall Study|Administrative Decision|8
6229124|NCT01732783|9902914|FG001|Overall Study|Administrative Decision|2
6229125|NCT01732783|9902915|FG002|Overall Study|Administrative Decision|1
6229126|NCT01732783|9902913|FG000|Overall Study|Withdrawal by Subject|1
6229127|NCT01732783|9902914|FG001|Overall Study|Withdrawal by Subject|0
6229128|NCT01732783|9902915|FG002|Overall Study|Withdrawal by Subject|0
6229129|NCT01732796|9902926|FG000|Overall Study|Adverse Event|16
6229130|NCT01732796|9902927|FG001|Overall Study|Adverse Event|16
6229131|NCT01732796|9902928|FG002|Overall Study|Adverse Event|4
6229132|NCT01732796|9902926|FG000|Overall Study|Lack of Efficacy|21
6229133|NCT01732796|9902927|FG001|Overall Study|Lack of Efficacy|18
6229134|NCT01732796|9902928|FG002|Overall Study|Lack of Efficacy|5
6229135|NCT01732796|9902926|FG000|Overall Study|Lost to Follow-up|2
6229136|NCT01732796|9902927|FG001|Overall Study|Lost to Follow-up|0
6229137|NCT01732796|9902928|FG002|Overall Study|Lost to Follow-up|0
6229138|NCT01732796|9902926|FG000|Overall Study|Withdrawal by Subject|6
6229139|NCT01732796|9902927|FG001|Overall Study|Withdrawal by Subject|8
6229140|NCT01732796|9902928|FG002|Overall Study|Withdrawal by Subject|2
6229141|NCT01732796|9902926|FG000|Overall Study|Other reason not defined above|1
6229142|NCT01732796|9902927|FG001|Overall Study|Other reason not defined above|0
6085404|NCT00652366|9694738|FG002|Overall Study|Other|3
6085405|NCT00652366|9694739|FG003|Overall Study|Other|4
6085406|NCT00652366|9694740|FG004|Overall Study|Other|0
6085407|NCT00652626|9694761|FG000|Initial Treatment Phase|Adverse Event|0
6085408|NCT00652626|9694762|FG001|Initial Treatment Phase|Adverse Event|0
6085409|NCT00652626|9694763|FG002|Initial Treatment Phase|Adverse Event|0
6085410|NCT00652626|9694764|FG003|Initial Treatment Phase|Adverse Event|0
6229143|NCT01732796|9902928|FG002|Overall Study|Other reason not defined above|2
6269623|NCT02141854|9969901|FG002|Treatment Period|Adverse Event|2
6269624|NCT02141854|9969902|FG003|Treatment Period|Adverse Event|0
6269625|NCT02141854|9969903|FG004|Treatment Period|Adverse Event|2
6269626|NCT02141854|9969904|FG005|Treatment Period|Adverse Event|2
6269627|NCT02141854|9969899|FG000|Treatment Period|Withdrawal by Subject|0
6269628|NCT02141854|9969900|FG001|Treatment Period|Withdrawal by Subject|2
6269629|NCT02141854|9969901|FG002|Treatment Period|Withdrawal by Subject|3
6269630|NCT02141854|9969902|FG003|Treatment Period|Withdrawal by Subject|3
6269631|NCT02141854|9969903|FG004|Treatment Period|Withdrawal by Subject|4
6269632|NCT02141854|9969904|FG005|Treatment Period|Withdrawal by Subject|7
6269633|NCT02141854|9969899|FG000|Treatment Period|Disease progression|0
6269634|NCT02141854|9969900|FG001|Treatment Period|Disease progression|2
6269635|NCT02141854|9969901|FG002|Treatment Period|Disease progression|1
6269636|NCT02141854|9969902|FG003|Treatment Period|Disease progression|3
6085411|NCT00652626|9694765|FG004|Initial Treatment Phase|Adverse Event|1
6269637|NCT02141854|9969903|FG004|Treatment Period|Disease progression|0
6269638|NCT02141854|9969904|FG005|Treatment Period|Disease progression|18
6269639|NCT02141854|9969899|FG000|Treatment Period|Lost to Follow-up|0
6269640|NCT02141854|9969900|FG001|Treatment Period|Lost to Follow-up|1
6269641|NCT02141854|9969901|FG002|Treatment Period|Lost to Follow-up|1
6269642|NCT02141854|9969902|FG003|Treatment Period|Lost to Follow-up|1
6269643|NCT02141854|9969903|FG004|Treatment Period|Lost to Follow-up|0
6269644|NCT02141854|9969904|FG005|Treatment Period|Lost to Follow-up|1
6269645|NCT02141984|9969920|FG000|Overall Study|Lack of Efficacy|2
6269646|NCT02141997|9969928|FG000|Overall Study|Adverse Event|0
6269647|NCT02141997|9969929|FG001|Overall Study|Adverse Event|2
6269648|NCT02141997|9969930|FG002|Overall Study|Adverse Event|0
6269649|NCT02141997|9969931|FG003|Overall Study|Adverse Event|1
6269650|NCT02141997|9969928|FG000|Overall Study|Participant noncompliance|1
6269651|NCT02141997|9969929|FG001|Overall Study|Participant noncompliance|0
6269652|NCT02141997|9969930|FG002|Overall Study|Participant noncompliance|0
6269653|NCT02141997|9969931|FG003|Overall Study|Participant noncompliance|0
6229144|NCT04537234|9902940|FG000|Overall Study|Withdrawal by Subject|2
6229145|NCT04537234|9902941|FG001|Overall Study|Withdrawal by Subject|0
6229146|NCT03478956|9902977|FG000|Overall Study|Adverse Event|1
6229147|NCT03478956|9902978|FG001|Overall Study|Adverse Event|0
6229148|NCT03478956|9902977|FG000|Overall Study|Withdrawal by Subject|0
6229149|NCT03478956|9902978|FG001|Overall Study|Withdrawal by Subject|1
6229150|NCT03478956|9902977|FG000|Overall Study|Ongoing in the Study|11
6229151|NCT03478956|9902978|FG001|Overall Study|Ongoing in the Study|11
6229152|NCT03348930|9902984|FG000|Washout (1 Week)|Lost to Follow-up|1
6229153|NCT03348930|9902985|FG001|Washout (1 Week)|Lost to Follow-up|1
6229154|NCT03282240|9902994|FG000|Overall Study|Adverse Event|2
6229155|NCT03282240|9902995|FG001|Overall Study|Adverse Event|2
6229156|NCT03282240|9902996|FG002|Overall Study|Adverse Event|0
6229157|NCT03282240|9902994|FG000|Overall Study|Lost to Follow-up|3
6229158|NCT03282240|9902995|FG001|Overall Study|Lost to Follow-up|0
6229159|NCT03282240|9902996|FG002|Overall Study|Lost to Follow-up|0
6229160|NCT03282240|9902994|FG000|Overall Study|Protocol Deviation|4
6229161|NCT03282240|9902995|FG001|Overall Study|Protocol Deviation|1
6229162|NCT03282240|9902996|FG002|Overall Study|Protocol Deviation|2
6229163|NCT03282240|9902994|FG000|Overall Study|Withdrawal by Subject|1
6229164|NCT03282240|9902995|FG001|Overall Study|Withdrawal by Subject|0
6229165|NCT03282240|9902996|FG002|Overall Study|Withdrawal by Subject|1
6229166|NCT03260868|9903009|FG000|Overall Study|Poor Compliance to Protocol|0
6229167|NCT03260868|9903010|FG001|Overall Study|Poor Compliance to Protocol|2
6229168|NCT03260868|9903009|FG000|Overall Study|Study Terminated By Sponsor|2
6229169|NCT03260868|9903010|FG001|Overall Study|Study Terminated By Sponsor|1
6229170|NCT03260868|9903009|FG000|Overall Study|Other than specified above|1
6229171|NCT03260868|9903010|FG001|Overall Study|Other than specified above|0
6229172|NCT03164616|9903028|FG000|Overall Study|Death|250
6229173|NCT03164616|9903029|FG001|Overall Study|Death|264
6229174|NCT03164616|9903030|FG002|Overall Study|Death|279
6229175|NCT03164616|9903028|FG000|Overall Study|Lost to Follow-up|2
6229176|NCT03164616|9903029|FG001|Overall Study|Lost to Follow-up|2
6229177|NCT03164616|9903030|FG002|Overall Study|Lost to Follow-up|2
6229178|NCT03164616|9903028|FG000|Overall Study|Withdrawal by Subject|6
6229179|NCT03164616|9903029|FG001|Overall Study|Withdrawal by Subject|7
6229180|NCT03164616|9903030|FG002|Overall Study|Withdrawal by Subject|16
6229181|NCT03157037|9903040|FG000|Overall Study|Death|1
6186951|NCT01377012|9840563|FG001|Extension Study, Weeks 104-260|Withdrawal by Subject|0
6186952|NCT01377012|9840564|FG002|Extension Study, Weeks 104-260|Withdrawal by Subject|3
6186953|NCT01377012|9840562|FG000|Extension Study, Weeks 104-260|Physician Decision|1
6186954|NCT01377012|9840563|FG001|Extension Study, Weeks 104-260|Physician Decision|0
6186955|NCT01377012|9840564|FG002|Extension Study, Weeks 104-260|Physician Decision|0
6186956|NCT01377012|9840562|FG000|Extension Study, Weeks 104-260|Lost to Follow-up|0
6186957|NCT01377012|9840563|FG001|Extension Study, Weeks 104-260|Lost to Follow-up|0
6229182|NCT03128931|9903064|FG000|Overall Study|Physician Decision|1
6229183|NCT03128931|9903064|FG000|Overall Study|Equipment Issues|3
6229184|NCT02611960|9903070|FG000|Overall Study|COVID-19 Association Unspecified Adverse Event|7
6229185|NCT02611960|9903071|FG001|Overall Study|COVID-19 Association Unspecified Adverse Event|8
6229186|NCT02611960|9903070|FG000|Overall Study|Death|87
6229187|NCT02611960|9903071|FG001|Overall Study|Death|85
6229188|NCT02611960|9903070|FG000|Overall Study|Withdrawal by Subject|0
6229189|NCT02611960|9903071|FG001|Overall Study|Withdrawal by Subject|1
6229190|NCT02611960|9903070|FG000|Overall Study|COVID-19 Association Unspecified Withdrawal By Participant|1
6229191|NCT02611960|9903071|FG001|Overall Study|COVID-19 Association Unspecified Withdrawal By Participant|4
6229192|NCT02611960|9903070|FG000|Overall Study|Participants Ongoing|22
6229193|NCT02611960|9903071|FG001|Overall Study|Participants Ongoing|18
6229194|NCT02498392|9903080|FG000|Double-blind(DB) Lead-in Period(3 Weeks)|Did not receive treatment|7
6229195|NCT02498392|9903081|FG001|Double-blind(DB) Lead-in Period(3 Weeks)|Did not receive treatment|0
6229196|NCT02498392|9903080|FG000|DB Treatment (6 Weeks)+Withdrawal Period|Adverse Event|3
6229197|NCT02498392|9903081|FG001|DB Treatment (6 Weeks)+Withdrawal Period|Adverse Event|0
6229198|NCT02498392|9903080|FG000|DB Treatment (6 Weeks)+Withdrawal Period|Lack of Efficacy|0
6229199|NCT02498392|9903081|FG001|DB Treatment (6 Weeks)+Withdrawal Period|Lack of Efficacy|2
6229200|NCT02498392|9903080|FG000|DB Treatment (6 Weeks)+Withdrawal Period|Lost to Follow-up|0
6229201|NCT02498392|9903081|FG001|DB Treatment (6 Weeks)+Withdrawal Period|Lost to Follow-up|2
6229202|NCT02498392|9903080|FG000|DB Treatment (6 Weeks)+Withdrawal Period|Withdrawal by Subject|2
6229203|NCT02498392|9903081|FG001|DB Treatment (6 Weeks)+Withdrawal Period|Withdrawal by Subject|3
6229204|NCT02498392|9903080|FG000|DB Treatment (6 Weeks)+Withdrawal Period|Other|1
6229205|NCT02498392|9903081|FG001|DB Treatment (6 Weeks)+Withdrawal Period|Other|3
6229206|NCT01899729|9903106|FG000|Overall Study|Adverse Event|1
6229207|NCT01899729|9903107|FG001|Overall Study|Adverse Event|0
6229208|NCT01899729|9903108|FG002|Overall Study|Adverse Event|0
6229209|NCT01899729|9903109|FG003|Overall Study|Adverse Event|0
6229210|NCT01899729|9903110|FG004|Overall Study|Adverse Event|1
6229211|NCT01899729|9903106|FG000|Overall Study|Withdrawal by Subject|1
6229212|NCT01899729|9903107|FG001|Overall Study|Withdrawal by Subject|2
6229213|NCT01899729|9903108|FG002|Overall Study|Withdrawal by Subject|0
6186958|NCT01377012|9840564|FG002|Extension Study, Weeks 104-260|Lost to Follow-up|1
6229214|NCT01899729|9903109|FG003|Overall Study|Withdrawal by Subject|0
6229215|NCT01899729|9903110|FG004|Overall Study|Withdrawal by Subject|0
6229216|NCT01899729|9903106|FG000|Overall Study|Lack of Efficacy|0
6229217|NCT01899729|9903107|FG001|Overall Study|Lack of Efficacy|0
6229218|NCT01899729|9903108|FG002|Overall Study|Lack of Efficacy|2
6229219|NCT01899729|9903109|FG003|Overall Study|Lack of Efficacy|0
6229220|NCT01899729|9903110|FG004|Overall Study|Lack of Efficacy|1
6229221|NCT01648205|9903131|FG000|Placebo|Pregnancy|1
6229222|NCT01648205|9903131|FG000|Placebo|Withdrawal by Subject|1
6229223|NCT01648205|9903131|FG000|Placebo|Protocol Violation|2
6229224|NCT01648205|9903131|FG000|Ranolazine|Death|1
6229225|NCT01648205|9903131|FG000|Ranolazine|Withdrawal by Subject|1
6229226|NCT01648205|9903131|FG000|Ranolazine|Protocol Violation|3
6269654|NCT02141997|9969928|FG000|Overall Study|Withdrew consent|1
6269655|NCT02141997|9969929|FG001|Overall Study|Withdrew consent|0
6269656|NCT02141997|9969930|FG002|Overall Study|Withdrew consent|3
6269657|NCT02141997|9969931|FG003|Overall Study|Withdrew consent|0
6269658|NCT02141997|9969928|FG000|Overall Study|Other|1
6269659|NCT02141997|9969929|FG001|Overall Study|Other|4
6269660|NCT02141997|9969930|FG002|Overall Study|Other|0
6269661|NCT02141997|9969931|FG003|Overall Study|Other|0
6269662|NCT02142283|9970020|FG000|Overall Study|Death|20
6269663|NCT02142283|9970021|FG001|Overall Study|Death|18
6269664|NCT02142283|9970020|FG000|Overall Study|Withdrawal by Subject|1
6269665|NCT02142283|9970021|FG001|Overall Study|Withdrawal by Subject|3
6269666|NCT02142387|9970042|FG000|Overall Study|<19 years old|49
6269667|NCT02142387|9970043|FG001|Overall Study|<19 years old|326
6269668|NCT02142387|9970042|FG000|Overall Study|non-cardiac etiology|504
6269669|NCT02142387|9970043|FG001|Overall Study|non-cardiac etiology|3431
6269670|NCT02142387|9970042|FG000|Overall Study|CPR not performed|74
6269671|NCT02142387|9970043|FG001|Overall Study|CPR not performed|473
6269672|NCT02142387|9970042|FG000|Overall Study|witnessed by paramedic|139
6269673|NCT02142387|9970043|FG001|Overall Study|witnessed by paramedic|917
6269674|NCT02142387|9970042|FG000|Overall Study|incomplete data|1
6269675|NCT02142387|9970043|FG001|Overall Study|incomplete data|9
6269676|NCT02142387|9970042|FG000|Overall Study|occurred not at home|298
6269677|NCT02142387|9970043|FG001|Overall Study|occurred not at home|2474
6269678|NCT02142504|9970052|FG000|Overall Study|Protocol Violation|2
6269679|NCT02142504|9970053|FG001|Overall Study|Protocol Violation|1
6269680|NCT02142504|9970054|FG002|Overall Study|Protocol Violation|2
6269681|NCT02142504|9970052|FG000|Overall Study|Adverse Event|2
6269682|NCT02142504|9970053|FG001|Overall Study|Adverse Event|3
6269683|NCT02142504|9970054|FG002|Overall Study|Adverse Event|4
6269684|NCT02142504|9970052|FG000|Overall Study|Lost to Follow-up|12
6269685|NCT02142504|9970053|FG001|Overall Study|Lost to Follow-up|19
6269686|NCT02142504|9970054|FG002|Overall Study|Lost to Follow-up|17
6269687|NCT02142504|9970052|FG000|Overall Study|Withdrawal by Subject|7
6269688|NCT02142504|9970053|FG001|Overall Study|Withdrawal by Subject|9
6269689|NCT02142504|9970054|FG002|Overall Study|Withdrawal by Subject|11
6269690|NCT02142504|9970052|FG000|Overall Study|Pregnancy|4
6269691|NCT02142504|9970053|FG001|Overall Study|Pregnancy|4
6269692|NCT02142504|9970054|FG002|Overall Study|Pregnancy|2
6269693|NCT02142504|9970052|FG000|Overall Study|Physician Decision|0
6269694|NCT02142504|9970053|FG001|Overall Study|Physician Decision|1
6269695|NCT02142504|9970054|FG002|Overall Study|Physician Decision|3
6269696|NCT02142504|9970052|FG000|Overall Study|Reason Not Specified|4
6269697|NCT02142504|9970053|FG001|Overall Study|Reason Not Specified|5
6269698|NCT02142504|9970054|FG002|Overall Study|Reason Not Specified|4
6269699|NCT02142712|9970070|FG000|Overall Study|Lost to Follow-up|1
6269700|NCT02142712|9970071|FG001|Overall Study|Lost to Follow-up|1
6269701|NCT02142712|9970072|FG002|Overall Study|Lost to Follow-up|1
6269702|NCT02142712|9970073|FG003|Overall Study|Lost to Follow-up|0
6269703|NCT02142738|9970084|FG000|Overall Study|Adverse Event|9
6269704|NCT02142738|9970085|FG001|Overall Study|Adverse Event|8
6269705|NCT02142738|9970084|FG000|Overall Study|Death|33
6269706|NCT02142738|9970085|FG001|Overall Study|Death|55
6269707|NCT02142738|9970084|FG000|Overall Study|Progressive Disease|0
6269708|NCT02142738|9970085|FG001|Overall Study|Progressive Disease|1
6269709|NCT02142738|9970084|FG000|Overall Study|Withdrawal by Subject|5
6269710|NCT02142738|9970085|FG001|Overall Study|Withdrawal by Subject|5
6269711|NCT02142738|9970084|FG000|Overall Study|Ongoing in Study|107
6269712|NCT02142738|9970085|FG001|Overall Study|Ongoing in Study|82
6269713|NCT02142894|9970091|FG000|Overall Study|Protocol Violation|8
6269714|NCT02143024|9970097|FG000|Overall Study|Lost to Follow-up|1
6269715|NCT02143024|9970098|FG001|Overall Study|Lost to Follow-up|1
6269716|NCT02143024|9970097|FG000|Overall Study|Withdrawal by Subject|1
6269717|NCT02143024|9970098|FG001|Overall Study|Withdrawal by Subject|0
6269718|NCT02143102|9970106|FG000|Overall Study|Lost to Follow-up|11
6269719|NCT02143102|9970107|FG001|Overall Study|Lost to Follow-up|0
6269720|NCT02143141|9970115|FG000|Overall Study|pain scores at 24 hours not collected|1
6269721|NCT02143141|9970116|FG001|Overall Study|pain scores at 24 hours not collected|0
6269722|NCT02143583|9970129|FG000|Overall Study|Withdrawal by Subject|1
6269723|NCT02143583|9970130|FG001|Overall Study|Withdrawal by Subject|0
6269724|NCT02143583|9970131|FG002|Overall Study|Withdrawal by Subject|1
6269725|NCT02143583|9970129|FG000|Overall Study|husband illness|0
6269726|NCT02143583|9970130|FG001|Overall Study|husband illness|0
6269727|NCT02143583|9970131|FG002|Overall Study|husband illness|1
6269728|NCT02143713|9970156|FG000|Treatment Period (6 Months)|Withdrawal by Subject|1
6229227|NCT01063517|9903154|FG000|Overall Study|Consent withdrawal|1
6229228|NCT01063517|9903155|FG001|Overall Study|Consent withdrawal|0
6229229|NCT01063517|9903154|FG000|Overall Study|Study reached data cut-off|19
6229230|NCT01063517|9903155|FG001|Overall Study|Study reached data cut-off|7
6229231|NCT01063517|9903154|FG000|Overall Study|Lost to Follow-up|4
6229232|NCT01063517|9903155|FG001|Overall Study|Lost to Follow-up|3
6229233|NCT01063517|9903154|FG000|Overall Study|Withdrawal by Subject|1
6229234|NCT01063517|9903155|FG001|Overall Study|Withdrawal by Subject|2
6229235|NCT01063517|9903154|FG000|Overall Study|Death|33
6229236|NCT01063517|9903155|FG001|Overall Study|Death|48
6229237|NCT00915681|9903161|FG000|Overall Study|Screening failures|46
6229238|NCT00145158|9903167|FG000|Overall Study|premature withdrawal|2
6229239|NCT00145158|9903168|FG001|Overall Study|premature withdrawal|3
6229240|NCT01732822|9903186|FG000|Overall Study|Withdrawal by Subject|123
6229241|NCT01732822|9903187|FG001|Overall Study|Withdrawal by Subject|113
6229242|NCT01732835|9903215|FG000|6-month Primary Endpoint|Did not receive device|19
6229243|NCT01732835|9903215|FG000|6-month Primary Endpoint|Withdrawal by Subject|2
6229244|NCT01732835|9903215|FG000|6-month Primary Endpoint|Adverse Event|3
6229245|NCT01732835|9903215|FG000|2-year Extended Follow-up|Withdrawal by Subject|1
6229246|NCT01732835|9903215|FG000|2-year Extended Follow-up|Adverse Event|3
6229247|NCT01732835|9903215|FG000|2-year Extended Follow-up|Death|1
6229248|NCT01732874|9903221|FG000|Overall Study|Withdrawal by Subject|5
6229249|NCT01732874|9903222|FG001|Overall Study|Withdrawal by Subject|1
6229250|NCT01732874|9903221|FG000|Overall Study|Death of Infant|3
6229251|NCT01732874|9903222|FG001|Overall Study|Death of Infant|2
6375453|NCT04075734|10165520|FG000|Overall Study|Lost to Follow-up|1
6375454|NCT04075734|10165521|FG001|Overall Study|Lost to Follow-up|1
6375455|NCT04075734|10165522|FG002|Overall Study|Lost to Follow-up|0
6229252|NCT01733121|9903255|FG000|Double-Blind Period (Week 0 to 6)|Adverse Event|2
6229253|NCT01733121|9903256|FG001|Double-Blind Period (Week 0 to 6)|Adverse Event|0
6229254|NCT01733121|9903255|FG000|Double-Blind Period (Week 0 to 6)|Non-compliance|3
6229255|NCT01733121|9903256|FG001|Double-Blind Period (Week 0 to 6)|Non-compliance|2
6229256|NCT01733121|9903255|FG000|Double-Blind Period (Week 0 to 6)|Withdrawal by Subject|1
6229257|NCT01733121|9903256|FG001|Double-Blind Period (Week 0 to 6)|Withdrawal by Subject|3
6229258|NCT01733121|9903255|FG000|Double-Blind Period (Week 0 to 6)|Lost to Follow-up|1
6229259|NCT01733121|9903256|FG001|Double-Blind Period (Week 0 to 6)|Lost to Follow-up|0
6229260|NCT01733316|9903295|FG000|RP103 Phase|Non-compliance|1
6229261|NCT01733316|9903295|FG000|Long Term Extension Phase|Adverse Event|1
6229262|NCT01733316|9903295|FG000|Long Term Extension Phase|Consent Withdrawn by Subject|2
6229263|NCT01733316|9903295|FG000|Long Term Extension Phase|Sponsor Decision|2
6229264|NCT01733329|9903308|FG000|Overall Study|Protocol Violation|1
6229265|NCT01733329|9903309|FG001|Overall Study|Protocol Violation|1
6229266|NCT01733329|9903308|FG000|Overall Study|Uterine artery injury|1
6229267|NCT01733329|9903309|FG001|Overall Study|Uterine artery injury|0
6229268|NCT01733680|9903346|FG000|Overall Study|Withdrawal by Subject|0
6229269|NCT01733680|9903347|FG001|Overall Study|Withdrawal by Subject|1
6229270|NCT01733732|9903359|FG000|Overall Study|Adverse Event|1
6229271|NCT01733732|9903360|FG001|Overall Study|Adverse Event|0
6229272|NCT01733732|9903359|FG000|Overall Study|Did not attend all study visits|1
6229273|NCT01733732|9903360|FG001|Overall Study|Did not attend all study visits|0
6229274|NCT01733758|9903389|FG000|Overall Study|Adverse Event|5
6229275|NCT01733758|9903390|FG001|Overall Study|Adverse Event|7
6229276|NCT01733758|9903391|FG002|Overall Study|Adverse Event|8
6229277|NCT01733758|9903392|FG003|Overall Study|Adverse Event|1
6229278|NCT01733758|9903389|FG000|Overall Study|Withdrawal by Subject|1
6229279|NCT01733758|9903390|FG001|Overall Study|Withdrawal by Subject|1
6229280|NCT01733758|9903391|FG002|Overall Study|Withdrawal by Subject|5
6229281|NCT01733758|9903392|FG003|Overall Study|Withdrawal by Subject|3
6229282|NCT01733758|9903389|FG000|Overall Study|Persistent Hyperglycemia|3
6229283|NCT01733758|9903390|FG001|Overall Study|Persistent Hyperglycemia|2
6229284|NCT01733758|9903391|FG002|Overall Study|Persistent Hyperglycemia|0
6229285|NCT01733758|9903392|FG003|Overall Study|Persistent Hyperglycemia|0
6229286|NCT01733758|9903389|FG000|Overall Study|Protocol Violation|0
6229287|NCT01733758|9903390|FG001|Overall Study|Protocol Violation|1
6229288|NCT01733758|9903391|FG002|Overall Study|Protocol Violation|2
6229289|NCT01733758|9903392|FG003|Overall Study|Protocol Violation|2
6229290|NCT01733758|9903389|FG000|Overall Study|Non-compliance|1
6229291|NCT01733758|9903390|FG001|Overall Study|Non-compliance|0
6229292|NCT01733758|9903391|FG002|Overall Study|Non-compliance|0
6229293|NCT01733758|9903392|FG003|Overall Study|Non-compliance|0
6229294|NCT01733758|9903389|FG000|Overall Study|Intro of New Anti-Diabetic Medication|4
6229295|NCT01733758|9903390|FG001|Overall Study|Intro of New Anti-Diabetic Medication|0
6229296|NCT01733758|9903391|FG002|Overall Study|Intro of New Anti-Diabetic Medication|0
6229297|NCT01733758|9903392|FG003|Overall Study|Intro of New Anti-Diabetic Medication|1
6229298|NCT01733758|9903389|FG000|Overall Study|Inv Decision, HbA1c not controlled|1
6229299|NCT01733758|9903390|FG001|Overall Study|Inv Decision, HbA1c not controlled|1
6229300|NCT01733758|9903391|FG002|Overall Study|Inv Decision, HbA1c not controlled|0
6229301|NCT01733758|9903392|FG003|Overall Study|Inv Decision, HbA1c not controlled|1
6229302|NCT01734382|9903438|FG000|Part 1|Adverse Event|2
6229303|NCT01734382|9903439|FG001|Part 1|Adverse Event|0
6375456|NCT04075734|10165520|FG000|Overall Study|Withdrawal by Subject|3
6229304|NCT01734382|9903440|FG002|Part 1|Adverse Event|0
6229305|NCT01734382|9903438|FG000|Part 2|Adverse Event|0
6229306|NCT01734382|9903439|FG001|Part 2|Adverse Event|0
6229307|NCT01734382|9903440|FG002|Part 2|Adverse Event|1
6229308|NCT01734382|9903438|FG000|Part 2|Lack of Efficacy|0
6229309|NCT01734382|9903439|FG001|Part 2|Lack of Efficacy|1
6229310|NCT01734382|9903440|FG002|Part 2|Lack of Efficacy|1
6229311|NCT01734382|9903438|FG000|Part 2|Other|0
6229312|NCT01734382|9903439|FG001|Part 2|Other|0
6229313|NCT01734382|9903440|FG002|Part 2|Other|1
6229314|NCT01734382|9903438|FG000|Part 2|Physician Decision|0
6229315|NCT01734382|9903439|FG001|Part 2|Physician Decision|0
6229316|NCT01734382|9903440|FG002|Part 2|Physician Decision|3
6229317|NCT01734382|9903438|FG000|Part 2|Protocol Violation|0
6229318|NCT01734382|9903439|FG001|Part 2|Protocol Violation|1
6229319|NCT01734382|9903440|FG002|Part 2|Protocol Violation|0
6229320|NCT01734382|9903438|FG000|Part 2|Withdrawal by Subject|0
6229321|NCT01734382|9903439|FG001|Part 2|Withdrawal by Subject|0
6229322|NCT01734382|9903440|FG002|Part 2|Withdrawal by Subject|1
6229323|NCT01734395|9903452|FG000|Overall Study|Other|65
6229324|NCT01734395|9903452|FG000|Overall Study|Lost to Follow-up|287
6229325|NCT01734395|9903452|FG000|Overall Study|Lack of Efficacy|5
6229326|NCT01734395|9903452|FG000|Overall Study|Adverse Event|40
6229327|NCT01734395|9903452|FG000|Overall Study|Withdrawal by Subject|10
6229328|NCT01734395|9903452|FG000|Overall Study|Missing the reasons for not completed|3
6229329|NCT01734434|9903460|FG000|Overall Study|Death Infant|3
6229330|NCT01734434|9903461|FG001|Overall Study|Death Infant|1
6229331|NCT01734434|9903462|FG002|Overall Study|Death Infant|17
6229332|NCT01734434|9903463|FG003|Overall Study|Death Infant|5
6229333|NCT01734434|9903460|FG000|Overall Study|Lost to Follow-up|2
6229334|NCT01734434|9903461|FG001|Overall Study|Lost to Follow-up|9
6229335|NCT01734434|9903462|FG002|Overall Study|Lost to Follow-up|67
6229336|NCT01734434|9903463|FG003|Overall Study|Lost to Follow-up|11
6229337|NCT01734434|9903460|FG000|Overall Study|No Live Birth|1
6229338|NCT01734434|9903461|FG001|Overall Study|No Live Birth|2
6229339|NCT01734434|9903462|FG002|Overall Study|No Live Birth|32
6229340|NCT01734434|9903463|FG003|Overall Study|No Live Birth|6
6229341|NCT01734434|9903460|FG000|Overall Study|Withdrawal by Subject|4
6229342|NCT01734434|9903461|FG001|Overall Study|Withdrawal by Subject|0
6229343|NCT01734434|9903462|FG002|Overall Study|Withdrawal by Subject|8
6229344|NCT01734434|9903463|FG003|Overall Study|Withdrawal by Subject|1
6229345|NCT01734434|9903460|FG000|Overall Study|Signed Adult Version of Consent Form|0
6229346|NCT01734434|9903461|FG001|Overall Study|Signed Adult Version of Consent Form|0
6229347|NCT01734434|9903462|FG002|Overall Study|Signed Adult Version of Consent Form|1
6229348|NCT01734434|9903463|FG003|Overall Study|Signed Adult Version of Consent Form|0
6229349|NCT01734434|9903460|FG000|Overall Study|Subject Not Reachable|0
6229350|NCT01734434|9903461|FG001|Overall Study|Subject Not Reachable|0
6229351|NCT01734434|9903462|FG002|Overall Study|Subject Not Reachable|1
6229352|NCT01734434|9903463|FG003|Overall Study|Subject Not Reachable|0
6229353|NCT01734434|9903460|FG000|Overall Study|Treatment Defaulter|0
6229354|NCT01734434|9903461|FG001|Overall Study|Treatment Defaulter|0
6229355|NCT01734434|9903462|FG002|Overall Study|Treatment Defaulter|1
6229356|NCT01734434|9903463|FG003|Overall Study|Treatment Defaulter|0
6229357|NCT01734434|9903460|FG000|Overall Study|Wrong Version of Consent Form Signed|0
6229358|NCT01734434|9903461|FG001|Overall Study|Wrong Version of Consent Form Signed|0
6229359|NCT01734434|9903462|FG002|Overall Study|Wrong Version of Consent Form Signed|1
6229360|NCT01734434|9903463|FG003|Overall Study|Wrong Version of Consent Form Signed|0
6229361|NCT01734434|9903460|FG000|Overall Study|17 Yr Old Subject Signed Consent form|0
6229362|NCT01734434|9903461|FG001|Overall Study|17 Yr Old Subject Signed Consent form|0
6229363|NCT01734434|9903462|FG002|Overall Study|17 Yr Old Subject Signed Consent form|1
6229364|NCT01734434|9903463|FG003|Overall Study|17 Yr Old Subject Signed Consent form|0
6229365|NCT01734772|9903512|FG000|Overall Study|Adverse Event|1
6229366|NCT01734772|9903513|FG001|Overall Study|Adverse Event|2
6229367|NCT01734772|9903512|FG000|Overall Study|Withdrawal by Subject|0
6229368|NCT01734772|9903513|FG001|Overall Study|Withdrawal by Subject|1
6229369|NCT01734785|9903528|FG000|Open-Label Period|Adverse Event|0
6229370|NCT01734785|9903529|FG001|Open-Label Period|Adverse Event|0
6229371|NCT01734785|9903530|FG002|Open-Label Period|Adverse Event|0
6229372|NCT01734785|9903531|FG003|Open-Label Period|Adverse Event|9
6229373|NCT01734785|9903528|FG000|Open-Label Period|Lack of Efficacy|0
6229374|NCT01734785|9903529|FG001|Open-Label Period|Lack of Efficacy|0
6229375|NCT01734785|9903530|FG002|Open-Label Period|Lack of Efficacy|0
6229376|NCT01734785|9903531|FG003|Open-Label Period|Lack of Efficacy|1
6229377|NCT01734785|9903528|FG000|Open-Label Period|Protocol Violation|0
6229378|NCT01734785|9903529|FG001|Open-Label Period|Protocol Violation|0
6229379|NCT01734785|9903530|FG002|Open-Label Period|Protocol Violation|0
6229380|NCT01734785|9903531|FG003|Open-Label Period|Protocol Violation|13
6229381|NCT01734785|9903528|FG000|Open-Label Period|Lost to Follow-up|0
6229382|NCT01734785|9903529|FG001|Open-Label Period|Lost to Follow-up|0
6229383|NCT01734785|9903530|FG002|Open-Label Period|Lost to Follow-up|0
6229384|NCT01734785|9903531|FG003|Open-Label Period|Lost to Follow-up|14
6229385|NCT01734785|9903528|FG000|Open-Label Period|Withdrawal by Subject|0
6229386|NCT01734785|9903529|FG001|Open-Label Period|Withdrawal by Subject|0
6229387|NCT01734785|9903530|FG002|Open-Label Period|Withdrawal by Subject|0
6229388|NCT01734785|9903531|FG003|Open-Label Period|Withdrawal by Subject|12
6229389|NCT01734785|9903528|FG000|Open-Label Period|Other Reasons|0
6229390|NCT01734785|9903529|FG001|Open-Label Period|Other Reasons|0
6229391|NCT01734785|9903530|FG002|Open-Label Period|Other Reasons|0
6229392|NCT01734785|9903531|FG003|Open-Label Period|Other Reasons|224
6229393|NCT01734785|9903528|FG000|Double-Blind Period|Adverse Event|0
6229394|NCT01734785|9903529|FG001|Double-Blind Period|Adverse Event|3
6229395|NCT01734785|9903530|FG002|Double-Blind Period|Adverse Event|2
6229396|NCT01734785|9903531|FG003|Double-Blind Period|Adverse Event|0
6229397|NCT01734785|9903528|FG000|Double-Blind Period|Lack of Efficacy|0
6229398|NCT01734785|9903529|FG001|Double-Blind Period|Lack of Efficacy|1
6229399|NCT01734785|9903530|FG002|Double-Blind Period|Lack of Efficacy|0
6229400|NCT01734785|9903531|FG003|Double-Blind Period|Lack of Efficacy|0
6229401|NCT01734785|9903528|FG000|Double-Blind Period|Protocol Violation|0
6229402|NCT01734785|9903529|FG001|Double-Blind Period|Protocol Violation|1
6229403|NCT01734785|9903530|FG002|Double-Blind Period|Protocol Violation|1
6229404|NCT01734785|9903531|FG003|Double-Blind Period|Protocol Violation|0
6229405|NCT01734785|9903528|FG000|Double-Blind Period|Lost to Follow-up|2
6229406|NCT01734785|9903529|FG001|Double-Blind Period|Lost to Follow-up|4
6229407|NCT01734785|9903530|FG002|Double-Blind Period|Lost to Follow-up|2
6229408|NCT01734785|9903531|FG003|Double-Blind Period|Lost to Follow-up|0
6229409|NCT01734785|9903528|FG000|Double-Blind Period|Withdrawal by Subject|2
6229410|NCT01734785|9903529|FG001|Double-Blind Period|Withdrawal by Subject|0
6229411|NCT01734785|9903530|FG002|Double-Blind Period|Withdrawal by Subject|0
6229412|NCT01734785|9903531|FG003|Double-Blind Period|Withdrawal by Subject|0
6229413|NCT01734785|9903528|FG000|Double-Blind Period|Not treated|1
6229414|NCT01734785|9903529|FG001|Double-Blind Period|Not treated|0
6229415|NCT01734785|9903530|FG002|Double-Blind Period|Not treated|0
6229416|NCT01734785|9903531|FG003|Double-Blind Period|Not treated|0
6229417|NCT01734811|9903542|FG000|Overall Study|Lost to Follow-up|2
6229418|NCT01734811|9903543|FG001|Overall Study|Lost to Follow-up|3
6229419|NCT01734811|9903542|FG000|Overall Study|Withdrawal by Subject|2
6229420|NCT01734811|9903543|FG001|Overall Study|Withdrawal by Subject|0
6229421|NCT01734850|9903552|FG000|Overall Study|Continued to Week 48 but recommenced ART|3
6229422|NCT01734850|9903553|FG001|Overall Study|Continued to Week 48 but recommenced ART|2
6229423|NCT01734850|9903554|FG002|Overall Study|Continued to Week 48 but recommenced ART|3
6229424|NCT01734850|9903552|FG000|Overall Study|Not infused due to manufacturing failure|0
6229425|NCT01734850|9903553|FG001|Overall Study|Not infused due to manufacturing failure|0
6229426|NCT01734850|9903554|FG002|Overall Study|Not infused due to manufacturing failure|1
6229427|NCT01734902|9903572|FG000|Overall Study|Other than listed|0
6229428|NCT01734902|9903573|FG001|Overall Study|Other than listed|2
6229429|NCT01734993|9903579|FG000|Overall Study|Adverse Event|1
6229430|NCT01734993|9903579|FG000|Overall Study|Lack of Efficacy|1
6229431|NCT01735175|9903586|FG000|Overall Study|Withdrawal by Subject|9
6229432|NCT01735175|9903587|FG001|Overall Study|Withdrawal by Subject|2
6229433|NCT01735175|9903586|FG000|Overall Study|Lost to Follow-up|4
6229434|NCT01735175|9903587|FG001|Overall Study|Lost to Follow-up|2
6229435|NCT01735175|9903586|FG000|Overall Study|Death|3
6229436|NCT01735175|9903587|FG001|Overall Study|Death|2
6229437|NCT01735175|9903586|FG000|Overall Study|Other (mostly EOS/EOT visit missing)|13
6229438|NCT01735175|9903587|FG001|Overall Study|Other (mostly EOS/EOT visit missing)|7
6229439|NCT01735201|9903601|FG000|Overall Study|Adverse Event|1
6229440|NCT01735201|9903602|FG001|Overall Study|Adverse Event|1
6229441|NCT01735201|9903603|FG002|Overall Study|Adverse Event|0
6229442|NCT01735201|9903604|FG003|Overall Study|Adverse Event|1
6229443|NCT01735201|9903605|FG004|Overall Study|Adverse Event|1
6229444|NCT01735201|9903606|FG005|Overall Study|Adverse Event|3
6229445|NCT01735201|9903607|FG006|Overall Study|Adverse Event|2
6229446|NCT01735201|9903608|FG007|Overall Study|Adverse Event|1
6229447|NCT01735201|9903601|FG000|Overall Study|Personal Reasons|1
6229448|NCT01735201|9903602|FG001|Overall Study|Personal Reasons|0
6229449|NCT01735201|9903603|FG002|Overall Study|Personal Reasons|0
6229450|NCT01735201|9903604|FG003|Overall Study|Personal Reasons|0
6229451|NCT01735201|9903605|FG004|Overall Study|Personal Reasons|0
6229452|NCT01735201|9903606|FG005|Overall Study|Personal Reasons|0
6229453|NCT01735201|9903607|FG006|Overall Study|Personal Reasons|0
6229454|NCT01735201|9903608|FG007|Overall Study|Personal Reasons|0
6229455|NCT01735201|9903601|FG000|Overall Study|Protocol Violation|1
6229456|NCT01735201|9903602|FG001|Overall Study|Protocol Violation|0
6229457|NCT01735201|9903603|FG002|Overall Study|Protocol Violation|0
6229458|NCT01735201|9903604|FG003|Overall Study|Protocol Violation|0
6229459|NCT01735201|9903605|FG004|Overall Study|Protocol Violation|0
6229460|NCT01735201|9903606|FG005|Overall Study|Protocol Violation|0
6229461|NCT01735201|9903607|FG006|Overall Study|Protocol Violation|0
6229462|NCT01735201|9903608|FG007|Overall Study|Protocol Violation|0
6229463|NCT01735201|9903601|FG000|Overall Study|Other Miscellaneous Reasons|0
6229464|NCT01735201|9903602|FG001|Overall Study|Other Miscellaneous Reasons|0
6229465|NCT01735201|9903603|FG002|Overall Study|Other Miscellaneous Reasons|0
6229466|NCT01735201|9903604|FG003|Overall Study|Other Miscellaneous Reasons|1
6229467|NCT01735201|9903605|FG004|Overall Study|Other Miscellaneous Reasons|0
6229468|NCT01735201|9903606|FG005|Overall Study|Other Miscellaneous Reasons|2
6229469|NCT01735201|9903607|FG006|Overall Study|Other Miscellaneous Reasons|1
6229470|NCT01735201|9903608|FG007|Overall Study|Other Miscellaneous Reasons|1
6229471|NCT01735279|9903632|FG000|Overall Study|Lost to Follow-up|11
6229472|NCT01735279|9903633|FG001|Overall Study|Lost to Follow-up|8
6229473|NCT01735396|9903639|FG000|Overall Study|not evaluable|1
6229474|NCT01735630|9903652|FG000|Overall Study|Adverse Event|8
6085412|NCT00652626|9694766|FG005|Initial Treatment Phase|Adverse Event|0
6085413|NCT00652626|9694767|FG006|Initial Treatment Phase|Adverse Event|0
6085414|NCT00652626|9694761|FG000|Initial Treatment Phase|Protocol Violation|0
6085415|NCT00652626|9694762|FG001|Initial Treatment Phase|Protocol Violation|0
6085416|NCT00652626|9694763|FG002|Initial Treatment Phase|Protocol Violation|0
6085417|NCT00652626|9694764|FG003|Initial Treatment Phase|Protocol Violation|1
6085418|NCT00652626|9694765|FG004|Initial Treatment Phase|Protocol Violation|0
6085419|NCT00652626|9694766|FG005|Initial Treatment Phase|Protocol Violation|0
6085420|NCT00652626|9694767|FG006|Initial Treatment Phase|Protocol Violation|0
6085421|NCT00652626|9694761|FG000|Initial Treatment Phase|Physician Decision|0
6085422|NCT00652626|9694762|FG001|Initial Treatment Phase|Physician Decision|0
6085423|NCT00652626|9694763|FG002|Initial Treatment Phase|Physician Decision|0
6085424|NCT00652626|9694764|FG003|Initial Treatment Phase|Physician Decision|0
6085425|NCT00652626|9694765|FG004|Initial Treatment Phase|Physician Decision|1
6085426|NCT00652626|9694766|FG005|Initial Treatment Phase|Physician Decision|0
6085427|NCT00652626|9694767|FG006|Initial Treatment Phase|Physician Decision|0
6085428|NCT00652626|9694761|FG000|Initial Treatment Phase|Sponsor Request|0
6085429|NCT00652626|9694762|FG001|Initial Treatment Phase|Sponsor Request|0
6085430|NCT00652626|9694763|FG002|Initial Treatment Phase|Sponsor Request|1
6229475|NCT01735630|9903653|FG001|Overall Study|Adverse Event|7
6229476|NCT01735630|9903652|FG000|Overall Study|Lost to Follow-up|1
6229477|NCT01735630|9903653|FG001|Overall Study|Lost to Follow-up|0
6229478|NCT01735630|9903652|FG000|Overall Study|Physician Decision|0
6229479|NCT01735630|9903653|FG001|Overall Study|Physician Decision|1
6229480|NCT01735630|9903652|FG000|Overall Study|Sponsor Decision|2
6229481|NCT01735630|9903653|FG001|Overall Study|Sponsor Decision|1
6229482|NCT01735630|9903652|FG000|Overall Study|Withdrawal by Subject|7
6229483|NCT01735630|9903653|FG001|Overall Study|Withdrawal by Subject|9
6229484|NCT01735916|9903671|FG000|Overall Study|Subject not eligible to be randomized|11
6229485|NCT01735916|9903672|FG001|Overall Study|Subject not eligible to be randomized|0
6229486|NCT01735916|9903673|FG002|Overall Study|Subject not eligible to be randomized|0
6229487|NCT01735916|9903671|FG000|Overall Study|Early termination of study by sponsor|4
6229488|NCT01735916|9903672|FG001|Overall Study|Early termination of study by sponsor|19
6229489|NCT01735916|9903673|FG002|Overall Study|Early termination of study by sponsor|7
6229490|NCT01735916|9903671|FG000|Overall Study|Withdrawal by Subject|3
6229491|NCT01735916|9903672|FG001|Overall Study|Withdrawal by Subject|0
6229492|NCT01735916|9903673|FG002|Overall Study|Withdrawal by Subject|0
6375457|NCT04075734|10165521|FG001|Overall Study|Withdrawal by Subject|0
6375458|NCT04075734|10165522|FG002|Overall Study|Withdrawal by Subject|0
6375459|NCT03633396|10165589|FG000|Overall Study|Withdrawal by Subject|4
6375460|NCT03633396|10165590|FG001|Overall Study|Withdrawal by Subject|4
6375461|NCT03633396|10165589|FG000|Overall Study|Adverse Event|1
6375462|NCT03633396|10165590|FG001|Overall Study|Adverse Event|1
6375463|NCT03633396|10165589|FG000|Overall Study|Lack of Efficacy|1
6375464|NCT03633396|10165590|FG001|Overall Study|Lack of Efficacy|0
6375465|NCT03633396|10165589|FG000|Overall Study|Coronavirus Disease 2019 (COVID-19) Restrictions|0
6375466|NCT03633396|10165590|FG001|Overall Study|Coronavirus Disease 2019 (COVID-19) Restrictions|1
6375467|NCT03612856|10165599|FG000|Pre-dose Period|Physician Decision|0
6375468|NCT03612856|10165600|FG001|Pre-dose Period|Physician Decision|1
6375469|NCT03612856|10165601|FG002|Pre-dose Period|Physician Decision|1
6375470|NCT03612856|10165599|FG000|Pre-dose Period|Withdrawal by Subject|0
6375471|NCT03612856|10165600|FG001|Pre-dose Period|Withdrawal by Subject|1
6375472|NCT03612856|10165601|FG002|Pre-dose Period|Withdrawal by Subject|0
6375473|NCT03607994|10165611|FG000|Overall Study|Discontinued intervention (started sessions and dropped out due to time commitment and schedule)|1
6375474|NCT03607994|10165612|FG001|Overall Study|Discontinued intervention (started sessions and dropped out due to time commitment and schedule)|1
6375475|NCT03150862|10165639|FG000|Overall Study|Death|2
6375476|NCT03150862|10165640|FG001|Overall Study|Death|7
6375477|NCT03150862|10165641|FG002|Overall Study|Death|8
6375478|NCT03150862|10165642|FG003|Overall Study|Death|27
6375479|NCT03150862|10165643|FG004|Overall Study|Death|4
6375480|NCT03150862|10165644|FG005|Overall Study|Death|8
6375481|NCT03150862|10165645|FG006|Overall Study|Death|6
6375482|NCT03150862|10165646|FG007|Overall Study|Death|21
6375483|NCT03150862|10165639|FG000|Overall Study|Withdrawal by Subject|1
6375484|NCT03150862|10165640|FG001|Overall Study|Withdrawal by Subject|1
6375485|NCT03150862|10165641|FG002|Overall Study|Withdrawal by Subject|0
6375486|NCT03150862|10165642|FG003|Overall Study|Withdrawal by Subject|3
6375487|NCT03150862|10165643|FG004|Overall Study|Withdrawal by Subject|1
6375488|NCT03150862|10165644|FG005|Overall Study|Withdrawal by Subject|1
6375489|NCT03150862|10165645|FG006|Overall Study|Withdrawal by Subject|1
6375490|NCT03150862|10165646|FG007|Overall Study|Withdrawal by Subject|3
6085431|NCT00652626|9694764|FG003|Initial Treatment Phase|Sponsor Request|0
6085432|NCT00652626|9694765|FG004|Initial Treatment Phase|Sponsor Request|0
6085433|NCT00652626|9694766|FG005|Initial Treatment Phase|Sponsor Request|0
6229493|NCT01735994|9903693|FG000|Overall Study|Withdrawal by Subject|6
6229494|NCT01735994|9903694|FG001|Overall Study|Withdrawal by Subject|4
6375491|NCT03150862|10165639|FG000|Overall Study|Lost to Follow-up|0
6375492|NCT03150862|10165640|FG001|Overall Study|Lost to Follow-up|0
6375493|NCT03150862|10165641|FG002|Overall Study|Lost to Follow-up|1
6229495|NCT01735994|9903693|FG000|Overall Study|Injury|2
6229496|NCT01735994|9903694|FG001|Overall Study|Injury|0
6229497|NCT01735994|9903693|FG000|Overall Study|Kicked off team|5
6229498|NCT01735994|9903694|FG001|Overall Study|Kicked off team|0
6229499|NCT01735994|9903693|FG000|Overall Study|Lost to Follow-up|50
6229500|NCT01735994|9903694|FG001|Overall Study|Lost to Follow-up|62
6229501|NCT01736124|9903724|FG000|Post-intervention Assessment|Death|2
6229502|NCT01736124|9903725|FG001|Post-intervention Assessment|Death|2
6229503|NCT01736124|9903724|FG000|Post-intervention Assessment|lost computer access|1
6229504|NCT01736124|9903725|FG001|Post-intervention Assessment|lost computer access|1
6229505|NCT01736124|9903724|FG000|Post-intervention Assessment|Moved away|3
6229506|NCT01736124|9903725|FG001|Post-intervention Assessment|Moved away|1
6229507|NCT01736124|9903724|FG000|Post-intervention Assessment|Withdrawal by Subject|11
6229508|NCT01736124|9903725|FG001|Post-intervention Assessment|Withdrawal by Subject|9
6229509|NCT01736124|9903724|FG000|Post-intervention Assessment|Illness|3
6229510|NCT01736124|9903725|FG001|Post-intervention Assessment|Illness|2
6229511|NCT01736124|9903724|FG000|Post-intervention Assessment|Lost to Follow-up|8
6229512|NCT01736124|9903725|FG001|Post-intervention Assessment|Lost to Follow-up|5
6229513|NCT01736124|9903724|FG000|Post-intervention Assessment|Temporarily away|3
6229514|NCT01736124|9903725|FG001|Post-intervention Assessment|Temporarily away|1
6229515|NCT01736124|9903724|FG000|6 Mo. Post-Intervention Assessment|Death|0
6229516|NCT01736124|9903725|FG001|6 Mo. Post-Intervention Assessment|Death|1
6229517|NCT01736124|9903724|FG000|6 Mo. Post-Intervention Assessment|Moved away|0
6229518|NCT01736124|9903725|FG001|6 Mo. Post-Intervention Assessment|Moved away|2
6229519|NCT01736124|9903724|FG000|6 Mo. Post-Intervention Assessment|Withdrawal by Subject|3
6229520|NCT01736124|9903725|FG001|6 Mo. Post-Intervention Assessment|Withdrawal by Subject|3
6229521|NCT01736124|9903724|FG000|6 Mo. Post-Intervention Assessment|Illness|1
6229522|NCT01736124|9903725|FG001|6 Mo. Post-Intervention Assessment|Illness|2
6229523|NCT01736124|9903724|FG000|6 Mo. Post-Intervention Assessment|Temporarily away|1
6229524|NCT01736124|9903725|FG001|6 Mo. Post-Intervention Assessment|Temporarily away|4
6229525|NCT01736124|9903724|FG000|12 Mo. Post-Intervention Assessment|Death|1
6229526|NCT01736124|9903725|FG001|12 Mo. Post-Intervention Assessment|Death|0
6229527|NCT01736124|9903724|FG000|12 Mo. Post-Intervention Assessment|Moved away|1
6229528|NCT01736124|9903725|FG001|12 Mo. Post-Intervention Assessment|Moved away|0
6229529|NCT01736124|9903724|FG000|12 Mo. Post-Intervention Assessment|Withdrawal by Subject|0
6229530|NCT01736124|9903725|FG001|12 Mo. Post-Intervention Assessment|Withdrawal by Subject|2
6229531|NCT01736124|9903724|FG000|12 Mo. Post-Intervention Assessment|End of study|10
6229532|NCT01736124|9903725|FG001|12 Mo. Post-Intervention Assessment|End of study|10
6229533|NCT01736176|9903733|FG000|Overall Study|Adverse Event|3
6229534|NCT01736176|9903733|FG000|Overall Study|Withdrawal by Subject|4
6229535|NCT01736176|9903733|FG000|Overall Study|Lack of Efficacy|3
6229536|NCT01736176|9903733|FG000|Overall Study|Unable to Complete PEG Placement|1
6229537|NCT01736189|9903741|FG000|Overall Study|Violation of registration criteria|41
6229538|NCT01736189|9903741|FG000|Overall Study|Protocol Violation|4
6229539|NCT01736189|9903741|FG000|Overall Study|Criteria and protocol violations|1
6229540|NCT01736215|9903745|FG000|Overall Study|Early termination of erythropoietin use|1
6229541|NCT01736215|9903745|FG000|Overall Study|Adverse Event|4
6229542|NCT01736215|9903745|FG000|Overall Study|Progressive disease stop chemotherapy|1
6229543|NCT01736215|9903745|FG000|Overall Study|Insufficient data to perform analysis|8
6229544|NCT01736254|9903779|FG000|Period 2 (Days 2 to 12)|Adverse Event|3
6229545|NCT01736254|9903779|FG000|Period 3 (Days 13 to 23)|Adverse Event|1
6229546|NCT01736397|9903802|FG000|Overall Study|Lack of Efficacy|1
6229547|NCT01736397|9903803|FG001|Overall Study|Lack of Efficacy|11
6229548|NCT01736397|9903802|FG000|Overall Study|Withdrawal by Subject|6
6229549|NCT01736397|9903803|FG001|Overall Study|Withdrawal by Subject|5
6229550|NCT01736397|9903802|FG000|Overall Study|Lost to Follow-up|0
6229551|NCT01736397|9903803|FG001|Overall Study|Lost to Follow-up|1
6229552|NCT01736397|9903802|FG000|Overall Study|Adverse Event|6
6229553|NCT01736397|9903803|FG001|Overall Study|Adverse Event|3
6229554|NCT01736397|9903802|FG000|Overall Study|Not stated|1
6229555|NCT01736397|9903803|FG001|Overall Study|Not stated|4
6229556|NCT01736475|9903811|FG000|Overall Study|Adverse Event|4
6229557|NCT01736475|9903812|FG001|Overall Study|Adverse Event|0
6229558|NCT01736475|9903811|FG000|Overall Study|Withdrawal by Subject|2
6375494|NCT03150862|10165642|FG003|Overall Study|Lost to Follow-up|0
6375495|NCT03150862|10165643|FG004|Overall Study|Lost to Follow-up|0
6375496|NCT03150862|10165644|FG005|Overall Study|Lost to Follow-up|0
6375497|NCT03150862|10165645|FG006|Overall Study|Lost to Follow-up|0
6375498|NCT03150862|10165646|FG007|Overall Study|Lost to Follow-up|2
6375499|NCT03150862|10165639|FG000|Overall Study|Sponsor's decision|0
6375500|NCT03150862|10165640|FG001|Overall Study|Sponsor's decision|0
6375501|NCT03150862|10165641|FG002|Overall Study|Sponsor's decision|0
6375502|NCT03150862|10165642|FG003|Overall Study|Sponsor's decision|10
6375503|NCT03150862|10165643|FG004|Overall Study|Sponsor's decision|3
6375504|NCT03150862|10165644|FG005|Overall Study|Sponsor's decision|0
6375505|NCT03150862|10165645|FG006|Overall Study|Sponsor's decision|1
6375506|NCT03150862|10165646|FG007|Overall Study|Sponsor's decision|1
6229559|NCT01736475|9903812|FG001|Overall Study|Withdrawal by Subject|0
6229560|NCT01736475|9903811|FG000|Overall Study|Protocol Violation|4
6229561|NCT01736475|9903812|FG001|Overall Study|Protocol Violation|0
6229562|NCT01736475|9903811|FG000|Overall Study|Other - Screen failure|1
6229563|NCT01736475|9903812|FG001|Overall Study|Other - Screen failure|0
6229564|NCT01736475|9903811|FG000|Overall Study|Other - Surgical procedure|1
6229565|NCT01736475|9903812|FG001|Overall Study|Other - Surgical procedure|0
6229566|NCT01736540|9903833|FG000|Overall Study|Did not complete scan within 45 days|2
6229567|NCT01736540|9903833|FG000|Overall Study|Death|1
6229568|NCT01736540|9903833|FG000|Overall Study|Abnormal test procedure|1
6229569|NCT01736540|9903833|FG000|Overall Study|Withdrawal by Subject|5
6229570|NCT01736540|9903833|FG000|Overall Study|Protocol Violation|1
6229571|NCT01736540|9903833|FG000|Overall Study|Unable to tolerate MRI; claustrophobic|1
6229572|NCT01736540|9903833|FG000|Overall Study|No show for MRI appointment|1
6229573|NCT01736540|9903833|FG000|Overall Study|Unable to make MRI appointment|3
6229574|NCT01736553|9903846|FG000|Overall Study|Death|12
6229575|NCT01736553|9903847|FG001|Overall Study|Death|0
6229576|NCT01736553|9903846|FG000|Overall Study|Withdrawal by Subject|5
6229577|NCT01736553|9903847|FG001|Overall Study|Withdrawal by Subject|2
6229578|NCT01736553|9903846|FG000|Overall Study|Lost to Follow-up|2
6229579|NCT01736553|9903847|FG001|Overall Study|Lost to Follow-up|2
6229580|NCT01736566|9903876|FG000|Long Term Follow-up|Still collecting data|42
6229581|NCT01736566|9903877|FG001|Long Term Follow-up|Still collecting data|0
6229582|NCT01736566|9903878|FG002|Long Term Follow-up|Still collecting data|49
6229583|NCT01736566|9903879|FG003|Long Term Follow-up|Still collecting data|0
6229584|NCT01736566|9903880|FG004|Long Term Follow-up|Still collecting data|1
6229585|NCT01736579|9903907|FG000|Overall Study|Termination of Study by Sponsor|2
6229586|NCT01736579|9903908|FG001|Overall Study|Termination of Study by Sponsor|2
6229587|NCT01736657|9903914|FG000|Overall Study|insufficient vascular access|1
6229588|NCT01736683|9903923|FG000|Overall Study|Disease Relapse|0
6229589|NCT01736683|9903924|FG001|Overall Study|Disease Relapse|0
6229590|NCT01736683|9903925|FG002|Overall Study|Disease Relapse|2
6229591|NCT01736683|9903926|FG003|Overall Study|Disease Relapse|1
6229592|NCT01736683|9903927|FG004|Overall Study|Disease Relapse|0
6229593|NCT01736683|9903923|FG000|Overall Study|Adverse Event|0
6229594|NCT01736683|9903924|FG001|Overall Study|Adverse Event|2
6229595|NCT01736683|9903925|FG002|Overall Study|Adverse Event|2
6229596|NCT01736683|9903926|FG003|Overall Study|Adverse Event|3
6229597|NCT01736683|9903927|FG004|Overall Study|Adverse Event|2
6229598|NCT01736683|9903923|FG000|Overall Study|Withdrawal by Subject|0
6229599|NCT01736683|9903924|FG001|Overall Study|Withdrawal by Subject|0
6229600|NCT01736683|9903925|FG002|Overall Study|Withdrawal by Subject|3
6229601|NCT01736683|9903926|FG003|Overall Study|Withdrawal by Subject|1
6229602|NCT01736683|9903927|FG004|Overall Study|Withdrawal by Subject|1
6229603|NCT01736683|9903923|FG000|Overall Study|Lack of Therapeutic Effect|7
6229604|NCT01736683|9903924|FG001|Overall Study|Lack of Therapeutic Effect|4
6229605|NCT01736683|9903925|FG002|Overall Study|Lack of Therapeutic Effect|13
6229606|NCT01736683|9903926|FG003|Overall Study|Lack of Therapeutic Effect|20
6229607|NCT01736683|9903927|FG004|Overall Study|Lack of Therapeutic Effect|1
6229608|NCT01736683|9903923|FG000|Overall Study|Progressive Disease|0
6229609|NCT01736683|9903924|FG001|Overall Study|Progressive Disease|0
6229610|NCT01736683|9903925|FG002|Overall Study|Progressive Disease|0
6229611|NCT01736683|9903926|FG003|Overall Study|Progressive Disease|1
6229612|NCT01736683|9903927|FG004|Overall Study|Progressive Disease|0
6229613|NCT01736683|9903923|FG000|Overall Study|Other|0
6229614|NCT01736683|9903924|FG001|Overall Study|Other|0
6229615|NCT01736683|9903925|FG002|Overall Study|Other|1
6229616|NCT01736683|9903926|FG003|Overall Study|Other|9
6229617|NCT01736683|9903927|FG004|Overall Study|Other|1
6229618|NCT01736696|9903948|FG000|Overall Study|Withdrawal by Subject|0
6229619|NCT01736696|9903949|FG001|Overall Study|Withdrawal by Subject|0
6229620|NCT01736696|9903950|FG002|Overall Study|Withdrawal by Subject|1
6229621|NCT01736696|9903951|FG003|Overall Study|Withdrawal by Subject|0
6229622|NCT01736696|9903952|FG004|Overall Study|Withdrawal by Subject|0
6229623|NCT01736696|9903953|FG005|Overall Study|Withdrawal by Subject|0
6229624|NCT01736696|9903954|FG006|Overall Study|Withdrawal by Subject|0
6229625|NCT01736917|9903996|FG000|Overall Study|Adverse Event|1
6229626|NCT01736917|9903996|FG000|Overall Study|Protocol Violation|10
6229627|NCT01737268|9904012|FG000|Overall Study|Adverse Event|6
6229628|NCT01737268|9904012|FG000|Overall Study|Worsening of Target Disease|2
6229629|NCT01737268|9904012|FG000|Overall Study|In consideration of the patient's safety|1
6269729|NCT02143713|9970157|FG001|Treatment Period (6 Months)|Withdrawal by Subject|2
6269730|NCT02143713|9970158|FG002|Treatment Period (6 Months)|Withdrawal by Subject|5
6269731|NCT02143713|9970159|FG003|Treatment Period (6 Months)|Withdrawal by Subject|4
6269732|NCT02143713|9970156|FG000|Treatment Period (6 Months)|Adverse Event|7
6269733|NCT02143713|9970157|FG001|Treatment Period (6 Months)|Adverse Event|8
6269734|NCT02143713|9970158|FG002|Treatment Period (6 Months)|Adverse Event|8
6269735|NCT02143713|9970159|FG003|Treatment Period (6 Months)|Adverse Event|9
6269736|NCT02143713|9970156|FG000|Treatment Period (6 Months)|Lost to Follow-up|3
6269737|NCT02143713|9970157|FG001|Treatment Period (6 Months)|Lost to Follow-up|0
6269738|NCT02143713|9970158|FG002|Treatment Period (6 Months)|Lost to Follow-up|4
6269739|NCT02143713|9970159|FG003|Treatment Period (6 Months)|Lost to Follow-up|3
6269740|NCT02143713|9970156|FG000|Treatment Period (6 Months)|Surgery or Invasive Intervention|2
6229630|NCT01737398|9904028|FG000|Overall Study|Adverse event or SAE|16
6229631|NCT01737398|9904029|FG001|Overall Study|Adverse event or SAE|1
6229632|NCT01737398|9904028|FG000|Overall Study|Stopping rule met|2
6229633|NCT01737398|9904029|FG001|Overall Study|Stopping rule met|1
6229634|NCT01737398|9904028|FG000|Overall Study|Voluntary withdrawal|2
6229635|NCT01737398|9904029|FG001|Overall Study|Voluntary withdrawal|3
6229636|NCT01737398|9904028|FG000|Overall Study|Ineligibility|1
6229637|NCT01737398|9904029|FG001|Overall Study|Ineligibility|0
6229638|NCT01737398|9904028|FG000|Overall Study|Liver transplant|1
6229639|NCT01737398|9904029|FG001|Overall Study|Liver transplant|0
6229640|NCT01737398|9904028|FG000|Overall Study|Disease progression|2
6229641|NCT01737398|9904029|FG001|Overall Study|Disease progression|3
6229642|NCT01737398|9904028|FG000|Overall Study|Sponsor's decision|2
6229643|NCT01737398|9904029|FG001|Overall Study|Sponsor's decision|0
6229644|NCT01737697|9904069|FG000|Acute Phase-Initial 48 Hours|Adverse Event|0
6229645|NCT01737697|9904070|FG001|Acute Phase-Initial 48 Hours|Adverse Event|1
6229646|NCT01737697|9904071|FG002|Acute Phase-Initial 48 Hours|Adverse Event|0
6229647|NCT01737697|9904072|FG003|Acute Phase-Initial 48 Hours|Adverse Event|1
6229648|NCT01737697|9904073|FG004|Acute Phase-Initial 48 Hours|Adverse Event|1
6229649|NCT01737697|9904074|FG005|Acute Phase-Initial 48 Hours|Adverse Event|0
6229650|NCT01737697|9904075|FG006|Acute Phase-Initial 48 Hours|Adverse Event|0
6229651|NCT01737697|9904076|FG007|Acute Phase-Initial 48 Hours|Adverse Event|0
6229652|NCT01737697|9904077|FG008|Acute Phase-Initial 48 Hours|Adverse Event|0
6229653|NCT01737697|9904078|FG009|Acute Phase-Initial 48 Hours|Adverse Event|0
6229654|NCT01737697|9904079|FG010|Acute Phase-Initial 48 Hours|Adverse Event|0
6229655|NCT01737697|9904080|FG011|Acute Phase-Initial 48 Hours|Adverse Event|0
6229656|NCT01737697|9904081|FG012|Acute Phase-Initial 48 Hours|Adverse Event|0
6229657|NCT01737697|9904082|FG013|Acute Phase-Initial 48 Hours|Adverse Event|0
6229658|NCT01737697|9904083|FG014|Acute Phase-Initial 48 Hours|Adverse Event|0
6229659|NCT01737697|9904069|FG000|Acute Phase-Initial 48 Hours|hypo-or hyperkalemia|1
6229660|NCT01737697|9904070|FG001|Acute Phase-Initial 48 Hours|hypo-or hyperkalemia|1
6229661|NCT01737697|9904071|FG002|Acute Phase-Initial 48 Hours|hypo-or hyperkalemia|3
6229662|NCT01737697|9904072|FG003|Acute Phase-Initial 48 Hours|hypo-or hyperkalemia|0
6229663|NCT01737697|9904073|FG004|Acute Phase-Initial 48 Hours|hypo-or hyperkalemia|0
6229664|NCT01737697|9904074|FG005|Acute Phase-Initial 48 Hours|hypo-or hyperkalemia|0
6229665|NCT01737697|9904075|FG006|Acute Phase-Initial 48 Hours|hypo-or hyperkalemia|0
6229666|NCT01737697|9904076|FG007|Acute Phase-Initial 48 Hours|hypo-or hyperkalemia|0
6229667|NCT01737697|9904077|FG008|Acute Phase-Initial 48 Hours|hypo-or hyperkalemia|0
6229668|NCT01737697|9904078|FG009|Acute Phase-Initial 48 Hours|hypo-or hyperkalemia|0
6229669|NCT01737697|9904079|FG010|Acute Phase-Initial 48 Hours|hypo-or hyperkalemia|0
6229670|NCT01737697|9904080|FG011|Acute Phase-Initial 48 Hours|hypo-or hyperkalemia|0
6229671|NCT01737697|9904081|FG012|Acute Phase-Initial 48 Hours|hypo-or hyperkalemia|0
6229672|NCT01737697|9904082|FG013|Acute Phase-Initial 48 Hours|hypo-or hyperkalemia|0
6229673|NCT01737697|9904083|FG014|Acute Phase-Initial 48 Hours|hypo-or hyperkalemia|0
6229674|NCT01737697|9904069|FG000|Acute Phase-Initial 48 Hours|Family emergency|0
6229675|NCT01737697|9904070|FG001|Acute Phase-Initial 48 Hours|Family emergency|0
6229676|NCT01737697|9904071|FG002|Acute Phase-Initial 48 Hours|Family emergency|0
6229677|NCT01737697|9904072|FG003|Acute Phase-Initial 48 Hours|Family emergency|1
6229678|NCT01737697|9904073|FG004|Acute Phase-Initial 48 Hours|Family emergency|0
6229679|NCT01737697|9904074|FG005|Acute Phase-Initial 48 Hours|Family emergency|0
6229680|NCT01737697|9904075|FG006|Acute Phase-Initial 48 Hours|Family emergency|0
6186959|NCT01377012|9840562|FG000|Extension Study, Weeks 104-260|Adverse Event|0
6186960|NCT01377012|9840563|FG001|Extension Study, Weeks 104-260|Adverse Event|2
6186961|NCT01377012|9840564|FG002|Extension Study, Weeks 104-260|Adverse Event|1
6186962|NCT01377194|9840575|FG000|Overall Study|Adverse Event|3
6186963|NCT01377194|9840576|FG001|Overall Study|Adverse Event|12
6186964|NCT01377194|9840577|FG002|Overall Study|Adverse Event|19
6186965|NCT01377194|9840575|FG000|Overall Study|Lack of Efficacy|3
6186966|NCT01377194|9840576|FG001|Overall Study|Lack of Efficacy|3
6186967|NCT01377194|9840577|FG002|Overall Study|Lack of Efficacy|3
6186968|NCT01377194|9840575|FG000|Overall Study|Protocol Violation|4
6229681|NCT01737697|9904076|FG007|Acute Phase-Initial 48 Hours|Family emergency|0
6229682|NCT01737697|9904077|FG008|Acute Phase-Initial 48 Hours|Family emergency|0
6229683|NCT01737697|9904078|FG009|Acute Phase-Initial 48 Hours|Family emergency|0
6229684|NCT01737697|9904079|FG010|Acute Phase-Initial 48 Hours|Family emergency|0
6229685|NCT01737697|9904080|FG011|Acute Phase-Initial 48 Hours|Family emergency|0
6229686|NCT01737697|9904081|FG012|Acute Phase-Initial 48 Hours|Family emergency|0
6229687|NCT01737697|9904082|FG013|Acute Phase-Initial 48 Hours|Family emergency|0
6229688|NCT01737697|9904083|FG014|Acute Phase-Initial 48 Hours|Family emergency|0
6229689|NCT01737697|9904069|FG000|Acute Phase-Initial 48 Hours|Sponsor's decision|0
6229690|NCT01737697|9904070|FG001|Acute Phase-Initial 48 Hours|Sponsor's decision|1
6229691|NCT01737697|9904071|FG002|Acute Phase-Initial 48 Hours|Sponsor's decision|0
6229692|NCT01737697|9904072|FG003|Acute Phase-Initial 48 Hours|Sponsor's decision|0
6229693|NCT01737697|9904073|FG004|Acute Phase-Initial 48 Hours|Sponsor's decision|0
6229694|NCT01737697|9904074|FG005|Acute Phase-Initial 48 Hours|Sponsor's decision|0
6229695|NCT01737697|9904075|FG006|Acute Phase-Initial 48 Hours|Sponsor's decision|0
6229696|NCT01737697|9904076|FG007|Acute Phase-Initial 48 Hours|Sponsor's decision|0
6186969|NCT01377194|9840576|FG001|Overall Study|Protocol Violation|10
6229697|NCT01737697|9904077|FG008|Acute Phase-Initial 48 Hours|Sponsor's decision|0
6229698|NCT01737697|9904078|FG009|Acute Phase-Initial 48 Hours|Sponsor's decision|0
6229699|NCT01737697|9904079|FG010|Acute Phase-Initial 48 Hours|Sponsor's decision|0
6229700|NCT01737697|9904080|FG011|Acute Phase-Initial 48 Hours|Sponsor's decision|0
6229701|NCT01737697|9904081|FG012|Acute Phase-Initial 48 Hours|Sponsor's decision|0
6229702|NCT01737697|9904082|FG013|Acute Phase-Initial 48 Hours|Sponsor's decision|0
6229703|NCT01737697|9904083|FG014|Acute Phase-Initial 48 Hours|Sponsor's decision|0
6229704|NCT01737697|9904069|FG000|Acute Phase-Initial 48 Hours|Lost to Follow-up|0
6229705|NCT01737697|9904070|FG001|Acute Phase-Initial 48 Hours|Lost to Follow-up|0
6229706|NCT01737697|9904071|FG002|Acute Phase-Initial 48 Hours|Lost to Follow-up|0
6229707|NCT01737697|9904072|FG003|Acute Phase-Initial 48 Hours|Lost to Follow-up|0
6229708|NCT01737697|9904073|FG004|Acute Phase-Initial 48 Hours|Lost to Follow-up|1
6229709|NCT01737697|9904074|FG005|Acute Phase-Initial 48 Hours|Lost to Follow-up|0
6229710|NCT01737697|9904075|FG006|Acute Phase-Initial 48 Hours|Lost to Follow-up|0
6229711|NCT01737697|9904076|FG007|Acute Phase-Initial 48 Hours|Lost to Follow-up|0
6229712|NCT01737697|9904077|FG008|Acute Phase-Initial 48 Hours|Lost to Follow-up|0
6229713|NCT01737697|9904078|FG009|Acute Phase-Initial 48 Hours|Lost to Follow-up|0
6229714|NCT01737697|9904079|FG010|Acute Phase-Initial 48 Hours|Lost to Follow-up|0
6229715|NCT01737697|9904080|FG011|Acute Phase-Initial 48 Hours|Lost to Follow-up|0
6229716|NCT01737697|9904081|FG012|Acute Phase-Initial 48 Hours|Lost to Follow-up|0
6229717|NCT01737697|9904082|FG013|Acute Phase-Initial 48 Hours|Lost to Follow-up|0
6229718|NCT01737697|9904083|FG014|Acute Phase-Initial 48 Hours|Lost to Follow-up|0
6229719|NCT01737697|9904069|FG000|Acute Phase-Initial 48 Hours|Withdrawal by Subject|0
6229720|NCT01737697|9904070|FG001|Acute Phase-Initial 48 Hours|Withdrawal by Subject|1
6229721|NCT01737697|9904071|FG002|Acute Phase-Initial 48 Hours|Withdrawal by Subject|1
6229722|NCT01737697|9904072|FG003|Acute Phase-Initial 48 Hours|Withdrawal by Subject|4
6229723|NCT01737697|9904073|FG004|Acute Phase-Initial 48 Hours|Withdrawal by Subject|1
6229724|NCT01737697|9904074|FG005|Acute Phase-Initial 48 Hours|Withdrawal by Subject|0
6229725|NCT01737697|9904075|FG006|Acute Phase-Initial 48 Hours|Withdrawal by Subject|0
6229726|NCT01737697|9904076|FG007|Acute Phase-Initial 48 Hours|Withdrawal by Subject|0
6229727|NCT01737697|9904077|FG008|Acute Phase-Initial 48 Hours|Withdrawal by Subject|0
6229728|NCT01737697|9904078|FG009|Acute Phase-Initial 48 Hours|Withdrawal by Subject|0
6229729|NCT01737697|9904079|FG010|Acute Phase-Initial 48 Hours|Withdrawal by Subject|0
6229730|NCT01737697|9904080|FG011|Acute Phase-Initial 48 Hours|Withdrawal by Subject|0
6229731|NCT01737697|9904081|FG012|Acute Phase-Initial 48 Hours|Withdrawal by Subject|0
6229732|NCT01737697|9904082|FG013|Acute Phase-Initial 48 Hours|Withdrawal by Subject|0
6229733|NCT01737697|9904083|FG014|Acute Phase-Initial 48 Hours|Withdrawal by Subject|0
6229734|NCT01737697|9904069|FG000|Subacute Phase|Adverse Event|0
6229735|NCT01737697|9904070|FG001|Subacute Phase|Adverse Event|0
6229736|NCT01737697|9904071|FG002|Subacute Phase|Adverse Event|0
6229737|NCT01737697|9904072|FG003|Subacute Phase|Adverse Event|0
6229738|NCT01737697|9904073|FG004|Subacute Phase|Adverse Event|0
6229739|NCT01737697|9904074|FG005|Subacute Phase|Adverse Event|1
6186970|NCT01377194|9840577|FG002|Overall Study|Protocol Violation|6
6186971|NCT01377194|9840575|FG000|Overall Study|Withdrawal by Subject|8
6186972|NCT01377194|9840576|FG001|Overall Study|Withdrawal by Subject|10
6186973|NCT01377194|9840577|FG002|Overall Study|Withdrawal by Subject|7
6186974|NCT01377194|9840575|FG000|Overall Study|Lost to Follow-up|14
6186975|NCT01377194|9840576|FG001|Overall Study|Lost to Follow-up|8
6186976|NCT01377194|9840577|FG002|Overall Study|Lost to Follow-up|11
6186977|NCT01377233|9840593|FG000|Open-label|Adverse Event|1
6186978|NCT01377233|9840594|FG001|Open-label|Adverse Event|0
6186979|NCT01377233|9840595|FG002|Open-label|Adverse Event|0
6186980|NCT01377233|9840596|FG003|Open-label|Adverse Event|0
6186981|NCT01377233|9840597|FG004|Open-label|Adverse Event|0
6186982|NCT01377233|9840593|FG000|Open-label|Withdrawal by Subject|3
6186983|NCT01377233|9840594|FG001|Open-label|Withdrawal by Subject|0
6186984|NCT01377233|9840595|FG002|Open-label|Withdrawal by Subject|0
6186985|NCT01377233|9840596|FG003|Open-label|Withdrawal by Subject|0
6186986|NCT01377233|9840597|FG004|Open-label|Withdrawal by Subject|0
6186987|NCT01377233|9840593|FG000|Double-blind|Adverse Event|0
6186988|NCT01377233|9840594|FG001|Double-blind|Adverse Event|1
6186989|NCT01377233|9840595|FG002|Double-blind|Adverse Event|2
6186990|NCT01377233|9840596|FG003|Double-blind|Adverse Event|2
6186991|NCT01377233|9840597|FG004|Double-blind|Adverse Event|0
6186992|NCT01377233|9840593|FG000|Double-blind|Protocol Violation|0
6186993|NCT01377233|9840594|FG001|Double-blind|Protocol Violation|0
6229740|NCT01737697|9904075|FG006|Subacute Phase|Adverse Event|1
6229741|NCT01737697|9904076|FG007|Subacute Phase|Adverse Event|1
6229742|NCT01737697|9904077|FG008|Subacute Phase|Adverse Event|1
6229743|NCT01737697|9904078|FG009|Subacute Phase|Adverse Event|1
6229744|NCT01737697|9904079|FG010|Subacute Phase|Adverse Event|4
6229745|NCT01737697|9904080|FG011|Subacute Phase|Adverse Event|1
6186994|NCT01377233|9840595|FG002|Double-blind|Protocol Violation|0
6186995|NCT01377233|9840596|FG003|Double-blind|Protocol Violation|0
6186996|NCT01377233|9840597|FG004|Double-blind|Protocol Violation|1
6229746|NCT01737697|9904081|FG012|Subacute Phase|Adverse Event|1
6229747|NCT01737697|9904082|FG013|Subacute Phase|Adverse Event|0
6229748|NCT01737697|9904083|FG014|Subacute Phase|Adverse Event|0
6229749|NCT01737697|9904069|FG000|Subacute Phase|Withdrawal by Subject|0
6229750|NCT01737697|9904070|FG001|Subacute Phase|Withdrawal by Subject|0
6229751|NCT01737697|9904071|FG002|Subacute Phase|Withdrawal by Subject|0
6229752|NCT01737697|9904072|FG003|Subacute Phase|Withdrawal by Subject|0
6229753|NCT01737697|9904073|FG004|Subacute Phase|Withdrawal by Subject|0
6229754|NCT01737697|9904074|FG005|Subacute Phase|Withdrawal by Subject|1
6229755|NCT01737697|9904075|FG006|Subacute Phase|Withdrawal by Subject|0
6229756|NCT01737697|9904076|FG007|Subacute Phase|Withdrawal by Subject|2
6229757|NCT01737697|9904077|FG008|Subacute Phase|Withdrawal by Subject|0
6229758|NCT01737697|9904078|FG009|Subacute Phase|Withdrawal by Subject|1
6229759|NCT01737697|9904079|FG010|Subacute Phase|Withdrawal by Subject|0
6229760|NCT01737697|9904080|FG011|Subacute Phase|Withdrawal by Subject|1
6229761|NCT01737697|9904081|FG012|Subacute Phase|Withdrawal by Subject|1
6229762|NCT01737697|9904082|FG013|Subacute Phase|Withdrawal by Subject|1
6229763|NCT01737697|9904083|FG014|Subacute Phase|Withdrawal by Subject|0
6229764|NCT01737697|9904069|FG000|Subacute Phase|Lost to Follow-up|0
6229765|NCT01737697|9904070|FG001|Subacute Phase|Lost to Follow-up|0
6229766|NCT01737697|9904071|FG002|Subacute Phase|Lost to Follow-up|0
6229767|NCT01737697|9904072|FG003|Subacute Phase|Lost to Follow-up|0
6229768|NCT01737697|9904073|FG004|Subacute Phase|Lost to Follow-up|0
6229769|NCT01737697|9904074|FG005|Subacute Phase|Lost to Follow-up|0
6229770|NCT01737697|9904075|FG006|Subacute Phase|Lost to Follow-up|0
6229771|NCT01737697|9904076|FG007|Subacute Phase|Lost to Follow-up|0
6229772|NCT01737697|9904077|FG008|Subacute Phase|Lost to Follow-up|0
6229773|NCT01737697|9904078|FG009|Subacute Phase|Lost to Follow-up|0
6229774|NCT01737697|9904079|FG010|Subacute Phase|Lost to Follow-up|0
6229775|NCT01737697|9904080|FG011|Subacute Phase|Lost to Follow-up|0
6229776|NCT01737697|9904081|FG012|Subacute Phase|Lost to Follow-up|0
6229777|NCT01737697|9904082|FG013|Subacute Phase|Lost to Follow-up|0
6229778|NCT01737697|9904083|FG014|Subacute Phase|Lost to Follow-up|1
6229779|NCT01737697|9904069|FG000|Subacute Phase|Hypo-or hyperkalemia|0
6229780|NCT01737697|9904070|FG001|Subacute Phase|Hypo-or hyperkalemia|0
6229781|NCT01737697|9904071|FG002|Subacute Phase|Hypo-or hyperkalemia|0
6229782|NCT01737697|9904072|FG003|Subacute Phase|Hypo-or hyperkalemia|0
6229783|NCT01737697|9904073|FG004|Subacute Phase|Hypo-or hyperkalemia|0
6229784|NCT01737697|9904074|FG005|Subacute Phase|Hypo-or hyperkalemia|0
6229785|NCT01737697|9904075|FG006|Subacute Phase|Hypo-or hyperkalemia|0
6229786|NCT01737697|9904076|FG007|Subacute Phase|Hypo-or hyperkalemia|0
6229787|NCT01737697|9904077|FG008|Subacute Phase|Hypo-or hyperkalemia|0
6229788|NCT01737697|9904078|FG009|Subacute Phase|Hypo-or hyperkalemia|0
6229789|NCT01737697|9904079|FG010|Subacute Phase|Hypo-or hyperkalemia|0
6229790|NCT01737697|9904080|FG011|Subacute Phase|Hypo-or hyperkalemia|1
6229791|NCT01737697|9904081|FG012|Subacute Phase|Hypo-or hyperkalemia|0
6229792|NCT01737697|9904082|FG013|Subacute Phase|Hypo-or hyperkalemia|1
6229793|NCT01737697|9904083|FG014|Subacute Phase|Hypo-or hyperkalemia|0
6229794|NCT01737697|9904069|FG000|Subacute Phase|Protocol Violation|0
6229795|NCT01737697|9904070|FG001|Subacute Phase|Protocol Violation|0
6229796|NCT01737697|9904071|FG002|Subacute Phase|Protocol Violation|0
6229797|NCT01737697|9904072|FG003|Subacute Phase|Protocol Violation|0
6229798|NCT01737697|9904073|FG004|Subacute Phase|Protocol Violation|0
6229799|NCT01737697|9904074|FG005|Subacute Phase|Protocol Violation|1
6229800|NCT01737697|9904075|FG006|Subacute Phase|Protocol Violation|0
6229801|NCT01737697|9904076|FG007|Subacute Phase|Protocol Violation|0
6229802|NCT01737697|9904077|FG008|Subacute Phase|Protocol Violation|0
6229803|NCT01737697|9904078|FG009|Subacute Phase|Protocol Violation|0
6229804|NCT01737697|9904079|FG010|Subacute Phase|Protocol Violation|1
6229805|NCT01737697|9904080|FG011|Subacute Phase|Protocol Violation|0
6229806|NCT01737697|9904081|FG012|Subacute Phase|Protocol Violation|0
6229807|NCT01737697|9904082|FG013|Subacute Phase|Protocol Violation|0
6229808|NCT01737697|9904083|FG014|Subacute Phase|Protocol Violation|0
6229809|NCT01737697|9904069|FG000|Subacute Phase|Physician Decision|0
6229810|NCT01737697|9904070|FG001|Subacute Phase|Physician Decision|0
6229811|NCT01737697|9904071|FG002|Subacute Phase|Physician Decision|0
6375507|NCT03150862|10165639|FG000|Overall Study|Change in Methylation status|0
6375508|NCT03150862|10165640|FG001|Overall Study|Change in Methylation status|0
6375509|NCT03150862|10165641|FG002|Overall Study|Change in Methylation status|0
6375510|NCT03150862|10165642|FG003|Overall Study|Change in Methylation status|0
6375511|NCT03150862|10165643|FG004|Overall Study|Change in Methylation status|1
6375512|NCT03150862|10165644|FG005|Overall Study|Change in Methylation status|0
6375513|NCT03150862|10165645|FG006|Overall Study|Change in Methylation status|0
6375514|NCT03150862|10165646|FG007|Overall Study|Change in Methylation status|0
6375515|NCT03150862|10165639|FG000|Overall Study|Roll over in to Long Term Extension|0
6375516|NCT03150862|10165640|FG001|Overall Study|Roll over in to Long Term Extension|0
6375517|NCT03150862|10165641|FG002|Overall Study|Roll over in to Long Term Extension|0
6375518|NCT03150862|10165642|FG003|Overall Study|Roll over in to Long Term Extension|0
6229812|NCT01737697|9904072|FG003|Subacute Phase|Physician Decision|0
6229813|NCT01737697|9904073|FG004|Subacute Phase|Physician Decision|0
6229814|NCT01737697|9904074|FG005|Subacute Phase|Physician Decision|0
6229815|NCT01737697|9904075|FG006|Subacute Phase|Physician Decision|0
6229816|NCT01737697|9904076|FG007|Subacute Phase|Physician Decision|0
6229817|NCT01737697|9904077|FG008|Subacute Phase|Physician Decision|1
6229818|NCT01737697|9904078|FG009|Subacute Phase|Physician Decision|0
6229819|NCT01737697|9904079|FG010|Subacute Phase|Physician Decision|0
6229820|NCT01737697|9904080|FG011|Subacute Phase|Physician Decision|0
6375519|NCT03150862|10165643|FG004|Overall Study|Roll over in to Long Term Extension|0
6375520|NCT03150862|10165644|FG005|Overall Study|Roll over in to Long Term Extension|0
6375521|NCT03150862|10165645|FG006|Overall Study|Roll over in to Long Term Extension|0
6375522|NCT03150862|10165646|FG007|Overall Study|Roll over in to Long Term Extension|1
6375523|NCT03150862|10165639|FG000|Overall Study|Progressive Disease|0
6375524|NCT03150862|10165640|FG001|Overall Study|Progressive Disease|0
6229821|NCT01737697|9904081|FG012|Subacute Phase|Physician Decision|0
6229822|NCT01737697|9904082|FG013|Subacute Phase|Physician Decision|0
6229823|NCT01737697|9904083|FG014|Subacute Phase|Physician Decision|0
6229824|NCT01737697|9904069|FG000|Subacute Phase|Death|0
6229825|NCT01737697|9904070|FG001|Subacute Phase|Death|0
6229826|NCT01737697|9904071|FG002|Subacute Phase|Death|0
6229827|NCT01737697|9904072|FG003|Subacute Phase|Death|0
6229828|NCT01737697|9904073|FG004|Subacute Phase|Death|0
6229829|NCT01737697|9904074|FG005|Subacute Phase|Death|0
6229830|NCT01737697|9904075|FG006|Subacute Phase|Death|0
6229831|NCT01737697|9904076|FG007|Subacute Phase|Death|0
6229832|NCT01737697|9904077|FG008|Subacute Phase|Death|0
6229833|NCT01737697|9904078|FG009|Subacute Phase|Death|0
6229834|NCT01737697|9904079|FG010|Subacute Phase|Death|1
6229835|NCT01737697|9904080|FG011|Subacute Phase|Death|0
6229836|NCT01737697|9904081|FG012|Subacute Phase|Death|0
6229837|NCT01737697|9904082|FG013|Subacute Phase|Death|0
6229838|NCT01737697|9904083|FG014|Subacute Phase|Death|0
6229839|NCT01737710|9904121|FG000|Overall Study|Lost to Follow-up|0
6229840|NCT01737710|9904122|FG001|Overall Study|Lost to Follow-up|2
6229841|NCT01737710|9904123|FG002|Overall Study|Lost to Follow-up|2
6229842|NCT01737710|9904124|FG003|Overall Study|Lost to Follow-up|0
6229843|NCT01737710|9904125|FG004|Overall Study|Lost to Follow-up|0
6229844|NCT01737710|9904121|FG000|Overall Study|Withdrawal by Subject|1
6229845|NCT01737710|9904122|FG001|Overall Study|Withdrawal by Subject|1
6229846|NCT01737710|9904123|FG002|Overall Study|Withdrawal by Subject|1
6229847|NCT01737710|9904124|FG003|Overall Study|Withdrawal by Subject|0
6229848|NCT01737710|9904125|FG004|Overall Study|Withdrawal by Subject|0
6229849|NCT01737710|9904121|FG000|Overall Study|Vaccinated in Error/Ineligible|1
6229850|NCT01737710|9904122|FG001|Overall Study|Vaccinated in Error/Ineligible|1
6229851|NCT01737710|9904123|FG002|Overall Study|Vaccinated in Error/Ineligible|0
6229852|NCT01737710|9904124|FG003|Overall Study|Vaccinated in Error/Ineligible|0
6229853|NCT01737710|9904125|FG004|Overall Study|Vaccinated in Error/Ineligible|0
6229854|NCT01737762|9904138|FG000|Overall Study|Adverse Event|2
6229855|NCT01737762|9904139|FG001|Overall Study|Adverse Event|2
6229856|NCT01737762|9904138|FG000|Overall Study|Lost to Follow-up|1
6229857|NCT01737762|9904139|FG001|Overall Study|Lost to Follow-up|0
6229858|NCT01737762|9904138|FG000|Overall Study|Withdrawal by Subject|2
6229859|NCT01737762|9904139|FG001|Overall Study|Withdrawal by Subject|2
6229860|NCT01737762|9904138|FG000|Overall Study|Progressive disease|1
6229861|NCT01737762|9904139|FG001|Overall Study|Progressive disease|2
6229862|NCT01737762|9904138|FG000|Overall Study|Physician Decision|1
6229863|NCT01737762|9904139|FG001|Overall Study|Physician Decision|1
6229864|NCT01737762|9904138|FG000|Overall Study|Moved from area|2
6229865|NCT01737762|9904139|FG001|Overall Study|Moved from area|1
6229866|NCT01737762|9904138|FG000|Overall Study|Trial termination|11
6229867|NCT01737762|9904139|FG001|Overall Study|Trial termination|9
6229868|NCT01737840|9904147|FG000|Overall Study|Diagnosed with an other pathology|2
6229869|NCT01737840|9904148|FG001|Overall Study|Diagnosed with an other pathology|2
6229870|NCT01737879|9904156|FG000|Overall Study|Death|1
6229871|NCT01737879|9904156|FG000|Overall Study|Sponsor decision|40
6229872|NCT01737931|9904163|FG000|Overall Study|Withdrawal by Subject|0
6229873|NCT01737931|9904164|FG001|Overall Study|Withdrawal by Subject|1
6229874|NCT01737931|9904165|FG002|Overall Study|Withdrawal by Subject|1
6229875|NCT01737931|9904163|FG000|Overall Study|Physician Decision|0
6229876|NCT01737931|9904164|FG001|Overall Study|Physician Decision|1
6229877|NCT01737931|9904165|FG002|Overall Study|Physician Decision|0
6229878|NCT01737996|9904190|FG000|Overall Study|Adverse Event|0
6229879|NCT01737996|9904191|FG001|Overall Study|Adverse Event|1
6229880|NCT01737996|9904192|FG002|Overall Study|Adverse Event|1
6229881|NCT01737996|9904190|FG000|Overall Study|Withdrawal by Subject|0
6229882|NCT01737996|9904191|FG001|Overall Study|Withdrawal by Subject|0
6229883|NCT01737996|9904192|FG002|Overall Study|Withdrawal by Subject|1
6229884|NCT01738191|9904202|FG000|Overall Study|Withdrawal by Subject|4
6229885|NCT01738191|9904203|FG001|Overall Study|Withdrawal by Subject|1
6229886|NCT01738438|9904218|FG000|Overall Study|Disease Progression|32
6229887|NCT01738438|9904218|FG000|Overall Study|Adverse Event|3
6229888|NCT01738477|9904224|FG000|Overall Study|Lost to Follow-up|1
6229889|NCT01738477|9904225|FG001|Overall Study|Lost to Follow-up|4
6229890|NCT01738503|9904239|FG000|Induction/Stabilization (Days -14 to -1)|Other|35
6229891|NCT01738503|9904240|FG001|Induction/Stabilization (Days -14 to -1)|Other|0
6229892|NCT01738503|9904241|FG002|Induction/Stabilization (Days -14 to -1)|Other|0
6229893|NCT01738503|9904242|FG003|Induction/Stabilization (Days -14 to -1)|Other|0
6229894|NCT01738503|9904243|FG004|Induction/Stabilization (Days -14 to -1)|Other|0
6229895|NCT01738503|9904244|FG005|Induction/Stabilization (Days -14 to -1)|Other|0
6229896|NCT01738503|9904245|FG006|Induction/Stabilization (Days -14 to -1)|Other|0
6229897|NCT01738503|9904239|FG000|Treatment Period|Adverse Event|0
6375525|NCT03150862|10165641|FG002|Overall Study|Progressive Disease|0
6375526|NCT03150862|10165642|FG003|Overall Study|Progressive Disease|0
6229898|NCT01738503|9904240|FG001|Treatment Period|Adverse Event|1
6229899|NCT01738503|9904241|FG002|Treatment Period|Adverse Event|0
6229900|NCT01738503|9904242|FG003|Treatment Period|Adverse Event|1
6229901|NCT01738503|9904243|FG004|Treatment Period|Adverse Event|2
6229902|NCT01738503|9904244|FG005|Treatment Period|Adverse Event|2
6229903|NCT01738503|9904245|FG006|Treatment Period|Adverse Event|2
6229904|NCT01738503|9904239|FG000|Treatment Period|Lost to Follow-up|0
6229905|NCT01738503|9904240|FG001|Treatment Period|Lost to Follow-up|0
6229906|NCT01738503|9904241|FG002|Treatment Period|Lost to Follow-up|3
6229907|NCT01738503|9904242|FG003|Treatment Period|Lost to Follow-up|4
6229908|NCT01738503|9904243|FG004|Treatment Period|Lost to Follow-up|1
6229909|NCT01738503|9904244|FG005|Treatment Period|Lost to Follow-up|1
6229910|NCT01738503|9904245|FG006|Treatment Period|Lost to Follow-up|5
6229911|NCT01738503|9904239|FG000|Treatment Period|Withdrawal by Subject|0
6229912|NCT01738503|9904240|FG001|Treatment Period|Withdrawal by Subject|1
6229913|NCT01738503|9904241|FG002|Treatment Period|Withdrawal by Subject|0
6229914|NCT01738503|9904242|FG003|Treatment Period|Withdrawal by Subject|1
6229915|NCT01738503|9904243|FG004|Treatment Period|Withdrawal by Subject|1
6229916|NCT01738503|9904244|FG005|Treatment Period|Withdrawal by Subject|1
6229917|NCT01738503|9904245|FG006|Treatment Period|Withdrawal by Subject|1
6229918|NCT01738503|9904239|FG000|Treatment Period|Protocol Violation|0
6229919|NCT01738503|9904240|FG001|Treatment Period|Protocol Violation|3
6229920|NCT01738503|9904241|FG002|Treatment Period|Protocol Violation|1
6229921|NCT01738503|9904242|FG003|Treatment Period|Protocol Violation|0
6229922|NCT01738503|9904243|FG004|Treatment Period|Protocol Violation|4
6229923|NCT01738503|9904244|FG005|Treatment Period|Protocol Violation|2
6229924|NCT01738503|9904245|FG006|Treatment Period|Protocol Violation|0
6229925|NCT01738503|9904239|FG000|Treatment Period|Other|0
6229926|NCT01738503|9904240|FG001|Treatment Period|Other|0
6229927|NCT01738503|9904241|FG002|Treatment Period|Other|1
6229928|NCT01738503|9904242|FG003|Treatment Period|Other|0
6229929|NCT01738503|9904243|FG004|Treatment Period|Other|0
6229930|NCT01738503|9904244|FG005|Treatment Period|Other|0
6229931|NCT01738503|9904245|FG006|Treatment Period|Other|0
6229932|NCT01738503|9904239|FG000|PET Imaging Sub-study|Adverse Event|0
6229933|NCT01738503|9904240|FG001|PET Imaging Sub-study|Adverse Event|0
6229934|NCT01738503|9904241|FG002|PET Imaging Sub-study|Adverse Event|0
6229935|NCT01738503|9904242|FG003|PET Imaging Sub-study|Adverse Event|0
6229936|NCT01738503|9904243|FG004|PET Imaging Sub-study|Adverse Event|0
6229937|NCT01738503|9904244|FG005|PET Imaging Sub-study|Adverse Event|1
6229938|NCT01738503|9904245|FG006|PET Imaging Sub-study|Adverse Event|0
6229939|NCT01738503|9904239|FG000|PET Imaging Sub-study|Scheduling issues with imaging facility|0
6229940|NCT01738503|9904240|FG001|PET Imaging Sub-study|Scheduling issues with imaging facility|0
6229941|NCT01738503|9904241|FG002|PET Imaging Sub-study|Scheduling issues with imaging facility|0
6229942|NCT01738503|9904242|FG003|PET Imaging Sub-study|Scheduling issues with imaging facility|0
6229943|NCT01738503|9904243|FG004|PET Imaging Sub-study|Scheduling issues with imaging facility|0
6229944|NCT01738503|9904244|FG005|PET Imaging Sub-study|Scheduling issues with imaging facility|1
6229945|NCT01738503|9904245|FG006|PET Imaging Sub-study|Scheduling issues with imaging facility|1
6229946|NCT01738581|9904269|FG000|Overall Study|Lost to Follow-up|1
6229947|NCT01738581|9904270|FG001|Overall Study|Lost to Follow-up|0
6229948|NCT01738594|9904279|FG000|Registration and Treatment Start|Adverse Event|0
6229949|NCT01738594|9904280|FG001|Registration and Treatment Start|Adverse Event|1
6229950|NCT01738594|9904281|FG002|Registration and Treatment Start|Adverse Event|0
6229951|NCT01738594|9904282|FG003|Registration and Treatment Start|Adverse Event|0
6229952|NCT01738594|9904283|FG004|Registration and Treatment Start|Adverse Event|0
6229953|NCT01738594|9904284|FG005|Registration and Treatment Start|Adverse Event|0
6229954|NCT01738594|9904285|FG006|Registration and Treatment Start|Adverse Event|0
6229955|NCT01738594|9904286|FG007|Registration and Treatment Start|Adverse Event|0
6229956|NCT01738594|9904279|FG000|Completed 2 Cycles/Reached 1st Response|Physician Decision|0
6229957|NCT01738594|9904280|FG001|Completed 2 Cycles/Reached 1st Response|Physician Decision|0
6229958|NCT01738594|9904281|FG002|Completed 2 Cycles/Reached 1st Response|Physician Decision|0
6229959|NCT01738594|9904282|FG003|Completed 2 Cycles/Reached 1st Response|Physician Decision|0
6229960|NCT01738594|9904283|FG004|Completed 2 Cycles/Reached 1st Response|Physician Decision|0
6229961|NCT01738594|9904284|FG005|Completed 2 Cycles/Reached 1st Response|Physician Decision|1
6229962|NCT01738594|9904285|FG006|Completed 2 Cycles/Reached 1st Response|Physician Decision|0
6229963|NCT01738594|9904286|FG007|Completed 2 Cycles/Reached 1st Response|Physician Decision|0
6229964|NCT01738594|9904279|FG000|Completed 4 Cycles of Treatment|Progressive disease|0
6229965|NCT01738594|9904280|FG001|Completed 4 Cycles of Treatment|Progressive disease|2
6229966|NCT01738594|9904281|FG002|Completed 4 Cycles of Treatment|Progressive disease|0
6229967|NCT01738594|9904282|FG003|Completed 4 Cycles of Treatment|Progressive disease|0
6229968|NCT01738594|9904283|FG004|Completed 4 Cycles of Treatment|Progressive disease|0
6229969|NCT01738594|9904284|FG005|Completed 4 Cycles of Treatment|Progressive disease|0
6229970|NCT01738594|9904285|FG006|Completed 4 Cycles of Treatment|Progressive disease|0
6229971|NCT01738594|9904286|FG007|Completed 4 Cycles of Treatment|Progressive disease|0
6229972|NCT01738594|9904279|FG000|Completed 4 Cycles of Treatment|No response/patient benefit|0
6229973|NCT01738594|9904280|FG001|Completed 4 Cycles of Treatment|No response/patient benefit|0
6375527|NCT03150862|10165643|FG004|Overall Study|Progressive Disease|0
6229974|NCT01738594|9904281|FG002|Completed 4 Cycles of Treatment|No response/patient benefit|0
6229975|NCT01738594|9904282|FG003|Completed 4 Cycles of Treatment|No response/patient benefit|0
6229976|NCT01738594|9904283|FG004|Completed 4 Cycles of Treatment|No response/patient benefit|0
6229977|NCT01738594|9904284|FG005|Completed 4 Cycles of Treatment|No response/patient benefit|1
6229978|NCT01738594|9904285|FG006|Completed 4 Cycles of Treatment|No response/patient benefit|0
6229979|NCT01738594|9904286|FG007|Completed 4 Cycles of Treatment|No response/patient benefit|0
6229980|NCT01738594|9904279|FG000|Went on to Continue Treatment Cycle 5|Progressive Disease|0
6229981|NCT01738594|9904280|FG001|Went on to Continue Treatment Cycle 5|Progressive Disease|0
6229982|NCT01738594|9904281|FG002|Went on to Continue Treatment Cycle 5|Progressive Disease|0
6229983|NCT01738594|9904282|FG003|Went on to Continue Treatment Cycle 5|Progressive Disease|0
6229984|NCT01738594|9904283|FG004|Went on to Continue Treatment Cycle 5|Progressive Disease|0
6229985|NCT01738594|9904284|FG005|Went on to Continue Treatment Cycle 5|Progressive Disease|1
6229986|NCT01738594|9904285|FG006|Went on to Continue Treatment Cycle 5|Progressive Disease|0
6229987|NCT01738594|9904286|FG007|Went on to Continue Treatment Cycle 5|Progressive Disease|0
6229988|NCT01738594|9904279|FG000|Went on to Continue Treatment Cycle 5|Withdrawal by Subject|0
6229989|NCT01738594|9904280|FG001|Went on to Continue Treatment Cycle 5|Withdrawal by Subject|0
6229990|NCT01738594|9904281|FG002|Went on to Continue Treatment Cycle 5|Withdrawal by Subject|0
6229991|NCT01738594|9904282|FG003|Went on to Continue Treatment Cycle 5|Withdrawal by Subject|0
6229992|NCT01738594|9904283|FG004|Went on to Continue Treatment Cycle 5|Withdrawal by Subject|1
6229993|NCT01738594|9904284|FG005|Went on to Continue Treatment Cycle 5|Withdrawal by Subject|0
6229994|NCT01738594|9904285|FG006|Went on to Continue Treatment Cycle 5|Withdrawal by Subject|0
6229995|NCT01738594|9904286|FG007|Went on to Continue Treatment Cycle 5|Withdrawal by Subject|0
6229996|NCT01738594|9904279|FG000|Follow up for 1 Year|Death|0
6229997|NCT01738594|9904280|FG001|Follow up for 1 Year|Death|0
6229998|NCT01738594|9904281|FG002|Follow up for 1 Year|Death|0
6229999|NCT01738594|9904282|FG003|Follow up for 1 Year|Death|0
6230000|NCT01738594|9904283|FG004|Follow up for 1 Year|Death|0
6230001|NCT01738594|9904284|FG005|Follow up for 1 Year|Death|1
6085434|NCT00652626|9694767|FG006|Initial Treatment Phase|Sponsor Request|0
6085435|NCT00652626|9694761|FG000|Initial Treatment Phase|Lost to Follow-up|0
6085436|NCT00652626|9694762|FG001|Initial Treatment Phase|Lost to Follow-up|0
6230002|NCT01738594|9904285|FG006|Follow up for 1 Year|Death|0
6230003|NCT01738594|9904286|FG007|Follow up for 1 Year|Death|0
6230004|NCT01738594|9904279|FG000|Follow up for 1 Year|Other|0
6230005|NCT01738594|9904280|FG001|Follow up for 1 Year|Other|0
6230006|NCT01738594|9904281|FG002|Follow up for 1 Year|Other|0
6230007|NCT01738594|9904282|FG003|Follow up for 1 Year|Other|0
6230008|NCT01738594|9904283|FG004|Follow up for 1 Year|Other|0
6230009|NCT01738594|9904284|FG005|Follow up for 1 Year|Other|2
6230010|NCT01738594|9904285|FG006|Follow up for 1 Year|Other|0
6230011|NCT01738594|9904286|FG007|Follow up for 1 Year|Other|0
6230012|NCT01738646|9904296|FG000|Overall Study|Still Receiving Treatment|2
6230013|NCT01738919|9904339|FG000|Overall Study|Lost to Follow-up|1
6230014|NCT01738919|9904340|FG001|Overall Study|Lost to Follow-up|0
6230015|NCT01738919|9904339|FG000|Overall Study|Immigrated|0
6230016|NCT01738919|9904340|FG001|Overall Study|Immigrated|1
6230017|NCT01738919|9904339|FG000|Overall Study|Withdrawal by Subject|0
6230018|NCT01738919|9904340|FG001|Overall Study|Withdrawal by Subject|1
6230019|NCT01738919|9904339|FG000|Overall Study|Not treated in accordance to guidelines|0
6230020|NCT01738919|9904340|FG001|Overall Study|Not treated in accordance to guidelines|1
6230021|NCT01738971|9904351|FG000|Overall Study|Lost to Follow-up|19
6230022|NCT01738971|9904352|FG001|Overall Study|Lost to Follow-up|30
6230023|NCT01738971|9904353|FG002|Overall Study|Lost to Follow-up|17
6230024|NCT01738984|9904363|FG000|Overall Study|Pregnancy|4
6230025|NCT01738984|9904364|FG001|Overall Study|Pregnancy|0
6230026|NCT01738984|9904363|FG000|Overall Study|Withdrawal by Subject|1
6230027|NCT01738984|9904364|FG001|Overall Study|Withdrawal by Subject|0
6230028|NCT01738984|9904363|FG000|Overall Study|Lost to Follow-up|59
6230029|NCT01738984|9904364|FG001|Overall Study|Lost to Follow-up|39
6230030|NCT01739309|9904397|FG000|Overall Study|On study treatment|3
6230031|NCT01739335|9904405|FG000|Overall Study|Lost to Follow-up|7
6230032|NCT01739335|9904406|FG001|Overall Study|Lost to Follow-up|4
6230033|NCT01739335|9904405|FG000|Overall Study|Ineligible patient randomized|0
6230034|NCT01739335|9904406|FG001|Overall Study|Ineligible patient randomized|1
6230035|NCT01739348|9904420|FG000|Part I (Base Study)|Adverse Event|41
6230036|NCT01739348|9904421|FG001|Part I (Base Study)|Adverse Event|52
6230037|NCT01739348|9904422|FG002|Part I (Base Study)|Adverse Event|8
6230038|NCT01739348|9904423|FG003|Part I (Base Study)|Adverse Event|33
6230039|NCT01739348|9904420|FG000|Part I (Base Study)|Death|10
6230040|NCT01739348|9904421|FG001|Part I (Base Study)|Death|7
6230041|NCT01739348|9904422|FG002|Part I (Base Study)|Death|2
6230042|NCT01739348|9904423|FG003|Part I (Base Study)|Death|8
6230043|NCT01739348|9904420|FG000|Part I (Base Study)|Lack of Efficacy|3
6230044|NCT01739348|9904421|FG001|Part I (Base Study)|Lack of Efficacy|8
6230045|NCT01739348|9904422|FG002|Part I (Base Study)|Lack of Efficacy|0
6085437|NCT00652626|9694763|FG002|Initial Treatment Phase|Lost to Follow-up|0
6230046|NCT01739348|9904423|FG003|Part I (Base Study)|Lack of Efficacy|7
6230047|NCT01739348|9904420|FG000|Part I (Base Study)|Lost to Follow-up|4
6085438|NCT00652626|9694764|FG003|Initial Treatment Phase|Lost to Follow-up|0
6230048|NCT01739348|9904421|FG001|Part I (Base Study)|Lost to Follow-up|2
6230049|NCT01739348|9904422|FG002|Part I (Base Study)|Lost to Follow-up|4
6230050|NCT01739348|9904423|FG003|Part I (Base Study)|Lost to Follow-up|4
6230051|NCT01739348|9904420|FG000|Part I (Base Study)|Non-Compliance with Study Drug|3
6230052|NCT01739348|9904421|FG001|Part I (Base Study)|Non-Compliance with Study Drug|2
6230053|NCT01739348|9904422|FG002|Part I (Base Study)|Non-Compliance with Study Drug|0
6230054|NCT01739348|9904423|FG003|Part I (Base Study)|Non-Compliance with Study Drug|0
6230055|NCT01739348|9904420|FG000|Part I (Base Study)|Physician Decision|10
6230056|NCT01739348|9904421|FG001|Part I (Base Study)|Physician Decision|7
6230057|NCT01739348|9904422|FG002|Part I (Base Study)|Physician Decision|1
6230058|NCT01739348|9904423|FG003|Part I (Base Study)|Physician Decision|4
6230059|NCT01739348|9904420|FG000|Part I (Base Study)|Protocol Violation|2
6230060|NCT01739348|9904421|FG001|Part I (Base Study)|Protocol Violation|0
6230061|NCT01739348|9904422|FG002|Part I (Base Study)|Protocol Violation|1
6230062|NCT01739348|9904423|FG003|Part I (Base Study)|Protocol Violation|2
6230063|NCT01739348|9904420|FG000|Part I (Base Study)|Screen Failure|2
6230064|NCT01739348|9904421|FG001|Part I (Base Study)|Screen Failure|0
6230065|NCT01739348|9904422|FG002|Part I (Base Study)|Screen Failure|0
6230066|NCT01739348|9904423|FG003|Part I (Base Study)|Screen Failure|0
6230067|NCT01739348|9904420|FG000|Part I (Base Study)|Site Discontinued Study Participation|1
6230068|NCT01739348|9904421|FG001|Part I (Base Study)|Site Discontinued Study Participation|3
6230069|NCT01739348|9904422|FG002|Part I (Base Study)|Site Discontinued Study Participation|0
6230070|NCT01739348|9904423|FG003|Part I (Base Study)|Site Discontinued Study Participation|0
6230071|NCT01739348|9904420|FG000|Part I (Base Study)|Study Terminated by Sponsor|72
6230072|NCT01739348|9904421|FG001|Part I (Base Study)|Study Terminated by Sponsor|73
6230073|NCT01739348|9904422|FG002|Part I (Base Study)|Study Terminated by Sponsor|0
6230074|NCT01739348|9904423|FG003|Part I (Base Study)|Study Terminated by Sponsor|86
6230075|NCT01739348|9904420|FG000|Part I (Base Study)|Participant Moved|4
6230076|NCT01739348|9904421|FG001|Part I (Base Study)|Participant Moved|3
6230077|NCT01739348|9904422|FG002|Part I (Base Study)|Participant Moved|1
6230078|NCT01739348|9904423|FG003|Part I (Base Study)|Participant Moved|7
6230079|NCT01739348|9904420|FG000|Part I (Base Study)|Trial Partner/Caregiver Withdrew Consent|27
6230080|NCT01739348|9904421|FG001|Part I (Base Study)|Trial Partner/Caregiver Withdrew Consent|25
6230081|NCT01739348|9904422|FG002|Part I (Base Study)|Trial Partner/Caregiver Withdrew Consent|2
6230082|NCT01739348|9904423|FG003|Part I (Base Study)|Trial Partner/Caregiver Withdrew Consent|18
6230083|NCT01739348|9904420|FG000|Part I (Base Study)|Withdrawal by Subject|23
6230084|NCT01739348|9904421|FG001|Part I (Base Study)|Withdrawal by Subject|21
6230085|NCT01739348|9904422|FG002|Part I (Base Study)|Withdrawal by Subject|7
6230086|NCT01739348|9904423|FG003|Part I (Base Study)|Withdrawal by Subject|20
6230087|NCT01739348|9904420|FG000|Part II (Extension Study)|Adverse Event|10
6230088|NCT01739348|9904421|FG001|Part II (Extension Study)|Adverse Event|11
6230089|NCT01739348|9904422|FG002|Part II (Extension Study)|Adverse Event|7
6230090|NCT01739348|9904423|FG003|Part II (Extension Study)|Adverse Event|26
6230091|NCT01739348|9904420|FG000|Part II (Extension Study)|Death|3
6230092|NCT01739348|9904421|FG001|Part II (Extension Study)|Death|3
6230093|NCT01739348|9904422|FG002|Part II (Extension Study)|Death|2
6230094|NCT01739348|9904423|FG003|Part II (Extension Study)|Death|6
6230095|NCT01739348|9904420|FG000|Part II (Extension Study)|Lack of Efficacy|1
6230096|NCT01739348|9904421|FG001|Part II (Extension Study)|Lack of Efficacy|5
6230097|NCT01739348|9904422|FG002|Part II (Extension Study)|Lack of Efficacy|0
6230098|NCT01739348|9904423|FG003|Part II (Extension Study)|Lack of Efficacy|1
6230099|NCT01739348|9904420|FG000|Part II (Extension Study)|Lost to Follow-up|3
6230100|NCT01739348|9904421|FG001|Part II (Extension Study)|Lost to Follow-up|4
6230101|NCT01739348|9904422|FG002|Part II (Extension Study)|Lost to Follow-up|0
6230102|NCT01739348|9904423|FG003|Part II (Extension Study)|Lost to Follow-up|1
6230103|NCT01739348|9904420|FG000|Part II (Extension Study)|Non-Compliance with Study Drug|0
6230104|NCT01739348|9904421|FG001|Part II (Extension Study)|Non-Compliance with Study Drug|0
6230105|NCT01739348|9904422|FG002|Part II (Extension Study)|Non-Compliance with Study Drug|0
6230106|NCT01739348|9904423|FG003|Part II (Extension Study)|Non-Compliance with Study Drug|1
6230107|NCT01739348|9904420|FG000|Part II (Extension Study)|Physician Decision|7
6230108|NCT01739348|9904421|FG001|Part II (Extension Study)|Physician Decision|11
6230109|NCT01739348|9904422|FG002|Part II (Extension Study)|Physician Decision|6
6230110|NCT01739348|9904423|FG003|Part II (Extension Study)|Physician Decision|12
6230111|NCT01739348|9904420|FG000|Part II (Extension Study)|Study Terminated by Sponsor|329
6230112|NCT01739348|9904421|FG001|Part II (Extension Study)|Study Terminated by Sponsor|315
6230113|NCT01739348|9904422|FG002|Part II (Extension Study)|Study Terminated by Sponsor|34
6230114|NCT01739348|9904423|FG003|Part II (Extension Study)|Study Terminated by Sponsor|323
6230115|NCT01739348|9904420|FG000|Part II (Extension Study)|Participant Moved|3
6230116|NCT01739348|9904421|FG001|Part II (Extension Study)|Participant Moved|3
6230117|NCT01739348|9904422|FG002|Part II (Extension Study)|Participant Moved|0
6230118|NCT01739348|9904423|FG003|Part II (Extension Study)|Participant Moved|3
6230119|NCT01739348|9904420|FG000|Part II (Extension Study)|Trial Partner/Caregiver Withdrew Consent|18
6230120|NCT01739348|9904421|FG001|Part II (Extension Study)|Trial Partner/Caregiver Withdrew Consent|12
6230121|NCT01739348|9904422|FG002|Part II (Extension Study)|Trial Partner/Caregiver Withdrew Consent|8
6230122|NCT01739348|9904423|FG003|Part II (Extension Study)|Trial Partner/Caregiver Withdrew Consent|16
6230123|NCT01739348|9904420|FG000|Part II (Extension Study)|Withdrawal by Subject|5
6230124|NCT01739348|9904421|FG001|Part II (Extension Study)|Withdrawal by Subject|2
6230125|NCT01739348|9904422|FG002|Part II (Extension Study)|Withdrawal by Subject|4
6230126|NCT01739348|9904423|FG003|Part II (Extension Study)|Withdrawal by Subject|7
6230127|NCT01739400|9904448|FG000|Overall Study|Physician Decision|3
6230128|NCT01739400|9904449|FG001|Overall Study|Physician Decision|0
6230129|NCT01739400|9904448|FG000|Overall Study|Lost to Follow-up|2
6230130|NCT01739400|9904449|FG001|Overall Study|Lost to Follow-up|0
6230131|NCT01739400|9904448|FG000|Overall Study|Death|5
6230132|NCT01739400|9904449|FG001|Overall Study|Death|2
6230133|NCT01739400|9904448|FG000|Overall Study|Withdrawal by Subject|7
6230134|NCT01739400|9904449|FG001|Overall Study|Withdrawal by Subject|7
6230135|NCT01739595|9904457|FG000|Overall Study|Adverse Event|3
6230136|NCT01739595|9904458|FG001|Overall Study|Adverse Event|0
6230137|NCT01739595|9904459|FG002|Overall Study|Adverse Event|0
6230138|NCT01739595|9904457|FG000|Overall Study|Lost to Follow-up|2
6230139|NCT01739595|9904458|FG001|Overall Study|Lost to Follow-up|0
6230140|NCT01739595|9904459|FG002|Overall Study|Lost to Follow-up|0
6230141|NCT01739595|9904457|FG000|Overall Study|Withdrawal by Subject|2
6230142|NCT01739595|9904458|FG001|Overall Study|Withdrawal by Subject|1
6230143|NCT01739595|9904459|FG002|Overall Study|Withdrawal by Subject|2
6230144|NCT01739595|9904457|FG000|Overall Study|Eligibility issue|3
6230145|NCT01739595|9904458|FG001|Overall Study|Eligibility issue|0
6230146|NCT01739595|9904459|FG002|Overall Study|Eligibility issue|0
6230147|NCT01739595|9904457|FG000|Overall Study|Protocol Violation|1
6230148|NCT01739595|9904458|FG001|Overall Study|Protocol Violation|0
6230149|NCT01739595|9904459|FG002|Overall Study|Protocol Violation|0
6230150|NCT01739595|9904457|FG000|Overall Study|Lab assessment|1
6230151|NCT01739595|9904458|FG001|Overall Study|Lab assessment|0
6230152|NCT01739595|9904459|FG002|Overall Study|Lab assessment|0
6230153|NCT01739595|9904457|FG000|Overall Study|Drug discrepancy|1
6230154|NCT01739595|9904458|FG001|Overall Study|Drug discrepancy|0
6230155|NCT01739595|9904459|FG002|Overall Study|Drug discrepancy|0
6230156|NCT01739764|9904478|FG000|Overall Study|Adverse Event|0
6230157|NCT01739764|9904479|FG001|Overall Study|Adverse Event|3
6230158|NCT01739764|9904480|FG002|Overall Study|Adverse Event|4
6230159|NCT01739764|9904478|FG000|Overall Study|Death|4
6230160|NCT01739764|9904479|FG001|Overall Study|Death|6
6230161|NCT01739764|9904480|FG002|Overall Study|Death|38
6230162|NCT01739764|9904478|FG000|Overall Study|Lost to Follow-up|0
6230163|NCT01739764|9904479|FG001|Overall Study|Lost to Follow-up|0
6230164|NCT01739764|9904480|FG002|Overall Study|Lost to Follow-up|5
6230165|NCT01739764|9904478|FG000|Overall Study|Non-Compliance|0
6230166|NCT01739764|9904479|FG001|Overall Study|Non-Compliance|0
6230167|NCT01739764|9904480|FG002|Overall Study|Non-Compliance|1
6230168|NCT01739764|9904478|FG000|Overall Study|Multiple Reasons|3
6230169|NCT01739764|9904479|FG001|Overall Study|Multiple Reasons|2
6230170|NCT01739764|9904480|FG002|Overall Study|Multiple Reasons|3
6230171|NCT01739764|9904478|FG000|Overall Study|Physician Decision|2
6230172|NCT01739764|9904479|FG001|Overall Study|Physician Decision|2
6230173|NCT01739764|9904480|FG002|Overall Study|Physician Decision|4
6230174|NCT01739764|9904478|FG000|Overall Study|Progressive Disease|3
6230175|NCT01739764|9904479|FG001|Overall Study|Progressive Disease|5
6230176|NCT01739764|9904480|FG002|Overall Study|Progressive Disease|16
6230177|NCT01739764|9904478|FG000|Overall Study|Protocol Violation|0
6230178|NCT01739764|9904479|FG001|Overall Study|Protocol Violation|0
6230179|NCT01739764|9904480|FG002|Overall Study|Protocol Violation|2
6230180|NCT01739764|9904478|FG000|Overall Study|Study Terminated by Sponsor|8
6230181|NCT01739764|9904479|FG001|Overall Study|Study Terminated by Sponsor|13
6230182|NCT01739764|9904480|FG002|Overall Study|Study Terminated by Sponsor|26
6230183|NCT01739764|9904478|FG000|Overall Study|Withdrawal by Subject|6
6230184|NCT01739764|9904479|FG001|Overall Study|Withdrawal by Subject|5
6230185|NCT01739764|9904480|FG002|Overall Study|Withdrawal by Subject|27
6230186|NCT01739790|9904490|FG000|Overall Study|Early Trial Termination|2
6230187|NCT01739790|9904491|FG001|Overall Study|Early Trial Termination|4
6230188|NCT01739803|9904499|FG000|Overall Study|Lost to Follow-up|9
6230189|NCT01739803|9904500|FG001|Overall Study|Lost to Follow-up|6
6230190|NCT01739933|9904508|FG000|Overall Study|Death|89
6230191|NCT01739933|9904509|FG001|Overall Study|Death|86
6230192|NCT01739933|9904508|FG000|Overall Study|Withdrawal by Subject|10
6230193|NCT01739933|9904509|FG001|Overall Study|Withdrawal by Subject|8
6230194|NCT01739933|9904508|FG000|Overall Study|Lost to Follow-up|3
6230195|NCT01739933|9904509|FG001|Overall Study|Lost to Follow-up|10
6230196|NCT01739933|9904508|FG000|Overall Study|Did not speak English required for neurospychological testing|4
6230197|NCT01739933|9904509|FG001|Overall Study|Did not speak English required for neurospychological testing|3
6230198|NCT01740089|9904518|FG000|First 12 Weeks of Treatment|Adverse Event|0
6230199|NCT01740089|9904519|FG001|First 12 Weeks of Treatment|Adverse Event|1
6230200|NCT01740089|9904520|FG002|First 12 Weeks of Treatment|Adverse Event|2
6230201|NCT01740089|9904518|FG000|First 12 Weeks of Treatment|Withdrawal by Subject|0
6230202|NCT01740089|9904519|FG001|First 12 Weeks of Treatment|Withdrawal by Subject|1
6230203|NCT01740089|9904520|FG002|First 12 Weeks of Treatment|Withdrawal by Subject|0
6230204|NCT01740089|9904518|FG000|After 12 Weeks|Lack of Efficacy|3
6230205|NCT01740089|9904519|FG001|After 12 Weeks|Lack of Efficacy|1
6230206|NCT01740089|9904520|FG002|After 12 Weeks|Lack of Efficacy|4
6230207|NCT01740089|9904518|FG000|After 12 Weeks|Adverse Event|2
6230208|NCT01740089|9904519|FG001|After 12 Weeks|Adverse Event|0
6230209|NCT01740089|9904520|FG002|After 12 Weeks|Adverse Event|5
6230210|NCT01740089|9904518|FG000|After 12 Weeks|Protocol Violation|1
6230211|NCT01740089|9904519|FG001|After 12 Weeks|Protocol Violation|1
6230212|NCT01740089|9904520|FG002|After 12 Weeks|Protocol Violation|1
6230213|NCT01740089|9904518|FG000|After 12 Weeks|Withdrawal by Subject|1
6230214|NCT01740089|9904519|FG001|After 12 Weeks|Withdrawal by Subject|1
6230215|NCT01740089|9904520|FG002|After 12 Weeks|Withdrawal by Subject|1
6230216|NCT01740128|9904531|FG000|Overall Study|Pregnancy|0
6230217|NCT01740128|9904532|FG001|Overall Study|Pregnancy|1
6230218|NCT01740128|9904531|FG000|Overall Study|Protocol Violation|1
6230219|NCT01740128|9904532|FG001|Overall Study|Protocol Violation|2
6230220|NCT01740128|9904531|FG000|Overall Study|Lost to Follow-up|2
6230221|NCT01740128|9904532|FG001|Overall Study|Lost to Follow-up|2
6230222|NCT01740128|9904531|FG000|Overall Study|Withdrawal by Subject|1
6230223|NCT01740128|9904532|FG001|Overall Study|Withdrawal by Subject|0
6230224|NCT01740128|9904531|FG000|Overall Study|Insufficient protocol compliance|2
6230225|NCT01740128|9904532|FG001|Overall Study|Insufficient protocol compliance|2
6230226|NCT01740323|9904553|FG000|Overall Study|Adverse Event|1
6230227|NCT01740323|9904554|FG001|Overall Study|Adverse Event|0
6230228|NCT01740323|9904553|FG000|Overall Study|Randomized but did not take study drug|1
6230229|NCT01740323|9904554|FG001|Overall Study|Randomized but did not take study drug|0
6230230|NCT01740388|9904579|FG000|Overall Study|Withdrawal by Subject|1
6230231|NCT01740388|9904580|FG001|Overall Study|Withdrawal by Subject|2
6230232|NCT01740388|9904579|FG000|Overall Study|Lost to Follow-up|2
6230233|NCT01740388|9904580|FG001|Overall Study|Lost to Follow-up|0
6230234|NCT01740388|9904579|FG000|Overall Study|Physician Decision|2
6230235|NCT01740388|9904580|FG001|Overall Study|Physician Decision|6
6230236|NCT01740388|9904579|FG000|Overall Study|Subjects missing data, completed|41
6230237|NCT01740388|9904580|FG001|Overall Study|Subjects missing data, completed|36
6230238|NCT01740401|9904586|FG000|Overall Study|Progression of disease|6
6230239|NCT01740401|9904586|FG000|Overall Study|Adverse Event|2
6230240|NCT01740401|9904586|FG000|Overall Study|Did not reach primary endpoint|2
6230241|NCT01740440|9904604|FG000|Overall Study|Lost to Follow-up|3
6230242|NCT01740791|9904639|FG000|Overall Study|Randomized but never treated|5
6230243|NCT01740791|9904640|FG001|Overall Study|Randomized but never treated|3
6230244|NCT01740791|9904641|FG002|Overall Study|Randomized but never treated|2
6230245|NCT01740791|9904642|FG003|Overall Study|Randomized but never treated|2
6230246|NCT01740791|9904643|FG004|Overall Study|Randomized but never treated|1
6230247|NCT01740791|9904644|FG005|Overall Study|Randomized but never treated|3
6230248|NCT01740791|9904639|FG000|Overall Study|Lost to Follow-up|2
6230249|NCT01740791|9904640|FG001|Overall Study|Lost to Follow-up|0
6230250|NCT01740791|9904641|FG002|Overall Study|Lost to Follow-up|2
6230251|NCT01740791|9904642|FG003|Overall Study|Lost to Follow-up|3
6230252|NCT01740791|9904643|FG004|Overall Study|Lost to Follow-up|2
6085439|NCT00652626|9694765|FG004|Initial Treatment Phase|Lost to Follow-up|1
6085440|NCT00652626|9694766|FG005|Initial Treatment Phase|Lost to Follow-up|0
6085441|NCT00652626|9694767|FG006|Initial Treatment Phase|Lost to Follow-up|0
6085442|NCT00652626|9694761|FG000|Extension Phase|Withdrawal by Subject|0
6085443|NCT00652626|9694762|FG001|Extension Phase|Withdrawal by Subject|0
6085444|NCT00652626|9694763|FG002|Extension Phase|Withdrawal by Subject|0
6085445|NCT00652626|9694764|FG003|Extension Phase|Withdrawal by Subject|0
6085446|NCT00652626|9694765|FG004|Extension Phase|Withdrawal by Subject|0
6085447|NCT00652626|9694766|FG005|Extension Phase|Withdrawal by Subject|2
6085448|NCT00652626|9694767|FG006|Extension Phase|Withdrawal by Subject|0
6085449|NCT00652626|9694761|FG000|Extension Phase|Adverse Event|0
6085450|NCT00652626|9694762|FG001|Extension Phase|Adverse Event|0
6085451|NCT00652626|9694763|FG002|Extension Phase|Adverse Event|0
6085452|NCT00652626|9694764|FG003|Extension Phase|Adverse Event|0
6085453|NCT00652626|9694765|FG004|Extension Phase|Adverse Event|0
6085454|NCT00652626|9694766|FG005|Extension Phase|Adverse Event|2
6085455|NCT00652626|9694767|FG006|Extension Phase|Adverse Event|1
6085456|NCT00652626|9694761|FG000|Extension Phase|No Longer Receiving Clinical Benefit|0
6085457|NCT00652626|9694762|FG001|Extension Phase|No Longer Receiving Clinical Benefit|0
6085458|NCT00652626|9694763|FG002|Extension Phase|No Longer Receiving Clinical Benefit|0
6085459|NCT00652626|9694764|FG003|Extension Phase|No Longer Receiving Clinical Benefit|0
6085460|NCT00652626|9694765|FG004|Extension Phase|No Longer Receiving Clinical Benefit|0
6085461|NCT00652626|9694766|FG005|Extension Phase|No Longer Receiving Clinical Benefit|6
6085462|NCT00652626|9694767|FG006|Extension Phase|No Longer Receiving Clinical Benefit|0
6085463|NCT00652626|9694761|FG000|Extension Phase|Physician Decision|0
6085464|NCT00652626|9694762|FG001|Extension Phase|Physician Decision|0
6085465|NCT00652626|9694763|FG002|Extension Phase|Physician Decision|0
6230253|NCT01740791|9904644|FG005|Overall Study|Lost to Follow-up|3
6230254|NCT01740791|9904639|FG000|Overall Study|Withdrew Consent|4
6230255|NCT01740791|9904640|FG001|Overall Study|Withdrew Consent|0
6230256|NCT01740791|9904641|FG002|Overall Study|Withdrew Consent|1
6230257|NCT01740791|9904642|FG003|Overall Study|Withdrew Consent|2
6230258|NCT01740791|9904643|FG004|Overall Study|Withdrew Consent|0
6230259|NCT01740791|9904644|FG005|Overall Study|Withdrew Consent|3
6230260|NCT01740791|9904639|FG000|Overall Study|Investigator's discretion|1
6230261|NCT01740791|9904640|FG001|Overall Study|Investigator's discretion|0
6230262|NCT01740791|9904641|FG002|Overall Study|Investigator's discretion|1
6230263|NCT01740791|9904642|FG003|Overall Study|Investigator's discretion|0
6230264|NCT01740791|9904643|FG004|Overall Study|Investigator's discretion|0
6230265|NCT01740791|9904644|FG005|Overall Study|Investigator's discretion|1
6230266|NCT01740791|9904639|FG000|Overall Study|Adverse Event|0
6230267|NCT01740791|9904640|FG001|Overall Study|Adverse Event|0
6230268|NCT01740791|9904641|FG002|Overall Study|Adverse Event|0
6230269|NCT01740791|9904642|FG003|Overall Study|Adverse Event|0
6230270|NCT01740791|9904643|FG004|Overall Study|Adverse Event|0
6230271|NCT01740791|9904644|FG005|Overall Study|Adverse Event|1
6230272|NCT01741012|9904706|FG000|Overall Study|Lost to Follow-up|1
6230273|NCT01741012|9904706|FG000|Overall Study|Withdrawal by Subject|2
6230274|NCT01741259|9904713|FG000|Overall Study|Protocol Violation|6
6230275|NCT01741259|9904714|FG001|Overall Study|Protocol Violation|4
6230276|NCT01741259|9904713|FG000|Overall Study|Withdrawal by Subject|0
6230277|NCT01741259|9904714|FG001|Overall Study|Withdrawal by Subject|2
6230278|NCT01741532|9904761|FG000|Overall Study|Adverse Event|4
6230279|NCT01741532|9904762|FG001|Overall Study|Adverse Event|0
6230280|NCT01741532|9904761|FG000|Overall Study|Withdrawal by Subject|1
6230281|NCT01741532|9904762|FG001|Overall Study|Withdrawal by Subject|1
6230282|NCT01741532|9904761|FG000|Overall Study|Protocol Violation|0
6230283|NCT01741532|9904762|FG001|Overall Study|Protocol Violation|1
6230284|NCT01741532|9904761|FG000|Overall Study|Worsening of the disease|3
6230285|NCT01741532|9904762|FG001|Overall Study|Worsening of the disease|1
6230286|NCT01741532|9904761|FG000|Overall Study|Sponsor decision|1
6230287|NCT01741532|9904762|FG001|Overall Study|Sponsor decision|0
6230288|NCT01741532|9904761|FG000|Overall Study|Medical event|1
6230289|NCT01741532|9904762|FG001|Overall Study|Medical event|0
6230290|NCT01741545|9904774|FG000|Treatment Period|Lack of Efficacy|0
6230291|NCT01741545|9904775|FG001|Treatment Period|Lack of Efficacy|1
6230292|NCT01741545|9904774|FG000|Treatment Period|Adverse event, non-fatal|1
6230293|NCT01741545|9904775|FG001|Treatment Period|Adverse event, non-fatal|3
6230294|NCT01741545|9904774|FG000|Follow-up Period (24 Weeks)|Other than specified|0
6230295|NCT01741545|9904775|FG001|Follow-up Period (24 Weeks)|Other than specified|1
6230296|NCT01741545|9904774|FG000|Follow-up Period (24 Weeks)|Withdrawal by Subject|1
6230297|NCT01741545|9904775|FG001|Follow-up Period (24 Weeks)|Withdrawal by Subject|1
6230298|NCT01741688|9904781|FG000|Overall Study|Lack of insurance coverage|2
6230299|NCT01741688|9904781|FG000|Overall Study|Withdrawal by Subject|1
6230300|NCT01741701|9904788|FG000|Overall Study|Adverse Event|5
6230301|NCT01741701|9904789|FG001|Overall Study|Adverse Event|1
6230302|NCT01741701|9904788|FG000|Overall Study|Withdrawal by Subject|0
6230303|NCT01741701|9904789|FG001|Overall Study|Withdrawal by Subject|1
6230304|NCT01741792|9904798|FG000|Overall Study|Death|6
6230305|NCT01741792|9904799|FG001|Overall Study|Death|1
6230306|NCT01741792|9904800|FG002|Overall Study|Death|12
6230307|NCT01742078|9904832|FG000|Overall Study|Withdrawal by Subject|0
6230308|NCT01742078|9904833|FG001|Overall Study|Withdrawal by Subject|0
6230309|NCT01742078|9904834|FG002|Overall Study|Withdrawal by Subject|0
6230310|NCT01742078|9904835|FG003|Overall Study|Withdrawal by Subject|1
6230311|NCT01742078|9904836|FG004|Overall Study|Withdrawal by Subject|0
6230312|NCT01742078|9904837|FG005|Overall Study|Withdrawal by Subject|0
6230313|NCT01742078|9904838|FG006|Overall Study|Withdrawal by Subject|0
6230314|NCT01742078|9904839|FG007|Overall Study|Withdrawal by Subject|0
6230315|NCT01742078|9904840|FG008|Overall Study|Withdrawal by Subject|0
6230316|NCT01742091|9904868|FG000|Overall Study|Adverse Event|0
6230317|NCT01742091|9904869|FG001|Overall Study|Adverse Event|0
6230318|NCT01742091|9904870|FG002|Overall Study|Adverse Event|0
6230319|NCT01742091|9904871|FG003|Overall Study|Adverse Event|0
6230320|NCT01742091|9904872|FG004|Overall Study|Adverse Event|1
6230321|NCT01742091|9904873|FG005|Overall Study|Adverse Event|0
6230322|NCT01742091|9904868|FG000|Overall Study|Physician Decision|0
6230323|NCT01742091|9904869|FG001|Overall Study|Physician Decision|0
6230324|NCT01742091|9904870|FG002|Overall Study|Physician Decision|0
6230325|NCT01742091|9904871|FG003|Overall Study|Physician Decision|0
6230326|NCT01742091|9904872|FG004|Overall Study|Physician Decision|0
6230327|NCT01742091|9904873|FG005|Overall Study|Physician Decision|1
6230328|NCT01742091|9904868|FG000|Overall Study|Withdrawal by Subject|0
6230329|NCT01742091|9904869|FG001|Overall Study|Withdrawal by Subject|0
6230330|NCT01742091|9904870|FG002|Overall Study|Withdrawal by Subject|0
6230331|NCT01742091|9904871|FG003|Overall Study|Withdrawal by Subject|1
6230332|NCT01742091|9904872|FG004|Overall Study|Withdrawal by Subject|0
6230333|NCT01742091|9904873|FG005|Overall Study|Withdrawal by Subject|0
6230334|NCT01742091|9904868|FG000|Overall Study|Lost to Follow-up|0
6230335|NCT01742091|9904869|FG001|Overall Study|Lost to Follow-up|0
6230336|NCT01742091|9904870|FG002|Overall Study|Lost to Follow-up|0
6230337|NCT01742091|9904871|FG003|Overall Study|Lost to Follow-up|0
6230338|NCT01742091|9904872|FG004|Overall Study|Lost to Follow-up|0
6230339|NCT01742091|9904873|FG005|Overall Study|Lost to Follow-up|1
6230340|NCT01742286|9904918|FG000|Escalation Phase|Administrative problems|1
6230341|NCT01742286|9904919|FG001|Escalation Phase|Administrative problems|1
6230342|NCT01742286|9904920|FG002|Escalation Phase|Administrative problems|0
6230343|NCT01742286|9904921|FG003|Escalation Phase|Administrative problems|0
6230344|NCT01742286|9904922|FG004|Escalation Phase|Administrative problems|0
6230345|NCT01742286|9904923|FG005|Escalation Phase|Administrative problems|0
6230346|NCT01742286|9904924|FG006|Escalation Phase|Administrative problems|2
6230347|NCT01742286|9904918|FG000|Escalation Phase|Adverse Event|0
6230348|NCT01742286|9904919|FG001|Escalation Phase|Adverse Event|1
6230349|NCT01742286|9904920|FG002|Escalation Phase|Adverse Event|2
6230350|NCT01742286|9904921|FG003|Escalation Phase|Adverse Event|0
6230351|NCT01742286|9904922|FG004|Escalation Phase|Adverse Event|0
6230352|NCT01742286|9904923|FG005|Escalation Phase|Adverse Event|1
6230353|NCT01742286|9904924|FG006|Escalation Phase|Adverse Event|0
6230354|NCT01742286|9904918|FG000|Escalation Phase|Disease progression|3
6230355|NCT01742286|9904919|FG001|Escalation Phase|Disease progression|7
6230356|NCT01742286|9904920|FG002|Escalation Phase|Disease progression|4
6230357|NCT01742286|9904921|FG003|Escalation Phase|Disease progression|1
6230358|NCT01742286|9904922|FG004|Escalation Phase|Disease progression|4
6230359|NCT01742286|9904923|FG005|Escalation Phase|Disease progression|3
6230360|NCT01742286|9904924|FG006|Escalation Phase|Disease progression|2
6230361|NCT01742286|9904918|FG000|Escalation Phase|Death|0
6230362|NCT01742286|9904919|FG001|Escalation Phase|Death|0
6230363|NCT01742286|9904920|FG002|Escalation Phase|Death|0
6230364|NCT01742286|9904921|FG003|Escalation Phase|Death|0
6230365|NCT01742286|9904922|FG004|Escalation Phase|Death|0
6230366|NCT01742286|9904923|FG005|Escalation Phase|Death|1
6230367|NCT01742286|9904924|FG006|Escalation Phase|Death|0
6230368|NCT01742286|9904918|FG000|Escalation Phase|Physician Decision|0
6230369|NCT01742286|9904919|FG001|Escalation Phase|Physician Decision|3
6230370|NCT01742286|9904920|FG002|Escalation Phase|Physician Decision|0
6230371|NCT01742286|9904921|FG003|Escalation Phase|Physician Decision|1
6230372|NCT01742286|9904922|FG004|Escalation Phase|Physician Decision|0
6230373|NCT01742286|9904923|FG005|Escalation Phase|Physician Decision|0
6230374|NCT01742286|9904924|FG006|Escalation Phase|Physician Decision|2
6230375|NCT01742286|9904918|FG000|Escalation Phase|Subject/guardian decision|1
6230376|NCT01742286|9904919|FG001|Escalation Phase|Subject/guardian decision|0
6230377|NCT01742286|9904920|FG002|Escalation Phase|Subject/guardian decision|0
6230378|NCT01742286|9904921|FG003|Escalation Phase|Subject/guardian decision|0
6230379|NCT01742286|9904922|FG004|Escalation Phase|Subject/guardian decision|0
6230380|NCT01742286|9904923|FG005|Escalation Phase|Subject/guardian decision|0
6230381|NCT01742286|9904924|FG006|Escalation Phase|Subject/guardian decision|0
6230382|NCT01742286|9904918|FG000|Expansion Phase|Administrative problems|0
6230383|NCT01742286|9904919|FG001|Expansion Phase|Administrative problems|0
6186997|NCT01377233|9840593|FG000|Double-blind|Withdrawal by Subject|0
6186998|NCT01377233|9840594|FG001|Double-blind|Withdrawal by Subject|0
6230384|NCT01742286|9904920|FG002|Expansion Phase|Administrative problems|0
6230385|NCT01742286|9904921|FG003|Expansion Phase|Administrative problems|0
6230386|NCT01742286|9904922|FG004|Expansion Phase|Administrative problems|0
6230387|NCT01742286|9904923|FG005|Expansion Phase|Administrative problems|0
6230388|NCT01742286|9904924|FG006|Expansion Phase|Administrative problems|5
6230389|NCT01742286|9904918|FG000|Expansion Phase|Physician Decision|0
6230390|NCT01742286|9904919|FG001|Expansion Phase|Physician Decision|0
6230391|NCT01742286|9904920|FG002|Expansion Phase|Physician Decision|4
6230392|NCT01742286|9904921|FG003|Expansion Phase|Physician Decision|0
6230393|NCT01742286|9904922|FG004|Expansion Phase|Physician Decision|0
6230394|NCT01742286|9904923|FG005|Expansion Phase|Physician Decision|0
6230395|NCT01742286|9904924|FG006|Expansion Phase|Physician Decision|9
6230396|NCT01742286|9904918|FG000|Expansion Phase|Adverse Event|0
6230397|NCT01742286|9904919|FG001|Expansion Phase|Adverse Event|0
6230398|NCT01742286|9904920|FG002|Expansion Phase|Adverse Event|0
6230399|NCT01742286|9904921|FG003|Expansion Phase|Adverse Event|0
6230400|NCT01742286|9904922|FG004|Expansion Phase|Adverse Event|0
6230401|NCT01742286|9904923|FG005|Expansion Phase|Adverse Event|0
6230402|NCT01742286|9904924|FG006|Expansion Phase|Adverse Event|6
6230403|NCT01742286|9904918|FG000|Expansion Phase|Disease progression|0
6230404|NCT01742286|9904919|FG001|Expansion Phase|Disease progression|0
6230405|NCT01742286|9904920|FG002|Expansion Phase|Disease progression|3
6230406|NCT01742286|9904921|FG003|Expansion Phase|Disease progression|0
6230407|NCT01742286|9904922|FG004|Expansion Phase|Disease progression|0
6186999|NCT01377233|9840595|FG002|Double-blind|Withdrawal by Subject|0
6187000|NCT01377233|9840596|FG003|Double-blind|Withdrawal by Subject|1
6187001|NCT01377233|9840597|FG004|Double-blind|Withdrawal by Subject|0
6187002|NCT01377233|9840593|FG000|Double-blind|Administrative or other|0
6187003|NCT01377233|9840594|FG001|Double-blind|Administrative or other|0
6187004|NCT01377233|9840595|FG002|Double-blind|Administrative or other|0
6187005|NCT01377233|9840596|FG003|Double-blind|Administrative or other|1
6187006|NCT01377233|9840597|FG004|Double-blind|Administrative or other|1
6187007|NCT01377389|9840613|FG000|Overall Study|Withdrawal by Subject|1
6230408|NCT01742286|9904923|FG005|Expansion Phase|Disease progression|0
6230409|NCT01742286|9904924|FG006|Expansion Phase|Disease progression|15
6230410|NCT01742286|9904918|FG000|Expansion Phase|Withdrawal by Subject|0
6230411|NCT01742286|9904919|FG001|Expansion Phase|Withdrawal by Subject|0
6230412|NCT01742286|9904920|FG002|Expansion Phase|Withdrawal by Subject|0
6230413|NCT01742286|9904921|FG003|Expansion Phase|Withdrawal by Subject|0
6187008|NCT01377389|9840613|FG000|Overall Study|Screen failure|2
6230414|NCT01742286|9904922|FG004|Expansion Phase|Withdrawal by Subject|0
6230415|NCT01742286|9904923|FG005|Expansion Phase|Withdrawal by Subject|0
6230416|NCT01742286|9904924|FG006|Expansion Phase|Withdrawal by Subject|1
6230417|NCT01742897|9904974|FG000|Overall Study|Adverse Event|3
6230418|NCT01742897|9904974|FG000|Overall Study|Withdrawal by Subject|1
6230419|NCT01742897|9904974|FG000|Overall Study|Other|1
6230420|NCT01743001|9904999|FG000|Overall Study|Physician Decision|1
6230421|NCT01743001|9905000|FG001|Overall Study|Physician Decision|0
6230422|NCT01743001|9904999|FG000|Overall Study|Pregnancy|1
6230423|NCT01743001|9905000|FG001|Overall Study|Pregnancy|0
6230424|NCT01743001|9904999|FG000|Overall Study|Death|1
6230425|NCT01743001|9905000|FG001|Overall Study|Death|0
6230426|NCT01743027|9905010|FG000|Overall Study|Adverse Event|2
6230427|NCT01743027|9905011|FG001|Overall Study|Adverse Event|0
6230428|NCT01743027|9905012|FG002|Overall Study|Adverse Event|0
6230429|NCT01743027|9905013|FG003|Overall Study|Adverse Event|0
6230430|NCT01743027|9905010|FG000|Overall Study|Lost to Follow-up|0
6230431|NCT01743027|9905011|FG001|Overall Study|Lost to Follow-up|0
6230432|NCT01743027|9905012|FG002|Overall Study|Lost to Follow-up|2
6230433|NCT01743027|9905013|FG003|Overall Study|Lost to Follow-up|0
6230434|NCT01743027|9905010|FG000|Overall Study|Progressive Disease|1
6230435|NCT01743027|9905011|FG001|Overall Study|Progressive Disease|4
6230436|NCT01743027|9905012|FG002|Overall Study|Progressive Disease|3
6230437|NCT01743027|9905013|FG003|Overall Study|Progressive Disease|0
6230438|NCT01743027|9905010|FG000|Overall Study|Protocol Violation|1
6230439|NCT01743027|9905011|FG001|Overall Study|Protocol Violation|1
6230440|NCT01743027|9905012|FG002|Overall Study|Protocol Violation|1
6230441|NCT01743027|9905013|FG003|Overall Study|Protocol Violation|0
6230442|NCT01743027|9905010|FG000|Overall Study|Withdrawal by Subject|1
6230443|NCT01743027|9905011|FG001|Overall Study|Withdrawal by Subject|0
6230444|NCT01743027|9905012|FG002|Overall Study|Withdrawal by Subject|3
6230445|NCT01743027|9905013|FG003|Overall Study|Withdrawal by Subject|1
6230446|NCT01743040|9905023|FG000|Overall Study|Death|1
6230447|NCT01743040|9905023|FG000|Overall Study|Lost to Follow-up|66
6230448|NCT01743040|9905023|FG000|Overall Study|Physician Decision|40
6230449|NCT01743040|9905023|FG000|Overall Study|Protocol Violation|1
6230450|NCT01743040|9905023|FG000|Overall Study|Withdrawal by Subject|121
6230451|NCT01743092|9905029|FG000|Overall Study|Lost to Follow-up|14
6230452|NCT01743092|9905030|FG001|Overall Study|Lost to Follow-up|15
6230453|NCT01743469|9905057|FG000|Active Treatment Phase|Adverse Event|10
6230454|NCT01743469|9905058|FG001|Active Treatment Phase|Adverse Event|5
6230455|NCT01743469|9905059|FG002|Active Treatment Phase|Adverse Event|8
6230456|NCT01743469|9905060|FG003|Active Treatment Phase|Adverse Event|1
6230457|NCT01743469|9905057|FG000|Active Treatment Phase|Disease Progression|40
6230458|NCT01743469|9905058|FG001|Active Treatment Phase|Disease Progression|47
6230459|NCT01743469|9905059|FG002|Active Treatment Phase|Disease Progression|30
6230460|NCT01743469|9905060|FG003|Active Treatment Phase|Disease Progression|20
6230461|NCT01743469|9905057|FG000|Active Treatment Phase|Withdrawal by Subject|2
6230462|NCT01743469|9905058|FG001|Active Treatment Phase|Withdrawal by Subject|3
6230463|NCT01743469|9905059|FG002|Active Treatment Phase|Withdrawal by Subject|0
6230464|NCT01743469|9905060|FG003|Active Treatment Phase|Withdrawal by Subject|0
6230465|NCT01743469|9905057|FG000|Active Treatment Phase|Missing|1
6085466|NCT00652626|9694764|FG003|Extension Phase|Physician Decision|0
6085467|NCT00652626|9694765|FG004|Extension Phase|Physician Decision|0
6187009|NCT01377480|9840636|FG000|Overall Study|Protocol Violation|0
6187010|NCT01377480|9840637|FG001|Overall Study|Protocol Violation|0
6187011|NCT01377480|9840638|FG002|Overall Study|Protocol Violation|0
6187012|NCT01377480|9840639|FG003|Overall Study|Protocol Violation|4
6187013|NCT01377480|9840636|FG000|Overall Study|Evidence of drug-induced hepatotoxicity|0
6187014|NCT01377480|9840637|FG001|Overall Study|Evidence of drug-induced hepatotoxicity|1
6187015|NCT01377480|9840638|FG002|Overall Study|Evidence of drug-induced hepatotoxicity|1
6187016|NCT01377480|9840639|FG003|Overall Study|Evidence of drug-induced hepatotoxicity|0
6187017|NCT01377480|9840636|FG000|Overall Study|Withdrawal by Subject|0
6187018|NCT01377480|9840637|FG001|Overall Study|Withdrawal by Subject|0
6187019|NCT01377480|9840638|FG002|Overall Study|Withdrawal by Subject|1
6187020|NCT01377480|9840639|FG003|Overall Study|Withdrawal by Subject|0
6230466|NCT01743469|9905058|FG001|Active Treatment Phase|Missing|0
6230467|NCT01743469|9905059|FG002|Active Treatment Phase|Missing|0
6230468|NCT01743469|9905060|FG003|Active Treatment Phase|Missing|0
6230469|NCT01743469|9905057|FG000|Follow-up Period - Post-Treatment|Withdrawal by Subject|1
6230470|NCT01743469|9905058|FG001|Follow-up Period - Post-Treatment|Withdrawal by Subject|0
6230471|NCT01743469|9905059|FG002|Follow-up Period - Post-Treatment|Withdrawal by Subject|1
6085468|NCT00652626|9694766|FG005|Extension Phase|Physician Decision|1
6187021|NCT01377480|9840636|FG000|Overall Study|Serious adverse event|0
6187022|NCT01377480|9840637|FG001|Overall Study|Serious adverse event|0
6230472|NCT01743469|9905060|FG003|Follow-up Period - Post-Treatment|Withdrawal by Subject|0
6230473|NCT01743469|9905057|FG000|Follow-up Period - Post-Treatment|Death|43
6230474|NCT01743469|9905058|FG001|Follow-up Period - Post-Treatment|Death|47
6230475|NCT01743469|9905059|FG002|Follow-up Period - Post-Treatment|Death|22
6230476|NCT01743469|9905060|FG003|Follow-up Period - Post-Treatment|Death|16
6230477|NCT01743469|9905057|FG000|Follow-up Period - Post-Treatment|Lost to Follow-up|1
6230478|NCT01743469|9905058|FG001|Follow-up Period - Post-Treatment|Lost to Follow-up|1
6230479|NCT01743469|9905059|FG002|Follow-up Period - Post-Treatment|Lost to Follow-up|0
6230480|NCT01743469|9905060|FG003|Follow-up Period - Post-Treatment|Lost to Follow-up|0
6230481|NCT01743560|9905085|FG000|Overall Study|Disease progression|26
6230482|NCT01743560|9905085|FG000|Overall Study|Adverse Event|8
6230483|NCT01743560|9905085|FG000|Overall Study|Death|3
6230484|NCT01743560|9905085|FG000|Overall Study|Withdrawal by Subject|2
6230485|NCT01743560|9905085|FG000|Overall Study|Protocol Violation|1
6230486|NCT01743560|9905085|FG000|Overall Study|>1 dose of study drug|3
6230487|NCT01743989|9905147|FG000|Treatment Phase|Unstable MR4.0|0
6230488|NCT01743989|9905148|FG001|Treatment Phase|Unstable MR4.0|6
6230489|NCT01743989|9905149|FG002|Treatment Phase|Unstable MR4.0|263
6230490|NCT01743989|9905147|FG000|Treatment Phase|Adverse Event|0
6230491|NCT01743989|9905148|FG001|Treatment Phase|Adverse Event|4
6230492|NCT01743989|9905149|FG002|Treatment Phase|Adverse Event|67
6230493|NCT01743989|9905147|FG000|Treatment Phase|Withdrawal by Subject|1
6230494|NCT01743989|9905148|FG001|Treatment Phase|Withdrawal by Subject|3
6230495|NCT01743989|9905149|FG002|Treatment Phase|Withdrawal by Subject|28
6230496|NCT01743989|9905147|FG000|Treatment Phase|Death|0
6230497|NCT01743989|9905148|FG001|Treatment Phase|Death|1
6230498|NCT01743989|9905149|FG002|Treatment Phase|Death|3
6230499|NCT01743989|9905147|FG000|Treatment Phase|Abnormal laboratory value(s)|0
6230500|NCT01743989|9905148|FG001|Treatment Phase|Abnormal laboratory value(s)|0
6230501|NCT01743989|9905149|FG002|Treatment Phase|Abnormal laboratory value(s)|3
6230502|NCT01743989|9905147|FG000|Treatment Phase|Protocol deviation|0
6230503|NCT01743989|9905148|FG001|Treatment Phase|Protocol deviation|0
6230504|NCT01743989|9905149|FG002|Treatment Phase|Protocol deviation|3
6230505|NCT01743989|9905147|FG000|Treatment Phase|Pregnancy|0
6230506|NCT01743989|9905148|FG001|Treatment Phase|Pregnancy|0
6085469|NCT00652626|9694767|FG006|Extension Phase|Physician Decision|1
6230507|NCT01743989|9905149|FG002|Treatment Phase|Pregnancy|2
6230508|NCT01743989|9905147|FG000|Treatment Phase|Lost to Follow-up|0
6230509|NCT01743989|9905148|FG001|Treatment Phase|Lost to Follow-up|0
6230510|NCT01743989|9905149|FG002|Treatment Phase|Lost to Follow-up|2
6230511|NCT01743989|9905147|FG000|Treatment Phase|Abnormal test procedure result(s)|0
6230512|NCT01743989|9905148|FG001|Treatment Phase|Abnormal test procedure result(s)|0
6230513|NCT01743989|9905149|FG002|Treatment Phase|Abnormal test procedure result(s)|1
6230514|NCT01743989|9905147|FG000|Treatment Phase|Administrative problems|0
6230515|NCT01743989|9905148|FG001|Treatment Phase|Administrative problems|0
6230516|NCT01743989|9905149|FG002|Treatment Phase|Administrative problems|1
6230517|NCT01743989|9905147|FG000|Treatment Phase|New cancer (CML) therapy|0
6230518|NCT01743989|9905148|FG001|Treatment Phase|New cancer (CML) therapy|1
6230519|NCT01743989|9905149|FG002|Treatment Phase|New cancer (CML) therapy|0
6230520|NCT01743989|9905147|FG000|Treatment Phase|Physician Decision|0
6230521|NCT01743989|9905148|FG001|Treatment Phase|Physician Decision|0
6230522|NCT01743989|9905149|FG002|Treatment Phase|Physician Decision|3
6230523|NCT01743989|9905147|FG000|Treatment Phase|Patient non-compliance to treatment|0
6230524|NCT01743989|9905148|FG001|Treatment Phase|Patient non-compliance to treatment|0
6230525|NCT01743989|9905149|FG002|Treatment Phase|Patient non-compliance to treatment|3
6230526|NCT01743989|9905147|FG000|Treatment Phase|Not randomized by mistake|0
6230527|NCT01743989|9905148|FG001|Treatment Phase|Not randomized by mistake|0
6230528|NCT01743989|9905149|FG002|Treatment Phase|Not randomized by mistake|1
6230529|NCT01743989|9905147|FG000|Treatment Phase|Included by mistake|0
6230530|NCT01743989|9905148|FG001|Treatment Phase|Included by mistake|0
6230531|NCT01743989|9905149|FG002|Treatment Phase|Included by mistake|1
6230532|NCT01743989|9905147|FG000|TFR Phase|Relapse (Loss of MMR/Confirmed loss of MR4.0)|82
6230533|NCT01743989|9905148|FG001|TFR Phase|Relapse (Loss of MMR/Confirmed loss of MR4.0)|59
6230534|NCT01743989|9905149|FG002|TFR Phase|Relapse (Loss of MMR/Confirmed loss of MR4.0)|0
6230535|NCT01743989|9905147|FG000|TFR Phase|Adverse Event|0
6230536|NCT01743989|9905148|FG001|TFR Phase|Adverse Event|1
6230537|NCT01743989|9905149|FG002|TFR Phase|Adverse Event|0
6230538|NCT01743989|9905147|FG000|TFR Phase|Lost to Follow-up|0
6230539|NCT01743989|9905148|FG001|TFR Phase|Lost to Follow-up|2
6230540|NCT01743989|9905149|FG002|TFR Phase|Lost to Follow-up|0
6230541|NCT01743989|9905147|FG000|TFR Phase|Physician Decision|0
6230542|NCT01743989|9905148|FG001|TFR Phase|Physician Decision|1
6230543|NCT01743989|9905149|FG002|TFR Phase|Physician Decision|0
6230544|NCT01743989|9905147|FG000|TFR Phase|Logistical problems|0
6230545|NCT01743989|9905148|FG001|TFR Phase|Logistical problems|2
6230546|NCT01743989|9905149|FG002|TFR Phase|Logistical problems|0
6230547|NCT01743989|9905147|FG000|TFR Phase|Protocol deviation|0
6230548|NCT01743989|9905148|FG001|TFR Phase|Protocol deviation|1
6230549|NCT01743989|9905149|FG002|TFR Phase|Protocol deviation|0
6230550|NCT01743989|9905147|FG000|TFR Phase|Withdrawal by Subject|0
6230551|NCT01743989|9905148|FG001|TFR Phase|Withdrawal by Subject|2
6230552|NCT01743989|9905149|FG002|TFR Phase|Withdrawal by Subject|0
6230553|NCT01743989|9905147|FG000|Re-treatment Phase|Adverse Event|8
6230554|NCT01743989|9905148|FG001|Re-treatment Phase|Adverse Event|4
6230555|NCT01743989|9905149|FG002|Re-treatment Phase|Adverse Event|0
6230556|NCT01743989|9905147|FG000|Re-treatment Phase|Death|1
6230557|NCT01743989|9905148|FG001|Re-treatment Phase|Death|1
6230558|NCT01743989|9905149|FG002|Re-treatment Phase|Death|0
6230559|NCT01743989|9905147|FG000|Re-treatment Phase|Administrative problems|1
6230560|NCT01743989|9905148|FG001|Re-treatment Phase|Administrative problems|1
6230561|NCT01743989|9905149|FG002|Re-treatment Phase|Administrative problems|0
6230562|NCT01743989|9905147|FG000|Re-treatment Phase|Withdrawal by Subject|5
6230563|NCT01743989|9905148|FG001|Re-treatment Phase|Withdrawal by Subject|1
6230564|NCT01743989|9905149|FG002|Re-treatment Phase|Withdrawal by Subject|0
6230565|NCT01743989|9905147|FG000|Re-treatment Phase|Unstable MR|1
6230566|NCT01743989|9905148|FG001|Re-treatment Phase|Unstable MR|0
6230567|NCT01743989|9905149|FG002|Re-treatment Phase|Unstable MR|0
6230568|NCT01743989|9905147|FG000|Re-treatment Phase|Physician Decision|0
6230569|NCT01743989|9905148|FG001|Re-treatment Phase|Physician Decision|1
6230570|NCT01743989|9905149|FG002|Re-treatment Phase|Physician Decision|0
6230571|NCT01743989|9905147|FG000|Re-treatment Phase|Lost to Follow-up|0
6230572|NCT01743989|9905148|FG001|Re-treatment Phase|Lost to Follow-up|1
6230573|NCT01743989|9905149|FG002|Re-treatment Phase|Lost to Follow-up|0
6230574|NCT01744197|9905162|FG000|Overall Study|Received 1 patch|2
6230575|NCT01744197|9905163|FG001|Overall Study|Received 1 patch|1
6230576|NCT01744197|9905162|FG000|Overall Study|No patch received|2
6230577|NCT01744197|9905163|FG001|Overall Study|No patch received|2
6230578|NCT01744392|9905189|FG000|Overall Study|Physician Decision|1
6230579|NCT01744483|9905197|FG000|Overall Study|Death|9
6230580|NCT01744483|9905198|FG001|Overall Study|Death|4
6230581|NCT01744483|9905199|FG002|Overall Study|Death|11
6230582|NCT01744483|9905197|FG000|Overall Study|Lost to Follow-up|8
6230583|NCT01744483|9905198|FG001|Overall Study|Lost to Follow-up|9
6230584|NCT01744483|9905199|FG002|Overall Study|Lost to Follow-up|11
6230585|NCT01744483|9905197|FG000|Overall Study|Protocol Violation|1
6230586|NCT01744483|9905198|FG001|Overall Study|Protocol Violation|2
6230587|NCT01744483|9905199|FG002|Overall Study|Protocol Violation|1
6230588|NCT01744483|9905197|FG000|Overall Study|Withdrawal by Subject|4
6230589|NCT01744483|9905198|FG001|Overall Study|Withdrawal by Subject|6
6230590|NCT01744483|9905199|FG002|Overall Study|Withdrawal by Subject|2
6230591|NCT01744483|9905197|FG000|Overall Study|No ICU Admit|5
6230592|NCT01744483|9905198|FG001|Overall Study|No ICU Admit|1
6230593|NCT01744483|9905199|FG002|Overall Study|No ICU Admit|2
6230594|NCT01744483|9905197|FG000|Overall Study|Routed to OSH|2
6230595|NCT01744483|9905198|FG001|Overall Study|Routed to OSH|0
6230596|NCT01744483|9905199|FG002|Overall Study|Routed to OSH|1
6230597|NCT01744496|9905209|FG000|Titration Period|Adverse Event|2
6230598|NCT01744496|9905210|FG001|Titration Period|Adverse Event|1
6230599|NCT01744496|9905209|FG000|Titration Period|Personal reasons|0
6230600|NCT01744496|9905210|FG001|Titration Period|Personal reasons|1
6230601|NCT01744496|9905209|FG000|Maintenance Period|Adverse Event|1
6230602|NCT01744496|9905210|FG001|Maintenance Period|Adverse Event|3
6230603|NCT01744496|9905209|FG000|Maintenance Period|Protocol Violation|1
6230604|NCT01744496|9905210|FG001|Maintenance Period|Protocol Violation|0
6230605|NCT01744496|9905209|FG000|Maintenance Period|Withdrawal by Subject|1
6230606|NCT01744496|9905210|FG001|Maintenance Period|Withdrawal by Subject|1
6230607|NCT01744496|9905209|FG000|Maintenance Period|Subject left town|1
6230608|NCT01744496|9905210|FG001|Maintenance Period|Subject left town|0
6230609|NCT01744665|9905233|FG000|Monitoring Phase|Adverse Event|4
6230610|NCT01744665|9905233|FG000|Monitoring Phase|Abnormal laboratory value(s)|1
6230611|NCT01744665|9905233|FG000|Monitoring Phase|Unsatisfactory therapeutic effect|7
6230612|NCT01744665|9905233|FG000|Monitoring Phase|Withdrawal by Subject|5
6230613|NCT01744665|9905233|FG000|Monitoring Phase|Did not achieve MR4.5|1
6230614|NCT01744665|9905233|FG000|Consolidation Phase|Adverse Event|2
6230615|NCT01744665|9905233|FG000|Consolidation Phase|Unsatisfactory therapeutic effect|4
6230616|NCT01744665|9905233|FG000|Consolidation Phase|Withdrawal by Subject|4
6230617|NCT01744665|9905233|FG000|Consolidation Phase|Administrative problems|9
6230618|NCT01744665|9905233|FG000|Re-initiation Phase|Administrative problems|10
6230619|NCT01744665|9905233|FG000|Re-initiation Phase|Adverse Event|1
6230620|NCT01744665|9905233|FG000|Re-initiation Phase|No longer required treatment|1
6230621|NCT01744665|9905233|FG000|Re-initiation Phase|Withdrawal by Subject|1
6230622|NCT01744691|9905240|FG000|Overall Study|Progressive Disease|18
6230623|NCT01744691|9905240|FG000|Overall Study|Unacceptable toxicity, AE or death|18
6230624|NCT01744691|9905240|FG000|Overall Study|Withdrawal of consent for treatment|3
6230625|NCT01744691|9905240|FG000|Overall Study|Physician Decision|4
6230626|NCT01744782|9905316|FG000|Overall Study|Death|1
6269741|NCT02143713|9970157|FG001|Treatment Period (6 Months)|Surgery or Invasive Intervention|0
6269742|NCT02143713|9970158|FG002|Treatment Period (6 Months)|Surgery or Invasive Intervention|0
6269743|NCT02143713|9970159|FG003|Treatment Period (6 Months)|Surgery or Invasive Intervention|2
6269744|NCT02143713|9970156|FG000|Treatment Period (6 Months)|Pregnancy|0
6269745|NCT02143713|9970157|FG001|Treatment Period (6 Months)|Pregnancy|2
6269746|NCT02143713|9970158|FG002|Treatment Period (6 Months)|Pregnancy|2
6269747|NCT02143713|9970159|FG003|Treatment Period (6 Months)|Pregnancy|0
6269748|NCT02143713|9970156|FG000|Treatment Period (6 Months)|Non-compliance|1
6269749|NCT02143713|9970157|FG001|Treatment Period (6 Months)|Non-compliance|0
6269750|NCT02143713|9970158|FG002|Treatment Period (6 Months)|Non-compliance|0
6269751|NCT02143713|9970159|FG003|Treatment Period (6 Months)|Non-compliance|3
6269752|NCT02143713|9970156|FG000|Treatment Period (6 Months)|Other|3
6269753|NCT02143713|9970157|FG001|Treatment Period (6 Months)|Other|0
6269754|NCT02143713|9970158|FG002|Treatment Period (6 Months)|Other|3
6269755|NCT02143713|9970159|FG003|Treatment Period (6 Months)|Other|2
6269756|NCT02143713|9970156|FG000|Treatment Period (6 Months)|Bone Mineral Density (BMD) Decrease|0
6269757|NCT02143713|9970157|FG001|Treatment Period (6 Months)|Bone Mineral Density (BMD) Decrease|0
6269758|NCT02143713|9970158|FG002|Treatment Period (6 Months)|Bone Mineral Density (BMD) Decrease|0
6269759|NCT02143713|9970159|FG003|Treatment Period (6 Months)|Bone Mineral Density (BMD) Decrease|4
6085470|NCT00652626|9694761|FG000|Extension Phase|Death|0
6085471|NCT00652626|9694762|FG001|Extension Phase|Death|0
6085472|NCT00652626|9694763|FG002|Extension Phase|Death|0
6085473|NCT00652626|9694764|FG003|Extension Phase|Death|0
6085474|NCT00652626|9694765|FG004|Extension Phase|Death|0
6085475|NCT00652626|9694766|FG005|Extension Phase|Death|1
6085476|NCT00652626|9694767|FG006|Extension Phase|Death|1
6085477|NCT00652743|9694788|FG000|Months 12-18|Lost to Follow-up|1
6085478|NCT00652743|9694789|FG001|Months 12-18|Lost to Follow-up|2
6187023|NCT01377480|9840638|FG002|Overall Study|Serious adverse event|1
6187024|NCT01377480|9840639|FG003|Overall Study|Serious adverse event|1
6187025|NCT01377480|9840636|FG000|Overall Study|Other|0
6187026|NCT01377480|9840637|FG001|Overall Study|Other|0
6187027|NCT01377480|9840638|FG002|Overall Study|Other|7
6187028|NCT01377480|9840639|FG003|Overall Study|Other|6
6187029|NCT01377844|9840694|FG000|Overall Study|Withdrawal by Subject|25
6187030|NCT01377844|9840695|FG001|Overall Study|Withdrawal by Subject|28
6187031|NCT01377844|9840694|FG000|Overall Study|Protocol Violation|2
6187032|NCT01377844|9840695|FG001|Overall Study|Protocol Violation|3
6187033|NCT01377844|9840694|FG000|Overall Study|Adverse Event|3
6187034|NCT01377844|9840695|FG001|Overall Study|Adverse Event|0
6187035|NCT01377844|9840694|FG000|Overall Study|Physician Decision|6
6187036|NCT01377844|9840695|FG001|Overall Study|Physician Decision|3
6187037|NCT01377844|9840694|FG000|Overall Study|Study terminated by Sponsor|0
6187038|NCT01377844|9840695|FG001|Overall Study|Study terminated by Sponsor|1
6187039|NCT01377922|9840704|FG000|Overall Study|rescue tx after part 2, entered part 4|1
6187040|NCT01377922|9840705|FG001|Overall Study|rescue tx after part 2, entered part 4|0
6187041|NCT01377987|9840711|FG000|Washout (7 Days)|Withdrawal by Subject|1
6187042|NCT01377987|9840712|FG001|Washout (7 Days)|Withdrawal by Subject|1
6187043|NCT01378104|9840724|FG000|Overall Study|Adverse Event|8
6187044|NCT01378104|9840725|FG001|Overall Study|Adverse Event|8
6187045|NCT01378104|9840724|FG000|Overall Study|Lack of Efficacy|7
6187046|NCT01378104|9840725|FG001|Overall Study|Lack of Efficacy|5
6187047|NCT01378104|9840724|FG000|Overall Study|Withdrawal by Subject|12
6187048|NCT01378104|9840725|FG001|Overall Study|Withdrawal by Subject|13
6187049|NCT01378117|9840736|FG000|Overall Study|withdrawal|2
6187050|NCT01378117|9840737|FG001|Overall Study|withdrawal|1
6187051|NCT01378117|9840738|FG002|Overall Study|withdrawal|2
6187052|NCT01378117|9840736|FG000|Overall Study|discharged before med given|2
6187053|NCT01378117|9840737|FG001|Overall Study|discharged before med given|0
6187054|NCT01378117|9840738|FG002|Overall Study|discharged before med given|1
6187055|NCT01378195|9840753|FG000|Overall Study|Lost to Follow-up|29
6187056|NCT01378195|9840754|FG001|Overall Study|Lost to Follow-up|18
6187057|NCT01378325|9840814|FG000|Overall Study|Protocol Violation|0
6187058|NCT01378325|9840815|FG001|Overall Study|Protocol Violation|1
6187059|NCT01378429|9840845|FG000|Overall Study|Noncompliance with study drug|1
6187060|NCT01378429|9840846|FG001|Overall Study|Noncompliance with study drug|0
6187061|NCT01378858|9840864|FG000|Overall Study|Withdrawal by Subject|4
6187062|NCT01378858|9840865|FG001|Overall Study|Withdrawal by Subject|4
6187063|NCT01378962|9840871|FG000|Overall Study|Death|14
6187064|NCT01378962|9840871|FG000|Overall Study|Lost to Follow-up|1
6187065|NCT01378962|9840871|FG000|Overall Study|Other|2
6043590|NCT00391053|9642299|FG002|Overall Study|Lost to Follow-up|0
6043591|NCT00391053|9642300|FG003|Overall Study|Lost to Follow-up|5
6043592|NCT00391053|9642297|FG000|Overall Study|Withdrawal by Subject|5
6043593|NCT00391053|9642298|FG001|Overall Study|Withdrawal by Subject|1
6043594|NCT00391053|9642299|FG002|Overall Study|Withdrawal by Subject|1
6043595|NCT00391053|9642300|FG003|Overall Study|Withdrawal by Subject|1
6043596|NCT00391092|9642321|FG000|Overall Study|Death|78
6043597|NCT00391092|9642322|FG001|Overall Study|Death|81
6043598|NCT00391092|9642321|FG000|Overall Study|Lost to Follow-up|13
6043599|NCT00391092|9642322|FG001|Overall Study|Lost to Follow-up|18
6043600|NCT00391092|9642321|FG000|Overall Study|Alive on treatment|29
6043601|NCT00391092|9642322|FG001|Overall Study|Alive on treatment|33
6043602|NCT00391092|9642321|FG000|Overall Study|Alive in follow-up|88
6043603|NCT00391092|9642322|FG001|Overall Study|Alive in follow-up|84
6043604|NCT00391118|9642331|FG000|Overall Study|Adverse Event|3
6043605|NCT00391118|9642332|FG001|Overall Study|Adverse Event|10
6043606|NCT00391118|9642333|FG002|Overall Study|Adverse Event|7
6043607|NCT00391118|9642331|FG000|Overall Study|Lost to Follow-up|0
6043608|NCT00391118|9642332|FG001|Overall Study|Lost to Follow-up|2
6043609|NCT00391118|9642333|FG002|Overall Study|Lost to Follow-up|3
6043610|NCT00391118|9642331|FG000|Overall Study|Withdrawal by Subject|0
6043611|NCT00391118|9642332|FG001|Overall Study|Withdrawal by Subject|9
6043612|NCT00391118|9642333|FG002|Overall Study|Withdrawal by Subject|1
6043613|NCT00391118|9642331|FG000|Overall Study|Death|0
6043614|NCT00391118|9642332|FG001|Overall Study|Death|1
6043615|NCT00391118|9642333|FG002|Overall Study|Death|0
6043616|NCT00391118|9642331|FG000|Overall Study|Physician Decision|0
6043617|NCT00391118|9642332|FG001|Overall Study|Physician Decision|3
6043618|NCT00391118|9642333|FG002|Overall Study|Physician Decision|0
6085479|NCT00652743|9694790|FG002|Months 12-18|Lost to Follow-up|7
6085480|NCT00652743|9694788|FG000|Months 24-30|Other|5
6187066|NCT01378975|9840877|FG000|Overall Study|Death|77
6187067|NCT01378975|9840878|FG001|Overall Study|Death|46
6085481|NCT00652743|9694789|FG001|Months 24-30|Other|1
6085482|NCT00652743|9694790|FG002|Months 24-30|Other|11
6043619|NCT00391118|9642331|FG000|Overall Study|Protocol Entry Criteria Not Met|0
6043620|NCT00391118|9642332|FG001|Overall Study|Protocol Entry Criteria Not Met|3
6043621|NCT00391118|9642333|FG002|Overall Study|Protocol Entry Criteria Not Met|1
6043622|NCT00391118|9642331|FG000|Overall Study|Progressive Disease|7
6043623|NCT00391118|9642332|FG001|Overall Study|Progressive Disease|26
6043624|NCT00391118|9642333|FG002|Overall Study|Progressive Disease|43
6043625|NCT00391118|9642331|FG000|Overall Study|Sponsor Decision|0
6043626|NCT00391118|9642332|FG001|Overall Study|Sponsor Decision|1
6187068|NCT01378975|9840877|FG000|Overall Study|Investigator Request|1
6187069|NCT01378975|9840878|FG001|Overall Study|Investigator Request|0
6187070|NCT01378975|9840877|FG000|Overall Study|Lost to Follow-up|4
6187071|NCT01378975|9840878|FG001|Overall Study|Lost to Follow-up|1
6187072|NCT01378975|9840877|FG000|Overall Study|Withdrew Consent|4
6187073|NCT01378975|9840878|FG001|Overall Study|Withdrew Consent|3
6187074|NCT01379508|9840913|FG000|Treatment to Week 104|Adverse Event|2
6187075|NCT01379508|9840914|FG001|Treatment to Week 104|Adverse Event|0
6187076|NCT01379508|9840915|FG002|Treatment to Week 104|Adverse Event|5
6187077|NCT01379508|9840916|FG003|Treatment to Week 104|Adverse Event|0
6187078|NCT01379508|9840913|FG000|Treatment to Week 104|Abnormal lab value|1
6187079|NCT01379508|9840914|FG001|Treatment to Week 104|Abnormal lab value|0
6187080|NCT01379508|9840915|FG002|Treatment to Week 104|Abnormal lab value|0
6187081|NCT01379508|9840916|FG003|Treatment to Week 104|Abnormal lab value|0
6187082|NCT01379508|9840913|FG000|Treatment to Week 104|Abnormal test procedure result(s)|1
6187083|NCT01379508|9840914|FG001|Treatment to Week 104|Abnormal test procedure result(s)|0
6187084|NCT01379508|9840915|FG002|Treatment to Week 104|Abnormal test procedure result(s)|0
6187085|NCT01379508|9840916|FG003|Treatment to Week 104|Abnormal test procedure result(s)|0
6187086|NCT01379508|9840913|FG000|Treatment to Week 104|Withdrawal by Subject|6
6187087|NCT01379508|9840914|FG001|Treatment to Week 104|Withdrawal by Subject|1
6187088|NCT01379508|9840915|FG002|Treatment to Week 104|Withdrawal by Subject|4
6187089|NCT01379508|9840916|FG003|Treatment to Week 104|Withdrawal by Subject|0
6187090|NCT01379508|9840913|FG000|Treatment to Week 104|Lost to Follow-up|5
6187091|NCT01379508|9840914|FG001|Treatment to Week 104|Lost to Follow-up|0
6187092|NCT01379508|9840915|FG002|Treatment to Week 104|Lost to Follow-up|3
6187093|NCT01379508|9840916|FG003|Treatment to Week 104|Lost to Follow-up|0
6187094|NCT01379508|9840913|FG000|Treatment to Week 104|Administrative problems|3
6187095|NCT01379508|9840914|FG001|Treatment to Week 104|Administrative problems|1
6187096|NCT01379508|9840915|FG002|Treatment to Week 104|Administrative problems|0
6187097|NCT01379508|9840916|FG003|Treatment to Week 104|Administrative problems|0
6187098|NCT01379508|9840913|FG000|Treatment to Week 104|Protocol Violation|1
6187099|NCT01379508|9840914|FG001|Treatment to Week 104|Protocol Violation|1
6187100|NCT01379508|9840915|FG002|Treatment to Week 104|Protocol Violation|1
6187101|NCT01379508|9840916|FG003|Treatment to Week 104|Protocol Violation|0
6187102|NCT01379508|9840913|FG000|Extension Period Weeks 109-156|Withdrawal by Subject|8
6187103|NCT01379508|9840914|FG001|Extension Period Weeks 109-156|Withdrawal by Subject|1
6187104|NCT01379508|9840915|FG002|Extension Period Weeks 109-156|Withdrawal by Subject|8
6187105|NCT01379508|9840916|FG003|Extension Period Weeks 109-156|Withdrawal by Subject|0
6187106|NCT01379508|9840913|FG000|Extension Period Weeks 109-156|Lost to Follow-up|6
6187107|NCT01379508|9840914|FG001|Extension Period Weeks 109-156|Lost to Follow-up|1
6187108|NCT01379508|9840915|FG002|Extension Period Weeks 109-156|Lost to Follow-up|5
6187109|NCT01379508|9840916|FG003|Extension Period Weeks 109-156|Lost to Follow-up|0
6187110|NCT01379508|9840913|FG000|Extension Period Weeks 109-156|Administrative problems|3
6187111|NCT01379508|9840914|FG001|Extension Period Weeks 109-156|Administrative problems|0
6187112|NCT01379508|9840915|FG002|Extension Period Weeks 109-156|Administrative problems|1
6187113|NCT01379508|9840916|FG003|Extension Period Weeks 109-156|Administrative problems|0
6187114|NCT01379508|9840913|FG000|Extension Period Weeks 109-156|Protocol Violation|2
6187115|NCT01379508|9840914|FG001|Extension Period Weeks 109-156|Protocol Violation|1
6187116|NCT01379508|9840915|FG002|Extension Period Weeks 109-156|Protocol Violation|0
6187117|NCT01379508|9840916|FG003|Extension Period Weeks 109-156|Protocol Violation|0
6187118|NCT01379521|9840932|FG000|Overall Study -Treatment Period|Adverse Event|3
6187119|NCT01379521|9840933|FG001|Overall Study -Treatment Period|Adverse Event|0
6187120|NCT01379521|9840932|FG000|Overall Study -Treatment Period|Abnormal test procedure results|0
6187121|NCT01379521|9840933|FG001|Overall Study -Treatment Period|Abnormal test procedure results|1
6187122|NCT01379521|9840932|FG000|Overall Study -Treatment Period|Disease Progression|23
6187123|NCT01379521|9840933|FG001|Overall Study -Treatment Period|Disease Progression|22
6187124|NCT01379521|9840932|FG000|Overall Study -Treatment Period|New Cancer Therapy|1
6187125|NCT01379521|9840933|FG001|Overall Study -Treatment Period|New Cancer Therapy|0
6187126|NCT01379521|9840932|FG000|Overall Study -Treatment Period|Protocol Deviation|0
6187127|NCT01379521|9840933|FG001|Overall Study -Treatment Period|Protocol Deviation|2
6187128|NCT01379521|9840932|FG000|Overall Study -Treatment Period|Withdrawal by Subject|3
6187129|NCT01379521|9840933|FG001|Overall Study -Treatment Period|Withdrawal by Subject|0
6187130|NCT01379521|9840932|FG000|Overall Study -Treatment Period|Administrative Problems|1
6230627|NCT01744977|9905351|FG000|Overall Study|Withdrawal by Subject|1
6230628|NCT01744977|9905352|FG001|Overall Study|Withdrawal by Subject|2
6230629|NCT01744977|9905351|FG000|Overall Study|Death|2
6230630|NCT01744977|9905352|FG001|Overall Study|Death|3
6230631|NCT01744977|9905351|FG000|Overall Study|Lost to Follow-up|2
6230632|NCT01744977|9905352|FG001|Overall Study|Lost to Follow-up|0
6230633|NCT01744977|9905351|FG000|Overall Study|No longer meets inclusion|6
6230634|NCT01744977|9905352|FG001|Overall Study|No longer meets inclusion|0
6230635|NCT01745094|9905371|FG000|Overall Study|Not Meeting the Eligibility Criteria|1
6230636|NCT01745094|9905372|FG001|Overall Study|Not Meeting the Eligibility Criteria|0
6230637|NCT01745094|9905373|FG002|Overall Study|Not Meeting the Eligibility Criteria|3
6230638|NCT01745094|9905374|FG003|Overall Study|Not Meeting the Eligibility Criteria|0
6230639|NCT01745094|9905371|FG000|Overall Study|Adverse Event|0
6230640|NCT01745094|9905372|FG001|Overall Study|Adverse Event|0
6230641|NCT01745094|9905373|FG002|Overall Study|Adverse Event|3
6230642|NCT01745094|9905374|FG003|Overall Study|Adverse Event|0
6230643|NCT01745094|9905371|FG000|Overall Study|Withdrawal by Subject|2
6230644|NCT01745094|9905372|FG001|Overall Study|Withdrawal by Subject|0
6230645|NCT01745094|9905373|FG002|Overall Study|Withdrawal by Subject|1
6230646|NCT01745094|9905374|FG003|Overall Study|Withdrawal by Subject|2
6230647|NCT01745094|9905371|FG000|Overall Study|Protocol Violation|1
6230648|NCT01745094|9905372|FG001|Overall Study|Protocol Violation|0
6230649|NCT01745094|9905373|FG002|Overall Study|Protocol Violation|3
6230650|NCT01745094|9905374|FG003|Overall Study|Protocol Violation|1
6230651|NCT01745094|9905371|FG000|Overall Study|Need Further Examinations Due to Biopsy|0
6230652|NCT01745094|9905372|FG001|Overall Study|Need Further Examinations Due to Biopsy|0
6230653|NCT01745094|9905373|FG002|Overall Study|Need Further Examinations Due to Biopsy|1
6230654|NCT01745094|9905374|FG003|Overall Study|Need Further Examinations Due to Biopsy|0
6230655|NCT01745094|9905371|FG000|Overall Study|Show no Stable Solifenacin Intake|0
6230656|NCT01745094|9905372|FG001|Overall Study|Show no Stable Solifenacin Intake|0
6230657|NCT01745094|9905373|FG002|Overall Study|Show no Stable Solifenacin Intake|1
6230658|NCT01745094|9905374|FG003|Overall Study|Show no Stable Solifenacin Intake|0
6230659|NCT01745094|9905371|FG000|Overall Study|Untenable Due to Recurrent Cystitis|1
6230660|NCT01745094|9905372|FG001|Overall Study|Untenable Due to Recurrent Cystitis|0
6230661|NCT01745094|9905373|FG002|Overall Study|Untenable Due to Recurrent Cystitis|0
6230662|NCT01745094|9905374|FG003|Overall Study|Untenable Due to Recurrent Cystitis|0
6230663|NCT01745120|9905389|FG000|Overall Study|Investigator decision|1
6230664|NCT01745120|9905390|FG001|Overall Study|Investigator decision|0
6230665|NCT01745146|9905414|FG000|Overall Study|Withdrawal by Subject|1
6230666|NCT01745146|9905415|FG001|Overall Study|Withdrawal by Subject|3
6230667|NCT01745146|9905414|FG000|Overall Study|Lost to Follow-up|2
6230668|NCT01745146|9905415|FG001|Overall Study|Lost to Follow-up|0
6230669|NCT01745367|9905428|FG000|Overall Study|Death|1
6230670|NCT01745367|9905429|FG001|Overall Study|Death|0
6230671|NCT01745367|9905428|FG000|Overall Study|Withdrawal by Subject|1
6230672|NCT01745367|9905429|FG001|Overall Study|Withdrawal by Subject|2
6230673|NCT01745367|9905428|FG000|Overall Study|Termination of The Study by The Sponsor|6
6230674|NCT01745367|9905429|FG001|Overall Study|Termination of The Study by The Sponsor|18
6230675|NCT01745367|9905428|FG000|Overall Study|Other Reasons Unspecified|0
6230676|NCT01745367|9905429|FG001|Overall Study|Other Reasons Unspecified|2
6230677|NCT01745380|9905437|FG000|Overall Study|Lost to Follow-up|1
6085483|NCT00652743|9694788|FG000|Months 36-42|Serious Adverse Events|0
6085484|NCT00652743|9694789|FG001|Months 36-42|Serious Adverse Events|1
6085485|NCT00652743|9694790|FG002|Months 36-42|Serious Adverse Events|1
6085486|NCT00652743|9694788|FG000|Months 36-42|Withdrawal by Subject|1
6085487|NCT00652743|9694789|FG001|Months 36-42|Withdrawal by Subject|1
6085488|NCT00652743|9694790|FG002|Months 36-42|Withdrawal by Subject|0
6085489|NCT00652743|9694788|FG000|Months 36-42|Lost to Follow-up|0
6085490|NCT00652743|9694789|FG001|Months 36-42|Lost to Follow-up|1
6230678|NCT01745380|9905438|FG001|Overall Study|Lost to Follow-up|0
6230679|NCT01745380|9905437|FG000|Overall Study|Lack of Efficacy|0
6230680|NCT01745380|9905438|FG001|Overall Study|Lack of Efficacy|1
6230681|NCT01745393|9905446|FG000|Treatment to End-of-treatment Assessment|Lost to Follow-up|20
6230682|NCT01745393|9905447|FG001|Treatment to End-of-treatment Assessment|Lost to Follow-up|8
6230683|NCT01745393|9905446|FG000|Treatment to End-of-treatment Assessment|Withdrawal by Subject|1
6230684|NCT01745393|9905447|FG001|Treatment to End-of-treatment Assessment|Withdrawal by Subject|0
6230685|NCT01745393|9905446|FG000|12-month Follow-up|Lost to Follow-up|6
6230686|NCT01745393|9905447|FG001|12-month Follow-up|Lost to Follow-up|5
6230687|NCT01745848|9905466|FG000|Overall Study|Adverse Event|6
6230688|NCT01746017|9905497|FG000|Period 1|Withdrawal by Subject|0
6230689|NCT01746017|9905498|FG001|Period 1|Withdrawal by Subject|0
6085491|NCT00652743|9694790|FG002|Months 36-42|Lost to Follow-up|0
6230690|NCT01746017|9905499|FG002|Period 1|Withdrawal by Subject|0
6230691|NCT01746017|9905500|FG003|Period 1|Withdrawal by Subject|0
6230692|NCT01746017|9905501|FG004|Period 1|Withdrawal by Subject|0
6230693|NCT01746017|9905502|FG005|Period 1|Withdrawal by Subject|0
6230694|NCT01746017|9905503|FG006|Period 1|Withdrawal by Subject|1
6230695|NCT01746017|9905504|FG007|Period 1|Withdrawal by Subject|0
6230696|NCT01746017|9905505|FG008|Period 1|Withdrawal by Subject|0
6230697|NCT01746017|9905506|FG009|Period 1|Withdrawal by Subject|0
6230698|NCT01746017|9905507|FG010|Period 1|Withdrawal by Subject|0
6230699|NCT01746017|9905497|FG000|Period 3|Withdrawal by Subject|0
6230700|NCT01746017|9905498|FG001|Period 3|Withdrawal by Subject|0
6230701|NCT01746017|9905499|FG002|Period 3|Withdrawal by Subject|0
6230702|NCT01746017|9905500|FG003|Period 3|Withdrawal by Subject|0
6230703|NCT01746017|9905501|FG004|Period 3|Withdrawal by Subject|0
6230704|NCT01746017|9905502|FG005|Period 3|Withdrawal by Subject|1
6230705|NCT01746017|9905503|FG006|Period 3|Withdrawal by Subject|0
6230706|NCT01746017|9905504|FG007|Period 3|Withdrawal by Subject|0
6230707|NCT01746017|9905505|FG008|Period 3|Withdrawal by Subject|0
6230708|NCT01746017|9905506|FG009|Period 3|Withdrawal by Subject|0
6230709|NCT01746017|9905507|FG010|Period 3|Withdrawal by Subject|0
6230710|NCT01746108|9905583|FG000|Overall Study|Migrated /moved from study area|0
6230711|NCT01746108|9905584|FG001|Overall Study|Migrated /moved from study area|1
6230712|NCT01746108|9905585|FG002|Overall Study|Migrated /moved from study area|0
6230713|NCT01746108|9905583|FG000|Overall Study|Adverse event, non-fatal|0
6230714|NCT01746108|9905584|FG001|Overall Study|Adverse event, non-fatal|1
6230715|NCT01746108|9905585|FG002|Overall Study|Adverse event, non-fatal|0
6230716|NCT01746108|9905583|FG000|Overall Study|Withdrawal by Subject|0
6230717|NCT01746108|9905584|FG001|Overall Study|Withdrawal by Subject|1
6230718|NCT01746108|9905585|FG002|Overall Study|Withdrawal by Subject|0
6230719|NCT01746108|9905583|FG000|Overall Study|Lost to Follow-up|0
6230720|NCT01746108|9905584|FG001|Overall Study|Lost to Follow-up|1
6230721|NCT01746108|9905585|FG002|Overall Study|Lost to Follow-up|0
6230722|NCT01746173|9905601|FG000|Overall Study|Disease Progression|2
6230723|NCT01746225|9905608|FG000|Overall Study|Death|1
6230724|NCT01746225|9905609|FG001|Overall Study|Death|0
6230725|NCT01746225|9905610|FG002|Overall Study|Death|1
6230726|NCT01746225|9905608|FG000|Overall Study|Withdrawal by Subject|5
6230727|NCT01746225|9905609|FG001|Overall Study|Withdrawal by Subject|15
6230728|NCT01746225|9905610|FG002|Overall Study|Withdrawal by Subject|19
6230729|NCT01746225|9905608|FG000|Overall Study|Physician Decision|14
6230730|NCT01746225|9905609|FG001|Overall Study|Physician Decision|11
6230731|NCT01746225|9905610|FG002|Overall Study|Physician Decision|3
6085492|NCT00652743|9694788|FG000|Months 36-42|Migrated/moved from study area|1
6230732|NCT01746225|9905608|FG000|Overall Study|Adverse Event|15
6230733|NCT01746225|9905609|FG001|Overall Study|Adverse Event|12
6230734|NCT01746225|9905610|FG002|Overall Study|Adverse Event|17
6230735|NCT01746225|9905608|FG000|Overall Study|Continuing Treatment|5
6230736|NCT01746225|9905609|FG001|Overall Study|Continuing Treatment|8
6230737|NCT01746225|9905610|FG002|Overall Study|Continuing Treatment|3
6230738|NCT01746368|9905624|FG000|Overall Study|Lost to Follow-up|2
6230739|NCT01746368|9905625|FG001|Overall Study|Lost to Follow-up|0
6230740|NCT01746368|9905624|FG000|Overall Study|Withdrawal by Subject|0
6230741|NCT01746368|9905625|FG001|Overall Study|Withdrawal by Subject|1
6230742|NCT01746732|9905662|FG000|Lead-In Period|Withdrawal by Subject|1
6230743|NCT01746732|9905663|FG001|Lead-In Period|Withdrawal by Subject|0
6230744|NCT01746732|9905664|FG002|Lead-In Period|Withdrawal by Subject|0
6230745|NCT01746732|9905662|FG000|Period 1|Physician Decision|0
6230746|NCT01746732|9905663|FG001|Period 1|Physician Decision|1
6230747|NCT01746732|9905664|FG002|Period 1|Physician Decision|0
6230748|NCT01746732|9905662|FG000|Period 2|Withdrawal by Subject|0
6230749|NCT01746732|9905663|FG001|Period 2|Withdrawal by Subject|0
6230750|NCT01746732|9905664|FG002|Period 2|Withdrawal by Subject|2
6230751|NCT01746732|9905662|FG000|Period 2|Adverse Event|0
6230752|NCT01746732|9905663|FG001|Period 2|Adverse Event|0
6230753|NCT01746732|9905664|FG002|Period 2|Adverse Event|1
6230754|NCT01746732|9905662|FG000|Period 2|Lost to Follow-up|0
6230755|NCT01746732|9905663|FG001|Period 2|Lost to Follow-up|0
6230756|NCT01746732|9905664|FG002|Period 2|Lost to Follow-up|1
6230757|NCT01746862|9905708|FG000|Overall Study|Withdrawal by Subject|1
6230758|NCT01746862|9905709|FG001|Overall Study|Withdrawal by Subject|1
6230759|NCT01746862|9905708|FG000|Overall Study|Protocol Violation|1
6230760|NCT01746862|9905709|FG001|Overall Study|Protocol Violation|0
6230761|NCT01746862|9905708|FG000|Overall Study|Consent withdrawal by parent's guardian|5
6230762|NCT01746862|9905709|FG001|Overall Study|Consent withdrawal by parent's guardian|2
6230763|NCT01746862|9905708|FG000|Overall Study|Entered puberty during the study|1
6230764|NCT01746862|9905709|FG001|Overall Study|Entered puberty during the study|0
6230765|NCT01746901|9905716|FG000|Naloxone Challenge Phase|Adverse Event|2
6230766|NCT01746901|9905717|FG001|Naloxone Challenge Phase|Adverse Event|0
6085493|NCT00652743|9694789|FG001|Months 36-42|Migrated/moved from study area|0
6230767|NCT01746901|9905718|FG002|Naloxone Challenge Phase|Adverse Event|0
6230768|NCT01746901|9905719|FG003|Naloxone Challenge Phase|Adverse Event|0
6230769|NCT01746901|9905720|FG004|Naloxone Challenge Phase|Adverse Event|0
6230770|NCT01746901|9905721|FG005|Naloxone Challenge Phase|Adverse Event|0
6230771|NCT01746901|9905722|FG006|Naloxone Challenge Phase|Adverse Event|0
6230772|NCT01746901|9905723|FG007|Naloxone Challenge Phase|Adverse Event|0
6230773|NCT01746901|9905724|FG008|Naloxone Challenge Phase|Adverse Event|0
6230774|NCT01746901|9905716|FG000|Naloxone Challenge Phase|Did not meet entrance criteria|1
6230775|NCT01746901|9905717|FG001|Naloxone Challenge Phase|Did not meet entrance criteria|0
6230776|NCT01746901|9905718|FG002|Naloxone Challenge Phase|Did not meet entrance criteria|0
6230777|NCT01746901|9905719|FG003|Naloxone Challenge Phase|Did not meet entrance criteria|0
6230778|NCT01746901|9905720|FG004|Naloxone Challenge Phase|Did not meet entrance criteria|0
6230779|NCT01746901|9905721|FG005|Naloxone Challenge Phase|Did not meet entrance criteria|0
6230780|NCT01746901|9905722|FG006|Naloxone Challenge Phase|Did not meet entrance criteria|0
6230781|NCT01746901|9905723|FG007|Naloxone Challenge Phase|Did not meet entrance criteria|0
6230782|NCT01746901|9905724|FG008|Naloxone Challenge Phase|Did not meet entrance criteria|0
6230783|NCT01746901|9905716|FG000|Drug Discrimination Phase: Day 1|Adverse Event|0
6230784|NCT01746901|9905717|FG001|Drug Discrimination Phase: Day 1|Adverse Event|3
6230785|NCT01746901|9905718|FG002|Drug Discrimination Phase: Day 1|Adverse Event|0
6230786|NCT01746901|9905719|FG003|Drug Discrimination Phase: Day 1|Adverse Event|0
6230787|NCT01746901|9905720|FG004|Drug Discrimination Phase: Day 1|Adverse Event|0
6230788|NCT01746901|9905721|FG005|Drug Discrimination Phase: Day 1|Adverse Event|0
6230789|NCT01746901|9905722|FG006|Drug Discrimination Phase: Day 1|Adverse Event|0
6230790|NCT01746901|9905723|FG007|Drug Discrimination Phase: Day 1|Adverse Event|0
6230791|NCT01746901|9905724|FG008|Drug Discrimination Phase: Day 1|Adverse Event|0
6230792|NCT01746901|9905716|FG000|Drug Discrimination Phase: Day 2|Adverse Event|0
6230793|NCT01746901|9905717|FG001|Drug Discrimination Phase: Day 2|Adverse Event|2
6230794|NCT01746901|9905718|FG002|Drug Discrimination Phase: Day 2|Adverse Event|1
6230795|NCT01746901|9905719|FG003|Drug Discrimination Phase: Day 2|Adverse Event|0
6230796|NCT01746901|9905720|FG004|Drug Discrimination Phase: Day 2|Adverse Event|0
6230797|NCT01746901|9905721|FG005|Drug Discrimination Phase: Day 2|Adverse Event|0
6230798|NCT01746901|9905722|FG006|Drug Discrimination Phase: Day 2|Adverse Event|0
6230799|NCT01746901|9905723|FG007|Drug Discrimination Phase: Day 2|Adverse Event|0
6230800|NCT01746901|9905724|FG008|Drug Discrimination Phase: Day 2|Adverse Event|0
6230801|NCT01746901|9905716|FG000|Drug Discrimination Phase: Day 2|Did not met entrance criteria|0
6230802|NCT01746901|9905717|FG001|Drug Discrimination Phase: Day 2|Did not met entrance criteria|9
6230803|NCT01746901|9905718|FG002|Drug Discrimination Phase: Day 2|Did not met entrance criteria|10
6230804|NCT01746901|9905719|FG003|Drug Discrimination Phase: Day 2|Did not met entrance criteria|0
6230805|NCT01746901|9905720|FG004|Drug Discrimination Phase: Day 2|Did not met entrance criteria|0
6230806|NCT01746901|9905721|FG005|Drug Discrimination Phase: Day 2|Did not met entrance criteria|0
6230807|NCT01746901|9905722|FG006|Drug Discrimination Phase: Day 2|Did not met entrance criteria|0
6230808|NCT01746901|9905723|FG007|Drug Discrimination Phase: Day 2|Did not met entrance criteria|0
6230809|NCT01746901|9905724|FG008|Drug Discrimination Phase: Day 2|Did not met entrance criteria|0
6230810|NCT01746901|9905716|FG000|Drug Discrimination Phase: Day 2|Protocol Violation|0
6085494|NCT00652743|9694790|FG002|Months 36-42|Migrated/moved from study area|0
6085495|NCT00652743|9694788|FG000|Months 36-42|Other|4
6085496|NCT00652743|9694789|FG001|Months 36-42|Other|2
6085497|NCT00652743|9694790|FG002|Months 36-42|Other|8
6085498|NCT00652834|9694801|FG000|Overall Study|Withdrawal by Subject|3
6085499|NCT00652834|9694801|FG000|Overall Study|Lost to Follow-up|2
6085500|NCT00652899|9694805|FG000|Overall Study|Death|1
6230811|NCT01746901|9905717|FG001|Drug Discrimination Phase: Day 2|Protocol Violation|3
6230812|NCT01746901|9905718|FG002|Drug Discrimination Phase: Day 2|Protocol Violation|3
6230813|NCT01746901|9905719|FG003|Drug Discrimination Phase: Day 2|Protocol Violation|0
6230814|NCT01746901|9905720|FG004|Drug Discrimination Phase: Day 2|Protocol Violation|0
6230815|NCT01746901|9905721|FG005|Drug Discrimination Phase: Day 2|Protocol Violation|0
6230816|NCT01746901|9905722|FG006|Drug Discrimination Phase: Day 2|Protocol Violation|0
6230817|NCT01746901|9905723|FG007|Drug Discrimination Phase: Day 2|Protocol Violation|0
6230818|NCT01746901|9905724|FG008|Drug Discrimination Phase: Day 2|Protocol Violation|0
6230819|NCT01746901|9905716|FG000|Treatment Phase: First Intervention|Protocol Violation|0
6230820|NCT01746901|9905717|FG001|Treatment Phase: First Intervention|Protocol Violation|0
6230821|NCT01746901|9905718|FG002|Treatment Phase: First Intervention|Protocol Violation|0
6230822|NCT01746901|9905719|FG003|Treatment Phase: First Intervention|Protocol Violation|0
6230823|NCT01746901|9905720|FG004|Treatment Phase: First Intervention|Protocol Violation|0
6230824|NCT01746901|9905721|FG005|Treatment Phase: First Intervention|Protocol Violation|0
6230825|NCT01746901|9905722|FG006|Treatment Phase: First Intervention|Protocol Violation|1
6230826|NCT01746901|9905723|FG007|Treatment Phase: First Intervention|Protocol Violation|0
6230827|NCT01746901|9905724|FG008|Treatment Phase: First Intervention|Protocol Violation|0
6230828|NCT01746901|9905716|FG000|Treatment Phase: Second Intervention|Withdrawal by Subject|0
6230829|NCT01746901|9905717|FG001|Treatment Phase: Second Intervention|Withdrawal by Subject|0
6230830|NCT01746901|9905718|FG002|Treatment Phase: Second Intervention|Withdrawal by Subject|0
6230831|NCT01746901|9905719|FG003|Treatment Phase: Second Intervention|Withdrawal by Subject|0
6230832|NCT01746901|9905720|FG004|Treatment Phase: Second Intervention|Withdrawal by Subject|0
6230833|NCT01746901|9905721|FG005|Treatment Phase: Second Intervention|Withdrawal by Subject|0
6230834|NCT01746901|9905722|FG006|Treatment Phase: Second Intervention|Withdrawal by Subject|0
6230835|NCT01746901|9905723|FG007|Treatment Phase: Second Intervention|Withdrawal by Subject|1
6230836|NCT01746901|9905724|FG008|Treatment Phase: Second Intervention|Withdrawal by Subject|0
6230837|NCT01746901|9905716|FG000|Treatment Phase: Third Intervention|Protocol Violation|0
6230838|NCT01746901|9905717|FG001|Treatment Phase: Third Intervention|Protocol Violation|0
6230839|NCT01746901|9905718|FG002|Treatment Phase: Third Intervention|Protocol Violation|0
6230840|NCT01746901|9905719|FG003|Treatment Phase: Third Intervention|Protocol Violation|0
6230841|NCT01746901|9905720|FG004|Treatment Phase: Third Intervention|Protocol Violation|0
6230842|NCT01746901|9905721|FG005|Treatment Phase: Third Intervention|Protocol Violation|1
6085501|NCT00652899|9694805|FG000|Overall Study|Treating physician decision|1
6230843|NCT01746901|9905722|FG006|Treatment Phase: Third Intervention|Protocol Violation|1
6230844|NCT01746901|9905723|FG007|Treatment Phase: Third Intervention|Protocol Violation|0
6230845|NCT01746901|9905724|FG008|Treatment Phase: Third Intervention|Protocol Violation|0
6230846|NCT01746901|9905716|FG000|Treatment Phase: Fourth Intervention|Lost to Follow-up|0
6230847|NCT01746901|9905717|FG001|Treatment Phase: Fourth Intervention|Lost to Follow-up|0
6230848|NCT01746901|9905718|FG002|Treatment Phase: Fourth Intervention|Lost to Follow-up|0
6230849|NCT01746901|9905719|FG003|Treatment Phase: Fourth Intervention|Lost to Follow-up|1
6230850|NCT01746901|9905720|FG004|Treatment Phase: Fourth Intervention|Lost to Follow-up|0
6230851|NCT01746901|9905721|FG005|Treatment Phase: Fourth Intervention|Lost to Follow-up|0
6230852|NCT01746901|9905722|FG006|Treatment Phase: Fourth Intervention|Lost to Follow-up|0
6230853|NCT01746901|9905723|FG007|Treatment Phase: Fourth Intervention|Lost to Follow-up|0
6230854|NCT01746901|9905724|FG008|Treatment Phase: Fourth Intervention|Lost to Follow-up|0
6230855|NCT01746901|9905716|FG000|Treatment Phase: Fourth Intervention|Adverse Event|0
6230856|NCT01746901|9905717|FG001|Treatment Phase: Fourth Intervention|Adverse Event|0
6230857|NCT01746901|9905718|FG002|Treatment Phase: Fourth Intervention|Adverse Event|0
6230858|NCT01746901|9905719|FG003|Treatment Phase: Fourth Intervention|Adverse Event|0
6230859|NCT01746901|9905720|FG004|Treatment Phase: Fourth Intervention|Adverse Event|0
6230860|NCT01746901|9905721|FG005|Treatment Phase: Fourth Intervention|Adverse Event|1
6230861|NCT01746901|9905722|FG006|Treatment Phase: Fourth Intervention|Adverse Event|0
6230862|NCT01746901|9905723|FG007|Treatment Phase: Fourth Intervention|Adverse Event|0
6230863|NCT01746901|9905724|FG008|Treatment Phase: Fourth Intervention|Adverse Event|1
6230864|NCT01746901|9905716|FG000|Treatment Phase: Fourth Intervention|Protocol Violation|0
6230865|NCT01746901|9905717|FG001|Treatment Phase: Fourth Intervention|Protocol Violation|0
6230866|NCT01746901|9905718|FG002|Treatment Phase: Fourth Intervention|Protocol Violation|0
6230867|NCT01746901|9905719|FG003|Treatment Phase: Fourth Intervention|Protocol Violation|0
6230868|NCT01746901|9905720|FG004|Treatment Phase: Fourth Intervention|Protocol Violation|0
6230869|NCT01746901|9905721|FG005|Treatment Phase: Fourth Intervention|Protocol Violation|0
6230870|NCT01746901|9905722|FG006|Treatment Phase: Fourth Intervention|Protocol Violation|1
6230871|NCT01746901|9905723|FG007|Treatment Phase: Fourth Intervention|Protocol Violation|0
6230872|NCT01746901|9905724|FG008|Treatment Phase: Fourth Intervention|Protocol Violation|1
6230873|NCT01747486|9905794|FG000|Stage 1|Physician Decision|3
6230874|NCT01747486|9905795|FG001|Stage 1|Physician Decision|0
6230875|NCT01747486|9905794|FG000|Stage 1|Withdrawal by Subject|4
6230876|NCT01747486|9905795|FG001|Stage 1|Withdrawal by Subject|3
6230877|NCT01747486|9905794|FG000|Stage 1|Disease progression|4
6230878|NCT01747486|9905795|FG001|Stage 1|Disease progression|9
6230879|NCT01747486|9905794|FG000|Stage 1|Death|1
6230880|NCT01747486|9905795|FG001|Stage 1|Death|1
6230881|NCT01747486|9905794|FG000|Stage 2|Physician Decision|2
6230882|NCT01747486|9905795|FG001|Stage 2|Physician Decision|0
6230883|NCT01747486|9905794|FG000|Stage 2|Withdrawal by Subject|1
6230884|NCT01747486|9905795|FG001|Stage 2|Withdrawal by Subject|0
6230885|NCT01747486|9905794|FG000|Stage 2|New Cancer Therapy|3
6230886|NCT01747486|9905795|FG001|Stage 2|New Cancer Therapy|0
6230887|NCT01747486|9905794|FG000|Stage 2|Disease Progression|3
6230888|NCT01747486|9905795|FG001|Stage 2|Disease Progression|0
6230889|NCT01747499|9905806|FG000|Overall Study|Steroid refractory aGvHD|1
6230890|NCT01747499|9905807|FG001|Overall Study|Steroid refractory aGvHD|0
6230891|NCT01747499|9905808|FG002|Overall Study|Steroid refractory aGvHD|0
6230892|NCT01747499|9905809|FG003|Overall Study|Steroid refractory aGvHD|1
6230893|NCT01747499|9905810|FG004|Overall Study|Steroid refractory aGvHD|4
6230894|NCT01747499|9905806|FG000|Overall Study|Physician Decision|0
6230895|NCT01747499|9905807|FG001|Overall Study|Physician Decision|1
6230896|NCT01747499|9905808|FG002|Overall Study|Physician Decision|0
6230897|NCT01747499|9905809|FG003|Overall Study|Physician Decision|0
6230898|NCT01747499|9905810|FG004|Overall Study|Physician Decision|2
6230899|NCT01747499|9905806|FG000|Overall Study|Death|0
6230900|NCT01747499|9905807|FG001|Overall Study|Death|0
6230901|NCT01747499|9905808|FG002|Overall Study|Death|0
6230902|NCT01747499|9905809|FG003|Overall Study|Death|1
6230903|NCT01747499|9905810|FG004|Overall Study|Death|1
6230904|NCT01747499|9905806|FG000|Overall Study|Withdrawal by Subject|0
6230905|NCT01747499|9905807|FG001|Overall Study|Withdrawal by Subject|0
6230906|NCT01747499|9905808|FG002|Overall Study|Withdrawal by Subject|0
6230907|NCT01747499|9905809|FG003|Overall Study|Withdrawal by Subject|0
6230908|NCT01747499|9905810|FG004|Overall Study|Withdrawal by Subject|6
6230909|NCT01747499|9905806|FG000|Overall Study|Developed AML and death|0
6230910|NCT01747499|9905807|FG001|Overall Study|Developed AML and death|0
6230911|NCT01747499|9905808|FG002|Overall Study|Developed AML and death|0
6230912|NCT01747499|9905809|FG003|Overall Study|Developed AML and death|0
6230913|NCT01747499|9905810|FG004|Overall Study|Developed AML and death|1
6230914|NCT01747499|9905806|FG000|Overall Study|Determined not to be eligible|0
6230915|NCT01747499|9905807|FG001|Overall Study|Determined not to be eligible|0
6230916|NCT01747499|9905808|FG002|Overall Study|Determined not to be eligible|0
6230917|NCT01747499|9905809|FG003|Overall Study|Determined not to be eligible|0
6230918|NCT01747499|9905810|FG004|Overall Study|Determined not to be eligible|1
6230919|NCT01747551|9905826|FG000|Overall Study|Progressive Disease|24
6230920|NCT01747551|9905827|FG001|Overall Study|Progressive Disease|17
6230921|NCT01747551|9905826|FG000|Overall Study|Death|3
6230922|NCT01747551|9905827|FG001|Overall Study|Death|1
6230923|NCT01747551|9905826|FG000|Overall Study|Adverse Event|7
6230924|NCT01747551|9905827|FG001|Overall Study|Adverse Event|1
6230925|NCT01747551|9905826|FG000|Overall Study|Prolonged Treatment Delay|2
6230926|NCT01747551|9905827|FG001|Overall Study|Prolonged Treatment Delay|0
6230927|NCT01747551|9905826|FG000|Overall Study|Withdrawal by Subject|3
6230928|NCT01747551|9905827|FG001|Overall Study|Withdrawal by Subject|1
6230929|NCT01747551|9905826|FG000|Overall Study|Physician Decision|2
6230930|NCT01747551|9905827|FG001|Overall Study|Physician Decision|1
6230931|NCT01747551|9905826|FG000|Overall Study|Other|2
6230932|NCT01747551|9905827|FG001|Overall Study|Other|0
6230933|NCT01747629|9905835|FG000|Overall Study|Adverse Event|1
6230934|NCT01747629|9905836|FG001|Overall Study|Adverse Event|2
6230935|NCT01747629|9905835|FG000|Overall Study|Withdrawal by Subject|2
6230936|NCT01747629|9905836|FG001|Overall Study|Withdrawal by Subject|2
6230937|NCT01747629|9905835|FG000|Overall Study|Noncompliance|1
6230938|NCT01747629|9905836|FG001|Overall Study|Noncompliance|1
6230939|NCT01747629|9905835|FG000|Overall Study|Inclusion criteria not met|1
6230940|NCT01747629|9905836|FG001|Overall Study|Inclusion criteria not met|0
6230941|NCT01747629|9905835|FG000|Overall Study|Not treated|1
6230942|NCT01747629|9905836|FG001|Overall Study|Not treated|0
6230943|NCT01747629|9905835|FG000|Overall Study|Other|2
6230944|NCT01747629|9905836|FG001|Overall Study|Other|1
6230945|NCT01747655|9905842|FG000|PEG-J Period (Duodopa Treatment)|Investigator Decision (Medical Event)|5
6230946|NCT01747655|9905843|FG001|PEG-J Period (Duodopa Treatment)|Investigator Decision (Medical Event)|0
6230947|NCT01747655|9905842|FG000|PEG-J Period (Duodopa Treatment)|Patient Decision|8
6230948|NCT01747655|9905843|FG001|PEG-J Period (Duodopa Treatment)|Patient Decision|0
6230949|NCT01747655|9905842|FG000|PEG-J Period (Duodopa Treatment)|Lost to Follow-up|1
6230950|NCT01747655|9905843|FG001|PEG-J Period (Duodopa Treatment)|Lost to Follow-up|0
6230951|NCT01747772|9905849|FG000|Overall Study|SWE Data Not Obtainable Prior to Biopsy|9
6230952|NCT01747811|9905859|FG000|Overall Study|Lack of Efficacy|2
6230953|NCT01747811|9905860|FG001|Overall Study|Lack of Efficacy|4
6230954|NCT01747837|9905870|FG000|Overall Study|Lost to Follow-up|5
6230955|NCT01747837|9905871|FG001|Overall Study|Lost to Follow-up|2
6230956|NCT01747837|9905870|FG000|Overall Study|Death|4
6230957|NCT01747837|9905871|FG001|Overall Study|Death|4
6230958|NCT01747876|9905905|FG000|Overall Study|Adverse Event|1
6230959|NCT01747876|9905906|FG001|Overall Study|Adverse Event|0
6230960|NCT01747876|9905907|FG002|Overall Study|Adverse Event|2
6230961|NCT01747876|9905905|FG000|Overall Study|Withdrawal by Subject|0
6230962|NCT01747876|9905906|FG001|Overall Study|Withdrawal by Subject|1
6230963|NCT01747876|9905907|FG002|Overall Study|Withdrawal by Subject|1
6230964|NCT01747876|9905905|FG000|Overall Study|Disease progression|4
6085502|NCT00652938|9694816|FG000|Overall Study|Adverse Event|1
6085503|NCT00652938|9694817|FG001|Overall Study|Adverse Event|0
6085504|NCT00652938|9694818|FG002|Overall Study|Adverse Event|2
6085505|NCT00652938|9694816|FG000|Overall Study|Withdrawal by Subject|0
6085506|NCT00652938|9694817|FG001|Overall Study|Withdrawal by Subject|6
6085507|NCT00652938|9694818|FG002|Overall Study|Withdrawal by Subject|1
6085508|NCT00652938|9694816|FG000|Overall Study|Lost to Follow-up|0
6085509|NCT00652938|9694817|FG001|Overall Study|Lost to Follow-up|0
6085510|NCT00652938|9694818|FG002|Overall Study|Lost to Follow-up|2
6085511|NCT00652938|9694816|FG000|Overall Study|fear of blood sampling|0
6085512|NCT00652938|9694817|FG001|Overall Study|fear of blood sampling|1
6085513|NCT00652938|9694818|FG002|Overall Study|fear of blood sampling|0
6085514|NCT00652951|9694829|FG000|Booster Phase|Adverse event, non-fatal|0
6085515|NCT00652951|9694830|FG001|Booster Phase|Adverse event, non-fatal|1
6230965|NCT01747876|9905906|FG001|Overall Study|Disease progression|13
6230966|NCT01747876|9905907|FG002|Overall Study|Disease progression|8
6230967|NCT01747876|9905905|FG000|Overall Study|Trtment duration compl. as per protocol|0
6230968|NCT01747876|9905906|FG001|Overall Study|Trtment duration compl. as per protocol|1
6230969|NCT01747876|9905907|FG002|Overall Study|Trtment duration compl. as per protocol|1
6230970|NCT01747915|9905921|FG000|Overall Study|Other|1
6230971|NCT01747915|9905922|FG001|Overall Study|Other|1
6230972|NCT01747915|9905923|FG002|Overall Study|Other|1
6230973|NCT01747915|9905921|FG000|Overall Study|Adverse Event|8
6230974|NCT01747915|9905922|FG001|Overall Study|Adverse Event|5
6230975|NCT01747915|9905923|FG002|Overall Study|Adverse Event|2
6230976|NCT01747915|9905921|FG000|Overall Study|Death|0
6230977|NCT01747915|9905922|FG001|Overall Study|Death|0
6230978|NCT01747915|9905923|FG002|Overall Study|Death|1
6230979|NCT01747915|9905921|FG000|Overall Study|Lack of Efficacy|0
6230980|NCT01747915|9905922|FG001|Overall Study|Lack of Efficacy|1
6230981|NCT01747915|9905923|FG002|Overall Study|Lack of Efficacy|0
6230982|NCT01747915|9905921|FG000|Overall Study|Lost to Follow-up|1
6085516|NCT00652951|9694831|FG002|Booster Phase|Adverse event, non-fatal|0
6085517|NCT00652951|9694829|FG000|Booster Phase|Other|1
6085518|NCT00652951|9694830|FG001|Booster Phase|Other|0
6085519|NCT00652951|9694831|FG002|Booster Phase|Other|0
6230983|NCT01747915|9905922|FG001|Overall Study|Lost to Follow-up|0
6230984|NCT01747915|9905923|FG002|Overall Study|Lost to Follow-up|0
6230985|NCT01747915|9905921|FG000|Overall Study|Withdrawal by Subject|4
6230986|NCT01747915|9905922|FG001|Overall Study|Withdrawal by Subject|4
6230987|NCT01747915|9905923|FG002|Overall Study|Withdrawal by Subject|1
6230988|NCT01747915|9905921|FG000|Overall Study|Protocol Violation|1
6230989|NCT01747915|9905922|FG001|Overall Study|Protocol Violation|0
6230990|NCT01747915|9905923|FG002|Overall Study|Protocol Violation|0
6230991|NCT01747915|9905921|FG000|Overall Study|Pregnancy|0
6230992|NCT01747915|9905922|FG001|Overall Study|Pregnancy|0
6230993|NCT01747915|9905923|FG002|Overall Study|Pregnancy|1
6230994|NCT01748071|9905983|FG000|Overall Study|Adverse Event|2
6230995|NCT01748071|9905984|FG001|Overall Study|Adverse Event|2
6230996|NCT01748071|9905985|FG002|Overall Study|Adverse Event|0
6230997|NCT01748292|9906004|FG000|Overall Study|Adverse Event|2
6230998|NCT01748292|9906005|FG001|Overall Study|Adverse Event|4
6230999|NCT01748292|9906004|FG000|Overall Study|Lost to Follow-up|0
6231000|NCT01748292|9906005|FG001|Overall Study|Lost to Follow-up|3
6231001|NCT01748292|9906004|FG000|Overall Study|Death|0
6231002|NCT01748292|9906005|FG001|Overall Study|Death|3
6231003|NCT01748292|9906004|FG000|Overall Study|Withdrawal by Subject|0
6231004|NCT01748292|9906005|FG001|Overall Study|Withdrawal by Subject|2
6231005|NCT01748552|9906023|FG000|Intervention Period 2 and Washout|Physician Decision|0
6231006|NCT01748552|9906024|FG001|Intervention Period 2 and Washout|Physician Decision|0
6231007|NCT01748552|9906025|FG002|Intervention Period 2 and Washout|Physician Decision|1
6231008|NCT01748552|9906026|FG003|Intervention Period 2 and Washout|Physician Decision|0
6231009|NCT01748552|9906027|FG004|Intervention Period 2 and Washout|Physician Decision|0
6231010|NCT01748552|9906028|FG005|Intervention Period 2 and Washout|Physician Decision|0
6231011|NCT01748552|9906029|FG006|Intervention Period 2 and Washout|Physician Decision|0
6231012|NCT01748552|9906030|FG007|Intervention Period 2 and Washout|Physician Decision|0
6231013|NCT01748552|9906031|FG008|Intervention Period 2 and Washout|Physician Decision|0
6231014|NCT01748552|9906032|FG009|Intervention Period 2 and Washout|Physician Decision|0
6231015|NCT01748552|9906033|FG010|Intervention Period 2 and Washout|Physician Decision|0
6231016|NCT01748552|9906034|FG011|Intervention Period 2 and Washout|Physician Decision|0
6231017|NCT01748552|9906023|FG000|Intervention Period 2 and Washout|Contingency dose not tested|0
6231018|NCT01748552|9906024|FG001|Intervention Period 2 and Washout|Contingency dose not tested|0
6231019|NCT01748552|9906025|FG002|Intervention Period 2 and Washout|Contingency dose not tested|0
6231020|NCT01748552|9906026|FG003|Intervention Period 2 and Washout|Contingency dose not tested|0
6231021|NCT01748552|9906027|FG004|Intervention Period 2 and Washout|Contingency dose not tested|0
6231022|NCT01748552|9906028|FG005|Intervention Period 2 and Washout|Contingency dose not tested|0
6231023|NCT01748552|9906029|FG006|Intervention Period 2 and Washout|Contingency dose not tested|3
6231024|NCT01748552|9906030|FG007|Intervention Period 2 and Washout|Contingency dose not tested|3
6231025|NCT01748552|9906031|FG008|Intervention Period 2 and Washout|Contingency dose not tested|3
6231026|NCT01748552|9906032|FG009|Intervention Period 2 and Washout|Contingency dose not tested|0
6231027|NCT01748552|9906033|FG010|Intervention Period 2 and Washout|Contingency dose not tested|0
6231028|NCT01748552|9906034|FG011|Intervention Period 2 and Washout|Contingency dose not tested|0
6231029|NCT01748760|9906092|FG000|Overall Study|Withdrawal by Subject|1
6231030|NCT01748760|9906093|FG001|Overall Study|Withdrawal by Subject|1
6231031|NCT01748760|9906092|FG000|Overall Study|Lost to Follow-up|5
6231032|NCT01748760|9906093|FG001|Overall Study|Lost to Follow-up|1
6231033|NCT01748825|9906150|FG000|Dose Escalation|Refused further treatment|2
6231034|NCT01748825|9906151|FG001|Dose Escalation|Refused further treatment|2
6231035|NCT01748825|9906152|FG002|Dose Escalation|Refused further treatment|0
6231036|NCT01748825|9906153|FG003|Dose Escalation|Refused further treatment|0
6231037|NCT01748825|9906154|FG004|Dose Escalation|Refused further treatment|1
6231038|NCT01748825|9906155|FG005|Dose Escalation|Refused further treatment|2
6231039|NCT01748825|9906156|FG006|Dose Escalation|Refused further treatment|0
6231040|NCT01748825|9906157|FG007|Dose Escalation|Refused further treatment|0
6231041|NCT01748825|9906158|FG008|Dose Escalation|Refused further treatment|0
6231042|NCT01748825|9906159|FG009|Dose Escalation|Refused further treatment|0
6231043|NCT01748825|9906150|FG000|Dose Escalation|Switched to alternative treatment|0
6231044|NCT01748825|9906151|FG001|Dose Escalation|Switched to alternative treatment|0
6231045|NCT01748825|9906152|FG002|Dose Escalation|Switched to alternative treatment|0
6231046|NCT01748825|9906153|FG003|Dose Escalation|Switched to alternative treatment|1
6231047|NCT01748825|9906154|FG004|Dose Escalation|Switched to alternative treatment|0
6231048|NCT01748825|9906155|FG005|Dose Escalation|Switched to alternative treatment|0
6231049|NCT01748825|9906156|FG006|Dose Escalation|Switched to alternative treatment|0
6231050|NCT01748825|9906157|FG007|Dose Escalation|Switched to alternative treatment|0
6231051|NCT01748825|9906158|FG008|Dose Escalation|Switched to alternative treatment|0
6231052|NCT01748825|9906159|FG009|Dose Escalation|Switched to alternative treatment|0
6231053|NCT01748825|9906150|FG000|Dose Escalation|Adverse Event|0
6231054|NCT01748825|9906151|FG001|Dose Escalation|Adverse Event|0
6231055|NCT01748825|9906152|FG002|Dose Escalation|Adverse Event|0
6231056|NCT01748825|9906153|FG003|Dose Escalation|Adverse Event|0
6231057|NCT01748825|9906154|FG004|Dose Escalation|Adverse Event|0
6231058|NCT01748825|9906155|FG005|Dose Escalation|Adverse Event|0
6231059|NCT01748825|9906156|FG006|Dose Escalation|Adverse Event|1
6231060|NCT01748825|9906157|FG007|Dose Escalation|Adverse Event|0
6231061|NCT01748825|9906158|FG008|Dose Escalation|Adverse Event|0
6231062|NCT01748825|9906159|FG009|Dose Escalation|Adverse Event|0
6231063|NCT01748825|9906150|FG000|Dose Expansion|Refused further treatment|0
6231064|NCT01748825|9906151|FG001|Dose Expansion|Refused further treatment|0
6231065|NCT01748825|9906152|FG002|Dose Expansion|Refused further treatment|0
6231066|NCT01748825|9906153|FG003|Dose Expansion|Refused further treatment|0
6231067|NCT01748825|9906154|FG004|Dose Expansion|Refused further treatment|0
6231068|NCT01748825|9906155|FG005|Dose Expansion|Refused further treatment|0
6231069|NCT01748825|9906156|FG006|Dose Expansion|Refused further treatment|0
6231070|NCT01748825|9906157|FG007|Dose Expansion|Refused further treatment|0
6231071|NCT01748825|9906158|FG008|Dose Expansion|Refused further treatment|1
6231072|NCT01748825|9906159|FG009|Dose Expansion|Refused further treatment|1
6231073|NCT01748825|9906150|FG000|Dose Expansion|Switched to alternative treatment|0
6231074|NCT01748825|9906151|FG001|Dose Expansion|Switched to alternative treatment|0
6231075|NCT01748825|9906152|FG002|Dose Expansion|Switched to alternative treatment|0
6231076|NCT01748825|9906153|FG003|Dose Expansion|Switched to alternative treatment|0
6231077|NCT01748825|9906154|FG004|Dose Expansion|Switched to alternative treatment|0
6231078|NCT01748825|9906155|FG005|Dose Expansion|Switched to alternative treatment|0
6231079|NCT01748825|9906156|FG006|Dose Expansion|Switched to alternative treatment|0
6231080|NCT01748825|9906157|FG007|Dose Expansion|Switched to alternative treatment|0
6231081|NCT01748825|9906158|FG008|Dose Expansion|Switched to alternative treatment|0
6231082|NCT01748825|9906159|FG009|Dose Expansion|Switched to alternative treatment|1
6231083|NCT01748825|9906150|FG000|Dose Expansion|Adverse Event|0
6231084|NCT01748825|9906151|FG001|Dose Expansion|Adverse Event|0
6231085|NCT01748825|9906152|FG002|Dose Expansion|Adverse Event|0
6231086|NCT01748825|9906153|FG003|Dose Expansion|Adverse Event|0
6231087|NCT01748825|9906154|FG004|Dose Expansion|Adverse Event|0
6231088|NCT01748825|9906155|FG005|Dose Expansion|Adverse Event|0
6231089|NCT01748825|9906156|FG006|Dose Expansion|Adverse Event|0
6231090|NCT01748825|9906157|FG007|Dose Expansion|Adverse Event|0
6231091|NCT01748825|9906158|FG008|Dose Expansion|Adverse Event|0
6231092|NCT01748825|9906159|FG009|Dose Expansion|Adverse Event|3
6231093|NCT01748825|9906150|FG000|Dose Expansion|Physician Decision|0
6231094|NCT01748825|9906151|FG001|Dose Expansion|Physician Decision|0
6231095|NCT01748825|9906152|FG002|Dose Expansion|Physician Decision|0
6231096|NCT01748825|9906153|FG003|Dose Expansion|Physician Decision|0
6231097|NCT01748825|9906154|FG004|Dose Expansion|Physician Decision|0
6231098|NCT01748825|9906155|FG005|Dose Expansion|Physician Decision|0
6231099|NCT01748825|9906156|FG006|Dose Expansion|Physician Decision|0
6231100|NCT01748825|9906157|FG007|Dose Expansion|Physician Decision|0
6231101|NCT01748825|9906158|FG008|Dose Expansion|Physician Decision|1
6231102|NCT01748825|9906159|FG009|Dose Expansion|Physician Decision|0
6231103|NCT01748994|9906221|FG000|Overall Study|Lost to Follow-up|8
6231104|NCT01748994|9906222|FG001|Overall Study|Lost to Follow-up|6
6231105|NCT01749033|9906231|FG000|Overall Study|Did not receive allocated intervention|3
6231106|NCT01749033|9906232|FG001|Overall Study|Did not receive allocated intervention|3
6231107|NCT01749033|9906233|FG002|Overall Study|Did not receive allocated intervention|0
6375528|NCT03150862|10165644|FG005|Overall Study|Progressive Disease|0
6375529|NCT03150862|10165645|FG006|Overall Study|Progressive Disease|0
6231108|NCT01749033|9906231|FG000|Overall Study|Lost to Follow-up|0
6231109|NCT01749033|9906232|FG001|Overall Study|Lost to Follow-up|2
6231110|NCT01749033|9906233|FG002|Overall Study|Lost to Follow-up|1
6231111|NCT01749735|9906284|FG000|Overall Study|Withdrawal by Subject|1
6231112|NCT01749735|9906285|FG001|Overall Study|Withdrawal by Subject|0
6231113|NCT01749800|9906294|FG000|Overall Study|not meeting inclusion criteria|3
6231114|NCT01749800|9906295|FG001|Overall Study|not meeting inclusion criteria|0
6231115|NCT01749800|9906296|FG002|Overall Study|not meeting inclusion criteria|0
6231116|NCT01749800|9906294|FG000|Overall Study|Withdrawal by Subject|0
6231117|NCT01749800|9906295|FG001|Overall Study|Withdrawal by Subject|1
6231118|NCT01749800|9906296|FG002|Overall Study|Withdrawal by Subject|0
6231119|NCT01749982|9906339|FG000|Overall Study|Physician Decision|0
6231120|NCT01749982|9906340|FG001|Overall Study|Physician Decision|0
6231121|NCT01749982|9906341|FG002|Overall Study|Physician Decision|0
6231122|NCT01749982|9906342|FG003|Overall Study|Physician Decision|1
6231123|NCT01749982|9906339|FG000|Overall Study|Lost to Follow-up|0
6231124|NCT01749982|9906340|FG001|Overall Study|Lost to Follow-up|0
6231125|NCT01749982|9906341|FG002|Overall Study|Lost to Follow-up|0
6231126|NCT01749982|9906342|FG003|Overall Study|Lost to Follow-up|1
6231127|NCT01749982|9906339|FG000|Overall Study|Withdrawal by Subject|0
6231128|NCT01749982|9906340|FG001|Overall Study|Withdrawal by Subject|0
6231129|NCT01749982|9906341|FG002|Overall Study|Withdrawal by Subject|0
6231130|NCT01749982|9906342|FG003|Overall Study|Withdrawal by Subject|1
6231131|NCT01750190|9906367|FG000|Overall Study|Adverse Event|47
6231132|NCT01750190|9906368|FG001|Overall Study|Adverse Event|19
6231133|NCT01750190|9906367|FG000|Overall Study|Death|38
6231134|NCT01750190|9906368|FG001|Overall Study|Death|11
6231135|NCT01750190|9906367|FG000|Overall Study|Lack of Efficacy (Including Erythropoiesis-Stimulating Agent Rescue)|2
6231136|NCT01750190|9906368|FG001|Overall Study|Lack of Efficacy (Including Erythropoiesis-Stimulating Agent Rescue)|43
6231137|NCT01750190|9906367|FG000|Overall Study|Lost to Follow-up|28
6231138|NCT01750190|9906368|FG001|Overall Study|Lost to Follow-up|7
6231139|NCT01750190|9906367|FG000|Overall Study|Physician Decision|16
6231140|NCT01750190|9906368|FG001|Overall Study|Physician Decision|17
6231141|NCT01750190|9906367|FG000|Overall Study|Protocol Violation|6
6231142|NCT01750190|9906368|FG001|Overall Study|Protocol Violation|5
6231143|NCT01750190|9906367|FG000|Overall Study|Study/Site Terminated by Sponsor|4
6231144|NCT01750190|9906368|FG001|Overall Study|Study/Site Terminated by Sponsor|1
6231145|NCT01750190|9906367|FG000|Overall Study|Withdrawal by Subject|83
6231146|NCT01750190|9906368|FG001|Overall Study|Withdrawal by Subject|89
6231147|NCT01750190|9906367|FG000|Overall Study|Kidney Transplant|8
6231148|NCT01750190|9906368|FG001|Overall Study|Kidney Transplant|4
6231149|NCT01750190|9906367|FG000|Overall Study|Dialysis|22
6231150|NCT01750190|9906368|FG001|Overall Study|Dialysis|8
6231151|NCT01750190|9906367|FG000|Overall Study|Other than Specified|13
6231152|NCT01750190|9906368|FG001|Overall Study|Other than Specified|4
6231153|NCT01750229|9906374|FG000|Randomized Crossover Phase|Adverse Event|1
6231154|NCT01750229|9906374|FG000|Randomized Crossover Phase|Withdrawal by Subject|1
6231155|NCT01750229|9906374|FG000|Long-term Follow-up Phase|Adverse Event|2
6231156|NCT01750229|9906374|FG000|Long-term Follow-up Phase|Withdrawal by Subject|1
6231157|NCT01750242|9906384|FG000|Overall Study|Unreadable Images|3
6231158|NCT01750268|9906401|FG000|Overall Study|Lost to Follow-up|0
6231159|NCT01750268|9906402|FG001|Overall Study|Lost to Follow-up|2
6231160|NCT01750268|9906401|FG000|Overall Study|Physician Decision|0
6231161|NCT01750268|9906402|FG001|Overall Study|Physician Decision|3
6231162|NCT01750268|9906401|FG000|Overall Study|Withdrawal by Subject|2
6231163|NCT01750268|9906402|FG001|Overall Study|Withdrawal by Subject|0
6231164|NCT01750294|9906408|FG000|Overall Study|Withdrawal by Subject|1
6231165|NCT01750294|9906408|FG000|Overall Study|Safety Endpoint|1
6231166|NCT01750346|9906415|FG000|Overall Study|Adverse Event|1
6231167|NCT01750346|9906416|FG001|Overall Study|Adverse Event|0
6231168|NCT01750346|9906417|FG002|Overall Study|Adverse Event|0
6231169|NCT01750684|9906445|FG000|Overall Study|Death|1
6231170|NCT01750684|9906446|FG001|Overall Study|Death|0
6231171|NCT01750684|9906445|FG000|Overall Study|Non-compliance with Study Drug|0
6231172|NCT01750684|9906446|FG001|Overall Study|Non-compliance with Study Drug|1
6231173|NCT01750684|9906445|FG000|Overall Study|Withdrawn by Sponsor|0
6231174|NCT01750684|9906446|FG001|Overall Study|Withdrawn by Sponsor|1
6231175|NCT01750684|9906445|FG000|Overall Study|Protocol Violation|1
6231176|NCT01750684|9906446|FG001|Overall Study|Protocol Violation|0
6231177|NCT01750697|9906453|FG000|Overall Study|Transferred Back to Local Hospital|1
6231178|NCT01750697|9906453|FG000|Overall Study|Physician and Family Decision|1
6231179|NCT01750697|9906453|FG000|Overall Study|Transferred to Adult Services|5
6231180|NCT01750697|9906453|FG000|Overall Study|Physician Decision|1
6231181|NCT01750697|9906453|FG000|Overall Study|Withdrawal by Subject|1
6231182|NCT01750840|9906460|FG000|Overall Study|Lost to Follow-up|4
6231183|NCT01750879|9906467|FG000|Overall Study|Adverse Event|8
6231184|NCT01750879|9906468|FG001|Overall Study|Adverse Event|0
6231185|NCT01750879|9906467|FG000|Overall Study|Lack of Efficacy|1
6231186|NCT01750879|9906468|FG001|Overall Study|Lack of Efficacy|0
6231187|NCT01750879|9906467|FG000|Overall Study|Withdrawal by Subject|1
6231188|NCT01750879|9906468|FG001|Overall Study|Withdrawal by Subject|0
6231189|NCT01750879|9906467|FG000|Overall Study|Did not complete per protocol|0
6231190|NCT01750879|9906468|FG001|Overall Study|Did not complete per protocol|3
6231191|NCT01750918|9906495|FG000|Overall Study|Last patient transitioned to a rollover protocol|0
6231192|NCT01750918|9906496|FG001|Overall Study|Last patient transitioned to a rollover protocol|0
6231193|NCT01750918|9906497|FG002|Overall Study|Last patient transitioned to a rollover protocol|5
6231194|NCT01750918|9906498|FG003|Overall Study|Last patient transitioned to a rollover protocol|2
6231195|NCT01750918|9906499|FG004|Overall Study|Last patient transitioned to a rollover protocol|0
6231196|NCT01750918|9906500|FG005|Overall Study|Last patient transitioned to a rollover protocol|2
6231197|NCT01750918|9906501|FG006|Overall Study|Last patient transitioned to a rollover protocol|1
6231198|NCT01750918|9906502|FG007|Overall Study|Last patient transitioned to a rollover protocol|1
6231199|NCT01750918|9906495|FG000|Overall Study|Lost to Follow-up|0
6231200|NCT01750918|9906496|FG001|Overall Study|Lost to Follow-up|0
6231201|NCT01750918|9906497|FG002|Overall Study|Lost to Follow-up|2
6231202|NCT01750918|9906498|FG003|Overall Study|Lost to Follow-up|2
6231203|NCT01750918|9906499|FG004|Overall Study|Lost to Follow-up|0
6231204|NCT01750918|9906500|FG005|Overall Study|Lost to Follow-up|0
6231205|NCT01750918|9906501|FG006|Overall Study|Lost to Follow-up|0
6231206|NCT01750918|9906502|FG007|Overall Study|Lost to Follow-up|1
6231207|NCT01750918|9906495|FG000|Overall Study|Withdrawal by Subject|0
6231208|NCT01750918|9906496|FG001|Overall Study|Withdrawal by Subject|0
6231209|NCT01750918|9906497|FG002|Overall Study|Withdrawal by Subject|1
6231210|NCT01750918|9906498|FG003|Overall Study|Withdrawal by Subject|2
6231211|NCT01750918|9906499|FG004|Overall Study|Withdrawal by Subject|1
6231212|NCT01750918|9906500|FG005|Overall Study|Withdrawal by Subject|1
6231213|NCT01750918|9906501|FG006|Overall Study|Withdrawal by Subject|2
6231214|NCT01750918|9906502|FG007|Overall Study|Withdrawal by Subject|2
6231215|NCT01751061|9906573|FG000|Overall Study|Death|1
6231216|NCT01751061|9906574|FG001|Overall Study|Death|0
6231217|NCT01751061|9906573|FG000|Overall Study|patient death|5
6231218|NCT01751061|9906574|FG001|Overall Study|patient death|0
6231219|NCT01751061|9906573|FG000|Overall Study|Lost to Follow-up|40
6231220|NCT01751061|9906574|FG001|Overall Study|Lost to Follow-up|25
6231221|NCT01751061|9906573|FG000|Overall Study|patient regained decisional capacity|4
6231222|NCT01751061|9906574|FG001|Overall Study|patient regained decisional capacity|8
6231223|NCT01751061|9906573|FG000|Overall Study|Withdrawal by Subject|4
6231224|NCT01751061|9906574|FG001|Overall Study|Withdrawal by Subject|1
6231225|NCT01751061|9906573|FG000|Overall Study|Physician Decision|2
6231226|NCT01751061|9906574|FG001|Overall Study|Physician Decision|0
6231227|NCT01751087|9906583|FG000|Overall Study|Withdrawal by Subject|1
6231228|NCT01751087|9906584|FG001|Overall Study|Withdrawal by Subject|0
6231229|NCT01751087|9906585|FG002|Overall Study|Withdrawal by Subject|0
6231230|NCT01751087|9906583|FG000|Overall Study|Physician Decision|0
6231231|NCT01751087|9906584|FG001|Overall Study|Physician Decision|0
6231232|NCT01751087|9906585|FG002|Overall Study|Physician Decision|1
6231233|NCT01751113|9906593|FG000|Treatment Period 1 (4 Weeks)|Adverse Event|0
6231234|NCT01751113|9906594|FG001|Treatment Period 1 (4 Weeks)|Adverse Event|0
6231235|NCT01751113|9906595|FG002|Treatment Period 1 (4 Weeks)|Adverse Event|0
6231236|NCT01751113|9906596|FG003|Treatment Period 1 (4 Weeks)|Adverse Event|1
6231237|NCT01751113|9906597|FG004|Treatment Period 1 (4 Weeks)|Adverse Event|1
6231238|NCT01751113|9906598|FG005|Treatment Period 1 (4 Weeks)|Adverse Event|0
6231239|NCT01751113|9906593|FG000|Treatment Period 3 (4 Weeks)|Adverse Event|0
6231240|NCT01751113|9906594|FG001|Treatment Period 3 (4 Weeks)|Adverse Event|0
6231241|NCT01751113|9906595|FG002|Treatment Period 3 (4 Weeks)|Adverse Event|0
6231242|NCT01751113|9906596|FG003|Treatment Period 3 (4 Weeks)|Adverse Event|0
6231243|NCT01751113|9906597|FG004|Treatment Period 3 (4 Weeks)|Adverse Event|0
6231244|NCT01751113|9906598|FG005|Treatment Period 3 (4 Weeks)|Adverse Event|1
6231245|NCT01751139|9906607|FG000|Overall Study|Other|135
6231246|NCT01751139|9906607|FG000|Overall Study|Sponsor study termination|1609
6231247|NCT01751139|9906607|FG000|Overall Study|Lost to Follow-up|240
6231248|NCT01751139|9906607|FG000|Overall Study|Withdrawal by Subject|251
6231249|NCT01751139|9906607|FG000|Overall Study|Adverse Event|1
6231250|NCT01751139|9906607|FG000|Overall Study|Death|31
6231251|NCT01751165|9906614|FG000|Overall Study|Adverse event, serious fatal|1
6231252|NCT01751165|9906615|FG001|Overall Study|Adverse event, serious fatal|0
6231253|NCT01751165|9906616|FG002|Overall Study|Adverse event, serious fatal|1
6231254|NCT01751165|9906614|FG000|Overall Study|Withdrawal by Subject|0
6231255|NCT01751165|9906615|FG001|Overall Study|Withdrawal by Subject|0
6231256|NCT01751165|9906616|FG002|Overall Study|Withdrawal by Subject|1
6231257|NCT01751165|9906614|FG000|Overall Study|Serious adverse event|0
6231258|NCT01751165|9906615|FG001|Overall Study|Serious adverse event|2
6231259|NCT01751165|9906616|FG002|Overall Study|Serious adverse event|0
6231260|NCT01751165|9906614|FG000|Overall Study|Lost to Follow-up|1
6231261|NCT01751165|9906615|FG001|Overall Study|Lost to Follow-up|1
6231262|NCT01751165|9906616|FG002|Overall Study|Lost to Follow-up|1
6231263|NCT01751178|9906629|FG000|Overall Study|Adverse Event|2
6231264|NCT01751178|9906630|FG001|Overall Study|Adverse Event|0
6231265|NCT01751178|9906631|FG002|Overall Study|Adverse Event|0
6231266|NCT01751178|9906629|FG000|Overall Study|Other Reason (unknown)|1
6231267|NCT01751178|9906630|FG001|Overall Study|Other Reason (unknown)|0
6231268|NCT01751178|9906631|FG002|Overall Study|Other Reason (unknown)|2
6269760|NCT02143713|9970156|FG000|Treatment Period (6 Months)|Exclusionary Medication|2
6269761|NCT02143713|9970157|FG001|Treatment Period (6 Months)|Exclusionary Medication|0
6269762|NCT02143713|9970158|FG002|Treatment Period (6 Months)|Exclusionary Medication|0
6269763|NCT02143713|9970159|FG003|Treatment Period (6 Months)|Exclusionary Medication|0
6269764|NCT02143713|9970156|FG000|Treatment Period (6 Months)|Lack of Efficacy|1
6269765|NCT02143713|9970157|FG001|Treatment Period (6 Months)|Lack of Efficacy|0
6269766|NCT02143713|9970158|FG002|Treatment Period (6 Months)|Lack of Efficacy|0
6269767|NCT02143713|9970159|FG003|Treatment Period (6 Months)|Lack of Efficacy|1
6269768|NCT02143713|9970156|FG000|Post-treatment Follow-up (12 Months)|Withdrawal by Subject|4
6269769|NCT02143713|9970157|FG001|Post-treatment Follow-up (12 Months)|Withdrawal by Subject|7
6269770|NCT02143713|9970158|FG002|Post-treatment Follow-up (12 Months)|Withdrawal by Subject|6
6269771|NCT02143713|9970159|FG003|Post-treatment Follow-up (12 Months)|Withdrawal by Subject|10
6269772|NCT02143713|9970156|FG000|Post-treatment Follow-up (12 Months)|Adverse Event|0
6269773|NCT02143713|9970157|FG001|Post-treatment Follow-up (12 Months)|Adverse Event|0
6269774|NCT02143713|9970158|FG002|Post-treatment Follow-up (12 Months)|Adverse Event|1
6269775|NCT02143713|9970159|FG003|Post-treatment Follow-up (12 Months)|Adverse Event|0
6269776|NCT02143713|9970156|FG000|Post-treatment Follow-up (12 Months)|Lost to Follow-up|3
6269777|NCT02143713|9970157|FG001|Post-treatment Follow-up (12 Months)|Lost to Follow-up|8
6269778|NCT02143713|9970158|FG002|Post-treatment Follow-up (12 Months)|Lost to Follow-up|11
6269779|NCT02143713|9970159|FG003|Post-treatment Follow-up (12 Months)|Lost to Follow-up|8
6269780|NCT02143713|9970156|FG000|Post-treatment Follow-up (12 Months)|Surgery or Invasive Intervention|2
6269781|NCT02143713|9970157|FG001|Post-treatment Follow-up (12 Months)|Surgery or Invasive Intervention|4
6269782|NCT02143713|9970158|FG002|Post-treatment Follow-up (12 Months)|Surgery or Invasive Intervention|4
6269783|NCT02143713|9970159|FG003|Post-treatment Follow-up (12 Months)|Surgery or Invasive Intervention|1
6269784|NCT02143713|9970156|FG000|Post-treatment Follow-up (12 Months)|Exclusionary Medication|0
6375530|NCT03150862|10165646|FG007|Overall Study|Progressive Disease|2
6375531|NCT03052608|10165675|FG000|Treatment Phase|Adverse Event|10
6375532|NCT03052608|10165676|FG001|Treatment Phase|Adverse Event|12
6375533|NCT03052608|10165675|FG000|Treatment Phase|Death|6
6375534|NCT03052608|10165676|FG001|Treatment Phase|Death|4
6375535|NCT03052608|10165675|FG000|Treatment Phase|Withdrawal by Subject|4
6269785|NCT02143713|9970157|FG001|Post-treatment Follow-up (12 Months)|Exclusionary Medication|1
6375536|NCT03052608|10165676|FG001|Treatment Phase|Withdrawal by Subject|12
6375537|NCT03052608|10165675|FG000|Treatment Phase|Global Deterioration of Health Status|0
6375538|NCT03052608|10165676|FG001|Treatment Phase|Global Deterioration of Health Status|3
6231269|NCT01751412|9906707|FG000|Overall Study|Disease Progression Before Treatment|1
6231270|NCT01751568|9906727|FG000|Overall Study|Participant never started treatment of raltegravir, was taken off-study.|1
6231271|NCT01751568|9906728|FG001|Overall Study|Participant never started treatment of raltegravir, was taken off-study.|0
6231272|NCT01751568|9906729|FG002|Overall Study|Participant never started treatment of raltegravir, was taken off-study.|0
6231273|NCT01751646|9906739|FG000|Overall Study|Lost to Follow-up|5
6231274|NCT01751646|9906740|FG001|Overall Study|Lost to Follow-up|1
6231275|NCT01751646|9906739|FG000|Overall Study|Withdrawal by Subject|0
6231276|NCT01751646|9906740|FG001|Overall Study|Withdrawal by Subject|4
6231277|NCT01751646|9906739|FG000|Overall Study|Starting hormone therapy|1
6231278|NCT01751646|9906740|FG001|Overall Study|Starting hormone therapy|0
6231279|NCT01751646|9906739|FG000|Overall Study|Missed 4 or more consecutive DOT visits|2
6231280|NCT01751646|9906740|FG001|Overall Study|Missed 4 or more consecutive DOT visits|3
6231281|NCT01751646|9906739|FG000|Overall Study|Inadvertent enrollment|1
6231282|NCT01751646|9906740|FG001|Overall Study|Inadvertent enrollment|1
6231283|NCT01751646|9906739|FG000|Overall Study|Moved out of the area|1
6231284|NCT01751646|9906740|FG001|Overall Study|Moved out of the area|5
6231285|NCT01751646|9906739|FG000|Overall Study|Inability to attend required visits|0
6231286|NCT01751646|9906740|FG001|Overall Study|Inability to attend required visits|1
6231287|NCT01751646|9906739|FG000|Overall Study|Off study due to multiple obligations|0
6085520|NCT00653159|9694850|FG000|Overall Study|Adverse Event|4
6085521|NCT00653159|9694851|FG001|Overall Study|Adverse Event|1
6085522|NCT00653159|9694850|FG000|Overall Study|Lost to Follow-up|1
6231288|NCT01751646|9906740|FG001|Overall Study|Off study due to multiple obligations|1
6231289|NCT01751646|9906739|FG000|Overall Study|Fails to comply with study requirements|0
6231290|NCT01751646|9906740|FG001|Overall Study|Fails to comply with study requirements|1
6231291|NCT01751646|9906739|FG000|Overall Study|Childcare issues|1
6231292|NCT01751646|9906740|FG001|Overall Study|Childcare issues|1
6231293|NCT01751724|9906752|FG000|Overall Study|extubated bef.start assigned treatment|1
6231294|NCT01751724|9906753|FG001|Overall Study|extubated bef.start assigned treatment|0
6231295|NCT01751724|9906752|FG000|Overall Study|withdrawn by parent|0
6231296|NCT01751724|9906753|FG001|Overall Study|withdrawn by parent|2
6231297|NCT01751802|9906761|FG000|Overall Study|Adverse Event|4
6231298|NCT01751802|9906762|FG001|Overall Study|Adverse Event|2
6231299|NCT01751867|9906776|FG000|Overall Study|Completed treatment,dropped in follow-up|4
6231300|NCT01751867|9906777|FG001|Overall Study|Completed treatment,dropped in follow-up|8
6231301|NCT01751867|9906776|FG000|Overall Study|Diease Progression|4
6231302|NCT01751867|9906777|FG001|Overall Study|Diease Progression|18
6231303|NCT01751867|9906776|FG000|Overall Study|Adverse Event|8
6231304|NCT01751867|9906777|FG001|Overall Study|Adverse Event|15
6231305|NCT01751867|9906776|FG000|Overall Study|Poor Compliance|0
6231306|NCT01751867|9906777|FG001|Overall Study|Poor Compliance|5
6231307|NCT01751867|9906776|FG000|Overall Study|Withdrawal by Subject|3
6231308|NCT01751867|9906777|FG001|Overall Study|Withdrawal by Subject|1
6231309|NCT01751867|9906776|FG000|Overall Study|Physician Decision|4
6231310|NCT01751867|9906777|FG001|Overall Study|Physician Decision|7
6231311|NCT01751867|9906776|FG000|Overall Study|Protocol Violation|0
6231312|NCT01751867|9906777|FG001|Overall Study|Protocol Violation|2
6231313|NCT01751867|9906776|FG000|Overall Study|Death|0
6231314|NCT01751867|9906777|FG001|Overall Study|Death|5
6231315|NCT01751867|9906776|FG000|Overall Study|Other|11
6085523|NCT00653159|9694851|FG001|Overall Study|Lost to Follow-up|2
6231316|NCT01751867|9906777|FG001|Overall Study|Other|37
6231317|NCT01751867|9906776|FG000|Overall Study|Randomized but not treated.|2
6231318|NCT01751867|9906777|FG001|Overall Study|Randomized but not treated.|1
6231319|NCT01752036|9906798|FG000|Overall Study|Death|2
6231320|NCT01752634|9906826|FG000|Up to Week 24 (Primary Analysis)|Subject/guardian decision|1
6231321|NCT01752634|9906827|FG001|Up to Week 24 (Primary Analysis)|Subject/guardian decision|1
6231322|NCT01752634|9906828|FG002|Up to Week 24 (Primary Analysis)|Subject/guardian decision|1
6231323|NCT01752634|9906829|FG003|Up to Week 24 (Primary Analysis)|Subject/guardian decision|0
6231324|NCT01752634|9906830|FG004|Up to Week 24 (Primary Analysis)|Subject/guardian decision|0
6231325|NCT01752634|9906831|FG005|Up to Week 24 (Primary Analysis)|Subject/guardian decision|3
6231326|NCT01752634|9906826|FG000|Up to Week 24 (Primary Analysis)|Physician Decision|0
6231327|NCT01752634|9906827|FG001|Up to Week 24 (Primary Analysis)|Physician Decision|1
6231328|NCT01752634|9906828|FG002|Up to Week 24 (Primary Analysis)|Physician Decision|0
6231329|NCT01752634|9906829|FG003|Up to Week 24 (Primary Analysis)|Physician Decision|0
6231330|NCT01752634|9906830|FG004|Up to Week 24 (Primary Analysis)|Physician Decision|0
6231331|NCT01752634|9906831|FG005|Up to Week 24 (Primary Analysis)|Physician Decision|0
6231332|NCT01752634|9906826|FG000|Up to Week 24 (Primary Analysis)|Lack of Efficacy|2
6231333|NCT01752634|9906827|FG001|Up to Week 24 (Primary Analysis)|Lack of Efficacy|3
6231334|NCT01752634|9906828|FG002|Up to Week 24 (Primary Analysis)|Lack of Efficacy|0
6231335|NCT01752634|9906829|FG003|Up to Week 24 (Primary Analysis)|Lack of Efficacy|0
6231336|NCT01752634|9906830|FG004|Up to Week 24 (Primary Analysis)|Lack of Efficacy|0
6085524|NCT00653224|9694859|FG000|Overall Study|Adverse Event|2
6231337|NCT01752634|9906831|FG005|Up to Week 24 (Primary Analysis)|Lack of Efficacy|3
6231338|NCT01752634|9906826|FG000|Up to Week 24 (Primary Analysis)|Adverse Event|3
6231339|NCT01752634|9906827|FG001|Up to Week 24 (Primary Analysis)|Adverse Event|0
6231340|NCT01752634|9906828|FG002|Up to Week 24 (Primary Analysis)|Adverse Event|2
6231341|NCT01752634|9906829|FG003|Up to Week 24 (Primary Analysis)|Adverse Event|0
6231342|NCT01752634|9906830|FG004|Up to Week 24 (Primary Analysis)|Adverse Event|0
6231343|NCT01752634|9906831|FG005|Up to Week 24 (Primary Analysis)|Adverse Event|4
6231344|NCT01752634|9906826|FG000|Week 24 to Week 260|Lack of Efficacy|15
6231345|NCT01752634|9906827|FG001|Week 24 to Week 260|Lack of Efficacy|7
6231346|NCT01752634|9906828|FG002|Week 24 to Week 260|Lack of Efficacy|7
6231347|NCT01752634|9906829|FG003|Week 24 to Week 260|Lack of Efficacy|3
6231348|NCT01752634|9906830|FG004|Week 24 to Week 260|Lack of Efficacy|4
6231349|NCT01752634|9906831|FG005|Week 24 to Week 260|Lack of Efficacy|0
6231350|NCT01752634|9906826|FG000|Week 24 to Week 260|Subject/guardian decision|12
6231351|NCT01752634|9906827|FG001|Week 24 to Week 260|Subject/guardian decision|10
6231352|NCT01752634|9906828|FG002|Week 24 to Week 260|Subject/guardian decision|9
6231353|NCT01752634|9906829|FG003|Week 24 to Week 260|Subject/guardian decision|5
6231354|NCT01752634|9906830|FG004|Week 24 to Week 260|Subject/guardian decision|5
6231355|NCT01752634|9906831|FG005|Week 24 to Week 260|Subject/guardian decision|0
6231356|NCT01752634|9906826|FG000|Week 24 to Week 260|Physician Decision|1
6231357|NCT01752634|9906827|FG001|Week 24 to Week 260|Physician Decision|2
6231358|NCT01752634|9906828|FG002|Week 24 to Week 260|Physician Decision|4
6231359|NCT01752634|9906829|FG003|Week 24 to Week 260|Physician Decision|2
6231360|NCT01752634|9906830|FG004|Week 24 to Week 260|Physician Decision|1
6231361|NCT01752634|9906831|FG005|Week 24 to Week 260|Physician Decision|0
6231362|NCT01752634|9906826|FG000|Week 24 to Week 260|Death|0
6231363|NCT01752634|9906827|FG001|Week 24 to Week 260|Death|1
6231364|NCT01752634|9906828|FG002|Week 24 to Week 260|Death|0
6231365|NCT01752634|9906829|FG003|Week 24 to Week 260|Death|0
6231366|NCT01752634|9906830|FG004|Week 24 to Week 260|Death|0
6231367|NCT01752634|9906831|FG005|Week 24 to Week 260|Death|0
6231368|NCT01752634|9906826|FG000|Week 24 to Week 260|Pregnancy|0
6231369|NCT01752634|9906827|FG001|Week 24 to Week 260|Pregnancy|0
6231370|NCT01752634|9906828|FG002|Week 24 to Week 260|Pregnancy|1
6231371|NCT01752634|9906829|FG003|Week 24 to Week 260|Pregnancy|0
6231372|NCT01752634|9906830|FG004|Week 24 to Week 260|Pregnancy|0
6231373|NCT01752634|9906831|FG005|Week 24 to Week 260|Pregnancy|0
6231374|NCT01752634|9906826|FG000|Week 24 to Week 260|Noncompliance with study treatment|0
6231375|NCT01752634|9906827|FG001|Week 24 to Week 260|Noncompliance with study treatment|0
6231376|NCT01752634|9906828|FG002|Week 24 to Week 260|Noncompliance with study treatment|1
6231377|NCT01752634|9906829|FG003|Week 24 to Week 260|Noncompliance with study treatment|0
6231378|NCT01752634|9906830|FG004|Week 24 to Week 260|Noncompliance with study treatment|0
6231379|NCT01752634|9906831|FG005|Week 24 to Week 260|Noncompliance with study treatment|0
6231380|NCT01752634|9906826|FG000|Week 24 to Week 260|Lost to Follow-up|2
6231381|NCT01752634|9906827|FG001|Week 24 to Week 260|Lost to Follow-up|2
6231382|NCT01752634|9906828|FG002|Week 24 to Week 260|Lost to Follow-up|3
6231383|NCT01752634|9906829|FG003|Week 24 to Week 260|Lost to Follow-up|0
6231384|NCT01752634|9906830|FG004|Week 24 to Week 260|Lost to Follow-up|2
6231385|NCT01752634|9906831|FG005|Week 24 to Week 260|Lost to Follow-up|0
6231386|NCT01752634|9906826|FG000|Week 24 to Week 260|Adverse Event|4
6231387|NCT01752634|9906827|FG001|Week 24 to Week 260|Adverse Event|8
6231388|NCT01752634|9906828|FG002|Week 24 to Week 260|Adverse Event|8
6231389|NCT01752634|9906829|FG003|Week 24 to Week 260|Adverse Event|4
6231390|NCT01752634|9906830|FG004|Week 24 to Week 260|Adverse Event|2
6231391|NCT01752634|9906831|FG005|Week 24 to Week 260|Adverse Event|0
6231392|NCT01752842|9906852|FG000|Overall Study|Adverse Event|3
6231393|NCT01752842|9906853|FG001|Overall Study|Adverse Event|0
6231394|NCT01752842|9906852|FG000|Overall Study|Withdrawal by Subject|0
6231395|NCT01752842|9906853|FG001|Overall Study|Withdrawal by Subject|2
6231396|NCT01752855|9906861|FG000|Overall Study|Adverse Event|1
6231397|NCT01752855|9906862|FG001|Overall Study|Adverse Event|0
6231398|NCT01752855|9906861|FG000|Overall Study|Withdrew Consent|0
6231399|NCT01752855|9906862|FG001|Overall Study|Withdrew Consent|2
6231400|NCT01752855|9906861|FG000|Overall Study|Lack of Efficacy|0
6231401|NCT01752855|9906862|FG001|Overall Study|Lack of Efficacy|2
6231402|NCT01752907|9906870|FG000|Overall Study|Withdrawal by Subject|4
6231403|NCT01752907|9906871|FG001|Overall Study|Withdrawal by Subject|10
6231404|NCT01752907|9906870|FG000|Overall Study|Lost to Follow-up|2
6231405|NCT01752907|9906871|FG001|Overall Study|Lost to Follow-up|1
6231406|NCT01752907|9906870|FG000|Overall Study|Decision by Sponsor|6
6231407|NCT01752907|9906871|FG001|Overall Study|Decision by Sponsor|9
6231408|NCT01752933|9906879|FG000|Treatment|Disease Progression|3
6231409|NCT01752933|9906880|FG001|Treatment|Disease Progression|29
6231410|NCT01752933|9906879|FG000|Treatment|Withdrawal by Subject|0
6231411|NCT01752933|9906880|FG001|Treatment|Withdrawal by Subject|5
6231412|NCT01752933|9906879|FG000|Treatment|Adverse Event|1
6231413|NCT01752933|9906880|FG001|Treatment|Adverse Event|4
6231414|NCT01752933|9906879|FG000|Treatment|Physician Decision|0
6231415|NCT01752933|9906880|FG001|Treatment|Physician Decision|3
6231416|NCT01752933|9906879|FG000|Treatment|Death|0
6231417|NCT01752933|9906880|FG001|Treatment|Death|2
6231418|NCT01752933|9906879|FG000|Treatment|Hepatocellular carcinoma not confirmed|0
6231419|NCT01752933|9906880|FG001|Treatment|Hepatocellular carcinoma not confirmed|1
6231420|NCT01752933|9906879|FG000|Treatment|Patient noncompliant|0
6085525|NCT00653224|9694860|FG001|Overall Study|Adverse Event|1
6085526|NCT00653224|9694859|FG000|Overall Study|Lack of Efficacy|1
6085527|NCT00653224|9694860|FG001|Overall Study|Lack of Efficacy|2
6085528|NCT00653224|9694859|FG000|Overall Study|Loss of efficacy|1
6085529|NCT00653224|9694860|FG001|Overall Study|Loss of efficacy|0
6085530|NCT00653224|9694859|FG000|Overall Study|Lost to Follow-up|1
6085531|NCT00653224|9694860|FG001|Overall Study|Lost to Follow-up|0
6085532|NCT00653224|9694859|FG000|Overall Study|Other|2
6085533|NCT00653224|9694860|FG001|Overall Study|Other|4
6085534|NCT00653263|9694866|FG000|Overall Study|Withdrawal by Subject|1
6231421|NCT01752933|9906880|FG001|Treatment|Patient noncompliant|1
6231422|NCT01752933|9906879|FG000|Treatment|Patient unable to travel to appointments|0
6231423|NCT01752933|9906880|FG001|Treatment|Patient unable to travel to appointments|1
6231424|NCT01752933|9906879|FG000|Overall Study and Follow-up|Death|4
6231425|NCT01752933|9906880|FG001|Overall Study and Follow-up|Death|34
6231426|NCT01752933|9906879|FG000|Overall Study and Follow-up|Sponsor terminated study/Database lock|0
6231427|NCT01752933|9906880|FG001|Overall Study and Follow-up|Sponsor terminated study/Database lock|7
6231428|NCT01752933|9906879|FG000|Overall Study and Follow-up|Withdrawal by Subject|0
6231429|NCT01752933|9906880|FG001|Overall Study and Follow-up|Withdrawal by Subject|3
6231430|NCT01752933|9906879|FG000|Overall Study and Follow-up|Lost to Follow-up|0
6231431|NCT01752933|9906880|FG001|Overall Study and Follow-up|Lost to Follow-up|2
6231432|NCT01752985|9906890|FG000|Treatment Period|Subject request to discontinue treatment|1
6231433|NCT01752985|9906891|FG001|Treatment Period|Subject request to discontinue treatment|0
6231434|NCT01752985|9906892|FG002|Treatment Period|Subject request to discontinue treatment|1
6231435|NCT01752985|9906890|FG000|Treatment Period|Subject no longer meets study criteria|0
6231436|NCT01752985|9906891|FG001|Treatment Period|Subject no longer meets study criteria|1
6231437|NCT01752985|9906892|FG002|Treatment Period|Subject no longer meets study criteria|1
6231438|NCT01752985|9906890|FG000|Treatment Period|Adverse Event|2
6231439|NCT01752985|9906891|FG001|Treatment Period|Adverse Event|1
6231440|NCT01752985|9906892|FG002|Treatment Period|Adverse Event|2
6231441|NCT01752985|9906890|FG000|Treatment Period|Withdrawal by Subject|1
6231442|NCT01752985|9906891|FG001|Treatment Period|Withdrawal by Subject|1
6231443|NCT01752985|9906892|FG002|Treatment Period|Withdrawal by Subject|0
6231444|NCT01752985|9906890|FG000|Treatment Period|Lost to Follow-up|0
6231445|NCT01752985|9906891|FG001|Treatment Period|Lost to Follow-up|0
6231446|NCT01752985|9906892|FG002|Treatment Period|Lost to Follow-up|1
6231447|NCT01753076|9906902|FG000|Overall Study|Adverse Event|17
6231448|NCT01753076|9906903|FG001|Overall Study|Adverse Event|18
6231449|NCT01753076|9906902|FG000|Overall Study|Lack of Efficacy|3
6231450|NCT01753076|9906903|FG001|Overall Study|Lack of Efficacy|1
6231451|NCT01753076|9906902|FG000|Overall Study|Lost to Follow-up|2
6231452|NCT01753076|9906903|FG001|Overall Study|Lost to Follow-up|1
6231453|NCT01753076|9906902|FG000|Overall Study|Physician Decision|4
6231454|NCT01753076|9906903|FG001|Overall Study|Physician Decision|2
6231455|NCT01753076|9906902|FG000|Overall Study|Withdrawal by Subject|14
6231456|NCT01753076|9906903|FG001|Overall Study|Withdrawal by Subject|24
6231457|NCT01753076|9906902|FG000|Overall Study|Other-Reached Protocol-defined Stopping|1
6231458|NCT01753076|9906903|FG001|Overall Study|Other-Reached Protocol-defined Stopping|0
6231459|NCT01753115|9906914|FG000|Overall Study|Lost to Follow-up|3
6231460|NCT01753115|9906915|FG001|Overall Study|Lost to Follow-up|6
6231461|NCT01753115|9906916|FG002|Overall Study|Lost to Follow-up|8
6231462|NCT01753115|9906914|FG000|Overall Study|Withdrawal by Subject|6
6231463|NCT01753115|9906915|FG001|Overall Study|Withdrawal by Subject|5
6231464|NCT01753115|9906916|FG002|Overall Study|Withdrawal by Subject|6
6231465|NCT01753115|9906914|FG000|Overall Study|Subject non-compliant|3
6231466|NCT01753115|9906915|FG001|Overall Study|Subject non-compliant|3
6231467|NCT01753115|9906916|FG002|Overall Study|Subject non-compliant|0
6231468|NCT01753115|9906914|FG000|Overall Study|Used excluded drug|0
6231469|NCT01753115|9906915|FG001|Overall Study|Used excluded drug|1
6231470|NCT01753115|9906916|FG002|Overall Study|Used excluded drug|0
6231471|NCT01753193|9906924|FG000|Overall Study|Withdrawal by Subject|23
6231472|NCT01753193|9906924|FG000|Overall Study|Lost to Follow-up|6
6231473|NCT01753193|9906924|FG000|Overall Study|Death|1
6231474|NCT01753193|9906924|FG000|Overall Study|Other|16
6231475|NCT01753297|9906930|FG000|Overall Study|Lost to Follow-up|7
6231476|NCT01753297|9906931|FG001|Overall Study|Lost to Follow-up|2
6231477|NCT01753297|9906930|FG000|Overall Study|Withdrawal by Subject|26
6231478|NCT01753297|9906931|FG001|Overall Study|Withdrawal by Subject|23
6231479|NCT01753297|9906930|FG000|Overall Study|Adverse Event (up to Month 36)|1
6231480|NCT01753297|9906931|FG001|Overall Study|Adverse Event (up to Month 36)|1
6231481|NCT01753297|9906930|FG000|Overall Study|Death|0
6231482|NCT01753297|9906931|FG001|Overall Study|Death|2
6231483|NCT01753297|9906930|FG000|Overall Study|Did not attend end of study visit|7
6231484|NCT01753297|9906931|FG001|Overall Study|Did not attend end of study visit|8
6231485|NCT01753310|9906941|FG000|Overall Study|Entered into open label extension study|25
6231486|NCT01753310|9906942|FG001|Overall Study|Entered into open label extension study|22
6231487|NCT01753310|9906941|FG000|Overall Study|Adverse Event|1
6231488|NCT01753310|9906942|FG001|Overall Study|Adverse Event|0
6085535|NCT00653263|9694866|FG000|Overall Study|Physician Decision|1
6085536|NCT00653328|9694870|FG000|Overall Study|Withdrawal by Subject|1
6187131|NCT01379521|9840933|FG001|Overall Study -Treatment Period|Administrative Problems|0
6187132|NCT01379521|9840932|FG000|Overall Study -Treatment Period|Death|2
6187133|NCT01379521|9840933|FG001|Overall Study -Treatment Period|Death|1
6187134|NCT01379521|9840932|FG000|Post-Treatment Evaluations|Disease Progression|22
6187135|NCT01379521|9840933|FG001|Post-Treatment Evaluations|Disease Progression|20
6187136|NCT01379521|9840932|FG000|Post-Treatment Evaluations|Withdrawal by Subject|2
6187137|NCT01379521|9840933|FG001|Post-Treatment Evaluations|Withdrawal by Subject|1
6231489|NCT01753310|9906941|FG000|Overall Study|Lost to Follow-up|2
6231490|NCT01753310|9906942|FG001|Overall Study|Lost to Follow-up|0
6231491|NCT01753310|9906941|FG000|Overall Study|Subject decision|2
6231492|NCT01753310|9906942|FG001|Overall Study|Subject decision|2
6231493|NCT01753310|9906941|FG000|Overall Study|Sponsor decision|1
6231494|NCT01753310|9906942|FG001|Overall Study|Sponsor decision|0
6231495|NCT01753310|9906941|FG000|Overall Study|Withdrawal by Subject|1
6231496|NCT01753310|9906942|FG001|Overall Study|Withdrawal by Subject|0
6231497|NCT01753323|9906951|FG000|Overall Study|Lack of Efficacy|0
6231498|NCT01753323|9906952|FG001|Overall Study|Lack of Efficacy|0
6231499|NCT01753323|9906953|FG002|Overall Study|Lack of Efficacy|8
6231500|NCT01753323|9906951|FG000|Overall Study|Protocol deviation|1
6231501|NCT01753323|9906952|FG001|Overall Study|Protocol deviation|0
6231502|NCT01753323|9906953|FG002|Overall Study|Protocol deviation|0
6231503|NCT01753323|9906951|FG000|Overall Study|Adverse Event|0
6231504|NCT01753323|9906952|FG001|Overall Study|Adverse Event|0
6231505|NCT01753323|9906953|FG002|Overall Study|Adverse Event|1
6231506|NCT01753336|9906962|FG000|Overall Study|Patient decision|12
6231507|NCT01753336|9906962|FG000|Overall Study|Lost to Follow-up|3
6231508|NCT01753336|9906962|FG000|Overall Study|Physician Decision|2
6231509|NCT01753336|9906962|FG000|Overall Study|Sponsor's decision|2
6231510|NCT01753336|9906962|FG000|Overall Study|Withdrawal by Subject|1
6231511|NCT01753401|9906977|FG000|Double-blind Period (8 Weeks)|Adverse Event|0
6231512|NCT01753401|9906978|FG001|Double-blind Period (8 Weeks)|Adverse Event|2
6231513|NCT01753401|9906979|FG002|Double-blind Period (8 Weeks)|Adverse Event|0
6231514|NCT01753401|9906980|FG003|Double-blind Period (8 Weeks)|Adverse Event|0
6231515|NCT01753401|9906977|FG000|Double-blind Period (8 Weeks)|Withdrawal by Subject|1
6231516|NCT01753401|9906978|FG001|Double-blind Period (8 Weeks)|Withdrawal by Subject|1
6231517|NCT01753401|9906979|FG002|Double-blind Period (8 Weeks)|Withdrawal by Subject|0
6231518|NCT01753401|9906980|FG003|Double-blind Period (8 Weeks)|Withdrawal by Subject|0
6231519|NCT01753401|9906977|FG000|Double-blind Period (8 Weeks)|Protocol Violation|0
6231520|NCT01753401|9906978|FG001|Double-blind Period (8 Weeks)|Protocol Violation|1
6231521|NCT01753401|9906979|FG002|Double-blind Period (8 Weeks)|Protocol Violation|0
6231522|NCT01753401|9906980|FG003|Double-blind Period (8 Weeks)|Protocol Violation|0
6231523|NCT01753401|9906977|FG000|Open Label Period (44 Weeks)|Adverse Event|0
6231524|NCT01753401|9906978|FG001|Open Label Period (44 Weeks)|Adverse Event|0
6231525|NCT01753401|9906979|FG002|Open Label Period (44 Weeks)|Adverse Event|3
6231526|NCT01753401|9906980|FG003|Open Label Period (44 Weeks)|Adverse Event|4
6231527|NCT01753401|9906977|FG000|Open Label Period (44 Weeks)|Withdrawal by Subject|0
6231528|NCT01753401|9906978|FG001|Open Label Period (44 Weeks)|Withdrawal by Subject|0
6231529|NCT01753401|9906979|FG002|Open Label Period (44 Weeks)|Withdrawal by Subject|0
6231530|NCT01753401|9906980|FG003|Open Label Period (44 Weeks)|Withdrawal by Subject|2
6231531|NCT01753401|9906977|FG000|Open Label Period (44 Weeks)|Lack of Efficacy|0
6231532|NCT01753401|9906978|FG001|Open Label Period (44 Weeks)|Lack of Efficacy|0
6231533|NCT01753401|9906979|FG002|Open Label Period (44 Weeks)|Lack of Efficacy|1
6231534|NCT01753401|9906980|FG003|Open Label Period (44 Weeks)|Lack of Efficacy|1
6231535|NCT01753401|9906977|FG000|Open Label Period (44 Weeks)|Reason not provided|0
6231536|NCT01753401|9906978|FG001|Open Label Period (44 Weeks)|Reason not provided|0
6231537|NCT01753401|9906979|FG002|Open Label Period (44 Weeks)|Reason not provided|0
6231538|NCT01753401|9906980|FG003|Open Label Period (44 Weeks)|Reason not provided|2
6231539|NCT01753518|9906992|FG000|Intention-to-Treat Analysis|Missing consent form|5
6231540|NCT01753518|9906993|FG001|Intention-to-Treat Analysis|Missing consent form|3
6231541|NCT01753518|9906992|FG000|Intention-to-Treat Analysis|Multifetal gestation|2
6231542|NCT01753518|9906993|FG001|Intention-to-Treat Analysis|Multifetal gestation|3
6231543|NCT01753518|9906992|FG000|Intention-to-Treat Analysis|Body Mass Index>50|0
6231544|NCT01753518|9906993|FG001|Intention-to-Treat Analysis|Body Mass Index>50|1
6231545|NCT01753518|9906992|FG000|Postpartum Follow-up|Lost to Follow-up|22
6231546|NCT01753518|9906993|FG001|Postpartum Follow-up|Lost to Follow-up|15
6231547|NCT01753570|9907012|FG000|Overall Study|Adverse Event|1
6231548|NCT01753570|9907013|FG001|Overall Study|Adverse Event|0
6231549|NCT01753570|9907014|FG002|Overall Study|Adverse Event|1
6231550|NCT01753570|9907012|FG000|Overall Study|Physician Decision|0
6231551|NCT01753570|9907013|FG001|Overall Study|Physician Decision|1
6231552|NCT01753570|9907014|FG002|Overall Study|Physician Decision|0
6231553|NCT01753570|9907012|FG000|Overall Study|Withdrawal by Subject|1
6231554|NCT01753570|9907013|FG001|Overall Study|Withdrawal by Subject|4
6231555|NCT01753570|9907014|FG002|Overall Study|Withdrawal by Subject|0
6231556|NCT01753856|9907064|FG000|Overall Study|Adverse Event|1
6231557|NCT01753856|9907065|FG001|Overall Study|Adverse Event|0
6187138|NCT01379521|9840932|FG000|Post-Treatment Evaluations|Death|1
6187139|NCT01379521|9840933|FG001|Post-Treatment Evaluations|Death|0
6187140|NCT01379534|9840941|FG000|Treatment Phase|Withdrawal by Subject|2
6231558|NCT01753856|9907064|FG000|Overall Study|Withdrawal by Subject|0
6231559|NCT01753856|9907065|FG001|Overall Study|Withdrawal by Subject|2
6231560|NCT01753856|9907064|FG000|Overall Study|Sponsor Decision|2
6231561|NCT01753856|9907065|FG001|Overall Study|Sponsor Decision|0
6231562|NCT01753999|9907074|FG000|Period 1 - Initial Assignment|Physician Decision|2
6231563|NCT01753999|9907075|FG001|Period 1 - Initial Assignment|Physician Decision|3
6231564|NCT01753999|9907074|FG000|Period 1 - Initial Assignment|Withdrawal by Subject|19
6231565|NCT01753999|9907075|FG001|Period 1 - Initial Assignment|Withdrawal by Subject|20
6231566|NCT01753999|9907074|FG000|Period 1 - Initial Assignment|Lost to Follow-up|18
6231567|NCT01753999|9907075|FG001|Period 1 - Initial Assignment|Lost to Follow-up|27
6231568|NCT01753999|9907074|FG000|Period 2 -Cross to Alternate Arm|Lost to Follow-up|13
6231569|NCT01753999|9907075|FG001|Period 2 -Cross to Alternate Arm|Lost to Follow-up|17
6231570|NCT01753999|9907074|FG000|Period 2 -Cross to Alternate Arm|Withdrawal by Subject|3
6231571|NCT01753999|9907075|FG001|Period 2 -Cross to Alternate Arm|Withdrawal by Subject|5
6231572|NCT01753999|9907074|FG000|Period 2 -Cross to Alternate Arm|Physician Decision|1
6231573|NCT01753999|9907075|FG001|Period 2 -Cross to Alternate Arm|Physician Decision|1
6375539|NCT03052608|10165675|FG000|Treatment Phase|Subject decided to continue study treatment as per clinical practice in another hospital.|0
6375540|NCT03052608|10165676|FG001|Treatment Phase|Subject decided to continue study treatment as per clinical practice in another hospital.|1
6375541|NCT03052608|10165675|FG000|Treatment Phase|Subject didn't receive study treatment.|0
6375542|NCT03052608|10165676|FG001|Treatment Phase|Subject didn't receive study treatment.|1
6375543|NCT03052608|10165675|FG000|Treatment Phase|Ongoing|103
6375544|NCT03052608|10165676|FG001|Treatment Phase|Ongoing|31
6375545|NCT03052608|10165675|FG000|Long-Term Follow-up Phase|Death|23
6375546|NCT03052608|10165676|FG001|Long-Term Follow-up Phase|Death|28
6375547|NCT03052608|10165675|FG000|Long-Term Follow-up Phase|Lost to Follow-up|0
6375548|NCT03052608|10165676|FG001|Long-Term Follow-up Phase|Lost to Follow-up|2
6375549|NCT03052608|10165675|FG000|Long-Term Follow-up Phase|Withdrawal by Subject|4
6375550|NCT03052608|10165676|FG001|Long-Term Follow-up Phase|Withdrawal by Subject|18
6231574|NCT01754129|9907086|FG000|Overall Study|Death|13
6231575|NCT01754129|9907086|FG000|Overall Study|Duodopa discontinuation|9
6231576|NCT01754129|9907086|FG000|Overall Study|Lost to Follow-up|7
6231577|NCT01754129|9907086|FG000|Overall Study|Withdrew consent|1
6231578|NCT01754129|9907086|FG000|Overall Study|Inclusion/exclusion criteria violation|3
6231579|NCT01754194|9907099|FG000|Overall Study|Lost to Follow-up|39
6231580|NCT01754194|9907100|FG001|Overall Study|Lost to Follow-up|14
6231581|NCT01754194|9907099|FG000|Overall Study|Withdrawal by Subject|4
6231582|NCT01754194|9907100|FG001|Overall Study|Withdrawal by Subject|5
6231583|NCT01754194|9907099|FG000|Overall Study|Other|9
6231584|NCT01754194|9907100|FG001|Overall Study|Other|8
6231585|NCT01754259|9907114|FG000|Overall Study|Withdrawal by Subject|2
6231586|NCT01754259|9907115|FG001|Overall Study|Withdrawal by Subject|4
6231587|NCT01754259|9907114|FG000|Overall Study|Adverse Event|3
6231588|NCT01754259|9907115|FG001|Overall Study|Adverse Event|1
6231589|NCT01754259|9907114|FG000|Overall Study|Lost to Follow-up|0
6231590|NCT01754259|9907115|FG001|Overall Study|Lost to Follow-up|1
6231591|NCT01754376|9907130|FG000|Overall Study|Adverse Event|1
6231592|NCT01754376|9907130|FG000|Overall Study|Lack of Efficacy|2
6231593|NCT01754402|9907151|FG000|Overall Study|Death|0
6231594|NCT01754402|9907152|FG001|Overall Study|Death|0
6231595|NCT01754402|9907153|FG002|Overall Study|Death|1
6231596|NCT01754402|9907151|FG000|Overall Study|Adverse Event|2
6231597|NCT01754402|9907152|FG001|Overall Study|Adverse Event|2
6231598|NCT01754402|9907153|FG002|Overall Study|Adverse Event|1
6231599|NCT01754402|9907151|FG000|Overall Study|Withdrawal by Subject|0
6231600|NCT01754402|9907152|FG001|Overall Study|Withdrawal by Subject|0
6231601|NCT01754402|9907153|FG002|Overall Study|Withdrawal by Subject|1
6231602|NCT01754402|9907151|FG000|Overall Study|Lack of Efficacy|0
6231603|NCT01754402|9907152|FG001|Overall Study|Lack of Efficacy|0
6231604|NCT01754402|9907153|FG002|Overall Study|Lack of Efficacy|1
6231605|NCT01754467|9907162|FG000|Overall Study|Lost to Follow-up|1
6231606|NCT01754493|9907176|FG000|Overall Study|Adverse Event|1
6231607|NCT01754493|9907176|FG000|Overall Study|Lost to Follow-up|3
6231608|NCT01754493|9907176|FG000|Overall Study|Withdrawal by Subject|1
6231609|NCT01754493|9907176|FG000|Overall Study|Moved out of town|1
6231610|NCT01754493|9907176|FG000|Overall Study|Scheduling conflict|1
6231611|NCT01754727|9907213|FG000|Overall Study|Adalimumab Treatment was not Documented|2
6231612|NCT01754753|9907219|FG000|Overall Study|Study close|43
6231613|NCT01754753|9907220|FG001|Overall Study|Study close|44
6231614|NCT01754753|9907219|FG000|Overall Study|Lost to Follow-up|9
6231615|NCT01754753|9907220|FG001|Overall Study|Lost to Follow-up|5
6231616|NCT01754766|9907229|FG000|Overall Study|Personal reasons|1
6231617|NCT01754766|9907230|FG001|Overall Study|Personal reasons|1
6231618|NCT01754766|9907231|FG002|Overall Study|Personal reasons|0
6231619|NCT01754922|9907250|FG000|Overall Study|Adverse Event|0
6231620|NCT01754922|9907251|FG001|Overall Study|Adverse Event|1
6231621|NCT01755026|9907260|FG000|Overall Study|Adverse Event|1
6231622|NCT01755026|9907261|FG001|Overall Study|Adverse Event|0
6231623|NCT01755026|9907260|FG000|Overall Study|Withdrawal by Subject|1
6231624|NCT01755026|9907261|FG001|Overall Study|Withdrawal by Subject|1
6231625|NCT01755091|9907270|FG000|Overall Study|Withdrawal by Subject|6
6375551|NCT03052608|10165675|FG000|Long-Term Follow-up Phase|Ongoing|122
6375552|NCT03052608|10165676|FG001|Long-Term Follow-up Phase|Ongoing|99
6231626|NCT01755091|9907271|FG001|Overall Study|Withdrawal by Subject|1
6231627|NCT01755091|9907272|FG002|Overall Study|Withdrawal by Subject|3
6231628|NCT01755091|9907270|FG000|Overall Study|Adverse Event|1
6231629|NCT01755091|9907271|FG001|Overall Study|Adverse Event|1
6231630|NCT01755091|9907272|FG002|Overall Study|Adverse Event|1
6231631|NCT01755091|9907270|FG000|Overall Study|Lost to Follow-up|1
6231632|NCT01755091|9907271|FG001|Overall Study|Lost to Follow-up|0
6231633|NCT01755091|9907272|FG002|Overall Study|Lost to Follow-up|1
6231634|NCT01755091|9907270|FG000|Overall Study|Physician Decision|1
6231635|NCT01755091|9907271|FG001|Overall Study|Physician Decision|1
6231636|NCT01755091|9907272|FG002|Overall Study|Physician Decision|2
6231637|NCT01755156|9907291|FG000|Phase A (Weeks 0-24)|Adverse Event|2
6231638|NCT01755156|9907292|FG001|Phase A (Weeks 0-24)|Adverse Event|3
6231639|NCT01755156|9907291|FG000|Phase A (Weeks 0-24)|Lack of Efficacy|1
6231640|NCT01755156|9907292|FG001|Phase A (Weeks 0-24)|Lack of Efficacy|0
6231641|NCT01755156|9907291|FG000|Phase A (Weeks 0-24)|Lost to Follow-up|5
6231642|NCT01755156|9907292|FG001|Phase A (Weeks 0-24)|Lost to Follow-up|3
6231643|NCT01755156|9907291|FG000|Phase A (Weeks 0-24)|Non-compliance with study drug|1
6231644|NCT01755156|9907292|FG001|Phase A (Weeks 0-24)|Non-compliance with study drug|0
6231645|NCT01755156|9907291|FG000|Phase A (Weeks 0-24)|Physician Decision|0
6231646|NCT01755156|9907292|FG001|Phase A (Weeks 0-24)|Physician Decision|1
6231647|NCT01755156|9907291|FG000|Phase A (Weeks 0-24)|Protocol Violation|1
6231648|NCT01755156|9907292|FG001|Phase A (Weeks 0-24)|Protocol Violation|1
6231649|NCT01755156|9907291|FG000|Phase A (Weeks 0-24)|Withdrawal by Subject|6
6231650|NCT01755156|9907292|FG001|Phase A (Weeks 0-24)|Withdrawal by Subject|13
6231651|NCT01755156|9907291|FG000|Phase A (Weeks 0-24)|Creatinine or eGFR Discon. Criteria|0
6187141|NCT01379534|9840942|FG001|Treatment Phase|Withdrawal by Subject|2
6187142|NCT01379534|9840941|FG000|Treatment Phase|Progressive disease|13
6187143|NCT01379534|9840942|FG001|Treatment Phase|Progressive disease|22
6187144|NCT01379534|9840941|FG000|Treatment Phase|Adverse Event|7
6187145|NCT01379534|9840942|FG001|Treatment Phase|Adverse Event|7
6187146|NCT01379534|9840941|FG000|Tumor Assessment Follow-up (f/u) Phase|Death|0
6187147|NCT01379534|9840942|FG001|Tumor Assessment Follow-up (f/u) Phase|Death|1
6187148|NCT01379534|9840941|FG000|Tumor Assessment Follow-up (f/u) Phase|Progressive disease|3
6187149|NCT01379534|9840942|FG001|Tumor Assessment Follow-up (f/u) Phase|Progressive disease|0
6187150|NCT01379534|9840941|FG000|Tumor Assessment Follow-up (f/u) Phase|Lost to Follow-up|0
6187151|NCT01379534|9840942|FG001|Tumor Assessment Follow-up (f/u) Phase|Lost to Follow-up|1
6187152|NCT01379534|9840941|FG000|Tumor Assessment Follow-up (f/u) Phase|Adverse Event|1
6187153|NCT01379534|9840942|FG001|Tumor Assessment Follow-up (f/u) Phase|Adverse Event|0
6187154|NCT01379573|9840948|FG000|Overall Study|Lost to Follow-up|1
6187155|NCT01379573|9840948|FG000|Overall Study|Screen Failure|10
6187156|NCT01379703|9840979|FG000|Study Start Through 9 Months|Lost to Follow-up|2
6187157|NCT01379703|9840980|FG001|Study Start Through 9 Months|Lost to Follow-up|61
6187158|NCT01379703|9840981|FG002|Study Start Through 9 Months|Lost to Follow-up|104
6187159|NCT01379703|9840979|FG000|Study Start Through 9 Months|Adverse Event|0
6187160|NCT01379703|9840980|FG001|Study Start Through 9 Months|Adverse Event|14
6187161|NCT01379703|9840981|FG002|Study Start Through 9 Months|Adverse Event|10
6187162|NCT01379703|9840979|FG000|Study Start Through 9 Months|Withdrawal by Subject|0
6187163|NCT01379703|9840980|FG001|Study Start Through 9 Months|Withdrawal by Subject|6
6187164|NCT01379703|9840981|FG002|Study Start Through 9 Months|Withdrawal by Subject|1
6187165|NCT01379703|9840979|FG000|Study Start Through 9 Months|Treatment Failure|0
6187166|NCT01379703|9840980|FG001|Study Start Through 9 Months|Treatment Failure|2
6187167|NCT01379703|9840981|FG002|Study Start Through 9 Months|Treatment Failure|2
6187168|NCT01379703|9840979|FG000|Study Start Through 9 Months|Patient Noncompliance|0
6187169|NCT01379703|9840980|FG001|Study Start Through 9 Months|Patient Noncompliance|0
6187170|NCT01379703|9840981|FG002|Study Start Through 9 Months|Patient Noncompliance|1
6187171|NCT01379703|9840979|FG000|Study Start Through 9 Months|Tuberculosis/TB treatment|0
6187172|NCT01379703|9840980|FG001|Study Start Through 9 Months|Tuberculosis/TB treatment|4
6187173|NCT01379703|9840981|FG002|Study Start Through 9 Months|Tuberculosis/TB treatment|0
6187174|NCT01379703|9840979|FG000|Study Start Through 9 Months|Medication not available|0
6187175|NCT01379703|9840980|FG001|Study Start Through 9 Months|Medication not available|2
6187176|NCT01379703|9840981|FG002|Study Start Through 9 Months|Medication not available|1
6187177|NCT01379703|9840979|FG000|Study Start Through 9 Months|Poor general condition|0
6187178|NCT01379703|9840980|FG001|Study Start Through 9 Months|Poor general condition|1
6187179|NCT01379703|9840981|FG002|Study Start Through 9 Months|Poor general condition|0
6187180|NCT01379703|9840979|FG000|Study Start Through 9 Months|Increased triglycerides|0
6187181|NCT01379703|9840980|FG001|Study Start Through 9 Months|Increased triglycerides|1
6187182|NCT01379703|9840981|FG002|Study Start Through 9 Months|Increased triglycerides|0
6187183|NCT01379703|9840979|FG000|Study Start Through 9 Months|Reason unknown|2
6187184|NCT01379703|9840980|FG001|Study Start Through 9 Months|Reason unknown|31
6187185|NCT01379703|9840981|FG002|Study Start Through 9 Months|Reason unknown|24
6187186|NCT01379703|9840979|FG000|9 Months Through 18 Months|Lost to Follow-up|0
6187187|NCT01379703|9840980|FG001|9 Months Through 18 Months|Lost to Follow-up|178
6193095|NCT01436110|9850728|FG002|Overall Study|Protocol Violation|1
6231652|NCT01755156|9907292|FG001|Phase A (Weeks 0-24)|Creatinine or eGFR Discon. Criteria|2
6231653|NCT01755156|9907291|FG000|Phase A (Weeks 0-24)|Need for Excluded Med. Discon. Criteria|1
6231654|NCT01755156|9907292|FG001|Phase A (Weeks 0-24)|Need for Excluded Med. Discon. Criteria|1
6231655|NCT01755156|9907291|FG000|Phase B (Weeks 24-104)|Lost to Follow-up|12
6231656|NCT01755156|9907292|FG001|Phase B (Weeks 24-104)|Lost to Follow-up|5
6231657|NCT01755156|9907291|FG000|Phase B (Weeks 24-104)|Withdrawal by Subject|27
6231658|NCT01755156|9907292|FG001|Phase B (Weeks 24-104)|Withdrawal by Subject|31
6231659|NCT01755195|9907319|FG000|Overall Study|Participant noncompliance|2
6231660|NCT01755195|9907319|FG000|Overall Study|Switched to alternative treatment|4
6231661|NCT01755195|9907319|FG000|Overall Study|Withdrawal by Subject|1
6231662|NCT01755195|9907319|FG000|Overall Study|Participant refused to start treatment|1
6231663|NCT01755195|9907319|FG000|Overall Study|Participant has been consented for another trial|1
6231664|NCT01755195|9907319|FG000|Overall Study|Refused further treatment|3
6231665|NCT01755195|9907319|FG000|Overall Study|Complicating disease/intercurrent illness|1
6231666|NCT01755234|9907325|FG000|Overall Study|Lost to Follow-up|11
6231667|NCT01755234|9907326|FG001|Overall Study|Lost to Follow-up|6
6231668|NCT01755234|9907325|FG000|Overall Study|Change in surgical case|2
6231669|NCT01755234|9907326|FG001|Overall Study|Change in surgical case|1
6231670|NCT01755234|9907325|FG000|Overall Study|case cancelled|1
6231671|NCT01755234|9907326|FG001|Overall Study|case cancelled|0
6231672|NCT01755234|9907325|FG000|Overall Study|Withdrawal by Subject|0
6231673|NCT01755234|9907326|FG001|Overall Study|Withdrawal by Subject|1
6231674|NCT01755234|9907325|FG000|Overall Study|unblinded|1
6231675|NCT01755234|9907326|FG001|Overall Study|unblinded|0
6231676|NCT01755416|9907332|FG000|First Intervention ( Upto 2 Days)|Withdrawal by Subject|1
6231677|NCT01755416|9907333|FG001|First Intervention ( Upto 2 Days)|Withdrawal by Subject|2
6231678|NCT01755546|9907346|FG000|Screened and Taper (Rollover and DeNovo)|Protocol Violation|1
6231679|NCT01755546|9907346|FG000|Screened and Taper (Rollover and DeNovo)|Withdrawal by Subject|3
6231680|NCT01755546|9907346|FG000|Screened and Taper (Rollover and DeNovo)|Lost to Follow-up|1
6231681|NCT01755546|9907346|FG000|Screened and Taper (Rollover and DeNovo)|Any other reason and screen failures|5
6231682|NCT01755546|9907346|FG000|Titration Phase|Adverse Event|11
6231683|NCT01755546|9907346|FG000|Titration Phase|Lack of Efficacy|18
6231684|NCT01755546|9907346|FG000|Titration Phase|Protocol Violation|9
6231685|NCT01755546|9907346|FG000|Titration Phase|Lost to Follow-up|2
6231686|NCT01755546|9907346|FG000|Titration Phase|Other and Continuing|22
6231687|NCT01755546|9907346|FG000|Titration Phase|Withdrawal by Subject|8
6231688|NCT01755546|9907346|FG000|Long Term Treatment|Adverse Event|12
6231689|NCT01755546|9907346|FG000|Long Term Treatment|Lack of Efficacy|6
6231690|NCT01755546|9907346|FG000|Long Term Treatment|Protocol Violation|10
6231691|NCT01755546|9907346|FG000|Long Term Treatment|Withdrawal by Subject|35
6231692|NCT01755546|9907346|FG000|Long Term Treatment|Lost to Follow-up|17
6231693|NCT01755546|9907346|FG000|Long Term Treatment|other and ongoing|41
6231694|NCT01755598|9907352|FG000|Overall Study|Other|109
6231695|NCT01755598|9907353|FG001|Overall Study|Other|109
6231696|NCT01755598|9907352|FG000|Overall Study|Lost to Follow-up|32
6231697|NCT01755598|9907353|FG001|Overall Study|Lost to Follow-up|43
6231698|NCT01755598|9907352|FG000|Overall Study|Migrated/moved from study area|76
6231699|NCT01755598|9907353|FG001|Overall Study|Migrated/moved from study area|65
6231700|NCT01755598|9907352|FG000|Overall Study|Withdrawal by Subject|22
6231701|NCT01755598|9907353|FG001|Overall Study|Withdrawal by Subject|31
6231702|NCT01755598|9907352|FG000|Overall Study|Protocol Violation|7
6231703|NCT01755598|9907353|FG001|Overall Study|Protocol Violation|7
6231704|NCT01755598|9907352|FG000|Overall Study|Adverse Event|19
6231705|NCT01755598|9907353|FG001|Overall Study|Adverse Event|28
6231706|NCT01755637|9907359|FG000|Period 1|Adverse Event|0
6231707|NCT01755637|9907360|FG001|Period 1|Adverse Event|1
6231708|NCT01755702|9907372|FG000|Wash Out Period I|Other Reason|3
6231709|NCT01755702|9907372|FG000|Washout Period II|Other Reason|5
6231710|NCT01755767|9907386|FG000|Overall Study|Progressive Disease|8
6231711|NCT01755767|9907387|FG001|Overall Study|Progressive Disease|7
6231712|NCT01755767|9907388|FG002|Overall Study|Progressive Disease|91
6231713|NCT01755767|9907389|FG003|Overall Study|Progressive Disease|43
6231714|NCT01755767|9907386|FG000|Overall Study|Clinical Disease Progression|4
6231715|NCT01755767|9907387|FG001|Overall Study|Clinical Disease Progression|2
6231716|NCT01755767|9907388|FG002|Overall Study|Clinical Disease Progression|29
6231717|NCT01755767|9907389|FG003|Overall Study|Clinical Disease Progression|20
6231718|NCT01755767|9907386|FG000|Overall Study|Radiographic Disease Progression|9
6231719|NCT01755767|9907387|FG001|Overall Study|Radiographic Disease Progression|4
6231720|NCT01755767|9907388|FG002|Overall Study|Radiographic Disease Progression|44
6231721|NCT01755767|9907389|FG003|Overall Study|Radiographic Disease Progression|27
6231722|NCT01755767|9907386|FG000|Overall Study|Adverse Event|6
6231723|NCT01755767|9907387|FG001|Overall Study|Adverse Event|0
6231724|NCT01755767|9907388|FG002|Overall Study|Adverse Event|28
6231725|NCT01755767|9907389|FG003|Overall Study|Adverse Event|11
6231726|NCT01755767|9907386|FG000|Overall Study|Death|1
6231727|NCT01755767|9907387|FG001|Overall Study|Death|2
6231728|NCT01755767|9907388|FG002|Overall Study|Death|15
6231729|NCT01755767|9907389|FG003|Overall Study|Death|4
6231730|NCT01755767|9907386|FG000|Overall Study|Subject Decision|0
6231731|NCT01755767|9907387|FG001|Overall Study|Subject Decision|0
6231732|NCT01755767|9907388|FG002|Overall Study|Subject Decision|10
6231733|NCT01755767|9907389|FG003|Overall Study|Subject Decision|3
6231734|NCT01755767|9907386|FG000|Overall Study|Withdrawal by Subject|0
6231735|NCT01755767|9907387|FG001|Overall Study|Withdrawal by Subject|0
6231736|NCT01755767|9907388|FG002|Overall Study|Withdrawal by Subject|2
6231737|NCT01755767|9907389|FG003|Overall Study|Withdrawal by Subject|1
6231738|NCT01755767|9907386|FG000|Overall Study|Other|0
6231739|NCT01755767|9907387|FG001|Overall Study|Other|0
6231740|NCT01755767|9907388|FG002|Overall Study|Other|2
6231741|NCT01755767|9907389|FG003|Overall Study|Other|3
6231742|NCT01755767|9907386|FG000|Overall Study|Ongoing Treatment as of 06 Jan 2017|0
6231743|NCT01755767|9907387|FG001|Overall Study|Ongoing Treatment as of 06 Jan 2017|0
6231744|NCT01755767|9907388|FG002|Overall Study|Ongoing Treatment as of 06 Jan 2017|5
6231745|NCT01755767|9907389|FG003|Overall Study|Ongoing Treatment as of 06 Jan 2017|2
6231746|NCT01755858|9907401|FG000|Overall Study|Adverse Event|1
6231747|NCT01755858|9907402|FG001|Overall Study|Adverse Event|1
6231748|NCT01756053|9907435|FG000|Period 1 (10 Days)|Protocol Violation|1
6231749|NCT01756053|9907436|FG001|Period 1 (10 Days)|Protocol Violation|1
6231750|NCT01756053|9907435|FG000|Period 2 (10 Days)|Protocol Violation|0
6231751|NCT01756053|9907436|FG001|Period 2 (10 Days)|Protocol Violation|2
6231752|NCT01756079|9907442|FG000|Treatment / Follow-up: Week 4 to Week 72|Withdrawal by Subject|4
6231753|NCT01756079|9907442|FG000|Treatment / Follow-up: Week 4 to Week 72|Adverse Event|5
6231754|NCT01756079|9907442|FG000|Treatment / Follow-up: Week 4 to Week 72|No information available|2
6231755|NCT01756079|9907442|FG000|Treatment / Follow-up: Week 4 to Week 72|Lack of Efficacy|20
6231756|NCT01756079|9907442|FG000|Treatment / Follow-up: Week 4 to Week 72|No boceprevir during Treatment Period|4
6231757|NCT01756157|9907447|FG000|First Intervention Period|Withdrawal by Subject|1
6231758|NCT01756157|9907448|FG001|First Intervention Period|Withdrawal by Subject|0
6231759|NCT01756157|9907447|FG000|First Intervention Period|Lost to Follow-up|0
6231760|NCT01756157|9907448|FG001|First Intervention Period|Lost to Follow-up|2
6231761|NCT01756235|9907471|FG000|Overall Study|Adalimumab Treatment was not Documented|2
6231762|NCT01756274|9907475|FG000|Overall Study|Protocol Violation|2
6231763|NCT01756274|9907475|FG000|Overall Study|Laboratory error|1
6231764|NCT01756300|9907480|FG000|Overall Study|Death|1
6231765|NCT01756300|9907480|FG000|Overall Study|Withdrawal by Subject|1
6231766|NCT01756352|9907501|FG000|Overall Study|moved away and lost to followup|1
6231767|NCT01756456|9907515|FG000|Treatment Period: Phase I/II|decision unrelated to adverse event|0
6231768|NCT01756456|9907516|FG001|Treatment Period: Phase I/II|decision unrelated to adverse event|0
6231769|NCT01756456|9907517|FG002|Treatment Period: Phase I/II|decision unrelated to adverse event|0
6231770|NCT01756456|9907518|FG003|Treatment Period: Phase I/II|decision unrelated to adverse event|1
6231771|NCT01756456|9907519|FG004|Treatment Period: Phase I/II|decision unrelated to adverse event|1
6231772|NCT01756456|9907520|FG005|Treatment Period: Phase I/II|decision unrelated to adverse event|1
6231773|NCT01756456|9907515|FG000|Treatment Period: Phase I/II|Lack of Efficacy|0
6231774|NCT01756456|9907516|FG001|Treatment Period: Phase I/II|Lack of Efficacy|0
6231775|NCT01756456|9907517|FG002|Treatment Period: Phase I/II|Lack of Efficacy|0
6231776|NCT01756456|9907518|FG003|Treatment Period: Phase I/II|Lack of Efficacy|2
6231777|NCT01756456|9907519|FG004|Treatment Period: Phase I/II|Lack of Efficacy|1
6231778|NCT01756456|9907520|FG005|Treatment Period: Phase I/II|Lack of Efficacy|0
6231779|NCT01756456|9907515|FG000|Treatment Period: Phase I/II|Withdrawal by Subject|0
6231780|NCT01756456|9907516|FG001|Treatment Period: Phase I/II|Withdrawal by Subject|1
6231781|NCT01756456|9907517|FG002|Treatment Period: Phase I/II|Withdrawal by Subject|0
6231782|NCT01756456|9907518|FG003|Treatment Period: Phase I/II|Withdrawal by Subject|0
6231783|NCT01756456|9907519|FG004|Treatment Period: Phase I/II|Withdrawal by Subject|0
6231784|NCT01756456|9907520|FG005|Treatment Period: Phase I/II|Withdrawal by Subject|0
6231785|NCT01756456|9907515|FG000|Treatment Period: Phase I/II|Adverse Event|1
6231786|NCT01756456|9907516|FG001|Treatment Period: Phase I/II|Adverse Event|0
6231787|NCT01756456|9907517|FG002|Treatment Period: Phase I/II|Adverse Event|2
6231788|NCT01756456|9907518|FG003|Treatment Period: Phase I/II|Adverse Event|3
6231789|NCT01756456|9907519|FG004|Treatment Period: Phase I/II|Adverse Event|9
6231790|NCT01756456|9907520|FG005|Treatment Period: Phase I/II|Adverse Event|1
6231791|NCT01756456|9907515|FG000|Treatment Period: Phase I/II|Other causes|0
6231792|NCT01756456|9907516|FG001|Treatment Period: Phase I/II|Other causes|0
6231793|NCT01756456|9907517|FG002|Treatment Period: Phase I/II|Other causes|0
6231794|NCT01756456|9907518|FG003|Treatment Period: Phase I/II|Other causes|1
6231795|NCT01756456|9907519|FG004|Treatment Period: Phase I/II|Other causes|2
6231796|NCT01756456|9907520|FG005|Treatment Period: Phase I/II|Other causes|2
6231797|NCT01756456|9907515|FG000|Follow Up Period Phase I/II|still in study after week 20|0
6231798|NCT01756456|9907516|FG001|Follow Up Period Phase I/II|still in study after week 20|0
6231799|NCT01756456|9907517|FG002|Follow Up Period Phase I/II|still in study after week 20|0
6231800|NCT01756456|9907518|FG003|Follow Up Period Phase I/II|still in study after week 20|25
6231801|NCT01756456|9907519|FG004|Follow Up Period Phase I/II|still in study after week 20|23
6231802|NCT01756456|9907520|FG005|Follow Up Period Phase I/II|still in study after week 20|25
6231803|NCT01756456|9907515|FG000|Follow Up Period Phase I/II|parent withdrew the consent to continue|0
6231804|NCT01756456|9907516|FG001|Follow Up Period Phase I/II|parent withdrew the consent to continue|1
6231805|NCT01756456|9907517|FG002|Follow Up Period Phase I/II|parent withdrew the consent to continue|0
6231806|NCT01756456|9907518|FG003|Follow Up Period Phase I/II|parent withdrew the consent to continue|0
6231807|NCT01756456|9907519|FG004|Follow Up Period Phase I/II|parent withdrew the consent to continue|0
6231808|NCT01756456|9907520|FG005|Follow Up Period Phase I/II|parent withdrew the consent to continue|0
6231809|NCT01756456|9907515|FG000|Follow Up Period Phase I/II|Lack of Efficacy|0
6231810|NCT01756456|9907516|FG001|Follow Up Period Phase I/II|Lack of Efficacy|0
6085537|NCT00653328|9694870|FG000|Overall Study|Adverse Event|2
6085538|NCT00653328|9694870|FG000|Overall Study|Disease progression|10
6231811|NCT01756456|9907517|FG002|Follow Up Period Phase I/II|Lack of Efficacy|0
6231812|NCT01756456|9907518|FG003|Follow Up Period Phase I/II|Lack of Efficacy|0
6231813|NCT01756456|9907519|FG004|Follow Up Period Phase I/II|Lack of Efficacy|0
6231814|NCT01756456|9907520|FG005|Follow Up Period Phase I/II|Lack of Efficacy|1
6231815|NCT01756456|9907515|FG000|Follow Up Period Phase I/II|Adverse Event|1
6231816|NCT01756456|9907516|FG001|Follow Up Period Phase I/II|Adverse Event|0
6231817|NCT01756456|9907517|FG002|Follow Up Period Phase I/II|Adverse Event|0
6231818|NCT01756456|9907518|FG003|Follow Up Period Phase I/II|Adverse Event|5
6231819|NCT01756456|9907519|FG004|Follow Up Period Phase I/II|Adverse Event|0
6231820|NCT01756456|9907520|FG005|Follow Up Period Phase I/II|Adverse Event|1
6231821|NCT01756456|9907515|FG000|Follow Up Period Phase I/II|Lost to Follow-up|0
6231822|NCT01756456|9907516|FG001|Follow Up Period Phase I/II|Lost to Follow-up|0
6231823|NCT01756456|9907517|FG002|Follow Up Period Phase I/II|Lost to Follow-up|1
6231824|NCT01756456|9907518|FG003|Follow Up Period Phase I/II|Lost to Follow-up|2
6231825|NCT01756456|9907519|FG004|Follow Up Period Phase I/II|Lost to Follow-up|0
6231826|NCT01756456|9907520|FG005|Follow Up Period Phase I/II|Lost to Follow-up|1
6231827|NCT01756456|9907515|FG000|Follow Up Period Phase I/II|Other causes|0
6231828|NCT01756456|9907516|FG001|Follow Up Period Phase I/II|Other causes|0
6231829|NCT01756456|9907517|FG002|Follow Up Period Phase I/II|Other causes|0
6231830|NCT01756456|9907518|FG003|Follow Up Period Phase I/II|Other causes|1
6231831|NCT01756456|9907519|FG004|Follow Up Period Phase I/II|Other causes|3
6231832|NCT01756456|9907520|FG005|Follow Up Period Phase I/II|Other causes|5
6231833|NCT01756833|9907545|FG000|Overall Study|Withdrawal by Subject|4
6231834|NCT01756833|9907546|FG001|Overall Study|Withdrawal by Subject|3
6231835|NCT01756846|9907554|FG000|Overall Study|Lost to Follow-up|5
6231836|NCT01756846|9907555|FG001|Overall Study|Lost to Follow-up|10
6231837|NCT01756846|9907554|FG000|Overall Study|Withdrawal by Subject|1
6231838|NCT01756846|9907555|FG001|Overall Study|Withdrawal by Subject|2
6231839|NCT01756898|9907574|FG000|Overall Study|Adverse Event|7
6231840|NCT01756898|9907575|FG001|Overall Study|Adverse Event|1
6231841|NCT01756898|9907576|FG002|Overall Study|Adverse Event|0
6231842|NCT01756898|9907577|FG003|Overall Study|Adverse Event|0
6231843|NCT01756898|9907574|FG000|Overall Study|Lack of Efficacy|4
6231844|NCT01756898|9907575|FG001|Overall Study|Lack of Efficacy|7
6231845|NCT01756898|9907576|FG002|Overall Study|Lack of Efficacy|6
6231846|NCT01756898|9907577|FG003|Overall Study|Lack of Efficacy|6
6231847|NCT01756898|9907574|FG000|Overall Study|Lost to Follow-up|2
6231848|NCT01756898|9907575|FG001|Overall Study|Lost to Follow-up|4
6231849|NCT01756898|9907576|FG002|Overall Study|Lost to Follow-up|2
6231850|NCT01756898|9907577|FG003|Overall Study|Lost to Follow-up|3
6231851|NCT01756898|9907574|FG000|Overall Study|Protocol Violation|1
6231852|NCT01756898|9907575|FG001|Overall Study|Protocol Violation|2
6231853|NCT01756898|9907576|FG002|Overall Study|Protocol Violation|2
6231854|NCT01756898|9907577|FG003|Overall Study|Protocol Violation|1
6231855|NCT01756898|9907574|FG000|Overall Study|Withdrew Consent|5
6231856|NCT01756898|9907575|FG001|Overall Study|Withdrew Consent|3
6231857|NCT01756898|9907576|FG002|Overall Study|Withdrew Consent|5
6231858|NCT01756898|9907577|FG003|Overall Study|Withdrew Consent|6
6231859|NCT01756898|9907574|FG000|Overall Study|Other|0
6231860|NCT01756898|9907575|FG001|Overall Study|Other|2
6231861|NCT01756898|9907576|FG002|Overall Study|Other|2
6231862|NCT01756898|9907577|FG003|Overall Study|Other|0
6231863|NCT01757171|9907610|FG000|Overall Study|Adverse Event|5
6231864|NCT01757171|9907611|FG001|Overall Study|Adverse Event|1
6231865|NCT01757171|9907610|FG000|Overall Study|Disease Progression|1
6231866|NCT01757171|9907611|FG001|Overall Study|Disease Progression|0
6231867|NCT01757171|9907610|FG000|Overall Study|Hospitalization|1
6231868|NCT01757171|9907611|FG001|Overall Study|Hospitalization|0
6231869|NCT01757171|9907610|FG000|Overall Study|ECOG decline|1
6231870|NCT01757171|9907611|FG001|Overall Study|ECOG decline|0
6231871|NCT01757184|9907619|FG000|Double-blind Period|Adverse Event|1
6231872|NCT01757184|9907620|FG001|Double-blind Period|Adverse Event|0
6231873|NCT01757184|9907621|FG002|Double-blind Period|Adverse Event|0
6231874|NCT01757184|9907622|FG003|Double-blind Period|Adverse Event|0
6231875|NCT01757184|9907619|FG000|Open-label Period|Lost to Follow-up|0
6231876|NCT01757184|9907620|FG001|Open-label Period|Lost to Follow-up|0
6231877|NCT01757184|9907621|FG002|Open-label Period|Lost to Follow-up|2
6231878|NCT01757184|9907622|FG003|Open-label Period|Lost to Follow-up|0
6085539|NCT00653328|9694870|FG000|Overall Study|Drug manufacturer no longing making drug|2
6085540|NCT00653432|9694876|FG000|Overall Study|Adverse Event|4
6231879|NCT01757184|9907619|FG000|Open-label Period|Withdrawal by Subject|0
6231880|NCT01757184|9907620|FG001|Open-label Period|Withdrawal by Subject|0
6231881|NCT01757184|9907621|FG002|Open-label Period|Withdrawal by Subject|1
6231882|NCT01757184|9907622|FG003|Open-label Period|Withdrawal by Subject|1
6231883|NCT01757184|9907619|FG000|Open-label Period|Discontinued by Sponsor|0
6231884|NCT01757184|9907620|FG001|Open-label Period|Discontinued by Sponsor|0
6231885|NCT01757184|9907621|FG002|Open-label Period|Discontinued by Sponsor|1
6231886|NCT01757184|9907622|FG003|Open-label Period|Discontinued by Sponsor|2
6231887|NCT01757197|9907636|FG000|Overall Study|Death|2
6231888|NCT01757275|9907642|FG000|Overall Study|Lost to Follow-up|1
6231889|NCT01757275|9907643|FG001|Overall Study|Lost to Follow-up|2
6231890|NCT01757275|9907642|FG000|Overall Study|Adverse Event|3
6231891|NCT01757275|9907643|FG001|Overall Study|Adverse Event|3
6231892|NCT01757275|9907642|FG000|Overall Study|Withdrawal by Subject|2
6231893|NCT01757275|9907643|FG001|Overall Study|Withdrawal by Subject|4
6231894|NCT01757275|9907642|FG000|Overall Study|Not treated|3
6231895|NCT01757275|9907643|FG001|Overall Study|Not treated|4
6231896|NCT01757288|9907652|FG000|Overall Study|Consent withdrawal|0
6231897|NCT01757288|9907653|FG001|Overall Study|Consent withdrawal|4
6231898|NCT01757288|9907654|FG002|Overall Study|Consent withdrawal|4
6231899|NCT01757288|9907652|FG000|Overall Study|Patient off study, IRB hold.|0
6231900|NCT01757288|9907653|FG001|Overall Study|Patient off study, IRB hold.|0
6231901|NCT01757288|9907654|FG002|Overall Study|Patient off study, IRB hold.|1
6231902|NCT01757288|9907652|FG000|Overall Study|Patient death prior to starting treatment|0
6231903|NCT01757288|9907653|FG001|Overall Study|Patient death prior to starting treatment|0
6231904|NCT01757288|9907654|FG002|Overall Study|Patient death prior to starting treatment|1
6231905|NCT01757288|9907652|FG000|Overall Study|Wrong medication administered|0
6231906|NCT01757288|9907653|FG001|Overall Study|Wrong medication administered|1
6231907|NCT01757288|9907654|FG002|Overall Study|Wrong medication administered|0
6231908|NCT01757288|9907652|FG000|Overall Study|Liver metastasis identified at CT simulation|0
6231909|NCT01757288|9907653|FG001|Overall Study|Liver metastasis identified at CT simulation|1
6231910|NCT01757288|9907654|FG002|Overall Study|Liver metastasis identified at CT simulation|0
6231911|NCT01757288|9907652|FG000|Overall Study|Not meeting protocol constraints|0
6231912|NCT01757288|9907653|FG001|Overall Study|Not meeting protocol constraints|1
6231913|NCT01757288|9907654|FG002|Overall Study|Not meeting protocol constraints|1
6231914|NCT01757288|9907652|FG000|Overall Study|Multiple missed appointments|0
6231915|NCT01757288|9907653|FG001|Overall Study|Multiple missed appointments|1
6231916|NCT01757288|9907654|FG002|Overall Study|Multiple missed appointments|0
6231917|NCT01757288|9907652|FG000|Overall Study|Mulitple hospitalization ( after first week of CRT)|0
6231918|NCT01757288|9907653|FG001|Overall Study|Mulitple hospitalization ( after first week of CRT)|0
6231919|NCT01757288|9907654|FG002|Overall Study|Mulitple hospitalization ( after first week of CRT)|1
6231920|NCT01757288|9907652|FG000|Overall Study|>2 weeks treatment break|0
6231921|NCT01757288|9907653|FG001|Overall Study|>2 weeks treatment break|0
6231922|NCT01757288|9907654|FG002|Overall Study|>2 weeks treatment break|1
6231923|NCT01757392|9907674|FG000|Overall Study|Withdrawal by Subject|1
6231924|NCT01757392|9907674|FG000|Overall Study|Screen Fail|3
6231925|NCT01757405|9907680|FG000|Overall Study|Lost to Follow-up|1
6231926|NCT01757405|9907681|FG001|Overall Study|Lost to Follow-up|1
6231927|NCT01757405|9907680|FG000|Overall Study|Withdrawal by Subject|0
6231928|NCT01757405|9907681|FG001|Overall Study|Withdrawal by Subject|1
6269786|NCT02143713|9970158|FG002|Post-treatment Follow-up (12 Months)|Exclusionary Medication|0
6269787|NCT02143713|9970159|FG003|Post-treatment Follow-up (12 Months)|Exclusionary Medication|1
6269788|NCT02143713|9970156|FG000|Post-treatment Follow-up (12 Months)|Other|3
6269789|NCT02143713|9970157|FG001|Post-treatment Follow-up (12 Months)|Other|4
6269790|NCT02143713|9970158|FG002|Post-treatment Follow-up (12 Months)|Other|7
6269791|NCT02143713|9970159|FG003|Post-treatment Follow-up (12 Months)|Other|7
6269792|NCT02143778|9970170|FG000|Overall Study|Withdrawal by Subject|2
6269793|NCT02143778|9970170|FG000|Overall Study|Device malfunction|1
6269794|NCT02143843|9970175|FG000|Overall Study|Adverse Event|8
6269795|NCT02143843|9970175|FG000|Overall Study|Lack of Efficacy|2
6269796|NCT02143843|9970175|FG000|Overall Study|Withdrawal by Subject|2
6269797|NCT02143947|9970181|FG000|Overall Study|Lost to Follow-up|4
6269798|NCT02143947|9970182|FG001|Overall Study|Lost to Follow-up|2
6269799|NCT02144012|9970196|FG000|Overall Study|Adverse Event|1
6269800|NCT02144012|9970197|FG001|Overall Study|Adverse Event|0
6269801|NCT02144012|9970196|FG000|Overall Study|Death|1
6269802|NCT02144012|9970197|FG001|Overall Study|Death|0
6269803|NCT02144012|9970196|FG000|Overall Study|Withdrawal by Subject|11
6269804|NCT02144012|9970197|FG001|Overall Study|Withdrawal by Subject|3
6269805|NCT02144012|9970196|FG000|Overall Study|Study Terminated by Sponsor|18
6269806|NCT02144012|9970197|FG001|Overall Study|Study Terminated by Sponsor|12
6269807|NCT02144012|9970196|FG000|Overall Study|Other|3
6269808|NCT02144012|9970197|FG001|Overall Study|Other|0
6269809|NCT02144077|9970205|FG000|Overall Study|Withdrawal by Subject|3
6269810|NCT02144077|9970206|FG001|Overall Study|Withdrawal by Subject|3
6269811|NCT02144077|9970205|FG000|Overall Study|Adverse Event|2
6269812|NCT02144077|9970206|FG001|Overall Study|Adverse Event|3
6269813|NCT02144077|9970205|FG000|Overall Study|Lost to Follow-up|2
6269814|NCT02144077|9970206|FG001|Overall Study|Lost to Follow-up|2
6269815|NCT02144077|9970205|FG000|Overall Study|Protocol Violation|1
6269816|NCT02144077|9970206|FG001|Overall Study|Protocol Violation|2
6269817|NCT02144077|9970205|FG000|Overall Study|Death|0
6269818|NCT02144077|9970206|FG001|Overall Study|Death|1
6269819|NCT02144077|9970205|FG000|Overall Study|no visits 7 & 8/no visits after visit 4|2
6269820|NCT02144077|9970206|FG001|Overall Study|no visits 7 & 8/no visits after visit 4|0
6269821|NCT02144220|9970212|FG000|Overall Study|technology incompatibility|9
6269822|NCT02144220|9970212|FG000|Overall Study|Lack of Efficacy|4
6269823|NCT02144220|9970212|FG000|Overall Study|Physician Decision|3
6231929|NCT01757691|9907712|FG000|Overall Study|Administrative problems|2
6231930|NCT01757691|9907713|FG001|Overall Study|Administrative problems|0
6231931|NCT01757704|9907721|FG000|Overall Study|Protocol Violation|1
6231932|NCT01757704|9907722|FG001|Overall Study|Protocol Violation|3
6231933|NCT01757821|9907732|FG000|Overall Study|Adverse Event|1
6231934|NCT01757847|9907742|FG000|Overall Study|Withdrawal by Subject|3
6231935|NCT01757847|9907743|FG001|Overall Study|Withdrawal by Subject|4
6231936|NCT01758289|9907756|FG000|Overall Study|Premature Study Termination|44
6231937|NCT01758289|9907756|FG000|Overall Study|Adverse Event|9
6231938|NCT01758523|9907795|FG000|Overall Study|Adverse Event|2
6231939|NCT01758523|9907796|FG001|Overall Study|Adverse Event|1
6231940|NCT01758523|9907795|FG000|Overall Study|Lack of Efficacy|4
6231941|NCT01758523|9907796|FG001|Overall Study|Lack of Efficacy|2
6231942|NCT01758523|9907795|FG000|Overall Study|Lost to Follow-up|3
6231943|NCT01758523|9907796|FG001|Overall Study|Lost to Follow-up|4
6231944|NCT01758523|9907795|FG000|Overall Study|Withdrawal by Subject|12
6231945|NCT01758523|9907796|FG001|Overall Study|Withdrawal by Subject|7
6231946|NCT01758731|9907817|FG000|Overall Study|Physician Decision|1
6231947|NCT01758900|9907823|FG000|Overall Study|difficulty for further intubation|7
6231948|NCT01758900|9907824|FG001|Overall Study|difficulty for further intubation|8
6231949|NCT01759264|9907843|FG000|Overall Study|Serious Adverse Events (SAEs)|1
6231950|NCT01759264|9907843|FG000|Overall Study|Adverse Event|1
6231951|NCT01759264|9907843|FG000|Overall Study|Other|2
6231952|NCT01759264|9907843|FG000|Overall Study|Lost to Follow-up|2
6231953|NCT01759264|9907843|FG000|Overall Study|Withdrawal by Subject|3
6231954|NCT01759264|9907843|FG000|Overall Study|Discontinued Humira Due to Business Trip|1
6231955|NCT01759290|9907859|FG000|Overall Study|Subjects withdrawn consent|5
6231956|NCT01759290|9907859|FG000|Overall Study|Physician Decision|2
6231957|NCT01759290|9907859|FG000|Overall Study|Death|17
6231958|NCT01759290|9907859|FG000|Overall Study|Lost to Follow-up|53
6231959|NCT01759290|9907859|FG000|Overall Study|Unknown reason|4
6231960|NCT01759368|9907865|FG000|Overall Study|Lost to Follow-up|1
6231961|NCT01759368|9907866|FG001|Overall Study|Lost to Follow-up|0
6231962|NCT01759381|9907876|FG000|Overall Study|Death|1
6231963|NCT01759381|9907877|FG001|Overall Study|Death|0
6231964|NCT01759407|9907885|FG000|Overall Study|Protocol Violation|0
6231965|NCT01759407|9907886|FG001|Overall Study|Protocol Violation|2
6231966|NCT01759420|9907892|FG000|Overall Study|Screen failure|5
6231967|NCT01759420|9907892|FG000|Overall Study|Inaccurate EKG machine readings|1
6231968|NCT01759446|9907901|FG000|Overall Study|Protocol Violation|1
6231969|NCT01759446|9907902|FG001|Overall Study|Protocol Violation|0
6231970|NCT01759446|9907903|FG002|Overall Study|Protocol Violation|1
6231971|NCT01759446|9907904|FG003|Overall Study|Protocol Violation|0
6231972|NCT01759446|9907905|FG004|Overall Study|Protocol Violation|0
6231973|NCT01759446|9907901|FG000|Overall Study|Withdrawal by Subject|0
6231974|NCT01759446|9907902|FG001|Overall Study|Withdrawal by Subject|1
6231975|NCT01759446|9907903|FG002|Overall Study|Withdrawal by Subject|0
6231976|NCT01759446|9907904|FG003|Overall Study|Withdrawal by Subject|1
6231977|NCT01759446|9907905|FG004|Overall Study|Withdrawal by Subject|0
6231978|NCT01759511|9907917|FG000|Overall Study|Adverse Event|4
6231979|NCT01759511|9907917|FG000|Overall Study|Death|2
6231980|NCT01759511|9907917|FG000|Overall Study|Lack of Efficacy|2
6231981|NCT01759511|9907917|FG000|Overall Study|Physician Decision|1
6231982|NCT01759511|9907917|FG000|Overall Study|Progressive Disease|5
6231983|NCT01759511|9907917|FG000|Overall Study|Protocol-Specified Criteria for Withdraw|4
6231984|NCT01759511|9907917|FG000|Overall Study|Study Terminated by Sponsor|13
6231985|NCT01759511|9907917|FG000|Overall Study|Withdrawal by Subject|3
6231986|NCT01759862|9907927|FG000|Overall Study|Physician Decision|3
6085541|NCT00653432|9694877|FG001|Overall Study|Adverse Event|1
6085542|NCT00653432|9694876|FG000|Overall Study|Withdrawal by Subject|4
6085543|NCT00653432|9694877|FG001|Overall Study|Withdrawal by Subject|5
6085544|NCT00653432|9694876|FG000|Overall Study|Lost to Follow-up|7
6085545|NCT00653432|9694877|FG001|Overall Study|Lost to Follow-up|6
6085546|NCT00653432|9694876|FG000|Overall Study|Use/Need of Con Therapy|2
6085547|NCT00653432|9694877|FG001|Overall Study|Use/Need of Con Therapy|1
6085548|NCT00653432|9694876|FG000|Overall Study|Other - Reason Not Provided|5
6085549|NCT00653432|9694877|FG001|Overall Study|Other - Reason Not Provided|3
6085550|NCT00653939|9694894|FG000|Overall Study|Adverse Event|1
6085551|NCT00653939|9694895|FG001|Overall Study|Adverse Event|3
6085552|NCT00653939|9694894|FG000|Overall Study|Withdrawal by Subject|3
6085553|NCT00653939|9694895|FG001|Overall Study|Withdrawal by Subject|3
6085554|NCT00653939|9694894|FG000|Overall Study|Physician Decision|4
6085555|NCT00653939|9694895|FG001|Overall Study|Physician Decision|0
6231987|NCT01759862|9907928|FG001|Overall Study|Physician Decision|1
6231988|NCT01759862|9907927|FG000|Overall Study|Adverse Event|0
6085556|NCT00653939|9694894|FG000|Overall Study|Disease Progression|2
6085557|NCT00653939|9694895|FG001|Overall Study|Disease Progression|3
6085558|NCT00653939|9694894|FG000|Overall Study|Other|2
6231989|NCT01759862|9907928|FG001|Overall Study|Adverse Event|1
6231990|NCT01760447|9907995|FG000|Weeks 0-20|Consent withdrawn by Parent/Guardian|0
6231991|NCT01760447|9907996|FG001|Weeks 0-20|Consent withdrawn by Parent/Guardian|0
6231992|NCT01760447|9907997|FG002|Weeks 0-20|Consent withdrawn by Parent/Guardian|1
6231993|NCT01760447|9907998|FG003|Weeks 0-20|Consent withdrawn by Parent/Guardian|3
6231994|NCT01760447|9907995|FG000|Weeks 0-20|Withdrawal by Subject|2
6231995|NCT01760447|9907996|FG001|Weeks 0-20|Withdrawal by Subject|0
6085559|NCT00653939|9694895|FG001|Overall Study|Other|6
6085560|NCT00653991|9694905|FG000|3 Month Follow-up|Participant would not respond|150
6085561|NCT00653991|9694906|FG001|3 Month Follow-up|Participant would not respond|157
6085562|NCT00653991|9694905|FG000|6 Month Follow-up|Participant would not respond|133
6085563|NCT00653991|9694906|FG001|6 Month Follow-up|Participant would not respond|141
6085564|NCT00654004|9694916|FG000|Overall Study|Lost to Follow-up|1
6085565|NCT00654004|9694917|FG001|Overall Study|Lost to Follow-up|0
6085566|NCT00654186|9694949|FG000|Overall Study|Withdrawal by Subject|5
6085567|NCT00654238|9694953|FG000|Overall Study|Screen Failures|4
6085568|NCT00654355|9694977|FG000|Overall Study|Lost to Follow-up|2
6085569|NCT00654355|9694978|FG001|Overall Study|Lost to Follow-up|2
6085570|NCT00654368|9694987|FG000|Overall Study|Ineligibility determined|6
6085571|NCT00654368|9694988|FG001|Overall Study|Ineligibility determined|0
6085572|NCT00654368|9694989|FG002|Overall Study|Ineligibility determined|0
6085573|NCT00654368|9694987|FG000|Overall Study|Protocol deviation|3
6085574|NCT00654368|9694988|FG001|Overall Study|Protocol deviation|2
6085575|NCT00654368|9694989|FG002|Overall Study|Protocol deviation|1
6085576|NCT00654368|9694987|FG000|Overall Study|Non-compliance|2
6085577|NCT00654368|9694988|FG001|Overall Study|Non-compliance|1
6085578|NCT00654368|9694989|FG002|Overall Study|Non-compliance|2
6085579|NCT00654368|9694987|FG000|Overall Study|Withdrawal by Subject|5
6085580|NCT00654368|9694988|FG001|Overall Study|Withdrawal by Subject|2
6085581|NCT00654368|9694989|FG002|Overall Study|Withdrawal by Subject|2
6085582|NCT00654368|9694987|FG000|Overall Study|Disease progression|21
6085583|NCT00654368|9694988|FG001|Overall Study|Disease progression|31
6085584|NCT00654368|9694989|FG002|Overall Study|Disease progression|13
6085585|NCT00654368|9694987|FG000|Overall Study|Requirement for alternative therapy|1
6085586|NCT00654368|9694988|FG001|Overall Study|Requirement for alternative therapy|1
6085587|NCT00654368|9694989|FG002|Overall Study|Requirement for alternative therapy|1
6085588|NCT00654368|9694987|FG000|Overall Study|Physician Decision|0
6085589|NCT00654368|9694988|FG001|Overall Study|Physician Decision|0
6085590|NCT00654368|9694989|FG002|Overall Study|Physician Decision|2
6085591|NCT00654368|9694987|FG000|Overall Study|Death|1
6085592|NCT00654368|9694988|FG001|Overall Study|Death|0
6085593|NCT00654368|9694989|FG002|Overall Study|Death|0
6085594|NCT00654368|9694987|FG000|Overall Study|Pregnancy|0
6085595|NCT00654368|9694988|FG001|Overall Study|Pregnancy|0
6085596|NCT00654368|9694989|FG002|Overall Study|Pregnancy|2
6085597|NCT00654368|9694987|FG000|Overall Study|Other|0
6085598|NCT00654368|9694988|FG001|Overall Study|Other|2
6085599|NCT00654368|9694989|FG002|Overall Study|Other|3
6085600|NCT00654368|9694987|FG000|Overall Study|Adverse Event|14
6085601|NCT00654368|9694988|FG001|Overall Study|Adverse Event|9
6085602|NCT00654368|9694989|FG002|Overall Study|Adverse Event|6
6085603|NCT00654381|9695000|FG000|1st Stage|Adverse Event|3
6085604|NCT00654381|9695001|FG001|1st Stage|Adverse Event|3
6085605|NCT00654381|9695002|FG002|1st Stage|Adverse Event|3
6187188|NCT01379703|9840981|FG002|9 Months Through 18 Months|Lost to Follow-up|0
6187189|NCT01379703|9840979|FG000|9 Months Through 18 Months|Withdrawal by Subject|0
6187190|NCT01379703|9840980|FG001|9 Months Through 18 Months|Withdrawal by Subject|11
6187191|NCT01379703|9840981|FG002|9 Months Through 18 Months|Withdrawal by Subject|0
6187192|NCT01379703|9840979|FG000|9 Months Through 18 Months|Adverse Event|0
6187193|NCT01379703|9840980|FG001|9 Months Through 18 Months|Adverse Event|6
6187194|NCT01379703|9840981|FG002|9 Months Through 18 Months|Adverse Event|0
6187195|NCT01379703|9840979|FG000|9 Months Through 18 Months|Treatment failure|0
6187196|NCT01379703|9840980|FG001|9 Months Through 18 Months|Treatment failure|5
6187197|NCT01379703|9840981|FG002|9 Months Through 18 Months|Treatment failure|0
6187198|NCT01379703|9840979|FG000|9 Months Through 18 Months|Patient Noncompliance|0
6231996|NCT01760447|9907997|FG002|Weeks 0-20|Withdrawal by Subject|1
6231997|NCT01760447|9907998|FG003|Weeks 0-20|Withdrawal by Subject|0
6231998|NCT01760447|9907995|FG000|Weeks 0-20|Lost to Follow-up|1
6187199|NCT01379703|9840980|FG001|9 Months Through 18 Months|Patient Noncompliance|4
6187200|NCT01379703|9840981|FG002|9 Months Through 18 Months|Patient Noncompliance|0
6187201|NCT01379703|9840979|FG000|9 Months Through 18 Months|Tuberculosis/TB treatment|0
6231999|NCT01760447|9907996|FG001|Weeks 0-20|Lost to Follow-up|0
6232000|NCT01760447|9907997|FG002|Weeks 0-20|Lost to Follow-up|1
6232001|NCT01760447|9907998|FG003|Weeks 0-20|Lost to Follow-up|1
6232002|NCT01760447|9907995|FG000|Weeks 0-20|Randomized but not treated|0
6085606|NCT00654381|9695003|FG003|1st Stage|Adverse Event|3
6232003|NCT01760447|9907996|FG001|Weeks 0-20|Randomized but not treated|0
6085607|NCT00654381|9695004|FG004|1st Stage|Adverse Event|2
6085608|NCT00654381|9695005|FG005|1st Stage|Adverse Event|1
6085609|NCT00654381|9695000|FG000|1st Stage|Withdrawal by Subject|0
6085610|NCT00654381|9695001|FG001|1st Stage|Withdrawal by Subject|0
6085611|NCT00654381|9695002|FG002|1st Stage|Withdrawal by Subject|0
6085612|NCT00654381|9695003|FG003|1st Stage|Withdrawal by Subject|1
6085613|NCT00654381|9695004|FG004|1st Stage|Withdrawal by Subject|0
6085614|NCT00654381|9695005|FG005|1st Stage|Withdrawal by Subject|1
6085615|NCT00654381|9695000|FG000|1st Stage|Investigator's decision|0
6187202|NCT01379703|9840980|FG001|9 Months Through 18 Months|Tuberculosis/TB treatment|2
6187203|NCT01379703|9840981|FG002|9 Months Through 18 Months|Tuberculosis/TB treatment|0
6187204|NCT01379703|9840979|FG000|9 Months Through 18 Months|Fatigue|0
6085616|NCT00654381|9695001|FG001|1st Stage|Investigator's decision|0
6085617|NCT00654381|9695002|FG002|1st Stage|Investigator's decision|0
6232004|NCT01760447|9907997|FG002|Weeks 0-20|Randomized but not treated|2
6232005|NCT01760447|9907998|FG003|Weeks 0-20|Randomized but not treated|0
6232006|NCT01760447|9907995|FG000|Weeks 20-54|Consent withdrawn by Parent/Guardian|1
6232007|NCT01760447|9907996|FG001|Weeks 20-54|Consent withdrawn by Parent/Guardian|1
6232008|NCT01760447|9907997|FG002|Weeks 20-54|Consent withdrawn by Parent/Guardian|1
6232009|NCT01760447|9907998|FG003|Weeks 20-54|Consent withdrawn by Parent/Guardian|0
6232010|NCT01760447|9907995|FG000|Weeks 20-54|Withdrawal by Subject|2
6232011|NCT01760447|9907996|FG001|Weeks 20-54|Withdrawal by Subject|1
6232012|NCT01760447|9907997|FG002|Weeks 20-54|Withdrawal by Subject|1
6232013|NCT01760447|9907998|FG003|Weeks 20-54|Withdrawal by Subject|2
6232014|NCT01760447|9907995|FG000|Weeks 20-54|Lost to Follow-up|0
6232015|NCT01760447|9907996|FG001|Weeks 20-54|Lost to Follow-up|0
6232016|NCT01760447|9907997|FG002|Weeks 20-54|Lost to Follow-up|1
6232017|NCT01760447|9907998|FG003|Weeks 20-54|Lost to Follow-up|2
6232018|NCT01760733|9908026|FG000|Waiting List|Death|18
6232019|NCT01760733|9908026|FG000|Waiting List|Removed from waiting list|41
6232020|NCT01760733|9908026|FG000|Waiting List|Not received a transplant yet|13
6232021|NCT01760733|9908026|FG000|Transplanted|Not reached 10 years post transplant|184
6232022|NCT01760733|9908026|FG000|Transplanted|Death|26
6232023|NCT01760733|9908026|FG000|Transplanted|Graft loss|7
6232024|NCT01760876|9908040|FG000|Overall Study|Non-cardiac death (head injury)|1
6232025|NCT01760876|9908040|FG000|Overall Study|Carcinoma of prostate|1
6232026|NCT01760876|9908040|FG000|Overall Study|Impaired renal function|1
6232027|NCT01760876|9908040|FG000|Overall Study|Major depression|1
6232028|NCT01760876|9908040|FG000|Overall Study|Very poor baseline OCT quality|2
6232029|NCT01760954|9908048|FG000|Treatment Period (6 Months)|Withdrawal by Subject|8
6232030|NCT01760954|9908049|FG001|Treatment Period (6 Months)|Withdrawal by Subject|8
6232031|NCT01760954|9908050|FG002|Treatment Period (6 Months)|Withdrawal by Subject|4
6232032|NCT01760954|9908051|FG003|Treatment Period (6 Months)|Withdrawal by Subject|5
6232033|NCT01760954|9908048|FG000|Treatment Period (6 Months)|Adverse Event|5
6232034|NCT01760954|9908049|FG001|Treatment Period (6 Months)|Adverse Event|3
6232035|NCT01760954|9908050|FG002|Treatment Period (6 Months)|Adverse Event|4
6232036|NCT01760954|9908051|FG003|Treatment Period (6 Months)|Adverse Event|10
6232037|NCT01760954|9908048|FG000|Treatment Period (6 Months)|Lost to Follow-up|9
6232038|NCT01760954|9908049|FG001|Treatment Period (6 Months)|Lost to Follow-up|1
6232039|NCT01760954|9908050|FG002|Treatment Period (6 Months)|Lost to Follow-up|4
6232040|NCT01760954|9908051|FG003|Treatment Period (6 Months)|Lost to Follow-up|3
6232041|NCT01760954|9908048|FG000|Treatment Period (6 Months)|Surgery or invasive intervention for end|3
6232042|NCT01760954|9908049|FG001|Treatment Period (6 Months)|Surgery or invasive intervention for end|3
6232043|NCT01760954|9908050|FG002|Treatment Period (6 Months)|Surgery or invasive intervention for end|3
6232044|NCT01760954|9908051|FG003|Treatment Period (6 Months)|Surgery or invasive intervention for end|2
6232045|NCT01760954|9908048|FG000|Treatment Period (6 Months)|Pregnancy|5
6232046|NCT01760954|9908049|FG001|Treatment Period (6 Months)|Pregnancy|0
6232047|NCT01760954|9908050|FG002|Treatment Period (6 Months)|Pregnancy|3
6232048|NCT01760954|9908051|FG003|Treatment Period (6 Months)|Pregnancy|2
6232049|NCT01760954|9908048|FG000|Treatment Period (6 Months)|Non-compliance|1
6232050|NCT01760954|9908049|FG001|Treatment Period (6 Months)|Non-compliance|4
6232051|NCT01760954|9908050|FG002|Treatment Period (6 Months)|Non-compliance|0
6232052|NCT01760954|9908051|FG003|Treatment Period (6 Months)|Non-compliance|3
6232053|NCT01760954|9908048|FG000|Treatment Period (6 Months)|Other|0
6232054|NCT01760954|9908049|FG001|Treatment Period (6 Months)|Other|3
6232055|NCT01760954|9908050|FG002|Treatment Period (6 Months)|Other|3
6232056|NCT01760954|9908051|FG003|Treatment Period (6 Months)|Other|1
6232057|NCT01760954|9908048|FG000|Treatment Period (6 Months)|Decrease in Bone Mineral Density (BMD)|1
6232058|NCT01760954|9908049|FG001|Treatment Period (6 Months)|Decrease in Bone Mineral Density (BMD)|6
6232059|NCT01760954|9908050|FG002|Treatment Period (6 Months)|Decrease in Bone Mineral Density (BMD)|0
6232060|NCT01760954|9908051|FG003|Treatment Period (6 Months)|Decrease in Bone Mineral Density (BMD)|0
6232061|NCT01760954|9908048|FG000|Treatment Period (6 Months)|Exclusionary Medication|1
6232062|NCT01760954|9908049|FG001|Treatment Period (6 Months)|Exclusionary Medication|0
6232063|NCT01760954|9908050|FG002|Treatment Period (6 Months)|Exclusionary Medication|0
6232064|NCT01760954|9908051|FG003|Treatment Period (6 Months)|Exclusionary Medication|0
6232065|NCT01760954|9908048|FG000|Post-treatment Follow-up (12 Months)|Withdrawal by Subject|6
6232066|NCT01760954|9908049|FG001|Post-treatment Follow-up (12 Months)|Withdrawal by Subject|6
6232067|NCT01760954|9908050|FG002|Post-treatment Follow-up (12 Months)|Withdrawal by Subject|4
6232068|NCT01760954|9908051|FG003|Post-treatment Follow-up (12 Months)|Withdrawal by Subject|9
6232069|NCT01760954|9908048|FG000|Post-treatment Follow-up (12 Months)|Lost to Follow-up|4
6232070|NCT01760954|9908049|FG001|Post-treatment Follow-up (12 Months)|Lost to Follow-up|7
6232071|NCT01760954|9908050|FG002|Post-treatment Follow-up (12 Months)|Lost to Follow-up|2
6232072|NCT01760954|9908051|FG003|Post-treatment Follow-up (12 Months)|Lost to Follow-up|0
6232073|NCT01760954|9908048|FG000|Post-treatment Follow-up (12 Months)|Surgery or invasive intervention|6
6232074|NCT01760954|9908049|FG001|Post-treatment Follow-up (12 Months)|Surgery or invasive intervention|10
6232075|NCT01760954|9908050|FG002|Post-treatment Follow-up (12 Months)|Surgery or invasive intervention|5
6232076|NCT01760954|9908051|FG003|Post-treatment Follow-up (12 Months)|Surgery or invasive intervention|5
6232077|NCT01760954|9908048|FG000|Post-treatment Follow-up (12 Months)|Received Exclusionary Medication|1
6232078|NCT01760954|9908049|FG001|Post-treatment Follow-up (12 Months)|Received Exclusionary Medication|4
6232079|NCT01760954|9908050|FG002|Post-treatment Follow-up (12 Months)|Received Exclusionary Medication|0
6232080|NCT01760954|9908051|FG003|Post-treatment Follow-up (12 Months)|Received Exclusionary Medication|0
6232081|NCT01760954|9908048|FG000|Post-treatment Follow-up (12 Months)|Return of Menses and Acceptable BMD|0
6232082|NCT01760954|9908049|FG001|Post-treatment Follow-up (12 Months)|Return of Menses and Acceptable BMD|0
6232083|NCT01760954|9908050|FG002|Post-treatment Follow-up (12 Months)|Return of Menses and Acceptable BMD|1
6232084|NCT01760954|9908051|FG003|Post-treatment Follow-up (12 Months)|Return of Menses and Acceptable BMD|0
6232085|NCT01760954|9908048|FG000|Post-treatment Follow-up (12 Months)|Other|13
6232086|NCT01760954|9908049|FG001|Post-treatment Follow-up (12 Months)|Other|8
6232087|NCT01760954|9908050|FG002|Post-treatment Follow-up (12 Months)|Other|9
6232088|NCT01760954|9908051|FG003|Post-treatment Follow-up (12 Months)|Other|6
6232089|NCT01761162|9908075|FG000|Overall Study|Withdrawal by Subject|3
6232090|NCT01761292|9908097|FG000|Part 1|Adverse Event|1
6232091|NCT01761292|9908097|FG000|Part 1|not receiving treatment in Part 1|1
6232092|NCT01761292|9908097|FG000|Extension 1|Withdrawal by Subject|1
6232093|NCT01761565|9908108|FG000|40 Consecutive Doses of SUF 15 mcg|Adverse Event|1
6232094|NCT01762345|9908138|FG000|Overall Study|Adverse Event|5
6232095|NCT01762345|9908138|FG000|Overall Study|Protocol Violation|2
6232096|NCT01762800|9908172|FG000|Overall Study|Adverse Event|8
6232097|NCT01762800|9908173|FG001|Overall Study|Adverse Event|13
6232098|NCT01762800|9908172|FG000|Overall Study|Lack of Efficacy|3
6232099|NCT01762800|9908173|FG001|Overall Study|Lack of Efficacy|2
6232100|NCT01762800|9908172|FG000|Overall Study|Study Closed/Terminated|0
6232101|NCT01762800|9908173|FG001|Overall Study|Study Closed/Terminated|1
6232102|NCT01762800|9908172|FG000|Overall Study|Physician Decision|1
6232103|NCT01762800|9908173|FG001|Overall Study|Physician Decision|1
6232104|NCT01762800|9908172|FG000|Overall Study|Withdrawal by Subject|7
6232105|NCT01762800|9908173|FG001|Overall Study|Withdrawal by Subject|4
6232106|NCT01762943|9908194|FG000|Overall Study|Physician Decision|1
6232107|NCT01762943|9908195|FG001|Overall Study|Physician Decision|1
6232108|NCT01762943|9908194|FG000|Overall Study|Protocol Violation|1
6232109|NCT01762943|9908195|FG001|Overall Study|Protocol Violation|0
6232110|NCT01762943|9908194|FG000|Overall Study|Withdrawal by Subject|2
6232111|NCT01762943|9908195|FG001|Overall Study|Withdrawal by Subject|1
6232112|NCT01763047|9908211|FG000|Period 1|Test Article Not Available|4
6232113|NCT01763047|9908212|FG001|Period 1|Test Article Not Available|1
6232114|NCT01763047|9908211|FG000|Period 1|Protocol Violation|4
6232115|NCT01763047|9908212|FG001|Period 1|Protocol Violation|4
6232116|NCT01763047|9908211|FG000|Period 1|No Longer Meets Eligibility criteria|1
6232117|NCT01763047|9908212|FG001|Period 1|No Longer Meets Eligibility criteria|0
6232118|NCT01763047|9908211|FG000|Period 1|Adverse Event|0
6232119|NCT01763047|9908212|FG001|Period 1|Adverse Event|1
6232120|NCT01763047|9908211|FG000|Period 1|Unsatisfactory Visual Response|0
6232121|NCT01763047|9908212|FG001|Period 1|Unsatisfactory Visual Response|3
6232122|NCT01763047|9908211|FG000|Period 1|Lens Power Not Available|0
6232123|NCT01763047|9908212|FG001|Period 1|Lens Power Not Available|1
6232124|NCT01763047|9908211|FG000|Period 1|Study Site office Closed|0
6232125|NCT01763047|9908212|FG001|Period 1|Study Site office Closed|1
6232126|NCT01763047|9908211|FG000|Period 2|Lens Discomfort|1
6232127|NCT01763047|9908212|FG001|Period 2|Lens Discomfort|0
6232128|NCT01763047|9908211|FG000|Period 2|No longer meets Eligibility Criteria|1
6232129|NCT01763047|9908212|FG001|Period 2|No longer meets Eligibility Criteria|0
6232130|NCT01763047|9908211|FG000|Period 2|Study Site office Closed|1
6232131|NCT01763047|9908212|FG001|Period 2|Study Site office Closed|1
6232132|NCT01763047|9908211|FG000|Period 2|Unsatisfactory Visual Response|1
6232133|NCT01763047|9908212|FG001|Period 2|Unsatisfactory Visual Response|1
6232134|NCT01763047|9908211|FG000|Period 2|Protocol Violation|0
6232135|NCT01763047|9908212|FG001|Period 2|Protocol Violation|2
6232136|NCT01763047|9908211|FG000|Period 2|Unsatisfactory lens Fitting|0
6232137|NCT01763047|9908212|FG001|Period 2|Unsatisfactory lens Fitting|1
6232138|NCT01763164|9908223|FG000|Treatment Phase|Participant/Guardian decision|26
6232139|NCT01763164|9908224|FG001|Treatment Phase|Participant/Guardian decision|14
6232140|NCT01763164|9908223|FG000|Treatment Phase|Protocol Violation|1
6232141|NCT01763164|9908224|FG001|Treatment Phase|Protocol Violation|1
6232142|NCT01763164|9908223|FG000|Treatment Phase|Progressive Disease|142
6232143|NCT01763164|9908224|FG001|Treatment Phase|Progressive Disease|76
6232144|NCT01763164|9908223|FG000|Treatment Phase|Physician Decision|24
6232145|NCT01763164|9908224|FG001|Treatment Phase|Physician Decision|13
6232146|NCT01763164|9908223|FG000|Treatment Phase|Death|10
6232147|NCT01763164|9908224|FG001|Treatment Phase|Death|1
6232148|NCT01763164|9908223|FG000|Treatment Phase|Adverse Event|66
6232149|NCT01763164|9908224|FG001|Treatment Phase|Adverse Event|8
6232150|NCT01763164|9908223|FG000|Treatment Phase|Randomized but not Treated|0
6232151|NCT01763164|9908224|FG001|Treatment Phase|Randomized but not Treated|19
6232152|NCT01763164|9908223|FG000|Treatment Phase|Other|0
6232153|NCT01763164|9908224|FG001|Treatment Phase|Other|1
6232154|NCT01763164|9908223|FG000|Follow up Phase|New therapy for study indication|12
6232155|NCT01763164|9908224|FG001|Follow up Phase|New therapy for study indication|3
6232156|NCT01763164|9908223|FG000|Follow up Phase|Death|21
6232157|NCT01763164|9908224|FG001|Follow up Phase|Death|4
6232158|NCT01763164|9908223|FG000|Follow up Phase|Subject/guardian decision|9
6232159|NCT01763164|9908224|FG001|Follow up Phase|Subject/guardian decision|2
6232160|NCT01763164|9908223|FG000|Follow up Phase|Progressive disease|127
6232161|NCT01763164|9908224|FG001|Follow up Phase|Progressive disease|62
6232162|NCT01763164|9908223|FG000|Follow up Phase|Physician Decision|10
6232163|NCT01763164|9908224|FG001|Follow up Phase|Physician Decision|3
6232164|NCT01763164|9908223|FG000|Follow up Phase|Lost to Follow-up|1
6232165|NCT01763164|9908224|FG001|Follow up Phase|Lost to Follow-up|0
6232166|NCT01763164|9908223|FG000|Follow up Phase|Adverse Event|17
6232167|NCT01763164|9908224|FG001|Follow up Phase|Adverse Event|1
6232168|NCT01763203|9908232|FG000|Overall Study|Death|4
6232169|NCT01763203|9908233|FG001|Overall Study|Death|7
6232170|NCT01763203|9908232|FG000|Overall Study|Lost to Follow-up|12
6232171|NCT01763203|9908233|FG001|Overall Study|Lost to Follow-up|12
6232172|NCT01763203|9908232|FG000|Overall Study|Withdrawal by Subject|8
6232173|NCT01763203|9908233|FG001|Overall Study|Withdrawal by Subject|12
6232174|NCT01763203|9908232|FG000|Overall Study|Moved out of study region|7
6232175|NCT01763203|9908233|FG001|Overall Study|Moved out of study region|10
6085618|NCT00654381|9695003|FG003|1st Stage|Investigator's decision|1
6085619|NCT00654381|9695004|FG004|1st Stage|Investigator's decision|0
6085620|NCT00654381|9695005|FG005|1st Stage|Investigator's decision|0
6232176|NCT01763203|9908232|FG000|Overall Study|Physician Decision|2
6232177|NCT01763203|9908233|FG001|Overall Study|Physician Decision|1
6232178|NCT01763684|9908335|FG000|Overall Study|Study terminated early due to low enrollment|126
6232179|NCT01763684|9908336|FG001|Overall Study|Study terminated early due to low enrollment|127
6232180|NCT01763684|9908335|FG000|Overall Study|Study surgery not performed|7
6232181|NCT01763684|9908336|FG001|Overall Study|Study surgery not performed|6
6232182|NCT01763827|9908348|FG000|Overall Study|Withdrawal by Subject|1
6232183|NCT01763827|9908349|FG001|Overall Study|Withdrawal by Subject|0
6232184|NCT01763827|9908350|FG002|Overall Study|Withdrawal by Subject|0
6232185|NCT01763827|9908351|FG003|Overall Study|Withdrawal by Subject|0
6232186|NCT01763827|9908352|FG004|Overall Study|Withdrawal by Subject|2
6232187|NCT01763827|9908353|FG005|Overall Study|Withdrawal by Subject|0
6232188|NCT01763827|9908348|FG000|Overall Study|Decision by sponsor|2
6232189|NCT01763827|9908349|FG001|Overall Study|Decision by sponsor|0
6232190|NCT01763827|9908350|FG002|Overall Study|Decision by sponsor|3
6232191|NCT01763827|9908351|FG003|Overall Study|Decision by sponsor|0
6232192|NCT01763827|9908352|FG004|Overall Study|Decision by sponsor|2
6232193|NCT01763827|9908353|FG005|Overall Study|Decision by sponsor|1
6232194|NCT01763827|9908348|FG000|Overall Study|Lost to Follow-up|0
6232195|NCT01763827|9908349|FG001|Overall Study|Lost to Follow-up|1
6232196|NCT01763827|9908350|FG002|Overall Study|Lost to Follow-up|1
6232197|NCT01763827|9908351|FG003|Overall Study|Lost to Follow-up|1
6232198|NCT01763827|9908352|FG004|Overall Study|Lost to Follow-up|2
6232199|NCT01763827|9908353|FG005|Overall Study|Lost to Follow-up|1
6232200|NCT01763866|9908391|FG000|Overall Study|Withdrawal by Subject|2
6232201|NCT01763866|9908392|FG001|Overall Study|Withdrawal by Subject|1
6232202|NCT01763866|9908393|FG002|Overall Study|Withdrawal by Subject|4
6232203|NCT01763866|9908394|FG003|Overall Study|Withdrawal by Subject|0
6232204|NCT01763866|9908395|FG004|Overall Study|Withdrawal by Subject|0
6232205|NCT01763866|9908396|FG005|Overall Study|Withdrawal by Subject|3
6232206|NCT01763866|9908397|FG006|Overall Study|Withdrawal by Subject|4
6232207|NCT01763866|9908398|FG007|Overall Study|Withdrawal by Subject|0
6232208|NCT01763866|9908399|FG008|Overall Study|Withdrawal by Subject|1
6232209|NCT01763866|9908400|FG009|Overall Study|Withdrawal by Subject|1
6232210|NCT01763866|9908401|FG010|Overall Study|Withdrawal by Subject|2
6232211|NCT01763866|9908402|FG011|Overall Study|Withdrawal by Subject|2
6232212|NCT01763866|9908403|FG012|Overall Study|Withdrawal by Subject|2
6232213|NCT01763866|9908404|FG013|Overall Study|Withdrawal by Subject|0
6232214|NCT01763866|9908405|FG014|Overall Study|Withdrawal by Subject|6
6232215|NCT01763866|9908406|FG015|Overall Study|Withdrawal by Subject|3
6232216|NCT01763866|9908407|FG016|Overall Study|Withdrawal by Subject|0
6232217|NCT01763866|9908408|FG017|Overall Study|Withdrawal by Subject|1
6232218|NCT01763866|9908409|FG018|Overall Study|Withdrawal by Subject|1
6232219|NCT01763866|9908410|FG019|Overall Study|Withdrawal by Subject|1
6232220|NCT01763866|9908411|FG020|Overall Study|Withdrawal by Subject|2
6232221|NCT01763866|9908412|FG021|Overall Study|Withdrawal by Subject|1
6232222|NCT01763866|9908413|FG022|Overall Study|Withdrawal by Subject|2
6232223|NCT01763866|9908414|FG023|Overall Study|Withdrawal by Subject|1
6232224|NCT01763866|9908391|FG000|Overall Study|Decision by sponsor|0
6232225|NCT01763866|9908392|FG001|Overall Study|Decision by sponsor|0
6232226|NCT01763866|9908393|FG002|Overall Study|Decision by sponsor|1
6232227|NCT01763866|9908394|FG003|Overall Study|Decision by sponsor|0
6232228|NCT01763866|9908395|FG004|Overall Study|Decision by sponsor|2
6232229|NCT01763866|9908396|FG005|Overall Study|Decision by sponsor|0
6232230|NCT01763866|9908397|FG006|Overall Study|Decision by sponsor|2
6232231|NCT01763866|9908398|FG007|Overall Study|Decision by sponsor|0
6232232|NCT01763866|9908399|FG008|Overall Study|Decision by sponsor|2
6232233|NCT01763866|9908400|FG009|Overall Study|Decision by sponsor|0
6085621|NCT00654381|9695000|FG000|2nd Stage|Adverse Event|2
6232234|NCT01763866|9908401|FG010|Overall Study|Decision by sponsor|6
6232235|NCT01763866|9908402|FG011|Overall Study|Decision by sponsor|0
6232236|NCT01763866|9908403|FG012|Overall Study|Decision by sponsor|1
6232237|NCT01763866|9908404|FG013|Overall Study|Decision by sponsor|0
6232238|NCT01763866|9908405|FG014|Overall Study|Decision by sponsor|5
6232239|NCT01763866|9908406|FG015|Overall Study|Decision by sponsor|0
6232240|NCT01763866|9908407|FG016|Overall Study|Decision by sponsor|0
6232241|NCT01763866|9908408|FG017|Overall Study|Decision by sponsor|0
6232242|NCT01763866|9908409|FG018|Overall Study|Decision by sponsor|4
6232243|NCT01763866|9908410|FG019|Overall Study|Decision by sponsor|0
6232244|NCT01763866|9908411|FG020|Overall Study|Decision by sponsor|2
6232245|NCT01763866|9908412|FG021|Overall Study|Decision by sponsor|0
6232246|NCT01763866|9908413|FG022|Overall Study|Decision by sponsor|1
6232247|NCT01763866|9908414|FG023|Overall Study|Decision by sponsor|0
6232248|NCT01763866|9908391|FG000|Overall Study|Lost to Follow-up|0
6232249|NCT01763866|9908392|FG001|Overall Study|Lost to Follow-up|0
6232250|NCT01763866|9908393|FG002|Overall Study|Lost to Follow-up|0
6232251|NCT01763866|9908394|FG003|Overall Study|Lost to Follow-up|0
6232252|NCT01763866|9908395|FG004|Overall Study|Lost to Follow-up|0
6232253|NCT01763866|9908396|FG005|Overall Study|Lost to Follow-up|0
6232254|NCT01763866|9908397|FG006|Overall Study|Lost to Follow-up|1
6232255|NCT01763866|9908398|FG007|Overall Study|Lost to Follow-up|0
6232256|NCT01763866|9908399|FG008|Overall Study|Lost to Follow-up|0
6232257|NCT01763866|9908400|FG009|Overall Study|Lost to Follow-up|0
6232258|NCT01763866|9908401|FG010|Overall Study|Lost to Follow-up|0
6232259|NCT01763866|9908402|FG011|Overall Study|Lost to Follow-up|0
6232260|NCT01763866|9908403|FG012|Overall Study|Lost to Follow-up|1
6232261|NCT01763866|9908404|FG013|Overall Study|Lost to Follow-up|0
6232262|NCT01763866|9908405|FG014|Overall Study|Lost to Follow-up|1
6232263|NCT01763866|9908406|FG015|Overall Study|Lost to Follow-up|0
6232264|NCT01763866|9908407|FG016|Overall Study|Lost to Follow-up|0
6232265|NCT01763866|9908408|FG017|Overall Study|Lost to Follow-up|0
6232266|NCT01763866|9908409|FG018|Overall Study|Lost to Follow-up|1
6232267|NCT01763866|9908410|FG019|Overall Study|Lost to Follow-up|1
6232268|NCT01763866|9908411|FG020|Overall Study|Lost to Follow-up|0
6232269|NCT01763866|9908412|FG021|Overall Study|Lost to Follow-up|0
6232270|NCT01763866|9908413|FG022|Overall Study|Lost to Follow-up|0
6232271|NCT01763866|9908414|FG023|Overall Study|Lost to Follow-up|1
6232272|NCT01763866|9908391|FG000|Overall Study|Death|0
6232273|NCT01763866|9908392|FG001|Overall Study|Death|0
6232274|NCT01763866|9908393|FG002|Overall Study|Death|0
6232275|NCT01763866|9908394|FG003|Overall Study|Death|0
6232276|NCT01763866|9908395|FG004|Overall Study|Death|0
6232277|NCT01763866|9908396|FG005|Overall Study|Death|0
6232278|NCT01763866|9908397|FG006|Overall Study|Death|0
6232279|NCT01763866|9908398|FG007|Overall Study|Death|0
6232280|NCT01763866|9908399|FG008|Overall Study|Death|0
6232281|NCT01763866|9908400|FG009|Overall Study|Death|0
6232282|NCT01763866|9908401|FG010|Overall Study|Death|0
6232283|NCT01763866|9908402|FG011|Overall Study|Death|0
6232284|NCT01763866|9908403|FG012|Overall Study|Death|0
6232285|NCT01763866|9908404|FG013|Overall Study|Death|0
6232286|NCT01763866|9908405|FG014|Overall Study|Death|0
6232287|NCT01763866|9908406|FG015|Overall Study|Death|0
6232288|NCT01763866|9908407|FG016|Overall Study|Death|1
6232289|NCT01763866|9908408|FG017|Overall Study|Death|0
6232290|NCT01763866|9908409|FG018|Overall Study|Death|0
6232291|NCT01763866|9908410|FG019|Overall Study|Death|0
6232292|NCT01763866|9908411|FG020|Overall Study|Death|0
6232293|NCT01763866|9908412|FG021|Overall Study|Death|0
6232294|NCT01763866|9908413|FG022|Overall Study|Death|0
6232295|NCT01763866|9908414|FG023|Overall Study|Death|0
6232296|NCT01763905|9908468|FG000|Overall Study|Withdrawal by Subject|1
6232297|NCT01763905|9908469|FG001|Overall Study|Withdrawal by Subject|1
6232298|NCT01763905|9908470|FG002|Overall Study|Withdrawal by Subject|0
6232299|NCT01763905|9908471|FG003|Overall Study|Withdrawal by Subject|1
6232300|NCT01763905|9908468|FG000|Overall Study|Decision by sponsor|5
6232301|NCT01763905|9908469|FG001|Overall Study|Decision by sponsor|0
6232302|NCT01763905|9908470|FG002|Overall Study|Decision by sponsor|8
6232303|NCT01763905|9908471|FG003|Overall Study|Decision by sponsor|0
6232304|NCT01763905|9908468|FG000|Overall Study|Lost to Follow-up|0
6232305|NCT01763905|9908469|FG001|Overall Study|Lost to Follow-up|0
6232306|NCT01763905|9908470|FG002|Overall Study|Lost to Follow-up|1
6232307|NCT01763905|9908471|FG003|Overall Study|Lost to Follow-up|0
6232308|NCT01763918|9908485|FG000|Overall Study|Withdrawal by Subject|2
6232309|NCT01763918|9908486|FG001|Overall Study|Withdrawal by Subject|1
6232310|NCT01763918|9908487|FG002|Overall Study|Withdrawal by Subject|1
6232311|NCT01763918|9908488|FG003|Overall Study|Withdrawal by Subject|2
6232312|NCT01763918|9908485|FG000|Overall Study|Sponsor Decision|4
6232313|NCT01763918|9908486|FG001|Overall Study|Sponsor Decision|0
6232314|NCT01763918|9908487|FG002|Overall Study|Sponsor Decision|9
6232315|NCT01763918|9908488|FG003|Overall Study|Sponsor Decision|0
6232316|NCT01763996|9908514|FG000|Treatment Period 2|Adverse Event|0
6232317|NCT01763996|9908515|FG001|Treatment Period 2|Adverse Event|1
6232318|NCT01764022|9908523|FG000|Overall Study|Death|3
6232319|NCT01764022|9908524|FG001|Overall Study|Death|5
6232320|NCT01764022|9908523|FG000|Overall Study|Withdrawal by Subject|2
6232321|NCT01764022|9908524|FG001|Overall Study|Withdrawal by Subject|6
6232322|NCT01764022|9908523|FG000|Overall Study|Lack of Efficacy|0
6232323|NCT01764022|9908524|FG001|Overall Study|Lack of Efficacy|1
6232324|NCT01764022|9908523|FG000|Overall Study|Physician Decision|0
6232325|NCT01764022|9908524|FG001|Overall Study|Physician Decision|2
6232326|NCT01764022|9908523|FG000|Overall Study|Lost to Follow-up|2
6232327|NCT01764022|9908524|FG001|Overall Study|Lost to Follow-up|0
6232328|NCT01764022|9908523|FG000|Overall Study|Protocol Violation|1
6232329|NCT01764022|9908524|FG001|Overall Study|Protocol Violation|0
6232330|NCT01764256|9908536|FG000|Received All Vaccinations|Adverse Event|1
6232331|NCT01764256|9908537|FG001|Received All Vaccinations|Adverse Event|1
6232332|NCT01764256|9908538|FG002|Received All Vaccinations|Adverse Event|0
6232333|NCT01764256|9908539|FG003|Received All Vaccinations|Adverse Event|0
6232334|NCT01764256|9908536|FG000|Received All Vaccinations|Did not meet inclusion criteria|0
6232335|NCT01764256|9908537|FG001|Received All Vaccinations|Did not meet inclusion criteria|0
6232336|NCT01764256|9908538|FG002|Received All Vaccinations|Did not meet inclusion criteria|1
6232337|NCT01764256|9908539|FG003|Received All Vaccinations|Did not meet inclusion criteria|0
6232338|NCT01764256|9908536|FG000|Received All Vaccinations|Lost to Follow-up|1
6232339|NCT01764256|9908537|FG001|Received All Vaccinations|Lost to Follow-up|0
6232340|NCT01764256|9908538|FG002|Received All Vaccinations|Lost to Follow-up|0
6232341|NCT01764256|9908539|FG003|Received All Vaccinations|Lost to Follow-up|0
6232342|NCT01764256|9908536|FG000|Completed Study|Lost to Follow-up|0
6232343|NCT01764256|9908537|FG001|Completed Study|Lost to Follow-up|0
6232344|NCT01764256|9908538|FG002|Completed Study|Lost to Follow-up|0
6232345|NCT01764256|9908539|FG003|Completed Study|Lost to Follow-up|1
6232346|NCT01764386|9908555|FG000|Controlled Treatment Period (CTP)|Adverse Event|35
6232347|NCT01764386|9908556|FG001|Controlled Treatment Period (CTP)|Adverse Event|0
6232348|NCT01764386|9908555|FG000|Controlled Treatment Period (CTP)|Wk 16 Efficacy and BP Criteria|32
6232349|NCT01764386|9908556|FG001|Controlled Treatment Period (CTP)|Wk 16 Efficacy and BP Criteria|0
6232350|NCT01764386|9908555|FG000|Controlled Treatment Period (CTP)|Lost to Follow-up|9
6232351|NCT01764386|9908556|FG001|Controlled Treatment Period (CTP)|Lost to Follow-up|5
6232352|NCT01764386|9908555|FG000|Controlled Treatment Period (CTP)|Withdrawal of Consent,Protocol Deviation|6
6232353|NCT01764386|9908556|FG001|Controlled Treatment Period (CTP)|Withdrawal of Consent,Protocol Deviation|2
6232354|NCT01764386|9908555|FG000|Uncontrolled Treatment Period (UTP)|Adverse Event|2
6232355|NCT01764386|9908556|FG001|Uncontrolled Treatment Period (UTP)|Adverse Event|13
6232356|NCT01764386|9908555|FG000|Uncontrolled Treatment Period (UTP)|Wk 42 Efficacy and BP Criteria|0
6232357|NCT01764386|9908556|FG001|Uncontrolled Treatment Period (UTP)|Wk 42 Efficacy and BP Criteria|26
6232358|NCT01764386|9908555|FG000|Uncontrolled Treatment Period (UTP)|Lost to Follow-up|9
6232359|NCT01764386|9908556|FG001|Uncontrolled Treatment Period (UTP)|Lost to Follow-up|9
6232360|NCT01764386|9908555|FG000|Uncontrolled Treatment Period (UTP)|Withdrawal of Consent,Protocol Deviation|5
6232361|NCT01764386|9908556|FG001|Uncontrolled Treatment Period (UTP)|Withdrawal of Consent,Protocol Deviation|5
6232362|NCT01764464|9908565|FG000|First Intervention|Withdrawal by Subject|1
6232363|NCT01764464|9908566|FG001|First Intervention|Withdrawal by Subject|0
6232364|NCT01764464|9908565|FG000|First Intervention|Lost to Follow-up|1
6232365|NCT01764464|9908566|FG001|First Intervention|Lost to Follow-up|0
6232366|NCT01764464|9908565|FG000|First Intervention|Adverse Event|0
6232367|NCT01764464|9908566|FG001|First Intervention|Adverse Event|2
6232368|NCT01764464|9908565|FG000|First Intervention|did not receive study drug|0
6232369|NCT01764464|9908566|FG001|First Intervention|did not receive study drug|1
6232370|NCT01764464|9908565|FG000|Second Intervention (Cross-over)|Adverse Event|2
6232371|NCT01764464|9908566|FG001|Second Intervention (Cross-over)|Adverse Event|0
6232372|NCT01764633|9908578|FG000|Overall Study|Withdrawal by Subject|105
6232373|NCT01764633|9908579|FG001|Overall Study|Withdrawal by Subject|88
6232374|NCT01764633|9908578|FG000|Overall Study|Lost to Follow-up|13
6232375|NCT01764633|9908579|FG001|Overall Study|Lost to Follow-up|5
6232376|NCT01764659|9908585|FG000|Overall Study|Death|1
6232377|NCT01764659|9908585|FG000|Overall Study|Physician Decision|1
6232378|NCT01764841|9908604|FG000|Overall Study|Logistical Difficulties|0
6232379|NCT01764841|9908605|FG001|Overall Study|Logistical Difficulties|1
6232380|NCT01764841|9908606|FG002|Overall Study|Logistical Difficulties|0
6232381|NCT01764841|9908607|FG003|Overall Study|Logistical Difficulties|0
6232382|NCT01764841|9908604|FG000|Overall Study|Death|3
6232383|NCT01764841|9908605|FG001|Overall Study|Death|0
6232384|NCT01764841|9908606|FG002|Overall Study|Death|1
6232385|NCT01764841|9908607|FG003|Overall Study|Death|4
6232386|NCT01764841|9908604|FG000|Overall Study|No Follow Up|1
6232387|NCT01764841|9908605|FG001|Overall Study|No Follow Up|0
6232388|NCT01764841|9908606|FG002|Overall Study|No Follow Up|1
6232389|NCT01764841|9908607|FG003|Overall Study|No Follow Up|0
6232390|NCT01764841|9908604|FG000|Overall Study|Protocol Violation|0
6232391|NCT01764841|9908605|FG001|Overall Study|Protocol Violation|1
6232392|NCT01764841|9908606|FG002|Overall Study|Protocol Violation|0
6232393|NCT01764841|9908607|FG003|Overall Study|Protocol Violation|0
6232394|NCT01764841|9908604|FG000|Overall Study|Withdrawal by Subject|16
6232395|NCT01764841|9908605|FG001|Overall Study|Withdrawal by Subject|24
6232396|NCT01764841|9908606|FG002|Overall Study|Withdrawal by Subject|11
6232397|NCT01764841|9908607|FG003|Overall Study|Withdrawal by Subject|15
6232398|NCT01764841|9908604|FG000|Overall Study|Lost to Follow-up|3
6232399|NCT01764841|9908605|FG001|Overall Study|Lost to Follow-up|0
6232400|NCT01764841|9908606|FG002|Overall Study|Lost to Follow-up|1
6232401|NCT01764841|9908607|FG003|Overall Study|Lost to Follow-up|0
6232402|NCT01764854|9908621|FG000|Overall Study|Adverse Event|0
6232403|NCT01764854|9908622|FG001|Overall Study|Adverse Event|0
6232404|NCT01764854|9908623|FG002|Overall Study|Adverse Event|2
6232405|NCT01764854|9908624|FG003|Overall Study|Adverse Event|0
6232406|NCT01764854|9908621|FG000|Overall Study|Withdrawal by Subject|0
6232407|NCT01764854|9908622|FG001|Overall Study|Withdrawal by Subject|0
6232408|NCT01764854|9908623|FG002|Overall Study|Withdrawal by Subject|1
6232409|NCT01764854|9908624|FG003|Overall Study|Withdrawal by Subject|0
6232410|NCT01764854|9908621|FG000|Overall Study|relocation|0
6232411|NCT01764854|9908622|FG001|Overall Study|relocation|0
6232412|NCT01764854|9908623|FG002|Overall Study|relocation|2
6232413|NCT01764854|9908624|FG003|Overall Study|relocation|0
6232414|NCT01764854|9908621|FG000|Overall Study|Protocol Violation|0
6232415|NCT01764854|9908622|FG001|Overall Study|Protocol Violation|0
6232416|NCT01764854|9908623|FG002|Overall Study|Protocol Violation|1
6232417|NCT01764854|9908624|FG003|Overall Study|Protocol Violation|2
6232418|NCT01764945|9908646|FG000|Overall Study|Adverse Event|0
6232419|NCT01764945|9908647|FG001|Overall Study|Adverse Event|1
6232420|NCT01764945|9908648|FG002|Overall Study|Adverse Event|0
6232421|NCT01764945|9908649|FG003|Overall Study|Adverse Event|0
6232422|NCT01764945|9908650|FG004|Overall Study|Adverse Event|0
6232423|NCT01764945|9908651|FG005|Overall Study|Adverse Event|0
6232424|NCT01764945|9908652|FG006|Overall Study|Adverse Event|1
6232425|NCT01764945|9908653|FG007|Overall Study|Adverse Event|0
6232426|NCT01765153|9908673|FG000|Training Phase 1|Format of intervention differed|1
6232427|NCT01765153|9908674|FG001|Training Phase 1|Format of intervention differed|0
6232428|NCT01765153|9908673|FG000|Training Phase 1|Poor participation in intervention|0
6232429|NCT01765153|9908674|FG001|Training Phase 1|Poor participation in intervention|1
6232430|NCT01765153|9908673|FG000|Rest Phase 1|Withdrawal by Subject|0
6232431|NCT01765153|9908674|FG001|Rest Phase 1|Withdrawal by Subject|1
6232432|NCT01765153|9908673|FG000|Training Phase 2|Withdrawal by Subject|0
6232433|NCT01765153|9908674|FG001|Training Phase 2|Withdrawal by Subject|1
6232434|NCT01765153|9908673|FG000|Rest Phase 2|Lost to Follow-up|2
6232435|NCT01765153|9908674|FG001|Rest Phase 2|Lost to Follow-up|1
6232436|NCT01765179|9908684|FG000|Overall Study|Adverse Event|3
6232437|NCT01765179|9908684|FG000|Overall Study|Lost to Follow-up|5
6375553|NCT02922725|10165689|FG000|Overall Study|Withdrawal by Subject|1
6375554|NCT02922725|10165690|FG001|Overall Study|Withdrawal by Subject|0
6375555|NCT02922725|10165691|FG002|Overall Study|Withdrawal by Subject|0
6375556|NCT02805257|10165700|FG000|Overall Study|Lost to Follow-up|7
6232438|NCT01765179|9908684|FG000|Overall Study|Non-compliance with study drug|2
6232439|NCT01765179|9908684|FG000|Overall Study|Protocol Violation|1
6232440|NCT01765179|9908684|FG000|Overall Study|Withdrawal by Subject|8
6232441|NCT01765179|9908684|FG000|Overall Study|Hematocrit >54%|3
6232442|NCT01765179|9908684|FG000|Overall Study|prohibited med|1
6232443|NCT01765179|9908684|FG000|Overall Study|Out of country unable to finish study|1
6232444|NCT01765179|9908684|FG000|Overall Study|lack of venous access|1
6232445|NCT01765179|9908684|FG000|Overall Study|work conflict|1
6232446|NCT01765179|9908684|FG000|Overall Study|Ca elevated 10.6|1
6232447|NCT01765192|9908690|FG000|Treatment Period 1|Adverse Event|0
6232448|NCT01765192|9908691|FG001|Treatment Period 1|Adverse Event|1
6232449|NCT01765192|9908690|FG000|Washout Period|Voluntary Withdrawal|1
6232450|NCT01765192|9908691|FG001|Washout Period|Voluntary Withdrawal|1
6232451|NCT01765192|9908690|FG000|Washout Period|Reason not specified|1
6232452|NCT01765192|9908691|FG001|Washout Period|Reason not specified|0
6232453|NCT01765192|9908690|FG000|Treatment Period 2|Reason not specified|0
6232454|NCT01765192|9908691|FG001|Treatment Period 2|Reason not specified|2
6232455|NCT01765192|9908690|FG000|End of Treatment Period 2 to Final Visit|Adverse Event|0
6232456|NCT01765192|9908691|FG001|End of Treatment Period 2 to Final Visit|Adverse Event|1
6232457|NCT01765270|9908699|FG000|Overall Study|Physician Decision|1
6232458|NCT01765270|9908700|FG001|Overall Study|Physician Decision|0
6232459|NCT01765270|9908699|FG000|Overall Study|Withdrawal by Subject|0
6232460|NCT01765270|9908700|FG001|Overall Study|Withdrawal by Subject|1
6232461|NCT01765426|9908711|FG000|Overall Study|Lost to Follow-up|0
6232462|NCT01765426|9908712|FG001|Overall Study|Lost to Follow-up|1
6232463|NCT01765426|9908713|FG002|Overall Study|Lost to Follow-up|0
6232464|NCT01765426|9908714|FG003|Overall Study|Lost to Follow-up|0
6232465|NCT01765543|9908744|FG000|Overall Study|Death|1
6232466|NCT01765543|9908744|FG000|Overall Study|Withdrawal by Subject|2
6232467|NCT01765569|9908752|FG000|Period B|Withdrawal by Subject|1
6232468|NCT01765569|9908752|FG000|Period C|Death|1
6232469|NCT01765582|9908762|FG000|Overall Study|Other|3
6232470|NCT01765582|9908763|FG001|Overall Study|Other|6
6232471|NCT01765582|9908764|FG002|Overall Study|Other|9
6232472|NCT01765582|9908762|FG000|Overall Study|Lost to Follow-up|2
6232473|NCT01765582|9908763|FG001|Overall Study|Lost to Follow-up|2
6375557|NCT02805257|10165701|FG001|Overall Study|Lost to Follow-up|6
6375558|NCT02805257|10165700|FG000|Overall Study|Death|0
6375559|NCT02805257|10165701|FG001|Overall Study|Death|1
6375560|NCT02367456|10165758|FG000|Overall Study|Death|8
6375561|NCT02367456|10165759|FG001|Overall Study|Death|21
6375562|NCT02367456|10165760|FG002|Overall Study|Death|14
6232474|NCT01765582|9908764|FG002|Overall Study|Lost to Follow-up|1
6232475|NCT01765582|9908762|FG000|Overall Study|Death|31
6232476|NCT01765582|9908763|FG001|Overall Study|Death|36
6232477|NCT01765582|9908764|FG002|Overall Study|Death|33
6232478|NCT01765582|9908762|FG000|Overall Study|Sponsor Decision|46
6232479|NCT01765582|9908763|FG001|Overall Study|Sponsor Decision|42
6232480|NCT01765582|9908764|FG002|Overall Study|Sponsor Decision|42
6232481|NCT01765582|9908762|FG000|Overall Study|Withdrawal of Consent|11
6232482|NCT01765582|9908763|FG001|Overall Study|Withdrawal of Consent|6
6375563|NCT02367456|10165758|FG000|Overall Study|Lost to Follow-up|1
6232483|NCT01765582|9908764|FG002|Overall Study|Withdrawal of Consent|10
6232484|NCT01765673|9908777|FG000|Overall Study|No transportation for 2nd/3rd visits|1
6232485|NCT01765751|9908796|FG000|Overall Study|Lost to Follow-up|0
6232486|NCT01765751|9908797|FG001|Overall Study|Lost to Follow-up|2
6232487|NCT01765751|9908798|FG002|Overall Study|Lost to Follow-up|1
6232488|NCT01765764|9908812|FG000|Treatment Period|Adverse Event|1
6232489|NCT01765764|9908813|FG001|Treatment Period|Adverse Event|2
6232490|NCT01765764|9908814|FG002|Treatment Period|Adverse Event|1
6232491|NCT01765764|9908812|FG000|Treatment Period|Lost to Follow-up|0
6232492|NCT01765764|9908813|FG001|Treatment Period|Lost to Follow-up|3
6232493|NCT01765764|9908814|FG002|Treatment Period|Lost to Follow-up|2
6232494|NCT01765764|9908812|FG000|Treatment Period|Personal Reasons|1
6232495|NCT01765764|9908813|FG001|Treatment Period|Personal Reasons|2
6232496|NCT01765764|9908814|FG002|Treatment Period|Personal Reasons|1
6232497|NCT01765764|9908812|FG000|Treatment Period|Other Miscellaneous Reasons|1
6232498|NCT01765764|9908813|FG001|Treatment Period|Other Miscellaneous Reasons|2
6232499|NCT01765764|9908814|FG002|Treatment Period|Other Miscellaneous Reasons|2
6232500|NCT01765920|9908828|FG000|Overall Study|Incorrect inclusion ineligible patient|2
6232501|NCT01765920|9908829|FG001|Overall Study|Incorrect inclusion ineligible patient|5
6232502|NCT01765920|9908828|FG000|Overall Study|Patient code disclosure|0
6232503|NCT01765920|9908829|FG001|Overall Study|Patient code disclosure|1
6232504|NCT01766037|9908861|FG000|Overall Study|Adverse Event|1
6232505|NCT01766037|9908862|FG001|Overall Study|Adverse Event|0
6232506|NCT01766037|9908861|FG000|Overall Study|Lack of Efficacy|1
6232507|NCT01766037|9908862|FG001|Overall Study|Lack of Efficacy|0
6232508|NCT01766037|9908861|FG000|Overall Study|Lost to Follow-up|0
6232509|NCT01766037|9908862|FG001|Overall Study|Lost to Follow-up|10
6232510|NCT01766037|9908861|FG000|Overall Study|Physician Decision|0
6232511|NCT01766037|9908862|FG001|Overall Study|Physician Decision|1
6232512|NCT01766037|9908861|FG000|Overall Study|Withdrawal by Subject|18
6232513|NCT01766037|9908862|FG001|Overall Study|Withdrawal by Subject|16
6232514|NCT01766037|9908861|FG000|Overall Study|Moved from area|5
6232515|NCT01766037|9908862|FG001|Overall Study|Moved from area|0
6232516|NCT01766037|9908861|FG000|Overall Study|medical - unrelated|1
6232517|NCT01766037|9908862|FG001|Overall Study|medical - unrelated|2
6232518|NCT01766037|9908861|FG000|Overall Study|nausea / discomfort|3
6232519|NCT01766037|9908862|FG001|Overall Study|nausea / discomfort|0
6269824|NCT02144220|9970212|FG000|Overall Study|Withdrawal by Subject|2
6269825|NCT02144220|9970212|FG000|Overall Study|Protocol Violation|1
6269826|NCT02144285|9970248|FG000|Overall Study|Withdrawal by Subject|0
6269827|NCT02144285|9970249|FG001|Overall Study|Withdrawal by Subject|0
6269828|NCT02144285|9970250|FG002|Overall Study|Withdrawal by Subject|0
6269829|NCT02144285|9970251|FG003|Overall Study|Withdrawal by Subject|0
6269830|NCT02144285|9970252|FG004|Overall Study|Withdrawal by Subject|1
6269831|NCT02144285|9970253|FG005|Overall Study|Withdrawal by Subject|0
6269832|NCT02144285|9970254|FG006|Overall Study|Withdrawal by Subject|0
6269833|NCT02144285|9970255|FG007|Overall Study|Withdrawal by Subject|0
6269834|NCT02144285|9970256|FG008|Overall Study|Withdrawal by Subject|0
6269835|NCT02144285|9970257|FG009|Overall Study|Withdrawal by Subject|0
6269836|NCT02144337|9970295|FG000|T2 Follow-up (Post-intervention)|Lack of Efficacy|1
6269837|NCT02144337|9970296|FG001|T2 Follow-up (Post-intervention)|Lack of Efficacy|1
6269838|NCT02144337|9970295|FG000|T2 Follow-up (Post-intervention)|Lost to Follow-up|2
6269839|NCT02144337|9970296|FG001|T2 Follow-up (Post-intervention)|Lost to Follow-up|0
6269840|NCT02144337|9970295|FG000|T2 Follow-up (Post-intervention)|Withdrawal by Subject|1
6269841|NCT02144337|9970296|FG001|T2 Follow-up (Post-intervention)|Withdrawal by Subject|0
6269842|NCT02144337|9970295|FG000|T3 Follow-up (3 Month Post-intervention)|Lost to Follow-up|2
6269843|NCT02144337|9970296|FG001|T3 Follow-up (3 Month Post-intervention)|Lost to Follow-up|0
6269844|NCT02144337|9970295|FG000|T3 Follow-up (3 Month Post-intervention)|Withdrawal by Subject|1
6269845|NCT02144337|9970296|FG001|T3 Follow-up (3 Month Post-intervention)|Withdrawal by Subject|0
6269846|NCT02144610|9970336|FG000|Overall Study|Physician Decision|1
6269847|NCT02144610|9970337|FG001|Overall Study|Physician Decision|0
6269848|NCT02144610|9970336|FG000|Overall Study|Withdrawal by Subject|1
6269849|NCT02144610|9970337|FG001|Overall Study|Withdrawal by Subject|5
6269850|NCT02144610|9970336|FG000|Overall Study|Death|2
6269851|NCT02144610|9970337|FG001|Overall Study|Death|2
6269852|NCT02144610|9970336|FG000|Overall Study|Study Discontinuation by Sponsor|19
6269853|NCT02144610|9970337|FG001|Overall Study|Study Discontinuation by Sponsor|14
6269854|NCT02144610|9970336|FG000|Overall Study|Other|0
6269855|NCT02144610|9970337|FG001|Overall Study|Other|1
6269856|NCT02144701|9970354|FG000|Overall Study|development of relapse, GVHD or death|9
6269857|NCT02144701|9970355|FG001|Overall Study|development of relapse, GVHD or death|3
6269858|NCT02145026|9970374|FG000|Overall Study|Adverse Event|2
6269859|NCT02145026|9970374|FG000|Overall Study|Death|4
6269860|NCT02145026|9970374|FG000|Overall Study|Withdrawal by Subject|2
6269861|NCT02145026|9970374|FG000|Overall Study|Physician Decision|4
6269862|NCT02145078|9970382|FG000|Overall Study|Death|1
6269863|NCT02145078|9970382|FG000|Overall Study|Reason not given|3
6269864|NCT02145156|9970389|FG000|Overall Study|No match to vaccination records|60
6269865|NCT02145156|9970390|FG001|Overall Study|No match to vaccination records|52
6269866|NCT02145156|9970391|FG002|Overall Study|No match to vaccination records|41
6269867|NCT02145182|9970401|FG000|Overall Study|Adverse Event|4
6232520|NCT01766050|9908868|FG000|Overall Study|Adverse Event|1
6232521|NCT01766050|9908868|FG000|Overall Study|Lost to Follow-up|1
6232522|NCT01766050|9908868|FG000|Overall Study|Withdrawal by Subject|2
6232523|NCT01766206|9908904|FG000|Overall Study|Withdrawal by Subject|22
6232524|NCT01766206|9908904|FG000|Overall Study|Lost to Follow-up|10
6232525|NCT01766206|9908904|FG000|Overall Study|Inappropriate enrollment|18
6232526|NCT01766206|9908904|FG000|Overall Study|Withdrawal and inappropriate enrollment|1
6232527|NCT01766310|9908924|FG000|Overall Study|Lost to Follow-up|1
6232528|NCT01766310|9908925|FG001|Overall Study|Lost to Follow-up|3
6232529|NCT01766336|9908933|FG000|Overall Study|Adverse Event|11
6232530|NCT01766336|9908934|FG001|Overall Study|Adverse Event|8
6232531|NCT01766336|9908933|FG000|Overall Study|Death|4
6232532|NCT01766336|9908934|FG001|Overall Study|Death|3
6232533|NCT01766336|9908933|FG000|Overall Study|Lost to Follow-up|1
6232534|NCT01766336|9908934|FG001|Overall Study|Lost to Follow-up|3
6232535|NCT01766336|9908933|FG000|Overall Study|Physician Decision|4
6232536|NCT01766336|9908934|FG001|Overall Study|Physician Decision|2
6232537|NCT01766336|9908933|FG000|Overall Study|Protocol Violation|0
6232538|NCT01766336|9908934|FG001|Overall Study|Protocol Violation|1
6232539|NCT01766336|9908933|FG000|Overall Study|Sponsor Decision|52
6232540|NCT01766336|9908934|FG001|Overall Study|Sponsor Decision|43
6232541|NCT01766336|9908933|FG000|Overall Study|Withdrawal by Subject|18
6232542|NCT01766336|9908934|FG001|Overall Study|Withdrawal by Subject|15
6232543|NCT01766401|9908942|FG000|Overall Study|Adverse Event|7
6232544|NCT01766401|9908943|FG001|Overall Study|Adverse Event|22
6232545|NCT01766401|9908942|FG000|Overall Study|Lack of Efficacy|1
6232546|NCT01766401|9908943|FG001|Overall Study|Lack of Efficacy|2
6232547|NCT01766401|9908942|FG000|Overall Study|Protocol Violation|3
6232548|NCT01766401|9908943|FG001|Overall Study|Protocol Violation|8
6232549|NCT01766401|9908942|FG000|Overall Study|Withdrawal by Subject|15
6232550|NCT01766401|9908943|FG001|Overall Study|Withdrawal by Subject|12
6232551|NCT01766401|9908942|FG000|Overall Study|Lost to Follow-up|10
6232552|NCT01766401|9908943|FG001|Overall Study|Lost to Follow-up|11
6232553|NCT01766401|9908942|FG000|Overall Study|Pregnancy|1
6232554|NCT01766401|9908943|FG001|Overall Study|Pregnancy|1
6232555|NCT01766778|9908978|FG000|Overall Study|Adverse Event|4
6232556|NCT01766778|9908979|FG001|Overall Study|Adverse Event|4
6232557|NCT01766778|9908978|FG000|Overall Study|Withdrawal by Subject|1
6232558|NCT01766778|9908979|FG001|Overall Study|Withdrawal by Subject|0
6232559|NCT01766817|9908988|FG000|Overall Study|Drug-related adverse event|1
6232560|NCT01766817|9908989|FG001|Overall Study|Drug-related adverse event|2
6232561|NCT01766817|9908990|FG002|Overall Study|Drug-related adverse event|1
6232562|NCT01766817|9908988|FG000|Overall Study|Drug-unrelated adverse event|3
6232563|NCT01766817|9908989|FG001|Overall Study|Drug-unrelated adverse event|3
6232564|NCT01766817|9908990|FG002|Overall Study|Drug-unrelated adverse event|3
6232565|NCT01766817|9908988|FG000|Overall Study|Death|1
6232566|NCT01766817|9908989|FG001|Overall Study|Death|1
6232567|NCT01766817|9908990|FG002|Overall Study|Death|0
6232568|NCT01766817|9908988|FG000|Overall Study|Unable to take study drug|0
6232569|NCT01766817|9908989|FG001|Overall Study|Unable to take study drug|1
6232570|NCT01766817|9908990|FG002|Overall Study|Unable to take study drug|0
6232571|NCT01766817|9908988|FG000|Overall Study|Withdrawal by Subject|2
6232572|NCT01766817|9908989|FG001|Overall Study|Withdrawal by Subject|0
6232573|NCT01766817|9908990|FG002|Overall Study|Withdrawal by Subject|3
6232574|NCT01766817|9908988|FG000|Overall Study|Subject non-compliance|0
6232575|NCT01766817|9908989|FG001|Overall Study|Subject non-compliance|1
6232576|NCT01766817|9908990|FG002|Overall Study|Subject non-compliance|2
6232577|NCT01766817|9908988|FG000|Overall Study|Physician Decision|3
6232578|NCT01766817|9908989|FG001|Overall Study|Physician Decision|3
6232579|NCT01766817|9908990|FG002|Overall Study|Physician Decision|4
6232580|NCT01766817|9908988|FG000|Overall Study|Other|1
6187205|NCT01379703|9840980|FG001|9 Months Through 18 Months|Fatigue|1
6187206|NCT01379703|9840981|FG002|9 Months Through 18 Months|Fatigue|0
6187207|NCT01379703|9840979|FG000|9 Months Through 18 Months|Reason Unknown|0
6187208|NCT01379703|9840980|FG001|9 Months Through 18 Months|Reason Unknown|23
6187209|NCT01379703|9840981|FG002|9 Months Through 18 Months|Reason Unknown|0
6187210|NCT01379768|9840993|FG000|Overall Study|Adverse Event|1
6187211|NCT01379768|9840994|FG001|Overall Study|Adverse Event|1
6187212|NCT01379768|9840995|FG002|Overall Study|Adverse Event|0
6187213|NCT01379768|9840993|FG000|Overall Study|Lost to Follow-up|2
6187214|NCT01379768|9840994|FG001|Overall Study|Lost to Follow-up|0
6232581|NCT01766817|9908989|FG001|Overall Study|Other|0
6232582|NCT01766817|9908990|FG002|Overall Study|Other|0
6232583|NCT01766921|9909000|FG000|Overall Study|Administrative Reason|5
6232584|NCT01766921|9909001|FG001|Overall Study|Administrative Reason|5
6232585|NCT01766921|9909000|FG000|Overall Study|Death|1
6232586|NCT01766921|9909001|FG001|Overall Study|Death|1
6232587|NCT01766921|9909000|FG000|Overall Study|Lost to Follow-up|1
6232588|NCT01766921|9909001|FG001|Overall Study|Lost to Follow-up|3
6232589|NCT01766921|9909000|FG000|Overall Study|Unclassified|2
6232590|NCT01766921|9909001|FG001|Overall Study|Unclassified|2
6232591|NCT01766921|9909000|FG000|Overall Study|Protocol Violation|1
6232592|NCT01766921|9909001|FG001|Overall Study|Protocol Violation|1
6232593|NCT01766921|9909000|FG000|Overall Study|Withdrawal by Subject|14
6232594|NCT01766921|9909001|FG001|Overall Study|Withdrawal by Subject|5
6232595|NCT01767116|9909046|FG000|Overall Study|Lost to Follow-up|2
6232596|NCT01767116|9909047|FG001|Overall Study|Lost to Follow-up|2
6232597|NCT01767142|9909053|FG000|Overall Study|Lost to Follow-up|3
6232598|NCT01767376|9909078|FG000|Overall Study|Lost to Follow-up|3
6232599|NCT01767376|9909079|FG001|Overall Study|Lost to Follow-up|2
6232600|NCT01767376|9909080|FG002|Overall Study|Lost to Follow-up|0
6232601|NCT01767376|9909078|FG000|Overall Study|Withdrawal by Subject|1
6232602|NCT01767376|9909079|FG001|Overall Study|Withdrawal by Subject|1
6232603|NCT01767376|9909080|FG002|Overall Study|Withdrawal by Subject|0
6232604|NCT01767467|9909096|FG000|Vaccination Phase (up to Month 2)|Adverse Event|8
6232605|NCT01767467|9909097|FG001|Vaccination Phase (up to Month 2)|Adverse Event|8
6232606|NCT01767467|9909096|FG000|Vaccination Phase (up to Month 2)|Protocol Violation|1
6232607|NCT01767467|9909097|FG001|Vaccination Phase (up to Month 2)|Protocol Violation|0
6232608|NCT01767467|9909096|FG000|Vaccination Phase (up to Month 2)|Withdrawal by Subject|7
6232609|NCT01767467|9909097|FG001|Vaccination Phase (up to Month 2)|Withdrawal by Subject|10
6232610|NCT01767467|9909096|FG000|Vaccination Phase (up to Month 2)|Suspected Herpes Zoster episode|0
6232611|NCT01767467|9909097|FG001|Vaccination Phase (up to Month 2)|Suspected Herpes Zoster episode|1
6232612|NCT01767467|9909096|FG000|Vaccination Phase (up to Month 2)|Physician Decision|1
6232613|NCT01767467|9909097|FG001|Vaccination Phase (up to Month 2)|Physician Decision|0
6232614|NCT01767467|9909096|FG000|Vaccination Phase (up to Month 2)|Subject unavailable|0
6232615|NCT01767467|9909097|FG001|Vaccination Phase (up to Month 2)|Subject unavailable|1
6232616|NCT01767467|9909096|FG000|End of Study Phase (up to Month 13)|Adverse Event|29
6232617|NCT01767467|9909097|FG001|End of Study Phase (up to Month 13)|Adverse Event|39
6232618|NCT01767467|9909096|FG000|End of Study Phase (up to Month 13)|Protocol Violation|2
6232619|NCT01767467|9909097|FG001|End of Study Phase (up to Month 13)|Protocol Violation|0
6232620|NCT01767467|9909096|FG000|End of Study Phase (up to Month 13)|Withdrawal by Subject|9
6232621|NCT01767467|9909097|FG001|End of Study Phase (up to Month 13)|Withdrawal by Subject|14
6232622|NCT01767467|9909096|FG000|End of Study Phase (up to Month 13)|Migrated/Moved from study area|0
6232623|NCT01767467|9909097|FG001|End of Study Phase (up to Month 13)|Migrated/Moved from study area|3
6232624|NCT01767467|9909096|FG000|End of Study Phase (up to Month 13)|Lost to Follow-up|6
6232625|NCT01767467|9909097|FG001|End of Study Phase (up to Month 13)|Lost to Follow-up|4
6232626|NCT01767467|9909096|FG000|End of Study Phase (up to Month 13)|Suspected Herpes Zoster episode|0
6232627|NCT01767467|9909097|FG001|End of Study Phase (up to Month 13)|Suspected Herpes Zoster episode|1
6232628|NCT01767467|9909096|FG000|End of Study Phase (up to Month 13)|Physician Decision|1
6232629|NCT01767467|9909097|FG001|End of Study Phase (up to Month 13)|Physician Decision|0
6232630|NCT01767467|9909096|FG000|End of Study Phase (up to Month 13)|Subject Unavailable|0
6232631|NCT01767467|9909097|FG001|End of Study Phase (up to Month 13)|Subject Unavailable|2
6232632|NCT01767493|9909110|FG000|Overall Study|screen failures|3
6232633|NCT01767519|9909126|FG000|Overall Study|Other Reasons|4
6232634|NCT01767519|9909127|FG001|Overall Study|Other Reasons|4
6232635|NCT01767519|9909128|FG002|Overall Study|Other Reasons|2
6232636|NCT01767519|9909126|FG000|Overall Study|Protocol Violation|0
6232637|NCT01767519|9909127|FG001|Overall Study|Protocol Violation|3
6232638|NCT01767519|9909128|FG002|Overall Study|Protocol Violation|0
6232639|NCT01767519|9909126|FG000|Overall Study|Personal Reasons|1
6232640|NCT01767519|9909127|FG001|Overall Study|Personal Reasons|0
6232641|NCT01767519|9909128|FG002|Overall Study|Personal Reasons|0
6232642|NCT01767519|9909126|FG000|Overall Study|Lost to Follow-up|3
6232643|NCT01767519|9909127|FG001|Overall Study|Lost to Follow-up|1
6232644|NCT01767519|9909128|FG002|Overall Study|Lost to Follow-up|2
6232645|NCT01767519|9909126|FG000|Overall Study|Lack of Efficacy|1
6232646|NCT01767519|9909127|FG001|Overall Study|Lack of Efficacy|0
6232647|NCT01767519|9909128|FG002|Overall Study|Lack of Efficacy|0
6232648|NCT01767519|9909126|FG000|Overall Study|Adverse Event|5
6232649|NCT01767519|9909127|FG001|Overall Study|Adverse Event|5
6232650|NCT01767519|9909128|FG002|Overall Study|Adverse Event|1
6232651|NCT01767597|9909138|FG000|Overall Study|Incomplete intervention|3
6232652|NCT01767597|9909139|FG001|Overall Study|Incomplete intervention|1
6232653|NCT01767597|9909138|FG000|Overall Study|Withdrawal by Subject|1
6232654|NCT01767597|9909139|FG001|Overall Study|Withdrawal by Subject|0
6232655|NCT01767857|9909170|FG000|Overall Study|Adverse Event|27
6232656|NCT01767857|9909171|FG001|Overall Study|Adverse Event|7
6232657|NCT01767857|9909170|FG000|Overall Study|Death|28
6232658|NCT01767857|9909171|FG001|Overall Study|Death|13
6232659|NCT01767857|9909170|FG000|Overall Study|Lack of Efficacy|299
6232660|NCT01767857|9909171|FG001|Overall Study|Lack of Efficacy|151
6232661|NCT01767857|9909170|FG000|Overall Study|Lost to Follow-up|1
6232662|NCT01767857|9909171|FG001|Overall Study|Lost to Follow-up|1
6232663|NCT01767857|9909170|FG000|Overall Study|Withdrawal by Subject|38
6232664|NCT01767857|9909171|FG001|Overall Study|Withdrawal by Subject|18
6232665|NCT01767857|9909170|FG000|Overall Study|Physician Decision|17
6232666|NCT01767857|9909171|FG001|Overall Study|Physician Decision|10
6232667|NCT01767857|9909170|FG000|Overall Study|Protocol Terminated|1
6232668|NCT01767857|9909171|FG001|Overall Study|Protocol Terminated|0
6232669|NCT01767857|9909170|FG000|Overall Study|Randomized But Never Treated|19
6232670|NCT01767857|9909171|FG001|Overall Study|Randomized But Never Treated|13
6232671|NCT01767909|9909180|FG000|Overall Study|Withdrawal by Subject|4
6232672|NCT01767909|9909181|FG001|Overall Study|Withdrawal by Subject|7
6232673|NCT01767909|9909180|FG000|Overall Study|Adverse Event|3
6232674|NCT01767909|9909181|FG001|Overall Study|Adverse Event|1
6232675|NCT01767909|9909180|FG000|Overall Study|Withdrawal by Study Partner|3
6232676|NCT01767909|9909181|FG001|Overall Study|Withdrawal by Study Partner|1
6232677|NCT01767909|9909180|FG000|Overall Study|Non-Compliance|2
6232678|NCT01767909|9909181|FG001|Overall Study|Non-Compliance|0
6375564|NCT02367456|10165759|FG001|Overall Study|Lost to Follow-up|3
6375565|NCT02367456|10165760|FG002|Overall Study|Lost to Follow-up|1
6375566|NCT02367456|10165758|FG000|Overall Study|Ongoing|0
6375567|NCT02367456|10165759|FG001|Overall Study|Ongoing|6
6375568|NCT02367456|10165760|FG002|Overall Study|Ongoing|15
6375569|NCT02367456|10165758|FG000|Overall Study|Other reason|3
6375570|NCT02367456|10165759|FG001|Overall Study|Other reason|0
6375571|NCT02367456|10165760|FG002|Overall Study|Other reason|0
6375572|NCT01275677|10165775|FG000|Overall Study|Not at risk for recurrence.|1
6375573|NCT01275677|10165776|FG001|Overall Study|Not at risk for recurrence.|1
6375574|NCT01275677|10165775|FG000|Overall Study|No follow-up|26
6375575|NCT01275677|10165776|FG001|Overall Study|No follow-up|37
6375576|NCT01275677|10165775|FG000|Overall Study|No clinical follow up.|1
6375577|NCT01275677|10165776|FG001|Overall Study|No clinical follow up.|4
6375578|NCT01103349|10165785|FG000|Overall Study|Adverse Event|8
6375579|NCT01103349|10165786|FG001|Overall Study|Adverse Event|5
6375580|NCT01103349|10165787|FG002|Overall Study|Adverse Event|3
6375581|NCT01103349|10165785|FG000|Overall Study|Consent withdrawn|1
6375582|NCT01103349|10165786|FG001|Overall Study|Consent withdrawn|0
6375583|NCT01103349|10165787|FG002|Overall Study|Consent withdrawn|0
6375584|NCT01103349|10165785|FG000|Overall Study|Incorrectly included in the trial|1
6375585|NCT01103349|10165786|FG001|Overall Study|Incorrectly included in the trial|0
6375586|NCT01103349|10165787|FG002|Overall Study|Incorrectly included in the trial|0
6375587|NCT01103349|10165785|FG000|Overall Study|Withdrawal by Subject|1
6375588|NCT01103349|10165786|FG001|Overall Study|Withdrawal by Subject|1
6375589|NCT01103349|10165787|FG002|Overall Study|Withdrawal by Subject|0
6375590|NCT01103349|10165785|FG000|Overall Study|did not want to take trial medication|0
6375591|NCT01103349|10165786|FG001|Overall Study|did not want to take trial medication|1
6375592|NCT01103349|10165787|FG002|Overall Study|did not want to take trial medication|0
6375593|NCT01103349|10165785|FG000|Overall Study|forgot to take medication|0
6375594|NCT01103349|10165786|FG001|Overall Study|forgot to take medication|0
6375595|NCT01103349|10165787|FG002|Overall Study|forgot to take medication|1
6375596|NCT01092143|10165800|FG000|Overall Study|Adverse Event|10
6375597|NCT01092143|10165801|FG001|Overall Study|Adverse Event|5
6375598|NCT01092143|10165802|FG002|Overall Study|Adverse Event|1
6375599|NCT01092143|10165803|FG003|Overall Study|Adverse Event|4
6375600|NCT01092143|10165804|FG004|Overall Study|Adverse Event|3
6375601|NCT01092143|10165800|FG000|Overall Study|Lost to Follow-up|1
6375602|NCT01092143|10165801|FG001|Overall Study|Lost to Follow-up|0
6375603|NCT01092143|10165802|FG002|Overall Study|Lost to Follow-up|1
6187215|NCT01379768|9840995|FG002|Overall Study|Lost to Follow-up|0
6187216|NCT01379937|9841019|FG000|Overall Study|Protocol Violation|0
6187217|NCT01379937|9841020|FG001|Overall Study|Protocol Violation|0
6187218|NCT01379937|9841021|FG002|Overall Study|Protocol Violation|0
6187219|NCT01379937|9841022|FG003|Overall Study|Protocol Violation|1
6187220|NCT01379937|9841019|FG000|Overall Study|Consent withdrawal|0
6187221|NCT01379937|9841020|FG001|Overall Study|Consent withdrawal|1
6187222|NCT01379937|9841021|FG002|Overall Study|Consent withdrawal|0
6187223|NCT01379937|9841022|FG003|Overall Study|Consent withdrawal|0
6232679|NCT01767909|9909180|FG000|Overall Study|Perceived Lack of Efficacy|1
6232680|NCT01767909|9909181|FG001|Overall Study|Perceived Lack of Efficacy|0
6232681|NCT01767909|9909180|FG000|Overall Study|Investigator Recommendation|0
6232682|NCT01767909|9909181|FG001|Overall Study|Investigator Recommendation|1
6232683|NCT01767909|9909180|FG000|Overall Study|Lost to Follow-up|0
6232684|NCT01767909|9909181|FG001|Overall Study|Lost to Follow-up|1
6232685|NCT01767909|9909180|FG000|Overall Study|LP uncessessful|0
6232686|NCT01767909|9909181|FG001|Overall Study|LP uncessessful|1
6232687|NCT01767987|9909195|FG000|Overall Study|Physician Decision|4
6232688|NCT01767987|9909196|FG001|Overall Study|Physician Decision|1
6232689|NCT01768117|9909225|FG000|Overall Study|Lost to Follow-up|1
6232690|NCT01768117|9909225|FG000|Overall Study|Withdrawal by Subject|2
6232691|NCT01768117|9909225|FG000|Overall Study|Protocol Violation|3
6232692|NCT01768286|9909233|FG000|Overall Study|Randomized But Not Treated|0
6232693|NCT01768286|9909234|FG001|Overall Study|Randomized But Not Treated|0
6232694|NCT01768286|9909235|FG002|Overall Study|Randomized But Not Treated|1
6232695|NCT01768286|9909236|FG003|Overall Study|Randomized But Not Treated|0
6375604|NCT01092143|10165803|FG003|Overall Study|Lost to Follow-up|0
6187224|NCT01379937|9841019|FG000|Overall Study|Lost to Follow-up|1
6187225|NCT01379937|9841020|FG001|Overall Study|Lost to Follow-up|2
6187226|NCT01379937|9841021|FG002|Overall Study|Lost to Follow-up|2
6375605|NCT01092143|10165804|FG004|Overall Study|Lost to Follow-up|0
6375606|NCT01092143|10165800|FG000|Overall Study|Consent withdrawn|2
6375607|NCT01092143|10165801|FG001|Overall Study|Consent withdrawn|1
6375608|NCT01092143|10165802|FG002|Overall Study|Consent withdrawn|0
6375609|NCT01092143|10165803|FG003|Overall Study|Consent withdrawn|1
6187227|NCT01379937|9841022|FG003|Overall Study|Lost to Follow-up|0
6232696|NCT01768286|9909233|FG000|Overall Study|Lack of Efficacy|7
6232697|NCT01768286|9909234|FG001|Overall Study|Lack of Efficacy|4
6232698|NCT01768286|9909235|FG002|Overall Study|Lack of Efficacy|0
6232699|NCT01768286|9909236|FG003|Overall Study|Lack of Efficacy|1
6232700|NCT01768286|9909233|FG000|Overall Study|Withdrew Consent|0
6232701|NCT01768286|9909234|FG001|Overall Study|Withdrew Consent|0
6232702|NCT01768286|9909235|FG002|Overall Study|Withdrew Consent|1
6232703|NCT01768286|9909236|FG003|Overall Study|Withdrew Consent|0
6232704|NCT01768559|9909273|FG000|Overall Study|Randomized but not treated|0
6232705|NCT01768559|9909274|FG001|Overall Study|Randomized but not treated|0
6232706|NCT01768559|9909275|FG002|Overall Study|Randomized but not treated|1
6232707|NCT01768559|9909273|FG000|Overall Study|Adverse Event|15
6232708|NCT01768559|9909274|FG001|Overall Study|Adverse Event|2
6232709|NCT01768559|9909275|FG002|Overall Study|Adverse Event|5
6232710|NCT01768559|9909273|FG000|Overall Study|Lack of Efficacy|6
6232711|NCT01768559|9909274|FG001|Overall Study|Lack of Efficacy|4
6232712|NCT01768559|9909275|FG002|Overall Study|Lack of Efficacy|0
6232713|NCT01768559|9909273|FG000|Overall Study|Poor compliance to protocol|0
6232714|NCT01768559|9909274|FG001|Overall Study|Poor compliance to protocol|3
6232715|NCT01768559|9909275|FG002|Overall Study|Poor compliance to protocol|2
6232716|NCT01768559|9909273|FG000|Overall Study|Other than specified|9
6232717|NCT01768559|9909274|FG001|Overall Study|Other than specified|8
6232718|NCT01768559|9909275|FG002|Overall Study|Other than specified|5
6232719|NCT01768572|9909290|FG000|Overall Study|Adverse Event|7
6232720|NCT01768572|9909291|FG001|Overall Study|Adverse Event|8
6232721|NCT01768572|9909292|FG002|Overall Study|Adverse Event|4
6232722|NCT01768572|9909290|FG000|Overall Study|Lack of Efficacy|1
6232723|NCT01768572|9909291|FG001|Overall Study|Lack of Efficacy|3
6232724|NCT01768572|9909292|FG002|Overall Study|Lack of Efficacy|1
6232725|NCT01768572|9909290|FG000|Overall Study|Other, Not due to an adverse event|1
6232726|NCT01768572|9909291|FG001|Overall Study|Other, Not due to an adverse event|1
6232727|NCT01768572|9909292|FG002|Overall Study|Other, Not due to an adverse event|1
6232728|NCT01768637|9909302|FG000|Overall Study|Lost to Follow-up|2
6232729|NCT01768637|9909303|FG001|Overall Study|Lost to Follow-up|7
6232730|NCT01768637|9909302|FG000|Overall Study|Difficult blood draw|1
6232731|NCT01768637|9909303|FG001|Overall Study|Difficult blood draw|0
6232732|NCT01768676|9909311|FG000|Overall Study|Adverse Event|3
6232733|NCT01768676|9909312|FG001|Overall Study|Adverse Event|3
6232734|NCT01768676|9909311|FG000|Overall Study|Lost to Follow-up|13
6232735|NCT01768676|9909312|FG001|Overall Study|Lost to Follow-up|16
6232736|NCT01768676|9909311|FG000|Overall Study|Protocol Violation|1
6232737|NCT01768676|9909312|FG001|Overall Study|Protocol Violation|1
6232738|NCT01768676|9909311|FG000|Overall Study|Physician Decision|4
6232739|NCT01768676|9909312|FG001|Overall Study|Physician Decision|1
6232740|NCT01768676|9909311|FG000|Overall Study|Withdrawal by Subject|3
6232741|NCT01768676|9909312|FG001|Overall Study|Withdrawal by Subject|10
6232742|NCT01768858|9909335|FG000|Overall Study|Lost to Follow-up|9
6232743|NCT01768858|9909335|FG000|Overall Study|Lack of Efficacy|8
6232744|NCT01768858|9909335|FG000|Overall Study|Serious Adverse Event|1
6232745|NCT01768858|9909335|FG000|Overall Study|Participant moved to Germany|1
6232746|NCT01768858|9909335|FG000|Overall Study|Aggravation of NY Heart Assoc 3 status|1
6232747|NCT01768858|9909335|FG000|Overall Study|Exanthema|1
6232748|NCT01768858|9909335|FG000|Overall Study|Withdrawal by Subject|1
6232749|NCT01769105|9909341|FG000|First Intervention|Protocol Violation|2
6232750|NCT01769105|9909342|FG001|First Intervention|Protocol Violation|2
6232751|NCT01769105|9909341|FG000|Cross-over|Lost to Follow-up|5
6232752|NCT01769105|9909342|FG001|Cross-over|Lost to Follow-up|0
6232753|NCT01769196|9909361|FG000|Overall Study|Adverse Event|24
6232754|NCT01769196|9909362|FG001|Overall Study|Adverse Event|20
6232755|NCT01769196|9909361|FG000|Overall Study|Death|21
6232756|NCT01769196|9909362|FG001|Overall Study|Death|26
6232757|NCT01769196|9909361|FG000|Overall Study|Investigator Discretion|7
6232758|NCT01769196|9909362|FG001|Overall Study|Investigator Discretion|3
6232759|NCT01769196|9909361|FG000|Overall Study|Lack of Efficacy|3
6232760|NCT01769196|9909362|FG001|Overall Study|Lack of Efficacy|2
6232761|NCT01769196|9909361|FG000|Overall Study|Progressive disease|11
6232762|NCT01769196|9909362|FG001|Overall Study|Progressive disease|6
6232763|NCT01769196|9909361|FG000|Overall Study|Protocol defined criteria for withdrawal|9
6232764|NCT01769196|9909362|FG001|Overall Study|Protocol defined criteria for withdrawal|11
6232765|NCT01769196|9909361|FG000|Overall Study|Protocol Violation|0
6232766|NCT01769196|9909362|FG001|Overall Study|Protocol Violation|3
6232767|NCT01769196|9909361|FG000|Overall Study|Study terminated by sponsor|160
6232768|NCT01769196|9909362|FG001|Overall Study|Study terminated by sponsor|161
6232769|NCT01769196|9909361|FG000|Overall Study|Participant never dosed with study drug|1
6232770|NCT01769196|9909362|FG001|Overall Study|Participant never dosed with study drug|0
6232771|NCT01769196|9909361|FG000|Overall Study|Withdrew consent|36
6232772|NCT01769196|9909362|FG001|Overall Study|Withdrew consent|40
6232773|NCT01769326|9909409|FG000|Overall Study|Lost to Follow-up|1
6232774|NCT01769326|9909410|FG001|Overall Study|Lost to Follow-up|2
6232775|NCT01769326|9909411|FG002|Overall Study|Lost to Follow-up|0
6232776|NCT01769326|9909412|FG003|Overall Study|Lost to Follow-up|0
6232777|NCT01769326|9909409|FG000|Overall Study|unrelated injry|1
6232778|NCT01769326|9909410|FG001|Overall Study|unrelated injry|1
6232779|NCT01769326|9909411|FG002|Overall Study|unrelated injry|0
6232780|NCT01769326|9909412|FG003|Overall Study|unrelated injry|0
6232781|NCT01769326|9909409|FG000|Overall Study|got a job|0
6232782|NCT01769326|9909410|FG001|Overall Study|got a job|1
6232783|NCT01769326|9909411|FG002|Overall Study|got a job|0
6232784|NCT01769326|9909412|FG003|Overall Study|got a job|0
6232785|NCT01769326|9909409|FG000|Overall Study|Got sick and could not complete study|0
6232786|NCT01769326|9909410|FG001|Overall Study|Got sick and could not complete study|0
6232787|NCT01769326|9909411|FG002|Overall Study|Got sick and could not complete study|1
6232788|NCT01769326|9909412|FG003|Overall Study|Got sick and could not complete study|0
6232789|NCT01769339|9909422|FG000|Overall Study|Lost to Follow-up|42
6232790|NCT01769339|9909422|FG000|Overall Study|Adverse Event|1
6232791|NCT01769378|9909459|FG000|Overall Study|Adverse Event|10
6232792|NCT01769378|9909460|FG001|Overall Study|Adverse Event|0
6232793|NCT01769378|9909459|FG000|Overall Study|Entry criteria not met|1
6232794|NCT01769378|9909460|FG001|Overall Study|Entry criteria not met|0
6232795|NCT01769378|9909459|FG000|Overall Study|Protocol Violation|1
6232796|NCT01769378|9909460|FG001|Overall Study|Protocol Violation|1
6232797|NCT01769378|9909459|FG000|Overall Study|Withdrawal by Subject|10
6232798|NCT01769378|9909460|FG001|Overall Study|Withdrawal by Subject|3
6232799|NCT01769378|9909459|FG000|Overall Study|Sponsor Decision|1
6232800|NCT01769378|9909460|FG001|Overall Study|Sponsor Decision|0
6232801|NCT01769378|9909459|FG000|Overall Study|Lost to Follow-up|2
6232802|NCT01769378|9909460|FG001|Overall Study|Lost to Follow-up|0
6232803|NCT01769391|9909468|FG000|Overall Study|Death|10
6232804|NCT01769391|9909469|FG001|Overall Study|Death|1
6232805|NCT01769391|9909468|FG000|Overall Study|Adverse Event|0
6232806|NCT01769391|9909469|FG001|Overall Study|Adverse Event|3
6232807|NCT01769391|9909468|FG000|Overall Study|Progressive Disease|1
6232808|NCT01769391|9909469|FG001|Overall Study|Progressive Disease|2
6232809|NCT01769391|9909468|FG000|Overall Study|Withdrawal by Subject|4
6232810|NCT01769391|9909469|FG001|Overall Study|Withdrawal by Subject|3
6232811|NCT01769391|9909468|FG000|Overall Study|Investigator Decision|2
6232812|NCT01769391|9909469|FG001|Overall Study|Investigator Decision|0
6232813|NCT01769404|9909481|FG000|Treatment Period 1|Did not meet eligibility criteria|1
6232814|NCT01769404|9909482|FG001|Treatment Period 1|Did not meet eligibility criteria|0
6232815|NCT01769404|9909481|FG000|Treatment Period 1|Withdrawal by Subject|3
6232816|NCT01769404|9909482|FG001|Treatment Period 1|Withdrawal by Subject|0
6232817|NCT01769404|9909481|FG000|Treatment Period 1|Sponsor decision|1
6232818|NCT01769404|9909482|FG001|Treatment Period 1|Sponsor decision|0
6232819|NCT01769404|9909481|FG000|Treatment Period 2|Sponsor decision|7
6232820|NCT01769404|9909482|FG001|Treatment Period 2|Sponsor decision|0
6232821|NCT01769456|9909490|FG000|Overall Study|Lost to Follow-up|19
6232822|NCT01769456|9909490|FG000|Overall Study|Withdrawal by Subject|3
6232823|NCT01769456|9909490|FG000|Overall Study|Did not receive PCC intervention|6
6232824|NCT01769456|9909490|FG000|Overall Study|Moved out of the area|3
6232825|NCT01769456|9909490|FG000|Overall Study|No wk 0 visit w/in 30 days of screening|5
6232826|NCT01769456|9909490|FG000|Overall Study|Parental request to youth to withdraw|1
6232827|NCT01769469|9909495|FG000|Overall Study|Consent Withdrawn|5
6232828|NCT01769469|9909495|FG000|Overall Study|Moved Out Of Area|3
6232829|NCT01769469|9909495|FG000|Overall Study|Lost to Follow-up|17
6232830|NCT01769469|9909495|FG000|Overall Study|Prem D/C from ATN 110/113 For Any Reason|7
6232831|NCT01769469|9909495|FG000|Overall Study|Subject Confirmed HIV Positive|3
6232832|NCT01769508|9909501|FG000|Overall Study|Death|3
6232833|NCT01769508|9909501|FG000|Overall Study|Withdrawal by Subject|1
6232834|NCT01769508|9909501|FG000|Overall Study|Adverse Event|1
6232835|NCT01769508|9909501|FG000|Overall Study|Lost to Follow-up|1
6232836|NCT01770145|9909541|FG000|Baseline|Adverse Event|20
6232837|NCT01770145|9909541|FG000|Baseline|Withdrawal by Subject|1
6232838|NCT01770145|9909541|FG000|Baseline|Lost to Follow-up|1
6232839|NCT01770145|9909541|FG000|Baseline|Unable to define optimal dose|4
6232840|NCT01770145|9909541|FG000|Treatment|Adverse Event|3
6232841|NCT01770145|9909541|FG000|Treatment|Withdrawal by Subject|1
6232842|NCT01770353|9909556|FG000|Overall Study|Progressive disease|2
6232843|NCT01770353|9909557|FG001|Overall Study|Progressive disease|1
6232844|NCT01770353|9909556|FG000|Overall Study|Adverse Event|0
6232845|NCT01770353|9909557|FG001|Overall Study|Adverse Event|1
6232846|NCT01770353|9909556|FG000|Overall Study|Protocol Violation|1
6232847|NCT01770353|9909557|FG001|Overall Study|Protocol Violation|0
6232848|NCT01770353|9909556|FG000|Overall Study|Physician Decision|0
6232849|NCT01770353|9909557|FG001|Overall Study|Physician Decision|3
6232850|NCT01770353|9909556|FG000|Overall Study|Clinical deterioration|3
6232851|NCT01770353|9909557|FG001|Overall Study|Clinical deterioration|6
6232852|NCT01770353|9909556|FG000|Overall Study|Toxicity related diarrhoea + progression|0
6232853|NCT01770353|9909557|FG001|Overall Study|Toxicity related diarrhoea + progression|1
6232854|NCT01770379|9909583|FG000|Overall Study|Technical issues|1
6232855|NCT01770379|9909584|FG001|Overall Study|Technical issues|0
6232856|NCT01770379|9909585|FG002|Overall Study|Technical issues|0
6232857|NCT01770379|9909583|FG000|Overall Study|Withdrawal by Subject|7
6232858|NCT01770379|9909584|FG001|Overall Study|Withdrawal by Subject|10
6232859|NCT01770379|9909585|FG002|Overall Study|Withdrawal by Subject|7
6232860|NCT01770379|9909583|FG000|Overall Study|study terminated by sponsor|22
6232861|NCT01770379|9909584|FG001|Overall Study|study terminated by sponsor|23
6232862|NCT01770379|9909585|FG002|Overall Study|study terminated by sponsor|22
6232863|NCT01770379|9909583|FG000|Overall Study|Protocol Violation|0
6232864|NCT01770379|9909584|FG001|Overall Study|Protocol Violation|1
6232865|NCT01770379|9909585|FG002|Overall Study|Protocol Violation|1
6232866|NCT01770379|9909583|FG000|Overall Study|Physician Decision|0
6232867|NCT01770379|9909584|FG001|Overall Study|Physician Decision|1
6232868|NCT01770379|9909585|FG002|Overall Study|Physician Decision|2
6232869|NCT01770379|9909583|FG000|Overall Study|Lost to Follow-up|0
6232870|NCT01770379|9909584|FG001|Overall Study|Lost to Follow-up|0
6232871|NCT01770379|9909585|FG002|Overall Study|Lost to Follow-up|2
6232872|NCT01770379|9909583|FG000|Overall Study|Lack of Efficacy|8
6232873|NCT01770379|9909584|FG001|Overall Study|Lack of Efficacy|6
6232874|NCT01770379|9909585|FG002|Overall Study|Lack of Efficacy|6
6232875|NCT01770379|9909583|FG000|Overall Study|Adverse Event|1
6232876|NCT01770379|9909584|FG001|Overall Study|Adverse Event|3
6232877|NCT01770379|9909585|FG002|Overall Study|Adverse Event|2
6232878|NCT01770392|9909595|FG000|Washout Period of at Least 14 Days|Adverse Event|1
6232879|NCT01770509|9909626|FG000|Overall Study|Injury|0
6232880|NCT01770509|9909627|FG001|Overall Study|Injury|1
6232881|NCT01770509|9909626|FG000|Overall Study|Lost to Follow-up|1
6232882|NCT01770509|9909627|FG001|Overall Study|Lost to Follow-up|2
6232883|NCT01770743|9909666|FG000|Overall Study|Adverse Event|1
6232884|NCT01770743|9909667|FG001|Overall Study|Adverse Event|0
6232885|NCT01770743|9909668|FG002|Overall Study|Adverse Event|0
6232886|NCT01770743|9909669|FG003|Overall Study|Adverse Event|0
6232887|NCT01770743|9909670|FG004|Overall Study|Adverse Event|0
6232888|NCT01770743|9909666|FG000|Overall Study|Withdrawal by Subject|0
6232889|NCT01770743|9909667|FG001|Overall Study|Withdrawal by Subject|0
6232890|NCT01770743|9909668|FG002|Overall Study|Withdrawal by Subject|1
6232891|NCT01770743|9909669|FG003|Overall Study|Withdrawal by Subject|1
6232892|NCT01770743|9909670|FG004|Overall Study|Withdrawal by Subject|1
6232893|NCT01770743|9909666|FG000|Overall Study|Lost to Follow-up|0
6232894|NCT01770743|9909667|FG001|Overall Study|Lost to Follow-up|2
6232895|NCT01770743|9909668|FG002|Overall Study|Lost to Follow-up|0
6232896|NCT01770743|9909669|FG003|Overall Study|Lost to Follow-up|0
6232897|NCT01770743|9909670|FG004|Overall Study|Lost to Follow-up|1
6232898|NCT01770743|9909666|FG000|Overall Study|Sponsor Terminated Subject|1
6232899|NCT01770743|9909667|FG001|Overall Study|Sponsor Terminated Subject|0
6232900|NCT01770743|9909668|FG002|Overall Study|Sponsor Terminated Subject|0
6232901|NCT01770743|9909669|FG003|Overall Study|Sponsor Terminated Subject|1
6232902|NCT01770743|9909670|FG004|Overall Study|Sponsor Terminated Subject|0
6232903|NCT01770743|9909666|FG000|Overall Study|Moving Out of State|0
6232904|NCT01770743|9909667|FG001|Overall Study|Moving Out of State|1
6232905|NCT01770743|9909668|FG002|Overall Study|Moving Out of State|0
6232906|NCT01770743|9909669|FG003|Overall Study|Moving Out of State|0
6232907|NCT01770743|9909670|FG004|Overall Study|Moving Out of State|0
6232908|NCT01770860|9909682|FG000|Overall Study|Withdrawal by Subject|4
6232909|NCT01770860|9909682|FG000|Overall Study|Lost to Follow-up|1
6232910|NCT01770860|9909682|FG000|Overall Study|Administrative decision made by the PI|1
6232911|NCT01770912|9909692|FG000|Overall Study|Lost to Follow-up|2
6232912|NCT01770912|9909693|FG001|Overall Study|Lost to Follow-up|0
6232913|NCT01771250|9909712|FG000|Period 1|Met exclusion criteria|1
6232914|NCT01771250|9909713|FG001|Period 1|Met exclusion criteria|0
6232915|NCT01771731|9909734|FG000|Overall Study|Physician Decision|1
6232916|NCT01771731|9909735|FG001|Overall Study|Physician Decision|0
6232917|NCT01771731|9909734|FG000|Overall Study|Protocol Violation|0
6232918|NCT01771731|9909735|FG001|Overall Study|Protocol Violation|1
6232919|NCT01771731|9909734|FG000|Overall Study|Adverse event: Pain Crisis|1
6232920|NCT01771731|9909735|FG001|Overall Study|Adverse event: Pain Crisis|1
6232921|NCT01771809|9909743|FG000|Overall Study|Adverse Event|4
6232922|NCT01771809|9909744|FG001|Overall Study|Adverse Event|12
6232923|NCT01771809|9909743|FG000|Overall Study|Protocol Violation|0
6232924|NCT01771809|9909744|FG001|Overall Study|Protocol Violation|1
6232925|NCT01771809|9909743|FG000|Overall Study|Withdrawal by Subject|34
6232926|NCT01771809|9909744|FG001|Overall Study|Withdrawal by Subject|42
6232927|NCT01771809|9909743|FG000|Overall Study|Lost to Follow-up|1
6232928|NCT01771809|9909744|FG001|Overall Study|Lost to Follow-up|3
6232929|NCT01771809|9909743|FG000|Overall Study|Other (Insufficient clinical response)|22
6232930|NCT01771809|9909744|FG001|Overall Study|Other (Insufficient clinical response)|20
6232931|NCT01771809|9909743|FG000|Overall Study|Death|1
6232932|NCT01771809|9909744|FG001|Overall Study|Death|0
6232933|NCT01771809|9909743|FG000|Overall Study|Other (other)|9
6232934|NCT01771809|9909744|FG001|Overall Study|Other (other)|5
6232935|NCT01771913|9909752|FG000|Overall Study|Withdrawal by Subject|1
6232936|NCT01771913|9909753|FG001|Overall Study|Withdrawal by Subject|0
6232937|NCT01772134|9909790|FG000|Overall Study|Adverse Event|6
6232938|NCT01772134|9909791|FG001|Overall Study|Adverse Event|5
6232939|NCT01772134|9909792|FG002|Overall Study|Adverse Event|10
6232940|NCT01772134|9909790|FG000|Overall Study|Withdrew Consent|3
6232941|NCT01772134|9909791|FG001|Overall Study|Withdrew Consent|1
6232942|NCT01772134|9909792|FG002|Overall Study|Withdrew Consent|5
6232943|NCT01772134|9909790|FG000|Overall Study|Lost to Follow-up|2
6232944|NCT01772134|9909791|FG001|Overall Study|Lost to Follow-up|0
6232945|NCT01772134|9909792|FG002|Overall Study|Lost to Follow-up|0
6232946|NCT01772134|9909790|FG000|Overall Study|Protocol Deviation|4
6232947|NCT01772134|9909791|FG001|Overall Study|Protocol Deviation|3
6232948|NCT01772134|9909792|FG002|Overall Study|Protocol Deviation|3
6232949|NCT01772134|9909790|FG000|Overall Study|Lack of Efficacy|11
6232950|NCT01772134|9909791|FG001|Overall Study|Lack of Efficacy|5
6232951|NCT01772134|9909792|FG002|Overall Study|Lack of Efficacy|3
6232952|NCT01772134|9909790|FG000|Overall Study|Protocol-defined Stopping Criteria|1
6232953|NCT01772134|9909791|FG001|Overall Study|Protocol-defined Stopping Criteria|0
6232954|NCT01772134|9909792|FG002|Overall Study|Protocol-defined Stopping Criteria|0
6232955|NCT01772134|9909790|FG000|Overall Study|Randomized Study Medication Not Received|2
6232956|NCT01772134|9909791|FG001|Overall Study|Randomized Study Medication Not Received|0
6232957|NCT01772134|9909792|FG002|Overall Study|Randomized Study Medication Not Received|1
6232958|NCT01772147|9909803|FG000|Overall Study|Adverse Event|13
6232959|NCT01772147|9909804|FG001|Overall Study|Adverse Event|10
6232960|NCT01772147|9909805|FG002|Overall Study|Adverse Event|6
6232961|NCT01772147|9909803|FG000|Overall Study|Withdrew Consent|7
6232962|NCT01772147|9909804|FG001|Overall Study|Withdrew Consent|8
6232963|NCT01772147|9909805|FG002|Overall Study|Withdrew Consent|4
6232964|NCT01772147|9909803|FG000|Overall Study|Lost to Follow-up|1
6232965|NCT01772147|9909804|FG001|Overall Study|Lost to Follow-up|0
6232966|NCT01772147|9909805|FG002|Overall Study|Lost to Follow-up|1
6232967|NCT01772147|9909803|FG000|Overall Study|Protocol Deviation|2
6232968|NCT01772147|9909804|FG001|Overall Study|Protocol Deviation|1
6232969|NCT01772147|9909805|FG002|Overall Study|Protocol Deviation|1
6232970|NCT01772147|9909803|FG000|Overall Study|Lack of Efficacy|8
6232971|NCT01772147|9909804|FG001|Overall Study|Lack of Efficacy|6
6232972|NCT01772147|9909805|FG002|Overall Study|Lack of Efficacy|6
6232973|NCT01772160|9909813|FG000|Overall Study|Death|3
6232974|NCT01772160|9909813|FG000|Overall Study|Eligibility criteria not fulfilled|3
6232975|NCT01772160|9909813|FG000|Overall Study|Consent withdrawal|3
6232976|NCT01772160|9909813|FG000|Overall Study|Migrated / moved from the study area|4
6232977|NCT01772160|9909813|FG000|Overall Study|Lost to Follow-up|30
6232978|NCT01772160|9909813|FG000|Overall Study|Other|5
6232979|NCT01772316|9909817|FG000|Overall Study|Serious adverse event|1
6232980|NCT01772316|9909817|FG000|Overall Study|Inform consent withdrawn|1
6232981|NCT01772316|9909817|FG000|Overall Study|Withdrawn by sponsor decision|5
6232982|NCT01772368|9909821|FG000|Overall Study|Adverse Event|1
6232983|NCT01772368|9909821|FG000|Overall Study|Withdrawal by Subject|3
6232984|NCT01772368|9909821|FG000|Overall Study|Protocol Violation|2
6232985|NCT01772368|9909821|FG000|Overall Study|Other|1
6232986|NCT01772537|9909840|FG000|Overall Study|unsuccessful lumbar drain placement|1
6232987|NCT01772537|9909841|FG001|Overall Study|unsuccessful lumbar drain placement|0
6232988|NCT01772537|9909842|FG002|Overall Study|unsuccessful lumbar drain placement|0
6269868|NCT02145182|9970402|FG001|Overall Study|Adverse Event|1
6269869|NCT02145182|9970401|FG000|Overall Study|Death|7
6269870|NCT02145182|9970402|FG001|Overall Study|Death|7
6269871|NCT02145182|9970401|FG000|Overall Study|Lost to Follow-up|2
6269872|NCT02145182|9970402|FG001|Overall Study|Lost to Follow-up|2
6269873|NCT02145182|9970401|FG000|Overall Study|Pre-transplant Withdrawal|0
6269874|NCT02145182|9970402|FG001|Overall Study|Pre-transplant Withdrawal|2
6269875|NCT02145182|9970401|FG000|Overall Study|Withdrawal by Subject|5
6269876|NCT02145182|9970402|FG001|Overall Study|Withdrawal by Subject|4
6269877|NCT02145429|9970428|FG000|Overall Study|Death|4
6269878|NCT02145429|9970429|FG001|Overall Study|Death|5
6269879|NCT02145429|9970428|FG000|Overall Study|Lost to Follow-up|4
6269880|NCT02145429|9970429|FG001|Overall Study|Lost to Follow-up|3
6269881|NCT02145429|9970428|FG000|Overall Study|Withdrawal by Subject|8
6269882|NCT02145429|9970429|FG001|Overall Study|Withdrawal by Subject|3
6269883|NCT02145468|9970437|FG000|Overall Study|Withdrawal by Subject|5
6269884|NCT02145468|9970438|FG001|Overall Study|Withdrawal by Subject|8
6269885|NCT02146105|9970470|FG000|Overall Study|Adverse Event|1
6269886|NCT02146105|9970470|FG000|Overall Study|Withdrawal by Subject|5
6269887|NCT02146131|9970476|FG000|Overall Study|Physician Decision|61
6269888|NCT02146131|9970477|FG001|Overall Study|Physician Decision|56
6269889|NCT02146248|9970483|FG000|Overall Study|Withdrawal by Subject|2
6271853|NCT02168478|9973880|FG000|Overall Study|Did Not Consent to Participation|2
6271854|NCT02168478|9973880|FG000|Overall Study|Did Not Meet Exclusionary Criteria|1
6271855|NCT02168491|9973884|FG000|Overall Study|Withdrawal by Subject|1
6271856|NCT02168777|9973907|FG000|Overall Study|Withdrawal by Subject|1
6271857|NCT02168777|9973908|FG001|Overall Study|Withdrawal by Subject|0
6271858|NCT02168777|9973909|FG002|Overall Study|Withdrawal by Subject|2
6271859|NCT02168777|9973907|FG000|Overall Study|Adverse Event|1
6271860|NCT02168777|9973908|FG001|Overall Study|Adverse Event|0
6271861|NCT02168777|9973909|FG002|Overall Study|Adverse Event|1
6271862|NCT02168777|9973907|FG000|Overall Study|Disease recurrence|0
6271863|NCT02168777|9973908|FG001|Overall Study|Disease recurrence|0
6271864|NCT02168777|9973909|FG002|Overall Study|Disease recurrence|1
6271865|NCT02168777|9973907|FG000|Overall Study|Radiological disease progression|0
6271866|NCT02168777|9973908|FG001|Overall Study|Radiological disease progression|5
6271867|NCT02168777|9973909|FG002|Overall Study|Radiological disease progression|5
6271868|NCT02168777|9973907|FG000|Overall Study|Clinical disease progression|0
6271869|NCT02168777|9973908|FG001|Overall Study|Clinical disease progression|1
6271870|NCT02168777|9973909|FG002|Overall Study|Clinical disease progression|2
6232989|NCT01772550|9909855|FG000|Overall Study|Unable to insert IV in antecubital vein|1
6232990|NCT01772550|9909856|FG001|Overall Study|Unable to insert IV in antecubital vein|1
6232991|NCT01772550|9909857|FG002|Overall Study|Unable to insert IV in antecubital vein|5
6232992|NCT01772550|9909855|FG000|Overall Study|Adverse Event|0
6232993|NCT01772550|9909856|FG001|Overall Study|Adverse Event|0
6232994|NCT01772550|9909857|FG002|Overall Study|Adverse Event|1
6232995|NCT01772576|9909865|FG000|Overall Study|Death|15
6232996|NCT01772576|9909865|FG000|Overall Study|Protocol Violation|1
6232997|NCT01772576|9909865|FG000|Overall Study|Lost to Follow-up|3
6232998|NCT01772576|9909865|FG000|Overall Study|Study device not used|3
6232999|NCT01772576|9909865|FG000|Overall Study|Adverse Event|6
6233000|NCT01772576|9909865|FG000|Overall Study|Withdrawal by Subject|6
6233001|NCT01772693|9909880|FG000|Overall Study|Health Concerns Unrelated to Study|2
6233002|NCT01772693|9909881|FG001|Overall Study|Health Concerns Unrelated to Study|1
6233003|NCT01772693|9909880|FG000|Overall Study|Withdrawal by Subject|2
6233004|NCT01772693|9909881|FG001|Overall Study|Withdrawal by Subject|0
6233005|NCT01772693|9909880|FG000|Overall Study|Alternative Treatment|2
6233006|NCT01772693|9909881|FG001|Overall Study|Alternative Treatment|0
6233007|NCT01772823|9909906|FG000|Behavioral Intervention (BL -3MV or PCC)|Lost to Follow-up|1
6187228|NCT01380080|9841043|FG000|Overall Study|Death|36
6187229|NCT01380080|9841044|FG001|Overall Study|Death|44
6187230|NCT01380080|9841043|FG000|Overall Study|Site is closing|28
6187231|NCT01380080|9841044|FG001|Overall Study|Site is closing|31
6187232|NCT01380080|9841043|FG000|Overall Study|Not able to get to clinic|7
6187233|NCT01380080|9841044|FG001|Overall Study|Not able to get to clinic|1
6187234|NCT01380080|9841043|FG000|Overall Study|Not willing to adhere to requirements|6
6187235|NCT01380080|9841044|FG001|Overall Study|Not willing to adhere to requirements|2
6187236|NCT01380080|9841043|FG000|Overall Study|Withdrawal by Subject|5
6187237|NCT01380080|9841044|FG001|Overall Study|Withdrawal by Subject|2
6187238|NCT01380080|9841043|FG000|Overall Study|Lost to Follow-up|3
6187239|NCT01380080|9841044|FG001|Overall Study|Lost to Follow-up|3
6187240|NCT01380093|9841050|FG000|Naloxone Challenge Phase|Screen failures|21
6187241|NCT01380093|9841051|FG001|Naloxone Challenge Phase|Screen failures|0
6187242|NCT01380093|9841052|FG002|Naloxone Challenge Phase|Screen failures|0
6187243|NCT01380093|9841053|FG003|Naloxone Challenge Phase|Screen failures|0
6187244|NCT01380093|9841054|FG004|Naloxone Challenge Phase|Screen failures|0
6233008|NCT01772823|9909907|FG001|Behavioral Intervention (BL -3MV or PCC)|Lost to Follow-up|0
6085622|NCT00654381|9695001|FG001|2nd Stage|Adverse Event|0
6085623|NCT00654381|9695002|FG002|2nd Stage|Adverse Event|2
6085624|NCT00654381|9695003|FG003|2nd Stage|Adverse Event|3
6085625|NCT00654381|9695004|FG004|2nd Stage|Adverse Event|7
6085626|NCT00654381|9695005|FG005|2nd Stage|Adverse Event|2
6085627|NCT00654381|9695000|FG000|2nd Stage|Withdrawal by Subject|0
6085628|NCT00654381|9695001|FG001|2nd Stage|Withdrawal by Subject|0
6085629|NCT00654381|9695002|FG002|2nd Stage|Withdrawal by Subject|0
6085630|NCT00654381|9695003|FG003|2nd Stage|Withdrawal by Subject|0
6085631|NCT00654381|9695004|FG004|2nd Stage|Withdrawal by Subject|1
6085632|NCT00654381|9695005|FG005|2nd Stage|Withdrawal by Subject|1
6085633|NCT00654381|9695000|FG000|2nd Stage|Investigator's decision|0
6085634|NCT00654381|9695001|FG001|2nd Stage|Investigator's decision|0
6187245|NCT01380093|9841055|FG005|Naloxone Challenge Phase|Screen failures|0
6187246|NCT01380093|9841056|FG006|Naloxone Challenge Phase|Screen failures|0
6187247|NCT01380093|9841057|FG007|Naloxone Challenge Phase|Screen failures|0
6187248|NCT01380093|9841058|FG008|Naloxone Challenge Phase|Screen failures|0
6187249|NCT01380093|9841050|FG000|Drug Discrimination Phase: Day 1|Discrimination failure|0
6187250|NCT01380093|9841051|FG001|Drug Discrimination Phase: Day 1|Discrimination failure|1
6187251|NCT01380093|9841052|FG002|Drug Discrimination Phase: Day 1|Discrimination failure|0
6187252|NCT01380093|9841053|FG003|Drug Discrimination Phase: Day 1|Discrimination failure|0
6187253|NCT01380093|9841054|FG004|Drug Discrimination Phase: Day 1|Discrimination failure|0
6187254|NCT01380093|9841055|FG005|Drug Discrimination Phase: Day 1|Discrimination failure|0
6187255|NCT01380093|9841056|FG006|Drug Discrimination Phase: Day 1|Discrimination failure|0
6085635|NCT00654381|9695002|FG002|2nd Stage|Investigator's decision|1
6085636|NCT00654381|9695003|FG003|2nd Stage|Investigator's decision|1
6085637|NCT00654381|9695004|FG004|2nd Stage|Investigator's decision|0
6085638|NCT00654381|9695005|FG005|2nd Stage|Investigator's decision|0
6233009|NCT01772823|9909906|FG000|Behavioral Intervention (BL -3MV or PCC)|Withdrawal by Subject|1
6233010|NCT01772823|9909907|FG001|Behavioral Intervention (BL -3MV or PCC)|Withdrawal by Subject|1
6233011|NCT01772823|9909906|FG000|Behavioral Intervention (BL -3MV or PCC)|Inadvertent enrollment|1
6233012|NCT01772823|9909907|FG001|Behavioral Intervention (BL -3MV or PCC)|Inadvertent enrollment|0
6233013|NCT01772823|9909906|FG000|Behavioral Intervention (BL -3MV or PCC)|Inelligible at rescreen|2
6233014|NCT01772823|9909907|FG001|Behavioral Intervention (BL -3MV or PCC)|Inelligible at rescreen|1
6233015|NCT01772823|9909906|FG000|Behavioral Intervention (BL -3MV or PCC)|Wk 0 not completed, 30 days of baseline|6
6233016|NCT01772823|9909907|FG001|Behavioral Intervention (BL -3MV or PCC)|Wk 0 not completed, 30 days of baseline|0
6085639|NCT00654381|9695000|FG000|Extension Stage|Adverse Event|1
6085640|NCT00654381|9695001|FG001|Extension Stage|Adverse Event|2
6085641|NCT00654381|9695002|FG002|Extension Stage|Adverse Event|9
6233017|NCT01772823|9909906|FG000|Behavioral Intervention (BL -3MV or PCC)|Moved out of area|1
6233018|NCT01772823|9909907|FG001|Behavioral Intervention (BL -3MV or PCC)|Moved out of area|0
6233019|NCT01772823|9909906|FG000|Treatment Phase (Week 0- Week 48)|Lost to Follow-up|15
6233020|NCT01772823|9909907|FG001|Treatment Phase (Week 0- Week 48)|Lost to Follow-up|13
6233021|NCT01772823|9909906|FG000|Treatment Phase (Week 0- Week 48)|Withdrawal by Subject|6
6233022|NCT01772823|9909907|FG001|Treatment Phase (Week 0- Week 48)|Withdrawal by Subject|1
6233023|NCT01772823|9909906|FG000|Treatment Phase (Week 0- Week 48)|Moved out of area|4
6233024|NCT01772823|9909907|FG001|Treatment Phase (Week 0- Week 48)|Moved out of area|3
6269890|NCT02146274|9970491|FG000|Overall Study|Protocol Violation|73
6375610|NCT01092143|10165804|FG004|Overall Study|Consent withdrawn|3
6375611|NCT01092143|10165800|FG000|Overall Study|Not treated|0
6375612|NCT01092143|10165801|FG001|Overall Study|Not treated|0
6375613|NCT01092143|10165802|FG002|Overall Study|Not treated|1
6375614|NCT01092143|10165803|FG003|Overall Study|Not treated|0
6375615|NCT01092143|10165804|FG004|Overall Study|Not treated|0
6375616|NCT01092143|10165800|FG000|Overall Study|did not reversibility criteria|0
6375617|NCT01092143|10165801|FG001|Overall Study|did not reversibility criteria|0
6375618|NCT01092143|10165802|FG002|Overall Study|did not reversibility criteria|1
6375619|NCT01092143|10165803|FG003|Overall Study|did not reversibility criteria|0
6375620|NCT01092143|10165804|FG004|Overall Study|did not reversibility criteria|0
6375621|NCT01092143|10165800|FG000|Overall Study|Increased Albuterol use for >2 days|0
6375622|NCT01092143|10165801|FG001|Overall Study|Increased Albuterol use for >2 days|1
6375623|NCT01092143|10165802|FG002|Overall Study|Increased Albuterol use for >2 days|0
6375624|NCT01092143|10165803|FG003|Overall Study|Increased Albuterol use for >2 days|0
6375625|NCT01092143|10165804|FG004|Overall Study|Increased Albuterol use for >2 days|0
6375626|NCT01092143|10165800|FG000|Overall Study|Ineligible patient|1
6375627|NCT01092143|10165801|FG001|Overall Study|Ineligible patient|0
6375628|NCT01092143|10165802|FG002|Overall Study|Ineligible patient|0
6375629|NCT01092143|10165803|FG003|Overall Study|Ineligible patient|0
6375630|NCT01092143|10165804|FG004|Overall Study|Ineligible patient|0
6375631|NCT01092143|10165800|FG000|Overall Study|Drop in FEV1 at visit 9|1
6085642|NCT00654381|9695003|FG003|Extension Stage|Adverse Event|7
6085643|NCT00654381|9695004|FG004|Extension Stage|Adverse Event|1
6085644|NCT00654381|9695005|FG005|Extension Stage|Adverse Event|1
6085645|NCT00654381|9695000|FG000|Extension Stage|Protocol Violation|0
6085646|NCT00654381|9695001|FG001|Extension Stage|Protocol Violation|0
6085647|NCT00654381|9695002|FG002|Extension Stage|Protocol Violation|0
6085648|NCT00654381|9695003|FG003|Extension Stage|Protocol Violation|1
6085649|NCT00654381|9695004|FG004|Extension Stage|Protocol Violation|0
6085650|NCT00654381|9695005|FG005|Extension Stage|Protocol Violation|0
6085651|NCT00654381|9695000|FG000|Extension Stage|Lack of Efficacy|0
6085652|NCT00654381|9695001|FG001|Extension Stage|Lack of Efficacy|0
6085653|NCT00654381|9695002|FG002|Extension Stage|Lack of Efficacy|1
6085654|NCT00654381|9695003|FG003|Extension Stage|Lack of Efficacy|0
6085655|NCT00654381|9695004|FG004|Extension Stage|Lack of Efficacy|0
6085656|NCT00654381|9695005|FG005|Extension Stage|Lack of Efficacy|0
6085657|NCT00654381|9695000|FG000|Extension Stage|Withdrawal by Subject|0
6375632|NCT01092143|10165801|FG001|Overall Study|Drop in FEV1 at visit 9|0
6375633|NCT01092143|10165802|FG002|Overall Study|Drop in FEV1 at visit 9|0
6375634|NCT01092143|10165803|FG003|Overall Study|Drop in FEV1 at visit 9|0
6375635|NCT01092143|10165804|FG004|Overall Study|Drop in FEV1 at visit 9|0
6375636|NCT01092143|10165800|FG000|Overall Study|Patient travel|0
6375637|NCT01092143|10165801|FG001|Overall Study|Patient travel|0
6375638|NCT01092143|10165802|FG002|Overall Study|Patient travel|0
6375639|NCT01092143|10165803|FG003|Overall Study|Patient travel|0
6375640|NCT01092143|10165804|FG004|Overall Study|Patient travel|1
6375641|NCT01092143|10165800|FG000|Overall Study|Non compliance with study medication|0
6375642|NCT01092143|10165801|FG001|Overall Study|Non compliance with study medication|0
6375643|NCT01092143|10165802|FG002|Overall Study|Non compliance with study medication|0
6375644|NCT01092143|10165803|FG003|Overall Study|Non compliance with study medication|0
6233025|NCT01772823|9909906|FG000|Treatment Phase (Week 0- Week 48)|Incarcerated|1
6233026|NCT01772823|9909907|FG001|Treatment Phase (Week 0- Week 48)|Incarcerated|0
6233027|NCT01772823|9909906|FG000|Treatment Phase (Week 0- Week 48)|Suicide gesture/disruptive behavior|1
6233028|NCT01772823|9909907|FG001|Treatment Phase (Week 0- Week 48)|Suicide gesture/disruptive behavior|0
6233029|NCT01772823|9909906|FG000|Treatment Phase (Week 0- Week 48)|Wk 0 not completed, 30 days of baseline|1
6233030|NCT01772823|9909907|FG001|Treatment Phase (Week 0- Week 48)|Wk 0 not completed, 30 days of baseline|1
6233031|NCT01772823|9909906|FG000|Extension Phase (Visits 24,48wks Post tx|Lost to Follow-up|6
6233032|NCT01772823|9909907|FG001|Extension Phase (Visits 24,48wks Post tx|Lost to Follow-up|5
6233033|NCT01772823|9909906|FG000|Extension Phase (Visits 24,48wks Post tx|Withdrawal by Subject|1
6233034|NCT01772823|9909907|FG001|Extension Phase (Visits 24,48wks Post tx|Withdrawal by Subject|2
6233035|NCT01772823|9909906|FG000|Extension Phase (Visits 24,48wks Post tx|Moved out of area|2
6233036|NCT01772823|9909907|FG001|Extension Phase (Visits 24,48wks Post tx|Moved out of area|2
6233037|NCT01772823|9909906|FG000|Extension Phase (Visits 24,48wks Post tx|Became unavailable for study visits|1
6233038|NCT01772823|9909907|FG001|Extension Phase (Visits 24,48wks Post tx|Became unavailable for study visits|0
6233039|NCT01773070|9909918|FG000|Overall Study|Withdrawal by Subject|24
6233040|NCT01773070|9909918|FG000|Overall Study|Lost to Follow-up|39
6233041|NCT01773070|9909918|FG000|Overall Study|Other|15
6233042|NCT01773070|9909918|FG000|Overall Study|Death (unrelated to study procedures)|3
6233043|NCT01773109|9909922|FG000|Overall Study|Symptomatic Progression|2
6233044|NCT01773109|9909922|FG000|Overall Study|Death|1
6233045|NCT01773122|9909930|FG000|Overall Study|Due to amended age eligibility criteria|3
6233046|NCT01773122|9909931|FG001|Overall Study|Due to amended age eligibility criteria|1
6233047|NCT01773122|9909932|FG002|Overall Study|Due to amended age eligibility criteria|0
6233048|NCT01773122|9909933|FG003|Overall Study|Due to amended age eligibility criteria|1
6233049|NCT01773226|9909959|FG000|Overall Study|Withdrawal by Subject|1
6233050|NCT01773291|9909966|FG000|Overall Study|Protocol Violation|1
6233051|NCT01773291|9909967|FG001|Overall Study|Protocol Violation|0
6233052|NCT01773291|9909968|FG002|Overall Study|Protocol Violation|0
6233053|NCT01773291|9909966|FG000|Overall Study|Withdrawal by Subject|0
6233054|NCT01773291|9909967|FG001|Overall Study|Withdrawal by Subject|0
6233055|NCT01773291|9909968|FG002|Overall Study|Withdrawal by Subject|1
6233056|NCT01773421|9909981|FG000|Treatment Phase|Other|0
6233057|NCT01773421|9909982|FG001|Treatment Phase|Other|0
6233058|NCT01773421|9909983|FG002|Treatment Phase|Other|2
6233059|NCT01773421|9909984|FG003|Treatment Phase|Other|0
6233060|NCT01773421|9909985|FG004|Treatment Phase|Other|0
6233061|NCT01773421|9909986|FG005|Treatment Phase|Other|0
6233062|NCT01773421|9909987|FG006|Treatment Phase|Other|0
6233063|NCT01773421|9909981|FG000|Treatment Phase|Adverse Event|0
6233064|NCT01773421|9909982|FG001|Treatment Phase|Adverse Event|0
6233065|NCT01773421|9909983|FG002|Treatment Phase|Adverse Event|3
6233066|NCT01773421|9909984|FG003|Treatment Phase|Adverse Event|1
6233067|NCT01773421|9909985|FG004|Treatment Phase|Adverse Event|0
6233068|NCT01773421|9909986|FG005|Treatment Phase|Adverse Event|0
6233069|NCT01773421|9909987|FG006|Treatment Phase|Adverse Event|0
6233070|NCT01773421|9909981|FG000|Treatment Phase|Withdrawal by Subject|0
6233071|NCT01773421|9909982|FG001|Treatment Phase|Withdrawal by Subject|0
6233072|NCT01773421|9909983|FG002|Treatment Phase|Withdrawal by Subject|1
6233073|NCT01773421|9909984|FG003|Treatment Phase|Withdrawal by Subject|1
6233074|NCT01773421|9909985|FG004|Treatment Phase|Withdrawal by Subject|0
6233075|NCT01773421|9909986|FG005|Treatment Phase|Withdrawal by Subject|0
6233076|NCT01773421|9909987|FG006|Treatment Phase|Withdrawal by Subject|0
6233077|NCT01773421|9909981|FG000|Extension Phase|Other|0
6233078|NCT01773421|9909982|FG001|Extension Phase|Other|0
6233079|NCT01773421|9909983|FG002|Extension Phase|Other|0
6233080|NCT01773421|9909984|FG003|Extension Phase|Other|0
6233081|NCT01773421|9909985|FG004|Extension Phase|Other|1
6233082|NCT01773421|9909986|FG005|Extension Phase|Other|2
6233083|NCT01773421|9909987|FG006|Extension Phase|Other|0
6233084|NCT01773421|9909981|FG000|Extension Phase|Adverse Event|0
6233085|NCT01773421|9909982|FG001|Extension Phase|Adverse Event|0
6233086|NCT01773421|9909983|FG002|Extension Phase|Adverse Event|0
6233087|NCT01773421|9909984|FG003|Extension Phase|Adverse Event|0
6233088|NCT01773421|9909985|FG004|Extension Phase|Adverse Event|2
6233089|NCT01773421|9909986|FG005|Extension Phase|Adverse Event|0
6375645|NCT01092143|10165804|FG004|Overall Study|Non compliance with study medication|1
6375646|NCT01092143|10165800|FG000|Overall Study|Randomized by mistake|0
6233090|NCT01773421|9909987|FG006|Extension Phase|Adverse Event|0
6233091|NCT01773473|9910005|FG000|Overall Study|Adverse Event|3
6233092|NCT01773473|9910006|FG001|Overall Study|Adverse Event|2
6233093|NCT01773473|9910005|FG000|Overall Study|Protocol Violation|0
6233094|NCT01773473|9910006|FG001|Overall Study|Protocol Violation|4
6233095|NCT01773473|9910005|FG000|Overall Study|Physician Decision|3
6233096|NCT01773473|9910006|FG001|Overall Study|Physician Decision|5
6233097|NCT01773473|9910005|FG000|Overall Study|Sponsor Decision|2
6233098|NCT01773473|9910006|FG001|Overall Study|Sponsor Decision|0
6233099|NCT01773473|9910005|FG000|Overall Study|Lack of Efficacy|0
6233100|NCT01773473|9910006|FG001|Overall Study|Lack of Efficacy|1
6233101|NCT01773473|9910005|FG000|Overall Study|Non-Compliance with study drug|1
6233102|NCT01773473|9910006|FG001|Overall Study|Non-Compliance with study drug|4
6233103|NCT01773473|9910005|FG000|Overall Study|Withdrawal by Subject|5
6233104|NCT01773473|9910006|FG001|Overall Study|Withdrawal by Subject|3
6233105|NCT01773473|9910005|FG000|Overall Study|Lost to Follow-up|2
6233106|NCT01773473|9910006|FG001|Overall Study|Lost to Follow-up|0
6233107|NCT01773889|9910012|FG000|Overall Study|lack of funding|2
6233108|NCT01773967|9910022|FG000|Overall Study|Lost to Follow-up|15
6233109|NCT01773967|9910023|FG001|Overall Study|Lost to Follow-up|13
6233110|NCT01773993|9910029|FG000|Overall Study|No Visit After Treatment|35
6233111|NCT01774084|9910045|FG000|Overall Study|Personal reasons|1
6233112|NCT01774084|9910046|FG001|Overall Study|Personal reasons|0
6233113|NCT01774097|9910054|FG000|Overall Study|Withdrawal by Subject|1
6233114|NCT01774097|9910055|FG001|Overall Study|Withdrawal by Subject|1
6233115|NCT01774097|9910054|FG000|Overall Study|Adverse Event|1
6233116|NCT01774097|9910055|FG001|Overall Study|Adverse Event|1
6233117|NCT01774110|9910063|FG000|Overall Study|Lost to Follow-up|7
6233118|NCT01774305|9910079|FG000|Overall Study|Physician Decision|1
6233119|NCT01774305|9910080|FG001|Overall Study|Physician Decision|0
6233120|NCT01774344|9910088|FG000|Overall Study|Withdrawal by Subject|3
6233121|NCT01774344|9910089|FG001|Overall Study|Withdrawal by Subject|10
6233122|NCT01774344|9910088|FG000|Overall Study|Protocol Violation|0
6233123|NCT01774344|9910089|FG001|Overall Study|Protocol Violation|1
6233124|NCT01774344|9910088|FG000|Overall Study|Lost to Follow-up|4
6233125|NCT01774344|9910089|FG001|Overall Study|Lost to Follow-up|10
6233126|NCT01774344|9910088|FG000|Overall Study|End of survival follow-up not available|2
6233127|NCT01774344|9910089|FG001|Overall Study|End of survival follow-up not available|2
6233128|NCT01774344|9910088|FG000|Overall Study|Data collection finished|4
6233129|NCT01774344|9910089|FG001|Overall Study|Data collection finished|14
6233130|NCT01774344|9910088|FG000|Overall Study|Other|0
6233131|NCT01774344|9910089|FG001|Overall Study|Other|1
6233132|NCT01774344|9910088|FG000|Overall Study|Did not enter Survival Follow up|49
6233133|NCT01774344|9910089|FG001|Overall Study|Did not enter Survival Follow up|83
6233134|NCT01774591|9910097|FG000|Overall Study|Physician Decision|1
6233135|NCT01774591|9910098|FG001|Overall Study|Physician Decision|1
6233136|NCT01774591|9910097|FG000|Overall Study|Withdrawal by Subject|0
6233137|NCT01774591|9910098|FG001|Overall Study|Withdrawal by Subject|1
6233138|NCT01774591|9910097|FG000|Overall Study|Adverse Event|0
6233139|NCT01774591|9910098|FG001|Overall Study|Adverse Event|2
6233140|NCT01774786|9910119|FG000|Overall Study|Death|300
6233141|NCT01774786|9910120|FG001|Overall Study|Death|319
6233142|NCT01774786|9910119|FG000|Overall Study|Lost to Follow-up|6
6233143|NCT01774786|9910120|FG001|Overall Study|Lost to Follow-up|7
6233144|NCT01774786|9910119|FG000|Overall Study|Withdrawal by Subject|18
6233145|NCT01774786|9910120|FG001|Overall Study|Withdrawal by Subject|14
6233146|NCT01774786|9910119|FG000|Overall Study|Physician Decision|2
6233147|NCT01774786|9910120|FG001|Overall Study|Physician Decision|0
6233148|NCT01774786|9910119|FG000|Overall Study|Non-compliance|0
6233149|NCT01774786|9910120|FG001|Overall Study|Non-compliance|1
6233150|NCT01774786|9910119|FG000|Overall Study|Reason Not Specified|2
6233151|NCT01774786|9910120|FG001|Overall Study|Reason Not Specified|5
6233152|NCT01774799|9910130|FG000|Overall Study|Lost to Follow-up|1
6233153|NCT01774799|9910131|FG001|Overall Study|Lost to Follow-up|1
6233154|NCT01774799|9910132|FG002|Overall Study|Lost to Follow-up|0
6187256|NCT01380093|9841057|FG007|Drug Discrimination Phase: Day 1|Discrimination failure|0
6187257|NCT01380093|9841058|FG008|Drug Discrimination Phase: Day 1|Discrimination failure|0
6187258|NCT01380093|9841050|FG000|Drug Discrimination Phase: Day 2|Physician Decision|0
6187259|NCT01380093|9841051|FG001|Drug Discrimination Phase: Day 2|Physician Decision|3
6187260|NCT01380093|9841052|FG002|Drug Discrimination Phase: Day 2|Physician Decision|1
6187261|NCT01380093|9841053|FG003|Drug Discrimination Phase: Day 2|Physician Decision|0
6187262|NCT01380093|9841054|FG004|Drug Discrimination Phase: Day 2|Physician Decision|0
6187263|NCT01380093|9841055|FG005|Drug Discrimination Phase: Day 2|Physician Decision|0
6233155|NCT01774799|9910133|FG003|Overall Study|Lost to Follow-up|0
6233156|NCT01774903|9910148|FG000|Overall Study|Adverse Event|7
6233157|NCT01774903|9910148|FG000|Overall Study|Withdrawal by Subject|2
6233158|NCT01774903|9910148|FG000|Overall Study|Lack of Efficacy|1
6233159|NCT01774903|9910148|FG000|Overall Study|Ineligible to continue the trial|1
6233160|NCT01774929|9910153|FG000|Overall Study|Adverse Event|3
6233161|NCT01774968|9910159|FG000|Overall Study|Adverse Event|4
6233162|NCT01774968|9910160|FG001|Overall Study|Adverse Event|4
6233163|NCT01774968|9910159|FG000|Overall Study|Death|0
6233164|NCT01774968|9910160|FG001|Overall Study|Death|1
6233165|NCT01774968|9910159|FG000|Overall Study|Lost to Follow-up|1
6233166|NCT01774968|9910160|FG001|Overall Study|Lost to Follow-up|3
6233167|NCT01774968|9910159|FG000|Overall Study|Physician Decision|5
6233168|NCT01774968|9910160|FG001|Overall Study|Physician Decision|1
6233169|NCT01774968|9910159|FG000|Overall Study|Protocol Violation|14
6233170|NCT01774968|9910160|FG001|Overall Study|Protocol Violation|13
6233171|NCT01774968|9910159|FG000|Overall Study|Sponsor Decision|0
6233172|NCT01774968|9910160|FG001|Overall Study|Sponsor Decision|2
6233173|NCT01774968|9910159|FG000|Overall Study|Withdrawal by Subject|6
6233174|NCT01774968|9910160|FG001|Overall Study|Withdrawal by Subject|11
6233175|NCT01774981|9910174|FG000|Overall Study|Adverse Event|0
6233176|NCT01774981|9910175|FG001|Overall Study|Adverse Event|0
6233177|NCT01774981|9910176|FG002|Overall Study|Adverse Event|0
6233178|NCT01774981|9910177|FG003|Overall Study|Adverse Event|0
6233179|NCT01774981|9910178|FG004|Overall Study|Adverse Event|0
6233180|NCT01774981|9910179|FG005|Overall Study|Adverse Event|1
6233181|NCT01774981|9910180|FG006|Overall Study|Adverse Event|0
6233182|NCT01774981|9910181|FG007|Overall Study|Adverse Event|0
6233183|NCT01774981|9910174|FG000|Overall Study|Withdrawal by Subject|0
6233184|NCT01774981|9910175|FG001|Overall Study|Withdrawal by Subject|0
6233185|NCT01774981|9910176|FG002|Overall Study|Withdrawal by Subject|0
6233186|NCT01774981|9910177|FG003|Overall Study|Withdrawal by Subject|0
6233187|NCT01774981|9910178|FG004|Overall Study|Withdrawal by Subject|0
6233188|NCT01774981|9910179|FG005|Overall Study|Withdrawal by Subject|0
6233189|NCT01774981|9910180|FG006|Overall Study|Withdrawal by Subject|0
6233190|NCT01774981|9910181|FG007|Overall Study|Withdrawal by Subject|1
6233191|NCT01774981|9910174|FG000|Overall Study|Death|0
6233192|NCT01774981|9910175|FG001|Overall Study|Death|0
6233193|NCT01774981|9910176|FG002|Overall Study|Death|0
6233194|NCT01774981|9910177|FG003|Overall Study|Death|0
6233195|NCT01774981|9910178|FG004|Overall Study|Death|1
6233196|NCT01774981|9910179|FG005|Overall Study|Death|0
6233197|NCT01774981|9910180|FG006|Overall Study|Death|0
6233198|NCT01774981|9910181|FG007|Overall Study|Death|0
6233199|NCT01775124|9910206|FG000|Core Period|Disease Progression|0
6233200|NCT01775124|9910207|FG001|Core Period|Disease Progression|1
6233201|NCT01775124|9910206|FG000|Core Period|Physician Decision|1
6233202|NCT01775124|9910207|FG001|Core Period|Physician Decision|1
6233203|NCT01775124|9910206|FG000|Core Period|Death|0
6233204|NCT01775124|9910207|FG001|Core Period|Death|1
6233205|NCT01775124|9910206|FG000|Core Period|Administrative problems|1
6233206|NCT01775124|9910207|FG001|Core Period|Administrative problems|0
6233207|NCT01775124|9910206|FG000|Core Period|Withdrawal by Subject|4
6233208|NCT01775124|9910207|FG001|Core Period|Withdrawal by Subject|2
6233209|NCT01775124|9910206|FG000|Core Period|Adverse Event|5
6233210|NCT01775124|9910207|FG001|Core Period|Adverse Event|5
6233211|NCT01775124|9910206|FG000|Extension Period|Adverse Event|3
6233212|NCT01775124|9910207|FG001|Extension Period|Adverse Event|2
6233213|NCT01775124|9910206|FG000|Extension Period|Physician Decision|0
6233214|NCT01775124|9910207|FG001|Extension Period|Physician Decision|2
6233215|NCT01775124|9910206|FG000|Extension Period|Administrative problems|0
6233216|NCT01775124|9910207|FG001|Extension Period|Administrative problems|1
6233217|NCT01775124|9910206|FG000|Extension Period|Lost to Follow-up|0
6233218|NCT01775124|9910207|FG001|Extension Period|Lost to Follow-up|1
6233219|NCT01775124|9910206|FG000|Extension Period|Withdrawal by Subject|9
6233220|NCT01775124|9910207|FG001|Extension Period|Withdrawal by Subject|12
6233221|NCT01775137|9910214|FG000|Overall Study|Death|1
6233222|NCT01775137|9910214|FG000|Overall Study|Protocol deviation|2
6233223|NCT01775137|9910214|FG000|Overall Study|Unsatisfactory therapeutic effect|2
6233224|NCT01775137|9910214|FG000|Overall Study|Adverse Event|1
6233225|NCT01775137|9910214|FG000|Overall Study|Withdrawal by participants|5
6233226|NCT01775189|9910221|FG000|Drug Discrimination Phase: Day 1|Adverse Event|0
6233227|NCT01775189|9910222|FG001|Drug Discrimination Phase: Day 1|Adverse Event|3
6233228|NCT01775189|9910223|FG002|Drug Discrimination Phase: Day 1|Adverse Event|0
6233229|NCT01775189|9910224|FG003|Drug Discrimination Phase: Day 1|Adverse Event|0
6233230|NCT01775189|9910225|FG004|Drug Discrimination Phase: Day 1|Adverse Event|0
6233231|NCT01775189|9910226|FG005|Drug Discrimination Phase: Day 1|Adverse Event|0
6233232|NCT01775189|9910227|FG006|Drug Discrimination Phase: Day 1|Adverse Event|0
6233233|NCT01775189|9910221|FG000|Drug Discrimination Phase: Day 2|Protocol Violation|0
6233234|NCT01775189|9910222|FG001|Drug Discrimination Phase: Day 2|Protocol Violation|1
6233235|NCT01775189|9910223|FG002|Drug Discrimination Phase: Day 2|Protocol Violation|0
6233236|NCT01775189|9910224|FG003|Drug Discrimination Phase: Day 2|Protocol Violation|0
6233237|NCT01775189|9910225|FG004|Drug Discrimination Phase: Day 2|Protocol Violation|0
6233238|NCT01775189|9910226|FG005|Drug Discrimination Phase: Day 2|Protocol Violation|0
6233239|NCT01775189|9910227|FG006|Drug Discrimination Phase: Day 2|Protocol Violation|0
6233240|NCT01775189|9910221|FG000|Drug Discrimination Phase: Day 2|Did Not Meet Entrance Criteria|0
6233241|NCT01775189|9910222|FG001|Drug Discrimination Phase: Day 2|Did Not Meet Entrance Criteria|2
6233242|NCT01775189|9910223|FG002|Drug Discrimination Phase: Day 2|Did Not Meet Entrance Criteria|7
6233243|NCT01775189|9910224|FG003|Drug Discrimination Phase: Day 2|Did Not Meet Entrance Criteria|0
6233244|NCT01775189|9910225|FG004|Drug Discrimination Phase: Day 2|Did Not Meet Entrance Criteria|0
6233245|NCT01775189|9910226|FG005|Drug Discrimination Phase: Day 2|Did Not Meet Entrance Criteria|0
6233246|NCT01775189|9910227|FG006|Drug Discrimination Phase: Day 2|Did Not Meet Entrance Criteria|0
6269891|NCT02146326|9970502|FG000|Overall Study|Lost to Follow-up|3
6233247|NCT01775189|9910221|FG000|Treatment Phase: Washout Period 1|Protocol Violation|0
6233248|NCT01775189|9910222|FG001|Treatment Phase: Washout Period 1|Protocol Violation|0
6233249|NCT01775189|9910223|FG002|Treatment Phase: Washout Period 1|Protocol Violation|0
6233250|NCT01775189|9910224|FG003|Treatment Phase: Washout Period 1|Protocol Violation|0
6233251|NCT01775189|9910225|FG004|Treatment Phase: Washout Period 1|Protocol Violation|0
6233252|NCT01775189|9910226|FG005|Treatment Phase: Washout Period 1|Protocol Violation|1
6233253|NCT01775189|9910227|FG006|Treatment Phase: Washout Period 1|Protocol Violation|0
6233254|NCT01775189|9910221|FG000|Treatment Phase: Washout Period 2|Protocol Violation|0
6233255|NCT01775189|9910222|FG001|Treatment Phase: Washout Period 2|Protocol Violation|0
6233256|NCT01775189|9910223|FG002|Treatment Phase: Washout Period 2|Protocol Violation|0
6233257|NCT01775189|9910224|FG003|Treatment Phase: Washout Period 2|Protocol Violation|1
6233258|NCT01775189|9910225|FG004|Treatment Phase: Washout Period 2|Protocol Violation|0
6233259|NCT01775189|9910226|FG005|Treatment Phase: Washout Period 2|Protocol Violation|0
6233260|NCT01775189|9910227|FG006|Treatment Phase: Washout Period 2|Protocol Violation|0
6233261|NCT01775189|9910221|FG000|Treatment Phase: Washout Period 3|Protocol Violation|0
6233262|NCT01775189|9910222|FG001|Treatment Phase: Washout Period 3|Protocol Violation|0
6233263|NCT01775189|9910223|FG002|Treatment Phase: Washout Period 3|Protocol Violation|0
6233264|NCT01775189|9910224|FG003|Treatment Phase: Washout Period 3|Protocol Violation|1
6233265|NCT01775189|9910225|FG004|Treatment Phase: Washout Period 3|Protocol Violation|0
6233266|NCT01775189|9910226|FG005|Treatment Phase: Washout Period 3|Protocol Violation|0
6233267|NCT01775189|9910227|FG006|Treatment Phase: Washout Period 3|Protocol Violation|1
6233268|NCT01775501|9910270|FG000|Overall Study|Discontinued prior to treatment|1
6233269|NCT01775553|9910274|FG000|Overall Study|Adverse Event|1
6233270|NCT01775553|9910274|FG000|Overall Study|Disease Progression|12
6233271|NCT01775670|9910280|FG000|Overall Study|Lost to Follow-up|1
6233272|NCT01775670|9910281|FG001|Overall Study|Lost to Follow-up|1
6233273|NCT01775787|9910315|FG000|First 7-10 Days|Adverse Event|0
6233274|NCT01775787|9910316|FG001|First 7-10 Days|Adverse Event|1
6233275|NCT01775787|9910315|FG000|First 7-10 Days|family emergency|0
6233276|NCT01775787|9910316|FG001|First 7-10 Days|family emergency|1
6233277|NCT01775787|9910315|FG000|First 7-10 Days|time commitment|0
6233278|NCT01775787|9910316|FG001|First 7-10 Days|time commitment|2
6233279|NCT01775787|9910315|FG000|First 7-10 Days|concerns with using IV|1
6233280|NCT01775787|9910316|FG001|First 7-10 Days|concerns with using IV|2
6233281|NCT01775787|9910315|FG000|Second 7-10 Days|time commitment|0
6233282|NCT01775787|9910316|FG001|Second 7-10 Days|time commitment|1
6233283|NCT01775787|9910315|FG000|Second 7-10 Days|concerns with using IV|0
6233284|NCT01775787|9910316|FG001|Second 7-10 Days|concerns with using IV|1
6233285|NCT01775904|9910361|FG000|LY2886721 Capsule (Water, Fasting)|Adverse Event|1
6233286|NCT01775904|9910361|FG000|LY2886721 ODT (Water, Fasting)|Adverse Event|1
6233287|NCT01775930|9910371|FG000|Overall Study|Futility stopping boundary met|1
6233288|NCT01775995|9910377|FG000|Overall Study|Lost to Follow-up|1
6375647|NCT01092143|10165801|FG001|Overall Study|Randomized by mistake|0
6375648|NCT01092143|10165802|FG002|Overall Study|Randomized by mistake|0
6375649|NCT01092143|10165803|FG003|Overall Study|Randomized by mistake|1
6375650|NCT01092143|10165804|FG004|Overall Study|Randomized by mistake|0
6085658|NCT00654381|9695001|FG001|Extension Stage|Withdrawal by Subject|0
6085659|NCT00654381|9695002|FG002|Extension Stage|Withdrawal by Subject|1
6375651|NCT01092143|10165800|FG000|Overall Study|Pregnancy|0
6375652|NCT01092143|10165801|FG001|Overall Study|Pregnancy|0
6375653|NCT01092143|10165802|FG002|Overall Study|Pregnancy|0
6375654|NCT01092143|10165803|FG003|Overall Study|Pregnancy|1
6375655|NCT01092143|10165804|FG004|Overall Study|Pregnancy|0
6375656|NCT01064648|10165819|FG000|Phase I Cohort1: Dose Level 1|Progression|5
6375657|NCT01064648|10165820|FG001|Phase I Cohort1: Dose Level 1|Progression|0
6375658|NCT01064648|10165821|FG002|Phase I Cohort1: Dose Level 1|Progression|0
6375659|NCT01064648|10165822|FG003|Phase I Cohort1: Dose Level 1|Progression|0
6375660|NCT01064648|10165819|FG000|Phase I Cohort1: Dose Level 1|Non-protocol specified|2
6375661|NCT01064648|10165820|FG001|Phase I Cohort1: Dose Level 1|Non-protocol specified|0
6375662|NCT01064648|10165821|FG002|Phase I Cohort1: Dose Level 1|Non-protocol specified|0
6375663|NCT01064648|10165822|FG003|Phase I Cohort1: Dose Level 1|Non-protocol specified|0
6375664|NCT01064648|10165819|FG000|Phase I Cohort 2: Dose Level 2|Adverse Event|0
6375665|NCT01064648|10165820|FG001|Phase I Cohort 2: Dose Level 2|Adverse Event|3
6375666|NCT01064648|10165821|FG002|Phase I Cohort 2: Dose Level 2|Adverse Event|0
6375667|NCT01064648|10165822|FG003|Phase I Cohort 2: Dose Level 2|Adverse Event|0
6375668|NCT01064648|10165819|FG000|Phase I Cohort 2: Dose Level 2|Withdrawal by Subject|0
6375669|NCT01064648|10165820|FG001|Phase I Cohort 2: Dose Level 2|Withdrawal by Subject|1
6375670|NCT01064648|10165821|FG002|Phase I Cohort 2: Dose Level 2|Withdrawal by Subject|0
6375671|NCT01064648|10165822|FG003|Phase I Cohort 2: Dose Level 2|Withdrawal by Subject|0
6375672|NCT01064648|10165819|FG000|Phase I Cohort 2: Dose Level 2|Progression|0
6375673|NCT01064648|10165820|FG001|Phase I Cohort 2: Dose Level 2|Progression|5
6375674|NCT01064648|10165821|FG002|Phase I Cohort 2: Dose Level 2|Progression|0
6375675|NCT01064648|10165822|FG003|Phase I Cohort 2: Dose Level 2|Progression|0
6375676|NCT01064648|10165819|FG000|Phase I Cohort 2: Dose Level 2|Non-protocol specified|0
6375677|NCT01064648|10165820|FG001|Phase I Cohort 2: Dose Level 2|Non-protocol specified|4
6375678|NCT01064648|10165821|FG002|Phase I Cohort 2: Dose Level 2|Non-protocol specified|0
6375679|NCT01064648|10165822|FG003|Phase I Cohort 2: Dose Level 2|Non-protocol specified|0
6375680|NCT01064648|10165819|FG000|Phase II|Adverse Event|0
6375681|NCT01064648|10165820|FG001|Phase II|Adverse Event|0
6375682|NCT01064648|10165821|FG002|Phase II|Adverse Event|15
6375683|NCT01064648|10165822|FG003|Phase II|Adverse Event|8
6375684|NCT01064648|10165819|FG000|Phase II|Death|0
6375685|NCT01064648|10165820|FG001|Phase II|Death|0
6375686|NCT01064648|10165821|FG002|Phase II|Death|4
6375687|NCT01064648|10165822|FG003|Phase II|Death|5
6375688|NCT01064648|10165819|FG000|Phase II|Withdrawal by Subject|0
6375689|NCT01064648|10165820|FG001|Phase II|Withdrawal by Subject|0
6375690|NCT01064648|10165821|FG002|Phase II|Withdrawal by Subject|2
6375691|NCT01064648|10165822|FG003|Phase II|Withdrawal by Subject|5
6375692|NCT01064648|10165819|FG000|Phase II|Progression|0
6375693|NCT01064648|10165820|FG001|Phase II|Progression|0
6375694|NCT01064648|10165821|FG002|Phase II|Progression|21
6375695|NCT01064648|10165822|FG003|Phase II|Progression|27
6375696|NCT01064648|10165819|FG000|Phase II|Non-protocol specified|0
6375697|NCT01064648|10165820|FG001|Phase II|Non-protocol specified|0
6375698|NCT01064648|10165821|FG002|Phase II|Non-protocol specified|5
6375699|NCT01064648|10165822|FG003|Phase II|Non-protocol specified|3
6375700|NCT01064648|10165819|FG000|Phase II|Under Review|0
6375701|NCT01064648|10165820|FG001|Phase II|Under Review|0
6233289|NCT01775995|9910378|FG001|Overall Study|Lost to Follow-up|1
6233290|NCT01776008|9910384|FG000|Overall Study|ineligible|2
6233291|NCT01776424|9910401|FG000|Overall Study|Lost to Follow-up|10
6233292|NCT01776424|9910402|FG001|Overall Study|Lost to Follow-up|8
6233293|NCT01776424|9910403|FG002|Overall Study|Lost to Follow-up|9
6233294|NCT01776424|9910401|FG000|Overall Study|Withdrawal by Subject|10
6233295|NCT01776424|9910402|FG001|Overall Study|Withdrawal by Subject|11
6233296|NCT01776424|9910403|FG002|Overall Study|Withdrawal by Subject|15
6233297|NCT01776541|9910413|FG000|Overall Study|Administrative Reason|6
6233298|NCT01776541|9910414|FG001|Overall Study|Administrative Reason|2
6233299|NCT01776541|9910413|FG000|Overall Study|Death|4
6233300|NCT01776541|9910414|FG001|Overall Study|Death|0
6233301|NCT01776541|9910413|FG000|Overall Study|Lost to Follow-up|27
6233302|NCT01776541|9910414|FG001|Overall Study|Lost to Follow-up|48
6233303|NCT01776541|9910413|FG000|Overall Study|Unclassified|5
6233304|NCT01776541|9910414|FG001|Overall Study|Unclassified|4
6233305|NCT01776541|9910413|FG000|Overall Study|Protocol Violation|2
6233306|NCT01776541|9910414|FG001|Overall Study|Protocol Violation|1
6233307|NCT01776541|9910413|FG000|Overall Study|Withdrawal by Subject|12
6233308|NCT01776541|9910414|FG001|Overall Study|Withdrawal by Subject|20
6233309|NCT01776554|9910423|FG000|Overall Study|Adverse Event|1
6233310|NCT01776554|9910424|FG001|Overall Study|Adverse Event|0
6233311|NCT01776554|9910423|FG000|Overall Study|Withdrawal by Subject|3
6233312|NCT01776554|9910424|FG001|Overall Study|Withdrawal by Subject|8
6233313|NCT01776554|9910423|FG000|Overall Study|Lost to Follow-up|6
6233314|NCT01776554|9910424|FG001|Overall Study|Lost to Follow-up|9
6233315|NCT01776554|9910423|FG000|Overall Study|Administrative Reason|2
6233316|NCT01776554|9910424|FG001|Overall Study|Administrative Reason|5
6233317|NCT01776554|9910423|FG000|Overall Study|Protocol Violation|1
6233318|NCT01776554|9910424|FG001|Overall Study|Protocol Violation|0
6233319|NCT01776554|9910423|FG000|Overall Study|Unclassified|4
6233320|NCT01776554|9910424|FG001|Overall Study|Unclassified|1
6233321|NCT01777139|9910459|FG000|Primary Reporting Phase (Up to 4 Years)|Adverse Event|7
6233322|NCT01777139|9910460|FG001|Primary Reporting Phase (Up to 4 Years)|Adverse Event|0
6233323|NCT01777139|9910459|FG000|Primary Reporting Phase (Up to 4 Years)|Lack of Efficacy|6
6233324|NCT01777139|9910460|FG001|Primary Reporting Phase (Up to 4 Years)|Lack of Efficacy|0
6233325|NCT01777139|9910459|FG000|Primary Reporting Phase (Up to 4 Years)|Withdrawal by Subject|8
6233326|NCT01777139|9910460|FG001|Primary Reporting Phase (Up to 4 Years)|Withdrawal by Subject|0
6233327|NCT01777139|9910459|FG000|Primary Reporting Phase (Up to 4 Years)|Other (Study drug discontinued)|3
6233328|NCT01777139|9910460|FG001|Primary Reporting Phase (Up to 4 Years)|Other (Study drug discontinued)|0
6233329|NCT01777139|9910459|FG000|Primary Reporting Phase (Up to 4 Years)|Other (Reached stopping criteria)|2
6233330|NCT01777139|9910460|FG001|Primary Reporting Phase (Up to 4 Years)|Other (Reached stopping criteria)|0
6233331|NCT01777139|9910459|FG000|Primary Reporting Phase (Up to 4 Years)|Other (Subjects entered SFUCP)|4
6233332|NCT01777139|9910460|FG001|Primary Reporting Phase (Up to 4 Years)|Other (Subjects entered SFUCP)|0
6233333|NCT01777139|9910459|FG000|SFUCP (Up to 1.4 Years)|Withdrawal by Subject|0
6233334|NCT01777139|9910460|FG001|SFUCP (Up to 1.4 Years)|Withdrawal by Subject|1
6233335|NCT01777139|9910459|FG000|SFUCP (Up to 1.4 Years)|Other-Study drug discontinued|0
6233336|NCT01777139|9910460|FG001|SFUCP (Up to 1.4 Years)|Other-Study drug discontinued|3
6233337|NCT01777152|9910469|FG000|Overall Study|Withdrawal by Subject|22
6375702|NCT01064648|10165821|FG002|Phase II|Under Review|2
6233338|NCT01777152|9910470|FG001|Overall Study|Withdrawal by Subject|16
6233339|NCT01777152|9910469|FG000|Overall Study|Lost to Follow-up|3
6233340|NCT01777152|9910470|FG001|Overall Study|Lost to Follow-up|5
6233341|NCT01777152|9910469|FG000|Overall Study|Death|68
6233342|NCT01777152|9910470|FG001|Overall Study|Death|89
6269892|NCT02146326|9970503|FG001|Overall Study|Lost to Follow-up|3
6375703|NCT01064648|10165822|FG003|Phase II|Under Review|0
6375704|NCT00593567|10165837|FG000|Overall Study|Adverse Event|2
6375705|NCT00593567|10165838|FG001|Overall Study|Adverse Event|0
6375706|NCT00593567|10165837|FG000|Overall Study|Physician Decision|2
6375707|NCT00593567|10165838|FG001|Overall Study|Physician Decision|0
6233343|NCT01777152|9910469|FG000|Overall Study|Not eligible, no study drug received|1
6233344|NCT01777152|9910470|FG001|Overall Study|Not eligible, no study drug received|0
6233345|NCT01777152|9910469|FG000|Overall Study|Change of diagnosis|1
6233346|NCT01777152|9910470|FG001|Overall Study|Change of diagnosis|0
6233347|NCT01777191|9910479|FG000|Treatment Period (Per) (Week 0-Week 12)|Adverse Event|2
6233348|NCT01777191|9910480|FG001|Treatment Period (Per) (Week 0-Week 12)|Adverse Event|1
6233349|NCT01777191|9910479|FG000|Treatment Period (Per) (Week 0-Week 12)|Entry Criteria Not Met|1
6233350|NCT01777191|9910480|FG001|Treatment Period (Per) (Week 0-Week 12)|Entry Criteria Not Met|1
6233351|NCT01777191|9910479|FG000|Treatment Period (Per) (Week 0-Week 12)|Protocol Violation|1
6233352|NCT01777191|9910480|FG001|Treatment Period (Per) (Week 0-Week 12)|Protocol Violation|2
6233353|NCT01777191|9910479|FG000|Treatment Period (Per) (Week 0-Week 12)|Withdrawal by Subject|0
6233354|NCT01777191|9910480|FG001|Treatment Period (Per) (Week 0-Week 12)|Withdrawal by Subject|3
6233355|NCT01777191|9910479|FG000|Treatment Period (Per) (Week 0-Week 12)|Lack of Efficacy|1
6233356|NCT01777191|9910480|FG001|Treatment Period (Per) (Week 0-Week 12)|Lack of Efficacy|1
6233357|NCT01777191|9910479|FG000|Treatment Period (Per) (Week 0-Week 12)|Lost to Follow-up|1
6233358|NCT01777191|9910480|FG001|Treatment Period (Per) (Week 0-Week 12)|Lost to Follow-up|0
6233359|NCT01777191|9910479|FG000|Safety Extension Per (Week 12-Week 48)|Adverse Event|3
6233360|NCT01777191|9910480|FG001|Safety Extension Per (Week 12-Week 48)|Adverse Event|3
6233361|NCT01777191|9910479|FG000|Safety Extension Per (Week 12-Week 48)|Death|0
6233362|NCT01777191|9910480|FG001|Safety Extension Per (Week 12-Week 48)|Death|1
6233363|NCT01777191|9910479|FG000|Safety Extension Per (Week 12-Week 48)|Withdrawal by Subject|4
6233364|NCT01777191|9910480|FG001|Safety Extension Per (Week 12-Week 48)|Withdrawal by Subject|4
6233365|NCT01777191|9910479|FG000|Safety Extension Per (Week 12-Week 48)|Lack of Efficacy|1
6233366|NCT01777191|9910480|FG001|Safety Extension Per (Week 12-Week 48)|Lack of Efficacy|2
6233367|NCT01777191|9910479|FG000|Safety Extension Per (Week 12-Week 48)|Lost to Follow-up|1
6233368|NCT01777191|9910480|FG001|Safety Extension Per (Week 12-Week 48)|Lost to Follow-up|3
6233369|NCT01777269|9910500|FG000|Overall Study|Adverse Event|24
6233370|NCT01777269|9910501|FG001|Overall Study|Adverse Event|33
6233371|NCT01777269|9910500|FG000|Overall Study|Lack of Efficacy|8
6233372|NCT01777269|9910501|FG001|Overall Study|Lack of Efficacy|10
6233373|NCT01777269|9910500|FG000|Overall Study|Protocol Violation|4
6233374|NCT01777269|9910501|FG001|Overall Study|Protocol Violation|4
6233375|NCT01777269|9910500|FG000|Overall Study|Participants reached stopping criteria|1
6233376|NCT01777269|9910501|FG001|Overall Study|Participants reached stopping criteria|1
6233377|NCT01777269|9910500|FG000|Overall Study|Lost to Follow-up|4
6233378|NCT01777269|9910501|FG001|Overall Study|Lost to Follow-up|0
6233379|NCT01777269|9910500|FG000|Overall Study|Physician Decision|5
6233380|NCT01777269|9910501|FG001|Overall Study|Physician Decision|2
6233381|NCT01777269|9910500|FG000|Overall Study|Withdrawal by Subject|9
6233382|NCT01777269|9910501|FG001|Overall Study|Withdrawal by Subject|9
6233383|NCT01777282|9910512|FG000|Overall Study|Persistent Hyperglycemia|0
6233384|NCT01777282|9910513|FG001|Overall Study|Persistent Hyperglycemia|0
6233385|NCT01777282|9910514|FG002|Overall Study|Persistent Hyperglycemia|1
6233386|NCT01777282|9910515|FG003|Overall Study|Persistent Hyperglycemia|0
6233387|NCT01777282|9910516|FG004|Overall Study|Persistent Hyperglycemia|0
6233388|NCT01777282|9910512|FG000|Overall Study|New Antidiabetic Medication|0
6233389|NCT01777282|9910513|FG001|Overall Study|New Antidiabetic Medication|0
6233390|NCT01777282|9910514|FG002|Overall Study|New Antidiabetic Medication|1
6233391|NCT01777282|9910515|FG003|Overall Study|New Antidiabetic Medication|0
6233392|NCT01777282|9910516|FG004|Overall Study|New Antidiabetic Medication|0
6233393|NCT01777282|9910512|FG000|Overall Study|Adverse Event|4
6233394|NCT01777282|9910513|FG001|Overall Study|Adverse Event|4
6233395|NCT01777282|9910514|FG002|Overall Study|Adverse Event|2
6233396|NCT01777282|9910515|FG003|Overall Study|Adverse Event|1
6233397|NCT01777282|9910516|FG004|Overall Study|Adverse Event|3
6233398|NCT01777282|9910512|FG000|Overall Study|Withdrawal by Subject|4
6233399|NCT01777282|9910513|FG001|Overall Study|Withdrawal by Subject|0
6233400|NCT01777282|9910514|FG002|Overall Study|Withdrawal by Subject|0
6233401|NCT01777282|9910515|FG003|Overall Study|Withdrawal by Subject|1
6233402|NCT01777282|9910516|FG004|Overall Study|Withdrawal by Subject|2
6233403|NCT01777282|9910512|FG000|Overall Study|Protocol Violation|2
6233404|NCT01777282|9910513|FG001|Overall Study|Protocol Violation|0
6233405|NCT01777282|9910514|FG002|Overall Study|Protocol Violation|1
6233406|NCT01777282|9910515|FG003|Overall Study|Protocol Violation|0
6233407|NCT01777282|9910516|FG004|Overall Study|Protocol Violation|2
6233408|NCT01777282|9910512|FG000|Overall Study|Moved, transfer abroad, did not enter FU|1
6233409|NCT01777282|9910513|FG001|Overall Study|Moved, transfer abroad, did not enter FU|0
6233410|NCT01777282|9910514|FG002|Overall Study|Moved, transfer abroad, did not enter FU|1
6233411|NCT01777282|9910515|FG003|Overall Study|Moved, transfer abroad, did not enter FU|0
6233412|NCT01777282|9910516|FG004|Overall Study|Moved, transfer abroad, did not enter FU|0
6233413|NCT01777308|9910530|FG000|Overall Study|Withdrawal by Subject|5
6233414|NCT01777308|9910531|FG001|Overall Study|Withdrawal by Subject|1
6233415|NCT01777308|9910530|FG000|Overall Study|Migrated/moved from study area|1
6233416|NCT01777308|9910531|FG001|Overall Study|Migrated/moved from study area|0
6233417|NCT01777308|9910530|FG000|Overall Study|Lost to Follow-up|7
6233418|NCT01777308|9910531|FG001|Overall Study|Lost to Follow-up|2
6233419|NCT01777308|9910530|FG000|Overall Study|Blood draw refusal at Visit 3|1
6233420|NCT01777308|9910531|FG001|Overall Study|Blood draw refusal at Visit 3|0
6233421|NCT01777321|9910540|FG000|Overall Study|Withdrawal by Subject|0
6233422|NCT01777321|9910541|FG001|Overall Study|Withdrawal by Subject|1
6233423|NCT01777334|9910549|FG000|Overall Study|Adverse Event|18
6233424|NCT01777334|9910550|FG001|Overall Study|Adverse Event|14
6233425|NCT01777334|9910549|FG000|Overall Study|Lack of Efficacy|15
6233426|NCT01777334|9910550|FG001|Overall Study|Lack of Efficacy|29
6233427|NCT01777334|9910549|FG000|Overall Study|Protocol Violation|3
6233428|NCT01777334|9910550|FG001|Overall Study|Protocol Violation|7
6233429|NCT01777334|9910549|FG000|Overall Study|Lost to Follow-up|3
6233430|NCT01777334|9910550|FG001|Overall Study|Lost to Follow-up|2
6233431|NCT01777334|9910549|FG000|Overall Study|Withdrawal by Subject|14
6233432|NCT01777334|9910550|FG001|Overall Study|Withdrawal by Subject|11
6233433|NCT01777490|9910578|FG000|Overall Study|Dyad withdrew with data use prohibition|0
6233434|NCT01777490|9910579|FG001|Overall Study|Dyad withdrew with data use prohibition|0
6233435|NCT01777490|9910580|FG002|Overall Study|Dyad withdrew with data use prohibition|1
6233436|NCT01777490|9910581|FG003|Overall Study|Dyad withdrew with data use prohibition|1
6233437|NCT01777542|9910593|FG000|Second Intervention (20 Weeks)|Adverse Event|0
6233438|NCT01777542|9910594|FG001|Second Intervention (20 Weeks)|Adverse Event|1
6233439|NCT01777581|9910612|FG000|Overall Study|Lost to Follow-up|1
6233440|NCT01777581|9910613|FG001|Overall Study|Lost to Follow-up|1
6233441|NCT01777581|9910612|FG000|Overall Study|Adverse Event|2
6233442|NCT01777581|9910613|FG001|Overall Study|Adverse Event|0
6233443|NCT01777581|9910612|FG000|Overall Study|Lack of Efficacy|0
6233444|NCT01777581|9910613|FG001|Overall Study|Lack of Efficacy|1
6233445|NCT01777620|9910621|FG000|Overall Study|Subject Withdrawal|1
6233446|NCT01777620|9910622|FG001|Overall Study|Subject Withdrawal|0
6233447|NCT01777763|9910630|FG000|Overall Study|Adverse Event|2
6233448|NCT01777763|9910631|FG001|Overall Study|Adverse Event|32
6233449|NCT01777763|9910630|FG000|Overall Study|Protocol Violation|1
6233450|NCT01777763|9910631|FG001|Overall Study|Protocol Violation|7
6233451|NCT01777763|9910630|FG000|Overall Study|Withdrawal by Subject|0
6233452|NCT01777763|9910631|FG001|Overall Study|Withdrawal by Subject|2
6233453|NCT01777763|9910630|FG000|Overall Study|Treatment Failure|1
6233454|NCT01777763|9910631|FG001|Overall Study|Treatment Failure|6
6233455|NCT01777776|9910641|FG000|Overall Study|Adverse Event|2
6233456|NCT01777776|9910642|FG001|Overall Study|Adverse Event|4
6233457|NCT01777776|9910643|FG002|Overall Study|Adverse Event|0
6233458|NCT01777776|9910644|FG003|Overall Study|Adverse Event|0
6233459|NCT01777776|9910641|FG000|Overall Study|Disease Progression|4
6233460|NCT01777776|9910642|FG001|Overall Study|Disease Progression|8
6233461|NCT01777776|9910643|FG002|Overall Study|Disease Progression|6
6233462|NCT01777776|9910644|FG003|Overall Study|Disease Progression|3
6233463|NCT01777776|9910641|FG000|Overall Study|Withdrawal by Subject|0
6233464|NCT01777776|9910642|FG001|Overall Study|Withdrawal by Subject|0
6233465|NCT01777776|9910643|FG002|Overall Study|Withdrawal by Subject|0
6233466|NCT01777776|9910644|FG003|Overall Study|Withdrawal by Subject|1
6233467|NCT01777932|9910663|FG000|Overall Study|Disease progression|136
6233468|NCT01777932|9910663|FG000|Overall Study|Death|3
6233469|NCT01777932|9910663|FG000|Overall Study|Adverse Event|34
6233470|NCT01777932|9910663|FG000|Overall Study|Lost to Follow-up|3
6233471|NCT01777932|9910663|FG000|Overall Study|Investigator decision|10
6233472|NCT01777932|9910663|FG000|Overall Study|Reimbursement limit|9
6233473|NCT01777932|9910663|FG000|Overall Study|Patient refused further treatment|10
6233474|NCT01777997|9910671|FG000|12 Week lead-in of no ART|Severe debilitation|2
6233475|NCT01777997|9910671|FG000|Weeks 0 to 24/48 on ART|Participant felt treatment not working|1
6233476|NCT01777997|9910671|FG000|Weeks 48 to 72/96 on ART|Death|1
6233477|NCT01777997|9910671|FG000|Weeks 48 to 72/96 on ART|Took prohibited/precautionary meds|1
6233478|NCT01778010|9910675|FG000|Overall Study|Withdrawal by Subject|2
6233479|NCT01778010|9910675|FG000|Overall Study|abnormal ECG before meds|1
6233480|NCT01778010|9910675|FG000|Overall Study|Arrested|1
6233481|NCT01778010|9910675|FG000|Overall Study|rash while on placebo|1
6233482|NCT01778023|9910694|FG000|Overall Study|Withdrawal by Subject|0
6233483|NCT01778023|9910695|FG001|Overall Study|Withdrawal by Subject|3
6233484|NCT01778049|9910703|FG000|Open Label Treatment Period|Adverse Event|5
6233485|NCT01778049|9910704|FG001|Open Label Treatment Period|Adverse Event|15
6233486|NCT01778049|9910705|FG002|Open Label Treatment Period|Adverse Event|0
6233487|NCT01778049|9910706|FG003|Open Label Treatment Period|Adverse Event|0
6233488|NCT01778049|9910707|FG004|Open Label Treatment Period|Adverse Event|0
6233489|NCT01778049|9910708|FG005|Open Label Treatment Period|Adverse Event|0
6233490|NCT01778049|9910703|FG000|Open Label Treatment Period|Lack of Efficacy|1
6233491|NCT01778049|9910704|FG001|Open Label Treatment Period|Lack of Efficacy|1
6233492|NCT01778049|9910705|FG002|Open Label Treatment Period|Lack of Efficacy|0
6233493|NCT01778049|9910706|FG003|Open Label Treatment Period|Lack of Efficacy|0
6233494|NCT01778049|9910707|FG004|Open Label Treatment Period|Lack of Efficacy|0
6233495|NCT01778049|9910708|FG005|Open Label Treatment Period|Lack of Efficacy|0
6375708|NCT00593567|10165837|FG000|Overall Study|Protocol Violation|13
6375709|NCT00593567|10165838|FG001|Overall Study|Protocol Violation|7
6233496|NCT01778049|9910703|FG000|Open Label Treatment Period|Protocol Violation|5
6233497|NCT01778049|9910704|FG001|Open Label Treatment Period|Protocol Violation|5
6233498|NCT01778049|9910705|FG002|Open Label Treatment Period|Protocol Violation|0
6233499|NCT01778049|9910706|FG003|Open Label Treatment Period|Protocol Violation|0
6375710|NCT00593567|10165837|FG000|Overall Study|Lack of Efficacy|2
6375711|NCT00593567|10165838|FG001|Overall Study|Lack of Efficacy|1
6375712|NCT00593567|10165837|FG000|Overall Study|Withdrawal by Subject|1
6375713|NCT00593567|10165838|FG001|Overall Study|Withdrawal by Subject|2
6233500|NCT01778049|9910707|FG004|Open Label Treatment Period|Protocol Violation|0
6233501|NCT01778049|9910708|FG005|Open Label Treatment Period|Protocol Violation|0
6233502|NCT01778049|9910703|FG000|Open Label Treatment Period|Lost to Follow-up|4
6233503|NCT01778049|9910704|FG001|Open Label Treatment Period|Lost to Follow-up|3
6233504|NCT01778049|9910705|FG002|Open Label Treatment Period|Lost to Follow-up|0
6233505|NCT01778049|9910706|FG003|Open Label Treatment Period|Lost to Follow-up|0
6233506|NCT01778049|9910707|FG004|Open Label Treatment Period|Lost to Follow-up|0
6233507|NCT01778049|9910708|FG005|Open Label Treatment Period|Lost to Follow-up|0
6233508|NCT01778049|9910703|FG000|Open Label Treatment Period|Withdrawal by Subject|4
6233509|NCT01778049|9910704|FG001|Open Label Treatment Period|Withdrawal by Subject|10
6233510|NCT01778049|9910705|FG002|Open Label Treatment Period|Withdrawal by Subject|0
6233511|NCT01778049|9910706|FG003|Open Label Treatment Period|Withdrawal by Subject|0
6233512|NCT01778049|9910707|FG004|Open Label Treatment Period|Withdrawal by Subject|0
6233513|NCT01778049|9910708|FG005|Open Label Treatment Period|Withdrawal by Subject|0
6233514|NCT01778049|9910703|FG000|Open Label Treatment Period|Not treated|2
6233515|NCT01778049|9910704|FG001|Open Label Treatment Period|Not treated|1
6233516|NCT01778049|9910705|FG002|Open Label Treatment Period|Not treated|0
6233517|NCT01778049|9910706|FG003|Open Label Treatment Period|Not treated|0
6233518|NCT01778049|9910707|FG004|Open Label Treatment Period|Not treated|0
6233519|NCT01778049|9910708|FG005|Open Label Treatment Period|Not treated|0
6233520|NCT01778049|9910703|FG000|Open Label Treatment Period|Other reason not defined above|77
6233521|NCT01778049|9910704|FG001|Open Label Treatment Period|Other reason not defined above|94
6233522|NCT01778049|9910705|FG002|Open Label Treatment Period|Other reason not defined above|0
6233523|NCT01778049|9910706|FG003|Open Label Treatment Period|Other reason not defined above|0
6233524|NCT01778049|9910707|FG004|Open Label Treatment Period|Other reason not defined above|0
6233525|NCT01778049|9910708|FG005|Open Label Treatment Period|Other reason not defined above|0
6233526|NCT01778049|9910703|FG000|Double Blind Treatment Period|Adverse Event|0
6233527|NCT01778049|9910704|FG001|Double Blind Treatment Period|Adverse Event|0
6233528|NCT01778049|9910705|FG002|Double Blind Treatment Period|Adverse Event|4
6233529|NCT01778049|9910706|FG003|Double Blind Treatment Period|Adverse Event|5
6233530|NCT01778049|9910707|FG004|Double Blind Treatment Period|Adverse Event|3
6233531|NCT01778049|9910708|FG005|Double Blind Treatment Period|Adverse Event|2
6233532|NCT01778049|9910703|FG000|Double Blind Treatment Period|Lack of Efficacy|0
6233533|NCT01778049|9910704|FG001|Double Blind Treatment Period|Lack of Efficacy|0
6233534|NCT01778049|9910705|FG002|Double Blind Treatment Period|Lack of Efficacy|0
6233535|NCT01778049|9910706|FG003|Double Blind Treatment Period|Lack of Efficacy|0
6233536|NCT01778049|9910707|FG004|Double Blind Treatment Period|Lack of Efficacy|0
6233537|NCT01778049|9910708|FG005|Double Blind Treatment Period|Lack of Efficacy|1
6233538|NCT01778049|9910703|FG000|Double Blind Treatment Period|Protocol Violation|0
6233539|NCT01778049|9910704|FG001|Double Blind Treatment Period|Protocol Violation|0
6233540|NCT01778049|9910705|FG002|Double Blind Treatment Period|Protocol Violation|2
6233541|NCT01778049|9910706|FG003|Double Blind Treatment Period|Protocol Violation|0
6085660|NCT00654381|9695003|FG003|Extension Stage|Withdrawal by Subject|1
6233542|NCT01778049|9910707|FG004|Double Blind Treatment Period|Protocol Violation|0
6233543|NCT01778049|9910708|FG005|Double Blind Treatment Period|Protocol Violation|0
6233544|NCT01778049|9910703|FG000|Double Blind Treatment Period|Lost to Follow-up|0
6085661|NCT00654381|9695004|FG004|Extension Stage|Withdrawal by Subject|1
6085662|NCT00654381|9695005|FG005|Extension Stage|Withdrawal by Subject|1
6187264|NCT01380093|9841056|FG006|Drug Discrimination Phase: Day 2|Physician Decision|0
6187265|NCT01380093|9841057|FG007|Drug Discrimination Phase: Day 2|Physician Decision|0
6187266|NCT01380093|9841058|FG008|Drug Discrimination Phase: Day 2|Physician Decision|0
6187267|NCT01380093|9841050|FG000|Drug Discrimination Phase: Day 2|Withdrawal by Subject|0
6187268|NCT01380093|9841051|FG001|Drug Discrimination Phase: Day 2|Withdrawal by Subject|1
6187269|NCT01380093|9841052|FG002|Drug Discrimination Phase: Day 2|Withdrawal by Subject|0
6187270|NCT01380093|9841053|FG003|Drug Discrimination Phase: Day 2|Withdrawal by Subject|0
6187271|NCT01380093|9841054|FG004|Drug Discrimination Phase: Day 2|Withdrawal by Subject|0
6187272|NCT01380093|9841055|FG005|Drug Discrimination Phase: Day 2|Withdrawal by Subject|0
6187273|NCT01380093|9841056|FG006|Drug Discrimination Phase: Day 2|Withdrawal by Subject|0
6187274|NCT01380093|9841057|FG007|Drug Discrimination Phase: Day 2|Withdrawal by Subject|0
6187275|NCT01380093|9841058|FG008|Drug Discrimination Phase: Day 2|Withdrawal by Subject|0
6187276|NCT01380093|9841050|FG000|Drug Discrimination Phase: Day 2|Discrimination failure|0
6187277|NCT01380093|9841051|FG001|Drug Discrimination Phase: Day 2|Discrimination failure|4
6187278|NCT01380093|9841052|FG002|Drug Discrimination Phase: Day 2|Discrimination failure|9
6187279|NCT01380093|9841053|FG003|Drug Discrimination Phase: Day 2|Discrimination failure|0
6187280|NCT01380093|9841054|FG004|Drug Discrimination Phase: Day 2|Discrimination failure|0
6187281|NCT01380093|9841055|FG005|Drug Discrimination Phase: Day 2|Discrimination failure|0
6233545|NCT01778049|9910704|FG001|Double Blind Treatment Period|Lost to Follow-up|0
6233546|NCT01778049|9910705|FG002|Double Blind Treatment Period|Lost to Follow-up|4
6375714|NCT00588770|10165846|FG000|Overall Study|Disease progression|85
6375715|NCT00588770|10165847|FG001|Overall Study|Disease progression|68
6085663|NCT00654381|9695000|FG000|Extension Stage|Closure of the trial site|0
6085664|NCT00654381|9695001|FG001|Extension Stage|Closure of the trial site|0
6085665|NCT00654381|9695002|FG002|Extension Stage|Closure of the trial site|0
6085666|NCT00654381|9695003|FG003|Extension Stage|Closure of the trial site|0
6085667|NCT00654381|9695004|FG004|Extension Stage|Closure of the trial site|1
6085668|NCT00654381|9695005|FG005|Extension Stage|Closure of the trial site|1
6085669|NCT00654420|9695026|FG000|Phase I (Dose Escalation)|Adverse Event|0
6085670|NCT00654420|9695027|FG001|Phase I (Dose Escalation)|Adverse Event|1
6085671|NCT00654420|9695028|FG002|Phase I (Dose Escalation)|Adverse Event|0
6085672|NCT00654420|9695029|FG003|Phase I (Dose Escalation)|Adverse Event|0
6085673|NCT00654420|9695026|FG000|Phase I (Dose Escalation)|Progressive Disease|4
6085674|NCT00654420|9695027|FG001|Phase I (Dose Escalation)|Progressive Disease|15
6085675|NCT00654420|9695028|FG002|Phase I (Dose Escalation)|Progressive Disease|0
6085676|NCT00654420|9695029|FG003|Phase I (Dose Escalation)|Progressive Disease|0
6233547|NCT01778049|9910706|FG003|Double Blind Treatment Period|Lost to Follow-up|1
6233548|NCT01778049|9910707|FG004|Double Blind Treatment Period|Lost to Follow-up|5
6233549|NCT01778049|9910708|FG005|Double Blind Treatment Period|Lost to Follow-up|2
6233550|NCT01778049|9910703|FG000|Double Blind Treatment Period|Withdrawal by Subject|0
6233551|NCT01778049|9910704|FG001|Double Blind Treatment Period|Withdrawal by Subject|0
6233552|NCT01778049|9910705|FG002|Double Blind Treatment Period|Withdrawal by Subject|1
6233553|NCT01778049|9910706|FG003|Double Blind Treatment Period|Withdrawal by Subject|2
6233554|NCT01778049|9910707|FG004|Double Blind Treatment Period|Withdrawal by Subject|0
6233555|NCT01778049|9910708|FG005|Double Blind Treatment Period|Withdrawal by Subject|1
6233556|NCT01778049|9910703|FG000|Double Blind Treatment Period|Not treated|0
6233557|NCT01778049|9910704|FG001|Double Blind Treatment Period|Not treated|0
6233558|NCT01778049|9910705|FG002|Double Blind Treatment Period|Not treated|0
6233559|NCT01778049|9910706|FG003|Double Blind Treatment Period|Not treated|2
6233560|NCT01778049|9910707|FG004|Double Blind Treatment Period|Not treated|2
6233561|NCT01778049|9910708|FG005|Double Blind Treatment Period|Not treated|0
6233562|NCT01778049|9910703|FG000|Double Blind Treatment Period|Other reason not defined above|0
6233563|NCT01778049|9910704|FG001|Double Blind Treatment Period|Other reason not defined above|0
6233564|NCT01778049|9910705|FG002|Double Blind Treatment Period|Other reason not defined above|4
6233565|NCT01778049|9910706|FG003|Double Blind Treatment Period|Other reason not defined above|2
6233566|NCT01778049|9910707|FG004|Double Blind Treatment Period|Other reason not defined above|2
6233567|NCT01778049|9910708|FG005|Double Blind Treatment Period|Other reason not defined above|1
6233568|NCT01778062|9910722|FG000|Overall Study|Adverse Event|1
6233569|NCT01778062|9910723|FG001|Overall Study|Adverse Event|3
6233570|NCT01778062|9910722|FG000|Overall Study|Consent Withdrawal|1
6233571|NCT01778062|9910723|FG001|Overall Study|Consent Withdrawal|5
6233572|NCT01778062|9910722|FG000|Overall Study|major protocol deviation|4
6233573|NCT01778062|9910723|FG001|Overall Study|major protocol deviation|3
6233574|NCT01778127|9910732|FG000|Overall Study|Lost to Follow-up|5
6375716|NCT00588770|10165846|FG000|Overall Study|Adverse Event|29
6375717|NCT00588770|10165847|FG001|Overall Study|Adverse Event|58
6375718|NCT00588770|10165846|FG000|Overall Study|Death|13
6375719|NCT00588770|10165847|FG001|Overall Study|Death|22
6375720|NCT00588770|10165846|FG000|Overall Study|Withdrawal by Subject|15
6375721|NCT00588770|10165847|FG001|Overall Study|Withdrawal by Subject|25
6375722|NCT00588770|10165846|FG000|Overall Study|Alternative therapy|2
6375723|NCT00588770|10165847|FG001|Overall Study|Alternative therapy|4
6375724|NCT00588770|10165846|FG000|Overall Study|Other complicating disease|3
6375725|NCT00588770|10165847|FG001|Overall Study|Other complicating disease|2
6375726|NCT00588770|10165846|FG000|Overall Study|Not start protocol therapy|0
6375727|NCT00588770|10165847|FG001|Overall Study|Not start protocol therapy|9
6375728|NCT00588770|10165846|FG000|Overall Study|Lack of Efficacy|8
6375729|NCT00588770|10165847|FG001|Overall Study|Lack of Efficacy|10
6375730|NCT00588770|10165846|FG000|Overall Study|Physician discretion|2
6375731|NCT00588770|10165847|FG001|Overall Study|Physician discretion|0
6375732|NCT00588770|10165846|FG000|Overall Study|Patient non-compliance|2
6375733|NCT00588770|10165847|FG001|Overall Study|Patient non-compliance|2
6375734|NCT00412880|10165853|FG000|Overall Study|Withdrew, overdose of study treatment|1
6085677|NCT00654420|9695026|FG000|Phase II|Adverse Event|0
6233575|NCT01778127|9910733|FG001|Overall Study|Lost to Follow-up|1
6233576|NCT01778127|9910734|FG002|Overall Study|Lost to Follow-up|2
6233577|NCT01778127|9910732|FG000|Overall Study|Withdrawal by Subject|3
6233578|NCT01778127|9910733|FG001|Overall Study|Withdrawal by Subject|1
6233579|NCT01778127|9910734|FG002|Overall Study|Withdrawal by Subject|4
6233580|NCT01778530|9910777|FG000|Overall Study|Progression on study|1
6233581|NCT01778530|9910777|FG000|Overall Study|Adverse event/side effect|1
6233582|NCT01778556|9910783|FG000|Intervention 1 (5 Days)|Protocol Violation|0
6233583|NCT01778556|9910784|FG001|Intervention 1 (5 Days)|Protocol Violation|1
6233584|NCT01778556|9910783|FG000|Intervention 1 (5 Days)|Withdrawal by Subject|0
6233585|NCT01778556|9910784|FG001|Intervention 1 (5 Days)|Withdrawal by Subject|1
6233586|NCT01778556|9910783|FG000|Intervention 2 (14 Days)|Protocol Violation|1
6233587|NCT01778556|9910784|FG001|Intervention 2 (14 Days)|Protocol Violation|0
6085678|NCT00654420|9695027|FG001|Phase II|Adverse Event|0
6085679|NCT00654420|9695028|FG002|Phase II|Adverse Event|3
6085680|NCT00654420|9695029|FG003|Phase II|Adverse Event|3
6085681|NCT00654420|9695026|FG000|Phase II|Lost to Follow-up|0
6233588|NCT01778556|9910783|FG000|Long-term Follow-up|noncompliance with metreleptin|1
6233589|NCT01778556|9910784|FG001|Long-term Follow-up|noncompliance with metreleptin|0
6233590|NCT01778751|9910805|FG000|Overall Study|Lost to Follow-up|1
6233591|NCT01778751|9910806|FG001|Overall Study|Lost to Follow-up|0
6233592|NCT01778751|9910805|FG000|Overall Study|Withdrawal by Subject|0
6233593|NCT01778751|9910806|FG001|Overall Study|Withdrawal by Subject|2
6233594|NCT01778751|9910805|FG000|Overall Study|Transfered care|1
6233595|NCT01778751|9910806|FG001|Overall Study|Transfered care|0
6233596|NCT01778855|9910814|FG000|Overall Study|Death|0
6233597|NCT01778855|9910815|FG001|Overall Study|Death|1
6233598|NCT01778985|9910823|FG000|Overall Study|Lost to Follow-up|1
6233599|NCT01778985|9910824|FG001|Overall Study|Lost to Follow-up|0
6233600|NCT01778985|9910823|FG000|Overall Study|Physician Decision|2
6233601|NCT01778985|9910824|FG001|Overall Study|Physician Decision|2
6233602|NCT01778985|9910823|FG000|Overall Study|Protocol Violation|4
6233603|NCT01778985|9910824|FG001|Overall Study|Protocol Violation|1
6269893|NCT02146326|9970504|FG002|Overall Study|Lost to Follow-up|11
6269894|NCT02146326|9970505|FG003|Overall Study|Lost to Follow-up|19
6269895|NCT02146326|9970502|FG000|Overall Study|Withdrawal by Subject|2
6269896|NCT02146326|9970503|FG001|Overall Study|Withdrawal by Subject|1
6269897|NCT02146326|9970504|FG002|Overall Study|Withdrawal by Subject|15
6269898|NCT02146326|9970505|FG003|Overall Study|Withdrawal by Subject|11
6269899|NCT02146326|9970502|FG000|Overall Study|Separated from mental health center|23
6269900|NCT02146326|9970503|FG001|Overall Study|Separated from mental health center|33
6269901|NCT02146326|9970504|FG002|Overall Study|Separated from mental health center|0
6269902|NCT02146326|9970505|FG003|Overall Study|Separated from mental health center|0
6269903|NCT02146326|9970502|FG000|Overall Study|Incarcerated|0
6269904|NCT02146326|9970503|FG001|Overall Study|Incarcerated|0
6269905|NCT02146326|9970504|FG002|Overall Study|Incarcerated|3
6269906|NCT02146326|9970505|FG003|Overall Study|Incarcerated|8
6269907|NCT02146326|9970502|FG000|Overall Study|Death|0
6269908|NCT02146326|9970503|FG001|Overall Study|Death|0
6269909|NCT02146326|9970504|FG002|Overall Study|Death|4
6269910|NCT02146326|9970505|FG003|Overall Study|Death|4
6269911|NCT02146326|9970502|FG000|Overall Study|Unable to complete interview|0
6269912|NCT02146326|9970503|FG001|Overall Study|Unable to complete interview|0
6269913|NCT02146326|9970504|FG002|Overall Study|Unable to complete interview|10
6269914|NCT02146326|9970505|FG003|Overall Study|Unable to complete interview|6
6269915|NCT02146352|9970521|FG000|Overall Study|Death|1
6269916|NCT02146352|9970521|FG000|Overall Study|Patient entered hospice care|1
6269917|NCT02146365|9970531|FG000|Overall Study|Lost to Follow-up|2
6269918|NCT02146365|9970532|FG001|Overall Study|Lost to Follow-up|1
6269919|NCT02146365|9970533|FG002|Overall Study|Lost to Follow-up|3
6269920|NCT02146365|9970534|FG003|Overall Study|Lost to Follow-up|3
6269921|NCT02146365|9970535|FG004|Overall Study|Lost to Follow-up|1
6269922|NCT02146365|9970536|FG005|Overall Study|Lost to Follow-up|1
6269923|NCT02146365|9970537|FG006|Overall Study|Lost to Follow-up|0
6269924|NCT02146365|9970538|FG007|Overall Study|Lost to Follow-up|1
6269925|NCT02146365|9970531|FG000|Overall Study|Withdrawal by Subject|1
6269926|NCT02146365|9970532|FG001|Overall Study|Withdrawal by Subject|2
6269927|NCT02146365|9970533|FG002|Overall Study|Withdrawal by Subject|1
6269928|NCT02146365|9970534|FG003|Overall Study|Withdrawal by Subject|5
6269929|NCT02146365|9970535|FG004|Overall Study|Withdrawal by Subject|1
6269930|NCT02146365|9970536|FG005|Overall Study|Withdrawal by Subject|0
6187282|NCT01380093|9841056|FG006|Drug Discrimination Phase: Day 2|Discrimination failure|0
6187283|NCT01380093|9841057|FG007|Drug Discrimination Phase: Day 2|Discrimination failure|0
6187284|NCT01380093|9841058|FG008|Drug Discrimination Phase: Day 2|Discrimination failure|0
6187285|NCT01380093|9841050|FG000|Drug Discrimination Phase: Day 2|Positive urine drug screen|0
6187286|NCT01380093|9841051|FG001|Drug Discrimination Phase: Day 2|Positive urine drug screen|1
6187287|NCT01380093|9841052|FG002|Drug Discrimination Phase: Day 2|Positive urine drug screen|1
6187288|NCT01380093|9841053|FG003|Drug Discrimination Phase: Day 2|Positive urine drug screen|0
6187289|NCT01380093|9841054|FG004|Drug Discrimination Phase: Day 2|Positive urine drug screen|0
6187290|NCT01380093|9841055|FG005|Drug Discrimination Phase: Day 2|Positive urine drug screen|0
6187291|NCT01380093|9841056|FG006|Drug Discrimination Phase: Day 2|Positive urine drug screen|0
6187292|NCT01380093|9841057|FG007|Drug Discrimination Phase: Day 2|Positive urine drug screen|0
6187293|NCT01380093|9841058|FG008|Drug Discrimination Phase: Day 2|Positive urine drug screen|0
6187294|NCT01380093|9841050|FG000|Drug Discrimination Phase: Day 2|Backup participant|0
6187295|NCT01380093|9841051|FG001|Drug Discrimination Phase: Day 2|Backup participant|0
6187296|NCT01380093|9841052|FG002|Drug Discrimination Phase: Day 2|Backup participant|1
6187297|NCT01380093|9841053|FG003|Drug Discrimination Phase: Day 2|Backup participant|0
6187298|NCT01380093|9841054|FG004|Drug Discrimination Phase: Day 2|Backup participant|0
6187299|NCT01380093|9841055|FG005|Drug Discrimination Phase: Day 2|Backup participant|0
6269931|NCT02146365|9970537|FG006|Overall Study|Withdrawal by Subject|0
6269932|NCT02146365|9970538|FG007|Overall Study|Withdrawal by Subject|0
6269933|NCT02146365|9970531|FG000|Overall Study|Unable to Comply with Protocol|0
6269934|NCT02146365|9970532|FG001|Overall Study|Unable to Comply with Protocol|1
6269935|NCT02146365|9970533|FG002|Overall Study|Unable to Comply with Protocol|1
6269936|NCT02146365|9970534|FG003|Overall Study|Unable to Comply with Protocol|0
6269937|NCT02146365|9970535|FG004|Overall Study|Unable to Comply with Protocol|0
6085682|NCT00654420|9695027|FG001|Phase II|Lost to Follow-up|0
6085683|NCT00654420|9695028|FG002|Phase II|Lost to Follow-up|0
6187300|NCT01380093|9841056|FG006|Drug Discrimination Phase: Day 2|Backup participant|0
6233604|NCT01779440|9910867|FG000|Overall Study|Withdrawal by Subject|3
6233605|NCT01779440|9910868|FG001|Overall Study|Withdrawal by Subject|5
6233606|NCT01779648|9910876|FG000|Overall Study|Protocol Violation|1
6233607|NCT01779648|9910877|FG001|Overall Study|Protocol Violation|0
6233608|NCT01779700|9910885|FG000|Overall Study|Adverse Event|4
6233609|NCT01779700|9910886|FG001|Overall Study|Adverse Event|3
6233610|NCT01779700|9910885|FG000|Overall Study|Withdrawal by Subject|0
6233611|NCT01779700|9910886|FG001|Overall Study|Withdrawal by Subject|2
6233612|NCT01779856|9910892|FG000|Overall Study|Withdrawal by Subject|15
6233613|NCT01779856|9910892|FG000|Overall Study|Death|3
6233614|NCT01779856|9910892|FG000|Overall Study|Physician Decision|1
6233615|NCT01779856|9910892|FG000|Overall Study|Inclusion/Exclusion Not Met|2
6233616|NCT01779856|9910892|FG000|Overall Study|Delays in scheduling implant|1
6233617|NCT01779856|9910892|FG000|Overall Study|Subject ineligible for Implant|2
6233618|NCT01779869|9910903|FG000|Overall Study|Physician Decision|2
6233619|NCT01780389|9910929|FG000|Overall Study|Adverse Event|1
6233620|NCT01780506|9910940|FG000|Double-Blind Phase|Randomized but not Treated|3
6233621|NCT01780506|9910941|FG001|Double-Blind Phase|Randomized but not Treated|2
6233622|NCT01780506|9910940|FG000|Double-Blind Phase|Adverse Event|4
6233623|NCT01780506|9910941|FG001|Double-Blind Phase|Adverse Event|14
6233624|NCT01780506|9910940|FG000|Double-Blind Phase|Death|1
6233625|NCT01780506|9910941|FG001|Double-Blind Phase|Death|2
6233626|NCT01780506|9910940|FG000|Double-Blind Phase|Pregnancy|2
6233627|NCT01780506|9910941|FG001|Double-Blind Phase|Pregnancy|1
6233628|NCT01780506|9910940|FG000|Double-Blind Phase|Lack of Efficacy|1
6233629|NCT01780506|9910941|FG001|Double-Blind Phase|Lack of Efficacy|1
6233630|NCT01780506|9910940|FG000|Double-Blind Phase|Investigator's Discretion|5
6233631|NCT01780506|9910941|FG001|Double-Blind Phase|Investigator's Discretion|2
6233632|NCT01780506|9910940|FG000|Double-Blind Phase|Non-Compliance with Study Drug|4
6233633|NCT01780506|9910941|FG001|Double-Blind Phase|Non-Compliance with Study Drug|3
6233634|NCT01780506|9910940|FG000|Double-Blind Phase|Protocol Violation|4
6233635|NCT01780506|9910941|FG001|Double-Blind Phase|Protocol Violation|3
6233636|NCT01780506|9910940|FG000|Double-Blind Phase|Withdrew Consent|23
6233637|NCT01780506|9910941|FG001|Double-Blind Phase|Withdrew Consent|24
6233638|NCT01780506|9910940|FG000|Double-Blind Phase|Lost to Follow-up|23
6233639|NCT01780506|9910941|FG001|Double-Blind Phase|Lost to Follow-up|26
6233640|NCT01780506|9910940|FG000|Open-Label Extension Phase|Enrolled but not Treated|0
6233641|NCT01780506|9910941|FG001|Open-Label Extension Phase|Enrolled but not Treated|1
6233642|NCT01780545|9910951|FG000|Overall Study|Withdrawal by Subject|3
6233643|NCT01780545|9910952|FG001|Overall Study|Withdrawal by Subject|1
6233644|NCT01780545|9910951|FG000|Overall Study|Lost to Follow-up|1
6233645|NCT01780545|9910952|FG001|Overall Study|Lost to Follow-up|1
6233646|NCT01780584|9910964|FG000|Overall Study|Death|1
6233647|NCT01780584|9910965|FG001|Overall Study|Death|0
6233648|NCT01780584|9910966|FG002|Overall Study|Death|1
6233649|NCT01780584|9910964|FG000|Overall Study|Adverse Event|0
6233650|NCT01780584|9910965|FG001|Overall Study|Adverse Event|1
6233651|NCT01780584|9910966|FG002|Overall Study|Adverse Event|0
6233652|NCT01780584|9910964|FG000|Overall Study|Protocol Violation|0
6233653|NCT01780584|9910965|FG001|Overall Study|Protocol Violation|0
6233654|NCT01780584|9910966|FG002|Overall Study|Protocol Violation|1
6233655|NCT01780662|9910977|FG000|Overall Study|Adverse Event|1
6233656|NCT01780662|9910978|FG001|Overall Study|Adverse Event|0
6187301|NCT01380093|9841057|FG007|Drug Discrimination Phase: Day 2|Backup participant|0
6187302|NCT01380093|9841058|FG008|Drug Discrimination Phase: Day 2|Backup participant|0
6187303|NCT01380093|9841050|FG000|Drug Discrimination Phase: Day 2|Sponsor decision|0
6187304|NCT01380093|9841051|FG001|Drug Discrimination Phase: Day 2|Sponsor decision|0
6187305|NCT01380093|9841052|FG002|Drug Discrimination Phase: Day 2|Sponsor decision|1
6187306|NCT01380093|9841053|FG003|Drug Discrimination Phase: Day 2|Sponsor decision|0
6187307|NCT01380093|9841054|FG004|Drug Discrimination Phase: Day 2|Sponsor decision|0
6187308|NCT01380093|9841055|FG005|Drug Discrimination Phase: Day 2|Sponsor decision|0
6187309|NCT01380093|9841056|FG006|Drug Discrimination Phase: Day 2|Sponsor decision|0
6187310|NCT01380093|9841057|FG007|Drug Discrimination Phase: Day 2|Sponsor decision|0
6187311|NCT01380093|9841058|FG008|Drug Discrimination Phase: Day 2|Sponsor decision|0
6187312|NCT01380093|9841050|FG000|Treatment Phase: Second Intervention|Other|0
6187313|NCT01380093|9841051|FG001|Treatment Phase: Second Intervention|Other|0
6187314|NCT01380093|9841052|FG002|Treatment Phase: Second Intervention|Other|0
6233657|NCT01780662|9910979|FG002|Overall Study|Adverse Event|2
6233658|NCT01780662|9910977|FG000|Overall Study|Physician Decision|0
6233659|NCT01780662|9910978|FG001|Overall Study|Physician Decision|5
6233660|NCT01780662|9910979|FG002|Overall Study|Physician Decision|7
6187315|NCT01380093|9841053|FG003|Treatment Phase: Second Intervention|Other|1
6187316|NCT01380093|9841054|FG004|Treatment Phase: Second Intervention|Other|0
6233661|NCT01780662|9910977|FG000|Overall Study|Protocol Violation|0
6233662|NCT01780662|9910978|FG001|Overall Study|Protocol Violation|1
6233663|NCT01780662|9910979|FG002|Overall Study|Protocol Violation|0
6233664|NCT01780662|9910977|FG000|Overall Study|Ineligible|0
6233665|NCT01780662|9910978|FG001|Overall Study|Ineligible|0
6233666|NCT01780662|9910979|FG002|Overall Study|Ineligible|1
6233667|NCT01780831|9910992|FG000|Overall Study|Withdrawal by Subject|0
6233668|NCT01780831|9910993|FG001|Overall Study|Withdrawal by Subject|0
6233669|NCT01780831|9910994|FG002|Overall Study|Withdrawal by Subject|4
6233670|NCT01780831|9910995|FG003|Overall Study|Withdrawal by Subject|0
6233671|NCT01780831|9910992|FG000|Overall Study|Lost to Follow-up|0
6233672|NCT01780831|9910993|FG001|Overall Study|Lost to Follow-up|0
6233673|NCT01780831|9910994|FG002|Overall Study|Lost to Follow-up|0
6233674|NCT01780831|9910995|FG003|Overall Study|Lost to Follow-up|1
6233675|NCT01780935|9911076|FG000|Overall Study|Admin problems due to early termination|321
6233676|NCT01780935|9911077|FG001|Overall Study|Admin problems due to early termination|309
6233677|NCT01780935|9911076|FG000|Overall Study|Adverse Event|2
6233678|NCT01780935|9911077|FG001|Overall Study|Adverse Event|4
6233679|NCT01780935|9911076|FG000|Overall Study|Death|1
6233680|NCT01780935|9911077|FG001|Overall Study|Death|6
6233681|NCT01780935|9911076|FG000|Overall Study|Lost to Follow-up|2
6233682|NCT01780935|9911077|FG001|Overall Study|Lost to Follow-up|6
6233683|NCT01780935|9911076|FG000|Overall Study|Physician Decision|1
6233684|NCT01780935|9911077|FG001|Overall Study|Physician Decision|1
6233685|NCT01780935|9911076|FG000|Overall Study|Protocol deviation|0
6233686|NCT01780935|9911077|FG001|Overall Study|Protocol deviation|1
6233687|NCT01780935|9911076|FG000|Overall Study|Patient withdrew consent|8
6233688|NCT01780935|9911077|FG001|Overall Study|Patient withdrew consent|9
6233689|NCT01780974|9911085|FG000|Overall Study|Death|1
6233690|NCT01780974|9911086|FG001|Overall Study|Death|0
6233691|NCT01780974|9911085|FG000|Overall Study|Adverse Event|1
6233692|NCT01780974|9911086|FG001|Overall Study|Adverse Event|3
6233693|NCT01780987|9911094|FG000|Overall Study|Adverse Event|0
6233694|NCT01780987|9911095|FG001|Overall Study|Adverse Event|4
6233695|NCT01780987|9911094|FG000|Overall Study|Withdrawal by Subject|2
6233696|NCT01780987|9911095|FG001|Overall Study|Withdrawal by Subject|0
6233697|NCT01780987|9911094|FG000|Overall Study|Request of Changing Hospital|0
6233698|NCT01780987|9911095|FG001|Overall Study|Request of Changing Hospital|1
6233699|NCT01780987|9911094|FG000|Overall Study|Changing Residence|1
6233700|NCT01780987|9911095|FG001|Overall Study|Changing Residence|0
6233701|NCT01780987|9911094|FG000|Overall Study|Not Receiving any Study Medication|0
6233702|NCT01780987|9911095|FG001|Overall Study|Not Receiving any Study Medication|1
6233703|NCT01781234|9911130|FG000|Overall Study|Adverse Event|2
6233704|NCT01781234|9911131|FG001|Overall Study|Adverse Event|0
6233705|NCT01781234|9911130|FG000|Overall Study|Protocol Violation|3
6233706|NCT01781234|9911131|FG001|Overall Study|Protocol Violation|0
6233707|NCT01781234|9911130|FG000|Overall Study|Withdrawal by Subject|4
6233708|NCT01781234|9911131|FG001|Overall Study|Withdrawal by Subject|3
6233709|NCT01781286|9911139|FG000|Overall Study|Lost to Follow-up|0
6233710|NCT01781286|9911140|FG001|Overall Study|Lost to Follow-up|0
6233711|NCT01781286|9911141|FG002|Overall Study|Lost to Follow-up|0
6233712|NCT01781286|9911142|FG003|Overall Study|Lost to Follow-up|0
6233713|NCT01781286|9911143|FG004|Overall Study|Lost to Follow-up|0
6233714|NCT01781286|9911144|FG005|Overall Study|Lost to Follow-up|1
6233715|NCT01781286|9911139|FG000|Overall Study|Time Constraints|2
6233716|NCT01781286|9911140|FG001|Overall Study|Time Constraints|0
6233717|NCT01781286|9911141|FG002|Overall Study|Time Constraints|2
6233718|NCT01781286|9911142|FG003|Overall Study|Time Constraints|0
6233719|NCT01781286|9911143|FG004|Overall Study|Time Constraints|0
6233720|NCT01781286|9911144|FG005|Overall Study|Time Constraints|0
6233721|NCT01781286|9911139|FG000|Overall Study|Noncompliance|0
6233722|NCT01781286|9911140|FG001|Overall Study|Noncompliance|0
6233723|NCT01781286|9911141|FG002|Overall Study|Noncompliance|0
6233724|NCT01781286|9911142|FG003|Overall Study|Noncompliance|1
6233725|NCT01781286|9911143|FG004|Overall Study|Noncompliance|0
6233726|NCT01781286|9911144|FG005|Overall Study|Noncompliance|0
6233727|NCT01781299|9911156|FG000|Overall Study|Withdrawal by Subject|0
6233728|NCT01781299|9911157|FG001|Overall Study|Withdrawal by Subject|1
6233729|NCT01781429|9911190|FG000|Overall Study|Death|0
6233730|NCT01781429|9911191|FG001|Overall Study|Death|0
6233731|NCT01781429|9911192|FG002|Overall Study|Death|0
6233732|NCT01781429|9911193|FG003|Overall Study|Death|0
6233733|NCT01781429|9911194|FG004|Overall Study|Death|0
6233734|NCT01781429|9911195|FG005|Overall Study|Death|0
6233735|NCT01781429|9911196|FG006|Overall Study|Death|0
6233736|NCT01781429|9911197|FG007|Overall Study|Death|0
6233737|NCT01781429|9911198|FG008|Overall Study|Death|0
6233738|NCT01781429|9911199|FG009|Overall Study|Death|1
6233739|NCT01781429|9911200|FG010|Overall Study|Death|0
6233740|NCT01781429|9911201|FG011|Overall Study|Death|0
6233741|NCT01781429|9911202|FG012|Overall Study|Death|1
6233742|NCT01781429|9911203|FG013|Overall Study|Death|0
6233743|NCT01781429|9911204|FG014|Overall Study|Death|1
6233744|NCT01781429|9911205|FG015|Overall Study|Death|0
6233745|NCT01781429|9911190|FG000|Overall Study|Withdrawal by Subject|0
6233746|NCT01781429|9911191|FG001|Overall Study|Withdrawal by Subject|0
6233747|NCT01781429|9911192|FG002|Overall Study|Withdrawal by Subject|0
6233748|NCT01781429|9911193|FG003|Overall Study|Withdrawal by Subject|0
6233749|NCT01781429|9911194|FG004|Overall Study|Withdrawal by Subject|0
6233750|NCT01781429|9911195|FG005|Overall Study|Withdrawal by Subject|0
6233751|NCT01781429|9911196|FG006|Overall Study|Withdrawal by Subject|0
6233752|NCT01781429|9911197|FG007|Overall Study|Withdrawal by Subject|0
6233753|NCT01781429|9911198|FG008|Overall Study|Withdrawal by Subject|1
6233754|NCT01781429|9911199|FG009|Overall Study|Withdrawal by Subject|3
6233755|NCT01781429|9911200|FG010|Overall Study|Withdrawal by Subject|1
6233756|NCT01781429|9911201|FG011|Overall Study|Withdrawal by Subject|1
6233757|NCT01781429|9911202|FG012|Overall Study|Withdrawal by Subject|5
6233758|NCT01781429|9911203|FG013|Overall Study|Withdrawal by Subject|2
6233759|NCT01781429|9911204|FG014|Overall Study|Withdrawal by Subject|3
6233760|NCT01781429|9911205|FG015|Overall Study|Withdrawal by Subject|0
6233761|NCT01781429|9911190|FG000|Overall Study|Disease Progression|1
6233762|NCT01781429|9911191|FG001|Overall Study|Disease Progression|0
6233763|NCT01781429|9911192|FG002|Overall Study|Disease Progression|1
6233764|NCT01781429|9911193|FG003|Overall Study|Disease Progression|1
6233765|NCT01781429|9911194|FG004|Overall Study|Disease Progression|1
6233766|NCT01781429|9911195|FG005|Overall Study|Disease Progression|4
6233767|NCT01781429|9911196|FG006|Overall Study|Disease Progression|7
6233768|NCT01781429|9911197|FG007|Overall Study|Disease Progression|4
6233769|NCT01781429|9911198|FG008|Overall Study|Disease Progression|6
6233770|NCT01781429|9911199|FG009|Overall Study|Disease Progression|15
6233771|NCT01781429|9911200|FG010|Overall Study|Disease Progression|15
6233772|NCT01781429|9911201|FG011|Overall Study|Disease Progression|15
6233773|NCT01781429|9911202|FG012|Overall Study|Disease Progression|15
6233774|NCT01781429|9911203|FG013|Overall Study|Disease Progression|4
6233775|NCT01781429|9911204|FG014|Overall Study|Disease Progression|11
6233776|NCT01781429|9911205|FG015|Overall Study|Disease Progression|0
6233777|NCT01781429|9911190|FG000|Overall Study|Unacceptable Toxicity|0
6233778|NCT01781429|9911191|FG001|Overall Study|Unacceptable Toxicity|0
6233779|NCT01781429|9911192|FG002|Overall Study|Unacceptable Toxicity|0
6233780|NCT01781429|9911193|FG003|Overall Study|Unacceptable Toxicity|0
6233781|NCT01781429|9911194|FG004|Overall Study|Unacceptable Toxicity|0
6233782|NCT01781429|9911195|FG005|Overall Study|Unacceptable Toxicity|0
6233783|NCT01781429|9911196|FG006|Overall Study|Unacceptable Toxicity|0
6233784|NCT01781429|9911197|FG007|Overall Study|Unacceptable Toxicity|0
6233785|NCT01781429|9911198|FG008|Overall Study|Unacceptable Toxicity|0
6233786|NCT01781429|9911199|FG009|Overall Study|Unacceptable Toxicity|0
6233787|NCT01781429|9911200|FG010|Overall Study|Unacceptable Toxicity|0
6233788|NCT01781429|9911201|FG011|Overall Study|Unacceptable Toxicity|2
6233789|NCT01781429|9911202|FG012|Overall Study|Unacceptable Toxicity|0
6233790|NCT01781429|9911203|FG013|Overall Study|Unacceptable Toxicity|0
6233791|NCT01781429|9911204|FG014|Overall Study|Unacceptable Toxicity|0
6233792|NCT01781429|9911205|FG015|Overall Study|Unacceptable Toxicity|0
6233793|NCT01781429|9911190|FG000|Overall Study|Patient Condition Changed|0
6233794|NCT01781429|9911191|FG001|Overall Study|Patient Condition Changed|0
6233795|NCT01781429|9911192|FG002|Overall Study|Patient Condition Changed|0
6233796|NCT01781429|9911193|FG003|Overall Study|Patient Condition Changed|0
6233797|NCT01781429|9911194|FG004|Overall Study|Patient Condition Changed|0
6233798|NCT01781429|9911195|FG005|Overall Study|Patient Condition Changed|0
6233799|NCT01781429|9911196|FG006|Overall Study|Patient Condition Changed|0
6233800|NCT01781429|9911197|FG007|Overall Study|Patient Condition Changed|0
6233801|NCT01781429|9911198|FG008|Overall Study|Patient Condition Changed|0
6233802|NCT01781429|9911199|FG009|Overall Study|Patient Condition Changed|4
6233803|NCT01781429|9911200|FG010|Overall Study|Patient Condition Changed|0
6233804|NCT01781429|9911201|FG011|Overall Study|Patient Condition Changed|1
6233805|NCT01781429|9911202|FG012|Overall Study|Patient Condition Changed|0
6233806|NCT01781429|9911203|FG013|Overall Study|Patient Condition Changed|1
6233807|NCT01781429|9911204|FG014|Overall Study|Patient Condition Changed|0
6233808|NCT01781429|9911205|FG015|Overall Study|Patient Condition Changed|0
6233809|NCT01781429|9911190|FG000|Overall Study|Other - as entered by PI in eCRF|0
6233810|NCT01781429|9911191|FG001|Overall Study|Other - as entered by PI in eCRF|1
6233811|NCT01781429|9911192|FG002|Overall Study|Other - as entered by PI in eCRF|0
6233812|NCT01781429|9911193|FG003|Overall Study|Other - as entered by PI in eCRF|0
6187317|NCT01380093|9841055|FG005|Treatment Phase: Second Intervention|Other|0
6187318|NCT01380093|9841056|FG006|Treatment Phase: Second Intervention|Other|0
6187319|NCT01380093|9841057|FG007|Treatment Phase: Second Intervention|Other|0
6187320|NCT01380093|9841058|FG008|Treatment Phase: Second Intervention|Other|0
6187321|NCT01380093|9841050|FG000|Treatment Phase: Third Intervention|Non-compliance|0
6187322|NCT01380093|9841051|FG001|Treatment Phase: Third Intervention|Non-compliance|0
6187323|NCT01380093|9841052|FG002|Treatment Phase: Third Intervention|Non-compliance|0
6187324|NCT01380093|9841053|FG003|Treatment Phase: Third Intervention|Non-compliance|0
6187325|NCT01380093|9841054|FG004|Treatment Phase: Third Intervention|Non-compliance|0
6187326|NCT01380093|9841055|FG005|Treatment Phase: Third Intervention|Non-compliance|0
6187327|NCT01380093|9841056|FG006|Treatment Phase: Third Intervention|Non-compliance|0
6233813|NCT01781429|9911194|FG004|Overall Study|Other - as entered by PI in eCRF|0
6233814|NCT01781429|9911195|FG005|Overall Study|Other - as entered by PI in eCRF|0
6233815|NCT01781429|9911196|FG006|Overall Study|Other - as entered by PI in eCRF|0
6233816|NCT01781429|9911197|FG007|Overall Study|Other - as entered by PI in eCRF|0
6233817|NCT01781429|9911198|FG008|Overall Study|Other - as entered by PI in eCRF|0
6233818|NCT01781429|9911199|FG009|Overall Study|Other - as entered by PI in eCRF|1
6233819|NCT01781429|9911200|FG010|Overall Study|Other - as entered by PI in eCRF|1
6233820|NCT01781429|9911201|FG011|Overall Study|Other - as entered by PI in eCRF|2
6233821|NCT01781429|9911202|FG012|Overall Study|Other - as entered by PI in eCRF|1
6233822|NCT01781429|9911203|FG013|Overall Study|Other - as entered by PI in eCRF|1
6233823|NCT01781429|9911204|FG014|Overall Study|Other - as entered by PI in eCRF|1
6233824|NCT01781429|9911205|FG015|Overall Study|Other - as entered by PI in eCRF|0
6233825|NCT01781429|9911190|FG000|Overall Study|Enrolled, but not treated|0
6233826|NCT01781429|9911191|FG001|Overall Study|Enrolled, but not treated|0
6233827|NCT01781429|9911192|FG002|Overall Study|Enrolled, but not treated|0
6233828|NCT01781429|9911193|FG003|Overall Study|Enrolled, but not treated|0
6233829|NCT01781429|9911194|FG004|Overall Study|Enrolled, but not treated|0
6233830|NCT01781429|9911195|FG005|Overall Study|Enrolled, but not treated|0
6233831|NCT01781429|9911196|FG006|Overall Study|Enrolled, but not treated|0
6233832|NCT01781429|9911197|FG007|Overall Study|Enrolled, but not treated|0
6233833|NCT01781429|9911198|FG008|Overall Study|Enrolled, but not treated|0
6233834|NCT01781429|9911199|FG009|Overall Study|Enrolled, but not treated|0
6233835|NCT01781429|9911200|FG010|Overall Study|Enrolled, but not treated|1
6233836|NCT01781429|9911201|FG011|Overall Study|Enrolled, but not treated|0
6233837|NCT01781429|9911202|FG012|Overall Study|Enrolled, but not treated|0
6233838|NCT01781429|9911203|FG013|Overall Study|Enrolled, but not treated|0
6233839|NCT01781429|9911204|FG014|Overall Study|Enrolled, but not treated|0
6233840|NCT01781429|9911205|FG015|Overall Study|Enrolled, but not treated|0
6233841|NCT01781572|9911308|FG000|MEK162 45mg BID+LEE011 200mg|Adverse Event|7
6233842|NCT01781572|9911309|FG001|MEK162 45mg BID+LEE011 200mg|Adverse Event|0
6233843|NCT01781572|9911310|FG002|MEK162 45mg BID+LEE011 200mg|Adverse Event|11
6233844|NCT01781572|9911308|FG000|MEK162 45mg BID+LEE011 200mg|Progressive disease|8
6233845|NCT01781572|9911309|FG001|MEK162 45mg BID+LEE011 200mg|Progressive disease|6
6233846|NCT01781572|9911310|FG002|MEK162 45mg BID+LEE011 200mg|Progressive disease|23
6233847|NCT01781572|9911308|FG000|MEK162 45mg BID+LEE011 200mg|Withdrawal by Subject|1
6233848|NCT01781572|9911309|FG001|MEK162 45mg BID+LEE011 200mg|Withdrawal by Subject|0
6233849|NCT01781572|9911310|FG002|MEK162 45mg BID+LEE011 200mg|Withdrawal by Subject|2
6233850|NCT01781572|9911308|FG000|MEK162 45mg BID+LEE011 200mg|Physician Decision|0
6233851|NCT01781572|9911309|FG001|MEK162 45mg BID+LEE011 200mg|Physician Decision|0
6233852|NCT01781572|9911310|FG002|MEK162 45mg BID+LEE011 200mg|Physician Decision|4
6233853|NCT01781572|9911308|FG000|MEK162 45mg BID+LEE011 200mg|Death|0
6233854|NCT01781572|9911309|FG001|MEK162 45mg BID+LEE011 200mg|Death|0
6233855|NCT01781572|9911310|FG002|MEK162 45mg BID+LEE011 200mg|Death|1
6233856|NCT01781572|9911308|FG000|MEK162 45mg BID+LEE011 250mg|Progressive Disease|2
6233857|NCT01781572|9911309|FG001|MEK162 45mg BID+LEE011 250mg|Progressive Disease|0
6233858|NCT01781572|9911310|FG002|MEK162 45mg BID+LEE011 250mg|Progressive Disease|0
6233859|NCT01781572|9911308|FG000|MEK162 45mg BID+LEE011 250mg|Withdrawal by Subject|1
6233860|NCT01781572|9911309|FG001|MEK162 45mg BID+LEE011 250mg|Withdrawal by Subject|0
6233861|NCT01781572|9911310|FG002|MEK162 45mg BID+LEE011 250mg|Withdrawal by Subject|0
6233862|NCT01781572|9911308|FG000|MEK162 30mg BID+LEE011 300mg|Adverse Event|1
6233863|NCT01781572|9911309|FG001|MEK162 30mg BID+LEE011 300mg|Adverse Event|0
6233864|NCT01781572|9911310|FG002|MEK162 30mg BID+LEE011 300mg|Adverse Event|0
6233865|NCT01781572|9911308|FG000|MEK162 30mg BID+LEE011 300mg|Progressive Disease|3
6233866|NCT01781572|9911309|FG001|MEK162 30mg BID+LEE011 300mg|Progressive Disease|2
6233867|NCT01781572|9911310|FG002|MEK162 30mg BID+LEE011 300mg|Progressive Disease|0
6233868|NCT01781572|9911308|FG000|MEK162 45mg BID+LEE011 300mg|Adverse Event|1
6233869|NCT01781572|9911309|FG001|MEK162 45mg BID+LEE011 300mg|Adverse Event|1
6233870|NCT01781572|9911310|FG002|MEK162 45mg BID+LEE011 300mg|Adverse Event|0
6233871|NCT01781572|9911308|FG000|MEK162 45mg BID+LEE011 300mg|Progressive Disease|4
6233872|NCT01781572|9911309|FG001|MEK162 45mg BID+LEE011 300mg|Progressive Disease|3
6233873|NCT01781572|9911310|FG002|MEK162 45mg BID+LEE011 300mg|Progressive Disease|0
6233874|NCT01781572|9911308|FG000|MEK162 45mg BID+LEE011 300mg|Death|1
6233875|NCT01781572|9911309|FG001|MEK162 45mg BID+LEE011 300mg|Death|0
6233876|NCT01781572|9911310|FG002|MEK162 45mg BID+LEE011 300mg|Death|0
6233877|NCT01781572|9911308|FG000|MEK162 30mg LEE011 200mg|Progressive Disease|0
6233878|NCT01781572|9911309|FG001|MEK162 30mg LEE011 200mg|Progressive Disease|5
6233879|NCT01781572|9911310|FG002|MEK162 30mg LEE011 200mg|Progressive Disease|0
6233880|NCT01781572|9911308|FG000|MEK162 45mg LEE011 450mg|Adverse Event|0
6233881|NCT01781572|9911309|FG001|MEK162 45mg LEE011 450mg|Adverse Event|1
6233882|NCT01781572|9911310|FG002|MEK162 45mg LEE011 450mg|Adverse Event|0
6233883|NCT01781572|9911308|FG000|MEK162 45mg LEE011 450mg|Physician Decision|0
6233884|NCT01781572|9911309|FG001|MEK162 45mg LEE011 450mg|Physician Decision|2
6233885|NCT01781572|9911310|FG002|MEK162 45mg LEE011 450mg|Physician Decision|0
6233886|NCT01781572|9911308|FG000|MEK162 45mg LEE011 450mg|Progressive Disease|0
6233887|NCT01781572|9911309|FG001|MEK162 45mg LEE011 450mg|Progressive Disease|6
6233888|NCT01781572|9911310|FG002|MEK162 45mg LEE011 450mg|Progressive Disease|0
6233889|NCT01781572|9911308|FG000|MEK162 45mg LEE011 600mg|Adverse Event|0
6233890|NCT01781572|9911309|FG001|MEK162 45mg LEE011 600mg|Adverse Event|1
6233891|NCT01781572|9911310|FG002|MEK162 45mg LEE011 600mg|Adverse Event|0
6233892|NCT01781572|9911308|FG000|MEK162 45mg LEE011 600mg|Progressive Disease|0
6233893|NCT01781572|9911309|FG001|MEK162 45mg LEE011 600mg|Progressive Disease|5
6233894|NCT01781572|9911310|FG002|MEK162 45mg LEE011 600mg|Progressive Disease|0
6233895|NCT01781611|9911341|FG000|Overall Study|Adverse Event|4
6233896|NCT01781611|9911342|FG001|Overall Study|Adverse Event|0
6233897|NCT01781832|9911358|FG000|Overall Study|Withdrawal by Subject|1
6233898|NCT01781962|9911362|FG000|Overall Study|Other Miscellaneous Reasons|5
6233899|NCT01781975|9911368|FG000|Overall Study|Death|1
6233900|NCT01781975|9911369|FG001|Overall Study|Death|0
6233901|NCT01781975|9911368|FG000|Overall Study|Withdrawal by Subject|1
6233902|NCT01781975|9911369|FG001|Overall Study|Withdrawal by Subject|1
6233903|NCT01782131|9911377|FG000|Overall Study|Death|93
6233904|NCT01782131|9911378|FG001|Overall Study|Death|96
6233905|NCT01782131|9911377|FG000|Overall Study|Lost to Follow-up|1
6233906|NCT01782131|9911378|FG001|Overall Study|Lost to Follow-up|3
6233907|NCT01782131|9911377|FG000|Overall Study|Withdrawal by Subject|10
6233908|NCT01782131|9911378|FG001|Overall Study|Withdrawal by Subject|10
6233909|NCT01782131|9911377|FG000|Overall Study|Randomized but not treated|5
6233910|NCT01782131|9911378|FG001|Overall Study|Randomized but not treated|5
6233911|NCT01782131|9911377|FG000|Overall Study|Reason not provided|0
6233912|NCT01782131|9911378|FG001|Overall Study|Reason not provided|1
6233913|NCT01782222|9911391|FG000|Overall Study|Adverse Event|4
6233914|NCT01782222|9911392|FG001|Overall Study|Adverse Event|5
6233915|NCT01782222|9911393|FG002|Overall Study|Adverse Event|3
6233916|NCT01782222|9911391|FG000|Overall Study|Lack of Efficacy|2
6233917|NCT01782222|9911392|FG001|Overall Study|Lack of Efficacy|1
6233918|NCT01782222|9911393|FG002|Overall Study|Lack of Efficacy|0
6233919|NCT01782222|9911391|FG000|Overall Study|Protocol Violation|1
6187328|NCT01380093|9841057|FG007|Treatment Phase: Third Intervention|Non-compliance|0
6187329|NCT01380093|9841058|FG008|Treatment Phase: Third Intervention|Non-compliance|1
6187330|NCT01380093|9841050|FG000|Treatment Phase: Third Intervention|Other|0
6187331|NCT01380093|9841051|FG001|Treatment Phase: Third Intervention|Other|0
6187332|NCT01380093|9841052|FG002|Treatment Phase: Third Intervention|Other|0
6187333|NCT01380093|9841053|FG003|Treatment Phase: Third Intervention|Other|0
6187334|NCT01380093|9841054|FG004|Treatment Phase: Third Intervention|Other|0
6187335|NCT01380093|9841055|FG005|Treatment Phase: Third Intervention|Other|0
6187336|NCT01380093|9841056|FG006|Treatment Phase: Third Intervention|Other|0
6187337|NCT01380093|9841057|FG007|Treatment Phase: Third Intervention|Other|0
6187338|NCT01380093|9841058|FG008|Treatment Phase: Third Intervention|Other|1
6193096|NCT01436110|9850726|FG000|Overall Study|Did Not Receive Trial Medication|1
6193097|NCT01436110|9850727|FG001|Overall Study|Did Not Receive Trial Medication|0
6193098|NCT01436110|9850728|FG002|Overall Study|Did Not Receive Trial Medication|3
6193099|NCT01436149|9850738|FG000|Antidepressant Lead-in Phase|Adverse Event|39
6193100|NCT01436149|9850739|FG001|Antidepressant Lead-in Phase|Adverse Event|0
6193101|NCT01436149|9850740|FG002|Antidepressant Lead-in Phase|Adverse Event|0
6193102|NCT01436149|9850738|FG000|Antidepressant Lead-in Phase|Protocol Violation|29
6193103|NCT01436149|9850739|FG001|Antidepressant Lead-in Phase|Protocol Violation|0
6193104|NCT01436149|9850740|FG002|Antidepressant Lead-in Phase|Protocol Violation|0
6193105|NCT01436149|9850738|FG000|Antidepressant Lead-in Phase|Withdrawal by Subject|61
6193106|NCT01436149|9850739|FG001|Antidepressant Lead-in Phase|Withdrawal by Subject|0
6193107|NCT01436149|9850740|FG002|Antidepressant Lead-in Phase|Withdrawal by Subject|0
6193108|NCT01436149|9850738|FG000|Antidepressant Lead-in Phase|Lost to Follow-up|96
6193109|NCT01436149|9850739|FG001|Antidepressant Lead-in Phase|Lost to Follow-up|0
6193110|NCT01436149|9850740|FG002|Antidepressant Lead-in Phase|Lost to Follow-up|0
6193111|NCT01436149|9850738|FG000|Antidepressant Lead-in Phase|Met BP Or Pulse Withdrawal Criteria|22
6193112|NCT01436149|9850739|FG001|Antidepressant Lead-in Phase|Met BP Or Pulse Withdrawal Criteria|0
6193113|NCT01436149|9850740|FG002|Antidepressant Lead-in Phase|Met BP Or Pulse Withdrawal Criteria|0
6193114|NCT01436149|9850738|FG000|Antidepressant Lead-in Phase|Other|119
6193115|NCT01436149|9850739|FG001|Antidepressant Lead-in Phase|Other|0
6193116|NCT01436149|9850740|FG002|Antidepressant Lead-in Phase|Other|0
6193117|NCT01436149|9850738|FG000|Randomized Phase|Adverse Event|9
6193118|NCT01436149|9850739|FG001|Randomized Phase|Adverse Event|10
6193119|NCT01436149|9850740|FG002|Randomized Phase|Adverse Event|11
6193120|NCT01436149|9850738|FG000|Randomized Phase|Protocol Violation|4
6193121|NCT01436149|9850739|FG001|Randomized Phase|Protocol Violation|5
6193122|NCT01436149|9850740|FG002|Randomized Phase|Protocol Violation|0
6193123|NCT01436149|9850738|FG000|Randomized Phase|Withdrawal by Subject|16
6193124|NCT01436149|9850739|FG001|Randomized Phase|Withdrawal by Subject|10
6193125|NCT01436149|9850740|FG002|Randomized Phase|Withdrawal by Subject|10
6193126|NCT01436149|9850738|FG000|Randomized Phase|Lost to Follow-up|34
6193127|NCT01436149|9850739|FG001|Randomized Phase|Lost to Follow-up|5
6193128|NCT01436149|9850740|FG002|Randomized Phase|Lost to Follow-up|6
6193129|NCT01436149|9850738|FG000|Randomized Phase|Lack of Efficacy|0
6193130|NCT01436149|9850739|FG001|Randomized Phase|Lack of Efficacy|0
6193131|NCT01436149|9850740|FG002|Randomized Phase|Lack of Efficacy|1
6193132|NCT01436149|9850738|FG000|Randomized Phase|Met BP Or Pulse Withdrawal Criteria|2
6193133|NCT01436149|9850739|FG001|Randomized Phase|Met BP Or Pulse Withdrawal Criteria|3
6193134|NCT01436149|9850740|FG002|Randomized Phase|Met BP Or Pulse Withdrawal Criteria|3
6193135|NCT01436149|9850738|FG000|Randomized Phase|Other|12
6193136|NCT01436149|9850739|FG001|Randomized Phase|Other|5
6193137|NCT01436149|9850740|FG002|Randomized Phase|Other|11
6193138|NCT01436162|9850748|FG000|Single-blind Lead-in Phase|Adverse Event|26
6193139|NCT01436162|9850749|FG001|Single-blind Lead-in Phase|Adverse Event|0
6193140|NCT01436162|9850750|FG002|Single-blind Lead-in Phase|Adverse Event|0
6193141|NCT01436162|9850748|FG000|Single-blind Lead-in Phase|Protocol Violation|24
6233920|NCT01782222|9911392|FG001|Overall Study|Protocol Violation|0
6233921|NCT01782222|9911393|FG002|Overall Study|Protocol Violation|0
6233922|NCT01782222|9911391|FG000|Overall Study|Withdrawal by Subject|1
6233923|NCT01782222|9911392|FG001|Overall Study|Withdrawal by Subject|4
6233924|NCT01782222|9911393|FG002|Overall Study|Withdrawal by Subject|1
6233925|NCT01782222|9911391|FG000|Overall Study|Moved to other state|0
6233926|NCT01782222|9911392|FG001|Overall Study|Moved to other state|1
6233927|NCT01782222|9911393|FG002|Overall Study|Moved to other state|0
6233928|NCT01782313|9911401|FG000|Reached First Response/Completed 2 Cycle|Adverse Event|3
6233929|NCT01782313|9911401|FG000|Reached First Response/Completed 2 Cycle|Progressive Disease|3
6233930|NCT01782313|9911401|FG000|Treated Cycle 3|Progressive Disease|21
6233931|NCT01782313|9911401|FG000|Treated Cycle 4/Reached 16 Week Response|Progressive Disease|5
6233932|NCT01782313|9911401|FG000|Treated Cycle 4/Reached 16 Week Response|Adverse Event|1
6233933|NCT01782313|9911401|FG000|Continued Treatment After 16 Weeks|Progressive Disease|6
6233934|NCT01782313|9911401|FG000|Continued Treatment After 16 Weeks|Withdrawal by Subject|1
6233935|NCT01782313|9911401|FG000|Survival Follow up|Lost to Follow-up|1
6233936|NCT01782326|9911407|FG000|Planned Treatment Epoch|Subject/guardian decision|149
6233937|NCT01782326|9911408|FG001|Planned Treatment Epoch|Subject/guardian decision|151
6233938|NCT01782326|9911407|FG000|Planned Treatment Epoch|Death|29
6233939|NCT01782326|9911408|FG001|Planned Treatment Epoch|Death|30
6233940|NCT01782326|9911407|FG000|Planned Treatment Epoch|Physician Decision|18
6233941|NCT01782326|9911408|FG001|Planned Treatment Epoch|Physician Decision|16
6233942|NCT01782326|9911407|FG000|Planned Treatment Epoch|Protocol deviation|2
6233943|NCT01782326|9911408|FG001|Planned Treatment Epoch|Protocol deviation|3
6233944|NCT01782326|9911407|FG000|Planned Treatment Epoch|Lost to Follow-up|4
6233945|NCT01782326|9911408|FG001|Planned Treatment Epoch|Lost to Follow-up|4
6233946|NCT01782326|9911407|FG000|Planned Treatment Epoch|Technical problems|0
6233947|NCT01782326|9911408|FG001|Planned Treatment Epoch|Technical problems|4
6233948|NCT01782326|9911407|FG000|Double-blind Treatment|Adverse Event|129
6233949|NCT01782326|9911408|FG001|Double-blind Treatment|Adverse Event|145
6233950|NCT01782326|9911407|FG000|Double-blind Treatment|Subject/guardian decision|111
6233951|NCT01782326|9911408|FG001|Double-blind Treatment|Subject/guardian decision|125
6233952|NCT01782326|9911407|FG000|Double-blind Treatment|Lack of Efficacy|17
6233953|NCT01782326|9911408|FG001|Double-blind Treatment|Lack of Efficacy|22
6233954|NCT01782326|9911407|FG000|Double-blind Treatment|Physician Decision|13
6233955|NCT01782326|9911408|FG001|Double-blind Treatment|Physician Decision|16
6233956|NCT01782326|9911407|FG000|Double-blind Treatment|Protocol deviation|8
6233957|NCT01782326|9911408|FG001|Double-blind Treatment|Protocol deviation|7
6233958|NCT01782326|9911407|FG000|Double-blind Treatment|Technical problems|0
6233959|NCT01782326|9911408|FG001|Double-blind Treatment|Technical problems|5
6233960|NCT01782378|9911416|FG000|First Series|Lost to Follow-up|7
6233961|NCT01782378|9911417|FG001|First Series|Lost to Follow-up|8
6233962|NCT01782378|9911416|FG000|Second Series|Partial Crossover Design- no Sham 2nd|0
6233963|NCT01782378|9911417|FG001|Second Series|Partial Crossover Design- no Sham 2nd|25
6233964|NCT01782378|9911416|FG000|Second Series|Lost to Follow-up|8
6233965|NCT01782378|9911417|FG001|Second Series|Lost to Follow-up|7
6233966|NCT01782378|9911416|FG000|Second Series|Did not choose to complete S2 Optional|18
6233967|NCT01782378|9911417|FG001|Second Series|Did not choose to complete S2 Optional|0
6233968|NCT01782469|9911423|FG000|Overall Study|Lost to Follow-up|1
6233969|NCT01782482|9911429|FG000|Overall Study|Adverse Event|2
6233970|NCT01782482|9911430|FG001|Overall Study|Adverse Event|1
6233971|NCT01782482|9911429|FG000|Overall Study|Lost to Follow-up|2
6233972|NCT01782482|9911430|FG001|Overall Study|Lost to Follow-up|3
6233973|NCT01782482|9911429|FG000|Overall Study|Physician Decision|1
6233974|NCT01782482|9911430|FG001|Overall Study|Physician Decision|0
6233975|NCT01782482|9911429|FG000|Overall Study|Protocol Violation|1
6233976|NCT01782482|9911430|FG001|Overall Study|Protocol Violation|0
6233977|NCT01782482|9911429|FG000|Overall Study|Withdrawal by Subject|2
6233978|NCT01782482|9911430|FG001|Overall Study|Withdrawal by Subject|3
6233979|NCT01782482|9911429|FG000|Overall Study|Randomized in Error|2
6233980|NCT01782482|9911430|FG001|Overall Study|Randomized in Error|2
6233981|NCT01782482|9911429|FG000|Overall Study|Habitually wearing toric lens OS|0
6233982|NCT01782482|9911430|FG001|Overall Study|Habitually wearing toric lens OS|1
6233983|NCT01782495|9911447|FG000|Overall Study|Adverse Event|0
6233984|NCT01782495|9911448|FG001|Overall Study|Adverse Event|0
6233985|NCT01782495|9911449|FG002|Overall Study|Adverse Event|0
6233986|NCT01782495|9911450|FG003|Overall Study|Adverse Event|0
6233987|NCT01782495|9911451|FG004|Overall Study|Adverse Event|0
6233988|NCT01782495|9911452|FG005|Overall Study|Adverse Event|0
6233989|NCT01782495|9911453|FG006|Overall Study|Adverse Event|0
6233990|NCT01782495|9911454|FG007|Overall Study|Adverse Event|2
6233991|NCT01782495|9911455|FG008|Overall Study|Adverse Event|0
6233992|NCT01782495|9911456|FG009|Overall Study|Adverse Event|0
6233993|NCT01782495|9911457|FG010|Overall Study|Adverse Event|0
6233994|NCT01782495|9911447|FG000|Overall Study|Withdrew Consent|0
6233995|NCT01782495|9911448|FG001|Overall Study|Withdrew Consent|1
6233996|NCT01782495|9911449|FG002|Overall Study|Withdrew Consent|0
6233997|NCT01782495|9911450|FG003|Overall Study|Withdrew Consent|0
6233998|NCT01782495|9911451|FG004|Overall Study|Withdrew Consent|0
6233999|NCT01782495|9911452|FG005|Overall Study|Withdrew Consent|0
6234000|NCT01782495|9911453|FG006|Overall Study|Withdrew Consent|0
6234001|NCT01782495|9911454|FG007|Overall Study|Withdrew Consent|1
6234002|NCT01782495|9911455|FG008|Overall Study|Withdrew Consent|0
6234003|NCT01782495|9911456|FG009|Overall Study|Withdrew Consent|0
6234004|NCT01782495|9911457|FG010|Overall Study|Withdrew Consent|0
6234005|NCT01782664|9911487|FG000|Overall Study|Adverse Event|2
6234006|NCT01782664|9911488|FG001|Overall Study|Adverse Event|2
6234007|NCT01782664|9911489|FG002|Overall Study|Adverse Event|2
6234008|NCT01782664|9911490|FG003|Overall Study|Adverse Event|2
6234009|NCT01782664|9911491|FG004|Overall Study|Adverse Event|0
6234010|NCT01782664|9911492|FG005|Overall Study|Adverse Event|0
6234011|NCT01782664|9911487|FG000|Overall Study|Lack of Efficacy|2
6234012|NCT01782664|9911488|FG001|Overall Study|Lack of Efficacy|0
6234013|NCT01782664|9911489|FG002|Overall Study|Lack of Efficacy|2
6234014|NCT01782664|9911490|FG003|Overall Study|Lack of Efficacy|2
6234015|NCT01782664|9911491|FG004|Overall Study|Lack of Efficacy|0
6234016|NCT01782664|9911492|FG005|Overall Study|Lack of Efficacy|0
6234017|NCT01782664|9911487|FG000|Overall Study|Protocol Violation|0
6234018|NCT01782664|9911488|FG001|Overall Study|Protocol Violation|1
6234019|NCT01782664|9911489|FG002|Overall Study|Protocol Violation|0
6234020|NCT01782664|9911490|FG003|Overall Study|Protocol Violation|1
6234021|NCT01782664|9911491|FG004|Overall Study|Protocol Violation|0
6234022|NCT01782664|9911492|FG005|Overall Study|Protocol Violation|0
6234023|NCT01782664|9911487|FG000|Overall Study|Withdrawal by Subject|2
6234024|NCT01782664|9911488|FG001|Overall Study|Withdrawal by Subject|2
6234025|NCT01782664|9911489|FG002|Overall Study|Withdrawal by Subject|0
6234026|NCT01782664|9911490|FG003|Overall Study|Withdrawal by Subject|0
6234027|NCT01782664|9911491|FG004|Overall Study|Withdrawal by Subject|0
6234028|NCT01782664|9911492|FG005|Overall Study|Withdrawal by Subject|0
6234029|NCT01782690|9911506|FG000|Overall Study|Not reported|7
6234030|NCT01782690|9911506|FG000|Overall Study|Toxicity of gemcitabine|1
6234031|NCT01782690|9911506|FG000|Overall Study|Toxicity of erlotinib|1
6234032|NCT01782690|9911506|FG000|Overall Study|Lost to Follow-up|31
6234033|NCT01782690|9911506|FG000|Overall Study|Withdrawal of informed consent|2
6234034|NCT01782690|9911506|FG000|Overall Study|Absent rash|9
6234035|NCT01782690|9911506|FG000|Overall Study|Physician Decision|13
6234036|NCT01782690|9911506|FG000|Overall Study|Patient's wish|21
6234037|NCT01782690|9911506|FG000|Overall Study|Tumor progression|74
6234038|NCT01782690|9911506|FG000|Overall Study|Death|133
6234039|NCT01782690|9911506|FG000|Overall Study|Study completion unknown|7
6234040|NCT01782742|9911512|FG000|Double-blind Treatment Phase|Adverse Event|1
6234041|NCT01782742|9911513|FG001|Double-blind Treatment Phase|Adverse Event|0
6234042|NCT01782859|9911527|FG000|Overall Study|Protocol Violation|6
6234043|NCT01782859|9911528|FG001|Overall Study|Protocol Violation|6
6234044|NCT01782859|9911527|FG000|Overall Study|Withdrawal by Subject|0
6234045|NCT01782859|9911528|FG001|Overall Study|Withdrawal by Subject|1
6234046|NCT01782872|9911539|FG000|Overall Study|Protocol Violation|0
6234047|NCT01782872|9911540|FG001|Overall Study|Protocol Violation|0
6234048|NCT01782872|9911541|FG002|Overall Study|Protocol Violation|0
6234049|NCT01782872|9911542|FG003|Overall Study|Protocol Violation|1
6234050|NCT01782872|9911539|FG000|Overall Study|Withdrawal by Subject|0
6234051|NCT01782872|9911540|FG001|Overall Study|Withdrawal by Subject|1
6234052|NCT01782872|9911541|FG002|Overall Study|Withdrawal by Subject|0
6234053|NCT01782872|9911542|FG003|Overall Study|Withdrawal by Subject|0
6234054|NCT01782885|9911554|FG000|Overall Study|Lost to Follow-up|4
6234055|NCT01782885|9911555|FG001|Overall Study|Lost to Follow-up|6
6234056|NCT01783418|9911597|FG000|Overall Study|Withdrawal by Subject|1
6234057|NCT01783418|9911598|FG001|Overall Study|Withdrawal by Subject|0
6234058|NCT01783444|9911607|FG000|Treatment Phase|Adverse Event|9
6234059|NCT01783444|9911608|FG001|Treatment Phase|Adverse Event|20
6234060|NCT01783444|9911609|FG002|Treatment Phase|Adverse Event|19
6234061|NCT01783444|9911607|FG000|Treatment Phase|Disease Progression|76
6234062|NCT01783444|9911608|FG001|Treatment Phase|Disease Progression|66
6234063|NCT01783444|9911609|FG002|Treatment Phase|Disease Progression|64
6234064|NCT01783444|9911607|FG000|Treatment Phase|Death|2
6234065|NCT01783444|9911608|FG001|Treatment Phase|Death|2
6234066|NCT01783444|9911609|FG002|Treatment Phase|Death|2
6234067|NCT01783444|9911607|FG000|Treatment Phase|Protocol Violation|1
6234068|NCT01783444|9911608|FG001|Treatment Phase|Protocol Violation|1
6234069|NCT01783444|9911609|FG002|Treatment Phase|Protocol Violation|2
6234070|NCT01783444|9911607|FG000|Treatment Phase|Withdrawal by Subject|6
6234071|NCT01783444|9911608|FG001|Treatment Phase|Withdrawal by Subject|8
6234072|NCT01783444|9911609|FG002|Treatment Phase|Withdrawal by Subject|9
6234073|NCT01783444|9911607|FG000|Treatment Phase|Administrative problems|2
6234074|NCT01783444|9911608|FG001|Treatment Phase|Administrative problems|0
6234075|NCT01783444|9911609|FG002|Treatment Phase|Administrative problems|1
6234076|NCT01783444|9911607|FG000|Treatment Phase|Physician Decision|8
6234077|NCT01783444|9911608|FG001|Treatment Phase|Physician Decision|6
6234078|NCT01783444|9911609|FG002|Treatment Phase|Physician Decision|5
6234079|NCT01783444|9911607|FG000|Post-Treatment Efficacy Follow-Up Phase|Disease Progression|7
6234080|NCT01783444|9911608|FG001|Post-Treatment Efficacy Follow-Up Phase|Disease Progression|8
6234081|NCT01783444|9911609|FG002|Post-Treatment Efficacy Follow-Up Phase|Disease Progression|11
6234082|NCT01783444|9911607|FG000|Post-Treatment Efficacy Follow-Up Phase|Death|9
6234083|NCT01783444|9911608|FG001|Post-Treatment Efficacy Follow-Up Phase|Death|7
6234084|NCT01783444|9911609|FG002|Post-Treatment Efficacy Follow-Up Phase|Death|5
6234085|NCT01783444|9911607|FG000|Post-Treatment Efficacy Follow-Up Phase|Withdrawal by Subject|4
6234086|NCT01783444|9911608|FG001|Post-Treatment Efficacy Follow-Up Phase|Withdrawal by Subject|8
6234087|NCT01783444|9911609|FG002|Post-Treatment Efficacy Follow-Up Phase|Withdrawal by Subject|8
6234088|NCT01783444|9911607|FG000|Post-Treatment Efficacy Follow-Up Phase|Administrative Problems|0
6234089|NCT01783444|9911608|FG001|Post-Treatment Efficacy Follow-Up Phase|Administrative Problems|1
6234090|NCT01783444|9911609|FG002|Post-Treatment Efficacy Follow-Up Phase|Administrative Problems|0
6234091|NCT01783444|9911607|FG000|Post-Treatment Efficacy Follow-Up Phase|New cancer therapy|7
6234092|NCT01783444|9911608|FG001|Post-Treatment Efficacy Follow-Up Phase|New cancer therapy|16
6234093|NCT01783444|9911609|FG002|Post-Treatment Efficacy Follow-Up Phase|New cancer therapy|15
6234094|NCT01783444|9911607|FG000|Post-Treatment Efficacy Follow-Up Phase|Followup phase completed as per protocol|69
6234095|NCT01783444|9911608|FG001|Post-Treatment Efficacy Follow-Up Phase|Followup phase completed as per protocol|53
6234096|NCT01783444|9911609|FG002|Post-Treatment Efficacy Follow-Up Phase|Followup phase completed as per protocol|52
6234097|NCT01783483|9911628|FG000|Overall Study|Death|3
6234098|NCT01783483|9911629|FG001|Overall Study|Death|3
6234099|NCT01783483|9911628|FG000|Overall Study|Lost to Follow-up|14
6234100|NCT01783483|9911629|FG001|Overall Study|Lost to Follow-up|10
6234101|NCT01783483|9911628|FG000|Overall Study|Withdrawal by Subject|2
6234102|NCT01783483|9911629|FG001|Overall Study|Withdrawal by Subject|1
6234103|NCT01783483|9911628|FG000|Overall Study|Physician Decision|1
6234104|NCT01783483|9911629|FG001|Overall Study|Physician Decision|1
6234105|NCT01783496|9911641|FG000|Overall Study|Lost to Follow-up|0
6234106|NCT01783496|9911642|FG001|Overall Study|Lost to Follow-up|0
6234107|NCT01783496|9911643|FG002|Overall Study|Lost to Follow-up|0
6234108|NCT01783496|9911644|FG003|Overall Study|Lost to Follow-up|2
6234109|NCT01783496|9911645|FG004|Overall Study|Lost to Follow-up|0
6234110|NCT01783496|9911646|FG005|Overall Study|Lost to Follow-up|1
6234111|NCT01783496|9911641|FG000|Overall Study|Withdrawal by Subject|1
6234112|NCT01783496|9911642|FG001|Overall Study|Withdrawal by Subject|0
6234113|NCT01783496|9911643|FG002|Overall Study|Withdrawal by Subject|0
6234114|NCT01783496|9911644|FG003|Overall Study|Withdrawal by Subject|0
6234115|NCT01783496|9911645|FG004|Overall Study|Withdrawal by Subject|0
6234116|NCT01783496|9911646|FG005|Overall Study|Withdrawal by Subject|0
6234117|NCT01783548|9911671|FG000|Overall Study|Adverse Event|8
6234118|NCT01783548|9911672|FG001|Overall Study|Adverse Event|4
6234119|NCT01783548|9911671|FG000|Overall Study|Withdrawal by Subject|11
6234120|NCT01783548|9911672|FG001|Overall Study|Withdrawal by Subject|8
6234121|NCT01783548|9911671|FG000|Overall Study|Non-compliance|4
6234122|NCT01783548|9911672|FG001|Overall Study|Non-compliance|0
6234123|NCT01783548|9911671|FG000|Overall Study|Protocol Violation|2
6234124|NCT01783548|9911672|FG001|Overall Study|Protocol Violation|2
6234125|NCT01783548|9911671|FG000|Overall Study|Lost to Follow-up|8
6234126|NCT01783548|9911672|FG001|Overall Study|Lost to Follow-up|3
6234127|NCT01783548|9911671|FG000|Overall Study|Lack of Efficacy|1
6234128|NCT01783548|9911672|FG001|Overall Study|Lack of Efficacy|1
6234129|NCT01783678|9911706|FG000|Overall Study|Randomized but Not Treated|0
6234130|NCT01783678|9911707|FG001|Overall Study|Randomized but Not Treated|0
6234131|NCT01783678|9911708|FG002|Overall Study|Randomized but Not Treated|0
6234132|NCT01783678|9911709|FG003|Overall Study|Randomized but Not Treated|1
6234133|NCT01783678|9911710|FG004|Overall Study|Randomized but Not Treated|0
6234134|NCT01783678|9911711|FG005|Overall Study|Randomized but Not Treated|0
6234135|NCT01783678|9911706|FG000|Overall Study|Lack of Efficacy|1
6234136|NCT01783678|9911707|FG001|Overall Study|Lack of Efficacy|13
6234137|NCT01783678|9911708|FG002|Overall Study|Lack of Efficacy|1
6234138|NCT01783678|9911709|FG003|Overall Study|Lack of Efficacy|3
6234139|NCT01783678|9911710|FG004|Overall Study|Lack of Efficacy|6
6234140|NCT01783678|9911711|FG005|Overall Study|Lack of Efficacy|5
6234141|NCT01783678|9911706|FG000|Overall Study|Lost to Follow-up|0
6234142|NCT01783678|9911707|FG001|Overall Study|Lost to Follow-up|4
6234143|NCT01783678|9911708|FG002|Overall Study|Lost to Follow-up|0
6234144|NCT01783678|9911709|FG003|Overall Study|Lost to Follow-up|2
6234145|NCT01783678|9911710|FG004|Overall Study|Lost to Follow-up|1
6234146|NCT01783678|9911711|FG005|Overall Study|Lost to Follow-up|0
6234147|NCT01783678|9911706|FG000|Overall Study|Withdrew Consent|1
6234148|NCT01783678|9911707|FG001|Overall Study|Withdrew Consent|1
6234149|NCT01783678|9911708|FG002|Overall Study|Withdrew Consent|0
6234150|NCT01783678|9911709|FG003|Overall Study|Withdrew Consent|2
6234151|NCT01783678|9911710|FG004|Overall Study|Withdrew Consent|0
6234152|NCT01783678|9911711|FG005|Overall Study|Withdrew Consent|0
6234153|NCT01783730|9911726|FG000|Overall Study|Failed to meet inclusion criteria|6
6234154|NCT01783743|9911732|FG000|Screening of Subjects by CTA During MDA|Absent at MDA|3427
6234155|NCT01783743|9911733|FG001|Screening of Subjects by CTA During MDA|Absent at MDA|4439
6234156|NCT01783743|9911732|FG000|Rescreening of Subjects by Senior Grader|Lost to Follow-up|591
6234157|NCT01783743|9911733|FG001|Rescreening of Subjects by Senior Grader|Lost to Follow-up|684
6234158|NCT01783743|9911732|FG000|Rescreening of Subjects by Senior Grader|Not part of the random sample selected|10305
6234159|NCT01783743|9911733|FG001|Rescreening of Subjects by Senior Grader|Not part of the random sample selected|10236
6234160|NCT01783821|9911741|FG000|Overall Study|Screen Failure|1
6234161|NCT01783821|9911742|FG001|Overall Study|Screen Failure|1
6234162|NCT01783886|9911776|FG000|Overall Study|Lost to Follow-up|0
6234163|NCT01783886|9911777|FG001|Overall Study|Lost to Follow-up|3
6234164|NCT01783886|9911778|FG002|Overall Study|Lost to Follow-up|0
6234165|NCT01783886|9911776|FG000|Overall Study|Protocol deviation|0
6234166|NCT01783886|9911777|FG001|Overall Study|Protocol deviation|0
6234167|NCT01783886|9911778|FG002|Overall Study|Protocol deviation|2
6234168|NCT01783886|9911776|FG000|Overall Study|Withdrawal of consent by participant|1
6234169|NCT01783886|9911777|FG001|Overall Study|Withdrawal of consent by participant|3
6234170|NCT01783886|9911778|FG002|Overall Study|Withdrawal of consent by participant|4
6234171|NCT01783886|9911776|FG000|Overall Study|Adverse Event|4
6234172|NCT01783886|9911777|FG001|Overall Study|Adverse Event|5
6234173|NCT01783886|9911778|FG002|Overall Study|Adverse Event|4
6234174|NCT01783938|9911801|FG000|Overall Study|Disease Progression|18
6234175|NCT01783938|9911802|FG001|Overall Study|Disease Progression|41
6234176|NCT01783938|9911801|FG000|Overall Study|Study Drug Toxicity|27
6234177|NCT01783938|9911802|FG001|Overall Study|Study Drug Toxicity|14
6234178|NCT01783938|9911801|FG000|Overall Study|Adverse Event Unrelated to Study Drug|4
6234179|NCT01783938|9911802|FG001|Overall Study|Adverse Event Unrelated to Study Drug|2
6234180|NCT01783938|9911801|FG000|Overall Study|Participant Request to Discontinue Study Treatment|2
6234181|NCT01783938|9911802|FG001|Overall Study|Participant Request to Discontinue Study Treatment|3
6234182|NCT01783938|9911801|FG000|Overall Study|Participant Withdrew Consent|2
6234183|NCT01783938|9911802|FG001|Overall Study|Participant Withdrew Consent|0
6234184|NCT01783938|9911801|FG000|Overall Study|Maximum Clinical Benefit|1
6234185|NCT01783938|9911802|FG001|Overall Study|Maximum Clinical Benefit|0
6234186|NCT01783938|9911801|FG000|Overall Study|Other Reasons|3
6234187|NCT01783938|9911802|FG001|Overall Study|Other Reasons|1
6234188|NCT01784029|9911822|FG000|Overall Study|Lost to Follow-up|19
6234189|NCT01784029|9911823|FG001|Overall Study|Lost to Follow-up|20
6234190|NCT01784029|9911824|FG002|Overall Study|Lost to Follow-up|22
6234191|NCT01784068|9911836|FG000|NTCS Phase|Adverse Event|5
6234192|NCT01784068|9911837|FG001|NTCS Phase|Adverse Event|0
6234193|NCT01784068|9911836|FG000|NTCS Phase|Physician Decision|2
6234194|NCT01784068|9911837|FG001|NTCS Phase|Physician Decision|0
6234195|NCT01784068|9911836|FG000|NTCS Phase|Patient/guardian decision|3
6234196|NCT01784068|9911837|FG001|NTCS Phase|Patient/guardian decision|0
6234197|NCT01784068|9911836|FG000|NTCS Phase|Death|2
6234198|NCT01784068|9911837|FG001|NTCS Phase|Death|0
6234199|NCT01784068|9911836|FG000|NTCS Phase|Completed phase = discontinuation of study except for TFR and TFR2 phases|203
6234200|NCT01784068|9911837|FG001|NTCS Phase|Completed phase = discontinuation of study except for TFR and TFR2 phases|0
6234201|NCT01784068|9911836|FG000|TFR Phase|Physician Decision|0
6234202|NCT01784068|9911837|FG001|TFR Phase|Physician Decision|1
6234203|NCT01784068|9911836|FG000|TFR Phase|Patient/guardian decision|0
6234204|NCT01784068|9911837|FG001|TFR Phase|Patient/guardian decision|3
6234205|NCT01784068|9911836|FG000|TFR Phase|Death|0
6234206|NCT01784068|9911837|FG001|TFR Phase|Death|1
6234207|NCT01784068|9911836|FG000|TFR Phase|Lack of Efficacy|0
6234208|NCT01784068|9911837|FG001|TFR Phase|Lack of Efficacy|88
6234209|NCT01784211|9911850|FG000|Part A (Days 1-15)|Adverse Event|1
6234210|NCT01784211|9911851|FG001|Part A (Days 1-15)|Adverse Event|1
6234211|NCT01784211|9911852|FG002|Part A (Days 1-15)|Adverse Event|0
6234212|NCT01784211|9911853|FG003|Part A (Days 1-15)|Adverse Event|0
6234213|NCT01784211|9911854|FG004|Part A (Days 1-15)|Adverse Event|0
6234214|NCT01784211|9911855|FG005|Part A (Days 1-15)|Adverse Event|0
6234215|NCT01784211|9911850|FG000|Part A (Days 1-15)|Withdrawal by Subject|2
6234216|NCT01784211|9911851|FG001|Part A (Days 1-15)|Withdrawal by Subject|1
6234217|NCT01784211|9911852|FG002|Part A (Days 1-15)|Withdrawal by Subject|0
6234218|NCT01784211|9911853|FG003|Part A (Days 1-15)|Withdrawal by Subject|0
6234219|NCT01784211|9911854|FG004|Part A (Days 1-15)|Withdrawal by Subject|0
6234220|NCT01784211|9911855|FG005|Part A (Days 1-15)|Withdrawal by Subject|0
6234221|NCT01784419|9911867|FG000|Overall Study|Adverse Event|3
6234222|NCT01784523|9911873|FG000|Overall Study|Study closed early|7
6234223|NCT01784523|9911874|FG001|Overall Study|Study closed early|4
6234224|NCT01784861|9911949|FG000|Overall Study|Adverse Event|0
6234225|NCT01784861|9911950|FG001|Overall Study|Adverse Event|0
6234226|NCT01784861|9911951|FG002|Overall Study|Adverse Event|1
6234227|NCT01784861|9911952|FG003|Overall Study|Adverse Event|2
6234228|NCT01784861|9911953|FG004|Overall Study|Adverse Event|1
6043627|NCT00391118|9642333|FG002|Overall Study|Sponsor Decision|3
6043628|NCT00391118|9642331|FG000|Overall Study|Protocol Violation|1
6043629|NCT00391118|9642332|FG001|Overall Study|Protocol Violation|0
6043630|NCT00391118|9642333|FG002|Overall Study|Protocol Violation|0
6043631|NCT00391222|9642347|FG000|Period II (Open-label Risperidone LAI)|Withdrawal by Subject|0
6043632|NCT00391222|9642348|FG001|Period II (Open-label Risperidone LAI)|Withdrawal by Subject|0
6043633|NCT00391222|9642349|FG002|Period II (Open-label Risperidone LAI)|Withdrawal by Subject|0
6043634|NCT00391222|9642350|FG003|Period II (Open-label Risperidone LAI)|Withdrawal by Subject|26
6043635|NCT00391222|9642347|FG000|Period II (Open-label Risperidone LAI)|Lost to Follow-up|0
6043636|NCT00391222|9642348|FG001|Period II (Open-label Risperidone LAI)|Lost to Follow-up|0
6043637|NCT00391222|9642349|FG002|Period II (Open-label Risperidone LAI)|Lost to Follow-up|0
6043638|NCT00391222|9642350|FG003|Period II (Open-label Risperidone LAI)|Lost to Follow-up|5
6043639|NCT00391222|9642347|FG000|Period II (Open-label Risperidone LAI)|Adverse Event|0
6043640|NCT00391222|9642348|FG001|Period II (Open-label Risperidone LAI)|Adverse Event|0
6234229|NCT01784861|9911954|FG005|Overall Study|Adverse Event|0
6234230|NCT01784861|9911949|FG000|Overall Study|Withdrawal by Subject|0
6234231|NCT01784861|9911950|FG001|Overall Study|Withdrawal by Subject|0
6234232|NCT01784861|9911951|FG002|Overall Study|Withdrawal by Subject|0
6043641|NCT00391222|9642349|FG002|Period II (Open-label Risperidone LAI)|Adverse Event|0
6043642|NCT00391222|9642350|FG003|Period II (Open-label Risperidone LAI)|Adverse Event|10
6043643|NCT00391222|9642347|FG000|Period II (Open-label Risperidone LAI)|Non-responder|0
6043644|NCT00391222|9642348|FG001|Period II (Open-label Risperidone LAI)|Non-responder|0
6043645|NCT00391222|9642349|FG002|Period II (Open-label Risperidone LAI)|Non-responder|0
6234233|NCT01784861|9911952|FG003|Overall Study|Withdrawal by Subject|1
6234234|NCT01784861|9911953|FG004|Overall Study|Withdrawal by Subject|0
6234235|NCT01784861|9911954|FG005|Overall Study|Withdrawal by Subject|0
6234236|NCT01784861|9911949|FG000|Overall Study|Physician Decision|0
6234237|NCT01784861|9911950|FG001|Overall Study|Physician Decision|0
6234238|NCT01784861|9911951|FG002|Overall Study|Physician Decision|0
6234239|NCT01784861|9911952|FG003|Overall Study|Physician Decision|2
6234240|NCT01784861|9911953|FG004|Overall Study|Physician Decision|0
6234241|NCT01784861|9911954|FG005|Overall Study|Physician Decision|1
6234242|NCT01784965|9911981|FG000|Overall Study|Withdrawal by Subject|6
6234243|NCT01784965|9911982|FG001|Overall Study|Withdrawal by Subject|3
6234244|NCT01784965|9911981|FG000|Overall Study|Adverse Event|0
6234245|NCT01784965|9911982|FG001|Overall Study|Adverse Event|8
6234246|NCT01785069|9911994|FG000|Overall Study|Implanted with nonstudy device|1
6234247|NCT01785069|9911995|FG001|Overall Study|Implanted with nonstudy device|2
6234248|NCT01785069|9911996|FG002|Overall Study|Implanted with nonstudy device|1
6234249|NCT01785069|9911997|FG003|Overall Study|Implanted with nonstudy device|0
6234250|NCT01785069|9911994|FG000|Overall Study|Death|0
6234251|NCT01785069|9911995|FG001|Overall Study|Death|0
6234252|NCT01785069|9911996|FG002|Overall Study|Death|2
6234253|NCT01785069|9911997|FG003|Overall Study|Death|0
6234254|NCT01785069|9911994|FG000|Overall Study|Subject choice|2
6234255|NCT01785069|9911995|FG001|Overall Study|Subject choice|2
6234256|NCT01785069|9911996|FG002|Overall Study|Subject choice|0
6234257|NCT01785069|9911997|FG003|Overall Study|Subject choice|1
6234258|NCT01785069|9911994|FG000|Overall Study|Lost to Follow-up|1
6234259|NCT01785069|9911995|FG001|Overall Study|Lost to Follow-up|2
6234260|NCT01785069|9911996|FG002|Overall Study|Lost to Follow-up|4
6234261|NCT01785069|9911997|FG003|Overall Study|Lost to Follow-up|1
6234262|NCT01785069|9911994|FG000|Overall Study|Reason not Specified|1
6234263|NCT01785069|9911995|FG001|Overall Study|Reason not Specified|2
6234264|NCT01785069|9911996|FG002|Overall Study|Reason not Specified|1
6234265|NCT01785069|9911997|FG003|Overall Study|Reason not Specified|4
6234266|NCT01785069|9911994|FG000|Overall Study|Not evaluable|7
6234267|NCT01785069|9911995|FG001|Overall Study|Not evaluable|4
6234268|NCT01785069|9911996|FG002|Overall Study|Not evaluable|5
6234269|NCT01785069|9911997|FG003|Overall Study|Not evaluable|8
6234270|NCT01785160|9912023|FG000|Treatment Period 1: Raltegravir|Not treated|1
6234271|NCT01785160|9912023|FG000|Washout Period of at Least 7 Days|Consent withdrawn|1
6269938|NCT02146365|9970536|FG005|Overall Study|Unable to Comply with Protocol|0
6269939|NCT02146365|9970537|FG006|Overall Study|Unable to Comply with Protocol|0
6269940|NCT02146365|9970538|FG007|Overall Study|Unable to Comply with Protocol|0
6269941|NCT02146365|9970531|FG000|Overall Study|Other|1
6269942|NCT02146365|9970532|FG001|Overall Study|Other|0
6085684|NCT00654420|9695029|FG003|Phase II|Lost to Follow-up|1
6085685|NCT00654420|9695026|FG000|Phase II|Physician Decision|0
6085686|NCT00654420|9695027|FG001|Phase II|Physician Decision|0
6085687|NCT00654420|9695028|FG002|Phase II|Physician Decision|0
6085688|NCT00654420|9695029|FG003|Phase II|Physician Decision|4
6085689|NCT00654420|9695026|FG000|Phase II|Progressive Disease|0
6085690|NCT00654420|9695027|FG001|Phase II|Progressive Disease|0
6085691|NCT00654420|9695028|FG002|Phase II|Progressive Disease|29
6269943|NCT02146365|9970533|FG002|Overall Study|Other|2
6269944|NCT02146365|9970534|FG003|Overall Study|Other|1
6269945|NCT02146365|9970535|FG004|Overall Study|Other|0
6269946|NCT02146365|9970536|FG005|Overall Study|Other|0
6269947|NCT02146365|9970537|FG006|Overall Study|Other|0
6085692|NCT00654420|9695029|FG003|Phase II|Progressive Disease|29
6085693|NCT00654420|9695026|FG000|Phase II|Withdrawal by Subject|0
6085694|NCT00654420|9695027|FG001|Phase II|Withdrawal by Subject|0
6269948|NCT02146365|9970538|FG007|Overall Study|Other|0
6269949|NCT02146430|9970560|FG000|Overall Study|Protocol Violation|5
6269950|NCT02146430|9970561|FG001|Overall Study|Protocol Violation|4
6269951|NCT02146430|9970562|FG002|Overall Study|Protocol Violation|8
6269952|NCT02146430|9970563|FG003|Overall Study|Protocol Violation|6
6269953|NCT02146430|9970560|FG000|Overall Study|Lack of Efficacy|13
6269954|NCT02146430|9970561|FG001|Overall Study|Lack of Efficacy|11
6269955|NCT02146430|9970562|FG002|Overall Study|Lack of Efficacy|8
6269956|NCT02146430|9970563|FG003|Overall Study|Lack of Efficacy|5
6269957|NCT02146430|9970560|FG000|Overall Study|Adverse Event|20
6269958|NCT02146430|9970561|FG001|Overall Study|Adverse Event|40
6269959|NCT02146430|9970562|FG002|Overall Study|Adverse Event|32
6269960|NCT02146430|9970563|FG003|Overall Study|Adverse Event|49
6043646|NCT00391222|9642350|FG003|Period II (Open-label Risperidone LAI)|Non-responder|97
6043647|NCT00391222|9642347|FG000|Period II (Open-label Risperidone LAI)|Other|0
6043648|NCT00391222|9642348|FG001|Period II (Open-label Risperidone LAI)|Other|0
6043649|NCT00391222|9642349|FG002|Period II (Open-label Risperidone LAI)|Other|0
6043650|NCT00391222|9642350|FG003|Period II (Open-label Risperidone LAI)|Other|24
6043651|NCT00391222|9642347|FG000|Period III (Double-Blind Treatment)|Withdrawal by Subject|15
6234272|NCT01785472|9912064|FG000|Overall Study|Adverse Event|5
6234273|NCT01785472|9912065|FG001|Overall Study|Adverse Event|4
6234274|NCT01785472|9912066|FG002|Overall Study|Adverse Event|6
6234275|NCT01785472|9912064|FG000|Overall Study|Lack of Efficacy|2
6234276|NCT01785472|9912065|FG001|Overall Study|Lack of Efficacy|0
6234277|NCT01785472|9912066|FG002|Overall Study|Lack of Efficacy|1
6234278|NCT01785472|9912064|FG000|Overall Study|Lost to Follow-up|1
6234279|NCT01785472|9912065|FG001|Overall Study|Lost to Follow-up|2
6234280|NCT01785472|9912066|FG002|Overall Study|Lost to Follow-up|0
6234281|NCT01785472|9912064|FG000|Overall Study|Physician Decision|1
6234282|NCT01785472|9912065|FG001|Overall Study|Physician Decision|1
6234283|NCT01785472|9912066|FG002|Overall Study|Physician Decision|1
6234284|NCT01785472|9912064|FG000|Overall Study|Protocol deviation|0
6234285|NCT01785472|9912065|FG001|Overall Study|Protocol deviation|2
6234286|NCT01785472|9912066|FG002|Overall Study|Protocol deviation|2
6234287|NCT01785472|9912064|FG000|Overall Study|Subject/guardian decision|15
6234288|NCT01785472|9912065|FG001|Overall Study|Subject/guardian decision|10
6234289|NCT01785472|9912066|FG002|Overall Study|Subject/guardian decision|11
6234290|NCT01785472|9912064|FG000|Overall Study|Technical problems|0
6234291|NCT01785472|9912065|FG001|Overall Study|Technical problems|0
6234292|NCT01785472|9912066|FG002|Overall Study|Technical problems|1
6234293|NCT01785524|9912078|FG000|Overall Study|Withdrawal by Subject|2
6234294|NCT01785524|9912079|FG001|Overall Study|Withdrawal by Subject|2
6234295|NCT01785602|9912087|FG000|Overall Study|Withdrawal by Subject|2
6234296|NCT01785602|9912088|FG001|Overall Study|Withdrawal by Subject|0
6234297|NCT01785602|9912087|FG000|Overall Study|Lost to Follow-up|1
6234298|NCT01785602|9912088|FG001|Overall Study|Lost to Follow-up|1
6234299|NCT01785602|9912087|FG000|Overall Study|Adverse Event|3
6234300|NCT01785602|9912088|FG001|Overall Study|Adverse Event|5
6234301|NCT01785602|9912087|FG000|Overall Study|Administrative problems|7
6234302|NCT01785602|9912088|FG001|Overall Study|Administrative problems|3
6234303|NCT01785615|9912097|FG000|Dietary Phase|Lost to Follow-up|0
6234304|NCT01785615|9912098|FG001|Dietary Phase|Lost to Follow-up|0
6234305|NCT01785615|9912099|FG002|Dietary Phase|Lost to Follow-up|0
6234306|NCT01785615|9912100|FG003|Dietary Phase|Lost to Follow-up|24
6234307|NCT01785628|9912114|FG000|Overall Study|Lost to Follow-up|2
6234308|NCT01785628|9912115|FG001|Overall Study|Lost to Follow-up|3
6234309|NCT01785849|9912136|FG000|Overall Study|Death|7
6234310|NCT01785849|9912137|FG001|Overall Study|Death|9
6234311|NCT01785849|9912136|FG000|Overall Study|Protocol Specified Criteria|29
6234312|NCT01785849|9912137|FG001|Overall Study|Protocol Specified Criteria|1
6234313|NCT01785849|9912136|FG000|Overall Study|Withdrawal by Subject|15
6187339|NCT01380145|9841081|FG000|Overall Study|Progressive disease|4
6187340|NCT01380184|9841087|FG000|Part 1 (19 Days)|Adverse Event|1
6187341|NCT01380184|9841087|FG000|Part 2|Adverse Event|5
6187342|NCT01380184|9841087|FG000|Part 2|Disease Progression|8
6187343|NCT01380184|9841087|FG000|Part 2|Lost to Follow-up|1
6187344|NCT01380327|9841103|FG000|Overall Study|Lost to Follow-up|0
6187345|NCT01380327|9841104|FG001|Overall Study|Lost to Follow-up|1
6187346|NCT01380327|9841105|FG002|Overall Study|Lost to Follow-up|1
6187347|NCT01380327|9841103|FG000|Overall Study|Protocol Violation|3
6187348|NCT01380327|9841104|FG001|Overall Study|Protocol Violation|2
6187349|NCT01380327|9841105|FG002|Overall Study|Protocol Violation|3
6187350|NCT01380327|9841103|FG000|Overall Study|Withdrawal by Subject|0
6187351|NCT01380327|9841104|FG001|Overall Study|Withdrawal by Subject|0
6187352|NCT01380327|9841105|FG002|Overall Study|Withdrawal by Subject|1
6187353|NCT01380327|9841103|FG000|Overall Study|Housing situation precluded ability to k|0
6187354|NCT01380327|9841104|FG001|Overall Study|Housing situation precluded ability to k|0
6187355|NCT01380327|9841105|FG002|Overall Study|Housing situation precluded ability to k|1
6187356|NCT01380327|9841103|FG000|Overall Study|Questionable onset of epilepsy|0
6187357|NCT01380327|9841104|FG001|Overall Study|Questionable onset of epilepsy|0
6187358|NCT01380327|9841105|FG002|Overall Study|Questionable onset of epilepsy|1
6187359|NCT01380379|9841118|FG000|Overall Study|Pregnancy|1
6187360|NCT01380535|9841124|FG000|Overall Study|Adverse Event|3
6187361|NCT01380535|9841125|FG001|Overall Study|Adverse Event|3
6187362|NCT01380535|9841124|FG000|Overall Study|Death|3
6187363|NCT01380535|9841125|FG001|Overall Study|Death|0
6187364|NCT01380535|9841124|FG000|Overall Study|Study site closed|0
6187365|NCT01380535|9841125|FG001|Overall Study|Study site closed|5
6234314|NCT01785849|9912137|FG001|Overall Study|Withdrawal by Subject|12
6234315|NCT01785849|9912136|FG000|Overall Study|Sponsor Decision|0
6234316|NCT01785849|9912137|FG001|Overall Study|Sponsor Decision|1
6187366|NCT01380535|9841124|FG000|Overall Study|Withdrawal by Subject|1
6187367|NCT01380535|9841125|FG001|Overall Study|Withdrawal by Subject|2
6234317|NCT01785849|9912136|FG000|Overall Study|Lost to Follow-up|10
6234318|NCT01785849|9912137|FG001|Overall Study|Lost to Follow-up|11
6234319|NCT01785875|9912143|FG000|Overall Study|Withdrawal by Subject|41
6234320|NCT01785875|9912144|FG001|Overall Study|Withdrawal by Subject|34
6234321|NCT01785875|9912145|FG002|Overall Study|Withdrawal by Subject|36
6234322|NCT01785875|9912143|FG000|Overall Study|Lost to Follow-up|19
6234323|NCT01785875|9912144|FG001|Overall Study|Lost to Follow-up|22
6234324|NCT01785875|9912145|FG002|Overall Study|Lost to Follow-up|6
6234325|NCT01785875|9912143|FG000|Overall Study|Death|27
6234326|NCT01785875|9912144|FG001|Overall Study|Death|16
6234327|NCT01785875|9912145|FG002|Overall Study|Death|7
6234328|NCT01785875|9912143|FG000|Overall Study|Sponsor Decision|0
6234329|NCT01785875|9912144|FG001|Overall Study|Sponsor Decision|2
6234330|NCT01785875|9912145|FG002|Overall Study|Sponsor Decision|0
6234331|NCT01785875|9912143|FG000|Overall Study|Protocol Specified Criteria|207
6234332|NCT01785875|9912144|FG001|Overall Study|Protocol Specified Criteria|214
6234333|NCT01785875|9912145|FG002|Overall Study|Protocol Specified Criteria|55
6234334|NCT01785875|9912143|FG000|Overall Study|Missing|0
6234335|NCT01785875|9912144|FG001|Overall Study|Missing|1
6234336|NCT01785875|9912145|FG002|Overall Study|Missing|3
6234337|NCT01786109|9912159|FG000|Overall Study|fail manometry barostat tube placement|1
6234338|NCT01786109|9912160|FG001|Overall Study|fail manometry barostat tube placement|0
6234339|NCT01786109|9912161|FG002|Overall Study|fail manometry barostat tube placement|0
6234340|NCT01786109|9912159|FG000|Overall Study|unrelated illness|0
6234341|NCT01786109|9912160|FG001|Overall Study|unrelated illness|0
6234342|NCT01786109|9912161|FG002|Overall Study|unrelated illness|1
6234343|NCT01786109|9912159|FG000|Overall Study|adverse effects colon preparation|0
6234344|NCT01786109|9912160|FG001|Overall Study|adverse effects colon preparation|0
6234345|NCT01786109|9912161|FG002|Overall Study|adverse effects colon preparation|1
6234346|NCT01786148|9912171|FG000|Overall Study|Lost to Follow-up|21
6234347|NCT01786148|9912172|FG001|Overall Study|Lost to Follow-up|13
6234348|NCT01786148|9912171|FG000|Overall Study|Death|0
6234349|NCT01786148|9912172|FG001|Overall Study|Death|1
6234350|NCT01786148|9912171|FG000|Overall Study|Withdrawal by Subject|0
6234351|NCT01786148|9912172|FG001|Overall Study|Withdrawal by Subject|7
6234352|NCT01786148|9912171|FG000|Overall Study|Incarceration|1
6234353|NCT01786148|9912172|FG001|Overall Study|Incarceration|1
6234354|NCT01786174|9912191|FG000|Overall Study|Discontinued Study Drug|2
6234355|NCT01786174|9912192|FG001|Overall Study|Discontinued Study Drug|0
6234356|NCT01786330|9912230|FG000|Overall Study|Withdrawal by Subject|0
6234357|NCT01786330|9912231|FG001|Overall Study|Withdrawal by Subject|1
6234358|NCT01786330|9912230|FG000|Overall Study|Lost to Follow-up|0
6234359|NCT01786330|9912231|FG001|Overall Study|Lost to Follow-up|1
6234360|NCT01786330|9912230|FG000|Overall Study|Excluded intraoperatively|0
6234361|NCT01786330|9912231|FG001|Overall Study|Excluded intraoperatively|1
6234362|NCT01786330|9912230|FG000|Overall Study|Protocol Violation|1
6234363|NCT01786330|9912231|FG001|Overall Study|Protocol Violation|0
6234364|NCT01786512|9912257|FG000|Overall Study|Lost to Follow-up|0
6234365|NCT01786512|9912258|FG001|Overall Study|Lost to Follow-up|0
6234366|NCT01786512|9912259|FG002|Overall Study|Lost to Follow-up|0
6234367|NCT01786512|9912260|FG003|Overall Study|Lost to Follow-up|0
6234368|NCT01786512|9912261|FG004|Overall Study|Lost to Follow-up|0
6234369|NCT01786512|9912262|FG005|Overall Study|Lost to Follow-up|0
6234370|NCT01786512|9912263|FG006|Overall Study|Lost to Follow-up|0
6234371|NCT01786512|9912264|FG007|Overall Study|Lost to Follow-up|0
6234372|NCT01786512|9912265|FG008|Overall Study|Lost to Follow-up|0
6234373|NCT01786512|9912266|FG009|Overall Study|Lost to Follow-up|1
6234374|NCT01786512|9912267|FG010|Overall Study|Lost to Follow-up|0
6234375|NCT01786512|9912257|FG000|Overall Study|Decision by sponsor|0
6234376|NCT01786512|9912258|FG001|Overall Study|Decision by sponsor|0
6234377|NCT01786512|9912259|FG002|Overall Study|Decision by sponsor|0
6234378|NCT01786512|9912260|FG003|Overall Study|Decision by sponsor|0
6234379|NCT01786512|9912261|FG004|Overall Study|Decision by sponsor|0
6234380|NCT01786512|9912262|FG005|Overall Study|Decision by sponsor|0
6234381|NCT01786512|9912263|FG006|Overall Study|Decision by sponsor|0
6234382|NCT01786512|9912264|FG007|Overall Study|Decision by sponsor|0
6234383|NCT01786512|9912265|FG008|Overall Study|Decision by sponsor|0
6234384|NCT01786512|9912266|FG009|Overall Study|Decision by sponsor|0
6234385|NCT01786512|9912267|FG010|Overall Study|Decision by sponsor|2
6234386|NCT01786512|9912257|FG000|Overall Study|Withdrawal by Subject|0
6234387|NCT01786512|9912258|FG001|Overall Study|Withdrawal by Subject|1
6234388|NCT01786512|9912259|FG002|Overall Study|Withdrawal by Subject|0
6234389|NCT01786512|9912260|FG003|Overall Study|Withdrawal by Subject|0
6234390|NCT01786512|9912261|FG004|Overall Study|Withdrawal by Subject|0
6234391|NCT01786512|9912262|FG005|Overall Study|Withdrawal by Subject|0
6234392|NCT01786512|9912263|FG006|Overall Study|Withdrawal by Subject|1
6234393|NCT01786512|9912264|FG007|Overall Study|Withdrawal by Subject|0
6234394|NCT01786512|9912265|FG008|Overall Study|Withdrawal by Subject|0
6234395|NCT01786512|9912266|FG009|Overall Study|Withdrawal by Subject|3
6234396|NCT01786512|9912267|FG010|Overall Study|Withdrawal by Subject|7
6234397|NCT01786512|9912257|FG000|Overall Study|Death|0
6234398|NCT01786512|9912258|FG001|Overall Study|Death|0
6234399|NCT01786512|9912259|FG002|Overall Study|Death|0
6234400|NCT01786512|9912260|FG003|Overall Study|Death|0
6234401|NCT01786512|9912261|FG004|Overall Study|Death|0
6234402|NCT01786512|9912262|FG005|Overall Study|Death|0
6234403|NCT01786512|9912263|FG006|Overall Study|Death|0
6234404|NCT01786512|9912264|FG007|Overall Study|Death|0
6234405|NCT01786512|9912265|FG008|Overall Study|Death|4
6234406|NCT01786512|9912266|FG009|Overall Study|Death|1
6234407|NCT01786512|9912267|FG010|Overall Study|Death|3
6234408|NCT01786551|9912299|FG000|Overall Study|Participant withdrew consent|2
6234409|NCT01786564|9912303|FG000|Overall Study|Lost to Follow-up|47
6234410|NCT01786564|9912303|FG000|Overall Study|Ineligible|17
6234411|NCT01786603|9912309|FG000|Overall Study|Death|5
6234412|NCT01786603|9912310|FG001|Overall Study|Death|1
6234413|NCT01786603|9912309|FG000|Overall Study|Adverse Event|6
6234414|NCT01786603|9912310|FG001|Overall Study|Adverse Event|2
6234415|NCT01786603|9912309|FG000|Overall Study|Physician decision to withdraw|6
6234416|NCT01786603|9912310|FG001|Overall Study|Physician decision to withdraw|7
6234417|NCT01786603|9912309|FG000|Overall Study|Lost to Follow-up|1
6234418|NCT01786603|9912310|FG001|Overall Study|Lost to Follow-up|2
6234419|NCT01786629|9912318|FG000|Overall Study|Lack of Efficacy|0
6234420|NCT01786629|9912319|FG001|Overall Study|Lack of Efficacy|4
6234421|NCT01786629|9912318|FG000|Overall Study|Adverse Event|0
6234422|NCT01786629|9912319|FG001|Overall Study|Adverse Event|1
6234423|NCT01786668|9912329|FG000|Overall Study|Adverse Event|0
6234424|NCT01786668|9912330|FG001|Overall Study|Adverse Event|1
6234425|NCT01786668|9912331|FG002|Overall Study|Adverse Event|1
6234426|NCT01786668|9912332|FG003|Overall Study|Adverse Event|2
6234427|NCT01786668|9912329|FG000|Overall Study|Withdrawal by Subject|0
6234428|NCT01786668|9912330|FG001|Overall Study|Withdrawal by Subject|0
6187368|NCT01380535|9841124|FG000|Overall Study|Protocol Violation|0
6187369|NCT01380535|9841125|FG001|Overall Study|Protocol Violation|2
6187370|NCT01380535|9841124|FG000|Overall Study|Lack of Efficacy|0
6187371|NCT01380535|9841125|FG001|Overall Study|Lack of Efficacy|3
6187372|NCT01380691|9841140|FG000|Washout (7 Days)|Protocol Violation|0
6187373|NCT01380691|9841141|FG001|Washout (7 Days)|Protocol Violation|0
6187374|NCT01380691|9841142|FG002|Washout (7 Days)|Protocol Violation|0
6187375|NCT01380691|9841143|FG003|Washout (7 Days)|Protocol Violation|1
6187376|NCT01380691|9841140|FG000|Washout (7 Days)|Withdrawal by Subject|0
6187377|NCT01380691|9841141|FG001|Washout (7 Days)|Withdrawal by Subject|0
6187378|NCT01380691|9841142|FG002|Washout (7 Days)|Withdrawal by Subject|1
6187379|NCT01380691|9841143|FG003|Washout (7 Days)|Withdrawal by Subject|0
6187380|NCT01380730|9841162|FG000|Overall Study|Death|0
6187381|NCT01380730|9841163|FG001|Overall Study|Death|0
6187382|NCT01380730|9841164|FG002|Overall Study|Death|0
6187383|NCT01380730|9841165|FG003|Overall Study|Death|0
6187384|NCT01380730|9841166|FG004|Overall Study|Death|1
6187385|NCT01380730|9841167|FG005|Overall Study|Death|0
6187386|NCT01380730|9841168|FG006|Overall Study|Death|0
6187387|NCT01380730|9841169|FG007|Overall Study|Death|0
6187388|NCT01380769|9841206|FG000|Overall Study|Withdrawal by Subject|7
6187389|NCT01380769|9841207|FG001|Overall Study|Withdrawal by Subject|11
6187390|NCT01380769|9841206|FG000|Overall Study|Physician Decision|1
6187391|NCT01380769|9841207|FG001|Overall Study|Physician Decision|1
6187392|NCT01380769|9841206|FG000|Overall Study|Adverse Event|1
6187393|NCT01380769|9841207|FG001|Overall Study|Adverse Event|1
6187394|NCT01380769|9841206|FG000|Overall Study|Protocol Violation|0
6187395|NCT01380769|9841207|FG001|Overall Study|Protocol Violation|1
6187396|NCT01380782|9841215|FG000|Overall Study|Adverse Event|0
6187397|NCT01380782|9841216|FG001|Overall Study|Adverse Event|1
6187398|NCT01380782|9841217|FG002|Overall Study|Adverse Event|0
6187399|NCT01380782|9841218|FG003|Overall Study|Adverse Event|0
6187400|NCT01380782|9841215|FG000|Overall Study|Death|1
6187401|NCT01380782|9841216|FG001|Overall Study|Death|0
6187402|NCT01380782|9841217|FG002|Overall Study|Death|0
6187403|NCT01380782|9841218|FG003|Overall Study|Death|0
6187404|NCT01380782|9841215|FG000|Overall Study|Lack of Efficacy|10
6187405|NCT01380782|9841216|FG001|Overall Study|Lack of Efficacy|9
6187406|NCT01380782|9841217|FG002|Overall Study|Lack of Efficacy|10
6187407|NCT01380782|9841218|FG003|Overall Study|Lack of Efficacy|3
6187408|NCT01380782|9841215|FG000|Overall Study|Physician Decision|1
6187409|NCT01380782|9841216|FG001|Overall Study|Physician Decision|0
6187410|NCT01380782|9841217|FG002|Overall Study|Physician Decision|0
6187411|NCT01380782|9841218|FG003|Overall Study|Physician Decision|0
6187412|NCT01380782|9841215|FG000|Overall Study|Withdrawal by Subject|0
6187413|NCT01380782|9841216|FG001|Overall Study|Withdrawal by Subject|0
6187414|NCT01380782|9841217|FG002|Overall Study|Withdrawal by Subject|1
6187415|NCT01380782|9841218|FG003|Overall Study|Withdrawal by Subject|1
6187416|NCT01380834|9841232|FG000|Overall Study|Physician Decision|1
6187417|NCT01380834|9841233|FG001|Overall Study|Physician Decision|0
6187418|NCT01380990|9841254|FG000|Overall Study|Treatment Failure|1
6187419|NCT01380990|9841255|FG001|Overall Study|Treatment Failure|0
6187420|NCT01380990|9841254|FG000|Overall Study|Death|0
6187421|NCT01380990|9841255|FG001|Overall Study|Death|1
6187422|NCT01381016|9841267|FG000|Overall Study|Lost to Follow-up|1
6187423|NCT01381016|9841268|FG001|Overall Study|Lost to Follow-up|1
6187424|NCT01381016|9841267|FG000|Overall Study|Screen Failure|2
6187425|NCT01381016|9841268|FG001|Overall Study|Screen Failure|2
6187426|NCT01381016|9841267|FG000|Overall Study|Withdrawal by Subject|0
6187427|NCT01381016|9841268|FG001|Overall Study|Withdrawal by Subject|1
6187428|NCT01381016|9841267|FG000|Overall Study|Physician Decision|0
6187429|NCT01381016|9841268|FG001|Overall Study|Physician Decision|2
6187430|NCT01381068|9841278|FG000|Overall Study|Death|1
6187431|NCT01381068|9841279|FG001|Overall Study|Death|0
6187432|NCT01381549|9841319|FG000|Overall Study|Ineligible: No organisms isolated|0
6187433|NCT01381549|9841320|FG001|Overall Study|Ineligible: No organisms isolated|0
6187434|NCT01381549|9841321|FG002|Overall Study|Ineligible: No organisms isolated|1
6187435|NCT01381562|9841333|FG000|Overall Study|Adverse Event|0
6187436|NCT01381562|9841334|FG001|Overall Study|Adverse Event|1
6234429|NCT01786668|9912331|FG002|Overall Study|Withdrawal by Subject|3
6234430|NCT01786668|9912332|FG003|Overall Study|Withdrawal by Subject|1
6234431|NCT01786668|9912329|FG000|Overall Study|Pregnancy|0
6187437|NCT01381562|9841335|FG002|Overall Study|Adverse Event|0
6187438|NCT01381575|9841346|FG000|Overall Study|Serious Adverse Event|1
6187439|NCT01381575|9841347|FG001|Overall Study|Serious Adverse Event|0
6187440|NCT01381575|9841348|FG002|Overall Study|Serious Adverse Event|0
6187441|NCT01381575|9841346|FG000|Overall Study|Non-Serious Adverse Event|0
6187442|NCT01381575|9841347|FG001|Overall Study|Non-Serious Adverse Event|0
6187443|NCT01381575|9841348|FG002|Overall Study|Non-Serious Adverse Event|1
6187444|NCT01381575|9841346|FG000|Overall Study|Protocol Violation|0
6187445|NCT01381575|9841347|FG001|Overall Study|Protocol Violation|1
6187446|NCT01381575|9841348|FG002|Overall Study|Protocol Violation|1
6187447|NCT01381575|9841346|FG000|Overall Study|Withdrawal by Subject|15
6234432|NCT01786668|9912330|FG001|Overall Study|Pregnancy|0
6234433|NCT01786668|9912331|FG002|Overall Study|Pregnancy|0
6234434|NCT01786668|9912332|FG003|Overall Study|Pregnancy|1
6234435|NCT01786668|9912329|FG000|Overall Study|Lost to Follow-up|1
6234436|NCT01786668|9912330|FG001|Overall Study|Lost to Follow-up|0
6234437|NCT01786668|9912331|FG002|Overall Study|Lost to Follow-up|1
6234438|NCT01786668|9912332|FG003|Overall Study|Lost to Follow-up|0
6234439|NCT01786707|9912344|FG000|Overall Study|Lost to Follow-up|1
6234440|NCT01786707|9912345|FG001|Overall Study|Lost to Follow-up|1
6234441|NCT01786993|9912386|FG000|Overall Study|Death|6
6234442|NCT01786993|9912387|FG001|Overall Study|Death|7
6234443|NCT01786993|9912386|FG000|Overall Study|Withdrawal by Subject|3
6234444|NCT01786993|9912387|FG001|Overall Study|Withdrawal by Subject|2
6234445|NCT01786993|9912386|FG000|Overall Study|Lost to Follow-up|0
6234446|NCT01786993|9912387|FG001|Overall Study|Lost to Follow-up|1
6234447|NCT01786993|9912386|FG000|Overall Study|Subject Non-Compliance|1
6085695|NCT00654420|9695028|FG002|Phase II|Withdrawal by Subject|4
6085696|NCT00654420|9695029|FG003|Phase II|Withdrawal by Subject|1
6085697|NCT00654420|9695026|FG000|Phase II|Missing Disposition Record|0
6085698|NCT00654420|9695027|FG001|Phase II|Missing Disposition Record|0
6085699|NCT00654420|9695028|FG002|Phase II|Missing Disposition Record|1
6085700|NCT00654420|9695029|FG003|Phase II|Missing Disposition Record|0
6085701|NCT00654498|9695041|FG000|Overall Study|Not Treated|1
6085702|NCT00654498|9695042|FG001|Overall Study|Not Treated|0
6085703|NCT00654498|9695041|FG000|Overall Study|Adverse Event|6
6085704|NCT00654498|9695042|FG001|Overall Study|Adverse Event|1
6085705|NCT00654498|9695041|FG000|Overall Study|Protocol Violation|1
6085706|NCT00654498|9695042|FG001|Overall Study|Protocol Violation|1
6085707|NCT00654498|9695041|FG000|Overall Study|Lost to Follow-up|1
6085708|NCT00654498|9695042|FG001|Overall Study|Lost to Follow-up|5
6085709|NCT00654498|9695041|FG000|Overall Study|Withdrawal by Subject|1
6085710|NCT00654498|9695042|FG001|Overall Study|Withdrawal by Subject|0
6085711|NCT00654498|9695041|FG000|Overall Study|Other reason not defined above|4
6085712|NCT00654498|9695042|FG001|Overall Study|Other reason not defined above|5
6085713|NCT00654641|9695080|FG000|Overall Study|Lost to Follow-up|2
6085714|NCT00654641|9695081|FG001|Overall Study|Lost to Follow-up|3
6085715|NCT00654732|9695093|FG000|Overall Study|Adverse Event|4
6085716|NCT00654732|9695094|FG001|Overall Study|Adverse Event|6
6085717|NCT00654745|9695100|FG000|Overall Study|Adverse Event|12
6085718|NCT00654745|9695100|FG000|Overall Study|Lost to Follow-up|7
6085719|NCT00654745|9695100|FG000|Overall Study|Protocol Violation|11
6085720|NCT00654745|9695100|FG000|Overall Study|Withdrawal by Subject|10
6085721|NCT00654745|9695100|FG000|Overall Study|poor ABPM, noncompliance, lab MAs|3
6085722|NCT00654875|9695125|FG000|Overall Study|Adverse Event|5
6085723|NCT00654875|9695126|FG001|Overall Study|Adverse Event|5
6085724|NCT00654875|9695125|FG000|Overall Study|Withdrawal by Subject|4
6085725|NCT00654875|9695126|FG001|Overall Study|Withdrawal by Subject|4
6085726|NCT00654875|9695125|FG000|Overall Study|Protocol Violation|3
6085727|NCT00654875|9695126|FG001|Overall Study|Protocol Violation|3
6085728|NCT00654875|9695125|FG000|Overall Study|Lack of Efficacy|2
6085729|NCT00654875|9695126|FG001|Overall Study|Lack of Efficacy|2
6085730|NCT00654875|9695125|FG000|Overall Study|Lost to Follow-up|1
6085731|NCT00654875|9695126|FG001|Overall Study|Lost to Follow-up|3
6085732|NCT00654875|9695125|FG000|Overall Study|Abnormal Test Procedure Result(s)|1
6085733|NCT00654875|9695126|FG001|Overall Study|Abnormal Test Procedure Result(s)|0
6085734|NCT00654875|9695125|FG000|Overall Study|Administrative Problems|1
6085735|NCT00654875|9695126|FG001|Overall Study|Administrative Problems|0
6087763|NCT00670449|9698232|FG001|Overall Study|Subject Withdrew Consent|2
6087764|NCT00670449|9698233|FG002|Overall Study|Subject Withdrew Consent|0
6087765|NCT00670449|9698234|FG003|Overall Study|Subject Withdrew Consent|1
6087766|NCT00670449|9698231|FG000|Overall Study|Unsatisfactory Therapeutic Effect|2
6087767|NCT00670449|9698232|FG001|Overall Study|Unsatisfactory Therapeutic Effect|0
6087768|NCT00670449|9698233|FG002|Overall Study|Unsatisfactory Therapeutic Effect|1
6087769|NCT00670449|9698234|FG003|Overall Study|Unsatisfactory Therapeutic Effect|0
6087770|NCT00670449|9698231|FG000|Overall Study|Abnormal Laboratory Value(s)|0
6087771|NCT00670449|9698232|FG001|Overall Study|Abnormal Laboratory Value(s)|2
6234448|NCT01786993|9912387|FG001|Overall Study|Subject Non-Compliance|0
6234449|NCT01786993|9912386|FG000|Overall Study|System Explant|1
6234450|NCT01786993|9912387|FG001|Overall Study|System Explant|0
6234451|NCT01786993|9912386|FG000|Overall Study|Hospice Admission|1
6234452|NCT01786993|9912387|FG001|Overall Study|Hospice Admission|0
6234453|NCT01787032|9912409|FG000|Overall Study|Protocol Violation|0
6234454|NCT01787032|9912410|FG001|Overall Study|Protocol Violation|0
6234455|NCT01787032|9912411|FG002|Overall Study|Protocol Violation|0
6234456|NCT01787032|9912412|FG003|Overall Study|Protocol Violation|0
6234457|NCT01787032|9912413|FG004|Overall Study|Protocol Violation|1
6234458|NCT01787032|9912414|FG005|Overall Study|Protocol Violation|1
6234459|NCT01787097|9912424|FG000|Overall Study|Withdrawal by Subject|1
6234460|NCT01787097|9912425|FG001|Overall Study|Withdrawal by Subject|0
6234461|NCT01787097|9912426|FG002|Overall Study|Withdrawal by Subject|0
6234462|NCT01787097|9912427|FG003|Overall Study|Withdrawal by Subject|0
6234463|NCT01787188|9912459|FG000|Overall Study|Adverse Event|2
6234464|NCT01787188|9912460|FG001|Overall Study|Adverse Event|4
6234465|NCT01787188|9912461|FG002|Overall Study|Adverse Event|6
6234466|NCT01787188|9912459|FG000|Overall Study|Lack of Efficacy|7
6234467|NCT01787188|9912460|FG001|Overall Study|Lack of Efficacy|3
6234468|NCT01787188|9912461|FG002|Overall Study|Lack of Efficacy|5
6234469|NCT01787188|9912459|FG000|Overall Study|Non-compliance with Study Drug|0
6234470|NCT01787188|9912460|FG001|Overall Study|Non-compliance with Study Drug|1
6234471|NCT01787188|9912461|FG002|Overall Study|Non-compliance with Study Drug|0
6234472|NCT01787188|9912459|FG000|Overall Study|Withdrawal by Subject|4
6234473|NCT01787188|9912460|FG001|Overall Study|Withdrawal by Subject|3
6234474|NCT01787188|9912461|FG002|Overall Study|Withdrawal by Subject|2
6234475|NCT01787188|9912459|FG000|Overall Study|Protocol Violation|3
6234476|NCT01787188|9912460|FG001|Overall Study|Protocol Violation|2
6234477|NCT01787188|9912461|FG002|Overall Study|Protocol Violation|3
6234478|NCT01787188|9912459|FG000|Overall Study|Lost to Follow-up|1
6234479|NCT01787188|9912460|FG001|Overall Study|Lost to Follow-up|2
6234480|NCT01787188|9912461|FG002|Overall Study|Lost to Follow-up|2
6234481|NCT01787188|9912459|FG000|Overall Study|Other, including patient moved|0
6234482|NCT01787188|9912460|FG001|Overall Study|Other, including patient moved|3
6234483|NCT01787188|9912461|FG002|Overall Study|Other, including patient moved|0
6234484|NCT01787279|9912481|FG000|Overall Study|Lost to Follow-up|2
6234485|NCT01787279|9912481|FG000|Overall Study|Lack of Efficacy|1
6234486|NCT01787292|9912485|FG000|Crossover Exercise Interventions|Withdrawal by Subject|2
6234487|NCT01787292|9912486|FG001|Crossover Exercise Interventions|Withdrawal by Subject|2
6234488|NCT01787292|9912485|FG000|Home Based Exercise Program|Withdrawal by Subject|3
6234489|NCT01787292|9912486|FG001|Home Based Exercise Program|Withdrawal by Subject|1
6234490|NCT01787331|9912497|FG000|Overall Study|Physician Decision|1
6234491|NCT01787331|9912497|FG000|Overall Study|Withdrawal by Subject|1
6234492|NCT01787461|9912520|FG000|Overall Study|Adverse Event|4
6234493|NCT01787461|9912521|FG001|Overall Study|Adverse Event|3
6234494|NCT01787461|9912520|FG000|Overall Study|Lost to Follow-up|3
6234495|NCT01787461|9912521|FG001|Overall Study|Lost to Follow-up|2
6375735|NCT00412880|10165853|FG000|Overall Study|Consent withdrawn|1
6375736|NCT00412880|10165853|FG000|Overall Study|Adverse Event|1
6375737|NCT00412880|10165853|FG000|Overall Study|Progressive disease|20
6234496|NCT01787461|9912520|FG000|Overall Study|No longer met eligibility criteria|1
6234497|NCT01787461|9912521|FG001|Overall Study|No longer met eligibility criteria|0
6234498|NCT01787461|9912520|FG000|Overall Study|Withdrawal by Subject|3
6234499|NCT01787461|9912521|FG001|Overall Study|Withdrawal by Subject|4
6234500|NCT01787461|9912520|FG000|Overall Study|Protocol Violation|3
6234501|NCT01787461|9912521|FG001|Overall Study|Protocol Violation|0
6234502|NCT01787591|9912529|FG000|Period 1 (Cross-over Arm 1)|Withdrawal by Subject|0
6234503|NCT01787591|9912530|FG001|Period 1 (Cross-over Arm 1)|Withdrawal by Subject|0
6234504|NCT01787591|9912531|FG002|Period 1 (Cross-over Arm 1)|Withdrawal by Subject|0
6234505|NCT01787591|9912532|FG003|Period 1 (Cross-over Arm 1)|Withdrawal by Subject|1
6234506|NCT01787760|9912555|FG000|Overall Study|Anisometropia > -1.00D in spherical equi|1
6234507|NCT01787760|9912556|FG001|Overall Study|Anisometropia > -1.00D in spherical equi|0
6234508|NCT01787760|9912557|FG002|Overall Study|Anisometropia > -1.00D in spherical equi|0
6234509|NCT01787760|9912555|FG000|Overall Study|Decompensated on left exotropia|0
6234510|NCT01787760|9912556|FG001|Overall Study|Decompensated on left exotropia|0
6234511|NCT01787760|9912557|FG002|Overall Study|Decompensated on left exotropia|1
6234512|NCT01787760|9912555|FG000|Overall Study|Dryness|0
6234513|NCT01787760|9912556|FG001|Overall Study|Dryness|1
6234514|NCT01787760|9912557|FG002|Overall Study|Dryness|0
6234515|NCT01787760|9912555|FG000|Overall Study|Relocation|1
6234516|NCT01787760|9912556|FG001|Overall Study|Relocation|1
6234517|NCT01787760|9912557|FG002|Overall Study|Relocation|0
6234518|NCT01787760|9912555|FG000|Overall Study|Lens discomfort|3
6234519|NCT01787760|9912556|FG001|Overall Study|Lens discomfort|0
6234520|NCT01787760|9912557|FG002|Overall Study|Lens discomfort|0
6234521|NCT01787760|9912555|FG000|Overall Study|Lens handling difficulty|1
6234522|NCT01787760|9912556|FG001|Overall Study|Lens handling difficulty|2
6234523|NCT01787760|9912557|FG002|Overall Study|Lens handling difficulty|0
6234524|NCT01787760|9912555|FG000|Overall Study|Protocol Violation|6
6234525|NCT01787760|9912556|FG001|Overall Study|Protocol Violation|0
6234526|NCT01787760|9912557|FG002|Overall Study|Protocol Violation|1
6234527|NCT01787760|9912555|FG000|Overall Study|Withdrawal by Subject|5
6234528|NCT01787760|9912556|FG001|Overall Study|Withdrawal by Subject|1
6234529|NCT01787760|9912557|FG002|Overall Study|Withdrawal by Subject|2
6234530|NCT01787760|9912555|FG000|Overall Study|Lost to Follow-up|1
6234531|NCT01787760|9912556|FG001|Overall Study|Lost to Follow-up|0
6234532|NCT01787760|9912557|FG002|Overall Study|Lost to Follow-up|1
6234533|NCT01787760|9912555|FG000|Overall Study|Stroke|1
6234534|NCT01787760|9912556|FG001|Overall Study|Stroke|0
6234535|NCT01787760|9912557|FG002|Overall Study|Stroke|0
6234536|NCT01787760|9912555|FG000|Overall Study|Unsatisfactory lens fitting performance|3
6234537|NCT01787760|9912556|FG001|Overall Study|Unsatisfactory lens fitting performance|6
6234538|NCT01787760|9912557|FG002|Overall Study|Unsatisfactory lens fitting performance|0
6234539|NCT01787760|9912555|FG000|Overall Study|Unsatisfactory physiological response|2
6234540|NCT01787760|9912556|FG001|Overall Study|Unsatisfactory physiological response|4
6187448|NCT01381575|9841347|FG001|Overall Study|Withdrawal by Subject|9
6187449|NCT01381575|9841348|FG002|Overall Study|Withdrawal by Subject|7
6187450|NCT01381575|9841346|FG000|Overall Study|Migrated/moved from study area|2
6187451|NCT01381575|9841347|FG001|Overall Study|Migrated/moved from study area|12
6187452|NCT01381575|9841348|FG002|Overall Study|Migrated/moved from study area|2
6187453|NCT01381575|9841346|FG000|Overall Study|Lost to Follow-up|8
6187454|NCT01381575|9841347|FG001|Overall Study|Lost to Follow-up|17
6187455|NCT01381575|9841348|FG002|Overall Study|Lost to Follow-up|9
6187456|NCT01381692|9841359|FG000|Overall Study|Adverse Event|1
6187457|NCT01381692|9841360|FG001|Overall Study|Adverse Event|0
6187458|NCT01381692|9841361|FG002|Overall Study|Adverse Event|0
6187459|NCT01381692|9841362|FG003|Overall Study|Adverse Event|0
6187460|NCT01381692|9841363|FG004|Overall Study|Adverse Event|0
6187461|NCT01381692|9841364|FG005|Overall Study|Adverse Event|0
6187462|NCT01381718|9841374|FG000|Overall Study|Withdrawal by Subject|2
6187463|NCT01381718|9841375|FG001|Overall Study|Withdrawal by Subject|5
6187464|NCT01381718|9841374|FG000|Overall Study|Lost to Follow-up|3
6187465|NCT01381718|9841375|FG001|Overall Study|Lost to Follow-up|5
6187466|NCT01381718|9841374|FG000|Overall Study|Toxicity, side effects or complications related to study|0
6187467|NCT01381718|9841375|FG001|Overall Study|Toxicity, side effects or complications related to study|3
6187468|NCT01381874|9841388|FG000|Overall Study|Lost to Follow-up|1
6187469|NCT01381874|9841389|FG001|Overall Study|Lost to Follow-up|1
6187470|NCT01381874|9841390|FG002|Overall Study|Lost to Follow-up|0
6187471|NCT01381874|9841388|FG000|Overall Study|Withdrawal by Subject|9
6187472|NCT01381874|9841389|FG001|Overall Study|Withdrawal by Subject|10
6187473|NCT01381874|9841390|FG002|Overall Study|Withdrawal by Subject|9
6187474|NCT01381874|9841388|FG000|Overall Study|Other|67
6187475|NCT01381874|9841389|FG001|Overall Study|Other|52
6187476|NCT01381874|9841390|FG002|Overall Study|Other|67
6187477|NCT01381900|9841401|FG000|Overall Study|Subject meets glycemic withdrawal crit.|2
6187478|NCT01381900|9841402|FG001|Overall Study|Subject meets glycemic withdrawal crit.|0
6187479|NCT01381900|9841403|FG002|Overall Study|Subject meets glycemic withdrawal crit.|0
6187480|NCT01381900|9841401|FG000|Overall Study|Adverse Event|4
6187481|NCT01381900|9841402|FG001|Overall Study|Adverse Event|6
6187482|NCT01381900|9841403|FG002|Overall Study|Adverse Event|7
6187483|NCT01381900|9841401|FG000|Overall Study|Noncompliance with study drug|0
6187484|NCT01381900|9841402|FG001|Overall Study|Noncompliance with study drug|0
6187485|NCT01381900|9841403|FG002|Overall Study|Noncompliance with study drug|1
6187486|NCT01381900|9841401|FG000|Overall Study|Physician Decision|0
6187487|NCT01381900|9841402|FG001|Overall Study|Physician Decision|1
6187488|NCT01381900|9841403|FG002|Overall Study|Physician Decision|1
6187489|NCT01381900|9841401|FG000|Overall Study|Protocol Violation|0
6187490|NCT01381900|9841402|FG001|Overall Study|Protocol Violation|1
6187491|NCT01381900|9841403|FG002|Overall Study|Protocol Violation|1
6187492|NCT01381900|9841401|FG000|Overall Study|Withdrawal by Subject|0
6187493|NCT01381900|9841402|FG001|Overall Study|Withdrawal by Subject|0
6187494|NCT01381900|9841403|FG002|Overall Study|Withdrawal by Subject|1
6187495|NCT01381900|9841401|FG000|Overall Study|Early withdraw|3
6187496|NCT01381900|9841402|FG001|Overall Study|Early withdraw|1
6187497|NCT01381900|9841403|FG002|Overall Study|Early withdraw|1
6187498|NCT01381926|9841413|FG000|Low/High Dose of 1st Treatment (2months)|Adverse Event|2
6187499|NCT01381926|9841414|FG001|Low/High Dose of 1st Treatment (2months)|Adverse Event|0
6187500|NCT01381926|9841413|FG000|Low/High Dose of 1st Treatment (2months)|Withdrawal by Subject|0
6187501|NCT01381926|9841414|FG001|Low/High Dose of 1st Treatment (2months)|Withdrawal by Subject|1
6187502|NCT01382212|9841450|FG000|Overall Study|Kidney transplant|1
6234541|NCT01787760|9912557|FG002|Overall Study|Unsatisfactory physiological response|0
6234542|NCT01787760|9912555|FG000|Overall Study|Unsatisfactory visual response|1
6234543|NCT01787760|9912556|FG001|Overall Study|Unsatisfactory visual response|1
6234544|NCT01787760|9912557|FG002|Overall Study|Unsatisfactory visual response|0
6187503|NCT01382212|9841450|FG000|Overall Study|Withdrew consent|1
6187504|NCT01382225|9841456|FG000|Overall Study|Adverse Event|3
6187505|NCT01382225|9841457|FG001|Overall Study|Adverse Event|2
6187506|NCT01382225|9841456|FG000|Overall Study|Protocol Violation|2
6234545|NCT01787760|9912555|FG000|Overall Study|Near vision blur|1
6234546|NCT01787760|9912556|FG001|Overall Study|Near vision blur|0
6234547|NCT01787760|9912557|FG002|Overall Study|Near vision blur|0
6234548|NCT01787825|9912570|FG000|Overall Study|Subject Did Not Ingest Capsules|1
6234549|NCT01787825|9912571|FG001|Overall Study|Subject Did Not Ingest Capsules|0
6234550|NCT01787825|9912570|FG000|Overall Study|Data Not Analyzable|5
6234551|NCT01787825|9912571|FG001|Overall Study|Data Not Analyzable|1
6234552|NCT01787838|9912578|FG000|Overall Study|refused|1413
6234553|NCT01788046|9912591|FG000|Overall Study|Withdrawal by Subject|12
6234554|NCT01788046|9912592|FG001|Overall Study|Withdrawal by Subject|12
6234555|NCT01788046|9912591|FG000|Overall Study|Lost to Follow-up|12
6234556|NCT01788046|9912592|FG001|Overall Study|Lost to Follow-up|19
6234557|NCT01788046|9912591|FG000|Overall Study|Death|7
6234558|NCT01788046|9912592|FG001|Overall Study|Death|5
6234559|NCT01788046|9912591|FG000|Overall Study|Protocol Specified Criteria|25
6234560|NCT01788046|9912592|FG001|Overall Study|Protocol Specified Criteria|1
6234561|NCT01788163|9912616|FG000|Overall Study|Other|53
6234562|NCT01788163|9912617|FG001|Overall Study|Other|0
6234563|NCT01788163|9912618|FG002|Overall Study|Other|0
6234564|NCT01788163|9912619|FG003|Overall Study|Other|0
6234565|NCT01788163|9912620|FG004|Overall Study|Other|0
6234566|NCT01788163|9912621|FG005|Overall Study|Other|7
6234567|NCT01788163|9912622|FG006|Overall Study|Other|1
6234568|NCT01788163|9912623|FG007|Overall Study|Other|48
6234569|NCT01788163|9912624|FG008|Overall Study|Other|15
6234570|NCT01788163|9912616|FG000|Overall Study|Withdrawal by Subject|2
6234571|NCT01788163|9912617|FG001|Overall Study|Withdrawal by Subject|0
6234572|NCT01788163|9912618|FG002|Overall Study|Withdrawal by Subject|0
6234573|NCT01788163|9912619|FG003|Overall Study|Withdrawal by Subject|0
6234574|NCT01788163|9912620|FG004|Overall Study|Withdrawal by Subject|0
6234575|NCT01788163|9912621|FG005|Overall Study|Withdrawal by Subject|0
6234576|NCT01788163|9912622|FG006|Overall Study|Withdrawal by Subject|0
6234577|NCT01788163|9912623|FG007|Overall Study|Withdrawal by Subject|0
6234578|NCT01788163|9912624|FG008|Overall Study|Withdrawal by Subject|1
6234579|NCT01788215|9912705|FG000|Overall Study|Withdrawal by Subject|0
6234580|NCT01788215|9912706|FG001|Overall Study|Withdrawal by Subject|1
6234581|NCT01788215|9912705|FG000|Overall Study|Lost to Follow-up|2
6234582|NCT01788215|9912706|FG001|Overall Study|Lost to Follow-up|0
6234583|NCT01788228|9912714|FG000|Overall Study|Migrated/moved from study area|1
6234584|NCT01788228|9912715|FG001|Overall Study|Migrated/moved from study area|0
6234585|NCT01788358|9912724|FG000|Overall Study|Other|11
6234586|NCT01788358|9912724|FG000|Overall Study|Logistical difficulties|1
6234587|NCT01788358|9912724|FG000|Overall Study|Lost to Follow-up|5
6234588|NCT01788358|9912724|FG000|Overall Study|Protocol Violation|3
6234589|NCT01788358|9912724|FG000|Overall Study|Withdrawal by Subject|26
6234590|NCT01788358|9912724|FG000|Overall Study|Lack of Efficacy|1
6234591|NCT01788358|9912724|FG000|Overall Study|Adverse Event|51
6187507|NCT01382225|9841457|FG001|Overall Study|Protocol Violation|1
6187508|NCT01382225|9841456|FG000|Overall Study|Subject Withdrew Consent|5
6187509|NCT01382225|9841457|FG001|Overall Study|Subject Withdrew Consent|2
6187510|NCT01382225|9841456|FG000|Overall Study|Other|4
6187511|NCT01382225|9841457|FG001|Overall Study|Other|2
6187512|NCT01382251|9841465|FG000|Overall Study|Surgeries cancelled or delayed|16
6187513|NCT01382251|9841466|FG001|Overall Study|Surgeries cancelled or delayed|16
6187514|NCT01382251|9841465|FG000|Overall Study|Lost to Follow-up|4
6187515|NCT01382251|9841466|FG001|Overall Study|Lost to Follow-up|4
6187516|NCT01382251|9841465|FG000|Overall Study|Contacted after study closed|1
6187517|NCT01382251|9841466|FG001|Overall Study|Contacted after study closed|1
6187518|NCT01382446|9841482|FG000|Overall Study|Withdrawal by Subject|0
6187519|NCT01382446|9841483|FG001|Overall Study|Withdrawal by Subject|1
6187520|NCT01382446|9841482|FG000|Overall Study|Removal from Mechanical Ventilation|3
6187521|NCT01382446|9841483|FG001|Overall Study|Removal from Mechanical Ventilation|3
6187522|NCT01382602|9841491|FG000|Overall Study|Protocol Violation|0
6187523|NCT01382602|9841492|FG001|Overall Study|Protocol Violation|3
6187524|NCT01382602|9841491|FG000|Overall Study|Withdrawal by Subject|0
6187525|NCT01382602|9841492|FG001|Overall Study|Withdrawal by Subject|1
6187526|NCT01382940|9841524|FG000|Overall Study|Adverse Event|19
6187527|NCT01382940|9841524|FG000|Overall Study|Lost to Follow-up|4
6187528|NCT01382940|9841524|FG000|Overall Study|Physician Decision|7
6187529|NCT01382940|9841524|FG000|Overall Study|Withdrawal by Subject|23
6187530|NCT01382940|9841524|FG000|Overall Study|Protocol Violation|20
6187531|NCT01383018|9841537|FG000|Overall Study|Adverse Event|14
6234592|NCT01788423|9912731|FG000|Overall Study|See Comments in Completed (above)|0
6187532|NCT01383018|9841537|FG000|Overall Study|Death|10
6234593|NCT01788423|9912732|FG001|Overall Study|See Comments in Completed (above)|4
6234594|NCT01788423|9912733|FG002|Overall Study|See Comments in Completed (above)|5
6234595|NCT01788566|9912741|FG000|Overall Study|Death|4
6187533|NCT01383018|9841537|FG000|Overall Study|Lost to Follow-up|5
6187534|NCT01383018|9841537|FG000|Overall Study|Physician Decision|5
6187535|NCT01383018|9841537|FG000|Overall Study|Withdrawal by Subject|9
6234596|NCT01788566|9912741|FG000|Overall Study|Adverse Event|1
6234597|NCT01788566|9912741|FG000|Overall Study|Clinical Progressive Disease|3
6234598|NCT01788943|9912756|FG000|Overall Study|Withdrawal by Subject|1
6234599|NCT01788943|9912757|FG001|Overall Study|Withdrawal by Subject|0
6234600|NCT01789047|9912765|FG000|Overall Study|Adverse Event|3
6234601|NCT01789047|9912766|FG001|Overall Study|Adverse Event|2
6234602|NCT01789047|9912765|FG000|Overall Study|Withdrawal by Subject|1
6234603|NCT01789047|9912766|FG001|Overall Study|Withdrawal by Subject|2
6234604|NCT01789203|9912783|FG000|Overall Study|Adverse Event|2
6234605|NCT01789203|9912784|FG001|Overall Study|Adverse Event|2
6234606|NCT01789203|9912783|FG000|Overall Study|Withdrawal by Subject|1
6234607|NCT01789203|9912784|FG001|Overall Study|Withdrawal by Subject|0
6234608|NCT01789203|9912783|FG000|Overall Study|Death|1
6234609|NCT01789203|9912784|FG001|Overall Study|Death|0
6234610|NCT01789203|9912783|FG000|Overall Study|Protocol Violation|2
6234611|NCT01789203|9912784|FG001|Overall Study|Protocol Violation|1
6234612|NCT01789203|9912783|FG000|Overall Study|Other|1
6234613|NCT01789203|9912784|FG001|Overall Study|Other|1
6234614|NCT01789203|9912783|FG000|Overall Study|patient non-adherent|2
6234615|NCT01789203|9912784|FG001|Overall Study|patient non-adherent|0
6234616|NCT01789281|9912798|FG000|Overall Study|Disease progression|15
6234617|NCT01789281|9912799|FG001|Overall Study|Disease progression|4
6234618|NCT01789281|9912798|FG000|Overall Study|Adverse Event|5
6234619|NCT01789281|9912799|FG001|Overall Study|Adverse Event|5
6234620|NCT01789281|9912798|FG000|Overall Study|Withdrawal by Subject|1
6234621|NCT01789281|9912799|FG001|Overall Study|Withdrawal by Subject|0
6234622|NCT01789281|9912798|FG000|Overall Study|Lost to Follow-up|1
6234623|NCT01789281|9912799|FG001|Overall Study|Lost to Follow-up|0
6234624|NCT01789281|9912798|FG000|Overall Study|Administrative problems|0
6234625|NCT01789281|9912799|FG001|Overall Study|Administrative problems|1
6234626|NCT01789320|9912806|FG000|Overall Study|Re-enrolled into study|1
6234627|NCT01789320|9912806|FG000|Overall Study|Lost to Follow-up|1
6234628|NCT01789476|9912812|FG000|Overall Study|Lack of Efficacy|6
6234629|NCT01789476|9912813|FG001|Overall Study|Lack of Efficacy|2
6234630|NCT01789476|9912812|FG000|Overall Study|Adverse Event|1
6234631|NCT01789476|9912813|FG001|Overall Study|Adverse Event|0
6234632|NCT01789476|9912812|FG000|Overall Study|Unable to get IV access|1
6234633|NCT01789476|9912813|FG001|Overall Study|Unable to get IV access|0
6234634|NCT01789567|9912819|FG000|Overall Study|Death|6
6234635|NCT01789606|9912825|FG000|Overall Study|Participant not Purchased the Product|0
6234636|NCT01789606|9912826|FG001|Overall Study|Participant not Purchased the Product|20
6234637|NCT01789606|9912825|FG000|Overall Study|Withdrawal by Subject|0
6234638|NCT01789606|9912826|FG001|Overall Study|Withdrawal by Subject|1
6234639|NCT01789606|9912825|FG000|Overall Study|Ineligible|6
6234640|NCT01789606|9912826|FG001|Overall Study|Ineligible|2
6234641|NCT01789606|9912825|FG000|Overall Study|Administrative Reasons|17
6234642|NCT01789606|9912826|FG001|Overall Study|Administrative Reasons|6
6234643|NCT01789606|9912825|FG000|Overall Study|No Study Medication Taken|0
6234644|NCT01789606|9912826|FG001|Overall Study|No Study Medication Taken|1
6234645|NCT01789606|9912825|FG000|Overall Study|Protocol Violation|0
6234646|NCT01789606|9912826|FG001|Overall Study|Protocol Violation|55
6234647|NCT01789606|9912825|FG000|Overall Study|Adverse Event|0
6234648|NCT01789606|9912826|FG001|Overall Study|Adverse Event|3
6234649|NCT01789606|9912825|FG000|Overall Study|Lost to Follow-up|0
6234650|NCT01789606|9912826|FG001|Overall Study|Lost to Follow-up|14
6234651|NCT01789606|9912825|FG000|Overall Study|Ineligible or not Willing to Continue|0
6234652|NCT01789606|9912826|FG001|Overall Study|Ineligible or not Willing to Continue|348
6234653|NCT01789970|9912866|FG000|Open-label Titration Period|Adverse Event|68
6234654|NCT01789970|9912867|FG001|Open-label Titration Period|Adverse Event|0
6234655|NCT01789970|9912868|FG002|Open-label Titration Period|Adverse Event|0
6234656|NCT01789970|9912866|FG000|Open-label Titration Period|Lack of Efficacy|31
6234657|NCT01789970|9912867|FG001|Open-label Titration Period|Lack of Efficacy|0
6234658|NCT01789970|9912868|FG002|Open-label Titration Period|Lack of Efficacy|0
6234659|NCT01789970|9912866|FG000|Open-label Titration Period|Withdrawal by Subject|31
6234660|NCT01789970|9912867|FG001|Open-label Titration Period|Withdrawal by Subject|0
6234661|NCT01789970|9912868|FG002|Open-label Titration Period|Withdrawal by Subject|0
6234662|NCT01789970|9912866|FG000|Open-label Titration Period|Protocol Violation|18
6234663|NCT01789970|9912867|FG001|Open-label Titration Period|Protocol Violation|0
6234664|NCT01789970|9912868|FG002|Open-label Titration Period|Protocol Violation|0
6234665|NCT01789970|9912866|FG000|Open-label Titration Period|Lost to Follow-up|5
6234666|NCT01789970|9912867|FG001|Open-label Titration Period|Lost to Follow-up|0
6234667|NCT01789970|9912868|FG002|Open-label Titration Period|Lost to Follow-up|0
6234668|NCT01789970|9912866|FG000|Open-label Titration Period|Noncompliance to study drug admin|11
6234669|NCT01789970|9912867|FG001|Open-label Titration Period|Noncompliance to study drug admin|0
6234670|NCT01789970|9912868|FG002|Open-label Titration Period|Noncompliance to study drug admin|0
6234671|NCT01789970|9912866|FG000|Open-label Titration Period|Noncompliance with study rescue meds|2
6234672|NCT01789970|9912867|FG001|Open-label Titration Period|Noncompliance with study rescue meds|0
6234673|NCT01789970|9912868|FG002|Open-label Titration Period|Noncompliance with study rescue meds|0
6234674|NCT01789970|9912866|FG000|Open-label Titration Period|Noncompliance with study procedures|8
6234675|NCT01789970|9912867|FG001|Open-label Titration Period|Noncompliance with study procedures|0
6234676|NCT01789970|9912868|FG002|Open-label Titration Period|Noncompliance with study procedures|0
6234677|NCT01789970|9912866|FG000|Open-label Titration Period|Pregnancy|2
6234678|NCT01789970|9912867|FG001|Open-label Titration Period|Pregnancy|0
6234679|NCT01789970|9912868|FG002|Open-label Titration Period|Pregnancy|0
6234680|NCT01789970|9912866|FG000|Open-label Titration Period|Other|76
6234681|NCT01789970|9912867|FG001|Open-label Titration Period|Other|0
6234682|NCT01789970|9912868|FG002|Open-label Titration Period|Other|0
6234683|NCT01789970|9912866|FG000|Open-label Titration Period|Dropped out prior to dosing|2
6234684|NCT01789970|9912867|FG001|Open-label Titration Period|Dropped out prior to dosing|0
6234685|NCT01789970|9912868|FG002|Open-label Titration Period|Dropped out prior to dosing|0
6234686|NCT01789970|9912866|FG000|Double-blind Treatment Period (12 Weeks)|Adverse Event|0
6234687|NCT01789970|9912867|FG001|Double-blind Treatment Period (12 Weeks)|Adverse Event|9
6234688|NCT01789970|9912868|FG002|Double-blind Treatment Period (12 Weeks)|Adverse Event|15
6234689|NCT01789970|9912866|FG000|Double-blind Treatment Period (12 Weeks)|Lack of Efficacy|0
6234690|NCT01789970|9912867|FG001|Double-blind Treatment Period (12 Weeks)|Lack of Efficacy|17
6234691|NCT01789970|9912868|FG002|Double-blind Treatment Period (12 Weeks)|Lack of Efficacy|5
6234692|NCT01789970|9912866|FG000|Double-blind Treatment Period (12 Weeks)|Withdrawal by Subject|0
6234693|NCT01789970|9912867|FG001|Double-blind Treatment Period (12 Weeks)|Withdrawal by Subject|7
6234694|NCT01789970|9912868|FG002|Double-blind Treatment Period (12 Weeks)|Withdrawal by Subject|9
6234695|NCT01789970|9912866|FG000|Double-blind Treatment Period (12 Weeks)|Protocol Violation|0
6234696|NCT01789970|9912867|FG001|Double-blind Treatment Period (12 Weeks)|Protocol Violation|9
6234697|NCT01789970|9912868|FG002|Double-blind Treatment Period (12 Weeks)|Protocol Violation|7
6234698|NCT01789970|9912866|FG000|Double-blind Treatment Period (12 Weeks)|Noncompliance to study drug admin|0
6234699|NCT01789970|9912867|FG001|Double-blind Treatment Period (12 Weeks)|Noncompliance to study drug admin|2
6234700|NCT01789970|9912868|FG002|Double-blind Treatment Period (12 Weeks)|Noncompliance to study drug admin|2
6234701|NCT01789970|9912866|FG000|Double-blind Treatment Period (12 Weeks)|Noncompliance with study procedures|0
6234702|NCT01789970|9912867|FG001|Double-blind Treatment Period (12 Weeks)|Noncompliance with study procedures|2
6234703|NCT01789970|9912868|FG002|Double-blind Treatment Period (12 Weeks)|Noncompliance with study procedures|1
6234704|NCT01789970|9912866|FG000|Double-blind Treatment Period (12 Weeks)|Lost to Follow-up|0
6234705|NCT01789970|9912867|FG001|Double-blind Treatment Period (12 Weeks)|Lost to Follow-up|1
6234706|NCT01789970|9912868|FG002|Double-blind Treatment Period (12 Weeks)|Lost to Follow-up|2
6234707|NCT01789970|9912866|FG000|Double-blind Treatment Period (12 Weeks)|Pregnancy|0
6234708|NCT01789970|9912867|FG001|Double-blind Treatment Period (12 Weeks)|Pregnancy|1
6234709|NCT01789970|9912868|FG002|Double-blind Treatment Period (12 Weeks)|Pregnancy|0
6234710|NCT01789970|9912866|FG000|Double-blind Treatment Period (12 Weeks)|Other|0
6234711|NCT01789970|9912867|FG001|Double-blind Treatment Period (12 Weeks)|Other|1
6234712|NCT01789970|9912868|FG002|Double-blind Treatment Period (12 Weeks)|Other|3
6234713|NCT01789970|9912866|FG000|Double-blind Treatment Period (12 Weeks)|Dropped out prior to dosing|0
6234714|NCT01789970|9912867|FG001|Double-blind Treatment Period (12 Weeks)|Dropped out prior to dosing|1
6234715|NCT01789970|9912868|FG002|Double-blind Treatment Period (12 Weeks)|Dropped out prior to dosing|0
6234716|NCT01790048|9912884|FG000|Overall Study|Incorrect Age|9
6234717|NCT01790048|9912885|FG001|Overall Study|Incorrect Age|14
6234718|NCT01790048|9912884|FG000|Overall Study|data entry error|0
6234719|NCT01790048|9912885|FG001|Overall Study|data entry error|1
6187536|NCT01383018|9841537|FG000|Overall Study|Subject not implanted|76
6187537|NCT01383018|9841537|FG000|Overall Study|Missed Visit|247
6187538|NCT01383018|9841537|FG000|Overall Study|Site closed early-not compliance related|7
6187539|NCT01383018|9841537|FG000|Overall Study|Patient moved away from site|1
6187540|NCT01383018|9841537|FG000|Overall Study|Subject Incarcerated|1
6187541|NCT01383096|9841554|FG000|Second Intervention (8 Days)|Vomited Study Drug within 30min of admin|0
6187542|NCT01383096|9841555|FG001|Second Intervention (8 Days)|Vomited Study Drug within 30min of admin|0
6187543|NCT01383096|9841556|FG002|Second Intervention (8 Days)|Vomited Study Drug within 30min of admin|1
6187544|NCT01383096|9841554|FG000|Second Intervention (8 Days)|Haemoglobin was <13.5 g/dL|0
6187545|NCT01383096|9841555|FG001|Second Intervention (8 Days)|Haemoglobin was <13.5 g/dL|1
6187546|NCT01383096|9841556|FG002|Second Intervention (8 Days)|Haemoglobin was <13.5 g/dL|1
6187547|NCT01383096|9841554|FG000|Third Intervention (8 Days)|Elevated AST|0
6187548|NCT01383096|9841555|FG001|Third Intervention (8 Days)|Elevated AST|1
6187549|NCT01383096|9841556|FG002|Third Intervention (8 Days)|Elevated AST|0
6187550|NCT01383096|9841554|FG000|Third Intervention (8 Days)|Vomited Study Drug within 30min of admin|1
6187551|NCT01383096|9841555|FG001|Third Intervention (8 Days)|Vomited Study Drug within 30min of admin|3
6187552|NCT01383096|9841556|FG002|Third Intervention (8 Days)|Vomited Study Drug within 30min of admin|0
6187553|NCT01383096|9841554|FG000|Third Intervention (8 Days)|Adverse Event|1
6187554|NCT01383096|9841555|FG001|Third Intervention (8 Days)|Adverse Event|0
6187555|NCT01383096|9841556|FG002|Third Intervention (8 Days)|Adverse Event|0
6187556|NCT01383096|9841554|FG000|Third Intervention (8 Days)|Withdrawal by Subject|1
6187557|NCT01383096|9841555|FG001|Third Intervention (8 Days)|Withdrawal by Subject|0
6187558|NCT01383096|9841556|FG002|Third Intervention (8 Days)|Withdrawal by Subject|0
6187559|NCT01383096|9841554|FG000|Third Intervention (8 Days)|QTcF was greater than 450 msec|1
6187560|NCT01383096|9841555|FG001|Third Intervention (8 Days)|QTcF was greater than 450 msec|0
6187561|NCT01383096|9841556|FG002|Third Intervention (8 Days)|QTcF was greater than 450 msec|0
6187562|NCT01383096|9841554|FG000|Fourth Intervention (8 Days)|Haemoglobin was <13.5 g/dL|1
6187563|NCT01383096|9841555|FG001|Fourth Intervention (8 Days)|Haemoglobin was <13.5 g/dL|0
6187564|NCT01383096|9841556|FG002|Fourth Intervention (8 Days)|Haemoglobin was <13.5 g/dL|0
6187565|NCT01383096|9841554|FG000|Fourth Intervention (8 Days)|QTcF was greater than 450 msec|1
6234720|NCT01790048|9912884|FG000|Overall Study|Other|0
6234721|NCT01790048|9912885|FG001|Overall Study|Other|2
6234722|NCT01790048|9912884|FG000|Overall Study|SAM at Enrollment|2
6234723|NCT01790048|9912885|FG001|Overall Study|SAM at Enrollment|0
6234724|NCT01790048|9912884|FG000|Overall Study|Measurement error|1
6234725|NCT01790048|9912885|FG001|Overall Study|Measurement error|0
6234726|NCT01790113|9912895|FG000|Overall Study|Adverse Event|2
6234727|NCT01790113|9912896|FG001|Overall Study|Adverse Event|7
6234728|NCT01790113|9912895|FG000|Overall Study|Study ended due to FDA clearance|1
6234729|NCT01790113|9912896|FG001|Overall Study|Study ended due to FDA clearance|68
6234730|NCT01790126|9912905|FG000|Overall Study|PSA Progression|12
6234731|NCT01790126|9912906|FG001|Overall Study|PSA Progression|16
6234732|NCT01790126|9912907|FG002|Overall Study|PSA Progression|16
6234733|NCT01790126|9912905|FG000|Overall Study|Other|5
6234734|NCT01790126|9912906|FG001|Overall Study|Other|4
6234735|NCT01790126|9912907|FG002|Overall Study|Other|8
6234736|NCT01790126|9912905|FG000|Overall Study|Initiation of Non-Protocol Therapy|3
6234737|NCT01790126|9912906|FG001|Overall Study|Initiation of Non-Protocol Therapy|4
6234738|NCT01790126|9912907|FG002|Overall Study|Initiation of Non-Protocol Therapy|2
6234739|NCT01790126|9912905|FG000|Overall Study|Withdrawal by Physician|1
6234740|NCT01790126|9912906|FG001|Overall Study|Withdrawal by Physician|1
6234741|NCT01790126|9912907|FG002|Overall Study|Withdrawal by Physician|2
6234742|NCT01790126|9912905|FG000|Overall Study|Withdrawal by Subject|3
6234743|NCT01790126|9912906|FG001|Overall Study|Withdrawal by Subject|1
6234744|NCT01790126|9912907|FG002|Overall Study|Withdrawal by Subject|2
6187566|NCT01383096|9841555|FG001|Fourth Intervention (8 Days)|QTcF was greater than 450 msec|0
6187567|NCT01383096|9841556|FG002|Fourth Intervention (8 Days)|QTcF was greater than 450 msec|0
6187568|NCT01383096|9841554|FG000|Fifth Intervention (8 Days)|Withdrawal by Subject|1
6187569|NCT01383096|9841555|FG001|Fifth Intervention (8 Days)|Withdrawal by Subject|0
6187570|NCT01383096|9841556|FG002|Fifth Intervention (8 Days)|Withdrawal by Subject|0
6187571|NCT01383096|9841554|FG000|Fifth Intervention (8 Days)|haemoglobin was <13.5 g/dL|1
6187572|NCT01383096|9841555|FG001|Fifth Intervention (8 Days)|haemoglobin was <13.5 g/dL|0
6187573|NCT01383096|9841556|FG002|Fifth Intervention (8 Days)|haemoglobin was <13.5 g/dL|0
6187574|NCT01383161|9841595|FG000|Overall Study|Adverse Event|5
6187575|NCT01383161|9841596|FG001|Overall Study|Adverse Event|1
6187576|NCT01383161|9841595|FG000|Overall Study|Withdrawal by Subject|0
6187577|NCT01383161|9841596|FG001|Overall Study|Withdrawal by Subject|2
6187578|NCT01383161|9841595|FG000|Overall Study|Lack of Efficacy|0
6187579|NCT01383161|9841596|FG001|Overall Study|Lack of Efficacy|1
6187580|NCT01383174|9841604|FG000|3 Month Assessment|Death|0
6187581|NCT01383174|9841605|FG001|3 Month Assessment|Death|1
6187582|NCT01383174|9841604|FG000|3 Month Assessment|Lost to Follow-up|2
6187583|NCT01383174|9841605|FG001|3 Month Assessment|Lost to Follow-up|0
6187584|NCT01383174|9841604|FG000|3 Month Assessment|Refused to complete|4
6187585|NCT01383174|9841605|FG001|3 Month Assessment|Refused to complete|0
6187586|NCT01383174|9841604|FG000|6 Month Assessment|Lost to Follow-up|1
6187587|NCT01383174|9841605|FG001|6 Month Assessment|Lost to Follow-up|1
6187588|NCT01383174|9841604|FG000|6 Month Assessment|Refused to complete|4
6187589|NCT01383174|9841605|FG001|6 Month Assessment|Refused to complete|0
6187590|NCT01383317|9841631|FG000|Overall Study|Lost to Follow-up|2
6187591|NCT01383317|9841632|FG001|Overall Study|Lost to Follow-up|1
6187592|NCT01383317|9841631|FG000|Overall Study|Death|1
6187593|NCT01383317|9841632|FG001|Overall Study|Death|0
6187594|NCT01383317|9841631|FG000|Overall Study|Adverse Event|0
6187595|NCT01383317|9841632|FG001|Overall Study|Adverse Event|1
6187596|NCT01383356|9841638|FG000|Period 1|Adverse Event|5
6187597|NCT01383356|9841639|FG001|Period 1|Adverse Event|3
6187598|NCT01383356|9841638|FG000|Period 1|Non-compliance|3
6187599|NCT01383356|9841639|FG001|Period 1|Non-compliance|0
6187600|NCT01383356|9841638|FG000|Period 1|Out of Range Mid-study-Test|0
6187601|NCT01383356|9841639|FG001|Period 1|Out of Range Mid-study-Test|1
6187602|NCT01383356|9841638|FG000|Period 1|Personal|0
6187603|NCT01383356|9841639|FG001|Period 1|Personal|2
6187604|NCT01383486|9841653|FG000|Overall Study|Lost to Follow-up|10
6187605|NCT01383486|9841653|FG000|Overall Study|Incomplete information for analysis|2
6187606|NCT01383486|9841653|FG000|Overall Study|Did not take any product|6
6187607|NCT01383499|9841658|FG000|Period 1 (4 Weeks)|Withdrawal by Subject|1
6187608|NCT01383499|9841659|FG001|Period 1 (4 Weeks)|Withdrawal by Subject|0
6187609|NCT01383499|9841660|FG002|Period 1 (4 Weeks)|Withdrawal by Subject|0
6187610|NCT01383499|9841661|FG003|Period 1 (4 Weeks)|Withdrawal by Subject|0
6187611|NCT01383707|9841687|FG000|Overall Study|Consent withdrawal|6
6187612|NCT01383707|9841687|FG000|Overall Study|Death|19
6187613|NCT01383707|9841687|FG000|Overall Study|Other|8
6187614|NCT01383707|9841687|FG000|Overall Study|Sponsor's decision|2
6187615|NCT01383707|9841687|FG000|Overall Study|Adverse Event|14
6187616|NCT01383707|9841687|FG000|Overall Study|Progressive disease|23
6234745|NCT01790126|9912905|FG000|Overall Study|Lost to Follow-up|1
6187617|NCT01383928|9841707|FG000|Overall Study|Initiation of ASCT|2
6187618|NCT01383928|9841708|FG001|Overall Study|Initiation of ASCT|1
6187619|NCT01383928|9841709|FG002|Overall Study|Initiation of ASCT|18
6187620|NCT01383928|9841707|FG000|Overall Study|Adverse Event|1
6187621|NCT01383928|9841708|FG001|Overall Study|Adverse Event|2
6187622|NCT01383928|9841709|FG002|Overall Study|Adverse Event|8
6187623|NCT01383928|9841707|FG000|Overall Study|Other|1
6234746|NCT01790126|9912906|FG001|Overall Study|Lost to Follow-up|0
6234747|NCT01790126|9912907|FG002|Overall Study|Lost to Follow-up|1
6234748|NCT01790126|9912905|FG000|Overall Study|Adverse Event|0
6234749|NCT01790126|9912906|FG001|Overall Study|Adverse Event|2
6234750|NCT01790126|9912907|FG002|Overall Study|Adverse Event|0
6234751|NCT01790126|9912905|FG000|Overall Study|Death|2
6234752|NCT01790126|9912906|FG001|Overall Study|Death|0
6234753|NCT01790126|9912907|FG002|Overall Study|Death|0
6234754|NCT01790126|9912905|FG000|Overall Study|Radiographic Progression|3
6234755|NCT01790126|9912906|FG001|Overall Study|Radiographic Progression|1
6234756|NCT01790126|9912907|FG002|Overall Study|Radiographic Progression|0
6234757|NCT01790295|9912934|FG000|Overall Study|Adverse Event|1
6234758|NCT01790295|9912934|FG000|Overall Study|Death|4
6234759|NCT01790295|9912934|FG000|Overall Study|Lack of Efficacy|2
6234760|NCT01790295|9912934|FG000|Overall Study|Study closure|4
6234761|NCT01790438|9912941|FG000|Overall Study|Adverse Event|3
6234762|NCT01790438|9912942|FG001|Overall Study|Adverse Event|2
6234763|NCT01790438|9912941|FG000|Overall Study|Death|4
6234764|NCT01790438|9912942|FG001|Overall Study|Death|0
6234765|NCT01790438|9912941|FG000|Overall Study|Lost to Follow-up|5
6234766|NCT01790438|9912942|FG001|Overall Study|Lost to Follow-up|2
6234767|NCT01790438|9912941|FG000|Overall Study|Withdrawal by Subject|13
6234768|NCT01790438|9912942|FG001|Overall Study|Withdrawal by Subject|2
6234769|NCT01790438|9912941|FG000|Overall Study|Physician Decision|3
6234770|NCT01790438|9912942|FG001|Overall Study|Physician Decision|1
6234771|NCT01790438|9912941|FG000|Overall Study|Sponsor Decision|0
6234772|NCT01790438|9912942|FG001|Overall Study|Sponsor Decision|3
6234773|NCT01790438|9912941|FG000|Overall Study|Protocol Required Discontinuation|7
6234774|NCT01790438|9912942|FG001|Overall Study|Protocol Required Discontinuation|1
6234775|NCT01790503|9912977|FG000|Overall Study|Adverse Event|1
6234776|NCT01790503|9912978|FG001|Overall Study|Adverse Event|0
6234777|NCT01790503|9912979|FG002|Overall Study|Adverse Event|0
6234778|NCT01790503|9912980|FG003|Overall Study|Adverse Event|0
6234779|NCT01790503|9912981|FG004|Overall Study|Adverse Event|0
6234780|NCT01790503|9912982|FG005|Overall Study|Adverse Event|2
6234781|NCT01790503|9912983|FG006|Overall Study|Adverse Event|0
6234782|NCT01790503|9912984|FG007|Overall Study|Adverse Event|0
6234783|NCT01790503|9912985|FG008|Overall Study|Adverse Event|2
6234784|NCT01790503|9912986|FG009|Overall Study|Adverse Event|4
6234785|NCT01790503|9912987|FG010|Overall Study|Adverse Event|7
6234786|NCT01790503|9912977|FG000|Overall Study|Withdrawal by Subject|0
6234787|NCT01790503|9912978|FG001|Overall Study|Withdrawal by Subject|0
6234788|NCT01790503|9912979|FG002|Overall Study|Withdrawal by Subject|1
6234789|NCT01790503|9912980|FG003|Overall Study|Withdrawal by Subject|1
6234790|NCT01790503|9912981|FG004|Overall Study|Withdrawal by Subject|1
6234791|NCT01790503|9912982|FG005|Overall Study|Withdrawal by Subject|2
6234792|NCT01790503|9912983|FG006|Overall Study|Withdrawal by Subject|1
6234793|NCT01790503|9912984|FG007|Overall Study|Withdrawal by Subject|0
6234794|NCT01790503|9912985|FG008|Overall Study|Withdrawal by Subject|0
6234795|NCT01790503|9912986|FG009|Overall Study|Withdrawal by Subject|0
6234796|NCT01790503|9912987|FG010|Overall Study|Withdrawal by Subject|1
6234797|NCT01790503|9912977|FG000|Overall Study|Disease progression|2
6234798|NCT01790503|9912978|FG001|Overall Study|Disease progression|1
6234799|NCT01790503|9912979|FG002|Overall Study|Disease progression|0
6234800|NCT01790503|9912980|FG003|Overall Study|Disease progression|1
6234801|NCT01790503|9912981|FG004|Overall Study|Disease progression|2
6234802|NCT01790503|9912982|FG005|Overall Study|Disease progression|1
6234803|NCT01790503|9912983|FG006|Overall Study|Disease progression|0
6234804|NCT01790503|9912984|FG007|Overall Study|Disease progression|1
6234805|NCT01790503|9912985|FG008|Overall Study|Disease progression|0
6234806|NCT01790503|9912986|FG009|Overall Study|Disease progression|17
6234807|NCT01790503|9912987|FG010|Overall Study|Disease progression|7
6234808|NCT01790503|9912977|FG000|Overall Study|Protocol Violation|0
6234809|NCT01790503|9912978|FG001|Overall Study|Protocol Violation|0
6234810|NCT01790503|9912979|FG002|Overall Study|Protocol Violation|0
6234811|NCT01790503|9912980|FG003|Overall Study|Protocol Violation|0
6234812|NCT01790503|9912981|FG004|Overall Study|Protocol Violation|0
6234813|NCT01790503|9912982|FG005|Overall Study|Protocol Violation|0
6234814|NCT01790503|9912983|FG006|Overall Study|Protocol Violation|0
6234815|NCT01790503|9912984|FG007|Overall Study|Protocol Violation|0
6234816|NCT01790503|9912985|FG008|Overall Study|Protocol Violation|0
6234817|NCT01790503|9912986|FG009|Overall Study|Protocol Violation|1
6234818|NCT01790503|9912987|FG010|Overall Study|Protocol Violation|0
6234819|NCT01790503|9912977|FG000|Overall Study|Physician Decision|0
6234820|NCT01790503|9912978|FG001|Overall Study|Physician Decision|0
6234821|NCT01790503|9912979|FG002|Overall Study|Physician Decision|0
6234822|NCT01790503|9912980|FG003|Overall Study|Physician Decision|0
6234823|NCT01790503|9912981|FG004|Overall Study|Physician Decision|0
6234824|NCT01790503|9912982|FG005|Overall Study|Physician Decision|0
6234825|NCT01790503|9912983|FG006|Overall Study|Physician Decision|0
6234826|NCT01790503|9912984|FG007|Overall Study|Physician Decision|0
6234827|NCT01790503|9912985|FG008|Overall Study|Physician Decision|0
6234828|NCT01790503|9912986|FG009|Overall Study|Physician Decision|1
6234829|NCT01790503|9912987|FG010|Overall Study|Physician Decision|1
6234830|NCT01790503|9912977|FG000|Overall Study|Death|0
6234831|NCT01790503|9912978|FG001|Overall Study|Death|0
6234832|NCT01790503|9912979|FG002|Overall Study|Death|0
6234833|NCT01790503|9912980|FG003|Overall Study|Death|0
6234834|NCT01790503|9912981|FG004|Overall Study|Death|0
6234835|NCT01790503|9912982|FG005|Overall Study|Death|0
6234836|NCT01790503|9912983|FG006|Overall Study|Death|0
6234837|NCT01790503|9912984|FG007|Overall Study|Death|0
6234838|NCT01790503|9912985|FG008|Overall Study|Death|0
6234839|NCT01790503|9912986|FG009|Overall Study|Death|1
6234840|NCT01790503|9912987|FG010|Overall Study|Death|0
6234841|NCT01790503|9912977|FG000|Overall Study|Non Compliance|0
6234842|NCT01790503|9912978|FG001|Overall Study|Non Compliance|0
6234843|NCT01790503|9912979|FG002|Overall Study|Non Compliance|0
6234844|NCT01790503|9912980|FG003|Overall Study|Non Compliance|0
6234845|NCT01790503|9912981|FG004|Overall Study|Non Compliance|1
6234846|NCT01790503|9912982|FG005|Overall Study|Non Compliance|0
6234847|NCT01790503|9912983|FG006|Overall Study|Non Compliance|0
6234848|NCT01790503|9912984|FG007|Overall Study|Non Compliance|0
6234849|NCT01790503|9912985|FG008|Overall Study|Non Compliance|0
6234850|NCT01790503|9912986|FG009|Overall Study|Non Compliance|0
6234851|NCT01790503|9912987|FG010|Overall Study|Non Compliance|0
6234852|NCT01790503|9912977|FG000|Overall Study|Other|0
6234853|NCT01790503|9912978|FG001|Overall Study|Other|0
6234854|NCT01790503|9912979|FG002|Overall Study|Other|0
6234855|NCT01790503|9912980|FG003|Overall Study|Other|0
6234856|NCT01790503|9912981|FG004|Overall Study|Other|1
6234857|NCT01790503|9912982|FG005|Overall Study|Other|0
6234858|NCT01790503|9912983|FG006|Overall Study|Other|0
6234859|NCT01790503|9912984|FG007|Overall Study|Other|0
6234860|NCT01790503|9912985|FG008|Overall Study|Other|1
6234861|NCT01790503|9912986|FG009|Overall Study|Other|2
6234862|NCT01790503|9912987|FG010|Overall Study|Other|0
6234863|NCT01790516|9913026|FG000|Overall Study|Physician Decision|1
6234864|NCT01790516|9913027|FG001|Overall Study|Physician Decision|0
6234865|NCT01790568|9913033|FG000|Overall Study|Progression prior to transplant|0
6234866|NCT01790568|9913034|FG001|Overall Study|Progression prior to transplant|1
6234867|NCT01790594|9913049|FG000|Overall Study|Death|1
6234868|NCT01790594|9913050|FG001|Overall Study|Death|0
6234869|NCT01790594|9913051|FG002|Overall Study|Death|0
6234870|NCT01790594|9913049|FG000|Overall Study|Physician Decision|2
6234871|NCT01790594|9913050|FG001|Overall Study|Physician Decision|1
6234872|NCT01790594|9913051|FG002|Overall Study|Physician Decision|0
6234873|NCT01790594|9913049|FG000|Overall Study|Withdrawal by Subject|2
6234874|NCT01790594|9913050|FG001|Overall Study|Withdrawal by Subject|0
6234875|NCT01790594|9913051|FG002|Overall Study|Withdrawal by Subject|0
6234876|NCT01790594|9913049|FG000|Overall Study|Transplant was not done|0
6234877|NCT01790594|9913050|FG001|Overall Study|Transplant was not done|0
6234878|NCT01790594|9913051|FG002|Overall Study|Transplant was not done|3
6234879|NCT01790594|9913049|FG000|Overall Study|Terminated prior to week 76|0
6234880|NCT01790594|9913050|FG001|Overall Study|Terminated prior to week 76|2
6234881|NCT01790594|9913051|FG002|Overall Study|Terminated prior to week 76|0
6234882|NCT01790633|9913060|FG000|Overall Study|Protocol Violation|1
6234883|NCT01790633|9913061|FG001|Overall Study|Protocol Violation|2
6234884|NCT01790633|9913060|FG000|Overall Study|Did not have serology performed|47
6234885|NCT01790633|9913061|FG001|Overall Study|Did not have serology performed|0
6234886|NCT01790633|9913060|FG000|Overall Study|RT failure and no follow-up ELISA|0
6234887|NCT01790633|9913061|FG001|Overall Study|RT failure and no follow-up ELISA|3
6234888|NCT01790828|9913091|FG000|Overall Study|Other|34
6234889|NCT01790932|9913095|FG000|Overall Study|Disease Progression|41
6234890|NCT01790932|9913095|FG000|Overall Study|Adverse Event|7
6234891|NCT01790932|9913095|FG000|Overall Study|Physician Decision|1
6234892|NCT01790932|9913095|FG000|Overall Study|Withdrawal by Subject|1
6234893|NCT01790984|9913101|FG000|First Dietary Intervention (12 Weeks)|Withdrawal by Subject|1
6234894|NCT01790984|9913102|FG001|First Dietary Intervention (12 Weeks)|Withdrawal by Subject|1
6234895|NCT01790984|9913103|FG002|First Dietary Intervention (12 Weeks)|Withdrawal by Subject|0
6234896|NCT01790984|9913104|FG003|First Dietary Intervention (12 Weeks)|Withdrawal by Subject|0
6234897|NCT01791127|9913127|FG000|Overall Study|Death|356
6234898|NCT01791127|9913127|FG000|Overall Study|Patient has withdrawn from study|293
6234899|NCT01791127|9913127|FG000|Overall Study|Lost to Follow-up|42
6234900|NCT01791127|9913127|FG000|Overall Study|All Siello leads are explanted|31
6234901|NCT01791127|9913127|FG000|Overall Study|Completion of 30 day safety registry|1
6234902|NCT01791127|9913127|FG000|Overall Study|Study terminated for EP Passion|749
6234903|NCT01791153|9913148|FG000|Part 1: Blinded Period|Adverse Event|7
6234904|NCT01791153|9913149|FG001|Part 1: Blinded Period|Adverse Event|3
6234905|NCT01791153|9913150|FG002|Part 1: Blinded Period|Adverse Event|2
6234906|NCT01791153|9913151|FG003|Part 1: Blinded Period|Adverse Event|0
6234907|NCT01791153|9913152|FG004|Part 1: Blinded Period|Adverse Event|0
6234908|NCT01791153|9913153|FG005|Part 1: Blinded Period|Adverse Event|0
6234909|NCT01791153|9913154|FG006|Part 1: Blinded Period|Adverse Event|0
6234910|NCT01791153|9913155|FG007|Part 1: Blinded Period|Adverse Event|0
6234911|NCT01791153|9913148|FG000|Part 1: Blinded Period|Lack of Efficacy|1
6234912|NCT01791153|9913149|FG001|Part 1: Blinded Period|Lack of Efficacy|3
6234913|NCT01791153|9913150|FG002|Part 1: Blinded Period|Lack of Efficacy|2
6234914|NCT01791153|9913151|FG003|Part 1: Blinded Period|Lack of Efficacy|2
6234915|NCT01791153|9913152|FG004|Part 1: Blinded Period|Lack of Efficacy|0
6234916|NCT01791153|9913153|FG005|Part 1: Blinded Period|Lack of Efficacy|0
6234917|NCT01791153|9913154|FG006|Part 1: Blinded Period|Lack of Efficacy|0
6234918|NCT01791153|9913155|FG007|Part 1: Blinded Period|Lack of Efficacy|0
6234919|NCT01791153|9913148|FG000|Part 1: Blinded Period|Non-Compliance|1
6234920|NCT01791153|9913149|FG001|Part 1: Blinded Period|Non-Compliance|0
6234921|NCT01791153|9913150|FG002|Part 1: Blinded Period|Non-Compliance|0
6234922|NCT01791153|9913151|FG003|Part 1: Blinded Period|Non-Compliance|0
6234923|NCT01791153|9913152|FG004|Part 1: Blinded Period|Non-Compliance|0
6234924|NCT01791153|9913153|FG005|Part 1: Blinded Period|Non-Compliance|0
6234925|NCT01791153|9913154|FG006|Part 1: Blinded Period|Non-Compliance|0
6234926|NCT01791153|9913155|FG007|Part 1: Blinded Period|Non-Compliance|0
6234927|NCT01791153|9913148|FG000|Part 1: Blinded Period|Physician Decision|0
6234928|NCT01791153|9913149|FG001|Part 1: Blinded Period|Physician Decision|0
6234929|NCT01791153|9913150|FG002|Part 1: Blinded Period|Physician Decision|0
6234930|NCT01791153|9913151|FG003|Part 1: Blinded Period|Physician Decision|1
6234931|NCT01791153|9913152|FG004|Part 1: Blinded Period|Physician Decision|0
6234932|NCT01791153|9913153|FG005|Part 1: Blinded Period|Physician Decision|0
6234933|NCT01791153|9913154|FG006|Part 1: Blinded Period|Physician Decision|0
6234934|NCT01791153|9913155|FG007|Part 1: Blinded Period|Physician Decision|0
6234935|NCT01791153|9913148|FG000|Part 1: Blinded Period|Protocol Violation|0
6234936|NCT01791153|9913149|FG001|Part 1: Blinded Period|Protocol Violation|0
6234937|NCT01791153|9913150|FG002|Part 1: Blinded Period|Protocol Violation|0
6234938|NCT01791153|9913151|FG003|Part 1: Blinded Period|Protocol Violation|1
6234939|NCT01791153|9913152|FG004|Part 1: Blinded Period|Protocol Violation|0
6234940|NCT01791153|9913153|FG005|Part 1: Blinded Period|Protocol Violation|0
6234941|NCT01791153|9913154|FG006|Part 1: Blinded Period|Protocol Violation|0
6234942|NCT01791153|9913155|FG007|Part 1: Blinded Period|Protocol Violation|0
6234943|NCT01791153|9913148|FG000|Part 1: Blinded Period|Withdrawal by Subject|6
6234944|NCT01791153|9913149|FG001|Part 1: Blinded Period|Withdrawal by Subject|2
6234945|NCT01791153|9913150|FG002|Part 1: Blinded Period|Withdrawal by Subject|2
6234946|NCT01791153|9913151|FG003|Part 1: Blinded Period|Withdrawal by Subject|1
6234947|NCT01791153|9913152|FG004|Part 1: Blinded Period|Withdrawal by Subject|0
6234948|NCT01791153|9913153|FG005|Part 1: Blinded Period|Withdrawal by Subject|0
6234949|NCT01791153|9913154|FG006|Part 1: Blinded Period|Withdrawal by Subject|0
6234950|NCT01791153|9913155|FG007|Part 1: Blinded Period|Withdrawal by Subject|0
6234951|NCT01791153|9913148|FG000|Part 2: Open-label Period|Adverse Event|0
6234952|NCT01791153|9913149|FG001|Part 2: Open-label Period|Adverse Event|0
6234953|NCT01791153|9913150|FG002|Part 2: Open-label Period|Adverse Event|0
6234954|NCT01791153|9913151|FG003|Part 2: Open-label Period|Adverse Event|0
6234955|NCT01791153|9913152|FG004|Part 2: Open-label Period|Adverse Event|0
6234956|NCT01791153|9913153|FG005|Part 2: Open-label Period|Adverse Event|1
6234957|NCT01791153|9913154|FG006|Part 2: Open-label Period|Adverse Event|1
6234958|NCT01791153|9913155|FG007|Part 2: Open-label Period|Adverse Event|2
6234959|NCT01791153|9913148|FG000|Part 2: Open-label Period|Death|0
6234960|NCT01791153|9913149|FG001|Part 2: Open-label Period|Death|0
6234961|NCT01791153|9913150|FG002|Part 2: Open-label Period|Death|0
6234962|NCT01791153|9913151|FG003|Part 2: Open-label Period|Death|0
6234963|NCT01791153|9913152|FG004|Part 2: Open-label Period|Death|0
6234964|NCT01791153|9913153|FG005|Part 2: Open-label Period|Death|1
6234965|NCT01791153|9913154|FG006|Part 2: Open-label Period|Death|1
6234966|NCT01791153|9913155|FG007|Part 2: Open-label Period|Death|1
6234967|NCT01791153|9913148|FG000|Part 2: Open-label Period|Lost to Follow-up|0
6187624|NCT01383928|9841708|FG001|Overall Study|Other|3
6187625|NCT01383928|9841709|FG002|Overall Study|Other|4
6187626|NCT01383928|9841707|FG000|Overall Study|Progressive Disease|1
6187627|NCT01383928|9841708|FG001|Overall Study|Progressive Disease|1
6187628|NCT01383928|9841709|FG002|Overall Study|Progressive Disease|5
6187629|NCT01383928|9841707|FG000|Overall Study|Withdrawal by Subject|0
6187630|NCT01383928|9841708|FG001|Overall Study|Withdrawal by Subject|0
6187631|NCT01383928|9841709|FG002|Overall Study|Withdrawal by Subject|4
6187632|NCT01383928|9841707|FG000|Overall Study|Unsatisfactory Therapeutic Response|0
6187633|NCT01383928|9841708|FG001|Overall Study|Unsatisfactory Therapeutic Response|0
6187634|NCT01383928|9841709|FG002|Overall Study|Unsatisfactory Therapeutic Response|1
6187635|NCT01383954|9841719|FG000|Overall Study|Lack of Efficacy|2
6187636|NCT01383954|9841719|FG000|Overall Study|Electronic Diary Too Cumbersome to Use|2
6187637|NCT01383954|9841719|FG000|Overall Study|Adverse Event|1
6187638|NCT01383954|9841719|FG000|Overall Study|Reason Not Specified|9
6187639|NCT01383993|9841726|FG000|Overall Study|Adverse Event|1
6187640|NCT01383993|9841727|FG001|Overall Study|Adverse Event|1
6187641|NCT01383993|9841728|FG002|Overall Study|Adverse Event|0
6187642|NCT01383993|9841726|FG000|Overall Study|Withdrawal by Subject|0
6187643|NCT01383993|9841727|FG001|Overall Study|Withdrawal by Subject|0
6187644|NCT01383993|9841728|FG002|Overall Study|Withdrawal by Subject|1
6234968|NCT01791153|9913149|FG001|Part 2: Open-label Period|Lost to Follow-up|0
6234969|NCT01791153|9913150|FG002|Part 2: Open-label Period|Lost to Follow-up|0
6234970|NCT01791153|9913151|FG003|Part 2: Open-label Period|Lost to Follow-up|0
6234971|NCT01791153|9913152|FG004|Part 2: Open-label Period|Lost to Follow-up|0
6234972|NCT01791153|9913153|FG005|Part 2: Open-label Period|Lost to Follow-up|0
6234973|NCT01791153|9913154|FG006|Part 2: Open-label Period|Lost to Follow-up|1
6234974|NCT01791153|9913155|FG007|Part 2: Open-label Period|Lost to Follow-up|0
6234975|NCT01791153|9913148|FG000|Part 2: Open-label Period|Lack of Efficacy|0
6187645|NCT01383993|9841726|FG000|Overall Study|Marketed voriconazole in post-therapy|2
6187646|NCT01383993|9841727|FG001|Overall Study|Marketed voriconazole in post-therapy|0
6234976|NCT01791153|9913149|FG001|Part 2: Open-label Period|Lack of Efficacy|0
6234977|NCT01791153|9913150|FG002|Part 2: Open-label Period|Lack of Efficacy|0
6234978|NCT01791153|9913151|FG003|Part 2: Open-label Period|Lack of Efficacy|0
6234979|NCT01791153|9913152|FG004|Part 2: Open-label Period|Lack of Efficacy|0
6234980|NCT01791153|9913153|FG005|Part 2: Open-label Period|Lack of Efficacy|0
6234981|NCT01791153|9913154|FG006|Part 2: Open-label Period|Lack of Efficacy|0
6234982|NCT01791153|9913155|FG007|Part 2: Open-label Period|Lack of Efficacy|1
6234983|NCT01791153|9913148|FG000|Part 2: Open-label Period|Withdrawal by Subject|0
6234984|NCT01791153|9913149|FG001|Part 2: Open-label Period|Withdrawal by Subject|0
6234985|NCT01791153|9913150|FG002|Part 2: Open-label Period|Withdrawal by Subject|0
6234986|NCT01791153|9913151|FG003|Part 2: Open-label Period|Withdrawal by Subject|0
6234987|NCT01791153|9913152|FG004|Part 2: Open-label Period|Withdrawal by Subject|1
6234988|NCT01791153|9913153|FG005|Part 2: Open-label Period|Withdrawal by Subject|1
6234989|NCT01791153|9913154|FG006|Part 2: Open-label Period|Withdrawal by Subject|3
6234990|NCT01791153|9913155|FG007|Part 2: Open-label Period|Withdrawal by Subject|2
6234991|NCT01791153|9913148|FG000|Part 2: Open-label Period|Physician Decision|0
6234992|NCT01791153|9913149|FG001|Part 2: Open-label Period|Physician Decision|0
6234993|NCT01791153|9913150|FG002|Part 2: Open-label Period|Physician Decision|0
6234994|NCT01791153|9913151|FG003|Part 2: Open-label Period|Physician Decision|0
6234995|NCT01791153|9913152|FG004|Part 2: Open-label Period|Physician Decision|1
6234996|NCT01791153|9913153|FG005|Part 2: Open-label Period|Physician Decision|1
6234997|NCT01791153|9913154|FG006|Part 2: Open-label Period|Physician Decision|0
6234998|NCT01791153|9913155|FG007|Part 2: Open-label Period|Physician Decision|0
6234999|NCT01791205|9913172|FG000|Phase II|Lack of Efficacy|6
6235000|NCT01791205|9913173|FG001|Phase II|Lack of Efficacy|0
6235001|NCT01791205|9913172|FG000|Phase II|Adverse Event|2
6235002|NCT01791205|9913173|FG001|Phase II|Adverse Event|0
6235003|NCT01791205|9913172|FG000|Phase II|Safety|1
6235004|NCT01791205|9913173|FG001|Phase II|Safety|0
6235005|NCT01791205|9913172|FG000|Phase II|Lost to Follow-up|1
6235006|NCT01791205|9913173|FG001|Phase II|Lost to Follow-up|0
6235007|NCT01791205|9913172|FG000|Phase II|Remission of disease|1
6235008|NCT01791205|9913173|FG001|Phase II|Remission of disease|0
6235009|NCT01791205|9913172|FG000|Phase II|Physician's decision|1
6235010|NCT01791205|9913173|FG001|Phase II|Physician's decision|0
6235011|NCT01791244|9913181|FG000|Overall Study|Adverse Event|5
6235012|NCT01791244|9913182|FG001|Overall Study|Adverse Event|7
6235013|NCT01791244|9913181|FG000|Overall Study|Insufficient clinical response|10
6235014|NCT01791244|9913182|FG001|Overall Study|Insufficient clinical response|10
6235015|NCT01791244|9913181|FG000|Overall Study|Laboratory Abnormality|0
6235016|NCT01791244|9913182|FG001|Overall Study|Laboratory Abnormality|1
6235017|NCT01791413|9913192|FG000|Overall Study|Lost to Follow-up|5
6235018|NCT01791413|9913193|FG001|Overall Study|Lost to Follow-up|1
6269961|NCT02146430|9970560|FG000|Overall Study|Reason missing or not reported|2
6269962|NCT02146430|9970561|FG001|Overall Study|Reason missing or not reported|3
6269963|NCT02146430|9970562|FG002|Overall Study|Reason missing or not reported|4
6269964|NCT02146430|9970563|FG003|Overall Study|Reason missing or not reported|5
6269965|NCT02146430|9970560|FG000|Overall Study|Withdrawal by Subject|27
6269966|NCT02146430|9970561|FG001|Overall Study|Withdrawal by Subject|29
6269967|NCT02146430|9970562|FG002|Overall Study|Withdrawal by Subject|30
6269968|NCT02146430|9970563|FG003|Overall Study|Withdrawal by Subject|34
6269969|NCT02146599|9970586|FG000|Overall Study|Failed to meet inclusion criteria|5
6269970|NCT02146833|9970590|FG000|Overall Study|Death|10
6269971|NCT02146833|9970590|FG000|Overall Study|No longer consented to study treatment|1
6269972|NCT02147067|9970596|FG000|Overall Study|Withdrawal by Subject|2
6269973|NCT02147067|9970597|FG001|Overall Study|Withdrawal by Subject|2
6269974|NCT02147093|9970605|FG000|Period 1|Lost to Follow-up|0
6269975|NCT02147093|9970606|FG001|Period 1|Lost to Follow-up|1
6269976|NCT02147093|9970605|FG000|Period 2|Protocol Violation|2
6269977|NCT02147093|9970606|FG001|Period 2|Protocol Violation|0
6269978|NCT02147132|9970612|FG000|Overall Study|Lost to Follow-up|1
6269979|NCT02147132|9970613|FG001|Overall Study|Lost to Follow-up|0
6269980|NCT02147132|9970614|FG002|Overall Study|Lost to Follow-up|0
6269981|NCT02147132|9970615|FG003|Overall Study|Lost to Follow-up|0
6269982|NCT02147158|9970631|FG000|Treatment Course 1|Adverse Event|1
6269983|NCT02147158|9970632|FG001|Treatment Course 1|Adverse Event|4
6269984|NCT02147158|9970633|FG002|Treatment Course 1|Adverse Event|3
6269985|NCT02147158|9970634|FG003|Treatment Course 1|Adverse Event|4
6269986|NCT02147158|9970635|FG004|Treatment Course 1|Adverse Event|1
6269987|NCT02147158|9970636|FG005|Treatment Course 1|Adverse Event|2
6269988|NCT02147158|9970631|FG000|Treatment Course 1|Lost to Follow-up|2
6269989|NCT02147158|9970632|FG001|Treatment Course 1|Lost to Follow-up|4
6269990|NCT02147158|9970633|FG002|Treatment Course 1|Lost to Follow-up|3
6269991|NCT02147158|9970634|FG003|Treatment Course 1|Lost to Follow-up|3
6269992|NCT02147158|9970635|FG004|Treatment Course 1|Lost to Follow-up|2
6269993|NCT02147158|9970636|FG005|Treatment Course 1|Lost to Follow-up|4
6269994|NCT02147158|9970631|FG000|Treatment Course 1|Protocol Violation|0
6269995|NCT02147158|9970632|FG001|Treatment Course 1|Protocol Violation|0
6269996|NCT02147158|9970633|FG002|Treatment Course 1|Protocol Violation|1
6269997|NCT02147158|9970634|FG003|Treatment Course 1|Protocol Violation|1
6269998|NCT02147158|9970635|FG004|Treatment Course 1|Protocol Violation|0
6269999|NCT02147158|9970636|FG005|Treatment Course 1|Protocol Violation|0
6235019|NCT01791517|9913212|FG000|Phase I: Period 1|Withdrawal by Subject|0
6235020|NCT01791517|9913213|FG001|Phase I: Period 1|Withdrawal by Subject|1
6235021|NCT01791517|9913214|FG002|Phase I: Period 1|Withdrawal by Subject|1
6235022|NCT01791517|9913215|FG003|Phase I: Period 1|Withdrawal by Subject|0
6235023|NCT01791517|9913216|FG004|Phase I: Period 1|Withdrawal by Subject|1
6235024|NCT01791517|9913217|FG005|Phase I: Period 1|Withdrawal by Subject|1
6235025|NCT01791517|9913218|FG006|Phase I: Period 1|Withdrawal by Subject|0
6235026|NCT01791517|9913219|FG007|Phase I: Period 1|Withdrawal by Subject|0
6235027|NCT01791517|9913220|FG008|Phase I: Period 1|Withdrawal by Subject|0
6235028|NCT01791517|9913221|FG009|Phase I: Period 1|Withdrawal by Subject|0
6235029|NCT01791517|9913222|FG010|Phase I: Period 1|Withdrawal by Subject|0
6235030|NCT01791517|9913223|FG011|Phase I: Period 1|Withdrawal by Subject|0
6235031|NCT01791517|9913212|FG000|Phase I: Period 1|Adverse Event|0
6187647|NCT01383993|9841728|FG002|Overall Study|Marketed voriconazole in post-therapy|0
6187648|NCT01384019|9841739|FG000|Overall Study|Withdrawal by Subject|3
6187649|NCT01384019|9841740|FG001|Overall Study|Withdrawal by Subject|0
6187650|NCT01384019|9841739|FG000|Overall Study|Death|1
6187651|NCT01384019|9841740|FG001|Overall Study|Death|0
6187652|NCT01384019|9841739|FG000|Overall Study|MRI refusal|6
6187653|NCT01384019|9841740|FG001|Overall Study|MRI refusal|6
6187654|NCT01384292|9841749|FG000|Part B|Severe non-compliance to protocol|1
6187655|NCT01384292|9841750|FG001|Part B|Severe non-compliance to protocol|0
6187656|NCT01384292|9841751|FG002|Part B|Severe non-compliance to protocol|0
6187657|NCT01384734|9841788|FG000|Overall Study|Adverse Event|0
6187658|NCT01384734|9841789|FG001|Overall Study|Adverse Event|3
6187659|NCT01384734|9841790|FG002|Overall Study|Adverse Event|0
6187660|NCT01384734|9841791|FG003|Overall Study|Adverse Event|2
6187661|NCT01384734|9841792|FG004|Overall Study|Adverse Event|7
6187662|NCT01384734|9841788|FG000|Overall Study|Death|1
6187663|NCT01384734|9841789|FG001|Overall Study|Death|0
6187664|NCT01384734|9841790|FG002|Overall Study|Death|1
6187665|NCT01384734|9841791|FG003|Overall Study|Death|0
6187666|NCT01384734|9841792|FG004|Overall Study|Death|0
6187667|NCT01384734|9841788|FG000|Overall Study|Continuation criteria not met|0
6187668|NCT01384734|9841789|FG001|Overall Study|Continuation criteria not met|0
6187669|NCT01384734|9841790|FG002|Overall Study|Continuation criteria not met|1
6187670|NCT01384734|9841791|FG003|Overall Study|Continuation criteria not met|1
6187671|NCT01384734|9841792|FG004|Overall Study|Continuation criteria not met|0
6187672|NCT01384734|9841788|FG000|Overall Study|Lack of Efficacy|3
6187673|NCT01384734|9841789|FG001|Overall Study|Lack of Efficacy|7
6187674|NCT01384734|9841790|FG002|Overall Study|Lack of Efficacy|4
6187675|NCT01384734|9841791|FG003|Overall Study|Lack of Efficacy|4
6187676|NCT01384734|9841792|FG004|Overall Study|Lack of Efficacy|2
6187677|NCT01384734|9841788|FG000|Overall Study|Lost to Follow-up|5
6187678|NCT01384734|9841789|FG001|Overall Study|Lost to Follow-up|3
6187679|NCT01384734|9841790|FG002|Overall Study|Lost to Follow-up|3
6187680|NCT01384734|9841791|FG003|Overall Study|Lost to Follow-up|8
6187681|NCT01384734|9841792|FG004|Overall Study|Lost to Follow-up|5
6187682|NCT01384734|9841788|FG000|Overall Study|Non-compliance with study drug|1
6187683|NCT01384734|9841789|FG001|Overall Study|Non-compliance with study drug|2
6187684|NCT01384734|9841790|FG002|Overall Study|Non-compliance with study drug|6
6187685|NCT01384734|9841791|FG003|Overall Study|Non-compliance with study drug|0
6187686|NCT01384734|9841792|FG004|Overall Study|Non-compliance with study drug|2
6187687|NCT01384734|9841788|FG000|Overall Study|Pregnancy|0
6187688|NCT01384734|9841789|FG001|Overall Study|Pregnancy|1
6187689|NCT01384734|9841790|FG002|Overall Study|Pregnancy|0
6187690|NCT01384734|9841791|FG003|Overall Study|Pregnancy|0
6187691|NCT01384734|9841792|FG004|Overall Study|Pregnancy|1
6187692|NCT01384734|9841788|FG000|Overall Study|Sponsor terminated|0
6187693|NCT01384734|9841789|FG001|Overall Study|Sponsor terminated|0
6187694|NCT01384734|9841790|FG002|Overall Study|Sponsor terminated|0
6187695|NCT01384734|9841791|FG003|Overall Study|Sponsor terminated|0
6187696|NCT01384734|9841792|FG004|Overall Study|Sponsor terminated|1
6187697|NCT01384734|9841788|FG000|Overall Study|Withdrawal by Subject|5
6187698|NCT01384734|9841789|FG001|Overall Study|Withdrawal by Subject|5
6187699|NCT01384734|9841790|FG002|Overall Study|Withdrawal by Subject|6
6187700|NCT01384734|9841791|FG003|Overall Study|Withdrawal by Subject|7
6187701|NCT01384734|9841792|FG004|Overall Study|Withdrawal by Subject|9
6187702|NCT01384734|9841788|FG000|Overall Study|Investigator relocating|0
6187703|NCT01384734|9841789|FG001|Overall Study|Investigator relocating|2
6187704|NCT01384734|9841790|FG002|Overall Study|Investigator relocating|0
6187705|NCT01384734|9841791|FG003|Overall Study|Investigator relocating|3
6187706|NCT01384734|9841792|FG004|Overall Study|Investigator relocating|1
6187707|NCT01384734|9841788|FG000|Overall Study|Unable to come back for visit|1
6187708|NCT01384734|9841789|FG001|Overall Study|Unable to come back for visit|0
6187709|NCT01384734|9841790|FG002|Overall Study|Unable to come back for visit|1
6187710|NCT01384734|9841791|FG003|Overall Study|Unable to come back for visit|1
6187711|NCT01384734|9841792|FG004|Overall Study|Unable to come back for visit|0
6187712|NCT01384734|9841788|FG000|Overall Study|Prison|0
6187713|NCT01384734|9841789|FG001|Overall Study|Prison|0
6187714|NCT01384734|9841790|FG002|Overall Study|Prison|1
6235032|NCT01791517|9913213|FG001|Phase I: Period 1|Adverse Event|0
6235033|NCT01791517|9913214|FG002|Phase I: Period 1|Adverse Event|1
6235034|NCT01791517|9913215|FG003|Phase I: Period 1|Adverse Event|1
6235035|NCT01791517|9913216|FG004|Phase I: Period 1|Adverse Event|0
6235036|NCT01791517|9913217|FG005|Phase I: Period 1|Adverse Event|0
6235037|NCT01791517|9913218|FG006|Phase I: Period 1|Adverse Event|0
6235038|NCT01791517|9913219|FG007|Phase I: Period 1|Adverse Event|0
6235039|NCT01791517|9913220|FG008|Phase I: Period 1|Adverse Event|0
6235040|NCT01791517|9913221|FG009|Phase I: Period 1|Adverse Event|0
6085736|NCT00654901|9695136|FG000|Overall Study|Lost to Follow-up|1
6235041|NCT01791517|9913222|FG010|Phase I: Period 1|Adverse Event|0
6235042|NCT01791517|9913223|FG011|Phase I: Period 1|Adverse Event|0
6235043|NCT01791517|9913212|FG000|Phase I: Period 1|Unsatisfactory Lens Fitting|1
6235044|NCT01791517|9913213|FG001|Phase I: Period 1|Unsatisfactory Lens Fitting|0
6235045|NCT01791517|9913214|FG002|Phase I: Period 1|Unsatisfactory Lens Fitting|0
6235046|NCT01791517|9913215|FG003|Phase I: Period 1|Unsatisfactory Lens Fitting|0
6235047|NCT01791517|9913216|FG004|Phase I: Period 1|Unsatisfactory Lens Fitting|0
6235048|NCT01791517|9913217|FG005|Phase I: Period 1|Unsatisfactory Lens Fitting|0
6235049|NCT01791517|9913218|FG006|Phase I: Period 1|Unsatisfactory Lens Fitting|0
6235050|NCT01791517|9913219|FG007|Phase I: Period 1|Unsatisfactory Lens Fitting|0
6235051|NCT01791517|9913220|FG008|Phase I: Period 1|Unsatisfactory Lens Fitting|0
6235052|NCT01791517|9913221|FG009|Phase I: Period 1|Unsatisfactory Lens Fitting|0
6235053|NCT01791517|9913222|FG010|Phase I: Period 1|Unsatisfactory Lens Fitting|0
6187715|NCT01384734|9841791|FG003|Overall Study|Prison|0
6187716|NCT01384734|9841792|FG004|Overall Study|Prison|0
6187717|NCT01384734|9841788|FG000|Overall Study|As per Exclusion criteria|0
6187718|NCT01384734|9841789|FG001|Overall Study|As per Exclusion criteria|1
6187719|NCT01384734|9841790|FG002|Overall Study|As per Exclusion criteria|0
6187720|NCT01384734|9841791|FG003|Overall Study|As per Exclusion criteria|0
6187721|NCT01384734|9841792|FG004|Overall Study|As per Exclusion criteria|0
6187722|NCT01384734|9841788|FG000|Overall Study|Missed End of treatment visit|0
6187723|NCT01384734|9841789|FG001|Overall Study|Missed End of treatment visit|0
6187724|NCT01384734|9841790|FG002|Overall Study|Missed End of treatment visit|0
6187725|NCT01384734|9841791|FG003|Overall Study|Missed End of treatment visit|1
6187726|NCT01384734|9841792|FG004|Overall Study|Missed End of treatment visit|0
6187727|NCT01384734|9841788|FG000|Overall Study|Adhesion problem|0
6187728|NCT01384734|9841789|FG001|Overall Study|Adhesion problem|0
6187729|NCT01384734|9841790|FG002|Overall Study|Adhesion problem|0
6187730|NCT01384734|9841791|FG003|Overall Study|Adhesion problem|1
6187731|NCT01384734|9841792|FG004|Overall Study|Adhesion problem|0
6187732|NCT01384734|9841788|FG000|Overall Study|Early termination|0
6187733|NCT01384734|9841789|FG001|Overall Study|Early termination|0
6187734|NCT01384734|9841790|FG002|Overall Study|Early termination|0
6187735|NCT01384734|9841791|FG003|Overall Study|Early termination|0
6187736|NCT01384734|9841792|FG004|Overall Study|Early termination|1
6187737|NCT01384734|9841788|FG000|Overall Study|Physician Decision|1
6187738|NCT01384734|9841789|FG001|Overall Study|Physician Decision|0
6187739|NCT01384734|9841790|FG002|Overall Study|Physician Decision|0
6187740|NCT01384734|9841791|FG003|Overall Study|Physician Decision|0
6187741|NCT01384734|9841792|FG004|Overall Study|Physician Decision|0
6187742|NCT01384760|9841803|FG000|Overall Study|Lost to Follow-up|0
6187743|NCT01384760|9841804|FG001|Overall Study|Lost to Follow-up|6
6187744|NCT01384760|9841803|FG000|Overall Study|Protocol Violation|16
6187745|NCT01384760|9841804|FG001|Overall Study|Protocol Violation|0
6187746|NCT01384877|9841812|FG000|Treatment 2|Lost to Follow-up|2
6187747|NCT01384877|9841813|FG001|Treatment 2|Lost to Follow-up|2
6187748|NCT01385098|9841819|FG000|Overall Study|Adverse Event|10
6187749|NCT01385098|9841819|FG000|Overall Study|Lost to Follow-up|4
6187750|NCT01385202|9841862|FG000|Overall Study|Lost to Follow-up|6
6187751|NCT01385202|9841862|FG000|Overall Study|Not Eligible|11
6187752|NCT01385202|9841862|FG000|Overall Study|Withdrawn|1
6187753|NCT01385371|9841878|FG000|Overall Study|Adverse Event|54
6187754|NCT01385371|9841879|FG001|Overall Study|Adverse Event|19
6187755|NCT01385371|9841878|FG000|Overall Study|Lost to Follow-up|16
6187756|NCT01385371|9841879|FG001|Overall Study|Lost to Follow-up|16
6187757|NCT01385371|9841878|FG000|Overall Study|Withdrawal by Subject|52
6187758|NCT01385371|9841879|FG001|Overall Study|Withdrawal by Subject|39
6187759|NCT01385371|9841878|FG000|Overall Study|Protocol Violation|25
6187760|NCT01385371|9841879|FG001|Overall Study|Protocol Violation|21
6187761|NCT01385371|9841878|FG000|Overall Study|Administrative|2
6187762|NCT01385371|9841879|FG001|Overall Study|Administrative|2
6235054|NCT01791517|9913223|FG011|Phase I: Period 1|Unsatisfactory Lens Fitting|0
6235055|NCT01791517|9913212|FG000|Phase I: Period 1|Protocol Violation|0
6085737|NCT00654901|9695137|FG001|Overall Study|Lost to Follow-up|0
6085738|NCT00654901|9695138|FG002|Overall Study|Lost to Follow-up|1
6187763|NCT01385566|9841891|FG000|Overall Study|Lost to Follow-up|1
6187764|NCT01385566|9841892|FG001|Overall Study|Lost to Follow-up|0
6187765|NCT01385566|9841893|FG002|Overall Study|Lost to Follow-up|0
6187766|NCT01385566|9841894|FG003|Overall Study|Lost to Follow-up|0
6187767|NCT01385566|9841895|FG004|Overall Study|Lost to Follow-up|0
6187768|NCT01385566|9841896|FG005|Overall Study|Lost to Follow-up|0
6187769|NCT01385566|9841891|FG000|Overall Study|Withdrawal by Subject|0
6187770|NCT01385566|9841892|FG001|Overall Study|Withdrawal by Subject|0
6187771|NCT01385566|9841893|FG002|Overall Study|Withdrawal by Subject|0
6187772|NCT01385566|9841894|FG003|Overall Study|Withdrawal by Subject|1
6187773|NCT01385566|9841895|FG004|Overall Study|Withdrawal by Subject|0
6235056|NCT01791517|9913213|FG001|Phase I: Period 1|Protocol Violation|1
6235057|NCT01791517|9913214|FG002|Phase I: Period 1|Protocol Violation|0
6235058|NCT01791517|9913215|FG003|Phase I: Period 1|Protocol Violation|0
6235059|NCT01791517|9913216|FG004|Phase I: Period 1|Protocol Violation|0
6235060|NCT01791517|9913217|FG005|Phase I: Period 1|Protocol Violation|0
6235061|NCT01791517|9913218|FG006|Phase I: Period 1|Protocol Violation|0
6235062|NCT01791517|9913219|FG007|Phase I: Period 1|Protocol Violation|0
6235063|NCT01791517|9913220|FG008|Phase I: Period 1|Protocol Violation|0
6235064|NCT01791517|9913221|FG009|Phase I: Period 1|Protocol Violation|0
6235065|NCT01791517|9913222|FG010|Phase I: Period 1|Protocol Violation|0
6235066|NCT01791517|9913223|FG011|Phase I: Period 1|Protocol Violation|0
6235067|NCT01791517|9913212|FG000|Phase I: Period 1|Lost to Follow-up|0
6235068|NCT01791517|9913213|FG001|Phase I: Period 1|Lost to Follow-up|0
6235069|NCT01791517|9913214|FG002|Phase I: Period 1|Lost to Follow-up|0
6235070|NCT01791517|9913215|FG003|Phase I: Period 1|Lost to Follow-up|1
6235071|NCT01791517|9913216|FG004|Phase I: Period 1|Lost to Follow-up|0
6235072|NCT01791517|9913217|FG005|Phase I: Period 1|Lost to Follow-up|0
6235073|NCT01791517|9913218|FG006|Phase I: Period 1|Lost to Follow-up|1
6235074|NCT01791517|9913219|FG007|Phase I: Period 1|Lost to Follow-up|0
6235075|NCT01791517|9913220|FG008|Phase I: Period 1|Lost to Follow-up|1
6235076|NCT01791517|9913221|FG009|Phase I: Period 1|Lost to Follow-up|1
6235077|NCT01791517|9913222|FG010|Phase I: Period 1|Lost to Follow-up|0
6235078|NCT01791517|9913223|FG011|Phase I: Period 1|Lost to Follow-up|0
6235079|NCT01791517|9913212|FG000|Phase I: Period 1|Lens Handling DIfficulties|0
6187774|NCT01385566|9841896|FG005|Overall Study|Withdrawal by Subject|0
6187775|NCT01385748|9841941|FG000|Overall Study|Withdrawal by Subject|7
6187776|NCT01385748|9841942|FG001|Overall Study|Withdrawal by Subject|4
6187777|NCT01385748|9841943|FG002|Overall Study|Withdrawal by Subject|5
6187778|NCT01385748|9841941|FG000|Overall Study|Noncompliance|3
6187779|NCT01385748|9841942|FG001|Overall Study|Noncompliance|1
6187780|NCT01385748|9841943|FG002|Overall Study|Noncompliance|6
6187781|NCT01385748|9841941|FG000|Overall Study|Other|1
6187782|NCT01385748|9841942|FG001|Overall Study|Other|7
6187783|NCT01385748|9841943|FG002|Overall Study|Other|1
6187784|NCT01385748|9841941|FG000|Overall Study|Adverse Event|4
6187785|NCT01385748|9841942|FG001|Overall Study|Adverse Event|2
6187786|NCT01385748|9841943|FG002|Overall Study|Adverse Event|1
6187787|NCT01385995|9841957|FG000|Period 1, 2 Months|Physician Decision|1
6187788|NCT01385995|9841958|FG001|Period 1, 2 Months|Physician Decision|0
6187789|NCT01386008|9841966|FG000|Overall Study|exited w/o incident /study discontinued|17
6187790|NCT01386008|9841966|FG000|Overall Study|Adverse Event|3
6187791|NCT01386554|9841977|FG000|Overall Study|Lost to Follow-up|0
6187792|NCT01386554|9841978|FG001|Overall Study|Lost to Follow-up|0
6187793|NCT01386554|9841979|FG002|Overall Study|Lost to Follow-up|1
6187794|NCT01386554|9841977|FG000|Overall Study|Adverse Event|2
6187795|NCT01386554|9841978|FG001|Overall Study|Adverse Event|5
6187796|NCT01386554|9841979|FG002|Overall Study|Adverse Event|2
6187797|NCT01386554|9841977|FG000|Overall Study|Progressive disease|1
6187798|NCT01386554|9841978|FG001|Overall Study|Progressive disease|2
6187799|NCT01386554|9841979|FG002|Overall Study|Progressive disease|2
6187800|NCT01386554|9841977|FG000|Overall Study|Administration of live vaccines|0
6187801|NCT01386554|9841978|FG001|Overall Study|Administration of live vaccines|1
6187802|NCT01386554|9841979|FG002|Overall Study|Administration of live vaccines|0
6187803|NCT01386554|9841977|FG000|Overall Study|Investigator discretion|0
6187804|NCT01386554|9841978|FG001|Overall Study|Investigator discretion|0
6187805|NCT01386554|9841979|FG002|Overall Study|Investigator discretion|1
6187806|NCT01386554|9841977|FG000|Overall Study|Reason not collected|0
6187807|NCT01386554|9841978|FG001|Overall Study|Reason not collected|1
6187808|NCT01386554|9841979|FG002|Overall Study|Reason not collected|0
6187809|NCT01386606|9841993|FG000|Overall Study|Adverse Event|0
6187810|NCT01386606|9841994|FG001|Overall Study|Adverse Event|1
6187811|NCT01386606|9841995|FG002|Overall Study|Adverse Event|0
6187812|NCT01386606|9841996|FG003|Overall Study|Adverse Event|0
6187813|NCT01386606|9841993|FG000|Overall Study|Withdrawal by Subject|0
6187814|NCT01386606|9841994|FG001|Overall Study|Withdrawal by Subject|1
6187815|NCT01386606|9841995|FG002|Overall Study|Withdrawal by Subject|1
6187816|NCT01386606|9841996|FG003|Overall Study|Withdrawal by Subject|0
6187817|NCT01386606|9841993|FG000|Overall Study|Protocol Violation|1
6187818|NCT01386606|9841994|FG001|Overall Study|Protocol Violation|0
6187819|NCT01386606|9841995|FG002|Overall Study|Protocol Violation|1
6187820|NCT01386606|9841996|FG003|Overall Study|Protocol Violation|1
6187821|NCT01386606|9841993|FG000|Overall Study|Lost to Follow-up|2
6187822|NCT01386606|9841994|FG001|Overall Study|Lost to Follow-up|0
6187823|NCT01386606|9841995|FG002|Overall Study|Lost to Follow-up|0
6187824|NCT01386606|9841996|FG003|Overall Study|Lost to Follow-up|0
6187825|NCT01386606|9841993|FG000|Overall Study|Subject incarcerated|0
6235080|NCT01791517|9913213|FG001|Phase I: Period 1|Lens Handling DIfficulties|0
6187826|NCT01386606|9841994|FG001|Overall Study|Subject incarcerated|1
6187827|NCT01386606|9841995|FG002|Overall Study|Subject incarcerated|0
6187828|NCT01386606|9841996|FG003|Overall Study|Subject incarcerated|0
6187829|NCT01386606|9841993|FG000|Overall Study|Unable to draw PK|1
6187830|NCT01386606|9841994|FG001|Overall Study|Unable to draw PK|0
6235081|NCT01791517|9913214|FG002|Phase I: Period 1|Lens Handling DIfficulties|0
6235082|NCT01791517|9913215|FG003|Phase I: Period 1|Lens Handling DIfficulties|0
6235083|NCT01791517|9913216|FG004|Phase I: Period 1|Lens Handling DIfficulties|0
6235084|NCT01791517|9913217|FG005|Phase I: Period 1|Lens Handling DIfficulties|0
6235085|NCT01791517|9913218|FG006|Phase I: Period 1|Lens Handling DIfficulties|0
6235086|NCT01791517|9913219|FG007|Phase I: Period 1|Lens Handling DIfficulties|0
6235087|NCT01791517|9913220|FG008|Phase I: Period 1|Lens Handling DIfficulties|0
6235088|NCT01791517|9913221|FG009|Phase I: Period 1|Lens Handling DIfficulties|0
6235089|NCT01791517|9913222|FG010|Phase I: Period 1|Lens Handling DIfficulties|0
6235090|NCT01791517|9913223|FG011|Phase I: Period 1|Lens Handling DIfficulties|1
6235091|NCT01791517|9913212|FG000|Phase I: Period 2|Unsatisfactory Lens Fit|1
6235092|NCT01791517|9913213|FG001|Phase I: Period 2|Unsatisfactory Lens Fit|0
6235093|NCT01791517|9913214|FG002|Phase I: Period 2|Unsatisfactory Lens Fit|0
6235094|NCT01791517|9913215|FG003|Phase I: Period 2|Unsatisfactory Lens Fit|0
6235095|NCT01791517|9913216|FG004|Phase I: Period 2|Unsatisfactory Lens Fit|0
6235096|NCT01791517|9913217|FG005|Phase I: Period 2|Unsatisfactory Lens Fit|0
6235097|NCT01791517|9913218|FG006|Phase I: Period 2|Unsatisfactory Lens Fit|0
6235098|NCT01791517|9913219|FG007|Phase I: Period 2|Unsatisfactory Lens Fit|0
6235099|NCT01791517|9913220|FG008|Phase I: Period 2|Unsatisfactory Lens Fit|0
6235100|NCT01791517|9913221|FG009|Phase I: Period 2|Unsatisfactory Lens Fit|0
6235101|NCT01791517|9913222|FG010|Phase I: Period 2|Unsatisfactory Lens Fit|0
6235102|NCT01791517|9913223|FG011|Phase I: Period 2|Unsatisfactory Lens Fit|0
6235103|NCT01791517|9913212|FG000|Phase I: Period 2|Protocol Violation|0
6235104|NCT01791517|9913213|FG001|Phase I: Period 2|Protocol Violation|0
6235105|NCT01791517|9913214|FG002|Phase I: Period 2|Protocol Violation|0
6235106|NCT01791517|9913215|FG003|Phase I: Period 2|Protocol Violation|1
6235107|NCT01791517|9913216|FG004|Phase I: Period 2|Protocol Violation|0
6235108|NCT01791517|9913217|FG005|Phase I: Period 2|Protocol Violation|0
6235109|NCT01791517|9913218|FG006|Phase I: Period 2|Protocol Violation|0
6235110|NCT01791517|9913219|FG007|Phase I: Period 2|Protocol Violation|0
6187831|NCT01386606|9841995|FG002|Overall Study|Unable to draw PK|0
6187832|NCT01386606|9841996|FG003|Overall Study|Unable to draw PK|0
6187833|NCT01386606|9841993|FG000|Overall Study|T levels too high|0
6187834|NCT01386606|9841994|FG001|Overall Study|T levels too high|1
6187835|NCT01386606|9841995|FG002|Overall Study|T levels too high|1
6187836|NCT01386606|9841996|FG003|Overall Study|T levels too high|0
6187837|NCT01386645|9842022|FG000|Overall Study|Physician Decision|0
6187838|NCT01386645|9842023|FG001|Overall Study|Physician Decision|0
6187839|NCT01386645|9842024|FG002|Overall Study|Physician Decision|1
6187840|NCT01386645|9842022|FG000|Overall Study|Withdrawal by Subject|0
6187841|NCT01386645|9842023|FG001|Overall Study|Withdrawal by Subject|1
6187842|NCT01386645|9842024|FG002|Overall Study|Withdrawal by Subject|1
6187843|NCT01386788|9842032|FG000|Overall Study|Lost to Follow-up|2
6187844|NCT01386944|9842036|FG000|Overall Study|Adverse Event|26
6187845|NCT01386944|9842036|FG000|Overall Study|Lack of Efficacy|14
6187846|NCT01386944|9842036|FG000|Overall Study|Lost to Follow-up|8
6187847|NCT01386944|9842036|FG000|Overall Study|Unspecified reason|8
6187848|NCT01386970|9842042|FG000|Overall Study|Withdrawal by Subject|0
6187849|NCT01386970|9842043|FG001|Overall Study|Withdrawal by Subject|1
6187850|NCT01386970|9842042|FG000|Overall Study|Adverse Event|4
6187851|NCT01386970|9842043|FG001|Overall Study|Adverse Event|1
6187852|NCT01387022|9842062|FG000|Overall Study|Death|1
6187853|NCT01387022|9842063|FG001|Overall Study|Death|1
6187854|NCT01387022|9842062|FG000|Overall Study|Lost to Follow-up|0
6187855|NCT01387022|9842063|FG001|Overall Study|Lost to Follow-up|3
6187856|NCT01387074|9842069|FG000|Overall Study|Lost to Follow-up|7
6187857|NCT01387074|9842069|FG000|Overall Study|Lack of Efficacy|1
6187858|NCT01387230|9842095|FG000|Overall Study|Adverse Event|0
6187859|NCT01387230|9842096|FG001|Overall Study|Adverse Event|1
6187860|NCT01387230|9842097|FG002|Overall Study|Adverse Event|3
6187861|NCT01387230|9842095|FG000|Overall Study|Lack of Efficacy|8
6187862|NCT01387230|9842096|FG001|Overall Study|Lack of Efficacy|5
6187863|NCT01387230|9842097|FG002|Overall Study|Lack of Efficacy|4
6187864|NCT01387230|9842095|FG000|Overall Study|Protocol-defined Stopping Criteria|6
6187865|NCT01387230|9842096|FG001|Overall Study|Protocol-defined Stopping Criteria|0
6187866|NCT01387230|9842097|FG002|Overall Study|Protocol-defined Stopping Criteria|5
6187867|NCT01387230|9842095|FG000|Overall Study|Lost to Follow-up|0
6187868|NCT01387230|9842096|FG001|Overall Study|Lost to Follow-up|0
6187869|NCT01387230|9842097|FG002|Overall Study|Lost to Follow-up|1
6187870|NCT01387230|9842095|FG000|Overall Study|Withdrawal by Subject|4
6187871|NCT01387230|9842096|FG001|Overall Study|Withdrawal by Subject|1
6187872|NCT01387230|9842097|FG002|Overall Study|Withdrawal by Subject|0
6187873|NCT01387269|9842107|FG000|Overall Study|Death|38
6187874|NCT01387269|9842108|FG001|Overall Study|Death|20
6187875|NCT01387269|9842107|FG000|Overall Study|Other|8
6187876|NCT01387269|9842108|FG001|Overall Study|Other|7
6187877|NCT01387269|9842107|FG000|Overall Study|Unrelated AE|12
6187878|NCT01387269|9842108|FG001|Overall Study|Unrelated AE|3
6235111|NCT01791517|9913220|FG008|Phase I: Period 2|Protocol Violation|0
6235112|NCT01791517|9913221|FG009|Phase I: Period 2|Protocol Violation|0
6187879|NCT01387269|9842107|FG000|Overall Study|Withdrawal by patient|32
6187880|NCT01387269|9842108|FG001|Overall Study|Withdrawal by patient|10
6187881|NCT01387269|9842107|FG000|Overall Study|Study drug-related AE|1
6187882|NCT01387269|9842108|FG001|Overall Study|Study drug-related AE|0
6187883|NCT01387269|9842107|FG000|Overall Study|Lost to Follow-up|1
6235113|NCT01791517|9913222|FG010|Phase I: Period 2|Protocol Violation|0
6235114|NCT01791517|9913223|FG011|Phase I: Period 2|Protocol Violation|0
6235115|NCT01791517|9913212|FG000|Phase I: Period 2|Withdrawal by Subject|0
6235116|NCT01791517|9913213|FG001|Phase I: Period 2|Withdrawal by Subject|0
6235117|NCT01791517|9913214|FG002|Phase I: Period 2|Withdrawal by Subject|0
6235118|NCT01791517|9913215|FG003|Phase I: Period 2|Withdrawal by Subject|0
6235119|NCT01791517|9913216|FG004|Phase I: Period 2|Withdrawal by Subject|0
6235120|NCT01791517|9913217|FG005|Phase I: Period 2|Withdrawal by Subject|0
6235121|NCT01791517|9913218|FG006|Phase I: Period 2|Withdrawal by Subject|0
6187884|NCT01387269|9842108|FG001|Overall Study|Lost to Follow-up|0
6187885|NCT01387282|9842116|FG000|Overall Study|Death|47
6187886|NCT01387282|9842117|FG001|Overall Study|Death|16
6187887|NCT01387282|9842116|FG000|Overall Study|Other|5
6187888|NCT01387282|9842117|FG001|Overall Study|Other|1
6187889|NCT01387282|9842116|FG000|Overall Study|Unrelated AE|6
6187890|NCT01387282|9842117|FG001|Overall Study|Unrelated AE|4
6187891|NCT01387282|9842116|FG000|Overall Study|Withdrawal by patient|33
6187892|NCT01387282|9842117|FG001|Overall Study|Withdrawal by patient|23
6187893|NCT01387282|9842116|FG000|Overall Study|Study drug-related AE|2
6187894|NCT01387282|9842117|FG001|Overall Study|Study drug-related AE|2
6187895|NCT01387282|9842116|FG000|Overall Study|Lost to Follow-up|4
6187896|NCT01387282|9842117|FG001|Overall Study|Lost to Follow-up|1
6187897|NCT01387347|9842125|FG000|Overall Study|Lost to Follow-up|2
6187898|NCT01387347|9842126|FG001|Overall Study|Lost to Follow-up|1
6193142|NCT01436162|9850749|FG001|Single-blind Lead-in Phase|Protocol Violation|0
6193143|NCT01436162|9850750|FG002|Single-blind Lead-in Phase|Protocol Violation|0
6193144|NCT01436162|9850748|FG000|Single-blind Lead-in Phase|Withdrawal by Subject|69
6193145|NCT01436162|9850749|FG001|Single-blind Lead-in Phase|Withdrawal by Subject|0
6193146|NCT01436162|9850750|FG002|Single-blind Lead-in Phase|Withdrawal by Subject|0
6193147|NCT01436162|9850748|FG000|Single-blind Lead-in Phase|Lost to Follow-up|43
6193148|NCT01436162|9850749|FG001|Single-blind Lead-in Phase|Lost to Follow-up|0
6193149|NCT01436162|9850750|FG002|Single-blind Lead-in Phase|Lost to Follow-up|0
6193150|NCT01436162|9850748|FG000|Single-blind Lead-in Phase|Met BP or Pulse Withdrawal Criteria|13
6193151|NCT01436162|9850749|FG001|Single-blind Lead-in Phase|Met BP or Pulse Withdrawal Criteria|0
6193152|NCT01436162|9850750|FG002|Single-blind Lead-in Phase|Met BP or Pulse Withdrawal Criteria|0
6193153|NCT01436162|9850748|FG000|Single-blind Lead-in Phase|Other|107
6193154|NCT01436162|9850749|FG001|Single-blind Lead-in Phase|Other|0
6193155|NCT01436162|9850750|FG002|Single-blind Lead-in Phase|Other|0
6193156|NCT01436162|9850748|FG000|Randomized Phase|Adverse Event|1
6193157|NCT01436162|9850749|FG001|Randomized Phase|Adverse Event|5
6193158|NCT01436162|9850750|FG002|Randomized Phase|Adverse Event|6
6193159|NCT01436162|9850748|FG000|Randomized Phase|Protocol Violation|4
6193160|NCT01436162|9850749|FG001|Randomized Phase|Protocol Violation|4
6193161|NCT01436162|9850750|FG002|Randomized Phase|Protocol Violation|2
6193162|NCT01436162|9850748|FG000|Randomized Phase|Withdrawal by Subject|16
6193163|NCT01436162|9850749|FG001|Randomized Phase|Withdrawal by Subject|9
6193164|NCT01436162|9850750|FG002|Randomized Phase|Withdrawal by Subject|8
6193165|NCT01436162|9850748|FG000|Randomized Phase|Lost to Follow-up|17
6193166|NCT01436162|9850749|FG001|Randomized Phase|Lost to Follow-up|5
6193167|NCT01436162|9850750|FG002|Randomized Phase|Lost to Follow-up|4
6193168|NCT01436162|9850748|FG000|Randomized Phase|Lack of Efficacy|0
6193169|NCT01436162|9850749|FG001|Randomized Phase|Lack of Efficacy|1
6193170|NCT01436162|9850750|FG002|Randomized Phase|Lack of Efficacy|1
6193171|NCT01436162|9850748|FG000|Randomized Phase|Met BP Or Pulse Withdrawal Criteria|4
6193172|NCT01436162|9850749|FG001|Randomized Phase|Met BP Or Pulse Withdrawal Criteria|2
6193173|NCT01436162|9850750|FG002|Randomized Phase|Met BP Or Pulse Withdrawal Criteria|0
6193174|NCT01436162|9850748|FG000|Randomized Phase|Other|2
6193175|NCT01436162|9850749|FG001|Randomized Phase|Other|5
6193176|NCT01436162|9850750|FG002|Randomized Phase|Other|4
6193177|NCT01436175|9850758|FG000|Overall Study|Adverse Event|111
6193178|NCT01436175|9850758|FG000|Overall Study|Protocol Violation|49
6193179|NCT01436175|9850758|FG000|Overall Study|Withdrawal by Subject|108
6193180|NCT01436175|9850758|FG000|Overall Study|Lost to Follow-up|89
6193181|NCT01436175|9850758|FG000|Overall Study|Lack of Efficacy|24
6193182|NCT01436175|9850758|FG000|Overall Study|Met blood pressure or pulse withdrawal|63
6193183|NCT01436175|9850758|FG000|Overall Study|Other|826
6193184|NCT01436201|9850763|FG000|Overall Study|Adverse Event|2
6193185|NCT01436201|9850763|FG000|Overall Study|Withdrawal by Subject|1
6193186|NCT01436201|9850763|FG000|Overall Study|Protocol Violation|1
6193187|NCT01436305|9850792|FG000|Overall Study|Death|1
6193188|NCT01436305|9850793|FG001|Overall Study|Death|0
6193189|NCT01436305|9850794|FG002|Overall Study|Death|0
6193190|NCT01436305|9850792|FG000|Overall Study|Lost to Follow-up|0
6193191|NCT01436305|9850793|FG001|Overall Study|Lost to Follow-up|1
6193192|NCT01436305|9850794|FG002|Overall Study|Lost to Follow-up|0
6193193|NCT01436305|9850792|FG000|Overall Study|Withdrawal by Subject|1
6193194|NCT01436305|9850793|FG001|Overall Study|Withdrawal by Subject|3
6193195|NCT01436305|9850794|FG002|Overall Study|Withdrawal by Subject|0
6193196|NCT01436357|9850804|FG000|Overall Study|Death|5
6193197|NCT01436357|9850805|FG001|Overall Study|Death|1
6193198|NCT01436357|9850804|FG000|Overall Study|Enrolled but not vaccinated|1
6235122|NCT01791517|9913219|FG007|Phase I: Period 2|Withdrawal by Subject|0
6235123|NCT01791517|9913220|FG008|Phase I: Period 2|Withdrawal by Subject|0
6235124|NCT01791517|9913221|FG009|Phase I: Period 2|Withdrawal by Subject|1
6235125|NCT01791517|9913222|FG010|Phase I: Period 2|Withdrawal by Subject|1
6235126|NCT01791517|9913223|FG011|Phase I: Period 2|Withdrawal by Subject|0
6235127|NCT01791517|9913212|FG000|Phase I: Period 2|Unsatisfactory Visual Response|0
6235128|NCT01791517|9913213|FG001|Phase I: Period 2|Unsatisfactory Visual Response|0
6235129|NCT01791517|9913214|FG002|Phase I: Period 2|Unsatisfactory Visual Response|0
6235130|NCT01791517|9913215|FG003|Phase I: Period 2|Unsatisfactory Visual Response|0
6235131|NCT01791517|9913216|FG004|Phase I: Period 2|Unsatisfactory Visual Response|0
6235132|NCT01791517|9913217|FG005|Phase I: Period 2|Unsatisfactory Visual Response|0
6235133|NCT01791517|9913218|FG006|Phase I: Period 2|Unsatisfactory Visual Response|0
6235134|NCT01791517|9913219|FG007|Phase I: Period 2|Unsatisfactory Visual Response|0
6235135|NCT01791517|9913220|FG008|Phase I: Period 2|Unsatisfactory Visual Response|0
6235136|NCT01791517|9913221|FG009|Phase I: Period 2|Unsatisfactory Visual Response|0
6235137|NCT01791517|9913222|FG010|Phase I: Period 2|Unsatisfactory Visual Response|1
6187899|NCT01387516|9842149|FG000|Overall Study|Lost to Follow-up|4
6187900|NCT01387516|9842150|FG001|Overall Study|Lost to Follow-up|4
6187901|NCT01387516|9842151|FG002|Overall Study|Lost to Follow-up|2
6187902|NCT01387516|9842152|FG003|Overall Study|Lost to Follow-up|3
6187903|NCT01387516|9842149|FG000|Overall Study|Withdrawal by Subject|1
6187904|NCT01387516|9842150|FG001|Overall Study|Withdrawal by Subject|1
6187905|NCT01387516|9842151|FG002|Overall Study|Withdrawal by Subject|2
6187906|NCT01387516|9842152|FG003|Overall Study|Withdrawal by Subject|0
6187907|NCT01387516|9842149|FG000|Overall Study|Death|0
6187908|NCT01387516|9842150|FG001|Overall Study|Death|0
6187909|NCT01387516|9842151|FG002|Overall Study|Death|0
6187910|NCT01387516|9842152|FG003|Overall Study|Death|1
6187911|NCT01387542|9842162|FG000|Overall Study|Adverse Event|3
6187912|NCT01387542|9842162|FG000|Overall Study|Withdrawal by Subject|1
6187913|NCT01387542|9842162|FG000|Overall Study|Changed diagnosis|1
6187914|NCT01387542|9842162|FG000|Overall Study|Insufficient response|1
6187915|NCT01387542|9842162|FG000|Overall Study|Non-compliant|1
6187916|NCT01387542|9842162|FG000|Overall Study|Lost to Follow-up|1
6187917|NCT01387594|9842181|FG000|Overall Study|Withdrawal by Subject|0
6187918|NCT01387594|9842182|FG001|Overall Study|Withdrawal by Subject|2
6187919|NCT01387594|9842181|FG000|Overall Study|Lost to Follow-up|0
6187920|NCT01387594|9842182|FG001|Overall Study|Lost to Follow-up|1
6187921|NCT01387607|9842193|FG000|Overall Study|Adverse Event|23
6187922|NCT01387607|9842194|FG001|Overall Study|Adverse Event|11
6187923|NCT01387607|9842193|FG000|Overall Study|Lack of Efficacy|8
6187924|NCT01387607|9842194|FG001|Overall Study|Lack of Efficacy|6
6187925|NCT01387607|9842193|FG000|Overall Study|Lost to Follow-up|2
6187926|NCT01387607|9842194|FG001|Overall Study|Lost to Follow-up|1
6187927|NCT01387607|9842193|FG000|Overall Study|No longer meets eligibility criteria|0
6187928|NCT01387607|9842194|FG001|Overall Study|No longer meets eligibility criteria|1
6187929|NCT01387607|9842193|FG000|Overall Study|Protocol Violation|1
6187930|NCT01387607|9842194|FG001|Overall Study|Protocol Violation|5
6187931|NCT01387607|9842193|FG000|Overall Study|Withdrawal by Subject|13
6187932|NCT01387607|9842194|FG001|Overall Study|Withdrawal by Subject|14
6187933|NCT01387607|9842193|FG000|Overall Study|Other|1
6187934|NCT01387607|9842194|FG001|Overall Study|Other|1
6187935|NCT01387607|9842193|FG000|Overall Study|Randomized, not treated|3
6187936|NCT01387607|9842194|FG001|Overall Study|Randomized, not treated|6
6187937|NCT01387737|9842228|FG000|Overall Study|Adverse Event|20
6187938|NCT01387737|9842229|FG001|Overall Study|Adverse Event|30
6187939|NCT01387737|9842228|FG000|Overall Study|Lack of Efficacy|1
6187940|NCT01387737|9842229|FG001|Overall Study|Lack of Efficacy|0
6187941|NCT01387737|9842228|FG000|Overall Study|Physician Decision|3
6187942|NCT01387737|9842229|FG001|Overall Study|Physician Decision|10
6187943|NCT01387737|9842228|FG000|Overall Study|Withdrawal by Subject|27
6187944|NCT01387737|9842229|FG001|Overall Study|Withdrawal by Subject|31
6187945|NCT01387737|9842228|FG000|Overall Study|Clearly not eligible for the study|1
6187946|NCT01387737|9842229|FG001|Overall Study|Clearly not eligible for the study|3
6187947|NCT01387789|9842235|FG000|Overall Study|Adverse Event|5
6187948|NCT01387789|9842235|FG000|Overall Study|Lack of Efficacy|2
6187949|NCT01387789|9842235|FG000|Overall Study|Lost to Follow-up|1
6187950|NCT01387932|9842250|FG000|Randomized and Treated|Physician Decision|3
6187951|NCT01387932|9842251|FG001|Randomized and Treated|Physician Decision|2
6187952|NCT01387932|9842250|FG000|Randomized and Treated|Withdrawal by Subject|4
6187953|NCT01387932|9842251|FG001|Randomized and Treated|Withdrawal by Subject|2
6187954|NCT01387932|9842250|FG000|Survival Follow-up|Liver Transplant|24
6187955|NCT01387932|9842251|FG001|Survival Follow-up|Liver Transplant|28
6187956|NCT01387932|9842250|FG000|Survival Follow-up|Additional treatment excluding liver transplant|52
6187957|NCT01387932|9842251|FG001|Survival Follow-up|Additional treatment excluding liver transplant|53
6187958|NCT01387932|9842250|FG000|Survival Follow-up|Withdrawal by Subject|2
6187959|NCT01387932|9842251|FG001|Survival Follow-up|Withdrawal by Subject|4
6187960|NCT01387932|9842250|FG000|Survival Follow-up|Lost to Follow-up|6
6187961|NCT01387932|9842251|FG001|Survival Follow-up|Lost to Follow-up|5
6187962|NCT01388166|9842259|FG000|Overall Study|Adverse Event|16
6187963|NCT01388166|9842259|FG000|Overall Study|Lost to Follow-up|30
6187964|NCT01388166|9842259|FG000|Overall Study|Others than specified above|13
6187965|NCT01388335|9842263|FG000|Period 1|Progressive Disease|1
6235138|NCT01791517|9913223|FG011|Phase I: Period 2|Unsatisfactory Visual Response|0
6235139|NCT01791517|9913212|FG000|Phase I: Period 2|Lens Discomfort|0
6235140|NCT01791517|9913213|FG001|Phase I: Period 2|Lens Discomfort|0
6235141|NCT01791517|9913214|FG002|Phase I: Period 2|Lens Discomfort|0
6235142|NCT01791517|9913215|FG003|Phase I: Period 2|Lens Discomfort|0
6235143|NCT01791517|9913216|FG004|Phase I: Period 2|Lens Discomfort|0
6235144|NCT01791517|9913217|FG005|Phase I: Period 2|Lens Discomfort|1
6235145|NCT01791517|9913218|FG006|Phase I: Period 2|Lens Discomfort|0
6235146|NCT01791517|9913219|FG007|Phase I: Period 2|Lens Discomfort|0
6235147|NCT01791517|9913220|FG008|Phase I: Period 2|Lens Discomfort|0
6235148|NCT01791517|9913221|FG009|Phase I: Period 2|Lens Discomfort|0
6235149|NCT01791517|9913222|FG010|Phase I: Period 2|Lens Discomfort|0
6235150|NCT01791517|9913223|FG011|Phase I: Period 2|Lens Discomfort|0
6235151|NCT01791517|9913212|FG000|Phase I: Period 2|Lost to Follow-up|0
6235152|NCT01791517|9913213|FG001|Phase I: Period 2|Lost to Follow-up|3
6235153|NCT01791517|9913214|FG002|Phase I: Period 2|Lost to Follow-up|2
6235154|NCT01791517|9913215|FG003|Phase I: Period 2|Lost to Follow-up|0
6235155|NCT01791517|9913216|FG004|Phase I: Period 2|Lost to Follow-up|0
6235156|NCT01791517|9913217|FG005|Phase I: Period 2|Lost to Follow-up|0
6235157|NCT01791517|9913218|FG006|Phase I: Period 2|Lost to Follow-up|0
6235158|NCT01791517|9913219|FG007|Phase I: Period 2|Lost to Follow-up|0
6235159|NCT01791517|9913220|FG008|Phase I: Period 2|Lost to Follow-up|0
6235160|NCT01791517|9913221|FG009|Phase I: Period 2|Lost to Follow-up|0
6187966|NCT01388335|9842263|FG000|Period 2|Progressive Disease|2
6187967|NCT01388335|9842263|FG000|Period 2|Sponsor Decision|1
6187968|NCT01388335|9842263|FG000|Safety Extension|Progressive Disease|7
6187969|NCT01388361|9842278|FG000|Overall Study|Adverse Event|0
6187970|NCT01388361|9842279|FG001|Overall Study|Adverse Event|5
6187971|NCT01388361|9842280|FG002|Overall Study|Adverse Event|1
6187972|NCT01388361|9842278|FG000|Overall Study|Protocol Violation|0
6187973|NCT01388361|9842279|FG001|Overall Study|Protocol Violation|0
6187974|NCT01388361|9842280|FG002|Overall Study|Protocol Violation|2
6187975|NCT01388361|9842278|FG000|Overall Study|Withdrawal criteria|12
6187976|NCT01388361|9842279|FG001|Overall Study|Withdrawal criteria|7
6187977|NCT01388361|9842280|FG002|Overall Study|Withdrawal criteria|10
6187978|NCT01388361|9842278|FG000|Overall Study|Unclassified|0
6187979|NCT01388361|9842279|FG001|Overall Study|Unclassified|0
6187980|NCT01388361|9842280|FG002|Overall Study|Unclassified|1
6187981|NCT01388478|9842288|FG000|Overall Study|Adverse Event|4
6187982|NCT01388478|9842288|FG000|Overall Study|Withdrawal by Subject|1
6187983|NCT01388530|9842292|FG000|Overall Study|Lost to Follow-up|5
6187984|NCT01388543|9842298|FG000|Day 14|Adverse Event|1
6187985|NCT01388543|9842299|FG001|Day 14|Adverse Event|4
6187986|NCT01388647|9842307|FG000|Overall Study|Adverse Event|1
6187987|NCT01388647|9842308|FG001|Overall Study|Adverse Event|2
6187988|NCT01388790|9842319|FG000|Overall Study|Ongoing at data cut-off date|8
6187989|NCT01388816|9842327|FG000|Overall Study|Adverse Event|0
6187990|NCT01388816|9842328|FG001|Overall Study|Adverse Event|2
6187991|NCT01388816|9842329|FG002|Overall Study|Adverse Event|0
6187992|NCT01388816|9842330|FG003|Overall Study|Adverse Event|0
6187993|NCT01388816|9842327|FG000|Overall Study|Lost to Follow-up|0
6187994|NCT01388816|9842328|FG001|Overall Study|Lost to Follow-up|1
6187995|NCT01388816|9842329|FG002|Overall Study|Lost to Follow-up|0
6187996|NCT01388816|9842330|FG003|Overall Study|Lost to Follow-up|0
6187997|NCT01388816|9842327|FG000|Overall Study|Withdrawal by Subject|2
6187998|NCT01388816|9842328|FG001|Overall Study|Withdrawal by Subject|1
6187999|NCT01388816|9842329|FG002|Overall Study|Withdrawal by Subject|1
6188000|NCT01388816|9842330|FG003|Overall Study|Withdrawal by Subject|0
6188001|NCT01388816|9842327|FG000|Overall Study|Protocol Violation|0
6188002|NCT01388816|9842328|FG001|Overall Study|Protocol Violation|0
6188003|NCT01388816|9842329|FG002|Overall Study|Protocol Violation|2
6188004|NCT01388816|9842330|FG003|Overall Study|Protocol Violation|0
6188005|NCT01388907|9842345|FG000|Overall Study|Adverse Event|2
6188006|NCT01388907|9842346|FG001|Overall Study|Adverse Event|0
6188007|NCT01388985|9842365|FG000|Overall Study|Death|0
6188008|NCT01388985|9842366|FG001|Overall Study|Death|1
6188009|NCT01388985|9842365|FG000|Overall Study|Lost to Follow-up|30
6188010|NCT01388985|9842366|FG001|Overall Study|Lost to Follow-up|30
6188011|NCT01388985|9842365|FG000|Overall Study|Withdrawal by Subject|13
6188012|NCT01388985|9842366|FG001|Overall Study|Withdrawal by Subject|4
6235161|NCT01791517|9913222|FG010|Phase I: Period 2|Lost to Follow-up|0
6188013|NCT01388985|9842365|FG000|Overall Study|Subject unavailable|1
6188014|NCT01388985|9842366|FG001|Overall Study|Subject unavailable|1
6188015|NCT01388985|9842365|FG000|Overall Study|Other (no reason)|0
6188016|NCT01388985|9842366|FG001|Overall Study|Other (no reason)|1
6188017|NCT01388985|9842365|FG000|Overall Study|Error of nurse|5
6188018|NCT01388985|9842366|FG001|Overall Study|Error of nurse|1
6188019|NCT01389102|9842382|FG000|Overall Study|Adverse Event|1
6188020|NCT01389102|9842383|FG001|Overall Study|Adverse Event|3
6188021|NCT01389102|9842384|FG002|Overall Study|Adverse Event|2
6188022|NCT01389102|9842385|FG003|Overall Study|Adverse Event|2
6188023|NCT01389102|9842386|FG004|Overall Study|Adverse Event|2
6188024|NCT01389102|9842387|FG005|Overall Study|Adverse Event|2
6235162|NCT01791517|9913223|FG011|Phase I: Period 2|Lost to Follow-up|0
6235163|NCT01791517|9913212|FG000|Phase I: Period 3|Lens Discomfort|0
6235164|NCT01791517|9913213|FG001|Phase I: Period 3|Lens Discomfort|0
6235165|NCT01791517|9913214|FG002|Phase I: Period 3|Lens Discomfort|0
6188025|NCT01389102|9842382|FG000|Overall Study|Hurricane Katrina|4
6235166|NCT01791517|9913215|FG003|Phase I: Period 3|Lens Discomfort|0
6235167|NCT01791517|9913216|FG004|Phase I: Period 3|Lens Discomfort|0
6235168|NCT01791517|9913217|FG005|Phase I: Period 3|Lens Discomfort|0
6235169|NCT01791517|9913218|FG006|Phase I: Period 3|Lens Discomfort|0
6235170|NCT01791517|9913219|FG007|Phase I: Period 3|Lens Discomfort|0
6235171|NCT01791517|9913220|FG008|Phase I: Period 3|Lens Discomfort|0
6235172|NCT01791517|9913221|FG009|Phase I: Period 3|Lens Discomfort|0
6235173|NCT01791517|9913222|FG010|Phase I: Period 3|Lens Discomfort|0
6235174|NCT01791517|9913223|FG011|Phase I: Period 3|Lens Discomfort|1
6235175|NCT01791517|9913212|FG000|Phase I: Period 3|Lost to Follow-up|0
6235176|NCT01791517|9913213|FG001|Phase I: Period 3|Lost to Follow-up|1
6235177|NCT01791517|9913214|FG002|Phase I: Period 3|Lost to Follow-up|0
6235178|NCT01791517|9913215|FG003|Phase I: Period 3|Lost to Follow-up|0
6235179|NCT01791517|9913216|FG004|Phase I: Period 3|Lost to Follow-up|1
6235180|NCT01791517|9913217|FG005|Phase I: Period 3|Lost to Follow-up|0
6235181|NCT01791517|9913218|FG006|Phase I: Period 3|Lost to Follow-up|0
6235182|NCT01791517|9913219|FG007|Phase I: Period 3|Lost to Follow-up|0
6235183|NCT01791517|9913220|FG008|Phase I: Period 3|Lost to Follow-up|0
6235184|NCT01791517|9913221|FG009|Phase I: Period 3|Lost to Follow-up|0
6235185|NCT01791517|9913222|FG010|Phase I: Period 3|Lost to Follow-up|0
6235186|NCT01791517|9913223|FG011|Phase I: Period 3|Lost to Follow-up|0
6235187|NCT01791517|9913212|FG000|Phase I: Period 3|Adverse Event|0
6235188|NCT01791517|9913213|FG001|Phase I: Period 3|Adverse Event|0
6235189|NCT01791517|9913214|FG002|Phase I: Period 3|Adverse Event|0
6235190|NCT01791517|9913215|FG003|Phase I: Period 3|Adverse Event|1
6235191|NCT01791517|9913216|FG004|Phase I: Period 3|Adverse Event|0
6235192|NCT01791517|9913217|FG005|Phase I: Period 3|Adverse Event|0
6235193|NCT01791517|9913218|FG006|Phase I: Period 3|Adverse Event|0
6235194|NCT01791517|9913219|FG007|Phase I: Period 3|Adverse Event|0
6235195|NCT01791517|9913220|FG008|Phase I: Period 3|Adverse Event|0
6235196|NCT01791517|9913221|FG009|Phase I: Period 3|Adverse Event|0
6235197|NCT01791517|9913222|FG010|Phase I: Period 3|Adverse Event|0
6235198|NCT01791517|9913223|FG011|Phase I: Period 3|Adverse Event|0
6235199|NCT01791517|9913212|FG000|Phase II|Lost to Follow-up|1
6235200|NCT01791517|9913213|FG001|Phase II|Lost to Follow-up|0
6235201|NCT01791517|9913214|FG002|Phase II|Lost to Follow-up|1
6235202|NCT01791517|9913215|FG003|Phase II|Lost to Follow-up|0
6188026|NCT01389102|9842383|FG001|Overall Study|Hurricane Katrina|2
6188027|NCT01389102|9842384|FG002|Overall Study|Hurricane Katrina|3
6188028|NCT01389102|9842385|FG003|Overall Study|Hurricane Katrina|0
6188029|NCT01389102|9842386|FG004|Overall Study|Hurricane Katrina|3
6188030|NCT01389102|9842387|FG005|Overall Study|Hurricane Katrina|1
6188031|NCT01389102|9842382|FG000|Overall Study|Lost to Follow-up|4
6188032|NCT01389102|9842383|FG001|Overall Study|Lost to Follow-up|1
6188033|NCT01389102|9842384|FG002|Overall Study|Lost to Follow-up|1
6188034|NCT01389102|9842385|FG003|Overall Study|Lost to Follow-up|2
6188035|NCT01389102|9842386|FG004|Overall Study|Lost to Follow-up|4
6188036|NCT01389102|9842387|FG005|Overall Study|Lost to Follow-up|1
6188037|NCT01389102|9842382|FG000|Overall Study|Protocol Violation|0
6188038|NCT01389102|9842383|FG001|Overall Study|Protocol Violation|0
6188039|NCT01389102|9842384|FG002|Overall Study|Protocol Violation|3
6188040|NCT01389102|9842385|FG003|Overall Study|Protocol Violation|0
6188041|NCT01389102|9842386|FG004|Overall Study|Protocol Violation|1
6188042|NCT01389102|9842387|FG005|Overall Study|Protocol Violation|1
6188043|NCT01389102|9842382|FG000|Overall Study|Withdrawal by Subject|7
6188044|NCT01389102|9842383|FG001|Overall Study|Withdrawal by Subject|4
6188045|NCT01389102|9842384|FG002|Overall Study|Withdrawal by Subject|9
6188046|NCT01389102|9842385|FG003|Overall Study|Withdrawal by Subject|2
6188047|NCT01389102|9842386|FG004|Overall Study|Withdrawal by Subject|3
6188048|NCT01389102|9842387|FG005|Overall Study|Withdrawal by Subject|3
6188049|NCT01389102|9842382|FG000|Overall Study|Subject Traveling Out of Country|0
6188050|NCT01389102|9842383|FG001|Overall Study|Subject Traveling Out of Country|0
6188051|NCT01389102|9842384|FG002|Overall Study|Subject Traveling Out of Country|0
6188052|NCT01389102|9842385|FG003|Overall Study|Subject Traveling Out of Country|1
6188053|NCT01389102|9842386|FG004|Overall Study|Subject Traveling Out of Country|0
6188054|NCT01389102|9842387|FG005|Overall Study|Subject Traveling Out of Country|0
6188055|NCT01389102|9842382|FG000|Overall Study|Subject Moved|2
6188056|NCT01389102|9842383|FG001|Overall Study|Subject Moved|0
6188057|NCT01389102|9842384|FG002|Overall Study|Subject Moved|1
6188058|NCT01389102|9842385|FG003|Overall Study|Subject Moved|0
6188059|NCT01389102|9842386|FG004|Overall Study|Subject Moved|0
6235203|NCT01791517|9913216|FG004|Phase II|Lost to Follow-up|1
6235204|NCT01791517|9913217|FG005|Phase II|Lost to Follow-up|2
6235205|NCT01791517|9913218|FG006|Phase II|Lost to Follow-up|0
6235206|NCT01791517|9913219|FG007|Phase II|Lost to Follow-up|1
6188060|NCT01389102|9842387|FG005|Overall Study|Subject Moved|0
6188061|NCT01389102|9842382|FG000|Overall Study|Unavailable due to husband's illness|0
6188062|NCT01389102|9842383|FG001|Overall Study|Unavailable due to husband's illness|1
6188063|NCT01389102|9842384|FG002|Overall Study|Unavailable due to husband's illness|0
6188064|NCT01389102|9842385|FG003|Overall Study|Unavailable due to husband's illness|0
6193199|NCT01436357|9850805|FG001|Overall Study|Enrolled but not vaccinated|1
6235207|NCT01791517|9913220|FG008|Phase II|Lost to Follow-up|1
6235208|NCT01791517|9913221|FG009|Phase II|Lost to Follow-up|1
6235209|NCT01791517|9913222|FG010|Phase II|Lost to Follow-up|0
6235210|NCT01791517|9913223|FG011|Phase II|Lost to Follow-up|0
6235211|NCT01791517|9913212|FG000|Phase II|Withdrawal by Subject|1
6235212|NCT01791517|9913213|FG001|Phase II|Withdrawal by Subject|0
6235213|NCT01791517|9913214|FG002|Phase II|Withdrawal by Subject|0
6235214|NCT01791517|9913215|FG003|Phase II|Withdrawal by Subject|0
6235215|NCT01791517|9913216|FG004|Phase II|Withdrawal by Subject|0
6235216|NCT01791517|9913217|FG005|Phase II|Withdrawal by Subject|2
6235217|NCT01791517|9913218|FG006|Phase II|Withdrawal by Subject|0
6235218|NCT01791517|9913219|FG007|Phase II|Withdrawal by Subject|1
6235219|NCT01791517|9913220|FG008|Phase II|Withdrawal by Subject|0
6235220|NCT01791517|9913221|FG009|Phase II|Withdrawal by Subject|0
6235221|NCT01791517|9913222|FG010|Phase II|Withdrawal by Subject|1
6235222|NCT01791517|9913223|FG011|Phase II|Withdrawal by Subject|0
6235223|NCT01791517|9913212|FG000|Phase II|Lack of Efficacy|0
6188065|NCT01389102|9842386|FG004|Overall Study|Unavailable due to husband's illness|0
6188066|NCT01389102|9842387|FG005|Overall Study|Unavailable due to husband's illness|0
6188067|NCT01389102|9842382|FG000|Overall Study|Investigator Judgement|0
6188068|NCT01389102|9842383|FG001|Overall Study|Investigator Judgement|1
6188069|NCT01389102|9842384|FG002|Overall Study|Investigator Judgement|0
6188070|NCT01389102|9842385|FG003|Overall Study|Investigator Judgement|0
6188071|NCT01389102|9842386|FG004|Overall Study|Investigator Judgement|0
6188072|NCT01389102|9842387|FG005|Overall Study|Investigator Judgement|0
6188073|NCT01389128|9842409|FG000|Overall Study|Fetal distress|1
6188074|NCT01389128|9842410|FG001|Overall Study|Fetal distress|0
6188075|NCT01389128|9842409|FG000|Overall Study|Cervix dilation stop|1
6188076|NCT01389128|9842410|FG001|Overall Study|Cervix dilation stop|2
6188077|NCT01389128|9842409|FG000|Overall Study|Rapid labor evolution|3
6188078|NCT01389128|9842410|FG001|Overall Study|Rapid labor evolution|2
6188079|NCT01389128|9842409|FG000|Overall Study|Intolerance to procedure|0
6188080|NCT01389128|9842410|FG001|Overall Study|Intolerance to procedure|2
6188081|NCT01389232|9842420|FG000|Overall Study|Had scaffold removed|15
6188082|NCT01389232|9842420|FG000|Overall Study|Personal reasons|2
6188083|NCT01389232|9842420|FG000|Overall Study|Adverse Event|1
6188084|NCT01389232|9842420|FG000|Overall Study|Death|1
6188085|NCT01389245|9842434|FG000|Overall Study|Protocol Violation|10
6188086|NCT01389245|9842434|FG000|Overall Study|Lost to Follow-up|3
6188087|NCT01389245|9842434|FG000|Overall Study|Withdrawal by Subject|2
6188088|NCT01389258|9842438|FG000|Overall Study|Lost to Follow-up|5
6188089|NCT01389323|9842455|FG000|Treatment Period (up to 48 Weeks)|Lack of Efficacy|41
6188090|NCT01389323|9842455|FG000|Treatment Period (up to 48 Weeks)|Adverse Event|24
6188091|NCT01389323|9842455|FG000|Treatment Period (up to 48 Weeks)|Participant's request to discontinue|6
6188092|NCT01389323|9842455|FG000|Treatment Period (up to 48 Weeks)|Withdrawal by Subject|7
6188093|NCT01389323|9842455|FG000|Treatment Period (up to 48 Weeks)|Lost to Follow-up|10
6188094|NCT01389323|9842455|FG000|Treatment Period (up to 48 Weeks)|Poor/non-compliance|5
6188095|NCT01389323|9842455|FG000|Treatment Period (up to 48 Weeks)|Did not meet study criteria|2
6188096|NCT01389323|9842455|FG000|Follow-up Period (up to 48 Weeks)|Withdrawal by Subject|10
6188097|NCT01389323|9842455|FG000|Follow-up Period (up to 48 Weeks)|Lost to Follow-up|22
6188098|NCT01389323|9842455|FG000|Follow-up Period (up to 48 Weeks)|Follow-up no longer needed per protocol|2
6188099|NCT01389323|9842455|FG000|Follow-up Period (up to 48 Weeks)|Other|3
6188100|NCT01389596|9842469|FG000|Overall Study|Protocol Violation|3
6188101|NCT01389596|9842470|FG001|Overall Study|Protocol Violation|4
6188102|NCT01389596|9842471|FG002|Overall Study|Protocol Violation|3
6188103|NCT01389596|9842469|FG000|Overall Study|Withdrawal by Subject|1
6188104|NCT01389596|9842470|FG001|Overall Study|Withdrawal by Subject|2
6188105|NCT01389596|9842471|FG002|Overall Study|Withdrawal by Subject|2
6188106|NCT01389596|9842469|FG000|Overall Study|Insufficient Clinical Response|3
6188107|NCT01389596|9842470|FG001|Overall Study|Insufficient Clinical Response|4
6188108|NCT01389596|9842471|FG002|Overall Study|Insufficient Clinical Response|5
6188109|NCT01389596|9842469|FG000|Overall Study|Adverse Event|1
6188110|NCT01389596|9842470|FG001|Overall Study|Adverse Event|4
6188111|NCT01389596|9842471|FG002|Overall Study|Adverse Event|0
6188112|NCT01389596|9842469|FG000|Overall Study|Death|0
6188113|NCT01389596|9842470|FG001|Overall Study|Death|1
6188114|NCT01389596|9842471|FG002|Overall Study|Death|0
6188115|NCT01389596|9842469|FG000|Overall Study|Other Unspecified|2
6188116|NCT01389596|9842470|FG001|Overall Study|Other Unspecified|1
6188117|NCT01389596|9842471|FG002|Overall Study|Other Unspecified|0
6188118|NCT01389752|9842479|FG000|Study Period 1|Sponsor decision|0
6188119|NCT01389752|9842480|FG001|Study Period 1|Sponsor decision|2
6188120|NCT01389752|9842479|FG000|Study Period 2|Sponsor decision|1
6188121|NCT01389752|9842480|FG001|Study Period 2|Sponsor decision|0
6188122|NCT01389882|9842505|FG000|Overall Study|Respiratory rate > 80/min during study|1
6188123|NCT01389882|9842506|FG001|Overall Study|Respiratory rate > 80/min during study|3
6188124|NCT01389882|9842505|FG000|Overall Study|Withdrawal by Subject|0
6188125|NCT01389882|9842506|FG001|Overall Study|Withdrawal by Subject|1
6188126|NCT01389973|9842512|FG000|Overall Study|Lost to Follow-up|1
6188127|NCT01389973|9842512|FG000|Overall Study|Trial Stopped by Sponsor|9
6188128|NCT01389973|9842512|FG000|Overall Study|Other|10
6235224|NCT01791517|9913213|FG001|Phase II|Lack of Efficacy|0
6235225|NCT01791517|9913214|FG002|Phase II|Lack of Efficacy|0
6235226|NCT01791517|9913215|FG003|Phase II|Lack of Efficacy|0
6235227|NCT01791517|9913216|FG004|Phase II|Lack of Efficacy|1
6235228|NCT01791517|9913217|FG005|Phase II|Lack of Efficacy|0
6235229|NCT01791517|9913218|FG006|Phase II|Lack of Efficacy|0
6235230|NCT01791517|9913219|FG007|Phase II|Lack of Efficacy|0
6235231|NCT01791517|9913220|FG008|Phase II|Lack of Efficacy|0
6235232|NCT01791517|9913221|FG009|Phase II|Lack of Efficacy|0
6188129|NCT01390038|9842516|FG000|Overall Study|Death|1
6188130|NCT01390038|9842516|FG000|Overall Study|Lost to Follow-up|1
6188131|NCT01390038|9842516|FG000|Overall Study|Withdrawal by Subject|4
6188132|NCT01390038|9842516|FG000|Overall Study|Simpliciti System Removal|2
6188133|NCT01390220|9842538|FG000|Test Dose Phase|Adverse Event|17
6188134|NCT01390220|9842539|FG001|Test Dose Phase|Adverse Event|0
6188135|NCT01390220|9842540|FG002|Test Dose Phase|Adverse Event|0
6188136|NCT01390220|9842538|FG000|Test Dose Phase|Withdrawal by Subject|8
6188137|NCT01390220|9842539|FG001|Test Dose Phase|Withdrawal by Subject|0
6188138|NCT01390220|9842540|FG002|Test Dose Phase|Withdrawal by Subject|0
6188139|NCT01390220|9842538|FG000|Test Dose Phase|Lost to Follow-up|2
6188140|NCT01390220|9842539|FG001|Test Dose Phase|Lost to Follow-up|0
6188141|NCT01390220|9842540|FG002|Test Dose Phase|Lost to Follow-up|0
6188142|NCT01390220|9842538|FG000|Test Dose Phase|Protocol Violation|8
6188143|NCT01390220|9842539|FG001|Test Dose Phase|Protocol Violation|0
6188144|NCT01390220|9842540|FG002|Test Dose Phase|Protocol Violation|0
6188145|NCT01390220|9842538|FG000|Test Dose Phase|No treated seizure cluster episode|37
6188146|NCT01390220|9842539|FG001|Test Dose Phase|No treated seizure cluster episode|0
6188147|NCT01390220|9842540|FG002|Test Dose Phase|No treated seizure cluster episode|0
6188148|NCT01390220|9842538|FG000|Test Dose Phase|Study/Site closure|6
6188149|NCT01390220|9842539|FG001|Test Dose Phase|Study/Site closure|0
6188150|NCT01390220|9842540|FG002|Test Dose Phase|Study/Site closure|0
6188151|NCT01390220|9842538|FG000|Test Dose Phase|Caregiver no longer available|5
6188152|NCT01390220|9842539|FG001|Test Dose Phase|Caregiver no longer available|0
6188153|NCT01390220|9842540|FG002|Test Dose Phase|Caregiver no longer available|0
6188154|NCT01390220|9842538|FG000|Test Dose Phase|Noncompliance|2
6188155|NCT01390220|9842539|FG001|Test Dose Phase|Noncompliance|0
6188156|NCT01390220|9842540|FG002|Test Dose Phase|Noncompliance|0
6188157|NCT01390220|9842538|FG000|Test Dose Phase|Logistical|6
6188158|NCT01390220|9842539|FG001|Test Dose Phase|Logistical|0
6188159|NCT01390220|9842540|FG002|Test Dose Phase|Logistical|0
6188160|NCT01390220|9842538|FG000|Comparative Phase|Withdrawal by Subject|0
6188161|NCT01390220|9842539|FG001|Comparative Phase|Withdrawal by Subject|1
6188162|NCT01390220|9842540|FG002|Comparative Phase|Withdrawal by Subject|0
6188163|NCT01390272|9842579|FG000|Overall Study|Death|3
6188164|NCT01390272|9842580|FG001|Overall Study|Death|2
6188165|NCT01390272|9842579|FG000|Overall Study|Withdrawal by Subject|9
6188166|NCT01390272|9842580|FG001|Overall Study|Withdrawal by Subject|5
6188167|NCT01390272|9842579|FG000|Overall Study|Patient moved, no longer eligible|5
6188168|NCT01390272|9842580|FG001|Overall Study|Patient moved, no longer eligible|8
6188169|NCT01390298|9842586|FG000|Overall Study|Death|1
6188170|NCT01390298|9842586|FG000|Overall Study|long term ICU admission|1
6188171|NCT01390298|9842586|FG000|Overall Study|Withdrawal by Subject|14
6188172|NCT01390298|9842586|FG000|Overall Study|Lost to Follow-up|7
6188173|NCT01390298|9842586|FG000|Overall Study|Surgery cancelled|1
6188174|NCT01390389|9842592|FG000|Overall Study|Withdrawal by Subject|2
6188175|NCT01390389|9842593|FG001|Overall Study|Withdrawal by Subject|0
6188176|NCT01390389|9842592|FG000|Overall Study|Screen Fail|2
6188177|NCT01390389|9842593|FG001|Overall Study|Screen Fail|1
6188178|NCT01390402|9842603|FG000|Overall Study|Death|1
6188179|NCT01390402|9842603|FG000|Overall Study|Disease Progression|4
6188180|NCT01390428|9842613|FG000|Overall Study|Elective Surgery|0
6188181|NCT01390428|9842614|FG001|Overall Study|Elective Surgery|0
6188182|NCT01390428|9842615|FG002|Overall Study|Elective Surgery|0
6188183|NCT01390428|9842616|FG003|Overall Study|Elective Surgery|0
6188184|NCT01390428|9842617|FG004|Overall Study|Elective Surgery|1
6188185|NCT01390428|9842618|FG005|Overall Study|Elective Surgery|0
6188186|NCT01390428|9842613|FG000|Overall Study|Withdrawal by Subject|0
6188187|NCT01390428|9842614|FG001|Overall Study|Withdrawal by Subject|0
6188188|NCT01390428|9842615|FG002|Overall Study|Withdrawal by Subject|1
6188189|NCT01390428|9842616|FG003|Overall Study|Withdrawal by Subject|0
6188190|NCT01390428|9842617|FG004|Overall Study|Withdrawal by Subject|0
6188191|NCT01390428|9842618|FG005|Overall Study|Withdrawal by Subject|0
6188192|NCT01390441|9842637|FG000|Treatment Period|Protocol Violation|0
6188193|NCT01390441|9842638|FG001|Treatment Period|Protocol Violation|1
6188194|NCT01390441|9842639|FG002|Treatment Period|Protocol Violation|0
6188195|NCT01390441|9842640|FG003|Treatment Period|Protocol Violation|0
6188196|NCT01390441|9842641|FG004|Treatment Period|Protocol Violation|0
6188197|NCT01390441|9842637|FG000|Treatment Period|Physician Decision|0
6188198|NCT01390441|9842638|FG001|Treatment Period|Physician Decision|0
6188199|NCT01390441|9842639|FG002|Treatment Period|Physician Decision|0
6188200|NCT01390441|9842640|FG003|Treatment Period|Physician Decision|1
6188201|NCT01390441|9842641|FG004|Treatment Period|Physician Decision|0
6188202|NCT01390441|9842637|FG000|Treatment Period|Lack of Efficacy|0
6188203|NCT01390441|9842638|FG001|Treatment Period|Lack of Efficacy|0
6188204|NCT01390441|9842639|FG002|Treatment Period|Lack of Efficacy|0
6188205|NCT01390441|9842640|FG003|Treatment Period|Lack of Efficacy|0
6188206|NCT01390441|9842641|FG004|Treatment Period|Lack of Efficacy|1
6235233|NCT01791517|9913222|FG010|Phase II|Lack of Efficacy|0
6235234|NCT01791517|9913223|FG011|Phase II|Lack of Efficacy|0
6235235|NCT01791517|9913212|FG000|Phase II|Adverse Event|0
6235236|NCT01791517|9913213|FG001|Phase II|Adverse Event|0
6235237|NCT01791517|9913214|FG002|Phase II|Adverse Event|0
6235238|NCT01791517|9913215|FG003|Phase II|Adverse Event|0
6235239|NCT01791517|9913216|FG004|Phase II|Adverse Event|0
6235240|NCT01791517|9913217|FG005|Phase II|Adverse Event|0
6235241|NCT01791517|9913218|FG006|Phase II|Adverse Event|2
6235242|NCT01791517|9913219|FG007|Phase II|Adverse Event|1
6235243|NCT01791517|9913220|FG008|Phase II|Adverse Event|0
6235244|NCT01791517|9913221|FG009|Phase II|Adverse Event|1
6085739|NCT00654901|9695139|FG003|Overall Study|Lost to Follow-up|0
6085740|NCT00654901|9695136|FG000|Overall Study|Withdrawal by Subject|3
6085741|NCT00654901|9695137|FG001|Overall Study|Withdrawal by Subject|0
6085742|NCT00654901|9695138|FG002|Overall Study|Withdrawal by Subject|1
6085743|NCT00654901|9695139|FG003|Overall Study|Withdrawal by Subject|0
6188207|NCT01390441|9842637|FG000|Treatment Period|Unknown due to early stopping of study|0
6188208|NCT01390441|9842638|FG001|Treatment Period|Unknown due to early stopping of study|0
6188209|NCT01390441|9842639|FG002|Treatment Period|Unknown due to early stopping of study|8
6188210|NCT01390441|9842640|FG003|Treatment Period|Unknown due to early stopping of study|11
6188211|NCT01390441|9842641|FG004|Treatment Period|Unknown due to early stopping of study|7
6188212|NCT01390441|9842637|FG000|Treatment Period|Adverse Event|0
6188213|NCT01390441|9842638|FG001|Treatment Period|Adverse Event|0
6188214|NCT01390441|9842639|FG002|Treatment Period|Adverse Event|1
6188215|NCT01390441|9842640|FG003|Treatment Period|Adverse Event|1
6188216|NCT01390441|9842641|FG004|Treatment Period|Adverse Event|2
6188217|NCT01390441|9842637|FG000|Treatment Period|Withdrawal by Subject|0
6188218|NCT01390441|9842638|FG001|Treatment Period|Withdrawal by Subject|0
6188219|NCT01390441|9842639|FG002|Treatment Period|Withdrawal by Subject|1
6188220|NCT01390441|9842640|FG003|Treatment Period|Withdrawal by Subject|0
6188221|NCT01390441|9842641|FG004|Treatment Period|Withdrawal by Subject|1
6188222|NCT01390441|9842637|FG000|Treatment Period|Lost to Follow-up|1
6188223|NCT01390441|9842638|FG001|Treatment Period|Lost to Follow-up|0
6188224|NCT01390441|9842639|FG002|Treatment Period|Lost to Follow-up|0
6188225|NCT01390441|9842640|FG003|Treatment Period|Lost to Follow-up|0
6188226|NCT01390441|9842641|FG004|Treatment Period|Lost to Follow-up|0
6188227|NCT01390441|9842637|FG000|Extension Period|Protocol Violation|3
6188228|NCT01390441|9842638|FG001|Extension Period|Protocol Violation|1
6188229|NCT01390441|9842639|FG002|Extension Period|Protocol Violation|0
6188230|NCT01390441|9842640|FG003|Extension Period|Protocol Violation|1
6188231|NCT01390441|9842641|FG004|Extension Period|Protocol Violation|0
6188232|NCT01390584|9842681|FG000|Step 1: Induction Tx (ABVD Then PET/CT)|Ineligible|0
6188233|NCT01390584|9842682|FG001|Step 1: Induction Tx (ABVD Then PET/CT)|Ineligible|0
6188234|NCT01390584|9842683|FG002|Step 1: Induction Tx (ABVD Then PET/CT)|Ineligible|1
6188235|NCT01390649|9842692|FG000|Overall Study|Physician Decision|1
6188236|NCT01390779|9842696|FG000|Overall Study|Physician Decision|1
6188237|NCT01390844|9842833|FG000|Treatment Phase|Adverse Event|12
6188238|NCT01390844|9842834|FG001|Treatment Phase|Adverse Event|2
6188239|NCT01390844|9842835|FG002|Treatment Phase|Adverse Event|3
6188240|NCT01390844|9842836|FG003|Treatment Phase|Adverse Event|2
6188241|NCT01390844|9842833|FG000|Treatment Phase|Treatment Failure|23
6188242|NCT01390844|9842834|FG001|Treatment Phase|Treatment Failure|25
6188243|NCT01390844|9842835|FG002|Treatment Phase|Treatment Failure|10
6188244|NCT01390844|9842836|FG003|Treatment Phase|Treatment Failure|13
6188245|NCT01390844|9842833|FG000|Treatment Phase|Non-Medical Reasons|5
6188246|NCT01390844|9842834|FG001|Treatment Phase|Non-Medical Reasons|1
6188247|NCT01390844|9842835|FG002|Treatment Phase|Non-Medical Reasons|8
6188248|NCT01390844|9842836|FG003|Treatment Phase|Non-Medical Reasons|1
6188249|NCT01390844|9842833|FG000|Treatment Phase|Non-GCP Compliant|0
6188250|NCT01390844|9842834|FG001|Treatment Phase|Non-GCP Compliant|0
6188251|NCT01390844|9842835|FG002|Treatment Phase|Non-GCP Compliant|10
6188252|NCT01390844|9842836|FG003|Treatment Phase|Non-GCP Compliant|3
6188253|NCT01390844|9842833|FG000|Follow-Up Phase|Non-Medical Reasons|1
6188254|NCT01390844|9842834|FG001|Follow-Up Phase|Non-Medical Reasons|1
6188255|NCT01390844|9842835|FG002|Follow-Up Phase|Non-Medical Reasons|1
6188256|NCT01390844|9842836|FG003|Follow-Up Phase|Non-Medical Reasons|0
6188257|NCT01390857|9842846|FG000|Overall Study|Protocol Violation|2
6188258|NCT01390857|9842846|FG000|Overall Study|Lost to Follow-up|1
6188259|NCT01390857|9842846|FG000|Overall Study|No Visit after the First Visit|7
6188260|NCT01390948|9842886|FG000|Overall Study|End of Study|1
6085744|NCT00654940|9695155|FG000|Period 1|Adverse Event|0
6188261|NCT01390948|9842887|FG001|Overall Study|End of Study|0
6188262|NCT01390948|9842888|FG002|Overall Study|End of Study|0
6188263|NCT01390948|9842886|FG000|Overall Study|Withdrew consent|2
6188264|NCT01390948|9842887|FG001|Overall Study|Withdrew consent|2
6188265|NCT01390948|9842888|FG002|Overall Study|Withdrew consent|0
6188266|NCT01390948|9842886|FG000|Overall Study|Progressive Disease|2
6188267|NCT01390948|9842887|FG001|Overall Study|Progressive Disease|5
6188268|NCT01390948|9842888|FG002|Overall Study|Progressive Disease|0
6188269|NCT01390948|9842886|FG000|Overall Study|Death during follow-up|10
6188270|NCT01390948|9842887|FG001|Overall Study|Death during follow-up|11
6235245|NCT01791517|9913222|FG010|Phase II|Adverse Event|0
6235246|NCT01791517|9913223|FG011|Phase II|Adverse Event|0
6235247|NCT01791517|9913212|FG000|Phase II|Lens Handling Difficulties|0
6235248|NCT01791517|9913213|FG001|Phase II|Lens Handling Difficulties|0
6235249|NCT01791517|9913214|FG002|Phase II|Lens Handling Difficulties|0
6235250|NCT01791517|9913215|FG003|Phase II|Lens Handling Difficulties|0
6235251|NCT01791517|9913216|FG004|Phase II|Lens Handling Difficulties|0
6235252|NCT01791517|9913217|FG005|Phase II|Lens Handling Difficulties|0
6235253|NCT01791517|9913218|FG006|Phase II|Lens Handling Difficulties|0
6085745|NCT00654940|9695156|FG001|Period 1|Adverse Event|1
6085746|NCT00654940|9695155|FG000|Period 1|Intolerable Pain Level|1
6085747|NCT00654940|9695156|FG001|Period 1|Intolerable Pain Level|0
6085748|NCT00655356|9695192|FG000|Overall Study|Withdrawal by Subject|3
6085749|NCT00655356|9695193|FG001|Overall Study|Withdrawal by Subject|4
6085750|NCT00655356|9695192|FG000|Overall Study|Sponsor Request|10
6085751|NCT00655356|9695193|FG001|Overall Study|Sponsor Request|4
6085752|NCT00655356|9695192|FG000|Overall Study|Adverse Event|1
6085753|NCT00655356|9695193|FG001|Overall Study|Adverse Event|1
6085754|NCT00655356|9695192|FG000|Overall Study|Protocol Violation|2
6188271|NCT01390948|9842888|FG002|Overall Study|Death during follow-up|1
6188272|NCT01391000|9842897|FG000|Overall Study|Lost to Follow-up|2
6188273|NCT01391000|9842898|FG001|Overall Study|Lost to Follow-up|0
6188274|NCT01391130|9842915|FG000|Overall Study|Withdrawal by Subject|3
6188275|NCT01391130|9842916|FG001|Overall Study|Withdrawal by Subject|2
6188276|NCT01391130|9842915|FG000|Overall Study|Physician Decision|2
6188277|NCT01391130|9842916|FG001|Overall Study|Physician Decision|3
6188278|NCT01391130|9842915|FG000|Overall Study|Did not Receive Drug|1
6188279|NCT01391130|9842916|FG001|Overall Study|Did not Receive Drug|1
6188280|NCT01391507|9842993|FG000|Overall Study|Death|0
6188281|NCT01391507|9842994|FG001|Overall Study|Death|0
6188282|NCT01391507|9842995|FG002|Overall Study|Death|0
6188283|NCT01391507|9842996|FG003|Overall Study|Death|1
6188284|NCT01391507|9842993|FG000|Overall Study|Adverse Event|1
6188285|NCT01391507|9842994|FG001|Overall Study|Adverse Event|1
6188286|NCT01391507|9842995|FG002|Overall Study|Adverse Event|2
6188287|NCT01391507|9842996|FG003|Overall Study|Adverse Event|2
6188288|NCT01391507|9842993|FG000|Overall Study|Withdrawal by Subject|1
6188289|NCT01391507|9842994|FG001|Overall Study|Withdrawal by Subject|2
6188290|NCT01391507|9842995|FG002|Overall Study|Withdrawal by Subject|1
6188291|NCT01391507|9842996|FG003|Overall Study|Withdrawal by Subject|1
6188292|NCT01391507|9842993|FG000|Overall Study|Lack of Efficacy|0
6188293|NCT01391507|9842994|FG001|Overall Study|Lack of Efficacy|0
6188294|NCT01391507|9842995|FG002|Overall Study|Lack of Efficacy|0
6188295|NCT01391507|9842996|FG003|Overall Study|Lack of Efficacy|1
6188296|NCT01391507|9842993|FG000|Overall Study|Protocol Violation|2
6188297|NCT01391507|9842994|FG001|Overall Study|Protocol Violation|1
6188298|NCT01391507|9842995|FG002|Overall Study|Protocol Violation|1
6188299|NCT01391507|9842996|FG003|Overall Study|Protocol Violation|2
6188300|NCT01391546|9843008|FG000|Overall Study|History of Herpes Zoster (HZ)|1
6188301|NCT01391546|9843009|FG001|Overall Study|History of Herpes Zoster (HZ)|0
6188302|NCT01391663|9843031|FG000|Overall Study|Withdrawal by Subject|0
6188303|NCT01391663|9843032|FG001|Overall Study|Withdrawal by Subject|0
6188304|NCT01391663|9843033|FG002|Overall Study|Withdrawal by Subject|1
6188305|NCT01391663|9843034|FG003|Overall Study|Withdrawal by Subject|0
6188306|NCT01391793|9843046|FG000|Overall Study|Ineligible|3
6188307|NCT01391793|9843047|FG001|Overall Study|Ineligible|0
6188308|NCT01391793|9843046|FG000|Overall Study|Urine Culture Negative or Indeterminate|71
6188309|NCT01391793|9843047|FG001|Overall Study|Urine Culture Negative or Indeterminate|87
6188310|NCT01391793|9843046|FG000|Overall Study|No DMSA|73
6188311|NCT01391793|9843047|FG001|Overall Study|No DMSA|57
6188312|NCT01391819|9843053|FG000|Overall Study|Withdrawal by Subject|56
6188313|NCT01391819|9843053|FG000|Overall Study|Migrated/moved from study area|82
6188314|NCT01391819|9843053|FG000|Overall Study|Lost to Follow-up|252
6188315|NCT01391819|9843053|FG000|Overall Study|Death|3
6188316|NCT01391819|9843053|FG000|Overall Study|Other|9
6085755|NCT00655356|9695193|FG001|Overall Study|Protocol Violation|1
6085756|NCT00655356|9695192|FG000|Overall Study|Other Reason|1
6188317|NCT01391832|9843062|FG000|Overall Study|Withdrawal by Subject|21
6188318|NCT01391832|9843063|FG001|Overall Study|Withdrawal by Subject|22
6188319|NCT01391832|9843062|FG000|Overall Study|Lost to Follow-up|0
6188320|NCT01391832|9843063|FG001|Overall Study|Lost to Follow-up|1
6235254|NCT01791517|9913219|FG007|Phase II|Lens Handling Difficulties|0
6235255|NCT01791517|9913220|FG008|Phase II|Lens Handling Difficulties|1
6235256|NCT01791517|9913221|FG009|Phase II|Lens Handling Difficulties|0
6235257|NCT01791517|9913222|FG010|Phase II|Lens Handling Difficulties|0
6235258|NCT01791517|9913223|FG011|Phase II|Lens Handling Difficulties|0
6235259|NCT01791517|9913212|FG000|Phase II|Unsatisfactory Lens Fitting|0
6235260|NCT01791517|9913213|FG001|Phase II|Unsatisfactory Lens Fitting|0
6235261|NCT01791517|9913214|FG002|Phase II|Unsatisfactory Lens Fitting|0
6235262|NCT01791517|9913215|FG003|Phase II|Unsatisfactory Lens Fitting|0
6235263|NCT01791517|9913216|FG004|Phase II|Unsatisfactory Lens Fitting|0
6235264|NCT01791517|9913217|FG005|Phase II|Unsatisfactory Lens Fitting|0
6235265|NCT01791517|9913218|FG006|Phase II|Unsatisfactory Lens Fitting|0
6188321|NCT01392183|9843089|FG000|First Drug Administration|Adverse Event|3
6188322|NCT01392183|9843090|FG001|First Drug Administration|Adverse Event|2
6188323|NCT01392183|9843089|FG000|First Drug Administration|Death|1
6188324|NCT01392183|9843090|FG001|First Drug Administration|Death|0
6188325|NCT01392183|9843089|FG000|First Drug Administration|Withdrawal by Subject|10
6188326|NCT01392183|9843090|FG001|First Drug Administration|Withdrawal by Subject|17
6188327|NCT01392300|9843100|FG000|Main Period (MP)|Predefined discontinuation criteria|2
6188328|NCT01392300|9843101|FG001|Main Period (MP)|Predefined discontinuation criteria|3
6188329|NCT01392300|9843102|FG002|Main Period (MP)|Predefined discontinuation criteria|0
6188330|NCT01392300|9843100|FG000|Main Period (MP)|Withdrawal by Subject|5
6188331|NCT01392300|9843101|FG001|Main Period (MP)|Withdrawal by Subject|1
6188332|NCT01392300|9843102|FG002|Main Period (MP)|Withdrawal by Subject|0
6188333|NCT01392300|9843100|FG000|Main Period (MP)|Lost to Follow-up|3
6188334|NCT01392300|9843101|FG001|Main Period (MP)|Lost to Follow-up|3
6188335|NCT01392300|9843102|FG002|Main Period (MP)|Lost to Follow-up|0
6188336|NCT01392300|9843100|FG000|Main Period (MP)|Non-compliance|1
6188337|NCT01392300|9843101|FG001|Main Period (MP)|Non-compliance|0
6188338|NCT01392300|9843102|FG002|Main Period (MP)|Non-compliance|0
6188339|NCT01392300|9843100|FG000|Open Label Extension (OLEX) Period|Protocol Violation|0
6188340|NCT01392300|9843101|FG001|Open Label Extension (OLEX) Period|Protocol Violation|0
6188341|NCT01392300|9843102|FG002|Open Label Extension (OLEX) Period|Protocol Violation|13
6188342|NCT01392300|9843100|FG000|Open Label Extension (OLEX) Period|Lack of Efficacy|0
6188343|NCT01392300|9843101|FG001|Open Label Extension (OLEX) Period|Lack of Efficacy|0
6188344|NCT01392300|9843102|FG002|Open Label Extension (OLEX) Period|Lack of Efficacy|3
6188345|NCT01392300|9843100|FG000|Open Label Extension (OLEX) Period|Non-compliance|0
6188346|NCT01392300|9843101|FG001|Open Label Extension (OLEX) Period|Non-compliance|0
6188347|NCT01392300|9843102|FG002|Open Label Extension (OLEX) Period|Non-compliance|1
6188348|NCT01392300|9843100|FG000|Open Label Extension (OLEX) Period|Death|0
6188349|NCT01392300|9843101|FG001|Open Label Extension (OLEX) Period|Death|0
6188350|NCT01392300|9843102|FG002|Open Label Extension (OLEX) Period|Death|4
6188351|NCT01392300|9843100|FG000|Open Label Extension (OLEX) Period|Adverse Event|0
6188352|NCT01392300|9843101|FG001|Open Label Extension (OLEX) Period|Adverse Event|0
6188353|NCT01392300|9843102|FG002|Open Label Extension (OLEX) Period|Adverse Event|7
6188354|NCT01392300|9843100|FG000|Open Label Extension (OLEX) Period|Withdrawal by Subject|0
6188355|NCT01392300|9843101|FG001|Open Label Extension (OLEX) Period|Withdrawal by Subject|0
6188356|NCT01392300|9843102|FG002|Open Label Extension (OLEX) Period|Withdrawal by Subject|17
6188357|NCT01392300|9843100|FG000|Open Label Extension (OLEX) Period|Lost to Follow-up|0
6188358|NCT01392300|9843101|FG001|Open Label Extension (OLEX) Period|Lost to Follow-up|0
6188359|NCT01392300|9843102|FG002|Open Label Extension (OLEX) Period|Lost to Follow-up|6
6188360|NCT01392326|9843112|FG000|Overall Study|Death|2
6188361|NCT01392326|9843113|FG001|Overall Study|Death|0
6188362|NCT01392326|9843114|FG002|Overall Study|Death|0
6188363|NCT01392326|9843112|FG000|Overall Study|Withdrawal by Subject|12
6188364|NCT01392326|9843113|FG001|Overall Study|Withdrawal by Subject|11
6188365|NCT01392326|9843114|FG002|Overall Study|Withdrawal by Subject|15
6188366|NCT01392326|9843112|FG000|Overall Study|Protocol Violation|2
6188367|NCT01392326|9843113|FG001|Overall Study|Protocol Violation|0
6188368|NCT01392326|9843114|FG002|Overall Study|Protocol Violation|0
6188369|NCT01392326|9843112|FG000|Overall Study|Pregnancy|0
6188370|NCT01392326|9843113|FG001|Overall Study|Pregnancy|0
6188371|NCT01392326|9843114|FG002|Overall Study|Pregnancy|1
6188372|NCT01392326|9843112|FG000|Overall Study|Physician Decision|7
6188373|NCT01392326|9843113|FG001|Overall Study|Physician Decision|5
6188374|NCT01392326|9843114|FG002|Overall Study|Physician Decision|2
6188375|NCT01392326|9843112|FG000|Overall Study|Lost to Follow-up|1
6188376|NCT01392326|9843113|FG001|Overall Study|Lost to Follow-up|3
6188377|NCT01392326|9843114|FG002|Overall Study|Lost to Follow-up|4
6188378|NCT01392326|9843112|FG000|Overall Study|Lack of Efficacy|14
6188379|NCT01392326|9843113|FG001|Overall Study|Lack of Efficacy|10
6188380|NCT01392326|9843114|FG002|Overall Study|Lack of Efficacy|15
6188381|NCT01392326|9843112|FG000|Overall Study|Adverse Event|9
6188382|NCT01392326|9843113|FG001|Overall Study|Adverse Event|6
6235266|NCT01791517|9913219|FG007|Phase II|Unsatisfactory Lens Fitting|0
6188383|NCT01392326|9843114|FG002|Overall Study|Adverse Event|11
6188384|NCT01392378|9843127|FG000|Infant Series|Adverse Event|0
6188385|NCT01392378|9843128|FG001|Infant Series|Adverse Event|0
6188386|NCT01392378|9843129|FG002|Infant Series|Adverse Event|0
6188387|NCT01392378|9843130|FG003|Infant Series|Adverse Event|1
6188388|NCT01392378|9843131|FG004|Infant Series|Adverse Event|0
6188389|NCT01392378|9843127|FG000|Infant Series|Lost to Follow-up|0
6235267|NCT01791517|9913220|FG008|Phase II|Unsatisfactory Lens Fitting|0
6235268|NCT01791517|9913221|FG009|Phase II|Unsatisfactory Lens Fitting|1
6188390|NCT01392378|9843128|FG001|Infant Series|Lost to Follow-up|0
6188391|NCT01392378|9843129|FG002|Infant Series|Lost to Follow-up|0
6188392|NCT01392378|9843130|FG003|Infant Series|Lost to Follow-up|1
6188393|NCT01392378|9843131|FG004|Infant Series|Lost to Follow-up|0
6188394|NCT01392378|9843127|FG000|Infant Series|Protocol Violation|0
6188395|NCT01392378|9843128|FG001|Infant Series|Protocol Violation|1
6188396|NCT01392378|9843129|FG002|Infant Series|Protocol Violation|0
6188397|NCT01392378|9843130|FG003|Infant Series|Protocol Violation|0
6188398|NCT01392378|9843131|FG004|Infant Series|Protocol Violation|0
6188399|NCT01392378|9843127|FG000|Infant Series|Withdrawal by Parent|4
6188400|NCT01392378|9843128|FG001|Infant Series|Withdrawal by Parent|1
6188401|NCT01392378|9843129|FG002|Infant Series|Withdrawal by Parent|0
6188402|NCT01392378|9843130|FG003|Infant Series|Withdrawal by Parent|0
6188403|NCT01392378|9843131|FG004|Infant Series|Withdrawal by Parent|0
6188404|NCT01392378|9843127|FG000|After Infant Series|Lost to Follow-up|0
6188405|NCT01392378|9843128|FG001|After Infant Series|Lost to Follow-up|0
6188406|NCT01392378|9843129|FG002|After Infant Series|Lost to Follow-up|1
6188407|NCT01392378|9843130|FG003|After Infant Series|Lost to Follow-up|0
6188408|NCT01392378|9843131|FG004|After Infant Series|Lost to Follow-up|0
6188409|NCT01392378|9843127|FG000|After Infant Series|Withdrawal by Parent|0
6188410|NCT01392378|9843128|FG001|After Infant Series|Withdrawal by Parent|1
6188411|NCT01392378|9843129|FG002|After Infant Series|Withdrawal by Parent|1
6188412|NCT01392378|9843130|FG003|After Infant Series|Withdrawal by Parent|0
6188413|NCT01392378|9843131|FG004|After Infant Series|Withdrawal by Parent|1
6188414|NCT01392378|9843127|FG000|Toddler Dose|Lost to Follow-up|0
6188415|NCT01392378|9843128|FG001|Toddler Dose|Lost to Follow-up|0
6188416|NCT01392378|9843129|FG002|Toddler Dose|Lost to Follow-up|0
6188417|NCT01392378|9843130|FG003|Toddler Dose|Lost to Follow-up|1
6188418|NCT01392378|9843131|FG004|Toddler Dose|Lost to Follow-up|0
6188419|NCT01392378|9843127|FG000|Toddler Dose|Withdrawal by Parent|0
6188420|NCT01392378|9843128|FG001|Toddler Dose|Withdrawal by Parent|1
6188421|NCT01392378|9843129|FG002|Toddler Dose|Withdrawal by Parent|0
6188422|NCT01392378|9843130|FG003|Toddler Dose|Withdrawal by Parent|1
6188423|NCT01392378|9843131|FG004|Toddler Dose|Withdrawal by Parent|1
6188424|NCT01392443|9843153|FG000|Overall Study|Disease progression|30
6188425|NCT01392443|9843153|FG000|Overall Study|Adverse Event|24
6188426|NCT01392443|9843153|FG000|Overall Study|Death|7
6188427|NCT01392443|9843153|FG000|Overall Study|Withdrawal by Subject|5
6188428|NCT01392443|9843153|FG000|Overall Study|Lost to Follow-up|1
6188429|NCT01392443|9843153|FG000|Overall Study|Protocol Violation|1
6188430|NCT01392469|9843157|FG000|Overall Study|Adverse Event|2
6188431|NCT01392469|9843157|FG000|Overall Study|Withdrawal by Subject|1
6188432|NCT01392469|9843157|FG000|Overall Study|Protocol Violation|1
6188433|NCT01392495|9843172|FG000|Overall Study|Death|3
6188434|NCT01392495|9843172|FG000|Overall Study|Administrative problems|8
6188435|NCT01392495|9843172|FG000|Overall Study|Withdrawal by Subject|2
6188436|NCT01392495|9843172|FG000|Overall Study|Adverse Event|3
6188437|NCT01392547|9843178|FG000|Overall Study|Adverse Event|2
6188438|NCT01392547|9843178|FG000|Overall Study|Non-compliance|2
6188439|NCT01392547|9843178|FG000|Overall Study|Withdrawal criteria|3
6188440|NCT01392547|9843178|FG000|Overall Study|Unclassified|1
6188441|NCT01392560|9843184|FG000|Overall Study|Adverse Event|2
6188442|NCT01392560|9843184|FG000|Overall Study|not entered|8
6188443|NCT01392560|9843184|FG000|Overall Study|discontinued during placebo run-in|2
6188444|NCT01392573|9843192|FG000|Overall Study|Adverse Event|1
6188445|NCT01392573|9843193|FG001|Overall Study|Adverse Event|3
6188446|NCT01392573|9843192|FG000|Overall Study|Lack of Efficacy|1
6188447|NCT01392573|9843193|FG001|Overall Study|Lack of Efficacy|2
6188448|NCT01392573|9843192|FG000|Overall Study|Protocol Violation|0
6188449|NCT01392573|9843193|FG001|Overall Study|Protocol Violation|2
6188450|NCT01392573|9843192|FG000|Overall Study|Withdrawal Criteria|13
6188451|NCT01392573|9843193|FG001|Overall Study|Withdrawal Criteria|15
6188452|NCT01392573|9843192|FG000|Overall Study|Site closure|8
6188453|NCT01392573|9843193|FG001|Overall Study|Site closure|7
6188454|NCT01392573|9843192|FG000|Overall Study|Unclassified|9
6188455|NCT01392573|9843193|FG001|Overall Study|Unclassified|6
6188456|NCT01392677|9843210|FG000|Overall Study|Adverse Event|3
6188457|NCT01392677|9843211|FG001|Overall Study|Adverse Event|1
6188458|NCT01392677|9843210|FG000|Overall Study|Withdrawal by Subject|0
6188459|NCT01392677|9843211|FG001|Overall Study|Withdrawal by Subject|2
6188460|NCT01392677|9843210|FG000|Overall Study|Incorrect enrollment|2
6188461|NCT01392677|9843211|FG001|Overall Study|Incorrect enrollment|3
6188462|NCT01392677|9843210|FG000|Overall Study|Other reason|3
6188463|NCT01392677|9843211|FG001|Overall Study|Other reason|2
6188464|NCT01392742|9843229|FG000|Overall Study|Premature study termination|42
6188465|NCT01392742|9843229|FG000|Overall Study|Failure to return|35
6188466|NCT01392742|9843229|FG000|Overall Study|No treatment/no cooperation/withdrew|12
6188467|NCT01392742|9843229|FG000|Overall Study|Lost to Follow-up|34
6188468|NCT01392742|9843229|FG000|Overall Study|Insufficient therapeutic response (ITR)|30
6188469|NCT01392742|9843229|FG000|Overall Study|ITR and Protocol deviation|1
6188470|NCT01392742|9843229|FG000|Overall Study|Adverse event/intercurrent illness|17
6188471|NCT01392742|9843229|FG000|Overall Study|Protocol Violation|14
6188472|NCT01392742|9843229|FG000|Overall Study|Other|3
6188473|NCT01392742|9843229|FG000|Overall Study|Missing information|13
6235269|NCT01791517|9913222|FG010|Phase II|Unsatisfactory Lens Fitting|0
6235270|NCT01791517|9913223|FG011|Phase II|Unsatisfactory Lens Fitting|0
6235271|NCT01791517|9913212|FG000|Phase II|Pre-Existing Ocular Issue|0
6235272|NCT01791517|9913213|FG001|Phase II|Pre-Existing Ocular Issue|0
6235273|NCT01791517|9913214|FG002|Phase II|Pre-Existing Ocular Issue|0
6188474|NCT01392963|9843243|FG000|Week 0 (First Intervention)|Lost to Follow-up|0
6188475|NCT01392963|9843244|FG001|Week 0 (First Intervention)|Lost to Follow-up|1
6188476|NCT01392963|9843243|FG000|Week 0 (First Intervention)|Withdrawal by Subject|0
6188477|NCT01392963|9843244|FG001|Week 0 (First Intervention)|Withdrawal by Subject|1
6188478|NCT01392963|9843243|FG000|Week 24 Follow-up|Lost to Follow-up|2
6188479|NCT01392963|9843244|FG001|Week 24 Follow-up|Lost to Follow-up|0
6188480|NCT01393106|9843257|FG000|Overall Study|Adverse Event|3
6188481|NCT01393106|9843257|FG000|Overall Study|Withdrawal by Subject|1
6188482|NCT01393106|9843257|FG000|Overall Study|Lack of Efficacy|1
6188483|NCT01393158|9843274|FG000|Overall Study|Adverse Event|1
6188484|NCT01393158|9843275|FG001|Overall Study|Adverse Event|0
6193200|NCT01436357|9850804|FG000|Overall Study|Incarceration|18
6193201|NCT01436357|9850805|FG001|Overall Study|Incarceration|20
6193202|NCT01436357|9850804|FG000|Overall Study|Lost to Follow-up|67
6193203|NCT01436357|9850805|FG001|Overall Study|Lost to Follow-up|61
6193204|NCT01436357|9850804|FG000|Overall Study|Protocol Violation|1
6193205|NCT01436357|9850805|FG001|Overall Study|Protocol Violation|0
6193206|NCT01436357|9850804|FG000|Overall Study|Withdrawal by Subject|26
6193207|NCT01436357|9850805|FG001|Overall Study|Withdrawal by Subject|38
6193208|NCT01436357|9850804|FG000|Overall Study|Physician Decision|3
6193209|NCT01436357|9850805|FG001|Overall Study|Physician Decision|4
6193210|NCT01436357|9850804|FG000|Overall Study|Moved out of area|1
6193211|NCT01436357|9850805|FG001|Overall Study|Moved out of area|2
6193212|NCT01436357|9850804|FG000|Overall Study|Subject in rehab|0
6193213|NCT01436357|9850805|FG001|Overall Study|Subject in rehab|1
6193214|NCT01436370|9850819|FG000|Overall Study|Lost to Follow-up|0
6193215|NCT01436370|9850820|FG001|Overall Study|Lost to Follow-up|0
6193216|NCT01436370|9850821|FG002|Overall Study|Lost to Follow-up|0
6193217|NCT01436370|9850822|FG003|Overall Study|Lost to Follow-up|0
6193218|NCT01436370|9850823|FG004|Overall Study|Lost to Follow-up|1
6193219|NCT01436370|9850824|FG005|Overall Study|Lost to Follow-up|0
6193220|NCT01436370|9850825|FG006|Overall Study|Lost to Follow-up|0
6193221|NCT01436370|9850826|FG007|Overall Study|Lost to Follow-up|0
6193222|NCT01436500|9850858|FG000|Overall Study|Death|1
6193223|NCT01436500|9850859|FG001|Overall Study|Death|0
6193224|NCT01436500|9850860|FG002|Overall Study|Death|0
6193225|NCT01436500|9850861|FG003|Overall Study|Death|0
6193226|NCT01436500|9850862|FG004|Overall Study|Death|0
6193227|NCT01436500|9850858|FG000|Overall Study|Adverse Event|0
6193228|NCT01436500|9850859|FG001|Overall Study|Adverse Event|2
6193229|NCT01436500|9850860|FG002|Overall Study|Adverse Event|2
6193230|NCT01436500|9850861|FG003|Overall Study|Adverse Event|0
6193231|NCT01436500|9850862|FG004|Overall Study|Adverse Event|1
6193232|NCT01436500|9850858|FG000|Overall Study|Withdrawal by Subject|0
6193233|NCT01436500|9850859|FG001|Overall Study|Withdrawal by Subject|0
6193234|NCT01436500|9850860|FG002|Overall Study|Withdrawal by Subject|2
6193235|NCT01436500|9850861|FG003|Overall Study|Withdrawal by Subject|0
6193236|NCT01436500|9850862|FG004|Overall Study|Withdrawal by Subject|2
6193237|NCT01436500|9850858|FG000|Overall Study|Physician Decision|0
6193238|NCT01436500|9850859|FG001|Overall Study|Physician Decision|0
6193239|NCT01436500|9850860|FG002|Overall Study|Physician Decision|1
6193240|NCT01436500|9850861|FG003|Overall Study|Physician Decision|0
6193241|NCT01436500|9850862|FG004|Overall Study|Physician Decision|0
6193242|NCT01436500|9850858|FG000|Overall Study|liver transplant|1
6193243|NCT01436500|9850859|FG001|Overall Study|liver transplant|0
6193244|NCT01436500|9850860|FG002|Overall Study|liver transplant|0
6193245|NCT01436500|9850861|FG003|Overall Study|liver transplant|0
6193246|NCT01436500|9850862|FG004|Overall Study|liver transplant|0
6193247|NCT01436500|9850858|FG000|Overall Study|initiation of dialysis|0
6193248|NCT01436500|9850859|FG001|Overall Study|initiation of dialysis|0
6193249|NCT01436500|9850860|FG002|Overall Study|initiation of dialysis|0
6193250|NCT01436500|9850861|FG003|Overall Study|initiation of dialysis|0
6193251|NCT01436500|9850862|FG004|Overall Study|initiation of dialysis|1
6193252|NCT01436500|9850858|FG000|Overall Study|discontinued study drug|1
6193253|NCT01436500|9850859|FG001|Overall Study|discontinued study drug|0
6193254|NCT01436500|9850860|FG002|Overall Study|discontinued study drug|0
6193255|NCT01436500|9850861|FG003|Overall Study|discontinued study drug|0
6193256|NCT01436500|9850862|FG004|Overall Study|discontinued study drug|0
6193257|NCT01436500|9850858|FG000|Overall Study|Other|0
6193258|NCT01436500|9850859|FG001|Overall Study|Other|1
6193259|NCT01436500|9850860|FG002|Overall Study|Other|0
6193260|NCT01436500|9850861|FG003|Overall Study|Other|1
6193261|NCT01436500|9850862|FG004|Overall Study|Other|0
6193377|NCT01438060|9851069|FG000|Acute Phase: Double-blind, 10 Weeks|Adverse Event|7
6193378|NCT01438060|9851070|FG001|Acute Phase: Double-blind, 10 Weeks|Adverse Event|9
6193379|NCT01438060|9851069|FG000|Acute Phase: Double-blind, 10 Weeks|Lack of Efficacy|6
6235274|NCT01791517|9913215|FG003|Phase II|Pre-Existing Ocular Issue|0
6193380|NCT01438060|9851070|FG001|Acute Phase: Double-blind, 10 Weeks|Lack of Efficacy|3
6193381|NCT01438060|9851069|FG000|Acute Phase: Double-blind, 10 Weeks|Withdrawal by Subject|3
6193382|NCT01438060|9851070|FG001|Acute Phase: Double-blind, 10 Weeks|Withdrawal by Subject|4
6235275|NCT01791517|9913216|FG004|Phase II|Pre-Existing Ocular Issue|0
6235276|NCT01791517|9913217|FG005|Phase II|Pre-Existing Ocular Issue|0
6235277|NCT01791517|9913218|FG006|Phase II|Pre-Existing Ocular Issue|0
6235278|NCT01791517|9913219|FG007|Phase II|Pre-Existing Ocular Issue|0
6235279|NCT01791517|9913220|FG008|Phase II|Pre-Existing Ocular Issue|0
6235280|NCT01791517|9913221|FG009|Phase II|Pre-Existing Ocular Issue|0
6235281|NCT01791517|9913222|FG010|Phase II|Pre-Existing Ocular Issue|0
6235282|NCT01791517|9913223|FG011|Phase II|Pre-Existing Ocular Issue|1
6235283|NCT01791725|9913244|FG000|Overall Study|Withdrawal by Subject|0
6235284|NCT01791725|9913245|FG001|Overall Study|Withdrawal by Subject|1
6235285|NCT01791725|9913246|FG002|Overall Study|Withdrawal by Subject|0
6235286|NCT01791803|9913258|FG000|Overall Study|Withdrawal by Subject|0
6235287|NCT01791803|9913259|FG001|Overall Study|Withdrawal by Subject|0
6235288|NCT01791803|9913260|FG002|Overall Study|Withdrawal by Subject|0
6235289|NCT01791803|9913261|FG003|Overall Study|Withdrawal by Subject|2
6235290|NCT01791803|9913258|FG000|Overall Study|Physician Decision|0
6235291|NCT01791803|9913259|FG001|Overall Study|Physician Decision|2
6235292|NCT01791803|9913260|FG002|Overall Study|Physician Decision|0
6235293|NCT01791803|9913261|FG003|Overall Study|Physician Decision|1
6235294|NCT01791803|9913258|FG000|Overall Study|Death|0
6235295|NCT01791803|9913259|FG001|Overall Study|Death|0
6235296|NCT01791803|9913260|FG002|Overall Study|Death|2
6235297|NCT01791803|9913261|FG003|Overall Study|Death|2
6235298|NCT01791894|9913274|FG000|Overall Study|Adverse Event|1
6235299|NCT01792115|9913295|FG000|Overall Study|Lost to Follow-up|0
6235300|NCT01792115|9913296|FG001|Overall Study|Lost to Follow-up|1
6235301|NCT01792115|9913297|FG002|Overall Study|Lost to Follow-up|0
6235302|NCT01792284|9913305|FG000|Lead-in Period|Adverse Event|15
6235303|NCT01792284|9913306|FG001|Lead-in Period|Adverse Event|0
6235304|NCT01792284|9913307|FG002|Lead-in Period|Adverse Event|0
6235305|NCT01792284|9913305|FG000|Lead-in Period|Lost to Follow-up|2
6235306|NCT01792284|9913306|FG001|Lead-in Period|Lost to Follow-up|0
6235307|NCT01792284|9913307|FG002|Lead-in Period|Lost to Follow-up|0
6235308|NCT01792284|9913305|FG000|Lead-in Period|Protocol Violation|1
6235309|NCT01792284|9913306|FG001|Lead-in Period|Protocol Violation|0
6235310|NCT01792284|9913307|FG002|Lead-in Period|Protocol Violation|0
6235311|NCT01792284|9913305|FG000|Lead-in Period|Withdrawal by Subject|10
6235312|NCT01792284|9913306|FG001|Lead-in Period|Withdrawal by Subject|0
6235313|NCT01792284|9913307|FG002|Lead-in Period|Withdrawal by Subject|0
6235314|NCT01792284|9913305|FG000|Lead-in Period|Physician Decision|1
6235315|NCT01792284|9913306|FG001|Lead-in Period|Physician Decision|0
6235316|NCT01792284|9913307|FG002|Lead-in Period|Physician Decision|0
6235317|NCT01792284|9913305|FG000|Lead-in Period|Protocol Required Discontinuation|1
6235318|NCT01792284|9913306|FG001|Lead-in Period|Protocol Required Discontinuation|0
6235319|NCT01792284|9913307|FG002|Lead-in Period|Protocol Required Discontinuation|0
6235320|NCT01792284|9913305|FG000|Randomization Period 1|Withdrawal by Subject|0
6235321|NCT01792284|9913306|FG001|Randomization Period 1|Withdrawal by Subject|1
6235322|NCT01792284|9913307|FG002|Randomization Period 1|Withdrawal by Subject|1
6235323|NCT01792284|9913305|FG000|Randomization Period 1|Physician Decision|0
6235324|NCT01792284|9913306|FG001|Randomization Period 1|Physician Decision|1
6235325|NCT01792284|9913307|FG002|Randomization Period 1|Physician Decision|1
6235326|NCT01792284|9913305|FG000|Randomization Period 1|Adverse Event|0
6235327|NCT01792284|9913306|FG001|Randomization Period 1|Adverse Event|0
6235328|NCT01792284|9913307|FG002|Randomization Period 1|Adverse Event|2
6235329|NCT01792284|9913305|FG000|Randomization Period 1|Lost to Follow-up|0
6235330|NCT01792284|9913306|FG001|Randomization Period 1|Lost to Follow-up|0
6235331|NCT01792284|9913307|FG002|Randomization Period 1|Lost to Follow-up|1
6235332|NCT01792284|9913305|FG000|Randomization Period 2|Protocol Violation|0
6235333|NCT01792284|9913306|FG001|Randomization Period 2|Protocol Violation|1
6235334|NCT01792284|9913307|FG002|Randomization Period 2|Protocol Violation|0
6235335|NCT01792284|9913305|FG000|Randomization Period 2|Withdrawal by Subject|0
6235336|NCT01792284|9913306|FG001|Randomization Period 2|Withdrawal by Subject|2
6235337|NCT01792284|9913307|FG002|Randomization Period 2|Withdrawal by Subject|0
6235338|NCT01792518|9913317|FG000|Overall Study|Adverse Event|3
6235339|NCT01792518|9913318|FG001|Overall Study|Adverse Event|4
6235340|NCT01792518|9913317|FG000|Overall Study|Protocol Violation|0
6235341|NCT01792518|9913318|FG001|Overall Study|Protocol Violation|1
6235342|NCT01792518|9913317|FG000|Overall Study|Lost to Follow-up|3
6235343|NCT01792518|9913318|FG001|Overall Study|Lost to Follow-up|1
6235344|NCT01792518|9913317|FG000|Overall Study|Withdrawal by Subject|2
6235345|NCT01792518|9913318|FG001|Overall Study|Withdrawal by Subject|0
6235346|NCT01792518|9913317|FG000|Overall Study|Other Reason|0
6235347|NCT01792518|9913318|FG001|Overall Study|Other Reason|1
6235348|NCT01792635|9913327|FG000|Part B|Adverse Event|0
6235349|NCT01792635|9913328|FG001|Part B|Adverse Event|0
6235350|NCT01792635|9913329|FG002|Part B|Adverse Event|1
6235351|NCT01792635|9913327|FG000|Part B|Study terminated|0
6235352|NCT01792635|9913328|FG001|Part B|Study terminated|4
6235353|NCT01792635|9913329|FG002|Part B|Study terminated|3
6235354|NCT01792830|9913360|FG000|Overall Study|Withdrawal by Subject|22
6235355|NCT01792830|9913361|FG001|Overall Study|Withdrawal by Subject|0
6235356|NCT01792830|9913362|FG002|Overall Study|Withdrawal by Subject|0
6235357|NCT01792830|9913363|FG003|Overall Study|Withdrawal by Subject|2
6235358|NCT01792830|9913364|FG004|Overall Study|Withdrawal by Subject|1
6235359|NCT01792830|9913365|FG005|Overall Study|Withdrawal by Subject|1
6235360|NCT01792830|9913366|FG006|Overall Study|Withdrawal by Subject|1
6235361|NCT01792830|9913367|FG007|Overall Study|Withdrawal by Subject|1
6235362|NCT01792830|9913368|FG008|Overall Study|Withdrawal by Subject|7
6235363|NCT01792830|9913369|FG009|Overall Study|Withdrawal by Subject|0
6235364|NCT01792830|9913370|FG010|Overall Study|Withdrawal by Subject|2
6235365|NCT01792830|9913360|FG000|Overall Study|Death|3
6235366|NCT01792830|9913361|FG001|Overall Study|Death|0
6235367|NCT01792830|9913362|FG002|Overall Study|Death|0
6235368|NCT01792830|9913363|FG003|Overall Study|Death|1
6235369|NCT01792830|9913364|FG004|Overall Study|Death|0
6235370|NCT01792830|9913365|FG005|Overall Study|Death|0
6235371|NCT01792830|9913366|FG006|Overall Study|Death|1
6235372|NCT01792830|9913367|FG007|Overall Study|Death|0
6235373|NCT01792830|9913368|FG008|Overall Study|Death|1
6235374|NCT01792830|9913369|FG009|Overall Study|Death|0
6235375|NCT01792830|9913370|FG010|Overall Study|Death|1
6235376|NCT01792830|9913360|FG000|Overall Study|Adverse Event|0
6235377|NCT01792830|9913361|FG001|Overall Study|Adverse Event|0
6235378|NCT01792830|9913362|FG002|Overall Study|Adverse Event|0
6235379|NCT01792830|9913363|FG003|Overall Study|Adverse Event|0
6235380|NCT01792830|9913364|FG004|Overall Study|Adverse Event|0
6235381|NCT01792830|9913365|FG005|Overall Study|Adverse Event|0
6235382|NCT01792830|9913366|FG006|Overall Study|Adverse Event|0
6235383|NCT01792830|9913367|FG007|Overall Study|Adverse Event|0
6235384|NCT01792830|9913368|FG008|Overall Study|Adverse Event|1
6235385|NCT01792830|9913369|FG009|Overall Study|Adverse Event|0
6235386|NCT01792830|9913370|FG010|Overall Study|Adverse Event|0
6188485|NCT01393301|9843289|FG000|Overall Study|Lost to Follow-up|5
6188486|NCT01393301|9843290|FG001|Overall Study|Lost to Follow-up|3
6188487|NCT01393301|9843289|FG000|Overall Study|Withdrawal by Subject|2
6188488|NCT01393301|9843290|FG001|Overall Study|Withdrawal by Subject|0
6188489|NCT01393301|9843289|FG000|Overall Study|Completed <7 sessions (intervention)|2
6188490|NCT01393301|9843290|FG001|Overall Study|Completed <7 sessions (intervention)|0
6188491|NCT01393405|9843305|FG000|Induction Period (week1-16)|Lack of Efficacy|70
6188492|NCT01393405|9843306|FG001|Induction Period (week1-16)|Lack of Efficacy|0
6188493|NCT01393405|9843307|FG002|Induction Period (week1-16)|Lack of Efficacy|0
6188494|NCT01393405|9843305|FG000|Induction Period (week1-16)|Adverse Event|16
6188495|NCT01393405|9843306|FG001|Induction Period (week1-16)|Adverse Event|0
6188496|NCT01393405|9843307|FG002|Induction Period (week1-16)|Adverse Event|0
6188497|NCT01393405|9843305|FG000|Induction Period (week1-16)|Withdrawal by Subject|9
6188498|NCT01393405|9843306|FG001|Induction Period (week1-16)|Withdrawal by Subject|0
6188499|NCT01393405|9843307|FG002|Induction Period (week1-16)|Withdrawal by Subject|0
6188500|NCT01393405|9843305|FG000|Maintenance Period Week|Lack of Efficacy|0
6188501|NCT01393405|9843306|FG001|Maintenance Period Week|Lack of Efficacy|22
6188502|NCT01393405|9843307|FG002|Maintenance Period Week|Lack of Efficacy|22
6188503|NCT01393405|9843305|FG000|Maintenance Period Week|Adverse Event|0
6188504|NCT01393405|9843306|FG001|Maintenance Period Week|Adverse Event|5
6188505|NCT01393405|9843307|FG002|Maintenance Period Week|Adverse Event|2
6188506|NCT01393405|9843305|FG000|Maintenance Period Week|Withdrawal by Subject|0
6188507|NCT01393405|9843306|FG001|Maintenance Period Week|Withdrawal by Subject|1
6188508|NCT01393405|9843307|FG002|Maintenance Period Week|Withdrawal by Subject|0
6188509|NCT01393405|9843305|FG000|Maintenance Period Week|Lost to Follow-up|0
6188510|NCT01393405|9843306|FG001|Maintenance Period Week|Lost to Follow-up|1
6188511|NCT01393405|9843307|FG002|Maintenance Period Week|Lost to Follow-up|0
6188512|NCT01393444|9843317|FG000|Overall Study|Withdrawal by Subject|1
6188513|NCT01393444|9843317|FG000|Overall Study|Determined ineligible during screening.|2
6188514|NCT01393600|9843338|FG000|Treatment Period 1 (Day 1 to 14)|Protocol Violation|0
6188515|NCT01393600|9843339|FG001|Treatment Period 1 (Day 1 to 14)|Protocol Violation|1
6188516|NCT01393600|9843340|FG002|Treatment Period 1 (Day 1 to 14)|Protocol Violation|0
6188517|NCT01393600|9843341|FG003|Treatment Period 1 (Day 1 to 14)|Protocol Violation|0
6188518|NCT01393600|9843338|FG000|Treatment Period 1 (Day 1 to 14)|Withdrawal by Subject|0
6188519|NCT01393600|9843339|FG001|Treatment Period 1 (Day 1 to 14)|Withdrawal by Subject|0
6188520|NCT01393600|9843340|FG002|Treatment Period 1 (Day 1 to 14)|Withdrawal by Subject|1
6188521|NCT01393600|9843341|FG003|Treatment Period 1 (Day 1 to 14)|Withdrawal by Subject|0
6188522|NCT01393600|9843338|FG000|Treatment Period 1 (Day 1 to 14)|Adverse Event|0
6188523|NCT01393600|9843339|FG001|Treatment Period 1 (Day 1 to 14)|Adverse Event|0
6188524|NCT01393600|9843340|FG002|Treatment Period 1 (Day 1 to 14)|Adverse Event|0
6188525|NCT01393600|9843341|FG003|Treatment Period 1 (Day 1 to 14)|Adverse Event|1
6188526|NCT01393600|9843338|FG000|Treatment Period 2 (Day 15 to 28)|Withdrawal by Subject|0
6188527|NCT01393600|9843339|FG001|Treatment Period 2 (Day 15 to 28)|Withdrawal by Subject|0
6188528|NCT01393600|9843340|FG002|Treatment Period 2 (Day 15 to 28)|Withdrawal by Subject|0
6188529|NCT01393600|9843341|FG003|Treatment Period 2 (Day 15 to 28)|Withdrawal by Subject|1
6188530|NCT01393600|9843338|FG000|Treatment Period 2 (Day 15 to 28)|Lost to Follow-up|0
6235387|NCT01793051|9913406|FG000|Overall Study|Withdrawal by Subject|6
6235388|NCT01793051|9913407|FG001|Overall Study|Withdrawal by Subject|4
6235389|NCT01793051|9913406|FG000|Overall Study|Adverse Event|0
6235390|NCT01793051|9913407|FG001|Overall Study|Adverse Event|2
6235391|NCT01793051|9913406|FG000|Overall Study|Too ill to continue|1
6235392|NCT01793051|9913407|FG001|Overall Study|Too ill to continue|0
6235393|NCT01793051|9913406|FG000|Overall Study|Switched chemo|1
6235394|NCT01793051|9913407|FG001|Overall Study|Switched chemo|1
6235395|NCT01793051|9913406|FG000|Overall Study|Lack of compliance|1
6235396|NCT01793051|9913407|FG001|Overall Study|Lack of compliance|0
6235397|NCT01793051|9913406|FG000|Overall Study|Requested to be removed from the study|1
6235398|NCT01793051|9913407|FG001|Overall Study|Requested to be removed from the study|1
6235399|NCT01793142|9913413|FG000|Overall Study|Randomized not treated|7
6235400|NCT01793688|9913421|FG000|Overall Study|Protocol Violation|2
6235401|NCT01793792|9913425|FG000|Overall Study|Death|5
6235402|NCT01793792|9913425|FG000|Overall Study|Lost to Follow-up|5
6235403|NCT01793792|9913425|FG000|Overall Study|Withdrawal by Subject|1
6235404|NCT01793792|9913425|FG000|Overall Study|Device Not Implanted|1
6235405|NCT01793883|9913432|FG000|Overall Study|Withdrawal by Subject|3
6188531|NCT01393600|9843339|FG001|Treatment Period 2 (Day 15 to 28)|Lost to Follow-up|0
6188532|NCT01393600|9843340|FG002|Treatment Period 2 (Day 15 to 28)|Lost to Follow-up|1
6188533|NCT01393600|9843341|FG003|Treatment Period 2 (Day 15 to 28)|Lost to Follow-up|0
6188534|NCT01393600|9843338|FG000|Treatment Period 2 (Day 15 to 28)|Physician Decision|0
6188535|NCT01393600|9843339|FG001|Treatment Period 2 (Day 15 to 28)|Physician Decision|0
6188536|NCT01393600|9843340|FG002|Treatment Period 2 (Day 15 to 28)|Physician Decision|1
6188537|NCT01393600|9843341|FG003|Treatment Period 2 (Day 15 to 28)|Physician Decision|0
6188538|NCT01393600|9843338|FG000|Follow-up Period (Day 29 to 35)|Withdrawal by Subject|0
6235406|NCT01793883|9913433|FG001|Overall Study|Withdrawal by Subject|7
6235407|NCT01793883|9913434|FG002|Overall Study|Withdrawal by Subject|3
6235408|NCT01793883|9913432|FG000|Overall Study|Subject noncompliance|0
6235409|NCT01793883|9913433|FG001|Overall Study|Subject noncompliance|1
6235410|NCT01793883|9913434|FG002|Overall Study|Subject noncompliance|1
6235411|NCT01793883|9913432|FG000|Overall Study|Lost to Follow-up|5
6235412|NCT01793883|9913433|FG001|Overall Study|Lost to Follow-up|1
6235413|NCT01793883|9913434|FG002|Overall Study|Lost to Follow-up|3
6235414|NCT01793883|9913432|FG000|Overall Study|Randomized in error|1
6235415|NCT01793883|9913433|FG001|Overall Study|Randomized in error|0
6235416|NCT01793883|9913434|FG002|Overall Study|Randomized in error|0
6235417|NCT01793883|9913432|FG000|Overall Study|Unable to complete spriometry|1
6235418|NCT01793883|9913433|FG001|Overall Study|Unable to complete spriometry|0
6235419|NCT01793883|9913434|FG002|Overall Study|Unable to complete spriometry|0
6235420|NCT01793883|9913432|FG000|Overall Study|Unable to complete measurements|1
6235421|NCT01793883|9913433|FG001|Overall Study|Unable to complete measurements|0
6235422|NCT01793883|9913434|FG002|Overall Study|Unable to complete measurements|0
6235423|NCT01793883|9913432|FG000|Overall Study|Met exclusion criteria|1
6235424|NCT01793883|9913433|FG001|Overall Study|Met exclusion criteria|0
6235425|NCT01793883|9913434|FG002|Overall Study|Met exclusion criteria|0
6235426|NCT01793883|9913432|FG000|Overall Study|Dosing error|0
6235427|NCT01793883|9913433|FG001|Overall Study|Dosing error|1
6235428|NCT01793883|9913434|FG002|Overall Study|Dosing error|0
6235429|NCT01793883|9913432|FG000|Overall Study|Respiratory distress during spirometry|0
6235430|NCT01793883|9913433|FG001|Overall Study|Respiratory distress during spirometry|0
6235431|NCT01793883|9913434|FG002|Overall Study|Respiratory distress during spirometry|1
6235432|NCT01793935|9913453|FG000|Overall Study|Pregnancy|1
6235433|NCT01793935|9913454|FG001|Overall Study|Pregnancy|0
6235434|NCT01793935|9913453|FG000|Overall Study|Protocol Violation|2
6235435|NCT01793935|9913454|FG001|Overall Study|Protocol Violation|1
6235436|NCT01793935|9913453|FG000|Overall Study|Adverse Event|2
6235437|NCT01793935|9913454|FG001|Overall Study|Adverse Event|0
6235438|NCT01793935|9913453|FG000|Overall Study|Patient did not take study medication|1
6235439|NCT01793935|9913454|FG001|Overall Study|Patient did not take study medication|1
6235440|NCT01793935|9913453|FG000|Overall Study|Lost to Follow-up|0
6235441|NCT01793935|9913454|FG001|Overall Study|Lost to Follow-up|1
6235442|NCT01794000|9913462|FG000|Double-Blind Phase (DBP)|Adverse Event|5
6235443|NCT01794000|9913463|FG001|Double-Blind Phase (DBP)|Adverse Event|2
6235444|NCT01794000|9913462|FG000|Double-Blind Phase (DBP)|Death|1
6235445|NCT01794000|9913463|FG001|Double-Blind Phase (DBP)|Death|2
6235446|NCT01794000|9913462|FG000|Double-Blind Phase (DBP)|Entry Criteria Not Met|2
6235447|NCT01794000|9913463|FG001|Double-Blind Phase (DBP)|Entry Criteria Not Met|0
6235448|NCT01794000|9913462|FG000|Double-Blind Phase (DBP)|Parent/Caregiver Decision|5
6235449|NCT01794000|9913463|FG001|Double-Blind Phase (DBP)|Parent/Caregiver Decision|2
6235450|NCT01794000|9913462|FG000|Double-Blind Phase (DBP)|Physician Decision|2
6235451|NCT01794000|9913463|FG001|Double-Blind Phase (DBP)|Physician Decision|0
6235452|NCT01794000|9913462|FG000|Double-Blind Phase (DBP)|Sponsor Decision|148
6235453|NCT01794000|9913463|FG001|Double-Blind Phase (DBP)|Sponsor Decision|149
6235454|NCT01794000|9913462|FG000|Double-Blind Phase (DBP)|Withdrawal by Subject|6
6235455|NCT01794000|9913463|FG001|Double-Blind Phase (DBP)|Withdrawal by Subject|11
6235456|NCT01794000|9913462|FG000|Open-Label Extension Phase (OLE)|Sponsor Decision|3
6235457|NCT01794000|9913463|FG001|Open-Label Extension Phase (OLE)|Sponsor Decision|0
6235458|NCT01794117|9913485|FG000|Overall Study|Adverse Event|1
6235459|NCT01794117|9913486|FG001|Overall Study|Adverse Event|0
6235460|NCT01794117|9913487|FG002|Overall Study|Adverse Event|0
6235461|NCT01794117|9913488|FG003|Overall Study|Adverse Event|0
6235462|NCT01794117|9913485|FG000|Overall Study|Participant noncompliance|0
6235463|NCT01794117|9913486|FG001|Overall Study|Participant noncompliance|1
6235464|NCT01794117|9913487|FG002|Overall Study|Participant noncompliance|0
6235465|NCT01794117|9913488|FG003|Overall Study|Participant noncompliance|0
6235466|NCT01794117|9913485|FG000|Overall Study|Refused further treatment|0
6235467|NCT01794117|9913486|FG001|Overall Study|Refused further treatment|2
6235468|NCT01794117|9913487|FG002|Overall Study|Refused further treatment|0
6235469|NCT01794117|9913488|FG003|Overall Study|Refused further treatment|0
6235470|NCT01794299|9913499|FG000|Overall Study|ATIR manufacturing not possible|1
6235471|NCT01794299|9913499|FG000|Overall Study|Death|14
6235472|NCT01794299|9913499|FG000|Overall Study|Graft failure|1
6235473|NCT01794299|9913499|FG000|Overall Study|ATIR batch rejected|2
6235474|NCT01794299|9913499|FG000|Overall Study|Relapse|2
6235475|NCT01794299|9913499|FG000|Overall Study|Discontinued from active follow-up|1
6235476|NCT01794299|9913499|FG000|Overall Study|Relapse and rejection of ATIR batch|1
6235477|NCT01794689|9913525|FG000|Intervention 1 (2 Nights)|Withdrawal by Subject|3
6235478|NCT01794689|9913526|FG001|Intervention 1 (2 Nights)|Withdrawal by Subject|0
6235479|NCT01794689|9913527|FG002|Intervention 1 (2 Nights)|Withdrawal by Subject|2
6235480|NCT01794689|9913528|FG003|Intervention 1 (2 Nights)|Withdrawal by Subject|4
6235481|NCT01794689|9913525|FG000|Intervention 1 (2 Nights)|Protocol Violation|1
6235482|NCT01794689|9913526|FG001|Intervention 1 (2 Nights)|Protocol Violation|0
6235483|NCT01794689|9913527|FG002|Intervention 1 (2 Nights)|Protocol Violation|1
6235484|NCT01794689|9913528|FG003|Intervention 1 (2 Nights)|Protocol Violation|0
6235485|NCT01794689|9913525|FG000|Intervention 1 (2 Nights)|Physician Decision|1
6235486|NCT01794689|9913526|FG001|Intervention 1 (2 Nights)|Physician Decision|1
6235487|NCT01794689|9913527|FG002|Intervention 1 (2 Nights)|Physician Decision|0
6235488|NCT01794689|9913528|FG003|Intervention 1 (2 Nights)|Physician Decision|0
6235489|NCT01794689|9913525|FG000|Intervention 1 (2 Nights)|Adverse Event|0
6235490|NCT01794689|9913526|FG001|Intervention 1 (2 Nights)|Adverse Event|1
6235491|NCT01794689|9913527|FG002|Intervention 1 (2 Nights)|Adverse Event|0
6235492|NCT01794689|9913528|FG003|Intervention 1 (2 Nights)|Adverse Event|0
6235493|NCT01794780|9913574|FG000|Overall Study|Adverse Event|0
6235494|NCT01794780|9913575|FG001|Overall Study|Adverse Event|1
6235495|NCT01794780|9913576|FG002|Overall Study|Adverse Event|2
6235496|NCT01794780|9913577|FG003|Overall Study|Adverse Event|0
6235497|NCT01794780|9913578|FG004|Overall Study|Adverse Event|0
6235498|NCT01794780|9913579|FG005|Overall Study|Adverse Event|0
6235499|NCT01794780|9913580|FG006|Overall Study|Adverse Event|0
6235500|NCT01794780|9913581|FG007|Overall Study|Adverse Event|0
6235501|NCT01794780|9913574|FG000|Overall Study|Death|0
6235502|NCT01794780|9913575|FG001|Overall Study|Death|2
6235503|NCT01794780|9913576|FG002|Overall Study|Death|14
6235504|NCT01794780|9913577|FG003|Overall Study|Death|1
6235505|NCT01794780|9913578|FG004|Overall Study|Death|0
6235506|NCT01794780|9913579|FG005|Overall Study|Death|9
6235507|NCT01794780|9913580|FG006|Overall Study|Death|4
6235508|NCT01794780|9913581|FG007|Overall Study|Death|0
6235509|NCT01794780|9913574|FG000|Overall Study|Lost to Follow-up|10
6235510|NCT01794780|9913575|FG001|Overall Study|Lost to Follow-up|64
6235511|NCT01794780|9913576|FG002|Overall Study|Lost to Follow-up|165
6235512|NCT01794780|9913577|FG003|Overall Study|Lost to Follow-up|53
6235513|NCT01794780|9913578|FG004|Overall Study|Lost to Follow-up|2
6235514|NCT01794780|9913579|FG005|Overall Study|Lost to Follow-up|99
6235515|NCT01794780|9913580|FG006|Overall Study|Lost to Follow-up|30
6235516|NCT01794780|9913581|FG007|Overall Study|Lost to Follow-up|5
6235517|NCT01794780|9913574|FG000|Overall Study|Withdrew informed consent|7
6235518|NCT01794780|9913575|FG001|Overall Study|Withdrew informed consent|17
6235519|NCT01794780|9913576|FG002|Overall Study|Withdrew informed consent|36
6235520|NCT01794780|9913577|FG003|Overall Study|Withdrew informed consent|9
6235521|NCT01794780|9913578|FG004|Overall Study|Withdrew informed consent|0
6235522|NCT01794780|9913579|FG005|Overall Study|Withdrew informed consent|48
6235523|NCT01794780|9913580|FG006|Overall Study|Withdrew informed consent|4
6235524|NCT01794780|9913581|FG007|Overall Study|Withdrew informed consent|3
6235525|NCT01794780|9913574|FG000|Overall Study|Other|0
6235526|NCT01794780|9913575|FG001|Overall Study|Other|12
6235527|NCT01794780|9913576|FG002|Overall Study|Other|25
6235528|NCT01794780|9913577|FG003|Overall Study|Other|20
6235529|NCT01794780|9913578|FG004|Overall Study|Other|1
6235530|NCT01794780|9913579|FG005|Overall Study|Other|24
6235531|NCT01794780|9913580|FG006|Overall Study|Other|4
6235532|NCT01794780|9913581|FG007|Overall Study|Other|1
6235533|NCT01794845|9913615|FG000|Overall Study|Withdrawal by Subject|1
6235534|NCT01794923|9913622|FG000|Overall Study|Adverse Event|0
6235535|NCT01794923|9913623|FG001|Overall Study|Adverse Event|0
6235536|NCT01794923|9913624|FG002|Overall Study|Adverse Event|1
6235537|NCT01794949|9913634|FG000|Overall Study|Lost to Follow-up|1
6235538|NCT01794949|9913635|FG001|Overall Study|Lost to Follow-up|0
6235539|NCT01795495|9913658|FG000|Overall Study|Protocol Violation|1
6235540|NCT01795495|9913659|FG001|Overall Study|Protocol Violation|0
6235541|NCT01795495|9913660|FG002|Overall Study|Protocol Violation|1
6235542|NCT01795495|9913658|FG000|Overall Study|Physician Decision|0
6235543|NCT01795495|9913659|FG001|Overall Study|Physician Decision|0
6235544|NCT01795495|9913660|FG002|Overall Study|Physician Decision|1
6235545|NCT01795547|9913677|FG000|Overall Study|Adverse Event|16
6235546|NCT01795547|9913678|FG001|Overall Study|Adverse Event|27
6235547|NCT01795547|9913677|FG000|Overall Study|Lack of Efficacy|8
6235548|NCT01795547|9913678|FG001|Overall Study|Lack of Efficacy|3
6235549|NCT01795547|9913677|FG000|Overall Study|Protocol Violation|6
6235550|NCT01795547|9913678|FG001|Overall Study|Protocol Violation|4
6235551|NCT01795547|9913677|FG000|Overall Study|Lost to Follow-up|2
6235552|NCT01795547|9913678|FG001|Overall Study|Lost to Follow-up|5
6235553|NCT01795547|9913677|FG000|Overall Study|Withdrawal of consent|7
6235554|NCT01795547|9913678|FG001|Overall Study|Withdrawal of consent|12
6235555|NCT01795547|9913677|FG000|Overall Study|Not Treated|4
6235556|NCT01795547|9913678|FG001|Overall Study|Not Treated|10
6235557|NCT01795547|9913677|FG000|Overall Study|Non-compliance with IMP|1
6235558|NCT01795547|9913678|FG001|Overall Study|Non-compliance with IMP|1
6235559|NCT01795547|9913677|FG000|Overall Study|Others|4
6235560|NCT01795547|9913678|FG001|Overall Study|Others|1
6235561|NCT01795547|9913677|FG000|Overall Study|Not stated|0
6235562|NCT01795547|9913678|FG001|Overall Study|Not stated|1
6235563|NCT01795638|9913688|FG000|Overall Study|Death|0
6235564|NCT01795638|9913689|FG001|Overall Study|Death|3
6235565|NCT01795638|9913688|FG000|Overall Study|transferred to quaternary hospital|2
6235566|NCT01795638|9913689|FG001|Overall Study|transferred to quaternary hospital|3
6235567|NCT01795638|9913688|FG000|Overall Study|Protocol Violation|3
6235568|NCT01795638|9913689|FG001|Overall Study|Protocol Violation|0
6235569|NCT01795638|9913688|FG000|Overall Study|discharged from hospital|7
6235570|NCT01795638|9913689|FG001|Overall Study|discharged from hospital|5
6235571|NCT01795638|9913688|FG000|Overall Study|Withdrawal by Subject|1
6235572|NCT01795638|9913689|FG001|Overall Study|Withdrawal by Subject|0
6235573|NCT01795898|9913724|FG000|Overall Study|Adverse Event|27
6235574|NCT01795898|9913724|FG000|Overall Study|Lost to Follow-up|20
6235575|NCT01795898|9913724|FG000|Overall Study|Withdrawal of consent|6
6235576|NCT01795898|9913724|FG000|Overall Study|Diagnosed with metastasis|1
6235577|NCT01795898|9913724|FG000|Overall Study|No pain|1
6235578|NCT01795898|9913724|FG000|Overall Study|Death|1
6235579|NCT01795898|9913724|FG000|Overall Study|Withdrew consent & had adverse events|3
6235580|NCT01795898|9913724|FG000|Overall Study|Physician Decision|1
6235581|NCT01795937|9913731|FG000|Overall Study|Withdrawal by Subject|1
6235582|NCT01795937|9913732|FG001|Overall Study|Withdrawal by Subject|0
6235583|NCT01795937|9913733|FG002|Overall Study|Withdrawal by Subject|0
6235584|NCT01795937|9913731|FG000|Overall Study|Physician Decision|0
6235585|NCT01795937|9913732|FG001|Overall Study|Physician Decision|1
6235586|NCT01795937|9913733|FG002|Overall Study|Physician Decision|0
6235587|NCT01796301|9913761|FG000|Overall Study|Withdrawal by Subject|15
6235588|NCT01796301|9913762|FG001|Overall Study|Withdrawal by Subject|15
6235589|NCT01796301|9913761|FG000|Overall Study|Lost to Follow-up|3
6235590|NCT01796301|9913762|FG001|Overall Study|Lost to Follow-up|3
6235591|NCT01796301|9913761|FG000|Overall Study|Death|0
6235592|NCT01796301|9913762|FG001|Overall Study|Death|1
6235593|NCT01796301|9913761|FG000|Overall Study|Decision by Sponsor|0
6235594|NCT01796301|9913762|FG001|Overall Study|Decision by Sponsor|1
6235595|NCT01796392|9913770|FG000|Overall Study|Withdrawal by Subject|2
6235596|NCT01796392|9913771|FG001|Overall Study|Withdrawal by Subject|0
6235597|NCT01796392|9913770|FG000|Overall Study|Death|5
6235598|NCT01796392|9913771|FG001|Overall Study|Death|1
6235599|NCT01796392|9913770|FG000|Overall Study|Excluded for medical reasons|1
6235600|NCT01796392|9913771|FG001|Overall Study|Excluded for medical reasons|2
6235601|NCT01796392|9913770|FG000|Overall Study|Lost to Follow-up|1
6235602|NCT01796392|9913771|FG001|Overall Study|Lost to Follow-up|0
6235603|NCT01796470|9913782|FG000|Overall Study|Adverse Event|4
6235604|NCT01796470|9913783|FG001|Overall Study|Adverse Event|2
6235605|NCT01796470|9913784|FG002|Overall Study|Adverse Event|2
6235606|NCT01796470|9913785|FG003|Overall Study|Adverse Event|1
6235607|NCT01796470|9913786|FG004|Overall Study|Adverse Event|3
6235608|NCT01796470|9913782|FG000|Overall Study|Death|2
6235609|NCT01796470|9913783|FG001|Overall Study|Death|0
6235610|NCT01796470|9913784|FG002|Overall Study|Death|0
6235611|NCT01796470|9913785|FG003|Overall Study|Death|0
6235612|NCT01796470|9913786|FG004|Overall Study|Death|1
6235613|NCT01796470|9913782|FG000|Overall Study|Initiated New Therapy|9
6235614|NCT01796470|9913783|FG001|Overall Study|Initiated New Therapy|0
6235615|NCT01796470|9913784|FG002|Overall Study|Initiated New Therapy|0
6235616|NCT01796470|9913785|FG003|Overall Study|Initiated New Therapy|0
6235617|NCT01796470|9913786|FG004|Overall Study|Initiated New Therapy|2
6235618|NCT01796470|9913782|FG000|Overall Study|Lost to Follow-up|0
6235619|NCT01796470|9913783|FG001|Overall Study|Lost to Follow-up|1
6235620|NCT01796470|9913784|FG002|Overall Study|Lost to Follow-up|0
6235621|NCT01796470|9913785|FG003|Overall Study|Lost to Follow-up|0
6235622|NCT01796470|9913786|FG004|Overall Study|Lost to Follow-up|0
6235623|NCT01796470|9913782|FG000|Overall Study|Physician Decision|5
6235624|NCT01796470|9913783|FG001|Overall Study|Physician Decision|4
6235625|NCT01796470|9913784|FG002|Overall Study|Physician Decision|1
6235626|NCT01796470|9913785|FG003|Overall Study|Physician Decision|0
6235627|NCT01796470|9913786|FG004|Overall Study|Physician Decision|1
6235628|NCT01796470|9913782|FG000|Overall Study|Progressive Disease|7
6235629|NCT01796470|9913783|FG001|Overall Study|Progressive Disease|7
6235630|NCT01796470|9913784|FG002|Overall Study|Progressive Disease|3
6235631|NCT01796470|9913785|FG003|Overall Study|Progressive Disease|2
6235632|NCT01796470|9913786|FG004|Overall Study|Progressive Disease|0
6235633|NCT01796470|9913782|FG000|Overall Study|Protocol Criteria for Withdrawal|1
6235634|NCT01796470|9913783|FG001|Overall Study|Protocol Criteria for Withdrawal|0
6235635|NCT01796470|9913784|FG002|Overall Study|Protocol Criteria for Withdrawal|0
6235636|NCT01796470|9913785|FG003|Overall Study|Protocol Criteria for Withdrawal|0
6235637|NCT01796470|9913786|FG004|Overall Study|Protocol Criteria for Withdrawal|0
6235638|NCT01796470|9913782|FG000|Overall Study|Withdrawal by Subject|7
6235639|NCT01796470|9913783|FG001|Overall Study|Withdrawal by Subject|0
6235640|NCT01796470|9913784|FG002|Overall Study|Withdrawal by Subject|0
6235641|NCT01796470|9913785|FG003|Overall Study|Withdrawal by Subject|0
6235642|NCT01796470|9913786|FG004|Overall Study|Withdrawal by Subject|1
6235643|NCT01796548|9913802|FG000|Overall Study|Lost to Follow-up|1
6235644|NCT01796548|9913802|FG000|Overall Study|Other|2
6235645|NCT01796860|9913819|FG000|Overall Study|Withdrawal by Subject|3
6235646|NCT01796964|9913834|FG000|Overall Study|Adverse Event|1
6235647|NCT01796964|9913835|FG001|Overall Study|Adverse Event|1
6235648|NCT01796964|9913834|FG000|Overall Study|Death|1
6235649|NCT01796964|9913835|FG001|Overall Study|Death|0
6235650|NCT01796964|9913834|FG000|Overall Study|Protocol Violation|0
6235651|NCT01796964|9913835|FG001|Overall Study|Protocol Violation|1
6235652|NCT01796964|9913834|FG000|Overall Study|Withdrawal by Subject|1
6235653|NCT01796964|9913835|FG001|Overall Study|Withdrawal by Subject|1
6235654|NCT01797081|9913864|FG000|Overall Study|Adverse Event|1
6235655|NCT01797081|9913865|FG001|Overall Study|Adverse Event|0
6235656|NCT01797081|9913866|FG002|Overall Study|Adverse Event|1
6235657|NCT01797081|9913867|FG003|Overall Study|Adverse Event|0
6235658|NCT01797081|9913864|FG000|Overall Study|Pregnancy|1
6235659|NCT01797081|9913865|FG001|Overall Study|Pregnancy|0
6235660|NCT01797081|9913866|FG002|Overall Study|Pregnancy|0
6235661|NCT01797081|9913867|FG003|Overall Study|Pregnancy|0
6235662|NCT01797081|9913864|FG000|Overall Study|Personal Reasons|12
6235663|NCT01797081|9913865|FG001|Overall Study|Personal Reasons|4
6235664|NCT01797081|9913866|FG002|Overall Study|Personal Reasons|4
6235665|NCT01797081|9913867|FG003|Overall Study|Personal Reasons|8
6235666|NCT01797081|9913864|FG000|Overall Study|Protocol Violation|0
6235667|NCT01797081|9913865|FG001|Overall Study|Protocol Violation|0
6235668|NCT01797081|9913866|FG002|Overall Study|Protocol Violation|0
6235669|NCT01797081|9913867|FG003|Overall Study|Protocol Violation|1
6235670|NCT01797094|9913877|FG000|Overall Study|Adverse Event|1
6235671|NCT01797094|9913878|FG001|Overall Study|Adverse Event|1
6235672|NCT01797094|9913877|FG000|Overall Study|Personal Reasons|4
6235673|NCT01797094|9913878|FG001|Overall Study|Personal Reasons|0
6235674|NCT01797094|9913877|FG000|Overall Study|Protocol Violation|0
6235675|NCT01797094|9913878|FG001|Overall Study|Protocol Violation|1
6235676|NCT01797094|9913877|FG000|Overall Study|Other Miscellaneous Reasons|1
6235677|NCT01797094|9913878|FG001|Overall Study|Other Miscellaneous Reasons|0
6235678|NCT01797120|9913886|FG000|Overall Study|Disesae progression|37
6235679|NCT01797120|9913887|FG001|Overall Study|Disesae progression|49
6235680|NCT01797120|9913886|FG000|Overall Study|Adverse Event|13
6235681|NCT01797120|9913887|FG001|Overall Study|Adverse Event|5
6235682|NCT01797120|9913886|FG000|Overall Study|Withdrawal by Subject|6
6235683|NCT01797120|9913887|FG001|Overall Study|Withdrawal by Subject|6
6235684|NCT01797120|9913886|FG000|Overall Study|Symptomatic progression|2
6235685|NCT01797120|9913887|FG001|Overall Study|Symptomatic progression|1
6235686|NCT01797120|9913886|FG000|Overall Study|Non-compliance|1
6235687|NCT01797120|9913887|FG001|Overall Study|Non-compliance|0
6235688|NCT01797120|9913886|FG000|Overall Study|Physician Decision|3
6235689|NCT01797120|9913887|FG001|Overall Study|Physician Decision|0
6235690|NCT01797120|9913886|FG000|Overall Study|still on treatment|2
6235691|NCT01797120|9913887|FG001|Overall Study|still on treatment|4
6235692|NCT01797120|9913886|FG000|Overall Study|never start protocol therapy|2
6235693|NCT01797120|9913887|FG001|Overall Study|never start protocol therapy|0
6235694|NCT01797185|9913901|FG000|Overall Study|Adverse Event|5
6235695|NCT01797185|9913902|FG001|Overall Study|Adverse Event|15
6235696|NCT01797185|9913903|FG002|Overall Study|Adverse Event|6
6235697|NCT01797185|9913901|FG000|Overall Study|Withdrawal by Subject|6
6235698|NCT01797185|9913902|FG001|Overall Study|Withdrawal by Subject|9
6235699|NCT01797185|9913903|FG002|Overall Study|Withdrawal by Subject|5
6235700|NCT01797185|9913901|FG000|Overall Study|Site terminated|8
6235701|NCT01797185|9913902|FG001|Overall Study|Site terminated|4
6235702|NCT01797185|9913903|FG002|Overall Study|Site terminated|0
6235703|NCT01797185|9913901|FG000|Overall Study|Lost to Follow-up|2
6235704|NCT01797185|9913902|FG001|Overall Study|Lost to Follow-up|6
6235705|NCT01797185|9913903|FG002|Overall Study|Lost to Follow-up|1
6235706|NCT01797185|9913901|FG000|Overall Study|Withdrawn per sponsor|5
6235707|NCT01797185|9913902|FG001|Overall Study|Withdrawn per sponsor|0
6235708|NCT01797185|9913903|FG002|Overall Study|Withdrawn per sponsor|0
6235709|NCT01797185|9913901|FG000|Overall Study|Physician Decision|1
6235710|NCT01797185|9913902|FG001|Overall Study|Physician Decision|3
6235711|NCT01797185|9913903|FG002|Overall Study|Physician Decision|0
6235712|NCT01797185|9913901|FG000|Overall Study|Protocol Violation|1
6235713|NCT01797185|9913902|FG001|Overall Study|Protocol Violation|1
6235714|NCT01797185|9913903|FG002|Overall Study|Protocol Violation|0
6235715|NCT01797263|9913913|FG000|Overall Study|Withdrawal by Subject|21
6235716|NCT01797263|9913914|FG001|Overall Study|Withdrawal by Subject|25
6235717|NCT01797263|9913913|FG000|Overall Study|Death|1
6235718|NCT01797263|9913914|FG001|Overall Study|Death|0
6235719|NCT01797263|9913913|FG000|Overall Study|Lost to Follow-up|15
6235720|NCT01797263|9913914|FG001|Overall Study|Lost to Follow-up|15
6235721|NCT01797302|9913923|FG000|Overall Study|Lost to Follow-up|16
6235722|NCT01797302|9913924|FG001|Overall Study|Lost to Follow-up|23
6235723|NCT01797302|9913925|FG002|Overall Study|Lost to Follow-up|22
6235724|NCT01797302|9913923|FG000|Overall Study|Withdrawal by Subject|1
6235725|NCT01797302|9913924|FG001|Overall Study|Withdrawal by Subject|3
6235726|NCT01797302|9913925|FG002|Overall Study|Withdrawal by Subject|4
6235727|NCT01797432|9913942|FG000|Overall Study|Lost to Follow-up|1
6235728|NCT01797432|9913942|FG000|Overall Study|Adverse Event|1
6235729|NCT01797432|9913942|FG000|Overall Study|Withdrawal by Subject|1
6235730|NCT01797432|9913942|FG000|Overall Study|lived too far from study site|1
6235731|NCT01797445|9913948|FG000|Double-Blind Phase|Randomized but Not Treated|4
6235732|NCT01797445|9913949|FG001|Double-Blind Phase|Randomized but Not Treated|2
6235733|NCT01797445|9913948|FG000|Double-Blind Phase|Adverse Event|3
6235734|NCT01797445|9913949|FG001|Double-Blind Phase|Adverse Event|0
6235735|NCT01797445|9913948|FG000|Double-Blind Phase|Death|5
6235736|NCT01797445|9913949|FG001|Double-Blind Phase|Death|4
6235737|NCT01797445|9913948|FG000|Double-Blind Phase|Pregnancy|0
6235738|NCT01797445|9913949|FG001|Double-Blind Phase|Pregnancy|1
6235739|NCT01797445|9913948|FG000|Double-Blind Phase|Lack of Efficacy|1
6235740|NCT01797445|9913949|FG001|Double-Blind Phase|Lack of Efficacy|2
6235741|NCT01797445|9913948|FG000|Double-Blind Phase|Investigator's Discretion|15
6235742|NCT01797445|9913949|FG001|Double-Blind Phase|Investigator's Discretion|17
6235743|NCT01797445|9913948|FG000|Double-Blind Phase|Noncompliance with Study Drug|5
6235744|NCT01797445|9913949|FG001|Double-Blind Phase|Noncompliance with Study Drug|1
6235745|NCT01797445|9913948|FG000|Double-Blind Phase|Protocol Violation|0
6235746|NCT01797445|9913949|FG001|Double-Blind Phase|Protocol Violation|1
6235747|NCT01797445|9913948|FG000|Double-Blind Phase|Withdrew Consent|20
6235748|NCT01797445|9913949|FG001|Double-Blind Phase|Withdrew Consent|35
6235749|NCT01797445|9913948|FG000|Double-Blind Phase|Lost to Follow-up|34
6235750|NCT01797445|9913949|FG001|Double-Blind Phase|Lost to Follow-up|26
6235751|NCT01797445|9913948|FG000|Open-Label Extension Phase|Investigator's Discretion|1
6235752|NCT01797445|9913949|FG001|Open-Label Extension Phase|Investigator's Discretion|0
6235753|NCT01797536|9913996|FG000|Overall Study|Adverse Event|0
6235754|NCT01797536|9913997|FG001|Overall Study|Adverse Event|1
6235755|NCT01797536|9913998|FG002|Overall Study|Adverse Event|0
6235756|NCT01797536|9913999|FG003|Overall Study|Adverse Event|0
6235757|NCT01797562|9914009|FG000|Overall Study|Protocol Violation|5
6235758|NCT01797705|9914035|FG000|Overall Study|Equipment anomalies during sleep studies|4
6235759|NCT01797705|9914035|FG000|Overall Study|Withdrawal by Subject|1
6235760|NCT01797731|9914041|FG000|Overall Study|Didn't have proper radiographs required|3
6235761|NCT01797731|9914042|FG001|Overall Study|Didn't have proper radiographs required|3
6235762|NCT01797783|9914050|FG000|Overall Study|Adverse Event|1
6235763|NCT01797783|9914051|FG001|Overall Study|Adverse Event|1
6235764|NCT01797783|9914050|FG000|Overall Study|Withdrawal by Subject|1
6235765|NCT01797783|9914051|FG001|Overall Study|Withdrawal by Subject|0
6235766|NCT01797835|9914073|FG000|Overall Study|Lost to Follow-up|31
6235767|NCT01797835|9914074|FG001|Overall Study|Lost to Follow-up|27
6235768|NCT01797965|9914084|FG000|Overall Study|Adverse Event|104
6235769|NCT01797965|9914085|FG001|Overall Study|Adverse Event|129
6235770|NCT01797965|9914086|FG002|Overall Study|Adverse Event|4
6235771|NCT01797965|9914087|FG003|Overall Study|Adverse Event|21
6235772|NCT01797965|9914084|FG000|Overall Study|Lost to Follow-up|9
6235773|NCT01797965|9914085|FG001|Overall Study|Lost to Follow-up|8
6235774|NCT01797965|9914086|FG002|Overall Study|Lost to Follow-up|1
6235775|NCT01797965|9914087|FG003|Overall Study|Lost to Follow-up|2
6235776|NCT01797965|9914084|FG000|Overall Study|Consent withdrawn|130
6235777|NCT01797965|9914085|FG001|Overall Study|Consent withdrawn|117
6235778|NCT01797965|9914086|FG002|Overall Study|Consent withdrawn|3
6235779|NCT01797965|9914087|FG003|Overall Study|Consent withdrawn|35
6235780|NCT01797965|9914084|FG000|Overall Study|Investigator decision|21
6235781|NCT01797965|9914085|FG001|Overall Study|Investigator decision|15
6235782|NCT01797965|9914086|FG002|Overall Study|Investigator decision|0
6235783|NCT01797965|9914087|FG003|Overall Study|Investigator decision|0
6235784|NCT01797965|9914084|FG000|Overall Study|Death|2
6235785|NCT01797965|9914085|FG001|Overall Study|Death|4
6235786|NCT01797965|9914086|FG002|Overall Study|Death|0
6235787|NCT01797965|9914087|FG003|Overall Study|Death|0
6235788|NCT01797965|9914084|FG000|Overall Study|Disease progression, defined by protocol|3
6235789|NCT01797965|9914085|FG001|Overall Study|Disease progression, defined by protocol|1
6235790|NCT01797965|9914086|FG002|Overall Study|Disease progression, defined by protocol|0
6235791|NCT01797965|9914087|FG003|Overall Study|Disease progression, defined by protocol|0
6235792|NCT01797965|9914084|FG000|Overall Study|Reason Not Specified|280
6235793|NCT01797965|9914085|FG001|Overall Study|Reason Not Specified|295
6235794|NCT01797965|9914086|FG002|Overall Study|Reason Not Specified|0
6235795|NCT01797965|9914087|FG003|Overall Study|Reason Not Specified|15
6235796|NCT01798056|9914100|FG000|Overall Study|Serious Adverse Event|13
6235797|NCT01798056|9914101|FG001|Overall Study|Serious Adverse Event|12
6235798|NCT01798056|9914100|FG000|Overall Study|Withdrawal by Subject|12
6235799|NCT01798056|9914101|FG001|Overall Study|Withdrawal by Subject|9
6235800|NCT01798056|9914100|FG000|Overall Study|Migrated/moved from study area|1
6235801|NCT01798056|9914101|FG001|Overall Study|Migrated/moved from study area|1
6235802|NCT01798056|9914100|FG000|Overall Study|Lost to Follow-up|1
6235803|NCT01798056|9914101|FG001|Overall Study|Lost to Follow-up|1
6235804|NCT01798056|9914100|FG000|Overall Study|Other|0
6235805|NCT01798056|9914101|FG001|Overall Study|Other|2
6235806|NCT01798134|9914109|FG000|Overall Study|Lost to Follow-up|1
6235807|NCT01798134|9914109|FG000|Overall Study|Withdrawal by Subject|3
6235808|NCT01798134|9914109|FG000|Overall Study|Death|2
6235809|NCT01798134|9914109|FG000|Overall Study|Adverse Event|3
6235810|NCT01798134|9914109|FG000|Overall Study|Physician Decision|3
6235811|NCT01798134|9914109|FG000|Overall Study|Liver transplant/surgery|4
6235812|NCT01798485|9914181|FG000|Overall Study|Adverse Event|32
6235813|NCT01798485|9914182|FG001|Overall Study|Adverse Event|40
6235814|NCT01798485|9914181|FG000|Overall Study|Withdrawal by Subject|27
6235815|NCT01798485|9914182|FG001|Overall Study|Withdrawal by Subject|31
6235816|NCT01798485|9914181|FG000|Overall Study|Lost to Follow-up|0
6235817|NCT01798485|9914182|FG001|Overall Study|Lost to Follow-up|3
6235818|NCT01798485|9914181|FG000|Overall Study|Physician Decision|14
6235819|NCT01798485|9914182|FG001|Overall Study|Physician Decision|10
6235820|NCT01798485|9914181|FG000|Overall Study|Objective Disease Progression|152
6235821|NCT01798485|9914182|FG001|Overall Study|Objective Disease Progression|106
6235822|NCT01798485|9914181|FG000|Overall Study|Death|25
6235823|NCT01798485|9914182|FG001|Overall Study|Death|22
6235824|NCT01798485|9914181|FG000|Overall Study|Sponsor Decision|61
6235825|NCT01798485|9914182|FG001|Overall Study|Sponsor Decision|54
6235826|NCT01798485|9914181|FG000|Overall Study|Clinical Progression|35
6235827|NCT01798485|9914182|FG001|Overall Study|Clinical Progression|24
6235828|NCT01798706|9914217|FG000|Overall Study|Adverse Event|15
6235829|NCT01798706|9914218|FG001|Overall Study|Adverse Event|10
6235830|NCT01798706|9914217|FG000|Overall Study|Lack of Efficacy|0
6235831|NCT01798706|9914218|FG001|Overall Study|Lack of Efficacy|2
6235832|NCT01798706|9914217|FG000|Overall Study|Poor compliance to protocol|1
6235833|NCT01798706|9914218|FG001|Overall Study|Poor compliance to protocol|0
6235834|NCT01798706|9914217|FG000|Overall Study|Other than specified above|5
6235835|NCT01798706|9914218|FG001|Overall Study|Other than specified above|9
6235836|NCT01798849|9914227|FG000|Overall Study|Physician Decision|0
6235837|NCT01798849|9914228|FG001|Overall Study|Physician Decision|0
6235838|NCT01798849|9914229|FG002|Overall Study|Physician Decision|1
6235839|NCT01798927|9914266|FG000|Overall Study|Withdrawal by Subject|1
6235840|NCT01798992|9914279|FG000|Overall Study|Administrative withdrawal|0
6235841|NCT01798992|9914280|FG001|Overall Study|Administrative withdrawal|1
6235842|NCT01798992|9914281|FG002|Overall Study|Administrative withdrawal|0
6235843|NCT01798992|9914282|FG003|Overall Study|Administrative withdrawal|1
6235844|NCT01798992|9914279|FG000|Overall Study|Lost to Follow-up|0
6235845|NCT01798992|9914280|FG001|Overall Study|Lost to Follow-up|1
6235846|NCT01798992|9914281|FG002|Overall Study|Lost to Follow-up|1
6235847|NCT01798992|9914282|FG003|Overall Study|Lost to Follow-up|0
6235848|NCT01798992|9914279|FG000|Overall Study|Insufficient biopsy tissue|0
6235849|NCT01798992|9914280|FG001|Overall Study|Insufficient biopsy tissue|0
6235850|NCT01798992|9914281|FG002|Overall Study|Insufficient biopsy tissue|1
6235851|NCT01798992|9914282|FG003|Overall Study|Insufficient biopsy tissue|0
6235852|NCT01799226|9914312|FG000|Overall Study|Withdrawal by Subject|1
6235853|NCT01799226|9914313|FG001|Overall Study|Withdrawal by Subject|0
6235854|NCT01799226|9914312|FG000|Overall Study|Disqualified at Day 14|1
6235855|NCT01799226|9914313|FG001|Overall Study|Disqualified at Day 14|0
6235856|NCT01799239|9914319|FG000|Period 1 (7 Days)|Lack of Efficacy|1
6235857|NCT01799239|9914320|FG001|Period 1 (7 Days)|Lack of Efficacy|0
6235858|NCT01799239|9914319|FG000|Period 1 (7 Days)|Withdrawal by Subject|2
6235859|NCT01799239|9914320|FG001|Period 1 (7 Days)|Withdrawal by Subject|0
6235860|NCT01799239|9914319|FG000|Period 1 (7 Days)|Protocol Violation|0
6235861|NCT01799239|9914320|FG001|Period 1 (7 Days)|Protocol Violation|1
6235862|NCT01799239|9914319|FG000|Period 2 (7 Days)|Withdrawal by Subject|1
6235863|NCT01799239|9914320|FG001|Period 2 (7 Days)|Withdrawal by Subject|1
6235864|NCT01799239|9914319|FG000|Period 2 (7 Days)|Protocol Violation|1
6235865|NCT01799239|9914320|FG001|Period 2 (7 Days)|Protocol Violation|0
6270000|NCT02147158|9970631|FG000|Treatment Course 1|Withdrawal of Consent|1
6270001|NCT02147158|9970632|FG001|Treatment Course 1|Withdrawal of Consent|1
6270002|NCT02147158|9970633|FG002|Treatment Course 1|Withdrawal of Consent|1
6270003|NCT02147158|9970634|FG003|Treatment Course 1|Withdrawal of Consent|5
6270004|NCT02147158|9970635|FG004|Treatment Course 1|Withdrawal of Consent|3
6270005|NCT02147158|9970636|FG005|Treatment Course 1|Withdrawal of Consent|2
6270006|NCT02147158|9970631|FG000|Off-Treatment Interval 1|Adverse Event|1
6270007|NCT02147158|9970632|FG001|Off-Treatment Interval 1|Adverse Event|0
6270008|NCT02147158|9970633|FG002|Off-Treatment Interval 1|Adverse Event|0
6270009|NCT02147158|9970634|FG003|Off-Treatment Interval 1|Adverse Event|1
6270010|NCT02147158|9970635|FG004|Off-Treatment Interval 1|Adverse Event|0
6270011|NCT02147158|9970636|FG005|Off-Treatment Interval 1|Adverse Event|0
6270012|NCT02147158|9970631|FG000|Off-Treatment Interval 1|Lost to Follow-up|2
6270013|NCT02147158|9970632|FG001|Off-Treatment Interval 1|Lost to Follow-up|1
6270014|NCT02147158|9970633|FG002|Off-Treatment Interval 1|Lost to Follow-up|3
6270015|NCT02147158|9970634|FG003|Off-Treatment Interval 1|Lost to Follow-up|2
6270016|NCT02147158|9970635|FG004|Off-Treatment Interval 1|Lost to Follow-up|4
6270017|NCT02147158|9970636|FG005|Off-Treatment Interval 1|Lost to Follow-up|2
6270018|NCT02147158|9970631|FG000|Off-Treatment Interval 1|Protocol Violation|1
6270019|NCT02147158|9970632|FG001|Off-Treatment Interval 1|Protocol Violation|0
6270020|NCT02147158|9970633|FG002|Off-Treatment Interval 1|Protocol Violation|2
6270021|NCT02147158|9970634|FG003|Off-Treatment Interval 1|Protocol Violation|0
6270022|NCT02147158|9970635|FG004|Off-Treatment Interval 1|Protocol Violation|1
6270023|NCT02147158|9970636|FG005|Off-Treatment Interval 1|Protocol Violation|0
6270024|NCT02147158|9970631|FG000|Off-Treatment Interval 1|Withdrawal of Consent|4
6270025|NCT02147158|9970632|FG001|Off-Treatment Interval 1|Withdrawal of Consent|3
6270026|NCT02147158|9970633|FG002|Off-Treatment Interval 1|Withdrawal of Consent|5
6270027|NCT02147158|9970634|FG003|Off-Treatment Interval 1|Withdrawal of Consent|10
6270028|NCT02147158|9970635|FG004|Off-Treatment Interval 1|Withdrawal of Consent|2
6270029|NCT02147158|9970636|FG005|Off-Treatment Interval 1|Withdrawal of Consent|3
6270030|NCT02147158|9970631|FG000|Off-Treatment Interval 1|Lack of Efficacy|0
6270031|NCT02147158|9970632|FG001|Off-Treatment Interval 1|Lack of Efficacy|0
6270032|NCT02147158|9970633|FG002|Off-Treatment Interval 1|Lack of Efficacy|2
6270033|NCT02147158|9970634|FG003|Off-Treatment Interval 1|Lack of Efficacy|0
6270034|NCT02147158|9970635|FG004|Off-Treatment Interval 1|Lack of Efficacy|1
6270035|NCT02147158|9970636|FG005|Off-Treatment Interval 1|Lack of Efficacy|0
6270036|NCT02147158|9970631|FG000|Off-Treatment Interval 1|Other Miscellaneous Reasons|2
6270037|NCT02147158|9970632|FG001|Off-Treatment Interval 1|Other Miscellaneous Reasons|0
6270038|NCT02147158|9970633|FG002|Off-Treatment Interval 1|Other Miscellaneous Reasons|3
6270039|NCT02147158|9970634|FG003|Off-Treatment Interval 1|Other Miscellaneous Reasons|2
6270040|NCT02147158|9970635|FG004|Off-Treatment Interval 1|Other Miscellaneous Reasons|0
6270041|NCT02147158|9970636|FG005|Off-Treatment Interval 1|Other Miscellaneous Reasons|0
6270042|NCT02147158|9970631|FG000|Treatment Course 2|Adverse Event|0
6270043|NCT02147158|9970632|FG001|Treatment Course 2|Adverse Event|4
6270044|NCT02147158|9970633|FG002|Treatment Course 2|Adverse Event|2
6270045|NCT02147158|9970634|FG003|Treatment Course 2|Adverse Event|1
6270046|NCT02147158|9970635|FG004|Treatment Course 2|Adverse Event|0
6270047|NCT02147158|9970636|FG005|Treatment Course 2|Adverse Event|1
6270048|NCT02147158|9970631|FG000|Treatment Course 2|Withdrawal of Consent|0
6270049|NCT02147158|9970632|FG001|Treatment Course 2|Withdrawal of Consent|1
6270050|NCT02147158|9970633|FG002|Treatment Course 2|Withdrawal of Consent|2
6270051|NCT02147158|9970634|FG003|Treatment Course 2|Withdrawal of Consent|3
6270052|NCT02147158|9970635|FG004|Treatment Course 2|Withdrawal of Consent|0
6270053|NCT02147158|9970636|FG005|Treatment Course 2|Withdrawal of Consent|0
6270054|NCT02147158|9970631|FG000|Treatment Course 2|Lost to Follow-up|1
6270055|NCT02147158|9970632|FG001|Treatment Course 2|Lost to Follow-up|0
6270056|NCT02147158|9970633|FG002|Treatment Course 2|Lost to Follow-up|1
6270057|NCT02147158|9970634|FG003|Treatment Course 2|Lost to Follow-up|1
6270058|NCT02147158|9970635|FG004|Treatment Course 2|Lost to Follow-up|0
6270059|NCT02147158|9970636|FG005|Treatment Course 2|Lost to Follow-up|1
6270060|NCT02147158|9970631|FG000|Off-Treatment Interval 2|Lack of Efficacy|0
6270061|NCT02147158|9970632|FG001|Off-Treatment Interval 2|Lack of Efficacy|1
6270062|NCT02147158|9970633|FG002|Off-Treatment Interval 2|Lack of Efficacy|1
6270063|NCT02147158|9970634|FG003|Off-Treatment Interval 2|Lack of Efficacy|0
6270064|NCT02147158|9970635|FG004|Off-Treatment Interval 2|Lack of Efficacy|0
6270065|NCT02147158|9970636|FG005|Off-Treatment Interval 2|Lack of Efficacy|0
6270066|NCT02147158|9970631|FG000|Off-Treatment Interval 2|Withdrawal of Consent|4
6270067|NCT02147158|9970632|FG001|Off-Treatment Interval 2|Withdrawal of Consent|0
6270068|NCT02147158|9970633|FG002|Off-Treatment Interval 2|Withdrawal of Consent|5
6270069|NCT02147158|9970634|FG003|Off-Treatment Interval 2|Withdrawal of Consent|4
6235866|NCT01799590|9914337|FG000|Overall Study|Adverse Event|13
6235867|NCT01799590|9914338|FG001|Overall Study|Adverse Event|7
6235868|NCT01799590|9914339|FG002|Overall Study|Adverse Event|5
6235869|NCT01799590|9914337|FG000|Overall Study|Pregnancy|2
6235870|NCT01799590|9914338|FG001|Overall Study|Pregnancy|0
6235871|NCT01799590|9914339|FG002|Overall Study|Pregnancy|0
6235872|NCT01799590|9914337|FG000|Overall Study|Lack of Efficacy|3
6235873|NCT01799590|9914338|FG001|Overall Study|Lack of Efficacy|1
6235874|NCT01799590|9914339|FG002|Overall Study|Lack of Efficacy|3
6235875|NCT01799590|9914337|FG000|Overall Study|Participants convenience|4
6235876|NCT01799590|9914338|FG001|Overall Study|Participants convenience|4
6235877|NCT01799590|9914339|FG002|Overall Study|Participants convenience|2
6235878|NCT01799590|9914337|FG000|Overall Study|Aggravation of complications|0
6235879|NCT01799590|9914338|FG001|Overall Study|Aggravation of complications|1
6235880|NCT01799590|9914339|FG002|Overall Study|Aggravation of complications|1
6235881|NCT01799590|9914337|FG000|Overall Study|Using drugs with restricted days of use|0
6235882|NCT01799590|9914338|FG001|Overall Study|Using drugs with restricted days of use|3
6235883|NCT01799590|9914339|FG002|Overall Study|Using drugs with restricted days of use|2
6235884|NCT01799590|9914337|FG000|Overall Study|Use of prohibited concomitant drugs|1
6235885|NCT01799590|9914338|FG001|Overall Study|Use of prohibited concomitant drugs|0
6235886|NCT01799590|9914339|FG002|Overall Study|Use of prohibited concomitant drugs|0
6235887|NCT01799590|9914337|FG000|Overall Study|Other|3
6235888|NCT01799590|9914338|FG001|Overall Study|Other|0
6235889|NCT01799590|9914339|FG002|Overall Study|Other|1
6235890|NCT01799720|9914350|FG000|Overall Study|Withdrawal by Subject|3
6235891|NCT01799720|9914351|FG001|Overall Study|Withdrawal by Subject|0
6235892|NCT01799720|9914352|FG002|Overall Study|Withdrawal by Subject|0
6235893|NCT01799720|9914350|FG000|Overall Study|Protocol Violation|0
6235894|NCT01799720|9914351|FG001|Overall Study|Protocol Violation|1
6235895|NCT01799720|9914352|FG002|Overall Study|Protocol Violation|0
6235896|NCT01799720|9914350|FG000|Overall Study|Pregnancy|0
6235897|NCT01799720|9914351|FG001|Overall Study|Pregnancy|0
6235898|NCT01799720|9914352|FG002|Overall Study|Pregnancy|1
6235899|NCT01799889|9914372|FG000|Overall Study|Adverse Event|4
6235900|NCT01799889|9914373|FG001|Overall Study|Adverse Event|4
6235901|NCT01799889|9914374|FG002|Overall Study|Adverse Event|5
6235902|NCT01799889|9914375|FG003|Overall Study|Adverse Event|1
6235903|NCT01799889|9914376|FG004|Overall Study|Adverse Event|11
6235904|NCT01799889|9914377|FG005|Overall Study|Adverse Event|1
6235905|NCT01799889|9914378|FG006|Overall Study|Adverse Event|5
6235906|NCT01799889|9914379|FG007|Overall Study|Adverse Event|2
6235907|NCT01799889|9914380|FG008|Overall Study|Adverse Event|3
6235908|NCT01799889|9914381|FG009|Overall Study|Adverse Event|1
6235909|NCT01799889|9914382|FG010|Overall Study|Adverse Event|1
6235910|NCT01799889|9914383|FG011|Overall Study|Adverse Event|0
6235911|NCT01799889|9914372|FG000|Overall Study|Death|1
6235912|NCT01799889|9914373|FG001|Overall Study|Death|0
6235913|NCT01799889|9914374|FG002|Overall Study|Death|5
6235914|NCT01799889|9914375|FG003|Overall Study|Death|3
6235915|NCT01799889|9914376|FG004|Overall Study|Death|1
6235916|NCT01799889|9914377|FG005|Overall Study|Death|0
6235917|NCT01799889|9914378|FG006|Overall Study|Death|0
6235918|NCT01799889|9914379|FG007|Overall Study|Death|0
6235919|NCT01799889|9914380|FG008|Overall Study|Death|1
6235920|NCT01799889|9914381|FG009|Overall Study|Death|0
6235921|NCT01799889|9914382|FG010|Overall Study|Death|1
6235922|NCT01799889|9914383|FG011|Overall Study|Death|0
6235923|NCT01799889|9914372|FG000|Overall Study|Lack of Efficacy|1
6235924|NCT01799889|9914373|FG001|Overall Study|Lack of Efficacy|1
6235925|NCT01799889|9914374|FG002|Overall Study|Lack of Efficacy|0
6235926|NCT01799889|9914375|FG003|Overall Study|Lack of Efficacy|1
6235927|NCT01799889|9914376|FG004|Overall Study|Lack of Efficacy|2
6235928|NCT01799889|9914377|FG005|Overall Study|Lack of Efficacy|2
6235929|NCT01799889|9914378|FG006|Overall Study|Lack of Efficacy|0
6235930|NCT01799889|9914379|FG007|Overall Study|Lack of Efficacy|0
6235931|NCT01799889|9914380|FG008|Overall Study|Lack of Efficacy|2
6235932|NCT01799889|9914381|FG009|Overall Study|Lack of Efficacy|0
6235933|NCT01799889|9914382|FG010|Overall Study|Lack of Efficacy|1
6235934|NCT01799889|9914383|FG011|Overall Study|Lack of Efficacy|0
6235935|NCT01799889|9914372|FG000|Overall Study|Lost to Follow-up|0
6235936|NCT01799889|9914373|FG001|Overall Study|Lost to Follow-up|1
6235937|NCT01799889|9914374|FG002|Overall Study|Lost to Follow-up|0
6235938|NCT01799889|9914375|FG003|Overall Study|Lost to Follow-up|0
6235939|NCT01799889|9914376|FG004|Overall Study|Lost to Follow-up|0
6235940|NCT01799889|9914377|FG005|Overall Study|Lost to Follow-up|0
6235941|NCT01799889|9914378|FG006|Overall Study|Lost to Follow-up|0
6235942|NCT01799889|9914379|FG007|Overall Study|Lost to Follow-up|0
6235943|NCT01799889|9914380|FG008|Overall Study|Lost to Follow-up|0
6235944|NCT01799889|9914381|FG009|Overall Study|Lost to Follow-up|0
6235945|NCT01799889|9914382|FG010|Overall Study|Lost to Follow-up|0
6235946|NCT01799889|9914383|FG011|Overall Study|Lost to Follow-up|0
6235947|NCT01799889|9914372|FG000|Overall Study|Physician Decision|3
6235948|NCT01799889|9914373|FG001|Overall Study|Physician Decision|2
6235949|NCT01799889|9914374|FG002|Overall Study|Physician Decision|4
6235950|NCT01799889|9914375|FG003|Overall Study|Physician Decision|4
6235951|NCT01799889|9914376|FG004|Overall Study|Physician Decision|5
6235952|NCT01799889|9914377|FG005|Overall Study|Physician Decision|5
6235953|NCT01799889|9914378|FG006|Overall Study|Physician Decision|5
6235954|NCT01799889|9914379|FG007|Overall Study|Physician Decision|2
6235955|NCT01799889|9914380|FG008|Overall Study|Physician Decision|6
6235956|NCT01799889|9914381|FG009|Overall Study|Physician Decision|0
6235957|NCT01799889|9914382|FG010|Overall Study|Physician Decision|0
6235958|NCT01799889|9914383|FG011|Overall Study|Physician Decision|1
6235959|NCT01799889|9914372|FG000|Overall Study|Progressive Disease|30
6235960|NCT01799889|9914373|FG001|Overall Study|Progressive Disease|26
6235961|NCT01799889|9914374|FG002|Overall Study|Progressive Disease|25
6235962|NCT01799889|9914375|FG003|Overall Study|Progressive Disease|30
6235963|NCT01799889|9914376|FG004|Overall Study|Progressive Disease|23
6235964|NCT01799889|9914377|FG005|Overall Study|Progressive Disease|9
6235965|NCT01799889|9914378|FG006|Overall Study|Progressive Disease|8
6235966|NCT01799889|9914379|FG007|Overall Study|Progressive Disease|13
6235967|NCT01799889|9914380|FG008|Overall Study|Progressive Disease|18
6235968|NCT01799889|9914381|FG009|Overall Study|Progressive Disease|5
6235969|NCT01799889|9914382|FG010|Overall Study|Progressive Disease|3
6235970|NCT01799889|9914383|FG011|Overall Study|Progressive Disease|1
6235971|NCT01799889|9914372|FG000|Overall Study|Specified Criteria for Withdrawal|0
6235972|NCT01799889|9914373|FG001|Overall Study|Specified Criteria for Withdrawal|1
6235973|NCT01799889|9914374|FG002|Overall Study|Specified Criteria for Withdrawal|1
6235974|NCT01799889|9914375|FG003|Overall Study|Specified Criteria for Withdrawal|0
6235975|NCT01799889|9914376|FG004|Overall Study|Specified Criteria for Withdrawal|0
6235976|NCT01799889|9914377|FG005|Overall Study|Specified Criteria for Withdrawal|0
6235977|NCT01799889|9914378|FG006|Overall Study|Specified Criteria for Withdrawal|0
6235978|NCT01799889|9914379|FG007|Overall Study|Specified Criteria for Withdrawal|0
6235979|NCT01799889|9914380|FG008|Overall Study|Specified Criteria for Withdrawal|0
6235980|NCT01799889|9914381|FG009|Overall Study|Specified Criteria for Withdrawal|0
6235981|NCT01799889|9914382|FG010|Overall Study|Specified Criteria for Withdrawal|0
6235982|NCT01799889|9914383|FG011|Overall Study|Specified Criteria for Withdrawal|0
6235983|NCT01799889|9914372|FG000|Overall Study|Study Terminated By Sponsor|1
6235984|NCT01799889|9914373|FG001|Overall Study|Study Terminated By Sponsor|0
6235985|NCT01799889|9914374|FG002|Overall Study|Study Terminated By Sponsor|0
6235986|NCT01799889|9914375|FG003|Overall Study|Study Terminated By Sponsor|0
6235987|NCT01799889|9914376|FG004|Overall Study|Study Terminated By Sponsor|2
6235988|NCT01799889|9914377|FG005|Overall Study|Study Terminated By Sponsor|1
6235989|NCT01799889|9914378|FG006|Overall Study|Study Terminated By Sponsor|0
6235990|NCT01799889|9914379|FG007|Overall Study|Study Terminated By Sponsor|2
6235991|NCT01799889|9914380|FG008|Overall Study|Study Terminated By Sponsor|1
6235992|NCT01799889|9914381|FG009|Overall Study|Study Terminated By Sponsor|1
6235993|NCT01799889|9914382|FG010|Overall Study|Study Terminated By Sponsor|0
6235994|NCT01799889|9914383|FG011|Overall Study|Study Terminated By Sponsor|0
6235995|NCT01799889|9914372|FG000|Overall Study|Withdrawal by Subject|1
6235996|NCT01799889|9914373|FG001|Overall Study|Withdrawal by Subject|6
6235997|NCT01799889|9914374|FG002|Overall Study|Withdrawal by Subject|4
6235998|NCT01799889|9914375|FG003|Overall Study|Withdrawal by Subject|0
6235999|NCT01799889|9914376|FG004|Overall Study|Withdrawal by Subject|5
6236000|NCT01799889|9914377|FG005|Overall Study|Withdrawal by Subject|1
6236001|NCT01799889|9914378|FG006|Overall Study|Withdrawal by Subject|3
6236002|NCT01799889|9914379|FG007|Overall Study|Withdrawal by Subject|1
6236003|NCT01799889|9914380|FG008|Overall Study|Withdrawal by Subject|2
6236004|NCT01799889|9914381|FG009|Overall Study|Withdrawal by Subject|1
6236005|NCT01799889|9914382|FG010|Overall Study|Withdrawal by Subject|1
6236006|NCT01799889|9914383|FG011|Overall Study|Withdrawal by Subject|1
6236007|NCT01799889|9914372|FG000|Overall Study|Non-Compliance With Study Drug|0
6236008|NCT01799889|9914373|FG001|Overall Study|Non-Compliance With Study Drug|0
6236009|NCT01799889|9914374|FG002|Overall Study|Non-Compliance With Study Drug|0
6236010|NCT01799889|9914375|FG003|Overall Study|Non-Compliance With Study Drug|0
6236011|NCT01799889|9914376|FG004|Overall Study|Non-Compliance With Study Drug|0
6236012|NCT01799889|9914377|FG005|Overall Study|Non-Compliance With Study Drug|1
6236013|NCT01799889|9914378|FG006|Overall Study|Non-Compliance With Study Drug|0
6188539|NCT01393600|9843339|FG001|Follow-up Period (Day 29 to 35)|Withdrawal by Subject|0
6188540|NCT01393600|9843340|FG002|Follow-up Period (Day 29 to 35)|Withdrawal by Subject|1
6188541|NCT01393600|9843341|FG003|Follow-up Period (Day 29 to 35)|Withdrawal by Subject|0
6188542|NCT01393613|9843357|FG000|Overall Study|Adverse Event|11
6188543|NCT01393613|9843358|FG001|Overall Study|Adverse Event|11
6188544|NCT01393613|9843359|FG002|Overall Study|Adverse Event|13
6188545|NCT01393613|9843360|FG003|Overall Study|Adverse Event|22
6188546|NCT01393613|9843357|FG000|Overall Study|Participant Met Withdrawal Criteria|0
6188547|NCT01393613|9843358|FG001|Overall Study|Participant Met Withdrawal Criteria|0
6188548|NCT01393613|9843359|FG002|Overall Study|Participant Met Withdrawal Criteria|2
6236014|NCT01799889|9914379|FG007|Overall Study|Non-Compliance With Study Drug|0
6236015|NCT01799889|9914380|FG008|Overall Study|Non-Compliance With Study Drug|0
6236016|NCT01799889|9914381|FG009|Overall Study|Non-Compliance With Study Drug|0
6236017|NCT01799889|9914382|FG010|Overall Study|Non-Compliance With Study Drug|0
6236018|NCT01799889|9914383|FG011|Overall Study|Non-Compliance With Study Drug|0
6236019|NCT01799941|9914420|FG000|Overall Study|Adverse Event|34
6236020|NCT01799941|9914420|FG000|Overall Study|Withdrawal by Subject|21
6236021|NCT01799941|9914420|FG000|Overall Study|Death|2
6236022|NCT01799941|9914420|FG000|Overall Study|Investigator Decision|4
6236023|NCT01799941|9914420|FG000|Overall Study|Lack of Efficacy|3
6236024|NCT01799941|9914420|FG000|Overall Study|Lost to Follow-up|17
6236025|NCT01799941|9914420|FG000|Overall Study|Other|15
6236026|NCT01799993|9914432|FG000|Overall Study|"Didn't complete CRF page End of FU"|30
6236027|NCT01799993|9914433|FG001|Overall Study|"Didn't complete CRF page End of FU"|40
6236028|NCT01799993|9914432|FG000|Overall Study|Death|61
6236029|NCT01799993|9914433|FG001|Overall Study|Death|45
6236030|NCT01799993|9914432|FG000|Overall Study|Withdrawal by Subject|23
6236031|NCT01799993|9914433|FG001|Overall Study|Withdrawal by Subject|24
6236032|NCT01799993|9914432|FG000|Overall Study|Lost to Follow-up|5
6236033|NCT01799993|9914433|FG001|Overall Study|Lost to Follow-up|8
6236034|NCT01799993|9914432|FG000|Overall Study|Withdrawal by parent/guardian/LAR|5
6236035|NCT01799993|9914433|FG001|Overall Study|Withdrawal by parent/guardian/LAR|3
6236036|NCT01799993|9914432|FG000|Overall Study|Protocol driven decision point|0
6236037|NCT01799993|9914433|FG001|Overall Study|Protocol driven decision point|3
6236038|NCT01799993|9914432|FG000|Overall Study|Protocol Violation|1
6236039|NCT01799993|9914433|FG001|Overall Study|Protocol Violation|1
6236040|NCT01799993|9914432|FG000|Overall Study|Deterioration of general conditions|2
6236041|NCT01799993|9914433|FG001|Overall Study|Deterioration of general conditions|0
6236042|NCT01799993|9914432|FG000|Overall Study|Screen failure|0
6236043|NCT01799993|9914433|FG001|Overall Study|Screen failure|1
6236044|NCT01799993|9914432|FG000|Overall Study|Adverse Event|1
6236045|NCT01799993|9914433|FG001|Overall Study|Adverse Event|0
6236046|NCT01799993|9914432|FG000|Overall Study|Lack of Efficacy|1
6236047|NCT01799993|9914433|FG001|Overall Study|Lack of Efficacy|0
6236048|NCT01799993|9914432|FG000|Overall Study|Recovery|0
6236049|NCT01799993|9914433|FG001|Overall Study|Recovery|1
6236050|NCT01799993|9914432|FG000|Overall Study|Logistical difficulties|1
6236051|NCT01799993|9914433|FG001|Overall Study|Logistical difficulties|0
6236052|NCT01799993|9914432|FG000|Overall Study|Protocol deviation|1
6236053|NCT01799993|9914433|FG001|Overall Study|Protocol deviation|0
6236054|NCT01799993|9914432|FG000|Overall Study|Non-compliance with medical device|1
6236055|NCT01799993|9914433|FG001|Overall Study|Non-compliance with medical device|0
6236056|NCT01799993|9914432|FG000|Overall Study|Withdrawal by parent/guardian|0
6236057|NCT01799993|9914433|FG001|Overall Study|Withdrawal by parent/guardian|1
6236058|NCT01799993|9914432|FG000|Overall Study|Other|1
6236059|NCT01799993|9914433|FG001|Overall Study|Other|0
6236060|NCT01799993|9914432|FG000|Overall Study|Subject didn't return for follow-up|0
6236061|NCT01799993|9914433|FG001|Overall Study|Subject didn't return for follow-up|1
6236062|NCT01800058|9914439|FG000|Overall Study|Lost to Follow-up|1
6236063|NCT01800201|9914446|FG000|Overall Study|Withdrawal by Subject|2
6236064|NCT01800201|9914447|FG001|Overall Study|Withdrawal by Subject|0
6236065|NCT01800201|9914446|FG000|Overall Study|patient privacy concerns|1
6236066|NCT01800201|9914447|FG001|Overall Study|patient privacy concerns|1
6236067|NCT01800201|9914446|FG000|Overall Study|did not want to use device|0
6236068|NCT01800201|9914447|FG001|Overall Study|did not want to use device|1
6236069|NCT01800201|9914446|FG000|Overall Study|PI withdrawal, cognitive concerns|0
6236070|NCT01800201|9914447|FG001|Overall Study|PI withdrawal, cognitive concerns|1
6236071|NCT01800903|9914522|FG000|Second Test Period|unable to catheterise|1
6236072|NCT01800903|9914523|FG001|Second Test Period|unable to catheterise|0
6236073|NCT01800903|9914524|FG002|Second Test Period|unable to catheterise|0
6236074|NCT01800903|9914525|FG003|Second Test Period|unable to catheterise|0
6236075|NCT01800903|9914526|FG004|Second Test Period|unable to catheterise|0
6236076|NCT01800903|9914527|FG005|Second Test Period|unable to catheterise|0
6236077|NCT01800916|9914533|FG000|Test Period 1 (1 Week)|Convex product user|0
6236078|NCT01800916|9914534|FG001|Test Period 1 (1 Week)|Convex product user|0
6236079|NCT01800916|9914535|FG002|Test Period 1 (1 Week)|Convex product user|0
6236080|NCT01800916|9914536|FG003|Test Period 1 (1 Week)|Convex product user|1
6236081|NCT01800916|9914537|FG004|Test Period 1 (1 Week)|Convex product user|0
6236082|NCT01800916|9914538|FG005|Test Period 1 (1 Week)|Convex product user|0
6236083|NCT01800916|9914539|FG006|Test Period 1 (1 Week)|Convex product user|0
6236084|NCT01800916|9914540|FG007|Test Period 1 (1 Week)|Convex product user|0
6236085|NCT01800916|9914541|FG008|Test Period 1 (1 Week)|Convex product user|0
6236086|NCT01800916|9914533|FG000|Test Period 1 (1 Week)|Adverse Event|0
6236087|NCT01800916|9914534|FG001|Test Period 1 (1 Week)|Adverse Event|0
6236088|NCT01800916|9914535|FG002|Test Period 1 (1 Week)|Adverse Event|0
6236089|NCT01800916|9914536|FG003|Test Period 1 (1 Week)|Adverse Event|0
6236090|NCT01800916|9914537|FG004|Test Period 1 (1 Week)|Adverse Event|1
6236091|NCT01800916|9914538|FG005|Test Period 1 (1 Week)|Adverse Event|0
6236092|NCT01800916|9914539|FG006|Test Period 1 (1 Week)|Adverse Event|0
6236093|NCT01800916|9914540|FG007|Test Period 1 (1 Week)|Adverse Event|0
6236094|NCT01800916|9914541|FG008|Test Period 1 (1 Week)|Adverse Event|0
6236095|NCT01800968|9914553|FG000|Overall Study|Death|23
6236096|NCT01800968|9914554|FG001|Overall Study|Death|16
6236097|NCT01800968|9914553|FG000|Overall Study|Lost to Follow-up|5
6236098|NCT01800968|9914554|FG001|Overall Study|Lost to Follow-up|7
6236099|NCT01800968|9914553|FG000|Overall Study|Withdrawal by Subject|7
6236100|NCT01800968|9914554|FG001|Overall Study|Withdrawal by Subject|9
6236101|NCT01800968|9914553|FG000|Overall Study|Physician Decision|1
6236102|NCT01800968|9914554|FG001|Overall Study|Physician Decision|0
6236103|NCT01801007|9914560|FG000|Overall Study|Adverse Event|2
6236104|NCT01801007|9914560|FG000|Overall Study|Lost to Follow-up|4
6236105|NCT01801007|9914560|FG000|Overall Study|Withdrawal by Subject|5
6236106|NCT01801111|9914564|FG000|Overall Study|Adverse Event|12
6236107|NCT01801111|9914564|FG000|Overall Study|Death|8
6236108|NCT01801111|9914564|FG000|Overall Study|Physician Decision|5
6236109|NCT01801111|9914564|FG000|Overall Study|Other|1
6236110|NCT01801111|9914564|FG000|Overall Study|Withdrawal by Subject|4
6236111|NCT01801111|9914564|FG000|Overall Study|Study Terminated by Sponsor|27
6236112|NCT01801111|9914564|FG000|Overall Study|Progressive Disease|81
6236113|NCT01801280|9914585|FG000|Period 1|Withdrawal by Subject|0
6236114|NCT01801280|9914586|FG001|Period 1|Withdrawal by Subject|1
6236115|NCT01801280|9914587|FG002|Period 1|Withdrawal by Subject|0
6236116|NCT01801280|9914588|FG003|Period 1|Withdrawal by Subject|0
6236117|NCT01801280|9914585|FG000|Period 2|Withdrawal by Subject|1
6236118|NCT01801280|9914586|FG001|Period 2|Withdrawal by Subject|0
6236119|NCT01801280|9914587|FG002|Period 2|Withdrawal by Subject|0
6236120|NCT01801280|9914588|FG003|Period 2|Withdrawal by Subject|0
6236121|NCT01801280|9914585|FG000|Period 4|Protocol Violation|0
6236122|NCT01801280|9914586|FG001|Period 4|Protocol Violation|0
6236123|NCT01801280|9914587|FG002|Period 4|Protocol Violation|1
6236124|NCT01801280|9914588|FG003|Period 4|Protocol Violation|0
6236125|NCT01801358|9914604|FG000|Overall Study|Adverse Event|0
6236126|NCT01801358|9914605|FG001|Overall Study|Adverse Event|2
6236127|NCT01801358|9914606|FG002|Overall Study|Adverse Event|1
6236128|NCT01801358|9914607|FG003|Overall Study|Adverse Event|0
6236129|NCT01801358|9914608|FG004|Overall Study|Adverse Event|0
6236130|NCT01801358|9914609|FG005|Overall Study|Adverse Event|1
6236131|NCT01801358|9914604|FG000|Overall Study|Physician Decision|0
6236132|NCT01801358|9914605|FG001|Overall Study|Physician Decision|0
6236133|NCT01801358|9914606|FG002|Overall Study|Physician Decision|1
6236134|NCT01801358|9914607|FG003|Overall Study|Physician Decision|0
6236135|NCT01801358|9914608|FG004|Overall Study|Physician Decision|0
6236136|NCT01801358|9914609|FG005|Overall Study|Physician Decision|0
6236137|NCT01801358|9914604|FG000|Overall Study|Progressive Disease|6
6236138|NCT01801358|9914605|FG001|Overall Study|Progressive Disease|4
6236139|NCT01801358|9914606|FG002|Overall Study|Progressive Disease|4
6236140|NCT01801358|9914607|FG003|Overall Study|Progressive Disease|5
6236141|NCT01801358|9914608|FG004|Overall Study|Progressive Disease|6
6236142|NCT01801358|9914609|FG005|Overall Study|Progressive Disease|5
6236143|NCT01801358|9914604|FG000|Overall Study|Withdrawal by Subject|0
6236144|NCT01801358|9914605|FG001|Overall Study|Withdrawal by Subject|0
6236145|NCT01801358|9914606|FG002|Overall Study|Withdrawal by Subject|0
6236146|NCT01801358|9914607|FG003|Overall Study|Withdrawal by Subject|1
6236147|NCT01801358|9914608|FG004|Overall Study|Withdrawal by Subject|0
6236148|NCT01801358|9914609|FG005|Overall Study|Withdrawal by Subject|2
6236149|NCT01801436|9914644|FG000|Overall Study|Withdrawal by Subject|3
6236150|NCT01801436|9914644|FG000|Overall Study|Adverse Event|2
6236151|NCT01801436|9914644|FG000|Overall Study|Progressive disease|4
6236152|NCT01801475|9914656|FG000|Overall Study|Withdrawal by Subject|0
6236153|NCT01801475|9914657|FG001|Overall Study|Withdrawal by Subject|0
6236154|NCT01801475|9914658|FG002|Overall Study|Withdrawal by Subject|0
6236155|NCT01801475|9914659|FG003|Overall Study|Withdrawal by Subject|0
6236156|NCT01801475|9914660|FG004|Overall Study|Withdrawal by Subject|1
6236157|NCT01801735|9914669|FG000|Overall Study|Adverse Event|79
6236158|NCT01801735|9914669|FG000|Overall Study|Lack of Efficacy|28
6236159|NCT01801735|9914669|FG000|Overall Study|Withdrawal by Subject|27
6236160|NCT01801735|9914669|FG000|Overall Study|Protocol Violation|25
6236161|NCT01801735|9914669|FG000|Overall Study|Lost to Follow-up|15
6236162|NCT01801735|9914669|FG000|Overall Study|Non-compliance with Trial Drug|13
6236163|NCT01801735|9914669|FG000|Overall Study|Physician Decision|3
6236164|NCT01801735|9914669|FG000|Overall Study|Death|1
6236165|NCT01801735|9914669|FG000|Overall Study|Other, including site closure|19
6236166|NCT01801865|9914673|FG000|Overall Study|Patients scanned on another MRI scanner|35
6236167|NCT01801865|9914673|FG000|Overall Study|Physician Decision|7
6236168|NCT01801917|9914681|FG000|Period 1 - Randomized|Adverse Event|1
6236169|NCT01801917|9914682|FG001|Period 1 - Randomized|Adverse Event|0
6236170|NCT01801917|9914683|FG002|Period 1 - Randomized|Adverse Event|1
6236171|NCT01801917|9914684|FG003|Period 1 - Randomized|Adverse Event|0
6236172|NCT01801930|9914699|FG000|Overall Study|Clear progression of the primary disease is observed|6
6236173|NCT01801930|9914700|FG001|Overall Study|Clear progression of the primary disease is observed|5
6236174|NCT01801930|9914701|FG002|Overall Study|Clear progression of the primary disease is observed|6
6236175|NCT01801930|9914702|FG003|Overall Study|Clear progression of the primary disease is observed|6
6236176|NCT01801930|9914699|FG000|Overall Study|DLT occurs|0
6236177|NCT01801930|9914700|FG001|Overall Study|DLT occurs|1
6236178|NCT01801930|9914701|FG002|Overall Study|DLT occurs|0
6236179|NCT01801930|9914702|FG003|Overall Study|DLT occurs|0
6236180|NCT01801982|9914712|FG000|Overall Study|Lost to Follow-up|1
6236181|NCT01802073|9914718|FG000|Overall Study|Lost to Follow-up|0
6236182|NCT01802073|9914719|FG001|Overall Study|Lost to Follow-up|1
6236183|NCT01802073|9914718|FG000|Overall Study|Non-compliant|4
6236184|NCT01802073|9914719|FG001|Overall Study|Non-compliant|2
6236185|NCT01802073|9914718|FG000|Overall Study|Withdrawal by Subject|1
6236186|NCT01802073|9914719|FG001|Overall Study|Withdrawal by Subject|1
6236187|NCT01802073|9914718|FG000|Overall Study|Physician Decision|0
6236188|NCT01802073|9914719|FG001|Overall Study|Physician Decision|7
6236189|NCT01802216|9914744|FG000|4 Month Visit|Participant did not show to visit|3
6236190|NCT01802216|9914745|FG001|4 Month Visit|Participant did not show to visit|4
6236191|NCT01802216|9914744|FG000|8 Month Visit|Participant did not show to visit|3
6236192|NCT01802216|9914745|FG001|8 Month Visit|Participant did not show to visit|5
6236193|NCT01802216|9914744|FG000|12 Month Visit|Participant did not show to visit|3
6236194|NCT01802216|9914745|FG001|12 Month Visit|Participant did not show to visit|4
6236195|NCT01802320|9914751|FG000|Overall Study|Death|1
6236196|NCT01802320|9914751|FG000|Overall Study|Withdrawal by Subject|1
6236197|NCT01802333|9914758|FG000|Overall Study|Ineligible|2
6236198|NCT01802333|9914759|FG001|Overall Study|Ineligible|6
6236199|NCT01802333|9914760|FG002|Overall Study|Ineligible|8
6236200|NCT01802333|9914758|FG000|Overall Study|Adverse Event|1
6236201|NCT01802333|9914759|FG001|Overall Study|Adverse Event|8
6236202|NCT01802333|9914760|FG002|Overall Study|Adverse Event|8
6236203|NCT01802333|9914758|FG000|Overall Study|Withdrawal by Subject|6
6236204|NCT01802333|9914759|FG001|Overall Study|Withdrawal by Subject|6
6236205|NCT01802333|9914760|FG002|Overall Study|Withdrawal by Subject|5
6236206|NCT01802333|9914758|FG000|Overall Study|Progression/relapse|1
6236207|NCT01802333|9914759|FG001|Overall Study|Progression/relapse|3
6236208|NCT01802333|9914760|FG002|Overall Study|Progression/relapse|0
6236209|NCT01802333|9914758|FG000|Overall Study|Death|7
6236210|NCT01802333|9914759|FG001|Overall Study|Death|14
6236211|NCT01802333|9914760|FG002|Overall Study|Death|13
6236212|NCT01802333|9914758|FG000|Overall Study|Other - not protocol specified|32
6236213|NCT01802333|9914759|FG001|Overall Study|Other - not protocol specified|22
6236214|NCT01802333|9914760|FG002|Overall Study|Other - not protocol specified|24
6236215|NCT01802333|9914758|FG000|Overall Study|Did not start treatment|0
6236216|NCT01802333|9914759|FG001|Overall Study|Did not start treatment|2
6236217|NCT01802333|9914760|FG002|Overall Study|Did not start treatment|5
6188549|NCT01393613|9843360|FG003|Overall Study|Participant Met Withdrawal Criteria|1
6188550|NCT01393613|9843357|FG000|Overall Study|Physician Decision|2
6188551|NCT01393613|9843358|FG001|Overall Study|Physician Decision|0
6188552|NCT01393613|9843359|FG002|Overall Study|Physician Decision|0
6188553|NCT01393613|9843360|FG003|Overall Study|Physician Decision|1
6188554|NCT01393613|9843357|FG000|Overall Study|Withdrawal by Subject|15
6188555|NCT01393613|9843358|FG001|Overall Study|Withdrawal by Subject|25
6188556|NCT01393613|9843359|FG002|Overall Study|Withdrawal by Subject|23
6188557|NCT01393613|9843360|FG003|Overall Study|Withdrawal by Subject|21
6188558|NCT01393613|9843357|FG000|Overall Study|Protocol Deviation|2
6188559|NCT01393613|9843358|FG001|Overall Study|Protocol Deviation|1
6188560|NCT01393613|9843359|FG002|Overall Study|Protocol Deviation|0
6188561|NCT01393613|9843360|FG003|Overall Study|Protocol Deviation|0
6188562|NCT01393613|9843357|FG000|Overall Study|Lack of Efficacy|9
6188563|NCT01393613|9843358|FG001|Overall Study|Lack of Efficacy|20
6188564|NCT01393613|9843359|FG002|Overall Study|Lack of Efficacy|16
6188565|NCT01393613|9843360|FG003|Overall Study|Lack of Efficacy|21
6188566|NCT01393626|9843376|FG000|Overall Study|Adverse Event|2
6188567|NCT01393626|9843377|FG001|Overall Study|Adverse Event|1
6188568|NCT01393626|9843378|FG002|Overall Study|Adverse Event|5
6188569|NCT01393626|9843379|FG003|Overall Study|Adverse Event|0
6188570|NCT01393626|9843376|FG000|Overall Study|Did not meet entrance criteria|1
6188571|NCT01393626|9843377|FG001|Overall Study|Did not meet entrance criteria|0
6236218|NCT01802385|9914776|FG000|Overall Study|Death|106
6236219|NCT01802385|9914777|FG001|Overall Study|Death|120
6236220|NCT01802411|9914785|FG000|Overall Study|Death|2
6236221|NCT01802411|9914786|FG001|Overall Study|Death|1
6236222|NCT01802411|9914785|FG000|Overall Study|Adverse Event|2
6236223|NCT01802411|9914786|FG001|Overall Study|Adverse Event|7
6236224|NCT01802411|9914785|FG000|Overall Study|Lack of Efficacy|8
6236225|NCT01802411|9914786|FG001|Overall Study|Lack of Efficacy|10
6236226|NCT01802411|9914785|FG000|Overall Study|Withdrawal by Subject|0
6236227|NCT01802411|9914786|FG001|Overall Study|Withdrawal by Subject|2
6236228|NCT01802411|9914785|FG000|Overall Study|Planned pleurodesis as part of the proc|1
6236229|NCT01802411|9914786|FG001|Overall Study|Planned pleurodesis as part of the proc|0
6236230|NCT01802411|9914785|FG000|Overall Study|Surgery aborted after bronchoscopy|1
6236231|NCT01802411|9914786|FG001|Overall Study|Surgery aborted after bronchoscopy|0
6236232|NCT01802411|9914785|FG000|Overall Study|Proc changed to video-asst thorascopic|0
6236233|NCT01802411|9914786|FG001|Overall Study|Proc changed to video-asst thorascopic|1
6236234|NCT01802437|9914794|FG000|Overall Study|Lost to Follow-up|1
6236235|NCT01802437|9914795|FG001|Overall Study|Lost to Follow-up|0
6236236|NCT01802437|9914794|FG000|Overall Study|Withdrawal by Subject|3
6236237|NCT01802437|9914795|FG001|Overall Study|Withdrawal by Subject|4
6236238|NCT01802515|9914804|FG000|Overall Study|Withdrawal by Subject|3
6236239|NCT01802515|9914805|FG001|Overall Study|Withdrawal by Subject|0
6236240|NCT01802515|9914806|FG002|Overall Study|Withdrawal by Subject|0
6236241|NCT01802580|9914825|FG000|Overall Study|Physician Decision|1
6236242|NCT01802580|9914826|FG001|Overall Study|Physician Decision|0
6236243|NCT01802580|9914825|FG000|Overall Study|Protocol Violation|2
6236244|NCT01802580|9914826|FG001|Overall Study|Protocol Violation|0
6236245|NCT01802580|9914825|FG000|Overall Study|Withdrawal by Subject|5
6236246|NCT01802580|9914826|FG001|Overall Study|Withdrawal by Subject|6
6236247|NCT01802580|9914825|FG000|Overall Study|Other|1
6236248|NCT01802580|9914826|FG001|Overall Study|Other|3
6236249|NCT01802580|9914825|FG000|Overall Study|Lack of Efficacy|0
6236250|NCT01802580|9914826|FG001|Overall Study|Lack of Efficacy|2
6236251|NCT01802775|9914845|FG000|Overall Study|Death|0
6236252|NCT01802775|9914846|FG001|Overall Study|Death|3
6236253|NCT01802775|9914845|FG000|Overall Study|Reason not provided|0
6236254|NCT01802775|9914846|FG001|Overall Study|Reason not provided|1
6236255|NCT01802775|9914845|FG000|Overall Study|Physician Decision|1
6236256|NCT01802775|9914846|FG001|Overall Study|Physician Decision|0
6236257|NCT01802775|9914845|FG000|Overall Study|Adverse Event|1
6236258|NCT01802775|9914846|FG001|Overall Study|Adverse Event|1
6236259|NCT01802775|9914845|FG000|Overall Study|Withdrawal by Subject|3
6188572|NCT01393626|9843378|FG002|Overall Study|Did not meet entrance criteria|0
6188573|NCT01393626|9843379|FG003|Overall Study|Did not meet entrance criteria|0
6188574|NCT01393626|9843376|FG000|Overall Study|Lack of Efficacy|6
6188575|NCT01393626|9843377|FG001|Overall Study|Lack of Efficacy|6
6188576|NCT01393626|9843378|FG002|Overall Study|Lack of Efficacy|4
6188577|NCT01393626|9843379|FG003|Overall Study|Lack of Efficacy|1
6188578|NCT01393626|9843376|FG000|Overall Study|Lost to Follow-up|1
6188579|NCT01393626|9843377|FG001|Overall Study|Lost to Follow-up|1
6188580|NCT01393626|9843378|FG002|Overall Study|Lost to Follow-up|1
6188581|NCT01393626|9843379|FG003|Overall Study|Lost to Follow-up|0
6188582|NCT01393626|9843376|FG000|Overall Study|Withdrawal by Subject|6
6188583|NCT01393626|9843377|FG001|Overall Study|Withdrawal by Subject|4
6236260|NCT01802775|9914846|FG001|Overall Study|Withdrawal by Subject|5
6236261|NCT01802775|9914845|FG000|Overall Study|Lost to Follow-up|1
6236262|NCT01802775|9914846|FG001|Overall Study|Lost to Follow-up|2
6236263|NCT01802879|9914852|FG000|Overall Study|Administrative problems|2
6236264|NCT01802879|9914852|FG000|Overall Study|Disease progression|6
6236265|NCT01803269|9914934|FG000|Overall Study|Withdrawal by Subject|3
6236266|NCT01803269|9914935|FG001|Overall Study|Withdrawal by Subject|0
6236267|NCT01803269|9914936|FG002|Overall Study|Withdrawal by Subject|0
6236268|NCT01803282|9914956|FG000|Overall Study|Progressive Disease|4
6236269|NCT01803282|9914957|FG001|Overall Study|Progressive Disease|3
6236270|NCT01803282|9914958|FG002|Overall Study|Progressive Disease|6
6236271|NCT01803282|9914959|FG003|Overall Study|Progressive Disease|22
6236272|NCT01803282|9914960|FG004|Overall Study|Progressive Disease|5
6236273|NCT01803282|9914961|FG005|Overall Study|Progressive Disease|8
6236274|NCT01803282|9914962|FG006|Overall Study|Progressive Disease|23
6236275|NCT01803282|9914963|FG007|Overall Study|Progressive Disease|24
6236276|NCT01803282|9914964|FG008|Overall Study|Progressive Disease|3
6236277|NCT01803282|9914965|FG009|Overall Study|Progressive Disease|29
6236278|NCT01803282|9914966|FG010|Overall Study|Progressive Disease|6
6236279|NCT01803282|9914967|FG011|Overall Study|Progressive Disease|11
6236280|NCT01803282|9914956|FG000|Overall Study|Death|0
6236281|NCT01803282|9914957|FG001|Overall Study|Death|0
6236282|NCT01803282|9914958|FG002|Overall Study|Death|0
6236283|NCT01803282|9914959|FG003|Overall Study|Death|0
6236284|NCT01803282|9914960|FG004|Overall Study|Death|2
6236285|NCT01803282|9914961|FG005|Overall Study|Death|1
6236286|NCT01803282|9914962|FG006|Overall Study|Death|1
6236287|NCT01803282|9914963|FG007|Overall Study|Death|5
6236288|NCT01803282|9914964|FG008|Overall Study|Death|1
6236289|NCT01803282|9914965|FG009|Overall Study|Death|1
6236290|NCT01803282|9914966|FG010|Overall Study|Death|0
6236291|NCT01803282|9914967|FG011|Overall Study|Death|0
6188584|NCT01393626|9843378|FG002|Overall Study|Withdrawal by Subject|0
6188585|NCT01393626|9843379|FG003|Overall Study|Withdrawal by Subject|0
6236292|NCT01803282|9914956|FG000|Overall Study|Withdrew Consent|0
6236293|NCT01803282|9914957|FG001|Overall Study|Withdrew Consent|0
6236294|NCT01803282|9914958|FG002|Overall Study|Withdrew Consent|0
6236295|NCT01803282|9914959|FG003|Overall Study|Withdrew Consent|6
6236296|NCT01803282|9914960|FG004|Overall Study|Withdrew Consent|1
6188586|NCT01393626|9843376|FG000|Overall Study|Other|1
6188587|NCT01393626|9843377|FG001|Overall Study|Other|0
6188588|NCT01393626|9843378|FG002|Overall Study|Other|0
6188589|NCT01393626|9843379|FG003|Overall Study|Other|0
6188590|NCT01393626|9843376|FG000|Overall Study|Protocol Violation|1
6188591|NCT01393626|9843377|FG001|Overall Study|Protocol Violation|0
6188592|NCT01393626|9843378|FG002|Overall Study|Protocol Violation|2
6188593|NCT01393626|9843379|FG003|Overall Study|Protocol Violation|0
6188594|NCT01393730|9843416|FG000|Overall Study|Withdrawal by Subject|3
6188595|NCT01393730|9843416|FG000|Overall Study|Other|2
6188596|NCT01393730|9843416|FG000|Overall Study|Adverse Event|1
6188597|NCT01393743|9843422|FG000|Core Study|Adverse Event|5
6188598|NCT01393743|9843423|FG001|Core Study|Adverse Event|9
6188599|NCT01393743|9843424|FG002|Core Study|Adverse Event|0
6188600|NCT01393743|9843422|FG000|Core Study|Lost to Follow-up|1
6188601|NCT01393743|9843423|FG001|Core Study|Lost to Follow-up|1
6188602|NCT01393743|9843424|FG002|Core Study|Lost to Follow-up|0
6188603|NCT01393743|9843422|FG000|Core Study|Participant's Choice|2
6188604|NCT01393743|9843423|FG001|Core Study|Participant's Choice|3
6188605|NCT01393743|9843424|FG002|Core Study|Participant's Choice|0
6188606|NCT01393743|9843422|FG000|Core Study|Inadequate therapeutic effect|2
6188607|NCT01393743|9843423|FG001|Core Study|Inadequate therapeutic effect|0
6188608|NCT01393743|9843424|FG002|Core Study|Inadequate therapeutic effect|0
6188609|NCT01393743|9843422|FG000|Extension Phase|Adverse Event|0
6188610|NCT01393743|9843423|FG001|Extension Phase|Adverse Event|0
6188611|NCT01393743|9843424|FG002|Extension Phase|Adverse Event|12
6188612|NCT01393743|9843422|FG000|Extension Phase|Lost to Follow-up|0
6188613|NCT01393743|9843423|FG001|Extension Phase|Lost to Follow-up|0
6188614|NCT01393743|9843424|FG002|Extension Phase|Lost to Follow-up|2
6188615|NCT01393743|9843422|FG000|Extension Phase|Participant choice|0
6188616|NCT01393743|9843423|FG001|Extension Phase|Participant choice|0
6188617|NCT01393743|9843424|FG002|Extension Phase|Participant choice|16
6188618|NCT01393743|9843422|FG000|Extension Phase|Inadequate therapeutic effect|0
6188619|NCT01393743|9843423|FG001|Extension Phase|Inadequate therapeutic effect|0
6193262|NCT01436643|9850887|FG000|2-week Pre-treatment|Abnormal test result|0
6236297|NCT01803282|9914961|FG005|Overall Study|Withdrew Consent|0
6236298|NCT01803282|9914962|FG006|Overall Study|Withdrew Consent|8
6236299|NCT01803282|9914963|FG007|Overall Study|Withdrew Consent|3
6236300|NCT01803282|9914964|FG008|Overall Study|Withdrew Consent|1
6236301|NCT01803282|9914965|FG009|Overall Study|Withdrew Consent|5
6236302|NCT01803282|9914966|FG010|Overall Study|Withdrew Consent|0
6236303|NCT01803282|9914967|FG011|Overall Study|Withdrew Consent|1
6236304|NCT01803282|9914956|FG000|Overall Study|Investigator's Discretion|0
6236305|NCT01803282|9914957|FG001|Overall Study|Investigator's Discretion|0
6236306|NCT01803282|9914958|FG002|Overall Study|Investigator's Discretion|0
6236307|NCT01803282|9914959|FG003|Overall Study|Investigator's Discretion|7
6236308|NCT01803282|9914960|FG004|Overall Study|Investigator's Discretion|2
6236309|NCT01803282|9914961|FG005|Overall Study|Investigator's Discretion|1
6236310|NCT01803282|9914962|FG006|Overall Study|Investigator's Discretion|7
6236311|NCT01803282|9914963|FG007|Overall Study|Investigator's Discretion|10
6236312|NCT01803282|9914964|FG008|Overall Study|Investigator's Discretion|6
6236313|NCT01803282|9914965|FG009|Overall Study|Investigator's Discretion|7
6236314|NCT01803282|9914966|FG010|Overall Study|Investigator's Discretion|1
6236315|NCT01803282|9914967|FG011|Overall Study|Investigator's Discretion|0
6236316|NCT01803282|9914956|FG000|Overall Study|Adverse Event|0
6236317|NCT01803282|9914957|FG001|Overall Study|Adverse Event|0
6236318|NCT01803282|9914958|FG002|Overall Study|Adverse Event|0
6236319|NCT01803282|9914959|FG003|Overall Study|Adverse Event|0
6236320|NCT01803282|9914960|FG004|Overall Study|Adverse Event|0
6236321|NCT01803282|9914961|FG005|Overall Study|Adverse Event|0
6236322|NCT01803282|9914962|FG006|Overall Study|Adverse Event|1
6236323|NCT01803282|9914963|FG007|Overall Study|Adverse Event|2
6236324|NCT01803282|9914964|FG008|Overall Study|Adverse Event|0
6236325|NCT01803282|9914965|FG009|Overall Study|Adverse Event|1
6236326|NCT01803282|9914966|FG010|Overall Study|Adverse Event|0
6236327|NCT01803282|9914967|FG011|Overall Study|Adverse Event|3
6236328|NCT01803282|9914956|FG000|Overall Study|Non-Compliance with Study Drug|0
6236329|NCT01803282|9914957|FG001|Overall Study|Non-Compliance with Study Drug|0
6236330|NCT01803282|9914958|FG002|Overall Study|Non-Compliance with Study Drug|0
6236331|NCT01803282|9914959|FG003|Overall Study|Non-Compliance with Study Drug|1
6236332|NCT01803282|9914960|FG004|Overall Study|Non-Compliance with Study Drug|0
6236333|NCT01803282|9914961|FG005|Overall Study|Non-Compliance with Study Drug|0
6236334|NCT01803282|9914962|FG006|Overall Study|Non-Compliance with Study Drug|0
6236335|NCT01803282|9914963|FG007|Overall Study|Non-Compliance with Study Drug|0
6236336|NCT01803282|9914964|FG008|Overall Study|Non-Compliance with Study Drug|0
6236337|NCT01803282|9914965|FG009|Overall Study|Non-Compliance with Study Drug|0
6236338|NCT01803282|9914966|FG010|Overall Study|Non-Compliance with Study Drug|0
6236339|NCT01803282|9914967|FG011|Overall Study|Non-Compliance with Study Drug|0
6236340|NCT01803282|9914956|FG000|Overall Study|Unknown Reason|0
6236341|NCT01803282|9914957|FG001|Overall Study|Unknown Reason|0
6236342|NCT01803282|9914958|FG002|Overall Study|Unknown Reason|0
6236343|NCT01803282|9914959|FG003|Overall Study|Unknown Reason|0
6236344|NCT01803282|9914960|FG004|Overall Study|Unknown Reason|0
6236345|NCT01803282|9914961|FG005|Overall Study|Unknown Reason|0
6236346|NCT01803282|9914962|FG006|Overall Study|Unknown Reason|0
6236347|NCT01803282|9914963|FG007|Overall Study|Unknown Reason|1
6236348|NCT01803282|9914964|FG008|Overall Study|Unknown Reason|0
6236349|NCT01803282|9914965|FG009|Overall Study|Unknown Reason|0
6236350|NCT01803282|9914966|FG010|Overall Study|Unknown Reason|0
6236351|NCT01803282|9914967|FG011|Overall Study|Unknown Reason|0
6236352|NCT01803282|9914956|FG000|Overall Study|Specified Criteria for Withdrawal|0
6236353|NCT01803282|9914957|FG001|Overall Study|Specified Criteria for Withdrawal|0
6236354|NCT01803282|9914958|FG002|Overall Study|Specified Criteria for Withdrawal|0
6236355|NCT01803282|9914959|FG003|Overall Study|Specified Criteria for Withdrawal|0
6236356|NCT01803282|9914960|FG004|Overall Study|Specified Criteria for Withdrawal|0
6236357|NCT01803282|9914961|FG005|Overall Study|Specified Criteria for Withdrawal|0
6236358|NCT01803282|9914962|FG006|Overall Study|Specified Criteria for Withdrawal|0
6236359|NCT01803282|9914963|FG007|Overall Study|Specified Criteria for Withdrawal|0
6236360|NCT01803282|9914964|FG008|Overall Study|Specified Criteria for Withdrawal|0
6236361|NCT01803282|9914965|FG009|Overall Study|Specified Criteria for Withdrawal|1
6236362|NCT01803282|9914966|FG010|Overall Study|Specified Criteria for Withdrawal|1
6236363|NCT01803282|9914967|FG011|Overall Study|Specified Criteria for Withdrawal|0
6236364|NCT01803282|9914956|FG000|Overall Study|Enrolled but Never Treated|0
6236365|NCT01803282|9914957|FG001|Overall Study|Enrolled but Never Treated|0
6236366|NCT01803282|9914958|FG002|Overall Study|Enrolled but Never Treated|0
6236367|NCT01803282|9914959|FG003|Overall Study|Enrolled but Never Treated|0
6236368|NCT01803282|9914960|FG004|Overall Study|Enrolled but Never Treated|1
6236369|NCT01803282|9914961|FG005|Overall Study|Enrolled but Never Treated|0
6236370|NCT01803282|9914962|FG006|Overall Study|Enrolled but Never Treated|1
6236371|NCT01803282|9914963|FG007|Overall Study|Enrolled but Never Treated|1
6236372|NCT01803282|9914964|FG008|Overall Study|Enrolled but Never Treated|0
6236373|NCT01803282|9914965|FG009|Overall Study|Enrolled but Never Treated|1
6236374|NCT01803282|9914966|FG010|Overall Study|Enrolled but Never Treated|0
6236375|NCT01803282|9914967|FG011|Overall Study|Enrolled but Never Treated|0
6236376|NCT01803464|9914997|FG000|Overall Study|Incomplete data|0
6236377|NCT01803464|9914998|FG001|Overall Study|Incomplete data|0
6236378|NCT01803464|9914999|FG002|Overall Study|Incomplete data|4
6236379|NCT01803464|9915000|FG003|Overall Study|Incomplete data|0
6236380|NCT01803464|9914997|FG000|Overall Study|Withdrawal by Subject|1
6236381|NCT01803464|9914998|FG001|Overall Study|Withdrawal by Subject|0
6236382|NCT01803464|9914999|FG002|Overall Study|Withdrawal by Subject|0
6236383|NCT01803464|9915000|FG003|Overall Study|Withdrawal by Subject|0
6236384|NCT01803607|9915016|FG000|Overall Study|Adverse Event|5
6236385|NCT01803607|9915017|FG001|Overall Study|Adverse Event|3
6236386|NCT01803607|9915016|FG000|Overall Study|Lack of Efficacy|0
6236387|NCT01803607|9915017|FG001|Overall Study|Lack of Efficacy|1
6236388|NCT01803607|9915016|FG000|Overall Study|Protocol Violation|3
6236389|NCT01803607|9915017|FG001|Overall Study|Protocol Violation|2
6236390|NCT01803607|9915016|FG000|Overall Study|Study terminated by sponsor|54
6236391|NCT01803607|9915017|FG001|Overall Study|Study terminated by sponsor|56
6236392|NCT01803607|9915016|FG000|Overall Study|Withdrawal by Subject|6
6236393|NCT01803607|9915017|FG001|Overall Study|Withdrawal by Subject|5
6236394|NCT01803646|9915025|FG000|Overall Study|Protocol Violation|1
6236395|NCT01803646|9915026|FG001|Overall Study|Protocol Violation|0
6236396|NCT01803646|9915025|FG000|Overall Study|Adverse Event|1
6236397|NCT01803646|9915026|FG001|Overall Study|Adverse Event|1
6236398|NCT01803646|9915025|FG000|Overall Study|Withdrawal by Subject|9
6236399|NCT01803646|9915026|FG001|Overall Study|Withdrawal by Subject|6
6236400|NCT01803646|9915025|FG000|Overall Study|Randomization error|1
6236401|NCT01803646|9915026|FG001|Overall Study|Randomization error|2
6236402|NCT01803646|9915025|FG000|Overall Study|Lost to Follow-up|5
6236403|NCT01803646|9915026|FG001|Overall Study|Lost to Follow-up|1
6236404|NCT01803737|9915034|FG000|Overall Study|Lack of Time|1
6236405|NCT01803737|9915035|FG001|Overall Study|Lack of Time|0
6236406|NCT01803737|9915034|FG000|Overall Study|Medical Reason|0
6236407|NCT01803737|9915035|FG001|Overall Study|Medical Reason|1
6236408|NCT01803737|9915034|FG000|Overall Study|Lost to Follow-up|0
6236409|NCT01803737|9915035|FG001|Overall Study|Lost to Follow-up|2
6236410|NCT01803880|9915044|FG000|Overall Study|Adverse Event|1
6236411|NCT01803880|9915045|FG001|Overall Study|Adverse Event|0
6236412|NCT01803880|9915046|FG002|Overall Study|Adverse Event|0
6236413|NCT01803880|9915044|FG000|Overall Study|Withdrawal by Subject|1
6236414|NCT01803880|9915045|FG001|Overall Study|Withdrawal by Subject|1
6236415|NCT01803880|9915046|FG002|Overall Study|Withdrawal by Subject|4
6236416|NCT01803880|9915044|FG000|Overall Study|Physician Decision|0
6236417|NCT01803880|9915045|FG001|Overall Study|Physician Decision|0
6236418|NCT01803880|9915046|FG002|Overall Study|Physician Decision|1
6236419|NCT01803880|9915044|FG000|Overall Study|Unable to return for follow-up visits|0
6236420|NCT01803880|9915045|FG001|Overall Study|Unable to return for follow-up visits|1
6236421|NCT01803880|9915046|FG002|Overall Study|Unable to return for follow-up visits|2
6236422|NCT01803880|9915044|FG000|Overall Study|Lost to Follow-up|1
6236423|NCT01803880|9915045|FG001|Overall Study|Lost to Follow-up|2
6236424|NCT01803880|9915046|FG002|Overall Study|Lost to Follow-up|3
6236425|NCT01803880|9915044|FG000|Overall Study|Protocol Violation|1
6236426|NCT01803880|9915045|FG001|Overall Study|Protocol Violation|0
6236427|NCT01803880|9915046|FG002|Overall Study|Protocol Violation|0
6236428|NCT01803880|9915044|FG000|Overall Study|Early study termination|0
6236429|NCT01803880|9915045|FG001|Overall Study|Early study termination|6
6236430|NCT01803880|9915046|FG002|Overall Study|Early study termination|5
6236431|NCT01803880|9915044|FG000|Overall Study|Incomplete data entry by sites|2
6236432|NCT01803880|9915045|FG001|Overall Study|Incomplete data entry by sites|0
6236433|NCT01803880|9915046|FG002|Overall Study|Incomplete data entry by sites|0
6236434|NCT01804049|9915068|FG000|Overall Study|Adverse Event|2
6236435|NCT01804049|9915069|FG001|Overall Study|Adverse Event|10
6236436|NCT01804049|9915068|FG000|Overall Study|Lost to Follow-up|2
6236437|NCT01804049|9915069|FG001|Overall Study|Lost to Follow-up|1
6236438|NCT01804049|9915068|FG000|Overall Study|Decreased interest/personal|4
6236439|NCT01804049|9915069|FG001|Overall Study|Decreased interest/personal|5
6236440|NCT01804049|9915068|FG000|Overall Study|Other health concerns|2
6236441|NCT01804049|9915069|FG001|Overall Study|Other health concerns|7
6236442|NCT01804049|9915068|FG000|Overall Study|Moved out of area|0
6236443|NCT01804049|9915069|FG001|Overall Study|Moved out of area|7
6236444|NCT01804049|9915068|FG000|Overall Study|other MD recommended|1
6236445|NCT01804049|9915069|FG001|Overall Study|other MD recommended|1
6236446|NCT01804049|9915068|FG000|Overall Study|Enrollment in dual studies|0
6236447|NCT01804049|9915069|FG001|Overall Study|Enrollment in dual studies|1
6236448|NCT01804140|9915112|FG000|Overall Study|No sampling or biopsy procedures done|114
6236449|NCT01804582|9915131|FG000|Overall Study|Lost to Follow-up|47
6236450|NCT01804582|9915132|FG001|Overall Study|Lost to Follow-up|56
6236451|NCT01804582|9915131|FG000|Overall Study|Physician Decision|2
6236452|NCT01804582|9915132|FG001|Overall Study|Physician Decision|0
6236453|NCT01804673|9915139|FG000|Overall Study|Adverse Event|4
6236454|NCT01804673|9915139|FG000|Overall Study|Withdrawal by Subject|1
6236455|NCT01804673|9915139|FG000|Overall Study|Lack of Efficacy|9
6236456|NCT01804673|9915139|FG000|Overall Study|Change to Oral Therapy|37
6236457|NCT01804673|9915139|FG000|Overall Study|No Further Therapy Required|84
6236458|NCT01804673|9915139|FG000|Overall Study|Use of Prohibited Medication|1
6188620|NCT01393743|9843424|FG002|Extension Phase|Inadequate therapeutic effect|7
6188621|NCT01393743|9843422|FG000|Extension Phase|Withdrawal by Subject|0
6188622|NCT01393743|9843423|FG001|Extension Phase|Withdrawal by Subject|0
6188623|NCT01393743|9843424|FG002|Extension Phase|Withdrawal by Subject|8
6188624|NCT01393743|9843422|FG000|Extension Phase|Pregnancy|0
6188625|NCT01393743|9843423|FG001|Extension Phase|Pregnancy|0
6188626|NCT01393743|9843424|FG002|Extension Phase|Pregnancy|1
6188627|NCT01393743|9843422|FG000|Extension Phase|Other|0
6188628|NCT01393743|9843423|FG001|Extension Phase|Other|0
6188629|NCT01393743|9843424|FG002|Extension Phase|Other|14
6188630|NCT01393821|9843437|FG000|Overall Study|Cancel|1
6188631|NCT01393821|9843438|FG001|Overall Study|Cancel|1
6188632|NCT01393821|9843437|FG000|Overall Study|not evaluable for primary endpoint|4
6188633|NCT01393821|9843438|FG001|Overall Study|not evaluable for primary endpoint|2
6188634|NCT01393899|9843447|FG000|Overall Study|Study terminated by sponsor|1
6188635|NCT01393899|9843448|FG001|Overall Study|Study terminated by sponsor|0
6188636|NCT01393899|9843449|FG002|Overall Study|Study terminated by sponsor|1
6188637|NCT01393899|9843447|FG000|Overall Study|Other|1
6188638|NCT01393899|9843448|FG001|Overall Study|Other|0
6188639|NCT01393899|9843449|FG002|Overall Study|Other|0
6188640|NCT01393899|9843447|FG000|Overall Study|Withdrawal by Subject|2
6188641|NCT01393899|9843448|FG001|Overall Study|Withdrawal by Subject|2
6188642|NCT01393899|9843449|FG002|Overall Study|Withdrawal by Subject|1
6188643|NCT01393899|9843447|FG000|Overall Study|Lost to Follow-up|0
6188644|NCT01393899|9843448|FG001|Overall Study|Lost to Follow-up|0
6188645|NCT01393899|9843449|FG002|Overall Study|Lost to Follow-up|1
6188646|NCT01393899|9843447|FG000|Overall Study|Does not meet entrance criteria|1
6188647|NCT01393899|9843448|FG001|Overall Study|Does not meet entrance criteria|0
6188648|NCT01393899|9843449|FG002|Overall Study|Does not meet entrance criteria|1
6188649|NCT01393899|9843447|FG000|Overall Study|Lack of Efficacy|26
6188650|NCT01393899|9843448|FG001|Overall Study|Lack of Efficacy|21
6188651|NCT01393899|9843449|FG002|Overall Study|Lack of Efficacy|16
6188652|NCT01393899|9843447|FG000|Overall Study|Adverse Event|1
6188653|NCT01393899|9843448|FG001|Overall Study|Adverse Event|5
6188654|NCT01393899|9843449|FG002|Overall Study|Adverse Event|3
6188655|NCT01393964|9843462|FG000|Overall Study|Disease Progression|4
6188656|NCT01393964|9843463|FG001|Overall Study|Disease Progression|3
6188657|NCT01393964|9843464|FG002|Overall Study|Disease Progression|5
6188658|NCT01393964|9843462|FG000|Overall Study|Study drug toxicity|1
6188659|NCT01393964|9843463|FG001|Overall Study|Study drug toxicity|0
6188660|NCT01393964|9843464|FG002|Overall Study|Study drug toxicity|0
6188661|NCT01393964|9843462|FG000|Overall Study|Withdrawal by Subject|0
6188662|NCT01393964|9843463|FG001|Overall Study|Withdrawal by Subject|0
6188663|NCT01393964|9843464|FG002|Overall Study|Withdrawal by Subject|1
6188664|NCT01393964|9843462|FG000|Overall Study|Adverse event unrelated to study drug|0
6188665|NCT01393964|9843463|FG001|Overall Study|Adverse event unrelated to study drug|3
6188666|NCT01393964|9843464|FG002|Overall Study|Adverse event unrelated to study drug|0
6188667|NCT01393964|9843462|FG000|Overall Study|Subject request stop study treatment|0
6188668|NCT01393964|9843463|FG001|Overall Study|Subject request stop study treatment|1
6188669|NCT01393964|9843464|FG002|Overall Study|Subject request stop study treatment|0
6188670|NCT01393964|9843462|FG000|Overall Study|Subject decided to move to transplant|1
6188671|NCT01393964|9843463|FG001|Overall Study|Subject decided to move to transplant|0
6188672|NCT01393964|9843464|FG002|Overall Study|Subject decided to move to transplant|0
6236459|NCT01804673|9915139|FG000|Overall Study|Other|4
6188673|NCT01393964|9843462|FG000|Overall Study|Subject switched to commercial supply|1
6188674|NCT01393964|9843463|FG001|Overall Study|Subject switched to commercial supply|0
6188675|NCT01393964|9843464|FG002|Overall Study|Subject switched to commercial supply|2
6236460|NCT01804842|9915146|FG000|Overall Study|Adverse Event|1
6236461|NCT01804842|9915147|FG001|Overall Study|Adverse Event|1
6236462|NCT01804842|9915148|FG002|Overall Study|Adverse Event|0
6236463|NCT01804842|9915146|FG000|Overall Study|Lost to Follow-up|1
6236464|NCT01804842|9915147|FG001|Overall Study|Lost to Follow-up|0
6236465|NCT01804842|9915148|FG002|Overall Study|Lost to Follow-up|0
6236466|NCT01804842|9915146|FG000|Overall Study|Non-Compliance|1
6236467|NCT01804842|9915147|FG001|Overall Study|Non-Compliance|1
6236468|NCT01804842|9915148|FG002|Overall Study|Non-Compliance|0
6236469|NCT01804842|9915146|FG000|Overall Study|Personal Reason|0
6236470|NCT01804842|9915147|FG001|Overall Study|Personal Reason|0
6236471|NCT01804842|9915148|FG002|Overall Study|Personal Reason|1
6236472|NCT01804946|9915169|FG000|Overall Study|Protocol Violation|1
6236473|NCT01804946|9915170|FG001|Overall Study|Protocol Violation|0
6236474|NCT01804946|9915169|FG000|Overall Study|Adverse Event|0
6236475|NCT01804946|9915170|FG001|Overall Study|Adverse Event|1
6236476|NCT01804946|9915169|FG000|Overall Study|Insufficient data available|0
6236477|NCT01804946|9915170|FG001|Overall Study|Insufficient data available|1
6236478|NCT01804946|9915169|FG000|Overall Study|Do not meet inclusion criteria|1
6236479|NCT01804946|9915170|FG001|Overall Study|Do not meet inclusion criteria|2
6236480|NCT01805037|9915195|FG000|1st Cycle of Maintenance (3 Weeks)|Lack of Efficacy|0
6188676|NCT01393964|9843462|FG000|Overall Study|Subject plateaued in terms of effect|1
6188677|NCT01393964|9843463|FG001|Overall Study|Subject plateaued in terms of effect|0
6188678|NCT01393964|9843464|FG002|Overall Study|Subject plateaued in terms of effect|0
6188679|NCT01393964|9843462|FG000|Overall Study|Investigator removed subject from study|0
6188680|NCT01393964|9843463|FG001|Overall Study|Investigator removed subject from study|1
6188681|NCT01393964|9843464|FG002|Overall Study|Investigator removed subject from study|0
6188682|NCT01393964|9843462|FG000|Overall Study|Subject converted to roll-over study|0
6188683|NCT01393964|9843463|FG001|Overall Study|Subject converted to roll-over study|1
6188684|NCT01393964|9843464|FG002|Overall Study|Subject converted to roll-over study|0
6188685|NCT01393964|9843462|FG000|Overall Study|Subject to receive non-protocol therapy|0
6188686|NCT01393964|9843463|FG001|Overall Study|Subject to receive non-protocol therapy|0
6188687|NCT01393964|9843464|FG002|Overall Study|Subject to receive non-protocol therapy|1
6188688|NCT01393990|9843496|FG000|Overall Study|Adverse Event|0
6188689|NCT01393990|9843497|FG001|Overall Study|Adverse Event|0
6188690|NCT01393990|9843498|FG002|Overall Study|Adverse Event|0
6188691|NCT01393990|9843499|FG003|Overall Study|Adverse Event|0
6188692|NCT01393990|9843500|FG004|Overall Study|Adverse Event|0
6188693|NCT01393990|9843501|FG005|Overall Study|Adverse Event|0
6188694|NCT01393990|9843502|FG006|Overall Study|Adverse Event|0
6188695|NCT01393990|9843503|FG007|Overall Study|Adverse Event|0
6188696|NCT01393990|9843504|FG008|Overall Study|Adverse Event|0
6188697|NCT01393990|9843505|FG009|Overall Study|Adverse Event|0
6188698|NCT01393990|9843506|FG010|Overall Study|Adverse Event|0
6188699|NCT01393990|9843507|FG011|Overall Study|Adverse Event|0
6188700|NCT01393990|9843508|FG012|Overall Study|Adverse Event|0
6188701|NCT01393990|9843509|FG013|Overall Study|Adverse Event|0
6188702|NCT01393990|9843510|FG014|Overall Study|Adverse Event|1
6188703|NCT01393990|9843511|FG015|Overall Study|Adverse Event|1
6188704|NCT01393990|9843512|FG016|Overall Study|Adverse Event|0
6188705|NCT01393990|9843513|FG017|Overall Study|Adverse Event|0
6188706|NCT01393990|9843496|FG000|Overall Study|Progressive Disease|1
6188707|NCT01393990|9843497|FG001|Overall Study|Progressive Disease|0
6188708|NCT01393990|9843498|FG002|Overall Study|Progressive Disease|0
6188709|NCT01393990|9843499|FG003|Overall Study|Progressive Disease|1
6188710|NCT01393990|9843500|FG004|Overall Study|Progressive Disease|1
6188711|NCT01393990|9843501|FG005|Overall Study|Progressive Disease|1
6188712|NCT01393990|9843502|FG006|Overall Study|Progressive Disease|1
6188713|NCT01393990|9843503|FG007|Overall Study|Progressive Disease|1
6188714|NCT01393990|9843504|FG008|Overall Study|Progressive Disease|3
6188715|NCT01393990|9843505|FG009|Overall Study|Progressive Disease|1
6188716|NCT01393990|9843506|FG010|Overall Study|Progressive Disease|0
6188717|NCT01393990|9843507|FG011|Overall Study|Progressive Disease|0
6188718|NCT01393990|9843508|FG012|Overall Study|Progressive Disease|0
6188719|NCT01393990|9843509|FG013|Overall Study|Progressive Disease|1
6188720|NCT01393990|9843510|FG014|Overall Study|Progressive Disease|6
6188721|NCT01393990|9843511|FG015|Overall Study|Progressive Disease|1
6188722|NCT01393990|9843512|FG016|Overall Study|Progressive Disease|0
6188723|NCT01393990|9843513|FG017|Overall Study|Progressive Disease|0
6188724|NCT01393990|9843496|FG000|Overall Study|Death|0
6188725|NCT01393990|9843497|FG001|Overall Study|Death|0
6188726|NCT01393990|9843498|FG002|Overall Study|Death|0
6188727|NCT01393990|9843499|FG003|Overall Study|Death|0
6188728|NCT01393990|9843500|FG004|Overall Study|Death|1
6188729|NCT01393990|9843501|FG005|Overall Study|Death|0
6188730|NCT01393990|9843502|FG006|Overall Study|Death|0
6188731|NCT01393990|9843503|FG007|Overall Study|Death|0
6188732|NCT01393990|9843504|FG008|Overall Study|Death|0
6188733|NCT01393990|9843505|FG009|Overall Study|Death|0
6188734|NCT01393990|9843506|FG010|Overall Study|Death|0
6188735|NCT01393990|9843507|FG011|Overall Study|Death|0
6188736|NCT01393990|9843508|FG012|Overall Study|Death|0
6236481|NCT01805037|9915196|FG001|1st Cycle of Maintenance (3 Weeks)|Lack of Efficacy|2
6236482|NCT01805037|9915195|FG000|1st Cycle of Maintenance (3 Weeks)|Withdrawal by Subject|0
6236483|NCT01805037|9915196|FG001|1st Cycle of Maintenance (3 Weeks)|Withdrawal by Subject|2
6236484|NCT01805037|9915195|FG000|1st Cycle of Maintenance (3 Weeks)|Adverse Event|0
6236485|NCT01805037|9915196|FG001|1st Cycle of Maintenance (3 Weeks)|Adverse Event|1
6236486|NCT01805037|9915195|FG000|1st Cycle of Maintenance (3 Weeks)|Death|0
6236487|NCT01805037|9915196|FG001|1st Cycle of Maintenance (3 Weeks)|Death|1
6236488|NCT01805037|9915195|FG000|2nd Cycle of Maintenance and Beyond|Adverse Event|0
6236489|NCT01805037|9915196|FG001|2nd Cycle of Maintenance and Beyond|Adverse Event|10
6236490|NCT01805037|9915195|FG000|2nd Cycle of Maintenance and Beyond|Progressive Disease|0
6236491|NCT01805037|9915196|FG001|2nd Cycle of Maintenance and Beyond|Progressive Disease|1
6236492|NCT01805037|9915195|FG000|2nd Cycle of Maintenance and Beyond|Withdrawal by Subject|0
6236493|NCT01805037|9915196|FG001|2nd Cycle of Maintenance and Beyond|Withdrawal by Subject|1
6236494|NCT01805037|9915195|FG000|Follow Up (up to 3 Years)|Death|0
6236495|NCT01805037|9915196|FG001|Follow Up (up to 3 Years)|Death|2
6236496|NCT01805037|9915195|FG000|Follow Up (up to 3 Years)|Withdrawal by Subject|0
6236497|NCT01805037|9915196|FG001|Follow Up (up to 3 Years)|Withdrawal by Subject|3
6236498|NCT01805037|9915195|FG000|Follow Up (up to 3 Years)|Lost to Follow-up|0
6236499|NCT01805037|9915196|FG001|Follow Up (up to 3 Years)|Lost to Follow-up|1
6236500|NCT01805180|9915218|FG000|Lead-in Donor Phase|screen failure|1
6236501|NCT01805180|9915219|FG001|Lead-in Donor Phase|screen failure|0
6236502|NCT01805180|9915220|FG002|Lead-in Donor Phase|screen failure|0
6236503|NCT01806064|9915322|FG000|Overall Study|Randomized Not Enrolled|0
6236504|NCT01806064|9915323|FG001|Overall Study|Randomized Not Enrolled|0
6236505|NCT01806064|9915324|FG002|Overall Study|Randomized Not Enrolled|0
6236506|NCT01806064|9915325|FG003|Overall Study|Randomized Not Enrolled|1
6236507|NCT01806064|9915326|FG004|Overall Study|Randomized Not Enrolled|2
6236508|NCT01806168|9915345|FG000|Overall Study|Adverse Event|1
6236509|NCT01806168|9915346|FG001|Overall Study|Adverse Event|0
6236510|NCT01806168|9915347|FG002|Overall Study|Adverse Event|0
6236511|NCT01806168|9915345|FG000|Overall Study|Withdrawal by Subject|0
6236512|NCT01806168|9915346|FG001|Overall Study|Withdrawal by Subject|1
6236513|NCT01806168|9915347|FG002|Overall Study|Withdrawal by Subject|2
6236514|NCT01806168|9915345|FG000|Overall Study|Protocol Violation|0
6236515|NCT01806168|9915346|FG001|Overall Study|Protocol Violation|0
6236516|NCT01806168|9915347|FG002|Overall Study|Protocol Violation|1
6236517|NCT01806298|9915368|FG000|Overall Study|Adverse Event|3
6236518|NCT01806298|9915368|FG000|Overall Study|Protocol Non-compliance|1
6236519|NCT01806298|9915368|FG000|Overall Study|Withdrawal by Subject|1
6236520|NCT01806298|9915368|FG000|Overall Study|Other|5
6236521|NCT01806389|9915372|FG000|Overall Study|Withdrawal by Subject|4
6236522|NCT01806506|9915388|FG000|Overall Study|Lost to Follow-up|2
6236523|NCT01806506|9915389|FG001|Overall Study|Lost to Follow-up|1
6236524|NCT01806545|9915397|FG000|Overall Study|Adverse Event|2
6236525|NCT01806545|9915398|FG001|Overall Study|Adverse Event|3
6236526|NCT01806545|9915397|FG000|Overall Study|Lost to Follow-up|1
6236527|NCT01806545|9915398|FG001|Overall Study|Lost to Follow-up|0
6236528|NCT01806545|9915397|FG000|Overall Study|Withdrawal by Subject|3
6236529|NCT01806545|9915398|FG001|Overall Study|Withdrawal by Subject|2
6236530|NCT01806584|9915410|FG000|Overall Study|Adverse Event|2
6188737|NCT01393990|9843509|FG013|Overall Study|Death|1
6236531|NCT01806584|9915411|FG001|Overall Study|Adverse Event|1
6236532|NCT01806584|9915410|FG000|Overall Study|Death|1
6236533|NCT01806584|9915411|FG001|Overall Study|Death|0
6236534|NCT01806584|9915410|FG000|Overall Study|Lost to Follow-up|0
6236535|NCT01806584|9915411|FG001|Overall Study|Lost to Follow-up|2
6236536|NCT01806584|9915410|FG000|Overall Study|Study terminated by sponsor|9
6236537|NCT01806584|9915411|FG001|Overall Study|Study terminated by sponsor|14
6236538|NCT01806584|9915410|FG000|Overall Study|Withdrawal by Subject|1
6236539|NCT01806584|9915411|FG001|Overall Study|Withdrawal by Subject|1
6236540|NCT01806584|9915410|FG000|Overall Study|Other unspecified|1
6236541|NCT01806584|9915411|FG001|Overall Study|Other unspecified|0
6236542|NCT01806597|9915420|FG000|Period 1 (Baseline to Week 16)|Adverse Event|1
6236543|NCT01806597|9915421|FG001|Period 1 (Baseline to Week 16)|Adverse Event|1
6236544|NCT01806597|9915422|FG002|Period 1 (Baseline to Week 16)|Adverse Event|0
6236545|NCT01806597|9915423|FG003|Period 1 (Baseline to Week 16)|Adverse Event|0
6188738|NCT01393990|9843510|FG014|Overall Study|Death|1
6188739|NCT01393990|9843511|FG015|Overall Study|Death|0
6188740|NCT01393990|9843512|FG016|Overall Study|Death|0
6188741|NCT01393990|9843513|FG017|Overall Study|Death|0
6188742|NCT01393990|9843496|FG000|Overall Study|Withdrawal by Subject|0
6188743|NCT01393990|9843497|FG001|Overall Study|Withdrawal by Subject|0
6188744|NCT01393990|9843498|FG002|Overall Study|Withdrawal by Subject|0
6188745|NCT01393990|9843499|FG003|Overall Study|Withdrawal by Subject|0
6188746|NCT01393990|9843500|FG004|Overall Study|Withdrawal by Subject|0
6236546|NCT01806597|9915424|FG004|Period 1 (Baseline to Week 16)|Adverse Event|2
6236547|NCT01806597|9915425|FG005|Period 1 (Baseline to Week 16)|Adverse Event|0
6188747|NCT01393990|9843501|FG005|Overall Study|Withdrawal by Subject|0
6188748|NCT01393990|9843502|FG006|Overall Study|Withdrawal by Subject|0
6236548|NCT01806597|9915420|FG000|Period 1 (Baseline to Week 16)|Lack of Efficacy|1
6236549|NCT01806597|9915421|FG001|Period 1 (Baseline to Week 16)|Lack of Efficacy|0
6236550|NCT01806597|9915422|FG002|Period 1 (Baseline to Week 16)|Lack of Efficacy|0
6236551|NCT01806597|9915423|FG003|Period 1 (Baseline to Week 16)|Lack of Efficacy|0
6271871|NCT02168777|9973907|FG000|Overall Study|Other reason|0
6236552|NCT01806597|9915424|FG004|Period 1 (Baseline to Week 16)|Lack of Efficacy|1
6236553|NCT01806597|9915425|FG005|Period 1 (Baseline to Week 16)|Lack of Efficacy|0
6236554|NCT01806597|9915420|FG000|Period 1 (Baseline to Week 16)|Protocol Violation|0
6236555|NCT01806597|9915421|FG001|Period 1 (Baseline to Week 16)|Protocol Violation|1
6236556|NCT01806597|9915422|FG002|Period 1 (Baseline to Week 16)|Protocol Violation|0
6236557|NCT01806597|9915423|FG003|Period 1 (Baseline to Week 16)|Protocol Violation|0
6236558|NCT01806597|9915424|FG004|Period 1 (Baseline to Week 16)|Protocol Violation|0
6236559|NCT01806597|9915425|FG005|Period 1 (Baseline to Week 16)|Protocol Violation|0
6236560|NCT01806597|9915420|FG000|Period 1 (Baseline to Week 16)|Withdrawal by Subject|3
6236561|NCT01806597|9915421|FG001|Period 1 (Baseline to Week 16)|Withdrawal by Subject|2
6236562|NCT01806597|9915422|FG002|Period 1 (Baseline to Week 16)|Withdrawal by Subject|0
6236563|NCT01806597|9915423|FG003|Period 1 (Baseline to Week 16)|Withdrawal by Subject|0
6236564|NCT01806597|9915424|FG004|Period 1 (Baseline to Week 16)|Withdrawal by Subject|2
6236565|NCT01806597|9915425|FG005|Period 1 (Baseline to Week 16)|Withdrawal by Subject|0
6236566|NCT01806597|9915420|FG000|Period 1 (Baseline to Week 16)|Physician Decision|0
6236567|NCT01806597|9915421|FG001|Period 1 (Baseline to Week 16)|Physician Decision|1
6188749|NCT01393990|9843503|FG007|Overall Study|Withdrawal by Subject|0
6188750|NCT01393990|9843504|FG008|Overall Study|Withdrawal by Subject|0
6188751|NCT01393990|9843505|FG009|Overall Study|Withdrawal by Subject|0
6188752|NCT01393990|9843506|FG010|Overall Study|Withdrawal by Subject|0
6188753|NCT01393990|9843507|FG011|Overall Study|Withdrawal by Subject|0
6188754|NCT01393990|9843508|FG012|Overall Study|Withdrawal by Subject|0
6188755|NCT01393990|9843509|FG013|Overall Study|Withdrawal by Subject|0
6188756|NCT01393990|9843510|FG014|Overall Study|Withdrawal by Subject|1
6188757|NCT01393990|9843511|FG015|Overall Study|Withdrawal by Subject|1
6188758|NCT01393990|9843512|FG016|Overall Study|Withdrawal by Subject|0
6188759|NCT01393990|9843513|FG017|Overall Study|Withdrawal by Subject|0
6188760|NCT01394185|9843621|FG000|Overall Study|Withdrawal by Subject|2
6188761|NCT01394185|9843622|FG001|Overall Study|Withdrawal by Subject|0
6188762|NCT01394185|9843623|FG002|Overall Study|Withdrawal by Subject|0
6188763|NCT01394185|9843624|FG003|Overall Study|Withdrawal by Subject|0
6188764|NCT01394185|9843625|FG004|Overall Study|Withdrawal by Subject|1
6188765|NCT01394185|9843626|FG005|Overall Study|Withdrawal by Subject|0
6188766|NCT01394185|9843621|FG000|Overall Study|Change in protocol|3
6188767|NCT01394185|9843622|FG001|Overall Study|Change in protocol|0
6188768|NCT01394185|9843623|FG002|Overall Study|Change in protocol|0
6188769|NCT01394185|9843624|FG003|Overall Study|Change in protocol|0
6188770|NCT01394185|9843625|FG004|Overall Study|Change in protocol|3
6188771|NCT01394185|9843626|FG005|Overall Study|Change in protocol|0
6188772|NCT01394185|9843621|FG000|Overall Study|Protocol Violation|1
6188773|NCT01394185|9843622|FG001|Overall Study|Protocol Violation|0
6188774|NCT01394185|9843623|FG002|Overall Study|Protocol Violation|0
6188775|NCT01394185|9843624|FG003|Overall Study|Protocol Violation|1
6188776|NCT01394185|9843625|FG004|Overall Study|Protocol Violation|0
6188777|NCT01394185|9843626|FG005|Overall Study|Protocol Violation|1
6188778|NCT01394250|9843636|FG000|Randomization and IV Placement Attempt|Unsuccessful IV Access on First Attempt|14
6236568|NCT01806597|9915422|FG002|Period 1 (Baseline to Week 16)|Physician Decision|0
6236569|NCT01806597|9915423|FG003|Period 1 (Baseline to Week 16)|Physician Decision|0
6236570|NCT01806597|9915424|FG004|Period 1 (Baseline to Week 16)|Physician Decision|0
6236571|NCT01806597|9915425|FG005|Period 1 (Baseline to Week 16)|Physician Decision|0
6236572|NCT01806597|9915420|FG000|Treatment Period 2 (Week 16 to Week 132)|Adverse Event|9
6236573|NCT01806597|9915421|FG001|Treatment Period 2 (Week 16 to Week 132)|Adverse Event|6
6236574|NCT01806597|9915422|FG002|Treatment Period 2 (Week 16 to Week 132)|Adverse Event|4
6236575|NCT01806597|9915423|FG003|Treatment Period 2 (Week 16 to Week 132)|Adverse Event|3
6236576|NCT01806597|9915424|FG004|Treatment Period 2 (Week 16 to Week 132)|Adverse Event|1
6236577|NCT01806597|9915425|FG005|Treatment Period 2 (Week 16 to Week 132)|Adverse Event|0
6236578|NCT01806597|9915420|FG000|Treatment Period 2 (Week 16 to Week 132)|Lack of Efficacy|12
6236579|NCT01806597|9915421|FG001|Treatment Period 2 (Week 16 to Week 132)|Lack of Efficacy|5
6236580|NCT01806597|9915422|FG002|Treatment Period 2 (Week 16 to Week 132)|Lack of Efficacy|3
6236581|NCT01806597|9915423|FG003|Treatment Period 2 (Week 16 to Week 132)|Lack of Efficacy|1
6236582|NCT01806597|9915424|FG004|Treatment Period 2 (Week 16 to Week 132)|Lack of Efficacy|0
6236583|NCT01806597|9915425|FG005|Treatment Period 2 (Week 16 to Week 132)|Lack of Efficacy|0
6236584|NCT01806597|9915420|FG000|Treatment Period 2 (Week 16 to Week 132)|Lost to Follow-up|2
6236585|NCT01806597|9915421|FG001|Treatment Period 2 (Week 16 to Week 132)|Lost to Follow-up|0
6236586|NCT01806597|9915422|FG002|Treatment Period 2 (Week 16 to Week 132)|Lost to Follow-up|0
6236587|NCT01806597|9915423|FG003|Treatment Period 2 (Week 16 to Week 132)|Lost to Follow-up|0
6236588|NCT01806597|9915424|FG004|Treatment Period 2 (Week 16 to Week 132)|Lost to Follow-up|0
6236589|NCT01806597|9915425|FG005|Treatment Period 2 (Week 16 to Week 132)|Lost to Follow-up|0
6236590|NCT01806597|9915420|FG000|Treatment Period 2 (Week 16 to Week 132)|Physician Decision|1
6236591|NCT01806597|9915421|FG001|Treatment Period 2 (Week 16 to Week 132)|Physician Decision|1
6236592|NCT01806597|9915422|FG002|Treatment Period 2 (Week 16 to Week 132)|Physician Decision|0
6236593|NCT01806597|9915423|FG003|Treatment Period 2 (Week 16 to Week 132)|Physician Decision|0
6236594|NCT01806597|9915424|FG004|Treatment Period 2 (Week 16 to Week 132)|Physician Decision|0
6236595|NCT01806597|9915425|FG005|Treatment Period 2 (Week 16 to Week 132)|Physician Decision|0
6236596|NCT01806597|9915420|FG000|Treatment Period 2 (Week 16 to Week 132)|Protocol Violation|2
6236597|NCT01806597|9915421|FG001|Treatment Period 2 (Week 16 to Week 132)|Protocol Violation|0
6236598|NCT01806597|9915422|FG002|Treatment Period 2 (Week 16 to Week 132)|Protocol Violation|0
6236599|NCT01806597|9915423|FG003|Treatment Period 2 (Week 16 to Week 132)|Protocol Violation|0
6236600|NCT01806597|9915424|FG004|Treatment Period 2 (Week 16 to Week 132)|Protocol Violation|0
6236601|NCT01806597|9915425|FG005|Treatment Period 2 (Week 16 to Week 132)|Protocol Violation|0
6236602|NCT01806597|9915420|FG000|Treatment Period 2 (Week 16 to Week 132)|study terminated by sponsor|0
6236603|NCT01806597|9915421|FG001|Treatment Period 2 (Week 16 to Week 132)|study terminated by sponsor|1
6236604|NCT01806597|9915422|FG002|Treatment Period 2 (Week 16 to Week 132)|study terminated by sponsor|0
6236605|NCT01806597|9915423|FG003|Treatment Period 2 (Week 16 to Week 132)|study terminated by sponsor|1
6236606|NCT01806597|9915424|FG004|Treatment Period 2 (Week 16 to Week 132)|study terminated by sponsor|0
6236607|NCT01806597|9915425|FG005|Treatment Period 2 (Week 16 to Week 132)|study terminated by sponsor|0
6236608|NCT01806597|9915420|FG000|Treatment Period 2 (Week 16 to Week 132)|Withdrawal by Subject|10
6236609|NCT01806597|9915421|FG001|Treatment Period 2 (Week 16 to Week 132)|Withdrawal by Subject|5
6236610|NCT01806597|9915422|FG002|Treatment Period 2 (Week 16 to Week 132)|Withdrawal by Subject|6
6236611|NCT01806597|9915423|FG003|Treatment Period 2 (Week 16 to Week 132)|Withdrawal by Subject|5
6236612|NCT01806597|9915424|FG004|Treatment Period 2 (Week 16 to Week 132)|Withdrawal by Subject|0
6236613|NCT01806597|9915425|FG005|Treatment Period 2 (Week 16 to Week 132)|Withdrawal by Subject|0
6236614|NCT01806597|9915420|FG000|Treatment Period 2 (Week 16 to Week 132)|non-compliance with study treatment|2
6236615|NCT01806597|9915421|FG001|Treatment Period 2 (Week 16 to Week 132)|non-compliance with study treatment|2
6236616|NCT01806597|9915422|FG002|Treatment Period 2 (Week 16 to Week 132)|non-compliance with study treatment|1
6236617|NCT01806597|9915423|FG003|Treatment Period 2 (Week 16 to Week 132)|non-compliance with study treatment|1
6236618|NCT01806597|9915424|FG004|Treatment Period 2 (Week 16 to Week 132)|non-compliance with study treatment|0
6236619|NCT01806597|9915425|FG005|Treatment Period 2 (Week 16 to Week 132)|non-compliance with study treatment|0
6236620|NCT01806597|9915420|FG000|Treatment Period 2 (Week 16 to Week 132)|Death|1
6236621|NCT01806597|9915421|FG001|Treatment Period 2 (Week 16 to Week 132)|Death|0
6236622|NCT01806597|9915422|FG002|Treatment Period 2 (Week 16 to Week 132)|Death|0
6236623|NCT01806597|9915423|FG003|Treatment Period 2 (Week 16 to Week 132)|Death|0
6236624|NCT01806597|9915424|FG004|Treatment Period 2 (Week 16 to Week 132)|Death|0
6236625|NCT01806597|9915425|FG005|Treatment Period 2 (Week 16 to Week 132)|Death|0
6236626|NCT01806597|9915420|FG000|Follow-up Period (Week 132 to Week 140)|Withdrawal by Subject|0
6236627|NCT01806597|9915421|FG001|Follow-up Period (Week 132 to Week 140)|Withdrawal by Subject|0
6236628|NCT01806597|9915422|FG002|Follow-up Period (Week 132 to Week 140)|Withdrawal by Subject|0
6236629|NCT01806597|9915423|FG003|Follow-up Period (Week 132 to Week 140)|Withdrawal by Subject|0
6236630|NCT01806597|9915424|FG004|Follow-up Period (Week 132 to Week 140)|Withdrawal by Subject|0
6236631|NCT01806597|9915425|FG005|Follow-up Period (Week 132 to Week 140)|Withdrawal by Subject|5
6236632|NCT01806597|9915420|FG000|Follow-up Period (Week 132 to Week 140)|Adverse Event|0
6236633|NCT01806597|9915421|FG001|Follow-up Period (Week 132 to Week 140)|Adverse Event|0
6236634|NCT01806597|9915422|FG002|Follow-up Period (Week 132 to Week 140)|Adverse Event|0
6236635|NCT01806597|9915423|FG003|Follow-up Period (Week 132 to Week 140)|Adverse Event|0
6236636|NCT01806597|9915424|FG004|Follow-up Period (Week 132 to Week 140)|Adverse Event|0
6236637|NCT01806597|9915425|FG005|Follow-up Period (Week 132 to Week 140)|Adverse Event|2
6236638|NCT01806597|9915420|FG000|Follow-up Period (Week 132 to Week 140)|Lack of Efficacy|0
6236639|NCT01806597|9915421|FG001|Follow-up Period (Week 132 to Week 140)|Lack of Efficacy|0
6236640|NCT01806597|9915422|FG002|Follow-up Period (Week 132 to Week 140)|Lack of Efficacy|0
6236641|NCT01806597|9915423|FG003|Follow-up Period (Week 132 to Week 140)|Lack of Efficacy|0
6236642|NCT01806597|9915424|FG004|Follow-up Period (Week 132 to Week 140)|Lack of Efficacy|0
6236643|NCT01806597|9915425|FG005|Follow-up Period (Week 132 to Week 140)|Lack of Efficacy|2
6236644|NCT01806597|9915420|FG000|Follow-up Period (Week 132 to Week 140)|Lost to Follow-up|0
6236645|NCT01806597|9915421|FG001|Follow-up Period (Week 132 to Week 140)|Lost to Follow-up|0
6236646|NCT01806597|9915422|FG002|Follow-up Period (Week 132 to Week 140)|Lost to Follow-up|0
6236647|NCT01806597|9915423|FG003|Follow-up Period (Week 132 to Week 140)|Lost to Follow-up|0
6236648|NCT01806597|9915424|FG004|Follow-up Period (Week 132 to Week 140)|Lost to Follow-up|0
6236649|NCT01806597|9915425|FG005|Follow-up Period (Week 132 to Week 140)|Lost to Follow-up|2
6236650|NCT01806597|9915420|FG000|Follow-up Period (Week 132 to Week 140)|Physician Decision|0
6236651|NCT01806597|9915421|FG001|Follow-up Period (Week 132 to Week 140)|Physician Decision|0
6236652|NCT01806597|9915422|FG002|Follow-up Period (Week 132 to Week 140)|Physician Decision|0
6236653|NCT01806597|9915423|FG003|Follow-up Period (Week 132 to Week 140)|Physician Decision|0
6236654|NCT01806597|9915424|FG004|Follow-up Period (Week 132 to Week 140)|Physician Decision|0
6236655|NCT01806597|9915425|FG005|Follow-up Period (Week 132 to Week 140)|Physician Decision|1
6236656|NCT01806623|9915439|FG000|Overall Study|Withdrawal by Subject|1
6236657|NCT01806623|9915439|FG000|Overall Study|Adverse Event|1
6236658|NCT01806623|9915439|FG000|Overall Study|Did not meet the inclusion criteria|56
6236659|NCT01806662|9915443|FG000|First Intervention (Weeks 0-16)|Withdrawal by Subject|4
6236660|NCT01806662|9915444|FG001|First Intervention (Weeks 0-16)|Withdrawal by Subject|0
6236661|NCT01806662|9915443|FG000|First Intervention (Weeks 0-16)|Adverse Event|0
6236662|NCT01806662|9915444|FG001|First Intervention (Weeks 0-16)|Adverse Event|1
6236663|NCT01806662|9915443|FG000|Second Intervention (Weeks 16-32)|Lack of Efficacy|2
6236664|NCT01806662|9915444|FG001|Second Intervention (Weeks 16-32)|Lack of Efficacy|3
6236665|NCT01806662|9915443|FG000|Second Intervention (Weeks 16-32)|Lost to Follow-up|0
6236666|NCT01806662|9915444|FG001|Second Intervention (Weeks 16-32)|Lost to Follow-up|1
6236667|NCT01806714|9915477|FG000|Overall Study|No functioning phone number|200
6236668|NCT01806714|9915478|FG001|Overall Study|No functioning phone number|170
6236669|NCT01806740|9915484|FG000|Overall Study|Withdrawal by Subject|4
6236670|NCT01806740|9915484|FG000|Overall Study|Physician Decision|1
6236671|NCT01806740|9915484|FG000|Overall Study|Patient's refusal of treatment|1
6236672|NCT01806779|9915493|FG000|Overall Study|Physician Decision|2
6236673|NCT01806779|9915494|FG001|Overall Study|Physician Decision|0
6236674|NCT01806779|9915495|FG002|Overall Study|Physician Decision|1
6236675|NCT01806779|9915493|FG000|Overall Study|Lack of Efficacy|1
6236676|NCT01806779|9915494|FG001|Overall Study|Lack of Efficacy|1
6236677|NCT01806779|9915495|FG002|Overall Study|Lack of Efficacy|0
6236678|NCT01806779|9915493|FG000|Overall Study|Lost to Follow-up|19
6236679|NCT01806779|9915494|FG001|Overall Study|Lost to Follow-up|20
6236680|NCT01806779|9915495|FG002|Overall Study|Lost to Follow-up|0
6236681|NCT01806779|9915493|FG000|Overall Study|Withdrawal by Subject|20
6236682|NCT01806779|9915494|FG001|Overall Study|Withdrawal by Subject|23
6236683|NCT01806779|9915495|FG002|Overall Study|Withdrawal by Subject|22
6236684|NCT01806896|9915512|FG000|Overall Study|Adverse Event|2
6236685|NCT01806896|9915513|FG001|Overall Study|Adverse Event|0
6236686|NCT01806896|9915512|FG000|Overall Study|Other|1
6236687|NCT01806896|9915513|FG001|Overall Study|Other|0
6236688|NCT01807065|9915555|FG000|Overall Study|Receive no sip-T due to IV access|1
6236689|NCT01807065|9915556|FG001|Overall Study|Receive no sip-T due to IV access|1
6270070|NCT02147158|9970635|FG004|Off-Treatment Interval 2|Withdrawal of Consent|0
6270071|NCT02147158|9970636|FG005|Off-Treatment Interval 2|Withdrawal of Consent|1
6270072|NCT02147158|9970631|FG000|Off-Treatment Interval 2|Lost to Follow-up|0
6270073|NCT02147158|9970632|FG001|Off-Treatment Interval 2|Lost to Follow-up|0
6270074|NCT02147158|9970633|FG002|Off-Treatment Interval 2|Lost to Follow-up|3
6270075|NCT02147158|9970634|FG003|Off-Treatment Interval 2|Lost to Follow-up|2
6270076|NCT02147158|9970635|FG004|Off-Treatment Interval 2|Lost to Follow-up|2
6270077|NCT02147158|9970636|FG005|Off-Treatment Interval 2|Lost to Follow-up|2
6270078|NCT02147158|9970631|FG000|Off-Treatment Interval 2|Protocol Violation|0
6270079|NCT02147158|9970632|FG001|Off-Treatment Interval 2|Protocol Violation|0
6270080|NCT02147158|9970633|FG002|Off-Treatment Interval 2|Protocol Violation|0
6270081|NCT02147158|9970634|FG003|Off-Treatment Interval 2|Protocol Violation|1
6270082|NCT02147158|9970635|FG004|Off-Treatment Interval 2|Protocol Violation|0
6270083|NCT02147158|9970636|FG005|Off-Treatment Interval 2|Protocol Violation|0
6270084|NCT02147158|9970631|FG000|Off-Treatment Interval 2|Other Miscellaneous Reasons|0
6270085|NCT02147158|9970632|FG001|Off-Treatment Interval 2|Other Miscellaneous Reasons|3
6236690|NCT01807156|9915575|FG000|Overall Study|Physician Decision|1
6236691|NCT01807221|9915585|FG000|Overall Study|Progressive disease|1
6236692|NCT01807221|9915586|FG001|Overall Study|Progressive disease|0
6236693|NCT01807221|9915587|FG002|Overall Study|Progressive disease|1
6236694|NCT01807221|9915588|FG003|Overall Study|Progressive disease|0
6236695|NCT01807221|9915589|FG004|Overall Study|Progressive disease|0
6236696|NCT01807221|9915590|FG005|Overall Study|Progressive disease|0
6236697|NCT01807221|9915585|FG000|Overall Study|Death|7
6236698|NCT01807221|9915586|FG001|Overall Study|Death|9
6236699|NCT01807221|9915587|FG002|Overall Study|Death|4
6236700|NCT01807221|9915588|FG003|Overall Study|Death|2
6236701|NCT01807221|9915589|FG004|Overall Study|Death|1
6236702|NCT01807221|9915590|FG005|Overall Study|Death|6
6236703|NCT01807221|9915585|FG000|Overall Study|Physician Decision|2
6236704|NCT01807221|9915586|FG001|Overall Study|Physician Decision|1
6236705|NCT01807221|9915587|FG002|Overall Study|Physician Decision|0
6236706|NCT01807221|9915588|FG003|Overall Study|Physician Decision|0
6236707|NCT01807221|9915589|FG004|Overall Study|Physician Decision|0
6236708|NCT01807221|9915590|FG005|Overall Study|Physician Decision|0
6236709|NCT01807221|9915585|FG000|Overall Study|Adverse Event|33
6236710|NCT01807221|9915586|FG001|Overall Study|Adverse Event|22
6236711|NCT01807221|9915587|FG002|Overall Study|Adverse Event|26
6236712|NCT01807221|9915588|FG003|Overall Study|Adverse Event|25
6236713|NCT01807221|9915589|FG004|Overall Study|Adverse Event|18
6236714|NCT01807221|9915590|FG005|Overall Study|Adverse Event|21
6236715|NCT01807221|9915585|FG000|Overall Study|Protocol Violation|0
6236716|NCT01807221|9915586|FG001|Overall Study|Protocol Violation|2
6236717|NCT01807221|9915587|FG002|Overall Study|Protocol Violation|1
6236718|NCT01807221|9915588|FG003|Overall Study|Protocol Violation|2
6236719|NCT01807221|9915589|FG004|Overall Study|Protocol Violation|0
6236720|NCT01807221|9915590|FG005|Overall Study|Protocol Violation|1
6236721|NCT01807221|9915585|FG000|Overall Study|Non-compliance|1
6236722|NCT01807221|9915586|FG001|Overall Study|Non-compliance|2
6236723|NCT01807221|9915587|FG002|Overall Study|Non-compliance|0
6236724|NCT01807221|9915588|FG003|Overall Study|Non-compliance|1
6236725|NCT01807221|9915589|FG004|Overall Study|Non-compliance|0
6236726|NCT01807221|9915590|FG005|Overall Study|Non-compliance|0
6236727|NCT01807221|9915585|FG000|Overall Study|Logistical difficulties|0
6236728|NCT01807221|9915586|FG001|Overall Study|Logistical difficulties|1
6236729|NCT01807221|9915587|FG002|Overall Study|Logistical difficulties|0
6236730|NCT01807221|9915588|FG003|Overall Study|Logistical difficulties|0
6236731|NCT01807221|9915589|FG004|Overall Study|Logistical difficulties|1
6236732|NCT01807221|9915590|FG005|Overall Study|Logistical difficulties|0
6236733|NCT01807221|9915585|FG000|Overall Study|Withdrawal by Subject|33
6236734|NCT01807221|9915586|FG001|Overall Study|Withdrawal by Subject|15
6236735|NCT01807221|9915587|FG002|Overall Study|Withdrawal by Subject|8
6236736|NCT01807221|9915588|FG003|Overall Study|Withdrawal by Subject|14
6236737|NCT01807221|9915589|FG004|Overall Study|Withdrawal by Subject|16
6236738|NCT01807221|9915590|FG005|Overall Study|Withdrawal by Subject|13
6236739|NCT01807221|9915585|FG000|Overall Study|Sponsor decision|2
6236740|NCT01807221|9915586|FG001|Overall Study|Sponsor decision|0
6236741|NCT01807221|9915587|FG002|Overall Study|Sponsor decision|1
6236742|NCT01807221|9915588|FG003|Overall Study|Sponsor decision|1
6236743|NCT01807221|9915589|FG004|Overall Study|Sponsor decision|0
6236744|NCT01807221|9915590|FG005|Overall Study|Sponsor decision|0
6236745|NCT01807221|9915585|FG000|Overall Study|Lost to Follow-up|1
6236746|NCT01807221|9915586|FG001|Overall Study|Lost to Follow-up|0
6236747|NCT01807221|9915587|FG002|Overall Study|Lost to Follow-up|2
6236748|NCT01807221|9915588|FG003|Overall Study|Lost to Follow-up|1
6236749|NCT01807221|9915589|FG004|Overall Study|Lost to Follow-up|0
6236750|NCT01807221|9915590|FG005|Overall Study|Lost to Follow-up|0
6236751|NCT01807234|9915610|FG000|Overall Study|Lost to Follow-up|2
6236752|NCT01807234|9915611|FG001|Overall Study|Lost to Follow-up|5
6236753|NCT01807234|9915612|FG002|Overall Study|Lost to Follow-up|1
6236754|NCT01807234|9915613|FG003|Overall Study|Lost to Follow-up|1
6236755|NCT01807234|9915614|FG004|Overall Study|Lost to Follow-up|1
6236756|NCT01807234|9915615|FG005|Overall Study|Lost to Follow-up|2
6236757|NCT01807234|9915610|FG000|Overall Study|Withdrawal by Subject|3
6236758|NCT01807234|9915611|FG001|Overall Study|Withdrawal by Subject|1
6236759|NCT01807234|9915612|FG002|Overall Study|Withdrawal by Subject|1
6236760|NCT01807234|9915613|FG003|Overall Study|Withdrawal by Subject|1
6236761|NCT01807234|9915614|FG004|Overall Study|Withdrawal by Subject|2
6236762|NCT01807234|9915615|FG005|Overall Study|Withdrawal by Subject|1
6236763|NCT01807234|9915610|FG000|Overall Study|Lack of Efficacy|0
6236764|NCT01807234|9915611|FG001|Overall Study|Lack of Efficacy|0
6236765|NCT01807234|9915612|FG002|Overall Study|Lack of Efficacy|0
6236766|NCT01807234|9915613|FG003|Overall Study|Lack of Efficacy|0
6236767|NCT01807234|9915614|FG004|Overall Study|Lack of Efficacy|1
6236768|NCT01807234|9915615|FG005|Overall Study|Lack of Efficacy|1
6236769|NCT01807299|9915629|FG000|Overall Study|Protocol Violation|3
6236770|NCT01807299|9915630|FG001|Overall Study|Protocol Violation|1
6236771|NCT01807299|9915631|FG002|Overall Study|Protocol Violation|0
6236772|NCT01807299|9915632|FG003|Overall Study|Protocol Violation|2
6236773|NCT01807520|9915649|FG000|Treatment Period 1 (0-16 Weeks)|Withdrawal by Subject|0
6236774|NCT01807520|9915650|FG001|Treatment Period 1 (0-16 Weeks)|Withdrawal by Subject|1
6236775|NCT01807520|9915651|FG002|Treatment Period 1 (0-16 Weeks)|Withdrawal by Subject|3
6236776|NCT01807520|9915652|FG003|Treatment Period 1 (0-16 Weeks)|Withdrawal by Subject|0
6236777|NCT01807520|9915653|FG004|Treatment Period 1 (0-16 Weeks)|Withdrawal by Subject|0
6236778|NCT01807520|9915654|FG005|Treatment Period 1 (0-16 Weeks)|Withdrawal by Subject|0
6236779|NCT01807520|9915655|FG006|Treatment Period 1 (0-16 Weeks)|Withdrawal by Subject|0
6236780|NCT01807520|9915649|FG000|Treatment Period 1 (0-16 Weeks)|Protocol deviation|1
6236781|NCT01807520|9915650|FG001|Treatment Period 1 (0-16 Weeks)|Protocol deviation|0
6188779|NCT01394250|9843637|FG001|Randomization and IV Placement Attempt|Unsuccessful IV Access on First Attempt|13
6188780|NCT01394250|9843636|FG000|Successful IV Placement & Follow-Up|Withdrawal by Subject|6
6236782|NCT01807520|9915651|FG002|Treatment Period 1 (0-16 Weeks)|Protocol deviation|1
6236783|NCT01807520|9915652|FG003|Treatment Period 1 (0-16 Weeks)|Protocol deviation|0
6236784|NCT01807520|9915653|FG004|Treatment Period 1 (0-16 Weeks)|Protocol deviation|0
6236785|NCT01807520|9915654|FG005|Treatment Period 1 (0-16 Weeks)|Protocol deviation|0
6236786|NCT01807520|9915655|FG006|Treatment Period 1 (0-16 Weeks)|Protocol deviation|0
6236787|NCT01807520|9915649|FG000|Treatment Period 1 (0-16 Weeks)|Physician Decision|0
6236788|NCT01807520|9915650|FG001|Treatment Period 1 (0-16 Weeks)|Physician Decision|0
6236789|NCT01807520|9915651|FG002|Treatment Period 1 (0-16 Weeks)|Physician Decision|1
6236790|NCT01807520|9915652|FG003|Treatment Period 1 (0-16 Weeks)|Physician Decision|0
6236791|NCT01807520|9915653|FG004|Treatment Period 1 (0-16 Weeks)|Physician Decision|0
6236792|NCT01807520|9915654|FG005|Treatment Period 1 (0-16 Weeks)|Physician Decision|0
6236793|NCT01807520|9915655|FG006|Treatment Period 1 (0-16 Weeks)|Physician Decision|0
6236794|NCT01807520|9915649|FG000|Treatment Period 1 (0-16 Weeks)|Lost to Follow-up|1
6236795|NCT01807520|9915650|FG001|Treatment Period 1 (0-16 Weeks)|Lost to Follow-up|0
6236796|NCT01807520|9915651|FG002|Treatment Period 1 (0-16 Weeks)|Lost to Follow-up|0
6236797|NCT01807520|9915652|FG003|Treatment Period 1 (0-16 Weeks)|Lost to Follow-up|0
6236798|NCT01807520|9915653|FG004|Treatment Period 1 (0-16 Weeks)|Lost to Follow-up|0
6236799|NCT01807520|9915654|FG005|Treatment Period 1 (0-16 Weeks)|Lost to Follow-up|0
6236800|NCT01807520|9915655|FG006|Treatment Period 1 (0-16 Weeks)|Lost to Follow-up|0
6236801|NCT01807520|9915649|FG000|Treatment Period 1 (0-16 Weeks)|Lack of Efficacy|0
6236802|NCT01807520|9915650|FG001|Treatment Period 1 (0-16 Weeks)|Lack of Efficacy|0
6236803|NCT01807520|9915651|FG002|Treatment Period 1 (0-16 Weeks)|Lack of Efficacy|2
6236804|NCT01807520|9915652|FG003|Treatment Period 1 (0-16 Weeks)|Lack of Efficacy|0
6236805|NCT01807520|9915653|FG004|Treatment Period 1 (0-16 Weeks)|Lack of Efficacy|0
6236806|NCT01807520|9915654|FG005|Treatment Period 1 (0-16 Weeks)|Lack of Efficacy|0
6236807|NCT01807520|9915655|FG006|Treatment Period 1 (0-16 Weeks)|Lack of Efficacy|0
6236808|NCT01807520|9915649|FG000|Treatment Period 1 (0-16 Weeks)|Adverse Event|2
6236809|NCT01807520|9915650|FG001|Treatment Period 1 (0-16 Weeks)|Adverse Event|0
6236810|NCT01807520|9915651|FG002|Treatment Period 1 (0-16 Weeks)|Adverse Event|0
6236811|NCT01807520|9915652|FG003|Treatment Period 1 (0-16 Weeks)|Adverse Event|0
6236812|NCT01807520|9915653|FG004|Treatment Period 1 (0-16 Weeks)|Adverse Event|0
6236813|NCT01807520|9915654|FG005|Treatment Period 1 (0-16 Weeks)|Adverse Event|0
6236814|NCT01807520|9915655|FG006|Treatment Period 1 (0-16 Weeks)|Adverse Event|0
6236815|NCT01807520|9915649|FG000|Treatment Period 2 (16-132 Weeks)|Study terminated|7
6236816|NCT01807520|9915650|FG001|Treatment Period 2 (16-132 Weeks)|Study terminated|4
6236817|NCT01807520|9915651|FG002|Treatment Period 2 (16-132 Weeks)|Study terminated|0
6236818|NCT01807520|9915652|FG003|Treatment Period 2 (16-132 Weeks)|Study terminated|0
6236819|NCT01807520|9915653|FG004|Treatment Period 2 (16-132 Weeks)|Study terminated|2
6236820|NCT01807520|9915654|FG005|Treatment Period 2 (16-132 Weeks)|Study terminated|0
6236821|NCT01807520|9915655|FG006|Treatment Period 2 (16-132 Weeks)|Study terminated|0
6236822|NCT01807520|9915649|FG000|Treatment Period 2 (16-132 Weeks)|Protocol deviation|0
6236823|NCT01807520|9915650|FG001|Treatment Period 2 (16-132 Weeks)|Protocol deviation|0
6236824|NCT01807520|9915651|FG002|Treatment Period 2 (16-132 Weeks)|Protocol deviation|0
6236825|NCT01807520|9915652|FG003|Treatment Period 2 (16-132 Weeks)|Protocol deviation|1
6236826|NCT01807520|9915653|FG004|Treatment Period 2 (16-132 Weeks)|Protocol deviation|0
6236827|NCT01807520|9915654|FG005|Treatment Period 2 (16-132 Weeks)|Protocol deviation|0
6236828|NCT01807520|9915655|FG006|Treatment Period 2 (16-132 Weeks)|Protocol deviation|0
6236829|NCT01807520|9915649|FG000|Treatment Period 2 (16-132 Weeks)|Pregnancy|1
6188781|NCT01394250|9843637|FG001|Successful IV Placement & Follow-Up|Withdrawal by Subject|11
6188782|NCT01394276|9843643|FG000|Overall Study|Related Adverse event (AEs)|15
6188783|NCT01394276|9843643|FG000|Overall Study|Not related AEs|9
6188784|NCT01394276|9843643|FG000|Overall Study|Remission of disease|2
6188785|NCT01394276|9843643|FG000|Overall Study|Insufficient therapeutic effect|17
6188786|NCT01394276|9843643|FG000|Overall Study|Insufficient compliance|9
6188787|NCT01394276|9843643|FG000|Overall Study|Lost to Follow-up|5
6188788|NCT01394276|9843643|FG000|Overall Study|Participant moved to another site|1
6188789|NCT01394276|9843643|FG000|Overall Study|Pregnancy|1
6188790|NCT01394276|9843643|FG000|Overall Study|unavailability of drug at the Hospital|2
6236830|NCT01807520|9915650|FG001|Treatment Period 2 (16-132 Weeks)|Pregnancy|0
6236831|NCT01807520|9915651|FG002|Treatment Period 2 (16-132 Weeks)|Pregnancy|0
6236832|NCT01807520|9915652|FG003|Treatment Period 2 (16-132 Weeks)|Pregnancy|0
6236833|NCT01807520|9915653|FG004|Treatment Period 2 (16-132 Weeks)|Pregnancy|0
6236834|NCT01807520|9915654|FG005|Treatment Period 2 (16-132 Weeks)|Pregnancy|0
6236835|NCT01807520|9915655|FG006|Treatment Period 2 (16-132 Weeks)|Pregnancy|0
6236836|NCT01807520|9915649|FG000|Treatment Period 2 (16-132 Weeks)|Non-compliant with study treatment|0
6236837|NCT01807520|9915650|FG001|Treatment Period 2 (16-132 Weeks)|Non-compliant with study treatment|2
6236838|NCT01807520|9915651|FG002|Treatment Period 2 (16-132 Weeks)|Non-compliant with study treatment|0
6236839|NCT01807520|9915652|FG003|Treatment Period 2 (16-132 Weeks)|Non-compliant with study treatment|0
6236840|NCT01807520|9915653|FG004|Treatment Period 2 (16-132 Weeks)|Non-compliant with study treatment|0
6236841|NCT01807520|9915654|FG005|Treatment Period 2 (16-132 Weeks)|Non-compliant with study treatment|0
6236842|NCT01807520|9915655|FG006|Treatment Period 2 (16-132 Weeks)|Non-compliant with study treatment|0
6236843|NCT01807520|9915649|FG000|Treatment Period 2 (16-132 Weeks)|Lost to Follow-up|4
6236844|NCT01807520|9915650|FG001|Treatment Period 2 (16-132 Weeks)|Lost to Follow-up|0
6236845|NCT01807520|9915651|FG002|Treatment Period 2 (16-132 Weeks)|Lost to Follow-up|0
6236846|NCT01807520|9915652|FG003|Treatment Period 2 (16-132 Weeks)|Lost to Follow-up|1
6236847|NCT01807520|9915653|FG004|Treatment Period 2 (16-132 Weeks)|Lost to Follow-up|0
6236848|NCT01807520|9915654|FG005|Treatment Period 2 (16-132 Weeks)|Lost to Follow-up|0
6236849|NCT01807520|9915655|FG006|Treatment Period 2 (16-132 Weeks)|Lost to Follow-up|0
6236850|NCT01807520|9915649|FG000|Treatment Period 2 (16-132 Weeks)|Lack of Efficacy|5
6236851|NCT01807520|9915650|FG001|Treatment Period 2 (16-132 Weeks)|Lack of Efficacy|3
6236852|NCT01807520|9915651|FG002|Treatment Period 2 (16-132 Weeks)|Lack of Efficacy|0
6236853|NCT01807520|9915652|FG003|Treatment Period 2 (16-132 Weeks)|Lack of Efficacy|0
6236854|NCT01807520|9915653|FG004|Treatment Period 2 (16-132 Weeks)|Lack of Efficacy|1
6236855|NCT01807520|9915654|FG005|Treatment Period 2 (16-132 Weeks)|Lack of Efficacy|0
6236856|NCT01807520|9915655|FG006|Treatment Period 2 (16-132 Weeks)|Lack of Efficacy|0
6236857|NCT01807520|9915649|FG000|Treatment Period 2 (16-132 Weeks)|Adverse Event|3
6236858|NCT01807520|9915650|FG001|Treatment Period 2 (16-132 Weeks)|Adverse Event|3
6236859|NCT01807520|9915651|FG002|Treatment Period 2 (16-132 Weeks)|Adverse Event|0
6236860|NCT01807520|9915652|FG003|Treatment Period 2 (16-132 Weeks)|Adverse Event|3
6236861|NCT01807520|9915653|FG004|Treatment Period 2 (16-132 Weeks)|Adverse Event|0
6236862|NCT01807520|9915654|FG005|Treatment Period 2 (16-132 Weeks)|Adverse Event|0
6236863|NCT01807520|9915655|FG006|Treatment Period 2 (16-132 Weeks)|Adverse Event|0
6236864|NCT01807520|9915649|FG000|Treatment Period 2 (16-132 Weeks)|Withdrawal by Subject|5
6236865|NCT01807520|9915650|FG001|Treatment Period 2 (16-132 Weeks)|Withdrawal by Subject|6
6236866|NCT01807520|9915651|FG002|Treatment Period 2 (16-132 Weeks)|Withdrawal by Subject|0
6236867|NCT01807520|9915652|FG003|Treatment Period 2 (16-132 Weeks)|Withdrawal by Subject|2
6236868|NCT01807520|9915653|FG004|Treatment Period 2 (16-132 Weeks)|Withdrawal by Subject|2
6236869|NCT01807520|9915654|FG005|Treatment Period 2 (16-132 Weeks)|Withdrawal by Subject|0
6236870|NCT01807520|9915655|FG006|Treatment Period 2 (16-132 Weeks)|Withdrawal by Subject|0
6236871|NCT01807520|9915649|FG000|Follow-up Period (132-140 Weeks)|Lack of Efficacy|0
6236872|NCT01807520|9915650|FG001|Follow-up Period (132-140 Weeks)|Lack of Efficacy|0
6236873|NCT01807520|9915651|FG002|Follow-up Period (132-140 Weeks)|Lack of Efficacy|0
6236874|NCT01807520|9915652|FG003|Follow-up Period (132-140 Weeks)|Lack of Efficacy|0
6236875|NCT01807520|9915653|FG004|Follow-up Period (132-140 Weeks)|Lack of Efficacy|0
6236876|NCT01807520|9915654|FG005|Follow-up Period (132-140 Weeks)|Lack of Efficacy|1
6236877|NCT01807520|9915655|FG006|Follow-up Period (132-140 Weeks)|Lack of Efficacy|0
6236878|NCT01807520|9915649|FG000|Follow-up Period (132-140 Weeks)|Study terminated|0
6236879|NCT01807520|9915650|FG001|Follow-up Period (132-140 Weeks)|Study terminated|0
6236880|NCT01807520|9915651|FG002|Follow-up Period (132-140 Weeks)|Study terminated|0
6236881|NCT01807520|9915652|FG003|Follow-up Period (132-140 Weeks)|Study terminated|0
6236882|NCT01807520|9915653|FG004|Follow-up Period (132-140 Weeks)|Study terminated|0
6236883|NCT01807520|9915654|FG005|Follow-up Period (132-140 Weeks)|Study terminated|1
6236884|NCT01807520|9915655|FG006|Follow-up Period (132-140 Weeks)|Study terminated|0
6236885|NCT01807520|9915649|FG000|Follow-up Period (132-140 Weeks)|Lost to Follow-up|0
6236886|NCT01807520|9915650|FG001|Follow-up Period (132-140 Weeks)|Lost to Follow-up|0
6236887|NCT01807520|9915651|FG002|Follow-up Period (132-140 Weeks)|Lost to Follow-up|0
6236888|NCT01807520|9915652|FG003|Follow-up Period (132-140 Weeks)|Lost to Follow-up|0
6236889|NCT01807520|9915653|FG004|Follow-up Period (132-140 Weeks)|Lost to Follow-up|0
6236890|NCT01807520|9915654|FG005|Follow-up Period (132-140 Weeks)|Lost to Follow-up|2
6236891|NCT01807520|9915655|FG006|Follow-up Period (132-140 Weeks)|Lost to Follow-up|1
6236892|NCT01807598|9915682|FG000|Overall Study|Withdrawal by Subject|4
6236893|NCT01807598|9915682|FG000|Overall Study|Adverse Event|1
6236894|NCT01807598|9915682|FG000|Overall Study|Other Physician Decision|1
6236895|NCT01807650|9915701|FG000|Overall Study|Lack of Full Wound Closure at Day 28|13
6236896|NCT01807650|9915701|FG000|Overall Study|Adverse Event|5
6236897|NCT01807650|9915701|FG000|Overall Study|Other|2
6236898|NCT01807923|9915754|FG000|Overall Study|Adverse Event|2
6236899|NCT01807923|9915755|FG001|Overall Study|Adverse Event|1
6236900|NCT01807923|9915756|FG002|Overall Study|Adverse Event|2
6236901|NCT01807923|9915754|FG000|Overall Study|Withdrawal of Consent (not due to AE)|0
6236902|NCT01807923|9915755|FG001|Overall Study|Withdrawal of Consent (not due to AE)|3
6236903|NCT01807923|9915756|FG002|Overall Study|Withdrawal of Consent (not due to AE)|2
6236904|NCT01807923|9915754|FG000|Overall Study|Physician Decision|0
6236905|NCT01807923|9915755|FG001|Overall Study|Physician Decision|0
6236906|NCT01807923|9915756|FG002|Overall Study|Physician Decision|1
6236907|NCT01807923|9915754|FG000|Overall Study|Not Eligible (Genotype)|0
6236908|NCT01807923|9915755|FG001|Overall Study|Not Eligible (Genotype)|0
6236909|NCT01807923|9915756|FG002|Overall Study|Not Eligible (Genotype)|1
6236910|NCT01807923|9915754|FG000|Overall Study|Randomized But Not Treated|3
6236911|NCT01807923|9915755|FG001|Overall Study|Randomized But Not Treated|2
6236912|NCT01807923|9915756|FG002|Overall Study|Randomized But Not Treated|5
6236913|NCT01807949|9915769|FG000|Overall Study|Adverse Event|1
6236914|NCT01807949|9915770|FG001|Overall Study|Adverse Event|2
6236915|NCT01807949|9915771|FG002|Overall Study|Adverse Event|2
6236916|NCT01807949|9915769|FG000|Overall Study|Withdrawal by Subject|1
6236917|NCT01807949|9915770|FG001|Overall Study|Withdrawal by Subject|2
6236918|NCT01807949|9915771|FG002|Overall Study|Withdrawal by Subject|2
6236919|NCT01807949|9915769|FG000|Overall Study|Non-Compliance|0
6236920|NCT01807949|9915770|FG001|Overall Study|Non-Compliance|0
6236921|NCT01807949|9915771|FG002|Overall Study|Non-Compliance|1
6236922|NCT01807949|9915769|FG000|Overall Study|Undefined|0
6236923|NCT01807949|9915770|FG001|Overall Study|Undefined|1
6236924|NCT01807949|9915771|FG002|Overall Study|Undefined|2
6236925|NCT01807949|9915769|FG000|Overall Study|Randomized But Not Treated|0
6236926|NCT01807949|9915770|FG001|Overall Study|Randomized But Not Treated|2
6236927|NCT01807949|9915771|FG002|Overall Study|Randomized But Not Treated|2
6236928|NCT01808066|9915781|FG000|Overall Study|Withdrawal by Subject|15
6236929|NCT01808092|9915788|FG000|Overall Study|Death|39
6236930|NCT01808092|9915789|FG001|Overall Study|Death|29
6236931|NCT01808092|9915788|FG000|Overall Study|Lost to Follow-up|3
6236932|NCT01808092|9915789|FG001|Overall Study|Lost to Follow-up|7
6236933|NCT01808092|9915788|FG000|Overall Study|Withdrawal by Subject|9
6236934|NCT01808092|9915789|FG001|Overall Study|Withdrawal by Subject|4
6236935|NCT01808092|9915788|FG000|Overall Study|Other Eligibility criteria|3
6236936|NCT01808092|9915789|FG001|Overall Study|Other Eligibility criteria|5
6236937|NCT01808118|9915795|FG000|Period 1|Adverse Event|15
6236938|NCT01808118|9915796|FG001|Period 1|Adverse Event|0
6236939|NCT01808118|9915797|FG002|Period 1|Adverse Event|0
6236940|NCT01808118|9915795|FG000|Period 1|Withdrew consent|24
6236941|NCT01808118|9915796|FG001|Period 1|Withdrew consent|0
6236942|NCT01808118|9915797|FG002|Period 1|Withdrew consent|0
6236943|NCT01808118|9915795|FG000|Period 1|Lost to Follow-up|9
6236944|NCT01808118|9915796|FG001|Period 1|Lost to Follow-up|0
6236945|NCT01808118|9915797|FG002|Period 1|Lost to Follow-up|0
6236946|NCT01808118|9915795|FG000|Period 1|Did not meet criteria for remission|303
6236947|NCT01808118|9915796|FG001|Period 1|Did not meet criteria for remission|0
6236948|NCT01808118|9915797|FG002|Period 1|Did not meet criteria for remission|0
6236949|NCT01808118|9915795|FG000|Period 1|Enrolled in error|7
6236950|NCT01808118|9915796|FG001|Period 1|Enrolled in error|0
6236951|NCT01808118|9915797|FG002|Period 1|Enrolled in error|0
6236952|NCT01808118|9915795|FG000|Period 1|Did not meet inclusion criteria|3
6236953|NCT01808118|9915796|FG001|Period 1|Did not meet inclusion criteria|0
6236954|NCT01808118|9915797|FG002|Period 1|Did not meet inclusion criteria|0
6236955|NCT01808118|9915795|FG000|Period 1|Non-conformance with inclusion criteria|3
6236956|NCT01808118|9915796|FG001|Period 1|Non-conformance with inclusion criteria|0
6236957|NCT01808118|9915797|FG002|Period 1|Non-conformance with inclusion criteria|0
6236958|NCT01808118|9915795|FG000|Period 1|Investigator decision: site closure|2
6236959|NCT01808118|9915796|FG001|Period 1|Investigator decision: site closure|0
6236960|NCT01808118|9915797|FG002|Period 1|Investigator decision: site closure|0
6236961|NCT01808118|9915795|FG000|Period 1|Non-compliance per sponsor|1
6236962|NCT01808118|9915796|FG001|Period 1|Non-compliance per sponsor|0
6236963|NCT01808118|9915797|FG002|Period 1|Non-compliance per sponsor|0
6236964|NCT01808118|9915795|FG000|Period 1|Lack of Efficacy|1
6236965|NCT01808118|9915796|FG001|Period 1|Lack of Efficacy|0
6236966|NCT01808118|9915797|FG002|Period 1|Lack of Efficacy|0
6236967|NCT01808118|9915795|FG000|Period 2|Adverse Event|0
6236968|NCT01808118|9915796|FG001|Period 2|Adverse Event|4
6236969|NCT01808118|9915797|FG002|Period 2|Adverse Event|0
6236970|NCT01808118|9915795|FG000|Period 2|Withdrew consent|0
6236971|NCT01808118|9915796|FG001|Period 2|Withdrew consent|7
6236972|NCT01808118|9915797|FG002|Period 2|Withdrew consent|6
6236973|NCT01808118|9915795|FG000|Period 2|Lost to Follow-up|0
6236974|NCT01808118|9915796|FG001|Period 2|Lost to Follow-up|0
6236975|NCT01808118|9915797|FG002|Period 2|Lost to Follow-up|2
6236976|NCT01808118|9915795|FG000|Period 2|Investigator no longer conducting trials|0
6236977|NCT01808118|9915796|FG001|Period 2|Investigator no longer conducting trials|1
6236978|NCT01808118|9915797|FG002|Period 2|Investigator no longer conducting trials|0
6236979|NCT01808118|9915795|FG000|Period 2|Switched to other therapy|0
6236980|NCT01808118|9915796|FG001|Period 2|Switched to other therapy|1
6236981|NCT01808118|9915797|FG002|Period 2|Switched to other therapy|0
6236982|NCT01808144|9915813|FG000|Overall Study|Death|1
6236983|NCT01808144|9915814|FG001|Overall Study|Death|0
6236984|NCT01808144|9915813|FG000|Overall Study|Withdrawal by Subject|16
6236985|NCT01808144|9915814|FG001|Overall Study|Withdrawal by Subject|23
6236986|NCT01808144|9915813|FG000|Overall Study|Lost to Follow-up|6
6236987|NCT01808144|9915814|FG001|Overall Study|Lost to Follow-up|3
6236988|NCT01808144|9915813|FG000|Overall Study|Protocol Violation|6
6236989|NCT01808144|9915814|FG001|Overall Study|Protocol Violation|6
6236990|NCT01808144|9915813|FG000|Overall Study|Gout flare|0
6236991|NCT01808144|9915814|FG001|Overall Study|Gout flare|1
6236992|NCT01808144|9915813|FG000|Overall Study|Adverse Event|11
6236993|NCT01808144|9915814|FG001|Overall Study|Adverse Event|15
6236994|NCT01808196|9915820|FG000|Overall Study|Lost to Follow-up|1
6236995|NCT01808209|9915826|FG000|Overall Study|Lost to Follow-up|0
6236996|NCT01808209|9915827|FG001|Overall Study|Lost to Follow-up|1
6236997|NCT01808222|9915837|FG000|Overall Study|mpMR scan was not performed|1
6236998|NCT01808248|9915843|FG000|Overall Study|Lack of Efficacy|3
6236999|NCT01808248|9915843|FG000|Overall Study|Withdrawal by Subject|1
6237000|NCT01808248|9915843|FG000|Overall Study|Lost to Follow-up|1
6237001|NCT01808313|9915849|FG000|Overall Study|Adverse Event|5
6237002|NCT01808313|9915849|FG000|Overall Study|Protocol Violation|2
6237003|NCT01808313|9915849|FG000|Overall Study|Met Protocol-defined Stopping Criteria|1
6237004|NCT01808313|9915849|FG000|Overall Study|Lost to Follow-up|1
6237005|NCT01808313|9915849|FG000|Overall Study|Physician Decision|1
6237006|NCT01808339|9915857|FG000|Treatment Period 1 (14 Days)|Met Protocol-defined Stopping Criteria|0
6237007|NCT01808339|9915858|FG001|Treatment Period 1 (14 Days)|Met Protocol-defined Stopping Criteria|0
6237008|NCT01808339|9915859|FG002|Treatment Period 1 (14 Days)|Met Protocol-defined Stopping Criteria|0
6237009|NCT01808339|9915860|FG003|Treatment Period 1 (14 Days)|Met Protocol-defined Stopping Criteria|1
6237010|NCT01808339|9915861|FG004|Treatment Period 1 (14 Days)|Met Protocol-defined Stopping Criteria|2
6237011|NCT01808339|9915862|FG005|Treatment Period 1 (14 Days)|Met Protocol-defined Stopping Criteria|1
6237012|NCT01808339|9915857|FG000|Treatment Period 1 (14 Days)|Withdrawal by Subject|0
6237013|NCT01808339|9915858|FG001|Treatment Period 1 (14 Days)|Withdrawal by Subject|1
6237014|NCT01808339|9915859|FG002|Treatment Period 1 (14 Days)|Withdrawal by Subject|0
6237015|NCT01808339|9915860|FG003|Treatment Period 1 (14 Days)|Withdrawal by Subject|1
6237016|NCT01808339|9915861|FG004|Treatment Period 1 (14 Days)|Withdrawal by Subject|0
6237017|NCT01808339|9915862|FG005|Treatment Period 1 (14 Days)|Withdrawal by Subject|0
6237018|NCT01808339|9915857|FG000|Treatment Period 3 (14 Days)|Met Protocol-defined Stopping Criteria|0
6237019|NCT01808339|9915858|FG001|Treatment Period 3 (14 Days)|Met Protocol-defined Stopping Criteria|0
6237020|NCT01808339|9915859|FG002|Treatment Period 3 (14 Days)|Met Protocol-defined Stopping Criteria|1
6237021|NCT01808339|9915860|FG003|Treatment Period 3 (14 Days)|Met Protocol-defined Stopping Criteria|0
6237022|NCT01808339|9915861|FG004|Treatment Period 3 (14 Days)|Met Protocol-defined Stopping Criteria|0
6237023|NCT01808339|9915862|FG005|Treatment Period 3 (14 Days)|Met Protocol-defined Stopping Criteria|0
6237024|NCT01808508|9915873|FG000|Overall Study|Lost to Follow-up|1
6237025|NCT01808508|9915874|FG001|Overall Study|Lost to Follow-up|0
6237026|NCT01808508|9915875|FG002|Overall Study|Lost to Follow-up|0
6237027|NCT01808534|9915883|FG000|Overall Study|Disease progression|3
6237028|NCT01808534|9915883|FG000|Overall Study|Physician Decision|1
6237029|NCT01808573|9915911|FG000|Overall Study|Death|212
6237030|NCT01808573|9915912|FG001|Overall Study|Death|240
6237031|NCT01808573|9915911|FG000|Overall Study|Withdrawal by Subject|12
6237032|NCT01808573|9915912|FG001|Overall Study|Withdrawal by Subject|10
6237033|NCT01808573|9915911|FG000|Overall Study|Lost to Follow-up|3
6237034|NCT01808573|9915912|FG001|Overall Study|Lost to Follow-up|0
6237035|NCT01808573|9915911|FG000|Overall Study|Discontinuation of study by sponsor|79
6237036|NCT01808573|9915912|FG001|Overall Study|Discontinuation of study by sponsor|64
6237037|NCT01808573|9915911|FG000|Overall Study|Randomized in Error|1
6237038|NCT01808573|9915912|FG001|Overall Study|Randomized in Error|0
6237039|NCT01808612|9915921|FG000|Treatment Period|Adverse Event|8
6237040|NCT01808612|9915922|FG001|Treatment Period|Adverse Event|4
6237041|NCT01808612|9915923|FG002|Treatment Period|Adverse Event|3
6237042|NCT01808612|9915921|FG000|Treatment Period|Lost to Follow-up|2
6237043|NCT01808612|9915922|FG001|Treatment Period|Lost to Follow-up|2
6237044|NCT01808612|9915923|FG002|Treatment Period|Lost to Follow-up|1
6237045|NCT01808612|9915921|FG000|Treatment Period|Protocol Violation|1
6237046|NCT01808612|9915922|FG001|Treatment Period|Protocol Violation|0
6237047|NCT01808612|9915923|FG002|Treatment Period|Protocol Violation|0
6237048|NCT01808612|9915921|FG000|Treatment Period|Withdrawal by Subject|1
6237049|NCT01808612|9915922|FG001|Treatment Period|Withdrawal by Subject|0
6237050|NCT01808612|9915923|FG002|Treatment Period|Withdrawal by Subject|4
6237051|NCT01808612|9915921|FG000|Treatment Period|Physician Decision|1
6237052|NCT01808612|9915922|FG001|Treatment Period|Physician Decision|0
6237053|NCT01808612|9915923|FG002|Treatment Period|Physician Decision|4
6237054|NCT01808612|9915921|FG000|Treatment Period|Sponsor Decision|1
6237055|NCT01808612|9915922|FG001|Treatment Period|Sponsor Decision|0
6237056|NCT01808612|9915923|FG002|Treatment Period|Sponsor Decision|0
6237057|NCT01808612|9915921|FG000|Treatment Period|Lack of Efficacy|1
6237058|NCT01808612|9915922|FG001|Treatment Period|Lack of Efficacy|1
6237059|NCT01808612|9915923|FG002|Treatment Period|Lack of Efficacy|2
6237060|NCT01808612|9915921|FG000|Discontinuation Period|Adverse Event|1
6237061|NCT01808612|9915922|FG001|Discontinuation Period|Adverse Event|0
6237062|NCT01808612|9915923|FG002|Discontinuation Period|Adverse Event|0
6237063|NCT01808612|9915921|FG000|Discontinuation Period|Physician Decision|1
6237064|NCT01808612|9915922|FG001|Discontinuation Period|Physician Decision|0
6237065|NCT01808612|9915923|FG002|Discontinuation Period|Physician Decision|0
6237066|NCT01808612|9915921|FG000|Discontinuation Period|Lost to Follow-up|0
6237067|NCT01808612|9915922|FG001|Discontinuation Period|Lost to Follow-up|1
6237068|NCT01808612|9915923|FG002|Discontinuation Period|Lost to Follow-up|0
6237069|NCT01808651|9915937|FG000|Study Period 1|Lost to Follow-up|1
6237070|NCT01808651|9915938|FG001|Study Period 1|Lost to Follow-up|3
6237071|NCT01808651|9915939|FG002|Study Period 1|Lost to Follow-up|0
6237072|NCT01808651|9915937|FG000|Study Period 1|Protocol Violation|1
6237073|NCT01808651|9915938|FG001|Study Period 1|Protocol Violation|0
6237074|NCT01808651|9915939|FG002|Study Period 1|Protocol Violation|1
6237075|NCT01808651|9915937|FG000|Study Period 1|Physician Decision|3
6237076|NCT01808651|9915938|FG001|Study Period 1|Physician Decision|2
6188791|NCT01394276|9843643|FG000|Overall Study|Symptoms of concurrent diseases|1
6188792|NCT01394523|9843659|FG000|Overall Study|Unable to place block|1
6188793|NCT01394523|9843660|FG001|Overall Study|Unable to place block|0
6188794|NCT01394523|9843661|FG002|Overall Study|Unable to place block|0
6188795|NCT01394627|9843678|FG000|First Intervention (1 Day)|poor intravenous access|0
6188796|NCT01394627|9843679|FG001|First Intervention (1 Day)|poor intravenous access|1
6188797|NCT01394627|9843678|FG000|Washout (1-3 Months)|concurrent enrollment in another study|1
6188798|NCT01394627|9843679|FG001|Washout (1-3 Months)|concurrent enrollment in another study|0
6237077|NCT01808651|9915939|FG002|Study Period 1|Physician Decision|0
6237078|NCT01808651|9915937|FG000|Study Period 1|Lack of Efficacy|2
6237079|NCT01808651|9915938|FG001|Study Period 1|Lack of Efficacy|1
6237080|NCT01808651|9915939|FG002|Study Period 1|Lack of Efficacy|0
6237081|NCT01808651|9915937|FG000|Study Period 1|Adverse Event|10
6237082|NCT01808651|9915938|FG001|Study Period 1|Adverse Event|4
6237083|NCT01808651|9915939|FG002|Study Period 1|Adverse Event|1
6237084|NCT01808651|9915937|FG000|Study Period 1|Participant Decision|9
6237085|NCT01808651|9915938|FG001|Study Period 1|Participant Decision|7
6237086|NCT01808651|9915939|FG002|Study Period 1|Participant Decision|3
6237087|NCT01808690|9915952|FG000|Overall Study|Withdrawal by Subject|1
6237088|NCT01808690|9915953|FG001|Overall Study|Withdrawal by Subject|2
6237089|NCT01809132|9915998|FG000|Overall Study|Withdrawal by Subject|0
6237090|NCT01809132|9915999|FG001|Overall Study|Withdrawal by Subject|0
6237091|NCT01809132|9916000|FG002|Overall Study|Withdrawal by Subject|1
6237092|NCT01809197|9916010|FG000|Overall Study|Lost to Follow-up|4
6237093|NCT01809197|9916011|FG001|Overall Study|Lost to Follow-up|2
6237094|NCT01809197|9916010|FG000|Overall Study|Adverse Event|2
6237095|NCT01809197|9916011|FG001|Overall Study|Adverse Event|3
6237096|NCT01809197|9916010|FG000|Overall Study|Failed slit lamp exam|1
6237097|NCT01809197|9916011|FG001|Overall Study|Failed slit lamp exam|0
6237098|NCT01809197|9916010|FG000|Overall Study|Non-Compliance|1
6237099|NCT01809197|9916011|FG001|Overall Study|Non-Compliance|1
6237100|NCT01809197|9916010|FG000|Overall Study|Decision Unrelated to an Adverse Event|1
6237101|NCT01809197|9916011|FG001|Overall Study|Decision Unrelated to an Adverse Event|0
6237102|NCT01809197|9916010|FG000|Overall Study|Withdrawal by Subject|1
6237103|NCT01809197|9916011|FG001|Overall Study|Withdrawal by Subject|1
6237104|NCT01809197|9916010|FG000|Overall Study|Product not available|0
6237105|NCT01809197|9916011|FG001|Overall Study|Product not available|1
6237106|NCT01809210|9916024|FG000|Overall Study|Withdrawal by Subject|0
6237107|NCT01809210|9916025|FG001|Overall Study|Withdrawal by Subject|0
6237108|NCT01809210|9916026|FG002|Overall Study|Withdrawal by Subject|1
6237109|NCT01809210|9916027|FG003|Overall Study|Withdrawal by Subject|1
6237110|NCT01809210|9916028|FG004|Overall Study|Withdrawal by Subject|1
6237111|NCT01809210|9916029|FG005|Overall Study|Withdrawal by Subject|0
6237112|NCT01809210|9916030|FG006|Overall Study|Withdrawal by Subject|4
6237113|NCT01809210|9916024|FG000|Overall Study|Death|1
6237114|NCT01809210|9916025|FG001|Overall Study|Death|1
6237115|NCT01809210|9916026|FG002|Overall Study|Death|2
6237116|NCT01809210|9916027|FG003|Overall Study|Death|0
6237117|NCT01809210|9916028|FG004|Overall Study|Death|1
6237118|NCT01809210|9916029|FG005|Overall Study|Death|3
6237119|NCT01809210|9916030|FG006|Overall Study|Death|1
6237120|NCT01809262|9916046|FG000|Period 1 (First Dose + Washout)|Adverse Event|0
6237121|NCT01809262|9916047|FG001|Period 1 (First Dose + Washout)|Adverse Event|0
6237122|NCT01809262|9916048|FG002|Period 1 (First Dose + Washout)|Adverse Event|0
6237123|NCT01809262|9916049|FG003|Period 1 (First Dose + Washout)|Adverse Event|0
6237124|NCT01809262|9916050|FG004|Period 1 (First Dose + Washout)|Adverse Event|1
6237125|NCT01809262|9916051|FG005|Period 1 (First Dose + Washout)|Adverse Event|0
6237126|NCT01809262|9916052|FG006|Period 1 (First Dose + Washout)|Adverse Event|0
6237127|NCT01809262|9916053|FG007|Period 1 (First Dose + Washout)|Adverse Event|0
6237128|NCT01809262|9916054|FG008|Period 1 (First Dose + Washout)|Adverse Event|0
6237129|NCT01809262|9916055|FG009|Period 1 (First Dose + Washout)|Adverse Event|0
6237130|NCT01809262|9916046|FG000|Period 3 (Third Dose + Washout)|Adverse Event|0
6237131|NCT01809262|9916047|FG001|Period 3 (Third Dose + Washout)|Adverse Event|1
6237132|NCT01809262|9916048|FG002|Period 3 (Third Dose + Washout)|Adverse Event|0
6237133|NCT01809262|9916049|FG003|Period 3 (Third Dose + Washout)|Adverse Event|0
6237134|NCT01809262|9916050|FG004|Period 3 (Third Dose + Washout)|Adverse Event|0
6237135|NCT01809262|9916051|FG005|Period 3 (Third Dose + Washout)|Adverse Event|0
6237136|NCT01809262|9916052|FG006|Period 3 (Third Dose + Washout)|Adverse Event|0
6237137|NCT01809262|9916053|FG007|Period 3 (Third Dose + Washout)|Adverse Event|0
6237138|NCT01809262|9916054|FG008|Period 3 (Third Dose + Washout)|Adverse Event|0
6237139|NCT01809262|9916055|FG009|Period 3 (Third Dose + Washout)|Adverse Event|0
6237140|NCT01809314|9916067|FG000|Overall Study|Withdrawal Prior to Treatment|1
6237141|NCT01809314|9916067|FG000|Overall Study|Adverse Event|6
6237142|NCT01809314|9916067|FG000|Overall Study|Insufficient Therapeutic Response|14
6237143|NCT01809314|9916067|FG000|Overall Study|Lost to Follow-up|724
6237144|NCT01809327|9916076|FG000|Overall Study|Lost to Follow-up|5
6237145|NCT01809327|9916077|FG001|Overall Study|Lost to Follow-up|2
6237146|NCT01809327|9916078|FG002|Overall Study|Lost to Follow-up|4
6237147|NCT01809327|9916079|FG003|Overall Study|Lost to Follow-up|2
6237148|NCT01809327|9916080|FG004|Overall Study|Lost to Follow-up|3
6237149|NCT01809327|9916076|FG000|Overall Study|Withdrawal by Subject|6
6237150|NCT01809327|9916077|FG001|Overall Study|Withdrawal by Subject|4
6237151|NCT01809327|9916078|FG002|Overall Study|Withdrawal by Subject|4
6237152|NCT01809327|9916079|FG003|Overall Study|Withdrawal by Subject|2
6237153|NCT01809327|9916080|FG004|Overall Study|Withdrawal by Subject|5
6237154|NCT01809327|9916076|FG000|Overall Study|Adverse Event|4
6237155|NCT01809327|9916077|FG001|Overall Study|Adverse Event|3
6237156|NCT01809327|9916078|FG002|Overall Study|Adverse Event|7
6237157|NCT01809327|9916079|FG003|Overall Study|Adverse Event|4
6237158|NCT01809327|9916080|FG004|Overall Study|Adverse Event|8
6237159|NCT01809327|9916076|FG000|Overall Study|Death|1
6237160|NCT01809327|9916077|FG001|Overall Study|Death|0
6237161|NCT01809327|9916078|FG002|Overall Study|Death|0
6237162|NCT01809327|9916079|FG003|Overall Study|Death|0
6237163|NCT01809327|9916080|FG004|Overall Study|Death|0
6237164|NCT01809327|9916076|FG000|Overall Study|Protocol Violation|0
6237165|NCT01809327|9916077|FG001|Overall Study|Protocol Violation|1
6237166|NCT01809327|9916078|FG002|Overall Study|Protocol Violation|0
6237167|NCT01809327|9916079|FG003|Overall Study|Protocol Violation|0
6237168|NCT01809327|9916080|FG004|Overall Study|Protocol Violation|0
6237169|NCT01809327|9916076|FG000|Overall Study|Physician Decision|1
6237170|NCT01809327|9916077|FG001|Overall Study|Physician Decision|1
6237171|NCT01809327|9916078|FG002|Overall Study|Physician Decision|0
6237172|NCT01809327|9916079|FG003|Overall Study|Physician Decision|0
6237173|NCT01809327|9916080|FG004|Overall Study|Physician Decision|0
6237174|NCT01809327|9916076|FG000|Overall Study|Pregnancy|1
6237175|NCT01809327|9916077|FG001|Overall Study|Pregnancy|0
6237176|NCT01809327|9916078|FG002|Overall Study|Pregnancy|0
6237177|NCT01809327|9916079|FG003|Overall Study|Pregnancy|0
6237178|NCT01809327|9916080|FG004|Overall Study|Pregnancy|0
6237179|NCT01809327|9916076|FG000|Overall Study|Other|14
6237180|NCT01809327|9916077|FG001|Overall Study|Other|15
6237181|NCT01809327|9916078|FG002|Overall Study|Other|7
6237182|NCT01809327|9916079|FG003|Overall Study|Other|4
6237183|NCT01809327|9916080|FG004|Overall Study|Other|9
6237184|NCT01810016|9916116|FG000|Overall Study|Progressive disease|1
6237185|NCT01810016|9916117|FG001|Overall Study|Progressive disease|1
6237186|NCT01810016|9916118|FG002|Overall Study|Progressive disease|0
6237187|NCT01810016|9916116|FG000|Overall Study|Death|0
6237188|NCT01810016|9916117|FG001|Overall Study|Death|0
6237189|NCT01810016|9916118|FG002|Overall Study|Death|1
6237190|NCT01810042|9916126|FG000|Overall Study|Lost to Follow-up|10
6237191|NCT01810263|9916132|FG000|Overall Study|Lost to Follow-up|8
6237192|NCT01810263|9916133|FG001|Overall Study|Lost to Follow-up|7
6237193|NCT01810380|9916151|FG000|Overall Study|Randomised not treated|2
6237194|NCT01810380|9916152|FG001|Overall Study|Randomised not treated|1
6237195|NCT01810380|9916153|FG002|Overall Study|Randomised not treated|1
6237196|NCT01810380|9916151|FG000|Overall Study|Adverse Event|11
6237197|NCT01810380|9916152|FG001|Overall Study|Adverse Event|14
6237198|NCT01810380|9916153|FG002|Overall Study|Adverse Event|4
6237199|NCT01810380|9916151|FG000|Overall Study|Lack of Efficacy|24
6237200|NCT01810380|9916152|FG001|Overall Study|Lack of Efficacy|10
6237201|NCT01810380|9916153|FG002|Overall Study|Lack of Efficacy|11
6237202|NCT01810380|9916151|FG000|Overall Study|Protocol Violation|1
6237203|NCT01810380|9916152|FG001|Overall Study|Protocol Violation|0
6237204|NCT01810380|9916153|FG002|Overall Study|Protocol Violation|1
6237205|NCT01810380|9916151|FG000|Overall Study|Withdrawal by Subject|6
6237206|NCT01810380|9916152|FG001|Overall Study|Withdrawal by Subject|0
6237207|NCT01810380|9916153|FG002|Overall Study|Withdrawal by Subject|6
6237208|NCT01810380|9916151|FG000|Overall Study|Administrative or other reasons|11
6237209|NCT01810380|9916152|FG001|Overall Study|Administrative or other reasons|13
6237210|NCT01810380|9916153|FG002|Overall Study|Administrative or other reasons|9
6237211|NCT01810432|9916161|FG000|Washout|Protocol Violation|0
6237212|NCT01810432|9916162|FG001|Washout|Protocol Violation|1
6237213|NCT01810432|9916161|FG000|Washout|Adverse Event|1
6237214|NCT01810432|9916162|FG001|Washout|Adverse Event|0
6237215|NCT01810432|9916161|FG000|Period 2|Withdrawal by Subject|2
6237216|NCT01810432|9916162|FG001|Period 2|Withdrawal by Subject|1
6237217|NCT01810432|9916161|FG000|Period 2|Physician Decision|1
6237218|NCT01810432|9916162|FG001|Period 2|Physician Decision|0
6237219|NCT01810432|9916161|FG000|Period 2|Lost to Follow-up|1
6237220|NCT01810432|9916162|FG001|Period 2|Lost to Follow-up|1
6237221|NCT01810783|9916181|FG000|Overall Study|Adverse Event|32
6237222|NCT01810783|9916181|FG000|Overall Study|Withdrawal by Subject|22
6237223|NCT01810783|9916181|FG000|Overall Study|Lack of Efficacy|12
6237224|NCT01810783|9916181|FG000|Overall Study|Lost to Follow-up|10
6237225|NCT01810783|9916181|FG000|Overall Study|Protocol Violation|5
6237226|NCT01810783|9916181|FG000|Overall Study|Non-compliance with IMP|4
6237227|NCT01810783|9916181|FG000|Overall Study|Adminstrative or other reason(s)|23
6237228|NCT01810783|9916181|FG000|Overall Study|Enrolled, not treated|1
6237229|NCT01810939|9916185|FG000|Part A Treatment Period|Non-compliance with Study Drug|1
6237230|NCT01810939|9916186|FG001|Part A Treatment Period|Non-compliance with Study Drug|0
6237231|NCT01810939|9916187|FG002|Part A Treatment Period|Non-compliance with Study Drug|0
6237232|NCT01810939|9916185|FG000|Part A Treatment Period|Protocol Violation|2
6237233|NCT01810939|9916186|FG001|Part A Treatment Period|Protocol Violation|0
6237234|NCT01810939|9916187|FG002|Part A Treatment Period|Protocol Violation|0
6237235|NCT01810939|9916185|FG000|Part A Treatment Period|Adverse Event|10
6237236|NCT01810939|9916186|FG001|Part A Treatment Period|Adverse Event|0
6237237|NCT01810939|9916187|FG002|Part A Treatment Period|Adverse Event|0
6237238|NCT01810939|9916185|FG000|Part A Treatment Period|Withdrawal by Subject|5
6237239|NCT01810939|9916186|FG001|Part A Treatment Period|Withdrawal by Subject|0
6237240|NCT01810939|9916187|FG002|Part A Treatment Period|Withdrawal by Subject|0
6237241|NCT01810939|9916185|FG000|Part A Treatment Period|Protocol-specified (eGFR)|2
6237242|NCT01810939|9916186|FG001|Part A Treatment Period|Protocol-specified (eGFR)|0
6237243|NCT01810939|9916187|FG002|Part A Treatment Period|Protocol-specified (eGFR)|0
6237244|NCT01810939|9916185|FG000|Part A Treatment Period|Protocol-specified (High K+)|3
6237245|NCT01810939|9916186|FG001|Part A Treatment Period|Protocol-specified (High K+)|0
6237246|NCT01810939|9916187|FG002|Part A Treatment Period|Protocol-specified (High K+)|0
6237247|NCT01810939|9916185|FG000|Part A Treatment Period|Protocol-specified (Low K+)|1
6237248|NCT01810939|9916186|FG001|Part A Treatment Period|Protocol-specified (Low K+)|0
6237249|NCT01810939|9916187|FG002|Part A Treatment Period|Protocol-specified (Low K+)|0
6237250|NCT01810939|9916185|FG000|Part B Placebo-Controlled Withdrawal|Physician Decision|0
6237251|NCT01810939|9916186|FG001|Part B Placebo-Controlled Withdrawal|Physician Decision|1
6237252|NCT01810939|9916187|FG002|Part B Placebo-Controlled Withdrawal|Physician Decision|1
6237253|NCT01810939|9916185|FG000|Part B Placebo-Controlled Withdrawal|Non-compliance with Study Drug|0
6237254|NCT01810939|9916186|FG001|Part B Placebo-Controlled Withdrawal|Non-compliance with Study Drug|1
6237255|NCT01810939|9916187|FG002|Part B Placebo-Controlled Withdrawal|Non-compliance with Study Drug|0
6237256|NCT01810939|9916185|FG000|Part B Placebo-Controlled Withdrawal|Adverse Event|0
6237257|NCT01810939|9916186|FG001|Part B Placebo-Controlled Withdrawal|Adverse Event|1
6237258|NCT01810939|9916187|FG002|Part B Placebo-Controlled Withdrawal|Adverse Event|1
6237259|NCT01810939|9916185|FG000|Part B Placebo-Controlled Withdrawal|Death|0
6237260|NCT01810939|9916186|FG001|Part B Placebo-Controlled Withdrawal|Death|0
6237261|NCT01810939|9916187|FG002|Part B Placebo-Controlled Withdrawal|Death|1
6237262|NCT01810939|9916185|FG000|Part B Placebo-Controlled Withdrawal|Withdrawal by Subject|0
6237263|NCT01810939|9916186|FG001|Part B Placebo-Controlled Withdrawal|Withdrawal by Subject|0
6237264|NCT01810939|9916187|FG002|Part B Placebo-Controlled Withdrawal|Withdrawal by Subject|1
6237265|NCT01810939|9916185|FG000|Part B Placebo-Controlled Withdrawal|Protocol-specified (eGFR)|0
6237266|NCT01810939|9916186|FG001|Part B Placebo-Controlled Withdrawal|Protocol-specified (eGFR)|1
6237267|NCT01810939|9916187|FG002|Part B Placebo-Controlled Withdrawal|Protocol-specified (eGFR)|1
6237268|NCT01810939|9916185|FG000|Part B Placebo-Controlled Withdrawal|Protocol-specified (K+ result)|0
6237269|NCT01810939|9916186|FG001|Part B Placebo-Controlled Withdrawal|Protocol-specified (K+ result)|1
6237270|NCT01810939|9916187|FG002|Part B Placebo-Controlled Withdrawal|Protocol-specified (K+ result)|2
6237271|NCT01810939|9916185|FG000|Part B Placebo-Controlled Withdrawal|Protocol-specified (High K+)|0
6237272|NCT01810939|9916186|FG001|Part B Placebo-Controlled Withdrawal|Protocol-specified (High K+)|2
6237273|NCT01810939|9916187|FG002|Part B Placebo-Controlled Withdrawal|Protocol-specified (High K+)|14
6237274|NCT01810939|9916185|FG000|Part B Placebo-Controlled Withdrawal|Protocol-specified (Low K+)|0
6237275|NCT01810939|9916186|FG001|Part B Placebo-Controlled Withdrawal|Protocol-specified (Low K+)|2
6237276|NCT01810939|9916187|FG002|Part B Placebo-Controlled Withdrawal|Protocol-specified (Low K+)|1
6237277|NCT01810939|9916185|FG000|Part B Placebo-Controlled Withdrawal|Lost to Follow-up|0
6237278|NCT01810939|9916186|FG001|Part B Placebo-Controlled Withdrawal|Lost to Follow-up|1
6237279|NCT01810939|9916187|FG002|Part B Placebo-Controlled Withdrawal|Lost to Follow-up|0
6237280|NCT01811186|9916249|FG000|Overall Study|Adverse Event|54
6237281|NCT01811186|9916250|FG001|Overall Study|Adverse Event|38
6237282|NCT01811186|9916249|FG000|Overall Study|Protocol Violation|5
6237283|NCT01811186|9916250|FG001|Overall Study|Protocol Violation|6
6237284|NCT01811186|9916249|FG000|Overall Study|Withdrawal by Subject|5
6237285|NCT01811186|9916250|FG001|Overall Study|Withdrawal by Subject|10
6237286|NCT01811186|9916249|FG000|Overall Study|Lack of Efficacy|3
6237287|NCT01811186|9916250|FG001|Overall Study|Lack of Efficacy|6
6237288|NCT01811186|9916249|FG000|Overall Study|Lost to Follow-up|4
6237289|NCT01811186|9916250|FG001|Overall Study|Lost to Follow-up|2
6237290|NCT01811225|9916264|FG000|Treatment Period 1|Adverse Event|2
6237291|NCT01811225|9916265|FG001|Treatment Period 1|Adverse Event|3
6237292|NCT01811225|9916264|FG000|Treatment Period 1|Lost to Follow-up|12
6237293|NCT01811225|9916265|FG001|Treatment Period 1|Lost to Follow-up|8
6237294|NCT01811225|9916264|FG000|Treatment Period 1|transporation|1
6237295|NCT01811225|9916265|FG001|Treatment Period 1|transporation|0
6237296|NCT01811225|9916264|FG000|Treatment Period 1|unable to remain smoke free overnight|10
6237297|NCT01811225|9916265|FG001|Treatment Period 1|unable to remain smoke free overnight|6
6237298|NCT01811225|9916264|FG000|Treatment Period 2|Lost to Follow-up|1
6237299|NCT01811225|9916265|FG001|Treatment Period 2|Lost to Follow-up|2
6237300|NCT01811225|9916264|FG000|Treatment Period 2|unable to remain smoke free overnight|3
6237301|NCT01811225|9916265|FG001|Treatment Period 2|unable to remain smoke free overnight|4
6237302|NCT01811238|9916271|FG000|Overall Study|Withdrawal by Subject|42
6237303|NCT01811238|9916271|FG000|Overall Study|Adverse Event|25
6237304|NCT01811238|9916271|FG000|Overall Study|Protocol Violation|4
6237305|NCT01811238|9916271|FG000|Overall Study|Lack of Efficacy|4
6237306|NCT01811238|9916271|FG000|Overall Study|subject refused study medication|6
6237307|NCT01811472|9916312|FG000|Overall Study|Adverse Event|1
6237308|NCT01811472|9916313|FG001|Overall Study|Adverse Event|0
6237309|NCT01811472|9916314|FG002|Overall Study|Adverse Event|4
6237310|NCT01811472|9916312|FG000|Overall Study|Lost to Follow-up|0
6237311|NCT01811472|9916313|FG001|Overall Study|Lost to Follow-up|0
6237312|NCT01811472|9916314|FG002|Overall Study|Lost to Follow-up|1
6237313|NCT01811472|9916312|FG000|Overall Study|Subject/guardian decision|1
6237314|NCT01811472|9916313|FG001|Overall Study|Subject/guardian decision|0
6237315|NCT01811472|9916314|FG002|Overall Study|Subject/guardian decision|0
6237316|NCT01811485|9916326|FG000|Overall Study|Adverse Event|1
6237317|NCT01811485|9916327|FG001|Overall Study|Adverse Event|3
6237318|NCT01811485|9916328|FG002|Overall Study|Adverse Event|2
6237319|NCT01811485|9916326|FG000|Overall Study|Unsatisfactory therapeutic effect|0
6237320|NCT01811485|9916327|FG001|Overall Study|Unsatisfactory therapeutic effect|0
6237321|NCT01811485|9916328|FG002|Overall Study|Unsatisfactory therapeutic effect|3
6237322|NCT01811485|9916326|FG000|Overall Study|Administrative problems|1
6237323|NCT01811485|9916327|FG001|Overall Study|Administrative problems|0
6237324|NCT01811485|9916328|FG002|Overall Study|Administrative problems|0
6237325|NCT01811485|9916326|FG000|Overall Study|Protocol Deviation|0
6237326|NCT01811485|9916327|FG001|Overall Study|Protocol Deviation|1
6237327|NCT01811485|9916328|FG002|Overall Study|Protocol Deviation|0
6237328|NCT01811563|9916341|FG000|Overall Study|Lost to Follow-up|5
6237329|NCT01811563|9916342|FG001|Overall Study|Lost to Follow-up|2
6237330|NCT01811563|9916341|FG000|Overall Study|Incorrect Randomization procedure|0
6237331|NCT01811563|9916342|FG001|Overall Study|Incorrect Randomization procedure|1
6237332|NCT01811706|9916371|FG000|First Intervention ( 4 Weeks)|Adverse Event|1
6237333|NCT01811706|9916372|FG001|First Intervention ( 4 Weeks)|Adverse Event|0
6237334|NCT01811732|9916382|FG000|Overall Study|Lost to Follow-up|24
6237335|NCT01811732|9916383|FG001|Overall Study|Lost to Follow-up|30
6237336|NCT01811732|9916382|FG000|Overall Study|Withdrawal by Subject|16
6237337|NCT01811732|9916383|FG001|Overall Study|Withdrawal by Subject|10
6237338|NCT01811732|9916382|FG000|Overall Study|Adverse Event|3
6237339|NCT01811732|9916383|FG001|Overall Study|Adverse Event|9
6237340|NCT01811732|9916382|FG000|Overall Study|Lack of Efficacy|3
6237341|NCT01811732|9916383|FG001|Overall Study|Lack of Efficacy|1
6237342|NCT01811732|9916382|FG000|Overall Study|Non-compliance with study drug/procedure|3
6237343|NCT01811732|9916383|FG001|Overall Study|Non-compliance with study drug/procedure|3
6237344|NCT01811732|9916382|FG000|Overall Study|Physician Decision|2
6237345|NCT01811732|9916383|FG001|Overall Study|Physician Decision|0
6237346|NCT01811732|9916382|FG000|Overall Study|Death|1
6237347|NCT01811732|9916383|FG001|Overall Study|Death|1
6237348|NCT01811732|9916382|FG000|Overall Study|Insufficient venous access|0
6237349|NCT01811732|9916383|FG001|Overall Study|Insufficient venous access|1
6237350|NCT01811732|9916382|FG000|Overall Study|Protocol Violation|0
6237351|NCT01811732|9916383|FG001|Overall Study|Protocol Violation|1
6237352|NCT01811732|9916382|FG000|Overall Study|Subject incarcerated|1
6237353|NCT01811732|9916383|FG001|Overall Study|Subject incarcerated|2
6237354|NCT01811732|9916382|FG000|Overall Study|Admitted to another facility|1
6237355|NCT01811732|9916383|FG001|Overall Study|Admitted to another facility|0
6237356|NCT01811732|9916382|FG000|Overall Study|Correct study drug not available on site|1
6237357|NCT01811732|9916383|FG001|Overall Study|Correct study drug not available on site|0
6237358|NCT01811953|9916409|FG000|Overall Study|Adverse Event|0
6237359|NCT01811953|9916410|FG001|Overall Study|Adverse Event|0
6237360|NCT01811953|9916411|FG002|Overall Study|Adverse Event|0
6237361|NCT01811953|9916412|FG003|Overall Study|Adverse Event|1
6237362|NCT01811953|9916413|FG004|Overall Study|Adverse Event|0
6237363|NCT01811953|9916414|FG005|Overall Study|Adverse Event|1
6237364|NCT01811953|9916409|FG000|Overall Study|Protocol Violation|0
6237365|NCT01811953|9916410|FG001|Overall Study|Protocol Violation|0
6237366|NCT01811953|9916411|FG002|Overall Study|Protocol Violation|0
6237367|NCT01811953|9916412|FG003|Overall Study|Protocol Violation|0
6237368|NCT01811953|9916413|FG004|Overall Study|Protocol Violation|1
6237369|NCT01811953|9916414|FG005|Overall Study|Protocol Violation|0
6237370|NCT01812057|9916452|FG000|Overall Study|Protocol Violation|1
6237371|NCT01812057|9916453|FG001|Overall Study|Protocol Violation|0
6237372|NCT01812057|9916452|FG000|Overall Study|Physician Decision|1
6237373|NCT01812057|9916453|FG001|Overall Study|Physician Decision|0
6237374|NCT01812109|9916463|FG000|Overall Study|research personnel delay|16
6237375|NCT01812109|9916463|FG000|Overall Study|NIRS Unattainable|17
6237376|NCT01812655|9916479|FG000|Overall Study|Protocol Violation|1
6237377|NCT01812655|9916480|FG001|Overall Study|Protocol Violation|1
6237378|NCT01812655|9916481|FG002|Overall Study|Protocol Violation|0
6237379|NCT01812707|9916509|FG000|Overall Study|Adverse Event|0
6237380|NCT01812707|9916510|FG001|Overall Study|Adverse Event|0
6237381|NCT01812707|9916511|FG002|Overall Study|Adverse Event|0
6237382|NCT01812707|9916512|FG003|Overall Study|Adverse Event|2
6237383|NCT01812707|9916509|FG000|Overall Study|Poor compliance to protocol|1
6237384|NCT01812707|9916510|FG001|Overall Study|Poor compliance to protocol|0
6237385|NCT01812707|9916511|FG002|Overall Study|Poor compliance to protocol|0
6237386|NCT01812707|9916512|FG003|Overall Study|Poor compliance to protocol|0
6237387|NCT01812707|9916509|FG000|Overall Study|Consent withdrawn by participant|1
6237388|NCT01812707|9916510|FG001|Overall Study|Consent withdrawn by participant|0
6237389|NCT01812707|9916511|FG002|Overall Study|Consent withdrawn by participant|0
6237390|NCT01812707|9916512|FG003|Overall Study|Consent withdrawn by participant|0
6237391|NCT01812759|9916526|FG000|Overall Study|Physician Decision|0
6237392|NCT01812759|9916527|FG001|Overall Study|Physician Decision|0
6237393|NCT01812759|9916528|FG002|Overall Study|Physician Decision|1
6237394|NCT01812837|9916539|FG000|Overall Study|Lost to Follow-up|1
6237395|NCT01812837|9916540|FG001|Overall Study|Lost to Follow-up|1
6237396|NCT01812837|9916541|FG002|Overall Study|Lost to Follow-up|0
6237397|NCT01812837|9916539|FG000|Overall Study|Protocol Violation|1
6237398|NCT01812837|9916540|FG001|Overall Study|Protocol Violation|0
6237399|NCT01812837|9916541|FG002|Overall Study|Protocol Violation|0
6237400|NCT01813019|9916551|FG000|Overall Study|Adverse Event|0
6237401|NCT01813019|9916552|FG001|Overall Study|Adverse Event|3
6237402|NCT01813019|9916551|FG000|Overall Study|Withdrawal by Subject|3
6237403|NCT01813019|9916552|FG001|Overall Study|Withdrawal by Subject|2
6237404|NCT01813019|9916551|FG000|Overall Study|administrative problems|2
6237405|NCT01813019|9916552|FG001|Overall Study|administrative problems|0
6237406|NCT01813019|9916551|FG000|Overall Study|Protocol Deviation|2
6237407|NCT01813019|9916552|FG001|Overall Study|Protocol Deviation|1
6237408|NCT01813058|9916560|FG000|Overall Study|Withdrawal by Subject|5
6237409|NCT01813058|9916561|FG001|Overall Study|Withdrawal by Subject|4
6237410|NCT01813071|9916576|FG000|Overall Study|Protocol Violation|0
6237411|NCT01813071|9916577|FG001|Overall Study|Protocol Violation|0
6237412|NCT01813071|9916578|FG002|Overall Study|Protocol Violation|0
6237413|NCT01813071|9916579|FG003|Overall Study|Protocol Violation|0
6237414|NCT01813071|9916580|FG004|Overall Study|Protocol Violation|1
6237415|NCT01813071|9916581|FG005|Overall Study|Protocol Violation|4
6237416|NCT01813071|9916582|FG006|Overall Study|Protocol Violation|2
6237417|NCT01813071|9916583|FG007|Overall Study|Protocol Violation|4
6237418|NCT01813071|9916584|FG008|Overall Study|Protocol Violation|2
6237419|NCT01813071|9916576|FG000|Overall Study|Withdrawal by Subject|0
6237420|NCT01813071|9916577|FG001|Overall Study|Withdrawal by Subject|0
6237421|NCT01813071|9916578|FG002|Overall Study|Withdrawal by Subject|0
6237422|NCT01813071|9916579|FG003|Overall Study|Withdrawal by Subject|0
6237423|NCT01813071|9916580|FG004|Overall Study|Withdrawal by Subject|0
6237424|NCT01813071|9916581|FG005|Overall Study|Withdrawal by Subject|1
6237425|NCT01813071|9916582|FG006|Overall Study|Withdrawal by Subject|0
6237426|NCT01813071|9916583|FG007|Overall Study|Withdrawal by Subject|0
6237427|NCT01813071|9916584|FG008|Overall Study|Withdrawal by Subject|0
6237428|NCT01813071|9916576|FG000|Overall Study|Adverse Event|0
6237429|NCT01813071|9916577|FG001|Overall Study|Adverse Event|0
6237430|NCT01813071|9916578|FG002|Overall Study|Adverse Event|0
6237431|NCT01813071|9916579|FG003|Overall Study|Adverse Event|0
6237432|NCT01813071|9916580|FG004|Overall Study|Adverse Event|0
6237433|NCT01813071|9916581|FG005|Overall Study|Adverse Event|1
6237434|NCT01813071|9916582|FG006|Overall Study|Adverse Event|0
6237435|NCT01813071|9916583|FG007|Overall Study|Adverse Event|0
6237436|NCT01813071|9916584|FG008|Overall Study|Adverse Event|0
6237437|NCT01813071|9916576|FG000|Overall Study|Physician Decision|0
6237438|NCT01813071|9916577|FG001|Overall Study|Physician Decision|0
6237439|NCT01813071|9916578|FG002|Overall Study|Physician Decision|0
6237440|NCT01813071|9916579|FG003|Overall Study|Physician Decision|0
6237441|NCT01813071|9916580|FG004|Overall Study|Physician Decision|0
6237442|NCT01813071|9916581|FG005|Overall Study|Physician Decision|0
6237443|NCT01813071|9916582|FG006|Overall Study|Physician Decision|1
6237444|NCT01813071|9916583|FG007|Overall Study|Physician Decision|0
6237445|NCT01813071|9916584|FG008|Overall Study|Physician Decision|0
6237446|NCT01813071|9916576|FG000|Overall Study|Met inc/exc criteria|0
6237447|NCT01813071|9916577|FG001|Overall Study|Met inc/exc criteria|0
6188799|NCT01394718|9843706|FG000|Overall Study|Met protocol-specific stopping criteria|2
6188800|NCT01394718|9843707|FG001|Overall Study|Met protocol-specific stopping criteria|1
6188801|NCT01394939|9843717|FG000|Overall Study|Adverse Event|1
6188802|NCT01394939|9843718|FG001|Overall Study|Adverse Event|3
6188803|NCT01394939|9843719|FG002|Overall Study|Adverse Event|0
6188804|NCT01394939|9843720|FG003|Overall Study|Adverse Event|2
6188805|NCT01394939|9843717|FG000|Overall Study|Death|0
6188806|NCT01394939|9843718|FG001|Overall Study|Death|2
6188807|NCT01394939|9843719|FG002|Overall Study|Death|0
6188808|NCT01394939|9843720|FG003|Overall Study|Death|0
6188809|NCT01394939|9843717|FG000|Overall Study|Physician Decision|0
6188810|NCT01394939|9843718|FG001|Overall Study|Physician Decision|1
6188811|NCT01394939|9843719|FG002|Overall Study|Physician Decision|0
6188812|NCT01394939|9843720|FG003|Overall Study|Physician Decision|0
6188813|NCT01394939|9843717|FG000|Overall Study|Withdrawal by Subject|0
6188814|NCT01394939|9843718|FG001|Overall Study|Withdrawal by Subject|2
6188815|NCT01394939|9843719|FG002|Overall Study|Withdrawal by Subject|0
6188816|NCT01394939|9843720|FG003|Overall Study|Withdrawal by Subject|2
6188817|NCT01394939|9843717|FG000|Overall Study|Others|0
6188818|NCT01394939|9843718|FG001|Overall Study|Others|2
6188819|NCT01394939|9843719|FG002|Overall Study|Others|0
6188820|NCT01394939|9843720|FG003|Overall Study|Others|3
6188821|NCT01394952|9843732|FG000|Overall Study|Lost to Follow-up|0
6188822|NCT01394952|9843733|FG001|Overall Study|Lost to Follow-up|5
6188823|NCT01394952|9843732|FG000|Overall Study|Withdrawal by Subject|10
6188824|NCT01394952|9843733|FG001|Overall Study|Withdrawal by Subject|5
6188825|NCT01394952|9843732|FG000|Overall Study|Physician Decision|2
6188826|NCT01394952|9843733|FG001|Overall Study|Physician Decision|0
6188827|NCT01394952|9843732|FG000|Overall Study|Sponsor Decision|5
6188828|NCT01394952|9843733|FG001|Overall Study|Sponsor Decision|7
6188829|NCT01394978|9843742|FG000|Overall Study|Withdrawal by Subject|2
6188830|NCT01394978|9843743|FG001|Overall Study|Withdrawal by Subject|4
6188831|NCT01394978|9843742|FG000|Overall Study|Lost to Follow-up|13
6188832|NCT01394978|9843743|FG001|Overall Study|Lost to Follow-up|20
6188833|NCT01394978|9843742|FG000|Overall Study|Death|6
6188834|NCT01394978|9843743|FG001|Overall Study|Death|7
6188835|NCT01394991|9843752|FG000|Overall Study|Adverse Event|0
6188836|NCT01394991|9843753|FG001|Overall Study|Adverse Event|4
6188837|NCT01394991|9843752|FG000|Overall Study|Lack of Efficacy|5
6237448|NCT01813071|9916578|FG002|Overall Study|Met inc/exc criteria|0
6237449|NCT01813071|9916579|FG003|Overall Study|Met inc/exc criteria|0
6237450|NCT01813071|9916580|FG004|Overall Study|Met inc/exc criteria|0
6188838|NCT01394991|9843753|FG001|Overall Study|Lack of Efficacy|7
6188839|NCT01394991|9843752|FG000|Overall Study|Lost to Follow-up|6
6237451|NCT01813071|9916581|FG005|Overall Study|Met inc/exc criteria|1
6237452|NCT01813071|9916582|FG006|Overall Study|Met inc/exc criteria|0
6237453|NCT01813071|9916583|FG007|Overall Study|Met inc/exc criteria|1
6237454|NCT01813071|9916584|FG008|Overall Study|Met inc/exc criteria|1
6237455|NCT01813357|9916651|FG000|Overall Study|Lost to Follow-up|5
6237456|NCT01813357|9916652|FG001|Overall Study|Lost to Follow-up|6
6237457|NCT01813422|9916660|FG000|Overall Study|Withdrawal by Subject|14
6237458|NCT01813422|9916661|FG001|Overall Study|Withdrawal by Subject|8
6237459|NCT01813422|9916660|FG000|Overall Study|Death|2
6237460|NCT01813422|9916661|FG001|Overall Study|Death|3
6237461|NCT01813422|9916660|FG000|Overall Study|Sponsor Decision|2
6237462|NCT01813422|9916661|FG001|Overall Study|Sponsor Decision|1
6237463|NCT01813422|9916660|FG000|Overall Study|Lost to Follow-up|2
6237464|NCT01813422|9916661|FG001|Overall Study|Lost to Follow-up|4
6270086|NCT02147158|9970633|FG002|Off-Treatment Interval 2|Other Miscellaneous Reasons|1
6270087|NCT02147158|9970634|FG003|Off-Treatment Interval 2|Other Miscellaneous Reasons|4
6270088|NCT02147158|9970635|FG004|Off-Treatment Interval 2|Other Miscellaneous Reasons|0
6188840|NCT01394991|9843753|FG001|Overall Study|Lost to Follow-up|8
6188841|NCT01394991|9843752|FG000|Overall Study|Physician Decision|1
6188842|NCT01394991|9843753|FG001|Overall Study|Physician Decision|3
6188843|NCT01394991|9843752|FG000|Overall Study|Protocol Violation|1
6188844|NCT01394991|9843753|FG001|Overall Study|Protocol Violation|1
6188845|NCT01394991|9843752|FG000|Overall Study|Withdrawal by Subject|20
6188846|NCT01394991|9843753|FG001|Overall Study|Withdrawal by Subject|17
6188847|NCT01394991|9843752|FG000|Overall Study|Chemotherapy Termination|10
6188848|NCT01394991|9843753|FG001|Overall Study|Chemotherapy Termination|15
6188849|NCT01394991|9843752|FG000|Overall Study|Disease Progression|7
6188850|NCT01394991|9843753|FG001|Overall Study|Disease Progression|7
6188851|NCT01394991|9843752|FG000|Overall Study|Prematurely Termination of Trial|9
6188852|NCT01394991|9843753|FG001|Overall Study|Prematurely Termination of Trial|10
6188853|NCT01395017|9843761|FG000|Overall Study|Lost to Follow-up|1
6270089|NCT02147158|9970636|FG005|Off-Treatment Interval 2|Other Miscellaneous Reasons|1
6270090|NCT02147197|9970656|FG000|Overall Study|Adverse Event|1
6270091|NCT02147197|9970657|FG001|Overall Study|Adverse Event|0
6270092|NCT02147197|9970658|FG002|Overall Study|Adverse Event|0
6270093|NCT02147197|9970656|FG000|Overall Study|Withdrawal of Consent|4
6270094|NCT02147197|9970657|FG001|Overall Study|Withdrawal of Consent|3
6270095|NCT02147197|9970658|FG002|Overall Study|Withdrawal of Consent|2
6270096|NCT02147197|9970656|FG000|Overall Study|Lost to Follow-up|2
6270097|NCT02147197|9970657|FG001|Overall Study|Lost to Follow-up|3
6270098|NCT02147197|9970658|FG002|Overall Study|Lost to Follow-up|1
6270099|NCT02147197|9970656|FG000|Overall Study|Protocol Violation|1
6270100|NCT02147197|9970657|FG001|Overall Study|Protocol Violation|0
6270101|NCT02147197|9970658|FG002|Overall Study|Protocol Violation|3
6270102|NCT02147197|9970656|FG000|Overall Study|Other Miscellaneous Reasons|1
6270103|NCT02147197|9970657|FG001|Overall Study|Other Miscellaneous Reasons|0
6270104|NCT02147197|9970658|FG002|Overall Study|Other Miscellaneous Reasons|3
6270105|NCT02147288|9970668|FG000|Overall Study|post-operative hematoma|1
6270106|NCT02147288|9970669|FG001|Overall Study|post-operative hematoma|1
6270107|NCT02147288|9970670|FG002|Overall Study|post-operative hematoma|0
6270108|NCT02147288|9970671|FG003|Overall Study|post-operative hematoma|0
6270109|NCT02147288|9970672|FG004|Overall Study|post-operative hematoma|0
6270110|NCT02147288|9970673|FG005|Overall Study|post-operative hematoma|0
6270111|NCT02147288|9970674|FG006|Overall Study|post-operative hematoma|0
6270112|NCT02147288|9970675|FG007|Overall Study|post-operative hematoma|0
6270113|NCT02147288|9970676|FG008|Overall Study|post-operative hematoma|0
6270114|NCT02147288|9970677|FG009|Overall Study|post-operative hematoma|0
6270115|NCT02147288|9970668|FG000|Overall Study|complications from concurrent hernia rep|0
6270116|NCT02147288|9970669|FG001|Overall Study|complications from concurrent hernia rep|1
6270117|NCT02147288|9970670|FG002|Overall Study|complications from concurrent hernia rep|0
6270118|NCT02147288|9970671|FG003|Overall Study|complications from concurrent hernia rep|0
6270119|NCT02147288|9970672|FG004|Overall Study|complications from concurrent hernia rep|0
6270120|NCT02147288|9970673|FG005|Overall Study|complications from concurrent hernia rep|0
6270121|NCT02147288|9970674|FG006|Overall Study|complications from concurrent hernia rep|0
6270122|NCT02147288|9970675|FG007|Overall Study|complications from concurrent hernia rep|0
6270123|NCT02147288|9970676|FG008|Overall Study|complications from concurrent hernia rep|0
6270124|NCT02147288|9970677|FG009|Overall Study|complications from concurrent hernia rep|0
6270125|NCT02147353|9970689|FG000|Overall Study|Lost to Follow-up|2
6270126|NCT02147353|9970690|FG001|Overall Study|Lost to Follow-up|0
6270127|NCT02147353|9970689|FG000|Overall Study|unable to make visits|4
6270128|NCT02147353|9970690|FG001|Overall Study|unable to make visits|0
6188854|NCT01395017|9843762|FG001|Overall Study|Lost to Follow-up|0
6188855|NCT01395017|9843761|FG000|Overall Study|Adverse Event|26
6188856|NCT01395017|9843762|FG001|Overall Study|Adverse Event|12
6188857|NCT01395017|9843761|FG000|Overall Study|Physician Decision|11
6188858|NCT01395017|9843762|FG001|Overall Study|Physician Decision|15
6270129|NCT02147353|9970689|FG000|Overall Study|medication noncompliance|3
6270130|NCT02147353|9970690|FG001|Overall Study|medication noncompliance|0
6270131|NCT02147561|9970705|FG000|Overall Study|Lost to Follow-up|3
6270132|NCT02147561|9970705|FG000|Overall Study|Subjects who didn't receive BOTOX|1
6270133|NCT02147587|9970711|FG000|Overall Study|Adverse Event|9
6270134|NCT02147587|9970712|FG001|Overall Study|Adverse Event|4
6188859|NCT01395017|9843761|FG000|Overall Study|Withdrawal by Subject|14
6237465|NCT01813474|9916670|FG000|Overall Study|Withdrawal by Subject|0
6237466|NCT01813474|9916671|FG001|Overall Study|Withdrawal by Subject|0
6237467|NCT01813474|9916672|FG002|Overall Study|Withdrawal by Subject|1
6237468|NCT01813474|9916670|FG000|Overall Study|Adverse Event|1
6237469|NCT01813474|9916671|FG001|Overall Study|Adverse Event|1
6237470|NCT01813474|9916672|FG002|Overall Study|Adverse Event|0
6237471|NCT01813474|9916670|FG000|Overall Study|Lack of Efficacy|2
6237472|NCT01813474|9916671|FG001|Overall Study|Lack of Efficacy|6
6237473|NCT01813474|9916672|FG002|Overall Study|Lack of Efficacy|9
6237474|NCT01813474|9916670|FG000|Overall Study|Death|0
6237475|NCT01813474|9916671|FG001|Overall Study|Death|0
6237476|NCT01813474|9916672|FG002|Overall Study|Death|1
6237477|NCT01813721|9916681|FG000|Overall Study|Ineligibility determined|63
6237478|NCT01813721|9916681|FG000|Overall Study|Withdrawal by Subject|1
6237479|NCT01813890|9916710|FG000|Overall Study|Adverse Event|0
6237480|NCT01813890|9916711|FG001|Overall Study|Adverse Event|3
6237481|NCT01813890|9916712|FG002|Overall Study|Adverse Event|4
6237482|NCT01813890|9916710|FG000|Overall Study|Lack of Efficacy|9
6237483|NCT01813890|9916711|FG001|Overall Study|Lack of Efficacy|1
6237484|NCT01813890|9916712|FG002|Overall Study|Lack of Efficacy|2
6237485|NCT01814007|9916720|FG000|Overall Study|Withdrawal by Subject|1
6237486|NCT01814046|9916727|FG000|Drug Administration|Death due to complications of RSV|1
6237487|NCT01814046|9916728|FG001|Drug Administration|Death due to complications of RSV|0
6237488|NCT01814046|9916729|FG002|Drug Administration|Death due to complications of RSV|0
6237489|NCT01814072|9916768|FG000|Overall Study|Lost to Follow-up|2
6237490|NCT01814072|9916769|FG001|Overall Study|Lost to Follow-up|2
6237491|NCT01814072|9916770|FG002|Overall Study|Lost to Follow-up|2
6237492|NCT01814072|9916771|FG003|Overall Study|Lost to Follow-up|0
6237493|NCT01814072|9916772|FG004|Overall Study|Lost to Follow-up|2
6237494|NCT01814072|9916773|FG005|Overall Study|Lost to Follow-up|3
6237495|NCT01814072|9916774|FG006|Overall Study|Lost to Follow-up|3
6237496|NCT01814072|9916775|FG007|Overall Study|Lost to Follow-up|1
6237497|NCT01814072|9916776|FG008|Overall Study|Lost to Follow-up|2
6237498|NCT01814072|9916777|FG009|Overall Study|Lost to Follow-up|3
6237499|NCT01814072|9916778|FG010|Overall Study|Lost to Follow-up|1
6237500|NCT01814072|9916779|FG011|Overall Study|Lost to Follow-up|2
6237501|NCT01814072|9916780|FG012|Overall Study|Lost to Follow-up|2
6237502|NCT01814072|9916781|FG013|Overall Study|Lost to Follow-up|1
6237503|NCT01814072|9916782|FG014|Overall Study|Lost to Follow-up|2
6237504|NCT01814072|9916783|FG015|Overall Study|Lost to Follow-up|1
6237505|NCT01814072|9916784|FG016|Overall Study|Lost to Follow-up|3
6237506|NCT01814072|9916785|FG017|Overall Study|Lost to Follow-up|1
6237507|NCT01814072|9916786|FG018|Overall Study|Lost to Follow-up|3
6237508|NCT01814072|9916787|FG019|Overall Study|Lost to Follow-up|3
6237509|NCT01814072|9916788|FG020|Overall Study|Lost to Follow-up|2
6237510|NCT01814072|9916789|FG021|Overall Study|Lost to Follow-up|1
6237511|NCT01814072|9916790|FG022|Overall Study|Lost to Follow-up|3
6237512|NCT01814072|9916791|FG023|Overall Study|Lost to Follow-up|1
6237513|NCT01814072|9916792|FG024|Overall Study|Lost to Follow-up|4
6237514|NCT01814072|9916793|FG025|Overall Study|Lost to Follow-up|1
6237515|NCT01814072|9916794|FG026|Overall Study|Lost to Follow-up|1
6237516|NCT01814072|9916795|FG027|Overall Study|Lost to Follow-up|2
6237517|NCT01814072|9916796|FG028|Overall Study|Lost to Follow-up|3
6237518|NCT01814072|9916797|FG029|Overall Study|Lost to Follow-up|3
6237519|NCT01814072|9916798|FG030|Overall Study|Lost to Follow-up|2
6237520|NCT01814072|9916799|FG031|Overall Study|Lost to Follow-up|0
6237521|NCT01814072|9916768|FG000|Overall Study|Withdrawal by Subject|2
6237522|NCT01814072|9916769|FG001|Overall Study|Withdrawal by Subject|0
6237523|NCT01814072|9916770|FG002|Overall Study|Withdrawal by Subject|1
6237524|NCT01814072|9916771|FG003|Overall Study|Withdrawal by Subject|0
6237525|NCT01814072|9916772|FG004|Overall Study|Withdrawal by Subject|2
6237526|NCT01814072|9916773|FG005|Overall Study|Withdrawal by Subject|3
6237527|NCT01814072|9916774|FG006|Overall Study|Withdrawal by Subject|1
6237528|NCT01814072|9916775|FG007|Overall Study|Withdrawal by Subject|0
6237529|NCT01814072|9916776|FG008|Overall Study|Withdrawal by Subject|1
6237530|NCT01814072|9916777|FG009|Overall Study|Withdrawal by Subject|2
6237531|NCT01814072|9916778|FG010|Overall Study|Withdrawal by Subject|0
6237532|NCT01814072|9916779|FG011|Overall Study|Withdrawal by Subject|0
6237533|NCT01814072|9916780|FG012|Overall Study|Withdrawal by Subject|1
6237534|NCT01814072|9916781|FG013|Overall Study|Withdrawal by Subject|1
6237535|NCT01814072|9916782|FG014|Overall Study|Withdrawal by Subject|1
6237536|NCT01814072|9916783|FG015|Overall Study|Withdrawal by Subject|1
6237537|NCT01814072|9916784|FG016|Overall Study|Withdrawal by Subject|0
6237538|NCT01814072|9916785|FG017|Overall Study|Withdrawal by Subject|0
6237539|NCT01814072|9916786|FG018|Overall Study|Withdrawal by Subject|0
6237540|NCT01814072|9916787|FG019|Overall Study|Withdrawal by Subject|2
6237541|NCT01814072|9916788|FG020|Overall Study|Withdrawal by Subject|0
6237542|NCT01814072|9916789|FG021|Overall Study|Withdrawal by Subject|0
6237543|NCT01814072|9916790|FG022|Overall Study|Withdrawal by Subject|1
6237544|NCT01814072|9916791|FG023|Overall Study|Withdrawal by Subject|0
6237545|NCT01814072|9916792|FG024|Overall Study|Withdrawal by Subject|2
6237546|NCT01814072|9916793|FG025|Overall Study|Withdrawal by Subject|1
6237547|NCT01814072|9916794|FG026|Overall Study|Withdrawal by Subject|1
6237548|NCT01814072|9916795|FG027|Overall Study|Withdrawal by Subject|2
6237549|NCT01814072|9916796|FG028|Overall Study|Withdrawal by Subject|1
6237550|NCT01814072|9916797|FG029|Overall Study|Withdrawal by Subject|0
6237551|NCT01814072|9916798|FG030|Overall Study|Withdrawal by Subject|0
6237552|NCT01814072|9916799|FG031|Overall Study|Withdrawal by Subject|0
6237553|NCT01814137|9916841|FG000|Overall Study|Adverse Event|0
6237554|NCT01814137|9916842|FG001|Overall Study|Adverse Event|1
6237555|NCT01814137|9916841|FG000|Overall Study|Withdrawal by Subject|2
6237556|NCT01814137|9916842|FG001|Overall Study|Withdrawal by Subject|2
6237557|NCT01814137|9916841|FG000|Overall Study|Physician Decision|1
6237558|NCT01814137|9916842|FG001|Overall Study|Physician Decision|1
6237559|NCT01814137|9916841|FG000|Overall Study|Unclassified|2
6237560|NCT01814137|9916842|FG001|Overall Study|Unclassified|1
6237561|NCT01814332|9916855|FG000|Overall Study|Adverse Event|8
6237562|NCT01814332|9916856|FG001|Overall Study|Adverse Event|3
6237563|NCT01814332|9916855|FG000|Overall Study|Withdrawal by Subject|3
6237564|NCT01814332|9916856|FG001|Overall Study|Withdrawal by Subject|8
6237565|NCT01814332|9916855|FG000|Overall Study|Protocol Violation|0
6237566|NCT01814332|9916856|FG001|Overall Study|Protocol Violation|4
6237567|NCT01814332|9916855|FG000|Overall Study|Lost to Follow-up|5
6237568|NCT01814332|9916856|FG001|Overall Study|Lost to Follow-up|1
6237569|NCT01814371|9916864|FG000|Overall Study|Lost to Follow-up|30
6237570|NCT01814371|9916865|FG001|Overall Study|Lost to Follow-up|27
6237571|NCT01814397|9916874|FG000|Overall Study|Adverse Event|7
6237572|NCT01814397|9916874|FG000|Overall Study|Withdrawal by Subject|7
6237573|NCT01814553|9916880|FG000|Overall Study|PD per clinical progression|6
6237574|NCT01814553|9916881|FG001|Overall Study|PD per clinical progression|8
6237575|NCT01814553|9916880|FG000|Overall Study|Other Adverse Event|4
6237576|NCT01814553|9916881|FG001|Overall Study|Other Adverse Event|5
6237577|NCT01814553|9916880|FG000|Overall Study|Withdrawal by Subject|1
6237578|NCT01814553|9916881|FG001|Overall Study|Withdrawal by Subject|1
6237579|NCT01814553|9916880|FG000|Overall Study|Other than stated|7
6237580|NCT01814553|9916881|FG001|Overall Study|Other than stated|8
6237581|NCT01814670|9916887|FG000|Overall Study|Protocol Violation|12
6237582|NCT01814696|9916893|FG000|Overall Study|Withdrawal by Subject|1
6237583|NCT01814696|9916894|FG001|Overall Study|Withdrawal by Subject|0
6237584|NCT01814696|9916893|FG000|Overall Study|Randomized to wrong group|1
6237585|NCT01814696|9916894|FG001|Overall Study|Randomized to wrong group|0
6237586|NCT01814748|9916902|FG000|Overall Study|Lost to Follow-up|1
6237587|NCT01814748|9916903|FG001|Overall Study|Lost to Follow-up|2
6237588|NCT01814748|9916902|FG000|Overall Study|Study site terminated by sponsor|1
6237589|NCT01814748|9916903|FG001|Overall Study|Study site terminated by sponsor|1
6237590|NCT01814748|9916902|FG000|Overall Study|Withdrawal by Subject|6
6237591|NCT01814748|9916903|FG001|Overall Study|Withdrawal by Subject|4
6237592|NCT01814761|9916911|FG000|Overall Study|Other Reasons|1
6237593|NCT01814761|9916912|FG001|Overall Study|Other Reasons|10
6237594|NCT01814761|9916911|FG000|Overall Study|Ocular Adverse Event|6
6237595|NCT01814761|9916912|FG001|Overall Study|Ocular Adverse Event|15
6237596|NCT01814761|9916911|FG000|Overall Study|Lost to Follow-up|1
6237597|NCT01814761|9916912|FG001|Overall Study|Lost to Follow-up|5
6237598|NCT01814800|9916933|FG000|Overall Study|Adverse Event|2
6237599|NCT01814800|9916933|FG000|Overall Study|Pregnancy|1
6237600|NCT01814800|9916933|FG000|Overall Study|Sponsor decision|1
6237601|NCT01814800|9916933|FG000|Overall Study|Subject relocation|1
6237602|NCT01814878|9916952|FG000|Overall Study|Adverse Event|16
6237603|NCT01814878|9916953|FG001|Overall Study|Adverse Event|5
6237604|NCT01814878|9916952|FG000|Overall Study|Withdrawal by Subject|20
6237605|NCT01814878|9916953|FG001|Overall Study|Withdrawal by Subject|16
6237606|NCT01814878|9916952|FG000|Overall Study|Protocol Violation|5
6237607|NCT01814878|9916953|FG001|Overall Study|Protocol Violation|5
6237608|NCT01814878|9916952|FG000|Overall Study|Physician Decision|3
6237609|NCT01814878|9916953|FG001|Overall Study|Physician Decision|1
6237610|NCT01814878|9916952|FG000|Overall Study|Screening failure (drop-out)|0
6237611|NCT01814878|9916953|FG001|Overall Study|Screening failure (drop-out)|3
6237612|NCT01814878|9916952|FG000|Overall Study|Other|2
6237613|NCT01814878|9916953|FG001|Overall Study|Other|0
6237614|NCT01815099|9916965|FG000|Overall Study|Lack of Efficacy|1
6237615|NCT01815099|9916965|FG000|Overall Study|unable to attend study visits|1
6237616|NCT01815138|9916972|FG000|Overall Study|Withdrawal by Subject|0
6237617|NCT01815138|9916973|FG001|Overall Study|Withdrawal by Subject|1
6237618|NCT01815138|9916972|FG000|Overall Study|Physician Decision|8
6237619|NCT01815138|9916973|FG001|Overall Study|Physician Decision|5
6237620|NCT01815424|9916998|FG000|Week 0 to 16|Adverse Event|1
6237621|NCT01815424|9916999|FG001|Week 0 to 16|Adverse Event|3
6237622|NCT01815424|9917000|FG002|Week 0 to 16|Adverse Event|3
6237623|NCT01815424|9917001|FG003|Week 0 to 16|Adverse Event|0
6237624|NCT01815424|9917002|FG004|Week 0 to 16|Adverse Event|0
6237625|NCT01815424|9916998|FG000|Week 0 to 16|Does Not Meet Entrance Criteria|2
6237626|NCT01815424|9916999|FG001|Week 0 to 16|Does Not Meet Entrance Criteria|0
6237627|NCT01815424|9917000|FG002|Week 0 to 16|Does Not Meet Entrance Criteria|0
6237628|NCT01815424|9917001|FG003|Week 0 to 16|Does Not Meet Entrance Criteria|0
6237629|NCT01815424|9917002|FG004|Week 0 to 16|Does Not Meet Entrance Criteria|0
6237630|NCT01815424|9916998|FG000|Week 0 to 16|Lost to Follow-up|0
6237631|NCT01815424|9916999|FG001|Week 0 to 16|Lost to Follow-up|1
6237632|NCT01815424|9917000|FG002|Week 0 to 16|Lost to Follow-up|0
6237633|NCT01815424|9917001|FG003|Week 0 to 16|Lost to Follow-up|0
6237634|NCT01815424|9917002|FG004|Week 0 to 16|Lost to Follow-up|0
6237635|NCT01815424|9916998|FG000|Week 0 to 16|Withdrawal by Subject|0
6237636|NCT01815424|9916999|FG001|Week 0 to 16|Withdrawal by Subject|0
6237637|NCT01815424|9917000|FG002|Week 0 to 16|Withdrawal by Subject|1
6237638|NCT01815424|9917001|FG003|Week 0 to 16|Withdrawal by Subject|0
6237639|NCT01815424|9917002|FG004|Week 0 to 16|Withdrawal by Subject|0
6237640|NCT01815424|9916998|FG000|Week 0 to 16|Other|1
6237641|NCT01815424|9916999|FG001|Week 0 to 16|Other|0
6237642|NCT01815424|9917000|FG002|Week 0 to 16|Other|3
6237643|NCT01815424|9917001|FG003|Week 0 to 16|Other|0
6237644|NCT01815424|9917002|FG004|Week 0 to 16|Other|0
6237645|NCT01815424|9916998|FG000|Week 0 to 16|Protocol Violation|1
6237646|NCT01815424|9916999|FG001|Week 0 to 16|Protocol Violation|0
6237647|NCT01815424|9917000|FG002|Week 0 to 16|Protocol Violation|0
6237648|NCT01815424|9917001|FG003|Week 0 to 16|Protocol Violation|0
6237649|NCT01815424|9917002|FG004|Week 0 to 16|Protocol Violation|0
6237650|NCT01815424|9916998|FG000|Week 0 to 16|Insufficient Clinical Response|2
6237651|NCT01815424|9916999|FG001|Week 0 to 16|Insufficient Clinical Response|0
6237652|NCT01815424|9917000|FG002|Week 0 to 16|Insufficient Clinical Response|4
6237653|NCT01815424|9917001|FG003|Week 0 to 16|Insufficient Clinical Response|0
6237654|NCT01815424|9917002|FG004|Week 0 to 16|Insufficient Clinical Response|0
6237655|NCT01815424|9916998|FG000|Week 16 to 52|Other|0
6237656|NCT01815424|9916999|FG001|Week 16 to 52|Other|1
6237657|NCT01815424|9917000|FG002|Week 16 to 52|Other|0
6237658|NCT01815424|9917001|FG003|Week 16 to 52|Other|0
6237659|NCT01815424|9917002|FG004|Week 16 to 52|Other|0
6237660|NCT01815424|9916998|FG000|Week 16 to 52|Adverse Event|0
6237661|NCT01815424|9916999|FG001|Week 16 to 52|Adverse Event|0
6237662|NCT01815424|9917000|FG002|Week 16 to 52|Adverse Event|0
6237663|NCT01815424|9917001|FG003|Week 16 to 52|Adverse Event|0
6237664|NCT01815424|9917002|FG004|Week 16 to 52|Adverse Event|1
6237665|NCT01815424|9916998|FG000|Week 16 to 52|Insufficient Clinical Response|1
6237666|NCT01815424|9916999|FG001|Week 16 to 52|Insufficient Clinical Response|0
6237667|NCT01815424|9917000|FG002|Week 16 to 52|Insufficient Clinical Response|0
6237668|NCT01815424|9917001|FG003|Week 16 to 52|Insufficient Clinical Response|1
6237669|NCT01815424|9917002|FG004|Week 16 to 52|Insufficient Clinical Response|1
6237670|NCT01815424|9916998|FG000|Week 16 to 52|Lost to Follow-up|0
6237671|NCT01815424|9916999|FG001|Week 16 to 52|Lost to Follow-up|2
6237672|NCT01815424|9917000|FG002|Week 16 to 52|Lost to Follow-up|0
6237673|NCT01815424|9917001|FG003|Week 16 to 52|Lost to Follow-up|2
6237674|NCT01815424|9917002|FG004|Week 16 to 52|Lost to Follow-up|1
6237675|NCT01815424|9916998|FG000|Week 16 to 52|Withdrawal by Subject|1
6237676|NCT01815424|9916999|FG001|Week 16 to 52|Withdrawal by Subject|2
6237677|NCT01815424|9917000|FG002|Week 16 to 52|Withdrawal by Subject|0
6237678|NCT01815424|9917001|FG003|Week 16 to 52|Withdrawal by Subject|0
6237679|NCT01815424|9917002|FG004|Week 16 to 52|Withdrawal by Subject|0
6237680|NCT01815736|9917053|FG000|Randomized Treatment Phase-Up to Week 96|Withdrew Consent|11
6237681|NCT01815736|9917054|FG001|Randomized Treatment Phase-Up to Week 96|Withdrew Consent|17
6237682|NCT01815736|9917053|FG000|Randomized Treatment Phase-Up to Week 96|Lost to Follow-up|10
6237683|NCT01815736|9917054|FG001|Randomized Treatment Phase-Up to Week 96|Lost to Follow-up|9
6237684|NCT01815736|9917053|FG000|Randomized Treatment Phase-Up to Week 96|Investigator's Discretion|11
6237685|NCT01815736|9917054|FG001|Randomized Treatment Phase-Up to Week 96|Investigator's Discretion|2
6237686|NCT01815736|9917053|FG000|Randomized Treatment Phase-Up to Week 96|Adverse Event|7
6237687|NCT01815736|9917054|FG001|Randomized Treatment Phase-Up to Week 96|Adverse Event|4
6237688|NCT01815736|9917053|FG000|Randomized Treatment Phase-Up to Week 96|Death|4
6237689|NCT01815736|9917054|FG001|Randomized Treatment Phase-Up to Week 96|Death|0
6237690|NCT01815736|9917053|FG000|Randomized Treatment Phase-Up to Week 96|Lack of Efficacy|1
6237691|NCT01815736|9917054|FG001|Randomized Treatment Phase-Up to Week 96|Lack of Efficacy|0
6237692|NCT01815736|9917053|FG000|Randomized Treatment Phase-Up to Week 96|Pregnancy|1
6237693|NCT01815736|9917054|FG001|Randomized Treatment Phase-Up to Week 96|Pregnancy|0
6237694|NCT01815736|9917053|FG000|Randomized Treatment Phase-Up to Week 96|Participants randomized and never treated|4
6237695|NCT01815736|9917054|FG001|Randomized Treatment Phase-Up to Week 96|Participants randomized and never treated|3
6237696|NCT01815736|9917053|FG000|Extension Treatment Phase- After Week 96|Investigator's Discretion|31
6237697|NCT01815736|9917054|FG001|Extension Treatment Phase- After Week 96|Investigator's Discretion|15
6237698|NCT01815736|9917053|FG000|Extension Treatment Phase- After Week 96|Lost to Follow-up|13
6237699|NCT01815736|9917054|FG001|Extension Treatment Phase- After Week 96|Lost to Follow-up|9
6237700|NCT01815736|9917053|FG000|Extension Treatment Phase- After Week 96|Withdrew Consent|5
6237701|NCT01815736|9917054|FG001|Extension Treatment Phase- After Week 96|Withdrew Consent|1
6237702|NCT01815736|9917053|FG000|Extension Treatment Phase- After Week 96|Adverse Event|1
6237703|NCT01815736|9917054|FG001|Extension Treatment Phase- After Week 96|Adverse Event|1
6237704|NCT01815736|9917053|FG000|Extension Treatment Phase- After Week 96|Death|1
6237705|NCT01815736|9917054|FG001|Extension Treatment Phase- After Week 96|Death|0
6237706|NCT01815840|9917064|FG000|Overall Study|Missing|1
6237707|NCT01815840|9917065|FG001|Overall Study|Missing|0
6237708|NCT01815840|9917064|FG000|Overall Study|Withdrew Consent|31
6237709|NCT01815840|9917065|FG001|Overall Study|Withdrew Consent|30
6237710|NCT01815840|9917064|FG000|Overall Study|Administrative/Other|1
6237711|NCT01815840|9917065|FG001|Overall Study|Administrative/Other|3
6237712|NCT01815840|9917064|FG000|Overall Study|Adverse Event|10
6237713|NCT01815840|9917065|FG001|Overall Study|Adverse Event|16
6237714|NCT01815840|9917064|FG000|Overall Study|Death|2
6237715|NCT01815840|9917065|FG001|Overall Study|Death|2
6237716|NCT01815840|9917064|FG000|Overall Study|Disease progression|3
6237717|NCT01815840|9917065|FG001|Overall Study|Disease progression|2
6237718|NCT01815840|9917064|FG000|Overall Study|Investigators Decision|2
6237719|NCT01815840|9917065|FG001|Overall Study|Investigators Decision|3
6237720|NCT01815840|9917064|FG000|Overall Study|Lost to Follow-up|3
6237721|NCT01815840|9917065|FG001|Overall Study|Lost to Follow-up|6
6237722|NCT01815840|9917064|FG000|Overall Study|Refused Treatment|5
6237723|NCT01815840|9917065|FG001|Overall Study|Refused Treatment|1
6237724|NCT01815840|9917064|FG000|Overall Study|Sponsor Termination Treatment|1
6237725|NCT01815840|9917065|FG001|Overall Study|Sponsor Termination Treatment|0
6237726|NCT01815918|9917073|FG000|Overall Study|Patient samples not analyzable|3
6237727|NCT01815918|9917074|FG001|Overall Study|Patient samples not analyzable|4
6237728|NCT01815918|9917073|FG000|Overall Study|Lack of Efficacy|15
6237729|NCT01815918|9917074|FG001|Overall Study|Lack of Efficacy|15
6237730|NCT01816048|9917084|FG000|Overall Study|Adverse Event|1
6237731|NCT01816048|9917084|FG000|Overall Study|Death|1
6237732|NCT01816048|9917084|FG000|Overall Study|Withdrawal by Subject|1
6237733|NCT01816048|9917084|FG000|Overall Study|Disease Progression|3
6237734|NCT01816061|9917091|FG000|Overall Study|Lost to Follow-up|13
6237735|NCT01816061|9917092|FG001|Overall Study|Lost to Follow-up|24
6237736|NCT01816074|9917102|FG000|Phase 1|Time commitment issues|0
6237737|NCT01816074|9917103|FG001|Phase 1|Time commitment issues|0
6237738|NCT01816074|9917104|FG002|Phase 1|Time commitment issues|1
6237739|NCT01816074|9917105|FG003|Phase 1|Time commitment issues|0
6237740|NCT01816074|9917102|FG000|Phase 2|Time commitment Issues|0
6237741|NCT01816074|9917103|FG001|Phase 2|Time commitment Issues|2
6237742|NCT01816074|9917104|FG002|Phase 2|Time commitment Issues|0
6237743|NCT01816074|9917105|FG003|Phase 2|Time commitment Issues|0
6237744|NCT01816074|9917102|FG000|Phase 2|Unsatisfied with Randomization assignmen|1
6237745|NCT01816074|9917103|FG001|Phase 2|Unsatisfied with Randomization assignmen|0
6237746|NCT01816074|9917104|FG002|Phase 2|Unsatisfied with Randomization assignmen|0
6237747|NCT01816074|9917105|FG003|Phase 2|Unsatisfied with Randomization assignmen|0
6237748|NCT01816074|9917102|FG000|Phase 2|Physician Decision|0
6237749|NCT01816074|9917103|FG001|Phase 2|Physician Decision|0
6237750|NCT01816074|9917104|FG002|Phase 2|Physician Decision|0
6237751|NCT01816074|9917105|FG003|Phase 2|Physician Decision|1
6237752|NCT01816074|9917102|FG000|Phase 2|Withdrawal by Subject|1
6237753|NCT01816074|9917103|FG001|Phase 2|Withdrawal by Subject|0
6237754|NCT01816074|9917104|FG002|Phase 2|Withdrawal by Subject|0
6237755|NCT01816074|9917105|FG003|Phase 2|Withdrawal by Subject|0
6237756|NCT01816243|9917133|FG000|Overall Study|Adverse Event|6
6237757|NCT01816243|9917133|FG000|Overall Study|Lost to Follow-up|1
6237758|NCT01816243|9917133|FG000|Overall Study|Lack of Efficacy|1
6237759|NCT01816243|9917133|FG000|Overall Study|Not eligible for the study|1
6237760|NCT01816243|9917133|FG000|Overall Study|Amputation|3
6237761|NCT01816295|9917139|FG000|Double Blind Phase|Adverse Event|11
6237762|NCT01816295|9917140|FG001|Double Blind Phase|Adverse Event|8
6237763|NCT01816295|9917139|FG000|Double Blind Phase|Entry Criteria Not Met|0
6237764|NCT01816295|9917140|FG001|Double Blind Phase|Entry Criteria Not Met|2
6237765|NCT01816295|9917139|FG000|Double Blind Phase|Lost to Follow-up|3
6237766|NCT01816295|9917140|FG001|Double Blind Phase|Lost to Follow-up|5
6237767|NCT01816295|9917139|FG000|Double Blind Phase|Physician Decision|2
6237768|NCT01816295|9917140|FG001|Double Blind Phase|Physician Decision|2
6237769|NCT01816295|9917139|FG000|Double Blind Phase|Protocol Violation|17
6237770|NCT01816295|9917140|FG001|Double Blind Phase|Protocol Violation|11
6237771|NCT01816295|9917139|FG000|Double Blind Phase|Sponsor Decision|8
6237772|NCT01816295|9917140|FG001|Double Blind Phase|Sponsor Decision|8
6237773|NCT01816295|9917139|FG000|Double Blind Phase|Withdrawal by Subject|22
6237774|NCT01816295|9917140|FG001|Double Blind Phase|Withdrawal by Subject|20
6237775|NCT01816295|9917139|FG000|OLE Phase|Adverse Event|17
6237776|NCT01816295|9917140|FG001|OLE Phase|Adverse Event|15
6237777|NCT01816295|9917139|FG000|OLE Phase|Death|1
6237778|NCT01816295|9917140|FG001|OLE Phase|Death|0
6237779|NCT01816295|9917139|FG000|OLE Phase|Entry Criteria Not Met|3
6237780|NCT01816295|9917140|FG001|OLE Phase|Entry Criteria Not Met|5
6237781|NCT01816295|9917139|FG000|OLE Phase|Lost to Follow-up|5
6237782|NCT01816295|9917140|FG001|OLE Phase|Lost to Follow-up|5
6237783|NCT01816295|9917139|FG000|OLE Phase|Physician Decision|3
6237784|NCT01816295|9917140|FG001|OLE Phase|Physician Decision|1
6237785|NCT01816295|9917139|FG000|OLE Phase|Protocol Violation|4
6237786|NCT01816295|9917140|FG001|OLE Phase|Protocol Violation|4
6237787|NCT01816295|9917139|FG000|OLE Phase|Sponsor Decision|7
6237788|NCT01816295|9917140|FG001|OLE Phase|Sponsor Decision|9
6237789|NCT01816295|9917139|FG000|OLE Phase|Withdrawal by Subject|10
6237790|NCT01816295|9917140|FG001|OLE Phase|Withdrawal by Subject|10
6237791|NCT01816295|9917139|FG000|OLE Phase|Lack of Efficacy|3
6237792|NCT01816295|9917140|FG001|OLE Phase|Lack of Efficacy|7
6237793|NCT01816477|9917164|FG000|Overall Study|Withdrawal by Subject|13
6237794|NCT01816477|9917165|FG001|Overall Study|Withdrawal by Subject|1
6237795|NCT01816477|9917164|FG000|Overall Study|Unable to tolerate catheter placement|3
6237796|NCT01816477|9917165|FG001|Overall Study|Unable to tolerate catheter placement|0
6237797|NCT01816594|9917173|FG000|Overall Study|Local Progress|0
6237798|NCT01816594|9917174|FG001|Overall Study|Local Progress|2
6237799|NCT01816594|9917173|FG000|Overall Study|Adverse Event|9
6237800|NCT01816594|9917174|FG001|Overall Study|Adverse Event|0
6237801|NCT01816594|9917173|FG000|Overall Study|Withdrawal by Subject|1
6237802|NCT01816594|9917174|FG001|Overall Study|Withdrawal by Subject|0
6237803|NCT01816594|9917173|FG000|Overall Study|Physician Decision|1
6237804|NCT01816594|9917174|FG001|Overall Study|Physician Decision|0
6237805|NCT01816685|9917188|FG000|Overall Study|Lost to Follow-up|7
6237806|NCT01816685|9917189|FG001|Overall Study|Lost to Follow-up|9
6237807|NCT01816685|9917188|FG000|Overall Study|Surgery Cancelled|3
6237808|NCT01816685|9917189|FG001|Overall Study|Surgery Cancelled|2
6237809|NCT01816763|9917207|FG000|Overall Study|The main reason for an incomplete survey|4
6237810|NCT01816763|9917208|FG001|Overall Study|The main reason for an incomplete survey|15
6237811|NCT01816763|9917209|FG002|Overall Study|The main reason for an incomplete survey|11
6237812|NCT01816893|9917231|FG000|Washout Period|Withdrawal by Subject|2
6237813|NCT01816893|9917232|FG001|Washout Period|Withdrawal by Subject|0
6237814|NCT01816906|9917240|FG000|Six Months|Did Not Show Up for Baseline Measurement|7
6237815|NCT01816906|9917241|FG001|Six Months|Did Not Show Up for Baseline Measurement|6
6237816|NCT01816906|9917240|FG000|Six Months|Lost to Follow-up|14
6237817|NCT01816906|9917241|FG001|Six Months|Lost to Follow-up|16
6237818|NCT01816906|9917240|FG000|12 Months|Adverse Event|2
6237819|NCT01816906|9917241|FG001|12 Months|Adverse Event|2
6237820|NCT01816906|9917240|FG000|12 Months|Death|0
6237821|NCT01816906|9917241|FG001|12 Months|Death|2
6237822|NCT01816906|9917240|FG000|12 Months|Lost to Follow-up|2
6237823|NCT01816906|9917241|FG001|12 Months|Lost to Follow-up|1
6237824|NCT01816984|9917257|FG000|Overall Study|declining health status|1
6237825|NCT01817075|9917263|FG000|Overall Study|Adverse Event|7
6237826|NCT01817075|9917264|FG001|Overall Study|Adverse Event|5
6237827|NCT01817075|9917263|FG000|Overall Study|Physician Decision|9
6237828|NCT01817075|9917264|FG001|Overall Study|Physician Decision|12
6237829|NCT01817075|9917263|FG000|Overall Study|Withdrawal by Subject|31
6237830|NCT01817075|9917264|FG001|Overall Study|Withdrawal by Subject|15
6237831|NCT01817075|9917263|FG000|Overall Study|Received Sorafenib after enrollment|0
6237832|NCT01817075|9917264|FG001|Overall Study|Received Sorafenib after enrollment|1
6237833|NCT01817075|9917263|FG000|Overall Study|Ineligible|0
6237834|NCT01817075|9917264|FG001|Overall Study|Ineligible|2
6237835|NCT01817530|9917294|FG000|Overall Study|Exclusionary Medication Received|0
6237836|NCT01817530|9917295|FG001|Overall Study|Exclusionary Medication Received|0
6237837|NCT01817530|9917296|FG002|Overall Study|Exclusionary Medication Received|0
6237838|NCT01817530|9917297|FG003|Overall Study|Exclusionary Medication Received|0
6237839|NCT01817530|9917298|FG004|Overall Study|Exclusionary Medication Received|1
6237840|NCT01817530|9917299|FG005|Overall Study|Exclusionary Medication Received|0
6237841|NCT01817530|9917300|FG006|Overall Study|Exclusionary Medication Received|0
6237842|NCT01817530|9917301|FG007|Overall Study|Exclusionary Medication Received|0
6237843|NCT01817530|9917294|FG000|Overall Study|Adverse Event|6
6237844|NCT01817530|9917295|FG001|Overall Study|Adverse Event|3
6237845|NCT01817530|9917296|FG002|Overall Study|Adverse Event|2
6237846|NCT01817530|9917297|FG003|Overall Study|Adverse Event|5
6237847|NCT01817530|9917298|FG004|Overall Study|Adverse Event|0
6237848|NCT01817530|9917299|FG005|Overall Study|Adverse Event|10
6237849|NCT01817530|9917300|FG006|Overall Study|Adverse Event|5
6237850|NCT01817530|9917301|FG007|Overall Study|Adverse Event|8
6237851|NCT01817530|9917294|FG000|Overall Study|Subject Noncompliant|3
6237852|NCT01817530|9917295|FG001|Overall Study|Subject Noncompliant|1
6237853|NCT01817530|9917296|FG002|Overall Study|Subject Noncompliant|0
6237854|NCT01817530|9917297|FG003|Overall Study|Subject Noncompliant|4
6237855|NCT01817530|9917298|FG004|Overall Study|Subject Noncompliant|0
6237856|NCT01817530|9917299|FG005|Overall Study|Subject Noncompliant|1
6237857|NCT01817530|9917300|FG006|Overall Study|Subject Noncompliant|1
6237858|NCT01817530|9917301|FG007|Overall Study|Subject Noncompliant|1
6237859|NCT01817530|9917294|FG000|Overall Study|Lack of Efficacy|1
6237860|NCT01817530|9917295|FG001|Overall Study|Lack of Efficacy|0
6237861|NCT01817530|9917296|FG002|Overall Study|Lack of Efficacy|0
6237862|NCT01817530|9917297|FG003|Overall Study|Lack of Efficacy|0
6237863|NCT01817530|9917298|FG004|Overall Study|Lack of Efficacy|0
6237864|NCT01817530|9917299|FG005|Overall Study|Lack of Efficacy|1
6237865|NCT01817530|9917300|FG006|Overall Study|Lack of Efficacy|0
6237866|NCT01817530|9917301|FG007|Overall Study|Lack of Efficacy|1
6237867|NCT01817530|9917294|FG000|Overall Study|Pregnancy|0
6237868|NCT01817530|9917295|FG001|Overall Study|Pregnancy|0
6237869|NCT01817530|9917296|FG002|Overall Study|Pregnancy|0
6237870|NCT01817530|9917297|FG003|Overall Study|Pregnancy|0
6237871|NCT01817530|9917298|FG004|Overall Study|Pregnancy|0
6237872|NCT01817530|9917299|FG005|Overall Study|Pregnancy|1
6237873|NCT01817530|9917300|FG006|Overall Study|Pregnancy|0
6237874|NCT01817530|9917301|FG007|Overall Study|Pregnancy|0
6237875|NCT01817530|9917294|FG000|Overall Study|Other|0
6237876|NCT01817530|9917295|FG001|Overall Study|Other|1
6237877|NCT01817530|9917296|FG002|Overall Study|Other|0
6237878|NCT01817530|9917297|FG003|Overall Study|Other|0
6237879|NCT01817530|9917298|FG004|Overall Study|Other|1
6237880|NCT01817530|9917299|FG005|Overall Study|Other|0
6237881|NCT01817530|9917300|FG006|Overall Study|Other|5
6237882|NCT01817530|9917301|FG007|Overall Study|Other|0
6237883|NCT01817530|9917294|FG000|Overall Study|Surgery or Invasive Intervention|1
6237884|NCT01817530|9917295|FG001|Overall Study|Surgery or Invasive Intervention|0
6237885|NCT01817530|9917296|FG002|Overall Study|Surgery or Invasive Intervention|0
6237886|NCT01817530|9917297|FG003|Overall Study|Surgery or Invasive Intervention|0
6237887|NCT01817530|9917298|FG004|Overall Study|Surgery or Invasive Intervention|1
6237888|NCT01817530|9917299|FG005|Overall Study|Surgery or Invasive Intervention|1
6237889|NCT01817530|9917300|FG006|Overall Study|Surgery or Invasive Intervention|1
6237890|NCT01817530|9917301|FG007|Overall Study|Surgery or Invasive Intervention|0
6237891|NCT01817530|9917294|FG000|Overall Study|Consent Withdrawn by Subject|3
6237892|NCT01817530|9917295|FG001|Overall Study|Consent Withdrawn by Subject|4
6237893|NCT01817530|9917296|FG002|Overall Study|Consent Withdrawn by Subject|7
6237894|NCT01817530|9917297|FG003|Overall Study|Consent Withdrawn by Subject|3
6237895|NCT01817530|9917298|FG004|Overall Study|Consent Withdrawn by Subject|5
6237896|NCT01817530|9917299|FG005|Overall Study|Consent Withdrawn by Subject|3
6237897|NCT01817530|9917300|FG006|Overall Study|Consent Withdrawn by Subject|3
6237898|NCT01817530|9917301|FG007|Overall Study|Consent Withdrawn by Subject|10
6237899|NCT01817530|9917294|FG000|Overall Study|Lost to Follow-up|1
6237900|NCT01817530|9917295|FG001|Overall Study|Lost to Follow-up|4
6237901|NCT01817530|9917296|FG002|Overall Study|Lost to Follow-up|2
6237902|NCT01817530|9917297|FG003|Overall Study|Lost to Follow-up|1
6237903|NCT01817530|9917298|FG004|Overall Study|Lost to Follow-up|3
6237904|NCT01817530|9917299|FG005|Overall Study|Lost to Follow-up|2
6237905|NCT01817530|9917300|FG006|Overall Study|Lost to Follow-up|8
6237906|NCT01817530|9917301|FG007|Overall Study|Lost to Follow-up|4
6237907|NCT01817582|9917322|FG000|Overall Study|Withdrawal by Subject|0
6237908|NCT01817582|9917323|FG001|Overall Study|Withdrawal by Subject|1
6237909|NCT01817582|9917324|FG002|Overall Study|Withdrawal by Subject|0
6237910|NCT01817582|9917322|FG000|Overall Study|Participant revealed masked treatment|1
6237911|NCT01817582|9917323|FG001|Overall Study|Participant revealed masked treatment|0
6237912|NCT01817582|9917324|FG002|Overall Study|Participant revealed masked treatment|0
6085757|NCT00655356|9695193|FG001|Overall Study|Other Reason|0
6085758|NCT00655486|9695208|FG000|Overall Study|Adverse Event|10
6085759|NCT00655486|9695208|FG000|Overall Study|Lack of Efficacy|8
6085760|NCT00655486|9695208|FG000|Overall Study|Withdrawal by Subject|4
6085761|NCT00655486|9695208|FG000|Overall Study|Protocol Violation|1
6085762|NCT00655486|9695208|FG000|Overall Study|Unsatisfactory compliance|2
6085763|NCT00655486|9695208|FG000|Overall Study|Other: Pregnancy|1
6085764|NCT00655486|9695208|FG000|Overall Study|Other: Could not tolerate BID dosing|1
6085765|NCT00655486|9695208|FG000|Overall Study|Other: Abnormal electrocardiogram (ECG)|1
6085766|NCT00655499|9695212|FG000|Overall Study|not eligible|4
6085767|NCT00655551|9695229|FG000|All Periods Combined|Adverse Event|0
6085768|NCT00655551|9695230|FG001|All Periods Combined|Adverse Event|3
6085769|NCT00655551|9695231|FG002|All Periods Combined|Adverse Event|4
6085770|NCT00655551|9695229|FG000|Period 2 (up to 7 Days)|Adverse Event|0
6085771|NCT00655551|9695230|FG001|Period 2 (up to 7 Days)|Adverse Event|1
6085772|NCT00655551|9695231|FG002|Period 2 (up to 7 Days)|Adverse Event|0
6085773|NCT00655551|9695229|FG000|Period 3 (up to 7 Days)|Adverse Event|0
6085774|NCT00655551|9695230|FG001|Period 3 (up to 7 Days)|Adverse Event|0
6085775|NCT00655551|9695231|FG002|Period 3 (up to 7 Days)|Adverse Event|4
6085776|NCT00655551|9695229|FG000|Period 4 (up to 7 Days)|Adverse Event|0
6085777|NCT00655551|9695230|FG001|Period 4 (up to 7 Days)|Adverse Event|2
6085778|NCT00655551|9695231|FG002|Period 4 (up to 7 Days)|Adverse Event|0
6085779|NCT00655564|9695239|FG000|Overall Study|Adverse Event|1
6085780|NCT00655564|9695239|FG000|Overall Study|Lost to Follow-up|1
6085781|NCT00655564|9695239|FG000|Overall Study|Desired Alternate Therapy|1
6085782|NCT00655629|9695246|FG000|Overall Study|Adverse Event|4
6085783|NCT00655629|9695247|FG001|Overall Study|Adverse Event|1
6085784|NCT00655629|9695246|FG000|Overall Study|Lack of Efficacy|2
6085785|NCT00655629|9695247|FG001|Overall Study|Lack of Efficacy|12
6085786|NCT00655629|9695246|FG000|Overall Study|Lost to Follow-up|4
6085787|NCT00655629|9695247|FG001|Overall Study|Lost to Follow-up|3
6085788|NCT00655629|9695246|FG000|Overall Study|Protocol Violation|5
6085789|NCT00655629|9695247|FG001|Overall Study|Protocol Violation|3
6085790|NCT00655629|9695246|FG000|Overall Study|consent withdrawn|6
6085791|NCT00655629|9695247|FG001|Overall Study|consent withdrawn|4
6085792|NCT00655668|9695270|FG000|Overall Study|Adverse Event|6
6085793|NCT00655668|9695270|FG000|Overall Study|Death|5
6085794|NCT00655668|9695270|FG000|Overall Study|Disease Progression|27
6085795|NCT00655668|9695270|FG000|Overall Study|Study Terminated|9
6085796|NCT00655668|9695270|FG000|Overall Study|Other|1
6085797|NCT00655668|9695270|FG000|Overall Study|New Lymphoma Treatment Started|4
6085798|NCT00655668|9695270|FG000|Overall Study|Withdrawal by Subject|2
6085799|NCT00655733|9695281|FG000|Overall Study|Lost to Follow-up|2
6085800|NCT00655733|9695282|FG001|Overall Study|Lost to Follow-up|2
6085801|NCT00655733|9695281|FG000|Overall Study|Adverse Event|2
6085802|NCT00655733|9695282|FG001|Overall Study|Adverse Event|2
6085803|NCT00655733|9695281|FG000|Overall Study|Withdrawal by Subject|3
6085804|NCT00655733|9695282|FG001|Overall Study|Withdrawal by Subject|3
6085805|NCT00655733|9695281|FG000|Overall Study|Physician Decision|0
6085806|NCT00655733|9695282|FG001|Overall Study|Physician Decision|1
6085807|NCT00655746|9695290|FG000|Overall Study|Withdrawal by Subject|1
6085808|NCT00655850|9695308|FG000|Overall Study|Death|2
6085809|NCT00655850|9695308|FG000|Overall Study|Withdrawal by Subject|1
6085810|NCT00655863|9695317|FG000|Overall Study|Lost to Follow-up|0
6085811|NCT00655863|9695318|FG001|Overall Study|Lost to Follow-up|0
6085812|NCT00655863|9695319|FG002|Overall Study|Lost to Follow-up|1
6085813|NCT00655876|9695329|FG000|Overall Study|Protocol Violation|9
6085814|NCT00655876|9695330|FG001|Overall Study|Protocol Violation|7
6085815|NCT00655889|9695336|FG000|Overall Study|Inadequate cell growth|1
6085816|NCT00655889|9695336|FG000|Overall Study|Protocol Violation|1
6085817|NCT00655928|9695342|FG000|Overall Study|Withdrawal by Subject|2
6085818|NCT00655928|9695343|FG001|Overall Study|Withdrawal by Subject|1
6085819|NCT00655928|9695342|FG000|Overall Study|Physician Decision|1
6085820|NCT00655928|9695343|FG001|Overall Study|Physician Decision|1
6085821|NCT00655980|9695352|FG000|Overall Study|surgery canceled; or subject or anesthes|26
6085822|NCT00655980|9695353|FG001|Overall Study|surgery canceled; or subject or anesthes|31
6085823|NCT00655980|9695354|FG002|Overall Study|surgery canceled; or subject or anesthes|5
6085824|NCT00656019|9695369|FG000|Overall Study|Not Eligible|10
6085825|NCT00656019|9695370|FG001|Overall Study|Not Eligible|0
6085826|NCT00656019|9695371|FG002|Overall Study|Not Eligible|0
6085827|NCT00656019|9695372|FG003|Overall Study|Not Eligible|0
6085828|NCT00656019|9695369|FG000|Overall Study|Withdrawal by Subject|2
6085829|NCT00656019|9695370|FG001|Overall Study|Withdrawal by Subject|0
6085830|NCT00656019|9695371|FG002|Overall Study|Withdrawal by Subject|0
6085831|NCT00656019|9695372|FG003|Overall Study|Withdrawal by Subject|0
6085832|NCT00656019|9695369|FG000|Overall Study|Lost to Follow-up|2
6085833|NCT00656019|9695370|FG001|Overall Study|Lost to Follow-up|1
6085834|NCT00656019|9695371|FG002|Overall Study|Lost to Follow-up|0
6085835|NCT00656019|9695372|FG003|Overall Study|Lost to Follow-up|0
6085836|NCT00656058|9695382|FG000|Overall Study|Withdrawal by Subject|2
6085837|NCT00656058|9695382|FG000|Overall Study|Withdrawal by Subject|4
6085838|NCT00656084|9695386|FG000|Overall Study|Adverse Event|4
6085839|NCT00656084|9695386|FG000|Overall Study|Withdrawal by Subject|1
6085840|NCT00656084|9695386|FG000|Overall Study|Patient Request|1
6085841|NCT00656084|9695386|FG000|Overall Study|Investigator Request|1
6085842|NCT00656136|9695392|FG000|Overall Study|Progressive disease|177
6085843|NCT00656136|9695393|FG001|Overall Study|Progressive disease|322
6085844|NCT00656136|9695392|FG000|Overall Study|Other Adverse Event|5
6085845|NCT00656136|9695393|FG001|Overall Study|Other Adverse Event|51
6085846|NCT00656136|9695392|FG000|Overall Study|Protocol Violation|2
6085847|NCT00656136|9695393|FG001|Overall Study|Protocol Violation|3
6085848|NCT00656136|9695392|FG000|Overall Study|Patient refused to take study medication|7
6085849|NCT00656136|9695393|FG001|Overall Study|Patient refused to take study medication|10
6085850|NCT00656136|9695392|FG000|Overall Study|Unknown and others|4
6085851|NCT00656136|9695393|FG001|Overall Study|Unknown and others|4
6085852|NCT00656175|9695401|FG000|Overall Study|Adverse Event|1
6085853|NCT00656175|9695402|FG001|Overall Study|Adverse Event|0
6085854|NCT00656175|9695401|FG000|Overall Study|Transportation issues|0
6085855|NCT00656175|9695402|FG001|Overall Study|Transportation issues|1
6085856|NCT00656292|9695419|FG000|Overall Study|Withdrawal by Subject|2
6085857|NCT00656292|9695420|FG001|Overall Study|Withdrawal by Subject|3
6085858|NCT00656292|9695419|FG000|Overall Study|Screen failure|1
6085859|NCT00656292|9695420|FG001|Overall Study|Screen failure|2
6085860|NCT00656370|9695435|FG000|Overall Study|Screen Failures|7
6085861|NCT00656370|9695435|FG000|Overall Study|Alternates|3
6085862|NCT00656474|9695451|FG000|Overall Study|Other Reason|1
6085863|NCT00656513|9695472|FG000|Overall Study|Protocol Violation|1
6085864|NCT00656513|9695473|FG001|Overall Study|Protocol Violation|0
6085865|NCT00656513|9695474|FG002|Overall Study|Protocol Violation|2
6085866|NCT00656513|9695472|FG000|Overall Study|Withdrawal by Subject|0
6237913|NCT01817582|9917322|FG000|Overall Study|Randomized but exclusion criteria met|1
6237914|NCT01817582|9917323|FG001|Overall Study|Randomized but exclusion criteria met|0
6237915|NCT01817582|9917324|FG002|Overall Study|Randomized but exclusion criteria met|0
6237916|NCT01817725|9917341|FG000|Overall Study|Withdrawal by Subject|1
6237917|NCT01817764|9917347|FG000|Overall Study|Adverse Event|7
6237918|NCT01817764|9917348|FG001|Overall Study|Adverse Event|10
6237919|NCT01817764|9917347|FG000|Overall Study|Lack of Efficacy|9
6237920|NCT01817764|9917348|FG001|Overall Study|Lack of Efficacy|7
6237921|NCT01817764|9917347|FG000|Overall Study|Protocol Violation|7
6237922|NCT01817764|9917348|FG001|Overall Study|Protocol Violation|5
6237923|NCT01817764|9917347|FG000|Overall Study|Lost to Follow-up|1
6237924|NCT01817764|9917348|FG001|Overall Study|Lost to Follow-up|4
6237925|NCT01817764|9917347|FG000|Overall Study|Withdrawal by Subject|10
6237926|NCT01817764|9917348|FG001|Overall Study|Withdrawal by Subject|12
6237927|NCT01817777|9917356|FG000|Observational Phase (8 Weeks)|Lost to Follow-up|3
6237928|NCT01817777|9917357|FG001|Observational Phase (8 Weeks)|Lost to Follow-up|0
6237929|NCT01817777|9917358|FG002|Observational Phase (8 Weeks)|Lost to Follow-up|0
6237930|NCT01817777|9917356|FG000|Observational Phase (8 Weeks)|Early Study Termination|2
6237931|NCT01817777|9917357|FG001|Observational Phase (8 Weeks)|Early Study Termination|0
6237932|NCT01817777|9917358|FG002|Observational Phase (8 Weeks)|Early Study Termination|0
6237933|NCT01817777|9917356|FG000|Interventional Phase (20 Weeks)|Withdrawal by Subject|0
6237934|NCT01817777|9917357|FG001|Interventional Phase (20 Weeks)|Withdrawal by Subject|3
6237935|NCT01817777|9917358|FG002|Interventional Phase (20 Weeks)|Withdrawal by Subject|0
6237936|NCT01817777|9917356|FG000|Interventional Phase (20 Weeks)|Lost to Follow-up|0
6237937|NCT01817777|9917357|FG001|Interventional Phase (20 Weeks)|Lost to Follow-up|1
6237938|NCT01817777|9917358|FG002|Interventional Phase (20 Weeks)|Lost to Follow-up|2
6085867|NCT00656513|9695473|FG001|Overall Study|Withdrawal by Subject|11
6085868|NCT00656513|9695474|FG002|Overall Study|Withdrawal by Subject|4
6085869|NCT00656513|9695472|FG000|Overall Study|Death|0
6085870|NCT00656513|9695473|FG001|Overall Study|Death|0
6085871|NCT00656513|9695474|FG002|Overall Study|Death|1
6085872|NCT00656513|9695472|FG000|Overall Study|Missing data|0
6085873|NCT00656513|9695473|FG001|Overall Study|Missing data|11
6085874|NCT00656513|9695474|FG002|Overall Study|Missing data|9
6085875|NCT00656513|9695472|FG000|Overall Study|Incomplete treatment|3
6085876|NCT00656513|9695473|FG001|Overall Study|Incomplete treatment|0
6085877|NCT00656513|9695474|FG002|Overall Study|Incomplete treatment|0
6085878|NCT00656513|9695472|FG000|Overall Study|Treatment completed outside of timeframe|0
6085879|NCT00656513|9695473|FG001|Overall Study|Treatment completed outside of timeframe|3
6237939|NCT01817777|9917356|FG000|Interventional Phase (20 Weeks)|Early Study Termination|0
6237940|NCT01817777|9917357|FG001|Interventional Phase (20 Weeks)|Early Study Termination|1
6237941|NCT01817777|9917358|FG002|Interventional Phase (20 Weeks)|Early Study Termination|3
6237942|NCT01817790|9917366|FG000|Overall Study|Adverse Event|0
6237943|NCT01817790|9917367|FG001|Overall Study|Adverse Event|2
6237944|NCT01817790|9917366|FG000|Overall Study|Lost to Follow-up|0
6237945|NCT01817790|9917367|FG001|Overall Study|Lost to Follow-up|1
6237946|NCT01817790|9917366|FG000|Overall Study|Protocol Violation|2
6237947|NCT01817790|9917367|FG001|Overall Study|Protocol Violation|1
6237948|NCT01817790|9917366|FG000|Overall Study|Withdrawal by Subject|1
6237949|NCT01817790|9917367|FG001|Overall Study|Withdrawal by Subject|3
6237950|NCT01817790|9917366|FG000|Overall Study|Other: Could not attend appointment|1
6237951|NCT01817790|9917367|FG001|Overall Study|Other: Could not attend appointment|1
6237952|NCT01817959|9917409|FG000|Overall Study|Graft loss|1
6237953|NCT01817959|9917410|FG001|Overall Study|Graft loss|1
6237954|NCT01817959|9917409|FG000|Overall Study|forbidden medication|1
6237955|NCT01817959|9917410|FG001|Overall Study|forbidden medication|1
6237956|NCT01817959|9917409|FG000|Overall Study|Adverse Event|1
6237957|NCT01817959|9917410|FG001|Overall Study|Adverse Event|0
6237958|NCT01817959|9917409|FG000|Overall Study|Patient didn't proceed to 1st Islet Inf|1
6237959|NCT01817959|9917410|FG001|Overall Study|Patient didn't proceed to 1st Islet Inf|1
6237960|NCT01818141|9917427|FG000|Overall Study|Withdrawal by Subject|2
6237961|NCT01818141|9917428|FG001|Overall Study|Withdrawal by Subject|0
6237962|NCT01818141|9917427|FG000|Overall Study|No baseline C.diff colonies|1
6237963|NCT01818141|9917428|FG001|Overall Study|No baseline C.diff colonies|1
6237964|NCT01818141|9917427|FG000|Overall Study|Lost to Follow-up|0
6237965|NCT01818141|9917428|FG001|Overall Study|Lost to Follow-up|2
6237966|NCT01818258|9917450|FG000|Overall Study|Death|3
6237967|NCT01818258|9917451|FG001|Overall Study|Death|0
6237968|NCT01818258|9917450|FG000|Overall Study|Withdrawal by Subject|0
6237969|NCT01818258|9917451|FG001|Overall Study|Withdrawal by Subject|1
6237970|NCT01818258|9917450|FG000|Overall Study|Lost to Follow-up|0
6237971|NCT01818258|9917451|FG001|Overall Study|Lost to Follow-up|1
6237972|NCT01818258|9917450|FG000|Overall Study|Unable to Travel to Clinic|0
6237973|NCT01818258|9917451|FG001|Overall Study|Unable to Travel to Clinic|1
6237974|NCT01818284|9917460|FG000|Overall Study|Not eligible due to White Blood Counts|4
6237975|NCT01818284|9917461|FG001|Overall Study|Not eligible due to White Blood Counts|4
6237976|NCT01818284|9917460|FG000|Overall Study|Death|0
6237977|NCT01818284|9917461|FG001|Overall Study|Death|2
6237978|NCT01818297|9917468|FG000|Blinded Phase (Randomization - 3 Months)|Adverse Event|0
6237979|NCT01818297|9917469|FG001|Blinded Phase (Randomization - 3 Months)|Adverse Event|1
6237980|NCT01818297|9917468|FG000|Open Label Phase (3-12 Months)|Physician Decision|1
6237981|NCT01818297|9917469|FG001|Open Label Phase (3-12 Months)|Physician Decision|0
6237982|NCT01818297|9917468|FG000|Open Label Phase (3-12 Months)|Early study closure|17
6237983|NCT01818297|9917469|FG001|Open Label Phase (3-12 Months)|Early study closure|10
6237984|NCT01818336|9917475|FG000|Overall Study|Declined retest visit|0
6237985|NCT01818336|9917476|FG001|Overall Study|Declined retest visit|11
6237986|NCT01818336|9917475|FG000|Overall Study|Lost to Follow-up|0
6237987|NCT01818336|9917476|FG001|Overall Study|Lost to Follow-up|1
6237988|NCT01818492|9917502|FG000|Overall Study|Adverse Event|2
6237989|NCT01818492|9917502|FG000|Overall Study|Death|3
6237990|NCT01818492|9917502|FG000|Overall Study|Withdrawal by Subject|1
6237991|NCT01818492|9917502|FG000|Overall Study|Additional therapy when not allowed PP|4
6237992|NCT01818531|9917534|FG000|Overall Study|Withdrawn for case delay after block|1
6237993|NCT01818531|9917535|FG001|Overall Study|Withdrawn for case delay after block|0
6237994|NCT01818531|9917534|FG000|Overall Study|Withdrawn for long-acting opioid patch|0
6237995|NCT01818531|9917535|FG001|Overall Study|Withdrawn for long-acting opioid patch|1
6237996|NCT01818531|9917534|FG000|Overall Study|Withdrawn for failure to place block|0
6237997|NCT01818531|9917535|FG001|Overall Study|Withdrawn for failure to place block|1
6237998|NCT01818596|9917543|FG000|Overall Study|Enrolled but Not Treated|4
6237999|NCT01818596|9917544|FG001|Overall Study|Enrolled but Not Treated|0
6238000|NCT01818596|9917543|FG000|Overall Study|Adverse Event|7
6238001|NCT01818596|9917544|FG001|Overall Study|Adverse Event|0
6238002|NCT01818596|9917543|FG000|Overall Study|Death|3
6238003|NCT01818596|9917544|FG001|Overall Study|Death|0
6238004|NCT01818596|9917543|FG000|Overall Study|Investigator's Discretion|4
6238005|NCT01818596|9917544|FG001|Overall Study|Investigator's Discretion|0
6238006|NCT01818596|9917543|FG000|Overall Study|Protocol Violation|1
6238007|NCT01818596|9917544|FG001|Overall Study|Protocol Violation|0
6238008|NCT01818596|9917543|FG000|Overall Study|Withdrew Consent|5
6238009|NCT01818596|9917544|FG001|Overall Study|Withdrew Consent|0
6238010|NCT01818596|9917543|FG000|Overall Study|Lost to Follow-up|7
6238011|NCT01818596|9917544|FG001|Overall Study|Lost to Follow-up|0
6238012|NCT01818700|9917551|FG000|Overall Study|Adverse Event|67
6238013|NCT01818700|9917551|FG000|Overall Study|Lack of Efficacy|2
6238014|NCT01818700|9917551|FG000|Overall Study|Lost to Follow-up|5
6238015|NCT01818700|9917551|FG000|Overall Study|Withdrawal by Subject|27
6238016|NCT01818700|9917551|FG000|Overall Study|Protocol Violation|2
6238017|NCT01818700|9917551|FG000|Overall Study|Other|1
6238018|NCT01818726|9917559|FG000|Overall Study|Administrative reasons|5
6238019|NCT01818726|9917560|FG001|Overall Study|Administrative reasons|1
6238020|NCT01818726|9917559|FG000|Overall Study|Withdrawal by Subject|0
6238021|NCT01818726|9917560|FG001|Overall Study|Withdrawal by Subject|1
6238022|NCT01818726|9917559|FG000|Overall Study|Decision to perform 2nd course of trtmnt|1
6238023|NCT01818726|9917560|FG001|Overall Study|Decision to perform 2nd course of trtmnt|0
6238024|NCT01818752|9917573|FG000|Overall Study|Adverse Event|64
6238025|NCT01818752|9917574|FG001|Overall Study|Adverse Event|74
6238026|NCT01818752|9917573|FG000|Overall Study|Death|14
6238027|NCT01818752|9917574|FG001|Overall Study|Death|18
6188860|NCT01395017|9843762|FG001|Overall Study|Withdrawal by Subject|8
6238028|NCT01818752|9917573|FG000|Overall Study|Non-compliance|16
6238029|NCT01818752|9917574|FG001|Overall Study|Non-compliance|20
6238030|NCT01818752|9917573|FG000|Overall Study|Withdrawal by Subject|15
6238031|NCT01818752|9917574|FG001|Overall Study|Withdrawal by Subject|14
6238032|NCT01818752|9917573|FG000|Overall Study|Physician Decision|9
6238033|NCT01818752|9917574|FG001|Overall Study|Physician Decision|8
6238034|NCT01818752|9917573|FG000|Overall Study|Disease Progression|54
6238035|NCT01818752|9917574|FG001|Overall Study|Disease Progression|48
6238036|NCT01818752|9917573|FG000|Overall Study|Other|7
6238037|NCT01818752|9917574|FG001|Overall Study|Other|8
6238038|NCT01818752|9917573|FG000|Overall Study|Continuing Treatment|1
6238039|NCT01818752|9917574|FG001|Overall Study|Continuing Treatment|4
6238040|NCT01818752|9917573|FG000|Overall Study|Randomized but not Dosed|7
6238041|NCT01818752|9917574|FG001|Overall Study|Randomized but not Dosed|4
6238042|NCT01818765|9917580|FG000|Overall Study|Death|2
6238043|NCT01819129|9917596|FG000|Overall Study|Other, Subject wanted HbA1c to be > 7%|1
6238044|NCT01819129|9917597|FG001|Overall Study|Other, Subject wanted HbA1c to be > 7%|0
6238045|NCT01819129|9917596|FG000|Overall Study|Other, weight gain, hypoglycaemic events|1
6238046|NCT01819129|9917597|FG001|Overall Study|Other, weight gain, hypoglycaemic events|0
6238047|NCT01819129|9917596|FG000|Overall Study|Other, Subject moved out of the country|0
6238048|NCT01819129|9917597|FG001|Overall Study|Other, Subject moved out of the country|1
6238049|NCT01819129|9917596|FG000|Overall Study|Withdrawal by Subject|15
6238050|NCT01819129|9917597|FG001|Overall Study|Withdrawal by Subject|15
6238051|NCT01819129|9917596|FG000|Overall Study|Lost to Follow-up|5
6238052|NCT01819129|9917597|FG001|Overall Study|Lost to Follow-up|2
6238053|NCT01819129|9917596|FG000|Overall Study|Lack of Efficacy|0
6238054|NCT01819129|9917597|FG001|Overall Study|Lack of Efficacy|1
6238055|NCT01819129|9917596|FG000|Overall Study|Adverse Event|1
6238056|NCT01819129|9917597|FG001|Overall Study|Adverse Event|4
6238057|NCT01819129|9917596|FG000|Overall Study|Death|1
6238058|NCT01819129|9917597|FG001|Overall Study|Death|1
6238059|NCT01819129|9917596|FG000|Overall Study|Withdrawal Criteria|20
6238060|NCT01819129|9917597|FG001|Overall Study|Withdrawal Criteria|15
6238061|NCT01819194|9917603|FG000|Overall Study|Loss of study articles|2
6238062|NCT01819272|9917617|FG000|Overall Study|Adverse Event|1
6238063|NCT01819272|9917618|FG001|Overall Study|Adverse Event|0
6238064|NCT01819272|9917619|FG002|Overall Study|Adverse Event|0
6238065|NCT01819272|9917620|FG003|Overall Study|Adverse Event|2
6238066|NCT01819272|9917621|FG004|Overall Study|Adverse Event|0
6238067|NCT01819272|9917622|FG005|Overall Study|Adverse Event|0
6238068|NCT01819272|9917617|FG000|Overall Study|Lost to Follow-up|3
6238069|NCT01819272|9917618|FG001|Overall Study|Lost to Follow-up|0
6238070|NCT01819272|9917619|FG002|Overall Study|Lost to Follow-up|1
6238071|NCT01819272|9917620|FG003|Overall Study|Lost to Follow-up|0
6238072|NCT01819272|9917621|FG004|Overall Study|Lost to Follow-up|0
6238073|NCT01819272|9917622|FG005|Overall Study|Lost to Follow-up|3
6238074|NCT01819272|9917617|FG000|Overall Study|Protocol Violation|0
6238075|NCT01819272|9917618|FG001|Overall Study|Protocol Violation|0
6238076|NCT01819272|9917619|FG002|Overall Study|Protocol Violation|0
6238077|NCT01819272|9917620|FG003|Overall Study|Protocol Violation|1
6238078|NCT01819272|9917621|FG004|Overall Study|Protocol Violation|2
6238079|NCT01819272|9917622|FG005|Overall Study|Protocol Violation|3
6238080|NCT01819272|9917617|FG000|Overall Study|Physician Decision|0
6238081|NCT01819272|9917618|FG001|Overall Study|Physician Decision|1
6238082|NCT01819272|9917619|FG002|Overall Study|Physician Decision|0
6238083|NCT01819272|9917620|FG003|Overall Study|Physician Decision|0
6238084|NCT01819272|9917621|FG004|Overall Study|Physician Decision|0
6238085|NCT01819272|9917622|FG005|Overall Study|Physician Decision|0
6238086|NCT01819272|9917617|FG000|Overall Study|Withdrawal of Consent|0
6238087|NCT01819272|9917618|FG001|Overall Study|Withdrawal of Consent|1
6238088|NCT01819272|9917619|FG002|Overall Study|Withdrawal of Consent|2
6238089|NCT01819272|9917620|FG003|Overall Study|Withdrawal of Consent|1
6238090|NCT01819272|9917621|FG004|Overall Study|Withdrawal of Consent|0
6238091|NCT01819272|9917622|FG005|Overall Study|Withdrawal of Consent|1
6238092|NCT01819272|9917617|FG000|Overall Study|Loss of Glucose Control|2
6238093|NCT01819272|9917618|FG001|Overall Study|Loss of Glucose Control|1
6238094|NCT01819272|9917619|FG002|Overall Study|Loss of Glucose Control|0
6238095|NCT01819272|9917620|FG003|Overall Study|Loss of Glucose Control|1
6238096|NCT01819272|9917621|FG004|Overall Study|Loss of Glucose Control|2
6238097|NCT01819272|9917622|FG005|Overall Study|Loss of Glucose Control|0
6238098|NCT01819506|9917664|FG000|Overall Study|Physician Decision|5
6238099|NCT01819506|9917665|FG001|Overall Study|Physician Decision|2
6238100|NCT01819506|9917664|FG000|Overall Study|Withdrawal by Subject|3
6238101|NCT01819506|9917665|FG001|Overall Study|Withdrawal by Subject|3
6238102|NCT01819727|9917677|FG000|Overall Study|Adverse Event|8
6238103|NCT01819727|9917678|FG001|Overall Study|Adverse Event|9
6238104|NCT01819727|9917677|FG000|Overall Study|Death|1
6238105|NCT01819727|9917678|FG001|Overall Study|Death|0
6238106|NCT01819727|9917677|FG000|Overall Study|Lost to Follow-up|1
6238107|NCT01819727|9917678|FG001|Overall Study|Lost to Follow-up|1
6238108|NCT01819727|9917677|FG000|Overall Study|Physician Decision|3
6238109|NCT01819727|9917678|FG001|Overall Study|Physician Decision|2
6238110|NCT01819727|9917677|FG000|Overall Study|Pregnancy|1
6238111|NCT01819727|9917678|FG001|Overall Study|Pregnancy|0
6238112|NCT01819727|9917677|FG000|Overall Study|Protocol Violation|0
6238113|NCT01819727|9917678|FG001|Overall Study|Protocol Violation|2
6238114|NCT01819727|9917677|FG000|Overall Study|Study Terminated by Sponsor|0
6238115|NCT01819727|9917678|FG001|Overall Study|Study Terminated by Sponsor|1
6238116|NCT01819727|9917677|FG000|Overall Study|Withdrawal by Subject|6
6238117|NCT01819727|9917678|FG001|Overall Study|Withdrawal by Subject|11
6238118|NCT01819727|9917677|FG000|Overall Study|Unable to demostrate ability self-inject|0
6238119|NCT01819727|9917678|FG001|Overall Study|Unable to demostrate ability self-inject|1
6238120|NCT01819727|9917677|FG000|Overall Study|Quit due to lack of health benifits|0
6238121|NCT01819727|9917678|FG001|Overall Study|Quit due to lack of health benifits|1
6238122|NCT01820260|9917727|FG000|Phase 1 (Part 1)|Subject withdrew after randomization before treatment assignment|0
6238123|NCT01820260|9917728|FG001|Phase 1 (Part 1)|Subject withdrew after randomization before treatment assignment|0
6238124|NCT01820260|9917729|FG002|Phase 1 (Part 1)|Subject withdrew after randomization before treatment assignment|0
6238125|NCT01820260|9917730|FG003|Phase 1 (Part 1)|Subject withdrew after randomization before treatment assignment|0
6238126|NCT01820260|9917731|FG004|Phase 1 (Part 1)|Subject withdrew after randomization before treatment assignment|0
6238127|NCT01820260|9917732|FG005|Phase 1 (Part 1)|Subject withdrew after randomization before treatment assignment|0
6238128|NCT01820260|9917733|FG006|Phase 1 (Part 1)|Subject withdrew after randomization before treatment assignment|1
6238129|NCT01820260|9917734|FG007|Phase 1 (Part 1)|Subject withdrew after randomization before treatment assignment|0
6238130|NCT01820260|9917735|FG008|Phase 1 (Part 1)|Subject withdrew after randomization before treatment assignment|0
6238131|NCT01820260|9917736|FG009|Phase 1 (Part 1)|Subject withdrew after randomization before treatment assignment|0
6238132|NCT01820260|9917737|FG010|Phase 1 (Part 1)|Subject withdrew after randomization before treatment assignment|0
6238133|NCT01820260|9917738|FG011|Phase 1 (Part 1)|Subject withdrew after randomization before treatment assignment|0
6238134|NCT01820260|9917739|FG012|Phase 1 (Part 1)|Subject withdrew after randomization before treatment assignment|0
6238135|NCT01820260|9917740|FG013|Phase 1 (Part 1)|Subject withdrew after randomization before treatment assignment|0
6238136|NCT01820260|9917727|FG000|Phase 2 (Part 2)|Withdrawal by Subject|0
6238137|NCT01820260|9917728|FG001|Phase 2 (Part 2)|Withdrawal by Subject|0
6238138|NCT01820260|9917729|FG002|Phase 2 (Part 2)|Withdrawal by Subject|0
6238139|NCT01820260|9917730|FG003|Phase 2 (Part 2)|Withdrawal by Subject|0
6238140|NCT01820260|9917731|FG004|Phase 2 (Part 2)|Withdrawal by Subject|0
6238141|NCT01820260|9917732|FG005|Phase 2 (Part 2)|Withdrawal by Subject|0
6238142|NCT01820260|9917733|FG006|Phase 2 (Part 2)|Withdrawal by Subject|0
6238143|NCT01820260|9917734|FG007|Phase 2 (Part 2)|Withdrawal by Subject|0
6238144|NCT01820260|9917735|FG008|Phase 2 (Part 2)|Withdrawal by Subject|0
6238145|NCT01820260|9917736|FG009|Phase 2 (Part 2)|Withdrawal by Subject|1
6238146|NCT01820260|9917737|FG010|Phase 2 (Part 2)|Withdrawal by Subject|0
6238147|NCT01820260|9917738|FG011|Phase 2 (Part 2)|Withdrawal by Subject|0
6238148|NCT01820260|9917739|FG012|Phase 2 (Part 2)|Withdrawal by Subject|0
6238149|NCT01820260|9917740|FG013|Phase 2 (Part 2)|Withdrawal by Subject|0
6238150|NCT01820364|9917776|FG000|Part I: LGX818|Death|1
6238151|NCT01820364|9917777|FG001|Part I: LGX818|Death|0
6238152|NCT01820364|9917776|FG000|Part I: LGX818|Administrative Problems|3
6238153|NCT01820364|9917777|FG001|Part I: LGX818|Administrative Problems|0
6238154|NCT01820364|9917776|FG000|Part I: LGX818|Adverse Event|6
6238155|NCT01820364|9917777|FG001|Part I: LGX818|Adverse Event|0
6238156|NCT01820364|9917776|FG000|Part I: LGX818|Disease Progression|4
6238157|NCT01820364|9917777|FG001|Part I: LGX818|Disease Progression|0
6238158|NCT01820364|9917776|FG000|Part II: LGX818 + MEK162|Study Termination|0
6238159|NCT01820364|9917777|FG001|Part II: LGX818 + MEK162|Study Termination|1
6270135|NCT02147587|9970711|FG000|Overall Study|Lack of Efficacy|2
6270136|NCT02147587|9970712|FG001|Overall Study|Lack of Efficacy|1
6270137|NCT02147626|9970729|FG000|Overall Study|Lost to Follow-up|4
6270138|NCT02147626|9970730|FG001|Overall Study|Lost to Follow-up|4
6270139|NCT02147626|9970729|FG000|Overall Study|Pregnancy|1
6270140|NCT02147626|9970730|FG001|Overall Study|Pregnancy|2
6270141|NCT02147626|9970729|FG000|Overall Study|Withdrawal by Subject|0
6270142|NCT02147626|9970730|FG001|Overall Study|Withdrawal by Subject|1
6270143|NCT02147691|9970738|FG000|Overall Study|Withdrawal by Subject|2
6270144|NCT02147691|9970739|FG001|Overall Study|Withdrawal by Subject|0
6270145|NCT02147691|9970738|FG000|Overall Study|Adverse Event|2
6270146|NCT02147691|9970739|FG001|Overall Study|Adverse Event|0
6270147|NCT02147691|9970738|FG000|Overall Study|Lost to Follow-up|0
6270148|NCT02147691|9970739|FG001|Overall Study|Lost to Follow-up|1
6270149|NCT02148211|9970789|FG000|Overall Study|Lost to Follow-up|352
6270150|NCT02148250|9970793|FG000|Screening|Withdrawal by Subject|5
6270151|NCT02148250|9970794|FG001|Screening|Withdrawal by Subject|0
6270152|NCT02148445|9970812|FG000|Overall Study|Death|1
6238160|NCT01820559|9917799|FG000|Overall Study|Adverse Event|4
6238161|NCT01820559|9917800|FG001|Overall Study|Adverse Event|6
6238162|NCT01820559|9917801|FG002|Overall Study|Adverse Event|13
6238163|NCT01820559|9917799|FG000|Overall Study|Withdrawal by Subject|1
6238164|NCT01820559|9917800|FG001|Overall Study|Withdrawal by Subject|2
6238165|NCT01820559|9917801|FG002|Overall Study|Withdrawal by Subject|5
6238166|NCT01820559|9917799|FG000|Overall Study|Protocol Violation|2
6238167|NCT01820559|9917800|FG001|Overall Study|Protocol Violation|1
6238168|NCT01820559|9917801|FG002|Overall Study|Protocol Violation|3
6238169|NCT01820559|9917799|FG000|Overall Study|Subject's non-compliance|1
6238170|NCT01820559|9917800|FG001|Overall Study|Subject's non-compliance|0
6238171|NCT01820559|9917801|FG002|Overall Study|Subject's non-compliance|2
6238172|NCT01820559|9917799|FG000|Overall Study|Lost to Follow-up|3
6238173|NCT01820559|9917800|FG001|Overall Study|Lost to Follow-up|2
6238174|NCT01820559|9917801|FG002|Overall Study|Lost to Follow-up|2
6238175|NCT01820559|9917799|FG000|Overall Study|At sponsor request|0
6238176|NCT01820559|9917800|FG001|Overall Study|At sponsor request|0
6238177|NCT01820559|9917801|FG002|Overall Study|At sponsor request|1
6238178|NCT01820559|9917799|FG000|Overall Study|Lack of Efficacy|3
6238179|NCT01820559|9917800|FG001|Overall Study|Lack of Efficacy|2
6238180|NCT01820559|9917801|FG002|Overall Study|Lack of Efficacy|3
6238181|NCT01820572|9917811|FG000|Randomization|Not Treated|2
6238182|NCT01820572|9917812|FG001|Randomization|Not Treated|1
6238183|NCT01820572|9917811|FG000|Treatment Period|Adverse Event|12
6238184|NCT01820572|9917812|FG001|Treatment Period|Adverse Event|7
6238185|NCT01820572|9917811|FG000|Treatment Period|Death|3
6238186|NCT01820572|9917812|FG001|Treatment Period|Death|3
6238187|NCT01820572|9917811|FG000|Treatment Period|Lack of Efficacy|1
6238188|NCT01820572|9917812|FG001|Treatment Period|Lack of Efficacy|0
6238189|NCT01820572|9917811|FG000|Treatment Period|poor/non compliance|0
6238190|NCT01820572|9917812|FG001|Treatment Period|poor/non compliance|3
6238191|NCT01820572|9917811|FG000|Treatment Period|request to discontinue|6
6238192|NCT01820572|9917812|FG001|Treatment Period|request to discontinue|11
6238193|NCT01820572|9917811|FG000|Treatment Period|No longer meets study criteria|3
6238194|NCT01820572|9917812|FG001|Treatment Period|No longer meets study criteria|10
6238195|NCT01820572|9917811|FG000|Treatment Period|withdrew consent|1
6238196|NCT01820572|9917812|FG001|Treatment Period|withdrew consent|2
6238197|NCT01820585|9917822|FG000|Overall Study|Adverse Event|9
6238198|NCT01820585|9917823|FG001|Overall Study|Adverse Event|13
6238199|NCT01820585|9917824|FG002|Overall Study|Adverse Event|23
6238200|NCT01820585|9917825|FG003|Overall Study|Adverse Event|34
6238201|NCT01820585|9917822|FG000|Overall Study|Lack of Efficacy|9
6238202|NCT01820585|9917823|FG001|Overall Study|Lack of Efficacy|7
6238203|NCT01820585|9917824|FG002|Overall Study|Lack of Efficacy|5
6238204|NCT01820585|9917825|FG003|Overall Study|Lack of Efficacy|1
6238205|NCT01820585|9917822|FG000|Overall Study|Withdrawal by Subject|3
6238206|NCT01820585|9917823|FG001|Overall Study|Withdrawal by Subject|7
6238207|NCT01820585|9917824|FG002|Overall Study|Withdrawal by Subject|3
6238208|NCT01820585|9917825|FG003|Overall Study|Withdrawal by Subject|8
6238209|NCT01820585|9917822|FG000|Overall Study|Lost to Follow-up|3
6238210|NCT01820585|9917823|FG001|Overall Study|Lost to Follow-up|3
6238211|NCT01820585|9917824|FG002|Overall Study|Lost to Follow-up|0
6238212|NCT01820585|9917825|FG003|Overall Study|Lost to Follow-up|3
6238213|NCT01820585|9917822|FG000|Overall Study|Protocol Violation|3
6238214|NCT01820585|9917823|FG001|Overall Study|Protocol Violation|1
6238215|NCT01820585|9917824|FG002|Overall Study|Protocol Violation|1
6238216|NCT01820585|9917825|FG003|Overall Study|Protocol Violation|1
6238217|NCT01820585|9917822|FG000|Overall Study|Subject non-compliance|0
6238218|NCT01820585|9917823|FG001|Overall Study|Subject non-compliance|0
6238219|NCT01820585|9917824|FG002|Overall Study|Subject non-compliance|1
6238220|NCT01820585|9917825|FG003|Overall Study|Subject non-compliance|2
6238221|NCT01820585|9917822|FG000|Overall Study|at sponsor request|0
6238222|NCT01820585|9917823|FG001|Overall Study|at sponsor request|0
6238223|NCT01820585|9917824|FG002|Overall Study|at sponsor request|1
6238224|NCT01820585|9917825|FG003|Overall Study|at sponsor request|0
6238225|NCT01820585|9917822|FG000|Overall Study|Pregnancy|0
6238226|NCT01820585|9917823|FG001|Overall Study|Pregnancy|1
6238227|NCT01820585|9917824|FG002|Overall Study|Pregnancy|0
6238228|NCT01820585|9917825|FG003|Overall Study|Pregnancy|0
6238229|NCT01820637|9917835|FG000|Overall Study|Death|2
6238230|NCT01820637|9917835|FG000|Overall Study|Withdrawal by Subject|1
6238231|NCT01821118|9917849|FG000|Overall Study|Death|0
6238232|NCT01821118|9917850|FG001|Overall Study|Death|1
6238233|NCT01821391|9917904|FG000|Overall Study|Adverse Event|1
6238234|NCT01821391|9917905|FG001|Overall Study|Adverse Event|0
6238235|NCT01821560|9917928|FG000|Overall Study|Lost to Follow-up|5
6238236|NCT01821560|9917929|FG001|Overall Study|Lost to Follow-up|5
6238237|NCT01821560|9917928|FG000|Overall Study|Withdrawal by Subject|1
6238238|NCT01821560|9917929|FG001|Overall Study|Withdrawal by Subject|1
6238239|NCT01821560|9917928|FG000|Overall Study|Protocol Violation|0
6238240|NCT01821560|9917929|FG001|Overall Study|Protocol Violation|1
6238241|NCT01821625|9917935|FG000|Overall Study|Withdrawal by Subject|2
6238242|NCT01821625|9917935|FG000|Overall Study|Lack of Efficacy|2
6238243|NCT01821625|9917935|FG000|Overall Study|Adverse Event|1
6238244|NCT01821625|9917935|FG000|Overall Study|Medical contraindication|1
6238245|NCT01821729|9917939|FG000|Overall Study|Withdrawal by Subject|1
6238246|NCT01821807|9917945|FG000|Overall Study|Lost to Follow-up|3
6238247|NCT01821807|9917946|FG001|Overall Study|Lost to Follow-up|1
6238248|NCT01821937|9917954|FG000|Overall Study|Adverse Event|0
6238249|NCT01821937|9917955|FG001|Overall Study|Adverse Event|3
6238250|NCT01822132|9917969|FG000|Overall Study|Lost to Follow-up|4
6238251|NCT01822132|9917970|FG001|Overall Study|Lost to Follow-up|2
6238252|NCT01822223|9917988|FG000|Overall Study|Death|0
6238253|NCT01822223|9917989|FG001|Overall Study|Death|1
6238254|NCT01822353|9918010|FG000|Overall Study|Adverse Event|1
6238255|NCT01822353|9918011|FG001|Overall Study|Adverse Event|3
6238256|NCT01822353|9918012|FG002|Overall Study|Adverse Event|1
6238257|NCT01822353|9918010|FG000|Overall Study|Pregnancy|0
6238258|NCT01822353|9918011|FG001|Overall Study|Pregnancy|1
6238259|NCT01822353|9918012|FG002|Overall Study|Pregnancy|0
6238260|NCT01822353|9918010|FG000|Overall Study|Withdrawal by Subject|3
6238261|NCT01822353|9918011|FG001|Overall Study|Withdrawal by Subject|1
6238262|NCT01822353|9918012|FG002|Overall Study|Withdrawal by Subject|0
6238263|NCT01822366|9918027|FG000|Overall Study|Lost to Follow-up|5
6238264|NCT01822366|9918028|FG001|Overall Study|Lost to Follow-up|1
6238265|NCT01822366|9918029|FG002|Overall Study|Lost to Follow-up|5
6238266|NCT01822366|9918030|FG003|Overall Study|Lost to Follow-up|1
6238267|NCT01822366|9918027|FG000|Overall Study|Withdrawal by Subject|0
6238268|NCT01822366|9918028|FG001|Overall Study|Withdrawal by Subject|6
6238269|NCT01822366|9918029|FG002|Overall Study|Withdrawal by Subject|0
6238270|NCT01822366|9918030|FG003|Overall Study|Withdrawal by Subject|6
6238271|NCT01822366|9918027|FG000|Overall Study|Partial Intervention Completion|0
6238272|NCT01822366|9918028|FG001|Overall Study|Partial Intervention Completion|15
6238273|NCT01822366|9918029|FG002|Overall Study|Partial Intervention Completion|0
6238274|NCT01822366|9918030|FG003|Overall Study|Partial Intervention Completion|15
6238275|NCT01822496|9918071|FG000|Overall Study|Protocol Violation|2
6238276|NCT01822496|9918072|FG001|Overall Study|Protocol Violation|2
6238277|NCT01822496|9918073|FG002|Overall Study|Protocol Violation|0
6238278|NCT01822496|9918074|FG003|Overall Study|Protocol Violation|1
6238279|NCT01822496|9918071|FG000|Overall Study|Withdrawal by Subject|0
6238280|NCT01822496|9918072|FG001|Overall Study|Withdrawal by Subject|0
6238281|NCT01822496|9918073|FG002|Overall Study|Withdrawal by Subject|0
6238282|NCT01822496|9918074|FG003|Overall Study|Withdrawal by Subject|3
6238283|NCT01822535|9918086|FG000|Visit 1 - Tetraplegia and Able-Bodied|Adverse Event|2
6238284|NCT01822535|9918087|FG001|Visit 1 - Tetraplegia and Able-Bodied|Adverse Event|0
6238285|NCT01822535|9918086|FG000|Visit 1 - Tetraplegia and Able-Bodied|Withdrawal by Subject|4
6238286|NCT01822535|9918087|FG001|Visit 1 - Tetraplegia and Able-Bodied|Withdrawal by Subject|2
6238287|NCT01822535|9918086|FG000|Visit 2 - Tetraplegia Only - Drug|Adverse Event|1
6238288|NCT01822535|9918087|FG001|Visit 2 - Tetraplegia Only - Drug|Adverse Event|0
6238289|NCT01822561|9918105|FG000|Overall Study|Withdrawal by Subject|2
6238290|NCT01822587|9918129|FG000|Overall Study|Lost to Follow-up|7
6238291|NCT01822587|9918130|FG001|Overall Study|Lost to Follow-up|9
6238292|NCT01822587|9918131|FG002|Overall Study|Lost to Follow-up|12
6238293|NCT01822587|9918129|FG000|Overall Study|Physician Decision|9
6238294|NCT01822587|9918130|FG001|Overall Study|Physician Decision|6
6238295|NCT01822587|9918131|FG002|Overall Study|Physician Decision|6
6238296|NCT01822665|9918139|FG000|Overall Study|Adverse Event|3
6238297|NCT01822665|9918139|FG000|Overall Study|Other Reason|5
6238298|NCT01822678|9918160|FG000|Overall Study|Withdrawal by Subject|5
6238299|NCT01822678|9918161|FG001|Overall Study|Withdrawal by Subject|4
6238300|NCT01822678|9918162|FG002|Overall Study|Withdrawal by Subject|4
6238301|NCT01822678|9918160|FG000|Overall Study|Adverse Event|4
6238302|NCT01822678|9918161|FG001|Overall Study|Adverse Event|3
6238303|NCT01822678|9918162|FG002|Overall Study|Adverse Event|1
6238304|NCT01822678|9918160|FG000|Overall Study|Lack of Efficacy|3
6238305|NCT01822678|9918161|FG001|Overall Study|Lack of Efficacy|6
6238306|NCT01822678|9918162|FG002|Overall Study|Lack of Efficacy|5
6238307|NCT01822678|9918160|FG000|Overall Study|Lost to Follow-up|0
6238308|NCT01822678|9918161|FG001|Overall Study|Lost to Follow-up|2
6238309|NCT01822678|9918162|FG002|Overall Study|Lost to Follow-up|1
6238310|NCT01822691|9918170|FG000|Overall Study|Withdrawal by Subject|2
6238311|NCT01822756|9918179|FG000|Overall Study|Adverse Event|0
6238312|NCT01822756|9918180|FG001|Overall Study|Adverse Event|0
6238313|NCT01822756|9918181|FG002|Overall Study|Adverse Event|0
6238314|NCT01822756|9918182|FG003|Overall Study|Adverse Event|2
6238315|NCT01822756|9918183|FG004|Overall Study|Adverse Event|0
6238316|NCT01822756|9918179|FG000|Overall Study|Disease progression|11
6238317|NCT01822756|9918180|FG001|Overall Study|Disease progression|1
6238318|NCT01822756|9918181|FG002|Overall Study|Disease progression|7
6238319|NCT01822756|9918182|FG003|Overall Study|Disease progression|2
6238320|NCT01822756|9918183|FG004|Overall Study|Disease progression|6
6238321|NCT01822756|9918179|FG000|Overall Study|Death|2
6238322|NCT01822756|9918180|FG001|Overall Study|Death|2
6238323|NCT01822756|9918181|FG002|Overall Study|Death|1
6238324|NCT01822756|9918182|FG003|Overall Study|Death|0
6238325|NCT01822756|9918183|FG004|Overall Study|Death|0
6238326|NCT01822756|9918179|FG000|Overall Study|Lost to Follow-up|1
6238327|NCT01822756|9918180|FG001|Overall Study|Lost to Follow-up|0
6238328|NCT01822756|9918181|FG002|Overall Study|Lost to Follow-up|1
6238329|NCT01822756|9918182|FG003|Overall Study|Lost to Follow-up|0
6238330|NCT01822756|9918183|FG004|Overall Study|Lost to Follow-up|1
6238331|NCT01822756|9918179|FG000|Overall Study|Physician Decision|0
6238332|NCT01822756|9918180|FG001|Overall Study|Physician Decision|1
6238333|NCT01822756|9918181|FG002|Overall Study|Physician Decision|0
6238334|NCT01822756|9918182|FG003|Overall Study|Physician Decision|0
6238335|NCT01822756|9918183|FG004|Overall Study|Physician Decision|0
6238336|NCT01822756|9918179|FG000|Overall Study|disease progression & patient preference|2
6238337|NCT01822756|9918180|FG001|Overall Study|disease progression & patient preference|0
6238338|NCT01822756|9918181|FG002|Overall Study|disease progression & patient preference|1
6238339|NCT01822756|9918182|FG003|Overall Study|disease progression & patient preference|0
6238340|NCT01822756|9918183|FG004|Overall Study|disease progression & patient preference|0
6238341|NCT01822821|9918197|FG000|Overall Study|Eligible surgery cancelled|1
6238342|NCT01822821|9918198|FG001|Overall Study|Eligible surgery cancelled|1
6188861|NCT01395017|9843761|FG000|Overall Study|Protocol deviation|1
6188862|NCT01395017|9843762|FG001|Overall Study|Protocol deviation|2
6188863|NCT01395017|9843761|FG000|Overall Study|Death|4
6188864|NCT01395017|9843762|FG001|Overall Study|Death|3
6188865|NCT01395017|9843761|FG000|Overall Study|Disease progression|42
6188866|NCT01395017|9843762|FG001|Overall Study|Disease progression|58
6188867|NCT01395017|9843761|FG000|Overall Study|Sponsor discontinued study|1
6238343|NCT01822821|9918197|FG000|Overall Study|Other reasons|1
6238344|NCT01822821|9918198|FG001|Overall Study|Other reasons|0
6238345|NCT01822899|9918210|FG000|Overall Study|Adverse Event|6
6238346|NCT01822899|9918211|FG001|Overall Study|Adverse Event|5
6238347|NCT01822899|9918210|FG000|Overall Study|Lack of Efficacy|6
6238348|NCT01822899|9918211|FG001|Overall Study|Lack of Efficacy|3
6238349|NCT01822899|9918210|FG000|Overall Study|Protocol Violation|6
6238350|NCT01822899|9918211|FG001|Overall Study|Protocol Violation|3
6238351|NCT01822899|9918210|FG000|Overall Study|Lost to Follow-up|1
6238352|NCT01822899|9918211|FG001|Overall Study|Lost to Follow-up|0
6238353|NCT01822899|9918210|FG000|Overall Study|Withdrawal by Subject|5
6238354|NCT01822899|9918211|FG001|Overall Study|Withdrawal by Subject|7
6238355|NCT01822925|9918221|FG000|Overall Study|Adverse Event|1
6238356|NCT01822925|9918222|FG001|Overall Study|Adverse Event|1
6188868|NCT01395017|9843762|FG001|Overall Study|Sponsor discontinued study|4
6188869|NCT01395030|9843769|FG000|Overall Study|Did not complete FCH PET/CT|7
6188870|NCT01395316|9843791|FG000|Overall Study|Lost to Follow-up|2
6188871|NCT01395316|9843791|FG000|Overall Study|poor MRI quality|1
6188872|NCT01395368|9843811|FG000|Overall Study|Physician Decision|14
6188873|NCT01395368|9843811|FG000|Overall Study|Withdrawal by Subject|2
6188874|NCT01395394|9843818|FG000|Baseline Study Visit|Protocol Violation|1
6188875|NCT01395394|9843819|FG001|Baseline Study Visit|Protocol Violation|0
6188876|NCT01395394|9843820|FG002|Baseline Study Visit|Protocol Violation|0
6188877|NCT01395524|9843831|FG000|Overall Study|Non-compliance with study schedule|1
6188878|NCT01395524|9843832|FG001|Overall Study|Non-compliance with study schedule|0
6188879|NCT01395524|9843833|FG002|Overall Study|Non-compliance with study schedule|1
6188880|NCT01395524|9843831|FG000|Overall Study|Lost to Follow-up|3
6188881|NCT01395524|9843832|FG001|Overall Study|Lost to Follow-up|1
6188882|NCT01395524|9843833|FG002|Overall Study|Lost to Follow-up|1
6188883|NCT01395524|9843831|FG000|Overall Study|Study-Specific Withdrawal Criteria|1
6188884|NCT01395524|9843832|FG001|Overall Study|Study-Specific Withdrawal Criteria|2
6188885|NCT01395524|9843833|FG002|Overall Study|Study-Specific Withdrawal Criteria|0
6188886|NCT01395524|9843831|FG000|Overall Study|Severe noncompliance with protocol|1
6188887|NCT01395524|9843832|FG001|Overall Study|Severe noncompliance with protocol|0
6188888|NCT01395524|9843833|FG002|Overall Study|Severe noncompliance with protocol|0
6188889|NCT01395524|9843831|FG000|Overall Study|Adverse Event|4
6188890|NCT01395524|9843832|FG001|Overall Study|Adverse Event|4
6188891|NCT01395524|9843833|FG002|Overall Study|Adverse Event|3
6188892|NCT01395524|9843831|FG000|Overall Study|Death|1
6188893|NCT01395524|9843832|FG001|Overall Study|Death|0
6188894|NCT01395524|9843833|FG002|Overall Study|Death|0
6188895|NCT01395524|9843831|FG000|Overall Study|Eligibility Criteria Not Fulfilled|2
6188896|NCT01395524|9843832|FG001|Overall Study|Eligibility Criteria Not Fulfilled|0
6188897|NCT01395524|9843833|FG002|Overall Study|Eligibility Criteria Not Fulfilled|0
6188898|NCT01395524|9843831|FG000|Overall Study|Withdrawal by Subject|4
6188899|NCT01395524|9843832|FG001|Overall Study|Withdrawal by Subject|8
6188900|NCT01395524|9843833|FG002|Overall Study|Withdrawal by Subject|8
6188901|NCT01395524|9843831|FG000|Overall Study|Did not receive treatment|1
6188902|NCT01395524|9843832|FG001|Overall Study|Did not receive treatment|1
6188903|NCT01395524|9843833|FG002|Overall Study|Did not receive treatment|3
6188904|NCT01395524|9843831|FG000|Overall Study|Subject had spinal surgery|0
6238357|NCT01822925|9918223|FG002|Overall Study|Adverse Event|1
6238358|NCT01822925|9918224|FG003|Overall Study|Adverse Event|1
6238359|NCT01822925|9918221|FG000|Overall Study|Lost to Follow-up|0
6238360|NCT01822925|9918222|FG001|Overall Study|Lost to Follow-up|1
6188905|NCT01395524|9843832|FG001|Overall Study|Subject had spinal surgery|0
6188906|NCT01395524|9843833|FG002|Overall Study|Subject had spinal surgery|1
6188907|NCT01395758|9843847|FG000|Open-label Treatment Period|Withdrawal by Subject|4
6188908|NCT01395758|9843848|FG001|Open-label Treatment Period|Withdrawal by Subject|0
6188909|NCT01395758|9843849|FG002|Open-label Treatment Period|Withdrawal by Subject|0
6188910|NCT01395784|9843856|FG000|Overall Study|Lost to Follow-up|7
6238361|NCT01822925|9918223|FG002|Overall Study|Lost to Follow-up|0
6238362|NCT01822925|9918224|FG003|Overall Study|Lost to Follow-up|0
6238363|NCT01822925|9918221|FG000|Overall Study|Protocol Violation|1
6238364|NCT01822925|9918222|FG001|Overall Study|Protocol Violation|0
6238365|NCT01822925|9918223|FG002|Overall Study|Protocol Violation|0
6238366|NCT01822925|9918224|FG003|Overall Study|Protocol Violation|1
6238367|NCT01822925|9918221|FG000|Overall Study|Withdrawal by Subject|2
6238368|NCT01822925|9918222|FG001|Overall Study|Withdrawal by Subject|0
6238369|NCT01822925|9918223|FG002|Overall Study|Withdrawal by Subject|2
6238370|NCT01822925|9918224|FG003|Overall Study|Withdrawal by Subject|2
6238371|NCT01822925|9918221|FG000|Overall Study|Taking prohibited medication|2
6238372|NCT01822925|9918222|FG001|Overall Study|Taking prohibited medication|0
6238373|NCT01822925|9918223|FG002|Overall Study|Taking prohibited medication|0
6238374|NCT01822925|9918224|FG003|Overall Study|Taking prohibited medication|1
6238375|NCT01823107|9918234|FG000|Overall Study|Withdrawal by Subject|1
6238376|NCT01823146|9918240|FG000|Overall Study|Withdrawal by Subject|0
6238377|NCT01823146|9918241|FG001|Overall Study|Withdrawal by Subject|1
6238378|NCT01823146|9918240|FG000|Overall Study|Lost to Follow-up|2
6238379|NCT01823146|9918241|FG001|Overall Study|Lost to Follow-up|1
6238380|NCT01823224|9918249|FG000|Overall Study|Lost to Follow-up|5
6238381|NCT01823224|9918250|FG001|Overall Study|Lost to Follow-up|6
6238382|NCT01823224|9918249|FG000|Overall Study|didn't qualify|1
6238383|NCT01823224|9918250|FG001|Overall Study|didn't qualify|2
6238384|NCT01823224|9918249|FG000|Overall Study|pharmacy error|0
6238385|NCT01823224|9918250|FG001|Overall Study|pharmacy error|1
6238386|NCT01823224|9918249|FG000|Overall Study|missed med dose|0
6238387|NCT01823224|9918250|FG001|Overall Study|missed med dose|1
6238388|NCT01823224|9918249|FG000|Overall Study|Withdrawal by Subject|0
6238389|NCT01823224|9918250|FG001|Overall Study|Withdrawal by Subject|1
6238390|NCT01823289|9918258|FG000|Overall Study|Lost to Follow-up|5
6238391|NCT01823289|9918258|FG000|Overall Study|Adverse Event|5
6238392|NCT01823289|9918258|FG000|Overall Study|Lack of Efficacy|1
6238393|NCT01823289|9918258|FG000|Overall Study|Physician Decision|9
6238394|NCT01823289|9918258|FG000|Overall Study|Administered contraindicated medicine|1
6238395|NCT01823289|9918258|FG000|Overall Study|Transaminase increased more than 3 times|1
6238396|NCT01823289|9918258|FG000|Overall Study|Drug affected efficacy and safety|1
6238397|NCT01823289|9918258|FG000|Overall Study|Creatinine clearance<30milliliter/minute|1
6238398|NCT01823328|9918264|FG000|Overall Study|Withdrawal by Subject|8
6238399|NCT01823328|9918265|FG001|Overall Study|Withdrawal by Subject|6
6238400|NCT01823341|9918271|FG000|Overall Study|Failed run-in|7
6238401|NCT01823341|9918271|FG000|Overall Study|Withdrawal by Subject|7
6238402|NCT01823341|9918271|FG000|Overall Study|Adverse Event|1
6238403|NCT01823536|9918300|FG000|Overall Study|Lost to Follow-up|1
6238404|NCT01823536|9918301|FG001|Overall Study|Lost to Follow-up|0
6238405|NCT01823536|9918302|FG002|Overall Study|Lost to Follow-up|0
6238406|NCT01823536|9918303|FG003|Overall Study|Lost to Follow-up|1
6238407|NCT01823536|9918304|FG004|Overall Study|Lost to Follow-up|1
6238408|NCT01823536|9918305|FG005|Overall Study|Lost to Follow-up|0
6238409|NCT01823536|9918300|FG000|Overall Study|Protocol Violation|0
6238410|NCT01823536|9918301|FG001|Overall Study|Protocol Violation|1
6238411|NCT01823536|9918302|FG002|Overall Study|Protocol Violation|0
6238412|NCT01823536|9918303|FG003|Overall Study|Protocol Violation|0
6238413|NCT01823536|9918304|FG004|Overall Study|Protocol Violation|0
6238414|NCT01823536|9918305|FG005|Overall Study|Protocol Violation|0
6238415|NCT01823536|9918300|FG000|Overall Study|Withdrawal by Subject|1
6238416|NCT01823536|9918301|FG001|Overall Study|Withdrawal by Subject|1
6238417|NCT01823536|9918302|FG002|Overall Study|Withdrawal by Subject|0
6238418|NCT01823536|9918303|FG003|Overall Study|Withdrawal by Subject|0
6238419|NCT01823536|9918304|FG004|Overall Study|Withdrawal by Subject|0
6238420|NCT01823536|9918305|FG005|Overall Study|Withdrawal by Subject|0
6238421|NCT01823536|9918300|FG000|Overall Study|Visit 1 delayed, unable to reschedule|0
6238422|NCT01823536|9918301|FG001|Overall Study|Visit 1 delayed, unable to reschedule|0
6238423|NCT01823536|9918302|FG002|Overall Study|Visit 1 delayed, unable to reschedule|1
6238424|NCT01823536|9918303|FG003|Overall Study|Visit 1 delayed, unable to reschedule|0
6238425|NCT01823536|9918304|FG004|Overall Study|Visit 1 delayed, unable to reschedule|0
6238426|NCT01823536|9918305|FG005|Overall Study|Visit 1 delayed, unable to reschedule|0
6238427|NCT01823536|9918300|FG000|Overall Study|Met exclusion criterion No 6|0
6238428|NCT01823536|9918301|FG001|Overall Study|Met exclusion criterion No 6|0
6238429|NCT01823536|9918302|FG002|Overall Study|Met exclusion criterion No 6|0
6238430|NCT01823536|9918303|FG003|Overall Study|Met exclusion criterion No 6|1
6238431|NCT01823536|9918304|FG004|Overall Study|Met exclusion criterion No 6|0
6238432|NCT01823536|9918305|FG005|Overall Study|Met exclusion criterion No 6|0
6238433|NCT01823536|9918300|FG000|Overall Study|Subject moved out of the state|0
6238434|NCT01823536|9918301|FG001|Overall Study|Subject moved out of the state|0
6238435|NCT01823536|9918302|FG002|Overall Study|Subject moved out of the state|0
6238436|NCT01823536|9918303|FG003|Overall Study|Subject moved out of the state|0
6238437|NCT01823536|9918304|FG004|Overall Study|Subject moved out of the state|1
6238438|NCT01823536|9918305|FG005|Overall Study|Subject moved out of the state|0
6238439|NCT01823679|9918356|FG000|Overall Study|Death|1
6238440|NCT01823835|9918376|FG000|Overall Study|Adverse Event|0
6238441|NCT01823835|9918377|FG001|Overall Study|Adverse Event|0
6238442|NCT01823835|9918378|FG002|Overall Study|Adverse Event|0
6238443|NCT01823835|9918379|FG003|Overall Study|Adverse Event|0
6238444|NCT01823835|9918380|FG004|Overall Study|Adverse Event|1
6238445|NCT01823835|9918381|FG005|Overall Study|Adverse Event|0
6238446|NCT01823835|9918382|FG006|Overall Study|Adverse Event|1
6238447|NCT01823835|9918383|FG007|Overall Study|Adverse Event|0
6238448|NCT01823835|9918384|FG008|Overall Study|Adverse Event|0
6238449|NCT01823835|9918385|FG009|Overall Study|Adverse Event|0
6238450|NCT01823835|9918386|FG010|Overall Study|Adverse Event|1
6238451|NCT01823835|9918387|FG011|Overall Study|Adverse Event|2
6238452|NCT01823835|9918388|FG012|Overall Study|Adverse Event|0
6238453|NCT01823835|9918389|FG013|Overall Study|Adverse Event|0
6238454|NCT01823835|9918390|FG014|Overall Study|Adverse Event|0
6238455|NCT01823835|9918376|FG000|Overall Study|Physician Decision|0
6188911|NCT01395784|9843856|FG000|Overall Study|Withdrawal by Subject|3
6188912|NCT01395784|9843856|FG000|Overall Study|Physician Decision|5
6188913|NCT01395810|9843895|FG000|Overall Study|Adverse Event|0
6188914|NCT01395810|9843896|FG001|Overall Study|Adverse Event|1
6188915|NCT01395810|9843897|FG002|Overall Study|Adverse Event|0
6188916|NCT01395810|9843898|FG003|Overall Study|Adverse Event|0
6188917|NCT01395810|9843895|FG000|Overall Study|Lack of Efficacy|0
6188918|NCT01395810|9843896|FG001|Overall Study|Lack of Efficacy|1
6188919|NCT01395810|9843897|FG002|Overall Study|Lack of Efficacy|0
6188920|NCT01395810|9843898|FG003|Overall Study|Lack of Efficacy|0
6188921|NCT01395810|9843895|FG000|Overall Study|Withdrawal criteria|0
6188922|NCT01395810|9843896|FG001|Overall Study|Withdrawal criteria|2
6188923|NCT01395810|9843897|FG002|Overall Study|Withdrawal criteria|0
6188924|NCT01395810|9843898|FG003|Overall Study|Withdrawal criteria|0
6188925|NCT01395810|9843895|FG000|Overall Study|Unclassified|2
6188926|NCT01395810|9843896|FG001|Overall Study|Unclassified|0
6188927|NCT01395810|9843897|FG002|Overall Study|Unclassified|0
6188928|NCT01395810|9843898|FG003|Overall Study|Unclassified|0
6188929|NCT01395823|9843911|FG000|Overall Study|Death|4
6188930|NCT01395823|9843912|FG001|Overall Study|Death|4
6188931|NCT01395823|9843911|FG000|Overall Study|Physician Decision|3
6188932|NCT01395823|9843912|FG001|Overall Study|Physician Decision|1
6188933|NCT01395823|9843911|FG000|Overall Study|Lost to Follow-up|1
6188934|NCT01395823|9843912|FG001|Overall Study|Lost to Follow-up|0
6188935|NCT01395823|9843911|FG000|Overall Study|Transplant|1
6188936|NCT01395823|9843912|FG001|Overall Study|Transplant|0
6188937|NCT01395823|9843911|FG000|Overall Study|GI symptoms|1
6188938|NCT01395823|9843912|FG001|Overall Study|GI symptoms|0
6188939|NCT01395823|9843911|FG000|Overall Study|Withdrawal by Subject|5
6188940|NCT01395823|9843912|FG001|Overall Study|Withdrawal by Subject|4
6188941|NCT01395888|9843920|FG000|2-week Run-in Period|Adverse Event|2
6188942|NCT01395888|9843921|FG001|2-week Run-in Period|Adverse Event|0
6188943|NCT01395888|9843922|FG002|2-week Run-in Period|Adverse Event|0
6188944|NCT01395888|9843920|FG000|2-week Run-in Period|Continuation Criteria Not Met|13
6188945|NCT01395888|9843921|FG001|2-week Run-in Period|Continuation Criteria Not Met|0
6188946|NCT01395888|9843922|FG002|2-week Run-in Period|Continuation Criteria Not Met|0
6188947|NCT01395888|9843920|FG000|2-week Run-in Period|Lost to Follow-up|1
6188948|NCT01395888|9843921|FG001|2-week Run-in Period|Lost to Follow-up|0
6188949|NCT01395888|9843922|FG002|2-week Run-in Period|Lost to Follow-up|0
6188950|NCT01395888|9843920|FG000|2-week Run-in Period|Protocol Violation|2
6188951|NCT01395888|9843921|FG001|2-week Run-in Period|Protocol Violation|0
6188952|NCT01395888|9843922|FG002|2-week Run-in Period|Protocol Violation|0
6188953|NCT01395888|9843920|FG000|2-week Run-in Period|Withdrawal by Subject|4
6188954|NCT01395888|9843921|FG001|2-week Run-in Period|Withdrawal by Subject|0
6188955|NCT01395888|9843922|FG002|2-week Run-in Period|Withdrawal by Subject|0
6238456|NCT01823835|9918377|FG001|Overall Study|Physician Decision|0
6238457|NCT01823835|9918378|FG002|Overall Study|Physician Decision|0
6238458|NCT01823835|9918379|FG003|Overall Study|Physician Decision|0
6238459|NCT01823835|9918380|FG004|Overall Study|Physician Decision|0
6238460|NCT01823835|9918381|FG005|Overall Study|Physician Decision|0
6238461|NCT01823835|9918382|FG006|Overall Study|Physician Decision|0
6238462|NCT01823835|9918383|FG007|Overall Study|Physician Decision|0
6238463|NCT01823835|9918384|FG008|Overall Study|Physician Decision|0
6238464|NCT01823835|9918385|FG009|Overall Study|Physician Decision|0
6238465|NCT01823835|9918386|FG010|Overall Study|Physician Decision|0
6238466|NCT01823835|9918387|FG011|Overall Study|Physician Decision|2
6238467|NCT01823835|9918388|FG012|Overall Study|Physician Decision|0
6238468|NCT01823835|9918389|FG013|Overall Study|Physician Decision|0
6238469|NCT01823835|9918390|FG014|Overall Study|Physician Decision|0
6238470|NCT01823835|9918376|FG000|Overall Study|Progressive Disease|3
6238471|NCT01823835|9918377|FG001|Overall Study|Progressive Disease|4
6238472|NCT01823835|9918378|FG002|Overall Study|Progressive Disease|3
6188956|NCT01395888|9843920|FG000|Treatment Period (TP)|Adverse Event|0
6188957|NCT01395888|9843921|FG001|Treatment Period (TP)|Adverse Event|7
6188958|NCT01395888|9843922|FG002|Treatment Period (TP)|Adverse Event|6
6188959|NCT01395888|9843920|FG000|Treatment Period (TP)|Lack of Efficacy|0
6188960|NCT01395888|9843921|FG001|Treatment Period (TP)|Lack of Efficacy|4
6188961|NCT01395888|9843922|FG002|Treatment Period (TP)|Lack of Efficacy|3
6188962|NCT01395888|9843920|FG000|Treatment Period (TP)|Protocol Violation|0
6188963|NCT01395888|9843921|FG001|Treatment Period (TP)|Protocol Violation|1
6238473|NCT01823835|9918379|FG003|Overall Study|Progressive Disease|6
6238474|NCT01823835|9918380|FG004|Overall Study|Progressive Disease|4
6238475|NCT01823835|9918381|FG005|Overall Study|Progressive Disease|6
6238476|NCT01823835|9918382|FG006|Overall Study|Progressive Disease|5
6238477|NCT01823835|9918383|FG007|Overall Study|Progressive Disease|3
6238478|NCT01823835|9918384|FG008|Overall Study|Progressive Disease|3
6238479|NCT01823835|9918385|FG009|Overall Study|Progressive Disease|18
6238480|NCT01823835|9918386|FG010|Overall Study|Progressive Disease|8
6238481|NCT01823835|9918387|FG011|Overall Study|Progressive Disease|46
6238482|NCT01823835|9918388|FG012|Overall Study|Progressive Disease|18
6238483|NCT01823835|9918389|FG013|Overall Study|Progressive Disease|4
6238484|NCT01823835|9918390|FG014|Overall Study|Progressive Disease|6
6238485|NCT01823835|9918376|FG000|Overall Study|Study Termination|0
6085880|NCT00656513|9695474|FG002|Overall Study|Treatment completed outside of timeframe|1
6085881|NCT00656513|9695472|FG000|Overall Study|Missing baseline form|0
6238486|NCT01823835|9918377|FG001|Overall Study|Study Termination|0
6238487|NCT01823835|9918378|FG002|Overall Study|Study Termination|0
6238488|NCT01823835|9918379|FG003|Overall Study|Study Termination|0
6238489|NCT01823835|9918380|FG004|Overall Study|Study Termination|1
6238490|NCT01823835|9918381|FG005|Overall Study|Study Termination|0
6238491|NCT01823835|9918382|FG006|Overall Study|Study Termination|0
6238492|NCT01823835|9918383|FG007|Overall Study|Study Termination|0
6238493|NCT01823835|9918384|FG008|Overall Study|Study Termination|0
6238494|NCT01823835|9918385|FG009|Overall Study|Study Termination|0
6238495|NCT01823835|9918386|FG010|Overall Study|Study Termination|0
6238496|NCT01823835|9918387|FG011|Overall Study|Study Termination|1
6238497|NCT01823835|9918388|FG012|Overall Study|Study Termination|0
6238498|NCT01823835|9918389|FG013|Overall Study|Study Termination|0
6238499|NCT01823835|9918390|FG014|Overall Study|Study Termination|0
6238500|NCT01823835|9918376|FG000|Overall Study|Withdrawal by Subject|0
6238501|NCT01823835|9918377|FG001|Overall Study|Withdrawal by Subject|0
6238502|NCT01823835|9918378|FG002|Overall Study|Withdrawal by Subject|1
6238503|NCT01823835|9918379|FG003|Overall Study|Withdrawal by Subject|0
6238504|NCT01823835|9918380|FG004|Overall Study|Withdrawal by Subject|0
6238505|NCT01823835|9918381|FG005|Overall Study|Withdrawal by Subject|0
6238506|NCT01823835|9918382|FG006|Overall Study|Withdrawal by Subject|0
6238507|NCT01823835|9918383|FG007|Overall Study|Withdrawal by Subject|0
6238508|NCT01823835|9918384|FG008|Overall Study|Withdrawal by Subject|0
6238509|NCT01823835|9918385|FG009|Overall Study|Withdrawal by Subject|1
6238510|NCT01823835|9918386|FG010|Overall Study|Withdrawal by Subject|1
6238511|NCT01823835|9918387|FG011|Overall Study|Withdrawal by Subject|2
6238512|NCT01823835|9918388|FG012|Overall Study|Withdrawal by Subject|1
6238513|NCT01823835|9918389|FG013|Overall Study|Withdrawal by Subject|0
6238514|NCT01823835|9918390|FG014|Overall Study|Withdrawal by Subject|0
6238515|NCT01823991|9918441|FG000|Overall Study|Withdrawal by Subject|8
6238516|NCT01823991|9918442|FG001|Overall Study|Withdrawal by Subject|5
6238517|NCT01824290|9918471|FG000|Period 1: Double Blind|Entry Criteria Not Met|1
6238518|NCT01824290|9918472|FG001|Period 1: Double Blind|Entry Criteria Not Met|0
6238519|NCT01824290|9918473|FG002|Period 1: Double Blind|Entry Criteria Not Met|0
6238520|NCT01824290|9918474|FG003|Period 1: Double Blind|Entry Criteria Not Met|0
6238521|NCT01824290|9918471|FG000|Period 1: Double Blind|Parent/Caregiver Decision|1
6238522|NCT01824290|9918472|FG001|Period 1: Double Blind|Parent/Caregiver Decision|1
6238523|NCT01824290|9918473|FG002|Period 1: Double Blind|Parent/Caregiver Decision|0
6238524|NCT01824290|9918474|FG003|Period 1: Double Blind|Parent/Caregiver Decision|0
6238525|NCT01824290|9918471|FG000|Period 1: Double Blind|Investigator Reported Clinical Worsening|1
6238526|NCT01824290|9918472|FG001|Period 1: Double Blind|Investigator Reported Clinical Worsening|1
6238527|NCT01824290|9918473|FG002|Period 1: Double Blind|Investigator Reported Clinical Worsening|0
6238528|NCT01824290|9918474|FG003|Period 1: Double Blind|Investigator Reported Clinical Worsening|0
6238529|NCT01824290|9918471|FG000|Period 2: Open-Label Treatment|Adverse Event|0
6238530|NCT01824290|9918472|FG001|Period 2: Open-Label Treatment|Adverse Event|0
6238531|NCT01824290|9918473|FG002|Period 2: Open-Label Treatment|Adverse Event|0
6238532|NCT01824290|9918474|FG003|Period 2: Open-Label Treatment|Adverse Event|1
6238533|NCT01824290|9918471|FG000|Period 2: Open-Label Treatment|Parent/caregiver Decision|0
6238534|NCT01824290|9918472|FG001|Period 2: Open-Label Treatment|Parent/caregiver Decision|0
6238535|NCT01824290|9918473|FG002|Period 2: Open-Label Treatment|Parent/caregiver Decision|1
6238536|NCT01824290|9918474|FG003|Period 2: Open-Label Treatment|Parent/caregiver Decision|1
6238537|NCT01824290|9918471|FG000|Period 2: Open-Label Treatment|Withdrawal by Subject|0
6238538|NCT01824290|9918472|FG001|Period 2: Open-Label Treatment|Withdrawal by Subject|0
6238539|NCT01824290|9918473|FG002|Period 2: Open-Label Treatment|Withdrawal by Subject|2
6238540|NCT01824290|9918474|FG003|Period 2: Open-Label Treatment|Withdrawal by Subject|1
6238541|NCT01824303|9918488|FG000|Randomized Study|Withdrawal by Subject|1
6238542|NCT01824303|9918489|FG001|Randomized Study|Withdrawal by Subject|1
6238543|NCT01824303|9918488|FG000|Randomized Study|Other Miscellaneous Reasons|1
6238544|NCT01824303|9918489|FG001|Randomized Study|Other Miscellaneous Reasons|0
6238545|NCT01824342|9918499|FG000|Overall Study|Withdrawal by Subject|0
6238546|NCT01824342|9918500|FG001|Overall Study|Withdrawal by Subject|3
6238547|NCT01824342|9918499|FG000|Overall Study|Adverse Event|1
6238548|NCT01824342|9918500|FG001|Overall Study|Adverse Event|1
6238549|NCT01824342|9918499|FG000|Overall Study|Disease Progression|1
6238550|NCT01824342|9918500|FG001|Overall Study|Disease Progression|1
6238551|NCT01824342|9918499|FG000|Overall Study|Physician Decision|5
6238552|NCT01824342|9918500|FG001|Overall Study|Physician Decision|0
6238553|NCT01824342|9918499|FG000|Overall Study|Death|2
6238554|NCT01824342|9918500|FG001|Overall Study|Death|0
6238555|NCT01824355|9918506|FG000|Overall Study|Adverse Event|2
6238556|NCT01824355|9918506|FG000|Overall Study|unevaluable reference method results per|1
6238557|NCT01824394|9918513|FG000|Overall Study|Early Termination|1
6238558|NCT01824394|9918514|FG001|Overall Study|Early Termination|1
6238559|NCT01824394|9918515|FG002|Overall Study|Early Termination|3
6238560|NCT01824394|9918513|FG000|Overall Study|Withdrawn due to Study Termination|91
6238561|NCT01824394|9918514|FG001|Overall Study|Withdrawn due to Study Termination|83
6238562|NCT01824394|9918515|FG002|Overall Study|Withdrawn due to Study Termination|41
6238563|NCT01824394|9918513|FG000|Overall Study|Lost to Follow-up|0
6238564|NCT01824394|9918514|FG001|Overall Study|Lost to Follow-up|9
6238565|NCT01824394|9918515|FG002|Overall Study|Lost to Follow-up|3
6238566|NCT01824394|9918513|FG000|Overall Study|Death|3
6238567|NCT01824394|9918514|FG001|Overall Study|Death|2
6238568|NCT01824394|9918515|FG002|Overall Study|Death|4
6238569|NCT01824394|9918513|FG000|Overall Study|Discontinued Subjects|1
6238570|NCT01824394|9918514|FG001|Overall Study|Discontinued Subjects|1
6238571|NCT01824394|9918515|FG002|Overall Study|Discontinued Subjects|2
6238572|NCT01824394|9918513|FG000|Overall Study|Excluded Subjects(No catheter inserted)|23
6238573|NCT01824394|9918514|FG001|Overall Study|Excluded Subjects(No catheter inserted)|20
6238574|NCT01824394|9918515|FG002|Overall Study|Excluded Subjects(No catheter inserted)|21
6238575|NCT01824472|9918530|FG000|Overall Study|Lost to Follow-up|0
6238576|NCT01824472|9918531|FG001|Overall Study|Lost to Follow-up|0
6238577|NCT01824472|9918532|FG002|Overall Study|Lost to Follow-up|1
6238578|NCT01824472|9918530|FG000|Overall Study|Withdrawal by Subject|1
6238579|NCT01824472|9918531|FG001|Overall Study|Withdrawal by Subject|5
6238580|NCT01824472|9918532|FG002|Overall Study|Withdrawal by Subject|3
6238581|NCT01824472|9918530|FG000|Overall Study|Ineligible post randomization&screening|0
6238582|NCT01824472|9918531|FG001|Overall Study|Ineligible post randomization&screening|2
6238583|NCT01824472|9918532|FG002|Overall Study|Ineligible post randomization&screening|0
6238584|NCT01824498|9918546|FG000|Washout (8 Weeks)|Withdrawal by Subject|2
6238585|NCT01824498|9918547|FG001|Washout (8 Weeks)|Withdrawal by Subject|0
6238586|NCT01824498|9918548|FG002|Washout (8 Weeks)|Withdrawal by Subject|2
6238587|NCT01824498|9918549|FG003|Washout (8 Weeks)|Withdrawal by Subject|1
6238588|NCT01824498|9918550|FG004|Washout (8 Weeks)|Withdrawal by Subject|1
6238589|NCT01824498|9918551|FG005|Washout (8 Weeks)|Withdrawal by Subject|0
6238590|NCT01824576|9918559|FG000|Overall Study|Device deficiency|2
6238591|NCT01824602|9918584|FG000|Overall Study|Withdrawal by Subject|0
6238592|NCT01824602|9918585|FG001|Overall Study|Withdrawal by Subject|0
6238593|NCT01824602|9918586|FG002|Overall Study|Withdrawal by Subject|1
6238594|NCT01824602|9918587|FG003|Overall Study|Withdrawal by Subject|2
6238595|NCT01824602|9918584|FG000|Overall Study|Patient non-compliance|0
6238596|NCT01824602|9918585|FG001|Overall Study|Patient non-compliance|0
6238597|NCT01824602|9918586|FG002|Overall Study|Patient non-compliance|1
6238598|NCT01824602|9918587|FG003|Overall Study|Patient non-compliance|0
6238599|NCT01824602|9918584|FG000|Overall Study|Adverse Event|1
6238600|NCT01824602|9918585|FG001|Overall Study|Adverse Event|0
6238601|NCT01824602|9918586|FG002|Overall Study|Adverse Event|2
6238602|NCT01824602|9918587|FG003|Overall Study|Adverse Event|2
6238603|NCT01824602|9918584|FG000|Overall Study|Treatment failure|0
6238604|NCT01824602|9918585|FG001|Overall Study|Treatment failure|0
6238605|NCT01824602|9918586|FG002|Overall Study|Treatment failure|0
6238606|NCT01824602|9918587|FG003|Overall Study|Treatment failure|1
6238607|NCT01824693|9918600|FG000|Overall Study|Death|0
6238608|NCT01824693|9918601|FG001|Overall Study|Death|1
6238609|NCT01824693|9918602|FG002|Overall Study|Death|0
6238610|NCT01824693|9918600|FG000|Overall Study|Physician Decision|1
6238611|NCT01824693|9918601|FG001|Overall Study|Physician Decision|1
6238612|NCT01824693|9918602|FG002|Overall Study|Physician Decision|1
6238613|NCT01824693|9918600|FG000|Overall Study|Withdrawal by Subject|0
6238614|NCT01824693|9918601|FG001|Overall Study|Withdrawal by Subject|0
6238615|NCT01824693|9918602|FG002|Overall Study|Withdrawal by Subject|1
6238616|NCT01824693|9918600|FG000|Overall Study|Progressive Disease|0
6238617|NCT01824693|9918601|FG001|Overall Study|Progressive Disease|5
6238618|NCT01824693|9918602|FG002|Overall Study|Progressive Disease|0
6238619|NCT01824693|9918600|FG000|Overall Study|Ineligible|0
6238620|NCT01824693|9918601|FG001|Overall Study|Ineligible|0
6238621|NCT01824693|9918602|FG002|Overall Study|Ineligible|3
6238622|NCT01824693|9918600|FG000|Overall Study|No Transplant Planned|0
6238623|NCT01824693|9918601|FG001|Overall Study|No Transplant Planned|0
6238624|NCT01824693|9918602|FG002|Overall Study|No Transplant Planned|10
6238625|NCT01824823|9918611|FG000|Overall Study|Lack of Efficacy|1
6238626|NCT01824823|9918612|FG001|Overall Study|Lack of Efficacy|1
6238627|NCT01824823|9918611|FG000|Overall Study|Off-treatment reason not submitted|1
6238628|NCT01824823|9918612|FG001|Overall Study|Off-treatment reason not submitted|0
6238629|NCT01824979|9918627|FG000|Overall Study|Withdrawal by Subject|5
6238630|NCT01824979|9918628|FG001|Overall Study|Withdrawal by Subject|0
6238631|NCT01824979|9918627|FG000|Overall Study|Physician Decision|2
6238632|NCT01824979|9918628|FG001|Overall Study|Physician Decision|0
6238633|NCT01824979|9918627|FG000|Overall Study|Protocol Violation|6
6238634|NCT01824979|9918628|FG001|Overall Study|Protocol Violation|13
6238635|NCT01825200|9918661|FG000|Overall Study|Lost to Follow-up|5
6238636|NCT01825200|9918662|FG001|Overall Study|Lost to Follow-up|6
6238637|NCT01825200|9918661|FG000|Overall Study|Withdrawal by Subject|0
6238638|NCT01825200|9918662|FG001|Overall Study|Withdrawal by Subject|1
6238639|NCT01825577|9918694|FG000|Overall Study|Physician Decision|2
6238640|NCT01825577|9918694|FG000|Overall Study|Withdrawal by Subject|1
6238641|NCT01825577|9918694|FG000|Overall Study|Withdrawn by family members|2
6238642|NCT01825577|9918694|FG000|Overall Study|Lack of Efficacy|3
6238643|NCT01825785|9918714|FG000|Overall Study|Adverse Event|0
6238644|NCT01825785|9918715|FG001|Overall Study|Adverse Event|0
6238645|NCT01825785|9918716|FG002|Overall Study|Adverse Event|0
6238646|NCT01825785|9918717|FG003|Overall Study|Adverse Event|0
6238647|NCT01825785|9918718|FG004|Overall Study|Adverse Event|1
6238648|NCT01825785|9918719|FG005|Overall Study|Adverse Event|0
6238649|NCT01825785|9918720|FG006|Overall Study|Adverse Event|0
6238650|NCT01825785|9918714|FG000|Overall Study|Withdrawal by Subject|0
6238651|NCT01825785|9918715|FG001|Overall Study|Withdrawal by Subject|0
6238652|NCT01825785|9918716|FG002|Overall Study|Withdrawal by Subject|0
6238653|NCT01825785|9918717|FG003|Overall Study|Withdrawal by Subject|0
6238654|NCT01825785|9918718|FG004|Overall Study|Withdrawal by Subject|1
6238655|NCT01825785|9918719|FG005|Overall Study|Withdrawal by Subject|1
6238656|NCT01825785|9918720|FG006|Overall Study|Withdrawal by Subject|0
6238657|NCT01825798|9918744|FG000|Overall Study|Adverse Event|1
6238658|NCT01825798|9918745|FG001|Overall Study|Adverse Event|5
6238659|NCT01825798|9918744|FG000|Overall Study|Lost to Follow-up|1
6238660|NCT01825798|9918745|FG001|Overall Study|Lost to Follow-up|0
6238661|NCT01825837|9918755|FG000|PART I|Withdrawal by Subject|0
6238662|NCT01825837|9918756|FG001|PART I|Withdrawal by Subject|0
6238663|NCT01825837|9918757|FG002|PART I|Withdrawal by Subject|0
6238664|NCT01825837|9918758|FG003|PART I|Withdrawal by Subject|6
6238665|NCT01825837|9918755|FG000|PART I|Patient non-compliance|0
6238666|NCT01825837|9918756|FG001|PART I|Patient non-compliance|0
6238667|NCT01825837|9918757|FG002|PART I|Patient non-compliance|0
6238668|NCT01825837|9918758|FG003|PART I|Patient non-compliance|1
6238669|NCT01825837|9918755|FG000|PART I|Treatment failure|0
6238670|NCT01825837|9918756|FG001|PART I|Treatment failure|0
6238671|NCT01825837|9918757|FG002|PART I|Treatment failure|0
6238672|NCT01825837|9918758|FG003|PART I|Treatment failure|7
6238673|NCT01825837|9918755|FG000|PART I|reason unspecified|0
6238674|NCT01825837|9918756|FG001|PART I|reason unspecified|0
6238675|NCT01825837|9918757|FG002|PART I|reason unspecified|0
6238676|NCT01825837|9918758|FG003|PART I|reason unspecified|3
6238677|NCT01825837|9918755|FG000|PART II|Withdrawal by Subject|3
6238678|NCT01825837|9918756|FG001|PART II|Withdrawal by Subject|3
6238679|NCT01825837|9918757|FG002|PART II|Withdrawal by Subject|7
6238680|NCT01825837|9918758|FG003|PART II|Withdrawal by Subject|0
6238681|NCT01825837|9918755|FG000|PART II|Patient non-compliance|5
6238682|NCT01825837|9918756|FG001|PART II|Patient non-compliance|2
6238683|NCT01825837|9918757|FG002|PART II|Patient non-compliance|4
6238684|NCT01825837|9918758|FG003|PART II|Patient non-compliance|0
6238685|NCT01825837|9918755|FG000|PART II|Adverse Event|3
6238686|NCT01825837|9918756|FG001|PART II|Adverse Event|3
6238687|NCT01825837|9918757|FG002|PART II|Adverse Event|1
6238688|NCT01825837|9918758|FG003|PART II|Adverse Event|0
6238689|NCT01825837|9918755|FG000|PART II|Treatment failure|6
6238690|NCT01825837|9918756|FG001|PART II|Treatment failure|4
6238691|NCT01825837|9918757|FG002|PART II|Treatment failure|5
6238692|NCT01825837|9918758|FG003|PART II|Treatment failure|0
6238693|NCT01825837|9918755|FG000|PART II|reason unspecified|2
6238694|NCT01825837|9918756|FG001|PART II|reason unspecified|2
6238695|NCT01825837|9918757|FG002|PART II|reason unspecified|2
6238696|NCT01825837|9918758|FG003|PART II|reason unspecified|0
6238697|NCT01825876|9918766|FG000|Period 2|Withdrawal by Subject|0
6238698|NCT01825876|9918767|FG001|Period 2|Withdrawal by Subject|1
6238699|NCT01825941|9918787|FG000|Overall Study|Lost to Follow-up|4
6238700|NCT01825941|9918788|FG001|Overall Study|Lost to Follow-up|1
6238701|NCT01826201|9918794|FG000|Overall Study|Non compliance with protocol|4
6238702|NCT01826214|9918802|FG000|Overall Study|Adverse Event|7
6238703|NCT01826214|9918803|FG001|Overall Study|Adverse Event|6
6238704|NCT01826214|9918802|FG000|Overall Study|Death|3
6238705|NCT01826214|9918803|FG001|Overall Study|Death|1
6238706|NCT01826214|9918802|FG000|Overall Study|Lost to Follow-up|1
6238707|NCT01826214|9918803|FG001|Overall Study|Lost to Follow-up|0
6238708|NCT01826214|9918802|FG000|Overall Study|Physician Decision|0
6238709|NCT01826214|9918803|FG001|Overall Study|Physician Decision|2
6238710|NCT01826214|9918802|FG000|Overall Study|Progressive disease|22
6238711|NCT01826214|9918803|FG001|Overall Study|Progressive disease|21
6238712|NCT01826214|9918802|FG000|Overall Study|Study terminated by Sponsor|0
6238713|NCT01826214|9918803|FG001|Overall Study|Study terminated by Sponsor|1
6238714|NCT01826214|9918802|FG000|Overall Study|Subject/guardian decision|2
6238715|NCT01826214|9918803|FG001|Overall Study|Subject/guardian decision|3
6238716|NCT01826370|9918813|FG000|Overall Study|Protocol Violation|6
6238717|NCT01826370|9918813|FG000|Overall Study|Lost to Follow-up|12
6238718|NCT01826370|9918813|FG000|Overall Study|Other reason not defined above|2
6238719|NCT01826422|9918819|FG000|Overall Study|Withdrawal by Subject|1
6238720|NCT01826422|9918820|FG001|Overall Study|Withdrawal by Subject|3
6238721|NCT01826448|9918828|FG000|Overall Study|Adverse Event|1
6238722|NCT01826448|9918829|FG001|Overall Study|Adverse Event|3
6238723|NCT01826448|9918828|FG000|Overall Study|Disease progression|2
6238724|NCT01826448|9918829|FG001|Overall Study|Disease progression|4
6238725|NCT01826448|9918828|FG000|Overall Study|Withdrawal by Subject|1
6238726|NCT01826448|9918829|FG001|Overall Study|Withdrawal by Subject|0
6238727|NCT01826448|9918828|FG000|Overall Study|Physician Decision|0
6238728|NCT01826448|9918829|FG001|Overall Study|Physician Decision|1
6238729|NCT01826448|9918828|FG000|Overall Study|2 active cancers|0
6238730|NCT01826448|9918829|FG001|Overall Study|2 active cancers|1
6238731|NCT01826487|9918837|FG000|Overall Study|Adverse Event|1
6238732|NCT01826487|9918838|FG001|Overall Study|Adverse Event|1
6238733|NCT01826487|9918837|FG000|Overall Study|Lost to Follow-up|1
6238734|NCT01826487|9918838|FG001|Overall Study|Lost to Follow-up|0
6238735|NCT01826487|9918837|FG000|Overall Study|Withdrawal by Subject|1
6238736|NCT01826487|9918838|FG001|Overall Study|Withdrawal by Subject|3
6238737|NCT01826487|9918837|FG000|Overall Study|Protocol Violation|1
6238738|NCT01826487|9918838|FG001|Overall Study|Protocol Violation|1
6238739|NCT01826604|9918859|FG000|Overall Study|Lost to Follow-up|8
6238740|NCT01826604|9918860|FG001|Overall Study|Lost to Follow-up|9
6238741|NCT01826825|9918879|FG000|Overall Study|Two patients consented and randomized to Mini-Cog did not have the Mini-Cog administered|0
6238742|NCT01826825|9918880|FG001|Overall Study|Two patients consented and randomized to Mini-Cog did not have the Mini-Cog administered|2
6238743|NCT01826981|9918912|FG000|Overall Study|Lack of Efficacy|0
6238744|NCT01826981|9918913|FG001|Overall Study|Lack of Efficacy|1
6238745|NCT01826981|9918914|FG002|Overall Study|Lack of Efficacy|0
6238746|NCT01826981|9918915|FG003|Overall Study|Lack of Efficacy|0
6238747|NCT01826981|9918916|FG004|Overall Study|Lack of Efficacy|5
6238748|NCT01826981|9918917|FG005|Overall Study|Lack of Efficacy|0
6238749|NCT01826981|9918918|FG006|Overall Study|Lack of Efficacy|0
6238750|NCT01826981|9918919|FG007|Overall Study|Lack of Efficacy|8
6238751|NCT01826981|9918920|FG008|Overall Study|Lack of Efficacy|7
6238752|NCT01826981|9918921|FG009|Overall Study|Lack of Efficacy|0
6238753|NCT01826981|9918922|FG010|Overall Study|Lack of Efficacy|1
6238754|NCT01826981|9918923|FG011|Overall Study|Lack of Efficacy|0
6238755|NCT01826981|9918924|FG012|Overall Study|Lack of Efficacy|0
6238756|NCT01826981|9918925|FG013|Overall Study|Lack of Efficacy|3
6238757|NCT01826981|9918926|FG014|Overall Study|Lack of Efficacy|0
6238758|NCT01826981|9918912|FG000|Overall Study|Lost to Follow-up|0
6238759|NCT01826981|9918913|FG001|Overall Study|Lost to Follow-up|0
6238760|NCT01826981|9918914|FG002|Overall Study|Lost to Follow-up|0
6238761|NCT01826981|9918915|FG003|Overall Study|Lost to Follow-up|0
6238762|NCT01826981|9918916|FG004|Overall Study|Lost to Follow-up|1
6238763|NCT01826981|9918917|FG005|Overall Study|Lost to Follow-up|1
6238764|NCT01826981|9918918|FG006|Overall Study|Lost to Follow-up|0
6238765|NCT01826981|9918919|FG007|Overall Study|Lost to Follow-up|1
6238766|NCT01826981|9918920|FG008|Overall Study|Lost to Follow-up|0
6238767|NCT01826981|9918921|FG009|Overall Study|Lost to Follow-up|1
6238768|NCT01826981|9918922|FG010|Overall Study|Lost to Follow-up|1
6238769|NCT01826981|9918923|FG011|Overall Study|Lost to Follow-up|1
6238770|NCT01826981|9918924|FG012|Overall Study|Lost to Follow-up|1
6238771|NCT01826981|9918925|FG013|Overall Study|Lost to Follow-up|0
6238772|NCT01826981|9918926|FG014|Overall Study|Lost to Follow-up|0
6238773|NCT01826981|9918912|FG000|Overall Study|Withdrew Consent|0
6238774|NCT01826981|9918913|FG001|Overall Study|Withdrew Consent|0
6238775|NCT01826981|9918914|FG002|Overall Study|Withdrew Consent|0
6238776|NCT01826981|9918915|FG003|Overall Study|Withdrew Consent|0
6238777|NCT01826981|9918916|FG004|Overall Study|Withdrew Consent|0
6238778|NCT01826981|9918917|FG005|Overall Study|Withdrew Consent|0
6238779|NCT01826981|9918918|FG006|Overall Study|Withdrew Consent|1
6238780|NCT01826981|9918919|FG007|Overall Study|Withdrew Consent|1
6238781|NCT01826981|9918920|FG008|Overall Study|Withdrew Consent|0
6238782|NCT01826981|9918921|FG009|Overall Study|Withdrew Consent|0
6238783|NCT01826981|9918922|FG010|Overall Study|Withdrew Consent|0
6238784|NCT01826981|9918923|FG011|Overall Study|Withdrew Consent|1
6238785|NCT01826981|9918924|FG012|Overall Study|Withdrew Consent|0
6238786|NCT01826981|9918925|FG013|Overall Study|Withdrew Consent|1
6238787|NCT01826981|9918926|FG014|Overall Study|Withdrew Consent|0
6238788|NCT01826981|9918912|FG000|Overall Study|Adverse Event|0
6238789|NCT01826981|9918913|FG001|Overall Study|Adverse Event|0
6238790|NCT01826981|9918914|FG002|Overall Study|Adverse Event|0
6238791|NCT01826981|9918915|FG003|Overall Study|Adverse Event|0
6238792|NCT01826981|9918916|FG004|Overall Study|Adverse Event|1
6238793|NCT01826981|9918917|FG005|Overall Study|Adverse Event|0
6238794|NCT01826981|9918918|FG006|Overall Study|Adverse Event|0
6238795|NCT01826981|9918919|FG007|Overall Study|Adverse Event|0
6238796|NCT01826981|9918920|FG008|Overall Study|Adverse Event|0
6238797|NCT01826981|9918921|FG009|Overall Study|Adverse Event|0
6238798|NCT01826981|9918922|FG010|Overall Study|Adverse Event|0
6238799|NCT01826981|9918923|FG011|Overall Study|Adverse Event|0
6238800|NCT01826981|9918924|FG012|Overall Study|Adverse Event|0
6238801|NCT01826981|9918925|FG013|Overall Study|Adverse Event|0
6238802|NCT01826981|9918926|FG014|Overall Study|Adverse Event|0
6238803|NCT01826981|9918912|FG000|Overall Study|Upper G-I Haemorrhage|0
6238804|NCT01826981|9918913|FG001|Overall Study|Upper G-I Haemorrhage|0
6238805|NCT01826981|9918914|FG002|Overall Study|Upper G-I Haemorrhage|0
6238806|NCT01826981|9918915|FG003|Overall Study|Upper G-I Haemorrhage|0
6238807|NCT01826981|9918916|FG004|Overall Study|Upper G-I Haemorrhage|0
6238808|NCT01826981|9918917|FG005|Overall Study|Upper G-I Haemorrhage|0
6238809|NCT01826981|9918918|FG006|Overall Study|Upper G-I Haemorrhage|0
6238810|NCT01826981|9918919|FG007|Overall Study|Upper G-I Haemorrhage|0
6238811|NCT01826981|9918920|FG008|Overall Study|Upper G-I Haemorrhage|0
6238812|NCT01826981|9918921|FG009|Overall Study|Upper G-I Haemorrhage|0
6238813|NCT01826981|9918922|FG010|Overall Study|Upper G-I Haemorrhage|0
6238814|NCT01826981|9918923|FG011|Overall Study|Upper G-I Haemorrhage|0
6238815|NCT01826981|9918924|FG012|Overall Study|Upper G-I Haemorrhage|0
6238816|NCT01826981|9918925|FG013|Overall Study|Upper G-I Haemorrhage|1
6238817|NCT01826981|9918926|FG014|Overall Study|Upper G-I Haemorrhage|0
6238818|NCT01826981|9918912|FG000|Overall Study|Enrolled/Randomized but Not Treated|0
6238819|NCT01826981|9918913|FG001|Overall Study|Enrolled/Randomized but Not Treated|0
6238820|NCT01826981|9918914|FG002|Overall Study|Enrolled/Randomized but Not Treated|0
6238821|NCT01826981|9918915|FG003|Overall Study|Enrolled/Randomized but Not Treated|0
6238822|NCT01826981|9918916|FG004|Overall Study|Enrolled/Randomized but Not Treated|0
6238823|NCT01826981|9918917|FG005|Overall Study|Enrolled/Randomized but Not Treated|0
6238824|NCT01826981|9918918|FG006|Overall Study|Enrolled/Randomized but Not Treated|0
6238825|NCT01826981|9918919|FG007|Overall Study|Enrolled/Randomized but Not Treated|1
6238826|NCT01826981|9918920|FG008|Overall Study|Enrolled/Randomized but Not Treated|0
6238827|NCT01826981|9918921|FG009|Overall Study|Enrolled/Randomized but Not Treated|0
6238828|NCT01826981|9918922|FG010|Overall Study|Enrolled/Randomized but Not Treated|0
6238829|NCT01826981|9918923|FG011|Overall Study|Enrolled/Randomized but Not Treated|0
6238830|NCT01826981|9918924|FG012|Overall Study|Enrolled/Randomized but Not Treated|0
6238831|NCT01826981|9918925|FG013|Overall Study|Enrolled/Randomized but Not Treated|0
6238832|NCT01826981|9918926|FG014|Overall Study|Enrolled/Randomized but Not Treated|0
6238833|NCT01827046|9918964|FG000|Overall Study|Lost to Follow-up|1
6238834|NCT01827046|9918965|FG001|Overall Study|Lost to Follow-up|5
6238835|NCT01827046|9918964|FG000|Overall Study|Withdrawal by Subject|0
6238836|NCT01827046|9918965|FG001|Overall Study|Withdrawal by Subject|4
6270153|NCT02148445|9970813|FG001|Overall Study|Death|3
6270154|NCT02148718|9970838|FG000|Overall Study|Protocol Violation|26
6270155|NCT02148718|9970838|FG000|Overall Study|Discontinued Study Prematurely|5
6270156|NCT02148952|9970867|FG000|Assessing Eligibility and Consent|Were not eligible for inclusion|1241
6270157|NCT02148952|9970868|FG001|Assessing Eligibility and Consent|Were not eligible for inclusion|1591
6270158|NCT02148952|9970867|FG000|Assessing Eligibility and Consent|Did not consent or declined follow-up|1862
6270159|NCT02148952|9970868|FG001|Assessing Eligibility and Consent|Did not consent or declined follow-up|1556
6270160|NCT02148952|9970867|FG000|Follow-Up|Lost to Follow-up|219
6270161|NCT02148952|9970868|FG001|Follow-Up|Lost to Follow-up|231
6270162|NCT02148952|9970867|FG000|Follow-Up|Withdrawal by Subject|46
6270163|NCT02148952|9970868|FG001|Follow-Up|Withdrawal by Subject|48
6270164|NCT02149108|9970884|FG000|Overall Study|Not treated|1
6270165|NCT02149108|9970885|FG001|Overall Study|Not treated|2
6270166|NCT02149108|9970884|FG000|Overall Study|Progressive Disease (PD)|324
6270167|NCT02149108|9970885|FG001|Overall Study|Progressive Disease (PD)|318
6270168|NCT02149108|9970884|FG000|Overall Study|Worsening/adverse event cancer disease|31
6270169|NCT02149108|9970885|FG001|Overall Study|Worsening/adverse event cancer disease|32
6270170|NCT02149108|9970884|FG000|Overall Study|Other Adverse Event (AE)|8
6270171|NCT02149108|9970885|FG001|Overall Study|Other Adverse Event (AE)|18
6270172|NCT02149108|9970884|FG000|Overall Study|Other not defined above|0
6270173|NCT02149108|9970885|FG001|Overall Study|Other not defined above|2
6270174|NCT02149108|9970884|FG000|Overall Study|Refusal to continue trial medication|15
6270175|NCT02149108|9970885|FG001|Overall Study|Refusal to continue trial medication|11
6270176|NCT02149108|9970884|FG000|Overall Study|Lost to Follow-up|1
6270177|NCT02149108|9970885|FG001|Overall Study|Lost to Follow-up|0
6270178|NCT02149199|9970904|FG000|Overall Study|Study specific withdrawal criteria|4
6270179|NCT02149199|9970905|FG001|Overall Study|Study specific withdrawal criteria|21
6270180|NCT02149199|9970906|FG002|Overall Study|Study specific withdrawal criteria|6
6270181|NCT02149199|9970904|FG000|Overall Study|Other|20
6270182|NCT02149199|9970905|FG001|Overall Study|Other|25
6270183|NCT02149199|9970906|FG002|Overall Study|Other|20
6270184|NCT02149199|9970904|FG000|Overall Study|Eligibility criteria not fulfilled|9
6270185|NCT02149199|9970905|FG001|Overall Study|Eligibility criteria not fulfilled|14
6270186|NCT02149199|9970906|FG002|Overall Study|Eligibility criteria not fulfilled|8
6270187|NCT02149199|9970904|FG000|Overall Study|Withdrawal by Subject|75
6270188|NCT02149199|9970905|FG001|Overall Study|Withdrawal by Subject|93
6270189|NCT02149199|9970906|FG002|Overall Study|Withdrawal by Subject|77
6270190|NCT02149199|9970904|FG000|Overall Study|Protocol Violation|16
6270191|NCT02149199|9970905|FG001|Overall Study|Protocol Violation|13
6270192|NCT02149199|9970906|FG002|Overall Study|Protocol Violation|15
6270193|NCT02149199|9970904|FG000|Overall Study|Lost to Follow-up|3
6270194|NCT02149199|9970905|FG001|Overall Study|Lost to Follow-up|12
6270195|NCT02149199|9970906|FG002|Overall Study|Lost to Follow-up|11
6270196|NCT02149199|9970904|FG000|Overall Study|Death|0
6270197|NCT02149199|9970905|FG001|Overall Study|Death|0
6270198|NCT02149199|9970906|FG002|Overall Study|Death|1
6270199|NCT02149199|9970904|FG000|Overall Study|Adverse Event|6
6270200|NCT02149199|9970905|FG001|Overall Study|Adverse Event|15
6270201|NCT02149199|9970906|FG002|Overall Study|Adverse Event|9
6270202|NCT02149264|9970914|FG000|Overall Study|Withdrawal by Subject|9
6270203|NCT02149264|9970914|FG000|Overall Study|Adverse Event|7
6270204|NCT02149264|9970914|FG000|Overall Study|Physician Decision|3
6270205|NCT02149264|9970914|FG000|Overall Study|Protocol Violation|1
6270206|NCT02149420|9970938|FG000|Core Study|Administrative problems|0
6270207|NCT02149420|9970939|FG001|Core Study|Administrative problems|1
6238837|NCT01827163|9918971|FG000|Overall Study|Hypersensitivity reaction to Paclitaxel|2
6238838|NCT01827163|9918971|FG000|Overall Study|Adverse Event|9
6238839|NCT01827254|9918975|FG000|Overall Study|Death|10
6238840|NCT01827254|9918975|FG000|Overall Study|Case report form not completed|4
6238841|NCT01827254|9918975|FG000|Overall Study|Invalidated centre|3
6238842|NCT01827254|9918975|FG000|Overall Study|Discontinued prior initiation: sunitinib|1
6238843|NCT01827254|9918975|FG000|Overall Study|Did not complete re-challenge|1
6238844|NCT01827254|9918975|FG000|Overall Study|Disease progression|36
6238845|NCT01827254|9918975|FG000|Overall Study|Intolerance to treatment|4
6238846|NCT01827267|9918985|FG000|Overall Study|Did not receive study drug|1
6238847|NCT01827267|9918986|FG001|Overall Study|Did not receive study drug|1
6238848|NCT01827267|9918985|FG000|Overall Study|Physician Decision|1
6238849|NCT01827267|9918986|FG001|Overall Study|Physician Decision|0
6238850|NCT01827267|9918985|FG000|Overall Study|Disease Progression|1
6238851|NCT01827267|9918986|FG001|Overall Study|Disease Progression|1
6238852|NCT01827267|9918985|FG000|Overall Study|Sponsor Discontinued Study|2
6238853|NCT01827267|9918986|FG001|Overall Study|Sponsor Discontinued Study|8
6238854|NCT01827267|9918985|FG000|Overall Study|Still on study|0
6238855|NCT01827267|9918986|FG001|Overall Study|Still on study|2
6238856|NCT01827319|9919002|FG000|Overall Study|Lost to Follow-up|3
6238857|NCT01827332|9919008|FG000|Overall Study|Lost to Follow-up|2
6238858|NCT01827332|9919009|FG001|Overall Study|Lost to Follow-up|1
6238859|NCT01827371|9919028|FG000|Overall Study|Adverse Event|0
6238860|NCT01827371|9919029|FG001|Overall Study|Adverse Event|0
6238861|NCT01827371|9919030|FG002|Overall Study|Adverse Event|4
6238862|NCT01827371|9919031|FG003|Overall Study|Adverse Event|2
6238863|NCT01827371|9919028|FG000|Overall Study|Lost to Follow-up|0
6238864|NCT01827371|9919029|FG001|Overall Study|Lost to Follow-up|2
6238865|NCT01827371|9919030|FG002|Overall Study|Lost to Follow-up|0
6238866|NCT01827371|9919031|FG003|Overall Study|Lost to Follow-up|4
6238867|NCT01827371|9919028|FG000|Overall Study|Protocol Violation|1
6238868|NCT01827371|9919029|FG001|Overall Study|Protocol Violation|0
6238869|NCT01827371|9919030|FG002|Overall Study|Protocol Violation|0
6238870|NCT01827371|9919031|FG003|Overall Study|Protocol Violation|0
6238871|NCT01827371|9919028|FG000|Overall Study|Withdrawal by Subject|1
6238872|NCT01827371|9919029|FG001|Overall Study|Withdrawal by Subject|2
6238873|NCT01827371|9919030|FG002|Overall Study|Withdrawal by Subject|2
6238874|NCT01827371|9919031|FG003|Overall Study|Withdrawal by Subject|3
6238875|NCT01827371|9919028|FG000|Overall Study|Physician Decision|0
6238876|NCT01827371|9919029|FG001|Overall Study|Physician Decision|1
6238877|NCT01827371|9919030|FG002|Overall Study|Physician Decision|0
6238878|NCT01827371|9919031|FG003|Overall Study|Physician Decision|1
6238879|NCT01827371|9919028|FG000|Overall Study|Temporary study halt to vaccinations|11
6238880|NCT01827371|9919029|FG001|Overall Study|Temporary study halt to vaccinations|2
6238881|NCT01827371|9919030|FG002|Overall Study|Temporary study halt to vaccinations|5
6238882|NCT01827371|9919031|FG003|Overall Study|Temporary study halt to vaccinations|13
6238883|NCT01827592|9919073|FG000|Overall Study|Adverse Event|11
6238884|NCT01827592|9919074|FG001|Overall Study|Adverse Event|9
6238885|NCT01827592|9919075|FG002|Overall Study|Adverse Event|2
6238886|NCT01827592|9919073|FG000|Overall Study|Physician Decision|0
6238887|NCT01827592|9919074|FG001|Overall Study|Physician Decision|2
6238888|NCT01827592|9919075|FG002|Overall Study|Physician Decision|1
6238889|NCT01827592|9919073|FG000|Overall Study|Protocol Violation|2
6238890|NCT01827592|9919074|FG001|Overall Study|Protocol Violation|1
6238891|NCT01827592|9919075|FG002|Overall Study|Protocol Violation|0
6238892|NCT01827592|9919073|FG000|Overall Study|Lost to Follow-up|1
6238893|NCT01827592|9919074|FG001|Overall Study|Lost to Follow-up|2
6238894|NCT01827592|9919075|FG002|Overall Study|Lost to Follow-up|2
6238895|NCT01827592|9919073|FG000|Overall Study|Withdrawal by Subject|12
6238896|NCT01827592|9919074|FG001|Overall Study|Withdrawal by Subject|11
6238897|NCT01827592|9919075|FG002|Overall Study|Withdrawal by Subject|11
6238898|NCT01827592|9919073|FG000|Overall Study|Patient's substantial non-compliance|1
6238899|NCT01827592|9919074|FG001|Overall Study|Patient's substantial non-compliance|1
6238900|NCT01827592|9919075|FG002|Overall Study|Patient's substantial non-compliance|6
6238901|NCT01827592|9919073|FG000|Overall Study|Trial terminated by Sponsor|47
6238902|NCT01827592|9919074|FG001|Overall Study|Trial terminated by Sponsor|53
6238903|NCT01827592|9919075|FG002|Overall Study|Trial terminated by Sponsor|51
6238904|NCT01827592|9919073|FG000|Overall Study|Others|0
6238905|NCT01827592|9919074|FG001|Overall Study|Others|1
6238906|NCT01827592|9919075|FG002|Overall Study|Others|3
6238907|NCT01827670|9919085|FG000|Overall Study|Withdrawal of Consent|3
6238908|NCT01827670|9919086|FG001|Overall Study|Withdrawal of Consent|2
6238909|NCT01827670|9919085|FG000|Overall Study|Lost to Follow-up|0
6238910|NCT01827670|9919086|FG001|Overall Study|Lost to Follow-up|1
6238911|NCT01827839|9919109|FG000|Overall Study|Adverse Event|1
6238912|NCT01827839|9919109|FG000|Overall Study|Consent Withdrawal|2
6238913|NCT01827943|9919133|FG000|Overall Study|Protocol Violation|8
6238914|NCT01827943|9919133|FG000|Overall Study|Never treated because of an rapid progression|1
6238915|NCT01828034|9919141|FG000|Overall Study|Withdrawal by Subject|0
6238916|NCT01828034|9919142|FG001|Overall Study|Withdrawal by Subject|0
6238917|NCT01828034|9919143|FG002|Overall Study|Withdrawal by Subject|0
6238918|NCT01828034|9919144|FG003|Overall Study|Withdrawal by Subject|1
6238919|NCT01828073|9919153|FG000|Overall Study|Lost to Follow-up|1
6238920|NCT01828073|9919154|FG001|Overall Study|Lost to Follow-up|2
6238921|NCT01828281|9919198|FG000|Overall Study|Withdrawal by Subject|1
6238922|NCT01828281|9919199|FG001|Overall Study|Withdrawal by Subject|0
6238923|NCT01828567|9919230|FG000|Overall Study|Lost to Follow-up|27
6238924|NCT01828567|9919231|FG001|Overall Study|Lost to Follow-up|9
6238925|NCT01828567|9919230|FG000|Overall Study|Excluded - did not meet criteria|4
6238926|NCT01828567|9919231|FG001|Overall Study|Excluded - did not meet criteria|1
6238927|NCT01829048|9919267|FG000|Overall Study|Withdrawal by Subject|0
6238928|NCT01829048|9919268|FG001|Overall Study|Withdrawal by Subject|0
6238929|NCT01829048|9919269|FG002|Overall Study|Withdrawal by Subject|0
6238930|NCT01829048|9919270|FG003|Overall Study|Withdrawal by Subject|2
6238931|NCT01829048|9919271|FG004|Overall Study|Withdrawal by Subject|0
6238932|NCT01829113|9919286|FG000|Overall Study|Disease Progression|37
6238933|NCT01829113|9919287|FG001|Overall Study|Disease Progression|48
6238934|NCT01829113|9919286|FG000|Overall Study|Adverse Event|14
6238935|NCT01829113|9919287|FG001|Overall Study|Adverse Event|10
6238936|NCT01829113|9919286|FG000|Overall Study|Withdrawal by Subject|17
6238937|NCT01829113|9919287|FG001|Overall Study|Withdrawal by Subject|10
6238938|NCT01829113|9919286|FG000|Overall Study|Death|4
6238939|NCT01829113|9919287|FG001|Overall Study|Death|6
6238940|NCT01829113|9919286|FG000|Overall Study|Sponsor Decision|1
6238941|NCT01829113|9919287|FG001|Overall Study|Sponsor Decision|1
6238942|NCT01829113|9919286|FG000|Overall Study|No Study Treatment Received|3
6238943|NCT01829113|9919287|FG001|Overall Study|No Study Treatment Received|2
6238944|NCT01829113|9919286|FG000|Overall Study|Physician Decision|1
6238945|NCT01829113|9919287|FG001|Overall Study|Physician Decision|1
6238946|NCT01829165|9919297|FG000|Overall Study|Did not complete intervention|2
6238947|NCT01829165|9919298|FG001|Overall Study|Did not complete intervention|0
6238948|NCT01829191|9919306|FG000|Overall Study|Relocation|0
6238949|NCT01829191|9919307|FG001|Overall Study|Relocation|1
6238950|NCT01829191|9919306|FG000|Overall Study|Lens discomfort|0
6238951|NCT01829191|9919307|FG001|Overall Study|Lens discomfort|3
6238952|NCT01829191|9919306|FG000|Overall Study|Lens handling difficulty|1
6238953|NCT01829191|9919307|FG001|Overall Study|Lens handling difficulty|4
6238954|NCT01829191|9919306|FG000|Overall Study|Protocol Violation|4
6238955|NCT01829191|9919307|FG001|Overall Study|Protocol Violation|1
6238956|NCT01829191|9919306|FG000|Overall Study|Withdrawal by Subject|2
6238957|NCT01829191|9919307|FG001|Overall Study|Withdrawal by Subject|3
6238958|NCT01829191|9919306|FG000|Overall Study|Lost to Follow-up|0
6238959|NCT01829191|9919307|FG001|Overall Study|Lost to Follow-up|1
6238960|NCT01829191|9919306|FG000|Overall Study|Subject was fit for ortho - k|0
6238961|NCT01829191|9919307|FG001|Overall Study|Subject was fit for ortho - k|1
6238962|NCT01829230|9919318|FG000|Overall Study|Protocol Violation|0
6238963|NCT01829230|9919319|FG001|Overall Study|Protocol Violation|2
6238964|NCT01829230|9919318|FG000|Overall Study|Withdrawal by Subject|0
6238965|NCT01829230|9919319|FG001|Overall Study|Withdrawal by Subject|1
6238966|NCT01829230|9919318|FG000|Overall Study|Lost to Follow-up|1
6238967|NCT01829230|9919319|FG001|Overall Study|Lost to Follow-up|1
6238968|NCT01829243|9919325|FG000|First Intervention|Screen Failure|4
6238969|NCT01829243|9919326|FG001|First Intervention|Screen Failure|2
6238970|NCT01829295|9919336|FG000|6-12 Months|Did not want to switch antimetabolites|0
6238971|NCT01829295|9919337|FG001|6-12 Months|Did not want to switch antimetabolites|0
6238972|NCT01829295|9919338|FG002|6-12 Months|Did not want to switch antimetabolites|9
6238973|NCT01829295|9919339|FG003|6-12 Months|Did not want to switch antimetabolites|11
6238974|NCT01829295|9919336|FG000|6-12 Months|Adverse Event|0
6238975|NCT01829295|9919337|FG001|6-12 Months|Adverse Event|0
6238976|NCT01829295|9919338|FG002|6-12 Months|Adverse Event|3
6238977|NCT01829295|9919339|FG003|6-12 Months|Adverse Event|2
6238978|NCT01829295|9919336|FG000|6-12 Months|Lost to Follow-up|2
6238979|NCT01829295|9919337|FG001|6-12 Months|Lost to Follow-up|0
6238980|NCT01829295|9919338|FG002|6-12 Months|Lost to Follow-up|0
6238981|NCT01829295|9919339|FG003|6-12 Months|Lost to Follow-up|0
6238982|NCT01829295|9919336|FG000|6-12 Months|Withdrawal by Subject|2
6238983|NCT01829295|9919337|FG001|6-12 Months|Withdrawal by Subject|2
6238984|NCT01829295|9919338|FG002|6-12 Months|Withdrawal by Subject|0
6238985|NCT01829295|9919339|FG003|6-12 Months|Withdrawal by Subject|0
6238986|NCT01829347|9919351|FG000|VTI-210|Death|5
6238987|NCT01829347|9919352|FG001|VTI-210|Death|3
6238988|NCT01829347|9919351|FG000|VTI-210|Withdrawal by Subject|1
6238989|NCT01829347|9919352|FG001|VTI-210|Withdrawal by Subject|0
6238990|NCT01829347|9919351|FG000|VTI-210E|Death|2
6238991|NCT01829347|9919352|FG001|VTI-210E|Death|1
6238992|NCT01829347|9919351|FG000|VTI-210E|Study terminated prematurely|1
6238993|NCT01829347|9919352|FG001|VTI-210E|Study terminated prematurely|5
6238994|NCT01829360|9919362|FG000|Overall Study|Protocol Violation|0
6238995|NCT01829360|9919363|FG001|Overall Study|Protocol Violation|0
6238996|NCT01829360|9919364|FG002|Overall Study|Protocol Violation|1
6238997|NCT01829360|9919365|FG003|Overall Study|Protocol Violation|0
6238998|NCT01829425|9919392|FG000|Overall Study|Withdrawal by Subject|4
6238999|NCT01829425|9919393|FG001|Overall Study|Withdrawal by Subject|3
6239000|NCT01829425|9919392|FG000|Overall Study|Lost to Follow-up|2
6239001|NCT01829425|9919393|FG001|Overall Study|Lost to Follow-up|1
6239002|NCT01829464|9919402|FG000|Overall Study|Adverse Event|1
6239003|NCT01829464|9919403|FG001|Overall Study|Adverse Event|0
6239004|NCT01829464|9919404|FG002|Overall Study|Adverse Event|0
6239005|NCT01829464|9919402|FG000|Overall Study|Lost to Follow-up|0
6239006|NCT01829464|9919403|FG001|Overall Study|Lost to Follow-up|0
6239007|NCT01829464|9919404|FG002|Overall Study|Lost to Follow-up|1
6239008|NCT01829464|9919402|FG000|Overall Study|Withdrawal by Subject|2
6239009|NCT01829464|9919403|FG001|Overall Study|Withdrawal by Subject|0
6239010|NCT01829464|9919404|FG002|Overall Study|Withdrawal by Subject|0
6239011|NCT01829464|9919402|FG000|Overall Study|Study terminated by sponsor|25
6239012|NCT01829464|9919403|FG001|Overall Study|Study terminated by sponsor|28
6239013|NCT01829464|9919404|FG002|Overall Study|Study terminated by sponsor|25
6239014|NCT01829464|9919402|FG000|Overall Study|Lack of Efficacy|0
6239015|NCT01829464|9919403|FG001|Overall Study|Lack of Efficacy|1
6239016|NCT01829464|9919404|FG002|Overall Study|Lack of Efficacy|0
6239017|NCT01830127|9919437|FG000|Overall Study|Adverse Event|1
6239018|NCT01830127|9919438|FG001|Overall Study|Adverse Event|6
6239019|NCT01830127|9919437|FG000|Overall Study|Lack of Efficacy|3
6239020|NCT01830127|9919438|FG001|Overall Study|Lack of Efficacy|0
6239021|NCT01830127|9919437|FG000|Overall Study|Withdrawal by Subject|1
6239022|NCT01830127|9919438|FG001|Overall Study|Withdrawal by Subject|1
6239023|NCT01830127|9919437|FG000|Overall Study|Other reason not defined above|0
6239024|NCT01830127|9919438|FG001|Overall Study|Other reason not defined above|2
6239025|NCT01830543|9919484|FG000|Overall Study|Subject Decision|19
6239026|NCT01830543|9919485|FG001|Overall Study|Subject Decision|21
6239027|NCT01830543|9919486|FG002|Overall Study|Subject Decision|57
6239028|NCT01830543|9919484|FG000|Overall Study|Adverse Event|91
6239029|NCT01830543|9919485|FG001|Overall Study|Adverse Event|77
6239030|NCT01830543|9919486|FG002|Overall Study|Adverse Event|76
6239031|NCT01830543|9919484|FG000|Overall Study|Death|20
6239032|NCT01830543|9919485|FG001|Overall Study|Death|22
6239033|NCT01830543|9919486|FG002|Overall Study|Death|22
6239034|NCT01830543|9919484|FG000|Overall Study|Protocol Violation|3
6239035|NCT01830543|9919485|FG001|Overall Study|Protocol Violation|7
6239036|NCT01830543|9919486|FG002|Overall Study|Protocol Violation|7
6239037|NCT01830543|9919484|FG000|Overall Study|Physician Decision|11
6239038|NCT01830543|9919485|FG001|Overall Study|Physician Decision|5
6239039|NCT01830543|9919486|FG002|Overall Study|Physician Decision|12
6239040|NCT01830543|9919484|FG000|Overall Study|Withdrawal by consent|3
6239041|NCT01830543|9919485|FG001|Overall Study|Withdrawal by consent|3
6239042|NCT01830543|9919486|FG002|Overall Study|Withdrawal by consent|3
6239043|NCT01830543|9919484|FG000|Overall Study|Other|12
6239044|NCT01830543|9919485|FG001|Overall Study|Other|17
6239045|NCT01830543|9919486|FG002|Overall Study|Other|37
6239046|NCT01830595|9919494|FG000|First Period|Withdrawal by Subject|1
6239047|NCT01830595|9919495|FG001|First Period|Withdrawal by Subject|3
6239048|NCT01830595|9919494|FG000|Washout|Withdrawal by Subject|2
6239049|NCT01830595|9919495|FG001|Washout|Withdrawal by Subject|2
6239050|NCT01830816|9919522|FG000|Overall Study|Progressive Disease|12
6239051|NCT01830816|9919523|FG001|Overall Study|Progressive Disease|7
6239052|NCT01830816|9919524|FG002|Overall Study|Progressive Disease|7
6239053|NCT01830816|9919522|FG000|Overall Study|Adverse Event|3
6239054|NCT01830816|9919523|FG001|Overall Study|Adverse Event|4
6239055|NCT01830816|9919524|FG002|Overall Study|Adverse Event|0
6239056|NCT01830816|9919522|FG000|Overall Study|Study Terminated by Sponsor|1
6239057|NCT01830816|9919523|FG001|Overall Study|Study Terminated by Sponsor|1
6239058|NCT01830816|9919524|FG002|Overall Study|Study Terminated by Sponsor|0
6239059|NCT01830816|9919522|FG000|Overall Study|Withdrawal by Subject|1
6239060|NCT01830816|9919523|FG001|Overall Study|Withdrawal by Subject|1
6239061|NCT01830816|9919524|FG002|Overall Study|Withdrawal by Subject|0
6239062|NCT01830816|9919522|FG000|Overall Study|Lost to Follow-up|0
6239063|NCT01830816|9919523|FG001|Overall Study|Lost to Follow-up|1
6239064|NCT01830816|9919524|FG002|Overall Study|Lost to Follow-up|0
6239065|NCT01830816|9919522|FG000|Overall Study|Symptomatic Deterioration|1
6239066|NCT01830816|9919523|FG001|Overall Study|Symptomatic Deterioration|0
6239067|NCT01830816|9919524|FG002|Overall Study|Symptomatic Deterioration|0
6239068|NCT01830816|9919522|FG000|Overall Study|Reason not Specified|2
6239069|NCT01830816|9919523|FG001|Overall Study|Reason not Specified|0
6239070|NCT01830816|9919524|FG002|Overall Study|Reason not Specified|0
6239071|NCT01830855|9919548|FG000|Overall Study|Other|7
6239072|NCT01830855|9919549|FG001|Overall Study|Other|1
6239073|NCT01830855|9919550|FG002|Overall Study|Other|4
6239074|NCT01830855|9919551|FG003|Overall Study|Other|4
6239075|NCT01830855|9919548|FG000|Overall Study|Medication error without associated AE|1
6239076|NCT01830855|9919549|FG001|Overall Study|Medication error without associated AE|0
6239077|NCT01830855|9919550|FG002|Overall Study|Medication error without associated AE|0
6239078|NCT01830855|9919551|FG003|Overall Study|Medication error without associated AE|1
6239079|NCT01830855|9919548|FG000|Overall Study|Pregnancy|3
6239080|NCT01830855|9919549|FG001|Overall Study|Pregnancy|1
6239081|NCT01830855|9919550|FG002|Overall Study|Pregnancy|2
6239082|NCT01830855|9919551|FG003|Overall Study|Pregnancy|1
6239083|NCT01830855|9919548|FG000|Overall Study|No longer meets eligibility criteria|11
6239084|NCT01830855|9919549|FG001|Overall Study|No longer meets eligibility criteria|2
6239085|NCT01830855|9919550|FG002|Overall Study|No longer meets eligibility criteria|3
6239086|NCT01830855|9919551|FG003|Overall Study|No longer meets eligibility criteria|5
6239087|NCT01830855|9919548|FG000|Overall Study|Adverse Event|11
6239088|NCT01830855|9919549|FG001|Overall Study|Adverse Event|5
6239089|NCT01830855|9919550|FG002|Overall Study|Adverse Event|6
6239090|NCT01830855|9919551|FG003|Overall Study|Adverse Event|3
6239091|NCT01830855|9919548|FG000|Overall Study|Protocol deviation|10
6239092|NCT01830855|9919549|FG001|Overall Study|Protocol deviation|5
6239093|NCT01830855|9919550|FG002|Overall Study|Protocol deviation|6
6239094|NCT01830855|9919551|FG003|Overall Study|Protocol deviation|6
6239095|NCT01830855|9919548|FG000|Overall Study|Withdrawal by Subject|33
6239096|NCT01830855|9919549|FG001|Overall Study|Withdrawal by Subject|14
6239097|NCT01830855|9919550|FG002|Overall Study|Withdrawal by Subject|10
6239098|NCT01830855|9919551|FG003|Overall Study|Withdrawal by Subject|12
6239099|NCT01830855|9919548|FG000|Overall Study|No longer willing to participate|32
6239100|NCT01830855|9919549|FG001|Overall Study|No longer willing to participate|13
6239101|NCT01830855|9919550|FG002|Overall Study|No longer willing to participate|12
6239102|NCT01830855|9919551|FG003|Overall Study|No longer willing to participate|17
6239103|NCT01830855|9919548|FG000|Overall Study|Lost to Follow-up|47
6239104|NCT01830855|9919549|FG001|Overall Study|Lost to Follow-up|20
6239105|NCT01830855|9919550|FG002|Overall Study|Lost to Follow-up|23
6239106|NCT01830855|9919551|FG003|Overall Study|Lost to Follow-up|33
6239107|NCT01830881|9919568|FG000|Overall Study|Changed decision to have an abortion|0
6239108|NCT01830881|9919569|FG001|Overall Study|Changed decision to have an abortion|1
6239109|NCT01830920|9919582|FG000|Overall Study|Adverse Event|1
6239110|NCT01830920|9919583|FG001|Overall Study|Adverse Event|0
6239111|NCT01830920|9919584|FG002|Overall Study|Adverse Event|1
6239112|NCT01830920|9919585|FG003|Overall Study|Adverse Event|0
6239113|NCT01830920|9919586|FG004|Overall Study|Adverse Event|0
6239114|NCT01830920|9919582|FG000|Overall Study|Withdrawal by Subject|2
6239115|NCT01830920|9919583|FG001|Overall Study|Withdrawal by Subject|2
6239116|NCT01830920|9919584|FG002|Overall Study|Withdrawal by Subject|1
6239117|NCT01830920|9919585|FG003|Overall Study|Withdrawal by Subject|7
6239118|NCT01830920|9919586|FG004|Overall Study|Withdrawal by Subject|1
6239119|NCT01830920|9919582|FG000|Overall Study|Death|3
6239120|NCT01830920|9919583|FG001|Overall Study|Death|3
6239121|NCT01830920|9919584|FG002|Overall Study|Death|5
6239122|NCT01830920|9919585|FG003|Overall Study|Death|4
6239123|NCT01830920|9919586|FG004|Overall Study|Death|4
6239124|NCT01830920|9919582|FG000|Overall Study|Other|15
6239125|NCT01830920|9919583|FG001|Overall Study|Other|1
6239126|NCT01830920|9919584|FG002|Overall Study|Other|1
6239127|NCT01830920|9919585|FG003|Overall Study|Other|5
6239128|NCT01830920|9919586|FG004|Overall Study|Other|3
6239129|NCT01830972|9919609|FG000|Part II|Withdrawal by Subject|2
6239130|NCT01830972|9919610|FG001|Part II|Withdrawal by Subject|2
6239131|NCT01830972|9919609|FG000|Part III|Withdrawal by Subject|1
6239132|NCT01830972|9919610|FG001|Part III|Withdrawal by Subject|0
6239133|NCT01830972|9919609|FG000|Part III|Noncompliance|1
6239134|NCT01830972|9919610|FG001|Part III|Noncompliance|0
6239135|NCT01830972|9919609|FG000|Part IV|Withdrawal by Subject|2
6239136|NCT01830972|9919610|FG001|Part IV|Withdrawal by Subject|1
6239137|NCT01830972|9919609|FG000|Part IV|Non-Compliance|1
6239138|NCT01830972|9919610|FG001|Part IV|Non-Compliance|0
6239139|NCT01831089|9919632|FG000|Cohort I: Dose Level 1|Progressive disease|3
6239140|NCT01831089|9919633|FG001|Cohort I: Dose Level 1|Progressive disease|0
6239141|NCT01831089|9919634|FG002|Cohort I: Dose Level 1|Progressive disease|0
6239142|NCT01831089|9919635|FG003|Cohort I: Dose Level 1|Progressive disease|0
6239143|NCT01831089|9919636|FG004|Cohort I: Dose Level 1|Progressive disease|0
6239144|NCT01831089|9919637|FG005|Cohort I: Dose Level 1|Progressive disease|0
6239145|NCT01831089|9919632|FG000|Cohort II: Dose Level 2|Progressive disease|0
6239146|NCT01831089|9919633|FG001|Cohort II: Dose Level 2|Progressive disease|2
6239147|NCT01831089|9919634|FG002|Cohort II: Dose Level 2|Progressive disease|0
6239148|NCT01831089|9919635|FG003|Cohort II: Dose Level 2|Progressive disease|0
6239149|NCT01831089|9919636|FG004|Cohort II: Dose Level 2|Progressive disease|0
6239150|NCT01831089|9919637|FG005|Cohort II: Dose Level 2|Progressive disease|0
6239151|NCT01831089|9919632|FG000|Cohort II: Dose Level 2|Clinical progressive disease|0
6239152|NCT01831089|9919633|FG001|Cohort II: Dose Level 2|Clinical progressive disease|1
6239153|NCT01831089|9919634|FG002|Cohort II: Dose Level 2|Clinical progressive disease|0
6239154|NCT01831089|9919635|FG003|Cohort II: Dose Level 2|Clinical progressive disease|0
6239155|NCT01831089|9919636|FG004|Cohort II: Dose Level 2|Clinical progressive disease|0
6239156|NCT01831089|9919637|FG005|Cohort II: Dose Level 2|Clinical progressive disease|0
6239157|NCT01831089|9919632|FG000|Cohort III: Dose Level 3|Progressive disease|0
6239158|NCT01831089|9919633|FG001|Cohort III: Dose Level 3|Progressive disease|0
6239159|NCT01831089|9919634|FG002|Cohort III: Dose Level 3|Progressive disease|3
6239160|NCT01831089|9919635|FG003|Cohort III: Dose Level 3|Progressive disease|0
6239161|NCT01831089|9919636|FG004|Cohort III: Dose Level 3|Progressive disease|0
6239162|NCT01831089|9919637|FG005|Cohort III: Dose Level 3|Progressive disease|0
6239163|NCT01831089|9919632|FG000|Cohort III: Dose Level 3|Withdrawal by Subject|0
6239164|NCT01831089|9919633|FG001|Cohort III: Dose Level 3|Withdrawal by Subject|0
6239165|NCT01831089|9919634|FG002|Cohort III: Dose Level 3|Withdrawal by Subject|1
6239166|NCT01831089|9919635|FG003|Cohort III: Dose Level 3|Withdrawal by Subject|0
6085882|NCT00656513|9695473|FG001|Overall Study|Missing baseline form|5
6085883|NCT00656513|9695474|FG002|Overall Study|Missing baseline form|5
6085884|NCT00656617|9695482|FG000|Overall Study|Adverse Event|1
6085885|NCT00656617|9695482|FG000|Overall Study|Death|2
6239167|NCT01831089|9919636|FG004|Cohort III: Dose Level 3|Withdrawal by Subject|0
6085886|NCT00656617|9695482|FG000|Overall Study|Insurance Issues|2
6239168|NCT01831089|9919637|FG005|Cohort III: Dose Level 3|Withdrawal by Subject|0
6239169|NCT01831089|9919632|FG000|Cohort III: Dose Level 3|Adverse Event|0
6239170|NCT01831089|9919633|FG001|Cohort III: Dose Level 3|Adverse Event|0
6239171|NCT01831089|9919634|FG002|Cohort III: Dose Level 3|Adverse Event|1
6239172|NCT01831089|9919635|FG003|Cohort III: Dose Level 3|Adverse Event|0
6239173|NCT01831089|9919636|FG004|Cohort III: Dose Level 3|Adverse Event|0
6239174|NCT01831089|9919637|FG005|Cohort III: Dose Level 3|Adverse Event|0
6239175|NCT01831089|9919632|FG000|Cohort III: Dose Level 3|Global end of study|0
6239176|NCT01831089|9919633|FG001|Cohort III: Dose Level 3|Global end of study|0
6239177|NCT01831089|9919634|FG002|Cohort III: Dose Level 3|Global end of study|1
6239178|NCT01831089|9919635|FG003|Cohort III: Dose Level 3|Global end of study|0
6239179|NCT01831089|9919636|FG004|Cohort III: Dose Level 3|Global end of study|0
6239180|NCT01831089|9919637|FG005|Cohort III: Dose Level 3|Global end of study|0
6239181|NCT01831089|9919632|FG000|Cohort IV: Dose Level 4|Progressive disease|0
6239182|NCT01831089|9919633|FG001|Cohort IV: Dose Level 4|Progressive disease|0
6239183|NCT01831089|9919634|FG002|Cohort IV: Dose Level 4|Progressive disease|0
6239184|NCT01831089|9919635|FG003|Cohort IV: Dose Level 4|Progressive disease|6
6239185|NCT01831089|9919636|FG004|Cohort IV: Dose Level 4|Progressive disease|0
6239186|NCT01831089|9919637|FG005|Cohort IV: Dose Level 4|Progressive disease|0
6239187|NCT01831089|9919632|FG000|Cohort V: Dose Level 5|Progressive disease|0
6239188|NCT01831089|9919633|FG001|Cohort V: Dose Level 5|Progressive disease|0
6239189|NCT01831089|9919634|FG002|Cohort V: Dose Level 5|Progressive disease|0
6239190|NCT01831089|9919635|FG003|Cohort V: Dose Level 5|Progressive disease|0
6239191|NCT01831089|9919636|FG004|Cohort V: Dose Level 5|Progressive disease|30
6239192|NCT01831089|9919637|FG005|Cohort V: Dose Level 5|Progressive disease|0
6239193|NCT01831089|9919632|FG000|Cohort V: Dose Level 5|Withdrawal by Subject|0
6239194|NCT01831089|9919633|FG001|Cohort V: Dose Level 5|Withdrawal by Subject|0
6239195|NCT01831089|9919634|FG002|Cohort V: Dose Level 5|Withdrawal by Subject|0
6239196|NCT01831089|9919635|FG003|Cohort V: Dose Level 5|Withdrawal by Subject|0
6239197|NCT01831089|9919636|FG004|Cohort V: Dose Level 5|Withdrawal by Subject|3
6239198|NCT01831089|9919637|FG005|Cohort V: Dose Level 5|Withdrawal by Subject|0
6239199|NCT01831089|9919632|FG000|Cohort V: Dose Level 5|Death|0
6239200|NCT01831089|9919633|FG001|Cohort V: Dose Level 5|Death|0
6239201|NCT01831089|9919634|FG002|Cohort V: Dose Level 5|Death|0
6239202|NCT01831089|9919635|FG003|Cohort V: Dose Level 5|Death|0
6239203|NCT01831089|9919636|FG004|Cohort V: Dose Level 5|Death|1
6239204|NCT01831089|9919637|FG005|Cohort V: Dose Level 5|Death|0
6239205|NCT01831089|9919632|FG000|Cohort V: Dose Level 5|Global end of study|0
6239206|NCT01831089|9919633|FG001|Cohort V: Dose Level 5|Global end of study|0
6239207|NCT01831089|9919634|FG002|Cohort V: Dose Level 5|Global end of study|0
6239208|NCT01831089|9919635|FG003|Cohort V: Dose Level 5|Global end of study|0
6239209|NCT01831089|9919636|FG004|Cohort V: Dose Level 5|Global end of study|2
6239210|NCT01831089|9919637|FG005|Cohort V: Dose Level 5|Global end of study|0
6239211|NCT01831089|9919632|FG000|Cohort V: Dose Level 5|Lost to Follow-up|0
6239212|NCT01831089|9919633|FG001|Cohort V: Dose Level 5|Lost to Follow-up|0
6239213|NCT01831089|9919634|FG002|Cohort V: Dose Level 5|Lost to Follow-up|0
6239214|NCT01831089|9919635|FG003|Cohort V: Dose Level 5|Lost to Follow-up|0
6239215|NCT01831089|9919636|FG004|Cohort V: Dose Level 5|Lost to Follow-up|1
6239216|NCT01831089|9919637|FG005|Cohort V: Dose Level 5|Lost to Follow-up|0
6239217|NCT01831089|9919632|FG000|Cohort B: Arm B|Progressive disease|0
6239218|NCT01831089|9919633|FG001|Cohort B: Arm B|Progressive disease|0
6239219|NCT01831089|9919634|FG002|Cohort B: Arm B|Progressive disease|0
6239220|NCT01831089|9919635|FG003|Cohort B: Arm B|Progressive disease|0
6239221|NCT01831089|9919636|FG004|Cohort B: Arm B|Progressive disease|0
6239222|NCT01831089|9919637|FG005|Cohort B: Arm B|Progressive disease|8
6239223|NCT01831089|9919632|FG000|Cohort B: Arm B|Physician Decision|0
6239224|NCT01831089|9919633|FG001|Cohort B: Arm B|Physician Decision|0
6239225|NCT01831089|9919634|FG002|Cohort B: Arm B|Physician Decision|0
6239226|NCT01831089|9919635|FG003|Cohort B: Arm B|Physician Decision|0
6239227|NCT01831089|9919636|FG004|Cohort B: Arm B|Physician Decision|0
6239228|NCT01831089|9919637|FG005|Cohort B: Arm B|Physician Decision|2
6239229|NCT01831089|9919632|FG000|Cohort B: Arm B|Never treated|0
6239230|NCT01831089|9919633|FG001|Cohort B: Arm B|Never treated|0
6239231|NCT01831089|9919634|FG002|Cohort B: Arm B|Never treated|0
6239232|NCT01831089|9919635|FG003|Cohort B: Arm B|Never treated|0
6239233|NCT01831089|9919636|FG004|Cohort B: Arm B|Never treated|0
6239234|NCT01831089|9919637|FG005|Cohort B: Arm B|Never treated|2
6239235|NCT01831089|9919632|FG000|Cohort B: Arm B|Adverse Event|0
6239236|NCT01831089|9919633|FG001|Cohort B: Arm B|Adverse Event|0
6239237|NCT01831089|9919634|FG002|Cohort B: Arm B|Adverse Event|0
6239238|NCT01831089|9919635|FG003|Cohort B: Arm B|Adverse Event|0
6239239|NCT01831089|9919636|FG004|Cohort B: Arm B|Adverse Event|0
6239240|NCT01831089|9919637|FG005|Cohort B: Arm B|Adverse Event|1
6239241|NCT01831089|9919632|FG000|Cohort B: Arm B|Global end of study|0
6239242|NCT01831089|9919633|FG001|Cohort B: Arm B|Global end of study|0
6239243|NCT01831089|9919634|FG002|Cohort B: Arm B|Global end of study|0
6239244|NCT01831089|9919635|FG003|Cohort B: Arm B|Global end of study|0
6239245|NCT01831089|9919636|FG004|Cohort B: Arm B|Global end of study|0
6239246|NCT01831089|9919637|FG005|Cohort B: Arm B|Global end of study|1
6239247|NCT01831258|9919678|FG000|Overall Study|Withdrawal by Subject|2
6239248|NCT01831258|9919679|FG001|Overall Study|Withdrawal by Subject|1
6239249|NCT01831258|9919678|FG000|Overall Study|Lost to Follow-up|3
6239250|NCT01831258|9919679|FG001|Overall Study|Lost to Follow-up|2
6239251|NCT01831427|9919698|FG000|Overall Study|Adverse Event|0
6239252|NCT01831427|9919699|FG001|Overall Study|Adverse Event|1
6239253|NCT01831427|9919700|FG002|Overall Study|Adverse Event|0
6239254|NCT01831427|9919701|FG003|Overall Study|Adverse Event|0
6239255|NCT01831427|9919702|FG004|Overall Study|Adverse Event|0
6239256|NCT01831427|9919703|FG005|Overall Study|Adverse Event|1
6239257|NCT01831427|9919704|FG006|Overall Study|Adverse Event|0
6239258|NCT01831427|9919705|FG007|Overall Study|Adverse Event|1
6239259|NCT01831427|9919706|FG008|Overall Study|Adverse Event|0
6239260|NCT01831427|9919707|FG009|Overall Study|Adverse Event|0
6239261|NCT01831427|9919708|FG010|Overall Study|Adverse Event|2
6239262|NCT01831427|9919698|FG000|Overall Study|Investigator's Discretion|0
6239263|NCT01831427|9919699|FG001|Overall Study|Investigator's Discretion|0
6239264|NCT01831427|9919700|FG002|Overall Study|Investigator's Discretion|0
6239265|NCT01831427|9919701|FG003|Overall Study|Investigator's Discretion|1
6239266|NCT01831427|9919702|FG004|Overall Study|Investigator's Discretion|0
6239267|NCT01831427|9919703|FG005|Overall Study|Investigator's Discretion|0
6239268|NCT01831427|9919704|FG006|Overall Study|Investigator's Discretion|0
6239269|NCT01831427|9919705|FG007|Overall Study|Investigator's Discretion|0
6239270|NCT01831427|9919706|FG008|Overall Study|Investigator's Discretion|0
6239271|NCT01831427|9919707|FG009|Overall Study|Investigator's Discretion|0
6239272|NCT01831427|9919708|FG010|Overall Study|Investigator's Discretion|0
6239273|NCT01831427|9919698|FG000|Overall Study|Withdrew Consent|0
6239274|NCT01831427|9919699|FG001|Overall Study|Withdrew Consent|0
6239275|NCT01831427|9919700|FG002|Overall Study|Withdrew Consent|0
6239276|NCT01831427|9919701|FG003|Overall Study|Withdrew Consent|0
6239277|NCT01831427|9919702|FG004|Overall Study|Withdrew Consent|0
6239278|NCT01831427|9919703|FG005|Overall Study|Withdrew Consent|0
6239279|NCT01831427|9919704|FG006|Overall Study|Withdrew Consent|2
6239280|NCT01831427|9919705|FG007|Overall Study|Withdrew Consent|0
6239281|NCT01831427|9919706|FG008|Overall Study|Withdrew Consent|0
6239282|NCT01831427|9919707|FG009|Overall Study|Withdrew Consent|1
6239283|NCT01831427|9919708|FG010|Overall Study|Withdrew Consent|1
6239284|NCT01831466|9919755|FG000|Overall Study|Protocol Violation|1
6239285|NCT01831466|9919756|FG001|Overall Study|Protocol Violation|1
6239286|NCT01831466|9919757|FG002|Overall Study|Protocol Violation|2
6239287|NCT01831466|9919758|FG003|Overall Study|Protocol Violation|0
6239288|NCT01831466|9919759|FG004|Overall Study|Protocol Violation|0
6239289|NCT01831466|9919760|FG005|Overall Study|Protocol Violation|1
6239290|NCT01831466|9919761|FG006|Overall Study|Protocol Violation|0
6239291|NCT01831466|9919762|FG007|Overall Study|Protocol Violation|0
6239292|NCT01831466|9919763|FG008|Overall Study|Protocol Violation|0
6239293|NCT01831466|9919764|FG009|Overall Study|Protocol Violation|0
6239294|NCT01831466|9919765|FG010|Overall Study|Protocol Violation|0
6239295|NCT01831466|9919766|FG011|Overall Study|Protocol Violation|0
6239296|NCT01831466|9919755|FG000|Overall Study|Other|2
6239297|NCT01831466|9919756|FG001|Overall Study|Other|3
6239298|NCT01831466|9919757|FG002|Overall Study|Other|2
6239299|NCT01831466|9919758|FG003|Overall Study|Other|2
6239300|NCT01831466|9919759|FG004|Overall Study|Other|2
6239301|NCT01831466|9919760|FG005|Overall Study|Other|1
6239302|NCT01831466|9919761|FG006|Overall Study|Other|0
6239303|NCT01831466|9919762|FG007|Overall Study|Other|0
6239304|NCT01831466|9919763|FG008|Overall Study|Other|0
6239305|NCT01831466|9919764|FG009|Overall Study|Other|0
6239306|NCT01831466|9919765|FG010|Overall Study|Other|0
6239307|NCT01831466|9919766|FG011|Overall Study|Other|0
6239308|NCT01831466|9919755|FG000|Overall Study|Non-compliance with study treatment|2
6239309|NCT01831466|9919756|FG001|Overall Study|Non-compliance with study treatment|1
6239310|NCT01831466|9919757|FG002|Overall Study|Non-compliance with study treatment|1
6239311|NCT01831466|9919758|FG003|Overall Study|Non-compliance with study treatment|0
6239312|NCT01831466|9919759|FG004|Overall Study|Non-compliance with study treatment|0
6239313|NCT01831466|9919760|FG005|Overall Study|Non-compliance with study treatment|1
6239314|NCT01831466|9919761|FG006|Overall Study|Non-compliance with study treatment|0
6239315|NCT01831466|9919762|FG007|Overall Study|Non-compliance with study treatment|0
6239316|NCT01831466|9919763|FG008|Overall Study|Non-compliance with study treatment|0
6239317|NCT01831466|9919764|FG009|Overall Study|Non-compliance with study treatment|0
6239318|NCT01831466|9919765|FG010|Overall Study|Non-compliance with study treatment|0
6239319|NCT01831466|9919766|FG011|Overall Study|Non-compliance with study treatment|0
6239320|NCT01831466|9919755|FG000|Overall Study|Death|0
6239321|NCT01831466|9919756|FG001|Overall Study|Death|1
6239322|NCT01831466|9919757|FG002|Overall Study|Death|0
6239323|NCT01831466|9919758|FG003|Overall Study|Death|0
6239324|NCT01831466|9919759|FG004|Overall Study|Death|0
6239325|NCT01831466|9919760|FG005|Overall Study|Death|0
6239326|NCT01831466|9919761|FG006|Overall Study|Death|0
6239327|NCT01831466|9919762|FG007|Overall Study|Death|0
6239328|NCT01831466|9919763|FG008|Overall Study|Death|0
6239329|NCT01831466|9919764|FG009|Overall Study|Death|0
6239330|NCT01831466|9919765|FG010|Overall Study|Death|0
6239331|NCT01831466|9919766|FG011|Overall Study|Death|0
6239332|NCT01831466|9919755|FG000|Overall Study|Withdrawal by Subject|6
6239333|NCT01831466|9919756|FG001|Overall Study|Withdrawal by Subject|3
6239334|NCT01831466|9919757|FG002|Overall Study|Withdrawal by Subject|3
6239335|NCT01831466|9919758|FG003|Overall Study|Withdrawal by Subject|3
6239336|NCT01831466|9919759|FG004|Overall Study|Withdrawal by Subject|3
6239337|NCT01831466|9919760|FG005|Overall Study|Withdrawal by Subject|5
6239338|NCT01831466|9919761|FG006|Overall Study|Withdrawal by Subject|0
6239339|NCT01831466|9919762|FG007|Overall Study|Withdrawal by Subject|0
6239340|NCT01831466|9919763|FG008|Overall Study|Withdrawal by Subject|0
6239341|NCT01831466|9919764|FG009|Overall Study|Withdrawal by Subject|1
6239342|NCT01831466|9919765|FG010|Overall Study|Withdrawal by Subject|0
6239343|NCT01831466|9919766|FG011|Overall Study|Withdrawal by Subject|1
6239344|NCT01831466|9919755|FG000|Overall Study|Lost to Follow-up|0
6239345|NCT01831466|9919756|FG001|Overall Study|Lost to Follow-up|1
6239346|NCT01831466|9919757|FG002|Overall Study|Lost to Follow-up|4
6239347|NCT01831466|9919758|FG003|Overall Study|Lost to Follow-up|2
6239348|NCT01831466|9919759|FG004|Overall Study|Lost to Follow-up|0
6239349|NCT01831466|9919760|FG005|Overall Study|Lost to Follow-up|3
6239350|NCT01831466|9919761|FG006|Overall Study|Lost to Follow-up|0
6239351|NCT01831466|9919762|FG007|Overall Study|Lost to Follow-up|0
6239352|NCT01831466|9919763|FG008|Overall Study|Lost to Follow-up|0
6239353|NCT01831466|9919764|FG009|Overall Study|Lost to Follow-up|1
6239354|NCT01831466|9919765|FG010|Overall Study|Lost to Follow-up|0
6239355|NCT01831466|9919766|FG011|Overall Study|Lost to Follow-up|1
6239356|NCT01831466|9919755|FG000|Overall Study|Lack of Efficacy|5
6239357|NCT01831466|9919756|FG001|Overall Study|Lack of Efficacy|8
6239358|NCT01831466|9919757|FG002|Overall Study|Lack of Efficacy|7
6239359|NCT01831466|9919758|FG003|Overall Study|Lack of Efficacy|6
6239360|NCT01831466|9919759|FG004|Overall Study|Lack of Efficacy|9
6239361|NCT01831466|9919760|FG005|Overall Study|Lack of Efficacy|8
6239362|NCT01831466|9919761|FG006|Overall Study|Lack of Efficacy|1
6239363|NCT01831466|9919762|FG007|Overall Study|Lack of Efficacy|1
6239364|NCT01831466|9919763|FG008|Overall Study|Lack of Efficacy|2
6239365|NCT01831466|9919764|FG009|Overall Study|Lack of Efficacy|2
6239366|NCT01831466|9919765|FG010|Overall Study|Lack of Efficacy|2
6239367|NCT01831466|9919766|FG011|Overall Study|Lack of Efficacy|0
6239368|NCT01831466|9919755|FG000|Overall Study|Adverse Event|0
6239369|NCT01831466|9919756|FG001|Overall Study|Adverse Event|0
6239370|NCT01831466|9919757|FG002|Overall Study|Adverse Event|4
6239371|NCT01831466|9919758|FG003|Overall Study|Adverse Event|6
6239372|NCT01831466|9919759|FG004|Overall Study|Adverse Event|3
6239373|NCT01831466|9919760|FG005|Overall Study|Adverse Event|7
6239374|NCT01831466|9919761|FG006|Overall Study|Adverse Event|0
6239375|NCT01831466|9919762|FG007|Overall Study|Adverse Event|1
6239376|NCT01831466|9919763|FG008|Overall Study|Adverse Event|1
6239377|NCT01831466|9919764|FG009|Overall Study|Adverse Event|1
6239378|NCT01831466|9919765|FG010|Overall Study|Adverse Event|0
6239379|NCT01831466|9919766|FG011|Overall Study|Adverse Event|2
6239380|NCT01831544|9919786|FG000|Overall Study|Death|1
6239381|NCT01831544|9919786|FG000|Overall Study|Still on original MVAD device|2
6239382|NCT01831726|9919790|FG000|Overall Study|Adverse Event|16
6239383|NCT01831726|9919790|FG000|Overall Study|Death|7
6239384|NCT01831726|9919790|FG000|Overall Study|Disease Progression|49
6239385|NCT01831726|9919790|FG000|Overall Study|Physician Decision|1
6239386|NCT01831726|9919790|FG000|Overall Study|Subject/guardian decision|7
6239387|NCT01831765|9919797|FG000|Overall Study|Lack of Efficacy|1
6239388|NCT01831765|9919798|FG001|Overall Study|Lack of Efficacy|0
6239389|NCT01831765|9919799|FG002|Overall Study|Lack of Efficacy|0
6239390|NCT01831765|9919797|FG000|Overall Study|Other, sponsor withdrew subject|0
6239391|NCT01831765|9919798|FG001|Overall Study|Other, sponsor withdrew subject|1
6239392|NCT01831765|9919799|FG002|Overall Study|Other, sponsor withdrew subject|0
6239393|NCT01831765|9919797|FG000|Overall Study|Pregnancy|1
6239394|NCT01831765|9919798|FG001|Overall Study|Pregnancy|1
6239395|NCT01831765|9919799|FG002|Overall Study|Pregnancy|2
6239396|NCT01831765|9919797|FG000|Overall Study|Death|0
6239397|NCT01831765|9919798|FG001|Overall Study|Death|1
6239398|NCT01831765|9919799|FG002|Overall Study|Death|1
6239399|NCT01831765|9919797|FG000|Overall Study|Other, site closed|1
6239400|NCT01831765|9919798|FG001|Overall Study|Other, site closed|1
6239401|NCT01831765|9919799|FG002|Overall Study|Other, site closed|0
6239402|NCT01831765|9919797|FG000|Overall Study|Adverse Event|5
6239403|NCT01831765|9919798|FG001|Overall Study|Adverse Event|3
6239404|NCT01831765|9919799|FG002|Overall Study|Adverse Event|3
6239405|NCT01831765|9919797|FG000|Overall Study|Withdrawal by Subject|22
6239406|NCT01831765|9919798|FG001|Overall Study|Withdrawal by Subject|7
6239407|NCT01831765|9919799|FG002|Overall Study|Withdrawal by Subject|17
6239408|NCT01831765|9919797|FG000|Overall Study|Withdrawal criteria|12
6239409|NCT01831765|9919798|FG001|Overall Study|Withdrawal criteria|10
6239410|NCT01831765|9919799|FG002|Overall Study|Withdrawal criteria|16
6239411|NCT01831765|9919797|FG000|Overall Study|Lost to Follow-up|2
6239412|NCT01831765|9919798|FG001|Overall Study|Lost to Follow-up|3
6239413|NCT01831765|9919799|FG002|Overall Study|Lost to Follow-up|3
6239414|NCT01831791|9919809|FG000|Overall Study|Withdrawal by Subject|10
6239415|NCT01831804|9919822|FG000|Overall Study|Adverse Event|0
6239416|NCT01831804|9919823|FG001|Overall Study|Adverse Event|0
6239417|NCT01831804|9919824|FG002|Overall Study|Adverse Event|0
6239418|NCT01831804|9919825|FG003|Overall Study|Adverse Event|0
6239419|NCT01831804|9919826|FG004|Overall Study|Adverse Event|0
6239420|NCT01831804|9919827|FG005|Overall Study|Adverse Event|0
6239421|NCT01831804|9919828|FG006|Overall Study|Adverse Event|1
6239422|NCT01831804|9919829|FG007|Overall Study|Adverse Event|0
6239423|NCT01831804|9919830|FG008|Overall Study|Adverse Event|1
6239424|NCT01831804|9919822|FG000|Overall Study|Protocol Violation|0
6239425|NCT01831804|9919823|FG001|Overall Study|Protocol Violation|0
6239426|NCT01831804|9919824|FG002|Overall Study|Protocol Violation|2
6239427|NCT01831804|9919825|FG003|Overall Study|Protocol Violation|0
6239428|NCT01831804|9919826|FG004|Overall Study|Protocol Violation|0
6239429|NCT01831804|9919827|FG005|Overall Study|Protocol Violation|0
6239430|NCT01831804|9919828|FG006|Overall Study|Protocol Violation|0
6239431|NCT01831804|9919829|FG007|Overall Study|Protocol Violation|0
6239432|NCT01831804|9919830|FG008|Overall Study|Protocol Violation|0
6239433|NCT01831804|9919822|FG000|Overall Study|Protocol defined stopping criteria|1
6239434|NCT01831804|9919823|FG001|Overall Study|Protocol defined stopping criteria|1
6239435|NCT01831804|9919824|FG002|Overall Study|Protocol defined stopping criteria|3
6239436|NCT01831804|9919825|FG003|Overall Study|Protocol defined stopping criteria|0
6239437|NCT01831804|9919826|FG004|Overall Study|Protocol defined stopping criteria|1
6239438|NCT01831804|9919827|FG005|Overall Study|Protocol defined stopping criteria|0
6239439|NCT01831804|9919828|FG006|Overall Study|Protocol defined stopping criteria|0
6239440|NCT01831804|9919829|FG007|Overall Study|Protocol defined stopping criteria|0
6239441|NCT01831804|9919830|FG008|Overall Study|Protocol defined stopping criteria|0
6239442|NCT01831804|9919822|FG000|Overall Study|Lost to Follow-up|0
6239443|NCT01831804|9919823|FG001|Overall Study|Lost to Follow-up|0
6239444|NCT01831804|9919824|FG002|Overall Study|Lost to Follow-up|1
6239445|NCT01831804|9919825|FG003|Overall Study|Lost to Follow-up|0
6239446|NCT01831804|9919826|FG004|Overall Study|Lost to Follow-up|0
6239447|NCT01831804|9919827|FG005|Overall Study|Lost to Follow-up|0
6239448|NCT01831804|9919828|FG006|Overall Study|Lost to Follow-up|0
6239449|NCT01831804|9919829|FG007|Overall Study|Lost to Follow-up|0
6239450|NCT01831804|9919830|FG008|Overall Study|Lost to Follow-up|1
6239451|NCT01831804|9919822|FG000|Overall Study|Investigator discretion|0
6239452|NCT01831804|9919823|FG001|Overall Study|Investigator discretion|0
6239453|NCT01831804|9919824|FG002|Overall Study|Investigator discretion|0
6239454|NCT01831804|9919825|FG003|Overall Study|Investigator discretion|0
6239455|NCT01831804|9919826|FG004|Overall Study|Investigator discretion|1
6239456|NCT01831804|9919827|FG005|Overall Study|Investigator discretion|0
6239457|NCT01831804|9919828|FG006|Overall Study|Investigator discretion|0
6239458|NCT01831804|9919829|FG007|Overall Study|Investigator discretion|1
6239459|NCT01831804|9919830|FG008|Overall Study|Investigator discretion|0
6239460|NCT01831804|9919822|FG000|Overall Study|Withdrew Consent|0
6239461|NCT01831804|9919823|FG001|Overall Study|Withdrew Consent|1
6239462|NCT01831804|9919824|FG002|Overall Study|Withdrew Consent|0
6239463|NCT01831804|9919825|FG003|Overall Study|Withdrew Consent|0
6239464|NCT01831804|9919826|FG004|Overall Study|Withdrew Consent|0
6239465|NCT01831804|9919827|FG005|Overall Study|Withdrew Consent|0
6239466|NCT01831804|9919828|FG006|Overall Study|Withdrew Consent|0
6239467|NCT01831804|9919829|FG007|Overall Study|Withdrew Consent|2
6239468|NCT01831804|9919830|FG008|Overall Study|Withdrew Consent|0
6239469|NCT01831817|9919863|FG000|Overall Study|Lost to Follow-up|1
6239470|NCT01831817|9919864|FG001|Overall Study|Lost to Follow-up|0
6239471|NCT01831817|9919865|FG002|Overall Study|Lost to Follow-up|0
6239472|NCT01831817|9919866|FG003|Overall Study|Lost to Follow-up|0
6239473|NCT01831817|9919863|FG000|Overall Study|Withdrawl of Consent|3
6239474|NCT01831817|9919864|FG001|Overall Study|Withdrawl of Consent|0
6239475|NCT01831817|9919865|FG002|Overall Study|Withdrawl of Consent|0
6239476|NCT01831817|9919866|FG003|Overall Study|Withdrawl of Consent|0
6239477|NCT01831856|9919878|FG000|Overall Study|Adverse Event|5
6239478|NCT01831856|9919879|FG001|Overall Study|Adverse Event|8
6239479|NCT01831856|9919878|FG000|Overall Study|Lack of Efficacy|13
6239480|NCT01831856|9919879|FG001|Overall Study|Lack of Efficacy|11
6239481|NCT01831856|9919878|FG000|Overall Study|Unsuccessful Electrical Cardioversion|16
6239482|NCT01831856|9919879|FG001|Overall Study|Unsuccessful Electrical Cardioversion|18
6239483|NCT01832038|9919916|FG000|Overall Study|Death|5
6239484|NCT01832038|9919916|FG000|Overall Study|Adverse Event|50
6239485|NCT01832038|9919916|FG000|Overall Study|Lack of Efficacy|81
6239486|NCT01832038|9919916|FG000|Overall Study|Protocol Violation|7
6239487|NCT01832038|9919916|FG000|Overall Study|Lost to Follow-up|10
6239488|NCT01832038|9919916|FG000|Overall Study|Withdrawal by Subject|49
6239489|NCT01832038|9919916|FG000|Overall Study|Visit non-compliance|2
6239490|NCT01832038|9919916|FG000|Overall Study|Subject refused to return visit|2
6239491|NCT01832038|9919916|FG000|Overall Study|Not convenient to come back to site|2
6239492|NCT01832038|9919916|FG000|Overall Study|Participant was asked to quit|5
6239493|NCT01832038|9919916|FG000|Overall Study|Back home|1
6239494|NCT01832038|9919916|FG000|Overall Study|Pregnancy|1
6239495|NCT01832038|9919916|FG000|Overall Study|Low compliance|3
6239496|NCT01832038|9919916|FG000|Overall Study|Prohibit procedure|2
6239497|NCT01832038|9919916|FG000|Overall Study|Not possible to visit the hospital|1
6239498|NCT01832038|9919916|FG000|Overall Study|Changes of implementation system|3
6239499|NCT01832038|9919916|FG000|Overall Study|Plan to pregnancy|7
6239500|NCT01832038|9919916|FG000|Overall Study|Bad mood and has suicidal thought|1
6239501|NCT01832038|9919916|FG000|Overall Study|Prohibited concomitant medication|1
6239502|NCT01832038|9919916|FG000|Overall Study|Pregnancy and abortion in EP0008 study|1
6239503|NCT01832038|9919916|FG000|Overall Study|Subject considered the efficacy was poor|1
6239504|NCT01832155|9919952|FG000|Beginning of Study: Baseline at 0 Week|Withdrawal by Subject|1
6239505|NCT01832155|9919953|FG001|Beginning of Study: Baseline at 0 Week|Withdrawal by Subject|0
6239506|NCT01832155|9919952|FG000|Mid-point of Study: 0 - 4 Weeks|Protocol Violation|1
6239507|NCT01832155|9919953|FG001|Mid-point of Study: 0 - 4 Weeks|Protocol Violation|0
6239508|NCT01832402|9919976|FG000|Overall Study|Lost to Follow-up|2
6239509|NCT01832402|9919977|FG001|Overall Study|Lost to Follow-up|0
6239510|NCT01832402|9919976|FG000|Overall Study|Withdrawal by Subject|3
6239511|NCT01832402|9919977|FG001|Overall Study|Withdrawal by Subject|3
6239512|NCT01832402|9919976|FG000|Overall Study|Declining Performance status|2
6239513|NCT01832402|9919977|FG001|Overall Study|Declining Performance status|1
6239514|NCT01832480|9919989|FG000|Overall Study|Lost to Follow-up|33
6239515|NCT01832480|9919990|FG001|Overall Study|Lost to Follow-up|30
6239516|NCT01832480|9919989|FG000|Overall Study|Withdrawal by Subject|0
6239517|NCT01832480|9919990|FG001|Overall Study|Withdrawal by Subject|2
6239518|NCT01832480|9919989|FG000|Overall Study|post randomization ineligible|8
6239519|NCT01832480|9919990|FG001|Overall Study|post randomization ineligible|10
6239520|NCT01832493|9919996|FG000|Overall Study|Physician Decision|2
6239521|NCT01832493|9919996|FG000|Overall Study|Protocol Violation|4
6085887|NCT00656617|9695482|FG000|Overall Study|Move to different clinical trial|2
6085888|NCT00656669|9695504|FG000|Paclitaxel/Sunitinib (Cycles 2-5)|Adverse Event|4
6239522|NCT01832493|9919996|FG000|Overall Study|Unable to place LV lead|2
6239523|NCT01832532|9920020|FG000|Overall Study|Withdrawal by Subject|5
6239524|NCT01832532|9920021|FG001|Overall Study|Withdrawal by Subject|2
6239525|NCT01832727|9920040|FG000|Overall Study|Adverse Event|4
6239526|NCT01832727|9920041|FG001|Overall Study|Adverse Event|6
6239527|NCT01832727|9920042|FG002|Overall Study|Adverse Event|1
6239528|NCT01832727|9920043|FG003|Overall Study|Adverse Event|0
6239529|NCT01832727|9920044|FG004|Overall Study|Adverse Event|1
6239530|NCT01832727|9920045|FG005|Overall Study|Adverse Event|1
6239531|NCT01832727|9920046|FG006|Overall Study|Adverse Event|2
6239532|NCT01832727|9920047|FG007|Overall Study|Adverse Event|1
6239533|NCT01832727|9920048|FG008|Overall Study|Adverse Event|9
6239534|NCT01832727|9920040|FG000|Overall Study|Disease progression|3
6239535|NCT01832727|9920041|FG001|Overall Study|Disease progression|0
6239536|NCT01832727|9920042|FG002|Overall Study|Disease progression|2
6239537|NCT01832727|9920043|FG003|Overall Study|Disease progression|1
6239538|NCT01832727|9920044|FG004|Overall Study|Disease progression|3
6239539|NCT01832727|9920045|FG005|Overall Study|Disease progression|3
6239540|NCT01832727|9920046|FG006|Overall Study|Disease progression|6
6239541|NCT01832727|9920047|FG007|Overall Study|Disease progression|2
6239542|NCT01832727|9920048|FG008|Overall Study|Disease progression|7
6239543|NCT01832727|9920040|FG000|Overall Study|Lost to Follow-up|0
6239544|NCT01832727|9920041|FG001|Overall Study|Lost to Follow-up|0
6239545|NCT01832727|9920042|FG002|Overall Study|Lost to Follow-up|0
6239546|NCT01832727|9920043|FG003|Overall Study|Lost to Follow-up|1
6239547|NCT01832727|9920044|FG004|Overall Study|Lost to Follow-up|0
6239548|NCT01832727|9920045|FG005|Overall Study|Lost to Follow-up|0
6239549|NCT01832727|9920046|FG006|Overall Study|Lost to Follow-up|0
6239550|NCT01832727|9920047|FG007|Overall Study|Lost to Follow-up|0
6239551|NCT01832727|9920048|FG008|Overall Study|Lost to Follow-up|0
6239552|NCT01832727|9920040|FG000|Overall Study|Physician Decision|1
6239553|NCT01832727|9920041|FG001|Overall Study|Physician Decision|0
6239554|NCT01832727|9920042|FG002|Overall Study|Physician Decision|0
6239555|NCT01832727|9920043|FG003|Overall Study|Physician Decision|1
6239556|NCT01832727|9920044|FG004|Overall Study|Physician Decision|0
6239557|NCT01832727|9920045|FG005|Overall Study|Physician Decision|1
6239558|NCT01832727|9920046|FG006|Overall Study|Physician Decision|0
6239559|NCT01832727|9920047|FG007|Overall Study|Physician Decision|0
6239560|NCT01832727|9920048|FG008|Overall Study|Physician Decision|0
6239561|NCT01832727|9920040|FG000|Overall Study|Withdrawal by Subject|1
6239562|NCT01832727|9920041|FG001|Overall Study|Withdrawal by Subject|1
6239563|NCT01832727|9920042|FG002|Overall Study|Withdrawal by Subject|0
6239564|NCT01832727|9920043|FG003|Overall Study|Withdrawal by Subject|1
6239565|NCT01832727|9920044|FG004|Overall Study|Withdrawal by Subject|0
6239566|NCT01832727|9920045|FG005|Overall Study|Withdrawal by Subject|1
6239567|NCT01832727|9920046|FG006|Overall Study|Withdrawal by Subject|0
6239568|NCT01832727|9920047|FG007|Overall Study|Withdrawal by Subject|2
6239569|NCT01832727|9920048|FG008|Overall Study|Withdrawal by Subject|1
6239570|NCT01832727|9920040|FG000|Overall Study|Study terminated by sponsor|0
6239571|NCT01832727|9920041|FG001|Overall Study|Study terminated by sponsor|0
6239572|NCT01832727|9920042|FG002|Overall Study|Study terminated by sponsor|0
6239573|NCT01832727|9920043|FG003|Overall Study|Study terminated by sponsor|0
6239574|NCT01832727|9920044|FG004|Overall Study|Study terminated by sponsor|0
6085889|NCT00656669|9695504|FG000|Paclitaxel/Sunitinib (Cycles 2-5)|Physician Decision|2
6239575|NCT01832727|9920045|FG005|Overall Study|Study terminated by sponsor|0
6239576|NCT01832727|9920046|FG006|Overall Study|Study terminated by sponsor|0
6239577|NCT01832727|9920047|FG007|Overall Study|Study terminated by sponsor|1
6239578|NCT01832727|9920048|FG008|Overall Study|Study terminated by sponsor|1
6239579|NCT01832766|9920091|FG000|Washout|Lost to Follow-up|0
6239580|NCT01832766|9920092|FG001|Washout|Lost to Follow-up|1
6239581|NCT01832818|9920098|FG000|Overall Study|Lost to Follow-up|6
6239582|NCT01833065|9920130|FG000|Overall Study|Adverse Event|6
6239583|NCT01833065|9920131|FG001|Overall Study|Adverse Event|1
6239584|NCT01833065|9920132|FG002|Overall Study|Adverse Event|0
6239585|NCT01833065|9920133|FG003|Overall Study|Adverse Event|2
6239586|NCT01833065|9920134|FG004|Overall Study|Adverse Event|3
6239587|NCT01833065|9920130|FG000|Overall Study|Protocol Violation|1
6239588|NCT01833065|9920131|FG001|Overall Study|Protocol Violation|0
6239589|NCT01833065|9920132|FG002|Overall Study|Protocol Violation|0
6239590|NCT01833065|9920133|FG003|Overall Study|Protocol Violation|0
6239591|NCT01833065|9920134|FG004|Overall Study|Protocol Violation|2
6239592|NCT01833065|9920130|FG000|Overall Study|Lost to Follow-up|1
6239593|NCT01833065|9920131|FG001|Overall Study|Lost to Follow-up|0
6239594|NCT01833065|9920132|FG002|Overall Study|Lost to Follow-up|0
6239595|NCT01833065|9920133|FG003|Overall Study|Lost to Follow-up|0
6239596|NCT01833065|9920134|FG004|Overall Study|Lost to Follow-up|3
6239597|NCT01833065|9920130|FG000|Overall Study|Withdrawal by Subject|6
6239598|NCT01833065|9920131|FG001|Overall Study|Withdrawal by Subject|2
6239599|NCT01833065|9920132|FG002|Overall Study|Withdrawal by Subject|4
6239600|NCT01833065|9920133|FG003|Overall Study|Withdrawal by Subject|3
6239601|NCT01833065|9920134|FG004|Overall Study|Withdrawal by Subject|11
6239602|NCT01833065|9920130|FG000|Overall Study|Subject's substantial non-compliance|0
6239603|NCT01833065|9920131|FG001|Overall Study|Subject's substantial non-compliance|1
6239604|NCT01833065|9920132|FG002|Overall Study|Subject's substantial non-compliance|0
6239605|NCT01833065|9920133|FG003|Overall Study|Subject's substantial non-compliance|0
6239606|NCT01833065|9920134|FG004|Overall Study|Subject's substantial non-compliance|0
6239607|NCT01833065|9920130|FG000|Overall Study|Trial terminated by sponsor|8
6239608|NCT01833065|9920131|FG001|Overall Study|Trial terminated by sponsor|8
6239609|NCT01833065|9920132|FG002|Overall Study|Trial terminated by sponsor|7
6239610|NCT01833065|9920133|FG003|Overall Study|Trial terminated by sponsor|3
6239611|NCT01833065|9920134|FG004|Overall Study|Trial terminated by sponsor|13
6239612|NCT01833065|9920130|FG000|Overall Study|Others|2
6239613|NCT01833065|9920131|FG001|Overall Study|Others|1
6239614|NCT01833065|9920132|FG002|Overall Study|Others|1
6239615|NCT01833065|9920133|FG003|Overall Study|Others|1
6239616|NCT01833065|9920134|FG004|Overall Study|Others|4
6239617|NCT01833143|9920166|FG000|Overall Study|Not Treated|1
6239618|NCT01833169|9920170|FG000|Overall Study|Disease Progression|99
6239619|NCT01833169|9920170|FG000|Overall Study|Adverse Event|33
6239620|NCT01833169|9920170|FG000|Overall Study|Withdrawal by Subject|9
6239621|NCT01833169|9920170|FG000|Overall Study|Death|3
6239622|NCT01833169|9920170|FG000|Overall Study|Physician Decision|2
6270208|NCT02149420|9970940|FG002|Core Study|Administrative problems|2
6270209|NCT02149420|9970938|FG000|Open Label VAY736 10 mg/kg Extension|Administrative problems|1
6270210|NCT02149420|9970939|FG001|Open Label VAY736 10 mg/kg Extension|Administrative problems|0
6270211|NCT02149420|9970940|FG002|Open Label VAY736 10 mg/kg Extension|Administrative problems|0
6270212|NCT02149810|9970964|FG000|Overall Study|Physician Decision|1
6270213|NCT02149810|9970965|FG001|Overall Study|Physician Decision|2
6270214|NCT02149810|9970964|FG000|Overall Study|Lost to Follow-up|2
6270215|NCT02149810|9970965|FG001|Overall Study|Lost to Follow-up|1
6270216|NCT02149810|9970964|FG000|Overall Study|Withdrawal by Subject|5
6270217|NCT02149810|9970965|FG001|Overall Study|Withdrawal by Subject|1
6270218|NCT02149836|9970971|FG000|Overall Study|Withdrawal by Subject|1
6270219|NCT02149875|9970978|FG000|Overall Study|Lost to Follow-up|3
6270220|NCT02149875|9970979|FG001|Overall Study|Lost to Follow-up|4
6270221|NCT02149875|9970980|FG002|Overall Study|Lost to Follow-up|5
6270222|NCT02149875|9970978|FG000|Overall Study|Withdrawal by Subject|3
6270223|NCT02149875|9970979|FG001|Overall Study|Withdrawal by Subject|2
6270224|NCT02149875|9970980|FG002|Overall Study|Withdrawal by Subject|2
6270225|NCT02149875|9970978|FG000|Overall Study|Physician Decision|1
6270226|NCT02149875|9970979|FG001|Overall Study|Physician Decision|2
6270227|NCT02149875|9970980|FG002|Overall Study|Physician Decision|2
6270228|NCT02150057|9970994|FG000|Overall Study|Lost to Follow-up|6
6270229|NCT02150057|9970995|FG001|Overall Study|Lost to Follow-up|4
6270230|NCT02150213|9971011|FG000|Overall Study|Lost to Follow-up|1
6270231|NCT02150213|9971011|FG000|Overall Study|Withdrawal by Subject|1
6270232|NCT02150343|9971019|FG000|Overall Study|Adverse Event|2
6270233|NCT02150343|9971020|FG001|Overall Study|Adverse Event|0
6270234|NCT02150343|9971021|FG002|Overall Study|Adverse Event|1
6270235|NCT02150343|9971022|FG003|Overall Study|Adverse Event|1
6270236|NCT02150343|9971019|FG000|Overall Study|Withdrawal by Subject|13
6270237|NCT02150343|9971020|FG001|Overall Study|Withdrawal by Subject|10
6270238|NCT02150343|9971021|FG002|Overall Study|Withdrawal by Subject|9
6270239|NCT02150343|9971022|FG003|Overall Study|Withdrawal by Subject|4
6270240|NCT02150343|9971019|FG000|Overall Study|Lost to Follow-up|4
6270241|NCT02150343|9971020|FG001|Overall Study|Lost to Follow-up|4
6270242|NCT02150343|9971021|FG002|Overall Study|Lost to Follow-up|2
6270243|NCT02150343|9971022|FG003|Overall Study|Lost to Follow-up|3
6270244|NCT02150343|9971019|FG000|Overall Study|Other|2
6270245|NCT02150343|9971020|FG001|Overall Study|Other|6
6270246|NCT02150343|9971021|FG002|Overall Study|Other|0
6270247|NCT02150343|9971022|FG003|Overall Study|Other|2
6270248|NCT02150954|9971070|FG000|Overall Study|Protocol Violation|1
6270249|NCT02150954|9971071|FG001|Overall Study|Protocol Violation|0
6270250|NCT02151058|9971080|FG000|Overall Study|Withdrawal by Subject|1
6239623|NCT01833455|9920185|FG000|Overall Study|Withdrawal by Subject|1
6239624|NCT01833455|9920186|FG001|Overall Study|Withdrawal by Subject|0
6239625|NCT01833494|9920217|FG000|Overall Study|Adverse Event|24
6239626|NCT01833494|9920217|FG000|Overall Study|Physician Decision|6
6239627|NCT01833494|9920217|FG000|Overall Study|Withdrawal by Subject|6
6239628|NCT01833494|9920217|FG000|Overall Study|Decrease in serum phosphorus|4
6239629|NCT01833494|9920217|FG000|Overall Study|Decrease in serum calcium|4
6239630|NCT01833494|9920217|FG000|Overall Study|Increase in serum ferritin|1
6239631|NCT01833520|9920223|FG000|Overall Study|Lack of Efficacy|3
6239632|NCT01833520|9920224|FG001|Overall Study|Lack of Efficacy|3
6239633|NCT01833520|9920225|FG002|Overall Study|Lack of Efficacy|8
6239634|NCT01833520|9920226|FG003|Overall Study|Lack of Efficacy|3
6239635|NCT01833533|9920240|FG000|Overall Study|Adverse Event|0
6239636|NCT01833533|9920241|FG001|Overall Study|Adverse Event|1
6239637|NCT01833533|9920240|FG000|Overall Study|Lost to Follow-up|4
6239638|NCT01833533|9920241|FG001|Overall Study|Lost to Follow-up|9
6239639|NCT01833533|9920240|FG000|Overall Study|To Enter an Extension Study|0
6239640|NCT01833533|9920241|FG001|Overall Study|To Enter an Extension Study|4
6239641|NCT01833533|9920240|FG000|Overall Study|Other|2
6239642|NCT01833533|9920241|FG001|Overall Study|Other|7
6239643|NCT01833832|9920282|FG000|Overall Study|Pt could not be cytoreduced for HIPEC|1
6239644|NCT01833897|9920290|FG000|Overall Study|Lack of Efficacy|1
6239645|NCT01834222|9920324|FG000|Overall Study|Not meet inclusion/exclusion criteria|1
6239646|NCT01834274|9920339|FG000|Overall Study|Study Termination|41
6239647|NCT01834274|9920340|FG001|Overall Study|Study Termination|38
6239648|NCT01834274|9920339|FG000|Overall Study|Withdrawal by Subject|1
6239649|NCT01834274|9920340|FG001|Overall Study|Withdrawal by Subject|1
6239650|NCT01834274|9920339|FG000|Overall Study|Lost to Follow-up|3
6239651|NCT01834274|9920340|FG001|Overall Study|Lost to Follow-up|1
6239652|NCT01834274|9920339|FG000|Overall Study|Other|2
6085890|NCT00656669|9695504|FG000|AC (Cycles 6-9)|Adverse Event|1
6085891|NCT00656669|9695504|FG000|AC (Cycles 6-9)|Did not start segment 3|1
6085892|NCT00656799|9695513|FG000|Overall Study|Death|2
6085893|NCT00656851|9695519|FG000|Overall Study|Withdrawal by Subject|0
6085894|NCT00656851|9695520|FG001|Overall Study|Withdrawal by Subject|4
6085895|NCT00657020|9695535|FG000|PERIOD 1|Adverse Event|0
6085896|NCT00657020|9695536|FG001|PERIOD 1|Adverse Event|1
6085897|NCT00657046|9695551|FG000|Overall Study|Adverse Event|1
6239653|NCT01834274|9920340|FG001|Overall Study|Other|1
6239654|NCT01834586|9920364|FG000|Overall Study|Adverse Event|1
6239655|NCT01834729|9920387|FG000|Overall Study|Did not return bowel diaries|0
6239656|NCT01834729|9920388|FG001|Overall Study|Did not return bowel diaries|0
6239657|NCT01834729|9920389|FG002|Overall Study|Did not return bowel diaries|3
6239658|NCT01834729|9920390|FG003|Overall Study|Did not return bowel diaries|0
6239659|NCT01834729|9920387|FG000|Overall Study|Withdrawal by Subject|1
6239660|NCT01834729|9920388|FG001|Overall Study|Withdrawal by Subject|1
6239661|NCT01834729|9920389|FG002|Overall Study|Withdrawal by Subject|0
6239662|NCT01834729|9920390|FG003|Overall Study|Withdrawal by Subject|0
6239663|NCT01834729|9920387|FG000|Overall Study|Adverse Event|0
6239664|NCT01834729|9920388|FG001|Overall Study|Adverse Event|0
6239665|NCT01834729|9920389|FG002|Overall Study|Adverse Event|0
6239666|NCT01834729|9920390|FG003|Overall Study|Adverse Event|2
6239667|NCT01835015|9920406|FG000|Overall Study|Adverse Event|0
6239668|NCT01835015|9920407|FG001|Overall Study|Adverse Event|0
6239669|NCT01835015|9920408|FG002|Overall Study|Adverse Event|1
6239670|NCT01835015|9920409|FG003|Overall Study|Adverse Event|0
6239671|NCT01835015|9920410|FG004|Overall Study|Adverse Event|0
6239672|NCT01835132|9920423|FG000|Initial Phase|Insufficient Therapeutic Response|2
6239673|NCT01835158|9920429|FG000|Overall Study|Withdrawal by Subject|1
6239674|NCT01835158|9920430|FG001|Overall Study|Withdrawal by Subject|6
6239675|NCT01835223|9920438|FG000|Overall Study|Adverse Event|1
6239676|NCT01835223|9920439|FG001|Overall Study|Adverse Event|0
6239677|NCT01835223|9920438|FG000|Overall Study|Withdrawal by Subject|2
6239678|NCT01835223|9920439|FG001|Overall Study|Withdrawal by Subject|0
6239679|NCT01835223|9920438|FG000|Overall Study|Disease progression|2
6239680|NCT01835223|9920439|FG001|Overall Study|Disease progression|1
6239681|NCT01835223|9920438|FG000|Overall Study|Became Inelligible|4
6239682|NCT01835223|9920439|FG001|Overall Study|Became Inelligible|0
6239683|NCT01835431|9920467|FG000|Overall Study|Adverse Event|1
6239684|NCT01835431|9920468|FG001|Overall Study|Adverse Event|0
6239685|NCT01835431|9920467|FG000|Overall Study|other|0
6239686|NCT01835431|9920468|FG001|Overall Study|other|2
6085898|NCT00657046|9695552|FG001|Overall Study|Adverse Event|1
6085899|NCT00657046|9695553|FG002|Overall Study|Adverse Event|0
6239687|NCT01835431|9920467|FG000|Overall Study|Withdrawal by Subject|6
6239688|NCT01835431|9920468|FG001|Overall Study|Withdrawal by Subject|10
6239689|NCT01835431|9920467|FG000|Overall Study|Protocol Violation|1
6239690|NCT01835431|9920468|FG001|Overall Study|Protocol Violation|0
6239691|NCT01835470|9920474|FG000|Long Term Treatment Period|Subject Request to Discontinue|1
6239692|NCT01835470|9920474|FG000|Long Term Treatment Period|Lack of Efficacy|3
6239693|NCT01835548|9920485|FG000|Dose Optimization Period|Adverse Event|0
6085900|NCT00657046|9695551|FG000|Overall Study|Protocol Violation|2
6239694|NCT01835548|9920486|FG001|Dose Optimization Period|Adverse Event|0
6085901|NCT00657046|9695552|FG001|Overall Study|Protocol Violation|2
6239695|NCT01835548|9920487|FG002|Dose Optimization Period|Adverse Event|1
6239696|NCT01835548|9920485|FG000|Dose Optimization Period|Withdrawal by Subject|0
6239697|NCT01835548|9920486|FG001|Dose Optimization Period|Withdrawal by Subject|0
6239698|NCT01835548|9920487|FG002|Dose Optimization Period|Withdrawal by Subject|1
6239699|NCT01835548|9920485|FG000|Double-Blind Treatment Period|Adverse Event|0
6239700|NCT01835548|9920486|FG001|Double-Blind Treatment Period|Adverse Event|1
6239701|NCT01835548|9920487|FG002|Double-Blind Treatment Period|Adverse Event|0
6239702|NCT01835548|9920485|FG000|Double-Blind Treatment Period|Withdrawal by Subject|0
6239703|NCT01835548|9920486|FG001|Double-Blind Treatment Period|Withdrawal by Subject|1
6239704|NCT01835548|9920487|FG002|Double-Blind Treatment Period|Withdrawal by Subject|0
6239705|NCT01835587|9920503|FG000|Overall Study|Disease Recurrence or Relapse|0
6239706|NCT01835587|9920504|FG001|Overall Study|Disease Recurrence or Relapse|3
6239707|NCT01835587|9920505|FG002|Overall Study|Disease Recurrence or Relapse|0
6239708|NCT01835587|9920506|FG003|Overall Study|Disease Recurrence or Relapse|3
6239709|NCT01835587|9920503|FG000|Overall Study|Withdrawal by Subject|2
6239710|NCT01835587|9920504|FG001|Overall Study|Withdrawal by Subject|0
6239711|NCT01835587|9920505|FG002|Overall Study|Withdrawal by Subject|0
6239712|NCT01835587|9920506|FG003|Overall Study|Withdrawal by Subject|3
6085902|NCT00657046|9695553|FG002|Overall Study|Protocol Violation|0
6085903|NCT00657046|9695551|FG000|Overall Study|Withdrawal by Subject|1
6085904|NCT00657046|9695552|FG001|Overall Study|Withdrawal by Subject|0
6239713|NCT01835587|9920503|FG000|Overall Study|Adverse Event|0
6239714|NCT01835587|9920504|FG001|Overall Study|Adverse Event|0
6239715|NCT01835587|9920505|FG002|Overall Study|Adverse Event|2
6239716|NCT01835587|9920506|FG003|Overall Study|Adverse Event|2
6239717|NCT01835587|9920503|FG000|Overall Study|Death|0
6239718|NCT01835587|9920504|FG001|Overall Study|Death|0
6239719|NCT01835587|9920505|FG002|Overall Study|Death|0
6239720|NCT01835587|9920506|FG003|Overall Study|Death|1
6239721|NCT01835587|9920503|FG000|Overall Study|Miscellaneous|0
6239722|NCT01835587|9920504|FG001|Overall Study|Miscellaneous|1
6239723|NCT01835587|9920505|FG002|Overall Study|Miscellaneous|0
6239724|NCT01835587|9920506|FG003|Overall Study|Miscellaneous|0
6239725|NCT01835899|9920550|FG000|Overall Study|Adverse Event|0
6239726|NCT01835899|9920551|FG001|Overall Study|Adverse Event|0
6239727|NCT01835899|9920552|FG002|Overall Study|Adverse Event|1
6239728|NCT01835899|9920550|FG000|Overall Study|Other than stated above|0
6239729|NCT01835899|9920551|FG001|Overall Study|Other than stated above|1
6239730|NCT01835899|9920552|FG002|Overall Study|Other than stated above|0
6239731|NCT01836198|9920617|FG000|Part A, Period 2|Protocol Violation|0
6239732|NCT01836198|9920618|FG001|Part A, Period 2|Protocol Violation|1
6239733|NCT01836198|9920619|FG002|Part A, Period 2|Protocol Violation|0
6239734|NCT01836276|9920637|FG000|Overall Study|Lost to Follow-up|28
6239735|NCT01836276|9920638|FG001|Overall Study|Lost to Follow-up|51
6239736|NCT01836458|9920657|FG000|Overall Study|Unsatisfactory therapeutic effect|3
6239737|NCT01836458|9920658|FG001|Overall Study|Unsatisfactory therapeutic effect|2
6239738|NCT01836458|9920659|FG002|Overall Study|Unsatisfactory therapeutic effect|5
6239739|NCT01836458|9920660|FG003|Overall Study|Unsatisfactory therapeutic effect|6
6239740|NCT01836471|9920675|FG000|Overall Study|Pregnancy|1
6239741|NCT01836471|9920676|FG001|Overall Study|Pregnancy|0
6239742|NCT01836471|9920677|FG002|Overall Study|Pregnancy|0
6239743|NCT01836471|9920678|FG003|Overall Study|Pregnancy|0
6239744|NCT01836471|9920679|FG004|Overall Study|Pregnancy|0
6239745|NCT01836471|9920675|FG000|Overall Study|Withdrawal by Subject|3
6239746|NCT01836471|9920676|FG001|Overall Study|Withdrawal by Subject|4
6239747|NCT01836471|9920677|FG002|Overall Study|Withdrawal by Subject|1
6239748|NCT01836471|9920678|FG003|Overall Study|Withdrawal by Subject|0
6239749|NCT01836471|9920679|FG004|Overall Study|Withdrawal by Subject|2
6239750|NCT01836471|9920675|FG000|Overall Study|Physician Decision|0
6239751|NCT01836471|9920676|FG001|Overall Study|Physician Decision|1
6239752|NCT01836471|9920677|FG002|Overall Study|Physician Decision|0
6239753|NCT01836471|9920678|FG003|Overall Study|Physician Decision|0
6239754|NCT01836471|9920679|FG004|Overall Study|Physician Decision|0
6239755|NCT01836471|9920675|FG000|Overall Study|Lost to Follow-up|0
6239756|NCT01836471|9920676|FG001|Overall Study|Lost to Follow-up|0
6239757|NCT01836471|9920677|FG002|Overall Study|Lost to Follow-up|0
6239758|NCT01836471|9920678|FG003|Overall Study|Lost to Follow-up|1
6239759|NCT01836471|9920679|FG004|Overall Study|Lost to Follow-up|1
6239760|NCT01836471|9920675|FG000|Overall Study|Adverse Event|6
6239761|NCT01836471|9920676|FG001|Overall Study|Adverse Event|3
6239762|NCT01836471|9920677|FG002|Overall Study|Adverse Event|1
6239763|NCT01836471|9920678|FG003|Overall Study|Adverse Event|1
6239764|NCT01836471|9920679|FG004|Overall Study|Adverse Event|2
6239765|NCT01836471|9920675|FG000|Overall Study|Non compliance with tx|1
6239766|NCT01836471|9920676|FG001|Overall Study|Non compliance with tx|1
6239767|NCT01836471|9920677|FG002|Overall Study|Non compliance with tx|0
6239768|NCT01836471|9920678|FG003|Overall Study|Non compliance with tx|0
6239769|NCT01836471|9920679|FG004|Overall Study|Non compliance with tx|0
6239770|NCT01836523|9920696|FG000|Overall Study|Adverse Event|15
6085905|NCT00657046|9695553|FG002|Overall Study|Withdrawal by Subject|0
6239771|NCT01836523|9920697|FG001|Overall Study|Adverse Event|41
6085906|NCT00657046|9695551|FG000|Overall Study|Death|0
6239772|NCT01836523|9920698|FG002|Overall Study|Adverse Event|49
6239773|NCT01836523|9920699|FG003|Overall Study|Adverse Event|14
6239774|NCT01836523|9920696|FG000|Overall Study|Protocol Violation|6
6239775|NCT01836523|9920697|FG001|Overall Study|Protocol Violation|3
6239776|NCT01836523|9920698|FG002|Overall Study|Protocol Violation|2
6239777|NCT01836523|9920699|FG003|Overall Study|Protocol Violation|4
6239778|NCT01836523|9920696|FG000|Overall Study|Met Withdrawal Criteria|13
6239779|NCT01836523|9920697|FG001|Overall Study|Met Withdrawal Criteria|13
6239780|NCT01836523|9920698|FG002|Overall Study|Met Withdrawal Criteria|21
6239781|NCT01836523|9920699|FG003|Overall Study|Met Withdrawal Criteria|27
6239782|NCT01836523|9920696|FG000|Overall Study|Unclassified|17
6239783|NCT01836523|9920697|FG001|Overall Study|Unclassified|28
6239784|NCT01836523|9920698|FG002|Overall Study|Unclassified|19
6239785|NCT01836523|9920699|FG003|Overall Study|Unclassified|29
6239786|NCT01836549|9920715|FG000|Overall Study|Did not receive study drug|0
6239787|NCT01836549|9920716|FG001|Overall Study|Did not receive study drug|0
6239788|NCT01836549|9920717|FG002|Overall Study|Did not receive study drug|1
6239789|NCT01836549|9920718|FG003|Overall Study|Did not receive study drug|0
6239790|NCT01836549|9920719|FG004|Overall Study|Did not receive study drug|0
6239791|NCT01836549|9920720|FG005|Overall Study|Did not receive study drug|0
6239792|NCT01836549|9920721|FG006|Overall Study|Did not receive study drug|0
6239793|NCT01836549|9920715|FG000|Overall Study|Patient declared ineligible|0
6239794|NCT01836549|9920716|FG001|Overall Study|Patient declared ineligible|0
6239795|NCT01836549|9920717|FG002|Overall Study|Patient declared ineligible|0
6239796|NCT01836549|9920718|FG003|Overall Study|Patient declared ineligible|1
6239797|NCT01836549|9920719|FG004|Overall Study|Patient declared ineligible|0
6239798|NCT01836549|9920720|FG005|Overall Study|Patient declared ineligible|0
6239799|NCT01836549|9920721|FG006|Overall Study|Patient declared ineligible|0
6239800|NCT01836549|9920715|FG000|Overall Study|Patient inevaluable to start therapy|0
6239801|NCT01836549|9920716|FG001|Overall Study|Patient inevaluable to start therapy|0
6239802|NCT01836549|9920717|FG002|Overall Study|Patient inevaluable to start therapy|0
6239803|NCT01836549|9920718|FG003|Overall Study|Patient inevaluable to start therapy|0
6239804|NCT01836549|9920719|FG004|Overall Study|Patient inevaluable to start therapy|0
6239805|NCT01836549|9920720|FG005|Overall Study|Patient inevaluable to start therapy|0
6239806|NCT01836549|9920721|FG006|Overall Study|Patient inevaluable to start therapy|1
6239807|NCT01837680|9920779|FG000|Overall Study|Lost to Follow-up|2
6239808|NCT01837680|9920780|FG001|Overall Study|Lost to Follow-up|2
6239809|NCT01837680|9920779|FG000|Overall Study|lack of insurance|0
6239810|NCT01837680|9920780|FG001|Overall Study|lack of insurance|2
6239811|NCT01837680|9920779|FG000|Overall Study|allergic reaction|6
6239812|NCT01837680|9920780|FG001|Overall Study|allergic reaction|0
6239813|NCT01837680|9920779|FG000|Overall Study|switched to oral hypoglycemic or diet|2
6239814|NCT01837680|9920780|FG001|Overall Study|switched to oral hypoglycemic or diet|4
6239815|NCT01837719|9920786|FG000|Period 2: Days 8-14 (Treatment B or A)|Withdrawal by Subject|1
6239816|NCT01837719|9920786|FG000|Period 5: Days 29-31 (Treatment E)|Poor compliance/noncompliance|1
6239817|NCT01837797|9920804|FG000|Period 1|Adverse Event|9
6239818|NCT01837797|9920805|FG001|Period 1|Adverse Event|0
6239819|NCT01837797|9920806|FG002|Period 1|Adverse Event|0
6239820|NCT01837797|9920807|FG003|Period 1|Adverse Event|0
6239821|NCT01837797|9920808|FG004|Period 1|Adverse Event|0
6239822|NCT01837797|9920804|FG000|Period 1|Withdrawal by Subject|6
6239823|NCT01837797|9920805|FG001|Period 1|Withdrawal by Subject|0
6239824|NCT01837797|9920806|FG002|Period 1|Withdrawal by Subject|0
6239825|NCT01837797|9920807|FG003|Period 1|Withdrawal by Subject|0
6239826|NCT01837797|9920808|FG004|Period 1|Withdrawal by Subject|0
6239827|NCT01837797|9920804|FG000|Period 1|Administrative reasons|76
6239828|NCT01837797|9920805|FG001|Period 1|Administrative reasons|0
6239829|NCT01837797|9920806|FG002|Period 1|Administrative reasons|0
6239830|NCT01837797|9920807|FG003|Period 1|Administrative reasons|0
6239831|NCT01837797|9920808|FG004|Period 1|Administrative reasons|0
6239832|NCT01837797|9920804|FG000|Period 1|Withdrawal of consent before treatment|1
6239833|NCT01837797|9920805|FG001|Period 1|Withdrawal of consent before treatment|0
6239834|NCT01837797|9920806|FG002|Period 1|Withdrawal of consent before treatment|0
6239835|NCT01837797|9920807|FG003|Period 1|Withdrawal of consent before treatment|0
6239836|NCT01837797|9920808|FG004|Period 1|Withdrawal of consent before treatment|0
6239837|NCT01837797|9920804|FG000|Period 1|Other|10
6239838|NCT01837797|9920805|FG001|Period 1|Other|0
6239839|NCT01837797|9920806|FG002|Period 1|Other|0
6239840|NCT01837797|9920807|FG003|Period 1|Other|0
6239841|NCT01837797|9920808|FG004|Period 1|Other|0
6239842|NCT01837797|9920804|FG000|Period 2|Administrative or other reasons|0
6239843|NCT01837797|9920805|FG001|Period 2|Administrative or other reasons|5
6239844|NCT01837797|9920806|FG002|Period 2|Administrative or other reasons|2
6239845|NCT01837797|9920807|FG003|Period 2|Administrative or other reasons|4
6239846|NCT01837797|9920808|FG004|Period 2|Administrative or other reasons|0
6239847|NCT01837797|9920804|FG000|Period 2|Adverse Event|0
6239848|NCT01837797|9920805|FG001|Period 2|Adverse Event|0
6239849|NCT01837797|9920806|FG002|Period 2|Adverse Event|0
6239850|NCT01837797|9920807|FG003|Period 2|Adverse Event|1
6239851|NCT01837797|9920808|FG004|Period 2|Adverse Event|0
6239852|NCT01837797|9920804|FG000|Period 3|Adverse Event|0
6239853|NCT01837797|9920805|FG001|Period 3|Adverse Event|0
6239854|NCT01837797|9920806|FG002|Period 3|Adverse Event|0
6239855|NCT01837797|9920807|FG003|Period 3|Adverse Event|0
6239856|NCT01837797|9920808|FG004|Period 3|Adverse Event|1
6239857|NCT01837797|9920804|FG000|Period 3|Administrative reasons|0
6239858|NCT01837797|9920805|FG001|Period 3|Administrative reasons|0
6239859|NCT01837797|9920806|FG002|Period 3|Administrative reasons|0
6239860|NCT01837797|9920807|FG003|Period 3|Administrative reasons|0
6239861|NCT01837797|9920808|FG004|Period 3|Administrative reasons|20
6239862|NCT01837797|9920804|FG000|Period 3|Other|0
6239863|NCT01837797|9920805|FG001|Period 3|Other|0
6239864|NCT01837797|9920806|FG002|Period 3|Other|0
6239865|NCT01837797|9920807|FG003|Period 3|Other|0
6239866|NCT01837797|9920808|FG004|Period 3|Other|2
6239867|NCT01837823|9920816|FG000|Overall Study|Lost to Follow-up|6
6239868|NCT01837966|9920839|FG000|Overall Study|Withdrawal by Subject|2
6239869|NCT01837966|9920840|FG001|Overall Study|Withdrawal by Subject|1
6239870|NCT01838044|9920848|FG000|Overall Study|Adverse Event|4
6239871|NCT01838044|9920849|FG001|Overall Study|Adverse Event|6
6239872|NCT01838044|9920848|FG000|Overall Study|Protocol Violation|3
6239873|NCT01838044|9920849|FG001|Overall Study|Protocol Violation|3
6239874|NCT01838044|9920848|FG000|Overall Study|Withdrawal by Subject|0
6239875|NCT01838044|9920849|FG001|Overall Study|Withdrawal by Subject|2
6239876|NCT01838044|9920848|FG000|Overall Study|Insufficient clinical response|1
6239877|NCT01838044|9920849|FG001|Overall Study|Insufficient clinical response|2
6239878|NCT01838044|9920848|FG000|Overall Study|Medication error without associated AE|0
6239879|NCT01838044|9920849|FG001|Overall Study|Medication error without associated AE|1
6239880|NCT01838044|9920848|FG000|Overall Study|Lost to Follow-up|0
6239881|NCT01838044|9920849|FG001|Overall Study|Lost to Follow-up|2
6239882|NCT01838200|9920858|FG000|Overall Study|Adverse Event|0
6239883|NCT01838200|9920859|FG001|Overall Study|Adverse Event|2
6239884|NCT01838200|9920858|FG000|Overall Study|Progressive disease|3
6239885|NCT01838200|9920859|FG001|Overall Study|Progressive disease|0
6239886|NCT01838213|9920867|FG000|Overall Study|Ineligible|166
6239887|NCT01838213|9920868|FG001|Overall Study|Ineligible|191
6239888|NCT01838447|9920903|FG000|Overall Study|Change in surgical plan|1
6239889|NCT01838447|9920904|FG001|Overall Study|Change in surgical plan|2
6239890|NCT01838447|9920903|FG000|Overall Study|Withdrawal by Subject|1
6239891|NCT01838447|9920904|FG001|Overall Study|Withdrawal by Subject|1
6239892|NCT01838499|9920912|FG000|Overall Study|Protocol Violation|0
6239893|NCT01838499|9920913|FG001|Overall Study|Protocol Violation|1
6239894|NCT01838499|9920912|FG000|Overall Study|Lost to Follow-up|2
6239895|NCT01838499|9920913|FG001|Overall Study|Lost to Follow-up|4
6239896|NCT01838499|9920912|FG000|Overall Study|Lack of Efficacy|1
6239897|NCT01838499|9920913|FG001|Overall Study|Lack of Efficacy|2
6239898|NCT01838499|9920912|FG000|Overall Study|Adverse Event|2
6239899|NCT01838499|9920913|FG001|Overall Study|Adverse Event|1
6239900|NCT01838499|9920912|FG000|Overall Study|Withdrawal by Subject|19
6239901|NCT01838499|9920913|FG001|Overall Study|Withdrawal by Subject|9
6239902|NCT01838551|9920919|FG000|Overall Study|Adverse Event|16
6239903|NCT01838551|9920919|FG000|Overall Study|Death|1
6239904|NCT01838551|9920919|FG000|Overall Study|Lack of Efficacy|10
6239905|NCT01838551|9920919|FG000|Overall Study|Physician Decision|4
6239906|NCT01838551|9920919|FG000|Overall Study|Withdrawal by Subject|10
6239907|NCT01838551|9920919|FG000|Overall Study|No reason reported (2); surgery (2), cancer (1), sponsor request (1), bad clinical condition (1)|7
6239908|NCT01838590|9920927|FG000|Overall Study|Lack of Efficacy|12
6239909|NCT01838590|9920928|FG001|Overall Study|Lack of Efficacy|4
6239910|NCT01838590|9920927|FG000|Overall Study|Lost to Follow-up|0
6239911|NCT01838590|9920928|FG001|Overall Study|Lost to Follow-up|1
6239912|NCT01838616|9920940|FG000|Titration Period|Adverse Event|18
6239913|NCT01838616|9920941|FG001|Titration Period|Adverse Event|48
6239914|NCT01838616|9920940|FG000|Titration Period|Lack of Efficacy|5
6239915|NCT01838616|9920941|FG001|Titration Period|Lack of Efficacy|12
6239916|NCT01838616|9920940|FG000|Titration Period|Withdrawal by Subject|5
6239917|NCT01838616|9920941|FG001|Titration Period|Withdrawal by Subject|5
6239918|NCT01838616|9920940|FG000|Titration Period|Technical problems|1
6239919|NCT01838616|9920941|FG001|Titration Period|Technical problems|0
6239920|NCT01838616|9920940|FG000|Titration Period|Other|1
6239921|NCT01838616|9920941|FG001|Titration Period|Other|0
6239922|NCT01838616|9920940|FG000|Titration Period|Protocol Violation|0
6239923|NCT01838616|9920941|FG001|Titration Period|Protocol Violation|1
6239924|NCT01838616|9920940|FG000|Continuation Period|Lack of Efficacy|3
6239925|NCT01838616|9920941|FG001|Continuation Period|Lack of Efficacy|5
6239926|NCT01838616|9920940|FG000|Continuation Period|Adverse Event|8
6239927|NCT01838616|9920941|FG001|Continuation Period|Adverse Event|4
6239928|NCT01838616|9920940|FG000|Continuation Period|Protocol Violation|2
6239929|NCT01838616|9920941|FG001|Continuation Period|Protocol Violation|0
6239930|NCT01838616|9920940|FG000|Continuation Period|Lost to Follow-up|1
6239931|NCT01838616|9920941|FG001|Continuation Period|Lost to Follow-up|0
6239932|NCT01838616|9920940|FG000|Continuation Period|Withdrawal by Subject|0
6239933|NCT01838616|9920941|FG001|Continuation Period|Withdrawal by Subject|4
6239934|NCT01838616|9920940|FG000|Continuation Period|Technical problems|0
6239935|NCT01838616|9920941|FG001|Continuation Period|Technical problems|1
6239936|NCT01838616|9920940|FG000|Pick-up Arm|Lack of Efficacy|4
6239937|NCT01838616|9920941|FG001|Pick-up Arm|Lack of Efficacy|0
6239938|NCT01838616|9920940|FG000|Pick-up Arm|Adverse Event|9
6239939|NCT01838616|9920941|FG001|Pick-up Arm|Adverse Event|0
6239940|NCT01838616|9920940|FG000|Pick-up Arm|Withdrawal by Subject|1
6239941|NCT01838616|9920941|FG001|Pick-up Arm|Withdrawal by Subject|0
6239942|NCT01838616|9920940|FG000|Pick-up Arm|Technical problems|1
6239943|NCT01838616|9920941|FG001|Pick-up Arm|Technical problems|0
6239944|NCT01838642|9920952|FG000|Overall Study|Died on study|1
6239945|NCT01838681|9920961|FG000|Period A|Adverse Event|39
6239946|NCT01838681|9920962|FG001|Period A|Adverse Event|0
6239947|NCT01838681|9920963|FG002|Period A|Adverse Event|0
6239948|NCT01838681|9920964|FG003|Period A|Adverse Event|0
6239949|NCT01838681|9920961|FG000|Period A|Lack of Efficacy|21
6239950|NCT01838681|9920962|FG001|Period A|Lack of Efficacy|0
6239951|NCT01838681|9920963|FG002|Period A|Lack of Efficacy|0
6239952|NCT01838681|9920964|FG003|Period A|Lack of Efficacy|0
6239953|NCT01838681|9920961|FG000|Period A|Early response|148
6239954|NCT01838681|9920962|FG001|Period A|Early response|0
6239955|NCT01838681|9920963|FG002|Period A|Early response|0
6239956|NCT01838681|9920964|FG003|Period A|Early response|0
6239957|NCT01838681|9920961|FG000|Period A|Withdrawal by Subject|70
6239958|NCT01838681|9920962|FG001|Period A|Withdrawal by Subject|0
6239959|NCT01838681|9920963|FG002|Period A|Withdrawal by Subject|0
6239960|NCT01838681|9920964|FG003|Period A|Withdrawal by Subject|0
6239961|NCT01838681|9920961|FG000|Period A|Protocol Violation|16
6239962|NCT01838681|9920962|FG001|Period A|Protocol Violation|0
6239963|NCT01838681|9920963|FG002|Period A|Protocol Violation|0
6239964|NCT01838681|9920964|FG003|Period A|Protocol Violation|0
6239965|NCT01838681|9920961|FG000|Period A|Non-compliance with IMP|6
6239966|NCT01838681|9920962|FG001|Period A|Non-compliance with IMP|0
6239967|NCT01838681|9920963|FG002|Period A|Non-compliance with IMP|0
6239968|NCT01838681|9920964|FG003|Period A|Non-compliance with IMP|0
6239969|NCT01838681|9920961|FG000|Period A|Lost to Follow-up|4
6239970|NCT01838681|9920962|FG001|Period A|Lost to Follow-up|0
6239971|NCT01838681|9920963|FG002|Period A|Lost to Follow-up|0
6239972|NCT01838681|9920964|FG003|Period A|Lost to Follow-up|0
6239973|NCT01838681|9920961|FG000|Period A|Withdrawal before treatment|4
6239974|NCT01838681|9920962|FG001|Period A|Withdrawal before treatment|0
6239975|NCT01838681|9920963|FG002|Period A|Withdrawal before treatment|0
6239976|NCT01838681|9920964|FG003|Period A|Withdrawal before treatment|0
6239977|NCT01838681|9920961|FG000|Period A|Administrative or other reasons|17
6239978|NCT01838681|9920962|FG001|Period A|Administrative or other reasons|0
6239979|NCT01838681|9920963|FG002|Period A|Administrative or other reasons|0
6239980|NCT01838681|9920964|FG003|Period A|Administrative or other reasons|0
6239981|NCT01838681|9920961|FG000|Period B/A+|Adverse Event|0
6239982|NCT01838681|9920962|FG001|Period B/A+|Adverse Event|13
6239983|NCT01838681|9920963|FG002|Period B/A+|Adverse Event|27
6239984|NCT01838681|9920964|FG003|Period B/A+|Adverse Event|16
6239985|NCT01838681|9920961|FG000|Period B/A+|Lack of Efficacy|0
6239986|NCT01838681|9920962|FG001|Period B/A+|Lack of Efficacy|9
6239987|NCT01838681|9920963|FG002|Period B/A+|Lack of Efficacy|11
6239988|NCT01838681|9920964|FG003|Period B/A+|Lack of Efficacy|6
6239989|NCT01838681|9920961|FG000|Period B/A+|Withdrawal by Subject|0
6239990|NCT01838681|9920962|FG001|Period B/A+|Withdrawal by Subject|28
6239991|NCT01838681|9920963|FG002|Period B/A+|Withdrawal by Subject|35
6239992|NCT01838681|9920964|FG003|Period B/A+|Withdrawal by Subject|47
6239993|NCT01838681|9920961|FG000|Period B/A+|Protocol Violation|0
6239994|NCT01838681|9920962|FG001|Period B/A+|Protocol Violation|1
6239995|NCT01838681|9920963|FG002|Period B/A+|Protocol Violation|4
6239996|NCT01838681|9920964|FG003|Period B/A+|Protocol Violation|6
6239997|NCT01838681|9920961|FG000|Period B/A+|Non-compliance with IMP|0
6239998|NCT01838681|9920962|FG001|Period B/A+|Non-compliance with IMP|2
6239999|NCT01838681|9920963|FG002|Period B/A+|Non-compliance with IMP|3
6240000|NCT01838681|9920964|FG003|Period B/A+|Non-compliance with IMP|3
6240001|NCT01838681|9920961|FG000|Period B/A+|Lost to Follow-up|0
6240002|NCT01838681|9920962|FG001|Period B/A+|Lost to Follow-up|2
6240003|NCT01838681|9920963|FG002|Period B/A+|Lost to Follow-up|5
6240004|NCT01838681|9920964|FG003|Period B/A+|Lost to Follow-up|11
6240005|NCT01838681|9920961|FG000|Period B/A+|Withdrawal before treatment|0
6240006|NCT01838681|9920962|FG001|Period B/A+|Withdrawal before treatment|1
6240007|NCT01838681|9920963|FG002|Period B/A+|Withdrawal before treatment|0
6240008|NCT01838681|9920964|FG003|Period B/A+|Withdrawal before treatment|0
6240009|NCT01838681|9920961|FG000|Period B/A+|Administrative or other reasons|0
6240010|NCT01838681|9920962|FG001|Period B/A+|Administrative or other reasons|6
6240011|NCT01838681|9920963|FG002|Period B/A+|Administrative or other reasons|10
6240012|NCT01838681|9920964|FG003|Period B/A+|Administrative or other reasons|28
6240013|NCT01838694|9920972|FG000|Overall Study|Adverse Event|0
6240014|NCT01838694|9920973|FG001|Overall Study|Adverse Event|1
6240015|NCT01838876|9920995|FG000|Overall Study|Adverse Event|49
6240016|NCT01838876|9920995|FG000|Overall Study|Insufficient Therapeutic Response|10
6240017|NCT01838876|9920995|FG000|Overall Study|Protocol Violation|34
6240018|NCT01838876|9920995|FG000|Overall Study|Withdrawal of Consent|33
6240019|NCT01838876|9920995|FG000|Overall Study|Lost to Follow-up|21
6240020|NCT01838876|9920995|FG000|Overall Study|Study or Site Terminated by Sponsor|1
6240021|NCT01838876|9920995|FG000|Overall Study|Reason not Specified|7
6240022|NCT01838876|9920995|FG000|Overall Study|Did not meet eligibility criteria|78
6240023|NCT01838941|9921001|FG000|Overall Study|Adverse Event|1
6240024|NCT01838941|9921001|FG000|Overall Study|Withdrawal by Subject|1
6240025|NCT01839188|9921032|FG000|Overall Study|Withdrawal by Subject|1
6240026|NCT01839279|9921044|FG000|Overall Study|Adverse Event|4
6240027|NCT01839279|9921045|FG001|Overall Study|Adverse Event|1
6240028|NCT01839279|9921046|FG002|Overall Study|Adverse Event|1
6240029|NCT01839279|9921044|FG000|Overall Study|Withdrawal by Subject|4
6240030|NCT01839279|9921045|FG001|Overall Study|Withdrawal by Subject|1
6240031|NCT01839279|9921046|FG002|Overall Study|Withdrawal by Subject|1
6240032|NCT01839279|9921044|FG000|Overall Study|Classified as 'Other'|5
6240033|NCT01839279|9921045|FG001|Overall Study|Classified as 'Other'|0
6240034|NCT01839279|9921046|FG002|Overall Study|Classified as 'Other'|0
6240035|NCT01839487|9921076|FG000|Run-in Phase (Maximum Exposure:295 Days)|Withdrawal by Subject|1
6240036|NCT01839487|9921077|FG001|Run-in Phase (Maximum Exposure:295 Days)|Withdrawal by Subject|0
6240037|NCT01839487|9921078|FG002|Run-in Phase (Maximum Exposure:295 Days)|Withdrawal by Subject|0
6240038|NCT01839487|9921079|FG003|Run-in Phase (Maximum Exposure:295 Days)|Withdrawal by Subject|0
6240039|NCT01839487|9921080|FG004|Run-in Phase (Maximum Exposure:295 Days)|Withdrawal by Subject|0
6240040|NCT01839487|9921081|FG005|Run-in Phase (Maximum Exposure:295 Days)|Withdrawal by Subject|0
6240041|NCT01839487|9921076|FG000|Run-in Phase (Maximum Exposure:295 Days)|Death|14
6240042|NCT01839487|9921077|FG001|Run-in Phase (Maximum Exposure:295 Days)|Death|6
6240043|NCT01839487|9921078|FG002|Run-in Phase (Maximum Exposure:295 Days)|Death|0
6240044|NCT01839487|9921079|FG003|Run-in Phase (Maximum Exposure:295 Days)|Death|0
6240045|NCT01839487|9921080|FG004|Run-in Phase (Maximum Exposure:295 Days)|Death|0
6240046|NCT01839487|9921081|FG005|Run-in Phase (Maximum Exposure:295 Days)|Death|0
6240047|NCT01839487|9921076|FG000|Run-in Phase (Maximum Exposure:295 Days)|Study Terminated by Sponsor|0
6240048|NCT01839487|9921077|FG001|Run-in Phase (Maximum Exposure:295 Days)|Study Terminated by Sponsor|1
6240049|NCT01839487|9921078|FG002|Run-in Phase (Maximum Exposure:295 Days)|Study Terminated by Sponsor|0
6240050|NCT01839487|9921079|FG003|Run-in Phase (Maximum Exposure:295 Days)|Study Terminated by Sponsor|0
6240051|NCT01839487|9921080|FG004|Run-in Phase (Maximum Exposure:295 Days)|Study Terminated by Sponsor|0
6240052|NCT01839487|9921081|FG005|Run-in Phase (Maximum Exposure:295 Days)|Study Terminated by Sponsor|0
6240053|NCT01839487|9921076|FG000|Run-in Phase (Maximum Exposure:295 Days)|Other than specified|1
6240054|NCT01839487|9921077|FG001|Run-in Phase (Maximum Exposure:295 Days)|Other than specified|0
6240055|NCT01839487|9921078|FG002|Run-in Phase (Maximum Exposure:295 Days)|Other than specified|0
6240056|NCT01839487|9921079|FG003|Run-in Phase (Maximum Exposure:295 Days)|Other than specified|0
6240057|NCT01839487|9921080|FG004|Run-in Phase (Maximum Exposure:295 Days)|Other than specified|0
6240058|NCT01839487|9921081|FG005|Run-in Phase (Maximum Exposure:295 Days)|Other than specified|0
6240059|NCT01839487|9921076|FG000|Phase 2 (Maximum Exposure:935 Days)|Withdrawal by Subject|0
6240060|NCT01839487|9921077|FG001|Phase 2 (Maximum Exposure:935 Days)|Withdrawal by Subject|0
6240061|NCT01839487|9921078|FG002|Phase 2 (Maximum Exposure:935 Days)|Withdrawal by Subject|12
6240062|NCT01839487|9921079|FG003|Phase 2 (Maximum Exposure:935 Days)|Withdrawal by Subject|9
6240063|NCT01839487|9921080|FG004|Phase 2 (Maximum Exposure:935 Days)|Withdrawal by Subject|4
6240064|NCT01839487|9921081|FG005|Phase 2 (Maximum Exposure:935 Days)|Withdrawal by Subject|8
6240065|NCT01839487|9921076|FG000|Phase 2 (Maximum Exposure:935 Days)|Death|0
6240066|NCT01839487|9921077|FG001|Phase 2 (Maximum Exposure:935 Days)|Death|0
6240067|NCT01839487|9921078|FG002|Phase 2 (Maximum Exposure:935 Days)|Death|46
6240068|NCT01839487|9921079|FG003|Phase 2 (Maximum Exposure:935 Days)|Death|49
6240069|NCT01839487|9921080|FG004|Phase 2 (Maximum Exposure:935 Days)|Death|71
6240070|NCT01839487|9921081|FG005|Phase 2 (Maximum Exposure:935 Days)|Death|32
6240071|NCT01839487|9921076|FG000|Phase 2 (Maximum Exposure:935 Days)|Lost to Follow-up|0
6240072|NCT01839487|9921077|FG001|Phase 2 (Maximum Exposure:935 Days)|Lost to Follow-up|0
6240073|NCT01839487|9921078|FG002|Phase 2 (Maximum Exposure:935 Days)|Lost to Follow-up|2
6240074|NCT01839487|9921079|FG003|Phase 2 (Maximum Exposure:935 Days)|Lost to Follow-up|0
6240075|NCT01839487|9921080|FG004|Phase 2 (Maximum Exposure:935 Days)|Lost to Follow-up|1
6240076|NCT01839487|9921081|FG005|Phase 2 (Maximum Exposure:935 Days)|Lost to Follow-up|0
6240077|NCT01839487|9921076|FG000|Phase 2 (Maximum Exposure:935 Days)|Study Terminated by Sponsor|0
6240078|NCT01839487|9921077|FG001|Phase 2 (Maximum Exposure:935 Days)|Study Terminated by Sponsor|0
6240079|NCT01839487|9921078|FG002|Phase 2 (Maximum Exposure:935 Days)|Study Terminated by Sponsor|0
6240080|NCT01839487|9921079|FG003|Phase 2 (Maximum Exposure:935 Days)|Study Terminated by Sponsor|1
6240081|NCT01839487|9921080|FG004|Phase 2 (Maximum Exposure:935 Days)|Study Terminated by Sponsor|10
6240082|NCT01839487|9921081|FG005|Phase 2 (Maximum Exposure:935 Days)|Study Terminated by Sponsor|3
6240083|NCT01839487|9921076|FG000|Phase 2 (Maximum Exposure:935 Days)|Other than specified|0
6240084|NCT01839487|9921077|FG001|Phase 2 (Maximum Exposure:935 Days)|Other than specified|0
6240085|NCT01839487|9921078|FG002|Phase 2 (Maximum Exposure:935 Days)|Other than specified|1
6240086|NCT01839487|9921079|FG003|Phase 2 (Maximum Exposure:935 Days)|Other than specified|3
6240087|NCT01839487|9921080|FG004|Phase 2 (Maximum Exposure:935 Days)|Other than specified|2
6240088|NCT01839487|9921081|FG005|Phase 2 (Maximum Exposure:935 Days)|Other than specified|1
6240089|NCT01839656|9921112|FG000|Overall Study|Withdrawal by Subject|1
6240090|NCT01839656|9921113|FG001|Overall Study|Withdrawal by Subject|1
6240091|NCT01839656|9921112|FG000|Overall Study|Adverse event, serious fatal|1
6240092|NCT01839656|9921113|FG001|Overall Study|Adverse event, serious fatal|4
6240093|NCT01839656|9921112|FG000|Overall Study|Early study closure|0
6240094|NCT01839656|9921113|FG001|Overall Study|Early study closure|11
6240095|NCT01839656|9921112|FG000|Overall Study|Adverse Event|1
6240096|NCT01839656|9921113|FG001|Overall Study|Adverse Event|0
6240097|NCT01839916|9921141|FG000|Overall Study|Death|9
6240098|NCT01839916|9921141|FG000|Overall Study|Physician Decision|17
6240099|NCT01839916|9921141|FG000|Overall Study|Relapse|12
6240100|NCT01839916|9921141|FG000|Overall Study|GVHD|2
6240101|NCT01839916|9921141|FG000|Overall Study|Graft Failure|1
6270251|NCT02151058|9971081|FG001|Overall Study|Withdrawal by Subject|1
6240102|NCT01840163|9921158|FG000|First Follow up -Primary Outcome|Lost to Follow-up|19
6240103|NCT01840163|9921159|FG001|First Follow up -Primary Outcome|Lost to Follow-up|16
6240104|NCT01840163|9921158|FG000|Systemic Follow Up-secondary Outcome|Lost to Follow-up|48
6240105|NCT01840163|9921159|FG001|Systemic Follow Up-secondary Outcome|Lost to Follow-up|40
6240106|NCT01840163|9921158|FG000|Systemic Follow Up-secondary Outcome|excluded -DCIS not eligible|43
6240107|NCT01840163|9921159|FG001|Systemic Follow Up-secondary Outcome|excluded -DCIS not eligible|35
6240108|NCT01840228|9921167|FG000|Overall Study|Lost to Follow-up|1
6240109|NCT01840228|9921168|FG001|Overall Study|Lost to Follow-up|1
6240110|NCT01840410|9921188|FG000|Overall Study|Physician Decision|1
6240111|NCT01840410|9921189|FG001|Overall Study|Physician Decision|2
6240112|NCT01840410|9921188|FG000|Overall Study|Pregnancy|1
6240113|NCT01840410|9921189|FG001|Overall Study|Pregnancy|0
6240114|NCT01840410|9921188|FG000|Overall Study|Protocol deviation|1
6240115|NCT01840410|9921189|FG001|Overall Study|Protocol deviation|0
6240116|NCT01840410|9921188|FG000|Overall Study|Lost to Follow-up|1
6240117|NCT01840410|9921189|FG001|Overall Study|Lost to Follow-up|0
6240118|NCT01840410|9921188|FG000|Overall Study|Withdrawal by Subject|2
6240119|NCT01840410|9921189|FG001|Overall Study|Withdrawal by Subject|1
6240120|NCT01840410|9921188|FG000|Overall Study|Adverse Event|1
6240121|NCT01840410|9921189|FG001|Overall Study|Adverse Event|1
6240122|NCT01840579|9921207|FG000|Overall Study|Status not recorded|0
6240123|NCT01840579|9921208|FG001|Overall Study|Status not recorded|0
6240124|NCT01840579|9921209|FG002|Overall Study|Status not recorded|2
6240125|NCT01840579|9921210|FG003|Overall Study|Status not recorded|3
6240126|NCT01840579|9921211|FG004|Overall Study|Status not recorded|4
6240127|NCT01840579|9921212|FG005|Overall Study|Status not recorded|3
6240128|NCT01840579|9921213|FG006|Overall Study|Status not recorded|0
6240129|NCT01840579|9921214|FG007|Overall Study|Status not recorded|3
6240130|NCT01840579|9921215|FG008|Overall Study|Status not recorded|3
6240131|NCT01840579|9921216|FG009|Overall Study|Status not recorded|3
6240132|NCT01840579|9921207|FG000|Overall Study|Progressive disease|3
6240133|NCT01840579|9921208|FG001|Overall Study|Progressive disease|5
6240134|NCT01840579|9921209|FG002|Overall Study|Progressive disease|0
6240135|NCT01840579|9921210|FG003|Overall Study|Progressive disease|0
6240136|NCT01840579|9921211|FG004|Overall Study|Progressive disease|0
6240137|NCT01840579|9921212|FG005|Overall Study|Progressive disease|0
6240138|NCT01840579|9921213|FG006|Overall Study|Progressive disease|0
6240139|NCT01840579|9921214|FG007|Overall Study|Progressive disease|0
6240140|NCT01840579|9921215|FG008|Overall Study|Progressive disease|0
6240141|NCT01840579|9921216|FG009|Overall Study|Progressive disease|0
6240142|NCT01840579|9921207|FG000|Overall Study|Ongoing in study|0
6240143|NCT01840579|9921208|FG001|Overall Study|Ongoing in study|1
6240144|NCT01840579|9921209|FG002|Overall Study|Ongoing in study|0
6240145|NCT01840579|9921210|FG003|Overall Study|Ongoing in study|0
6240146|NCT01840579|9921211|FG004|Overall Study|Ongoing in study|0
6240147|NCT01840579|9921212|FG005|Overall Study|Ongoing in study|0
6240148|NCT01840579|9921213|FG006|Overall Study|Ongoing in study|0
6240149|NCT01840579|9921214|FG007|Overall Study|Ongoing in study|0
6240150|NCT01840579|9921215|FG008|Overall Study|Ongoing in study|0
6240151|NCT01840579|9921216|FG009|Overall Study|Ongoing in study|0
6240152|NCT01840579|9921207|FG000|Overall Study|Death|0
6240153|NCT01840579|9921208|FG001|Overall Study|Death|0
6240154|NCT01840579|9921209|FG002|Overall Study|Death|0
6240155|NCT01840579|9921210|FG003|Overall Study|Death|0
6240156|NCT01840579|9921211|FG004|Overall Study|Death|0
6240157|NCT01840579|9921212|FG005|Overall Study|Death|1
6240158|NCT01840579|9921213|FG006|Overall Study|Death|0
6240159|NCT01840579|9921214|FG007|Overall Study|Death|0
6240160|NCT01840579|9921215|FG008|Overall Study|Death|0
6240161|NCT01840579|9921216|FG009|Overall Study|Death|0
6240162|NCT01840579|9921207|FG000|Overall Study|Adverse Event|0
6240163|NCT01840579|9921208|FG001|Overall Study|Adverse Event|1
6240164|NCT01840579|9921209|FG002|Overall Study|Adverse Event|0
6240165|NCT01840579|9921210|FG003|Overall Study|Adverse Event|0
6240166|NCT01840579|9921211|FG004|Overall Study|Adverse Event|0
6240167|NCT01840579|9921212|FG005|Overall Study|Adverse Event|0
6240168|NCT01840579|9921213|FG006|Overall Study|Adverse Event|0
6240169|NCT01840579|9921214|FG007|Overall Study|Adverse Event|0
6240170|NCT01840579|9921215|FG008|Overall Study|Adverse Event|0
6240171|NCT01840579|9921216|FG009|Overall Study|Adverse Event|0
6240172|NCT01840579|9921207|FG000|Overall Study|Follow-up ended by Sponsor|0
6240173|NCT01840579|9921208|FG001|Overall Study|Follow-up ended by Sponsor|0
6240174|NCT01840579|9921209|FG002|Overall Study|Follow-up ended by Sponsor|0
6240175|NCT01840579|9921210|FG003|Overall Study|Follow-up ended by Sponsor|0
6240176|NCT01840579|9921211|FG004|Overall Study|Follow-up ended by Sponsor|0
6240177|NCT01840579|9921212|FG005|Overall Study|Follow-up ended by Sponsor|0
6240178|NCT01840579|9921213|FG006|Overall Study|Follow-up ended by Sponsor|2
6240179|NCT01840579|9921214|FG007|Overall Study|Follow-up ended by Sponsor|0
6240180|NCT01840579|9921215|FG008|Overall Study|Follow-up ended by Sponsor|0
6240181|NCT01840579|9921216|FG009|Overall Study|Follow-up ended by Sponsor|0
6270252|NCT02151058|9971082|FG002|Overall Study|Withdrawal by Subject|3
6270253|NCT02151058|9971080|FG000|Overall Study|Lost to Follow-up|1
6270254|NCT02151058|9971081|FG001|Overall Study|Lost to Follow-up|0
6270255|NCT02151058|9971082|FG002|Overall Study|Lost to Follow-up|2
6270256|NCT02151110|9971098|FG000|Overall Study|Withdrawal by Subject|0
6270257|NCT02151110|9971099|FG001|Overall Study|Withdrawal by Subject|0
6240182|NCT01840605|9921252|FG000|Overall Study|Adverse Event|0
6240183|NCT01840605|9921253|FG001|Overall Study|Adverse Event|1
6240184|NCT01840605|9921252|FG000|Overall Study|Physician Decision|2
6240185|NCT01840605|9921253|FG001|Overall Study|Physician Decision|1
6240186|NCT01840943|9921270|FG000|Overall Study|Withdrawal by Subject|5
6240187|NCT01840943|9921271|FG001|Overall Study|Withdrawal by Subject|6
6240188|NCT01840943|9921270|FG000|Overall Study|Physician Decision|4
6240189|NCT01840943|9921271|FG001|Overall Study|Physician Decision|2
6240190|NCT01840943|9921270|FG000|Overall Study|Lost to Follow-up|4
6240191|NCT01840943|9921271|FG001|Overall Study|Lost to Follow-up|4
6240192|NCT01841060|9921285|FG000|Overall Study|Protocol Violation|10
6240193|NCT01841073|9921291|FG000|Overall Study|Adverse Event|1
6240194|NCT01841073|9921292|FG001|Overall Study|Adverse Event|1
6240195|NCT01841073|9921291|FG000|Overall Study|Physician Decision|1
6240196|NCT01841073|9921292|FG001|Overall Study|Physician Decision|0
6240197|NCT01841073|9921291|FG000|Overall Study|Lost to Follow-up|0
6240198|NCT01841073|9921292|FG001|Overall Study|Lost to Follow-up|2
6240199|NCT01841554|9921330|FG000|Overall Study|Death|7
6240200|NCT01841554|9921330|FG000|Overall Study|No Implantation|1
6240201|NCT01841554|9921330|FG000|Overall Study|Discontinued Follow Up|5
6240202|NCT01841554|9921330|FG000|Overall Study|Study exit due to secondary intervention|6
6240203|NCT01841567|9921334|FG000|Overall Study|Adverse Event|3
6240204|NCT01841593|9921340|FG000|First Intervention (Days 1 to 7)|Protocol Violation|0
6240205|NCT01841593|9921341|FG001|First Intervention (Days 1 to 7)|Protocol Violation|1
6240206|NCT01841593|9921340|FG000|Second Intervention (Days 8 to 14)|Adverse Event|1
6240207|NCT01841593|9921341|FG001|Second Intervention (Days 8 to 14)|Adverse Event|0
6240208|NCT01841697|9921370|FG000|Overall Study|Death|0
6240209|NCT01841697|9921371|FG001|Overall Study|Death|1
6240210|NCT01841697|9921370|FG000|Overall Study|Lost to Follow-up|4
6240211|NCT01841697|9921371|FG001|Overall Study|Lost to Follow-up|1
6240212|NCT01841697|9921370|FG000|Overall Study|Withdrawal by Subject|16
6240213|NCT01841697|9921371|FG001|Overall Study|Withdrawal by Subject|16
6240214|NCT01841762|9921377|FG000|Screening Period|Other, 2 PAH-SYMPACT cycles not complete|51
6188964|NCT01395888|9843922|FG002|Treatment Period (TP)|Protocol Violation|5
6188965|NCT01395888|9843920|FG000|Treatment Period (TP)|Met Protocol-defined Stopping Criteria|0
6188966|NCT01395888|9843921|FG001|Treatment Period (TP)|Met Protocol-defined Stopping Criteria|1
6188967|NCT01395888|9843922|FG002|Treatment Period (TP)|Met Protocol-defined Stopping Criteria|0
6188968|NCT01395888|9843920|FG000|Treatment Period (TP)|Withdrawal by Subject|0
6188969|NCT01395888|9843921|FG001|Treatment Period (TP)|Withdrawal by Subject|2
6188970|NCT01395888|9843922|FG002|Treatment Period (TP)|Withdrawal by Subject|3
6188971|NCT01395901|9843930|FG000|Overall Study|Lost to Follow-up|4
6188972|NCT01395901|9843931|FG001|Overall Study|Lost to Follow-up|0
6188973|NCT01395901|9843930|FG000|Overall Study|Randomized but not received study drug|5
6188974|NCT01395901|9843931|FG001|Overall Study|Randomized but not received study drug|4
6188975|NCT01395901|9843930|FG000|Overall Study|Adverse Event|0
6188976|NCT01395901|9843931|FG001|Overall Study|Adverse Event|1
6188977|NCT01395901|9843930|FG000|Overall Study|Withdrawal of consent|1
6188978|NCT01395901|9843931|FG001|Overall Study|Withdrawal of consent|0
6240215|NCT01841762|9921377|FG000|Treatment Period|Adverse Event|16
6240216|NCT01841762|9921377|FG000|Treatment Period|Death|1
6240217|NCT01841762|9921377|FG000|Treatment Period|Withdrawal by Subject|7
6240218|NCT01841762|9921377|FG000|Treatment Period|Lost to Follow-up|1
6240219|NCT01841762|9921377|FG000|Treatment Period|Physician Decision|2
6240220|NCT01841762|9921377|FG000|Treatment Period|Other, including non-compliance|5
6240221|NCT01841762|9921377|FG000|Post-Treatment Safety Follow-Up Period|Death|1
6240222|NCT01841762|9921377|FG000|Post-Treatment Safety Follow-Up Period|Withdrawal by Subject|7
6240223|NCT01841762|9921377|FG000|Post-Treatment Safety Follow-Up Period|Lost to Follow-up|6
6240224|NCT01841762|9921377|FG000|Post-Treatment Safety Follow-Up Period|Other, administrative error|1
6240225|NCT01841970|9921381|FG000|Overall Study|Withdrawal by Subject|1
6240226|NCT01841970|9921381|FG000|Overall Study|Physician Decision|2
6240227|NCT01841970|9921381|FG000|Overall Study|Lost to Follow-up|8
6240228|NCT01842308|9921402|FG000|Overall Study|Withdrawal by Subject|0
6240229|NCT01842308|9921403|FG001|Overall Study|Withdrawal by Subject|0
6240230|NCT01842308|9921404|FG002|Overall Study|Withdrawal by Subject|0
6240231|NCT01842308|9921405|FG003|Overall Study|Withdrawal by Subject|0
6240232|NCT01842308|9921406|FG004|Overall Study|Withdrawal by Subject|1
6240233|NCT01842334|9921421|FG000|Overall Study|Withdrawal by Subject|3
6240234|NCT01842334|9921422|FG001|Overall Study|Withdrawal by Subject|3
6240235|NCT01842334|9921421|FG000|Overall Study|Moved away mid-study|0
6085907|NCT00657046|9695552|FG001|Overall Study|Death|0
6188979|NCT01395914|9843939|FG000|Overall Study|Unrelated to study drug AE|6
6188980|NCT01395914|9843940|FG001|Overall Study|Unrelated to study drug AE|1
6188981|NCT01395914|9843939|FG000|Overall Study|Death|23
6240236|NCT01842334|9921422|FG001|Overall Study|Moved away mid-study|1
6240237|NCT01842438|9921430|FG000|T1: Immediately After the Intervention|Withdrawal by Subject|6
6240238|NCT01842438|9921431|FG001|T1: Immediately After the Intervention|Withdrawal by Subject|8
6240239|NCT01842438|9921430|FG000|T2: 6month Follow-up|Withdrawal by Subject|4
6240240|NCT01842438|9921431|FG001|T2: 6month Follow-up|Withdrawal by Subject|3
6240241|NCT01842438|9921430|FG000|T2: 6month Follow-up|Death|0
6240242|NCT01842438|9921431|FG001|T2: 6month Follow-up|Death|1
6240243|NCT01842581|9921448|FG000|Overall Study|Adverse Event|6
6240244|NCT01842581|9921449|FG001|Overall Study|Adverse Event|4
6240245|NCT01842581|9921448|FG000|Overall Study|HE breakthrough|26
6240246|NCT01842581|9921449|FG001|Overall Study|HE breakthrough|13
6240247|NCT01842581|9921448|FG000|Overall Study|Liver transplant|2
6240248|NCT01842581|9921449|FG001|Overall Study|Liver transplant|0
6240249|NCT01842581|9921448|FG000|Overall Study|Lost to Follow-up|2
6240250|NCT01842581|9921449|FG001|Overall Study|Lost to Follow-up|5
6240251|NCT01842581|9921448|FG000|Overall Study|Withdrawal by Subject|5
6240252|NCT01842581|9921449|FG001|Overall Study|Withdrawal by Subject|7
6240253|NCT01842581|9921448|FG000|Overall Study|Other than specified|3
6240254|NCT01842581|9921449|FG001|Overall Study|Other than specified|1
6240255|NCT01842607|9921459|FG000|Overall Study|Adverse Event|11
6240256|NCT01842607|9921459|FG000|Overall Study|Lack of Efficacy|19
6240257|NCT01842607|9921459|FG000|Overall Study|Protocol Violation|8
6240258|NCT01842607|9921459|FG000|Overall Study|Protocol defined stopping criteria|2
6240259|NCT01842607|9921459|FG000|Overall Study|Lost to Follow-up|3
6240260|NCT01842607|9921459|FG000|Overall Study|Physician Decision|9
6240261|NCT01842607|9921459|FG000|Overall Study|Withdrawal by Subject|14
6240262|NCT01842620|9921463|FG000|Period 1|Withdrawal by Subject|1
6240263|NCT01842620|9921464|FG001|Period 1|Withdrawal by Subject|0
6240264|NCT01842633|9921473|FG000|Overall Study|Screen Failure|1
6240265|NCT01842633|9921474|FG001|Overall Study|Screen Failure|0
6240266|NCT01842633|9921475|FG002|Overall Study|Screen Failure|0
6240267|NCT01842633|9921473|FG000|Overall Study|Adverse Event|1
6240268|NCT01842633|9921474|FG001|Overall Study|Adverse Event|1
6240269|NCT01842633|9921475|FG002|Overall Study|Adverse Event|0
6240270|NCT01842633|9921473|FG000|Overall Study|Withdrawal by Subject|0
6240271|NCT01842633|9921474|FG001|Overall Study|Withdrawal by Subject|1
6240272|NCT01842633|9921475|FG002|Overall Study|Withdrawal by Subject|0
6240273|NCT01842633|9921473|FG000|Overall Study|Technical issues|1
6240274|NCT01842633|9921474|FG001|Overall Study|Technical issues|0
6240275|NCT01842633|9921475|FG002|Overall Study|Technical issues|0
6240276|NCT01842958|9921519|FG000|Overall Study|Lost to Follow-up|1
6240277|NCT01842958|9921520|FG001|Overall Study|Lost to Follow-up|1
6240278|NCT01843023|9921528|FG000|Overall Study|Death|1
6240279|NCT01843023|9921529|FG001|Overall Study|Death|0
6240280|NCT01843023|9921528|FG000|Overall Study|Lost to Follow-up|24
6240281|NCT01843023|9921529|FG001|Overall Study|Lost to Follow-up|29
6240282|NCT01843023|9921528|FG000|Overall Study|Withdrawal by Subject|8
6240283|NCT01843023|9921529|FG001|Overall Study|Withdrawal by Subject|6
6240284|NCT01843062|9921537|FG000|Overall Study|Protocol Violation|1
6240285|NCT01843062|9921538|FG001|Overall Study|Protocol Violation|0
6240286|NCT01843062|9921537|FG000|Overall Study|New treatment following progression|2
6240287|NCT01843062|9921538|FG001|Overall Study|New treatment following progression|0
6240288|NCT01843062|9921537|FG000|Overall Study|Pregnancy|1
6240289|NCT01843062|9921538|FG001|Overall Study|Pregnancy|0
6240290|NCT01843062|9921537|FG000|Overall Study|Adverse Event|2
6240291|NCT01843062|9921538|FG001|Overall Study|Adverse Event|0
6240292|NCT01843062|9921537|FG000|Overall Study|Incorrect randomisation|1
6240293|NCT01843062|9921538|FG001|Overall Study|Incorrect randomisation|0
6240294|NCT01843062|9921537|FG000|Overall Study|Withdrawal by Subject|12
6240295|NCT01843062|9921538|FG001|Overall Study|Withdrawal by Subject|3
6240296|NCT01843062|9921537|FG000|Overall Study|Death|1
6240297|NCT01843062|9921538|FG001|Overall Study|Death|2
6240298|NCT01843062|9921537|FG000|Overall Study|Lost to Follow-up|2
6240299|NCT01843062|9921538|FG001|Overall Study|Lost to Follow-up|4
6240300|NCT01843192|9921547|FG000|Overall Study|Intra-operative exclusions per protocol|2
6240301|NCT01843192|9921548|FG001|Overall Study|Intra-operative exclusions per protocol|6
6240302|NCT01843192|9921549|FG002|Overall Study|Intra-operative exclusions per protocol|2
6240303|NCT01843205|9921557|FG000|First Treatment (11 Days)|Withdrawal by Subject|1
6240304|NCT01843205|9921558|FG001|First Treatment (11 Days)|Withdrawal by Subject|0
6240305|NCT01843348|9921567|FG000|Overall Study|Withdrawal by Subject|4
6240306|NCT01843348|9921568|FG001|Overall Study|Withdrawal by Subject|16
6240307|NCT01843348|9921569|FG002|Overall Study|Withdrawal by Subject|18
6240308|NCT01843348|9921567|FG000|Overall Study|Lost to Follow-up|5
6240309|NCT01843348|9921568|FG001|Overall Study|Lost to Follow-up|4
6240310|NCT01843348|9921569|FG002|Overall Study|Lost to Follow-up|2
6240311|NCT01843348|9921567|FG000|Overall Study|Death|5
6240312|NCT01843348|9921568|FG001|Overall Study|Death|3
6240313|NCT01843348|9921569|FG002|Overall Study|Death|4
6240314|NCT01843348|9921567|FG000|Overall Study|Graft loss/retransplantation|5
6240315|NCT01843348|9921568|FG001|Overall Study|Graft loss/retransplantation|8
6240316|NCT01843348|9921569|FG002|Overall Study|Graft loss/retransplantation|11
6240317|NCT01843348|9921567|FG000|Overall Study|Various reasons|4
6240318|NCT01843348|9921568|FG001|Overall Study|Various reasons|9
6240319|NCT01843348|9921569|FG002|Overall Study|Various reasons|6
6240320|NCT01843660|9921595|FG000|Overall Study|Other|30
6240321|NCT01843673|9921599|FG000|Overall Study|Lack of Efficacy|2
6240322|NCT01843673|9921599|FG000|Overall Study|Withdrawal by Subject|4
6240323|NCT01843777|9921616|FG000|Overall Study|Withdrawal by Subject|1
6240324|NCT01843777|9921617|FG001|Overall Study|Withdrawal by Subject|0
6240325|NCT01843803|9921625|FG000|Overall Study|not a Veteran, did not see provider|1
6240326|NCT01843803|9921626|FG001|Overall Study|not a Veteran, did not see provider|3
6240327|NCT01843842|9921634|FG000|Overall Study|Do not meet inclusion criteria|1
6240328|NCT01843842|9921635|FG001|Overall Study|Do not meet inclusion criteria|1
6240329|NCT01843933|9921652|FG000|Overall Study|Data lost|6
6240330|NCT01843933|9921653|FG001|Overall Study|Data lost|4
6240331|NCT01843972|9921669|FG000|Overall Study|Withdrawal by Subject|0
6240332|NCT01843972|9921670|FG001|Overall Study|Withdrawal by Subject|0
6240333|NCT01843972|9921671|FG002|Overall Study|Withdrawal by Subject|0
6240334|NCT01843972|9921672|FG003|Overall Study|Withdrawal by Subject|0
6240335|NCT01843972|9921673|FG004|Overall Study|Withdrawal by Subject|1
6240336|NCT01843972|9921674|FG005|Overall Study|Withdrawal by Subject|0
6240337|NCT01843972|9921675|FG006|Overall Study|Withdrawal by Subject|0
6240338|NCT01843972|9921676|FG007|Overall Study|Withdrawal by Subject|0
6240339|NCT01843972|9921677|FG008|Overall Study|Withdrawal by Subject|0
6240340|NCT01843972|9921678|FG009|Overall Study|Withdrawal by Subject|0
6240341|NCT01844076|9921718|FG000|Overall Study|Adverse Event|1
6240342|NCT01844076|9921719|FG001|Overall Study|Adverse Event|0
6240343|NCT01844076|9921720|FG002|Overall Study|Adverse Event|0
6240344|NCT01844076|9921721|FG003|Overall Study|Adverse Event|0
6240345|NCT01844076|9921718|FG000|Overall Study|Withdrawal by Subject|1
6240346|NCT01844076|9921719|FG001|Overall Study|Withdrawal by Subject|0
6240347|NCT01844076|9921720|FG002|Overall Study|Withdrawal by Subject|0
6240348|NCT01844076|9921721|FG003|Overall Study|Withdrawal by Subject|0
6240349|NCT01844115|9921733|FG000|Overall Study|Adverse Event|4
6240350|NCT01844115|9921734|FG001|Overall Study|Adverse Event|22
6240351|NCT01844115|9921733|FG000|Overall Study|Lack of Efficacy|1
6240352|NCT01844115|9921734|FG001|Overall Study|Lack of Efficacy|4
6240353|NCT01844115|9921733|FG000|Overall Study|Protocol Violation|12
6240354|NCT01844115|9921734|FG001|Overall Study|Protocol Violation|10
6240355|NCT01844115|9921733|FG000|Overall Study|Withdrawal by Subject|11
6240356|NCT01844115|9921734|FG001|Overall Study|Withdrawal by Subject|11
6240357|NCT01844115|9921733|FG000|Overall Study|Lost to Follow-up|11
6240358|NCT01844115|9921734|FG001|Overall Study|Lost to Follow-up|10
6240359|NCT01844115|9921733|FG000|Overall Study|Pregnancy|0
6240360|NCT01844115|9921734|FG001|Overall Study|Pregnancy|1
6240361|NCT01844284|9921751|FG000|Overall Study|Lost to Follow-up|12
6240362|NCT01844284|9921752|FG001|Overall Study|Lost to Follow-up|7
6240363|NCT01844375|9921760|FG000|Overall Study|Protocol Violation|1
6240364|NCT01844375|9921761|FG001|Overall Study|Protocol Violation|1
6240365|NCT01844531|9921788|FG000|Overall Study|Withdrawal by Subject|0
6240366|NCT01844531|9921789|FG001|Overall Study|Withdrawal by Subject|1
6240367|NCT01844531|9921790|FG002|Overall Study|Withdrawal by Subject|0
6240368|NCT01844531|9921791|FG003|Overall Study|Withdrawal by Subject|0
6085908|NCT00657046|9695553|FG002|Overall Study|Death|1
6085909|NCT00657046|9695551|FG000|Overall Study|Surgery|0
6240369|NCT01844583|9921803|FG000|Overall Study|Didn't complete dosing;PK/ECG assessment|8
6240370|NCT01844583|9921804|FG001|Overall Study|Didn't complete dosing;PK/ECG assessment|10
6240371|NCT01844687|9921815|FG000|Visit 1|Protocol Violation|3
6240372|NCT01844687|9921815|FG000|Visit 1|Lost to Follow-up|5
6240373|NCT01844687|9921815|FG000|Visit 2|Withdrawal by Subject|1
6240374|NCT01844687|9921815|FG000|Visit 2|Protocol Violation|1
6240375|NCT01844687|9921815|FG000|Visit 3|Lost to Follow-up|1
6240376|NCT01844687|9921815|FG000|Visit 3|Withdrawal by Subject|3
6240377|NCT01844687|9921815|FG000|Visit 3|child care problems|1
6240378|NCT01844687|9921815|FG000|Visit 4|Pregnancy|1
6085910|NCT00657046|9695552|FG001|Overall Study|Surgery|0
6085911|NCT00657046|9695553|FG002|Overall Study|Surgery|1
6085912|NCT00657150|9695563|FG000|Overall Study|Adverse Event|19
6085913|NCT00657150|9695564|FG001|Overall Study|Adverse Event|10
6085914|NCT00657150|9695563|FG000|Overall Study|Non-compliant with protocol|5
6085915|NCT00657150|9695564|FG001|Overall Study|Non-compliant with protocol|9
6085916|NCT00657150|9695563|FG000|Overall Study|Lost to Follow-up|2
6085917|NCT00657150|9695564|FG001|Overall Study|Lost to Follow-up|0
6085918|NCT00657150|9695563|FG000|Overall Study|Withdrawal by Subject|51
6085919|NCT00657150|9695564|FG001|Overall Study|Withdrawal by Subject|36
6085920|NCT00657150|9695563|FG000|Overall Study|Other|38
6085921|NCT00657150|9695564|FG001|Overall Study|Other|38
6085922|NCT00657150|9695563|FG000|Treatment|Adverse Event|60
6085923|NCT00657150|9695564|FG001|Treatment|Adverse Event|53
6085924|NCT00657150|9695563|FG000|Treatment|Non-compliant with protocol|10
6085925|NCT00657150|9695564|FG001|Treatment|Non-compliant with protocol|9
6085926|NCT00657150|9695563|FG000|Treatment|Lost to Follow-up|1
6085927|NCT00657150|9695564|FG001|Treatment|Lost to Follow-up|0
6085928|NCT00657150|9695563|FG000|Treatment|Withdrawal by Subject|23
6085929|NCT00657150|9695564|FG001|Treatment|Withdrawal by Subject|20
6240379|NCT01844687|9921815|FG000|Visit 4|Lost to Follow-up|1
6240380|NCT01844687|9921815|FG000|Visit 4|Withdrawal by Subject|2
6240381|NCT01844700|9921839|FG000|Overall Study|Lack of Efficacy|1
6240382|NCT01844700|9921840|FG001|Overall Study|Lack of Efficacy|0
6240383|NCT01844700|9921839|FG000|Overall Study|refused medication switch|1
6240384|NCT01844700|9921840|FG001|Overall Study|refused medication switch|0
6240385|NCT01844700|9921839|FG000|Overall Study|Withdrawal by Subject|1
6240386|NCT01844700|9921840|FG001|Overall Study|Withdrawal by Subject|0
6240387|NCT01844700|9921839|FG000|Overall Study|stopped taking meds|0
6240388|NCT01844700|9921840|FG001|Overall Study|stopped taking meds|1
6240389|NCT01844765|9921848|FG000|Overall Study|Adverse Event|6
6240390|NCT01844765|9921849|FG001|Overall Study|Adverse Event|8
6240391|NCT01844765|9921848|FG000|Overall Study|Withdrawal by Subject|2
6240392|NCT01844765|9921849|FG001|Overall Study|Withdrawal by Subject|3
6240393|NCT01844765|9921848|FG000|Overall Study|Disease progression|1
6240394|NCT01844765|9921849|FG001|Overall Study|Disease progression|0
6240395|NCT01844765|9921848|FG000|Overall Study|Administrative problems|3
6240396|NCT01844765|9921849|FG001|Overall Study|Administrative problems|4
6240397|NCT01844765|9921848|FG000|Overall Study|Protocol deviation|2
6240398|NCT01844765|9921849|FG001|Overall Study|Protocol deviation|0
6240399|NCT01844765|9921848|FG000|Overall Study|Untreated|1
6240400|NCT01844765|9921849|FG001|Overall Study|Untreated|0
6240401|NCT01844778|9921863|FG000|Overall Study|Protocol deviation|0
6240402|NCT01844778|9921864|FG001|Overall Study|Protocol deviation|1
6240403|NCT01844778|9921865|FG002|Overall Study|Protocol deviation|2
6240404|NCT01844778|9921863|FG000|Overall Study|Withdrawal by Subject|2
6240405|NCT01844778|9921864|FG001|Overall Study|Withdrawal by Subject|0
6240406|NCT01844778|9921865|FG002|Overall Study|Withdrawal by Subject|0
6240407|NCT01844778|9921863|FG000|Overall Study|Adverse Event|0
6240408|NCT01844778|9921864|FG001|Overall Study|Adverse Event|2
6240409|NCT01844778|9921865|FG002|Overall Study|Adverse Event|2
6240410|NCT01844817|9921879|FG000|Enrolled and Randomized|Withdrawal by Subject|2
6240411|NCT01844817|9921880|FG001|Enrolled and Randomized|Withdrawal by Subject|3
6240412|NCT01844817|9921879|FG000|Treatment|Progressive Disease|27
6240413|NCT01844817|9921880|FG001|Treatment|Progressive Disease|36
6240414|NCT01844817|9921879|FG000|Treatment|Adverse Event|17
6240415|NCT01844817|9921880|FG001|Treatment|Adverse Event|9
6240416|NCT01844817|9921879|FG000|Treatment|Withdrawal by Subject|10
6240417|NCT01844817|9921880|FG001|Treatment|Withdrawal by Subject|6
6240418|NCT01844817|9921879|FG000|Treatment|Death|10
6240419|NCT01844817|9921880|FG001|Treatment|Death|8
6240420|NCT01844817|9921879|FG000|Treatment|Lost to Follow-up|0
6240421|NCT01844817|9921880|FG001|Treatment|Lost to Follow-up|1
6240422|NCT01844817|9921879|FG000|Treatment|Other|0
6240423|NCT01844817|9921880|FG001|Treatment|Other|3
6240424|NCT01844830|9921889|FG000|Overall Study|Withdrawal by Subject|1
6240425|NCT01844830|9921890|FG001|Overall Study|Withdrawal by Subject|0
6240426|NCT01844895|9921896|FG000|Day 1 to Day 28 - Pre-filled Syringe|Adverse Event|1
6240427|NCT01844895|9921896|FG000|Day 1 to Day 28 - Pre-filled Syringe|Withdrawal by Subject|1
6240428|NCT01844895|9921896|FG000|Day 1 to Day 28 - Pre-filled Syringe|Clinic Closed|1
6240429|NCT01844895|9921896|FG000|Day 29 - Day113 - Autoinjector|Adverse Event|1
6240430|NCT01844895|9921896|FG000|Day 29 - Day113 - Autoinjector|Withdrawal by Subject|1
6240431|NCT01844895|9921896|FG000|Day 29 - Day113 - Autoinjector|Difficulty using device|3
6240432|NCT01844895|9921896|FG000|Day 29 - Day113 - Autoinjector|planned surgery|1
6240433|NCT01845025|9921911|FG000|Overall Study|Adverse Event|6
6240434|NCT01845025|9921912|FG001|Overall Study|Adverse Event|3
6240435|NCT01845025|9921911|FG000|Overall Study|Unsatisfactory therapeutic effect|4
6240436|NCT01845025|9921912|FG001|Overall Study|Unsatisfactory therapeutic effect|2
6240437|NCT01845025|9921911|FG000|Overall Study|Withdrawal by Subject|48
6240438|NCT01845025|9921912|FG001|Overall Study|Withdrawal by Subject|44
6240439|NCT01845025|9921911|FG000|Overall Study|Lost to Follow-up|13
6240440|NCT01845025|9921912|FG001|Overall Study|Lost to Follow-up|13
6240441|NCT01845025|9921911|FG000|Overall Study|Administrative problems|8
6240442|NCT01845025|9921912|FG001|Overall Study|Administrative problems|8
6240443|NCT01845025|9921911|FG000|Overall Study|Death|2
6240444|NCT01845025|9921912|FG001|Overall Study|Death|0
6240445|NCT01845025|9921911|FG000|Overall Study|Protocol deviation|3
6240446|NCT01845025|9921912|FG001|Overall Study|Protocol deviation|6
6240447|NCT01845025|9921911|FG000|Overall Study|Missing|1
6240448|NCT01845025|9921912|FG001|Overall Study|Missing|1
6240449|NCT01845077|9921921|FG000|Washout Period|Lost to Follow-up|0
6240450|NCT01845077|9921922|FG001|Washout Period|Lost to Follow-up|1
6240451|NCT01845077|9921923|FG002|Washout Period|Lost to Follow-up|0
6240452|NCT01845077|9921924|FG003|Washout Period|Lost to Follow-up|1
6240453|NCT01845077|9921925|FG004|Washout Period|Lost to Follow-up|0
6240454|NCT01845077|9921926|FG005|Washout Period|Lost to Follow-up|1
6240455|NCT01845077|9921921|FG000|Washout Period|Adverse Event|1
6240456|NCT01845077|9921922|FG001|Washout Period|Adverse Event|0
6240457|NCT01845077|9921923|FG002|Washout Period|Adverse Event|0
6240458|NCT01845077|9921924|FG003|Washout Period|Adverse Event|0
6240459|NCT01845077|9921925|FG004|Washout Period|Adverse Event|0
6240460|NCT01845077|9921926|FG005|Washout Period|Adverse Event|0
6240461|NCT01845077|9921921|FG000|Washout Period|elevated lab values (not clinic. sign.)|0
6240462|NCT01845077|9921922|FG001|Washout Period|elevated lab values (not clinic. sign.)|0
6240463|NCT01845077|9921923|FG002|Washout Period|elevated lab values (not clinic. sign.)|1
6240464|NCT01845077|9921924|FG003|Washout Period|elevated lab values (not clinic. sign.)|0
6240465|NCT01845077|9921925|FG004|Washout Period|elevated lab values (not clinic. sign.)|0
6240466|NCT01845077|9921926|FG005|Washout Period|elevated lab values (not clinic. sign.)|0
6240467|NCT01845077|9921921|FG000|Washout Period|Protocol Violation|0
6240468|NCT01845077|9921922|FG001|Washout Period|Protocol Violation|0
6240469|NCT01845077|9921923|FG002|Washout Period|Protocol Violation|0
6240470|NCT01845077|9921924|FG003|Washout Period|Protocol Violation|1
6240471|NCT01845077|9921925|FG004|Washout Period|Protocol Violation|1
6240472|NCT01845077|9921926|FG005|Washout Period|Protocol Violation|0
6240473|NCT01845818|9921976|FG000|Overall Study|Withdrawal by Subject|0
6240474|NCT01845818|9921977|FG001|Overall Study|Withdrawal by Subject|1
6240475|NCT01845818|9921976|FG000|Overall Study|Lost to Follow-up|7
6240476|NCT01845818|9921977|FG001|Overall Study|Lost to Follow-up|5
6240477|NCT01845818|9921976|FG000|Overall Study|Administrative Reasons|3
6240478|NCT01845818|9921977|FG001|Overall Study|Administrative Reasons|1
6240479|NCT01845818|9921976|FG000|Overall Study|Serious Adverse Event|1
6240480|NCT01845818|9921977|FG001|Overall Study|Serious Adverse Event|1
6240481|NCT01845818|9921976|FG000|Overall Study|Other|25
6240482|NCT01845818|9921977|FG001|Overall Study|Other|8
6240483|NCT01845818|9921976|FG000|Overall Study|Did Not Receive Any Dose of Adalimumab|5
6240484|NCT01845818|9921977|FG001|Overall Study|Did Not Receive Any Dose of Adalimumab|0
6240485|NCT01845818|9921976|FG000|Overall Study|No Follow-Up Data Available|4
6240486|NCT01845818|9921977|FG001|Overall Study|No Follow-Up Data Available|1
6240487|NCT01845831|9921987|FG000|Inpatient Phase|Withdrawal by Subject|1
6240488|NCT01845831|9921988|FG001|Inpatient Phase|Withdrawal by Subject|1
6240489|NCT01845831|9921989|FG002|Inpatient Phase|Withdrawal by Subject|0
6240490|NCT01845831|9921990|FG003|Inpatient Phase|Withdrawal by Subject|0
6240491|NCT01845831|9921991|FG004|Inpatient Phase|Withdrawal by Subject|0
6240492|NCT01845974|9922004|FG000|Overall Study|screen failure|1
6240493|NCT01845974|9922005|FG001|Overall Study|screen failure|0
6240494|NCT01846039|9922011|FG000|Overall Study|Protocol Violation|1
6240495|NCT01846039|9922011|FG000|Overall Study|Subject Withdrew Consent|1
6240496|NCT01846104|9922015|FG000|Overall Study|Withdrawal by Subject|1
6240497|NCT01846208|9922022|FG000|Overall Study|Withdrew prior to treatment|1
6240498|NCT01846208|9922023|FG001|Overall Study|Withdrew prior to treatment|1
6240499|NCT01846208|9922024|FG002|Overall Study|Withdrew prior to treatment|1
6240500|NCT01846208|9922022|FG000|Overall Study|Dosing Symptoms|1
6240501|NCT01846208|9922023|FG001|Overall Study|Dosing Symptoms|2
6240502|NCT01846208|9922024|FG002|Overall Study|Dosing Symptoms|6
6240503|NCT01846208|9922022|FG000|Overall Study|Withdrawal by Subject|5
6240504|NCT01846208|9922023|FG001|Overall Study|Withdrawal by Subject|0
6240505|NCT01846208|9922024|FG002|Overall Study|Withdrawal by Subject|0
6240506|NCT01846208|9922022|FG000|Overall Study|Non-compliance|1
6240507|NCT01846208|9922023|FG001|Overall Study|Non-compliance|1
6240508|NCT01846208|9922024|FG002|Overall Study|Non-compliance|0
6240509|NCT01846208|9922022|FG000|Overall Study|Developed Eosinophilic Esophagitis (EoE)|1
6240510|NCT01846208|9922023|FG001|Overall Study|Developed Eosinophilic Esophagitis (EoE)|0
6240511|NCT01846208|9922024|FG002|Overall Study|Developed Eosinophilic Esophagitis (EoE)|0
6240512|NCT01846208|9922022|FG000|Overall Study|Refused SU OFC|0
6240513|NCT01846208|9922023|FG001|Overall Study|Refused SU OFC|0
6240514|NCT01846208|9922024|FG002|Overall Study|Refused SU OFC|1
6240515|NCT01846221|9922034|FG000|Overall Study|Catheter Failure|2
6240516|NCT01846221|9922035|FG001|Overall Study|Catheter Failure|0
6240517|NCT01846221|9922034|FG000|Overall Study|Age Exclusion|1
6188982|NCT01395914|9843940|FG001|Overall Study|Death|17
6188983|NCT01395914|9843939|FG000|Overall Study|Other|9
6188984|NCT01395914|9843940|FG001|Overall Study|Other|3
6188985|NCT01395914|9843939|FG000|Overall Study|Withdrawal by patient|27
6188986|NCT01395914|9843940|FG001|Overall Study|Withdrawal by patient|14
6188987|NCT01395914|9843939|FG000|Overall Study|Study drug-related AE|1
6188988|NCT01395914|9843940|FG001|Overall Study|Study drug-related AE|0
6188989|NCT01395914|9843939|FG000|Overall Study|Lost to Follow-up|6
6188990|NCT01395914|9843940|FG001|Overall Study|Lost to Follow-up|2
6188991|NCT01396005|9843961|FG000|Overall Study|Withdrawal by Subject|0
6188992|NCT01396005|9843962|FG001|Overall Study|Withdrawal by Subject|1
6188993|NCT01396005|9843961|FG000|Overall Study|Non-compliance with protocol|0
6188994|NCT01396005|9843962|FG001|Overall Study|Non-compliance with protocol|1
6240518|NCT01846221|9922035|FG001|Overall Study|Age Exclusion|0
6240519|NCT01846299|9922043|FG000|Overall Study|Physician Decision|4
6240520|NCT01846299|9922044|FG001|Overall Study|Physician Decision|2
6240521|NCT01846299|9922043|FG000|Overall Study|Protocol deviation|1
6240522|NCT01846299|9922044|FG001|Overall Study|Protocol deviation|0
6240523|NCT01846299|9922043|FG000|Overall Study|Death|1
6240524|NCT01846299|9922044|FG001|Overall Study|Death|2
6240525|NCT01846299|9922043|FG000|Overall Study|Lost to Follow-up|3
6240526|NCT01846299|9922044|FG001|Overall Study|Lost to Follow-up|0
6240527|NCT01846299|9922043|FG000|Overall Study|Withdrawal by Subject|1
6240528|NCT01846299|9922044|FG001|Overall Study|Withdrawal by Subject|6
6240529|NCT01846299|9922043|FG000|Overall Study|Adverse Event|2
6240530|NCT01846299|9922044|FG001|Overall Study|Adverse Event|0
6240531|NCT01846416|9922055|FG000|Treatment Phase|Death|2
6188995|NCT01396057|9843981|FG000|Overall Study|Adverse Event|2
6240532|NCT01846416|9922056|FG001|Treatment Phase|Death|9
6240533|NCT01846416|9922057|FG002|Treatment Phase|Death|1
6240534|NCT01846416|9922055|FG000|Treatment Phase|Withdrawal by Subject|2
6240535|NCT01846416|9922056|FG001|Treatment Phase|Withdrawal by Subject|4
6240536|NCT01846416|9922057|FG002|Treatment Phase|Withdrawal by Subject|2
6240537|NCT01846416|9922055|FG000|Treatment Phase|Other|1
6240538|NCT01846416|9922056|FG001|Treatment Phase|Other|5
6240539|NCT01846416|9922057|FG002|Treatment Phase|Other|1
6240540|NCT01846416|9922055|FG000|Treatment Phase|Physician Decision|1
6240541|NCT01846416|9922056|FG001|Treatment Phase|Physician Decision|2
6240542|NCT01846416|9922057|FG002|Treatment Phase|Physician Decision|0
6240543|NCT01846416|9922055|FG000|Treatment Phase|Adverse Event|3
6240544|NCT01846416|9922056|FG001|Treatment Phase|Adverse Event|4
6240545|NCT01846416|9922057|FG002|Treatment Phase|Adverse Event|0
6240546|NCT01846416|9922055|FG000|Treatment Phase|Non-compliance|0
6240547|NCT01846416|9922056|FG001|Treatment Phase|Non-compliance|2
6240548|NCT01846416|9922057|FG002|Treatment Phase|Non-compliance|0
6240549|NCT01846416|9922055|FG000|Treatment Phase|Study Terminated by Sponsor|1
6240550|NCT01846416|9922056|FG001|Treatment Phase|Study Terminated by Sponsor|4
6240551|NCT01846416|9922057|FG002|Treatment Phase|Study Terminated by Sponsor|0
6240552|NCT01846416|9922055|FG000|Treatment Phase|Progressive Disease|21
6240553|NCT01846416|9922056|FG001|Treatment Phase|Progressive Disease|63
6240554|NCT01846416|9922057|FG002|Treatment Phase|Progressive Disease|9
6240555|NCT01846416|9922055|FG000|Survival Follow-up|Death|21
6240556|NCT01846416|9922056|FG001|Survival Follow-up|Death|62
6240557|NCT01846416|9922057|FG002|Survival Follow-up|Death|9
6240558|NCT01846416|9922055|FG000|Survival Follow-up|Lost to Follow-up|0
6240559|NCT01846416|9922056|FG001|Survival Follow-up|Lost to Follow-up|2
6240560|NCT01846416|9922057|FG002|Survival Follow-up|Lost to Follow-up|2
6240561|NCT01846416|9922055|FG000|Survival Follow-up|Withdrawal by Subject|2
6240562|NCT01846416|9922056|FG001|Survival Follow-up|Withdrawal by Subject|7
6240563|NCT01846416|9922057|FG002|Survival Follow-up|Withdrawal by Subject|0
6240564|NCT01846416|9922055|FG000|Survival Follow-up|Study Terminated by Sponsor|2
6240565|NCT01846416|9922056|FG001|Survival Follow-up|Study Terminated by Sponsor|8
6240566|NCT01846416|9922057|FG002|Survival Follow-up|Study Terminated by Sponsor|0
6240567|NCT01846416|9922055|FG000|Survival Follow-up|Other|3
6240568|NCT01846416|9922056|FG001|Survival Follow-up|Other|1
6240569|NCT01846416|9922057|FG002|Survival Follow-up|Other|1
6240570|NCT01846442|9922070|FG000|Overall Study|Adverse Event|2
6240571|NCT01846442|9922071|FG001|Overall Study|Adverse Event|4
6240572|NCT01846442|9922072|FG002|Overall Study|Adverse Event|2
6240573|NCT01846442|9922073|FG003|Overall Study|Adverse Event|1
6240574|NCT01846442|9922070|FG000|Overall Study|Lost to Follow-up|0
6240575|NCT01846442|9922071|FG001|Overall Study|Lost to Follow-up|0
6240576|NCT01846442|9922072|FG002|Overall Study|Lost to Follow-up|1
6240577|NCT01846442|9922073|FG003|Overall Study|Lost to Follow-up|0
6240578|NCT01846442|9922070|FG000|Overall Study|Withdrawal by Subject|3
6240579|NCT01846442|9922071|FG001|Overall Study|Withdrawal by Subject|2
6240580|NCT01846442|9922072|FG002|Overall Study|Withdrawal by Subject|0
6240581|NCT01846442|9922073|FG003|Overall Study|Withdrawal by Subject|1
6240582|NCT01846442|9922070|FG000|Overall Study|Left the city/Lost medication|1
6240583|NCT01846442|9922071|FG001|Overall Study|Left the city/Lost medication|0
6240584|NCT01846442|9922072|FG002|Overall Study|Left the city/Lost medication|1
6240585|NCT01846442|9922073|FG003|Overall Study|Left the city/Lost medication|1
6240586|NCT01846507|9922113|FG000|Overall Study|Lost to Follow-up|4
6240587|NCT01846507|9922113|FG000|Overall Study|Protocol Violation|1
6240588|NCT01846507|9922113|FG000|Overall Study|Missing data|2
6240589|NCT01846611|9922121|FG000|Overall Study|Lost to Follow-up|4
6240590|NCT01846611|9922122|FG001|Overall Study|Lost to Follow-up|6
6240591|NCT01846611|9922121|FG000|Overall Study|Withdrawal by Subject|15
6240592|NCT01846611|9922122|FG001|Overall Study|Withdrawal by Subject|19
6240593|NCT01846611|9922121|FG000|Overall Study|Other|19
6240594|NCT01846611|9922122|FG001|Overall Study|Other|18
6240595|NCT01846624|9922128|FG000|Overall Study|Died during induction, no midostaurin|1
6240596|NCT01846741|9922173|FG000|Baseline Visit|Subject did not meet entry criteria|2
6240597|NCT01847092|9922262|FG000|Overall Study|Adverse Event|12
6240598|NCT01847092|9922263|FG001|Overall Study|Adverse Event|3
6240599|NCT01847092|9922262|FG000|Overall Study|Withdrawal by Subject|5
6240600|NCT01847092|9922263|FG001|Overall Study|Withdrawal by Subject|5
6240601|NCT01847092|9922262|FG000|Overall Study|Protocol Specified|8
6240602|NCT01847092|9922263|FG001|Overall Study|Protocol Specified|0
6240603|NCT01847092|9922262|FG000|Overall Study|Physician Decision|1
6240604|NCT01847092|9922263|FG001|Overall Study|Physician Decision|1
6240605|NCT01847092|9922262|FG000|Overall Study|Protocol Violation|0
6240606|NCT01847092|9922263|FG001|Overall Study|Protocol Violation|2
6240607|NCT01847209|9922282|FG000|Overall Study|Withdrawal by Subject|1
6240608|NCT01847209|9922282|FG000|Overall Study|No lung nodule found on intraop CT scan|1
6270258|NCT02151110|9971100|FG002|Overall Study|Withdrawal by Subject|0
6270259|NCT02151110|9971101|FG003|Overall Study|Withdrawal by Subject|0
6270260|NCT02151110|9971102|FG004|Overall Study|Withdrawal by Subject|0
6270261|NCT02151110|9971103|FG005|Overall Study|Withdrawal by Subject|0
6270262|NCT02151110|9971104|FG006|Overall Study|Withdrawal by Subject|0
6270263|NCT02151110|9971105|FG007|Overall Study|Withdrawal by Subject|1
6270264|NCT02151110|9971098|FG000|Overall Study|Lost to Follow-up|0
6270265|NCT02151110|9971099|FG001|Overall Study|Lost to Follow-up|0
6270266|NCT02151110|9971100|FG002|Overall Study|Lost to Follow-up|0
6270267|NCT02151110|9971101|FG003|Overall Study|Lost to Follow-up|0
6270268|NCT02151110|9971102|FG004|Overall Study|Lost to Follow-up|0
6270269|NCT02151110|9971103|FG005|Overall Study|Lost to Follow-up|0
6270270|NCT02151110|9971104|FG006|Overall Study|Lost to Follow-up|0
6270271|NCT02151110|9971105|FG007|Overall Study|Lost to Follow-up|2
6270272|NCT02151149|9971132|FG000|Treatment Period|Death|2
6270273|NCT02151149|9971133|FG001|Treatment Period|Death|3
6270274|NCT02151149|9971132|FG000|Treatment Period|Adverse Event|17
6270275|NCT02151149|9971133|FG001|Treatment Period|Adverse Event|14
6270276|NCT02151149|9971132|FG000|Treatment Period|Progressive Disease|25
6270277|NCT02151149|9971133|FG001|Treatment Period|Progressive Disease|24
6240609|NCT01847313|9922288|FG000|Overall Study|Death|0
6240610|NCT01847313|9922289|FG001|Overall Study|Death|1
6240611|NCT01847313|9922288|FG000|Overall Study|Withdrawal by Subject|0
6240612|NCT01847313|9922289|FG001|Overall Study|Withdrawal by Subject|1
6240613|NCT01847443|9922299|FG000|Study Period 1|Withdrawal by Subject|0
6240614|NCT01847443|9922300|FG001|Study Period 1|Withdrawal by Subject|1
6240615|NCT01847443|9922301|FG002|Study Period 1|Withdrawal by Subject|0
6240616|NCT01847443|9922302|FG003|Study Period 1|Withdrawal by Subject|0
6240617|NCT01847443|9922299|FG000|Washout Period Before Study Period 2|Adverse Event|1
6240618|NCT01847443|9922300|FG001|Washout Period Before Study Period 2|Adverse Event|1
6240619|NCT01847443|9922301|FG002|Washout Period Before Study Period 2|Adverse Event|0
6240620|NCT01847443|9922302|FG003|Washout Period Before Study Period 2|Adverse Event|0
6240621|NCT01847443|9922299|FG000|Washout Period Before Study Period 2|Other reason|1
6240622|NCT01847443|9922300|FG001|Washout Period Before Study Period 2|Other reason|0
6240623|NCT01847443|9922301|FG002|Washout Period Before Study Period 2|Other reason|0
6240624|NCT01847443|9922302|FG003|Washout Period Before Study Period 2|Other reason|0
6240625|NCT01847443|9922299|FG000|Washout Period Before Study Period 3|Other reason|1
6240626|NCT01847443|9922300|FG001|Washout Period Before Study Period 3|Other reason|0
6240627|NCT01847443|9922301|FG002|Washout Period Before Study Period 3|Other reason|0
6240628|NCT01847443|9922302|FG003|Washout Period Before Study Period 3|Other reason|0
6240629|NCT01847443|9922299|FG000|Washout Period Before Study Period 4|Withdrawal by Subject|1
6240630|NCT01847443|9922300|FG001|Washout Period Before Study Period 4|Withdrawal by Subject|0
6240631|NCT01847443|9922301|FG002|Washout Period Before Study Period 4|Withdrawal by Subject|0
6240632|NCT01847443|9922302|FG003|Washout Period Before Study Period 4|Withdrawal by Subject|0
6240633|NCT01847443|9922299|FG000|Washout Period Before Study Period 4|Positive alcohol test|1
6240634|NCT01847443|9922300|FG001|Washout Period Before Study Period 4|Positive alcohol test|0
6240635|NCT01847443|9922301|FG002|Washout Period Before Study Period 4|Positive alcohol test|0
6240636|NCT01847443|9922302|FG003|Washout Period Before Study Period 4|Positive alcohol test|0
6240637|NCT01847755|9922403|FG000|Overall Study|Adverse Event|2
6240638|NCT01847755|9922403|FG000|Overall Study|Withdrawal by Subject|2
6240639|NCT01847755|9922403|FG000|Overall Study|Physician Decision|1
6240640|NCT01847885|9922409|FG000|Initial Enrollment (Consented)|Protocol Violation|1
6240641|NCT01847885|9922410|FG001|Initial Enrollment (Consented)|Protocol Violation|0
6240642|NCT01847885|9922411|FG002|Initial Enrollment (Consented)|Protocol Violation|0
6240643|NCT01847885|9922409|FG000|Initial Enrollment (Consented)|Withdrawal by Subject|2
6240644|NCT01847885|9922410|FG001|Initial Enrollment (Consented)|Withdrawal by Subject|0
6240645|NCT01847885|9922411|FG002|Initial Enrollment (Consented)|Withdrawal by Subject|0
6240646|NCT01847885|9922409|FG000|Initial Enrollment (Consented)|Screen failure|39
6240647|NCT01847885|9922410|FG001|Initial Enrollment (Consented)|Screen failure|0
6240648|NCT01847885|9922411|FG002|Initial Enrollment (Consented)|Screen failure|0
6240649|NCT01847885|9922409|FG000|Initial Enrollment (Consented)|Pending prior to enrollment stop|6
6240650|NCT01847885|9922410|FG001|Initial Enrollment (Consented)|Pending prior to enrollment stop|0
6240651|NCT01847885|9922411|FG002|Initial Enrollment (Consented)|Pending prior to enrollment stop|0
6240652|NCT01847885|9922409|FG000|Randomization|Protocol Violation|0
6240653|NCT01847885|9922410|FG001|Randomization|Protocol Violation|1
6240654|NCT01847885|9922411|FG002|Randomization|Protocol Violation|0
6240655|NCT01847885|9922409|FG000|Randomization|Withdrawal by Subject|0
6240656|NCT01847885|9922410|FG001|Randomization|Withdrawal by Subject|0
6240657|NCT01847885|9922411|FG002|Randomization|Withdrawal by Subject|2
6240658|NCT01847885|9922409|FG000|Randomization|Screen Failure|0
6240659|NCT01847885|9922410|FG001|Randomization|Screen Failure|3
6240660|NCT01847885|9922411|FG002|Randomization|Screen Failure|0
6240661|NCT01848145|9922456|FG000|Infusion 1: Week 1, Day 1 - 226 Minutes|Adverse Event|1
6240662|NCT01848145|9922456|FG000|Infusion 2: Week 1, Day 3 - 167 Minutes|Adverse Event|1
6240663|NCT01848145|9922456|FG000|Infusion 2: Week 1, Day 3 - 167 Minutes|Disease Progression|1
6240664|NCT01848145|9922456|FG000|Infusion 3: Week 2, Day 1 - 120 Minutes|Adverse Event|1
6240665|NCT01848145|9922456|FG000|Subsequent Infusions: Weeks 3-8|Disease Progression|6
6240666|NCT01848145|9922456|FG000|Subsequent Infusions: Weeks 3-8|Withdrawal by Subject|3
6240667|NCT01848145|9922456|FG000|Subsequent Infusions: Weeks 3-8|Death|1
6240668|NCT01848210|9922481|FG000|Overall Study|Informed Consent Form Withdrawal|28
6240669|NCT01848210|9922482|FG001|Overall Study|Informed Consent Form Withdrawal|24
6240670|NCT01848210|9922481|FG000|Overall Study|Lost to Follow-up|24
6240671|NCT01848210|9922482|FG001|Overall Study|Lost to Follow-up|12
6240672|NCT01848210|9922481|FG000|Overall Study|Protocol Violation|3
6240673|NCT01848210|9922482|FG001|Overall Study|Protocol Violation|5
6240674|NCT01848210|9922481|FG000|Overall Study|Use of Forbidden Drugs|9
6240675|NCT01848210|9922482|FG001|Overall Study|Use of Forbidden Drugs|10
6240676|NCT01848210|9922481|FG000|Overall Study|Impedition Condition|5
6240677|NCT01848210|9922482|FG001|Overall Study|Impedition Condition|9
6240678|NCT01848210|9922481|FG000|Overall Study|Adverse Event|7
6240679|NCT01848210|9922482|FG001|Overall Study|Adverse Event|9
6240680|NCT01848210|9922481|FG000|Overall Study|Discontinuation Criterion|5
6240681|NCT01848210|9922482|FG001|Overall Study|Discontinuation Criterion|7
6240682|NCT01848210|9922481|FG000|Overall Study|Hypesensitivity|1
6240683|NCT01848210|9922482|FG001|Overall Study|Hypesensitivity|0
6240684|NCT01848210|9922481|FG000|Overall Study|Hepatic Function Alteration|4
6240685|NCT01848210|9922482|FG001|Overall Study|Hepatic Function Alteration|0
6240686|NCT01848210|9922481|FG000|Overall Study|Chronic Venous Insufficiency Course|1
6240687|NCT01848210|9922482|FG001|Overall Study|Chronic Venous Insufficiency Course|2
6240688|NCT01848210|9922481|FG000|Overall Study|Administrative|1
6240689|NCT01848210|9922482|FG001|Overall Study|Administrative|0
6240690|NCT01848288|9922488|FG000|Overall Study|Death|1
6240691|NCT01848288|9922488|FG000|Overall Study|Protocol Violation|1
6240692|NCT01848288|9922488|FG000|Overall Study|Withdrawal by Subject|1
6240693|NCT01848353|9922497|FG000|Phase 1|Withdrawal by Subject|3
6240694|NCT01848353|9922498|FG001|Phase 1|Withdrawal by Subject|1
6240695|NCT01848353|9922499|FG002|Phase 1|Withdrawal by Subject|0
6240696|NCT01848353|9922500|FG003|Phase 1|Withdrawal by Subject|0
6240697|NCT01848353|9922497|FG000|Phase 2|Withdrawal by Subject|3
6240698|NCT01848353|9922498|FG001|Phase 2|Withdrawal by Subject|2
6240699|NCT01848353|9922499|FG002|Phase 2|Withdrawal by Subject|0
6240700|NCT01848353|9922500|FG003|Phase 2|Withdrawal by Subject|0
6240701|NCT01848353|9922497|FG000|Phase 3|Withdrawal by Subject|1
6240702|NCT01848353|9922498|FG001|Phase 3|Withdrawal by Subject|1
6240703|NCT01848353|9922499|FG002|Phase 3|Withdrawal by Subject|0
6240704|NCT01848353|9922500|FG003|Phase 3|Withdrawal by Subject|0
6240705|NCT01848457|9922526|FG000|Overall Study|Death|1
6240706|NCT01848457|9922527|FG001|Overall Study|Death|0
6240707|NCT01848457|9922528|FG002|Overall Study|Death|0
6240708|NCT01848457|9922529|FG003|Overall Study|Death|0
6240709|NCT01848483|9922549|FG000|Overall Study|Death|2
6240710|NCT01848483|9922550|FG001|Overall Study|Death|1
6240711|NCT01848483|9922549|FG000|Overall Study|Lost to Follow-up|6
6240712|NCT01848483|9922550|FG001|Overall Study|Lost to Follow-up|8
6240713|NCT01848483|9922549|FG000|Overall Study|Withdrawal by Subject|1
6240714|NCT01848483|9922550|FG001|Overall Study|Withdrawal by Subject|0
6240715|NCT01848483|9922549|FG000|Overall Study|Incarceration|2
6240716|NCT01848483|9922550|FG001|Overall Study|Incarceration|2
6240717|NCT01848756|9922557|FG000|Overall Study|Adverse Event|1
6240718|NCT01848756|9922557|FG000|Overall Study|Withdrawal by Subject|1
6240719|NCT01848756|9922557|FG000|Overall Study|Enrolled in Error|1
6240720|NCT01848834|9922576|FG000|Overall Study|Adverse Event|3
6240721|NCT01848834|9922577|FG001|Overall Study|Adverse Event|11
6240722|NCT01848834|9922578|FG002|Overall Study|Adverse Event|3
6240723|NCT01848834|9922579|FG003|Overall Study|Adverse Event|5
6240724|NCT01848834|9922580|FG004|Overall Study|Adverse Event|9
6240725|NCT01848834|9922576|FG000|Overall Study|Death|2
6240726|NCT01848834|9922577|FG001|Overall Study|Death|11
6240727|NCT01848834|9922578|FG002|Overall Study|Death|1
6240728|NCT01848834|9922579|FG003|Overall Study|Death|8
6240729|NCT01848834|9922580|FG004|Overall Study|Death|27
6240730|NCT01848834|9922576|FG000|Overall Study|Excluded Medication|5
6240731|NCT01848834|9922577|FG001|Overall Study|Excluded Medication|4
6240732|NCT01848834|9922578|FG002|Overall Study|Excluded Medication|3
6240733|NCT01848834|9922579|FG003|Overall Study|Excluded Medication|6
6240734|NCT01848834|9922580|FG004|Overall Study|Excluded Medication|6
6240735|NCT01848834|9922576|FG000|Overall Study|Lost to Follow-up|5
6240736|NCT01848834|9922577|FG001|Overall Study|Lost to Follow-up|5
6240737|NCT01848834|9922578|FG002|Overall Study|Lost to Follow-up|3
6240738|NCT01848834|9922579|FG003|Overall Study|Lost to Follow-up|0
6240739|NCT01848834|9922580|FG004|Overall Study|Lost to Follow-up|3
6240740|NCT01848834|9922576|FG000|Overall Study|Physician Decision|1
6240741|NCT01848834|9922577|FG001|Overall Study|Physician Decision|3
6240742|NCT01848834|9922578|FG002|Overall Study|Physician Decision|4
6240743|NCT01848834|9922579|FG003|Overall Study|Physician Decision|0
6240744|NCT01848834|9922580|FG004|Overall Study|Physician Decision|11
6240745|NCT01848834|9922576|FG000|Overall Study|Protocol Violation|0
6240746|NCT01848834|9922577|FG001|Overall Study|Protocol Violation|0
6240747|NCT01848834|9922578|FG002|Overall Study|Protocol Violation|0
6240748|NCT01848834|9922579|FG003|Overall Study|Protocol Violation|0
6240749|NCT01848834|9922580|FG004|Overall Study|Protocol Violation|1
6240750|NCT01848834|9922576|FG000|Overall Study|Sponsor Decision|1
6240751|NCT01848834|9922577|FG001|Overall Study|Sponsor Decision|1
6240752|NCT01848834|9922578|FG002|Overall Study|Sponsor Decision|0
6240753|NCT01848834|9922579|FG003|Overall Study|Sponsor Decision|1
6240754|NCT01848834|9922580|FG004|Overall Study|Sponsor Decision|1
6240755|NCT01848834|9922576|FG000|Overall Study|Withdrawal by Subject|2
6240756|NCT01848834|9922577|FG001|Overall Study|Withdrawal by Subject|13
6240757|NCT01848834|9922578|FG002|Overall Study|Withdrawal by Subject|10
6240758|NCT01848834|9922579|FG003|Overall Study|Withdrawal by Subject|6
6240759|NCT01848834|9922580|FG004|Overall Study|Withdrawal by Subject|36
6240760|NCT01848938|9922616|FG000|Overall Study|Lost to Follow-up|1
6240761|NCT01848938|9922617|FG001|Overall Study|Lost to Follow-up|1
6240762|NCT01848990|9922635|FG000|Overall Study|Adverse Event|6
6240763|NCT01848990|9922636|FG001|Overall Study|Adverse Event|2
6240764|NCT01848990|9922637|FG002|Overall Study|Adverse Event|0
6240765|NCT01848990|9922635|FG000|Overall Study|Lost to Follow-up|6
6240766|NCT01848990|9922636|FG001|Overall Study|Lost to Follow-up|2
6240767|NCT01848990|9922637|FG002|Overall Study|Lost to Follow-up|2
6240768|NCT01848990|9922635|FG000|Overall Study|Protocol Violation|1
6240769|NCT01848990|9922636|FG001|Overall Study|Protocol Violation|1
6240770|NCT01848990|9922637|FG002|Overall Study|Protocol Violation|0
6240771|NCT01848990|9922635|FG000|Overall Study|Withdrawal by Subject|29
6240772|NCT01848990|9922636|FG001|Overall Study|Withdrawal by Subject|10
6240773|NCT01848990|9922637|FG002|Overall Study|Withdrawal by Subject|11
6240774|NCT01848990|9922635|FG000|Overall Study|Physician Decision|1
6240775|NCT01848990|9922636|FG001|Overall Study|Physician Decision|1
6240776|NCT01848990|9922637|FG002|Overall Study|Physician Decision|0
6240777|NCT01848990|9922635|FG000|Overall Study|Non Compliance|1
6240778|NCT01848990|9922636|FG001|Overall Study|Non Compliance|0
6240779|NCT01848990|9922637|FG002|Overall Study|Non Compliance|0
6240780|NCT01848990|9922635|FG000|Overall Study|Death|1
6240781|NCT01848990|9922636|FG001|Overall Study|Death|0
6240782|NCT01848990|9922637|FG002|Overall Study|Death|1
6240783|NCT01848990|9922635|FG000|Overall Study|Other|1
6240784|NCT01848990|9922636|FG001|Overall Study|Other|4
6240785|NCT01848990|9922637|FG002|Overall Study|Other|2
6240786|NCT01849055|9922655|FG000|Overall Study|Withdrawal by Subject|0
6240787|NCT01849055|9922656|FG001|Overall Study|Withdrawal by Subject|0
6240788|NCT01849055|9922657|FG002|Overall Study|Withdrawal by Subject|1
6240789|NCT01849055|9922658|FG003|Overall Study|Withdrawal by Subject|0
6240790|NCT01849055|9922659|FG004|Overall Study|Withdrawal by Subject|0
6240791|NCT01849055|9922660|FG005|Overall Study|Withdrawal by Subject|0
6240792|NCT01849276|9922696|FG000|Followed for Survival for 5 Years|Death|1
6240793|NCT01849276|9922696|FG000|Followed for Survival for 5 Years|Early termination of the study|1
6240794|NCT01849289|9922702|FG000|Overall Study|Adverse Event|3
6240795|NCT01849289|9922703|FG001|Overall Study|Adverse Event|3
6240796|NCT01849289|9922702|FG000|Overall Study|Protocol Violation|3
6240797|NCT01849289|9922703|FG001|Overall Study|Protocol Violation|3
6240798|NCT01849289|9922702|FG000|Overall Study|Withdrawal criteria|1
6240799|NCT01849289|9922703|FG001|Overall Study|Withdrawal criteria|0
6240800|NCT01849289|9922702|FG000|Overall Study|Unclassified|25
6240801|NCT01849289|9922703|FG001|Overall Study|Unclassified|18
6240802|NCT01849458|9922714|FG000|Overall Study|Lost to Follow-up|4
6240803|NCT01849497|9922720|FG000|Overall Study|Withdrawal by Subject|1
6240804|NCT01849497|9922721|FG001|Overall Study|Withdrawal by Subject|2
6240805|NCT01849497|9922720|FG000|Overall Study|Sponsor Decision|0
6240806|NCT01849497|9922721|FG001|Overall Study|Sponsor Decision|1
6240807|NCT01849497|9922720|FG000|Overall Study|Lost to Follow-up|0
6240808|NCT01849497|9922721|FG001|Overall Study|Lost to Follow-up|1
6240809|NCT01849562|9922730|FG000|Overall Study|Lost to Follow-up|1
6240810|NCT01849562|9922731|FG001|Overall Study|Lost to Follow-up|0
6240811|NCT01849562|9922732|FG002|Overall Study|Lost to Follow-up|0
6240812|NCT01849562|9922730|FG000|Overall Study|Non-compliance with Study Drug|1
6240813|NCT01849562|9922731|FG001|Overall Study|Non-compliance with Study Drug|0
6240814|NCT01849562|9922732|FG002|Overall Study|Non-compliance with Study Drug|0
6240815|NCT01849588|9922752|FG000|Overall Study|Lack of Efficacy|3
6240816|NCT01849848|9922805|FG000|Overall Study|Physician Decision|1
6240817|NCT01849848|9922805|FG000|Overall Study|Progression of the primary disease|3
6240818|NCT01850030|9922811|FG000|Overall Study|Adverse Event|64
6240819|NCT01850030|9922812|FG001|Overall Study|Adverse Event|82
6240820|NCT01850030|9922811|FG000|Overall Study|Lack of Efficacy|3
6240821|NCT01850030|9922812|FG001|Overall Study|Lack of Efficacy|1
6240822|NCT01850030|9922811|FG000|Overall Study|Lost to Follow-up|5
6240823|NCT01850030|9922812|FG001|Overall Study|Lost to Follow-up|5
6240824|NCT01850030|9922811|FG000|Overall Study|Withdrawal by Subject|3
6240825|NCT01850030|9922812|FG001|Overall Study|Withdrawal by Subject|4
6240826|NCT01850030|9922811|FG000|Overall Study|Protocol Violation|24
6240827|NCT01850030|9922812|FG001|Overall Study|Protocol Violation|28
6240828|NCT01850030|9922811|FG000|Overall Study|pregnancy not confirmed at visit 4|248
6240829|NCT01850030|9922812|FG001|Overall Study|pregnancy not confirmed at visit 4|249
6240830|NCT01850446|9922833|FG000|Overall Study|Lack of Efficacy|1
6240831|NCT01850446|9922834|FG001|Overall Study|Lack of Efficacy|0
6240832|NCT01850446|9922833|FG000|Overall Study|Withdrawal by Subject|4
6240833|NCT01850446|9922834|FG001|Overall Study|Withdrawal by Subject|0
6240834|NCT01850446|9922833|FG000|Overall Study|Protocol Violation|0
6240835|NCT01850446|9922834|FG001|Overall Study|Protocol Violation|2
6240836|NCT01850589|9922860|FG000|Overall Study|Withdrawal by Subject|8
6240837|NCT01850589|9922861|FG001|Overall Study|Withdrawal by Subject|0
6240838|NCT01850602|9922869|FG000|Overall Study|Adverse Event|7
6240839|NCT01850602|9922870|FG001|Overall Study|Adverse Event|10
6240840|NCT01850602|9922869|FG000|Overall Study|Physician Decision|2
6240841|NCT01850602|9922870|FG001|Overall Study|Physician Decision|1
6240842|NCT01850602|9922869|FG000|Overall Study|Withdrawal by Subject|2
6240843|NCT01850602|9922870|FG001|Overall Study|Withdrawal by Subject|4
6240844|NCT01850602|9922869|FG000|Overall Study|Decrease in serum calcium|2
6240845|NCT01850602|9922870|FG001|Overall Study|Decrease in serum calcium|3
6240846|NCT01850602|9922869|FG000|Overall Study|Increase in serum ferritin|1
6240847|NCT01850602|9922870|FG001|Overall Study|Increase in serum ferritin|0
6240848|NCT01850615|9922878|FG000|Overall Study|Protocol Violation|4
6240849|NCT01850615|9922879|FG001|Overall Study|Protocol Violation|1
6240850|NCT01850615|9922878|FG000|Overall Study|Adverse Event|2
6240851|NCT01850615|9922879|FG001|Overall Study|Adverse Event|1
6240852|NCT01850615|9922878|FG000|Overall Study|Withdrawal by Subject|3
6240853|NCT01850615|9922879|FG001|Overall Study|Withdrawal by Subject|1
6240854|NCT01850615|9922878|FG000|Overall Study|Lost to Follow-up|0
6240855|NCT01850615|9922879|FG001|Overall Study|Lost to Follow-up|1
6240856|NCT01850615|9922878|FG000|Overall Study|Unclassified|0
6240857|NCT01850615|9922879|FG001|Overall Study|Unclassified|1
6240858|NCT01850641|9922885|FG000|Overall Study|Physician Decision|1
6240859|NCT01850641|9922885|FG000|Overall Study|Decrease in serum phosphorus|1
6240860|NCT01850641|9922885|FG000|Overall Study|Decrease in serum calcium|2
6240861|NCT01850641|9922885|FG000|Overall Study|Increase in serum ferritin|1
6240862|NCT01850823|9922905|FG000|Overall Study|Early Visit Window|0
6240863|NCT01850823|9922906|FG001|Overall Study|Early Visit Window|1
6240864|NCT01850823|9922907|FG002|Overall Study|Early Visit Window|4
6240865|NCT01850823|9922905|FG000|Overall Study|Enrolled in Error|0
6240866|NCT01850823|9922906|FG001|Overall Study|Enrolled in Error|1
6240867|NCT01850823|9922907|FG002|Overall Study|Enrolled in Error|2
6240868|NCT01850823|9922905|FG000|Overall Study|Lack of Efficacy|1
6240869|NCT01850823|9922906|FG001|Overall Study|Lack of Efficacy|0
6240870|NCT01850823|9922907|FG002|Overall Study|Lack of Efficacy|0
6240871|NCT01850823|9922905|FG000|Overall Study|Lost to Follow-up|0
6240872|NCT01850823|9922906|FG001|Overall Study|Lost to Follow-up|0
6240873|NCT01850823|9922907|FG002|Overall Study|Lost to Follow-up|1
6240874|NCT01850823|9922905|FG000|Overall Study|Restricted Medication|0
6240875|NCT01850823|9922906|FG001|Overall Study|Restricted Medication|0
6240876|NCT01850823|9922907|FG002|Overall Study|Restricted Medication|2
6240877|NCT01850823|9922905|FG000|Overall Study|Significant worstening of SAR|0
6240878|NCT01850823|9922906|FG001|Overall Study|Significant worstening of SAR|1
6240879|NCT01850823|9922907|FG002|Overall Study|Significant worstening of SAR|0
6240880|NCT01850823|9922905|FG000|Overall Study|Withdrawal by Subject|2
6240881|NCT01850823|9922906|FG001|Overall Study|Withdrawal by Subject|0
6240882|NCT01850823|9922907|FG002|Overall Study|Withdrawal by Subject|1
6240883|NCT01851330|9922920|FG000|Overall Study|Lack of Efficacy|10
6240884|NCT01851330|9922921|FG001|Overall Study|Lack of Efficacy|9
6240885|NCT01851330|9922922|FG002|Overall Study|Lack of Efficacy|2
6240886|NCT01851330|9922920|FG000|Overall Study|Lost to Follow-up|1
6240887|NCT01851330|9922921|FG001|Overall Study|Lost to Follow-up|6
6240888|NCT01851330|9922922|FG002|Overall Study|Lost to Follow-up|9
6240889|NCT01851330|9922920|FG000|Overall Study|Withdrew Consent|2
6240890|NCT01851330|9922921|FG001|Overall Study|Withdrew Consent|1
6240891|NCT01851330|9922922|FG002|Overall Study|Withdrew Consent|0
6240892|NCT01851330|9922920|FG000|Overall Study|Investigator's Discretion|0
6240893|NCT01851330|9922921|FG001|Overall Study|Investigator's Discretion|0
6240894|NCT01851330|9922922|FG002|Overall Study|Investigator's Discretion|1
6240895|NCT01851590|9922933|FG000|Overall Study|Withdrawal by Subject|0
6240896|NCT01851590|9922934|FG001|Overall Study|Withdrawal by Subject|0
6240897|NCT01851590|9922935|FG002|Overall Study|Withdrawal by Subject|1
6240898|NCT01851590|9922933|FG000|Overall Study|Adverse Event|0
6240899|NCT01851590|9922934|FG001|Overall Study|Adverse Event|0
6240900|NCT01851590|9922935|FG002|Overall Study|Adverse Event|2
6240901|NCT01851590|9922933|FG000|Overall Study|Lack of Efficacy|0
6240902|NCT01851590|9922934|FG001|Overall Study|Lack of Efficacy|1
6240903|NCT01851590|9922935|FG002|Overall Study|Lack of Efficacy|0
6240904|NCT01851720|9922958|FG000|Overall Study|Lost to Follow-up|0
6240905|NCT01851720|9922959|FG001|Overall Study|Lost to Follow-up|1
6240906|NCT01851863|9922973|FG000|Overall Study|Did not receive study medication|2
6240907|NCT01851863|9922974|FG001|Overall Study|Did not receive study medication|5
6085930|NCT00657150|9695563|FG000|Treatment|Other|13
6085931|NCT00657150|9695564|FG001|Treatment|Other|15
6085932|NCT00657267|9695570|FG000|Overall Study|Progressive disease|45
6085933|NCT00657267|9695570|FG000|Overall Study|Adverse Event|9
6085934|NCT00657358|9695580|FG000|Overall Study|Lack of Efficacy|6
6240908|NCT01851863|9922975|FG002|Overall Study|Did not receive study medication|3
6240909|NCT01851863|9922976|FG003|Overall Study|Did not receive study medication|0
6240910|NCT01851863|9922973|FG000|Overall Study|Lost to Follow-up|3
6240911|NCT01851863|9922974|FG001|Overall Study|Lost to Follow-up|4
6240912|NCT01851863|9922975|FG002|Overall Study|Lost to Follow-up|2
6240913|NCT01851863|9922976|FG003|Overall Study|Lost to Follow-up|3
6240914|NCT01852045|9923024|FG000|Overall Study|Adverse Event|1
6240915|NCT01852045|9923025|FG001|Overall Study|Adverse Event|0
6240916|NCT01852045|9923026|FG002|Overall Study|Adverse Event|0
6240917|NCT01852045|9923024|FG000|Overall Study|Lack of Efficacy|3
6240918|NCT01852045|9923025|FG001|Overall Study|Lack of Efficacy|0
6240919|NCT01852045|9923026|FG002|Overall Study|Lack of Efficacy|0
6240920|NCT01852045|9923024|FG000|Overall Study|Lost to Follow-up|0
6240921|NCT01852045|9923025|FG001|Overall Study|Lost to Follow-up|1
6240922|NCT01852045|9923026|FG002|Overall Study|Lost to Follow-up|1
6240923|NCT01852045|9923024|FG000|Overall Study|Withdrawal by Subject|1
6240924|NCT01852045|9923025|FG001|Overall Study|Withdrawal by Subject|0
6240925|NCT01852045|9923026|FG002|Overall Study|Withdrawal by Subject|1
6240926|NCT01852045|9923024|FG000|Overall Study|Other Miscellaneous Reasons|1
6240927|NCT01852045|9923025|FG001|Overall Study|Other Miscellaneous Reasons|3
6240928|NCT01852045|9923026|FG002|Overall Study|Other Miscellaneous Reasons|2
6240929|NCT01852058|9923037|FG000|Treatment Cycle 1, Occurred in Study 120|Lost to Follow-up|1
6240930|NCT01852058|9923038|FG001|Treatment Cycle 1, Occurred in Study 120|Lost to Follow-up|0
6240931|NCT01852058|9923039|FG002|Treatment Cycle 1, Occurred in Study 120|Lost to Follow-up|0
6240932|NCT01852058|9923040|FG003|Treatment Cycle 1, Occurred in Study 120|Lost to Follow-up|0
6240933|NCT01852058|9923041|FG004|Treatment Cycle 1, Occurred in Study 120|Lost to Follow-up|0
6085935|NCT00657371|9695585|FG000|Overall Study|Poor bowel preparation|15
6085936|NCT00657371|9695585|FG000|Overall Study|Unable to intubate the cecum|5
6240934|NCT01852058|9923042|FG005|Treatment Cycle 1, Occurred in Study 120|Lost to Follow-up|0
6240935|NCT01852058|9923043|FG006|Treatment Cycle 1, Occurred in Study 120|Lost to Follow-up|0
6240936|NCT01852058|9923044|FG007|Treatment Cycle 1, Occurred in Study 120|Lost to Follow-up|0
6240937|NCT01852058|9923045|FG008|Treatment Cycle 1, Occurred in Study 120|Lost to Follow-up|0
6240938|NCT01852058|9923046|FG009|Treatment Cycle 1, Occurred in Study 120|Lost to Follow-up|0
6240939|NCT01852058|9923047|FG010|Treatment Cycle 1, Occurred in Study 120|Lost to Follow-up|0
6240940|NCT01852058|9923048|FG011|Treatment Cycle 1, Occurred in Study 120|Lost to Follow-up|0
6240941|NCT01852058|9923037|FG000|Treatment Cycle2:Retreatment 1,Study 121|Adverse Event|0
6240942|NCT01852058|9923038|FG001|Treatment Cycle2:Retreatment 1,Study 121|Adverse Event|0
6240943|NCT01852058|9923039|FG002|Treatment Cycle2:Retreatment 1,Study 121|Adverse Event|0
6240944|NCT01852058|9923040|FG003|Treatment Cycle2:Retreatment 1,Study 121|Adverse Event|0
6240945|NCT01852058|9923041|FG004|Treatment Cycle2:Retreatment 1,Study 121|Adverse Event|1
6240946|NCT01852058|9923042|FG005|Treatment Cycle2:Retreatment 1,Study 121|Adverse Event|0
6240947|NCT01852058|9923043|FG006|Treatment Cycle2:Retreatment 1,Study 121|Adverse Event|0
6240948|NCT01852058|9923044|FG007|Treatment Cycle2:Retreatment 1,Study 121|Adverse Event|0
6240949|NCT01852058|9923045|FG008|Treatment Cycle2:Retreatment 1,Study 121|Adverse Event|0
6240950|NCT01852058|9923046|FG009|Treatment Cycle2:Retreatment 1,Study 121|Adverse Event|0
6240951|NCT01852058|9923047|FG010|Treatment Cycle2:Retreatment 1,Study 121|Adverse Event|0
6240952|NCT01852058|9923048|FG011|Treatment Cycle2:Retreatment 1,Study 121|Adverse Event|0
6240953|NCT01852058|9923037|FG000|Treatment Cycle2:Retreatment 1,Study 121|Lack of Efficacy|0
6240954|NCT01852058|9923038|FG001|Treatment Cycle2:Retreatment 1,Study 121|Lack of Efficacy|0
6240955|NCT01852058|9923039|FG002|Treatment Cycle2:Retreatment 1,Study 121|Lack of Efficacy|0
6240956|NCT01852058|9923040|FG003|Treatment Cycle2:Retreatment 1,Study 121|Lack of Efficacy|0
6240957|NCT01852058|9923041|FG004|Treatment Cycle2:Retreatment 1,Study 121|Lack of Efficacy|1
6240958|NCT01852058|9923042|FG005|Treatment Cycle2:Retreatment 1,Study 121|Lack of Efficacy|1
6240959|NCT01852058|9923043|FG006|Treatment Cycle2:Retreatment 1,Study 121|Lack of Efficacy|0
6240960|NCT01852058|9923044|FG007|Treatment Cycle2:Retreatment 1,Study 121|Lack of Efficacy|0
6240961|NCT01852058|9923045|FG008|Treatment Cycle2:Retreatment 1,Study 121|Lack of Efficacy|0
6240962|NCT01852058|9923046|FG009|Treatment Cycle2:Retreatment 1,Study 121|Lack of Efficacy|0
6240963|NCT01852058|9923047|FG010|Treatment Cycle2:Retreatment 1,Study 121|Lack of Efficacy|0
6240964|NCT01852058|9923048|FG011|Treatment Cycle2:Retreatment 1,Study 121|Lack of Efficacy|0
6240965|NCT01852058|9923037|FG000|Treatment Cycle2:Retreatment 1,Study 121|Lost to Follow-up|0
6240966|NCT01852058|9923038|FG001|Treatment Cycle2:Retreatment 1,Study 121|Lost to Follow-up|0
6240967|NCT01852058|9923039|FG002|Treatment Cycle2:Retreatment 1,Study 121|Lost to Follow-up|0
6240968|NCT01852058|9923040|FG003|Treatment Cycle2:Retreatment 1,Study 121|Lost to Follow-up|0
6240969|NCT01852058|9923041|FG004|Treatment Cycle2:Retreatment 1,Study 121|Lost to Follow-up|1
6240970|NCT01852058|9923042|FG005|Treatment Cycle2:Retreatment 1,Study 121|Lost to Follow-up|0
6240971|NCT01852058|9923043|FG006|Treatment Cycle2:Retreatment 1,Study 121|Lost to Follow-up|0
6240972|NCT01852058|9923044|FG007|Treatment Cycle2:Retreatment 1,Study 121|Lost to Follow-up|0
6240973|NCT01852058|9923045|FG008|Treatment Cycle2:Retreatment 1,Study 121|Lost to Follow-up|0
6240974|NCT01852058|9923046|FG009|Treatment Cycle2:Retreatment 1,Study 121|Lost to Follow-up|0
6240975|NCT01852058|9923047|FG010|Treatment Cycle2:Retreatment 1,Study 121|Lost to Follow-up|0
6240976|NCT01852058|9923048|FG011|Treatment Cycle2:Retreatment 1,Study 121|Lost to Follow-up|0
6240977|NCT01852058|9923037|FG000|Treatment Cycle2:Retreatment 1,Study 121|Withdrawal by Subject|0
6240978|NCT01852058|9923038|FG001|Treatment Cycle2:Retreatment 1,Study 121|Withdrawal by Subject|0
6240979|NCT01852058|9923039|FG002|Treatment Cycle2:Retreatment 1,Study 121|Withdrawal by Subject|0
6240980|NCT01852058|9923040|FG003|Treatment Cycle2:Retreatment 1,Study 121|Withdrawal by Subject|0
6240981|NCT01852058|9923041|FG004|Treatment Cycle2:Retreatment 1,Study 121|Withdrawal by Subject|3
6240982|NCT01852058|9923042|FG005|Treatment Cycle2:Retreatment 1,Study 121|Withdrawal by Subject|1
6240983|NCT01852058|9923043|FG006|Treatment Cycle2:Retreatment 1,Study 121|Withdrawal by Subject|0
6240984|NCT01852058|9923044|FG007|Treatment Cycle2:Retreatment 1,Study 121|Withdrawal by Subject|0
6240985|NCT01852058|9923045|FG008|Treatment Cycle2:Retreatment 1,Study 121|Withdrawal by Subject|0
6240986|NCT01852058|9923046|FG009|Treatment Cycle2:Retreatment 1,Study 121|Withdrawal by Subject|0
6240987|NCT01852058|9923047|FG010|Treatment Cycle2:Retreatment 1,Study 121|Withdrawal by Subject|0
6240988|NCT01852058|9923048|FG011|Treatment Cycle2:Retreatment 1,Study 121|Withdrawal by Subject|0
6240989|NCT01852058|9923037|FG000|Treatment Cycle2:Retreatment 1,Study 121|Protocol Deviation|0
6240990|NCT01852058|9923038|FG001|Treatment Cycle2:Retreatment 1,Study 121|Protocol Deviation|0
6240991|NCT01852058|9923039|FG002|Treatment Cycle2:Retreatment 1,Study 121|Protocol Deviation|0
6240992|NCT01852058|9923040|FG003|Treatment Cycle2:Retreatment 1,Study 121|Protocol Deviation|1
6240993|NCT01852058|9923041|FG004|Treatment Cycle2:Retreatment 1,Study 121|Protocol Deviation|0
6240994|NCT01852058|9923042|FG005|Treatment Cycle2:Retreatment 1,Study 121|Protocol Deviation|0
6240995|NCT01852058|9923043|FG006|Treatment Cycle2:Retreatment 1,Study 121|Protocol Deviation|0
6240996|NCT01852058|9923044|FG007|Treatment Cycle2:Retreatment 1,Study 121|Protocol Deviation|0
6240997|NCT01852058|9923045|FG008|Treatment Cycle2:Retreatment 1,Study 121|Protocol Deviation|0
6240998|NCT01852058|9923046|FG009|Treatment Cycle2:Retreatment 1,Study 121|Protocol Deviation|0
6240999|NCT01852058|9923047|FG010|Treatment Cycle2:Retreatment 1,Study 121|Protocol Deviation|0
6241000|NCT01852058|9923048|FG011|Treatment Cycle2:Retreatment 1,Study 121|Protocol Deviation|0
6241001|NCT01852058|9923037|FG000|Treatment Cycle2:Retreatment 1,Study 121|Reason not Specified|0
6241002|NCT01852058|9923038|FG001|Treatment Cycle2:Retreatment 1,Study 121|Reason not Specified|0
6241003|NCT01852058|9923039|FG002|Treatment Cycle2:Retreatment 1,Study 121|Reason not Specified|0
6241004|NCT01852058|9923040|FG003|Treatment Cycle2:Retreatment 1,Study 121|Reason not Specified|0
6241005|NCT01852058|9923041|FG004|Treatment Cycle2:Retreatment 1,Study 121|Reason not Specified|1
6241006|NCT01852058|9923042|FG005|Treatment Cycle2:Retreatment 1,Study 121|Reason not Specified|7
6241007|NCT01852058|9923043|FG006|Treatment Cycle2:Retreatment 1,Study 121|Reason not Specified|0
6241008|NCT01852058|9923044|FG007|Treatment Cycle2:Retreatment 1,Study 121|Reason not Specified|0
6241009|NCT01852058|9923045|FG008|Treatment Cycle2:Retreatment 1,Study 121|Reason not Specified|0
6241010|NCT01852058|9923046|FG009|Treatment Cycle2:Retreatment 1,Study 121|Reason not Specified|0
6241011|NCT01852058|9923047|FG010|Treatment Cycle2:Retreatment 1,Study 121|Reason not Specified|0
6241012|NCT01852058|9923048|FG011|Treatment Cycle2:Retreatment 1,Study 121|Reason not Specified|0
6241013|NCT01852058|9923037|FG000|Treatment Cycle3:Retreatment 2,Study 121|Withdrawal by Subject|0
6241014|NCT01852058|9923038|FG001|Treatment Cycle3:Retreatment 2,Study 121|Withdrawal by Subject|0
6241015|NCT01852058|9923039|FG002|Treatment Cycle3:Retreatment 2,Study 121|Withdrawal by Subject|0
6241016|NCT01852058|9923040|FG003|Treatment Cycle3:Retreatment 2,Study 121|Withdrawal by Subject|0
6241017|NCT01852058|9923041|FG004|Treatment Cycle3:Retreatment 2,Study 121|Withdrawal by Subject|0
6241018|NCT01852058|9923042|FG005|Treatment Cycle3:Retreatment 2,Study 121|Withdrawal by Subject|0
6241019|NCT01852058|9923043|FG006|Treatment Cycle3:Retreatment 2,Study 121|Withdrawal by Subject|0
6241020|NCT01852058|9923044|FG007|Treatment Cycle3:Retreatment 2,Study 121|Withdrawal by Subject|1
6241021|NCT01852058|9923045|FG008|Treatment Cycle3:Retreatment 2,Study 121|Withdrawal by Subject|0
6241022|NCT01852058|9923046|FG009|Treatment Cycle3:Retreatment 2,Study 121|Withdrawal by Subject|0
6241023|NCT01852058|9923047|FG010|Treatment Cycle3:Retreatment 2,Study 121|Withdrawal by Subject|0
6241024|NCT01852058|9923048|FG011|Treatment Cycle3:Retreatment 2,Study 121|Withdrawal by Subject|0
6241025|NCT01852058|9923037|FG000|Treatment Cycle3:Retreatment 2,Study 121|Reason Not Specified|0
6241026|NCT01852058|9923038|FG001|Treatment Cycle3:Retreatment 2,Study 121|Reason Not Specified|0
6241027|NCT01852058|9923039|FG002|Treatment Cycle3:Retreatment 2,Study 121|Reason Not Specified|0
6241028|NCT01852058|9923040|FG003|Treatment Cycle3:Retreatment 2,Study 121|Reason Not Specified|0
6241029|NCT01852058|9923041|FG004|Treatment Cycle3:Retreatment 2,Study 121|Reason Not Specified|0
6241030|NCT01852058|9923042|FG005|Treatment Cycle3:Retreatment 2,Study 121|Reason Not Specified|0
6241031|NCT01852058|9923043|FG006|Treatment Cycle3:Retreatment 2,Study 121|Reason Not Specified|0
6241032|NCT01852058|9923044|FG007|Treatment Cycle3:Retreatment 2,Study 121|Reason Not Specified|0
6241033|NCT01852058|9923045|FG008|Treatment Cycle3:Retreatment 2,Study 121|Reason Not Specified|1
6241034|NCT01852058|9923046|FG009|Treatment Cycle3:Retreatment 2,Study 121|Reason Not Specified|0
6241035|NCT01852058|9923047|FG010|Treatment Cycle3:Retreatment 2,Study 121|Reason Not Specified|0
6241036|NCT01852058|9923048|FG011|Treatment Cycle3:Retreatment 2,Study 121|Reason Not Specified|0
6241037|NCT01852110|9923117|FG000|Overall Study|Adverse Event|12
6241038|NCT01852110|9923118|FG001|Overall Study|Adverse Event|5
6241039|NCT01852110|9923119|FG002|Overall Study|Adverse Event|0
6241040|NCT01852110|9923120|FG003|Overall Study|Adverse Event|0
6241041|NCT01852110|9923121|FG004|Overall Study|Adverse Event|0
6241042|NCT01852110|9923122|FG005|Overall Study|Adverse Event|0
6241043|NCT01852110|9923117|FG000|Overall Study|Lost to Follow-up|1
6241044|NCT01852110|9923118|FG001|Overall Study|Lost to Follow-up|3
6241045|NCT01852110|9923119|FG002|Overall Study|Lost to Follow-up|0
6241046|NCT01852110|9923120|FG003|Overall Study|Lost to Follow-up|0
6241047|NCT01852110|9923121|FG004|Overall Study|Lost to Follow-up|0
6241048|NCT01852110|9923122|FG005|Overall Study|Lost to Follow-up|0
6241049|NCT01852110|9923117|FG000|Overall Study|Non-compliance with Study Drug|2
6241050|NCT01852110|9923118|FG001|Overall Study|Non-compliance with Study Drug|1
6241051|NCT01852110|9923119|FG002|Overall Study|Non-compliance with Study Drug|0
6241052|NCT01852110|9923120|FG003|Overall Study|Non-compliance with Study Drug|0
6241053|NCT01852110|9923121|FG004|Overall Study|Non-compliance with Study Drug|0
6241054|NCT01852110|9923122|FG005|Overall Study|Non-compliance with Study Drug|0
6241055|NCT01852110|9923117|FG000|Overall Study|Physician Decision|1
6241056|NCT01852110|9923118|FG001|Overall Study|Physician Decision|0
6241057|NCT01852110|9923119|FG002|Overall Study|Physician Decision|0
6241058|NCT01852110|9923120|FG003|Overall Study|Physician Decision|0
6241059|NCT01852110|9923121|FG004|Overall Study|Physician Decision|0
6241060|NCT01852110|9923122|FG005|Overall Study|Physician Decision|0
6241061|NCT01852110|9923117|FG000|Overall Study|Protocol Violation|0
6241062|NCT01852110|9923118|FG001|Overall Study|Protocol Violation|1
6241063|NCT01852110|9923119|FG002|Overall Study|Protocol Violation|0
6241064|NCT01852110|9923120|FG003|Overall Study|Protocol Violation|0
6241065|NCT01852110|9923121|FG004|Overall Study|Protocol Violation|0
6241066|NCT01852110|9923122|FG005|Overall Study|Protocol Violation|0
6241067|NCT01852110|9923117|FG000|Overall Study|Study Terminated by Sponsor|30
6241068|NCT01852110|9923118|FG001|Overall Study|Study Terminated by Sponsor|32
6241069|NCT01852110|9923119|FG002|Overall Study|Study Terminated by Sponsor|0
6241070|NCT01852110|9923120|FG003|Overall Study|Study Terminated by Sponsor|0
6241071|NCT01852110|9923121|FG004|Overall Study|Study Terminated by Sponsor|0
6241072|NCT01852110|9923122|FG005|Overall Study|Study Terminated by Sponsor|0
6241073|NCT01852110|9923117|FG000|Overall Study|Withdrawal by Subject|4
6241074|NCT01852110|9923118|FG001|Overall Study|Withdrawal by Subject|4
6241075|NCT01852110|9923119|FG002|Overall Study|Withdrawal by Subject|0
6241076|NCT01852110|9923120|FG003|Overall Study|Withdrawal by Subject|0
6241077|NCT01852110|9923121|FG004|Overall Study|Withdrawal by Subject|0
6241078|NCT01852110|9923122|FG005|Overall Study|Withdrawal by Subject|0
6241079|NCT01852162|9923138|FG000|Overall Study|Adverse Event|1
6241080|NCT01852162|9923139|FG001|Overall Study|Adverse Event|0
6241081|NCT01852162|9923138|FG000|Overall Study|Withdrawal by Subject|3
6241082|NCT01852162|9923139|FG001|Overall Study|Withdrawal by Subject|1
6241083|NCT01852214|9923164|FG000|Period 1|Adverse Event|1
6241084|NCT01852214|9923165|FG001|Period 1|Adverse Event|2
6241085|NCT01852214|9923164|FG000|Period 1|Withdrawal by Subject|0
6241086|NCT01852214|9923165|FG001|Period 1|Withdrawal by Subject|1
6241087|NCT01852214|9923164|FG000|Washout Period|Withdrawal by Subject|0
6241088|NCT01852214|9923165|FG001|Washout Period|Withdrawal by Subject|1
6241089|NCT01852292|9923174|FG000|Overall Study|Untreated - did not receive study drug|3
6241090|NCT01852292|9923175|FG001|Overall Study|Untreated - did not receive study drug|1
6241091|NCT01852292|9923174|FG000|Overall Study|Death|9
6241092|NCT01852292|9923175|FG001|Overall Study|Death|8
6241093|NCT01852292|9923174|FG000|Overall Study|Patient/guardian decision|8
6241094|NCT01852292|9923175|FG001|Overall Study|Patient/guardian decision|4
6241095|NCT01852292|9923174|FG000|Overall Study|Adverse Event|8
6241096|NCT01852292|9923175|FG001|Overall Study|Adverse Event|11
6241097|NCT01852292|9923174|FG000|Overall Study|Physician Decision|6
6241098|NCT01852292|9923175|FG001|Overall Study|Physician Decision|2
6241099|NCT01852292|9923174|FG000|Overall Study|Protocol Violation|2
6241100|NCT01852292|9923175|FG001|Overall Study|Protocol Violation|0
6241101|NCT01852292|9923174|FG000|Overall Study|Non-compliance with study treatment|1
6241102|NCT01852292|9923175|FG001|Overall Study|Non-compliance with study treatment|0
6241103|NCT01852292|9923174|FG000|Overall Study|Study terminated by Sponsor|0
6241104|NCT01852292|9923175|FG001|Overall Study|Study terminated by Sponsor|1
6241105|NCT01852292|9923174|FG000|Overall Study|Progressive disease|42
6241106|NCT01852292|9923175|FG001|Overall Study|Progressive disease|52
6241107|NCT01852591|9923213|FG000|Overall Study|Withdrawal by Subject|2
6241108|NCT01852591|9923213|FG000|Overall Study|Not Evaluable at Time of Analysis|1
6241109|NCT01852825|9923233|FG000|Overall Study|Withdrawal by Subject|2
6241110|NCT01852825|9923234|FG001|Overall Study|Withdrawal by Subject|0
6241111|NCT01852825|9923235|FG002|Overall Study|Withdrawal by Subject|0
6241112|NCT01852942|9923245|FG000|Overall Study|Physician Decision|1
6241113|NCT01852942|9923246|FG001|Overall Study|Physician Decision|0
6241114|NCT01852942|9923245|FG000|Overall Study|Death|1
6241115|NCT01852942|9923246|FG001|Overall Study|Death|1
6241116|NCT01852942|9923245|FG000|Overall Study|Withdrawal by Subject|2
6241117|NCT01852942|9923246|FG001|Overall Study|Withdrawal by Subject|3
6241118|NCT01852942|9923245|FG000|Overall Study|Lost to Follow-up|1
6241119|NCT01852942|9923246|FG001|Overall Study|Lost to Follow-up|2
6241120|NCT01853046|9923264|FG000|Overall Study|Withdrawal by Subject|1
6241121|NCT01853046|9923265|FG001|Overall Study|Withdrawal by Subject|1
6241122|NCT01853046|9923264|FG000|Overall Study|Adverse Event|4
6241123|NCT01853046|9923265|FG001|Overall Study|Adverse Event|2
6241124|NCT01853046|9923264|FG000|Overall Study|Disease progression|13
6241125|NCT01853046|9923265|FG001|Overall Study|Disease progression|3
6241126|NCT01853072|9923274|FG000|Overall Study|Adverse event prior to treatment|0
6241127|NCT01853072|9923275|FG001|Overall Study|Adverse event prior to treatment|1
6241128|NCT01853072|9923274|FG000|Overall Study|Adverse Event|0
6241129|NCT01853072|9923275|FG001|Overall Study|Adverse Event|3
6241130|NCT01853072|9923274|FG000|Overall Study|Death|1
6241131|NCT01853072|9923275|FG001|Overall Study|Death|4
6241132|NCT01853072|9923274|FG000|Overall Study|Lost to Follow-up|0
6241133|NCT01853072|9923275|FG001|Overall Study|Lost to Follow-up|3
6241134|NCT01853072|9923274|FG000|Overall Study|Non-compliance with study drug|0
6241135|NCT01853072|9923275|FG001|Overall Study|Non-compliance with study drug|1
6241136|NCT01853072|9923274|FG000|Overall Study|Physician Decision|1
6241137|NCT01853072|9923275|FG001|Overall Study|Physician Decision|1
6241138|NCT01853072|9923274|FG000|Overall Study|Withdrawal by Subject|1
6241139|NCT01853072|9923275|FG001|Overall Study|Withdrawal by Subject|2
6241140|NCT01853072|9923274|FG000|Overall Study|Reason not specified|9
6241141|NCT01853072|9923275|FG001|Overall Study|Reason not specified|6
6241142|NCT01853137|9923289|FG000|Overall Study|Lost to Follow-up|4
6241143|NCT01853137|9923290|FG001|Overall Study|Lost to Follow-up|1
6241144|NCT01853228|9923302|FG000|Phase 1|Lack of Efficacy|8
6241145|NCT01853228|9923303|FG001|Phase 1|Lack of Efficacy|0
6241146|NCT01853228|9923302|FG000|Phase 1|Other|1
6241147|NCT01853228|9923303|FG001|Phase 1|Other|0
6241148|NCT01853228|9923302|FG000|Phase 2|Physician Decision|0
6241149|NCT01853228|9923303|FG001|Phase 2|Physician Decision|1
6241150|NCT01853228|9923302|FG000|Phase 2|Proceed To Transplant|0
6241151|NCT01853228|9923303|FG001|Phase 2|Proceed To Transplant|3
6241152|NCT01853228|9923302|FG000|Phase 2|Lack of Efficacy|0
6241153|NCT01853228|9923303|FG001|Phase 2|Lack of Efficacy|4
6241154|NCT01853254|9923308|FG000|Overall Study|Abnormal Laboratory Test|1
6241155|NCT01853254|9923308|FG000|Overall Study|Adverse Event/Intercurrent Illness|3
6241156|NCT01853254|9923308|FG000|Overall Study|Death|1
6241157|NCT01853254|9923308|FG000|Overall Study|Failure to Return|43
6241158|NCT01853254|9923308|FG000|Overall Study|Insufficient Therapeutic Response|22
6241159|NCT01853254|9923308|FG000|Overall Study|Refusal of Treatment|1
6241160|NCT01853254|9923308|FG000|Overall Study|Other Protocol Violation|1
6241161|NCT01853254|9923308|FG000|Overall Study|Withdrawal of Consent|16
6241162|NCT01853254|9923308|FG000|Overall Study|Administrative/Other|16
6241163|NCT01853280|9923314|FG000|Overall Study|Lack of Efficacy|2
6241164|NCT01853280|9923315|FG001|Overall Study|Lack of Efficacy|2
6241165|NCT01853280|9923314|FG000|Overall Study|Lost to Follow-up|0
6241166|NCT01853280|9923315|FG001|Overall Study|Lost to Follow-up|1
6241167|NCT01853280|9923314|FG000|Overall Study|Physician Decision|0
6241168|NCT01853280|9923315|FG001|Overall Study|Physician Decision|1
6241169|NCT01853280|9923314|FG000|Overall Study|Withdrawal by Subject|0
6241170|NCT01853280|9923315|FG001|Overall Study|Withdrawal by Subject|1
6241171|NCT01853280|9923314|FG000|Overall Study|Ineligible|0
6241172|NCT01853280|9923315|FG001|Overall Study|Ineligible|1
6241173|NCT01853384|9923337|FG000|Randomized|Adverse Event|5
6241174|NCT01853384|9923338|FG001|Randomized|Adverse Event|3
6241175|NCT01853384|9923337|FG000|Randomized|Death|1
6241176|NCT01853384|9923338|FG001|Randomized|Death|2
6241177|NCT01853384|9923337|FG000|Randomized|Lost to Follow-up|1
6241178|NCT01853384|9923338|FG001|Randomized|Lost to Follow-up|1
6241179|NCT01853384|9923337|FG000|Randomized|Withdrawal by Subject|5
6241180|NCT01853384|9923338|FG001|Randomized|Withdrawal by Subject|3
6241181|NCT01853384|9923337|FG000|Randomized|Sponsor Decision|47
6241182|NCT01853384|9923338|FG001|Randomized|Sponsor Decision|34
6241183|NCT01853384|9923337|FG000|Randomized|Other|3
6241184|NCT01853384|9923338|FG001|Randomized|Other|3
6241185|NCT01853384|9923337|FG000|Completed Follow up Visit 1|Early Termination|13
6241186|NCT01853384|9923338|FG001|Completed Follow up Visit 1|Early Termination|9
6241187|NCT01853384|9923337|FG000|Completed Follow up Visit 1|Withdrawal by Subject|1
6241188|NCT01853384|9923338|FG001|Completed Follow up Visit 1|Withdrawal by Subject|0
6241189|NCT01853384|9923337|FG000|Completed Follow up Visit 2|Adverse Event|1
6241190|NCT01853384|9923338|FG001|Completed Follow up Visit 2|Adverse Event|0
6241191|NCT01853384|9923337|FG000|Completed Follow up Visit 2|Withdrawal by Subject|1
6241192|NCT01853384|9923338|FG001|Completed Follow up Visit 2|Withdrawal by Subject|2
6241193|NCT01853384|9923337|FG000|Completed Follow up Visit 2|Death|1
6241194|NCT01853384|9923338|FG001|Completed Follow up Visit 2|Death|0
6241195|NCT01853384|9923337|FG000|Completed Follow up Visit 2|Lost to Follow-up|0
6241196|NCT01853384|9923338|FG001|Completed Follow up Visit 2|Lost to Follow-up|1
6241197|NCT01853397|9923348|FG000|Overall Study|Withdrawal by Subject|0
6241198|NCT01853397|9923349|FG001|Overall Study|Withdrawal by Subject|0
6241199|NCT01853397|9923350|FG002|Overall Study|Withdrawal by Subject|0
6241200|NCT01853397|9923351|FG003|Overall Study|Withdrawal by Subject|1
6241201|NCT01853397|9923348|FG000|Overall Study|Subject Noncompliance|0
6241202|NCT01853397|9923349|FG001|Overall Study|Subject Noncompliance|0
6241203|NCT01853397|9923350|FG002|Overall Study|Subject Noncompliance|0
6241204|NCT01853397|9923351|FG003|Overall Study|Subject Noncompliance|1
6241205|NCT01853462|9923363|FG000|Overall Study|Withdrawal by Subject|1
6241206|NCT01853462|9923364|FG001|Overall Study|Withdrawal by Subject|1
6241207|NCT01853475|9923375|FG000|Overall Study|Withdrawal by Subject|0
6241208|NCT01853475|9923376|FG001|Overall Study|Withdrawal by Subject|1
6241209|NCT01853475|9923377|FG002|Overall Study|Withdrawal by Subject|0
6241210|NCT01853618|9923416|FG000|Overall Study|Bile duct stent blockage/progressive dis|1
6241211|NCT01853618|9923417|FG001|Overall Study|Bile duct stent blockage/progressive dis|0
6241212|NCT01853618|9923418|FG002|Overall Study|Bile duct stent blockage/progressive dis|0
6241213|NCT01853618|9923419|FG003|Overall Study|Bile duct stent blockage/progressive dis|0
6241214|NCT01853618|9923420|FG004|Overall Study|Bile duct stent blockage/progressive dis|0
6241215|NCT01853618|9923416|FG000|Overall Study|Progressive disease|1
6241216|NCT01853618|9923417|FG001|Overall Study|Progressive disease|1
6241217|NCT01853618|9923418|FG002|Overall Study|Progressive disease|1
6241218|NCT01853618|9923419|FG003|Overall Study|Progressive disease|1
6241219|NCT01853618|9923420|FG004|Overall Study|Progressive disease|2
6241220|NCT01853618|9923416|FG000|Overall Study|Physician Decision|0
6241221|NCT01853618|9923417|FG001|Overall Study|Physician Decision|1
6241222|NCT01853618|9923418|FG002|Overall Study|Physician Decision|1
6241223|NCT01853618|9923419|FG003|Overall Study|Physician Decision|0
6241224|NCT01853618|9923420|FG004|Overall Study|Physician Decision|0
6241225|NCT01853618|9923416|FG000|Overall Study|Refused further treatment|0
6241226|NCT01853618|9923417|FG001|Overall Study|Refused further treatment|0
6241227|NCT01853618|9923418|FG002|Overall Study|Refused further treatment|0
6241228|NCT01853618|9923419|FG003|Overall Study|Refused further treatment|0
6241229|NCT01853618|9923420|FG004|Overall Study|Refused further treatment|1
6270278|NCT02151149|9971132|FG000|Treatment Period|Symptomatic Deterioration|2
6270279|NCT02151149|9971133|FG001|Treatment Period|Symptomatic Deterioration|10
6270280|NCT02151149|9971132|FG000|Treatment Period|Withdrawal by Subject|13
6270281|NCT02151149|9971133|FG001|Treatment Period|Withdrawal by Subject|11
6270282|NCT02151149|9971132|FG000|Treatment Period|Miscellaneous|8
6270283|NCT02151149|9971133|FG001|Treatment Period|Miscellaneous|7
6270284|NCT02151149|9971132|FG000|Treatment Period|Participants randomized but not treated|3
6270285|NCT02151149|9971133|FG001|Treatment Period|Participants randomized but not treated|2
6270286|NCT02151149|9971132|FG000|Follow-Up Period|Lost to Follow-up|2
6270287|NCT02151149|9971133|FG001|Follow-Up Period|Lost to Follow-up|3
6270288|NCT02151149|9971132|FG000|Follow-Up Period|Death|37
6241230|NCT01853644|9923433|FG000|Registration and Treatment Start|Did not start treatment|1
6241231|NCT01853644|9923433|FG000|Reached First Response/Complete 2 Cycles|Adverse Event|2
6241232|NCT01853644|9923433|FG000|Reached First Response/Complete 2 Cycles|Withdrawal by Subject|1
6241233|NCT01853644|9923433|FG000|Reached First Response/Complete 2 Cycles|Other|1
6241234|NCT01853644|9923433|FG000|Reached First Response/Complete 2 Cycles|Progressive Disease|2
6241235|NCT01853644|9923433|FG000|Continued Treatment After First Response|Adverse Event|2
6241236|NCT01853644|9923433|FG000|Continued Treatment After First Response|Progressive Diseaes|10
6241237|NCT01853696|9923439|FG000|Overall Study|Withdrawal by Subject|1
6241238|NCT01853696|9923440|FG001|Overall Study|Withdrawal by Subject|1
6241239|NCT01853696|9923439|FG000|Overall Study|Lost to Follow-up|5
6241240|NCT01853696|9923440|FG001|Overall Study|Lost to Follow-up|4
6241241|NCT01853839|9923457|FG000|Overall Study|Violated inclusion criteria|2
6241242|NCT01853839|9923457|FG000|Overall Study|Not meet ITT population definition|58
6241243|NCT01853839|9923457|FG000|Overall Study|End of treatment visit too early|33
6241244|NCT01853839|9923457|FG000|Overall Study|Lost to follow-up or no valid BP measure|336
6241245|NCT01853878|9923467|FG000|Overall Study|Recurrence|2
6241246|NCT01853878|9923468|FG001|Overall Study|Recurrence|0
6241247|NCT01853878|9923467|FG000|Overall Study|Adverse Event|2
6241248|NCT01853878|9923468|FG001|Overall Study|Adverse Event|0
6241249|NCT01853878|9923467|FG000|Overall Study|Withdrawal by Subject|3
6241250|NCT01853878|9923468|FG001|Overall Study|Withdrawal by Subject|1
6241251|NCT01853878|9923467|FG000|Overall Study|Migrated/moved from the study area|1
6241252|NCT01853878|9923468|FG001|Overall Study|Migrated/moved from the study area|0
6241253|NCT01853878|9923467|FG000|Overall Study|Other|55
6241254|NCT01853878|9923468|FG001|Overall Study|Other|43
6241255|NCT01854047|9923492|FG000|Overall Study|Lack of Efficacy|1
6241256|NCT01854047|9923493|FG001|Overall Study|Lack of Efficacy|0
6241257|NCT01854047|9923494|FG002|Overall Study|Lack of Efficacy|0
6241258|NCT01854047|9923495|FG003|Overall Study|Lack of Efficacy|0
6241259|NCT01854047|9923496|FG004|Overall Study|Lack of Efficacy|0
6241260|NCT01854047|9923492|FG000|Overall Study|Poor compliance to protocol|3
6241261|NCT01854047|9923493|FG001|Overall Study|Poor compliance to protocol|0
6241262|NCT01854047|9923494|FG002|Overall Study|Poor compliance to protocol|2
6241263|NCT01854047|9923495|FG003|Overall Study|Poor compliance to protocol|0
6241264|NCT01854047|9923496|FG004|Overall Study|Poor compliance to protocol|0
6241265|NCT01854047|9923492|FG000|Overall Study|Adverse Event|5
6241266|NCT01854047|9923493|FG001|Overall Study|Adverse Event|4
6241267|NCT01854047|9923494|FG002|Overall Study|Adverse Event|6
6241268|NCT01854047|9923495|FG003|Overall Study|Adverse Event|10
6241269|NCT01854047|9923496|FG004|Overall Study|Adverse Event|7
6241270|NCT01854047|9923492|FG000|Overall Study|Randomized but not treated|0
6241271|NCT01854047|9923493|FG001|Overall Study|Randomized but not treated|1
6241272|NCT01854047|9923494|FG002|Overall Study|Randomized but not treated|2
6241273|NCT01854047|9923495|FG003|Overall Study|Randomized but not treated|0
6241274|NCT01854047|9923496|FG004|Overall Study|Randomized but not treated|4
6241275|NCT01854047|9923492|FG000|Overall Study|Other than specified above|3
6241276|NCT01854047|9923493|FG001|Overall Study|Other than specified above|3
6241277|NCT01854047|9923494|FG002|Overall Study|Other than specified above|3
6241278|NCT01854047|9923495|FG003|Overall Study|Other than specified above|5
6241279|NCT01854047|9923496|FG004|Overall Study|Other than specified above|8
6241280|NCT01854528|9923564|FG000|Overall Study|Adverse Event|0
6241281|NCT01854528|9923565|FG001|Overall Study|Adverse Event|4
6241282|NCT01854528|9923564|FG000|Overall Study|Withdrawal by Subject|0
6241283|NCT01854528|9923565|FG001|Overall Study|Withdrawal by Subject|2
6241284|NCT01854528|9923564|FG000|Overall Study|Virologic Failure|0
6241285|NCT01854528|9923565|FG001|Overall Study|Virologic Failure|9
6241286|NCT01854645|9923595|FG000|Overall Study|Protocol-Specified Criteria|13
6241287|NCT01854645|9923596|FG001|Overall Study|Protocol-Specified Criteria|10
6241288|NCT01854645|9923597|FG002|Overall Study|Protocol-Specified Criteria|8
6241289|NCT01854645|9923598|FG003|Overall Study|Protocol-Specified Criteria|5
6241290|NCT01854645|9923599|FG004|Overall Study|Protocol-Specified Criteria|7
6241291|NCT01854645|9923595|FG000|Overall Study|Administrative Reasons / Missing|0
6241292|NCT01854645|9923596|FG001|Overall Study|Administrative Reasons / Missing|0
6241293|NCT01854645|9923597|FG002|Overall Study|Administrative Reasons / Missing|0
6241294|NCT01854645|9923598|FG003|Overall Study|Administrative Reasons / Missing|1
6241295|NCT01854645|9923599|FG004|Overall Study|Administrative Reasons / Missing|1
6241296|NCT01854645|9923595|FG000|Overall Study|Protocol Violation|3
6241297|NCT01854645|9923596|FG001|Overall Study|Protocol Violation|0
6241298|NCT01854645|9923597|FG002|Overall Study|Protocol Violation|5
6241299|NCT01854645|9923598|FG003|Overall Study|Protocol Violation|4
6241300|NCT01854645|9923599|FG004|Overall Study|Protocol Violation|1
6241301|NCT01854645|9923595|FG000|Overall Study|Lost to Follow-up|10
6241302|NCT01854645|9923596|FG001|Overall Study|Lost to Follow-up|7
6241303|NCT01854645|9923597|FG002|Overall Study|Lost to Follow-up|8
6241304|NCT01854645|9923598|FG003|Overall Study|Lost to Follow-up|5
6241305|NCT01854645|9923599|FG004|Overall Study|Lost to Follow-up|0
6241306|NCT01854645|9923595|FG000|Overall Study|Physician Decision|1
6241307|NCT01854645|9923596|FG001|Overall Study|Physician Decision|5
6241308|NCT01854645|9923597|FG002|Overall Study|Physician Decision|3
6241309|NCT01854645|9923598|FG003|Overall Study|Physician Decision|3
6241310|NCT01854645|9923599|FG004|Overall Study|Physician Decision|7
6241311|NCT01854645|9923595|FG000|Overall Study|Withdrawal by Subject|31
6241312|NCT01854645|9923596|FG001|Overall Study|Withdrawal by Subject|41
6241313|NCT01854645|9923597|FG002|Overall Study|Withdrawal by Subject|30
6241314|NCT01854645|9923598|FG003|Overall Study|Withdrawal by Subject|21
6241315|NCT01854645|9923599|FG004|Overall Study|Withdrawal by Subject|24
6241316|NCT01854645|9923595|FG000|Overall Study|Lack of Efficacy|7
6241317|NCT01854645|9923596|FG001|Overall Study|Lack of Efficacy|12
6241318|NCT01854645|9923597|FG002|Overall Study|Lack of Efficacy|9
6241319|NCT01854645|9923598|FG003|Overall Study|Lack of Efficacy|3
6241320|NCT01854645|9923599|FG004|Overall Study|Lack of Efficacy|9
6241321|NCT01854645|9923595|FG000|Overall Study|Adverse Event|33
6241322|NCT01854645|9923596|FG001|Overall Study|Adverse Event|31
6241323|NCT01854645|9923597|FG002|Overall Study|Adverse Event|19
6241324|NCT01854645|9923598|FG003|Overall Study|Adverse Event|20
6241325|NCT01854645|9923599|FG004|Overall Study|Adverse Event|11
6241326|NCT01854658|9923615|FG000|Overall Study|Protocol Violation|6
6241327|NCT01854658|9923616|FG001|Overall Study|Protocol Violation|2
6241328|NCT01854658|9923617|FG002|Overall Study|Protocol Violation|2
6241329|NCT01854658|9923618|FG003|Overall Study|Protocol Violation|1
6241330|NCT01854658|9923615|FG000|Overall Study|Physician Decision|7
6241331|NCT01854658|9923616|FG001|Overall Study|Physician Decision|5
6241332|NCT01854658|9923617|FG002|Overall Study|Physician Decision|2
6241333|NCT01854658|9923618|FG003|Overall Study|Physician Decision|4
6241334|NCT01854658|9923615|FG000|Overall Study|Lost to Follow-up|8
6241335|NCT01854658|9923616|FG001|Overall Study|Lost to Follow-up|9
6241336|NCT01854658|9923617|FG002|Overall Study|Lost to Follow-up|8
6241337|NCT01854658|9923618|FG003|Overall Study|Lost to Follow-up|4
6241338|NCT01854658|9923615|FG000|Overall Study|Withdrawal by Subject|28
6241339|NCT01854658|9923616|FG001|Overall Study|Withdrawal by Subject|21
6241340|NCT01854658|9923617|FG002|Overall Study|Withdrawal by Subject|29
6241341|NCT01854658|9923618|FG003|Overall Study|Withdrawal by Subject|15
6241342|NCT01854658|9923615|FG000|Overall Study|Protocol-specified criteria|15
6241343|NCT01854658|9923616|FG001|Overall Study|Protocol-specified criteria|15
6241344|NCT01854658|9923617|FG002|Overall Study|Protocol-specified criteria|10
6241345|NCT01854658|9923618|FG003|Overall Study|Protocol-specified criteria|7
6241346|NCT01854658|9923615|FG000|Overall Study|Lack of Efficacy|3
6241347|NCT01854658|9923616|FG001|Overall Study|Lack of Efficacy|8
6241348|NCT01854658|9923617|FG002|Overall Study|Lack of Efficacy|4
6241349|NCT01854658|9923618|FG003|Overall Study|Lack of Efficacy|7
6241350|NCT01854658|9923615|FG000|Overall Study|Adverse Event|21
6241351|NCT01854658|9923616|FG001|Overall Study|Adverse Event|14
6241352|NCT01854658|9923617|FG002|Overall Study|Adverse Event|23
6241353|NCT01854658|9923618|FG003|Overall Study|Adverse Event|19
6241354|NCT01854658|9923615|FG000|Overall Study|Administrative reasons|5
6241355|NCT01854658|9923616|FG001|Overall Study|Administrative reasons|1
6241356|NCT01854658|9923617|FG002|Overall Study|Administrative reasons|2
6241357|NCT01854658|9923618|FG003|Overall Study|Administrative reasons|2
6241358|NCT01854697|9923633|FG000|Overall Study|Adverse Event|1
6188996|NCT01396057|9843982|FG001|Overall Study|Adverse Event|6
6188997|NCT01396057|9843981|FG000|Overall Study|Unsatisfactory therapeutic effect|2
6188998|NCT01396057|9843982|FG001|Overall Study|Unsatisfactory therapeutic effect|6
6188999|NCT01396057|9843981|FG000|Overall Study|Protocol deviation|4
6189000|NCT01396057|9843982|FG001|Overall Study|Protocol deviation|4
6189001|NCT01396057|9843981|FG000|Overall Study|Consent withdrawn|3
6189002|NCT01396057|9843982|FG001|Overall Study|Consent withdrawn|2
6189003|NCT01396070|9843988|FG000|Overall Study|Withdrawal by Subject|2
6189004|NCT01396070|9843988|FG000|Overall Study|Death|2
6189005|NCT01396070|9843988|FG000|Overall Study|Adverse Event|8
6189006|NCT01396070|9843988|FG000|Overall Study|Physician Decision|3
6189007|NCT01396070|9843988|FG000|Overall Study|Lack of Efficacy|4
6189008|NCT01396083|9843995|FG000|Overall Study|Adverse Event|2
6241359|NCT01854697|9923634|FG001|Overall Study|Adverse Event|0
6241360|NCT01854697|9923635|FG002|Overall Study|Adverse Event|0
6241361|NCT01854697|9923636|FG003|Overall Study|Adverse Event|0
6241362|NCT01854697|9923637|FG004|Overall Study|Adverse Event|1
6241363|NCT01854697|9923633|FG000|Overall Study|Lost to Follow-up|4
6241364|NCT01854697|9923634|FG001|Overall Study|Lost to Follow-up|1
6241365|NCT01854697|9923635|FG002|Overall Study|Lost to Follow-up|1
6241366|NCT01854697|9923636|FG003|Overall Study|Lost to Follow-up|2
6241367|NCT01854697|9923637|FG004|Overall Study|Lost to Follow-up|0
6241368|NCT01854697|9923633|FG000|Overall Study|To enter another AbbVie study|1
6241369|NCT01854697|9923634|FG001|Overall Study|To enter another AbbVie study|0
6241370|NCT01854697|9923635|FG002|Overall Study|To enter another AbbVie study|0
6241371|NCT01854697|9923636|FG003|Overall Study|To enter another AbbVie study|0
6241372|NCT01854697|9923637|FG004|Overall Study|To enter another AbbVie study|1
6241373|NCT01854697|9923633|FG000|Overall Study|Withdrew Consent|0
6241374|NCT01854697|9923634|FG001|Overall Study|Withdrew Consent|1
6241375|NCT01854697|9923635|FG002|Overall Study|Withdrew Consent|0
6241376|NCT01854697|9923636|FG003|Overall Study|Withdrew Consent|1
6241377|NCT01854697|9923637|FG004|Overall Study|Withdrew Consent|0
6241378|NCT01854697|9923633|FG000|Overall Study|Other|0
6241379|NCT01854697|9923634|FG001|Overall Study|Other|1
6241380|NCT01854697|9923635|FG002|Overall Study|Other|1
6189009|NCT01396083|9843996|FG001|Overall Study|Adverse Event|28
6189010|NCT01396083|9843995|FG000|Overall Study|Unsatisfactory therapeutic effect|2
6189011|NCT01396083|9843996|FG001|Overall Study|Unsatisfactory therapeutic effect|13
6241381|NCT01854697|9923636|FG003|Overall Study|Other|0
6241382|NCT01854697|9923637|FG004|Overall Study|Other|0
6241383|NCT01854710|9923647|FG000|Overall Study|Withdrawal by Subject|2
6241384|NCT01854710|9923648|FG001|Overall Study|Withdrawal by Subject|1
6241385|NCT01854710|9923649|FG002|Overall Study|Withdrawal by Subject|0
6241386|NCT01854710|9923650|FG003|Overall Study|Withdrawal by Subject|0
6241387|NCT01854710|9923651|FG004|Overall Study|Withdrawal by Subject|0
6241388|NCT01854710|9923652|FG005|Overall Study|Withdrawal by Subject|0
6241389|NCT01854710|9923647|FG000|Overall Study|CRI procedural error|2
6241390|NCT01854710|9923648|FG001|Overall Study|CRI procedural error|2
6241391|NCT01854710|9923649|FG002|Overall Study|CRI procedural error|2
6241392|NCT01854710|9923650|FG003|Overall Study|CRI procedural error|2
6241393|NCT01854710|9923651|FG004|Overall Study|CRI procedural error|2
6241394|NCT01854710|9923652|FG005|Overall Study|CRI procedural error|2
6241395|NCT01854775|9923665|FG000|Treatment Phase (48 Weeks)|Withdrawal by Subject|1
6241396|NCT01854775|9923666|FG001|Treatment Phase (48 Weeks)|Withdrawal by Subject|1
6241397|NCT01854775|9923667|FG002|Treatment Phase (48 Weeks)|Withdrawal by Subject|0
6241398|NCT01854775|9923665|FG000|Treatment Phase (48 Weeks)|Lost to Follow-up|1
6241399|NCT01854775|9923666|FG001|Treatment Phase (48 Weeks)|Lost to Follow-up|0
6241400|NCT01854775|9923667|FG002|Treatment Phase (48 Weeks)|Lost to Follow-up|0
6241401|NCT01854775|9923665|FG000|Treatment Phase (48 Weeks)|Still on Study up to the Data-Cut-Date|0
6241402|NCT01854775|9923666|FG001|Treatment Phase (48 Weeks)|Still on Study up to the Data-Cut-Date|0
6241403|NCT01854775|9923667|FG002|Treatment Phase (48 Weeks)|Still on Study up to the Data-Cut-Date|9
6241404|NCT01854775|9923665|FG000|Extension Phase|Pregnancy|3
6241405|NCT01854775|9923666|FG001|Extension Phase|Pregnancy|0
6241406|NCT01854775|9923667|FG002|Extension Phase|Pregnancy|0
6241407|NCT01854775|9923665|FG000|Extension Phase|Investigator's Discretion|1
6241408|NCT01854775|9923666|FG001|Extension Phase|Investigator's Discretion|0
6241409|NCT01854775|9923667|FG002|Extension Phase|Investigator's Discretion|0
6241410|NCT01854775|9923665|FG000|Extension Phase|Non-Compliance with Study Drug|1
6241411|NCT01854775|9923666|FG001|Extension Phase|Non-Compliance with Study Drug|0
6241412|NCT01854775|9923667|FG002|Extension Phase|Non-Compliance with Study Drug|0
6241413|NCT01854775|9923665|FG000|Extension Phase|Lost to Follow-up|2
6241414|NCT01854775|9923666|FG001|Extension Phase|Lost to Follow-up|0
6241415|NCT01854775|9923667|FG002|Extension Phase|Lost to Follow-up|0
6241416|NCT01854775|9923665|FG000|Extension Phase|Still on Study|32
6241417|NCT01854775|9923666|FG001|Extension Phase|Still on Study|47
6241418|NCT01854775|9923667|FG002|Extension Phase|Still on Study|18
6241419|NCT01854827|9923675|FG000|Overall Study|Death|1
6241420|NCT01854879|9923679|FG000|Overall Study|Could not complete testing within the scheduled time.|1
6241421|NCT01854879|9923679|FG000|Overall Study|screen fail|3
6241422|NCT01854879|9923679|FG000|Overall Study|incomplete data set|1
6241423|NCT01854918|9923689|FG000|SOC-controlled Period (Year 1)|Withdrawal by Subject|20
6241424|NCT01854918|9923690|FG001|SOC-controlled Period (Year 1)|Withdrawal by Subject|49
6241425|NCT01854918|9923689|FG000|SOC-controlled Period (Year 1)|Decision by Sponsor|2
6241426|NCT01854918|9923690|FG001|SOC-controlled Period (Year 1)|Decision by Sponsor|1
6241427|NCT01854918|9923689|FG000|SOC-controlled Period (Year 1)|Lost to Follow-up|3
6241428|NCT01854918|9923690|FG001|SOC-controlled Period (Year 1)|Lost to Follow-up|8
6241429|NCT01854918|9923689|FG000|SOC-controlled Period (Year 1)|Death|5
6241430|NCT01854918|9923690|FG001|SOC-controlled Period (Year 1)|Death|5
6241431|NCT01854918|9923689|FG000|All-IP Period (Years 2 and 3)|Withdrawal by Subject|78
6241432|NCT01854918|9923690|FG001|All-IP Period (Years 2 and 3)|Withdrawal by Subject|117
6241433|NCT01854918|9923689|FG000|All-IP Period (Years 2 and 3)|Decision by Sponsor|8
6241434|NCT01854918|9923690|FG001|All-IP Period (Years 2 and 3)|Decision by Sponsor|11
6241435|NCT01854918|9923689|FG000|All-IP Period (Years 2 and 3)|Lost to Follow-up|27
6241436|NCT01854918|9923690|FG001|All-IP Period (Years 2 and 3)|Lost to Follow-up|51
6241437|NCT01854918|9923689|FG000|All-IP Period (Years 2 and 3)|Death|5
6241438|NCT01854918|9923690|FG001|All-IP Period (Years 2 and 3)|Death|16
6241439|NCT01854944|9923706|FG000|Overall Study|Withdrawal by Subject|0
6241440|NCT01854944|9923707|FG001|Overall Study|Withdrawal by Subject|0
6241441|NCT01854944|9923708|FG002|Overall Study|Withdrawal by Subject|1
6241442|NCT01855048|9923736|FG000|Overall Study|Withdrawal by Subject|0
6241443|NCT01855048|9923737|FG001|Overall Study|Withdrawal by Subject|1
6241444|NCT01855048|9923738|FG002|Overall Study|Withdrawal by Subject|0
6241445|NCT01855048|9923739|FG003|Overall Study|Withdrawal by Subject|0
6241446|NCT01855048|9923740|FG004|Overall Study|Withdrawal by Subject|1
6241447|NCT01855048|9923741|FG005|Overall Study|Withdrawal by Subject|0
6241448|NCT01855074|9923765|FG000|Overall Study|Adverse Event|1
6241449|NCT01855074|9923765|FG000|Overall Study|Lost to Follow-up|4
6241450|NCT01855074|9923765|FG000|Overall Study|Withdrawal by Subject|8
6241451|NCT01855074|9923765|FG000|Overall Study|Started but not treated|1
6241452|NCT01855126|9923771|FG000|First Intervention (8 Weeks)|Withdrawal by Subject|4
6241453|NCT01855126|9923772|FG001|First Intervention (8 Weeks)|Withdrawal by Subject|6
6241454|NCT01855126|9923771|FG000|Second Intervention (8 Weeks)|Withdrawal by Subject|2
6241455|NCT01855126|9923772|FG001|Second Intervention (8 Weeks)|Withdrawal by Subject|2
6241456|NCT01855243|9923785|FG000|Overall Study|develpoed diabetic ketoacidosis|1
6241457|NCT01855243|9923786|FG001|Overall Study|develpoed diabetic ketoacidosis|0
6241458|NCT01855243|9923787|FG002|Overall Study|develpoed diabetic ketoacidosis|0
6241459|NCT01855399|9923801|FG000|6 Month|Lost to Follow-up|12
6241460|NCT01855399|9923802|FG001|6 Month|Lost to Follow-up|9
6241461|NCT01855399|9923801|FG000|6 Month|Withdrawal by Subject|8
6241462|NCT01855399|9923802|FG001|6 Month|Withdrawal by Subject|6
6241463|NCT01855399|9923801|FG000|12 Month|Lost to Follow-up|7
6241464|NCT01855399|9923802|FG001|12 Month|Lost to Follow-up|11
6241465|NCT01855425|9923808|FG000|Overall Study|Physician Decision|20
6241466|NCT01855750|9923814|FG000|Overall Study|Death|78
6241467|NCT01855750|9923815|FG001|Overall Study|Death|78
6241468|NCT01855750|9923814|FG000|Overall Study|Lost to Follow-up|9
6241469|NCT01855750|9923815|FG001|Overall Study|Lost to Follow-up|23
6241470|NCT01855750|9923814|FG000|Overall Study|Withdrawal by Subject|35
6241471|NCT01855750|9923815|FG001|Overall Study|Withdrawal by Subject|28
6241472|NCT01855750|9923814|FG000|Overall Study|Sponsor ends the study|297
6241473|NCT01855750|9923815|FG001|Overall Study|Sponsor ends the study|290
6241474|NCT01855789|9923821|FG000|1) Baseline up to Week 24|Adverse Event|37
6241475|NCT01855789|9923822|FG001|1) Baseline up to Week 24|Adverse Event|0
6241476|NCT01855789|9923823|FG002|1) Baseline up to Week 24|Adverse Event|0
6241477|NCT01855789|9923824|FG003|1) Baseline up to Week 24|Adverse Event|0
6241478|NCT01855789|9923821|FG000|1) Baseline up to Week 24|Death|2
6241479|NCT01855789|9923822|FG001|1) Baseline up to Week 24|Death|0
6241480|NCT01855789|9923823|FG002|1) Baseline up to Week 24|Death|0
6241481|NCT01855789|9923824|FG003|1) Baseline up to Week 24|Death|0
6241482|NCT01855789|9923821|FG000|1) Baseline up to Week 24|Lack of Efficacy|16
6241483|NCT01855789|9923822|FG001|1) Baseline up to Week 24|Lack of Efficacy|0
6241484|NCT01855789|9923823|FG002|1) Baseline up to Week 24|Lack of Efficacy|0
6241485|NCT01855789|9923824|FG003|1) Baseline up to Week 24|Lack of Efficacy|0
6241486|NCT01855789|9923821|FG000|1) Baseline up to Week 24|Lost to Follow-up|11
6241487|NCT01855789|9923822|FG001|1) Baseline up to Week 24|Lost to Follow-up|0
6241488|NCT01855789|9923823|FG002|1) Baseline up to Week 24|Lost to Follow-up|0
6241489|NCT01855789|9923824|FG003|1) Baseline up to Week 24|Lost to Follow-up|0
6241490|NCT01855789|9923821|FG000|1) Baseline up to Week 24|Protocol Violation|4
6241491|NCT01855789|9923822|FG001|1) Baseline up to Week 24|Protocol Violation|0
6241492|NCT01855789|9923823|FG002|1) Baseline up to Week 24|Protocol Violation|0
6241493|NCT01855789|9923824|FG003|1) Baseline up to Week 24|Protocol Violation|0
6241494|NCT01855789|9923821|FG000|1) Baseline up to Week 24|Withdrawal by Subject|31
6241495|NCT01855789|9923822|FG001|1) Baseline up to Week 24|Withdrawal by Subject|0
6241496|NCT01855789|9923823|FG002|1) Baseline up to Week 24|Withdrawal by Subject|0
6241497|NCT01855789|9923824|FG003|1) Baseline up to Week 24|Withdrawal by Subject|0
6241498|NCT01855789|9923821|FG000|1) Baseline up to Week 24|Physician Decision|4
6241499|NCT01855789|9923822|FG001|1) Baseline up to Week 24|Physician Decision|0
6241500|NCT01855789|9923823|FG002|1) Baseline up to Week 24|Physician Decision|0
6241501|NCT01855789|9923824|FG003|1) Baseline up to Week 24|Physician Decision|0
6241502|NCT01855789|9923821|FG000|1) Baseline up to Week 24|Pregnancy|1
6241503|NCT01855789|9923822|FG001|1) Baseline up to Week 24|Pregnancy|0
6241504|NCT01855789|9923823|FG002|1) Baseline up to Week 24|Pregnancy|0
6241505|NCT01855789|9923824|FG003|1) Baseline up to Week 24|Pregnancy|0
6241506|NCT01855789|9923821|FG000|1) Baseline up to Week 24|Participant Non-compliance|3
6241507|NCT01855789|9923822|FG001|1) Baseline up to Week 24|Participant Non-compliance|0
6241508|NCT01855789|9923823|FG002|1) Baseline up to Week 24|Participant Non-compliance|0
6241509|NCT01855789|9923824|FG003|1) Baseline up to Week 24|Participant Non-compliance|0
6241510|NCT01855789|9923821|FG000|1) Baseline up to Week 24|Sponsor Decision|3
6241511|NCT01855789|9923822|FG001|1) Baseline up to Week 24|Sponsor Decision|0
6241512|NCT01855789|9923823|FG002|1) Baseline up to Week 24|Sponsor Decision|0
6241513|NCT01855789|9923824|FG003|1) Baseline up to Week 24|Sponsor Decision|0
6241514|NCT01855789|9923821|FG000|1) Baseline up to Week 24|Other|4
6241515|NCT01855789|9923822|FG001|1) Baseline up to Week 24|Other|0
6241516|NCT01855789|9923823|FG002|1) Baseline up to Week 24|Other|0
6241517|NCT01855789|9923824|FG003|1) Baseline up to Week 24|Other|0
6241518|NCT01855789|9923821|FG000|2) Week 24 up to End of Study|Adverse Event|0
6241519|NCT01855789|9923822|FG001|2) Week 24 up to End of Study|Adverse Event|4
6241520|NCT01855789|9923823|FG002|2) Week 24 up to End of Study|Adverse Event|5
6241521|NCT01855789|9923824|FG003|2) Week 24 up to End of Study|Adverse Event|21
6241522|NCT01855789|9923821|FG000|2) Week 24 up to End of Study|Serious Hypersensitivity Reaction|0
6241523|NCT01855789|9923822|FG001|2) Week 24 up to End of Study|Serious Hypersensitivity Reaction|0
6241524|NCT01855789|9923823|FG002|2) Week 24 up to End of Study|Serious Hypersensitivity Reaction|0
6241525|NCT01855789|9923824|FG003|2) Week 24 up to End of Study|Serious Hypersensitivity Reaction|1
6241526|NCT01855789|9923821|FG000|2) Week 24 up to End of Study|Lack of Efficacy|0
6241527|NCT01855789|9923822|FG001|2) Week 24 up to End of Study|Lack of Efficacy|2
6241528|NCT01855789|9923823|FG002|2) Week 24 up to End of Study|Lack of Efficacy|5
6241529|NCT01855789|9923824|FG003|2) Week 24 up to End of Study|Lack of Efficacy|16
6241530|NCT01855789|9923821|FG000|2) Week 24 up to End of Study|Lost to Follow-up|0
6241531|NCT01855789|9923822|FG001|2) Week 24 up to End of Study|Lost to Follow-up|1
6241532|NCT01855789|9923823|FG002|2) Week 24 up to End of Study|Lost to Follow-up|1
6241533|NCT01855789|9923824|FG003|2) Week 24 up to End of Study|Lost to Follow-up|4
6241534|NCT01855789|9923821|FG000|2) Week 24 up to End of Study|Protocol Violation|0
6241535|NCT01855789|9923822|FG001|2) Week 24 up to End of Study|Protocol Violation|0
6241536|NCT01855789|9923823|FG002|2) Week 24 up to End of Study|Protocol Violation|0
6241537|NCT01855789|9923824|FG003|2) Week 24 up to End of Study|Protocol Violation|1
6241538|NCT01855789|9923821|FG000|2) Week 24 up to End of Study|Withdrawal by Subject|0
6241539|NCT01855789|9923822|FG001|2) Week 24 up to End of Study|Withdrawal by Subject|7
6241540|NCT01855789|9923823|FG002|2) Week 24 up to End of Study|Withdrawal by Subject|5
6241541|NCT01855789|9923824|FG003|2) Week 24 up to End of Study|Withdrawal by Subject|8
6241542|NCT01855789|9923821|FG000|2) Week 24 up to End of Study|Physician Decision|0
6241543|NCT01855789|9923822|FG001|2) Week 24 up to End of Study|Physician Decision|0
6241544|NCT01855789|9923823|FG002|2) Week 24 up to End of Study|Physician Decision|2
6241545|NCT01855789|9923824|FG003|2) Week 24 up to End of Study|Physician Decision|4
6241546|NCT01855789|9923821|FG000|2) Week 24 up to End of Study|Participant Non-compliance|0
6241547|NCT01855789|9923822|FG001|2) Week 24 up to End of Study|Participant Non-compliance|1
6241548|NCT01855789|9923823|FG002|2) Week 24 up to End of Study|Participant Non-compliance|0
6241549|NCT01855789|9923824|FG003|2) Week 24 up to End of Study|Participant Non-compliance|1
6241550|NCT01855789|9923821|FG000|2) Week 24 up to End of Study|Sponsor Decision|0
6241551|NCT01855789|9923822|FG001|2) Week 24 up to End of Study|Sponsor Decision|0
6241552|NCT01855789|9923823|FG002|2) Week 24 up to End of Study|Sponsor Decision|0
6241553|NCT01855789|9923824|FG003|2) Week 24 up to End of Study|Sponsor Decision|1
6241554|NCT01855789|9923821|FG000|2) Week 24 up to End of Study|Other|0
6241555|NCT01855789|9923822|FG001|2) Week 24 up to End of Study|Other|0
6241556|NCT01855789|9923823|FG002|2) Week 24 up to End of Study|Other|0
6241557|NCT01855789|9923824|FG003|2) Week 24 up to End of Study|Other|1
6241558|NCT01855828|9923830|FG000|Overall Study|Adverse Event|1
6241559|NCT01855828|9923830|FG000|Overall Study|Withdrawal by Subject|1
6241560|NCT01855919|9923841|FG000|Overall Study|Adverse Event|16
6241561|NCT01855919|9923842|FG001|Overall Study|Adverse Event|8
6241562|NCT01855919|9923841|FG000|Overall Study|Lack of Efficacy|1
6241563|NCT01855919|9923842|FG001|Overall Study|Lack of Efficacy|3
6241564|NCT01855919|9923841|FG000|Overall Study|Withdrawal by Subject|4
6241565|NCT01855919|9923842|FG001|Overall Study|Withdrawal by Subject|10
6241566|NCT01855919|9923841|FG000|Overall Study|Entry Criteria Not Met|1
6241567|NCT01855919|9923842|FG001|Overall Study|Entry Criteria Not Met|1
6241568|NCT01855919|9923841|FG000|Overall Study|Protocol Violation|1
6241569|NCT01855919|9923842|FG001|Overall Study|Protocol Violation|4
6241570|NCT01855945|9923861|FG000|Overall Study|Adverse Event|0
6085937|NCT00657371|9695585|FG000|Overall Study|Protocol Violation|2
6241571|NCT01855945|9923862|FG001|Overall Study|Adverse Event|0
6241572|NCT01855945|9923863|FG002|Overall Study|Adverse Event|0
6241573|NCT01855945|9923864|FG003|Overall Study|Adverse Event|0
6241574|NCT01855945|9923865|FG004|Overall Study|Adverse Event|0
6241575|NCT01855945|9923866|FG005|Overall Study|Adverse Event|0
6241576|NCT01855945|9923867|FG006|Overall Study|Adverse Event|1
6241577|NCT01855945|9923868|FG007|Overall Study|Adverse Event|0
6241578|NCT01855945|9923869|FG008|Overall Study|Adverse Event|0
6241579|NCT01855945|9923870|FG009|Overall Study|Adverse Event|0
6241580|NCT01855945|9923871|FG010|Overall Study|Adverse Event|0
6241581|NCT01855945|9923872|FG011|Overall Study|Adverse Event|0
6241582|NCT01855945|9923861|FG000|Overall Study|Death|0
6241583|NCT01855945|9923862|FG001|Overall Study|Death|0
6241584|NCT01855945|9923863|FG002|Overall Study|Death|0
6241585|NCT01855945|9923864|FG003|Overall Study|Death|0
6241586|NCT01855945|9923865|FG004|Overall Study|Death|0
6241587|NCT01855945|9923866|FG005|Overall Study|Death|0
6241588|NCT01855945|9923867|FG006|Overall Study|Death|2
6241589|NCT01855945|9923868|FG007|Overall Study|Death|0
6241590|NCT01855945|9923869|FG008|Overall Study|Death|0
6241591|NCT01855945|9923870|FG009|Overall Study|Death|0
6241592|NCT01855945|9923871|FG010|Overall Study|Death|0
6241593|NCT01855945|9923872|FG011|Overall Study|Death|0
6241594|NCT01855945|9923861|FG000|Overall Study|Lost to Follow-up|11
6241595|NCT01855945|9923862|FG001|Overall Study|Lost to Follow-up|10
6241596|NCT01855945|9923863|FG002|Overall Study|Lost to Follow-up|7
6241597|NCT01855945|9923864|FG003|Overall Study|Lost to Follow-up|3
6241598|NCT01855945|9923865|FG004|Overall Study|Lost to Follow-up|0
6241599|NCT01855945|9923866|FG005|Overall Study|Lost to Follow-up|3
6241600|NCT01855945|9923867|FG006|Overall Study|Lost to Follow-up|4
6241601|NCT01855945|9923868|FG007|Overall Study|Lost to Follow-up|7
6241602|NCT01855945|9923869|FG008|Overall Study|Lost to Follow-up|2
6241603|NCT01855945|9923870|FG009|Overall Study|Lost to Follow-up|0
6241604|NCT01855945|9923871|FG010|Overall Study|Lost to Follow-up|0
6241605|NCT01855945|9923872|FG011|Overall Study|Lost to Follow-up|2
6241606|NCT01855945|9923861|FG000|Overall Study|Other - Unclassified|1
6241607|NCT01855945|9923862|FG001|Overall Study|Other - Unclassified|1
6241608|NCT01855945|9923863|FG002|Overall Study|Other - Unclassified|1
6241609|NCT01855945|9923864|FG003|Overall Study|Other - Unclassified|0
6241610|NCT01855945|9923865|FG004|Overall Study|Other - Unclassified|0
6241611|NCT01855945|9923866|FG005|Overall Study|Other - Unclassified|0
6241612|NCT01855945|9923867|FG006|Overall Study|Other - Unclassified|2
6241613|NCT01855945|9923868|FG007|Overall Study|Other - Unclassified|1
6241614|NCT01855945|9923869|FG008|Overall Study|Other - Unclassified|0
6241615|NCT01855945|9923870|FG009|Overall Study|Other - Unclassified|0
6241616|NCT01855945|9923871|FG010|Overall Study|Other - Unclassified|1
6241617|NCT01855945|9923872|FG011|Overall Study|Other - Unclassified|0
6241618|NCT01855945|9923861|FG000|Overall Study|Withdrawal by Subject|4
6241619|NCT01855945|9923862|FG001|Overall Study|Withdrawal by Subject|0
6241620|NCT01855945|9923863|FG002|Overall Study|Withdrawal by Subject|4
6241621|NCT01855945|9923864|FG003|Overall Study|Withdrawal by Subject|1
6241622|NCT01855945|9923865|FG004|Overall Study|Withdrawal by Subject|1
6241623|NCT01855945|9923866|FG005|Overall Study|Withdrawal by Subject|0
6241624|NCT01855945|9923867|FG006|Overall Study|Withdrawal by Subject|1
6241625|NCT01855945|9923868|FG007|Overall Study|Withdrawal by Subject|0
6241626|NCT01855945|9923869|FG008|Overall Study|Withdrawal by Subject|0
6241627|NCT01855945|9923870|FG009|Overall Study|Withdrawal by Subject|2
6241628|NCT01855945|9923871|FG010|Overall Study|Withdrawal by Subject|4
6241629|NCT01855945|9923872|FG011|Overall Study|Withdrawal by Subject|1
6241630|NCT01855958|9923937|FG000|Overall Study|Withdrawal by Subject|1
6241631|NCT01855958|9923938|FG001|Overall Study|Withdrawal by Subject|0
6241632|NCT01856114|9923960|FG000|Overall Study|Withdrawal by Subject|1
6241633|NCT01856114|9923961|FG001|Overall Study|Withdrawal by Subject|0
6241634|NCT01856114|9923960|FG000|Overall Study|Adverse Event|1
6241635|NCT01856114|9923961|FG001|Overall Study|Adverse Event|0
6241636|NCT01856257|9923974|FG000|Overall Study|Death|2
6189012|NCT01396083|9843995|FG000|Overall Study|Consent withdrawn|4
6189013|NCT01396083|9843996|FG001|Overall Study|Consent withdrawn|5
6189014|NCT01396083|9843995|FG000|Overall Study|Protocol deviation(s)|0
6189015|NCT01396083|9843996|FG001|Overall Study|Protocol deviation(s)|1
6189016|NCT01396083|9843995|FG000|Overall Study|Abnormal laboratory value(s)|1
6189017|NCT01396083|9843996|FG001|Overall Study|Abnormal laboratory value(s)|0
6189018|NCT01396083|9843995|FG000|Overall Study|Administrative problems|1
6189019|NCT01396083|9843996|FG001|Overall Study|Administrative problems|0
6189020|NCT01396083|9843995|FG000|Overall Study|Lost to Follow-up|1
6189021|NCT01396083|9843996|FG001|Overall Study|Lost to Follow-up|0
6189022|NCT01396148|9844002|FG000|Overall Study|Patient Decision|1
6189023|NCT01396161|9844015|FG000|Overall Study|Withdrawal by Subject|0
6189024|NCT01396161|9844016|FG001|Overall Study|Withdrawal by Subject|0
6189025|NCT01396161|9844017|FG002|Overall Study|Withdrawal by Subject|0
6189026|NCT01396161|9844018|FG003|Overall Study|Withdrawal by Subject|0
6189027|NCT01396161|9844019|FG004|Overall Study|Withdrawal by Subject|1
6189028|NCT01396161|9844020|FG005|Overall Study|Withdrawal by Subject|0
6189029|NCT01396161|9844021|FG006|Overall Study|Withdrawal by Subject|0
6189030|NCT01396161|9844015|FG000|Overall Study|Other|0
6189031|NCT01396161|9844016|FG001|Overall Study|Other|0
6189032|NCT01396161|9844017|FG002|Overall Study|Other|0
6189033|NCT01396161|9844018|FG003|Overall Study|Other|0
6189034|NCT01396161|9844019|FG004|Overall Study|Other|0
6189035|NCT01396161|9844020|FG005|Overall Study|Other|0
6189036|NCT01396161|9844021|FG006|Overall Study|Other|1
6189037|NCT01396187|9844047|FG000|Overall Study|Adverse Event|0
6189038|NCT01396187|9844048|FG001|Overall Study|Adverse Event|1
6189039|NCT01396187|9844049|FG002|Overall Study|Adverse Event|0
6189040|NCT01396187|9844050|FG003|Overall Study|Adverse Event|0
6189041|NCT01396187|9844051|FG004|Overall Study|Adverse Event|0
6189042|NCT01396187|9844047|FG000|Overall Study|Withdrawal by Subject|0
6189043|NCT01396187|9844048|FG001|Overall Study|Withdrawal by Subject|1
6189044|NCT01396187|9844049|FG002|Overall Study|Withdrawal by Subject|1
6189045|NCT01396187|9844050|FG003|Overall Study|Withdrawal by Subject|0
6189046|NCT01396187|9844051|FG004|Overall Study|Withdrawal by Subject|0
6189047|NCT01396187|9844047|FG000|Overall Study|Other|1
6189048|NCT01396187|9844048|FG001|Overall Study|Other|1
6189049|NCT01396187|9844049|FG002|Overall Study|Other|0
6189050|NCT01396187|9844050|FG003|Overall Study|Other|0
6189051|NCT01396187|9844051|FG004|Overall Study|Other|1
6189052|NCT01396265|9844099|FG000|Rifa+Afatinib|Withdrawal by Subject|1
6189053|NCT01396317|9844107|FG000|Overall Study|Adverse Event|1
6189054|NCT01396317|9844108|FG001|Overall Study|Adverse Event|0
6189055|NCT01396395|9844123|FG000|Overall Study|Withdrawal by Subject|10
6189056|NCT01396395|9844124|FG001|Overall Study|Withdrawal by Subject|12
6189057|NCT01396395|9844123|FG000|Overall Study|Protocol Violation|3
6189058|NCT01396395|9844124|FG001|Overall Study|Protocol Violation|1
6189059|NCT01396395|9844123|FG000|Overall Study|Adverse Event|10
6189060|NCT01396395|9844124|FG001|Overall Study|Adverse Event|2
6189061|NCT01396395|9844123|FG000|Overall Study|Lost to Follow-up|17
6189062|NCT01396395|9844124|FG001|Overall Study|Lost to Follow-up|11
6189063|NCT01396395|9844123|FG000|Overall Study|Other|0
6189064|NCT01396395|9844124|FG001|Overall Study|Other|1
6189065|NCT01396421|9844136|FG000|Overall Study|Lost to Follow-up|0
6189066|NCT01396421|9844137|FG001|Overall Study|Lost to Follow-up|0
6189067|NCT01396421|9844138|FG002|Overall Study|Lost to Follow-up|0
6189068|NCT01396421|9844139|FG003|Overall Study|Lost to Follow-up|1
6189069|NCT01396421|9844136|FG000|Overall Study|Adverse Event|17
6189070|NCT01396421|9844137|FG001|Overall Study|Adverse Event|15
6189071|NCT01396421|9844138|FG002|Overall Study|Adverse Event|12
6189072|NCT01396421|9844139|FG003|Overall Study|Adverse Event|32
6189073|NCT01396421|9844136|FG000|Overall Study|Participant Met Withdrawal Criteria|1
6189074|NCT01396421|9844137|FG001|Overall Study|Participant Met Withdrawal Criteria|0
6189075|NCT01396421|9844138|FG002|Overall Study|Participant Met Withdrawal Criteria|1
6189076|NCT01396421|9844139|FG003|Overall Study|Participant Met Withdrawal Criteria|0
6189077|NCT01396421|9844136|FG000|Overall Study|Physician Decision|1
6241637|NCT01856257|9923975|FG001|Overall Study|Death|0
6241638|NCT01856257|9923976|FG002|Overall Study|Death|0
6241639|NCT01856257|9923977|FG003|Overall Study|Death|0
6241640|NCT01856257|9923974|FG000|Overall Study|Physician Decision|0
6241641|NCT01856257|9923975|FG001|Overall Study|Physician Decision|0
6241642|NCT01856257|9923976|FG002|Overall Study|Physician Decision|0
6241643|NCT01856257|9923977|FG003|Overall Study|Physician Decision|1
6241644|NCT01856257|9923974|FG000|Overall Study|Withdrawal by Subject|1
6241645|NCT01856257|9923975|FG001|Overall Study|Withdrawal by Subject|1
6241646|NCT01856257|9923976|FG002|Overall Study|Withdrawal by Subject|0
6241647|NCT01856257|9923977|FG003|Overall Study|Withdrawal by Subject|0
6241648|NCT01856257|9923974|FG000|Overall Study|Donor complication|0
6241649|NCT01856257|9923975|FG001|Overall Study|Donor complication|0
6241650|NCT01856257|9923976|FG002|Overall Study|Donor complication|0
6241651|NCT01856257|9923977|FG003|Overall Study|Donor complication|1
6241652|NCT01856309|9923990|FG000|Overall Study|Death|4
6241653|NCT01856309|9923991|FG001|Overall Study|Death|6
6241654|NCT01856309|9923992|FG002|Overall Study|Death|11
6241655|NCT01856309|9923993|FG003|Overall Study|Death|6
6241656|NCT01856309|9923990|FG000|Overall Study|Lost to Follow-up|6
6241657|NCT01856309|9923991|FG001|Overall Study|Lost to Follow-up|2
6241658|NCT01856309|9923992|FG002|Overall Study|Lost to Follow-up|4
6241659|NCT01856309|9923993|FG003|Overall Study|Lost to Follow-up|8
6241660|NCT01856309|9923990|FG000|Overall Study|Withdrawal by Subject|11
6241661|NCT01856309|9923991|FG001|Overall Study|Withdrawal by Subject|13
6241662|NCT01856309|9923992|FG002|Overall Study|Withdrawal by Subject|28
6241663|NCT01856309|9923993|FG003|Overall Study|Withdrawal by Subject|26
6241664|NCT01856309|9923990|FG000|Overall Study|Other|227
6241665|NCT01856309|9923991|FG001|Overall Study|Other|225
6241666|NCT01856309|9923992|FG002|Overall Study|Other|447
6241667|NCT01856309|9923993|FG003|Overall Study|Other|469
6241668|NCT01856309|9923990|FG000|Overall Study|Lack of Efficacy|14
6241669|NCT01856309|9923991|FG001|Overall Study|Lack of Efficacy|9
6241670|NCT01856309|9923992|FG002|Overall Study|Lack of Efficacy|40
6241671|NCT01856309|9923993|FG003|Overall Study|Lack of Efficacy|25
6241672|NCT01856309|9923990|FG000|Overall Study|Adverse Event|31
6241673|NCT01856309|9923991|FG001|Overall Study|Adverse Event|31
6241674|NCT01856309|9923992|FG002|Overall Study|Adverse Event|55
6241675|NCT01856309|9923993|FG003|Overall Study|Adverse Event|65
6241676|NCT01856309|9923990|FG000|Overall Study|Pregnancy|0
6241677|NCT01856309|9923991|FG001|Overall Study|Pregnancy|0
6241678|NCT01856309|9923992|FG002|Overall Study|Pregnancy|0
6241679|NCT01856309|9923993|FG003|Overall Study|Pregnancy|1
6241680|NCT01856309|9923990|FG000|Overall Study|Physician Decision|6
6241681|NCT01856309|9923991|FG001|Overall Study|Physician Decision|1
6241682|NCT01856309|9923992|FG002|Overall Study|Physician Decision|6
6241683|NCT01856309|9923993|FG003|Overall Study|Physician Decision|8
6241684|NCT01856309|9923990|FG000|Overall Study|Noncompliance With Study Drug|0
6241685|NCT01856309|9923991|FG001|Overall Study|Noncompliance With Study Drug|1
6241686|NCT01856309|9923992|FG002|Overall Study|Noncompliance With Study Drug|4
6241687|NCT01856309|9923993|FG003|Overall Study|Noncompliance With Study Drug|1
6241688|NCT01856543|9924018|FG000|Overall Study|Treatment discontinued|6
6241689|NCT01856543|9924019|FG001|Overall Study|Treatment discontinued|3
6241690|NCT01856543|9924018|FG000|Overall Study|Withdrawn before start|7
6241691|NCT01856543|9924019|FG001|Overall Study|Withdrawn before start|3
6241692|NCT01856569|9924026|FG000|Overall Study|Other|1
6241693|NCT01856569|9924026|FG000|Overall Study|Changed Site/Structure|1
6241694|NCT01856569|9924026|FG000|Overall Study|Lost to Follow-up|3
6241695|NCT01856569|9924026|FG000|Overall Study|Did not met inclusion criteria|8
6241696|NCT01856582|9924030|FG000|Overall Study|Died prior to Boost infusion|1
6241697|NCT01856595|9924043|FG000|Overall Study|Withdrawal by Subject|0
6241698|NCT01856595|9924044|FG001|Overall Study|Withdrawal by Subject|1
6241699|NCT01856595|9924045|FG002|Overall Study|Withdrawal by Subject|0
6241700|NCT01856595|9924046|FG003|Overall Study|Withdrawal by Subject|0
6241701|NCT01856595|9924047|FG004|Overall Study|Withdrawal by Subject|0
6241702|NCT01856595|9924048|FG005|Overall Study|Withdrawal by Subject|0
6241703|NCT01856595|9924049|FG006|Overall Study|Withdrawal by Subject|1
6241704|NCT01856595|9924050|FG007|Overall Study|Withdrawal by Subject|0
6241705|NCT01856595|9924051|FG008|Overall Study|Withdrawal by Subject|0
6241706|NCT01856673|9924089|FG000|Overall Study|Withdrawal by Subject|44
6241707|NCT01856673|9924090|FG001|Overall Study|Withdrawal by Subject|50
6241708|NCT01856673|9924091|FG002|Overall Study|Withdrawal by Subject|33
6241709|NCT01856673|9924089|FG000|Overall Study|Lost to Follow-up|31
6241710|NCT01856673|9924090|FG001|Overall Study|Lost to Follow-up|34
6241711|NCT01856673|9924091|FG002|Overall Study|Lost to Follow-up|0
6241712|NCT01856673|9924089|FG000|Overall Study|Unknown reasons|9
6241713|NCT01856673|9924090|FG001|Overall Study|Unknown reasons|0
6241714|NCT01856673|9924091|FG002|Overall Study|Unknown reasons|0
6241715|NCT01856673|9924089|FG000|Overall Study|Psychologist decision|1
6241716|NCT01856673|9924090|FG001|Overall Study|Psychologist decision|0
6241717|NCT01856673|9924091|FG002|Overall Study|Psychologist decision|0
6241718|NCT01856673|9924089|FG000|Overall Study|Paperwork errors|8
6241719|NCT01856673|9924090|FG001|Overall Study|Paperwork errors|0
6241720|NCT01856673|9924091|FG002|Overall Study|Paperwork errors|0
6241721|NCT01856673|9924089|FG000|Overall Study|Death|1
6241722|NCT01856673|9924090|FG001|Overall Study|Death|1
6241723|NCT01856673|9924091|FG002|Overall Study|Death|0
6241724|NCT01856673|9924089|FG000|Overall Study|Protocol Violation|1
6241725|NCT01856673|9924090|FG001|Overall Study|Protocol Violation|0
6241726|NCT01856673|9924091|FG002|Overall Study|Protocol Violation|1
6241727|NCT01856686|9924101|FG000|Overall Study|Lost to Follow-up|5
6241728|NCT01856686|9924102|FG001|Overall Study|Lost to Follow-up|11
6241729|NCT01856790|9924130|FG000|Closed Loop Control|Withdrawal by Subject|2
6241730|NCT01856790|9924130|FG000|Closed Loop Control + Liraglutide|Withdrawal by Subject|2
6241731|NCT01856907|9924144|FG000|Overall Study|Pregnancy|0
6241732|NCT01856907|9924145|FG001|Overall Study|Pregnancy|1
6241733|NCT01856907|9924146|FG002|Overall Study|Pregnancy|0
6241734|NCT01856907|9924144|FG000|Overall Study|Pregnancy|0
6241735|NCT01856907|9924145|FG001|Overall Study|Pregnancy|1
6241736|NCT01856907|9924146|FG002|Overall Study|Pregnancy|0
6241737|NCT01856907|9924144|FG000|Overall Study|Withdrawal by Subject|0
6241738|NCT01856907|9924145|FG001|Overall Study|Withdrawal by Subject|1
6241739|NCT01856907|9924146|FG002|Overall Study|Withdrawal by Subject|0
6241740|NCT01857102|9924161|FG000|Period 1|No longer meets Eligibility Criteria|0
6241741|NCT01857102|9924162|FG001|Period 1|No longer meets Eligibility Criteria|2
6241742|NCT01857102|9924161|FG000|Period 1|Lost to Follow-up|0
6241743|NCT01857102|9924162|FG001|Period 1|Lost to Follow-up|3
6241744|NCT01857102|9924161|FG000|Period 1|Unsatisfactory Lens Fit|1
6241745|NCT01857102|9924162|FG001|Period 1|Unsatisfactory Lens Fit|0
6241746|NCT01857102|9924161|FG000|Period 1|Unsatisfactory Visual Response|1
6241747|NCT01857102|9924162|FG001|Period 1|Unsatisfactory Visual Response|0
6241748|NCT01857102|9924161|FG000|Period 1|Physician Decision|1
6241749|NCT01857102|9924162|FG001|Period 1|Physician Decision|0
6241750|NCT01857102|9924161|FG000|Period 2|Lens Discomfort|1
6241751|NCT01857102|9924162|FG001|Period 2|Lens Discomfort|0
6241752|NCT01857102|9924161|FG000|Period 2|Unsatisfactory Lens Fit|1
6241753|NCT01857102|9924162|FG001|Period 2|Unsatisfactory Lens Fit|0
6241754|NCT01857206|9924172|FG000|Overall Study|ADMINISTRATIVE REASON|0
6241755|NCT01857206|9924173|FG001|Overall Study|ADMINISTRATIVE REASON|1
6241756|NCT01857206|9924172|FG000|Overall Study|Lost to Follow-up|9
6241757|NCT01857206|9924173|FG001|Overall Study|Lost to Follow-up|6
6241758|NCT01857206|9924172|FG000|Overall Study|Unclassified|3
6241759|NCT01857206|9924173|FG001|Overall Study|Unclassified|3
6241760|NCT01857206|9924172|FG000|Overall Study|Withdrawal by Subject|1
6241761|NCT01857206|9924173|FG001|Overall Study|Withdrawal by Subject|0
6241762|NCT01857310|9924227|FG000|Secondary Analysis: Semen Quality at 6m|Lost to Follow-up|315
6241763|NCT01857310|9924228|FG001|Secondary Analysis: Semen Quality at 6m|Lost to Follow-up|282
6241764|NCT01857323|9924234|FG000|Overall Study|Adverse Event|1
6241765|NCT01857323|9924234|FG000|Overall Study|Withdrawal by Subject|3
6241766|NCT01857323|9924234|FG000|Overall Study|Non-compliance|1
6241767|NCT01857323|9924234|FG000|Overall Study|Protocol Violation|6
6241768|NCT01857323|9924234|FG000|Overall Study|Lost to Follow-up|1
6241769|NCT01857323|9924234|FG000|Overall Study|Other|4
6241770|NCT01857323|9924234|FG000|Overall Study|Did not complete 180 doses|48
6241771|NCT01857531|9924245|FG000|Overall Study|Withdrawal by Subject|4
6241772|NCT01857583|9924253|FG000|Overall Study|Adverse Event|0
6241773|NCT01857583|9924254|FG001|Overall Study|Adverse Event|0
6241774|NCT01857583|9924255|FG002|Overall Study|Adverse Event|1
6241775|NCT01857583|9924256|FG003|Overall Study|Adverse Event|1
6241776|NCT01857583|9924253|FG000|Overall Study|Death|0
6241777|NCT01857583|9924254|FG001|Overall Study|Death|1
6241778|NCT01857583|9924255|FG002|Overall Study|Death|1
6241779|NCT01857583|9924256|FG003|Overall Study|Death|0
6241780|NCT01857583|9924253|FG000|Overall Study|Physician Decision|0
6241781|NCT01857583|9924254|FG001|Overall Study|Physician Decision|0
6241782|NCT01857583|9924255|FG002|Overall Study|Physician Decision|0
6241783|NCT01857583|9924256|FG003|Overall Study|Physician Decision|1
6241784|NCT01857583|9924253|FG000|Overall Study|Withdrawal by Subject|1
6241785|NCT01857583|9924254|FG001|Overall Study|Withdrawal by Subject|0
6241786|NCT01857583|9924255|FG002|Overall Study|Withdrawal by Subject|1
6241787|NCT01857583|9924256|FG003|Overall Study|Withdrawal by Subject|2
6241788|NCT01857622|9924269|FG000|Overall Study|Adverse Event|5
6241789|NCT01857622|9924270|FG001|Overall Study|Adverse Event|0
6241790|NCT01857622|9924271|FG002|Overall Study|Adverse Event|2
6241791|NCT01857622|9924269|FG000|Overall Study|Physician Decision|1
6241792|NCT01857622|9924270|FG001|Overall Study|Physician Decision|0
6241793|NCT01857622|9924271|FG002|Overall Study|Physician Decision|0
6241794|NCT01857622|9924269|FG000|Overall Study|Protocol Violation|4
6241795|NCT01857622|9924270|FG001|Overall Study|Protocol Violation|1
6241796|NCT01857622|9924271|FG002|Overall Study|Protocol Violation|0
6241797|NCT01857622|9924269|FG000|Overall Study|Withdrawal by Subject|1
6241798|NCT01857622|9924270|FG001|Overall Study|Withdrawal by Subject|0
6241799|NCT01857622|9924271|FG002|Overall Study|Withdrawal by Subject|0
6241800|NCT01857869|9924295|FG000|Primary/Challenge Phase|Lost to Follow-up|2
6241801|NCT01857869|9924296|FG001|Primary/Challenge Phase|Lost to Follow-up|0
6241802|NCT01857869|9924297|FG002|Primary/Challenge Phase|Lost to Follow-up|0
6241803|NCT01857869|9924298|FG003|Primary/Challenge Phase|Lost to Follow-up|0
6241804|NCT01857869|9924299|FG004|Primary/Challenge Phase|Lost to Follow-up|0
6241805|NCT01857869|9924300|FG005|Primary/Challenge Phase|Lost to Follow-up|0
6241806|NCT01857869|9924301|FG006|Primary/Challenge Phase|Lost to Follow-up|0
6241807|NCT01857869|9924302|FG007|Primary/Challenge Phase|Lost to Follow-up|0
6241808|NCT01857869|9924303|FG008|Primary/Challenge Phase|Lost to Follow-up|0
6241809|NCT01857869|9924304|FG009|Primary/Challenge Phase|Lost to Follow-up|0
6241810|NCT01857869|9924295|FG000|Primary/Challenge Phase|Pregnancy|1
6241811|NCT01857869|9924296|FG001|Primary/Challenge Phase|Pregnancy|0
6241812|NCT01857869|9924297|FG002|Primary/Challenge Phase|Pregnancy|0
6241813|NCT01857869|9924298|FG003|Primary/Challenge Phase|Pregnancy|0
6241814|NCT01857869|9924299|FG004|Primary/Challenge Phase|Pregnancy|0
6241815|NCT01857869|9924300|FG005|Primary/Challenge Phase|Pregnancy|0
6241816|NCT01857869|9924301|FG006|Primary/Challenge Phase|Pregnancy|0
6241817|NCT01857869|9924302|FG007|Primary/Challenge Phase|Pregnancy|0
6241818|NCT01857869|9924303|FG008|Primary/Challenge Phase|Pregnancy|0
6241819|NCT01857869|9924304|FG009|Primary/Challenge Phase|Pregnancy|0
6241820|NCT01857869|9924295|FG000|Primary/Challenge Phase|Protocol Violation|1
6241821|NCT01857869|9924296|FG001|Primary/Challenge Phase|Protocol Violation|0
6241822|NCT01857869|9924297|FG002|Primary/Challenge Phase|Protocol Violation|0
6241823|NCT01857869|9924298|FG003|Primary/Challenge Phase|Protocol Violation|0
6241824|NCT01857869|9924299|FG004|Primary/Challenge Phase|Protocol Violation|0
6241825|NCT01857869|9924300|FG005|Primary/Challenge Phase|Protocol Violation|0
6241826|NCT01857869|9924301|FG006|Primary/Challenge Phase|Protocol Violation|0
6241827|NCT01857869|9924302|FG007|Primary/Challenge Phase|Protocol Violation|0
6241828|NCT01857869|9924303|FG008|Primary/Challenge Phase|Protocol Violation|0
6241829|NCT01857869|9924304|FG009|Primary/Challenge Phase|Protocol Violation|0
6241830|NCT01857869|9924295|FG000|Primary/Challenge Phase|Other|1
6241831|NCT01857869|9924296|FG001|Primary/Challenge Phase|Other|1
6241832|NCT01857869|9924297|FG002|Primary/Challenge Phase|Other|0
6241833|NCT01857869|9924298|FG003|Primary/Challenge Phase|Other|0
6241834|NCT01857869|9924299|FG004|Primary/Challenge Phase|Other|0
6241835|NCT01857869|9924300|FG005|Primary/Challenge Phase|Other|0
6241836|NCT01857869|9924301|FG006|Primary/Challenge Phase|Other|0
6241837|NCT01857869|9924302|FG007|Primary/Challenge Phase|Other|0
6241838|NCT01857869|9924303|FG008|Primary/Challenge Phase|Other|0
6241839|NCT01857869|9924304|FG009|Primary/Challenge Phase|Other|0
6241840|NCT01857869|9924295|FG000|Booster/Rechallenge Phase|Withdrawal by Subject|0
6241841|NCT01857869|9924296|FG001|Booster/Rechallenge Phase|Withdrawal by Subject|0
6241842|NCT01857869|9924297|FG002|Booster/Rechallenge Phase|Withdrawal by Subject|0
6241843|NCT01857869|9924298|FG003|Booster/Rechallenge Phase|Withdrawal by Subject|1
6241844|NCT01857869|9924299|FG004|Booster/Rechallenge Phase|Withdrawal by Subject|0
6241845|NCT01857869|9924300|FG005|Booster/Rechallenge Phase|Withdrawal by Subject|0
6241846|NCT01857869|9924301|FG006|Booster/Rechallenge Phase|Withdrawal by Subject|0
6241847|NCT01857869|9924302|FG007|Booster/Rechallenge Phase|Withdrawal by Subject|0
6241848|NCT01857869|9924303|FG008|Booster/Rechallenge Phase|Withdrawal by Subject|0
6241849|NCT01857869|9924304|FG009|Booster/Rechallenge Phase|Withdrawal by Subject|0
6241850|NCT01857869|9924295|FG000|Booster/Rechallenge Phase|Volunteer took antibiotic pre-challenge|0
6241851|NCT01857869|9924296|FG001|Booster/Rechallenge Phase|Volunteer took antibiotic pre-challenge|0
6241852|NCT01857869|9924297|FG002|Booster/Rechallenge Phase|Volunteer took antibiotic pre-challenge|0
6241853|NCT01857869|9924298|FG003|Booster/Rechallenge Phase|Volunteer took antibiotic pre-challenge|1
6241854|NCT01857869|9924299|FG004|Booster/Rechallenge Phase|Volunteer took antibiotic pre-challenge|0
6241855|NCT01857869|9924300|FG005|Booster/Rechallenge Phase|Volunteer took antibiotic pre-challenge|0
6241856|NCT01857869|9924301|FG006|Booster/Rechallenge Phase|Volunteer took antibiotic pre-challenge|0
6241857|NCT01857869|9924302|FG007|Booster/Rechallenge Phase|Volunteer took antibiotic pre-challenge|0
6241858|NCT01857869|9924303|FG008|Booster/Rechallenge Phase|Volunteer took antibiotic pre-challenge|0
6241859|NCT01857869|9924304|FG009|Booster/Rechallenge Phase|Volunteer took antibiotic pre-challenge|0
6241860|NCT01857973|9924336|FG000|Overall Study|Subject did not meet required BG range|3
6241861|NCT01857973|9924336|FG000|Overall Study|drop out after 3 failed attempts|1
6241862|NCT01857973|9924336|FG000|Overall Study|Physician Decision|1
6241863|NCT01858194|9924351|FG000|Overall Study|Total Artificial Heart Implant|0
6241864|NCT01858194|9924352|FG001|Overall Study|Total Artificial Heart Implant|1
6241865|NCT01858194|9924351|FG000|Overall Study|Lost to Follow-up|0
6241866|NCT01858194|9924352|FG001|Overall Study|Lost to Follow-up|1
6241867|NCT01858363|9924362|FG000|Overall Study|Death|35
6241868|NCT01858363|9924363|FG001|Overall Study|Death|9
6241869|NCT01858363|9924362|FG000|Overall Study|Withdrawal by Subject|28
6241870|NCT01858363|9924363|FG001|Overall Study|Withdrawal by Subject|14
6241871|NCT01858363|9924362|FG000|Overall Study|Lost to Follow-up|13
6241872|NCT01858363|9924363|FG001|Overall Study|Lost to Follow-up|3
6241873|NCT01858376|9924369|FG000|Overall Study|Dropped d/t lab work not fitting criter|4
6241874|NCT01858389|9924375|FG000|Overall Study|Death|1
6241875|NCT01858389|9924376|FG001|Overall Study|Death|3
6241876|NCT01858389|9924375|FG000|Overall Study|Study terminated by sponsor|0
6241877|NCT01858389|9924376|FG001|Overall Study|Study terminated by sponsor|2
6241878|NCT01858389|9924375|FG000|Overall Study|Withdrawal by Subject|0
6241879|NCT01858389|9924376|FG001|Overall Study|Withdrawal by Subject|1
6241880|NCT01858389|9924375|FG000|Overall Study|Progressive disease|10
6241881|NCT01858389|9924376|FG001|Overall Study|Progressive disease|11
6241882|NCT01858389|9924375|FG000|Overall Study|Other|2
6241883|NCT01858389|9924376|FG001|Overall Study|Other|4
6241884|NCT01858389|9924375|FG000|Overall Study|Adverse Event|3
6241885|NCT01858389|9924376|FG001|Overall Study|Adverse Event|1
6241886|NCT01858389|9924375|FG000|Overall Study|Did not receive treatment|0
6241887|NCT01858389|9924376|FG001|Overall Study|Did not receive treatment|3
6241888|NCT01858532|9924397|FG000|Overall Study|Adverse Event|58
6241889|NCT01858532|9924398|FG001|Overall Study|Adverse Event|50
6241890|NCT01858532|9924399|FG002|Overall Study|Adverse Event|23
6241891|NCT01858532|9924400|FG003|Overall Study|Adverse Event|28
6241892|NCT01858532|9924397|FG000|Overall Study|Withdrew consent|71
6241893|NCT01858532|9924398|FG001|Overall Study|Withdrew consent|93
6241894|NCT01858532|9924399|FG002|Overall Study|Withdrew consent|46
6241895|NCT01858532|9924400|FG003|Overall Study|Withdrew consent|27
6241896|NCT01858532|9924397|FG000|Overall Study|Lost to Follow-up|17
6241897|NCT01858532|9924398|FG001|Overall Study|Lost to Follow-up|26
6241898|NCT01858532|9924399|FG002|Overall Study|Lost to Follow-up|11
6241899|NCT01858532|9924400|FG003|Overall Study|Lost to Follow-up|14
6241900|NCT01858532|9924397|FG000|Overall Study|Deterioration of medical status|3
6241901|NCT01858532|9924398|FG001|Overall Study|Deterioration of medical status|4
6241902|NCT01858532|9924399|FG002|Overall Study|Deterioration of medical status|3
6241903|NCT01858532|9924400|FG003|Overall Study|Deterioration of medical status|7
6241904|NCT01858532|9924397|FG000|Overall Study|Investigator request|3
6241905|NCT01858532|9924398|FG001|Overall Study|Investigator request|4
6241906|NCT01858532|9924399|FG002|Overall Study|Investigator request|2
6241907|NCT01858532|9924400|FG003|Overall Study|Investigator request|6
6241908|NCT01858532|9924397|FG000|Overall Study|Other, not specified|29
6241909|NCT01858532|9924398|FG001|Overall Study|Other, not specified|15
6241910|NCT01858532|9924399|FG002|Overall Study|Other, not specified|13
6241911|NCT01858532|9924400|FG003|Overall Study|Other, not specified|11
6241912|NCT01858558|9924421|FG000|Overall Study|Death|1
6241913|NCT01858558|9924422|FG001|Overall Study|Death|1
6241914|NCT01858558|9924421|FG000|Overall Study|Lost to Follow-up|1
6241915|NCT01858558|9924422|FG001|Overall Study|Lost to Follow-up|0
6241916|NCT01858558|9924421|FG000|Overall Study|Disease progression|3
6241917|NCT01858558|9924422|FG001|Overall Study|Disease progression|1
6241918|NCT01858558|9924421|FG000|Overall Study|Product contamination|2
6241919|NCT01858558|9924422|FG001|Overall Study|Product contamination|0
6241920|NCT01858558|9924421|FG000|Overall Study|Failed expansion of cell product|2
6241921|NCT01858558|9924422|FG001|Overall Study|Failed expansion of cell product|0
6241922|NCT01858636|9924428|FG000|Overall Study|No Device Deployment Attempted|24
6085938|NCT00657371|9695585|FG000|Overall Study|Device- related reasons|13
6085939|NCT00657371|9695585|FG000|Overall Study|Pre-existing medical condition|4
6085940|NCT00657540|9695591|FG000|Overall Study|Lost to Follow-up|1
6085941|NCT00657540|9695592|FG001|Overall Study|Lost to Follow-up|4
6241923|NCT01858636|9924428|FG000|Overall Study|Physician Decision|1
6241924|NCT01858636|9924428|FG000|Overall Study|Death|1
6241925|NCT01858636|9924428|FG000|Overall Study|Lost to Follow-up|1
6241926|NCT01858636|9924428|FG000|Overall Study|Withdrawal by Subject|1
6241927|NCT01858701|9924433|FG000|Period 1, First 30 Days of Wear|Withdrawal by Subject|0
6241928|NCT01858701|9924434|FG001|Period 1, First 30 Days of Wear|Withdrawal by Subject|1
6241929|NCT01858701|9924433|FG000|Washout Period, 1-13 Days|Inclusion/Exclusion Criteria Not Met|1
6241930|NCT01858701|9924434|FG001|Washout Period, 1-13 Days|Inclusion/Exclusion Criteria Not Met|0
6241931|NCT01858701|9924433|FG000|Washout Period, 1-13 Days|Withdrawal by Subject|1
6241932|NCT01858701|9924434|FG001|Washout Period, 1-13 Days|Withdrawal by Subject|2
6241933|NCT01858701|9924433|FG000|Period 2, Second 30 Days of Wear|Comfort|0
6241934|NCT01858701|9924434|FG001|Period 2, Second 30 Days of Wear|Comfort|1
6241935|NCT01858766|9924468|FG000|Overall Study|Randomized but Never Treated|0
6241936|NCT01858766|9924469|FG001|Overall Study|Randomized but Never Treated|0
6241937|NCT01858766|9924470|FG002|Overall Study|Randomized but Never Treated|0
6241938|NCT01858766|9924471|FG003|Overall Study|Randomized but Never Treated|0
6241939|NCT01858766|9924472|FG004|Overall Study|Randomized but Never Treated|0
6241940|NCT01858766|9924473|FG005|Overall Study|Randomized but Never Treated|1
6241941|NCT01858766|9924474|FG006|Overall Study|Randomized but Never Treated|0
6241942|NCT01858766|9924475|FG007|Overall Study|Randomized but Never Treated|0
6241943|NCT01858766|9924476|FG008|Overall Study|Randomized but Never Treated|0
6241944|NCT01858766|9924477|FG009|Overall Study|Randomized but Never Treated|0
6241945|NCT01858766|9924478|FG010|Overall Study|Randomized but Never Treated|0
6241946|NCT01858766|9924479|FG011|Overall Study|Randomized but Never Treated|0
6241947|NCT01858766|9924480|FG012|Overall Study|Randomized but Never Treated|0
6241948|NCT01858766|9924481|FG013|Overall Study|Randomized but Never Treated|0
6241949|NCT01858766|9924482|FG014|Overall Study|Randomized but Never Treated|0
6241950|NCT01858766|9924483|FG015|Overall Study|Randomized but Never Treated|0
6241951|NCT01858766|9924484|FG016|Overall Study|Randomized but Never Treated|0
6241952|NCT01858766|9924485|FG017|Overall Study|Randomized but Never Treated|1
6241953|NCT01858766|9924486|FG018|Overall Study|Randomized but Never Treated|0
6241954|NCT01858766|9924468|FG000|Overall Study|Death|0
6241955|NCT01858766|9924469|FG001|Overall Study|Death|0
6241956|NCT01858766|9924470|FG002|Overall Study|Death|1
6241957|NCT01858766|9924471|FG003|Overall Study|Death|0
6241958|NCT01858766|9924472|FG004|Overall Study|Death|0
6241959|NCT01858766|9924473|FG005|Overall Study|Death|0
6241960|NCT01858766|9924474|FG006|Overall Study|Death|0
6241961|NCT01858766|9924475|FG007|Overall Study|Death|0
6241962|NCT01858766|9924476|FG008|Overall Study|Death|0
6241963|NCT01858766|9924477|FG009|Overall Study|Death|0
6241964|NCT01858766|9924478|FG010|Overall Study|Death|0
6241965|NCT01858766|9924479|FG011|Overall Study|Death|0
6241966|NCT01858766|9924480|FG012|Overall Study|Death|0
6241967|NCT01858766|9924481|FG013|Overall Study|Death|0
6241968|NCT01858766|9924482|FG014|Overall Study|Death|0
6241969|NCT01858766|9924483|FG015|Overall Study|Death|0
6241970|NCT01858766|9924484|FG016|Overall Study|Death|0
6241971|NCT01858766|9924485|FG017|Overall Study|Death|0
6241972|NCT01858766|9924486|FG018|Overall Study|Death|0
6241973|NCT01858766|9924468|FG000|Overall Study|Lack of Efficacy|1
6241974|NCT01858766|9924469|FG001|Overall Study|Lack of Efficacy|0
6241975|NCT01858766|9924470|FG002|Overall Study|Lack of Efficacy|0
6241976|NCT01858766|9924471|FG003|Overall Study|Lack of Efficacy|0
6241977|NCT01858766|9924472|FG004|Overall Study|Lack of Efficacy|1
6241978|NCT01858766|9924473|FG005|Overall Study|Lack of Efficacy|2
6241979|NCT01858766|9924474|FG006|Overall Study|Lack of Efficacy|0
6241980|NCT01858766|9924475|FG007|Overall Study|Lack of Efficacy|0
6241981|NCT01858766|9924476|FG008|Overall Study|Lack of Efficacy|0
6241982|NCT01858766|9924477|FG009|Overall Study|Lack of Efficacy|0
6241983|NCT01858766|9924478|FG010|Overall Study|Lack of Efficacy|0
6241984|NCT01858766|9924479|FG011|Overall Study|Lack of Efficacy|3
6241985|NCT01858766|9924480|FG012|Overall Study|Lack of Efficacy|5
6241986|NCT01858766|9924481|FG013|Overall Study|Lack of Efficacy|3
6241987|NCT01858766|9924482|FG014|Overall Study|Lack of Efficacy|5
6241988|NCT01858766|9924483|FG015|Overall Study|Lack of Efficacy|5
6241989|NCT01858766|9924484|FG016|Overall Study|Lack of Efficacy|2
6241990|NCT01858766|9924485|FG017|Overall Study|Lack of Efficacy|3
6241991|NCT01858766|9924486|FG018|Overall Study|Lack of Efficacy|3
6241992|NCT01858766|9924468|FG000|Overall Study|Lost to Follow-up|0
6241993|NCT01858766|9924469|FG001|Overall Study|Lost to Follow-up|0
6241994|NCT01858766|9924470|FG002|Overall Study|Lost to Follow-up|0
6241995|NCT01858766|9924471|FG003|Overall Study|Lost to Follow-up|0
6241996|NCT01858766|9924472|FG004|Overall Study|Lost to Follow-up|0
6241997|NCT01858766|9924473|FG005|Overall Study|Lost to Follow-up|1
6241998|NCT01858766|9924474|FG006|Overall Study|Lost to Follow-up|0
6241999|NCT01858766|9924475|FG007|Overall Study|Lost to Follow-up|2
6242000|NCT01858766|9924476|FG008|Overall Study|Lost to Follow-up|0
6242001|NCT01858766|9924477|FG009|Overall Study|Lost to Follow-up|0
6242002|NCT01858766|9924478|FG010|Overall Study|Lost to Follow-up|0
6242003|NCT01858766|9924479|FG011|Overall Study|Lost to Follow-up|1
6242004|NCT01858766|9924480|FG012|Overall Study|Lost to Follow-up|0
6242005|NCT01858766|9924481|FG013|Overall Study|Lost to Follow-up|0
6242006|NCT01858766|9924482|FG014|Overall Study|Lost to Follow-up|3
6242007|NCT01858766|9924483|FG015|Overall Study|Lost to Follow-up|1
6242008|NCT01858766|9924484|FG016|Overall Study|Lost to Follow-up|1
6242009|NCT01858766|9924485|FG017|Overall Study|Lost to Follow-up|0
6242010|NCT01858766|9924486|FG018|Overall Study|Lost to Follow-up|1
6242011|NCT01858766|9924468|FG000|Overall Study|Withdrew Consent|0
6242012|NCT01858766|9924469|FG001|Overall Study|Withdrew Consent|0
6242013|NCT01858766|9924470|FG002|Overall Study|Withdrew Consent|0
6242014|NCT01858766|9924471|FG003|Overall Study|Withdrew Consent|0
6242015|NCT01858766|9924472|FG004|Overall Study|Withdrew Consent|0
6242016|NCT01858766|9924473|FG005|Overall Study|Withdrew Consent|0
6242017|NCT01858766|9924474|FG006|Overall Study|Withdrew Consent|0
6242018|NCT01858766|9924475|FG007|Overall Study|Withdrew Consent|0
6242019|NCT01858766|9924476|FG008|Overall Study|Withdrew Consent|0
6242020|NCT01858766|9924477|FG009|Overall Study|Withdrew Consent|0
6242021|NCT01858766|9924478|FG010|Overall Study|Withdrew Consent|0
6242022|NCT01858766|9924479|FG011|Overall Study|Withdrew Consent|1
6242023|NCT01858766|9924480|FG012|Overall Study|Withdrew Consent|0
6242024|NCT01858766|9924481|FG013|Overall Study|Withdrew Consent|0
6242025|NCT01858766|9924482|FG014|Overall Study|Withdrew Consent|0
6242026|NCT01858766|9924483|FG015|Overall Study|Withdrew Consent|0
6242027|NCT01858766|9924484|FG016|Overall Study|Withdrew Consent|0
6242028|NCT01858766|9924485|FG017|Overall Study|Withdrew Consent|0
6242029|NCT01858766|9924486|FG018|Overall Study|Withdrew Consent|0
6242030|NCT01859143|9924536|FG000|Overall Study|Lost to Follow-up|2
6242031|NCT01859143|9924537|FG001|Overall Study|Lost to Follow-up|0
6242032|NCT01859390|9924606|FG000|Overall Study|Insufficient Sputum Collected|1
6242033|NCT01859390|9924607|FG001|Overall Study|Insufficient Sputum Collected|3
6242034|NCT01859390|9924606|FG000|Overall Study|Sample Missing Collection Date|0
6242035|NCT01859390|9924607|FG001|Overall Study|Sample Missing Collection Date|1
6242036|NCT01859390|9924606|FG000|Overall Study|Tube Cracked|0
6242037|NCT01859390|9924607|FG001|Overall Study|Tube Cracked|2
6242038|NCT01859390|9924606|FG000|Overall Study|Shipment Error|0
6242039|NCT01859390|9924607|FG001|Overall Study|Shipment Error|1
6242040|NCT01859403|9924615|FG000|Primary Endpoint Measure|Lost to Follow-up|0
6242041|NCT01859403|9924616|FG001|Primary Endpoint Measure|Lost to Follow-up|2
6242042|NCT01859403|9924615|FG000|Primary Endpoint Measure|Withdrawal by Subject|1
6242043|NCT01859403|9924616|FG001|Primary Endpoint Measure|Withdrawal by Subject|1
6242044|NCT01859403|9924615|FG000|Primary Endpoint Measure|Physician Decision|0
6242045|NCT01859403|9924616|FG001|Primary Endpoint Measure|Physician Decision|1
6242046|NCT01859403|9924615|FG000|Secondary Endpoint Measure|Withdrawal by Subject|6
6242047|NCT01859403|9924616|FG001|Secondary Endpoint Measure|Withdrawal by Subject|8
6242048|NCT01859494|9924622|FG000|Overall Study|Adverse Event|1
6242049|NCT01859507|9924626|FG000|Overall Study|left the country|4
6242050|NCT01859598|9924631|FG000|Visit 2 at 3 Months|Lost to Follow-up|1742
6242051|NCT01859702|9924645|FG000|Overall Study|Protocol deviation|3
6242052|NCT01859702|9924645|FG000|Overall Study|Adverse Event|2
6270289|NCT02151149|9971133|FG001|Follow-Up Period|Death|34
6270290|NCT02151266|9971149|FG000|Overall Study|Lost to Follow-up|1
6270291|NCT02151266|9971150|FG001|Overall Study|Lost to Follow-up|4
6270292|NCT02151266|9971151|FG002|Overall Study|Lost to Follow-up|1
6270293|NCT02151266|9971149|FG000|Overall Study|Did NOT receive intervention|3
6270294|NCT02151266|9971150|FG001|Overall Study|Did NOT receive intervention|6
6270295|NCT02151266|9971151|FG002|Overall Study|Did NOT receive intervention|2
6270296|NCT02151266|9971149|FG000|Overall Study|Not able to exercise|4
6270297|NCT02151266|9971150|FG001|Overall Study|Not able to exercise|5
6270298|NCT02151266|9971151|FG002|Overall Study|Not able to exercise|4
6270299|NCT02151461|9971180|FG000|Overall Study|Adverse Event|5
6270300|NCT02151461|9971181|FG001|Overall Study|Adverse Event|1
6270301|NCT02151461|9971182|FG002|Overall Study|Adverse Event|0
6270302|NCT02151461|9971183|FG003|Overall Study|Adverse Event|2
6270303|NCT02151461|9971180|FG000|Overall Study|Lost to Follow-up|0
6270304|NCT02151461|9971181|FG001|Overall Study|Lost to Follow-up|0
6270305|NCT02151461|9971182|FG002|Overall Study|Lost to Follow-up|1
6270306|NCT02151461|9971183|FG003|Overall Study|Lost to Follow-up|1
6270307|NCT02151461|9971180|FG000|Overall Study|Withdrawal by Subject|1
6270308|NCT02151461|9971181|FG001|Overall Study|Withdrawal by Subject|0
6270309|NCT02151461|9971182|FG002|Overall Study|Withdrawal by Subject|1
6270310|NCT02151461|9971183|FG003|Overall Study|Withdrawal by Subject|1
6270311|NCT02151461|9971180|FG000|Overall Study|Treatment discontinuation|0
6270312|NCT02151461|9971181|FG001|Overall Study|Treatment discontinuation|0
6270313|NCT02151461|9971182|FG002|Overall Study|Treatment discontinuation|1
6270314|NCT02151461|9971183|FG003|Overall Study|Treatment discontinuation|0
6270315|NCT02151591|9971212|FG000|Overall Study|Lost to Follow-up|6
6270316|NCT02151591|9971213|FG001|Overall Study|Lost to Follow-up|3
6270317|NCT02151643|9971224|FG000|Overall Study|Adverse Event|2
6270318|NCT02151643|9971225|FG001|Overall Study|Adverse Event|0
6270319|NCT02151643|9971226|FG002|Overall Study|Adverse Event|1
6270320|NCT02151643|9971227|FG003|Overall Study|Adverse Event|4
6270321|NCT02151643|9971228|FG004|Overall Study|Adverse Event|0
6270322|NCT02151643|9971224|FG000|Overall Study|Withdrawal by Subject|0
6270323|NCT02151643|9971225|FG001|Overall Study|Withdrawal by Subject|1
6270324|NCT02151643|9971226|FG002|Overall Study|Withdrawal by Subject|1
6270325|NCT02151643|9971227|FG003|Overall Study|Withdrawal by Subject|1
6270326|NCT02151643|9971228|FG004|Overall Study|Withdrawal by Subject|1
6270327|NCT02151643|9971224|FG000|Overall Study|Hyperphosphataemia|1
6270328|NCT02151643|9971225|FG001|Overall Study|Hyperphosphataemia|0
6270329|NCT02151643|9971226|FG002|Overall Study|Hyperphosphataemia|0
6270330|NCT02151643|9971227|FG003|Overall Study|Hyperphosphataemia|0
6270331|NCT02151643|9971228|FG004|Overall Study|Hyperphosphataemia|1
6189078|NCT01396421|9844137|FG001|Overall Study|Physician Decision|1
6189079|NCT01396421|9844138|FG002|Overall Study|Physician Decision|0
6189080|NCT01396421|9844139|FG003|Overall Study|Physician Decision|3
6189081|NCT01396421|9844136|FG000|Overall Study|Withdrawal by Subject|31
6270332|NCT02151643|9971224|FG000|Overall Study|High Ferritin levels|3
6270333|NCT02151643|9971225|FG001|Overall Study|High Ferritin levels|3
6270334|NCT02151643|9971226|FG002|Overall Study|High Ferritin levels|2
6270335|NCT02151643|9971227|FG003|Overall Study|High Ferritin levels|2
6270336|NCT02151643|9971228|FG004|Overall Study|High Ferritin levels|1
6270337|NCT02151682|9971242|FG000|Part 1: 14 Days Morphine or Tapentadol|Adverse Event|0
6270338|NCT02151682|9971243|FG001|Part 1: 14 Days Morphine or Tapentadol|Adverse Event|2
6270339|NCT02151682|9971244|FG002|Part 1: 14 Days Morphine or Tapentadol|Adverse Event|0
6270340|NCT02151682|9971245|FG003|Part 1: 14 Days Morphine or Tapentadol|Adverse Event|0
6270341|NCT02151682|9971246|FG004|Part 1: 14 Days Morphine or Tapentadol|Adverse Event|0
6270342|NCT02151682|9971247|FG005|Part 1: 14 Days Morphine or Tapentadol|Adverse Event|0
6189082|NCT01396421|9844137|FG001|Overall Study|Withdrawal by Subject|24
6189083|NCT01396421|9844138|FG002|Overall Study|Withdrawal by Subject|13
6189084|NCT01396421|9844139|FG003|Overall Study|Withdrawal by Subject|21
6189085|NCT01396421|9844136|FG000|Overall Study|Protocol Deviation|2
6189086|NCT01396421|9844137|FG001|Overall Study|Protocol Deviation|1
6189087|NCT01396421|9844138|FG002|Overall Study|Protocol Deviation|1
6270343|NCT02151682|9971242|FG000|Part 1: 14 Days Morphine or Tapentadol|Withdrawal by Subject|0
6270344|NCT02151682|9971243|FG001|Part 1: 14 Days Morphine or Tapentadol|Withdrawal by Subject|1
6270345|NCT02151682|9971244|FG002|Part 1: 14 Days Morphine or Tapentadol|Withdrawal by Subject|0
6270346|NCT02151682|9971245|FG003|Part 1: 14 Days Morphine or Tapentadol|Withdrawal by Subject|0
6270347|NCT02151682|9971246|FG004|Part 1: 14 Days Morphine or Tapentadol|Withdrawal by Subject|0
6270348|NCT02151682|9971247|FG005|Part 1: 14 Days Morphine or Tapentadol|Withdrawal by Subject|0
6270349|NCT02151682|9971242|FG000|Part 1: 14 Days Morphine or Tapentadol|Technical problems|0
6270350|NCT02151682|9971243|FG001|Part 1: 14 Days Morphine or Tapentadol|Technical problems|1
6270351|NCT02151682|9971244|FG002|Part 1: 14 Days Morphine or Tapentadol|Technical problems|0
6085942|NCT00657618|9695602|FG000|Overall Study|Adverse Event|32
6242053|NCT01859715|9924652|FG000|Overall Study|No 2nd VAS|16
6242054|NCT01859715|9924653|FG001|Overall Study|No 2nd VAS|8
6242055|NCT01859715|9924654|FG002|Overall Study|No 2nd VAS|23
6242056|NCT01859741|9924672|FG000|Overall Study|Death|3
6242057|NCT01859741|9924673|FG001|Overall Study|Death|2
6242058|NCT01859741|9924674|FG002|Overall Study|Death|4
6242059|NCT01859741|9924675|FG003|Overall Study|Death|3
6242060|NCT01859741|9924676|FG004|Overall Study|Death|5
6242061|NCT01859741|9924677|FG005|Overall Study|Death|4
6242062|NCT01859741|9924678|FG006|Overall Study|Death|51
6242063|NCT01859741|9924679|FG007|Overall Study|Death|51
6242064|NCT01859741|9924672|FG000|Overall Study|Lost to Follow-up|0
6242065|NCT01859741|9924673|FG001|Overall Study|Lost to Follow-up|0
6242066|NCT01859741|9924674|FG002|Overall Study|Lost to Follow-up|0
6242067|NCT01859741|9924675|FG003|Overall Study|Lost to Follow-up|0
6242068|NCT01859741|9924676|FG004|Overall Study|Lost to Follow-up|0
6242069|NCT01859741|9924677|FG005|Overall Study|Lost to Follow-up|1
6242070|NCT01859741|9924678|FG006|Overall Study|Lost to Follow-up|0
6242071|NCT01859741|9924679|FG007|Overall Study|Lost to Follow-up|4
6242072|NCT01859741|9924672|FG000|Overall Study|Withdrawal by Subject|0
6242073|NCT01859741|9924673|FG001|Overall Study|Withdrawal by Subject|1
6242074|NCT01859741|9924674|FG002|Overall Study|Withdrawal by Subject|2
6242075|NCT01859741|9924675|FG003|Overall Study|Withdrawal by Subject|0
6242076|NCT01859741|9924676|FG004|Overall Study|Withdrawal by Subject|0
6242077|NCT01859741|9924677|FG005|Overall Study|Withdrawal by Subject|1
6242078|NCT01859741|9924678|FG006|Overall Study|Withdrawal by Subject|1
6242079|NCT01859741|9924679|FG007|Overall Study|Withdrawal by Subject|1
6242080|NCT01859741|9924672|FG000|Overall Study|Study Terminated by Sponsor|0
6242081|NCT01859741|9924673|FG001|Overall Study|Study Terminated by Sponsor|0
6242082|NCT01859741|9924674|FG002|Overall Study|Study Terminated by Sponsor|0
6242083|NCT01859741|9924675|FG003|Overall Study|Study Terminated by Sponsor|0
6242084|NCT01859741|9924676|FG004|Overall Study|Study Terminated by Sponsor|1
6242085|NCT01859741|9924677|FG005|Overall Study|Study Terminated by Sponsor|0
6242086|NCT01859741|9924678|FG006|Overall Study|Study Terminated by Sponsor|16
6242087|NCT01859741|9924679|FG007|Overall Study|Study Terminated by Sponsor|14
6242088|NCT01859741|9924672|FG000|Overall Study|Other|0
6242089|NCT01859741|9924673|FG001|Overall Study|Other|0
6242090|NCT01859741|9924674|FG002|Overall Study|Other|0
6242091|NCT01859741|9924675|FG003|Overall Study|Other|0
6242092|NCT01859741|9924676|FG004|Overall Study|Other|0
6242093|NCT01859741|9924677|FG005|Overall Study|Other|0
6242094|NCT01859741|9924678|FG006|Overall Study|Other|2
6242095|NCT01859741|9924679|FG007|Overall Study|Other|0
6242096|NCT01859793|9924699|FG000|First Intervention (8 Weeks)|Protocol Violation|2
6242097|NCT01859793|9924700|FG001|First Intervention (8 Weeks)|Protocol Violation|0
6242098|NCT01859793|9924699|FG000|First Intervention (8 Weeks)|Adverse Event|1
6242099|NCT01859793|9924700|FG001|First Intervention (8 Weeks)|Adverse Event|0
6242100|NCT01859793|9924699|FG000|First Intervention (8 Weeks)|Withdrawal by Subject|2
6242101|NCT01859793|9924700|FG001|First Intervention (8 Weeks)|Withdrawal by Subject|1
6242102|NCT01859793|9924699|FG000|Washout Period (4 Weeks)|Lost to Follow-up|1
6242103|NCT01859793|9924700|FG001|Washout Period (4 Weeks)|Lost to Follow-up|1
6242104|NCT01859923|9924710|FG000|Overall Study|Adverse Event|0
6242105|NCT01859923|9924711|FG001|Overall Study|Adverse Event|0
6242106|NCT01859923|9924712|FG002|Overall Study|Adverse Event|1
6242107|NCT01859923|9924713|FG003|Overall Study|Adverse Event|1
6242108|NCT01859949|9924728|FG000|Overall Study|Family Matters|0
6242109|NCT01859949|9924729|FG001|Overall Study|Family Matters|1
6242110|NCT01859949|9924728|FG000|Overall Study|Physician Decision|2
6242111|NCT01859949|9924729|FG001|Overall Study|Physician Decision|4
6242112|NCT01859949|9924728|FG000|Overall Study|Withdrawal by Subject|11
6242113|NCT01859949|9924729|FG001|Overall Study|Withdrawal by Subject|10
6242114|NCT01859949|9924728|FG000|Overall Study|Protocol Violation|1
6242115|NCT01859949|9924729|FG001|Overall Study|Protocol Violation|1
6242116|NCT01859949|9924728|FG000|Overall Study|Adverse Event|0
6242117|NCT01859949|9924729|FG001|Overall Study|Adverse Event|1
6242118|NCT01859988|9924741|FG000|Overall Study|Withdrawal by Subject|6
6242119|NCT01859988|9924742|FG001|Overall Study|Withdrawal by Subject|3
6242120|NCT01859988|9924743|FG002|Overall Study|Withdrawal by Subject|4
6085943|NCT00657618|9695602|FG000|Overall Study|Withdrawal by Subject|8
6242121|NCT01859988|9924744|FG003|Overall Study|Withdrawal by Subject|3
6242122|NCT01859988|9924745|FG004|Overall Study|Withdrawal by Subject|2
6242123|NCT01859988|9924746|FG005|Overall Study|Withdrawal by Subject|2
6242124|NCT01859988|9924741|FG000|Overall Study|Lack of Efficacy|1
6242125|NCT01859988|9924742|FG001|Overall Study|Lack of Efficacy|1
6242126|NCT01859988|9924743|FG002|Overall Study|Lack of Efficacy|5
6242127|NCT01859988|9924744|FG003|Overall Study|Lack of Efficacy|0
6242128|NCT01859988|9924745|FG004|Overall Study|Lack of Efficacy|7
6242129|NCT01859988|9924746|FG005|Overall Study|Lack of Efficacy|9
6085944|NCT00657618|9695602|FG000|Overall Study|negative for leishmaniasis|2
6242130|NCT01859988|9924741|FG000|Overall Study|Physician Decision|1
6242131|NCT01859988|9924742|FG001|Overall Study|Physician Decision|3
6242132|NCT01859988|9924743|FG002|Overall Study|Physician Decision|1
6242133|NCT01859988|9924744|FG003|Overall Study|Physician Decision|3
6242134|NCT01859988|9924745|FG004|Overall Study|Physician Decision|4
6242135|NCT01859988|9924746|FG005|Overall Study|Physician Decision|1
6242136|NCT01859988|9924741|FG000|Overall Study|Adverse Event|2
6242137|NCT01859988|9924742|FG001|Overall Study|Adverse Event|1
6242138|NCT01859988|9924743|FG002|Overall Study|Adverse Event|3
6242139|NCT01859988|9924744|FG003|Overall Study|Adverse Event|1
6242140|NCT01859988|9924745|FG004|Overall Study|Adverse Event|2
6242141|NCT01859988|9924746|FG005|Overall Study|Adverse Event|2
6242142|NCT01859988|9924741|FG000|Overall Study|Lost to Follow-up|1
6242143|NCT01859988|9924742|FG001|Overall Study|Lost to Follow-up|2
6242144|NCT01859988|9924743|FG002|Overall Study|Lost to Follow-up|3
6242145|NCT01859988|9924744|FG003|Overall Study|Lost to Follow-up|0
6242146|NCT01859988|9924745|FG004|Overall Study|Lost to Follow-up|3
6242147|NCT01859988|9924746|FG005|Overall Study|Lost to Follow-up|2
6242148|NCT01859988|9924741|FG000|Overall Study|Protocol Violation|0
6242149|NCT01859988|9924742|FG001|Overall Study|Protocol Violation|0
6242150|NCT01859988|9924743|FG002|Overall Study|Protocol Violation|1
6242151|NCT01859988|9924744|FG003|Overall Study|Protocol Violation|0
6242152|NCT01859988|9924745|FG004|Overall Study|Protocol Violation|0
6242153|NCT01859988|9924746|FG005|Overall Study|Protocol Violation|0
6242154|NCT01859988|9924741|FG000|Overall Study|Other than specified above|0
6242155|NCT01859988|9924742|FG001|Overall Study|Other than specified above|2
6242156|NCT01859988|9924743|FG002|Overall Study|Other than specified above|11
6242157|NCT01859988|9924744|FG003|Overall Study|Other than specified above|3
6242158|NCT01859988|9924745|FG004|Overall Study|Other than specified above|5
6242159|NCT01859988|9924746|FG005|Overall Study|Other than specified above|3
6242160|NCT01860079|9924762|FG000|Overall Study|Physician Decision|14
6242161|NCT01860079|9924763|FG001|Overall Study|Physician Decision|22
6242162|NCT01860534|9924806|FG000|ROP #1|Needed treatment for ROP|0
6242163|NCT01860534|9924807|FG001|ROP #1|Needed treatment for ROP|1
6242164|NCT01860534|9924806|FG000|ROP #2|discharged prior to ROP #2|1
6242165|NCT01860534|9924807|FG001|ROP #2|discharged prior to ROP #2|0
6242166|NCT01860677|9924844|FG000|Second Intervention (1 Day)|Lost to Follow-up|7
6242167|NCT01860677|9924845|FG001|Second Intervention (1 Day)|Lost to Follow-up|0
6242168|NCT01860703|9924852|FG000|Overall Study|Adverse Event|1
6242169|NCT01860703|9924853|FG001|Overall Study|Adverse Event|4
6242170|NCT01860703|9924854|FG002|Overall Study|Adverse Event|0
6242171|NCT01860703|9924855|FG003|Overall Study|Adverse Event|2
6242172|NCT01860703|9924852|FG000|Overall Study|Withdrawal by Subject|0
6242173|NCT01860703|9924853|FG001|Overall Study|Withdrawal by Subject|1
6242174|NCT01860703|9924854|FG002|Overall Study|Withdrawal by Subject|0
6242175|NCT01860703|9924855|FG003|Overall Study|Withdrawal by Subject|0
6242176|NCT01860703|9924852|FG000|Overall Study|Personal reason|1
6242177|NCT01860703|9924853|FG001|Overall Study|Personal reason|0
6242178|NCT01860703|9924854|FG002|Overall Study|Personal reason|1
6242179|NCT01860703|9924855|FG003|Overall Study|Personal reason|0
6242180|NCT01860846|9924880|FG000|Overall Study|Lost to Follow-up|33
6242181|NCT01860989|9924910|FG000|Overall Study|Unsatisfactory therapeutic|5
6242182|NCT01861522|9924955|FG000|Overall Study|Adverse Event|1
6242183|NCT01861522|9924956|FG001|Overall Study|Adverse Event|0
6242184|NCT01861522|9924955|FG000|Overall Study|Withdrawal by Subject|2
6242185|NCT01861522|9924956|FG001|Overall Study|Withdrawal by Subject|0
6242186|NCT01862029|9925036|FG000|Overall Study|Physician Decision|1
6242187|NCT01862250|9925052|FG000|Overall Study|Adverse Event|4
6242188|NCT01862328|9925063|FG000|Overall Study|Progressive Disease|3
6242189|NCT01862328|9925064|FG001|Overall Study|Progressive Disease|11
6242190|NCT01862328|9925065|FG002|Overall Study|Progressive Disease|5
6242191|NCT01862328|9925066|FG003|Overall Study|Progressive Disease|6
6242192|NCT01862328|9925067|FG004|Overall Study|Progressive Disease|7
6242193|NCT01862328|9925068|FG005|Overall Study|Progressive Disease|4
6242194|NCT01862328|9925069|FG006|Overall Study|Progressive Disease|3
6242195|NCT01862328|9925063|FG000|Overall Study|Adverse Event|0
6242196|NCT01862328|9925064|FG001|Overall Study|Adverse Event|4
6242197|NCT01862328|9925065|FG002|Overall Study|Adverse Event|0
6242198|NCT01862328|9925066|FG003|Overall Study|Adverse Event|1
6242199|NCT01862328|9925067|FG004|Overall Study|Adverse Event|0
6242200|NCT01862328|9925068|FG005|Overall Study|Adverse Event|2
6242201|NCT01862328|9925069|FG006|Overall Study|Adverse Event|4
6242202|NCT01862328|9925063|FG000|Overall Study|Other|0
6242203|NCT01862328|9925064|FG001|Overall Study|Other|2
6242204|NCT01862328|9925065|FG002|Overall Study|Other|1
6242205|NCT01862328|9925066|FG003|Overall Study|Other|0
6242206|NCT01862328|9925067|FG004|Overall Study|Other|4
6242207|NCT01862328|9925068|FG005|Overall Study|Other|0
6242208|NCT01862328|9925069|FG006|Overall Study|Other|1
6242209|NCT01862328|9925063|FG000|Overall Study|Withdrawal by Subject|1
6242210|NCT01862328|9925064|FG001|Overall Study|Withdrawal by Subject|1
6242211|NCT01862328|9925065|FG002|Overall Study|Withdrawal by Subject|0
6242212|NCT01862328|9925066|FG003|Overall Study|Withdrawal by Subject|0
6242213|NCT01862328|9925067|FG004|Overall Study|Withdrawal by Subject|1
6242214|NCT01862328|9925068|FG005|Overall Study|Withdrawal by Subject|1
6242215|NCT01862328|9925069|FG006|Overall Study|Withdrawal by Subject|1
6242216|NCT01862328|9925063|FG000|Overall Study|Symptomatic Deterioration|0
6242217|NCT01862328|9925064|FG001|Overall Study|Symptomatic Deterioration|0
6242218|NCT01862328|9925065|FG002|Overall Study|Symptomatic Deterioration|0
6242219|NCT01862328|9925066|FG003|Overall Study|Symptomatic Deterioration|0
6242220|NCT01862328|9925067|FG004|Overall Study|Symptomatic Deterioration|0
6242221|NCT01862328|9925068|FG005|Overall Study|Symptomatic Deterioration|0
6242222|NCT01862328|9925069|FG006|Overall Study|Symptomatic Deterioration|1
6242223|NCT01862484|9925102|FG000|Overall Study|Lack of Efficacy|1
6242224|NCT01862484|9925103|FG001|Overall Study|Lack of Efficacy|1
6242225|NCT01862484|9925102|FG000|Overall Study|Lost to Follow-up|1
6242226|NCT01862484|9925103|FG001|Overall Study|Lost to Follow-up|2
6242227|NCT01862484|9925102|FG000|Overall Study|Protocol Violation|0
6242228|NCT01862484|9925103|FG001|Overall Study|Protocol Violation|2
6242229|NCT01862484|9925102|FG000|Overall Study|Withdrawal by Subject|0
6242230|NCT01862484|9925103|FG001|Overall Study|Withdrawal by Subject|3
6242231|NCT01862640|9925131|FG000|Overall Study|Adverse Event|4
6242232|NCT01862640|9925132|FG001|Overall Study|Adverse Event|10
6242233|NCT01862640|9925133|FG002|Overall Study|Adverse Event|6
6242234|NCT01862640|9925134|FG003|Overall Study|Adverse Event|8
6242235|NCT01862640|9925131|FG000|Overall Study|Participant Met Withdrawal Criteria|1
6242236|NCT01862640|9925132|FG001|Overall Study|Participant Met Withdrawal Criteria|1
6242237|NCT01862640|9925133|FG002|Overall Study|Participant Met Withdrawal Criteria|2
6242238|NCT01862640|9925134|FG003|Overall Study|Participant Met Withdrawal Criteria|1
6242239|NCT01862640|9925131|FG000|Overall Study|Participant Withdrawn by Investigator|0
6242240|NCT01862640|9925132|FG001|Overall Study|Participant Withdrawn by Investigator|1
6242241|NCT01862640|9925133|FG002|Overall Study|Participant Withdrawn by Investigator|1
6242242|NCT01862640|9925134|FG003|Overall Study|Participant Withdrawn by Investigator|1
6242243|NCT01862640|9925131|FG000|Overall Study|Withdrawal by Subject|2
6242244|NCT01862640|9925132|FG001|Overall Study|Withdrawal by Subject|4
6242245|NCT01862640|9925133|FG002|Overall Study|Withdrawal by Subject|8
6242246|NCT01862640|9925134|FG003|Overall Study|Withdrawal by Subject|5
6242247|NCT01862640|9925131|FG000|Overall Study|Protocol Deviation|0
6242248|NCT01862640|9925132|FG001|Overall Study|Protocol Deviation|0
6242249|NCT01862640|9925133|FG002|Overall Study|Protocol Deviation|1
6242250|NCT01862640|9925134|FG003|Overall Study|Protocol Deviation|0
6242251|NCT01862796|9925146|FG000|Overall Study|Prohibited medications|0
6242252|NCT01862796|9925147|FG001|Overall Study|Prohibited medications|0
6242253|NCT01862796|9925148|FG002|Overall Study|Prohibited medications|1
6242254|NCT01862874|9925158|FG000|Overall Study|Randomized not treated|1
6242255|NCT01862874|9925159|FG001|Overall Study|Randomized not treated|0
6242256|NCT01862874|9925158|FG000|Overall Study|Adverse Event|0
6242257|NCT01862874|9925159|FG001|Overall Study|Adverse Event|3
6242258|NCT01862874|9925158|FG000|Overall Study|Lost to Follow-up|26
6242259|NCT01862874|9925159|FG001|Overall Study|Lost to Follow-up|29
6242260|NCT01862874|9925158|FG000|Overall Study|Physician Decision|5
6242261|NCT01862874|9925159|FG001|Overall Study|Physician Decision|3
6242262|NCT01862874|9925158|FG000|Overall Study|Withdrawn by parent/guardian|1
6242263|NCT01862874|9925159|FG001|Overall Study|Withdrawn by parent/guardian|1
6242264|NCT01862874|9925158|FG000|Overall Study|Withdrawal by Subject|46
6242265|NCT01862874|9925159|FG001|Overall Study|Withdrawal by Subject|40
6242266|NCT01862874|9925158|FG000|Overall Study|Death|0
6242267|NCT01862874|9925159|FG001|Overall Study|Death|1
6242268|NCT01862991|9925168|FG000|Overall Study|Lost to Follow-up|2
6242269|NCT01862991|9925169|FG001|Overall Study|Lost to Follow-up|1
6242270|NCT01862991|9925170|FG002|Overall Study|Lost to Follow-up|1
6242271|NCT01862991|9925168|FG000|Overall Study|Protocol Violation|1
6242272|NCT01862991|9925169|FG001|Overall Study|Protocol Violation|0
6242273|NCT01862991|9925170|FG002|Overall Study|Protocol Violation|0
6242274|NCT01863368|9925203|FG000|Phase I, Day 0 to Day 35|Adverse Event|2
6242275|NCT01863368|9925204|FG001|Phase I, Day 0 to Day 35|Adverse Event|4
6242276|NCT01863368|9925203|FG000|Phase I, Day 0 to Day 35|Lost to Follow-up|1
6242277|NCT01863368|9925204|FG001|Phase I, Day 0 to Day 35|Lost to Follow-up|0
6242278|NCT01863368|9925203|FG000|Phase I, Day 0 to Day 35|Withdrawal by subject prior to treatment|0
6242279|NCT01863368|9925204|FG001|Phase I, Day 0 to Day 35|Withdrawal by subject prior to treatment|1
6242280|NCT01863368|9925203|FG000|Phase I, Day 0 to Day 35|Withdrawal by Subject|0
6242281|NCT01863368|9925204|FG001|Phase I, Day 0 to Day 35|Withdrawal by Subject|2
6242282|NCT01863368|9925203|FG000|Phase II, Day 35 to Day 90|Adverse Event|1
6242283|NCT01863368|9925204|FG001|Phase II, Day 35 to Day 90|Adverse Event|0
6242284|NCT01863368|9925203|FG000|Phase II, Day 35 to Day 90|Lost to Follow-up|1
6242285|NCT01863368|9925204|FG001|Phase II, Day 35 to Day 90|Lost to Follow-up|0
6242286|NCT01863433|9925211|FG000|Overall Study|Protocol Violation|1
6242287|NCT01863667|9925230|FG000|Overall Study|Adverse Event|1
6242288|NCT01863667|9925231|FG001|Overall Study|Adverse Event|0
6242289|NCT01863667|9925230|FG000|Overall Study|Study terminated by Sponsor|30
6242290|NCT01863667|9925231|FG001|Overall Study|Study terminated by Sponsor|30
6242291|NCT01863667|9925230|FG000|Overall Study|Withdrawal by Subject|2
6242292|NCT01863667|9925231|FG001|Overall Study|Withdrawal by Subject|2
6242293|NCT01863680|9925237|FG000|Overall Study|Adverse Event|17
6242294|NCT01863680|9925237|FG000|Overall Study|Risk of OHSS|17
6242295|NCT01863680|9925237|FG000|Overall Study|Spontaneous pregnancy|2
6242296|NCT01863680|9925237|FG000|Overall Study|Withdrawal by Subject|1
6242297|NCT01863680|9925237|FG000|Overall Study|Did not undergo IVF/ET|14
6242298|NCT01863680|9925237|FG000|Overall Study|Other|6
6242299|NCT01863732|9925245|FG000|Overall Study|Adverse Event|2
6242300|NCT01863732|9925246|FG001|Overall Study|Adverse Event|0
6242301|NCT01863732|9925247|FG002|Overall Study|Adverse Event|3
6242302|NCT01863732|9925248|FG003|Overall Study|Adverse Event|3
6242303|NCT01863732|9925245|FG000|Overall Study|Lack of Efficacy|1
6242304|NCT01863732|9925246|FG001|Overall Study|Lack of Efficacy|0
6242305|NCT01863732|9925247|FG002|Overall Study|Lack of Efficacy|2
6242306|NCT01863732|9925248|FG003|Overall Study|Lack of Efficacy|1
6242307|NCT01863732|9925245|FG000|Overall Study|Lost to Follow-up|2
6242308|NCT01863732|9925246|FG001|Overall Study|Lost to Follow-up|2
6242309|NCT01863732|9925247|FG002|Overall Study|Lost to Follow-up|1
6242310|NCT01863732|9925248|FG003|Overall Study|Lost to Follow-up|1
6242311|NCT01863732|9925245|FG000|Overall Study|Physician Decision|1
6242312|NCT01863732|9925246|FG001|Overall Study|Physician Decision|0
6242313|NCT01863732|9925247|FG002|Overall Study|Physician Decision|1
6242314|NCT01863732|9925248|FG003|Overall Study|Physician Decision|0
6242315|NCT01863732|9925245|FG000|Overall Study|Pregnancy|0
6242316|NCT01863732|9925246|FG001|Overall Study|Pregnancy|0
6242317|NCT01863732|9925247|FG002|Overall Study|Pregnancy|0
6242318|NCT01863732|9925248|FG003|Overall Study|Pregnancy|1
6242319|NCT01863732|9925245|FG000|Overall Study|Technical problems|0
6242320|NCT01863732|9925246|FG001|Overall Study|Technical problems|1
6242321|NCT01863732|9925247|FG002|Overall Study|Technical problems|1
6242322|NCT01863732|9925248|FG003|Overall Study|Technical problems|0
6242323|NCT01863732|9925245|FG000|Overall Study|Subject/guardian decision|6
6242324|NCT01863732|9925246|FG001|Overall Study|Subject/guardian decision|9
6242325|NCT01863732|9925247|FG002|Overall Study|Subject/guardian decision|3
6242326|NCT01863732|9925248|FG003|Overall Study|Subject/guardian decision|1
6242327|NCT01863732|9925245|FG000|Overall Study|Death|1
6242328|NCT01863732|9925246|FG001|Overall Study|Death|0
6242329|NCT01863732|9925247|FG002|Overall Study|Death|0
6242330|NCT01863732|9925248|FG003|Overall Study|Death|1
6242331|NCT01863758|9925257|FG000|Prophylactic Treatment-Phase II|investigator Error of Early Termination|1
6242332|NCT01863758|9925257|FG000|Prophylactic Treatment-Phase II|Lost to Follow-up|1
6242333|NCT01863771|9925261|FG000|Induction Phase|Adverse Event|9
6242334|NCT01863771|9925262|FG001|Induction Phase|Adverse Event|0
6242335|NCT01863771|9925263|FG002|Induction Phase|Adverse Event|0
6242336|NCT01863771|9925264|FG003|Induction Phase|Adverse Event|0
6242337|NCT01863771|9925261|FG000|Induction Phase|Lack of Efficacy|10
6242338|NCT01863771|9925262|FG001|Induction Phase|Lack of Efficacy|0
6242339|NCT01863771|9925263|FG002|Induction Phase|Lack of Efficacy|0
6085945|NCT00657618|9695602|FG000|Overall Study|didn't start due to schedule conflicts|1
6085946|NCT00657709|9695615|FG000|Overall Study|AE or Death|7
6085947|NCT00657709|9695616|FG001|Overall Study|AE or Death|7
6242340|NCT01863771|9925264|FG003|Induction Phase|Lack of Efficacy|0
6242341|NCT01863771|9925261|FG000|Induction Phase|Withdrawal by Subject|2
6242342|NCT01863771|9925262|FG001|Induction Phase|Withdrawal by Subject|0
6242343|NCT01863771|9925263|FG002|Induction Phase|Withdrawal by Subject|0
6242344|NCT01863771|9925264|FG003|Induction Phase|Withdrawal by Subject|0
6242345|NCT01863771|9925261|FG000|Maintenance Phase|Adverse Event|0
6242346|NCT01863771|9925262|FG001|Maintenance Phase|Adverse Event|0
6242347|NCT01863771|9925263|FG002|Maintenance Phase|Adverse Event|1
6242348|NCT01863771|9925264|FG003|Maintenance Phase|Adverse Event|1
6242349|NCT01863771|9925261|FG000|Maintenance Phase|Lack of Efficacy|0
6242350|NCT01863771|9925262|FG001|Maintenance Phase|Lack of Efficacy|3
6242351|NCT01863771|9925263|FG002|Maintenance Phase|Lack of Efficacy|7
6242352|NCT01863771|9925264|FG003|Maintenance Phase|Lack of Efficacy|38
6242353|NCT01863771|9925261|FG000|Maintenance Phase|Physician Decision|0
6242354|NCT01863771|9925262|FG001|Maintenance Phase|Physician Decision|0
6242355|NCT01863771|9925263|FG002|Maintenance Phase|Physician Decision|2
6242356|NCT01863771|9925264|FG003|Maintenance Phase|Physician Decision|1
6242357|NCT01863771|9925261|FG000|Maintenance Phase|Pregnancy|0
6242358|NCT01863771|9925262|FG001|Maintenance Phase|Pregnancy|1
6242359|NCT01863771|9925263|FG002|Maintenance Phase|Pregnancy|0
6242360|NCT01863771|9925264|FG003|Maintenance Phase|Pregnancy|0
6242361|NCT01863771|9925261|FG000|Maintenance Phase|Withdrawal by Subject|0
6242362|NCT01863771|9925262|FG001|Maintenance Phase|Withdrawal by Subject|1
6242363|NCT01863771|9925263|FG002|Maintenance Phase|Withdrawal by Subject|2
6242364|NCT01863771|9925264|FG003|Maintenance Phase|Withdrawal by Subject|3
6242365|NCT01863849|9925274|FG000|Overall Study|Lost to Follow-up|1
6242366|NCT01863849|9925275|FG001|Overall Study|Lost to Follow-up|0
6242367|NCT01863953|9925285|FG000|Overall Study|Adverse Event|0
6242368|NCT01863953|9925286|FG001|Overall Study|Adverse Event|0
6242369|NCT01863953|9925287|FG002|Overall Study|Adverse Event|1
6242370|NCT01864005|9925297|FG000|Overall Study|Protocol Violation|0
6242371|NCT01864005|9925298|FG001|Overall Study|Protocol Violation|1
6242372|NCT01864005|9925297|FG000|Overall Study|Withdrawal by Subject|0
6242373|NCT01864005|9925298|FG001|Overall Study|Withdrawal by Subject|1
6242374|NCT01864005|9925297|FG000|Overall Study|Incorrect enrolment|1
6242375|NCT01864005|9925298|FG001|Overall Study|Incorrect enrolment|0
6242376|NCT01864005|9925297|FG000|Overall Study|Disease need|1
6242377|NCT01864005|9925298|FG001|Overall Study|Disease need|1
6242378|NCT01864005|9925297|FG000|Overall Study|Need GP IIb/IIIa|1
6242379|NCT01864005|9925298|FG001|Overall Study|Need GP IIb/IIIa|3
6242380|NCT01864148|9925309|FG000|Overall Study|Other|2
6242381|NCT01864148|9925310|FG001|Overall Study|Other|1
6242382|NCT01864148|9925311|FG002|Overall Study|Other|1
6242383|NCT01864148|9925312|FG003|Overall Study|Other|3
6242384|NCT01864148|9925313|FG004|Overall Study|Other|1
6242385|NCT01864148|9925309|FG000|Overall Study|Death|0
6242386|NCT01864148|9925310|FG001|Overall Study|Death|0
6242387|NCT01864148|9925311|FG002|Overall Study|Death|0
6085948|NCT00657709|9695617|FG002|Overall Study|AE or Death|6
6085949|NCT00657709|9695618|FG003|Overall Study|AE or Death|7
6085950|NCT00657709|9695619|FG004|Overall Study|AE or Death|1
6085951|NCT00657709|9695615|FG000|Overall Study|Withdrawal by Subject|7
6085952|NCT00657709|9695616|FG001|Overall Study|Withdrawal by Subject|15
6085953|NCT00657709|9695617|FG002|Overall Study|Withdrawal by Subject|15
6085954|NCT00657709|9695618|FG003|Overall Study|Withdrawal by Subject|5
6189088|NCT01396421|9844139|FG003|Overall Study|Protocol Deviation|0
6189089|NCT01396421|9844136|FG000|Overall Study|Lack of Efficacy|7
6189090|NCT01396421|9844137|FG001|Overall Study|Lack of Efficacy|17
6189091|NCT01396421|9844138|FG002|Overall Study|Lack of Efficacy|7
6189092|NCT01396421|9844139|FG003|Overall Study|Lack of Efficacy|18
6189093|NCT01396434|9844166|FG000|Overall Study|Lost to Follow-up|1
6189094|NCT01396434|9844167|FG001|Overall Study|Lost to Follow-up|0
6189095|NCT01396434|9844168|FG002|Overall Study|Lost to Follow-up|0
6189096|NCT01396434|9844166|FG000|Overall Study|Other|10
6189097|NCT01396434|9844167|FG001|Overall Study|Other|0
6189098|NCT01396434|9844168|FG002|Overall Study|Other|0
6189099|NCT01396447|9844180|FG000|Overall Study|Did Not Receive Treatment|3
6189100|NCT01396447|9844181|FG001|Overall Study|Did Not Receive Treatment|2
6189101|NCT01396447|9844182|FG002|Overall Study|Did Not Receive Treatment|1
6189102|NCT01396447|9844183|FG003|Overall Study|Did Not Receive Treatment|0
6189103|NCT01396447|9844180|FG000|Overall Study|Adverse Event|15
6189104|NCT01396447|9844181|FG001|Overall Study|Adverse Event|12
6189105|NCT01396447|9844182|FG002|Overall Study|Adverse Event|12
6189106|NCT01396447|9844183|FG003|Overall Study|Adverse Event|17
6189107|NCT01396447|9844180|FG000|Overall Study|Insufficient Therapeutic Response|5
6189108|NCT01396447|9844181|FG001|Overall Study|Insufficient Therapeutic Response|5
6189109|NCT01396447|9844182|FG002|Overall Study|Insufficient Therapeutic Response|2
6189110|NCT01396447|9844183|FG003|Overall Study|Insufficient Therapeutic Response|4
6189111|NCT01396447|9844180|FG000|Overall Study|Protocol Violation|5
6189112|NCT01396447|9844181|FG001|Overall Study|Protocol Violation|2
6189113|NCT01396447|9844182|FG002|Overall Study|Protocol Violation|3
6189114|NCT01396447|9844183|FG003|Overall Study|Protocol Violation|7
6189115|NCT01396447|9844180|FG000|Overall Study|Withdrawal of Consent|11
6189116|NCT01396447|9844181|FG001|Overall Study|Withdrawal of Consent|9
6189117|NCT01396447|9844182|FG002|Overall Study|Withdrawal of Consent|4
6189118|NCT01396447|9844183|FG003|Overall Study|Withdrawal of Consent|15
6189119|NCT01396447|9844180|FG000|Overall Study|Lost to Follow-up|4
6189120|NCT01396447|9844181|FG001|Overall Study|Lost to Follow-up|8
6189121|NCT01396447|9844182|FG002|Overall Study|Lost to Follow-up|7
6189122|NCT01396447|9844183|FG003|Overall Study|Lost to Follow-up|9
6189123|NCT01396447|9844180|FG000|Overall Study|Other Miscellaneous Reasons|0
6189124|NCT01396447|9844181|FG001|Overall Study|Other Miscellaneous Reasons|2
6189125|NCT01396447|9844182|FG002|Overall Study|Other Miscellaneous Reasons|1
6189126|NCT01396447|9844183|FG003|Overall Study|Other Miscellaneous Reasons|0
6189127|NCT01396512|9844208|FG000|Overall Study|Withdrawal by Subject|0
6189128|NCT01396512|9844209|FG001|Overall Study|Withdrawal by Subject|1
6189129|NCT01396525|9844215|FG000|Overall Study|Withdrawal by Subject|8
6189130|NCT01396525|9844215|FG000|Overall Study|Death|14
6189131|NCT01396525|9844215|FG000|Overall Study|Lost to Follow-up|4
6189132|NCT01397084|9844239|FG000|Overall Study|Severe Non-Compliance to Protocol|1
6189133|NCT01397084|9844239|FG000|Overall Study|Protocol Violation|2
6189134|NCT01397084|9844239|FG000|Overall Study|Adverse Event|2
6189135|NCT01397084|9844239|FG000|Overall Study|Withdrawal by Subject|1
6189136|NCT01397084|9844239|FG000|Overall Study|Lost to Follow-up|1
6189137|NCT01397084|9844239|FG000|Overall Study|Used other proton pump inhibitor|1
6189138|NCT01397253|9844245|FG000|Overall Study|Reviewed by only 1 pharmacist|126
6189139|NCT01397253|9844246|FG001|Overall Study|Reviewed by only 1 pharmacist|149
6189140|NCT01397409|9844262|FG000|Stage 2|Adverse Event|0
6189141|NCT01397409|9844263|FG001|Stage 2|Adverse Event|0
6189142|NCT01397409|9844264|FG002|Stage 2|Adverse Event|0
6189143|NCT01397409|9844265|FG003|Stage 2|Adverse Event|0
6189144|NCT01397409|9844266|FG004|Stage 2|Adverse Event|6
6189145|NCT01397409|9844267|FG005|Stage 2|Adverse Event|3
6189146|NCT01397409|9844268|FG006|Stage 2|Adverse Event|0
6189147|NCT01397409|9844269|FG007|Stage 2|Adverse Event|0
6189148|NCT01397409|9844270|FG008|Stage 2|Adverse Event|0
6189149|NCT01397409|9844271|FG009|Stage 2|Adverse Event|0
6189150|NCT01397409|9844262|FG000|Stage 2|Personal Reasons|0
6189151|NCT01397409|9844263|FG001|Stage 2|Personal Reasons|0
6189152|NCT01397409|9844264|FG002|Stage 2|Personal Reasons|0
6189153|NCT01397409|9844265|FG003|Stage 2|Personal Reasons|0
6189154|NCT01397409|9844266|FG004|Stage 2|Personal Reasons|1
6189155|NCT01397409|9844267|FG005|Stage 2|Personal Reasons|0
6189156|NCT01397409|9844268|FG006|Stage 2|Personal Reasons|0
6085955|NCT00657709|9695619|FG004|Overall Study|Withdrawal by Subject|9
6189157|NCT01397409|9844269|FG007|Stage 2|Personal Reasons|0
6189158|NCT01397409|9844270|FG008|Stage 2|Personal Reasons|0
6189159|NCT01397409|9844271|FG009|Stage 2|Personal Reasons|0
6189160|NCT01397409|9844262|FG000|Stage 2|Other Miscellaneous Reasons|0
6189161|NCT01397409|9844263|FG001|Stage 2|Other Miscellaneous Reasons|0
6189162|NCT01397409|9844264|FG002|Stage 2|Other Miscellaneous Reasons|0
6189163|NCT01397409|9844265|FG003|Stage 2|Other Miscellaneous Reasons|0
6242388|NCT01864148|9925312|FG003|Overall Study|Death|1
6242389|NCT01864148|9925313|FG004|Overall Study|Death|0
6242390|NCT01864148|9925309|FG000|Overall Study|Investigator Decision|5
6242391|NCT01864148|9925310|FG001|Overall Study|Investigator Decision|0
6242392|NCT01864148|9925311|FG002|Overall Study|Investigator Decision|0
6242393|NCT01864148|9925312|FG003|Overall Study|Investigator Decision|4
6242394|NCT01864148|9925313|FG004|Overall Study|Investigator Decision|6
6242395|NCT01864148|9925309|FG000|Overall Study|Withdrawal by Subject|9
6242396|NCT01864148|9925310|FG001|Overall Study|Withdrawal by Subject|2
6242397|NCT01864148|9925311|FG002|Overall Study|Withdrawal by Subject|6
6242398|NCT01864148|9925312|FG003|Overall Study|Withdrawal by Subject|8
6242399|NCT01864148|9925313|FG004|Overall Study|Withdrawal by Subject|8
6242400|NCT01864148|9925309|FG000|Overall Study|Lost to Follow-up|0
6242401|NCT01864148|9925310|FG001|Overall Study|Lost to Follow-up|0
6242402|NCT01864148|9925311|FG002|Overall Study|Lost to Follow-up|0
6242403|NCT01864148|9925312|FG003|Overall Study|Lost to Follow-up|2
6242404|NCT01864148|9925313|FG004|Overall Study|Lost to Follow-up|1
6242405|NCT01864148|9925309|FG000|Overall Study|Adverse Event|4
6242406|NCT01864148|9925310|FG001|Overall Study|Adverse Event|2
6242407|NCT01864148|9925311|FG002|Overall Study|Adverse Event|4
6242408|NCT01864148|9925312|FG003|Overall Study|Adverse Event|7
6242409|NCT01864148|9925313|FG004|Overall Study|Adverse Event|7
6242410|NCT01864148|9925309|FG000|Overall Study|Not Dosed|0
6242411|NCT01864148|9925310|FG001|Overall Study|Not Dosed|0
6242412|NCT01864148|9925311|FG002|Overall Study|Not Dosed|0
6242413|NCT01864148|9925312|FG003|Overall Study|Not Dosed|1
6242414|NCT01864148|9925313|FG004|Overall Study|Not Dosed|0
6242415|NCT01864174|9925332|FG000|Double Blind Treatment - All Treated|Removed due to site non-compliance|15
6242416|NCT01864174|9925333|FG001|Double Blind Treatment - All Treated|Removed due to site non-compliance|14
6242417|NCT01864174|9925332|FG000|Double Blind - Compliant Randomized|Adverse Event|6
6242418|NCT01864174|9925333|FG001|Double Blind - Compliant Randomized|Adverse Event|1
6242419|NCT01864174|9925332|FG000|Double Blind - Compliant Randomized|Subject Request to Discontinue Treatment|2
6242420|NCT01864174|9925333|FG001|Double Blind - Compliant Randomized|Subject Request to Discontinue Treatment|0
6242421|NCT01864174|9925332|FG000|Double Blind - Compliant Randomized|Subject Withdrew Consent|4
6242422|NCT01864174|9925333|FG001|Double Blind - Compliant Randomized|Subject Withdrew Consent|5
6242423|NCT01864174|9925332|FG000|Double Blind - Compliant Randomized|Death|1
6242424|NCT01864174|9925333|FG001|Double Blind - Compliant Randomized|Death|0
6242425|NCT01864174|9925332|FG000|Double Blind - Compliant Randomized|Lost to Follow-up|3
6242426|NCT01864174|9925333|FG001|Double Blind - Compliant Randomized|Lost to Follow-up|10
6242427|NCT01864174|9925332|FG000|Double Blind - Compliant Randomized|Poor/Non-compliance|1
6242428|NCT01864174|9925333|FG001|Double Blind - Compliant Randomized|Poor/Non-compliance|0
6242429|NCT01864174|9925332|FG000|Double Blind - Compliant Randomized|Other|6
6242430|NCT01864174|9925333|FG001|Double Blind - Compliant Randomized|Other|10
6242431|NCT01864174|9925332|FG000|Off Treatment Follow-Up|Other|2
6242432|NCT01864174|9925333|FG001|Off Treatment Follow-Up|Other|0
6242433|NCT01864174|9925332|FG000|Off Treatment Follow-Up|Subject Withdrew Consent|1
6242434|NCT01864174|9925333|FG001|Off Treatment Follow-Up|Subject Withdrew Consent|0
6242435|NCT01864200|9925341|FG000|Overall Study|Lost to Follow-up|1
6242436|NCT01864200|9925342|FG001|Overall Study|Lost to Follow-up|3
6242437|NCT01864200|9925341|FG000|Overall Study|Protocol Violation|1
6242438|NCT01864200|9925342|FG001|Overall Study|Protocol Violation|0
6242439|NCT01864291|9925348|FG000|Overall Study|need for revision surgery|2
6242440|NCT01864525|9925363|FG000|Overall Study|Adverse Event|1
6242441|NCT01864525|9925364|FG001|Overall Study|Adverse Event|0
6242442|NCT01864564|9925376|FG000|Overall Study|Lost to Follow-up|17
6242443|NCT01864564|9925377|FG001|Overall Study|Lost to Follow-up|23
6242444|NCT01864564|9925376|FG000|Overall Study|Withdrawal by Subject|20
6242445|NCT01864564|9925377|FG001|Overall Study|Withdrawal by Subject|11
6242446|NCT01864564|9925376|FG000|Overall Study|Protocol Violation|0
6242447|NCT01864564|9925377|FG001|Overall Study|Protocol Violation|27
6242448|NCT01864564|9925376|FG000|Overall Study|not reported|0
6242449|NCT01864564|9925377|FG001|Overall Study|not reported|34
6242450|NCT01865084|9925386|FG000|Double Blind Period (DB)|Adverse Event|2
6242451|NCT01865084|9925387|FG001|Double Blind Period (DB)|Adverse Event|2
6242452|NCT01865084|9925388|FG002|Double Blind Period (DB)|Adverse Event|1
6242453|NCT01865084|9925386|FG000|Double Blind Period (DB)|Protocol Violation|0
6242454|NCT01865084|9925387|FG001|Double Blind Period (DB)|Protocol Violation|0
6242455|NCT01865084|9925388|FG002|Double Blind Period (DB)|Protocol Violation|1
6242456|NCT01865084|9925386|FG000|Double Blind Period (DB)|Withdrawal by Parent/Guardian|2
6242457|NCT01865084|9925387|FG001|Double Blind Period (DB)|Withdrawal by Parent/Guardian|2
6242458|NCT01865084|9925388|FG002|Double Blind Period (DB)|Withdrawal by Parent/Guardian|4
6242459|NCT01865084|9925386|FG000|Double Blind Period (DB)|Withdrawal by Subject|1
6242460|NCT01865084|9925387|FG001|Double Blind Period (DB)|Withdrawal by Subject|0
6242461|NCT01865084|9925388|FG002|Double Blind Period (DB)|Withdrawal by Subject|0
6242462|NCT01865084|9925386|FG000|Open Label Extension (OLE) Period|Adverse Event|0
6242463|NCT01865084|9925387|FG001|Open Label Extension (OLE) Period|Adverse Event|0
6242464|NCT01865084|9925388|FG002|Open Label Extension (OLE) Period|Adverse Event|1
6242465|NCT01865084|9925386|FG000|Open Label Extension (OLE) Period|Lack of Efficacy|0
6242466|NCT01865084|9925387|FG001|Open Label Extension (OLE) Period|Lack of Efficacy|0
6271872|NCT02168777|9973908|FG001|Overall Study|Other reason|1
6242467|NCT01865084|9925388|FG002|Open Label Extension (OLE) Period|Lack of Efficacy|2
6189164|NCT01397409|9844266|FG004|Stage 2|Other Miscellaneous Reasons|1
6189165|NCT01397409|9844267|FG005|Stage 2|Other Miscellaneous Reasons|1
6189166|NCT01397409|9844268|FG006|Stage 2|Other Miscellaneous Reasons|0
6189167|NCT01397409|9844269|FG007|Stage 2|Other Miscellaneous Reasons|0
6189168|NCT01397409|9844270|FG008|Stage 2|Other Miscellaneous Reasons|0
6189169|NCT01397409|9844271|FG009|Stage 2|Other Miscellaneous Reasons|0
6189170|NCT01397409|9844262|FG000|Stage 3|Adverse Event|0
6189171|NCT01397409|9844263|FG001|Stage 3|Adverse Event|0
6189172|NCT01397409|9844264|FG002|Stage 3|Adverse Event|0
6242468|NCT01865084|9925386|FG000|Open Label Extension (OLE) Period|Lost to Follow-up|0
6242469|NCT01865084|9925387|FG001|Open Label Extension (OLE) Period|Lost to Follow-up|1
6242470|NCT01865084|9925388|FG002|Open Label Extension (OLE) Period|Lost to Follow-up|0
6242471|NCT01865084|9925386|FG000|Open Label Extension (OLE) Period|Withdrawal by Parent/Guardian|0
6242472|NCT01865084|9925387|FG001|Open Label Extension (OLE) Period|Withdrawal by Parent/Guardian|8
6242473|NCT01865084|9925388|FG002|Open Label Extension (OLE) Period|Withdrawal by Parent/Guardian|2
6242474|NCT01865084|9925386|FG000|Open Label Extension (OLE) Period|Withdrawal by Subject|0
6242475|NCT01865084|9925387|FG001|Open Label Extension (OLE) Period|Withdrawal by Subject|2
6242476|NCT01865084|9925388|FG002|Open Label Extension (OLE) Period|Withdrawal by Subject|2
6242477|NCT01865448|9925402|FG000|Overall Study|Adverse Event|1
6242478|NCT01865448|9925403|FG001|Overall Study|Adverse Event|1
6242479|NCT01865448|9925402|FG000|Overall Study|Pregnancy|0
6242480|NCT01865448|9925403|FG001|Overall Study|Pregnancy|1
6242481|NCT01865448|9925402|FG000|Overall Study|dropout unrelated to study|1
6242482|NCT01865448|9925403|FG001|Overall Study|dropout unrelated to study|1
6242483|NCT01865487|9925416|FG000|Overall Study|Lost to Follow-up|0
6242484|NCT01865487|9925417|FG001|Overall Study|Lost to Follow-up|0
6242485|NCT01865487|9925418|FG002|Overall Study|Lost to Follow-up|0
6242486|NCT01865487|9925419|FG003|Overall Study|Lost to Follow-up|1
6242487|NCT01865487|9925420|FG004|Overall Study|Lost to Follow-up|0
6242488|NCT01865487|9925421|FG005|Overall Study|Lost to Follow-up|0
6242489|NCT01865487|9925422|FG006|Overall Study|Lost to Follow-up|1
6242490|NCT01865487|9925423|FG007|Overall Study|Lost to Follow-up|0
6242491|NCT01865487|9925424|FG008|Overall Study|Lost to Follow-up|0
6242492|NCT01865487|9925425|FG009|Overall Study|Lost to Follow-up|0
6242493|NCT01865487|9925416|FG000|Overall Study|Withdrawal by Subject|0
6242494|NCT01865487|9925417|FG001|Overall Study|Withdrawal by Subject|0
6242495|NCT01865487|9925418|FG002|Overall Study|Withdrawal by Subject|0
6242496|NCT01865487|9925419|FG003|Overall Study|Withdrawal by Subject|0
6242497|NCT01865487|9925420|FG004|Overall Study|Withdrawal by Subject|1
6242498|NCT01865487|9925421|FG005|Overall Study|Withdrawal by Subject|0
6242499|NCT01865487|9925422|FG006|Overall Study|Withdrawal by Subject|0
6242500|NCT01865487|9925423|FG007|Overall Study|Withdrawal by Subject|0
6242501|NCT01865487|9925424|FG008|Overall Study|Withdrawal by Subject|0
6242502|NCT01865487|9925425|FG009|Overall Study|Withdrawal by Subject|0
6242503|NCT01865552|9925459|FG000|Period 1|Adverse Event|1
6242504|NCT01865552|9925460|FG001|Period 1|Adverse Event|0
6242505|NCT01865552|9925461|FG002|Period 1|Adverse Event|0
6242506|NCT01865552|9925462|FG003|Period 1|Adverse Event|1
6242507|NCT01865552|9925463|FG004|Period 1|Adverse Event|1
6242508|NCT01865552|9925464|FG005|Period 1|Adverse Event|1
6242509|NCT01865552|9925459|FG000|Period 1|Pathological lab|0
6242510|NCT01865552|9925460|FG001|Period 1|Pathological lab|0
6242511|NCT01865552|9925461|FG002|Period 1|Pathological lab|0
6242512|NCT01865552|9925462|FG003|Period 1|Pathological lab|0
6242513|NCT01865552|9925463|FG004|Period 1|Pathological lab|1
6242514|NCT01865552|9925464|FG005|Period 1|Pathological lab|0
6242515|NCT01865552|9925459|FG000|Period 1|Other|0
6242516|NCT01865552|9925460|FG001|Period 1|Other|0
6242517|NCT01865552|9925461|FG002|Period 1|Other|0
6242518|NCT01865552|9925462|FG003|Period 1|Other|0
6242519|NCT01865552|9925463|FG004|Period 1|Other|1
6242520|NCT01865552|9925464|FG005|Period 1|Other|0
6242521|NCT01865747|9925484|FG000|Overall Study (ITT)|Adverse Event|32
6242522|NCT01865747|9925485|FG001|Overall Study (ITT)|Adverse Event|31
6242523|NCT01865747|9925484|FG000|Overall Study (ITT)|Clinical Deterioration|29
6242524|NCT01865747|9925485|FG001|Overall Study (ITT)|Clinical Deterioration|50
6242525|NCT01865747|9925484|FG000|Overall Study (ITT)|Lack of Efficacy|3
6242526|NCT01865747|9925485|FG001|Overall Study (ITT)|Lack of Efficacy|0
6242527|NCT01865747|9925484|FG000|Overall Study (ITT)|Protocol Violation|1
6242528|NCT01865747|9925485|FG001|Overall Study (ITT)|Protocol Violation|1
6242529|NCT01865747|9925484|FG000|Overall Study (ITT)|Physician Decision|5
6242530|NCT01865747|9925485|FG001|Overall Study (ITT)|Physician Decision|2
6242531|NCT01865747|9925484|FG000|Overall Study (ITT)|Withdrawal by Subject|6
6242532|NCT01865747|9925485|FG001|Overall Study (ITT)|Withdrawal by Subject|11
6242533|NCT01865747|9925484|FG000|Overall Study (ITT)|Sponsor Decision|0
6242534|NCT01865747|9925485|FG001|Overall Study (ITT)|Sponsor Decision|1
6242535|NCT01865747|9925484|FG000|Overall Study (ITT)|Progressive Disease|122
6242536|NCT01865747|9925485|FG001|Overall Study (ITT)|Progressive Disease|158
6242537|NCT01865747|9925484|FG000|Overall Study (ITT)|Reason Not Provided|0
6242538|NCT01865747|9925485|FG001|Overall Study (ITT)|Reason Not Provided|1
6242539|NCT01865747|9925484|FG000|Primary Intent to Treat (PITT)|Adverse Event|21
6189173|NCT01397409|9844265|FG003|Stage 3|Adverse Event|0
6189174|NCT01397409|9844266|FG004|Stage 3|Adverse Event|0
6189175|NCT01397409|9844267|FG005|Stage 3|Adverse Event|0
6085956|NCT00657709|9695615|FG000|Overall Study|Lost to Follow-up|9
6085957|NCT00657709|9695616|FG001|Overall Study|Lost to Follow-up|9
6085958|NCT00657709|9695617|FG002|Overall Study|Lost to Follow-up|7
6085959|NCT00657709|9695618|FG003|Overall Study|Lost to Follow-up|1
6085960|NCT00657709|9695619|FG004|Overall Study|Lost to Follow-up|21
6085961|NCT00657709|9695615|FG000|Overall Study|Protocol Violation|0
6085962|NCT00657709|9695616|FG001|Overall Study|Protocol Violation|2
6085963|NCT00657709|9695617|FG002|Overall Study|Protocol Violation|0
6085964|NCT00657709|9695618|FG003|Overall Study|Protocol Violation|1
6085965|NCT00657709|9695619|FG004|Overall Study|Protocol Violation|2
6085966|NCT00658021|9695648|FG000|28-Week Treatment Period|Adverse Event|3
6085967|NCT00658021|9695649|FG001|28-Week Treatment Period|Adverse Event|1
6085968|NCT00658021|9695650|FG002|28-Week Treatment Period|Adverse Event|0
6242540|NCT01865747|9925485|FG001|Primary Intent to Treat (PITT)|Adverse Event|20
6242541|NCT01865747|9925484|FG000|Primary Intent to Treat (PITT)|Clinical Deterioration|18
6242542|NCT01865747|9925485|FG001|Primary Intent to Treat (PITT)|Clinical Deterioration|29
6242543|NCT01865747|9925484|FG000|Primary Intent to Treat (PITT)|Lack of Efficacy|2
6085969|NCT00658021|9695648|FG000|28-Week Treatment Period|Developed study withdrawal criteria|0
6085970|NCT00658021|9695649|FG001|28-Week Treatment Period|Developed study withdrawal criteria|2
6242544|NCT01865747|9925485|FG001|Primary Intent to Treat (PITT)|Lack of Efficacy|0
6242545|NCT01865747|9925484|FG000|Primary Intent to Treat (PITT)|Protocol Violation|1
6242546|NCT01865747|9925485|FG001|Primary Intent to Treat (PITT)|Protocol Violation|1
6242547|NCT01865747|9925484|FG000|Primary Intent to Treat (PITT)|Physician Decision|4
6085971|NCT00658021|9695650|FG002|28-Week Treatment Period|Developed study withdrawal criteria|0
6085972|NCT00658021|9695648|FG000|28-Week Treatment Period|Protocol Violation|0
6085973|NCT00658021|9695649|FG001|28-Week Treatment Period|Protocol Violation|2
6242548|NCT01865747|9925485|FG001|Primary Intent to Treat (PITT)|Physician Decision|2
6242549|NCT01865747|9925484|FG000|Primary Intent to Treat (PITT)|Withdrawal by Subject|3
6242550|NCT01865747|9925485|FG001|Primary Intent to Treat (PITT)|Withdrawal by Subject|7
6242551|NCT01865747|9925484|FG000|Primary Intent to Treat (PITT)|Progressive Disease|82
6242552|NCT01865747|9925485|FG001|Primary Intent to Treat (PITT)|Progressive Disease|92
6242553|NCT01865747|9925484|FG000|Primary Intent to Treat (PITT)|Other|0
6242554|NCT01865747|9925485|FG001|Primary Intent to Treat (PITT)|Other|1
6242555|NCT01865812|9925491|FG000|Overall Study|Adverse Event|2
6242556|NCT01866098|9925498|FG000|Overall Study|Lost to Follow-up|11
6242557|NCT01866098|9925499|FG001|Overall Study|Lost to Follow-up|18
6242558|NCT01866098|9925500|FG002|Overall Study|Lost to Follow-up|13
6242559|NCT01866098|9925498|FG000|Overall Study|Physician Decision|0
6242560|NCT01866098|9925499|FG001|Overall Study|Physician Decision|1
6242561|NCT01866098|9925500|FG002|Overall Study|Physician Decision|2
6242562|NCT01866098|9925498|FG000|Overall Study|Adverse Event|1
6242563|NCT01866098|9925499|FG001|Overall Study|Adverse Event|5
6242564|NCT01866098|9925500|FG002|Overall Study|Adverse Event|4
6242565|NCT01866098|9925498|FG000|Overall Study|Protocol Violation|1
6242566|NCT01866098|9925499|FG001|Overall Study|Protocol Violation|0
6242567|NCT01866098|9925500|FG002|Overall Study|Protocol Violation|0
6242568|NCT01866098|9925498|FG000|Overall Study|Withdrawal by Subject|1
6242569|NCT01866098|9925499|FG001|Overall Study|Withdrawal by Subject|2
6242570|NCT01866098|9925500|FG002|Overall Study|Withdrawal by Subject|0
6242571|NCT01866098|9925498|FG000|Overall Study|Unrelated Hospitalization|2
6242572|NCT01866098|9925499|FG001|Overall Study|Unrelated Hospitalization|0
6242573|NCT01866098|9925500|FG002|Overall Study|Unrelated Hospitalization|1
6242574|NCT01866098|9925498|FG000|Overall Study|Non-compliance|1
6242575|NCT01866098|9925499|FG001|Overall Study|Non-compliance|0
6242576|NCT01866098|9925500|FG002|Overall Study|Non-compliance|1
6242577|NCT01866098|9925498|FG000|Overall Study|Pregnancy|2
6242578|NCT01866098|9925499|FG001|Overall Study|Pregnancy|0
6242579|NCT01866098|9925500|FG002|Overall Study|Pregnancy|0
6242580|NCT01866098|9925498|FG000|Overall Study|Death|0
6242581|NCT01866098|9925499|FG001|Overall Study|Death|1
6242582|NCT01866098|9925500|FG002|Overall Study|Death|0
6242583|NCT01866293|9925524|FG000|Overall Study|Adverse Event|2
6242584|NCT01866319|9925560|FG000|Overall Study|Adverse Event|12
6242585|NCT01866319|9925561|FG001|Overall Study|Adverse Event|5
6242586|NCT01866319|9925562|FG002|Overall Study|Adverse Event|9
6242587|NCT01866319|9925560|FG000|Overall Study|Clinical progression|3
6242588|NCT01866319|9925561|FG001|Overall Study|Clinical progression|2
6242589|NCT01866319|9925562|FG002|Overall Study|Clinical progression|2
6085974|NCT00658021|9695650|FG002|28-Week Treatment Period|Protocol Violation|1
6085975|NCT00658021|9695648|FG000|28-Week Treatment Period|Withdrawal by Subject|1
6242590|NCT01866319|9925560|FG000|Overall Study|Death|153
6242591|NCT01866319|9925561|FG001|Overall Study|Death|154
6242592|NCT01866319|9925562|FG002|Overall Study|Death|147
6242593|NCT01866319|9925560|FG000|Overall Study|Lost to Follow-up|6
6242594|NCT01866319|9925561|FG001|Overall Study|Lost to Follow-up|3
6242595|NCT01866319|9925562|FG002|Overall Study|Lost to Follow-up|8
6242596|NCT01866319|9925560|FG000|Overall Study|Physician Decision|1
6242597|NCT01866319|9925561|FG001|Overall Study|Physician Decision|0
6242598|NCT01866319|9925562|FG002|Overall Study|Physician Decision|1
6242599|NCT01866319|9925560|FG000|Overall Study|Protocol Violation|0
6242600|NCT01866319|9925561|FG001|Overall Study|Protocol Violation|0
6242601|NCT01866319|9925562|FG002|Overall Study|Protocol Violation|1
6085976|NCT00658021|9695649|FG001|28-Week Treatment Period|Withdrawal by Subject|1
6242602|NCT01866319|9925560|FG000|Overall Study|Withdrawal by Subject|32
6242603|NCT01866319|9925561|FG001|Overall Study|Withdrawal by Subject|14
6242604|NCT01866319|9925562|FG002|Overall Study|Withdrawal by Subject|12
6242605|NCT01866423|9925577|FG000|Overall Study|Lack of Efficacy|3
6242606|NCT01866423|9925577|FG000|Overall Study|Sponsor Decision|1
6242607|NCT01866826|9925585|FG000|Phase I -Initial Randomization - 4 Weeks|Post Enrollment Withdrawal|1
6242608|NCT01866826|9925586|FG001|Phase I -Initial Randomization - 4 Weeks|Post Enrollment Withdrawal|0
6242609|NCT01866826|9925585|FG000|Wash-Out Period - 4 -6 Weeks|Withdrawal by Subject|0
6242610|NCT01866826|9925586|FG001|Wash-Out Period - 4 -6 Weeks|Withdrawal by Subject|2
6242611|NCT01866826|9925585|FG000|Wash-Out Period - 4 -6 Weeks|Post Enrollment Withdrawal|0
6242612|NCT01866826|9925586|FG001|Wash-Out Period - 4 -6 Weeks|Post Enrollment Withdrawal|1
6242613|NCT01866917|9925598|FG000|Overall Study|Pharmacist stopped dispensing treatment|4
6242614|NCT01866917|9925599|FG001|Overall Study|Pharmacist stopped dispensing treatment|6
6242615|NCT01867008|9925617|FG000|Overall Study|Withdrawal by Subject|1
6242616|NCT01867021|9925623|FG000|Overall Study|Adverse Event|0
6242617|NCT01867021|9925624|FG001|Overall Study|Adverse Event|1
6242618|NCT01867021|9925623|FG000|Overall Study|Not Eligible|0
6242619|NCT01867021|9925624|FG001|Overall Study|Not Eligible|1
6242620|NCT01867021|9925623|FG000|Overall Study|Death|1
6242621|NCT01867021|9925624|FG001|Overall Study|Death|0
6242622|NCT01867021|9925623|FG000|Overall Study|Lost to Follow-up|0
6242623|NCT01867021|9925624|FG001|Overall Study|Lost to Follow-up|2
6242624|NCT01867021|9925623|FG000|Overall Study|Withdrawal by Subject|1
6242625|NCT01867021|9925624|FG001|Overall Study|Withdrawal by Subject|6
6242626|NCT01867047|9925637|FG000|Overall Study|Lost to Follow-up|3
6242627|NCT01867047|9925638|FG001|Overall Study|Lost to Follow-up|3
6242628|NCT01867047|9925637|FG000|Overall Study|Withdrawal by Subject|2
6242629|NCT01867047|9925638|FG001|Overall Study|Withdrawal by Subject|0
6242630|NCT01867047|9925637|FG000|Overall Study|Physician Decision|2
6242631|NCT01867047|9925638|FG001|Overall Study|Physician Decision|0
6242632|NCT01867047|9925637|FG000|Overall Study|surgery not indicated in protocol|1
6242633|NCT01867047|9925638|FG001|Overall Study|surgery not indicated in protocol|2
6242634|NCT01867086|9925648|FG000|Overall Study|Disease Progression|1
6242635|NCT01867216|9925668|FG000|Overall Study|Withdrawal by Subject|2
6242636|NCT01867216|9925669|FG001|Overall Study|Withdrawal by Subject|0
6242637|NCT01867216|9925670|FG002|Overall Study|Withdrawal by Subject|0
6242638|NCT01867216|9925671|FG003|Overall Study|Withdrawal by Subject|0
6242639|NCT01867216|9925672|FG004|Overall Study|Withdrawal by Subject|1
6242640|NCT01867216|9925673|FG005|Overall Study|Withdrawal by Subject|0
6242641|NCT01867216|9925674|FG006|Overall Study|Withdrawal by Subject|1
6242642|NCT01867216|9925668|FG000|Overall Study|Physician Decision|1
6242643|NCT01867216|9925669|FG001|Overall Study|Physician Decision|0
6242644|NCT01867216|9925670|FG002|Overall Study|Physician Decision|0
6242645|NCT01867216|9925671|FG003|Overall Study|Physician Decision|0
6242646|NCT01867216|9925672|FG004|Overall Study|Physician Decision|0
6242647|NCT01867216|9925673|FG005|Overall Study|Physician Decision|0
6242648|NCT01867216|9925674|FG006|Overall Study|Physician Decision|0
6242649|NCT01867216|9925668|FG000|Overall Study|Unable to Place Catheter for Blood Draws|1
6242650|NCT01867216|9925669|FG001|Overall Study|Unable to Place Catheter for Blood Draws|0
6242651|NCT01867216|9925670|FG002|Overall Study|Unable to Place Catheter for Blood Draws|0
6242652|NCT01867216|9925671|FG003|Overall Study|Unable to Place Catheter for Blood Draws|0
6242653|NCT01867216|9925672|FG004|Overall Study|Unable to Place Catheter for Blood Draws|0
6242654|NCT01867216|9925673|FG005|Overall Study|Unable to Place Catheter for Blood Draws|0
6242655|NCT01867216|9925674|FG006|Overall Study|Unable to Place Catheter for Blood Draws|0
6242656|NCT01867294|9925700|FG000|Overall Study|Withdrawal by Subject|1
6242657|NCT01867294|9925701|FG001|Overall Study|Withdrawal by Subject|1
6242658|NCT01867294|9925702|FG002|Overall Study|Withdrawal by Subject|0
6242659|NCT01867294|9925703|FG003|Overall Study|Withdrawal by Subject|0
6242660|NCT01867307|9925713|FG000|Overall Study|Protocol Violation|2
6242661|NCT01867307|9925714|FG001|Overall Study|Protocol Violation|0
6242662|NCT01867307|9925713|FG000|Overall Study|Other Adverse Event|1
6242663|NCT01867307|9925714|FG001|Overall Study|Other Adverse Event|3
6242664|NCT01867424|9925722|FG000|Overall Study|Patient noncompliance|2
6242665|NCT01867424|9925723|FG001|Overall Study|Patient noncompliance|1
6242666|NCT01867580|9925744|FG000|Overall Study|Withdrawal by Subject|2
6242667|NCT01867580|9925745|FG001|Overall Study|Withdrawal by Subject|3
6242668|NCT01867580|9925744|FG000|Overall Study|Physician Decision|17
6242669|NCT01867580|9925745|FG001|Overall Study|Physician Decision|12
6242670|NCT01867580|9925744|FG000|Overall Study|Lost to Follow-up|3
6242671|NCT01867580|9925745|FG001|Overall Study|Lost to Follow-up|5
6242672|NCT01867580|9925744|FG000|Overall Study|Sponsor terminated study|1
6242673|NCT01867580|9925745|FG001|Overall Study|Sponsor terminated study|0
6242674|NCT01867580|9925744|FG000|Overall Study|Missed follow-up assessment|2
6242675|NCT01867580|9925745|FG001|Overall Study|Missed follow-up assessment|1
6242676|NCT01867580|9925744|FG000|Overall Study|Interruption to therapy|3
6242677|NCT01867580|9925745|FG001|Overall Study|Interruption to therapy|0
6242678|NCT01867580|9925744|FG000|Overall Study|Osteomyelitis|0
6242679|NCT01867580|9925745|FG001|Overall Study|Osteomyelitis|1
6242680|NCT01867580|9925744|FG000|Overall Study|Continuation of therapy|0
6242681|NCT01867580|9925745|FG001|Overall Study|Continuation of therapy|1
6242682|NCT01867580|9925744|FG000|Overall Study|Wound recurrence|0
6242683|NCT01867580|9925745|FG001|Overall Study|Wound recurrence|1
6270352|NCT02151682|9971245|FG003|Part 1: 14 Days Morphine or Tapentadol|Technical problems|0
6270353|NCT02151682|9971246|FG004|Part 1: 14 Days Morphine or Tapentadol|Technical problems|0
6270354|NCT02151682|9971247|FG005|Part 1: 14 Days Morphine or Tapentadol|Technical problems|0
6270355|NCT02151682|9971242|FG000|Part 1: 14 Days Morphine or Tapentadol|No need for opioid|1
6270356|NCT02151682|9971243|FG001|Part 1: 14 Days Morphine or Tapentadol|No need for opioid|1
6270357|NCT02151682|9971244|FG002|Part 1: 14 Days Morphine or Tapentadol|No need for opioid|0
6270358|NCT02151682|9971245|FG003|Part 1: 14 Days Morphine or Tapentadol|No need for opioid|0
6270359|NCT02151682|9971246|FG004|Part 1: 14 Days Morphine or Tapentadol|No need for opioid|0
6270360|NCT02151682|9971247|FG005|Part 1: 14 Days Morphine or Tapentadol|No need for opioid|0
6270361|NCT02151682|9971242|FG000|Part 1: 14 Days Morphine or Tapentadol|Missing|1
6270362|NCT02151682|9971243|FG001|Part 1: 14 Days Morphine or Tapentadol|Missing|0
6270363|NCT02151682|9971244|FG002|Part 1: 14 Days Morphine or Tapentadol|Missing|0
6270364|NCT02151682|9971245|FG003|Part 1: 14 Days Morphine or Tapentadol|Missing|0
6270365|NCT02151682|9971246|FG004|Part 1: 14 Days Morphine or Tapentadol|Missing|0
6270366|NCT02151682|9971247|FG005|Part 1: 14 Days Morphine or Tapentadol|Missing|0
6270367|NCT02151682|9971242|FG000|Part 2: Tapent. Extension or Observation|Adverse Event|0
6270368|NCT02151682|9971243|FG001|Part 2: Tapent. Extension or Observation|Adverse Event|0
6270369|NCT02151682|9971244|FG002|Part 2: Tapent. Extension or Observation|Adverse Event|3
6270370|NCT02151682|9971245|FG003|Part 2: Tapent. Extension or Observation|Adverse Event|0
6270371|NCT02151682|9971246|FG004|Part 2: Tapent. Extension or Observation|Adverse Event|0
6270372|NCT02151682|9971247|FG005|Part 2: Tapent. Extension or Observation|Adverse Event|0
6270373|NCT02151682|9971242|FG000|Part 2: Tapent. Extension or Observation|Death|0
6270374|NCT02151682|9971243|FG001|Part 2: Tapent. Extension or Observation|Death|0
6270375|NCT02151682|9971244|FG002|Part 2: Tapent. Extension or Observation|Death|0
6270376|NCT02151682|9971245|FG003|Part 2: Tapent. Extension or Observation|Death|2
6270377|NCT02151682|9971246|FG004|Part 2: Tapent. Extension or Observation|Death|0
6270378|NCT02151682|9971247|FG005|Part 2: Tapent. Extension or Observation|Death|0
6270379|NCT02151682|9971242|FG000|Part 2: Tapent. Extension or Observation|Withdrawal by Subject|0
6270380|NCT02151682|9971243|FG001|Part 2: Tapent. Extension or Observation|Withdrawal by Subject|0
6270381|NCT02151682|9971244|FG002|Part 2: Tapent. Extension or Observation|Withdrawal by Subject|1
6270382|NCT02151682|9971245|FG003|Part 2: Tapent. Extension or Observation|Withdrawal by Subject|1
6270383|NCT02151682|9971246|FG004|Part 2: Tapent. Extension or Observation|Withdrawal by Subject|0
6270384|NCT02151682|9971247|FG005|Part 2: Tapent. Extension or Observation|Withdrawal by Subject|0
6270385|NCT02151682|9971242|FG000|Part 2: Tapent. Extension or Observation|Lack of Efficacy|0
6270386|NCT02151682|9971243|FG001|Part 2: Tapent. Extension or Observation|Lack of Efficacy|0
6270387|NCT02151682|9971244|FG002|Part 2: Tapent. Extension or Observation|Lack of Efficacy|3
6270388|NCT02151682|9971245|FG003|Part 2: Tapent. Extension or Observation|Lack of Efficacy|0
6270389|NCT02151682|9971246|FG004|Part 2: Tapent. Extension or Observation|Lack of Efficacy|0
6270390|NCT02151682|9971247|FG005|Part 2: Tapent. Extension or Observation|Lack of Efficacy|0
6270391|NCT02151682|9971242|FG000|Part 2: Tapent. Extension or Observation|Protocol Violation|0
6242684|NCT01867658|9925760|FG000|Overall Study|Withdrawal by Subject|6
6242685|NCT01867658|9925760|FG000|Overall Study|Death|2
6242686|NCT01867658|9925760|FG000|Overall Study|Subject could not be contacted|1
6242687|NCT01867671|9925766|FG000|Overall Study|Adverse Event|5
6242688|NCT01867671|9925767|FG001|Overall Study|Adverse Event|3
6242689|NCT01867671|9925766|FG000|Overall Study|Anaphylaxis|0
6242690|NCT01867671|9925767|FG001|Overall Study|Anaphylaxis|1
6242691|NCT01867671|9925766|FG000|Overall Study|Inability to reach 3 mg peanut/placebo|2
6242692|NCT01867671|9925767|FG001|Overall Study|Inability to reach 3 mg peanut/placebo|0
6242693|NCT01867671|9925766|FG000|Overall Study|Lost to Follow-up|0
6242694|NCT01867671|9925767|FG001|Overall Study|Lost to Follow-up|1
6242695|NCT01867671|9925766|FG000|Overall Study|Non-compliance with Study Drug|1
6242696|NCT01867671|9925767|FG001|Overall Study|Non-compliance with Study Drug|2
6242697|NCT01867671|9925766|FG000|Overall Study|Withdrawal by Subject|21
6242698|NCT01867671|9925767|FG001|Overall Study|Withdrawal by Subject|21
6242699|NCT01867710|9925777|FG000|Overall Study|Death|25
6085977|NCT00658021|9695650|FG002|28-Week Treatment Period|Withdrawal by Subject|3
6085978|NCT00658021|9695648|FG000|28-Week Treatment Period|Physician Decision|1
6085979|NCT00658021|9695649|FG001|28-Week Treatment Period|Physician Decision|2
6085980|NCT00658021|9695650|FG002|28-Week Treatment Period|Physician Decision|1
6242700|NCT01867710|9925778|FG001|Overall Study|Death|15
6242701|NCT01867710|9925779|FG002|Overall Study|Death|27
6242702|NCT01867710|9925780|FG003|Overall Study|Death|20
6242703|NCT01867710|9925777|FG000|Overall Study|Lost to Follow-up|3
6242704|NCT01867710|9925778|FG001|Overall Study|Lost to Follow-up|4
6242705|NCT01867710|9925779|FG002|Overall Study|Lost to Follow-up|3
6242706|NCT01867710|9925780|FG003|Overall Study|Lost to Follow-up|2
6242707|NCT01867710|9925777|FG000|Overall Study|Withdrawal of consent|2
6242708|NCT01867710|9925778|FG001|Overall Study|Withdrawal of consent|5
6242709|NCT01867710|9925779|FG002|Overall Study|Withdrawal of consent|1
6242710|NCT01867710|9925780|FG003|Overall Study|Withdrawal of consent|2
6242711|NCT01867710|9925777|FG000|Overall Study|Study Terminated by Sponsor|9
6242712|NCT01867710|9925778|FG001|Overall Study|Study Terminated by Sponsor|13
6242713|NCT01867710|9925779|FG002|Overall Study|Study Terminated by Sponsor|8
6242714|NCT01867710|9925780|FG003|Overall Study|Study Terminated by Sponsor|16
6242715|NCT01867710|9925777|FG000|Overall Study|Biochemical progression|0
6242716|NCT01867710|9925778|FG001|Overall Study|Biochemical progression|1
6242717|NCT01867710|9925779|FG002|Overall Study|Biochemical progression|0
6242718|NCT01867710|9925780|FG003|Overall Study|Biochemical progression|0
6242719|NCT01867710|9925777|FG000|Overall Study|Clinical progression|0
6242720|NCT01867710|9925778|FG001|Overall Study|Clinical progression|0
6242721|NCT01867710|9925779|FG002|Overall Study|Clinical progression|1
6242722|NCT01867710|9925780|FG003|Overall Study|Clinical progression|0
6242723|NCT01867710|9925777|FG000|Overall Study|Disease progression|1
6242724|NCT01867710|9925778|FG001|Overall Study|Disease progression|0
6242725|NCT01867710|9925779|FG002|Overall Study|Disease progression|0
6242726|NCT01867710|9925780|FG003|Overall Study|Disease progression|0
6242727|NCT01867710|9925777|FG000|Overall Study|Patient decision|0
6242728|NCT01867710|9925778|FG001|Overall Study|Patient decision|0
6242729|NCT01867710|9925779|FG002|Overall Study|Patient decision|0
6242730|NCT01867710|9925780|FG003|Overall Study|Patient decision|1
6242731|NCT01867710|9925777|FG000|Overall Study|Patient to follow subsequent treatment|0
6242732|NCT01867710|9925778|FG001|Overall Study|Patient to follow subsequent treatment|1
6242733|NCT01867710|9925779|FG002|Overall Study|Patient to follow subsequent treatment|0
6242734|NCT01867710|9925780|FG003|Overall Study|Patient to follow subsequent treatment|0
6242735|NCT01867710|9925777|FG000|Overall Study|Progressive disease|1
6242736|NCT01867710|9925778|FG001|Overall Study|Progressive disease|0
6242737|NCT01867710|9925779|FG002|Overall Study|Progressive disease|0
6242738|NCT01867710|9925780|FG003|Overall Study|Progressive disease|0
6242739|NCT01867710|9925777|FG000|Overall Study|Protocol Violation|0
6242740|NCT01867710|9925778|FG001|Overall Study|Protocol Violation|0
6242741|NCT01867710|9925779|FG002|Overall Study|Protocol Violation|0
6242742|NCT01867710|9925780|FG003|Overall Study|Protocol Violation|1
6242743|NCT01867710|9925777|FG000|Overall Study|PSA-progression|0
6242744|NCT01867710|9925778|FG001|Overall Study|PSA-progression|1
6242745|NCT01867710|9925779|FG002|Overall Study|PSA-progression|0
6242746|NCT01867710|9925780|FG003|Overall Study|PSA-progression|0
6242747|NCT01867710|9925777|FG000|Overall Study|Study medication no longer effective|0
6242748|NCT01867710|9925778|FG001|Overall Study|Study medication no longer effective|1
6242749|NCT01867710|9925779|FG002|Overall Study|Study medication no longer effective|0
6242750|NCT01867710|9925780|FG003|Overall Study|Study medication no longer effective|0
6242751|NCT01868009|9925790|FG000|Period 1 (5-9 Days)|Adverse Event|0
6242752|NCT01868009|9925791|FG001|Period 1 (5-9 Days)|Adverse Event|2
6242753|NCT01868009|9925790|FG000|Period 2 (5-9 Days)|Adverse Event|1
6242754|NCT01868009|9925791|FG001|Period 2 (5-9 Days)|Adverse Event|0
6085981|NCT00658021|9695648|FG000|28-Week Treatment Period|Withdrawal by parent/guardian|1
6242755|NCT01868009|9925790|FG000|Period 2 (5-9 Days)|Protocol-defined Stopping Criteria|1
6242756|NCT01868009|9925791|FG001|Period 2 (5-9 Days)|Protocol-defined Stopping Criteria|0
6242757|NCT01868022|9925806|FG000|Overall Study|Withdrawal by Subject|0
6242758|NCT01868022|9925807|FG001|Overall Study|Withdrawal by Subject|0
6242759|NCT01868022|9925808|FG002|Overall Study|Withdrawal by Subject|1
6242760|NCT01868022|9925809|FG003|Overall Study|Withdrawal by Subject|1
6242761|NCT01868022|9925810|FG004|Overall Study|Withdrawal by Subject|0
6242762|NCT01868022|9925811|FG005|Overall Study|Withdrawal by Subject|0
6242763|NCT01868022|9925812|FG006|Overall Study|Withdrawal by Subject|0
6242764|NCT01868022|9925813|FG007|Overall Study|Withdrawal by Subject|1
6242765|NCT01868022|9925814|FG008|Overall Study|Withdrawal by Subject|0
6242766|NCT01868022|9925806|FG000|Overall Study|Adverse Event|0
6242767|NCT01868022|9925807|FG001|Overall Study|Adverse Event|0
6242768|NCT01868022|9925808|FG002|Overall Study|Adverse Event|0
6242769|NCT01868022|9925809|FG003|Overall Study|Adverse Event|0
6242770|NCT01868022|9925810|FG004|Overall Study|Adverse Event|2
6242771|NCT01868022|9925811|FG005|Overall Study|Adverse Event|0
6242772|NCT01868022|9925812|FG006|Overall Study|Adverse Event|0
6242773|NCT01868022|9925813|FG007|Overall Study|Adverse Event|2
6242774|NCT01868022|9925814|FG008|Overall Study|Adverse Event|2
6242775|NCT01868022|9925806|FG000|Overall Study|Physician Decision|0
6242776|NCT01868022|9925807|FG001|Overall Study|Physician Decision|0
6242777|NCT01868022|9925808|FG002|Overall Study|Physician Decision|0
6242778|NCT01868022|9925809|FG003|Overall Study|Physician Decision|0
6242779|NCT01868022|9925810|FG004|Overall Study|Physician Decision|0
6242780|NCT01868022|9925811|FG005|Overall Study|Physician Decision|1
6242781|NCT01868022|9925812|FG006|Overall Study|Physician Decision|0
6242782|NCT01868022|9925813|FG007|Overall Study|Physician Decision|2
6242783|NCT01868022|9925814|FG008|Overall Study|Physician Decision|0
6242784|NCT01868022|9925806|FG000|Overall Study|Study closed/terminated|0
6242785|NCT01868022|9925807|FG001|Overall Study|Study closed/terminated|0
6242786|NCT01868022|9925808|FG002|Overall Study|Study closed/terminated|0
6242787|NCT01868022|9925809|FG003|Overall Study|Study closed/terminated|0
6242788|NCT01868022|9925810|FG004|Overall Study|Study closed/terminated|0
6242789|NCT01868022|9925811|FG005|Overall Study|Study closed/terminated|0
6242790|NCT01868022|9925812|FG006|Overall Study|Study closed/terminated|0
6242791|NCT01868022|9925813|FG007|Overall Study|Study closed/terminated|1
6242792|NCT01868022|9925814|FG008|Overall Study|Study closed/terminated|0
6242793|NCT01868022|9925806|FG000|Overall Study|Ongoing|0
6242794|NCT01868022|9925807|FG001|Overall Study|Ongoing|0
6242795|NCT01868022|9925808|FG002|Overall Study|Ongoing|0
6242796|NCT01868022|9925809|FG003|Overall Study|Ongoing|0
6242797|NCT01868022|9925810|FG004|Overall Study|Ongoing|0
6242798|NCT01868022|9925811|FG005|Overall Study|Ongoing|0
6242799|NCT01868022|9925812|FG006|Overall Study|Ongoing|0
6242800|NCT01868022|9925813|FG007|Overall Study|Ongoing|3
6242801|NCT01868022|9925814|FG008|Overall Study|Ongoing|0
6242802|NCT01868035|9925840|FG000|Overall Study|Lost to Follow-up|3
6242803|NCT01868035|9925840|FG000|Overall Study|Withdrawal by Subject|1
6242804|NCT01868035|9925840|FG000|Overall Study|Progressive Disease|2
6242805|NCT01868035|9925840|FG000|Overall Study|Non-compliance|1
6242806|NCT01868074|9925846|FG000|Overall Study|Lost to Follow-up|3
6242807|NCT01868074|9925847|FG001|Overall Study|Lost to Follow-up|2
6242808|NCT01868074|9925846|FG000|Overall Study|Withdrawal by Subject|4
6242809|NCT01868074|9925847|FG001|Overall Study|Withdrawal by Subject|2
6242810|NCT01868165|9925853|FG000|Overall Study|Withdrawal by Subject|36
6242811|NCT01868165|9925853|FG000|Overall Study|Physician Decision|2
6242812|NCT01868165|9925853|FG000|Overall Study|Lost to Follow-up|3
6242813|NCT01868165|9925853|FG000|Overall Study|Death|4
6242814|NCT01868243|9925859|FG000|Overall Study|Death|0
6242815|NCT01868243|9925860|FG001|Overall Study|Death|1
6242816|NCT01868477|9925922|FG000|Overall Study|Adverse Event|2
6242817|NCT01868477|9925923|FG001|Overall Study|Adverse Event|4
6242818|NCT01868477|9925922|FG000|Overall Study|Disease progression|1
6242819|NCT01868477|9925923|FG001|Overall Study|Disease progression|1
6242820|NCT01868477|9925922|FG000|Overall Study|Withdrawal by Subject|1
6242821|NCT01868477|9925923|FG001|Overall Study|Withdrawal by Subject|0
6242822|NCT01868503|9925936|FG000|Overall Study|Withdrawal by Subject|1
6242823|NCT01868503|9925936|FG000|Overall Study|Protocol Violation|1
6242824|NCT01868542|9925944|FG000|Overall Study|Protocol Violation|0
6242825|NCT01868542|9925945|FG001|Overall Study|Protocol Violation|1
6242826|NCT01868542|9925944|FG000|Overall Study|Unclassified|0
6242827|NCT01868542|9925945|FG001|Overall Study|Unclassified|1
6242828|NCT01868594|9925953|FG000|Overall Study|Do not meet inclusion criteria|4
6242829|NCT01868594|9925954|FG001|Overall Study|Do not meet inclusion criteria|3
6242830|NCT01868646|9925973|FG000|Overall Study|Do not meet inclusion criteria|3
6242831|NCT01868646|9925974|FG001|Overall Study|Do not meet inclusion criteria|5
6242832|NCT01868893|9925998|FG000|Overall Study|Adverse Event|2
6242833|NCT01868893|9925998|FG000|Overall Study|Commercial availability of study drug|17
6242834|NCT01868893|9925998|FG000|Overall Study|Neutropenia|1
6242835|NCT01868997|9926006|FG000|Overall Study|Adverse Event|2
6242836|NCT01868997|9926007|FG001|Overall Study|Adverse Event|5
6242837|NCT01868997|9926006|FG000|Overall Study|Lack of Efficacy|2
6242838|NCT01868997|9926007|FG001|Overall Study|Lack of Efficacy|0
6242839|NCT01868997|9926006|FG000|Overall Study|Other|3
6242840|NCT01868997|9926007|FG001|Overall Study|Other|1
6242841|NCT01869192|9926040|FG000|Preoperative Chemotherapy to Surgery|patient choice|2
6242842|NCT01869192|9926041|FG001|Preoperative Chemotherapy to Surgery|patient choice|1
6242843|NCT01869192|9926040|FG000|Postoperative Chemotherapy|Physician Decision|0
6242844|NCT01869192|9926041|FG001|Postoperative Chemotherapy|Physician Decision|2
6242845|NCT01869348|9926049|FG000|Overall Study|Withdrawal by Subject|1
6242846|NCT01869348|9926050|FG001|Overall Study|Withdrawal by Subject|1
6242847|NCT01869699|9926097|FG000|Overall Study|Withdrawal by Subject|1
6242848|NCT01869699|9926098|FG001|Overall Study|Withdrawal by Subject|0
6242849|NCT01869725|9926104|FG000|Overall Study|ineligible after registration|1
6242850|NCT01869725|9926104|FG000|Overall Study|Death|1
6242851|NCT01869725|9926104|FG000|Overall Study|Lost to Follow-up|2
6242852|NCT01869764|9926110|FG000|Overall Study|Withdrawal by Subject|0
6242853|NCT01869764|9926111|FG001|Overall Study|Withdrawal by Subject|2
6242854|NCT01869777|9926117|FG000|Overall Study|Excluded from the analysis, ineligible|1
6242855|NCT01869959|9926125|FG000|Randomization Period|Physician Decision|0
6242856|NCT01869959|9926126|FG001|Randomization Period|Physician Decision|0
6242857|NCT01869959|9926127|FG002|Randomization Period|Physician Decision|0
6242858|NCT01869959|9926128|FG003|Randomization Period|Physician Decision|0
6242859|NCT01869959|9926129|FG004|Randomization Period|Physician Decision|1
6242860|NCT01869959|9926125|FG000|Treatment Period|Adverse Event|1
6242861|NCT01869959|9926126|FG001|Treatment Period|Adverse Event|0
6242862|NCT01869959|9926127|FG002|Treatment Period|Adverse Event|3
6242863|NCT01869959|9926128|FG003|Treatment Period|Adverse Event|1
6242864|NCT01869959|9926129|FG004|Treatment Period|Adverse Event|0
6242865|NCT01869959|9926125|FG000|Treatment Period|Sponsor decision|0
6242866|NCT01869959|9926126|FG001|Treatment Period|Sponsor decision|1
6242867|NCT01869959|9926127|FG002|Treatment Period|Sponsor decision|0
6242868|NCT01869959|9926128|FG003|Treatment Period|Sponsor decision|1
6242869|NCT01869959|9926129|FG004|Treatment Period|Sponsor decision|0
6242870|NCT01869959|9926125|FG000|Treatment Period|Withdrawal by Subject|0
6242871|NCT01869959|9926126|FG001|Treatment Period|Withdrawal by Subject|1
6242872|NCT01869959|9926127|FG002|Treatment Period|Withdrawal by Subject|0
6242873|NCT01869959|9926128|FG003|Treatment Period|Withdrawal by Subject|0
6242874|NCT01869959|9926129|FG004|Treatment Period|Withdrawal by Subject|0
6242875|NCT01870076|9926143|FG000|Overall Study|Withdrawal by Subject|1
6242876|NCT01870076|9926144|FG001|Overall Study|Withdrawal by Subject|0
6242877|NCT01870076|9926145|FG002|Overall Study|Withdrawal by Subject|1
6242878|NCT01870076|9926146|FG003|Overall Study|Withdrawal by Subject|0
6242879|NCT01870297|9926163|FG000|Overall Study|Adverse Event|0
6242880|NCT01870297|9926164|FG001|Overall Study|Adverse Event|0
6242881|NCT01870297|9926165|FG002|Overall Study|Adverse Event|0
6242882|NCT01870297|9926166|FG003|Overall Study|Adverse Event|0
6242883|NCT01870297|9926167|FG004|Overall Study|Adverse Event|2
6242884|NCT01870297|9926168|FG005|Overall Study|Adverse Event|0
6242885|NCT01870297|9926169|FG006|Overall Study|Adverse Event|0
6242886|NCT01870297|9926163|FG000|Overall Study|Lost to Follow-up|0
6242887|NCT01870297|9926164|FG001|Overall Study|Lost to Follow-up|1
6242888|NCT01870297|9926165|FG002|Overall Study|Lost to Follow-up|1
6242889|NCT01870297|9926166|FG003|Overall Study|Lost to Follow-up|0
6242890|NCT01870297|9926167|FG004|Overall Study|Lost to Follow-up|0
6242891|NCT01870297|9926168|FG005|Overall Study|Lost to Follow-up|0
6242892|NCT01870297|9926169|FG006|Overall Study|Lost to Follow-up|0
6242893|NCT01870297|9926163|FG000|Overall Study|Withdrawal by Subject|0
6242894|NCT01870297|9926164|FG001|Overall Study|Withdrawal by Subject|0
6242895|NCT01870297|9926165|FG002|Overall Study|Withdrawal by Subject|0
6242896|NCT01870297|9926166|FG003|Overall Study|Withdrawal by Subject|0
6242897|NCT01870297|9926167|FG004|Overall Study|Withdrawal by Subject|1
6242898|NCT01870297|9926168|FG005|Overall Study|Withdrawal by Subject|1
6242899|NCT01870297|9926169|FG006|Overall Study|Withdrawal by Subject|1
6242900|NCT01870297|9926163|FG000|Overall Study|Sponsor Decision|0
6242901|NCT01870297|9926164|FG001|Overall Study|Sponsor Decision|6
6242902|NCT01870297|9926165|FG002|Overall Study|Sponsor Decision|0
6242903|NCT01870297|9926166|FG003|Overall Study|Sponsor Decision|0
6242904|NCT01870297|9926167|FG004|Overall Study|Sponsor Decision|0
6242905|NCT01870297|9926168|FG005|Overall Study|Sponsor Decision|0
6242906|NCT01870297|9926169|FG006|Overall Study|Sponsor Decision|1
6242907|NCT01870583|9926208|FG000|Overall Study|Protocol Violation|0
6242908|NCT01870583|9926209|FG001|Overall Study|Protocol Violation|5
6242909|NCT01870583|9926210|FG002|Overall Study|Protocol Violation|3
6242910|NCT01870583|9926208|FG000|Overall Study|Lost to Follow-up|11
6242911|NCT01870583|9926209|FG001|Overall Study|Lost to Follow-up|13
6242912|NCT01870583|9926210|FG002|Overall Study|Lost to Follow-up|5
6242913|NCT01870726|9926234|FG000|Overall Study|Withdrawal of informed consent|0
6242914|NCT01870726|9926235|FG001|Overall Study|Withdrawal of informed consent|0
6242915|NCT01870726|9926236|FG002|Overall Study|Withdrawal of informed consent|0
6242916|NCT01870726|9926237|FG003|Overall Study|Withdrawal of informed consent|1
6242917|NCT01870726|9926238|FG004|Overall Study|Withdrawal of informed consent|0
6242918|NCT01870726|9926239|FG005|Overall Study|Withdrawal of informed consent|0
6242919|NCT01870726|9926240|FG006|Overall Study|Withdrawal of informed consent|0
6242920|NCT01870726|9926234|FG000|Overall Study|Withdrawal by Subject|0
6242921|NCT01870726|9926235|FG001|Overall Study|Withdrawal by Subject|1
6242922|NCT01870726|9926236|FG002|Overall Study|Withdrawal by Subject|0
6242923|NCT01870726|9926237|FG003|Overall Study|Withdrawal by Subject|0
6242924|NCT01870726|9926238|FG004|Overall Study|Withdrawal by Subject|0
6242925|NCT01870726|9926239|FG005|Overall Study|Withdrawal by Subject|0
6242926|NCT01870726|9926240|FG006|Overall Study|Withdrawal by Subject|0
6242927|NCT01870726|9926234|FG000|Overall Study|Adverse Event|0
6242928|NCT01870726|9926235|FG001|Overall Study|Adverse Event|0
6242929|NCT01870726|9926236|FG002|Overall Study|Adverse Event|0
6242930|NCT01870726|9926237|FG003|Overall Study|Adverse Event|0
6242931|NCT01870726|9926238|FG004|Overall Study|Adverse Event|1
6242932|NCT01870726|9926239|FG005|Overall Study|Adverse Event|1
6242933|NCT01870726|9926240|FG006|Overall Study|Adverse Event|0
6242934|NCT01870726|9926234|FG000|Overall Study|Progressive disease|5
6242935|NCT01870726|9926235|FG001|Overall Study|Progressive disease|5
6242936|NCT01870726|9926236|FG002|Overall Study|Progressive disease|4
6242937|NCT01870726|9926237|FG003|Overall Study|Progressive disease|5
6242938|NCT01870726|9926238|FG004|Overall Study|Progressive disease|6
6242939|NCT01870726|9926239|FG005|Overall Study|Progressive disease|4
6242940|NCT01870726|9926240|FG006|Overall Study|Progressive disease|10
6242941|NCT01870739|9926267|FG000|Single Drug Treatment (12 Weeks)|Protocol deviation|0
6242942|NCT01870739|9926268|FG001|Single Drug Treatment (12 Weeks)|Protocol deviation|1
6242943|NCT01870739|9926267|FG000|Single Drug Treatment (12 Weeks)|Adverse Event|0
6242944|NCT01870739|9926268|FG001|Single Drug Treatment (12 Weeks)|Adverse Event|1
6242945|NCT01870739|9926267|FG000|Single Drug Treatment (12 Weeks)|Administrative problems|3
6242946|NCT01870739|9926268|FG001|Single Drug Treatment (12 Weeks)|Administrative problems|2
6242947|NCT01870739|9926267|FG000|Add-on Period (40 Weeks)|Adverse Event|0
6242948|NCT01870739|9926268|FG001|Add-on Period (40 Weeks)|Adverse Event|1
6242949|NCT01870739|9926267|FG000|Add-on Period (40 Weeks)|Unsatisfactory therapeutic effect|1
6242950|NCT01870739|9926268|FG001|Add-on Period (40 Weeks)|Unsatisfactory therapeutic effect|0
6242951|NCT01870739|9926267|FG000|Add-on Period (40 Weeks)|Protocol deviation|1
6242952|NCT01870739|9926268|FG001|Add-on Period (40 Weeks)|Protocol deviation|1
6242953|NCT01870739|9926267|FG000|Add-on Period (40 Weeks)|Patient withdrew consent|1
6242954|NCT01870739|9926268|FG001|Add-on Period (40 Weeks)|Patient withdrew consent|0
6242955|NCT01870778|9926286|FG000|Overall Study|Withdrawal by Subject|8
6242956|NCT01870778|9926287|FG001|Overall Study|Withdrawal by Subject|7
6242957|NCT01870778|9926286|FG000|Overall Study|Lost to Follow-up|0
6242958|NCT01870778|9926287|FG001|Overall Study|Lost to Follow-up|2
6242959|NCT01870843|9926293|FG000|Overall Study|Adverse Event|10
6242960|NCT01870843|9926293|FG000|Overall Study|Lost to Follow-up|24
6242961|NCT01870843|9926293|FG000|Overall Study|Death|1
6242962|NCT01870843|9926293|FG000|Overall Study|Withdrawal by Subject|18
6242963|NCT01870869|9926312|FG000|Overall Study|Implanted with nonstudy device|1
6242964|NCT01870869|9926313|FG001|Overall Study|Implanted with nonstudy device|3
6242965|NCT01870869|9926314|FG002|Overall Study|Implanted with nonstudy device|14
6242966|NCT01870869|9926315|FG003|Overall Study|Implanted with nonstudy device|4
6242967|NCT01870869|9926312|FG000|Overall Study|Death|0
6242968|NCT01870869|9926313|FG001|Overall Study|Death|0
6242969|NCT01870869|9926314|FG002|Overall Study|Death|7
6242970|NCT01870869|9926315|FG003|Overall Study|Death|1
6242971|NCT01870869|9926312|FG000|Overall Study|Subject choice|6
6242972|NCT01870869|9926313|FG001|Overall Study|Subject choice|2
6242973|NCT01870869|9926314|FG002|Overall Study|Subject choice|22
6242974|NCT01870869|9926315|FG003|Overall Study|Subject choice|8
6242975|NCT01870869|9926312|FG000|Overall Study|Lost to Follow-up|10
6242976|NCT01870869|9926313|FG001|Overall Study|Lost to Follow-up|2
6242977|NCT01870869|9926314|FG002|Overall Study|Lost to Follow-up|25
6242978|NCT01870869|9926315|FG003|Overall Study|Lost to Follow-up|3
6242979|NCT01870869|9926312|FG000|Overall Study|Reason not Specified|1
6242980|NCT01870869|9926313|FG001|Overall Study|Reason not Specified|2
6242981|NCT01870869|9926314|FG002|Overall Study|Reason not Specified|20
6242982|NCT01870869|9926315|FG003|Overall Study|Reason not Specified|4
6242983|NCT01870869|9926312|FG000|Overall Study|Not evaluable|10
6242984|NCT01870869|9926313|FG001|Overall Study|Not evaluable|5
6242985|NCT01870869|9926314|FG002|Overall Study|Not evaluable|42
6242986|NCT01870869|9926315|FG003|Overall Study|Not evaluable|10
6242987|NCT01870921|9926325|FG000|Overall Study|Subject decision|80
6242988|NCT01870921|9926325|FG000|Overall Study|Severe non-compliance to protocol|7
6242989|NCT01870921|9926325|FG000|Overall Study|Subject Lost to Follow up|2
6242990|NCT01870921|9926325|FG000|Overall Study|Other|1
6242991|NCT01870973|9926331|FG000|Overall Study|Lost to Follow-up|10
6242992|NCT01870973|9926332|FG001|Overall Study|Lost to Follow-up|3
6242993|NCT01870999|9926341|FG000|Overall Study|Adverse Event|0
6242994|NCT01870999|9926342|FG001|Overall Study|Adverse Event|4
6242995|NCT01870999|9926343|FG002|Overall Study|Adverse Event|1
6242996|NCT01870999|9926341|FG000|Overall Study|Subject met withdrawal criteria|3
6242997|NCT01870999|9926342|FG001|Overall Study|Subject met withdrawal criteria|2
6242998|NCT01870999|9926343|FG002|Overall Study|Subject met withdrawal criteria|0
6242999|NCT01870999|9926341|FG000|Overall Study|Subject withdrawn by Investigator|1
6243000|NCT01870999|9926342|FG001|Overall Study|Subject withdrawn by Investigator|0
6243001|NCT01870999|9926343|FG002|Overall Study|Subject withdrawn by Investigator|0
6243002|NCT01870999|9926341|FG000|Overall Study|Withdrawal by Subject|0
6243003|NCT01870999|9926342|FG001|Overall Study|Withdrawal by Subject|2
6243004|NCT01870999|9926343|FG002|Overall Study|Withdrawal by Subject|5
6243005|NCT01870999|9926341|FG000|Overall Study|Protocol Violation|0
6243006|NCT01870999|9926342|FG001|Overall Study|Protocol Violation|0
6243007|NCT01870999|9926343|FG002|Overall Study|Protocol Violation|1
6243008|NCT01871090|9926357|FG000|Overall Study|Interrogation not done in Emergency Room|1
6243009|NCT01871090|9926358|FG001|Overall Study|Interrogation not done in Emergency Room|22
6243010|NCT01871090|9926357|FG000|Overall Study|Interrogation not completed correctly|1
6243011|NCT01871090|9926358|FG001|Overall Study|Interrogation not completed correctly|0
6243012|NCT01871090|9926357|FG000|Overall Study|Subject Non-Compliance|0
6243013|NCT01871090|9926358|FG001|Overall Study|Subject Non-Compliance|1
6243014|NCT01871142|9926364|FG000|Overall Study|Adverse Event|1
6243015|NCT01871285|9926380|FG000|First Intervention (1 Day)|Adverse Event|1
6243016|NCT01871285|9926381|FG001|First Intervention (1 Day)|Adverse Event|0
6243017|NCT01871285|9926382|FG002|First Intervention (1 Day)|Adverse Event|0
6243018|NCT01871285|9926383|FG003|First Intervention (1 Day)|Adverse Event|0
6243019|NCT01871285|9926380|FG000|First Intervention (1 Day)|Lost to Follow-up|0
6243020|NCT01871285|9926381|FG001|First Intervention (1 Day)|Lost to Follow-up|1
6243021|NCT01871285|9926382|FG002|First Intervention (1 Day)|Lost to Follow-up|1
6243022|NCT01871285|9926383|FG003|First Intervention (1 Day)|Lost to Follow-up|0
6243023|NCT01871402|9926395|FG000|Overall Study|Lost to Follow-up|1
6243024|NCT01871402|9926396|FG001|Overall Study|Lost to Follow-up|0
6243025|NCT01871402|9926395|FG000|Overall Study|Withdrawal by Subject|0
6243026|NCT01871402|9926396|FG001|Overall Study|Withdrawal by Subject|2
6243027|NCT01871402|9926395|FG000|Overall Study|Non-compliance|0
6243028|NCT01871402|9926396|FG001|Overall Study|Non-compliance|1
6243029|NCT01871519|9926429|FG000|Overall Study|Death|26
6243030|NCT01871519|9926429|FG000|Overall Study|Lost to Follow-up|15
6243031|NCT01871519|9926429|FG000|Overall Study|Withdrawal by Subject|49
6243032|NCT01871532|9926436|FG000|Overall Study|Withdrawal by Subject|1
6243033|NCT01871532|9926437|FG001|Overall Study|Withdrawal by Subject|2
6243034|NCT01871545|9926445|FG000|Overall Study|Death|2
6243035|NCT01871545|9926446|FG001|Overall Study|Death|0
6243036|NCT01871545|9926445|FG000|Overall Study|Lack of Efficacy|11
6243037|NCT01871545|9926446|FG001|Overall Study|Lack of Efficacy|2
6243038|NCT01871545|9926445|FG000|Overall Study|Physician Decision|4
6243039|NCT01871545|9926446|FG001|Overall Study|Physician Decision|0
6243040|NCT01871545|9926445|FG000|Overall Study|Withdrawal by Subject|0
6243041|NCT01871545|9926446|FG001|Overall Study|Withdrawal by Subject|1
6243042|NCT01871558|9926457|FG000|Overall Study|Other reason|0
6243043|NCT01871558|9926458|FG001|Overall Study|Other reason|1
6243044|NCT01871558|9926457|FG000|Overall Study|antidiabetic drug prematurely stopped|1
6243045|NCT01871558|9926458|FG001|Overall Study|antidiabetic drug prematurely stopped|1
6243046|NCT01871558|9926457|FG000|Overall Study|Withdrawal by Subject|2
6243047|NCT01871558|9926458|FG001|Overall Study|Withdrawal by Subject|0
6243048|NCT01871805|9926470|FG000|Phase I|Death|7
6243049|NCT01871805|9926471|FG001|Phase I|Death|4
6243050|NCT01871805|9926472|FG002|Phase I|Death|6
6243051|NCT01871805|9926473|FG003|Phase I|Death|2
6243052|NCT01871805|9926474|FG004|Phase I|Death|9
6243053|NCT01871805|9926475|FG005|Phase I|Death|0
6243054|NCT01871805|9926470|FG000|Phase I|Alive in Survival Follow-up|0
6243055|NCT01871805|9926471|FG001|Phase I|Alive in Survival Follow-up|2
6243056|NCT01871805|9926472|FG002|Phase I|Alive in Survival Follow-up|4
6243057|NCT01871805|9926473|FG003|Phase I|Alive in Survival Follow-up|5
6243058|NCT01871805|9926474|FG004|Phase I|Alive in Survival Follow-up|4
6243059|NCT01871805|9926475|FG005|Phase I|Alive in Survival Follow-up|0
6243060|NCT01871805|9926470|FG000|Phase I|Lost to Follow-up|0
6243061|NCT01871805|9926471|FG001|Phase I|Lost to Follow-up|1
6243062|NCT01871805|9926472|FG002|Phase I|Lost to Follow-up|3
6243063|NCT01871805|9926473|FG003|Phase I|Lost to Follow-up|0
6243064|NCT01871805|9926474|FG004|Phase I|Lost to Follow-up|0
6243065|NCT01871805|9926475|FG005|Phase I|Lost to Follow-up|0
6243066|NCT01871805|9926470|FG000|Phase II|Death|0
6243067|NCT01871805|9926471|FG001|Phase II|Death|0
6243068|NCT01871805|9926472|FG002|Phase II|Death|0
6243069|NCT01871805|9926473|FG003|Phase II|Death|0
6243070|NCT01871805|9926474|FG004|Phase II|Death|0
6243071|NCT01871805|9926475|FG005|Phase II|Death|45
6243072|NCT01871805|9926470|FG000|Phase II|Alive in Survival Follow-up|0
6243073|NCT01871805|9926471|FG001|Phase II|Alive in Survival Follow-up|0
6243074|NCT01871805|9926472|FG002|Phase II|Alive in Survival Follow-up|0
6243075|NCT01871805|9926473|FG003|Phase II|Alive in Survival Follow-up|0
6243076|NCT01871805|9926474|FG004|Phase II|Alive in Survival Follow-up|0
6243077|NCT01871805|9926475|FG005|Phase II|Alive in Survival Follow-up|29
6243078|NCT01871805|9926470|FG000|Phase II|Lost to Follow-up|0
6243079|NCT01871805|9926471|FG001|Phase II|Lost to Follow-up|0
6243080|NCT01871805|9926472|FG002|Phase II|Lost to Follow-up|0
6243081|NCT01871805|9926473|FG003|Phase II|Lost to Follow-up|0
6243082|NCT01871805|9926474|FG004|Phase II|Lost to Follow-up|0
6243083|NCT01871805|9926475|FG005|Phase II|Lost to Follow-up|13
6243084|NCT01871870|9926506|FG000|Overall Study|Hardware issues|7
6243085|NCT01871870|9926506|FG000|Overall Study|hyperglycemia|2
6243086|NCT01872078|9926514|FG000|Overall Study|Adverse Event|0
6243087|NCT01872078|9926515|FG001|Overall Study|Adverse Event|0
6243088|NCT01872078|9926516|FG002|Overall Study|Adverse Event|1
6243089|NCT01872078|9926517|FG003|Overall Study|Adverse Event|0
6243090|NCT01872078|9926514|FG000|Overall Study|Dose administration non-compliance|0
6243091|NCT01872078|9926515|FG001|Overall Study|Dose administration non-compliance|0
6243092|NCT01872078|9926516|FG002|Overall Study|Dose administration non-compliance|0
6243093|NCT01872078|9926517|FG003|Overall Study|Dose administration non-compliance|1
6243094|NCT01872078|9926514|FG000|Overall Study|Protocol Violation|0
6243095|NCT01872078|9926515|FG001|Overall Study|Protocol Violation|0
6243096|NCT01872078|9926516|FG002|Overall Study|Protocol Violation|1
6243097|NCT01872078|9926517|FG003|Overall Study|Protocol Violation|0
6243098|NCT01872078|9926514|FG000|Overall Study|Withdrawal by Subject|0
6243099|NCT01872078|9926515|FG001|Overall Study|Withdrawal by Subject|0
6243100|NCT01872078|9926516|FG002|Overall Study|Withdrawal by Subject|1
6243101|NCT01872078|9926517|FG003|Overall Study|Withdrawal by Subject|0
6243102|NCT01872078|9926514|FG000|Overall Study|Patient met exclusion criterion 16.|0
6243103|NCT01872078|9926515|FG001|Overall Study|Patient met exclusion criterion 16.|0
6243104|NCT01872078|9926516|FG002|Overall Study|Patient met exclusion criterion 16.|0
6243105|NCT01872078|9926517|FG003|Overall Study|Patient met exclusion criterion 16.|1
6243106|NCT01872611|9926547|FG000|Overall Study|Adverse Event|3
6243107|NCT01872611|9926548|FG001|Overall Study|Adverse Event|1
6243108|NCT01872611|9926547|FG000|Overall Study|Adverse Event, prior to treatment|0
6243109|NCT01872611|9926548|FG001|Overall Study|Adverse Event, prior to treatment|1
6243110|NCT01872611|9926547|FG000|Overall Study|Death|0
6243111|NCT01872611|9926548|FG001|Overall Study|Death|1
6243112|NCT01872611|9926547|FG000|Overall Study|Death, prior to treatment|0
6243113|NCT01872611|9926548|FG001|Overall Study|Death, prior to treatment|1
6243114|NCT01872611|9926547|FG000|Overall Study|Lost to Follow-up|8
6243115|NCT01872611|9926548|FG001|Overall Study|Lost to Follow-up|1
6243116|NCT01872611|9926547|FG000|Overall Study|Physician Decision|1
6243117|NCT01872611|9926548|FG001|Overall Study|Physician Decision|0
6243118|NCT01872611|9926547|FG000|Overall Study|Withdrawal by Subject|6
6243119|NCT01872611|9926548|FG001|Overall Study|Withdrawal by Subject|1
6243120|NCT01872611|9926547|FG000|Overall Study|Reason not provided|6
6243121|NCT01872611|9926548|FG001|Overall Study|Reason not provided|6
6243122|NCT01872689|9926560|FG000|Double-Blind/Placebo-Controlled Period|Lack of Efficacy|0
6243123|NCT01872689|9926561|FG001|Double-Blind/Placebo-Controlled Period|Lack of Efficacy|1
6243124|NCT01872689|9926562|FG002|Double-Blind/Placebo-Controlled Period|Lack of Efficacy|0
6243125|NCT01872689|9926563|FG003|Double-Blind/Placebo-Controlled Period|Lack of Efficacy|0
6243126|NCT01872689|9926560|FG000|Double-Blind/Placebo-Controlled Period|Other|1
6243127|NCT01872689|9926561|FG001|Double-Blind/Placebo-Controlled Period|Other|1
6243128|NCT01872689|9926562|FG002|Double-Blind/Placebo-Controlled Period|Other|6
6243129|NCT01872689|9926563|FG003|Double-Blind/Placebo-Controlled Period|Other|3
6243130|NCT01872689|9926560|FG000|Double-Blind/Placebo-Controlled Period|Withdrawal by Subject|9
6243131|NCT01872689|9926561|FG001|Double-Blind/Placebo-Controlled Period|Withdrawal by Subject|8
6243132|NCT01872689|9926562|FG002|Double-Blind/Placebo-Controlled Period|Withdrawal by Subject|14
6243133|NCT01872689|9926563|FG003|Double-Blind/Placebo-Controlled Period|Withdrawal by Subject|16
6243134|NCT01872689|9926560|FG000|Double-Blind/Placebo-Controlled Period|Protocol Violation|0
6243135|NCT01872689|9926561|FG001|Double-Blind/Placebo-Controlled Period|Protocol Violation|0
6243136|NCT01872689|9926562|FG002|Double-Blind/Placebo-Controlled Period|Protocol Violation|1
6243137|NCT01872689|9926563|FG003|Double-Blind/Placebo-Controlled Period|Protocol Violation|1
6243138|NCT01872689|9926560|FG000|Double-Blind/Placebo-Controlled Period|Physician Decision|0
6243139|NCT01872689|9926561|FG001|Double-Blind/Placebo-Controlled Period|Physician Decision|3
6243140|NCT01872689|9926562|FG002|Double-Blind/Placebo-Controlled Period|Physician Decision|3
6243141|NCT01872689|9926563|FG003|Double-Blind/Placebo-Controlled Period|Physician Decision|1
6243142|NCT01872689|9926560|FG000|Double-Blind/Placebo-Controlled Period|Lost to Follow-up|1
6243143|NCT01872689|9926561|FG001|Double-Blind/Placebo-Controlled Period|Lost to Follow-up|0
6243144|NCT01872689|9926562|FG002|Double-Blind/Placebo-Controlled Period|Lost to Follow-up|0
6243145|NCT01872689|9926563|FG003|Double-Blind/Placebo-Controlled Period|Lost to Follow-up|1
6243146|NCT01872689|9926560|FG000|Double-Blind/Placebo-Controlled Period|Death|3
6243147|NCT01872689|9926561|FG001|Double-Blind/Placebo-Controlled Period|Death|4
6243148|NCT01872689|9926562|FG002|Double-Blind/Placebo-Controlled Period|Death|14
6243149|NCT01872689|9926563|FG003|Double-Blind/Placebo-Controlled Period|Death|9
6243150|NCT01872689|9926560|FG000|Double-Blind/Placebo-Controlled Period|Adverse Event|6
6243151|NCT01872689|9926561|FG001|Double-Blind/Placebo-Controlled Period|Adverse Event|3
6243152|NCT01872689|9926562|FG002|Double-Blind/Placebo-Controlled Period|Adverse Event|10
6243153|NCT01872689|9926563|FG003|Double-Blind/Placebo-Controlled Period|Adverse Event|7
6243154|NCT01872689|9926560|FG000|Open-Label Period (Only For Monotherapy)|Other|2
6243155|NCT01872689|9926561|FG001|Open-Label Period (Only For Monotherapy)|Other|3
6243156|NCT01872689|9926562|FG002|Open-Label Period (Only For Monotherapy)|Other|0
6243157|NCT01872689|9926563|FG003|Open-Label Period (Only For Monotherapy)|Other|0
6243158|NCT01872689|9926560|FG000|Open-Label Period (Only For Monotherapy)|Withdrawal by Subject|11
6243159|NCT01872689|9926561|FG001|Open-Label Period (Only For Monotherapy)|Withdrawal by Subject|12
6243160|NCT01872689|9926562|FG002|Open-Label Period (Only For Monotherapy)|Withdrawal by Subject|0
6243161|NCT01872689|9926563|FG003|Open-Label Period (Only For Monotherapy)|Withdrawal by Subject|0
6243162|NCT01872689|9926560|FG000|Open-Label Period (Only For Monotherapy)|Physician Decision|0
6243163|NCT01872689|9926561|FG001|Open-Label Period (Only For Monotherapy)|Physician Decision|1
6243164|NCT01872689|9926562|FG002|Open-Label Period (Only For Monotherapy)|Physician Decision|0
6243165|NCT01872689|9926563|FG003|Open-Label Period (Only For Monotherapy)|Physician Decision|0
6243166|NCT01872689|9926560|FG000|Open-Label Period (Only For Monotherapy)|Lost to Follow-up|1
6243167|NCT01872689|9926561|FG001|Open-Label Period (Only For Monotherapy)|Lost to Follow-up|3
6243168|NCT01872689|9926562|FG002|Open-Label Period (Only For Monotherapy)|Lost to Follow-up|0
6243169|NCT01872689|9926563|FG003|Open-Label Period (Only For Monotherapy)|Lost to Follow-up|0
6243170|NCT01872689|9926560|FG000|Open-Label Period (Only For Monotherapy)|Death|5
6243171|NCT01872689|9926561|FG001|Open-Label Period (Only For Monotherapy)|Death|3
6243172|NCT01872689|9926562|FG002|Open-Label Period (Only For Monotherapy)|Death|0
6243173|NCT01872689|9926563|FG003|Open-Label Period (Only For Monotherapy)|Death|0
6243174|NCT01872689|9926560|FG000|Open-Label Period (Only For Monotherapy)|Adverse Event|2
6243175|NCT01872689|9926561|FG001|Open-Label Period (Only For Monotherapy)|Adverse Event|1
6243176|NCT01872689|9926562|FG002|Open-Label Period (Only For Monotherapy)|Adverse Event|0
6243177|NCT01872689|9926563|FG003|Open-Label Period (Only For Monotherapy)|Adverse Event|0
6243178|NCT01872715|9926576|FG000|Overall Study|Adverse Event|1
6243179|NCT01872715|9926576|FG000|Overall Study|Protocol Violation|1
6243180|NCT01872715|9926576|FG000|Overall Study|Withdrawal by Subject|2
6243181|NCT01872910|9926601|FG000|Overall Study|Lost to Follow-up|2
6243182|NCT01872910|9926602|FG001|Overall Study|Lost to Follow-up|0
6243183|NCT01872910|9926603|FG002|Overall Study|Lost to Follow-up|2
6243184|NCT01872910|9926604|FG003|Overall Study|Lost to Follow-up|0
6243185|NCT01872910|9926605|FG004|Overall Study|Lost to Follow-up|0
6243186|NCT01872910|9926606|FG005|Overall Study|Lost to Follow-up|0
6243187|NCT01873417|9926630|FG000|Overall Study|Did Not Receive Any Study Drug|4
6243188|NCT01873417|9926630|FG000|Overall Study|Adverse Event|24
6243189|NCT01873417|9926630|FG000|Overall Study|Lost to Follow-up|2
6243190|NCT01873417|9926630|FG000|Overall Study|Withdrawal by Subject|2
6243191|NCT01873417|9926630|FG000|Overall Study|Physician Decision|3
6243192|NCT01873495|9926634|FG000|Overall Study|Withdrawal by Subject|1
6243193|NCT01873495|9926634|FG000|Overall Study|Physician Decision|3
6243194|NCT01873495|9926634|FG000|Overall Study|Adverse Event|1
6243195|NCT01873495|9926634|FG000|Overall Study|Removed for Transplantation|1
6243196|NCT01873495|9926634|FG000|Overall Study|AML (Acute Myelogenous Leukemia) Relapse|1
6243197|NCT01873586|9926638|FG000|Overall Study|Lost to Follow-up|3
6243198|NCT01873729|9926645|FG000|Overall Study|Withdrawal by Subject|1
6243199|NCT01873742|9926651|FG000|Overall Study|Lost to Follow-up|68
6243200|NCT01873742|9926652|FG001|Overall Study|Lost to Follow-up|76
6243201|NCT01873859|9926664|FG000|Overall Study|Withdrawal by Subject|0
6243202|NCT01873859|9926665|FG001|Overall Study|Withdrawal by Subject|4
6243203|NCT01873950|9926672|FG000|Period 5|Withdrawal by Subject|0
6243204|NCT01873950|9926673|FG001|Period 5|Withdrawal by Subject|0
6243205|NCT01873950|9926674|FG002|Period 5|Withdrawal by Subject|0
6243206|NCT01873950|9926675|FG003|Period 5|Withdrawal by Subject|1
6243207|NCT01873950|9926676|FG004|Period 5|Withdrawal by Subject|0
6243208|NCT01874054|9926699|FG000|Overall Study|Withdrawal by Subject|3
6243209|NCT01874054|9926699|FG000|Overall Study|Study Termination by Sponsor|42
6243210|NCT01874054|9926699|FG000|Overall Study|Lost to Follow-up|5
6243211|NCT01874054|9926699|FG000|Overall Study|Death|5
6243212|NCT01874145|9926725|FG000|Core Period|Non-compliance|1
6243213|NCT01874145|9926726|FG001|Core Period|Non-compliance|0
6243214|NCT01874145|9926725|FG000|Core Period|Protocol Violation|1
6243215|NCT01874145|9926726|FG001|Core Period|Protocol Violation|1
6243216|NCT01874145|9926725|FG000|Core Period|Physician Decision|1
6243217|NCT01874145|9926726|FG001|Core Period|Physician Decision|1
6243218|NCT01874145|9926725|FG000|Core Period|Adverse Event|0
6243219|NCT01874145|9926726|FG001|Core Period|Adverse Event|1
6243220|NCT01874145|9926725|FG000|Core Period|Withdrawal by Subject|0
6243221|NCT01874145|9926726|FG001|Core Period|Withdrawal by Subject|4
6243222|NCT01874145|9926725|FG000|Extension Period|Adverse Event|3
6243223|NCT01874145|9926726|FG001|Extension Period|Adverse Event|2
6243224|NCT01874145|9926725|FG000|Extension Period|Withdrawal by Subject|2
6243225|NCT01874145|9926726|FG001|Extension Period|Withdrawal by Subject|1
6243226|NCT01874145|9926725|FG000|Extension Period|Lost to Follow-up|1
6243227|NCT01874145|9926726|FG001|Extension Period|Lost to Follow-up|1
6243228|NCT01874275|9926747|FG000|Overall Study|Lost to Follow-up|1
6243229|NCT01874275|9926748|FG001|Overall Study|Lost to Follow-up|0
6243230|NCT01874288|9926765|FG000|Overall Study|Withdrawal by Subject|1
6243231|NCT01874288|9926766|FG001|Overall Study|Withdrawal by Subject|0
6243232|NCT01874288|9926767|FG002|Overall Study|Withdrawal by Subject|2
6243233|NCT01874288|9926768|FG003|Overall Study|Withdrawal by Subject|1
6243234|NCT01874288|9926769|FG004|Overall Study|Withdrawal by Subject|1
6243235|NCT01874288|9926765|FG000|Overall Study|Physician Decision|0
6243236|NCT01874288|9926766|FG001|Overall Study|Physician Decision|0
6243237|NCT01874288|9926767|FG002|Overall Study|Physician Decision|0
6243238|NCT01874288|9926768|FG003|Overall Study|Physician Decision|1
6243239|NCT01874288|9926769|FG004|Overall Study|Physician Decision|0
6243240|NCT01874288|9926765|FG000|Overall Study|Progressive disease|2
6243241|NCT01874288|9926766|FG001|Overall Study|Progressive disease|0
6243242|NCT01874288|9926767|FG002|Overall Study|Progressive disease|3
6243243|NCT01874288|9926768|FG003|Overall Study|Progressive disease|5
6243244|NCT01874288|9926769|FG004|Overall Study|Progressive disease|1
6243245|NCT01874340|9926786|FG000|Overall Study|Study terminated by Sponsor|6
6243246|NCT01874340|9926787|FG001|Overall Study|Study terminated by Sponsor|8
6243247|NCT01874340|9926788|FG002|Overall Study|Study terminated by Sponsor|8
6243248|NCT01874340|9926789|FG003|Overall Study|Study terminated by Sponsor|4
6243249|NCT01874340|9926786|FG000|Overall Study|Withdrawal by Subject|0
6243250|NCT01874340|9926787|FG001|Overall Study|Withdrawal by Subject|0
6243251|NCT01874340|9926788|FG002|Overall Study|Withdrawal by Subject|0
6243252|NCT01874340|9926789|FG003|Overall Study|Withdrawal by Subject|1
6243253|NCT01874431|9926811|FG000|Overall Study|Physician Decision|0
6243254|NCT01874431|9926812|FG001|Overall Study|Physician Decision|0
6243255|NCT01874431|9926813|FG002|Overall Study|Physician Decision|1
6243256|NCT01874431|9926814|FG003|Overall Study|Physician Decision|0
6243257|NCT01874431|9926815|FG004|Overall Study|Physician Decision|0
6243258|NCT01874431|9926816|FG005|Overall Study|Physician Decision|0
6243259|NCT01874431|9926817|FG006|Overall Study|Physician Decision|0
6243260|NCT01874431|9926818|FG007|Overall Study|Physician Decision|0
6243261|NCT01874431|9926811|FG000|Overall Study|Adverse Event|5
6243262|NCT01874431|9926812|FG001|Overall Study|Adverse Event|4
6243263|NCT01874431|9926813|FG002|Overall Study|Adverse Event|6
6243264|NCT01874431|9926814|FG003|Overall Study|Adverse Event|5
6243265|NCT01874431|9926815|FG004|Overall Study|Adverse Event|2
6243266|NCT01874431|9926816|FG005|Overall Study|Adverse Event|8
6243267|NCT01874431|9926817|FG006|Overall Study|Adverse Event|2
6243268|NCT01874431|9926818|FG007|Overall Study|Adverse Event|3
6243269|NCT01874431|9926811|FG000|Overall Study|Protocol Violation|1
6243270|NCT01874431|9926812|FG001|Overall Study|Protocol Violation|1
6243271|NCT01874431|9926813|FG002|Overall Study|Protocol Violation|1
6243272|NCT01874431|9926814|FG003|Overall Study|Protocol Violation|0
6243273|NCT01874431|9926815|FG004|Overall Study|Protocol Violation|3
6243274|NCT01874431|9926816|FG005|Overall Study|Protocol Violation|2
6243275|NCT01874431|9926817|FG006|Overall Study|Protocol Violation|1
6243276|NCT01874431|9926818|FG007|Overall Study|Protocol Violation|1
6243277|NCT01874431|9926811|FG000|Overall Study|Non-compliance|0
6243278|NCT01874431|9926812|FG001|Overall Study|Non-compliance|0
6243279|NCT01874431|9926813|FG002|Overall Study|Non-compliance|0
6243280|NCT01874431|9926814|FG003|Overall Study|Non-compliance|0
6243281|NCT01874431|9926815|FG004|Overall Study|Non-compliance|1
6243282|NCT01874431|9926816|FG005|Overall Study|Non-compliance|0
6243283|NCT01874431|9926817|FG006|Overall Study|Non-compliance|1
6243284|NCT01874431|9926818|FG007|Overall Study|Non-compliance|0
6243285|NCT01874431|9926811|FG000|Overall Study|Logistical difficulties|0
6243286|NCT01874431|9926812|FG001|Overall Study|Logistical difficulties|0
6243287|NCT01874431|9926813|FG002|Overall Study|Logistical difficulties|0
6243288|NCT01874431|9926814|FG003|Overall Study|Logistical difficulties|0
6243289|NCT01874431|9926815|FG004|Overall Study|Logistical difficulties|0
6243290|NCT01874431|9926816|FG005|Overall Study|Logistical difficulties|0
6085982|NCT00658021|9695649|FG001|28-Week Treatment Period|Withdrawal by parent/guardian|1
6085983|NCT00658021|9695650|FG002|28-Week Treatment Period|Withdrawal by parent/guardian|1
6243291|NCT01874431|9926817|FG006|Overall Study|Logistical difficulties|1
6243292|NCT01874431|9926818|FG007|Overall Study|Logistical difficulties|0
6243293|NCT01874431|9926811|FG000|Overall Study|Withdrawal by Subject|0
6243294|NCT01874431|9926812|FG001|Overall Study|Withdrawal by Subject|0
6243295|NCT01874431|9926813|FG002|Overall Study|Withdrawal by Subject|1
6243296|NCT01874431|9926814|FG003|Overall Study|Withdrawal by Subject|2
6243297|NCT01874431|9926815|FG004|Overall Study|Withdrawal by Subject|1
6243298|NCT01874431|9926816|FG005|Overall Study|Withdrawal by Subject|1
6243299|NCT01874431|9926817|FG006|Overall Study|Withdrawal by Subject|3
6243300|NCT01874431|9926818|FG007|Overall Study|Withdrawal by Subject|0
6243301|NCT01874431|9926811|FG000|Overall Study|Sponsor decision|0
6243302|NCT01874431|9926812|FG001|Overall Study|Sponsor decision|0
6243303|NCT01874431|9926813|FG002|Overall Study|Sponsor decision|0
6243304|NCT01874431|9926814|FG003|Overall Study|Sponsor decision|0
6243305|NCT01874431|9926815|FG004|Overall Study|Sponsor decision|1
6243306|NCT01874431|9926816|FG005|Overall Study|Sponsor decision|0
6243307|NCT01874431|9926817|FG006|Overall Study|Sponsor decision|0
6243308|NCT01874431|9926818|FG007|Overall Study|Sponsor decision|0
6243309|NCT01874431|9926811|FG000|Overall Study|Lost to Follow-up|0
6243310|NCT01874431|9926812|FG001|Overall Study|Lost to Follow-up|0
6243311|NCT01874431|9926813|FG002|Overall Study|Lost to Follow-up|1
6243312|NCT01874431|9926814|FG003|Overall Study|Lost to Follow-up|0
6085984|NCT00658021|9695648|FG000|28-Week Treatment Period|Loss of glucose control|1
6085985|NCT00658021|9695649|FG001|28-Week Treatment Period|Loss of glucose control|1
6243313|NCT01874431|9926815|FG004|Overall Study|Lost to Follow-up|0
6243314|NCT01874431|9926816|FG005|Overall Study|Lost to Follow-up|0
6243315|NCT01874431|9926817|FG006|Overall Study|Lost to Follow-up|0
6243316|NCT01874431|9926818|FG007|Overall Study|Lost to Follow-up|0
6085986|NCT00658021|9695650|FG002|28-Week Treatment Period|Loss of glucose control|10
6085987|NCT00658021|9695648|FG000|28-Week Treatment Period|Other|2
6243317|NCT01874535|9926838|FG000|Overall Study|Lost to Follow-up|10
6243318|NCT01874535|9926839|FG001|Overall Study|Lost to Follow-up|9
6243319|NCT01874535|9926838|FG000|Overall Study|incomplete symptom resolution|45
6243320|NCT01874535|9926839|FG001|Overall Study|incomplete symptom resolution|35
6243321|NCT01874665|9926847|FG000|Overall Study|Adverse Event|6
6243322|NCT01874665|9926848|FG001|Overall Study|Adverse Event|2
6243323|NCT01874665|9926847|FG000|Overall Study|Withdrawal by Subject|4
6243324|NCT01874665|9926848|FG001|Overall Study|Withdrawal by Subject|1
6243325|NCT01874665|9926847|FG000|Overall Study|Physician Decision|3
6243326|NCT01874665|9926848|FG001|Overall Study|Physician Decision|0
6243327|NCT01874665|9926847|FG000|Overall Study|Clinical Progressive Disease|4
6243328|NCT01874665|9926848|FG001|Overall Study|Clinical Progressive Disease|3
6243329|NCT01874665|9926847|FG000|Overall Study|Study Terminated by Sponsor|0
6243330|NCT01874665|9926848|FG001|Overall Study|Study Terminated by Sponsor|2
6243331|NCT01874665|9926847|FG000|Overall Study|Documented Progressive Disease|11
6243332|NCT01874665|9926848|FG001|Overall Study|Documented Progressive Disease|7
6243333|NCT01874665|9926847|FG000|Overall Study|Other|2
6243334|NCT01874665|9926848|FG001|Overall Study|Other|0
6243335|NCT01875237|9926895|FG000|Overall Study|GVDH before DLI|1
6243336|NCT01875237|9926896|FG001|Overall Study|GVDH before DLI|0
6243337|NCT01875237|9926895|FG000|Overall Study|DLI cells could not be produced|1
6243338|NCT01875237|9926896|FG001|Overall Study|DLI cells could not be produced|0
6243339|NCT01875250|9926906|FG000|Overall Study|Adverse Event|2
6243340|NCT01875250|9926907|FG001|Overall Study|Adverse Event|0
6243341|NCT01875367|9926917|FG000|Overall Study|Not complete at least 2 questionaries|4
6243342|NCT01875367|9926918|FG001|Overall Study|Not complete at least 2 questionaries|2
6243343|NCT01875367|9926917|FG000|Overall Study|Not receive study treatment|1
6243344|NCT01875367|9926918|FG001|Overall Study|Not receive study treatment|0
6243345|NCT01875445|9926930|FG000|Overall Study|Lost to Follow-up|5
6243346|NCT01875445|9926931|FG001|Overall Study|Lost to Follow-up|0
6243347|NCT01875445|9926930|FG000|Overall Study|Withdrawal by Subject|2
6243348|NCT01875445|9926931|FG001|Overall Study|Withdrawal by Subject|0
6243349|NCT01875471|9926939|FG000|Overall Study|Adverse Event|0
6243350|NCT01875471|9926940|FG001|Overall Study|Adverse Event|1
6243351|NCT01875471|9926939|FG000|Overall Study|Unsatisfactory Lens Fitting|1
6243352|NCT01875471|9926940|FG001|Overall Study|Unsatisfactory Lens Fitting|0
6270392|NCT02151682|9971243|FG001|Part 2: Tapent. Extension or Observation|Protocol Violation|0
6270393|NCT02151682|9971244|FG002|Part 2: Tapent. Extension or Observation|Protocol Violation|1
6270394|NCT02151682|9971245|FG003|Part 2: Tapent. Extension or Observation|Protocol Violation|0
6270395|NCT02151682|9971246|FG004|Part 2: Tapent. Extension or Observation|Protocol Violation|0
6270396|NCT02151682|9971247|FG005|Part 2: Tapent. Extension or Observation|Protocol Violation|0
6270397|NCT02151682|9971242|FG000|Part 2: Tapent. Extension or Observation|No need for opioid|0
6270398|NCT02151682|9971243|FG001|Part 2: Tapent. Extension or Observation|No need for opioid|0
6270399|NCT02151682|9971244|FG002|Part 2: Tapent. Extension or Observation|No need for opioid|13
6270400|NCT02151682|9971245|FG003|Part 2: Tapent. Extension or Observation|No need for opioid|0
6270401|NCT02151682|9971246|FG004|Part 2: Tapent. Extension or Observation|No need for opioid|0
6270402|NCT02151682|9971247|FG005|Part 2: Tapent. Extension or Observation|No need for opioid|0
6270403|NCT02151682|9971242|FG000|Part 2: Tapent. Extension or Observation|Missing|0
6270404|NCT02151682|9971243|FG001|Part 2: Tapent. Extension or Observation|Missing|0
6270405|NCT02151682|9971244|FG002|Part 2: Tapent. Extension or Observation|Missing|0
6270406|NCT02151682|9971245|FG003|Part 2: Tapent. Extension or Observation|Missing|1
6270407|NCT02151682|9971246|FG004|Part 2: Tapent. Extension or Observation|Missing|0
6270408|NCT02151682|9971247|FG005|Part 2: Tapent. Extension or Observation|Missing|0
6270409|NCT02151682|9971242|FG000|Part 2: Tapent. Extension or Observation|Various other|0
6270410|NCT02151682|9971243|FG001|Part 2: Tapent. Extension or Observation|Various other|0
6270411|NCT02151682|9971244|FG002|Part 2: Tapent. Extension or Observation|Various other|6
6270412|NCT02151682|9971245|FG003|Part 2: Tapent. Extension or Observation|Various other|0
6270413|NCT02151682|9971246|FG004|Part 2: Tapent. Extension or Observation|Various other|0
6270414|NCT02151682|9971247|FG005|Part 2: Tapent. Extension or Observation|Various other|0
6270415|NCT02151682|9971242|FG000|Part 2: Tapent. Extension or Observation|Final post-treatment visit not performed|0
6270416|NCT02151682|9971243|FG001|Part 2: Tapent. Extension or Observation|Final post-treatment visit not performed|0
6270417|NCT02151682|9971244|FG002|Part 2: Tapent. Extension or Observation|Final post-treatment visit not performed|1
6270418|NCT02151682|9971245|FG003|Part 2: Tapent. Extension or Observation|Final post-treatment visit not performed|0
6270419|NCT02151682|9971246|FG004|Part 2: Tapent. Extension or Observation|Final post-treatment visit not performed|0
6270420|NCT02151682|9971247|FG005|Part 2: Tapent. Extension or Observation|Final post-treatment visit not performed|0
6270421|NCT02151682|9971242|FG000|Part 2: Observ. Aft. Tapent. Extension|Withdrawal by Subject|0
6270422|NCT02151682|9971243|FG001|Part 2: Observ. Aft. Tapent. Extension|Withdrawal by Subject|0
6270423|NCT02151682|9971244|FG002|Part 2: Observ. Aft. Tapent. Extension|Withdrawal by Subject|0
6270424|NCT02151682|9971245|FG003|Part 2: Observ. Aft. Tapent. Extension|Withdrawal by Subject|0
6270425|NCT02151682|9971246|FG004|Part 2: Observ. Aft. Tapent. Extension|Withdrawal by Subject|0
6270426|NCT02151682|9971247|FG005|Part 2: Observ. Aft. Tapent. Extension|Withdrawal by Subject|1
6270427|NCT02151682|9971242|FG000|Part 2: Observ. Aft. Tapent. Extension|Death|0
6270428|NCT02151682|9971243|FG001|Part 2: Observ. Aft. Tapent. Extension|Death|0
6270429|NCT02151682|9971244|FG002|Part 2: Observ. Aft. Tapent. Extension|Death|0
6270430|NCT02151682|9971245|FG003|Part 2: Observ. Aft. Tapent. Extension|Death|0
6270431|NCT02151682|9971246|FG004|Part 2: Observ. Aft. Tapent. Extension|Death|0
6270432|NCT02151682|9971247|FG005|Part 2: Observ. Aft. Tapent. Extension|Death|1
6270433|NCT02151682|9971242|FG000|Part 2: Observ. Aft. Tapent. Extension|Missing|0
6270434|NCT02151682|9971243|FG001|Part 2: Observ. Aft. Tapent. Extension|Missing|0
6270435|NCT02151682|9971244|FG002|Part 2: Observ. Aft. Tapent. Extension|Missing|0
6270436|NCT02151682|9971245|FG003|Part 2: Observ. Aft. Tapent. Extension|Missing|0
6270437|NCT02151682|9971246|FG004|Part 2: Observ. Aft. Tapent. Extension|Missing|0
6270438|NCT02151682|9971247|FG005|Part 2: Observ. Aft. Tapent. Extension|Missing|3
6270439|NCT02151682|9971242|FG000|Part 2: Observ. Aft. Tapent. Extension|Various other|0
6270440|NCT02151682|9971243|FG001|Part 2: Observ. Aft. Tapent. Extension|Various other|0
6270441|NCT02151682|9971244|FG002|Part 2: Observ. Aft. Tapent. Extension|Various other|0
6270442|NCT02151682|9971245|FG003|Part 2: Observ. Aft. Tapent. Extension|Various other|0
6270443|NCT02151682|9971246|FG004|Part 2: Observ. Aft. Tapent. Extension|Various other|0
6243353|NCT01875731|9926957|FG000|Overall Study|Fail to obtain lab sample|1
6243354|NCT01875731|9926958|FG001|Overall Study|Fail to obtain lab sample|0
6243355|NCT01875848|9926972|FG000|Overall Study|Withdrawal by Subject|2
6243356|NCT01875848|9926973|FG001|Overall Study|Withdrawal by Subject|0
6243357|NCT01875874|9926989|FG000|Overall Study|Death|3
6243358|NCT01875991|9927007|FG000|Overall Study|Withdrawal by Subject|6
6243359|NCT01875991|9927008|FG001|Overall Study|Withdrawal by Subject|6
6243360|NCT01875991|9927007|FG000|Overall Study|Sponsor Decision|1
6243361|NCT01875991|9927008|FG001|Overall Study|Sponsor Decision|0
6243362|NCT01876043|9927017|FG000|Overall Study|Death|1
6243363|NCT01876043|9927017|FG000|Overall Study|Withdrawal by Subject|1
6243364|NCT01876082|9927023|FG000|Overall Study|Withdrawal by Subject|0
6243365|NCT01876082|9927024|FG001|Overall Study|Withdrawal by Subject|2
6243366|NCT01876082|9927023|FG000|Overall Study|Protocol Violation|1
6243367|NCT01876082|9927024|FG001|Overall Study|Protocol Violation|0
6243368|NCT01876082|9927023|FG000|Overall Study|Adverse Event|1
6243369|NCT01876082|9927024|FG001|Overall Study|Adverse Event|1
6243370|NCT01876082|9927023|FG000|Overall Study|treatment interruption of more than 21 consecutive days observed in cycle 1|0
6243371|NCT01876082|9927024|FG001|Overall Study|treatment interruption of more than 21 consecutive days observed in cycle 1|1
6243372|NCT01876251|9927042|FG000|Overall Study|Clinical progression|1
6243373|NCT01876251|9927043|FG001|Overall Study|Clinical progression|0
6243374|NCT01876251|9927044|FG002|Overall Study|Clinical progression|0
6243375|NCT01876251|9927042|FG000|Overall Study|Death|2
6085988|NCT00658021|9695649|FG001|28-Week Treatment Period|Other|3
6085989|NCT00658021|9695650|FG002|28-Week Treatment Period|Other|1
6085990|NCT00658021|9695648|FG000|28-Week Treatment Period|Did not receive treatment|2
6243376|NCT01876251|9927043|FG001|Overall Study|Death|0
6243377|NCT01876251|9927044|FG002|Overall Study|Death|1
6243378|NCT01876251|9927042|FG000|Overall Study|Participant started new treatment|1
6243379|NCT01876251|9927043|FG001|Overall Study|Participant started new treatment|0
6243380|NCT01876251|9927044|FG002|Overall Study|Participant started new treatment|1
6243381|NCT01876251|9927042|FG000|Overall Study|Participant refused further follow-up|0
6243382|NCT01876251|9927043|FG001|Overall Study|Participant refused further follow-up|0
6243383|NCT01876251|9927044|FG002|Overall Study|Participant refused further follow-up|1
6243384|NCT01876251|9927042|FG000|Overall Study|Study terminated|1
6243385|NCT01876251|9927043|FG001|Overall Study|Study terminated|0
6243386|NCT01876251|9927044|FG002|Overall Study|Study terminated|0
6243387|NCT01876251|9927042|FG000|Overall Study|Objective progression or relapse|10
6243388|NCT01876251|9927043|FG001|Overall Study|Objective progression or relapse|3
6243389|NCT01876251|9927044|FG002|Overall Study|Objective progression or relapse|8
6243390|NCT01876368|9927068|FG000|Overall Study|Adverse Event|2
6243391|NCT01876368|9927069|FG001|Overall Study|Adverse Event|5
6243392|NCT01876368|9927068|FG000|Overall Study|Lack of Efficacy|1
6243393|NCT01876368|9927069|FG001|Overall Study|Lack of Efficacy|0
6243394|NCT01876368|9927068|FG000|Overall Study|Lost to Follow-up|0
6243395|NCT01876368|9927069|FG001|Overall Study|Lost to Follow-up|1
6243396|NCT01876368|9927068|FG000|Overall Study|Non-compliance with study treatment|0
6243397|NCT01876368|9927069|FG001|Overall Study|Non-compliance with study treatment|1
6243398|NCT01876368|9927068|FG000|Overall Study|Physician Decision|0
6243399|NCT01876368|9927069|FG001|Overall Study|Physician Decision|2
6243400|NCT01876368|9927068|FG000|Overall Study|Protocol deviation|3
6243401|NCT01876368|9927069|FG001|Overall Study|Protocol deviation|3
6243402|NCT01876368|9927068|FG000|Overall Study|Subject/guardian decision|3
6243403|NCT01876368|9927069|FG001|Overall Study|Subject/guardian decision|1
6243404|NCT01876381|9927075|FG000|Overall Study|Lack of Efficacy|5
6243405|NCT01876381|9927075|FG000|Overall Study|Physician Decision|1
6243406|NCT01876381|9927075|FG000|Overall Study|Withdrawal by Subject|1
6243407|NCT01876420|9927079|FG000|Overall Study|Missed 30 day visit|1
6243408|NCT01876446|9927085|FG000|Overall Study|Death|0
6243409|NCT01876446|9927086|FG001|Overall Study|Death|1
6243410|NCT01876446|9927085|FG000|Overall Study|Withdrawal by Subject|1
6243411|NCT01876446|9927086|FG001|Overall Study|Withdrawal by Subject|2
6243412|NCT01876446|9927085|FG000|Overall Study|Physician Decision|1
6243413|NCT01876446|9927086|FG001|Overall Study|Physician Decision|3
6243414|NCT01876511|9927104|FG000|Overall Study|Disease Progression-clinical/radiologic|11
6243415|NCT01876511|9927105|FG001|Overall Study|Disease Progression-clinical/radiologic|24
6243416|NCT01876511|9927106|FG002|Overall Study|Disease Progression-clinical/radiologic|16
6243417|NCT01876511|9927104|FG000|Overall Study|Death (unrelated)|3
6243418|NCT01876511|9927105|FG001|Overall Study|Death (unrelated)|0
6243419|NCT01876511|9927106|FG002|Overall Study|Death (unrelated)|2
6243420|NCT01876511|9927104|FG000|Overall Study|Drug-related Toxicity|5
6243421|NCT01876511|9927105|FG001|Overall Study|Drug-related Toxicity|1
6243422|NCT01876511|9927106|FG002|Overall Study|Drug-related Toxicity|6
6243423|NCT01876511|9927104|FG000|Overall Study|Patient Decision|3
6243424|NCT01876511|9927105|FG001|Overall Study|Patient Decision|0
6243425|NCT01876511|9927106|FG002|Overall Study|Patient Decision|6
6243426|NCT01876511|9927104|FG000|Overall Study|Physician Decision|1
6243427|NCT01876511|9927105|FG001|Overall Study|Physician Decision|0
6243428|NCT01876511|9927106|FG002|Overall Study|Physician Decision|1
6243429|NCT01876706|9927116|FG000|Overall Study|BPH Intervention|9
6243430|NCT01876706|9927116|FG000|Overall Study|Lost to Follow-up|7
6085991|NCT00658021|9695649|FG001|28-Week Treatment Period|Did not receive treatment|0
6243431|NCT01876706|9927116|FG000|Overall Study|Withdrawals|6
6243432|NCT01876706|9927116|FG000|Overall Study|Death|3
6243433|NCT01876732|9927120|FG000|Overall Study|MMA was not over 800mg/dL|75
6243434|NCT01876784|9927127|FG000|Overall Study|Withdrawal by Subject|17
6243435|NCT01876784|9927128|FG001|Overall Study|Withdrawal by Subject|2
6243436|NCT01876784|9927127|FG000|Overall Study|Adverse Event|15
6243437|NCT01876784|9927128|FG001|Overall Study|Adverse Event|2
6243438|NCT01876784|9927127|FG000|Overall Study|Protocol Violation|1
6243439|NCT01876784|9927128|FG001|Overall Study|Protocol Violation|0
6243440|NCT01876784|9927127|FG000|Overall Study|Disease progression|37
6243441|NCT01876784|9927128|FG001|Overall Study|Disease progression|67
6243442|NCT01876784|9927127|FG000|Overall Study|Lost to Follow-up|0
6243443|NCT01876784|9927128|FG001|Overall Study|Lost to Follow-up|1
6243444|NCT01876784|9927127|FG000|Overall Study|Death|1
6243445|NCT01876784|9927128|FG001|Overall Study|Death|0
6243446|NCT01876784|9927127|FG000|Overall Study|Randomized but not treated|2
6243447|NCT01876784|9927128|FG001|Overall Study|Randomized but not treated|1
6243448|NCT01876784|9927127|FG000|Overall Study|Other than specified above|5
6243449|NCT01876784|9927128|FG001|Overall Study|Other than specified above|6
6243450|NCT01876784|9927127|FG000|Overall Study|Ongoing|41
6243451|NCT01876784|9927128|FG001|Overall Study|Ongoing|40
6243452|NCT01876810|9927134|FG000|Overall Study|Physician Decision|0
6243453|NCT01876810|9927135|FG001|Overall Study|Physician Decision|1
6243454|NCT01876823|9927144|FG000|Overall Study|Withdrawal by Subject|5
6243455|NCT01876823|9927144|FG000|Overall Study|Physician Decision|2
6243456|NCT01876823|9927144|FG000|Overall Study|Patients moved|2
6243457|NCT01876901|9927150|FG000|Overall Study|Protocol Violation|10
6243458|NCT01876901|9927151|FG001|Overall Study|Protocol Violation|2
6243459|NCT01876901|9927150|FG000|Overall Study|No or other surgical intervention|7
6243460|NCT01876901|9927151|FG001|Overall Study|No or other surgical intervention|5
6243461|NCT01876979|9927160|FG000|Overall Study|Physician Decision|2
6243462|NCT01876979|9927161|FG001|Overall Study|Physician Decision|3
6243463|NCT01877083|9927177|FG000|Treatment Phase|Disease Progression|10
6243464|NCT01877083|9927177|FG000|Treatment Phase|Clinical Progression|1
6243465|NCT01877083|9927177|FG000|Treatment Phase|Adverse Event|6
6243466|NCT01877083|9927177|FG000|Treatment Phase|Withdrawal by Subject|2
6243467|NCT01877083|9927177|FG000|Treatment Phase|Lost to Follow-up|1
6243468|NCT01877083|9927177|FG000|Extension Phase|Disease Progression|3
6243469|NCT01877083|9927177|FG000|Extension Phase|Adverse Event|2
6243470|NCT01877187|9927198|FG000|Overall Study|Death|2
6243471|NCT01877187|9927198|FG000|Overall Study|Withdrawal by Subject|4
6243472|NCT01877187|9927198|FG000|Overall Study|Lost to Follow-up|3
6243473|NCT01877187|9927198|FG000|Overall Study|Declining clinical status|11
6243474|NCT01877187|9927198|FG000|Overall Study|Liver transplant|2
6243475|NCT01877239|9927205|FG000|Overall Study|Adverse Event|4
6243476|NCT01877239|9927205|FG000|Overall Study|Disease Remission|1
6243477|NCT01877239|9927205|FG000|Overall Study|Withdrawal by Subject|4
6243478|NCT01877239|9927205|FG000|Overall Study|Other|2
6243479|NCT01877239|9927205|FG000|Overall Study|Lack of Efficacy|4
6243480|NCT01877239|9927205|FG000|Overall Study|Data not available|35
6243481|NCT01877265|9927209|FG000|Treatment Period 1|Sponsor Decision|0
6243482|NCT01877265|9927210|FG001|Treatment Period 1|Sponsor Decision|0
6243483|NCT01877265|9927211|FG002|Treatment Period 1|Sponsor Decision|1
6243484|NCT01877265|9927212|FG003|Treatment Period 1|Sponsor Decision|0
6243485|NCT01877265|9927213|FG004|Treatment Period 1|Sponsor Decision|0
6085992|NCT00658021|9695650|FG002|28-Week Treatment Period|Did not receive treatment|0
6085993|NCT00658021|9695648|FG000|Long-term Safety Follow-up Period|Withdrawal by Subject|0
6085994|NCT00658021|9695649|FG001|Long-term Safety Follow-up Period|Withdrawal by Subject|1
6085995|NCT00658021|9695650|FG002|Long-term Safety Follow-up Period|Withdrawal by Subject|0
6085996|NCT00658021|9695648|FG000|Long-term Safety Follow-up Period|Physician Decision|0
6085997|NCT00658021|9695649|FG001|Long-term Safety Follow-up Period|Physician Decision|2
6085998|NCT00658021|9695650|FG002|Long-term Safety Follow-up Period|Physician Decision|0
6085999|NCT00658320|9695671|FG000|Core Study: 12 Months|Subject withdrew consent|5
6086000|NCT00658320|9695672|FG001|Core Study: 12 Months|Subject withdrew consent|3
6086001|NCT00658320|9695671|FG000|Extension Study: Month 12 to Month 24|Subject withdrew consent|3
6086002|NCT00658320|9695672|FG001|Extension Study: Month 12 to Month 24|Subject withdrew consent|0
6086003|NCT00658320|9695671|FG000|Extension Study: Month 12 to Month 24|Did not receive study drug in Extension|3
6086004|NCT00658320|9695672|FG001|Extension Study: Month 12 to Month 24|Did not receive study drug in Extension|7
6086005|NCT00658320|9695671|FG000|Extension Study: After Month 24|Subject withdrew consent|2
6086006|NCT00658320|9695672|FG001|Extension Study: After Month 24|Subject withdrew consent|0
6086007|NCT00658333|9695682|FG000|Overall Study|Adverse Event|2
6243486|NCT01877265|9927214|FG005|Treatment Period 1|Sponsor Decision|0
6243487|NCT01877265|9927209|FG000|Washout Period 2 (at Least 14 Days)|Lost to Follow-up|0
6243488|NCT01877265|9927210|FG001|Washout Period 2 (at Least 14 Days)|Lost to Follow-up|0
6086008|NCT00658333|9695683|FG001|Overall Study|Adverse Event|1
6243489|NCT01877265|9927211|FG002|Washout Period 2 (at Least 14 Days)|Lost to Follow-up|0
6243490|NCT01877265|9927212|FG003|Washout Period 2 (at Least 14 Days)|Lost to Follow-up|0
6243491|NCT01877265|9927213|FG004|Washout Period 2 (at Least 14 Days)|Lost to Follow-up|0
6243492|NCT01877265|9927214|FG005|Washout Period 2 (at Least 14 Days)|Lost to Follow-up|1
6243493|NCT01877265|9927209|FG000|Treatment Period 3|Lost to Follow-up|1
6086009|NCT00658359|9695692|FG000|Overall Study|Death|3
6086010|NCT00658359|9695693|FG001|Overall Study|Death|1
6086011|NCT00658359|9695694|FG002|Overall Study|Death|2
6086012|NCT00658359|9695692|FG000|Overall Study|Adverse Event|13
6086013|NCT00658359|9695693|FG001|Overall Study|Adverse Event|6
6086014|NCT00658359|9695694|FG002|Overall Study|Adverse Event|9
6086015|NCT00658359|9695692|FG000|Overall Study|Protocol Violation|1
6086016|NCT00658359|9695693|FG001|Overall Study|Protocol Violation|0
6086017|NCT00658359|9695694|FG002|Overall Study|Protocol Violation|0
6086018|NCT00658359|9695692|FG000|Overall Study|Includes protocol Amendments 3 and 4|2
6086019|NCT00658359|9695693|FG001|Overall Study|Includes protocol Amendments 3 and 4|31
6086020|NCT00658359|9695694|FG002|Overall Study|Includes protocol Amendments 3 and 4|29
6243494|NCT01877265|9927210|FG001|Treatment Period 3|Lost to Follow-up|0
6243495|NCT01877265|9927211|FG002|Treatment Period 3|Lost to Follow-up|0
6243496|NCT01877265|9927212|FG003|Treatment Period 3|Lost to Follow-up|0
6243497|NCT01877265|9927213|FG004|Treatment Period 3|Lost to Follow-up|0
6243498|NCT01877265|9927214|FG005|Treatment Period 3|Lost to Follow-up|0
6243499|NCT01877278|9927227|FG000|Overall Study|Lost to Follow-up|3
6243500|NCT01877278|9927228|FG001|Overall Study|Lost to Follow-up|3
6243501|NCT01877408|9927236|FG000|Overall Study|Lost to Follow-up|0
6243502|NCT01877408|9927237|FG001|Overall Study|Lost to Follow-up|2
6243503|NCT01877421|9927276|FG000|Phase 2|Lost to Follow-up|0
6243504|NCT01877421|9927277|FG001|Phase 2|Lost to Follow-up|0
6243505|NCT01877421|9927278|FG002|Phase 2|Lost to Follow-up|0
6243506|NCT01877421|9927279|FG003|Phase 2|Lost to Follow-up|0
6243507|NCT01877421|9927280|FG004|Phase 2|Lost to Follow-up|0
6243508|NCT01877421|9927281|FG005|Phase 2|Lost to Follow-up|0
6243509|NCT01877421|9927282|FG006|Phase 2|Lost to Follow-up|1
6243510|NCT01877421|9927283|FG007|Phase 2|Lost to Follow-up|0
6243511|NCT01877421|9927284|FG008|Phase 2|Lost to Follow-up|0
6243512|NCT01877421|9927285|FG009|Phase 2|Lost to Follow-up|0
6243513|NCT01877421|9927286|FG010|Phase 2|Lost to Follow-up|0
6243514|NCT01877421|9927287|FG011|Phase 2|Lost to Follow-up|0
6243515|NCT01877421|9927288|FG012|Phase 2|Lost to Follow-up|0
6243516|NCT01877421|9927289|FG013|Phase 2|Lost to Follow-up|0
6243517|NCT01877421|9927290|FG014|Phase 2|Lost to Follow-up|0
6243518|NCT01877421|9927291|FG015|Phase 2|Lost to Follow-up|0
6243519|NCT01877421|9927292|FG016|Phase 2|Lost to Follow-up|0
6243520|NCT01877421|9927293|FG017|Phase 2|Lost to Follow-up|0
6243521|NCT01877421|9927276|FG000|Phase 2|Withdrawal by Subject|0
6243522|NCT01877421|9927277|FG001|Phase 2|Withdrawal by Subject|0
6243523|NCT01877421|9927278|FG002|Phase 2|Withdrawal by Subject|0
6243524|NCT01877421|9927279|FG003|Phase 2|Withdrawal by Subject|0
6243525|NCT01877421|9927280|FG004|Phase 2|Withdrawal by Subject|0
6243526|NCT01877421|9927281|FG005|Phase 2|Withdrawal by Subject|0
6243527|NCT01877421|9927282|FG006|Phase 2|Withdrawal by Subject|0
6243528|NCT01877421|9927283|FG007|Phase 2|Withdrawal by Subject|0
6243529|NCT01877421|9927284|FG008|Phase 2|Withdrawal by Subject|1
6243530|NCT01877421|9927285|FG009|Phase 2|Withdrawal by Subject|0
6243531|NCT01877421|9927286|FG010|Phase 2|Withdrawal by Subject|1
6243532|NCT01877421|9927287|FG011|Phase 2|Withdrawal by Subject|0
6243533|NCT01877421|9927288|FG012|Phase 2|Withdrawal by Subject|1
6086021|NCT00658359|9695692|FG000|Overall Study|Withdrawal by Subject|7
6086022|NCT00658359|9695693|FG001|Overall Study|Withdrawal by Subject|4
6086023|NCT00658359|9695694|FG002|Overall Study|Withdrawal by Subject|2
6189176|NCT01397409|9844268|FG006|Stage 3|Adverse Event|0
6189177|NCT01397409|9844269|FG007|Stage 3|Adverse Event|1
6189178|NCT01397409|9844270|FG008|Stage 3|Adverse Event|0
6189179|NCT01397409|9844271|FG009|Stage 3|Adverse Event|0
6189180|NCT01397409|9844262|FG000|Stage 3|Other Miscellaneous Reasons|0
6189181|NCT01397409|9844263|FG001|Stage 3|Other Miscellaneous Reasons|0
6189182|NCT01397409|9844264|FG002|Stage 3|Other Miscellaneous Reasons|0
6189183|NCT01397409|9844265|FG003|Stage 3|Other Miscellaneous Reasons|0
6189184|NCT01397409|9844266|FG004|Stage 3|Other Miscellaneous Reasons|0
6189185|NCT01397409|9844267|FG005|Stage 3|Other Miscellaneous Reasons|0
6189186|NCT01397409|9844268|FG006|Stage 3|Other Miscellaneous Reasons|0
6189187|NCT01397409|9844269|FG007|Stage 3|Other Miscellaneous Reasons|1
6189188|NCT01397409|9844270|FG008|Stage 3|Other Miscellaneous Reasons|0
6189189|NCT01397409|9844271|FG009|Stage 3|Other Miscellaneous Reasons|0
6189190|NCT01397422|9844298|FG000|Overall Study|Adverse Event|0
6189191|NCT01397422|9844299|FG001|Overall Study|Adverse Event|3
6189192|NCT01397422|9844300|FG002|Overall Study|Adverse Event|3
6189193|NCT01397422|9844301|FG003|Overall Study|Adverse Event|8
6189194|NCT01397422|9844298|FG000|Overall Study|Withdrawal by Subject|1
6189195|NCT01397422|9844299|FG001|Overall Study|Withdrawal by Subject|0
6189196|NCT01397422|9844300|FG002|Overall Study|Withdrawal by Subject|0
6189197|NCT01397422|9844301|FG003|Overall Study|Withdrawal by Subject|0
6243534|NCT01877421|9927289|FG013|Phase 2|Withdrawal by Subject|0
6243535|NCT01877421|9927290|FG014|Phase 2|Withdrawal by Subject|0
6243536|NCT01877421|9927291|FG015|Phase 2|Withdrawal by Subject|1
6243537|NCT01877421|9927292|FG016|Phase 2|Withdrawal by Subject|0
6243538|NCT01877421|9927293|FG017|Phase 2|Withdrawal by Subject|0
6243539|NCT01877421|9927276|FG000|Phase 2|Protocol Violation|0
6243540|NCT01877421|9927277|FG001|Phase 2|Protocol Violation|0
6243541|NCT01877421|9927278|FG002|Phase 2|Protocol Violation|0
6243542|NCT01877421|9927279|FG003|Phase 2|Protocol Violation|0
6243543|NCT01877421|9927280|FG004|Phase 2|Protocol Violation|0
6243544|NCT01877421|9927281|FG005|Phase 2|Protocol Violation|0
6243545|NCT01877421|9927282|FG006|Phase 2|Protocol Violation|0
6243546|NCT01877421|9927283|FG007|Phase 2|Protocol Violation|0
6243547|NCT01877421|9927284|FG008|Phase 2|Protocol Violation|0
6243548|NCT01877421|9927285|FG009|Phase 2|Protocol Violation|0
6243549|NCT01877421|9927286|FG010|Phase 2|Protocol Violation|1
6243550|NCT01877421|9927287|FG011|Phase 2|Protocol Violation|0
6243551|NCT01877421|9927288|FG012|Phase 2|Protocol Violation|0
6243552|NCT01877421|9927289|FG013|Phase 2|Protocol Violation|0
6243553|NCT01877421|9927290|FG014|Phase 2|Protocol Violation|0
6243554|NCT01877421|9927291|FG015|Phase 2|Protocol Violation|0
6243555|NCT01877421|9927292|FG016|Phase 2|Protocol Violation|0
6243556|NCT01877421|9927293|FG017|Phase 2|Protocol Violation|0
6243557|NCT01877551|9927379|FG000|Overall Study|Physician Decision|0
6243558|NCT01877551|9927380|FG001|Overall Study|Physician Decision|1
6243559|NCT01877668|9927408|FG000|Overall Study|Death|0
6243560|NCT01877668|9927409|FG001|Overall Study|Death|0
6243561|NCT01877668|9927410|FG002|Overall Study|Death|0
6243562|NCT01877668|9927411|FG003|Overall Study|Death|1
6243563|NCT01877668|9927412|FG004|Overall Study|Death|0
6243564|NCT01877668|9927408|FG000|Overall Study|No longer met study criteria|1
6243565|NCT01877668|9927409|FG001|Overall Study|No longer met study criteria|0
6243566|NCT01877668|9927410|FG002|Overall Study|No longer met study criteria|1
6086024|NCT00658359|9695692|FG000|Overall Study|Lost to Follow-up|2
6086025|NCT00658359|9695693|FG001|Overall Study|Lost to Follow-up|2
6086026|NCT00658359|9695694|FG002|Overall Study|Lost to Follow-up|4
6086027|NCT00658359|9695692|FG000|Overall Study|Lack of Efficacy|0
6086028|NCT00658359|9695693|FG001|Overall Study|Lack of Efficacy|1
6086029|NCT00658359|9695694|FG002|Overall Study|Lack of Efficacy|0
6086030|NCT00658528|9695727|FG000|Overall Study|Adverse Event|5
6086031|NCT00658528|9695728|FG001|Overall Study|Adverse Event|7
6243567|NCT01877668|9927411|FG003|Overall Study|No longer met study criteria|0
6243568|NCT01877668|9927412|FG004|Overall Study|No longer met study criteria|0
6243569|NCT01877668|9927408|FG000|Overall Study|Insufficient clinical response|0
6243570|NCT01877668|9927409|FG001|Overall Study|Insufficient clinical response|1
6243571|NCT01877668|9927410|FG002|Overall Study|Insufficient clinical response|2
6243572|NCT01877668|9927411|FG003|Overall Study|Insufficient clinical response|2
6243573|NCT01877668|9927412|FG004|Overall Study|Insufficient clinical response|0
6243574|NCT01877668|9927408|FG000|Overall Study|Lost to Follow-up|0
6243575|NCT01877668|9927409|FG001|Overall Study|Lost to Follow-up|2
6243576|NCT01877668|9927410|FG002|Overall Study|Lost to Follow-up|1
6243577|NCT01877668|9927411|FG003|Overall Study|Lost to Follow-up|0
6243578|NCT01877668|9927412|FG004|Overall Study|Lost to Follow-up|0
6243579|NCT01877668|9927408|FG000|Overall Study|Withdrawal by Subject|2
6243580|NCT01877668|9927409|FG001|Overall Study|Withdrawal by Subject|0
6243581|NCT01877668|9927410|FG002|Overall Study|Withdrawal by Subject|3
6243582|NCT01877668|9927411|FG003|Overall Study|Withdrawal by Subject|2
6243583|NCT01877668|9927412|FG004|Overall Study|Withdrawal by Subject|2
6243584|NCT01877668|9927408|FG000|Overall Study|Other|1
6243585|NCT01877668|9927409|FG001|Overall Study|Other|1
6243586|NCT01877668|9927410|FG002|Overall Study|Other|1
6243587|NCT01877668|9927411|FG003|Overall Study|Other|1
6243588|NCT01877668|9927412|FG004|Overall Study|Other|3
6243589|NCT01877668|9927408|FG000|Overall Study|Protocol Violation|1
6243590|NCT01877668|9927409|FG001|Overall Study|Protocol Violation|1
6243591|NCT01877668|9927410|FG002|Overall Study|Protocol Violation|0
6243592|NCT01877668|9927411|FG003|Overall Study|Protocol Violation|0
6243593|NCT01877668|9927412|FG004|Overall Study|Protocol Violation|3
6243594|NCT01877668|9927408|FG000|Overall Study|Adverse event related to study drug|2
6243595|NCT01877668|9927409|FG001|Overall Study|Adverse event related to study drug|2
6243596|NCT01877668|9927410|FG002|Overall Study|Adverse event related to study drug|2
6243597|NCT01877668|9927411|FG003|Overall Study|Adverse event related to study drug|2
6243598|NCT01877668|9927412|FG004|Overall Study|Adverse event related to study drug|1
6243599|NCT01877668|9927408|FG000|Overall Study|Adverse event unrelated to study drug|4
6243600|NCT01877668|9927409|FG001|Overall Study|Adverse event unrelated to study drug|1
6243601|NCT01877668|9927410|FG002|Overall Study|Adverse event unrelated to study drug|2
6243602|NCT01877668|9927411|FG003|Overall Study|Adverse event unrelated to study drug|0
6243603|NCT01877668|9927412|FG004|Overall Study|Adverse event unrelated to study drug|1
6243604|NCT01877720|9927428|FG000|Overall Study|Adverse Event|1
6243605|NCT01877720|9927429|FG001|Overall Study|Adverse Event|0
6243606|NCT01877915|9927437|FG000|Overall Study|Lost to Follow-up|10
6243607|NCT01877915|9927438|FG001|Overall Study|Lost to Follow-up|9
6243608|NCT01877915|9927437|FG000|Overall Study|Withdrawal by Subject|42
6243609|NCT01877915|9927438|FG001|Overall Study|Withdrawal by Subject|55
6243610|NCT01877915|9927437|FG000|Overall Study|Other|2
6243611|NCT01877915|9927438|FG001|Overall Study|Other|4
6086032|NCT00658528|9695727|FG000|Overall Study|Lost to Follow-up|14
6086033|NCT00658528|9695728|FG001|Overall Study|Lost to Follow-up|22
6243612|NCT01878084|9927456|FG000|Overall Study|Physician Decision|2
6243613|NCT01878097|9927463|FG000|Baseline|Surveys not fully completed|2497
6243614|NCT01878097|9927464|FG001|Baseline|Surveys not fully completed|1800
6243615|NCT01878097|9927463|FG000|Implementation Year 1|Surveys not fully completed|3202
6243616|NCT01878097|9927464|FG001|Implementation Year 1|Surveys not fully completed|2549
6243617|NCT01878097|9927463|FG000|Implementation Year 2|Surveys not fully completed|3281
6243618|NCT01878097|9927464|FG001|Implementation Year 2|Surveys not fully completed|2841
6243619|NCT01878097|9927463|FG000|Implementation Year 3|Surveys not fully completed|3494
6243620|NCT01878097|9927464|FG001|Implementation Year 3|Surveys not fully completed|2980
6243621|NCT01878097|9927463|FG000|Implementation Year 4|Surveys not fully completed|3604
6243622|NCT01878097|9927464|FG001|Implementation Year 4|Surveys not fully completed|3007
6243623|NCT01878149|9927472|FG000|Overall Study|Did Not Meet Eligibility Criteria|2
6243624|NCT01878149|9927473|FG001|Overall Study|Did Not Meet Eligibility Criteria|2
6243625|NCT01878175|9927479|FG000|Overall Study|Developed contraindicated health problem|2
6243626|NCT01878214|9927486|FG000|Overall Study|Withdrawal by Subject|18
6243627|NCT01878214|9927487|FG001|Overall Study|Withdrawal by Subject|7
6243628|NCT01878214|9927486|FG000|Overall Study|Death|0
6243629|NCT01878214|9927487|FG001|Overall Study|Death|1
6243630|NCT01878214|9927486|FG000|Overall Study|Lost to Follow-up|35
6243631|NCT01878214|9927487|FG001|Overall Study|Lost to Follow-up|36
6243632|NCT01878253|9927493|FG000|Overall Study|Death|1
6086034|NCT00658528|9695727|FG000|Overall Study|Withdrawal by Subject|8
6086035|NCT00658528|9695728|FG001|Overall Study|Withdrawal by Subject|6
6086036|NCT00658528|9695727|FG000|Overall Study|Withdrawal of consent|5
6086037|NCT00658528|9695728|FG001|Overall Study|Withdrawal of consent|6
6086038|NCT00658528|9695727|FG000|Overall Study|Other|8
6086039|NCT00658528|9695728|FG001|Overall Study|Other|4
6086040|NCT00658541|9695734|FG000|Washout Period of 7 Days|Withdrawal by Subject|1
6086041|NCT00658541|9695735|FG001|Washout Period of 7 Days|Withdrawal by Subject|1
6086042|NCT00658541|9695734|FG000|Washout Period of 7 Days|Withdrawal by Subject|0
6086043|NCT00658541|9695735|FG001|Washout Period of 7 Days|Withdrawal by Subject|1
6086044|NCT00658567|9695744|FG000|Overall Study|Adverse Event|5
6086045|NCT00658567|9695745|FG001|Overall Study|Adverse Event|2
6086046|NCT00658567|9695746|FG002|Overall Study|Adverse Event|3
6086047|NCT00658567|9695744|FG000|Overall Study|Voluntary Withdrawal of Consent|2
6086048|NCT00658567|9695745|FG001|Overall Study|Voluntary Withdrawal of Consent|0
6086049|NCT00658567|9695746|FG002|Overall Study|Voluntary Withdrawal of Consent|2
6086050|NCT00658567|9695744|FG000|Overall Study|Physician Decision|0
6086051|NCT00658567|9695745|FG001|Overall Study|Physician Decision|1
6086052|NCT00658567|9695746|FG002|Overall Study|Physician Decision|0
6243633|NCT01878253|9927493|FG000|Overall Study|SIdus System Removal|3
6243634|NCT01878253|9927493|FG000|Overall Study|Withdrawal by Subject|1
6243635|NCT01878253|9927493|FG000|Overall Study|Lost to Follow-up|2
6243636|NCT01878253|9927493|FG000|Overall Study|Completed Study w/o Follow-up Data|2
6243637|NCT01878292|9927505|FG000|Randomized|Protocol Violation|1
6243638|NCT01878292|9927506|FG001|Randomized|Protocol Violation|0
6243639|NCT01878292|9927507|FG002|Randomized|Protocol Violation|0
6243640|NCT01878292|9927505|FG000|Randomized|Lost to Follow-up|1
6243641|NCT01878292|9927506|FG001|Randomized|Lost to Follow-up|0
6243642|NCT01878292|9927507|FG002|Randomized|Lost to Follow-up|0
6243643|NCT01878292|9927505|FG000|Randomized|Adverse Event|1
6243644|NCT01878292|9927506|FG001|Randomized|Adverse Event|0
6243645|NCT01878292|9927507|FG002|Randomized|Adverse Event|0
6243646|NCT01878292|9927505|FG000|Double-blind Treatment Period|Other Reasons|2
6243647|NCT01878292|9927506|FG001|Double-blind Treatment Period|Other Reasons|0
6243648|NCT01878292|9927507|FG002|Double-blind Treatment Period|Other Reasons|0
6243649|NCT01878292|9927505|FG000|Double-blind Treatment Period|Lost to Follow-up|6
6243650|NCT01878292|9927506|FG001|Double-blind Treatment Period|Lost to Follow-up|3
6243651|NCT01878292|9927507|FG002|Double-blind Treatment Period|Lost to Follow-up|1
6243652|NCT01878292|9927505|FG000|Double-blind Treatment Period|Withdrawal by Subject|9
6243653|NCT01878292|9927506|FG001|Double-blind Treatment Period|Withdrawal by Subject|7
6243654|NCT01878292|9927507|FG002|Double-blind Treatment Period|Withdrawal by Subject|8
6243655|NCT01878292|9927505|FG000|Double-blind Treatment Period|Protocol Violation|3
6243656|NCT01878292|9927506|FG001|Double-blind Treatment Period|Protocol Violation|4
6243657|NCT01878292|9927507|FG002|Double-blind Treatment Period|Protocol Violation|2
6243658|NCT01878292|9927505|FG000|Double-blind Treatment Period|Lack of Efficacy|5
6243659|NCT01878292|9927506|FG001|Double-blind Treatment Period|Lack of Efficacy|3
6243660|NCT01878292|9927507|FG002|Double-blind Treatment Period|Lack of Efficacy|0
6243661|NCT01878292|9927505|FG000|Double-blind Treatment Period|Adverse Event|4
6243662|NCT01878292|9927506|FG001|Double-blind Treatment Period|Adverse Event|9
6243663|NCT01878292|9927507|FG002|Double-blind Treatment Period|Adverse Event|8
6243664|NCT01878292|9927505|FG000|Double-blind Down-Taper Period|Withdrawal by Subject|5
6243665|NCT01878292|9927506|FG001|Double-blind Down-Taper Period|Withdrawal by Subject|8
6243666|NCT01878292|9927507|FG002|Double-blind Down-Taper Period|Withdrawal by Subject|4
6086053|NCT00658567|9695744|FG000|Overall Study|At Discretion of Sponsor|1
6086054|NCT00658567|9695745|FG001|Overall Study|At Discretion of Sponsor|1
6243667|NCT01878383|9927517|FG000|Overall Study|Lost to Follow-up|0
6243668|NCT01878383|9927518|FG001|Overall Study|Lost to Follow-up|1499
6243669|NCT01878890|9927588|FG000|Overall Study|Protocol Violation|0
6086055|NCT00658567|9695746|FG002|Overall Study|At Discretion of Sponsor|1
6243670|NCT01878890|9927589|FG001|Overall Study|Protocol Violation|1
6243671|NCT01878890|9927590|FG002|Overall Study|Protocol Violation|0
6243672|NCT01878890|9927591|FG003|Overall Study|Protocol Violation|0
6243673|NCT01879072|9927606|FG000|Overall Study|Withdrawal by Subject|121
6243674|NCT01879072|9927606|FG000|Overall Study|Not Transplanted|30
6243675|NCT01879319|9927621|FG000|Overall Study|Withdrawal by Subject|1
6243676|NCT01879319|9927622|FG001|Overall Study|Withdrawal by Subject|0
6243677|NCT01879319|9927621|FG000|Overall Study|Lost to Follow-up|1
6243678|NCT01879319|9927622|FG001|Overall Study|Lost to Follow-up|5
6243679|NCT01879410|9927677|FG000|Overall Study|Adverse Event|9
6243680|NCT01879410|9927678|FG001|Overall Study|Adverse Event|14
6243681|NCT01879410|9927677|FG000|Overall Study|Lack of Efficacy|4
6243682|NCT01879410|9927678|FG001|Overall Study|Lack of Efficacy|6
6243683|NCT01879410|9927677|FG000|Overall Study|Protocol Violation|1
6243684|NCT01879410|9927678|FG001|Overall Study|Protocol Violation|7
6243685|NCT01879410|9927677|FG000|Overall Study|Lost to Follow-up|2
6243686|NCT01879410|9927678|FG001|Overall Study|Lost to Follow-up|1
6243687|NCT01879410|9927677|FG000|Overall Study|Withdrawal by Subject|7
6243688|NCT01879410|9927678|FG001|Overall Study|Withdrawal by Subject|8
6243689|NCT01879410|9927677|FG000|Overall Study|Randomised in Error|1
6243690|NCT01879410|9927678|FG001|Overall Study|Randomised in Error|2
6243691|NCT01879553|9927690|FG000|Overall Study|Withdrawal by Subject|1
6243692|NCT01879553|9927691|FG001|Overall Study|Withdrawal by Subject|0
6243693|NCT01879579|9927700|FG000|Overall Study|Phone incompatible with texting platform|3
6243694|NCT01879579|9927701|FG001|Overall Study|Phone incompatible with texting platform|0
6243695|NCT01879579|9927700|FG000|Overall Study|Did not enroll in texting platform|1
6243696|NCT01879579|9927701|FG001|Overall Study|Did not enroll in texting platform|0
6243697|NCT01879579|9927700|FG000|Overall Study|Did not initiate insulin treatment|1
6086056|NCT00658606|9695756|FG000|Overall Study|Adverse Event|2
6086057|NCT00658606|9695757|FG001|Overall Study|Adverse Event|1
6243698|NCT01879579|9927701|FG001|Overall Study|Did not initiate insulin treatment|0
6243699|NCT01879579|9927700|FG000|Overall Study|Phenotypic type 1 diabetes|0
6243700|NCT01879579|9927701|FG001|Overall Study|Phenotypic type 1 diabetes|1
6243701|NCT01879579|9927700|FG000|Overall Study|Discontinued insulin - possible allergy|0
6243702|NCT01879579|9927701|FG001|Overall Study|Discontinued insulin - possible allergy|1
6243703|NCT01879618|9927710|FG000|Overall Study|Does not meet entrance criteria|1
6243704|NCT01879618|9927710|FG000|Overall Study|Withdrawal by Subject|1
6243705|NCT01879618|9927710|FG000|Overall Study|Surgery;changed schedule; not available|8
6243706|NCT01879618|9927710|FG000|Overall Study|Protocol Violation|6
6243707|NCT01879618|9927710|FG000|Overall Study|Adverse Event|5
6243708|NCT01879683|9927714|FG000|Overall Study|Did not Complete 4-week Follow-up Visit|1
6243709|NCT01879722|9927728|FG000|Overall Study|Pretreatment Event/Adverse Event|0
6243710|NCT01879722|9927729|FG001|Overall Study|Pretreatment Event/Adverse Event|1
6243711|NCT01879722|9927730|FG002|Overall Study|Pretreatment Event/Adverse Event|0
6243712|NCT01879722|9927731|FG003|Overall Study|Pretreatment Event/Adverse Event|1
6243713|NCT01879722|9927732|FG004|Overall Study|Pretreatment Event/Adverse Event|1
6243714|NCT01879722|9927733|FG005|Overall Study|Pretreatment Event/Adverse Event|0
6243715|NCT01879722|9927734|FG006|Overall Study|Pretreatment Event/Adverse Event|0
6243716|NCT01879722|9927735|FG007|Overall Study|Pretreatment Event/Adverse Event|1
6243717|NCT01879722|9927736|FG008|Overall Study|Pretreatment Event/Adverse Event|1
6243718|NCT01879722|9927737|FG009|Overall Study|Pretreatment Event/Adverse Event|0
6243719|NCT01879722|9927728|FG000|Overall Study|Voluntary Withdrawal|0
6243720|NCT01879722|9927729|FG001|Overall Study|Voluntary Withdrawal|0
6243721|NCT01879722|9927730|FG002|Overall Study|Voluntary Withdrawal|0
6243722|NCT01879722|9927731|FG003|Overall Study|Voluntary Withdrawal|0
6243723|NCT01879722|9927732|FG004|Overall Study|Voluntary Withdrawal|0
6243724|NCT01879722|9927733|FG005|Overall Study|Voluntary Withdrawal|0
6243725|NCT01879722|9927734|FG006|Overall Study|Voluntary Withdrawal|0
6243726|NCT01879722|9927735|FG007|Overall Study|Voluntary Withdrawal|0
6243727|NCT01879722|9927736|FG008|Overall Study|Voluntary Withdrawal|1
6243728|NCT01879722|9927737|FG009|Overall Study|Voluntary Withdrawal|0
6270444|NCT02151682|9971247|FG005|Part 2: Observ. Aft. Tapent. Extension|Various other|2
6270445|NCT02151773|9971265|FG000|Overall Study|Protocol Deviation|64
6270446|NCT02151786|9971269|FG000|Overall Study|Unavailability of Case Report Form|26
6270447|NCT02151786|9971269|FG000|Overall Study|Outside the Contract Period|1
6270448|NCT02151786|9971269|FG000|Overall Study|Randomized, not Treated|1
6270449|NCT02151786|9971269|FG000|Overall Study|Unavailability of Information|8
6270450|NCT02151851|9971275|FG000|Overall Study|Lack of Efficacy|67
6270451|NCT02151851|9971276|FG001|Overall Study|Lack of Efficacy|94
6270452|NCT02151851|9971275|FG000|Overall Study|Protocol Violation|0
6270453|NCT02151851|9971276|FG001|Overall Study|Protocol Violation|1
6270454|NCT02151851|9971275|FG000|Overall Study|Withdrawal by Subject|2
6270455|NCT02151851|9971276|FG001|Overall Study|Withdrawal by Subject|5
6270456|NCT02151851|9971275|FG000|Overall Study|Medical impairment|1
6270457|NCT02151851|9971276|FG001|Overall Study|Medical impairment|0
6270458|NCT02151851|9971275|FG000|Overall Study|Low compliance to study visits|0
6270459|NCT02151851|9971276|FG001|Overall Study|Low compliance to study visits|1
6270460|NCT02151851|9971275|FG000|Overall Study|Subject entered into study in error|0
6086058|NCT00658606|9695756|FG000|Overall Study|Lack of Efficacy|6
6270461|NCT02151851|9971276|FG001|Overall Study|Subject entered into study in error|1
6270462|NCT02151851|9971275|FG000|Overall Study|Adverse Event|6
6270463|NCT02151851|9971276|FG001|Overall Study|Adverse Event|28
6270464|NCT02151903|9971295|FG000|Overall Study|Withdrawal by Subject|1
6270465|NCT02151903|9971296|FG001|Overall Study|Withdrawal by Subject|0
6270466|NCT02151903|9971295|FG000|Overall Study|Progressive disease|2
6086059|NCT00658606|9695757|FG001|Overall Study|Lack of Efficacy|3
6243729|NCT04495829|9927771|FG000|Overall Study|Lost to Follow-up|2
6243730|NCT04495829|9927771|FG000|Overall Study|Inclusion criterion not met|3
6243731|NCT03861052|9927779|FG000|Overall Study|Adverse Event|1
6243732|NCT03861052|9927780|FG001|Overall Study|Adverse Event|1
6243733|NCT03861052|9927781|FG002|Overall Study|Adverse Event|2
6243734|NCT03861052|9927782|FG003|Overall Study|Adverse Event|4
6243735|NCT03861052|9927779|FG000|Overall Study|Lost to Follow-up|0
6243736|NCT03861052|9927780|FG001|Overall Study|Lost to Follow-up|0
6243737|NCT03861052|9927781|FG002|Overall Study|Lost to Follow-up|0
6243738|NCT03861052|9927782|FG003|Overall Study|Lost to Follow-up|1
6243739|NCT03861052|9927779|FG000|Overall Study|Physician Decision|0
6243740|NCT03861052|9927780|FG001|Overall Study|Physician Decision|1
6243741|NCT03861052|9927781|FG002|Overall Study|Physician Decision|0
6243742|NCT03861052|9927782|FG003|Overall Study|Physician Decision|0
6243743|NCT03861052|9927779|FG000|Overall Study|Withdrawal by Subject|2
6243744|NCT03861052|9927780|FG001|Overall Study|Withdrawal by Subject|5
6243745|NCT03861052|9927781|FG002|Overall Study|Withdrawal by Subject|3
6243746|NCT03861052|9927782|FG003|Overall Study|Withdrawal by Subject|0
6243747|NCT03861052|9927779|FG000|Overall Study|Relocation to other city|1
6243748|NCT03861052|9927780|FG001|Overall Study|Relocation to other city|0
6243749|NCT03861052|9927781|FG002|Overall Study|Relocation to other city|0
6243750|NCT03861052|9927782|FG003|Overall Study|Relocation to other city|0
6243751|NCT03846453|9927799|FG000|Placebo Run-in (14 Days)|Eligibility Criteria Not Met|465
6243752|NCT03846453|9927800|FG001|Placebo Run-in (14 Days)|Eligibility Criteria Not Met|0
6243753|NCT03846453|9927801|FG002|Placebo Run-in (14 Days)|Eligibility Criteria Not Met|0
6243754|NCT03846453|9927799|FG000|Placebo Run-in (14 Days)|Withdrawal by Subject|3
6243755|NCT03846453|9927800|FG001|Placebo Run-in (14 Days)|Withdrawal by Subject|0
6243756|NCT03846453|9927801|FG002|Placebo Run-in (14 Days)|Withdrawal by Subject|0
6243757|NCT03846453|9927799|FG000|Placebo Run-in (14 Days)|Physician Decision|1
6243758|NCT03846453|9927800|FG001|Placebo Run-in (14 Days)|Physician Decision|0
6243759|NCT03846453|9927801|FG002|Placebo Run-in (14 Days)|Physician Decision|0
6243760|NCT03846453|9927799|FG000|Placebo Run-in (14 Days)|Other|2
6243761|NCT03846453|9927800|FG001|Placebo Run-in (14 Days)|Other|0
6243762|NCT03846453|9927801|FG002|Placebo Run-in (14 Days)|Other|0
6243763|NCT03846453|9927799|FG000|Randomized Treatment Period (Days 57±3)|Adverse Event|0
6243764|NCT03846453|9927800|FG001|Randomized Treatment Period (Days 57±3)|Adverse Event|16
6243765|NCT03846453|9927801|FG002|Randomized Treatment Period (Days 57±3)|Adverse Event|8
6243766|NCT03846453|9927799|FG000|Randomized Treatment Period (Days 57±3)|Protocol Violation|0
6243767|NCT03846453|9927800|FG001|Randomized Treatment Period (Days 57±3)|Protocol Violation|6
6243768|NCT03846453|9927801|FG002|Randomized Treatment Period (Days 57±3)|Protocol Violation|5
6243769|NCT03846453|9927799|FG000|Randomized Treatment Period (Days 57±3)|Administrative Reasons|0
6243770|NCT03846453|9927800|FG001|Randomized Treatment Period (Days 57±3)|Administrative Reasons|2
6243771|NCT03846453|9927801|FG002|Randomized Treatment Period (Days 57±3)|Administrative Reasons|4
6243772|NCT03846453|9927799|FG000|Randomized Treatment Period (Days 57±3)|Withdrawal by Subject|0
6243773|NCT03846453|9927800|FG001|Randomized Treatment Period (Days 57±3)|Withdrawal by Subject|2
6243774|NCT03846453|9927801|FG002|Randomized Treatment Period (Days 57±3)|Withdrawal by Subject|4
6243775|NCT03846453|9927799|FG000|Randomized Treatment Period (Days 57±3)|Other|0
6243776|NCT03846453|9927800|FG001|Randomized Treatment Period (Days 57±3)|Other|1
6243777|NCT03846453|9927801|FG002|Randomized Treatment Period (Days 57±3)|Other|4
6243780|NCT03605862|9927820|FG000|Overall Study|Withdrawal by Subject|12
6243781|NCT03605862|9927821|FG001|Overall Study|Withdrawal by Subject|9
6243782|NCT03605862|9927820|FG000|Overall Study|Adverse Event|2
6243783|NCT03605862|9927821|FG001|Overall Study|Adverse Event|1
6243784|NCT03605862|9927820|FG000|Overall Study|Physician Decision|3
6243785|NCT03605862|9927821|FG001|Overall Study|Physician Decision|1
6243786|NCT03605862|9927820|FG000|Overall Study|"Other reasons included failure to attend follow up visits or inability to use the eDiary."|11
6243787|NCT03605862|9927821|FG001|Overall Study|"Other reasons included failure to attend follow up visits or inability to use the eDiary."|15
6243788|NCT03541252|9927828|FG000|Overall Study|Withdrawal by Subject|1
6243789|NCT03401112|9927837|FG000|Overall Study|Adverse Event|1
6243790|NCT03401112|9927838|FG001|Overall Study|Adverse Event|2
6243791|NCT03401112|9927839|FG002|Overall Study|Adverse Event|3
6243792|NCT03401112|9927840|FG003|Overall Study|Adverse Event|2
6243793|NCT03401112|9927841|FG004|Overall Study|Adverse Event|0
6243794|NCT03401112|9927837|FG000|Overall Study|Lost to Follow-up|1
6243795|NCT03401112|9927838|FG001|Overall Study|Lost to Follow-up|0
6243796|NCT03401112|9927839|FG002|Overall Study|Lost to Follow-up|0
6243797|NCT03401112|9927840|FG003|Overall Study|Lost to Follow-up|0
6243798|NCT03401112|9927841|FG004|Overall Study|Lost to Follow-up|0
6243799|NCT03401112|9927837|FG000|Overall Study|Noncompliance|1
6243800|NCT03401112|9927838|FG001|Overall Study|Noncompliance|2
6243801|NCT03401112|9927839|FG002|Overall Study|Noncompliance|3
6243802|NCT03401112|9927840|FG003|Overall Study|Noncompliance|0
6243803|NCT03401112|9927841|FG004|Overall Study|Noncompliance|0
6243804|NCT03401112|9927837|FG000|Overall Study|Did not Meet Inclusion Criteria|1
6243805|NCT03401112|9927838|FG001|Overall Study|Did not Meet Inclusion Criteria|0
6243806|NCT03401112|9927839|FG002|Overall Study|Did not Meet Inclusion Criteria|0
6243807|NCT03401112|9927840|FG003|Overall Study|Did not Meet Inclusion Criteria|0
6243808|NCT03401112|9927841|FG004|Overall Study|Did not Meet Inclusion Criteria|0
6243809|NCT03401112|9927837|FG000|Overall Study|Withdrawal by Subject|0
6243810|NCT03401112|9927838|FG001|Overall Study|Withdrawal by Subject|3
6243811|NCT03401112|9927839|FG002|Overall Study|Withdrawal by Subject|2
6243812|NCT03401112|9927840|FG003|Overall Study|Withdrawal by Subject|1
6243813|NCT03401112|9927841|FG004|Overall Study|Withdrawal by Subject|0
6243814|NCT03401112|9927837|FG000|Overall Study|Physician Decision|0
6243815|NCT03401112|9927838|FG001|Overall Study|Physician Decision|0
6243816|NCT03401112|9927839|FG002|Overall Study|Physician Decision|0
6243817|NCT03401112|9927840|FG003|Overall Study|Physician Decision|2
6243818|NCT03401112|9927841|FG004|Overall Study|Physician Decision|0
6243819|NCT03401112|9927837|FG000|Overall Study|Study was Terminated by Sponsor|0
6243820|NCT03401112|9927838|FG001|Overall Study|Study was Terminated by Sponsor|0
6243821|NCT03401112|9927839|FG002|Overall Study|Study was Terminated by Sponsor|0
6243822|NCT03401112|9927840|FG003|Overall Study|Study was Terminated by Sponsor|1
6243823|NCT03401112|9927841|FG004|Overall Study|Study was Terminated by Sponsor|0
6243824|NCT03401112|9927837|FG000|Overall Study|Day 1 Assessment not Done|1
6243825|NCT03401112|9927838|FG001|Overall Study|Day 1 Assessment not Done|0
6243826|NCT03401112|9927839|FG002|Overall Study|Day 1 Assessment not Done|0
6243827|NCT03401112|9927840|FG003|Overall Study|Day 1 Assessment not Done|0
6243828|NCT03401112|9927841|FG004|Overall Study|Day 1 Assessment not Done|0
6243829|NCT03401112|9927837|FG000|Overall Study|Not Dosed|0
6243830|NCT03401112|9927838|FG001|Overall Study|Not Dosed|0
6243831|NCT03401112|9927839|FG002|Overall Study|Not Dosed|1
6243832|NCT03401112|9927840|FG003|Overall Study|Not Dosed|0
6243833|NCT03401112|9927841|FG004|Overall Study|Not Dosed|0
6243834|NCT03401112|9927837|FG000|Overall Study|Missed Clinical Visit|0
6243835|NCT03401112|9927838|FG001|Overall Study|Missed Clinical Visit|0
6243836|NCT03401112|9927839|FG002|Overall Study|Missed Clinical Visit|1
6243837|NCT03401112|9927840|FG003|Overall Study|Missed Clinical Visit|0
6243838|NCT03401112|9927841|FG004|Overall Study|Missed Clinical Visit|0
6243839|NCT03401112|9927837|FG000|Overall Study|Missed Doses|0
6243840|NCT03401112|9927838|FG001|Overall Study|Missed Doses|0
6243841|NCT03401112|9927839|FG002|Overall Study|Missed Doses|1
6243842|NCT03401112|9927840|FG003|Overall Study|Missed Doses|0
6243843|NCT03401112|9927841|FG004|Overall Study|Missed Doses|0
6243844|NCT03383666|9927868|FG000|Overall Study|Withdrawal by Subject|2
6243845|NCT03383666|9927868|FG000|Overall Study|Lost to Follow-up|2
6270467|NCT02151903|9971296|FG001|Overall Study|Progressive disease|1
6270468|NCT02152007|9971354|FG000|Overall Study|Withdrawal by Subject|1
6270469|NCT02152137|9971368|FG000|Overall Study|Withdrawal by Subject|1
6270470|NCT02152137|9971368|FG000|Overall Study|Originally assigned to Arm B|3
6086060|NCT00658606|9695756|FG000|Overall Study|Lost to Follow-up|1
6270471|NCT02152163|9971374|FG000|Overall Study|Physician Decision|12
6270472|NCT02152163|9971375|FG001|Overall Study|Physician Decision|13
6270473|NCT02152345|9971383|FG000|Overall Study|Case Cancellations|2
6270474|NCT02152345|9971384|FG001|Overall Study|Case Cancellations|4
6270475|NCT02152345|9971383|FG000|Overall Study|Withdrawal by Subject|2
6270476|NCT02152345|9971384|FG001|Overall Study|Withdrawal by Subject|1
6270477|NCT02152371|9971392|FG000|Overall Study|Adverse Event|6
6270478|NCT02152371|9971393|FG001|Overall Study|Adverse Event|2
6270479|NCT02152371|9971392|FG000|Overall Study|Withdrawal by Subject|3
6270480|NCT02152371|9971393|FG001|Overall Study|Withdrawal by Subject|7
6270481|NCT02152371|9971392|FG000|Overall Study|Protocol Violation|2
6270482|NCT02152371|9971393|FG001|Overall Study|Protocol Violation|3
6270483|NCT02152371|9971392|FG000|Overall Study|Lost to Follow-up|1
6270484|NCT02152371|9971393|FG001|Overall Study|Lost to Follow-up|0
6270485|NCT02152371|9971392|FG000|Overall Study|Lack of Efficacy|0
6270486|NCT02152371|9971393|FG001|Overall Study|Lack of Efficacy|1
6270487|NCT02152371|9971392|FG000|Overall Study|Physician Decision|0
6270488|NCT02152371|9971393|FG001|Overall Study|Physician Decision|2
6270489|NCT02152371|9971392|FG000|Overall Study|Reason Not Given|0
6270490|NCT02152371|9971393|FG001|Overall Study|Reason Not Given|1
6270491|NCT02152384|9971399|FG000|Period 1|Withdrawal by Subject|0
6270492|NCT02152384|9971400|FG001|Period 1|Withdrawal by Subject|1
6270493|NCT02152384|9971399|FG000|Period 1|Adverse Event|1
6270494|NCT02152384|9971400|FG001|Period 1|Adverse Event|1
6270495|NCT02152605|9971428|FG000|Overall Study|Adverse Event|6
6270496|NCT02152605|9971429|FG001|Overall Study|Adverse Event|8
6270497|NCT02152605|9971428|FG000|Overall Study|Lack of Efficacy|7
6270498|NCT02152605|9971429|FG001|Overall Study|Lack of Efficacy|4
6270499|NCT02152605|9971428|FG000|Overall Study|Protocol deviation|1
6270500|NCT02152605|9971429|FG001|Overall Study|Protocol deviation|4
6270501|NCT02152605|9971428|FG000|Overall Study|Lost to Follow-up|1
6270502|NCT02152605|9971429|FG001|Overall Study|Lost to Follow-up|0
6270503|NCT02152605|9971428|FG000|Overall Study|Withdrew consent|4
6270504|NCT02152605|9971429|FG001|Overall Study|Withdrew consent|2
6270505|NCT02152631|9971438|FG000|Overall Study|Adverse Event|32
6270506|NCT02152631|9971439|FG001|Overall Study|Adverse Event|4
6270507|NCT02152631|9971438|FG000|Overall Study|Withdrawal by Subject|13
6270508|NCT02152631|9971439|FG001|Overall Study|Withdrawal by Subject|16
6270509|NCT02152631|9971438|FG000|Overall Study|Noncompliance with study drug|1
6270510|NCT02152631|9971439|FG001|Overall Study|Noncompliance with study drug|0
6243846|NCT03041701|9927883|FG000|Ph I: Dose Level 1 and 2 Dose Escalation|Not evaluable for toxicity|1
6243847|NCT03041701|9927884|FG001|Ph I: Dose Level 1 and 2 Dose Escalation|Not evaluable for toxicity|1
6243848|NCT03041701|9927885|FG002|Ph I: Dose Level 1 and 2 Dose Escalation|Not evaluable for toxicity|0
6243849|NCT03041701|9927883|FG000|Ph 2:Dose Level 1 Maximum Tolerated Dose|Unacceptable further treatment|0
6243850|NCT03041701|9927884|FG001|Ph 2:Dose Level 1 Maximum Tolerated Dose|Unacceptable further treatment|0
6243851|NCT03041701|9927885|FG002|Ph 2:Dose Level 1 Maximum Tolerated Dose|Unacceptable further treatment|1
6243852|NCT03000179|9927896|FG000|Overall Study|Lost to Follow-up|2
6243853|NCT02876835|9927902|FG000|Treatment Period (51.1 Month)|Other|1
6243854|NCT02876835|9927903|FG001|Treatment Period (51.1 Month)|Other|0
6243855|NCT02876835|9927902|FG000|Treatment Period (51.1 Month)|Investigator Site Closed|6
6243856|NCT02876835|9927903|FG001|Treatment Period (51.1 Month)|Investigator Site Closed|13
6243857|NCT02876835|9927902|FG000|Treatment Period (51.1 Month)|Withdrawal by Subject|32
6243858|NCT02876835|9927903|FG001|Treatment Period (51.1 Month)|Withdrawal by Subject|23
6243859|NCT02876835|9927902|FG000|Treatment Period (51.1 Month)|Lost to Follow-up|25
6243860|NCT02876835|9927903|FG001|Treatment Period (51.1 Month)|Lost to Follow-up|29
6243861|NCT02860039|9927912|FG000|Overall Study|Death|4
6243862|NCT02860039|9927913|FG001|Overall Study|Death|0
6243863|NCT02860039|9927912|FG000|Overall Study|Lost to Follow-up|2
6243864|NCT02860039|9927913|FG001|Overall Study|Lost to Follow-up|2
6243865|NCT02860039|9927912|FG000|Overall Study|Protocol Violation|3
6243866|NCT02860039|9927913|FG001|Overall Study|Protocol Violation|1
6243867|NCT02860039|9927912|FG000|Overall Study|Withdrawal by Subject|1
6243868|NCT02860039|9927913|FG001|Overall Study|Withdrawal by Subject|0
6243869|NCT02860039|9927912|FG000|Overall Study|Not otherwise eligible|1
6243870|NCT02860039|9927913|FG001|Overall Study|Not otherwise eligible|1
6243871|NCT01492361|9927942|FG000|Overall Study|Withdrawal by Subject|281
6243872|NCT01492361|9927943|FG001|Overall Study|Withdrawal by Subject|297
6243873|NCT01492361|9927942|FG000|Overall Study|Physician Decision|12
6243874|NCT01492361|9927943|FG001|Overall Study|Physician Decision|12
6243875|NCT01492361|9927942|FG000|Overall Study|Lost to Follow-up|6
6243876|NCT01492361|9927943|FG001|Overall Study|Lost to Follow-up|13
6243877|NCT01492361|9927942|FG000|Overall Study|Other than specified above|106
6243878|NCT01492361|9927943|FG001|Overall Study|Other than specified above|138
6243879|NCT01296711|9927957|FG000|Overall Study|Adverse Event|3
6243880|NCT01296711|9927958|FG001|Overall Study|Adverse Event|1
6243881|NCT01296711|9927959|FG002|Overall Study|Adverse Event|4
6243882|NCT01296711|9927960|FG003|Overall Study|Adverse Event|3
6243883|NCT01296711|9927961|FG004|Overall Study|Adverse Event|1
6243884|NCT01296711|9927962|FG005|Overall Study|Adverse Event|6
6243885|NCT01296711|9927963|FG006|Overall Study|Adverse Event|11
6243886|NCT01296711|9927964|FG007|Overall Study|Adverse Event|3
6243887|NCT01296711|9927957|FG000|Overall Study|Lack of Efficacy|1
6243888|NCT01296711|9927958|FG001|Overall Study|Lack of Efficacy|4
6243889|NCT01296711|9927959|FG002|Overall Study|Lack of Efficacy|1
6243890|NCT01296711|9927960|FG003|Overall Study|Lack of Efficacy|1
6243891|NCT01296711|9927961|FG004|Overall Study|Lack of Efficacy|1
6243892|NCT01296711|9927962|FG005|Overall Study|Lack of Efficacy|0
6243893|NCT01296711|9927963|FG006|Overall Study|Lack of Efficacy|2
6243894|NCT01296711|9927964|FG007|Overall Study|Lack of Efficacy|3
6243895|NCT01296711|9927957|FG000|Overall Study|Lost to Follow-up|0
6243896|NCT01296711|9927958|FG001|Overall Study|Lost to Follow-up|0
6243897|NCT01296711|9927959|FG002|Overall Study|Lost to Follow-up|1
6243898|NCT01296711|9927960|FG003|Overall Study|Lost to Follow-up|1
6243899|NCT01296711|9927961|FG004|Overall Study|Lost to Follow-up|2
6243900|NCT01296711|9927962|FG005|Overall Study|Lost to Follow-up|0
6243901|NCT01296711|9927963|FG006|Overall Study|Lost to Follow-up|4
6243902|NCT01296711|9927964|FG007|Overall Study|Lost to Follow-up|2
6243903|NCT01296711|9927957|FG000|Overall Study|Protocol Violation|0
6243904|NCT01296711|9927958|FG001|Overall Study|Protocol Violation|0
6243905|NCT01296711|9927959|FG002|Overall Study|Protocol Violation|0
6243906|NCT01296711|9927960|FG003|Overall Study|Protocol Violation|1
6243907|NCT01296711|9927961|FG004|Overall Study|Protocol Violation|1
6243908|NCT01296711|9927962|FG005|Overall Study|Protocol Violation|0
6243909|NCT01296711|9927963|FG006|Overall Study|Protocol Violation|0
6243910|NCT01296711|9927964|FG007|Overall Study|Protocol Violation|0
6243911|NCT01296711|9927957|FG000|Overall Study|Withdrawal by Subject|4
6243912|NCT01296711|9927958|FG001|Overall Study|Withdrawal by Subject|2
6243913|NCT01296711|9927959|FG002|Overall Study|Withdrawal by Subject|2
6243914|NCT01296711|9927960|FG003|Overall Study|Withdrawal by Subject|1
6243915|NCT01296711|9927961|FG004|Overall Study|Withdrawal by Subject|1
6243916|NCT01296711|9927962|FG005|Overall Study|Withdrawal by Subject|1
6243917|NCT01296711|9927963|FG006|Overall Study|Withdrawal by Subject|2
6243918|NCT01296711|9927964|FG007|Overall Study|Withdrawal by Subject|1
6243919|NCT01296711|9927957|FG000|Overall Study|Study termination|8
6243920|NCT01296711|9927958|FG001|Overall Study|Study termination|1
6243921|NCT01296711|9927959|FG002|Overall Study|Study termination|5
6243922|NCT01296711|9927960|FG003|Overall Study|Study termination|4
6243923|NCT01296711|9927961|FG004|Overall Study|Study termination|4
6243924|NCT01296711|9927962|FG005|Overall Study|Study termination|4
6243925|NCT01296711|9927963|FG006|Overall Study|Study termination|8
6243926|NCT01296711|9927964|FG007|Overall Study|Study termination|10
6243927|NCT01296711|9927957|FG000|Overall Study|Continued elevated liver enzymes|0
6243928|NCT01296711|9927958|FG001|Overall Study|Continued elevated liver enzymes|0
6243929|NCT01296711|9927959|FG002|Overall Study|Continued elevated liver enzymes|0
6243930|NCT01296711|9927960|FG003|Overall Study|Continued elevated liver enzymes|1
6243931|NCT01296711|9927961|FG004|Overall Study|Continued elevated liver enzymes|0
6243932|NCT01296711|9927962|FG005|Overall Study|Continued elevated liver enzymes|0
6243933|NCT01296711|9927963|FG006|Overall Study|Continued elevated liver enzymes|0
6243934|NCT01296711|9927964|FG007|Overall Study|Continued elevated liver enzymes|0
6243935|NCT01296711|9927957|FG000|Overall Study|Methotrexate discontinued|0
6243936|NCT01296711|9927958|FG001|Overall Study|Methotrexate discontinued|0
6243937|NCT01296711|9927959|FG002|Overall Study|Methotrexate discontinued|0
6243938|NCT01296711|9927960|FG003|Overall Study|Methotrexate discontinued|1
6243939|NCT01296711|9927961|FG004|Overall Study|Methotrexate discontinued|0
6243940|NCT01296711|9927962|FG005|Overall Study|Methotrexate discontinued|0
6243941|NCT01296711|9927963|FG006|Overall Study|Methotrexate discontinued|0
6243942|NCT01296711|9927964|FG007|Overall Study|Methotrexate discontinued|0
6243943|NCT01296711|9927957|FG000|Overall Study|Investigator discretion|0
6243944|NCT01296711|9927958|FG001|Overall Study|Investigator discretion|0
6243945|NCT01296711|9927959|FG002|Overall Study|Investigator discretion|0
6243946|NCT01296711|9927960|FG003|Overall Study|Investigator discretion|0
6243947|NCT01296711|9927961|FG004|Overall Study|Investigator discretion|0
6243948|NCT01296711|9927962|FG005|Overall Study|Investigator discretion|0
6243949|NCT01296711|9927963|FG006|Overall Study|Investigator discretion|1
6243950|NCT01296711|9927964|FG007|Overall Study|Investigator discretion|0
6243951|NCT01296711|9927957|FG000|Overall Study|Other|0
6243952|NCT01296711|9927958|FG001|Overall Study|Other|0
6243953|NCT01296711|9927959|FG002|Overall Study|Other|0
6243954|NCT01296711|9927960|FG003|Overall Study|Other|0
6243955|NCT01296711|9927961|FG004|Overall Study|Other|0
6243956|NCT01296711|9927962|FG005|Overall Study|Other|0
6243957|NCT01296711|9927963|FG006|Overall Study|Other|1
6243958|NCT01296711|9927964|FG007|Overall Study|Other|0
6243959|NCT01296711|9927957|FG000|Overall Study|Required restricted steroid injections|0
6243960|NCT01296711|9927958|FG001|Overall Study|Required restricted steroid injections|0
6243961|NCT01296711|9927959|FG002|Overall Study|Required restricted steroid injections|0
6243962|NCT01296711|9927960|FG003|Overall Study|Required restricted steroid injections|0
6243963|NCT01296711|9927961|FG004|Overall Study|Required restricted steroid injections|0
6243964|NCT01296711|9927962|FG005|Overall Study|Required restricted steroid injections|0
6243965|NCT01296711|9927963|FG006|Overall Study|Required restricted steroid injections|1
6243966|NCT01296711|9927964|FG007|Overall Study|Required restricted steroid injections|0
6243967|NCT01296711|9927957|FG000|Overall Study|Ongoing missed appointments|0
6243968|NCT01296711|9927958|FG001|Overall Study|Ongoing missed appointments|0
6243969|NCT01296711|9927959|FG002|Overall Study|Ongoing missed appointments|0
6243970|NCT01296711|9927960|FG003|Overall Study|Ongoing missed appointments|0
6243971|NCT01296711|9927961|FG004|Overall Study|Ongoing missed appointments|0
6243972|NCT01296711|9927962|FG005|Overall Study|Ongoing missed appointments|0
6243973|NCT01296711|9927963|FG006|Overall Study|Ongoing missed appointments|1
6243974|NCT01296711|9927964|FG007|Overall Study|Ongoing missed appointments|0
6243975|NCT01296711|9927957|FG000|Overall Study|Failure to comply with visits|0
6243976|NCT01296711|9927958|FG001|Overall Study|Failure to comply with visits|0
6243977|NCT01296711|9927959|FG002|Overall Study|Failure to comply with visits|0
6243978|NCT01296711|9927960|FG003|Overall Study|Failure to comply with visits|0
6243979|NCT01296711|9927961|FG004|Overall Study|Failure to comply with visits|0
6243980|NCT01296711|9927962|FG005|Overall Study|Failure to comply with visits|0
6243981|NCT01296711|9927963|FG006|Overall Study|Failure to comply with visits|0
6243982|NCT01296711|9927964|FG007|Overall Study|Failure to comply with visits|1
6243983|NCT01296711|9927957|FG000|Overall Study|Patient decision due to transport|0
6243984|NCT01296711|9927958|FG001|Overall Study|Patient decision due to transport|0
6243985|NCT01296711|9927959|FG002|Overall Study|Patient decision due to transport|0
6243986|NCT01296711|9927960|FG003|Overall Study|Patient decision due to transport|0
6243987|NCT01296711|9927961|FG004|Overall Study|Patient decision due to transport|0
6243988|NCT01296711|9927962|FG005|Overall Study|Patient decision due to transport|0
6243989|NCT01296711|9927963|FG006|Overall Study|Patient decision due to transport|0
6243990|NCT01296711|9927964|FG007|Overall Study|Patient decision due to transport|1
6243991|NCT00084656|9927985|FG000|Overall Study|Other reasons|0
6243992|NCT00084656|9927986|FG001|Overall Study|Other reasons|12
6243993|NCT00084656|9927987|FG002|Overall Study|Other reasons|11
6243994|NCT00084656|9927985|FG000|Overall Study|Withdrawal by Subject|15
6243995|NCT00084656|9927986|FG001|Overall Study|Withdrawal by Subject|4
6243996|NCT00084656|9927987|FG002|Overall Study|Withdrawal by Subject|4
6243997|NCT00084656|9927985|FG000|Overall Study|Disease relapse|0
6243998|NCT00084656|9927986|FG001|Overall Study|Disease relapse|9
6243999|NCT00084656|9927987|FG002|Overall Study|Disease relapse|10
6244000|NCT00084656|9927985|FG000|Overall Study|Disease progression|9
6244001|NCT00084656|9927986|FG001|Overall Study|Disease progression|0
6244002|NCT00084656|9927987|FG002|Overall Study|Disease progression|0
6244003|NCT00084656|9927985|FG000|Overall Study|Lost to Follow-up|1
6244004|NCT00084656|9927986|FG001|Overall Study|Lost to Follow-up|0
6244005|NCT00084656|9927987|FG002|Overall Study|Lost to Follow-up|1
6244006|NCT01879852|9928026|FG000|Overall Study|Withdrawal by Subject|2
6244007|NCT01879852|9928027|FG001|Overall Study|Withdrawal by Subject|0
6244008|NCT01880086|9928063|FG000|Overall Study|Lost to Follow-up|1
6244009|NCT01880086|9928064|FG001|Overall Study|Lost to Follow-up|1
6244010|NCT01880424|9928098|FG000|Overall Study|Adverse Event|7
6244011|NCT01880424|9928099|FG001|Overall Study|Adverse Event|6
6244012|NCT01880424|9928098|FG000|Overall Study|Lack of Efficacy|1
6244013|NCT01880424|9928099|FG001|Overall Study|Lack of Efficacy|4
6244014|NCT01880424|9928098|FG000|Overall Study|Lost to Follow-up|3
6244015|NCT01880424|9928099|FG001|Overall Study|Lost to Follow-up|2
6244016|NCT01880424|9928098|FG000|Overall Study|Protocol Violation|11
6244017|NCT01880424|9928099|FG001|Overall Study|Protocol Violation|13
6244018|NCT01880424|9928098|FG000|Overall Study|Withdrawal by Subject|10
6244019|NCT01880424|9928099|FG001|Overall Study|Withdrawal by Subject|30
6244020|NCT01880424|9928098|FG000|Overall Study|Other|1
6244021|NCT01880424|9928099|FG001|Overall Study|Other|0
6244022|NCT01880437|9928108|FG000|Overall Study|Death|12
6244023|NCT01880437|9928109|FG001|Overall Study|Death|4
6244024|NCT01880437|9928110|FG002|Overall Study|Death|17
6244025|NCT01880437|9928108|FG000|Overall Study|Study terminated by Sponsor|3
6244026|NCT01880437|9928109|FG001|Overall Study|Study terminated by Sponsor|0
6244027|NCT01880437|9928110|FG002|Overall Study|Study terminated by Sponsor|2
6244028|NCT01880515|9928122|FG000|Overall Study|Lost to Follow-up|3
6244029|NCT01880515|9928123|FG001|Overall Study|Lost to Follow-up|2
6244030|NCT01880515|9928122|FG000|Overall Study|Disease Progression|5
6244031|NCT01880515|9928123|FG001|Overall Study|Disease Progression|7
6244032|NCT01880528|9928132|FG000|Overall Study|Other|1
6244033|NCT01880528|9928133|FG001|Overall Study|Other|1
6244034|NCT01880554|9928139|FG000|Overall Study|Protocol Violation|14
6244035|NCT01880554|9928139|FG000|Overall Study|Simon's design requirements|2
6244036|NCT01880593|9928146|FG000|Overall Study|Adverse Event|1
6244037|NCT01880593|9928147|FG001|Overall Study|Adverse Event|0
6244038|NCT01880593|9928146|FG000|Overall Study|Lack of Efficacy|1
6244039|NCT01880593|9928147|FG001|Overall Study|Lack of Efficacy|5
6244040|NCT01880593|9928146|FG000|Overall Study|Withdrawal by Subject|6
6244041|NCT01880593|9928147|FG001|Overall Study|Withdrawal by Subject|1
6244042|NCT01880736|9928175|FG000|Overall Study|Adverse Event|0
6244043|NCT01880736|9928176|FG001|Overall Study|Adverse Event|0
6244044|NCT01880736|9928177|FG002|Overall Study|Adverse Event|0
6244045|NCT01880736|9928178|FG003|Overall Study|Adverse Event|1
6244046|NCT01880736|9928175|FG000|Overall Study|Withdrawal Criteria|1
6244047|NCT01880736|9928176|FG001|Overall Study|Withdrawal Criteria|2
6244048|NCT01880736|9928177|FG002|Overall Study|Withdrawal Criteria|1
6244049|NCT01880736|9928178|FG003|Overall Study|Withdrawal Criteria|5
6244050|NCT01881009|9928199|FG000|Summer Camp Session (6 Days)|Unable to wear device|0
6244051|NCT01881009|9928200|FG001|Summer Camp Session (6 Days)|Unable to wear device|1
6244052|NCT01881126|9928231|FG000|Overall Study|Non-compliance|1
6244053|NCT01881126|9928232|FG001|Overall Study|Non-compliance|1
6244054|NCT01881126|9928231|FG000|Overall Study|Adverse Event|0
6244055|NCT01881126|9928232|FG001|Overall Study|Adverse Event|1
6244056|NCT01881230|9928241|FG000|Overall Study|Death|2
6244057|NCT01881230|9928242|FG001|Overall Study|Death|0
6244058|NCT01881230|9928243|FG002|Overall Study|Death|1
6244059|NCT01881230|9928241|FG000|Overall Study|Adverse Event|9
6244060|NCT01881230|9928242|FG001|Overall Study|Adverse Event|13
6244061|NCT01881230|9928243|FG002|Overall Study|Adverse Event|12
6244062|NCT01881230|9928241|FG000|Overall Study|Progressive Disease|31
6244063|NCT01881230|9928242|FG001|Overall Study|Progressive Disease|35
6244064|NCT01881230|9928243|FG002|Overall Study|Progressive Disease|36
6244065|NCT01881230|9928241|FG000|Overall Study|Symptomatic Deterioration|3
6244066|NCT01881230|9928242|FG001|Overall Study|Symptomatic Deterioration|3
6244067|NCT01881230|9928243|FG002|Overall Study|Symptomatic Deterioration|1
6244068|NCT01881230|9928241|FG000|Overall Study|Withdrawal by Subject|6
6244069|NCT01881230|9928242|FG001|Overall Study|Withdrawal by Subject|4
6244070|NCT01881230|9928243|FG002|Overall Study|Withdrawal by Subject|6
6244071|NCT01881230|9928241|FG000|Overall Study|Physician Decision|4
6244072|NCT01881230|9928242|FG001|Overall Study|Physician Decision|3
6244073|NCT01881230|9928243|FG002|Overall Study|Physician Decision|6
6244074|NCT01881230|9928241|FG000|Overall Study|Non-Compliance with Study Drug|1
6244075|NCT01881230|9928242|FG001|Overall Study|Non-Compliance with Study Drug|2
6244076|NCT01881230|9928243|FG002|Overall Study|Non-Compliance with Study Drug|0
6244077|NCT01881230|9928241|FG000|Overall Study|Given Commercially Available Drug|0
6244078|NCT01881230|9928242|FG001|Overall Study|Given Commercially Available Drug|0
6244079|NCT01881230|9928243|FG002|Overall Study|Given Commercially Available Drug|2
6244080|NCT01881230|9928241|FG000|Overall Study|Protocol Violation|1
6244081|NCT01881230|9928242|FG001|Overall Study|Protocol Violation|1
6244082|NCT01881230|9928243|FG002|Overall Study|Protocol Violation|0
6244083|NCT01881230|9928241|FG000|Overall Study|Miscellaneous|3
6244084|NCT01881230|9928242|FG001|Overall Study|Miscellaneous|3
6244085|NCT01881230|9928243|FG002|Overall Study|Miscellaneous|0
6244086|NCT01881230|9928241|FG000|Overall Study|Untreated: Other|0
6244087|NCT01881230|9928242|FG001|Overall Study|Untreated: Other|0
6244088|NCT01881230|9928243|FG002|Overall Study|Untreated: Other|1
6244089|NCT01881230|9928241|FG000|Overall Study|Untreated: Death|0
6244090|NCT01881230|9928242|FG001|Overall Study|Untreated: Death|0
6244091|NCT01881230|9928243|FG002|Overall Study|Untreated: Death|1
6244092|NCT01881230|9928241|FG000|Overall Study|Untreated: Withdrawal Before Study Start|1
6244093|NCT01881230|9928242|FG001|Overall Study|Untreated: Withdrawal Before Study Start|0
6244094|NCT01881230|9928243|FG002|Overall Study|Untreated: Withdrawal Before Study Start|0
6244095|NCT01881620|9928277|FG000|Overall Study|Protocol Violation|4
6244096|NCT01881737|9928281|FG000|Overall Study|Inclusion/Exclusion Criteria Not Met|3
6244097|NCT01881737|9928281|FG000|Overall Study|Withdrawal by Subject|1
6244098|NCT01881737|9928281|FG000|Overall Study|Worsening of baseline behavior|1
6244099|NCT01881750|9928289|FG000|Overall Study|Changes in concomitant therapies|2
6244100|NCT01881750|9928290|FG001|Overall Study|Changes in concomitant therapies|3
6244101|NCT01881750|9928289|FG000|Overall Study|Lost to Follow-up|0
6244102|NCT01881750|9928290|FG001|Overall Study|Lost to Follow-up|1
6244103|NCT01881776|9928301|FG000|Overall Study|Lost to Follow-up|1
6244104|NCT01881776|9928302|FG001|Overall Study|Lost to Follow-up|2
6244105|NCT01881776|9928303|FG002|Overall Study|Lost to Follow-up|1
6244106|NCT01881776|9928301|FG000|Overall Study|Protocol Violation|0
6244107|NCT01881776|9928302|FG001|Overall Study|Protocol Violation|2
6244108|NCT01881776|9928303|FG002|Overall Study|Protocol Violation|1
6244109|NCT01881789|9928317|FG000|Overall Study|Withdrawal by Subject|0
6244110|NCT01881789|9928318|FG001|Overall Study|Withdrawal by Subject|2
6244111|NCT01881789|9928319|FG002|Overall Study|Withdrawal by Subject|1
6244112|NCT01881789|9928320|FG003|Overall Study|Withdrawal by Subject|0
6244113|NCT01881789|9928321|FG004|Overall Study|Withdrawal by Subject|1
6244114|NCT01881789|9928322|FG005|Overall Study|Withdrawal by Subject|1
6244115|NCT01881789|9928317|FG000|Overall Study|Study Terminated by Sponsor|0
6244116|NCT01881789|9928318|FG001|Overall Study|Study Terminated by Sponsor|0
6244117|NCT01881789|9928319|FG002|Overall Study|Study Terminated by Sponsor|0
6244118|NCT01881789|9928320|FG003|Overall Study|Study Terminated by Sponsor|0
6244119|NCT01881789|9928321|FG004|Overall Study|Study Terminated by Sponsor|0
6244120|NCT01881789|9928322|FG005|Overall Study|Study Terminated by Sponsor|1
6244121|NCT01881789|9928317|FG000|Overall Study|Other|3
6244122|NCT01881789|9928318|FG001|Overall Study|Other|5
6244123|NCT01881789|9928319|FG002|Overall Study|Other|2
6244124|NCT01881789|9928320|FG003|Overall Study|Other|3
6244125|NCT01881789|9928321|FG004|Overall Study|Other|1
6244126|NCT01881789|9928322|FG005|Overall Study|Other|1
6244127|NCT01882088|9928361|FG000|Overall Study|Intolerance of esophageal manometry|1
6244128|NCT01882088|9928361|FG000|Overall Study|no possibility to place the catheter|1
6244129|NCT01882088|9928361|FG000|Overall Study|Protocol Violation|1
6244130|NCT01882088|9928361|FG000|Overall Study|inadequate pH-impedance tracings|2
6244131|NCT01882257|9928368|FG000|Study Origination to Beginning Therapy|Withdrawal by Subject|0
6244132|NCT01882257|9928369|FG001|Study Origination to Beginning Therapy|Withdrawal by Subject|2
6244133|NCT01882257|9928370|FG002|Study Origination to Beginning Therapy|Withdrawal by Subject|1
6244134|NCT01882257|9928368|FG000|Therapy Portion of Study (12 Months)|Withdrawal by Subject|0
6244135|NCT01882257|9928369|FG001|Therapy Portion of Study (12 Months)|Withdrawal by Subject|11
6244136|NCT01882257|9928370|FG002|Therapy Portion of Study (12 Months)|Withdrawal by Subject|4
6244137|NCT01882439|9928385|FG000|Overall Study|Adverse event related to study drug|3
6244138|NCT01882439|9928386|FG001|Overall Study|Adverse event related to study drug|8
6244139|NCT01882439|9928387|FG002|Overall Study|Adverse event related to study drug|1
6244140|NCT01882439|9928388|FG003|Overall Study|Adverse event related to study drug|2
6244141|NCT01882439|9928385|FG000|Overall Study|Pregnancy|0
6244142|NCT01882439|9928386|FG001|Overall Study|Pregnancy|1
6244143|NCT01882439|9928387|FG002|Overall Study|Pregnancy|0
6244144|NCT01882439|9928388|FG003|Overall Study|Pregnancy|0
6244145|NCT01882439|9928385|FG000|Overall Study|Protocol Violation|2
6244146|NCT01882439|9928386|FG001|Overall Study|Protocol Violation|2
6244147|NCT01882439|9928387|FG002|Overall Study|Protocol Violation|0
6244148|NCT01882439|9928388|FG003|Overall Study|Protocol Violation|1
6244149|NCT01882439|9928385|FG000|Overall Study|No longer willing to participate|1
6244150|NCT01882439|9928386|FG001|Overall Study|No longer willing to participate|4
6244151|NCT01882439|9928387|FG002|Overall Study|No longer willing to participate|2
6244152|NCT01882439|9928388|FG003|Overall Study|No longer willing to participate|3
6244153|NCT01882439|9928385|FG000|Overall Study|Medication error with no associated AE|0
6244154|NCT01882439|9928386|FG001|Overall Study|Medication error with no associated AE|0
6244155|NCT01882439|9928387|FG002|Overall Study|Medication error with no associated AE|2
6244156|NCT01882439|9928388|FG003|Overall Study|Medication error with no associated AE|0
6244157|NCT01882439|9928385|FG000|Overall Study|Insufficient clinical response|1
6244158|NCT01882439|9928386|FG001|Overall Study|Insufficient clinical response|4
6244159|NCT01882439|9928387|FG002|Overall Study|Insufficient clinical response|4
6244160|NCT01882439|9928388|FG003|Overall Study|Insufficient clinical response|2
6244161|NCT01882439|9928385|FG000|Overall Study|Adverse event unrelated to study drug|2
6244162|NCT01882439|9928386|FG001|Overall Study|Adverse event unrelated to study drug|2
6244163|NCT01882439|9928387|FG002|Overall Study|Adverse event unrelated to study drug|1
6244164|NCT01882439|9928388|FG003|Overall Study|Adverse event unrelated to study drug|1
6244165|NCT01882465|9928403|FG000|Period 1|Lens Discomfort|0
6244166|NCT01882465|9928404|FG001|Period 1|Lens Discomfort|0
6244167|NCT01882465|9928405|FG002|Period 1|Lens Discomfort|0
6244168|NCT01882465|9928406|FG003|Period 1|Lens Discomfort|1
6244169|NCT01882465|9928407|FG004|Period 1|Lens Discomfort|0
6244170|NCT01882465|9928408|FG005|Period 1|Lens Discomfort|0
6244171|NCT01882465|9928409|FG006|Period 1|Lens Discomfort|0
6244172|NCT01882465|9928403|FG000|Period 1|Withdrawal by Subject|0
6244173|NCT01882465|9928404|FG001|Period 1|Withdrawal by Subject|0
6244174|NCT01882465|9928405|FG002|Period 1|Withdrawal by Subject|0
6244175|NCT01882465|9928406|FG003|Period 1|Withdrawal by Subject|0
6244176|NCT01882465|9928407|FG004|Period 1|Withdrawal by Subject|0
6244177|NCT01882465|9928408|FG005|Period 1|Withdrawal by Subject|0
6244178|NCT01882465|9928409|FG006|Period 1|Withdrawal by Subject|1
6244179|NCT01882465|9928403|FG000|Period 2|Protocol Violation|0
6244180|NCT01882465|9928404|FG001|Period 2|Protocol Violation|0
6244181|NCT01882465|9928405|FG002|Period 2|Protocol Violation|0
6244182|NCT01882465|9928406|FG003|Period 2|Protocol Violation|0
6244183|NCT01882465|9928407|FG004|Period 2|Protocol Violation|1
6244184|NCT01882465|9928408|FG005|Period 2|Protocol Violation|0
6244185|NCT01882465|9928409|FG006|Period 2|Protocol Violation|0
6189198|NCT01397422|9844298|FG000|Overall Study|Increased bradykinesia related to PD|1
6189199|NCT01397422|9844299|FG001|Overall Study|Increased bradykinesia related to PD|0
6189200|NCT01397422|9844300|FG002|Overall Study|Increased bradykinesia related to PD|0
6189201|NCT01397422|9844301|FG003|Overall Study|Increased bradykinesia related to PD|0
6189202|NCT01397448|9844316|FG000|Overall Study|Adverse Event|4
6189203|NCT01397448|9844317|FG001|Overall Study|Adverse Event|4
6189204|NCT01397448|9844318|FG002|Overall Study|Adverse Event|6
6189205|NCT01397448|9844316|FG000|Overall Study|Withdrawal by Subject|4
6189206|NCT01397448|9844317|FG001|Overall Study|Withdrawal by Subject|4
6189207|NCT01397448|9844318|FG002|Overall Study|Withdrawal by Subject|3
6189208|NCT01397448|9844316|FG000|Overall Study|Lack of Efficacy|2
6189209|NCT01397448|9844317|FG001|Overall Study|Lack of Efficacy|0
6189210|NCT01397448|9844318|FG002|Overall Study|Lack of Efficacy|5
6189211|NCT01397448|9844316|FG000|Overall Study|Other|8
6189212|NCT01397448|9844317|FG001|Overall Study|Other|7
6189213|NCT01397448|9844318|FG002|Overall Study|Other|4
6189214|NCT01397461|9844329|FG000|Overall Study|Withdrawal by Subject|2
6189215|NCT01397461|9844330|FG001|Overall Study|Withdrawal by Subject|1
6189216|NCT01397461|9844331|FG002|Overall Study|Withdrawal by Subject|0
6189217|NCT01397461|9844329|FG000|Overall Study|Lost to Follow-up|0
6189218|NCT01397461|9844330|FG001|Overall Study|Lost to Follow-up|2
6189219|NCT01397461|9844331|FG002|Overall Study|Lost to Follow-up|1
6189220|NCT01397461|9844329|FG000|Overall Study|Lack of Efficacy|0
6189221|NCT01397461|9844330|FG001|Overall Study|Lack of Efficacy|3
6189222|NCT01397461|9844331|FG002|Overall Study|Lack of Efficacy|0
6189223|NCT01397461|9844329|FG000|Overall Study|Not treated|0
6189224|NCT01397461|9844330|FG001|Overall Study|Not treated|0
6189225|NCT01397461|9844331|FG002|Overall Study|Not treated|1
6189226|NCT01397747|9844371|FG000|Overall Study|Multitarget DNA test excluded|689
6189227|NCT01397747|9844371|FG000|Overall Study|Colonoscopy excluded|304
6189228|NCT01397747|9844371|FG000|Overall Study|FIT excluded|34
6189229|NCT01397786|9844379|FG000|Phase A|Lost to Follow-up|0
6189230|NCT01397786|9844380|FG001|Phase A|Lost to Follow-up|0
6189231|NCT01397786|9844381|FG002|Phase A|Lost to Follow-up|6
6189232|NCT01397786|9844379|FG000|Phase A|Adverse Event|0
6189233|NCT01397786|9844380|FG001|Phase A|Adverse Event|0
6189234|NCT01397786|9844381|FG002|Phase A|Adverse Event|8
6189235|NCT01397786|9844379|FG000|Phase A|Subject Met Withdrawal Criteria|0
6189236|NCT01397786|9844380|FG001|Phase A|Subject Met Withdrawal Criteria|0
6189237|NCT01397786|9844381|FG002|Phase A|Subject Met Withdrawal Criteria|7
6189238|NCT01397786|9844379|FG000|Phase A|Physician Decision|0
6189239|NCT01397786|9844380|FG001|Phase A|Physician Decision|0
6189240|NCT01397786|9844381|FG002|Phase A|Physician Decision|1
6189241|NCT01397786|9844379|FG000|Phase A|Withdrawal by Subject|0
6189242|NCT01397786|9844380|FG001|Phase A|Withdrawal by Subject|0
6189243|NCT01397786|9844381|FG002|Phase A|Withdrawal by Subject|5
6189244|NCT01397786|9844379|FG000|Phase A|Lack of Efficacy|0
6189245|NCT01397786|9844380|FG001|Phase A|Lack of Efficacy|0
6189246|NCT01397786|9844381|FG002|Phase A|Lack of Efficacy|1
6189247|NCT01397786|9844379|FG000|Phase B|Lost to Follow-up|22
6189248|NCT01397786|9844380|FG001|Phase B|Lost to Follow-up|12
6189249|NCT01397786|9844381|FG002|Phase B|Lost to Follow-up|22
6189250|NCT01397786|9844379|FG000|Phase B|Adverse Event|109
6189251|NCT01397786|9844380|FG001|Phase B|Adverse Event|23
6189252|NCT01397786|9844381|FG002|Phase B|Adverse Event|27
6189253|NCT01397786|9844379|FG000|Phase B|Subject Met Withdrawal Criteria|38
6189254|NCT01397786|9844380|FG001|Phase B|Subject Met Withdrawal Criteria|5
6189255|NCT01397786|9844381|FG002|Phase B|Subject Met Withdrawal Criteria|38
6189256|NCT01397786|9844379|FG000|Phase B|Physician Decision|9
6189257|NCT01397786|9844380|FG001|Phase B|Physician Decision|1
6189258|NCT01397786|9844381|FG002|Phase B|Physician Decision|3
6189259|NCT01397786|9844379|FG000|Phase B|Withdrawal by Subject|102
6189260|NCT01397786|9844380|FG001|Phase B|Withdrawal by Subject|45
6189261|NCT01397786|9844381|FG002|Phase B|Withdrawal by Subject|30
6189262|NCT01397786|9844379|FG000|Phase B|Protocol Deviation|1
6189263|NCT01397786|9844380|FG001|Phase B|Protocol Deviation|2
6189264|NCT01397786|9844381|FG002|Phase B|Protocol Deviation|4
6189265|NCT01397786|9844379|FG000|Phase B|Lack of Efficacy|22
6189266|NCT01397786|9844380|FG001|Phase B|Lack of Efficacy|7
6189267|NCT01397786|9844381|FG002|Phase B|Lack of Efficacy|14
6189268|NCT01397825|9844397|FG000|Overall Study|Progressive Disease|10
6189269|NCT01397825|9844398|FG001|Overall Study|Progressive Disease|3
6189270|NCT01397825|9844399|FG002|Overall Study|Progressive Disease|11
6244186|NCT01882647|9928429|FG000|Overall Study|Lost to Follow-up|2
6189271|NCT01397825|9844400|FG003|Overall Study|Progressive Disease|1
6189272|NCT01397825|9844401|FG004|Overall Study|Progressive Disease|0
6189273|NCT01397825|9844397|FG000|Overall Study|Symptomatic Deterioration|2
6189274|NCT01397825|9844398|FG001|Overall Study|Symptomatic Deterioration|0
6189275|NCT01397825|9844399|FG002|Overall Study|Symptomatic Deterioration|4
6189276|NCT01397825|9844400|FG003|Overall Study|Symptomatic Deterioration|0
6244187|NCT01882647|9928430|FG001|Overall Study|Lost to Follow-up|2
6244188|NCT01882647|9928429|FG000|Overall Study|Withdrawal by Subject|0
6244189|NCT01882647|9928430|FG001|Overall Study|Withdrawal by Subject|4
6244190|NCT01882803|9928449|FG000|Overall Study|Disease Progression|53
6244191|NCT01882803|9928449|FG000|Overall Study|Adverse Event|22
6244192|NCT01882803|9928449|FG000|Overall Study|Death|7
6244193|NCT01882803|9928449|FG000|Overall Study|Physician Decision|7
6244194|NCT01882803|9928449|FG000|Overall Study|Protocol Violation|1
6244195|NCT01882803|9928449|FG000|Overall Study|Withdrawal by Subject|4
6244196|NCT01882829|9928454|FG000|Overall Study|Adverse Event|4
6244197|NCT01882829|9928454|FG000|Overall Study|Protocol Violation|1
6244198|NCT01882829|9928454|FG000|Overall Study|Withdrawal by Subject|1
6244199|NCT01882907|9928464|FG000|Overall Study|Adverse Event|3
6244200|NCT01882907|9928465|FG001|Overall Study|Adverse Event|1
6244201|NCT01882907|9928464|FG000|Overall Study|Lack of Efficacy|0
6244202|NCT01882907|9928465|FG001|Overall Study|Lack of Efficacy|3
6244203|NCT01882907|9928464|FG000|Overall Study|Lost to Follow-up|1
6244204|NCT01882907|9928465|FG001|Overall Study|Lost to Follow-up|4
6244205|NCT01882907|9928464|FG000|Overall Study|Protocol Violation|10
6244206|NCT01882907|9928465|FG001|Overall Study|Protocol Violation|14
6244207|NCT01882907|9928464|FG000|Overall Study|Withdrawal by Subject|0
6244208|NCT01882907|9928465|FG001|Overall Study|Withdrawal by Subject|6
6244209|NCT01882985|9928473|FG000|Overall Study|Lost to Follow-up|1
6244210|NCT01882985|9928473|FG000|Overall Study|Withdrawal by Subject|1
6244211|NCT01883362|9928483|FG000|Treatment|Adverse Event|1
6244212|NCT01883362|9928484|FG001|Treatment|Adverse Event|8
6244213|NCT01883362|9928483|FG000|Treatment|Withdrawal by Subject|6
6244214|NCT01883362|9928484|FG001|Treatment|Withdrawal by Subject|2
6244215|NCT01883362|9928483|FG000|Treatment|Administrative problems|4
6244216|NCT01883362|9928484|FG001|Treatment|Administrative problems|1
6244217|NCT01883362|9928483|FG000|Treatment|Relapse|4
6244218|NCT01883362|9928484|FG001|Treatment|Relapse|2
6244219|NCT01883362|9928483|FG000|Treatment|Randomized, not treated|1
6244220|NCT01883362|9928484|FG001|Treatment|Randomized, not treated|1
6244221|NCT01883362|9928483|FG000|Post Treatment Follow-up|Protocol Violation|0
6244222|NCT01883362|9928484|FG001|Post Treatment Follow-up|Protocol Violation|1
6244223|NCT01883362|9928483|FG000|Post Treatment Follow-up|Withdrawal by Subject|4
6244224|NCT01883362|9928484|FG001|Post Treatment Follow-up|Withdrawal by Subject|3
6244225|NCT01883362|9928483|FG000|Post Treatment Follow-up|Lost to Follow-up|1
6244226|NCT01883362|9928484|FG001|Post Treatment Follow-up|Lost to Follow-up|4
6244227|NCT01883362|9928483|FG000|Post Treatment Follow-up|Administrative problems|2
6244228|NCT01883362|9928484|FG001|Post Treatment Follow-up|Administrative problems|0
6244229|NCT01883362|9928483|FG000|Post Treatment Follow-up|Death|8
6244230|NCT01883362|9928484|FG001|Post Treatment Follow-up|Death|4
6244231|NCT01883362|9928483|FG000|Post Treatment Follow-up|Relapse|1
6244232|NCT01883362|9928484|FG001|Post Treatment Follow-up|Relapse|2
6244233|NCT01883453|9928515|FG000|Overall Study|No episode of common cold|25
6244234|NCT01883453|9928516|FG001|Overall Study|No episode of common cold|23
6244235|NCT01883492|9928524|FG000|Overall Study|Lost to Follow-up|3
6244236|NCT01883492|9928525|FG001|Overall Study|Lost to Follow-up|4
6244237|NCT01883492|9928524|FG000|Overall Study|Surgery on contra-lateral hip|0
6244238|NCT01883492|9928525|FG001|Overall Study|Surgery on contra-lateral hip|1
6244239|NCT01883492|9928524|FG000|Overall Study|Poor X-ray quality|7
6244240|NCT01883492|9928525|FG001|Overall Study|Poor X-ray quality|4
6244241|NCT01883492|9928524|FG000|Overall Study|Withdrawal by Subject|1
6244242|NCT01883492|9928525|FG001|Overall Study|Withdrawal by Subject|0
6244243|NCT01883492|9928524|FG000|Overall Study|inappropriate implant used|1
6244244|NCT01883492|9928525|FG001|Overall Study|inappropriate implant used|1
6244245|NCT01883492|9928524|FG000|Overall Study|bone anatomy did not meet study criteria|1
6244246|NCT01883492|9928525|FG001|Overall Study|bone anatomy did not meet study criteria|1
6244247|NCT01883635|9928533|FG000|Overall Study|Withdrawal by Subject|4
6244248|NCT01883635|9928534|FG001|Overall Study|Withdrawal by Subject|0
6244249|NCT01883895|9928551|FG000|Overall Study|Lost to Follow-up|2
6244250|NCT01884025|9928570|FG000|Overall Study|Lost to Follow-up|3
6244251|NCT01884025|9928571|FG001|Overall Study|Lost to Follow-up|4
6244252|NCT01884311|9928586|FG000|Overall Study|Withdrawal by Subject|3
6244253|NCT01884311|9928586|FG000|Overall Study|withdrew consent due to AEs|1
6189277|NCT01397825|9844401|FG004|Overall Study|Symptomatic Deterioration|0
6189278|NCT01397825|9844397|FG000|Overall Study|Adverse Event|0
6189279|NCT01397825|9844398|FG001|Overall Study|Adverse Event|1
6189280|NCT01397825|9844399|FG002|Overall Study|Adverse Event|5
6189281|NCT01397825|9844400|FG003|Overall Study|Adverse Event|1
6189282|NCT01397825|9844401|FG004|Overall Study|Adverse Event|0
6189283|NCT01397825|9844397|FG000|Overall Study|Withdrawal by Subject|1
6189284|NCT01397825|9844398|FG001|Overall Study|Withdrawal by Subject|0
6244254|NCT01884311|9928586|FG000|Overall Study|Precautionary measure|1
6244255|NCT01884337|9928595|FG000|Treatment|Adverse Event|2
6244256|NCT01884337|9928596|FG001|Treatment|Adverse Event|2
6244257|NCT01884337|9928595|FG000|Treatment|Subj. request to discont. treatment|2
6244258|NCT01884337|9928596|FG001|Treatment|Subj. request to discont. treatment|0
6244259|NCT01884337|9928595|FG000|Follow-up Period|Lost to Follow-up|1
6244260|NCT01884337|9928596|FG001|Follow-up Period|Lost to Follow-up|1
6244261|NCT01884350|9928604|FG000|Primary Efficacy Analysis Set (24 Weeks)|Subject Withdrew Consent|17
6244262|NCT01884350|9928605|FG001|Primary Efficacy Analysis Set (24 Weeks)|Subject Withdrew Consent|20
6244263|NCT01884350|9928606|FG002|Primary Efficacy Analysis Set (24 Weeks)|Subject Withdrew Consent|0
6244264|NCT01884350|9928604|FG000|Primary Efficacy Analysis Set (24 Weeks)|Death|6
6244265|NCT01884350|9928605|FG001|Primary Efficacy Analysis Set (24 Weeks)|Death|4
6244266|NCT01884350|9928606|FG002|Primary Efficacy Analysis Set (24 Weeks)|Death|0
6189285|NCT01397825|9844399|FG002|Overall Study|Withdrawal by Subject|5
6189286|NCT01397825|9844400|FG003|Overall Study|Withdrawal by Subject|1
6189287|NCT01397825|9844401|FG004|Overall Study|Withdrawal by Subject|0
6189288|NCT01397890|9844426|FG000|Overall Study|Withdrawal by Subject|7
6189289|NCT01397890|9844427|FG001|Overall Study|Withdrawal by Subject|11
6189290|NCT01397890|9844426|FG000|Overall Study|Eligibility Criteria Not Fulfilled|7
6244267|NCT01884350|9928604|FG000|Primary Efficacy Analysis Set (24 Weeks)|Lost to Follow-up|0
6244268|NCT01884350|9928605|FG001|Primary Efficacy Analysis Set (24 Weeks)|Lost to Follow-up|1
6244269|NCT01884350|9928606|FG002|Primary Efficacy Analysis Set (24 Weeks)|Lost to Follow-up|0
6244270|NCT01884350|9928604|FG000|Primary Efficacy Analysis Set (24 Weeks)|Serious Adverse Event|7
6244271|NCT01884350|9928605|FG001|Primary Efficacy Analysis Set (24 Weeks)|Serious Adverse Event|6
6244272|NCT01884350|9928606|FG002|Primary Efficacy Analysis Set (24 Weeks)|Serious Adverse Event|0
6244273|NCT01884350|9928604|FG000|Primary Efficacy Analysis Set (24 Weeks)|Adverse Event|15
6244274|NCT01884350|9928605|FG001|Primary Efficacy Analysis Set (24 Weeks)|Adverse Event|11
6244275|NCT01884350|9928606|FG002|Primary Efficacy Analysis Set (24 Weeks)|Adverse Event|0
6244276|NCT01884350|9928604|FG000|Primary Efficacy Analysis Set (24 Weeks)|Drug Interruption >30 Consecutive Days|0
6244277|NCT01884350|9928605|FG001|Primary Efficacy Analysis Set (24 Weeks)|Drug Interruption >30 Consecutive Days|2
6244278|NCT01884350|9928606|FG002|Primary Efficacy Analysis Set (24 Weeks)|Drug Interruption >30 Consecutive Days|0
6244279|NCT01884350|9928604|FG000|Primary Efficacy Analysis Set (24 Weeks)|Inclusion/exclusion criterion|2
6244280|NCT01884350|9928605|FG001|Primary Efficacy Analysis Set (24 Weeks)|Inclusion/exclusion criterion|5
6244281|NCT01884350|9928606|FG002|Primary Efficacy Analysis Set (24 Weeks)|Inclusion/exclusion criterion|0
6244282|NCT01884350|9928604|FG000|Primary Efficacy Analysis Set (24 Weeks)|Helping Hand not used|2
6244283|NCT01884350|9928605|FG001|Primary Efficacy Analysis Set (24 Weeks)|Helping Hand not used|0
6244284|NCT01884350|9928606|FG002|Primary Efficacy Analysis Set (24 Weeks)|Helping Hand not used|0
6244285|NCT01884350|9928604|FG000|Primary Efficacy Analysis Set (24 Weeks)|Helping Hand not used, treatment taken|1
6244286|NCT01884350|9928605|FG001|Primary Efficacy Analysis Set (24 Weeks)|Helping Hand not used, treatment taken|1
6244287|NCT01884350|9928606|FG002|Primary Efficacy Analysis Set (24 Weeks)|Helping Hand not used, treatment taken|0
6244288|NCT01884350|9928604|FG000|Primary Efficacy Analysis Set (24 Weeks)|Withdrawal by Subject|1
6244289|NCT01884350|9928605|FG001|Primary Efficacy Analysis Set (24 Weeks)|Withdrawal by Subject|1
6244290|NCT01884350|9928606|FG002|Primary Efficacy Analysis Set (24 Weeks)|Withdrawal by Subject|0
6244291|NCT01884350|9928604|FG000|Primary Efficacy Analysis Set (24 Weeks)|Medical reason|3
6244292|NCT01884350|9928605|FG001|Primary Efficacy Analysis Set (24 Weeks)|Medical reason|3
6244293|NCT01884350|9928606|FG002|Primary Efficacy Analysis Set (24 Weeks)|Medical reason|0
6244294|NCT01884350|9928604|FG000|Primary Efficacy Analysis Set (48 Weeks)|Subject Withdrew Consent|21
6244295|NCT01884350|9928605|FG001|Primary Efficacy Analysis Set (48 Weeks)|Subject Withdrew Consent|0
6244296|NCT01884350|9928606|FG002|Primary Efficacy Analysis Set (48 Weeks)|Subject Withdrew Consent|2
6244297|NCT01884350|9928604|FG000|Primary Efficacy Analysis Set (48 Weeks)|Death|7
6244298|NCT01884350|9928605|FG001|Primary Efficacy Analysis Set (48 Weeks)|Death|3
6244299|NCT01884350|9928606|FG002|Primary Efficacy Analysis Set (48 Weeks)|Death|3
6244300|NCT01884350|9928604|FG000|Primary Efficacy Analysis Set (48 Weeks)|Lost to Follow-up|1
6244301|NCT01884350|9928605|FG001|Primary Efficacy Analysis Set (48 Weeks)|Lost to Follow-up|0
6244302|NCT01884350|9928606|FG002|Primary Efficacy Analysis Set (48 Weeks)|Lost to Follow-up|1
6244303|NCT01884350|9928604|FG000|Primary Efficacy Analysis Set (48 Weeks)|Serious Adverse Event|17
6244304|NCT01884350|9928605|FG001|Primary Efficacy Analysis Set (48 Weeks)|Serious Adverse Event|6
6244305|NCT01884350|9928606|FG002|Primary Efficacy Analysis Set (48 Weeks)|Serious Adverse Event|3
6244306|NCT01884350|9928604|FG000|Primary Efficacy Analysis Set (48 Weeks)|Adverse Event|17
6244307|NCT01884350|9928605|FG001|Primary Efficacy Analysis Set (48 Weeks)|Adverse Event|3
6244308|NCT01884350|9928606|FG002|Primary Efficacy Analysis Set (48 Weeks)|Adverse Event|0
6244309|NCT01884350|9928604|FG000|Primary Efficacy Analysis Set (48 Weeks)|Drug Interruption >30 Consecutive Days|3
6244310|NCT01884350|9928605|FG001|Primary Efficacy Analysis Set (48 Weeks)|Drug Interruption >30 Consecutive Days|0
6244311|NCT01884350|9928606|FG002|Primary Efficacy Analysis Set (48 Weeks)|Drug Interruption >30 Consecutive Days|2
6244312|NCT01884350|9928604|FG000|Primary Efficacy Analysis Set (48 Weeks)|Helping Hand not used|4
6244313|NCT01884350|9928605|FG001|Primary Efficacy Analysis Set (48 Weeks)|Helping Hand not used|0
6270511|NCT02152631|9971438|FG000|Overall Study|Physician Decision|1
6189291|NCT01397890|9844427|FG001|Overall Study|Eligibility Criteria Not Fulfilled|6
6189292|NCT01397890|9844426|FG000|Overall Study|Death|2
6189293|NCT01397890|9844427|FG001|Overall Study|Death|3
6189294|NCT01397890|9844426|FG000|Overall Study|Lost to Follow-up|1
6244314|NCT01884350|9928606|FG002|Primary Efficacy Analysis Set (48 Weeks)|Helping Hand not used|0
6244315|NCT01884350|9928604|FG000|Primary Efficacy Analysis Set (48 Weeks)|Helping Hand not used, treatment taken|3
6244316|NCT01884350|9928605|FG001|Primary Efficacy Analysis Set (48 Weeks)|Helping Hand not used, treatment taken|0
6244317|NCT01884350|9928606|FG002|Primary Efficacy Analysis Set (48 Weeks)|Helping Hand not used, treatment taken|0
6244318|NCT01884350|9928604|FG000|Primary Efficacy Analysis Set (48 Weeks)|Medical reason|4
6244319|NCT01884350|9928605|FG001|Primary Efficacy Analysis Set (48 Weeks)|Medical reason|1
6244320|NCT01884350|9928606|FG002|Primary Efficacy Analysis Set (48 Weeks)|Medical reason|0
6244321|NCT01884350|9928604|FG000|Primary Efficacy Analysis Set (48 Weeks)|Subject decision|1
6244322|NCT01884350|9928605|FG001|Primary Efficacy Analysis Set (48 Weeks)|Subject decision|0
6244323|NCT01884350|9928606|FG002|Primary Efficacy Analysis Set (48 Weeks)|Subject decision|0
6244324|NCT01884350|9928604|FG000|Primary Efficacy Analysis Set (48 Weeks)|Inclusion / Exclusion Criterion|2
6244325|NCT01884350|9928605|FG001|Primary Efficacy Analysis Set (48 Weeks)|Inclusion / Exclusion Criterion|0
6244326|NCT01884350|9928606|FG002|Primary Efficacy Analysis Set (48 Weeks)|Inclusion / Exclusion Criterion|0
6244327|NCT01884545|9928637|FG000|Overall Study|Lost to Follow-up|6
6244328|NCT01884545|9928638|FG001|Overall Study|Lost to Follow-up|4
6244329|NCT01884545|9928639|FG002|Overall Study|Lost to Follow-up|9
6244330|NCT01884545|9928640|FG003|Overall Study|Lost to Follow-up|4
6244331|NCT01884545|9928637|FG000|Overall Study|Patient withdrawn|7
6244332|NCT01884545|9928638|FG001|Overall Study|Patient withdrawn|12
6244333|NCT01884545|9928639|FG002|Overall Study|Patient withdrawn|5
6244334|NCT01884545|9928640|FG003|Overall Study|Patient withdrawn|5
6244335|NCT01884545|9928637|FG000|Overall Study|Non-adherence|0
6244336|NCT01884545|9928638|FG001|Overall Study|Non-adherence|2
6244337|NCT01884545|9928639|FG002|Overall Study|Non-adherence|0
6244338|NCT01884545|9928640|FG003|Overall Study|Non-adherence|0
6244339|NCT01884571|9928650|FG000|Overall Study|Adverse Event|1
6244340|NCT01884571|9928650|FG000|Overall Study|Death|2
6244341|NCT01884571|9928650|FG000|Overall Study|Withdrawal by Subject|2
6244342|NCT01884571|9928650|FG000|Overall Study|Disease progression|3
6244343|NCT01884597|9928657|FG000|Overall Study|Adverse Event|0
6244344|NCT01884597|9928658|FG001|Overall Study|Adverse Event|0
6244345|NCT01884597|9928659|FG002|Overall Study|Adverse Event|1
6244346|NCT01884597|9928657|FG000|Overall Study|Lack of Efficacy|1
6244347|NCT01884597|9928658|FG001|Overall Study|Lack of Efficacy|0
6244348|NCT01884597|9928659|FG002|Overall Study|Lack of Efficacy|0
6244349|NCT01884597|9928657|FG000|Overall Study|Death|0
6244350|NCT01884597|9928658|FG001|Overall Study|Death|1
6244351|NCT01884597|9928659|FG002|Overall Study|Death|0
6244352|NCT01884675|9928675|FG000|Overall Study|Study closed/terminated|3
6244353|NCT01884675|9928676|FG001|Overall Study|Study closed/terminated|2
6244354|NCT01884688|9928684|FG000|Overall Study|Screen Failure|2
6244355|NCT01885000|9928699|FG000|Overall Study|Adverse Event|1
6244356|NCT01885000|9928700|FG001|Overall Study|Adverse Event|0
6244357|NCT01885000|9928699|FG000|Overall Study|Withdrawal by Subject|1
6244358|NCT01885000|9928700|FG001|Overall Study|Withdrawal by Subject|1
6244359|NCT01885000|9928699|FG000|Overall Study|Protocol Violation|0
6244360|NCT01885000|9928700|FG001|Overall Study|Protocol Violation|1
6244361|NCT01885104|9928708|FG000|Overall Study|Withdrawal of Consent|1
6244362|NCT01885104|9928709|FG001|Overall Study|Withdrawal of Consent|0
6244363|NCT01885104|9928708|FG000|Overall Study|Lost to Follow-up|0
6244364|NCT01885104|9928709|FG001|Overall Study|Lost to Follow-up|1
6244365|NCT01885104|9928708|FG000|Overall Study|Physician Decision|1
6244366|NCT01885104|9928709|FG001|Overall Study|Physician Decision|0
6244367|NCT01885182|9928726|FG000|Overall Study|Adverse Event|11
6244368|NCT01885182|9928727|FG001|Overall Study|Adverse Event|13
6244369|NCT01885182|9928726|FG000|Overall Study|Withdrawal by Subject|13
6244370|NCT01885182|9928727|FG001|Overall Study|Withdrawal by Subject|6
6244371|NCT01885182|9928726|FG000|Overall Study|Lost to Follow-up|2
6244372|NCT01885182|9928727|FG001|Overall Study|Lost to Follow-up|2
6244373|NCT01885182|9928726|FG000|Overall Study|Lack of Efficacy|8
6244374|NCT01885182|9928727|FG001|Overall Study|Lack of Efficacy|1
6244375|NCT01885195|9928735|FG000|Overall Study|Adverse Event|29
6244376|NCT01885195|9928735|FG000|Overall Study|Death|1
6244377|NCT01885195|9928735|FG000|Overall Study|Disease Progression|67
6244378|NCT01885195|9928735|FG000|Overall Study|Protocol Deviation|2
6244379|NCT01885195|9928735|FG000|Overall Study|Physician Decision|3
6244380|NCT01885195|9928735|FG000|Overall Study|Patient/guardian decision|8
6244381|NCT01885208|9928741|FG000|Overall Study|Unclassified|32
6244382|NCT01885208|9928742|FG001|Overall Study|Unclassified|38
6244383|NCT01885559|9928750|FG000|Overall Study|Lost to Follow-up|15
6244384|NCT01885559|9928751|FG001|Overall Study|Lost to Follow-up|16
6244385|NCT01885559|9928750|FG000|Overall Study|Less than full participation|9
6244386|NCT01885559|9928751|FG001|Overall Study|Less than full participation|19
6244387|NCT01885559|9928750|FG000|Overall Study|Protocol Violation|0
6244388|NCT01885559|9928751|FG001|Overall Study|Protocol Violation|1
6244389|NCT01885936|9928794|FG000|Overall Study|Withdrawal by Subject|1
6244390|NCT01885936|9928795|FG001|Overall Study|Withdrawal by Subject|0
6244391|NCT01886105|9928801|FG000|Overall Study|Lack of Efficacy|3
6244392|NCT01886287|9928810|FG000|Overall Study|Radiographic disease progression|1
6244393|NCT01886287|9928810|FG000|Overall Study|Clinical progression due to disease|1
6270512|NCT02152631|9971439|FG001|Overall Study|Physician Decision|2
6270513|NCT02152631|9971438|FG000|Overall Study|Lost to Follow-up|0
6244394|NCT01886300|9928814|FG000|Overall Study|Trial terminated by sponsor|16
6244395|NCT01886313|9928820|FG000|Overall Study|Adverse Event|1
6244396|NCT01886313|9928821|FG001|Overall Study|Adverse Event|1
6244397|NCT01886378|9928827|FG000|Overall Study|Adverse Event|1
6244398|NCT01886378|9928827|FG000|Overall Study|Withdrawal by Subject|4
6244399|NCT01886690|9928833|FG000|Overall Study|Protocol Violation|0
6244400|NCT01886690|9928834|FG001|Overall Study|Protocol Violation|1
6244401|NCT01886690|9928833|FG000|Overall Study|Personal Reasons|0
6086061|NCT00658606|9695757|FG001|Overall Study|Lost to Follow-up|0
6086062|NCT00658606|9695756|FG000|Overall Study|Withdrawal by Subject|7
6086063|NCT00658606|9695757|FG001|Overall Study|Withdrawal by Subject|16
6244402|NCT01886690|9928834|FG001|Overall Study|Personal Reasons|1
6244403|NCT01886716|9928844|FG000|Week 1|Lost to Follow-up|0
6244404|NCT01886716|9928845|FG001|Week 1|Lost to Follow-up|0
6244405|NCT01886716|9928846|FG002|Week 1|Lost to Follow-up|2
6244406|NCT01886716|9928847|FG003|Week 1|Lost to Follow-up|2
6244407|NCT01886716|9928844|FG000|Week 2|Lost to Follow-up|3
6244408|NCT01886716|9928845|FG001|Week 2|Lost to Follow-up|2
6244409|NCT01886716|9928846|FG002|Week 2|Lost to Follow-up|1
6244410|NCT01886716|9928847|FG003|Week 2|Lost to Follow-up|3
6244411|NCT01886716|9928844|FG000|Week 3|Lost to Follow-up|1
6244412|NCT01886716|9928845|FG001|Week 3|Lost to Follow-up|1
6244413|NCT01886716|9928846|FG002|Week 3|Lost to Follow-up|0
6244414|NCT01886716|9928847|FG003|Week 3|Lost to Follow-up|1
6244415|NCT01886781|9928859|FG000|Overall Study|Protocol Violation|5
6244416|NCT01886781|9928860|FG001|Overall Study|Protocol Violation|0
6244417|NCT01886781|9928859|FG000|Overall Study|Adverse Event|1
6244418|NCT01886781|9928860|FG001|Overall Study|Adverse Event|0
6244419|NCT01886781|9928859|FG000|Overall Study|Lost to Follow-up|5
6244420|NCT01886781|9928860|FG001|Overall Study|Lost to Follow-up|0
6244421|NCT01886781|9928859|FG000|Overall Study|Withdrawal by Subject|2
6244422|NCT01886781|9928860|FG001|Overall Study|Withdrawal by Subject|1
6244423|NCT01886781|9928859|FG000|Overall Study|Worsening of symptoms|1
6244424|NCT01886781|9928860|FG001|Overall Study|Worsening of symptoms|1
6244425|NCT01886833|9928882|FG000|Overall Study|IgA not available from both periods|204
6244426|NCT01887210|9928913|FG000|Overall Study|Withdrawal by Subject|1
6244427|NCT01887210|9928914|FG001|Overall Study|Withdrawal by Subject|3
6244428|NCT01887210|9928913|FG000|Overall Study|Lost to Follow-up|0
6244429|NCT01887210|9928914|FG001|Overall Study|Lost to Follow-up|1
6244430|NCT01887353|9928936|FG000|Overall Study|Study stopped early|4
6244431|NCT01887353|9928937|FG001|Overall Study|Study stopped early|3
6244432|NCT01887418|9928946|FG000|Overall Study|Travelling difficulties|0
6244433|NCT01887418|9928947|FG001|Overall Study|Travelling difficulties|0
6244434|NCT01887418|9928948|FG002|Overall Study|Travelling difficulties|1
6244435|NCT01887600|9928980|FG000|Overall Study|Death|39
6244436|NCT01887600|9928981|FG001|Overall Study|Death|16
6244437|NCT01887600|9928980|FG000|Overall Study|Lack of Efficacy|3
6244438|NCT01887600|9928981|FG001|Overall Study|Lack of Efficacy|26
6244439|NCT01887600|9928980|FG000|Overall Study|Lost to Follow-up|5
6244440|NCT01887600|9928981|FG001|Overall Study|Lost to Follow-up|1
6244441|NCT01887600|9928980|FG000|Overall Study|Physician Decision|7
6244442|NCT01887600|9928981|FG001|Overall Study|Physician Decision|8
6244443|NCT01887600|9928980|FG000|Overall Study|Protocol Deviation|3
6244444|NCT01887600|9928981|FG001|Overall Study|Protocol Deviation|0
6244445|NCT01887600|9928980|FG000|Overall Study|Withdrawal by Subject|58
6244446|NCT01887600|9928981|FG001|Overall Study|Withdrawal by Subject|52
6244447|NCT01887600|9928980|FG000|Overall Study|Adverse Event|21
6244448|NCT01887600|9928981|FG001|Overall Study|Adverse Event|9
6244449|NCT01887600|9928980|FG000|Overall Study|Non-compliance with study drug|3
6244450|NCT01887600|9928981|FG001|Overall Study|Non-compliance with study drug|0
6244451|NCT01887600|9928980|FG000|Overall Study|Miscellaneous|6
6244452|NCT01887600|9928981|FG001|Overall Study|Miscellaneous|2
6244453|NCT01887600|9928980|FG000|Overall Study|Progressive Disease|1
6244454|NCT01887600|9928981|FG001|Overall Study|Progressive Disease|0
6244455|NCT01887678|9928990|FG000|Overall Study|Adverse Event|4
6244456|NCT01887678|9928991|FG001|Overall Study|Adverse Event|6
6244457|NCT01887678|9928990|FG000|Overall Study|Exceeded rescue medication dosage|4
6244458|NCT01887678|9928991|FG001|Overall Study|Exceeded rescue medication dosage|5
6244459|NCT01887678|9928990|FG000|Overall Study|Withdrawal of consent|3
6244460|NCT01887678|9928991|FG001|Overall Study|Withdrawal of consent|4
6244461|NCT01887678|9928990|FG000|Overall Study|Lost to Follow-up|4
6244462|NCT01887678|9928991|FG001|Overall Study|Lost to Follow-up|2
6244463|NCT01887678|9928990|FG000|Overall Study|Deterioration of clinical condition|0
6244464|NCT01887678|9928991|FG001|Overall Study|Deterioration of clinical condition|4
6244465|NCT01887678|9928990|FG000|Overall Study|Lack of Efficacy|1
6244466|NCT01887678|9928991|FG001|Overall Study|Lack of Efficacy|2
6244467|NCT01887678|9928990|FG000|Overall Study|Non-compliance|0
6244468|NCT01887678|9928991|FG001|Overall Study|Non-compliance|3
6244469|NCT01887678|9928990|FG000|Overall Study|Specified|1
6244470|NCT01887678|9928991|FG001|Overall Study|Specified|2
6244471|NCT01887717|9928999|FG000|Overall Study|Withdrawal by Subject|1
6244472|NCT01887717|9929000|FG001|Overall Study|Withdrawal by Subject|7
6244473|NCT01887717|9928999|FG000|Overall Study|Physician Decision|0
6244474|NCT01887717|9929000|FG001|Overall Study|Physician Decision|2
6244475|NCT01887717|9928999|FG000|Overall Study|Administrative reasons|5
6244476|NCT01887717|9929000|FG001|Overall Study|Administrative reasons|2
6244477|NCT01888003|9929028|FG000|Overall Study|Study Terminated|5
6244478|NCT01888003|9929029|FG001|Overall Study|Study Terminated|6
6244479|NCT01888003|9929030|FG002|Overall Study|Study Terminated|40
6244480|NCT01888367|9929041|FG000|Overall Study|Physician Decision|3
6244481|NCT01888367|9929042|FG001|Overall Study|Physician Decision|4
6244482|NCT01888367|9929043|FG002|Overall Study|Physician Decision|2
6244483|NCT01888367|9929041|FG000|Overall Study|Death|2
6244484|NCT01888367|9929042|FG001|Overall Study|Death|0
6244485|NCT01888367|9929043|FG002|Overall Study|Death|1
6244486|NCT01888367|9929041|FG000|Overall Study|Withdrawal by Subject|1
6244487|NCT01888367|9929042|FG001|Overall Study|Withdrawal by Subject|0
6244488|NCT01888367|9929043|FG002|Overall Study|Withdrawal by Subject|1
6244489|NCT01888367|9929041|FG000|Overall Study|Lost to Follow-up|1
6244490|NCT01888367|9929042|FG001|Overall Study|Lost to Follow-up|1
6244491|NCT01888367|9929043|FG002|Overall Study|Lost to Follow-up|0
6244492|NCT01888367|9929041|FG000|Overall Study|Protocol Violation|0
6244493|NCT01888367|9929042|FG001|Overall Study|Protocol Violation|0
6244494|NCT01888367|9929043|FG002|Overall Study|Protocol Violation|1
6244495|NCT01888367|9929041|FG000|Overall Study|30-Day Visit Too Early (< 28 Days)|1
6244496|NCT01888367|9929042|FG001|Overall Study|30-Day Visit Too Early (< 28 Days)|0
6244497|NCT01888367|9929043|FG002|Overall Study|30-Day Visit Too Early (< 28 Days)|0
6244498|NCT01888432|9929053|FG000|12-month Analysis (FAS)|Lost to Follow-up|0
6244499|NCT01888432|9929054|FG001|12-month Analysis (FAS)|Lost to Follow-up|2
6244500|NCT01888432|9929053|FG000|12-month Analysis (FAS)|Physician Decision|1
6244501|NCT01888432|9929054|FG001|12-month Analysis (FAS)|Physician Decision|1
6244502|NCT01888432|9929053|FG000|12-month Analysis (FAS)|Withdrawal by Subject|6
6244503|NCT01888432|9929054|FG001|12-month Analysis (FAS)|Withdrawal by Subject|3
6244504|NCT01888432|9929053|FG000|12-month Analysis (FAS)|Death|4
6244505|NCT01888432|9929054|FG001|12-month Analysis (FAS)|Death|3
6244506|NCT01888432|9929053|FG000|24-month Analysis (FAS)|Graft loss|0
6244507|NCT01888432|9929054|FG001|24-month Analysis (FAS)|Graft loss|1
6244508|NCT01888432|9929053|FG000|24-month Analysis (FAS)|Lost to Follow-up|0
6244509|NCT01888432|9929054|FG001|24-month Analysis (FAS)|Lost to Follow-up|2
6244510|NCT01888432|9929053|FG000|24-month Analysis (FAS)|Physician Decision|2
6244511|NCT01888432|9929054|FG001|24-month Analysis (FAS)|Physician Decision|4
6244512|NCT01888432|9929053|FG000|24-month Analysis (FAS)|Withdrawal by Subject|7
6244513|NCT01888432|9929054|FG001|24-month Analysis (FAS)|Withdrawal by Subject|6
6244514|NCT01888432|9929053|FG000|24-month Analysis (FAS)|Death|8
6244515|NCT01888432|9929054|FG001|24-month Analysis (FAS)|Death|4
6244516|NCT01888432|9929053|FG000|36-month Analysis (Extension)|Death|1
6244517|NCT01888432|9929054|FG001|36-month Analysis (Extension)|Death|0
6244518|NCT01888497|9929070|FG000|Washout Period 1|Withdrawal by Subject|0
6244519|NCT01888497|9929071|FG001|Washout Period 1|Withdrawal by Subject|0
6244520|NCT01888497|9929072|FG002|Washout Period 1|Withdrawal by Subject|1
6244521|NCT01888497|9929073|FG003|Washout Period 1|Withdrawal by Subject|1
6244522|NCT01888497|9929070|FG000|Washout Period 2|Adverse Event|0
6244523|NCT01888497|9929071|FG001|Washout Period 2|Adverse Event|0
6244524|NCT01888497|9929072|FG002|Washout Period 2|Adverse Event|0
6086064|NCT00658606|9695756|FG000|Overall Study|Lack of Compliance|0
6086065|NCT00658606|9695757|FG001|Overall Study|Lack of Compliance|3
6086066|NCT00658632|9695783|FG000|Overall Study|Adverse Event|13
6086067|NCT00658632|9695784|FG001|Overall Study|Adverse Event|11
6086068|NCT00658632|9695783|FG000|Overall Study|Lost to Follow-up|25
6244525|NCT01888497|9929073|FG003|Washout Period 2|Adverse Event|1
6244526|NCT01888497|9929070|FG000|Washout Period 2|Withdrawal by Subject|0
6244527|NCT01888497|9929071|FG001|Washout Period 2|Withdrawal by Subject|0
6244528|NCT01888497|9929072|FG002|Washout Period 2|Withdrawal by Subject|0
6244529|NCT01888497|9929073|FG003|Washout Period 2|Withdrawal by Subject|1
6244530|NCT01888640|9929086|FG000|Overall Study|Lost to Follow-up|1
6244531|NCT01888640|9929087|FG001|Overall Study|Lost to Follow-up|2
6244532|NCT01888640|9929088|FG002|Overall Study|Lost to Follow-up|0
6244533|NCT01888640|9929086|FG000|Overall Study|Withdrawal by Subject|15
6244534|NCT01888640|9929087|FG001|Overall Study|Withdrawal by Subject|11
6244535|NCT01888640|9929088|FG002|Overall Study|Withdrawal by Subject|4
6244536|NCT01888640|9929086|FG000|Overall Study|Minimum dose not met|10
6244537|NCT01888640|9929087|FG001|Overall Study|Minimum dose not met|16
6244538|NCT01888640|9929088|FG002|Overall Study|Minimum dose not met|0
6244539|NCT01888640|9929086|FG000|Overall Study|Given wrong unit (placebo)|1
6244540|NCT01888640|9929087|FG001|Overall Study|Given wrong unit (placebo)|0
6244541|NCT01888640|9929088|FG002|Overall Study|Given wrong unit (placebo)|0
6244542|NCT01888640|9929086|FG000|Overall Study|Excluded for prior TENS|0
6244543|NCT01888640|9929087|FG001|Overall Study|Excluded for prior TENS|1
6244544|NCT01888640|9929088|FG002|Overall Study|Excluded for prior TENS|0
6244545|NCT01888640|9929086|FG000|Overall Study|Researcher Termination of Participant|0
6244546|NCT01888640|9929087|FG001|Overall Study|Researcher Termination of Participant|1
6244547|NCT01888640|9929088|FG002|Overall Study|Researcher Termination of Participant|1
6244548|NCT01888874|9929106|FG000|Period 1 (Baseline up to Week 12)|Withdrawal by Subject|2
6244549|NCT01888874|9929107|FG001|Period 1 (Baseline up to Week 12)|Withdrawal by Subject|2
6244550|NCT01888874|9929108|FG002|Period 1 (Baseline up to Week 12)|Withdrawal by Subject|3
6244551|NCT01888874|9929109|FG003|Period 1 (Baseline up to Week 12)|Withdrawal by Subject|4
6244552|NCT01888874|9929110|FG004|Period 1 (Baseline up to Week 12)|Withdrawal by Subject|3
6270514|NCT02152631|9971439|FG001|Overall Study|Lost to Follow-up|1
6244553|NCT01888874|9929111|FG005|Period 1 (Baseline up to Week 12)|Withdrawal by Subject|0
6244554|NCT01888874|9929112|FG006|Period 1 (Baseline up to Week 12)|Withdrawal by Subject|0
6244555|NCT01888874|9929106|FG000|Period 1 (Baseline up to Week 12)|Other|1
6244556|NCT01888874|9929107|FG001|Period 1 (Baseline up to Week 12)|Other|0
6244557|NCT01888874|9929108|FG002|Period 1 (Baseline up to Week 12)|Other|1
6244558|NCT01888874|9929109|FG003|Period 1 (Baseline up to Week 12)|Other|1
6244559|NCT01888874|9929110|FG004|Period 1 (Baseline up to Week 12)|Other|3
6244560|NCT01888874|9929111|FG005|Period 1 (Baseline up to Week 12)|Other|3
6244561|NCT01888874|9929112|FG006|Period 1 (Baseline up to Week 12)|Other|0
6244562|NCT01888874|9929106|FG000|Period 1 (Baseline up to Week 12)|Physician Decision|0
6244563|NCT01888874|9929107|FG001|Period 1 (Baseline up to Week 12)|Physician Decision|0
6244564|NCT01888874|9929108|FG002|Period 1 (Baseline up to Week 12)|Physician Decision|0
6244565|NCT01888874|9929109|FG003|Period 1 (Baseline up to Week 12)|Physician Decision|0
6244566|NCT01888874|9929110|FG004|Period 1 (Baseline up to Week 12)|Physician Decision|0
6244567|NCT01888874|9929111|FG005|Period 1 (Baseline up to Week 12)|Physician Decision|0
6244568|NCT01888874|9929112|FG006|Period 1 (Baseline up to Week 12)|Physician Decision|1
6244569|NCT01888874|9929106|FG000|Period 1 (Baseline up to Week 12)|Adverse Event|0
6244570|NCT01888874|9929107|FG001|Period 1 (Baseline up to Week 12)|Adverse Event|2
6244571|NCT01888874|9929108|FG002|Period 1 (Baseline up to Week 12)|Adverse Event|3
6244572|NCT01888874|9929109|FG003|Period 1 (Baseline up to Week 12)|Adverse Event|1
6244573|NCT01888874|9929110|FG004|Period 1 (Baseline up to Week 12)|Adverse Event|2
6244574|NCT01888874|9929111|FG005|Period 1 (Baseline up to Week 12)|Adverse Event|1
6244575|NCT01888874|9929112|FG006|Period 1 (Baseline up to Week 12)|Adverse Event|0
6244576|NCT01888874|9929106|FG000|Period 1 (Baseline up to Week 12)|Adverse event and treatment failure|0
6244577|NCT01888874|9929107|FG001|Period 1 (Baseline up to Week 12)|Adverse event and treatment failure|0
6244578|NCT01888874|9929108|FG002|Period 1 (Baseline up to Week 12)|Adverse event and treatment failure|0
6244579|NCT01888874|9929109|FG003|Period 1 (Baseline up to Week 12)|Adverse event and treatment failure|0
6244580|NCT01888874|9929110|FG004|Period 1 (Baseline up to Week 12)|Adverse event and treatment failure|1
6244581|NCT01888874|9929111|FG005|Period 1 (Baseline up to Week 12)|Adverse event and treatment failure|0
6244582|NCT01888874|9929112|FG006|Period 1 (Baseline up to Week 12)|Adverse event and treatment failure|0
6244583|NCT01888874|9929106|FG000|Period 1 (Baseline up to Week 12)|Non-compliance with the study procedures|0
6244584|NCT01888874|9929107|FG001|Period 1 (Baseline up to Week 12)|Non-compliance with the study procedures|1
6244585|NCT01888874|9929108|FG002|Period 1 (Baseline up to Week 12)|Non-compliance with the study procedures|0
6244586|NCT01888874|9929109|FG003|Period 1 (Baseline up to Week 12)|Non-compliance with the study procedures|0
6244587|NCT01888874|9929110|FG004|Period 1 (Baseline up to Week 12)|Non-compliance with the study procedures|0
6244588|NCT01888874|9929111|FG005|Period 1 (Baseline up to Week 12)|Non-compliance with the study procedures|0
6244589|NCT01888874|9929112|FG006|Period 1 (Baseline up to Week 12)|Non-compliance with the study procedures|0
6244590|NCT01888874|9929106|FG000|Period 1 (Baseline up to Week 12)|Lost to Follow-up|0
6244591|NCT01888874|9929107|FG001|Period 1 (Baseline up to Week 12)|Lost to Follow-up|1
6244592|NCT01888874|9929108|FG002|Period 1 (Baseline up to Week 12)|Lost to Follow-up|0
6244593|NCT01888874|9929109|FG003|Period 1 (Baseline up to Week 12)|Lost to Follow-up|0
6244594|NCT01888874|9929110|FG004|Period 1 (Baseline up to Week 12)|Lost to Follow-up|0
6244595|NCT01888874|9929111|FG005|Period 1 (Baseline up to Week 12)|Lost to Follow-up|1
6244596|NCT01888874|9929112|FG006|Period 1 (Baseline up to Week 12)|Lost to Follow-up|0
6244597|NCT01888874|9929106|FG000|Period 2 (Week 13 to Week 24)|Withdrawal by Subject|1
6244598|NCT01888874|9929107|FG001|Period 2 (Week 13 to Week 24)|Withdrawal by Subject|1
6244599|NCT01888874|9929108|FG002|Period 2 (Week 13 to Week 24)|Withdrawal by Subject|2
6244600|NCT01888874|9929109|FG003|Period 2 (Week 13 to Week 24)|Withdrawal by Subject|0
6244601|NCT01888874|9929110|FG004|Period 2 (Week 13 to Week 24)|Withdrawal by Subject|1
6244602|NCT01888874|9929111|FG005|Period 2 (Week 13 to Week 24)|Withdrawal by Subject|0
6244603|NCT01888874|9929112|FG006|Period 2 (Week 13 to Week 24)|Withdrawal by Subject|0
6244604|NCT01888874|9929106|FG000|Period 2 (Week 13 to Week 24)|Adverse event and treatment failure|0
6244605|NCT01888874|9929107|FG001|Period 2 (Week 13 to Week 24)|Adverse event and treatment failure|0
6244606|NCT01888874|9929108|FG002|Period 2 (Week 13 to Week 24)|Adverse event and treatment failure|0
6244607|NCT01888874|9929109|FG003|Period 2 (Week 13 to Week 24)|Adverse event and treatment failure|0
6244608|NCT01888874|9929110|FG004|Period 2 (Week 13 to Week 24)|Adverse event and treatment failure|1
6244609|NCT01888874|9929111|FG005|Period 2 (Week 13 to Week 24)|Adverse event and treatment failure|0
6244610|NCT01888874|9929112|FG006|Period 2 (Week 13 to Week 24)|Adverse event and treatment failure|0
6244611|NCT01888874|9929106|FG000|Period 2 (Week 13 to Week 24)|Non compliance with study medication|0
6244612|NCT01888874|9929107|FG001|Period 2 (Week 13 to Week 24)|Non compliance with study medication|0
6244613|NCT01888874|9929108|FG002|Period 2 (Week 13 to Week 24)|Non compliance with study medication|2
6244614|NCT01888874|9929109|FG003|Period 2 (Week 13 to Week 24)|Non compliance with study medication|0
6244615|NCT01888874|9929110|FG004|Period 2 (Week 13 to Week 24)|Non compliance with study medication|0
6244616|NCT01888874|9929111|FG005|Period 2 (Week 13 to Week 24)|Non compliance with study medication|1
6244617|NCT01888874|9929112|FG006|Period 2 (Week 13 to Week 24)|Non compliance with study medication|0
6244618|NCT01888874|9929106|FG000|Period 2 (Week 13 to Week 24)|Treatment failure|0
6244619|NCT01888874|9929107|FG001|Period 2 (Week 13 to Week 24)|Treatment failure|0
6244620|NCT01888874|9929108|FG002|Period 2 (Week 13 to Week 24)|Treatment failure|1
6244621|NCT01888874|9929109|FG003|Period 2 (Week 13 to Week 24)|Treatment failure|0
6244622|NCT01888874|9929110|FG004|Period 2 (Week 13 to Week 24)|Treatment failure|0
6244623|NCT01888874|9929111|FG005|Period 2 (Week 13 to Week 24)|Treatment failure|0
6244624|NCT01888874|9929112|FG006|Period 2 (Week 13 to Week 24)|Treatment failure|0
6244625|NCT01888874|9929106|FG000|Period 2 (Week 13 to Week 24)|Adverse Event|2
6244626|NCT01888874|9929107|FG001|Period 2 (Week 13 to Week 24)|Adverse Event|0
6244627|NCT01888874|9929108|FG002|Period 2 (Week 13 to Week 24)|Adverse Event|3
6244628|NCT01888874|9929109|FG003|Period 2 (Week 13 to Week 24)|Adverse Event|2
6244629|NCT01888874|9929110|FG004|Period 2 (Week 13 to Week 24)|Adverse Event|1
6244630|NCT01888874|9929111|FG005|Period 2 (Week 13 to Week 24)|Adverse Event|1
6244631|NCT01888874|9929112|FG006|Period 2 (Week 13 to Week 24)|Adverse Event|3
6244632|NCT01888874|9929106|FG000|Period 2 (Week 13 to Week 24)|Lost to Follow-up|0
6244633|NCT01888874|9929107|FG001|Period 2 (Week 13 to Week 24)|Lost to Follow-up|1
6244634|NCT01888874|9929108|FG002|Period 2 (Week 13 to Week 24)|Lost to Follow-up|0
6244635|NCT01888874|9929109|FG003|Period 2 (Week 13 to Week 24)|Lost to Follow-up|0
6244636|NCT01888874|9929110|FG004|Period 2 (Week 13 to Week 24)|Lost to Follow-up|0
6244637|NCT01888874|9929111|FG005|Period 2 (Week 13 to Week 24)|Lost to Follow-up|1
6244638|NCT01888874|9929112|FG006|Period 2 (Week 13 to Week 24)|Lost to Follow-up|0
6244639|NCT01888900|9929131|FG000|Overall Study|failed treatment|0
6244640|NCT01888900|9929132|FG001|Overall Study|failed treatment|2
6244641|NCT01888965|9929144|FG000|Overall Study|Adverse Event|5
6244642|NCT01888965|9929144|FG000|Overall Study|Lack of Efficacy|4
6244643|NCT01889069|9929150|FG000|Overall Study|Death|18
6244644|NCT01889069|9929150|FG000|Overall Study|Progression of Disease|14
6244645|NCT01889069|9929150|FG000|Overall Study|Lost to Follow-up|6
6244646|NCT01889069|9929150|FG000|Overall Study|Other|4
6244647|NCT01889069|9929150|FG000|Overall Study|Consent Withdrawal|3
6244648|NCT01889238|9929160|FG000|Overall Study|Treatment ongoing|9
6244649|NCT01889251|9929166|FG000|Overall Study|Adverse Event|1
6244650|NCT01889251|9929167|FG001|Overall Study|Adverse Event|0
6244651|NCT01889602|9929189|FG000|First Intervention|Adverse Event|1
6244652|NCT01889602|9929190|FG001|First Intervention|Adverse Event|1
6244653|NCT01889602|9929191|FG002|First Intervention|Adverse Event|1
6244654|NCT01889602|9929189|FG000|First Intervention|Protocol Violation|0
6244655|NCT01889602|9929190|FG001|First Intervention|Protocol Violation|1
6244656|NCT01889602|9929191|FG002|First Intervention|Protocol Violation|1
6244657|NCT01889602|9929189|FG000|First Intervention|Study ending|0
6244658|NCT01889602|9929190|FG001|First Intervention|Study ending|1
6244659|NCT01889602|9929191|FG002|First Intervention|Study ending|0
6244660|NCT01889602|9929189|FG000|Second Intervention|Adverse Event|0
6244661|NCT01889602|9929190|FG001|Second Intervention|Adverse Event|0
6244662|NCT01889602|9929191|FG002|Second Intervention|Adverse Event|1
6244663|NCT01889602|9929189|FG000|Second Intervention|Study ending|1
6244664|NCT01889602|9929190|FG001|Second Intervention|Study ending|0
6244665|NCT01889602|9929191|FG002|Second Intervention|Study ending|0
6244666|NCT01889602|9929189|FG000|Second Intervention|Withdrawal by Subject|0
6244667|NCT01889602|9929190|FG001|Second Intervention|Withdrawal by Subject|0
6244668|NCT01889602|9929191|FG002|Second Intervention|Withdrawal by Subject|1
6244669|NCT01889602|9929189|FG000|Third Intervention|Protocol Violation|1
6244670|NCT01889602|9929190|FG001|Third Intervention|Protocol Violation|0
6244671|NCT01889602|9929191|FG002|Third Intervention|Protocol Violation|0
6244672|NCT01889602|9929189|FG000|Third Intervention|Withdrawal by Subject|2
6244673|NCT01889602|9929190|FG001|Third Intervention|Withdrawal by Subject|2
6244674|NCT01889602|9929191|FG002|Third Intervention|Withdrawal by Subject|0
6244675|NCT01889862|9929231|FG000|Part 1 (Up to 13 Weeks)|Adverse Event|4
6244676|NCT01889862|9929232|FG001|Part 1 (Up to 13 Weeks)|Adverse Event|0
6244677|NCT01889862|9929233|FG002|Part 1 (Up to 13 Weeks)|Adverse Event|0
6244678|NCT01889862|9929234|FG003|Part 1 (Up to 13 Weeks)|Adverse Event|0
6244679|NCT01889862|9929235|FG004|Part 1 (Up to 13 Weeks)|Adverse Event|0
6244680|NCT01889862|9929231|FG000|Part 1 (Up to 13 Weeks)|Withdrawal by Subject|2
6244681|NCT01889862|9929232|FG001|Part 1 (Up to 13 Weeks)|Withdrawal by Subject|0
6244682|NCT01889862|9929233|FG002|Part 1 (Up to 13 Weeks)|Withdrawal by Subject|0
6244683|NCT01889862|9929234|FG003|Part 1 (Up to 13 Weeks)|Withdrawal by Subject|0
6244684|NCT01889862|9929235|FG004|Part 1 (Up to 13 Weeks)|Withdrawal by Subject|0
6244685|NCT01889862|9929231|FG000|Part 1 (Up to 13 Weeks)|Lost to Follow-up|4
6244686|NCT01889862|9929232|FG001|Part 1 (Up to 13 Weeks)|Lost to Follow-up|0
6244687|NCT01889862|9929233|FG002|Part 1 (Up to 13 Weeks)|Lost to Follow-up|0
6244688|NCT01889862|9929234|FG003|Part 1 (Up to 13 Weeks)|Lost to Follow-up|0
6244689|NCT01889862|9929235|FG004|Part 1 (Up to 13 Weeks)|Lost to Follow-up|0
6244690|NCT01889862|9929231|FG000|Part 1 (Up to 13 Weeks)|Physician Decision|2
6244691|NCT01889862|9929232|FG001|Part 1 (Up to 13 Weeks)|Physician Decision|0
6244692|NCT01889862|9929233|FG002|Part 1 (Up to 13 Weeks)|Physician Decision|0
6244693|NCT01889862|9929234|FG003|Part 1 (Up to 13 Weeks)|Physician Decision|0
6244694|NCT01889862|9929235|FG004|Part 1 (Up to 13 Weeks)|Physician Decision|0
6244695|NCT01889862|9929231|FG000|Part 2 (8 Weeks)|Withdrawal by Subject|0
6244696|NCT01889862|9929232|FG001|Part 2 (8 Weeks)|Withdrawal by Subject|0
6244697|NCT01889862|9929233|FG002|Part 2 (8 Weeks)|Withdrawal by Subject|1
6244698|NCT01889862|9929234|FG003|Part 2 (8 Weeks)|Withdrawal by Subject|0
6244699|NCT01889862|9929235|FG004|Part 2 (8 Weeks)|Withdrawal by Subject|0
6244700|NCT01889862|9929231|FG000|Part 4 (Up to 274 Weeks)|Adverse Event|0
6244701|NCT01889862|9929232|FG001|Part 4 (Up to 274 Weeks)|Adverse Event|0
6244702|NCT01889862|9929233|FG002|Part 4 (Up to 274 Weeks)|Adverse Event|0
6244703|NCT01889862|9929234|FG003|Part 4 (Up to 274 Weeks)|Adverse Event|0
6244704|NCT01889862|9929235|FG004|Part 4 (Up to 274 Weeks)|Adverse Event|5
6244705|NCT01889862|9929231|FG000|Part 4 (Up to 274 Weeks)|Subject withdrew consent|0
6244706|NCT01889862|9929232|FG001|Part 4 (Up to 274 Weeks)|Subject withdrew consent|0
6244707|NCT01889862|9929233|FG002|Part 4 (Up to 274 Weeks)|Subject withdrew consent|0
6244708|NCT01889862|9929234|FG003|Part 4 (Up to 274 Weeks)|Subject withdrew consent|0
6244709|NCT01889862|9929235|FG004|Part 4 (Up to 274 Weeks)|Subject withdrew consent|14
6244710|NCT01889862|9929231|FG000|Part 4 (Up to 274 Weeks)|Lost to Follow-up|0
6244711|NCT01889862|9929232|FG001|Part 4 (Up to 274 Weeks)|Lost to Follow-up|0
6244712|NCT01889862|9929233|FG002|Part 4 (Up to 274 Weeks)|Lost to Follow-up|0
6244713|NCT01889862|9929234|FG003|Part 4 (Up to 274 Weeks)|Lost to Follow-up|0
6244714|NCT01889862|9929235|FG004|Part 4 (Up to 274 Weeks)|Lost to Follow-up|4
6244715|NCT01889862|9929231|FG000|Part 4 (Up to 274 Weeks)|Physician Decision|0
6244716|NCT01889862|9929232|FG001|Part 4 (Up to 274 Weeks)|Physician Decision|0
6244717|NCT01889862|9929233|FG002|Part 4 (Up to 274 Weeks)|Physician Decision|0
6244718|NCT01889862|9929234|FG003|Part 4 (Up to 274 Weeks)|Physician Decision|0
6244719|NCT01889862|9929235|FG004|Part 4 (Up to 274 Weeks)|Physician Decision|5
6244720|NCT01889862|9929231|FG000|Part 4 (Up to 274 Weeks)|Protocol deviations|0
6244721|NCT01889862|9929232|FG001|Part 4 (Up to 274 Weeks)|Protocol deviations|0
6244722|NCT01889862|9929233|FG002|Part 4 (Up to 274 Weeks)|Protocol deviations|0
6244723|NCT01889862|9929234|FG003|Part 4 (Up to 274 Weeks)|Protocol deviations|0
6244724|NCT01889862|9929235|FG004|Part 4 (Up to 274 Weeks)|Protocol deviations|2
6244725|NCT01890109|9929283|FG000|Overall Study|Withdrawal by Subject|0
6244726|NCT01890109|9929284|FG001|Overall Study|Withdrawal by Subject|3
6244727|NCT01890109|9929283|FG000|Overall Study|Lost to Follow-up|1
6244728|NCT01890109|9929284|FG001|Overall Study|Lost to Follow-up|2
6244729|NCT01890122|9929295|FG000|Overall Study|Adverse Event|1
6244730|NCT01890122|9929296|FG001|Overall Study|Adverse Event|1
6244731|NCT01890122|9929297|FG002|Overall Study|Adverse Event|1
6244732|NCT01890122|9929298|FG003|Overall Study|Adverse Event|2
6244733|NCT01890122|9929295|FG000|Overall Study|Major Protocol Deviation|3
6244734|NCT01890122|9929296|FG001|Overall Study|Major Protocol Deviation|1
6244735|NCT01890122|9929297|FG002|Overall Study|Major Protocol Deviation|0
6244736|NCT01890122|9929298|FG003|Overall Study|Major Protocol Deviation|1
6244737|NCT01890122|9929295|FG000|Overall Study|Lost to Follow-up|0
6244738|NCT01890122|9929296|FG001|Overall Study|Lost to Follow-up|1
6244739|NCT01890122|9929297|FG002|Overall Study|Lost to Follow-up|2
6244740|NCT01890122|9929298|FG003|Overall Study|Lost to Follow-up|2
6244741|NCT01890122|9929295|FG000|Overall Study|Voluntary Withdrawal|8
6244742|NCT01890122|9929296|FG001|Overall Study|Voluntary Withdrawal|8
6244743|NCT01890122|9929297|FG002|Overall Study|Voluntary Withdrawal|2
6244744|NCT01890122|9929298|FG003|Overall Study|Voluntary Withdrawal|11
6244745|NCT01890122|9929295|FG000|Overall Study|Lack of Efficacy|14
6244746|NCT01890122|9929296|FG001|Overall Study|Lack of Efficacy|24
6244747|NCT01890122|9929297|FG002|Overall Study|Lack of Efficacy|7
6244748|NCT01890122|9929298|FG003|Overall Study|Lack of Efficacy|41
6244749|NCT01890122|9929295|FG000|Overall Study|Reason not Specified|0
6244750|NCT01890122|9929296|FG001|Overall Study|Reason not Specified|1
6244751|NCT01890122|9929297|FG002|Overall Study|Reason not Specified|1
6244752|NCT01890122|9929298|FG003|Overall Study|Reason not Specified|2
6244753|NCT01890122|9929295|FG000|Overall Study|Randomized but not Treated|1
6244754|NCT01890122|9929296|FG001|Overall Study|Randomized but not Treated|1
6244755|NCT01890122|9929297|FG002|Overall Study|Randomized but not Treated|0
6244756|NCT01890122|9929298|FG003|Overall Study|Randomized but not Treated|0
6244757|NCT01890148|9929308|FG000|Overall Study|Adverse Event|1
6244758|NCT01890265|9929327|FG000|Overall Study|Other (Unspecified reason)|0
6244759|NCT01890265|9929328|FG001|Overall Study|Other (Unspecified reason)|1
6244760|NCT01890265|9929329|FG002|Overall Study|Other (Unspecified reason)|0
6244761|NCT01890265|9929330|FG003|Overall Study|Other (Unspecified reason)|0
6244762|NCT01890265|9929331|FG004|Overall Study|Other (Unspecified reason)|0
6244763|NCT01890265|9929332|FG005|Overall Study|Other (Unspecified reason)|0
6244764|NCT01890265|9929327|FG000|Overall Study|Progressive disease|6
6244765|NCT01890265|9929328|FG001|Overall Study|Progressive disease|6
6244766|NCT01890265|9929329|FG002|Overall Study|Progressive disease|0
6244767|NCT01890265|9929330|FG003|Overall Study|Progressive disease|0
6244768|NCT01890265|9929331|FG004|Overall Study|Progressive disease|0
6244769|NCT01890265|9929332|FG005|Overall Study|Progressive disease|0
6244770|NCT01890265|9929327|FG000|Overall Study|Adverse Event|2
6244771|NCT01890265|9929328|FG001|Overall Study|Adverse Event|1
6244772|NCT01890265|9929329|FG002|Overall Study|Adverse Event|0
6244773|NCT01890265|9929330|FG003|Overall Study|Adverse Event|0
6244774|NCT01890265|9929331|FG004|Overall Study|Adverse Event|0
6244775|NCT01890265|9929332|FG005|Overall Study|Adverse Event|0
6244776|NCT01890265|9929327|FG000|Overall Study|Death|2
6244777|NCT01890265|9929328|FG001|Overall Study|Death|3
6244778|NCT01890265|9929329|FG002|Overall Study|Death|1
6244779|NCT01890265|9929330|FG003|Overall Study|Death|0
6244780|NCT01890265|9929331|FG004|Overall Study|Death|0
6244781|NCT01890265|9929332|FG005|Overall Study|Death|0
6244782|NCT01890265|9929327|FG000|Overall Study|Withdrawal by Subject|0
6244783|NCT01890265|9929328|FG001|Overall Study|Withdrawal by Subject|2
6244784|NCT01890265|9929329|FG002|Overall Study|Withdrawal by Subject|3
6244785|NCT01890265|9929330|FG003|Overall Study|Withdrawal by Subject|0
6244786|NCT01890265|9929331|FG004|Overall Study|Withdrawal by Subject|2
6244787|NCT01890265|9929332|FG005|Overall Study|Withdrawal by Subject|0
6244788|NCT01890421|9929355|FG000|Overall Study|Adverse Event|1
6244789|NCT01890421|9929355|FG000|Overall Study|Other reason|10
6244790|NCT01890434|9929359|FG000|Overall Study|Adverse Event|8
6244791|NCT01890434|9929359|FG000|Overall Study|PCI at external hospital|1
6244792|NCT01890434|9929359|FG000|Overall Study|Assessment discrepancy|1
6244793|NCT01890434|9929359|FG000|Overall Study|CRC didn't contact participant for FU|1
6244794|NCT01890434|9929359|FG000|Overall Study|Could not get whole set of images|1
6244795|NCT01890434|9929359|FG000|Overall Study|Decline to return for GSPECT|1
6244796|NCT01890434|9929359|FG000|Overall Study|GSPECT at rest was not done|1
6244797|NCT01890434|9929359|FG000|Overall Study|Participant didn't complete MRI|1
6244798|NCT01890434|9929359|FG000|Overall Study|Uncontactable by phone|1
6244799|NCT01890434|9929359|FG000|Overall Study|Moved out of position|1
6244800|NCT01890434|9929359|FG000|Overall Study|Unable to contact|1
6244801|NCT01890434|9929359|FG000|Overall Study|Withdrawal by PI for ICA not performed|2
6244802|NCT01890473|9929365|FG000|Overall Study|Lost to Follow-up|1
6244803|NCT01890473|9929366|FG001|Overall Study|Lost to Follow-up|0
6244804|NCT01890473|9929365|FG000|Overall Study|Poor/non-compliance|1
6244805|NCT01890473|9929366|FG001|Overall Study|Poor/non-compliance|0
6244806|NCT01890512|9929374|FG000|Overall Study|Physician Decision|1
6244807|NCT01890512|9929374|FG000|Overall Study|Withdrawal by Subject|1
6244808|NCT01890512|9929374|FG000|Overall Study|Protocol Violation|1
6244809|NCT01890707|9929393|FG000|Overall Study|Lost to Follow-up|1
6244810|NCT01890707|9929394|FG001|Overall Study|Lost to Follow-up|1
6244811|NCT01890746|9929402|FG000|Overall Study|Death|39
6244812|NCT01890746|9929403|FG001|Overall Study|Death|30
6244813|NCT01890746|9929402|FG000|Overall Study|Adverse Event|1
6244814|NCT01890746|9929403|FG001|Overall Study|Adverse Event|0
6244815|NCT01890746|9929402|FG000|Overall Study|Lost to Follow-up|4
6244816|NCT01890746|9929403|FG001|Overall Study|Lost to Follow-up|1
6244817|NCT01890746|9929402|FG000|Overall Study|Physician Decision|3
6244818|NCT01890746|9929403|FG001|Overall Study|Physician Decision|2
6244819|NCT01890746|9929402|FG000|Overall Study|Withdrawal by Subject|5
6244820|NCT01890746|9929403|FG001|Overall Study|Withdrawal by Subject|8
6244821|NCT01890785|9929415|FG000|Third Intervention|Withdrawal by Subject|0
6244822|NCT01890785|9929416|FG001|Third Intervention|Withdrawal by Subject|1
6244823|NCT01890785|9929417|FG002|Third Intervention|Withdrawal by Subject|0
6244824|NCT01890785|9929418|FG003|Third Intervention|Withdrawal by Subject|0
6244825|NCT01890785|9929419|FG004|Third Intervention|Withdrawal by Subject|0
6244826|NCT01890785|9929420|FG005|Third Intervention|Withdrawal by Subject|0
6244827|NCT01890915|9929431|FG000|Overall Study|Adverse Event|1
6244828|NCT01890915|9929432|FG001|Overall Study|Adverse Event|0
6244829|NCT01890915|9929431|FG000|Overall Study|Protocol Violation|2
6244830|NCT01890915|9929432|FG001|Overall Study|Protocol Violation|0
6244831|NCT01890915|9929431|FG000|Overall Study|Equipment Malfunction|0
6244832|NCT01890915|9929432|FG001|Overall Study|Equipment Malfunction|1
6244833|NCT01890967|9929453|FG000|Overall Study|Adverse Event|3
6244834|NCT01890967|9929454|FG001|Overall Study|Adverse Event|3
6244835|NCT01890967|9929455|FG002|Overall Study|Adverse Event|3
6244836|NCT01890967|9929456|FG003|Overall Study|Adverse Event|2
6244837|NCT01890967|9929457|FG004|Overall Study|Adverse Event|1
6244838|NCT01890967|9929458|FG005|Overall Study|Adverse Event|7
6244839|NCT01890967|9929453|FG000|Overall Study|Death|1
6244840|NCT01890967|9929454|FG001|Overall Study|Death|0
6244841|NCT01890967|9929455|FG002|Overall Study|Death|0
6244842|NCT01890967|9929456|FG003|Overall Study|Death|0
6244843|NCT01890967|9929457|FG004|Overall Study|Death|0
6244844|NCT01890967|9929458|FG005|Overall Study|Death|0
6244845|NCT01890967|9929453|FG000|Overall Study|Lost to Follow-up|1
6244846|NCT01890967|9929454|FG001|Overall Study|Lost to Follow-up|1
6244847|NCT01890967|9929455|FG002|Overall Study|Lost to Follow-up|1
6244848|NCT01890967|9929456|FG003|Overall Study|Lost to Follow-up|1
6244849|NCT01890967|9929457|FG004|Overall Study|Lost to Follow-up|0
6244850|NCT01890967|9929458|FG005|Overall Study|Lost to Follow-up|1
6244851|NCT01890967|9929453|FG000|Overall Study|Protocol Violation|0
6244852|NCT01890967|9929454|FG001|Overall Study|Protocol Violation|3
6244853|NCT01890967|9929455|FG002|Overall Study|Protocol Violation|3
6244854|NCT01890967|9929456|FG003|Overall Study|Protocol Violation|2
6244855|NCT01890967|9929457|FG004|Overall Study|Protocol Violation|4
6244856|NCT01890967|9929458|FG005|Overall Study|Protocol Violation|1
6244857|NCT01890967|9929453|FG000|Overall Study|Sponsor Decision|2
6244858|NCT01890967|9929454|FG001|Overall Study|Sponsor Decision|0
6244859|NCT01890967|9929455|FG002|Overall Study|Sponsor Decision|1
6244860|NCT01890967|9929456|FG003|Overall Study|Sponsor Decision|3
6244861|NCT01890967|9929457|FG004|Overall Study|Sponsor Decision|2
6244862|NCT01890967|9929458|FG005|Overall Study|Sponsor Decision|3
6244863|NCT01890967|9929453|FG000|Overall Study|Withdrawal by Subject|3
6244864|NCT01890967|9929454|FG001|Overall Study|Withdrawal by Subject|4
6244865|NCT01890967|9929455|FG002|Overall Study|Withdrawal by Subject|2
6244866|NCT01890967|9929456|FG003|Overall Study|Withdrawal by Subject|3
6244867|NCT01890967|9929457|FG004|Overall Study|Withdrawal by Subject|3
6244868|NCT01890967|9929458|FG005|Overall Study|Withdrawal by Subject|1
6244869|NCT01891357|9929511|FG000|Overall Study|Protocol Violation|3
6244870|NCT01891669|9929525|FG000|Overall Study|Death|0
6244871|NCT01891669|9929526|FG001|Overall Study|Death|0
6244872|NCT01891669|9929527|FG002|Overall Study|Death|0
6244873|NCT01891669|9929528|FG003|Overall Study|Death|0
6244874|NCT01891669|9929529|FG004|Overall Study|Death|0
6244875|NCT01891669|9929530|FG005|Overall Study|Death|0
6244876|NCT01891669|9929531|FG006|Overall Study|Death|0
6244877|NCT01891669|9929532|FG007|Overall Study|Death|1
6244878|NCT01891669|9929533|FG008|Overall Study|Death|0
6244879|NCT01891669|9929534|FG009|Overall Study|Death|1
6244880|NCT01891669|9929525|FG000|Overall Study|Withdrawal by Subject|1
6244881|NCT01891669|9929526|FG001|Overall Study|Withdrawal by Subject|1
6244882|NCT01891669|9929527|FG002|Overall Study|Withdrawal by Subject|0
6244883|NCT01891669|9929528|FG003|Overall Study|Withdrawal by Subject|0
6244884|NCT01891669|9929529|FG004|Overall Study|Withdrawal by Subject|0
6244885|NCT01891669|9929530|FG005|Overall Study|Withdrawal by Subject|0
6244886|NCT01891669|9929531|FG006|Overall Study|Withdrawal by Subject|1
6244887|NCT01891669|9929532|FG007|Overall Study|Withdrawal by Subject|2
6244888|NCT01891669|9929533|FG008|Overall Study|Withdrawal by Subject|1
6244889|NCT01891669|9929534|FG009|Overall Study|Withdrawal by Subject|1
6244890|NCT01891669|9929525|FG000|Overall Study|Other|1
6244891|NCT01891669|9929526|FG001|Overall Study|Other|0
6244892|NCT01891669|9929527|FG002|Overall Study|Other|0
6244893|NCT01891669|9929528|FG003|Overall Study|Other|0
6244894|NCT01891669|9929529|FG004|Overall Study|Other|0
6244895|NCT01891669|9929530|FG005|Overall Study|Other|0
6244896|NCT01891669|9929531|FG006|Overall Study|Other|0
6244897|NCT01891669|9929532|FG007|Overall Study|Other|1
6244898|NCT01891669|9929533|FG008|Overall Study|Other|0
6244899|NCT01891669|9929534|FG009|Overall Study|Other|0
6244900|NCT01891721|9929568|FG000|Overall Study|Lost to Follow-up|10
6244901|NCT01891721|9929569|FG001|Overall Study|Lost to Follow-up|5
6244902|NCT01891721|9929570|FG002|Overall Study|Lost to Follow-up|1
6244903|NCT01891864|9929591|FG000|Treatment Period 1|Protocol Violation / IMP non-compliance|1
6244904|NCT01891864|9929592|FG001|Treatment Period 1|Protocol Violation / IMP non-compliance|1
6244905|NCT01891864|9929593|FG002|Treatment Period 1|Protocol Violation / IMP non-compliance|0
6244906|NCT01891864|9929594|FG003|Treatment Period 1|Protocol Violation / IMP non-compliance|0
6244907|NCT01891864|9929595|FG004|Treatment Period 1|Protocol Violation / IMP non-compliance|0
6244908|NCT01891864|9929596|FG005|Treatment Period 1|Protocol Violation / IMP non-compliance|0
6244909|NCT01891864|9929591|FG000|Treatment Period 1|Physician Decision|0
6244910|NCT01891864|9929592|FG001|Treatment Period 1|Physician Decision|1
6244911|NCT01891864|9929593|FG002|Treatment Period 1|Physician Decision|0
6244912|NCT01891864|9929594|FG003|Treatment Period 1|Physician Decision|0
6244913|NCT01891864|9929595|FG004|Treatment Period 1|Physician Decision|0
6244914|NCT01891864|9929596|FG005|Treatment Period 1|Physician Decision|0
6244915|NCT01891864|9929591|FG000|Treatment Period 1|Adverse Event, Serious, Fatal|0
6244916|NCT01891864|9929592|FG001|Treatment Period 1|Adverse Event, Serious, Fatal|1
6244917|NCT01891864|9929593|FG002|Treatment Period 1|Adverse Event, Serious, Fatal|0
6244918|NCT01891864|9929594|FG003|Treatment Period 1|Adverse Event, Serious, Fatal|0
6244919|NCT01891864|9929595|FG004|Treatment Period 1|Adverse Event, Serious, Fatal|0
6244920|NCT01891864|9929596|FG005|Treatment Period 1|Adverse Event, Serious, Fatal|0
6244921|NCT01891864|9929591|FG000|Treatment Period 1|Adverse Event / Injection Site Reaction|4
6244922|NCT01891864|9929592|FG001|Treatment Period 1|Adverse Event / Injection Site Reaction|4
6244923|NCT01891864|9929593|FG002|Treatment Period 1|Adverse Event / Injection Site Reaction|0
6244924|NCT01891864|9929594|FG003|Treatment Period 1|Adverse Event / Injection Site Reaction|0
6244925|NCT01891864|9929595|FG004|Treatment Period 1|Adverse Event / Injection Site Reaction|0
6244926|NCT01891864|9929596|FG005|Treatment Period 1|Adverse Event / Injection Site Reaction|0
6244927|NCT01891864|9929591|FG000|Treatment Period 1|Withdrawal by Subject|2
6244928|NCT01891864|9929592|FG001|Treatment Period 1|Withdrawal by Subject|5
6244929|NCT01891864|9929593|FG002|Treatment Period 1|Withdrawal by Subject|0
6244930|NCT01891864|9929594|FG003|Treatment Period 1|Withdrawal by Subject|0
6244931|NCT01891864|9929595|FG004|Treatment Period 1|Withdrawal by Subject|0
6244932|NCT01891864|9929596|FG005|Treatment Period 1|Withdrawal by Subject|0
6244933|NCT01891864|9929591|FG000|Treatment Period 1|Lost to Follow-up|1
6244934|NCT01891864|9929592|FG001|Treatment Period 1|Lost to Follow-up|0
6244935|NCT01891864|9929593|FG002|Treatment Period 1|Lost to Follow-up|0
6244936|NCT01891864|9929594|FG003|Treatment Period 1|Lost to Follow-up|0
6244937|NCT01891864|9929595|FG004|Treatment Period 1|Lost to Follow-up|0
6244938|NCT01891864|9929596|FG005|Treatment Period 1|Lost to Follow-up|0
6244939|NCT01891864|9929591|FG000|Treatment Period 2|Protocol Violation|0
6244940|NCT01891864|9929592|FG001|Treatment Period 2|Protocol Violation|0
6244941|NCT01891864|9929593|FG002|Treatment Period 2|Protocol Violation|0
6244942|NCT01891864|9929594|FG003|Treatment Period 2|Protocol Violation|1
6244943|NCT01891864|9929595|FG004|Treatment Period 2|Protocol Violation|0
6244944|NCT01891864|9929596|FG005|Treatment Period 2|Protocol Violation|0
6244945|NCT01891864|9929591|FG000|Treatment Period 2|Physician Decision|0
6244946|NCT01891864|9929592|FG001|Treatment Period 2|Physician Decision|0
6244947|NCT01891864|9929593|FG002|Treatment Period 2|Physician Decision|1
6244948|NCT01891864|9929594|FG003|Treatment Period 2|Physician Decision|0
6244949|NCT01891864|9929595|FG004|Treatment Period 2|Physician Decision|0
6244950|NCT01891864|9929596|FG005|Treatment Period 2|Physician Decision|0
6244951|NCT01891864|9929591|FG000|Treatment Period 2|Site Termination|0
6244952|NCT01891864|9929592|FG001|Treatment Period 2|Site Termination|0
6244953|NCT01891864|9929593|FG002|Treatment Period 2|Site Termination|1
6244954|NCT01891864|9929594|FG003|Treatment Period 2|Site Termination|2
6244955|NCT01891864|9929595|FG004|Treatment Period 2|Site Termination|0
6244956|NCT01891864|9929596|FG005|Treatment Period 2|Site Termination|0
6244957|NCT01891864|9929591|FG000|Treatment Period 2|Lack of Efficacy|0
6244958|NCT01891864|9929592|FG001|Treatment Period 2|Lack of Efficacy|0
6244959|NCT01891864|9929593|FG002|Treatment Period 2|Lack of Efficacy|1
6244960|NCT01891864|9929594|FG003|Treatment Period 2|Lack of Efficacy|0
6244961|NCT01891864|9929595|FG004|Treatment Period 2|Lack of Efficacy|1
6244962|NCT01891864|9929596|FG005|Treatment Period 2|Lack of Efficacy|0
6244963|NCT01891864|9929591|FG000|Treatment Period 2|Adverse Event|0
6244964|NCT01891864|9929592|FG001|Treatment Period 2|Adverse Event|0
6244965|NCT01891864|9929593|FG002|Treatment Period 2|Adverse Event|1
6244966|NCT01891864|9929594|FG003|Treatment Period 2|Adverse Event|2
6244967|NCT01891864|9929595|FG004|Treatment Period 2|Adverse Event|0
6244968|NCT01891864|9929596|FG005|Treatment Period 2|Adverse Event|4
6244969|NCT01891864|9929591|FG000|Treatment Period 2|Termination of Site|0
6244970|NCT01891864|9929592|FG001|Treatment Period 2|Termination of Site|0
6244971|NCT01891864|9929593|FG002|Treatment Period 2|Termination of Site|0
6244972|NCT01891864|9929594|FG003|Treatment Period 2|Termination of Site|0
6244973|NCT01891864|9929595|FG004|Treatment Period 2|Termination of Site|2
6244974|NCT01891864|9929596|FG005|Treatment Period 2|Termination of Site|0
6244975|NCT01891864|9929591|FG000|Treatment Period 2|Withdrawal by Subject|0
6244976|NCT01891864|9929592|FG001|Treatment Period 2|Withdrawal by Subject|0
6244977|NCT01891864|9929593|FG002|Treatment Period 2|Withdrawal by Subject|3
6244978|NCT01891864|9929594|FG003|Treatment Period 2|Withdrawal by Subject|4
6244979|NCT01891864|9929595|FG004|Treatment Period 2|Withdrawal by Subject|1
6244980|NCT01891864|9929596|FG005|Treatment Period 2|Withdrawal by Subject|1
6244981|NCT01891864|9929591|FG000|Extension Period|Lack of Efficacy|0
6244982|NCT01891864|9929592|FG001|Extension Period|Lack of Efficacy|0
6244983|NCT01891864|9929593|FG002|Extension Period|Lack of Efficacy|0
6244984|NCT01891864|9929594|FG003|Extension Period|Lack of Efficacy|1
6244985|NCT01891864|9929595|FG004|Extension Period|Lack of Efficacy|1
6244986|NCT01891864|9929596|FG005|Extension Period|Lack of Efficacy|0
6244987|NCT01891864|9929591|FG000|Extension Period|Pregnancy|0
6244988|NCT01891864|9929592|FG001|Extension Period|Pregnancy|0
6244989|NCT01891864|9929593|FG002|Extension Period|Pregnancy|1
6244990|NCT01891864|9929594|FG003|Extension Period|Pregnancy|0
6244991|NCT01891864|9929595|FG004|Extension Period|Pregnancy|0
6244992|NCT01891864|9929596|FG005|Extension Period|Pregnancy|0
6244993|NCT01891864|9929591|FG000|Extension Period|Adverse Event|0
6244994|NCT01891864|9929592|FG001|Extension Period|Adverse Event|0
6244995|NCT01891864|9929593|FG002|Extension Period|Adverse Event|4
6244996|NCT01891864|9929594|FG003|Extension Period|Adverse Event|2
6244997|NCT01891864|9929595|FG004|Extension Period|Adverse Event|2
6244998|NCT01891864|9929596|FG005|Extension Period|Adverse Event|0
6244999|NCT01891864|9929591|FG000|Extension Period|Withdrawal by Subject|0
6245000|NCT01891864|9929592|FG001|Extension Period|Withdrawal by Subject|0
6245001|NCT01891864|9929593|FG002|Extension Period|Withdrawal by Subject|1
6245002|NCT01891864|9929594|FG003|Extension Period|Withdrawal by Subject|2
6245003|NCT01891864|9929595|FG004|Extension Period|Withdrawal by Subject|4
6245004|NCT01891864|9929596|FG005|Extension Period|Withdrawal by Subject|0
6086069|NCT00658632|9695784|FG001|Overall Study|Lost to Follow-up|23
6086070|NCT00658632|9695783|FG000|Overall Study|Withdrawal by Subject|10
6086071|NCT00658632|9695784|FG001|Overall Study|Withdrawal by Subject|7
6245005|NCT01891864|9929591|FG000|Extension Period|Lost to Follow-up|0
6245006|NCT01891864|9929592|FG001|Extension Period|Lost to Follow-up|0
6245007|NCT01891864|9929593|FG002|Extension Period|Lost to Follow-up|2
6245008|NCT01891864|9929594|FG003|Extension Period|Lost to Follow-up|0
6245009|NCT01891864|9929595|FG004|Extension Period|Lost to Follow-up|0
6245010|NCT01891864|9929596|FG005|Extension Period|Lost to Follow-up|0
6245011|NCT01891890|9929611|FG000|Overall Study|Lost to Follow-up|0
6245012|NCT01891890|9929612|FG001|Overall Study|Lost to Follow-up|0
6245013|NCT01891890|9929613|FG002|Overall Study|Lost to Follow-up|1
6086072|NCT00658632|9695783|FG000|Overall Study|Lack of Efficacy|0
6086073|NCT00658632|9695784|FG001|Overall Study|Lack of Efficacy|1
6245014|NCT01891890|9929611|FG000|Overall Study|Study ended before endpoint reached|7
6245015|NCT01891890|9929612|FG001|Overall Study|Study ended before endpoint reached|3
6245016|NCT01891890|9929613|FG002|Overall Study|Study ended before endpoint reached|6
6245017|NCT01892020|9929634|FG000|Period 1|Adverse Event|1
6245018|NCT01892020|9929635|FG001|Period 1|Adverse Event|1
6245019|NCT01892020|9929634|FG000|Period 1|Protocol Violation|2
6245020|NCT01892020|9929635|FG001|Period 1|Protocol Violation|4
6245021|NCT01892020|9929634|FG000|Period 1|Unclassified|0
6245022|NCT01892020|9929635|FG001|Period 1|Unclassified|1
6245023|NCT01892020|9929634|FG000|Period 2|Protocol Violation|1
6245024|NCT01892020|9929635|FG001|Period 2|Protocol Violation|0
6245025|NCT01892163|9929643|FG000|Overall Study|Death|1
6245026|NCT01892163|9929644|FG001|Overall Study|Death|1
6245027|NCT01892163|9929643|FG000|Overall Study|Lost to Follow-up|1
6245028|NCT01892163|9929644|FG001|Overall Study|Lost to Follow-up|0
6245029|NCT01892189|9929659|FG000|Washout Period 1 (7 Days)|Adverse Event|0
6245030|NCT01892189|9929660|FG001|Washout Period 1 (7 Days)|Adverse Event|0
6245031|NCT01892189|9929661|FG002|Washout Period 1 (7 Days)|Adverse Event|0
6245032|NCT01892189|9929662|FG003|Washout Period 1 (7 Days)|Adverse Event|0
6245033|NCT01892189|9929663|FG004|Washout Period 1 (7 Days)|Adverse Event|0
6245034|NCT01892189|9929664|FG005|Washout Period 1 (7 Days)|Adverse Event|0
6245035|NCT01892189|9929665|FG006|Washout Period 1 (7 Days)|Adverse Event|0
6245036|NCT01892189|9929666|FG007|Washout Period 1 (7 Days)|Adverse Event|0
6245037|NCT01892189|9929667|FG008|Washout Period 1 (7 Days)|Adverse Event|1
6245038|NCT01892189|9929659|FG000|Washout Period 1 (7 Days)|Withdrawal by Subject|0
6245039|NCT01892189|9929660|FG001|Washout Period 1 (7 Days)|Withdrawal by Subject|0
6245040|NCT01892189|9929661|FG002|Washout Period 1 (7 Days)|Withdrawal by Subject|2
6245041|NCT01892189|9929662|FG003|Washout Period 1 (7 Days)|Withdrawal by Subject|1
6245042|NCT01892189|9929663|FG004|Washout Period 1 (7 Days)|Withdrawal by Subject|0
6245043|NCT01892189|9929664|FG005|Washout Period 1 (7 Days)|Withdrawal by Subject|0
6245044|NCT01892189|9929665|FG006|Washout Period 1 (7 Days)|Withdrawal by Subject|1
6245045|NCT01892189|9929666|FG007|Washout Period 1 (7 Days)|Withdrawal by Subject|0
6245046|NCT01892189|9929667|FG008|Washout Period 1 (7 Days)|Withdrawal by Subject|1
6245047|NCT01892189|9929659|FG000|Washout Period 1 (7 Days)|Noncompliance, Irritability|0
6245048|NCT01892189|9929660|FG001|Washout Period 1 (7 Days)|Noncompliance, Irritability|0
6245049|NCT01892189|9929661|FG002|Washout Period 1 (7 Days)|Noncompliance, Irritability|0
6245050|NCT01892189|9929662|FG003|Washout Period 1 (7 Days)|Noncompliance, Irritability|0
6245051|NCT01892189|9929663|FG004|Washout Period 1 (7 Days)|Noncompliance, Irritability|0
6245052|NCT01892189|9929664|FG005|Washout Period 1 (7 Days)|Noncompliance, Irritability|1
6245053|NCT01892189|9929665|FG006|Washout Period 1 (7 Days)|Noncompliance, Irritability|0
6245054|NCT01892189|9929666|FG007|Washout Period 1 (7 Days)|Noncompliance, Irritability|0
6245055|NCT01892189|9929667|FG008|Washout Period 1 (7 Days)|Noncompliance, Irritability|0
6245056|NCT01892293|9929691|FG000|Overall Study|Apheresed but not treated|4
6245057|NCT01892345|9929706|FG000|Overall Study|Adverse Event|0
6245058|NCT01892345|9929707|FG001|Overall Study|Adverse Event|2
6245059|NCT01892345|9929706|FG000|Overall Study|Death|1
6245060|NCT01892345|9929707|FG001|Overall Study|Death|0
6245061|NCT01892345|9929706|FG000|Overall Study|Lost to Follow-up|3
6245062|NCT01892345|9929707|FG001|Overall Study|Lost to Follow-up|0
6245063|NCT01892345|9929706|FG000|Overall Study|Withdrawal by Subject|12
6245064|NCT01892345|9929707|FG001|Overall Study|Withdrawal by Subject|1
6245065|NCT01892436|9929717|FG000|Overall Study|Withdrawal by Subject|8
6245066|NCT01892436|9929718|FG001|Overall Study|Withdrawal by Subject|15
6245067|NCT01892436|9929719|FG002|Overall Study|Withdrawal by Subject|4
6245068|NCT01892436|9929720|FG003|Overall Study|Withdrawal by Subject|4
6245069|NCT01892436|9929717|FG000|Overall Study|Death|1
6245070|NCT01892436|9929718|FG001|Overall Study|Death|1
6245071|NCT01892436|9929719|FG002|Overall Study|Death|0
6245072|NCT01892436|9929720|FG003|Overall Study|Death|0
6245073|NCT01892436|9929717|FG000|Overall Study|Physician Decision|2
6245074|NCT01892436|9929718|FG001|Overall Study|Physician Decision|1
6245075|NCT01892436|9929719|FG002|Overall Study|Physician Decision|0
6245076|NCT01892436|9929720|FG003|Overall Study|Physician Decision|1
6245077|NCT01892436|9929717|FG000|Overall Study|Pregnancy|0
6245078|NCT01892436|9929718|FG001|Overall Study|Pregnancy|2
6245079|NCT01892436|9929719|FG002|Overall Study|Pregnancy|1
6245080|NCT01892436|9929720|FG003|Overall Study|Pregnancy|0
6245081|NCT01892436|9929717|FG000|Overall Study|Technical problems|2
6245082|NCT01892436|9929718|FG001|Overall Study|Technical problems|1
6245083|NCT01892436|9929719|FG002|Overall Study|Technical problems|1
6245084|NCT01892436|9929720|FG003|Overall Study|Technical problems|1
6245085|NCT01892436|9929717|FG000|Overall Study|Lack of Efficacy|1
6245086|NCT01892436|9929718|FG001|Overall Study|Lack of Efficacy|2
6245087|NCT01892436|9929719|FG002|Overall Study|Lack of Efficacy|2
6245088|NCT01892436|9929720|FG003|Overall Study|Lack of Efficacy|2
6245089|NCT01892436|9929717|FG000|Overall Study|Lost to Follow-up|1
6245090|NCT01892436|9929718|FG001|Overall Study|Lost to Follow-up|1
6245091|NCT01892436|9929719|FG002|Overall Study|Lost to Follow-up|1
6245092|NCT01892436|9929720|FG003|Overall Study|Lost to Follow-up|3
6245093|NCT01892436|9929717|FG000|Overall Study|non-compliance with treatment|1
6245094|NCT01892436|9929718|FG001|Overall Study|non-compliance with treatment|0
6245095|NCT01892436|9929719|FG002|Overall Study|non-compliance with treatment|0
6245096|NCT01892436|9929720|FG003|Overall Study|non-compliance with treatment|0
6245097|NCT01892436|9929717|FG000|Overall Study|Adverse Event|7
6245098|NCT01892436|9929718|FG001|Overall Study|Adverse Event|6
6245099|NCT01892436|9929719|FG002|Overall Study|Adverse Event|2
6245100|NCT01892436|9929720|FG003|Overall Study|Adverse Event|3
6245101|NCT01892501|9929730|FG000|Overall Study|Protocol Violation|2
6245102|NCT01892501|9929730|FG000|Overall Study|Puncture not carried out|9
6245103|NCT01892501|9929730|FG000|Overall Study|Radiological monitoring not carried out|5
6245104|NCT01892501|9929730|FG000|Overall Study|Non-contributory histological result|12
6245105|NCT01892540|9929737|FG000|Overall Study|Did not complete PET/MRI|0
6245106|NCT01892540|9929738|FG001|Overall Study|Did not complete PET/MRI|0
6245107|NCT01892540|9929739|FG002|Overall Study|Did not complete PET/MRI|2
6245108|NCT01892540|9929737|FG000|Overall Study|Did not fit in scanner|0
6245109|NCT01892540|9929738|FG001|Overall Study|Did not fit in scanner|0
6245110|NCT01892540|9929739|FG002|Overall Study|Did not fit in scanner|1
6245111|NCT01892657|9929747|FG000|Overall Study|Withdrawal by Subject|6
6245112|NCT01892657|9929747|FG000|Overall Study|Protocol Violation|12
6245113|NCT01893203|9929780|FG000|Overall Study|Withdrawal by Subject|1
6245114|NCT01893281|9929784|FG000|Overall Study|Adverse Event|1
6245115|NCT01893281|9929784|FG000|Overall Study|Protocol Violation|1
6245116|NCT01893281|9929784|FG000|Overall Study|Withdrawal by Subject|1
6245117|NCT01893346|9929792|FG000|Overall Study|Lost to Follow-up|0
6245118|NCT01893346|9929793|FG001|Overall Study|Lost to Follow-up|1
6245119|NCT01893346|9929794|FG002|Overall Study|Lost to Follow-up|0
6245120|NCT01893346|9929795|FG003|Overall Study|Lost to Follow-up|0
6245121|NCT01893346|9929792|FG000|Overall Study|Protocol Violation|1
6245122|NCT01893346|9929793|FG001|Overall Study|Protocol Violation|0
6245123|NCT01893346|9929794|FG002|Overall Study|Protocol Violation|0
6245124|NCT01893346|9929795|FG003|Overall Study|Protocol Violation|0
6245125|NCT01893346|9929792|FG000|Overall Study|Withdrawal by Subject|2
6245126|NCT01893346|9929793|FG001|Overall Study|Withdrawal by Subject|0
6245127|NCT01893346|9929794|FG002|Overall Study|Withdrawal by Subject|0
6245128|NCT01893346|9929795|FG003|Overall Study|Withdrawal by Subject|0
6245129|NCT01893411|9929817|FG000|Overall Study|Protocol Violation|1
6245130|NCT01893411|9929818|FG001|Overall Study|Protocol Violation|0
6245131|NCT01893411|9929819|FG002|Overall Study|Protocol Violation|0
6245132|NCT01893411|9929817|FG000|Overall Study|Physician Decision|1
6245133|NCT01893411|9929818|FG001|Overall Study|Physician Decision|1
6245134|NCT01893411|9929819|FG002|Overall Study|Physician Decision|2
6245135|NCT01893411|9929817|FG000|Overall Study|Lack of Efficacy|2
6245136|NCT01893411|9929818|FG001|Overall Study|Lack of Efficacy|1
6245137|NCT01893411|9929819|FG002|Overall Study|Lack of Efficacy|0
6245138|NCT01893411|9929817|FG000|Overall Study|Other|3
6245139|NCT01893411|9929818|FG001|Overall Study|Other|1
6245140|NCT01893411|9929819|FG002|Overall Study|Other|3
6245141|NCT01893411|9929817|FG000|Overall Study|Adverse Event|1
6245142|NCT01893411|9929818|FG001|Overall Study|Adverse Event|0
6245143|NCT01893411|9929819|FG002|Overall Study|Adverse Event|0
6245144|NCT01893411|9929817|FG000|Overall Study|Withdrawal by Subject|7
6245145|NCT01893411|9929818|FG001|Overall Study|Withdrawal by Subject|4
6245146|NCT01893411|9929819|FG002|Overall Study|Withdrawal by Subject|3
6245147|NCT01893411|9929817|FG000|Overall Study|Lost to Follow-up|2
6245148|NCT01893411|9929818|FG001|Overall Study|Lost to Follow-up|0
6245149|NCT01893411|9929819|FG002|Overall Study|Lost to Follow-up|1
6245150|NCT01893827|9929848|FG000|Overall Study|Lost to Follow-up|19
6245151|NCT01893827|9929849|FG001|Overall Study|Lost to Follow-up|26
6245152|NCT01893905|9929866|FG000|Overall Study|Withdrawal by Subject|1
6245153|NCT01893905|9929867|FG001|Overall Study|Withdrawal by Subject|0
6245154|NCT01893905|9929866|FG000|Overall Study|Adverse Event|9
6245155|NCT01893905|9929867|FG001|Overall Study|Adverse Event|3
6245156|NCT01893905|9929866|FG000|Overall Study|Lack of Efficacy|5
6245157|NCT01893905|9929867|FG001|Overall Study|Lack of Efficacy|7
6245158|NCT01893905|9929866|FG000|Overall Study|Lost to Follow-up|1
6245159|NCT01893905|9929867|FG001|Overall Study|Lost to Follow-up|0
6245160|NCT01893905|9929866|FG000|Overall Study|Protocol Violation|6
6245161|NCT01893905|9929867|FG001|Overall Study|Protocol Violation|1
6245162|NCT01893905|9929866|FG000|Overall Study|Lack of adherence to treatment|2
6245163|NCT01893905|9929867|FG001|Overall Study|Lack of adherence to treatment|0
6245164|NCT01893905|9929866|FG000|Overall Study|Other reason|1
6245165|NCT01893905|9929867|FG001|Overall Study|Other reason|3
6245166|NCT01894022|9929884|FG000|Overall Study|Death|1
6245167|NCT01894022|9929885|FG001|Overall Study|Death|0
6245168|NCT01894022|9929884|FG000|Overall Study|Adverse Event, non-fatal|1
6245169|NCT01894022|9929885|FG001|Overall Study|Adverse Event, non-fatal|0
6245170|NCT01894022|9929884|FG000|Overall Study|Study Closed/terminated|7
6245171|NCT01894022|9929885|FG001|Overall Study|Study Closed/terminated|10
6245172|NCT01894100|9929903|FG000|Overall Study|Lost to Follow-up|0
6245173|NCT01894100|9929904|FG001|Overall Study|Lost to Follow-up|1
6245174|NCT01894100|9929903|FG000|Overall Study|Withdrawal by Subject|3
6245175|NCT01894100|9929904|FG001|Overall Study|Withdrawal by Subject|0
6245176|NCT01894152|9929910|FG000|Overall Study|No DMR and no Stent thrombosis|151
6245177|NCT01894230|9929925|FG000|Overall Study|Lost to Follow-up|2
6245178|NCT01894230|9929926|FG001|Overall Study|Lost to Follow-up|2
6245179|NCT01894230|9929925|FG000|Overall Study|Withdrawal by Subject|4
6245180|NCT01894230|9929926|FG001|Overall Study|Withdrawal by Subject|4
6245181|NCT01894230|9929925|FG000|Overall Study|Non-adherent|0
6245182|NCT01894230|9929926|FG001|Overall Study|Non-adherent|1
6245183|NCT01894230|9929925|FG000|Overall Study|Death|1
6245184|NCT01894230|9929926|FG001|Overall Study|Death|0
6245185|NCT01894243|9929935|FG000|Overall Study|Adverse Event|0
6245186|NCT01894243|9929936|FG001|Overall Study|Adverse Event|1
6245187|NCT01894243|9929937|FG002|Overall Study|Adverse Event|2
6245188|NCT01894243|9929935|FG000|Overall Study|Death|0
6245189|NCT01894243|9929936|FG001|Overall Study|Death|0
6245190|NCT01894243|9929937|FG002|Overall Study|Death|3
6245191|NCT01894243|9929935|FG000|Overall Study|Lack of Efficacy|3
6245192|NCT01894243|9929936|FG001|Overall Study|Lack of Efficacy|3
6245193|NCT01894243|9929937|FG002|Overall Study|Lack of Efficacy|1
6245194|NCT01894243|9929935|FG000|Overall Study|Condition under investigation worsened|8
6086074|NCT00658632|9695783|FG000|Overall Study|Withdrawal of consent|8
6245195|NCT01894243|9929936|FG001|Overall Study|Condition under investigation worsened|6
6245196|NCT01894243|9929937|FG002|Overall Study|Condition under investigation worsened|2
6245197|NCT01894243|9929935|FG000|Overall Study|Subject decision|1
6245198|NCT01894243|9929936|FG001|Overall Study|Subject decision|0
6245199|NCT01894243|9929937|FG002|Overall Study|Subject decision|0
6245200|NCT01894243|9929935|FG000|Overall Study|Other|1
6245201|NCT01894243|9929936|FG001|Overall Study|Other|0
6245202|NCT01894243|9929937|FG002|Overall Study|Other|0
6270515|NCT02152631|9971438|FG000|Overall Study|On Treatment|19
6270516|NCT02152631|9971439|FG001|Overall Study|On Treatment|3
6270517|NCT02152761|9971462|FG000|Epoch: Treatment Epoch|Technical problems|0
6270518|NCT02152761|9971463|FG001|Epoch: Treatment Epoch|Technical problems|0
6270519|NCT02152761|9971464|FG002|Epoch: Treatment Epoch|Technical problems|0
6270520|NCT02152761|9971465|FG003|Epoch: Treatment Epoch|Technical problems|1
6270521|NCT02152761|9971462|FG000|Epoch: Treatment Epoch|Lost to Follow-up|0
6270522|NCT02152761|9971463|FG001|Epoch: Treatment Epoch|Lost to Follow-up|2
6270523|NCT02152761|9971464|FG002|Epoch: Treatment Epoch|Lost to Follow-up|0
6270524|NCT02152761|9971465|FG003|Epoch: Treatment Epoch|Lost to Follow-up|0
6270525|NCT02152761|9971462|FG000|Epoch: Treatment Epoch|Withdrawal by Subject|7
6270526|NCT02152761|9971463|FG001|Epoch: Treatment Epoch|Withdrawal by Subject|8
6270527|NCT02152761|9971464|FG002|Epoch: Treatment Epoch|Withdrawal by Subject|3
6270528|NCT02152761|9971465|FG003|Epoch: Treatment Epoch|Withdrawal by Subject|5
6270529|NCT02152761|9971462|FG000|Epoch: Treatment Epoch|Adverse Event|3
6270530|NCT02152761|9971463|FG001|Epoch: Treatment Epoch|Adverse Event|6
6270531|NCT02152761|9971464|FG002|Epoch: Treatment Epoch|Adverse Event|1
6270532|NCT02152761|9971465|FG003|Epoch: Treatment Epoch|Adverse Event|2
6270533|NCT02152761|9971462|FG000|Epoch: Treatment Epoch|Death|0
6270534|NCT02152761|9971463|FG001|Epoch: Treatment Epoch|Death|3
6270535|NCT02152761|9971464|FG002|Epoch: Treatment Epoch|Death|1
6270536|NCT02152761|9971465|FG003|Epoch: Treatment Epoch|Death|0
6270537|NCT02152761|9971462|FG000|Epoch: Treatment Epoch|Non-compliance with treatment|1
6270538|NCT02152761|9971463|FG001|Epoch: Treatment Epoch|Non-compliance with treatment|1
6270539|NCT02152761|9971464|FG002|Epoch: Treatment Epoch|Non-compliance with treatment|0
6270540|NCT02152761|9971465|FG003|Epoch: Treatment Epoch|Non-compliance with treatment|0
6270541|NCT02152761|9971462|FG000|Epoch: Post-treatment Follow-up Epoch|Withdrawal by Subject|1
6270542|NCT02152761|9971463|FG001|Epoch: Post-treatment Follow-up Epoch|Withdrawal by Subject|3
6270543|NCT02152761|9971464|FG002|Epoch: Post-treatment Follow-up Epoch|Withdrawal by Subject|0
6270544|NCT02152761|9971465|FG003|Epoch: Post-treatment Follow-up Epoch|Withdrawal by Subject|1
6270545|NCT02152761|9971462|FG000|Epoch: Post-treatment Follow-up Epoch|Lost to Follow-up|1
6270546|NCT02152761|9971463|FG001|Epoch: Post-treatment Follow-up Epoch|Lost to Follow-up|4
6270547|NCT02152761|9971464|FG002|Epoch: Post-treatment Follow-up Epoch|Lost to Follow-up|0
6270548|NCT02152761|9971465|FG003|Epoch: Post-treatment Follow-up Epoch|Lost to Follow-up|0
6270549|NCT02152761|9971462|FG000|Epoch: Post-treatment Follow-up Epoch|Adverse Event|1
6270550|NCT02152761|9971463|FG001|Epoch: Post-treatment Follow-up Epoch|Adverse Event|0
6270551|NCT02152761|9971464|FG002|Epoch: Post-treatment Follow-up Epoch|Adverse Event|0
6270552|NCT02152761|9971465|FG003|Epoch: Post-treatment Follow-up Epoch|Adverse Event|0
6270553|NCT02152761|9971462|FG000|Epoch: Post-treatment Follow-up Epoch|Death|1
6270554|NCT02152761|9971463|FG001|Epoch: Post-treatment Follow-up Epoch|Death|0
6270555|NCT02152761|9971464|FG002|Epoch: Post-treatment Follow-up Epoch|Death|0
6270556|NCT02152761|9971465|FG003|Epoch: Post-treatment Follow-up Epoch|Death|1
6270557|NCT02153073|9971490|FG000|Overall Study|Case Report Forms Uncollected|230
6270558|NCT02153073|9971490|FG000|Overall Study|Protocol Deviation|68
6270559|NCT02153086|9971494|FG000|Overall Study|Not enrolled >=28 days and <=56 days|2
6270560|NCT02153086|9971494|FG000|Overall Study|Other|2
6270561|NCT02153112|9971537|FG000|Overall Study|Adverse Event|0
6270562|NCT02153112|9971538|FG001|Overall Study|Adverse Event|0
6270563|NCT02153112|9971539|FG002|Overall Study|Adverse Event|1
6270564|NCT02153112|9971540|FG003|Overall Study|Adverse Event|0
6270565|NCT02153112|9971541|FG004|Overall Study|Adverse Event|0
6270566|NCT02153112|9971542|FG005|Overall Study|Adverse Event|0
6270567|NCT02153112|9971543|FG006|Overall Study|Adverse Event|0
6270568|NCT02153112|9971544|FG007|Overall Study|Adverse Event|0
6270569|NCT02153112|9971545|FG008|Overall Study|Adverse Event|0
6270570|NCT02153112|9971546|FG009|Overall Study|Adverse Event|0
6270571|NCT02153112|9971537|FG000|Overall Study|Lost to Follow-up|1
6270572|NCT02153112|9971538|FG001|Overall Study|Lost to Follow-up|1
6270573|NCT02153112|9971539|FG002|Overall Study|Lost to Follow-up|0
6270574|NCT02153112|9971540|FG003|Overall Study|Lost to Follow-up|0
6270575|NCT02153112|9971541|FG004|Overall Study|Lost to Follow-up|2
6270576|NCT02153112|9971542|FG005|Overall Study|Lost to Follow-up|1
6245203|NCT01894256|9929955|FG000|Part A|Adverse Event|0
6245204|NCT01894256|9929956|FG001|Part A|Adverse Event|1
6245205|NCT01894256|9929957|FG002|Part A|Adverse Event|0
6245206|NCT01894256|9929955|FG000|Part B|Death|0
6245207|NCT01894256|9929956|FG001|Part B|Death|1
6245208|NCT01894256|9929957|FG002|Part B|Death|1
6245209|NCT01894256|9929955|FG000|Part B|Withdrawal by Subject|0
6245210|NCT01894256|9929956|FG001|Part B|Withdrawal by Subject|1
6245211|NCT01894256|9929957|FG002|Part B|Withdrawal by Subject|0
6245212|NCT01894256|9929955|FG000|Part B|Lack of Efficacy|15
6245213|NCT01894256|9929956|FG001|Part B|Lack of Efficacy|12
6245214|NCT01894256|9929957|FG002|Part B|Lack of Efficacy|13
6245215|NCT01894477|9929970|FG000|Overall Study|Protocol Violation|0
6245216|NCT01894477|9929971|FG001|Overall Study|Protocol Violation|1
6245217|NCT01894477|9929970|FG000|Overall Study|protocol changed due SC changed to cord|0
6245218|NCT01894477|9929971|FG001|Overall Study|protocol changed due SC changed to cord|1
6245219|NCT01894516|9929986|FG000|Period 1 (Baseline up to Week 12)|Other|0
6245220|NCT01894516|9929987|FG001|Period 1 (Baseline up to Week 12)|Other|1
6245221|NCT01894516|9929988|FG002|Period 1 (Baseline up to Week 12)|Other|1
6245222|NCT01894516|9929989|FG003|Period 1 (Baseline up to Week 12)|Other|0
6245223|NCT01894516|9929986|FG000|Period 1 (Baseline up to Week 12)|Adverse event and treatment failure|2
6245224|NCT01894516|9929987|FG001|Period 1 (Baseline up to Week 12)|Adverse event and treatment failure|0
6245225|NCT01894516|9929988|FG002|Period 1 (Baseline up to Week 12)|Adverse event and treatment failure|0
6245226|NCT01894516|9929989|FG003|Period 1 (Baseline up to Week 12)|Adverse event and treatment failure|0
6245227|NCT01894516|9929986|FG000|Period 1 (Baseline up to Week 12)|Non compliance with the study medication|1
6245228|NCT01894516|9929987|FG001|Period 1 (Baseline up to Week 12)|Non compliance with the study medication|1
6245229|NCT01894516|9929988|FG002|Period 1 (Baseline up to Week 12)|Non compliance with the study medication|0
6245230|NCT01894516|9929989|FG003|Period 1 (Baseline up to Week 12)|Non compliance with the study medication|0
6245231|NCT01894516|9929986|FG000|Period 1 (Baseline up to Week 12)|Treatment failure|0
6245232|NCT01894516|9929987|FG001|Period 1 (Baseline up to Week 12)|Treatment failure|0
6245233|NCT01894516|9929988|FG002|Period 1 (Baseline up to Week 12)|Treatment failure|1
6245234|NCT01894516|9929989|FG003|Period 1 (Baseline up to Week 12)|Treatment failure|0
6245235|NCT01894516|9929986|FG000|Period 1 (Baseline up to Week 12)|Adverse Event|2
6245236|NCT01894516|9929987|FG001|Period 1 (Baseline up to Week 12)|Adverse Event|0
6245237|NCT01894516|9929988|FG002|Period 1 (Baseline up to Week 12)|Adverse Event|0
6245238|NCT01894516|9929989|FG003|Period 1 (Baseline up to Week 12)|Adverse Event|1
6245239|NCT01894516|9929986|FG000|Period 1 (Baseline up to Week 12)|Withdrawal by Subject|2
6245240|NCT01894516|9929987|FG001|Period 1 (Baseline up to Week 12)|Withdrawal by Subject|3
6245241|NCT01894516|9929988|FG002|Period 1 (Baseline up to Week 12)|Withdrawal by Subject|1
6245242|NCT01894516|9929989|FG003|Period 1 (Baseline up to Week 12)|Withdrawal by Subject|2
6245243|NCT01894516|9929986|FG000|Period 2 (Week 13 to Week 24)|Adverse Event|0
6245244|NCT01894516|9929987|FG001|Period 2 (Week 13 to Week 24)|Adverse Event|2
6245245|NCT01894516|9929988|FG002|Period 2 (Week 13 to Week 24)|Adverse Event|3
6245246|NCT01894516|9929989|FG003|Period 2 (Week 13 to Week 24)|Adverse Event|1
6245247|NCT01894516|9929986|FG000|Period 2 (Week 13 to Week 24)|Withdrawal by Subject|0
6245248|NCT01894516|9929987|FG001|Period 2 (Week 13 to Week 24)|Withdrawal by Subject|0
6245249|NCT01894516|9929988|FG002|Period 2 (Week 13 to Week 24)|Withdrawal by Subject|2
6245250|NCT01894516|9929989|FG003|Period 2 (Week 13 to Week 24)|Withdrawal by Subject|0
6245251|NCT01894568|9930009|FG000|Overall Study|Adverse Event|2
6245252|NCT01894568|9930010|FG001|Overall Study|Adverse Event|3
6245253|NCT01894568|9930009|FG000|Overall Study|Protocol required discontinuation|2
6245254|NCT01894568|9930010|FG001|Overall Study|Protocol required discontinuation|1
6245255|NCT01894568|9930009|FG000|Overall Study|Withdrawal by Subject|5
6245256|NCT01894568|9930010|FG001|Overall Study|Withdrawal by Subject|5
6245257|NCT01894568|9930009|FG000|Overall Study|Physician Decision|1
6245258|NCT01894568|9930010|FG001|Overall Study|Physician Decision|0
6245259|NCT01894568|9930009|FG000|Overall Study|Lost to Follow-up|0
6245260|NCT01894568|9930010|FG001|Overall Study|Lost to Follow-up|1
6245261|NCT01894581|9930019|FG000|Overall Study|Withdrawal by Subject|2
6245262|NCT01894581|9930020|FG001|Overall Study|Withdrawal by Subject|3
6245263|NCT01894581|9930019|FG000|Overall Study|Screen Failure|3
6245264|NCT01894581|9930020|FG001|Overall Study|Screen Failure|4
6245265|NCT01894607|9930026|FG000|Overall Study|Ineligible|1
6245266|NCT01894620|9930032|FG000|Overall Study|Withdrawal by Subject|0
6245267|NCT01894620|9930033|FG001|Overall Study|Withdrawal by Subject|1
6245268|NCT01894776|9930046|FG000|Overall Study|Withdrawal by Subject|1
6245269|NCT01894841|9930052|FG000|Overall Study|Withdrawal by Subject|9
6245270|NCT01894841|9930053|FG001|Overall Study|Withdrawal by Subject|4
6245271|NCT01894841|9930052|FG000|Overall Study|Withdrawn by investigator|2
6245272|NCT01894841|9930053|FG001|Overall Study|Withdrawn by investigator|2
6245273|NCT01894841|9930052|FG000|Overall Study|Lost to Follow-up|7
6245274|NCT01894841|9930053|FG001|Overall Study|Lost to Follow-up|3
6245275|NCT01894919|9930097|FG000|Overall Study|Withdrawal by Subject|1
6245276|NCT01894919|9930098|FG001|Overall Study|Withdrawal by Subject|0
6245277|NCT01894919|9930099|FG002|Overall Study|Withdrawal by Subject|0
6245278|NCT01894919|9930100|FG003|Overall Study|Withdrawal by Subject|0
6245279|NCT01894919|9930101|FG004|Overall Study|Withdrawal by Subject|1
6245280|NCT01894919|9930102|FG005|Overall Study|Withdrawal by Subject|0
6245281|NCT01894919|9930103|FG006|Overall Study|Withdrawal by Subject|0
6245282|NCT01894919|9930104|FG007|Overall Study|Withdrawal by Subject|0
6245283|NCT01894919|9930105|FG008|Overall Study|Withdrawal by Subject|0
6245284|NCT01894919|9930106|FG009|Overall Study|Withdrawal by Subject|1
6245285|NCT01894919|9930107|FG010|Overall Study|Withdrawal by Subject|1
6245286|NCT01894919|9930108|FG011|Overall Study|Withdrawal by Subject|0
6245287|NCT01894919|9930109|FG012|Overall Study|Withdrawal by Subject|0
6245288|NCT01894919|9930097|FG000|Overall Study|Adverse Event|0
6245289|NCT01894919|9930098|FG001|Overall Study|Adverse Event|0
6245290|NCT01894919|9930099|FG002|Overall Study|Adverse Event|0
6245291|NCT01894919|9930100|FG003|Overall Study|Adverse Event|0
6245292|NCT01894919|9930101|FG004|Overall Study|Adverse Event|0
6245293|NCT01894919|9930102|FG005|Overall Study|Adverse Event|0
6245294|NCT01894919|9930103|FG006|Overall Study|Adverse Event|0
6245295|NCT01894919|9930104|FG007|Overall Study|Adverse Event|0
6245296|NCT01894919|9930105|FG008|Overall Study|Adverse Event|0
6245297|NCT01894919|9930106|FG009|Overall Study|Adverse Event|0
6245298|NCT01894919|9930107|FG010|Overall Study|Adverse Event|1
6245299|NCT01894919|9930108|FG011|Overall Study|Adverse Event|0
6245300|NCT01894919|9930109|FG012|Overall Study|Adverse Event|0
6245301|NCT01894919|9930097|FG000|Overall Study|Other-Unspecified|1
6245302|NCT01894919|9930098|FG001|Overall Study|Other-Unspecified|0
6245303|NCT01894919|9930099|FG002|Overall Study|Other-Unspecified|0
6245304|NCT01894919|9930100|FG003|Overall Study|Other-Unspecified|0
6245305|NCT01894919|9930101|FG004|Overall Study|Other-Unspecified|0
6245306|NCT01894919|9930102|FG005|Overall Study|Other-Unspecified|0
6245307|NCT01894919|9930103|FG006|Overall Study|Other-Unspecified|0
6245308|NCT01894919|9930104|FG007|Overall Study|Other-Unspecified|0
6245309|NCT01894919|9930105|FG008|Overall Study|Other-Unspecified|0
6245310|NCT01894919|9930106|FG009|Overall Study|Other-Unspecified|0
6245311|NCT01894919|9930107|FG010|Overall Study|Other-Unspecified|0
6245312|NCT01894919|9930108|FG011|Overall Study|Other-Unspecified|0
6245313|NCT01894919|9930109|FG012|Overall Study|Other-Unspecified|0
6245314|NCT01894919|9930097|FG000|Overall Study|Lost to Follow-up|0
6245315|NCT01894919|9930098|FG001|Overall Study|Lost to Follow-up|0
6245316|NCT01894919|9930099|FG002|Overall Study|Lost to Follow-up|0
6245317|NCT01894919|9930100|FG003|Overall Study|Lost to Follow-up|0
6245318|NCT01894919|9930101|FG004|Overall Study|Lost to Follow-up|2
6245319|NCT01894919|9930102|FG005|Overall Study|Lost to Follow-up|0
6245320|NCT01894919|9930103|FG006|Overall Study|Lost to Follow-up|0
6245321|NCT01894919|9930104|FG007|Overall Study|Lost to Follow-up|0
6245322|NCT01894919|9930105|FG008|Overall Study|Lost to Follow-up|0
6245323|NCT01894919|9930106|FG009|Overall Study|Lost to Follow-up|0
6245324|NCT01894919|9930107|FG010|Overall Study|Lost to Follow-up|0
6245325|NCT01894919|9930108|FG011|Overall Study|Lost to Follow-up|0
6245326|NCT01894919|9930109|FG012|Overall Study|Lost to Follow-up|0
6245327|NCT01894984|9930153|FG000|Overall Study|Other|314
6245328|NCT01894984|9930154|FG001|Overall Study|Other|175
6245329|NCT01895101|9930180|FG000|Overall Study|OPCAB procedure|1
6245330|NCT01895101|9930181|FG001|Overall Study|OPCAB procedure|1
6245331|NCT01895101|9930182|FG002|Overall Study|OPCAB procedure|3
6245332|NCT01895101|9930180|FG000|Overall Study|Withdrawal by Subject|0
6245333|NCT01895101|9930181|FG001|Overall Study|Withdrawal by Subject|1
6245334|NCT01895101|9930182|FG002|Overall Study|Withdrawal by Subject|2
6245335|NCT01895101|9930180|FG000|Overall Study|another study, enrolled in other study|0
6245336|NCT01895101|9930181|FG001|Overall Study|another study, enrolled in other study|1
6245337|NCT01895101|9930182|FG002|Overall Study|another study, enrolled in other study|0
6245338|NCT01895101|9930180|FG000|Overall Study|Death|0
6245339|NCT01895101|9930181|FG001|Overall Study|Death|1
6245340|NCT01895101|9930182|FG002|Overall Study|Death|0
6245341|NCT01895101|9930180|FG000|Overall Study|coagulation disorder|0
6245342|NCT01895101|9930181|FG001|Overall Study|coagulation disorder|1
6245343|NCT01895101|9930182|FG002|Overall Study|coagulation disorder|0
6245344|NCT01895270|9930202|FG000|Study Medications Induction (W1-4)|Withdrawal by Subject|0
6245345|NCT01895270|9930203|FG001|Study Medications Induction (W1-4)|Withdrawal by Subject|2
6245346|NCT01895270|9930202|FG000|Study Medications Induction (W1-4)|Vitals outside of ISR dosing parameters|3
6245347|NCT01895270|9930203|FG001|Study Medications Induction (W1-4)|Vitals outside of ISR dosing parameters|2
6245348|NCT01895270|9930202|FG000|Study Medications Induction (W1-4)|noncompliance- missed medications|3
6245349|NCT01895270|9930203|FG001|Study Medications Induction (W1-4)|noncompliance- missed medications|1
6245350|NCT01895270|9930202|FG000|Study Medications Induction (W1-4)|Blood pressure issues|0
6245351|NCT01895270|9930203|FG001|Study Medications Induction (W1-4)|Blood pressure issues|1
6245352|NCT01895270|9930202|FG000|Buprenorphine Taper (W5 to W6D3)|noncompliance - missed medication|3
6245353|NCT01895270|9930203|FG001|Buprenorphine Taper (W5 to W6D3)|noncompliance - missed medication|5
6245354|NCT01895270|9930202|FG000|Isradipine Taper (W7-8)|Lost to Follow-up|0
6245355|NCT01895270|9930203|FG001|Isradipine Taper (W7-8)|Lost to Follow-up|1
6245356|NCT01895270|9930202|FG000|Isradipine Taper (W7-8)|Withdrawal by Subject|0
6245357|NCT01895270|9930203|FG001|Isradipine Taper (W7-8)|Withdrawal by Subject|1
6245358|NCT01895309|9930211|FG000|Overall Study|Adverse Event|13
6245359|NCT01895309|9930212|FG001|Overall Study|Adverse Event|17
6245360|NCT01895309|9930211|FG000|Overall Study|Protocol Violation|1
6245361|NCT01895309|9930212|FG001|Overall Study|Protocol Violation|0
6245362|NCT01895309|9930211|FG000|Overall Study|Lack of Efficacy|1
6245363|NCT01895309|9930212|FG001|Overall Study|Lack of Efficacy|3
6245364|NCT01895309|9930211|FG000|Overall Study|Lost to Follow-up|1
6245365|NCT01895309|9930212|FG001|Overall Study|Lost to Follow-up|3
6245366|NCT01895309|9930211|FG000|Overall Study|Physician Decision|15
6245367|NCT01895309|9930212|FG001|Overall Study|Physician Decision|10
6245368|NCT01895309|9930211|FG000|Overall Study|Withdrawal by Subject|9
6245369|NCT01895309|9930212|FG001|Overall Study|Withdrawal by Subject|18
6245370|NCT01895322|9930222|FG000|Overall Study|Adverse Event|1
6245371|NCT01895322|9930222|FG000|Overall Study|Withdrawal by Subject|2
6245372|NCT01895322|9930222|FG000|Overall Study|Protocol Violation|10
6245373|NCT01895335|9930227|FG000|Overall Study|Adverse Event|106
6245374|NCT01895335|9930227|FG000|Overall Study|Lack of Efficacy|53
6245375|NCT01895335|9930227|FG000|Overall Study|Poor Compliance to Protocol|11
6245376|NCT01895335|9930227|FG000|Overall Study|Included But Not treated|1
6245377|NCT01895335|9930227|FG000|Overall Study|Other than Specified Above|44
6245378|NCT01895361|9930234|FG000|Overall Study|Adverse Event|1
6245379|NCT01895361|9930235|FG001|Overall Study|Adverse Event|1
6245380|NCT01895361|9930236|FG002|Overall Study|Adverse Event|3
6245381|NCT01895361|9930234|FG000|Overall Study|Death|2
6245382|NCT01895361|9930235|FG001|Overall Study|Death|1
6245383|NCT01895361|9930236|FG002|Overall Study|Death|2
6245384|NCT01895361|9930234|FG000|Overall Study|Lost to Follow-up|4
6245385|NCT01895361|9930235|FG001|Overall Study|Lost to Follow-up|4
6245386|NCT01895361|9930236|FG002|Overall Study|Lost to Follow-up|6
6245387|NCT01895361|9930234|FG000|Overall Study|Non-compliance with study|1
6245388|NCT01895361|9930235|FG001|Overall Study|Non-compliance with study|3
6245389|NCT01895361|9930236|FG002|Overall Study|Non-compliance with study|1
6245390|NCT01895361|9930234|FG000|Overall Study|Physician Decision|2
6245391|NCT01895361|9930235|FG001|Overall Study|Physician Decision|2
6245392|NCT01895361|9930236|FG002|Overall Study|Physician Decision|2
6245393|NCT01895361|9930234|FG000|Overall Study|Withdrawal by Subject|7
6245394|NCT01895361|9930235|FG001|Overall Study|Withdrawal by Subject|6
6245395|NCT01895361|9930236|FG002|Overall Study|Withdrawal by Subject|6
6245396|NCT01895361|9930234|FG000|Overall Study|Lack of Efficacy|0
6245397|NCT01895361|9930235|FG001|Overall Study|Lack of Efficacy|1
6245398|NCT01895361|9930236|FG002|Overall Study|Lack of Efficacy|0
6245399|NCT01895361|9930234|FG000|Overall Study|Reasons different from categories above|7
6245400|NCT01895361|9930235|FG001|Overall Study|Reasons different from categories above|3
6245401|NCT01895361|9930236|FG002|Overall Study|Reasons different from categories above|4
6245402|NCT01895452|9930246|FG000|Overall Study|Adverse Event|1
6245403|NCT01895452|9930247|FG001|Overall Study|Adverse Event|4
6245404|NCT01895452|9930246|FG000|Overall Study|Lost to Follow-up|1
6245405|NCT01895452|9930247|FG001|Overall Study|Lost to Follow-up|5
6245406|NCT01895452|9930246|FG000|Overall Study|Pregnancy|0
6245407|NCT01895452|9930247|FG001|Overall Study|Pregnancy|1
6245408|NCT01895452|9930246|FG000|Overall Study|Withdrawal by Subject|2
6245409|NCT01895452|9930247|FG001|Overall Study|Withdrawal by Subject|14
6245410|NCT01895452|9930246|FG000|Overall Study|Underlying disease|0
6245411|NCT01895452|9930247|FG001|Overall Study|Underlying disease|3
6245412|NCT01895452|9930246|FG000|Overall Study|Noncompliance with study drug|0
6245413|NCT01895452|9930247|FG001|Overall Study|Noncompliance with study drug|1
6245414|NCT01895543|9930253|FG000|Overall Study|Withdrawal by Subject|43
6245415|NCT01895543|9930253|FG000|Overall Study|Lost to Follow-up|25
6245416|NCT01895543|9930253|FG000|Overall Study|Adverse Event|28
6245417|NCT01895543|9930253|FG000|Overall Study|Subject's substantial non-compliance|6
6245418|NCT01895543|9930253|FG000|Overall Study|Protocol Violation|1
6245419|NCT01895543|9930253|FG000|Overall Study|Physician Decision|2
6245420|NCT01895543|9930253|FG000|Overall Study|Other (Not fulfilling above criteria)|24
6245421|NCT01895608|9930261|FG000|Overall Study|change in health status|0
6245422|NCT01895608|9930262|FG001|Overall Study|change in health status|1
6245423|NCT01895608|9930263|FG002|Overall Study|change in health status|1
6245424|NCT01895608|9930264|FG003|Overall Study|change in health status|0
6245425|NCT01895608|9930261|FG000|Overall Study|Withdrawal by Subject|0
6245426|NCT01895608|9930262|FG001|Overall Study|Withdrawal by Subject|0
6245427|NCT01895608|9930263|FG002|Overall Study|Withdrawal by Subject|2
6245428|NCT01895608|9930264|FG003|Overall Study|Withdrawal by Subject|0
6245429|NCT01895777|9930293|FG000|Overall Study|Adverse Event|1
6245430|NCT01895777|9930294|FG001|Overall Study|Adverse Event|2
6245431|NCT01895777|9930293|FG000|Overall Study|Lost to Follow-up|2
6245432|NCT01895777|9930294|FG001|Overall Study|Lost to Follow-up|0
6245433|NCT01895777|9930293|FG000|Overall Study|Not treated|1
6245434|NCT01895777|9930294|FG001|Overall Study|Not treated|0
6245435|NCT01895777|9930293|FG000|Overall Study|Other reasons|3
6245436|NCT01895777|9930294|FG001|Overall Study|Other reasons|2
6245437|NCT01895777|9930293|FG000|Overall Study|Non-compliance with the CTP|2
6245438|NCT01895777|9930294|FG001|Overall Study|Non-compliance with the CTP|1
6245439|NCT01896050|9930331|FG000|Overall Study|Adverse Event|37
6245440|NCT01896050|9930332|FG001|Overall Study|Adverse Event|2
6245441|NCT01896050|9930331|FG000|Overall Study|Death|1
6245442|NCT01896050|9930332|FG001|Overall Study|Death|0
6245443|NCT01896128|9930356|FG000|Overall Study|Withdrawal by Subject|3
6245444|NCT01896128|9930357|FG001|Overall Study|Withdrawal by Subject|3
6245445|NCT01896193|9930367|FG000|Overall Study|Lack of Efficacy|20
6245446|NCT01896193|9930368|FG001|Overall Study|Lack of Efficacy|11
6245447|NCT01896193|9930367|FG000|Overall Study|Protocol Violation|0
6245448|NCT01896193|9930368|FG001|Overall Study|Protocol Violation|1
6245449|NCT01896193|9930367|FG000|Overall Study|Withdrew Consent|1
6245450|NCT01896193|9930368|FG001|Overall Study|Withdrew Consent|0
6245451|NCT01896232|9930382|FG000|Overall Study|Death|6
6245452|NCT01896232|9930383|FG001|Overall Study|Death|10
6245453|NCT01896232|9930382|FG000|Overall Study|Withdrawal by Subject|32
6245454|NCT01896232|9930383|FG001|Overall Study|Withdrawal by Subject|31
6245455|NCT01896232|9930382|FG000|Overall Study|Sponsor Decision|2
6245456|NCT01896232|9930383|FG001|Overall Study|Sponsor Decision|0
6245457|NCT01896232|9930382|FG000|Overall Study|Lost to Follow-up|9
6245458|NCT01896232|9930383|FG001|Overall Study|Lost to Follow-up|12
6245459|NCT01896271|9930389|FG000|Overall Study|Physician Decision|10
6245460|NCT01896297|9930393|FG000|Overall Study|Died in post treatment phase|1
6245461|NCT01896557|9930415|FG000|Clopidogrel Alone|Adverse Event|1
6245462|NCT01896557|9930416|FG001|Clopidogrel Alone|Adverse Event|0
6245463|NCT01896557|9930415|FG000|Clopidogrel + GI Protector|low adherence|1
6245464|NCT01896557|9930416|FG001|Clopidogrel + GI Protector|low adherence|1
6245465|NCT01896557|9930415|FG000|Clopidogrel + GI Protector|Reading error|1
6245466|NCT01896557|9930416|FG001|Clopidogrel + GI Protector|Reading error|3
6245467|NCT01896700|9930433|FG000|Overall Study|Adverse Event|4
6245468|NCT01896700|9930434|FG001|Overall Study|Adverse Event|5
6245469|NCT01896700|9930433|FG000|Overall Study|Withdrawal by Subject|0
6245470|NCT01896700|9930434|FG001|Overall Study|Withdrawal by Subject|1
6245471|NCT01896726|9930440|FG000|Treatment Period 2 (Days 23-31)|Adverse Event|1
6245472|NCT01896726|9930440|FG000|Treatment Period 2 (Days 23-31)|Lost to Follow-up|1
6245473|NCT01896856|9930453|FG000|Overall Study|Transportation issues / Non-compliance|0
6245474|NCT01896856|9930454|FG001|Overall Study|Transportation issues / Non-compliance|0
6245475|NCT01896856|9930455|FG002|Overall Study|Transportation issues / Non-compliance|1
6245476|NCT01896856|9930456|FG003|Overall Study|Transportation issues / Non-compliance|0
6245477|NCT01896856|9930457|FG004|Overall Study|Transportation issues / Non-compliance|0
6245478|NCT01896856|9930458|FG005|Overall Study|Transportation issues / Non-compliance|0
6245479|NCT01896869|9930475|FG000|Overall Study|Withdrawal by Subject|0
6245480|NCT01896869|9930476|FG001|Overall Study|Withdrawal by Subject|6
6245481|NCT01896869|9930475|FG000|Overall Study|Lost to Follow-up|1
6245482|NCT01896869|9930476|FG001|Overall Study|Lost to Follow-up|0
6245483|NCT01896895|9930487|FG000|Double-blind MP|Physician Decision|0
6245484|NCT01896895|9930488|FG001|Double-blind MP|Physician Decision|0
6245485|NCT01896895|9930489|FG002|Double-blind MP|Physician Decision|1
6245486|NCT01896895|9930490|FG003|Double-blind MP|Physician Decision|0
6245487|NCT01896895|9930487|FG000|Double-blind MP|Withdrawal by Subject|0
6245488|NCT01896895|9930488|FG001|Double-blind MP|Withdrawal by Subject|2
6245489|NCT01896895|9930489|FG002|Double-blind MP|Withdrawal by Subject|1
6245490|NCT01896895|9930490|FG003|Double-blind MP|Withdrawal by Subject|0
6245491|NCT01896895|9930487|FG000|Double-blind MP|Lost to Follow-up|1
6245492|NCT01896895|9930488|FG001|Double-blind MP|Lost to Follow-up|0
6245493|NCT01896895|9930489|FG002|Double-blind MP|Lost to Follow-up|1
6245494|NCT01896895|9930490|FG003|Double-blind MP|Lost to Follow-up|0
6245495|NCT01896934|9930503|FG000|Overall Study|Adverse Event|1
6245496|NCT01896934|9930503|FG000|Overall Study|Withdrawal by Subject|1
6245497|NCT01896986|9930509|FG000|Overall Study|samples lost|14
6245498|NCT01896986|9930510|FG001|Overall Study|samples lost|23
6245499|NCT01897233|9930534|FG000|Part B (24 Weeks)|Adverse Event|1
6245500|NCT01897233|9930534|FG000|Part B (24 Weeks)|Withdrawal by Subject|2
6245501|NCT01897233|9930534|FG000|Part B (24 Weeks)|Physician Decision|1
6245502|NCT01897493|9930563|FG000|Period 1 (Day 1 Through Day 6 Predose)|Withdrawal by Subject|1
6245503|NCT01897532|9930572|FG000|Discontinuation From Treatment|Not Treated|7
6245504|NCT01897532|9930573|FG001|Discontinuation From Treatment|Not Treated|5
6245505|NCT01897532|9930572|FG000|Discontinuation From Treatment|Other reason than specified|196
6245506|NCT01897532|9930573|FG001|Discontinuation From Treatment|Other reason than specified|176
6245507|NCT01897532|9930572|FG000|Discontinuation From Treatment|Withdrawal by Subject|333
6245508|NCT01897532|9930573|FG001|Discontinuation From Treatment|Withdrawal by Subject|281
6245509|NCT01897532|9930572|FG000|Discontinuation From Treatment|Non compliance|24
6245510|NCT01897532|9930573|FG001|Discontinuation From Treatment|Non compliance|15
6245511|NCT01897532|9930572|FG000|Discontinuation From Treatment|Adverse event/ CV outcome event|402
6245512|NCT01897532|9930573|FG001|Discontinuation From Treatment|Adverse event/ CV outcome event|362
6245513|NCT01897532|9930572|FG000|Discontinuation From Trial|Not Treated|7
6245514|NCT01897532|9930573|FG001|Discontinuation From Trial|Not Treated|5
6245515|NCT01897532|9930572|FG000|Discontinuation From Trial|Patient lost to follow-up for MACE|55
6245516|NCT01897532|9930573|FG001|Discontinuation From Trial|Patient lost to follow-up for MACE|36
6245517|NCT01897714|9930585|FG000|Phase I (Dose Escalation)|Disease progression|3
6245518|NCT01897714|9930586|FG001|Phase I (Dose Escalation)|Disease progression|5
6245519|NCT01897714|9930587|FG002|Phase I (Dose Escalation)|Disease progression|1
6245520|NCT01897714|9930588|FG003|Phase I (Dose Escalation)|Disease progression|3
6245521|NCT01897714|9930589|FG004|Phase I (Dose Escalation)|Disease progression|0
6245522|NCT01897714|9930590|FG005|Phase I (Dose Escalation)|Disease progression|0
6245523|NCT01897714|9930585|FG000|Phase I (Dose Escalation)|Adverse Event|0
6245524|NCT01897714|9930586|FG001|Phase I (Dose Escalation)|Adverse Event|1
6245525|NCT01897714|9930587|FG002|Phase I (Dose Escalation)|Adverse Event|4
6245526|NCT01897714|9930588|FG003|Phase I (Dose Escalation)|Adverse Event|3
6245527|NCT01897714|9930589|FG004|Phase I (Dose Escalation)|Adverse Event|0
6245528|NCT01897714|9930590|FG005|Phase I (Dose Escalation)|Adverse Event|0
6245529|NCT01897714|9930585|FG000|Phase I (Dose Escalation)|Other|0
6245530|NCT01897714|9930586|FG001|Phase I (Dose Escalation)|Other|1
6245531|NCT01897714|9930587|FG002|Phase I (Dose Escalation)|Other|0
6245532|NCT01897714|9930588|FG003|Phase I (Dose Escalation)|Other|0
6245533|NCT01897714|9930589|FG004|Phase I (Dose Escalation)|Other|0
6245534|NCT01897714|9930590|FG005|Phase I (Dose Escalation)|Other|0
6245535|NCT01897714|9930585|FG000|Phase II (MTD)|Withdrawal by Subject|0
6245536|NCT01897714|9930586|FG001|Phase II (MTD)|Withdrawal by Subject|0
6245537|NCT01897714|9930587|FG002|Phase II (MTD)|Withdrawal by Subject|0
6245538|NCT01897714|9930588|FG003|Phase II (MTD)|Withdrawal by Subject|0
6245539|NCT01897714|9930589|FG004|Phase II (MTD)|Withdrawal by Subject|0
6245540|NCT01897714|9930590|FG005|Phase II (MTD)|Withdrawal by Subject|1
6245541|NCT01897714|9930585|FG000|Phase II (MTD)|Lost to Follow-up|0
6245542|NCT01897714|9930586|FG001|Phase II (MTD)|Lost to Follow-up|0
6245543|NCT01897714|9930587|FG002|Phase II (MTD)|Lost to Follow-up|0
6245544|NCT01897714|9930588|FG003|Phase II (MTD)|Lost to Follow-up|0
6245545|NCT01897714|9930589|FG004|Phase II (MTD)|Lost to Follow-up|1
6245546|NCT01897714|9930590|FG005|Phase II (MTD)|Lost to Follow-up|0
6245547|NCT01897714|9930585|FG000|Phase II (MTD)|Death|0
6245548|NCT01897714|9930586|FG001|Phase II (MTD)|Death|0
6245549|NCT01897714|9930587|FG002|Phase II (MTD)|Death|0
6245550|NCT01897714|9930588|FG003|Phase II (MTD)|Death|0
6245551|NCT01897714|9930589|FG004|Phase II (MTD)|Death|25
6245552|NCT01897714|9930590|FG005|Phase II (MTD)|Death|10
6245553|NCT01897714|9930585|FG000|Phase II (MTD)|Study terminated with patient alive|0
6245554|NCT01897714|9930586|FG001|Phase II (MTD)|Study terminated with patient alive|0
6245555|NCT01897714|9930587|FG002|Phase II (MTD)|Study terminated with patient alive|0
6245556|NCT01897714|9930588|FG003|Phase II (MTD)|Study terminated with patient alive|0
6245557|NCT01897714|9930589|FG004|Phase II (MTD)|Study terminated with patient alive|1
6245558|NCT01897714|9930590|FG005|Phase II (MTD)|Study terminated with patient alive|0
6245559|NCT01897714|9930585|FG000|Phase II (MTD)|Other|0
6245560|NCT01897714|9930586|FG001|Phase II (MTD)|Other|0
6245561|NCT01897714|9930587|FG002|Phase II (MTD)|Other|0
6245562|NCT01897714|9930588|FG003|Phase II (MTD)|Other|0
6245563|NCT01897714|9930589|FG004|Phase II (MTD)|Other|3
6245564|NCT01897714|9930590|FG005|Phase II (MTD)|Other|0
6245565|NCT01897727|9930608|FG000|Overall Study|Exclusion: central sleep apnea|0
6245566|NCT01897727|9930609|FG001|Overall Study|Exclusion: central sleep apnea|1
6245567|NCT01897896|9930634|FG000|Overall Study|Death|1
6245568|NCT01897896|9930635|FG001|Overall Study|Death|0
6245569|NCT01897896|9930634|FG000|Overall Study|Adverse Event|11
6245570|NCT01897896|9930635|FG001|Overall Study|Adverse Event|1
6245571|NCT01897896|9930634|FG000|Overall Study|Lost to Follow-up|1
6245572|NCT01897896|9930635|FG001|Overall Study|Lost to Follow-up|0
6245573|NCT01897896|9930634|FG000|Overall Study|Non-compliance with study drug dosing|1
6245574|NCT01897896|9930635|FG001|Overall Study|Non-compliance with study drug dosing|1
6245575|NCT01897896|9930634|FG000|Overall Study|Withdrawal by Subject|7
6245576|NCT01897896|9930635|FG001|Overall Study|Withdrawal by Subject|1
6245577|NCT01897896|9930634|FG000|Overall Study|Require drug that interfere with study|1
6245578|NCT01897896|9930635|FG001|Overall Study|Require drug that interfere with study|4
6245579|NCT01897896|9930634|FG000|Overall Study|Protocol Violation|1
6245580|NCT01897896|9930635|FG001|Overall Study|Protocol Violation|1
6245581|NCT01897896|9930634|FG000|Overall Study|Withdrawal per Investigator's judgement|1
6245582|NCT01897896|9930635|FG001|Overall Study|Withdrawal per Investigator's judgement|1
6245583|NCT01897896|9930634|FG000|Overall Study|Caregiver can no longer participate|0
6245584|NCT01897896|9930635|FG001|Overall Study|Caregiver can no longer participate|2
6245585|NCT01897896|9930634|FG000|Overall Study|Other than specified|2
6245586|NCT01897896|9930635|FG001|Overall Study|Other than specified|1
6245587|NCT01898078|9930654|FG000|Overall Study|Progressive Disease|1
6245588|NCT01898078|9930655|FG001|Overall Study|Progressive Disease|5
6245589|NCT01898078|9930654|FG000|Overall Study|Adverse Event|2
6245590|NCT01898078|9930655|FG001|Overall Study|Adverse Event|1
6245591|NCT01898078|9930654|FG000|Overall Study|Withdrawal by Subject|1
6245592|NCT01898078|9930655|FG001|Overall Study|Withdrawal by Subject|1
6245593|NCT01898078|9930654|FG000|Overall Study|Symptomatic Deterioration|2
6245594|NCT01898078|9930655|FG001|Overall Study|Symptomatic Deterioration|0
6245595|NCT01898078|9930654|FG000|Overall Study|Reason not Specified|0
6245596|NCT01898078|9930655|FG001|Overall Study|Reason not Specified|1
6245597|NCT01898091|9930665|FG000|Overall Study|Lost to Follow-up|1
6245598|NCT01898091|9930666|FG001|Overall Study|Lost to Follow-up|1
6245599|NCT01898091|9930665|FG000|Overall Study|Withdrawal by Subject|1
6245600|NCT01898091|9930666|FG001|Overall Study|Withdrawal by Subject|5
6245601|NCT01898130|9930672|FG000|Treatment|Withdrawal by Subject|2
6245602|NCT01898130|9930672|FG000|Treatment|Progressive Disease|4
6245603|NCT01898130|9930672|FG000|Follow up Until PD or Death|Lost to Follow-up|1
6245604|NCT01898195|9930679|FG000|Smoking Abstinence|Did not have good measurements|35
6245605|NCT01898195|9930680|FG001|Smoking Abstinence|Did not have good measurements|38
6245606|NCT01898195|9930681|FG002|Smoking Abstinence|Did not have good measurements|36
6245607|NCT01898208|9930692|FG000|Overall Study|Positive blood culture|17
6245608|NCT01898208|9930693|FG001|Overall Study|Positive blood culture|23
6245609|NCT01898208|9930694|FG002|Overall Study|Positive blood culture|15
6245610|NCT01898208|9930692|FG000|Overall Study|Death/comfort care within 24 hours|10
6245611|NCT01898208|9930693|FG001|Overall Study|Death/comfort care within 24 hours|9
6086075|NCT00658632|9695784|FG001|Overall Study|Withdrawal of consent|14
6245612|NCT01898208|9930694|FG002|Overall Study|Death/comfort care within 24 hours|8
6245613|NCT01898208|9930692|FG000|Overall Study|Negative Gram Stain|6
6245614|NCT01898208|9930693|FG001|Overall Study|Negative Gram Stain|9
6245615|NCT01898208|9930694|FG002|Overall Study|Negative Gram Stain|6
6245616|NCT01898208|9930692|FG000|Overall Study|Non-Blood Specimens in Bottles|3
6245617|NCT01898208|9930693|FG001|Overall Study|Non-Blood Specimens in Bottles|5
6245618|NCT01898208|9930694|FG002|Overall Study|Non-Blood Specimens in Bottles|4
6245619|NCT01898208|9930692|FG000|Overall Study|System/Technical Error|1
6245620|NCT01898208|9930693|FG001|Overall Study|System/Technical Error|2
6245621|NCT01898208|9930694|FG002|Overall Study|System/Technical Error|3
6245622|NCT01898208|9930692|FG000|Overall Study|Lost to Follow-up|3
6245623|NCT01898208|9930693|FG001|Overall Study|Lost to Follow-up|1
6245624|NCT01898208|9930694|FG002|Overall Study|Lost to Follow-up|1
6245625|NCT01898286|9930702|FG000|Overall Study|Withdrawal by Subject|1
6245626|NCT01898286|9930702|FG000|Overall Study|Protocol Violation|1
6245627|NCT01898286|9930702|FG000|Overall Study|Lost to Follow-up|1
6245628|NCT01898299|9930708|FG000|Post Treatment (One Month)|Lost to Follow-up|3
6245629|NCT01898299|9930709|FG001|Post Treatment (One Month)|Lost to Follow-up|4
6245630|NCT01898442|9930730|FG000|Overall Study|Hemolysis/technical problems|1
6245631|NCT01898442|9930731|FG001|Overall Study|Hemolysis/technical problems|2
6245632|NCT01898442|9930732|FG002|Overall Study|Hemolysis/technical problems|2
6245633|NCT01898442|9930730|FG000|Overall Study|Patient vomited pills|0
6245634|NCT01898442|9930731|FG001|Overall Study|Patient vomited pills|0
6245635|NCT01898442|9930732|FG002|Overall Study|Patient vomited pills|1
6245636|NCT01898598|9930742|FG000|Overall Study|Adverse Event|1
6245637|NCT01898598|9930743|FG001|Overall Study|Adverse Event|0
6245638|NCT01898598|9930742|FG000|Overall Study|Withdrawal by Subject|3
6245639|NCT01898598|9930743|FG001|Overall Study|Withdrawal by Subject|0
6245640|NCT01898598|9930742|FG000|Overall Study|Lost to Follow-up|0
6245641|NCT01898598|9930743|FG001|Overall Study|Lost to Follow-up|1
6245642|NCT01898598|9930742|FG000|Overall Study|Other|0
6245643|NCT01898598|9930743|FG001|Overall Study|Other|1
6245644|NCT01898806|9930778|FG000|Overall Study|Withdrawal by Subject|2
6245645|NCT01898806|9930778|FG000|Overall Study|Physician Decision|1
6245646|NCT01898884|9930787|FG000|Multiple Dose Period|Adverse Event|0
6245647|NCT01898884|9930788|FG001|Multiple Dose Period|Adverse Event|0
6245648|NCT01898884|9930789|FG002|Multiple Dose Period|Adverse Event|0
6245649|NCT01898884|9930790|FG003|Multiple Dose Period|Adverse Event|0
6245650|NCT01898884|9930791|FG004|Multiple Dose Period|Adverse Event|0
6245651|NCT01898884|9930792|FG005|Multiple Dose Period|Adverse Event|0
6245652|NCT01898884|9930793|FG006|Multiple Dose Period|Adverse Event|1
6245653|NCT01898884|9930794|FG007|Multiple Dose Period|Adverse Event|0
6245654|NCT01898884|9930795|FG008|Multiple Dose Period|Adverse Event|0
6245655|NCT01898884|9930787|FG000|Multiple Dose Period|Randomized Not Treated|0
6245656|NCT01898884|9930788|FG001|Multiple Dose Period|Randomized Not Treated|0
6245657|NCT01898884|9930789|FG002|Multiple Dose Period|Randomized Not Treated|0
6245658|NCT01898884|9930790|FG003|Multiple Dose Period|Randomized Not Treated|0
6245659|NCT01898884|9930791|FG004|Multiple Dose Period|Randomized Not Treated|0
6245660|NCT01898884|9930792|FG005|Multiple Dose Period|Randomized Not Treated|0
6245661|NCT01898884|9930793|FG006|Multiple Dose Period|Randomized Not Treated|0
6245662|NCT01898884|9930794|FG007|Multiple Dose Period|Randomized Not Treated|0
6245663|NCT01898884|9930795|FG008|Multiple Dose Period|Randomized Not Treated|1
6245664|NCT01898923|9930833|FG000|Overall Study|Lack of Efficacy|5
6245665|NCT01898923|9930834|FG001|Overall Study|Lack of Efficacy|6
6245666|NCT01898923|9930833|FG000|Overall Study|Adverse Event|3
6245667|NCT01898923|9930834|FG001|Overall Study|Adverse Event|1
6245668|NCT01898923|9930833|FG000|Overall Study|Lost to Follow-up|0
6245669|NCT01898923|9930834|FG001|Overall Study|Lost to Follow-up|1
6245670|NCT01898923|9930833|FG000|Overall Study|Withdrawal by Subject|4
6245671|NCT01898923|9930834|FG001|Overall Study|Withdrawal by Subject|7
6245672|NCT01898923|9930833|FG000|Overall Study|Physician Decision|3
6245673|NCT01898923|9930834|FG001|Overall Study|Physician Decision|4
6245674|NCT01898923|9930833|FG000|Overall Study|One of the subjects IS NO LONGER USING AQUACEL STANDARD OF CARE AND WAS REMOVED FROM THE STUDY|1
6245675|NCT01898923|9930834|FG001|Overall Study|One of the subjects IS NO LONGER USING AQUACEL STANDARD OF CARE AND WAS REMOVED FROM THE STUDY|2
6245676|NCT01899053|9930854|FG000|Overall Study|Progressive Disease|4
6245677|NCT01899053|9930855|FG001|Overall Study|Progressive Disease|0
6086076|NCT00658632|9695783|FG000|Overall Study|Pregnancy|1
6245678|NCT01899053|9930856|FG002|Overall Study|Progressive Disease|3
6245679|NCT01899053|9930857|FG003|Overall Study|Progressive Disease|0
6245680|NCT01899053|9930858|FG004|Overall Study|Progressive Disease|3
6245681|NCT01899053|9930859|FG005|Overall Study|Progressive Disease|1
6245682|NCT01899053|9930860|FG006|Overall Study|Progressive Disease|1
6245683|NCT01899053|9930861|FG007|Overall Study|Progressive Disease|1
6245684|NCT01899053|9930862|FG008|Overall Study|Progressive Disease|4
6245685|NCT01899053|9930863|FG009|Overall Study|Progressive Disease|3
6245686|NCT01899053|9930864|FG010|Overall Study|Progressive Disease|12
6245687|NCT01899053|9930865|FG011|Overall Study|Progressive Disease|5
6245688|NCT01899053|9930866|FG012|Overall Study|Progressive Disease|8
6245689|NCT01899053|9930867|FG013|Overall Study|Progressive Disease|17
6245690|NCT01899053|9930854|FG000|Overall Study|Adverse Event|1
6245691|NCT01899053|9930855|FG001|Overall Study|Adverse Event|1
6245692|NCT01899053|9930856|FG002|Overall Study|Adverse Event|1
6245693|NCT01899053|9930857|FG003|Overall Study|Adverse Event|3
6245694|NCT01899053|9930858|FG004|Overall Study|Adverse Event|1
6245695|NCT01899053|9930859|FG005|Overall Study|Adverse Event|1
6245696|NCT01899053|9930860|FG006|Overall Study|Adverse Event|1
6245697|NCT01899053|9930861|FG007|Overall Study|Adverse Event|0
6245698|NCT01899053|9930862|FG008|Overall Study|Adverse Event|2
6245699|NCT01899053|9930863|FG009|Overall Study|Adverse Event|0
6245700|NCT01899053|9930864|FG010|Overall Study|Adverse Event|3
6245701|NCT01899053|9930865|FG011|Overall Study|Adverse Event|1
6245702|NCT01899053|9930866|FG012|Overall Study|Adverse Event|2
6245703|NCT01899053|9930867|FG013|Overall Study|Adverse Event|2
6245704|NCT01899053|9930854|FG000|Overall Study|Reason Not Specified|0
6245705|NCT01899053|9930855|FG001|Overall Study|Reason Not Specified|0
6245706|NCT01899053|9930856|FG002|Overall Study|Reason Not Specified|0
6245707|NCT01899053|9930857|FG003|Overall Study|Reason Not Specified|0
6245708|NCT01899053|9930858|FG004|Overall Study|Reason Not Specified|0
6245709|NCT01899053|9930859|FG005|Overall Study|Reason Not Specified|0
6245710|NCT01899053|9930860|FG006|Overall Study|Reason Not Specified|1
6245711|NCT01899053|9930861|FG007|Overall Study|Reason Not Specified|0
6245712|NCT01899053|9930862|FG008|Overall Study|Reason Not Specified|0
6245713|NCT01899053|9930863|FG009|Overall Study|Reason Not Specified|0
6245714|NCT01899053|9930864|FG010|Overall Study|Reason Not Specified|0
6245715|NCT01899053|9930865|FG011|Overall Study|Reason Not Specified|0
6245716|NCT01899053|9930866|FG012|Overall Study|Reason Not Specified|1
6245717|NCT01899053|9930867|FG013|Overall Study|Reason Not Specified|0
6245718|NCT01899053|9930854|FG000|Overall Study|Withdrawal by Subject|1
6245719|NCT01899053|9930855|FG001|Overall Study|Withdrawal by Subject|1
6245720|NCT01899053|9930856|FG002|Overall Study|Withdrawal by Subject|2
6245721|NCT01899053|9930857|FG003|Overall Study|Withdrawal by Subject|0
6245722|NCT01899053|9930858|FG004|Overall Study|Withdrawal by Subject|2
6245723|NCT01899053|9930859|FG005|Overall Study|Withdrawal by Subject|0
6245724|NCT01899053|9930860|FG006|Overall Study|Withdrawal by Subject|0
6245725|NCT01899053|9930861|FG007|Overall Study|Withdrawal by Subject|1
6245726|NCT01899053|9930862|FG008|Overall Study|Withdrawal by Subject|0
6245727|NCT01899053|9930863|FG009|Overall Study|Withdrawal by Subject|0
6086077|NCT00658632|9695784|FG001|Overall Study|Pregnancy|1
6086078|NCT00658632|9695783|FG000|Overall Study|Other|7
6086079|NCT00658632|9695784|FG001|Overall Study|Other|8
6086080|NCT00658658|9695795|FG000|Overall Study|Withdrawal by Subject|0
6086081|NCT00658658|9695796|FG001|Overall Study|Withdrawal by Subject|1
6086082|NCT00658658|9695797|FG002|Overall Study|Withdrawal by Subject|0
6086083|NCT00658658|9695798|FG003|Overall Study|Withdrawal by Subject|0
6086084|NCT00658658|9695799|FG004|Overall Study|Withdrawal by Subject|0
6086085|NCT00658658|9695795|FG000|Overall Study|Death|4
6086086|NCT00658658|9695796|FG001|Overall Study|Death|0
6086087|NCT00658658|9695797|FG002|Overall Study|Death|0
6245728|NCT01899053|9930864|FG010|Overall Study|Withdrawal by Subject|0
6245729|NCT01899053|9930865|FG011|Overall Study|Withdrawal by Subject|0
6245730|NCT01899053|9930866|FG012|Overall Study|Withdrawal by Subject|1
6245731|NCT01899053|9930867|FG013|Overall Study|Withdrawal by Subject|1
6245732|NCT01899053|9930854|FG000|Overall Study|Protocol Violation|0
6245733|NCT01899053|9930855|FG001|Overall Study|Protocol Violation|0
6245734|NCT01899053|9930856|FG002|Overall Study|Protocol Violation|1
6245735|NCT01899053|9930857|FG003|Overall Study|Protocol Violation|0
6245736|NCT01899053|9930858|FG004|Overall Study|Protocol Violation|0
6245737|NCT01899053|9930859|FG005|Overall Study|Protocol Violation|0
6245738|NCT01899053|9930860|FG006|Overall Study|Protocol Violation|0
6245739|NCT01899053|9930861|FG007|Overall Study|Protocol Violation|0
6245740|NCT01899053|9930862|FG008|Overall Study|Protocol Violation|0
6245741|NCT01899053|9930863|FG009|Overall Study|Protocol Violation|0
6245742|NCT01899053|9930864|FG010|Overall Study|Protocol Violation|0
6245743|NCT01899053|9930865|FG011|Overall Study|Protocol Violation|0
6245744|NCT01899053|9930866|FG012|Overall Study|Protocol Violation|0
6245745|NCT01899053|9930867|FG013|Overall Study|Protocol Violation|0
6086088|NCT00658658|9695798|FG003|Overall Study|Death|1
6086089|NCT00658658|9695799|FG004|Overall Study|Death|1
6086090|NCT00658658|9695795|FG000|Overall Study|Disease Progression|0
6086091|NCT00658658|9695796|FG001|Overall Study|Disease Progression|1
6245746|NCT01899053|9930854|FG000|Overall Study|Unsatisfactory Therapeutic Response|1
6245747|NCT01899053|9930855|FG001|Overall Study|Unsatisfactory Therapeutic Response|1
6245748|NCT01899053|9930856|FG002|Overall Study|Unsatisfactory Therapeutic Response|0
6245749|NCT01899053|9930857|FG003|Overall Study|Unsatisfactory Therapeutic Response|0
6245750|NCT01899053|9930858|FG004|Overall Study|Unsatisfactory Therapeutic Response|0
6245751|NCT01899053|9930859|FG005|Overall Study|Unsatisfactory Therapeutic Response|0
6245752|NCT01899053|9930860|FG006|Overall Study|Unsatisfactory Therapeutic Response|0
6245753|NCT01899053|9930861|FG007|Overall Study|Unsatisfactory Therapeutic Response|0
6245754|NCT01899053|9930862|FG008|Overall Study|Unsatisfactory Therapeutic Response|0
6245755|NCT01899053|9930863|FG009|Overall Study|Unsatisfactory Therapeutic Response|0
6245756|NCT01899053|9930864|FG010|Overall Study|Unsatisfactory Therapeutic Response|1
6245757|NCT01899053|9930865|FG011|Overall Study|Unsatisfactory Therapeutic Response|0
6245758|NCT01899053|9930866|FG012|Overall Study|Unsatisfactory Therapeutic Response|0
6245759|NCT01899053|9930867|FG013|Overall Study|Unsatisfactory Therapeutic Response|0
6245760|NCT01899053|9930854|FG000|Overall Study|Symptomatic Deterioration|0
6245761|NCT01899053|9930855|FG001|Overall Study|Symptomatic Deterioration|0
6245762|NCT01899053|9930856|FG002|Overall Study|Symptomatic Deterioration|0
6245763|NCT01899053|9930857|FG003|Overall Study|Symptomatic Deterioration|0
6245764|NCT01899053|9930858|FG004|Overall Study|Symptomatic Deterioration|0
6245765|NCT01899053|9930859|FG005|Overall Study|Symptomatic Deterioration|1
6245766|NCT01899053|9930860|FG006|Overall Study|Symptomatic Deterioration|0
6245767|NCT01899053|9930861|FG007|Overall Study|Symptomatic Deterioration|1
6245768|NCT01899053|9930862|FG008|Overall Study|Symptomatic Deterioration|0
6245769|NCT01899053|9930863|FG009|Overall Study|Symptomatic Deterioration|0
6245770|NCT01899053|9930864|FG010|Overall Study|Symptomatic Deterioration|0
6245771|NCT01899053|9930865|FG011|Overall Study|Symptomatic Deterioration|1
6245772|NCT01899053|9930866|FG012|Overall Study|Symptomatic Deterioration|2
6245773|NCT01899053|9930867|FG013|Overall Study|Symptomatic Deterioration|0
6245774|NCT01899742|9930917|FG000|Overall Study|Adverse Event|5
6245775|NCT01899742|9930918|FG001|Overall Study|Adverse Event|4
6245776|NCT01899742|9930917|FG000|Overall Study|Lack of Efficacy|1
6245777|NCT01899742|9930918|FG001|Overall Study|Lack of Efficacy|5
6245778|NCT01899742|9930917|FG000|Overall Study|Protocol Violation|2
6245779|NCT01899742|9930918|FG001|Overall Study|Protocol Violation|2
6245780|NCT01899742|9930917|FG000|Overall Study|Withdrawal by Subject|9
6245781|NCT01899742|9930918|FG001|Overall Study|Withdrawal by Subject|5
6245782|NCT01899768|9930924|FG000|Part A|Adverse Event|2
6245783|NCT01899768|9930924|FG000|Part A|Withdrawal by Subject|1
6245784|NCT01899768|9930924|FG000|Part B|Adverse Event|1
6245785|NCT01899768|9930924|FG000|Part B|Withdrawal by Subject|1
6245786|NCT01900054|9930936|FG000|Overall Study|Physician Decision|1
6245787|NCT01900054|9930936|FG000|Overall Study|Withdrawal by Subject|1
6245788|NCT01900314|9930964|FG000|Overall Study|Lost to Follow-up|1
6245789|NCT01900314|9930965|FG001|Overall Study|Lost to Follow-up|0
6245790|NCT01900314|9930964|FG000|Overall Study|Protocol Violation|0
6245791|NCT01900314|9930965|FG001|Overall Study|Protocol Violation|1
6245792|NCT01900314|9930964|FG000|Overall Study|Withdrawal by Subject|3
6245793|NCT01900314|9930965|FG001|Overall Study|Withdrawal by Subject|3
6245794|NCT01900431|9930987|FG000|Principal Treatment Period (Part A)|Adverse Event|1
6245795|NCT01900431|9930988|FG001|Principal Treatment Period (Part A)|Adverse Event|3
6245796|NCT01900431|9930989|FG002|Principal Treatment Period (Part A)|Adverse Event|0
6245797|NCT01900431|9930987|FG000|Principal Treatment Period (Part A)|Lack of Efficacy|6
6245798|NCT01900431|9930988|FG001|Principal Treatment Period (Part A)|Lack of Efficacy|6
6245799|NCT01900431|9930989|FG002|Principal Treatment Period (Part A)|Lack of Efficacy|0
6245800|NCT01900431|9930987|FG000|Principal Treatment Period (Part A)|Other than specified above|0
6245801|NCT01900431|9930988|FG001|Principal Treatment Period (Part A)|Other than specified above|1
6245802|NCT01900431|9930989|FG002|Principal Treatment Period (Part A)|Other than specified above|0
6245803|NCT01900431|9930987|FG000|Extended Treatment Period (Part B)|Adverse Event|0
6245804|NCT01900431|9930988|FG001|Extended Treatment Period (Part B)|Adverse Event|2
6245805|NCT01900431|9930989|FG002|Extended Treatment Period (Part B)|Adverse Event|0
6245806|NCT01900431|9930987|FG000|Extended Treatment Period (Part B)|Lack of Efficacy|1
6245807|NCT01900431|9930988|FG001|Extended Treatment Period (Part B)|Lack of Efficacy|7
6245808|NCT01900431|9930989|FG002|Extended Treatment Period (Part B)|Lack of Efficacy|0
6245809|NCT01900431|9930987|FG000|Extended Treatment Period (Part B)|Other than specified above|0
6245810|NCT01900431|9930988|FG001|Extended Treatment Period (Part B)|Other than specified above|1
6245811|NCT01900431|9930989|FG002|Extended Treatment Period (Part B)|Other than specified above|0
6245812|NCT01900431|9930987|FG000|Open-Label Treatment Period (Part C)|Adverse Event|0
6245813|NCT01900431|9930988|FG001|Open-Label Treatment Period (Part C)|Adverse Event|0
6245814|NCT01900431|9930989|FG002|Open-Label Treatment Period (Part C)|Adverse Event|2
6245815|NCT01900431|9930987|FG000|Open-Label Treatment Period (Part C)|Lack of Efficacy|0
6245816|NCT01900431|9930988|FG001|Open-Label Treatment Period (Part C)|Lack of Efficacy|0
6245817|NCT01900431|9930989|FG002|Open-Label Treatment Period (Part C)|Lack of Efficacy|3
6245818|NCT01900431|9930987|FG000|Open-Label Treatment Period (Part C)|Withdrawal by Subject|0
6245819|NCT01900431|9930988|FG001|Open-Label Treatment Period (Part C)|Withdrawal by Subject|0
6245820|NCT01900431|9930989|FG002|Open-Label Treatment Period (Part C)|Withdrawal by Subject|3
6245821|NCT01900652|9931008|FG000|Overall Study|Progressive Disease|1
6245822|NCT01900652|9931009|FG001|Overall Study|Progressive Disease|0
6245823|NCT01900652|9931008|FG000|Overall Study|Consent withdrawn by subject|1
6245824|NCT01900652|9931009|FG001|Overall Study|Consent withdrawn by subject|1
6245825|NCT01900652|9931008|FG000|Overall Study|Death|3
6245826|NCT01900652|9931009|FG001|Overall Study|Death|0
6245827|NCT01900652|9931008|FG000|Overall Study|Adverse Event|2
6245828|NCT01900652|9931009|FG001|Overall Study|Adverse Event|1
6245829|NCT01900652|9931008|FG000|Overall Study|Physician Decision|1
6245830|NCT01900652|9931009|FG001|Overall Study|Physician Decision|1
6245831|NCT01900665|9931022|FG000|Placebo Controlled Period|Death|9
6245832|NCT01900665|9931023|FG001|Placebo Controlled Period|Death|16
6245833|NCT01900665|9931022|FG000|Placebo Controlled Period|Adverse Event|48
6245834|NCT01900665|9931023|FG001|Placebo Controlled Period|Adverse Event|39
6245835|NCT01900665|9931022|FG000|Placebo Controlled Period|Protocol Violation|1
6245836|NCT01900665|9931023|FG001|Placebo Controlled Period|Protocol Violation|7
6245837|NCT01900665|9931022|FG000|Placebo Controlled Period|Withdrawal by Subject|33
6245838|NCT01900665|9931023|FG001|Placebo Controlled Period|Withdrawal by Subject|45
6245839|NCT01900665|9931022|FG000|Placebo Controlled Period|Physician Decision|11
6245840|NCT01900665|9931023|FG001|Placebo Controlled Period|Physician Decision|7
6245841|NCT01900665|9931022|FG000|Placebo Controlled Period|Lost to Follow-up|3
6245842|NCT01900665|9931023|FG001|Placebo Controlled Period|Lost to Follow-up|0
6245843|NCT01900665|9931022|FG000|Placebo Controlled Period|Caregiver Decision|33
6245844|NCT01900665|9931023|FG001|Placebo Controlled Period|Caregiver Decision|41
6245845|NCT01900665|9931022|FG000|Placebo Controlled Period|Entry Criteria Not Met|5
6245846|NCT01900665|9931023|FG001|Placebo Controlled Period|Entry Criteria Not Met|9
6245847|NCT01900665|9931022|FG000|Open Label Period|Adverse Event|16
6245848|NCT01900665|9931023|FG001|Open Label Period|Adverse Event|20
6245849|NCT01900665|9931022|FG000|Open Label Period|Death|5
6245850|NCT01900665|9931023|FG001|Open Label Period|Death|6
6245851|NCT01900665|9931022|FG000|Open Label Period|Lost to Follow-up|1
6245852|NCT01900665|9931023|FG001|Open Label Period|Lost to Follow-up|1
6245853|NCT01900665|9931022|FG000|Open Label Period|Parent/Caregiver Decision|33
6245854|NCT01900665|9931023|FG001|Open Label Period|Parent/Caregiver Decision|34
6245855|NCT01900665|9931022|FG000|Open Label Period|Physician Decision|4
6245856|NCT01900665|9931023|FG001|Open Label Period|Physician Decision|4
6245857|NCT01900665|9931022|FG000|Open Label Period|Protocol Violation|0
6245858|NCT01900665|9931023|FG001|Open Label Period|Protocol Violation|1
6245859|NCT01900665|9931022|FG000|Open Label Period|Sponsor Decision|802
6245860|NCT01900665|9931023|FG001|Open Label Period|Sponsor Decision|765
6245861|NCT01900665|9931022|FG000|Open Label Period|Withdrawal by Subject|20
6245862|NCT01900665|9931023|FG001|Open Label Period|Withdrawal by Subject|28
6245863|NCT01900899|9931048|FG000|Overall Study|Withdrawal by Subject|7
6245864|NCT01900899|9931049|FG001|Overall Study|Withdrawal by Subject|1
6245865|NCT01900899|9931048|FG000|Overall Study|Migrated from study area|2
6245866|NCT01900899|9931049|FG001|Overall Study|Migrated from study area|0
6270577|NCT02153112|9971543|FG006|Overall Study|Lost to Follow-up|1
6270578|NCT02153112|9971544|FG007|Overall Study|Lost to Follow-up|0
6270579|NCT02153112|9971545|FG008|Overall Study|Lost to Follow-up|1
6270580|NCT02153112|9971546|FG009|Overall Study|Lost to Follow-up|1
6270581|NCT02153112|9971537|FG000|Overall Study|Withdrawal by Subject|3
6270582|NCT02153112|9971538|FG001|Overall Study|Withdrawal by Subject|1
6270583|NCT02153112|9971539|FG002|Overall Study|Withdrawal by Subject|2
6270584|NCT02153112|9971540|FG003|Overall Study|Withdrawal by Subject|2
6270585|NCT02153112|9971541|FG004|Overall Study|Withdrawal by Subject|1
6270586|NCT02153112|9971542|FG005|Overall Study|Withdrawal by Subject|1
6270587|NCT02153112|9971543|FG006|Overall Study|Withdrawal by Subject|7
6270588|NCT02153112|9971544|FG007|Overall Study|Withdrawal by Subject|2
6270589|NCT02153112|9971545|FG008|Overall Study|Withdrawal by Subject|13
6270590|NCT02153112|9971546|FG009|Overall Study|Withdrawal by Subject|12
6270591|NCT02153112|9971537|FG000|Overall Study|Reason not Specified|0
6270592|NCT02153112|9971538|FG001|Overall Study|Reason not Specified|0
6270593|NCT02153112|9971539|FG002|Overall Study|Reason not Specified|0
6270594|NCT02153112|9971540|FG003|Overall Study|Reason not Specified|0
6270595|NCT02153112|9971541|FG004|Overall Study|Reason not Specified|0
6270596|NCT02153112|9971542|FG005|Overall Study|Reason not Specified|0
6270597|NCT02153112|9971543|FG006|Overall Study|Reason not Specified|0
6270598|NCT02153112|9971544|FG007|Overall Study|Reason not Specified|0
6270599|NCT02153112|9971545|FG008|Overall Study|Reason not Specified|1
6270600|NCT02153112|9971546|FG009|Overall Study|Reason not Specified|1
6270601|NCT02153346|9971570|FG000|Overall Study|Lost to Follow-up|11
6270602|NCT02153359|9971575|FG000|Intervention 2 (1 Month)|Lost to Follow-up|0
6270603|NCT02153359|9971576|FG001|Intervention 2 (1 Month)|Lost to Follow-up|2
6270604|NCT02153398|9971590|FG000|Overall Study|Withdrawal by Subject|1
6270605|NCT02153398|9971591|FG001|Overall Study|Withdrawal by Subject|0
6270606|NCT02153398|9971592|FG002|Overall Study|Withdrawal by Subject|0
6270607|NCT02153398|9971593|FG003|Overall Study|Withdrawal by Subject|0
6270608|NCT02153398|9971594|FG004|Overall Study|Withdrawal by Subject|0
6270609|NCT02153398|9971590|FG000|Overall Study|Adverse Event|0
6270610|NCT02153398|9971591|FG001|Overall Study|Adverse Event|0
6270611|NCT02153398|9971592|FG002|Overall Study|Adverse Event|1
6270612|NCT02153398|9971593|FG003|Overall Study|Adverse Event|1
6270613|NCT02153398|9971594|FG004|Overall Study|Adverse Event|0
6271873|NCT02168777|9973909|FG002|Overall Study|Other reason|0
6271874|NCT02168803|9973923|FG000|Overall Study|Lost to Follow-up|1
6271875|NCT02168803|9973924|FG001|Overall Study|Lost to Follow-up|0
6086092|NCT00658658|9695797|FG002|Overall Study|Disease Progression|0
6271876|NCT02168803|9973925|FG002|Overall Study|Lost to Follow-up|1
6271877|NCT02168803|9973923|FG000|Overall Study|Withdrawal by Subject|1
6271878|NCT02168803|9973924|FG001|Overall Study|Withdrawal by Subject|1
6271879|NCT02168803|9973925|FG002|Overall Study|Withdrawal by Subject|2
6271880|NCT02168803|9973923|FG000|Overall Study|Physician Decision|0
6271881|NCT02168803|9973924|FG001|Overall Study|Physician Decision|1
6271882|NCT02168803|9973925|FG002|Overall Study|Physician Decision|0
6271883|NCT02168803|9973923|FG000|Overall Study|Adverse Event|0
6271884|NCT02168803|9973924|FG001|Overall Study|Adverse Event|1
6271885|NCT02168803|9973925|FG002|Overall Study|Adverse Event|1
6245867|NCT01901055|9931057|FG000|Randomization But Not Titrated|Did not come to titration study|1
6245868|NCT01901055|9931058|FG001|Randomization But Not Titrated|Did not come to titration study|1
6245869|NCT01901055|9931057|FG000|Randomization But Not Titrated|Physician Decision|0
6245870|NCT01901055|9931058|FG001|Randomization But Not Titrated|Physician Decision|1
6245871|NCT01901055|9931057|FG000|Started Protocol to Week 6|Physician Decision|2
6245872|NCT01901055|9931058|FG001|Started Protocol to Week 6|Physician Decision|1
6245873|NCT01901055|9931057|FG000|Started Protocol to Week 6|complains of difficulty with wearing mask|0
6245874|NCT01901055|9931058|FG001|Started Protocol to Week 6|complains of difficulty with wearing mask|2
6245875|NCT01901055|9931057|FG000|Started Protocol to Week 6|Participant had not disclosed that they had been previously been on CPAP|1
6245876|NCT01901055|9931058|FG001|Started Protocol to Week 6|Participant had not disclosed that they had been previously been on CPAP|0
6245877|NCT01901055|9931057|FG000|Started Protocol to Week 6|Withdrawal by Subject|0
6245878|NCT01901055|9931058|FG001|Started Protocol to Week 6|Withdrawal by Subject|1
6245879|NCT01901055|9931057|FG000|Week 12 Assessment|Medical procedure that may interfere with wearing CPAPP mask|1
6245880|NCT01901055|9931058|FG001|Week 12 Assessment|Medical procedure that may interfere with wearing CPAPP mask|0
6245881|NCT01901055|9931057|FG000|Week 12 Assessment|Withdrawal by Subject|0
6245882|NCT01901055|9931058|FG001|Week 12 Assessment|Withdrawal by Subject|4
6245883|NCT01901055|9931057|FG000|Week 24|Withdrawal by Subject|13
6245884|NCT01901055|9931058|FG001|Week 24|Withdrawal by Subject|19
6245885|NCT01901055|9931057|FG000|Week 24|Physician Decision|1
6245886|NCT01901055|9931058|FG001|Week 24|Physician Decision|0
6245887|NCT01901055|9931057|FG000|Week 36|Withdrawal by Subject|0
6245888|NCT01901055|9931058|FG001|Week 36|Withdrawal by Subject|5
6245889|NCT01901146|9931069|FG000|Neoadjuvant Phase|Death|1
6245890|NCT01901146|9931070|FG001|Neoadjuvant Phase|Death|2
6245891|NCT01901146|9931071|FG002|Neoadjuvant Phase|Death|0
6245892|NCT01901146|9931072|FG003|Neoadjuvant Phase|Death|0
6245893|NCT01901146|9931073|FG004|Neoadjuvant Phase|Death|0
6245894|NCT01901146|9931069|FG000|Neoadjuvant Phase|Disease Progression or Recurrence|2
6245895|NCT01901146|9931070|FG001|Neoadjuvant Phase|Disease Progression or Recurrence|3
6245896|NCT01901146|9931071|FG002|Neoadjuvant Phase|Disease Progression or Recurrence|0
6245897|NCT01901146|9931072|FG003|Neoadjuvant Phase|Disease Progression or Recurrence|0
6245898|NCT01901146|9931073|FG004|Neoadjuvant Phase|Disease Progression or Recurrence|0
6245899|NCT01901146|9931069|FG000|Neoadjuvant Phase|Lost to Follow-up|0
6245900|NCT01901146|9931070|FG001|Neoadjuvant Phase|Lost to Follow-up|1
6245901|NCT01901146|9931071|FG002|Neoadjuvant Phase|Lost to Follow-up|0
6245902|NCT01901146|9931072|FG003|Neoadjuvant Phase|Lost to Follow-up|0
6245903|NCT01901146|9931073|FG004|Neoadjuvant Phase|Lost to Follow-up|0
6245904|NCT01901146|9931069|FG000|Neoadjuvant Phase|Physician Decision|1
6245905|NCT01901146|9931070|FG001|Neoadjuvant Phase|Physician Decision|2
6245906|NCT01901146|9931071|FG002|Neoadjuvant Phase|Physician Decision|0
6245907|NCT01901146|9931072|FG003|Neoadjuvant Phase|Physician Decision|0
6245908|NCT01901146|9931073|FG004|Neoadjuvant Phase|Physician Decision|0
6245909|NCT01901146|9931069|FG000|Neoadjuvant Phase|Withdrawal by Subject|2
6245910|NCT01901146|9931070|FG001|Neoadjuvant Phase|Withdrawal by Subject|5
6245911|NCT01901146|9931071|FG002|Neoadjuvant Phase|Withdrawal by Subject|0
6245912|NCT01901146|9931072|FG003|Neoadjuvant Phase|Withdrawal by Subject|0
6245913|NCT01901146|9931073|FG004|Neoadjuvant Phase|Withdrawal by Subject|0
6245914|NCT01901146|9931069|FG000|Neoadjuvant Phase|Requirement for Alternative Therapy|0
6245915|NCT01901146|9931070|FG001|Neoadjuvant Phase|Requirement for Alternative Therapy|1
6245916|NCT01901146|9931071|FG002|Neoadjuvant Phase|Requirement for Alternative Therapy|0
6245917|NCT01901146|9931072|FG003|Neoadjuvant Phase|Requirement for Alternative Therapy|0
6245918|NCT01901146|9931073|FG004|Neoadjuvant Phase|Requirement for Alternative Therapy|0
6245919|NCT01901146|9931069|FG000|Adjuvant Phase|Other|0
6245920|NCT01901146|9931070|FG001|Adjuvant Phase|Other|0
6245921|NCT01901146|9931071|FG002|Adjuvant Phase|Other|1
6245922|NCT01901146|9931072|FG003|Adjuvant Phase|Other|0
6245923|NCT01901146|9931073|FG004|Adjuvant Phase|Other|0
6245924|NCT01901146|9931069|FG000|Adjuvant Phase|Death|0
6245925|NCT01901146|9931070|FG001|Adjuvant Phase|Death|0
6245926|NCT01901146|9931071|FG002|Adjuvant Phase|Death|0
6245927|NCT01901146|9931072|FG003|Adjuvant Phase|Death|0
6245928|NCT01901146|9931073|FG004|Adjuvant Phase|Death|3
6245929|NCT01901146|9931069|FG000|Adjuvant Phase|Disease Progression or Recurrence|0
6245930|NCT01901146|9931070|FG001|Adjuvant Phase|Disease Progression or Recurrence|0
6245931|NCT01901146|9931071|FG002|Adjuvant Phase|Disease Progression or Recurrence|12
6245932|NCT01901146|9931072|FG003|Adjuvant Phase|Disease Progression or Recurrence|4
6245933|NCT01901146|9931073|FG004|Adjuvant Phase|Disease Progression or Recurrence|3
6245934|NCT01901146|9931069|FG000|Adjuvant Phase|Physician Decision|0
6245935|NCT01901146|9931070|FG001|Adjuvant Phase|Physician Decision|0
6245936|NCT01901146|9931071|FG002|Adjuvant Phase|Physician Decision|9
6245937|NCT01901146|9931072|FG003|Adjuvant Phase|Physician Decision|2
6245938|NCT01901146|9931073|FG004|Adjuvant Phase|Physician Decision|4
6245939|NCT01901146|9931069|FG000|Adjuvant Phase|Withdrawal by Subject|0
6245940|NCT01901146|9931070|FG001|Adjuvant Phase|Withdrawal by Subject|0
6245941|NCT01901146|9931071|FG002|Adjuvant Phase|Withdrawal by Subject|4
6245942|NCT01901146|9931072|FG003|Adjuvant Phase|Withdrawal by Subject|1
6245943|NCT01901146|9931073|FG004|Adjuvant Phase|Withdrawal by Subject|4
6245944|NCT01901185|9931082|FG000|Overall Study|Withdrawal by Subject|2
6245945|NCT01901302|9931106|FG000|Overall Study|Adverse Event|2
6245946|NCT01901302|9931107|FG001|Overall Study|Adverse Event|1
6245947|NCT01901302|9931106|FG000|Overall Study|Lack of Efficacy|0
6245948|NCT01901302|9931107|FG001|Overall Study|Lack of Efficacy|2
6245949|NCT01901302|9931106|FG000|Overall Study|Study Terminated by Sponsor|23
6245950|NCT01901302|9931107|FG001|Overall Study|Study Terminated by Sponsor|20
6245951|NCT01901302|9931106|FG000|Overall Study|Withdrawal by Subject|2
6245952|NCT01901302|9931107|FG001|Overall Study|Withdrawal by Subject|0
6245953|NCT01901328|9931115|FG000|Overall Study|Lost to Follow-up|1
6245954|NCT01901328|9931116|FG001|Overall Study|Lost to Follow-up|0
6245955|NCT01901328|9931115|FG000|Overall Study|Physician Decision|0
6245956|NCT01901328|9931116|FG001|Overall Study|Physician Decision|1
6245957|NCT01901328|9931115|FG000|Overall Study|Protocol Violation|1
6245958|NCT01901328|9931116|FG001|Overall Study|Protocol Violation|1
6245959|NCT01901328|9931115|FG000|Overall Study|Study Terminated by Sponsor|19
6245960|NCT01901328|9931116|FG001|Overall Study|Study Terminated by Sponsor|16
6245961|NCT01901328|9931115|FG000|Overall Study|Withdrawal by Subject|1
6245962|NCT01901328|9931116|FG001|Overall Study|Withdrawal by Subject|2
6245963|NCT01901328|9931115|FG000|Overall Study|Lack of Efficacy|0
6245964|NCT01901328|9931116|FG001|Overall Study|Lack of Efficacy|1
6245965|NCT01901341|9931125|FG000|Overall Study|Adverse Event|4
6245966|NCT01901341|9931126|FG001|Overall Study|Adverse Event|2
6245967|NCT01901341|9931125|FG000|Overall Study|Lack of Efficacy|0
6245968|NCT01901341|9931126|FG001|Overall Study|Lack of Efficacy|2
6245969|NCT01901341|9931125|FG000|Overall Study|Lost to Follow-up|0
6245970|NCT01901341|9931126|FG001|Overall Study|Lost to Follow-up|1
6245971|NCT01901341|9931125|FG000|Overall Study|Protocol Violation|2
6245972|NCT01901341|9931126|FG001|Overall Study|Protocol Violation|0
6245973|NCT01901341|9931125|FG000|Overall Study|Study Terminated by Sponsor|13
6245974|NCT01901341|9931126|FG001|Overall Study|Study Terminated by Sponsor|15
6245975|NCT01901341|9931125|FG000|Overall Study|Withdrawal by Subject|1
6245976|NCT01901341|9931126|FG001|Overall Study|Withdrawal by Subject|1
6245977|NCT01901393|9931135|FG000|Overall Study|Adverse Event|1
6245978|NCT01901393|9931136|FG001|Overall Study|Adverse Event|0
6245979|NCT01901419|9931144|FG000|Overall Study|Protocol Violation|2
6245980|NCT01901419|9931145|FG001|Overall Study|Protocol Violation|6
6245981|NCT01901419|9931144|FG000|Overall Study|unavailable researchers|6
6245982|NCT01901419|9931145|FG001|Overall Study|unavailable researchers|3
6245983|NCT01901614|9931167|FG000|Overall Study|Adverse Event|0
6245984|NCT01901614|9931168|FG001|Overall Study|Adverse Event|1
6245985|NCT01901614|9931167|FG000|Overall Study|Lost to Follow-up|1
6245986|NCT01901614|9931168|FG001|Overall Study|Lost to Follow-up|0
6245987|NCT01901614|9931167|FG000|Overall Study|Screen Fail|1
6245988|NCT01901614|9931168|FG001|Overall Study|Screen Fail|0
6245989|NCT01901653|9931187|FG000|Overall Study|Death|2
6245990|NCT01901653|9931188|FG001|Overall Study|Death|1
6245991|NCT01901653|9931189|FG002|Overall Study|Death|8
6245992|NCT01901653|9931190|FG003|Overall Study|Death|3
6245993|NCT01901653|9931191|FG004|Overall Study|Death|2
6245994|NCT01901653|9931192|FG005|Overall Study|Death|2
6245995|NCT01901653|9931193|FG006|Overall Study|Death|6
6245996|NCT01901653|9931194|FG007|Overall Study|Death|9
6245997|NCT01901653|9931195|FG008|Overall Study|Death|1
6245998|NCT01901653|9931196|FG009|Overall Study|Death|16
6245999|NCT01901653|9931197|FG010|Overall Study|Death|2
6246000|NCT01901653|9931198|FG011|Overall Study|Death|15
6246001|NCT01901653|9931199|FG012|Overall Study|Death|4
6246002|NCT01901653|9931187|FG000|Overall Study|Lost to Follow-up|1
6246003|NCT01901653|9931188|FG001|Overall Study|Lost to Follow-up|0
6246004|NCT01901653|9931189|FG002|Overall Study|Lost to Follow-up|2
6246005|NCT01901653|9931190|FG003|Overall Study|Lost to Follow-up|0
6246006|NCT01901653|9931191|FG004|Overall Study|Lost to Follow-up|0
6246007|NCT01901653|9931192|FG005|Overall Study|Lost to Follow-up|1
6246008|NCT01901653|9931193|FG006|Overall Study|Lost to Follow-up|0
6246009|NCT01901653|9931194|FG007|Overall Study|Lost to Follow-up|1
6246010|NCT01901653|9931195|FG008|Overall Study|Lost to Follow-up|0
6246011|NCT01901653|9931196|FG009|Overall Study|Lost to Follow-up|0
6246012|NCT01901653|9931197|FG010|Overall Study|Lost to Follow-up|0
6246013|NCT01901653|9931198|FG011|Overall Study|Lost to Follow-up|0
6246014|NCT01901653|9931199|FG012|Overall Study|Lost to Follow-up|0
6246015|NCT01901653|9931187|FG000|Overall Study|Withdrawal by Subject|0
6246016|NCT01901653|9931188|FG001|Overall Study|Withdrawal by Subject|0
6246017|NCT01901653|9931189|FG002|Overall Study|Withdrawal by Subject|0
6246018|NCT01901653|9931190|FG003|Overall Study|Withdrawal by Subject|0
6246019|NCT01901653|9931191|FG004|Overall Study|Withdrawal by Subject|0
6246020|NCT01901653|9931192|FG005|Overall Study|Withdrawal by Subject|0
6246021|NCT01901653|9931193|FG006|Overall Study|Withdrawal by Subject|1
6246022|NCT01901653|9931194|FG007|Overall Study|Withdrawal by Subject|0
6246023|NCT01901653|9931195|FG008|Overall Study|Withdrawal by Subject|0
6246024|NCT01901653|9931196|FG009|Overall Study|Withdrawal by Subject|0
6246025|NCT01901653|9931197|FG010|Overall Study|Withdrawal by Subject|0
6246026|NCT01901653|9931198|FG011|Overall Study|Withdrawal by Subject|0
6246027|NCT01901653|9931199|FG012|Overall Study|Withdrawal by Subject|0
6246028|NCT01901653|9931187|FG000|Overall Study|Alive at Study Termination by Sponsor|0
6246029|NCT01901653|9931188|FG001|Overall Study|Alive at Study Termination by Sponsor|0
6246030|NCT01901653|9931189|FG002|Overall Study|Alive at Study Termination by Sponsor|1
6246031|NCT01901653|9931190|FG003|Overall Study|Alive at Study Termination by Sponsor|0
6246032|NCT01901653|9931191|FG004|Overall Study|Alive at Study Termination by Sponsor|0
6246033|NCT01901653|9931192|FG005|Overall Study|Alive at Study Termination by Sponsor|0
6246034|NCT01901653|9931193|FG006|Overall Study|Alive at Study Termination by Sponsor|0
6246035|NCT01901653|9931194|FG007|Overall Study|Alive at Study Termination by Sponsor|0
6246036|NCT01901653|9931195|FG008|Overall Study|Alive at Study Termination by Sponsor|0
6246037|NCT01901653|9931196|FG009|Overall Study|Alive at Study Termination by Sponsor|2
6246038|NCT01901653|9931197|FG010|Overall Study|Alive at Study Termination by Sponsor|0
6246039|NCT01901653|9931198|FG011|Overall Study|Alive at Study Termination by Sponsor|1
6246040|NCT01901653|9931199|FG012|Overall Study|Alive at Study Termination by Sponsor|1
6246041|NCT01901848|9931248|FG000|Randomized and Treated|Lost to Follow-up|3
6246042|NCT01901848|9931249|FG001|Randomized and Treated|Lost to Follow-up|6
6246043|NCT01901848|9931248|FG000|Removed From Analyses|CPT practice cases to establish fidelity|10
6246044|NCT01901848|9931249|FG001|Removed From Analyses|CPT practice cases to establish fidelity|0
6246045|NCT01901874|9931255|FG000|Screening Committee Retrospective Review|Protocol Violation|47
6246046|NCT01901874|9931255|FG000|30-Day MAE Evaluation|Insufficient Follow-up|1
6246047|NCT01901874|9931255|FG000|1-Year (365-Day) MAE Evaluation|Death|7
6246048|NCT01901874|9931255|FG000|1-Year (365-Day) MAE Evaluation|Lost to Follow-up|5
6246049|NCT01901874|9931255|FG000|1-Year (365-Day) MAE Evaluation|Withdrawal by Subject|2
6246050|NCT01901874|9931255|FG000|1-Year (365-Day) MAE Evaluation|Insufficient Follow-up|6
6246051|NCT01902134|9931274|FG000|Overall Study|Adverse Event|3
6246052|NCT01902134|9931275|FG001|Overall Study|Adverse Event|1
6246053|NCT01902134|9931276|FG002|Overall Study|Adverse Event|2
6246054|NCT01902134|9931277|FG003|Overall Study|Adverse Event|1
6246055|NCT01902134|9931278|FG004|Overall Study|Adverse Event|1
6246056|NCT01902134|9931279|FG005|Overall Study|Adverse Event|3
6246057|NCT01902134|9931274|FG000|Overall Study|Lack of Efficacy|0
6246058|NCT01902134|9931275|FG001|Overall Study|Lack of Efficacy|0
6246059|NCT01902134|9931276|FG002|Overall Study|Lack of Efficacy|2
6246060|NCT01902134|9931277|FG003|Overall Study|Lack of Efficacy|0
6246061|NCT01902134|9931278|FG004|Overall Study|Lack of Efficacy|0
6246062|NCT01902134|9931279|FG005|Overall Study|Lack of Efficacy|1
6246063|NCT01902134|9931274|FG000|Overall Study|Physician Decision|0
6246064|NCT01902134|9931275|FG001|Overall Study|Physician Decision|1
6246065|NCT01902134|9931276|FG002|Overall Study|Physician Decision|0
6246066|NCT01902134|9931277|FG003|Overall Study|Physician Decision|0
6246067|NCT01902134|9931278|FG004|Overall Study|Physician Decision|0
6246068|NCT01902134|9931279|FG005|Overall Study|Physician Decision|0
6246069|NCT01902134|9931274|FG000|Overall Study|Protocol Violation|0
6246070|NCT01902134|9931275|FG001|Overall Study|Protocol Violation|0
6246071|NCT01902134|9931276|FG002|Overall Study|Protocol Violation|0
6246072|NCT01902134|9931277|FG003|Overall Study|Protocol Violation|0
6246073|NCT01902134|9931278|FG004|Overall Study|Protocol Violation|0
6246074|NCT01902134|9931279|FG005|Overall Study|Protocol Violation|1
6246075|NCT01902134|9931274|FG000|Overall Study|Withdrawal by Subject|4
6246076|NCT01902134|9931275|FG001|Overall Study|Withdrawal by Subject|8
6246077|NCT01902134|9931276|FG002|Overall Study|Withdrawal by Subject|9
6246078|NCT01902134|9931277|FG003|Overall Study|Withdrawal by Subject|1
6246079|NCT01902134|9931278|FG004|Overall Study|Withdrawal by Subject|5
6246080|NCT01902134|9931279|FG005|Overall Study|Withdrawal by Subject|4
6246081|NCT01902134|9931274|FG000|Overall Study|no compliance|1
6246082|NCT01902134|9931275|FG001|Overall Study|no compliance|0
6246083|NCT01902134|9931276|FG002|Overall Study|no compliance|0
6246084|NCT01902134|9931277|FG003|Overall Study|no compliance|0
6246085|NCT01902134|9931278|FG004|Overall Study|no compliance|0
6246086|NCT01902134|9931279|FG005|Overall Study|no compliance|0
6246087|NCT01902134|9931274|FG000|Overall Study|Other|0
6246088|NCT01902134|9931275|FG001|Overall Study|Other|1
6246089|NCT01902134|9931276|FG002|Overall Study|Other|2
6246090|NCT01902134|9931277|FG003|Overall Study|Other|0
6246091|NCT01902134|9931278|FG004|Overall Study|Other|1
6246092|NCT01902134|9931279|FG005|Overall Study|Other|0
6246093|NCT01902303|9931297|FG000|Overall Study|Adverse Event|0
6246094|NCT01902303|9931298|FG001|Overall Study|Adverse Event|1
6246095|NCT01902303|9931297|FG000|Overall Study|Lost to Follow-up|0
6246096|NCT01902303|9931298|FG001|Overall Study|Lost to Follow-up|1
6246097|NCT01902303|9931297|FG000|Overall Study|Protocol Violation|2
6246098|NCT01902303|9931298|FG001|Overall Study|Protocol Violation|2
6246099|NCT01902303|9931297|FG000|Overall Study|subject lost investigational product|0
6246100|NCT01902303|9931298|FG001|Overall Study|subject lost investigational product|1
6246101|NCT01902303|9931297|FG000|Overall Study|Did not develop a cold sore|21
6246102|NCT01902303|9931298|FG001|Overall Study|Did not develop a cold sore|19
6246103|NCT01902628|9931315|FG000|Overall Study|Withdrawal of participant's consent|7
6246104|NCT01902628|9931315|FG000|Overall Study|Adverse Event|41
6246105|NCT01902628|9931315|FG000|Overall Study|Lost to Follow-up|35
6246106|NCT01903031|9931351|FG000|Overall Study|Not Able to Attend Clinic|1
6246107|NCT01903031|9931352|FG001|Overall Study|Not Able to Attend Clinic|1
6246108|NCT01903031|9931353|FG002|Overall Study|Not Able to Attend Clinic|0
6246109|NCT01903031|9931351|FG000|Overall Study|Missed Day 21 Primary Endpoint Visit|1
6246110|NCT01903031|9931352|FG001|Overall Study|Missed Day 21 Primary Endpoint Visit|0
6246111|NCT01903031|9931353|FG002|Overall Study|Missed Day 21 Primary Endpoint Visit|0
6246112|NCT01903031|9931351|FG000|Overall Study|Adverse Event|0
6246113|NCT01903031|9931352|FG001|Overall Study|Adverse Event|1
6246114|NCT01903031|9931353|FG002|Overall Study|Adverse Event|0
6246115|NCT01903031|9931351|FG000|Overall Study|Withdrawal by Subject|0
6246116|NCT01903031|9931352|FG001|Overall Study|Withdrawal by Subject|1
6246117|NCT01903031|9931353|FG002|Overall Study|Withdrawal by Subject|1
6246118|NCT01903031|9931351|FG000|Overall Study|Protocol Violation|0
6246119|NCT01903031|9931352|FG001|Overall Study|Protocol Violation|0
6246120|NCT01903031|9931353|FG002|Overall Study|Protocol Violation|2
6246121|NCT01903031|9931351|FG000|Overall Study|Lost to Follow-up|0
6246122|NCT01903031|9931352|FG001|Overall Study|Lost to Follow-up|0
6246123|NCT01903031|9931353|FG002|Overall Study|Lost to Follow-up|1
6246124|NCT01903031|9931351|FG000|Overall Study|NuvaRing removed prior to Day 21 visit|0
6246125|NCT01903031|9931352|FG001|Overall Study|NuvaRing removed prior to Day 21 visit|0
6246126|NCT01903031|9931353|FG002|Overall Study|NuvaRing removed prior to Day 21 visit|1
6246127|NCT01903252|9931384|FG000|Double-Blind Induction|Adverse Event|20
6246128|NCT01903252|9931385|FG001|Double-Blind Induction|Adverse Event|18
6246129|NCT01903252|9931386|FG002|Double-Blind Induction|Adverse Event|0
6246130|NCT01903252|9931387|FG003|Double-Blind Induction|Adverse Event|0
6246131|NCT01903252|9931388|FG004|Double-Blind Induction|Adverse Event|0
6246132|NCT01903252|9931389|FG005|Double-Blind Induction|Adverse Event|0
6246133|NCT01903252|9931384|FG000|Double-Blind Induction|Withdrawal by Subject|10
6246134|NCT01903252|9931385|FG001|Double-Blind Induction|Withdrawal by Subject|13
6246135|NCT01903252|9931386|FG002|Double-Blind Induction|Withdrawal by Subject|0
6246136|NCT01903252|9931387|FG003|Double-Blind Induction|Withdrawal by Subject|0
6246137|NCT01903252|9931388|FG004|Double-Blind Induction|Withdrawal by Subject|0
6246138|NCT01903252|9931389|FG005|Double-Blind Induction|Withdrawal by Subject|0
6246139|NCT01903252|9931384|FG000|Double-Blind Induction|Physician Decision|2
6246140|NCT01903252|9931385|FG001|Double-Blind Induction|Physician Decision|3
6086093|NCT00658658|9695798|FG003|Overall Study|Disease Progression|1
6086094|NCT00658658|9695799|FG004|Overall Study|Disease Progression|3
6086095|NCT00658658|9695795|FG000|Overall Study|Protocol-specified Criteria|1
6086096|NCT00658658|9695796|FG001|Overall Study|Protocol-specified Criteria|0
6086097|NCT00658658|9695797|FG002|Overall Study|Protocol-specified Criteria|0
6086098|NCT00658658|9695798|FG003|Overall Study|Protocol-specified Criteria|0
6086099|NCT00658658|9695799|FG004|Overall Study|Protocol-specified Criteria|0
6086100|NCT00658658|9695795|FG000|Overall Study|Other|0
6086101|NCT00658658|9695796|FG001|Overall Study|Other|0
6086102|NCT00658658|9695797|FG002|Overall Study|Other|0
6086103|NCT00658658|9695798|FG003|Overall Study|Other|0
6086104|NCT00658658|9695799|FG004|Overall Study|Other|1
6086105|NCT00658684|9695814|FG000|Overall Study|Adverse Event|10
6086106|NCT00658684|9695815|FG001|Overall Study|Adverse Event|8
6086107|NCT00658684|9695816|FG002|Overall Study|Adverse Event|2
6086108|NCT00658684|9695817|FG003|Overall Study|Adverse Event|0
6086109|NCT00658684|9695814|FG000|Overall Study|Withdrawal by Subject|6
6086110|NCT00658684|9695815|FG001|Overall Study|Withdrawal by Subject|4
6246141|NCT01903252|9931386|FG002|Double-Blind Induction|Physician Decision|0
6246142|NCT01903252|9931387|FG003|Double-Blind Induction|Physician Decision|0
6246143|NCT01903252|9931388|FG004|Double-Blind Induction|Physician Decision|0
6246144|NCT01903252|9931389|FG005|Double-Blind Induction|Physician Decision|0
6246145|NCT01903252|9931384|FG000|Double-Blind Induction|non-compliance,|7
6246146|NCT01903252|9931385|FG001|Double-Blind Induction|non-compliance,|7
6246147|NCT01903252|9931386|FG002|Double-Blind Induction|non-compliance,|0
6246148|NCT01903252|9931387|FG003|Double-Blind Induction|non-compliance,|0
6246149|NCT01903252|9931388|FG004|Double-Blind Induction|non-compliance,|0
6246150|NCT01903252|9931389|FG005|Double-Blind Induction|non-compliance,|0
6246151|NCT01903252|9931384|FG000|Extended Induction, Open-Label|Adverse Event|0
6246152|NCT01903252|9931385|FG001|Extended Induction, Open-Label|Adverse Event|0
6246153|NCT01903252|9931386|FG002|Extended Induction, Open-Label|Adverse Event|17
6246154|NCT01903252|9931387|FG003|Extended Induction, Open-Label|Adverse Event|0
6246155|NCT01903252|9931388|FG004|Extended Induction, Open-Label|Adverse Event|0
6246156|NCT01903252|9931389|FG005|Extended Induction, Open-Label|Adverse Event|0
6246157|NCT01903252|9931384|FG000|Extended Induction, Open-Label|Withdrawal by Subject|0
6246158|NCT01903252|9931385|FG001|Extended Induction, Open-Label|Withdrawal by Subject|0
6246159|NCT01903252|9931386|FG002|Extended Induction, Open-Label|Withdrawal by Subject|5
6246160|NCT01903252|9931387|FG003|Extended Induction, Open-Label|Withdrawal by Subject|0
6246161|NCT01903252|9931388|FG004|Extended Induction, Open-Label|Withdrawal by Subject|0
6246162|NCT01903252|9931389|FG005|Extended Induction, Open-Label|Withdrawal by Subject|0
6246163|NCT01903252|9931384|FG000|Extended Induction, Open-Label|Physician Decision|0
6246164|NCT01903252|9931385|FG001|Extended Induction, Open-Label|Physician Decision|0
6246165|NCT01903252|9931386|FG002|Extended Induction, Open-Label|Physician Decision|1
6086111|NCT00658684|9695816|FG002|Overall Study|Withdrawal by Subject|1
6086112|NCT00658684|9695817|FG003|Overall Study|Withdrawal by Subject|1
6086113|NCT00658684|9695814|FG000|Overall Study|Lack of Efficacy|1
6086114|NCT00658684|9695815|FG001|Overall Study|Lack of Efficacy|1
6086115|NCT00658684|9695816|FG002|Overall Study|Lack of Efficacy|0
6246166|NCT01903252|9931387|FG003|Extended Induction, Open-Label|Physician Decision|0
6246167|NCT01903252|9931388|FG004|Extended Induction, Open-Label|Physician Decision|0
6246168|NCT01903252|9931389|FG005|Extended Induction, Open-Label|Physician Decision|0
6246169|NCT01903252|9931384|FG000|Maintenance, Open-Label|Adverse Event|0
6246170|NCT01903252|9931385|FG001|Maintenance, Open-Label|Adverse Event|0
6246171|NCT01903252|9931386|FG002|Maintenance, Open-Label|Adverse Event|0
6246172|NCT01903252|9931387|FG003|Maintenance, Open-Label|Adverse Event|3
6246173|NCT01903252|9931388|FG004|Maintenance, Open-Label|Adverse Event|9
6246174|NCT01903252|9931389|FG005|Maintenance, Open-Label|Adverse Event|14
6246175|NCT01903252|9931384|FG000|Maintenance, Open-Label|Withdrawal by Subject|0
6246176|NCT01903252|9931385|FG001|Maintenance, Open-Label|Withdrawal by Subject|0
6246177|NCT01903252|9931386|FG002|Maintenance, Open-Label|Withdrawal by Subject|0
6246178|NCT01903252|9931387|FG003|Maintenance, Open-Label|Withdrawal by Subject|1
6246179|NCT01903252|9931388|FG004|Maintenance, Open-Label|Withdrawal by Subject|6
6246180|NCT01903252|9931389|FG005|Maintenance, Open-Label|Withdrawal by Subject|2
6246181|NCT01903252|9931384|FG000|Maintenance, Open-Label|Other|0
6246182|NCT01903252|9931385|FG001|Maintenance, Open-Label|Other|0
6246183|NCT01903252|9931386|FG002|Maintenance, Open-Label|Other|0
6246184|NCT01903252|9931387|FG003|Maintenance, Open-Label|Other|2
6246185|NCT01903252|9931388|FG004|Maintenance, Open-Label|Other|6
6246186|NCT01903252|9931389|FG005|Maintenance, Open-Label|Other|2
6246187|NCT01903356|9931416|FG000|Overall Study|Lost to Follow-up|7
6246188|NCT01903356|9931416|FG000|Overall Study|Violated inclusion/exclusion criteria|5
6246189|NCT01903356|9931416|FG000|Overall Study|Violated the dosage and administration|3
6246190|NCT01903434|9931420|FG000|Washout Period 1 (at Least 14 Days)|Adverse Event|1
6246191|NCT01903434|9931421|FG001|Washout Period 1 (at Least 14 Days)|Adverse Event|0
6246192|NCT01903434|9931420|FG000|Washout Period 1 (at Least 14 Days)|Withdrawal by Subject|0
6246193|NCT01903434|9931421|FG001|Washout Period 1 (at Least 14 Days)|Withdrawal by Subject|2
6246194|NCT01903460|9931431|FG000|Overall Study|Adverse Event|0
6246195|NCT01903460|9931432|FG001|Overall Study|Adverse Event|0
6246196|NCT01903460|9931433|FG002|Overall Study|Adverse Event|0
6246197|NCT01903460|9931434|FG003|Overall Study|Adverse Event|1
6246198|NCT01903525|9931445|FG000|Overall Study|Lost to Follow-up|5
6246199|NCT01903525|9931446|FG001|Overall Study|Lost to Follow-up|9
6246200|NCT01903525|9931445|FG000|Overall Study|Adverse Event|0
6246201|NCT01903525|9931446|FG001|Overall Study|Adverse Event|1
6246202|NCT01903720|9931461|FG000|Overall Study|Inclusion / exclusion criteria not met|6
6246203|NCT01903720|9931461|FG000|Overall Study|Adverse Event|1
6246204|NCT01903720|9931461|FG000|Overall Study|Rescinding of informed consent|2
6246205|NCT01903720|9931461|FG000|Overall Study|Lost to Follow-up|2
6246206|NCT01903720|9931461|FG000|Overall Study|Treatment with alternative drug|1
6246207|NCT01903733|9931469|FG000|Overall Study|Death|23
6246208|NCT01903733|9931470|FG001|Overall Study|Death|54
6246209|NCT01903733|9931471|FG002|Overall Study|Death|30
6246210|NCT01903733|9931472|FG003|Overall Study|Death|98
6246211|NCT01903733|9931469|FG000|Overall Study|Participant refused further follow-up|35
6246212|NCT01903733|9931470|FG001|Overall Study|Participant refused further follow-up|38
6246213|NCT01903733|9931471|FG002|Overall Study|Participant refused further follow-up|13
6246214|NCT01903733|9931472|FG003|Overall Study|Participant refused further follow-up|9
6246215|NCT01903733|9931469|FG000|Overall Study|Lost to Follow-up|18
6246216|NCT01903733|9931470|FG001|Overall Study|Lost to Follow-up|19
6246217|NCT01903733|9931471|FG002|Overall Study|Lost to Follow-up|6
6246218|NCT01903733|9931472|FG003|Overall Study|Lost to Follow-up|9
6246219|NCT01903733|9931469|FG000|Overall Study|Other|10
6246220|NCT01903733|9931470|FG001|Overall Study|Other|15
6246221|NCT01903733|9931471|FG002|Overall Study|Other|12
6246222|NCT01903733|9931472|FG003|Overall Study|Other|3
6246223|NCT01903733|9931469|FG000|Overall Study|Missing|2
6246224|NCT01903733|9931470|FG001|Overall Study|Missing|0
6246225|NCT01903733|9931471|FG002|Overall Study|Missing|0
6246226|NCT01903733|9931472|FG003|Overall Study|Missing|0
6246227|NCT01903733|9931469|FG000|Overall Study|Investigator request|18
6246228|NCT01903733|9931470|FG001|Overall Study|Investigator request|0
6246229|NCT01903733|9931471|FG002|Overall Study|Investigator request|0
6246230|NCT01903733|9931472|FG003|Overall Study|Investigator request|0
6246231|NCT01903811|9931511|FG000|Overall Study|No measurable disease|1
6246232|NCT01903811|9931512|FG001|Overall Study|No measurable disease|1
6246233|NCT01903811|9931511|FG000|Overall Study|Incomplete/discontinued prior therapy|1
6246234|NCT01903811|9931512|FG001|Overall Study|Incomplete/discontinued prior therapy|1
6246235|NCT01903811|9931511|FG000|Overall Study|Baseline lab missing/incomplete/untimely|6
6246236|NCT01903811|9931512|FG001|Overall Study|Baseline lab missing/incomplete/untimely|11
6246237|NCT01903811|9931511|FG000|Overall Study|Withdrawal by Subject|0
6246238|NCT01903811|9931512|FG001|Overall Study|Withdrawal by Subject|1
6246239|NCT01903837|9931525|FG000|Part A|Withdrawal by Subject|4
6246240|NCT01903837|9931526|FG001|Part A|Withdrawal by Subject|9
6246241|NCT01903837|9931527|FG002|Part A|Withdrawal by Subject|8
6246242|NCT01903837|9931528|FG003|Part A|Withdrawal by Subject|5
6246243|NCT01903837|9931525|FG000|Part A|Adverse Event|3
6246244|NCT01903837|9931526|FG001|Part A|Adverse Event|6
6246245|NCT01903837|9931527|FG002|Part A|Adverse Event|9
6246246|NCT01903837|9931528|FG003|Part A|Adverse Event|6
6246247|NCT01903837|9931525|FG000|Part A|Lost to Follow-up|9
6246248|NCT01903837|9931526|FG001|Part A|Lost to Follow-up|7
6246249|NCT01903837|9931527|FG002|Part A|Lost to Follow-up|7
6246250|NCT01903837|9931528|FG003|Part A|Lost to Follow-up|2
6246251|NCT01903837|9931525|FG000|Part A|Non-compliance with study drug|1
6246252|NCT01903837|9931526|FG001|Part A|Non-compliance with study drug|4
6246253|NCT01903837|9931527|FG002|Part A|Non-compliance with study drug|4
6246254|NCT01903837|9931528|FG003|Part A|Non-compliance with study drug|0
6246255|NCT01903837|9931525|FG000|Part A|Physician Decision|1
6246256|NCT01903837|9931526|FG001|Part A|Physician Decision|1
6246257|NCT01903837|9931527|FG002|Part A|Physician Decision|0
6246258|NCT01903837|9931528|FG003|Part A|Physician Decision|0
6246259|NCT01903837|9931525|FG000|Part A|Protocol Violation|1
6246260|NCT01903837|9931526|FG001|Part A|Protocol Violation|1
6246261|NCT01903837|9931527|FG002|Part A|Protocol Violation|0
6246262|NCT01903837|9931528|FG003|Part A|Protocol Violation|0
6246263|NCT01903837|9931525|FG000|Part B|Lost to Follow-up|0
6246264|NCT01903837|9931526|FG001|Part B|Lost to Follow-up|3
6246265|NCT01903837|9931527|FG002|Part B|Lost to Follow-up|3
6246266|NCT01903837|9931528|FG003|Part B|Lost to Follow-up|4
6246267|NCT01903837|9931525|FG000|Part B|Withdrawal by Subject|1
6246268|NCT01903837|9931526|FG001|Part B|Withdrawal by Subject|2
6246269|NCT01903837|9931527|FG002|Part B|Withdrawal by Subject|0
6246270|NCT01903837|9931528|FG003|Part B|Withdrawal by Subject|3
6246271|NCT01903837|9931525|FG000|Part B|Adverse Event|3
6246272|NCT01903837|9931526|FG001|Part B|Adverse Event|0
6246273|NCT01903837|9931527|FG002|Part B|Adverse Event|2
6246274|NCT01903837|9931528|FG003|Part B|Adverse Event|0
6246275|NCT01903837|9931525|FG000|Part B|Non-compliance with study drug|2
6246276|NCT01903837|9931526|FG001|Part B|Non-compliance with study drug|0
6246277|NCT01903837|9931527|FG002|Part B|Non-compliance with study drug|0
6246278|NCT01903837|9931528|FG003|Part B|Non-compliance with study drug|1
6246279|NCT01903837|9931525|FG000|Part B|Incarceration|2
6246280|NCT01903837|9931526|FG001|Part B|Incarceration|0
6246281|NCT01903837|9931527|FG002|Part B|Incarceration|0
6246282|NCT01903837|9931528|FG003|Part B|Incarceration|1
6246283|NCT01903837|9931525|FG000|Part B|Physician Decision|1
6246284|NCT01903837|9931526|FG001|Part B|Physician Decision|0
6246285|NCT01903837|9931527|FG002|Part B|Physician Decision|0
6246286|NCT01903837|9931528|FG003|Part B|Physician Decision|2
6246287|NCT01903837|9931525|FG000|Part B|Lack of Efficacy|0
6246288|NCT01903837|9931526|FG001|Part B|Lack of Efficacy|1
6246289|NCT01903837|9931527|FG002|Part B|Lack of Efficacy|0
6246290|NCT01903837|9931528|FG003|Part B|Lack of Efficacy|0
6246291|NCT01903863|9931561|FG000|Overall Study|Physician Decision|2
6246292|NCT01903863|9931562|FG001|Overall Study|Physician Decision|0
6246293|NCT01903876|9931570|FG000|Baseline to Post-Intervention Period|Lost to Follow-up|184
6246294|NCT01903876|9931571|FG001|Baseline to Post-Intervention Period|Lost to Follow-up|108
6246295|NCT01903876|9931570|FG000|Six-Month Follow-up Period|Lost to Follow-up|91
6246296|NCT01903876|9931571|FG001|Six-Month Follow-up Period|Lost to Follow-up|145
6246297|NCT01903993|9931579|FG000|Overall Study|Death|118
6246298|NCT01903993|9931580|FG001|Overall Study|Death|121
6246299|NCT01903993|9931579|FG000|Overall Study|Withdrawal by Subject|15
6246300|NCT01903993|9931580|FG001|Overall Study|Withdrawal by Subject|4
6246301|NCT01903993|9931579|FG000|Overall Study|Lost to Follow-up|2
6246302|NCT01903993|9931580|FG001|Overall Study|Lost to Follow-up|3
6246303|NCT01903993|9931579|FG000|Overall Study|Study Terminated by Sponsor|8
6246304|NCT01903993|9931580|FG001|Overall Study|Study Terminated by Sponsor|14
6246305|NCT01903993|9931579|FG000|Overall Study|Terminated by Sponsor After 31 Aug 2018|0
6246306|NCT01903993|9931580|FG001|Overall Study|Terminated by Sponsor After 31 Aug 2018|2
6246307|NCT01904019|9931587|FG000|1 Year Follow-up|Withdrawal by Subject|4
6246308|NCT01904019|9931587|FG000|1 Year Follow-up|Impossibility to contact patient|5
6246309|NCT01904019|9931587|FG000|3 Year Follow-up|Withdrawal by Subject|1
6246310|NCT01904019|9931587|FG000|3 Year Follow-up|Impossibility to contact patient|14
6246311|NCT01904019|9931587|FG000|5 Year Follow-up|Withdrawal by Subject|2
6246312|NCT01904019|9931587|FG000|5 Year Follow-up|Impossibility to contact patient|4
6246313|NCT01904058|9931595|FG000|Overall Study|Adverse Event|2
6246314|NCT01904058|9931596|FG001|Overall Study|Adverse Event|0
6246315|NCT01904058|9931597|FG002|Overall Study|Adverse Event|0
6246316|NCT01904058|9931598|FG003|Overall Study|Adverse Event|0
6246317|NCT01904058|9931595|FG000|Overall Study|Withdrawal by Subject|1
6246318|NCT01904058|9931596|FG001|Overall Study|Withdrawal by Subject|0
6246319|NCT01904058|9931597|FG002|Overall Study|Withdrawal by Subject|1
6246320|NCT01904058|9931598|FG003|Overall Study|Withdrawal by Subject|0
6246321|NCT01904058|9931595|FG000|Overall Study|Pregnancy|0
6246322|NCT01904058|9931596|FG001|Overall Study|Pregnancy|0
6246323|NCT01904058|9931597|FG002|Overall Study|Pregnancy|0
6246324|NCT01904058|9931598|FG003|Overall Study|Pregnancy|1
6246325|NCT01904149|9931633|FG000|Overall Study|Adverse Event|3
6246326|NCT01904149|9931634|FG001|Overall Study|Adverse Event|4
6246327|NCT01904149|9931635|FG002|Overall Study|Adverse Event|0
6246328|NCT01904149|9931636|FG003|Overall Study|Adverse Event|1
6246329|NCT01904149|9931637|FG004|Overall Study|Adverse Event|1
6246330|NCT01904149|9931638|FG005|Overall Study|Adverse Event|2
6246331|NCT01904149|9931633|FG000|Overall Study|Lack of Efficacy|0
6246332|NCT01904149|9931634|FG001|Overall Study|Lack of Efficacy|3
6246333|NCT01904149|9931635|FG002|Overall Study|Lack of Efficacy|1
6246334|NCT01904149|9931636|FG003|Overall Study|Lack of Efficacy|3
6246335|NCT01904149|9931637|FG004|Overall Study|Lack of Efficacy|3
6246336|NCT01904149|9931638|FG005|Overall Study|Lack of Efficacy|1
6246337|NCT01904149|9931633|FG000|Overall Study|Withdrawal by Subject|1
6246338|NCT01904149|9931634|FG001|Overall Study|Withdrawal by Subject|3
6246339|NCT01904149|9931635|FG002|Overall Study|Withdrawal by Subject|1
6246340|NCT01904149|9931636|FG003|Overall Study|Withdrawal by Subject|0
6246341|NCT01904149|9931637|FG004|Overall Study|Withdrawal by Subject|1
6246342|NCT01904149|9931638|FG005|Overall Study|Withdrawal by Subject|0
6246343|NCT01904149|9931633|FG000|Overall Study|Protocol Violation|0
6246344|NCT01904149|9931634|FG001|Overall Study|Protocol Violation|1
6246345|NCT01904149|9931635|FG002|Overall Study|Protocol Violation|0
6246346|NCT01904149|9931636|FG003|Overall Study|Protocol Violation|0
6246347|NCT01904149|9931637|FG004|Overall Study|Protocol Violation|0
6246348|NCT01904149|9931638|FG005|Overall Study|Protocol Violation|0
6246349|NCT01904149|9931633|FG000|Overall Study|non compliance with study drug|1
6246350|NCT01904149|9931634|FG001|Overall Study|non compliance with study drug|0
6246351|NCT01904149|9931635|FG002|Overall Study|non compliance with study drug|0
6246352|NCT01904149|9931636|FG003|Overall Study|non compliance with study drug|0
6246353|NCT01904149|9931637|FG004|Overall Study|non compliance with study drug|0
6246354|NCT01904149|9931638|FG005|Overall Study|non compliance with study drug|0
6246355|NCT01904383|9931654|FG000|Overall Study|CRF not collected|117
6246356|NCT01904383|9931654|FG000|Overall Study|Reason not listed|147
6246357|NCT01904383|9931654|FG000|Overall Study|Lost to Follow-up|674
6246358|NCT01904383|9931654|FG000|Overall Study|Lack of Efficacy|370
6246359|NCT01904383|9931654|FG000|Overall Study|Improvement|141
6246360|NCT01904383|9931654|FG000|Overall Study|Adverse Event|271
6246361|NCT01904383|9931654|FG000|Overall Study|No patient visit after entry|54
6246362|NCT01904604|9931674|FG000|Overall Study|Withdrew before receiving dosing|0
6246363|NCT01904604|9931675|FG001|Overall Study|Withdrew before receiving dosing|1
6246364|NCT01904604|9931676|FG002|Overall Study|Withdrew before receiving dosing|0
6246365|NCT01904604|9931674|FG000|Overall Study|Non-compliance|1
6246366|NCT01904604|9931675|FG001|Overall Study|Non-compliance|0
6246367|NCT01904604|9931676|FG002|Overall Study|Non-compliance|0
6246368|NCT01904604|9931674|FG000|Overall Study|Anxiety about OFC/Refused OFC|2
6246369|NCT01904604|9931675|FG001|Overall Study|Anxiety about OFC/Refused OFC|0
6246370|NCT01904604|9931676|FG002|Overall Study|Anxiety about OFC/Refused OFC|0
6246371|NCT01904604|9931674|FG000|Overall Study|Patch site reactions|1
6246372|NCT01904604|9931675|FG001|Overall Study|Patch site reactions|1
6246373|NCT01904604|9931676|FG002|Overall Study|Patch site reactions|0
6246374|NCT01904604|9931674|FG000|Overall Study|Increased syncope|0
6246375|NCT01904604|9931675|FG001|Overall Study|Increased syncope|1
6246376|NCT01904604|9931676|FG002|Overall Study|Increased syncope|0
6246377|NCT01904604|9931674|FG000|Overall Study|Unrelated illness|0
6246378|NCT01904604|9931675|FG001|Overall Study|Unrelated illness|1
6246379|NCT01904604|9931676|FG002|Overall Study|Unrelated illness|0
6246380|NCT01904604|9931674|FG000|Overall Study|Passed Week 52 OFC|1
6246381|NCT01904604|9931675|FG001|Overall Study|Passed Week 52 OFC|0
6246382|NCT01904604|9931676|FG002|Overall Study|Passed Week 52 OFC|0
6246383|NCT01904604|9931674|FG000|Overall Study|Withdrawal by Subject|1
6246384|NCT01904604|9931675|FG001|Overall Study|Withdrawal by Subject|2
6246385|NCT01904604|9931676|FG002|Overall Study|Withdrawal by Subject|0
6246386|NCT01904604|9931674|FG000|Overall Study|Participant Relocated|1
6246387|NCT01904604|9931675|FG001|Overall Study|Participant Relocated|1
6246388|NCT01904604|9931676|FG002|Overall Study|Participant Relocated|1
6246389|NCT01904604|9931674|FG000|Overall Study|Lost to Follow-up|0
6246390|NCT01904604|9931675|FG001|Overall Study|Lost to Follow-up|0
6246391|NCT01904604|9931676|FG002|Overall Study|Lost to Follow-up|1
6246392|NCT01904721|9931694|FG000|Overall Study|Other Reasons|0
6246393|NCT01904721|9931695|FG001|Overall Study|Other Reasons|0
6246394|NCT01904721|9931696|FG002|Overall Study|Other Reasons|1
6246395|NCT01904721|9931697|FG003|Overall Study|Other Reasons|1
6246396|NCT01904721|9931698|FG004|Overall Study|Other Reasons|2
6246397|NCT01904721|9931699|FG005|Overall Study|Other Reasons|2
6246398|NCT01904721|9931700|FG006|Overall Study|Other Reasons|2
6246399|NCT01904721|9931694|FG000|Overall Study|Personal Reasons|0
6246400|NCT01904721|9931695|FG001|Overall Study|Personal Reasons|0
6246401|NCT01904721|9931696|FG002|Overall Study|Personal Reasons|0
6189295|NCT01397890|9844427|FG001|Overall Study|Lost to Follow-up|4
6189296|NCT01397890|9844426|FG000|Overall Study|Condition under Investigation Worsened|1
6189297|NCT01397890|9844427|FG001|Overall Study|Condition under Investigation Worsened|3
6189298|NCT01397890|9844426|FG000|Overall Study|Adverse Event|1
6189299|NCT01397890|9844427|FG001|Overall Study|Adverse Event|2
6189300|NCT01397890|9844426|FG000|Overall Study|Severe Non-Compliance to Protocol|2
6189301|NCT01397890|9844427|FG001|Overall Study|Severe Non-Compliance to Protocol|1
6189302|NCT01397890|9844426|FG000|Overall Study|Others|2
6189303|NCT01397890|9844427|FG001|Overall Study|Others|1
6189304|NCT01398176|9844448|FG000|Overall Study|Lost to Follow-up|1
6246402|NCT01904721|9931697|FG003|Overall Study|Personal Reasons|0
6189305|NCT01398176|9844449|FG001|Overall Study|Lost to Follow-up|3
6189306|NCT01398176|9844448|FG000|Overall Study|Physician Decision|2
6246403|NCT01904721|9931698|FG004|Overall Study|Personal Reasons|2
6246404|NCT01904721|9931699|FG005|Overall Study|Personal Reasons|3
6246405|NCT01904721|9931700|FG006|Overall Study|Personal Reasons|3
6246406|NCT01904721|9931694|FG000|Overall Study|Lost to Follow-up|0
6246407|NCT01904721|9931695|FG001|Overall Study|Lost to Follow-up|0
6246408|NCT01904721|9931696|FG002|Overall Study|Lost to Follow-up|0
6246409|NCT01904721|9931697|FG003|Overall Study|Lost to Follow-up|0
6246410|NCT01904721|9931698|FG004|Overall Study|Lost to Follow-up|1
6246411|NCT01904721|9931699|FG005|Overall Study|Lost to Follow-up|3
6246412|NCT01904721|9931700|FG006|Overall Study|Lost to Follow-up|1
6246413|NCT01904721|9931694|FG000|Overall Study|Lack of Efficacy|0
6246414|NCT01904721|9931695|FG001|Overall Study|Lack of Efficacy|0
6246415|NCT01904721|9931696|FG002|Overall Study|Lack of Efficacy|0
6246416|NCT01904721|9931697|FG003|Overall Study|Lack of Efficacy|0
6246417|NCT01904721|9931698|FG004|Overall Study|Lack of Efficacy|0
6246418|NCT01904721|9931699|FG005|Overall Study|Lack of Efficacy|0
6246419|NCT01904721|9931700|FG006|Overall Study|Lack of Efficacy|1
6246420|NCT01904721|9931694|FG000|Overall Study|Adverse Event|0
6086116|NCT00658684|9695817|FG003|Overall Study|Lack of Efficacy|0
6246421|NCT01904721|9931695|FG001|Overall Study|Adverse Event|0
6246422|NCT01904721|9931696|FG002|Overall Study|Adverse Event|0
6246423|NCT01904721|9931697|FG003|Overall Study|Adverse Event|0
6246424|NCT01904721|9931698|FG004|Overall Study|Adverse Event|3
6246425|NCT01904721|9931699|FG005|Overall Study|Adverse Event|1
6246426|NCT01904721|9931700|FG006|Overall Study|Adverse Event|0
6246427|NCT01904760|9931714|FG000|Overall Study|Protocol Violation|1
6246428|NCT01904760|9931715|FG001|Overall Study|Protocol Violation|0
6246429|NCT01904773|9931721|FG000|Screen|Screen failure|3
6246430|NCT01904773|9931722|FG001|Screen|Screen failure|0
6246431|NCT01904773|9931723|FG002|Screen|Screen failure|0
6246432|NCT01904773|9931724|FG003|Screen|Screen failure|0
6246433|NCT01904773|9931725|FG004|Screen|Screen failure|0
6246434|NCT01904773|9931726|FG005|Screen|Screen failure|0
6246435|NCT01904773|9931727|FG006|Screen|Screen failure|0
6246436|NCT01904773|9931728|FG007|Screen|Screen failure|0
6246437|NCT01904773|9931729|FG008|Screen|Screen failure|0
6246438|NCT01904773|9931721|FG000|Screen|Withdrawal by Subject|1
6246439|NCT01904773|9931722|FG001|Screen|Withdrawal by Subject|0
6246440|NCT01904773|9931723|FG002|Screen|Withdrawal by Subject|0
6246441|NCT01904773|9931724|FG003|Screen|Withdrawal by Subject|0
6246442|NCT01904773|9931725|FG004|Screen|Withdrawal by Subject|0
6246443|NCT01904773|9931726|FG005|Screen|Withdrawal by Subject|0
6246444|NCT01904773|9931727|FG006|Screen|Withdrawal by Subject|0
6246445|NCT01904773|9931728|FG007|Screen|Withdrawal by Subject|0
6246446|NCT01904773|9931729|FG008|Screen|Withdrawal by Subject|0
6246447|NCT01904773|9931721|FG000|Part 1 - Multiple Dose AZD5213 2.0 mg|Adverse Event|1
6246448|NCT01904773|9931722|FG001|Part 1 - Multiple Dose AZD5213 2.0 mg|Adverse Event|0
6246449|NCT01904773|9931723|FG002|Part 1 - Multiple Dose AZD5213 2.0 mg|Adverse Event|0
6246450|NCT01904773|9931724|FG003|Part 1 - Multiple Dose AZD5213 2.0 mg|Adverse Event|0
6246451|NCT01904773|9931725|FG004|Part 1 - Multiple Dose AZD5213 2.0 mg|Adverse Event|0
6246452|NCT01904773|9931726|FG005|Part 1 - Multiple Dose AZD5213 2.0 mg|Adverse Event|0
6246453|NCT01904773|9931727|FG006|Part 1 - Multiple Dose AZD5213 2.0 mg|Adverse Event|0
6246454|NCT01904773|9931728|FG007|Part 1 - Multiple Dose AZD5213 2.0 mg|Adverse Event|0
6246455|NCT01904773|9931729|FG008|Part 1 - Multiple Dose AZD5213 2.0 mg|Adverse Event|0
6246456|NCT01904773|9931721|FG000|First Intervention|Adverse Event|0
6246457|NCT01904773|9931722|FG001|First Intervention|Adverse Event|0
6246458|NCT01904773|9931723|FG002|First Intervention|Adverse Event|0
6246459|NCT01904773|9931724|FG003|First Intervention|Adverse Event|0
6246460|NCT01904773|9931725|FG004|First Intervention|Adverse Event|0
6246461|NCT01904773|9931726|FG005|First Intervention|Adverse Event|0
6246462|NCT01904773|9931727|FG006|First Intervention|Adverse Event|1
6246463|NCT01904773|9931728|FG007|First Intervention|Adverse Event|0
6246464|NCT01904773|9931729|FG008|First Intervention|Adverse Event|0
6246465|NCT01904773|9931721|FG000|Placebo Washout First Intervention|Condition worsened|0
6246466|NCT01904773|9931722|FG001|Placebo Washout First Intervention|Condition worsened|1
6246467|NCT01904773|9931723|FG002|Placebo Washout First Intervention|Condition worsened|0
6246468|NCT01904773|9931724|FG003|Placebo Washout First Intervention|Condition worsened|0
6246469|NCT01904773|9931725|FG004|Placebo Washout First Intervention|Condition worsened|0
6246470|NCT01904773|9931726|FG005|Placebo Washout First Intervention|Condition worsened|0
6246471|NCT01904773|9931727|FG006|Placebo Washout First Intervention|Condition worsened|0
6246472|NCT01904773|9931728|FG007|Placebo Washout First Intervention|Condition worsened|0
6246473|NCT01904773|9931729|FG008|Placebo Washout First Intervention|Condition worsened|0
6246474|NCT01904773|9931721|FG000|Fifth Intervention|Adverse Event|0
6246475|NCT01904773|9931722|FG001|Fifth Intervention|Adverse Event|0
6246476|NCT01904773|9931723|FG002|Fifth Intervention|Adverse Event|0
6246477|NCT01904773|9931724|FG003|Fifth Intervention|Adverse Event|0
6246478|NCT01904773|9931725|FG004|Fifth Intervention|Adverse Event|0
6246479|NCT01904773|9931726|FG005|Fifth Intervention|Adverse Event|0
6246480|NCT01904773|9931727|FG006|Fifth Intervention|Adverse Event|0
6246481|NCT01904773|9931728|FG007|Fifth Intervention|Adverse Event|1
6246482|NCT01904773|9931729|FG008|Fifth Intervention|Adverse Event|0
6246483|NCT01904773|9931721|FG000|Placebo Washout Fifth Intervention|Study specific withdrawal criteria|0
6246484|NCT01904773|9931722|FG001|Placebo Washout Fifth Intervention|Study specific withdrawal criteria|1
6086117|NCT00658684|9695814|FG000|Overall Study|Protocol Violation|1
6246485|NCT01904773|9931723|FG002|Placebo Washout Fifth Intervention|Study specific withdrawal criteria|0
6246486|NCT01904773|9931724|FG003|Placebo Washout Fifth Intervention|Study specific withdrawal criteria|0
6246487|NCT01904773|9931725|FG004|Placebo Washout Fifth Intervention|Study specific withdrawal criteria|0
6246488|NCT01904773|9931726|FG005|Placebo Washout Fifth Intervention|Study specific withdrawal criteria|0
6086118|NCT00658684|9695815|FG001|Overall Study|Protocol Violation|1
6246489|NCT01904773|9931727|FG006|Placebo Washout Fifth Intervention|Study specific withdrawal criteria|0
6246490|NCT01904773|9931728|FG007|Placebo Washout Fifth Intervention|Study specific withdrawal criteria|0
6246491|NCT01904773|9931729|FG008|Placebo Washout Fifth Intervention|Study specific withdrawal criteria|0
6246492|NCT01905267|9931760|FG000|Overall Study|Physician Decision|2
6246493|NCT01905267|9931761|FG001|Overall Study|Physician Decision|2
6246494|NCT01905540|9931792|FG000|Period 3|Other|1
6246495|NCT01905540|9931793|FG001|Period 3|Other|0
6246496|NCT01905540|9931794|FG002|Period 3|Other|1
6246497|NCT01905540|9931795|FG003|Period 3|Other|1
6246498|NCT01905553|9931807|FG000|Period 2|Adverse Event|1
6246499|NCT01905553|9931808|FG001|Period 2|Adverse Event|0
6246500|NCT01905592|9931816|FG000|Overall Study|Disease Progression|51
6246501|NCT01905592|9931817|FG001|Overall Study|Disease Progression|104
6246502|NCT01905592|9931816|FG000|Overall Study|Toxicity|1
6246503|NCT01905592|9931817|FG001|Overall Study|Toxicity|16
6246504|NCT01905592|9931816|FG000|Overall Study|Physician Decision|0
6246505|NCT01905592|9931817|FG001|Overall Study|Physician Decision|2
6246506|NCT01905592|9931816|FG000|Overall Study|New anti-cancer|1
6246507|NCT01905592|9931817|FG001|Overall Study|New anti-cancer|0
6246508|NCT01905592|9931816|FG000|Overall Study|Protocol Violation|0
6246509|NCT01905592|9931817|FG001|Overall Study|Protocol Violation|1
6246510|NCT01905592|9931816|FG000|Overall Study|Sponsor's decision|1
6246511|NCT01905592|9931817|FG001|Overall Study|Sponsor's decision|0
6246512|NCT01905592|9931816|FG000|Overall Study|Not treated|7
6246513|NCT01905592|9931817|FG001|Overall Study|Not treated|3
6246514|NCT01905592|9931816|FG000|Overall Study|Ongoing in Study|0
6246515|NCT01905592|9931817|FG001|Overall Study|Ongoing in Study|7
6246516|NCT01905592|9931816|FG000|Overall Study|Withdrawal by Subject|10
6246517|NCT01905592|9931817|FG001|Overall Study|Withdrawal by Subject|2
6246518|NCT01905657|9931826|FG000|Overall Study|Adverse Event|23
6246519|NCT01905657|9931827|FG001|Overall Study|Adverse Event|17
6246520|NCT01905657|9931828|FG002|Overall Study|Adverse Event|18
6246521|NCT01905657|9931826|FG000|Overall Study|Clinical Progression|103
6246522|NCT01905657|9931827|FG001|Overall Study|Clinical Progression|78
6246523|NCT01905657|9931828|FG002|Overall Study|Clinical Progression|59
6246524|NCT01905657|9931826|FG000|Overall Study|Death|40
6246525|NCT01905657|9931827|FG001|Overall Study|Death|43
6246526|NCT01905657|9931828|FG002|Overall Study|Death|47
6246527|NCT01905657|9931826|FG000|Overall Study|Excluded Medication|13
6246528|NCT01905657|9931827|FG001|Overall Study|Excluded Medication|16
6246529|NCT01905657|9931828|FG002|Overall Study|Excluded Medication|9
6246530|NCT01905657|9931826|FG000|Overall Study|Lost to Follow-up|1
6246531|NCT01905657|9931827|FG001|Overall Study|Lost to Follow-up|2
6246532|NCT01905657|9931828|FG002|Overall Study|Lost to Follow-up|1
6246533|NCT01905657|9931826|FG000|Overall Study|Physician Decision|5
6246534|NCT01905657|9931827|FG001|Overall Study|Physician Decision|8
6246535|NCT01905657|9931828|FG002|Overall Study|Physician Decision|12
6246536|NCT01905657|9931826|FG000|Overall Study|Protocol Violation|2
6246537|NCT01905657|9931827|FG001|Overall Study|Protocol Violation|1
6246538|NCT01905657|9931828|FG002|Overall Study|Protocol Violation|1
6246539|NCT01905657|9931826|FG000|Overall Study|Screen Failure|0
6246540|NCT01905657|9931827|FG001|Overall Study|Screen Failure|1
6246541|NCT01905657|9931828|FG002|Overall Study|Screen Failure|0
6246542|NCT01905657|9931826|FG000|Overall Study|Withdrawal by Subject|15
6246543|NCT01905657|9931827|FG001|Overall Study|Withdrawal by Subject|21
6246544|NCT01905657|9931828|FG002|Overall Study|Withdrawal by Subject|53
6246545|NCT01905657|9931826|FG000|Overall Study|Sponsor Decision|1
6246546|NCT01905657|9931827|FG001|Overall Study|Sponsor Decision|0
6246547|NCT01905657|9931828|FG002|Overall Study|Sponsor Decision|0
6246548|NCT01905683|9931839|FG000|Overall Study|Protocol Violation|1
6246549|NCT01905683|9931839|FG000|Overall Study|Re-injection criteria not met; others|13
6246550|NCT01905683|9931839|FG000|Overall Study|Physician Decision|1
6246551|NCT01905683|9931839|FG000|Overall Study|Lack of Efficacy|8
6246552|NCT01905683|9931839|FG000|Overall Study|Withdrawal by Subject|20
6246553|NCT01905683|9931839|FG000|Overall Study|Adverse Event|4
6246554|NCT01905683|9931839|FG000|Overall Study|Lost to Follow-up|4
6246555|NCT01905943|9931843|FG000|Overall Study|Withdrawal of consent|90
6246556|NCT01905943|9931843|FG000|Overall Study|Lost to Follow-up|16
6246557|NCT01905943|9931843|FG000|Overall Study|Investigator discretion|7
6246558|NCT01905943|9931843|FG000|Overall Study|Death|186
6246559|NCT01905943|9931843|FG000|Overall Study|Adverse Event|3
6246560|NCT01905943|9931843|FG000|Overall Study|Other|12
6246561|NCT01906008|9931873|FG000|Overall Study|Lost to Follow-up|2
6246562|NCT01906008|9931874|FG001|Overall Study|Lost to Follow-up|0
6246563|NCT01906008|9931873|FG000|Overall Study|Oxaliplatin toxicity|2
6246564|NCT01906008|9931874|FG001|Overall Study|Oxaliplatin toxicity|0
6246565|NCT01906008|9931873|FG000|Overall Study|Protocol Violation|0
6246566|NCT01906008|9931874|FG001|Overall Study|Protocol Violation|1
6246567|NCT01906008|9931873|FG000|Overall Study|Withdrawal by Subject|1
6246568|NCT01906008|9931874|FG001|Overall Study|Withdrawal by Subject|5
6246569|NCT01906008|9931873|FG000|Overall Study|Did not start study med|3
6246570|NCT01906008|9931874|FG001|Overall Study|Did not start study med|4
6246571|NCT01906008|9931873|FG000|Overall Study|Oxaliplatin stops|10
6246572|NCT01906008|9931874|FG001|Overall Study|Oxaliplatin stops|8
6246573|NCT01906008|9931873|FG000|Overall Study|Hospice|1
6246574|NCT01906008|9931874|FG001|Overall Study|Hospice|0
6246575|NCT01906008|9931873|FG000|Overall Study|Physician Decision|3
6246576|NCT01906008|9931874|FG001|Overall Study|Physician Decision|3
6246577|NCT01906008|9931873|FG000|Overall Study|Lack of compliance of study med|5
6246578|NCT01906008|9931874|FG001|Overall Study|Lack of compliance of study med|3
6246579|NCT01906008|9931873|FG000|Overall Study|Adverse Event|0
6246580|NCT01906008|9931874|FG001|Overall Study|Adverse Event|3
6246581|NCT01906346|9931880|FG000|Overall Study|AEs|1
6246582|NCT01906372|9931886|FG000|Overall Study|Withdrawal by Subject|2
6246583|NCT01906476|9931893|FG000|Overall Study|Lost to Follow-up|17
6246584|NCT01906476|9931894|FG001|Overall Study|Lost to Follow-up|16
6246585|NCT01907087|9931939|FG000|Overall Study|Withdrawal by Subject|1
6246586|NCT01907100|9931947|FG000|Overall Study|PD based on modified RECIST criteria|31
6246587|NCT01907100|9931948|FG001|Overall Study|PD based on modified RECIST criteria|32
6246588|NCT01907100|9931949|FG002|Overall Study|PD based on modified RECIST criteria|95
6246589|NCT01907100|9931950|FG003|Overall Study|PD based on modified RECIST criteria|92
6246590|NCT01907100|9931947|FG000|Overall Study|Withdrawal by Subject|2
6246591|NCT01907100|9931948|FG001|Overall Study|Withdrawal by Subject|5
6246592|NCT01907100|9931949|FG002|Overall Study|Withdrawal by Subject|10
6246593|NCT01907100|9931950|FG003|Overall Study|Withdrawal by Subject|13
6246594|NCT01907100|9931947|FG000|Overall Study|Protocol Violation|0
6246595|NCT01907100|9931948|FG001|Overall Study|Protocol Violation|0
6246596|NCT01907100|9931949|FG002|Overall Study|Protocol Violation|1
6246597|NCT01907100|9931950|FG003|Overall Study|Protocol Violation|1
6246598|NCT01907100|9931947|FG000|Overall Study|Lost to Follow-up|0
6246599|NCT01907100|9931948|FG001|Overall Study|Lost to Follow-up|0
6246600|NCT01907100|9931949|FG002|Overall Study|Lost to Follow-up|0
6246601|NCT01907100|9931950|FG003|Overall Study|Lost to Follow-up|1
6246602|NCT01907100|9931947|FG000|Overall Study|Not treated|2
6246603|NCT01907100|9931948|FG001|Overall Study|Not treated|0
6246604|NCT01907100|9931949|FG002|Overall Study|Not treated|1
6246605|NCT01907100|9931950|FG003|Overall Study|Not treated|2
6246606|NCT01907100|9931947|FG000|Overall Study|Other than reasons specified|1
6246607|NCT01907100|9931948|FG001|Overall Study|Other than reasons specified|0
6246608|NCT01907100|9931949|FG002|Overall Study|Other than reasons specified|10
6246609|NCT01907100|9931950|FG003|Overall Study|Other than reasons specified|6
6246610|NCT01907100|9931947|FG000|Overall Study|Adverse event (AE)|6
6246611|NCT01907100|9931948|FG001|Overall Study|Adverse event (AE)|3
6246612|NCT01907100|9931949|FG002|Overall Study|Adverse event (AE)|22
6246613|NCT01907100|9931950|FG003|Overall Study|Adverse event (AE)|23
6246614|NCT01907100|9931947|FG000|Overall Study|Worsening/AE underlying cancer disease|0
6246615|NCT01907100|9931948|FG001|Overall Study|Worsening/AE underlying cancer disease|0
6246616|NCT01907100|9931949|FG002|Overall Study|Worsening/AE underlying cancer disease|8
6246617|NCT01907100|9931950|FG003|Overall Study|Worsening/AE underlying cancer disease|8
6246618|NCT01907217|9931981|FG000|Overall Study|Withdrawal by Subject|0
6246619|NCT01907217|9931982|FG001|Overall Study|Withdrawal by Subject|2
6246620|NCT01907516|9932016|FG000|First Intervention (3 Weeks)|Withdrawal by Subject|5
6246621|NCT01907516|9932017|FG001|First Intervention (3 Weeks)|Withdrawal by Subject|9
6246622|NCT01907516|9932016|FG000|First Intervention (3 Weeks)|Lost to Follow-up|1
6246623|NCT01907516|9932017|FG001|First Intervention (3 Weeks)|Lost to Follow-up|3
6246624|NCT01907516|9932016|FG000|First Intervention (3 Weeks)|Delivered before second arm|3
6246625|NCT01907516|9932017|FG001|First Intervention (3 Weeks)|Delivered before second arm|4
6246626|NCT01907516|9932016|FG000|First Intervention (3 Weeks)|Developed DKA during study|1
6246627|NCT01907516|9932017|FG001|First Intervention (3 Weeks)|Developed DKA during study|0
6246628|NCT01907737|9932028|FG000|Overall Study|Withdrawal by Subject|1
6246629|NCT01907815|9932040|FG000|Overall Study|Withdrawal by Subject|1
6246630|NCT01907815|9932041|FG001|Overall Study|Withdrawal by Subject|0
6246631|NCT01907828|9932051|FG000|Overall Study|Exclusion criteria not met|0
6246632|NCT01907828|9932052|FG001|Overall Study|Exclusion criteria not met|1
6246633|NCT01907828|9932051|FG000|Overall Study|Withdrawal by Subject|3
6246634|NCT01907828|9932052|FG001|Overall Study|Withdrawal by Subject|4
6246635|NCT01907828|9932051|FG000|Overall Study|Lost to Follow-up|3
6246636|NCT01907828|9932052|FG001|Overall Study|Lost to Follow-up|0
6246637|NCT01907828|9932051|FG000|Overall Study|Participant refused 24-month follow-up|1
6246638|NCT01907828|9932052|FG001|Overall Study|Participant refused 24-month follow-up|0
6246639|NCT01907828|9932051|FG000|Overall Study|Participant met exclusion criteria|0
6246640|NCT01907828|9932052|FG001|Overall Study|Participant met exclusion criteria|1
6246641|NCT01907854|9932060|FG000|Overall Study|Protocol Violation|1
6246642|NCT01907854|9932061|FG001|Overall Study|Protocol Violation|1
6246643|NCT01907854|9932060|FG000|Overall Study|Withdrawal by Subject|9
6246644|NCT01907854|9932061|FG001|Overall Study|Withdrawal by Subject|7
6246645|NCT01907854|9932060|FG000|Overall Study|Lost to Follow-up|2
6246646|NCT01907854|9932061|FG001|Overall Study|Lost to Follow-up|2
6246647|NCT01907854|9932060|FG000|Overall Study|Unclassified|4
6246648|NCT01907854|9932061|FG001|Overall Study|Unclassified|3
6246649|NCT01907906|9932069|FG000|Overall Study|Withdrawal by Subject|1
6246650|NCT01907906|9932070|FG001|Overall Study|Withdrawal by Subject|0
6246651|NCT01907906|9932069|FG000|Overall Study|Physician Decision|3
6246652|NCT01907906|9932070|FG001|Overall Study|Physician Decision|1
6246653|NCT01908101|9932090|FG000|Overall Study|Physician Decision|1
6246654|NCT01908101|9932090|FG000|Overall Study|Withdrawal by Subject|1
6246655|NCT01908101|9932090|FG000|Overall Study|Incorrect Diagnosis|2
6246656|NCT01908101|9932090|FG000|Overall Study|Incorrect Starting Dose|1
6246657|NCT01908101|9932090|FG000|Overall Study|Did not complete the first cycle|4
6246658|NCT01908140|9932105|FG000|Overall Study|Other or Progressive Disease|5
6246659|NCT01908140|9932106|FG001|Overall Study|Other or Progressive Disease|12
6246660|NCT01908140|9932105|FG000|Overall Study|Lack of Efficacy|7
6246661|NCT01908140|9932106|FG001|Overall Study|Lack of Efficacy|5
6246662|NCT01908140|9932105|FG000|Overall Study|Withdrawal by Subject|23
6246663|NCT01908140|9932106|FG001|Overall Study|Withdrawal by Subject|24
6246664|NCT01908140|9932105|FG000|Overall Study|Lost to Follow-up|1
6246665|NCT01908140|9932106|FG001|Overall Study|Lost to Follow-up|6
6246666|NCT01908140|9932105|FG000|Overall Study|Protocol Violation|8
6246667|NCT01908140|9932106|FG001|Overall Study|Protocol Violation|9
6246668|NCT01908140|9932105|FG000|Overall Study|Adverse Event|22
6246669|NCT01908140|9932106|FG001|Overall Study|Adverse Event|23
6246670|NCT01908205|9932114|FG000|Overall Study|Lost to Follow-up|2
6246671|NCT01908205|9932115|FG001|Overall Study|Lost to Follow-up|0
6246672|NCT01908205|9932114|FG000|Overall Study|Withdrawal by Subject|3
6246673|NCT01908205|9932115|FG001|Overall Study|Withdrawal by Subject|1
6246674|NCT01908426|9932136|FG000|Overall Study|Adverse Event|98
6246675|NCT01908426|9932137|FG001|Overall Study|Adverse Event|11
6246676|NCT01908426|9932136|FG000|Overall Study|Clinical Deterioration|72
6246677|NCT01908426|9932137|FG001|Overall Study|Clinical Deterioration|38
6246678|NCT01908426|9932136|FG000|Overall Study|Lack of Efficacy|3
6246679|NCT01908426|9932137|FG001|Overall Study|Lack of Efficacy|0
6246680|NCT01908426|9932136|FG000|Overall Study|Lost to Follow-up|0
6246681|NCT01908426|9932137|FG001|Overall Study|Lost to Follow-up|1
6246682|NCT01908426|9932136|FG000|Overall Study|Physician Decision|3
6246683|NCT01908426|9932137|FG001|Overall Study|Physician Decision|3
6246684|NCT01908426|9932136|FG000|Overall Study|Withdrawal by Subject|11
6246685|NCT01908426|9932137|FG001|Overall Study|Withdrawal by Subject|6
6246686|NCT01908426|9932136|FG000|Overall Study|Progressive Disease|206
6246687|NCT01908426|9932137|FG001|Overall Study|Progressive Disease|152
6246688|NCT01908426|9932136|FG000|Overall Study|Protocol Violation|1
6246689|NCT01908426|9932137|FG001|Overall Study|Protocol Violation|0
6246690|NCT01908426|9932136|FG000|Overall Study|No Study Treatment Given|3
6246691|NCT01908426|9932137|FG001|Overall Study|No Study Treatment Given|0
6246692|NCT01908582|9932159|FG000|Period 2|Physician Decision|1
6246693|NCT01908582|9932159|FG000|Period 2|Withdrawal by Subject|1
6246694|NCT01908634|9932166|FG000|Water-based Strawberry Beverage Wit Meal|Withdrawal by Subject|1
6246695|NCT01908634|9932166|FG000|Milk-based Strawberry Beverage w/o Meal|Withdrawal by Subject|5
6246696|NCT01908699|9932176|FG000|Overall Study|Adverse Event|8
6246697|NCT01908699|9932177|FG001|Overall Study|Adverse Event|12
6246698|NCT01908699|9932176|FG000|Overall Study|Lack of Efficacy|2
6246699|NCT01908699|9932177|FG001|Overall Study|Lack of Efficacy|2
6246700|NCT01908699|9932176|FG000|Overall Study|Lost to Follow-up|2
6246701|NCT01908699|9932177|FG001|Overall Study|Lost to Follow-up|4
6246702|NCT01908699|9932176|FG000|Overall Study|Physician Decision|8
6246703|NCT01908699|9932177|FG001|Overall Study|Physician Decision|8
6246704|NCT01908699|9932176|FG000|Overall Study|Withdrawal by Subject|15
6246705|NCT01908699|9932177|FG001|Overall Study|Withdrawal by Subject|10
6246706|NCT01908699|9932176|FG000|Overall Study|Pregnancy|0
6246707|NCT01908699|9932177|FG001|Overall Study|Pregnancy|1
6246708|NCT01908699|9932176|FG000|Overall Study|Randomized in Error|1
6246709|NCT01908699|9932177|FG001|Overall Study|Randomized in Error|0
6246710|NCT01908699|9932176|FG000|Overall Study|Death|9
6246711|NCT01908699|9932177|FG001|Overall Study|Death|12
6246712|NCT01908699|9932176|FG000|Overall Study|Progressive Disease|30
6246713|NCT01908699|9932177|FG001|Overall Study|Progressive Disease|29
6270614|NCT02153736|9971657|FG000|Overall Study|Lost to Follow-up|1
6270615|NCT02153736|9971658|FG001|Overall Study|Lost to Follow-up|0
6270616|NCT02153736|9971657|FG000|Overall Study|Medical status change made ineligible|1
6270617|NCT02153736|9971658|FG001|Overall Study|Medical status change made ineligible|0
6270618|NCT02153736|9971657|FG000|Overall Study|Death|0
6270619|NCT02153736|9971658|FG001|Overall Study|Death|1
6270620|NCT02153736|9971657|FG000|Overall Study|Withdrawal by Subject|0
6270621|NCT02153736|9971658|FG001|Overall Study|Withdrawal by Subject|1
6270622|NCT02153788|9971666|FG000|Overall Study|Physician Decision|2
6270623|NCT02153788|9971667|FG001|Overall Study|Physician Decision|1
6270624|NCT02153827|9971675|FG000|Overall Study|Lost to Follow-up|3
6270625|NCT02153827|9971676|FG001|Overall Study|Lost to Follow-up|9
6270626|NCT02153905|9971684|FG000|Overall Study|Death|1
6270627|NCT02153905|9971685|FG001|Overall Study|Death|0
6270628|NCT02153918|9971691|FG000|Overall Study|Refused further treatment|1
6270629|NCT02154061|9971735|FG000|Overall Study|Pregnancy|1
6270630|NCT02154061|9971736|FG001|Overall Study|Pregnancy|0
6270631|NCT02154061|9971735|FG000|Overall Study|enrolled but not vaccinated|1
6270632|NCT02154061|9971736|FG001|Overall Study|enrolled but not vaccinated|0
6270633|NCT02154139|9971742|FG000|Overall Study|Injection not administered|2
6270634|NCT02154139|9971742|FG000|Overall Study|Other|2
6270635|NCT02154139|9971742|FG000|Overall Study|Investigator transferred|3
6270636|NCT02154347|9971761|FG000|Double-blind Period|Adverse Event|1
6270637|NCT02154347|9971762|FG001|Double-blind Period|Adverse Event|2
6270638|NCT02154347|9971761|FG000|Double-blind Period|Lack of Efficacy|1
6270639|NCT02154347|9971762|FG001|Double-blind Period|Lack of Efficacy|0
6270640|NCT02154347|9971761|FG000|Double-blind Period|Physician Decision|0
6270641|NCT02154347|9971762|FG001|Double-blind Period|Physician Decision|1
6246714|NCT01908803|9932202|FG000|Overall Study|Adverse Event|1
6246715|NCT01908803|9932203|FG001|Overall Study|Adverse Event|0
6246716|NCT01908803|9932202|FG000|Overall Study|Physician Decision|0
6246717|NCT01908803|9932203|FG001|Overall Study|Physician Decision|1
6246718|NCT01908803|9932202|FG000|Overall Study|Withdrawal by Subject|1
6246719|NCT01908803|9932203|FG001|Overall Study|Withdrawal by Subject|0
6246720|NCT01908803|9932202|FG000|Overall Study|Randomization Error|1
6246721|NCT01908803|9932203|FG001|Overall Study|Randomization Error|0
6246722|NCT01908803|9932202|FG000|Overall Study|Adverse Event (pre-treatment)|1
6246723|NCT01908803|9932203|FG001|Overall Study|Adverse Event (pre-treatment)|0
6246724|NCT01908816|9932214|FG000|Overall Study|Subject's no longer requires study drug|0
6246725|NCT01908816|9932215|FG001|Overall Study|Subject's no longer requires study drug|0
6246726|NCT01908816|9932216|FG002|Overall Study|Subject's no longer requires study drug|0
6246727|NCT01908816|9932217|FG003|Overall Study|Subject's no longer requires study drug|1
6246728|NCT01908816|9932214|FG000|Overall Study|Protocol deviation|1
6246729|NCT01908816|9932215|FG001|Overall Study|Protocol deviation|2
6246730|NCT01908816|9932216|FG002|Overall Study|Protocol deviation|1
6246731|NCT01908816|9932217|FG003|Overall Study|Protocol deviation|1
6246732|NCT01908816|9932214|FG000|Overall Study|Withdrawal by Subject|0
6246733|NCT01908816|9932215|FG001|Overall Study|Withdrawal by Subject|4
6246734|NCT01908816|9932216|FG002|Overall Study|Withdrawal by Subject|2
6246735|NCT01908816|9932217|FG003|Overall Study|Withdrawal by Subject|2
6246736|NCT01908816|9932214|FG000|Overall Study|Lost to Follow-up|3
6246737|NCT01908816|9932215|FG001|Overall Study|Lost to Follow-up|5
6246738|NCT01908816|9932216|FG002|Overall Study|Lost to Follow-up|4
6246739|NCT01908816|9932217|FG003|Overall Study|Lost to Follow-up|2
6246740|NCT01908816|9932214|FG000|Overall Study|Death|1
6246741|NCT01908816|9932215|FG001|Overall Study|Death|0
6246742|NCT01908816|9932216|FG002|Overall Study|Death|7
6246743|NCT01908816|9932217|FG003|Overall Study|Death|1
6246744|NCT01908816|9932214|FG000|Overall Study|Unsatisfactory therapeutic effect|1
6246745|NCT01908816|9932215|FG001|Overall Study|Unsatisfactory therapeutic effect|13
6246746|NCT01908816|9932216|FG002|Overall Study|Unsatisfactory therapeutic effect|1
6246747|NCT01908816|9932217|FG003|Overall Study|Unsatisfactory therapeutic effect|0
6246748|NCT01908816|9932214|FG000|Overall Study|Early termination|87
6246749|NCT01908816|9932215|FG001|Overall Study|Early termination|60
6246750|NCT01908816|9932216|FG002|Overall Study|Early termination|43
6246751|NCT01908816|9932217|FG003|Overall Study|Early termination|28
6246752|NCT01908829|9932233|FG000|Overall Study|Adverse Event|13
6246753|NCT01908829|9932234|FG001|Overall Study|Adverse Event|11
6246754|NCT01908829|9932235|FG002|Overall Study|Adverse Event|13
6246755|NCT01908829|9932233|FG000|Overall Study|Lost to Follow-up|4
6246756|NCT01908829|9932234|FG001|Overall Study|Lost to Follow-up|2
6246757|NCT01908829|9932235|FG002|Overall Study|Lost to Follow-up|1
6246758|NCT01908829|9932233|FG000|Overall Study|Randomized no double-blind drug received|1
6246759|NCT01908829|9932234|FG001|Overall Study|Randomized no double-blind drug received|0
6246760|NCT01908829|9932235|FG002|Overall Study|Randomized no double-blind drug received|1
6246761|NCT01908829|9932233|FG000|Overall Study|Discontinued (no EoT page)|2
6246762|NCT01908829|9932234|FG001|Overall Study|Discontinued (no EoT page)|0
6246763|NCT01908829|9932235|FG002|Overall Study|Discontinued (no EoT page)|0
6246764|NCT01908829|9932233|FG000|Overall Study|Miscellaneous|0
6246765|NCT01908829|9932234|FG001|Overall Study|Miscellaneous|2
6246766|NCT01908829|9932235|FG002|Overall Study|Miscellaneous|0
6246767|NCT01908829|9932233|FG000|Overall Study|Protocol Violation|2
6246768|NCT01908829|9932234|FG001|Overall Study|Protocol Violation|2
6246769|NCT01908829|9932235|FG002|Overall Study|Protocol Violation|0
6246770|NCT01908829|9932233|FG000|Overall Study|Lack of Efficacy|1
6246771|NCT01908829|9932234|FG001|Overall Study|Lack of Efficacy|3
6246772|NCT01908829|9932235|FG002|Overall Study|Lack of Efficacy|2
6246773|NCT01908829|9932233|FG000|Overall Study|Withdrawal by Subject|26
6246774|NCT01908829|9932234|FG001|Overall Study|Withdrawal by Subject|29
6246775|NCT01908829|9932235|FG002|Overall Study|Withdrawal by Subject|22
6246776|NCT01908907|9932254|FG000|Overall Study|Physician Decision|1
6246777|NCT01908907|9932255|FG001|Overall Study|Physician Decision|0
6246778|NCT01908907|9932254|FG000|Overall Study|Protocol Violation|1
6246779|NCT01908907|9932255|FG001|Overall Study|Protocol Violation|0
6246780|NCT01909336|9932307|FG000|Overall Study|Lost to Follow-up|4
6246781|NCT01909336|9932308|FG001|Overall Study|Lost to Follow-up|2
6246782|NCT01909336|9932309|FG002|Overall Study|Lost to Follow-up|2
6246783|NCT01909336|9932307|FG000|Overall Study|Physician Decision|0
6246784|NCT01909336|9932308|FG001|Overall Study|Physician Decision|1
6246785|NCT01909336|9932309|FG002|Overall Study|Physician Decision|1
6246786|NCT01909466|9932317|FG000|Overall Study|Lost to Follow-up|5
6246787|NCT01909466|9932318|FG001|Overall Study|Lost to Follow-up|7
6246788|NCT01909466|9932317|FG000|Overall Study|Adverse Event|3
6246789|NCT01909466|9932318|FG001|Overall Study|Adverse Event|4
6246790|NCT01909466|9932317|FG000|Overall Study|Met Withdrawal Criteria|0
6246791|NCT01909466|9932318|FG001|Overall Study|Met Withdrawal Criteria|3
6246792|NCT01909466|9932317|FG000|Overall Study|Physician Decision|2
6246793|NCT01909466|9932318|FG001|Overall Study|Physician Decision|0
6246794|NCT01909466|9932317|FG000|Overall Study|Withdrawal by Subject|11
6246795|NCT01909466|9932318|FG001|Overall Study|Withdrawal by Subject|9
6246796|NCT01909466|9932317|FG000|Overall Study|Lack of Efficacy|1
6246797|NCT01909466|9932318|FG001|Overall Study|Lack of Efficacy|0
6246798|NCT01909674|9932324|FG000|Overall Study|Withdrawal by Subject|5
6246799|NCT01909674|9932325|FG001|Overall Study|Withdrawal by Subject|2
6246800|NCT01909778|9932356|FG000|Overall Study|failed screening|1
6246801|NCT01909791|9932365|FG000|Overall Study|Death|9
6246802|NCT01909791|9932366|FG001|Overall Study|Death|8
6246803|NCT01909791|9932367|FG002|Overall Study|Death|4
6246804|NCT01909791|9932365|FG000|Overall Study|Withdrawal by Subject|5
6246805|NCT01909791|9932366|FG001|Overall Study|Withdrawal by Subject|9
6246806|NCT01909791|9932367|FG002|Overall Study|Withdrawal by Subject|13
6246807|NCT01909791|9932365|FG000|Overall Study|Lost to Follow-up|5
6246808|NCT01909791|9932366|FG001|Overall Study|Lost to Follow-up|11
6246809|NCT01909791|9932367|FG002|Overall Study|Lost to Follow-up|10
6246810|NCT01909791|9932365|FG000|Overall Study|Missed Visit|2
6246811|NCT01909791|9932366|FG001|Overall Study|Missed Visit|0
6246812|NCT01909791|9932367|FG002|Overall Study|Missed Visit|1
6246813|NCT01909804|9932392|FG000|Overall Study|Randomized but Never Treated|0
6246814|NCT01909804|9932393|FG001|Overall Study|Randomized but Never Treated|0
6246815|NCT01909804|9932394|FG002|Overall Study|Randomized but Never Treated|0
6246816|NCT01909804|9932395|FG003|Overall Study|Randomized but Never Treated|0
6246817|NCT01909804|9932396|FG004|Overall Study|Randomized but Never Treated|0
6246818|NCT01909804|9932397|FG005|Overall Study|Randomized but Never Treated|0
6246819|NCT01909804|9932398|FG006|Overall Study|Randomized but Never Treated|1
6246820|NCT01909804|9932399|FG007|Overall Study|Randomized but Never Treated|0
6246821|NCT01909804|9932400|FG008|Overall Study|Randomized but Never Treated|0
6246822|NCT01909804|9932401|FG009|Overall Study|Randomized but Never Treated|0
6246823|NCT01909804|9932402|FG010|Overall Study|Randomized but Never Treated|0
6246824|NCT01909804|9932403|FG011|Overall Study|Randomized but Never Treated|1
6246825|NCT01909804|9932392|FG000|Overall Study|Death|0
6246826|NCT01909804|9932393|FG001|Overall Study|Death|0
6246827|NCT01909804|9932394|FG002|Overall Study|Death|0
6189307|NCT01398176|9844449|FG001|Overall Study|Physician Decision|3
6189308|NCT01398358|9844467|FG000|Overall Study|Lost to Follow-up|11
6189309|NCT01398358|9844468|FG001|Overall Study|Lost to Follow-up|21
6189310|NCT01398358|9844469|FG002|Overall Study|Lost to Follow-up|18
6189311|NCT01398358|9844467|FG000|Overall Study|Withdrawal by Subject|3
6189312|NCT01398358|9844468|FG001|Overall Study|Withdrawal by Subject|2
6189313|NCT01398358|9844469|FG002|Overall Study|Withdrawal by Subject|2
6189314|NCT01398358|9844467|FG000|Overall Study|no longer eligible|1
6189315|NCT01398358|9844468|FG001|Overall Study|no longer eligible|0
6189316|NCT01398358|9844469|FG002|Overall Study|no longer eligible|1
6189317|NCT01398410|9844479|FG000|Overall Study|Adverse Event|12
6189318|NCT01398410|9844480|FG001|Overall Study|Adverse Event|16
6189319|NCT01398410|9844479|FG000|Overall Study|Participants Choice|8
6189320|NCT01398410|9844480|FG001|Overall Study|Participants Choice|11
6189321|NCT01398410|9844479|FG000|Overall Study|Inadequate Therapeutic Effect|2
6189322|NCT01398410|9844480|FG001|Overall Study|Inadequate Therapeutic Effect|0
6189323|NCT01398410|9844479|FG000|Overall Study|Other|36
6189324|NCT01398410|9844480|FG001|Overall Study|Other|29
6189325|NCT01398514|9844501|FG000|Overall Study|Adverse Event|1
6189326|NCT01398514|9844502|FG001|Overall Study|Adverse Event|0
6189327|NCT01398514|9844501|FG000|Overall Study|Non-compliance with study procedures|2
6189328|NCT01398514|9844502|FG001|Overall Study|Non-compliance with study procedures|0
6189329|NCT01398514|9844501|FG000|Overall Study|Physiologic non-responsiveness|1
6189330|NCT01398514|9844502|FG001|Overall Study|Physiologic non-responsiveness|3
6189331|NCT01398514|9844501|FG000|Overall Study|Failure to show a conditioned response|4
6189332|NCT01398514|9844502|FG001|Overall Study|Failure to show a conditioned response|3
6246828|NCT01909804|9932395|FG003|Overall Study|Death|0
6246829|NCT01909804|9932396|FG004|Overall Study|Death|0
6246830|NCT01909804|9932397|FG005|Overall Study|Death|0
6246831|NCT01909804|9932398|FG006|Overall Study|Death|0
6246832|NCT01909804|9932399|FG007|Overall Study|Death|0
6246833|NCT01909804|9932400|FG008|Overall Study|Death|0
6246834|NCT01909804|9932401|FG009|Overall Study|Death|0
6246835|NCT01909804|9932402|FG010|Overall Study|Death|1
6246836|NCT01909804|9932403|FG011|Overall Study|Death|0
6246837|NCT01909804|9932392|FG000|Overall Study|Lack of Efficacy|4
6246838|NCT01909804|9932393|FG001|Overall Study|Lack of Efficacy|1
6246839|NCT01909804|9932394|FG002|Overall Study|Lack of Efficacy|0
6246840|NCT01909804|9932395|FG003|Overall Study|Lack of Efficacy|0
6246841|NCT01909804|9932396|FG004|Overall Study|Lack of Efficacy|7
6246842|NCT01909804|9932397|FG005|Overall Study|Lack of Efficacy|3
6246843|NCT01909804|9932398|FG006|Overall Study|Lack of Efficacy|1
6246844|NCT01909804|9932399|FG007|Overall Study|Lack of Efficacy|1
6246845|NCT01909804|9932400|FG008|Overall Study|Lack of Efficacy|0
6246846|NCT01909804|9932401|FG009|Overall Study|Lack of Efficacy|1
6246847|NCT01909804|9932402|FG010|Overall Study|Lack of Efficacy|0
6246848|NCT01909804|9932403|FG011|Overall Study|Lack of Efficacy|1
6246849|NCT01909804|9932392|FG000|Overall Study|Withdrew Consent|0
6246850|NCT01909804|9932393|FG001|Overall Study|Withdrew Consent|0
6246851|NCT01909804|9932394|FG002|Overall Study|Withdrew Consent|0
6246852|NCT01909804|9932395|FG003|Overall Study|Withdrew Consent|0
6189333|NCT01398787|9844514|FG000|Overall Study|Adverse Event|1
6189334|NCT01398956|9844533|FG000|Overall Study|Withdrawal by Subject|4
6246853|NCT01909804|9932396|FG004|Overall Study|Withdrew Consent|1
6246854|NCT01909804|9932397|FG005|Overall Study|Withdrew Consent|1
6246855|NCT01909804|9932398|FG006|Overall Study|Withdrew Consent|0
6246856|NCT01909804|9932399|FG007|Overall Study|Withdrew Consent|0
6246857|NCT01909804|9932400|FG008|Overall Study|Withdrew Consent|0
6246858|NCT01909804|9932401|FG009|Overall Study|Withdrew Consent|0
6246859|NCT01909804|9932402|FG010|Overall Study|Withdrew Consent|0
6246860|NCT01909804|9932403|FG011|Overall Study|Withdrew Consent|0
6246861|NCT01909804|9932392|FG000|Overall Study|Protocol Violation|0
6246862|NCT01909804|9932393|FG001|Overall Study|Protocol Violation|0
6246863|NCT01909804|9932394|FG002|Overall Study|Protocol Violation|0
6246864|NCT01909804|9932395|FG003|Overall Study|Protocol Violation|0
6246865|NCT01909804|9932396|FG004|Overall Study|Protocol Violation|0
6246866|NCT01909804|9932397|FG005|Overall Study|Protocol Violation|0
6086119|NCT00658684|9695816|FG002|Overall Study|Protocol Violation|0
6086120|NCT00658684|9695817|FG003|Overall Study|Protocol Violation|0
6086121|NCT00658684|9695814|FG000|Overall Study|Pregnancy|1
6086122|NCT00658684|9695815|FG001|Overall Study|Pregnancy|1
6246867|NCT01909804|9932398|FG006|Overall Study|Protocol Violation|0
6246868|NCT01909804|9932399|FG007|Overall Study|Protocol Violation|0
6246869|NCT01909804|9932400|FG008|Overall Study|Protocol Violation|0
6246870|NCT01909804|9932401|FG009|Overall Study|Protocol Violation|0
6246871|NCT01909804|9932402|FG010|Overall Study|Protocol Violation|0
6246872|NCT01909804|9932403|FG011|Overall Study|Protocol Violation|1
6246873|NCT01909973|9932427|FG000|Overall Study|Lost to Follow-up|1
6086123|NCT00658684|9695816|FG002|Overall Study|Pregnancy|0
6246874|NCT01909973|9932428|FG001|Overall Study|Lost to Follow-up|0
6246875|NCT01910116|9932440|FG000|Overall Study|Adverse Event|0
6246876|NCT01910116|9932441|FG001|Overall Study|Adverse Event|3
6246877|NCT01910116|9932440|FG000|Overall Study|Lack of Efficacy|3
6246878|NCT01910116|9932441|FG001|Overall Study|Lack of Efficacy|4
6246879|NCT01910116|9932440|FG000|Overall Study|Lost to Follow-up|1
6246880|NCT01910116|9932441|FG001|Overall Study|Lost to Follow-up|0
6246881|NCT01910116|9932440|FG000|Overall Study|Protocol Violation|1
6246882|NCT01910116|9932441|FG001|Overall Study|Protocol Violation|2
6246883|NCT01910116|9932440|FG000|Overall Study|Withdrawal by Subject|8
6246884|NCT01910116|9932441|FG001|Overall Study|Withdrawal by Subject|3
6246885|NCT01910116|9932440|FG000|Overall Study|uncertain allocation|1
6246886|NCT01910116|9932441|FG001|Overall Study|uncertain allocation|3
6246887|NCT01910116|9932440|FG000|Overall Study|incomplete data|0
6246888|NCT01910116|9932441|FG001|Overall Study|incomplete data|1
6246889|NCT01910129|9932449|FG000|Randomized Phase 2|Withdrawal by Subject|2
6246890|NCT01910129|9932450|FG001|Randomized Phase 2|Withdrawal by Subject|1
6246891|NCT01910129|9932451|FG002|Randomized Phase 2|Withdrawal by Subject|0
6246892|NCT01910129|9932449|FG000|Randomized Phase 3|Withdrawal by Subject|0
6246893|NCT01910129|9932450|FG001|Randomized Phase 3|Withdrawal by Subject|1
6246894|NCT01910129|9932451|FG002|Randomized Phase 3|Withdrawal by Subject|0
6246895|NCT01910181|9932469|FG000|Overall Study|Death|37
6246896|NCT01910181|9932469|FG000|Overall Study|Lost to Follow-up|3
6246897|NCT01910181|9932469|FG000|Overall Study|Study Terminated by Sponsor|6
6246898|NCT01910298|9932476|FG000|Overall Study|Adverse Event|1
6246899|NCT01910298|9932477|FG001|Overall Study|Adverse Event|0
6246900|NCT01910298|9932476|FG000|Overall Study|Withdrawal by Subject|2
6246901|NCT01910298|9932477|FG001|Overall Study|Withdrawal by Subject|7
6246902|NCT01910298|9932476|FG000|Overall Study|Protocol Deviation|0
6246903|NCT01910298|9932477|FG001|Overall Study|Protocol Deviation|5
6246904|NCT01910298|9932476|FG000|Overall Study|Lost to Follow-up|1
6246905|NCT01910298|9932477|FG001|Overall Study|Lost to Follow-up|1
6246906|NCT01910298|9932476|FG000|Overall Study|Study Terminated by Sponsor|1
6246907|NCT01910298|9932477|FG001|Overall Study|Study Terminated by Sponsor|17
6246908|NCT01910298|9932476|FG000|Overall Study|Other Miscellaneous Reasons|0
6246909|NCT01910298|9932477|FG001|Overall Study|Other Miscellaneous Reasons|2
6246910|NCT01910519|9932493|FG000|Overall Study|Withdrawal by Subject|2
6246911|NCT01910519|9932494|FG001|Overall Study|Withdrawal by Subject|0
6246912|NCT01910519|9932493|FG000|Overall Study|Adverse Event|2
6246913|NCT01910519|9932494|FG001|Overall Study|Adverse Event|0
6246914|NCT01911260|9932553|FG000|Supplementation Period|transference or evasion of school|7
6246915|NCT01911260|9932554|FG001|Supplementation Period|transference or evasion of school|9
6246916|NCT01911260|9932555|FG002|Supplementation Period|transference or evasion of school|7
6246917|NCT01911260|9932556|FG003|Supplementation Period|transference or evasion of school|6
6246918|NCT01911260|9932553|FG000|Supplementation Period|Adverse Event|2
6246919|NCT01911260|9932554|FG001|Supplementation Period|Adverse Event|0
6246920|NCT01911260|9932555|FG002|Supplementation Period|Adverse Event|1
6246921|NCT01911260|9932556|FG003|Supplementation Period|Adverse Event|0
6246922|NCT01911260|9932553|FG000|Supplementation Period|refused to receive supplement|1
6246923|NCT01911260|9932554|FG001|Supplementation Period|refused to receive supplement|0
6246924|NCT01911260|9932555|FG002|Supplementation Period|refused to receive supplement|1
6246925|NCT01911260|9932556|FG003|Supplementation Period|refused to receive supplement|0
6246926|NCT01911260|9932553|FG000|Supplementation Period|less than 12 weeks supplementation|0
6246927|NCT01911260|9932554|FG001|Supplementation Period|less than 12 weeks supplementation|3
6246928|NCT01911260|9932555|FG002|Supplementation Period|less than 12 weeks supplementation|1
6246929|NCT01911260|9932556|FG003|Supplementation Period|less than 12 weeks supplementation|2
6086124|NCT00658684|9695817|FG003|Overall Study|Pregnancy|0
6246930|NCT01911260|9932553|FG000|Follow-up Period|transference or evasion of school|13
6246931|NCT01911260|9932554|FG001|Follow-up Period|transference or evasion of school|20
6246932|NCT01911260|9932555|FG002|Follow-up Period|transference or evasion of school|15
6246933|NCT01911260|9932556|FG003|Follow-up Period|transference or evasion of school|12
6246934|NCT01911273|9932568|FG000|Overall Study|Progression of Disease|1
6246935|NCT01911273|9932569|FG001|Overall Study|Progression of Disease|0
6246936|NCT01911273|9932568|FG000|Overall Study|Withdrawal by Subject|0
6246937|NCT01911273|9932569|FG001|Overall Study|Withdrawal by Subject|2
6246938|NCT01911429|9932613|FG000|Overall Study|Adverse Event|5
6246939|NCT01911429|9932614|FG001|Overall Study|Adverse Event|3
6246940|NCT01911429|9932615|FG002|Overall Study|Adverse Event|9
6246941|NCT01911429|9932613|FG000|Overall Study|Lack of Efficacy|1
6246942|NCT01911429|9932614|FG001|Overall Study|Lack of Efficacy|2
6246943|NCT01911429|9932615|FG002|Overall Study|Lack of Efficacy|4
6246944|NCT01911429|9932613|FG000|Overall Study|Lost to Follow-up|0
6246945|NCT01911429|9932614|FG001|Overall Study|Lost to Follow-up|0
6246946|NCT01911429|9932615|FG002|Overall Study|Lost to Follow-up|1
6246947|NCT01911429|9932613|FG000|Overall Study|Protocol Violation|0
6246948|NCT01911429|9932614|FG001|Overall Study|Protocol Violation|0
6246949|NCT01911429|9932615|FG002|Overall Study|Protocol Violation|1
6246950|NCT01911429|9932613|FG000|Overall Study|Withdrawal by Subject|5
6246951|NCT01911429|9932614|FG001|Overall Study|Withdrawal by Subject|5
6246952|NCT01911429|9932615|FG002|Overall Study|Withdrawal by Subject|4
6246953|NCT01911429|9932613|FG000|Overall Study|Accidental randomization|0
6246954|NCT01911429|9932614|FG001|Overall Study|Accidental randomization|0
6246955|NCT01911429|9932615|FG002|Overall Study|Accidental randomization|1
6246956|NCT01911429|9932613|FG000|Overall Study|subject left study|1
6246957|NCT01911429|9932614|FG001|Overall Study|subject left study|0
6246958|NCT01911429|9932615|FG002|Overall Study|subject left study|0
6246959|NCT01911442|9932626|FG000|Overall Study|Adverse Event|2
6246960|NCT01911442|9932627|FG001|Overall Study|Adverse Event|2
6246961|NCT01911442|9932628|FG002|Overall Study|Adverse Event|4
6246962|NCT01911442|9932626|FG000|Overall Study|Lack of Efficacy|1
6246963|NCT01911442|9932627|FG001|Overall Study|Lack of Efficacy|1
6246964|NCT01911442|9932628|FG002|Overall Study|Lack of Efficacy|1
6246965|NCT01911442|9932626|FG000|Overall Study|Lost to Follow-up|2
6246966|NCT01911442|9932627|FG001|Overall Study|Lost to Follow-up|0
6246967|NCT01911442|9932628|FG002|Overall Study|Lost to Follow-up|1
6246968|NCT01911442|9932626|FG000|Overall Study|Withdrawal by Subject|1
6246969|NCT01911442|9932627|FG001|Overall Study|Withdrawal by Subject|0
6246970|NCT01911442|9932628|FG002|Overall Study|Withdrawal by Subject|6
6246971|NCT01911442|9932626|FG000|Overall Study|Mother's Work Schedule|0
6246972|NCT01911442|9932627|FG001|Overall Study|Mother's Work Schedule|1
6246973|NCT01911442|9932628|FG002|Overall Study|Mother's Work Schedule|0
6246974|NCT01911546|9932640|FG000|Overall Study|Lost to Follow-up|1
6246975|NCT01911546|9932640|FG000|Overall Study|Everolimus was discontinued|5
6246976|NCT01911780|9932662|FG000|Double-blind Period (8 Weeks)|Adverse Event|1
6246977|NCT01911780|9932663|FG001|Double-blind Period (8 Weeks)|Adverse Event|2
6246978|NCT01911780|9932662|FG000|Double-blind Period (8 Weeks)|Consent withdrawn not due to AEs|1
6246979|NCT01911780|9932663|FG001|Double-blind Period (8 Weeks)|Consent withdrawn not due to AEs|1
6246980|NCT01911780|9932662|FG000|Double-blind Period (8 Weeks)|Personal reason|1
6246981|NCT01911780|9932663|FG001|Double-blind Period (8 Weeks)|Personal reason|0
6246982|NCT01911780|9932662|FG000|Extension Period (52 Weeks)|Adverse Event|3
6246983|NCT01911780|9932663|FG001|Extension Period (52 Weeks)|Adverse Event|0
6246984|NCT01911780|9932662|FG000|Extension Period (52 Weeks)|Consent withdrawn not due to AEs|0
6246985|NCT01911780|9932663|FG001|Extension Period (52 Weeks)|Consent withdrawn not due to AEs|2
6246986|NCT01911780|9932662|FG000|Extension Period (52 Weeks)|Personal reason|1
6246987|NCT01911780|9932663|FG001|Extension Period (52 Weeks)|Personal reason|1
6246988|NCT01911819|9932676|FG000|Overall Study|Adverse Event|0
6246989|NCT01911819|9932677|FG001|Overall Study|Adverse Event|1
6246990|NCT01911819|9932678|FG002|Overall Study|Adverse Event|0
6246991|NCT01911819|9932676|FG000|Overall Study|Withdrawal by Subject|1
6246992|NCT01911819|9932677|FG001|Overall Study|Withdrawal by Subject|1
6246993|NCT01911819|9932678|FG002|Overall Study|Withdrawal by Subject|0
6246994|NCT01911845|9932686|FG000|Overall Study|Adverse Event|2
6246995|NCT01911845|9932686|FG000|Overall Study|Lost to Follow-up|1
6246996|NCT01911845|9932686|FG000|Overall Study|Other (not specified)|3
6246997|NCT01912222|9932704|FG000|Part A: Pharmacokinetic Period|Not evaluable for PK analyses|1
6246998|NCT01912222|9932705|FG001|Part A: Pharmacokinetic Period|Not evaluable for PK analyses|2
6246999|NCT01912222|9932706|FG002|Part A: Pharmacokinetic Period|Not evaluable for PK analyses|2
6247000|NCT01912222|9932704|FG000|Part B: Treatment Period|Progressive disease|10
6247001|NCT01912222|9932705|FG001|Part B: Treatment Period|Progressive disease|12
6247002|NCT01912222|9932706|FG002|Part B: Treatment Period|Progressive disease|15
6247003|NCT01912222|9932704|FG000|Part B: Treatment Period|Adverse Event|1
6247004|NCT01912222|9932705|FG001|Part B: Treatment Period|Adverse Event|2
6247005|NCT01912222|9932706|FG002|Part B: Treatment Period|Adverse Event|3
6247006|NCT01912222|9932704|FG000|Part B: Treatment Period|Withdrawal by Subject|2
6247007|NCT01912222|9932705|FG001|Part B: Treatment Period|Withdrawal by Subject|1
6247008|NCT01912222|9932706|FG002|Part B: Treatment Period|Withdrawal by Subject|2
6247009|NCT01912287|9932722|FG000|Overall Study|Ineligible|1
6247010|NCT01912287|9932723|FG001|Overall Study|Ineligible|0
6247011|NCT01912287|9932724|FG002|Overall Study|Ineligible|1
6247012|NCT01912287|9932722|FG000|Overall Study|No-show|0
6247013|NCT01912287|9932723|FG001|Overall Study|No-show|0
6247014|NCT01912287|9932724|FG002|Overall Study|No-show|1
6247015|NCT01912287|9932722|FG000|Overall Study|Dissatisfaction with assigned treatment|4
6247016|NCT01912287|9932723|FG001|Overall Study|Dissatisfaction with assigned treatment|2
6247017|NCT01912287|9932724|FG002|Overall Study|Dissatisfaction with assigned treatment|1
6247018|NCT01912287|9932722|FG000|Overall Study|Felt treatment no longer needed|0
6247019|NCT01912287|9932723|FG001|Overall Study|Felt treatment no longer needed|1
6247020|NCT01912287|9932724|FG002|Overall Study|Felt treatment no longer needed|0
6189335|NCT01398956|9844533|FG000|Overall Study|AE, non-serious non-fatal|4
6189336|NCT01398956|9844533|FG000|Overall Study|Withdrawal Criteria No.3|1
6189337|NCT01398956|9844533|FG000|Overall Study|Subject moved a long distance|1
6193263|NCT01436643|9850888|FG001|2-week Pre-treatment|Abnormal test result|0
6193264|NCT01436643|9850889|FG002|2-week Pre-treatment|Abnormal test result|0
6193265|NCT01436643|9850890|FG003|2-week Pre-treatment|Abnormal test result|1
6247021|NCT01912287|9932722|FG000|Overall Study|Life circumstances|4
6247022|NCT01912287|9932723|FG001|Overall Study|Life circumstances|2
6247023|NCT01912287|9932724|FG002|Overall Study|Life circumstances|0
6247024|NCT01912287|9932722|FG000|Overall Study|Lost Interest|1
6247025|NCT01912287|9932723|FG001|Overall Study|Lost Interest|0
6247026|NCT01912287|9932724|FG002|Overall Study|Lost Interest|0
6247027|NCT01912287|9932722|FG000|Overall Study|Uknown reason - subject drop out|5
6247028|NCT01912287|9932723|FG001|Overall Study|Uknown reason - subject drop out|7
6247029|NCT01912287|9932724|FG002|Overall Study|Uknown reason - subject drop out|3
6247030|NCT01912287|9932722|FG000|Overall Study|Missed Assesment|1
6247031|NCT01912287|9932723|FG001|Overall Study|Missed Assesment|1
6247032|NCT01912287|9932724|FG002|Overall Study|Missed Assesment|1
6247033|NCT01912287|9932722|FG000|Overall Study|Scheduling/change in availability|17
6247034|NCT01912287|9932723|FG001|Overall Study|Scheduling/change in availability|10
6247035|NCT01912287|9932724|FG002|Overall Study|Scheduling/change in availability|8
6247036|NCT01912339|9932734|FG000|Blinded (0 to 3 Months)|Declined to participate|1
6247037|NCT01912339|9932735|FG001|Blinded (0 to 3 Months)|Declined to participate|0
6247038|NCT01912339|9932736|FG002|Blinded (0 to 3 Months)|Declined to participate|0
6247039|NCT01912339|9932734|FG000|Blinded (0 to 3 Months)|Open Prostatectomy|1
6247040|NCT01912339|9932735|FG001|Blinded (0 to 3 Months)|Open Prostatectomy|0
6247041|NCT01912339|9932736|FG002|Blinded (0 to 3 Months)|Open Prostatectomy|0
6247042|NCT01912339|9932734|FG000|Unblinded (3 to 6 Months/Crossover)|Withdrawal by Subject|1
6247043|NCT01912339|9932735|FG001|Unblinded (3 to 6 Months/Crossover)|Withdrawal by Subject|0
6247044|NCT01912339|9932736|FG002|Unblinded (3 to 6 Months/Crossover)|Withdrawal by Subject|0
6247045|NCT01912339|9932734|FG000|Unblinded (6 Months/Crossover to 5 Yrs)|Lost to Follow-up|5
6247046|NCT01912339|9932735|FG001|Unblinded (6 Months/Crossover to 5 Yrs)|Lost to Follow-up|0
6247047|NCT01912339|9932736|FG002|Unblinded (6 Months/Crossover to 5 Yrs)|Lost to Follow-up|0
6247048|NCT01912339|9932734|FG000|Unblinded (6 Months/Crossover to 5 Yrs)|Missed Visit|5
6247049|NCT01912339|9932735|FG001|Unblinded (6 Months/Crossover to 5 Yrs)|Missed Visit|0
6247050|NCT01912339|9932736|FG002|Unblinded (6 Months/Crossover to 5 Yrs)|Missed Visit|0
6247051|NCT01912339|9932734|FG000|Unblinded (6 Months/Crossover to 5 Yrs)|Withdrawal by Subject|1
6247052|NCT01912339|9932735|FG001|Unblinded (6 Months/Crossover to 5 Yrs)|Withdrawal by Subject|0
6086125|NCT00658723|9695835|FG000|Overall Study|Lost to Follow-up|0
6086126|NCT00658723|9695836|FG001|Overall Study|Lost to Follow-up|2
6086127|NCT00658723|9695837|FG002|Overall Study|Lost to Follow-up|2
6086128|NCT00658723|9695835|FG000|Overall Study|Death|2
6086129|NCT00658723|9695836|FG001|Overall Study|Death|1
6086130|NCT00658723|9695837|FG002|Overall Study|Death|4
6086131|NCT00658723|9695835|FG000|Overall Study|Scheduling Issue|1
6086132|NCT00658723|9695836|FG001|Overall Study|Scheduling Issue|1
6086133|NCT00658723|9695837|FG002|Overall Study|Scheduling Issue|0
6086134|NCT00658723|9695835|FG000|Overall Study|Withdrawal by Subject|1
6086135|NCT00658723|9695836|FG001|Overall Study|Withdrawal by Subject|0
6086136|NCT00658723|9695837|FG002|Overall Study|Withdrawal by Subject|1
6193266|NCT01436643|9850887|FG000|2-week Pre-treatment|Adverse Event|0
6193267|NCT01436643|9850888|FG001|2-week Pre-treatment|Adverse Event|0
6193268|NCT01436643|9850889|FG002|2-week Pre-treatment|Adverse Event|0
6193269|NCT01436643|9850890|FG003|2-week Pre-treatment|Adverse Event|5
6193270|NCT01436643|9850887|FG000|2-week Pre-treatment|Protocol Violation|0
6193271|NCT01436643|9850888|FG001|2-week Pre-treatment|Protocol Violation|0
6193272|NCT01436643|9850889|FG002|2-week Pre-treatment|Protocol Violation|0
6193273|NCT01436643|9850890|FG003|2-week Pre-treatment|Protocol Violation|4
6193274|NCT01436643|9850887|FG000|Core Phase (16 Weeks)|Adverse Event|0
6193275|NCT01436643|9850888|FG001|Core Phase (16 Weeks)|Adverse Event|3
6193276|NCT01436643|9850889|FG002|Core Phase (16 Weeks)|Adverse Event|1
6193277|NCT01436643|9850890|FG003|Core Phase (16 Weeks)|Adverse Event|0
6193278|NCT01436643|9850887|FG000|Core Phase (16 Weeks)|Abnormal Test result|0
6193279|NCT01436643|9850888|FG001|Core Phase (16 Weeks)|Abnormal Test result|0
6086137|NCT00658775|9695859|FG000|Overall Study|Adverse Event|4
6086138|NCT00658775|9695860|FG001|Overall Study|Adverse Event|6
6086139|NCT00658775|9695859|FG000|Overall Study|Lost to Follow-up|17
6193280|NCT01436643|9850889|FG002|Core Phase (16 Weeks)|Abnormal Test result|1
6193281|NCT01436643|9850890|FG003|Core Phase (16 Weeks)|Abnormal Test result|0
6193282|NCT01436643|9850887|FG000|Core Phase (16 Weeks)|Protocol Violation|1
6247053|NCT01912339|9932736|FG002|Unblinded (6 Months/Crossover to 5 Yrs)|Withdrawal by Subject|3
6247054|NCT01912339|9932734|FG000|Unblinded (6 Months/Crossover to 5 Yrs)|BPH Medication|1
6247055|NCT01912339|9932735|FG001|Unblinded (6 Months/Crossover to 5 Yrs)|BPH Medication|0
6247056|NCT01912339|9932736|FG002|Unblinded (6 Months/Crossover to 5 Yrs)|BPH Medication|0
6247057|NCT01912339|9932734|FG000|Unblinded (6 Months/Crossover to 5 Yrs)|TURP/Laser|1
6247058|NCT01912339|9932735|FG001|Unblinded (6 Months/Crossover to 5 Yrs)|TURP/Laser|0
6247059|NCT01912339|9932736|FG002|Unblinded (6 Months/Crossover to 5 Yrs)|TURP/Laser|0
6247060|NCT01912339|9932734|FG000|Unblinded (6 Months/Crossover to 5 Yrs)|Physician Decision|0
6247061|NCT01912339|9932735|FG001|Unblinded (6 Months/Crossover to 5 Yrs)|Physician Decision|0
6247062|NCT01912339|9932736|FG002|Unblinded (6 Months/Crossover to 5 Yrs)|Physician Decision|1
6247063|NCT01912339|9932734|FG000|Unblinded (6 Months/Crossover to 5 Yrs)|Death|0
6247064|NCT01912339|9932735|FG001|Unblinded (6 Months/Crossover to 5 Yrs)|Death|0
6247065|NCT01912339|9932736|FG002|Unblinded (6 Months/Crossover to 5 Yrs)|Death|1
6247066|NCT01912339|9932734|FG000|Unblinded (6 Months/Crossover to 5 Yrs)|Subject started on Cialis|0
6247067|NCT01912339|9932735|FG001|Unblinded (6 Months/Crossover to 5 Yrs)|Subject started on Cialis|0
6247068|NCT01912339|9932736|FG002|Unblinded (6 Months/Crossover to 5 Yrs)|Subject started on Cialis|1
6247069|NCT01912339|9932734|FG000|Unblinded (6 Months/Crossover to 5 Yrs)|Had PVP - Prostate laser surgery|0
6247070|NCT01912339|9932735|FG001|Unblinded (6 Months/Crossover to 5 Yrs)|Had PVP - Prostate laser surgery|0
6247071|NCT01912339|9932736|FG002|Unblinded (6 Months/Crossover to 5 Yrs)|Had PVP - Prostate laser surgery|1
6247072|NCT01912339|9932734|FG000|Unblinded (6 Months/Crossover to 5 Yrs)|Still in Study|120
6247073|NCT01912339|9932735|FG001|Unblinded (6 Months/Crossover to 5 Yrs)|Still in Study|0
6247074|NCT01912339|9932736|FG002|Unblinded (6 Months/Crossover to 5 Yrs)|Still in Study|46
6247075|NCT01912456|9932748|FG000|Period 1|Physician Decision|0
6247076|NCT01912456|9932749|FG001|Period 1|Physician Decision|0
6247077|NCT01912456|9932750|FG002|Period 1|Physician Decision|1
6247078|NCT01912456|9932751|FG003|Period 1|Physician Decision|0
6247079|NCT01912456|9932748|FG000|Period 1|non-compliance|1
6247080|NCT01912456|9932749|FG001|Period 1|non-compliance|0
6247081|NCT01912456|9932750|FG002|Period 1|non-compliance|0
6247082|NCT01912456|9932751|FG003|Period 1|non-compliance|1
6247083|NCT01912456|9932748|FG000|Period 1|Adverse Event|1
6247084|NCT01912456|9932749|FG001|Period 1|Adverse Event|0
6247085|NCT01912456|9932750|FG002|Period 1|Adverse Event|0
6247086|NCT01912456|9932751|FG003|Period 1|Adverse Event|1
6247087|NCT01912456|9932748|FG000|Period 1|Withdrawal by Subject|0
6247088|NCT01912456|9932749|FG001|Period 1|Withdrawal by Subject|1
6247089|NCT01912456|9932750|FG002|Period 1|Withdrawal by Subject|1
6247090|NCT01912456|9932751|FG003|Period 1|Withdrawal by Subject|1
6247091|NCT01912456|9932748|FG000|Period 2|Lack of Efficacy|0
6247092|NCT01912456|9932749|FG001|Period 2|Lack of Efficacy|2
6247093|NCT01912456|9932750|FG002|Period 2|Lack of Efficacy|0
6247094|NCT01912456|9932751|FG003|Period 2|Lack of Efficacy|0
6247095|NCT01912456|9932748|FG000|Period 2|Adverse Event|0
6247096|NCT01912456|9932749|FG001|Period 2|Adverse Event|0
6247097|NCT01912456|9932750|FG002|Period 2|Adverse Event|0
6247098|NCT01912456|9932751|FG003|Period 2|Adverse Event|1
6247099|NCT01912599|9932770|FG000|Overall Study|Withdrawal by Subject|0
6247100|NCT01912599|9932771|FG001|Overall Study|Withdrawal by Subject|1
6247101|NCT01912612|9932779|FG000|Overall Study|Adverse Event|4
6247102|NCT01912612|9932780|FG001|Overall Study|Adverse Event|0
6247103|NCT01912612|9932781|FG002|Overall Study|Adverse Event|0
6247104|NCT01912612|9932779|FG000|Overall Study|Withdrew consent|1
6247105|NCT01912612|9932780|FG001|Overall Study|Withdrew consent|0
6247106|NCT01912612|9932781|FG002|Overall Study|Withdrew consent|0
6247107|NCT01912612|9932779|FG000|Overall Study|Study design change|0
6247108|NCT01912612|9932780|FG001|Overall Study|Study design change|0
6247109|NCT01912612|9932781|FG002|Overall Study|Study design change|3
6247110|NCT01912729|9932800|FG000|Overall Study|Withdrawal by Subject|0
6247111|NCT01912729|9932801|FG001|Overall Study|Withdrawal by Subject|1
6247112|NCT01912768|9932809|FG000|Overall Study|Adverse Event|2
6247113|NCT01912768|9932810|FG001|Overall Study|Adverse Event|0
6247114|NCT01912768|9932809|FG000|Overall Study|Lost to Follow-up|2
6247115|NCT01912768|9932810|FG001|Overall Study|Lost to Follow-up|1
6247116|NCT01912768|9932809|FG000|Overall Study|Withdrawal by Subject|5
6247117|NCT01912768|9932810|FG001|Overall Study|Withdrawal by Subject|3
6247118|NCT01912768|9932809|FG000|Overall Study|Randomized in error|1
6247119|NCT01912768|9932810|FG001|Overall Study|Randomized in error|0
6247120|NCT01912781|9932819|FG000|Overall Study|Withdrawal by Subject|2
6247121|NCT01912781|9932820|FG001|Overall Study|Withdrawal by Subject|0
6247122|NCT01912807|9932829|FG000|Overall Study|Did not meet elegibility criteria|6
6247123|NCT01912807|9932830|FG001|Overall Study|Did not meet elegibility criteria|4
6247124|NCT01912807|9932829|FG000|Overall Study|Lost to Follow-up|36
6247125|NCT01912807|9932830|FG001|Overall Study|Lost to Follow-up|37
6247126|NCT01912872|9932840|FG000|Overall Study|Lost to Follow-up|2
6247127|NCT01912872|9932841|FG001|Overall Study|Lost to Follow-up|3
6247128|NCT01912872|9932842|FG002|Overall Study|Lost to Follow-up|5
6247129|NCT01912872|9932843|FG003|Overall Study|Lost to Follow-up|5
6247130|NCT01912872|9932840|FG000|Overall Study|Other unspecified|3
6247131|NCT01912872|9932841|FG001|Overall Study|Other unspecified|1
6247132|NCT01912872|9932842|FG002|Overall Study|Other unspecified|3
6247133|NCT01912872|9932843|FG003|Overall Study|Other unspecified|0
6247134|NCT01912872|9932840|FG000|Overall Study|Informed consent withdrawn|0
6247135|NCT01912872|9932841|FG001|Overall Study|Informed consent withdrawn|0
6247136|NCT01912872|9932842|FG002|Overall Study|Informed consent withdrawn|1
6247137|NCT01912872|9932843|FG003|Overall Study|Informed consent withdrawn|1
6247138|NCT01912872|9932840|FG000|Overall Study|Non-compliance with lab inc/exclusion|0
6247139|NCT01912872|9932841|FG001|Overall Study|Non-compliance with lab inc/exclusion|0
6247140|NCT01912872|9932842|FG002|Overall Study|Non-compliance with lab inc/exclusion|0
6247141|NCT01912872|9932843|FG003|Overall Study|Non-compliance with lab inc/exclusion|1
6247142|NCT01912872|9932840|FG000|Overall Study|Protocol Violation|0
6247143|NCT01912872|9932841|FG001|Overall Study|Protocol Violation|0
6247144|NCT01912872|9932842|FG002|Overall Study|Protocol Violation|1
6247145|NCT01912872|9932843|FG003|Overall Study|Protocol Violation|0
6247146|NCT01912872|9932840|FG000|Overall Study|Unsatisfactory therapeutic effect|0
6247147|NCT01912872|9932841|FG001|Overall Study|Unsatisfactory therapeutic effect|0
6247148|NCT01912872|9932842|FG002|Overall Study|Unsatisfactory therapeutic effect|0
6247149|NCT01912872|9932843|FG003|Overall Study|Unsatisfactory therapeutic effect|2
6247150|NCT01912872|9932840|FG000|Overall Study|Withdrawal of study medication|0
6247151|NCT01912872|9932841|FG001|Overall Study|Withdrawal of study medication|0
6247152|NCT01912872|9932842|FG002|Overall Study|Withdrawal of study medication|0
6247153|NCT01912872|9932843|FG003|Overall Study|Withdrawal of study medication|2
6247154|NCT01912872|9932840|FG000|Overall Study|Missing|0
6247155|NCT01912872|9932841|FG001|Overall Study|Missing|0
6247156|NCT01912872|9932842|FG002|Overall Study|Missing|0
6247157|NCT01912872|9932843|FG003|Overall Study|Missing|1
6247158|NCT01912963|9932857|FG000|Overall Study|Disease Progression (RECIST1.1)|6
6247159|NCT01912963|9932858|FG001|Overall Study|Disease Progression (RECIST1.1)|9
6247160|NCT01912963|9932859|FG002|Overall Study|Disease Progression (RECIST1.1)|5
6247161|NCT01912963|9932857|FG000|Overall Study|Disease Progression (not RECIST1.1)|0
6247162|NCT01912963|9932858|FG001|Overall Study|Disease Progression (not RECIST1.1)|7
6247163|NCT01912963|9932859|FG002|Overall Study|Disease Progression (not RECIST1.1)|1
6247164|NCT01912963|9932857|FG000|Overall Study|Adverse Event|0
6247165|NCT01912963|9932858|FG001|Overall Study|Adverse Event|1
6247166|NCT01912963|9932859|FG002|Overall Study|Adverse Event|1
6247167|NCT01912963|9932857|FG000|Overall Study|Withdrawal by Subject|0
6247168|NCT01912963|9932858|FG001|Overall Study|Withdrawal by Subject|1
6247169|NCT01912963|9932859|FG002|Overall Study|Withdrawal by Subject|0
6247170|NCT01912963|9932857|FG000|Overall Study|Sought treatment locally|0
6086140|NCT00658775|9695860|FG001|Overall Study|Lost to Follow-up|18
6086141|NCT00658775|9695859|FG000|Overall Study|Withdrawal by Subject|6
6086142|NCT00658775|9695860|FG001|Overall Study|Withdrawal by Subject|4
6086143|NCT00658775|9695859|FG000|Overall Study|Withdrawal of consent|8
6086144|NCT00658775|9695860|FG001|Overall Study|Withdrawal of consent|7
6086145|NCT00658775|9695859|FG000|Overall Study|Other|7
6247171|NCT01912963|9932858|FG001|Overall Study|Sought treatment locally|1
6247172|NCT01912963|9932859|FG002|Overall Study|Sought treatment locally|0
6247173|NCT01913041|9932867|FG000|Overall Study|Protocol Violation|35
6247174|NCT01913041|9932867|FG000|Overall Study|Withdrawal by Subject|3
6247175|NCT01913041|9932867|FG000|Overall Study|Physician Decision|1
6247176|NCT01913340|9932877|FG000|Overall Study|Death|2
6247177|NCT01913340|9932878|FG001|Overall Study|Death|5
6247178|NCT01913340|9932877|FG000|Overall Study|Lost to Follow-up|1
6247179|NCT01913340|9932878|FG001|Overall Study|Lost to Follow-up|1
6247180|NCT01913353|9932886|FG000|Overall Study|Adverse Event|2
6247181|NCT01913353|9932887|FG001|Overall Study|Adverse Event|0
6247182|NCT01913353|9932886|FG000|Overall Study|Physician Decision|0
6247183|NCT01913353|9932887|FG001|Overall Study|Physician Decision|2
6247184|NCT01913353|9932886|FG000|Overall Study|Withdrawal by Subject|20
6247185|NCT01913353|9932887|FG001|Overall Study|Withdrawal by Subject|6
6247186|NCT01913353|9932886|FG000|Overall Study|multiple reasons|10
6247187|NCT01913353|9932887|FG001|Overall Study|multiple reasons|7
6247188|NCT01913405|9932900|FG000|Overall Study|Withdrawal by Subject|1
6247189|NCT01913405|9932900|FG000|Overall Study|Adverse Event|1
6247190|NCT01913470|9932919|FG000|Overall Study|Lost to Follow-up|0
6247191|NCT01913470|9932920|FG001|Overall Study|Lost to Follow-up|1
6247192|NCT01913470|9932919|FG000|Overall Study|Physician Decision|0
6247193|NCT01913470|9932920|FG001|Overall Study|Physician Decision|1
6247194|NCT01913470|9932919|FG000|Overall Study|Withdrawal by Subject|0
6247195|NCT01913470|9932920|FG001|Overall Study|Withdrawal by Subject|1
6247196|NCT01913483|9932929|FG000|Overall Study|Withdrawal by Subject|1
6247197|NCT01913483|9932930|FG001|Overall Study|Withdrawal by Subject|2
6247198|NCT01913483|9932929|FG000|Overall Study|Lost to Follow-up|6
6247199|NCT01913483|9932930|FG001|Overall Study|Lost to Follow-up|3
6247200|NCT01913483|9932929|FG000|Overall Study|Death|14
6247201|NCT01913483|9932930|FG001|Overall Study|Death|17
6086146|NCT00658775|9695860|FG001|Overall Study|Other|8
6247202|NCT01913639|9932962|FG000|Overall Study|Not Eligible|3
6247203|NCT01914393|9932999|FG000|Overall Study|Protocol Violation|11
6086147|NCT00658788|9695866|FG000|Overall Study|Adverse Event|11
6247204|NCT01914393|9933000|FG001|Overall Study|Protocol Violation|3
6247205|NCT01914393|9933001|FG002|Overall Study|Protocol Violation|19
6247206|NCT01914393|9932999|FG000|Overall Study|Lack of Efficacy|11
6247207|NCT01914393|9933000|FG001|Overall Study|Lack of Efficacy|16
6247208|NCT01914393|9933001|FG002|Overall Study|Lack of Efficacy|5
6247209|NCT01914393|9932999|FG000|Overall Study|no reason given|14
6247210|NCT01914393|9933000|FG001|Overall Study|no reason given|8
6247211|NCT01914393|9933001|FG002|Overall Study|no reason given|16
6247212|NCT01914393|9932999|FG000|Overall Study|Adverse Event|29
6247213|NCT01914393|9933000|FG001|Overall Study|Adverse Event|18
6247214|NCT01914393|9933001|FG002|Overall Study|Adverse Event|31
6247215|NCT01914393|9932999|FG000|Overall Study|Withdrawal by Subject|38
6247216|NCT01914393|9933000|FG001|Overall Study|Withdrawal by Subject|20
6247217|NCT01914393|9933001|FG002|Overall Study|Withdrawal by Subject|47
6247218|NCT01914393|9932999|FG000|Overall Study|Lost to Follow-up|12
6247219|NCT01914393|9933000|FG001|Overall Study|Lost to Follow-up|6
6247220|NCT01914393|9933001|FG002|Overall Study|Lost to Follow-up|19
6247221|NCT01914393|9932999|FG000|Overall Study|subject never dosed|0
6247222|NCT01914393|9933000|FG001|Overall Study|subject never dosed|0
6247223|NCT01914393|9933001|FG002|Overall Study|subject never dosed|1
6247224|NCT01914666|9933021|FG000|Treatment Period|Lack of Efficacy|0
6247225|NCT01914666|9933022|FG001|Treatment Period|Lack of Efficacy|0
6247226|NCT01914666|9933023|FG002|Treatment Period|Lack of Efficacy|2
6247227|NCT01914666|9933021|FG000|Treatment Period|Adverse Event|10
6247228|NCT01914666|9933022|FG001|Treatment Period|Adverse Event|4
6247229|NCT01914666|9933023|FG002|Treatment Period|Adverse Event|2
6247230|NCT01914666|9933021|FG000|Treatment Period|Withdrawal by Subject|3
6247231|NCT01914666|9933022|FG001|Treatment Period|Withdrawal by Subject|2
6247232|NCT01914666|9933023|FG002|Treatment Period|Withdrawal by Subject|2
6247233|NCT01914666|9933021|FG000|Treatment Period|Physician Decision|0
6247234|NCT01914666|9933022|FG001|Treatment Period|Physician Decision|0
6247235|NCT01914666|9933023|FG002|Treatment Period|Physician Decision|2
6247236|NCT01914679|9933029|FG000|Overall Study|Lack of Efficacy|1
6247237|NCT01914679|9933029|FG000|Overall Study|Sponsor terminated study|4
6247238|NCT01914757|9933036|FG000|Overall Study|Severe non-compliance to protocol|3
6247239|NCT01914757|9933037|FG001|Overall Study|Severe non-compliance to protocol|1
6247240|NCT01914757|9933038|FG002|Overall Study|Severe non-compliance to protocol|2
6247241|NCT01914757|9933036|FG000|Overall Study|Lost to Follow-up|5
6247242|NCT01914757|9933037|FG001|Overall Study|Lost to Follow-up|8
6247243|NCT01914757|9933038|FG002|Overall Study|Lost to Follow-up|6
6247244|NCT01914757|9933036|FG000|Overall Study|Withdrawal by Subject|15
6247245|NCT01914757|9933037|FG001|Overall Study|Withdrawal by Subject|27
6247246|NCT01914757|9933038|FG002|Overall Study|Withdrawal by Subject|19
6247247|NCT01914757|9933036|FG000|Overall Study|Death|2
6247248|NCT01914757|9933037|FG001|Overall Study|Death|2
6247249|NCT01914757|9933038|FG002|Overall Study|Death|1
6247250|NCT01914757|9933036|FG000|Overall Study|Adverse Event|4
6247251|NCT01914757|9933037|FG001|Overall Study|Adverse Event|3
6247252|NCT01914757|9933038|FG002|Overall Study|Adverse Event|4
6247253|NCT01914757|9933036|FG000|Overall Study|Study specific withdrawal criteria|0
6247254|NCT01914757|9933037|FG001|Overall Study|Study specific withdrawal criteria|1
6247255|NCT01914757|9933038|FG002|Overall Study|Study specific withdrawal criteria|0
6247256|NCT01914757|9933036|FG000|Overall Study|Eligibility criteria not fulfilled|2
6247257|NCT01914757|9933037|FG001|Overall Study|Eligibility criteria not fulfilled|0
6247258|NCT01914757|9933038|FG002|Overall Study|Eligibility criteria not fulfilled|2
6247259|NCT01914757|9933036|FG000|Overall Study|Other reasons|5
6247260|NCT01914757|9933037|FG001|Overall Study|Other reasons|9
6247261|NCT01914757|9933038|FG002|Overall Study|Other reasons|4
6247262|NCT01914926|9933048|FG000|Overall Study|Adverse Event|1
6247263|NCT01914926|9933049|FG001|Overall Study|Adverse Event|0
6247264|NCT01914926|9933048|FG000|Overall Study|uncooperative, agitated and removed|0
6247265|NCT01914926|9933049|FG001|Overall Study|uncooperative, agitated and removed|1
6247266|NCT01915095|9933062|FG000|Overall Study|Some subjects were unable to commit to the training study.|0
6247267|NCT01915095|9933063|FG001|Overall Study|Some subjects were unable to commit to the training study.|0
6247268|NCT01915095|9933064|FG002|Overall Study|Some subjects were unable to commit to the training study.|0
6247269|NCT01915095|9933065|FG003|Overall Study|Some subjects were unable to commit to the training study.|4
6247270|NCT01915095|9933066|FG004|Overall Study|Some subjects were unable to commit to the training study.|6
6247271|NCT01915303|9933121|FG000|Core Phase|Adverse Event|7
6247272|NCT01915303|9933121|FG000|Core Phase|Unsatisfactory therapeutic effect|3
6247273|NCT01915303|9933121|FG000|Core Phase|Death|2
6247274|NCT01915303|9933121|FG000|Core Phase|Protocol Violation|2
6247275|NCT01915303|9933121|FG000|Core Phase|Abnormal lab value|1
6247276|NCT01915303|9933121|FG000|Core Phase|Withdrawal by Subject|1
6247277|NCT01915303|9933121|FG000|Extension Phase|Unsatisfactory therapeutic effect|8
6247278|NCT01915303|9933121|FG000|Extension Phase|Withdrawal by Subject|4
6247279|NCT01915303|9933121|FG000|Extension Phase|Adverse Event|3
6247280|NCT01915303|9933121|FG000|Extension Phase|Death|1
6247281|NCT01915303|9933121|FG000|Extension Phase|Protocol Violation|1
6247282|NCT01915732|9933136|FG000|Overall Study|Withdrawal by Subject|18
6247283|NCT01915732|9933137|FG001|Overall Study|Withdrawal by Subject|18
6247284|NCT01915732|9933136|FG000|Overall Study|Failure to Meet Randomization Criteria|1
6247285|NCT01915732|9933137|FG001|Overall Study|Failure to Meet Randomization Criteria|0
6247286|NCT01915732|9933136|FG000|Overall Study|Adverse Event|12
6247287|NCT01915732|9933137|FG001|Overall Study|Adverse Event|4
6247288|NCT01915732|9933136|FG000|Overall Study|Protocol Violation|5
6086148|NCT00658788|9695866|FG000|Overall Study|Withdrawal by Subject|13
6086149|NCT00658788|9695866|FG000|Overall Study|Lost to Follow-up|18
6086150|NCT00658788|9695866|FG000|Overall Study|Treatment Discontinuation|32
6086151|NCT00658879|9695879|FG000|Overall Study|Protocol Violation|1
6247289|NCT01915732|9933137|FG001|Overall Study|Protocol Violation|5
6247290|NCT01915732|9933136|FG000|Overall Study|Lack of Efficacy|6
6247291|NCT01915732|9933137|FG001|Overall Study|Lack of Efficacy|11
6247292|NCT01915732|9933136|FG000|Overall Study|Lost to Follow-up|22
6247293|NCT01915732|9933137|FG001|Overall Study|Lost to Follow-up|26
6247294|NCT01915732|9933136|FG000|Overall Study|Par. Improved, Voluntary (Vol) exit|1
6247295|NCT01915732|9933137|FG001|Overall Study|Par. Improved, Voluntary (Vol) exit|0
6247296|NCT01915732|9933136|FG000|Overall Study|Par. Conscious Ineffective Vol Exit|1
6247297|NCT01915732|9933137|FG001|Overall Study|Par. Conscious Ineffective Vol Exit|0
6247298|NCT01915732|9933136|FG000|Overall Study|Drug Release Error|1
6247299|NCT01915732|9933137|FG001|Overall Study|Drug Release Error|0
6247300|NCT01915732|9933136|FG000|Overall Study|Recovered|1
6247301|NCT01915732|9933137|FG001|Overall Study|Recovered|0
6247302|NCT01915732|9933136|FG000|Overall Study|Pregnancy|1
6247303|NCT01915732|9933137|FG001|Overall Study|Pregnancy|0
6247304|NCT01915732|9933136|FG000|Overall Study|Poor Perceived Efficacy|1
6247305|NCT01915732|9933137|FG001|Overall Study|Poor Perceived Efficacy|0
6247306|NCT01915732|9933136|FG000|Overall Study|Par. Unable to Come to the Hospital|0
6247307|NCT01915732|9933137|FG001|Overall Study|Par. Unable to Come to the Hospital|1
6247308|NCT01915732|9933136|FG000|Overall Study|Got Well|0
6247309|NCT01915732|9933137|FG001|Overall Study|Got Well|1
6247310|NCT01915732|9933136|FG000|Overall Study|Par. not Willing to Continue Treatment|0
6247311|NCT01915732|9933137|FG001|Overall Study|Par. not Willing to Continue Treatment|1
6247312|NCT01915732|9933136|FG000|Overall Study|Par. Refused to Hospital Visits|0
6247313|NCT01915732|9933137|FG001|Overall Study|Par. Refused to Hospital Visits|1
6247314|NCT01915732|9933136|FG000|Overall Study|Job Transfer|0
6247315|NCT01915732|9933137|FG001|Overall Study|Job Transfer|1
6247316|NCT01915732|9933136|FG000|Overall Study|Improper Facial Procedure|0
6247317|NCT01915732|9933137|FG001|Overall Study|Improper Facial Procedure|1
6247318|NCT01915732|9933136|FG000|Overall Study|Poor Conscious Effect|0
6247319|NCT01915732|9933137|FG001|Overall Study|Poor Conscious Effect|1
6247320|NCT01915771|9933143|FG000|Day 1|Withdrawal by Subject|1
6247321|NCT01915771|9933143|FG000|Day 15|Withdrawal by Subject|1
6247322|NCT01915849|9933164|FG000|Treatment Period 1 (4 Days)|Protocol Violation|1
6247323|NCT01915849|9933165|FG001|Treatment Period 1 (4 Days)|Protocol Violation|0
6247324|NCT01915849|9933166|FG002|Treatment Period 1 (4 Days)|Protocol Violation|0
6247325|NCT01915849|9933167|FG003|Treatment Period 1 (4 Days)|Protocol Violation|0
6247326|NCT01915849|9933164|FG000|Treatment Period 1 (4 Days)|Withdrawal by Subject|1
6247327|NCT01915849|9933165|FG001|Treatment Period 1 (4 Days)|Withdrawal by Subject|0
6247328|NCT01915849|9933166|FG002|Treatment Period 1 (4 Days)|Withdrawal by Subject|0
6247329|NCT01915849|9933167|FG003|Treatment Period 1 (4 Days)|Withdrawal by Subject|0
6247330|NCT01915914|9933177|FG000|Acute Phase|Withdrawal by Subject|4
6247331|NCT01915914|9933178|FG001|Acute Phase|Withdrawal by Subject|0
6247332|NCT01915914|9933179|FG002|Acute Phase|Withdrawal by Subject|0
6247333|NCT01915914|9933180|FG003|Acute Phase|Withdrawal by Subject|0
6247334|NCT01915914|9933177|FG000|Acute Phase|Lost to Follow-up|4
6247335|NCT01915914|9933178|FG001|Acute Phase|Lost to Follow-up|0
6247336|NCT01915914|9933179|FG002|Acute Phase|Lost to Follow-up|0
6247337|NCT01915914|9933180|FG003|Acute Phase|Lost to Follow-up|0
6247338|NCT01915914|9933177|FG000|Acute Phase|Physician Decision|1
6247339|NCT01915914|9933178|FG001|Acute Phase|Physician Decision|0
6247340|NCT01915914|9933179|FG002|Acute Phase|Physician Decision|0
6247341|NCT01915914|9933180|FG003|Acute Phase|Physician Decision|0
6247342|NCT01915914|9933177|FG000|Acute Phase|Accepted Other Topic Therapies|1
6247343|NCT01915914|9933178|FG001|Acute Phase|Accepted Other Topic Therapies|0
6247344|NCT01915914|9933179|FG002|Acute Phase|Accepted Other Topic Therapies|0
6247345|NCT01915914|9933180|FG003|Acute Phase|Accepted Other Topic Therapies|0
6086152|NCT00658996|9695883|FG000|First Intervention|Positive slit lamp finding|1
6086153|NCT00658996|9695884|FG001|First Intervention|Positive slit lamp finding|0
6086154|NCT00658996|9695883|FG000|First Intervention|Lack of lenses|0
6086155|NCT00658996|9695884|FG001|First Intervention|Lack of lenses|1
6086156|NCT00658996|9695883|FG000|Crossover Period|Physician Decision|1
6086157|NCT00658996|9695884|FG001|Crossover Period|Physician Decision|0
6086158|NCT00658996|9695883|FG000|Crossover Period|Ineligible|1
6086159|NCT00658996|9695884|FG001|Crossover Period|Ineligible|1
6086160|NCT00658996|9695883|FG000|Second Intervention|Developed a stye on upper lid|1
6086161|NCT00658996|9695884|FG001|Second Intervention|Developed a stye on upper lid|0
6086162|NCT00658996|9695883|FG000|Second Intervention|Positive slit lamp finding|0
6086163|NCT00658996|9695884|FG001|Second Intervention|Positive slit lamp finding|1
6247346|NCT01915914|9933177|FG000|Acute Phase|"Not Achieved treatment success"|1
6247347|NCT01915914|9933178|FG001|Acute Phase|"Not Achieved treatment success"|0
6247348|NCT01915914|9933179|FG002|Acute Phase|"Not Achieved treatment success"|0
6247349|NCT01915914|9933180|FG003|Acute Phase|"Not Achieved treatment success"|0
6247350|NCT01915914|9933177|FG000|Acute Phase|Missing|1
6247351|NCT01915914|9933178|FG001|Acute Phase|Missing|0
6247352|NCT01915914|9933179|FG002|Acute Phase|Missing|0
6247353|NCT01915914|9933180|FG003|Acute Phase|Missing|0
6247354|NCT01915914|9933177|FG000|Maintenance Phase|Withdrawal by Subject|0
6247355|NCT01915914|9933178|FG001|Maintenance Phase|Withdrawal by Subject|1
6247356|NCT01915914|9933179|FG002|Maintenance Phase|Withdrawal by Subject|1
6247357|NCT01915914|9933180|FG003|Maintenance Phase|Withdrawal by Subject|0
6086164|NCT00659230|9695901|FG000|Overall Study|Lost to Follow-up|2
6086165|NCT00659230|9695902|FG001|Overall Study|Lost to Follow-up|5
6086166|NCT00659230|9695901|FG000|Overall Study|Lost source documentation|5
6086167|NCT00659230|9695902|FG001|Overall Study|Lost source documentation|4
6086168|NCT00659230|9695901|FG000|Overall Study|Did not return post-randomization|2
6086169|NCT00659230|9695902|FG001|Overall Study|Did not return post-randomization|3
6086170|NCT00659269|9695910|FG000|Overall Study|Physician Decision|1
6086171|NCT00659269|9695911|FG001|Overall Study|Physician Decision|1
6247358|NCT01915914|9933177|FG000|Maintenance Phase|Lost to Follow-up|0
6247359|NCT01915914|9933178|FG001|Maintenance Phase|Lost to Follow-up|4
6247360|NCT01915914|9933179|FG002|Maintenance Phase|Lost to Follow-up|1
6247361|NCT01915914|9933180|FG003|Maintenance Phase|Lost to Follow-up|0
6247362|NCT01915914|9933177|FG000|Maintenance Phase|Missing|0
6247363|NCT01915914|9933178|FG001|Maintenance Phase|Missing|1
6247364|NCT01915914|9933179|FG002|Maintenance Phase|Missing|0
6247365|NCT01915914|9933180|FG003|Maintenance Phase|Missing|0
6247366|NCT01915914|9933177|FG000|Follow-up Phase|Withdrawal by Subject|0
6247367|NCT01915914|9933178|FG001|Follow-up Phase|Withdrawal by Subject|0
6247368|NCT01915914|9933179|FG002|Follow-up Phase|Withdrawal by Subject|0
6247369|NCT01915914|9933180|FG003|Follow-up Phase|Withdrawal by Subject|1
6247370|NCT01915914|9933177|FG000|Follow-up Phase|Physician Decision|0
6247371|NCT01915914|9933178|FG001|Follow-up Phase|Physician Decision|0
6247372|NCT01915914|9933179|FG002|Follow-up Phase|Physician Decision|0
6247373|NCT01915914|9933180|FG003|Follow-up Phase|Physician Decision|1
6247374|NCT01915940|9933200|FG000|Pre-randomization Washout Period|Not Qualified for Randomization|39
6247375|NCT01915940|9933201|FG001|Pre-randomization Washout Period|Not Qualified for Randomization|0
6247376|NCT01915940|9933202|FG002|Pre-randomization Washout Period|Not Qualified for Randomization|0
6247377|NCT01915940|9933200|FG000|Treatment Period|Decision of Participant|0
6247378|NCT01915940|9933201|FG001|Treatment Period|Decision of Participant|1
6247379|NCT01915940|9933202|FG002|Treatment Period|Decision of Participant|3
6247380|NCT01915940|9933200|FG000|Treatment Period|Adverse Event|0
6247381|NCT01915940|9933201|FG001|Treatment Period|Adverse Event|9
6247382|NCT01915940|9933202|FG002|Treatment Period|Adverse Event|1
6247383|NCT01915940|9933200|FG000|Treatment Period|Other Miscellaneous Reasons|0
6247384|NCT01915940|9933201|FG001|Treatment Period|Other Miscellaneous Reasons|1
6247385|NCT01915940|9933202|FG002|Treatment Period|Other Miscellaneous Reasons|0
6247386|NCT01916109|9933208|FG000|Overall Study|Withdrawal by Subject|1
6247387|NCT01916226|9933216|FG000|Overall Study|Adverse Event|1
6247388|NCT01916226|9933217|FG001|Overall Study|Adverse Event|0
6247389|NCT01916226|9933218|FG002|Overall Study|Adverse Event|1
6247390|NCT01916226|9933219|FG003|Overall Study|Adverse Event|1
6247391|NCT01916226|9933216|FG000|Overall Study|Lack of Efficacy|0
6247392|NCT01916226|9933217|FG001|Overall Study|Lack of Efficacy|0
6247393|NCT01916226|9933218|FG002|Overall Study|Lack of Efficacy|2
6247394|NCT01916226|9933219|FG003|Overall Study|Lack of Efficacy|1
6247395|NCT01916226|9933216|FG000|Overall Study|Protocol Violation|0
6247396|NCT01916226|9933217|FG001|Overall Study|Protocol Violation|1
6247397|NCT01916226|9933218|FG002|Overall Study|Protocol Violation|0
6247398|NCT01916226|9933219|FG003|Overall Study|Protocol Violation|1
6247399|NCT01916226|9933216|FG000|Overall Study|Physician Decision|0
6247400|NCT01916226|9933217|FG001|Overall Study|Physician Decision|0
6247401|NCT01916226|9933218|FG002|Overall Study|Physician Decision|0
6247402|NCT01916226|9933219|FG003|Overall Study|Physician Decision|1
6247403|NCT01916304|9933230|FG000|Overall Study|Screening failure|17
6247404|NCT01916824|9933276|FG000|Overall Study|Lost to Follow-up|3
6247405|NCT01916824|9933277|FG001|Overall Study|Lost to Follow-up|6
6247406|NCT01916824|9933276|FG000|Overall Study|Physician Decision|2
6247407|NCT01916824|9933277|FG001|Overall Study|Physician Decision|0
6247408|NCT01916824|9933276|FG000|Overall Study|Withdrawal by Subject|2
6247409|NCT01916824|9933277|FG001|Overall Study|Withdrawal by Subject|3
6270642|NCT02154347|9971761|FG000|Double-blind Period|Withdrawal by Subject|1
6270643|NCT02154347|9971762|FG001|Double-blind Period|Withdrawal by Subject|1
6270644|NCT02154347|9971761|FG000|Open-label Period|Adverse Event|3
6270645|NCT02154347|9971762|FG001|Open-label Period|Adverse Event|4
6270646|NCT02154347|9971761|FG000|Open-label Period|Lack of Efficacy|4
6270647|NCT02154347|9971762|FG001|Open-label Period|Lack of Efficacy|19
6270648|NCT02154347|9971761|FG000|Open-label Period|Protocol Violation|0
6270649|NCT02154347|9971762|FG001|Open-label Period|Protocol Violation|1
6270650|NCT02154347|9971761|FG000|Open-label Period|Withdrawal by Subject|0
6270651|NCT02154347|9971762|FG001|Open-label Period|Withdrawal by Subject|1
6270652|NCT02154425|9971778|FG000|Screening Period|Adverse Event|1
6086172|NCT00659334|9695942|FG000|Overall Study|Screen Failure|8
6086173|NCT00659334|9695943|FG001|Overall Study|Screen Failure|5
6270653|NCT02154581|9971797|FG000|Overall Study|Lost to Follow-up|7
6270654|NCT02154581|9971798|FG001|Overall Study|Lost to Follow-up|8
6270655|NCT02155283|9971861|FG000|Overall Study|Lost to Follow-up|3
6270656|NCT02155283|9971861|FG000|Overall Study|Withdrawal by Subject|1
6270657|NCT02155283|9971861|FG000|Overall Study|Protocol Violation|3
6270658|NCT02155309|9971867|FG000|Overall Study|Protocol Violation|0
6270659|NCT02155309|9971868|FG001|Overall Study|Protocol Violation|0
6270660|NCT02155309|9971869|FG002|Overall Study|Protocol Violation|1
6270661|NCT02155322|9971876|FG000|Overall Study|Adverse Event|1
6270662|NCT02155322|9971876|FG000|Overall Study|Physician Decision|1
6270663|NCT02155322|9971876|FG000|Overall Study|Relapse/Recurrence|8
6270664|NCT02155322|9971876|FG000|Overall Study|Withdrawal by Subject|4
6247410|NCT01917006|9933303|FG000|Randomized-treatment Period|Lost to Follow-up|1
6247411|NCT01917006|9933304|FG001|Randomized-treatment Period|Lost to Follow-up|0
6247412|NCT01917006|9933305|FG002|Randomized-treatment Period|Lost to Follow-up|0
6247413|NCT01917006|9933306|FG003|Randomized-treatment Period|Lost to Follow-up|1
6247414|NCT01917006|9933307|FG004|Randomized-treatment Period|Lost to Follow-up|0
6247415|NCT01917006|9933308|FG005|Randomized-treatment Period|Lost to Follow-up|0
6247416|NCT01917006|9933309|FG006|Randomized-treatment Period|Lost to Follow-up|0
6247417|NCT01917006|9933310|FG007|Randomized-treatment Period|Lost to Follow-up|0
6247418|NCT01917006|9933303|FG000|Randomized-treatment Period|Personal Reasons|0
6247419|NCT01917006|9933304|FG001|Randomized-treatment Period|Personal Reasons|0
6247420|NCT01917006|9933305|FG002|Randomized-treatment Period|Personal Reasons|0
6247421|NCT01917006|9933306|FG003|Randomized-treatment Period|Personal Reasons|0
6247422|NCT01917006|9933307|FG004|Randomized-treatment Period|Personal Reasons|0
6247423|NCT01917006|9933308|FG005|Randomized-treatment Period|Personal Reasons|1
6247424|NCT01917006|9933309|FG006|Randomized-treatment Period|Personal Reasons|0
6247425|NCT01917006|9933310|FG007|Randomized-treatment Period|Personal Reasons|0
6247426|NCT01917006|9933303|FG000|Randomized-treatment Period|Protocol Violation|1
6247427|NCT01917006|9933304|FG001|Randomized-treatment Period|Protocol Violation|0
6247428|NCT01917006|9933305|FG002|Randomized-treatment Period|Protocol Violation|0
6247429|NCT01917006|9933306|FG003|Randomized-treatment Period|Protocol Violation|0
6247430|NCT01917006|9933307|FG004|Randomized-treatment Period|Protocol Violation|0
6247431|NCT01917006|9933308|FG005|Randomized-treatment Period|Protocol Violation|0
6247432|NCT01917006|9933309|FG006|Randomized-treatment Period|Protocol Violation|0
6247433|NCT01917006|9933310|FG007|Randomized-treatment Period|Protocol Violation|0
6247434|NCT01917006|9933303|FG000|Randomized-treatment Period|Other Miscellaneous Reasons|0
6247435|NCT01917006|9933304|FG001|Randomized-treatment Period|Other Miscellaneous Reasons|0
6247436|NCT01917006|9933305|FG002|Randomized-treatment Period|Other Miscellaneous Reasons|0
6247437|NCT01917006|9933306|FG003|Randomized-treatment Period|Other Miscellaneous Reasons|0
6247438|NCT01917006|9933307|FG004|Randomized-treatment Period|Other Miscellaneous Reasons|0
6247439|NCT01917006|9933308|FG005|Randomized-treatment Period|Other Miscellaneous Reasons|0
6247440|NCT01917006|9933309|FG006|Randomized-treatment Period|Other Miscellaneous Reasons|1
6247441|NCT01917006|9933310|FG007|Randomized-treatment Period|Other Miscellaneous Reasons|0
6247442|NCT01917006|9933303|FG000|Open-label Period|Adverse Event|0
6247443|NCT01917006|9933304|FG001|Open-label Period|Adverse Event|0
6247444|NCT01917006|9933305|FG002|Open-label Period|Adverse Event|0
6247445|NCT01917006|9933306|FG003|Open-label Period|Adverse Event|0
6247446|NCT01917006|9933307|FG004|Open-label Period|Adverse Event|0
6247447|NCT01917006|9933308|FG005|Open-label Period|Adverse Event|0
6247448|NCT01917006|9933309|FG006|Open-label Period|Adverse Event|0
6247449|NCT01917006|9933310|FG007|Open-label Period|Adverse Event|1
6247450|NCT01917006|9933303|FG000|Open-label Period|Lost to Follow-up|0
6247451|NCT01917006|9933304|FG001|Open-label Period|Lost to Follow-up|0
6247452|NCT01917006|9933305|FG002|Open-label Period|Lost to Follow-up|0
6247453|NCT01917006|9933306|FG003|Open-label Period|Lost to Follow-up|0
6247454|NCT01917006|9933307|FG004|Open-label Period|Lost to Follow-up|0
6247455|NCT01917006|9933308|FG005|Open-label Period|Lost to Follow-up|0
6247456|NCT01917006|9933309|FG006|Open-label Period|Lost to Follow-up|0
6247457|NCT01917006|9933310|FG007|Open-label Period|Lost to Follow-up|1
6247458|NCT01917084|9933327|FG000|Overall Study|Withdrawal by Subject|1
6247459|NCT01917344|9933353|FG000|Overall Study|Withdrawal by Subject|1
6247460|NCT01917526|9933368|FG000|Overall Study|Protocol Violation|1
6247461|NCT01917526|9933369|FG001|Overall Study|Protocol Violation|1
6247462|NCT01917656|9933377|FG000|Overall Study|Adverse Event|11
6247463|NCT01917656|9933378|FG001|Overall Study|Adverse Event|0
6247464|NCT01917656|9933377|FG000|Overall Study|Withdrawal criteria|8
6247465|NCT01917656|9933378|FG001|Overall Study|Withdrawal criteria|14
6086174|NCT00659334|9695944|FG002|Overall Study|Screen Failure|0
6086175|NCT00659334|9695945|FG003|Overall Study|Screen Failure|0
6086176|NCT00659334|9695946|FG004|Overall Study|Screen Failure|0
6086177|NCT00659334|9695947|FG005|Overall Study|Screen Failure|0
6086178|NCT00659334|9695948|FG006|Overall Study|Screen Failure|1
6086179|NCT00659373|9695972|FG000|Overall Study|Withdrawal by Subject|3
6086180|NCT00659373|9695973|FG001|Overall Study|Withdrawal by Subject|5
6086181|NCT00659373|9695972|FG000|Overall Study|Assessment Missed|2
6086182|NCT00659373|9695973|FG001|Overall Study|Assessment Missed|2
6086183|NCT00659425|9695989|FG000|Overall Study|Disease progression|1
6086184|NCT00659425|9695990|FG001|Overall Study|Disease progression|0
6086185|NCT00659425|9695991|FG002|Overall Study|Disease progression|0
6086186|NCT00659425|9695992|FG003|Overall Study|Disease progression|1
6086187|NCT00659425|9695993|FG004|Overall Study|Disease progression|0
6247466|NCT01917656|9933377|FG000|Overall Study|Unclassified|0
6247467|NCT01917656|9933378|FG001|Overall Study|Unclassified|3
6247468|NCT01917656|9933377|FG000|Overall Study|Withdrawal by Subject|4
6247469|NCT01917656|9933378|FG001|Overall Study|Withdrawal by Subject|3
6247470|NCT01917656|9933377|FG000|Overall Study|Lost to Follow-up|3
6247471|NCT01917656|9933378|FG001|Overall Study|Lost to Follow-up|4
6247472|NCT01917747|9933391|FG000|Overall Study|Withdrawal by Subject|1
6247473|NCT01917747|9933392|FG001|Overall Study|Withdrawal by Subject|2
6247474|NCT01917747|9933391|FG000|Overall Study|Lost to Follow-up|18
6247475|NCT01917747|9933392|FG001|Overall Study|Lost to Follow-up|9
6247476|NCT01917968|9933423|FG000|Overall Study|Death|3
6247477|NCT01917968|9933424|FG001|Overall Study|Death|2
6247478|NCT01917968|9933423|FG000|Overall Study|Lost to Follow-up|21
6247479|NCT01917968|9933424|FG001|Overall Study|Lost to Follow-up|39
6247480|NCT01917968|9933423|FG000|Overall Study|Physician Decision|1
6247481|NCT01917968|9933424|FG001|Overall Study|Physician Decision|2
6247482|NCT01917968|9933423|FG000|Overall Study|Withdrawal by Subject|20
6247483|NCT01917968|9933424|FG001|Overall Study|Withdrawal by Subject|35
6247484|NCT01917968|9933423|FG000|Overall Study|Subject Relocation|5
6247485|NCT01917968|9933424|FG001|Overall Study|Subject Relocation|1
6247486|NCT01917968|9933423|FG000|Overall Study|36M Missed Visit|3
6247487|NCT01917968|9933424|FG001|Overall Study|36M Missed Visit|2
6247488|NCT01917968|9933423|FG000|Overall Study|Subject Noncompliance to Scheduled 36M Follow Up Visit|1
6247489|NCT01917968|9933424|FG001|Overall Study|Subject Noncompliance to Scheduled 36M Follow Up Visit|0
6247490|NCT01917968|9933423|FG000|Overall Study|Change in Family Circumstances|0
6247491|NCT01917968|9933424|FG001|Overall Study|Change in Family Circumstances|1
6247492|NCT01917968|9933423|FG000|Overall Study|No Data Available|0
6247493|NCT01917968|9933424|FG001|Overall Study|No Data Available|2
6247494|NCT01918085|9933451|FG000|Test Period 1: Strata Strip|Adverse Event|0
6247495|NCT01918085|9933452|FG001|Test Period 1: Strata Strip|Adverse Event|1
6247496|NCT01918306|9933467|FG000|Overall Study|progresive disease|4
6247497|NCT01918306|9933468|FG001|Overall Study|progresive disease|0
6247498|NCT01918306|9933469|FG002|Overall Study|progresive disease|1
6247499|NCT01918306|9933470|FG003|Overall Study|progresive disease|1
6247500|NCT01918306|9933467|FG000|Overall Study|Withdrawal by Subject|0
6247501|NCT01918306|9933468|FG001|Overall Study|Withdrawal by Subject|0
6247502|NCT01918306|9933469|FG002|Overall Study|Withdrawal by Subject|0
6247503|NCT01918306|9933470|FG003|Overall Study|Withdrawal by Subject|2
6247504|NCT01918306|9933467|FG000|Overall Study|neutropenia|1
6247505|NCT01918306|9933468|FG001|Overall Study|neutropenia|0
6247506|NCT01918306|9933469|FG002|Overall Study|neutropenia|0
6247507|NCT01918306|9933470|FG003|Overall Study|neutropenia|0
6247508|NCT01918306|9933467|FG000|Overall Study|Lack of Efficacy|1
6247509|NCT01918306|9933468|FG001|Overall Study|Lack of Efficacy|0
6247510|NCT01918306|9933469|FG002|Overall Study|Lack of Efficacy|0
6247511|NCT01918306|9933470|FG003|Overall Study|Lack of Efficacy|0
6247512|NCT01918306|9933467|FG000|Overall Study|progress disease, crossover|0
6247513|NCT01918306|9933468|FG001|Overall Study|progress disease, crossover|0
6247514|NCT01918306|9933469|FG002|Overall Study|progress disease, crossover|1
6247515|NCT01918306|9933470|FG003|Overall Study|progress disease, crossover|0
6247516|NCT01918332|9933494|FG000|Overall Study|Adverse Event|0
6247517|NCT01918332|9933495|FG001|Overall Study|Adverse Event|0
6247518|NCT01918332|9933496|FG002|Overall Study|Adverse Event|0
6247519|NCT01918332|9933497|FG003|Overall Study|Adverse Event|1
6247520|NCT01918332|9933494|FG000|Overall Study|Withdrawal by Subject|2
6247521|NCT01918332|9933495|FG001|Overall Study|Withdrawal by Subject|3
6247522|NCT01918332|9933496|FG002|Overall Study|Withdrawal by Subject|2
6247523|NCT01918332|9933497|FG003|Overall Study|Withdrawal by Subject|3
6247524|NCT01918332|9933494|FG000|Overall Study|Protocol Violation|6
6247525|NCT01918332|9933495|FG001|Overall Study|Protocol Violation|2
6247526|NCT01918332|9933496|FG002|Overall Study|Protocol Violation|6
6247527|NCT01918332|9933497|FG003|Overall Study|Protocol Violation|3
6247528|NCT01918332|9933494|FG000|Overall Study|lipid result by central lab did not meet|0
6247529|NCT01918332|9933495|FG001|Overall Study|lipid result by central lab did not meet|0
6247530|NCT01918332|9933496|FG002|Overall Study|lipid result by central lab did not meet|1
6247531|NCT01918332|9933497|FG003|Overall Study|lipid result by central lab did not meet|0
6247532|NCT01918371|9933509|FG000|Overall Study|Missing Data|1
6247533|NCT01918371|9933510|FG001|Overall Study|Missing Data|1
6247534|NCT01918774|9933520|FG000|Overall Study|Lost prior to first CBTw session|4
6247535|NCT01918774|9933520|FG000|Overall Study|Lost to Follow-up|1
6247536|NCT01919112|9933536|FG000|Secondary Analysis-day 30|Death|1
6247537|NCT01919112|9933537|FG001|Secondary Analysis-day 30|Death|1
6247538|NCT01919112|9933538|FG002|Secondary Analysis-day 30|Death|1
6247539|NCT01919112|9933536|FG000|Secondary Analysis-day 30|Lost to Follow-up|1
6247540|NCT01919112|9933537|FG001|Secondary Analysis-day 30|Lost to Follow-up|0
6247541|NCT01919112|9933538|FG002|Secondary Analysis-day 30|Lost to Follow-up|0
6247542|NCT01919164|9933551|FG000|Overall Study|Adverse Event|6
6247543|NCT01919164|9933552|FG001|Overall Study|Adverse Event|4
6247544|NCT01919164|9933553|FG002|Overall Study|Adverse Event|9
6247545|NCT01919164|9933554|FG003|Overall Study|Adverse Event|3
6247546|NCT01919164|9933555|FG004|Overall Study|Adverse Event|2
6247547|NCT01919164|9933551|FG000|Overall Study|Lost to Follow-up|2
6247548|NCT01919164|9933552|FG001|Overall Study|Lost to Follow-up|2
6247549|NCT01919164|9933553|FG002|Overall Study|Lost to Follow-up|2
6247550|NCT01919164|9933554|FG003|Overall Study|Lost to Follow-up|0
6247551|NCT01919164|9933555|FG004|Overall Study|Lost to Follow-up|4
6247552|NCT01919164|9933551|FG000|Overall Study|Death|1
6247553|NCT01919164|9933552|FG001|Overall Study|Death|0
6247554|NCT01919164|9933553|FG002|Overall Study|Death|0
6247555|NCT01919164|9933554|FG003|Overall Study|Death|0
6247556|NCT01919164|9933555|FG004|Overall Study|Death|0
6247557|NCT01919164|9933551|FG000|Overall Study|Protocol Violation|6
6247558|NCT01919164|9933552|FG001|Overall Study|Protocol Violation|0
6247559|NCT01919164|9933553|FG002|Overall Study|Protocol Violation|3
6247560|NCT01919164|9933554|FG003|Overall Study|Protocol Violation|2
6247561|NCT01919164|9933555|FG004|Overall Study|Protocol Violation|2
6247562|NCT01919164|9933551|FG000|Overall Study|Disease progression|2
6247563|NCT01919164|9933552|FG001|Overall Study|Disease progression|2
6247564|NCT01919164|9933553|FG002|Overall Study|Disease progression|1
6247565|NCT01919164|9933554|FG003|Overall Study|Disease progression|2
6247566|NCT01919164|9933555|FG004|Overall Study|Disease progression|1
6247567|NCT01919164|9933551|FG000|Overall Study|Withdrew consent|13
6247568|NCT01919164|9933552|FG001|Overall Study|Withdrew consent|13
6247569|NCT01919164|9933553|FG002|Overall Study|Withdrew consent|14
6247570|NCT01919164|9933554|FG003|Overall Study|Withdrew consent|14
6247571|NCT01919164|9933555|FG004|Overall Study|Withdrew consent|9
6247572|NCT01919164|9933551|FG000|Overall Study|Other Un-specified|13
6247573|NCT01919164|9933552|FG001|Overall Study|Other Un-specified|9
6247574|NCT01919164|9933553|FG002|Overall Study|Other Un-specified|8
6247575|NCT01919164|9933554|FG003|Overall Study|Other Un-specified|7
6247576|NCT01919164|9933555|FG004|Overall Study|Other Un-specified|15
6247577|NCT01919190|9933569|FG000|Overall Study|Intra-op findings, etc.|3
6247578|NCT01919190|9933570|FG001|Overall Study|Intra-op findings, etc.|0
6247579|NCT01919229|9933593|FG000|Overall Study|Subject/guardian decision|0
6247580|NCT01919229|9933594|FG001|Overall Study|Subject/guardian decision|0
6247581|NCT01919229|9933595|FG002|Overall Study|Subject/guardian decision|1
6247582|NCT01919307|9933603|FG000|Overall Study|Withdrawal by Subject|9
6247583|NCT01919398|9933610|FG000|Overall Study|Progressive Disease|0
6247584|NCT01919398|9933611|FG001|Overall Study|Progressive Disease|0
6247585|NCT01919398|9933612|FG002|Overall Study|Progressive Disease|4
6247586|NCT01919411|9933622|FG000|Overall Study|Lost to Follow-up|2
6247587|NCT01919411|9933623|FG001|Overall Study|Lost to Follow-up|4
6247588|NCT01919411|9933622|FG000|Overall Study|Physician Decision|1
6247589|NCT01919411|9933623|FG001|Overall Study|Physician Decision|0
6247590|NCT01919411|9933622|FG000|Overall Study|Protocol Violation|2
6247591|NCT01919411|9933623|FG001|Overall Study|Protocol Violation|1
6247592|NCT01919489|9933648|FG000|Overall Study|Rejected the need of injections|4
6247593|NCT01919489|9933649|FG001|Overall Study|Rejected the need of injections|7
6247594|NCT01919489|9933648|FG000|Overall Study|Adverse Event|10
6247595|NCT01919489|9933649|FG001|Overall Study|Adverse Event|0
6247596|NCT01919489|9933648|FG000|Overall Study|Hospital readmission|2
6247597|NCT01919489|9933649|FG001|Overall Study|Hospital readmission|9
6247598|NCT01919489|9933648|FG000|Overall Study|Death|2
6247599|NCT01919489|9933649|FG001|Overall Study|Death|1
6247600|NCT01919489|9933648|FG000|Overall Study|Lost to Follow-up|38
6247601|NCT01919489|9933649|FG001|Overall Study|Lost to Follow-up|27
6247602|NCT01919723|9933676|FG000|Overall Study|Blood Samples Hemolyzed|2
6247603|NCT01919723|9933677|FG001|Overall Study|Blood Samples Hemolyzed|2
6247604|NCT01919801|9933685|FG000|Overall Study|Withdrawal by Subject|1
6247605|NCT01919801|9933686|FG001|Overall Study|Withdrawal by Subject|0
6247606|NCT01919801|9933685|FG000|Overall Study|Physician Decision|0
6247607|NCT01919801|9933686|FG001|Overall Study|Physician Decision|1
6247608|NCT01919801|9933685|FG000|Overall Study|Lost to Follow-up|0
6247609|NCT01919801|9933686|FG001|Overall Study|Lost to Follow-up|1
6247610|NCT01919801|9933685|FG000|Overall Study|Other|0
6247611|NCT01919801|9933686|FG001|Overall Study|Other|1
6247612|NCT01919814|9933692|FG000|Overall Study|Adverse Event|1
6247613|NCT01919814|9933693|FG001|Overall Study|Adverse Event|0
6247614|NCT01919814|9933692|FG000|Overall Study|Protocol Violation|1
6247615|NCT01919814|9933693|FG001|Overall Study|Protocol Violation|0
6247616|NCT01919814|9933692|FG000|Overall Study|Withdrawal by Subject|1
6247617|NCT01919814|9933693|FG001|Overall Study|Withdrawal by Subject|0
6247618|NCT01919970|9933701|FG000|Overall Study|Withdrawal by Subject|3
6247619|NCT01919970|9933702|FG001|Overall Study|Withdrawal by Subject|0
6247620|NCT01920061|9933732|FG000|Overall Study|Death|1
6247621|NCT01920061|9933733|FG001|Overall Study|Death|1
6247622|NCT01920061|9933734|FG002|Overall Study|Death|0
6247623|NCT01920061|9933735|FG003|Overall Study|Death|1
6247624|NCT01920061|9933736|FG004|Overall Study|Death|1
6247625|NCT01920061|9933737|FG005|Overall Study|Death|0
6247626|NCT01920061|9933738|FG006|Overall Study|Death|0
6247627|NCT01920061|9933739|FG007|Overall Study|Death|1
6247628|NCT01920061|9933740|FG008|Overall Study|Death|0
6247629|NCT01920061|9933741|FG009|Overall Study|Death|1
6247630|NCT01920061|9933742|FG010|Overall Study|Death|0
6247631|NCT01920061|9933743|FG011|Overall Study|Death|1
6247632|NCT01920061|9933744|FG012|Overall Study|Death|0
6247633|NCT01920061|9933745|FG013|Overall Study|Death|2
6247634|NCT01920061|9933746|FG014|Overall Study|Death|0
6247635|NCT01920061|9933747|FG015|Overall Study|Death|0
6247636|NCT01920061|9933748|FG016|Overall Study|Death|0
6247637|NCT01920061|9933749|FG017|Overall Study|Death|0
6247638|NCT01920061|9933750|FG018|Overall Study|Death|1
6247639|NCT01920061|9933751|FG019|Overall Study|Death|0
6247640|NCT01920061|9933732|FG000|Overall Study|Lost to Follow-up|0
6247641|NCT01920061|9933733|FG001|Overall Study|Lost to Follow-up|2
6247642|NCT01920061|9933734|FG002|Overall Study|Lost to Follow-up|0
6247643|NCT01920061|9933735|FG003|Overall Study|Lost to Follow-up|0
6247644|NCT01920061|9933736|FG004|Overall Study|Lost to Follow-up|0
6247645|NCT01920061|9933737|FG005|Overall Study|Lost to Follow-up|0
6247646|NCT01920061|9933738|FG006|Overall Study|Lost to Follow-up|1
6247647|NCT01920061|9933739|FG007|Overall Study|Lost to Follow-up|0
6247648|NCT01920061|9933740|FG008|Overall Study|Lost to Follow-up|0
6247649|NCT01920061|9933741|FG009|Overall Study|Lost to Follow-up|0
6247650|NCT01920061|9933742|FG010|Overall Study|Lost to Follow-up|3
6247651|NCT01920061|9933743|FG011|Overall Study|Lost to Follow-up|0
6247652|NCT01920061|9933744|FG012|Overall Study|Lost to Follow-up|0
6247653|NCT01920061|9933745|FG013|Overall Study|Lost to Follow-up|0
6247654|NCT01920061|9933746|FG014|Overall Study|Lost to Follow-up|0
6247655|NCT01920061|9933747|FG015|Overall Study|Lost to Follow-up|0
6247656|NCT01920061|9933748|FG016|Overall Study|Lost to Follow-up|0
6247657|NCT01920061|9933749|FG017|Overall Study|Lost to Follow-up|1
6247658|NCT01920061|9933750|FG018|Overall Study|Lost to Follow-up|4
6247659|NCT01920061|9933751|FG019|Overall Study|Lost to Follow-up|3
6247660|NCT01920061|9933732|FG000|Overall Study|Other|1
6247661|NCT01920061|9933733|FG001|Overall Study|Other|1
6247662|NCT01920061|9933734|FG002|Overall Study|Other|2
6247663|NCT01920061|9933735|FG003|Overall Study|Other|1
6247664|NCT01920061|9933736|FG004|Overall Study|Other|0
6247665|NCT01920061|9933737|FG005|Overall Study|Other|1
6247666|NCT01920061|9933738|FG006|Overall Study|Other|0
6247667|NCT01920061|9933739|FG007|Overall Study|Other|0
6247668|NCT01920061|9933740|FG008|Overall Study|Other|0
6247669|NCT01920061|9933741|FG009|Overall Study|Other|1
6247670|NCT01920061|9933742|FG010|Overall Study|Other|1
6247671|NCT01920061|9933743|FG011|Overall Study|Other|2
6247672|NCT01920061|9933744|FG012|Overall Study|Other|1
6247673|NCT01920061|9933745|FG013|Overall Study|Other|4
6247674|NCT01920061|9933746|FG014|Overall Study|Other|0
6247675|NCT01920061|9933747|FG015|Overall Study|Other|1
6247676|NCT01920061|9933748|FG016|Overall Study|Other|1
6247677|NCT01920061|9933749|FG017|Overall Study|Other|0
6247678|NCT01920061|9933750|FG018|Overall Study|Other|1
6247679|NCT01920061|9933751|FG019|Overall Study|Other|1
6247680|NCT01920061|9933732|FG000|Overall Study|Participant refused further follow-up|0
6247681|NCT01920061|9933733|FG001|Overall Study|Participant refused further follow-up|0
6247682|NCT01920061|9933734|FG002|Overall Study|Participant refused further follow-up|0
6247683|NCT01920061|9933735|FG003|Overall Study|Participant refused further follow-up|0
6247684|NCT01920061|9933736|FG004|Overall Study|Participant refused further follow-up|1
6247685|NCT01920061|9933737|FG005|Overall Study|Participant refused further follow-up|1
6247686|NCT01920061|9933738|FG006|Overall Study|Participant refused further follow-up|0
6247687|NCT01920061|9933739|FG007|Overall Study|Participant refused further follow-up|0
6247688|NCT01920061|9933740|FG008|Overall Study|Participant refused further follow-up|1
6247689|NCT01920061|9933741|FG009|Overall Study|Participant refused further follow-up|0
6247690|NCT01920061|9933742|FG010|Overall Study|Participant refused further follow-up|1
6247691|NCT01920061|9933743|FG011|Overall Study|Participant refused further follow-up|0
6247692|NCT01920061|9933744|FG012|Overall Study|Participant refused further follow-up|1
6247693|NCT01920061|9933745|FG013|Overall Study|Participant refused further follow-up|0
6247694|NCT01920061|9933746|FG014|Overall Study|Participant refused further follow-up|1
6247695|NCT01920061|9933747|FG015|Overall Study|Participant refused further follow-up|2
6247696|NCT01920061|9933748|FG016|Overall Study|Participant refused further follow-up|1
6247697|NCT01920061|9933749|FG017|Overall Study|Participant refused further follow-up|1
6247698|NCT01920061|9933750|FG018|Overall Study|Participant refused further follow-up|0
6247699|NCT01920061|9933751|FG019|Overall Study|Participant refused further follow-up|0
6247700|NCT01920152|9933816|FG000|Overall Study|Withdrawal by Subject|1
6247701|NCT01920152|9933817|FG001|Overall Study|Withdrawal by Subject|2
6247702|NCT01920178|9933825|FG000|Overall Study|Lost to Follow-up|2
6247703|NCT01920178|9933826|FG001|Overall Study|Lost to Follow-up|1
6247704|NCT01920477|9933847|FG000|Overall Study|Adverse Event|0
6247705|NCT01920477|9933848|FG001|Overall Study|Adverse Event|1
6247706|NCT01920477|9933847|FG000|Overall Study|Lack of Efficacy|1
6247707|NCT01920477|9933848|FG001|Overall Study|Lack of Efficacy|0
6247708|NCT01920477|9933847|FG000|Overall Study|Study closed/terminated|14
6247709|NCT01920477|9933848|FG001|Overall Study|Study closed/terminated|15
6247710|NCT01920477|9933847|FG000|Overall Study|Withdrawal by Subject|0
6247711|NCT01920477|9933848|FG001|Overall Study|Withdrawal by Subject|1
6247712|NCT01920555|9933859|FG000|Overall Study|Physician Decision|1
6247713|NCT01920555|9933860|FG001|Overall Study|Physician Decision|2
6247714|NCT01920555|9933861|FG002|Overall Study|Physician Decision|1
6247715|NCT01920555|9933862|FG003|Overall Study|Physician Decision|2
6247716|NCT01920555|9933863|FG004|Overall Study|Physician Decision|0
6247717|NCT01920555|9933859|FG000|Overall Study|Lack of Efficacy|2
6247718|NCT01920555|9933860|FG001|Overall Study|Lack of Efficacy|0
6247719|NCT01920555|9933861|FG002|Overall Study|Lack of Efficacy|0
6247720|NCT01920555|9933862|FG003|Overall Study|Lack of Efficacy|0
6247721|NCT01920555|9933863|FG004|Overall Study|Lack of Efficacy|0
6247722|NCT01920555|9933859|FG000|Overall Study|Travel Difficulties|1
6247723|NCT01920555|9933860|FG001|Overall Study|Travel Difficulties|1
6247724|NCT01920555|9933861|FG002|Overall Study|Travel Difficulties|0
6247725|NCT01920555|9933862|FG003|Overall Study|Travel Difficulties|0
6247726|NCT01920555|9933863|FG004|Overall Study|Travel Difficulties|1
6247727|NCT01920555|9933859|FG000|Overall Study|Lost to Follow-up|0
6247728|NCT01920555|9933860|FG001|Overall Study|Lost to Follow-up|1
6247729|NCT01920555|9933861|FG002|Overall Study|Lost to Follow-up|0
6247730|NCT01920555|9933862|FG003|Overall Study|Lost to Follow-up|1
6247731|NCT01920555|9933863|FG004|Overall Study|Lost to Follow-up|0
6247732|NCT01920568|9933877|FG000|Overall Study|Adverse Event|27
6247733|NCT01920568|9933878|FG001|Overall Study|Adverse Event|8
6247734|NCT01920568|9933877|FG000|Overall Study|Protocol Violation|5
6247735|NCT01920568|9933878|FG001|Overall Study|Protocol Violation|3
6247736|NCT01920568|9933877|FG000|Overall Study|Lost to Follow-up|2
6247737|NCT01920568|9933878|FG001|Overall Study|Lost to Follow-up|2
6247738|NCT01920568|9933877|FG000|Overall Study|Physician Decision|13
6247739|NCT01920568|9933878|FG001|Overall Study|Physician Decision|4
6247740|NCT01920568|9933877|FG000|Overall Study|Withdrawal by Subject|79
6247741|NCT01920568|9933878|FG001|Overall Study|Withdrawal by Subject|55
6247742|NCT01920568|9933877|FG000|Overall Study|Death due to disease progression|25
6247743|NCT01920568|9933878|FG001|Overall Study|Death due to disease progression|12
6247744|NCT01920594|9933887|FG000|Overall Study|Adverse Event|4
6247745|NCT01920594|9933888|FG001|Overall Study|Adverse Event|2
6247746|NCT01920594|9933887|FG000|Overall Study|Lost to Follow-up|1
6247747|NCT01920594|9933888|FG001|Overall Study|Lost to Follow-up|0
6247748|NCT01920594|9933887|FG000|Overall Study|Recovery|2
6247749|NCT01920594|9933888|FG001|Overall Study|Recovery|0
6247750|NCT01920594|9933887|FG000|Overall Study|Investigator discretion|0
6247751|NCT01920594|9933888|FG001|Overall Study|Investigator discretion|1
6247752|NCT01920711|9933896|FG000|Overall Study|Death|347
6247753|NCT01920711|9933897|FG001|Overall Study|Death|356
6247754|NCT01920711|9933896|FG000|Overall Study|Lost to Follow-up|13
6247755|NCT01920711|9933897|FG001|Overall Study|Lost to Follow-up|14
6247756|NCT01920711|9933896|FG000|Overall Study|Withdrawal by Subject|4
6247757|NCT01920711|9933897|FG001|Overall Study|Withdrawal by Subject|3
6247758|NCT01920854|9933924|FG000|Overall Study|Withdrawal by Subject|1
6247759|NCT01920854|9933925|FG001|Overall Study|Withdrawal by Subject|0
6247760|NCT01920854|9933926|FG002|Overall Study|Withdrawal by Subject|0
6247761|NCT01920854|9933927|FG003|Overall Study|Withdrawal by Subject|0
6247762|NCT01920854|9933928|FG004|Overall Study|Withdrawal by Subject|1
6247763|NCT01920854|9933929|FG005|Overall Study|Withdrawal by Subject|0
6247764|NCT01920854|9933930|FG006|Overall Study|Withdrawal by Subject|1
6247765|NCT01920893|9933967|FG000|Overall Study|Adverse Event|5
6247766|NCT01920893|9933968|FG001|Overall Study|Adverse Event|2
6247767|NCT01920893|9933967|FG000|Overall Study|Lack of Efficacy|2
6247768|NCT01920893|9933968|FG001|Overall Study|Lack of Efficacy|0
6247769|NCT01920958|9933975|FG000|Overall Study|Did Not Fulfill Inclusion Criteria|5
6247770|NCT01921101|9933981|FG000|Overall Study|Death|16
6247771|NCT01921101|9933982|FG001|Overall Study|Death|6
6247772|NCT01921179|9933990|FG000|5 Week Randomized GOALS vs EDU Training|Withdrawal by Subject|3
6247773|NCT01921179|9933991|FG001|5 Week Randomized GOALS vs EDU Training|Withdrawal by Subject|3
6247774|NCT01921179|9933990|FG000|Long Term Follow-up After GOALS Training|Lost to Follow-up|2
6247775|NCT01921179|9933991|FG001|Long Term Follow-up After GOALS Training|Lost to Follow-up|0
6247776|NCT01921205|9934000|FG000|Overall Study|Adverse Event|12
6247777|NCT01921205|9934001|FG001|Overall Study|Adverse Event|7
6247778|NCT01921205|9934000|FG000|Overall Study|Lack of Efficacy|1
6247779|NCT01921205|9934001|FG001|Overall Study|Lack of Efficacy|0
6247780|NCT01921205|9934000|FG000|Overall Study|Protocol Violation|1
6247781|NCT01921205|9934001|FG001|Overall Study|Protocol Violation|3
6247782|NCT01921205|9934000|FG000|Overall Study|Lost to Follow-up|1
6247783|NCT01921205|9934001|FG001|Overall Study|Lost to Follow-up|1
6247784|NCT01921205|9934000|FG000|Overall Study|Withdrawal by Subject|6
6247785|NCT01921205|9934001|FG001|Overall Study|Withdrawal by Subject|5
6247786|NCT01921205|9934000|FG000|Overall Study|Use Of Prohibited Medication|0
6247787|NCT01921205|9934001|FG001|Overall Study|Use Of Prohibited Medication|1
6247788|NCT01921205|9934000|FG000|Overall Study|The Excessive Use Of Rescue Medication|0
6247789|NCT01921205|9934001|FG001|Overall Study|The Excessive Use Of Rescue Medication|1
6247790|NCT01921205|9934000|FG000|Overall Study|Non Compliance Of The Parent|0
6247791|NCT01921205|9934001|FG001|Overall Study|Non Compliance Of The Parent|1
6247792|NCT01921205|9934000|FG000|Overall Study|Non Compliance Of Child|0
6247793|NCT01921205|9934001|FG001|Overall Study|Non Compliance Of Child|1
6247794|NCT01921257|9934007|FG000|Overall Study|Adverse Event|1
6247795|NCT01921257|9934007|FG000|Overall Study|Protocol Violation|1
6247796|NCT01921257|9934007|FG000|Overall Study|Withdrawal by Subject|1
6247797|NCT01921270|9934012|FG000|Overall Study|Withdrawal by Subject|1
6247798|NCT01921348|9934031|FG000|Overall Study|Withdrawal by Subject|1
6247799|NCT01921348|9934032|FG001|Overall Study|Withdrawal by Subject|0
6247800|NCT01921348|9934031|FG000|Overall Study|Lost to Follow-up|0
6247801|NCT01921348|9934032|FG001|Overall Study|Lost to Follow-up|2
6247802|NCT01921387|9934038|FG000|Overall Study|Adverse Event|1
6247803|NCT01921517|9934049|FG000|Overall Study|Lost to Follow-up|5
6247804|NCT01921517|9934050|FG001|Overall Study|Lost to Follow-up|0
6247805|NCT01921517|9934049|FG000|Overall Study|Newly diagnosed health concern|2
6247806|NCT01921517|9934050|FG001|Overall Study|Newly diagnosed health concern|0
6247807|NCT01921517|9934049|FG000|Overall Study|Physician Decision|0
6247808|NCT01921517|9934050|FG001|Overall Study|Physician Decision|2
6247809|NCT01921517|9934049|FG000|Overall Study|Withdrawal by Subject|7
6247810|NCT01921517|9934050|FG001|Overall Study|Withdrawal by Subject|3
6247811|NCT01921517|9934049|FG000|Overall Study|Subject missed final imaging|1
6247812|NCT01921517|9934050|FG001|Overall Study|Subject missed final imaging|4
6247813|NCT01921829|9934077|FG000|Overall Study|Withdrawal by Subject|0
6247814|NCT01921829|9934078|FG001|Overall Study|Withdrawal by Subject|1
6247815|NCT01922011|9934111|FG000|Overall Study|Protocol Violation|0
6247816|NCT01922011|9934112|FG001|Overall Study|Protocol Violation|1
6247817|NCT01922011|9934111|FG000|Overall Study|Physician Decision|0
6247818|NCT01922011|9934112|FG001|Overall Study|Physician Decision|1
6247819|NCT01922011|9934111|FG000|Overall Study|Parent/Guardian Decision|3
6247820|NCT01922011|9934112|FG001|Overall Study|Parent/Guardian Decision|0
6247821|NCT01922011|9934111|FG000|Overall Study|Lost to Follow-up|0
6247822|NCT01922011|9934112|FG001|Overall Study|Lost to Follow-up|1
6247823|NCT01922011|9934111|FG000|Overall Study|Missed Test-of-Cure Visit|0
6247824|NCT01922011|9934112|FG001|Overall Study|Missed Test-of-Cure Visit|2
6247825|NCT01922011|9934111|FG000|Overall Study|Not Treated|1
6247826|NCT01922011|9934112|FG001|Overall Study|Not Treated|0
6189338|NCT01399047|9844562|FG000|Overall Study|Withdrawal by Subject|0
6189339|NCT01399047|9844563|FG001|Overall Study|Withdrawal by Subject|1
6189340|NCT01399099|9844571|FG000|Overall Study|Lost to Follow-up|11
6189341|NCT01399099|9844571|FG000|Overall Study|Physician Decision|1
6189342|NCT01399099|9844571|FG000|Overall Study|Protocol Violation|1
6189343|NCT01399099|9844571|FG000|Overall Study|Skin Irritation|13
6189344|NCT01399099|9844571|FG000|Overall Study|Infection|1
6189345|NCT01399099|9844571|FG000|Overall Study|Miscellaneous|4
6189346|NCT01399125|9844578|FG000|Overall Study|Adverse Event|32
6189347|NCT01399125|9844579|FG001|Overall Study|Adverse Event|30
6189348|NCT01399125|9844578|FG000|Overall Study|Abnormal Lab values|0
6189349|NCT01399125|9844579|FG001|Overall Study|Abnormal Lab values|1
6189350|NCT01399125|9844578|FG000|Overall Study|Unsatisfactory Therapeutic Effect|0
6189351|NCT01399125|9844579|FG001|Overall Study|Unsatisfactory Therapeutic Effect|4
6189352|NCT01399125|9844578|FG000|Overall Study|Withdrawal by Subject|5
6189353|NCT01399125|9844579|FG001|Overall Study|Withdrawal by Subject|8
6189354|NCT01399125|9844578|FG000|Overall Study|Lost to Follow-up|2
6189355|NCT01399125|9844579|FG001|Overall Study|Lost to Follow-up|3
6189356|NCT01399125|9844578|FG000|Overall Study|Administrative Problems|7
6189357|NCT01399125|9844579|FG001|Overall Study|Administrative Problems|11
6189358|NCT01399125|9844578|FG000|Overall Study|Death|0
6189359|NCT01399125|9844579|FG001|Overall Study|Death|1
6189360|NCT01399125|9844578|FG000|Overall Study|Protocol Deviation|5
6189361|NCT01399125|9844579|FG001|Overall Study|Protocol Deviation|2
6189362|NCT01399190|9844585|FG000|Overall Study|Not Eligible for Final Analysis|5
6189363|NCT01399190|9844585|FG000|Overall Study|Adverse Event|8
6189364|NCT01399190|9844585|FG000|Overall Study|Participant's Request|5
6189365|NCT01399190|9844585|FG000|Overall Study|Physician Decision|2
6189366|NCT01399372|9844606|FG000|Overall Study|Protocol Violation|3
6189367|NCT01399372|9844607|FG001|Overall Study|Protocol Violation|1
6189368|NCT01399593|9844615|FG000|Overall Study|Physician Decision|1
6189369|NCT01399593|9844616|FG001|Overall Study|Physician Decision|0
6189370|NCT01399593|9844615|FG000|Overall Study|Adverse Event|1
6189371|NCT01399593|9844616|FG001|Overall Study|Adverse Event|0
6189372|NCT01399593|9844615|FG000|Overall Study|Death|1
6189373|NCT01399593|9844616|FG001|Overall Study|Death|1
6189374|NCT01399593|9844615|FG000|Overall Study|Transplantectomy|0
6189375|NCT01399593|9844616|FG001|Overall Study|Transplantectomy|1
6189376|NCT01399619|9844624|FG000|Overall Study|Adverse Event|10
6189377|NCT01399619|9844625|FG001|Overall Study|Adverse Event|0
6189378|NCT01399619|9844626|FG002|Overall Study|Adverse Event|4
6189379|NCT01399619|9844627|FG003|Overall Study|Adverse Event|10
6189380|NCT01399619|9844624|FG000|Overall Study|Lack of Efficacy|9
6189381|NCT01399619|9844625|FG001|Overall Study|Lack of Efficacy|0
6189382|NCT01399619|9844626|FG002|Overall Study|Lack of Efficacy|5
6189383|NCT01399619|9844627|FG003|Overall Study|Lack of Efficacy|0
6189384|NCT01399619|9844624|FG000|Overall Study|Withdrawal by Subject|6
6189385|NCT01399619|9844625|FG001|Overall Study|Withdrawal by Subject|0
6189386|NCT01399619|9844626|FG002|Overall Study|Withdrawal by Subject|3
6189387|NCT01399619|9844627|FG003|Overall Study|Withdrawal by Subject|4
6189388|NCT01399619|9844624|FG000|Overall Study|Protocol Violation|0
6189389|NCT01399619|9844625|FG001|Overall Study|Protocol Violation|0
6189390|NCT01399619|9844626|FG002|Overall Study|Protocol Violation|0
6247827|NCT01922011|9934111|FG000|Overall Study|Lack of willing home health agency|1
6247828|NCT01922011|9934112|FG001|Overall Study|Lack of willing home health agency|0
6247829|NCT01922011|9934111|FG000|Overall Study|Randomized in error|1
6247830|NCT01922011|9934112|FG001|Overall Study|Randomized in error|0
6247831|NCT01922037|9934135|FG000|Overall Study|Withdrawal by Subject|2
6247832|NCT01922037|9934136|FG001|Overall Study|Withdrawal by Subject|44
6247833|NCT01922037|9934135|FG000|Overall Study|Adverse Event|1
6247834|NCT01922037|9934136|FG001|Overall Study|Adverse Event|7
6189391|NCT01399619|9844627|FG003|Overall Study|Protocol Violation|1
6189392|NCT01399619|9844624|FG000|Overall Study|Not treated|0
6189393|NCT01399619|9844625|FG001|Overall Study|Not treated|0
6189394|NCT01399619|9844626|FG002|Overall Study|Not treated|0
6189395|NCT01399619|9844627|FG003|Overall Study|Not treated|2
6189396|NCT01399697|9844645|FG000|Overall Study|Adverse Event|13
6189397|NCT01399697|9844646|FG001|Overall Study|Adverse Event|3
6189398|NCT01399697|9844647|FG002|Overall Study|Adverse Event|1
6189399|NCT01399697|9844645|FG000|Overall Study|Lost to Follow-up|2
6189400|NCT01399697|9844646|FG001|Overall Study|Lost to Follow-up|0
6189401|NCT01399697|9844647|FG002|Overall Study|Lost to Follow-up|0
6247835|NCT01922037|9934135|FG000|Overall Study|Death|0
6247836|NCT01922037|9934136|FG001|Overall Study|Death|5
6247837|NCT01922037|9934135|FG000|Overall Study|Pregnancy|0
6247838|NCT01922037|9934136|FG001|Overall Study|Pregnancy|2
6247839|NCT01922037|9934135|FG000|Overall Study|Participant non-compliance|4
6247840|NCT01922037|9934136|FG001|Overall Study|Participant non-compliance|46
6247841|NCT01922037|9934135|FG000|Overall Study|Investigator/Sponsor decision|1
6247842|NCT01922037|9934136|FG001|Overall Study|Investigator/Sponsor decision|4
6247843|NCT01922037|9934135|FG000|Overall Study|Other unspecified|2
6247844|NCT01922037|9934136|FG001|Overall Study|Other unspecified|66
6247845|NCT01922089|9934203|FG000|Overall Study|Adverse Event|18
6247846|NCT01922089|9934204|FG001|Overall Study|Adverse Event|13
6247847|NCT01922089|9934203|FG000|Overall Study|Protocol Deviation|10
6247848|NCT01922089|9934204|FG001|Overall Study|Protocol Deviation|7
6247849|NCT01922089|9934203|FG000|Overall Study|Withdrawal by Subject|3
6247850|NCT01922089|9934204|FG001|Overall Study|Withdrawal by Subject|4
6247851|NCT01922089|9934203|FG000|Overall Study|administrative problems|4
6247852|NCT01922089|9934204|FG001|Overall Study|administrative problems|1
6247853|NCT01922089|9934203|FG000|Overall Study|Physician Decision|2
6247854|NCT01922089|9934204|FG001|Overall Study|Physician Decision|3
6247855|NCT01922089|9934203|FG000|Overall Study|Death|2
6247856|NCT01922089|9934204|FG001|Overall Study|Death|1
6247857|NCT01922089|9934203|FG000|Overall Study|Lost to Follow-up|0
6247858|NCT01922089|9934204|FG001|Overall Study|Lost to Follow-up|1
6247859|NCT01922102|9934213|FG000|Overall Study|Withdrawal by Subject|7
6247860|NCT01922102|9934214|FG001|Overall Study|Withdrawal by Subject|3
6247861|NCT01922102|9934215|FG002|Overall Study|Withdrawal by Subject|7
6247862|NCT01922102|9934213|FG000|Overall Study|Physician Decision|0
6247863|NCT01922102|9934214|FG001|Overall Study|Physician Decision|2
6247864|NCT01922102|9934215|FG002|Overall Study|Physician Decision|1
6247865|NCT01922102|9934213|FG000|Overall Study|Adverse Event|1
6247866|NCT01922102|9934214|FG001|Overall Study|Adverse Event|2
6247867|NCT01922102|9934215|FG002|Overall Study|Adverse Event|0
6247868|NCT01922102|9934213|FG000|Overall Study|Lost to Follow-up|1
6247869|NCT01922102|9934214|FG001|Overall Study|Lost to Follow-up|0
6247870|NCT01922102|9934215|FG002|Overall Study|Lost to Follow-up|0
6247871|NCT01922102|9934213|FG000|Overall Study|Administrative problems|0
6247872|NCT01922102|9934214|FG001|Overall Study|Administrative problems|2
6247873|NCT01922102|9934215|FG002|Overall Study|Administrative problems|0
6247874|NCT01922258|9934242|FG000|Overall Study|Lost to Follow-up|1
6247875|NCT01922258|9934243|FG001|Overall Study|Lost to Follow-up|1
6247876|NCT01922258|9934242|FG000|Overall Study|Adverse Event|9
6247877|NCT01922258|9934243|FG001|Overall Study|Adverse Event|2
6247878|NCT01922258|9934242|FG000|Overall Study|Met Withdrawal Criteria|0
6247879|NCT01922258|9934243|FG001|Overall Study|Met Withdrawal Criteria|4
6247880|NCT01922258|9934242|FG000|Overall Study|Withdrawn by the Investigator|1
6247881|NCT01922258|9934243|FG001|Overall Study|Withdrawn by the Investigator|4
6247882|NCT01922258|9934242|FG000|Overall Study|Withdrawal by participant|5
6247883|NCT01922258|9934243|FG001|Overall Study|Withdrawal by participant|5
6247884|NCT01922271|9934251|FG000|WASHOUT Period|Withdrawal by Subject|1
6247885|NCT01922271|9934252|FG001|WASHOUT Period|Withdrawal by Subject|0
6247886|NCT01922349|9934275|FG000|Multiple Rising Dose (MRD) Period|Adverse Event|0
6247887|NCT01922349|9934276|FG001|Multiple Rising Dose (MRD) Period|Adverse Event|0
6247888|NCT01922349|9934277|FG002|Multiple Rising Dose (MRD) Period|Adverse Event|0
6247889|NCT01922349|9934278|FG003|Multiple Rising Dose (MRD) Period|Adverse Event|1
6247890|NCT01922739|9934314|FG000|Titration/Adjustment Period|Adverse Event|3
6086188|NCT00659425|9695994|FG005|Overall Study|Disease progression|2
6086189|NCT00659425|9695995|FG006|Overall Study|Disease progression|4
6086190|NCT00659425|9695996|FG007|Overall Study|Disease progression|3
6086191|NCT00659425|9695997|FG008|Overall Study|Disease progression|5
6086192|NCT00659425|9695998|FG009|Overall Study|Disease progression|3
6086193|NCT00659425|9695989|FG000|Overall Study|Death|0
6086194|NCT00659425|9695990|FG001|Overall Study|Death|0
6086195|NCT00659425|9695991|FG002|Overall Study|Death|0
6086196|NCT00659425|9695992|FG003|Overall Study|Death|1
6086197|NCT00659425|9695993|FG004|Overall Study|Death|0
6189402|NCT01399697|9844645|FG000|Overall Study|Withdrawal by Subject|8
6189403|NCT01399697|9844646|FG001|Overall Study|Withdrawal by Subject|0
6189404|NCT01399697|9844647|FG002|Overall Study|Withdrawal by Subject|0
6189405|NCT01399697|9844645|FG000|Overall Study|Investigator Decisión|1
6189406|NCT01399697|9844646|FG001|Overall Study|Investigator Decisión|0
6189407|NCT01399697|9844647|FG002|Overall Study|Investigator Decisión|2
6189408|NCT01399697|9844645|FG000|Overall Study|Lack of Efficacy|9
6189409|NCT01399697|9844646|FG001|Overall Study|Lack of Efficacy|0
6189410|NCT01399697|9844647|FG002|Overall Study|Lack of Efficacy|1
6189411|NCT01399697|9844645|FG000|Overall Study|Protocol Violation|2
6189412|NCT01399697|9844646|FG001|Overall Study|Protocol Violation|0
6189413|NCT01399697|9844647|FG002|Overall Study|Protocol Violation|0
6189414|NCT01399697|9844645|FG000|Overall Study|Non-Compliant|1
6086198|NCT00659425|9695994|FG005|Overall Study|Death|0
6086199|NCT00659425|9695995|FG006|Overall Study|Death|1
6189415|NCT01399697|9844646|FG001|Overall Study|Non-Compliant|0
6247891|NCT01922739|9934314|FG000|Titration/Adjustment Period|Withdrawal by Subject|5
6247892|NCT01922739|9934314|FG000|Titration/Adjustment Period|Lost to Follow-up|1
6247893|NCT01922739|9934314|FG000|Titration/Adjustment Period|Lack of Efficacy|3
6247894|NCT01922739|9934314|FG000|Open-label Treatment Period|Adverse Event|6
6247895|NCT01922739|9934314|FG000|Open-label Treatment Period|Withdrawal by Subject|14
6247896|NCT01922739|9934314|FG000|Open-label Treatment Period|Noncompliance to study medication|3
6247897|NCT01922739|9934314|FG000|Open-label Treatment Period|Protocol Violation|5
6247898|NCT01922739|9934314|FG000|Open-label Treatment Period|Pregnancy|1
6247899|NCT01922739|9934314|FG000|Open-label Treatment Period|Noncompliance to study procedures|1
6247900|NCT01922739|9934314|FG000|Open-label Treatment Period|Lost to Follow-up|2
6247901|NCT01922739|9934314|FG000|Open-label Treatment Period|Physician Decision|1
6247902|NCT01922739|9934314|FG000|Open-label Treatment Period|Sponsor request - investigator leaving|1
6247903|NCT01922934|9934332|FG000|Eligible Patients|Death|0
6247904|NCT01922934|9934333|FG001|Eligible Patients|Death|7
6247905|NCT01922934|9934332|FG000|Eligible Patients|Physician Decision|17
6247906|NCT01922934|9934333|FG001|Eligible Patients|Physician Decision|0
6247907|NCT01922934|9934332|FG000|Eligible Patients|Did not meet inclusion criteria|36
6247908|NCT01922934|9934333|FG001|Eligible Patients|Did not meet inclusion criteria|81
6247909|NCT01922934|9934332|FG000|Visit 0 - Patient Contacted & Consented|Patient declined to participate|169
6247910|NCT01922934|9934333|FG001|Visit 0 - Patient Contacted & Consented|Patient declined to participate|0
6247911|NCT01922934|9934332|FG000|Visit 0 - Patient Contacted & Consented|No response or could not reach|66
6247912|NCT01922934|9934333|FG001|Visit 0 - Patient Contacted & Consented|No response or could not reach|0
6247913|NCT01922934|9934332|FG000|Visit 1- Weight Measured|Did not have weight recorded (visit 1)|21
6247914|NCT01922934|9934333|FG001|Visit 1- Weight Measured|Did not have weight recorded (visit 1)|1284
6247915|NCT01923181|9934368|FG000|Overall Study|Protocol Violation|2
6247916|NCT01923181|9934369|FG001|Overall Study|Protocol Violation|2
6247917|NCT01923181|9934370|FG002|Overall Study|Protocol Violation|0
6247918|NCT01923181|9934371|FG003|Overall Study|Protocol Violation|2
6247919|NCT01923181|9934372|FG004|Overall Study|Protocol Violation|2
6247920|NCT01923181|9934373|FG005|Overall Study|Protocol Violation|1
6086200|NCT00659425|9695996|FG007|Overall Study|Death|0
6086201|NCT00659425|9695997|FG008|Overall Study|Death|0
6086202|NCT00659425|9695998|FG009|Overall Study|Death|0
6086203|NCT00659425|9695989|FG000|Overall Study|Adverse Event|0
6247921|NCT01923181|9934374|FG006|Overall Study|Protocol Violation|1
6247922|NCT01923181|9934375|FG007|Overall Study|Protocol Violation|2
6247923|NCT01923181|9934376|FG008|Overall Study|Protocol Violation|1
6247924|NCT01923181|9934368|FG000|Overall Study|Withdrawal by Subject|0
6247925|NCT01923181|9934369|FG001|Overall Study|Withdrawal by Subject|1
6247926|NCT01923181|9934370|FG002|Overall Study|Withdrawal by Subject|0
6247927|NCT01923181|9934371|FG003|Overall Study|Withdrawal by Subject|1
6247928|NCT01923181|9934372|FG004|Overall Study|Withdrawal by Subject|4
6247929|NCT01923181|9934373|FG005|Overall Study|Withdrawal by Subject|2
6247930|NCT01923181|9934374|FG006|Overall Study|Withdrawal by Subject|4
6247931|NCT01923181|9934375|FG007|Overall Study|Withdrawal by Subject|3
6247932|NCT01923181|9934376|FG008|Overall Study|Withdrawal by Subject|1
6247933|NCT01923181|9934368|FG000|Overall Study|Other|1
6247934|NCT01923181|9934369|FG001|Overall Study|Other|0
6247935|NCT01923181|9934370|FG002|Overall Study|Other|0
6247936|NCT01923181|9934371|FG003|Overall Study|Other|1
6247937|NCT01923181|9934372|FG004|Overall Study|Other|0
6247938|NCT01923181|9934373|FG005|Overall Study|Other|0
6247939|NCT01923181|9934374|FG006|Overall Study|Other|0
6247940|NCT01923181|9934375|FG007|Overall Study|Other|0
6247941|NCT01923181|9934376|FG008|Overall Study|Other|0
6247942|NCT01923181|9934368|FG000|Overall Study|Lost to Follow-up|0
6247943|NCT01923181|9934369|FG001|Overall Study|Lost to Follow-up|3
6247944|NCT01923181|9934370|FG002|Overall Study|Lost to Follow-up|2
6247945|NCT01923181|9934371|FG003|Overall Study|Lost to Follow-up|1
6247946|NCT01923181|9934372|FG004|Overall Study|Lost to Follow-up|2
6247947|NCT01923181|9934373|FG005|Overall Study|Lost to Follow-up|1
6247948|NCT01923181|9934374|FG006|Overall Study|Lost to Follow-up|3
6247949|NCT01923181|9934375|FG007|Overall Study|Lost to Follow-up|3
6247950|NCT01923181|9934376|FG008|Overall Study|Lost to Follow-up|1
6247951|NCT01923285|9934401|FG000|Overall Study|Withdrawal by Subject|7
6247952|NCT01923285|9934402|FG001|Overall Study|Withdrawal by Subject|6
6247953|NCT01923311|9934410|FG000|Overall Study|Pregnancy|1
6247954|NCT01923311|9934411|FG001|Overall Study|Pregnancy|0
6247955|NCT01923311|9934410|FG000|Overall Study|Investigator's Discretion|1
6247956|NCT01923311|9934411|FG001|Overall Study|Investigator's Discretion|0
6247957|NCT01923311|9934410|FG000|Overall Study|Non-Compliance with Study Drug|2
6247958|NCT01923311|9934411|FG001|Overall Study|Non-Compliance with Study Drug|1
6247959|NCT01923311|9934410|FG000|Overall Study|Withdrew Consent|1
6247960|NCT01923311|9934411|FG001|Overall Study|Withdrew Consent|0
6247961|NCT01923311|9934410|FG000|Overall Study|Study Terminated by Sponsor|12
6247962|NCT01923311|9934411|FG001|Overall Study|Study Terminated by Sponsor|0
6247963|NCT01923363|9934418|FG000|Overall Study|Protocol Violation|1
6247964|NCT01923389|9934424|FG000|Overall Study|Protocol Violation|1
6247965|NCT01923389|9934425|FG001|Overall Study|Protocol Violation|0
6247966|NCT01923428|9934436|FG000|Overall Study|Adverse Event|8
6247967|NCT01923428|9934437|FG001|Overall Study|Adverse Event|6
6247968|NCT01923428|9934438|FG002|Overall Study|Adverse Event|3
6247969|NCT01923428|9934439|FG003|Overall Study|Adverse Event|3
6247970|NCT01923428|9934436|FG000|Overall Study|Withdrawal by Subject|5
6247971|NCT01923428|9934437|FG001|Overall Study|Withdrawal by Subject|3
6086204|NCT00659425|9695990|FG001|Overall Study|Adverse Event|0
6086205|NCT00659425|9695991|FG002|Overall Study|Adverse Event|0
6247972|NCT01923428|9934438|FG002|Overall Study|Withdrawal by Subject|0
6247973|NCT01923428|9934439|FG003|Overall Study|Withdrawal by Subject|4
6247974|NCT01923428|9934436|FG000|Overall Study|Lost to Follow-up|2
6247975|NCT01923428|9934437|FG001|Overall Study|Lost to Follow-up|1
6247976|NCT01923428|9934438|FG002|Overall Study|Lost to Follow-up|5
6247977|NCT01923428|9934439|FG003|Overall Study|Lost to Follow-up|0
6247978|NCT01923428|9934436|FG000|Overall Study|Protocol Violation|3
6247979|NCT01923428|9934437|FG001|Overall Study|Protocol Violation|0
6247980|NCT01923428|9934438|FG002|Overall Study|Protocol Violation|2
6247981|NCT01923428|9934439|FG003|Overall Study|Protocol Violation|1
6247982|NCT01923428|9934436|FG000|Overall Study|Non Compliance to treatment|1
6247983|NCT01923428|9934437|FG001|Overall Study|Non Compliance to treatment|2
6247984|NCT01923428|9934438|FG002|Overall Study|Non Compliance to treatment|0
6247985|NCT01923428|9934439|FG003|Overall Study|Non Compliance to treatment|1
6247986|NCT01923428|9934436|FG000|Overall Study|Lack of Efficacy|0
6247987|NCT01923428|9934437|FG001|Overall Study|Lack of Efficacy|0
6247988|NCT01923428|9934438|FG002|Overall Study|Lack of Efficacy|1
6247989|NCT01923428|9934439|FG003|Overall Study|Lack of Efficacy|1
6247990|NCT01923467|9934449|FG000|Overall Study|Lost to Follow-up|62
6247991|NCT01923467|9934449|FG000|Overall Study|Subject non-interest|479
6247992|NCT01923740|9934455|FG000|Overall Study|Lost to Follow-up|4
6247993|NCT01923740|9934456|FG001|Overall Study|Lost to Follow-up|9
6247994|NCT01923740|9934455|FG000|Overall Study|Withdrawal by Subject|2
6189416|NCT01399697|9844647|FG002|Overall Study|Non-Compliant|0
6247995|NCT01923740|9934456|FG001|Overall Study|Withdrawal by Subject|0
6247996|NCT01923896|9934473|FG000|Overall Study|Adverse Event|1
6247997|NCT01923896|9934474|FG001|Overall Study|Adverse Event|0
6247998|NCT01924182|9934499|FG000|Overall Study|Withdrawal by Subject|1
6247999|NCT01924182|9934500|FG001|Overall Study|Withdrawal by Subject|0
6248000|NCT01924299|9934508|FG000|Period 2|Withdrawal by Subject|1
6248001|NCT01924299|9934509|FG001|Period 2|Withdrawal by Subject|0
6248002|NCT01924299|9934508|FG000|Period 2|Adverse Event|0
6248003|NCT01924299|9934509|FG001|Period 2|Adverse Event|1
6248004|NCT01924364|9934521|FG000|Overall Study|Physician Decision|3
6270665|NCT02155608|9971945|FG000|1a: 4 Week Double Blind Sham Controlled|Lost to Follow-up|0
6270666|NCT02155608|9971946|FG001|1a: 4 Week Double Blind Sham Controlled|Lost to Follow-up|1
6270667|NCT02155608|9971945|FG000|1b: 1 Week Blinded Post Treatment|Lost to Follow-up|1
6189417|NCT01399697|9844645|FG000|Overall Study|Inclusion Error|2
6189418|NCT01399697|9844646|FG001|Overall Study|Inclusion Error|0
6189419|NCT01399697|9844647|FG002|Overall Study|Inclusion Error|0
6270668|NCT02155608|9971946|FG001|1b: 1 Week Blinded Post Treatment|Lost to Follow-up|1
6189420|NCT01399697|9844645|FG000|Overall Study|Positive result for hepatitis B|1
6189421|NCT01399697|9844646|FG001|Overall Study|Positive result for hepatitis B|0
6189422|NCT01399697|9844647|FG002|Overall Study|Positive result for hepatitis B|0
6189423|NCT01399697|9844645|FG000|Overall Study|Clinical RA remission|1
6189424|NCT01399697|9844646|FG001|Overall Study|Clinical RA remission|0
6189425|NCT01399697|9844647|FG002|Overall Study|Clinical RA remission|0
6189426|NCT01399697|9844645|FG000|Overall Study|Sponsor Decision|1
6189427|NCT01399697|9844646|FG001|Overall Study|Sponsor Decision|0
6189428|NCT01399697|9844647|FG002|Overall Study|Sponsor Decision|0
6189429|NCT01399723|9844660|FG000|Overall Study|Lost to Follow-up|0
6189430|NCT01399723|9844661|FG001|Overall Study|Lost to Follow-up|1
6189431|NCT01399736|9844670|FG000|Overall Study|Withdrawal by Subject|4
6189432|NCT01399736|9844671|FG001|Overall Study|Withdrawal by Subject|2
6189433|NCT01399736|9844670|FG000|Overall Study|Lost to Follow-up|0
6189434|NCT01399736|9844671|FG001|Overall Study|Lost to Follow-up|2
6189435|NCT01399788|9844685|FG000|First Intervention Period|Adverse Event|1
6189436|NCT01399788|9844686|FG001|First Intervention Period|Adverse Event|0
6189437|NCT01399905|9844712|FG000|Overall Study|Withdrawal by Subject|1
6189438|NCT01399905|9844713|FG001|Overall Study|Withdrawal by Subject|1
6189439|NCT01400113|9844726|FG000|Overall Study|Withdrawal by Subject|1
6189440|NCT01400113|9844727|FG001|Overall Study|Withdrawal by Subject|1
6270669|NCT02155660|9971962|FG000|Overall Study|Other Reason|8
6270670|NCT02155660|9971963|FG001|Overall Study|Other Reason|6
6270671|NCT02155660|9971964|FG002|Overall Study|Other Reason|10
6270672|NCT02155660|9971965|FG003|Overall Study|Other Reason|10
6270673|NCT02155660|9971962|FG000|Overall Study|Study-specific withdrawal criteria|0
6270674|NCT02155660|9971963|FG001|Overall Study|Study-specific withdrawal criteria|1
6270675|NCT02155660|9971964|FG002|Overall Study|Study-specific withdrawal criteria|1
6248005|NCT01924429|9934547|FG000|Washout Period (2 Weeks)|Withdrawal by Subject|3
6248006|NCT01924429|9934548|FG001|Washout Period (2 Weeks)|Withdrawal by Subject|2
6248007|NCT01924689|9934585|FG000|Overall Study|Death|0
6248008|NCT01924689|9934586|FG001|Overall Study|Death|1
6248009|NCT01924689|9934587|FG002|Overall Study|Death|0
6248010|NCT01924689|9934588|FG003|Overall Study|Death|1
6248011|NCT01924689|9934589|FG004|Overall Study|Death|0
6248012|NCT01924689|9934590|FG005|Overall Study|Death|0
6248013|NCT01924689|9934585|FG000|Overall Study|Disease progression|0
6248014|NCT01924689|9934586|FG001|Overall Study|Disease progression|0
6248015|NCT01924689|9934587|FG002|Overall Study|Disease progression|2
6248016|NCT01924689|9934588|FG003|Overall Study|Disease progression|0
6248017|NCT01924689|9934589|FG004|Overall Study|Disease progression|3
6248018|NCT01924689|9934590|FG005|Overall Study|Disease progression|2
6248019|NCT01924689|9934585|FG000|Overall Study|New therapy or study|3
6248020|NCT01924689|9934586|FG001|Overall Study|New therapy or study|2
6248021|NCT01924689|9934587|FG002|Overall Study|New therapy or study|1
6248022|NCT01924689|9934588|FG003|Overall Study|New therapy or study|4
6248023|NCT01924689|9934589|FG004|Overall Study|New therapy or study|2
6248024|NCT01924689|9934590|FG005|Overall Study|New therapy or study|0
6248025|NCT01924689|9934585|FG000|Overall Study|Withdrawal of consent|0
6248026|NCT01924689|9934586|FG001|Overall Study|Withdrawal of consent|0
6248027|NCT01924689|9934587|FG002|Overall Study|Withdrawal of consent|1
6248028|NCT01924689|9934588|FG003|Overall Study|Withdrawal of consent|1
6248029|NCT01924689|9934589|FG004|Overall Study|Withdrawal of consent|0
6248030|NCT01924689|9934590|FG005|Overall Study|Withdrawal of consent|0
6248031|NCT01924689|9934585|FG000|Overall Study|Other|0
6248032|NCT01924689|9934586|FG001|Overall Study|Other|0
6248033|NCT01924689|9934587|FG002|Overall Study|Other|0
6248034|NCT01924689|9934588|FG003|Overall Study|Other|0
6248035|NCT01924689|9934589|FG004|Overall Study|Other|1
6248036|NCT01924689|9934590|FG005|Overall Study|Other|0
6248037|NCT01924754|9934611|FG000|Overall Study|Lost to Follow-up|1
6248038|NCT01924754|9934612|FG001|Overall Study|Lost to Follow-up|2
6248039|NCT01924754|9934613|FG002|Overall Study|Lost to Follow-up|1
6248040|NCT01924754|9934611|FG000|Overall Study|Pregnancy|0
6248041|NCT01924754|9934612|FG001|Overall Study|Pregnancy|1
6248042|NCT01924754|9934613|FG002|Overall Study|Pregnancy|2
6248043|NCT01924767|9934629|FG000|Overall Study|Adverse Event|1
6248044|NCT01924767|9934630|FG001|Overall Study|Adverse Event|0
6248045|NCT01924767|9934631|FG002|Overall Study|Adverse Event|1
6248046|NCT01924767|9934632|FG003|Overall Study|Adverse Event|0
6248047|NCT01924767|9934633|FG004|Overall Study|Adverse Event|0
6248048|NCT01924806|9934652|FG000|Overall Study|Physician Decision|2
6248049|NCT01924806|9934653|FG001|Overall Study|Physician Decision|1
6248050|NCT01924845|9934659|FG000|Overall Study|Adverse Event|3
6248051|NCT01924845|9934659|FG000|Overall Study|Withdrawal by Subject|2
6248052|NCT01924845|9934659|FG000|Overall Study|Protocol Violation|1
6248053|NCT01925014|9934694|FG000|Overall Study|Inappropriate enrollment|4
6248054|NCT01925014|9934695|FG001|Overall Study|Inappropriate enrollment|6
6248055|NCT01925014|9934694|FG000|Overall Study|Withdrawal by Subject|5
6248056|NCT01925014|9934695|FG001|Overall Study|Withdrawal by Subject|13
6248057|NCT01925170|9934708|FG000|Overall Study|Unverified cancer status|53
6248058|NCT01925183|9934716|FG000|Overall Study|Adverse Event|1
6248059|NCT01925183|9934717|FG001|Overall Study|Adverse Event|0
6248060|NCT01925209|9934727|FG000|Treatment Epoch|Physician Decision|1
6248061|NCT01925209|9934728|FG001|Treatment Epoch|Physician Decision|0
6248062|NCT01925209|9934729|FG002|Treatment Epoch|Physician Decision|0
6248063|NCT01925209|9934730|FG003|Treatment Epoch|Physician Decision|0
6248064|NCT01925209|9934727|FG000|Treatment Epoch|Non-compliance with study treatment|0
6248065|NCT01925209|9934728|FG001|Treatment Epoch|Non-compliance with study treatment|0
6248066|NCT01925209|9934729|FG002|Treatment Epoch|Non-compliance with study treatment|0
6248067|NCT01925209|9934730|FG003|Treatment Epoch|Non-compliance with study treatment|1
6248068|NCT01925209|9934727|FG000|Treatment Epoch|Death|1
6248069|NCT01925209|9934728|FG001|Treatment Epoch|Death|0
6248070|NCT01925209|9934729|FG002|Treatment Epoch|Death|0
6248071|NCT01925209|9934730|FG003|Treatment Epoch|Death|0
6248072|NCT01925209|9934727|FG000|Treatment Epoch|Protocol deviation|0
6248073|NCT01925209|9934728|FG001|Treatment Epoch|Protocol deviation|0
6248074|NCT01925209|9934729|FG002|Treatment Epoch|Protocol deviation|1
6248075|NCT01925209|9934730|FG003|Treatment Epoch|Protocol deviation|1
6248076|NCT01925209|9934727|FG000|Treatment Epoch|Withdrawal by Subject|4
6248077|NCT01925209|9934728|FG001|Treatment Epoch|Withdrawal by Subject|3
6248078|NCT01925209|9934729|FG002|Treatment Epoch|Withdrawal by Subject|3
6248079|NCT01925209|9934730|FG003|Treatment Epoch|Withdrawal by Subject|2
6248080|NCT01925209|9934727|FG000|Treatment Epoch|Adverse Event|3
6248081|NCT01925209|9934728|FG001|Treatment Epoch|Adverse Event|5
6248082|NCT01925209|9934729|FG002|Treatment Epoch|Adverse Event|3
6248083|NCT01925209|9934730|FG003|Treatment Epoch|Adverse Event|1
6248084|NCT01925209|9934727|FG000|Maintenance Treatment Epoch|Withdrawal by Subject|0
6248085|NCT01925209|9934728|FG001|Maintenance Treatment Epoch|Withdrawal by Subject|1
6248086|NCT01925209|9934729|FG002|Maintenance Treatment Epoch|Withdrawal by Subject|1
6248087|NCT01925209|9934730|FG003|Maintenance Treatment Epoch|Withdrawal by Subject|2
6248088|NCT01925209|9934727|FG000|Maintenance Treatment Epoch|Adverse Event|0
6248089|NCT01925209|9934728|FG001|Maintenance Treatment Epoch|Adverse Event|0
6248090|NCT01925209|9934729|FG002|Maintenance Treatment Epoch|Adverse Event|1
6248091|NCT01925209|9934730|FG003|Maintenance Treatment Epoch|Adverse Event|0
6248092|NCT01925209|9934727|FG000|Follow-up|Adverse Event|1
6248093|NCT01925209|9934728|FG001|Follow-up|Adverse Event|4
6248094|NCT01925209|9934729|FG002|Follow-up|Adverse Event|0
6248095|NCT01925209|9934730|FG003|Follow-up|Adverse Event|1
6248096|NCT01925209|9934727|FG000|Follow-up|Physician Decision|0
6248097|NCT01925209|9934728|FG001|Follow-up|Physician Decision|0
6248098|NCT01925209|9934729|FG002|Follow-up|Physician Decision|1
6248099|NCT01925209|9934730|FG003|Follow-up|Physician Decision|0
6248100|NCT01925209|9934727|FG000|Follow-up|Non-compliance with study treatment|0
6248101|NCT01925209|9934728|FG001|Follow-up|Non-compliance with study treatment|0
6248102|NCT01925209|9934729|FG002|Follow-up|Non-compliance with study treatment|0
6248103|NCT01925209|9934730|FG003|Follow-up|Non-compliance with study treatment|1
6248104|NCT01925209|9934727|FG000|Follow-up|Withdrawal by Subject|0
6248105|NCT01925209|9934728|FG001|Follow-up|Withdrawal by Subject|2
6248106|NCT01925209|9934729|FG002|Follow-up|Withdrawal by Subject|0
6248107|NCT01925209|9934730|FG003|Follow-up|Withdrawal by Subject|2
6248108|NCT01925274|9934743|FG000|Overall Study|Death|1
6248109|NCT01925274|9934744|FG001|Overall Study|Death|0
6248110|NCT01925274|9934745|FG002|Overall Study|Death|0
6248111|NCT01925274|9934743|FG000|Overall Study|Lost to Follow-up|0
6248112|NCT01925274|9934744|FG001|Overall Study|Lost to Follow-up|1
6248113|NCT01925274|9934745|FG002|Overall Study|Lost to Follow-up|0
6248114|NCT01925274|9934743|FG000|Overall Study|Withdrawal by Subject|1
6248115|NCT01925274|9934744|FG001|Overall Study|Withdrawal by Subject|2
6248116|NCT01925274|9934745|FG002|Overall Study|Withdrawal by Subject|0
6248117|NCT01925274|9934743|FG000|Overall Study|Study terminated by sponsor|4
6248118|NCT01925274|9934744|FG001|Overall Study|Study terminated by sponsor|0
6248119|NCT01925274|9934745|FG002|Overall Study|Study terminated by sponsor|0
6248120|NCT01925274|9934743|FG000|Overall Study|Protocol amendment|1
6248121|NCT01925274|9934744|FG001|Overall Study|Protocol amendment|3
6248122|NCT01925274|9934745|FG002|Overall Study|Protocol amendment|6
6248123|NCT01925339|9934757|FG000|Overall Study|Adverse Event|2
6248124|NCT01925339|9934758|FG001|Overall Study|Adverse Event|0
6248125|NCT01925417|9934781|FG000|Overall Study|Withdrawal by Subject|2
6248126|NCT01925417|9934781|FG000|Overall Study|Death|1
6248127|NCT01925612|9934800|FG000|Overall Study|Progressive Disease|1
6248128|NCT01925612|9934801|FG001|Overall Study|Progressive Disease|1
6248129|NCT01925612|9934802|FG002|Overall Study|Progressive Disease|1
6248130|NCT01925612|9934803|FG003|Overall Study|Progressive Disease|0
6248131|NCT01925612|9934804|FG004|Overall Study|Progressive Disease|0
6248132|NCT01925612|9934800|FG000|Overall Study|Adverse Event|3
6248133|NCT01925612|9934801|FG001|Overall Study|Adverse Event|3
6248134|NCT01925612|9934802|FG002|Overall Study|Adverse Event|0
6248135|NCT01925612|9934803|FG003|Overall Study|Adverse Event|1
6248136|NCT01925612|9934804|FG004|Overall Study|Adverse Event|2
6248137|NCT01925703|9934820|FG000|Overall Study|Physician Decision|1
6248138|NCT01925703|9934820|FG000|Overall Study|Lost to Follow-up|2
6248139|NCT01925703|9934820|FG000|Overall Study|Discharge prior to full iron repletion|1
6248140|NCT01925768|9934826|FG000|Placebo-controlled Phase (Week 0 - 24)|Lost to Follow-up|1
6248141|NCT01925768|9934827|FG001|Placebo-controlled Phase (Week 0 - 24)|Lost to Follow-up|0
6248142|NCT01925768|9934826|FG000|Placebo-controlled Phase (Week 0 - 24)|Protocol Violation|1
6248143|NCT01925768|9934827|FG001|Placebo-controlled Phase (Week 0 - 24)|Protocol Violation|2
6248144|NCT01925768|9934826|FG000|Placebo-controlled Phase (Week 0 - 24)|Adverse Event|5
6248145|NCT01925768|9934827|FG001|Placebo-controlled Phase (Week 0 - 24)|Adverse Event|10
6248146|NCT01925768|9934826|FG000|Placebo-controlled Phase (Week 0 - 24)|Lack of Efficacy|3
6248147|NCT01925768|9934827|FG001|Placebo-controlled Phase (Week 0 - 24)|Lack of Efficacy|6
6248148|NCT01925768|9934826|FG000|Placebo-controlled Phase (Week 0 - 24)|Withdrawal by Subject|1
6248149|NCT01925768|9934827|FG001|Placebo-controlled Phase (Week 0 - 24)|Withdrawal by Subject|4
6248150|NCT01925768|9934826|FG000|Placebo-controlled Phase (Week 0 - 24)|Non-compliance with study drug|0
6248151|NCT01925768|9934827|FG001|Placebo-controlled Phase (Week 0 - 24)|Non-compliance with study drug|1
6248152|NCT01925768|9934826|FG000|ActiveTreatment/Extension (Weeks 24-104)|Lack of Efficacy|6
6248153|NCT01925768|9934827|FG001|ActiveTreatment/Extension (Weeks 24-104)|Lack of Efficacy|6
6248154|NCT01925768|9934826|FG000|ActiveTreatment/Extension (Weeks 24-104)|Withdrawal by Subject|7
6248155|NCT01925768|9934827|FG001|ActiveTreatment/Extension (Weeks 24-104)|Withdrawal by Subject|9
6248156|NCT01925768|9934826|FG000|ActiveTreatment/Extension (Weeks 24-104)|Lost to Follow-up|2
6248157|NCT01925768|9934827|FG001|ActiveTreatment/Extension (Weeks 24-104)|Lost to Follow-up|1
6248158|NCT01925768|9934826|FG000|ActiveTreatment/Extension (Weeks 24-104)|Death|0
6248159|NCT01925768|9934827|FG001|ActiveTreatment/Extension (Weeks 24-104)|Death|1
6248160|NCT01925768|9934826|FG000|ActiveTreatment/Extension (Weeks 24-104)|Adverse Event|5
6248161|NCT01925768|9934827|FG001|ActiveTreatment/Extension (Weeks 24-104)|Adverse Event|1
6248162|NCT01925950|9934848|FG000|Part 2|Withdrawal by Subject|1
6248163|NCT01925950|9934849|FG001|Part 2|Withdrawal by Subject|0
6248164|NCT01925989|9934857|FG000|Period 1|Sponsor Decision|1
6248165|NCT01925989|9934858|FG001|Period 1|Sponsor Decision|1
6248166|NCT01925989|9934859|FG002|Period 1|Sponsor Decision|0
6248167|NCT01925989|9934857|FG000|Period 1|Withdrawal by Subject|0
6248168|NCT01925989|9934858|FG001|Period 1|Withdrawal by Subject|1
6248169|NCT01925989|9934859|FG002|Period 1|Withdrawal by Subject|0
6248170|NCT01926015|9934873|FG000|Overall Study|Withdrawal by parent/guardian|0
6248171|NCT01926015|9934874|FG001|Overall Study|Withdrawal by parent/guardian|1
6248172|NCT01926015|9934873|FG000|Overall Study|Randomized not treated|2
6248173|NCT01926015|9934874|FG001|Overall Study|Randomized not treated|0
6248174|NCT01926028|9934883|FG000|Overall Study|Lost to Follow-up|7
6248175|NCT01926028|9934884|FG001|Overall Study|Lost to Follow-up|6
6248176|NCT01926028|9934885|FG002|Overall Study|Lost to Follow-up|0
6248177|NCT01926028|9934883|FG000|Overall Study|Physician Decision|1
6248178|NCT01926028|9934884|FG001|Overall Study|Physician Decision|5
6248179|NCT01926028|9934885|FG002|Overall Study|Physician Decision|0
6248180|NCT01926028|9934883|FG000|Overall Study|Withdrawal by Subject|9
6248181|NCT01926028|9934884|FG001|Overall Study|Withdrawal by Subject|9
6086206|NCT00659425|9695992|FG003|Overall Study|Adverse Event|0
6086207|NCT00659425|9695993|FG004|Overall Study|Adverse Event|0
6248182|NCT01926028|9934885|FG002|Overall Study|Withdrawal by Subject|2
6248183|NCT01926028|9934883|FG000|Overall Study|Non compliance or other reasons|4
6248184|NCT01926028|9934884|FG001|Overall Study|Non compliance or other reasons|2
6248185|NCT01926028|9934885|FG002|Overall Study|Non compliance or other reasons|0
6248186|NCT01926119|9934894|FG000|Overall Study|Withdrawal by Subject|1
6248187|NCT01926444|9934902|FG000|Overall Study|Colonoscopy not performed|0
6248188|NCT01926444|9934903|FG001|Overall Study|Colonoscopy not performed|0
6248189|NCT01926444|9934904|FG002|Overall Study|Colonoscopy not performed|4
6248190|NCT01926444|9934905|FG003|Overall Study|Colonoscopy not performed|2
6248191|NCT01926509|9934932|FG000|Overall Study|vital sign met discontinuation criteria|1
6248192|NCT01926509|9934933|FG001|Overall Study|vital sign met discontinuation criteria|0
6248193|NCT01926509|9934934|FG002|Overall Study|vital sign met discontinuation criteria|0
6248194|NCT01926509|9934935|FG003|Overall Study|vital sign met discontinuation criteria|0
6248195|NCT01926626|9934945|FG000|Overall Study|Withdrawal by Subject|15
6248196|NCT01926626|9934945|FG000|Overall Study|Lost to Follow-up|7
6248197|NCT01926782|9934955|FG000|Overall Study|Participant moved|2
6248198|NCT01926782|9934956|FG001|Overall Study|Participant moved|0
6248199|NCT01926782|9934957|FG002|Overall Study|Participant moved|1
6248200|NCT01926782|9934958|FG003|Overall Study|Participant moved|1
6248201|NCT01926782|9934959|FG004|Overall Study|Participant moved|0
6248202|NCT01926782|9934960|FG005|Overall Study|Participant moved|3
6248203|NCT01926782|9934955|FG000|Overall Study|Physician Decision|0
6248204|NCT01926782|9934956|FG001|Overall Study|Physician Decision|2
6248205|NCT01926782|9934957|FG002|Overall Study|Physician Decision|1
6248206|NCT01926782|9934958|FG003|Overall Study|Physician Decision|1
6248207|NCT01926782|9934959|FG004|Overall Study|Physician Decision|0
6248208|NCT01926782|9934960|FG005|Overall Study|Physician Decision|0
6248209|NCT01926782|9934955|FG000|Overall Study|Other than specified|2
6248210|NCT01926782|9934956|FG001|Overall Study|Other than specified|3
6248211|NCT01926782|9934957|FG002|Overall Study|Other than specified|5
6248212|NCT01926782|9934958|FG003|Overall Study|Other than specified|12
6248213|NCT01926782|9934959|FG004|Overall Study|Other than specified|4
6248214|NCT01926782|9934960|FG005|Overall Study|Other than specified|11
6248215|NCT01926782|9934955|FG000|Overall Study|Adverse Event|13
6248216|NCT01926782|9934956|FG001|Overall Study|Adverse Event|4
6248217|NCT01926782|9934957|FG002|Overall Study|Adverse Event|17
6248218|NCT01926782|9934958|FG003|Overall Study|Adverse Event|4
6248219|NCT01926782|9934959|FG004|Overall Study|Adverse Event|3
6248220|NCT01926782|9934960|FG005|Overall Study|Adverse Event|14
6248221|NCT01926782|9934955|FG000|Overall Study|Poor compliance to protocol|5
6248222|NCT01926782|9934956|FG001|Overall Study|Poor compliance to protocol|3
6248223|NCT01926782|9934957|FG002|Overall Study|Poor compliance to protocol|8
6248224|NCT01926782|9934958|FG003|Overall Study|Poor compliance to protocol|0
6248225|NCT01926782|9934959|FG004|Overall Study|Poor compliance to protocol|1
6248226|NCT01926782|9934960|FG005|Overall Study|Poor compliance to protocol|6
6248227|NCT01926782|9934955|FG000|Overall Study|Randomized and not treated|0
6248228|NCT01926782|9934956|FG001|Overall Study|Randomized and not treated|0
6248229|NCT01926782|9934957|FG002|Overall Study|Randomized and not treated|0
6248230|NCT01926782|9934958|FG003|Overall Study|Randomized and not treated|1
6248231|NCT01926782|9934959|FG004|Overall Study|Randomized and not treated|0
6248232|NCT01926782|9934960|FG005|Overall Study|Randomized and not treated|0
6248233|NCT01926782|9934955|FG000|Overall Study|Withdrawal by Subject|6
6248234|NCT01926782|9934956|FG001|Overall Study|Withdrawal by Subject|1
6248235|NCT01926782|9934957|FG002|Overall Study|Withdrawal by Subject|8
6248236|NCT01926782|9934958|FG003|Overall Study|Withdrawal by Subject|1
6248237|NCT01926782|9934959|FG004|Overall Study|Withdrawal by Subject|0
6248238|NCT01926782|9934960|FG005|Overall Study|Withdrawal by Subject|5
6086208|NCT00659425|9695994|FG005|Overall Study|Adverse Event|1
6248239|NCT01926782|9934955|FG000|Overall Study|Related to study drug administration|0
6248240|NCT01926782|9934956|FG001|Overall Study|Related to study drug administration|0
6248241|NCT01926782|9934957|FG002|Overall Study|Related to study drug administration|0
6248242|NCT01926782|9934958|FG003|Overall Study|Related to study drug administration|0
6248243|NCT01926782|9934959|FG004|Overall Study|Related to study drug administration|0
6248244|NCT01926782|9934960|FG005|Overall Study|Related to study drug administration|2
6248245|NCT01926886|9934975|FG000|Overall Study|Administrative/other|1
6248246|NCT01926886|9934976|FG001|Overall Study|Administrative/other|0
6248247|NCT01926886|9934975|FG000|Overall Study|Adverse event/intercurrent illness|4
6248248|NCT01926886|9934976|FG001|Overall Study|Adverse event/intercurrent illness|0
6248249|NCT01926886|9934975|FG000|Overall Study|Disease progression/recurrence|4
6248250|NCT01926886|9934976|FG001|Overall Study|Disease progression/recurrence|0
6248251|NCT01926886|9934975|FG000|Overall Study|Withdrawal by Subject|15
6248252|NCT01926886|9934976|FG001|Overall Study|Withdrawal by Subject|0
6248253|NCT01926886|9934975|FG000|Overall Study|Failure to return|3
6248254|NCT01926886|9934976|FG001|Overall Study|Failure to return|0
6248255|NCT01926886|9934975|FG000|Overall Study|Recurrence of disease|1
6248256|NCT01926886|9934976|FG001|Overall Study|Recurrence of disease|0
6248257|NCT01926886|9934975|FG000|Overall Study|Progression of disease|2
6248258|NCT01926886|9934976|FG001|Overall Study|Progression of disease|0
6248259|NCT01926886|9934975|FG000|Overall Study|Death|1
6248260|NCT01926886|9934976|FG001|Overall Study|Death|0
6248261|NCT01926886|9934975|FG000|Overall Study|Did not cooperate|1
6248262|NCT01926886|9934976|FG001|Overall Study|Did not cooperate|0
6248263|NCT01927055|9934994|FG000|Open-label|Adverse Event|6
6248264|NCT01927055|9934995|FG001|Open-label|Adverse Event|0
6248265|NCT01927055|9934996|FG002|Open-label|Adverse Event|0
6248266|NCT01927055|9934994|FG000|Open-label|Withdrawal by Subject|1
6248267|NCT01927055|9934995|FG001|Open-label|Withdrawal by Subject|0
6248268|NCT01927055|9934996|FG002|Open-label|Withdrawal by Subject|0
6248269|NCT01927055|9934994|FG000|Open-label|Study Stopped|4
6248270|NCT01927055|9934995|FG001|Open-label|Study Stopped|0
6248271|NCT01927055|9934996|FG002|Open-label|Study Stopped|0
6189441|NCT01400139|9844733|FG000|HYD Core Study|Adverse Event|210
6189442|NCT01400139|9844733|FG000|HYD Core Study|Lack of Efficacy|59
6189443|NCT01400139|9844733|FG000|HYD Core Study|Withdrawal by Subject|114
6189444|NCT01400139|9844733|FG000|HYD Core Study|Lost to Follow-up|39
6189445|NCT01400139|9844733|FG000|HYD Core Study|Confirmed or suspected diversion|20
6189446|NCT01400139|9844733|FG000|HYD Core Study|Administrative|56
6189447|NCT01400139|9844733|FG000|HYD Core Study|Did not qualify for Maintenance Period|14
6189448|NCT01400139|9844733|FG000|HYD Extension Period|Adverse Event|8
6189449|NCT01400139|9844733|FG000|HYD Extension Period|Withdrawal by Subject|5
6189450|NCT01400139|9844733|FG000|HYD Extension Period|Administrative|10
6189451|NCT01400243|9844741|FG000|Overall Study|Protocol Violation|8
6189452|NCT01400243|9844742|FG001|Overall Study|Protocol Violation|11
6189453|NCT01400412|9844752|FG000|Overall Study|Lost to Follow-up|4
6189454|NCT01400412|9844753|FG001|Overall Study|Lost to Follow-up|7
6189455|NCT01400412|9844752|FG000|Overall Study|Withdrawal by Subject|3
6189456|NCT01400412|9844753|FG001|Overall Study|Withdrawal by Subject|4
6189457|NCT01400412|9844752|FG000|Overall Study|Unable to complete|3
6189458|NCT01400412|9844753|FG001|Overall Study|Unable to complete|3
6189459|NCT01400412|9844752|FG000|Overall Study|Never started study treatment|0
6189460|NCT01400412|9844753|FG001|Overall Study|Never started study treatment|3
6189461|NCT01400425|9844761|FG000|Overall Study|Withdrawal by Subject|10
6086209|NCT00659425|9695995|FG006|Overall Study|Adverse Event|0
6248272|NCT01927055|9934994|FG000|Open-label|Supine Hypertension|4
6248273|NCT01927055|9934995|FG001|Open-label|Supine Hypertension|0
6248274|NCT01927055|9934996|FG002|Open-label|Supine Hypertension|0
6248275|NCT01927055|9934994|FG000|Open-label|Difficulty attending study visits|1
6248276|NCT01927055|9934995|FG001|Open-label|Difficulty attending study visits|0
6248277|NCT01927055|9934996|FG002|Open-label|Difficulty attending study visits|0
6248278|NCT01927055|9934994|FG000|Double-Blind|Adverse Event|0
6248279|NCT01927055|9934995|FG001|Double-Blind|Adverse Event|1
6248280|NCT01927055|9934996|FG002|Double-Blind|Adverse Event|1
6248281|NCT01927055|9934994|FG000|Double-Blind|Protocol Violation|0
6248282|NCT01927055|9934995|FG001|Double-Blind|Protocol Violation|0
6248283|NCT01927055|9934996|FG002|Double-Blind|Protocol Violation|1
6248284|NCT01927055|9934994|FG000|Double-Blind|Withdrawal by Subject|0
6248285|NCT01927055|9934995|FG001|Double-Blind|Withdrawal by Subject|2
6248286|NCT01927055|9934996|FG002|Double-Blind|Withdrawal by Subject|3
6248287|NCT01927055|9934994|FG000|Double-Blind|Study Stopped|0
6086210|NCT00659425|9695996|FG007|Overall Study|Adverse Event|3
6086211|NCT00659425|9695997|FG008|Overall Study|Adverse Event|1
6086212|NCT00659425|9695998|FG009|Overall Study|Adverse Event|4
6086213|NCT00659425|9695989|FG000|Overall Study|Investigator Discretion|0
6086214|NCT00659425|9695990|FG001|Overall Study|Investigator Discretion|0
6086215|NCT00659425|9695991|FG002|Overall Study|Investigator Discretion|0
6086216|NCT00659425|9695992|FG003|Overall Study|Investigator Discretion|0
6189462|NCT01400451|9844770|FG000|Combination Treatment (or Intended)|Withdrawal by Subject|2
6189463|NCT01400451|9844771|FG001|Combination Treatment (or Intended)|Withdrawal by Subject|1
6189464|NCT01400451|9844772|FG002|Combination Treatment (or Intended)|Withdrawal by Subject|1
6248288|NCT01927055|9934995|FG001|Double-Blind|Study Stopped|7
6248289|NCT01927055|9934996|FG002|Double-Blind|Study Stopped|7
6086217|NCT00659425|9695993|FG004|Overall Study|Investigator Discretion|0
6248290|NCT01927055|9934994|FG000|Double-Blind|Supine Hypertension|0
6248291|NCT01927055|9934995|FG001|Double-Blind|Supine Hypertension|0
6248292|NCT01927055|9934996|FG002|Double-Blind|Supine Hypertension|1
6248293|NCT01927055|9934994|FG000|Double-Blind|Extended Vacation|0
6248294|NCT01927055|9934995|FG001|Double-Blind|Extended Vacation|1
6248295|NCT01927055|9934996|FG002|Double-Blind|Extended Vacation|0
6248296|NCT01927341|9935012|FG000|Phase 1b|Lost to Follow-up|1
6086218|NCT00659425|9695994|FG005|Overall Study|Investigator Discretion|1
6086219|NCT00659425|9695995|FG006|Overall Study|Investigator Discretion|0
6086220|NCT00659425|9695996|FG007|Overall Study|Investigator Discretion|3
6086221|NCT00659425|9695997|FG008|Overall Study|Investigator Discretion|0
6086222|NCT00659425|9695998|FG009|Overall Study|Investigator Discretion|0
6086223|NCT00659425|9695989|FG000|Overall Study|Other|0
6248297|NCT01927341|9935013|FG001|Phase 1b|Lost to Follow-up|0
6248298|NCT01927341|9935014|FG002|Phase 1b|Lost to Follow-up|0
6248299|NCT01927341|9935015|FG003|Phase 1b|Lost to Follow-up|0
6248300|NCT01927341|9935016|FG004|Phase 1b|Lost to Follow-up|0
6248301|NCT01927341|9935012|FG000|Phase 1b|Death|2
6248302|NCT01927341|9935013|FG001|Phase 1b|Death|0
6248303|NCT01927341|9935014|FG002|Phase 1b|Death|0
6248304|NCT01927341|9935015|FG003|Phase 1b|Death|0
6248305|NCT01927341|9935016|FG004|Phase 1b|Death|0
6248306|NCT01927341|9935012|FG000|Phase 1b|Follow-up completed|7
6248307|NCT01927341|9935013|FG001|Phase 1b|Follow-up completed|0
6248308|NCT01927341|9935014|FG002|Phase 1b|Follow-up completed|0
6248309|NCT01927341|9935015|FG003|Phase 1b|Follow-up completed|0
6248310|NCT01927341|9935016|FG004|Phase 1b|Follow-up completed|0
6248311|NCT01927341|9935012|FG000|Phase 2|Lost to Follow-up|0
6248312|NCT01927341|9935013|FG001|Phase 2|Lost to Follow-up|1
6248313|NCT01927341|9935014|FG002|Phase 2|Lost to Follow-up|0
6248314|NCT01927341|9935015|FG003|Phase 2|Lost to Follow-up|0
6248315|NCT01927341|9935016|FG004|Phase 2|Lost to Follow-up|0
6248316|NCT01927341|9935012|FG000|Phase 2|Participant withdrew consent|0
6248317|NCT01927341|9935013|FG001|Phase 2|Participant withdrew consent|2
6248318|NCT01927341|9935014|FG002|Phase 2|Participant withdrew consent|1
6248319|NCT01927341|9935015|FG003|Phase 2|Participant withdrew consent|2
6248320|NCT01927341|9935016|FG004|Phase 2|Participant withdrew consent|3
6248321|NCT01927341|9935012|FG000|Phase 2|Death|0
6248322|NCT01927341|9935013|FG001|Phase 2|Death|4
6248323|NCT01927341|9935014|FG002|Phase 2|Death|0
6248324|NCT01927341|9935015|FG003|Phase 2|Death|3
6248325|NCT01927341|9935016|FG004|Phase 2|Death|2
6248326|NCT01927341|9935012|FG000|Phase 2|New cancer therapy|0
6248327|NCT01927341|9935013|FG001|Phase 2|New cancer therapy|1
6248328|NCT01927341|9935014|FG002|Phase 2|New cancer therapy|0
6248329|NCT01927341|9935015|FG003|Phase 2|New cancer therapy|4
6248330|NCT01927341|9935016|FG004|Phase 2|New cancer therapy|1
6248331|NCT01927341|9935012|FG000|Phase 2|Disease progression|0
6248332|NCT01927341|9935013|FG001|Phase 2|Disease progression|1
6248333|NCT01927341|9935014|FG002|Phase 2|Disease progression|1
6248334|NCT01927341|9935015|FG003|Phase 2|Disease progression|1
6248335|NCT01927341|9935016|FG004|Phase 2|Disease progression|0
6248336|NCT01927341|9935012|FG000|Phase 2|Follow-up completed|0
6248337|NCT01927341|9935013|FG001|Phase 2|Follow-up completed|6
6248338|NCT01927341|9935014|FG002|Phase 2|Follow-up completed|3
6248339|NCT01927341|9935015|FG003|Phase 2|Follow-up completed|5
6248340|NCT01927341|9935016|FG004|Phase 2|Follow-up completed|2
6248341|NCT01927367|9935034|FG000|Overall Study|Withdrawal by Subject|7
6248342|NCT01927367|9935035|FG001|Overall Study|Withdrawal by Subject|4
6248343|NCT01927367|9935034|FG000|Overall Study|No baseline data|0
6248344|NCT01927367|9935035|FG001|Overall Study|No baseline data|1
6248345|NCT01927497|9935043|FG000|Overall Study|Death|0
6248346|NCT01927497|9935044|FG001|Overall Study|Death|1
6248347|NCT01927497|9935043|FG000|Overall Study|Protocol Violation|2
6248348|NCT01927497|9935044|FG001|Overall Study|Protocol Violation|0
6248349|NCT01927562|9935050|FG000|Overall Study|Lost to Follow-up|30
6248350|NCT01927562|9935050|FG000|Overall Study|Withdrawal by Subject|3
6248351|NCT01927562|9935050|FG000|Overall Study|Physician Decision|5
6248352|NCT01927627|9935062|FG000|Overall Study|Adverse Event|3
6248353|NCT01927627|9935062|FG000|Overall Study|Lack of Efficacy|1
6248354|NCT01927627|9935062|FG000|Overall Study|Financial Concerns|1
6248355|NCT01927757|9935070|FG000|Overall Study|Withdrawal by Subject|14
6248356|NCT01927757|9935070|FG000|Overall Study|Lost to Follow-up|2
6248357|NCT01927757|9935070|FG000|Overall Study|Decision by Sponsor|2
6248358|NCT01927757|9935070|FG000|Overall Study|Other|1
6086224|NCT00659425|9695990|FG001|Overall Study|Other|1
6248359|NCT01927757|9935070|FG000|Overall Study|Ethical Reasons|4
6248360|NCT01927861|9935080|FG000|Extension Phase (104 Weeks)|Adverse Event|0
6248361|NCT01927861|9935081|FG001|Extension Phase (104 Weeks)|Adverse Event|2
6248362|NCT01927861|9935080|FG000|Extension Phase (104 Weeks)|Unclassified|0
6248363|NCT01927861|9935081|FG001|Extension Phase (104 Weeks)|Unclassified|1
6248364|NCT01928225|9935116|FG000|Overall Study|Pregnancy|1
6248365|NCT01928225|9935117|FG001|Overall Study|Pregnancy|0
6248366|NCT01928225|9935116|FG000|Overall Study|basaloid cervical cancer|1
6248367|NCT01928225|9935117|FG001|Overall Study|basaloid cervical cancer|0
6248368|NCT01928225|9935116|FG000|Overall Study|Lost to Follow-up|1
6248369|NCT01928225|9935117|FG001|Overall Study|Lost to Follow-up|3
6248370|NCT01928329|9935135|FG000|Overall Study|Withdrew Consent Prior to Receiving Drug|1
6248371|NCT01928329|9935136|FG001|Overall Study|Withdrew Consent Prior to Receiving Drug|3
6248372|NCT01928329|9935135|FG000|Overall Study|Removed from Study Prior to Receiving Dr|0
6248373|NCT01928329|9935136|FG001|Overall Study|Removed from Study Prior to Receiving Dr|1
6248374|NCT01928329|9935135|FG000|Overall Study|Adverse Event|5
6248375|NCT01928329|9935136|FG001|Overall Study|Adverse Event|3
6248376|NCT01928329|9935135|FG000|Overall Study|Stopping Rule: Lost Greater than 5kg|4
6248377|NCT01928329|9935136|FG001|Overall Study|Stopping Rule: Lost Greater than 5kg|1
6248378|NCT01928329|9935135|FG000|Overall Study|Withdrawal by Subject|1
6248379|NCT01928329|9935136|FG001|Overall Study|Withdrawal by Subject|5
6248380|NCT01928329|9935135|FG000|Overall Study|Physician Decision|1
6248381|NCT01928329|9935136|FG001|Overall Study|Physician Decision|1
6248382|NCT01928381|9935142|FG000|Screening for Pain Training|Did not qualify (inclusion/Exclusion)|60
6248383|NCT01928381|9935143|FG001|Screening for Pain Training|Did not qualify (inclusion/Exclusion)|0
6248384|NCT01928381|9935144|FG002|Screening for Pain Training|Did not qualify (inclusion/Exclusion)|0
6248385|NCT01928381|9935145|FG003|Screening for Pain Training|Did not qualify (inclusion/Exclusion)|0
6248386|NCT01928381|9935146|FG004|Screening for Pain Training|Did not qualify (inclusion/Exclusion)|0
6248387|NCT01928381|9935147|FG005|Screening for Pain Training|Did not qualify (inclusion/Exclusion)|0
6248388|NCT01928381|9935148|FG006|Screening for Pain Training|Did not qualify (inclusion/Exclusion)|0
6248389|NCT01928381|9935142|FG000|Part 1 - Pain Training|Pain training criteria not met|29
6248390|NCT01928381|9935143|FG001|Part 1 - Pain Training|Pain training criteria not met|0
6248391|NCT01928381|9935144|FG002|Part 1 - Pain Training|Pain training criteria not met|0
6248392|NCT01928381|9935145|FG003|Part 1 - Pain Training|Pain training criteria not met|0
6248393|NCT01928381|9935146|FG004|Part 1 - Pain Training|Pain training criteria not met|0
6248394|NCT01928381|9935147|FG005|Part 1 - Pain Training|Pain training criteria not met|0
6248395|NCT01928381|9935148|FG006|Part 1 - Pain Training|Pain training criteria not met|0
6248396|NCT01928381|9935142|FG000|Part 1 - Pain Training|Withdrawal by Subject|1
6248397|NCT01928381|9935143|FG001|Part 1 - Pain Training|Withdrawal by Subject|0
6248398|NCT01928381|9935144|FG002|Part 1 - Pain Training|Withdrawal by Subject|0
6248399|NCT01928381|9935145|FG003|Part 1 - Pain Training|Withdrawal by Subject|0
6248400|NCT01928381|9935146|FG004|Part 1 - Pain Training|Withdrawal by Subject|0
6248401|NCT01928381|9935147|FG005|Part 1 - Pain Training|Withdrawal by Subject|0
6248402|NCT01928381|9935148|FG006|Part 1 - Pain Training|Withdrawal by Subject|0
6248403|NCT01928381|9935142|FG000|Part 1 - Pain Training|Lost to Follow-up|4
6248404|NCT01928381|9935143|FG001|Part 1 - Pain Training|Lost to Follow-up|0
6248405|NCT01928381|9935144|FG002|Part 1 - Pain Training|Lost to Follow-up|0
6248406|NCT01928381|9935145|FG003|Part 1 - Pain Training|Lost to Follow-up|0
6248407|NCT01928381|9935146|FG004|Part 1 - Pain Training|Lost to Follow-up|0
6248408|NCT01928381|9935147|FG005|Part 1 - Pain Training|Lost to Follow-up|0
6248409|NCT01928381|9935148|FG006|Part 1 - Pain Training|Lost to Follow-up|0
6248410|NCT01928381|9935142|FG000|Part 1 - Pain Training|Protocol Violation|1
6248411|NCT01928381|9935143|FG001|Part 1 - Pain Training|Protocol Violation|0
6248412|NCT01928381|9935144|FG002|Part 1 - Pain Training|Protocol Violation|0
6248413|NCT01928381|9935145|FG003|Part 1 - Pain Training|Protocol Violation|0
6248414|NCT01928381|9935146|FG004|Part 1 - Pain Training|Protocol Violation|0
6248415|NCT01928381|9935147|FG005|Part 1 - Pain Training|Protocol Violation|0
6248416|NCT01928381|9935148|FG006|Part 1 - Pain Training|Protocol Violation|0
6248417|NCT01928381|9935142|FG000|Placebo run-in & Part 2 Eligibility|Adverse Event|1
6248418|NCT01928381|9935143|FG001|Placebo run-in & Part 2 Eligibility|Adverse Event|0
6248419|NCT01928381|9935144|FG002|Placebo run-in & Part 2 Eligibility|Adverse Event|0
6248420|NCT01928381|9935145|FG003|Placebo run-in & Part 2 Eligibility|Adverse Event|0
6248421|NCT01928381|9935146|FG004|Placebo run-in & Part 2 Eligibility|Adverse Event|0
6248422|NCT01928381|9935147|FG005|Placebo run-in & Part 2 Eligibility|Adverse Event|0
6248423|NCT01928381|9935148|FG006|Placebo run-in & Part 2 Eligibility|Adverse Event|0
6248424|NCT01928381|9935142|FG000|Placebo run-in & Part 2 Eligibility|Withdrawal by Subject|2
6248425|NCT01928381|9935143|FG001|Placebo run-in & Part 2 Eligibility|Withdrawal by Subject|0
6248426|NCT01928381|9935144|FG002|Placebo run-in & Part 2 Eligibility|Withdrawal by Subject|0
6248427|NCT01928381|9935145|FG003|Placebo run-in & Part 2 Eligibility|Withdrawal by Subject|0
6248428|NCT01928381|9935146|FG004|Placebo run-in & Part 2 Eligibility|Withdrawal by Subject|0
6248429|NCT01928381|9935147|FG005|Placebo run-in & Part 2 Eligibility|Withdrawal by Subject|0
6248430|NCT01928381|9935148|FG006|Placebo run-in & Part 2 Eligibility|Withdrawal by Subject|0
6248431|NCT01928381|9935142|FG000|Placebo run-in & Part 2 Eligibility|Lost to Follow-up|1
6248432|NCT01928381|9935143|FG001|Placebo run-in & Part 2 Eligibility|Lost to Follow-up|0
6248433|NCT01928381|9935144|FG002|Placebo run-in & Part 2 Eligibility|Lost to Follow-up|0
6248434|NCT01928381|9935145|FG003|Placebo run-in & Part 2 Eligibility|Lost to Follow-up|0
6248435|NCT01928381|9935146|FG004|Placebo run-in & Part 2 Eligibility|Lost to Follow-up|0
6248436|NCT01928381|9935147|FG005|Placebo run-in & Part 2 Eligibility|Lost to Follow-up|0
6248437|NCT01928381|9935148|FG006|Placebo run-in & Part 2 Eligibility|Lost to Follow-up|0
6248438|NCT01928381|9935142|FG000|Placebo run-in & Part 2 Eligibility|Eligibility for Part 2 not met|10
6248439|NCT01928381|9935143|FG001|Placebo run-in & Part 2 Eligibility|Eligibility for Part 2 not met|0
6248440|NCT01928381|9935144|FG002|Placebo run-in & Part 2 Eligibility|Eligibility for Part 2 not met|0
6248441|NCT01928381|9935145|FG003|Placebo run-in & Part 2 Eligibility|Eligibility for Part 2 not met|0
6248442|NCT01928381|9935146|FG004|Placebo run-in & Part 2 Eligibility|Eligibility for Part 2 not met|0
6248443|NCT01928381|9935147|FG005|Placebo run-in & Part 2 Eligibility|Eligibility for Part 2 not met|0
6248444|NCT01928381|9935148|FG006|Placebo run-in & Part 2 Eligibility|Eligibility for Part 2 not met|0
6248445|NCT01928381|9935142|FG000|Part 2 - First Intervention|Withdrawal by Subject|0
6248446|NCT01928381|9935143|FG001|Part 2 - First Intervention|Withdrawal by Subject|0
6248447|NCT01928381|9935144|FG002|Part 2 - First Intervention|Withdrawal by Subject|1
6248448|NCT01928381|9935145|FG003|Part 2 - First Intervention|Withdrawal by Subject|0
6248449|NCT01928381|9935146|FG004|Part 2 - First Intervention|Withdrawal by Subject|0
6248450|NCT01928381|9935147|FG005|Part 2 - First Intervention|Withdrawal by Subject|0
6248451|NCT01928381|9935148|FG006|Part 2 - First Intervention|Withdrawal by Subject|0
6248452|NCT01928381|9935142|FG000|Part 2 - First Intervention|Study specific withdrawal criteria|0
6248453|NCT01928381|9935143|FG001|Part 2 - First Intervention|Study specific withdrawal criteria|0
6248454|NCT01928381|9935144|FG002|Part 2 - First Intervention|Study specific withdrawal criteria|1
6248455|NCT01928381|9935145|FG003|Part 2 - First Intervention|Study specific withdrawal criteria|0
6248456|NCT01928381|9935146|FG004|Part 2 - First Intervention|Study specific withdrawal criteria|0
6248457|NCT01928381|9935147|FG005|Part 2 - First Intervention|Study specific withdrawal criteria|0
6248458|NCT01928381|9935148|FG006|Part 2 - First Intervention|Study specific withdrawal criteria|0
6248459|NCT01928381|9935142|FG000|Part 2 - First Intervention|Eligibility criterion not met|0
6248460|NCT01928381|9935143|FG001|Part 2 - First Intervention|Eligibility criterion not met|0
6248461|NCT01928381|9935144|FG002|Part 2 - First Intervention|Eligibility criterion not met|0
6248462|NCT01928381|9935145|FG003|Part 2 - First Intervention|Eligibility criterion not met|0
6248463|NCT01928381|9935146|FG004|Part 2 - First Intervention|Eligibility criterion not met|0
6248464|NCT01928381|9935147|FG005|Part 2 - First Intervention|Eligibility criterion not met|1
6248465|NCT01928381|9935148|FG006|Part 2 - First Intervention|Eligibility criterion not met|1
6248466|NCT01928381|9935142|FG000|Part 2 - First Intervention|Lost to Follow-up|0
6248467|NCT01928381|9935143|FG001|Part 2 - First Intervention|Lost to Follow-up|0
6248468|NCT01928381|9935144|FG002|Part 2 - First Intervention|Lost to Follow-up|0
6248469|NCT01928381|9935145|FG003|Part 2 - First Intervention|Lost to Follow-up|1
6248470|NCT01928381|9935146|FG004|Part 2 - First Intervention|Lost to Follow-up|0
6248471|NCT01928381|9935147|FG005|Part 2 - First Intervention|Lost to Follow-up|0
6248472|NCT01928381|9935148|FG006|Part 2 - First Intervention|Lost to Follow-up|0
6248473|NCT01928381|9935142|FG000|Washout First Intervention|Protocol Violation|0
6248474|NCT01928381|9935143|FG001|Washout First Intervention|Protocol Violation|0
6248475|NCT01928381|9935144|FG002|Washout First Intervention|Protocol Violation|0
6248476|NCT01928381|9935145|FG003|Washout First Intervention|Protocol Violation|0
6248477|NCT01928381|9935146|FG004|Washout First Intervention|Protocol Violation|1
6248478|NCT01928381|9935147|FG005|Washout First Intervention|Protocol Violation|0
6248479|NCT01928381|9935148|FG006|Washout First Intervention|Protocol Violation|0
6248480|NCT01928381|9935142|FG000|Part 2 - Second Intervention|Lost to Follow-up|0
6248481|NCT01928381|9935143|FG001|Part 2 - Second Intervention|Lost to Follow-up|1
6248482|NCT01928381|9935144|FG002|Part 2 - Second Intervention|Lost to Follow-up|0
6248483|NCT01928381|9935145|FG003|Part 2 - Second Intervention|Lost to Follow-up|1
6248484|NCT01928381|9935146|FG004|Part 2 - Second Intervention|Lost to Follow-up|0
6248485|NCT01928381|9935147|FG005|Part 2 - Second Intervention|Lost to Follow-up|0
6248486|NCT01928381|9935148|FG006|Part 2 - Second Intervention|Lost to Follow-up|0
6248487|NCT01928381|9935142|FG000|Part 2 - Post Third Intervention|Protocol Violation|0
6248488|NCT01928381|9935143|FG001|Part 2 - Post Third Intervention|Protocol Violation|0
6248489|NCT01928381|9935144|FG002|Part 2 - Post Third Intervention|Protocol Violation|1
6248490|NCT01928381|9935145|FG003|Part 2 - Post Third Intervention|Protocol Violation|0
6248491|NCT01928381|9935146|FG004|Part 2 - Post Third Intervention|Protocol Violation|0
6248492|NCT01928381|9935147|FG005|Part 2 - Post Third Intervention|Protocol Violation|0
6248493|NCT01928381|9935148|FG006|Part 2 - Post Third Intervention|Protocol Violation|0
6248494|NCT01928433|9935161|FG000|Overall Study|Adverse Event|5
6248495|NCT01928433|9935162|FG001|Overall Study|Adverse Event|2
6248496|NCT01928433|9935163|FG002|Overall Study|Adverse Event|5
6248497|NCT01928433|9935161|FG000|Overall Study|Protocol Violation|0
6248498|NCT01928433|9935162|FG001|Overall Study|Protocol Violation|0
6248499|NCT01928433|9935163|FG002|Overall Study|Protocol Violation|2
6248500|NCT01928433|9935161|FG000|Overall Study|Lack of Efficacy|5
6248501|NCT01928433|9935162|FG001|Overall Study|Lack of Efficacy|4
6248502|NCT01928433|9935163|FG002|Overall Study|Lack of Efficacy|4
6248503|NCT01928433|9935161|FG000|Overall Study|Withdrawal by Subject|0
6248504|NCT01928433|9935162|FG001|Overall Study|Withdrawal by Subject|4
6248505|NCT01928433|9935163|FG002|Overall Study|Withdrawal by Subject|0
6248506|NCT01928433|9935161|FG000|Overall Study|Negative screening urine culture|7
6248507|NCT01928433|9935162|FG001|Overall Study|Negative screening urine culture|6
6086225|NCT00659425|9695991|FG002|Overall Study|Other|1
6248508|NCT01928433|9935163|FG002|Overall Study|Negative screening urine culture|10
6248509|NCT01928433|9935161|FG000|Overall Study|Lost to Follow-up|0
6248510|NCT01928433|9935162|FG001|Overall Study|Lost to Follow-up|2
6248511|NCT01928433|9935163|FG002|Overall Study|Lost to Follow-up|3
6248512|NCT01928433|9935161|FG000|Overall Study|Other reasons|3
6248513|NCT01928433|9935162|FG001|Overall Study|Other reasons|3
6248514|NCT01928433|9935163|FG002|Overall Study|Other reasons|4
6248515|NCT01928472|9935189|FG000|Overall Study|Death|0
6248516|NCT01928472|9935190|FG001|Overall Study|Death|0
6248517|NCT01928472|9935191|FG002|Overall Study|Death|1
6248518|NCT01928472|9935192|FG003|Overall Study|Death|0
6248519|NCT01928472|9935189|FG000|Overall Study|Withdrawal by Subject|4
6248520|NCT01928472|9935190|FG001|Overall Study|Withdrawal by Subject|4
6248521|NCT01928472|9935191|FG002|Overall Study|Withdrawal by Subject|1
6248522|NCT01928472|9935192|FG003|Overall Study|Withdrawal by Subject|2
6248523|NCT01928472|9935189|FG000|Overall Study|Lost to Follow-up|2
6248524|NCT01928472|9935190|FG001|Overall Study|Lost to Follow-up|3
6248525|NCT01928472|9935191|FG002|Overall Study|Lost to Follow-up|4
6248526|NCT01928472|9935192|FG003|Overall Study|Lost to Follow-up|0
6248527|NCT01928472|9935189|FG000|Overall Study|Administrative Reason|2
6248528|NCT01928472|9935190|FG001|Overall Study|Administrative Reason|1
6248529|NCT01928472|9935191|FG002|Overall Study|Administrative Reason|0
6248530|NCT01928472|9935192|FG003|Overall Study|Administrative Reason|0
6248531|NCT01928472|9935189|FG000|Overall Study|Unclassified|0
6248532|NCT01928472|9935190|FG001|Overall Study|Unclassified|0
6248533|NCT01928472|9935191|FG002|Overall Study|Unclassified|1
6248534|NCT01928472|9935192|FG003|Overall Study|Unclassified|0
6248535|NCT01928485|9935205|FG000|Overall Study|Physician Decision|0
6248536|NCT01928485|9935206|FG001|Overall Study|Physician Decision|1
6248537|NCT01928719|9935260|FG000|Overall Study|Lost to Follow-up|26
6248538|NCT01928719|9935261|FG001|Overall Study|Lost to Follow-up|11
6248539|NCT01928719|9935260|FG000|Overall Study|Withdrawal by Subject|22
6248540|NCT01928719|9935261|FG001|Overall Study|Withdrawal by Subject|7
6248541|NCT01928719|9935260|FG000|Overall Study|Protocol Violation|3
6248542|NCT01928719|9935261|FG001|Overall Study|Protocol Violation|1
6248543|NCT01928719|9935260|FG000|Overall Study|Adverse Event|1
6248544|NCT01928719|9935261|FG001|Overall Study|Adverse Event|0
6248545|NCT01928758|9935271|FG000|Overall Study|Lost to Follow-up|14
6248546|NCT01928758|9935272|FG001|Overall Study|Lost to Follow-up|9
6248547|NCT01928758|9935271|FG000|Overall Study|Withdrawal by Subject|5
6248548|NCT01928758|9935272|FG001|Overall Study|Withdrawal by Subject|2
6248549|NCT01928758|9935271|FG000|Overall Study|Adverse Event|3
6248550|NCT01928758|9935272|FG001|Overall Study|Adverse Event|5
6248551|NCT01928758|9935271|FG000|Overall Study|Protocol Violation|3
6248552|NCT01928758|9935272|FG001|Overall Study|Protocol Violation|4
6248553|NCT01928771|9935282|FG000|Overall Study|Adverse Event|6
6248554|NCT01928771|9935283|FG001|Overall Study|Adverse Event|5
6248555|NCT01928771|9935284|FG002|Overall Study|Adverse Event|1
6248556|NCT01928771|9935282|FG000|Overall Study|Death|2
6248557|NCT01928771|9935283|FG001|Overall Study|Death|2
6248558|NCT01928771|9935284|FG002|Overall Study|Death|2
6248559|NCT01928771|9935282|FG000|Overall Study|Lost to Follow-up|5
6248560|NCT01928771|9935283|FG001|Overall Study|Lost to Follow-up|6
6248561|NCT01928771|9935284|FG002|Overall Study|Lost to Follow-up|3
6248562|NCT01928771|9935282|FG000|Overall Study|Withdrawal by Subject|20
6248563|NCT01928771|9935283|FG001|Overall Study|Withdrawal by Subject|15
6248564|NCT01928771|9935284|FG002|Overall Study|Withdrawal by Subject|17
6248565|NCT01928771|9935282|FG000|Overall Study|Study-Specific Withdrawal Criteria|0
6248566|NCT01928771|9935283|FG001|Overall Study|Study-Specific Withdrawal Criteria|1
6248567|NCT01928771|9935284|FG002|Overall Study|Study-Specific Withdrawal Criteria|1
6248568|NCT01928771|9935282|FG000|Overall Study|Other Reasons|9
6248569|NCT01928771|9935283|FG001|Overall Study|Other Reasons|9
6248570|NCT01928771|9935284|FG002|Overall Study|Other Reasons|14
6248571|NCT01928771|9935282|FG000|Overall Study|Severe Non-Compliance to Protocol|4
6248572|NCT01928771|9935283|FG001|Overall Study|Severe Non-Compliance to Protocol|2
6248573|NCT01928771|9935284|FG002|Overall Study|Severe Non-Compliance to Protocol|2
6248574|NCT01928862|9935317|FG000|Overall Study|Lost to Follow-up|1
6248575|NCT01928862|9935318|FG001|Overall Study|Lost to Follow-up|0
6248576|NCT01928862|9935319|FG002|Overall Study|Lost to Follow-up|0
6248577|NCT01928862|9935320|FG003|Overall Study|Lost to Follow-up|0
6248578|NCT01928862|9935321|FG004|Overall Study|Lost to Follow-up|1
6248579|NCT01928927|9935336|FG000|Overall Study|Lost to Follow-up|1
6248580|NCT01928927|9935337|FG001|Overall Study|Lost to Follow-up|0
6248581|NCT01928927|9935336|FG000|Overall Study|Withdrawal by Subject|1
6248582|NCT01928927|9935337|FG001|Overall Study|Withdrawal by Subject|1
6248583|NCT01928940|9935349|FG000|Overall Study|Adverse Event|0
6248584|NCT01928940|9935350|FG001|Overall Study|Adverse Event|1
6248585|NCT01929018|9935359|FG000|Overall Study|Lost to Follow-up|1
6248586|NCT01929018|9935360|FG001|Overall Study|Lost to Follow-up|0
6248587|NCT01929018|9935359|FG000|Overall Study|Hospitalization|0
6248588|NCT01929018|9935360|FG001|Overall Study|Hospitalization|1
6248589|NCT01929031|9935370|FG000|Overall Study|Adverse Event|3
6248590|NCT01929031|9935371|FG001|Overall Study|Adverse Event|1
6248591|NCT01929031|9935372|FG002|Overall Study|Adverse Event|1
6248592|NCT01929031|9935373|FG003|Overall Study|Adverse Event|0
6248593|NCT01929031|9935374|FG004|Overall Study|Adverse Event|0
6248594|NCT01929031|9935375|FG005|Overall Study|Adverse Event|0
6248595|NCT01929031|9935370|FG000|Overall Study|Protocol Violation|1
6248596|NCT01929031|9935371|FG001|Overall Study|Protocol Violation|0
6248597|NCT01929031|9935372|FG002|Overall Study|Protocol Violation|0
6248598|NCT01929031|9935373|FG003|Overall Study|Protocol Violation|0
6248599|NCT01929031|9935374|FG004|Overall Study|Protocol Violation|0
6248600|NCT01929031|9935375|FG005|Overall Study|Protocol Violation|1
6248601|NCT01929031|9935370|FG000|Overall Study|Reason other than specified above|0
6248602|NCT01929031|9935371|FG001|Overall Study|Reason other than specified above|1
6248603|NCT01929031|9935372|FG002|Overall Study|Reason other than specified above|0
6248604|NCT01929031|9935373|FG003|Overall Study|Reason other than specified above|0
6248605|NCT01929031|9935374|FG004|Overall Study|Reason other than specified above|1
6248606|NCT01929031|9935375|FG005|Overall Study|Reason other than specified above|0
6248607|NCT01929044|9935387|FG000|Overall Study|Adverse Event|1
6248608|NCT01929044|9935388|FG001|Overall Study|Adverse Event|0
6248609|NCT01929044|9935387|FG000|Overall Study|Protocol Violation|9
6248610|NCT01929044|9935388|FG001|Overall Study|Protocol Violation|14
6248611|NCT01929044|9935387|FG000|Overall Study|Not Treated|1
6248612|NCT01929044|9935388|FG001|Overall Study|Not Treated|3
6248613|NCT01929083|9935405|FG000|Intervention 1|Lost to Follow-up|2
6248614|NCT01929083|9935406|FG001|Intervention 1|Lost to Follow-up|0
6248615|NCT01929083|9935405|FG000|Intervention 1|Nonadherent to study medications|1
6248616|NCT01929083|9935406|FG001|Intervention 1|Nonadherent to study medications|0
6248617|NCT01929083|9935405|FG000|Intervention 2|Adverse Event|0
6248618|NCT01929083|9935406|FG001|Intervention 2|Adverse Event|1
6248619|NCT01929109|9935417|FG000|Period 1 (All Groups)|Deviation from protocol|0
6248620|NCT01929109|9935418|FG001|Period 1 (All Groups)|Deviation from protocol|0
6248621|NCT01929109|9935419|FG002|Period 1 (All Groups)|Deviation from protocol|1
6248622|NCT01929109|9935420|FG003|Period 1 (All Groups)|Deviation from protocol|0
6248623|NCT01929109|9935421|FG004|Period 1 (All Groups)|Deviation from protocol|0
6248624|NCT01929135|9935438|FG000|Overall Study|Lost to Follow-up|1
6248625|NCT01929135|9935439|FG001|Overall Study|Lost to Follow-up|1
6248626|NCT01929226|9935449|FG000|Overall Study|Lost to Follow-up|4
6248627|NCT01929226|9935450|FG001|Overall Study|Lost to Follow-up|0
6248628|NCT01929226|9935449|FG000|Overall Study|Withdrawal by Subject|1
6248629|NCT01929226|9935450|FG001|Overall Study|Withdrawal by Subject|1
6248630|NCT01929317|9935463|FG000|Dose Increase Effect Verification Phase|Adverse Event|5
6248631|NCT01929317|9935464|FG001|Dose Increase Effect Verification Phase|Adverse Event|1
6248632|NCT01929317|9935463|FG000|Dose Increase Effect Verification Phase|Physician Decision|1
6248633|NCT01929317|9935464|FG001|Dose Increase Effect Verification Phase|Physician Decision|0
6248634|NCT01929317|9935463|FG000|Dose Increase Effect Verification Phase|Withdrawal by Subject|3
6248635|NCT01929317|9935464|FG001|Dose Increase Effect Verification Phase|Withdrawal by Subject|0
6248636|NCT01929317|9935463|FG000|Long-term Phase|Adverse Event|5
6248637|NCT01929317|9935464|FG001|Long-term Phase|Adverse Event|1
6248638|NCT01929317|9935463|FG000|Long-term Phase|Physician Decision|3
6248639|NCT01929317|9935464|FG001|Long-term Phase|Physician Decision|0
6248640|NCT01929317|9935463|FG000|Long-term Phase|Withdrawal by Subject|4
6248641|NCT01929317|9935464|FG001|Long-term Phase|Withdrawal by Subject|0
6248642|NCT01929317|9935463|FG000|Long-term Phase|Protocol Violation|1
6248643|NCT01929317|9935464|FG001|Long-term Phase|Protocol Violation|0
6248644|NCT01929317|9935463|FG000|Long-term Phase|Protocol-defined Stopping Criteria|1
6248645|NCT01929317|9935464|FG001|Long-term Phase|Protocol-defined Stopping Criteria|0
6248646|NCT01929317|9935463|FG000|Long-term Phase|Study Closed/Terminated|5
6248647|NCT01929317|9935464|FG001|Long-term Phase|Study Closed/Terminated|3
6248648|NCT01929343|9935479|FG000|Overall Study|Physician Decision|0
6248649|NCT01929343|9935480|FG001|Overall Study|Physician Decision|2
6248650|NCT01929343|9935481|FG002|Overall Study|Physician Decision|0
6248651|NCT01929343|9935479|FG000|Overall Study|Withdrawal by Subject|1
6248652|NCT01929343|9935480|FG001|Overall Study|Withdrawal by Subject|0
6248653|NCT01929343|9935481|FG002|Overall Study|Withdrawal by Subject|0
6248654|NCT01929395|9935492|FG000|Overall Study|Did not complete - non-related toxicity|1
6248655|NCT01929395|9935493|FG001|Overall Study|Did not complete - non-related toxicity|0
6248656|NCT01929395|9935494|FG002|Overall Study|Did not complete - non-related toxicity|0
6248657|NCT01929395|9935492|FG000|Overall Study|Withdrawal by Subject|0
6248658|NCT01929395|9935493|FG001|Overall Study|Withdrawal by Subject|1
6248659|NCT01929395|9935494|FG002|Overall Study|Withdrawal by Subject|0
6248660|NCT01929395|9935492|FG000|Overall Study|Screen Fail|0
6248661|NCT01929395|9935493|FG001|Overall Study|Screen Fail|0
6248662|NCT01929395|9935494|FG002|Overall Study|Screen Fail|1
6248663|NCT01929408|9935502|FG000|Overall Study|received HCT as initial treatment|8
6248664|NCT01929681|9935527|FG000|Overall Study|Withdrawal by Subject|1
6248665|NCT01929681|9935528|FG001|Overall Study|Withdrawal by Subject|0
6248666|NCT01929681|9935527|FG000|Overall Study|Physician Decision|1
6248667|NCT01929681|9935528|FG001|Overall Study|Physician Decision|1
6248668|NCT01929707|9935534|FG000|Intervention Period 1|Lost to Follow-up|0
6248669|NCT01929707|9935535|FG001|Intervention Period 1|Lost to Follow-up|0
6248670|NCT01929707|9935536|FG002|Intervention Period 1|Lost to Follow-up|0
6248671|NCT01929707|9935537|FG003|Intervention Period 1|Lost to Follow-up|1
6248672|NCT01929707|9935538|FG004|Intervention Period 1|Lost to Follow-up|0
6248673|NCT01929707|9935539|FG005|Intervention Period 1|Lost to Follow-up|0
6248674|NCT01929707|9935540|FG006|Intervention Period 1|Lost to Follow-up|0
6248675|NCT01929707|9935541|FG007|Intervention Period 1|Lost to Follow-up|0
6248676|NCT01929707|9935534|FG000|Intervention Period 1|Withdrawal by Subject|0
6248677|NCT01929707|9935535|FG001|Intervention Period 1|Withdrawal by Subject|0
6248678|NCT01929707|9935536|FG002|Intervention Period 1|Withdrawal by Subject|0
6248679|NCT01929707|9935537|FG003|Intervention Period 1|Withdrawal by Subject|2
6248680|NCT01929707|9935538|FG004|Intervention Period 1|Withdrawal by Subject|0
6248681|NCT01929707|9935539|FG005|Intervention Period 1|Withdrawal by Subject|0
6248682|NCT01929707|9935540|FG006|Intervention Period 1|Withdrawal by Subject|0
6248683|NCT01929707|9935541|FG007|Intervention Period 1|Withdrawal by Subject|0
6248684|NCT01929707|9935534|FG000|Intervention Period 2|Withdrawal by Subject|0
6248685|NCT01929707|9935535|FG001|Intervention Period 2|Withdrawal by Subject|0
6248686|NCT01929707|9935536|FG002|Intervention Period 2|Withdrawal by Subject|0
6248687|NCT01929707|9935537|FG003|Intervention Period 2|Withdrawal by Subject|0
6248688|NCT01929707|9935538|FG004|Intervention Period 2|Withdrawal by Subject|0
6248689|NCT01929707|9935539|FG005|Intervention Period 2|Withdrawal by Subject|2
6248690|NCT01929707|9935540|FG006|Intervention Period 2|Withdrawal by Subject|0
6248691|NCT01929707|9935541|FG007|Intervention Period 2|Withdrawal by Subject|0
6248692|NCT01929863|9935566|FG000|Period 1:Intervention Period 1 (7 Days)|Adverse Event|1
6248693|NCT01929863|9935567|FG001|Period 1:Intervention Period 1 (7 Days)|Adverse Event|0
6248694|NCT01929863|9935566|FG000|Period 1:Intervention Period 1 (7 Days)|Withdrawal by Subject|0
6248695|NCT01929863|9935567|FG001|Period 1:Intervention Period 1 (7 Days)|Withdrawal by Subject|1
6248696|NCT01929863|9935566|FG000|Period 3:Intervention Period 2 (7 Days)|Adverse Event|0
6248697|NCT01929863|9935567|FG001|Period 3:Intervention Period 2 (7 Days)|Adverse Event|1
6248698|NCT01929876|9935578|FG000|Period 2|Non-Compliance|1
6248699|NCT01929980|9935586|FG000|Overall Study|Physician Decision|1
6248700|NCT01929993|9935592|FG000|Overall Study|Protocol Violation|4
6248701|NCT01929993|9935593|FG001|Overall Study|Protocol Violation|6
6248702|NCT01929993|9935592|FG000|Overall Study|Absent CIN, invasion present or artifact|26
6248703|NCT01929993|9935593|FG001|Overall Study|Absent CIN, invasion present or artifact|22
6248704|NCT01930045|9935599|FG000|Pause (up to 37 Days)|Withdrawal by Subject|0
6248705|NCT01930045|9935600|FG001|Pause (up to 37 Days)|Withdrawal by Subject|0
6248706|NCT01930045|9935601|FG002|Pause (up to 37 Days)|Withdrawal by Subject|0
6248707|NCT01930045|9935602|FG003|Pause (up to 37 Days)|Withdrawal by Subject|0
6248708|NCT01930045|9935603|FG004|Pause (up to 37 Days)|Withdrawal by Subject|0
6248709|NCT01930045|9935604|FG005|Pause (up to 37 Days)|Withdrawal by Subject|1
6248710|NCT01930045|9935599|FG000|Pause (up to 37 Days)|Protocol Violation|0
6248711|NCT01930045|9935600|FG001|Pause (up to 37 Days)|Protocol Violation|0
6248712|NCT01930045|9935601|FG002|Pause (up to 37 Days)|Protocol Violation|0
6248713|NCT01930045|9935602|FG003|Pause (up to 37 Days)|Protocol Violation|0
6248714|NCT01930045|9935603|FG004|Pause (up to 37 Days)|Protocol Violation|0
6248715|NCT01930045|9935604|FG005|Pause (up to 37 Days)|Protocol Violation|1
6248716|NCT01930162|9935628|FG000|Overall Study|Abnormal test procedure result(s)|4
6248717|NCT01930162|9935628|FG000|Overall Study|Death|1
6270676|NCT02155660|9971965|FG003|Overall Study|Study-specific withdrawal criteria|1
6270677|NCT02155660|9971962|FG000|Overall Study|Severe non-compliance|0
6270678|NCT02155660|9971963|FG001|Overall Study|Severe non-compliance|4
6270679|NCT02155660|9971964|FG002|Overall Study|Severe non-compliance|0
6270680|NCT02155660|9971965|FG003|Overall Study|Severe non-compliance|1
6270681|NCT02155660|9971962|FG000|Overall Study|Adverse Event|2
6270682|NCT02155660|9971963|FG001|Overall Study|Adverse Event|6
6270683|NCT02155660|9971964|FG002|Overall Study|Adverse Event|3
6270684|NCT02155660|9971965|FG003|Overall Study|Adverse Event|1
6270685|NCT02155660|9971962|FG000|Overall Study|Lost to Follow-up|3
6270686|NCT02155660|9971963|FG001|Overall Study|Lost to Follow-up|6
6270687|NCT02155660|9971964|FG002|Overall Study|Lost to Follow-up|5
6270688|NCT02155660|9971965|FG003|Overall Study|Lost to Follow-up|8
6270689|NCT02155660|9971962|FG000|Overall Study|Death|17
6270690|NCT02155660|9971963|FG001|Overall Study|Death|19
6270691|NCT02155660|9971964|FG002|Overall Study|Death|17
6270692|NCT02155660|9971965|FG003|Overall Study|Death|19
6270693|NCT02155660|9971962|FG000|Overall Study|Withdrawal by Subject|28
6270694|NCT02155660|9971963|FG001|Overall Study|Withdrawal by Subject|31
6270695|NCT02155660|9971964|FG002|Overall Study|Withdrawal by Subject|24
6270696|NCT02155660|9971965|FG003|Overall Study|Withdrawal by Subject|21
6270697|NCT02155712|9971977|FG000|Primary Objective|Death|3
6270698|NCT02155712|9971978|FG001|Primary Objective|Death|0
6270699|NCT02155712|9971977|FG000|Primary Objective|Lost to Follow-up|22
6270700|NCT02155712|9971978|FG001|Primary Objective|Lost to Follow-up|0
6270701|NCT02155712|9971977|FG000|Primary Objective|No 2-Year Forms but not Terminated|13
6270702|NCT02155712|9971978|FG001|Primary Objective|No 2-Year Forms but not Terminated|0
6270703|NCT02155712|9971977|FG000|Primary Objective|Revision/Removal of Tibial Baseplate|1
6270704|NCT02155712|9971978|FG001|Primary Objective|Revision/Removal of Tibial Baseplate|0
6270705|NCT02155712|9971977|FG000|Primary Objective|Withdrawal by Subject|21
6270706|NCT02155712|9971978|FG001|Primary Objective|Withdrawal by Subject|0
6270707|NCT02155738|9972003|FG000|Overall Study|Missing critical information|1
6270708|NCT02155738|9972004|FG001|Overall Study|Missing critical information|0
6270709|NCT02155738|9972005|FG002|Overall Study|Missing critical information|0
6270710|NCT02155738|9972006|FG003|Overall Study|Missing critical information|1
6270711|NCT02155829|9972018|FG000|Overall Study|Adverse Event|1
6270712|NCT02155829|9972019|FG001|Overall Study|Adverse Event|0
6270713|NCT02155829|9972018|FG000|Overall Study|Withdrawal by Subject|3
6270714|NCT02155829|9972019|FG001|Overall Study|Withdrawal by Subject|3
6270715|NCT02155829|9972018|FG000|Overall Study|Protocol Violation|2
6270716|NCT02155829|9972019|FG001|Overall Study|Protocol Violation|0
6270717|NCT02155881|9972028|FG000|Overall Study|Withdrawal by Subject|0
6270718|NCT02155881|9972029|FG001|Overall Study|Withdrawal by Subject|2
6270719|NCT02155881|9972028|FG000|Overall Study|Inappropriately randomized|2
6270720|NCT02155881|9972029|FG001|Overall Study|Inappropriately randomized|2
6270721|NCT02155985|9972038|FG000|Overall Study|Withdrawal by Subject|0
6270722|NCT02155985|9972039|FG001|Overall Study|Withdrawal by Subject|0
6270723|NCT02155985|9972040|FG002|Overall Study|Withdrawal by Subject|1
6270724|NCT02155985|9972038|FG000|Overall Study|Lost to Follow-up|1
6270725|NCT02155985|9972039|FG001|Overall Study|Lost to Follow-up|0
6270726|NCT02155985|9972040|FG002|Overall Study|Lost to Follow-up|0
6270727|NCT02156076|9972052|FG000|Treatment Period|no longer meets study criteria|0
6248718|NCT01930175|9935636|FG000|Core Study|Lost to Follow-up|0
6248719|NCT01930175|9935637|FG001|Core Study|Lost to Follow-up|1
6248720|NCT01930175|9935638|FG002|Core Study|Lost to Follow-up|0
6248721|NCT01930175|9935636|FG000|Core Study|Adverse Event|0
6248722|NCT01930175|9935637|FG001|Core Study|Adverse Event|0
6248723|NCT01930175|9935638|FG002|Core Study|Adverse Event|1
6248724|NCT01930188|9935650|FG000|Overall Study|unclassified|4
6248725|NCT01930188|9935651|FG001|Overall Study|unclassified|5
6248726|NCT01930188|9935652|FG002|Overall Study|unclassified|3
6248727|NCT01930188|9935650|FG000|Overall Study|Missing follow-up information|2
6248728|NCT01930188|9935651|FG001|Overall Study|Missing follow-up information|2
6248729|NCT01930188|9935652|FG002|Overall Study|Missing follow-up information|3
6248730|NCT01930188|9935650|FG000|Overall Study|Lost to Follow-up|5
6248731|NCT01930188|9935651|FG001|Overall Study|Lost to Follow-up|2
6248732|NCT01930188|9935652|FG002|Overall Study|Lost to Follow-up|2
6248733|NCT01930188|9935650|FG000|Overall Study|Death|2
6248734|NCT01930188|9935651|FG001|Overall Study|Death|1
6248735|NCT01930188|9935652|FG002|Overall Study|Death|3
6248736|NCT01930188|9935650|FG000|Overall Study|Withdrawal by Subject|9
6248737|NCT01930188|9935651|FG001|Overall Study|Withdrawal by Subject|11
6248738|NCT01930188|9935652|FG002|Overall Study|Withdrawal by Subject|8
6248739|NCT01930214|9935664|FG000|Overall Study|Death|4
6248740|NCT01930214|9935665|FG001|Overall Study|Death|4
6248741|NCT01930214|9935666|FG002|Overall Study|Death|11
6248742|NCT01930214|9935664|FG000|Overall Study|Lost to Follow-up|12
6248743|NCT01930214|9935665|FG001|Overall Study|Lost to Follow-up|13
6248744|NCT01930214|9935666|FG002|Overall Study|Lost to Follow-up|12
6248745|NCT01930214|9935664|FG000|Overall Study|Voluntary withdrawal of infomed consent|2
6248746|NCT01930214|9935665|FG001|Overall Study|Voluntary withdrawal of infomed consent|4
6248747|NCT01930214|9935666|FG002|Overall Study|Voluntary withdrawal of infomed consent|2
6248748|NCT01930214|9935664|FG000|Overall Study|Physician Decision|2
6248749|NCT01930214|9935665|FG001|Overall Study|Physician Decision|0
6248750|NCT01930214|9935666|FG002|Overall Study|Physician Decision|0
6248751|NCT01930799|9935708|FG000|Overall Study|Withdrawal by Subject|3
6248752|NCT01930799|9935708|FG000|Overall Study|Lost to Follow-up|5
6248753|NCT01930890|9935716|FG000|Overall Study|Study Termination|14
6248754|NCT01930890|9935717|FG001|Overall Study|Study Termination|28
6248755|NCT01930890|9935718|FG002|Overall Study|Study Termination|13
6248756|NCT01930890|9935719|FG003|Overall Study|Study Termination|25
6248757|NCT01930890|9935716|FG000|Overall Study|Death|0
6248758|NCT01930890|9935717|FG001|Overall Study|Death|0
6248759|NCT01930890|9935718|FG002|Overall Study|Death|0
6248760|NCT01930890|9935719|FG003|Overall Study|Death|1
6248761|NCT01930890|9935716|FG000|Overall Study|Investigator Decision|0
6248762|NCT01930890|9935717|FG001|Overall Study|Investigator Decision|1
6248763|NCT01930890|9935718|FG002|Overall Study|Investigator Decision|0
6248764|NCT01930890|9935719|FG003|Overall Study|Investigator Decision|0
6248765|NCT01930890|9935716|FG000|Overall Study|Consent Withdrawn|0
6248766|NCT01930890|9935717|FG001|Overall Study|Consent Withdrawn|3
6248767|NCT01930890|9935718|FG002|Overall Study|Consent Withdrawn|0
6248768|NCT01930890|9935719|FG003|Overall Study|Consent Withdrawn|1
6248769|NCT01930890|9935716|FG000|Overall Study|Adverse Event|0
6248770|NCT01930890|9935717|FG001|Overall Study|Adverse Event|1
6248771|NCT01930890|9935718|FG002|Overall Study|Adverse Event|0
6248772|NCT01930890|9935719|FG003|Overall Study|Adverse Event|0
6248773|NCT01931059|9935731|FG000|Day 1|Pregnancy|0
6248774|NCT01931059|9935732|FG001|Day 1|Pregnancy|1
6248775|NCT01931059|9935731|FG000|Day3|Lost to Follow-up|1
6248776|NCT01931059|9935732|FG001|Day3|Lost to Follow-up|0
6248777|NCT01931150|9935746|FG000|Overall Study|Withdrawal by Subject|1
6248778|NCT01931150|9935747|FG001|Overall Study|Withdrawal by Subject|2
6248779|NCT01931202|9935760|FG000|Overall Study|Withdrawal by Subject|0
6248780|NCT01931202|9935761|FG001|Overall Study|Withdrawal by Subject|0
6248781|NCT01931202|9935762|FG002|Overall Study|Withdrawal by Subject|2
6248782|NCT01931202|9935760|FG000|Overall Study|Lost to Follow-up|0
6248783|NCT01931202|9935761|FG001|Overall Study|Lost to Follow-up|5
6248784|NCT01931202|9935762|FG002|Overall Study|Lost to Follow-up|2
6248785|NCT01931397|9935773|FG000|Overall Study|Physician Decision|2
6248786|NCT01931397|9935773|FG000|Overall Study|Withdrawal by Subject|8
6248787|NCT01931397|9935773|FG000|Overall Study|moved out of state|1
6248788|NCT01931462|9935781|FG000|Overall Study|Withdrawal by Subject|1
6248789|NCT01931475|9935787|FG000|Period 1: Double-Blind Treatment Phase|Adverse Event|20
6248790|NCT01931475|9935788|FG001|Period 1: Double-Blind Treatment Phase|Adverse Event|10
6248791|NCT01931475|9935787|FG000|Period 1: Double-Blind Treatment Phase|Lost to Follow-up|1
6248792|NCT01931475|9935788|FG001|Period 1: Double-Blind Treatment Phase|Lost to Follow-up|0
6248793|NCT01931475|9935787|FG000|Period 1: Double-Blind Treatment Phase|Withdrawal by Subject|16
6248794|NCT01931475|9935788|FG001|Period 1: Double-Blind Treatment Phase|Withdrawal by Subject|12
6248795|NCT01931475|9935787|FG000|Period 1: Double-Blind Treatment Phase|Lack of Efficacy|2
6248796|NCT01931475|9935788|FG001|Period 1: Double-Blind Treatment Phase|Lack of Efficacy|3
6248797|NCT01931475|9935787|FG000|Period 1: Double-Blind Treatment Phase|Physician Decision|0
6248798|NCT01931475|9935788|FG001|Period 1: Double-Blind Treatment Phase|Physician Decision|1
6248799|NCT01931475|9935787|FG000|Period 2: Extension Treatment Phase|Adverse Event|0
6248800|NCT01931475|9935788|FG001|Period 2: Extension Treatment Phase|Adverse Event|8
6248801|NCT01931475|9935787|FG000|Period 2: Extension Treatment Phase|Protocol Violation|1
6248802|NCT01931475|9935788|FG001|Period 2: Extension Treatment Phase|Protocol Violation|0
6248803|NCT01931475|9935787|FG000|Period 2: Extension Treatment Phase|Withdrawal by Subject|0
6248804|NCT01931475|9935788|FG001|Period 2: Extension Treatment Phase|Withdrawal by Subject|9
6248805|NCT01931475|9935787|FG000|Period 2: Extension Treatment Phase|Physician Decision|1
6248806|NCT01931475|9935788|FG001|Period 2: Extension Treatment Phase|Physician Decision|1
6248807|NCT01931475|9935787|FG000|Period 2: Extension Treatment Phase|Study Terminated by Sponsor|1
6248808|NCT01931475|9935788|FG001|Period 2: Extension Treatment Phase|Study Terminated by Sponsor|0
6248809|NCT01931475|9935787|FG000|Period 2: Extension Treatment Phase|Lack of Efficacy|1
6248810|NCT01931475|9935788|FG001|Period 2: Extension Treatment Phase|Lack of Efficacy|1
6248811|NCT01931566|9935815|FG000|Overall Study|Randomized But Not Treated|6
6248812|NCT01931566|9935816|FG001|Overall Study|Randomized But Not Treated|9
6248813|NCT01931566|9935817|FG002|Overall Study|Randomized But Not Treated|14
6248814|NCT01931566|9935815|FG000|Overall Study|Adverse Event|37
6248815|NCT01931566|9935816|FG001|Overall Study|Adverse Event|167
6248816|NCT01931566|9935817|FG002|Overall Study|Adverse Event|132
6248817|NCT01931566|9935815|FG000|Overall Study|Major Protocol Deviation|5
6248818|NCT01931566|9935816|FG001|Overall Study|Major Protocol Deviation|14
6248819|NCT01931566|9935817|FG002|Overall Study|Major Protocol Deviation|21
6248820|NCT01931566|9935815|FG000|Overall Study|Lost to Follow-up|3
6248821|NCT01931566|9935816|FG001|Overall Study|Lost to Follow-up|26
6248822|NCT01931566|9935817|FG002|Overall Study|Lost to Follow-up|23
6248823|NCT01931566|9935815|FG000|Overall Study|Voluntary Withdrawal|78
6248824|NCT01931566|9935816|FG001|Overall Study|Voluntary Withdrawal|245
6248825|NCT01931566|9935817|FG002|Overall Study|Voluntary Withdrawal|225
6248826|NCT01931566|9935815|FG000|Overall Study|Study Termination|289
6248827|NCT01931566|9935816|FG001|Overall Study|Study Termination|968
6248828|NCT01931566|9935817|FG002|Overall Study|Study Termination|1037
6248829|NCT01931566|9935815|FG000|Overall Study|Reason Not Specified|11
6248830|NCT01931566|9935816|FG001|Overall Study|Reason Not Specified|47
6248831|NCT01931566|9935817|FG002|Overall Study|Reason Not Specified|53
6248832|NCT01931566|9935815|FG000|Overall Study|Missing|0
6248833|NCT01931566|9935816|FG001|Overall Study|Missing|0
6248834|NCT01931566|9935817|FG002|Overall Study|Missing|1
6248835|NCT01931670|9935829|FG000|Treatment Period|Exclusionary Medication Received|1
6248836|NCT01931670|9935830|FG001|Treatment Period|Exclusionary Medication Received|1
6248837|NCT01931670|9935831|FG002|Treatment Period|Exclusionary Medication Received|1
6248838|NCT01931670|9935829|FG000|Treatment Period|Surgery/Invasive Intervention|4
6248839|NCT01931670|9935830|FG001|Treatment Period|Surgery/Invasive Intervention|2
6248840|NCT01931670|9935831|FG002|Treatment Period|Surgery/Invasive Intervention|0
6248841|NCT01931670|9935829|FG000|Treatment Period|Subject Noncompliant|4
6248842|NCT01931670|9935830|FG001|Treatment Period|Subject Noncompliant|9
6248843|NCT01931670|9935831|FG002|Treatment Period|Subject Noncompliant|5
6248844|NCT01931670|9935829|FG000|Treatment Period|Adverse Event|19
6248845|NCT01931670|9935830|FG001|Treatment Period|Adverse Event|8
6248846|NCT01931670|9935831|FG002|Treatment Period|Adverse Event|21
6248847|NCT01931670|9935829|FG000|Treatment Period|Lack of Efficacy|11
6248848|NCT01931670|9935830|FG001|Treatment Period|Lack of Efficacy|2
6248849|NCT01931670|9935831|FG002|Treatment Period|Lack of Efficacy|2
6248850|NCT01931670|9935829|FG000|Treatment Period|Pregnancy|7
6248851|NCT01931670|9935830|FG001|Treatment Period|Pregnancy|2
6248852|NCT01931670|9935831|FG002|Treatment Period|Pregnancy|0
6248853|NCT01931670|9935829|FG000|Treatment Period|Other|8
6248854|NCT01931670|9935830|FG001|Treatment Period|Other|7
6248855|NCT01931670|9935831|FG002|Treatment Period|Other|2
6248856|NCT01931670|9935829|FG000|Treatment Period|Consent Withdrawn by Subject|17
6248857|NCT01931670|9935830|FG001|Treatment Period|Consent Withdrawn by Subject|12
6248858|NCT01931670|9935831|FG002|Treatment Period|Consent Withdrawn by Subject|7
6248859|NCT01931670|9935829|FG000|Treatment Period|Lost to Follow-up|19
6248860|NCT01931670|9935830|FG001|Treatment Period|Lost to Follow-up|5
6248861|NCT01931670|9935831|FG002|Treatment Period|Lost to Follow-up|7
6248862|NCT01931670|9935829|FG000|Post-Treatment Follow-Up (PTFU) Period|Exclusionary Medication Received|3
6248863|NCT01931670|9935830|FG001|Post-Treatment Follow-Up (PTFU) Period|Exclusionary Medication Received|0
6248864|NCT01931670|9935831|FG002|Post-Treatment Follow-Up (PTFU) Period|Exclusionary Medication Received|0
6248865|NCT01931670|9935829|FG000|Post-Treatment Follow-Up (PTFU) Period|Adverse Event|0
6248866|NCT01931670|9935830|FG001|Post-Treatment Follow-Up (PTFU) Period|Adverse Event|2
6248867|NCT01931670|9935831|FG002|Post-Treatment Follow-Up (PTFU) Period|Adverse Event|1
6248868|NCT01931670|9935829|FG000|Post-Treatment Follow-Up (PTFU) Period|Surgery/Invasive Intervention|4
6248869|NCT01931670|9935830|FG001|Post-Treatment Follow-Up (PTFU) Period|Surgery/Invasive Intervention|4
6248870|NCT01931670|9935831|FG002|Post-Treatment Follow-Up (PTFU) Period|Surgery/Invasive Intervention|2
6248871|NCT01931670|9935829|FG000|Post-Treatment Follow-Up (PTFU) Period|Other|6
6248872|NCT01931670|9935830|FG001|Post-Treatment Follow-Up (PTFU) Period|Other|3
6248873|NCT01931670|9935831|FG002|Post-Treatment Follow-Up (PTFU) Period|Other|3
6248874|NCT01931670|9935829|FG000|Post-Treatment Follow-Up (PTFU) Period|Consent Withdrawn by Subject|6
6248875|NCT01931670|9935830|FG001|Post-Treatment Follow-Up (PTFU) Period|Consent Withdrawn by Subject|3
6248876|NCT01931670|9935831|FG002|Post-Treatment Follow-Up (PTFU) Period|Consent Withdrawn by Subject|13
6248877|NCT01931670|9935829|FG000|Post-Treatment Follow-Up (PTFU) Period|Lost to Follow-up|0
6248878|NCT01931670|9935830|FG001|Post-Treatment Follow-Up (PTFU) Period|Lost to Follow-up|0
6248879|NCT01931670|9935831|FG002|Post-Treatment Follow-Up (PTFU) Period|Lost to Follow-up|2
6248880|NCT01931735|9935849|FG000|Randomized Phase|Lost to Follow-up|2
6248881|NCT01931735|9935850|FG001|Randomized Phase|Lost to Follow-up|2
6248882|NCT01931735|9935851|FG002|Randomized Phase|Lost to Follow-up|5
6248883|NCT01931735|9935852|FG003|Randomized Phase|Lost to Follow-up|0
6248884|NCT01931735|9935849|FG000|Observational Non-Randomized Phase|Adverse Event|0
6248885|NCT01931735|9935850|FG001|Observational Non-Randomized Phase|Adverse Event|0
6248886|NCT01931735|9935851|FG002|Observational Non-Randomized Phase|Adverse Event|0
6248887|NCT01931735|9935852|FG003|Observational Non-Randomized Phase|Adverse Event|1
6248888|NCT01931735|9935849|FG000|Observational Non-Randomized Phase|Withdrawal by Subject|0
6248889|NCT01931735|9935850|FG001|Observational Non-Randomized Phase|Withdrawal by Subject|0
6248890|NCT01931735|9935851|FG002|Observational Non-Randomized Phase|Withdrawal by Subject|0
6248891|NCT01931735|9935852|FG003|Observational Non-Randomized Phase|Withdrawal by Subject|1
6248892|NCT01931839|9935869|FG000|Overall Study|Death|0
6248893|NCT01931839|9935870|FG001|Overall Study|Death|1
6248894|NCT01931839|9935871|FG002|Overall Study|Death|2
6248895|NCT01931839|9935872|FG003|Overall Study|Death|0
6248896|NCT01931839|9935873|FG004|Overall Study|Death|0
6248897|NCT01931839|9935874|FG005|Overall Study|Death|0
6248898|NCT01931839|9935875|FG006|Overall Study|Death|0
6248899|NCT01931839|9935869|FG000|Overall Study|Physician Decision|1
6248900|NCT01931839|9935870|FG001|Overall Study|Physician Decision|0
6248901|NCT01931839|9935871|FG002|Overall Study|Physician Decision|1
6248902|NCT01931839|9935872|FG003|Overall Study|Physician Decision|0
6248903|NCT01931839|9935873|FG004|Overall Study|Physician Decision|0
6248904|NCT01931839|9935874|FG005|Overall Study|Physician Decision|0
6248905|NCT01931839|9935875|FG006|Overall Study|Physician Decision|1
6248906|NCT01931839|9935869|FG000|Overall Study|Withdrawal of consent|0
6248907|NCT01931839|9935870|FG001|Overall Study|Withdrawal of consent|0
6248908|NCT01931839|9935871|FG002|Overall Study|Withdrawal of consent|0
6248909|NCT01931839|9935872|FG003|Overall Study|Withdrawal of consent|0
6248910|NCT01931839|9935873|FG004|Overall Study|Withdrawal of consent|1
6248911|NCT01931839|9935874|FG005|Overall Study|Withdrawal of consent|0
6248912|NCT01931839|9935875|FG006|Overall Study|Withdrawal of consent|0
6248913|NCT01931839|9935869|FG000|Overall Study|Adverse Event|9
6248914|NCT01931839|9935870|FG001|Overall Study|Adverse Event|4
6248915|NCT01931839|9935871|FG002|Overall Study|Adverse Event|1
6248916|NCT01931839|9935872|FG003|Overall Study|Adverse Event|3
6248917|NCT01931839|9935873|FG004|Overall Study|Adverse Event|0
6248918|NCT01931839|9935874|FG005|Overall Study|Adverse Event|0
6248919|NCT01931839|9935875|FG006|Overall Study|Adverse Event|1
6248920|NCT01931839|9935869|FG000|Overall Study|Withdrawal of consent (not due to AE)|11
6248921|NCT01931839|9935870|FG001|Overall Study|Withdrawal of consent (not due to AE)|8
6248922|NCT01931839|9935871|FG002|Overall Study|Withdrawal of consent (not due to AE)|13
6248923|NCT01931839|9935872|FG003|Overall Study|Withdrawal of consent (not due to AE)|3
6248924|NCT01931839|9935873|FG004|Overall Study|Withdrawal of consent (not due to AE)|0
6248925|NCT01931839|9935874|FG005|Overall Study|Withdrawal of consent (not due to AE)|2
6248926|NCT01931839|9935875|FG006|Overall Study|Withdrawal of consent (not due to AE)|2
6248927|NCT01931839|9935869|FG000|Overall Study|Other non-compliance|15
6248928|NCT01931839|9935870|FG001|Overall Study|Other non-compliance|9
6248929|NCT01931839|9935871|FG002|Overall Study|Other non-compliance|12
6248930|NCT01931839|9935872|FG003|Overall Study|Other non-compliance|3
6248931|NCT01931839|9935873|FG004|Overall Study|Other non-compliance|0
6248932|NCT01931839|9935874|FG005|Overall Study|Other non-compliance|3
6248933|NCT01931839|9935875|FG006|Overall Study|Other non-compliance|0
6248934|NCT01931839|9935869|FG000|Overall Study|Lost to Follow-up|1
6248935|NCT01931839|9935870|FG001|Overall Study|Lost to Follow-up|2
6248936|NCT01931839|9935871|FG002|Overall Study|Lost to Follow-up|4
6043652|NCT00391222|9642348|FG001|Period III (Double-Blind Treatment)|Withdrawal by Subject|12
6043653|NCT00391222|9642349|FG002|Period III (Double-Blind Treatment)|Withdrawal by Subject|6
6043654|NCT00391222|9642350|FG003|Period III (Double-Blind Treatment)|Withdrawal by Subject|0
6043655|NCT00391222|9642347|FG000|Period III (Double-Blind Treatment)|Lost to Follow-up|2
6043656|NCT00391222|9642348|FG001|Period III (Double-Blind Treatment)|Lost to Follow-up|4
6043657|NCT00391222|9642349|FG002|Period III (Double-Blind Treatment)|Lost to Follow-up|4
6043658|NCT00391222|9642350|FG003|Period III (Double-Blind Treatment)|Lost to Follow-up|0
6043659|NCT00391222|9642347|FG000|Period III (Double-Blind Treatment)|Adverse Event|5
6043660|NCT00391222|9642348|FG001|Period III (Double-Blind Treatment)|Adverse Event|2
6248937|NCT01931839|9935872|FG003|Overall Study|Lost to Follow-up|5
6248938|NCT01931839|9935873|FG004|Overall Study|Lost to Follow-up|0
6248939|NCT01931839|9935874|FG005|Overall Study|Lost to Follow-up|0
6248940|NCT01931839|9935875|FG006|Overall Study|Lost to Follow-up|0
6248941|NCT01931839|9935869|FG000|Overall Study|Other|4
6248942|NCT01931839|9935870|FG001|Overall Study|Other|2
6248943|NCT01931839|9935871|FG002|Overall Study|Other|6
6248944|NCT01931839|9935872|FG003|Overall Study|Other|0
6248945|NCT01931839|9935873|FG004|Overall Study|Other|0
6248946|NCT01931839|9935874|FG005|Overall Study|Other|0
6248947|NCT01931839|9935875|FG006|Overall Study|Other|0
6248948|NCT01931865|9935895|FG000|Overall Study|Lost to Follow-up|2
6248949|NCT01931865|9935895|FG000|Overall Study|Withdrawal by Subject|2
6248950|NCT01931956|9935915|FG000|Overall Study|Death|42
6248951|NCT01931956|9935916|FG001|Overall Study|Death|7
6248952|NCT01931956|9935917|FG002|Overall Study|Death|379
6248953|NCT01931956|9935918|FG003|Overall Study|Death|96
6248954|NCT01931956|9935915|FG000|Overall Study|Withdrawal by Subject|5
6248955|NCT01931956|9935916|FG001|Overall Study|Withdrawal by Subject|0
6248956|NCT01931956|9935917|FG002|Overall Study|Withdrawal by Subject|70
6248957|NCT01931956|9935918|FG003|Overall Study|Withdrawal by Subject|30
6248958|NCT01931956|9935915|FG000|Overall Study|Lost to Follow-up|2
6248959|NCT01931956|9935916|FG001|Overall Study|Lost to Follow-up|0
6248960|NCT01931956|9935917|FG002|Overall Study|Lost to Follow-up|11
6248961|NCT01931956|9935918|FG003|Overall Study|Lost to Follow-up|7
6248962|NCT01931956|9935915|FG000|Overall Study|Expected|2
6248963|NCT01931956|9935916|FG001|Overall Study|Expected|0
6248964|NCT01931956|9935917|FG002|Overall Study|Expected|6
6248965|NCT01931956|9935918|FG003|Overall Study|Expected|0
6248966|NCT01931956|9935915|FG000|Overall Study|Not due|0
6248967|NCT01931956|9935916|FG001|Overall Study|Not due|0
6248968|NCT01931956|9935917|FG002|Overall Study|Not due|21
6248969|NCT01931956|9935918|FG003|Overall Study|Not due|0
6248970|NCT01931995|9935943|FG000|First Intervention (1 Day)|Withdrawal by Subject|2
6248971|NCT01931995|9935944|FG001|First Intervention (1 Day)|Withdrawal by Subject|2
6248972|NCT01931995|9935943|FG000|First Intervention (1 Day)|Physician Decision|1
6248973|NCT01931995|9935944|FG001|First Intervention (1 Day)|Physician Decision|1
6248974|NCT01931995|9935943|FG000|First Intervention (1 Day)|Lost to Follow-up|1
6248975|NCT01931995|9935944|FG001|First Intervention (1 Day)|Lost to Follow-up|1
6248976|NCT01932294|9935976|FG000|Overall Study|Death|43
6248977|NCT01932294|9935976|FG000|Overall Study|Lost to Follow-up|8
6248978|NCT01932294|9935976|FG000|Overall Study|VAD Implantation|20
6248979|NCT01932294|9935976|FG000|Overall Study|Heart Transplantation|16
6248980|NCT01932294|9935976|FG000|Overall Study|Transferred to other hospitals|12
6248981|NCT01932437|9935983|FG000|Cohort 5 - ETI-204 24 mg/kg or Placebo|Lost to Follow-up|0
6248982|NCT01932437|9935984|FG001|Cohort 5 - ETI-204 24 mg/kg or Placebo|Lost to Follow-up|0
6248983|NCT01932437|9935985|FG002|Cohort 5 - ETI-204 24 mg/kg or Placebo|Lost to Follow-up|0
6248984|NCT01932437|9935986|FG003|Cohort 5 - ETI-204 24 mg/kg or Placebo|Lost to Follow-up|0
6248985|NCT01932437|9935987|FG004|Cohort 5 - ETI-204 24 mg/kg or Placebo|Lost to Follow-up|0
6248986|NCT01932437|9935988|FG005|Cohort 5 - ETI-204 24 mg/kg or Placebo|Lost to Follow-up|1
6248987|NCT01932697|9936020|FG000|Overall Study|Received a different amount of tx|1
6248988|NCT01932697|9936021|FG001|Overall Study|Received a different amount of tx|0
6248989|NCT01932697|9936020|FG000|Overall Study|Ineligible|1
6248990|NCT01932697|9936021|FG001|Overall Study|Ineligible|0
6248991|NCT01932762|9936033|FG000|Overall Study|Withdrawal by Subject|1
6248992|NCT01932762|9936034|FG001|Overall Study|Withdrawal by Subject|2
6248993|NCT01932762|9936035|FG002|Overall Study|Withdrawal by Subject|0
6248994|NCT01932762|9936036|FG003|Overall Study|Withdrawal by Subject|0
6248995|NCT01932762|9936033|FG000|Overall Study|Lost to Follow-up|4
6248996|NCT01932762|9936034|FG001|Overall Study|Lost to Follow-up|0
6248997|NCT01932762|9936035|FG002|Overall Study|Lost to Follow-up|0
6248998|NCT01932762|9936036|FG003|Overall Study|Lost to Follow-up|1
6248999|NCT01932762|9936033|FG000|Overall Study|Physician Decision|1
6249000|NCT01932762|9936034|FG001|Overall Study|Physician Decision|0
6249001|NCT01932762|9936035|FG002|Overall Study|Physician Decision|0
6249002|NCT01932762|9936036|FG003|Overall Study|Physician Decision|0
6249003|NCT01932788|9936048|FG000|Overall Study|Protocol Violation|18
6249004|NCT01932788|9936049|FG001|Overall Study|Protocol Violation|0
6249005|NCT01932788|9936048|FG000|Overall Study|Lost to Follow-up|18
6249006|NCT01932788|9936049|FG001|Overall Study|Lost to Follow-up|46
6249007|NCT01932788|9936048|FG000|Overall Study|Lack of Efficacy|2
6249008|NCT01932788|9936049|FG001|Overall Study|Lack of Efficacy|0
6249009|NCT01932788|9936048|FG000|Overall Study|Withdrawal by Subject|0
6249010|NCT01932788|9936049|FG001|Overall Study|Withdrawal by Subject|5
6249011|NCT01932970|9936055|FG000|Overall Study|Withdrawal by Subject|5
6249012|NCT01932970|9936055|FG000|Overall Study|Death|1
6249013|NCT01932970|9936055|FG000|Overall Study|Lost to Follow-up|2
6249014|NCT01932970|9936055|FG000|Overall Study|Protocol Specified Criteria|10
6249015|NCT01932996|9936061|FG000|Overall Study|Protocol Violation|2
6249016|NCT01932996|9936062|FG001|Overall Study|Protocol Violation|0
6249017|NCT01933048|9936070|FG000|Overall Study|Lost to Follow-up|15
6249018|NCT01933048|9936071|FG001|Overall Study|Lost to Follow-up|18
6249019|NCT01933048|9936070|FG000|Overall Study|personal reasons|1
6249020|NCT01933048|9936071|FG001|Overall Study|personal reasons|1
6249021|NCT01933048|9936070|FG000|Overall Study|Protocol Violation|7
6249022|NCT01933048|9936071|FG001|Overall Study|Protocol Violation|8
6249023|NCT01933048|9936070|FG000|Overall Study|Physician Decision|1
6249024|NCT01933048|9936071|FG001|Overall Study|Physician Decision|0
6249025|NCT01933048|9936070|FG000|Overall Study|unknown reasons|1
6249026|NCT01933048|9936071|FG001|Overall Study|unknown reasons|1
6249027|NCT01933113|9936080|FG000|Overall Study|Fractured nonfunctioning lead.|1
6249028|NCT01933217|9936086|FG000|Randomization (4 Weeks)|Withdrawal by Subject|1
6249029|NCT01933217|9936087|FG001|Randomization (4 Weeks)|Withdrawal by Subject|3
6249030|NCT01933217|9936086|FG000|Randomization (4 Weeks)|Lost to Follow-up|1
6249031|NCT01933217|9936087|FG001|Randomization (4 Weeks)|Lost to Follow-up|1
6249032|NCT01933334|9936110|FG000|Overall Study|Adverse Event|5
6249033|NCT01933334|9936111|FG001|Overall Study|Adverse Event|1
6249034|NCT01933334|9936110|FG000|Overall Study|Withdrawal by Subject|0
6249035|NCT01933334|9936111|FG001|Overall Study|Withdrawal by Subject|1
6249036|NCT01933594|9936154|FG000|Overall Study|Lost to Follow-up|1
6249037|NCT01933594|9936155|FG001|Overall Study|Lost to Follow-up|0
6249038|NCT01933594|9936156|FG002|Overall Study|Lost to Follow-up|0
6249039|NCT01933594|9936157|FG003|Overall Study|Lost to Follow-up|0
6249040|NCT01933594|9936158|FG004|Overall Study|Lost to Follow-up|1
6249041|NCT01933594|9936159|FG005|Overall Study|Lost to Follow-up|0
6249042|NCT01933594|9936154|FG000|Overall Study|Ineligible for subsequent study step|0
6249043|NCT01933594|9936155|FG001|Overall Study|Ineligible for subsequent study step|0
6249044|NCT01933594|9936156|FG002|Overall Study|Ineligible for subsequent study step|0
6249045|NCT01933594|9936157|FG003|Overall Study|Ineligible for subsequent study step|0
6249046|NCT01933594|9936158|FG004|Overall Study|Ineligible for subsequent study step|1
6249047|NCT01933594|9936159|FG005|Overall Study|Ineligible for subsequent study step|0
6249048|NCT01933672|9936177|FG000|Metformin Run-in Period|Adverse Event|1
6249049|NCT01933672|9936178|FG001|Metformin Run-in Period|Adverse Event|0
6249050|NCT01933672|9936179|FG002|Metformin Run-in Period|Adverse Event|0
6249051|NCT01933672|9936180|FG003|Metformin Run-in Period|Adverse Event|0
6249052|NCT01933672|9936181|FG004|Metformin Run-in Period|Adverse Event|0
6249053|NCT01933672|9936182|FG005|Metformin Run-in Period|Adverse Event|0
6249054|NCT01933672|9936183|FG006|Metformin Run-in Period|Adverse Event|0
6249055|NCT01933672|9936177|FG000|Metformin Run-in Period|No longer meets eligibility criteria|4
6249056|NCT01933672|9936178|FG001|Metformin Run-in Period|No longer meets eligibility criteria|0
6249057|NCT01933672|9936179|FG002|Metformin Run-in Period|No longer meets eligibility criteria|0
6249058|NCT01933672|9936180|FG003|Metformin Run-in Period|No longer meets eligibility criteria|0
6249059|NCT01933672|9936181|FG004|Metformin Run-in Period|No longer meets eligibility criteria|0
6249060|NCT01933672|9936182|FG005|Metformin Run-in Period|No longer meets eligibility criteria|0
6249061|NCT01933672|9936183|FG006|Metformin Run-in Period|No longer meets eligibility criteria|0
6249062|NCT01933672|9936177|FG000|Metformin Run-in Period|Other|5
6249063|NCT01933672|9936178|FG001|Metformin Run-in Period|Other|0
6249064|NCT01933672|9936179|FG002|Metformin Run-in Period|Other|0
6249065|NCT01933672|9936180|FG003|Metformin Run-in Period|Other|0
6249066|NCT01933672|9936181|FG004|Metformin Run-in Period|Other|0
6249067|NCT01933672|9936182|FG005|Metformin Run-in Period|Other|0
6249068|NCT01933672|9936183|FG006|Metformin Run-in Period|Other|0
6249069|NCT01933672|9936177|FG000|First Intervention Period (12-16 Days)|Lost to Follow-up|0
6249070|NCT01933672|9936178|FG001|First Intervention Period (12-16 Days)|Lost to Follow-up|0
6249071|NCT01933672|9936179|FG002|First Intervention Period (12-16 Days)|Lost to Follow-up|0
6249072|NCT01933672|9936180|FG003|First Intervention Period (12-16 Days)|Lost to Follow-up|0
6249073|NCT01933672|9936181|FG004|First Intervention Period (12-16 Days)|Lost to Follow-up|1
6249074|NCT01933672|9936182|FG005|First Intervention Period (12-16 Days)|Lost to Follow-up|0
6249075|NCT01933672|9936183|FG006|First Intervention Period (12-16 Days)|Lost to Follow-up|0
6249076|NCT01933672|9936177|FG000|First Intervention Period (12-16 Days)|Other|0
6249077|NCT01933672|9936178|FG001|First Intervention Period (12-16 Days)|Other|0
6249078|NCT01933672|9936179|FG002|First Intervention Period (12-16 Days)|Other|1
6249079|NCT01933672|9936180|FG003|First Intervention Period (12-16 Days)|Other|0
6249080|NCT01933672|9936181|FG004|First Intervention Period (12-16 Days)|Other|0
6249081|NCT01933672|9936182|FG005|First Intervention Period (12-16 Days)|Other|1
6249082|NCT01933672|9936183|FG006|First Intervention Period (12-16 Days)|Other|0
6249083|NCT01933672|9936177|FG000|Second Intervention Period (12-16 Days)|Other|0
6249084|NCT01933672|9936178|FG001|Second Intervention Period (12-16 Days)|Other|1
6249085|NCT01933672|9936179|FG002|Second Intervention Period (12-16 Days)|Other|1
6249086|NCT01933672|9936180|FG003|Second Intervention Period (12-16 Days)|Other|0
6249087|NCT01933672|9936181|FG004|Second Intervention Period (12-16 Days)|Other|0
6249088|NCT01933672|9936182|FG005|Second Intervention Period (12-16 Days)|Other|0
6249089|NCT01933672|9936183|FG006|Second Intervention Period (12-16 Days)|Other|0
6249090|NCT01933672|9936177|FG000|Third Intervention Period (12-16 Days)|Lost to Follow-up|0
6249091|NCT01933672|9936178|FG001|Third Intervention Period (12-16 Days)|Lost to Follow-up|0
6249092|NCT01933672|9936179|FG002|Third Intervention Period (12-16 Days)|Lost to Follow-up|0
6249093|NCT01933672|9936180|FG003|Third Intervention Period (12-16 Days)|Lost to Follow-up|1
6249094|NCT01933672|9936181|FG004|Third Intervention Period (12-16 Days)|Lost to Follow-up|0
6249095|NCT01933672|9936182|FG005|Third Intervention Period (12-16 Days)|Lost to Follow-up|0
6249096|NCT01933672|9936183|FG006|Third Intervention Period (12-16 Days)|Lost to Follow-up|0
6249097|NCT01933672|9936177|FG000|Third Intervention Period (12-16 Days)|Withdrawal by Subject|0
6249098|NCT01933672|9936178|FG001|Third Intervention Period (12-16 Days)|Withdrawal by Subject|1
6249099|NCT01933672|9936179|FG002|Third Intervention Period (12-16 Days)|Withdrawal by Subject|0
6249100|NCT01933672|9936180|FG003|Third Intervention Period (12-16 Days)|Withdrawal by Subject|0
6249101|NCT01933672|9936181|FG004|Third Intervention Period (12-16 Days)|Withdrawal by Subject|0
6249102|NCT01933672|9936182|FG005|Third Intervention Period (12-16 Days)|Withdrawal by Subject|0
6249103|NCT01933672|9936183|FG006|Third Intervention Period (12-16 Days)|Withdrawal by Subject|0
6249104|NCT01933789|9936214|FG000|Overall Study|Death|0
6249105|NCT01933789|9936215|FG001|Overall Study|Death|0
6249106|NCT01933789|9936216|FG002|Overall Study|Death|0
6249107|NCT01933789|9936217|FG003|Overall Study|Death|0
6249108|NCT01933789|9936218|FG004|Overall Study|Death|21
6249109|NCT01933789|9936219|FG005|Overall Study|Death|32
6249110|NCT01933789|9936220|FG006|Overall Study|Death|0
6249111|NCT01933789|9936221|FG007|Overall Study|Death|0
6249112|NCT01933789|9936222|FG008|Overall Study|Death|0
6249113|NCT01933789|9936214|FG000|Overall Study|Lost to Follow-up|0
6249114|NCT01933789|9936215|FG001|Overall Study|Lost to Follow-up|0
6249115|NCT01933789|9936216|FG002|Overall Study|Lost to Follow-up|0
6249116|NCT01933789|9936217|FG003|Overall Study|Lost to Follow-up|1
6249117|NCT01933789|9936218|FG004|Overall Study|Lost to Follow-up|8
6249118|NCT01933789|9936219|FG005|Overall Study|Lost to Follow-up|9
6249119|NCT01933789|9936220|FG006|Overall Study|Lost to Follow-up|1
6249120|NCT01933789|9936221|FG007|Overall Study|Lost to Follow-up|4
6249121|NCT01933789|9936222|FG008|Overall Study|Lost to Follow-up|0
6249122|NCT01933789|9936214|FG000|Overall Study|Withdrawal by Subject|2
6249123|NCT01933789|9936215|FG001|Overall Study|Withdrawal by Subject|1
6249124|NCT01933789|9936216|FG002|Overall Study|Withdrawal by Subject|0
6249125|NCT01933789|9936217|FG003|Overall Study|Withdrawal by Subject|0
6249126|NCT01933789|9936218|FG004|Overall Study|Withdrawal by Subject|17
6249127|NCT01933789|9936219|FG005|Overall Study|Withdrawal by Subject|16
6249128|NCT01933789|9936220|FG006|Overall Study|Withdrawal by Subject|1
6249129|NCT01933789|9936221|FG007|Overall Study|Withdrawal by Subject|4
6249130|NCT01933789|9936222|FG008|Overall Study|Withdrawal by Subject|0
6249131|NCT01933789|9936214|FG000|Overall Study|Became Ineligible|4
6249132|NCT01933789|9936215|FG001|Overall Study|Became Ineligible|0
6249133|NCT01933789|9936216|FG002|Overall Study|Became Ineligible|0
6249134|NCT01933789|9936217|FG003|Overall Study|Became Ineligible|0
6249135|NCT01933789|9936218|FG004|Overall Study|Became Ineligible|13
6249136|NCT01933789|9936219|FG005|Overall Study|Became Ineligible|10
6249137|NCT01933789|9936220|FG006|Overall Study|Became Ineligible|13
6249138|NCT01933789|9936221|FG007|Overall Study|Became Ineligible|6
6249139|NCT01933789|9936222|FG008|Overall Study|Became Ineligible|0
6249140|NCT01933880|9936244|FG000|Overall Study|Withdrawal by Subject|5
6249141|NCT01933880|9936245|FG001|Overall Study|Withdrawal by Subject|0
6249142|NCT01933880|9936244|FG000|Overall Study|Lack of Efficacy|1
6249143|NCT01933880|9936245|FG001|Overall Study|Lack of Efficacy|0
6249144|NCT01933880|9936244|FG000|Overall Study|Concomitant medication Interference|0
6249145|NCT01933880|9936245|FG001|Overall Study|Concomitant medication Interference|1
6249146|NCT01933880|9936244|FG000|Overall Study|Followup exceeded 4 days to visit window|19
6249147|NCT01933880|9936245|FG001|Overall Study|Followup exceeded 4 days to visit window|0
6249148|NCT01933880|9936244|FG000|Overall Study|Other|4
6249149|NCT01933880|9936245|FG001|Overall Study|Other|0
6249150|NCT01933880|9936244|FG000|Overall Study|Protocol Violation|1
6249151|NCT01933880|9936245|FG001|Overall Study|Protocol Violation|0
6249152|NCT01933919|9936258|FG000|Double-blind Placebo-controlled Phase|Adverse Event|0
6249153|NCT01933919|9936259|FG001|Double-blind Placebo-controlled Phase|Adverse Event|1
6249154|NCT01933919|9936258|FG000|Double-blind Placebo-controlled Phase|Withdrawal by Subject|0
6249155|NCT01933919|9936259|FG001|Double-blind Placebo-controlled Phase|Withdrawal by Subject|1
6249156|NCT01933919|9936258|FG000|Double-blind Placebo-controlled Phase|Lack of Efficacy|0
6249157|NCT01933919|9936259|FG001|Double-blind Placebo-controlled Phase|Lack of Efficacy|2
6249158|NCT01933919|9936258|FG000|Open-label Long-term Phase|Adverse Event|2
6249159|NCT01933919|9936259|FG001|Open-label Long-term Phase|Adverse Event|0
6249160|NCT01933919|9936258|FG000|Open-label Long-term Phase|Withdrawal by Subject|3
6249161|NCT01933919|9936259|FG001|Open-label Long-term Phase|Withdrawal by Subject|4
6249162|NCT01933919|9936258|FG000|Open-label Long-term Phase|Lost to Follow-up|1
6249163|NCT01933919|9936259|FG001|Open-label Long-term Phase|Lost to Follow-up|0
6249164|NCT01933919|9936258|FG000|Open-label Long-term Phase|Other|1
6249165|NCT01933919|9936259|FG001|Open-label Long-term Phase|Other|2
6249166|NCT01934010|9936293|FG000|Overall Study|Adverse Event|1
6249167|NCT01934010|9936294|FG001|Overall Study|Adverse Event|1
6249168|NCT01934010|9936295|FG002|Overall Study|Adverse Event|0
6249169|NCT01934010|9936293|FG000|Overall Study|Withdrawal by Subject|15
6249170|NCT01934010|9936294|FG001|Overall Study|Withdrawal by Subject|6
6249171|NCT01934010|9936295|FG002|Overall Study|Withdrawal by Subject|2
6249172|NCT01934010|9936293|FG000|Overall Study|Lost to Follow-up|7
6249173|NCT01934010|9936294|FG001|Overall Study|Lost to Follow-up|4
6249174|NCT01934010|9936295|FG002|Overall Study|Lost to Follow-up|0
6249175|NCT01934140|9936314|FG000|Persistence Phase (Year 6-10)|Other|24
6249176|NCT01934140|9936315|FG001|Persistence Phase (Year 6-10)|Other|6
6249177|NCT01934140|9936314|FG000|Persistence Phase (Year 6-10)|Lost to Follow-up|5
6249178|NCT01934140|9936315|FG001|Persistence Phase (Year 6-10)|Lost to Follow-up|2
6249179|NCT01934140|9936314|FG000|Persistence Phase (Year 6-10)|Migrated/moved from study area|31
6249180|NCT01934140|9936315|FG001|Persistence Phase (Year 6-10)|Migrated/moved from study area|10
6249181|NCT01934140|9936314|FG000|Persistence Phase (Year 6-10)|Eligibility criteria not fulfilled|2
6249182|NCT01934140|9936315|FG001|Persistence Phase (Year 6-10)|Eligibility criteria not fulfilled|0
6249183|NCT01934140|9936314|FG000|Persistence Phase (Year 6-10)|Missed at least 1 persistence visit|21
6249184|NCT01934140|9936315|FG001|Persistence Phase (Year 6-10)|Missed at least 1 persistence visit|7
6249185|NCT01934140|9936314|FG000|Booster Phase (6 Months)|Lost to Follow-up|1
6249186|NCT01934140|9936315|FG001|Booster Phase (6 Months)|Lost to Follow-up|0
6249187|NCT01934140|9936314|FG000|Booster Phase (6 Months)|Missed at least 1 booster visit|2
6249188|NCT01934140|9936315|FG001|Booster Phase (6 Months)|Missed at least 1 booster visit|1
6249189|NCT01934140|9936314|FG000|Booster Phase (6 Months)|Migrated/moved from study area|2
6249190|NCT01934140|9936315|FG001|Booster Phase (6 Months)|Migrated/moved from study area|2
6249191|NCT01934192|9936327|FG000|Overall Study|Protocol Violation|0
6249192|NCT01934192|9936328|FG001|Overall Study|Protocol Violation|0
6249193|NCT01934192|9936329|FG002|Overall Study|Protocol Violation|0
6249194|NCT01934192|9936330|FG003|Overall Study|Protocol Violation|1
6249195|NCT01934192|9936327|FG000|Overall Study|Other: reached stopping criteria|6
6249196|NCT01934192|9936328|FG001|Overall Study|Other: reached stopping criteria|5
6249197|NCT01934192|9936329|FG002|Overall Study|Other: reached stopping criteria|1
6249198|NCT01934192|9936330|FG003|Overall Study|Other: reached stopping criteria|0
6249199|NCT01934192|9936327|FG000|Overall Study|Physician Decision|3
6249200|NCT01934192|9936328|FG001|Overall Study|Physician Decision|2
6249201|NCT01934192|9936329|FG002|Overall Study|Physician Decision|0
6249202|NCT01934192|9936330|FG003|Overall Study|Physician Decision|0
6249203|NCT01934218|9936353|FG000|Double-blind Phase|Adverse Event|8
6249204|NCT01934218|9936354|FG001|Double-blind Phase|Adverse Event|8
6249205|NCT01934218|9936353|FG000|Double-blind Phase|Lack of Efficacy|6
6249206|NCT01934218|9936354|FG001|Double-blind Phase|Lack of Efficacy|7
6249207|NCT01934218|9936353|FG000|Double-blind Phase|Lost to Follow-up|7
6249208|NCT01934218|9936354|FG001|Double-blind Phase|Lost to Follow-up|14
6249209|NCT01934218|9936353|FG000|Double-blind Phase|Physician Decision|1
6249210|NCT01934218|9936354|FG001|Double-blind Phase|Physician Decision|2
6249211|NCT01934218|9936353|FG000|Double-blind Phase|Protocol Violation|4
6249212|NCT01934218|9936354|FG001|Double-blind Phase|Protocol Violation|0
6249213|NCT01934218|9936353|FG000|Double-blind Phase|Withdrawal by Subject|16
6249214|NCT01934218|9936354|FG001|Double-blind Phase|Withdrawal by Subject|13
6249215|NCT01934218|9936353|FG000|Double-blind Phase|Noncompliance with Study Protocol|5
6249216|NCT01934218|9936354|FG001|Double-blind Phase|Noncompliance with Study Protocol|8
6249217|NCT01934218|9936353|FG000|Double-blind Phase|Protocol Violation of Study Eligibility|1
6249218|NCT01934218|9936354|FG001|Double-blind Phase|Protocol Violation of Study Eligibility|2
6249219|NCT01934218|9936353|FG000|Open-Label Phase|Adverse Event|2
6249220|NCT01934218|9936354|FG001|Open-Label Phase|Adverse Event|4
6249221|NCT01934218|9936353|FG000|Open-Label Phase|Lack of Efficacy|1
6249222|NCT01934218|9936354|FG001|Open-Label Phase|Lack of Efficacy|4
6249223|NCT01934218|9936353|FG000|Open-Label Phase|Lost to Follow-up|4
6249224|NCT01934218|9936354|FG001|Open-Label Phase|Lost to Follow-up|2
6249225|NCT01934218|9936353|FG000|Open-Label Phase|Physician Decision|1
6249226|NCT01934218|9936354|FG001|Open-Label Phase|Physician Decision|0
6249227|NCT01934218|9936353|FG000|Open-Label Phase|Protocol Violation|1
6249228|NCT01934218|9936354|FG001|Open-Label Phase|Protocol Violation|0
6249229|NCT01934218|9936353|FG000|Open-Label Phase|Withdrawal by Subject|13
6249230|NCT01934218|9936354|FG001|Open-Label Phase|Withdrawal by Subject|11
6249231|NCT01934218|9936353|FG000|Open-Label Phase|Noncompliance with Study Protocol|4
6249232|NCT01934218|9936354|FG001|Open-Label Phase|Noncompliance with Study Protocol|2
6249233|NCT01934218|9936353|FG000|Open-Label Phase|Failure to Exam Primary Evaluation|0
6249234|NCT01934218|9936354|FG001|Open-Label Phase|Failure to Exam Primary Evaluation|1
6249235|NCT01934335|9936366|FG000|Overall Study|Withdrawal by Subject|1
6249236|NCT01934335|9936367|FG001|Overall Study|Withdrawal by Subject|1
6249237|NCT01934556|9936384|FG000|Overall Study|Withdrawal by Subject|0
6249238|NCT01934556|9936385|FG001|Overall Study|Withdrawal by Subject|1
6249239|NCT01934556|9936386|FG002|Overall Study|Withdrawal by Subject|1
6249240|NCT01934556|9936384|FG000|Overall Study|Lost to Follow-up|4
6249241|NCT01934556|9936385|FG001|Overall Study|Lost to Follow-up|10
6249242|NCT01934556|9936386|FG002|Overall Study|Lost to Follow-up|7
6249243|NCT01934556|9936384|FG000|Overall Study|Death|1
6249244|NCT01934556|9936385|FG001|Overall Study|Death|5
6249245|NCT01934556|9936386|FG002|Overall Study|Death|2
6249246|NCT01934790|9936400|FG000|Treatment|Adverse Event|3
6249247|NCT01934790|9936400|FG000|Treatment|Clinical progression|6
6249248|NCT01934790|9936400|FG000|Treatment|Radiological progression|4
6249249|NCT01934790|9936400|FG000|Treatment|Withdrawal by Subject|2
6249250|NCT01934790|9936400|FG000|Treatment|Study drug never administered|1
6249251|NCT01934790|9936400|FG000|Active Follow up|Death|20
6249252|NCT01934790|9936400|FG000|Active Follow up|Physician Decision|2
6249253|NCT01934790|9936400|FG000|Active Follow up|Progressive disease|1
6249254|NCT01934790|9936400|FG000|Active Follow up|Other reason|1
6249255|NCT01934894|9936406|FG000|Overall Study|Adverse Event|1
6249256|NCT01934894|9936407|FG001|Overall Study|Adverse Event|2
6249257|NCT01934894|9936406|FG000|Overall Study|Death|2
6249258|NCT01934894|9936407|FG001|Overall Study|Death|0
6249259|NCT01934894|9936406|FG000|Overall Study|Withdrawal by Subject|0
6249260|NCT01934894|9936407|FG001|Overall Study|Withdrawal by Subject|1
6249261|NCT01934894|9936406|FG000|Overall Study|Progressive Disease|3
6249262|NCT01934894|9936407|FG001|Overall Study|Progressive Disease|2
6249263|NCT01934972|9936418|FG000|Overall Study|Withdrawal by Subject|9
6249264|NCT01934972|9936419|FG001|Overall Study|Withdrawal by Subject|6
6249265|NCT01935700|9936449|FG000|Overall Study|Withdrawal by Subject|1
6249266|NCT01935700|9936450|FG001|Overall Study|Withdrawal by Subject|0
6249267|NCT01935700|9936449|FG000|Overall Study|Physician Decision|4
6249268|NCT01935700|9936450|FG001|Overall Study|Physician Decision|0
6249269|NCT01936181|9936482|FG000|Randomised, Double-blind|Adverse Event|27
6249270|NCT01936181|9936483|FG001|Randomised, Double-blind|Adverse Event|21
6249271|NCT01936181|9936484|FG002|Randomised, Double-blind|Adverse Event|0
6249272|NCT01936181|9936485|FG003|Randomised, Double-blind|Adverse Event|0
6249273|NCT01936181|9936482|FG000|Randomised, Double-blind|Protocol Violation|1
6249274|NCT01936181|9936483|FG001|Randomised, Double-blind|Protocol Violation|5
6249275|NCT01936181|9936484|FG002|Randomised, Double-blind|Protocol Violation|0
6249276|NCT01936181|9936485|FG003|Randomised, Double-blind|Protocol Violation|0
6249277|NCT01936181|9936482|FG000|Randomised, Double-blind|Lack of Efficacy|5
6249278|NCT01936181|9936483|FG001|Randomised, Double-blind|Lack of Efficacy|6
6249279|NCT01936181|9936484|FG002|Randomised, Double-blind|Lack of Efficacy|0
6249280|NCT01936181|9936485|FG003|Randomised, Double-blind|Lack of Efficacy|0
6249281|NCT01936181|9936482|FG000|Randomised, Double-blind|Lost to Follow-up|0
6249282|NCT01936181|9936483|FG001|Randomised, Double-blind|Lost to Follow-up|1
6249283|NCT01936181|9936484|FG002|Randomised, Double-blind|Lost to Follow-up|0
6249284|NCT01936181|9936485|FG003|Randomised, Double-blind|Lost to Follow-up|0
6249285|NCT01936181|9936482|FG000|Randomised, Double-blind|Pregnancy|0
6249286|NCT01936181|9936483|FG001|Randomised, Double-blind|Pregnancy|1
6249287|NCT01936181|9936484|FG002|Randomised, Double-blind|Pregnancy|0
6249288|NCT01936181|9936485|FG003|Randomised, Double-blind|Pregnancy|0
6249289|NCT01936181|9936482|FG000|Randomised, Double-blind|Physician Decision|4
6249290|NCT01936181|9936483|FG001|Randomised, Double-blind|Physician Decision|4
6249291|NCT01936181|9936484|FG002|Randomised, Double-blind|Physician Decision|0
6086226|NCT00659425|9695992|FG003|Overall Study|Other|2
6086227|NCT00659425|9695993|FG004|Overall Study|Other|4
6086228|NCT00659425|9695994|FG005|Overall Study|Other|0
6086229|NCT00659425|9695995|FG006|Overall Study|Other|3
6249292|NCT01936181|9936485|FG003|Randomised, Double-blind|Physician Decision|0
6249293|NCT01936181|9936482|FG000|Randomised, Double-blind|Withdrawal by Subject|23
6249294|NCT01936181|9936483|FG001|Randomised, Double-blind|Withdrawal by Subject|26
6249295|NCT01936181|9936484|FG002|Randomised, Double-blind|Withdrawal by Subject|0
6249296|NCT01936181|9936485|FG003|Randomised, Double-blind|Withdrawal by Subject|0
6249297|NCT01936181|9936482|FG000|Randomised, Double-blind|Subjects from Eastern Ukraine sites|4
6249298|NCT01936181|9936483|FG001|Randomised, Double-blind|Subjects from Eastern Ukraine sites|4
6249299|NCT01936181|9936484|FG002|Randomised, Double-blind|Subjects from Eastern Ukraine sites|0
6249300|NCT01936181|9936485|FG003|Randomised, Double-blind|Subjects from Eastern Ukraine sites|0
6249301|NCT01936181|9936482|FG000|Transition-extension|Adverse Event|3
6249302|NCT01936181|9936483|FG001|Transition-extension|Adverse Event|0
6249303|NCT01936181|9936484|FG002|Transition-extension|Adverse Event|3
6249304|NCT01936181|9936485|FG003|Transition-extension|Adverse Event|1
6249305|NCT01936181|9936482|FG000|Transition-extension|Lost to Follow-up|3
6249306|NCT01936181|9936483|FG001|Transition-extension|Lost to Follow-up|0
6249307|NCT01936181|9936484|FG002|Transition-extension|Lost to Follow-up|1
6249308|NCT01936181|9936485|FG003|Transition-extension|Lost to Follow-up|2
6249309|NCT01936181|9936482|FG000|Transition-extension|Physician Decision|2
6249310|NCT01936181|9936483|FG001|Transition-extension|Physician Decision|0
6249311|NCT01936181|9936484|FG002|Transition-extension|Physician Decision|0
6249312|NCT01936181|9936485|FG003|Transition-extension|Physician Decision|1
6249313|NCT01936181|9936482|FG000|Transition-extension|Withdrawal by Subject|7
6249314|NCT01936181|9936483|FG001|Transition-extension|Withdrawal by Subject|0
6249315|NCT01936181|9936484|FG002|Transition-extension|Withdrawal by Subject|2
6249316|NCT01936181|9936485|FG003|Transition-extension|Withdrawal by Subject|1
6249317|NCT01936623|9936562|FG000|Overall Study|Lost to Follow-up|0
6249318|NCT01936623|9936563|FG001|Overall Study|Lost to Follow-up|5
6249319|NCT01936649|9936569|FG000|Overall Study|Withdrawal by Subject|4
6249320|NCT01936649|9936569|FG000|Overall Study|Physician Decision|2
6249321|NCT01936649|9936569|FG000|Overall Study|Protocol Violation|2
6249322|NCT01936649|9936569|FG000|Overall Study|Other than specified above|5
6249323|NCT01936870|9936593|FG000|Overall Study|No Visit After Treatment|176
6249324|NCT01936870|9936593|FG000|Overall Study|Protocol Violation|12
6249325|NCT01936870|9936593|FG000|Overall Study|No Drug Administration|1
6249326|NCT01936948|9936618|FG000|Overall Study|no 30-day follow-up data|0
6249327|NCT01936948|9936619|FG001|Overall Study|no 30-day follow-up data|3
6249328|NCT01936948|9936620|FG002|Overall Study|no 30-day follow-up data|3
6249329|NCT01936948|9936621|FG003|Overall Study|no 30-day follow-up data|3
6249330|NCT01937117|9936636|FG000|Overall Study|Disease Progression|7
6249331|NCT01937117|9936636|FG000|Overall Study|Physician Decision|4
6249332|NCT01937117|9936636|FG000|Overall Study|Adverse Event|2
6249333|NCT01937130|9936644|FG000|Overall Study|Withdrawal by Subject|0
6249334|NCT01937130|9936645|FG001|Overall Study|Withdrawal by Subject|0
6249335|NCT01937130|9936646|FG002|Overall Study|Withdrawal by Subject|0
6249336|NCT01937130|9936647|FG003|Overall Study|Withdrawal by Subject|1
6249337|NCT01937130|9936644|FG000|Overall Study|Adverse Event|0
6249338|NCT01937130|9936645|FG001|Overall Study|Adverse Event|1
6249339|NCT01937130|9936646|FG002|Overall Study|Adverse Event|0
6249340|NCT01937130|9936647|FG003|Overall Study|Adverse Event|1
6249341|NCT01937130|9936644|FG000|Overall Study|Death|1
6249342|NCT01937130|9936645|FG001|Overall Study|Death|1
6249343|NCT01937130|9936646|FG002|Overall Study|Death|1
6249344|NCT01937130|9936647|FG003|Overall Study|Death|0
6249345|NCT01937130|9936644|FG000|Overall Study|Lost to Follow-up|2
6249346|NCT01937130|9936645|FG001|Overall Study|Lost to Follow-up|0
6249347|NCT01937130|9936646|FG002|Overall Study|Lost to Follow-up|2
6086230|NCT00659425|9695996|FG007|Overall Study|Other|2
6086231|NCT00659425|9695997|FG008|Overall Study|Other|0
6249348|NCT01937130|9936647|FG003|Overall Study|Lost to Follow-up|0
6249349|NCT01937130|9936644|FG000|Overall Study|Physician Decision|0
6249350|NCT01937130|9936645|FG001|Overall Study|Physician Decision|1
6249351|NCT01937130|9936646|FG002|Overall Study|Physician Decision|0
6249352|NCT01937130|9936647|FG003|Overall Study|Physician Decision|0
6249353|NCT01937130|9936644|FG000|Overall Study|Patients unable to swallow|0
6249354|NCT01937130|9936645|FG001|Overall Study|Patients unable to swallow|1
6249355|NCT01937130|9936646|FG002|Overall Study|Patients unable to swallow|0
6249356|NCT01937130|9936647|FG003|Overall Study|Patients unable to swallow|0
6249357|NCT01937130|9936644|FG000|Overall Study|Patient lost to FU due to death|2
6249358|NCT01937130|9936645|FG001|Overall Study|Patient lost to FU due to death|0
6249359|NCT01937130|9936646|FG002|Overall Study|Patient lost to FU due to death|0
6249360|NCT01937130|9936647|FG003|Overall Study|Patient lost to FU due to death|0
6249361|NCT01937299|9936672|FG000|Overall Study|Adverse Event|13
6249362|NCT01937299|9936673|FG001|Overall Study|Adverse Event|0
6249363|NCT01937299|9936672|FG000|Overall Study|Lack of Efficacy|0
6249364|NCT01937299|9936673|FG001|Overall Study|Lack of Efficacy|4
6249365|NCT01937299|9936672|FG000|Overall Study|Withdrawal by Subject|1
6249366|NCT01937299|9936673|FG001|Overall Study|Withdrawal by Subject|0
6249367|NCT01937312|9936682|FG000|Overall Study|Adverse Event|10
6249368|NCT01937312|9936683|FG001|Overall Study|Adverse Event|1
6249369|NCT01937312|9936682|FG000|Overall Study|Lack of Efficacy|0
6249370|NCT01937312|9936683|FG001|Overall Study|Lack of Efficacy|1
6249371|NCT01937312|9936682|FG000|Overall Study|Withdrawal of subject prior to treatment|1
6249372|NCT01937312|9936683|FG001|Overall Study|Withdrawal of subject prior to treatment|1
6249373|NCT01937351|9936692|FG000|Overall Study|Withdrawal by Subject|4
6249374|NCT01937351|9936693|FG001|Overall Study|Withdrawal by Subject|2
6249375|NCT01937351|9936692|FG000|Overall Study|Death|1
6249376|NCT01937351|9936693|FG001|Overall Study|Death|0
6249377|NCT01937351|9936692|FG000|Overall Study|Not treated w device, per protocol fail|4
6249378|NCT01937351|9936693|FG001|Overall Study|Not treated w device, per protocol fail|0
6249379|NCT01937364|9936700|FG000|Overall Study|Adverse Event|2
6249380|NCT01937364|9936701|FG001|Overall Study|Adverse Event|1
6249381|NCT01937390|9936707|FG000|Overall Study|Death|2
6249382|NCT01937390|9936707|FG000|Overall Study|Lost to Follow-up|7
6249383|NCT01937390|9936707|FG000|Overall Study|Withdrawal by Subject|5
6249384|NCT01937390|9936707|FG000|Overall Study|Fail to return|21
6249385|NCT01937559|9936724|FG000|Overall Study|Physician Decision|3
6249386|NCT01937559|9936725|FG001|Overall Study|Physician Decision|3
6249387|NCT01937559|9936726|FG002|Overall Study|Physician Decision|0
6249388|NCT01937559|9936724|FG000|Overall Study|Withdrawal by Subject|6
6249389|NCT01937559|9936725|FG001|Overall Study|Withdrawal by Subject|4
6249390|NCT01937559|9936726|FG002|Overall Study|Withdrawal by Subject|0
6249391|NCT01937559|9936724|FG000|Overall Study|screen fail|2
6249392|NCT01937559|9936725|FG001|Overall Study|screen fail|4
6249393|NCT01937559|9936726|FG002|Overall Study|screen fail|0
6249394|NCT01937715|9936754|FG000|Overall Study|Death|0
6249395|NCT01937715|9936755|FG001|Overall Study|Death|0
6249396|NCT01937715|9936756|FG002|Overall Study|Death|0
6249397|NCT01937715|9936757|FG003|Overall Study|Death|1
6249398|NCT01937715|9936758|FG004|Overall Study|Death|0
6249399|NCT01937715|9936754|FG000|Overall Study|Withdrawal by Subject|0
6249400|NCT01937715|9936755|FG001|Overall Study|Withdrawal by Subject|1
6249401|NCT01937715|9936756|FG002|Overall Study|Withdrawal by Subject|0
6249402|NCT01937715|9936757|FG003|Overall Study|Withdrawal by Subject|0
6249403|NCT01937715|9936758|FG004|Overall Study|Withdrawal by Subject|2
6249404|NCT01937715|9936754|FG000|Overall Study|Other|0
6249405|NCT01937715|9936755|FG001|Overall Study|Other|0
6249406|NCT01937715|9936756|FG002|Overall Study|Other|0
6249407|NCT01937715|9936757|FG003|Overall Study|Other|3
6249408|NCT01937715|9936758|FG004|Overall Study|Other|0
6270728|NCT02156076|9972053|FG001|Treatment Period|no longer meets study criteria|0
6270729|NCT02156076|9972054|FG002|Treatment Period|no longer meets study criteria|1
6270730|NCT02156076|9972055|FG003|Treatment Period|no longer meets study criteria|0
6270731|NCT02156076|9972052|FG000|Treatment Period|Poor/non-compliance|0
6270732|NCT02156076|9972053|FG001|Treatment Period|Poor/non-compliance|1
6270733|NCT02156076|9972054|FG002|Treatment Period|Poor/non-compliance|0
6270734|NCT02156076|9972055|FG003|Treatment Period|Poor/non-compliance|0
6270735|NCT02156076|9972052|FG000|Treatment Period|Lost to Follow-up|0
6270736|NCT02156076|9972053|FG001|Treatment Period|Lost to Follow-up|0
6270737|NCT02156076|9972054|FG002|Treatment Period|Lost to Follow-up|0
6270738|NCT02156076|9972055|FG003|Treatment Period|Lost to Follow-up|1
6270739|NCT02156076|9972052|FG000|Treatment Period|Withdrawal by Subject|0
6270740|NCT02156076|9972053|FG001|Treatment Period|Withdrawal by Subject|0
6270741|NCT02156076|9972054|FG002|Treatment Period|Withdrawal by Subject|1
6270742|NCT02156076|9972055|FG003|Treatment Period|Withdrawal by Subject|0
6270743|NCT02156076|9972052|FG000|Treatment Period|Subject request to discontinue treatment|0
6270744|NCT02156076|9972053|FG001|Treatment Period|Subject request to discontinue treatment|1
6270745|NCT02156076|9972054|FG002|Treatment Period|Subject request to discontinue treatment|0
6270746|NCT02156076|9972055|FG003|Treatment Period|Subject request to discontinue treatment|0
6270747|NCT02156076|9972052|FG000|Treatment Period|Adverse Event|0
6270748|NCT02156076|9972053|FG001|Treatment Period|Adverse Event|0
6270749|NCT02156076|9972054|FG002|Treatment Period|Adverse Event|0
6249409|NCT01937871|9936773|FG000|Overall Study|Adverse Event|6
6249410|NCT01937871|9936774|FG001|Overall Study|Adverse Event|6
6249411|NCT01937871|9936775|FG002|Overall Study|Adverse Event|2
6249412|NCT01937871|9936773|FG000|Overall Study|Lost to Follow-up|8
6249413|NCT01937871|9936774|FG001|Overall Study|Lost to Follow-up|2
6249414|NCT01937871|9936775|FG002|Overall Study|Lost to Follow-up|4
6249415|NCT01937871|9936773|FG000|Overall Study|Withdrawal by Subject|9
6249416|NCT01937871|9936774|FG001|Overall Study|Withdrawal by Subject|6
6249417|NCT01937871|9936775|FG002|Overall Study|Withdrawal by Subject|4
6249418|NCT01937871|9936773|FG000|Overall Study|Physician Decision|0
6249419|NCT01937871|9936774|FG001|Overall Study|Physician Decision|1
6249420|NCT01937871|9936775|FG002|Overall Study|Physician Decision|0
6249421|NCT01937871|9936773|FG000|Overall Study|Entry Criteria Not Met|1
6249422|NCT01937871|9936774|FG001|Overall Study|Entry Criteria Not Met|2
6249423|NCT01937871|9936775|FG002|Overall Study|Entry Criteria Not Met|1
6249424|NCT01937884|9936788|FG000|Overall Study|Withdrawal by Subject|1
6249425|NCT01937884|9936789|FG001|Overall Study|Withdrawal by Subject|0
6086232|NCT00659425|9695998|FG009|Overall Study|Other|6
6249426|NCT01938001|9936816|FG000|Overall Study|Withdrawal by Subject|25
6249427|NCT01938001|9936817|FG001|Overall Study|Withdrawal by Subject|17
6249428|NCT01938001|9936816|FG000|Overall Study|Non-compliant|1
6249429|NCT01938001|9936817|FG001|Overall Study|Non-compliant|0
6249430|NCT01938001|9936816|FG000|Overall Study|Participant Moved|0
6249431|NCT01938001|9936817|FG001|Overall Study|Participant Moved|1
6249432|NCT01938001|9936816|FG000|Overall Study|Lost to Follow-up|1
6249433|NCT01938001|9936817|FG001|Overall Study|Lost to Follow-up|3
6249434|NCT01938001|9936816|FG000|Overall Study|Death|16
6249435|NCT01938001|9936817|FG001|Overall Study|Death|26
6249436|NCT01938391|9936881|FG000|6 Month Follow up|Withdrawal by Subject|1
6249437|NCT01938391|9936881|FG000|12 Month Follow up|Physician Decision|1
6249438|NCT01938391|9936881|FG000|12 Month Follow up|Withdrawal by Subject|1
6249439|NCT01938430|9936899|FG000|Overall Study|Randomized but Not Treated|0
6249440|NCT01938430|9936900|FG001|Overall Study|Randomized but Not Treated|0
6249441|NCT01938430|9936901|FG002|Overall Study|Randomized but Not Treated|0
6249442|NCT01938430|9936902|FG003|Overall Study|Randomized but Not Treated|0
6249443|NCT01938430|9936903|FG004|Overall Study|Randomized but Not Treated|0
6249444|NCT01938430|9936904|FG005|Overall Study|Randomized but Not Treated|0
6249445|NCT01938430|9936905|FG006|Overall Study|Randomized but Not Treated|0
6249446|NCT01938430|9936906|FG007|Overall Study|Randomized but Not Treated|0
6249447|NCT01938430|9936907|FG008|Overall Study|Randomized but Not Treated|0
6249448|NCT01938430|9936908|FG009|Overall Study|Randomized but Not Treated|0
6249449|NCT01938430|9936909|FG010|Overall Study|Randomized but Not Treated|1
6249450|NCT01938430|9936910|FG011|Overall Study|Randomized but Not Treated|0
6249451|NCT01938430|9936911|FG012|Overall Study|Randomized but Not Treated|0
6249452|NCT01938430|9936912|FG013|Overall Study|Randomized but Not Treated|1
6249453|NCT01938430|9936899|FG000|Overall Study|Adverse Event|0
6249454|NCT01938430|9936900|FG001|Overall Study|Adverse Event|0
6249455|NCT01938430|9936901|FG002|Overall Study|Adverse Event|0
6249456|NCT01938430|9936902|FG003|Overall Study|Adverse Event|0
6249457|NCT01938430|9936903|FG004|Overall Study|Adverse Event|0
6249458|NCT01938430|9936904|FG005|Overall Study|Adverse Event|0
6249459|NCT01938430|9936905|FG006|Overall Study|Adverse Event|1
6249460|NCT01938430|9936906|FG007|Overall Study|Adverse Event|0
6249461|NCT01938430|9936907|FG008|Overall Study|Adverse Event|0
6249462|NCT01938430|9936908|FG009|Overall Study|Adverse Event|0
6249463|NCT01938430|9936909|FG010|Overall Study|Adverse Event|0
6249464|NCT01938430|9936910|FG011|Overall Study|Adverse Event|0
6249465|NCT01938430|9936911|FG012|Overall Study|Adverse Event|0
6249466|NCT01938430|9936912|FG013|Overall Study|Adverse Event|0
6249467|NCT01938430|9936899|FG000|Overall Study|Death|1
6249468|NCT01938430|9936900|FG001|Overall Study|Death|2
6249469|NCT01938430|9936901|FG002|Overall Study|Death|2
6249470|NCT01938430|9936902|FG003|Overall Study|Death|1
6249471|NCT01938430|9936903|FG004|Overall Study|Death|0
6249472|NCT01938430|9936904|FG005|Overall Study|Death|0
6249473|NCT01938430|9936905|FG006|Overall Study|Death|1
6249474|NCT01938430|9936906|FG007|Overall Study|Death|1
6249475|NCT01938430|9936907|FG008|Overall Study|Death|2
6249476|NCT01938430|9936908|FG009|Overall Study|Death|3
6249477|NCT01938430|9936909|FG010|Overall Study|Death|0
6249478|NCT01938430|9936910|FG011|Overall Study|Death|0
6249479|NCT01938430|9936911|FG012|Overall Study|Death|0
6249480|NCT01938430|9936912|FG013|Overall Study|Death|0
6086233|NCT00659438|9696035|FG000|Overall Study|Withdrawal by Subject|2
6086234|NCT00659438|9696036|FG001|Overall Study|Withdrawal by Subject|2
6249481|NCT01938430|9936899|FG000|Overall Study|Investigator's Discretion|0
6249482|NCT01938430|9936900|FG001|Overall Study|Investigator's Discretion|0
6249483|NCT01938430|9936901|FG002|Overall Study|Investigator's Discretion|1
6249484|NCT01938430|9936902|FG003|Overall Study|Investigator's Discretion|0
6249485|NCT01938430|9936903|FG004|Overall Study|Investigator's Discretion|0
6249486|NCT01938430|9936904|FG005|Overall Study|Investigator's Discretion|0
6249487|NCT01938430|9936905|FG006|Overall Study|Investigator's Discretion|0
6249488|NCT01938430|9936906|FG007|Overall Study|Investigator's Discretion|0
6249489|NCT01938430|9936907|FG008|Overall Study|Investigator's Discretion|0
6249490|NCT01938430|9936908|FG009|Overall Study|Investigator's Discretion|0
6249491|NCT01938430|9936909|FG010|Overall Study|Investigator's Discretion|0
6249492|NCT01938430|9936910|FG011|Overall Study|Investigator's Discretion|0
6249493|NCT01938430|9936911|FG012|Overall Study|Investigator's Discretion|0
6249494|NCT01938430|9936912|FG013|Overall Study|Investigator's Discretion|0
6249495|NCT01938430|9936899|FG000|Overall Study|Lack of Efficacy|3
6249496|NCT01938430|9936900|FG001|Overall Study|Lack of Efficacy|1
6249497|NCT01938430|9936901|FG002|Overall Study|Lack of Efficacy|1
6249498|NCT01938430|9936902|FG003|Overall Study|Lack of Efficacy|1
6249499|NCT01938430|9936903|FG004|Overall Study|Lack of Efficacy|0
6249500|NCT01938430|9936904|FG005|Overall Study|Lack of Efficacy|0
6249501|NCT01938430|9936905|FG006|Overall Study|Lack of Efficacy|0
6249502|NCT01938430|9936906|FG007|Overall Study|Lack of Efficacy|0
6249503|NCT01938430|9936907|FG008|Overall Study|Lack of Efficacy|1
6249504|NCT01938430|9936908|FG009|Overall Study|Lack of Efficacy|0
6249505|NCT01938430|9936909|FG010|Overall Study|Lack of Efficacy|2
6249506|NCT01938430|9936910|FG011|Overall Study|Lack of Efficacy|1
6249507|NCT01938430|9936911|FG012|Overall Study|Lack of Efficacy|0
6249508|NCT01938430|9936912|FG013|Overall Study|Lack of Efficacy|0
6249509|NCT01938430|9936899|FG000|Overall Study|Lost to Follow-up|0
6249510|NCT01938430|9936900|FG001|Overall Study|Lost to Follow-up|0
6249511|NCT01938430|9936901|FG002|Overall Study|Lost to Follow-up|1
6249512|NCT01938430|9936902|FG003|Overall Study|Lost to Follow-up|0
6249513|NCT01938430|9936903|FG004|Overall Study|Lost to Follow-up|0
6249514|NCT01938430|9936904|FG005|Overall Study|Lost to Follow-up|1
6249515|NCT01938430|9936905|FG006|Overall Study|Lost to Follow-up|0
6249516|NCT01938430|9936906|FG007|Overall Study|Lost to Follow-up|0
6249517|NCT01938430|9936907|FG008|Overall Study|Lost to Follow-up|0
6249518|NCT01938430|9936908|FG009|Overall Study|Lost to Follow-up|0
6249519|NCT01938430|9936909|FG010|Overall Study|Lost to Follow-up|0
6249520|NCT01938430|9936910|FG011|Overall Study|Lost to Follow-up|0
6249521|NCT01938430|9936911|FG012|Overall Study|Lost to Follow-up|0
6249522|NCT01938430|9936912|FG013|Overall Study|Lost to Follow-up|0
6249523|NCT01938430|9936899|FG000|Overall Study|Withdrew Consent|0
6249524|NCT01938430|9936900|FG001|Overall Study|Withdrew Consent|0
6249525|NCT01938430|9936901|FG002|Overall Study|Withdrew Consent|0
6249526|NCT01938430|9936902|FG003|Overall Study|Withdrew Consent|0
6249527|NCT01938430|9936903|FG004|Overall Study|Withdrew Consent|0
6249528|NCT01938430|9936904|FG005|Overall Study|Withdrew Consent|0
6249529|NCT01938430|9936905|FG006|Overall Study|Withdrew Consent|0
6249530|NCT01938430|9936906|FG007|Overall Study|Withdrew Consent|0
6249531|NCT01938430|9936907|FG008|Overall Study|Withdrew Consent|1
6249532|NCT01938430|9936908|FG009|Overall Study|Withdrew Consent|0
6249533|NCT01938430|9936909|FG010|Overall Study|Withdrew Consent|0
6249534|NCT01938430|9936910|FG011|Overall Study|Withdrew Consent|0
6249535|NCT01938430|9936911|FG012|Overall Study|Withdrew Consent|0
6249536|NCT01938430|9936912|FG013|Overall Study|Withdrew Consent|0
6249537|NCT01938573|9936967|FG000|Overall Study|Lack of Efficacy|1
6249538|NCT01938573|9936968|FG001|Overall Study|Lack of Efficacy|0
6249539|NCT01938573|9936967|FG000|Overall Study|Operation at other hospital|1
6249540|NCT01938573|9936968|FG001|Overall Study|Operation at other hospital|0
6249541|NCT01938625|9936975|FG000|Overall Study|Withdrawal by Subject|0
6249542|NCT01938625|9936976|FG001|Overall Study|Withdrawal by Subject|1
6249543|NCT01938625|9936975|FG000|Overall Study|Adverse Event|0
6249544|NCT01938625|9936976|FG001|Overall Study|Adverse Event|1
6249545|NCT01938846|9936994|FG000|Overall Study|Progressive disease|26
6249546|NCT01938846|9936995|FG001|Overall Study|Progressive disease|18
6249547|NCT01938846|9936996|FG002|Overall Study|Progressive disease|16
6249548|NCT01938846|9936994|FG000|Overall Study|Adverse Event|8
6249549|NCT01938846|9936995|FG001|Overall Study|Adverse Event|4
6249550|NCT01938846|9936996|FG002|Overall Study|Adverse Event|3
6249551|NCT01938846|9936994|FG000|Overall Study|Withdrawal by Subject|2
6249552|NCT01938846|9936995|FG001|Overall Study|Withdrawal by Subject|2
6249553|NCT01938846|9936996|FG002|Overall Study|Withdrawal by Subject|1
6249554|NCT01938846|9936994|FG000|Overall Study|Other than listed|5
6249555|NCT01938846|9936995|FG001|Overall Study|Other than listed|1
6249556|NCT01938846|9936996|FG002|Overall Study|Other than listed|4
6249557|NCT01939002|9937046|FG000|Overall Study|Adverse Event|13
6249558|NCT01939002|9937047|FG001|Overall Study|Adverse Event|13
6249559|NCT01939002|9937046|FG000|Overall Study|Withdrawal by Subject|5
6249560|NCT01939002|9937047|FG001|Overall Study|Withdrawal by Subject|3
6249561|NCT01939002|9937046|FG000|Overall Study|Other|1
6249562|NCT01939002|9937047|FG001|Overall Study|Other|2
6249563|NCT01939028|9937058|FG000|Overall Study|Withdrawal by Subject|5
6249564|NCT01939028|9937058|FG000|Overall Study|Physician Decision|7
6249565|NCT01939158|9937075|FG000|Overall Study|Adverse Event|1
6249566|NCT01939158|9937076|FG001|Overall Study|Adverse Event|0
6249567|NCT01939158|9937077|FG002|Overall Study|Adverse Event|0
6249568|NCT01939158|9937078|FG003|Overall Study|Adverse Event|0
6249569|NCT01939158|9937075|FG000|Overall Study|Withdrawal by Subject|22
6249570|NCT01939158|9937076|FG001|Overall Study|Withdrawal by Subject|25
6249571|NCT01939158|9937077|FG002|Overall Study|Withdrawal by Subject|15
6249572|NCT01939158|9937078|FG003|Overall Study|Withdrawal by Subject|17
6249573|NCT01939158|9937075|FG000|Overall Study|Migrated/moved from study area|5
6249574|NCT01939158|9937076|FG001|Overall Study|Migrated/moved from study area|7
6249575|NCT01939158|9937077|FG002|Overall Study|Migrated/moved from study area|3
6249576|NCT01939158|9937078|FG003|Overall Study|Migrated/moved from study area|6
6249577|NCT01939158|9937075|FG000|Overall Study|Lost to Follow-up|18
6249578|NCT01939158|9937076|FG001|Overall Study|Lost to Follow-up|17
6249579|NCT01939158|9937077|FG002|Overall Study|Lost to Follow-up|17
6249580|NCT01939158|9937078|FG003|Overall Study|Lost to Follow-up|17
6249581|NCT01939158|9937075|FG000|Overall Study|Death|0
6249582|NCT01939158|9937076|FG001|Overall Study|Death|0
6249583|NCT01939158|9937077|FG002|Overall Study|Death|1
6249584|NCT01939158|9937078|FG003|Overall Study|Death|1
6249585|NCT01939158|9937075|FG000|Overall Study|No longer meets eligibility criteria|0
6249586|NCT01939158|9937076|FG001|Overall Study|No longer meets eligibility criteria|0
6249587|NCT01939158|9937077|FG002|Overall Study|No longer meets eligibility criteria|1
6249588|NCT01939158|9937078|FG003|Overall Study|No longer meets eligibility criteria|0
6249589|NCT01939158|9937075|FG000|Overall Study|Other|1
6249590|NCT01939158|9937076|FG001|Overall Study|Other|3
6249591|NCT01939158|9937077|FG002|Overall Study|Other|4
6249592|NCT01939158|9937078|FG003|Overall Study|Other|3
6249593|NCT01939197|9937099|FG000|Overall Study|Withdrawal by Subject|1
6249594|NCT01939197|9937100|FG001|Overall Study|Withdrawal by Subject|0
6249595|NCT01939197|9937101|FG002|Overall Study|Withdrawal by Subject|0
6249596|NCT01939197|9937102|FG003|Overall Study|Withdrawal by Subject|0
6249597|NCT01939197|9937103|FG004|Overall Study|Withdrawal by Subject|1
6249598|NCT01939197|9937104|FG005|Overall Study|Withdrawal by Subject|0
6249599|NCT01939197|9937105|FG006|Overall Study|Withdrawal by Subject|0
6249600|NCT01939197|9937099|FG000|Overall Study|Lost to Follow-up|0
6249601|NCT01939197|9937100|FG001|Overall Study|Lost to Follow-up|1
6249602|NCT01939197|9937101|FG002|Overall Study|Lost to Follow-up|0
6249603|NCT01939197|9937102|FG003|Overall Study|Lost to Follow-up|1
6249604|NCT01939197|9937103|FG004|Overall Study|Lost to Follow-up|3
6249605|NCT01939197|9937104|FG005|Overall Study|Lost to Follow-up|1
6249606|NCT01939197|9937105|FG006|Overall Study|Lost to Follow-up|2
6249607|NCT01939314|9937154|FG000|Overall Study|Withdrawal by Subject|3
6249608|NCT01939314|9937155|FG001|Overall Study|Withdrawal by Subject|1
6249609|NCT01939314|9937154|FG000|Overall Study|Protocol Violation|1
6249610|NCT01939314|9937155|FG001|Overall Study|Protocol Violation|0
6249611|NCT01939314|9937154|FG000|Overall Study|Pregnancy|0
6249612|NCT01939314|9937155|FG001|Overall Study|Pregnancy|1
6249613|NCT01939314|9937154|FG000|Overall Study|Lost to Follow-up|5
6249614|NCT01939314|9937155|FG001|Overall Study|Lost to Follow-up|6
6249615|NCT01939353|9937163|FG000|Placebo Run-in (1 Week)|Withdrew Consent|3
6249616|NCT01939353|9937163|FG000|Placebo Run-in (1 Week)|Lost to Follow-up|1
6249617|NCT01939353|9937163|FG000|CTN SR Treatment Phase (4 Weeks)|Treatment Emergent Adverse Event (TEAE)/Serious Adverse Event (SAE)|2
6249618|NCT01939353|9937163|FG000|CTN SR Treatment Phase (4 Weeks)|Lost to Follow-up|1
6249619|NCT01939353|9937163|FG000|CTN SR Treatment Phase (4 Weeks)|Withdrew Consent|1
6249620|NCT01939366|9937172|FG000|Overall Study|Adverse Event|8
6249621|NCT01939366|9937173|FG001|Overall Study|Adverse Event|17
6249622|NCT01939366|9937174|FG002|Overall Study|Adverse Event|30
6249623|NCT01939366|9937175|FG003|Overall Study|Adverse Event|8
6249624|NCT01939366|9937176|FG004|Overall Study|Adverse Event|5
6249625|NCT01939366|9937172|FG000|Overall Study|Lack of Efficacy|2
6249626|NCT01939366|9937173|FG001|Overall Study|Lack of Efficacy|1
6249627|NCT01939366|9937174|FG002|Overall Study|Lack of Efficacy|1
6249628|NCT01939366|9937175|FG003|Overall Study|Lack of Efficacy|1
6249629|NCT01939366|9937176|FG004|Overall Study|Lack of Efficacy|3
6249630|NCT01939366|9937172|FG000|Overall Study|Lost to Follow-up|1
6249631|NCT01939366|9937173|FG001|Overall Study|Lost to Follow-up|1
6249632|NCT01939366|9937174|FG002|Overall Study|Lost to Follow-up|0
6249633|NCT01939366|9937175|FG003|Overall Study|Lost to Follow-up|0
6249634|NCT01939366|9937176|FG004|Overall Study|Lost to Follow-up|0
6249635|NCT01939366|9937172|FG000|Overall Study|Withdrawal by Subject|1
6249636|NCT01939366|9937173|FG001|Overall Study|Withdrawal by Subject|0
6249637|NCT01939366|9937174|FG002|Overall Study|Withdrawal by Subject|2
6249638|NCT01939366|9937175|FG003|Overall Study|Withdrawal by Subject|2
6249639|NCT01939366|9937176|FG004|Overall Study|Withdrawal by Subject|3
6249640|NCT01939366|9937172|FG000|Overall Study|Inclusion criteria not met|0
6249641|NCT01939366|9937173|FG001|Overall Study|Inclusion criteria not met|1
6249642|NCT01939366|9937174|FG002|Overall Study|Inclusion criteria not met|1
6086235|NCT00659438|9696035|FG000|Overall Study|Death|11
6086236|NCT00659438|9696036|FG001|Overall Study|Death|6
6086237|NCT00659438|9696035|FG000|Overall Study|Lost to Follow-up|1
6086238|NCT00659438|9696036|FG001|Overall Study|Lost to Follow-up|0
6086239|NCT00659490|9696045|FG000|Overall Study|Lost to Follow-up|2
6086240|NCT00659490|9696046|FG001|Overall Study|Lost to Follow-up|0
6086241|NCT00659490|9696047|FG002|Overall Study|Lost to Follow-up|1
6086242|NCT00659529|9696055|FG000|Overall Study|Withdrawal by Subject|4
6086243|NCT00659529|9696055|FG000|Overall Study|Protocol Violation|3
6086244|NCT00659529|9696055|FG000|Overall Study|Screen failure|9
6086245|NCT00659581|9696059|FG000|Overall Study|Adverse Event|1006
6086246|NCT00659581|9696059|FG000|Overall Study|Lack of Efficacy|1183
6249643|NCT01939366|9937175|FG003|Overall Study|Inclusion criteria not met|0
6249644|NCT01939366|9937176|FG004|Overall Study|Inclusion criteria not met|1
6249645|NCT01939366|9937172|FG000|Overall Study|Other|0
6249646|NCT01939366|9937173|FG001|Overall Study|Other|0
6249647|NCT01939366|9937174|FG002|Overall Study|Other|2
6249648|NCT01939366|9937175|FG003|Overall Study|Other|2
6086247|NCT00659581|9696059|FG000|Overall Study|Other|6393
6086248|NCT00659607|9696063|FG000|Overall Study|No blood pressure recorded|147
6249649|NCT01939366|9937176|FG004|Overall Study|Other|1
6249650|NCT01939366|9937172|FG000|Overall Study|Protocol Violation|0
6249651|NCT01939366|9937173|FG001|Overall Study|Protocol Violation|0
6249652|NCT01939366|9937174|FG002|Overall Study|Protocol Violation|0
6249653|NCT01939366|9937175|FG003|Overall Study|Protocol Violation|1
6249654|NCT01939366|9937176|FG004|Overall Study|Protocol Violation|0
6249655|NCT01939366|9937172|FG000|Overall Study|Sponsor decision|0
6249656|NCT01939366|9937173|FG001|Overall Study|Sponsor decision|0
6249657|NCT01939366|9937174|FG002|Overall Study|Sponsor decision|0
6249658|NCT01939366|9937175|FG003|Overall Study|Sponsor decision|0
6249659|NCT01939366|9937176|FG004|Overall Study|Sponsor decision|2
6086249|NCT00659607|9696063|FG000|Overall Study|Unknown measuring date of blood pressure|85
6086250|NCT00659607|9696063|FG000|Overall Study|'Unable to evaluate' for the final asses|67
6086251|NCT00659607|9696063|FG000|Overall Study|No recorded efficacy data|15
6189465|NCT01400451|9844770|FG000|Combination Treatment (or Intended)|Drug Toxicity|0
6189466|NCT01400451|9844771|FG001|Combination Treatment (or Intended)|Drug Toxicity|1
6249660|NCT01939366|9937172|FG000|Overall Study|GCP non-compliance at site|2
6249661|NCT01939366|9937173|FG001|Overall Study|GCP non-compliance at site|3
6249662|NCT01939366|9937174|FG002|Overall Study|GCP non-compliance at site|2
6189467|NCT01400451|9844772|FG002|Combination Treatment (or Intended)|Drug Toxicity|0
6249663|NCT01939366|9937175|FG003|Overall Study|GCP non-compliance at site|3
6249664|NCT01939366|9937176|FG004|Overall Study|GCP non-compliance at site|3
6249665|NCT01939496|9937200|FG000|Overall Study|Adverse Event|2
6249666|NCT01939496|9937201|FG001|Overall Study|Adverse Event|0
6249667|NCT01939496|9937202|FG002|Overall Study|Adverse Event|0
6249668|NCT01939496|9937200|FG000|Overall Study|Lost to Follow-up|1
6249669|NCT01939496|9937201|FG001|Overall Study|Lost to Follow-up|1
6249670|NCT01939496|9937202|FG002|Overall Study|Lost to Follow-up|0
6249671|NCT01939496|9937200|FG000|Overall Study|Physician Decision|1
6249672|NCT01939496|9937201|FG001|Overall Study|Physician Decision|0
6249673|NCT01939496|9937202|FG002|Overall Study|Physician Decision|0
6249674|NCT01939496|9937200|FG000|Overall Study|Protocol Violation|3
6249675|NCT01939496|9937201|FG001|Overall Study|Protocol Violation|0
6249676|NCT01939496|9937202|FG002|Overall Study|Protocol Violation|0
6249677|NCT01939496|9937200|FG000|Overall Study|Withdrawal by Subject|0
6249678|NCT01939496|9937201|FG001|Overall Study|Withdrawal by Subject|1
6249679|NCT01939496|9937202|FG002|Overall Study|Withdrawal by Subject|1
6249680|NCT01939496|9937200|FG000|Overall Study|Blood Pressure Withdrawal Criteria|0
6249681|NCT01939496|9937201|FG001|Overall Study|Blood Pressure Withdrawal Criteria|1
6189468|NCT01400451|9844770|FG000|Combination Treatment (or Intended)|Adverse Event|1
6249682|NCT01939496|9937202|FG002|Overall Study|Blood Pressure Withdrawal Criteria|0
6249683|NCT01939496|9937200|FG000|Overall Study|Other|2
6249684|NCT01939496|9937201|FG001|Overall Study|Other|0
6249685|NCT01939496|9937202|FG002|Overall Study|Other|1
6249686|NCT01939548|9937213|FG000|Overall Study|Non compliance|0
6249687|NCT01939548|9937214|FG001|Overall Study|Non compliance|2
6249688|NCT01939548|9937215|FG002|Overall Study|Non compliance|0
6249689|NCT01939548|9937213|FG000|Overall Study|Study Terminated by Sponsor|17
6249690|NCT01939548|9937214|FG001|Overall Study|Study Terminated by Sponsor|19
6249691|NCT01939548|9937215|FG002|Overall Study|Study Terminated by Sponsor|12
6249692|NCT01939548|9937213|FG000|Overall Study|Insufficient Clinical Response|1
6249693|NCT01939548|9937214|FG001|Overall Study|Insufficient Clinical Response|0
6249694|NCT01939548|9937215|FG002|Overall Study|Insufficient Clinical Response|0
6249695|NCT01939548|9937213|FG000|Overall Study|Did Not Meet Entrance Criteria|1
6249696|NCT01939548|9937214|FG001|Overall Study|Did Not Meet Entrance Criteria|0
6249697|NCT01939548|9937215|FG002|Overall Study|Did Not Meet Entrance Criteria|0
6249698|NCT01939548|9937213|FG000|Overall Study|Withdrawal by Subject|4
6249699|NCT01939548|9937214|FG001|Overall Study|Withdrawal by Subject|4
6249700|NCT01939548|9937215|FG002|Overall Study|Withdrawal by Subject|1
6249701|NCT01939548|9937213|FG000|Overall Study|Protocol Violation|7
6249702|NCT01939548|9937214|FG001|Overall Study|Protocol Violation|6
6249703|NCT01939548|9937215|FG002|Overall Study|Protocol Violation|5
6249704|NCT01939548|9937213|FG000|Overall Study|Lost to Follow-up|5
6249705|NCT01939548|9937214|FG001|Overall Study|Lost to Follow-up|5
6189469|NCT01400451|9844771|FG001|Combination Treatment (or Intended)|Adverse Event|0
6189470|NCT01400451|9844772|FG002|Combination Treatment (or Intended)|Adverse Event|0
6189471|NCT01400451|9844770|FG000|Combination Treatment (or Intended)|Disease Progression|3
6189472|NCT01400451|9844771|FG001|Combination Treatment (or Intended)|Disease Progression|1
6189473|NCT01400451|9844772|FG002|Combination Treatment (or Intended)|Disease Progression|1
6189474|NCT01400451|9844770|FG000|Combination Treatment (or Intended)|Dose-limiting toxicity|0
6189475|NCT01400451|9844771|FG001|Combination Treatment (or Intended)|Dose-limiting toxicity|1
6189476|NCT01400451|9844772|FG002|Combination Treatment (or Intended)|Dose-limiting toxicity|0
6249706|NCT01939548|9937215|FG002|Overall Study|Lost to Follow-up|3
6249707|NCT01939548|9937213|FG000|Overall Study|Adverse Event|2
6249708|NCT01939548|9937214|FG001|Overall Study|Adverse Event|9
6249709|NCT01939548|9937215|FG002|Overall Study|Adverse Event|7
6249710|NCT01939548|9937213|FG000|Overall Study|Death|0
6249711|NCT01939548|9937214|FG001|Overall Study|Death|0
6249712|NCT01939548|9937215|FG002|Overall Study|Death|1
6249713|NCT01939548|9937213|FG000|Overall Study|Participant dropped|0
6249714|NCT01939548|9937214|FG001|Overall Study|Participant dropped|0
6249715|NCT01939548|9937215|FG002|Overall Study|Participant dropped|1
6249716|NCT01939548|9937213|FG000|Overall Study|Participant unwilling to continue|0
6249717|NCT01939548|9937214|FG001|Overall Study|Participant unwilling to continue|1
6249718|NCT01939548|9937215|FG002|Overall Study|Participant unwilling to continue|0
6249719|NCT01939548|9937213|FG000|Overall Study|Participant withdrew consent|0
6249720|NCT01939548|9937214|FG001|Overall Study|Participant withdrew consent|2
6249721|NCT01939548|9937215|FG002|Overall Study|Participant withdrew consent|0
6249722|NCT01939548|9937213|FG000|Overall Study|Did not complete follow-up|0
6249723|NCT01939548|9937214|FG001|Overall Study|Did not complete follow-up|1
6249724|NCT01939548|9937215|FG002|Overall Study|Did not complete follow-up|0
6249725|NCT01939899|9937228|FG000|Lead-in Dose Finding Phase|Death|0
6249726|NCT01939899|9937229|FG001|Lead-in Dose Finding Phase|Death|3
6249727|NCT01939899|9937230|FG002|Lead-in Dose Finding Phase|Death|1
6249728|NCT01939899|9937231|FG003|Lead-in Dose Finding Phase|Death|0
6249729|NCT01939899|9937232|FG004|Lead-in Dose Finding Phase|Death|0
6249730|NCT01939899|9937228|FG000|Lead-in Dose Finding Phase|Disease Progression|2
6249731|NCT01939899|9937229|FG001|Lead-in Dose Finding Phase|Disease Progression|4
6249732|NCT01939899|9937230|FG002|Lead-in Dose Finding Phase|Disease Progression|3
6249733|NCT01939899|9937231|FG003|Lead-in Dose Finding Phase|Disease Progression|0
6249734|NCT01939899|9937232|FG004|Lead-in Dose Finding Phase|Disease Progression|0
6249735|NCT01939899|9937228|FG000|Lead-in Dose Finding Phase|Other|0
6249736|NCT01939899|9937229|FG001|Lead-in Dose Finding Phase|Other|0
6249737|NCT01939899|9937230|FG002|Lead-in Dose Finding Phase|Other|1
6249738|NCT01939899|9937231|FG003|Lead-in Dose Finding Phase|Other|0
6249739|NCT01939899|9937232|FG004|Lead-in Dose Finding Phase|Other|0
6249740|NCT01939899|9937228|FG000|Phase 2|Withdrawal by Subject|0
6249741|NCT01939899|9937229|FG001|Phase 2|Withdrawal by Subject|0
6249742|NCT01939899|9937230|FG002|Phase 2|Withdrawal by Subject|0
6249743|NCT01939899|9937231|FG003|Phase 2|Withdrawal by Subject|2
6249744|NCT01939899|9937232|FG004|Phase 2|Withdrawal by Subject|0
6249745|NCT01939899|9937228|FG000|Phase 2|Disease Progression|0
6249746|NCT01939899|9937229|FG001|Phase 2|Disease Progression|0
6249747|NCT01939899|9937230|FG002|Phase 2|Disease Progression|0
6249748|NCT01939899|9937231|FG003|Phase 2|Disease Progression|9
6249749|NCT01939899|9937232|FG004|Phase 2|Disease Progression|1
6249750|NCT01939977|9937258|FG000|Overall Study|Adverse Event|4
6249751|NCT01939977|9937259|FG001|Overall Study|Adverse Event|3
6249752|NCT01939977|9937258|FG000|Overall Study|Lack of Efficacy|3
6249753|NCT01939977|9937259|FG001|Overall Study|Lack of Efficacy|0
6249754|NCT01939977|9937258|FG000|Overall Study|Physician Decision|1
6249755|NCT01939977|9937259|FG001|Overall Study|Physician Decision|1
6249756|NCT01939977|9937258|FG000|Overall Study|Withdrawal by Subject|0
6249757|NCT01939977|9937259|FG001|Overall Study|Withdrawal by Subject|2
6249758|NCT01939977|9937258|FG000|Overall Study|Did not meet inclusion criteria|1
6249759|NCT01939977|9937259|FG001|Overall Study|Did not meet inclusion criteria|0
6249760|NCT01939977|9937258|FG000|Overall Study|Did not receive study medication|0
6249761|NCT01939977|9937259|FG001|Overall Study|Did not receive study medication|1
6249762|NCT01940120|9937265|FG000|Overall Study|Death|40
6249763|NCT01940120|9937265|FG000|Overall Study|Withdrawal by Subject|8
6249764|NCT01940354|9937298|FG000|Overall Study|Withdrawal by Subject|4
6249765|NCT01940354|9937299|FG001|Overall Study|Withdrawal by Subject|2
6249766|NCT01940484|9937305|FG000|Overall Study|Withdrawal by Subject|3
6249767|NCT01940484|9937305|FG000|Overall Study|Underwent transplantation|4
6249768|NCT01940484|9937305|FG000|Overall Study|Death|2
6249769|NCT01940484|9937305|FG000|Overall Study|Adverse Event|1
6249770|NCT01940497|9937311|FG000|Overall Study|Adverse Event/Intercurrent Illness|11
6249771|NCT01940497|9937312|FG001|Overall Study|Adverse Event/Intercurrent Illness|8
6249772|NCT01940497|9937311|FG000|Overall Study|Recurrence of Disease Postsurgery|1
6249773|NCT01940497|9937312|FG001|Overall Study|Recurrence of Disease Postsurgery|3
6249774|NCT01940497|9937311|FG000|Overall Study|Violation of Entry Criteria|1
6249775|NCT01940497|9937312|FG001|Overall Study|Violation of Entry Criteria|1
6249776|NCT01940497|9937311|FG000|Overall Study|Refused Treatment|1
6249777|NCT01940497|9937312|FG001|Overall Study|Refused Treatment|3
6249778|NCT01940497|9937311|FG000|Overall Study|Withdrew Consent|6
6249779|NCT01940497|9937312|FG001|Overall Study|Withdrew Consent|2
6249780|NCT01940497|9937311|FG000|Overall Study|Administrative/Other|1
6249781|NCT01940497|9937312|FG001|Overall Study|Administrative/Other|1
6249782|NCT01940705|9937351|FG000|Overall Study|Lost to Follow-up|1
6249783|NCT01940705|9937352|FG001|Overall Study|Lost to Follow-up|3
6249784|NCT01940705|9937353|FG002|Overall Study|Lost to Follow-up|2
6249785|NCT01940705|9937354|FG003|Overall Study|Lost to Follow-up|2
6249786|NCT01940705|9937351|FG000|Overall Study|Withdrawal by Subject|2
6249787|NCT01940705|9937352|FG001|Overall Study|Withdrawal by Subject|2
6249788|NCT01940705|9937353|FG002|Overall Study|Withdrawal by Subject|3
6249789|NCT01940705|9937354|FG003|Overall Study|Withdrawal by Subject|2
6249790|NCT01940705|9937351|FG000|Overall Study|Intervention not given|0
6249791|NCT01940705|9937352|FG001|Overall Study|Intervention not given|3
6249792|NCT01940705|9937353|FG002|Overall Study|Intervention not given|3
6249793|NCT01940705|9937354|FG003|Overall Study|Intervention not given|0
6249794|NCT01940705|9937351|FG000|Overall Study|Withdrawal by team - hearing aid change|1
6249795|NCT01940705|9937352|FG001|Overall Study|Withdrawal by team - hearing aid change|0
6249796|NCT01940705|9937353|FG002|Overall Study|Withdrawal by team - hearing aid change|0
6249797|NCT01940705|9937354|FG003|Overall Study|Withdrawal by team - hearing aid change|0
6249798|NCT01940887|9937369|FG000|Year 1|Protocol Violation|0
6249799|NCT01940887|9937370|FG001|Year 1|Protocol Violation|1
6249800|NCT01940887|9937369|FG000|Year 1|Physician Decision|7
6249801|NCT01940887|9937370|FG001|Year 1|Physician Decision|3
6249802|NCT01940887|9937369|FG000|Year 1|Death|5
6249803|NCT01940887|9937370|FG001|Year 1|Death|3
6249804|NCT01940887|9937369|FG000|Year 1|Adverse Event|7
6249805|NCT01940887|9937370|FG001|Year 1|Adverse Event|6
6249806|NCT01940887|9937369|FG000|Year 1|Withdrawal by Subject|18
6249807|NCT01940887|9937370|FG001|Year 1|Withdrawal by Subject|9
6249808|NCT01940887|9937369|FG000|Year 1|Lost to Follow-up|2
6249809|NCT01940887|9937370|FG001|Year 1|Lost to Follow-up|1
6249810|NCT01940887|9937369|FG000|Year 2|Physician Decision|8
6249811|NCT01940887|9937370|FG001|Year 2|Physician Decision|1
6249812|NCT01940887|9937369|FG000|Year 2|Death|0
6249813|NCT01940887|9937370|FG001|Year 2|Death|2
6249814|NCT01940887|9937369|FG000|Year 2|Sponsor Decision, early termination|192
6249815|NCT01940887|9937370|FG001|Year 2|Sponsor Decision, early termination|203
6249816|NCT01940887|9937369|FG000|Year 2|Adverse Event|8
6249817|NCT01940887|9937370|FG001|Year 2|Adverse Event|2
6249818|NCT01940887|9937369|FG000|Year 2|Withdrawal by Subject|8
6249819|NCT01940887|9937370|FG001|Year 2|Withdrawal by Subject|8
6249820|NCT01940887|9937369|FG000|Year 2|Lost to Follow-up|1
6249821|NCT01940887|9937370|FG001|Year 2|Lost to Follow-up|6
6249822|NCT01940900|9937378|FG000|Overall Study|Physician Decision|4
6249823|NCT01940900|9937379|FG001|Overall Study|Physician Decision|0
6249824|NCT01940900|9937378|FG000|Overall Study|Adverse Event|10
6249825|NCT01940900|9937379|FG001|Overall Study|Adverse Event|15
6249826|NCT01940900|9937378|FG000|Overall Study|Withdrawal by Subject|11
6249827|NCT01940900|9937379|FG001|Overall Study|Withdrawal by Subject|15
6249828|NCT01940900|9937378|FG000|Overall Study|Lost to Follow-up|1
6249829|NCT01940900|9937379|FG001|Overall Study|Lost to Follow-up|0
6249830|NCT01940900|9937378|FG000|Overall Study|Sponsor Decision|1
6249831|NCT01940900|9937379|FG001|Overall Study|Sponsor Decision|0
6249832|NCT01940900|9937378|FG000|Overall Study|subject non-compliance|1
6249833|NCT01940900|9937379|FG001|Overall Study|subject non-compliance|1
6249834|NCT01940900|9937378|FG000|Overall Study|other|1
6249835|NCT01940900|9937379|FG001|Overall Study|other|0
6249836|NCT01940939|9937387|FG000|Overall Study|Withdrawal by Subject|2
6249837|NCT01940939|9937388|FG001|Overall Study|Withdrawal by Subject|8
6249838|NCT01941030|9937396|FG000|Overall Study|Death|3
6249839|NCT01941030|9937397|FG001|Overall Study|Death|2
6249840|NCT01941030|9937396|FG000|Overall Study|Lost to Follow-up|6
6249841|NCT01941030|9937397|FG001|Overall Study|Lost to Follow-up|5
6249842|NCT01941030|9937396|FG000|Overall Study|Withdrawal by Subject|4
6249843|NCT01941030|9937397|FG001|Overall Study|Withdrawal by Subject|6
6249844|NCT01941095|9937403|FG000|Overall Study|Insufficient therapeutic response|13
6249845|NCT01941095|9937403|FG000|Overall Study|Anaphylaxis or serious hypersensitivity|2
6249846|NCT01941095|9937403|FG000|Overall Study|Adverse Event|11
6249847|NCT01941095|9937403|FG000|Overall Study|Physician Decision|3
6249848|NCT01941095|9937403|FG000|Overall Study|Withdrawal by Subject|17
6249849|NCT01941095|9937403|FG000|Overall Study|Lost to Follow-up|10
6249850|NCT01941186|9937410|FG000|Follow-up|Lost to Follow-up|1
6249851|NCT01941186|9937411|FG001|Follow-up|Lost to Follow-up|0
6249852|NCT01941498|9937456|FG000|Overall Study|Relocated out of state|1
6249853|NCT01941537|9937477|FG000|Overall Study|Lack of Efficacy|1
6249854|NCT01941537|9937478|FG001|Overall Study|Lack of Efficacy|2
6249855|NCT01941537|9937477|FG000|Overall Study|Lost to Follow-up|1
6249856|NCT01941537|9937478|FG001|Overall Study|Lost to Follow-up|0
6249857|NCT01941537|9937477|FG000|Overall Study|Pregnancy|1
6249858|NCT01941537|9937478|FG001|Overall Study|Pregnancy|0
6249859|NCT01941537|9937477|FG000|Overall Study|Adverse Event|1
6249860|NCT01941537|9937478|FG001|Overall Study|Adverse Event|0
6249861|NCT01941537|9937477|FG000|Overall Study|Withdrawal by Subject|0
6249862|NCT01941537|9937478|FG001|Overall Study|Withdrawal by Subject|1
6249863|NCT01941940|9937523|FG000|Overall Study|Adverse Event|11
6249864|NCT01941940|9937523|FG000|Overall Study|Lost to Follow-up|2
6249865|NCT01941940|9937523|FG000|Overall Study|Physician Decision|2
6249866|NCT01941940|9937523|FG000|Overall Study|Withdrawal by Subject|15
6249867|NCT01941940|9937523|FG000|Overall Study|Death|1
6249868|NCT01941940|9937523|FG000|Overall Study|Other|1
6249869|NCT01941940|9937523|FG000|Overall Study|Other|1
6249870|NCT01942148|9937527|FG000|Overall Study|Adverse Event|4
6249871|NCT01942148|9937527|FG000|Overall Study|Lack of Efficacy|2
6249872|NCT01942148|9937527|FG000|Overall Study|Physician Decision|11
6249873|NCT01942148|9937527|FG000|Overall Study|Protocol Violation|1
6249874|NCT01942148|9937527|FG000|Overall Study|Withdrawal by Subject|8
6249875|NCT01942148|9937527|FG000|Overall Study|Use of the prohibition medicine|1
6249876|NCT01942161|9937534|FG000|Overall Study|Adverse Event|1
6249877|NCT01942161|9937535|FG001|Overall Study|Adverse Event|2
6249878|NCT01942161|9937536|FG002|Overall Study|Adverse Event|5
6249879|NCT01942161|9937534|FG000|Overall Study|Physician Decision|3
6249880|NCT01942161|9937535|FG001|Overall Study|Physician Decision|1
6249881|NCT01942161|9937536|FG002|Overall Study|Physician Decision|0
6249882|NCT01942161|9937534|FG000|Overall Study|Protocol Violation|1
6249883|NCT01942161|9937535|FG001|Overall Study|Protocol Violation|0
6249884|NCT01942161|9937536|FG002|Overall Study|Protocol Violation|0
6249885|NCT01942161|9937534|FG000|Overall Study|Withdrawal by Subject|3
6249886|NCT01942161|9937535|FG001|Overall Study|Withdrawal by Subject|3
6249887|NCT01942161|9937536|FG002|Overall Study|Withdrawal by Subject|1
6249888|NCT01942486|9937544|FG000|Overall Study|Lost to Follow-up|27
6249889|NCT01942590|9937550|FG000|Overall Study|Withdrawal by Subject|0
6249890|NCT01942590|9937551|FG001|Overall Study|Withdrawal by Subject|1
6249891|NCT01942590|9937550|FG000|Overall Study|Adverse Event|1
6249892|NCT01942590|9937551|FG001|Overall Study|Adverse Event|0
6249893|NCT01942733|9937606|FG000|Overall Study|Lost to Follow-up|1
6249894|NCT01942733|9937606|FG000|Overall Study|Non-compliance with IMP|1
6249895|NCT01942733|9937606|FG000|Overall Study|Administrative|1
6249896|NCT01942785|9937610|FG000|Overall Study|Adverse Event|2
6249897|NCT01942785|9937610|FG000|Overall Study|Withdrawal by Subject|1
6249898|NCT01942785|9937610|FG000|Overall Study|Protocol Violation|1
6249899|NCT01942993|9937616|FG000|Overall Study|Lost to Follow-up|1
6249900|NCT01942993|9937616|FG000|Overall Study|Physician Decision|1
6249901|NCT01943292|9937648|FG000|Overall Study|Withdrawal by Subject|1
6249902|NCT01943292|9937649|FG001|Overall Study|Withdrawal by Subject|0
6249903|NCT01943292|9937650|FG002|Overall Study|Withdrawal by Subject|0
6249904|NCT01943435|9937667|FG000|Baseline Eligibility and Randomization|Withdrawal by Subject|4
6249905|NCT01943435|9937668|FG001|Baseline Eligibility and Randomization|Withdrawal by Subject|12
6249906|NCT01943435|9937669|FG002|Baseline Eligibility and Randomization|Withdrawal by Subject|3
6249907|NCT01943435|9937667|FG000|Intervention Period|Withdrawal by Subject|3
6249908|NCT01943435|9937668|FG001|Intervention Period|Withdrawal by Subject|3
6249909|NCT01943435|9937669|FG002|Intervention Period|Withdrawal by Subject|4
6249910|NCT01943435|9937667|FG000|2 Month Follow up|Lost to Follow-up|2
6249911|NCT01943435|9937668|FG001|2 Month Follow up|Lost to Follow-up|3
6249912|NCT01943435|9937669|FG002|2 Month Follow up|Lost to Follow-up|0
6249913|NCT01943435|9937667|FG000|6 Month Follow up|Lost to Follow-up|12
6249914|NCT01943435|9937668|FG001|6 Month Follow up|Lost to Follow-up|7
6249915|NCT01943435|9937669|FG002|6 Month Follow up|Lost to Follow-up|15
6249916|NCT01943539|9937703|FG000|Overall Study|Non-compliance with at-home intervention|4
6249917|NCT01943539|9937704|FG001|Overall Study|Non-compliance with at-home intervention|0
6249918|NCT01943552|9937713|FG000|Overall Study|Adverse Event|3
6249919|NCT01943552|9937714|FG001|Overall Study|Adverse Event|2
6249920|NCT01943552|9937713|FG000|Overall Study|Withdrawal by Subject|6
6249921|NCT01943552|9937714|FG001|Overall Study|Withdrawal by Subject|6
6249922|NCT01943552|9937713|FG000|Overall Study|Other Reasons|16
6249923|NCT01943552|9937714|FG001|Overall Study|Other Reasons|17
6249924|NCT01943591|9937735|FG000|Overall Study|Lost to Follow-up|3
6249925|NCT01943591|9937736|FG001|Overall Study|Lost to Follow-up|4
6249926|NCT01943591|9937735|FG000|Overall Study|Death|2
6249927|NCT01943591|9937736|FG001|Overall Study|Death|7
6249928|NCT01943799|9937746|FG000|Overall Study|Lost to Follow-up|0
6249929|NCT01943799|9937747|FG001|Overall Study|Lost to Follow-up|1
6249930|NCT01943799|9937748|FG002|Overall Study|Lost to Follow-up|1
6249931|NCT01943799|9937749|FG003|Overall Study|Lost to Follow-up|0
6249932|NCT01943799|9937746|FG000|Overall Study|Protocol Violation|1
6249933|NCT01943799|9937747|FG001|Overall Study|Protocol Violation|0
6249934|NCT01943799|9937748|FG002|Overall Study|Protocol Violation|0
6249935|NCT01943799|9937749|FG003|Overall Study|Protocol Violation|0
6249936|NCT01943799|9937746|FG000|Overall Study|Withdrawal by Subject|4
6249937|NCT01943799|9937747|FG001|Overall Study|Withdrawal by Subject|2
6249938|NCT01943799|9937748|FG002|Overall Study|Withdrawal by Subject|1
6249939|NCT01943799|9937749|FG003|Overall Study|Withdrawal by Subject|0
6249940|NCT01943851|9937777|FG000|Part 1 (Up to 86.9 Weeks)|Withdrawal by Subject|0
6249941|NCT01943851|9937778|FG001|Part 1 (Up to 86.9 Weeks)|Withdrawal by Subject|0
6249942|NCT01943851|9937779|FG002|Part 1 (Up to 86.9 Weeks)|Withdrawal by Subject|0
6249943|NCT01943851|9937780|FG003|Part 1 (Up to 86.9 Weeks)|Withdrawal by Subject|1
6249944|NCT01943851|9937781|FG004|Part 1 (Up to 86.9 Weeks)|Withdrawal by Subject|0
6249945|NCT01943851|9937782|FG005|Part 1 (Up to 86.9 Weeks)|Withdrawal by Subject|0
6249946|NCT01943851|9937783|FG006|Part 1 (Up to 86.9 Weeks)|Withdrawal by Subject|1
6249947|NCT01943851|9937784|FG007|Part 1 (Up to 86.9 Weeks)|Withdrawal by Subject|1
6249948|NCT01943851|9937785|FG008|Part 1 (Up to 86.9 Weeks)|Withdrawal by Subject|1
6249949|NCT01943851|9937786|FG009|Part 1 (Up to 86.9 Weeks)|Withdrawal by Subject|0
6249950|NCT01943851|9937787|FG010|Part 1 (Up to 86.9 Weeks)|Withdrawal by Subject|0
6249951|NCT01943851|9937788|FG011|Part 1 (Up to 86.9 Weeks)|Withdrawal by Subject|0
6086252|NCT00659607|9696063|FG000|Overall Study|Inconsistent BP measuring date|2
6249952|NCT01943851|9937789|FG012|Part 1 (Up to 86.9 Weeks)|Withdrawal by Subject|0
6249953|NCT01943851|9937790|FG013|Part 1 (Up to 86.9 Weeks)|Withdrawal by Subject|0
6249954|NCT01943851|9937791|FG014|Part 1 (Up to 86.9 Weeks)|Withdrawal by Subject|0
6249955|NCT01943851|9937792|FG015|Part 1 (Up to 86.9 Weeks)|Withdrawal by Subject|0
6249956|NCT01943851|9937793|FG016|Part 1 (Up to 86.9 Weeks)|Withdrawal by Subject|0
6249957|NCT01943851|9937794|FG017|Part 1 (Up to 86.9 Weeks)|Withdrawal by Subject|0
6249958|NCT01943851|9937777|FG000|Part 1 (Up to 86.9 Weeks)|Lost to Follow-up|0
6249959|NCT01943851|9937778|FG001|Part 1 (Up to 86.9 Weeks)|Lost to Follow-up|0
6249960|NCT01943851|9937779|FG002|Part 1 (Up to 86.9 Weeks)|Lost to Follow-up|0
6249961|NCT01943851|9937780|FG003|Part 1 (Up to 86.9 Weeks)|Lost to Follow-up|0
6249962|NCT01943851|9937781|FG004|Part 1 (Up to 86.9 Weeks)|Lost to Follow-up|1
6249963|NCT01943851|9937782|FG005|Part 1 (Up to 86.9 Weeks)|Lost to Follow-up|0
6249964|NCT01943851|9937783|FG006|Part 1 (Up to 86.9 Weeks)|Lost to Follow-up|0
6249965|NCT01943851|9937784|FG007|Part 1 (Up to 86.9 Weeks)|Lost to Follow-up|1
6249966|NCT01943851|9937785|FG008|Part 1 (Up to 86.9 Weeks)|Lost to Follow-up|0
6249967|NCT01943851|9937786|FG009|Part 1 (Up to 86.9 Weeks)|Lost to Follow-up|0
6249968|NCT01943851|9937787|FG010|Part 1 (Up to 86.9 Weeks)|Lost to Follow-up|0
6249969|NCT01943851|9937788|FG011|Part 1 (Up to 86.9 Weeks)|Lost to Follow-up|0
6249970|NCT01943851|9937789|FG012|Part 1 (Up to 86.9 Weeks)|Lost to Follow-up|0
6249971|NCT01943851|9937790|FG013|Part 1 (Up to 86.9 Weeks)|Lost to Follow-up|0
6249972|NCT01943851|9937791|FG014|Part 1 (Up to 86.9 Weeks)|Lost to Follow-up|0
6249973|NCT01943851|9937792|FG015|Part 1 (Up to 86.9 Weeks)|Lost to Follow-up|0
6249974|NCT01943851|9937793|FG016|Part 1 (Up to 86.9 Weeks)|Lost to Follow-up|0
6249975|NCT01943851|9937794|FG017|Part 1 (Up to 86.9 Weeks)|Lost to Follow-up|0
6249976|NCT01943851|9937777|FG000|Part 1 (Up to 86.9 Weeks)|Investigator discretion|0
6249977|NCT01943851|9937778|FG001|Part 1 (Up to 86.9 Weeks)|Investigator discretion|0
6249978|NCT01943851|9937779|FG002|Part 1 (Up to 86.9 Weeks)|Investigator discretion|0
6249979|NCT01943851|9937780|FG003|Part 1 (Up to 86.9 Weeks)|Investigator discretion|0
6249980|NCT01943851|9937781|FG004|Part 1 (Up to 86.9 Weeks)|Investigator discretion|0
6249981|NCT01943851|9937782|FG005|Part 1 (Up to 86.9 Weeks)|Investigator discretion|0
6249982|NCT01943851|9937783|FG006|Part 1 (Up to 86.9 Weeks)|Investigator discretion|0
6249983|NCT01943851|9937784|FG007|Part 1 (Up to 86.9 Weeks)|Investigator discretion|0
6249984|NCT01943851|9937785|FG008|Part 1 (Up to 86.9 Weeks)|Investigator discretion|0
6249985|NCT01943851|9937786|FG009|Part 1 (Up to 86.9 Weeks)|Investigator discretion|0
6249986|NCT01943851|9937787|FG010|Part 1 (Up to 86.9 Weeks)|Investigator discretion|0
6249987|NCT01943851|9937788|FG011|Part 1 (Up to 86.9 Weeks)|Investigator discretion|0
6249988|NCT01943851|9937789|FG012|Part 1 (Up to 86.9 Weeks)|Investigator discretion|0
6249989|NCT01943851|9937790|FG013|Part 1 (Up to 86.9 Weeks)|Investigator discretion|1
6249990|NCT01943851|9937791|FG014|Part 1 (Up to 86.9 Weeks)|Investigator discretion|0
6249991|NCT01943851|9937792|FG015|Part 1 (Up to 86.9 Weeks)|Investigator discretion|0
6249992|NCT01943851|9937793|FG016|Part 1 (Up to 86.9 Weeks)|Investigator discretion|0
6249993|NCT01943851|9937794|FG017|Part 1 (Up to 86.9 Weeks)|Investigator discretion|0
6249994|NCT01943851|9937777|FG000|Part 2 (Up to 36.4 Weeks)|Withdrawal by Subject|0
6249995|NCT01943851|9937778|FG001|Part 2 (Up to 36.4 Weeks)|Withdrawal by Subject|0
6249996|NCT01943851|9937779|FG002|Part 2 (Up to 36.4 Weeks)|Withdrawal by Subject|0
6249997|NCT01943851|9937780|FG003|Part 2 (Up to 36.4 Weeks)|Withdrawal by Subject|0
6249998|NCT01943851|9937781|FG004|Part 2 (Up to 36.4 Weeks)|Withdrawal by Subject|0
6249999|NCT01943851|9937782|FG005|Part 2 (Up to 36.4 Weeks)|Withdrawal by Subject|0
6250000|NCT01943851|9937783|FG006|Part 2 (Up to 36.4 Weeks)|Withdrawal by Subject|0
6250001|NCT01943851|9937784|FG007|Part 2 (Up to 36.4 Weeks)|Withdrawal by Subject|0
6250002|NCT01943851|9937785|FG008|Part 2 (Up to 36.4 Weeks)|Withdrawal by Subject|0
6250003|NCT01943851|9937786|FG009|Part 2 (Up to 36.4 Weeks)|Withdrawal by Subject|0
6250004|NCT01943851|9937787|FG010|Part 2 (Up to 36.4 Weeks)|Withdrawal by Subject|0
6250005|NCT01943851|9937788|FG011|Part 2 (Up to 36.4 Weeks)|Withdrawal by Subject|0
6250006|NCT01943851|9937789|FG012|Part 2 (Up to 36.4 Weeks)|Withdrawal by Subject|0
6250007|NCT01943851|9937790|FG013|Part 2 (Up to 36.4 Weeks)|Withdrawal by Subject|0
6250008|NCT01943851|9937791|FG014|Part 2 (Up to 36.4 Weeks)|Withdrawal by Subject|0
6250009|NCT01943851|9937792|FG015|Part 2 (Up to 36.4 Weeks)|Withdrawal by Subject|2
6189477|NCT01400503|9844794|FG000|Overall Study|Withdrawal by Subject|1
6189478|NCT01400503|9844794|FG000|Overall Study|Study Terminated by Sponsor|58
6189479|NCT01400503|9844794|FG000|Overall Study|Other|1
6189480|NCT01400516|9844800|FG000|Primary Trial|Withdrawal by Subject|0
6189481|NCT01400516|9844801|FG001|Primary Trial|Withdrawal by Subject|2
6189482|NCT01400698|9844811|FG000|Overall Study|Lost to Follow-up|2
6189483|NCT01400698|9844812|FG001|Overall Study|Lost to Follow-up|5
6189484|NCT01400698|9844813|FG002|Overall Study|Lost to Follow-up|2
6189485|NCT01400698|9844814|FG003|Overall Study|Lost to Follow-up|1
6189486|NCT01400698|9844815|FG004|Overall Study|Lost to Follow-up|4
6189487|NCT01400698|9844816|FG005|Overall Study|Lost to Follow-up|3
6189488|NCT01400698|9844811|FG000|Overall Study|Withdrawal by Subject|8
6189489|NCT01400698|9844812|FG001|Overall Study|Withdrawal by Subject|2
6189490|NCT01400698|9844813|FG002|Overall Study|Withdrawal by Subject|0
6189491|NCT01400698|9844814|FG003|Overall Study|Withdrawal by Subject|4
6189492|NCT01400698|9844815|FG004|Overall Study|Withdrawal by Subject|1
6189493|NCT01400698|9844816|FG005|Overall Study|Withdrawal by Subject|3
6189494|NCT01400698|9844811|FG000|Overall Study|Protocol Violation|0
6189495|NCT01400698|9844812|FG001|Overall Study|Protocol Violation|1
6189496|NCT01400698|9844813|FG002|Overall Study|Protocol Violation|0
6250010|NCT01943851|9937793|FG016|Part 2 (Up to 36.4 Weeks)|Withdrawal by Subject|0
6250011|NCT01943851|9937794|FG017|Part 2 (Up to 36.4 Weeks)|Withdrawal by Subject|0
6250012|NCT01943851|9937777|FG000|Part 2 (Up to 36.4 Weeks)|Study closed/terminated|0
6250013|NCT01943851|9937778|FG001|Part 2 (Up to 36.4 Weeks)|Study closed/terminated|0
6250014|NCT01943851|9937779|FG002|Part 2 (Up to 36.4 Weeks)|Study closed/terminated|0
6250015|NCT01943851|9937780|FG003|Part 2 (Up to 36.4 Weeks)|Study closed/terminated|0
6250016|NCT01943851|9937781|FG004|Part 2 (Up to 36.4 Weeks)|Study closed/terminated|0
6250017|NCT01943851|9937782|FG005|Part 2 (Up to 36.4 Weeks)|Study closed/terminated|0
6250018|NCT01943851|9937783|FG006|Part 2 (Up to 36.4 Weeks)|Study closed/terminated|0
6250019|NCT01943851|9937784|FG007|Part 2 (Up to 36.4 Weeks)|Study closed/terminated|0
6189497|NCT01400698|9844814|FG003|Overall Study|Protocol Violation|0
6189498|NCT01400698|9844815|FG004|Overall Study|Protocol Violation|1
6189499|NCT01400698|9844816|FG005|Overall Study|Protocol Violation|0
6250020|NCT01943851|9937785|FG008|Part 2 (Up to 36.4 Weeks)|Study closed/terminated|0
6250021|NCT01943851|9937786|FG009|Part 2 (Up to 36.4 Weeks)|Study closed/terminated|0
6250022|NCT01943851|9937787|FG010|Part 2 (Up to 36.4 Weeks)|Study closed/terminated|0
6250023|NCT01943851|9937788|FG011|Part 2 (Up to 36.4 Weeks)|Study closed/terminated|0
6250024|NCT01943851|9937789|FG012|Part 2 (Up to 36.4 Weeks)|Study closed/terminated|0
6250025|NCT01943851|9937790|FG013|Part 2 (Up to 36.4 Weeks)|Study closed/terminated|0
6250026|NCT01943851|9937791|FG014|Part 2 (Up to 36.4 Weeks)|Study closed/terminated|0
6250027|NCT01943851|9937792|FG015|Part 2 (Up to 36.4 Weeks)|Study closed/terminated|4
6250028|NCT01943851|9937793|FG016|Part 2 (Up to 36.4 Weeks)|Study closed/terminated|3
6250029|NCT01943851|9937794|FG017|Part 2 (Up to 36.4 Weeks)|Study closed/terminated|1
6250030|NCT01943916|9937839|FG000|Overall Study|Technically invalid images|10
6250031|NCT01943916|9937839|FG000|Overall Study|Enrollment Failure|23
6250032|NCT01943916|9937839|FG000|Overall Study|Pilot Phase exclusion|100
6250033|NCT01943916|9937839|FG000|Overall Study|Quality Assurance Reader Fail|130
6250034|NCT01943916|9937839|FG000|Overall Study|Technical Failure|39
6250035|NCT01943916|9937839|FG000|Overall Study|Protocol Deviation No Biopsy|25
6250036|NCT01943916|9937839|FG000|Overall Study|No Truth Panel Review|38
6250037|NCT01943916|9937839|FG000|Overall Study|Protocol Deviation|1
6250038|NCT01944046|9937850|FG000|Randomized to DB|Adverse Event|5
6250039|NCT01944046|9937851|FG001|Randomized to DB|Adverse Event|2
6250040|NCT01944046|9937850|FG000|Randomized to DB|Clinical Worsening|3
6250041|NCT01944046|9937851|FG001|Randomized to DB|Clinical Worsening|2
6250042|NCT01944046|9937850|FG000|Randomized to DB|Lost to Follow-up|3
6250043|NCT01944046|9937851|FG001|Randomized to DB|Lost to Follow-up|3
6250044|NCT01944046|9937850|FG000|Randomized to DB|Withdrawal by Subject|2
6250045|NCT01944046|9937851|FG001|Randomized to DB|Withdrawal by Subject|4
6250046|NCT01944046|9937850|FG000|Randomized to DB|Physician Decision|1
6250047|NCT01944046|9937851|FG001|Randomized to DB|Physician Decision|2
6250048|NCT01944046|9937850|FG000|Randomized to DB|Did not have baseline ABC-SW|2
6250049|NCT01944046|9937851|FG001|Randomized to DB|Did not have baseline ABC-SW|0
6250050|NCT01944046|9937850|FG000|Randomized to DB|Did not have a postbaseline ABC SW|5
6250051|NCT01944046|9937851|FG001|Randomized to DB|Did not have a postbaseline ABC SW|6
6250052|NCT01944046|9937850|FG000|Open Label Eligible and Consented|Lost to Follow-up|3
6250053|NCT01944046|9937851|FG001|Open Label Eligible and Consented|Lost to Follow-up|5
6250054|NCT01944046|9937850|FG000|Open Label Eligible and Consented|Adverse Event|6
6250055|NCT01944046|9937851|FG001|Open Label Eligible and Consented|Adverse Event|1
6250056|NCT01944046|9937850|FG000|Open Label Eligible and Consented|Clinical Worsening|4
6250057|NCT01944046|9937851|FG001|Open Label Eligible and Consented|Clinical Worsening|2
6250058|NCT01944046|9937850|FG000|Open Label Eligible and Consented|Withdrawal by Subject|1
6250059|NCT01944046|9937851|FG001|Open Label Eligible and Consented|Withdrawal by Subject|0
6250060|NCT01944098|9937863|FG000|Overall Study|Physician Decision|1
6250061|NCT01944098|9937864|FG001|Overall Study|Physician Decision|0
6250062|NCT01944462|9937915|FG000|PPPP Educational Program|Lost to Follow-up|60
6250063|NCT01944631|9937922|FG000|Overall Study|Adverse Event|1
6250064|NCT01944631|9937923|FG001|Overall Study|Adverse Event|0
6250065|NCT01944631|9937922|FG000|Overall Study|Lost to Follow-up|3
6250066|NCT01944631|9937923|FG001|Overall Study|Lost to Follow-up|1
6250067|NCT01944631|9937922|FG000|Overall Study|Withdrawal by Subject|0
6250068|NCT01944631|9937923|FG001|Overall Study|Withdrawal by Subject|1
6250069|NCT01944670|9937938|FG000|Overall Study|Lost to Follow-up|2
6250070|NCT01944722|9937944|FG000|Overall Study|Didn't meet Inclusion/Exclusion Criteria|171
6250071|NCT01944722|9937944|FG000|Overall Study|Specimen Shipping Issues|34
6250072|NCT01944722|9937944|FG000|Overall Study|Improper Storage/Transport|5
6250073|NCT01944722|9937944|FG000|Overall Study|Insufficient Volume for Test|1
6250074|NCT01944722|9937944|FG000|Overall Study|Missing Specimens|3
6250075|NCT01944722|9937944|FG000|Overall Study|Specimens Mislabeled|2
6250076|NCT01944722|9937944|FG000|Overall Study|Withdrawal by Subject|8
6250077|NCT01944722|9937944|FG000|Overall Study|NILM Subjects <30 years old|8106
6250078|NCT01944722|9937944|FG000|Overall Study|Unsatisfactory Cytology Result|63
6250079|NCT01944722|9937944|FG000|Overall Study|>ASCUS Cytology|1122
6250080|NCT01944774|9937956|FG000|Overall Study|Withdrawal by Subject|2
6250081|NCT01944774|9937957|FG001|Overall Study|Withdrawal by Subject|3
6250082|NCT01944774|9937958|FG002|Overall Study|Withdrawal by Subject|3
6250083|NCT01944774|9937956|FG000|Overall Study|Adverse Event|3
6250084|NCT01944774|9937957|FG001|Overall Study|Adverse Event|2
6250085|NCT01944774|9937958|FG002|Overall Study|Adverse Event|3
6250086|NCT01944774|9937956|FG000|Overall Study|Lack of Efficacy|1
6250087|NCT01944774|9937957|FG001|Overall Study|Lack of Efficacy|2
6250088|NCT01944774|9937958|FG002|Overall Study|Lack of Efficacy|2
6250089|NCT01944774|9937956|FG000|Overall Study|Lost to Follow-up|0
6250090|NCT01944774|9937957|FG001|Overall Study|Lost to Follow-up|1
6250091|NCT01944774|9937958|FG002|Overall Study|Lost to Follow-up|0
6250092|NCT01944839|9937971|FG000|Overall Study|Physician Decision|2
6250093|NCT01944839|9937972|FG001|Overall Study|Physician Decision|2
6250094|NCT01944839|9937971|FG000|Overall Study|Protocol Violation|0
6250095|NCT01944839|9937972|FG001|Overall Study|Protocol Violation|1
6250096|NCT01944839|9937971|FG000|Overall Study|Adverse Event|10
6250097|NCT01944839|9937972|FG001|Overall Study|Adverse Event|5
6250098|NCT01944839|9937971|FG000|Overall Study|Withdrawal by Subject|9
6250099|NCT01944839|9937972|FG001|Overall Study|Withdrawal by Subject|17
6250100|NCT01944839|9937971|FG000|Overall Study|Lost to Follow-up|1
6250101|NCT01944839|9937972|FG001|Overall Study|Lost to Follow-up|0
6250102|NCT01944839|9937971|FG000|Overall Study|Subject non-compliance|0
6250103|NCT01944839|9937972|FG001|Overall Study|Subject non-compliance|3
6250104|NCT01944969|9937998|FG000|Overall Study|Adverse Event|1
6250105|NCT01944969|9937998|FG000|Overall Study|Lack of Efficacy|1
6250106|NCT01944969|9937998|FG000|Overall Study|Non-compliance with IMP|1
6250107|NCT01944969|9937998|FG000|Overall Study|Administrative or other reasons|23
6250108|NCT01945034|9938007|FG000|Overall Study|Medication Error|0
6250109|NCT01945034|9938008|FG001|Overall Study|Medication Error|1
6250110|NCT01945034|9938009|FG002|Overall Study|Medication Error|0
6250111|NCT01945034|9938007|FG000|Overall Study|Withdrawal by Subject|0
6250112|NCT01945034|9938008|FG001|Overall Study|Withdrawal by Subject|3
6250113|NCT01945034|9938009|FG002|Overall Study|Withdrawal by Subject|1
6250114|NCT01945034|9938007|FG000|Overall Study|Other|0
6250115|NCT01945034|9938008|FG001|Overall Study|Other|1
6250116|NCT01945034|9938009|FG002|Overall Study|Other|3
6250117|NCT01945034|9938007|FG000|Overall Study|Lost to Follow-up|0
6250118|NCT01945034|9938008|FG001|Overall Study|Lost to Follow-up|0
6250119|NCT01945034|9938009|FG002|Overall Study|Lost to Follow-up|2
6250120|NCT01945034|9938007|FG000|Overall Study|Protocol Violation|1
6250121|NCT01945034|9938008|FG001|Overall Study|Protocol Violation|0
6250122|NCT01945034|9938009|FG002|Overall Study|Protocol Violation|1
6250123|NCT01945086|9938020|FG000|Overall Study|Withdrawal by Subject|1
6250124|NCT01945086|9938021|FG001|Overall Study|Withdrawal by Subject|0
6250125|NCT01945086|9938022|FG002|Overall Study|Withdrawal by Subject|1
6250126|NCT01945086|9938020|FG000|Overall Study|Adverse Event|0
6250127|NCT01945086|9938021|FG001|Overall Study|Adverse Event|0
6250128|NCT01945086|9938022|FG002|Overall Study|Adverse Event|1
6270750|NCT02156076|9972055|FG003|Treatment Period|Adverse Event|1
6270751|NCT02156076|9972052|FG000|Follow-up Period|Withdrawal by Subject|1
6270752|NCT02156076|9972053|FG001|Follow-up Period|Withdrawal by Subject|0
6270753|NCT02156076|9972054|FG002|Follow-up Period|Withdrawal by Subject|0
6270754|NCT02156076|9972055|FG003|Follow-up Period|Withdrawal by Subject|0
6270755|NCT02156271|9972093|FG000|Overall Study|Physician Decision|4
6270756|NCT02156271|9972094|FG001|Overall Study|Physician Decision|3
6270757|NCT02156466|9972105|FG000|Overall Study|Adverse Event|0
6270758|NCT02156466|9972106|FG001|Overall Study|Adverse Event|0
6270759|NCT02156466|9972107|FG002|Overall Study|Adverse Event|1
6270760|NCT02156466|9972108|FG003|Overall Study|Adverse Event|1
6270761|NCT02156466|9972109|FG004|Overall Study|Adverse Event|0
6270762|NCT02156466|9972105|FG000|Overall Study|Quantiferon Positivity|0
6270763|NCT02156466|9972106|FG001|Overall Study|Quantiferon Positivity|0
6270764|NCT02156466|9972107|FG002|Overall Study|Quantiferon Positivity|0
6270765|NCT02156466|9972108|FG003|Overall Study|Quantiferon Positivity|1
6270766|NCT02156466|9972109|FG004|Overall Study|Quantiferon Positivity|0
6270767|NCT02156492|9972133|FG000|Period 1|No Reason Given|0
6270768|NCT02156492|9972134|FG001|Period 1|No Reason Given|1
6270769|NCT02156492|9972135|FG002|Period 1|No Reason Given|0
6270770|NCT02156492|9972133|FG000|Period 3|Adverse Event|0
6270771|NCT02156492|9972134|FG001|Period 3|Adverse Event|1
6270772|NCT02156492|9972135|FG002|Period 3|Adverse Event|0
6270773|NCT02156804|9972166|FG000|Overall Study|Withdrawal by Subject|1
6270774|NCT02157298|9972202|FG000|Overall Study|Adverse Event|1
6270775|NCT02157298|9972203|FG001|Overall Study|Adverse Event|0
6270776|NCT02157298|9972202|FG000|Overall Study|Subject no longer meets study criteria|1
6270777|NCT02157298|9972203|FG001|Overall Study|Subject no longer meets study criteria|2
6270778|NCT02157298|9972202|FG000|Overall Study|Poor/Non-compliance|1
6270779|NCT02157298|9972203|FG001|Overall Study|Poor/Non-compliance|0
6270780|NCT02157298|9972202|FG000|Overall Study|Withdrawal by Subject|1
6270781|NCT02157298|9972203|FG001|Overall Study|Withdrawal by Subject|0
6270782|NCT02157376|9972211|FG000|Overall Study|Death|10
6270783|NCT02157376|9972212|FG001|Overall Study|Death|4
6270784|NCT02157376|9972211|FG000|Overall Study|Eligibility criteria not fulfilled|0
6270785|NCT02157376|9972212|FG001|Overall Study|Eligibility criteria not fulfilled|1
6270786|NCT02157376|9972211|FG000|Overall Study|Withdrawal by Subject|3
6270787|NCT02157376|9972212|FG001|Overall Study|Withdrawal by Subject|8
6270788|NCT02157376|9972211|FG000|Overall Study|Not treated|8
6270789|NCT02157376|9972212|FG001|Overall Study|Not treated|3
6270790|NCT02157376|9972211|FG000|Overall Study|Investigator's misjudgement|1
6270791|NCT02157376|9972212|FG001|Overall Study|Investigator's misjudgement|2
6270792|NCT02157506|9972223|FG000|Overall Study|Adverse Event|0
6270793|NCT02157506|9972224|FG001|Overall Study|Adverse Event|1
6270794|NCT02157506|9972225|FG002|Overall Study|Adverse Event|0
6270795|NCT02157506|9972226|FG003|Overall Study|Adverse Event|0
6270796|NCT02157506|9972227|FG004|Overall Study|Adverse Event|0
6270797|NCT02157506|9972223|FG000|Overall Study|Lost to Follow-up|0
6270798|NCT02157506|9972224|FG001|Overall Study|Lost to Follow-up|0
6270799|NCT02157506|9972225|FG002|Overall Study|Lost to Follow-up|1
6270800|NCT02157506|9972226|FG003|Overall Study|Lost to Follow-up|0
6270801|NCT02157506|9972227|FG004|Overall Study|Lost to Follow-up|0
6270802|NCT02157519|9972241|FG000|Overall Study|Death|3
6270803|NCT02157519|9972242|FG001|Overall Study|Death|1
6270804|NCT02157519|9972241|FG000|Overall Study|Withdrawal by Subject|7
6270805|NCT02157519|9972242|FG001|Overall Study|Withdrawal by Subject|0
6270806|NCT02157519|9972241|FG000|Overall Study|Lost to Follow-up|1
6250129|NCT01945216|9938048|FG000|Overall Study|Case report forms (CRF) uncollected|52
6250130|NCT01945216|9938048|FG000|Overall Study|Protocol Violation|42
6250131|NCT01945216|9938048|FG000|Overall Study|CRF not assured by investigators|5
6250132|NCT01945242|9938058|FG000|Overall Study|Physician Decision|3
6250133|NCT01945242|9938059|FG001|Overall Study|Physician Decision|3
6250134|NCT01945281|9938068|FG000|Overall Study|Adverse Event|1
6250135|NCT01945281|9938069|FG001|Overall Study|Adverse Event|0
6250136|NCT01945281|9938068|FG000|Overall Study|Death|3
6250137|NCT01945281|9938069|FG001|Overall Study|Death|3
6250138|NCT01945281|9938068|FG000|Overall Study|Physician Decision|1
6250139|NCT01945281|9938069|FG001|Overall Study|Physician Decision|1
6250140|NCT01945281|9938068|FG000|Overall Study|Technical Problems|1
6250141|NCT01945281|9938069|FG001|Overall Study|Technical Problems|0
6250142|NCT01945489|9938092|FG000|Cycle 1|Adverse Event|2
6250143|NCT01945489|9938093|FG001|Cycle 1|Adverse Event|0
6250144|NCT01945489|9938092|FG000|Cycle 1|Lost to Follow-up|4
6250145|NCT01945489|9938093|FG001|Cycle 1|Lost to Follow-up|0
6250146|NCT01945489|9938092|FG000|Cycle 1|Personal Reasons|4
6250147|NCT01945489|9938093|FG001|Cycle 1|Personal Reasons|2
6250148|NCT01945489|9938092|FG000|Cycle 1|Protocol Violation|0
6250149|NCT01945489|9938093|FG001|Cycle 1|Protocol Violation|1
6250150|NCT01945489|9938092|FG000|Cycle 1|Other Miscellaneous Reasons|3
6250151|NCT01945489|9938093|FG001|Cycle 1|Other Miscellaneous Reasons|1
6250152|NCT01945489|9938092|FG000|Cycle 2|Adverse Event|1
6250153|NCT01945489|9938093|FG001|Cycle 2|Adverse Event|0
6250154|NCT01945489|9938092|FG000|Cycle 2|Lost to Follow-up|0
6250155|NCT01945489|9938093|FG001|Cycle 2|Lost to Follow-up|1
6250156|NCT01945580|9938102|FG000|Overall Study|Withdrawal by Subject|13
6250157|NCT01945580|9938103|FG001|Overall Study|Withdrawal by Subject|35
6250158|NCT01945580|9938102|FG000|Overall Study|Physician Decision|3
6250159|NCT01945580|9938103|FG001|Overall Study|Physician Decision|2
6250160|NCT01945580|9938102|FG000|Overall Study|Lost to Follow-up|26
6250161|NCT01945580|9938103|FG001|Overall Study|Lost to Follow-up|39
6250162|NCT01945580|9938102|FG000|Overall Study|Death|7
6250163|NCT01945580|9938103|FG001|Overall Study|Death|2
6250164|NCT01945580|9938102|FG000|Overall Study|Patient moved out of state|0
6250165|NCT01945580|9938103|FG001|Overall Study|Patient moved out of state|1
6250166|NCT01945580|9938102|FG000|Overall Study|Moved out of state and firmly desired to withdraw. AE still not recovered and not resolved.|1
6250167|NCT01945580|9938103|FG001|Overall Study|Moved out of state and firmly desired to withdraw. AE still not recovered and not resolved.|0
6250168|NCT01945580|9938102|FG000|Overall Study|Family illness - unable to return|0
6250169|NCT01945580|9938103|FG001|Overall Study|Family illness - unable to return|1
6086253|NCT00659815|9696112|FG000|Overall Study|Study related symptoms and complaints|2
6250170|NCT01945580|9938102|FG000|Overall Study|Weather emergency at time visit due; per sponsor completed study due to being too far out of window|0
6250171|NCT01945580|9938103|FG001|Overall Study|Weather emergency at time visit due; per sponsor completed study due to being too far out of window|1
6250172|NCT01945580|9938102|FG000|Overall Study|Death in family, then rescheduled but considered too far out of window to bring back|0
6250173|NCT01945580|9938103|FG001|Overall Study|Death in family, then rescheduled but considered too far out of window to bring back|1
6250174|NCT01945580|9938102|FG000|Overall Study|Noncompliance with 36 month visit|1
6250175|NCT01945580|9938103|FG001|Overall Study|Noncompliance with 36 month visit|0
6250176|NCT01945580|9938102|FG000|Overall Study|The patient moved.|1
6250177|NCT01945580|9938103|FG001|Overall Study|The patient moved.|0
6250178|NCT01945580|9938102|FG000|Overall Study|No data available|0
6250179|NCT01945580|9938103|FG001|Overall Study|No data available|2
6250180|NCT01945593|9938117|FG000|Overall Study|Adverse Event|0
6250181|NCT01945593|9938118|FG001|Overall Study|Adverse Event|0
6250182|NCT01945593|9938119|FG002|Overall Study|Adverse Event|0
6250183|NCT01945593|9938120|FG003|Overall Study|Adverse Event|5
6250184|NCT01945593|9938117|FG000|Overall Study|Physician Decision|0
6250185|NCT01945593|9938118|FG001|Overall Study|Physician Decision|0
6250186|NCT01945593|9938119|FG002|Overall Study|Physician Decision|1
6250187|NCT01945593|9938120|FG003|Overall Study|Physician Decision|1
6250188|NCT01945593|9938117|FG000|Overall Study|Withdrawal by Subject|0
6250189|NCT01945593|9938118|FG001|Overall Study|Withdrawal by Subject|2
6250190|NCT01945593|9938119|FG002|Overall Study|Withdrawal by Subject|0
6250191|NCT01945593|9938120|FG003|Overall Study|Withdrawal by Subject|4
6250192|NCT01945593|9938117|FG000|Overall Study|Protocol Violation|0
6250193|NCT01945593|9938118|FG001|Overall Study|Protocol Violation|2
6250194|NCT01945593|9938119|FG002|Overall Study|Protocol Violation|1
6250195|NCT01945593|9938120|FG003|Overall Study|Protocol Violation|3
6250196|NCT01945593|9938117|FG000|Overall Study|Death|0
6250197|NCT01945593|9938118|FG001|Overall Study|Death|0
6250198|NCT01945593|9938119|FG002|Overall Study|Death|1
6250199|NCT01945593|9938120|FG003|Overall Study|Death|0
6250200|NCT01945593|9938117|FG000|Overall Study|Other: Terminated|0
6250201|NCT01945593|9938118|FG001|Overall Study|Other: Terminated|0
6250202|NCT01945593|9938119|FG002|Overall Study|Other: Terminated|0
6250203|NCT01945593|9938120|FG003|Overall Study|Other: Terminated|1
6250204|NCT01945593|9938117|FG000|Overall Study|Other: Surgical Procedure|0
6250205|NCT01945593|9938118|FG001|Overall Study|Other: Surgical Procedure|2
6250206|NCT01945593|9938119|FG002|Overall Study|Other: Surgical Procedure|0
6250207|NCT01945593|9938120|FG003|Overall Study|Other: Surgical Procedure|6
6250208|NCT01945593|9938117|FG000|Overall Study|Other: Screen Failure|0
6250209|NCT01945593|9938118|FG001|Overall Study|Other: Screen Failure|2
6250210|NCT01945593|9938119|FG002|Overall Study|Other: Screen Failure|0
6250211|NCT01945593|9938120|FG003|Overall Study|Other: Screen Failure|0
6250212|NCT01945710|9938142|FG000|Overall Study|Progressive Disease|5
6250213|NCT01945710|9938143|FG001|Overall Study|Progressive Disease|4
6250214|NCT01945710|9938144|FG002|Overall Study|Progressive Disease|3
6250215|NCT01945710|9938145|FG003|Overall Study|Progressive Disease|2
6250216|NCT01945710|9938146|FG004|Overall Study|Progressive Disease|7
6250217|NCT01945710|9938147|FG005|Overall Study|Progressive Disease|3
6250218|NCT01945710|9938148|FG006|Overall Study|Progressive Disease|19
6250219|NCT01945710|9938142|FG000|Overall Study|Adverse Event|0
6250220|NCT01945710|9938143|FG001|Overall Study|Adverse Event|1
6250221|NCT01945710|9938144|FG002|Overall Study|Adverse Event|0
6250222|NCT01945710|9938145|FG003|Overall Study|Adverse Event|0
6250223|NCT01945710|9938146|FG004|Overall Study|Adverse Event|0
6250224|NCT01945710|9938147|FG005|Overall Study|Adverse Event|0
6250225|NCT01945710|9938148|FG006|Overall Study|Adverse Event|0
6250226|NCT01945710|9938142|FG000|Overall Study|Other|2
6250227|NCT01945710|9938143|FG001|Overall Study|Other|0
6250228|NCT01945710|9938144|FG002|Overall Study|Other|3
6250229|NCT01945710|9938145|FG003|Overall Study|Other|1
6250230|NCT01945710|9938146|FG004|Overall Study|Other|1
6250231|NCT01945710|9938147|FG005|Overall Study|Other|0
6250232|NCT01945710|9938148|FG006|Overall Study|Other|4
6250233|NCT01945710|9938142|FG000|Overall Study|Withdrawal by Subject|0
6250234|NCT01945710|9938143|FG001|Overall Study|Withdrawal by Subject|1
6250235|NCT01945710|9938144|FG002|Overall Study|Withdrawal by Subject|1
6250236|NCT01945710|9938145|FG003|Overall Study|Withdrawal by Subject|0
6250237|NCT01945710|9938146|FG004|Overall Study|Withdrawal by Subject|1
6250238|NCT01945710|9938147|FG005|Overall Study|Withdrawal by Subject|0
6250239|NCT01945710|9938148|FG006|Overall Study|Withdrawal by Subject|0
6250240|NCT01945866|9938168|FG000|Overall Study|Eyes did not complete or were dropped|2
6250241|NCT01945866|9938169|FG001|Overall Study|Eyes did not complete or were dropped|0
6250242|NCT01945944|9938178|FG000|Overall Study|Adverse Event|0
6250243|NCT01945944|9938179|FG001|Overall Study|Adverse Event|2
6250244|NCT01945944|9938178|FG000|Overall Study|Physician Decision|1
6250245|NCT01945944|9938179|FG001|Overall Study|Physician Decision|0
6250246|NCT01945944|9938178|FG000|Overall Study|Withdrawal by Subject|0
6250247|NCT01945944|9938179|FG001|Overall Study|Withdrawal by Subject|1
6250248|NCT01945996|9938204|FG000|Overall Study|Lost to Follow-up|3
6250249|NCT01945996|9938205|FG001|Overall Study|Lost to Follow-up|5
6250250|NCT01946152|9938226|FG000|Overall Study|Adverse Event|1
6250251|NCT01946152|9938227|FG001|Overall Study|Adverse Event|0
6250252|NCT01946152|9938228|FG002|Overall Study|Adverse Event|0
6250253|NCT01946152|9938229|FG003|Overall Study|Adverse Event|0
6250254|NCT01946152|9938226|FG000|Overall Study|Withdrawal by Subject|0
6250255|NCT01946152|9938227|FG001|Overall Study|Withdrawal by Subject|2
6250256|NCT01946152|9938228|FG002|Overall Study|Withdrawal by Subject|0
6250257|NCT01946152|9938229|FG003|Overall Study|Withdrawal by Subject|0
6250258|NCT01946152|9938226|FG000|Overall Study|Progression|0
6250259|NCT01946152|9938227|FG001|Overall Study|Progression|1
6250260|NCT01946152|9938228|FG002|Overall Study|Progression|4
6250261|NCT01946152|9938229|FG003|Overall Study|Progression|7
6250262|NCT01946152|9938226|FG000|Overall Study|Physician Decision|0
6250263|NCT01946152|9938227|FG001|Overall Study|Physician Decision|0
6250264|NCT01946152|9938228|FG002|Overall Study|Physician Decision|1
6250265|NCT01946152|9938229|FG003|Overall Study|Physician Decision|0
6250266|NCT01946152|9938226|FG000|Overall Study|Second malignancy|0
6250267|NCT01946152|9938227|FG001|Overall Study|Second malignancy|0
6250268|NCT01946152|9938228|FG002|Overall Study|Second malignancy|1
6250269|NCT01946152|9938229|FG003|Overall Study|Second malignancy|0
6250270|NCT01946152|9938226|FG000|Overall Study|Adverse Event|0
6250271|NCT01946152|9938227|FG001|Overall Study|Adverse Event|0
6250272|NCT01946152|9938228|FG002|Overall Study|Adverse Event|0
6250273|NCT01946152|9938229|FG003|Overall Study|Adverse Event|1
6250274|NCT01946165|9938243|FG000|Overall Study|Physician Decision|2
6250275|NCT01946165|9938244|FG001|Overall Study|Physician Decision|0
6250276|NCT01946165|9938243|FG000|Overall Study|Withdrawal by Subject|0
6250277|NCT01946165|9938244|FG001|Overall Study|Withdrawal by Subject|2
6250278|NCT01946178|9938251|FG000|Overall Study|Pregnancy|1
6250279|NCT01946178|9938251|FG000|Overall Study|Lost to Follow-up|1
6250280|NCT01946191|9938261|FG000|Allocation|Did not complete orientation|1
6250281|NCT01946191|9938262|FG001|Allocation|Did not complete orientation|1
6250282|NCT01946191|9938261|FG000|Follow-Up, 24-mo Endpoint|Withdrawal by Subject|4
6250283|NCT01946191|9938262|FG001|Follow-Up, 24-mo Endpoint|Withdrawal by Subject|2
6250284|NCT01946191|9938261|FG000|Follow-Up, 24-mo Endpoint|Protocol Violation|0
6250285|NCT01946191|9938262|FG001|Follow-Up, 24-mo Endpoint|Protocol Violation|1
6250286|NCT01946191|9938261|FG000|Follow-Up, 24-mo Endpoint|Lost to Follow-up|13
6250287|NCT01946191|9938262|FG001|Follow-Up, 24-mo Endpoint|Lost to Follow-up|15
6250288|NCT01946282|9938278|FG000|Year 1|Did not return FIT kit|4186
6250289|NCT01946282|9938279|FG001|Year 1|Did not return FIT kit|608
6250290|NCT01946282|9938280|FG002|Year 1|Did not return FIT kit|654
6250291|NCT01946282|9938278|FG000|Year 2|Did not return FIT kit|803
6250292|NCT01946282|9938279|FG001|Year 2|Did not return FIT kit|131
6250293|NCT01946282|9938280|FG002|Year 2|Did not return FIT kit|115
6250294|NCT01946282|9938278|FG000|Year 3|Did not return FIT kit|288
6250295|NCT01946282|9938279|FG001|Year 3|Did not return FIT kit|43
6250296|NCT01946282|9938280|FG002|Year 3|Did not return FIT kit|30
6250297|NCT01946412|9938290|FG000|Overall Study|Adverse Event|1
6250298|NCT01946412|9938290|FG000|Overall Study|Non-Compliance|1
6250299|NCT01946412|9938290|FG000|Overall Study|Continued with commercial Kalydeco|2
6250300|NCT01946412|9938290|FG000|Overall Study|Difficulty in swallowing|1
6250301|NCT01946425|9938298|FG000|Overall Study|Protocol Violation|1
6250302|NCT01946425|9938299|FG001|Overall Study|Protocol Violation|0
6250303|NCT01946425|9938298|FG000|Overall Study|Withdrawal by Subject|1
6250304|NCT01946425|9938299|FG001|Overall Study|Withdrawal by Subject|0
6250305|NCT01946438|9938310|FG000|Overall Study|Adverse Event|0
6250306|NCT01946438|9938311|FG001|Overall Study|Adverse Event|0
6250307|NCT01946438|9938312|FG002|Overall Study|Adverse Event|0
6250308|NCT01946438|9938313|FG003|Overall Study|Adverse Event|1
6250309|NCT01946438|9938310|FG000|Overall Study|Serious Adverse event|1
6250310|NCT01946438|9938311|FG001|Overall Study|Serious Adverse event|0
6250311|NCT01946438|9938312|FG002|Overall Study|Serious Adverse event|0
6250312|NCT01946438|9938313|FG003|Overall Study|Serious Adverse event|0
6250313|NCT01946438|9938310|FG000|Overall Study|Protocol Violation|0
6250314|NCT01946438|9938311|FG001|Overall Study|Protocol Violation|0
6250315|NCT01946438|9938312|FG002|Overall Study|Protocol Violation|1
6250316|NCT01946438|9938313|FG003|Overall Study|Protocol Violation|0
6250317|NCT01946438|9938310|FG000|Overall Study|Withdrawal by Subject|1
6250318|NCT01946438|9938311|FG001|Overall Study|Withdrawal by Subject|0
6250319|NCT01946438|9938312|FG002|Overall Study|Withdrawal by Subject|0
6250320|NCT01946438|9938313|FG003|Overall Study|Withdrawal by Subject|0
6250321|NCT01946529|9938332|FG000|End of Window Therapy (2 Courses)|Physician Decision|0
6250322|NCT01946529|9938333|FG001|End of Window Therapy (2 Courses)|Physician Decision|1
6250323|NCT01946529|9938334|FG002|End of Window Therapy (2 Courses)|Physician Decision|0
6250324|NCT01946529|9938332|FG000|Completion of All Therapy|Some pts. still receiving study therapy|1
6250325|NCT01946529|9938333|FG001|Completion of All Therapy|Some pts. still receiving study therapy|16
6250326|NCT01946529|9938334|FG002|Completion of All Therapy|Some pts. still receiving study therapy|6
6250327|NCT01946802|9938341|FG000|Overall Study|Death|1
6250328|NCT01946802|9938341|FG000|Overall Study|Withdrawal by Subject|2
6250329|NCT01946802|9938341|FG000|Overall Study|Combined septic shock|1
6250330|NCT01946802|9938341|FG000|Overall Study|Protocol Violation|1
6250331|NCT01946880|9938347|FG000|Overall Study|Lost to Follow-up|1
6250332|NCT01946880|9938348|FG001|Overall Study|Lost to Follow-up|0
6250333|NCT01946880|9938347|FG000|Overall Study|Physician Decision|1
6250334|NCT01946880|9938348|FG001|Overall Study|Physician Decision|1
6250335|NCT01946880|9938347|FG000|Overall Study|Withdrawal by Subject|3
6250336|NCT01946880|9938348|FG001|Overall Study|Withdrawal by Subject|2
6250337|NCT01946880|9938347|FG000|Overall Study|Met Primary Endpoint|1
6250338|NCT01946880|9938348|FG001|Overall Study|Met Primary Endpoint|0
6250339|NCT01946880|9938347|FG000|Overall Study|Personal and Family Issues|1
6250340|NCT01946880|9938348|FG001|Overall Study|Personal and Family Issues|0
6250341|NCT01947127|9938356|FG000|Overall Study|Protocol Violation|18
6250342|NCT01947127|9938357|FG001|Overall Study|Protocol Violation|38
6250343|NCT01947127|9938356|FG000|Overall Study|Withdrawal by Subject|1
6250344|NCT01947127|9938357|FG001|Overall Study|Withdrawal by Subject|1
6250345|NCT01947127|9938356|FG000|Overall Study|Data loss|4
6250346|NCT01947127|9938357|FG001|Overall Study|Data loss|4
6250347|NCT01947283|9938377|FG000|Overall Study|Death|1
6250348|NCT01947283|9938378|FG001|Overall Study|Death|1
6250349|NCT01947283|9938379|FG002|Overall Study|Death|1
6250350|NCT01947283|9938380|FG003|Overall Study|Death|0
6250351|NCT01947283|9938381|FG004|Overall Study|Death|0
6250352|NCT01947283|9938382|FG005|Overall Study|Death|0
6250353|NCT01947283|9938383|FG006|Overall Study|Death|0
6250354|NCT01947283|9938377|FG000|Overall Study|Lost to Follow-up|4
6250355|NCT01947283|9938378|FG001|Overall Study|Lost to Follow-up|6
6250356|NCT01947283|9938379|FG002|Overall Study|Lost to Follow-up|5
6250357|NCT01947283|9938380|FG003|Overall Study|Lost to Follow-up|5
6250358|NCT01947283|9938381|FG004|Overall Study|Lost to Follow-up|0
6250359|NCT01947283|9938382|FG005|Overall Study|Lost to Follow-up|2
6250360|NCT01947283|9938383|FG006|Overall Study|Lost to Follow-up|5
6250361|NCT01947283|9938377|FG000|Overall Study|Withdrawal by Subject|10
6250362|NCT01947283|9938378|FG001|Overall Study|Withdrawal by Subject|8
6250363|NCT01947283|9938379|FG002|Overall Study|Withdrawal by Subject|4
6250364|NCT01947283|9938380|FG003|Overall Study|Withdrawal by Subject|1
6250365|NCT01947283|9938381|FG004|Overall Study|Withdrawal by Subject|0
6250366|NCT01947283|9938382|FG005|Overall Study|Withdrawal by Subject|0
6250367|NCT01947283|9938383|FG006|Overall Study|Withdrawal by Subject|2
6250368|NCT01947283|9938377|FG000|Overall Study|No Clinical Recording|12
6250369|NCT01947283|9938378|FG001|Overall Study|No Clinical Recording|6
6250370|NCT01947283|9938379|FG002|Overall Study|No Clinical Recording|8
6250371|NCT01947283|9938380|FG003|Overall Study|No Clinical Recording|10
6250372|NCT01947283|9938381|FG004|Overall Study|No Clinical Recording|0
6250373|NCT01947283|9938382|FG005|Overall Study|No Clinical Recording|0
6250374|NCT01947283|9938383|FG006|Overall Study|No Clinical Recording|0
6250375|NCT01947283|9938377|FG000|Overall Study|Non-coding Clinical Recording language|0
6250376|NCT01947283|9938378|FG001|Overall Study|Non-coding Clinical Recording language|0
6250377|NCT01947283|9938379|FG002|Overall Study|Non-coding Clinical Recording language|0
6270807|NCT02157519|9972242|FG001|Overall Study|Lost to Follow-up|0
6250378|NCT01947283|9938380|FG003|Overall Study|Non-coding Clinical Recording language|1
6250379|NCT01947283|9938381|FG004|Overall Study|Non-coding Clinical Recording language|0
6250380|NCT01947283|9938382|FG005|Overall Study|Non-coding Clinical Recording language|0
6250381|NCT01947283|9938383|FG006|Overall Study|Non-coding Clinical Recording language|0
6250382|NCT01947283|9938377|FG000|Overall Study|Missing Follow-up Assessment|2
6250383|NCT01947283|9938378|FG001|Overall Study|Missing Follow-up Assessment|2
6250384|NCT01947283|9938379|FG002|Overall Study|Missing Follow-up Assessment|3
6250385|NCT01947283|9938380|FG003|Overall Study|Missing Follow-up Assessment|0
6250386|NCT01947283|9938381|FG004|Overall Study|Missing Follow-up Assessment|0
6250387|NCT01947283|9938382|FG005|Overall Study|Missing Follow-up Assessment|2
6250388|NCT01947283|9938383|FG006|Overall Study|Missing Follow-up Assessment|0
6250389|NCT01947283|9938377|FG000|Overall Study|No patients were enrolled in study|0
6250390|NCT01947283|9938378|FG001|Overall Study|No patients were enrolled in study|0
6250391|NCT01947283|9938379|FG002|Overall Study|No patients were enrolled in study|0
6250392|NCT01947283|9938380|FG003|Overall Study|No patients were enrolled in study|0
6250393|NCT01947283|9938381|FG004|Overall Study|No patients were enrolled in study|0
6250394|NCT01947283|9938382|FG005|Overall Study|No patients were enrolled in study|3
6250395|NCT01947283|9938383|FG006|Overall Study|No patients were enrolled in study|1
6250396|NCT01947491|9938413|FG000|Overall Study|Lost to Follow-up|5
6250397|NCT01947491|9938414|FG001|Overall Study|Lost to Follow-up|3
6250398|NCT01947491|9938415|FG002|Overall Study|Lost to Follow-up|1
6250399|NCT01947491|9938416|FG003|Overall Study|Lost to Follow-up|2
6250400|NCT01947491|9938413|FG000|Overall Study|Lack of Efficacy|1
6250401|NCT01947491|9938414|FG001|Overall Study|Lack of Efficacy|0
6250402|NCT01947491|9938415|FG002|Overall Study|Lack of Efficacy|0
6250403|NCT01947491|9938416|FG003|Overall Study|Lack of Efficacy|1
6250404|NCT01947491|9938413|FG000|Overall Study|Protocol Violation|1
6250405|NCT01947491|9938414|FG001|Overall Study|Protocol Violation|0
6250406|NCT01947491|9938415|FG002|Overall Study|Protocol Violation|0
6250407|NCT01947491|9938416|FG003|Overall Study|Protocol Violation|0
6250408|NCT01947491|9938413|FG000|Overall Study|Withdrawal by Subject|1
6250409|NCT01947491|9938414|FG001|Overall Study|Withdrawal by Subject|1
6250410|NCT01947491|9938415|FG002|Overall Study|Withdrawal by Subject|1
6250411|NCT01947491|9938416|FG003|Overall Study|Withdrawal by Subject|0
6250412|NCT01947491|9938413|FG000|Overall Study|Worsening of condition|0
6250413|NCT01947491|9938414|FG001|Overall Study|Worsening of condition|1
6250414|NCT01947491|9938415|FG002|Overall Study|Worsening of condition|0
6250415|NCT01947491|9938416|FG003|Overall Study|Worsening of condition|0
6250416|NCT01947491|9938413|FG000|Overall Study|Adverse Event|0
6250417|NCT01947491|9938414|FG001|Overall Study|Adverse Event|1
6250418|NCT01947491|9938415|FG002|Overall Study|Adverse Event|0
6250419|NCT01947491|9938416|FG003|Overall Study|Adverse Event|2
6250420|NCT01947517|9938428|FG000|Overall Study|Withdrawal by Subject|1
6250421|NCT01947517|9938429|FG001|Overall Study|Withdrawal by Subject|1
6250422|NCT01947582|9938435|FG000|Overall Study|Withdrawal by Subject|1
6250423|NCT01947855|9938455|FG000|Overall Study|Withdrawal by Subject|1
6250424|NCT01947855|9938456|FG001|Overall Study|Withdrawal by Subject|0
6250425|NCT01947855|9938457|FG002|Overall Study|Withdrawal by Subject|0
6250426|NCT01947894|9938468|FG000|Overall Study|Other|3
6250427|NCT01947894|9938469|FG001|Overall Study|Other|4
6250428|NCT01947894|9938470|FG002|Overall Study|Other|3
6250429|NCT01947894|9938468|FG000|Overall Study|Withdrawal by Subject|12
6250430|NCT01947894|9938469|FG001|Overall Study|Withdrawal by Subject|4
6250431|NCT01947894|9938470|FG002|Overall Study|Withdrawal by Subject|1
6250432|NCT01947894|9938468|FG000|Overall Study|Death|12
6250433|NCT01947894|9938469|FG001|Overall Study|Death|1
6250434|NCT01947894|9938470|FG002|Overall Study|Death|0
6250435|NCT01947894|9938468|FG000|Overall Study|Physician Decision|2
6250436|NCT01947894|9938469|FG001|Overall Study|Physician Decision|0
6250437|NCT01947894|9938470|FG002|Overall Study|Physician Decision|0
6250438|NCT01947894|9938468|FG000|Overall Study|Adverse Event|5
6250439|NCT01947894|9938469|FG001|Overall Study|Adverse Event|1
6250440|NCT01947894|9938470|FG002|Overall Study|Adverse Event|0
6250441|NCT01947894|9938468|FG000|Overall Study|Switched to other growth hormone brand|53
6250442|NCT01947894|9938469|FG001|Overall Study|Switched to other growth hormone brand|8
6250443|NCT01947894|9938470|FG002|Overall Study|Switched to other growth hormone brand|23
6250444|NCT01948050|9938510|FG000|Overall Study|Withdrawal by Subject|0
6250445|NCT01948050|9938511|FG001|Overall Study|Withdrawal by Subject|1
6250446|NCT01948063|9938519|FG000|Overall Study|Boston MCI halted research protocol|0
6250447|NCT01948063|9938520|FG001|Overall Study|Boston MCI halted research protocol|1
6250448|NCT01948063|9938519|FG000|Overall Study|Discovered an enrollment in other study|0
6250449|NCT01948063|9938520|FG001|Overall Study|Discovered an enrollment in other study|1
6250450|NCT01948063|9938519|FG000|Overall Study|Blood samples were accidentally thawed|1
6250451|NCT01948063|9938520|FG001|Overall Study|Blood samples were accidentally thawed|0
6250452|NCT01948076|9938528|FG000|Overall Study|Withdrawal by Subject|0
6250453|NCT01948076|9938529|FG001|Overall Study|Withdrawal by Subject|1
6250454|NCT01948193|9938541|FG000|Overall Study|Serious event|2
6250455|NCT01948193|9938541|FG000|Overall Study|Lost to Follow-up|7
6250456|NCT01948258|9938546|FG000|Overall Study|Pregnancy|41
6250457|NCT01948258|9938546|FG000|Overall Study|Did not complete by cut-off date|35
6250458|NCT01948258|9938546|FG000|Overall Study|Lost to Follow-up|27
6250459|NCT01948258|9938546|FG000|Overall Study|Withdrawal by SPD|8
6250460|NCT01948258|9938546|FG000|Overall Study|Withdrawal by Subject|6
6250461|NCT01948258|9938546|FG000|Overall Study|Health Care Professional|43
6250462|NCT01948258|9938546|FG000|Overall Study|Removed from statistical analysis|2
6250463|NCT01948427|9938586|FG000|Overall Study|Serious Adverse Event|3
6250464|NCT01948427|9938587|FG001|Overall Study|Serious Adverse Event|0
6250465|NCT01948427|9938588|FG002|Overall Study|Serious Adverse Event|0
6250466|NCT01948427|9938589|FG003|Overall Study|Serious Adverse Event|0
6250467|NCT01948427|9938590|FG004|Overall Study|Serious Adverse Event|1
6250468|NCT01948427|9938586|FG000|Overall Study|Investigator Request|0
6250469|NCT01948427|9938587|FG001|Overall Study|Investigator Request|8
6250470|NCT01948427|9938588|FG002|Overall Study|Investigator Request|0
6250471|NCT01948427|9938589|FG003|Overall Study|Investigator Request|0
6250472|NCT01948427|9938590|FG004|Overall Study|Investigator Request|6
6250473|NCT01948427|9938586|FG000|Overall Study|Lost to Follow-up|1
6250474|NCT01948427|9938587|FG001|Overall Study|Lost to Follow-up|0
6250475|NCT01948427|9938588|FG002|Overall Study|Lost to Follow-up|0
6250476|NCT01948427|9938589|FG003|Overall Study|Lost to Follow-up|0
6250477|NCT01948427|9938590|FG004|Overall Study|Lost to Follow-up|4
6250478|NCT01948427|9938586|FG000|Overall Study|Withdrawal by Subject|2
6250479|NCT01948427|9938587|FG001|Overall Study|Withdrawal by Subject|0
6250480|NCT01948427|9938588|FG002|Overall Study|Withdrawal by Subject|0
6250481|NCT01948427|9938589|FG003|Overall Study|Withdrawal by Subject|0
6250482|NCT01948427|9938590|FG004|Overall Study|Withdrawal by Subject|1
6250483|NCT01948427|9938586|FG000|Overall Study|Other, Not Specified|1
6250484|NCT01948427|9938587|FG001|Overall Study|Other, Not Specified|9
6250485|NCT01948427|9938588|FG002|Overall Study|Other, Not Specified|0
6250486|NCT01948427|9938589|FG003|Overall Study|Other, Not Specified|0
6250487|NCT01948427|9938590|FG004|Overall Study|Other, Not Specified|2
6250488|NCT01948791|9938615|FG000|Overall Study|Adverse Event|12
6250489|NCT01948791|9938615|FG000|Overall Study|Lack of Efficacy|3
6250490|NCT01948791|9938615|FG000|Overall Study|Protocol Violation|2
6250491|NCT01948791|9938615|FG000|Overall Study|Withdrawal by Subject|5
6250492|NCT01948791|9938615|FG000|Overall Study|Lost to Follow-up|6
6250493|NCT01948791|9938615|FG000|Overall Study|Management issues|1
6250494|NCT01948791|9938615|FG000|Overall Study|Others|7
6250495|NCT01948791|9938615|FG000|Overall Study|Screening failure|35
6250496|NCT01948830|9938621|FG000|Overall Study|Physician Decision|1
6250497|NCT01948830|9938622|FG001|Overall Study|Physician Decision|3
6250498|NCT01948830|9938621|FG000|Overall Study|Protocol deviation|1
6250499|NCT01948830|9938622|FG001|Overall Study|Protocol deviation|2
6250500|NCT01948830|9938621|FG000|Overall Study|Lost to Follow-up|5
6250501|NCT01948830|9938622|FG001|Overall Study|Lost to Follow-up|4
6250502|NCT01948830|9938621|FG000|Overall Study|Withdrawal by Subject|14
6250503|NCT01948830|9938622|FG001|Overall Study|Withdrawal by Subject|17
6250504|NCT01948830|9938621|FG000|Overall Study|Adverse Event|9
6250505|NCT01948830|9938622|FG001|Overall Study|Adverse Event|2
6250506|NCT01948830|9938621|FG000|Overall Study|Death|3
6250507|NCT01948830|9938622|FG001|Overall Study|Death|4
6250508|NCT01948908|9938631|FG000|Overall Study|Protocol Violation|1
6250509|NCT01948908|9938632|FG001|Overall Study|Protocol Violation|0
6250510|NCT01948908|9938633|FG002|Overall Study|Protocol Violation|2
6250511|NCT01949051|9938671|FG000|Treatment Period 1 (7 Days)|Protocol Violation|1
6250512|NCT01949051|9938672|FG001|Treatment Period 1 (7 Days)|Protocol Violation|0
6250513|NCT01949051|9938673|FG002|Treatment Period 1 (7 Days)|Protocol Violation|0
6250514|NCT01949051|9938674|FG003|Treatment Period 1 (7 Days)|Protocol Violation|1
6250515|NCT01949051|9938675|FG004|Treatment Period 1 (7 Days)|Protocol Violation|0
6250516|NCT01949051|9938676|FG005|Treatment Period 1 (7 Days)|Protocol Violation|0
6250517|NCT01949051|9938671|FG000|Treatment Period 1 (7 Days)|Lost to Follow-up|1
6250518|NCT01949051|9938672|FG001|Treatment Period 1 (7 Days)|Lost to Follow-up|0
6250519|NCT01949051|9938673|FG002|Treatment Period 1 (7 Days)|Lost to Follow-up|0
6250520|NCT01949051|9938674|FG003|Treatment Period 1 (7 Days)|Lost to Follow-up|0
6250521|NCT01949051|9938675|FG004|Treatment Period 1 (7 Days)|Lost to Follow-up|0
6250522|NCT01949051|9938676|FG005|Treatment Period 1 (7 Days)|Lost to Follow-up|0
6250523|NCT01949051|9938671|FG000|Treatment Period 2 (7 Days)|Protocol Violation|0
6250524|NCT01949051|9938672|FG001|Treatment Period 2 (7 Days)|Protocol Violation|0
6250525|NCT01949051|9938673|FG002|Treatment Period 2 (7 Days)|Protocol Violation|0
6250526|NCT01949051|9938674|FG003|Treatment Period 2 (7 Days)|Protocol Violation|0
6250527|NCT01949051|9938675|FG004|Treatment Period 2 (7 Days)|Protocol Violation|0
6250528|NCT01949051|9938676|FG005|Treatment Period 2 (7 Days)|Protocol Violation|1
6250529|NCT01949051|9938671|FG000|Treatment Period 2 (7 Days)|Lost to Follow-up|0
6250530|NCT01949051|9938672|FG001|Treatment Period 2 (7 Days)|Lost to Follow-up|1
6250531|NCT01949051|9938673|FG002|Treatment Period 2 (7 Days)|Lost to Follow-up|0
6250532|NCT01949051|9938674|FG003|Treatment Period 2 (7 Days)|Lost to Follow-up|0
6250533|NCT01949051|9938675|FG004|Treatment Period 2 (7 Days)|Lost to Follow-up|0
6250534|NCT01949051|9938676|FG005|Treatment Period 2 (7 Days)|Lost to Follow-up|0
6250535|NCT01949051|9938671|FG000|Treatment Period 2 (7 Days)|Withdrawal by Subject|0
6250536|NCT01949051|9938672|FG001|Treatment Period 2 (7 Days)|Withdrawal by Subject|0
6250537|NCT01949051|9938673|FG002|Treatment Period 2 (7 Days)|Withdrawal by Subject|1
6250538|NCT01949051|9938674|FG003|Treatment Period 2 (7 Days)|Withdrawal by Subject|0
6250539|NCT01949051|9938675|FG004|Treatment Period 2 (7 Days)|Withdrawal by Subject|0
6250540|NCT01949051|9938676|FG005|Treatment Period 2 (7 Days)|Withdrawal by Subject|0
6250541|NCT01949090|9938689|FG000|Overall Study|Serious Adverse Event|0
6250542|NCT01949090|9938690|FG001|Overall Study|Serious Adverse Event|1
6250543|NCT01949090|9938691|FG002|Overall Study|Serious Adverse Event|2
6250544|NCT01949090|9938692|FG003|Overall Study|Serious Adverse Event|0
6250545|NCT01949090|9938693|FG004|Overall Study|Serious Adverse Event|1
6250546|NCT01949090|9938689|FG000|Overall Study|Withdrawal by Subject|2
6250547|NCT01949090|9938690|FG001|Overall Study|Withdrawal by Subject|0
6250548|NCT01949090|9938691|FG002|Overall Study|Withdrawal by Subject|0
6250549|NCT01949090|9938692|FG003|Overall Study|Withdrawal by Subject|0
6250550|NCT01949090|9938693|FG004|Overall Study|Withdrawal by Subject|1
6250551|NCT01949090|9938689|FG000|Overall Study|Protocol non-compliance|0
6250552|NCT01949090|9938690|FG001|Overall Study|Protocol non-compliance|0
6250553|NCT01949090|9938691|FG002|Overall Study|Protocol non-compliance|0
6250554|NCT01949090|9938692|FG003|Overall Study|Protocol non-compliance|0
6250555|NCT01949090|9938693|FG004|Overall Study|Protocol non-compliance|1
6250556|NCT01949090|9938689|FG000|Overall Study|Lost to Follow-up|2
6250557|NCT01949090|9938690|FG001|Overall Study|Lost to Follow-up|1
6250558|NCT01949090|9938691|FG002|Overall Study|Lost to Follow-up|0
6250559|NCT01949090|9938692|FG003|Overall Study|Lost to Follow-up|1
6250560|NCT01949090|9938693|FG004|Overall Study|Lost to Follow-up|1
6250561|NCT01949116|9938708|FG000|Overall Study|Death|2
6250562|NCT01949116|9938709|FG001|Overall Study|Death|0
6250563|NCT01949116|9938708|FG000|Overall Study|Lost to Follow-up|1
6250564|NCT01949116|9938709|FG001|Overall Study|Lost to Follow-up|3
6250565|NCT01949116|9938708|FG000|Overall Study|Withdrawal by Subject|5
6250566|NCT01949116|9938709|FG001|Overall Study|Withdrawal by Subject|3
6250567|NCT01949142|9938721|FG000|Overall Study|Withdrawal of consent|1
6250568|NCT01949142|9938722|FG001|Overall Study|Withdrawal of consent|0
6250569|NCT01949142|9938721|FG000|Overall Study|Lost to Follow-up|1
6250570|NCT01949142|9938722|FG001|Overall Study|Lost to Follow-up|1
6250571|NCT01949142|9938721|FG000|Overall Study|Parent changed their mind|1
6250572|NCT01949142|9938722|FG001|Overall Study|Parent changed their mind|0
6250573|NCT01949155|9938731|FG000|Overall Study|Lost to Follow-up|1
6250574|NCT01949155|9938732|FG001|Overall Study|Lost to Follow-up|0
6250575|NCT01949155|9938731|FG000|Overall Study|Protocol Violation|1
6250576|NCT01949155|9938732|FG001|Overall Study|Protocol Violation|0
6250577|NCT01949480|9938754|FG000|Overall Study|Physician Decision|5
6250578|NCT01949480|9938755|FG001|Overall Study|Physician Decision|8
6250579|NCT01949532|9938763|FG000|Overall Study|On-study at the Data Cut-off Date|3
6250580|NCT01949532|9938764|FG001|Overall Study|On-study at the Data Cut-off Date|3
6250581|NCT01949662|9938789|FG000|Overall Study|Death|9
6250582|NCT01949662|9938790|FG001|Overall Study|Death|7
6250583|NCT01949662|9938789|FG000|Overall Study|Discharged before an agitation event|8
6250584|NCT01949662|9938790|FG001|Overall Study|Discharged before an agitation event|3
6250585|NCT01949662|9938789|FG000|Overall Study|Dropped out|1
6250586|NCT01949662|9938790|FG001|Overall Study|Dropped out|3
6250587|NCT01949662|9938789|FG000|Overall Study|Ineligible|0
6250588|NCT01949662|9938790|FG001|Overall Study|Ineligible|1
6250589|NCT01949870|9938804|FG000|Overall Study|Lack of Efficacy|2
6250590|NCT01949870|9938804|FG000|Overall Study|Adverse Event|1
6250591|NCT01949870|9938804|FG000|Overall Study|Study termination|1
6250592|NCT01949870|9938804|FG000|Overall Study|Eligibility requirements not fulfilled|2
6250593|NCT01950013|9938811|FG000|Overall Study|Withdrawal by Subject|0
6250594|NCT01950013|9938812|FG001|Overall Study|Withdrawal by Subject|2
6250595|NCT01950013|9938813|FG002|Overall Study|Withdrawal by Subject|0
6250596|NCT01950169|9938842|FG000|Overall Study|Withdrawal by Subject|2
6250597|NCT01950169|9938843|FG001|Overall Study|Withdrawal by Subject|8
6250598|NCT01950169|9938844|FG002|Overall Study|Withdrawal by Subject|1
6250599|NCT01950169|9938842|FG000|Overall Study|Death|1
6250600|NCT01950169|9938843|FG001|Overall Study|Death|0
6250601|NCT01950169|9938844|FG002|Overall Study|Death|0
6250602|NCT01950273|9938864|FG000|Overall Study|Protocol Violation|1
6250603|NCT01950273|9938865|FG001|Overall Study|Protocol Violation|0
6250604|NCT01950273|9938864|FG000|Overall Study|Withdrawal by Subject|2
6250605|NCT01950273|9938865|FG001|Overall Study|Withdrawal by Subject|0
6250606|NCT01950273|9938864|FG000|Overall Study|Other not defined above|1
6250607|NCT01950273|9938865|FG001|Overall Study|Other not defined above|0
6250608|NCT01950364|9938886|FG000|Overall Study|Adverse Event|3
6250609|NCT01950364|9938887|FG001|Overall Study|Adverse Event|0
6250610|NCT01950364|9938886|FG000|Overall Study|Stem Cell Transplant|2
6250611|NCT01950364|9938887|FG001|Overall Study|Stem Cell Transplant|6
6250612|NCT01950364|9938886|FG000|Overall Study|Disease Progression|5
6250613|NCT01950364|9938887|FG001|Overall Study|Disease Progression|2
6250614|NCT01950364|9938886|FG000|Overall Study|Withdrawal by Subject|0
6250615|NCT01950364|9938887|FG001|Overall Study|Withdrawal by Subject|1
6250616|NCT01950364|9938886|FG000|Overall Study|Protocol Violation|0
6250617|NCT01950364|9938887|FG001|Overall Study|Protocol Violation|1
6250618|NCT01950741|9938897|FG000|Overall Study|Lost to Follow-up|1
6250619|NCT01950741|9938897|FG000|Overall Study|Death|1
6250620|NCT01950741|9938897|FG000|Overall Study|Withdrawal by Subject|1
6250621|NCT01950819|9938908|FG000|Overall Study|Graft Loss|35
6250622|NCT01950819|9938909|FG001|Overall Study|Graft Loss|30
6250623|NCT01950819|9938908|FG000|Overall Study|Death|29
6250624|NCT01950819|9938909|FG001|Overall Study|Death|34
6250625|NCT01950819|9938908|FG000|Overall Study|Subject / Gardian decision|54
6250626|NCT01950819|9938909|FG001|Overall Study|Subject / Gardian decision|51
6250627|NCT01950819|9938908|FG000|Overall Study|technical problems|2
6250628|NCT01950819|9938909|FG001|Overall Study|technical problems|0
6250629|NCT01950819|9938908|FG000|Overall Study|Pregnancy|0
6250630|NCT01950819|9938909|FG001|Overall Study|Pregnancy|2
6250631|NCT01950819|9938908|FG000|Overall Study|Lost to Follow-up|9
6250632|NCT01950819|9938909|FG001|Overall Study|Lost to Follow-up|17
6250633|NCT01951092|9938921|FG000|Overall Study|Lost to Follow-up|10
6250634|NCT01951092|9938921|FG000|Overall Study|Incarceration|1
6250635|NCT01951092|9938921|FG000|Overall Study|Transfer of Care|1
6250636|NCT01951105|9938928|FG000|Overall Study|Adverse Event|0
6250637|NCT01951105|9938929|FG001|Overall Study|Adverse Event|5
6250638|NCT01951105|9938930|FG002|Overall Study|Adverse Event|0
6250639|NCT01951105|9938928|FG000|Overall Study|Lost to Follow-up|0
6250640|NCT01951105|9938929|FG001|Overall Study|Lost to Follow-up|1
6250641|NCT01951105|9938930|FG002|Overall Study|Lost to Follow-up|0
6250642|NCT01951105|9938928|FG000|Overall Study|Protocol Violation|1
6250643|NCT01951105|9938929|FG001|Overall Study|Protocol Violation|1
6250644|NCT01951105|9938930|FG002|Overall Study|Protocol Violation|1
6250645|NCT01951105|9938928|FG000|Overall Study|Withdrawal by Subject|0
6250646|NCT01951105|9938929|FG001|Overall Study|Withdrawal by Subject|3
6250647|NCT01951105|9938930|FG002|Overall Study|Withdrawal by Subject|1
6250648|NCT01951157|9938956|FG000|Overall Study|Progressive Disease|12
6250649|NCT01951157|9938957|FG001|Overall Study|Progressive Disease|13
6250650|NCT01951157|9938958|FG002|Overall Study|Progressive Disease|10
6250651|NCT01951157|9938956|FG000|Overall Study|Treatment-unrelated AE|1
6250652|NCT01951157|9938957|FG001|Overall Study|Treatment-unrelated AE|0
6250653|NCT01951157|9938958|FG002|Overall Study|Treatment-unrelated AE|3
6250654|NCT01951157|9938956|FG000|Overall Study|Study Termination|0
6250655|NCT01951157|9938957|FG001|Overall Study|Study Termination|0
6250656|NCT01951157|9938958|FG002|Overall Study|Study Termination|1
6250657|NCT01951157|9938956|FG000|Overall Study|Physician Decision|5
6250658|NCT01951157|9938957|FG001|Overall Study|Physician Decision|3
6250659|NCT01951157|9938958|FG002|Overall Study|Physician Decision|2
6250660|NCT01951157|9938956|FG000|Overall Study|Non-treatmentrelated death|2
6250661|NCT01951157|9938957|FG001|Overall Study|Non-treatmentrelated death|2
6250662|NCT01951157|9938958|FG002|Overall Study|Non-treatmentrelated death|2
6250663|NCT01951157|9938956|FG000|Overall Study|No treated|0
6250664|NCT01951157|9938957|FG001|Overall Study|No treated|1
6250665|NCT01951157|9938958|FG002|Overall Study|No treated|0
6250666|NCT01951157|9938956|FG000|Overall Study|Treatment-related AE|2
6250667|NCT01951157|9938957|FG001|Overall Study|Treatment-related AE|0
6250668|NCT01951157|9938958|FG002|Overall Study|Treatment-related AE|4
6250669|NCT01951157|9938956|FG000|Overall Study|Consent withdrawn by subject|0
6250670|NCT01951157|9938957|FG001|Overall Study|Consent withdrawn by subject|1
6250671|NCT01951157|9938958|FG002|Overall Study|Consent withdrawn by subject|3
6250672|NCT01951157|9938956|FG000|Overall Study|Treatment-related death|0
6250673|NCT01951157|9938957|FG001|Overall Study|Treatment-related death|2
6250674|NCT01951157|9938958|FG002|Overall Study|Treatment-related death|0
6250675|NCT01951170|9938967|FG000|Overall Study|Investigator decision|1
6250676|NCT01951261|9938973|FG000|Overall Study|Death|1
6250677|NCT01951261|9938974|FG001|Overall Study|Death|0
6250678|NCT01951261|9938973|FG000|Overall Study|Lost to Follow-up|4
6250679|NCT01951261|9938974|FG001|Overall Study|Lost to Follow-up|3
6250680|NCT01951261|9938973|FG000|Overall Study|Protocol Violation|4
6250681|NCT01951261|9938974|FG001|Overall Study|Protocol Violation|3
6250682|NCT01951417|9939014|FG000|Overall Study|Withdrawal by Subject|1
6250683|NCT01951417|9939014|FG000|Overall Study|Protocol Violation|2
6250684|NCT01951417|9939014|FG000|Overall Study|Lost to Follow-up|6
6250685|NCT01951573|9939022|FG000|Washout Period|Adverse Event|0
6250686|NCT01951573|9939023|FG001|Washout Period|Adverse Event|1
6250687|NCT01951586|9939031|FG000|Overall Study|Death|61
6250688|NCT01951586|9939032|FG001|Overall Study|Death|120
6250689|NCT01951586|9939031|FG000|Overall Study|Withdrawal by Subject|8
6250690|NCT01951586|9939032|FG001|Overall Study|Withdrawal by Subject|17
6250691|NCT01951586|9939031|FG000|Overall Study|Lost to Follow-up|0
6250692|NCT01951586|9939032|FG001|Overall Study|Lost to Follow-up|1
6250693|NCT01951586|9939031|FG000|Overall Study|Sponsor Decision|9
6250694|NCT01951586|9939032|FG001|Overall Study|Sponsor Decision|10
6250695|NCT01951625|9939044|FG000|Treatment Period|Protocol Violation|2
6250696|NCT01951625|9939045|FG001|Treatment Period|Protocol Violation|0
6250697|NCT01951625|9939046|FG002|Treatment Period|Protocol Violation|1
6250698|NCT01951625|9939047|FG003|Treatment Period|Protocol Violation|3
6250699|NCT01951625|9939048|FG004|Treatment Period|Protocol Violation|2
6250700|NCT01951625|9939044|FG000|Treatment Period|Physician Decision|0
6250701|NCT01951625|9939045|FG001|Treatment Period|Physician Decision|0
6250702|NCT01951625|9939046|FG002|Treatment Period|Physician Decision|0
6250703|NCT01951625|9939047|FG003|Treatment Period|Physician Decision|0
6250704|NCT01951625|9939048|FG004|Treatment Period|Physician Decision|1
6250705|NCT01951625|9939044|FG000|Treatment Period|Protocol driven decision point|0
6250706|NCT01951625|9939045|FG001|Treatment Period|Protocol driven decision point|5
6250707|NCT01951625|9939046|FG002|Treatment Period|Protocol driven decision point|0
6250708|NCT01951625|9939047|FG003|Treatment Period|Protocol driven decision point|2
6250709|NCT01951625|9939048|FG004|Treatment Period|Protocol driven decision point|1
6250710|NCT01951625|9939044|FG000|Treatment Period|Non compliance with study drug|1
6250711|NCT01951625|9939045|FG001|Treatment Period|Non compliance with study drug|2
6250712|NCT01951625|9939046|FG002|Treatment Period|Non compliance with study drug|2
6250713|NCT01951625|9939047|FG003|Treatment Period|Non compliance with study drug|0
6250714|NCT01951625|9939048|FG004|Treatment Period|Non compliance with study drug|0
6250715|NCT01951625|9939044|FG000|Treatment Period|Death|3
6250716|NCT01951625|9939045|FG001|Treatment Period|Death|2
6250717|NCT01951625|9939046|FG002|Treatment Period|Death|2
6250718|NCT01951625|9939047|FG003|Treatment Period|Death|1
6250719|NCT01951625|9939048|FG004|Treatment Period|Death|2
6250720|NCT01951625|9939044|FG000|Treatment Period|Adverse Event|7
6250721|NCT01951625|9939045|FG001|Treatment Period|Adverse Event|10
6250722|NCT01951625|9939046|FG002|Treatment Period|Adverse Event|9
6250723|NCT01951625|9939047|FG003|Treatment Period|Adverse Event|8
6250724|NCT01951625|9939048|FG004|Treatment Period|Adverse Event|8
6250725|NCT01951625|9939044|FG000|Treatment Period|Withdrawal by Subject|5
6250726|NCT01951625|9939045|FG001|Treatment Period|Withdrawal by Subject|2
6250727|NCT01951625|9939046|FG002|Treatment Period|Withdrawal by Subject|1
6250728|NCT01951625|9939047|FG003|Treatment Period|Withdrawal by Subject|7
6250729|NCT01951625|9939048|FG004|Treatment Period|Withdrawal by Subject|3
6250730|NCT01951625|9939044|FG000|Treatment Period|Lost to Follow-up|1
6250731|NCT01951625|9939045|FG001|Treatment Period|Lost to Follow-up|0
6250732|NCT01951625|9939046|FG002|Treatment Period|Lost to Follow-up|0
6250733|NCT01951625|9939047|FG003|Treatment Period|Lost to Follow-up|1
6250734|NCT01951625|9939048|FG004|Treatment Period|Lost to Follow-up|0
6250735|NCT01951625|9939044|FG000|Follow Up Period|Non-compliance with study drug|1
6250736|NCT01951625|9939045|FG001|Follow Up Period|Non-compliance with study drug|0
6250737|NCT01951625|9939046|FG002|Follow Up Period|Non-compliance with study drug|0
6250738|NCT01951625|9939047|FG003|Follow Up Period|Non-compliance with study drug|0
6250739|NCT01951625|9939048|FG004|Follow Up Period|Non-compliance with study drug|0
6250740|NCT01951625|9939044|FG000|Follow Up Period|Death|1
6250741|NCT01951625|9939045|FG001|Follow Up Period|Death|3
6250742|NCT01951625|9939046|FG002|Follow Up Period|Death|2
6250743|NCT01951625|9939047|FG003|Follow Up Period|Death|2
6250744|NCT01951625|9939048|FG004|Follow Up Period|Death|1
6250745|NCT01951625|9939044|FG000|Follow Up Period|Logistical difficulties|1
6250746|NCT01951625|9939045|FG001|Follow Up Period|Logistical difficulties|2
6250747|NCT01951625|9939046|FG002|Follow Up Period|Logistical difficulties|0
6250748|NCT01951625|9939047|FG003|Follow Up Period|Logistical difficulties|0
6250749|NCT01951625|9939048|FG004|Follow Up Period|Logistical difficulties|0
6250750|NCT01951625|9939044|FG000|Follow Up Period|Adverse Event|0
6250751|NCT01951625|9939045|FG001|Follow Up Period|Adverse Event|3
6250752|NCT01951625|9939046|FG002|Follow Up Period|Adverse Event|2
6250753|NCT01951625|9939047|FG003|Follow Up Period|Adverse Event|3
6250754|NCT01951625|9939048|FG004|Follow Up Period|Adverse Event|5
6250755|NCT01951625|9939044|FG000|Follow Up Period|Withdrawal by Subject|4
6250756|NCT01951625|9939045|FG001|Follow Up Period|Withdrawal by Subject|1
6250757|NCT01951625|9939046|FG002|Follow Up Period|Withdrawal by Subject|0
6250758|NCT01951625|9939047|FG003|Follow Up Period|Withdrawal by Subject|5
6086254|NCT00659815|9696113|FG001|Overall Study|Study related symptoms and complaints|1
6086255|NCT00659815|9696112|FG000|Overall Study|Inability to maintain wearing schedule|1
6086256|NCT00659815|9696113|FG001|Overall Study|Inability to maintain wearing schedule|2
6250759|NCT01951625|9939048|FG004|Follow Up Period|Withdrawal by Subject|3
6250760|NCT01951625|9939044|FG000|Follow Up Period|Lost to Follow-up|1
6250761|NCT01951625|9939045|FG001|Follow Up Period|Lost to Follow-up|0
6250762|NCT01951625|9939046|FG002|Follow Up Period|Lost to Follow-up|0
6250763|NCT01951625|9939047|FG003|Follow Up Period|Lost to Follow-up|1
6250764|NCT01951625|9939048|FG004|Follow Up Period|Lost to Follow-up|1
6250765|NCT01951638|9939066|FG000|Treatment Period|Protocol Violation|0
6250766|NCT01951638|9939067|FG001|Treatment Period|Protocol Violation|0
6250767|NCT01951638|9939068|FG002|Treatment Period|Protocol Violation|0
6250768|NCT01951638|9939069|FG003|Treatment Period|Protocol Violation|2
6250769|NCT01951638|9939070|FG004|Treatment Period|Protocol Violation|0
6250770|NCT01951638|9939066|FG000|Treatment Period|Protocol-driven decision point|1
6250771|NCT01951638|9939067|FG001|Treatment Period|Protocol-driven decision point|3
6250772|NCT01951638|9939068|FG002|Treatment Period|Protocol-driven decision point|0
6250773|NCT01951638|9939069|FG003|Treatment Period|Protocol-driven decision point|0
6250774|NCT01951638|9939070|FG004|Treatment Period|Protocol-driven decision point|0
6250775|NCT01951638|9939066|FG000|Treatment Period|Logistical difficulties|0
6086257|NCT00659815|9696112|FG000|Overall Study|Withdrawal by Subject|1
6086258|NCT00659815|9696113|FG001|Overall Study|Withdrawal by Subject|1
6189500|NCT01400698|9844811|FG000|Overall Study|Non-compliance|0
6189501|NCT01400698|9844812|FG001|Overall Study|Non-compliance|1
6189502|NCT01400698|9844813|FG002|Overall Study|Non-compliance|0
6189503|NCT01400698|9844814|FG003|Overall Study|Non-compliance|1
6189504|NCT01400698|9844815|FG004|Overall Study|Non-compliance|0
6189505|NCT01400698|9844816|FG005|Overall Study|Non-compliance|0
6189506|NCT01400698|9844811|FG000|Overall Study|Adverse Event|1
6189507|NCT01400698|9844812|FG001|Overall Study|Adverse Event|0
6189508|NCT01400698|9844813|FG002|Overall Study|Adverse Event|0
6189509|NCT01400698|9844814|FG003|Overall Study|Adverse Event|0
6189510|NCT01400698|9844815|FG004|Overall Study|Adverse Event|0
6250776|NCT01951638|9939067|FG001|Treatment Period|Logistical difficulties|1
6250777|NCT01951638|9939068|FG002|Treatment Period|Logistical difficulties|1
6250778|NCT01951638|9939069|FG003|Treatment Period|Logistical difficulties|0
6250779|NCT01951638|9939070|FG004|Treatment Period|Logistical difficulties|0
6250780|NCT01951638|9939066|FG000|Treatment Period|Withdrawal by Subject|9
6250781|NCT01951638|9939067|FG001|Treatment Period|Withdrawal by Subject|6
6250782|NCT01951638|9939068|FG002|Treatment Period|Withdrawal by Subject|4
6250783|NCT01951638|9939069|FG003|Treatment Period|Withdrawal by Subject|5
6250784|NCT01951638|9939070|FG004|Treatment Period|Withdrawal by Subject|4
6250785|NCT01951638|9939066|FG000|Treatment Period|Death|0
6250786|NCT01951638|9939067|FG001|Treatment Period|Death|0
6250787|NCT01951638|9939068|FG002|Treatment Period|Death|0
6250788|NCT01951638|9939069|FG003|Treatment Period|Death|3
6250789|NCT01951638|9939070|FG004|Treatment Period|Death|1
6250790|NCT01951638|9939066|FG000|Treatment Period|Adverse Event|3
6250791|NCT01951638|9939067|FG001|Treatment Period|Adverse Event|4
6250792|NCT01951638|9939068|FG002|Treatment Period|Adverse Event|8
6250793|NCT01951638|9939069|FG003|Treatment Period|Adverse Event|6
6250794|NCT01951638|9939070|FG004|Treatment Period|Adverse Event|5
6250795|NCT01951638|9939066|FG000|Follow-up Period|Protocol Violation|0
6250796|NCT01951638|9939067|FG001|Follow-up Period|Protocol Violation|0
6250797|NCT01951638|9939068|FG002|Follow-up Period|Protocol Violation|0
6250798|NCT01951638|9939069|FG003|Follow-up Period|Protocol Violation|1
6250799|NCT01951638|9939070|FG004|Follow-up Period|Protocol Violation|0
6250800|NCT01951638|9939066|FG000|Follow-up Period|Logistical difficulties|0
6250801|NCT01951638|9939067|FG001|Follow-up Period|Logistical difficulties|2
6250802|NCT01951638|9939068|FG002|Follow-up Period|Logistical difficulties|0
6250803|NCT01951638|9939069|FG003|Follow-up Period|Logistical difficulties|0
6250804|NCT01951638|9939070|FG004|Follow-up Period|Logistical difficulties|1
6250805|NCT01951638|9939066|FG000|Follow-up Period|Withdrawal by Subject|1
6250806|NCT01951638|9939067|FG001|Follow-up Period|Withdrawal by Subject|5
6250807|NCT01951638|9939068|FG002|Follow-up Period|Withdrawal by Subject|2
6250808|NCT01951638|9939069|FG003|Follow-up Period|Withdrawal by Subject|1
6250809|NCT01951638|9939070|FG004|Follow-up Period|Withdrawal by Subject|2
6250810|NCT01951638|9939066|FG000|Follow-up Period|Lost to Follow-up|0
6250811|NCT01951638|9939067|FG001|Follow-up Period|Lost to Follow-up|1
6250812|NCT01951638|9939068|FG002|Follow-up Period|Lost to Follow-up|0
6250813|NCT01951638|9939069|FG003|Follow-up Period|Lost to Follow-up|1
6250814|NCT01951638|9939070|FG004|Follow-up Period|Lost to Follow-up|0
6250815|NCT01951638|9939066|FG000|Follow-up Period|Death|1
6250816|NCT01951638|9939067|FG001|Follow-up Period|Death|0
6250817|NCT01951638|9939068|FG002|Follow-up Period|Death|1
6250818|NCT01951638|9939069|FG003|Follow-up Period|Death|4
6250819|NCT01951638|9939070|FG004|Follow-up Period|Death|1
6250820|NCT01951638|9939066|FG000|Follow-up Period|Adverse Event|0
6250821|NCT01951638|9939067|FG001|Follow-up Period|Adverse Event|1
6250822|NCT01951638|9939068|FG002|Follow-up Period|Adverse Event|2
6250823|NCT01951638|9939069|FG003|Follow-up Period|Adverse Event|1
6250824|NCT01951638|9939070|FG004|Follow-up Period|Adverse Event|1
6270808|NCT02157779|9972260|FG000|Overall Study|Logistical|9
6270809|NCT02157779|9972261|FG001|Overall Study|Logistical|3
6270810|NCT02157779|9972260|FG000|Overall Study|Stopped attending, reason unknown|11
6270811|NCT02157779|9972261|FG001|Overall Study|Stopped attending, reason unknown|7
6270812|NCT02157779|9972260|FG000|Overall Study|No response to outreach after Baseline|1
6270813|NCT02157779|9972261|FG001|Overall Study|No response to outreach after Baseline|1
6270814|NCT02157779|9972260|FG000|Overall Study|Moved|1
6270815|NCT02157779|9972261|FG001|Overall Study|Moved|0
6270816|NCT02157779|9972260|FG000|Overall Study|Medical|1
6270817|NCT02157779|9972261|FG001|Overall Study|Medical|0
6270818|NCT02157779|9972260|FG000|Overall Study|Legal issue|1
6270819|NCT02157779|9972261|FG001|Overall Study|Legal issue|0
6270820|NCT02157935|9972282|FG000|Overall Study|Withdrawal by Subject|25
6270821|NCT02157935|9972283|FG001|Overall Study|Withdrawal by Subject|39
6270822|NCT02157935|9972282|FG000|Overall Study|Screen failure|1
6270823|NCT02157935|9972283|FG001|Overall Study|Screen failure|2
6270824|NCT02157935|9972282|FG000|Overall Study|Protocol Violation|1
6270825|NCT02157935|9972283|FG001|Overall Study|Protocol Violation|0
6270826|NCT02157935|9972282|FG000|Overall Study|Progressive disease|0
6270827|NCT02157935|9972283|FG001|Overall Study|Progressive disease|2
6270828|NCT02157935|9972282|FG000|Overall Study|Other|5
6270829|NCT02157935|9972283|FG001|Overall Study|Other|12
6270830|NCT02157935|9972282|FG000|Overall Study|Lack of Efficacy|0
6270831|NCT02157935|9972283|FG001|Overall Study|Lack of Efficacy|1
6270832|NCT02157935|9972282|FG000|Overall Study|Death|4
6270833|NCT02157935|9972283|FG001|Overall Study|Death|4
6270834|NCT02157935|9972282|FG000|Overall Study|Adverse Event|3
6270835|NCT02157935|9972283|FG001|Overall Study|Adverse Event|5
6270836|NCT02157948|9972291|FG000|Overall Study|Withdrawal by Subject|4
6270837|NCT02157948|9972292|FG001|Overall Study|Withdrawal by Subject|5
6270838|NCT02157948|9972291|FG000|Overall Study|Lost to Follow-up|3
6250825|NCT01951703|9939093|FG000|First Intervention|Withdrawal by Subject|1
6250826|NCT01951703|9939094|FG001|First Intervention|Withdrawal by Subject|0
6250827|NCT01951703|9939093|FG000|First Intervention|Subject was not compliant|1
6250828|NCT01951703|9939094|FG001|First Intervention|Subject was not compliant|1
6250829|NCT01951703|9939093|FG000|First Intervention|Physician Decision|1
6250830|NCT01951703|9939094|FG001|First Intervention|Physician Decision|0
6250831|NCT01951703|9939093|FG000|Second Intervention|Protocol Violation|0
6250832|NCT01951703|9939094|FG001|Second Intervention|Protocol Violation|1
6250833|NCT01951703|9939093|FG000|Second Intervention|Unsatisfactory Lens fitting|0
6250834|NCT01951703|9939094|FG001|Second Intervention|Unsatisfactory Lens fitting|1
6250835|NCT01952015|9939141|FG000|Induction|Protocol Violation|1
6250836|NCT01952015|9939141|FG000|Maintenance|Adverse Event|2
6250837|NCT01952015|9939141|FG000|Treatment Period 3|Physician Decision|9
6250838|NCT01952041|9939159|FG000|Overall Study|Lost to Follow-up|9
6250839|NCT01952041|9939160|FG001|Overall Study|Lost to Follow-up|16
6250840|NCT01952041|9939159|FG000|Overall Study|Withdrawal by Subject|7
6250841|NCT01952041|9939160|FG001|Overall Study|Withdrawal by Subject|5
6250842|NCT01952041|9939159|FG000|Overall Study|Death|1
6250843|NCT01952041|9939160|FG001|Overall Study|Death|0
6250844|NCT01952054|9939166|FG000|Overall Study|Physician Decision|1
6250845|NCT01952080|9939174|FG000|Overall Study|Withdrawal by Subject|0
6250846|NCT01952080|9939175|FG001|Overall Study|Withdrawal by Subject|0
6250847|NCT01952080|9939176|FG002|Overall Study|Withdrawal by Subject|0
6250848|NCT01952080|9939177|FG003|Overall Study|Withdrawal by Subject|1
6250849|NCT01952080|9939174|FG000|Overall Study|Protocol Non-compliance|0
6250850|NCT01952080|9939175|FG001|Overall Study|Protocol Non-compliance|1
6250851|NCT01952080|9939176|FG002|Overall Study|Protocol Non-compliance|0
6250852|NCT01952080|9939177|FG003|Overall Study|Protocol Non-compliance|0
6250853|NCT01952145|9939189|FG000|Overall Study|Protocol Violation|2
6250854|NCT01952145|9939190|FG001|Overall Study|Protocol Violation|1
6250855|NCT01952145|9939189|FG000|Overall Study|Death|0
6250856|NCT01952145|9939190|FG001|Overall Study|Death|1
6250857|NCT01952145|9939189|FG000|Overall Study|Adverse Event|9
6250858|NCT01952145|9939190|FG001|Overall Study|Adverse Event|0
6250859|NCT01952145|9939189|FG000|Overall Study|Withdrawal Criteria|16
6250860|NCT01952145|9939190|FG001|Overall Study|Withdrawal Criteria|11
6250861|NCT01952145|9939189|FG000|Overall Study|Unclassified|1
6250862|NCT01952145|9939190|FG001|Overall Study|Unclassified|1
6250863|NCT01952366|9939202|FG000|Overall Study|Death|22
6250864|NCT01952366|9939202|FG000|Overall Study|Withdrawal by Subject|9
6250865|NCT01952665|9939256|FG000|Overall Study|Physician Decision|3
6250866|NCT01952665|9939257|FG001|Overall Study|Physician Decision|2
6250867|NCT01952665|9939256|FG000|Overall Study|Lost to Follow-up|1
6250868|NCT01952665|9939257|FG001|Overall Study|Lost to Follow-up|2
6250869|NCT01952665|9939256|FG000|Overall Study|Adverse Event|2
6250870|NCT01952665|9939257|FG001|Overall Study|Adverse Event|1
6250871|NCT01952665|9939256|FG000|Overall Study|Protocol Violation|0
6250872|NCT01952665|9939257|FG001|Overall Study|Protocol Violation|1
6250873|NCT01952691|9939285|FG000|Overall Study|Lost to Follow-up|2
6250874|NCT01952834|9939289|FG000|Overall Study|Adverse Event|1
6250875|NCT01953003|9939296|FG000|Overall Study|Not treated|0
6250876|NCT01953003|9939297|FG001|Overall Study|Not treated|1
6250877|NCT01953003|9939296|FG000|Overall Study|Progressive disease|35
6250878|NCT01953003|9939297|FG001|Overall Study|Progressive disease|45
6250879|NCT01953003|9939296|FG000|Overall Study|Related Adverse events|7
6250880|NCT01953003|9939297|FG001|Overall Study|Related Adverse events|2
6250881|NCT01953003|9939296|FG000|Overall Study|Non-related adverse events|0
6250882|NCT01953003|9939297|FG001|Overall Study|Non-related adverse events|2
6250883|NCT01953003|9939296|FG000|Overall Study|Protocol Violation|0
6250884|NCT01953003|9939297|FG001|Overall Study|Protocol Violation|1
6250885|NCT01953003|9939296|FG000|Overall Study|Withdrawal by Subject|14
6250886|NCT01953003|9939297|FG001|Overall Study|Withdrawal by Subject|4
6250887|NCT01953224|9939320|FG000|Overall Study|Lost to Follow-up|1
6250888|NCT01953224|9939321|FG001|Overall Study|Lost to Follow-up|1
6250889|NCT01953224|9939320|FG000|Overall Study|Withdrawal by Subject|1
6250890|NCT01953224|9939321|FG001|Overall Study|Withdrawal by Subject|2
6250891|NCT01953328|9939344|FG000|Overall Study|Withdrawal by Subject|0
6250892|NCT01953328|9939345|FG001|Overall Study|Withdrawal by Subject|0
6250893|NCT01953328|9939346|FG002|Overall Study|Withdrawal by Subject|0
6250894|NCT01953328|9939347|FG003|Overall Study|Withdrawal by Subject|0
6250895|NCT01953328|9939348|FG004|Overall Study|Withdrawal by Subject|1
6250896|NCT01953328|9939349|FG005|Overall Study|Withdrawal by Subject|0
6250897|NCT01953328|9939350|FG006|Overall Study|Withdrawal by Subject|0
6250898|NCT01953328|9939351|FG007|Overall Study|Withdrawal by Subject|0
6250899|NCT01953328|9939344|FG000|Overall Study|Lost to Follow-up|0
6250900|NCT01953328|9939345|FG001|Overall Study|Lost to Follow-up|0
6250901|NCT01953328|9939346|FG002|Overall Study|Lost to Follow-up|0
6250902|NCT01953328|9939347|FG003|Overall Study|Lost to Follow-up|0
6250903|NCT01953328|9939348|FG004|Overall Study|Lost to Follow-up|1
6250904|NCT01953328|9939349|FG005|Overall Study|Lost to Follow-up|0
6250905|NCT01953328|9939350|FG006|Overall Study|Lost to Follow-up|0
6250906|NCT01953328|9939351|FG007|Overall Study|Lost to Follow-up|0
6250907|NCT01953354|9939371|FG000|Overall Study|Withdrawal by Subject|0
6250908|NCT01953354|9939372|FG001|Overall Study|Withdrawal by Subject|1
6250909|NCT01953354|9939371|FG000|Overall Study|Decision of Sponsor|0
6250910|NCT01953354|9939372|FG001|Overall Study|Decision of Sponsor|1
6250911|NCT01953354|9939371|FG000|Overall Study|Disease Exacerbation|1
6250912|NCT01953354|9939372|FG001|Overall Study|Disease Exacerbation|0
6250913|NCT01953601|9939403|FG000|Part 1 (Base Study)|Adverse Event|24
6250914|NCT01953601|9939404|FG001|Part 1 (Base Study)|Adverse Event|37
6250915|NCT01953601|9939405|FG002|Part 1 (Base Study)|Adverse Event|15
6250916|NCT01953601|9939403|FG000|Part 1 (Base Study)|Death|2
6250917|NCT01953601|9939404|FG001|Part 1 (Base Study)|Death|0
6250918|NCT01953601|9939405|FG002|Part 1 (Base Study)|Death|3
6250919|NCT01953601|9939403|FG000|Part 1 (Base Study)|Lack of Efficacy|3
6250920|NCT01953601|9939404|FG001|Part 1 (Base Study)|Lack of Efficacy|1
6250921|NCT01953601|9939405|FG002|Part 1 (Base Study)|Lack of Efficacy|4
6250922|NCT01953601|9939403|FG000|Part 1 (Base Study)|Lost to Follow-up|1
6250923|NCT01953601|9939404|FG001|Part 1 (Base Study)|Lost to Follow-up|3
6250924|NCT01953601|9939405|FG002|Part 1 (Base Study)|Lost to Follow-up|6
6250925|NCT01953601|9939403|FG000|Part 1 (Base Study)|Non-compliance with study drug|0
6250926|NCT01953601|9939404|FG001|Part 1 (Base Study)|Non-compliance with study drug|3
6250927|NCT01953601|9939405|FG002|Part 1 (Base Study)|Non-compliance with study drug|1
6250928|NCT01953601|9939403|FG000|Part 1 (Base Study)|Physician Decision|3
6250929|NCT01953601|9939404|FG001|Part 1 (Base Study)|Physician Decision|7
6250930|NCT01953601|9939405|FG002|Part 1 (Base Study)|Physician Decision|4
6250931|NCT01953601|9939403|FG000|Part 1 (Base Study)|Screen failure|1
6250932|NCT01953601|9939404|FG001|Part 1 (Base Study)|Screen failure|0
6250933|NCT01953601|9939405|FG002|Part 1 (Base Study)|Screen failure|1
6250934|NCT01953601|9939403|FG000|Part 1 (Base Study)|Site discontinued study participation|2
6250935|NCT01953601|9939404|FG001|Part 1 (Base Study)|Site discontinued study participation|0
6250936|NCT01953601|9939405|FG002|Part 1 (Base Study)|Site discontinued study participation|0
6250937|NCT01953601|9939403|FG000|Part 1 (Base Study)|Study terminated by sponsor|174
6250938|NCT01953601|9939404|FG001|Part 1 (Base Study)|Study terminated by sponsor|169
6250939|NCT01953601|9939405|FG002|Part 1 (Base Study)|Study terminated by sponsor|179
6250940|NCT01953601|9939403|FG000|Part 1 (Base Study)|Discontinued due to caregiver withdrawal|7
6250941|NCT01953601|9939404|FG001|Part 1 (Base Study)|Discontinued due to caregiver withdrawal|8
6250942|NCT01953601|9939405|FG002|Part 1 (Base Study)|Discontinued due to caregiver withdrawal|10
6250943|NCT01953601|9939403|FG000|Part 1 (Base Study)|Subject moved|2
6250944|NCT01953601|9939404|FG001|Part 1 (Base Study)|Subject moved|2
6250945|NCT01953601|9939405|FG002|Part 1 (Base Study)|Subject moved|1
6250946|NCT01953601|9939403|FG000|Part 1 (Base Study)|Withdrawal by Subject|32
6250947|NCT01953601|9939404|FG001|Part 1 (Base Study)|Withdrawal by Subject|23
6250948|NCT01953601|9939405|FG002|Part 1 (Base Study)|Withdrawal by Subject|22
6250949|NCT01953601|9939403|FG000|Part 2 (Extension Study)|Adverse Event|1
6250950|NCT01953601|9939404|FG001|Part 2 (Extension Study)|Adverse Event|1
6250951|NCT01953601|9939405|FG002|Part 2 (Extension Study)|Adverse Event|10
6250952|NCT01953601|9939403|FG000|Part 2 (Extension Study)|Death|0
6250953|NCT01953601|9939404|FG001|Part 2 (Extension Study)|Death|3
6250954|NCT01953601|9939405|FG002|Part 2 (Extension Study)|Death|0
6250955|NCT01953601|9939403|FG000|Part 2 (Extension Study)|Lack of Efficacy|2
6250956|NCT01953601|9939404|FG001|Part 2 (Extension Study)|Lack of Efficacy|0
6250957|NCT01953601|9939405|FG002|Part 2 (Extension Study)|Lack of Efficacy|0
6250958|NCT01953601|9939403|FG000|Part 2 (Extension Study)|Lost to Follow-up|2
6250959|NCT01953601|9939404|FG001|Part 2 (Extension Study)|Lost to Follow-up|1
6250960|NCT01953601|9939405|FG002|Part 2 (Extension Study)|Lost to Follow-up|1
6250961|NCT01953601|9939403|FG000|Part 2 (Extension Study)|Physician Decision|2
6250962|NCT01953601|9939404|FG001|Part 2 (Extension Study)|Physician Decision|0
6250963|NCT01953601|9939405|FG002|Part 2 (Extension Study)|Physician Decision|2
6250964|NCT01953601|9939403|FG000|Part 2 (Extension Study)|Site discontinued study participation|0
6250965|NCT01953601|9939404|FG001|Part 2 (Extension Study)|Site discontinued study participation|1
6250966|NCT01953601|9939405|FG002|Part 2 (Extension Study)|Site discontinued study participation|1
6250967|NCT01953601|9939403|FG000|Part 2 (Extension Study)|Study terminated by sponsor|185
6250968|NCT01953601|9939404|FG001|Part 2 (Extension Study)|Study terminated by sponsor|178
6250969|NCT01953601|9939405|FG002|Part 2 (Extension Study)|Study terminated by sponsor|187
6250970|NCT01953601|9939403|FG000|Part 2 (Extension Study)|Discontinued due to caregiver withdrawal|1
6250971|NCT01953601|9939404|FG001|Part 2 (Extension Study)|Discontinued due to caregiver withdrawal|3
6250972|NCT01953601|9939405|FG002|Part 2 (Extension Study)|Discontinued due to caregiver withdrawal|0
6250973|NCT01953601|9939403|FG000|Part 2 (Extension Study)|Subject moved|0
6250974|NCT01953601|9939404|FG001|Part 2 (Extension Study)|Subject moved|0
6250975|NCT01953601|9939405|FG002|Part 2 (Extension Study)|Subject moved|1
6250976|NCT01953601|9939403|FG000|Part 2 (Extension Study)|Withdrawal by Subject|5
6250977|NCT01953601|9939404|FG001|Part 2 (Extension Study)|Withdrawal by Subject|4
6250978|NCT01953601|9939405|FG002|Part 2 (Extension Study)|Withdrawal by Subject|2
6250979|NCT01953692|9939425|FG000|Overall Study|Adverse Event|5
6250980|NCT01953692|9939426|FG001|Overall Study|Adverse Event|2
6250981|NCT01953692|9939427|FG002|Overall Study|Adverse Event|4
6250982|NCT01953692|9939428|FG003|Overall Study|Adverse Event|2
6250983|NCT01953692|9939429|FG004|Overall Study|Adverse Event|1
6250984|NCT01953692|9939430|FG005|Overall Study|Adverse Event|2
6250985|NCT01953692|9939431|FG006|Overall Study|Adverse Event|0
6250986|NCT01953692|9939432|FG007|Overall Study|Adverse Event|0
6250987|NCT01953692|9939433|FG008|Overall Study|Adverse Event|0
6250988|NCT01953692|9939425|FG000|Overall Study|Clinical Progression|0
6250989|NCT01953692|9939426|FG001|Overall Study|Clinical Progression|15
6250990|NCT01953692|9939427|FG002|Overall Study|Clinical Progression|7
6250991|NCT01953692|9939428|FG003|Overall Study|Clinical Progression|5
6250992|NCT01953692|9939429|FG004|Overall Study|Clinical Progression|0
6250993|NCT01953692|9939430|FG005|Overall Study|Clinical Progression|7
6250994|NCT01953692|9939431|FG006|Overall Study|Clinical Progression|20
6250995|NCT01953692|9939432|FG007|Overall Study|Clinical Progression|3
6250996|NCT01953692|9939433|FG008|Overall Study|Clinical Progression|3
6250997|NCT01953692|9939425|FG000|Overall Study|Death|5
6250998|NCT01953692|9939426|FG001|Overall Study|Death|0
6250999|NCT01953692|9939427|FG002|Overall Study|Death|2
6251000|NCT01953692|9939428|FG003|Overall Study|Death|2
6251001|NCT01953692|9939429|FG004|Overall Study|Death|1
6251002|NCT01953692|9939430|FG005|Overall Study|Death|3
6251003|NCT01953692|9939431|FG006|Overall Study|Death|6
6251004|NCT01953692|9939432|FG007|Overall Study|Death|2
6251005|NCT01953692|9939433|FG008|Overall Study|Death|1
6251006|NCT01953692|9939425|FG000|Overall Study|Excluded Medication|1
6251007|NCT01953692|9939426|FG001|Overall Study|Excluded Medication|0
6251008|NCT01953692|9939427|FG002|Overall Study|Excluded Medication|0
6251009|NCT01953692|9939428|FG003|Overall Study|Excluded Medication|0
6251010|NCT01953692|9939429|FG004|Overall Study|Excluded Medication|0
6251011|NCT01953692|9939430|FG005|Overall Study|Excluded Medication|0
6251012|NCT01953692|9939431|FG006|Overall Study|Excluded Medication|0
6251013|NCT01953692|9939432|FG007|Overall Study|Excluded Medication|0
6251014|NCT01953692|9939433|FG008|Overall Study|Excluded Medication|0
6251015|NCT01953692|9939425|FG000|Overall Study|Lost to Follow-up|1
6251016|NCT01953692|9939426|FG001|Overall Study|Lost to Follow-up|0
6251017|NCT01953692|9939427|FG002|Overall Study|Lost to Follow-up|3
6251018|NCT01953692|9939428|FG003|Overall Study|Lost to Follow-up|1
6251019|NCT01953692|9939429|FG004|Overall Study|Lost to Follow-up|0
6251020|NCT01953692|9939430|FG005|Overall Study|Lost to Follow-up|1
6251021|NCT01953692|9939431|FG006|Overall Study|Lost to Follow-up|0
6251022|NCT01953692|9939432|FG007|Overall Study|Lost to Follow-up|0
6251023|NCT01953692|9939433|FG008|Overall Study|Lost to Follow-up|0
6251024|NCT01953692|9939425|FG000|Overall Study|Physician Decision|11
6251025|NCT01953692|9939426|FG001|Overall Study|Physician Decision|4
6251026|NCT01953692|9939427|FG002|Overall Study|Physician Decision|2
6251027|NCT01953692|9939428|FG003|Overall Study|Physician Decision|2
6251028|NCT01953692|9939429|FG004|Overall Study|Physician Decision|1
6251029|NCT01953692|9939430|FG005|Overall Study|Physician Decision|2
6251030|NCT01953692|9939431|FG006|Overall Study|Physician Decision|4
6251031|NCT01953692|9939432|FG007|Overall Study|Physician Decision|1
6251032|NCT01953692|9939433|FG008|Overall Study|Physician Decision|0
6251033|NCT01953692|9939425|FG000|Overall Study|Protocol Violation|0
6251034|NCT01953692|9939426|FG001|Overall Study|Protocol Violation|2
6251035|NCT01953692|9939427|FG002|Overall Study|Protocol Violation|1
6251036|NCT01953692|9939428|FG003|Overall Study|Protocol Violation|0
6251037|NCT01953692|9939429|FG004|Overall Study|Protocol Violation|0
6251038|NCT01953692|9939430|FG005|Overall Study|Protocol Violation|0
6251039|NCT01953692|9939431|FG006|Overall Study|Protocol Violation|0
6251040|NCT01953692|9939432|FG007|Overall Study|Protocol Violation|1
6251041|NCT01953692|9939433|FG008|Overall Study|Protocol Violation|0
6251042|NCT01953692|9939425|FG000|Overall Study|Study for Cohort 5 Terminated by Sponsor|0
6251043|NCT01953692|9939426|FG001|Overall Study|Study for Cohort 5 Terminated by Sponsor|0
6251044|NCT01953692|9939427|FG002|Overall Study|Study for Cohort 5 Terminated by Sponsor|0
6251045|NCT01953692|9939428|FG003|Overall Study|Study for Cohort 5 Terminated by Sponsor|0
6251046|NCT01953692|9939429|FG004|Overall Study|Study for Cohort 5 Terminated by Sponsor|0
6251047|NCT01953692|9939430|FG005|Overall Study|Study for Cohort 5 Terminated by Sponsor|0
6251048|NCT01953692|9939431|FG006|Overall Study|Study for Cohort 5 Terminated by Sponsor|0
6251049|NCT01953692|9939432|FG007|Overall Study|Study for Cohort 5 Terminated by Sponsor|2
6251050|NCT01953692|9939433|FG008|Overall Study|Study for Cohort 5 Terminated by Sponsor|0
6251051|NCT01953692|9939425|FG000|Overall Study|Withdrawal by Subject|4
6251052|NCT01953692|9939426|FG001|Overall Study|Withdrawal by Subject|2
6251053|NCT01953692|9939427|FG002|Overall Study|Withdrawal by Subject|1
6251054|NCT01953692|9939428|FG003|Overall Study|Withdrawal by Subject|2
6251055|NCT01953692|9939429|FG004|Overall Study|Withdrawal by Subject|0
6251056|NCT01953692|9939430|FG005|Overall Study|Withdrawal by Subject|3
6251057|NCT01953692|9939431|FG006|Overall Study|Withdrawal by Subject|2
6251058|NCT01953692|9939432|FG007|Overall Study|Withdrawal by Subject|1
6251059|NCT01953692|9939433|FG008|Overall Study|Withdrawal by Subject|1
6251060|NCT01953783|9939463|FG000|Overall Study|Progressive disease|2
6251061|NCT01953913|9939477|FG000|Overall Study|Disease Progression|349
6251062|NCT01953913|9939477|FG000|Overall Study|Worsening of underlying cancer|22
6251063|NCT01953913|9939477|FG000|Overall Study|Adverse Event|20
6251064|NCT01953913|9939477|FG000|Overall Study|Protocol Violation|6
6251065|NCT01953913|9939477|FG000|Overall Study|Lost to Follow-up|4
6251066|NCT01953913|9939477|FG000|Overall Study|Withdrawal by Subject|32
6251067|NCT01953913|9939477|FG000|Overall Study|Other than listed|108
6251068|NCT01953913|9939477|FG000|Overall Study|Not Treated|1
6251069|NCT01954017|9939484|FG000|Overall Study|Adverse Event|0
6251070|NCT01954017|9939485|FG001|Overall Study|Adverse Event|0
6251071|NCT01954017|9939486|FG002|Overall Study|Adverse Event|1
6251072|NCT01954017|9939484|FG000|Overall Study|Death|2
6251073|NCT01954017|9939485|FG001|Overall Study|Death|1
6251074|NCT01954017|9939486|FG002|Overall Study|Death|1
6251075|NCT01954017|9939484|FG000|Overall Study|Withdrawal by Subject|0
6251076|NCT01954017|9939485|FG001|Overall Study|Withdrawal by Subject|1
6251077|NCT01954017|9939486|FG002|Overall Study|Withdrawal by Subject|0
6251078|NCT01954017|9939484|FG000|Overall Study|Protocol Violation|0
6251079|NCT01954017|9939485|FG001|Overall Study|Protocol Violation|3
6251080|NCT01954017|9939486|FG002|Overall Study|Protocol Violation|2
6251081|NCT01954017|9939484|FG000|Overall Study|Necrotizing enterocolitis|1
6251082|NCT01954017|9939485|FG001|Overall Study|Necrotizing enterocolitis|0
6251083|NCT01954017|9939486|FG002|Overall Study|Necrotizing enterocolitis|1
6251084|NCT01954017|9939484|FG000|Overall Study|Enteral intake stopped >7 days|0
6251085|NCT01954017|9939485|FG001|Overall Study|Enteral intake stopped >7 days|1
6251086|NCT01954017|9939486|FG002|Overall Study|Enteral intake stopped >7 days|1
6251087|NCT01954017|9939484|FG000|Overall Study|All other reasons|2
6251088|NCT01954017|9939485|FG001|Overall Study|All other reasons|2
6251089|NCT01954017|9939486|FG002|Overall Study|All other reasons|7
6251090|NCT01954056|9939522|FG000|Birth to 22-26 Mos. Corrected GA|Lost to Follow-up|1
6251091|NCT01954056|9939523|FG001|Birth to 22-26 Mos. Corrected GA|Lost to Follow-up|0
6251092|NCT01954082|9939531|FG000|Overall Study|Study Suspension|42
6251093|NCT01954082|9939532|FG001|Overall Study|Study Suspension|36
6251094|NCT01954082|9939531|FG000|Overall Study|Adverse Event|10
6251095|NCT01954082|9939532|FG001|Overall Study|Adverse Event|4
6251096|NCT01954082|9939531|FG000|Overall Study|Intolerance|0
6251097|NCT01954082|9939532|FG001|Overall Study|Intolerance|1
6251098|NCT01954082|9939531|FG000|Overall Study|Non-compliance|6
6251099|NCT01954082|9939532|FG001|Overall Study|Non-compliance|4
6251100|NCT01954082|9939531|FG000|Overall Study|Physician Decision|2
6251101|NCT01954082|9939532|FG001|Overall Study|Physician Decision|0
6251102|NCT01954082|9939531|FG000|Overall Study|Parent Decision|1
6251103|NCT01954082|9939532|FG001|Overall Study|Parent Decision|0
6251104|NCT01954082|9939531|FG000|Overall Study|Withdrawal by Subject|0
6251105|NCT01954082|9939532|FG001|Overall Study|Withdrawal by Subject|1
6251106|NCT01954082|9939531|FG000|Overall Study|Discontinued Early Prior to Transfer|3
6251107|NCT01954082|9939532|FG001|Overall Study|Discontinued Early Prior to Transfer|2
6251108|NCT01954082|9939531|FG000|Overall Study|Redirection of Care|0
6251109|NCT01954082|9939532|FG001|Overall Study|Redirection of Care|2
6251110|NCT01954082|9939531|FG000|Overall Study|Miscalculation of Final Dose Day|0
6251111|NCT01954082|9939532|FG001|Overall Study|Miscalculation of Final Dose Day|3
6251112|NCT01954082|9939531|FG000|Overall Study|Comfort Care|0
6251113|NCT01954082|9939532|FG001|Overall Study|Comfort Care|1
6086259|NCT00659880|9696123|FG000|Overall Study|Lost to Follow-up|5
6251114|NCT01954082|9939531|FG000|Overall Study|Infant Moved|0
6251115|NCT01954082|9939532|FG001|Overall Study|Infant Moved|1
6251116|NCT01954082|9939531|FG000|Overall Study|Randomized not Treated|4
6251117|NCT01954082|9939532|FG001|Overall Study|Randomized not Treated|2
6251118|NCT01954121|9939540|FG000|Overall Study|Lack of Efficacy|94
6251119|NCT01954121|9939541|FG001|Overall Study|Lack of Efficacy|41
6251120|NCT01954121|9939540|FG000|Overall Study|Protocol Violation|0
6251121|NCT01954121|9939541|FG001|Overall Study|Protocol Violation|2
6251122|NCT01954121|9939540|FG000|Overall Study|Lost to Follow-up|5
6251123|NCT01954121|9939541|FG001|Overall Study|Lost to Follow-up|6
6251124|NCT01954121|9939540|FG000|Overall Study|Withdrawal by Subject|18
6251125|NCT01954121|9939541|FG001|Overall Study|Withdrawal by Subject|12
6251126|NCT01954121|9939540|FG000|Overall Study|Pregnancy|1
6251127|NCT01954121|9939541|FG001|Overall Study|Pregnancy|1
6251128|NCT01954121|9939540|FG000|Overall Study|AE, serious fatal|1
6251129|NCT01954121|9939541|FG001|Overall Study|AE, serious fatal|0
6251130|NCT01954121|9939540|FG000|Overall Study|AE, non-serious non-fatal|5
6251131|NCT01954121|9939541|FG001|Overall Study|AE, non-serious non-fatal|22
6251132|NCT01954121|9939540|FG000|Overall Study|SAE, non-fatal|1
6251133|NCT01954121|9939541|FG001|Overall Study|SAE, non-fatal|4
6251134|NCT01954121|9939540|FG000|Overall Study|Non-compliant with study procedures|1
6251135|NCT01954121|9939541|FG001|Overall Study|Non-compliant with study procedures|0
6251136|NCT01954121|9939540|FG000|Overall Study|Non-compliant patient|1
6251137|NCT01954121|9939541|FG001|Overall Study|Non-compliant patient|1
6251138|NCT01954121|9939540|FG000|Overall Study|Subject did not follow instructions|0
6251139|NCT01954121|9939541|FG001|Overall Study|Subject did not follow instructions|2
6251140|NCT01954251|9939549|FG000|Overall Study|Adverse Event|5
6251141|NCT01954251|9939550|FG001|Overall Study|Adverse Event|7
6251142|NCT01954251|9939549|FG000|Overall Study|Lost to Follow-up|6
6251143|NCT01954251|9939550|FG001|Overall Study|Lost to Follow-up|6
6251144|NCT01954251|9939549|FG000|Overall Study|Withdrawal by Subject|2
6251145|NCT01954251|9939550|FG001|Overall Study|Withdrawal by Subject|6
6251146|NCT01954342|9939578|FG000|Overall Study|Missing data from 13-16week study visit|0
6251147|NCT01954342|9939579|FG001|Overall Study|Missing data from 13-16week study visit|0
6251148|NCT01954342|9939580|FG002|Overall Study|Missing data from 13-16week study visit|0
6270839|NCT02157948|9972292|FG001|Overall Study|Lost to Follow-up|2
6086260|NCT00659984|9696137|FG000|Overall Study|Adverse Event|1
6086261|NCT00660010|9696147|FG000|Overall Study|Withdrawal by Subject|2
6086262|NCT00660010|9696147|FG000|Overall Study|Lost to Follow-up|3
6189511|NCT01400698|9844816|FG005|Overall Study|Adverse Event|0
6189512|NCT01400698|9844811|FG000|Overall Study|Other|4
6189513|NCT01400698|9844812|FG001|Overall Study|Other|2
6189514|NCT01400698|9844813|FG002|Overall Study|Other|0
6189515|NCT01400698|9844814|FG003|Overall Study|Other|2
6189516|NCT01400698|9844815|FG004|Overall Study|Other|1
6189517|NCT01400698|9844816|FG005|Overall Study|Other|0
6189518|NCT01400815|9844828|FG000|Overall Study|Adverse Event|3
6189519|NCT01400815|9844829|FG001|Overall Study|Adverse Event|0
6189520|NCT01400815|9844828|FG000|Overall Study|Death|0
6189521|NCT01400815|9844829|FG001|Overall Study|Death|1
6189522|NCT01400815|9844828|FG000|Overall Study|Lost to Follow-up|18
6189523|NCT01400815|9844829|FG001|Overall Study|Lost to Follow-up|11
6189524|NCT01400815|9844828|FG000|Overall Study|Protocol Violation|0
6189525|NCT01400815|9844829|FG001|Overall Study|Protocol Violation|1
6189526|NCT01400815|9844828|FG000|Overall Study|Physician Decision|1
6189527|NCT01400815|9844829|FG001|Overall Study|Physician Decision|0
6189528|NCT01400815|9844828|FG000|Overall Study|Withdrawal by Subject|15
6189529|NCT01400815|9844829|FG001|Overall Study|Withdrawal by Subject|8
6189530|NCT01400815|9844828|FG000|Overall Study|Subject in jail|1
6189531|NCT01400815|9844829|FG001|Overall Study|Subject in jail|0
6189532|NCT01400841|9844835|FG000|Initial Study Phase (6 Months)|Death|1
6189533|NCT01400841|9844835|FG000|Extended Study Phase (2 Years)|Adverse Event|2
6189534|NCT01400893|9844845|FG000|Overall Study|Death|27
6189535|NCT01400893|9844846|FG001|Overall Study|Death|21
6189536|NCT01400893|9844845|FG000|Overall Study|Lost to Follow-up|0
6189537|NCT01400893|9844846|FG001|Overall Study|Lost to Follow-up|6
6189538|NCT01400919|9844867|FG000|Overall Study|Withdrawal by Subject|4
6189539|NCT01400919|9844867|FG000|Overall Study|Lost to Follow-up|2
6189540|NCT01400919|9844867|FG000|Overall Study|Missed visit|2
6189541|NCT01400932|9844873|FG000|Overall Study|Adverse Event|10
6189542|NCT01400932|9844874|FG001|Overall Study|Adverse Event|5
6189543|NCT01400932|9844873|FG000|Overall Study|Lack of Efficacy|0
6189544|NCT01400932|9844874|FG001|Overall Study|Lack of Efficacy|3
6189545|NCT01400932|9844873|FG000|Overall Study|Withdrawal by Subject|2
6189546|NCT01400932|9844874|FG001|Overall Study|Withdrawal by Subject|6
6189547|NCT01400932|9844873|FG000|Overall Study|Lost to Follow-up|1
6189548|NCT01400932|9844874|FG001|Overall Study|Lost to Follow-up|0
6189549|NCT01400932|9844873|FG000|Overall Study|Protocol Deviation|0
6189550|NCT01400932|9844874|FG001|Overall Study|Protocol Deviation|1
6189551|NCT01400932|9844873|FG000|Overall Study|Met Protocol-defined Stopping Criteria|1
6189552|NCT01400932|9844874|FG001|Overall Study|Met Protocol-defined Stopping Criteria|0
6189553|NCT01400958|9844882|FG000|Overall Study|Physician Decision|0
6189554|NCT01400958|9844883|FG001|Overall Study|Physician Decision|1
6189555|NCT01400958|9844882|FG000|Overall Study|Withdrawal by Subject|0
6189556|NCT01400958|9844883|FG001|Overall Study|Withdrawal by Subject|1
6189557|NCT01400958|9844882|FG000|Overall Study|Adverse Event|1
6189558|NCT01400958|9844883|FG001|Overall Study|Adverse Event|0
6189559|NCT01400971|9844889|FG000|Overall Study|Death|82
6189560|NCT01400971|9844889|FG000|Overall Study|Lost to Follow-up|196
6189561|NCT01400971|9844889|FG000|Overall Study|Lost to follow up + Subject Decision|2
6189562|NCT01400971|9844889|FG000|Overall Study|Physician Decision|57
6189563|NCT01400971|9844889|FG000|Overall Study|Withdrawal by Subject|158
6189564|NCT01400971|9844889|FG000|Overall Study|Other|422
6189565|NCT01401010|9844895|FG000|Overall Study|Could not interpret assay results|1
6189566|NCT01401010|9844896|FG001|Overall Study|Could not interpret assay results|0
6189567|NCT01401062|9844915|FG000|Overall Study|Death|9
6189568|NCT01401062|9844916|FG001|Overall Study|Death|7
6189569|NCT01401062|9844915|FG000|Overall Study|Physician Decision|1
6189570|NCT01401062|9844916|FG001|Overall Study|Physician Decision|0
6189571|NCT01401062|9844915|FG000|Overall Study|Withdrawal by Subject|1
6189572|NCT01401062|9844916|FG001|Overall Study|Withdrawal by Subject|1
6189573|NCT01401153|9844933|FG000|First Test Day|Learning disabilities; illness|1
6189574|NCT01401153|9844934|FG001|First Test Day|Learning disabilities; illness|10
6189575|NCT01401153|9844933|FG000|Second Test Day|illness|0
6189576|NCT01401153|9844934|FG001|Second Test Day|illness|5
6189577|NCT01401283|9844982|FG000|Overall Study|surgery cancelled|5
6189578|NCT01401283|9844983|FG001|Overall Study|surgery cancelled|8
6189579|NCT01401283|9844982|FG000|Overall Study|preoperative arrhythmia|5
6189580|NCT01401283|9844983|FG001|Overall Study|preoperative arrhythmia|0
6189581|NCT01401283|9844982|FG000|Overall Study|no central venous access|0
6189582|NCT01401283|9844983|FG001|Overall Study|no central venous access|1
6189583|NCT01401283|9844982|FG000|Overall Study|suspicion of malignant hyperthermia|0
6189584|NCT01401283|9844983|FG001|Overall Study|suspicion of malignant hyperthermia|1
6251149|NCT01954342|9939581|FG003|Overall Study|Missing data from 13-16week study visit|1
6251150|NCT01954342|9939578|FG000|Overall Study|Miscarriage|0
6251151|NCT01954342|9939579|FG001|Overall Study|Miscarriage|0
6251152|NCT01954342|9939580|FG002|Overall Study|Miscarriage|0
6251153|NCT01954342|9939581|FG003|Overall Study|Miscarriage|3
6251154|NCT01954342|9939578|FG000|Overall Study|Lost to Follow-up|0
6251155|NCT01954342|9939579|FG001|Overall Study|Lost to Follow-up|0
6251156|NCT01954342|9939580|FG002|Overall Study|Lost to Follow-up|0
6251157|NCT01954342|9939581|FG003|Overall Study|Lost to Follow-up|5
6251158|NCT01954342|9939578|FG000|Overall Study|Preterm delivery|0
6251159|NCT01954342|9939579|FG001|Overall Study|Preterm delivery|0
6251160|NCT01954342|9939580|FG002|Overall Study|Preterm delivery|0
6251161|NCT01954342|9939581|FG003|Overall Study|Preterm delivery|3
6251162|NCT01954342|9939578|FG000|Overall Study|Pre-eclampsia|0
6251163|NCT01954342|9939579|FG001|Overall Study|Pre-eclampsia|0
6251164|NCT01954342|9939580|FG002|Overall Study|Pre-eclampsia|0
6251165|NCT01954342|9939581|FG003|Overall Study|Pre-eclampsia|4
6086263|NCT00660010|9696147|FG000|Overall Study|Adverse Event|1
6251166|NCT01954342|9939578|FG000|Overall Study|Unreliable Data|0
6251167|NCT01954342|9939579|FG001|Overall Study|Unreliable Data|0
6251168|NCT01954342|9939580|FG002|Overall Study|Unreliable Data|0
6251169|NCT01954342|9939581|FG003|Overall Study|Unreliable Data|2
6251170|NCT01954394|9939593|FG000|Overall Study|Enrolled but not treated|1
6251171|NCT01954394|9939594|FG001|Overall Study|Enrolled but not treated|0
6251172|NCT01954394|9939593|FG000|Overall Study|Adverse Event|10
6251173|NCT01954394|9939594|FG001|Overall Study|Adverse Event|23
6251174|NCT01954394|9939593|FG000|Overall Study|Poor compliance to protocol|7
6251175|NCT01954394|9939594|FG001|Overall Study|Poor compliance to protocol|7
6251176|NCT01954394|9939593|FG000|Overall Study|Participant Moved|0
6251177|NCT01954394|9939594|FG001|Overall Study|Participant Moved|4
6251178|NCT01954394|9939593|FG000|Overall Study|Related to Study Drug administration|2
6251179|NCT01954394|9939594|FG001|Overall Study|Related to Study Drug administration|2
6251180|NCT01954394|9939593|FG000|Overall Study|Other than specified above|10
6251181|NCT01954394|9939594|FG001|Overall Study|Other than specified above|21
6251182|NCT01954745|9939615|FG000|Overall Study|Radiological Progression|11
6251183|NCT01954745|9939615|FG000|Overall Study|Clinical Progression|5
6251184|NCT01954745|9939615|FG000|Overall Study|Adverse Event|2
6251185|NCT01954745|9939615|FG000|Overall Study|Death|1
6251186|NCT01954771|9939622|FG000|Overall Study|Missing HbA1c of end-point|1
6251187|NCT01954771|9939623|FG001|Overall Study|Missing HbA1c of end-point|1
6251188|NCT01954771|9939624|FG002|Overall Study|Missing HbA1c of end-point|0
6251189|NCT01954771|9939622|FG000|Overall Study|Missing CGMS of end-point|1
6251190|NCT01954771|9939623|FG001|Overall Study|Missing CGMS of end-point|1
6251191|NCT01954771|9939624|FG002|Overall Study|Missing CGMS of end-point|0
6251192|NCT01954771|9939622|FG000|Overall Study|Missing HbA1c and CGMS of end-point|5
6251193|NCT01954771|9939623|FG001|Overall Study|Missing HbA1c and CGMS of end-point|1
6251194|NCT01954771|9939624|FG002|Overall Study|Missing HbA1c and CGMS of end-point|3
6251195|NCT01954927|9939637|FG000|Overall Study|Withdrawal by Subject|3
6251196|NCT01954927|9939638|FG001|Overall Study|Withdrawal by Subject|1
6251197|NCT01955005|9939646|FG000|Overall Study|Withdrawal by Subject|3
6251198|NCT01955005|9939647|FG001|Overall Study|Withdrawal by Subject|5
6251199|NCT01955044|9939656|FG000|Overall Study|Death|1
6251200|NCT01955044|9939657|FG001|Overall Study|Death|1
6251201|NCT01955044|9939658|FG002|Overall Study|Death|0
6251202|NCT01955083|9939668|FG000|Overall Study|Lost to Follow-up|1
6251203|NCT01955083|9939669|FG001|Overall Study|Lost to Follow-up|1
6251204|NCT01955122|9939701|FG000|Overall Study|Physician Decision|5
6251205|NCT01955122|9939702|FG001|Overall Study|Physician Decision|5
6251206|NCT01955161|9939717|FG000|Overall Study|Withdrawal before treatment|2
6251207|NCT01955161|9939718|FG001|Overall Study|Withdrawal before treatment|0
6251208|NCT01955161|9939719|FG002|Overall Study|Withdrawal before treatment|1
6251209|NCT01955161|9939717|FG000|Overall Study|Adverse Event|10
6251210|NCT01955161|9939718|FG001|Overall Study|Adverse Event|14
6251211|NCT01955161|9939719|FG002|Overall Study|Adverse Event|15
6251212|NCT01955161|9939717|FG000|Overall Study|Death|1
6251213|NCT01955161|9939718|FG001|Overall Study|Death|1
6251214|NCT01955161|9939719|FG002|Overall Study|Death|3
6251215|NCT01955161|9939717|FG000|Overall Study|Withdrawal by Subject|9
6251216|NCT01955161|9939718|FG001|Overall Study|Withdrawal by Subject|8
6251217|NCT01955161|9939719|FG002|Overall Study|Withdrawal by Subject|12
6251218|NCT01955161|9939717|FG000|Overall Study|Protocol Violation|2
6251219|NCT01955161|9939718|FG001|Overall Study|Protocol Violation|0
6251220|NCT01955161|9939719|FG002|Overall Study|Protocol Violation|0
6251221|NCT01955161|9939717|FG000|Overall Study|Other reason: physician decision|0
6251222|NCT01955161|9939718|FG001|Overall Study|Other reason: physician decision|1
6251223|NCT01955161|9939719|FG002|Overall Study|Other reason: physician decision|1
6251224|NCT01955161|9939717|FG000|Overall Study|Other reason: disallowed medication|1
6086264|NCT00660010|9696147|FG000|Overall Study|Noncompliance with visit schedule|3
6251225|NCT01955161|9939718|FG001|Overall Study|Other reason: disallowed medication|0
6251226|NCT01955161|9939719|FG002|Overall Study|Other reason: disallowed medication|1
6251227|NCT01955161|9939717|FG000|Overall Study|Other reason: caregiver unavailable|1
6251228|NCT01955161|9939718|FG001|Overall Study|Other reason: caregiver unavailable|0
6251229|NCT01955161|9939719|FG002|Overall Study|Other reason: caregiver unavailable|0
6251230|NCT01955161|9939717|FG000|Overall Study|Other reason: moved to nursing home|0
6251231|NCT01955161|9939718|FG001|Overall Study|Other reason: moved to nursing home|1
6251232|NCT01955161|9939719|FG002|Overall Study|Other reason: moved to nursing home|0
6251233|NCT01955161|9939717|FG000|Overall Study|Other reason: insufficient compliance|0
6251234|NCT01955161|9939718|FG001|Overall Study|Other reason: insufficient compliance|0
6251235|NCT01955161|9939719|FG002|Overall Study|Other reason: insufficient compliance|1
6251236|NCT01955161|9939717|FG000|Overall Study|Other reason: primary biliary cirrhosis|1
6251237|NCT01955161|9939718|FG001|Overall Study|Other reason: primary biliary cirrhosis|0
6251238|NCT01955161|9939719|FG002|Overall Study|Other reason: primary biliary cirrhosis|0
6251239|NCT01955161|9939717|FG000|Overall Study|Other reason: patient's will|0
6251240|NCT01955161|9939718|FG001|Overall Study|Other reason: patient's will|0
6251241|NCT01955161|9939719|FG002|Overall Study|Other reason: patient's will|1
6251242|NCT01955707|9939811|FG000|Overall Study|Adverse Event|1
6251243|NCT01955707|9939812|FG001|Overall Study|Adverse Event|2
6251244|NCT01955707|9939811|FG000|Overall Study|Lost to Follow-up|2
6251245|NCT01955707|9939812|FG001|Overall Study|Lost to Follow-up|1
6251246|NCT01955707|9939811|FG000|Overall Study|Withdrawal by Subject|0
6251247|NCT01955707|9939812|FG001|Overall Study|Withdrawal by Subject|3
6251248|NCT01955707|9939811|FG000|Overall Study|Death|13
6251249|NCT01955707|9939812|FG001|Overall Study|Death|14
6251250|NCT01955707|9939811|FG000|Overall Study|Other|4
6251251|NCT01955707|9939812|FG001|Overall Study|Other|2
6251252|NCT01955733|9939872|FG000|Period 1|Lost to Follow-up|1
6251253|NCT01955733|9939873|FG001|Period 1|Lost to Follow-up|0
6251254|NCT01955733|9939874|FG002|Period 1|Lost to Follow-up|0
6251255|NCT01955733|9939872|FG000|Period 2|Adverse Event|1
6251256|NCT01955733|9939873|FG001|Period 2|Adverse Event|0
6251257|NCT01955733|9939874|FG002|Period 2|Adverse Event|0
6251258|NCT01955733|9939872|FG000|Period 2|Physician Decision|0
6251259|NCT01955733|9939873|FG001|Period 2|Physician Decision|0
6251260|NCT01955733|9939874|FG002|Period 2|Physician Decision|1
6251261|NCT01955733|9939872|FG000|Period 2|Withdrawal by Subject|1
6251262|NCT01955733|9939873|FG001|Period 2|Withdrawal by Subject|3
6251263|NCT01955733|9939874|FG002|Period 2|Withdrawal by Subject|2
6251264|NCT01955733|9939872|FG000|Period 2|Study terminated by sponsor|8
6251265|NCT01955733|9939873|FG001|Period 2|Study terminated by sponsor|14
6251266|NCT01955733|9939874|FG002|Period 2|Study terminated by sponsor|16
6251267|NCT01955733|9939872|FG000|Period 2|Lost to Follow-up|2
6251268|NCT01955733|9939873|FG001|Period 2|Lost to Follow-up|0
6251269|NCT01955733|9939874|FG002|Period 2|Lost to Follow-up|0
6251270|NCT01955733|9939872|FG000|Period 2|Other not defined above|0
6251271|NCT01955733|9939873|FG001|Period 2|Other not defined above|2
6251272|NCT01955733|9939874|FG002|Period 2|Other not defined above|2
6251273|NCT01956123|9939918|FG000|COS Cycle 2|Protocol Violation|8
6251274|NCT01956123|9939919|FG001|COS Cycle 2|Protocol Violation|3
6251275|NCT01956123|9939920|FG002|COS Cycle 2|Protocol Violation|0
6251276|NCT01956123|9939921|FG003|COS Cycle 2|Protocol Violation|0
6251277|NCT01956123|9939918|FG000|COS Cycle 2|Adverse Event|3
6251278|NCT01956123|9939919|FG001|COS Cycle 2|Adverse Event|4
6251279|NCT01956123|9939920|FG002|COS Cycle 2|Adverse Event|0
6251280|NCT01956123|9939921|FG003|COS Cycle 2|Adverse Event|0
6251281|NCT01956123|9939918|FG000|COS Cycle 2|Personal Reasons|2
6251282|NCT01956123|9939919|FG001|COS Cycle 2|Personal Reasons|0
6251283|NCT01956123|9939920|FG002|COS Cycle 2|Personal Reasons|0
6251284|NCT01956123|9939921|FG003|COS Cycle 2|Personal Reasons|0
6251285|NCT01956123|9939918|FG000|COS Cycle 2|Withdrawal by Subject|1
6251286|NCT01956123|9939919|FG001|COS Cycle 2|Withdrawal by Subject|0
6251287|NCT01956123|9939920|FG002|COS Cycle 2|Withdrawal by Subject|0
6251288|NCT01956123|9939921|FG003|COS Cycle 2|Withdrawal by Subject|0
6251289|NCT01956123|9939918|FG000|COS Cycle 3|Protocol Violation|0
6251290|NCT01956123|9939919|FG001|COS Cycle 3|Protocol Violation|0
6251291|NCT01956123|9939920|FG002|COS Cycle 3|Protocol Violation|2
6251292|NCT01956123|9939921|FG003|COS Cycle 3|Protocol Violation|1
6251293|NCT01956123|9939918|FG000|COS Cycle 3|Adverse Event|0
6251294|NCT01956123|9939919|FG001|COS Cycle 3|Adverse Event|0
6251295|NCT01956123|9939920|FG002|COS Cycle 3|Adverse Event|3
6251296|NCT01956123|9939921|FG003|COS Cycle 3|Adverse Event|0
6251297|NCT01956123|9939918|FG000|COS Cycle 3|Personal Reasons|0
6251298|NCT01956123|9939919|FG001|COS Cycle 3|Personal Reasons|0
6251299|NCT01956123|9939920|FG002|COS Cycle 3|Personal Reasons|1
6251300|NCT01956123|9939921|FG003|COS Cycle 3|Personal Reasons|0
6251301|NCT01956123|9939918|FG000|COS Cycle 3|Withdrawal by Subject|0
6251302|NCT01956123|9939919|FG001|COS Cycle 3|Withdrawal by Subject|0
6251303|NCT01956123|9939920|FG002|COS Cycle 3|Withdrawal by Subject|0
6251304|NCT01956123|9939921|FG003|COS Cycle 3|Withdrawal by Subject|1
6251305|NCT01956240|9939934|FG000|Overall Study|Lost to Follow-up|6
6251306|NCT01956240|9939935|FG001|Overall Study|Lost to Follow-up|20
6251307|NCT01956240|9939934|FG000|Overall Study|Adverse Event|17
6251308|NCT01956240|9939935|FG001|Overall Study|Adverse Event|4
6251309|NCT01956773|9939960|FG000|Overall Study|Lost to Follow-up|628
6251310|NCT01956773|9939961|FG001|Overall Study|Lost to Follow-up|1
6251311|NCT01957111|9939974|FG000|Overall Study|Withdrawal by Subject|1
6251312|NCT01957111|9939975|FG001|Overall Study|Withdrawal by Subject|1
6251313|NCT01957137|9939981|FG000|Randomized Portion|Adverse Event|1
6251314|NCT01957137|9939981|FG000|Randomized Portion|Withdrawal by Subject|1
6251315|NCT01957150|9939995|FG000|Overall Study|Adverse Event|23
6251316|NCT01957150|9939996|FG001|Overall Study|Adverse Event|20
6251317|NCT01957150|9939995|FG000|Overall Study|Withdrawal by Subject|13
6251318|NCT01957150|9939996|FG001|Overall Study|Withdrawal by Subject|17
6251319|NCT01957150|9939995|FG000|Overall Study|Physician Decision|3
6251320|NCT01957150|9939996|FG001|Overall Study|Physician Decision|6
6251321|NCT01957150|9939995|FG000|Overall Study|Lost to Follow-up|4
6251322|NCT01957150|9939996|FG001|Overall Study|Lost to Follow-up|4
6251323|NCT01957150|9939995|FG000|Overall Study|Protocol Violation|1
6251324|NCT01957150|9939996|FG001|Overall Study|Protocol Violation|0
6251325|NCT01957150|9939995|FG000|Overall Study|Lack of Efficacy|11
6251326|NCT01957150|9939996|FG001|Overall Study|Lack of Efficacy|11
6251327|NCT01957163|9940005|FG000|Overall Study|Adverse Event|5
6251328|NCT01957163|9940006|FG001|Overall Study|Adverse Event|2
6251329|NCT01957163|9940007|FG002|Overall Study|Adverse Event|4
6251330|NCT01957163|9940005|FG000|Overall Study|Lack of Efficacy|5
6251331|NCT01957163|9940006|FG001|Overall Study|Lack of Efficacy|4
6251332|NCT01957163|9940007|FG002|Overall Study|Lack of Efficacy|9
6251333|NCT01957163|9940005|FG000|Overall Study|Protocol Violation|1
6251334|NCT01957163|9940006|FG001|Overall Study|Protocol Violation|2
6251335|NCT01957163|9940007|FG002|Overall Study|Protocol Violation|0
6251336|NCT01957163|9940005|FG000|Overall Study|Met Protocol-Defined Stopping Criteria|0
6251337|NCT01957163|9940006|FG001|Overall Study|Met Protocol-Defined Stopping Criteria|0
6251338|NCT01957163|9940007|FG002|Overall Study|Met Protocol-Defined Stopping Criteria|1
6251339|NCT01957163|9940005|FG000|Overall Study|Lost to Follow-up|0
6251340|NCT01957163|9940006|FG001|Overall Study|Lost to Follow-up|1
6251341|NCT01957163|9940007|FG002|Overall Study|Lost to Follow-up|0
6251342|NCT01957163|9940005|FG000|Overall Study|Withdrawal by Subject|4
6251343|NCT01957163|9940006|FG001|Overall Study|Withdrawal by Subject|2
6251344|NCT01957163|9940007|FG002|Overall Study|Withdrawal by Subject|4
6251345|NCT01957202|9940015|FG000|Treatment Period 2 (8 Days)|Withdrawal by Subject|0
6251346|NCT01957202|9940016|FG001|Treatment Period 2 (8 Days)|Withdrawal by Subject|1
6251347|NCT01957202|9940017|FG002|Treatment Period 2 (8 Days)|Withdrawal by Subject|0
6251348|NCT01957202|9940018|FG003|Treatment Period 2 (8 Days)|Withdrawal by Subject|0
6251349|NCT01957202|9940019|FG004|Treatment Period 2 (8 Days)|Withdrawal by Subject|0
6251350|NCT01957202|9940020|FG005|Treatment Period 2 (8 Days)|Withdrawal by Subject|0
6251351|NCT01957202|9940021|FG006|Treatment Period 2 (8 Days)|Withdrawal by Subject|0
6251352|NCT01957202|9940022|FG007|Treatment Period 2 (8 Days)|Withdrawal by Subject|0
6251353|NCT01957202|9940023|FG008|Treatment Period 2 (8 Days)|Withdrawal by Subject|0
6251354|NCT01957202|9940024|FG009|Treatment Period 2 (8 Days)|Withdrawal by Subject|0
6251355|NCT01957202|9940025|FG010|Treatment Period 2 (8 Days)|Withdrawal by Subject|0
6251356|NCT01957202|9940026|FG011|Treatment Period 2 (8 Days)|Withdrawal by Subject|0
6251357|NCT01957202|9940027|FG012|Treatment Period 2 (8 Days)|Withdrawal by Subject|0
6251358|NCT01957202|9940028|FG013|Treatment Period 2 (8 Days)|Withdrawal by Subject|0
6251359|NCT01957202|9940029|FG014|Treatment Period 2 (8 Days)|Withdrawal by Subject|0
6251360|NCT01957202|9940030|FG015|Treatment Period 2 (8 Days)|Withdrawal by Subject|0
6251361|NCT01957202|9940031|FG016|Treatment Period 2 (8 Days)|Withdrawal by Subject|1
6251362|NCT01957202|9940032|FG017|Treatment Period 2 (8 Days)|Withdrawal by Subject|0
6251363|NCT01957202|9940015|FG000|Treatment Period 3 (8 Days)|Adverse Event|0
6251364|NCT01957202|9940016|FG001|Treatment Period 3 (8 Days)|Adverse Event|0
6251365|NCT01957202|9940017|FG002|Treatment Period 3 (8 Days)|Adverse Event|0
6251366|NCT01957202|9940018|FG003|Treatment Period 3 (8 Days)|Adverse Event|0
6251367|NCT01957202|9940019|FG004|Treatment Period 3 (8 Days)|Adverse Event|0
6251368|NCT01957202|9940020|FG005|Treatment Period 3 (8 Days)|Adverse Event|0
6251369|NCT01957202|9940021|FG006|Treatment Period 3 (8 Days)|Adverse Event|0
6251370|NCT01957202|9940022|FG007|Treatment Period 3 (8 Days)|Adverse Event|0
6251371|NCT01957202|9940023|FG008|Treatment Period 3 (8 Days)|Adverse Event|0
6251372|NCT01957202|9940024|FG009|Treatment Period 3 (8 Days)|Adverse Event|0
6251373|NCT01957202|9940025|FG010|Treatment Period 3 (8 Days)|Adverse Event|0
6251374|NCT01957202|9940026|FG011|Treatment Period 3 (8 Days)|Adverse Event|0
6251375|NCT01957202|9940027|FG012|Treatment Period 3 (8 Days)|Adverse Event|0
6251376|NCT01957202|9940028|FG013|Treatment Period 3 (8 Days)|Adverse Event|0
6251377|NCT01957202|9940029|FG014|Treatment Period 3 (8 Days)|Adverse Event|0
6251378|NCT01957202|9940030|FG015|Treatment Period 3 (8 Days)|Adverse Event|0
6251379|NCT01957202|9940031|FG016|Treatment Period 3 (8 Days)|Adverse Event|1
6251380|NCT01957202|9940032|FG017|Treatment Period 3 (8 Days)|Adverse Event|0
6251381|NCT01957215|9940044|FG000|Overall Study|Adverse Event|2
6251382|NCT01957215|9940045|FG001|Overall Study|Adverse Event|2
6251383|NCT01957215|9940044|FG000|Overall Study|Lost to Follow-up|3
6251384|NCT01957215|9940045|FG001|Overall Study|Lost to Follow-up|3
6251385|NCT01957215|9940044|FG000|Overall Study|Protocol Violation|1
6251386|NCT01957215|9940045|FG001|Overall Study|Protocol Violation|2
6251387|NCT01957215|9940044|FG000|Overall Study|Withdrawal by Subject|7
6251388|NCT01957215|9940045|FG001|Overall Study|Withdrawal by Subject|5
6251389|NCT01957397|9940068|FG000|Test Period 1|sudden leakage/small bag|1
6251390|NCT01957397|9940069|FG001|Test Period 1|sudden leakage/small bag|1
6251391|NCT01957397|9940068|FG000|Test Period 1|Withdrawal by Subject|1
6251392|NCT01957397|9940069|FG001|Test Period 1|Withdrawal by Subject|0
6251393|NCT01957397|9940068|FG000|Test Period 2|Adverse Event|0
6251394|NCT01957397|9940069|FG001|Test Period 2|Adverse Event|1
6251395|NCT01957397|9940068|FG000|Test Period 3|Adverse Event|1
6251396|NCT01957397|9940069|FG001|Test Period 3|Adverse Event|2
6251397|NCT01957397|9940068|FG000|Test Period 3|the adhesive did not work|1
6251398|NCT01957397|9940069|FG001|Test Period 3|the adhesive did not work|0
6251399|NCT01957462|9940083|FG000|Test Period 1|Withdrawal by Subject|1
6251400|NCT01957462|9940084|FG001|Test Period 1|Withdrawal by Subject|0
6251401|NCT01957462|9940083|FG000|Test Period 1|Adverse Event|1
6251402|NCT01957462|9940084|FG001|Test Period 1|Adverse Event|0
6251403|NCT01957475|9940090|FG000|Test Period 1|Withdrawal by Subject|1
6251404|NCT01957475|9940091|FG001|Test Period 1|Withdrawal by Subject|0
6251405|NCT01957475|9940090|FG000|Test Period 1|Other|1
6251406|NCT01957475|9940091|FG001|Test Period 1|Other|0
6251407|NCT01957475|9940090|FG000|Test Period 1|Lack of Efficacy|0
6251408|NCT01957475|9940091|FG001|Test Period 1|Lack of Efficacy|1
6251409|NCT01957475|9940090|FG000|Test Period 2|Adverse Event|1
6251410|NCT01957475|9940091|FG001|Test Period 2|Adverse Event|0
6251411|NCT01957488|9940097|FG000|Test Period 1 (2 Weeks)|Lost to Follow-up|2
6251412|NCT01957488|9940098|FG001|Test Period 1 (2 Weeks)|Lost to Follow-up|0
6251413|NCT01957488|9940099|FG002|Test Period 1 (2 Weeks)|Lost to Follow-up|1
6251414|NCT01957488|9940100|FG003|Test Period 1 (2 Weeks)|Lost to Follow-up|1
6251415|NCT01957488|9940101|FG004|Test Period 1 (2 Weeks)|Lost to Follow-up|0
6251416|NCT01957488|9940102|FG005|Test Period 1 (2 Weeks)|Lost to Follow-up|0
6251417|NCT01957488|9940097|FG000|Test Period 1 (2 Weeks)|Protocol Violation|1
6251418|NCT01957488|9940098|FG001|Test Period 1 (2 Weeks)|Protocol Violation|2
6251419|NCT01957488|9940099|FG002|Test Period 1 (2 Weeks)|Protocol Violation|2
6251420|NCT01957488|9940100|FG003|Test Period 1 (2 Weeks)|Protocol Violation|1
6251421|NCT01957488|9940101|FG004|Test Period 1 (2 Weeks)|Protocol Violation|0
6251422|NCT01957488|9940102|FG005|Test Period 1 (2 Weeks)|Protocol Violation|3
6251423|NCT01957488|9940097|FG000|Test Period 1 (2 Weeks)|Adverse Event|0
6251424|NCT01957488|9940098|FG001|Test Period 1 (2 Weeks)|Adverse Event|1
6251425|NCT01957488|9940099|FG002|Test Period 1 (2 Weeks)|Adverse Event|1
6251426|NCT01957488|9940100|FG003|Test Period 1 (2 Weeks)|Adverse Event|0
6251427|NCT01957488|9940101|FG004|Test Period 1 (2 Weeks)|Adverse Event|1
6251428|NCT01957488|9940102|FG005|Test Period 1 (2 Weeks)|Adverse Event|0
6251429|NCT01957488|9940097|FG000|Test Period 1 (2 Weeks)|Withdrawal by Subject|0
6251430|NCT01957488|9940098|FG001|Test Period 1 (2 Weeks)|Withdrawal by Subject|0
6251431|NCT01957488|9940099|FG002|Test Period 1 (2 Weeks)|Withdrawal by Subject|0
6251432|NCT01957488|9940100|FG003|Test Period 1 (2 Weeks)|Withdrawal by Subject|1
6251433|NCT01957488|9940101|FG004|Test Period 1 (2 Weeks)|Withdrawal by Subject|1
6251434|NCT01957488|9940102|FG005|Test Period 1 (2 Weeks)|Withdrawal by Subject|2
6251435|NCT01957488|9940097|FG000|Test Period 1 (2 Weeks)|subject did not want to wait for cut bag|0
6251436|NCT01957488|9940098|FG001|Test Period 1 (2 Weeks)|subject did not want to wait for cut bag|0
6251437|NCT01957488|9940099|FG002|Test Period 1 (2 Weeks)|subject did not want to wait for cut bag|0
6251438|NCT01957488|9940100|FG003|Test Period 1 (2 Weeks)|subject did not want to wait for cut bag|0
6251439|NCT01957488|9940101|FG004|Test Period 1 (2 Weeks)|subject did not want to wait for cut bag|1
6251440|NCT01957488|9940102|FG005|Test Period 1 (2 Weeks)|subject did not want to wait for cut bag|0
6251441|NCT01957488|9940097|FG000|Test Period 1 (2 Weeks)|screen failure|0
6251442|NCT01957488|9940098|FG001|Test Period 1 (2 Weeks)|screen failure|0
6251443|NCT01957488|9940099|FG002|Test Period 1 (2 Weeks)|screen failure|0
6251444|NCT01957488|9940100|FG003|Test Period 1 (2 Weeks)|screen failure|0
6251445|NCT01957488|9940101|FG004|Test Period 1 (2 Weeks)|screen failure|0
6251446|NCT01957488|9940102|FG005|Test Period 1 (2 Weeks)|screen failure|1
6251447|NCT01957488|9940097|FG000|Test Period 2 (2 Weeks)|Protocol Violation|2
6251448|NCT01957488|9940098|FG001|Test Period 2 (2 Weeks)|Protocol Violation|0
6251449|NCT01957488|9940099|FG002|Test Period 2 (2 Weeks)|Protocol Violation|1
6251450|NCT01957488|9940100|FG003|Test Period 2 (2 Weeks)|Protocol Violation|1
6251451|NCT01957488|9940101|FG004|Test Period 2 (2 Weeks)|Protocol Violation|0
6251452|NCT01957488|9940102|FG005|Test Period 2 (2 Weeks)|Protocol Violation|0
6251453|NCT01957488|9940097|FG000|Test Period 2 (2 Weeks)|Other|1
6251454|NCT01957488|9940098|FG001|Test Period 2 (2 Weeks)|Other|0
6251455|NCT01957488|9940099|FG002|Test Period 2 (2 Weeks)|Other|0
6251456|NCT01957488|9940100|FG003|Test Period 2 (2 Weeks)|Other|0
6251457|NCT01957488|9940101|FG004|Test Period 2 (2 Weeks)|Other|0
6251458|NCT01957488|9940102|FG005|Test Period 2 (2 Weeks)|Other|0
6251459|NCT01957488|9940097|FG000|Test Period 2 (2 Weeks)|Withdrawal by Subject|0
6251460|NCT01957488|9940098|FG001|Test Period 2 (2 Weeks)|Withdrawal by Subject|1
6251461|NCT01957488|9940099|FG002|Test Period 2 (2 Weeks)|Withdrawal by Subject|0
6251462|NCT01957488|9940100|FG003|Test Period 2 (2 Weeks)|Withdrawal by Subject|0
6251463|NCT01957488|9940101|FG004|Test Period 2 (2 Weeks)|Withdrawal by Subject|0
6251464|NCT01957488|9940102|FG005|Test Period 2 (2 Weeks)|Withdrawal by Subject|0
6251465|NCT01957488|9940097|FG000|Test Period 2 (2 Weeks)|Adverse Event|0
6251466|NCT01957488|9940098|FG001|Test Period 2 (2 Weeks)|Adverse Event|0
6251467|NCT01957488|9940099|FG002|Test Period 2 (2 Weeks)|Adverse Event|0
6251468|NCT01957488|9940100|FG003|Test Period 2 (2 Weeks)|Adverse Event|0
6251469|NCT01957488|9940101|FG004|Test Period 2 (2 Weeks)|Adverse Event|2
6251470|NCT01957488|9940102|FG005|Test Period 2 (2 Weeks)|Adverse Event|0
6251471|NCT01957488|9940097|FG000|Test Period 2 (2 Weeks)|Discontinue due to personal problems|0
6251472|NCT01957488|9940098|FG001|Test Period 2 (2 Weeks)|Discontinue due to personal problems|0
6251473|NCT01957488|9940099|FG002|Test Period 2 (2 Weeks)|Discontinue due to personal problems|0
6251474|NCT01957488|9940100|FG003|Test Period 2 (2 Weeks)|Discontinue due to personal problems|0
6251475|NCT01957488|9940101|FG004|Test Period 2 (2 Weeks)|Discontinue due to personal problems|0
6251476|NCT01957488|9940102|FG005|Test Period 2 (2 Weeks)|Discontinue due to personal problems|1
6251477|NCT01957488|9940097|FG000|Test Period 3 (2 Weeks)|Withdrawal by Subject|1
6251478|NCT01957488|9940098|FG001|Test Period 3 (2 Weeks)|Withdrawal by Subject|0
6251479|NCT01957488|9940099|FG002|Test Period 3 (2 Weeks)|Withdrawal by Subject|0
6251480|NCT01957488|9940100|FG003|Test Period 3 (2 Weeks)|Withdrawal by Subject|0
6251481|NCT01957488|9940101|FG004|Test Period 3 (2 Weeks)|Withdrawal by Subject|0
6251482|NCT01957488|9940102|FG005|Test Period 3 (2 Weeks)|Withdrawal by Subject|0
6251483|NCT01957488|9940097|FG000|Test Period 3 (2 Weeks)|Lack of Efficacy|0
6251484|NCT01957488|9940098|FG001|Test Period 3 (2 Weeks)|Lack of Efficacy|1
6251485|NCT01957488|9940099|FG002|Test Period 3 (2 Weeks)|Lack of Efficacy|0
6251486|NCT01957488|9940100|FG003|Test Period 3 (2 Weeks)|Lack of Efficacy|0
6251487|NCT01957488|9940101|FG004|Test Period 3 (2 Weeks)|Lack of Efficacy|0
6251488|NCT01957488|9940102|FG005|Test Period 3 (2 Weeks)|Lack of Efficacy|0
6251489|NCT01957553|9940110|FG000|Test Period 1 (21 +- 1 Days)|Lack of Efficacy|2
6251490|NCT01957553|9940111|FG001|Test Period 1 (21 +- 1 Days)|Lack of Efficacy|3
6251491|NCT01957553|9940110|FG000|Test Period 1 (21 +- 1 Days)|Adverse Event|2
6251492|NCT01957553|9940111|FG001|Test Period 1 (21 +- 1 Days)|Adverse Event|0
6251493|NCT01957553|9940110|FG000|Test Period 1 (21 +- 1 Days)|Withdrawal by Subject|2
6251494|NCT01957553|9940111|FG001|Test Period 1 (21 +- 1 Days)|Withdrawal by Subject|0
6251495|NCT01957553|9940110|FG000|Test Period 1 (21 +- 1 Days)|screen failure|1
6251496|NCT01957553|9940111|FG001|Test Period 1 (21 +- 1 Days)|screen failure|0
6251497|NCT01957553|9940110|FG000|Test Period 2 (21 +- 1 Days)|Adverse Event|1
6251498|NCT01957553|9940111|FG001|Test Period 2 (21 +- 1 Days)|Adverse Event|3
6251499|NCT01957553|9940110|FG000|Test Period 2 (21 +- 1 Days)|Lack of Efficacy|1
6251500|NCT01957553|9940111|FG001|Test Period 2 (21 +- 1 Days)|Lack of Efficacy|2
6251501|NCT01957553|9940110|FG000|Test Period 2 (21 +- 1 Days)|completed early by mistake|0
6251502|NCT01957553|9940111|FG001|Test Period 2 (21 +- 1 Days)|completed early by mistake|1
6251503|NCT01957553|9940110|FG000|Test Period 2 (21 +- 1 Days)|device deficiency without AE|0
6251504|NCT01957553|9940111|FG001|Test Period 2 (21 +- 1 Days)|device deficiency without AE|1
6251505|NCT01957553|9940110|FG000|Test Period 2 (21 +- 1 Days)|Other|1
6251506|NCT01957553|9940111|FG001|Test Period 2 (21 +- 1 Days)|Other|0
6251507|NCT01957579|9940121|FG000|Overall Study|Withdrawal of concent|0
6251508|NCT01957579|9940122|FG001|Overall Study|Withdrawal of concent|1
6251509|NCT01957579|9940123|FG002|Overall Study|Withdrawal of concent|0
6251510|NCT01957579|9940124|FG003|Overall Study|Withdrawal of concent|0
6251511|NCT01957579|9940121|FG000|Overall Study|Death|0
6251512|NCT01957579|9940122|FG001|Overall Study|Death|0
6251513|NCT01957579|9940123|FG002|Overall Study|Death|2
6251514|NCT01957579|9940124|FG003|Overall Study|Death|0
6251515|NCT01957644|9940156|FG000|Overall Study|Adverse Event|4
6251516|NCT01957644|9940157|FG001|Overall Study|Adverse Event|2
6251517|NCT01957644|9940158|FG002|Overall Study|Adverse Event|0
6251518|NCT01957644|9940159|FG003|Overall Study|Adverse Event|0
6251519|NCT01957644|9940160|FG004|Overall Study|Adverse Event|1
6251520|NCT01957644|9940156|FG000|Overall Study|Progressive disease / relapse|0
6251521|NCT01957644|9940157|FG001|Overall Study|Progressive disease / relapse|1
6251522|NCT01957644|9940158|FG002|Overall Study|Progressive disease / relapse|0
6251523|NCT01957644|9940159|FG003|Overall Study|Progressive disease / relapse|1
6251524|NCT01957644|9940160|FG004|Overall Study|Progressive disease / relapse|0
6251525|NCT01957644|9940156|FG000|Overall Study|Other reason|1
6251526|NCT01957644|9940157|FG001|Overall Study|Other reason|2
6251527|NCT01957644|9940158|FG002|Overall Study|Other reason|1
6251528|NCT01957644|9940159|FG003|Overall Study|Other reason|1
6251529|NCT01957644|9940160|FG004|Overall Study|Other reason|0
6251530|NCT01957644|9940156|FG000|Overall Study|Withdrawal by Subject|1
6251531|NCT01957644|9940157|FG001|Overall Study|Withdrawal by Subject|0
6251532|NCT01957644|9940158|FG002|Overall Study|Withdrawal by Subject|0
6251533|NCT01957644|9940159|FG003|Overall Study|Withdrawal by Subject|0
6251534|NCT01957644|9940160|FG004|Overall Study|Withdrawal by Subject|0
6251535|NCT01957644|9940156|FG000|Overall Study|Protocol Violation|0
6251536|NCT01957644|9940157|FG001|Overall Study|Protocol Violation|1
6251537|NCT01957644|9940158|FG002|Overall Study|Protocol Violation|0
6251538|NCT01957644|9940159|FG003|Overall Study|Protocol Violation|0
6251539|NCT01957644|9940160|FG004|Overall Study|Protocol Violation|0
6251540|NCT01957709|9940178|FG000|Overall Study|Patient refused to complete post-tx bx|1
6251541|NCT01957787|9940186|FG000|Overall Study|Death|18
6251542|NCT01957787|9940186|FG000|Overall Study|Lost to Follow-up|3
6251543|NCT01957787|9940186|FG000|Overall Study|Withdrawal by Subject|3
6251544|NCT01957787|9940186|FG000|Overall Study|Entered Hospice or Similar Program|2
6251545|NCT01957787|9940186|FG000|Overall Study|Index Tumor(s) Resected|2
6251546|NCT01957787|9940186|FG000|Overall Study|Index Tumor was Primary Lung Cancer|2
6251547|NCT01957787|9940186|FG000|Overall Study|Local therapy, not cryoablation|6
6251548|NCT01957865|9940193|FG000|Overall Study|Found HIV negative|0
6251549|NCT01957865|9940194|FG001|Overall Study|Found HIV negative|0
6251550|NCT01957865|9940195|FG002|Overall Study|Found HIV negative|1
6251551|NCT01957865|9940193|FG000|Overall Study|Lost to Follow-up|0
6251552|NCT01957865|9940194|FG001|Overall Study|Lost to Follow-up|2
6251553|NCT01957865|9940195|FG002|Overall Study|Lost to Follow-up|2
6251554|NCT01958008|9940220|FG000|Overall Study|Worsening of disease under study|0
6251555|NCT01958008|9940221|FG001|Overall Study|Worsening of disease under study|0
6251556|NCT01958008|9940222|FG002|Overall Study|Worsening of disease under study|1
6251557|NCT01958008|9940223|FG003|Overall Study|Worsening of disease under study|0
6251558|NCT01958008|9940220|FG000|Overall Study|Other adverse event|1
6251559|NCT01958008|9940221|FG001|Overall Study|Other adverse event|0
6251560|NCT01958008|9940222|FG002|Overall Study|Other adverse event|0
6251561|NCT01958008|9940223|FG003|Overall Study|Other adverse event|0
6251562|NCT01958060|9940242|FG000|Overall Study|Not treated|2
6251563|NCT01958060|9940243|FG001|Overall Study|Not treated|0
6251564|NCT01958060|9940244|FG002|Overall Study|Not treated|0
6251565|NCT01958060|9940245|FG003|Overall Study|Not treated|0
6251566|NCT01958060|9940246|FG004|Overall Study|Not treated|1
6251567|NCT01958060|9940247|FG005|Overall Study|Not treated|0
6251568|NCT01958125|9940294|FG000|Overall Study|Missing diary data|2
6251569|NCT01958125|9940295|FG001|Overall Study|Missing diary data|6
6251570|NCT01958125|9940294|FG000|Overall Study|No headache attacks|0
6251571|NCT01958125|9940295|FG001|Overall Study|No headache attacks|2
6251572|NCT01958164|9940303|FG000|Overall Study|Adverse Event|0
6251573|NCT01958164|9940304|FG001|Overall Study|Adverse Event|2
6251574|NCT01958164|9940303|FG000|Overall Study|Lost to Follow-up|2
6251575|NCT01958164|9940304|FG001|Overall Study|Lost to Follow-up|3
6251576|NCT01958281|9940313|FG000|Overall Study|Lack of Efficacy|5
6251577|NCT01958281|9940314|FG001|Overall Study|Lack of Efficacy|2
6251578|NCT01958281|9940315|FG002|Overall Study|Lack of Efficacy|0
6251579|NCT01958281|9940313|FG000|Overall Study|Adverse Event|0
6251580|NCT01958281|9940314|FG001|Overall Study|Adverse Event|2
6251581|NCT01958281|9940315|FG002|Overall Study|Adverse Event|0
6251582|NCT01958281|9940313|FG000|Overall Study|Withdrew Consent|1
6251583|NCT01958281|9940314|FG001|Overall Study|Withdrew Consent|0
6251584|NCT01958281|9940315|FG002|Overall Study|Withdrew Consent|0
6251585|NCT01958294|9940324|FG000|Overall Study|Clinical Circumstances|2
6270840|NCT02157948|9972291|FG000|Overall Study|Protocol Specified Criteria|2
6270841|NCT02157948|9972292|FG001|Overall Study|Protocol Specified Criteria|1
6270842|NCT02157948|9972291|FG000|Overall Study|Decision by Sponsor|0
6270843|NCT02157948|9972292|FG001|Overall Study|Decision by Sponsor|1
6270844|NCT02158039|9972298|FG000|Overall Study|Withdrawal by Subject|1
6270845|NCT02158039|9972298|FG000|Overall Study|Screen Failure|9
6270846|NCT02158247|9972304|FG000|Overall Study|Invisible vocal cords|5
6270847|NCT02158364|9972329|FG000|Overall Study|Case report forms uncollected|10
6270848|NCT02158364|9972329|FG000|Overall Study|Protocol Deviation|50
6270849|NCT02158442|9972335|FG000|Overall Study|Withdrawal by Subject|1
6270850|NCT02158442|9972336|FG001|Overall Study|Withdrawal by Subject|0
6270851|NCT02158442|9972335|FG000|Overall Study|Perfusion staff not available|1
6270852|NCT02158442|9972336|FG001|Overall Study|Perfusion staff not available|0
6270853|NCT02158533|9972370|FG000|Stage 1|Adverse Event|6
6270854|NCT02158533|9972371|FG001|Stage 1|Adverse Event|4
6270855|NCT02158533|9972372|FG002|Stage 1|Adverse Event|7
6270856|NCT02158533|9972373|FG003|Stage 1|Adverse Event|0
6270857|NCT02158533|9972374|FG004|Stage 1|Adverse Event|0
6270858|NCT02158533|9972375|FG005|Stage 1|Adverse Event|0
6270859|NCT02158533|9972370|FG000|Stage 1|Withdrawal by Subject|3
6270860|NCT02158533|9972371|FG001|Stage 1|Withdrawal by Subject|2
6270861|NCT02158533|9972372|FG002|Stage 1|Withdrawal by Subject|1
6270862|NCT02158533|9972373|FG003|Stage 1|Withdrawal by Subject|0
6270863|NCT02158533|9972374|FG004|Stage 1|Withdrawal by Subject|0
6270864|NCT02158533|9972375|FG005|Stage 1|Withdrawal by Subject|0
6270865|NCT02158533|9972370|FG000|Stage 1|Lack of Efficacy|1
6270866|NCT02158533|9972371|FG001|Stage 1|Lack of Efficacy|0
6270867|NCT02158533|9972372|FG002|Stage 1|Lack of Efficacy|0
6270868|NCT02158533|9972373|FG003|Stage 1|Lack of Efficacy|0
6270869|NCT02158533|9972374|FG004|Stage 1|Lack of Efficacy|0
6270870|NCT02158533|9972375|FG005|Stage 1|Lack of Efficacy|0
6270871|NCT02158533|9972370|FG000|Stage 1|Lost to Follow-up|3
6270872|NCT02158533|9972371|FG001|Stage 1|Lost to Follow-up|1
6270873|NCT02158533|9972372|FG002|Stage 1|Lost to Follow-up|0
6270874|NCT02158533|9972373|FG003|Stage 1|Lost to Follow-up|0
6270875|NCT02158533|9972374|FG004|Stage 1|Lost to Follow-up|0
6270876|NCT02158533|9972375|FG005|Stage 1|Lost to Follow-up|0
6270877|NCT02158533|9972370|FG000|Stage 1|Failure to Meet Eligibility Criteria|0
6270878|NCT02158533|9972371|FG001|Stage 1|Failure to Meet Eligibility Criteria|1
6270879|NCT02158533|9972372|FG002|Stage 1|Failure to Meet Eligibility Criteria|0
6270880|NCT02158533|9972373|FG003|Stage 1|Failure to Meet Eligibility Criteria|0
6270881|NCT02158533|9972374|FG004|Stage 1|Failure to Meet Eligibility Criteria|0
6270882|NCT02158533|9972375|FG005|Stage 1|Failure to Meet Eligibility Criteria|0
6270883|NCT02158533|9972370|FG000|Stage 1|Non-compliance with study visits|1
6270884|NCT02158533|9972371|FG001|Stage 1|Non-compliance with study visits|0
6270885|NCT02158533|9972372|FG002|Stage 1|Non-compliance with study visits|0
6270886|NCT02158533|9972373|FG003|Stage 1|Non-compliance with study visits|0
6270887|NCT02158533|9972374|FG004|Stage 1|Non-compliance with study visits|0
6270888|NCT02158533|9972375|FG005|Stage 1|Non-compliance with study visits|0
6270889|NCT02158533|9972370|FG000|Stage 2|Adverse Event|0
6270890|NCT02158533|9972371|FG001|Stage 2|Adverse Event|0
6270891|NCT02158533|9972372|FG002|Stage 2|Adverse Event|0
6270892|NCT02158533|9972373|FG003|Stage 2|Adverse Event|0
6270893|NCT02158533|9972374|FG004|Stage 2|Adverse Event|0
6270894|NCT02158533|9972375|FG005|Stage 2|Adverse Event|1
6270895|NCT02158533|9972370|FG000|Stage 2|Lack of Efficacy|0
6270896|NCT02158533|9972371|FG001|Stage 2|Lack of Efficacy|0
6251586|NCT01958437|9940350|FG000|Overall Study|Incidental MRI findings|0
6251587|NCT01958437|9940351|FG001|Overall Study|Incidental MRI findings|0
6251588|NCT01958437|9940352|FG002|Overall Study|Incidental MRI findings|1
6251589|NCT01958437|9940353|FG003|Overall Study|Incidental MRI findings|1
6251590|NCT01958476|9940372|FG000|Overall Study|Parent requested exclusion from analysis|1
6251591|NCT01958476|9940373|FG001|Overall Study|Parent requested exclusion from analysis|0
6251592|NCT01958489|9940379|FG000|Period 2|Adverse Event|0
6251593|NCT01958489|9940380|FG001|Period 2|Adverse Event|1
6251594|NCT01958619|9940404|FG000|Overall Study|Protocol Violation|2
6251595|NCT01958619|9940405|FG001|Overall Study|Protocol Violation|0
6251596|NCT01958619|9940406|FG002|Overall Study|Protocol Violation|1
6251597|NCT01958619|9940407|FG003|Overall Study|Protocol Violation|0
6251598|NCT01958671|9940435|FG000|Overall Study|Adverse Event|1
6251599|NCT01958671|9940436|FG001|Overall Study|Adverse Event|1
6251600|NCT01958671|9940437|FG002|Overall Study|Adverse Event|5
6251601|NCT01958671|9940435|FG000|Overall Study|Death|1
6251602|NCT01958671|9940436|FG001|Overall Study|Death|0
6251603|NCT01958671|9940437|FG002|Overall Study|Death|0
6251604|NCT01958671|9940435|FG000|Overall Study|Excluded medication|0
6251605|NCT01958671|9940436|FG001|Overall Study|Excluded medication|0
6251606|NCT01958671|9940437|FG002|Overall Study|Excluded medication|1
6251607|NCT01958671|9940435|FG000|Overall Study|Hyperglycemia|0
6251608|NCT01958671|9940436|FG001|Overall Study|Hyperglycemia|0
6251609|NCT01958671|9940437|FG002|Overall Study|Hyperglycemia|2
6251610|NCT01958671|9940435|FG000|Overall Study|Lost to Follow-up|7
6251611|NCT01958671|9940436|FG001|Overall Study|Lost to Follow-up|11
6251612|NCT01958671|9940437|FG002|Overall Study|Lost to Follow-up|7
6251613|NCT01958671|9940435|FG000|Overall Study|Non-compliance with study drug|1
6251614|NCT01958671|9940436|FG001|Overall Study|Non-compliance with study drug|1
6251615|NCT01958671|9940437|FG002|Overall Study|Non-compliance with study drug|1
6251616|NCT01958671|9940435|FG000|Overall Study|Pregnancy|0
6251617|NCT01958671|9940436|FG001|Overall Study|Pregnancy|0
6251618|NCT01958671|9940437|FG002|Overall Study|Pregnancy|1
6251619|NCT01958671|9940435|FG000|Overall Study|Protocol Violation|0
6251620|NCT01958671|9940436|FG001|Overall Study|Protocol Violation|1
6251621|NCT01958671|9940437|FG002|Overall Study|Protocol Violation|0
6251622|NCT01958671|9940435|FG000|Overall Study|Study site terminated by sponsor|1
6251623|NCT01958671|9940436|FG001|Overall Study|Study site terminated by sponsor|0
6251624|NCT01958671|9940437|FG002|Overall Study|Study site terminated by sponsor|1
6251625|NCT01958671|9940435|FG000|Overall Study|Participant moved|0
6251626|NCT01958671|9940436|FG001|Overall Study|Participant moved|0
6251627|NCT01958671|9940437|FG002|Overall Study|Participant moved|1
6251628|NCT01958671|9940435|FG000|Overall Study|Withdrawal by Subject|8
6251629|NCT01958671|9940436|FG001|Overall Study|Withdrawal by Subject|10
6251630|NCT01958671|9940437|FG002|Overall Study|Withdrawal by Subject|13
6251631|NCT01958827|9940453|FG000|Overall Study|Adverse Event|3
6251632|NCT01958827|9940453|FG000|Overall Study|Lack of Efficacy|6
6251633|NCT01958827|9940453|FG000|Overall Study|Concomitant Prohibited Medicine for AE|1
6251634|NCT01958918|9940459|FG000|Overall Study|Death|1
6251635|NCT01958918|9940460|FG001|Overall Study|Death|3
6251636|NCT01958918|9940459|FG000|Overall Study|Lost to Follow-up|4
6251637|NCT01958918|9940460|FG001|Overall Study|Lost to Follow-up|7
6251638|NCT01958918|9940459|FG000|Overall Study|Withdrawal by Subject|13
6251639|NCT01958918|9940460|FG001|Overall Study|Withdrawal by Subject|8
6251640|NCT01958918|9940459|FG000|Overall Study|Lack of Efficacy|13
6251641|NCT01958918|9940460|FG001|Overall Study|Lack of Efficacy|10
6251642|NCT01958918|9940459|FG000|Overall Study|Adverse Event|12
6251643|NCT01958918|9940460|FG001|Overall Study|Adverse Event|12
6251644|NCT01958918|9940459|FG000|Overall Study|administrative problems|0
6251645|NCT01958918|9940460|FG001|Overall Study|administrative problems|2
6251646|NCT01959035|9940466|FG000|Overall Study|Adverse Event|5
6251647|NCT01959035|9940466|FG000|Overall Study|Withdrawal by Subject|4
6251648|NCT01959035|9940466|FG000|Overall Study|Lost to Follow-up|1
6251649|NCT01959035|9940466|FG000|Overall Study|Other (no primary reason given)|1
6251650|NCT01959165|9940484|FG000|Overall Study|Adverse Event|0
6251651|NCT01959165|9940485|FG001|Overall Study|Adverse Event|0
6251652|NCT01959165|9940486|FG002|Overall Study|Adverse Event|0
6251653|NCT01959165|9940487|FG003|Overall Study|Adverse Event|1
6251654|NCT01959165|9940484|FG000|Overall Study|Lack of Efficacy|1
6251655|NCT01959165|9940485|FG001|Overall Study|Lack of Efficacy|0
6251656|NCT01959165|9940486|FG002|Overall Study|Lack of Efficacy|0
6251657|NCT01959165|9940487|FG003|Overall Study|Lack of Efficacy|0
6251658|NCT01959165|9940484|FG000|Overall Study|overdose|0
6251659|NCT01959165|9940485|FG001|Overall Study|overdose|0
6251660|NCT01959165|9940486|FG002|Overall Study|overdose|0
6251661|NCT01959165|9940487|FG003|Overall Study|overdose|1
6251662|NCT01959165|9940484|FG000|Overall Study|Welfare recipient|0
6251663|NCT01959165|9940485|FG001|Overall Study|Welfare recipient|1
6251664|NCT01959165|9940486|FG002|Overall Study|Welfare recipient|0
6251665|NCT01959165|9940487|FG003|Overall Study|Welfare recipient|0
6251666|NCT01959230|9940506|FG000|Overall Study|Failure to follow study procedures|0
6251667|NCT01959230|9940507|FG001|Overall Study|Failure to follow study procedures|1
6251668|NCT01959230|9940506|FG000|Overall Study|Administrative reasons|2
6251669|NCT01959230|9940507|FG001|Overall Study|Administrative reasons|0
6251670|NCT01959230|9940506|FG000|Overall Study|Withdrawal by Subject|2
6251671|NCT01959230|9940507|FG001|Overall Study|Withdrawal by Subject|0
6251672|NCT01959243|9940515|FG000|Overall Study|Investigator Decision|3
6251673|NCT01959243|9940516|FG001|Overall Study|Investigator Decision|0
6251674|NCT01959243|9940515|FG000|Overall Study|Adverse Event|5
6251675|NCT01959243|9940516|FG001|Overall Study|Adverse Event|2
6251676|NCT01959243|9940515|FG000|Overall Study|Administrative reasons|2
6251677|NCT01959243|9940516|FG001|Overall Study|Administrative reasons|1
6251678|NCT01959243|9940515|FG000|Overall Study|Lost to Follow-up|3
6251679|NCT01959243|9940516|FG001|Overall Study|Lost to Follow-up|1
6251680|NCT01959334|9940524|FG000|Second Dose|Adverse Event|1
6251681|NCT01959334|9940525|FG001|Second Dose|Adverse Event|0
6251682|NCT01959334|9940524|FG000|Third Dose|Adverse Event|0
6251683|NCT01959334|9940525|FG001|Third Dose|Adverse Event|1
6251684|NCT01959347|9940533|FG000|Overall Study|Protocol Violation|9
6086265|NCT00660023|9696151|FG000|Overall Study|Adverse Event|2
6086266|NCT00660023|9696151|FG000|Overall Study|Death|8
6086267|NCT00660023|9696151|FG000|Overall Study|Blood Transfusion|5
6086268|NCT00660023|9696151|FG000|Overall Study|Renal Transplantation|3
6251685|NCT01959347|9940534|FG001|Overall Study|Protocol Violation|7
6251686|NCT01959412|9940540|FG000|Overall Study|Protocol deviation|1
6251687|NCT01959412|9940541|FG001|Overall Study|Protocol deviation|1
6251688|NCT01959412|9940542|FG002|Overall Study|Protocol deviation|0
6251689|NCT01959412|9940543|FG003|Overall Study|Protocol deviation|1
6251690|NCT01959412|9940544|FG004|Overall Study|Protocol deviation|3
6251691|NCT01959412|9940545|FG005|Overall Study|Protocol deviation|0
6251692|NCT01959412|9940540|FG000|Overall Study|Adverse Event|0
6251693|NCT01959412|9940541|FG001|Overall Study|Adverse Event|0
6251694|NCT01959412|9940542|FG002|Overall Study|Adverse Event|0
6251695|NCT01959412|9940543|FG003|Overall Study|Adverse Event|1
6251696|NCT01959412|9940544|FG004|Overall Study|Adverse Event|0
6251697|NCT01959412|9940545|FG005|Overall Study|Adverse Event|0
6251698|NCT01959425|9940561|FG000|Overall Study|Withdrawal by Subject|5
6251699|NCT01959425|9940562|FG001|Overall Study|Withdrawal by Subject|4
6251700|NCT01959425|9940561|FG000|Overall Study|Lost to Follow-up|1
6251701|NCT01959425|9940562|FG001|Overall Study|Lost to Follow-up|0
6251702|NCT01959425|9940561|FG000|Overall Study|Discontinued Subjects|6
6251703|NCT01959425|9940562|FG001|Overall Study|Discontinued Subjects|4
6251704|NCT01959503|9940583|FG000|Overall Study|Death|2
6251705|NCT01959503|9940584|FG001|Overall Study|Death|1
6251706|NCT01959503|9940583|FG000|Overall Study|Randomized but not treated|1
6251707|NCT01959503|9940584|FG001|Overall Study|Randomized but not treated|1
6251708|NCT01959516|9940590|FG000|Epoch 1|Adverse Event|4
6251709|NCT01959516|9940591|FG001|Epoch 1|Adverse Event|1
6251710|NCT01959516|9940590|FG000|Epoch 1|unsatisfactory therapeutic effect|1
6251711|NCT01959516|9940591|FG001|Epoch 1|unsatisfactory therapeutic effect|0
6251712|NCT01959516|9940590|FG000|Epoch 1|Subject withdrew consent|3
6251713|NCT01959516|9940591|FG001|Epoch 1|Subject withdrew consent|2
6251714|NCT01959516|9940590|FG000|Epoch 1|Administrative problems|1
6251715|NCT01959516|9940591|FG001|Epoch 1|Administrative problems|0
6251716|NCT01959516|9940590|FG000|Epoch 1|Use of prohibited treatment|1
6251717|NCT01959516|9940591|FG001|Epoch 1|Use of prohibited treatment|0
6251718|NCT01959516|9940590|FG000|Epoch 1|Moderate or severe COPD exacerbation|0
6251719|NCT01959516|9940591|FG001|Epoch 1|Moderate or severe COPD exacerbation|1
6251720|NCT01959516|9940590|FG000|Epoch 1|Protocol deviation|0
6251721|NCT01959516|9940591|FG001|Epoch 1|Protocol deviation|1
6251722|NCT01959516|9940590|FG000|Epoch 2|unsatisfactory therapeutic effect|1
6251723|NCT01959516|9940591|FG001|Epoch 2|unsatisfactory therapeutic effect|0
6251724|NCT01959516|9940590|FG000|Epoch 2|Subject withdrew consent|1
6251725|NCT01959516|9940591|FG001|Epoch 2|Subject withdrew consent|0
6251726|NCT01959516|9940590|FG000|Epoch 2|Moderate or severe COPD exacerbation|0
6251727|NCT01959516|9940591|FG001|Epoch 2|Moderate or severe COPD exacerbation|1
6251728|NCT01959529|9940599|FG000|Overall Study|Adverse event (not hypoglycaemia)|0
6251729|NCT01959529|9940600|FG001|Overall Study|Adverse event (not hypoglycaemia)|1
6251730|NCT01959529|9940599|FG000|Overall Study|Lost to Follow-up|4
6251731|NCT01959529|9940600|FG001|Overall Study|Lost to Follow-up|1
6251732|NCT01959529|9940599|FG000|Overall Study|Other|70
6251733|NCT01959529|9940600|FG001|Overall Study|Other|68
6251734|NCT01959529|9940599|FG000|Overall Study|Hypoglycaemia|1
6251735|NCT01959529|9940600|FG001|Overall Study|Hypoglycaemia|1
6251736|NCT01959529|9940599|FG000|Overall Study|Lack of glycaemic control|1
6251737|NCT01959529|9940600|FG001|Overall Study|Lack of glycaemic control|1
6251738|NCT01959581|9940611|FG000|Overall Study|Lost to Follow-up|5
6251739|NCT01959607|9940617|FG000|First Intervention (Day 1)|Withdrawal by Subject|1
6251740|NCT01959607|9940618|FG001|First Intervention (Day 1)|Withdrawal by Subject|1
6251741|NCT01959607|9940619|FG002|First Intervention (Day 1)|Withdrawal by Subject|0
6251742|NCT01959607|9940620|FG003|First Intervention (Day 1)|Withdrawal by Subject|0
6251743|NCT01959672|9940629|FG000|Overall Study|Death|1
6251744|NCT01959698|9940647|FG000|Overall Study|Adverse Event|0
6251745|NCT01959698|9940648|FG001|Overall Study|Adverse Event|0
6251746|NCT01959698|9940649|FG002|Overall Study|Adverse Event|0
6251747|NCT01959698|9940650|FG003|Overall Study|Adverse Event|0
6086269|NCT00660023|9696151|FG000|Overall Study|Withdrawal by Subject|1
6086270|NCT00660023|9696151|FG000|Overall Study|Missed Pregnancy Test|1
6251748|NCT01959698|9940651|FG004|Overall Study|Adverse Event|0
6251749|NCT01959698|9940652|FG005|Overall Study|Adverse Event|0
6251750|NCT01959698|9940653|FG006|Overall Study|Adverse Event|1
6251751|NCT01959698|9940647|FG000|Overall Study|Physician Decision|1
6251752|NCT01959698|9940648|FG001|Overall Study|Physician Decision|0
6251753|NCT01959698|9940649|FG002|Overall Study|Physician Decision|1
6251754|NCT01959698|9940650|FG003|Overall Study|Physician Decision|2
6251755|NCT01959698|9940651|FG004|Overall Study|Physician Decision|0
6251756|NCT01959698|9940652|FG005|Overall Study|Physician Decision|3
6251757|NCT01959698|9940653|FG006|Overall Study|Physician Decision|3
6251758|NCT01959841|9940673|FG000|Overall Study|Adverse Event|1
6251759|NCT01959841|9940674|FG001|Overall Study|Adverse Event|3
6251760|NCT01959841|9940675|FG002|Overall Study|Adverse Event|2
6251761|NCT01959841|9940673|FG000|Overall Study|Lack of Efficacy|5
6251762|NCT01959841|9940674|FG001|Overall Study|Lack of Efficacy|0
6251763|NCT01959841|9940675|FG002|Overall Study|Lack of Efficacy|0
6251764|NCT01959841|9940673|FG000|Overall Study|Lost to Follow-up|1
6251765|NCT01959841|9940674|FG001|Overall Study|Lost to Follow-up|1
6251766|NCT01959841|9940675|FG002|Overall Study|Lost to Follow-up|0
6251767|NCT01959841|9940673|FG000|Overall Study|Physician Decision|0
6251768|NCT01959841|9940674|FG001|Overall Study|Physician Decision|2
6251769|NCT01959841|9940675|FG002|Overall Study|Physician Decision|3
6251770|NCT01959841|9940673|FG000|Overall Study|Protocol Violation|16
6251771|NCT01959841|9940674|FG001|Overall Study|Protocol Violation|23
6251772|NCT01959841|9940675|FG002|Overall Study|Protocol Violation|16
6251773|NCT01959841|9940673|FG000|Overall Study|Withdrawal by Subject|7
6251774|NCT01959841|9940674|FG001|Overall Study|Withdrawal by Subject|7
6251775|NCT01959841|9940675|FG002|Overall Study|Withdrawal by Subject|5
6251776|NCT01959841|9940673|FG000|Overall Study|Clinical laboratory value|2
6251777|NCT01959841|9940674|FG001|Overall Study|Clinical laboratory value|6
6251778|NCT01959841|9940675|FG002|Overall Study|Clinical laboratory value|6
6251779|NCT01959841|9940673|FG000|Overall Study|Platelet count below on day1 or 4|11
6251780|NCT01959841|9940674|FG001|Overall Study|Platelet count below on day1 or 4|15
6251781|NCT01959841|9940675|FG002|Overall Study|Platelet count below on day1 or 4|11
6251782|NCT01959880|9940687|FG000|Overall Study|Withdrawal by Subject|11
6251783|NCT01959880|9940688|FG001|Overall Study|Withdrawal by Subject|13
6251784|NCT01959880|9940689|FG002|Overall Study|Withdrawal by Subject|8
6251785|NCT01959880|9940690|FG003|Overall Study|Withdrawal by Subject|7
6251786|NCT01959880|9940687|FG000|Overall Study|Death|1
6251787|NCT01959880|9940688|FG001|Overall Study|Death|10
6251788|NCT01959880|9940689|FG002|Overall Study|Death|1
6251789|NCT01959880|9940690|FG003|Overall Study|Death|2
6251790|NCT01959880|9940687|FG000|Overall Study|Lost to Follow-up|95
6251791|NCT01959880|9940688|FG001|Overall Study|Lost to Follow-up|18
6251792|NCT01959880|9940689|FG002|Overall Study|Lost to Follow-up|15
6251793|NCT01959880|9940690|FG003|Overall Study|Lost to Follow-up|8
6251794|NCT01959880|9940687|FG000|Overall Study|Explantation w/o study device reimplant.|22
6251795|NCT01959880|9940688|FG001|Overall Study|Explantation w/o study device reimplant.|17
6251796|NCT01959880|9940689|FG002|Overall Study|Explantation w/o study device reimplant.|5
6251797|NCT01959880|9940690|FG003|Overall Study|Explantation w/o study device reimplant.|12
6251798|NCT01959880|9940687|FG000|Overall Study|Study completed early-FDA approved|1003
6251799|NCT01959880|9940688|FG001|Overall Study|Study completed early-FDA approved|311
6251800|NCT01959880|9940689|FG002|Overall Study|Study completed early-FDA approved|179
6251801|NCT01959880|9940690|FG003|Overall Study|Study completed early-FDA approved|152
6251802|NCT01959919|9940700|FG000|Overall Study|Did not meet the eligibility criteria|2
6251803|NCT01959932|9940707|FG000|Overall Study|Withdrawal by Subject|1
6251804|NCT01959932|9940708|FG001|Overall Study|Withdrawal by Subject|0
6251805|NCT01959932|9940709|FG002|Overall Study|Withdrawal by Subject|0
6251806|NCT01960114|9940752|FG000|Overall Study|Adverse Event|1
6251807|NCT01960114|9940753|FG001|Overall Study|Adverse Event|0
6251808|NCT01960114|9940752|FG000|Overall Study|Could not swallow study medication|0
6251809|NCT01960114|9940753|FG001|Overall Study|Could not swallow study medication|1
6251810|NCT01960140|9940759|FG000|Period 2 (Days 3-18)|Adverse Event|2
6251811|NCT01960257|9940767|FG000|Stage 1 (1-3 Weeks)|Only participated in PK Substudy|12
6251812|NCT01960257|9940768|FG001|Stage 1 (1-3 Weeks)|Only participated in PK Substudy|0
6251813|NCT01960257|9940769|FG002|Stage 1 (1-3 Weeks)|Only participated in PK Substudy|0
6251814|NCT01960257|9940767|FG000|Stage 1 (1-3 Weeks)|Withdrawal by Subject|3
6251815|NCT01960257|9940768|FG001|Stage 1 (1-3 Weeks)|Withdrawal by Subject|0
6251816|NCT01960257|9940769|FG002|Stage 1 (1-3 Weeks)|Withdrawal by Subject|0
6251817|NCT01960257|9940767|FG000|Stage 1 (1-3 Weeks)|Adverse Event|1
6251818|NCT01960257|9940768|FG001|Stage 1 (1-3 Weeks)|Adverse Event|0
6251819|NCT01960257|9940769|FG002|Stage 1 (1-3 Weeks)|Adverse Event|0
6251820|NCT01960296|9940781|FG000|Overall Study|Postponed surgery|1
6251821|NCT01960296|9940782|FG001|Overall Study|Postponed surgery|0
6251822|NCT01960296|9940781|FG000|Overall Study|Received different procedure|1
6251823|NCT01960296|9940782|FG001|Overall Study|Received different procedure|3
6251824|NCT01960348|9940790|FG000|Overall Study|Adverse event, not serious|2
6251825|NCT01960348|9940791|FG001|Overall Study|Adverse event, not serious|2
6251826|NCT01960348|9940790|FG000|Overall Study|Adverse event, serious fatal|6
6251827|NCT01960348|9940791|FG001|Overall Study|Adverse event, serious fatal|5
6251828|NCT01960348|9940790|FG000|Overall Study|Adverse event, serious non-fatal|0
6251829|NCT01960348|9940791|FG001|Overall Study|Adverse event, serious non-fatal|3
6251830|NCT01960348|9940790|FG000|Overall Study|Withdrawal by Subject|1
6251831|NCT01960348|9940791|FG001|Overall Study|Withdrawal by Subject|11
6251832|NCT01960348|9940790|FG000|Overall Study|Physician Decision|0
6251833|NCT01960348|9940791|FG001|Overall Study|Physician Decision|1
6251834|NCT01960348|9940790|FG000|Overall Study|Protocol Violation|1
6251835|NCT01960348|9940791|FG001|Overall Study|Protocol Violation|0
6251836|NCT01960413|9940812|FG000|Overall Study|Withdrawal by Subject|1
6251837|NCT01960413|9940813|FG001|Overall Study|Withdrawal by Subject|1
6251838|NCT01960413|9940812|FG000|Overall Study|Physician Decision|1
6251839|NCT01960413|9940813|FG001|Overall Study|Physician Decision|0
6251840|NCT01960413|9940812|FG000|Overall Study|Lost to Follow-up|2
6251841|NCT01960413|9940813|FG001|Overall Study|Lost to Follow-up|0
6251842|NCT01960725|9940830|FG000|Overall Study|Lost to Follow-up|4
6251843|NCT01960725|9940831|FG001|Overall Study|Lost to Follow-up|3
6251844|NCT01960725|9940830|FG000|Overall Study|Withdrawal by Subject|1
6251845|NCT01960725|9940831|FG001|Overall Study|Withdrawal by Subject|0
6251846|NCT01960725|9940830|FG000|Overall Study|unable to obtain blood sample|1
6251847|NCT01960725|9940831|FG001|Overall Study|unable to obtain blood sample|2
6251848|NCT01960790|9940837|FG000|Overall Study|Survey forms could not be recovered|3
6251849|NCT01960790|9940837|FG000|Overall Study|Treat with Humira outside survey period|3
6251850|NCT01960790|9940837|FG000|Overall Study|Transferred to another hospital|4
6251851|NCT01960790|9940837|FG000|Overall Study|Unevaluable for safety|1
6251852|NCT01960816|9940841|FG000|Overall Study|Lost to Follow-up|1
6251853|NCT01960842|9940845|FG000|Overall Study|Adverse Event|1
6251854|NCT01960842|9940845|FG000|Overall Study|Withdrawal by Subject|2
6251855|NCT01960855|9940854|FG000|Overall Study|Subject noncompliant|1
6251856|NCT01960855|9940855|FG001|Overall Study|Subject noncompliant|0
6251857|NCT01960855|9940856|FG002|Overall Study|Subject noncompliant|0
6251858|NCT01960855|9940857|FG003|Overall Study|Subject noncompliant|0
6251859|NCT01960855|9940858|FG004|Overall Study|Subject noncompliant|0
6251860|NCT01960855|9940854|FG000|Overall Study|Adverse Event|2
6251861|NCT01960855|9940855|FG001|Overall Study|Adverse Event|0
6251862|NCT01960855|9940856|FG002|Overall Study|Adverse Event|6
6251863|NCT01960855|9940857|FG003|Overall Study|Adverse Event|2
6251864|NCT01960855|9940858|FG004|Overall Study|Adverse Event|2
6251865|NCT01960855|9940854|FG000|Overall Study|Lack of Efficacy|1
6251866|NCT01960855|9940855|FG001|Overall Study|Lack of Efficacy|1
6251867|NCT01960855|9940856|FG002|Overall Study|Lack of Efficacy|0
6251868|NCT01960855|9940857|FG003|Overall Study|Lack of Efficacy|0
6251869|NCT01960855|9940858|FG004|Overall Study|Lack of Efficacy|0
6251870|NCT01960855|9940854|FG000|Overall Study|Other|2
6251871|NCT01960855|9940855|FG001|Overall Study|Other|1
6251872|NCT01960855|9940856|FG002|Overall Study|Other|1
6251873|NCT01960855|9940857|FG003|Overall Study|Other|1
6251874|NCT01960855|9940858|FG004|Overall Study|Other|0
6251875|NCT01960855|9940854|FG000|Overall Study|Consent withdrawn by subject|3
6251876|NCT01960855|9940855|FG001|Overall Study|Consent withdrawn by subject|1
6251877|NCT01960855|9940856|FG002|Overall Study|Consent withdrawn by subject|2
6251878|NCT01960855|9940857|FG003|Overall Study|Consent withdrawn by subject|1
6251879|NCT01960855|9940858|FG004|Overall Study|Consent withdrawn by subject|1
6251880|NCT01960855|9940854|FG000|Overall Study|Lost to Follow-up|2
6251881|NCT01960855|9940855|FG001|Overall Study|Lost to Follow-up|1
6251882|NCT01960855|9940856|FG002|Overall Study|Lost to Follow-up|0
6251883|NCT01960855|9940857|FG003|Overall Study|Lost to Follow-up|0
6251884|NCT01960855|9940858|FG004|Overall Study|Lost to Follow-up|2
6251885|NCT01960907|9940872|FG000|Overall Study|Death|4
6251886|NCT01960907|9940873|FG001|Overall Study|Death|3
6251887|NCT01960907|9940872|FG000|Overall Study|Withdrawal by Subject|32
6251888|NCT01960907|9940873|FG001|Overall Study|Withdrawal by Subject|42
6251889|NCT01960998|9940884|FG000|Overall Study|Lost to Follow-up|3
6251890|NCT01960998|9940885|FG001|Overall Study|Lost to Follow-up|7
6251891|NCT01960998|9940884|FG000|Overall Study|Death|0
6251892|NCT01960998|9940885|FG001|Overall Study|Death|1
6251893|NCT01960998|9940884|FG000|Overall Study|Withdrawal by Subject|8
6251894|NCT01960998|9940885|FG001|Overall Study|Withdrawal by Subject|2
6251895|NCT01960998|9940884|FG000|Overall Study|lost computer access|0
6251896|NCT01960998|9940885|FG001|Overall Study|lost computer access|1
6251897|NCT01961115|9940900|FG000|Overall Study|Disease Progression|1
6251898|NCT01961115|9940901|FG001|Overall Study|Disease Progression|0
6251899|NCT01961115|9940902|FG002|Overall Study|Disease Progression|3
6251900|NCT01961115|9940900|FG000|Overall Study|Adverse Event|1
6251901|NCT01961115|9940901|FG001|Overall Study|Adverse Event|0
6251902|NCT01961115|9940902|FG002|Overall Study|Adverse Event|1
6251903|NCT01961297|9940920|FG000|Overall Study|unconfirmed diagnosis of SD|2
6251904|NCT01961297|9940921|FG001|Overall Study|unconfirmed diagnosis of SD|1
6251905|NCT01961323|9940927|FG000|Overall Study|Withdrawal by Subject|7
6251906|NCT01961323|9940927|FG000|Overall Study|Lost to Follow-up|8
6251907|NCT01961323|9940927|FG000|Overall Study|screen failure|34
6251908|NCT01961349|9940934|FG000|Overall Study|Withdrawal by Subject|1
6251909|NCT01961349|9940935|FG001|Overall Study|Withdrawal by Subject|4
6251910|NCT01961349|9940936|FG002|Overall Study|Withdrawal by Subject|0
6251911|NCT01961349|9940934|FG000|Overall Study|Adverse Event|0
6251912|NCT01961349|9940935|FG001|Overall Study|Adverse Event|0
6251913|NCT01961349|9940936|FG002|Overall Study|Adverse Event|1
6251914|NCT01961349|9940934|FG000|Overall Study|registration error, personal reason etc|2
6251915|NCT01961349|9940935|FG001|Overall Study|registration error, personal reason etc|2
6251916|NCT01961349|9940936|FG002|Overall Study|registration error, personal reason etc|1
6251917|NCT01961544|9940948|FG000|Overall Study|Protocol Violation|1
6251918|NCT01961544|9940948|FG000|Overall Study|Withdrawal by Subject|7
6251919|NCT01961544|9940948|FG000|Overall Study|Adverse Event|1
6251920|NCT01961544|9940948|FG000|Overall Study|Physician Decision|2
6251921|NCT01961544|9940948|FG000|Overall Study|Poor Tolerance|1
6251922|NCT01961544|9940948|FG000|Overall Study|Aggravation of Steral Pain|1
6251923|NCT01961609|9940954|FG000|Initiation|Missing|3
6251924|NCT01961609|9940955|FG001|Initiation|Missing|2
6251925|NCT01961609|9940956|FG002|Initiation|Missing|0
6251926|NCT01961609|9940957|FG003|Initiation|Missing|0
6251927|NCT01961609|9940954|FG000|Initiation|Protocol deviation|1
6251928|NCT01961609|9940955|FG001|Initiation|Protocol deviation|0
6251929|NCT01961609|9940956|FG002|Initiation|Protocol deviation|0
6251930|NCT01961609|9940957|FG003|Initiation|Protocol deviation|0
6251931|NCT01961609|9940954|FG000|Initiation|Death|0
6251932|NCT01961609|9940955|FG001|Initiation|Death|1
6251933|NCT01961609|9940956|FG002|Initiation|Death|0
6251934|NCT01961609|9940957|FG003|Initiation|Death|0
6251935|NCT01961609|9940954|FG000|Initiation|Administrative problems|1
6251936|NCT01961609|9940955|FG001|Initiation|Administrative problems|0
6251937|NCT01961609|9940956|FG002|Initiation|Administrative problems|0
6251938|NCT01961609|9940957|FG003|Initiation|Administrative problems|0
6251939|NCT01961609|9940954|FG000|Initiation|Withdrawal by Subject|1
6251940|NCT01961609|9940955|FG001|Initiation|Withdrawal by Subject|2
6251941|NCT01961609|9940956|FG002|Initiation|Withdrawal by Subject|0
6251942|NCT01961609|9940957|FG003|Initiation|Withdrawal by Subject|0
6251943|NCT01961609|9940954|FG000|Initiation|Lack of Efficacy|2
6251944|NCT01961609|9940955|FG001|Initiation|Lack of Efficacy|1
6251945|NCT01961609|9940956|FG002|Initiation|Lack of Efficacy|0
6251946|NCT01961609|9940957|FG003|Initiation|Lack of Efficacy|0
6251947|NCT01961609|9940954|FG000|Initiation|Abnormal lab values|0
6251948|NCT01961609|9940955|FG001|Initiation|Abnormal lab values|1
6251949|NCT01961609|9940956|FG002|Initiation|Abnormal lab values|0
6251950|NCT01961609|9940957|FG003|Initiation|Abnormal lab values|0
6251951|NCT01961609|9940954|FG000|Initiation|Adverse Event|3
6251952|NCT01961609|9940955|FG001|Initiation|Adverse Event|5
6251953|NCT01961609|9940956|FG002|Initiation|Adverse Event|0
6251954|NCT01961609|9940957|FG003|Initiation|Adverse Event|0
6251955|NCT01961609|9940954|FG000|Initiation|Randomized but not treated|1
6251956|NCT01961609|9940955|FG001|Initiation|Randomized but not treated|1
6251957|NCT01961609|9940956|FG002|Initiation|Randomized but not treated|0
6251958|NCT01961609|9940957|FG003|Initiation|Randomized but not treated|0
6251959|NCT01961609|9940954|FG000|Maintenance 1 (Weeks 17 - 48)|Reason for discontinuation is missing|1
6251960|NCT01961609|9940955|FG001|Maintenance 1 (Weeks 17 - 48)|Reason for discontinuation is missing|0
6251961|NCT01961609|9940956|FG002|Maintenance 1 (Weeks 17 - 48)|Reason for discontinuation is missing|3
6251962|NCT01961609|9940957|FG003|Maintenance 1 (Weeks 17 - 48)|Reason for discontinuation is missing|0
6251963|NCT01961609|9940954|FG000|Maintenance 1 (Weeks 17 - 48)|Protocol deviation|3
6251964|NCT01961609|9940955|FG001|Maintenance 1 (Weeks 17 - 48)|Protocol deviation|0
6251965|NCT01961609|9940956|FG002|Maintenance 1 (Weeks 17 - 48)|Protocol deviation|1
6251966|NCT01961609|9940957|FG003|Maintenance 1 (Weeks 17 - 48)|Protocol deviation|0
6251967|NCT01961609|9940954|FG000|Maintenance 1 (Weeks 17 - 48)|Withdrawal by Subject|0
6251968|NCT01961609|9940955|FG001|Maintenance 1 (Weeks 17 - 48)|Withdrawal by Subject|1
6251969|NCT01961609|9940956|FG002|Maintenance 1 (Weeks 17 - 48)|Withdrawal by Subject|1
6251970|NCT01961609|9940957|FG003|Maintenance 1 (Weeks 17 - 48)|Withdrawal by Subject|0
6251971|NCT01961609|9940954|FG000|Maintenance 1 (Weeks 17 - 48)|Lack of Efficacy|13
6251972|NCT01961609|9940955|FG001|Maintenance 1 (Weeks 17 - 48)|Lack of Efficacy|4
6251973|NCT01961609|9940956|FG002|Maintenance 1 (Weeks 17 - 48)|Lack of Efficacy|10
6251974|NCT01961609|9940957|FG003|Maintenance 1 (Weeks 17 - 48)|Lack of Efficacy|0
6251975|NCT01961609|9940954|FG000|Maintenance 1 (Weeks 17 - 48)|Adverse Event|6
6251976|NCT01961609|9940955|FG001|Maintenance 1 (Weeks 17 - 48)|Adverse Event|6
6251977|NCT01961609|9940956|FG002|Maintenance 1 (Weeks 17 - 48)|Adverse Event|3
6251978|NCT01961609|9940957|FG003|Maintenance 1 (Weeks 17 - 48)|Adverse Event|0
6251979|NCT01961609|9940954|FG000|Maintenance 1 (Weeks 17 - 48)|Abnormal laboratory value|0
6251980|NCT01961609|9940955|FG001|Maintenance 1 (Weeks 17 - 48)|Abnormal laboratory value|0
6251981|NCT01961609|9940956|FG002|Maintenance 1 (Weeks 17 - 48)|Abnormal laboratory value|1
6251982|NCT01961609|9940957|FG003|Maintenance 1 (Weeks 17 - 48)|Abnormal laboratory value|0
6251983|NCT01961609|9940954|FG000|Maintanence 2 (Weeks 49 - 72)|Reason for discontinuation is missing|7
6251984|NCT01961609|9940955|FG001|Maintanence 2 (Weeks 49 - 72)|Reason for discontinuation is missing|5
6251985|NCT01961609|9940956|FG002|Maintanence 2 (Weeks 49 - 72)|Reason for discontinuation is missing|0
6251986|NCT01961609|9940957|FG003|Maintanence 2 (Weeks 49 - 72)|Reason for discontinuation is missing|4
6251987|NCT01961609|9940954|FG000|Maintanence 2 (Weeks 49 - 72)|Protocol deviation|0
6251988|NCT01961609|9940955|FG001|Maintanence 2 (Weeks 49 - 72)|Protocol deviation|0
6251989|NCT01961609|9940956|FG002|Maintanence 2 (Weeks 49 - 72)|Protocol deviation|1
6251990|NCT01961609|9940957|FG003|Maintanence 2 (Weeks 49 - 72)|Protocol deviation|0
6251991|NCT01961609|9940954|FG000|Maintanence 2 (Weeks 49 - 72)|Lost to Follow-up|1
6251992|NCT01961609|9940955|FG001|Maintanence 2 (Weeks 49 - 72)|Lost to Follow-up|0
6251993|NCT01961609|9940956|FG002|Maintanence 2 (Weeks 49 - 72)|Lost to Follow-up|0
6251994|NCT01961609|9940957|FG003|Maintanence 2 (Weeks 49 - 72)|Lost to Follow-up|0
6251995|NCT01961609|9940954|FG000|Maintanence 2 (Weeks 49 - 72)|Withdrawal by Subject|0
6251996|NCT01961609|9940955|FG001|Maintanence 2 (Weeks 49 - 72)|Withdrawal by Subject|1
6251997|NCT01961609|9940956|FG002|Maintanence 2 (Weeks 49 - 72)|Withdrawal by Subject|0
6251998|NCT01961609|9940957|FG003|Maintanence 2 (Weeks 49 - 72)|Withdrawal by Subject|0
6251999|NCT01961609|9940954|FG000|Maintanence 2 (Weeks 49 - 72)|Lack of Efficacy|3
6252000|NCT01961609|9940955|FG001|Maintanence 2 (Weeks 49 - 72)|Lack of Efficacy|0
6252001|NCT01961609|9940956|FG002|Maintanence 2 (Weeks 49 - 72)|Lack of Efficacy|3
6086271|NCT00660023|9696151|FG000|Overall Study|Other Screening Failure|9
6086272|NCT00660179|9696171|FG000|Overall Study|Death|44
6086273|NCT00660179|9696172|FG001|Overall Study|Death|47
6086274|NCT00660179|9696173|FG002|Overall Study|Death|34
6086275|NCT00660179|9696171|FG000|Overall Study|Withdrawal of consent|4
6086276|NCT00660179|9696172|FG001|Overall Study|Withdrawal of consent|6
6252002|NCT01961609|9940957|FG003|Maintanence 2 (Weeks 49 - 72)|Lack of Efficacy|1
6252003|NCT01961609|9940954|FG000|Maintanence 2 (Weeks 49 - 72)|Adverse Event|1
6252004|NCT01961609|9940955|FG001|Maintanence 2 (Weeks 49 - 72)|Adverse Event|0
6252005|NCT01961609|9940956|FG002|Maintanence 2 (Weeks 49 - 72)|Adverse Event|0
6252006|NCT01961609|9940957|FG003|Maintanence 2 (Weeks 49 - 72)|Adverse Event|2
6252007|NCT01961687|9940974|FG000|Overall Study|Lost to Follow-up|19
6252008|NCT01961687|9940974|FG000|Overall Study|Re-operation|17
6252009|NCT01961687|9940974|FG000|Overall Study|Death|7
6252010|NCT01961687|9940974|FG000|Overall Study|Withdrawal by Subject|6
6252011|NCT01961687|9940974|FG000|Overall Study|Adverse Event|6
6252012|NCT01961687|9940974|FG000|Overall Study|Moved to area without study site|2
6252013|NCT01961687|9940974|FG000|Overall Study|Sponsor decision|2
6252014|NCT01961687|9940974|FG000|Overall Study|Physician Decision|1
6252015|NCT01961687|9940974|FG000|Overall Study|Unable to meet follow-up requirements|1
6252016|NCT01961882|9940980|FG000|Overall Study|Adverse Event|3
6252017|NCT01961882|9940981|FG001|Overall Study|Adverse Event|2
6252018|NCT01961882|9940980|FG000|Overall Study|Physician Decision|1
6252019|NCT01961882|9940981|FG001|Overall Study|Physician Decision|0
6252020|NCT01961882|9940980|FG000|Overall Study|Withdrawal by Subject|4
6252021|NCT01961882|9940981|FG001|Overall Study|Withdrawal by Subject|1
6252022|NCT01961882|9940980|FG000|Overall Study|Relapse of AML|39
6252023|NCT01961882|9940981|FG001|Overall Study|Relapse of AML|37
6252024|NCT01961882|9940980|FG000|Overall Study|Use of prohibited concomitant drug or therapy|2
6252025|NCT01961882|9940981|FG001|Overall Study|Use of prohibited concomitant drug or therapy|2
6252026|NCT01961882|9940980|FG000|Overall Study|Subject found to be ineligible for the trial after registration|1
6252027|NCT01961882|9940981|FG001|Overall Study|Subject found to be ineligible for the trial after registration|0
6252028|NCT01962103|9941011|FG000|Phase 1|Adverse Event|4
6252029|NCT01962103|9941012|FG001|Phase 1|Adverse Event|0
6252030|NCT01962103|9941013|FG002|Phase 1|Adverse Event|2
6252031|NCT01962103|9941014|FG003|Phase 1|Adverse Event|1
6252032|NCT01962103|9941015|FG004|Phase 1|Adverse Event|2
6252033|NCT01962103|9941016|FG005|Phase 1|Adverse Event|2
6252034|NCT01962103|9941017|FG006|Phase 1|Adverse Event|0
6252035|NCT01962103|9941018|FG007|Phase 1|Adverse Event|0
6252036|NCT01962103|9941019|FG008|Phase 1|Adverse Event|0
6252037|NCT01962103|9941011|FG000|Phase 1|Progressive Disease|8
6252038|NCT01962103|9941012|FG001|Phase 1|Progressive Disease|6
6252039|NCT01962103|9941013|FG002|Phase 1|Progressive Disease|8
6252040|NCT01962103|9941014|FG003|Phase 1|Progressive Disease|4
6252041|NCT01962103|9941015|FG004|Phase 1|Progressive Disease|5
6252042|NCT01962103|9941016|FG005|Phase 1|Progressive Disease|4
6252043|NCT01962103|9941017|FG006|Phase 1|Progressive Disease|0
6252044|NCT01962103|9941018|FG007|Phase 1|Progressive Disease|0
6252045|NCT01962103|9941019|FG008|Phase 1|Progressive Disease|0
6252046|NCT01962103|9941011|FG000|Phase 1|Withdrawal by Subject|0
6252047|NCT01962103|9941012|FG001|Phase 1|Withdrawal by Subject|0
6252048|NCT01962103|9941013|FG002|Phase 1|Withdrawal by Subject|0
6252049|NCT01962103|9941014|FG003|Phase 1|Withdrawal by Subject|2
6252050|NCT01962103|9941015|FG004|Phase 1|Withdrawal by Subject|0
6252051|NCT01962103|9941016|FG005|Phase 1|Withdrawal by Subject|0
6252052|NCT01962103|9941017|FG006|Phase 1|Withdrawal by Subject|0
6252053|NCT01962103|9941018|FG007|Phase 1|Withdrawal by Subject|0
6252054|NCT01962103|9941019|FG008|Phase 1|Withdrawal by Subject|0
6086277|NCT00660179|9696173|FG002|Overall Study|Withdrawal of consent|4
6252055|NCT01962103|9941011|FG000|Phase 1|Withdrawal by Parent/Guardian|0
6252056|NCT01962103|9941012|FG001|Phase 1|Withdrawal by Parent/Guardian|0
6252057|NCT01962103|9941013|FG002|Phase 1|Withdrawal by Parent/Guardian|2
6252058|NCT01962103|9941014|FG003|Phase 1|Withdrawal by Parent/Guardian|1
6252059|NCT01962103|9941015|FG004|Phase 1|Withdrawal by Parent/Guardian|0
6252060|NCT01962103|9941016|FG005|Phase 1|Withdrawal by Parent/Guardian|0
6252061|NCT01962103|9941017|FG006|Phase 1|Withdrawal by Parent/Guardian|0
6252062|NCT01962103|9941018|FG007|Phase 1|Withdrawal by Parent/Guardian|0
6252063|NCT01962103|9941019|FG008|Phase 1|Withdrawal by Parent/Guardian|0
6252064|NCT01962103|9941011|FG000|Phase 1|Physician Decision|0
6252065|NCT01962103|9941012|FG001|Phase 1|Physician Decision|0
6252066|NCT01962103|9941013|FG002|Phase 1|Physician Decision|0
6252067|NCT01962103|9941014|FG003|Phase 1|Physician Decision|1
6252068|NCT01962103|9941015|FG004|Phase 1|Physician Decision|0
6086278|NCT00660179|9696171|FG000|Overall Study|Lost to Follow-up|7
6086279|NCT00660179|9696172|FG001|Overall Study|Lost to Follow-up|5
6252069|NCT01962103|9941016|FG005|Phase 1|Physician Decision|0
6252070|NCT01962103|9941017|FG006|Phase 1|Physician Decision|0
6252071|NCT01962103|9941018|FG007|Phase 1|Physician Decision|0
6252072|NCT01962103|9941019|FG008|Phase 1|Physician Decision|0
6252073|NCT01962103|9941011|FG000|Phase 1|Symptomatic Deterioration|3
6252074|NCT01962103|9941012|FG001|Phase 1|Symptomatic Deterioration|2
6252075|NCT01962103|9941013|FG002|Phase 1|Symptomatic Deterioration|2
6252076|NCT01962103|9941014|FG003|Phase 1|Symptomatic Deterioration|2
6252077|NCT01962103|9941015|FG004|Phase 1|Symptomatic Deterioration|1
6252078|NCT01962103|9941016|FG005|Phase 1|Symptomatic Deterioration|1
6252079|NCT01962103|9941017|FG006|Phase 1|Symptomatic Deterioration|0
6252080|NCT01962103|9941018|FG007|Phase 1|Symptomatic Deterioration|0
6252081|NCT01962103|9941019|FG008|Phase 1|Symptomatic Deterioration|0
6252082|NCT01962103|9941011|FG000|Phase 1|Miscellaneous|1
6252083|NCT01962103|9941012|FG001|Phase 1|Miscellaneous|0
6252084|NCT01962103|9941013|FG002|Phase 1|Miscellaneous|0
6252085|NCT01962103|9941014|FG003|Phase 1|Miscellaneous|0
6252086|NCT01962103|9941015|FG004|Phase 1|Miscellaneous|0
6252087|NCT01962103|9941016|FG005|Phase 1|Miscellaneous|0
6252088|NCT01962103|9941017|FG006|Phase 1|Miscellaneous|0
6252089|NCT01962103|9941018|FG007|Phase 1|Miscellaneous|0
6252090|NCT01962103|9941019|FG008|Phase 1|Miscellaneous|0
6252091|NCT01962103|9941011|FG000|Phase 2|Adverse Event|0
6252092|NCT01962103|9941012|FG001|Phase 2|Adverse Event|0
6252093|NCT01962103|9941013|FG002|Phase 2|Adverse Event|0
6252094|NCT01962103|9941014|FG003|Phase 2|Adverse Event|0
6252095|NCT01962103|9941015|FG004|Phase 2|Adverse Event|0
6252096|NCT01962103|9941016|FG005|Phase 2|Adverse Event|0
6252097|NCT01962103|9941017|FG006|Phase 2|Adverse Event|1
6252098|NCT01962103|9941018|FG007|Phase 2|Adverse Event|0
6252099|NCT01962103|9941019|FG008|Phase 2|Adverse Event|3
6252100|NCT01962103|9941011|FG000|Phase 2|Progressive Disease|0
6252101|NCT01962103|9941012|FG001|Phase 2|Progressive Disease|0
6252102|NCT01962103|9941013|FG002|Phase 2|Progressive Disease|0
6252103|NCT01962103|9941014|FG003|Phase 2|Progressive Disease|0
6252104|NCT01962103|9941015|FG004|Phase 2|Progressive Disease|0
6252105|NCT01962103|9941016|FG005|Phase 2|Progressive Disease|0
6252106|NCT01962103|9941017|FG006|Phase 2|Progressive Disease|11
6252107|NCT01962103|9941018|FG007|Phase 2|Progressive Disease|12
6252108|NCT01962103|9941019|FG008|Phase 2|Progressive Disease|11
6252109|NCT01962103|9941011|FG000|Phase 2|Symptomatic Deterioration|0
6252110|NCT01962103|9941012|FG001|Phase 2|Symptomatic Deterioration|0
6252111|NCT01962103|9941013|FG002|Phase 2|Symptomatic Deterioration|0
6252112|NCT01962103|9941014|FG003|Phase 2|Symptomatic Deterioration|0
6252113|NCT01962103|9941015|FG004|Phase 2|Symptomatic Deterioration|0
6252114|NCT01962103|9941016|FG005|Phase 2|Symptomatic Deterioration|0
6252115|NCT01962103|9941017|FG006|Phase 2|Symptomatic Deterioration|2
6252116|NCT01962103|9941018|FG007|Phase 2|Symptomatic Deterioration|2
6252117|NCT01962103|9941019|FG008|Phase 2|Symptomatic Deterioration|0
6252118|NCT01962207|9941043|FG000|Persistence Phase (5 Years)|Lost to Follow-up|2
6252119|NCT01962207|9941044|FG001|Persistence Phase (5 Years)|Lost to Follow-up|1
6252120|NCT01962207|9941045|FG002|Persistence Phase (5 Years)|Lost to Follow-up|5
6252121|NCT01962207|9941046|FG003|Persistence Phase (5 Years)|Lost to Follow-up|2
6252122|NCT01962207|9941043|FG000|Persistence Phase (5 Years)|Migrated/moved from study area|2
6252123|NCT01962207|9941044|FG001|Persistence Phase (5 Years)|Migrated/moved from study area|0
6252124|NCT01962207|9941045|FG002|Persistence Phase (5 Years)|Migrated/moved from study area|4
6252125|NCT01962207|9941046|FG003|Persistence Phase (5 Years)|Migrated/moved from study area|0
6252126|NCT01962207|9941043|FG000|Persistence Phase (5 Years)|Withdrawal by Subject|4
6252127|NCT01962207|9941044|FG001|Persistence Phase (5 Years)|Withdrawal by Subject|5
6086280|NCT00660179|9696173|FG002|Overall Study|Lost to Follow-up|2
6086281|NCT00660179|9696171|FG000|Overall Study|Administrative reason|0
6086282|NCT00660179|9696172|FG001|Overall Study|Administrative reason|0
6086283|NCT00660179|9696173|FG002|Overall Study|Administrative reason|1
6086284|NCT00660179|9696171|FG000|Overall Study|Incorrect randomization|1
6086285|NCT00660179|9696172|FG001|Overall Study|Incorrect randomization|0
6086286|NCT00660179|9696173|FG002|Overall Study|Incorrect randomization|0
6086287|NCT00660192|9696183|FG000|Overall Study|Lost to Follow-up|2
6086288|NCT00660192|9696184|FG001|Overall Study|Lost to Follow-up|3
6086289|NCT00660309|9696192|FG000|Overall Study|Adverse Event|2
6086290|NCT00660309|9696193|FG001|Overall Study|Adverse Event|0
6086291|NCT00660309|9696192|FG000|Overall Study|Withdrawal by Subject|0
6252128|NCT01962207|9941045|FG002|Persistence Phase (5 Years)|Withdrawal by Subject|18
6252129|NCT01962207|9941046|FG003|Persistence Phase (5 Years)|Withdrawal by Subject|4
6252130|NCT01962207|9941043|FG000|Persistence Phase (5 Years)|Eligibility criteria not fulfilled|0
6086292|NCT00660309|9696193|FG001|Overall Study|Withdrawal by Subject|3
6086293|NCT00660387|9696202|FG000|Overall Study|Adverse Event|1
6086294|NCT00660387|9696203|FG001|Overall Study|Adverse Event|2
6252131|NCT01962207|9941044|FG001|Persistence Phase (5 Years)|Eligibility criteria not fulfilled|0
6252132|NCT01962207|9941045|FG002|Persistence Phase (5 Years)|Eligibility criteria not fulfilled|3
6252133|NCT01962207|9941046|FG003|Persistence Phase (5 Years)|Eligibility criteria not fulfilled|1
6252134|NCT01962207|9941043|FG000|Persistence Phase (5 Years)|Adverse Event|0
6252135|NCT01962207|9941044|FG001|Persistence Phase (5 Years)|Adverse Event|0
6252136|NCT01962207|9941045|FG002|Persistence Phase (5 Years)|Adverse Event|1
6252137|NCT01962207|9941046|FG003|Persistence Phase (5 Years)|Adverse Event|0
6252138|NCT01962207|9941043|FG000|Persistence Phase (5 Years)|Missed at least 1 persistence visit|21
6252139|NCT01962207|9941044|FG001|Persistence Phase (5 Years)|Missed at least 1 persistence visit|7
6270897|NCT02158533|9972372|FG002|Stage 2|Lack of Efficacy|0
6252140|NCT01962207|9941045|FG002|Persistence Phase (5 Years)|Missed at least 1 persistence visit|13
6252141|NCT01962207|9941046|FG003|Persistence Phase (5 Years)|Missed at least 1 persistence visit|5
6252142|NCT01962298|9941065|FG000|Overall Study|Protocol Violation|1
6252143|NCT01962298|9941066|FG001|Overall Study|Protocol Violation|0
6252144|NCT01962298|9941067|FG002|Overall Study|Protocol Violation|1
6252145|NCT01962298|9941068|FG003|Overall Study|Protocol Violation|1
6252146|NCT01962298|9941069|FG004|Overall Study|Protocol Violation|0
6252147|NCT01962298|9941065|FG000|Overall Study|Data quality insufficient|2
6252148|NCT01962298|9941066|FG001|Overall Study|Data quality insufficient|0
6252149|NCT01962298|9941067|FG002|Overall Study|Data quality insufficient|3
6252150|NCT01962298|9941068|FG003|Overall Study|Data quality insufficient|1
6252151|NCT01962298|9941069|FG004|Overall Study|Data quality insufficient|4
6252152|NCT01962298|9941065|FG000|Overall Study|Insufficient data|0
6252153|NCT01962298|9941066|FG001|Overall Study|Insufficient data|2
6252154|NCT01962298|9941067|FG002|Overall Study|Insufficient data|1
6252155|NCT01962298|9941068|FG003|Overall Study|Insufficient data|0
6252156|NCT01962298|9941069|FG004|Overall Study|Insufficient data|1
6252157|NCT01962298|9941065|FG000|Overall Study|Incorrect data recorded|0
6252158|NCT01962298|9941066|FG001|Overall Study|Incorrect data recorded|1
6252159|NCT01962298|9941067|FG002|Overall Study|Incorrect data recorded|0
6252160|NCT01962298|9941068|FG003|Overall Study|Incorrect data recorded|0
6189585|NCT01401322|9844989|FG000|Overall Study|Withdrawal by Subject|1
6189586|NCT01401322|9844989|FG000|Overall Study|Physician Decision|1
6189587|NCT01401361|9844993|FG000|Overall Study|Withdrawal by Subject|16
6189588|NCT01401361|9844993|FG000|Overall Study|Lack of Efficacy|6
6189589|NCT01401361|9844993|FG000|Overall Study|Physician Decision|1
6189590|NCT01401361|9844993|FG000|Overall Study|Lost to Follow-up|3
6189591|NCT01401361|9844993|FG000|Overall Study|Subject/family decision post procedure|2
6189592|NCT01401452|9844997|FG000|Overall Study|Adverse reaction|9
6189593|NCT01401452|9844997|FG000|Overall Study|Lost to Follow-up|12
6189594|NCT01401452|9844997|FG000|Overall Study|Lack of Efficacy|30
6189595|NCT01401452|9844997|FG000|Overall Study|Participant developed breast cancer|1
6189596|NCT01401452|9844997|FG000|Overall Study|Tx stopped due to financial reasons|1
6189597|NCT01401452|9844997|FG000|Overall Study|Tx stopped by psychiatrist|1
6189598|NCT01401452|9844997|FG000|Overall Study|No more visits within the 36 wk followup|4
6189599|NCT01401452|9844997|FG000|Overall Study|Subject did not come to follow up visits|2
6189600|NCT01401452|9844997|FG000|Overall Study|Subject didn't return for routine visits|1
6189601|NCT01401452|9844997|FG000|Overall Study|Subject moved to another city|1
6252161|NCT01962298|9941069|FG004|Overall Study|Incorrect data recorded|0
6252162|NCT01962298|9941065|FG000|Overall Study|Physician Decision|0
6252163|NCT01962298|9941066|FG001|Overall Study|Physician Decision|1
6252164|NCT01962298|9941067|FG002|Overall Study|Physician Decision|0
6252165|NCT01962298|9941068|FG003|Overall Study|Physician Decision|0
6252166|NCT01962298|9941069|FG004|Overall Study|Physician Decision|1
6252167|NCT01962441|9941093|FG000|Randomized Period|Randomized but Never Treated|4
6086295|NCT00660387|9696202|FG000|Overall Study|Lack of Efficacy|0
6252168|NCT01962441|9941094|FG001|Randomized Period|Randomized but Never Treated|2
6252169|NCT01962441|9941095|FG002|Randomized Period|Randomized but Never Treated|3
6252170|NCT01962441|9941093|FG000|Randomized Period|Lost to Follow-up|2
6252171|NCT01962441|9941094|FG001|Randomized Period|Lost to Follow-up|4
6252172|NCT01962441|9941095|FG002|Randomized Period|Lost to Follow-up|4
6252173|NCT01962441|9941093|FG000|Randomized Period|Withdrew Consent|3
6252174|NCT01962441|9941094|FG001|Randomized Period|Withdrew Consent|3
6252175|NCT01962441|9941095|FG002|Randomized Period|Withdrew Consent|2
6252176|NCT01962441|9941093|FG000|Randomized Period|Adverse Event|1
6252177|NCT01962441|9941094|FG001|Randomized Period|Adverse Event|1
6252178|NCT01962441|9941095|FG002|Randomized Period|Adverse Event|0
6252179|NCT01962441|9941093|FG000|Randomized Period|Death|0
6252180|NCT01962441|9941094|FG001|Randomized Period|Death|0
6252181|NCT01962441|9941095|FG002|Randomized Period|Death|2
6252182|NCT01962441|9941093|FG000|Randomized Period|Protocol Violation|0
6252183|NCT01962441|9941094|FG001|Randomized Period|Protocol Violation|1
6252184|NCT01962441|9941095|FG002|Randomized Period|Protocol Violation|0
6252185|NCT01962441|9941093|FG000|Retreatment Substudy|Lack of Efficacy|1
6252186|NCT01962441|9941094|FG001|Retreatment Substudy|Lack of Efficacy|0
6252187|NCT01962441|9941095|FG002|Retreatment Substudy|Lack of Efficacy|0
6252188|NCT01962441|9941093|FG000|Retreatment Substudy|Lost to Follow-up|1
6252189|NCT01962441|9941094|FG001|Retreatment Substudy|Lost to Follow-up|0
6252190|NCT01962441|9941095|FG002|Retreatment Substudy|Lost to Follow-up|0
6252191|NCT01962493|9941106|FG000|Overall Study|Adverse Event|1
6252192|NCT01962493|9941107|FG001|Overall Study|Adverse Event|2
6252193|NCT01962493|9941106|FG000|Overall Study|Protocol Violation|0
6252194|NCT01962493|9941107|FG001|Overall Study|Protocol Violation|1
6252195|NCT01962493|9941106|FG000|Overall Study|Withdrawal by Subject|4
6252196|NCT01962493|9941107|FG001|Overall Study|Withdrawal by Subject|2
6252197|NCT01962896|9941149|FG000|Overall Study|Lack of Efficacy|4
6252198|NCT01962922|9941156|FG000|PK Portion Day 7|Withdrawal by Subject|3
6252199|NCT01962922|9941157|FG001|PK Portion Day 7|Withdrawal by Subject|0
6252200|NCT01962922|9941156|FG000|PK Portion Day 7|non-compliance|1
6252201|NCT01962922|9941157|FG001|PK Portion Day 7|non-compliance|0
6189602|NCT01401452|9844997|FG000|Overall Study|Subject's wife wants to get pregnant|1
6189603|NCT01401452|9844997|FG000|Overall Study|Psoriatic arthritis|1
6252202|NCT01962922|9941156|FG000|Extendion Portion (up to Month 6)|no longer wished to participate in study|4
6252203|NCT01962922|9941157|FG001|Extendion Portion (up to Month 6)|no longer wished to participate in study|3
6252204|NCT01962922|9941156|FG000|Extendion Portion (up to Month 6)|Physician Decision|1
6252205|NCT01962922|9941157|FG001|Extendion Portion (up to Month 6)|Physician Decision|0
6252206|NCT01962987|9941179|FG000|Overall Study|Adverse Event|4
6252207|NCT01962987|9941180|FG001|Overall Study|Adverse Event|4
6252208|NCT01962987|9941181|FG002|Overall Study|Adverse Event|0
6252209|NCT01962987|9941179|FG000|Overall Study|Lost to Follow-up|0
6252210|NCT01962987|9941180|FG001|Overall Study|Lost to Follow-up|0
6252211|NCT01962987|9941181|FG002|Overall Study|Lost to Follow-up|1
6252212|NCT01962987|9941179|FG000|Overall Study|Non compliance with dosing requirements|4
6252213|NCT01962987|9941180|FG001|Overall Study|Non compliance with dosing requirements|2
6252214|NCT01962987|9941181|FG002|Overall Study|Non compliance with dosing requirements|0
6252215|NCT01962987|9941179|FG000|Overall Study|Miscellaneous|1
6252216|NCT01962987|9941180|FG001|Overall Study|Miscellaneous|9
6252217|NCT01962987|9941181|FG002|Overall Study|Miscellaneous|2
6252218|NCT01962987|9941179|FG000|Overall Study|Restricted medication|5
6252219|NCT01962987|9941180|FG001|Overall Study|Restricted medication|1
6252220|NCT01962987|9941181|FG002|Overall Study|Restricted medication|1
6252221|NCT01962987|9941179|FG000|Overall Study|Serious Adverse Event|1
6252222|NCT01962987|9941180|FG001|Overall Study|Serious Adverse Event|0
6252223|NCT01962987|9941181|FG002|Overall Study|Serious Adverse Event|0
6252224|NCT01962987|9941179|FG000|Overall Study|Withdrawal by Subject|11
6252225|NCT01962987|9941180|FG001|Overall Study|Withdrawal by Subject|10
6252226|NCT01962987|9941181|FG002|Overall Study|Withdrawal by Subject|6
6252227|NCT01962987|9941179|FG000|Overall Study|Randomized in Error|4
6252228|NCT01962987|9941180|FG001|Overall Study|Randomized in Error|2
6252229|NCT01962987|9941181|FG002|Overall Study|Randomized in Error|2
6252230|NCT01963117|9941215|FG000|Overall Study|Death|1
6252231|NCT01963260|9941269|FG000|Overall Study|Withdrawal by Subject|2
6252232|NCT01963260|9941270|FG001|Overall Study|Withdrawal by Subject|0
6252233|NCT01963260|9941271|FG002|Overall Study|Withdrawal by Subject|0
6252234|NCT01963260|9941272|FG003|Overall Study|Withdrawal by Subject|1
6252235|NCT01963260|9941273|FG004|Overall Study|Withdrawal by Subject|2
6252236|NCT01963260|9941274|FG005|Overall Study|Withdrawal by Subject|0
6252237|NCT01963260|9941275|FG006|Overall Study|Withdrawal by Subject|0
6252238|NCT01963260|9941276|FG007|Overall Study|Withdrawal by Subject|0
6252239|NCT01963260|9941277|FG008|Overall Study|Withdrawal by Subject|0
6252240|NCT01963260|9941278|FG009|Overall Study|Withdrawal by Subject|0
6252241|NCT01963403|9941309|FG000|Overall Study|Lost to Follow-up|2
6252242|NCT01963403|9941310|FG001|Overall Study|Lost to Follow-up|3
6252243|NCT01963403|9941309|FG000|Overall Study|Implant removal|0
6252244|NCT01963403|9941310|FG001|Overall Study|Implant removal|1
6252245|NCT01963611|9941327|FG000|Overall Study|Adverse Event|1
6252246|NCT01963611|9941328|FG001|Overall Study|Adverse Event|1
6252247|NCT01963611|9941329|FG002|Overall Study|Adverse Event|3
6252248|NCT01963611|9941330|FG003|Overall Study|Adverse Event|4
6252249|NCT01963611|9941331|FG004|Overall Study|Adverse Event|3
6252250|NCT01963611|9941327|FG000|Overall Study|Protocol Violation|0
6252251|NCT01963611|9941328|FG001|Overall Study|Protocol Violation|0
6252252|NCT01963611|9941329|FG002|Overall Study|Protocol Violation|0
6252253|NCT01963611|9941330|FG003|Overall Study|Protocol Violation|1
6252254|NCT01963611|9941331|FG004|Overall Study|Protocol Violation|0
6252255|NCT01963611|9941327|FG000|Overall Study|Lack of Efficacy|0
6252256|NCT01963611|9941328|FG001|Overall Study|Lack of Efficacy|0
6252257|NCT01963611|9941329|FG002|Overall Study|Lack of Efficacy|0
6252258|NCT01963611|9941330|FG003|Overall Study|Lack of Efficacy|1
6252259|NCT01963611|9941331|FG004|Overall Study|Lack of Efficacy|0
6252260|NCT01963611|9941327|FG000|Overall Study|Withdrawal by Subject|3
6252261|NCT01963611|9941328|FG001|Overall Study|Withdrawal by Subject|2
6252262|NCT01963611|9941329|FG002|Overall Study|Withdrawal by Subject|1
6252263|NCT01963611|9941330|FG003|Overall Study|Withdrawal by Subject|1
6252264|NCT01963611|9941331|FG004|Overall Study|Withdrawal by Subject|3
6252265|NCT01963611|9941327|FG000|Overall Study|Other|47
6252266|NCT01963611|9941328|FG001|Overall Study|Other|46
6252267|NCT01963611|9941329|FG002|Overall Study|Other|48
6252268|NCT01963611|9941330|FG003|Overall Study|Other|45
6252269|NCT01963611|9941331|FG004|Overall Study|Other|45
6252270|NCT01963676|9941346|FG000|Overall Study|Withdrawal by Subject|1
6252271|NCT01963676|9941347|FG001|Overall Study|Withdrawal by Subject|0
6252272|NCT01963767|9941355|FG000|Overall Study|Withdrawal by Subject|4
6252273|NCT01963767|9941356|FG001|Overall Study|Withdrawal by Subject|2
6252274|NCT01963767|9941355|FG000|Overall Study|Adverse Event|2
6252275|NCT01963767|9941356|FG001|Overall Study|Adverse Event|0
6252276|NCT01964105|9941414|FG000|Overall Study|Lost to Follow-up|2
6252277|NCT01964105|9941415|FG001|Overall Study|Lost to Follow-up|13
6252278|NCT01964105|9941416|FG002|Overall Study|Lost to Follow-up|0
6270898|NCT02158533|9972373|FG003|Stage 2|Lack of Efficacy|0
6270899|NCT02158533|9972374|FG004|Stage 2|Lack of Efficacy|1
6270900|NCT02158533|9972375|FG005|Stage 2|Lack of Efficacy|0
6270901|NCT02158533|9972370|FG000|Stage 2|Lost to Follow-up|0
6270902|NCT02158533|9972371|FG001|Stage 2|Lost to Follow-up|0
6270903|NCT02158533|9972372|FG002|Stage 2|Lost to Follow-up|0
6270904|NCT02158533|9972373|FG003|Stage 2|Lost to Follow-up|1
6270905|NCT02158533|9972374|FG004|Stage 2|Lost to Follow-up|1
6252279|NCT01964222|9941426|FG000|Overall Study|Lost to Follow-up|7
6252280|NCT01964222|9941427|FG001|Overall Study|Lost to Follow-up|5
6252281|NCT01964222|9941426|FG000|Overall Study|Withdrawal by Subject|6
6252282|NCT01964222|9941427|FG001|Overall Study|Withdrawal by Subject|6
6252283|NCT01964222|9941426|FG000|Overall Study|Screening Failure|2
6252284|NCT01964222|9941427|FG001|Overall Study|Screening Failure|0
6252285|NCT01964300|9941435|FG000|Overall Study|Ineligible after enrollment|0
6252286|NCT01964300|9941436|FG001|Overall Study|Ineligible after enrollment|1
6252287|NCT01964300|9941435|FG000|Overall Study|Adverse Event|1
6252288|NCT01964300|9941436|FG001|Overall Study|Adverse Event|1
6252289|NCT01964300|9941435|FG000|Overall Study|Lack of Efficacy|3
6252290|NCT01964300|9941436|FG001|Overall Study|Lack of Efficacy|5
6252291|NCT01964300|9941435|FG000|Overall Study|Withdrawal by Subject|0
6252292|NCT01964300|9941436|FG001|Overall Study|Withdrawal by Subject|1
6252293|NCT01964300|9941435|FG000|Overall Study|To receive alternative therapy|1
6252294|NCT01964300|9941436|FG001|Overall Study|To receive alternative therapy|2
6252295|NCT01964300|9941435|FG000|Overall Study|Enlargement of cyst requiring drainage|1
6252296|NCT01964300|9941436|FG001|Overall Study|Enlargement of cyst requiring drainage|0
6252297|NCT01964300|9941435|FG000|Overall Study|Weight criteria not met|0
6252298|NCT01964300|9941436|FG001|Overall Study|Weight criteria not met|1
6252299|NCT01964326|9941442|FG000|Overall Study|Adverse Event|48
6252300|NCT01964326|9941442|FG000|Overall Study|Death|2
6252301|NCT01964326|9941442|FG000|Overall Study|Protocol Violation|4
6252302|NCT01964326|9941442|FG000|Overall Study|Lost to Follow-up|88
6252303|NCT01964326|9941442|FG000|Overall Study|Withdrawal by Subject|87
6252304|NCT01964326|9941442|FG000|Overall Study|Pregnancy|1
6252305|NCT01964326|9941442|FG000|Overall Study|No Longer Meets Eligibility Criteria|1
6252306|NCT01964326|9941442|FG000|Overall Study|Physician Decision|55
6252307|NCT01964326|9941442|FG000|Overall Study|Investigator Discretion|1
6252308|NCT01964326|9941442|FG000|Overall Study|Other|9
6252309|NCT01964326|9941442|FG000|Overall Study|Did not meet eligibility criteria|1
6252310|NCT01964352|9941450|FG000|Overall Study|Adverse Event|13
6252311|NCT01964352|9941451|FG001|Overall Study|Adverse Event|3
6252312|NCT01964352|9941452|FG002|Overall Study|Adverse Event|4
6252313|NCT01964352|9941453|FG003|Overall Study|Adverse Event|3
6189604|NCT01401452|9844997|FG000|Overall Study|Participant stopped Tx|2
6189605|NCT01401452|9844997|FG000|Overall Study|Discontinuation for personal reasons|1
6189606|NCT01401452|9844997|FG000|Overall Study|Treatment failure|1
6252314|NCT01964352|9941450|FG000|Overall Study|Lack of Efficacy|6
6252315|NCT01964352|9941451|FG001|Overall Study|Lack of Efficacy|0
6252316|NCT01964352|9941452|FG002|Overall Study|Lack of Efficacy|0
6252317|NCT01964352|9941453|FG003|Overall Study|Lack of Efficacy|0
6252318|NCT01964352|9941450|FG000|Overall Study|Protocol Violation|2
6252319|NCT01964352|9941451|FG001|Overall Study|Protocol Violation|4
6252320|NCT01964352|9941452|FG002|Overall Study|Protocol Violation|0
6252321|NCT01964352|9941453|FG003|Overall Study|Protocol Violation|2
6252322|NCT01964352|9941450|FG000|Overall Study|Lost to Follow-up|1
6252323|NCT01964352|9941451|FG001|Overall Study|Lost to Follow-up|0
6252324|NCT01964352|9941452|FG002|Overall Study|Lost to Follow-up|0
6252325|NCT01964352|9941453|FG003|Overall Study|Lost to Follow-up|1
6252326|NCT01964352|9941450|FG000|Overall Study|Withdrawal by Subject|4
6252327|NCT01964352|9941451|FG001|Overall Study|Withdrawal by Subject|2
6252328|NCT01964352|9941452|FG002|Overall Study|Withdrawal by Subject|1
6189607|NCT01401452|9844997|FG000|Overall Study|Unsatisfactory output|1
6189608|NCT01401452|9844997|FG000|Overall Study|Subject withdrew because of Tx success|1
6189609|NCT01401452|9844997|FG000|Overall Study|Subject chose to discontinue treatment|1
6189610|NCT01401452|9844997|FG000|Overall Study|Participant withdrew consent|1
6189611|NCT01401465|9845003|FG000|Treatment Period 1|Adverse Event|4
6189612|NCT01401465|9845004|FG001|Treatment Period 1|Adverse Event|1
6189613|NCT01401465|9845003|FG000|Treatment Period 1|Pregnancy|0
6189614|NCT01401465|9845004|FG001|Treatment Period 1|Pregnancy|1
6189615|NCT01401465|9845003|FG000|Treatment Period 1|Protocol Violation|5
6189616|NCT01401465|9845004|FG001|Treatment Period 1|Protocol Violation|0
6189617|NCT01401465|9845003|FG000|Treatment Period 1|Withdrawal by Subject|1
6189618|NCT01401465|9845004|FG001|Treatment Period 1|Withdrawal by Subject|4
6189619|NCT01401465|9845003|FG000|Treatment Period 1|Non-Compliance to Study Drug|1
6189620|NCT01401465|9845004|FG001|Treatment Period 1|Non-Compliance to Study Drug|0
6189621|NCT01401465|9845003|FG000|Treatment Period 1|Inability to Meet Continuation Criteria|3
6189622|NCT01401465|9845004|FG001|Treatment Period 1|Inability to Meet Continuation Criteria|9
6189623|NCT01401465|9845003|FG000|Treatment Period 1|Scheduling Difficulties|1
6189624|NCT01401465|9845004|FG001|Treatment Period 1|Scheduling Difficulties|1
6189625|NCT01401465|9845003|FG000|Treatment Period 2|Lost to Follow-up|0
6189626|NCT01401465|9845004|FG001|Treatment Period 2|Lost to Follow-up|1
6189627|NCT01401465|9845003|FG000|Treatment Period 2|Withdrawal by Subject|0
6189628|NCT01401465|9845004|FG001|Treatment Period 2|Withdrawal by Subject|1
6189629|NCT01401478|9845013|FG000|Overall Study|Study drug not available|6
6252329|NCT01964352|9941453|FG003|Overall Study|Withdrawal by Subject|0
6252330|NCT01964352|9941450|FG000|Overall Study|Other than stated above|0
6252331|NCT01964352|9941451|FG001|Overall Study|Other than stated above|2
6189630|NCT01401478|9845013|FG000|Overall Study|Adverse Event|5
6189631|NCT01401478|9845013|FG000|Overall Study|Hyperphosphatemia|5
6252332|NCT01964352|9941452|FG002|Overall Study|Other than stated above|1
6252333|NCT01964352|9941453|FG003|Overall Study|Other than stated above|2
6252334|NCT01964378|9941465|FG000|Overall Study|Disc. due to death before first dosing|0
6252335|NCT01964378|9941466|FG001|Overall Study|Disc. due to death before first dosing|1
6252336|NCT01964378|9941465|FG000|Overall Study|Disc. due to AE before first dosing|1
6252337|NCT01964378|9941466|FG001|Overall Study|Disc. due to AE before first dosing|0
6252338|NCT01964378|9941465|FG000|Overall Study|Death|3
6252339|NCT01964378|9941466|FG001|Overall Study|Death|2
6252340|NCT01964378|9941465|FG000|Overall Study|Adverse Event|12
6252341|NCT01964378|9941466|FG001|Overall Study|Adverse Event|5
6252342|NCT01964378|9941465|FG000|Overall Study|Lack of Efficacy|0
6252343|NCT01964378|9941466|FG001|Overall Study|Lack of Efficacy|1
6252344|NCT01964378|9941465|FG000|Overall Study|Protocol Violation|0
6252345|NCT01964378|9941466|FG001|Overall Study|Protocol Violation|1
6252346|NCT01964378|9941465|FG000|Overall Study|Lost to Follow-up|0
6252347|NCT01964378|9941466|FG001|Overall Study|Lost to Follow-up|1
6252348|NCT01964378|9941465|FG000|Overall Study|Withdrawal by Subject|7
6252349|NCT01964378|9941466|FG001|Overall Study|Withdrawal by Subject|5
6252350|NCT01964378|9941465|FG000|Overall Study|Inclusion/exclusion criteria not met|1
6252351|NCT01964378|9941466|FG001|Overall Study|Inclusion/exclusion criteria not met|3
6252352|NCT01964378|9941465|FG000|Overall Study|Other|1
6252353|NCT01964378|9941466|FG001|Overall Study|Other|2
6252354|NCT01964430|9941474|FG000|Overall Study|Adverse Event|71
6252355|NCT01964430|9941475|FG001|Overall Study|Adverse Event|37
6252356|NCT01964430|9941474|FG000|Overall Study|Withdrawal by Subject|36
6252357|NCT01964430|9941475|FG001|Overall Study|Withdrawal by Subject|27
6252358|NCT01964430|9941474|FG000|Overall Study|Death|1
6252359|NCT01964430|9941475|FG001|Overall Study|Death|3
6252360|NCT01964430|9941474|FG000|Overall Study|Protocol Deviation|0
6252361|NCT01964430|9941475|FG001|Overall Study|Protocol Deviation|1
6252362|NCT01964430|9941474|FG000|Overall Study|Physician Decision|5
6252363|NCT01964430|9941475|FG001|Overall Study|Physician Decision|4
6252364|NCT01964430|9941474|FG000|Overall Study|Disease Relapse|28
6252365|NCT01964430|9941475|FG001|Overall Study|Disease Relapse|38
6252366|NCT01964430|9941474|FG000|Overall Study|Miscellaneous|1
6252367|NCT01964430|9941475|FG001|Overall Study|Miscellaneous|3
6252368|NCT01964430|9941474|FG000|Overall Study|Randomized but not Treated|3
6252369|NCT01964430|9941475|FG001|Overall Study|Randomized but not Treated|11
6252370|NCT01964521|9941481|FG000|Overall Study|Lost to Follow-up|4
6252371|NCT01964547|9941488|FG000|Overall Study|Adverse Event|8
6252372|NCT01964547|9941489|FG001|Overall Study|Adverse Event|2
6252373|NCT01964547|9941488|FG000|Overall Study|Withdrawal by Subject|4
6252374|NCT01964547|9941489|FG001|Overall Study|Withdrawal by Subject|7
6252375|NCT01964547|9941488|FG000|Overall Study|Lost to Follow-up|0
6252376|NCT01964547|9941489|FG001|Overall Study|Lost to Follow-up|1
6252377|NCT01964547|9941488|FG000|Overall Study|Withdrawal by Investigator|0
6252378|NCT01964547|9941489|FG001|Overall Study|Withdrawal by Investigator|1
6252379|NCT01964716|9941497|FG000|Overall Study|Withdrawal by Subject|2
6252380|NCT01964716|9941498|FG001|Overall Study|Withdrawal by Subject|3
6252381|NCT01964716|9941497|FG000|Overall Study|Lost to Follow-up|1
6252382|NCT01964716|9941498|FG001|Overall Study|Lost to Follow-up|2
6252383|NCT01964716|9941497|FG000|Overall Study|No longer met eligibility criteria|1
6252384|NCT01964716|9941498|FG001|Overall Study|No longer met eligibility criteria|1
6252385|NCT01964716|9941497|FG000|Overall Study|Death|1
6252386|NCT01964716|9941498|FG001|Overall Study|Death|0
6252387|NCT01964755|9941512|FG000|Overall Study|Death|2
6252388|NCT01964898|9941518|FG000|Overall Study|ineligible post-randomization|1
6252389|NCT01964898|9941519|FG001|Overall Study|ineligible post-randomization|1
6252390|NCT01964898|9941518|FG000|Overall Study|did not receive the allocated interventi|2
6252391|NCT01964898|9941519|FG001|Overall Study|did not receive the allocated interventi|1
6252392|NCT01964898|9941518|FG000|Overall Study|Lost to Follow-up|3
6252393|NCT01964898|9941519|FG001|Overall Study|Lost to Follow-up|5
6252394|NCT01964898|9941518|FG000|Overall Study|Withdrawal by Subject|1
6252395|NCT01964898|9941519|FG001|Overall Study|Withdrawal by Subject|0
6252396|NCT01964924|9941525|FG000|Trametinib Monotherapy|Progression|19
6252397|NCT01964924|9941526|FG001|Trametinib Monotherapy|Progression|0
6252398|NCT01964950|9941537|FG000|Overall Study|Protocol Violation|25
6252399|NCT01964963|9941544|FG000|Overall Study|Case Report Forms Uncollected|888
6252400|NCT01964963|9941544|FG000|Overall Study|Protocol Deviation|50
6252401|NCT01964963|9941544|FG000|Overall Study|Data Reliability was not Assured|5
6252402|NCT01964976|9941550|FG000|Overall Study|Protocol Violation|31
6252403|NCT01965158|9941574|FG000|Overall Study|Adverse Event|14
6252404|NCT01965158|9941575|FG001|Overall Study|Adverse Event|5
6252405|NCT01965158|9941574|FG000|Overall Study|Withdrawal by Subject|16
6252406|NCT01965158|9941575|FG001|Overall Study|Withdrawal by Subject|24
6252407|NCT01965158|9941574|FG000|Overall Study|Lost to Follow-up|7
6252408|NCT01965158|9941575|FG001|Overall Study|Lost to Follow-up|5
6252409|NCT01965158|9941574|FG000|Overall Study|Protocol Violation|1
6252410|NCT01965158|9941575|FG001|Overall Study|Protocol Violation|1
6252411|NCT01965158|9941574|FG000|Overall Study|Other - Miscellaneous|3
6252412|NCT01965158|9941575|FG001|Overall Study|Other - Miscellaneous|0
6252413|NCT01965262|9941581|FG000|Second Intervention (7 Days)|Discontinued|0
6252414|NCT01965262|9941582|FG001|Second Intervention (7 Days)|Discontinued|1
6252415|NCT01965262|9941581|FG000|Second Intervention (7 Days)|Poor lens fit|0
6252416|NCT01965262|9941582|FG001|Second Intervention (7 Days)|Poor lens fit|9
6252417|NCT01965262|9941581|FG000|Second Intervention (7 Days)|Poor visual acuity|1
6252418|NCT01965262|9941582|FG001|Second Intervention (7 Days)|Poor visual acuity|0
6252419|NCT01965327|9941609|FG000|Overall Study|Physician Decision|2
6252420|NCT01965431|9941622|FG000|Overall Study|Adverse Event|0
6252421|NCT01965431|9941623|FG001|Overall Study|Adverse Event|1
6252422|NCT01965431|9941624|FG002|Overall Study|Adverse Event|0
6252423|NCT01965431|9941625|FG003|Overall Study|Adverse Event|0
6252424|NCT01965431|9941626|FG004|Overall Study|Adverse Event|0
6252425|NCT01965431|9941627|FG005|Overall Study|Adverse Event|0
6252426|NCT01965431|9941622|FG000|Overall Study|Other than stated above|6
6252427|NCT01965431|9941623|FG001|Overall Study|Other than stated above|5
6252428|NCT01965431|9941624|FG002|Overall Study|Other than stated above|6
6252429|NCT01965431|9941625|FG003|Overall Study|Other than stated above|6
6252430|NCT01965431|9941626|FG004|Overall Study|Other than stated above|6
6252431|NCT01965431|9941627|FG005|Overall Study|Other than stated above|6
6252432|NCT01965535|9941639|FG000|Overall Study|Lack of Efficacy|2
6252433|NCT01965535|9941640|FG001|Overall Study|Lack of Efficacy|1
6252434|NCT01965600|9941653|FG000|Washout Period of Approximately 15 Days|Study terminated by Sponsor|1
6252435|NCT01965600|9941654|FG001|Washout Period of Approximately 15 Days|Study terminated by Sponsor|3
6252436|NCT01965600|9941655|FG002|Washout Period of Approximately 15 Days|Study terminated by Sponsor|2
6252437|NCT01965600|9941656|FG003|Washout Period of Approximately 15 Days|Study terminated by Sponsor|1
6252438|NCT01965600|9941653|FG000|Washout Period of Approximately 15 Days|Withdrawal by Subject|0
6252439|NCT01965600|9941654|FG001|Washout Period of Approximately 15 Days|Withdrawal by Subject|1
6252440|NCT01965600|9941655|FG002|Washout Period of Approximately 15 Days|Withdrawal by Subject|0
6252441|NCT01965600|9941656|FG003|Washout Period of Approximately 15 Days|Withdrawal by Subject|0
6252442|NCT01965600|9941653|FG000|Washout Period of Approximately 15 Days|Did not meet entrance criteria|1
6252443|NCT01965600|9941654|FG001|Washout Period of Approximately 15 Days|Did not meet entrance criteria|0
6252444|NCT01965600|9941655|FG002|Washout Period of Approximately 15 Days|Did not meet entrance criteria|0
6252445|NCT01965600|9941656|FG003|Washout Period of Approximately 15 Days|Did not meet entrance criteria|0
6252446|NCT01965600|9941653|FG000|Washout Period of Approximately 15 Days|Adverse Event|0
6252447|NCT01965600|9941654|FG001|Washout Period of Approximately 15 Days|Adverse Event|0
6252448|NCT01965600|9941655|FG002|Washout Period of Approximately 15 Days|Adverse Event|0
6252449|NCT01965600|9941656|FG003|Washout Period of Approximately 15 Days|Adverse Event|1
6252450|NCT01965600|9941653|FG000|Second Intervention|Study terminated by Sponsor|0
6252451|NCT01965600|9941654|FG001|Second Intervention|Study terminated by Sponsor|0
6252452|NCT01965600|9941655|FG002|Second Intervention|Study terminated by Sponsor|2
6252453|NCT01965600|9941656|FG003|Second Intervention|Study terminated by Sponsor|2
6252454|NCT01965652|9941666|FG000|Overall Study|Adverse Event|40
6252455|NCT01965652|9941667|FG001|Overall Study|Adverse Event|37
6252456|NCT01965652|9941666|FG000|Overall Study|Withdrawal by Subject|62
6252457|NCT01965652|9941667|FG001|Overall Study|Withdrawal by Subject|69
6252458|NCT01965652|9941666|FG000|Overall Study|Lost to Follow-up|53
6252459|NCT01965652|9941667|FG001|Overall Study|Lost to Follow-up|40
6252460|NCT01965652|9941666|FG000|Overall Study|Protocol Violation|34
6252461|NCT01965652|9941667|FG001|Overall Study|Protocol Violation|38
6252462|NCT01965652|9941666|FG000|Overall Study|Death|3
6252463|NCT01965652|9941667|FG001|Overall Study|Death|4
6252464|NCT01965652|9941666|FG000|Overall Study|Other - Miscellaneous|18
6252465|NCT01965652|9941667|FG001|Overall Study|Other - Miscellaneous|21
6252466|NCT01965652|9941666|FG000|Overall Study|Pregnancy|0
6252467|NCT01965652|9941667|FG001|Overall Study|Pregnancy|1
6252468|NCT01965834|9941690|FG000|Overall Study|Lack of Efficacy|4
6252469|NCT01965860|9941697|FG000|Overall Study|Pregnancy|1
6252470|NCT01965860|9941698|FG001|Overall Study|Pregnancy|0
6252471|NCT01965860|9941699|FG002|Overall Study|Pregnancy|1
6252472|NCT01965860|9941697|FG000|Overall Study|Logistics|1
6252473|NCT01965860|9941698|FG001|Overall Study|Logistics|0
6252474|NCT01965860|9941699|FG002|Overall Study|Logistics|0
6252475|NCT01965938|9941714|FG000|Overall Study|Withdrawal by Subject|1
6252476|NCT01965938|9941715|FG001|Overall Study|Withdrawal by Subject|0
6252477|NCT01966003|9941725|FG000|Overall Study|Death|43
6252478|NCT01966003|9941726|FG001|Overall Study|Death|36
6252479|NCT01966003|9941725|FG000|Overall Study|Protocol Violation|6
6252480|NCT01966003|9941726|FG001|Overall Study|Protocol Violation|4
6252481|NCT01966003|9941725|FG000|Overall Study|Lost to Follow-up|4
6252482|NCT01966003|9941726|FG001|Overall Study|Lost to Follow-up|3
6252483|NCT01966003|9941725|FG000|Overall Study|Physician Decision|12
6252484|NCT01966003|9941726|FG001|Overall Study|Physician Decision|13
6252485|NCT01966003|9941725|FG000|Overall Study|Withdrawal by Subject|29
6252486|NCT01966003|9941726|FG001|Overall Study|Withdrawal by Subject|19
6252487|NCT01966003|9941725|FG000|Overall Study|Plan to Receive Other Anticancer Therapy|131
6252488|NCT01966003|9941726|FG001|Overall Study|Plan to Receive Other Anticancer Therapy|127
6252489|NCT01966003|9941725|FG000|Overall Study|Plan to Receive Commercial Bevacizumab|44
6252490|NCT01966003|9941726|FG001|Overall Study|Plan to Receive Commercial Bevacizumab|67
6252491|NCT01966003|9941725|FG000|Overall Study|Other|1
6252492|NCT01966003|9941726|FG001|Overall Study|Other|1
6252493|NCT01966042|9941732|FG000|Overall Study|Death|2
6252494|NCT01966068|9941738|FG000|Overall Study|Withdrawal by Subject|57
6252495|NCT01966068|9941738|FG000|Overall Study|Lost to Follow-up|81
6252496|NCT01966107|9941745|FG000|Overall Study|excluded from FAS|21
6252497|NCT01966107|9941746|FG001|Overall Study|excluded from FAS|20
6252498|NCT01966107|9941745|FG000|Overall Study|discontinued treatment|345
6252499|NCT01966107|9941746|FG001|Overall Study|discontinued treatment|372
6252500|NCT01966107|9941745|FG000|Overall Study|due to study closure|164
6252501|NCT01966107|9941746|FG001|Overall Study|due to study closure|186
6252502|NCT01966107|9941745|FG000|Overall Study|withdrew from the study|272
6252503|NCT01966107|9941746|FG001|Overall Study|withdrew from the study|303
6252504|NCT01966120|9941754|FG000|Overall Study|Withdrawal by Subject|0
6252505|NCT01966120|9941755|FG001|Overall Study|Withdrawal by Subject|5
6252506|NCT01966120|9941754|FG000|Overall Study|Lost to Follow-up|1
6252507|NCT01966120|9941755|FG001|Overall Study|Lost to Follow-up|1
6252508|NCT01966432|9941802|FG000|Overall Study|Lost to Follow-up|3
6252509|NCT01966432|9941803|FG001|Overall Study|Lost to Follow-up|2
6252510|NCT01966432|9941804|FG002|Overall Study|Lost to Follow-up|5
6252511|NCT01966432|9941802|FG000|Overall Study|Withdrawal by Subject|1
6252512|NCT01966432|9941803|FG001|Overall Study|Withdrawal by Subject|3
6252513|NCT01966432|9941804|FG002|Overall Study|Withdrawal by Subject|0
6252514|NCT01966432|9941802|FG000|Overall Study|Subject Incarcerated|0
6252515|NCT01966432|9941803|FG001|Overall Study|Subject Incarcerated|0
6252516|NCT01966432|9941804|FG002|Overall Study|Subject Incarcerated|1
6252517|NCT01966432|9941802|FG000|Overall Study|SBIRT program ended|1
6252518|NCT01966432|9941803|FG001|Overall Study|SBIRT program ended|8
6252519|NCT01966432|9941804|FG002|Overall Study|SBIRT program ended|20
6252520|NCT01966445|9941820|FG000|Part1 (Median Exposure of 6.143 Weeks)|Lost to Follow-up|0
6252521|NCT01966445|9941821|FG001|Part1 (Median Exposure of 6.143 Weeks)|Lost to Follow-up|0
6252522|NCT01966445|9941822|FG002|Part1 (Median Exposure of 6.143 Weeks)|Lost to Follow-up|0
6252523|NCT01966445|9941823|FG003|Part1 (Median Exposure of 6.143 Weeks)|Lost to Follow-up|2
6252524|NCT01966445|9941824|FG004|Part1 (Median Exposure of 6.143 Weeks)|Lost to Follow-up|0
6252525|NCT01966445|9941825|FG005|Part1 (Median Exposure of 6.143 Weeks)|Lost to Follow-up|1
6252526|NCT01966445|9941826|FG006|Part1 (Median Exposure of 6.143 Weeks)|Lost to Follow-up|0
6252527|NCT01966445|9941820|FG000|Part1 (Median Exposure of 6.143 Weeks)|Physician Decision|0
6252528|NCT01966445|9941821|FG001|Part1 (Median Exposure of 6.143 Weeks)|Physician Decision|1
6252529|NCT01966445|9941822|FG002|Part1 (Median Exposure of 6.143 Weeks)|Physician Decision|0
6252530|NCT01966445|9941823|FG003|Part1 (Median Exposure of 6.143 Weeks)|Physician Decision|1
6252531|NCT01966445|9941824|FG004|Part1 (Median Exposure of 6.143 Weeks)|Physician Decision|1
6252532|NCT01966445|9941825|FG005|Part1 (Median Exposure of 6.143 Weeks)|Physician Decision|0
6252533|NCT01966445|9941826|FG006|Part1 (Median Exposure of 6.143 Weeks)|Physician Decision|0
6252534|NCT01966445|9941820|FG000|Part1 (Median Exposure of 6.143 Weeks)|Withdrawal by Subject|0
6252535|NCT01966445|9941821|FG001|Part1 (Median Exposure of 6.143 Weeks)|Withdrawal by Subject|1
6252536|NCT01966445|9941822|FG002|Part1 (Median Exposure of 6.143 Weeks)|Withdrawal by Subject|1
6252537|NCT01966445|9941823|FG003|Part1 (Median Exposure of 6.143 Weeks)|Withdrawal by Subject|0
6252538|NCT01966445|9941824|FG004|Part1 (Median Exposure of 6.143 Weeks)|Withdrawal by Subject|2
6252539|NCT01966445|9941825|FG005|Part1 (Median Exposure of 6.143 Weeks)|Withdrawal by Subject|0
6252540|NCT01966445|9941826|FG006|Part1 (Median Exposure of 6.143 Weeks)|Withdrawal by Subject|0
6252541|NCT01966445|9941820|FG000|Part2 (Median Exposure of 7.143 Weeks)|Physician Decision|0
6252542|NCT01966445|9941821|FG001|Part2 (Median Exposure of 7.143 Weeks)|Physician Decision|0
6252543|NCT01966445|9941822|FG002|Part2 (Median Exposure of 7.143 Weeks)|Physician Decision|0
6252544|NCT01966445|9941823|FG003|Part2 (Median Exposure of 7.143 Weeks)|Physician Decision|0
6252545|NCT01966445|9941824|FG004|Part2 (Median Exposure of 7.143 Weeks)|Physician Decision|0
6252546|NCT01966445|9941825|FG005|Part2 (Median Exposure of 7.143 Weeks)|Physician Decision|0
6252547|NCT01966445|9941826|FG006|Part2 (Median Exposure of 7.143 Weeks)|Physician Decision|3
6252548|NCT01966445|9941820|FG000|Part2 (Median Exposure of 7.143 Weeks)|Withdrawal by Subject|0
6252549|NCT01966445|9941821|FG001|Part2 (Median Exposure of 7.143 Weeks)|Withdrawal by Subject|0
6252550|NCT01966445|9941822|FG002|Part2 (Median Exposure of 7.143 Weeks)|Withdrawal by Subject|0
6252551|NCT01966445|9941823|FG003|Part2 (Median Exposure of 7.143 Weeks)|Withdrawal by Subject|0
6252552|NCT01966445|9941824|FG004|Part2 (Median Exposure of 7.143 Weeks)|Withdrawal by Subject|0
6252553|NCT01966445|9941825|FG005|Part2 (Median Exposure of 7.143 Weeks)|Withdrawal by Subject|0
6252554|NCT01966445|9941826|FG006|Part2 (Median Exposure of 7.143 Weeks)|Withdrawal by Subject|2
6252555|NCT01967069|9941945|FG000|Overall Study|Adverse Event|2
6252556|NCT01967069|9941946|FG001|Overall Study|Adverse Event|2
6252557|NCT01967069|9941945|FG000|Overall Study|Lost to Follow-up|5
6252558|NCT01967069|9941946|FG001|Overall Study|Lost to Follow-up|2
6252559|NCT01967069|9941945|FG000|Overall Study|Withdrawal by Subject|1
6252560|NCT01967069|9941946|FG001|Overall Study|Withdrawal by Subject|3
6252561|NCT01967069|9941945|FG000|Overall Study|Lack of Efficacy|0
6252562|NCT01967069|9941946|FG001|Overall Study|Lack of Efficacy|1
6252563|NCT01967134|9941968|FG000|Overall Study|Lost to Follow-up|0
6252564|NCT01967134|9941969|FG001|Overall Study|Lost to Follow-up|1
6252565|NCT01967134|9941970|FG002|Overall Study|Lost to Follow-up|0
6252566|NCT01967147|9941980|FG000|Overall Study|Adverse Event|5
6252567|NCT01967147|9941981|FG001|Overall Study|Adverse Event|2
6252568|NCT01967147|9941980|FG000|Overall Study|Lack of Efficacy|1
6252569|NCT01967147|9941981|FG001|Overall Study|Lack of Efficacy|4
6252570|NCT01967147|9941980|FG000|Overall Study|Lost to Follow-up|1
6252571|NCT01967147|9941981|FG001|Overall Study|Lost to Follow-up|2
6252572|NCT01967147|9941980|FG000|Overall Study|Withdrawal by Subject|2
6252573|NCT01967147|9941981|FG001|Overall Study|Withdrawal by Subject|4
6252574|NCT01967147|9941980|FG000|Overall Study|Non-compliance with Study Drug|0
6252575|NCT01967147|9941981|FG001|Overall Study|Non-compliance with Study Drug|3
6252576|NCT01967147|9941980|FG000|Overall Study|Other|4
6252577|NCT01967147|9941981|FG001|Overall Study|Other|5
6252578|NCT01967173|9941996|FG000|Overall Study|Lost to Follow-up|5
6252579|NCT01967173|9941997|FG001|Overall Study|Lost to Follow-up|3
6252580|NCT01967173|9941998|FG002|Overall Study|Lost to Follow-up|2
6252581|NCT01967173|9941999|FG003|Overall Study|Lost to Follow-up|4
6252582|NCT01967173|9942000|FG004|Overall Study|Lost to Follow-up|8
6252583|NCT01967173|9942001|FG005|Overall Study|Lost to Follow-up|12
6252584|NCT01967173|9942002|FG006|Overall Study|Lost to Follow-up|6
6252585|NCT01967173|9942003|FG007|Overall Study|Lost to Follow-up|8
6252586|NCT01967173|9941996|FG000|Overall Study|Physician Decision|2
6252587|NCT01967173|9941997|FG001|Overall Study|Physician Decision|0
6252588|NCT01967173|9941998|FG002|Overall Study|Physician Decision|2
6252589|NCT01967173|9941999|FG003|Overall Study|Physician Decision|1
6252590|NCT01967173|9942000|FG004|Overall Study|Physician Decision|1
6252591|NCT01967173|9942001|FG005|Overall Study|Physician Decision|1
6252592|NCT01967173|9942002|FG006|Overall Study|Physician Decision|1
6252593|NCT01967173|9942003|FG007|Overall Study|Physician Decision|0
6252594|NCT01967173|9941996|FG000|Overall Study|Lack of Efficacy|2
6252595|NCT01967173|9941997|FG001|Overall Study|Lack of Efficacy|0
6252596|NCT01967173|9941998|FG002|Overall Study|Lack of Efficacy|2
6252597|NCT01967173|9941999|FG003|Overall Study|Lack of Efficacy|2
6252598|NCT01967173|9942000|FG004|Overall Study|Lack of Efficacy|0
6252599|NCT01967173|9942001|FG005|Overall Study|Lack of Efficacy|1
6252600|NCT01967173|9942002|FG006|Overall Study|Lack of Efficacy|0
6252601|NCT01967173|9942003|FG007|Overall Study|Lack of Efficacy|2
6252602|NCT01967173|9941996|FG000|Overall Study|Pregnancy|0
6252603|NCT01967173|9941997|FG001|Overall Study|Pregnancy|0
6252604|NCT01967173|9941998|FG002|Overall Study|Pregnancy|0
6252605|NCT01967173|9941999|FG003|Overall Study|Pregnancy|0
6252606|NCT01967173|9942000|FG004|Overall Study|Pregnancy|0
6252607|NCT01967173|9942001|FG005|Overall Study|Pregnancy|0
6252608|NCT01967173|9942002|FG006|Overall Study|Pregnancy|1
6252609|NCT01967173|9942003|FG007|Overall Study|Pregnancy|1
6252610|NCT01967173|9941996|FG000|Overall Study|Adverse Event|0
6252611|NCT01967173|9941997|FG001|Overall Study|Adverse Event|0
6252612|NCT01967173|9941998|FG002|Overall Study|Adverse Event|0
6252613|NCT01967173|9941999|FG003|Overall Study|Adverse Event|0
6252614|NCT01967173|9942000|FG004|Overall Study|Adverse Event|0
6252615|NCT01967173|9942001|FG005|Overall Study|Adverse Event|0
6252616|NCT01967173|9942002|FG006|Overall Study|Adverse Event|0
6252617|NCT01967173|9942003|FG007|Overall Study|Adverse Event|1
6252618|NCT01967173|9941996|FG000|Overall Study|Withdrawal by Subject|15
6252619|NCT01967173|9941997|FG001|Overall Study|Withdrawal by Subject|14
6252620|NCT01967173|9941998|FG002|Overall Study|Withdrawal by Subject|10
6252621|NCT01967173|9941999|FG003|Overall Study|Withdrawal by Subject|7
6252622|NCT01967173|9942000|FG004|Overall Study|Withdrawal by Subject|8
6252623|NCT01967173|9942001|FG005|Overall Study|Withdrawal by Subject|9
6252624|NCT01967173|9942002|FG006|Overall Study|Withdrawal by Subject|10
6252625|NCT01967173|9942003|FG007|Overall Study|Withdrawal by Subject|12
6252626|NCT01967225|9942019|FG000|Overall Study|Adverse Event|3
6252627|NCT01967225|9942020|FG001|Overall Study|Adverse Event|1
6252628|NCT01967225|9942019|FG000|Overall Study|Withdrawal by Subject|2
6252629|NCT01967225|9942020|FG001|Overall Study|Withdrawal by Subject|1
6252630|NCT01967225|9942019|FG000|Overall Study|Lack of Efficacy|1
6252631|NCT01967225|9942020|FG001|Overall Study|Lack of Efficacy|1
6252632|NCT01967225|9942019|FG000|Overall Study|Switching to other therapy|2
6252633|NCT01967225|9942020|FG001|Overall Study|Switching to other therapy|0
6252634|NCT01967225|9942019|FG000|Overall Study|Protocol driven decision point|1
6252635|NCT01967225|9942020|FG001|Overall Study|Protocol driven decision point|0
6252636|NCT01967225|9942019|FG000|Overall Study|Logistical difficulties|1
6252637|NCT01967225|9942020|FG001|Overall Study|Logistical difficulties|0
6252638|NCT01967225|9942019|FG000|Overall Study|Protocol Violation|2
6252639|NCT01967225|9942020|FG001|Overall Study|Protocol Violation|0
6252640|NCT01967277|9942030|FG000|Overall Study|Lost to Follow-up|1
6252641|NCT01967277|9942031|FG001|Overall Study|Lost to Follow-up|2
6252642|NCT01967277|9942030|FG000|Overall Study|Unrelated illness|0
6252643|NCT01967277|9942031|FG001|Overall Study|Unrelated illness|1
6252644|NCT01967537|9942065|FG000|Overall Study|Withdrawal by Subject|52
6252645|NCT01967537|9942065|FG000|Overall Study|Refuse treatment|2
6252646|NCT01967537|9942065|FG000|Overall Study|Lost to Follow-up|6
6252647|NCT01967550|9942071|FG000|Overall Study|Withdrawal by Subject|1
6252648|NCT01967550|9942072|FG001|Overall Study|Withdrawal by Subject|0
6252649|NCT01967550|9942071|FG000|Overall Study|Adverse Event|2
6252650|NCT01967550|9942072|FG001|Overall Study|Adverse Event|0
6252651|NCT01967550|9942071|FG000|Overall Study|Protocol Violation|2
6252652|NCT01967550|9942072|FG001|Overall Study|Protocol Violation|1
6252653|NCT01967550|9942071|FG000|Overall Study|Non Compliance|0
6252654|NCT01967550|9942072|FG001|Overall Study|Non Compliance|1
6252655|NCT01967576|9942078|FG000|Overall Study|Withdrawal by Subject|3
6252656|NCT01967576|9942078|FG000|Overall Study|Progressed/Removed from treatment|1
6252657|NCT01967576|9942078|FG000|Overall Study|Study closing at site|1
6252658|NCT01967576|9942078|FG000|Overall Study|Adverse Event|1
6252659|NCT01967576|9942078|FG000|Overall Study|Refused further treatment|1
6252660|NCT01967628|9942084|FG000|Overall Study|Withdrawal by Subject|2
6252661|NCT01967628|9942085|FG001|Overall Study|Withdrawal by Subject|0
6252662|NCT01967628|9942084|FG000|Overall Study|Unable to complete bronchoscopy|4
6252663|NCT01967628|9942085|FG001|Overall Study|Unable to complete bronchoscopy|6
6252664|NCT01967628|9942084|FG000|Overall Study|Lost to Follow-up|1
6252665|NCT01967628|9942085|FG001|Overall Study|Lost to Follow-up|0
6252666|NCT01967628|9942084|FG000|Overall Study|Low protein concentration in sample|20
6252667|NCT01967628|9942085|FG001|Overall Study|Low protein concentration in sample|25
6252668|NCT01967706|9942098|FG000|First Intervention (Day 1)|Withdrawal by Subject|1
6252669|NCT01967706|9942099|FG001|First Intervention (Day 1)|Withdrawal by Subject|0
6252670|NCT01967706|9942100|FG002|First Intervention (Day 1)|Withdrawal by Subject|0
6252671|NCT01967706|9942101|FG003|First Intervention (Day 1)|Withdrawal by Subject|0
6252672|NCT01967719|9942112|FG000|First Intervention (Day 1)|Withdrawal by Subject|0
6252673|NCT01967719|9942113|FG001|First Intervention (Day 1)|Withdrawal by Subject|1
6252674|NCT01967719|9942114|FG002|First Intervention (Day 1)|Withdrawal by Subject|0
6252675|NCT01967719|9942115|FG003|First Intervention (Day 1)|Withdrawal by Subject|1
6252676|NCT01967719|9942112|FG000|Second Intervention (Day 3)|Withdrawal by Subject|0
6252677|NCT01967719|9942113|FG001|Second Intervention (Day 3)|Withdrawal by Subject|1
6252678|NCT01967719|9942114|FG002|Second Intervention (Day 3)|Withdrawal by Subject|0
6252679|NCT01967719|9942115|FG003|Second Intervention (Day 3)|Withdrawal by Subject|0
6252680|NCT01967732|9942127|FG000|Washout Period of 1 Day (Day 0)|Dropped due to personal reasons|0
6252681|NCT01967732|9942128|FG001|Washout Period of 1 Day (Day 0)|Dropped due to personal reasons|1
6252682|NCT01967732|9942129|FG002|Washout Period of 1 Day (Day 0)|Dropped due to personal reasons|0
6252683|NCT01967732|9942130|FG003|Washout Period of 1 Day (Day 0)|Dropped due to personal reasons|0
6252684|NCT01967732|9942127|FG000|First Intervention (Day 1)|Poor venous access|0
6252685|NCT01967732|9942128|FG001|First Intervention (Day 1)|Poor venous access|1
6252686|NCT01967732|9942129|FG002|First Intervention (Day 1)|Poor venous access|0
6252687|NCT01967732|9942130|FG003|First Intervention (Day 1)|Poor venous access|0
6252688|NCT01967888|9942153|FG000|Overall Study|Lost to Follow-up|6
6252689|NCT01967888|9942154|FG001|Overall Study|Lost to Follow-up|4
6252690|NCT01967888|9942153|FG000|Overall Study|Withdrawal by Subject|1
6252691|NCT01967888|9942154|FG001|Overall Study|Withdrawal by Subject|1
6252692|NCT01967888|9942153|FG000|Overall Study|Did Not Have Transplant|1
6252693|NCT01967888|9942154|FG001|Overall Study|Did Not Have Transplant|0
6252694|NCT01967888|9942153|FG000|Overall Study|Research visit not done, data recorded|1
6252695|NCT01967888|9942154|FG001|Overall Study|Research visit not done, data recorded|0
6252696|NCT01967888|9942153|FG000|Overall Study|Subject excluded after randomization|1
6252697|NCT01967888|9942154|FG001|Overall Study|Subject excluded after randomization|0
6252698|NCT01967888|9942153|FG000|Overall Study|Patient didn't proceed to pancreatectomy|0
6252699|NCT01967888|9942154|FG001|Overall Study|Patient didn't proceed to pancreatectomy|1
6252700|NCT01967888|9942153|FG000|Overall Study|Subject Unable To Comply With Final Day|0
6252701|NCT01967888|9942154|FG001|Overall Study|Subject Unable To Comply With Final Day|1
6252702|NCT01967940|9942163|FG000|Part 2|Enrolled in Part 2 and Never Treated|0
6252703|NCT01967940|9942164|FG001|Part 2|Enrolled in Part 2 and Never Treated|0
6252704|NCT01967940|9942165|FG002|Part 2|Enrolled in Part 2 and Never Treated|0
6252705|NCT01967940|9942166|FG003|Part 2|Enrolled in Part 2 and Never Treated|1
6252706|NCT01967940|9942163|FG000|Part 2|Adverse Event|0
6252707|NCT01967940|9942164|FG001|Part 2|Adverse Event|0
6252708|NCT01967940|9942165|FG002|Part 2|Adverse Event|0
6252709|NCT01967940|9942166|FG003|Part 2|Adverse Event|1
6252710|NCT01967940|9942163|FG000|Part 2|Unknown Reason|0
6252711|NCT01967940|9942164|FG001|Part 2|Unknown Reason|0
6252712|NCT01967940|9942165|FG002|Part 2|Unknown Reason|0
6252713|NCT01967940|9942166|FG003|Part 2|Unknown Reason|1
6252714|NCT01968031|9942179|FG000|Overall Study|Adverse Event|13
6252715|NCT01968031|9942180|FG001|Overall Study|Adverse Event|10
6252716|NCT01968031|9942181|FG002|Overall Study|Adverse Event|22
6252717|NCT01968031|9942179|FG000|Overall Study|Withdrawal by Subject|3
6252718|NCT01968031|9942180|FG001|Overall Study|Withdrawal by Subject|7
6252719|NCT01968031|9942181|FG002|Overall Study|Withdrawal by Subject|3
6252720|NCT01968031|9942179|FG000|Overall Study|Did not meet entry criteria|1
6252721|NCT01968031|9942180|FG001|Overall Study|Did not meet entry criteria|1
6252722|NCT01968031|9942181|FG002|Overall Study|Did not meet entry criteria|1
6252723|NCT01968031|9942179|FG000|Overall Study|Noncompliance|0
6252724|NCT01968031|9942180|FG001|Overall Study|Noncompliance|0
6252725|NCT01968031|9942181|FG002|Overall Study|Noncompliance|2
6252726|NCT01968031|9942179|FG000|Overall Study|Failed inclusion criteria|0
6252727|NCT01968031|9942180|FG001|Overall Study|Failed inclusion criteria|2
6252728|NCT01968031|9942181|FG002|Overall Study|Failed inclusion criteria|0
6252729|NCT01968031|9942179|FG000|Overall Study|Death|0
6252730|NCT01968031|9942180|FG001|Overall Study|Death|0
6252731|NCT01968031|9942181|FG002|Overall Study|Death|1
6252732|NCT01968031|9942179|FG000|Overall Study|Prohibited concomitant medication|1
6252733|NCT01968031|9942180|FG001|Overall Study|Prohibited concomitant medication|0
6252734|NCT01968031|9942181|FG002|Overall Study|Prohibited concomitant medication|0
6252735|NCT01968070|9942213|FG000|Period 1|Withdrawal by Subject|0
6252736|NCT01968070|9942214|FG001|Period 1|Withdrawal by Subject|1
6252737|NCT01968070|9942215|FG002|Period 1|Withdrawal by Subject|0
6252738|NCT01968070|9942216|FG003|Period 1|Withdrawal by Subject|0
6252739|NCT01968070|9942217|FG004|Period 1|Withdrawal by Subject|0
6252740|NCT01968070|9942218|FG005|Period 1|Withdrawal by Subject|0
6252741|NCT01968070|9942219|FG006|Period 1|Withdrawal by Subject|1
6252742|NCT01968070|9942220|FG007|Period 1|Withdrawal by Subject|0
6252743|NCT01968070|9942221|FG008|Period 1|Withdrawal by Subject|0
6252744|NCT01968070|9942222|FG009|Period 1|Withdrawal by Subject|0
6252745|NCT01968070|9942223|FG010|Period 1|Withdrawal by Subject|0
6252746|NCT01968070|9942224|FG011|Period 1|Withdrawal by Subject|0
6252747|NCT01968070|9942225|FG012|Period 1|Withdrawal by Subject|0
6252748|NCT01968070|9942226|FG013|Period 1|Withdrawal by Subject|0
6252749|NCT01968070|9942227|FG014|Period 1|Withdrawal by Subject|0
6252750|NCT01968070|9942228|FG015|Period 1|Withdrawal by Subject|1
6252751|NCT01968070|9942229|FG016|Period 1|Withdrawal by Subject|0
6252752|NCT01968070|9942230|FG017|Period 1|Withdrawal by Subject|0
6252753|NCT01968070|9942213|FG000|Period 1|Protocol Violation|0
6252754|NCT01968070|9942214|FG001|Period 1|Protocol Violation|0
6252755|NCT01968070|9942215|FG002|Period 1|Protocol Violation|0
6252756|NCT01968070|9942216|FG003|Period 1|Protocol Violation|1
6252757|NCT01968070|9942217|FG004|Period 1|Protocol Violation|1
6252758|NCT01968070|9942218|FG005|Period 1|Protocol Violation|0
6252759|NCT01968070|9942219|FG006|Period 1|Protocol Violation|0
6252760|NCT01968070|9942220|FG007|Period 1|Protocol Violation|0
6252761|NCT01968070|9942221|FG008|Period 1|Protocol Violation|0
6252762|NCT01968070|9942222|FG009|Period 1|Protocol Violation|0
6252763|NCT01968070|9942223|FG010|Period 1|Protocol Violation|0
6252764|NCT01968070|9942224|FG011|Period 1|Protocol Violation|0
6252765|NCT01968070|9942225|FG012|Period 1|Protocol Violation|0
6252766|NCT01968070|9942226|FG013|Period 1|Protocol Violation|0
6252767|NCT01968070|9942227|FG014|Period 1|Protocol Violation|0
6252768|NCT01968070|9942228|FG015|Period 1|Protocol Violation|0
6252769|NCT01968070|9942229|FG016|Period 1|Protocol Violation|0
6252770|NCT01968070|9942230|FG017|Period 1|Protocol Violation|0
6252771|NCT01968070|9942213|FG000|Period 1|Lost to Follow-up|0
6252772|NCT01968070|9942214|FG001|Period 1|Lost to Follow-up|0
6252773|NCT01968070|9942215|FG002|Period 1|Lost to Follow-up|0
6252774|NCT01968070|9942216|FG003|Period 1|Lost to Follow-up|1
6252775|NCT01968070|9942217|FG004|Period 1|Lost to Follow-up|0
6252776|NCT01968070|9942218|FG005|Period 1|Lost to Follow-up|0
6252777|NCT01968070|9942219|FG006|Period 1|Lost to Follow-up|0
6252778|NCT01968070|9942220|FG007|Period 1|Lost to Follow-up|0
6252779|NCT01968070|9942221|FG008|Period 1|Lost to Follow-up|0
6252780|NCT01968070|9942222|FG009|Period 1|Lost to Follow-up|0
6252781|NCT01968070|9942223|FG010|Period 1|Lost to Follow-up|0
6252782|NCT01968070|9942224|FG011|Period 1|Lost to Follow-up|0
6252783|NCT01968070|9942225|FG012|Period 1|Lost to Follow-up|0
6252784|NCT01968070|9942226|FG013|Period 1|Lost to Follow-up|0
6252785|NCT01968070|9942227|FG014|Period 1|Lost to Follow-up|0
6252786|NCT01968070|9942228|FG015|Period 1|Lost to Follow-up|0
6252787|NCT01968070|9942229|FG016|Period 1|Lost to Follow-up|0
6189632|NCT01401478|9845013|FG000|Overall Study|Lost to Follow-up|5
6189633|NCT01401478|9845013|FG000|Overall Study|Kidney transplantation|3
6189634|NCT01401478|9845013|FG000|Overall Study|Withdrawal by Subject|3
6189635|NCT01401478|9845013|FG000|Overall Study|Blood samples not available|1
6189636|NCT01401478|9845013|FG000|Overall Study|Hyperphosphatemia and adverse event|1
6189637|NCT01401478|9845013|FG000|Overall Study|Low intact parathyroid hormone|1
6189638|NCT01401478|9845013|FG000|Overall Study|Serious adverse event|1
6189639|NCT01401530|9845033|FG000|Overall Study|Disease Progression|1
6189640|NCT01401530|9845034|FG001|Overall Study|Disease Progression|2
6189641|NCT01401530|9845035|FG002|Overall Study|Disease Progression|1
6189642|NCT01401530|9845033|FG000|Overall Study|Adverse Event|1
6189643|NCT01401530|9845034|FG001|Overall Study|Adverse Event|1
6189644|NCT01401530|9845035|FG002|Overall Study|Adverse Event|1
6189645|NCT01401530|9845033|FG000|Overall Study|Participant Choice|1
6189646|NCT01401530|9845034|FG001|Overall Study|Participant Choice|2
6252788|NCT01968070|9942230|FG017|Period 1|Lost to Follow-up|0
6252789|NCT01968070|9942213|FG000|Period 1|Adverse Event|0
6252790|NCT01968070|9942214|FG001|Period 1|Adverse Event|0
6252791|NCT01968070|9942215|FG002|Period 1|Adverse Event|0
6252792|NCT01968070|9942216|FG003|Period 1|Adverse Event|0
6252793|NCT01968070|9942217|FG004|Period 1|Adverse Event|0
6252794|NCT01968070|9942218|FG005|Period 1|Adverse Event|0
6252795|NCT01968070|9942219|FG006|Period 1|Adverse Event|1
6252796|NCT01968070|9942220|FG007|Period 1|Adverse Event|0
6252797|NCT01968070|9942221|FG008|Period 1|Adverse Event|0
6189647|NCT01401530|9845035|FG002|Overall Study|Participant Choice|1
6189648|NCT01401530|9845033|FG000|Overall Study|Physician Decision|0
6252798|NCT01968070|9942222|FG009|Period 1|Adverse Event|0
6252799|NCT01968070|9942223|FG010|Period 1|Adverse Event|0
6252800|NCT01968070|9942224|FG011|Period 1|Adverse Event|0
6252801|NCT01968070|9942225|FG012|Period 1|Adverse Event|0
6252802|NCT01968070|9942226|FG013|Period 1|Adverse Event|0
6252803|NCT01968070|9942227|FG014|Period 1|Adverse Event|0
6252804|NCT01968070|9942228|FG015|Period 1|Adverse Event|0
6252805|NCT01968070|9942229|FG016|Period 1|Adverse Event|0
6252806|NCT01968070|9942230|FG017|Period 1|Adverse Event|0
6252807|NCT01968070|9942213|FG000|Period 1|Physician Decision|0
6252808|NCT01968070|9942214|FG001|Period 1|Physician Decision|0
6252809|NCT01968070|9942215|FG002|Period 1|Physician Decision|0
6252810|NCT01968070|9942216|FG003|Period 1|Physician Decision|0
6252811|NCT01968070|9942217|FG004|Period 1|Physician Decision|0
6252812|NCT01968070|9942218|FG005|Period 1|Physician Decision|0
6252813|NCT01968070|9942219|FG006|Period 1|Physician Decision|0
6252814|NCT01968070|9942220|FG007|Period 1|Physician Decision|0
6252815|NCT01968070|9942221|FG008|Period 1|Physician Decision|0
6252816|NCT01968070|9942222|FG009|Period 1|Physician Decision|0
6252817|NCT01968070|9942223|FG010|Period 1|Physician Decision|0
6252818|NCT01968070|9942224|FG011|Period 1|Physician Decision|1
6252819|NCT01968070|9942225|FG012|Period 1|Physician Decision|0
6252820|NCT01968070|9942226|FG013|Period 1|Physician Decision|0
6252821|NCT01968070|9942227|FG014|Period 1|Physician Decision|0
6252822|NCT01968070|9942228|FG015|Period 1|Physician Decision|0
6252823|NCT01968070|9942229|FG016|Period 1|Physician Decision|0
6252824|NCT01968070|9942230|FG017|Period 1|Physician Decision|0
6252825|NCT01968070|9942213|FG000|Period 2|Withdrawal by Subject|0
6252826|NCT01968070|9942214|FG001|Period 2|Withdrawal by Subject|0
6252827|NCT01968070|9942215|FG002|Period 2|Withdrawal by Subject|0
6252828|NCT01968070|9942216|FG003|Period 2|Withdrawal by Subject|0
6252829|NCT01968070|9942217|FG004|Period 2|Withdrawal by Subject|1
6252830|NCT01968070|9942218|FG005|Period 2|Withdrawal by Subject|0
6252831|NCT01968070|9942219|FG006|Period 2|Withdrawal by Subject|0
6252832|NCT01968070|9942220|FG007|Period 2|Withdrawal by Subject|0
6252833|NCT01968070|9942221|FG008|Period 2|Withdrawal by Subject|0
6252834|NCT01968070|9942222|FG009|Period 2|Withdrawal by Subject|0
6252835|NCT01968070|9942223|FG010|Period 2|Withdrawal by Subject|0
6252836|NCT01968070|9942224|FG011|Period 2|Withdrawal by Subject|0
6252837|NCT01968070|9942225|FG012|Period 2|Withdrawal by Subject|0
6252838|NCT01968070|9942226|FG013|Period 2|Withdrawal by Subject|0
6252839|NCT01968070|9942227|FG014|Period 2|Withdrawal by Subject|0
6252840|NCT01968070|9942228|FG015|Period 2|Withdrawal by Subject|0
6252841|NCT01968070|9942229|FG016|Period 2|Withdrawal by Subject|0
6252842|NCT01968070|9942230|FG017|Period 2|Withdrawal by Subject|0
6252843|NCT01968213|9942279|FG000|Overall Study|Ongoing|90
6252844|NCT01968213|9942280|FG001|Overall Study|Ongoing|9
6252845|NCT01968434|9942360|FG000|Overall Study|Lost to Follow-up|3
6252846|NCT01968434|9942361|FG001|Overall Study|Lost to Follow-up|6
6252847|NCT01968551|9942379|FG000|Open Label Phase (48 Weeks)|Randomized but Never Treated|1
6252848|NCT01968551|9942380|FG001|Open Label Phase (48 Weeks)|Randomized but Never Treated|1
6252849|NCT01968551|9942381|FG002|Open Label Phase (48 Weeks)|Randomized but Never Treated|0
6252850|NCT01968551|9942379|FG000|Open Label Phase (48 Weeks)|Investigator's Discretion|0
6252851|NCT01968551|9942380|FG001|Open Label Phase (48 Weeks)|Investigator's Discretion|1
6252852|NCT01968551|9942381|FG002|Open Label Phase (48 Weeks)|Investigator's Discretion|0
6252853|NCT01968551|9942379|FG000|Open Label Phase (48 Weeks)|Withdrew Consent|1
6252854|NCT01968551|9942380|FG001|Open Label Phase (48 Weeks)|Withdrew Consent|1
6252855|NCT01968551|9942381|FG002|Open Label Phase (48 Weeks)|Withdrew Consent|3
6252856|NCT01968551|9942379|FG000|Open Label Phase (48 Weeks)|Lost to Follow-up|0
6252857|NCT01968551|9942380|FG001|Open Label Phase (48 Weeks)|Lost to Follow-up|0
6252858|NCT01968551|9942381|FG002|Open Label Phase (48 Weeks)|Lost to Follow-up|2
6252859|NCT01968551|9942379|FG000|Extension Phase|Adverse Event|0
6252860|NCT01968551|9942380|FG001|Extension Phase|Adverse Event|0
6252861|NCT01968551|9942381|FG002|Extension Phase|Adverse Event|2
6252862|NCT01968551|9942379|FG000|Extension Phase|Death|0
6252863|NCT01968551|9942380|FG001|Extension Phase|Death|1
6252864|NCT01968551|9942381|FG002|Extension Phase|Death|0
6252865|NCT01968551|9942379|FG000|Extension Phase|Withdrew Consent|0
6252866|NCT01968551|9942380|FG001|Extension Phase|Withdrew Consent|0
6252867|NCT01968551|9942381|FG002|Extension Phase|Withdrew Consent|1
6252868|NCT01968551|9942379|FG000|Extension Phase|Lost to Follow-up|1
6252869|NCT01968551|9942380|FG001|Extension Phase|Lost to Follow-up|0
6252870|NCT01968551|9942381|FG002|Extension Phase|Lost to Follow-up|1
6252871|NCT01968694|9942395|FG000|Washout (1 Month)|Lost to Follow-up|0
6252872|NCT01968694|9942396|FG001|Washout (1 Month)|Lost to Follow-up|1
6252873|NCT01968707|9942412|FG000|Overall Study|Did not meet treatment day baseline|49
6252874|NCT01968707|9942413|FG001|Overall Study|Did not meet treatment day baseline|12
6252875|NCT01968707|9942414|FG002|Overall Study|Did not meet treatment day baseline|41
6252876|NCT01968707|9942415|FG003|Overall Study|Did not meet treatment day baseline|44
6252877|NCT01968707|9942416|FG004|Overall Study|Did not meet treatment day baseline|36
6252878|NCT01968707|9942417|FG005|Overall Study|Did not meet treatment day baseline|11
6252879|NCT01968707|9942418|FG006|Overall Study|Did not meet treatment day baseline|34
6252880|NCT01968707|9942419|FG007|Overall Study|Did not meet treatment day baseline|35
6252881|NCT01968811|9942452|FG000|Overall Study|Protocol Violation|4
6252882|NCT01968811|9942452|FG000|Overall Study|post op.ref. of subject to other hospita|1
6252883|NCT01968954|9942458|FG000|Overall Study|Adverse Event|6
6252884|NCT01968954|9942459|FG001|Overall Study|Adverse Event|3
6252885|NCT01968954|9942458|FG000|Overall Study|Death|1
6252886|NCT01968954|9942459|FG001|Overall Study|Death|2
6252887|NCT01968954|9942458|FG000|Overall Study|Lost to Follow-up|6
6252888|NCT01968954|9942459|FG001|Overall Study|Lost to Follow-up|4
6252889|NCT01968954|9942458|FG000|Overall Study|Withdrawal by Subject|20
6252890|NCT01968954|9942459|FG001|Overall Study|Withdrawal by Subject|23
6252891|NCT01968954|9942458|FG000|Overall Study|Other|7
6252892|NCT01968954|9942459|FG001|Overall Study|Other|8
6252893|NCT01968954|9942458|FG000|Overall Study|Protocol Violation|0
6252894|NCT01968954|9942459|FG001|Overall Study|Protocol Violation|1
6252895|NCT01968954|9942458|FG000|Overall Study|Did not met inclusion criteria|0
6252896|NCT01968954|9942459|FG001|Overall Study|Did not met inclusion criteria|2
6252897|NCT01968967|9942468|FG000|Treatment Period|Other|22
6252898|NCT01968967|9942469|FG001|Treatment Period|Other|22
6252899|NCT01968967|9942470|FG002|Treatment Period|Other|0
6252900|NCT01968967|9942471|FG003|Treatment Period|Other|0
6252901|NCT01968967|9942472|FG004|Treatment Period|Other|0
6252902|NCT01968967|9942468|FG000|Treatment Period|Withdrawal by Subject|71
6252903|NCT01968967|9942469|FG001|Treatment Period|Withdrawal by Subject|61
6252904|NCT01968967|9942470|FG002|Treatment Period|Withdrawal by Subject|0
6252905|NCT01968967|9942471|FG003|Treatment Period|Withdrawal by Subject|0
6252906|NCT01968967|9942472|FG004|Treatment Period|Withdrawal by Subject|0
6252907|NCT01968967|9942468|FG000|Treatment Period|Did Not Meet Entrance Criteria|2
6252908|NCT01968967|9942469|FG001|Treatment Period|Did Not Meet Entrance Criteria|3
6252909|NCT01968967|9942470|FG002|Treatment Period|Did Not Meet Entrance Criteria|0
6252910|NCT01968967|9942471|FG003|Treatment Period|Did Not Meet Entrance Criteria|0
6252911|NCT01968967|9942472|FG004|Treatment Period|Did Not Meet Entrance Criteria|0
6252912|NCT01968967|9942468|FG000|Treatment Period|Lost to Follow-up|26
6252913|NCT01968967|9942469|FG001|Treatment Period|Lost to Follow-up|31
6252914|NCT01968967|9942470|FG002|Treatment Period|Lost to Follow-up|0
6252915|NCT01968967|9942471|FG003|Treatment Period|Lost to Follow-up|0
6252916|NCT01968967|9942472|FG004|Treatment Period|Lost to Follow-up|0
6252917|NCT01968967|9942468|FG000|Treatment Period|Protocol Violation|1
6252918|NCT01968967|9942469|FG001|Treatment Period|Protocol Violation|2
6252919|NCT01968967|9942470|FG002|Treatment Period|Protocol Violation|0
6252920|NCT01968967|9942471|FG003|Treatment Period|Protocol Violation|0
6252921|NCT01968967|9942472|FG004|Treatment Period|Protocol Violation|0
6252922|NCT01968967|9942468|FG000|Treatment Period|Adverse Event|9
6252923|NCT01968967|9942469|FG001|Treatment Period|Adverse Event|8
6252924|NCT01968967|9942470|FG002|Treatment Period|Adverse Event|0
6252925|NCT01968967|9942471|FG003|Treatment Period|Adverse Event|0
6252926|NCT01968967|9942472|FG004|Treatment Period|Adverse Event|0
6252927|NCT01968967|9942468|FG000|Treatment Period|Death|9
6252928|NCT01968967|9942469|FG001|Treatment Period|Death|2
6252929|NCT01968967|9942470|FG002|Treatment Period|Death|0
6252930|NCT01968967|9942471|FG003|Treatment Period|Death|0
6252931|NCT01968967|9942472|FG004|Treatment Period|Death|0
6252932|NCT01968967|9942468|FG000|Treatment Period|Randomized Not Treated|6
6252933|NCT01968967|9942469|FG001|Treatment Period|Randomized Not Treated|5
6252934|NCT01968967|9942470|FG002|Treatment Period|Randomized Not Treated|0
6252935|NCT01968967|9942471|FG003|Treatment Period|Randomized Not Treated|0
6252936|NCT01968967|9942472|FG004|Treatment Period|Randomized Not Treated|0
6252937|NCT01968967|9942468|FG000|Extension Period|Withdrew Consent|0
6252938|NCT01968967|9942469|FG001|Extension Period|Withdrew Consent|0
6252939|NCT01968967|9942470|FG002|Extension Period|Withdrew Consent|2
6252940|NCT01968967|9942471|FG003|Extension Period|Withdrew Consent|0
6252941|NCT01968967|9942472|FG004|Extension Period|Withdrew Consent|5
6252942|NCT01968980|9942488|FG000|Overall Study|Death|0
6252943|NCT01968980|9942489|FG001|Overall Study|Death|1
6252944|NCT01968980|9942488|FG000|Overall Study|Adverse Event|1
6252945|NCT01968980|9942489|FG001|Overall Study|Adverse Event|3
6252946|NCT01968980|9942488|FG000|Overall Study|Does not meet entry criteria|1
6252947|NCT01968980|9942489|FG001|Overall Study|Does not meet entry criteria|3
6252948|NCT01968980|9942488|FG000|Overall Study|Withdrawal by Subject|13
6252949|NCT01968980|9942489|FG001|Overall Study|Withdrawal by Subject|5
6252950|NCT01968980|9942488|FG000|Overall Study|Other unspecified|1
6252951|NCT01968980|9942489|FG001|Overall Study|Other unspecified|2
6252952|NCT01969058|9942498|FG000|Overall Study|Withdrawal by Subject|2
6252953|NCT01969058|9942499|FG001|Overall Study|Withdrawal by Subject|0
6252954|NCT01969058|9942498|FG000|Overall Study|Adverse Event|1
6252955|NCT01969058|9942499|FG001|Overall Study|Adverse Event|0
6252956|NCT01969084|9942507|FG000|Overall Study|Adverse Event|0
6252957|NCT01969084|9942508|FG001|Overall Study|Adverse Event|1
6270906|NCT02158533|9972375|FG005|Stage 2|Lost to Follow-up|2
6270907|NCT02158533|9972370|FG000|Stage 2|Withdrawal by Subject|0
6270908|NCT02158533|9972371|FG001|Stage 2|Withdrawal by Subject|0
6270909|NCT02158533|9972372|FG002|Stage 2|Withdrawal by Subject|0
6270910|NCT02158533|9972373|FG003|Stage 2|Withdrawal by Subject|0
6270911|NCT02158533|9972374|FG004|Stage 2|Withdrawal by Subject|1
6270912|NCT02158533|9972375|FG005|Stage 2|Withdrawal by Subject|2
6270913|NCT02158533|9972370|FG000|Stage 2|Physician Decision|0
6270914|NCT02158533|9972371|FG001|Stage 2|Physician Decision|0
6270915|NCT02158533|9972372|FG002|Stage 2|Physician Decision|0
6270916|NCT02158533|9972373|FG003|Stage 2|Physician Decision|0
6252958|NCT01969500|9942565|FG000|Overall Study|Death|0
6252959|NCT01969500|9942566|FG001|Overall Study|Death|1
6252960|NCT01969500|9942565|FG000|Overall Study|extended hospitalization|1
6252961|NCT01969500|9942566|FG001|Overall Study|extended hospitalization|1
6252962|NCT01969721|9942585|FG000|Overall Study|Adverse Event|3
6252963|NCT01969721|9942586|FG001|Overall Study|Adverse Event|8
6252964|NCT01969721|9942587|FG002|Overall Study|Adverse Event|3
6252965|NCT01969721|9942588|FG003|Overall Study|Adverse Event|2
6252966|NCT01969721|9942585|FG000|Overall Study|Lack of Efficacy|0
6252967|NCT01969721|9942586|FG001|Overall Study|Lack of Efficacy|0
6252968|NCT01969721|9942587|FG002|Overall Study|Lack of Efficacy|1
6252969|NCT01969721|9942588|FG003|Overall Study|Lack of Efficacy|0
6252970|NCT01969721|9942585|FG000|Overall Study|Non compliant with protocol|1
6252971|NCT01969721|9942586|FG001|Overall Study|Non compliant with protocol|1
6252972|NCT01969721|9942587|FG002|Overall Study|Non compliant with protocol|0
6252973|NCT01969721|9942588|FG003|Overall Study|Non compliant with protocol|2
6252974|NCT01969721|9942585|FG000|Overall Study|Other not defined above|0
6252975|NCT01969721|9942586|FG001|Overall Study|Other not defined above|2
6252976|NCT01969721|9942587|FG002|Overall Study|Other not defined above|0
6252977|NCT01969721|9942588|FG003|Overall Study|Other not defined above|0
6252978|NCT01969721|9942585|FG000|Overall Study|Discontinued during washout periods.|0
6252979|NCT01969721|9942586|FG001|Overall Study|Discontinued during washout periods.|1
6252980|NCT01969721|9942587|FG002|Overall Study|Discontinued during washout periods.|1
6252981|NCT01969721|9942588|FG003|Overall Study|Discontinued during washout periods.|2
6252982|NCT01969799|9942617|FG000|Overall Study|Adverse Event|0
6252983|NCT01969799|9942618|FG001|Overall Study|Adverse Event|1
6252984|NCT01969799|9942617|FG000|Overall Study|Death|16
6252985|NCT01969799|9942618|FG001|Overall Study|Death|11
6252986|NCT01969799|9942617|FG000|Overall Study|Lost to Follow-up|0
6252987|NCT01969799|9942618|FG001|Overall Study|Lost to Follow-up|2
6252988|NCT01969799|9942617|FG000|Overall Study|Physician Decision|1
6252989|NCT01969799|9942618|FG001|Overall Study|Physician Decision|0
6252990|NCT01969851|9942627|FG000|Overall Study|Adverse Event|0
6252991|NCT01969851|9942628|FG001|Overall Study|Adverse Event|0
6252992|NCT01969851|9942629|FG002|Overall Study|Adverse Event|3
6252993|NCT01969851|9942627|FG000|Overall Study|Lack of Efficacy|0
6252994|NCT01969851|9942628|FG001|Overall Study|Lack of Efficacy|3
6252995|NCT01969851|9942629|FG002|Overall Study|Lack of Efficacy|1
6252996|NCT01969851|9942627|FG000|Overall Study|Withdrawal by Subject|1
6252997|NCT01969851|9942628|FG001|Overall Study|Withdrawal by Subject|0
6252998|NCT01969851|9942629|FG002|Overall Study|Withdrawal by Subject|1
6252999|NCT01969851|9942627|FG000|Overall Study|No effective dose in Titration period|0
6253000|NCT01969851|9942628|FG001|Overall Study|No effective dose in Titration period|0
6253001|NCT01969851|9942629|FG002|Overall Study|No effective dose in Titration period|1
6253002|NCT01969851|9942627|FG000|Overall Study|Sponsor decision|0
6253003|NCT01969851|9942628|FG001|Overall Study|Sponsor decision|0
6253004|NCT01969851|9942629|FG002|Overall Study|Sponsor decision|1
6253005|NCT01970007|9942641|FG000|Overall Study|Death|5
6253006|NCT01970007|9942641|FG000|Overall Study|Withdrawal by Subject|23
6253007|NCT01970007|9942641|FG000|Overall Study|Lost to Follow-up|24
6253008|NCT01970007|9942641|FG000|Overall Study|"Other endpoint"|3
6253009|NCT01970241|9942656|FG000|Overall Study|Withdrawal by Subject|2
6253010|NCT01970241|9942657|FG001|Overall Study|Withdrawal by Subject|0
6253011|NCT01970241|9942656|FG000|Overall Study|Steroid d/c;discharge<48 hrs.|15
6253012|NCT01970241|9942657|FG001|Overall Study|Steroid d/c;discharge<48 hrs.|8
6253013|NCT01970371|9942668|FG000|Overall Study|Death|8
6253014|NCT01970371|9942669|FG001|Overall Study|Death|13
6253015|NCT01970371|9942670|FG002|Overall Study|Death|12
6253016|NCT01970371|9942668|FG000|Overall Study|Lost to Follow-up|0
6253017|NCT01970371|9942669|FG001|Overall Study|Lost to Follow-up|0
6253018|NCT01970371|9942670|FG002|Overall Study|Lost to Follow-up|1
6253019|NCT01970397|9942682|FG000|Overall Study|Adverse Event|0
6253020|NCT01970397|9942683|FG001|Overall Study|Adverse Event|1
6253021|NCT01970397|9942682|FG000|Overall Study|Lost to Follow-up|0
6253022|NCT01970397|9942683|FG001|Overall Study|Lost to Follow-up|1
6253023|NCT01970397|9942682|FG000|Overall Study|Personal Reasons|1
6253024|NCT01970397|9942683|FG001|Overall Study|Personal Reasons|2
6253025|NCT01970397|9942682|FG000|Overall Study|Protocol Violation|1
6253026|NCT01970397|9942683|FG001|Overall Study|Protocol Violation|1
6253027|NCT01970475|9942691|FG000|Overall Study|Withdrawal by Subject|11
6253028|NCT01970475|9942692|FG001|Overall Study|Withdrawal by Subject|6
6253029|NCT01970475|9942691|FG000|Overall Study|Adverse Event|7
6253030|NCT01970475|9942692|FG001|Overall Study|Adverse Event|3
6253031|NCT01970475|9942691|FG000|Overall Study|Lost to Follow-up|2
6253032|NCT01970475|9942692|FG001|Overall Study|Lost to Follow-up|2
6253033|NCT01970475|9942691|FG000|Overall Study|Protocol Violation|1
6253034|NCT01970475|9942692|FG001|Overall Study|Protocol Violation|0
6253035|NCT01970488|9942700|FG000|Part 1: Through Week 16|Protocol-specified Criteria|1
6253036|NCT01970488|9942701|FG001|Part 1: Through Week 16|Protocol-specified Criteria|2
6253037|NCT01970488|9942702|FG002|Part 1: Through Week 16|Protocol-specified Criteria|0
6253038|NCT01970488|9942703|FG003|Part 1: Through Week 16|Protocol-specified Criteria|0
6253039|NCT01970488|9942704|FG004|Part 1: Through Week 16|Protocol-specified Criteria|0
6253040|NCT01970488|9942700|FG000|Part 1: Through Week 16|Protocol Violation|1
6253041|NCT01970488|9942701|FG001|Part 1: Through Week 16|Protocol Violation|2
6253042|NCT01970488|9942702|FG002|Part 1: Through Week 16|Protocol Violation|0
6253043|NCT01970488|9942703|FG003|Part 1: Through Week 16|Protocol Violation|0
6253044|NCT01970488|9942704|FG004|Part 1: Through Week 16|Protocol Violation|0
6253045|NCT01970488|9942700|FG000|Part 1: Through Week 16|Adverse Event|6
6253046|NCT01970488|9942701|FG001|Part 1: Through Week 16|Adverse Event|5
6253047|NCT01970488|9942702|FG002|Part 1: Through Week 16|Adverse Event|0
6253048|NCT01970488|9942703|FG003|Part 1: Through Week 16|Adverse Event|0
6253049|NCT01970488|9942704|FG004|Part 1: Through Week 16|Adverse Event|0
6253050|NCT01970488|9942700|FG000|Part 1: Through Week 16|Withdrawal by Subject|3
6253051|NCT01970488|9942701|FG001|Part 1: Through Week 16|Withdrawal by Subject|2
6253052|NCT01970488|9942702|FG002|Part 1: Through Week 16|Withdrawal by Subject|0
6253053|NCT01970488|9942703|FG003|Part 1: Through Week 16|Withdrawal by Subject|0
6253054|NCT01970488|9942704|FG004|Part 1: Through Week 16|Withdrawal by Subject|0
6253055|NCT01970488|9942700|FG000|Part 1: Through Week 16|Lost to Follow-up|0
6253056|NCT01970488|9942701|FG001|Part 1: Through Week 16|Lost to Follow-up|2
6253057|NCT01970488|9942702|FG002|Part 1: Through Week 16|Lost to Follow-up|0
6253058|NCT01970488|9942703|FG003|Part 1: Through Week 16|Lost to Follow-up|0
6253059|NCT01970488|9942704|FG004|Part 1: Through Week 16|Lost to Follow-up|0
6253060|NCT01970488|9942700|FG000|Part 2: Post Week 16|Physician Decision|0
6253061|NCT01970488|9942701|FG001|Part 2: Post Week 16|Physician Decision|0
6253062|NCT01970488|9942702|FG002|Part 2: Post Week 16|Physician Decision|0
6253063|NCT01970488|9942703|FG003|Part 2: Post Week 16|Physician Decision|0
6253064|NCT01970488|9942704|FG004|Part 2: Post Week 16|Physician Decision|1
6253065|NCT01970488|9942700|FG000|Part 2: Post Week 16|Non-compliance|0
6253066|NCT01970488|9942701|FG001|Part 2: Post Week 16|Non-compliance|0
6253067|NCT01970488|9942702|FG002|Part 2: Post Week 16|Non-compliance|1
6253068|NCT01970488|9942703|FG003|Part 2: Post Week 16|Non-compliance|0
6253069|NCT01970488|9942704|FG004|Part 2: Post Week 16|Non-compliance|0
6253070|NCT01970488|9942700|FG000|Part 2: Post Week 16|Lack of Efficacy|0
6253071|NCT01970488|9942701|FG001|Part 2: Post Week 16|Lack of Efficacy|0
6253072|NCT01970488|9942702|FG002|Part 2: Post Week 16|Lack of Efficacy|2
6253073|NCT01970488|9942703|FG003|Part 2: Post Week 16|Lack of Efficacy|3
6253074|NCT01970488|9942704|FG004|Part 2: Post Week 16|Lack of Efficacy|1
6253075|NCT01970488|9942700|FG000|Part 2: Post Week 16|Adverse Event|0
6253076|NCT01970488|9942701|FG001|Part 2: Post Week 16|Adverse Event|0
6253077|NCT01970488|9942702|FG002|Part 2: Post Week 16|Adverse Event|5
6253078|NCT01970488|9942703|FG003|Part 2: Post Week 16|Adverse Event|1
6253079|NCT01970488|9942704|FG004|Part 2: Post Week 16|Adverse Event|1
6253080|NCT01970488|9942700|FG000|Part 2: Post Week 16|Withdrawal by Subject|0
6253081|NCT01970488|9942701|FG001|Part 2: Post Week 16|Withdrawal by Subject|0
6253082|NCT01970488|9942702|FG002|Part 2: Post Week 16|Withdrawal by Subject|8
6253083|NCT01970488|9942703|FG003|Part 2: Post Week 16|Withdrawal by Subject|3
6253084|NCT01970488|9942704|FG004|Part 2: Post Week 16|Withdrawal by Subject|3
6253085|NCT01970488|9942700|FG000|Part 2: Post Week 16|Lost to Follow-up|0
6253086|NCT01970488|9942701|FG001|Part 2: Post Week 16|Lost to Follow-up|0
6253087|NCT01970488|9942702|FG002|Part 2: Post Week 16|Lost to Follow-up|1
6253088|NCT01970488|9942703|FG003|Part 2: Post Week 16|Lost to Follow-up|1
6253089|NCT01970488|9942704|FG004|Part 2: Post Week 16|Lost to Follow-up|2
6253090|NCT01970527|9942721|FG000|Pre-treatment/Baseline|Screen fail- participant had brain mets|1
6253091|NCT01970527|9942722|FG001|Pre-treatment/Baseline|Screen fail- participant had brain mets|0
6253092|NCT01970527|9942721|FG000|Treatment|Disease progression|0
6253093|NCT01970527|9942722|FG001|Treatment|Disease progression|1
6253094|NCT01970527|9942721|FG000|Treatment|Participant did not tolerate Ipilimumab|0
6253095|NCT01970527|9942722|FG001|Treatment|Participant did not tolerate Ipilimumab|1
6253096|NCT01970527|9942721|FG000|Treatment|Death|0
6253097|NCT01970527|9942722|FG001|Treatment|Death|1
6253098|NCT01970527|9942721|FG000|Follow-up Clinic Visit|Disease progression|1
6253099|NCT01970527|9942722|FG001|Follow-up Clinic Visit|Disease progression|1
6253100|NCT01970527|9942721|FG000|Follow-up Clinic Visit|Withdrawal by Subject|0
6086296|NCT00660387|9696203|FG001|Overall Study|Lack of Efficacy|1
6086297|NCT00660387|9696202|FG000|Overall Study|Protocol Violation|1
6086298|NCT00660387|9696203|FG001|Overall Study|Protocol Violation|0
6086299|NCT00660400|9696209|FG000|Overall Study|Lack of insurance approval|1
6189649|NCT01401530|9845034|FG001|Overall Study|Physician Decision|1
6189650|NCT01401530|9845035|FG002|Overall Study|Physician Decision|0
6253101|NCT01970527|9942722|FG001|Follow-up Clinic Visit|Withdrawal by Subject|1
6253102|NCT01970527|9942721|FG000|Follow-up Clinic Visit|Lost to Follow-up|0
6253103|NCT01970527|9942722|FG001|Follow-up Clinic Visit|Lost to Follow-up|1
6253104|NCT01970540|9942734|FG000|Overall Study|Non-treatment-related AE|0
6253105|NCT01970540|9942735|FG001|Overall Study|Non-treatment-related AE|0
6253106|NCT01970540|9942736|FG002|Overall Study|Non-treatment-related AE|1
6253107|NCT01970540|9942734|FG000|Overall Study|Progressive disease|55
6086300|NCT00660400|9696209|FG000|Overall Study|Suboptimal organ function|1
6189651|NCT01401647|9845087|FG000|Overall Study|Withdrawal by Subject|1
6189652|NCT01401647|9845088|FG001|Overall Study|Withdrawal by Subject|5
6189653|NCT01401647|9845089|FG002|Overall Study|Withdrawal by Subject|2
6189654|NCT01401647|9845087|FG000|Overall Study|Lost to Follow-up|3
6189655|NCT01401647|9845088|FG001|Overall Study|Lost to Follow-up|3
6189656|NCT01401647|9845089|FG002|Overall Study|Lost to Follow-up|1
6253108|NCT01970540|9942735|FG001|Overall Study|Progressive disease|23
6253109|NCT01970540|9942736|FG002|Overall Study|Progressive disease|10
6253110|NCT01970540|9942734|FG000|Overall Study|Treatment delay over protocol|0
6253111|NCT01970540|9942735|FG001|Overall Study|Treatment delay over protocol|0
6253112|NCT01970540|9942736|FG002|Overall Study|Treatment delay over protocol|1
6253113|NCT01970540|9942734|FG000|Overall Study|Physician Decision|7
6253114|NCT01970540|9942735|FG001|Overall Study|Physician Decision|2
6253115|NCT01970540|9942736|FG002|Overall Study|Physician Decision|0
6253116|NCT01970540|9942734|FG000|Overall Study|Clinical progression|0
6253117|NCT01970540|9942735|FG001|Overall Study|Clinical progression|1
6253118|NCT01970540|9942736|FG002|Overall Study|Clinical progression|1
6253119|NCT01970540|9942734|FG000|Overall Study|End of study|2
6253120|NCT01970540|9942735|FG001|Overall Study|End of study|0
6253121|NCT01970540|9942736|FG002|Overall Study|End of study|2
6253122|NCT01970540|9942734|FG000|Overall Study|Adverse Event|0
6253123|NCT01970540|9942735|FG001|Overall Study|Adverse Event|2
6253124|NCT01970540|9942736|FG002|Overall Study|Adverse Event|1
6253125|NCT01970540|9942734|FG000|Overall Study|Treatment-related AE|4
6253126|NCT01970540|9942735|FG001|Overall Study|Treatment-related AE|0
6253127|NCT01970540|9942736|FG002|Overall Study|Treatment-related AE|2
6253128|NCT01970540|9942734|FG000|Overall Study|Withdrawal by Subject|4
6253129|NCT01970540|9942735|FG001|Overall Study|Withdrawal by Subject|0
6253130|NCT01970540|9942736|FG002|Overall Study|Withdrawal by Subject|1
6253131|NCT01970540|9942734|FG000|Overall Study|Clinical deterioration|1
6253132|NCT01970540|9942735|FG001|Overall Study|Clinical deterioration|0
6253133|NCT01970540|9942736|FG002|Overall Study|Clinical deterioration|0
6253134|NCT01970592|9942755|FG000|Overall Study|Withdrawal by Subject|4
6253135|NCT01970592|9942755|FG000|Overall Study|Physician Decision|1
6253136|NCT01970592|9942755|FG000|Overall Study|Adverse Event|1
6253137|NCT01970878|9942767|FG000|Overall Study|Withdrawal by Subject|11
6253138|NCT01970878|9942768|FG001|Overall Study|Withdrawal by Subject|10
6253139|NCT01970878|9942769|FG002|Overall Study|Withdrawal by Subject|14
6253140|NCT01970878|9942770|FG003|Overall Study|Withdrawal by Subject|7
6253141|NCT01970878|9942767|FG000|Overall Study|Lost to Follow-up|1
6253142|NCT01970878|9942768|FG001|Overall Study|Lost to Follow-up|3
6253143|NCT01970878|9942769|FG002|Overall Study|Lost to Follow-up|2
6253144|NCT01970878|9942770|FG003|Overall Study|Lost to Follow-up|4
6253145|NCT01970878|9942767|FG000|Overall Study|Administrative Reasons|1
6253146|NCT01970878|9942768|FG001|Overall Study|Administrative Reasons|0
6253147|NCT01970878|9942769|FG002|Overall Study|Administrative Reasons|0
6253148|NCT01970878|9942770|FG003|Overall Study|Administrative Reasons|4
6086301|NCT00660400|9696209|FG000|Overall Study|Intracranial hemorrhage|1
6086302|NCT00660400|9696209|FG000|Overall Study|Withdrawal by Subject|1
6086303|NCT00660660|9696257|FG000|Overall Study|Adverse Event|1
6086304|NCT00660660|9696258|FG001|Overall Study|Adverse Event|0
6086305|NCT00660660|9696257|FG000|Overall Study|Lost to Follow-up|0
6086306|NCT00660660|9696258|FG001|Overall Study|Lost to Follow-up|6
6253149|NCT01970878|9942767|FG000|Overall Study|Lack of Efficacy|2
6253150|NCT01970878|9942768|FG001|Overall Study|Lack of Efficacy|1
6253151|NCT01970878|9942769|FG002|Overall Study|Lack of Efficacy|2
6253152|NCT01970878|9942770|FG003|Overall Study|Lack of Efficacy|0
6253153|NCT01970878|9942767|FG000|Overall Study|Adverse Event|12
6253154|NCT01970878|9942768|FG001|Overall Study|Adverse Event|7
6253155|NCT01970878|9942769|FG002|Overall Study|Adverse Event|4
6253156|NCT01970878|9942770|FG003|Overall Study|Adverse Event|3
6253157|NCT01970878|9942767|FG000|Overall Study|Protocol Specified Criteria|10
6253158|NCT01970878|9942768|FG001|Overall Study|Protocol Specified Criteria|4
6086307|NCT00660660|9696257|FG000|Overall Study|Lack of Efficacy|0
6086308|NCT00660660|9696258|FG001|Overall Study|Lack of Efficacy|2
6086309|NCT00660660|9696257|FG000|Overall Study|Withdrawal by Subject|3
6086310|NCT00660660|9696258|FG001|Overall Study|Withdrawal by Subject|0
6253159|NCT01970878|9942769|FG002|Overall Study|Protocol Specified Criteria|3
6253160|NCT01970878|9942770|FG003|Overall Study|Protocol Specified Criteria|6
6253161|NCT01970878|9942767|FG000|Overall Study|Physician Decision|0
6253162|NCT01970878|9942768|FG001|Overall Study|Physician Decision|1
6253163|NCT01970878|9942769|FG002|Overall Study|Physician Decision|1
6253164|NCT01970878|9942770|FG003|Overall Study|Physician Decision|0
6253165|NCT01970878|9942767|FG000|Overall Study|No Completion Status|0
6253166|NCT01970878|9942768|FG001|Overall Study|No Completion Status|1
6253167|NCT01970878|9942769|FG002|Overall Study|No Completion Status|0
6086311|NCT00660660|9696257|FG000|Overall Study|Incorrect enrollment and other|0
6189657|NCT01401842|9845103|FG000|Overall Study|Withdrawal by Subject|3
6189658|NCT01401842|9845104|FG001|Overall Study|Withdrawal by Subject|2
6189659|NCT01401842|9845103|FG000|Overall Study|academic reason|4
6189660|NCT01401842|9845104|FG001|Overall Study|academic reason|1
6189661|NCT01401842|9845103|FG000|Overall Study|changed companies|20
6189662|NCT01401842|9845104|FG001|Overall Study|changed companies|34
6189663|NCT01401842|9845103|FG000|Overall Study|discharged from US Army|3
6189664|NCT01401842|9845104|FG001|Overall Study|discharged from US Army|4
6189665|NCT01401842|9845103|FG000|Overall Study|invalid follow-up strength data|1
6189666|NCT01401842|9845104|FG001|Overall Study|invalid follow-up strength data|4
6189667|NCT01401842|9845103|FG000|Overall Study|on profile|9
6189668|NCT01401842|9845104|FG001|Overall Study|on profile|5
6189669|NCT01401842|9845103|FG000|Overall Study|other/unknown|28
6189670|NCT01401842|9845104|FG001|Overall Study|other/unknown|17
6189671|NCT01401959|9845124|FG000|Enrolled|Withdrawal by Subject|1
6189672|NCT01401959|9845125|FG001|Enrolled|Withdrawal by Subject|0
6189673|NCT01401959|9845126|FG002|Enrolled|Withdrawal by Subject|0
6189674|NCT01401959|9845124|FG000|Treated|Disease Progression|2
6189675|NCT01401959|9845125|FG001|Treated|Disease Progression|2
6189676|NCT01401959|9845126|FG002|Treated|Disease Progression|1
6189677|NCT01401959|9845124|FG000|Treated|Adverse Event|4
6189678|NCT01401959|9845125|FG001|Treated|Adverse Event|3
6189679|NCT01401959|9845126|FG002|Treated|Adverse Event|2
6189680|NCT01401959|9845124|FG000|Treated|Withdrawal by Subject|1
6189681|NCT01401959|9845125|FG001|Treated|Withdrawal by Subject|2
6189682|NCT01401959|9845126|FG002|Treated|Withdrawal by Subject|2
6189683|NCT01401959|9845124|FG000|Treated|Protocol Violation|0
6189684|NCT01401959|9845125|FG001|Treated|Protocol Violation|1
6189685|NCT01401959|9845126|FG002|Treated|Protocol Violation|0
6189686|NCT01402011|9845139|FG000|Delayed Treatment Period|Withdrawal by Subject|1
6189687|NCT01402011|9845140|FG001|Delayed Treatment Period|Withdrawal by Subject|0
6189688|NCT01402011|9845141|FG002|Delayed Treatment Period|Withdrawal by Subject|0
6189689|NCT01402011|9845139|FG000|Active Treatment Period|Withdrawal by Subject|1
6189690|NCT01402011|9845140|FG001|Active Treatment Period|Withdrawal by Subject|3
6189691|NCT01402011|9845141|FG002|Active Treatment Period|Withdrawal by Subject|0
6189692|NCT01402011|9845139|FG000|Nine Month Follow-up|Withdrawal by Subject|0
6189693|NCT01402011|9845140|FG001|Nine Month Follow-up|Withdrawal by Subject|1
6189694|NCT01402011|9845141|FG002|Nine Month Follow-up|Withdrawal by Subject|0
6189695|NCT01402063|9845163|FG000|Overall Study|Withdrawal by Subject|3
6189696|NCT01402063|9845164|FG001|Overall Study|Withdrawal by Subject|3
6189697|NCT01402102|9845172|FG000|Overall Study|Protocol Violation|1
6189698|NCT01402102|9845173|FG001|Overall Study|Protocol Violation|0
6189699|NCT01402102|9845172|FG000|Overall Study|Insufficiency of compliance|1
6189700|NCT01402102|9845173|FG001|Overall Study|Insufficiency of compliance|1
6189701|NCT01402102|9845172|FG000|Overall Study|Withdrawal by Subject|0
6189702|NCT01402102|9845173|FG001|Overall Study|Withdrawal by Subject|2
6189703|NCT01402284|9845209|FG000|Overall Study|Withdrawal consent|2
6189704|NCT01402284|9845209|FG000|Overall Study|Follows up at Memorial Sloan Kettering|1
6189705|NCT01402284|9845209|FG000|Overall Study|Physician Decision|1
6189706|NCT01402284|9845209|FG000|Overall Study|Disease progression on study|10
6189707|NCT01402492|9845250|FG000|Overall Study|Withdrawal by Subject|17
6189708|NCT01402492|9845251|FG001|Overall Study|Withdrawal by Subject|11
6189709|NCT01402492|9845252|FG002|Overall Study|Withdrawal by Subject|11
6189710|NCT01402492|9845250|FG000|Overall Study|Adverse Event|2
6189711|NCT01402492|9845251|FG001|Overall Study|Adverse Event|3
6189712|NCT01402492|9845252|FG002|Overall Study|Adverse Event|4
6189713|NCT01402492|9845250|FG000|Overall Study|Physician Decision|0
6189714|NCT01402492|9845251|FG001|Overall Study|Physician Decision|3
6189715|NCT01402492|9845252|FG002|Overall Study|Physician Decision|0
6189716|NCT01402492|9845250|FG000|Overall Study|Incarcerated (N=3)|2
6189717|NCT01402492|9845251|FG001|Overall Study|Incarcerated (N=3)|0
6189718|NCT01402492|9845252|FG002|Overall Study|Incarcerated (N=3)|1
6189719|NCT01402544|9845260|FG000|Overall Study|Withdrawal by Subject|6
6189720|NCT01402570|9845264|FG000|Overall Study|Adverse Event|1
6189721|NCT01402700|9845269|FG000|Overall Study|Death|3
6189722|NCT01402700|9845269|FG000|Overall Study|Withdrawal by Subject|3
6189723|NCT01402700|9845269|FG000|Overall Study|Missed Visit|1
6189724|NCT01402817|9845273|FG000|Overall Study|Withdrawal by Subject|3
6253168|NCT01970878|9942770|FG003|Overall Study|No Completion Status|0
6253169|NCT01970982|9942790|FG000|Overall Study|Withdrawal by Subject|0
6253170|NCT01970982|9942791|FG001|Overall Study|Withdrawal by Subject|0
6253171|NCT01970982|9942792|FG002|Overall Study|Withdrawal by Subject|2
6253172|NCT01970995|9942804|FG000|Confinement Period (Population at Day 5)|Withdrawal by Subject|1
6253173|NCT01970995|9942805|FG001|Confinement Period (Population at Day 5)|Withdrawal by Subject|1
6253174|NCT01970995|9942806|FG002|Confinement Period (Population at Day 5)|Withdrawal by Subject|1
6253175|NCT01970995|9942804|FG000|End of Study (Population at Day 90)|Withdrawal by Subject|1
6253176|NCT01970995|9942805|FG001|End of Study (Population at Day 90)|Withdrawal by Subject|0
6253177|NCT01970995|9942806|FG002|End of Study (Population at Day 90)|Withdrawal by Subject|1
6253178|NCT01971203|9942821|FG000|Overall Study|Protocol Violation|3
6253179|NCT01971203|9942822|FG001|Overall Study|Protocol Violation|2
6253180|NCT01971203|9942821|FG000|Overall Study|Withdrawal by Subject|5
6253181|NCT01971203|9942822|FG001|Overall Study|Withdrawal by Subject|6
6253182|NCT01971203|9942821|FG000|Overall Study|Adverse Event|1
6253183|NCT01971203|9942822|FG001|Overall Study|Adverse Event|0
6253184|NCT01971346|9942837|FG000|Overall Study|Protocol Violation|3
6086312|NCT00660660|9696258|FG001|Overall Study|Incorrect enrollment and other|1
6253185|NCT01971346|9942837|FG000|Overall Study|Lost to Follow-up|2
6253186|NCT01971346|9942837|FG000|Overall Study|Withdrawal by Subject|2
6253187|NCT01971346|9942837|FG000|Overall Study|Physician Decision|1
6253188|NCT01971476|9942868|FG000|Cohort 1: 2 to <12 Years|Other not defined|3
6253189|NCT01971476|9942869|FG001|Cohort 1: 2 to <12 Years|Other not defined|3
6253190|NCT01971476|9942870|FG002|Cohort 1: 2 to <12 Years|Other not defined|6
6253191|NCT01971476|9942868|FG000|Cohort 2: 12 to <18 Years|Other not defined|6
6253192|NCT01971476|9942869|FG001|Cohort 2: 12 to <18 Years|Other not defined|3
6253193|NCT01971476|9942870|FG002|Cohort 2: 12 to <18 Years|Other not defined|0
6253194|NCT01971476|9942868|FG000|Cohort 2: 12 to <18 Years|Adverse Event|0
6253195|NCT01971476|9942869|FG001|Cohort 2: 12 to <18 Years|Adverse Event|1
6253196|NCT01971476|9942870|FG002|Cohort 2: 12 to <18 Years|Adverse Event|0
6253197|NCT01971554|9942891|FG000|Overall Study|Lost to Follow-up|1
6253198|NCT01971554|9942892|FG001|Overall Study|Lost to Follow-up|0
6253199|NCT01971554|9942893|FG002|Overall Study|Lost to Follow-up|0
6253200|NCT01971554|9942894|FG003|Overall Study|Lost to Follow-up|0
6253201|NCT01971567|9942906|FG000|Overall Study|Withdrawal by Subject|3
6253202|NCT01971567|9942907|FG001|Overall Study|Withdrawal by Subject|2
6253203|NCT01971567|9942906|FG000|Overall Study|Lost to Follow-up|1
6253204|NCT01971567|9942907|FG001|Overall Study|Lost to Follow-up|0
6253205|NCT01971645|9942932|FG000|Overall Study|Adverse Event|1
6253206|NCT01971645|9942933|FG001|Overall Study|Adverse Event|0
6253207|NCT01971645|9942934|FG002|Overall Study|Adverse Event|0
6253208|NCT01971645|9942932|FG000|Overall Study|Lost to Follow-up|1
6253209|NCT01971645|9942933|FG001|Overall Study|Lost to Follow-up|0
6253210|NCT01971645|9942934|FG002|Overall Study|Lost to Follow-up|1
6253211|NCT01971645|9942932|FG000|Overall Study|Protocol Violation|0
6253212|NCT01971645|9942933|FG001|Overall Study|Protocol Violation|0
6253213|NCT01971645|9942934|FG002|Overall Study|Protocol Violation|1
6253214|NCT01971723|9942944|FG000|Overall Study|Withdrawal by Subject|1
6253215|NCT01971723|9942945|FG001|Overall Study|Withdrawal by Subject|1
6253216|NCT01971723|9942944|FG000|Overall Study|Protocol Violation|1
6253217|NCT01971723|9942945|FG001|Overall Study|Protocol Violation|2
6253218|NCT01972074|9942967|FG000|Overall Study|Adverse Event|4
6253219|NCT01972074|9942968|FG001|Overall Study|Adverse Event|1
6253220|NCT01972074|9942969|FG002|Overall Study|Adverse Event|0
6253221|NCT01972074|9942967|FG000|Overall Study|Lack of Efficacy|1
6253222|NCT01972074|9942968|FG001|Overall Study|Lack of Efficacy|1
6253223|NCT01972074|9942969|FG002|Overall Study|Lack of Efficacy|0
6253224|NCT01972074|9942967|FG000|Overall Study|Lost to Follow-up|0
6253225|NCT01972074|9942968|FG001|Overall Study|Lost to Follow-up|1
6253226|NCT01972074|9942969|FG002|Overall Study|Lost to Follow-up|1
6253227|NCT01972074|9942967|FG000|Overall Study|Withdrawal by Subject|1
6253228|NCT01972074|9942968|FG001|Overall Study|Withdrawal by Subject|1
6253229|NCT01972074|9942969|FG002|Overall Study|Withdrawal by Subject|1
6253230|NCT01972074|9942967|FG000|Overall Study|Scanner Unavailable|0
6253231|NCT01972074|9942968|FG001|Overall Study|Scanner Unavailable|0
6253232|NCT01972074|9942969|FG002|Overall Study|Scanner Unavailable|1
6253233|NCT01972152|9942976|FG000|First Treatment Visit|Lost to Follow-up|0
6253234|NCT01972152|9942977|FG001|First Treatment Visit|Lost to Follow-up|1
6253235|NCT01972152|9942978|FG002|First Treatment Visit|Lost to Follow-up|0
6253236|NCT01972152|9942979|FG003|First Treatment Visit|Lost to Follow-up|0
6253237|NCT01972152|9942980|FG004|First Treatment Visit|Lost to Follow-up|0
6253238|NCT01972152|9942981|FG005|First Treatment Visit|Lost to Follow-up|0
6253239|NCT01972152|9942976|FG000|Second Treatment Visit|Protocol Violation|0
6253240|NCT01972152|9942977|FG001|Second Treatment Visit|Protocol Violation|1
6253241|NCT01972152|9942978|FG002|Second Treatment Visit|Protocol Violation|0
6253242|NCT01972152|9942979|FG003|Second Treatment Visit|Protocol Violation|0
6253243|NCT01972152|9942980|FG004|Second Treatment Visit|Protocol Violation|0
6253244|NCT01972152|9942981|FG005|Second Treatment Visit|Protocol Violation|0
6253245|NCT01972308|9943007|FG000|Overall Study|Withdrawal by Subject|0
6253246|NCT01972308|9943008|FG001|Overall Study|Withdrawal by Subject|1
6253247|NCT01972308|9943007|FG000|Overall Study|Lost to Follow-up|4
6253248|NCT01972308|9943008|FG001|Overall Study|Lost to Follow-up|6
6253249|NCT01972308|9943007|FG000|Overall Study|Death|4
6253250|NCT01972308|9943008|FG001|Overall Study|Death|1
6253251|NCT01972438|9943018|FG000|Baseline-Month 3 Crossover Period|Death|1
6253252|NCT01972438|9943019|FG001|Baseline-Month 3 Crossover Period|Death|0
6253253|NCT01972438|9943018|FG000|Baseline-Month 3 Crossover Period|Did not meet inclusion criteria|1
6253254|NCT01972438|9943019|FG001|Baseline-Month 3 Crossover Period|Did not meet inclusion criteria|0
6253255|NCT01972438|9943018|FG000|Baseline-Month 3 Crossover Period|Unable to donate blood|0
6253256|NCT01972438|9943019|FG001|Baseline-Month 3 Crossover Period|Unable to donate blood|1
6253257|NCT01972438|9943018|FG000|Baseline-Month 3 Crossover Period|Scheduling difficulties (Missed Month 3)|1
6253258|NCT01972438|9943019|FG001|Baseline-Month 3 Crossover Period|Scheduling difficulties (Missed Month 3)|2
6253259|NCT01972438|9943018|FG000|Months 3-6 Crossover Period|Early Study Closure|0
6253260|NCT01972438|9943019|FG001|Months 3-6 Crossover Period|Early Study Closure|1
6253261|NCT01972438|9943018|FG000|Months 6-12 Study Period|Death|1
6253262|NCT01972438|9943019|FG001|Months 6-12 Study Period|Death|0
6253263|NCT01972438|9943018|FG000|Months 6-12 Study Period|Early Study Closure|2
6253264|NCT01972438|9943019|FG001|Months 6-12 Study Period|Early Study Closure|2
6253265|NCT01972438|9943018|FG000|Post Month 12 Study Period|Early Study Closure|3
6253266|NCT01972438|9943019|FG001|Post Month 12 Study Period|Early Study Closure|4
6253267|NCT01972464|9943029|FG000|Treatment Period (Week 1 Through Week 8)|Lost to Follow-up|2
6253268|NCT01972464|9943030|FG001|Treatment Period (Week 1 Through Week 8)|Lost to Follow-up|3
6253269|NCT01972464|9943029|FG000|Treatment Period (Week 1 Through Week 8)|Patient Relocated|1
6253270|NCT01972464|9943030|FG001|Treatment Period (Week 1 Through Week 8)|Patient Relocated|0
6253271|NCT01972464|9943029|FG000|Treatment Period (Week 1 Through Week 8)|Withdrawal by Subject|0
6253272|NCT01972464|9943030|FG001|Treatment Period (Week 1 Through Week 8)|Withdrawal by Subject|1
6253273|NCT01972464|9943029|FG000|3-Month Follow-Up (Week 20)|Lost to Follow-up|1
6253274|NCT01972464|9943030|FG001|3-Month Follow-Up (Week 20)|Lost to Follow-up|1
6253275|NCT01972529|9943050|FG000|Overall Study|Adverse Event|0
6253276|NCT01972529|9943051|FG001|Overall Study|Adverse Event|1
6253277|NCT01972529|9943052|FG002|Overall Study|Adverse Event|0
6253278|NCT01972529|9943053|FG003|Overall Study|Adverse Event|0
6253279|NCT01972529|9943050|FG000|Overall Study|Lost to Follow-up|1
6253280|NCT01972529|9943051|FG001|Overall Study|Lost to Follow-up|0
6253281|NCT01972529|9943052|FG002|Overall Study|Lost to Follow-up|0
6253282|NCT01972529|9943053|FG003|Overall Study|Lost to Follow-up|0
6253283|NCT01972529|9943050|FG000|Overall Study|Participant Choice|0
6253284|NCT01972529|9943051|FG001|Overall Study|Participant Choice|1
6253285|NCT01972529|9943052|FG002|Overall Study|Participant Choice|0
6253286|NCT01972529|9943053|FG003|Overall Study|Participant Choice|0
6253287|NCT01972529|9943050|FG000|Overall Study|Withdrawl of Consent|1
6253288|NCT01972529|9943051|FG001|Overall Study|Withdrawl of Consent|2
6253289|NCT01972529|9943052|FG002|Overall Study|Withdrawl of Consent|0
6253290|NCT01972529|9943053|FG003|Overall Study|Withdrawl of Consent|1
6253291|NCT01972529|9943050|FG000|Overall Study|Other|0
6253292|NCT01972529|9943051|FG001|Overall Study|Other|0
6253293|NCT01972529|9943052|FG002|Overall Study|Other|0
6253294|NCT01972529|9943053|FG003|Overall Study|Other|2
6253295|NCT01972529|9943050|FG000|Overall Study|Not treated|0
6253296|NCT01972529|9943051|FG001|Overall Study|Not treated|1
6253297|NCT01972529|9943052|FG002|Overall Study|Not treated|2
6253298|NCT01972529|9943053|FG003|Overall Study|Not treated|1
6253299|NCT01972568|9943067|FG000|Overall Study|Other events|3
6253300|NCT01972568|9943068|FG001|Overall Study|Other events|0
6253301|NCT01972568|9943069|FG002|Overall Study|Other events|0
6253302|NCT01972568|9943067|FG000|Overall Study|Lack of Efficacy|0
6253303|NCT01972568|9943068|FG001|Overall Study|Lack of Efficacy|1
6253304|NCT01972568|9943069|FG002|Overall Study|Lack of Efficacy|2
6253305|NCT01972568|9943067|FG000|Overall Study|Protocol Violation|1
6253306|NCT01972568|9943068|FG001|Overall Study|Protocol Violation|2
6253307|NCT01972568|9943069|FG002|Overall Study|Protocol Violation|2
6253308|NCT01972568|9943067|FG000|Overall Study|Withdrawal by Subject|6
6253309|NCT01972568|9943068|FG001|Overall Study|Withdrawal by Subject|3
6253310|NCT01972568|9943069|FG002|Overall Study|Withdrawal by Subject|7
6253311|NCT01972568|9943067|FG000|Overall Study|Lost to Follow-up|1
6253312|NCT01972568|9943068|FG001|Overall Study|Lost to Follow-up|0
6253313|NCT01972568|9943069|FG002|Overall Study|Lost to Follow-up|0
6253314|NCT01972568|9943067|FG000|Overall Study|Adverse Event|5
6253315|NCT01972568|9943068|FG001|Overall Study|Adverse Event|6
6253316|NCT01972568|9943069|FG002|Overall Study|Adverse Event|5
6253317|NCT01972659|9943079|FG000|Overall Study|Protocol Violation|2
6253318|NCT01972659|9943080|FG001|Overall Study|Protocol Violation|2
6253319|NCT01972659|9943079|FG000|Overall Study|problems realted to acceleromyograph|2
6253320|NCT01972659|9943080|FG001|Overall Study|problems realted to acceleromyograph|1
6253321|NCT01972724|9943089|FG000|Double-Blind|Rescue Criteria Met|1
6253322|NCT01972724|9943090|FG001|Double-Blind|Rescue Criteria Met|0
6253323|NCT01972724|9943091|FG002|Double-Blind|Rescue Criteria Met|0
6253324|NCT01972724|9943089|FG000|Double-Blind|Adverse Event|1
6253325|NCT01972724|9943090|FG001|Double-Blind|Adverse Event|0
6253326|NCT01972724|9943091|FG002|Double-Blind|Adverse Event|0
6253327|NCT01972724|9943089|FG000|Double-Blind|Withdrawal of Consent|2
6253328|NCT01972724|9943090|FG001|Double-Blind|Withdrawal of Consent|1
6253329|NCT01972724|9943091|FG002|Double-Blind|Withdrawal of Consent|0
6253330|NCT01972724|9943089|FG000|Double-Blind|Significant Protocol Deviation|5
6253331|NCT01972724|9943090|FG001|Double-Blind|Significant Protocol Deviation|8
6253332|NCT01972724|9943091|FG002|Double-Blind|Significant Protocol Deviation|0
6253333|NCT01972724|9943089|FG000|Open-Label|Withdrew Consent|0
6253334|NCT01972724|9943090|FG001|Open-Label|Withdrew Consent|0
6253335|NCT01972724|9943091|FG002|Open-Label|Withdrew Consent|3
6253336|NCT01972724|9943089|FG000|Open-Label|Significant Protocol Deviation|0
6253337|NCT01972724|9943090|FG001|Open-Label|Significant Protocol Deviation|0
6253338|NCT01972724|9943091|FG002|Open-Label|Significant Protocol Deviation|2
6253339|NCT01972776|9943105|FG000|Part 1|Withdrawal by Subject|0
6253340|NCT01972776|9943106|FG001|Part 1|Withdrawal by Subject|0
6253341|NCT01972776|9943107|FG002|Part 1|Withdrawal by Subject|1
6253342|NCT01972776|9943108|FG003|Part 1|Withdrawal by Subject|0
6253343|NCT01972776|9943109|FG004|Part 1|Withdrawal by Subject|0
6253344|NCT01972776|9943110|FG005|Part 1|Withdrawal by Subject|0
6253345|NCT01972776|9943105|FG000|Part 1|Adverse Event|0
6253346|NCT01972776|9943106|FG001|Part 1|Adverse Event|0
6253347|NCT01972776|9943107|FG002|Part 1|Adverse Event|1
6253348|NCT01972776|9943108|FG003|Part 1|Adverse Event|1
6253349|NCT01972776|9943109|FG004|Part 1|Adverse Event|0
6253350|NCT01972776|9943110|FG005|Part 1|Adverse Event|0
6253351|NCT01972776|9943105|FG000|Part 2|Adverse Event|0
6253352|NCT01972776|9943106|FG001|Part 2|Adverse Event|0
6253353|NCT01972776|9943107|FG002|Part 2|Adverse Event|0
6253354|NCT01972776|9943108|FG003|Part 2|Adverse Event|0
6253355|NCT01972776|9943109|FG004|Part 2|Adverse Event|3
6253356|NCT01972776|9943110|FG005|Part 2|Adverse Event|0
6253357|NCT01972776|9943105|FG000|Part 2|Administrative problems|0
6253358|NCT01972776|9943106|FG001|Part 2|Administrative problems|0
6253359|NCT01972776|9943107|FG002|Part 2|Administrative problems|0
6253360|NCT01972776|9943108|FG003|Part 2|Administrative problems|0
6253361|NCT01972776|9943109|FG004|Part 2|Administrative problems|10
6253362|NCT01972776|9943110|FG005|Part 2|Administrative problems|7
6253363|NCT01972789|9943126|FG000|Overall Study|Adverse Event|11
6253364|NCT01972789|9943127|FG001|Overall Study|Adverse Event|4
6253365|NCT01972789|9943126|FG000|Overall Study|Subject withdrew consent|14
6253366|NCT01972789|9943127|FG001|Overall Study|Subject withdrew consent|12
6253367|NCT01972789|9943126|FG000|Overall Study|Lost to Follow-up|4
6253368|NCT01972789|9943127|FG001|Overall Study|Lost to Follow-up|7
6253369|NCT01972789|9943126|FG000|Overall Study|Death|7
6253370|NCT01972789|9943127|FG001|Overall Study|Death|5
6253371|NCT01972789|9943126|FG000|Overall Study|Protocol deviation|1
6253372|NCT01972789|9943127|FG001|Overall Study|Protocol deviation|0
6253373|NCT01972789|9943126|FG000|Overall Study|Physician Decision|3
6253374|NCT01972789|9943127|FG001|Overall Study|Physician Decision|2
6253375|NCT01972841|9943139|FG000|Overall Study|Randomized but Never Received Treatment|2
6253376|NCT01972841|9943140|FG001|Overall Study|Randomized but Never Received Treatment|5
6253377|NCT01972841|9943141|FG002|Overall Study|Randomized but Never Received Treatment|4
6253378|NCT01972841|9943142|FG003|Overall Study|Randomized but Never Received Treatment|2
6253379|NCT01972841|9943143|FG004|Overall Study|Randomized but Never Received Treatment|6
6253380|NCT01972841|9943144|FG005|Overall Study|Randomized but Never Received Treatment|13
6253381|NCT01972841|9943139|FG000|Overall Study|Adverse Event|13
6253382|NCT01972841|9943140|FG001|Overall Study|Adverse Event|8
6253383|NCT01972841|9943141|FG002|Overall Study|Adverse Event|12
6253384|NCT01972841|9943142|FG003|Overall Study|Adverse Event|9
6253385|NCT01972841|9943143|FG004|Overall Study|Adverse Event|21
6253386|NCT01972841|9943144|FG005|Overall Study|Adverse Event|26
6253387|NCT01972841|9943139|FG000|Overall Study|Lack of Efficacy|1
6253388|NCT01972841|9943140|FG001|Overall Study|Lack of Efficacy|0
6253389|NCT01972841|9943141|FG002|Overall Study|Lack of Efficacy|0
6253390|NCT01972841|9943142|FG003|Overall Study|Lack of Efficacy|2
6253391|NCT01972841|9943143|FG004|Overall Study|Lack of Efficacy|4
6253392|NCT01972841|9943144|FG005|Overall Study|Lack of Efficacy|1
6253393|NCT01972841|9943139|FG000|Overall Study|Lost to Follow-up|4
6253394|NCT01972841|9943140|FG001|Overall Study|Lost to Follow-up|2
6253395|NCT01972841|9943141|FG002|Overall Study|Lost to Follow-up|4
6253396|NCT01972841|9943142|FG003|Overall Study|Lost to Follow-up|2
6253397|NCT01972841|9943143|FG004|Overall Study|Lost to Follow-up|9
6253398|NCT01972841|9943144|FG005|Overall Study|Lost to Follow-up|3
6253399|NCT01972841|9943139|FG000|Overall Study|Protocol Violation|2
6253400|NCT01972841|9943140|FG001|Overall Study|Protocol Violation|2
6253401|NCT01972841|9943141|FG002|Overall Study|Protocol Violation|3
6253402|NCT01972841|9943142|FG003|Overall Study|Protocol Violation|5
6253403|NCT01972841|9943143|FG004|Overall Study|Protocol Violation|9
6253404|NCT01972841|9943144|FG005|Overall Study|Protocol Violation|4
6253405|NCT01972841|9943139|FG000|Overall Study|Withdrawal by participants|21
6253406|NCT01972841|9943140|FG001|Overall Study|Withdrawal by participants|27
6253407|NCT01972841|9943141|FG002|Overall Study|Withdrawal by participants|23
6253408|NCT01972841|9943142|FG003|Overall Study|Withdrawal by participants|16
6253409|NCT01972841|9943143|FG004|Overall Study|Withdrawal by participants|33
6253410|NCT01972841|9943144|FG005|Overall Study|Withdrawal by participants|34
6253411|NCT01972841|9943139|FG000|Overall Study|Miscellaneous|0
6253412|NCT01972841|9943140|FG001|Overall Study|Miscellaneous|0
6253413|NCT01972841|9943141|FG002|Overall Study|Miscellaneous|4
6253414|NCT01972841|9943142|FG003|Overall Study|Miscellaneous|1
6253415|NCT01972841|9943143|FG004|Overall Study|Miscellaneous|0
6253416|NCT01972841|9943144|FG005|Overall Study|Miscellaneous|4
6253417|NCT01972841|9943139|FG000|Overall Study|Did not have end of treatment page|0
6253418|NCT01972841|9943140|FG001|Overall Study|Did not have end of treatment page|0
6253419|NCT01972841|9943141|FG002|Overall Study|Did not have end of treatment page|0
6253420|NCT01972841|9943142|FG003|Overall Study|Did not have end of treatment page|0
6253421|NCT01972841|9943143|FG004|Overall Study|Did not have end of treatment page|1
6253422|NCT01972841|9943144|FG005|Overall Study|Did not have end of treatment page|0
6253423|NCT01973218|9943179|FG000|Overall Study|Adverse Event|1
6253424|NCT01973218|9943180|FG001|Overall Study|Adverse Event|0
6253425|NCT01973218|9943179|FG000|Overall Study|Withdrawal by Subject|1
6253426|NCT01973218|9943180|FG001|Overall Study|Withdrawal by Subject|0
6253427|NCT01973231|9943190|FG000|Overall Study|Protocol Violation|1
6253428|NCT01973231|9943191|FG001|Overall Study|Protocol Violation|1
6253429|NCT01973231|9943190|FG000|Overall Study|Lost to Follow-up|1
6253430|NCT01973231|9943191|FG001|Overall Study|Lost to Follow-up|1
6253431|NCT01973231|9943190|FG000|Overall Study|unclassified|2
6253432|NCT01973231|9943191|FG001|Overall Study|unclassified|1
6253433|NCT01973231|9943190|FG000|Overall Study|Withdrawal by Subject|7
6253434|NCT01973231|9943191|FG001|Overall Study|Withdrawal by Subject|9
6253435|NCT01973283|9943197|FG000|Overall Study|Lost to Follow-up|4
6253436|NCT01973387|9943239|FG000|Overall Study|Adverse Event|14
6253437|NCT01973387|9943240|FG001|Overall Study|Adverse Event|4
6253438|NCT01973387|9943239|FG000|Overall Study|Withdrawal by Subject|7
6253439|NCT01973387|9943240|FG001|Overall Study|Withdrawal by Subject|4
6253440|NCT01973387|9943239|FG000|Overall Study|Study terminated by sponsor|63
6253441|NCT01973387|9943240|FG001|Overall Study|Study terminated by sponsor|0
6253442|NCT01973387|9943239|FG000|Overall Study|Progressive disease or relapse|16
6253443|NCT01973387|9943240|FG001|Overall Study|Progressive disease or relapse|5
6253444|NCT01973387|9943239|FG000|Overall Study|Death|4
6253445|NCT01973387|9943240|FG001|Overall Study|Death|3
6253446|NCT01973387|9943239|FG000|Overall Study|Randomized, not treated|2
6253447|NCT01973387|9943240|FG001|Overall Study|Randomized, not treated|2
6253448|NCT01973439|9943256|FG000|Overall Study|Lost samples from one PK Day|2
6253449|NCT01973439|9943256|FG000|Overall Study|Vomiting after commencing once daily|1
6253450|NCT01973439|9943256|FG000|Overall Study|PK curve incomplete|2
6253451|NCT01973491|9943260|FG000|Baseline Control Period (8 Weeks)|Did not meet Eligibility Criteria|17
6253452|NCT01973491|9943260|FG000|Baseline Control Period (8 Weeks)|Withdrawal by Subject|1
6253453|NCT01973491|9943260|FG000|Treatment Period (16 Weeks)|Adverse Event|1
6253454|NCT01973569|9943267|FG000|Overall Study|Adverse Event|9
6253455|NCT01973569|9943268|FG001|Overall Study|Adverse Event|2
6253456|NCT01973569|9943269|FG002|Overall Study|Adverse Event|4
6253457|NCT01973569|9943267|FG000|Overall Study|Protocol Violation|2
6253458|NCT01973569|9943268|FG001|Overall Study|Protocol Violation|1
6253459|NCT01973569|9943269|FG002|Overall Study|Protocol Violation|3
6253460|NCT01973569|9943267|FG000|Overall Study|Withdrawal by Subject|7
6253461|NCT01973569|9943268|FG001|Overall Study|Withdrawal by Subject|5
6253462|NCT01973569|9943269|FG002|Overall Study|Withdrawal by Subject|2
6253463|NCT01973569|9943267|FG000|Overall Study|Invasive dental treatment|3
6253464|NCT01973569|9943268|FG001|Overall Study|Invasive dental treatment|5
6253465|NCT01973569|9943269|FG002|Overall Study|Invasive dental treatment|6
6253466|NCT01973569|9943267|FG000|Overall Study|Prohibited concomitant d|1
6253467|NCT01973569|9943268|FG001|Overall Study|Prohibited concomitant d|5
6253468|NCT01973569|9943269|FG002|Overall Study|Prohibited concomitant d|0
6253469|NCT01973569|9943267|FG000|Overall Study|Disease progression|0
6253470|NCT01973569|9943268|FG001|Overall Study|Disease progression|3
6253471|NCT01973569|9943269|FG002|Overall Study|Disease progression|0
6253472|NCT01973569|9943267|FG000|Overall Study|Other|1
6253473|NCT01973569|9943268|FG001|Overall Study|Other|1
6253474|NCT01973569|9943269|FG002|Overall Study|Other|0
6253475|NCT01973569|9943267|FG000|Overall Study|Did not receive study drug|6
6253476|NCT01973569|9943268|FG001|Overall Study|Did not receive study drug|3
6253477|NCT01973569|9943269|FG002|Overall Study|Did not receive study drug|3
6253478|NCT01973595|9943281|FG000|Washout|Withdrawal by Subject|1
6253479|NCT01973595|9943282|FG001|Washout|Withdrawal by Subject|0
6253480|NCT01973595|9943283|FG002|Washout|Withdrawal by Subject|1
6253481|NCT01973595|9943284|FG003|Washout|Withdrawal by Subject|0
6253482|NCT01973998|9943331|FG000|Overall Study|Death|2
6253483|NCT01973998|9943332|FG001|Overall Study|Death|2
6253484|NCT01974141|9943366|FG000|Overall Study|Other Reasons|28
6253485|NCT01974141|9943367|FG001|Overall Study|Other Reasons|18
6253486|NCT01974141|9943366|FG000|Overall Study|Protocol Violation|2
6253487|NCT01974141|9943367|FG001|Overall Study|Protocol Violation|6
6253488|NCT01974141|9943366|FG000|Overall Study|Personal Reasons|21
6253489|NCT01974141|9943367|FG001|Overall Study|Personal Reasons|20
6253490|NCT01974141|9943366|FG000|Overall Study|Lost to Follow-up|38
6253491|NCT01974141|9943367|FG001|Overall Study|Lost to Follow-up|29
6253492|NCT01974141|9943366|FG000|Overall Study|Pregnancy|3
6253493|NCT01974141|9943367|FG001|Overall Study|Pregnancy|3
6253494|NCT01974141|9943366|FG000|Overall Study|Lack of Efficacy|0
6253495|NCT01974141|9943367|FG001|Overall Study|Lack of Efficacy|1
6253496|NCT01974141|9943366|FG000|Overall Study|Adverse Event|4
6253497|NCT01974141|9943367|FG001|Overall Study|Adverse Event|5
6253498|NCT01974323|9943384|FG000|Overall Study|Other Reasons|25
6253499|NCT01974323|9943385|FG001|Overall Study|Other Reasons|28
6253500|NCT01974323|9943384|FG000|Overall Study|Protocol Violation|2
6253501|NCT01974323|9943385|FG001|Overall Study|Protocol Violation|2
6253502|NCT01974323|9943384|FG000|Overall Study|Personal Reasons|15
6253503|NCT01974323|9943385|FG001|Overall Study|Personal Reasons|19
6253504|NCT01974323|9943384|FG000|Overall Study|Lost to Follow-up|45
6253505|NCT01974323|9943385|FG001|Overall Study|Lost to Follow-up|40
6253506|NCT01974323|9943384|FG000|Overall Study|Pregnancy|2
6253507|NCT01974323|9943385|FG001|Overall Study|Pregnancy|1
6253508|NCT01974323|9943384|FG000|Overall Study|Lack of Efficacy|1
6253509|NCT01974323|9943385|FG001|Overall Study|Lack of Efficacy|1
6253510|NCT01974323|9943384|FG000|Overall Study|Adverse Event|2
6253511|NCT01974323|9943385|FG001|Overall Study|Adverse Event|2
6253512|NCT01974752|9943531|FG000|Overall Study|Death|33
6253513|NCT01974752|9943532|FG001|Overall Study|Death|11
6253514|NCT01974752|9943531|FG000|Overall Study|Lost to Follow-up|2
6253515|NCT01974752|9943532|FG001|Overall Study|Lost to Follow-up|0
6253516|NCT01974752|9943531|FG000|Overall Study|Withdrawal by Subject|2
6253517|NCT01974752|9943532|FG001|Overall Study|Withdrawal by Subject|3
6253518|NCT01974752|9943531|FG000|Overall Study|Other Eligibility Criteria|0
6253519|NCT01974752|9943532|FG001|Overall Study|Other Eligibility Criteria|1
6253520|NCT01974817|9943538|FG000|Overall Study|Death|4
6253521|NCT01974817|9943538|FG000|Overall Study|Lost to Follow-up|2
6253522|NCT01974817|9943538|FG000|Overall Study|Protocol Violation|2
6253523|NCT01974895|9943544|FG000|Overall Study|Protocol Violation|1
6253524|NCT01974895|9943545|FG001|Overall Study|Protocol Violation|0
6253525|NCT01974895|9943544|FG000|Overall Study|Lost to Follow-up|4
6253526|NCT01974895|9943545|FG001|Overall Study|Lost to Follow-up|6
6253527|NCT01974895|9943544|FG000|Overall Study|Withdrawal by Subject|0
6253528|NCT01974895|9943545|FG001|Overall Study|Withdrawal by Subject|1
6253529|NCT01974895|9943544|FG000|Overall Study|Other (Missed Visit)|1
6253530|NCT01974895|9943545|FG001|Overall Study|Other (Missed Visit)|0
6253531|NCT01974895|9943544|FG000|Overall Study|Other (Reason unknown)|9
6253532|NCT01974895|9943545|FG001|Overall Study|Other (Reason unknown)|8
6253533|NCT01975220|9943564|FG000|Test Period 1|Not treated|0
6253534|NCT01975220|9943565|FG001|Test Period 1|Not treated|1
6253535|NCT01975220|9943566|FG002|Test Period 1|Not treated|0
6253536|NCT01975220|9943567|FG003|Test Period 1|Not treated|0
6253537|NCT01975220|9943568|FG004|Test Period 1|Not treated|0
6253538|NCT01975220|9943569|FG005|Test Period 1|Not treated|0
6253539|NCT01975246|9943586|FG000|Overall Study|Adverse Event|2
6253540|NCT01975246|9943587|FG001|Overall Study|Adverse Event|1
6253541|NCT01975246|9943586|FG000|Overall Study|Lack of Efficacy|1
6253542|NCT01975246|9943587|FG001|Overall Study|Lack of Efficacy|0
6253543|NCT01975246|9943586|FG000|Overall Study|Protocol Violation|1
6253544|NCT01975246|9943587|FG001|Overall Study|Protocol Violation|0
6253545|NCT01975246|9943586|FG000|Overall Study|Other than stated|0
6253546|NCT01975246|9943587|FG001|Overall Study|Other than stated|1
6253547|NCT01975285|9943595|FG000|Overall Study|Failed Block and follow up|2
6253548|NCT01975285|9943596|FG001|Overall Study|Failed Block and follow up|2
6253549|NCT01975376|9943604|FG000|Overall Study|Adverse Event|5
6253550|NCT01975376|9943605|FG001|Overall Study|Adverse Event|5
6253551|NCT01975376|9943604|FG000|Overall Study|Death|65
6253552|NCT01975376|9943605|FG001|Overall Study|Death|72
6253553|NCT01975376|9943604|FG000|Overall Study|Lost to Follow-up|70
6253554|NCT01975376|9943605|FG001|Overall Study|Lost to Follow-up|66
6253555|NCT01975376|9943604|FG000|Overall Study|Withdrew consent|68
6253556|NCT01975376|9943605|FG001|Overall Study|Withdrew consent|62
6253557|NCT01975376|9943604|FG000|Overall Study|Other|2
6253558|NCT01975376|9943605|FG001|Overall Study|Other|4
6253559|NCT01975376|9943604|FG000|Overall Study|Randomized, Not Treated|16
6253560|NCT01975376|9943605|FG001|Overall Study|Randomized, Not Treated|8
6253561|NCT01975389|9943613|FG000|Overall Study|Adverse Event|10
6253562|NCT01975389|9943614|FG001|Overall Study|Adverse Event|6
6253563|NCT01975389|9943613|FG000|Overall Study|Death|61
6253564|NCT01975389|9943614|FG001|Overall Study|Death|54
6253565|NCT01975389|9943613|FG000|Overall Study|Lost to Follow-up|81
6253566|NCT01975389|9943614|FG001|Overall Study|Lost to Follow-up|86
6253567|NCT01975389|9943613|FG000|Overall Study|Withdrawal by Subject|90
6253568|NCT01975389|9943614|FG001|Overall Study|Withdrawal by Subject|76
6253569|NCT01975389|9943613|FG000|Overall Study|Other|6
6253570|NCT01975389|9943614|FG001|Overall Study|Other|9
6253571|NCT01975389|9943613|FG000|Overall Study|Randomized, not treated|4
6253572|NCT01975389|9943614|FG001|Overall Study|Randomized, not treated|5
6253573|NCT01975428|9943622|FG000|Overall Study|Lost to Follow-up|17
6253574|NCT01975428|9943623|FG001|Overall Study|Lost to Follow-up|4
6253575|NCT01975428|9943622|FG000|Overall Study|Withdrawal by Subject|3
6253576|NCT01975428|9943623|FG001|Overall Study|Withdrawal by Subject|10
6253577|NCT01975675|9943650|FG000|Overall Study|Death|0
6253578|NCT01975675|9943651|FG001|Overall Study|Death|1
6253579|NCT01975675|9943652|FG002|Overall Study|Death|0
6253580|NCT01975675|9943653|FG003|Overall Study|Death|0
6253581|NCT01975701|9943663|FG000|Overall Study|Lost to Follow-up|1
6253582|NCT01975701|9943663|FG000|Overall Study|Death|23
6253583|NCT01975701|9943663|FG000|Overall Study|Physician Decision|1
6253584|NCT01975831|9943676|FG000|Overall Study|Adverse Event|1
6253585|NCT01975831|9943677|FG001|Overall Study|Adverse Event|2
6253586|NCT01975831|9943678|FG002|Overall Study|Adverse Event|2
6253587|NCT01975831|9943679|FG003|Overall Study|Adverse Event|0
6253588|NCT01975831|9943680|FG004|Overall Study|Adverse Event|1
6253589|NCT01975831|9943681|FG005|Overall Study|Adverse Event|1
6253590|NCT01975831|9943682|FG006|Overall Study|Adverse Event|3
6253591|NCT01975831|9943683|FG007|Overall Study|Adverse Event|4
6253592|NCT01975831|9943684|FG008|Overall Study|Adverse Event|1
6253593|NCT01975831|9943676|FG000|Overall Study|Death|1
6253594|NCT01975831|9943677|FG001|Overall Study|Death|1
6253595|NCT01975831|9943678|FG002|Overall Study|Death|0
6253596|NCT01975831|9943679|FG003|Overall Study|Death|0
6253597|NCT01975831|9943680|FG004|Overall Study|Death|1
6253598|NCT01975831|9943681|FG005|Overall Study|Death|0
6253599|NCT01975831|9943682|FG006|Overall Study|Death|1
6253600|NCT01975831|9943683|FG007|Overall Study|Death|0
6253601|NCT01975831|9943684|FG008|Overall Study|Death|0
6253602|NCT01975831|9943676|FG000|Overall Study|Progressive Disease|1
6253603|NCT01975831|9943677|FG001|Overall Study|Progressive Disease|3
6253604|NCT01975831|9943678|FG002|Overall Study|Progressive Disease|2
6253605|NCT01975831|9943679|FG003|Overall Study|Progressive Disease|4
6253606|NCT01975831|9943680|FG004|Overall Study|Progressive Disease|13
6253607|NCT01975831|9943681|FG005|Overall Study|Progressive Disease|9
6253608|NCT01975831|9943682|FG006|Overall Study|Progressive Disease|10
6253609|NCT01975831|9943683|FG007|Overall Study|Progressive Disease|8
6253610|NCT01975831|9943684|FG008|Overall Study|Progressive Disease|10
6253611|NCT01975831|9943676|FG000|Overall Study|Withdrawal by Subject|0
6253612|NCT01975831|9943677|FG001|Overall Study|Withdrawal by Subject|3
6253613|NCT01975831|9943678|FG002|Overall Study|Withdrawal by Subject|0
6253614|NCT01975831|9943679|FG003|Overall Study|Withdrawal by Subject|0
6253615|NCT01975831|9943680|FG004|Overall Study|Withdrawal by Subject|3
6253616|NCT01975831|9943681|FG005|Overall Study|Withdrawal by Subject|1
6253617|NCT01975831|9943682|FG006|Overall Study|Withdrawal by Subject|1
6253618|NCT01975831|9943683|FG007|Overall Study|Withdrawal by Subject|0
6253619|NCT01975831|9943684|FG008|Overall Study|Withdrawal by Subject|0
6253620|NCT01975831|9943676|FG000|Overall Study|Physician Decision|0
6253621|NCT01975831|9943677|FG001|Overall Study|Physician Decision|0
6253622|NCT01975831|9943678|FG002|Overall Study|Physician Decision|0
6253623|NCT01975831|9943679|FG003|Overall Study|Physician Decision|0
6253624|NCT01975831|9943680|FG004|Overall Study|Physician Decision|0
6253625|NCT01975831|9943681|FG005|Overall Study|Physician Decision|1
6253626|NCT01975831|9943682|FG006|Overall Study|Physician Decision|0
6253627|NCT01975831|9943683|FG007|Overall Study|Physician Decision|1
6253628|NCT01975831|9943684|FG008|Overall Study|Physician Decision|0
6253629|NCT01975831|9943676|FG000|Overall Study|Initiation of Subsequent Therapy|0
6253630|NCT01975831|9943677|FG001|Overall Study|Initiation of Subsequent Therapy|0
6253631|NCT01975831|9943678|FG002|Overall Study|Initiation of Subsequent Therapy|0
6253632|NCT01975831|9943679|FG003|Overall Study|Initiation of Subsequent Therapy|0
6253633|NCT01975831|9943680|FG004|Overall Study|Initiation of Subsequent Therapy|0
6253634|NCT01975831|9943681|FG005|Overall Study|Initiation of Subsequent Therapy|1
6253635|NCT01975831|9943682|FG006|Overall Study|Initiation of Subsequent Therapy|0
6253636|NCT01975831|9943683|FG007|Overall Study|Initiation of Subsequent Therapy|2
6253637|NCT01975831|9943684|FG008|Overall Study|Initiation of Subsequent Therapy|0
6253638|NCT01975831|9943676|FG000|Overall Study|Entered Hospice|0
6253639|NCT01975831|9943677|FG001|Overall Study|Entered Hospice|0
6253640|NCT01975831|9943678|FG002|Overall Study|Entered Hospice|0
6253641|NCT01975831|9943679|FG003|Overall Study|Entered Hospice|0
6253642|NCT01975831|9943680|FG004|Overall Study|Entered Hospice|0
6253643|NCT01975831|9943681|FG005|Overall Study|Entered Hospice|1
6253644|NCT01975831|9943682|FG006|Overall Study|Entered Hospice|0
6253645|NCT01975831|9943683|FG007|Overall Study|Entered Hospice|0
6253646|NCT01975831|9943684|FG008|Overall Study|Entered Hospice|0
6253647|NCT01975831|9943676|FG000|Overall Study|Unable to Treat Within Protocol Windows|0
6253648|NCT01975831|9943677|FG001|Overall Study|Unable to Treat Within Protocol Windows|0
6253649|NCT01975831|9943678|FG002|Overall Study|Unable to Treat Within Protocol Windows|0
6253650|NCT01975831|9943679|FG003|Overall Study|Unable to Treat Within Protocol Windows|0
6253651|NCT01975831|9943680|FG004|Overall Study|Unable to Treat Within Protocol Windows|0
6253652|NCT01975831|9943681|FG005|Overall Study|Unable to Treat Within Protocol Windows|0
6253653|NCT01975831|9943682|FG006|Overall Study|Unable to Treat Within Protocol Windows|1
6253654|NCT01975831|9943683|FG007|Overall Study|Unable to Treat Within Protocol Windows|0
6253655|NCT01975831|9943684|FG008|Overall Study|Unable to Treat Within Protocol Windows|1
6253656|NCT01975948|9943735|FG000|Overall Study|Withdrawal by Subject|17
6253657|NCT01975948|9943736|FG001|Overall Study|Withdrawal by Subject|21
6253658|NCT01975948|9943737|FG002|Overall Study|Withdrawal by Subject|7
6253659|NCT01975948|9943738|FG003|Overall Study|Withdrawal by Subject|6
6253660|NCT01976104|9943756|FG000|Overall Study|Adverse Event|0
6253661|NCT01976104|9943757|FG001|Overall Study|Adverse Event|0
6253662|NCT01976104|9943758|FG002|Overall Study|Adverse Event|1
6253663|NCT01976104|9943759|FG003|Overall Study|Adverse Event|0
6253664|NCT01976104|9943756|FG000|Overall Study|Lost to Follow-up|3
6253665|NCT01976104|9943757|FG001|Overall Study|Lost to Follow-up|0
6253666|NCT01976104|9943758|FG002|Overall Study|Lost to Follow-up|1
6253667|NCT01976104|9943759|FG003|Overall Study|Lost to Follow-up|1
6253668|NCT01976104|9943756|FG000|Overall Study|Subject Choice|0
6086313|NCT00660660|9696257|FG000|Overall Study|New medication after randomization|1
6086314|NCT00660660|9696258|FG001|Overall Study|New medication after randomization|0
6086315|NCT00660699|9696264|FG000|Overall Study|Withdrawal by Subject|2
6086316|NCT00660790|9696268|FG000|Baseline to 3 Months|Death|1
6086317|NCT00660790|9696268|FG000|Baseline to 3 Months|Withdrawal by Subject|2
6086318|NCT00660790|9696268|FG000|3 Months to 2 Years|Withdrawal by Subject|17
6086319|NCT00660816|9696274|FG000|Overall Study|Adverse Event|1
6253669|NCT01976104|9943757|FG001|Overall Study|Subject Choice|1
6253670|NCT01976104|9943758|FG002|Overall Study|Subject Choice|0
6253671|NCT01976104|9943759|FG003|Overall Study|Subject Choice|1
6253672|NCT01976104|9943756|FG000|Overall Study|Withdrawal by Subject|3
6253673|NCT01976104|9943757|FG001|Overall Study|Withdrawal by Subject|0
6253674|NCT01976104|9943758|FG002|Overall Study|Withdrawal by Subject|0
6253675|NCT01976104|9943759|FG003|Overall Study|Withdrawal by Subject|1
6253676|NCT01976104|9943756|FG000|Overall Study|Other|0
6253677|NCT01976104|9943757|FG001|Overall Study|Other|1
6253678|NCT01976104|9943758|FG002|Overall Study|Other|0
6253679|NCT01976104|9943759|FG003|Overall Study|Other|0
6253680|NCT01976299|9943772|FG000|Overall Study|Withdrawal by Subject|3
6253681|NCT01976299|9943773|FG001|Overall Study|Withdrawal by Subject|1
6253682|NCT01976299|9943772|FG000|Overall Study|Death|4
6253683|NCT01976299|9943773|FG001|Overall Study|Death|2
6253684|NCT01976299|9943772|FG000|Overall Study|Lost to Follow-up|7
6253685|NCT01976299|9943773|FG001|Overall Study|Lost to Follow-up|1
6253686|NCT01976299|9943772|FG000|Overall Study|See clarification above in comments|9
6253687|NCT01976299|9943773|FG001|Overall Study|See clarification above in comments|2
6253688|NCT01976312|9943781|FG000|Overall Study|Pregnancy|0
6253689|NCT01976312|9943782|FG001|Overall Study|Pregnancy|1
6253690|NCT01976312|9943781|FG000|Overall Study|Lost to Follow-up|2
6253691|NCT01976312|9943782|FG001|Overall Study|Lost to Follow-up|0
6253692|NCT01976312|9943781|FG000|Overall Study|Withdrawal by Subject|7
6253693|NCT01976312|9943782|FG001|Overall Study|Withdrawal by Subject|2
6253694|NCT01976312|9943781|FG000|Overall Study|Adverse Event|6
6253695|NCT01976312|9943782|FG001|Overall Study|Adverse Event|6
6253696|NCT01976312|9943781|FG000|Overall Study|Protocol Violation|2
6253697|NCT01976312|9943782|FG001|Overall Study|Protocol Violation|0
6253698|NCT01976338|9943791|FG000|Overall Study|Physician Decision|0
6253699|NCT01976338|9943792|FG001|Overall Study|Physician Decision|1
6253700|NCT01976338|9943791|FG000|Overall Study|Lost to Follow-up|3
6253701|NCT01976338|9943792|FG001|Overall Study|Lost to Follow-up|0
6253702|NCT01976338|9943791|FG000|Overall Study|Withdrawal by Subject|5
6086320|NCT00660816|9696275|FG001|Overall Study|Adverse Event|2
6253703|NCT01976338|9943792|FG001|Overall Study|Withdrawal by Subject|2
6253704|NCT01976338|9943791|FG000|Overall Study|Adverse Event|5
6253705|NCT01976338|9943792|FG001|Overall Study|Adverse Event|1
6270917|NCT02158533|9972374|FG004|Stage 2|Physician Decision|1
6270918|NCT02158533|9972375|FG005|Stage 2|Physician Decision|0
6270919|NCT02158533|9972370|FG000|Stage 2|Pregnancy|0
6253706|NCT01976364|9943799|FG000|Main Study (36 Months)|Adverse Event|63
6253707|NCT01976364|9943800|FG001|Main Study (36 Months)|Adverse Event|0
6253708|NCT01976364|9943801|FG002|Main Study (36 Months)|Adverse Event|0
6253709|NCT01976364|9943799|FG000|Main Study (36 Months)|Withdrawn due to pregnancy|5
6253710|NCT01976364|9943800|FG001|Main Study (36 Months)|Withdrawn due to pregnancy|0
6253711|NCT01976364|9943801|FG002|Main Study (36 Months)|Withdrawn due to pregnancy|0
6253712|NCT01976364|9943799|FG000|Main Study (36 Months)|Other|13
6253713|NCT01976364|9943800|FG001|Main Study (36 Months)|Other|0
6253714|NCT01976364|9943801|FG002|Main Study (36 Months)|Other|0
6253715|NCT01976364|9943799|FG000|Main Study (36 Months)|No longer met eligibility criteria|2
6253716|NCT01976364|9943800|FG001|Main Study (36 Months)|No longer met eligibility criteria|0
6253717|NCT01976364|9943801|FG002|Main Study (36 Months)|No longer met eligibility criteria|0
6253718|NCT01976364|9943799|FG000|Main Study (36 Months)|Medication error|1
6253719|NCT01976364|9943800|FG001|Main Study (36 Months)|Medication error|0
6253720|NCT01976364|9943801|FG002|Main Study (36 Months)|Medication error|0
6253721|NCT01976364|9943799|FG000|Main Study (36 Months)|Lost to Follow-up|10
6253722|NCT01976364|9943800|FG001|Main Study (36 Months)|Lost to Follow-up|0
6253723|NCT01976364|9943801|FG002|Main Study (36 Months)|Lost to Follow-up|0
6253724|NCT01976364|9943799|FG000|Main Study (36 Months)|Lack of Efficacy|40
6253725|NCT01976364|9943800|FG001|Main Study (36 Months)|Lack of Efficacy|0
6253726|NCT01976364|9943801|FG002|Main Study (36 Months)|Lack of Efficacy|0
6253727|NCT01976364|9943799|FG000|Main Study (36 Months)|Protocol Violation|13
6253728|NCT01976364|9943800|FG001|Main Study (36 Months)|Protocol Violation|0
6253729|NCT01976364|9943801|FG002|Main Study (36 Months)|Protocol Violation|0
6253730|NCT01976364|9943799|FG000|Main Study (36 Months)|Withdrawal by Subject|69
6253731|NCT01976364|9943800|FG001|Main Study (36 Months)|Withdrawal by Subject|0
6253732|NCT01976364|9943801|FG002|Main Study (36 Months)|Withdrawal by Subject|0
6253733|NCT01976364|9943799|FG000|Main Study (36 Months)|Death|5
6253734|NCT01976364|9943800|FG001|Main Study (36 Months)|Death|0
6253735|NCT01976364|9943801|FG002|Main Study (36 Months)|Death|0
6253736|NCT01976364|9943799|FG000|Sub-study (12 Months)|Lost to Follow-up|0
6253737|NCT01976364|9943800|FG001|Sub-study (12 Months)|Lost to Follow-up|1
6253738|NCT01976364|9943801|FG002|Sub-study (12 Months)|Lost to Follow-up|0
6253739|NCT01976364|9943799|FG000|Sub-study (12 Months)|Withdrawal by Subject|0
6253740|NCT01976364|9943800|FG001|Sub-study (12 Months)|Withdrawal by Subject|0
6253741|NCT01976364|9943801|FG002|Sub-study (12 Months)|Withdrawal by Subject|1
6253742|NCT01976364|9943799|FG000|Sub-study (12 Months)|Protocol Violation|0
6253743|NCT01976364|9943800|FG001|Sub-study (12 Months)|Protocol Violation|1
6253744|NCT01976364|9943801|FG002|Sub-study (12 Months)|Protocol Violation|1
6253745|NCT01976364|9943799|FG000|Sub-study (12 Months)|Adverse Event|0
6253746|NCT01976364|9943800|FG001|Sub-study (12 Months)|Adverse Event|4
6253747|NCT01976364|9943801|FG002|Sub-study (12 Months)|Adverse Event|3
6253748|NCT01976507|9943837|FG000|Overall Study|Adverse Event|6
6253749|NCT01976507|9943837|FG000|Overall Study|ablation not done, drug not given|1
6253750|NCT01976624|9943852|FG000|Overall Study|Participants contraindicated|2
6253751|NCT01976624|9943852|FG000|Overall Study|Participants age less than 19 years|12
6253752|NCT01976663|9943860|FG000|Overall Study|Completed 18 mos but no repeat treatment|24
6253753|NCT01976663|9943860|FG000|Overall Study|Personal Reasons|6
6253754|NCT01976663|9943860|FG000|Overall Study|Withdrawal by Subject|4
6253755|NCT01976663|9943860|FG000|Overall Study|Screen Failure|3
6253756|NCT01976663|9943860|FG000|Overall Study|Adverse Event|2
6253757|NCT01976663|9943860|FG000|Overall Study|Lost to Follow-up|3
6253758|NCT01976728|9943872|FG000|Overall Study|Subject missed multiple doses of IMP|1
6253759|NCT01976728|9943873|FG001|Overall Study|Subject missed multiple doses of IMP|0
6253760|NCT01976728|9943874|FG002|Overall Study|Subject missed multiple doses of IMP|0
6253761|NCT01976728|9943875|FG003|Overall Study|Subject missed multiple doses of IMP|0
6253762|NCT01976741|9943911|FG000|Overall Study|Withdrawal by Subject|1
6253763|NCT01976741|9943912|FG001|Overall Study|Withdrawal by Subject|0
6253764|NCT01976741|9943913|FG002|Overall Study|Withdrawal by Subject|1
6253765|NCT01976741|9943914|FG003|Overall Study|Withdrawal by Subject|1
6253766|NCT01976741|9943915|FG004|Overall Study|Withdrawal by Subject|0
6253767|NCT01976741|9943916|FG005|Overall Study|Withdrawal by Subject|0
6253768|NCT01976741|9943917|FG006|Overall Study|Withdrawal by Subject|1
6253769|NCT01976741|9943918|FG007|Overall Study|Withdrawal by Subject|4
6253770|NCT01976741|9943919|FG008|Overall Study|Withdrawal by Subject|0
6253771|NCT01976741|9943920|FG009|Overall Study|Withdrawal by Subject|0
6253772|NCT01976741|9943911|FG000|Overall Study|Adverse Event|0
6253773|NCT01976741|9943912|FG001|Overall Study|Adverse Event|0
6253774|NCT01976741|9943913|FG002|Overall Study|Adverse Event|2
6253775|NCT01976741|9943914|FG003|Overall Study|Adverse Event|0
6253776|NCT01976741|9943915|FG004|Overall Study|Adverse Event|0
6253777|NCT01976741|9943916|FG005|Overall Study|Adverse Event|0
6253778|NCT01976741|9943917|FG006|Overall Study|Adverse Event|3
6253779|NCT01976741|9943918|FG007|Overall Study|Adverse Event|8
6253780|NCT01976741|9943919|FG008|Overall Study|Adverse Event|1
6253781|NCT01976741|9943920|FG009|Overall Study|Adverse Event|4
6253782|NCT01976806|9943956|FG000|Overall Study|Lost to Follow-up|1
6253783|NCT01976806|9943957|FG001|Overall Study|Lost to Follow-up|4
6253784|NCT01976806|9943956|FG000|Overall Study|Adverse Event|1
6253785|NCT01976806|9943957|FG001|Overall Study|Adverse Event|1
6253786|NCT01976806|9943956|FG000|Overall Study|Withdrawal by Subject|1
6253787|NCT01976806|9943957|FG001|Overall Study|Withdrawal by Subject|1
6253788|NCT01976845|9943975|FG000|Overall Study|Physician Decision|8
6253789|NCT01976845|9943976|FG001|Overall Study|Physician Decision|8
6253790|NCT01976845|9943977|FG002|Overall Study|Physician Decision|3
6253791|NCT01977040|9944009|FG000|Overall Study|Vasa previa not confirmed|2
6253792|NCT01977092|9944019|FG000|Overall Study|Death|3
6253793|NCT01977092|9944020|FG001|Overall Study|Death|4
6253794|NCT01977092|9944019|FG000|Overall Study|Lost to Follow-up|23
6253795|NCT01977092|9944020|FG001|Overall Study|Lost to Follow-up|14
6253796|NCT01977092|9944019|FG000|Overall Study|Withdrawal by Subject|2
6253797|NCT01977092|9944020|FG001|Overall Study|Withdrawal by Subject|1
6253798|NCT01977092|9944019|FG000|Overall Study|In prison|3
6253799|NCT01977092|9944020|FG001|Overall Study|In prison|11
6253800|NCT01977222|9944026|FG000|Overall Study|Withdrawal by Subject|1
6253801|NCT01977352|9944032|FG000|Overall Study|Lost to Follow-up|1
6253802|NCT01977352|9944033|FG001|Overall Study|Lost to Follow-up|2
6253803|NCT01977456|9944039|FG000|Overall Study|Death|5
6253804|NCT01977482|9944049|FG000|Overall Study|Adverse Event|0
6253805|NCT01977482|9944050|FG001|Overall Study|Adverse Event|1
6253806|NCT01977482|9944051|FG002|Overall Study|Adverse Event|1
6253807|NCT01977482|9944052|FG003|Overall Study|Adverse Event|0
6253808|NCT01977482|9944053|FG004|Overall Study|Adverse Event|2
6253809|NCT01977482|9944054|FG005|Overall Study|Adverse Event|0
6253810|NCT01977482|9944049|FG000|Overall Study|Lost to Follow-up|1
6253811|NCT01977482|9944050|FG001|Overall Study|Lost to Follow-up|0
6253812|NCT01977482|9944051|FG002|Overall Study|Lost to Follow-up|0
6253813|NCT01977482|9944052|FG003|Overall Study|Lost to Follow-up|0
6253814|NCT01977482|9944053|FG004|Overall Study|Lost to Follow-up|0
6253815|NCT01977482|9944054|FG005|Overall Study|Lost to Follow-up|0
6253816|NCT01977482|9944049|FG000|Overall Study|Physician Decision|0
6253817|NCT01977482|9944050|FG001|Overall Study|Physician Decision|1
6253818|NCT01977482|9944051|FG002|Overall Study|Physician Decision|0
6253819|NCT01977482|9944052|FG003|Overall Study|Physician Decision|0
6253820|NCT01977482|9944053|FG004|Overall Study|Physician Decision|0
6253821|NCT01977482|9944054|FG005|Overall Study|Physician Decision|0
6253822|NCT01977482|9944049|FG000|Overall Study|Protocol Violation|0
6253823|NCT01977482|9944050|FG001|Overall Study|Protocol Violation|0
6253824|NCT01977482|9944051|FG002|Overall Study|Protocol Violation|1
6253825|NCT01977482|9944052|FG003|Overall Study|Protocol Violation|0
6253826|NCT01977482|9944053|FG004|Overall Study|Protocol Violation|0
6253827|NCT01977482|9944054|FG005|Overall Study|Protocol Violation|0
6253828|NCT01977482|9944049|FG000|Overall Study|Other-Protocol-defined Stopping Criteria|0
6253829|NCT01977482|9944050|FG001|Overall Study|Other-Protocol-defined Stopping Criteria|3
6253830|NCT01977482|9944051|FG002|Overall Study|Other-Protocol-defined Stopping Criteria|2
6253831|NCT01977482|9944052|FG003|Overall Study|Other-Protocol-defined Stopping Criteria|1
6253832|NCT01977482|9944053|FG004|Overall Study|Other-Protocol-defined Stopping Criteria|0
6253833|NCT01977482|9944054|FG005|Overall Study|Other-Protocol-defined Stopping Criteria|0
6253834|NCT01977482|9944049|FG000|Overall Study|Withdrawal by Subject|2
6253835|NCT01977482|9944050|FG001|Overall Study|Withdrawal by Subject|4
6253836|NCT01977482|9944051|FG002|Overall Study|Withdrawal by Subject|1
6253837|NCT01977482|9944052|FG003|Overall Study|Withdrawal by Subject|3
6253838|NCT01977482|9944053|FG004|Overall Study|Withdrawal by Subject|1
6253839|NCT01977482|9944054|FG005|Overall Study|Withdrawal by Subject|5
6253840|NCT01977573|9944086|FG000|Overall Study|Adverse Event|7
6253841|NCT01977573|9944087|FG001|Overall Study|Adverse Event|0
6253842|NCT01977573|9944088|FG002|Overall Study|Adverse Event|2
6253843|NCT01977573|9944089|FG003|Overall Study|Adverse Event|1
6253844|NCT01977573|9944086|FG000|Overall Study|Lost to Follow-up|1
6253845|NCT01977573|9944087|FG001|Overall Study|Lost to Follow-up|0
6253846|NCT01977573|9944088|FG002|Overall Study|Lost to Follow-up|0
6253847|NCT01977573|9944089|FG003|Overall Study|Lost to Follow-up|1
6253848|NCT01977573|9944086|FG000|Overall Study|Physician Decision|1
6253849|NCT01977573|9944087|FG001|Overall Study|Physician Decision|0
6253850|NCT01977573|9944088|FG002|Overall Study|Physician Decision|0
6253851|NCT01977573|9944089|FG003|Overall Study|Physician Decision|0
6253852|NCT01977573|9944086|FG000|Overall Study|Protocol Violation|3
6253853|NCT01977573|9944087|FG001|Overall Study|Protocol Violation|1
6253854|NCT01977573|9944088|FG002|Overall Study|Protocol Violation|0
6253855|NCT01977573|9944089|FG003|Overall Study|Protocol Violation|0
6253856|NCT01977573|9944086|FG000|Overall Study|Reached Defined Stopping Criteria|2
6253857|NCT01977573|9944087|FG001|Overall Study|Reached Defined Stopping Criteria|1
6253858|NCT01977573|9944088|FG002|Overall Study|Reached Defined Stopping Criteria|1
6253859|NCT01977573|9944089|FG003|Overall Study|Reached Defined Stopping Criteria|0
6253860|NCT01977573|9944086|FG000|Overall Study|Withdrawal by Subject|6
6253861|NCT01977573|9944087|FG001|Overall Study|Withdrawal by Subject|1
6253862|NCT01977573|9944088|FG002|Overall Study|Withdrawal by Subject|1
6253863|NCT01977573|9944089|FG003|Overall Study|Withdrawal by Subject|1
6253864|NCT01977612|9944111|FG000|Overall Study|Lost to Follow-up|1
6253865|NCT01977612|9944112|FG001|Overall Study|Lost to Follow-up|1
6253866|NCT01977625|9944118|FG000|First Intervention (4 Weeks)|Withdrawal by Subject|3
6253867|NCT01977625|9944119|FG001|First Intervention (4 Weeks)|Withdrawal by Subject|0
6253868|NCT01977625|9944118|FG000|Second Intervention (4 Weeks)|Withdrawal by Subject|1
6253869|NCT01977625|9944119|FG001|Second Intervention (4 Weeks)|Withdrawal by Subject|0
6253870|NCT01977651|9944127|FG000|4 Month Treatment Period|Adverse Event|34
6253871|NCT01977651|9944127|FG000|4 Month Treatment Period|Death|3
6253872|NCT01977651|9944127|FG000|4 Month Treatment Period|Progressive Disease|43
6253873|NCT01977651|9944127|FG000|4 Month Treatment Period|Withdrawal by Subject|17
6253874|NCT01977651|9944127|FG000|4 Month Treatment Period|Physician Decision|4
6253875|NCT01977651|9944127|FG000|1 Year Extension Period|Adverse Event|14
6253876|NCT01977651|9944127|FG000|1 Year Extension Period|Death|10
6253877|NCT01977651|9944127|FG000|1 Year Extension Period|Lost to Follow-up|2
6253878|NCT01977651|9944127|FG000|1 Year Extension Period|Progressive Disease|86
6253879|NCT01977651|9944127|FG000|1 Year Extension Period|Withdrawal by Subject|11
6253880|NCT01977651|9944127|FG000|1 Year Extension Period|Physician Decision|6
6253881|NCT01977651|9944127|FG000|1 Year Extension Period|Miscellaneous|1
6253882|NCT01977651|9944127|FG000|Post 1 Year Extension Period|Adverse Event|5
6253883|NCT01977651|9944127|FG000|Post 1 Year Extension Period|Death|13
6253884|NCT01977651|9944127|FG000|Post 1 Year Extension Period|Progressive Disease|60
6253885|NCT01977651|9944127|FG000|Post 1 Year Extension Period|Withdrawal by Subject|13
6253886|NCT01977651|9944127|FG000|Post 1 Year Extension Period|Physician Decision|4
6253887|NCT01977651|9944127|FG000|Post 1 Year Extension Period|Miscellaneous|49
6253888|NCT01977677|9944134|FG000|Overall Study|Unrelated Adverse Event|0
6253889|NCT01977677|9944135|FG001|Overall Study|Unrelated Adverse Event|0
6253890|NCT01977677|9944136|FG002|Overall Study|Unrelated Adverse Event|1
6253891|NCT01977690|9944146|FG000|Overall Study|Withdrawal by Subject|0
6253892|NCT01977690|9944147|FG001|Overall Study|Withdrawal by Subject|4
6253893|NCT01977794|9944164|FG000|Overall Study|Adverse Event|2
6253894|NCT01977794|9944165|FG001|Overall Study|Adverse Event|2
6253895|NCT01977794|9944164|FG000|Overall Study|Lost to Follow-up|2
6253896|NCT01977794|9944165|FG001|Overall Study|Lost to Follow-up|1
6253897|NCT01977794|9944164|FG000|Overall Study|Protocol Violation|1
6253898|NCT01977794|9944165|FG001|Overall Study|Protocol Violation|0
6253899|NCT01977794|9944164|FG000|Overall Study|Death|1
6253900|NCT01977794|9944165|FG001|Overall Study|Death|1
6253901|NCT01977794|9944164|FG000|Overall Study|Withdrew consent|2
6253902|NCT01977794|9944165|FG001|Overall Study|Withdrew consent|1
6253903|NCT01977794|9944164|FG000|Overall Study|Other|0
6086321|NCT00660816|9696274|FG000|Overall Study|Withdrawal by Subject|1
6253904|NCT01977794|9944165|FG001|Overall Study|Other|1
6253905|NCT01977820|9944173|FG000|Overall Study|Sponsor terminated the study|1
6253906|NCT01977820|9944174|FG001|Overall Study|Sponsor terminated the study|1
6253907|NCT01977846|9944182|FG000|Total Study - Prospective|Death|0
6253908|NCT01977846|9944183|FG001|Total Study - Prospective|Death|1
6253909|NCT01977846|9944182|FG000|Total Study - Prospective|Lost to Follow-up|0
6253910|NCT01977846|9944183|FG001|Total Study - Prospective|Lost to Follow-up|8
6253911|NCT01977846|9944182|FG000|Total Study - Prospective|Withdrawal by Subject|0
6253912|NCT01977846|9944183|FG001|Total Study - Prospective|Withdrawal by Subject|13
6253913|NCT01977846|9944182|FG000|Total Study - Prospective|Not available at time of visit|0
6253914|NCT01977846|9944183|FG001|Total Study - Prospective|Not available at time of visit|5
6253915|NCT01977846|9944182|FG000|Total Study - Prospective|No show|0
6253916|NCT01977846|9944183|FG001|Total Study - Prospective|No show|1
6253917|NCT01977846|9944182|FG000|Total Study - Prospective|Protocol Violation|0
6253918|NCT01977846|9944183|FG001|Total Study - Prospective|Protocol Violation|1
6253919|NCT01977898|9944192|FG000|Overall Study|Non functioning catheter|1
6253920|NCT01977898|9944193|FG001|Overall Study|Non functioning catheter|1
6253921|NCT01977937|9944201|FG000|Overall Study|Withdrawal by Subject|2
6253922|NCT01977937|9944202|FG001|Overall Study|Withdrawal by Subject|1
6253923|NCT01977937|9944201|FG000|Overall Study|Adverse Event|1
6253924|NCT01977937|9944202|FG001|Overall Study|Adverse Event|0
6253925|NCT01977937|9944201|FG000|Overall Study|Physician Decision|0
6253926|NCT01977937|9944202|FG001|Overall Study|Physician Decision|1
6253927|NCT01978093|9944210|FG000|Overall Study|Death|1
6253928|NCT01978093|9944211|FG001|Overall Study|Death|0
6253929|NCT01978093|9944210|FG000|Overall Study|Adverse Event|0
6253930|NCT01978093|9944211|FG001|Overall Study|Adverse Event|5
6253931|NCT01978093|9944210|FG000|Overall Study|Protocol Violation|8
6253932|NCT01978093|9944211|FG001|Overall Study|Protocol Violation|2
6253933|NCT01978093|9944210|FG000|Overall Study|Withdrawal by Subject|29
6253934|NCT01978093|9944211|FG001|Overall Study|Withdrawal by Subject|25
6253935|NCT01978093|9944210|FG000|Overall Study|Lost to Follow-up|11
6253936|NCT01978093|9944211|FG001|Overall Study|Lost to Follow-up|15
6253937|NCT01978093|9944210|FG000|Overall Study|Migrated/moved from study area|11
6086322|NCT00660816|9696275|FG001|Overall Study|Withdrawal by Subject|0
6086323|NCT00660816|9696274|FG000|Overall Study|Death|0
6086324|NCT00660816|9696275|FG001|Overall Study|Death|2
6253938|NCT01978093|9944211|FG001|Overall Study|Migrated/moved from study area|13
6253939|NCT01978093|9944210|FG000|Overall Study|Loss of kaiser coverage|4
6253940|NCT01978093|9944211|FG001|Overall Study|Loss of kaiser coverage|10
6253941|NCT01978093|9944210|FG000|Overall Study|Lost kaiser health plan unable to contac|1
6253942|NCT01978093|9944211|FG001|Overall Study|Lost kaiser health plan unable to contac|0
6253943|NCT01978093|9944210|FG000|Overall Study|Mother lost custody of child|0
6253944|NCT01978093|9944211|FG001|Overall Study|Mother lost custody of child|1
6253945|NCT01978093|9944210|FG000|Overall Study|Child was in care of grandmother|0
6270920|NCT02158533|9972371|FG001|Stage 2|Pregnancy|0
6253946|NCT01978093|9944211|FG001|Overall Study|Child was in care of grandmother|1
6253947|NCT01978093|9944210|FG000|Overall Study|N/A for vaccine administration|0
6253948|NCT01978093|9944211|FG001|Overall Study|N/A for vaccine administration|1
6253949|NCT01978119|9944220|FG000|Treatment Period 1 (12 Weeks)|Participants reached stopping criteria|1
6253950|NCT01978119|9944221|FG001|Treatment Period 1 (12 Weeks)|Participants reached stopping criteria|0
6253951|NCT01978119|9944220|FG000|Treatment Period 1 (12 Weeks)|Withdrawal by Subject|1
6253952|NCT01978119|9944221|FG001|Treatment Period 1 (12 Weeks)|Withdrawal by Subject|0
6253953|NCT01978119|9944220|FG000|Treatment Period 2 (12 Weeks)|Withdrawal by Subject|0
6253954|NCT01978119|9944221|FG001|Treatment Period 2 (12 Weeks)|Withdrawal by Subject|2
6253955|NCT01978145|9944227|FG000|Treatment Period 1|Adverse Event|1
6253956|NCT01978145|9944228|FG001|Treatment Period 1|Adverse Event|9
6253957|NCT01978145|9944227|FG000|Treatment Period 1|Physician Decision|1
6253958|NCT01978145|9944228|FG001|Treatment Period 1|Physician Decision|0
6253959|NCT01978145|9944227|FG000|Treatment Period 1|Withdrawal by Subject|5
6253960|NCT01978145|9944228|FG001|Treatment Period 1|Withdrawal by Subject|4
6253961|NCT01978145|9944227|FG000|Treatment Period 1|Par. reached defined stopping criteria|2
6253962|NCT01978145|9944228|FG001|Treatment Period 1|Par. reached defined stopping criteria|3
6253963|NCT01978145|9944227|FG000|Washout Period 1|Adverse Event|0
6253964|NCT01978145|9944228|FG001|Washout Period 1|Adverse Event|1
6253965|NCT01978145|9944227|FG000|Washout Period 1|Withdrawal by Subject|1
6253966|NCT01978145|9944228|FG001|Washout Period 1|Withdrawal by Subject|1
6253967|NCT01978145|9944227|FG000|Washout Period 1|Par. reached defined stopping criteria|0
6253968|NCT01978145|9944228|FG001|Washout Period 1|Par. reached defined stopping criteria|1
6253969|NCT01978145|9944227|FG000|Treatment Period 2|Adverse Event|3
6253970|NCT01978145|9944228|FG001|Treatment Period 2|Adverse Event|3
6253971|NCT01978145|9944227|FG000|Treatment Period 2|Protocol Violation|0
6253972|NCT01978145|9944228|FG001|Treatment Period 2|Protocol Violation|1
6253973|NCT01978145|9944227|FG000|Treatment Period 2|Lost to Follow-up|1
6253974|NCT01978145|9944228|FG001|Treatment Period 2|Lost to Follow-up|1
6253975|NCT01978145|9944227|FG000|Treatment Period 2|Withdrawal by Subject|7
6253976|NCT01978145|9944228|FG001|Treatment Period 2|Withdrawal by Subject|4
6253977|NCT01978145|9944227|FG000|Treatment Period 2|Par. reached defined stopping criteria|8
6253978|NCT01978145|9944228|FG001|Treatment Period 2|Par. reached defined stopping criteria|5
6253979|NCT01978184|9944236|FG000|Overall Study|Progressive disease|5
6253980|NCT01978184|9944237|FG001|Overall Study|Progressive disease|5
6253981|NCT01978184|9944236|FG000|Overall Study|Other than PDA|2
6253982|NCT01978184|9944237|FG001|Overall Study|Other than PDA|2
6253983|NCT01978184|9944236|FG000|Overall Study|Physician Decision|0
6253984|NCT01978184|9944237|FG001|Overall Study|Physician Decision|3
6253985|NCT01978184|9944236|FG000|Overall Study|Noncompliance|1
6253986|NCT01978184|9944237|FG001|Overall Study|Noncompliance|2
6253987|NCT01978184|9944236|FG000|Overall Study|Death|1
6253988|NCT01978184|9944237|FG001|Overall Study|Death|0
6253989|NCT01978184|9944236|FG000|Overall Study|Withdrew- toxicities or physical decline|4
6253990|NCT01978184|9944237|FG001|Overall Study|Withdrew- toxicities or physical decline|8
6253991|NCT01978236|9944243|FG000|Overall Study|Discontinued due to study close|2
6253992|NCT01978262|9944247|FG000|Overall Study|Withdrawal by Subject|9
6253993|NCT01978262|9944247|FG000|Overall Study|Lost to Follow-up|2
6253994|NCT01978912|9944315|FG000|Overall Study|Adverse Event|0
6253995|NCT01978912|9944316|FG001|Overall Study|Adverse Event|1
6253996|NCT01978912|9944317|FG002|Overall Study|Adverse Event|0
6253997|NCT01978912|9944318|FG003|Overall Study|Adverse Event|0
6253998|NCT01978912|9944315|FG000|Overall Study|Lost to Follow-up|1
6253999|NCT01978912|9944316|FG001|Overall Study|Lost to Follow-up|1
6254000|NCT01978912|9944317|FG002|Overall Study|Lost to Follow-up|0
6254001|NCT01978912|9944318|FG003|Overall Study|Lost to Follow-up|1
6254002|NCT01978912|9944315|FG000|Overall Study|Withdrawal by Subject|1
6254003|NCT01978912|9944316|FG001|Overall Study|Withdrawal by Subject|0
6254004|NCT01978912|9944317|FG002|Overall Study|Withdrawal by Subject|2
6254005|NCT01978912|9944318|FG003|Overall Study|Withdrawal by Subject|2
6254006|NCT01978912|9944315|FG000|Overall Study|Lumbar Surgery|1
6254007|NCT01978912|9944316|FG001|Overall Study|Lumbar Surgery|0
6254008|NCT01978912|9944317|FG002|Overall Study|Lumbar Surgery|1
6254009|NCT01978912|9944318|FG003|Overall Study|Lumbar Surgery|0
6254010|NCT01978912|9944315|FG000|Overall Study|Intradiscal Steroid Injection|0
6254011|NCT01978912|9944316|FG001|Overall Study|Intradiscal Steroid Injection|1
6254012|NCT01978912|9944317|FG002|Overall Study|Intradiscal Steroid Injection|0
6254013|NCT01978912|9944318|FG003|Overall Study|Intradiscal Steroid Injection|0
6189725|NCT01402817|9845273|FG000|Overall Study|Study Suspended by FDA|8
6189726|NCT01402869|9845281|FG000|Overall Study|Required Tooth Extraction|0
6189727|NCT01402869|9845282|FG001|Overall Study|Required Tooth Extraction|0
6189728|NCT01402869|9845283|FG002|Overall Study|Required Tooth Extraction|1
6189729|NCT01402908|9845293|FG000|Overall Study|Withdrawal by Subject|30
6189730|NCT01402908|9845294|FG001|Overall Study|Withdrawal by Subject|17
6189731|NCT01402908|9845293|FG000|Overall Study|Lost to Follow-up|3
6189732|NCT01402908|9845294|FG001|Overall Study|Lost to Follow-up|1
6189733|NCT01402908|9845293|FG000|Overall Study|Physician Decision|1
6189734|NCT01402908|9845294|FG001|Overall Study|Physician Decision|0
6254014|NCT01979016|9944330|FG000|Overall Study|Withdrawal by Subject|2
6254015|NCT01979016|9944331|FG001|Overall Study|Withdrawal by Subject|0
6254016|NCT01979016|9944330|FG000|Overall Study|Adverse Event|0
6254017|NCT01979016|9944331|FG001|Overall Study|Adverse Event|1
6254018|NCT01979185|9944371|FG000|Period 2|Other|0
6254019|NCT01979185|9944372|FG001|Period 2|Other|1
6254020|NCT01979523|9944407|FG000|Overall Study|Withdrawal by Subject|1
6254021|NCT01979523|9944408|FG001|Overall Study|Withdrawal by Subject|0
6254022|NCT01979614|9944417|FG000|Overall Study|Adverse Event|1
6254023|NCT01979614|9944418|FG001|Overall Study|Adverse Event|1
6254024|NCT01979835|9944424|FG000|Primary Outcome SA Measurment|failed insertion|18
6254025|NCT01979835|9944424|FG000|Follow-up|Lost to Follow-up|32
6254026|NCT01979952|9944430|FG000|Overall Study|Adverse Event|4
6254027|NCT01979952|9944431|FG001|Overall Study|Adverse Event|5
6254028|NCT01979952|9944430|FG000|Overall Study|Protocol Violation|1
6254029|NCT01979952|9944431|FG001|Overall Study|Protocol Violation|0
6254030|NCT01979952|9944430|FG000|Overall Study|Withdrawal by Subject|2
6254031|NCT01979952|9944431|FG001|Overall Study|Withdrawal by Subject|1
6254032|NCT01979952|9944430|FG000|Overall Study|Other than specified above|1
6254033|NCT01979952|9944431|FG001|Overall Study|Other than specified above|0
6254034|NCT01980056|9944440|FG000|Overall Study|Death|1
6254035|NCT01980056|9944441|FG001|Overall Study|Death|1
6254036|NCT01980056|9944442|FG002|Overall Study|Death|0
6254037|NCT01980095|9944456|FG000|Overall Study|Lost to Follow-up|6
6254038|NCT01980095|9944457|FG001|Overall Study|Lost to Follow-up|7
6254039|NCT01980095|9944456|FG000|Overall Study|Withdrawal by Subject|2
6254040|NCT01980095|9944457|FG001|Overall Study|Withdrawal by Subject|3
6254041|NCT01980095|9944456|FG000|Overall Study|Poor compliance|5
6254042|NCT01980095|9944457|FG001|Overall Study|Poor compliance|0
6254043|NCT01980095|9944456|FG000|Overall Study|Safety issue|0
6254044|NCT01980095|9944457|FG001|Overall Study|Safety issue|1
6254045|NCT01980095|9944456|FG000|Overall Study|Study drug discontinued|1
6254046|NCT01980095|9944457|FG001|Overall Study|Study drug discontinued|0
6254047|NCT01980095|9944456|FG000|Overall Study|Randomized by mistake|1
6254048|NCT01980095|9944457|FG001|Overall Study|Randomized by mistake|0
6254049|NCT01980628|9944496|FG000|Overall Study|Adverse Event|12
6254050|NCT01980628|9944496|FG000|Overall Study|Physician Decision|5
6254051|NCT01980628|9944496|FG000|Overall Study|Withdrawal by Subject|4
6254052|NCT01980628|9944496|FG000|Overall Study|PD, Subj non-Compliant,Study Terminated|42
6254053|NCT01980706|9944513|FG000|Overall Study|Withdrawal by Subject|9
6254054|NCT01980706|9944514|FG001|Overall Study|Withdrawal by Subject|6
6254055|NCT01980706|9944515|FG002|Overall Study|Withdrawal by Subject|2
6254056|NCT01980706|9944513|FG000|Overall Study|Adverse Event|1
6254057|NCT01980706|9944514|FG001|Overall Study|Adverse Event|2
6254058|NCT01980706|9944515|FG002|Overall Study|Adverse Event|5
6254059|NCT01980706|9944513|FG000|Overall Study|Lost to Follow-up|3
6254060|NCT01980706|9944514|FG001|Overall Study|Lost to Follow-up|4
6254061|NCT01980706|9944515|FG002|Overall Study|Lost to Follow-up|3
6254062|NCT01980706|9944513|FG000|Overall Study|miscellaneous|4
6254063|NCT01980706|9944514|FG001|Overall Study|miscellaneous|5
6254064|NCT01980706|9944515|FG002|Overall Study|miscellaneous|3
6254065|NCT01980888|9944534|FG000|Overall Study|Study Terminated by Sponsor|116
6254066|NCT01980888|9944535|FG001|Overall Study|Study Terminated by Sponsor|122
6254067|NCT01980888|9944534|FG000|Overall Study|Withdrew Consent|17
6254068|NCT01980888|9944535|FG001|Overall Study|Withdrew Consent|6
6086325|NCT00660816|9696274|FG000|Overall Study|Lack of Efficacy|1
6086326|NCT00660816|9696275|FG001|Overall Study|Lack of Efficacy|0
6086327|NCT00660816|9696274|FG000|Overall Study|Physician Decision|0
6254069|NCT01980888|9944534|FG000|Overall Study|Investigator's Discretion|8
6254070|NCT01980888|9944535|FG001|Overall Study|Investigator's Discretion|3
6254071|NCT01980888|9944534|FG000|Overall Study|Non-Compliance with Study Drug|3
6254072|NCT01980888|9944535|FG001|Overall Study|Non-Compliance with Study Drug|2
6254073|NCT01980992|9944548|FG000|52 Weeks Blinded Study Treatment|Dosing Symptoms|0
6254074|NCT01980992|9944549|FG001|52 Weeks Blinded Study Treatment|Dosing Symptoms|3
6254075|NCT01980992|9944548|FG000|52 Weeks Blinded Study Treatment|Withdrawal by Subject|1
6254076|NCT01980992|9944549|FG001|52 Weeks Blinded Study Treatment|Withdrawal by Subject|1
6254077|NCT01980992|9944548|FG000|52 Weeks Blinded Study Treatment|Non-compliance|1
6254078|NCT01980992|9944549|FG001|52 Weeks Blinded Study Treatment|Non-compliance|0
6254079|NCT01980992|9944548|FG000|52 Weeks Open Label Active Wheat OIT|Dosing Symptoms|2
6086328|NCT00660816|9696275|FG001|Overall Study|Physician Decision|2
6086329|NCT00660816|9696274|FG000|Overall Study|Protocol Violation|1
6254080|NCT01980992|9944549|FG001|52 Weeks Open Label Active Wheat OIT|Dosing Symptoms|0
6254081|NCT01980992|9944548|FG000|52 Weeks Open Label Active Wheat OIT|Non-compliance|1
6254082|NCT01980992|9944549|FG001|52 Weeks Open Label Active Wheat OIT|Non-compliance|0
6254083|NCT01980992|9944548|FG000|52 Weeks Open Label Active Wheat OIT|Lost to Follow-up|0
6254084|NCT01980992|9944549|FG001|52 Weeks Open Label Active Wheat OIT|Lost to Follow-up|1
6254085|NCT01981109|9944571|FG000|Overall Study|Death|36
6254086|NCT01981109|9944571|FG000|Overall Study|Withdrawal by Subject|40
6254087|NCT01981109|9944571|FG000|Overall Study|Lost to Follow-up|9
6254088|NCT01981109|9944571|FG000|Overall Study|No Discontinuation Documentation|37
6254089|NCT01981109|9944571|FG000|Overall Study|Study Termination|100
6254090|NCT01981109|9944571|FG000|Overall Study|No data available|2
6254091|NCT01981122|9944578|FG000|Overall Study|Withdrawal by Subject|0
6254092|NCT01981122|9944579|FG001|Overall Study|Withdrawal by Subject|2
6254093|NCT01981122|9944578|FG000|Overall Study|Protocol Violation|0
6254094|NCT01981122|9944579|FG001|Overall Study|Protocol Violation|1
6254095|NCT01981122|9944578|FG000|Overall Study|Lost to Follow-up|0
6254096|NCT01981122|9944579|FG001|Overall Study|Lost to Follow-up|1
6254097|NCT01981122|9944578|FG000|Overall Study|Investigator Or Dendreon Discretion|0
6254098|NCT01981122|9944579|FG001|Overall Study|Investigator Or Dendreon Discretion|1
6254099|NCT01981122|9944578|FG000|Overall Study|Death|14
6254100|NCT01981122|9944579|FG001|Overall Study|Death|15
6254101|NCT01981187|9944585|FG000|Overall Study|Participant/guardian decision|2
6254102|NCT01981187|9944585|FG000|Overall Study|Physician Decision|1
6254103|NCT01981187|9944585|FG000|Overall Study|Disease progression|2
6254104|NCT01981187|9944585|FG000|Overall Study|Adverse Event|7
6254105|NCT01981356|9944591|FG000|Overall Study|Lost to Follow-up|4
6254106|NCT01981356|9944592|FG001|Overall Study|Lost to Follow-up|1
6254107|NCT01981356|9944591|FG000|Overall Study|Withdrawal by Subject|1
6254108|NCT01981356|9944592|FG001|Overall Study|Withdrawal by Subject|1
6254109|NCT01981356|9944591|FG000|Overall Study|Protocol Violation|2
6254110|NCT01981356|9944592|FG001|Overall Study|Protocol Violation|0
6254111|NCT01981473|9944602|FG000|Overall Study|Incorrect diagnosis of RA|0
6254112|NCT01981473|9944603|FG001|Overall Study|Incorrect diagnosis of RA|0
6254113|NCT01981473|9944604|FG002|Overall Study|Incorrect diagnosis of RA|1
6254114|NCT01981473|9944602|FG000|Overall Study|Received treatment for < 6 months|0
6254115|NCT01981473|9944603|FG001|Overall Study|Received treatment for < 6 months|0
6254116|NCT01981473|9944604|FG002|Overall Study|Received treatment for < 6 months|1
6254117|NCT01981473|9944602|FG000|Overall Study|Received treatment for >24 months|2
6254118|NCT01981473|9944603|FG001|Overall Study|Received treatment for >24 months|0
6254119|NCT01981473|9944604|FG002|Overall Study|Received treatment for >24 months|6
6189735|NCT01402947|9845302|FG000|First Intervention|Adverse Event|0
6189736|NCT01402947|9845303|FG001|First Intervention|Adverse Event|1
6189737|NCT01402986|9845313|FG000|Overall Study|Withdrawal by Subject|7
6189738|NCT01402986|9845314|FG001|Overall Study|Withdrawal by Subject|10
6189739|NCT01402986|9845315|FG002|Overall Study|Withdrawal by Subject|7
6254120|NCT01981616|9944632|FG000|Overall Study|Adverse Event|0
6254121|NCT01981616|9944633|FG001|Overall Study|Adverse Event|1
6254122|NCT01981616|9944632|FG000|Overall Study|Protocol Violation|1
6254123|NCT01981616|9944633|FG001|Overall Study|Protocol Violation|0
6254124|NCT01981954|9944666|FG000|Titration Period|Protocol Deviation|1
6254125|NCT01981954|9944666|FG000|Fixed-Dose Assessment Period|Lack of Efficacy|1
6254126|NCT01982292|9944702|FG000|Overall Study|Adverse Event|2
6254127|NCT01982292|9944703|FG001|Overall Study|Adverse Event|0
6254128|NCT01982292|9944702|FG000|Overall Study|Death|1
6254129|NCT01982292|9944703|FG001|Overall Study|Death|0
6254130|NCT01982292|9944702|FG000|Overall Study|Lost to Follow-up|2
6254131|NCT01982292|9944703|FG001|Overall Study|Lost to Follow-up|0
6254132|NCT01982292|9944702|FG000|Overall Study|Non-Compliance With Study Treatment|1
6254133|NCT01982292|9944703|FG001|Overall Study|Non-Compliance With Study Treatment|0
6254134|NCT01982292|9944702|FG000|Overall Study|Protocol Deviation|1
6254135|NCT01982292|9944703|FG001|Overall Study|Protocol Deviation|0
6254136|NCT01982292|9944702|FG000|Overall Study|Patient/Guardian Decision|3
6254137|NCT01982292|9944703|FG001|Overall Study|Patient/Guardian Decision|1
6254138|NCT01982292|9944702|FG000|Overall Study|Technical Problems|2
6254139|NCT01982292|9944703|FG001|Overall Study|Technical Problems|0
6254140|NCT01982331|9944711|FG000|Received Vaccination 2|Adverse Event|1
6254141|NCT01982331|9944712|FG001|Received Vaccination 2|Adverse Event|2
6189740|NCT01402986|9845316|FG003|Overall Study|Withdrawal by Subject|13
6189741|NCT01402986|9845313|FG000|Overall Study|Death|0
6189742|NCT01402986|9845314|FG001|Overall Study|Death|0
6189743|NCT01402986|9845315|FG002|Overall Study|Death|0
6189744|NCT01402986|9845316|FG003|Overall Study|Death|2
6189745|NCT01402986|9845313|FG000|Overall Study|Lost to Follow-up|0
6189746|NCT01402986|9845314|FG001|Overall Study|Lost to Follow-up|0
6189747|NCT01402986|9845315|FG002|Overall Study|Lost to Follow-up|0
6189748|NCT01402986|9845316|FG003|Overall Study|Lost to Follow-up|1
6189749|NCT01402986|9845313|FG000|Overall Study|Other|2
6189750|NCT01402986|9845314|FG001|Overall Study|Other|5
6189751|NCT01402986|9845315|FG002|Overall Study|Other|1
6189752|NCT01402986|9845316|FG003|Overall Study|Other|6
6189753|NCT01403051|9845328|FG000|Overall Study|Protocol Violation|2
6189754|NCT01403051|9845329|FG001|Overall Study|Protocol Violation|0
6189755|NCT01403051|9845328|FG000|Overall Study|Death|1
6189756|NCT01403051|9845329|FG001|Overall Study|Death|0
6189757|NCT01403051|9845328|FG000|Overall Study|Withdrawal by Subject|2
6189758|NCT01403051|9845329|FG001|Overall Study|Withdrawal by Subject|1
6254142|NCT01982331|9944711|FG000|Received Vaccination 2|Withdrawal by Subject|0
6254143|NCT01982331|9944712|FG001|Received Vaccination 2|Withdrawal by Subject|1
6254144|NCT01982331|9944711|FG000|Completed Study (Day 112)|Withdrawal by Subject|2
6254145|NCT01982331|9944712|FG001|Completed Study (Day 112)|Withdrawal by Subject|0
6254146|NCT01982435|9944720|FG000|Overall Study|Adverse Event|1
6254147|NCT01982435|9944721|FG001|Overall Study|Adverse Event|0
6254148|NCT01982682|9944735|FG000|Overall Study|Physician Decision|1
6254149|NCT01982773|9944751|FG000|Overall Study|Withdrawal by Subject|1
6254150|NCT01982773|9944752|FG001|Overall Study|Withdrawal by Subject|3
6254151|NCT01982773|9944751|FG000|Overall Study|Lost to Follow-up|7
6254152|NCT01982773|9944752|FG001|Overall Study|Lost to Follow-up|1
6254153|NCT01982812|9944769|FG000|Overall Study|Death|1
6254154|NCT01982812|9944770|FG001|Overall Study|Death|5
6254155|NCT01982812|9944769|FG000|Overall Study|Adverse Event|0
6254156|NCT01982812|9944770|FG001|Overall Study|Adverse Event|5
6254157|NCT01982942|9944778|FG000|Overall Study|Adverse Event|10
6254158|NCT01982942|9944779|FG001|Overall Study|Adverse Event|5
6254159|NCT01982942|9944778|FG000|Overall Study|Lost to Follow-up|4
6254160|NCT01982942|9944779|FG001|Overall Study|Lost to Follow-up|3
6254161|NCT01982942|9944778|FG000|Overall Study|Multiple sclerosis progression|3
6254162|NCT01982942|9944779|FG001|Overall Study|Multiple sclerosis progression|2
6254163|NCT01982942|9944778|FG000|Overall Study|Wanted to try therapy not permitted|1
6254164|NCT01982942|9944779|FG001|Overall Study|Wanted to try therapy not permitted|0
6254165|NCT01982942|9944778|FG000|Overall Study|Subject declined future visits|0
6254166|NCT01982942|9944779|FG001|Overall Study|Subject declined future visits|1
6254167|NCT01982942|9944778|FG000|Overall Study|Left geographical area|2
6254168|NCT01982942|9944779|FG001|Overall Study|Left geographical area|0
6254169|NCT01982942|9944778|FG000|Overall Study|Too many pills|1
6254170|NCT01982942|9944779|FG001|Overall Study|Too many pills|0
6254171|NCT01982942|9944778|FG000|Overall Study|MS Relapse|0
6254172|NCT01982942|9944779|FG001|Overall Study|MS Relapse|1
6254173|NCT01982942|9944778|FG000|Overall Study|Chose to join a stem cell trial|0
6254174|NCT01982942|9944779|FG001|Overall Study|Chose to join a stem cell trial|1
6254175|NCT01982942|9944778|FG000|Overall Study|Subject bedridden, rapidly declining|0
6254176|NCT01982942|9944779|FG001|Overall Study|Subject bedridden, rapidly declining|1
6254177|NCT01982955|9944790|FG000|Overall Study|Randomized but not treated|0
6254178|NCT01982955|9944791|FG001|Overall Study|Randomized but not treated|0
6254179|NCT01982955|9944792|FG002|Overall Study|Randomized but not treated|0
6254180|NCT01982955|9944793|FG003|Overall Study|Randomized but not treated|1
6254181|NCT01982955|9944794|FG004|Overall Study|Randomized but not treated|0
6254182|NCT01982955|9944790|FG000|Overall Study|Ongoing|0
6254183|NCT01982955|9944791|FG001|Overall Study|Ongoing|0
6254184|NCT01982955|9944792|FG002|Overall Study|Ongoing|4
6254185|NCT01982955|9944793|FG003|Overall Study|Ongoing|0
6254186|NCT01982955|9944794|FG004|Overall Study|Ongoing|0
6270921|NCT02158533|9972372|FG002|Stage 2|Pregnancy|0
6270922|NCT02158533|9972373|FG003|Stage 2|Pregnancy|1
6270923|NCT02158533|9972374|FG004|Stage 2|Pregnancy|0
6270924|NCT02158533|9972375|FG005|Stage 2|Pregnancy|0
6270925|NCT02158533|9972370|FG000|Stage 2|Psychiatrist decision to try new tx|0
6270926|NCT02158533|9972371|FG001|Stage 2|Psychiatrist decision to try new tx|0
6270927|NCT02158533|9972372|FG002|Stage 2|Psychiatrist decision to try new tx|0
6270928|NCT02158533|9972373|FG003|Stage 2|Psychiatrist decision to try new tx|1
6270929|NCT02158533|9972374|FG004|Stage 2|Psychiatrist decision to try new tx|0
6270930|NCT02158533|9972375|FG005|Stage 2|Psychiatrist decision to try new tx|0
6270931|NCT02158533|9972370|FG000|Stage 2|Non-adherence with study visits|0
6270932|NCT02158533|9972371|FG001|Stage 2|Non-adherence with study visits|0
6270933|NCT02158533|9972372|FG002|Stage 2|Non-adherence with study visits|0
6270934|NCT02158533|9972373|FG003|Stage 2|Non-adherence with study visits|0
6270935|NCT02158533|9972374|FG004|Stage 2|Non-adherence with study visits|0
6270936|NCT02158533|9972375|FG005|Stage 2|Non-adherence with study visits|1
6270937|NCT02158546|9972393|FG000|Overall Study|Physician Decision|0
6270938|NCT02158546|9972394|FG001|Overall Study|Physician Decision|1
6270939|NCT02158546|9972395|FG002|Overall Study|Physician Decision|0
6270940|NCT02158546|9972396|FG003|Overall Study|Physician Decision|0
6270941|NCT02158546|9972393|FG000|Overall Study|Non-compliance|0
6270942|NCT02158546|9972394|FG001|Overall Study|Non-compliance|1
6270943|NCT02158546|9972395|FG002|Overall Study|Non-compliance|0
6270944|NCT02158546|9972396|FG003|Overall Study|Non-compliance|1
6270945|NCT02158546|9972393|FG000|Overall Study|Failure to meet eligibility criteria|0
6270946|NCT02158546|9972394|FG001|Overall Study|Failure to meet eligibility criteria|1
6270947|NCT02158546|9972395|FG002|Overall Study|Failure to meet eligibility criteria|0
6270948|NCT02158546|9972396|FG003|Overall Study|Failure to meet eligibility criteria|0
6270949|NCT02158546|9972393|FG000|Overall Study|Lack of Efficacy|1
6270950|NCT02158546|9972394|FG001|Overall Study|Lack of Efficacy|1
6270951|NCT02158546|9972395|FG002|Overall Study|Lack of Efficacy|0
6270952|NCT02158546|9972396|FG003|Overall Study|Lack of Efficacy|0
6270953|NCT02158546|9972393|FG000|Overall Study|Adverse Event|2
6270954|NCT02158546|9972394|FG001|Overall Study|Adverse Event|2
6270955|NCT02158546|9972395|FG002|Overall Study|Adverse Event|0
6270956|NCT02158546|9972396|FG003|Overall Study|Adverse Event|0
6270957|NCT02158546|9972393|FG000|Overall Study|Withdrawal by Subject|6
6270958|NCT02158546|9972394|FG001|Overall Study|Withdrawal by Subject|2
6270959|NCT02158546|9972395|FG002|Overall Study|Withdrawal by Subject|1
6270960|NCT02158546|9972396|FG003|Overall Study|Withdrawal by Subject|0
6270961|NCT02158546|9972393|FG000|Overall Study|Lost to Follow-up|5
6270962|NCT02158546|9972394|FG001|Overall Study|Lost to Follow-up|4
6270963|NCT02158546|9972395|FG002|Overall Study|Lost to Follow-up|0
6270964|NCT02158546|9972396|FG003|Overall Study|Lost to Follow-up|1
6270965|NCT02158546|9972393|FG000|Overall Study|Site Excluded|5
6270966|NCT02158546|9972394|FG001|Overall Study|Site Excluded|5
6270967|NCT02158546|9972395|FG002|Overall Study|Site Excluded|3
6270968|NCT02158546|9972396|FG003|Overall Study|Site Excluded|4
6270969|NCT02158663|9972412|FG000|Overall Study|Withdrawal by Subject|5
6270970|NCT02158663|9972413|FG001|Overall Study|Withdrawal by Subject|4
6270971|NCT02158728|9972421|FG000|Overall Study|no procedure according to CIP done|3
6254187|NCT01983111|9944835|FG000|Overall Study|Withdrawal by Subject|8
6254188|NCT01983111|9944836|FG001|Overall Study|Withdrawal by Subject|6
6254189|NCT01983111|9944835|FG000|Overall Study|Adverse Event|4
6254190|NCT01983111|9944836|FG001|Overall Study|Adverse Event|0
6254191|NCT01983111|9944835|FG000|Overall Study|Protocol Violation|0
6254192|NCT01983111|9944836|FG001|Overall Study|Protocol Violation|1
6254193|NCT01983254|9944855|FG000|Overall Study|Death|6
6254194|NCT01983254|9944856|FG001|Overall Study|Death|6
6254195|NCT01983254|9944855|FG000|Overall Study|Lost to Follow-up|17
6254196|NCT01983254|9944856|FG001|Overall Study|Lost to Follow-up|16
6254197|NCT01983254|9944855|FG000|Overall Study|too ill|11
6254198|NCT01983254|9944856|FG001|Overall Study|too ill|8
6254199|NCT01983293|9944864|FG000|Overall Study|Withdrawal by Subject|29
6254200|NCT01983293|9944865|FG001|Overall Study|Withdrawal by Subject|15
6254201|NCT01983293|9944864|FG000|Overall Study|Missing 12-month visit|3
6254202|NCT01983293|9944865|FG001|Overall Study|Missing 12-month visit|3
6254203|NCT01983293|9944864|FG000|Overall Study|Missing NYHA/Patient Global Assessment|1
6254204|NCT01983293|9944865|FG001|Overall Study|Missing NYHA/Patient Global Assessment|1
6254205|NCT01983683|9944891|FG000|Overall Study|Withdrawal by Subject|14
6254206|NCT01983683|9944892|FG001|Overall Study|Withdrawal by Subject|18
6254207|NCT01983683|9944891|FG000|Overall Study|Death|11
6254208|NCT01983683|9944892|FG001|Overall Study|Death|15
6254209|NCT01983683|9944891|FG000|Overall Study|Physician Decision|8
6254210|NCT01983683|9944892|FG001|Overall Study|Physician Decision|9
6254211|NCT01983683|9944891|FG000|Overall Study|Lost to Follow-up|4
6254212|NCT01983683|9944892|FG001|Overall Study|Lost to Follow-up|8
6254213|NCT01983683|9944891|FG000|Overall Study|Sponsor Decision|1
6254214|NCT01983683|9944892|FG001|Overall Study|Sponsor Decision|1
6254215|NCT01983930|9944945|FG000|Overall Study|Withdrawal by Subject|9
6254216|NCT01983930|9944946|FG001|Overall Study|Withdrawal by Subject|8
6254217|NCT01983930|9944945|FG000|Overall Study|Adverse Event|0
6254218|NCT01983930|9944946|FG001|Overall Study|Adverse Event|1
6254219|NCT01983969|9944956|FG000|Overall Study|Disease Progression|0
6254220|NCT01983969|9944957|FG001|Overall Study|Disease Progression|1
6254221|NCT01983969|9944958|FG002|Overall Study|Disease Progression|0
6254222|NCT01984164|9944972|FG000|Overall Study|Withdrawal by Subject|4
6254223|NCT01984164|9944973|FG001|Overall Study|Withdrawal by Subject|3
6254224|NCT01984164|9944972|FG000|Overall Study|Adverse Event|5
6254225|NCT01984164|9944973|FG001|Overall Study|Adverse Event|19
6254226|NCT01984164|9944972|FG000|Overall Study|Lost to Follow-up|1
6254227|NCT01984164|9944973|FG001|Overall Study|Lost to Follow-up|3
6254228|NCT01984229|9944981|FG000|Safety Follow-up Period|Adverse Event|1
6254229|NCT01984229|9944982|FG001|Safety Follow-up Period|Adverse Event|1
6254230|NCT01984229|9944981|FG000|Safety Follow-up Period|Lost to Follow-up|1
6254231|NCT01984229|9944982|FG001|Safety Follow-up Period|Lost to Follow-up|0
6254232|NCT01984242|9944997|FG000|Overall Study|Death|52
6254233|NCT01984242|9944998|FG001|Overall Study|Death|50
6254234|NCT01984242|9944999|FG002|Overall Study|Death|52
6254235|NCT01984242|9944997|FG000|Overall Study|Withdrawal by Subject|5
6254236|NCT01984242|9944998|FG001|Overall Study|Withdrawal by Subject|3
6254237|NCT01984242|9944999|FG002|Overall Study|Withdrawal by Subject|10
6254238|NCT01984242|9944997|FG000|Overall Study|Physician Decision|0
6254239|NCT01984242|9944998|FG001|Overall Study|Physician Decision|0
6254240|NCT01984242|9944999|FG002|Overall Study|Physician Decision|1
6254241|NCT01984242|9944997|FG000|Overall Study|Lost to Follow-up|4
6254242|NCT01984242|9944998|FG001|Overall Study|Lost to Follow-up|0
6254243|NCT01984242|9944999|FG002|Overall Study|Lost to Follow-up|3
6254244|NCT01984242|9944997|FG000|Overall Study|Sponsor Decision|1
6254245|NCT01984242|9944998|FG001|Overall Study|Sponsor Decision|0
6254246|NCT01984242|9944999|FG002|Overall Study|Sponsor Decision|0
6254247|NCT01984242|9944997|FG000|Overall Study|Non-Compliance|1
6254248|NCT01984242|9944998|FG001|Overall Study|Non-Compliance|0
6254249|NCT01984242|9944999|FG002|Overall Study|Non-Compliance|0
6254250|NCT01984242|9944997|FG000|Overall Study|Study terminated by Sponsor|38
6254251|NCT01984242|9944998|FG001|Overall Study|Study terminated by Sponsor|50
6254252|NCT01984242|9944999|FG002|Overall Study|Study terminated by Sponsor|34
6254253|NCT01984242|9944997|FG000|Overall Study|Disease Progression|0
6254254|NCT01984242|9944998|FG001|Overall Study|Disease Progression|0
6254255|NCT01984242|9944999|FG002|Overall Study|Disease Progression|1
6254256|NCT01984294|9945018|FG000|Overall Study|Randomized but Never Treated|0
6254257|NCT01984294|9945019|FG001|Overall Study|Randomized but Never Treated|0
6254258|NCT01984294|9945020|FG002|Overall Study|Randomized but Never Treated|1
6254259|NCT01984294|9945018|FG000|Overall Study|Lack of Efficacy|4
6254260|NCT01984294|9945019|FG001|Overall Study|Lack of Efficacy|2
6254261|NCT01984294|9945020|FG002|Overall Study|Lack of Efficacy|6
6254262|NCT01984294|9945018|FG000|Overall Study|Adverse Event|0
6254263|NCT01984294|9945019|FG001|Overall Study|Adverse Event|1
6254264|NCT01984294|9945020|FG002|Overall Study|Adverse Event|0
6254265|NCT01984424|9945045|FG000|Overall Study|Withdrawal by Subject|3
6254266|NCT01984424|9945046|FG001|Overall Study|Withdrawal by Subject|5
6254267|NCT01984424|9945045|FG000|Overall Study|Sponsor Decision|0
6254268|NCT01984424|9945046|FG001|Overall Study|Sponsor Decision|1
6254269|NCT01984424|9945045|FG000|Overall Study|Lost to Follow-up|0
6254270|NCT01984424|9945046|FG001|Overall Study|Lost to Follow-up|1
6254271|NCT01984684|9945058|FG000|Overall Study|Lost to Follow-up|25
6254272|NCT01984684|9945059|FG001|Overall Study|Lost to Follow-up|24
6254273|NCT01984684|9945058|FG000|Overall Study|Adverse Event|8
6254274|NCT01984684|9945059|FG001|Overall Study|Adverse Event|12
6254275|NCT01984684|9945058|FG000|Overall Study|Withdrawal by Subject|9
6254276|NCT01984684|9945059|FG001|Overall Study|Withdrawal by Subject|9
6254277|NCT01984684|9945058|FG000|Overall Study|Lack of Efficacy|3
6254278|NCT01984684|9945059|FG001|Overall Study|Lack of Efficacy|6
6254279|NCT01984684|9945058|FG000|Overall Study|Physician Decision|4
6254280|NCT01984684|9945059|FG001|Overall Study|Physician Decision|2
6254281|NCT01984684|9945058|FG000|Overall Study|Protocol Violation|4
6254282|NCT01984684|9945059|FG001|Overall Study|Protocol Violation|2
6254283|NCT01984684|9945058|FG000|Overall Study|Death|0
6254284|NCT01984684|9945059|FG001|Overall Study|Death|1
6254285|NCT01984684|9945058|FG000|Overall Study|Noncompliance with study drug|2
6254286|NCT01984684|9945059|FG001|Overall Study|Noncompliance with study drug|1
6254287|NCT01984684|9945058|FG000|Overall Study|Subject incarcerated|1
6254288|NCT01984684|9945059|FG001|Overall Study|Subject incarcerated|0
6254289|NCT01984684|9945058|FG000|Overall Study|Study drug not available at site|1
6254290|NCT01984684|9945059|FG001|Overall Study|Study drug not available at site|1
6254291|NCT01984684|9945058|FG000|Overall Study|Subject had inadequate IV access|0
6254292|NCT01984684|9945059|FG001|Overall Study|Subject had inadequate IV access|1
6254293|NCT01984697|9945070|FG000|Overall Study|Adverse Event|0
6254294|NCT01984697|9945071|FG001|Overall Study|Adverse Event|0
6254295|NCT01984697|9945072|FG002|Overall Study|Adverse Event|2
6254296|NCT01984697|9945073|FG003|Overall Study|Adverse Event|0
6254297|NCT01984697|9945074|FG004|Overall Study|Adverse Event|0
6254298|NCT01984697|9945070|FG000|Overall Study|Lost to Follow-up|14
6254299|NCT01984697|9945071|FG001|Overall Study|Lost to Follow-up|5
6254300|NCT01984697|9945072|FG002|Overall Study|Lost to Follow-up|10
6254301|NCT01984697|9945073|FG003|Overall Study|Lost to Follow-up|6
6254302|NCT01984697|9945074|FG004|Overall Study|Lost to Follow-up|21
6254303|NCT01984697|9945070|FG000|Overall Study|Physician Decision|3
6254304|NCT01984697|9945071|FG001|Overall Study|Physician Decision|0
6254305|NCT01984697|9945072|FG002|Overall Study|Physician Decision|0
6254306|NCT01984697|9945073|FG003|Overall Study|Physician Decision|1
6254307|NCT01984697|9945074|FG004|Overall Study|Physician Decision|0
6254308|NCT01984697|9945070|FG000|Overall Study|Protocol Violation|8
6254309|NCT01984697|9945071|FG001|Overall Study|Protocol Violation|5
6254310|NCT01984697|9945072|FG002|Overall Study|Protocol Violation|3
6254311|NCT01984697|9945073|FG003|Overall Study|Protocol Violation|2
6254312|NCT01984697|9945074|FG004|Overall Study|Protocol Violation|0
6254313|NCT01984697|9945070|FG000|Overall Study|Withdrawal by Subject|15
6254314|NCT01984697|9945071|FG001|Overall Study|Withdrawal by Subject|21
6254315|NCT01984697|9945072|FG002|Overall Study|Withdrawal by Subject|13
6254316|NCT01984697|9945073|FG003|Overall Study|Withdrawal by Subject|11
6254317|NCT01984697|9945074|FG004|Overall Study|Withdrawal by Subject|13
6254318|NCT01984697|9945070|FG000|Overall Study|Missed last follow-up visit|1
6254319|NCT01984697|9945071|FG001|Overall Study|Missed last follow-up visit|0
6254320|NCT01984697|9945072|FG002|Overall Study|Missed last follow-up visit|0
6086330|NCT00660816|9696275|FG001|Overall Study|Protocol Violation|0
6086331|NCT00660816|9696274|FG000|Overall Study|Disease Progression|16
6086332|NCT00660816|9696275|FG001|Overall Study|Disease Progression|12
6086333|NCT00660816|9696274|FG000|Overall Study|Complicating Disease|0
6086334|NCT00660816|9696275|FG001|Overall Study|Complicating Disease|1
6086335|NCT00660829|9696283|FG000|Overall Study|Adverse Event|3
6086336|NCT00660829|9696284|FG001|Overall Study|Adverse Event|4
6086337|NCT00660829|9696283|FG000|Overall Study|Lack of Efficacy|2
6086338|NCT00660829|9696284|FG001|Overall Study|Lack of Efficacy|3
6086339|NCT00660829|9696283|FG000|Overall Study|Non-Compliance|0
6086340|NCT00660829|9696284|FG001|Overall Study|Non-Compliance|4
6086341|NCT00660829|9696283|FG000|Overall Study|Withdrawal by Subject|1
6086342|NCT00660829|9696284|FG001|Overall Study|Withdrawal by Subject|2
6086343|NCT00660829|9696283|FG000|Overall Study|Lost to Follow-up|3
6086344|NCT00660829|9696284|FG001|Overall Study|Lost to Follow-up|2
6086345|NCT00660829|9696283|FG000|Overall Study|Other|9
6086346|NCT00660829|9696284|FG001|Overall Study|Other|4
6086347|NCT00660907|9696292|FG000|Overall Study|Incorrect Enrollment|1
6086348|NCT00660907|9696293|FG001|Overall Study|Incorrect Enrollment|1
6086349|NCT00660907|9696292|FG000|Overall Study|Adverse Event|33
6086350|NCT00660907|9696293|FG001|Overall Study|Adverse Event|19
6086351|NCT00660907|9696292|FG000|Overall Study|Subject No Longer Meets Study Criteria|6
6086352|NCT00660907|9696293|FG001|Overall Study|Subject No Longer Meets Study Criteria|27
6086353|NCT00660907|9696292|FG000|Overall Study|Withdrawal by Subject|23
6086354|NCT00660907|9696293|FG001|Overall Study|Withdrawal by Subject|32
6086355|NCT00660907|9696292|FG000|Overall Study|Lost to Follow-up|3
6086356|NCT00660907|9696293|FG001|Overall Study|Lost to Follow-up|3
6254321|NCT01984697|9945073|FG003|Overall Study|Missed last follow-up visit|0
6254322|NCT01984697|9945074|FG004|Overall Study|Missed last follow-up visit|0
6086357|NCT00660907|9696292|FG000|Overall Study|Poor/Non-Compliance|5
6086358|NCT00660907|9696293|FG001|Overall Study|Poor/Non-Compliance|1
6086359|NCT00660907|9696292|FG000|Overall Study|Safety|1
6086360|NCT00660907|9696293|FG001|Overall Study|Safety|0
6086361|NCT00660907|9696292|FG000|Overall Study|Death|1
6254323|NCT01984697|9945070|FG000|Overall Study|Death|0
6254324|NCT01984697|9945071|FG001|Overall Study|Death|0
6254325|NCT01984697|9945072|FG002|Overall Study|Death|0
6254326|NCT01984697|9945073|FG003|Overall Study|Death|1
6189759|NCT01403051|9845328|FG000|Overall Study|Lost to Follow-up|5
6189760|NCT01403051|9845329|FG001|Overall Study|Lost to Follow-up|5
6189761|NCT01403064|9845340|FG000|Overall Study|Death|0
6189762|NCT01403064|9845341|FG001|Overall Study|Death|0
6189763|NCT01403064|9845342|FG002|Overall Study|Death|1
6189764|NCT01403064|9845343|FG003|Overall Study|Death|1
6189765|NCT01403064|9845340|FG000|Overall Study|Withdrawal by Subject|0
6189766|NCT01403064|9845341|FG001|Overall Study|Withdrawal by Subject|0
6189767|NCT01403064|9845342|FG002|Overall Study|Withdrawal by Subject|1
6189768|NCT01403064|9845343|FG003|Overall Study|Withdrawal by Subject|1
6189769|NCT01403064|9845340|FG000|Overall Study|Other|1
6189770|NCT01403064|9845341|FG001|Overall Study|Other|0
6086362|NCT00660907|9696293|FG001|Overall Study|Death|3
6086363|NCT00660907|9696292|FG000|Overall Study|Various|11
6086364|NCT00660907|9696293|FG001|Overall Study|Various|8
6086365|NCT00661089|9696321|FG000|Overall Study|1 subject withdrawal|0
6086366|NCT00661089|9696322|FG001|Overall Study|1 subject withdrawal|1
6086367|NCT00661089|9696321|FG000|Overall Study|death at 8 weeks due to new stroke|0
6086368|NCT00661089|9696322|FG001|Overall Study|death at 8 weeks due to new stroke|1
6086369|NCT00661193|9696358|FG000|Overall Study|Adverse Event|2
6086370|NCT00661193|9696359|FG001|Overall Study|Adverse Event|1
6086371|NCT00661193|9696358|FG000|Overall Study|Withdrawal by Subject|3
6086372|NCT00661193|9696359|FG001|Overall Study|Withdrawal by Subject|1
6086373|NCT00661193|9696358|FG000|Overall Study|Progression|27
6086374|NCT00661193|9696359|FG001|Overall Study|Progression|24
6086375|NCT00661193|9696358|FG000|Overall Study|Not protocol specified|1
6086376|NCT00661193|9696359|FG001|Overall Study|Not protocol specified|0
6086377|NCT00661258|9696367|FG000|Overall Study|Death|1
6086378|NCT00661258|9696368|FG001|Overall Study|Death|0
6086379|NCT00661258|9696367|FG000|Overall Study|caught by police and in detox center|2
6086380|NCT00661258|9696368|FG001|Overall Study|caught by police and in detox center|1
6086381|NCT00661271|9696376|FG000|Overall Study|Lost to Follow-up|28
6086382|NCT00661271|9696377|FG001|Overall Study|Lost to Follow-up|25
6086383|NCT00661362|9696385|FG000|Overall Study|Adverse Event|5
6086384|NCT00661362|9696386|FG001|Overall Study|Adverse Event|4
6086385|NCT00661362|9696385|FG000|Overall Study|Incorrect enrollment|2
6086386|NCT00661362|9696386|FG001|Overall Study|Incorrect enrollment|0
6086387|NCT00661362|9696385|FG000|Overall Study|Study specific discontinuation criteria|4
6086388|NCT00661362|9696386|FG001|Overall Study|Study specific discontinuation criteria|11
6086389|NCT00661362|9696385|FG000|Overall Study|Withdrawal by Subject|13
6086390|NCT00661362|9696386|FG001|Overall Study|Withdrawal by Subject|23
6086391|NCT00661362|9696385|FG000|Overall Study|Lost to Follow-up|3
6086392|NCT00661362|9696386|FG001|Overall Study|Lost to Follow-up|1
6086393|NCT00661362|9696385|FG000|Overall Study|Severe non-compliance to protocol|0
6086394|NCT00661362|9696386|FG001|Overall Study|Severe non-compliance to protocol|1
6086395|NCT00661362|9696385|FG000|Overall Study|Safety reasons|1
6086396|NCT00661362|9696386|FG001|Overall Study|Safety reasons|0
6086397|NCT00661362|9696385|FG000|Overall Study|Metformin dose haven't decreasd to 2.5 g|1
6086398|NCT00661362|9696386|FG001|Overall Study|Metformin dose haven't decreasd to 2.5 g|0
6086399|NCT00661388|9696392|FG000|Overall Study|Adverse Event|14
6086400|NCT00661388|9696392|FG000|Overall Study|Protocol Violation|7
6086401|NCT00661388|9696392|FG000|Overall Study|Renal transplantation|1
6086402|NCT00661388|9696392|FG000|Overall Study|Dialysis initiation|1
6086403|NCT00661388|9696392|FG000|Overall Study|Administrative reasons|1
6086404|NCT00661427|9696398|FG000|Overall Study|Adverse Event|5
6086405|NCT00661427|9696399|FG001|Overall Study|Adverse Event|5
6086406|NCT00661427|9696398|FG000|Overall Study|Patient not treated|0
6086407|NCT00661427|9696399|FG001|Overall Study|Patient not treated|2
6086408|NCT00661492|9696427|FG000|Overall Study|Adverse Event|16
6086409|NCT00661492|9696428|FG001|Overall Study|Adverse Event|13
6086410|NCT00661492|9696427|FG000|Overall Study|Disease Progression|44
6086411|NCT00661492|9696428|FG001|Overall Study|Disease Progression|14
6086412|NCT00661492|9696427|FG000|Overall Study|Patient Request|6
6086413|NCT00661492|9696428|FG001|Overall Study|Patient Request|1
6086414|NCT00661492|9696427|FG000|Overall Study|Investigator Request|1
6086415|NCT00661492|9696428|FG001|Overall Study|Investigator Request|0
6086416|NCT00661492|9696427|FG000|Overall Study|Lost to Follow-up|0
6086417|NCT00661492|9696428|FG001|Overall Study|Lost to Follow-up|1
6086418|NCT00661492|9696427|FG000|Overall Study|Other|1
6086419|NCT00661492|9696428|FG001|Overall Study|Other|0
6086420|NCT00661505|9696434|FG000|Overall Study|Adverse Event|3
6086421|NCT00661505|9696434|FG000|Overall Study|Protocol Violation|14
6086422|NCT00661505|9696434|FG000|Overall Study|Withdrawal by Subject|8
6086423|NCT00661505|9696434|FG000|Overall Study|Lost to Follow-up|3
6086424|NCT00661505|9696434|FG000|Overall Study|Other|2
6086425|NCT00661531|9696439|FG000|Overall Study|Withdrawal by Subject|3
6189771|NCT01403064|9845342|FG002|Overall Study|Other|2
6189772|NCT01403064|9845343|FG003|Overall Study|Other|1
6189773|NCT01403116|9845364|FG000|Overall Study|Adverse Event|7
6086426|NCT00661609|9696473|FG000|Overall Study|Adverse Event|4
6086427|NCT00661609|9696473|FG000|Overall Study|Death|20
6086428|NCT00661609|9696473|FG000|Overall Study|Withdrawal by Subject|2
6086429|NCT00661609|9696473|FG000|Overall Study|PI Decision|1
6086430|NCT00661609|9696473|FG000|Overall Study|Survival follow up stage discontinued|11
6086431|NCT00661609|9696473|FG000|Overall Study|Disease progression|3
6086432|NCT00661622|9696479|FG000|Overall Study|Protocol Violation|1
6086433|NCT00661622|9696480|FG001|Overall Study|Protocol Violation|0
6086434|NCT00661661|9696489|FG000|Overall Study|Adverse Event|99
6086435|NCT00661661|9696490|FG001|Overall Study|Adverse Event|24
6086436|NCT00661661|9696489|FG000|Overall Study|Lack of Efficacy|3
6086437|NCT00661661|9696490|FG001|Overall Study|Lack of Efficacy|2
6086438|NCT00661661|9696489|FG000|Overall Study|Lost to Follow-up|0
6086439|NCT00661661|9696490|FG001|Overall Study|Lost to Follow-up|1
6086440|NCT00661661|9696489|FG000|Overall Study|Withdrawal by Subject|15
6086441|NCT00661661|9696490|FG001|Overall Study|Withdrawal by Subject|5
6086442|NCT00661661|9696489|FG000|Overall Study|Other|22
6086443|NCT00661661|9696490|FG001|Overall Study|Other|7
6086444|NCT00661661|9696489|FG000|Overall Study|Not assigned treatment|1
6086445|NCT00661661|9696490|FG001|Overall Study|Not assigned treatment|0
6086446|NCT00661687|9696511|FG000|Overall Study|Study related symptoms and complaints|5
6086447|NCT00661687|9696511|FG000|Overall Study|Positive slit lamp findings|4
6086448|NCT00661687|9696511|FG000|Overall Study|Inability to maintain wearing schedule|3
6086449|NCT00661687|9696511|FG000|Overall Study|Physician Decision|1
6086450|NCT00661687|9696511|FG000|Overall Study|Adverse Event|2
6086451|NCT00661713|9696525|FG000|Overall Study|Death|1
6086452|NCT00661713|9696526|FG001|Overall Study|Death|0
6086453|NCT00661713|9696527|FG002|Overall Study|Death|0
6086454|NCT00661713|9696528|FG003|Overall Study|Death|0
6086455|NCT00661713|9696529|FG004|Overall Study|Death|1
6086456|NCT00661713|9696530|FG005|Overall Study|Death|0
6086457|NCT00661713|9696531|FG006|Overall Study|Death|0
6086458|NCT00661713|9696532|FG007|Overall Study|Death|0
6086459|NCT00661713|9696525|FG000|Overall Study|Unable to Classify|1
6086460|NCT00661713|9696526|FG001|Overall Study|Unable to Classify|0
6086461|NCT00661713|9696527|FG002|Overall Study|Unable to Classify|0
6086462|NCT00661713|9696528|FG003|Overall Study|Unable to Classify|0
6086463|NCT00661713|9696529|FG004|Overall Study|Unable to Classify|0
6086464|NCT00661713|9696530|FG005|Overall Study|Unable to Classify|0
6086465|NCT00661713|9696531|FG006|Overall Study|Unable to Classify|0
6086466|NCT00661713|9696532|FG007|Overall Study|Unable to Classify|0
6086467|NCT00661713|9696525|FG000|Overall Study|Protocol Violation|1
6086468|NCT00661713|9696526|FG001|Overall Study|Protocol Violation|6
6086469|NCT00661713|9696527|FG002|Overall Study|Protocol Violation|3
6086470|NCT00661713|9696528|FG003|Overall Study|Protocol Violation|3
6086471|NCT00661713|9696529|FG004|Overall Study|Protocol Violation|0
6086472|NCT00661713|9696530|FG005|Overall Study|Protocol Violation|2
6086473|NCT00661713|9696531|FG006|Overall Study|Protocol Violation|2
6086474|NCT00661713|9696532|FG007|Overall Study|Protocol Violation|1
6086475|NCT00661713|9696525|FG000|Overall Study|Withdrawal by Subject|11
6086476|NCT00661713|9696526|FG001|Overall Study|Withdrawal by Subject|25
6086477|NCT00661713|9696527|FG002|Overall Study|Withdrawal by Subject|12
6086478|NCT00661713|9696528|FG003|Overall Study|Withdrawal by Subject|21
6086479|NCT00661713|9696529|FG004|Overall Study|Withdrawal by Subject|12
6086480|NCT00661713|9696530|FG005|Overall Study|Withdrawal by Subject|26
6086481|NCT00661713|9696531|FG006|Overall Study|Withdrawal by Subject|45
6086482|NCT00661713|9696532|FG007|Overall Study|Withdrawal by Subject|9
6086483|NCT00661713|9696525|FG000|Overall Study|Lost to Follow-up|2
6086484|NCT00661713|9696526|FG001|Overall Study|Lost to Follow-up|7
6086485|NCT00661713|9696527|FG002|Overall Study|Lost to Follow-up|2
6086486|NCT00661713|9696528|FG003|Overall Study|Lost to Follow-up|2
6086487|NCT00661713|9696529|FG004|Overall Study|Lost to Follow-up|5
6086488|NCT00661713|9696530|FG005|Overall Study|Lost to Follow-up|7
6086489|NCT00661713|9696531|FG006|Overall Study|Lost to Follow-up|14
6086490|NCT00661713|9696532|FG007|Overall Study|Lost to Follow-up|1
6086491|NCT00661713|9696525|FG000|Overall Study|Administrative Reason|0
6086492|NCT00661713|9696526|FG001|Overall Study|Administrative Reason|1
6086493|NCT00661713|9696527|FG002|Overall Study|Administrative Reason|0
6086494|NCT00661713|9696528|FG003|Overall Study|Administrative Reason|2
6086495|NCT00661713|9696529|FG004|Overall Study|Administrative Reason|2
6086496|NCT00661713|9696530|FG005|Overall Study|Administrative Reason|2
6086497|NCT00661713|9696531|FG006|Overall Study|Administrative Reason|1
6086498|NCT00661713|9696532|FG007|Overall Study|Administrative Reason|0
6086499|NCT00661713|9696525|FG000|Overall Study|Adverse Event|0
6086500|NCT00661713|9696526|FG001|Overall Study|Adverse Event|0
6086501|NCT00661713|9696527|FG002|Overall Study|Adverse Event|0
6086502|NCT00661713|9696528|FG003|Overall Study|Adverse Event|0
6086503|NCT00661713|9696529|FG004|Overall Study|Adverse Event|0
6086504|NCT00661713|9696530|FG005|Overall Study|Adverse Event|0
6086505|NCT00661713|9696531|FG006|Overall Study|Adverse Event|1
6086506|NCT00661713|9696532|FG007|Overall Study|Adverse Event|0
6086507|NCT00661713|9696525|FG000|Overall Study|Inappropriate Enrollment|0
6086508|NCT00661713|9696526|FG001|Overall Study|Inappropriate Enrollment|0
6086509|NCT00661713|9696527|FG002|Overall Study|Inappropriate Enrollment|0
6086510|NCT00661713|9696528|FG003|Overall Study|Inappropriate Enrollment|0
6086511|NCT00661713|9696529|FG004|Overall Study|Inappropriate Enrollment|0
6086512|NCT00661713|9696530|FG005|Overall Study|Inappropriate Enrollment|0
6086513|NCT00661713|9696531|FG006|Overall Study|Inappropriate Enrollment|1
6086514|NCT00661713|9696532|FG007|Overall Study|Inappropriate Enrollment|0
6086515|NCT00661726|9696552|FG000|Overall Study|Adverse Event|1
6086516|NCT00661778|9696556|FG000|Overall Study|Disease Progression|23
6086517|NCT00661778|9696556|FG000|Overall Study|Adverse Event|18
6086518|NCT00661778|9696556|FG000|Overall Study|Reason not Specified|6
6086519|NCT00661778|9696556|FG000|Overall Study|Protocol Violation|2
6086520|NCT00661778|9696556|FG000|Overall Study|Withdrawal of Consent|1
6086521|NCT00661830|9696562|FG000|Overall Study|Death|37
6086522|NCT00661830|9696563|FG001|Overall Study|Death|33
6086523|NCT00661830|9696562|FG000|Overall Study|Lost to Follow-up|1
6086524|NCT00661830|9696563|FG001|Overall Study|Lost to Follow-up|3
6086525|NCT00661830|9696562|FG000|Overall Study|Withdrawal by Subject|1
6189774|NCT01403116|9845365|FG001|Overall Study|Adverse Event|4
6254327|NCT01984697|9945074|FG004|Overall Study|Death|0
6254328|NCT01984697|9945070|FG000|Overall Study|Pregnancy|2
6254329|NCT01984697|9945071|FG001|Overall Study|Pregnancy|0
6254330|NCT01984697|9945072|FG002|Overall Study|Pregnancy|1
6254331|NCT01984697|9945073|FG003|Overall Study|Pregnancy|0
6254332|NCT01984697|9945074|FG004|Overall Study|Pregnancy|1
6254333|NCT01984892|9945086|FG000|Overall Study|Progressive disease|7
6254334|NCT01985126|9945092|FG000|Overall Study|Death|15
6254335|NCT01985126|9945093|FG001|Overall Study|Death|69
6254336|NCT01985126|9945092|FG000|Overall Study|Lost to Follow-up|0
6254337|NCT01985126|9945093|FG001|Overall Study|Lost to Follow-up|8
6086526|NCT00661830|9696563|FG001|Overall Study|Withdrawal by Subject|1
6086527|NCT00661830|9696562|FG000|Overall Study|Other reason|1
6086528|NCT00661830|9696563|FG001|Overall Study|Other reason|5
6189775|NCT01403116|9845364|FG000|Overall Study|Lost to Follow-up|7
6189776|NCT01403116|9845365|FG001|Overall Study|Lost to Follow-up|5
6189777|NCT01403116|9845364|FG000|Overall Study|Withdrawal by Subject|12
6189778|NCT01403116|9845365|FG001|Overall Study|Withdrawal by Subject|15
6189779|NCT01403116|9845364|FG000|Overall Study|Non-compliance of study drug|3
6189780|NCT01403116|9845365|FG001|Overall Study|Non-compliance of study drug|0
6189781|NCT01403116|9845364|FG000|Overall Study|Protocol Violation|0
6189782|NCT01403116|9845365|FG001|Overall Study|Protocol Violation|1
6189783|NCT01403116|9845364|FG000|Overall Study|undisclosed Hx of Prostate Ca|1
6189784|NCT01403116|9845365|FG001|Overall Study|undisclosed Hx of Prostate Ca|0
6189785|NCT01403116|9845364|FG000|Overall Study|Hct >54%|2
6189786|NCT01403116|9845365|FG001|Overall Study|Hct >54%|0
6189787|NCT01403116|9845364|FG000|Overall Study|unable to keep appointments|0
6189788|NCT01403116|9845365|FG001|Overall Study|unable to keep appointments|2
6189789|NCT01403610|9845405|FG000|Overall Study|Withdrawal by Subject|2
6189790|NCT01403610|9845406|FG001|Overall Study|Withdrawal by Subject|0
6189791|NCT01403610|9845407|FG002|Overall Study|Withdrawal by Subject|0
6189792|NCT01403610|9845408|FG003|Overall Study|Withdrawal by Subject|0
6189793|NCT01403610|9845405|FG000|Overall Study|Didn't recover from surgery sufficiently|0
6189794|NCT01403610|9845406|FG001|Overall Study|Didn't recover from surgery sufficiently|3
6189795|NCT01403610|9845407|FG002|Overall Study|Didn't recover from surgery sufficiently|0
6189796|NCT01403610|9845408|FG003|Overall Study|Didn't recover from surgery sufficiently|0
6189797|NCT01403805|9845420|FG000|Overall Study|Withdrawal by Subject|0
6189798|NCT01403805|9845421|FG001|Overall Study|Withdrawal by Subject|4
6254338|NCT01985126|9945092|FG000|Overall Study|Study Terminated By Sponsor|1
6189799|NCT01403805|9845420|FG000|Overall Study|Lost to Follow-up|0
6189800|NCT01403805|9845421|FG001|Overall Study|Lost to Follow-up|2
6189801|NCT01403805|9845420|FG000|Overall Study|Death|0
6254339|NCT01985126|9945093|FG001|Overall Study|Study Terminated By Sponsor|22
6254340|NCT01985126|9945092|FG000|Overall Study|Withdrawal by Subject|2
6254341|NCT01985126|9945093|FG001|Overall Study|Withdrawal by Subject|7
6254342|NCT01985321|9945101|FG000|Overall Study|Protocol Violation|4
6254343|NCT01985321|9945102|FG001|Overall Study|Protocol Violation|3
6254344|NCT01985321|9945101|FG000|Overall Study|Withdrawal by Subject|1
6254345|NCT01985321|9945102|FG001|Overall Study|Withdrawal by Subject|0
6254346|NCT01985321|9945101|FG000|Overall Study|Lost to Follow-up|5
6254347|NCT01985321|9945102|FG001|Overall Study|Lost to Follow-up|2
6254348|NCT01985321|9945101|FG000|Overall Study|Subject treated wrong type of sore|1
6254349|NCT01985321|9945102|FG001|Overall Study|Subject treated wrong type of sore|0
6254350|NCT01985334|9945116|FG000|Overall Study|Administrative problems|1
6254351|NCT01985334|9945117|FG001|Overall Study|Administrative problems|1
6254352|NCT01985334|9945118|FG002|Overall Study|Administrative problems|0
6254353|NCT01985334|9945119|FG003|Overall Study|Administrative problems|2
6254354|NCT01985334|9945120|FG004|Overall Study|Administrative problems|0
6254355|NCT01985334|9945121|FG005|Overall Study|Administrative problems|1
6254356|NCT01985334|9945122|FG006|Overall Study|Administrative problems|1
6254357|NCT01985334|9945123|FG007|Overall Study|Administrative problems|3
6254358|NCT01985334|9945116|FG000|Overall Study|Death|1
6254359|NCT01985334|9945117|FG001|Overall Study|Death|0
6254360|NCT01985334|9945118|FG002|Overall Study|Death|0
6254361|NCT01985334|9945119|FG003|Overall Study|Death|3
6254362|NCT01985334|9945120|FG004|Overall Study|Death|0
6254363|NCT01985334|9945121|FG005|Overall Study|Death|0
6254364|NCT01985334|9945122|FG006|Overall Study|Death|1
6254365|NCT01985334|9945123|FG007|Overall Study|Death|2
6254366|NCT01985334|9945116|FG000|Overall Study|Worsening of disease|0
6254367|NCT01985334|9945117|FG001|Overall Study|Worsening of disease|0
6254368|NCT01985334|9945118|FG002|Overall Study|Worsening of disease|0
6254369|NCT01985334|9945119|FG003|Overall Study|Worsening of disease|1
6254370|NCT01985334|9945120|FG004|Overall Study|Worsening of disease|0
6254371|NCT01985334|9945121|FG005|Overall Study|Worsening of disease|3
6254372|NCT01985334|9945122|FG006|Overall Study|Worsening of disease|0
6254373|NCT01985334|9945123|FG007|Overall Study|Worsening of disease|1
6254374|NCT01985334|9945116|FG000|Overall Study|Other|2
6254375|NCT01985334|9945117|FG001|Overall Study|Other|9
6254376|NCT01985334|9945118|FG002|Overall Study|Other|7
6254377|NCT01985334|9945119|FG003|Overall Study|Other|17
6254378|NCT01985334|9945120|FG004|Overall Study|Other|4
6254379|NCT01985334|9945121|FG005|Overall Study|Other|8
6254380|NCT01985334|9945122|FG006|Overall Study|Other|4
6254381|NCT01985334|9945123|FG007|Overall Study|Other|7
6254382|NCT01985334|9945116|FG000|Overall Study|Protocol deviation|6
6254383|NCT01985334|9945117|FG001|Overall Study|Protocol deviation|31
6254384|NCT01985334|9945118|FG002|Overall Study|Protocol deviation|25
6254385|NCT01985334|9945119|FG003|Overall Study|Protocol deviation|84
6254386|NCT01985334|9945120|FG004|Overall Study|Protocol deviation|17
6254387|NCT01985334|9945121|FG005|Overall Study|Protocol deviation|47
6254388|NCT01985334|9945122|FG006|Overall Study|Protocol deviation|15
6254389|NCT01985334|9945123|FG007|Overall Study|Protocol deviation|42
6254390|NCT01985334|9945116|FG000|Overall Study|Moderate / severe COPD exacerbation|5
6254391|NCT01985334|9945117|FG001|Overall Study|Moderate / severe COPD exacerbation|14
6254392|NCT01985334|9945118|FG002|Overall Study|Moderate / severe COPD exacerbation|12
6254393|NCT01985334|9945119|FG003|Overall Study|Moderate / severe COPD exacerbation|40
6254394|NCT01985334|9945120|FG004|Overall Study|Moderate / severe COPD exacerbation|6
6254395|NCT01985334|9945121|FG005|Overall Study|Moderate / severe COPD exacerbation|40
6254396|NCT01985334|9945122|FG006|Overall Study|Moderate / severe COPD exacerbation|8
6254397|NCT01985334|9945123|FG007|Overall Study|Moderate / severe COPD exacerbation|19
6254398|NCT01985334|9945116|FG000|Overall Study|Subject withdrawal of consent|3
6254399|NCT01985334|9945117|FG001|Overall Study|Subject withdrawal of consent|6
6254400|NCT01985334|9945118|FG002|Overall Study|Subject withdrawal of consent|2
6254401|NCT01985334|9945119|FG003|Overall Study|Subject withdrawal of consent|28
6254402|NCT01985334|9945120|FG004|Overall Study|Subject withdrawal of consent|4
6254403|NCT01985334|9945121|FG005|Overall Study|Subject withdrawal of consent|19
6254404|NCT01985334|9945122|FG006|Overall Study|Subject withdrawal of consent|0
6254405|NCT01985334|9945123|FG007|Overall Study|Subject withdrawal of consent|20
6254406|NCT01985334|9945116|FG000|Overall Study|Adverse Event|0
6254407|NCT01985334|9945117|FG001|Overall Study|Adverse Event|8
6254408|NCT01985334|9945118|FG002|Overall Study|Adverse Event|2
6254409|NCT01985334|9945119|FG003|Overall Study|Adverse Event|26
6254410|NCT01985334|9945120|FG004|Overall Study|Adverse Event|3
6254411|NCT01985334|9945121|FG005|Overall Study|Adverse Event|18
6254412|NCT01985334|9945122|FG006|Overall Study|Adverse Event|3
6254413|NCT01985334|9945123|FG007|Overall Study|Adverse Event|15
6254414|NCT01985334|9945116|FG000|Overall Study|Other|4
6254415|NCT01985334|9945117|FG001|Overall Study|Other|2
6254416|NCT01985334|9945118|FG002|Overall Study|Other|3
6254417|NCT01985334|9945119|FG003|Overall Study|Other|10
6254418|NCT01985334|9945120|FG004|Overall Study|Other|1
6254419|NCT01985334|9945121|FG005|Overall Study|Other|6
6254420|NCT01985334|9945122|FG006|Overall Study|Other|2
6254421|NCT01985334|9945123|FG007|Overall Study|Other|2
6254422|NCT01985334|9945116|FG000|Overall Study|Medication non-compliance|0
6254423|NCT01985334|9945117|FG001|Overall Study|Medication non-compliance|4
6254424|NCT01985334|9945118|FG002|Overall Study|Medication non-compliance|1
6254425|NCT01985334|9945119|FG003|Overall Study|Medication non-compliance|6
6254426|NCT01985334|9945120|FG004|Overall Study|Medication non-compliance|2
6254427|NCT01985334|9945121|FG005|Overall Study|Medication non-compliance|3
6254428|NCT01985334|9945122|FG006|Overall Study|Medication non-compliance|1
6254429|NCT01985334|9945123|FG007|Overall Study|Medication non-compliance|3
6254430|NCT01985334|9945116|FG000|Overall Study|Use of prohibited treatment|1
6254431|NCT01985334|9945117|FG001|Overall Study|Use of prohibited treatment|4
6086529|NCT00661999|9696594|FG000|Overall Study|Adverse Event|11
6086530|NCT00661999|9696595|FG001|Overall Study|Adverse Event|5
6086531|NCT00661999|9696596|FG002|Overall Study|Adverse Event|8
6086532|NCT00661999|9696594|FG000|Overall Study|Death|8
6086533|NCT00661999|9696595|FG001|Overall Study|Death|6
6086534|NCT00661999|9696596|FG002|Overall Study|Death|3
6086535|NCT00661999|9696594|FG000|Overall Study|Other Reasons|5
6086536|NCT00661999|9696595|FG001|Overall Study|Other Reasons|12
6086537|NCT00661999|9696596|FG002|Overall Study|Other Reasons|23
6086538|NCT00661999|9696594|FG000|Overall Study|Withdrawal by Subject|30
6086539|NCT00661999|9696595|FG001|Overall Study|Withdrawal by Subject|23
6086540|NCT00661999|9696596|FG002|Overall Study|Withdrawal by Subject|14
6086541|NCT00661999|9696594|FG000|Overall Study|Alternative Treatment|1
6086542|NCT00661999|9696595|FG001|Overall Study|Alternative Treatment|0
6086543|NCT00661999|9696596|FG002|Overall Study|Alternative Treatment|0
6086544|NCT00661999|9696594|FG000|Overall Study|Other Medical Problems|4
6086545|NCT00661999|9696595|FG001|Overall Study|Other Medical Problems|4
6086546|NCT00661999|9696596|FG002|Overall Study|Other Medical Problems|9
6086547|NCT00662012|9696604|FG000|Overall Study|Lost to Follow-up|85
6086548|NCT00662012|9696604|FG000|Overall Study|Death|1
6086549|NCT00662012|9696604|FG000|Overall Study|Withdrawal by Subject|1
6086550|NCT00662025|9696608|FG000|Overall Study|Objective progression or relapse|51
6086551|NCT00662025|9696608|FG000|Overall Study|Adverse Event|7
6086552|NCT00662025|9696608|FG000|Overall Study|Withdrawal by Subject|1
6086553|NCT00662025|9696608|FG000|Overall Study|Results of other clinical study|2
6086554|NCT00662025|9696608|FG000|Overall Study|Target lesion cannot be evaluated|1
6086555|NCT00662025|9696608|FG000|Overall Study|Domestic circumstances|1
6086556|NCT00662038|9696612|FG000|Overall Study|Reason not specified|3
6086557|NCT00662038|9696612|FG000|Overall Study|Withdrawn consent|22
6254432|NCT01985334|9945118|FG002|Overall Study|Use of prohibited treatment|1
6254433|NCT01985334|9945119|FG003|Overall Study|Use of prohibited treatment|2
6254434|NCT01985334|9945120|FG004|Overall Study|Use of prohibited treatment|1
6254435|NCT01985334|9945121|FG005|Overall Study|Use of prohibited treatment|6
6254436|NCT01985334|9945122|FG006|Overall Study|Use of prohibited treatment|2
6254437|NCT01985334|9945123|FG007|Overall Study|Use of prohibited treatment|0
6254438|NCT01985334|9945116|FG000|Overall Study|Investigator decision|0
6254439|NCT01985334|9945117|FG001|Overall Study|Investigator decision|3
6254440|NCT01985334|9945118|FG002|Overall Study|Investigator decision|0
6254441|NCT01985334|9945119|FG003|Overall Study|Investigator decision|7
6254442|NCT01985334|9945120|FG004|Overall Study|Investigator decision|1
6254443|NCT01985334|9945121|FG005|Overall Study|Investigator decision|1
6254444|NCT01985334|9945122|FG006|Overall Study|Investigator decision|0
6254445|NCT01985334|9945123|FG007|Overall Study|Investigator decision|4
6254446|NCT01985334|9945116|FG000|Overall Study|Lost to Follow-up|0
6254447|NCT01985334|9945117|FG001|Overall Study|Lost to Follow-up|2
6254448|NCT01985334|9945118|FG002|Overall Study|Lost to Follow-up|0
6254449|NCT01985334|9945119|FG003|Overall Study|Lost to Follow-up|3
6254450|NCT01985334|9945120|FG004|Overall Study|Lost to Follow-up|1
6254451|NCT01985334|9945121|FG005|Overall Study|Lost to Follow-up|4
6254452|NCT01985334|9945122|FG006|Overall Study|Lost to Follow-up|0
6254453|NCT01985334|9945123|FG007|Overall Study|Lost to Follow-up|3
6254454|NCT01985360|9945157|FG000|Overall Study|Withdrawal by Subject|4
6254455|NCT01985360|9945158|FG001|Overall Study|Withdrawal by Subject|0
6254456|NCT01985360|9945157|FG000|Overall Study|Lost to Follow-up|5
6254457|NCT01985360|9945158|FG001|Overall Study|Lost to Follow-up|3
6254458|NCT01986010|9945246|FG000|Overall Study|Adverse Event|0
6254459|NCT01986010|9945247|FG001|Overall Study|Adverse Event|1
6254460|NCT01986010|9945248|FG002|Overall Study|Adverse Event|0
6086558|NCT00662038|9696612|FG000|Overall Study|Withdrawal by Subject|83
6086559|NCT00662038|9696612|FG000|Overall Study|Sponsor decision|1
6086560|NCT00662038|9696612|FG000|Overall Study|Physician Decision|19
6086561|NCT00662038|9696612|FG000|Overall Study|Lung transplantation|44
6086562|NCT00662038|9696612|FG000|Overall Study|Lost to Follow-up|1
6086563|NCT00662038|9696612|FG000|Overall Study|Death|95
6086564|NCT00662038|9696612|FG000|Overall Study|Adverse Event|358
6086565|NCT00662038|9696612|FG000|Overall Study|Continued treatment|5
6086566|NCT00662129|9696616|FG000|Overall Study|Protocol Violation|1
6254461|NCT01986010|9945249|FG003|Overall Study|Adverse Event|0
6254462|NCT01986010|9945250|FG004|Overall Study|Adverse Event|0
6254463|NCT01986010|9945251|FG005|Overall Study|Adverse Event|0
6254464|NCT01986010|9945252|FG006|Overall Study|Adverse Event|0
6254465|NCT01986010|9945253|FG007|Overall Study|Adverse Event|0
6254466|NCT01986010|9945254|FG008|Overall Study|Adverse Event|0
6254467|NCT01986010|9945255|FG009|Overall Study|Adverse Event|0
6086567|NCT00662129|9696616|FG000|Overall Study|Cancel prior to beginning treatment|1
6086568|NCT00662129|9696616|FG000|Overall Study|Ineligible|1
6086569|NCT00662259|9696643|FG000|Overall Study|Adverse Event|2
6254468|NCT01986010|9945256|FG010|Overall Study|Adverse Event|0
6254469|NCT01986010|9945257|FG011|Overall Study|Adverse Event|0
6254470|NCT01986010|9945258|FG012|Overall Study|Adverse Event|0
6254471|NCT01986010|9945259|FG013|Overall Study|Adverse Event|0
6254472|NCT01986010|9945260|FG014|Overall Study|Adverse Event|0
6254473|NCT01986010|9945261|FG015|Overall Study|Adverse Event|1
6254474|NCT01986010|9945262|FG016|Overall Study|Adverse Event|0
6254475|NCT01986010|9945246|FG000|Overall Study|Lost to Follow-up|2
6254476|NCT01986010|9945247|FG001|Overall Study|Lost to Follow-up|1
6254477|NCT01986010|9945248|FG002|Overall Study|Lost to Follow-up|2
6254478|NCT01986010|9945249|FG003|Overall Study|Lost to Follow-up|2
6254479|NCT01986010|9945250|FG004|Overall Study|Lost to Follow-up|2
6254480|NCT01986010|9945251|FG005|Overall Study|Lost to Follow-up|2
6254481|NCT01986010|9945252|FG006|Overall Study|Lost to Follow-up|0
6254482|NCT01986010|9945253|FG007|Overall Study|Lost to Follow-up|0
6254483|NCT01986010|9945254|FG008|Overall Study|Lost to Follow-up|4
6254484|NCT01986010|9945255|FG009|Overall Study|Lost to Follow-up|2
6254485|NCT01986010|9945256|FG010|Overall Study|Lost to Follow-up|0
6254486|NCT01986010|9945257|FG011|Overall Study|Lost to Follow-up|1
6254487|NCT01986010|9945258|FG012|Overall Study|Lost to Follow-up|1
6254488|NCT01986010|9945259|FG013|Overall Study|Lost to Follow-up|1
6254489|NCT01986010|9945260|FG014|Overall Study|Lost to Follow-up|2
6254490|NCT01986010|9945261|FG015|Overall Study|Lost to Follow-up|0
6254491|NCT01986010|9945262|FG016|Overall Study|Lost to Follow-up|0
6254492|NCT01986010|9945246|FG000|Overall Study|Physician Decision|0
6254493|NCT01986010|9945247|FG001|Overall Study|Physician Decision|0
6254494|NCT01986010|9945248|FG002|Overall Study|Physician Decision|0
6254495|NCT01986010|9945249|FG003|Overall Study|Physician Decision|0
6254496|NCT01986010|9945250|FG004|Overall Study|Physician Decision|0
6254497|NCT01986010|9945251|FG005|Overall Study|Physician Decision|0
6254498|NCT01986010|9945252|FG006|Overall Study|Physician Decision|0
6254499|NCT01986010|9945253|FG007|Overall Study|Physician Decision|0
6254500|NCT01986010|9945254|FG008|Overall Study|Physician Decision|0
6254501|NCT01986010|9945255|FG009|Overall Study|Physician Decision|0
6254502|NCT01986010|9945256|FG010|Overall Study|Physician Decision|0
6254503|NCT01986010|9945257|FG011|Overall Study|Physician Decision|0
6254504|NCT01986010|9945258|FG012|Overall Study|Physician Decision|0
6254505|NCT01986010|9945259|FG013|Overall Study|Physician Decision|0
6254506|NCT01986010|9945260|FG014|Overall Study|Physician Decision|1
6254507|NCT01986010|9945261|FG015|Overall Study|Physician Decision|0
6254508|NCT01986010|9945262|FG016|Overall Study|Physician Decision|0
6254509|NCT01986010|9945246|FG000|Overall Study|Withdrawal by Subject|2
6254510|NCT01986010|9945247|FG001|Overall Study|Withdrawal by Subject|2
6254511|NCT01986010|9945248|FG002|Overall Study|Withdrawal by Subject|3
6254512|NCT01986010|9945249|FG003|Overall Study|Withdrawal by Subject|0
6254513|NCT01986010|9945250|FG004|Overall Study|Withdrawal by Subject|2
6254514|NCT01986010|9945251|FG005|Overall Study|Withdrawal by Subject|4
6254515|NCT01986010|9945252|FG006|Overall Study|Withdrawal by Subject|0
6254516|NCT01986010|9945253|FG007|Overall Study|Withdrawal by Subject|0
6254517|NCT01986010|9945254|FG008|Overall Study|Withdrawal by Subject|0
6254518|NCT01986010|9945255|FG009|Overall Study|Withdrawal by Subject|0
6254519|NCT01986010|9945256|FG010|Overall Study|Withdrawal by Subject|0
6254520|NCT01986010|9945257|FG011|Overall Study|Withdrawal by Subject|2
6254521|NCT01986010|9945258|FG012|Overall Study|Withdrawal by Subject|0
6254522|NCT01986010|9945259|FG013|Overall Study|Withdrawal by Subject|1
6254523|NCT01986010|9945260|FG014|Overall Study|Withdrawal by Subject|2
6254524|NCT01986010|9945261|FG015|Overall Study|Withdrawal by Subject|0
6254525|NCT01986010|9945262|FG016|Overall Study|Withdrawal by Subject|0
6254526|NCT01986010|9945246|FG000|Overall Study|Status Not Recorded|2
6254527|NCT01986010|9945247|FG001|Overall Study|Status Not Recorded|4
6254528|NCT01986010|9945248|FG002|Overall Study|Status Not Recorded|2
6189802|NCT01403805|9845421|FG001|Overall Study|Death|1
6189803|NCT01403987|9845434|FG000|Overall Study|Residents forgot their secret PIN|18
6189804|NCT01403987|9845435|FG001|Overall Study|Residents forgot their secret PIN|17
6189805|NCT01403987|9845436|FG002|Overall Study|Residents forgot their secret PIN|18
6189806|NCT01404208|9845500|FG000|Overall Study|Discontinued|3
6189807|NCT01404208|9845501|FG001|Overall Study|Discontinued|0
6189808|NCT01404234|9845507|FG000|Overall Study|Withdrawal by Subject|2
6189809|NCT01404325|9845522|FG000|Overall Study|Lost to Follow-up|1
6189810|NCT01404325|9845523|FG001|Overall Study|Lost to Follow-up|0
6189811|NCT01404325|9845522|FG000|Overall Study|Death|2
6189812|NCT01404325|9845523|FG001|Overall Study|Death|0
6189813|NCT01404325|9845522|FG000|Overall Study|Graft loss/Retransplantation|1
6254529|NCT01986010|9945249|FG003|Overall Study|Status Not Recorded|0
6254530|NCT01986010|9945250|FG004|Overall Study|Status Not Recorded|1
6254531|NCT01986010|9945251|FG005|Overall Study|Status Not Recorded|2
6254532|NCT01986010|9945252|FG006|Overall Study|Status Not Recorded|0
6254533|NCT01986010|9945253|FG007|Overall Study|Status Not Recorded|0
6254534|NCT01986010|9945254|FG008|Overall Study|Status Not Recorded|2
6254535|NCT01986010|9945255|FG009|Overall Study|Status Not Recorded|1
6254536|NCT01986010|9945256|FG010|Overall Study|Status Not Recorded|7
6254537|NCT01986010|9945257|FG011|Overall Study|Status Not Recorded|7
6254538|NCT01986010|9945258|FG012|Overall Study|Status Not Recorded|9
6254539|NCT01986010|9945259|FG013|Overall Study|Status Not Recorded|9
6254540|NCT01986010|9945260|FG014|Overall Study|Status Not Recorded|5
6254541|NCT01986010|9945261|FG015|Overall Study|Status Not Recorded|10
6254542|NCT01986010|9945262|FG016|Overall Study|Status Not Recorded|4
6254543|NCT01986062|9945310|FG000|Overall Study|Lost to Follow-up|1
6254544|NCT01986062|9945311|FG001|Overall Study|Lost to Follow-up|0
6254545|NCT01986062|9945310|FG000|Overall Study|Withdrawal by Subject|0
6254546|NCT01986062|9945311|FG001|Overall Study|Withdrawal by Subject|1
6254547|NCT01986140|9945319|FG000|Overall Study|Withdrawal by Subject|31
6254548|NCT01986140|9945320|FG001|Overall Study|Withdrawal by Subject|25
6254549|NCT01986140|9945319|FG000|Overall Study|alternative treatment|1
6254550|NCT01986140|9945320|FG001|Overall Study|alternative treatment|1
6254551|NCT01986140|9945319|FG000|Overall Study|found not eligible|3
6254552|NCT01986140|9945320|FG001|Overall Study|found not eligible|0
6254553|NCT01986140|9945319|FG000|Overall Study|Adverse Event|0
6254554|NCT01986140|9945320|FG001|Overall Study|Adverse Event|1
6254555|NCT01986140|9945319|FG000|Overall Study|progression disease|0
6254556|NCT01986140|9945320|FG001|Overall Study|progression disease|1
6254557|NCT01986231|9945326|FG000|Overall Study|Adverse Event|1
6254558|NCT01986348|9945334|FG000|Overall Study|Death|8
6254559|NCT01986348|9945335|FG001|Overall Study|Death|22
6254560|NCT01986348|9945336|FG002|Overall Study|Death|10
6254561|NCT01986348|9945337|FG003|Overall Study|Death|21
6254562|NCT01986348|9945334|FG000|Overall Study|Lost to Follow-up|0
6254563|NCT01986348|9945335|FG001|Overall Study|Lost to Follow-up|0
6254564|NCT01986348|9945336|FG002|Overall Study|Lost to Follow-up|0
6254565|NCT01986348|9945337|FG003|Overall Study|Lost to Follow-up|2
6254566|NCT01986348|9945334|FG000|Overall Study|Physician Decision|0
6254567|NCT01986348|9945335|FG001|Overall Study|Physician Decision|0
6254568|NCT01986348|9945336|FG002|Overall Study|Physician Decision|0
6254569|NCT01986348|9945337|FG003|Overall Study|Physician Decision|1
6254570|NCT01986348|9945334|FG000|Overall Study|Progressive Disease|0
6254571|NCT01986348|9945335|FG001|Overall Study|Progressive Disease|0
6254572|NCT01986348|9945336|FG002|Overall Study|Progressive Disease|2
6254573|NCT01986348|9945337|FG003|Overall Study|Progressive Disease|0
6254574|NCT01986348|9945334|FG000|Overall Study|Withdrawal by Participant|0
6254575|NCT01986348|9945335|FG001|Overall Study|Withdrawal by Participant|1
6254576|NCT01986348|9945336|FG002|Overall Study|Withdrawal by Participant|2
6254577|NCT01986348|9945337|FG003|Overall Study|Withdrawal by Participant|1
6254578|NCT01986348|9945334|FG000|Overall Study|Study Terminated by Sponsor|0
6254579|NCT01986348|9945335|FG001|Overall Study|Study Terminated by Sponsor|0
6254580|NCT01986348|9945336|FG002|Overall Study|Study Terminated by Sponsor|0
6254581|NCT01986348|9945337|FG003|Overall Study|Study Terminated by Sponsor|3
6254582|NCT01986348|9945334|FG000|Overall Study|Other-unspecified|0
6254583|NCT01986348|9945335|FG001|Overall Study|Other-unspecified|1
6254584|NCT01986348|9945336|FG002|Overall Study|Other-unspecified|0
6254585|NCT01986348|9945337|FG003|Overall Study|Other-unspecified|2
6254586|NCT01986647|9945363|FG000|Overall Study|Lost to Follow-up|4
6254587|NCT01986647|9945364|FG001|Overall Study|Lost to Follow-up|1
6254588|NCT01986647|9945365|FG002|Overall Study|Lost to Follow-up|4
6254589|NCT01986647|9945366|FG003|Overall Study|Lost to Follow-up|4
6254590|NCT01986647|9945363|FG000|Overall Study|Withdrawal by Subject|1
6254591|NCT01986647|9945364|FG001|Overall Study|Withdrawal by Subject|3
6254592|NCT01986647|9945365|FG002|Overall Study|Withdrawal by Subject|2
6254593|NCT01986647|9945366|FG003|Overall Study|Withdrawal by Subject|3
6254594|NCT01986647|9945363|FG000|Overall Study|Health|5
6254595|NCT01986647|9945364|FG001|Overall Study|Health|3
6254596|NCT01986647|9945365|FG002|Overall Study|Health|6
6189814|NCT01404325|9845523|FG001|Overall Study|Graft loss/Retransplantation|0
6189815|NCT01404325|9845522|FG000|Overall Study|non-specified reason|0
6189816|NCT01404325|9845523|FG001|Overall Study|non-specified reason|2
6193283|NCT01436643|9850888|FG001|Core Phase (16 Weeks)|Protocol Violation|1
6193284|NCT01436643|9850889|FG002|Core Phase (16 Weeks)|Protocol Violation|1
6193285|NCT01436643|9850890|FG003|Core Phase (16 Weeks)|Protocol Violation|0
6193286|NCT01437267|9850931|FG000|Overall Study|Withdrawal by Subject|0
6193287|NCT01437267|9850932|FG001|Overall Study|Withdrawal by Subject|0
6193288|NCT01437267|9850933|FG002|Overall Study|Withdrawal by Subject|0
6193289|NCT01437267|9850934|FG003|Overall Study|Withdrawal by Subject|1
6193290|NCT01437267|9850935|FG004|Overall Study|Withdrawal by Subject|0
6193291|NCT01437267|9850936|FG005|Overall Study|Withdrawal by Subject|0
6193292|NCT01437267|9850931|FG000|Overall Study|Protocol Violation|0
6193293|NCT01437267|9850932|FG001|Overall Study|Protocol Violation|1
6193294|NCT01437267|9850933|FG002|Overall Study|Protocol Violation|0
6193295|NCT01437267|9850934|FG003|Overall Study|Protocol Violation|0
6193296|NCT01437267|9850935|FG004|Overall Study|Protocol Violation|0
6193297|NCT01437267|9850936|FG005|Overall Study|Protocol Violation|0
6193298|NCT01437319|9850950|FG000|Phase I|Lost to Follow-up|2
6193299|NCT01437319|9850951|FG001|Phase I|Lost to Follow-up|0
6193300|NCT01437319|9850952|FG002|Phase I|Lost to Follow-up|0
6193301|NCT01437319|9850950|FG000|Phase I|Protocol Violation|1
6193302|NCT01437319|9850951|FG001|Phase I|Protocol Violation|0
6193303|NCT01437319|9850952|FG002|Phase I|Protocol Violation|0
6193304|NCT01437319|9850950|FG000|Phase I|Study related symptoms/complaints|27
6254597|NCT01986647|9945366|FG003|Overall Study|Health|4
6254598|NCT01986829|9945402|FG000|Overall Study|Death|1
6254599|NCT01986855|9945412|FG000|Overall Study|Adverse Event|1
6254600|NCT01986855|9945413|FG001|Overall Study|Adverse Event|0
6254601|NCT01986855|9945414|FG002|Overall Study|Adverse Event|0
6254602|NCT01986855|9945412|FG000|Overall Study|Death|3
6254603|NCT01986855|9945413|FG001|Overall Study|Death|4
6254604|NCT01986855|9945414|FG002|Overall Study|Death|4
6254605|NCT01986855|9945412|FG000|Overall Study|Lost to Follow-up|2
6254606|NCT01986855|9945413|FG001|Overall Study|Lost to Follow-up|1
6254607|NCT01986855|9945414|FG002|Overall Study|Lost to Follow-up|0
6254608|NCT01986855|9945412|FG000|Overall Study|Screen Failure|0
6254609|NCT01986855|9945413|FG001|Overall Study|Screen Failure|1
6254610|NCT01986855|9945414|FG002|Overall Study|Screen Failure|0
6254611|NCT01986855|9945412|FG000|Overall Study|Participant Moved|0
6254612|NCT01986855|9945413|FG001|Overall Study|Participant Moved|0
6254613|NCT01986855|9945414|FG002|Overall Study|Participant Moved|2
6254614|NCT01986855|9945412|FG000|Overall Study|Withdrawal by Subject|7
6254615|NCT01986855|9945413|FG001|Overall Study|Withdrawal by Subject|8
6254616|NCT01986855|9945414|FG002|Overall Study|Withdrawal by Subject|5
6254617|NCT01986881|9945425|FG000|Overall Study|Death|228
6254618|NCT01986881|9945426|FG001|Overall Study|Death|233
6254619|NCT01986881|9945427|FG002|Overall Study|Death|247
6254620|NCT01986881|9945425|FG000|Overall Study|Lost to Follow-up|51
6254621|NCT01986881|9945426|FG001|Overall Study|Lost to Follow-up|44
6254622|NCT01986881|9945427|FG002|Overall Study|Lost to Follow-up|55
6254623|NCT01986881|9945425|FG000|Overall Study|Physician Decision|7
6254624|NCT01986881|9945426|FG001|Overall Study|Physician Decision|4
6254625|NCT01986881|9945427|FG002|Overall Study|Physician Decision|6
6254626|NCT01986881|9945425|FG000|Overall Study|Study Site Terminated by Sponsor|2
6254627|NCT01986881|9945426|FG001|Overall Study|Study Site Terminated by Sponsor|2
6254628|NCT01986881|9945427|FG002|Overall Study|Study Site Terminated by Sponsor|3
6254629|NCT01986881|9945425|FG000|Overall Study|Withdrawal by Subject|41
6254630|NCT01986881|9945426|FG001|Overall Study|Withdrawal by Subject|60
6254631|NCT01986881|9945427|FG002|Overall Study|Withdrawal by Subject|45
6254632|NCT01986881|9945425|FG000|Overall Study|Subject Moved|0
6254633|NCT01986881|9945426|FG001|Overall Study|Subject Moved|1
6254634|NCT01986881|9945427|FG002|Overall Study|Subject Moved|0
6254635|NCT01986881|9945425|FG000|Overall Study|Other|1
6254636|NCT01986881|9945426|FG001|Overall Study|Other|2
6254637|NCT01986881|9945427|FG002|Overall Study|Other|2
6254638|NCT01986907|9945458|FG000|Overall Study|Adverse Event|11
6254639|NCT01986907|9945458|FG000|Overall Study|Unsatisfactory therapeutic effect|24
6254640|NCT01986907|9945458|FG000|Overall Study|Protocol Violation|4
6254641|NCT01986907|9945458|FG000|Overall Study|Withdrawal by Subject|76
6254642|NCT01986907|9945458|FG000|Overall Study|Lost to Follow-up|38
6254643|NCT01986907|9945458|FG000|Overall Study|Death|9
6254644|NCT01986920|9945465|FG000|A- 101 25%|Withdrawal by Subject|1
6254645|NCT01986920|9945466|FG001|A- 101 25%|Withdrawal by Subject|0
6254646|NCT01986920|9945467|FG002|A- 101 25%|Withdrawal by Subject|0
6254647|NCT01986920|9945468|FG003|A- 101 25%|Withdrawal by Subject|0
6254648|NCT01986920|9945465|FG000|A-101 32.5%|Withdrawal by Subject|0
6254649|NCT01986920|9945466|FG001|A-101 32.5%|Withdrawal by Subject|1
6254650|NCT01986920|9945467|FG002|A-101 32.5%|Withdrawal by Subject|0
6254651|NCT01986920|9945468|FG003|A-101 32.5%|Withdrawal by Subject|0
6254652|NCT01986920|9945465|FG000|A-101 40%|Withdrawal by Subject|0
6254653|NCT01986920|9945466|FG001|A-101 40%|Withdrawal by Subject|0
6254654|NCT01986920|9945467|FG002|A-101 40%|Withdrawal by Subject|1
6254655|NCT01986920|9945468|FG003|A-101 40%|Withdrawal by Subject|0
6254656|NCT01986920|9945465|FG000|Placebo|Withdrawal by Subject|0
6254657|NCT01986920|9945466|FG001|Placebo|Withdrawal by Subject|0
6254658|NCT01986920|9945467|FG002|Placebo|Withdrawal by Subject|0
6254659|NCT01986920|9945468|FG003|Placebo|Withdrawal by Subject|1
6254660|NCT01986985|9945487|FG000|Overall Study|Withdrawal by Subject|4
6254661|NCT01986985|9945487|FG000|Overall Study|Scan not completed due to malfunction|3
6254662|NCT01987102|9945502|FG000|2 Courses of HDMTX With SOC Rescue|Adverse Event|2
6254663|NCT01987102|9945503|FG001|2 Courses of HDMTX With SOC Rescue|Adverse Event|2
6254664|NCT01987102|9945502|FG000|2 Courses of HDMTX With SOC Rescue|Laboratory abnormality|1
6254665|NCT01987102|9945503|FG001|2 Courses of HDMTX With SOC Rescue|Laboratory abnormality|2
6254666|NCT01987102|9945502|FG000|2 Courses of HDMTX With SOC Rescue|Change in planned chemotherapy|1
6254667|NCT01987102|9945503|FG001|2 Courses of HDMTX With SOC Rescue|Change in planned chemotherapy|0
6254668|NCT01987102|9945502|FG000|2 Courses of HDMTX With SOC Rescue|Protocol Violation|0
6254669|NCT01987102|9945503|FG001|2 Courses of HDMTX With SOC Rescue|Protocol Violation|1
6254670|NCT01987102|9945502|FG000|2 Courses of HDMTX With SOC Rescue|Incorrectly included|0
6254671|NCT01987102|9945503|FG001|2 Courses of HDMTX With SOC Rescue|Incorrectly included|1
6254672|NCT01987102|9945502|FG000|2 Courses of HDMTX With MOD Rescue|Adverse Event|0
6254673|NCT01987102|9945503|FG001|2 Courses of HDMTX With MOD Rescue|Adverse Event|1
6254674|NCT01987232|9945534|FG000|Overall Study|Ongoing in Study|0
6254675|NCT01987232|9945535|FG001|Overall Study|Ongoing in Study|0
6254676|NCT01987232|9945536|FG002|Overall Study|Ongoing in Study|0
6254677|NCT01987232|9945537|FG003|Overall Study|Ongoing in Study|1
6254678|NCT01987232|9945538|FG004|Overall Study|Ongoing in Study|0
6254679|NCT01987427|9945614|FG000|Overall Study|Adverse Event|4
6254680|NCT01987427|9945615|FG001|Overall Study|Adverse Event|2
6254681|NCT01987427|9945616|FG002|Overall Study|Adverse Event|8
6254682|NCT01987427|9945614|FG000|Overall Study|Lost to Follow-up|6
6254683|NCT01987427|9945615|FG001|Overall Study|Lost to Follow-up|6
6254684|NCT01987427|9945616|FG002|Overall Study|Lost to Follow-up|9
6254685|NCT01987427|9945614|FG000|Overall Study|Withdrawal by Subject|2
6254686|NCT01987427|9945615|FG001|Overall Study|Withdrawal by Subject|1
6254687|NCT01987427|9945616|FG002|Overall Study|Withdrawal by Subject|3
6254688|NCT01987427|9945614|FG000|Overall Study|Lack of Efficacy|1
6254689|NCT01987427|9945615|FG001|Overall Study|Lack of Efficacy|0
6254690|NCT01987427|9945616|FG002|Overall Study|Lack of Efficacy|0
6254691|NCT01987427|9945614|FG000|Overall Study|Other|1
6254692|NCT01987427|9945615|FG001|Overall Study|Other|1
6254693|NCT01987427|9945616|FG002|Overall Study|Other|0
6254694|NCT01987453|9945627|FG000|Overall Study|Death|0
6254695|NCT01987453|9945628|FG001|Overall Study|Death|0
6254696|NCT01987453|9945629|FG002|Overall Study|Death|1
6254697|NCT01987453|9945627|FG000|Overall Study|Lack of Efficacy|1
6254698|NCT01987453|9945628|FG001|Overall Study|Lack of Efficacy|12
6254699|NCT01987453|9945629|FG002|Overall Study|Lack of Efficacy|0
6254700|NCT01987479|9945641|FG000|Overall Study|Protocol Violation|1
6254701|NCT01987479|9945641|FG000|Overall Study|Physician Decision|2
6254702|NCT01987479|9945641|FG000|Overall Study|Participant/legal guardian decision|1
6254703|NCT01987479|9945641|FG000|Overall Study|Other|5
6254704|NCT01987479|9945641|FG000|Overall Study|Lost to Follow-up|1
6254705|NCT01987479|9945641|FG000|Overall Study|Adverse Event|7
6270972|NCT02158728|9972421|FG000|Overall Study|no qualified dataset|24
6270973|NCT02158806|9972427|FG000|Overall Study|Death|2
6270974|NCT02158806|9972428|FG001|Overall Study|Death|0
6270975|NCT02158806|9972427|FG000|Overall Study|Withdrawal by Subject|2
6270976|NCT02158806|9972428|FG001|Overall Study|Withdrawal by Subject|0
6270977|NCT02158806|9972427|FG000|Overall Study|Lost to Follow-up|0
6270978|NCT02158806|9972428|FG001|Overall Study|Lost to Follow-up|3
6270979|NCT02158806|9972427|FG000|Overall Study|Moved out of area|0
6270980|NCT02158806|9972428|FG001|Overall Study|Moved out of area|1
6270981|NCT02158806|9972427|FG000|Overall Study|Transferred to palliative care|0
6270982|NCT02158806|9972428|FG001|Overall Study|Transferred to palliative care|1
6270983|NCT02158884|9972434|FG000|Baseline Assessment|Missed performance assessment|3
6270984|NCT02158884|9972434|FG000|Baseline Assessment|Missed SMFA|1
6270985|NCT02158884|9972434|FG000|Intervention: IDEO and PT Program|Did not complete PT intervention|6
6270986|NCT02158884|9972434|FG000|Post Intervention (~4 Weeks)|Did not complete performance assessment|10
6270987|NCT02158884|9972434|FG000|6 Month Assessment|Missed SMFA|20
6270988|NCT02158884|9972434|FG000|12 Month Assessment|Missed SMFA|17
6270989|NCT02158936|9972441|FG000|Overall Study|Study closed/ terminated|57
6270990|NCT02158936|9972442|FG001|Overall Study|Study closed/ terminated|77
6270991|NCT02158936|9972441|FG000|Overall Study|Azacitidine tx discontinued|53
6270992|NCT02158936|9972442|FG001|Overall Study|Azacitidine tx discontinued|46
6270993|NCT02158936|9972441|FG000|Overall Study|Adverse Event|39
6270994|NCT02158936|9972442|FG001|Overall Study|Adverse Event|24
6270995|NCT02158936|9972441|FG000|Overall Study|Withdrawal by Subject|15
6270996|NCT02158936|9972442|FG001|Overall Study|Withdrawal by Subject|16
6270997|NCT02158936|9972441|FG000|Overall Study|Physician Decision|15
6270998|NCT02158936|9972442|FG001|Overall Study|Physician Decision|13
6270999|NCT02158936|9972441|FG000|Overall Study|Lost to Follow-up|0
6271000|NCT02158936|9972442|FG001|Overall Study|Lost to Follow-up|1
6271001|NCT02158949|9972450|FG000|Overall Study|Withdrawal by Subject|1
6271002|NCT02158949|9972451|FG001|Overall Study|Withdrawal by Subject|0
6271003|NCT02158949|9972450|FG000|Overall Study|Lost to Follow-up|5
6271004|NCT02158949|9972451|FG001|Overall Study|Lost to Follow-up|11
6271005|NCT02158975|9972457|FG000|Overall Study|Did not complete 1 cycle nor > 1dose|1
6271006|NCT02159053|9972465|FG000|Overall Study|Death|2
6271007|NCT02159053|9972466|FG001|Overall Study|Death|0
6271008|NCT02159053|9972467|FG002|Overall Study|Death|1
6271009|NCT02159053|9972465|FG000|Overall Study|Physician Decision|0
6271010|NCT02159053|9972466|FG001|Overall Study|Physician Decision|1
6271011|NCT02159053|9972467|FG002|Overall Study|Physician Decision|1
6271012|NCT02159053|9972465|FG000|Overall Study|Lack of Efficacy|3
6271013|NCT02159053|9972466|FG001|Overall Study|Lack of Efficacy|4
6271014|NCT02159053|9972467|FG002|Overall Study|Lack of Efficacy|7
6271015|NCT02159053|9972465|FG000|Overall Study|Adverse Event|7
6271016|NCT02159053|9972466|FG001|Overall Study|Adverse Event|6
6271017|NCT02159053|9972467|FG002|Overall Study|Adverse Event|5
6271018|NCT02159053|9972465|FG000|Overall Study|Participants/guardian decision|8
6271019|NCT02159053|9972466|FG001|Overall Study|Participants/guardian decision|10
6271020|NCT02159053|9972467|FG002|Overall Study|Participants/guardian decision|6
6271021|NCT02159183|9972497|FG000|Analysis After the 36 Months Follow-up|Protocol Violation|2
6271022|NCT02159183|9972498|FG001|Analysis After the 36 Months Follow-up|Protocol Violation|1
6271023|NCT02159183|9972497|FG000|Analysis After the 36 Months Follow-up|Adverse Event|1
6271024|NCT02159183|9972498|FG001|Analysis After the 36 Months Follow-up|Adverse Event|0
6271025|NCT02159183|9972497|FG000|Analysis After the 36 Months Follow-up|Death|0
6271026|NCT02159183|9972498|FG001|Analysis After the 36 Months Follow-up|Death|1
6271027|NCT02159183|9972497|FG000|Analysis of Primary Endpoint (12 Mts)|Adverse Event|1
6271028|NCT02159183|9972498|FG001|Analysis of Primary Endpoint (12 Mts)|Adverse Event|0
6271029|NCT02159183|9972497|FG000|Analysis of Primary Endpoint (12 Mts)|Protocol Violation|2
6271030|NCT02159183|9972498|FG001|Analysis of Primary Endpoint (12 Mts)|Protocol Violation|1
6271031|NCT02159352|9972506|FG000|Overall Study|Adverse Event|3
6271032|NCT02159352|9972507|FG001|Overall Study|Adverse Event|1
6271033|NCT02159352|9972506|FG000|Overall Study|Withdrawal by Subject|0
6271034|NCT02159352|9972507|FG001|Overall Study|Withdrawal by Subject|1
6271035|NCT02159365|9972532|FG000|Overall Study|Disease Progression|23
6271036|NCT02159365|9972532|FG000|Overall Study|Other reasons|11
6271037|NCT02159365|9972532|FG000|Overall Study|Administrative reason by Sponsor|9
6271038|NCT02159365|9972532|FG000|Overall Study|Adverse Event unrelated to study drug|9
6254706|NCT01987505|9945647|FG000|Overall Study|Other|9
6254707|NCT01987505|9945647|FG000|Overall Study|Withdrawal by Subject|2
6254708|NCT01987505|9945647|FG000|Overall Study|Other Reason|2
6254709|NCT01987505|9945647|FG000|Overall Study|Lost to Follow-up|15
6254710|NCT01987505|9945647|FG000|Overall Study|Investigator Decision|2
6254711|NCT01987505|9945647|FG000|Overall Study|Death|4
6254712|NCT01987557|9945656|FG000|Overall Study|Protocol Violation|1
6254713|NCT01987557|9945657|FG001|Overall Study|Protocol Violation|0
6254714|NCT01987557|9945658|FG002|Overall Study|Protocol Violation|1
6254715|NCT01987557|9945656|FG000|Overall Study|Withdrawal by Subject|2
6254716|NCT01987557|9945657|FG001|Overall Study|Withdrawal by Subject|1
6254717|NCT01987557|9945658|FG002|Overall Study|Withdrawal by Subject|2
6254718|NCT01987557|9945656|FG000|Overall Study|Adverse Event|0
6254719|NCT01987557|9945657|FG001|Overall Study|Adverse Event|2
6254720|NCT01987557|9945658|FG002|Overall Study|Adverse Event|0
6254721|NCT01987596|9945677|FG000|Overall Study|Physician Decision|1
6254722|NCT01987596|9945678|FG001|Overall Study|Physician Decision|0
6254723|NCT01987596|9945677|FG000|Overall Study|Progressive Disease; missing all period|0
6254724|NCT01987596|9945678|FG001|Overall Study|Progressive Disease; missing all period|1
6254725|NCT01987609|9945690|FG000|Overall Study|Adverse Event|1
6254726|NCT01987765|9945708|FG000|Overall Study|Protocol Violation|65
6254727|NCT01987765|9945708|FG000|Overall Study|Lost to Follow-up|37
6254728|NCT01987817|9945714|FG000|Overall Study|Adverse Event|4
6254729|NCT01987817|9945715|FG001|Overall Study|Adverse Event|0
6254730|NCT01987817|9945714|FG000|Overall Study|Withdrawal by Subject|1
6254731|NCT01987817|9945715|FG001|Overall Study|Withdrawal by Subject|1
6254732|NCT01987817|9945714|FG000|Overall Study|Physician Decision|1
6254733|NCT01987817|9945715|FG001|Overall Study|Physician Decision|0
6254734|NCT01987830|9945722|FG000|Overall Study|Never received baseline scan|1
6254735|NCT01987895|9945728|FG000|Overall Study|Withdrawal by Subject|12
6254736|NCT01987895|9945729|FG001|Overall Study|Withdrawal by Subject|7
6254737|NCT01987895|9945728|FG000|Overall Study|Physician Decision|8
6254738|NCT01987895|9945729|FG001|Overall Study|Physician Decision|10
6254739|NCT01987895|9945728|FG000|Overall Study|Death|7
6254740|NCT01987895|9945729|FG001|Overall Study|Death|7
6254741|NCT01987895|9945728|FG000|Overall Study|Lost to Follow-up|3
6254742|NCT01987895|9945729|FG001|Overall Study|Lost to Follow-up|5
6254743|NCT01987895|9945728|FG000|Overall Study|randomized before giving IC|0
6254744|NCT01987895|9945729|FG001|Overall Study|randomized before giving IC|1
6254745|NCT01987908|9945735|FG000|Placebo Lead-in Period|Adverse Event|2
6254746|NCT01987908|9945736|FG001|Placebo Lead-in Period|Adverse Event|0
6254747|NCT01987908|9945737|FG002|Placebo Lead-in Period|Adverse Event|0
6254748|NCT01987908|9945735|FG000|Placebo Lead-in Period|Physician Decision|2
6254749|NCT01987908|9945736|FG001|Placebo Lead-in Period|Physician Decision|0
6254750|NCT01987908|9945737|FG002|Placebo Lead-in Period|Physician Decision|0
6254751|NCT01987908|9945735|FG000|Placebo Lead-in Period|Withdrawal by Subject|1
6254752|NCT01987908|9945736|FG001|Placebo Lead-in Period|Withdrawal by Subject|0
6254753|NCT01987908|9945737|FG002|Placebo Lead-in Period|Withdrawal by Subject|0
6254754|NCT01987908|9945735|FG000|Placebo Lead-in Period|Other: Study Termination by Sponsor|4
6254755|NCT01987908|9945736|FG001|Placebo Lead-in Period|Other: Study Termination by Sponsor|0
6254756|NCT01987908|9945737|FG002|Placebo Lead-in Period|Other: Study Termination by Sponsor|0
6254757|NCT01987908|9945735|FG000|Treatment Period|Adverse Event|0
6254758|NCT01987908|9945736|FG001|Treatment Period|Adverse Event|1
6254759|NCT01987908|9945737|FG002|Treatment Period|Adverse Event|1
6254760|NCT01987908|9945735|FG000|Post-Treatment Observation Period|Other: Study Termination by Sponsor|0
6254761|NCT01987908|9945736|FG001|Post-Treatment Observation Period|Other: Study Termination by Sponsor|2
6254762|NCT01987908|9945737|FG002|Post-Treatment Observation Period|Other: Study Termination by Sponsor|0
6254763|NCT01987908|9945735|FG000|Post-Treatment Observation Period|Other: Bad Veins|0
6254764|NCT01987908|9945736|FG001|Post-Treatment Observation Period|Other: Bad Veins|1
6254765|NCT01987908|9945737|FG002|Post-Treatment Observation Period|Other: Bad Veins|0
6254766|NCT01987960|9945763|FG000|Period 1|Adverse Event|24
6254767|NCT01987960|9945764|FG001|Period 1|Adverse Event|0
6254768|NCT01987960|9945765|FG002|Period 1|Adverse Event|0
6254769|NCT01987960|9945766|FG003|Period 1|Adverse Event|0
6254770|NCT01987960|9945763|FG000|Period 1|Lack of Efficacy|4
6254771|NCT01987960|9945764|FG001|Period 1|Lack of Efficacy|0
6254772|NCT01987960|9945765|FG002|Period 1|Lack of Efficacy|0
6254773|NCT01987960|9945766|FG003|Period 1|Lack of Efficacy|0
6254774|NCT01987960|9945763|FG000|Period 1|Non-compliance with IMP|6
6254775|NCT01987960|9945764|FG001|Period 1|Non-compliance with IMP|0
6254776|NCT01987960|9945765|FG002|Period 1|Non-compliance with IMP|0
6254777|NCT01987960|9945766|FG003|Period 1|Non-compliance with IMP|0
6254778|NCT01987960|9945763|FG000|Period 1|Protocol Violation|12
6254779|NCT01987960|9945764|FG001|Period 1|Protocol Violation|0
6254780|NCT01987960|9945765|FG002|Period 1|Protocol Violation|0
6254781|NCT01987960|9945766|FG003|Period 1|Protocol Violation|0
6254782|NCT01987960|9945763|FG000|Period 1|Withdrawal by Subject|21
6254783|NCT01987960|9945764|FG001|Period 1|Withdrawal by Subject|0
6254784|NCT01987960|9945765|FG002|Period 1|Withdrawal by Subject|0
6254785|NCT01987960|9945766|FG003|Period 1|Withdrawal by Subject|0
6254786|NCT01987960|9945763|FG000|Period 1|Lost to Follow-up|40
6254787|NCT01987960|9945764|FG001|Period 1|Lost to Follow-up|0
6254788|NCT01987960|9945765|FG002|Period 1|Lost to Follow-up|0
6254789|NCT01987960|9945766|FG003|Period 1|Lost to Follow-up|0
6254790|NCT01987960|9945763|FG000|Period 1|administrative or other reason|75
6254791|NCT01987960|9945764|FG001|Period 1|administrative or other reason|0
6254792|NCT01987960|9945765|FG002|Period 1|administrative or other reason|0
6254793|NCT01987960|9945766|FG003|Period 1|administrative or other reason|0
6254794|NCT01987960|9945763|FG000|Period 1|Withdrawal of consent before treatment|4
6254795|NCT01987960|9945764|FG001|Period 1|Withdrawal of consent before treatment|0
6254796|NCT01987960|9945765|FG002|Period 1|Withdrawal of consent before treatment|0
6254797|NCT01987960|9945766|FG003|Period 1|Withdrawal of consent before treatment|0
6254798|NCT01987960|9945763|FG000|Period 2|Adverse Event|0
6254799|NCT01987960|9945764|FG001|Period 2|Adverse Event|0
6254800|NCT01987960|9945765|FG002|Period 2|Adverse Event|1
6254801|NCT01987960|9945766|FG003|Period 2|Adverse Event|0
6254802|NCT01987960|9945763|FG000|Period 2|Withdrawal by Subject|0
6254803|NCT01987960|9945764|FG001|Period 2|Withdrawal by Subject|0
6254804|NCT01987960|9945765|FG002|Period 2|Withdrawal by Subject|1
6254805|NCT01987960|9945766|FG003|Period 2|Withdrawal by Subject|0
6254806|NCT01987960|9945763|FG000|Period 2|Administrative or other reason|0
6254807|NCT01987960|9945764|FG001|Period 2|Administrative or other reason|5
6254808|NCT01987960|9945765|FG002|Period 2|Administrative or other reason|7
6254809|NCT01987960|9945766|FG003|Period 2|Administrative or other reason|0
6086570|NCT00662259|9696644|FG001|Overall Study|Adverse Event|0
6254810|NCT01987960|9945763|FG000|Period 3|Adverse Event|0
6254811|NCT01987960|9945764|FG001|Period 3|Adverse Event|0
6254812|NCT01987960|9945765|FG002|Period 3|Adverse Event|0
6254813|NCT01987960|9945766|FG003|Period 3|Adverse Event|7
6254814|NCT01987960|9945763|FG000|Period 3|Non-compliance with IMP|0
6254815|NCT01987960|9945764|FG001|Period 3|Non-compliance with IMP|0
6254816|NCT01987960|9945765|FG002|Period 3|Non-compliance with IMP|0
6254817|NCT01987960|9945766|FG003|Period 3|Non-compliance with IMP|1
6254818|NCT01987960|9945763|FG000|Period 3|Protocol Violation|0
6254819|NCT01987960|9945764|FG001|Period 3|Protocol Violation|0
6254820|NCT01987960|9945765|FG002|Period 3|Protocol Violation|0
6254821|NCT01987960|9945766|FG003|Period 3|Protocol Violation|6
6254822|NCT01987960|9945763|FG000|Period 3|Withdrawal by Subject|0
6254823|NCT01987960|9945764|FG001|Period 3|Withdrawal by Subject|0
6254824|NCT01987960|9945765|FG002|Period 3|Withdrawal by Subject|0
6254825|NCT01987960|9945766|FG003|Period 3|Withdrawal by Subject|9
6254826|NCT01987960|9945763|FG000|Period 3|Lost to Follow-up|0
6254827|NCT01987960|9945764|FG001|Period 3|Lost to Follow-up|0
6254828|NCT01987960|9945765|FG002|Period 3|Lost to Follow-up|0
6254829|NCT01987960|9945766|FG003|Period 3|Lost to Follow-up|5
6254830|NCT01987960|9945763|FG000|Period 3|Administrative or other reason|0
6254831|NCT01987960|9945764|FG001|Period 3|Administrative or other reason|0
6254832|NCT01987960|9945765|FG002|Period 3|Administrative or other reason|0
6254833|NCT01987960|9945766|FG003|Period 3|Administrative or other reason|43
6254834|NCT01987986|9945780|FG000|Overall Study|Lost to Follow-up|1
6254835|NCT01987986|9945781|FG001|Overall Study|Lost to Follow-up|0
6254836|NCT01987986|9945782|FG002|Overall Study|Lost to Follow-up|0
6254837|NCT01987986|9945783|FG003|Overall Study|Lost to Follow-up|0
6254838|NCT01987986|9945780|FG000|Overall Study|Adverse Event|1
6254839|NCT01987986|9945781|FG001|Overall Study|Adverse Event|0
6254840|NCT01987986|9945782|FG002|Overall Study|Adverse Event|2
6254841|NCT01987986|9945783|FG003|Overall Study|Adverse Event|0
6254842|NCT01988012|9945793|FG000|Overall Study|Adverse Event|5
6254843|NCT01988012|9945793|FG000|Overall Study|Insufficient Therapeutic Response|3
6254844|NCT01988012|9945793|FG000|Overall Study|Patient Withdrawal of Consent|4
6254845|NCT01988012|9945793|FG000|Overall Study|Lost to Follow-up|1
6254846|NCT01988012|9945793|FG000|Overall Study|Physician Decision|1
6254847|NCT01988012|9945793|FG000|Overall Study|Protocol Violation|1
6254848|NCT01988090|9945799|FG000|Start Treament After Randomization|Withdrawal by Subject|2
6254849|NCT01988090|9945800|FG001|Start Treament After Randomization|Withdrawal by Subject|3
6254850|NCT01988090|9945799|FG000|Start Treament After Randomization|Protocol Violation|0
6254851|NCT01988090|9945800|FG001|Start Treament After Randomization|Protocol Violation|1
6254852|NCT01988090|9945799|FG000|Complete Study After Start|Withdrawal by Subject|2
6254853|NCT01988090|9945800|FG001|Complete Study After Start|Withdrawal by Subject|0
6254854|NCT01988090|9945799|FG000|Complete Study After Start|Protocol Violation|1
6254855|NCT01988090|9945800|FG001|Complete Study After Start|Protocol Violation|1
6254856|NCT01988103|9945809|FG000|Placebo-Controlled Phase Week 0-16|Adverse Event|3
6254857|NCT01988103|9945810|FG001|Placebo-Controlled Phase Week 0-16|Adverse Event|10
6254858|NCT01988103|9945811|FG002|Placebo-Controlled Phase Week 0-16|Adverse Event|6
6254859|NCT01988103|9945812|FG003|Placebo-Controlled Phase Week 0-16|Adverse Event|0
6254860|NCT01988103|9945813|FG004|Placebo-Controlled Phase Week 0-16|Adverse Event|0
6254861|NCT01988103|9945809|FG000|Placebo-Controlled Phase Week 0-16|Lack of Efficacy|1
6254862|NCT01988103|9945810|FG001|Placebo-Controlled Phase Week 0-16|Lack of Efficacy|2
6254863|NCT01988103|9945811|FG002|Placebo-Controlled Phase Week 0-16|Lack of Efficacy|2
6254864|NCT01988103|9945812|FG003|Placebo-Controlled Phase Week 0-16|Lack of Efficacy|0
6254865|NCT01988103|9945813|FG004|Placebo-Controlled Phase Week 0-16|Lack of Efficacy|0
6086571|NCT00662311|9696657|FG000|Overall Study|Respiratory Infection|1
6254866|NCT01988103|9945809|FG000|Placebo-Controlled Phase Week 0-16|Withdrawal by Subject|8
6254867|NCT01988103|9945810|FG001|Placebo-Controlled Phase Week 0-16|Withdrawal by Subject|4
6254868|NCT01988103|9945811|FG002|Placebo-Controlled Phase Week 0-16|Withdrawal by Subject|1
6254869|NCT01988103|9945812|FG003|Placebo-Controlled Phase Week 0-16|Withdrawal by Subject|0
6254870|NCT01988103|9945813|FG004|Placebo-Controlled Phase Week 0-16|Withdrawal by Subject|0
6254871|NCT01988103|9945809|FG000|Active Treatment Phase (Weeks 16-68)|Adverse Event|0
6254872|NCT01988103|9945810|FG001|Active Treatment Phase (Weeks 16-68)|Adverse Event|6
6254873|NCT01988103|9945811|FG002|Active Treatment Phase (Weeks 16-68)|Adverse Event|3
6254874|NCT01988103|9945812|FG003|Active Treatment Phase (Weeks 16-68)|Adverse Event|3
6254875|NCT01988103|9945813|FG004|Active Treatment Phase (Weeks 16-68)|Adverse Event|2
6254876|NCT01988103|9945809|FG000|Active Treatment Phase (Weeks 16-68)|Lack of Efficacy|0
6254877|NCT01988103|9945810|FG001|Active Treatment Phase (Weeks 16-68)|Lack of Efficacy|1
6254878|NCT01988103|9945811|FG002|Active Treatment Phase (Weeks 16-68)|Lack of Efficacy|2
6254879|NCT01988103|9945812|FG003|Active Treatment Phase (Weeks 16-68)|Lack of Efficacy|0
6254880|NCT01988103|9945813|FG004|Active Treatment Phase (Weeks 16-68)|Lack of Efficacy|0
6254881|NCT01988103|9945809|FG000|Active Treatment Phase (Weeks 16-68)|Withdrawal by Subject|0
6254882|NCT01988103|9945810|FG001|Active Treatment Phase (Weeks 16-68)|Withdrawal by Subject|5
6254883|NCT01988103|9945811|FG002|Active Treatment Phase (Weeks 16-68)|Withdrawal by Subject|4
6254884|NCT01988103|9945812|FG003|Active Treatment Phase (Weeks 16-68)|Withdrawal by Subject|0
6254885|NCT01988103|9945813|FG004|Active Treatment Phase (Weeks 16-68)|Withdrawal by Subject|1
6254886|NCT01988103|9945809|FG000|Active Treatment Phase (Weeks 16-68)|Principal Investigator Signature Missing|0
6254887|NCT01988103|9945810|FG001|Active Treatment Phase (Weeks 16-68)|Principal Investigator Signature Missing|1
6254888|NCT01988103|9945811|FG002|Active Treatment Phase (Weeks 16-68)|Principal Investigator Signature Missing|2
6254889|NCT01988103|9945812|FG003|Active Treatment Phase (Weeks 16-68)|Principal Investigator Signature Missing|0
6254890|NCT01988103|9945813|FG004|Active Treatment Phase (Weeks 16-68)|Principal Investigator Signature Missing|2
6254891|NCT01988402|9945860|FG000|Overall Study|Adverse Event|1
6254892|NCT01988402|9945861|FG001|Overall Study|Adverse Event|2
6254893|NCT01988402|9945860|FG000|Overall Study|Withdrawal by Subject|1
6254894|NCT01988402|9945861|FG001|Overall Study|Withdrawal by Subject|0
6254895|NCT01988662|9945875|FG000|Overall Study|Subject/guardian decision|1
6254896|NCT01988662|9945876|FG001|Overall Study|Subject/guardian decision|1
6254897|NCT01988662|9945875|FG000|Overall Study|Adverse Event|3
6254898|NCT01988662|9945876|FG001|Overall Study|Adverse Event|1
6254899|NCT01988779|9945885|FG000|Overall Study|Withdrawal by Subject|2
6254900|NCT01988779|9945886|FG001|Overall Study|Withdrawal by Subject|2
6254901|NCT01988779|9945885|FG000|Overall Study|Protocol Violation|1
6254902|NCT01988779|9945886|FG001|Overall Study|Protocol Violation|0
6254903|NCT01989156|9945924|FG000|Confinement Period (Population at Day 5)|Withdrawal by Subject|0
6254904|NCT01989156|9945925|FG001|Confinement Period (Population at Day 5)|Withdrawal by Subject|1
6254905|NCT01989156|9945926|FG002|Confinement Period (Population at Day 5)|Withdrawal by Subject|3
6254906|NCT01989156|9945924|FG000|Confinement Period (Population at Day 5)|Patient Anxiety|0
6254907|NCT01989156|9945925|FG001|Confinement Period (Population at Day 5)|Patient Anxiety|0
6254908|NCT01989156|9945926|FG002|Confinement Period (Population at Day 5)|Patient Anxiety|1
6254909|NCT01989156|9945924|FG000|Confinement Period (Population at Day 5)|Adverse Event|0
6254910|NCT01989156|9945925|FG001|Confinement Period (Population at Day 5)|Adverse Event|0
6254911|NCT01989156|9945926|FG002|Confinement Period (Population at Day 5)|Adverse Event|1
6189817|NCT01404949|9845599|FG000|Overall Study|Not Treated|1
6189818|NCT01404988|9845606|FG000|Overall Study|Death|2
6189819|NCT01404988|9845607|FG001|Overall Study|Death|0
6189820|NCT01404988|9845608|FG002|Overall Study|Death|2
6189821|NCT01404988|9845606|FG000|Overall Study|Adverse Event|1
6189822|NCT01404988|9845607|FG001|Overall Study|Adverse Event|0
6189823|NCT01404988|9845608|FG002|Overall Study|Adverse Event|0
6189824|NCT01404988|9845606|FG000|Overall Study|Withdrawal by Subject|2
6189825|NCT01404988|9845607|FG001|Overall Study|Withdrawal by Subject|2
6189826|NCT01404988|9845608|FG002|Overall Study|Withdrawal by Subject|0
6189827|NCT01404988|9845606|FG000|Overall Study|Lost to Follow-up|1
6189828|NCT01404988|9845607|FG001|Overall Study|Lost to Follow-up|2
6189829|NCT01404988|9845608|FG002|Overall Study|Lost to Follow-up|1
6189830|NCT01405027|9845621|FG000|Overall Study|Withdrawn consent|3
6189831|NCT01405027|9845622|FG001|Overall Study|Withdrawn consent|0
6189832|NCT01405027|9845621|FG000|Overall Study|Lost to Follow-up|16
6189833|NCT01405027|9845622|FG001|Overall Study|Lost to Follow-up|24
6189834|NCT01405027|9845621|FG000|Overall Study|Investigator judgement|0
6189835|NCT01405027|9845622|FG001|Overall Study|Investigator judgement|2
6189836|NCT01405027|9845621|FG000|Overall Study|Death|1
6189837|NCT01405027|9845622|FG001|Overall Study|Death|0
6189838|NCT01405027|9845621|FG000|Overall Study|Other or Unknown|12
6189839|NCT01405027|9845622|FG001|Overall Study|Other or Unknown|25
6189840|NCT01405053|9845632|FG000|Overall Study|Adverse Event|3
6189841|NCT01405053|9845633|FG001|Overall Study|Adverse Event|0
6189842|NCT01405053|9845632|FG000|Overall Study|Lost to Follow-up|0
6189843|NCT01405053|9845633|FG001|Overall Study|Lost to Follow-up|1
6189844|NCT01405053|9845632|FG000|Overall Study|Participant choice|2
6189845|NCT01405053|9845633|FG001|Overall Study|Participant choice|1
6189846|NCT01405053|9845632|FG000|Overall Study|Inadequate therapeutic effect|2
6189847|NCT01405053|9845633|FG001|Overall Study|Inadequate therapeutic effect|1
6189848|NCT01405053|9845632|FG000|Overall Study|Withdrawal by Subject|3
6189849|NCT01405053|9845633|FG001|Overall Study|Withdrawal by Subject|4
6189850|NCT01405053|9845632|FG000|Overall Study|Other|0
6254912|NCT01989156|9945924|FG000|End of Study (Population at Day 90)|Withdrawal by Subject|2
6254913|NCT01989156|9945925|FG001|End of Study (Population at Day 90)|Withdrawal by Subject|2
6254914|NCT01989156|9945926|FG002|End of Study (Population at Day 90)|Withdrawal by Subject|2
6254915|NCT01989156|9945924|FG000|End of Study (Population at Day 90)|Lost to Follow-up|3
6254916|NCT01989156|9945925|FG001|End of Study (Population at Day 90)|Lost to Follow-up|2
6254917|NCT01989156|9945926|FG002|End of Study (Population at Day 90)|Lost to Follow-up|0
6254918|NCT01989156|9945924|FG000|End of Study (Population at Day 90)|Physician Decision|1
6254919|NCT01989156|9945925|FG001|End of Study (Population at Day 90)|Physician Decision|0
6254920|NCT01989156|9945926|FG002|End of Study (Population at Day 90)|Physician Decision|1
6254921|NCT01989156|9945924|FG000|End of Study (Population at Day 90)|Moved out of state|1
6254922|NCT01989156|9945925|FG001|End of Study (Population at Day 90)|Moved out of state|0
6254923|NCT01989156|9945926|FG002|End of Study (Population at Day 90)|Moved out of state|0
6254924|NCT01989156|9945924|FG000|End of Study (Population at Day 90)|Employment Conflict|0
6254925|NCT01989156|9945925|FG001|End of Study (Population at Day 90)|Employment Conflict|1
6254926|NCT01989156|9945926|FG002|End of Study (Population at Day 90)|Employment Conflict|0
6254927|NCT01989169|9945936|FG000|Period 2|Adverse Event|0
6254928|NCT01989169|9945937|FG001|Period 2|Adverse Event|1
6254929|NCT01989208|9945952|FG000|200 mg (7 Days)|Protocol Violation|0
6254930|NCT01989208|9945953|FG001|200 mg (7 Days)|Protocol Violation|1
6254931|NCT01989455|9945980|FG000|Overall Study|Adverse Event|0
6254932|NCT01989455|9945981|FG001|Overall Study|Adverse Event|1
6254933|NCT01989455|9945982|FG002|Overall Study|Adverse Event|0
6254934|NCT01989455|9945983|FG003|Overall Study|Adverse Event|0
6254935|NCT01989455|9945984|FG004|Overall Study|Adverse Event|0
6254936|NCT01989455|9945980|FG000|Overall Study|Withdrawal by Subject|0
6254937|NCT01989455|9945981|FG001|Overall Study|Withdrawal by Subject|1
6254938|NCT01989455|9945982|FG002|Overall Study|Withdrawal by Subject|0
6254939|NCT01989455|9945983|FG003|Overall Study|Withdrawal by Subject|0
6254940|NCT01989455|9945984|FG004|Overall Study|Withdrawal by Subject|0
6254941|NCT01989455|9945980|FG000|Overall Study|Technical problems with infusion|0
6254942|NCT01989455|9945981|FG001|Overall Study|Technical problems with infusion|0
6254943|NCT01989455|9945982|FG002|Overall Study|Technical problems with infusion|1
6254944|NCT01989455|9945983|FG003|Overall Study|Technical problems with infusion|0
6254945|NCT01989455|9945984|FG004|Overall Study|Technical problems with infusion|1
6254946|NCT01989468|9946003|FG000|Overall Study|Adverse Event|10
6254947|NCT01989468|9946004|FG001|Overall Study|Adverse Event|15
6254948|NCT01989468|9946005|FG002|Overall Study|Adverse Event|4
6254949|NCT01989468|9946006|FG003|Overall Study|Adverse Event|5
6254950|NCT01989468|9946007|FG004|Overall Study|Adverse Event|4
6254951|NCT01989468|9946003|FG000|Overall Study|Lack of Efficacy|11
6254952|NCT01989468|9946004|FG001|Overall Study|Lack of Efficacy|11
6254953|NCT01989468|9946005|FG002|Overall Study|Lack of Efficacy|7
6254954|NCT01989468|9946006|FG003|Overall Study|Lack of Efficacy|4
6254955|NCT01989468|9946007|FG004|Overall Study|Lack of Efficacy|2
6254956|NCT01989468|9946003|FG000|Overall Study|Lost to Follow-up|5
6254957|NCT01989468|9946004|FG001|Overall Study|Lost to Follow-up|2
6254958|NCT01989468|9946005|FG002|Overall Study|Lost to Follow-up|0
6254959|NCT01989468|9946006|FG003|Overall Study|Lost to Follow-up|1
6254960|NCT01989468|9946007|FG004|Overall Study|Lost to Follow-up|1
6254961|NCT01989468|9946003|FG000|Overall Study|Physician Decision|4
6254962|NCT01989468|9946004|FG001|Overall Study|Physician Decision|1
6254963|NCT01989468|9946005|FG002|Overall Study|Physician Decision|0
6254964|NCT01989468|9946006|FG003|Overall Study|Physician Decision|1
6254965|NCT01989468|9946007|FG004|Overall Study|Physician Decision|0
6254966|NCT01989468|9946003|FG000|Overall Study|Pregnancy|0
6254967|NCT01989468|9946004|FG001|Overall Study|Pregnancy|1
6189851|NCT01405053|9845633|FG001|Overall Study|Other|1
6189852|NCT01405196|9845643|FG000|Overall Study|Study Terminated by Sponsor|0
6189853|NCT01405196|9845644|FG001|Overall Study|Study Terminated by Sponsor|0
6189854|NCT01405196|9845645|FG002|Overall Study|Study Terminated by Sponsor|9
6189855|NCT01405196|9845646|FG003|Overall Study|Study Terminated by Sponsor|0
6189856|NCT01405196|9845643|FG000|Overall Study|Other|2
6189857|NCT01405196|9845644|FG001|Overall Study|Other|2
6189858|NCT01405196|9845645|FG002|Overall Study|Other|5
6189859|NCT01405196|9845646|FG003|Overall Study|Other|0
6189860|NCT01405196|9845643|FG000|Overall Study|Withdrawal by Subject|4
6189861|NCT01405196|9845644|FG001|Overall Study|Withdrawal by Subject|6
6189862|NCT01405196|9845645|FG002|Overall Study|Withdrawal by Subject|3
6189863|NCT01405196|9845646|FG003|Overall Study|Withdrawal by Subject|6
6189864|NCT01405196|9845643|FG000|Overall Study|Adverse Event|2
6189865|NCT01405196|9845644|FG001|Overall Study|Adverse Event|2
6189866|NCT01405196|9845645|FG002|Overall Study|Adverse Event|0
6189867|NCT01405196|9845646|FG003|Overall Study|Adverse Event|2
6189868|NCT01405196|9845643|FG000|Overall Study|Death|1
6189869|NCT01405196|9845644|FG001|Overall Study|Death|0
6189870|NCT01405196|9845645|FG002|Overall Study|Death|3
6189871|NCT01405196|9845646|FG003|Overall Study|Death|0
6254968|NCT01989468|9946005|FG002|Overall Study|Pregnancy|0
6254969|NCT01989468|9946006|FG003|Overall Study|Pregnancy|0
6254970|NCT01989468|9946007|FG004|Overall Study|Pregnancy|0
6254971|NCT01989468|9946003|FG000|Overall Study|Technical Problems|3
6254972|NCT01989468|9946004|FG001|Overall Study|Technical Problems|1
6254973|NCT01989468|9946005|FG002|Overall Study|Technical Problems|3
6254974|NCT01989468|9946006|FG003|Overall Study|Technical Problems|1
6254975|NCT01989468|9946007|FG004|Overall Study|Technical Problems|0
6254976|NCT01989468|9946003|FG000|Overall Study|Subject Guardian Decision|11
6254977|NCT01989468|9946004|FG001|Overall Study|Subject Guardian Decision|6
6254978|NCT01989468|9946005|FG002|Overall Study|Subject Guardian Decision|4
6254979|NCT01989468|9946006|FG003|Overall Study|Subject Guardian Decision|4
6254980|NCT01989468|9946007|FG004|Overall Study|Subject Guardian Decision|1
6254981|NCT01989468|9946003|FG000|Overall Study|Death|3
6254982|NCT01989468|9946004|FG001|Overall Study|Death|0
6254983|NCT01989468|9946005|FG002|Overall Study|Death|1
6254984|NCT01989468|9946006|FG003|Overall Study|Death|0
6254985|NCT01989468|9946007|FG004|Overall Study|Death|0
6254986|NCT01989546|9946020|FG000|Overall Study|Clinical Progression|1
6254987|NCT01989546|9946020|FG000|Overall Study|Disease progression on study|8
6254988|NCT01989572|9946030|FG000|Overall Study|Lack of Efficacy|35
6254989|NCT01989572|9946031|FG001|Overall Study|Lack of Efficacy|48
6254990|NCT01989572|9946032|FG002|Overall Study|Lack of Efficacy|48
6189872|NCT01405196|9845643|FG000|Overall Study|Lost to Follow-up|2
6189873|NCT01405196|9845644|FG001|Overall Study|Lost to Follow-up|2
6189874|NCT01405196|9845645|FG002|Overall Study|Lost to Follow-up|3
6189875|NCT01405196|9845646|FG003|Overall Study|Lost to Follow-up|1
6189876|NCT01405456|9845667|FG000|Overall Study|Lost to Follow-up|2
6189877|NCT01405456|9845668|FG001|Overall Study|Lost to Follow-up|1
6189878|NCT01405456|9845667|FG000|Overall Study|Physician Decision|1
6189879|NCT01405456|9845668|FG001|Overall Study|Physician Decision|0
6189880|NCT01405508|9845683|FG000|Overall Study|AE, non-serious non-fatal|1
6189881|NCT01405508|9845684|FG001|Overall Study|AE, non-serious non-fatal|1
6189882|NCT01405508|9845685|FG002|Overall Study|AE, non-serious non-fatal|0
6189883|NCT01405508|9845686|FG003|Overall Study|AE, non-serious non-fatal|0
6189884|NCT01405560|9845696|FG000|Overall Study|Physician Decision|1
6189885|NCT01405742|9845700|FG000|Overall Study|Lost to Follow-up|1
6189886|NCT01405742|9845701|FG001|Overall Study|Lost to Follow-up|0
6189887|NCT01405768|9845709|FG000|Overall Study|Didn't complete questionnaire correctly|4
6189888|NCT01405768|9845710|FG001|Overall Study|Didn't complete questionnaire correctly|0
6189889|NCT01405820|9845728|FG000|Randomized Treatment Period|Adverse Event|3
6189890|NCT01405820|9845729|FG001|Randomized Treatment Period|Adverse Event|3
6189891|NCT01405820|9845730|FG002|Randomized Treatment Period|Adverse Event|3
6189892|NCT01405820|9845731|FG003|Randomized Treatment Period|Adverse Event|0
6189893|NCT01405820|9845732|FG004|Randomized Treatment Period|Adverse Event|2
6189894|NCT01405820|9845733|FG005|Randomized Treatment Period|Adverse Event|1
6189895|NCT01405820|9845728|FG000|Randomized Treatment Period|Withdrawal by Subject|6
6189896|NCT01405820|9845729|FG001|Randomized Treatment Period|Withdrawal by Subject|2
6189897|NCT01405820|9845730|FG002|Randomized Treatment Period|Withdrawal by Subject|2
6189898|NCT01405820|9845731|FG003|Randomized Treatment Period|Withdrawal by Subject|2
6189899|NCT01405820|9845732|FG004|Randomized Treatment Period|Withdrawal by Subject|0
6189900|NCT01405820|9845733|FG005|Randomized Treatment Period|Withdrawal by Subject|0
6189901|NCT01405820|9845728|FG000|Randomized Treatment Period|Other|2
6189902|NCT01405820|9845729|FG001|Randomized Treatment Period|Other|2
6189903|NCT01405820|9845730|FG002|Randomized Treatment Period|Other|1
6189904|NCT01405820|9845731|FG003|Randomized Treatment Period|Other|1
6189905|NCT01405820|9845732|FG004|Randomized Treatment Period|Other|0
6189906|NCT01405820|9845733|FG005|Randomized Treatment Period|Other|0
6189907|NCT01405820|9845728|FG000|Randomized Treatment Period|Physician Decision|0
6189908|NCT01405820|9845729|FG001|Randomized Treatment Period|Physician Decision|2
6189909|NCT01405820|9845730|FG002|Randomized Treatment Period|Physician Decision|1
6189910|NCT01405820|9845731|FG003|Randomized Treatment Period|Physician Decision|0
6189911|NCT01405820|9845732|FG004|Randomized Treatment Period|Physician Decision|0
6189912|NCT01405820|9845733|FG005|Randomized Treatment Period|Physician Decision|0
6189913|NCT01405820|9845728|FG000|Randomized Treatment Period|Rescue|0
6189914|NCT01405820|9845729|FG001|Randomized Treatment Period|Rescue|1
6189915|NCT01405820|9845730|FG002|Randomized Treatment Period|Rescue|13
6189916|NCT01405820|9845731|FG003|Randomized Treatment Period|Rescue|10
6189917|NCT01405820|9845732|FG004|Randomized Treatment Period|Rescue|8
6189918|NCT01405820|9845733|FG005|Randomized Treatment Period|Rescue|8
6189919|NCT01405820|9845728|FG000|Randomized Treatment Period|Incorrect Study Treatment|0
6189920|NCT01405820|9845729|FG001|Randomized Treatment Period|Incorrect Study Treatment|0
6254991|NCT01989572|9946033|FG003|Overall Study|Lack of Efficacy|43
6254992|NCT01989572|9946034|FG004|Overall Study|Lack of Efficacy|71
6189921|NCT01405820|9845730|FG002|Randomized Treatment Period|Incorrect Study Treatment|3
6189922|NCT01405820|9845731|FG003|Randomized Treatment Period|Incorrect Study Treatment|0
6189923|NCT01405820|9845732|FG004|Randomized Treatment Period|Incorrect Study Treatment|2
6254993|NCT01989572|9946035|FG005|Overall Study|Lack of Efficacy|79
6254994|NCT01989572|9946030|FG000|Overall Study|Adverse Event|2
6254995|NCT01989572|9946031|FG001|Overall Study|Adverse Event|1
6254996|NCT01989572|9946032|FG002|Overall Study|Adverse Event|3
6254997|NCT01989572|9946033|FG003|Overall Study|Adverse Event|0
6254998|NCT01989572|9946034|FG004|Overall Study|Adverse Event|3
6254999|NCT01989572|9946035|FG005|Overall Study|Adverse Event|0
6255000|NCT01989572|9946030|FG000|Overall Study|Death|0
6255001|NCT01989572|9946031|FG001|Overall Study|Death|0
6255002|NCT01989572|9946032|FG002|Overall Study|Death|0
6255003|NCT01989572|9946033|FG003|Overall Study|Death|0
6255004|NCT01989572|9946034|FG004|Overall Study|Death|1
6255005|NCT01989572|9946035|FG005|Overall Study|Death|0
6255006|NCT01989572|9946030|FG000|Overall Study|Withdrawal by Subject|4
6255007|NCT01989572|9946031|FG001|Overall Study|Withdrawal by Subject|1
6255008|NCT01989572|9946032|FG002|Overall Study|Withdrawal by Subject|5
6255009|NCT01989572|9946033|FG003|Overall Study|Withdrawal by Subject|1
6255010|NCT01989572|9946034|FG004|Overall Study|Withdrawal by Subject|12
6255011|NCT01989572|9946035|FG005|Overall Study|Withdrawal by Subject|4
6255012|NCT01989572|9946030|FG000|Overall Study|complicating disease|1
6255013|NCT01989572|9946031|FG001|Overall Study|complicating disease|1
6255014|NCT01989572|9946032|FG002|Overall Study|complicating disease|2
6255015|NCT01989572|9946033|FG003|Overall Study|complicating disease|0
6255016|NCT01989572|9946034|FG004|Overall Study|complicating disease|1
6255017|NCT01989572|9946035|FG005|Overall Study|complicating disease|0
6255018|NCT01989572|9946030|FG000|Overall Study|error|2
6255019|NCT01989572|9946031|FG001|Overall Study|error|1
6255020|NCT01989572|9946032|FG002|Overall Study|error|1
6255021|NCT01989572|9946033|FG003|Overall Study|error|1
6255022|NCT01989572|9946034|FG004|Overall Study|error|1
6255023|NCT01989572|9946035|FG005|Overall Study|error|1
6189924|NCT01405820|9845733|FG005|Randomized Treatment Period|Incorrect Study Treatment|0
6189925|NCT01405820|9845728|FG000|Randomized Treatment Period|Treatment Arm Closed|0
6189926|NCT01405820|9845729|FG001|Randomized Treatment Period|Treatment Arm Closed|0
6189927|NCT01405820|9845730|FG002|Randomized Treatment Period|Treatment Arm Closed|20
6189928|NCT01405820|9845731|FG003|Randomized Treatment Period|Treatment Arm Closed|36
6189929|NCT01405820|9845732|FG004|Randomized Treatment Period|Treatment Arm Closed|33
6189930|NCT01405820|9845733|FG005|Randomized Treatment Period|Treatment Arm Closed|28
6189931|NCT01405820|9845728|FG000|Randomized Treatment Period|Death|0
6189932|NCT01405820|9845729|FG001|Randomized Treatment Period|Death|0
6189933|NCT01405820|9845730|FG002|Randomized Treatment Period|Death|0
6189934|NCT01405820|9845731|FG003|Randomized Treatment Period|Death|1
6255024|NCT01989572|9946030|FG000|Overall Study|maximum dose reached|0
6189935|NCT01405820|9845732|FG004|Randomized Treatment Period|Death|0
6189936|NCT01405820|9845733|FG005|Randomized Treatment Period|Death|0
6189937|NCT01405820|9845728|FG000|Randomized Treatment Period|Withdrew Prior to Dosing|0
6189938|NCT01405820|9845729|FG001|Randomized Treatment Period|Withdrew Prior to Dosing|0
6189939|NCT01405820|9845730|FG002|Randomized Treatment Period|Withdrew Prior to Dosing|0
6189940|NCT01405820|9845731|FG003|Randomized Treatment Period|Withdrew Prior to Dosing|1
6189941|NCT01405820|9845732|FG004|Randomized Treatment Period|Withdrew Prior to Dosing|0
6189942|NCT01405820|9845733|FG005|Randomized Treatment Period|Withdrew Prior to Dosing|0
6189943|NCT01405820|9845728|FG000|Open-Label Treatment Period|Withdrawal by Subject|3
6189944|NCT01405820|9845729|FG001|Open-Label Treatment Period|Withdrawal by Subject|1
6189945|NCT01405820|9845730|FG002|Open-Label Treatment Period|Withdrawal by Subject|1
6189946|NCT01405820|9845731|FG003|Open-Label Treatment Period|Withdrawal by Subject|1
6189947|NCT01405820|9845732|FG004|Open-Label Treatment Period|Withdrawal by Subject|0
6189948|NCT01405820|9845733|FG005|Open-Label Treatment Period|Withdrawal by Subject|1
6189949|NCT01405820|9845728|FG000|Open-Label Treatment Period|Other|1
6189950|NCT01405820|9845729|FG001|Open-Label Treatment Period|Other|1
6189951|NCT01405820|9845730|FG002|Open-Label Treatment Period|Other|1
6189952|NCT01405820|9845731|FG003|Open-Label Treatment Period|Other|1
6189953|NCT01405820|9845732|FG004|Open-Label Treatment Period|Other|1
6189954|NCT01405820|9845733|FG005|Open-Label Treatment Period|Other|1
6189955|NCT01405820|9845728|FG000|Open-Label Treatment Period|Physician Decision|0
6189956|NCT01405820|9845729|FG001|Open-Label Treatment Period|Physician Decision|0
6189957|NCT01405820|9845730|FG002|Open-Label Treatment Period|Physician Decision|1
6189958|NCT01405820|9845731|FG003|Open-Label Treatment Period|Physician Decision|2
6189959|NCT01405820|9845732|FG004|Open-Label Treatment Period|Physician Decision|1
6189960|NCT01405820|9845733|FG005|Open-Label Treatment Period|Physician Decision|0
6189961|NCT01405820|9845728|FG000|Open-Label Treatment Period|Adverse Event|0
6189962|NCT01405820|9845729|FG001|Open-Label Treatment Period|Adverse Event|0
6189963|NCT01405820|9845730|FG002|Open-Label Treatment Period|Adverse Event|0
6189964|NCT01405820|9845731|FG003|Open-Label Treatment Period|Adverse Event|1
6189965|NCT01405820|9845732|FG004|Open-Label Treatment Period|Adverse Event|0
6189966|NCT01405820|9845733|FG005|Open-Label Treatment Period|Adverse Event|0
6189967|NCT01405898|9845755|FG000|Overall Study|Withdrawal by Subject|2
6189968|NCT01405898|9845756|FG001|Overall Study|Withdrawal by Subject|2
6189969|NCT01405911|9845765|FG000|Overall Study|Pre-treatment lab AE|0
6189970|NCT01405911|9845766|FG001|Overall Study|Pre-treatment lab AE|1
6189971|NCT01405911|9845767|FG002|Overall Study|Pre-treatment lab AE|0
6189972|NCT01405911|9845765|FG000|Overall Study|Lost to Follow-up|0
6189973|NCT01405911|9845766|FG001|Overall Study|Lost to Follow-up|1
6255025|NCT01989572|9946031|FG001|Overall Study|maximum dose reached|1
6255026|NCT01989572|9946032|FG002|Overall Study|maximum dose reached|0
6255027|NCT01989572|9946033|FG003|Overall Study|maximum dose reached|0
6255028|NCT01989572|9946034|FG004|Overall Study|maximum dose reached|1
6255029|NCT01989572|9946035|FG005|Overall Study|maximum dose reached|0
6255030|NCT01989572|9946030|FG000|Overall Study|unknown/not specify|3
6255031|NCT01989572|9946031|FG001|Overall Study|unknown/not specify|4
6255032|NCT01989572|9946032|FG002|Overall Study|unknown/not specify|1
6255033|NCT01989572|9946033|FG003|Overall Study|unknown/not specify|3
6255034|NCT01989572|9946034|FG004|Overall Study|unknown/not specify|3
6255035|NCT01989572|9946035|FG005|Overall Study|unknown/not specify|5
6255036|NCT01989572|9946030|FG000|Overall Study|not start protocol therapy|5
6255037|NCT01989572|9946031|FG001|Overall Study|not start protocol therapy|1
6255038|NCT01989572|9946032|FG002|Overall Study|not start protocol therapy|2
6255039|NCT01989572|9946033|FG003|Overall Study|not start protocol therapy|3
6255040|NCT01989572|9946034|FG004|Overall Study|not start protocol therapy|4
6255041|NCT01989572|9946035|FG005|Overall Study|not start protocol therapy|18
6255042|NCT01989572|9946030|FG000|Overall Study|alternative therapy|3
6255043|NCT01989572|9946031|FG001|Overall Study|alternative therapy|0
6255044|NCT01989572|9946032|FG002|Overall Study|alternative therapy|0
6255045|NCT01989572|9946033|FG003|Overall Study|alternative therapy|0
6255046|NCT01989572|9946034|FG004|Overall Study|alternative therapy|1
6255047|NCT01989572|9946035|FG005|Overall Study|alternative therapy|3
6255048|NCT01989689|9946055|FG000|Treatment Period 1 ( 3 Months)|Lost to Follow-up|0
6255049|NCT01989689|9946056|FG001|Treatment Period 1 ( 3 Months)|Lost to Follow-up|2
6255050|NCT01989689|9946055|FG000|Treatment Period 1 ( 3 Months)|Withdrawal by Subject|0
6255051|NCT01989689|9946056|FG001|Treatment Period 1 ( 3 Months)|Withdrawal by Subject|1
6255052|NCT01989754|9946066|FG000|Overall Study|Withdrawal by Subject|10
6255053|NCT01989754|9946067|FG001|Overall Study|Withdrawal by Subject|14
6255054|NCT01989754|9946066|FG000|Overall Study|Lost to Follow-up|28
6255055|NCT01989754|9946067|FG001|Overall Study|Lost to Follow-up|20
6255056|NCT01989754|9946066|FG000|Overall Study|Closed Site|1
6255057|NCT01989754|9946067|FG001|Overall Study|Closed Site|1
6271039|NCT02159365|9972532|FG000|Overall Study|Study drug toxicity|7
6189974|NCT01405911|9845767|FG002|Overall Study|Lost to Follow-up|0
6189975|NCT01405911|9845765|FG000|Overall Study|Protocol Violation|1
6189976|NCT01405911|9845766|FG001|Overall Study|Protocol Violation|0
6189977|NCT01405911|9845767|FG002|Overall Study|Protocol Violation|0
6189978|NCT01405911|9845765|FG000|Overall Study|Withdrawal by Subject|3
6189979|NCT01405911|9845766|FG001|Overall Study|Withdrawal by Subject|1
6189980|NCT01405911|9845767|FG002|Overall Study|Withdrawal by Subject|1
6189981|NCT01405924|9845775|FG000|Overall Study|Protocol Violation|8
6189982|NCT01405924|9845775|FG000|Overall Study|Missing/Incomplete Data|2
6189983|NCT01405950|9845792|FG000|Overall Study|Withdrawal by Subject|1
6189984|NCT01405950|9845793|FG001|Overall Study|Withdrawal by Subject|0
6189985|NCT01405950|9845794|FG002|Overall Study|Withdrawal by Subject|0
6189986|NCT01405950|9845795|FG003|Overall Study|Withdrawal by Subject|0
6189987|NCT01406015|9845805|FG000|Overall Study|Withdrawal by Subject|3
6189988|NCT01406015|9845806|FG001|Overall Study|Withdrawal by Subject|3
6189989|NCT01406574|9845842|FG000|Overall Study|Adverse Event|0
6189990|NCT01406574|9845843|FG001|Overall Study|Adverse Event|0
6189991|NCT01406574|9845844|FG002|Overall Study|Adverse Event|1
6189992|NCT01406574|9845845|FG003|Overall Study|Adverse Event|3
6189993|NCT01406574|9845842|FG000|Overall Study|Physician Decision|0
6189994|NCT01406574|9845843|FG001|Overall Study|Physician Decision|0
6189995|NCT01406574|9845844|FG002|Overall Study|Physician Decision|0
6189996|NCT01406574|9845845|FG003|Overall Study|Physician Decision|1
6189997|NCT01406574|9845842|FG000|Overall Study|Withdrawal by Subject|0
6189998|NCT01406574|9845843|FG001|Overall Study|Withdrawal by Subject|1
6189999|NCT01406574|9845844|FG002|Overall Study|Withdrawal by Subject|0
6190000|NCT01406574|9845845|FG003|Overall Study|Withdrawal by Subject|0
6190001|NCT01406574|9845842|FG000|Overall Study|Definite progression of primary disease|1
6190002|NCT01406574|9845843|FG001|Overall Study|Definite progression of primary disease|0
6190003|NCT01406574|9845844|FG002|Overall Study|Definite progression of primary disease|0
6190004|NCT01406574|9845845|FG003|Overall Study|Definite progression of primary disease|0
6190005|NCT01406652|9845858|FG000|Overall Study|Lost-to-follow-up|3
6190006|NCT01406652|9845859|FG001|Overall Study|Lost-to-follow-up|4
6190007|NCT01406652|9845858|FG000|Overall Study|Withdrawal by Subject|2
6190008|NCT01406652|9845859|FG001|Overall Study|Withdrawal by Subject|2
6190009|NCT01406652|9845858|FG000|Overall Study|Insufficient follow-up|5
6190010|NCT01406652|9845859|FG001|Overall Study|Insufficient follow-up|4
6190011|NCT01406652|9845858|FG000|Overall Study|Infection not sure|10
6190012|NCT01406652|9845859|FG001|Overall Study|Infection not sure|10
6190013|NCT01406717|9845869|FG000|Overall Study|Subject non-compliance|4
6271040|NCT02159365|9972532|FG000|Overall Study|Maximum clinical benefit|3
6271041|NCT02159365|9972532|FG000|Overall Study|Subject request to discontinue treatment|3
6271042|NCT02159365|9972532|FG000|Overall Study|Subject withdrew consent|3
6190014|NCT01406717|9845870|FG001|Overall Study|Subject non-compliance|3
6190015|NCT01406717|9845869|FG000|Overall Study|Protocol Violation|5
6190016|NCT01406717|9845870|FG001|Overall Study|Protocol Violation|1
6190017|NCT01406717|9845869|FG000|Overall Study|Lost to Follow-up|14
6190018|NCT01406717|9845870|FG001|Overall Study|Lost to Follow-up|8
6190019|NCT01406717|9845869|FG000|Overall Study|Withdrawal by Subject|19
6271043|NCT02159365|9972532|FG000|Overall Study|Death|1
6271044|NCT02159365|9972532|FG000|Overall Study|Lost to Follow-up|1
6271045|NCT02159469|9972536|FG000|Overall Study|Missing Completion status|1
6271046|NCT02159469|9972536|FG000|Overall Study|Adverse Event|5
6271047|NCT02159469|9972536|FG000|Overall Study|Non-compliance|2
6255058|NCT01990261|9946095|FG000|Overall Study|Death Before Treatment Start|2
6255059|NCT01990261|9946095|FG000|Overall Study|Death due to Disease Progression (PD)|10
6255060|NCT01990261|9946095|FG000|Overall Study|Death From other Causes|1
6255061|NCT01990261|9946095|FG000|Overall Study|Disease Progression (PD)|8
6255062|NCT01990261|9946095|FG000|Overall Study|PD Before Treatment Start|1
6255063|NCT01990261|9946095|FG000|Overall Study|Dossier not Approved|1
6255064|NCT01990261|9946095|FG000|Overall Study|Lost to Follow-up|2
6255065|NCT01990300|9946099|FG000|Overall Study|Case Report Forms Uncollected|89
6255066|NCT01990300|9946099|FG000|Overall Study|Protocol Deviation|53
6255067|NCT01990313|9946103|FG000|Overall Study|Lost to Follow-up|1
6255068|NCT01990339|9946107|FG000|Overall Study|Data Not Available|49
6255069|NCT01990339|9946107|FG000|Overall Study|Voluntary Withdrawal|1402
6255070|NCT01990339|9946107|FG000|Overall Study|Lost to Follow-up|861
6255071|NCT01990495|9946113|FG000|Overall Study|Physician Decision|5
6255072|NCT01990495|9946114|FG001|Overall Study|Physician Decision|4
6255073|NCT01990534|9946122|FG000|Overall Study|Death|22
6255074|NCT01990534|9946122|FG000|Overall Study|Progressive disease|3
6255075|NCT01990534|9946122|FG000|Overall Study|Protocol Violation|1
6255076|NCT01990534|9946122|FG000|Overall Study|Withdrawal of Informed Consent|2
6255077|NCT01990534|9946122|FG000|Overall Study|Symptomatic Deterioration|1
6255078|NCT01990534|9946122|FG000|Overall Study|Withdrawal by Subject|3
6255079|NCT01990534|9946122|FG000|Overall Study|Reason not Specified|2
6255080|NCT01990534|9946122|FG000|Overall Study|Lost to Follow-up|1
6255081|NCT01990560|9946126|FG000|Overall Study|Withdrawal by Subject|1
6255082|NCT01990573|9946133|FG000|Overall Study|Physician Decision|0
6255083|NCT01990573|9946134|FG001|Overall Study|Physician Decision|0
6255084|NCT01990573|9946135|FG002|Overall Study|Physician Decision|1
6255085|NCT01990612|9946145|FG000|Overall Study|Lost to Follow-up|2
6255086|NCT01990612|9946146|FG001|Overall Study|Lost to Follow-up|1
6255087|NCT01990612|9946145|FG000|Overall Study|Withdrawal by Subject|5
6255088|NCT01990612|9946146|FG001|Overall Study|Withdrawal by Subject|2
6255089|NCT01990664|9946154|FG000|Overall Study|Lost to Follow-up|2
6255090|NCT01990664|9946155|FG001|Overall Study|Lost to Follow-up|6
6255091|NCT01990664|9946154|FG000|Overall Study|Withdrawal by Subject|2
6255092|NCT01990664|9946155|FG001|Overall Study|Withdrawal by Subject|3
6255093|NCT01990664|9946154|FG000|Overall Study|Protocol Violation|1
6255094|NCT01990664|9946155|FG001|Overall Study|Protocol Violation|0
6255095|NCT01990664|9946154|FG000|Overall Study|Lens Discomfort|1
6255096|NCT01990664|9946155|FG001|Overall Study|Lens Discomfort|1
6255097|NCT01990664|9946154|FG000|Overall Study|Lens Handling Difficulties|1
6255098|NCT01990664|9946155|FG001|Overall Study|Lens Handling Difficulties|0
6255099|NCT01990664|9946154|FG000|Overall Study|Unsatisfactory Visual Response|0
6255100|NCT01990664|9946155|FG001|Overall Study|Unsatisfactory Visual Response|1
6255101|NCT01990742|9946181|FG000|Overall Study|Withdrawal by facility|407
6255102|NCT01990742|9946182|FG001|Overall Study|Withdrawal by facility|1083
6255103|NCT01990742|9946181|FG000|Overall Study|Facility closed|0
6255104|NCT01990742|9946182|FG001|Overall Study|Facility closed|270
6255105|NCT01990768|9946191|FG000|Intervention Started|Found to be ineligible|14
6255106|NCT01990768|9946192|FG001|Intervention Started|Found to be ineligible|13
6255107|NCT01990768|9946193|FG002|Intervention Started|Found to be ineligible|11
6255108|NCT01990768|9946191|FG000|Intervention Started|Study drug issue or kit malfunction|9
6255109|NCT01990768|9946192|FG001|Intervention Started|Study drug issue or kit malfunction|6
6255110|NCT01990768|9946193|FG002|Intervention Started|Study drug issue or kit malfunction|7
6255111|NCT01990768|9946191|FG000|Intervention Started|Patient became ineligible due to vitals|5
6255112|NCT01990768|9946192|FG001|Intervention Started|Patient became ineligible due to vitals|5
6255113|NCT01990768|9946193|FG002|Intervention Started|Patient became ineligible due to vitals|2
6255114|NCT01990768|9946191|FG000|Intervention Started|Not enough time for EMS to enroll|4
6255115|NCT01990768|9946192|FG001|Intervention Started|Not enough time for EMS to enroll|3
6255116|NCT01990768|9946193|FG002|Intervention Started|Not enough time for EMS to enroll|0
6255117|NCT01990768|9946191|FG000|Intervention Started|Patient care priority|1
6255118|NCT01990768|9946192|FG001|Intervention Started|Patient care priority|2
6255119|NCT01990768|9946193|FG002|Intervention Started|Patient care priority|3
6255120|NCT01990768|9946191|FG000|Intervention Started|IV lost|2
6255121|NCT01990768|9946192|FG001|Intervention Started|IV lost|2
6255122|NCT01990768|9946193|FG002|Intervention Started|IV lost|2
6255123|NCT01990768|9946191|FG000|Intervention Started|Required CPR|1
6255124|NCT01990768|9946192|FG001|Intervention Started|Required CPR|1
6255125|NCT01990768|9946193|FG002|Intervention Started|Required CPR|0
6255126|NCT01990768|9946191|FG000|Intervention Started|Seizure or hx of seizure|0
6255127|NCT01990768|9946192|FG001|Intervention Started|Seizure or hx of seizure|0
6255128|NCT01990768|9946193|FG002|Intervention Started|Seizure or hx of seizure|2
6255129|NCT01990768|9946191|FG000|Intervention Started|Discovered to be pregnant|0
6255130|NCT01990768|9946192|FG001|Intervention Started|Discovered to be pregnant|1
6255131|NCT01990768|9946193|FG002|Intervention Started|Discovered to be pregnant|0
6255132|NCT01990768|9946191|FG000|Prehospital Study Drug Infusion|Protocol non-compliance|4
6255133|NCT01990768|9946192|FG001|Prehospital Study Drug Infusion|Protocol non-compliance|11
6255134|NCT01990768|9946193|FG002|Prehospital Study Drug Infusion|Protocol non-compliance|10
6255135|NCT01990768|9946191|FG000|Prehospital Study Drug Infusion|Seizure or concern for seizure|4
6255136|NCT01990768|9946192|FG001|Prehospital Study Drug Infusion|Seizure or concern for seizure|3
6255137|NCT01990768|9946193|FG002|Prehospital Study Drug Infusion|Seizure or concern for seizure|4
6255138|NCT01990768|9946191|FG000|Prehospital Study Drug Infusion|Required CPR|2
6255139|NCT01990768|9946192|FG001|Prehospital Study Drug Infusion|Required CPR|6
6255140|NCT01990768|9946193|FG002|Prehospital Study Drug Infusion|Required CPR|0
6255141|NCT01990768|9946191|FG000|Prehospital Study Drug Infusion|Other safety concern|2
6255142|NCT01990768|9946192|FG001|Prehospital Study Drug Infusion|Other safety concern|1
6255143|NCT01990768|9946193|FG002|Prehospital Study Drug Infusion|Other safety concern|1
6255144|NCT01990768|9946191|FG000|Prehospital Study Drug Infusion|Death|3
6255145|NCT01990768|9946192|FG001|Prehospital Study Drug Infusion|Death|1
6255146|NCT01990768|9946193|FG002|Prehospital Study Drug Infusion|Death|1
6255147|NCT01990768|9946191|FG000|Prehospital Study Drug Infusion|Discharged|2
6255148|NCT01990768|9946192|FG001|Prehospital Study Drug Infusion|Discharged|1
6255149|NCT01990768|9946193|FG002|Prehospital Study Drug Infusion|Discharged|0
6255150|NCT01990768|9946191|FG000|Prehospital Study Drug Infusion|Withdrawal by Subject|1
6255151|NCT01990768|9946192|FG001|Prehospital Study Drug Infusion|Withdrawal by Subject|0
6255152|NCT01990768|9946193|FG002|Prehospital Study Drug Infusion|Withdrawal by Subject|0
6255153|NCT01990768|9946191|FG000|Prehospital Study Drug Infusion|Emergency unblinding|0
6255154|NCT01990768|9946192|FG001|Prehospital Study Drug Infusion|Emergency unblinding|0
6255155|NCT01990768|9946193|FG002|Prehospital Study Drug Infusion|Emergency unblinding|1
6255156|NCT01990768|9946191|FG000|Prehospital Study Drug Infusion|Unknown if completed|1
6255157|NCT01990768|9946192|FG001|Prehospital Study Drug Infusion|Unknown if completed|4
6255158|NCT01990768|9946193|FG002|Prehospital Study Drug Infusion|Unknown if completed|2
6255159|NCT01990768|9946191|FG000|In-Hospital Study Drug Infusion|Discharged|19
6255160|NCT01990768|9946192|FG001|In-Hospital Study Drug Infusion|Discharged|18
6255161|NCT01990768|9946193|FG002|In-Hospital Study Drug Infusion|Discharged|13
6255162|NCT01990768|9946191|FG000|In-Hospital Study Drug Infusion|Protocol non-compliance|14
6255163|NCT01990768|9946192|FG001|In-Hospital Study Drug Infusion|Protocol non-compliance|17
6255164|NCT01990768|9946193|FG002|In-Hospital Study Drug Infusion|Protocol non-compliance|10
6255165|NCT01990768|9946191|FG000|In-Hospital Study Drug Infusion|Withdrawal by Subject|13
6255166|NCT01990768|9946192|FG001|In-Hospital Study Drug Infusion|Withdrawal by Subject|7
6255167|NCT01990768|9946193|FG002|In-Hospital Study Drug Infusion|Withdrawal by Subject|12
6255168|NCT01990768|9946191|FG000|In-Hospital Study Drug Infusion|Death or comfort care|12
6255169|NCT01990768|9946192|FG001|In-Hospital Study Drug Infusion|Death or comfort care|11
6255170|NCT01990768|9946193|FG002|In-Hospital Study Drug Infusion|Death or comfort care|6
6255171|NCT01990768|9946191|FG000|In-Hospital Study Drug Infusion|Emergency unblinding|11
6255172|NCT01990768|9946192|FG001|In-Hospital Study Drug Infusion|Emergency unblinding|4
6255173|NCT01990768|9946193|FG002|In-Hospital Study Drug Infusion|Emergency unblinding|7
6255174|NCT01990768|9946191|FG000|In-Hospital Study Drug Infusion|Seizure or concern for seizure|8
6255175|NCT01990768|9946192|FG001|In-Hospital Study Drug Infusion|Seizure or concern for seizure|9
6043661|NCT00391222|9642349|FG002|Period III (Double-Blind Treatment)|Adverse Event|4
6043662|NCT00391222|9642350|FG003|Period III (Double-Blind Treatment)|Adverse Event|0
6043663|NCT00391222|9642347|FG000|Period III (Double-Blind Treatment)|Pregnancy|0
6043664|NCT00391222|9642348|FG001|Period III (Double-Blind Treatment)|Pregnancy|2
6043665|NCT00391222|9642349|FG002|Period III (Double-Blind Treatment)|Pregnancy|0
6043666|NCT00391222|9642350|FG003|Period III (Double-Blind Treatment)|Pregnancy|0
6043667|NCT00391222|9642347|FG000|Period III (Double-Blind Treatment)|Study Medication Non-compliant|0
6043668|NCT00391222|9642348|FG001|Period III (Double-Blind Treatment)|Study Medication Non-compliant|1
6043669|NCT00391222|9642349|FG002|Period III (Double-Blind Treatment)|Study Medication Non-compliant|3
6043670|NCT00391222|9642350|FG003|Period III (Double-Blind Treatment)|Study Medication Non-compliant|0
6043671|NCT00391222|9642347|FG000|Period III (Double-Blind Treatment)|Other|6
6043672|NCT00391222|9642348|FG001|Period III (Double-Blind Treatment)|Other|1
6043673|NCT00391222|9642349|FG002|Period III (Double-Blind Treatment)|Other|6
6043674|NCT00391222|9642350|FG003|Period III (Double-Blind Treatment)|Other|0
6043675|NCT00391274|9642362|FG000|Overall Study|Death Due to Study Disease|55
6043676|NCT00391274|9642363|FG001|Overall Study|Death Due to Study Disease|45
6043677|NCT00391274|9642362|FG000|Overall Study|Lost to Follow-up|0
6043678|NCT00391274|9642363|FG001|Overall Study|Lost to Follow-up|3
6043679|NCT00391274|9642362|FG000|Overall Study|Physician Decision|4
6043680|NCT00391274|9642363|FG001|Overall Study|Physician Decision|2
6043681|NCT00391274|9642362|FG000|Overall Study|Withdrawal by Subject|0
6043682|NCT00391274|9642363|FG001|Overall Study|Withdrawal by Subject|3
6043683|NCT00391274|9642362|FG000|Overall Study|Death Due to Adverse Event|1
6043684|NCT00391274|9642363|FG001|Overall Study|Death Due to Adverse Event|3
6043685|NCT00391274|9642362|FG000|Overall Study|Death Due to Indeterminate Cause|1
6043686|NCT00391274|9642363|FG001|Overall Study|Death Due to Indeterminate Cause|0
6043687|NCT00391274|9642362|FG000|Overall Study|Death Not Study Related|0
6043688|NCT00391274|9642363|FG001|Overall Study|Death Not Study Related|1
6043689|NCT00391391|9642373|FG000|Overall Study|Adverse Event|0
6043690|NCT00391391|9642374|FG001|Overall Study|Adverse Event|0
6043691|NCT00391391|9642375|FG002|Overall Study|Adverse Event|0
6043692|NCT00391391|9642376|FG003|Overall Study|Adverse Event|1
6043693|NCT00391391|9642373|FG000|Overall Study|Lost to Follow-up|1
6043694|NCT00391391|9642374|FG001|Overall Study|Lost to Follow-up|3
6043695|NCT00391391|9642375|FG002|Overall Study|Lost to Follow-up|7
6255176|NCT01990768|9946193|FG002|In-Hospital Study Drug Infusion|Seizure or concern for seizure|17
6255177|NCT01990768|9946191|FG000|In-Hospital Study Drug Infusion|CVA/thrombotic event or concern for one|5
6255178|NCT01990768|9946192|FG001|In-Hospital Study Drug Infusion|CVA/thrombotic event or concern for one|5
6255179|NCT01990768|9946193|FG002|In-Hospital Study Drug Infusion|CVA/thrombotic event or concern for one|4
6043696|NCT00391391|9642376|FG003|Overall Study|Lost to Follow-up|4
6043697|NCT00391391|9642373|FG000|Overall Study|Protocol Violation|2
6043698|NCT00391391|9642374|FG001|Overall Study|Protocol Violation|3
6043699|NCT00391391|9642375|FG002|Overall Study|Protocol Violation|6
6043700|NCT00391391|9642376|FG003|Overall Study|Protocol Violation|7
6043701|NCT00391391|9642373|FG000|Overall Study|Withdrawal by Subject|6
6043702|NCT00391391|9642374|FG001|Overall Study|Withdrawal by Subject|4
6043703|NCT00391391|9642375|FG002|Overall Study|Withdrawal by Subject|10
6043704|NCT00391391|9642376|FG003|Overall Study|Withdrawal by Subject|7
6043705|NCT00391586|9642408|FG000|Overall Study|Progressive disease|13
6043706|NCT00391586|9642408|FG000|Overall Study|Adverse Event|5
6043707|NCT00391586|9642408|FG000|Overall Study|Physician Decision|2
6043708|NCT00391586|9642408|FG000|Overall Study|Death|4
6043709|NCT00391625|9642423|FG000|Month 14|Withdrawal by Subject|1
6043710|NCT00391625|9642423|FG000|Month 50|Physician Decision|1
6043711|NCT00391768|9642470|FG000|Overall Study|Withdrawal by Subject|0
6043712|NCT00391768|9642471|FG001|Overall Study|Withdrawal by Subject|0
6043713|NCT00391768|9642472|FG002|Overall Study|Withdrawal by Subject|1
6043714|NCT00391768|9642473|FG003|Overall Study|Withdrawal by Subject|0
6043715|NCT00391768|9642474|FG004|Overall Study|Withdrawal by Subject|0
6043716|NCT00391768|9642475|FG005|Overall Study|Withdrawal by Subject|1
6043717|NCT00391768|9642476|FG006|Overall Study|Withdrawal by Subject|1
6043718|NCT00391768|9642470|FG000|Overall Study|Lost to Follow-up|0
6043719|NCT00391768|9642471|FG001|Overall Study|Lost to Follow-up|0
6043720|NCT00391768|9642472|FG002|Overall Study|Lost to Follow-up|0
6043721|NCT00391768|9642473|FG003|Overall Study|Lost to Follow-up|1
6043722|NCT00391768|9642474|FG004|Overall Study|Lost to Follow-up|2
6043723|NCT00391768|9642475|FG005|Overall Study|Lost to Follow-up|2
6043724|NCT00391768|9642476|FG006|Overall Study|Lost to Follow-up|3
6043725|NCT00391807|9642510|FG000|Overall Study|Did not receive study medication|23
6043726|NCT00391807|9642510|FG000|Overall Study|Adverse Event|177
6043727|NCT00391807|9642510|FG000|Overall Study|Pregnancy|25
6043728|NCT00391807|9642510|FG000|Overall Study|Lost to Follow-up|227
6043729|NCT00391807|9642510|FG000|Overall Study|Withdrawal by Subject|147
6043730|NCT00391807|9642510|FG000|Overall Study|Protocol Violation|20
6043731|NCT00391807|9642510|FG000|Overall Study|Various|96
6043732|NCT00391846|9642516|FG000|Overall Study|Adverse Event|4
6043733|NCT00391846|9642517|FG001|Overall Study|Adverse Event|1
6190020|NCT01406717|9845870|FG001|Overall Study|Withdrawal by Subject|15
6190021|NCT01406717|9845869|FG000|Overall Study|Adverse Event|1
6190022|NCT01406717|9845870|FG001|Overall Study|Adverse Event|2
6190023|NCT01406717|9845869|FG000|Overall Study|Lack of Efficacy|0
6190024|NCT01406717|9845870|FG001|Overall Study|Lack of Efficacy|1
6190025|NCT01406717|9845869|FG000|Overall Study|Non-completion of visit activity|0
6190026|NCT01406717|9845870|FG001|Overall Study|Non-completion of visit activity|1
6190027|NCT01406795|9845886|FG000|Overall Study|Withdrawal by Subject|1
6190028|NCT01406873|9845892|FG000|Overall Study|Withdrawal by Subject|1
6190029|NCT01406873|9845893|FG001|Overall Study|Withdrawal by Subject|1
6190030|NCT01406938|9845911|FG000|Induction Period|Subject/guardian decision|6
6190031|NCT01406938|9845912|FG001|Induction Period|Subject/guardian decision|8
6190032|NCT01406938|9845913|FG002|Induction Period|Subject/guardian decision|0
6190033|NCT01406938|9845914|FG003|Induction Period|Subject/guardian decision|0
6190034|NCT01406938|9845915|FG004|Induction Period|Subject/guardian decision|0
6190035|NCT01406938|9845916|FG005|Induction Period|Subject/guardian decision|0
6190036|NCT01406938|9845911|FG000|Induction Period|Protocol deviation|1
6190037|NCT01406938|9845912|FG001|Induction Period|Protocol deviation|0
6190038|NCT01406938|9845913|FG002|Induction Period|Protocol deviation|0
6190039|NCT01406938|9845914|FG003|Induction Period|Protocol deviation|0
6190040|NCT01406938|9845915|FG004|Induction Period|Protocol deviation|0
6190041|NCT01406938|9845916|FG005|Induction Period|Protocol deviation|0
6190042|NCT01406938|9845911|FG000|Induction Period|Adverse Event|8
6190043|NCT01406938|9845912|FG001|Induction Period|Adverse Event|9
6190044|NCT01406938|9845913|FG002|Induction Period|Adverse Event|0
6190045|NCT01406938|9845914|FG003|Induction Period|Adverse Event|0
6190046|NCT01406938|9845915|FG004|Induction Period|Adverse Event|0
6190047|NCT01406938|9845916|FG005|Induction Period|Adverse Event|0
6190048|NCT01406938|9845911|FG000|Induction Period|Lack of Efficacy|1
6190049|NCT01406938|9845912|FG001|Induction Period|Lack of Efficacy|0
6190050|NCT01406938|9845913|FG002|Induction Period|Lack of Efficacy|0
6190051|NCT01406938|9845914|FG003|Induction Period|Lack of Efficacy|0
6190052|NCT01406938|9845915|FG004|Induction Period|Lack of Efficacy|0
6190053|NCT01406938|9845916|FG005|Induction Period|Lack of Efficacy|0
6190054|NCT01406938|9845911|FG000|Induction Period|Lost to Follow-up|2
6190055|NCT01406938|9845912|FG001|Induction Period|Lost to Follow-up|3
6043734|NCT00391846|9642516|FG000|Overall Study|Did not meet the required elig. crit|2
6043735|NCT00391846|9642517|FG001|Overall Study|Did not meet the required elig. crit|2
6043736|NCT00391846|9642516|FG000|Overall Study|Withdrawal by Subject|2
6043737|NCT00391846|9642517|FG001|Overall Study|Withdrawal by Subject|3
6255180|NCT01990768|9946191|FG000|In-Hospital Study Drug Infusion|Required CPR|3
6255181|NCT01990768|9946192|FG001|In-Hospital Study Drug Infusion|Required CPR|7
6255182|NCT01990768|9946193|FG002|In-Hospital Study Drug Infusion|Required CPR|1
6255183|NCT01990768|9946191|FG000|In-Hospital Study Drug Infusion|Other safety concern|4
6255184|NCT01990768|9946192|FG001|In-Hospital Study Drug Infusion|Other safety concern|2
6255185|NCT01990768|9946193|FG002|In-Hospital Study Drug Infusion|Other safety concern|3
6255186|NCT01990768|9946191|FG000|In-Hospital Study Drug Infusion|Taken into police custody|4
6255187|NCT01990768|9946192|FG001|In-Hospital Study Drug Infusion|Taken into police custody|0
6255188|NCT01990768|9946193|FG002|In-Hospital Study Drug Infusion|Taken into police custody|3
6255189|NCT01990768|9946191|FG000|In-Hospital Study Drug Infusion|Found not to be injured|1
6255190|NCT01990768|9946192|FG001|In-Hospital Study Drug Infusion|Found not to be injured|1
6255191|NCT01990768|9946193|FG002|In-Hospital Study Drug Infusion|Found not to be injured|1
6255192|NCT01990768|9946191|FG000|In-Hospital Study Drug Infusion|Transfer to non-participating facility|1
6255193|NCT01990768|9946192|FG001|In-Hospital Study Drug Infusion|Transfer to non-participating facility|1
6255194|NCT01990768|9946193|FG002|In-Hospital Study Drug Infusion|Transfer to non-participating facility|0
6255195|NCT01990768|9946191|FG000|In-Hospital Study Drug Infusion|Other procoagulant administered|0
6255196|NCT01990768|9946192|FG001|In-Hospital Study Drug Infusion|Other procoagulant administered|1
6255197|NCT01990768|9946193|FG002|In-Hospital Study Drug Infusion|Other procoagulant administered|2
6255198|NCT01990768|9946191|FG000|In-Hospital Study Drug Infusion|Unknown if completed|0
6255199|NCT01990768|9946192|FG001|In-Hospital Study Drug Infusion|Unknown if completed|0
6255200|NCT01990768|9946193|FG002|In-Hospital Study Drug Infusion|Unknown if completed|1
6255201|NCT01990768|9946191|FG000|6-Month Follow-up|Withdrawal by Subject|25
6255202|NCT01990768|9946192|FG001|6-Month Follow-up|Withdrawal by Subject|25
6255203|NCT01990768|9946193|FG002|6-Month Follow-up|Withdrawal by Subject|26
6255204|NCT01990768|9946191|FG000|6-Month Follow-up|Calls unreturned or refused contact|4
6255205|NCT01990768|9946192|FG001|6-Month Follow-up|Calls unreturned or refused contact|15
6255206|NCT01990768|9946193|FG002|6-Month Follow-up|Calls unreturned or refused contact|20
6255207|NCT01990768|9946191|FG000|6-Month Follow-up|No contact information|5
6255208|NCT01990768|9946192|FG001|6-Month Follow-up|No contact information|6
6255209|NCT01990768|9946193|FG002|6-Month Follow-up|No contact information|5
6255210|NCT01990768|9946191|FG000|6-Month Follow-up|Homeless|4
6255211|NCT01990768|9946192|FG001|6-Month Follow-up|Homeless|3
6255212|NCT01990768|9946193|FG002|6-Month Follow-up|Homeless|6
6255213|NCT01990768|9946191|FG000|6-Month Follow-up|Prisoner at time of enrollment|0
6255214|NCT01990768|9946192|FG001|6-Month Follow-up|Prisoner at time of enrollment|0
6255215|NCT01990768|9946193|FG002|6-Month Follow-up|Prisoner at time of enrollment|1
6255216|NCT01990768|9946191|FG000|6-Month Follow-up|Prisoner at time of follow-up|0
6255217|NCT01990768|9946192|FG001|6-Month Follow-up|Prisoner at time of follow-up|2
6255218|NCT01990768|9946193|FG002|6-Month Follow-up|Prisoner at time of follow-up|0
6255219|NCT01990768|9946191|FG000|6-Month Follow-up|Patient at psychiatric hospital|1
6255220|NCT01990768|9946192|FG001|6-Month Follow-up|Patient at psychiatric hospital|0
6255221|NCT01990768|9946193|FG002|6-Month Follow-up|Patient at psychiatric hospital|0
6255222|NCT01990859|9946298|FG000|Treatment (4 Doses Over 12 Weeks)|Progressive Disease|5
6255223|NCT01990859|9946298|FG000|Week 12 to Week 24 Post Dosing Follow Up|Disease Progression|17
6255224|NCT01990950|9946307|FG000|Overall Study|Death|3
6255225|NCT01990950|9946307|FG000|Overall Study|Lost to Follow-up|2
6255226|NCT01990950|9946307|FG000|Overall Study|Withdrawal by Subject|6
6255227|NCT01991197|9946313|FG000|Overall Study|Lost to Follow-up|1
6255228|NCT01991197|9946314|FG001|Overall Study|Lost to Follow-up|1
6255229|NCT01991197|9946313|FG000|Overall Study|Physician Decision|0
6255230|NCT01991197|9946314|FG001|Overall Study|Physician Decision|2
6255231|NCT01991197|9946313|FG000|Overall Study|Withdrawal by Subject|2
6190056|NCT01406938|9845913|FG002|Induction Period|Lost to Follow-up|0
6190057|NCT01406938|9845914|FG003|Induction Period|Lost to Follow-up|0
6190058|NCT01406938|9845915|FG004|Induction Period|Lost to Follow-up|0
6190059|NCT01406938|9845916|FG005|Induction Period|Lost to Follow-up|0
6190060|NCT01406938|9845911|FG000|Maintenance Period|Adverse Event|0
6190061|NCT01406938|9845912|FG001|Maintenance Period|Adverse Event|0
6190062|NCT01406938|9845913|FG002|Maintenance Period|Adverse Event|2
6190063|NCT01406938|9845914|FG003|Maintenance Period|Adverse Event|8
6190064|NCT01406938|9845915|FG004|Maintenance Period|Adverse Event|4
6190065|NCT01406938|9845916|FG005|Maintenance Period|Adverse Event|2
6190066|NCT01406938|9845911|FG000|Maintenance Period|Death|0
6190067|NCT01406938|9845912|FG001|Maintenance Period|Death|0
6190068|NCT01406938|9845913|FG002|Maintenance Period|Death|0
6190069|NCT01406938|9845914|FG003|Maintenance Period|Death|0
6190070|NCT01406938|9845915|FG004|Maintenance Period|Death|1
6190071|NCT01406938|9845916|FG005|Maintenance Period|Death|0
6190072|NCT01406938|9845911|FG000|Maintenance Period|Subject/guardian decision|0
6190073|NCT01406938|9845912|FG001|Maintenance Period|Subject/guardian decision|0
6190074|NCT01406938|9845913|FG002|Maintenance Period|Subject/guardian decision|11
6255232|NCT01991197|9946314|FG001|Overall Study|Withdrawal by Subject|0
6255233|NCT01991314|9946327|FG000|Overall Study|Adverse Event|5
6255234|NCT01991314|9946328|FG001|Overall Study|Adverse Event|1
6255235|NCT01991314|9946327|FG000|Overall Study|Lost to Follow-up|6
6255236|NCT01991314|9946328|FG001|Overall Study|Lost to Follow-up|10
6255237|NCT01991470|9946334|FG000|Enlite 1 Period|Withdrawal by Subject|18
6190075|NCT01406938|9845914|FG003|Maintenance Period|Subject/guardian decision|7
6255238|NCT01991470|9946334|FG000|Enlite 1 Period|Adverse Event|1
6255239|NCT01991470|9946334|FG000|Enlite 1 Period|Inclusion/Exclusion not met|1
6255240|NCT01991470|9946334|FG000|Enlite 3 Period|Lost to Follow-up|1
6255241|NCT01991470|9946334|FG000|Enlite 3 Period|Physician Decision|2
6255242|NCT01991470|9946334|FG000|Enlite 3 Period|Physician Decision|8
6255243|NCT01991470|9946334|FG000|Enlite 3 Period|DUE TO MULTIPLE SENSOR ISSUES|1
6255244|NCT01991483|9946350|FG000|Dose Level 600 mg|Withdrawal by Subject|0
6255245|NCT01991483|9946351|FG001|Dose Level 600 mg|Withdrawal by Subject|0
6255246|NCT01991483|9946352|FG002|Dose Level 600 mg|Withdrawal by Subject|1
6255247|NCT01991483|9946353|FG003|Dose Level 600 mg|Withdrawal by Subject|0
6255248|NCT01991483|9946350|FG000|Dose Level 600 mg|Physician Decision|0
6255249|NCT01991483|9946351|FG001|Dose Level 600 mg|Physician Decision|0
6255250|NCT01991483|9946352|FG002|Dose Level 600 mg|Physician Decision|1
6255251|NCT01991483|9946353|FG003|Dose Level 600 mg|Physician Decision|0
6255252|NCT01991483|9946350|FG000|Dose Level 1000 mg|Protocol Violation|0
6255253|NCT01991483|9946351|FG001|Dose Level 1000 mg|Protocol Violation|0
6255254|NCT01991483|9946352|FG002|Dose Level 1000 mg|Protocol Violation|0
6255255|NCT01991483|9946353|FG003|Dose Level 1000 mg|Protocol Violation|1
6255256|NCT01991743|9946383|FG000|Overall Study|external cephalic version not performed|0
6255257|NCT01991743|9946384|FG001|Overall Study|external cephalic version not performed|0
6255258|NCT01991743|9946385|FG002|Overall Study|external cephalic version not performed|1
6255259|NCT01991743|9946386|FG003|Overall Study|external cephalic version not performed|0
6255260|NCT01991795|9946398|FG000|Overall Study|Lost to Follow-up|6
6255261|NCT01991795|9946399|FG001|Overall Study|Lost to Follow-up|4
6255262|NCT01991795|9946398|FG000|Overall Study|Withdrawal by Subject|117
6255263|NCT01991795|9946399|FG001|Overall Study|Withdrawal by Subject|94
6255264|NCT01991795|9946398|FG000|Overall Study|Site prematurely closed by sponsor|26
6255265|NCT01991795|9946399|FG001|Overall Study|Site prematurely closed by sponsor|25
6255266|NCT01991977|9946429|FG000|Overall Study|Withdrew prior to receiving treatment|7
6255267|NCT01991977|9946429|FG000|Overall Study|Withdrew after start of treatment|5
6255268|NCT01992094|9946458|FG000|Overall Study|ADMINISTRATIVE REASON|6
6255269|NCT01992094|9946459|FG001|Overall Study|ADMINISTRATIVE REASON|7
6255270|NCT01992094|9946460|FG002|Overall Study|ADMINISTRATIVE REASON|1
6255271|NCT01992094|9946458|FG000|Overall Study|Adverse Event|1
6255272|NCT01992094|9946459|FG001|Overall Study|Adverse Event|0
6255273|NCT01992094|9946460|FG002|Overall Study|Adverse Event|0
6255274|NCT01992094|9946458|FG000|Overall Study|Death|5
6255275|NCT01992094|9946459|FG001|Overall Study|Death|5
6255276|NCT01992094|9946460|FG002|Overall Study|Death|2
6255277|NCT01992094|9946458|FG000|Overall Study|Lost to Follow-up|26
6255278|NCT01992094|9946459|FG001|Overall Study|Lost to Follow-up|9
6255279|NCT01992094|9946460|FG002|Overall Study|Lost to Follow-up|13
6255280|NCT01992094|9946458|FG000|Overall Study|OTHER|4
6255281|NCT01992094|9946459|FG001|Overall Study|OTHER|0
6255282|NCT01992094|9946460|FG002|Overall Study|OTHER|0
6255283|NCT01992094|9946458|FG000|Overall Study|Protocol Violation|1
6255284|NCT01992094|9946459|FG001|Overall Study|Protocol Violation|0
6255285|NCT01992094|9946460|FG002|Overall Study|Protocol Violation|1
6255286|NCT01992094|9946458|FG000|Overall Study|Withdrawal by Subject|7
6255287|NCT01992094|9946459|FG001|Overall Study|Withdrawal by Subject|3
6255288|NCT01992094|9946460|FG002|Overall Study|Withdrawal by Subject|4
6255289|NCT01992107|9946487|FG000|Overall Study|Administrative reasons|2
6255290|NCT01992107|9946488|FG001|Overall Study|Administrative reasons|0
6255291|NCT01992107|9946489|FG002|Overall Study|Administrative reasons|0
6255292|NCT01992107|9946487|FG000|Overall Study|Adverse Event|0
6255293|NCT01992107|9946488|FG001|Overall Study|Adverse Event|1
6255294|NCT01992107|9946489|FG002|Overall Study|Adverse Event|0
6255295|NCT01992107|9946487|FG000|Overall Study|Lost to Follow-up|46
6255296|NCT01992107|9946488|FG001|Overall Study|Lost to Follow-up|22
6255297|NCT01992107|9946489|FG002|Overall Study|Lost to Follow-up|26
6255298|NCT01992107|9946487|FG000|Overall Study|noncompliance and were unavailable|7
6255299|NCT01992107|9946488|FG001|Overall Study|noncompliance and were unavailable|3
6255300|NCT01992107|9946489|FG002|Overall Study|noncompliance and were unavailable|2
6255301|NCT01992107|9946487|FG000|Overall Study|Withdrawal by Subject|13
6255302|NCT01992107|9946488|FG001|Overall Study|Withdrawal by Subject|7
6255303|NCT01992107|9946489|FG002|Overall Study|Withdrawal by Subject|8
6255304|NCT01992159|9946518|FG000|Overall Study|Withdrawal by Subject|4
6255305|NCT01992159|9946519|FG001|Overall Study|Withdrawal by Subject|7
6255306|NCT01992159|9946520|FG002|Overall Study|Withdrawal by Subject|0
6255307|NCT01992159|9946521|FG003|Overall Study|Withdrawal by Subject|3
6255308|NCT01992159|9946518|FG000|Overall Study|Adverse Event|0
6255309|NCT01992159|9946519|FG001|Overall Study|Adverse Event|1
6255310|NCT01992159|9946520|FG002|Overall Study|Adverse Event|0
6255311|NCT01992159|9946521|FG003|Overall Study|Adverse Event|1
6255312|NCT01992159|9946518|FG000|Overall Study|Death|0
6255313|NCT01992159|9946519|FG001|Overall Study|Death|0
6255314|NCT01992159|9946520|FG002|Overall Study|Death|1
6255315|NCT01992159|9946521|FG003|Overall Study|Death|0
6255316|NCT01992536|9946586|FG000|Overall Study|Administrative Reason|0
6255317|NCT01992536|9946587|FG001|Overall Study|Administrative Reason|0
6255318|NCT01992536|9946588|FG002|Overall Study|Administrative Reason|0
6255319|NCT01992536|9946589|FG003|Overall Study|Administrative Reason|0
6255320|NCT01992536|9946590|FG004|Overall Study|Administrative Reason|0
6255321|NCT01992536|9946591|FG005|Overall Study|Administrative Reason|0
6255322|NCT01992536|9946592|FG006|Overall Study|Administrative Reason|7
6255323|NCT01992536|9946593|FG007|Overall Study|Administrative Reason|0
6255324|NCT01992536|9946594|FG008|Overall Study|Administrative Reason|0
6255325|NCT01992536|9946595|FG009|Overall Study|Administrative Reason|0
6255326|NCT01992536|9946586|FG000|Overall Study|Lost to Follow-up|4
6255327|NCT01992536|9946587|FG001|Overall Study|Lost to Follow-up|2
6255328|NCT01992536|9946588|FG002|Overall Study|Lost to Follow-up|1
6255329|NCT01992536|9946589|FG003|Overall Study|Lost to Follow-up|0
6255330|NCT01992536|9946590|FG004|Overall Study|Lost to Follow-up|0
6190076|NCT01406938|9845915|FG004|Maintenance Period|Subject/guardian decision|10
6190077|NCT01406938|9845916|FG005|Maintenance Period|Subject/guardian decision|7
6190078|NCT01406938|9845911|FG000|Maintenance Period|Protocol Violation|0
6190079|NCT01406938|9845912|FG001|Maintenance Period|Protocol Violation|0
6190080|NCT01406938|9845913|FG002|Maintenance Period|Protocol Violation|2
6190081|NCT01406938|9845914|FG003|Maintenance Period|Protocol Violation|2
6190082|NCT01406938|9845915|FG004|Maintenance Period|Protocol Violation|2
6190083|NCT01406938|9845916|FG005|Maintenance Period|Protocol Violation|2
6190084|NCT01406938|9845911|FG000|Maintenance Period|Pregnancy|0
6190085|NCT01406938|9845912|FG001|Maintenance Period|Pregnancy|0
6190086|NCT01406938|9845913|FG002|Maintenance Period|Pregnancy|0
6190087|NCT01406938|9845914|FG003|Maintenance Period|Pregnancy|0
6190088|NCT01406938|9845915|FG004|Maintenance Period|Pregnancy|1
6190089|NCT01406938|9845916|FG005|Maintenance Period|Pregnancy|0
6190090|NCT01406938|9845911|FG000|Maintenance Period|Lost to Follow-up|0
6190091|NCT01406938|9845912|FG001|Maintenance Period|Lost to Follow-up|0
6190092|NCT01406938|9845913|FG002|Maintenance Period|Lost to Follow-up|0
6190093|NCT01406938|9845914|FG003|Maintenance Period|Lost to Follow-up|0
6190094|NCT01406938|9845915|FG004|Maintenance Period|Lost to Follow-up|4
6190095|NCT01406938|9845916|FG005|Maintenance Period|Lost to Follow-up|0
6190096|NCT01406938|9845911|FG000|Maintenance Period|Lack of Efficacy|0
6190097|NCT01406938|9845912|FG001|Maintenance Period|Lack of Efficacy|0
6190098|NCT01406938|9845913|FG002|Maintenance Period|Lack of Efficacy|2
6190099|NCT01406938|9845914|FG003|Maintenance Period|Lack of Efficacy|1
6190100|NCT01406938|9845915|FG004|Maintenance Period|Lack of Efficacy|3
6190101|NCT01406938|9845916|FG005|Maintenance Period|Lack of Efficacy|5
6190102|NCT01406938|9845911|FG000|Follow up|Lack of Efficacy|3
6190103|NCT01406938|9845912|FG001|Follow up|Lack of Efficacy|2
6190104|NCT01406938|9845913|FG002|Follow up|Lack of Efficacy|1
6190105|NCT01406938|9845914|FG003|Follow up|Lack of Efficacy|0
6190106|NCT01406938|9845915|FG004|Follow up|Lack of Efficacy|0
6190107|NCT01406938|9845916|FG005|Follow up|Lack of Efficacy|0
6190108|NCT01406938|9845911|FG000|Follow up|Patient/guardian decision|4
6190109|NCT01406938|9845912|FG001|Follow up|Patient/guardian decision|2
6190110|NCT01406938|9845913|FG002|Follow up|Patient/guardian decision|4
6190111|NCT01406938|9845914|FG003|Follow up|Patient/guardian decision|2
6190112|NCT01406938|9845915|FG004|Follow up|Patient/guardian decision|4
6190113|NCT01406938|9845916|FG005|Follow up|Patient/guardian decision|1
6190114|NCT01406938|9845911|FG000|Follow up|Protocol Violation|0
6190115|NCT01406938|9845912|FG001|Follow up|Protocol Violation|0
6190116|NCT01406938|9845913|FG002|Follow up|Protocol Violation|1
6190117|NCT01406938|9845914|FG003|Follow up|Protocol Violation|0
6190118|NCT01406938|9845915|FG004|Follow up|Protocol Violation|0
6190119|NCT01406938|9845916|FG005|Follow up|Protocol Violation|0
6190120|NCT01406938|9845911|FG000|Follow up|Physician Decision|0
6190121|NCT01406938|9845912|FG001|Follow up|Physician Decision|0
6190122|NCT01406938|9845913|FG002|Follow up|Physician Decision|2
6190123|NCT01406938|9845914|FG003|Follow up|Physician Decision|0
6190124|NCT01406938|9845915|FG004|Follow up|Physician Decision|3
6190125|NCT01406938|9845916|FG005|Follow up|Physician Decision|1
6190126|NCT01406938|9845911|FG000|Follow up|Lost to Follow-up|1
6190127|NCT01406938|9845912|FG001|Follow up|Lost to Follow-up|1
6190128|NCT01406938|9845913|FG002|Follow up|Lost to Follow-up|0
6190129|NCT01406938|9845914|FG003|Follow up|Lost to Follow-up|1
6190130|NCT01406938|9845915|FG004|Follow up|Lost to Follow-up|2
6190131|NCT01406938|9845916|FG005|Follow up|Lost to Follow-up|1
6190132|NCT01407276|9845980|FG000|Overall Study|Withdrawal by Subject|0
6190133|NCT01407276|9845981|FG001|Overall Study|Withdrawal by Subject|0
6190134|NCT01407276|9845982|FG002|Overall Study|Withdrawal by Subject|0
6190135|NCT01407276|9845983|FG003|Overall Study|Withdrawal by Subject|0
6190136|NCT01407276|9845984|FG004|Overall Study|Withdrawal by Subject|0
6190137|NCT01407276|9845985|FG005|Overall Study|Withdrawal by Subject|0
6190138|NCT01407276|9845986|FG006|Overall Study|Withdrawal by Subject|0
6190139|NCT01407276|9845987|FG007|Overall Study|Withdrawal by Subject|1
6190140|NCT01407354|9846012|FG000|First Intervention|Withdrawal by Subject|0
6190141|NCT01407354|9846013|FG001|First Intervention|Withdrawal by Subject|2
6190142|NCT01407354|9846012|FG000|First Intervention|Adverse Event|1
6190143|NCT01407354|9846013|FG001|First Intervention|Adverse Event|0
6190144|NCT01407354|9846012|FG000|First Intervention|Physician Decision|1
6190145|NCT01407354|9846013|FG001|First Intervention|Physician Decision|0
6190146|NCT01407367|9846022|FG000|Overall Study|Death|24
6255331|NCT01992536|9946591|FG005|Overall Study|Lost to Follow-up|1
6255332|NCT01992536|9946592|FG006|Overall Study|Lost to Follow-up|0
6255333|NCT01992536|9946593|FG007|Overall Study|Lost to Follow-up|0
6255334|NCT01992536|9946594|FG008|Overall Study|Lost to Follow-up|1
6255335|NCT01992536|9946595|FG009|Overall Study|Lost to Follow-up|1
6255336|NCT01992536|9946586|FG000|Overall Study|Withdrawal by Subject|0
6255337|NCT01992536|9946587|FG001|Overall Study|Withdrawal by Subject|1
6255338|NCT01992536|9946588|FG002|Overall Study|Withdrawal by Subject|0
6255339|NCT01992536|9946589|FG003|Overall Study|Withdrawal by Subject|2
6255340|NCT01992536|9946590|FG004|Overall Study|Withdrawal by Subject|0
6255341|NCT01992536|9946591|FG005|Overall Study|Withdrawal by Subject|0
6255342|NCT01992536|9946592|FG006|Overall Study|Withdrawal by Subject|0
6255343|NCT01992536|9946593|FG007|Overall Study|Withdrawal by Subject|0
6255344|NCT01992536|9946594|FG008|Overall Study|Withdrawal by Subject|0
6255345|NCT01992536|9946595|FG009|Overall Study|Withdrawal by Subject|0
6255346|NCT01992549|9946637|FG000|Overall Study|Lost to Follow-up|2
6255347|NCT01992549|9946637|FG000|Overall Study|Serious Adverse Event|1
6255348|NCT01992549|9946637|FG000|Overall Study|Product Switch to Extend Half Life|1
6255349|NCT01992757|9946647|FG000|Overall Study|2 patients excluded due to FFP given.|2
6255350|NCT01993017|9946667|FG000|Overall Study|Death|23
6255351|NCT01993017|9946668|FG001|Overall Study|Death|26
6255352|NCT01993017|9946669|FG002|Overall Study|Death|18
6255353|NCT01993017|9946667|FG000|Overall Study|Could not be contacted|43
6255354|NCT01993017|9946668|FG001|Overall Study|Could not be contacted|42
6255355|NCT01993017|9946669|FG002|Overall Study|Could not be contacted|38
6255356|NCT01993017|9946667|FG000|Overall Study|Dropped out|19
6255357|NCT01993017|9946668|FG001|Overall Study|Dropped out|6
6255358|NCT01993017|9946669|FG002|Overall Study|Dropped out|11
6255359|NCT01993017|9946667|FG000|Overall Study|Other reasons|17
6255360|NCT01993017|9946668|FG001|Overall Study|Other reasons|11
6255361|NCT01993017|9946669|FG002|Overall Study|Other reasons|7
6255362|NCT01993017|9946667|FG000|Overall Study|Ineligible after randomization|4
6255363|NCT01993017|9946668|FG001|Overall Study|Ineligible after randomization|5
6255364|NCT01993017|9946669|FG002|Overall Study|Ineligible after randomization|5
6255365|NCT01993030|9946680|FG000|Overall Study|Adverse Event|0
6255366|NCT01993030|9946681|FG001|Overall Study|Adverse Event|4
6255367|NCT01993186|9946710|FG000|Double-Blind Placebo-Controlled Period|Protocol Violation|1
6255368|NCT01993186|9946711|FG001|Double-Blind Placebo-Controlled Period|Protocol Violation|0
6255369|NCT01993186|9946710|FG000|Double-Blind Placebo-Controlled Period|Withdrawal by Subject|1
6255370|NCT01993186|9946711|FG001|Double-Blind Placebo-Controlled Period|Withdrawal by Subject|0
6255371|NCT01993186|9946710|FG000|Open-Label Extension Period|Other, Not Specified|0
6255372|NCT01993186|9946711|FG001|Open-Label Extension Period|Other, Not Specified|1
6255373|NCT01993186|9946710|FG000|Open-Label Extension Period|Adverse Event|1
6255374|NCT01993186|9946711|FG001|Open-Label Extension Period|Adverse Event|0
6255375|NCT01993186|9946710|FG000|Open-Label Extension Period|Principal Investigator Decision|1
6255376|NCT01993186|9946711|FG001|Open-Label Extension Period|Principal Investigator Decision|0
6255377|NCT01993186|9946710|FG000|Open-Label Extension Period|Withdrawal by Subject|4
6255378|NCT01993186|9946711|FG001|Open-Label Extension Period|Withdrawal by Subject|5
6255379|NCT01993186|9946710|FG000|Open-Label Extension Period|Subject Non-Compliance|1
6190147|NCT01407367|9846023|FG001|Overall Study|Death|32
6190148|NCT01407367|9846022|FG000|Overall Study|Renal Replacement Therapy (RRT)|12
6190149|NCT01407367|9846023|FG001|Overall Study|Renal Replacement Therapy (RRT)|29
6190150|NCT01407367|9846022|FG000|Overall Study|Withdrawal by Subject|4
6190151|NCT01407367|9846023|FG001|Overall Study|Withdrawal by Subject|15
6190152|NCT01407367|9846022|FG000|Overall Study|Lost to Follow-up|0
6190153|NCT01407367|9846023|FG001|Overall Study|Lost to Follow-up|2
6190154|NCT01407926|9846047|FG000|Overall Study|Lost to Follow-up|55
6190155|NCT01408030|9846065|FG000|Treatment Phase (on Drug)|Lost to Follow-up|1
6190156|NCT01408030|9846066|FG001|Treatment Phase (on Drug)|Lost to Follow-up|0
6190157|NCT01408030|9846067|FG002|Treatment Phase (on Drug)|Lost to Follow-up|1
6190158|NCT01408030|9846068|FG003|Treatment Phase (on Drug)|Lost to Follow-up|0
6190159|NCT01408030|9846065|FG000|Treatment Phase (on Drug)|Lack of Efficacy|2
6190160|NCT01408030|9846066|FG001|Treatment Phase (on Drug)|Lack of Efficacy|6
6190161|NCT01408030|9846067|FG002|Treatment Phase (on Drug)|Lack of Efficacy|0
6190162|NCT01408030|9846068|FG003|Treatment Phase (on Drug)|Lack of Efficacy|3
6190163|NCT01408030|9846065|FG000|Treatment Phase (on Drug)|Protocol Violation|0
6190164|NCT01408030|9846066|FG001|Treatment Phase (on Drug)|Protocol Violation|1
6190165|NCT01408030|9846067|FG002|Treatment Phase (on Drug)|Protocol Violation|0
6190166|NCT01408030|9846068|FG003|Treatment Phase (on Drug)|Protocol Violation|0
6190167|NCT01408030|9846065|FG000|Observation Phase (Off Drug)|Lost to Follow-up|0
6190168|NCT01408030|9846066|FG001|Observation Phase (Off Drug)|Lost to Follow-up|2
6190169|NCT01408030|9846067|FG002|Observation Phase (Off Drug)|Lost to Follow-up|2
6190170|NCT01408030|9846068|FG003|Observation Phase (Off Drug)|Lost to Follow-up|0
6190171|NCT01408030|9846065|FG000|Observation Phase (Off Drug)|Withdrawal by Subject|3
6190172|NCT01408030|9846066|FG001|Observation Phase (Off Drug)|Withdrawal by Subject|2
6190173|NCT01408030|9846067|FG002|Observation Phase (Off Drug)|Withdrawal by Subject|1
6190174|NCT01408030|9846068|FG003|Observation Phase (Off Drug)|Withdrawal by Subject|3
6190175|NCT01408030|9846065|FG000|Observation Phase (Off Drug)|Physician Decision|0
6255380|NCT01993186|9946711|FG001|Open-Label Extension Period|Subject Non-Compliance|0
6255381|NCT01993329|9946728|FG000|Period 2|Adverse Event|0
6255382|NCT01993329|9946729|FG001|Period 2|Adverse Event|0
6255383|NCT01993329|9946730|FG002|Period 2|Adverse Event|0
6255384|NCT01993329|9946731|FG003|Period 2|Adverse Event|0
6255385|NCT01993329|9946732|FG004|Period 2|Adverse Event|0
6255386|NCT01993329|9946733|FG005|Period 2|Adverse Event|1
6255387|NCT01993329|9946728|FG000|Wash-out|Personal reasons|0
6255388|NCT01993329|9946729|FG001|Wash-out|Personal reasons|1
6255389|NCT01993329|9946730|FG002|Wash-out|Personal reasons|0
6255390|NCT01993329|9946731|FG003|Wash-out|Personal reasons|0
6255391|NCT01993329|9946732|FG004|Wash-out|Personal reasons|0
6255392|NCT01993329|9946733|FG005|Wash-out|Personal reasons|0
6255393|NCT01993615|9946747|FG000|Overall Study|Death|1
6255394|NCT01993615|9946748|FG001|Overall Study|Death|0
6255395|NCT01993667|9946756|FG000|Overall Study|Insufficient data to analyze|16
6255396|NCT01993667|9946757|FG001|Overall Study|Insufficient data to analyze|16
6255397|NCT01993667|9946756|FG000|Overall Study|Insufficient altitude reached|3
6255398|NCT01993667|9946757|FG001|Overall Study|Insufficient altitude reached|1
6255399|NCT01993667|9946756|FG000|Overall Study|Lost to Follow-up|2
6255400|NCT01993667|9946757|FG001|Overall Study|Lost to Follow-up|2
6255401|NCT01993823|9946765|FG000|Overall Study|Requested by the patient|6
6255402|NCT01993823|9946766|FG001|Overall Study|Requested by the patient|11
6255403|NCT01993823|9946765|FG000|Overall Study|Protocol Violation|0
6255404|NCT01993823|9946766|FG001|Overall Study|Protocol Violation|1
6255405|NCT01993823|9946765|FG000|Overall Study|Lost to Follow-up|1
6255406|NCT01993823|9946766|FG001|Overall Study|Lost to Follow-up|4
6255407|NCT01993836|9946775|FG000|Overall Study|Surgery Cancelled|3
6255408|NCT01993836|9946776|FG001|Overall Study|Surgery Cancelled|0
6255409|NCT01993836|9946777|FG002|Overall Study|Surgery Cancelled|0
6255410|NCT01993836|9946775|FG000|Overall Study|Physician Decision|2
6255411|NCT01993836|9946776|FG001|Overall Study|Physician Decision|1
6255412|NCT01993836|9946777|FG002|Overall Study|Physician Decision|0
6255413|NCT01993836|9946775|FG000|Overall Study|Death|0
6255414|NCT01993836|9946776|FG001|Overall Study|Death|2
6255415|NCT01993836|9946777|FG002|Overall Study|Death|0
6255416|NCT01993836|9946775|FG000|Overall Study|Withdrawal by Subject|12
6255417|NCT01993836|9946776|FG001|Overall Study|Withdrawal by Subject|10
6255418|NCT01993836|9946777|FG002|Overall Study|Withdrawal by Subject|5
6255419|NCT01993888|9946808|FG000|Overall Study|Death|1
6255420|NCT01993888|9946809|FG001|Overall Study|Death|1
6255421|NCT01993888|9946808|FG000|Overall Study|Lost to Follow-up|1
6255422|NCT01993888|9946809|FG001|Overall Study|Lost to Follow-up|1
6255423|NCT01993888|9946808|FG000|Overall Study|Withdrawal by Subject|0
6255424|NCT01993888|9946809|FG001|Overall Study|Withdrawal by Subject|1
6255425|NCT01993927|9946815|FG000|Overall Study|Case Report Forms Uncollected|18
6255426|NCT01993927|9946815|FG000|Overall Study|Protocol Violation|11
6255427|NCT01993940|9946821|FG000|Overall Study|Adverse Event|16
6255428|NCT01993940|9946822|FG001|Overall Study|Adverse Event|11
6255429|NCT01993940|9946821|FG000|Overall Study|Withdrawal by Subject|15
6255430|NCT01993940|9946822|FG001|Overall Study|Withdrawal by Subject|19
6255431|NCT01993940|9946821|FG000|Overall Study|Lost to Follow-up|2
6255432|NCT01993940|9946822|FG001|Overall Study|Lost to Follow-up|5
6255433|NCT01993940|9946821|FG000|Overall Study|Protocol Violation|5
6255434|NCT01993940|9946822|FG001|Overall Study|Protocol Violation|8
6255435|NCT01993940|9946821|FG000|Overall Study|Death|1
6255436|NCT01993940|9946822|FG001|Overall Study|Death|0
6255437|NCT01993940|9946821|FG000|Overall Study|Other - Miscellaneous|1
6255438|NCT01993940|9946822|FG001|Overall Study|Other - Miscellaneous|1
6255439|NCT01994226|9946846|FG000|Overall Study|Protocol Violation|13
6255440|NCT01994226|9946847|FG001|Overall Study|Protocol Violation|10
6255441|NCT01994226|9946846|FG000|Overall Study|Early Cessation of treatment|6
6255442|NCT01994226|9946847|FG001|Overall Study|Early Cessation of treatment|11
6255443|NCT01994291|9946856|FG000|Overall Study|Adverse Event|4
6255444|NCT01994291|9946857|FG001|Overall Study|Adverse Event|1
6255445|NCT01994291|9946858|FG002|Overall Study|Adverse Event|3
6255446|NCT01994291|9946856|FG000|Overall Study|Lost to Follow-up|1
6255447|NCT01994291|9946857|FG001|Overall Study|Lost to Follow-up|1
6255448|NCT01994291|9946858|FG002|Overall Study|Lost to Follow-up|0
6255449|NCT01994291|9946856|FG000|Overall Study|Does not meet entrance criteria|1
6255450|NCT01994291|9946857|FG001|Overall Study|Does not meet entrance criteria|0
6255451|NCT01994291|9946858|FG002|Overall Study|Does not meet entrance criteria|0
6255452|NCT01994291|9946856|FG000|Overall Study|Medication error without associated AE|1
6255453|NCT01994291|9946857|FG001|Overall Study|Medication error without associated AE|0
6255454|NCT01994291|9946858|FG002|Overall Study|Medication error without associated AE|1
6255455|NCT01994291|9946856|FG000|Overall Study|Protocol Violation|1
6255456|NCT01994291|9946857|FG001|Overall Study|Protocol Violation|0
6255457|NCT01994291|9946858|FG002|Overall Study|Protocol Violation|0
6255458|NCT01994291|9946856|FG000|Overall Study|Withdrawal by Subject|6
6255459|NCT01994291|9946857|FG001|Overall Study|Withdrawal by Subject|3
6255460|NCT01994291|9946858|FG002|Overall Study|Withdrawal by Subject|5
6255461|NCT01994291|9946856|FG000|Overall Study|Other|1
6255462|NCT01994291|9946857|FG001|Overall Study|Other|2
6255463|NCT01994291|9946858|FG002|Overall Study|Other|0
6255464|NCT01994395|9946869|FG000|Overall Study|Withdrawal by Subject|1
6255465|NCT01994395|9946870|FG001|Overall Study|Withdrawal by Subject|2
6255466|NCT01994590|9946891|FG000|Overall Study|Adverse Event|1
6255467|NCT01994590|9946891|FG000|Overall Study|Trial Terminated|1
6255468|NCT01994629|9946897|FG000|Overall Study|Withdrawal by Subject|1
6255469|NCT01994629|9946898|FG001|Overall Study|Withdrawal by Subject|0
6255470|NCT01994629|9946897|FG000|Overall Study|Lost to Follow-up|0
6255471|NCT01994629|9946898|FG001|Overall Study|Lost to Follow-up|3
6255472|NCT01994720|9946906|FG000|Overall Study|Withdrawal by Subject|46
6255473|NCT01994720|9946907|FG001|Overall Study|Withdrawal by Subject|56
6255474|NCT01994837|9946937|FG000|Overall Study|Progressive disease per protocol|23
6255475|NCT01994837|9946937|FG000|Overall Study|Adv event related to progressive disease|3
6086572|NCT00662311|9696658|FG001|Overall Study|Respiratory Infection|0
6255476|NCT01994837|9946937|FG000|Overall Study|Fatal progressive disease|2
6255477|NCT01994837|9946937|FG000|Overall Study|Adverse event not related to progression|1
6255478|NCT01994837|9946937|FG000|Overall Study|Chose palliative care|1
6255479|NCT01994837|9946937|FG000|Overall Study|Proceeded to transplant|1
6255480|NCT01994837|9946937|FG000|Overall Study|Removed from study due to no response|1
6255481|NCT01994850|9946941|FG000|Overall Study|Physician Decision|1
6255482|NCT01994850|9946941|FG000|Overall Study|Withdrawal by Subject|1
6255483|NCT01994863|9946945|FG000|Period 1|Adverse Event|4
6255484|NCT01994863|9946946|FG001|Period 1|Adverse Event|0
6255485|NCT01994863|9946945|FG000|Period 1|Withdrawal by Subject|1
6255486|NCT01994863|9946946|FG001|Period 1|Withdrawal by Subject|0
6255487|NCT01994863|9946945|FG000|Period 1|Trial stopped by sponsor|1
6255488|NCT01994863|9946946|FG001|Period 1|Trial stopped by sponsor|3
6255489|NCT01994863|9946945|FG000|Period 1|Lack of Efficacy|1
6255490|NCT01994863|9946946|FG001|Period 1|Lack of Efficacy|0
6255491|NCT01994863|9946945|FG000|Period 2|Adverse Event|0
6255492|NCT01994863|9946946|FG001|Period 2|Adverse Event|1
6255493|NCT01994863|9946945|FG000|Period 2|Lack of Efficacy|0
6255494|NCT01994863|9946946|FG001|Period 2|Lack of Efficacy|2
6255495|NCT01994863|9946945|FG000|Period 2|Withdrawal by Subject|1
6255496|NCT01994863|9946946|FG001|Period 2|Withdrawal by Subject|1
6255497|NCT01994876|9946952|FG000|Test Period 1|Withdrawal by Subject|0
6255498|NCT01994876|9946953|FG001|Test Period 1|Withdrawal by Subject|1
6255499|NCT01994876|9946952|FG000|Test Period 1|Adverse Event|0
6086573|NCT00662311|9696659|FG002|Overall Study|Respiratory Infection|0
6086574|NCT00662363|9696669|FG000|Overall Study|Withdrawal by Subject|6
6255500|NCT01994876|9946953|FG001|Test Period 1|Adverse Event|1
6255501|NCT01994876|9946952|FG000|Test Period 2|Adverse Event|1
6255502|NCT01994876|9946953|FG001|Test Period 2|Adverse Event|0
6255503|NCT01994876|9946952|FG000|Test Period 2|Protocol Violation|0
6255504|NCT01994876|9946953|FG001|Test Period 2|Protocol Violation|1
6255505|NCT01994889|9946964|FG000|Overall Study|Adverse Event|5
6255506|NCT01994889|9946965|FG001|Overall Study|Adverse Event|12
6255507|NCT01994889|9946966|FG002|Overall Study|Adverse Event|11
6255508|NCT01994889|9946964|FG000|Overall Study|Cardiac Device Implantation|0
6255509|NCT01994889|9946965|FG001|Overall Study|Cardiac Device Implantation|2
6255510|NCT01994889|9946966|FG002|Overall Study|Cardiac Device Implantation|0
6255511|NCT01994889|9946964|FG000|Overall Study|Organ Transplantation|1
6255512|NCT01994889|9946965|FG001|Overall Study|Organ Transplantation|5
6255513|NCT01994889|9946966|FG002|Overall Study|Organ Transplantation|5
6255514|NCT01994889|9946964|FG000|Overall Study|No longer willing to participate|8
6255515|NCT01994889|9946965|FG001|Overall Study|No longer willing to participate|17
6255516|NCT01994889|9946966|FG002|Overall Study|No longer willing to participate|37
6255517|NCT01994889|9946964|FG000|Overall Study|Lost to Follow-up|0
6255518|NCT01994889|9946965|FG001|Overall Study|Lost to Follow-up|1
6255519|NCT01994889|9946966|FG002|Overall Study|Lost to Follow-up|0
6255520|NCT01994889|9946964|FG000|Overall Study|Protocol Violation|0
6255521|NCT01994889|9946965|FG001|Overall Study|Protocol Violation|1
6255522|NCT01994889|9946966|FG002|Overall Study|Protocol Violation|1
6255523|NCT01994889|9946964|FG000|Overall Study|Death|14
6255524|NCT01994889|9946965|FG001|Overall Study|Death|25
6190176|NCT01408030|9846066|FG001|Observation Phase (Off Drug)|Physician Decision|1
6190177|NCT01408030|9846067|FG002|Observation Phase (Off Drug)|Physician Decision|2
6190178|NCT01408030|9846068|FG003|Observation Phase (Off Drug)|Physician Decision|0
6190179|NCT01408030|9846065|FG000|Observation Phase (Off Drug)|Other|1
6190180|NCT01408030|9846066|FG001|Observation Phase (Off Drug)|Other|1
6190181|NCT01408030|9846067|FG002|Observation Phase (Off Drug)|Other|1
6190182|NCT01408030|9846068|FG003|Observation Phase (Off Drug)|Other|1
6190183|NCT01408043|9846078|FG000|Overall Study|unable to collect cells|1
6190184|NCT01408147|9846084|FG000|Overall Study|Withdrawal by Subject|0
6190185|NCT01408147|9846085|FG001|Overall Study|Withdrawal by Subject|1
6190186|NCT01408277|9846093|FG000|Overall Study|Adverse Event|3
6190187|NCT01408277|9846094|FG001|Overall Study|Adverse Event|4
6190188|NCT01408277|9846093|FG000|Overall Study|Lost to Follow-up|1
6190189|NCT01408277|9846094|FG001|Overall Study|Lost to Follow-up|0
6190190|NCT01408277|9846093|FG000|Overall Study|Withdrawal by Subject|2
6190191|NCT01408277|9846094|FG001|Overall Study|Withdrawal by Subject|0
6255525|NCT01994889|9946966|FG002|Overall Study|Death|38
6255526|NCT01994902|9946973|FG000|Test Period 1|Withdrawal by Subject|3
6086575|NCT00662363|9696670|FG001|Overall Study|Withdrawal by Subject|5
6086576|NCT00662363|9696669|FG000|Overall Study|Adverse Event|0
6190192|NCT01408277|9846093|FG000|Overall Study|Protocol Violation|2
6190193|NCT01408277|9846094|FG001|Overall Study|Protocol Violation|0
6255527|NCT01994902|9946974|FG001|Test Period 1|Withdrawal by Subject|0
6255528|NCT01994902|9946973|FG000|Test Period 1|device deficiency with adverse event|0
6255529|NCT01994902|9946974|FG001|Test Period 1|device deficiency with adverse event|1
6255530|NCT01994902|9946973|FG000|Test Period 1|Adverse Event|2
6255531|NCT01994902|9946974|FG001|Test Period 1|Adverse Event|1
6255532|NCT01994902|9946973|FG000|Test Period 1|Lack of Efficacy|0
6255533|NCT01994902|9946974|FG001|Test Period 1|Lack of Efficacy|1
6255534|NCT01994902|9946973|FG000|Test Period 1|bag too small|1
6255535|NCT01994902|9946974|FG001|Test Period 1|bag too small|0
6255536|NCT01994902|9946973|FG000|Test Period 2|Withdrawal by Subject|0
6255537|NCT01994902|9946974|FG001|Test Period 2|Withdrawal by Subject|2
6255538|NCT01994902|9946973|FG000|Test Period 2|Lack of Efficacy|0
6255539|NCT01994902|9946974|FG001|Test Period 2|Lack of Efficacy|1
6255540|NCT01994902|9946973|FG000|Test Period 2|Other|0
6255541|NCT01994902|9946974|FG001|Test Period 2|Other|3
6255542|NCT01994954|9946982|FG000|Overall Study|Death|1
6255543|NCT01994954|9946983|FG001|Overall Study|Death|0
6255544|NCT01994954|9946982|FG000|Overall Study|Withdrawal by Subject|9
6255545|NCT01994954|9946983|FG001|Overall Study|Withdrawal by Subject|14
6255546|NCT01994954|9946982|FG000|Overall Study|Physician Decision|2
6255547|NCT01994954|9946983|FG001|Overall Study|Physician Decision|2
6255548|NCT01994954|9946982|FG000|Overall Study|Lost to Follow-up|8
6255549|NCT01994954|9946983|FG001|Overall Study|Lost to Follow-up|10
6255550|NCT01994954|9946982|FG000|Overall Study|6 Month Follow-up Not Complete|5
6255551|NCT01994954|9946983|FG001|Overall Study|6 Month Follow-up Not Complete|4
6255552|NCT01995071|9947037|FG000|Overall Study|Adverse Event|0
6255553|NCT01995071|9947038|FG001|Overall Study|Adverse Event|0
6255554|NCT01995071|9947039|FG002|Overall Study|Adverse Event|0
6255555|NCT01995071|9947040|FG003|Overall Study|Adverse Event|0
6255556|NCT01995071|9947041|FG004|Overall Study|Adverse Event|0
6255557|NCT01995071|9947042|FG005|Overall Study|Adverse Event|0
6255558|NCT01995071|9947043|FG006|Overall Study|Adverse Event|1
6255559|NCT01995071|9947044|FG007|Overall Study|Adverse Event|0
6255560|NCT01995071|9947045|FG008|Overall Study|Adverse Event|0
6255561|NCT01995071|9947046|FG009|Overall Study|Adverse Event|0
6255562|NCT01995071|9947047|FG010|Overall Study|Adverse Event|0
6255563|NCT01995071|9947048|FG011|Overall Study|Adverse Event|0
6255564|NCT01995071|9947037|FG000|Overall Study|Moved|0
6255565|NCT01995071|9947038|FG001|Overall Study|Moved|0
6255566|NCT01995071|9947039|FG002|Overall Study|Moved|1
6255567|NCT01995071|9947040|FG003|Overall Study|Moved|0
6255568|NCT01995071|9947041|FG004|Overall Study|Moved|1
6255569|NCT01995071|9947042|FG005|Overall Study|Moved|0
6255570|NCT01995071|9947043|FG006|Overall Study|Moved|0
6255571|NCT01995071|9947044|FG007|Overall Study|Moved|0
6255572|NCT01995071|9947045|FG008|Overall Study|Moved|0
6255573|NCT01995071|9947046|FG009|Overall Study|Moved|0
6255574|NCT01995071|9947047|FG010|Overall Study|Moved|1
6255575|NCT01995071|9947048|FG011|Overall Study|Moved|0
6255576|NCT01995071|9947037|FG000|Overall Study|Lost to Follow-up|1
6255577|NCT01995071|9947038|FG001|Overall Study|Lost to Follow-up|0
6255578|NCT01995071|9947039|FG002|Overall Study|Lost to Follow-up|0
6255579|NCT01995071|9947040|FG003|Overall Study|Lost to Follow-up|0
6255580|NCT01995071|9947041|FG004|Overall Study|Lost to Follow-up|0
6255581|NCT01995071|9947042|FG005|Overall Study|Lost to Follow-up|0
6255582|NCT01995071|9947043|FG006|Overall Study|Lost to Follow-up|0
6255583|NCT01995071|9947044|FG007|Overall Study|Lost to Follow-up|1
6255584|NCT01995071|9947045|FG008|Overall Study|Lost to Follow-up|1
6255585|NCT01995071|9947046|FG009|Overall Study|Lost to Follow-up|0
6255586|NCT01995071|9947047|FG010|Overall Study|Lost to Follow-up|0
6190194|NCT01408303|9846103|FG000|Overall Study|Adverse Event|3
6190195|NCT01408303|9846104|FG001|Overall Study|Adverse Event|7
6190196|NCT01408303|9846105|FG002|Overall Study|Adverse Event|2
6190197|NCT01408303|9846103|FG000|Overall Study|Lost to Follow-up|0
6190198|NCT01408303|9846104|FG001|Overall Study|Lost to Follow-up|1
6190199|NCT01408303|9846105|FG002|Overall Study|Lost to Follow-up|2
6190200|NCT01408303|9846103|FG000|Overall Study|Withdrawal by Subject|2
6190201|NCT01408303|9846104|FG001|Overall Study|Withdrawal by Subject|3
6190202|NCT01408303|9846105|FG002|Overall Study|Withdrawal by Subject|1
6190203|NCT01408303|9846103|FG000|Overall Study|Protocol Violation|0
6190204|NCT01408303|9846104|FG001|Overall Study|Protocol Violation|1
6190205|NCT01408303|9846105|FG002|Overall Study|Protocol Violation|0
6190206|NCT01408303|9846103|FG000|Overall Study|Noncompliance|1
6190207|NCT01408303|9846104|FG001|Overall Study|Noncompliance|0
6190208|NCT01408303|9846105|FG002|Overall Study|Noncompliance|1
6190209|NCT01408459|9846124|FG000|Overall Study|Withdrawal by Subject|1
6190210|NCT01408459|9846125|FG001|Overall Study|Withdrawal by Subject|1
6190211|NCT01408485|9846132|FG000|Overall Study|Withdrawal by Subject|21
6190212|NCT01408537|9846136|FG000|Overall Study|Withdrawal by Subject|2
6255587|NCT01995071|9947048|FG011|Overall Study|Lost to Follow-up|0
6255588|NCT01995071|9947037|FG000|Overall Study|Incarcerated|0
6255589|NCT01995071|9947038|FG001|Overall Study|Incarcerated|0
6255590|NCT01995071|9947039|FG002|Overall Study|Incarcerated|0
6255591|NCT01995071|9947040|FG003|Overall Study|Incarcerated|0
6255592|NCT01995071|9947041|FG004|Overall Study|Incarcerated|0
6255593|NCT01995071|9947042|FG005|Overall Study|Incarcerated|0
6255594|NCT01995071|9947043|FG006|Overall Study|Incarcerated|0
6255595|NCT01995071|9947044|FG007|Overall Study|Incarcerated|1
6255596|NCT01995071|9947045|FG008|Overall Study|Incarcerated|0
6255597|NCT01995071|9947046|FG009|Overall Study|Incarcerated|0
6255598|NCT01995071|9947047|FG010|Overall Study|Incarcerated|0
6255599|NCT01995071|9947048|FG011|Overall Study|Incarcerated|0
6255600|NCT01995136|9947089|FG000|Overall Study|Change in residence|1
6255601|NCT01995201|9947095|FG000|From Baseline Until Week 24|Adverse Event|4
6255602|NCT01995201|9947096|FG001|From Baseline Until Week 24|Adverse Event|15
6255603|NCT01995201|9947097|FG002|From Baseline Until Week 24|Adverse Event|0
6255604|NCT01995201|9947098|FG003|From Baseline Until Week 24|Adverse Event|0
6255605|NCT01995201|9947099|FG004|From Baseline Until Week 24|Adverse Event|0
6255606|NCT01995201|9947100|FG005|From Baseline Until Week 24|Adverse Event|0
6255607|NCT01995201|9947101|FG006|From Baseline Until Week 24|Adverse Event|0
6255608|NCT01995201|9947095|FG000|From Baseline Until Week 24|Anaphylaxis or hypersensitivity reaction|0
6255609|NCT01995201|9947096|FG001|From Baseline Until Week 24|Anaphylaxis or hypersensitivity reaction|3
6255610|NCT01995201|9947097|FG002|From Baseline Until Week 24|Anaphylaxis or hypersensitivity reaction|0
6255611|NCT01995201|9947098|FG003|From Baseline Until Week 24|Anaphylaxis or hypersensitivity reaction|0
6255612|NCT01995201|9947099|FG004|From Baseline Until Week 24|Anaphylaxis or hypersensitivity reaction|0
6255613|NCT01995201|9947100|FG005|From Baseline Until Week 24|Anaphylaxis or hypersensitivity reaction|0
6255614|NCT01995201|9947101|FG006|From Baseline Until Week 24|Anaphylaxis or hypersensitivity reaction|0
6255615|NCT01995201|9947095|FG000|From Baseline Until Week 24|Death|0
6255616|NCT01995201|9947096|FG001|From Baseline Until Week 24|Death|1
6255617|NCT01995201|9947097|FG002|From Baseline Until Week 24|Death|0
6255618|NCT01995201|9947098|FG003|From Baseline Until Week 24|Death|0
6255619|NCT01995201|9947099|FG004|From Baseline Until Week 24|Death|0
6255620|NCT01995201|9947100|FG005|From Baseline Until Week 24|Death|0
6255621|NCT01995201|9947101|FG006|From Baseline Until Week 24|Death|0
6255622|NCT01995201|9947095|FG000|From Baseline Until Week 24|Lack of Efficacy|2
6255623|NCT01995201|9947096|FG001|From Baseline Until Week 24|Lack of Efficacy|5
6255624|NCT01995201|9947097|FG002|From Baseline Until Week 24|Lack of Efficacy|0
6255625|NCT01995201|9947098|FG003|From Baseline Until Week 24|Lack of Efficacy|0
6255626|NCT01995201|9947099|FG004|From Baseline Until Week 24|Lack of Efficacy|0
6255627|NCT01995201|9947100|FG005|From Baseline Until Week 24|Lack of Efficacy|0
6255628|NCT01995201|9947101|FG006|From Baseline Until Week 24|Lack of Efficacy|0
6255629|NCT01995201|9947095|FG000|From Baseline Until Week 24|Lost to Follow-up|2
6255630|NCT01995201|9947096|FG001|From Baseline Until Week 24|Lost to Follow-up|3
6255631|NCT01995201|9947097|FG002|From Baseline Until Week 24|Lost to Follow-up|0
6255632|NCT01995201|9947098|FG003|From Baseline Until Week 24|Lost to Follow-up|0
6255633|NCT01995201|9947099|FG004|From Baseline Until Week 24|Lost to Follow-up|0
6255634|NCT01995201|9947100|FG005|From Baseline Until Week 24|Lost to Follow-up|0
6255635|NCT01995201|9947101|FG006|From Baseline Until Week 24|Lost to Follow-up|0
6255636|NCT01995201|9947095|FG000|From Baseline Until Week 24|Withdrawal by Subject|2
6255637|NCT01995201|9947096|FG001|From Baseline Until Week 24|Withdrawal by Subject|8
6255638|NCT01995201|9947097|FG002|From Baseline Until Week 24|Withdrawal by Subject|0
6255639|NCT01995201|9947098|FG003|From Baseline Until Week 24|Withdrawal by Subject|0
6255640|NCT01995201|9947099|FG004|From Baseline Until Week 24|Withdrawal by Subject|0
6255641|NCT01995201|9947100|FG005|From Baseline Until Week 24|Withdrawal by Subject|0
6255642|NCT01995201|9947101|FG006|From Baseline Until Week 24|Withdrawal by Subject|0
6255643|NCT01995201|9947095|FG000|From Baseline Until Week 24|Physician Decision|0
6255644|NCT01995201|9947096|FG001|From Baseline Until Week 24|Physician Decision|2
6255645|NCT01995201|9947097|FG002|From Baseline Until Week 24|Physician Decision|0
6255646|NCT01995201|9947098|FG003|From Baseline Until Week 24|Physician Decision|0
6255647|NCT01995201|9947099|FG004|From Baseline Until Week 24|Physician Decision|0
6255648|NCT01995201|9947100|FG005|From Baseline Until Week 24|Physician Decision|0
6086577|NCT00662363|9696670|FG001|Overall Study|Adverse Event|3
6086578|NCT00662363|9696669|FG000|Overall Study|Discharged early from rehab|4
6086579|NCT00662363|9696670|FG001|Overall Study|Discharged early from rehab|1
6086580|NCT00662363|9696669|FG000|Overall Study|Protocol Violation|1
6190213|NCT01408537|9846136|FG000|Overall Study|Protocol Violation|3
6190214|NCT01408537|9846136|FG000|Overall Study|Lost to Follow-up|3
6190215|NCT01408563|9846151|FG000|Overall Study|Ineligible after consent/ registration|2
6190216|NCT01408576|9846158|FG000|Overall Study|Lack of Efficacy|17
6190217|NCT01408576|9846159|FG001|Overall Study|Lack of Efficacy|30
6190218|NCT01408576|9846160|FG002|Overall Study|Lack of Efficacy|48
6190219|NCT01408576|9846158|FG000|Overall Study|Protocol Violation|1
6190220|NCT01408576|9846159|FG001|Overall Study|Protocol Violation|2
6190221|NCT01408576|9846160|FG002|Overall Study|Protocol Violation|2
6190222|NCT01408576|9846158|FG000|Overall Study|Lost to Follow-up|10
6190223|NCT01408576|9846159|FG001|Overall Study|Lost to Follow-up|9
6190224|NCT01408576|9846160|FG002|Overall Study|Lost to Follow-up|17
6190225|NCT01408576|9846158|FG000|Overall Study|Withdrawal by Subject|34
6190226|NCT01408576|9846159|FG001|Overall Study|Withdrawal by Subject|60
6255649|NCT01995201|9947101|FG006|From Baseline Until Week 24|Physician Decision|0
6255650|NCT01995201|9947095|FG000|From Baseline Until Week 24|Protocol Violation|0
6255651|NCT01995201|9947096|FG001|From Baseline Until Week 24|Protocol Violation|9
6255652|NCT01995201|9947097|FG002|From Baseline Until Week 24|Protocol Violation|0
6255653|NCT01995201|9947098|FG003|From Baseline Until Week 24|Protocol Violation|0
6255654|NCT01995201|9947099|FG004|From Baseline Until Week 24|Protocol Violation|0
6086581|NCT00662363|9696670|FG001|Overall Study|Protocol Violation|1
6190227|NCT01408576|9846160|FG002|Overall Study|Withdrawal by Subject|66
6190228|NCT01408576|9846158|FG000|Overall Study|Sponsor terminated study|89
6086582|NCT00662532|9696680|FG000|Overall Study|Adverse Event|0
6086583|NCT00662532|9696681|FG001|Overall Study|Adverse Event|1
6086584|NCT00662532|9696680|FG000|Overall Study|Lost to Follow-up|0
6086585|NCT00662532|9696681|FG001|Overall Study|Lost to Follow-up|1
6086586|NCT00662558|9696698|FG000|Overall Study|Adverse Event|21
6086587|NCT00662558|9696699|FG001|Overall Study|Adverse Event|59
6086588|NCT00662558|9696698|FG000|Overall Study|Lack of Efficacy|4
6086589|NCT00662558|9696699|FG001|Overall Study|Lack of Efficacy|7
6086590|NCT00662558|9696698|FG000|Overall Study|Lost to Follow-up|13
6086591|NCT00662558|9696699|FG001|Overall Study|Lost to Follow-up|10
6086592|NCT00662558|9696698|FG000|Overall Study|Other|9
6086593|NCT00662558|9696699|FG001|Overall Study|Other|14
6086594|NCT00662558|9696698|FG000|Overall Study|Withdrawal by Subject|7
6086595|NCT00662558|9696699|FG001|Overall Study|Withdrawal by Subject|12
6190229|NCT01408576|9846159|FG001|Overall Study|Sponsor terminated study|333
6190230|NCT01408576|9846160|FG002|Overall Study|Sponsor terminated study|330
6255655|NCT01995201|9947100|FG005|From Baseline Until Week 24|Protocol Violation|0
6255656|NCT01995201|9947101|FG006|From Baseline Until Week 24|Protocol Violation|0
6255657|NCT01995201|9947095|FG000|From Week 24 Until Week 48|Adverse Event|0
6255658|NCT01995201|9947096|FG001|From Week 24 Until Week 48|Adverse Event|0
6255659|NCT01995201|9947097|FG002|From Week 24 Until Week 48|Adverse Event|2
6255660|NCT01995201|9947098|FG003|From Week 24 Until Week 48|Adverse Event|1
6255661|NCT01995201|9947099|FG004|From Week 24 Until Week 48|Adverse Event|1
6255662|NCT01995201|9947100|FG005|From Week 24 Until Week 48|Adverse Event|3
6255663|NCT01995201|9947101|FG006|From Week 24 Until Week 48|Adverse Event|1
6255664|NCT01995201|9947095|FG000|From Week 24 Until Week 48|Death|0
6255665|NCT01995201|9947096|FG001|From Week 24 Until Week 48|Death|0
6255666|NCT01995201|9947097|FG002|From Week 24 Until Week 48|Death|0
6190231|NCT01408576|9846158|FG000|Overall Study|AE, serious fatal|4
6190232|NCT01408576|9846159|FG001|Overall Study|AE, serious fatal|4
6190233|NCT01408576|9846160|FG002|Overall Study|AE, serious fatal|1
6190234|NCT01408576|9846158|FG000|Overall Study|SAE, non-fatal|11
6190235|NCT01408576|9846159|FG001|Overall Study|SAE, non-fatal|23
6190236|NCT01408576|9846160|FG002|Overall Study|SAE, non-fatal|14
6190237|NCT01408576|9846158|FG000|Overall Study|AE, non-serious non-fatal|12
6190238|NCT01408576|9846159|FG001|Overall Study|AE, non-serious non-fatal|19
6190239|NCT01408576|9846160|FG002|Overall Study|AE, non-serious non-fatal|11
6190240|NCT01408576|9846158|FG000|Overall Study|SAE, non-fatal+AE, non-serious non-fatal|0
6190241|NCT01408576|9846159|FG001|Overall Study|SAE, non-fatal+AE, non-serious non-fatal|1
6190242|NCT01408576|9846160|FG002|Overall Study|SAE, non-fatal+AE, non-serious non-fatal|1
6190243|NCT01408576|9846158|FG000|Overall Study|AE, unknown type|0
6190244|NCT01408576|9846159|FG001|Overall Study|AE, unknown type|1
6190245|NCT01408576|9846160|FG002|Overall Study|AE, unknown type|0
6190246|NCT01408576|9846158|FG000|Overall Study|Other|10
6190247|NCT01408576|9846159|FG001|Overall Study|Other|16
6190248|NCT01408576|9846160|FG002|Overall Study|Other|18
6190249|NCT01408628|9846180|FG000|Consented|Withdrawal by Subject|12
6190250|NCT01408628|9846180|FG000|Completed 6 Month Follow-Up|Lost to Follow-up|3
6190251|NCT01408628|9846180|FG000|Completed 6 Month Follow-Up|Protocol Violation|6
6190252|NCT01408628|9846180|FG000|Completed 6 Month Follow-Up|Withdrawal by Subject|5
6190253|NCT01408706|9846187|FG000|Overall Study|Physician Decision|1
6190254|NCT01408706|9846188|FG001|Overall Study|Physician Decision|0
6190255|NCT01408732|9846245|FG000|Overall Study|Withdrawal by Subject|2
6190256|NCT01408732|9846246|FG001|Overall Study|Withdrawal by Subject|2
6190257|NCT01408888|9846257|FG000|First Intervention|Adverse Event|0
6190258|NCT01408888|9846258|FG001|First Intervention|Adverse Event|1
6190259|NCT01408888|9846257|FG000|First Intervention|Withdrawal by Subject|0
6190260|NCT01408888|9846258|FG001|First Intervention|Withdrawal by Subject|2
6190261|NCT01408888|9846257|FG000|Second Intervention|Withdrawal by Subject|1
6190262|NCT01408888|9846258|FG001|Second Intervention|Withdrawal by Subject|0
6190263|NCT01408888|9846257|FG000|Second Intervention|Adverse Event|1
6190264|NCT01408888|9846258|FG001|Second Intervention|Adverse Event|0
6190265|NCT01408901|9846278|FG000|6-Week Follow-Up|Lost to Follow-up|2
6190266|NCT01408901|9846279|FG001|6-Week Follow-Up|Lost to Follow-up|1
6190267|NCT01408901|9846280|FG002|6-Week Follow-Up|Lost to Follow-up|3
6190268|NCT01408901|9846281|FG003|6-Week Follow-Up|Lost to Follow-up|2
6190269|NCT01408901|9846278|FG000|6-Week Follow-Up|Death|1
6190270|NCT01408901|9846279|FG001|6-Week Follow-Up|Death|0
6190271|NCT01408901|9846280|FG002|6-Week Follow-Up|Death|0
6190272|NCT01408901|9846281|FG003|6-Week Follow-Up|Death|0
6190273|NCT01408901|9846278|FG000|6-Week Follow-Up|Cancelled visit|0
6190274|NCT01408901|9846279|FG001|6-Week Follow-Up|Cancelled visit|1
6190275|NCT01408901|9846280|FG002|6-Week Follow-Up|Cancelled visit|0
6190276|NCT01408901|9846281|FG003|6-Week Follow-Up|Cancelled visit|2
6190277|NCT01408901|9846278|FG000|12-Week Follow-Up (Primary Endpoint)|Lost to Follow-up|0
6255667|NCT01995201|9947098|FG003|From Week 24 Until Week 48|Death|0
6255668|NCT01995201|9947099|FG004|From Week 24 Until Week 48|Death|0
6255669|NCT01995201|9947100|FG005|From Week 24 Until Week 48|Death|2
6086596|NCT00662558|9696698|FG000|Overall Study|Randomized But Did Not Receive Treatment|2
6086597|NCT00662558|9696699|FG001|Overall Study|Randomized But Did Not Receive Treatment|8
6255670|NCT01995201|9947101|FG006|From Week 24 Until Week 48|Death|0
6190278|NCT01408901|9846279|FG001|12-Week Follow-Up (Primary Endpoint)|Lost to Follow-up|0
6190279|NCT01408901|9846280|FG002|12-Week Follow-Up (Primary Endpoint)|Lost to Follow-up|0
6255671|NCT01995201|9947095|FG000|From Week 24 Until Week 48|Lack of Efficacy|0
6255672|NCT01995201|9947096|FG001|From Week 24 Until Week 48|Lack of Efficacy|0
6255673|NCT01995201|9947097|FG002|From Week 24 Until Week 48|Lack of Efficacy|1
6255674|NCT01995201|9947098|FG003|From Week 24 Until Week 48|Lack of Efficacy|0
6255675|NCT01995201|9947099|FG004|From Week 24 Until Week 48|Lack of Efficacy|0
6255676|NCT01995201|9947100|FG005|From Week 24 Until Week 48|Lack of Efficacy|2
6255677|NCT01995201|9947101|FG006|From Week 24 Until Week 48|Lack of Efficacy|1
6255678|NCT01995201|9947095|FG000|From Week 24 Until Week 48|Lost to Follow-up|0
6255679|NCT01995201|9947096|FG001|From Week 24 Until Week 48|Lost to Follow-up|0
6255680|NCT01995201|9947097|FG002|From Week 24 Until Week 48|Lost to Follow-up|0
6255681|NCT01995201|9947098|FG003|From Week 24 Until Week 48|Lost to Follow-up|0
6255682|NCT01995201|9947099|FG004|From Week 24 Until Week 48|Lost to Follow-up|1
6255683|NCT01995201|9947100|FG005|From Week 24 Until Week 48|Lost to Follow-up|1
6255684|NCT01995201|9947101|FG006|From Week 24 Until Week 48|Lost to Follow-up|0
6255685|NCT01995201|9947095|FG000|From Week 24 Until Week 48|Withdrawal by Subject|0
6255686|NCT01995201|9947096|FG001|From Week 24 Until Week 48|Withdrawal by Subject|0
6255687|NCT01995201|9947097|FG002|From Week 24 Until Week 48|Withdrawal by Subject|1
6255688|NCT01995201|9947098|FG003|From Week 24 Until Week 48|Withdrawal by Subject|0
6255689|NCT01995201|9947099|FG004|From Week 24 Until Week 48|Withdrawal by Subject|1
6255690|NCT01995201|9947100|FG005|From Week 24 Until Week 48|Withdrawal by Subject|0
6255691|NCT01995201|9947101|FG006|From Week 24 Until Week 48|Withdrawal by Subject|0
6255692|NCT01995201|9947095|FG000|From Week 24 Until Week 48|Physician Decision|0
6255693|NCT01995201|9947096|FG001|From Week 24 Until Week 48|Physician Decision|0
6255694|NCT01995201|9947097|FG002|From Week 24 Until Week 48|Physician Decision|0
6086598|NCT00662649|9696709|FG000|Core Study (24 Months)|Withdrawal by Subject|31
6086599|NCT00662649|9696710|FG001|Core Study (24 Months)|Withdrawal by Subject|17
6086600|NCT00662649|9696711|FG002|Core Study (24 Months)|Withdrawal by Subject|28
6086601|NCT00662649|9696712|FG003|Core Study (24 Months)|Withdrawal by Subject|0
6086602|NCT00662649|9696713|FG004|Core Study (24 Months)|Withdrawal by Subject|0
6086603|NCT00662649|9696709|FG000|Core Study (24 Months)|Adverse Event|22
6086604|NCT00662649|9696710|FG001|Core Study (24 Months)|Adverse Event|13
6190280|NCT01408901|9846281|FG003|12-Week Follow-Up (Primary Endpoint)|Lost to Follow-up|2
6255695|NCT01995201|9947098|FG003|From Week 24 Until Week 48|Physician Decision|0
6255696|NCT01995201|9947099|FG004|From Week 24 Until Week 48|Physician Decision|1
6255697|NCT01995201|9947100|FG005|From Week 24 Until Week 48|Physician Decision|0
6255698|NCT01995201|9947101|FG006|From Week 24 Until Week 48|Physician Decision|0
6255699|NCT01995201|9947095|FG000|From Week 24 Until Week 48|Protocol Violation|0
6255700|NCT01995201|9947096|FG001|From Week 24 Until Week 48|Protocol Violation|0
6255701|NCT01995201|9947097|FG002|From Week 24 Until Week 48|Protocol Violation|1
6255702|NCT01995201|9947098|FG003|From Week 24 Until Week 48|Protocol Violation|0
6255703|NCT01995201|9947099|FG004|From Week 24 Until Week 48|Protocol Violation|2
6255704|NCT01995201|9947100|FG005|From Week 24 Until Week 48|Protocol Violation|0
6255705|NCT01995201|9947101|FG006|From Week 24 Until Week 48|Protocol Violation|0
6255706|NCT01995266|9947122|FG000|Overall Study|Death|1
6255707|NCT01995266|9947122|FG000|Overall Study|Lack of Efficacy|6
6255708|NCT01995266|9947122|FG000|Overall Study|Adverse Event|2
6255709|NCT01995357|9947126|FG000|Period 5|Lack of Efficacy|1
6255710|NCT01995357|9947127|FG001|Period 5|Lack of Efficacy|0
6255711|NCT01995357|9947128|FG002|Period 5|Lack of Efficacy|0
6190281|NCT01408901|9846278|FG000|12-Week Follow-Up (Primary Endpoint)|Death|1
6190282|NCT01408901|9846279|FG001|12-Week Follow-Up (Primary Endpoint)|Death|0
6190283|NCT01408901|9846280|FG002|12-Week Follow-Up (Primary Endpoint)|Death|0
6190284|NCT01408901|9846281|FG003|12-Week Follow-Up (Primary Endpoint)|Death|0
6255712|NCT01995357|9947129|FG003|Period 5|Lack of Efficacy|0
6255713|NCT01995357|9947130|FG004|Period 5|Lack of Efficacy|0
6190285|NCT01408901|9846278|FG000|12-Week Follow-Up (Primary Endpoint)|Cancelled visit|0
6190286|NCT01408901|9846279|FG001|12-Week Follow-Up (Primary Endpoint)|Cancelled visit|2
6190287|NCT01408901|9846280|FG002|12-Week Follow-Up (Primary Endpoint)|Cancelled visit|0
6190288|NCT01408901|9846281|FG003|12-Week Follow-Up (Primary Endpoint)|Cancelled visit|1
6190289|NCT01408901|9846278|FG000|26-Week Follow-Up|Lost to Follow-up|1
6190290|NCT01408901|9846279|FG001|26-Week Follow-Up|Lost to Follow-up|1
6190291|NCT01408901|9846280|FG002|26-Week Follow-Up|Lost to Follow-up|0
6190292|NCT01408901|9846281|FG003|26-Week Follow-Up|Lost to Follow-up|1
6190293|NCT01408901|9846278|FG000|26-Week Follow-Up|Death|0
6190294|NCT01408901|9846279|FG001|26-Week Follow-Up|Death|1
6190295|NCT01408901|9846280|FG002|26-Week Follow-Up|Death|0
6190296|NCT01408901|9846281|FG003|26-Week Follow-Up|Death|0
6190297|NCT01408914|9846296|FG000|Overall Study|Could not complete tx in protocol period|5
6190298|NCT01408914|9846297|FG001|Overall Study|Could not complete tx in protocol period|5
6190299|NCT01408914|9846298|FG002|Overall Study|Could not complete tx in protocol period|6
6190300|NCT01408914|9846296|FG000|Overall Study|Lost to Follow-up|4
6190301|NCT01408914|9846297|FG001|Overall Study|Lost to Follow-up|1
6190302|NCT01408914|9846298|FG002|Overall Study|Lost to Follow-up|2
6190303|NCT01408914|9846296|FG000|Overall Study|Physician Decision|1
6190304|NCT01408914|9846297|FG001|Overall Study|Physician Decision|1
6190305|NCT01408914|9846298|FG002|Overall Study|Physician Decision|0
6255714|NCT01995357|9947131|FG005|Period 5|Lack of Efficacy|0
6255715|NCT01995357|9947126|FG000|Period 5|Adverse Event|1
6255716|NCT01995357|9947127|FG001|Period 5|Adverse Event|0
6255717|NCT01995357|9947128|FG002|Period 5|Adverse Event|1
6255718|NCT01995357|9947129|FG003|Period 5|Adverse Event|0
6255719|NCT01995357|9947130|FG004|Period 5|Adverse Event|0
6255720|NCT01995357|9947131|FG005|Period 5|Adverse Event|0
6255721|NCT01995461|9947147|FG000|Overall Study|Death|1
6255722|NCT01995461|9947147|FG000|Overall Study|Lost to Follow-up|2
6255723|NCT01995461|9947147|FG000|Overall Study|Withdrawal by Subject|2
6255724|NCT01995513|9947160|FG000|Open Label Treatment Period|Other|9
6255725|NCT01995513|9947161|FG001|Open Label Treatment Period|Other|0
6255726|NCT01995513|9947162|FG002|Open Label Treatment Period|Other|0
6255727|NCT01995513|9947160|FG000|Open Label Treatment Period|Withdrawal by Subject|14
6255728|NCT01995513|9947161|FG001|Open Label Treatment Period|Withdrawal by Subject|0
6255729|NCT01995513|9947162|FG002|Open Label Treatment Period|Withdrawal by Subject|0
6255730|NCT01995513|9947160|FG000|Open Label Treatment Period|Protocol Violation|1
6255731|NCT01995513|9947161|FG001|Open Label Treatment Period|Protocol Violation|0
6255732|NCT01995513|9947162|FG002|Open Label Treatment Period|Protocol Violation|0
6255733|NCT01995513|9947160|FG000|Open Label Treatment Period|Disease Progression|64
6255734|NCT01995513|9947161|FG001|Open Label Treatment Period|Disease Progression|0
6255735|NCT01995513|9947162|FG002|Open Label Treatment Period|Disease Progression|0
6255736|NCT01995513|9947160|FG000|Open Label Treatment Period|No PSA response at week 13|43
6255737|NCT01995513|9947161|FG001|Open Label Treatment Period|No PSA response at week 13|0
6255738|NCT01995513|9947162|FG002|Open Label Treatment Period|No PSA response at week 13|0
6255739|NCT01995513|9947160|FG000|Open Label Treatment Period|Adverse Event|35
6255740|NCT01995513|9947161|FG001|Open Label Treatment Period|Adverse Event|0
6255741|NCT01995513|9947162|FG002|Open Label Treatment Period|Adverse Event|0
6255742|NCT01995513|9947160|FG000|Open Label Treatment Period|Death|8
6255743|NCT01995513|9947161|FG001|Open Label Treatment Period|Death|0
6255744|NCT01995513|9947162|FG002|Open Label Treatment Period|Death|0
6255745|NCT01995513|9947160|FG000|Open Label Treatment Period|Ongoing as of data cutoff (07 Oct 2016)|84
6255746|NCT01995513|9947161|FG001|Open Label Treatment Period|Ongoing as of data cutoff (07 Oct 2016)|0
6255747|NCT01995513|9947162|FG002|Open Label Treatment Period|Ongoing as of data cutoff (07 Oct 2016)|0
6255748|NCT01995513|9947160|FG000|Double Blind Treatment Period|Adverse Event|0
6255749|NCT01995513|9947161|FG001|Double Blind Treatment Period|Adverse Event|12
6255750|NCT01995513|9947162|FG002|Double Blind Treatment Period|Adverse Event|5
6255751|NCT01995513|9947160|FG000|Double Blind Treatment Period|Other|0
6255752|NCT01995513|9947161|FG001|Double Blind Treatment Period|Other|1
6255753|NCT01995513|9947162|FG002|Double Blind Treatment Period|Other|2
6255754|NCT01995513|9947160|FG000|Double Blind Treatment Period|Withdrawal by Subject|0
6255755|NCT01995513|9947161|FG001|Double Blind Treatment Period|Withdrawal by Subject|4
6255756|NCT01995513|9947162|FG002|Double Blind Treatment Period|Withdrawal by Subject|6
6255757|NCT01995513|9947160|FG000|Double Blind Treatment Period|Death|0
6255758|NCT01995513|9947161|FG001|Double Blind Treatment Period|Death|0
6255759|NCT01995513|9947162|FG002|Double Blind Treatment Period|Death|1
6255760|NCT01995513|9947160|FG000|Double Blind Treatment Period|Disease Progression|0
6255761|NCT01995513|9947161|FG001|Double Blind Treatment Period|Disease Progression|82
6255762|NCT01995513|9947162|FG002|Double Blind Treatment Period|Disease Progression|93
6255763|NCT01995513|9947160|FG000|Double Blind Treatment Period|Ongoing as of data cutoff (07 Oct 2016)|0
6255764|NCT01995513|9947161|FG001|Double Blind Treatment Period|Ongoing as of data cutoff (07 Oct 2016)|27
6255765|NCT01995513|9947162|FG002|Double Blind Treatment Period|Ongoing as of data cutoff (07 Oct 2016)|18
6255766|NCT01995526|9947172|FG000|Overall Study|Physician Decision|1
6255767|NCT01995539|9947176|FG000|Overall Study|Screening Failure|1
6255768|NCT01995539|9947176|FG000|Overall Study|Withdrawal by Investigator|15
6255769|NCT01995539|9947176|FG000|Overall Study|Withdrawal by Subject|11
6255770|NCT01995539|9947176|FG000|Overall Study|Lost to Follow-up|5
6255771|NCT01995539|9947176|FG000|Overall Study|Subject missed visit 3,4, came in for V5|1
6255772|NCT01995552|9947180|FG000|Overall Study|Protocol Violation|1
6255773|NCT01995552|9947180|FG000|Overall Study|Lack of Efficacy|15
6255774|NCT01995552|9947180|FG000|Overall Study|Death|1
6255775|NCT01995825|9947188|FG000|Overall Study|Withdrawal by Subject|1
6255776|NCT01995825|9947189|FG001|Overall Study|Withdrawal by Subject|0
6255777|NCT01995838|9947202|FG000|Overall Study|Lost to Follow-up|0
6255778|NCT01995838|9947203|FG001|Overall Study|Lost to Follow-up|1
6255779|NCT01995838|9947204|FG002|Overall Study|Lost to Follow-up|0
6255780|NCT01995838|9947205|FG003|Overall Study|Lost to Follow-up|0
6255781|NCT01995838|9947206|FG004|Overall Study|Lost to Follow-up|0
6255782|NCT01995838|9947207|FG005|Overall Study|Lost to Follow-up|0
6255783|NCT01995838|9947208|FG006|Overall Study|Lost to Follow-up|1
6255784|NCT01995838|9947202|FG000|Overall Study|Participant choice|2
6255785|NCT01995838|9947203|FG001|Overall Study|Participant choice|0
6255786|NCT01995838|9947204|FG002|Overall Study|Participant choice|0
6255787|NCT01995838|9947205|FG003|Overall Study|Participant choice|0
6255788|NCT01995838|9947206|FG004|Overall Study|Participant choice|0
6255789|NCT01995838|9947207|FG005|Overall Study|Participant choice|1
6255790|NCT01995838|9947208|FG006|Overall Study|Participant choice|1
6255791|NCT01995838|9947202|FG000|Overall Study|Adverse Event|0
6255792|NCT01995838|9947203|FG001|Overall Study|Adverse Event|0
6255793|NCT01995838|9947204|FG002|Overall Study|Adverse Event|0
6255794|NCT01995838|9947205|FG003|Overall Study|Adverse Event|0
6255795|NCT01995838|9947206|FG004|Overall Study|Adverse Event|0
6255796|NCT01995838|9947207|FG005|Overall Study|Adverse Event|0
6255797|NCT01995838|9947208|FG006|Overall Study|Adverse Event|1
6255798|NCT01995838|9947202|FG000|Overall Study|Withdrawal by Subject|0
6255799|NCT01995838|9947203|FG001|Overall Study|Withdrawal by Subject|0
6255800|NCT01995838|9947204|FG002|Overall Study|Withdrawal by Subject|0
6255801|NCT01995838|9947205|FG003|Overall Study|Withdrawal by Subject|0
6255802|NCT01995838|9947206|FG004|Overall Study|Withdrawal by Subject|1
6255803|NCT01995838|9947207|FG005|Overall Study|Withdrawal by Subject|0
6255804|NCT01995838|9947208|FG006|Overall Study|Withdrawal by Subject|0
6255805|NCT01995838|9947202|FG000|Overall Study|Other|3
6255806|NCT01995838|9947203|FG001|Overall Study|Other|1
6255807|NCT01995838|9947204|FG002|Overall Study|Other|0
6255808|NCT01995838|9947205|FG003|Overall Study|Other|2
6255809|NCT01995838|9947206|FG004|Overall Study|Other|1
6255810|NCT01995838|9947207|FG005|Overall Study|Other|1
6255811|NCT01995838|9947208|FG006|Overall Study|Other|2
6255812|NCT01996033|9947225|FG000|Overall Study|Death|1
6255813|NCT01996033|9947225|FG000|Overall Study|Physician Decision|1
6255814|NCT01996033|9947225|FG000|Overall Study|Withdrawal by Subject|4
6255815|NCT01996033|9947225|FG000|Overall Study|Lost to Follow-up|3
6255816|NCT01996241|9947231|FG000|Overall Study|Lost to Follow-up|252
6255817|NCT01996241|9947232|FG001|Overall Study|Lost to Follow-up|235
6255818|NCT01996254|9947242|FG000|Overall Study|Change in Eligibility|0
6255819|NCT01996254|9947243|FG001|Overall Study|Change in Eligibility|2
6255820|NCT01996254|9947244|FG002|Overall Study|Change in Eligibility|0
6255821|NCT01996254|9947242|FG000|Overall Study|Withdrawal by Subject|0
6255822|NCT01996254|9947243|FG001|Overall Study|Withdrawal by Subject|3
6255823|NCT01996254|9947244|FG002|Overall Study|Withdrawal by Subject|4
6255824|NCT01996254|9947242|FG000|Overall Study|Lost to Follow-up|1
6255825|NCT01996254|9947243|FG001|Overall Study|Lost to Follow-up|0
6255826|NCT01996254|9947244|FG002|Overall Study|Lost to Follow-up|4
6255827|NCT01996319|9947256|FG000|Overall Study|Protocol Violation|1
6255828|NCT01996319|9947257|FG001|Overall Study|Protocol Violation|0
6255829|NCT01996319|9947256|FG000|Overall Study|Severe or moderate (COPD) Exacerbation|5
6255830|NCT01996319|9947257|FG001|Overall Study|Severe or moderate (COPD) Exacerbation|1
6255831|NCT01996319|9947256|FG000|Overall Study|Adverse Event|2
6255832|NCT01996319|9947257|FG001|Overall Study|Adverse Event|2
6255833|NCT01996332|9947263|FG000|Overall Study|Adverse Event|117
6255834|NCT01996332|9947263|FG000|Overall Study|Lack of Efficacy|1245
6255835|NCT01996332|9947263|FG000|Overall Study|Death|264
6255836|NCT01996332|9947263|FG000|Overall Study|Protocol Violation|9
6255837|NCT01996332|9947263|FG000|Overall Study|Withdrawal by Subject|71
6255838|NCT01996332|9947263|FG000|Overall Study|Other|20
6255839|NCT01996332|9947263|FG000|Overall Study|Clinical Deterioration|28
6255840|NCT01996332|9947263|FG000|Overall Study|Physician Decision|17
6255841|NCT01996332|9947263|FG000|Overall Study|Lost to Follow-up|34
6271048|NCT02159469|9972536|FG000|Overall Study|Withdrawal by Subject|9
6271049|NCT02159469|9972536|FG000|Overall Study|Lost to Follow-up|1
6271050|NCT02159469|9972536|FG000|Overall Study|Sponsor's request|2
6271051|NCT02159469|9972536|FG000|Overall Study|Met Stopping Criteria|3
6271052|NCT02159469|9972536|FG000|Overall Study|Other|1
6271053|NCT02159469|9972536|FG000|Overall Study|Multiple|29
6271054|NCT02159482|9972541|FG000|Overall Study|Withdrawal by Subject|2
6271055|NCT02159482|9972541|FG000|Overall Study|Physician Decision|3
6271056|NCT02159521|9972545|FG000|Overall Study|Enrolled but not treated|3
6271057|NCT02159521|9972545|FG000|Overall Study|Withdrawal by Subject|7
6271058|NCT02159521|9972545|FG000|Overall Study|Lost to Follow-up|6
6271059|NCT02159521|9972545|FG000|Overall Study|Death|1
6271060|NCT02159521|9972545|FG000|Overall Study|Other than specified|1
6271061|NCT02159729|9972565|FG000|Overall Study|Adverse Event|0
6271062|NCT02159729|9972566|FG001|Overall Study|Adverse Event|1
6271063|NCT02159729|9972565|FG000|Overall Study|Subject's Request|13
6271064|NCT02159729|9972566|FG001|Overall Study|Subject's Request|10
6271065|NCT02159729|9972565|FG000|Overall Study|Lost to Follow-up|24
6271066|NCT02159729|9972566|FG001|Overall Study|Lost to Follow-up|9
6271067|NCT02159729|9972565|FG000|Overall Study|Non compliance|2
6271068|NCT02159729|9972566|FG001|Overall Study|Non compliance|0
6271069|NCT02159729|9972565|FG000|Overall Study|Other Unspecified|3
6271070|NCT02159729|9972566|FG001|Overall Study|Other Unspecified|1
6271071|NCT02159807|9972579|FG000|Overall Study|Adverse Event|0
6271072|NCT02159807|9972580|FG001|Overall Study|Adverse Event|0
6271073|NCT02159807|9972581|FG002|Overall Study|Adverse Event|1
6271074|NCT02159807|9972579|FG000|Overall Study|No CSF|1
6271075|NCT02159807|9972580|FG001|Overall Study|No CSF|1
6271076|NCT02159807|9972581|FG002|Overall Study|No CSF|1
6271077|NCT02159807|9972579|FG000|Overall Study|elevated blood pressure|0
6271078|NCT02159807|9972580|FG001|Overall Study|elevated blood pressure|0
6271079|NCT02159807|9972581|FG002|Overall Study|elevated blood pressure|1
6271080|NCT02159950|9972610|FG000|Overall Study|Adverse Event|0
6271081|NCT02159950|9972611|FG001|Overall Study|Adverse Event|1
6271082|NCT02159950|9972610|FG000|Overall Study|Progression|0
6271083|NCT02159950|9972611|FG001|Overall Study|Progression|1
6271084|NCT02160002|9972630|FG000|Overall Study|Withdrawal by Subject|2
6271085|NCT02160002|9972631|FG001|Overall Study|Withdrawal by Subject|1
6271086|NCT02160041|9972637|FG000|Overall Study|Adverse Event|11
6271087|NCT02160041|9972637|FG000|Overall Study|Death|2
6271088|NCT02160041|9972637|FG000|Overall Study|disease progression|57
6271089|NCT02160041|9972637|FG000|Overall Study|Protocol Violation|1
6255842|NCT01996592|9947267|FG000|Overall Study|no response to text/no diary entry|32
6255843|NCT01996592|9947267|FG000|Overall Study|change in surgical date|4
6255844|NCT01996592|9947267|FG000|Overall Study|Withdrawal by Subject|5
6255845|NCT01996592|9947267|FG000|Overall Study|change in mode of delivery|4
6255846|NCT01996709|9947303|FG000|Overall Study|Withdrawal by Subject|1
6255847|NCT01996709|9947304|FG001|Overall Study|Withdrawal by Subject|0
6255848|NCT01996709|9947303|FG000|Overall Study|Lost to Follow-up|3
6255849|NCT01996709|9947304|FG001|Overall Study|Lost to Follow-up|0
6255850|NCT01996709|9947303|FG000|Overall Study|Subject Non-Compliant|1
6255851|NCT01996709|9947304|FG001|Overall Study|Subject Non-Compliant|0
6255852|NCT01996709|9947303|FG000|Overall Study|Failed Inclusion/Exclusion Criteria|0
6255853|NCT01996709|9947304|FG001|Overall Study|Failed Inclusion/Exclusion Criteria|1
6255854|NCT01996748|9947316|FG000|Overall Study|Personal reason|1
6255855|NCT01996748|9947317|FG001|Overall Study|Personal reason|0
6255856|NCT01996748|9947316|FG000|Overall Study|Physician Decision|2
6255857|NCT01996748|9947317|FG001|Overall Study|Physician Decision|0
6255858|NCT01996748|9947316|FG000|Overall Study|Adverse Event|1
6255859|NCT01996748|9947317|FG001|Overall Study|Adverse Event|4
6255860|NCT01996748|9947316|FG000|Overall Study|Withdrawal by Subject|0
6255861|NCT01996748|9947317|FG001|Overall Study|Withdrawal by Subject|1
6255862|NCT01996748|9947316|FG000|Overall Study|Lost to Follow-up|4
6255863|NCT01996748|9947317|FG001|Overall Study|Lost to Follow-up|1
6255864|NCT01996826|9947336|FG000|Overall Study|Lost to Follow-up|6
6255865|NCT01996826|9947337|FG001|Overall Study|Lost to Follow-up|2
6255866|NCT01996826|9947336|FG000|Overall Study|Physician Decision|1
6255867|NCT01996826|9947337|FG001|Overall Study|Physician Decision|1
6255868|NCT01996904|9947358|FG000|Overall Study|Lost to Follow-up|38
6190306|NCT01408914|9846296|FG000|Overall Study|Withdrawal by Subject|1
6190307|NCT01408914|9846297|FG001|Overall Study|Withdrawal by Subject|0
6190308|NCT01408914|9846298|FG002|Overall Study|Withdrawal by Subject|1
6190309|NCT01408914|9846296|FG000|Overall Study|Moved out of study jurisdiction|1
6190310|NCT01408914|9846297|FG001|Overall Study|Moved out of study jurisdiction|1
6190311|NCT01408914|9846298|FG002|Overall Study|Moved out of study jurisdiction|0
6190312|NCT01408914|9846296|FG000|Overall Study|Late exclusion|0
6190313|NCT01408914|9846297|FG001|Overall Study|Late exclusion|3
6190314|NCT01408914|9846298|FG002|Overall Study|Late exclusion|3
6190315|NCT01408914|9846296|FG000|Overall Study|Change in local TB/HIV norms|0
6190316|NCT01408914|9846297|FG001|Overall Study|Change in local TB/HIV norms|1
6190317|NCT01408914|9846298|FG002|Overall Study|Change in local TB/HIV norms|1
6190318|NCT01409382|9846351|FG000|Overall Study|Lost to Follow-up|1
6190319|NCT01409382|9846352|FG001|Overall Study|Lost to Follow-up|1
6190320|NCT01409382|9846351|FG000|Overall Study|Protocol Violation|0
6190321|NCT01409382|9846352|FG001|Overall Study|Protocol Violation|3
6190322|NCT01409382|9846351|FG000|Overall Study|Multiple pregnancy|2
6190323|NCT01409382|9846352|FG001|Overall Study|Multiple pregnancy|4
6190324|NCT01409382|9846351|FG000|Overall Study|Still pregnant when study ended|13
6190325|NCT01409382|9846352|FG001|Overall Study|Still pregnant when study ended|2
6190326|NCT01409382|9846351|FG000|Overall Study|Did not manage to get pregnant|64
6190327|NCT01409382|9846352|FG001|Overall Study|Did not manage to get pregnant|70
6190328|NCT01409382|9846351|FG000|Overall Study|Had a 2nd trimester loss after accident|1
6190329|NCT01409382|9846352|FG001|Overall Study|Had a 2nd trimester loss after accident|0
6190330|NCT01409434|9846362|FG000|Overall Study|Protocol Violation|4
6190331|NCT01409564|9846368|FG000|Overall Study|low medication compliance|4
6190332|NCT01409564|9846369|FG001|Overall Study|low medication compliance|3
6190333|NCT01409564|9846368|FG000|Overall Study|brain abnormalities found in T1 MR|1
6190334|NCT01409564|9846369|FG001|Overall Study|brain abnormalities found in T1 MR|2
6190335|NCT01409707|9846382|FG000|Overall Study|Withdrawal by Subject|5
6190336|NCT01409707|9846383|FG001|Overall Study|Withdrawal by Subject|17
6190337|NCT01409707|9846384|FG002|Overall Study|Withdrawal by Subject|16
6190338|NCT01409811|9846391|FG000|Overall Study|Insurance denial|1
6190339|NCT01409837|9846397|FG000|Overall Study|Withdrawal by Subject|2
6190340|NCT01409837|9846398|FG001|Overall Study|Withdrawal by Subject|1
6190341|NCT01409837|9846397|FG000|Overall Study|Lost to Follow-up|1
6190342|NCT01409837|9846398|FG001|Overall Study|Lost to Follow-up|0
6190343|NCT01409837|9846397|FG000|Overall Study|Physician Decision|0
6190344|NCT01409837|9846398|FG001|Overall Study|Physician Decision|1
6190345|NCT01409915|9846408|FG000|Overall Study|Adverse Event|0
6190346|NCT01409915|9846409|FG001|Overall Study|Adverse Event|2
6190347|NCT01409915|9846408|FG000|Overall Study|Withdrawal by Subject|0
6190348|NCT01409915|9846409|FG001|Overall Study|Withdrawal by Subject|1
6190349|NCT01409915|9846408|FG000|Overall Study|Protocol Violation|1
6190350|NCT01409915|9846409|FG001|Overall Study|Protocol Violation|0
6190351|NCT01409928|9846415|FG000|Overall Study|Physician Decision|12
6190352|NCT01409993|9846421|FG000|Overall Study|Adverse Event|4
6190353|NCT01409993|9846422|FG001|Overall Study|Adverse Event|4
6190354|NCT01409993|9846423|FG002|Overall Study|Adverse Event|3
6190355|NCT01409993|9846424|FG003|Overall Study|Adverse Event|1
6190356|NCT01409993|9846421|FG000|Overall Study|Withdrawal by Subject|0
6190357|NCT01409993|9846422|FG001|Overall Study|Withdrawal by Subject|0
6190358|NCT01409993|9846423|FG002|Overall Study|Withdrawal by Subject|0
6190359|NCT01409993|9846424|FG003|Overall Study|Withdrawal by Subject|4
6190360|NCT01409993|9846421|FG000|Overall Study|Lost to Follow-up|0
6190361|NCT01409993|9846422|FG001|Overall Study|Lost to Follow-up|1
6255869|NCT01996904|9947359|FG001|Overall Study|Lost to Follow-up|27
6255870|NCT01997281|9947401|FG000|Overall Study|Withdrawal by Subject|1
6255871|NCT01997281|9947402|FG001|Overall Study|Withdrawal by Subject|0
6255872|NCT01997333|9947410|FG000|Randomization and Treatment|Disease Progression|70
6255873|NCT01997333|9947411|FG001|Randomization and Treatment|Disease Progression|159
6255874|NCT01997333|9947410|FG000|Randomization and Treatment|Adverse Event|10
6255875|NCT01997333|9947411|FG001|Randomization and Treatment|Adverse Event|32
6255876|NCT01997333|9947410|FG000|Randomization and Treatment|Physician Decision|0
6255877|NCT01997333|9947411|FG001|Randomization and Treatment|Physician Decision|4
6255878|NCT01997333|9947410|FG000|Randomization and Treatment|Withdrawal by Subject|6
6255879|NCT01997333|9947411|FG001|Randomization and Treatment|Withdrawal by Subject|3
6255880|NCT01997333|9947410|FG000|Randomization and Treatment|Did not receive treatment|17
6255881|NCT01997333|9947411|FG001|Randomization and Treatment|Did not receive treatment|5
6255882|NCT01997333|9947410|FG000|Survival Follow up|Withdrawal by Subject|15
6255883|NCT01997333|9947411|FG001|Survival Follow up|Withdrawal by Subject|6
6255884|NCT01997333|9947410|FG000|Survival Follow up|Lost to Follow-up|0
6255885|NCT01997333|9947411|FG001|Survival Follow up|Lost to Follow-up|6
6255886|NCT01997333|9947410|FG000|Survival Follow up|Various|1
6255887|NCT01997333|9947411|FG001|Survival Follow up|Various|2
6255888|NCT01997892|9947475|FG000|Overall Study|Physician Decision|2
6255889|NCT01997892|9947475|FG000|Overall Study|Lost to Follow-up|6
6255890|NCT01997892|9947475|FG000|Overall Study|Death|14
6255891|NCT01997892|9947475|FG000|Overall Study|Renal transplant|8
6255892|NCT01997892|9947475|FG000|Overall Study|Other|3
6255893|NCT01997892|9947475|FG000|Overall Study|Study completion data not recorded|35
6255894|NCT01998243|9947490|FG000|Overall Study|Pregnancy|0
6255895|NCT01998243|9947491|FG001|Overall Study|Pregnancy|1
6255896|NCT01998243|9947490|FG000|Overall Study|Protocol Violation|5
6255897|NCT01998243|9947491|FG001|Overall Study|Protocol Violation|2
6255898|NCT01998243|9947490|FG000|Overall Study|Withdrawal by Subject|3
6255899|NCT01998243|9947491|FG001|Overall Study|Withdrawal by Subject|4
6255900|NCT01998399|9947514|FG000|Overall Study|Lost to Follow-up|1
6255901|NCT01998399|9947515|FG001|Overall Study|Lost to Follow-up|3
6255902|NCT01998399|9947514|FG000|Overall Study|Death|4
6255903|NCT01998399|9947515|FG001|Overall Study|Death|2
6255904|NCT01998399|9947514|FG000|Overall Study|Study stopped before dosing completed|3
6255905|NCT01998399|9947515|FG001|Overall Study|Study stopped before dosing completed|3
6255906|NCT01998399|9947514|FG000|Overall Study|Withdrawal by Subject|0
6255907|NCT01998399|9947515|FG001|Overall Study|Withdrawal by Subject|1
6255908|NCT01998477|9947536|FG000|Overall Study|Lost to Follow-up|4
6255909|NCT01998477|9947537|FG001|Overall Study|Lost to Follow-up|5
6255910|NCT01998477|9947536|FG000|Overall Study|Withdrawal by Subject|6
6255911|NCT01998477|9947537|FG001|Overall Study|Withdrawal by Subject|0
6255912|NCT01998581|9947570|FG000|Overall Study|Refused repeat treatment|20
6255913|NCT01998581|9947571|FG001|Overall Study|Refused repeat treatment|4
6190362|NCT01409993|9846423|FG002|Overall Study|Lost to Follow-up|0
6190363|NCT01409993|9846424|FG003|Overall Study|Lost to Follow-up|0
6190364|NCT01410110|9846469|FG000|Overall Study|Withdrawal by Subject|4
6190365|NCT01410110|9846470|FG001|Overall Study|Withdrawal by Subject|2
6190366|NCT01410227|9846476|FG000|Overall Study|Adverse Event|1
6190367|NCT01410227|9846477|FG001|Overall Study|Adverse Event|0
6190368|NCT01410227|9846478|FG002|Overall Study|Adverse Event|0
6190369|NCT01410227|9846479|FG003|Overall Study|Adverse Event|0
6190370|NCT01410227|9846476|FG000|Overall Study|Withdrawal by Subject|3
6190371|NCT01410227|9846477|FG001|Overall Study|Withdrawal by Subject|0
6190372|NCT01410227|9846478|FG002|Overall Study|Withdrawal by Subject|1
6190373|NCT01410227|9846479|FG003|Overall Study|Withdrawal by Subject|0
6190374|NCT01410227|9846476|FG000|Overall Study|Pregnancy|0
6190375|NCT01410227|9846477|FG001|Overall Study|Pregnancy|0
6190376|NCT01410227|9846478|FG002|Overall Study|Pregnancy|0
6190377|NCT01410227|9846479|FG003|Overall Study|Pregnancy|1
6190378|NCT01410227|9846476|FG000|Overall Study|Met Excl. Criteria After Starting Study|0
6190379|NCT01410227|9846477|FG001|Overall Study|Met Excl. Criteria After Starting Study|0
6190380|NCT01410227|9846478|FG002|Overall Study|Met Excl. Criteria After Starting Study|1
6190381|NCT01410227|9846479|FG003|Overall Study|Met Excl. Criteria After Starting Study|0
6190382|NCT01410240|9846492|FG000|Overall Study|Physician Decision|0
6190383|NCT01410240|9846493|FG001|Overall Study|Physician Decision|0
6255914|NCT01998581|9947570|FG000|Overall Study|Protocol Violation|1
6255915|NCT01998581|9947571|FG001|Overall Study|Protocol Violation|0
6255916|NCT01998581|9947570|FG000|Overall Study|Withdrawal by Subject|8
6190384|NCT01410240|9846494|FG002|Overall Study|Physician Decision|1
6190385|NCT01410240|9846492|FG000|Overall Study|Missed week 6 assessments|1
6190386|NCT01410240|9846493|FG001|Overall Study|Missed week 6 assessments|1
6190387|NCT01410240|9846494|FG002|Overall Study|Missed week 6 assessments|1
6255917|NCT01998581|9947571|FG001|Overall Study|Withdrawal by Subject|1
6255918|NCT01998581|9947570|FG000|Overall Study|Lost to Follow-up|12
6255919|NCT01998581|9947571|FG001|Overall Study|Lost to Follow-up|4
6255920|NCT01998581|9947570|FG000|Overall Study|Adverse Event|1
6255921|NCT01998581|9947571|FG001|Overall Study|Adverse Event|1
6255922|NCT01998581|9947570|FG000|Overall Study|Other reasons|3
6255923|NCT01998581|9947571|FG001|Overall Study|Other reasons|2
6255924|NCT01998581|9947570|FG000|Overall Study|Randomized but withdrew before treatment|1
6255925|NCT01998581|9947571|FG001|Overall Study|Randomized but withdrew before treatment|0
6255926|NCT01998633|9947580|FG000|Overall Study|Death|1
6255927|NCT01998737|9947590|FG000|Overall Study|Corrupted database|23
6255928|NCT01998737|9947591|FG001|Overall Study|Corrupted database|0
6255929|NCT01998880|9947599|FG000|Overall Study|Adverse Events or Intercurrent Illness|16
6255930|NCT01998880|9947600|FG001|Overall Study|Adverse Events or Intercurrent Illness|16
6255931|NCT01998880|9947599|FG000|Overall Study|Disease Progression|1
6255932|NCT01998880|9947600|FG001|Overall Study|Disease Progression|8
6255933|NCT01998880|9947599|FG000|Overall Study|Withdrew Consent|2
6255934|NCT01998880|9947600|FG001|Overall Study|Withdrew Consent|1
6255935|NCT01998880|9947599|FG000|Overall Study|Death|3
6255936|NCT01998880|9947600|FG001|Overall Study|Death|6
6255937|NCT01998880|9947599|FG000|Overall Study|Insufficient Therapeutic Response|1
6255938|NCT01998880|9947600|FG001|Overall Study|Insufficient Therapeutic Response|5
6255939|NCT01998880|9947599|FG000|Overall Study|Administrative/Other|1
6255940|NCT01998880|9947600|FG001|Overall Study|Administrative/Other|1
6255941|NCT01998880|9947599|FG000|Overall Study|Refused Treatment/Did Not Cooperate|1
6255942|NCT01998880|9947600|FG001|Overall Study|Refused Treatment/Did Not Cooperate|0
6255943|NCT01998880|9947599|FG000|Overall Study|Violation of Selection Criteria at Entry|0
6255944|NCT01998880|9947600|FG001|Overall Study|Violation of Selection Criteria at Entry|1
6255945|NCT01998880|9947599|FG000|Overall Study|Did Not Receive Treatment|3
6255946|NCT01998880|9947600|FG001|Overall Study|Did Not Receive Treatment|2
6255947|NCT01998893|9947606|FG000|Overall Study|Adverse Event|2
6255948|NCT01998893|9947606|FG000|Overall Study|Death|1
6255949|NCT01998893|9947606|FG000|Overall Study|Lost to Follow-up|8
6255950|NCT01998893|9947606|FG000|Overall Study|Physician Decision|2
6255951|NCT01998893|9947606|FG000|Overall Study|Protocol Violation|2
6255952|NCT01998893|9947606|FG000|Overall Study|Withdrawal by Subject|1
6255953|NCT01998893|9947606|FG000|Overall Study|Transformation to high-grade lymphoma|1
6255954|NCT01998906|9947613|FG000|Overall Study|Participants ongoing in follow-up|77
6190388|NCT01410357|9846511|FG000|Overall Study|Death|2
6190389|NCT01410357|9846512|FG001|Overall Study|Death|1
6190390|NCT01410357|9846511|FG000|Overall Study|Withdrawal by Subject|1
6190391|NCT01410357|9846512|FG001|Overall Study|Withdrawal by Subject|2
6190392|NCT01410357|9846511|FG000|Overall Study|Lost to Follow-up|23
6190393|NCT01410357|9846512|FG001|Overall Study|Lost to Follow-up|21
6190394|NCT01410448|9846531|FG000|Overall Study|No conversion to everolimus|0
6190395|NCT01410448|9846532|FG001|Overall Study|No conversion to everolimus|24
6190396|NCT01410448|9846531|FG000|Overall Study|Graft loss|4
6190397|NCT01410448|9846532|FG001|Overall Study|Graft loss|1
6190398|NCT01410448|9846531|FG000|Overall Study|Administrative issues|2
6190399|NCT01410448|9846532|FG001|Overall Study|Administrative issues|1
6190400|NCT01410448|9846531|FG000|Overall Study|Lost to Follow-up|1
6190401|NCT01410448|9846532|FG001|Overall Study|Lost to Follow-up|0
6190402|NCT01410448|9846531|FG000|Overall Study|Withdrawal by Subject|3
6190403|NCT01410448|9846532|FG001|Overall Study|Withdrawal by Subject|2
6190404|NCT01410448|9846531|FG000|Overall Study|Protocol Violation|0
6190405|NCT01410448|9846532|FG001|Overall Study|Protocol Violation|4
6190406|NCT01410448|9846531|FG000|Overall Study|Death|2
6190407|NCT01410448|9846532|FG001|Overall Study|Death|3
6190408|NCT01410474|9846540|FG000|Overall Study|Withdrawal by Subject|0
6190409|NCT01410474|9846541|FG001|Overall Study|Withdrawal by Subject|1
6190410|NCT01410604|9846570|FG000|Overall Study|Adverse Event|2
6190411|NCT01410604|9846571|FG001|Overall Study|Adverse Event|1
6190412|NCT01410604|9846570|FG000|Overall Study|Lost to Follow-up|1
6190413|NCT01410604|9846571|FG001|Overall Study|Lost to Follow-up|0
6190414|NCT01410604|9846570|FG000|Overall Study|Physician Decision|0
6190415|NCT01410604|9846571|FG001|Overall Study|Physician Decision|1
6190416|NCT01411085|9846594|FG000|Overall Study|Physician Decision|1
6190417|NCT01411085|9846594|FG000|Overall Study|Protocol Violation|1
6190418|NCT01411085|9846594|FG000|Overall Study|Adverse Event|1
6190419|NCT01411215|9846615|FG000|Overall Study|Adverse Event|1
6190420|NCT01411215|9846616|FG001|Overall Study|Adverse Event|2
6255955|NCT01998906|9947614|FG001|Overall Study|Participants ongoing in follow-up|60
6255956|NCT01998906|9947615|FG002|Overall Study|Participants ongoing in follow-up|58
6190421|NCT01411215|9846615|FG000|Overall Study|Lack of Efficacy|2
6190422|NCT01411215|9846616|FG001|Overall Study|Lack of Efficacy|4
6190423|NCT01411215|9846615|FG000|Overall Study|Lost to Follow-up|12
6190424|NCT01411215|9846616|FG001|Overall Study|Lost to Follow-up|18
6190425|NCT01411215|9846615|FG000|Overall Study|Did not meet entrance criteria|0
6190426|NCT01411215|9846616|FG001|Overall Study|Did not meet entrance criteria|1
6190427|NCT01411215|9846615|FG000|Overall Study|Study terminated by sponsor|2
6190428|NCT01411215|9846616|FG001|Overall Study|Study terminated by sponsor|15
6190429|NCT01411215|9846615|FG000|Overall Study|Protocol Violation|3
6255957|NCT01998906|9947613|FG000|Overall Study|Death|21
6255958|NCT01998906|9947614|FG001|Overall Study|Death|30
6255959|NCT01998906|9947615|FG002|Overall Study|Death|17
6255960|NCT01998906|9947613|FG000|Overall Study|Lack of Efficacy|10
6255961|NCT01998906|9947614|FG001|Overall Study|Lack of Efficacy|9
6255962|NCT01998906|9947615|FG002|Overall Study|Lack of Efficacy|8
6255963|NCT01998906|9947613|FG000|Overall Study|Failure to return|0
6255964|NCT01998906|9947614|FG001|Overall Study|Failure to return|2
6255965|NCT01998906|9947615|FG002|Overall Study|Failure to return|4
6255966|NCT01998906|9947613|FG000|Overall Study|Violation of Selection Criteria|0
6255967|NCT01998906|9947614|FG001|Overall Study|Violation of Selection Criteria|0
6255968|NCT01998906|9947615|FG002|Overall Study|Violation of Selection Criteria|1
6255969|NCT01998906|9947613|FG000|Overall Study|Withdrawal by Subject|1
6255970|NCT01998906|9947614|FG001|Overall Study|Withdrawal by Subject|4
6255971|NCT01998906|9947615|FG002|Overall Study|Withdrawal by Subject|3
6255972|NCT01998906|9947613|FG000|Overall Study|Administrative/Other|2
6255973|NCT01998906|9947614|FG001|Overall Study|Administrative/Other|1
6255974|NCT01998906|9947615|FG002|Overall Study|Administrative/Other|3
6255975|NCT01998906|9947613|FG000|Overall Study|Other|3
6255976|NCT01998906|9947614|FG001|Overall Study|Other|8
6255977|NCT01998906|9947615|FG002|Overall Study|Other|4
6255978|NCT01998919|9947628|FG000|Overall Study|Death|2
6255979|NCT01998919|9947629|FG001|Overall Study|Death|2
6255980|NCT01998919|9947628|FG000|Overall Study|Adverse Event|0
6255981|NCT01998919|9947629|FG001|Overall Study|Adverse Event|5
6255982|NCT01998919|9947628|FG000|Overall Study|Disease progression|31
6255983|NCT01998919|9947629|FG001|Overall Study|Disease progression|22
6255984|NCT01998919|9947628|FG000|Overall Study|Withdrawal by Subject|2
6255985|NCT01998919|9947629|FG001|Overall Study|Withdrawal by Subject|4
6255986|NCT01998919|9947628|FG000|Overall Study|Lost to Follow-up|2
6255987|NCT01998919|9947629|FG001|Overall Study|Lost to Follow-up|0
6255988|NCT01998919|9947628|FG000|Overall Study|Other|5
6255989|NCT01998919|9947629|FG001|Overall Study|Other|2
6255990|NCT01998958|9947642|FG000|Period 1 (Panel A and B)|Withdrawal by Subject|0
6255991|NCT01998958|9947643|FG001|Period 1 (Panel A and B)|Withdrawal by Subject|1
6255992|NCT01998958|9947644|FG002|Period 1 (Panel A and B)|Withdrawal by Subject|0
6255993|NCT01998958|9947645|FG003|Period 1 (Panel A and B)|Withdrawal by Subject|0
6255994|NCT01998958|9947646|FG004|Period 1 (Panel A and B)|Withdrawal by Subject|0
6255995|NCT01998958|9947647|FG005|Period 1 (Panel A and B)|Withdrawal by Subject|0
6190430|NCT01411215|9846616|FG001|Overall Study|Protocol Violation|5
6190431|NCT01411215|9846615|FG000|Overall Study|Withdrawal by Subject|34
6190432|NCT01411215|9846616|FG001|Overall Study|Withdrawal by Subject|21
6190433|NCT01411215|9846615|FG000|Overall Study|Other|12
6190434|NCT01411215|9846616|FG001|Overall Study|Other|17
6190435|NCT01411215|9846615|FG000|Overall Study|Screen failure|0
6190436|NCT01411215|9846616|FG001|Overall Study|Screen failure|1
6190437|NCT01411228|9846625|FG000|Overall Study|Lost to Follow-up|0
6190438|NCT01411228|9846626|FG001|Overall Study|Lost to Follow-up|0
6190439|NCT01411228|9846627|FG002|Overall Study|Lost to Follow-up|1
6190440|NCT01411228|9846625|FG000|Overall Study|Withdrawal by Subject|1
6190441|NCT01411228|9846626|FG001|Overall Study|Withdrawal by Subject|0
6190442|NCT01411228|9846627|FG002|Overall Study|Withdrawal by Subject|0
6190443|NCT01411319|9846635|FG000|Overall Study|Lost to Follow-up|1
6193305|NCT01437319|9850951|FG001|Phase I|Study related symptoms/complaints|0
6193306|NCT01437319|9850952|FG002|Phase I|Study related symptoms/complaints|0
6193307|NCT01437319|9850950|FG000|Phase I|Withdrawal by Subject|25
6193308|NCT01437319|9850951|FG001|Phase I|Withdrawal by Subject|0
6193309|NCT01437319|9850952|FG002|Phase I|Withdrawal by Subject|0
6193310|NCT01437319|9850950|FG000|Phase II|Withdrawal by Subject|0
6193311|NCT01437319|9850951|FG001|Phase II|Withdrawal by Subject|8
6193312|NCT01437319|9850952|FG002|Phase II|Withdrawal by Subject|16
6193313|NCT01437319|9850950|FG000|Phase II|Lost to Follow-up|0
6193314|NCT01437319|9850951|FG001|Phase II|Lost to Follow-up|7
6193315|NCT01437319|9850952|FG002|Phase II|Lost to Follow-up|2
6193316|NCT01437319|9850950|FG000|Phase II|Study related symptoms/complaints|0
6193317|NCT01437319|9850951|FG001|Phase II|Study related symptoms/complaints|28
6193318|NCT01437319|9850952|FG002|Phase II|Study related symptoms/complaints|19
6193319|NCT01437319|9850950|FG000|Phase II|Protocol Violation|0
6193320|NCT01437319|9850951|FG001|Phase II|Protocol Violation|1
6193321|NCT01437319|9850952|FG002|Phase II|Protocol Violation|0
6193322|NCT01437397|9850966|FG000|Overall Study|Lost to Follow-up|9
6193323|NCT01437397|9850967|FG001|Overall Study|Lost to Follow-up|4
6193324|NCT01437397|9850968|FG002|Overall Study|Lost to Follow-up|2
6193325|NCT01437397|9850969|FG003|Overall Study|Lost to Follow-up|4
6193326|NCT01437397|9850970|FG004|Overall Study|Lost to Follow-up|5
6193327|NCT01437397|9850966|FG000|Overall Study|Withdrawal by Subject|11
6193328|NCT01437397|9850967|FG001|Overall Study|Withdrawal by Subject|12
6193329|NCT01437397|9850968|FG002|Overall Study|Withdrawal by Subject|24
6255996|NCT01998958|9947648|FG006|Period 1 (Panel A and B)|Withdrawal by Subject|0
6255997|NCT01998958|9947649|FG007|Period 1 (Panel A and B)|Withdrawal by Subject|0
6255998|NCT01998958|9947650|FG008|Period 1 (Panel A and B)|Withdrawal by Subject|0
6255999|NCT01998958|9947651|FG009|Period 1 (Panel A and B)|Withdrawal by Subject|0
6256000|NCT01998958|9947652|FG010|Period 1 (Panel A and B)|Withdrawal by Subject|0
6193330|NCT01437397|9850969|FG003|Overall Study|Withdrawal by Subject|11
6193331|NCT01437397|9850970|FG004|Overall Study|Withdrawal by Subject|22
6193332|NCT01437397|9850966|FG000|Overall Study|Protocol Violation|10
6193333|NCT01437397|9850967|FG001|Overall Study|Protocol Violation|12
6193334|NCT01437397|9850968|FG002|Overall Study|Protocol Violation|13
6193335|NCT01437397|9850969|FG003|Overall Study|Protocol Violation|21
6256001|NCT01998958|9947653|FG011|Period 1 (Panel A and B)|Withdrawal by Subject|0
6256002|NCT01998958|9947654|FG012|Period 1 (Panel A and B)|Withdrawal by Subject|0
6256003|NCT01998958|9947655|FG013|Period 1 (Panel A and B)|Withdrawal by Subject|0
6256004|NCT01998958|9947656|FG014|Period 1 (Panel A and B)|Withdrawal by Subject|0
6190444|NCT01411774|9846688|FG000|Overall Study|Withdrawal by Subject|0
6256005|NCT01998958|9947657|FG015|Period 1 (Panel A and B)|Withdrawal by Subject|0
6256006|NCT01998958|9947658|FG016|Period 1 (Panel A and B)|Withdrawal by Subject|0
6256007|NCT01998958|9947659|FG017|Period 1 (Panel A and B)|Withdrawal by Subject|0
6256008|NCT01998958|9947660|FG018|Period 1 (Panel A and B)|Withdrawal by Subject|0
6256009|NCT01998958|9947661|FG019|Period 1 (Panel A and B)|Withdrawal by Subject|0
6256010|NCT01998958|9947662|FG020|Period 1 (Panel A and B)|Withdrawal by Subject|0
6256011|NCT01998958|9947663|FG021|Period 1 (Panel A and B)|Withdrawal by Subject|0
6256012|NCT01998958|9947664|FG022|Period 1 (Panel A and B)|Withdrawal by Subject|0
6256013|NCT01998958|9947665|FG023|Period 1 (Panel A and B)|Withdrawal by Subject|0
6256014|NCT01998958|9947666|FG024|Period 1 (Panel A and B)|Withdrawal by Subject|0
6256015|NCT01998958|9947667|FG025|Period 1 (Panel A and B)|Withdrawal by Subject|0
6256016|NCT01998958|9947668|FG026|Period 1 (Panel A and B)|Withdrawal by Subject|0
6256017|NCT01998958|9947669|FG027|Period 1 (Panel A and B)|Withdrawal by Subject|0
6256018|NCT01998958|9947670|FG028|Period 1 (Panel A and B)|Withdrawal by Subject|0
6256019|NCT01998958|9947671|FG029|Period 1 (Panel A and B)|Withdrawal by Subject|0
6256020|NCT01998958|9947672|FG030|Period 1 (Panel A and B)|Withdrawal by Subject|0
6256021|NCT01998958|9947673|FG031|Period 1 (Panel A and B)|Withdrawal by Subject|0
6256022|NCT01998958|9947642|FG000|Period 1 (Panel A and B)|Lack of Efficacy|0
6256023|NCT01998958|9947643|FG001|Period 1 (Panel A and B)|Lack of Efficacy|1
6256024|NCT01998958|9947644|FG002|Period 1 (Panel A and B)|Lack of Efficacy|0
6256025|NCT01998958|9947645|FG003|Period 1 (Panel A and B)|Lack of Efficacy|0
6190445|NCT01411774|9846689|FG001|Overall Study|Withdrawal by Subject|3
6190446|NCT01411839|9846697|FG000|Overall Study|Lost to Follow-up|4
6190447|NCT01411839|9846698|FG001|Overall Study|Lost to Follow-up|3
6190448|NCT01411852|9846706|FG000|Prehospital Intervention Phase|No qualifying SBP|5
6190449|NCT01411852|9846707|FG001|Prehospital Intervention Phase|No qualifying SBP|4
6190450|NCT01411852|9846706|FG000|Prehospital Intervention Phase|Cardiopulmonary resuscitation (CPR)|2
6190451|NCT01411852|9846707|FG001|Prehospital Intervention Phase|Cardiopulmonary resuscitation (CPR)|2
6190452|NCT01411852|9846706|FG000|Prehospital Intervention Phase|Found to be under age|0
6190453|NCT01411852|9846707|FG001|Prehospital Intervention Phase|Found to be under age|1
6190454|NCT01411852|9846706|FG000|Prehospital Intervention Phase|Severe head injury with GCS≤8|5
6190455|NCT01411852|9846707|FG001|Prehospital Intervention Phase|Severe head injury with GCS≤8|0
6190456|NCT01411852|9846706|FG000|Hospital Intervention Phase|Severe head injury|5
6190457|NCT01411852|9846707|FG001|Hospital Intervention Phase|Severe head injury|4
6190458|NCT01411852|9846706|FG000|Hospital Intervention Phase|No qualifying SBP|5
6190459|NCT01411852|9846707|FG001|Hospital Intervention Phase|No qualifying SBP|1
6190460|NCT01411852|9846706|FG000|Hospital Intervention Phase|Miscommunication error|1
6190461|NCT01411852|9846707|FG001|Hospital Intervention Phase|Miscommunication error|2
6190462|NCT01411852|9846706|FG000|Hospital Intervention Phase|CPR administered|3
6190463|NCT01411852|9846707|FG001|Hospital Intervention Phase|CPR administered|1
6190464|NCT01411852|9846706|FG000|Hospital Intervention Phase|Misunderstanding of protocol|4
6190465|NCT01411852|9846707|FG001|Hospital Intervention Phase|Misunderstanding of protocol|1
6190466|NCT01411852|9846706|FG000|Hospital Intervention Phase|Diagnosis of sepsis|0
6190467|NCT01411852|9846707|FG001|Hospital Intervention Phase|Diagnosis of sepsis|2
6190468|NCT01411852|9846706|FG000|Hospital Intervention Phase|Diagnosis of dehydration|0
6190469|NCT01411852|9846707|FG001|Hospital Intervention Phase|Diagnosis of dehydration|1
6190470|NCT01411852|9846706|FG000|Hospital Intervention Phase|Physician/hospital staff noncompliance|0
6190471|NCT01411852|9846707|FG001|Hospital Intervention Phase|Physician/hospital staff noncompliance|4
6190472|NCT01411852|9846706|FG000|Hospital Intervention Phase|Other ineligible|2
6190473|NCT01411852|9846707|FG001|Hospital Intervention Phase|Other ineligible|2
6190474|NCT01411852|9846706|FG000|Hospital Intervention Phase|Spinal cord injury|2
6190475|NCT01411852|9846707|FG001|Hospital Intervention Phase|Spinal cord injury|0
6190476|NCT01411852|9846706|FG000|Hospital Intervention Phase|Withdrawal by Subject|1
6190477|NCT01411852|9846707|FG001|Hospital Intervention Phase|Withdrawal by Subject|0
6190478|NCT01411852|9846706|FG000|Hospital Intervention Phase|Vascular access failed|1
6190479|NCT01411852|9846707|FG001|Hospital Intervention Phase|Vascular access failed|0
6190480|NCT01411891|9846717|FG000|Overall Study|Catheter dislodgement or loss to follow-|3
6190481|NCT01411891|9846718|FG001|Overall Study|Catheter dislodgement or loss to follow-|2
6190482|NCT01411917|9846726|FG000|Overall Study|Patient did not undergo scheduled surger|0
6190483|NCT01411917|9846727|FG001|Overall Study|Patient did not undergo scheduled surger|1
6190484|NCT01411995|9846735|FG000|Overall Study|Failed IUD insertion|0
6190485|NCT01411995|9846736|FG001|Overall Study|Failed IUD insertion|1
6190486|NCT01412021|9846742|FG000|Overall Study|Case Report Forms Not Retrieved|7
6190487|NCT01412021|9846742|FG000|Overall Study|Treatment Prior to Approval|3
6190488|NCT01412021|9846742|FG000|Overall Study|Transferred to Other Hospital|9
6190489|NCT01412060|9846746|FG000|Open-label Run-in Period (RIP)|Adverse Event|86
6190490|NCT01412060|9846747|FG001|Open-label Run-in Period (RIP)|Adverse Event|0
6193336|NCT01437397|9850970|FG004|Overall Study|Protocol Violation|19
6256026|NCT01998958|9947646|FG004|Period 1 (Panel A and B)|Lack of Efficacy|0
6256027|NCT01998958|9947647|FG005|Period 1 (Panel A and B)|Lack of Efficacy|0
6256028|NCT01998958|9947648|FG006|Period 1 (Panel A and B)|Lack of Efficacy|0
6256029|NCT01998958|9947649|FG007|Period 1 (Panel A and B)|Lack of Efficacy|0
6256030|NCT01998958|9947650|FG008|Period 1 (Panel A and B)|Lack of Efficacy|0
6256031|NCT01998958|9947651|FG009|Period 1 (Panel A and B)|Lack of Efficacy|0
6256032|NCT01998958|9947652|FG010|Period 1 (Panel A and B)|Lack of Efficacy|0
6256033|NCT01998958|9947653|FG011|Period 1 (Panel A and B)|Lack of Efficacy|0
6256034|NCT01998958|9947654|FG012|Period 1 (Panel A and B)|Lack of Efficacy|0
6256035|NCT01998958|9947655|FG013|Period 1 (Panel A and B)|Lack of Efficacy|0
6256036|NCT01998958|9947656|FG014|Period 1 (Panel A and B)|Lack of Efficacy|0
6256037|NCT01998958|9947657|FG015|Period 1 (Panel A and B)|Lack of Efficacy|0
6256038|NCT01998958|9947658|FG016|Period 1 (Panel A and B)|Lack of Efficacy|0
6256039|NCT01998958|9947659|FG017|Period 1 (Panel A and B)|Lack of Efficacy|0
6256040|NCT01998958|9947660|FG018|Period 1 (Panel A and B)|Lack of Efficacy|0
6256041|NCT01998958|9947661|FG019|Period 1 (Panel A and B)|Lack of Efficacy|0
6256042|NCT01998958|9947662|FG020|Period 1 (Panel A and B)|Lack of Efficacy|0
6256043|NCT01998958|9947663|FG021|Period 1 (Panel A and B)|Lack of Efficacy|0
6256044|NCT01998958|9947664|FG022|Period 1 (Panel A and B)|Lack of Efficacy|0
6256045|NCT01998958|9947665|FG023|Period 1 (Panel A and B)|Lack of Efficacy|0
6256046|NCT01998958|9947666|FG024|Period 1 (Panel A and B)|Lack of Efficacy|0
6256047|NCT01998958|9947667|FG025|Period 1 (Panel A and B)|Lack of Efficacy|0
6256048|NCT01998958|9947668|FG026|Period 1 (Panel A and B)|Lack of Efficacy|0
6256049|NCT01998958|9947669|FG027|Period 1 (Panel A and B)|Lack of Efficacy|0
6256050|NCT01998958|9947670|FG028|Period 1 (Panel A and B)|Lack of Efficacy|0
6256051|NCT01998958|9947671|FG029|Period 1 (Panel A and B)|Lack of Efficacy|0
6256052|NCT01998958|9947672|FG030|Period 1 (Panel A and B)|Lack of Efficacy|0
6256053|NCT01998958|9947673|FG031|Period 1 (Panel A and B)|Lack of Efficacy|0
6256054|NCT01998958|9947642|FG000|Period 1 (Panel A and B)|Adverse Event|0
6256055|NCT01998958|9947643|FG001|Period 1 (Panel A and B)|Adverse Event|1
6256056|NCT01998958|9947644|FG002|Period 1 (Panel A and B)|Adverse Event|0
6256057|NCT01998958|9947645|FG003|Period 1 (Panel A and B)|Adverse Event|0
6256058|NCT01998958|9947646|FG004|Period 1 (Panel A and B)|Adverse Event|0
6256059|NCT01998958|9947647|FG005|Period 1 (Panel A and B)|Adverse Event|0
6256060|NCT01998958|9947648|FG006|Period 1 (Panel A and B)|Adverse Event|0
6190491|NCT01412060|9846748|FG002|Open-label Run-in Period (RIP)|Adverse Event|0
6256061|NCT01998958|9947649|FG007|Period 1 (Panel A and B)|Adverse Event|0
6256062|NCT01998958|9947650|FG008|Period 1 (Panel A and B)|Adverse Event|0
6256063|NCT01998958|9947651|FG009|Period 1 (Panel A and B)|Adverse Event|0
6256064|NCT01998958|9947652|FG010|Period 1 (Panel A and B)|Adverse Event|0
6256065|NCT01998958|9947653|FG011|Period 1 (Panel A and B)|Adverse Event|0
6256066|NCT01998958|9947654|FG012|Period 1 (Panel A and B)|Adverse Event|0
6256067|NCT01998958|9947655|FG013|Period 1 (Panel A and B)|Adverse Event|0
6256068|NCT01998958|9947656|FG014|Period 1 (Panel A and B)|Adverse Event|0
6256069|NCT01998958|9947657|FG015|Period 1 (Panel A and B)|Adverse Event|0
6256070|NCT01998958|9947658|FG016|Period 1 (Panel A and B)|Adverse Event|0
6256071|NCT01998958|9947659|FG017|Period 1 (Panel A and B)|Adverse Event|0
6256072|NCT01998958|9947660|FG018|Period 1 (Panel A and B)|Adverse Event|0
6256073|NCT01998958|9947661|FG019|Period 1 (Panel A and B)|Adverse Event|0
6256074|NCT01998958|9947662|FG020|Period 1 (Panel A and B)|Adverse Event|0
6256075|NCT01998958|9947663|FG021|Period 1 (Panel A and B)|Adverse Event|0
6256076|NCT01998958|9947664|FG022|Period 1 (Panel A and B)|Adverse Event|0
6190492|NCT01412060|9846746|FG000|Open-label Run-in Period (RIP)|Insufficient Therapeutic Response|66
6190493|NCT01412060|9846747|FG001|Open-label Run-in Period (RIP)|Insufficient Therapeutic Response|0
6190494|NCT01412060|9846748|FG002|Open-label Run-in Period (RIP)|Insufficient Therapeutic Response|0
6190495|NCT01412060|9846746|FG000|Open-label Run-in Period (RIP)|Protocol Violation|27
6190496|NCT01412060|9846747|FG001|Open-label Run-in Period (RIP)|Protocol Violation|0
6190497|NCT01412060|9846748|FG002|Open-label Run-in Period (RIP)|Protocol Violation|0
6190498|NCT01412060|9846746|FG000|Open-label Run-in Period (RIP)|Withdrawal of Consent|117
6190499|NCT01412060|9846747|FG001|Open-label Run-in Period (RIP)|Withdrawal of Consent|0
6190500|NCT01412060|9846748|FG002|Open-label Run-in Period (RIP)|Withdrawal of Consent|0
6190501|NCT01412060|9846746|FG000|Open-label Run-in Period (RIP)|Lost to Follow-up|32
6190502|NCT01412060|9846747|FG001|Open-label Run-in Period (RIP)|Lost to Follow-up|0
6190503|NCT01412060|9846748|FG002|Open-label Run-in Period (RIP)|Lost to Follow-up|0
6190504|NCT01412060|9846746|FG000|Open-label Run-in Period (RIP)|Other Miscellaneous Reasons|19
6190505|NCT01412060|9846747|FG001|Open-label Run-in Period (RIP)|Other Miscellaneous Reasons|0
6190506|NCT01412060|9846748|FG002|Open-label Run-in Period (RIP)|Other Miscellaneous Reasons|0
6256077|NCT01998958|9947665|FG023|Period 1 (Panel A and B)|Adverse Event|0
6256078|NCT01998958|9947666|FG024|Period 1 (Panel A and B)|Adverse Event|0
6256079|NCT01998958|9947667|FG025|Period 1 (Panel A and B)|Adverse Event|0
6256080|NCT01998958|9947668|FG026|Period 1 (Panel A and B)|Adverse Event|0
6256081|NCT01998958|9947669|FG027|Period 1 (Panel A and B)|Adverse Event|0
6256082|NCT01998958|9947670|FG028|Period 1 (Panel A and B)|Adverse Event|0
6256083|NCT01998958|9947671|FG029|Period 1 (Panel A and B)|Adverse Event|0
6256084|NCT01998958|9947672|FG030|Period 1 (Panel A and B)|Adverse Event|0
6256085|NCT01998958|9947673|FG031|Period 1 (Panel A and B)|Adverse Event|0
6256086|NCT01998958|9947642|FG000|Period 1 (Panel A and B)|Other|1
6256087|NCT01998958|9947643|FG001|Period 1 (Panel A and B)|Other|0
6256088|NCT01998958|9947644|FG002|Period 1 (Panel A and B)|Other|0
6256089|NCT01998958|9947645|FG003|Period 1 (Panel A and B)|Other|0
6256090|NCT01998958|9947646|FG004|Period 1 (Panel A and B)|Other|0
6256091|NCT01998958|9947647|FG005|Period 1 (Panel A and B)|Other|0
6256092|NCT01998958|9947648|FG006|Period 1 (Panel A and B)|Other|0
6256093|NCT01998958|9947649|FG007|Period 1 (Panel A and B)|Other|0
6256094|NCT01998958|9947650|FG008|Period 1 (Panel A and B)|Other|0
6256095|NCT01998958|9947651|FG009|Period 1 (Panel A and B)|Other|0
6256096|NCT01998958|9947652|FG010|Period 1 (Panel A and B)|Other|0
6256097|NCT01998958|9947653|FG011|Period 1 (Panel A and B)|Other|0
6256098|NCT01998958|9947654|FG012|Period 1 (Panel A and B)|Other|0
6256099|NCT01998958|9947655|FG013|Period 1 (Panel A and B)|Other|0
6086605|NCT00662649|9696711|FG002|Core Study (24 Months)|Adverse Event|18
6086606|NCT00662649|9696712|FG003|Core Study (24 Months)|Adverse Event|0
6086607|NCT00662649|9696713|FG004|Core Study (24 Months)|Adverse Event|0
6086608|NCT00662649|9696709|FG000|Core Study (24 Months)|Unsatisfactory therapeutic effect|13
6086609|NCT00662649|9696710|FG001|Core Study (24 Months)|Unsatisfactory therapeutic effect|6
6086610|NCT00662649|9696711|FG002|Core Study (24 Months)|Unsatisfactory therapeutic effect|25
6086611|NCT00662649|9696712|FG003|Core Study (24 Months)|Unsatisfactory therapeutic effect|0
6086612|NCT00662649|9696713|FG004|Core Study (24 Months)|Unsatisfactory therapeutic effect|0
6086613|NCT00662649|9696709|FG000|Core Study (24 Months)|Abnormal laboratory value(s)|20
6190507|NCT01412060|9846746|FG000|Period Between RIP and SP|Adverse Event|4
6190508|NCT01412060|9846747|FG001|Period Between RIP and SP|Adverse Event|0
6190509|NCT01412060|9846748|FG002|Period Between RIP and SP|Adverse Event|0
6190510|NCT01412060|9846746|FG000|Period Between RIP and SP|Insufficient Therapeutic Response|19
6256100|NCT01998958|9947656|FG014|Period 1 (Panel A and B)|Other|0
6190511|NCT01412060|9846747|FG001|Period Between RIP and SP|Insufficient Therapeutic Response|0
6190512|NCT01412060|9846748|FG002|Period Between RIP and SP|Insufficient Therapeutic Response|0
6190513|NCT01412060|9846746|FG000|Period Between RIP and SP|Protocol Violation|2
6190514|NCT01412060|9846747|FG001|Period Between RIP and SP|Protocol Violation|0
6190515|NCT01412060|9846748|FG002|Period Between RIP and SP|Protocol Violation|0
6190516|NCT01412060|9846746|FG000|Period Between RIP and SP|Withdrawal of Consent|1
6190517|NCT01412060|9846747|FG001|Period Between RIP and SP|Withdrawal of Consent|0
6190518|NCT01412060|9846748|FG002|Period Between RIP and SP|Withdrawal of Consent|0
6190519|NCT01412060|9846746|FG000|Period Between RIP and SP|Lost to Follow-up|5
6190520|NCT01412060|9846747|FG001|Period Between RIP and SP|Lost to Follow-up|0
6190521|NCT01412060|9846748|FG002|Period Between RIP and SP|Lost to Follow-up|0
6190522|NCT01412060|9846746|FG000|Period Between RIP and SP|Other Miscellaneous Reasons|23
6190523|NCT01412060|9846747|FG001|Period Between RIP and SP|Other Miscellaneous Reasons|0
6190524|NCT01412060|9846748|FG002|Period Between RIP and SP|Other Miscellaneous Reasons|0
6190525|NCT01412060|9846746|FG000|Open-label Stabilization Period (SP)|Adverse Event|9
6190526|NCT01412060|9846747|FG001|Open-label Stabilization Period (SP)|Adverse Event|0
6190527|NCT01412060|9846748|FG002|Open-label Stabilization Period (SP)|Adverse Event|0
6190528|NCT01412060|9846746|FG000|Open-label Stabilization Period (SP)|Insufficient Therapeutic Response|9
6190529|NCT01412060|9846747|FG001|Open-label Stabilization Period (SP)|Insufficient Therapeutic Response|0
6190530|NCT01412060|9846748|FG002|Open-label Stabilization Period (SP)|Insufficient Therapeutic Response|0
6190531|NCT01412060|9846746|FG000|Open-label Stabilization Period (SP)|Protocol Violation|14
6190532|NCT01412060|9846747|FG001|Open-label Stabilization Period (SP)|Protocol Violation|0
6190533|NCT01412060|9846748|FG002|Open-label Stabilization Period (SP)|Protocol Violation|0
6190534|NCT01412060|9846746|FG000|Open-label Stabilization Period (SP)|Withdrawal of Consent|40
6190535|NCT01412060|9846747|FG001|Open-label Stabilization Period (SP)|Withdrawal of Consent|0
6190536|NCT01412060|9846748|FG002|Open-label Stabilization Period (SP)|Withdrawal of Consent|0
6190537|NCT01412060|9846746|FG000|Open-label Stabilization Period (SP)|Lost to Follow-up|9
6190538|NCT01412060|9846747|FG001|Open-label Stabilization Period (SP)|Lost to Follow-up|0
6190539|NCT01412060|9846748|FG002|Open-label Stabilization Period (SP)|Lost to Follow-up|0
6190540|NCT01412060|9846746|FG000|Open-label Stabilization Period (SP)|Other Miscellaneous Reasons|19
6190541|NCT01412060|9846747|FG001|Open-label Stabilization Period (SP)|Other Miscellaneous Reasons|0
6190542|NCT01412060|9846748|FG002|Open-label Stabilization Period (SP)|Other Miscellaneous Reasons|0
6190543|NCT01412060|9846746|FG000|Period Between SP and DBP|Protocol Violation|2
6190544|NCT01412060|9846747|FG001|Period Between SP and DBP|Protocol Violation|0
6190545|NCT01412060|9846748|FG002|Period Between SP and DBP|Protocol Violation|0
6190546|NCT01412060|9846746|FG000|Period Between SP and DBP|Withdrawal of Consent|2
6190547|NCT01412060|9846747|FG001|Period Between SP and DBP|Withdrawal of Consent|0
6190548|NCT01412060|9846748|FG002|Period Between SP and DBP|Withdrawal of Consent|0
6256101|NCT01998958|9947657|FG015|Period 1 (Panel A and B)|Other|0
6256102|NCT01998958|9947658|FG016|Period 1 (Panel A and B)|Other|0
6256103|NCT01998958|9947659|FG017|Period 1 (Panel A and B)|Other|0
6256104|NCT01998958|9947660|FG018|Period 1 (Panel A and B)|Other|0
6256105|NCT01998958|9947661|FG019|Period 1 (Panel A and B)|Other|0
6256106|NCT01998958|9947662|FG020|Period 1 (Panel A and B)|Other|0
6256107|NCT01998958|9947663|FG021|Period 1 (Panel A and B)|Other|0
6256108|NCT01998958|9947664|FG022|Period 1 (Panel A and B)|Other|0
6256109|NCT01998958|9947665|FG023|Period 1 (Panel A and B)|Other|0
6256110|NCT01998958|9947666|FG024|Period 1 (Panel A and B)|Other|0
6190549|NCT01412060|9846746|FG000|Period Between SP and DBP|Lost to Follow-up|1
6190550|NCT01412060|9846747|FG001|Period Between SP and DBP|Lost to Follow-up|0
6190551|NCT01412060|9846748|FG002|Period Between SP and DBP|Lost to Follow-up|0
6190552|NCT01412060|9846746|FG000|Period Between SP and DBP|Did Not Met Criteria to Enter Next Phase|4
6190553|NCT01412060|9846747|FG001|Period Between SP and DBP|Did Not Met Criteria to Enter Next Phase|0
6190554|NCT01412060|9846748|FG002|Period Between SP and DBP|Did Not Met Criteria to Enter Next Phase|0
6190555|NCT01412060|9846746|FG000|Period Between SP and DBP|Other Miscellaneous Reasons|55
6190556|NCT01412060|9846747|FG001|Period Between SP and DBP|Other Miscellaneous Reasons|0
6190557|NCT01412060|9846748|FG002|Period Between SP and DBP|Other Miscellaneous Reasons|0
6190558|NCT01412060|9846746|FG000|Double-blind Treatment Phase (DBP)|Adverse Event|0
6190559|NCT01412060|9846747|FG001|Double-blind Treatment Phase (DBP)|Adverse Event|5
6190560|NCT01412060|9846748|FG002|Double-blind Treatment Phase (DBP)|Adverse Event|6
6190561|NCT01412060|9846746|FG000|Double-blind Treatment Phase (DBP)|Protocol Violation|0
6190562|NCT01412060|9846747|FG001|Double-blind Treatment Phase (DBP)|Protocol Violation|4
6190563|NCT01412060|9846748|FG002|Double-blind Treatment Phase (DBP)|Protocol Violation|5
6190564|NCT01412060|9846746|FG000|Double-blind Treatment Phase (DBP)|Withdrawal of Consent|0
6190565|NCT01412060|9846747|FG001|Double-blind Treatment Phase (DBP)|Withdrawal of Consent|10
6190566|NCT01412060|9846748|FG002|Double-blind Treatment Phase (DBP)|Withdrawal of Consent|15
6190567|NCT01412060|9846746|FG000|Double-blind Treatment Phase (DBP)|Lost to Follow-up|0
6190568|NCT01412060|9846747|FG001|Double-blind Treatment Phase (DBP)|Lost to Follow-up|6
6190569|NCT01412060|9846748|FG002|Double-blind Treatment Phase (DBP)|Lost to Follow-up|5
6190570|NCT01412060|9846746|FG000|Double-blind Treatment Phase (DBP)|Other Miscellaneous Reasons|0
6190571|NCT01412060|9846747|FG001|Double-blind Treatment Phase (DBP)|Other Miscellaneous Reasons|11
6190572|NCT01412060|9846748|FG002|Double-blind Treatment Phase (DBP)|Other Miscellaneous Reasons|27
6190573|NCT01412060|9846746|FG000|Double-blind Treatment Phase (DBP)|Relapse|0
6190574|NCT01412060|9846747|FG001|Double-blind Treatment Phase (DBP)|Relapse|47
6190575|NCT01412060|9846748|FG002|Double-blind Treatment Phase (DBP)|Relapse|25
6190576|NCT01412151|9846762|FG000|Week 0 - 306 - Treatment Period|Death|1
6190577|NCT01412151|9846762|FG000|Week 0 - 306 - Treatment Period|Withdrawal by Subject|1
6190578|NCT01412151|9846762|FG000|Week 0 - 306 - Treatment Period|Withdrawal by Investigator|3
6190579|NCT01412151|9846762|FG000|Week 306 - 310 - Washout Period|Withdrawal by Subject|2
6190580|NCT01412229|9846772|FG000|Overall Study|Physician Decision|1
6190581|NCT01412424|9846803|FG000|Core Treatment Period|Treatment Failure|24
6190582|NCT01412424|9846803|FG000|Core Treatment Period|Adverse Event|21
6190583|NCT01412424|9846803|FG000|Core Treatment Period|Patient Request|5
6190584|NCT01412424|9846803|FG000|Core Treatment Period|Lost to Follow-up|2
6190585|NCT01412424|9846803|FG000|Core Treatment Period|Sponsor Request|1
6190586|NCT01412424|9846803|FG000|Extension Treatment Period|Adverse Event|2
6190587|NCT01412424|9846803|FG000|Extension Treatment Period|Treatment Failure|2
6190588|NCT01412424|9846803|FG000|Extension Treatment Period|Patient Request|2
6190589|NCT01412801|9846844|FG000|Overall Study|Death|0
6190590|NCT01412801|9846845|FG001|Overall Study|Death|1
6190591|NCT01412801|9846846|FG002|Overall Study|Death|0
6190592|NCT01412801|9846847|FG003|Overall Study|Death|4
6190593|NCT01412801|9846848|FG004|Overall Study|Death|2
6190594|NCT01412801|9846849|FG005|Overall Study|Death|2
6190595|NCT01412801|9846844|FG000|Overall Study|Lost to Follow-up|1
6190596|NCT01412801|9846845|FG001|Overall Study|Lost to Follow-up|2
6190597|NCT01412801|9846846|FG002|Overall Study|Lost to Follow-up|4
6190598|NCT01412801|9846847|FG003|Overall Study|Lost to Follow-up|0
6190599|NCT01412801|9846848|FG004|Overall Study|Lost to Follow-up|1
6190600|NCT01412801|9846849|FG005|Overall Study|Lost to Follow-up|1
6190601|NCT01412801|9846844|FG000|Overall Study|Withdrawal by Subject|3
6190602|NCT01412801|9846845|FG001|Overall Study|Withdrawal by Subject|2
6190603|NCT01412801|9846846|FG002|Overall Study|Withdrawal by Subject|1
6190604|NCT01412801|9846847|FG003|Overall Study|Withdrawal by Subject|0
6190605|NCT01412801|9846848|FG004|Overall Study|Withdrawal by Subject|0
6190606|NCT01412801|9846849|FG005|Overall Study|Withdrawal by Subject|0
6190607|NCT01412801|9846844|FG000|Overall Study|Relocated to another area|0
6190608|NCT01412801|9846845|FG001|Overall Study|Relocated to another area|0
6190609|NCT01412801|9846846|FG002|Overall Study|Relocated to another area|2
6190610|NCT01412801|9846847|FG003|Overall Study|Relocated to another area|0
6190611|NCT01412801|9846848|FG004|Overall Study|Relocated to another area|0
6190612|NCT01412801|9846849|FG005|Overall Study|Relocated to another area|0
6190613|NCT01412879|9846883|FG000|Initial Registration (Induction Therapy)|Adverse Event|5
6190614|NCT01412879|9846884|FG001|Initial Registration (Induction Therapy)|Adverse Event|3
6190615|NCT01412879|9846885|FG002|Initial Registration (Induction Therapy)|Adverse Event|0
6190616|NCT01412879|9846883|FG000|Initial Registration (Induction Therapy)|Refusal Unrelated to Adverse Event|1
6190617|NCT01412879|9846884|FG001|Initial Registration (Induction Therapy)|Refusal Unrelated to Adverse Event|3
6256111|NCT01998958|9947667|FG025|Period 1 (Panel A and B)|Other|0
6256112|NCT01998958|9947668|FG026|Period 1 (Panel A and B)|Other|0
6256113|NCT01998958|9947669|FG027|Period 1 (Panel A and B)|Other|0
6256114|NCT01998958|9947670|FG028|Period 1 (Panel A and B)|Other|0
6256115|NCT01998958|9947671|FG029|Period 1 (Panel A and B)|Other|0
6256116|NCT01998958|9947672|FG030|Period 1 (Panel A and B)|Other|0
6256117|NCT01998958|9947673|FG031|Period 1 (Panel A and B)|Other|0
6256118|NCT01998958|9947642|FG000|Period 2 (Panel A and B)|Adverse Event|0
6256119|NCT01998958|9947643|FG001|Period 2 (Panel A and B)|Adverse Event|0
6256120|NCT01998958|9947644|FG002|Period 2 (Panel A and B)|Adverse Event|0
6256121|NCT01998958|9947645|FG003|Period 2 (Panel A and B)|Adverse Event|0
6256122|NCT01998958|9947646|FG004|Period 2 (Panel A and B)|Adverse Event|0
6256123|NCT01998958|9947647|FG005|Period 2 (Panel A and B)|Adverse Event|0
6256124|NCT01998958|9947648|FG006|Period 2 (Panel A and B)|Adverse Event|0
6256125|NCT01998958|9947649|FG007|Period 2 (Panel A and B)|Adverse Event|0
6256126|NCT01998958|9947650|FG008|Period 2 (Panel A and B)|Adverse Event|0
6256127|NCT01998958|9947651|FG009|Period 2 (Panel A and B)|Adverse Event|0
6256128|NCT01998958|9947652|FG010|Period 2 (Panel A and B)|Adverse Event|1
6256129|NCT01998958|9947653|FG011|Period 2 (Panel A and B)|Adverse Event|0
6256130|NCT01998958|9947654|FG012|Period 2 (Panel A and B)|Adverse Event|0
6256131|NCT01998958|9947655|FG013|Period 2 (Panel A and B)|Adverse Event|0
6256132|NCT01998958|9947656|FG014|Period 2 (Panel A and B)|Adverse Event|1
6256133|NCT01998958|9947657|FG015|Period 2 (Panel A and B)|Adverse Event|0
6256134|NCT01998958|9947658|FG016|Period 2 (Panel A and B)|Adverse Event|0
6256135|NCT01998958|9947659|FG017|Period 2 (Panel A and B)|Adverse Event|0
6256136|NCT01998958|9947660|FG018|Period 2 (Panel A and B)|Adverse Event|0
6256137|NCT01998958|9947661|FG019|Period 2 (Panel A and B)|Adverse Event|0
6256138|NCT01998958|9947662|FG020|Period 2 (Panel A and B)|Adverse Event|0
6256139|NCT01998958|9947663|FG021|Period 2 (Panel A and B)|Adverse Event|0
6256140|NCT01998958|9947664|FG022|Period 2 (Panel A and B)|Adverse Event|0
6190618|NCT01412879|9846885|FG002|Initial Registration (Induction Therapy)|Refusal Unrelated to Adverse Event|0
6190619|NCT01412879|9846883|FG000|Initial Registration (Induction Therapy)|Progression/Relapse|0
6190620|NCT01412879|9846884|FG001|Initial Registration (Induction Therapy)|Progression/Relapse|1
6190621|NCT01412879|9846885|FG002|Initial Registration (Induction Therapy)|Progression/Relapse|0
6190622|NCT01412879|9846883|FG000|Initial Registration (Induction Therapy)|Reasons not Protocol Specified|6
6190623|NCT01412879|9846884|FG001|Initial Registration (Induction Therapy)|Reasons not Protocol Specified|1
6190624|NCT01412879|9846885|FG002|Initial Registration (Induction Therapy)|Reasons not Protocol Specified|0
6190625|NCT01412879|9846883|FG000|Initial Registration (Induction Therapy)|Treatment not Given|1
6190626|NCT01412879|9846884|FG001|Initial Registration (Induction Therapy)|Treatment not Given|0
6190627|NCT01412879|9846885|FG002|Initial Registration (Induction Therapy)|Treatment not Given|0
6190628|NCT01412944|9846907|FG000|IV: Per Previous CAIN457A2304 Treatment|Withdrawal by Subject|0
6190629|NCT01412944|9846908|FG001|IV: Per Previous CAIN457A2304 Treatment|Withdrawal by Subject|0
6190630|NCT01412944|9846909|FG002|IV: Per Previous CAIN457A2304 Treatment|Withdrawal by Subject|1
6190631|NCT01412944|9846910|FG003|IV: Per Previous CAIN457A2304 Treatment|Withdrawal by Subject|0
6190632|NCT01412944|9846911|FG004|IV: Per Previous CAIN457A2304 Treatment|Withdrawal by Subject|0
6190633|NCT01412944|9846912|FG005|IV: Per Previous CAIN457A2304 Treatment|Withdrawal by Subject|0
6190634|NCT01412944|9846907|FG000|IV: Per Previous CAIN457A2304 Treatment|Protocol deviation|0
6190635|NCT01412944|9846908|FG001|IV: Per Previous CAIN457A2304 Treatment|Protocol deviation|0
6190636|NCT01412944|9846909|FG002|IV: Per Previous CAIN457A2304 Treatment|Protocol deviation|0
6190637|NCT01412944|9846910|FG003|IV: Per Previous CAIN457A2304 Treatment|Protocol deviation|0
6190638|NCT01412944|9846911|FG004|IV: Per Previous CAIN457A2304 Treatment|Protocol deviation|0
6190639|NCT01412944|9846912|FG005|IV: Per Previous CAIN457A2304 Treatment|Protocol deviation|1
6190640|NCT01412944|9846907|FG000|IV: Per Previous CAIN457A2304 Treatment|Lost to Follow-up|0
6190641|NCT01412944|9846908|FG001|IV: Per Previous CAIN457A2304 Treatment|Lost to Follow-up|0
6190642|NCT01412944|9846909|FG002|IV: Per Previous CAIN457A2304 Treatment|Lost to Follow-up|0
6190643|NCT01412944|9846910|FG003|IV: Per Previous CAIN457A2304 Treatment|Lost to Follow-up|0
6190644|NCT01412944|9846911|FG004|IV: Per Previous CAIN457A2304 Treatment|Lost to Follow-up|0
6190645|NCT01412944|9846912|FG005|IV: Per Previous CAIN457A2304 Treatment|Lost to Follow-up|1
6190646|NCT01412944|9846907|FG000|IV: Per CAIN457A2307|Withdrawal by Subject|1
6190647|NCT01412944|9846908|FG001|IV: Per CAIN457A2307|Withdrawal by Subject|0
6190648|NCT01412944|9846909|FG002|IV: Per CAIN457A2307|Withdrawal by Subject|0
6190649|NCT01412944|9846910|FG003|IV: Per CAIN457A2307|Withdrawal by Subject|0
6190650|NCT01412944|9846911|FG004|IV: Per CAIN457A2307|Withdrawal by Subject|0
6190651|NCT01412944|9846912|FG005|IV: Per CAIN457A2307|Withdrawal by Subject|0
6190652|NCT01412944|9846907|FG000|IV: Per CAIN457A2307|Protocol deviation|0
6190653|NCT01412944|9846908|FG001|IV: Per CAIN457A2307|Protocol deviation|1
6190654|NCT01412944|9846909|FG002|IV: Per CAIN457A2307|Protocol deviation|0
6256141|NCT01998958|9947665|FG023|Period 2 (Panel A and B)|Adverse Event|0
6256142|NCT01998958|9947666|FG024|Period 2 (Panel A and B)|Adverse Event|0
6256143|NCT01998958|9947667|FG025|Period 2 (Panel A and B)|Adverse Event|0
6256144|NCT01998958|9947668|FG026|Period 2 (Panel A and B)|Adverse Event|0
6256145|NCT01998958|9947669|FG027|Period 2 (Panel A and B)|Adverse Event|0
6256146|NCT01998958|9947670|FG028|Period 2 (Panel A and B)|Adverse Event|0
6256147|NCT01998958|9947671|FG029|Period 2 (Panel A and B)|Adverse Event|0
6256148|NCT01998958|9947672|FG030|Period 2 (Panel A and B)|Adverse Event|0
6256149|NCT01998958|9947673|FG031|Period 2 (Panel A and B)|Adverse Event|0
6256150|NCT01998958|9947642|FG000|Period 2 (Panel A and B)|Withdrawal by Subject|0
6256151|NCT01998958|9947643|FG001|Period 2 (Panel A and B)|Withdrawal by Subject|0
6256152|NCT01998958|9947644|FG002|Period 2 (Panel A and B)|Withdrawal by Subject|0
6256153|NCT01998958|9947645|FG003|Period 2 (Panel A and B)|Withdrawal by Subject|0
6256154|NCT01998958|9947646|FG004|Period 2 (Panel A and B)|Withdrawal by Subject|0
6256155|NCT01998958|9947647|FG005|Period 2 (Panel A and B)|Withdrawal by Subject|0
6256156|NCT01998958|9947648|FG006|Period 2 (Panel A and B)|Withdrawal by Subject|0
6256157|NCT01998958|9947649|FG007|Period 2 (Panel A and B)|Withdrawal by Subject|0
6256158|NCT01998958|9947650|FG008|Period 2 (Panel A and B)|Withdrawal by Subject|0
6256159|NCT01998958|9947651|FG009|Period 2 (Panel A and B)|Withdrawal by Subject|0
6256160|NCT01998958|9947652|FG010|Period 2 (Panel A and B)|Withdrawal by Subject|0
6256161|NCT01998958|9947653|FG011|Period 2 (Panel A and B)|Withdrawal by Subject|0
6256162|NCT01998958|9947654|FG012|Period 2 (Panel A and B)|Withdrawal by Subject|0
6256163|NCT01998958|9947655|FG013|Period 2 (Panel A and B)|Withdrawal by Subject|0
6256164|NCT01998958|9947656|FG014|Period 2 (Panel A and B)|Withdrawal by Subject|1
6256165|NCT01998958|9947657|FG015|Period 2 (Panel A and B)|Withdrawal by Subject|0
6256166|NCT01998958|9947658|FG016|Period 2 (Panel A and B)|Withdrawal by Subject|0
6256167|NCT01998958|9947659|FG017|Period 2 (Panel A and B)|Withdrawal by Subject|0
6256168|NCT01998958|9947660|FG018|Period 2 (Panel A and B)|Withdrawal by Subject|1
6256169|NCT01998958|9947661|FG019|Period 2 (Panel A and B)|Withdrawal by Subject|0
6256170|NCT01998958|9947662|FG020|Period 2 (Panel A and B)|Withdrawal by Subject|0
6256171|NCT01998958|9947663|FG021|Period 2 (Panel A and B)|Withdrawal by Subject|0
6256172|NCT01998958|9947664|FG022|Period 2 (Panel A and B)|Withdrawal by Subject|0
6256173|NCT01998958|9947665|FG023|Period 2 (Panel A and B)|Withdrawal by Subject|0
6256174|NCT01998958|9947666|FG024|Period 2 (Panel A and B)|Withdrawal by Subject|0
6256175|NCT01998958|9947667|FG025|Period 2 (Panel A and B)|Withdrawal by Subject|0
6256176|NCT01998958|9947668|FG026|Period 2 (Panel A and B)|Withdrawal by Subject|0
6256177|NCT01998958|9947669|FG027|Period 2 (Panel A and B)|Withdrawal by Subject|0
6256178|NCT01998958|9947670|FG028|Period 2 (Panel A and B)|Withdrawal by Subject|0
6256179|NCT01998958|9947671|FG029|Period 2 (Panel A and B)|Withdrawal by Subject|0
6256180|NCT01998958|9947672|FG030|Period 2 (Panel A and B)|Withdrawal by Subject|0
6256181|NCT01998958|9947673|FG031|Period 2 (Panel A and B)|Withdrawal by Subject|0
6256182|NCT01998958|9947642|FG000|Open Label Phase (Optional)|Adverse Event|0
6256183|NCT01998958|9947643|FG001|Open Label Phase (Optional)|Adverse Event|0
6256184|NCT01998958|9947644|FG002|Open Label Phase (Optional)|Adverse Event|0
6256185|NCT01998958|9947645|FG003|Open Label Phase (Optional)|Adverse Event|0
6256186|NCT01998958|9947646|FG004|Open Label Phase (Optional)|Adverse Event|0
6256187|NCT01998958|9947647|FG005|Open Label Phase (Optional)|Adverse Event|0
6086614|NCT00662649|9696710|FG001|Core Study (24 Months)|Abnormal laboratory value(s)|9
6086615|NCT00662649|9696711|FG002|Core Study (24 Months)|Abnormal laboratory value(s)|1
6086616|NCT00662649|9696712|FG003|Core Study (24 Months)|Abnormal laboratory value(s)|0
6086617|NCT00662649|9696713|FG004|Core Study (24 Months)|Abnormal laboratory value(s)|0
6086618|NCT00662649|9696709|FG000|Core Study (24 Months)|Lost to Follow-up|3
6086619|NCT00662649|9696710|FG001|Core Study (24 Months)|Lost to Follow-up|5
6086620|NCT00662649|9696711|FG002|Core Study (24 Months)|Lost to Follow-up|7
6086621|NCT00662649|9696712|FG003|Core Study (24 Months)|Lost to Follow-up|0
6086622|NCT00662649|9696713|FG004|Core Study (24 Months)|Lost to Follow-up|0
6086623|NCT00662649|9696709|FG000|Core Study (24 Months)|Protocol Violation|5
6086624|NCT00662649|9696710|FG001|Core Study (24 Months)|Protocol Violation|5
6086625|NCT00662649|9696711|FG002|Core Study (24 Months)|Protocol Violation|4
6086626|NCT00662649|9696712|FG003|Core Study (24 Months)|Protocol Violation|0
6086627|NCT00662649|9696713|FG004|Core Study (24 Months)|Protocol Violation|0
6190655|NCT01412944|9846910|FG003|IV: Per CAIN457A2307|Protocol deviation|0
6190656|NCT01412944|9846911|FG004|IV: Per CAIN457A2307|Protocol deviation|0
6190657|NCT01412944|9846912|FG005|IV: Per CAIN457A2307|Protocol deviation|0
6190658|NCT01412944|9846907|FG000|IV: Per CAIN457A2307|Lost to Follow-up|0
6190659|NCT01412944|9846908|FG001|IV: Per CAIN457A2307|Lost to Follow-up|1
6190660|NCT01412944|9846909|FG002|IV: Per CAIN457A2307|Lost to Follow-up|0
6190661|NCT01412944|9846910|FG003|IV: Per CAIN457A2307|Lost to Follow-up|0
6190662|NCT01412944|9846911|FG004|IV: Per CAIN457A2307|Lost to Follow-up|0
6190663|NCT01412944|9846912|FG005|IV: Per CAIN457A2307|Lost to Follow-up|0
6190664|NCT01412944|9846907|FG000|Entire: IV + Maintenance|Withdrawal by Subject|0
6190665|NCT01412944|9846908|FG001|Entire: IV + Maintenance|Withdrawal by Subject|0
6190666|NCT01412944|9846909|FG002|Entire: IV + Maintenance|Withdrawal by Subject|1
6190667|NCT01412944|9846910|FG003|Entire: IV + Maintenance|Withdrawal by Subject|1
6190668|NCT01412944|9846911|FG004|Entire: IV + Maintenance|Withdrawal by Subject|1
6190669|NCT01412944|9846912|FG005|Entire: IV + Maintenance|Withdrawal by Subject|0
6190670|NCT01412944|9846907|FG000|Entire: IV + Maintenance|Adverse Event|0
6190671|NCT01412944|9846908|FG001|Entire: IV + Maintenance|Adverse Event|0
6190672|NCT01412944|9846909|FG002|Entire: IV + Maintenance|Adverse Event|0
6190673|NCT01412944|9846910|FG003|Entire: IV + Maintenance|Adverse Event|0
6190674|NCT01412944|9846911|FG004|Entire: IV + Maintenance|Adverse Event|1
6190675|NCT01412944|9846912|FG005|Entire: IV + Maintenance|Adverse Event|0
6190676|NCT01412944|9846907|FG000|Entire: IV + Maintenance|Protocol deviation|0
6190677|NCT01412944|9846908|FG001|Entire: IV + Maintenance|Protocol deviation|0
6190678|NCT01412944|9846909|FG002|Entire: IV + Maintenance|Protocol deviation|0
6190679|NCT01412944|9846910|FG003|Entire: IV + Maintenance|Protocol deviation|0
6086628|NCT00662649|9696709|FG000|Core Study (24 Months)|Abnormal test procedure result(s)|2
6086629|NCT00662649|9696710|FG001|Core Study (24 Months)|Abnormal test procedure result(s)|1
6086630|NCT00662649|9696711|FG002|Core Study (24 Months)|Abnormal test procedure result(s)|1
6190680|NCT01412944|9846911|FG004|Entire: IV + Maintenance|Protocol deviation|0
6256188|NCT01998958|9947648|FG006|Open Label Phase (Optional)|Adverse Event|0
6256189|NCT01998958|9947649|FG007|Open Label Phase (Optional)|Adverse Event|0
6256190|NCT01998958|9947650|FG008|Open Label Phase (Optional)|Adverse Event|0
6256191|NCT01998958|9947651|FG009|Open Label Phase (Optional)|Adverse Event|0
6256192|NCT01998958|9947652|FG010|Open Label Phase (Optional)|Adverse Event|0
6190681|NCT01412944|9846912|FG005|Entire: IV + Maintenance|Protocol deviation|1
6190682|NCT01412944|9846907|FG000|Entire: IV + Maintenance|Lost to Follow-up|0
6190683|NCT01412944|9846908|FG001|Entire: IV + Maintenance|Lost to Follow-up|0
6190684|NCT01412944|9846909|FG002|Entire: IV + Maintenance|Lost to Follow-up|0
6190685|NCT01412944|9846910|FG003|Entire: IV + Maintenance|Lost to Follow-up|0
6190686|NCT01412944|9846911|FG004|Entire: IV + Maintenance|Lost to Follow-up|0
6190687|NCT01412944|9846912|FG005|Entire: IV + Maintenance|Lost to Follow-up|1
6190688|NCT01412944|9846907|FG000|Entire: IV + Maintenance|Lack of Efficacy|0
6190689|NCT01412944|9846908|FG001|Entire: IV + Maintenance|Lack of Efficacy|0
6190690|NCT01412944|9846909|FG002|Entire: IV + Maintenance|Lack of Efficacy|0
6190691|NCT01412944|9846910|FG003|Entire: IV + Maintenance|Lack of Efficacy|0
6190692|NCT01412944|9846911|FG004|Entire: IV + Maintenance|Lack of Efficacy|1
6190693|NCT01412944|9846912|FG005|Entire: IV + Maintenance|Lack of Efficacy|0
6190694|NCT01412944|9846907|FG000|Entire: IV + Maintenance|Withdrawal by Subject|2
6190695|NCT01412944|9846908|FG001|Entire: IV + Maintenance|Withdrawal by Subject|1
6190696|NCT01412944|9846909|FG002|Entire: IV + Maintenance|Withdrawal by Subject|0
6190697|NCT01412944|9846910|FG003|Entire: IV + Maintenance|Withdrawal by Subject|0
6190698|NCT01412944|9846911|FG004|Entire: IV + Maintenance|Withdrawal by Subject|0
6190699|NCT01412944|9846912|FG005|Entire: IV + Maintenance|Withdrawal by Subject|0
6190700|NCT01412944|9846907|FG000|Entire: IV + Maintenance|Protocol deviation|0
6190701|NCT01412944|9846908|FG001|Entire: IV + Maintenance|Protocol deviation|1
6190702|NCT01412944|9846909|FG002|Entire: IV + Maintenance|Protocol deviation|0
6190703|NCT01412944|9846910|FG003|Entire: IV + Maintenance|Protocol deviation|0
6190704|NCT01412944|9846911|FG004|Entire: IV + Maintenance|Protocol deviation|0
6190705|NCT01412944|9846912|FG005|Entire: IV + Maintenance|Protocol deviation|0
6190706|NCT01412944|9846907|FG000|Entire: IV + Maintenance|Lost to Follow-up|0
6190707|NCT01412944|9846908|FG001|Entire: IV + Maintenance|Lost to Follow-up|1
6190708|NCT01412944|9846909|FG002|Entire: IV + Maintenance|Lost to Follow-up|0
6190709|NCT01412944|9846910|FG003|Entire: IV + Maintenance|Lost to Follow-up|0
6190710|NCT01412944|9846911|FG004|Entire: IV + Maintenance|Lost to Follow-up|0
6190711|NCT01412944|9846912|FG005|Entire: IV + Maintenance|Lost to Follow-up|0
6190712|NCT01412944|9846907|FG000|Entire: IV + Maintenance|Lack of Efficacy|0
6190713|NCT01412944|9846908|FG001|Entire: IV + Maintenance|Lack of Efficacy|1
6190714|NCT01412944|9846909|FG002|Entire: IV + Maintenance|Lack of Efficacy|0
6190715|NCT01412944|9846910|FG003|Entire: IV + Maintenance|Lack of Efficacy|0
6190716|NCT01412944|9846911|FG004|Entire: IV + Maintenance|Lack of Efficacy|0
6190717|NCT01412944|9846912|FG005|Entire: IV + Maintenance|Lack of Efficacy|0
6190718|NCT01412944|9846907|FG000|Entire: IV + Maintenance|Adverse Event|0
6190719|NCT01412944|9846908|FG001|Entire: IV + Maintenance|Adverse Event|1
6190720|NCT01412944|9846909|FG002|Entire: IV + Maintenance|Adverse Event|0
6190721|NCT01412944|9846910|FG003|Entire: IV + Maintenance|Adverse Event|0
6190722|NCT01412944|9846911|FG004|Entire: IV + Maintenance|Adverse Event|0
6190723|NCT01412944|9846912|FG005|Entire: IV + Maintenance|Adverse Event|0
6190724|NCT01412957|9846930|FG000|Overall Study|Withdrawal by Subject|6
6190725|NCT01412957|9846931|FG001|Overall Study|Withdrawal by Subject|22
6190726|NCT01412957|9846930|FG000|Overall Study|Lost to Follow-up|7
6190727|NCT01412957|9846931|FG001|Overall Study|Lost to Follow-up|2
6190728|NCT01412957|9846930|FG000|Overall Study|Death|136
6190729|NCT01412957|9846931|FG001|Overall Study|Death|133
6190730|NCT01412983|9846937|FG000|1st Period|Ineligible|0
6190731|NCT01412983|9846938|FG001|1st Period|Ineligible|1
6190732|NCT01412983|9846937|FG000|1st Period|Positive slit lamp finding|0
6190733|NCT01412983|9846938|FG001|1st Period|Positive slit lamp finding|1
6190734|NCT01412983|9846937|FG000|1st Period|Unacceptable lens movement|0
6190735|NCT01412983|9846938|FG001|1st Period|Unacceptable lens movement|1
6190736|NCT01412983|9846937|FG000|1st Period|Inability to maintain wear|0
6190737|NCT01412983|9846938|FG001|1st Period|Inability to maintain wear|1
6190738|NCT01413178|9846956|FG000|Overall Study|Toxicity|1
6190739|NCT01413178|9846957|FG001|Overall Study|Toxicity|0
6190740|NCT01413178|9846956|FG000|Overall Study|Ineligible|0
6190741|NCT01413178|9846957|FG001|Overall Study|Ineligible|2
6190742|NCT01413191|9846963|FG000|Overall Study|Lost to Follow-up|5
6190743|NCT01413191|9846963|FG000|Overall Study|Disease Progression|5
6190744|NCT01413191|9846963|FG000|Overall Study|Death|1
6190745|NCT01413204|9846970|FG000|Overall Study|Adverse Event|1
6190746|NCT01413204|9846971|FG001|Overall Study|Adverse Event|2
6190747|NCT01413204|9846972|FG002|Overall Study|Adverse Event|2
6190748|NCT01413204|9846970|FG000|Overall Study|Physician Decision|3
6190749|NCT01413204|9846971|FG001|Overall Study|Physician Decision|0
6190750|NCT01413204|9846972|FG002|Overall Study|Physician Decision|2
6190751|NCT01413204|9846970|FG000|Overall Study|Withdrawal by Subject|1
6256193|NCT01998958|9947653|FG011|Open Label Phase (Optional)|Adverse Event|0
6256194|NCT01998958|9947654|FG012|Open Label Phase (Optional)|Adverse Event|0
6256195|NCT01998958|9947655|FG013|Open Label Phase (Optional)|Adverse Event|0
6256196|NCT01998958|9947656|FG014|Open Label Phase (Optional)|Adverse Event|0
6256197|NCT01998958|9947657|FG015|Open Label Phase (Optional)|Adverse Event|0
6256198|NCT01998958|9947658|FG016|Open Label Phase (Optional)|Adverse Event|0
6256199|NCT01998958|9947659|FG017|Open Label Phase (Optional)|Adverse Event|0
6256200|NCT01998958|9947660|FG018|Open Label Phase (Optional)|Adverse Event|0
6256201|NCT01998958|9947661|FG019|Open Label Phase (Optional)|Adverse Event|0
6256202|NCT01998958|9947662|FG020|Open Label Phase (Optional)|Adverse Event|0
6256203|NCT01998958|9947663|FG021|Open Label Phase (Optional)|Adverse Event|0
6256204|NCT01998958|9947664|FG022|Open Label Phase (Optional)|Adverse Event|0
6256205|NCT01998958|9947665|FG023|Open Label Phase (Optional)|Adverse Event|1
6256206|NCT01998958|9947666|FG024|Open Label Phase (Optional)|Adverse Event|0
6256207|NCT01998958|9947667|FG025|Open Label Phase (Optional)|Adverse Event|0
6256208|NCT01998958|9947668|FG026|Open Label Phase (Optional)|Adverse Event|0
6256209|NCT01998958|9947669|FG027|Open Label Phase (Optional)|Adverse Event|0
6256210|NCT01998958|9947670|FG028|Open Label Phase (Optional)|Adverse Event|0
6256211|NCT01998958|9947671|FG029|Open Label Phase (Optional)|Adverse Event|0
6256212|NCT01998958|9947672|FG030|Open Label Phase (Optional)|Adverse Event|0
6256213|NCT01998958|9947673|FG031|Open Label Phase (Optional)|Adverse Event|0
6256214|NCT01998958|9947642|FG000|Open Label Phase (Optional)|Other|0
6256215|NCT01998958|9947643|FG001|Open Label Phase (Optional)|Other|0
6190752|NCT01413204|9846971|FG001|Overall Study|Withdrawal by Subject|4
6190753|NCT01413204|9846972|FG002|Overall Study|Withdrawal by Subject|4
6190754|NCT01413204|9846970|FG000|Overall Study|Clearly not eligible for the study|0
6190755|NCT01413204|9846971|FG001|Overall Study|Clearly not eligible for the study|0
6190756|NCT01413204|9846972|FG002|Overall Study|Clearly not eligible for the study|1
6190757|NCT01413204|9846970|FG000|Overall Study|Fasting plasma glucose level increased|1
6190758|NCT01413204|9846971|FG001|Overall Study|Fasting plasma glucose level increased|0
6190759|NCT01413204|9846972|FG002|Overall Study|Fasting plasma glucose level increased|10
6190760|NCT01413360|9846980|FG000|Overall Study|Lost to Follow-up|2
6190761|NCT01413360|9846980|FG000|Overall Study|Adverse Event|1
6190762|NCT01413503|9846984|FG000|Overall Study|Lost to Follow-up|1
6190763|NCT01413542|9846999|FG000|Overall Study|Physician Decision|1
6190764|NCT01413542|9847000|FG001|Overall Study|Physician Decision|0
6190765|NCT01413542|9847001|FG002|Overall Study|Physician Decision|3
6190766|NCT01413542|9847002|FG003|Overall Study|Physician Decision|0
6190767|NCT01413542|9846999|FG000|Overall Study|Adverse Event|0
6190768|NCT01413542|9847000|FG001|Overall Study|Adverse Event|0
6190769|NCT01413542|9847001|FG002|Overall Study|Adverse Event|0
6190770|NCT01413542|9847002|FG003|Overall Study|Adverse Event|1
6190771|NCT01413958|9847034|FG000|Overall Study|Lost to Follow-up|0
6190772|NCT01413958|9847035|FG001|Overall Study|Lost to Follow-up|1
6190773|NCT01414075|9847078|FG000|Overall Study|Adverse Event|1
6190774|NCT01414075|9847079|FG001|Overall Study|Adverse Event|0
6190775|NCT01414075|9847080|FG002|Overall Study|Adverse Event|1
6190776|NCT01414075|9847081|FG003|Overall Study|Adverse Event|0
6190777|NCT01414075|9847078|FG000|Overall Study|Death|1
6190778|NCT01414075|9847079|FG001|Overall Study|Death|0
6190779|NCT01414075|9847080|FG002|Overall Study|Death|0
6190780|NCT01414075|9847081|FG003|Overall Study|Death|1
6190781|NCT01414075|9847078|FG000|Overall Study|Withdrawal by Subject|0
6190782|NCT01414075|9847079|FG001|Overall Study|Withdrawal by Subject|0
6190783|NCT01414075|9847080|FG002|Overall Study|Withdrawal by Subject|0
6190784|NCT01414075|9847081|FG003|Overall Study|Withdrawal by Subject|1
6190785|NCT01414075|9847078|FG000|Overall Study|Other than specified|1
6190786|NCT01414075|9847079|FG001|Overall Study|Other than specified|0
6190787|NCT01414075|9847080|FG002|Overall Study|Other than specified|1
6190788|NCT01414075|9847081|FG003|Overall Study|Other than specified|0
6190789|NCT01414114|9847091|FG000|Overall Study|Adverse Event|2
6190790|NCT01414114|9847091|FG000|Overall Study|Withdrawal by Subject|1
6190791|NCT01414114|9847091|FG000|Overall Study|Other|2
6190792|NCT01414205|9847116|FG000|Overall Study|Death|5
6190793|NCT01414205|9847117|FG001|Overall Study|Death|1
6190794|NCT01414205|9847116|FG000|Overall Study|Lost to Follow-up|1
6190795|NCT01414205|9847117|FG001|Overall Study|Lost to Follow-up|4
6190796|NCT01414205|9847116|FG000|Overall Study|Physician Decision|0
6190797|NCT01414205|9847117|FG001|Overall Study|Physician Decision|1
6190798|NCT01414205|9847116|FG000|Overall Study|Randomized but not Treated|1
6190799|NCT01414205|9847117|FG001|Overall Study|Randomized but not Treated|1
6190800|NCT01414257|9847132|FG000|Overall Study|No Visit After First Day of Treatment|12
6190801|NCT01414257|9847132|FG000|Overall Study|Protocol Violation|10
6190802|NCT01414738|9847172|FG000|Overall Study|Death|26
6190803|NCT01414738|9847172|FG000|Overall Study|Refused testing|5
6190804|NCT01414738|9847172|FG000|Overall Study|Lost to Follow-up|2
6190805|NCT01414738|9847172|FG000|Overall Study|Refused, disease progression|8
6190806|NCT01414738|9847172|FG000|Overall Study|(Unknown) NOS (Not Otherwise Specified)|3
6190807|NCT01414855|9847176|FG000|Overall Study|Death|17
6190808|NCT01414855|9847176|FG000|Overall Study|Lost to Follow-up|5
6190809|NCT01414855|9847176|FG000|Overall Study|Withdrawal by Subject|7
6190810|NCT01415349|9847184|FG000|Treatment Period 1|Adverse Event|0
6190811|NCT01415349|9847185|FG001|Treatment Period 1|Adverse Event|1
6256216|NCT01998958|9947644|FG002|Open Label Phase (Optional)|Other|0
6256217|NCT01998958|9947645|FG003|Open Label Phase (Optional)|Other|0
6256218|NCT01998958|9947646|FG004|Open Label Phase (Optional)|Other|0
6256219|NCT01998958|9947647|FG005|Open Label Phase (Optional)|Other|0
6256220|NCT01998958|9947648|FG006|Open Label Phase (Optional)|Other|0
6256221|NCT01998958|9947649|FG007|Open Label Phase (Optional)|Other|0
6256222|NCT01998958|9947650|FG008|Open Label Phase (Optional)|Other|0
6256223|NCT01998958|9947651|FG009|Open Label Phase (Optional)|Other|0
6256224|NCT01998958|9947652|FG010|Open Label Phase (Optional)|Other|0
6256225|NCT01998958|9947653|FG011|Open Label Phase (Optional)|Other|0
6256226|NCT01998958|9947654|FG012|Open Label Phase (Optional)|Other|0
6256227|NCT01998958|9947655|FG013|Open Label Phase (Optional)|Other|0
6256228|NCT01998958|9947656|FG014|Open Label Phase (Optional)|Other|0
6256229|NCT01998958|9947657|FG015|Open Label Phase (Optional)|Other|0
6256230|NCT01998958|9947658|FG016|Open Label Phase (Optional)|Other|0
6256231|NCT01998958|9947659|FG017|Open Label Phase (Optional)|Other|0
6256232|NCT01998958|9947660|FG018|Open Label Phase (Optional)|Other|0
6256233|NCT01998958|9947661|FG019|Open Label Phase (Optional)|Other|0
6256234|NCT01998958|9947662|FG020|Open Label Phase (Optional)|Other|0
6256235|NCT01998958|9947663|FG021|Open Label Phase (Optional)|Other|0
6256236|NCT01998958|9947664|FG022|Open Label Phase (Optional)|Other|5
6256237|NCT01998958|9947665|FG023|Open Label Phase (Optional)|Other|1
6256238|NCT01998958|9947666|FG024|Open Label Phase (Optional)|Other|0
6256239|NCT01998958|9947667|FG025|Open Label Phase (Optional)|Other|0
6256240|NCT01998958|9947668|FG026|Open Label Phase (Optional)|Other|0
6256241|NCT01998958|9947669|FG027|Open Label Phase (Optional)|Other|0
6256242|NCT01998958|9947670|FG028|Open Label Phase (Optional)|Other|0
6256243|NCT01998958|9947671|FG029|Open Label Phase (Optional)|Other|0
6256244|NCT01998958|9947672|FG030|Open Label Phase (Optional)|Other|0
6256245|NCT01998958|9947673|FG031|Open Label Phase (Optional)|Other|0
6256246|NCT01998958|9947642|FG000|Open Label Phase (Optional)|Lost to Follow-up|0
6256247|NCT01998958|9947643|FG001|Open Label Phase (Optional)|Lost to Follow-up|0
6256248|NCT01998958|9947644|FG002|Open Label Phase (Optional)|Lost to Follow-up|0
6256249|NCT01998958|9947645|FG003|Open Label Phase (Optional)|Lost to Follow-up|0
6256250|NCT01998958|9947646|FG004|Open Label Phase (Optional)|Lost to Follow-up|0
6190812|NCT01415349|9847184|FG000|Treatment Period 1|Withdrawal by Subject|0
6190813|NCT01415349|9847185|FG001|Treatment Period 1|Withdrawal by Subject|1
6190814|NCT01415401|9847191|FG000|Overall Study|Adverse Event|5
6190815|NCT01415401|9847191|FG000|Overall Study|DId not meet inclusion/exclusion criteri|1
6190816|NCT01415401|9847191|FG000|Overall Study|Terminated by Sponsor|1
6190817|NCT01415440|9847217|FG000|Overall Study|Lost to Follow-up|0
6190818|NCT01415440|9847218|FG001|Overall Study|Lost to Follow-up|1
6190819|NCT01415440|9847219|FG002|Overall Study|Lost to Follow-up|2
6190820|NCT01415440|9847217|FG000|Overall Study|Physician Decision|3
6190821|NCT01415440|9847218|FG001|Overall Study|Physician Decision|0
6190822|NCT01415440|9847219|FG002|Overall Study|Physician Decision|0
6190823|NCT01415440|9847217|FG000|Overall Study|Withdrawal by Subject|1
6190824|NCT01415440|9847218|FG001|Overall Study|Withdrawal by Subject|0
6190825|NCT01415440|9847219|FG002|Overall Study|Withdrawal by Subject|0
6190826|NCT01415518|9847232|FG000|Overall Study|Withdrawal by Subject|2
6190827|NCT01415518|9847233|FG001|Overall Study|Withdrawal by Subject|12
6190828|NCT01415518|9847232|FG000|Overall Study|Protocol Violation|6
6190829|NCT01415518|9847233|FG001|Overall Study|Protocol Violation|8
6190830|NCT01415518|9847232|FG000|Overall Study|Lost to Follow-up|3
6190831|NCT01415518|9847233|FG001|Overall Study|Lost to Follow-up|5
6190832|NCT01415518|9847232|FG000|Overall Study|Adverse Event|3
6190833|NCT01415518|9847233|FG001|Overall Study|Adverse Event|4
6190834|NCT01415518|9847232|FG000|Overall Study|Death|1
6190835|NCT01415518|9847233|FG001|Overall Study|Death|1
6190836|NCT01415518|9847232|FG000|Overall Study|Condition under Investigation Worsened|1
6190837|NCT01415518|9847233|FG001|Overall Study|Condition under Investigation Worsened|1
6190838|NCT01415531|9847241|FG000|Overall Study|Adverse Event|7
6190839|NCT01415531|9847242|FG001|Overall Study|Adverse Event|10
6190840|NCT01415531|9847241|FG000|Overall Study|Lack of Efficacy|3
6190841|NCT01415531|9847242|FG001|Overall Study|Lack of Efficacy|2
6190842|NCT01415531|9847241|FG000|Overall Study|Protocol Violation|0
6190843|NCT01415531|9847242|FG001|Overall Study|Protocol Violation|1
6190844|NCT01415531|9847241|FG000|Overall Study|Withdrawal by Subject|5
6190845|NCT01415531|9847242|FG001|Overall Study|Withdrawal by Subject|4
6190846|NCT01415531|9847241|FG000|Overall Study|Lost to Follow-up|6
6190847|NCT01415531|9847242|FG001|Overall Study|Lost to Follow-up|14
6190848|NCT01415531|9847241|FG000|Overall Study|Lack of Compliance|1
6190849|NCT01415531|9847242|FG001|Overall Study|Lack of Compliance|4
6190850|NCT01415531|9847241|FG000|Overall Study|Other Reasons|3
6190851|NCT01415531|9847242|FG001|Overall Study|Other Reasons|2
6190852|NCT01415908|9847259|FG000|Overall Study|Withdrawal by Subject|1
6256251|NCT01998958|9947647|FG005|Open Label Phase (Optional)|Lost to Follow-up|0
6256252|NCT01998958|9947648|FG006|Open Label Phase (Optional)|Lost to Follow-up|0
6256253|NCT01998958|9947649|FG007|Open Label Phase (Optional)|Lost to Follow-up|0
6190853|NCT01415908|9847260|FG001|Overall Study|Withdrawal by Subject|0
6190854|NCT01415921|9847268|FG000|Overall Study|Adverse Event|0
6190855|NCT01415921|9847269|FG001|Overall Study|Adverse Event|1
6190856|NCT01415921|9847268|FG000|Overall Study|Physician Decision|1
6256254|NCT01998958|9947650|FG008|Open Label Phase (Optional)|Lost to Follow-up|0
6256255|NCT01998958|9947651|FG009|Open Label Phase (Optional)|Lost to Follow-up|0
6256256|NCT01998958|9947652|FG010|Open Label Phase (Optional)|Lost to Follow-up|0
6256257|NCT01998958|9947653|FG011|Open Label Phase (Optional)|Lost to Follow-up|0
6256258|NCT01998958|9947654|FG012|Open Label Phase (Optional)|Lost to Follow-up|0
6256259|NCT01998958|9947655|FG013|Open Label Phase (Optional)|Lost to Follow-up|0
6256260|NCT01998958|9947656|FG014|Open Label Phase (Optional)|Lost to Follow-up|0
6256261|NCT01998958|9947657|FG015|Open Label Phase (Optional)|Lost to Follow-up|0
6256262|NCT01998958|9947658|FG016|Open Label Phase (Optional)|Lost to Follow-up|0
6256263|NCT01998958|9947659|FG017|Open Label Phase (Optional)|Lost to Follow-up|0
6256264|NCT01998958|9947660|FG018|Open Label Phase (Optional)|Lost to Follow-up|0
6256265|NCT01998958|9947661|FG019|Open Label Phase (Optional)|Lost to Follow-up|0
6256266|NCT01998958|9947662|FG020|Open Label Phase (Optional)|Lost to Follow-up|0
6256267|NCT01998958|9947663|FG021|Open Label Phase (Optional)|Lost to Follow-up|0
6256268|NCT01998958|9947664|FG022|Open Label Phase (Optional)|Lost to Follow-up|1
6256269|NCT01998958|9947665|FG023|Open Label Phase (Optional)|Lost to Follow-up|0
6256270|NCT01998958|9947666|FG024|Open Label Phase (Optional)|Lost to Follow-up|0
6256271|NCT01998958|9947667|FG025|Open Label Phase (Optional)|Lost to Follow-up|0
6256272|NCT01998958|9947668|FG026|Open Label Phase (Optional)|Lost to Follow-up|0
6256273|NCT01998958|9947669|FG027|Open Label Phase (Optional)|Lost to Follow-up|0
6256274|NCT01998958|9947670|FG028|Open Label Phase (Optional)|Lost to Follow-up|0
6256275|NCT01998958|9947671|FG029|Open Label Phase (Optional)|Lost to Follow-up|0
6256276|NCT01998958|9947672|FG030|Open Label Phase (Optional)|Lost to Follow-up|0
6256277|NCT01998958|9947673|FG031|Open Label Phase (Optional)|Lost to Follow-up|0
6256278|NCT01998958|9947642|FG000|Open Label Phase (Optional)|Lack of Efficacy|0
6256279|NCT01998958|9947643|FG001|Open Label Phase (Optional)|Lack of Efficacy|0
6256280|NCT01998958|9947644|FG002|Open Label Phase (Optional)|Lack of Efficacy|0
6256281|NCT01998958|9947645|FG003|Open Label Phase (Optional)|Lack of Efficacy|0
6256282|NCT01998958|9947646|FG004|Open Label Phase (Optional)|Lack of Efficacy|0
6256283|NCT01998958|9947647|FG005|Open Label Phase (Optional)|Lack of Efficacy|0
6256284|NCT01998958|9947648|FG006|Open Label Phase (Optional)|Lack of Efficacy|0
6256285|NCT01998958|9947649|FG007|Open Label Phase (Optional)|Lack of Efficacy|0
6256286|NCT01998958|9947650|FG008|Open Label Phase (Optional)|Lack of Efficacy|0
6256287|NCT01998958|9947651|FG009|Open Label Phase (Optional)|Lack of Efficacy|0
6190857|NCT01415921|9847269|FG001|Overall Study|Physician Decision|1
6190858|NCT01415921|9847268|FG000|Overall Study|Withdrawal by Subject|0
6190859|NCT01415921|9847269|FG001|Overall Study|Withdrawal by Subject|1
6190860|NCT01415921|9847268|FG000|Overall Study|Other|2
6190861|NCT01415921|9847269|FG001|Overall Study|Other|0
6190862|NCT01416142|9847306|FG000|PureVision2 HD|Inability to maintain lens wear|0
6190863|NCT01416142|9847307|FG001|PureVision2 HD|Inability to maintain lens wear|0
6190864|NCT01416142|9847308|FG002|PureVision2 HD|Inability to maintain lens wear|1
6190865|NCT01416155|9847316|FG000|Overall Study|Adverse Event|8
6190866|NCT01416155|9847316|FG000|Overall Study|Positive for anti-BG00002 antibodies|2
6190867|NCT01416155|9847316|FG000|Overall Study|Withdrawal by Subject|33
6190868|NCT01416155|9847316|FG000|Overall Study|Investigator decision|8
6190869|NCT01416155|9847316|FG000|Overall Study|Other|7
6190870|NCT01416181|9847322|FG000|Part 1|Other|10
6190871|NCT01416181|9847323|FG001|Part 1|Other|24
6190872|NCT01416181|9847322|FG000|Part 1|Death|0
6190873|NCT01416181|9847323|FG001|Part 1|Death|1
6190874|NCT01416181|9847322|FG000|Part 1|Investigator Decision|7
6190875|NCT01416181|9847323|FG001|Part 1|Investigator Decision|6
6190876|NCT01416181|9847322|FG000|Part 1|Withdrawal by Subject|74
6190877|NCT01416181|9847323|FG001|Part 1|Withdrawal by Subject|48
6190878|NCT01416181|9847322|FG000|Part 1|Lack of Efficacy|16
6190879|NCT01416181|9847323|FG001|Part 1|Lack of Efficacy|8
6190880|NCT01416181|9847322|FG000|Part 1|Lost to Follow-up|1
6190881|NCT01416181|9847323|FG001|Part 1|Lost to Follow-up|1
6190882|NCT01416181|9847322|FG000|Part 1|Adverse Event|15
6190883|NCT01416181|9847323|FG001|Part 1|Adverse Event|18
6190884|NCT01416181|9847322|FG000|Part 1|Ongoing in Follow-Up|14
6190885|NCT01416181|9847323|FG001|Part 1|Ongoing in Follow-Up|8
6190886|NCT01416181|9847322|FG000|Part 2|Adverse Event|11
6190887|NCT01416181|9847323|FG001|Part 2|Adverse Event|4
6190888|NCT01416181|9847322|FG000|Part 2|Other|234
6190889|NCT01416181|9847323|FG001|Part 2|Other|267
6190890|NCT01416181|9847322|FG000|Part 2|Investigator Decision|6
6190891|NCT01416181|9847323|FG001|Part 2|Investigator Decision|7
6190892|NCT01416181|9847322|FG000|Part 2|Withdrawal by Subject|14
6256288|NCT01998958|9947652|FG010|Open Label Phase (Optional)|Lack of Efficacy|0
6256289|NCT01998958|9947653|FG011|Open Label Phase (Optional)|Lack of Efficacy|0
6256290|NCT01998958|9947654|FG012|Open Label Phase (Optional)|Lack of Efficacy|0
6256291|NCT01998958|9947655|FG013|Open Label Phase (Optional)|Lack of Efficacy|0
6256292|NCT01998958|9947656|FG014|Open Label Phase (Optional)|Lack of Efficacy|0
6190893|NCT01416181|9847323|FG001|Part 2|Withdrawal by Subject|5
6190894|NCT01416181|9847322|FG000|Part 2|Lack of Efficacy|4
6190895|NCT01416181|9847323|FG001|Part 2|Lack of Efficacy|1
6190896|NCT01416181|9847322|FG000|Part 2|Lost to Follow-up|2
6190897|NCT01416181|9847323|FG001|Part 2|Lost to Follow-up|2
6190898|NCT01416389|9847346|FG000|Overall Study|Lost to Follow-up|1
6190899|NCT01416389|9847347|FG001|Overall Study|Lost to Follow-up|0
6190900|NCT01416389|9847346|FG000|Overall Study|Started New Therapy|2
6190901|NCT01416389|9847347|FG001|Overall Study|Started New Therapy|0
6190902|NCT01416441|9847355|FG000|Overall Study|Lost to Follow-up|5
6256293|NCT01998958|9947657|FG015|Open Label Phase (Optional)|Lack of Efficacy|0
6256294|NCT01998958|9947658|FG016|Open Label Phase (Optional)|Lack of Efficacy|0
6256295|NCT01998958|9947659|FG017|Open Label Phase (Optional)|Lack of Efficacy|0
6256296|NCT01998958|9947660|FG018|Open Label Phase (Optional)|Lack of Efficacy|0
6256297|NCT01998958|9947661|FG019|Open Label Phase (Optional)|Lack of Efficacy|0
6256298|NCT01998958|9947662|FG020|Open Label Phase (Optional)|Lack of Efficacy|0
6256299|NCT01998958|9947663|FG021|Open Label Phase (Optional)|Lack of Efficacy|1
6256300|NCT01998958|9947664|FG022|Open Label Phase (Optional)|Lack of Efficacy|2
6256301|NCT01998958|9947665|FG023|Open Label Phase (Optional)|Lack of Efficacy|0
6256302|NCT01998958|9947666|FG024|Open Label Phase (Optional)|Lack of Efficacy|0
6256303|NCT01998958|9947667|FG025|Open Label Phase (Optional)|Lack of Efficacy|0
6256304|NCT01998958|9947668|FG026|Open Label Phase (Optional)|Lack of Efficacy|0
6256305|NCT01998958|9947669|FG027|Open Label Phase (Optional)|Lack of Efficacy|0
6256306|NCT01998958|9947670|FG028|Open Label Phase (Optional)|Lack of Efficacy|0
6256307|NCT01998958|9947671|FG029|Open Label Phase (Optional)|Lack of Efficacy|0
6256308|NCT01998958|9947672|FG030|Open Label Phase (Optional)|Lack of Efficacy|0
6256309|NCT01998958|9947673|FG031|Open Label Phase (Optional)|Lack of Efficacy|0
6256310|NCT01998958|9947642|FG000|Open Label Phase (Optional)|Withdrawal by Subject|0
6256311|NCT01998958|9947643|FG001|Open Label Phase (Optional)|Withdrawal by Subject|0
6256312|NCT01998958|9947644|FG002|Open Label Phase (Optional)|Withdrawal by Subject|0
6256313|NCT01998958|9947645|FG003|Open Label Phase (Optional)|Withdrawal by Subject|0
6256314|NCT01998958|9947646|FG004|Open Label Phase (Optional)|Withdrawal by Subject|0
6256315|NCT01998958|9947647|FG005|Open Label Phase (Optional)|Withdrawal by Subject|0
6256316|NCT01998958|9947648|FG006|Open Label Phase (Optional)|Withdrawal by Subject|0
6256317|NCT01998958|9947649|FG007|Open Label Phase (Optional)|Withdrawal by Subject|0
6256318|NCT01998958|9947650|FG008|Open Label Phase (Optional)|Withdrawal by Subject|0
6256319|NCT01998958|9947651|FG009|Open Label Phase (Optional)|Withdrawal by Subject|0
6256320|NCT01998958|9947652|FG010|Open Label Phase (Optional)|Withdrawal by Subject|0
6256321|NCT01998958|9947653|FG011|Open Label Phase (Optional)|Withdrawal by Subject|0
6256322|NCT01998958|9947654|FG012|Open Label Phase (Optional)|Withdrawal by Subject|0
6256323|NCT01998958|9947655|FG013|Open Label Phase (Optional)|Withdrawal by Subject|0
6256324|NCT01998958|9947656|FG014|Open Label Phase (Optional)|Withdrawal by Subject|0
6256325|NCT01998958|9947657|FG015|Open Label Phase (Optional)|Withdrawal by Subject|0
6256326|NCT01998958|9947658|FG016|Open Label Phase (Optional)|Withdrawal by Subject|0
6256327|NCT01998958|9947659|FG017|Open Label Phase (Optional)|Withdrawal by Subject|0
6256328|NCT01998958|9947660|FG018|Open Label Phase (Optional)|Withdrawal by Subject|0
6256329|NCT01998958|9947661|FG019|Open Label Phase (Optional)|Withdrawal by Subject|0
6256330|NCT01998958|9947662|FG020|Open Label Phase (Optional)|Withdrawal by Subject|0
6256331|NCT01998958|9947663|FG021|Open Label Phase (Optional)|Withdrawal by Subject|2
6256332|NCT01998958|9947664|FG022|Open Label Phase (Optional)|Withdrawal by Subject|1
6256333|NCT01998958|9947665|FG023|Open Label Phase (Optional)|Withdrawal by Subject|2
6256334|NCT01998958|9947666|FG024|Open Label Phase (Optional)|Withdrawal by Subject|0
6256335|NCT01998958|9947667|FG025|Open Label Phase (Optional)|Withdrawal by Subject|0
6256336|NCT01998958|9947668|FG026|Open Label Phase (Optional)|Withdrawal by Subject|0
6256337|NCT01998958|9947669|FG027|Open Label Phase (Optional)|Withdrawal by Subject|0
6256338|NCT01998958|9947670|FG028|Open Label Phase (Optional)|Withdrawal by Subject|0
6256339|NCT01998958|9947671|FG029|Open Label Phase (Optional)|Withdrawal by Subject|0
6256340|NCT01998958|9947672|FG030|Open Label Phase (Optional)|Withdrawal by Subject|0
6256341|NCT01998958|9947673|FG031|Open Label Phase (Optional)|Withdrawal by Subject|0
6256342|NCT01998984|9947727|FG000|Overall Study|Adverse Event|0
6256343|NCT01998984|9947728|FG001|Overall Study|Adverse Event|0
6256344|NCT01998984|9947729|FG002|Overall Study|Adverse Event|0
6256345|NCT01998984|9947730|FG003|Overall Study|Adverse Event|1
6256346|NCT01998984|9947727|FG000|Overall Study|Lost to Follow-up|0
6256347|NCT01998984|9947728|FG001|Overall Study|Lost to Follow-up|1
6256348|NCT01998984|9947729|FG002|Overall Study|Lost to Follow-up|0
6086631|NCT00662649|9696712|FG003|Core Study (24 Months)|Abnormal test procedure result(s)|0
6086632|NCT00662649|9696713|FG004|Core Study (24 Months)|Abnormal test procedure result(s)|0
6086633|NCT00662649|9696709|FG000|Core Study (24 Months)|Death|1
6086634|NCT00662649|9696710|FG001|Core Study (24 Months)|Death|0
6190903|NCT01416441|9847355|FG000|Overall Study|Adverse Event|6
6190904|NCT01416441|9847355|FG000|Overall Study|Sponsor Discontinued Trial Site|43
6190905|NCT01416441|9847355|FG000|Overall Study|Subject Met Withdrawal Criteria|10
6190906|NCT01416441|9847355|FG000|Overall Study|Investigator Withdrew Subject|2
6190907|NCT01416441|9847355|FG000|Overall Study|Subject Withdrew Consent|12
6190908|NCT01416441|9847355|FG000|Overall Study|Lack of Efficacy as Determined by the Investigator|3
6190909|NCT01416571|9847359|FG000|Overall Study|Lost to Follow-up|2
6190910|NCT01416610|9847382|FG000|Overall Study|Adverse Event|4
6190911|NCT01416610|9847382|FG000|Overall Study|Adverse Event -Patient decision|3
6190912|NCT01416610|9847382|FG000|Overall Study|Lack of Efficacy|4
6190913|NCT01416610|9847382|FG000|Overall Study|No reason given|5
6190914|NCT01416610|9847382|FG000|Overall Study|Withdrawal by Subject|13
6256349|NCT01998984|9947730|FG003|Overall Study|Lost to Follow-up|1
6086635|NCT00662649|9696711|FG002|Core Study (24 Months)|Death|2
6190915|NCT01416610|9847382|FG000|Overall Study|Lost to Follow-up|7
6190916|NCT01416610|9847382|FG000|Overall Study|Sufficient treatment duration (PCR neg.)|7
6190917|NCT01416805|9847401|FG000|Overall Study|Lost to Follow-up|4
6256350|NCT01998984|9947727|FG000|Overall Study|Withdrawal by Subject|0
6256351|NCT01998984|9947728|FG001|Overall Study|Withdrawal by Subject|0
6256352|NCT01998984|9947729|FG002|Overall Study|Withdrawal by Subject|1
6256353|NCT01998984|9947730|FG003|Overall Study|Withdrawal by Subject|0
6256354|NCT01998984|9947727|FG000|Overall Study|Other|0
6256355|NCT01998984|9947728|FG001|Overall Study|Other|0
6256356|NCT01998984|9947729|FG002|Overall Study|Other|0
6256357|NCT01998984|9947730|FG003|Overall Study|Other|1
6256358|NCT01999114|9947745|FG000|Overall Study|Adverse Event|8
6256359|NCT01999114|9947746|FG001|Overall Study|Adverse Event|7
6256360|NCT01999114|9947747|FG002|Overall Study|Adverse Event|2
6256361|NCT01999114|9947748|FG003|Overall Study|Adverse Event|2
6256362|NCT01999114|9947749|FG004|Overall Study|Adverse Event|1
6256363|NCT01999114|9947745|FG000|Overall Study|Withdrawal by Subject|0
6256364|NCT01999114|9947746|FG001|Overall Study|Withdrawal by Subject|0
6256365|NCT01999114|9947747|FG002|Overall Study|Withdrawal by Subject|1
6256366|NCT01999114|9947748|FG003|Overall Study|Withdrawal by Subject|0
6086636|NCT00662649|9696712|FG003|Core Study (24 Months)|Death|0
6256367|NCT01999114|9947749|FG004|Overall Study|Withdrawal by Subject|1
6256368|NCT01999114|9947745|FG000|Overall Study|Lost to Follow-up|0
6256369|NCT01999114|9947746|FG001|Overall Study|Lost to Follow-up|0
6256370|NCT01999114|9947747|FG002|Overall Study|Lost to Follow-up|1
6256371|NCT01999114|9947748|FG003|Overall Study|Lost to Follow-up|0
6256372|NCT01999114|9947749|FG004|Overall Study|Lost to Follow-up|0
6256373|NCT01999114|9947745|FG000|Overall Study|Administrative|0
6256374|NCT01999114|9947746|FG001|Overall Study|Administrative|0
6256375|NCT01999114|9947747|FG002|Overall Study|Administrative|1
6256376|NCT01999114|9947748|FG003|Overall Study|Administrative|1
6256377|NCT01999114|9947749|FG004|Overall Study|Administrative|2
6256378|NCT01999218|9947795|FG000|Overall Study|Hyperglycemia|18
6256379|NCT01999218|9947796|FG001|Overall Study|Hyperglycemia|17
6256380|NCT01999218|9947797|FG002|Overall Study|Hyperglycemia|17
6256381|NCT01999218|9947795|FG000|Overall Study|Lack of Efficacy|1
6256382|NCT01999218|9947796|FG001|Overall Study|Lack of Efficacy|0
6256383|NCT01999218|9947797|FG002|Overall Study|Lack of Efficacy|1
6256384|NCT01999218|9947795|FG000|Overall Study|Lost to Follow-up|22
6256385|NCT01999218|9947796|FG001|Overall Study|Lost to Follow-up|17
6256386|NCT01999218|9947797|FG002|Overall Study|Lost to Follow-up|18
6256387|NCT01999218|9947795|FG000|Overall Study|Non-Compliance With Study Drug|6
6256388|NCT01999218|9947796|FG001|Overall Study|Non-Compliance With Study Drug|4
6256389|NCT01999218|9947797|FG002|Overall Study|Non-Compliance With Study Drug|1
6256390|NCT01999218|9947795|FG000|Overall Study|Physician Decision|1
6256391|NCT01999218|9947796|FG001|Overall Study|Physician Decision|4
6256392|NCT01999218|9947797|FG002|Overall Study|Physician Decision|6
6256393|NCT01999218|9947795|FG000|Overall Study|Protocol Violation|4
6256394|NCT01999218|9947796|FG001|Overall Study|Protocol Violation|5
6256395|NCT01999218|9947797|FG002|Overall Study|Protocol Violation|4
6256396|NCT01999218|9947795|FG000|Overall Study|Screen failure|0
6256397|NCT01999218|9947796|FG001|Overall Study|Screen failure|1
6256398|NCT01999218|9947797|FG002|Overall Study|Screen failure|0
6256399|NCT01999218|9947795|FG000|Overall Study|Study Terminated By Sponsor|7
6256400|NCT01999218|9947796|FG001|Overall Study|Study Terminated By Sponsor|5
6256401|NCT01999218|9947797|FG002|Overall Study|Study Terminated By Sponsor|12
6256402|NCT01999218|9947795|FG000|Overall Study|Participant moves|2
6256403|NCT01999218|9947796|FG001|Overall Study|Participant moves|5
6256404|NCT01999218|9947797|FG002|Overall Study|Participant moves|3
6256405|NCT01999218|9947795|FG000|Overall Study|Withdrawal by Subject|28
6256406|NCT01999218|9947796|FG001|Overall Study|Withdrawal by Subject|29
6256407|NCT01999218|9947797|FG002|Overall Study|Withdrawal by Subject|34
6256408|NCT01999218|9947795|FG000|Overall Study|Creatinine/eGFR|0
6256409|NCT01999218|9947796|FG001|Overall Study|Creatinine/eGFR|0
6256410|NCT01999218|9947797|FG002|Overall Study|Creatinine/eGFR|1
6256411|NCT01999218|9947795|FG000|Overall Study|Death|7
6256412|NCT01999218|9947796|FG001|Overall Study|Death|1
6256413|NCT01999218|9947797|FG002|Overall Study|Death|2
6256414|NCT01999218|9947795|FG000|Overall Study|Excluded Medication|1
6256415|NCT01999218|9947796|FG001|Overall Study|Excluded Medication|1
6256416|NCT01999218|9947797|FG002|Overall Study|Excluded Medication|2
6256417|NCT01999218|9947795|FG000|Overall Study|Adverse Event|9
6256418|NCT01999218|9947796|FG001|Overall Study|Adverse Event|7
6256419|NCT01999218|9947797|FG002|Overall Study|Adverse Event|7
6256420|NCT01999218|9947795|FG000|Overall Study|Treated but excluded at 1 trial site|3
6256421|NCT01999218|9947796|FG001|Overall Study|Treated but excluded at 1 trial site|5
6256422|NCT01999218|9947797|FG002|Overall Study|Treated but excluded at 1 trial site|2
6256423|NCT01999322|9947826|FG000|Overall Study|Adverse Event|1
6256424|NCT01999322|9947827|FG001|Overall Study|Adverse Event|0
6256425|NCT01999335|9947838|FG000|Overall Study|Discontinued before receiving treatment|0
6256426|NCT01999335|9947839|FG001|Overall Study|Discontinued before receiving treatment|0
6256427|NCT01999335|9947840|FG002|Overall Study|Discontinued before receiving treatment|0
6256428|NCT01999335|9947841|FG003|Overall Study|Discontinued before receiving treatment|0
6256429|NCT01999335|9947842|FG004|Overall Study|Discontinued before receiving treatment|2
6256430|NCT01999465|9947878|FG000|Overall Study|Lost to Follow-up|0
6256431|NCT01999465|9947879|FG001|Overall Study|Lost to Follow-up|2
6256432|NCT01999465|9947878|FG000|Overall Study|Protocol Violation|0
6256433|NCT01999465|9947879|FG001|Overall Study|Protocol Violation|1
6256434|NCT01999868|9947910|FG000|Lead-in Phase (Week 0 - 12)|Lost to Follow-up|0
6256435|NCT01999868|9947911|FG001|Lead-in Phase (Week 0 - 12)|Lost to Follow-up|0
6256436|NCT01999868|9947912|FG002|Lead-in Phase (Week 0 - 12)|Lost to Follow-up|5
6256437|NCT01999868|9947910|FG000|Blinded Treatment Phase (Week 12 - 40)|Adverse Event|1
6256438|NCT01999868|9947911|FG001|Blinded Treatment Phase (Week 12 - 40)|Adverse Event|1
6256439|NCT01999868|9947912|FG002|Blinded Treatment Phase (Week 12 - 40)|Adverse Event|0
6256440|NCT01999868|9947910|FG000|Blinded Treatment Phase (Week 12 - 40)|Lost to Follow-up|3
6256441|NCT01999868|9947911|FG001|Blinded Treatment Phase (Week 12 - 40)|Lost to Follow-up|4
6256442|NCT01999868|9947912|FG002|Blinded Treatment Phase (Week 12 - 40)|Lost to Follow-up|0
6256443|NCT01999868|9947910|FG000|Blinded Treatment Phase (Week 12 - 40)|Pregnancy|0
6256444|NCT01999868|9947911|FG001|Blinded Treatment Phase (Week 12 - 40)|Pregnancy|1
6256445|NCT01999868|9947912|FG002|Blinded Treatment Phase (Week 12 - 40)|Pregnancy|0
6256446|NCT01999868|9947910|FG000|Blinded Treatment Phase (Week 12 - 40)|Withdrawal by Subject|0
6256447|NCT01999868|9947911|FG001|Blinded Treatment Phase (Week 12 - 40)|Withdrawal by Subject|2
6256448|NCT01999868|9947912|FG002|Blinded Treatment Phase (Week 12 - 40)|Withdrawal by Subject|0
6256449|NCT01999868|9947910|FG000|Blinded Treatment Phase (Week 12 - 40)|Met study drug Discontinuation Criteria|1
6256450|NCT01999868|9947911|FG001|Blinded Treatment Phase (Week 12 - 40)|Met study drug Discontinuation Criteria|2
6256451|NCT01999868|9947912|FG002|Blinded Treatment Phase (Week 12 - 40)|Met study drug Discontinuation Criteria|0
6256452|NCT01999868|9947910|FG000|Blinded Treatment Phase (Week 12 - 40)|Met psoriasis relapse criterion|8
6256453|NCT01999868|9947911|FG001|Blinded Treatment Phase (Week 12 - 40)|Met psoriasis relapse criterion|1
6256454|NCT01999868|9947912|FG002|Blinded Treatment Phase (Week 12 - 40)|Met psoriasis relapse criterion|0
6256455|NCT01999868|9947910|FG000|Blinded Treatment Phase (Week 12 - 40)|Transportation issues|1
6256456|NCT01999868|9947911|FG001|Blinded Treatment Phase (Week 12 - 40)|Transportation issues|0
6256457|NCT01999868|9947912|FG002|Blinded Treatment Phase (Week 12 - 40)|Transportation issues|0
6256458|NCT01999868|9947910|FG000|Blinded Treatment Phase (Week 12 - 40)|Worsening psoriasis|4
6256459|NCT01999868|9947911|FG001|Blinded Treatment Phase (Week 12 - 40)|Worsening psoriasis|0
6256460|NCT01999868|9947912|FG002|Blinded Treatment Phase (Week 12 - 40)|Worsening psoriasis|0
6256461|NCT01999868|9947910|FG000|Blinded Observation Phase (Week 40 - 88)|Adverse Event|0
6256462|NCT01999868|9947911|FG001|Blinded Observation Phase (Week 40 - 88)|Adverse Event|1
6256463|NCT01999868|9947912|FG002|Blinded Observation Phase (Week 40 - 88)|Adverse Event|0
6256464|NCT01999868|9947910|FG000|Blinded Observation Phase (Week 40 - 88)|Lost to Follow-up|0
6256465|NCT01999868|9947911|FG001|Blinded Observation Phase (Week 40 - 88)|Lost to Follow-up|1
6256466|NCT01999868|9947912|FG002|Blinded Observation Phase (Week 40 - 88)|Lost to Follow-up|0
6256467|NCT01999868|9947910|FG000|Blinded Observation Phase (Week 40 - 88)|Withdrawal by Subject|1
6256468|NCT01999868|9947911|FG001|Blinded Observation Phase (Week 40 - 88)|Withdrawal by Subject|2
6256469|NCT01999868|9947912|FG002|Blinded Observation Phase (Week 40 - 88)|Withdrawal by Subject|0
6256470|NCT01999868|9947910|FG000|Blinded Observation Phase (Week 40 - 88)|Met psoriasis relapse criterion|10
6256471|NCT01999868|9947911|FG001|Blinded Observation Phase (Week 40 - 88)|Met psoriasis relapse criterion|19
6256472|NCT01999868|9947912|FG002|Blinded Observation Phase (Week 40 - 88)|Met psoriasis relapse criterion|0
6256473|NCT01999868|9947910|FG000|Blinded Observation Phase (Week 40 - 88)|Terminated early from study in error|0
6256474|NCT01999868|9947911|FG001|Blinded Observation Phase (Week 40 - 88)|Terminated early from study in error|2
6256475|NCT01999868|9947912|FG002|Blinded Observation Phase (Week 40 - 88)|Terminated early from study in error|0
6256476|NCT01999868|9947910|FG000|Blinded Observation Phase (Week 40 - 88)|Worsening psoriasis|12
6256477|NCT01999868|9947911|FG001|Blinded Observation Phase (Week 40 - 88)|Worsening psoriasis|4
6256478|NCT01999868|9947912|FG002|Blinded Observation Phase (Week 40 - 88)|Worsening psoriasis|0
6256479|NCT01999894|9947920|FG000|Overall Study|Adverse Event|9
6256480|NCT01999894|9947920|FG000|Overall Study|Lack of Efficacy|5
6256481|NCT01999894|9947920|FG000|Overall Study|Protocol Violation|1
6256482|NCT01999894|9947920|FG000|Overall Study|Withdrawal by Subject|7
6256483|NCT01999894|9947920|FG000|Overall Study|Lost to Follow-up|10
6256484|NCT01999894|9947920|FG000|Overall Study|Other Reason|3
6256485|NCT01999894|9947920|FG000|Overall Study|Inclusion/exclusion criteria not met|1
6256486|NCT01999946|9947937|FG000|Overall Study|Participant not released from jail|2
6256487|NCT01999946|9947938|FG001|Overall Study|Participant not released from jail|2
6256488|NCT01999946|9947939|FG002|Overall Study|Participant not released from jail|0
6256489|NCT01999946|9947937|FG000|Overall Study|Not included in primary outcome analysis|0
6256490|NCT01999946|9947938|FG001|Overall Study|Not included in primary outcome analysis|0
6256491|NCT01999946|9947939|FG002|Overall Study|Not included in primary outcome analysis|79
6256492|NCT01999972|9947952|FG000|Dose Escalation Part|Participant refused further follow-up|1
6256493|NCT01999972|9947953|FG001|Dose Escalation Part|Participant refused further follow-up|0
6256494|NCT01999972|9947954|FG002|Dose Escalation Part|Participant refused further follow-up|1
6256495|NCT01999972|9947955|FG003|Dose Escalation Part|Participant refused further follow-up|1
6256496|NCT01999972|9947956|FG004|Dose Escalation Part|Participant refused further follow-up|0
6256497|NCT01999972|9947957|FG005|Dose Escalation Part|Participant refused further follow-up|0
6256498|NCT01999972|9947952|FG000|Dose Escalation Part|Death|0
6256499|NCT01999972|9947953|FG001|Dose Escalation Part|Death|1
6256500|NCT01999972|9947954|FG002|Dose Escalation Part|Death|0
6256501|NCT01999972|9947955|FG003|Dose Escalation Part|Death|0
6256502|NCT01999972|9947956|FG004|Dose Escalation Part|Death|0
6256503|NCT01999972|9947957|FG005|Dose Escalation Part|Death|0
6256504|NCT01999972|9947952|FG000|Dose Escalation Part|Enrolled but not treated|0
6256505|NCT01999972|9947953|FG001|Dose Escalation Part|Enrolled but not treated|0
6086637|NCT00662649|9696713|FG004|Core Study (24 Months)|Death|0
6086638|NCT00662649|9696709|FG000|Extension Study (Month 24 to 60)|Abnormal laboratory value(s)|10
6256506|NCT01999972|9947954|FG002|Dose Escalation Part|Enrolled but not treated|1
6256507|NCT01999972|9947955|FG003|Dose Escalation Part|Enrolled but not treated|1
6256508|NCT01999972|9947956|FG004|Dose Escalation Part|Enrolled but not treated|0
6256509|NCT01999972|9947957|FG005|Dose Escalation Part|Enrolled but not treated|0
6256510|NCT01999972|9947952|FG000|Dose Escalation Part|Disease progression|3
6256511|NCT01999972|9947953|FG001|Dose Escalation Part|Disease progression|2
6256512|NCT01999972|9947954|FG002|Dose Escalation Part|Disease progression|3
6256513|NCT01999972|9947955|FG003|Dose Escalation Part|Disease progression|6
6256514|NCT01999972|9947956|FG004|Dose Escalation Part|Disease progression|0
6256515|NCT01999972|9947957|FG005|Dose Escalation Part|Disease progression|0
6256516|NCT01999972|9947952|FG000|Dose Escalation Part|Adverse Event|0
6256517|NCT01999972|9947953|FG001|Dose Escalation Part|Adverse Event|0
6256518|NCT01999972|9947954|FG002|Dose Escalation Part|Adverse Event|0
6256519|NCT01999972|9947955|FG003|Dose Escalation Part|Adverse Event|2
6256520|NCT01999972|9947956|FG004|Dose Escalation Part|Adverse Event|0
6256521|NCT01999972|9947957|FG005|Dose Escalation Part|Adverse Event|0
6256522|NCT01999972|9947952|FG000|Dose Escalation Part|Global deterioration of health status|1
6256523|NCT01999972|9947953|FG001|Dose Escalation Part|Global deterioration of health status|0
6256524|NCT01999972|9947954|FG002|Dose Escalation Part|Global deterioration of health status|0
6256525|NCT01999972|9947955|FG003|Dose Escalation Part|Global deterioration of health status|1
6256526|NCT01999972|9947956|FG004|Dose Escalation Part|Global deterioration of health status|0
6256527|NCT01999972|9947957|FG005|Dose Escalation Part|Global deterioration of health status|0
6256528|NCT01999972|9947952|FG000|Dose Expansion Part|Death|0
6256529|NCT01999972|9947953|FG001|Dose Expansion Part|Death|0
6256530|NCT01999972|9947954|FG002|Dose Expansion Part|Death|0
6256531|NCT01999972|9947955|FG003|Dose Expansion Part|Death|0
6256532|NCT01999972|9947956|FG004|Dose Expansion Part|Death|2
6256533|NCT01999972|9947957|FG005|Dose Expansion Part|Death|1
6256534|NCT01999972|9947952|FG000|Dose Expansion Part|Disease progression|0
6256535|NCT01999972|9947953|FG001|Dose Expansion Part|Disease progression|0
6256536|NCT01999972|9947954|FG002|Dose Expansion Part|Disease progression|0
6256537|NCT01999972|9947955|FG003|Dose Expansion Part|Disease progression|0
6256538|NCT01999972|9947956|FG004|Dose Expansion Part|Disease progression|9
6256539|NCT01999972|9947957|FG005|Dose Expansion Part|Disease progression|3
6256540|NCT01999972|9947952|FG000|Dose Expansion Part|Sponsor decision|0
6256541|NCT01999972|9947953|FG001|Dose Expansion Part|Sponsor decision|0
6256542|NCT01999972|9947954|FG002|Dose Expansion Part|Sponsor decision|0
6256543|NCT01999972|9947955|FG003|Dose Expansion Part|Sponsor decision|0
6256544|NCT01999972|9947956|FG004|Dose Expansion Part|Sponsor decision|1
6256545|NCT01999972|9947957|FG005|Dose Expansion Part|Sponsor decision|0
6256546|NCT01999972|9947952|FG000|Dose Expansion Part|Adverse Event|0
6256547|NCT01999972|9947953|FG001|Dose Expansion Part|Adverse Event|0
6256548|NCT01999972|9947954|FG002|Dose Expansion Part|Adverse Event|0
6256549|NCT01999972|9947955|FG003|Dose Expansion Part|Adverse Event|0
6256550|NCT01999972|9947956|FG004|Dose Expansion Part|Adverse Event|4
6256551|NCT01999972|9947957|FG005|Dose Expansion Part|Adverse Event|2
6256552|NCT01999972|9947952|FG000|Dose Expansion Part|Participant's non-compliance|0
6256553|NCT01999972|9947953|FG001|Dose Expansion Part|Participant's non-compliance|0
6256554|NCT01999972|9947954|FG002|Dose Expansion Part|Participant's non-compliance|0
6256555|NCT01999972|9947955|FG003|Dose Expansion Part|Participant's non-compliance|0
6256556|NCT01999972|9947956|FG004|Dose Expansion Part|Participant's non-compliance|0
6256557|NCT01999972|9947957|FG005|Dose Expansion Part|Participant's non-compliance|1
6256558|NCT01999972|9947952|FG000|Dose Expansion Part|Participant refused further follow-up|0
6256559|NCT01999972|9947953|FG001|Dose Expansion Part|Participant refused further follow-up|0
6256560|NCT01999972|9947954|FG002|Dose Expansion Part|Participant refused further follow-up|0
6256561|NCT01999972|9947955|FG003|Dose Expansion Part|Participant refused further follow-up|0
6256562|NCT01999972|9947956|FG004|Dose Expansion Part|Participant refused further follow-up|4
6256563|NCT01999972|9947957|FG005|Dose Expansion Part|Participant refused further follow-up|0
6256564|NCT01999972|9947952|FG000|Dose Expansion Part|Changed to standard of care|0
6256565|NCT01999972|9947953|FG001|Dose Expansion Part|Changed to standard of care|0
6256566|NCT01999972|9947954|FG002|Dose Expansion Part|Changed to standard of care|0
6256567|NCT01999972|9947955|FG003|Dose Expansion Part|Changed to standard of care|0
6256568|NCT01999972|9947956|FG004|Dose Expansion Part|Changed to standard of care|1
6256569|NCT01999972|9947957|FG005|Dose Expansion Part|Changed to standard of care|0
6256570|NCT02000440|9947994|FG000|Overall Study|Adverse Event|3
6256571|NCT02000440|9947994|FG000|Overall Study|Other-Protocol-defined Stopping Criteria|1
6256572|NCT02000531|9948000|FG000|Overall Study|Lost to Follow-up|1
6086639|NCT00662649|9696710|FG001|Extension Study (Month 24 to 60)|Abnormal laboratory value(s)|5
6256573|NCT02000531|9948001|FG001|Overall Study|Lost to Follow-up|0
6086640|NCT00662649|9696711|FG002|Extension Study (Month 24 to 60)|Abnormal laboratory value(s)|0
6256574|NCT02000531|9948000|FG000|Overall Study|Discontinued due to data cut-off|3
6256575|NCT02000531|9948001|FG001|Overall Study|Discontinued due to data cut-off|8
6256576|NCT02000752|9948018|FG000|Overall Study|Dystocic delivery|19
6256577|NCT02000752|9948019|FG001|Overall Study|Dystocic delivery|8
6256578|NCT02000752|9948018|FG000|Overall Study|Shift Changes|12
6256579|NCT02000752|9948019|FG001|Overall Study|Shift Changes|5
6256580|NCT02000817|9948029|FG000|Overall Study|Withdrawal by Subject|2
6256581|NCT02000817|9948030|FG001|Overall Study|Withdrawal by Subject|0
6256582|NCT02000817|9948031|FG002|Overall Study|Withdrawal by Subject|0
6256583|NCT02000817|9948032|FG003|Overall Study|Withdrawal by Subject|0
6256584|NCT02000817|9948029|FG000|Overall Study|Adverse Event|0
6256585|NCT02000817|9948030|FG001|Overall Study|Adverse Event|1
6256586|NCT02000817|9948031|FG002|Overall Study|Adverse Event|0
6256587|NCT02000817|9948032|FG003|Overall Study|Adverse Event|0
6256588|NCT02000817|9948029|FG000|Overall Study|Lost to Follow-up|0
6256589|NCT02000817|9948030|FG001|Overall Study|Lost to Follow-up|0
6256590|NCT02000817|9948031|FG002|Overall Study|Lost to Follow-up|1
6256591|NCT02000817|9948032|FG003|Overall Study|Lost to Follow-up|0
6256592|NCT02000921|9948057|FG000|Overall Study|Withdrawal by Subject|3
6256593|NCT02000921|9948058|FG001|Overall Study|Withdrawal by Subject|10
6256594|NCT02000921|9948059|FG002|Overall Study|Withdrawal by Subject|5
6256595|NCT02000921|9948057|FG000|Overall Study|Lost to Follow-up|2
6256596|NCT02000921|9948058|FG001|Overall Study|Lost to Follow-up|4
6256597|NCT02000921|9948059|FG002|Overall Study|Lost to Follow-up|5
6256598|NCT02000921|9948057|FG000|Overall Study|Physician Decision|0
6256599|NCT02000921|9948058|FG001|Overall Study|Physician Decision|2
6256600|NCT02000921|9948059|FG002|Overall Study|Physician Decision|0
6256601|NCT02001051|9948086|FG000|Overall Study|Deemed not eligible following enrollment|0
6256602|NCT02001051|9948087|FG001|Overall Study|Deemed not eligible following enrollment|1
6256603|NCT02001064|9948095|FG000|Overall Study|Withdrawal by Subject|2
6256604|NCT02001064|9948096|FG001|Overall Study|Withdrawal by Subject|1
6256605|NCT02001181|9948104|FG000|Overall Study|Adverse Event|0
6256606|NCT02001181|9948105|FG001|Overall Study|Adverse Event|2
6256607|NCT02001181|9948104|FG000|Overall Study|Lost to Follow-up|1
6256608|NCT02001181|9948105|FG001|Overall Study|Lost to Follow-up|0
6256609|NCT02001181|9948104|FG000|Overall Study|Withdrawal by Subject|0
6256610|NCT02001181|9948105|FG001|Overall Study|Withdrawal by Subject|1
6256611|NCT02001194|9948115|FG000|Intervention Period (13 Weeks)|No longer interested|1
6256612|NCT02001194|9948116|FG001|Intervention Period (13 Weeks)|No longer interested|0
6256613|NCT02001194|9948117|FG002|Intervention Period (13 Weeks)|No longer interested|2
6256614|NCT02001194|9948118|FG003|Intervention Period (13 Weeks)|No longer interested|2
6256615|NCT02001194|9948115|FG000|Follow-Up Period (13 Weeks)|No longer interested|3
6256616|NCT02001194|9948116|FG001|Follow-Up Period (13 Weeks)|No longer interested|2
6256617|NCT02001194|9948117|FG002|Follow-Up Period (13 Weeks)|No longer interested|1
6256618|NCT02001194|9948118|FG003|Follow-Up Period (13 Weeks)|No longer interested|0
6256619|NCT02001558|9948130|FG000|Overall Study|Lost to Follow-up|8
6256620|NCT02001558|9948131|FG001|Overall Study|Lost to Follow-up|14
6256621|NCT02001688|9948140|FG000|Overall Study|Withdrawal by Subject|0
6256622|NCT02001688|9948141|FG001|Overall Study|Withdrawal by Subject|0
6256623|NCT02001688|9948142|FG002|Overall Study|Withdrawal by Subject|1
6256624|NCT02001688|9948140|FG000|Overall Study|Adverse Event|0
6256625|NCT02001688|9948141|FG001|Overall Study|Adverse Event|1
6256626|NCT02001688|9948142|FG002|Overall Study|Adverse Event|0
6256627|NCT02001987|9948160|FG000|Core Study Period (24 Weeks)|Adverse Event|9
6256628|NCT02001987|9948160|FG000|Core Study Period (24 Weeks)|Death|1
6256629|NCT02001987|9948160|FG000|Core Study Period (24 Weeks)|Non-Serious Hypersensitivity Reaction|2
6256630|NCT02001987|9948160|FG000|Core Study Period (24 Weeks)|Physician Decision|1
6256631|NCT02001987|9948160|FG000|Core Study Period (24 Weeks)|Withdrawal by Subject|4
6256632|NCT02001987|9948160|FG000|Core Study Period (24 Weeks)|Protocol Violation|3
6256633|NCT02001987|9948160|FG000|Core Study Period (24 Weeks)|Lack of Efficacy|3
6256634|NCT02001987|9948160|FG000|LTE Period (52 Weeks)|Lost to Follow-up|2
6256635|NCT02001987|9948160|FG000|LTE Period (52 Weeks)|Physician Decision|2
6256636|NCT02001987|9948160|FG000|LTE Period (52 Weeks)|Withdrawal by Subject|1
6256637|NCT02001987|9948160|FG000|LTE Period (52 Weeks)|Lack of Efficacy|1
6256638|NCT02001987|9948160|FG000|LTE Period (52 Weeks)|Other|3
6256639|NCT02002091|9948171|FG000|Screening|Lost to Follow-up|10
6256640|NCT02002091|9948172|FG001|Screening|Lost to Follow-up|12
6256641|NCT02002091|9948171|FG000|Screening|Death|3
6256642|NCT02002091|9948172|FG001|Screening|Death|2
6256643|NCT02002182|9948209|FG000|Overall Study|Withdraw from study|3
6256644|NCT02002182|9948210|FG001|Overall Study|Withdraw from study|1
6256645|NCT02002182|9948209|FG000|Overall Study|Health Reasons|1
6256646|NCT02002182|9948210|FG001|Overall Study|Health Reasons|0
6256647|NCT02002182|9948209|FG000|Overall Study|Death|1
6256648|NCT02002182|9948210|FG001|Overall Study|Death|0
6256649|NCT02002221|9948227|FG000|Overall Study|Adverse Event|2
6256650|NCT02002221|9948228|FG001|Overall Study|Adverse Event|1
6256651|NCT02002221|9948227|FG000|Overall Study|Unsatisfactory therapeutic effect|0
6256652|NCT02002221|9948228|FG001|Overall Study|Unsatisfactory therapeutic effect|1
6256653|NCT02002221|9948227|FG000|Overall Study|Patient withdrew consent|0
6256654|NCT02002221|9948228|FG001|Overall Study|Patient withdrew consent|1
6256655|NCT02002533|9948251|FG000|Overall Study|Withdrawal by Subject|6
6256656|NCT02002533|9948252|FG001|Overall Study|Withdrawal by Subject|13
6256657|NCT02002533|9948251|FG000|Overall Study|Protocol Violation|0
6256658|NCT02002533|9948252|FG001|Overall Study|Protocol Violation|1
6256659|NCT02002533|9948251|FG000|Overall Study|Adverse Event|0
6256660|NCT02002533|9948252|FG001|Overall Study|Adverse Event|3
6256661|NCT02002533|9948251|FG000|Overall Study|Lost to Follow-up|0
6256662|NCT02002533|9948252|FG001|Overall Study|Lost to Follow-up|1
6256663|NCT02002689|9948269|FG000|Overall Study|Disease Progression|7
6256664|NCT02002689|9948269|FG000|Overall Study|Adverse Event|3
6256665|NCT02002884|9948313|FG000|Main Period (MP)|Other|0
6256666|NCT02002884|9948314|FG001|Main Period (MP)|Other|3
6256667|NCT02002884|9948315|FG002|Main Period (MP)|Other|3
6256668|NCT02002884|9948316|FG003|Main Period (MP)|Other|0
6256669|NCT02002884|9948313|FG000|Main Period (MP)|Adverse Event|0
6256670|NCT02002884|9948314|FG001|Main Period (MP)|Adverse Event|1
6256671|NCT02002884|9948315|FG002|Main Period (MP)|Adverse Event|1
6256672|NCT02002884|9948316|FG003|Main Period (MP)|Adverse Event|0
6256673|NCT02002884|9948313|FG000|Main Period (MP)|Withdrawal by Subject|6
6256674|NCT02002884|9948314|FG001|Main Period (MP)|Withdrawal by Subject|2
6256675|NCT02002884|9948315|FG002|Main Period (MP)|Withdrawal by Subject|2
6256676|NCT02002884|9948316|FG003|Main Period (MP)|Withdrawal by Subject|0
6256677|NCT02002884|9948313|FG000|Main Period (MP)|Lost to Follow-up|0
6256678|NCT02002884|9948314|FG001|Main Period (MP)|Lost to Follow-up|0
6256679|NCT02002884|9948315|FG002|Main Period (MP)|Lost to Follow-up|2
6256680|NCT02002884|9948316|FG003|Main Period (MP)|Lost to Follow-up|0
6256681|NCT02002884|9948313|FG000|Open-Label Extension Period (OLEX)|Other|0
6256682|NCT02002884|9948314|FG001|Open-Label Extension Period (OLEX)|Other|0
6256683|NCT02002884|9948315|FG002|Open-Label Extension Period (OLEX)|Other|0
6256684|NCT02002884|9948316|FG003|Open-Label Extension Period (OLEX)|Other|24
6256685|NCT02002884|9948313|FG000|Open-Label Extension Period (OLEX)|Physician Decision|0
6256686|NCT02002884|9948314|FG001|Open-Label Extension Period (OLEX)|Physician Decision|0
6256687|NCT02002884|9948315|FG002|Open-Label Extension Period (OLEX)|Physician Decision|0
6256688|NCT02002884|9948316|FG003|Open-Label Extension Period (OLEX)|Physician Decision|1
6256689|NCT02002884|9948313|FG000|Open-Label Extension Period (OLEX)|Adverse Event|0
6086641|NCT00662649|9696712|FG003|Extension Study (Month 24 to 60)|Abnormal laboratory value(s)|8
6256690|NCT02002884|9948314|FG001|Open-Label Extension Period (OLEX)|Adverse Event|0
6256691|NCT02002884|9948315|FG002|Open-Label Extension Period (OLEX)|Adverse Event|0
6256692|NCT02002884|9948316|FG003|Open-Label Extension Period (OLEX)|Adverse Event|5
6256693|NCT02002884|9948313|FG000|Open-Label Extension Period (OLEX)|Withdrawal by Subject|0
6256694|NCT02002884|9948314|FG001|Open-Label Extension Period (OLEX)|Withdrawal by Subject|0
6256695|NCT02002884|9948315|FG002|Open-Label Extension Period (OLEX)|Withdrawal by Subject|0
6256696|NCT02002884|9948316|FG003|Open-Label Extension Period (OLEX)|Withdrawal by Subject|10
6256697|NCT02002884|9948313|FG000|Open-Label Extension Period (OLEX)|Lost to Follow-up|0
6256698|NCT02002884|9948314|FG001|Open-Label Extension Period (OLEX)|Lost to Follow-up|0
6256699|NCT02002884|9948315|FG002|Open-Label Extension Period (OLEX)|Lost to Follow-up|0
6256700|NCT02002884|9948316|FG003|Open-Label Extension Period (OLEX)|Lost to Follow-up|10
6256701|NCT02002975|9948330|FG000|Overall Study|Case Report Forms Uncollected|135
6256702|NCT02002975|9948330|FG000|Overall Study|Protocol Deviation|437
6256703|NCT02003014|9948334|FG000|Overall Study|Case report forms uncollected|9
6256704|NCT02003014|9948334|FG000|Overall Study|Treatment started after contract period|1
6256705|NCT02003014|9948334|FG000|Overall Study|Patient did not visit the study site|5
6256706|NCT02003014|9948334|FG000|Overall Study|Investigator's transfer|4
6256707|NCT02003183|9948349|FG000|Overall Study|Lost to Follow-up|0
6256708|NCT02003183|9948350|FG001|Overall Study|Lost to Follow-up|2
6256709|NCT02003365|9948363|FG000|Overall Study|Lost to Follow-up|0
6256710|NCT02003365|9948364|FG001|Overall Study|Lost to Follow-up|0
6256711|NCT02003365|9948365|FG002|Overall Study|Lost to Follow-up|1
6256712|NCT02003391|9948375|FG000|Overall Study|Withdrawal by Subject|2
6256713|NCT02003391|9948376|FG001|Overall Study|Withdrawal by Subject|1
6256714|NCT02003391|9948375|FG000|Overall Study|Protocol Violation|0
6256715|NCT02003391|9948376|FG001|Overall Study|Protocol Violation|1
6256716|NCT02003391|9948375|FG000|Overall Study|Adverse Event|1
6256717|NCT02003391|9948376|FG001|Overall Study|Adverse Event|0
6256718|NCT02003534|9948397|FG000|Overall Study|Lost to Follow-up|47
6256719|NCT02003573|9948404|FG000|Overall Study|Progressive disease|2
6256720|NCT02003573|9948405|FG001|Overall Study|Progressive disease|0
6256721|NCT02003573|9948406|FG002|Overall Study|Progressive disease|1
6256722|NCT02003573|9948404|FG000|Overall Study|Other Adverse event|0
6256723|NCT02003573|9948405|FG001|Overall Study|Other Adverse event|1
6256724|NCT02003573|9948406|FG002|Overall Study|Other Adverse event|1
6256725|NCT02003573|9948404|FG000|Overall Study|Refuse to take trial medication|0
6256726|NCT02003573|9948405|FG001|Overall Study|Refuse to take trial medication|1
6256727|NCT02003573|9948406|FG002|Overall Study|Refuse to take trial medication|1
6256728|NCT02003573|9948404|FG000|Overall Study|Other than specified|1
6256729|NCT02003573|9948405|FG001|Overall Study|Other than specified|2
6256730|NCT02003573|9948406|FG002|Overall Study|Other than specified|3
6271090|NCT02160041|9972637|FG000|Overall Study|non-compliance with study|1
6271091|NCT02160041|9972637|FG000|Overall Study|Physician Decision|3
6271092|NCT02160041|9972637|FG000|Overall Study|Withdrawal by Subject|8
6271093|NCT02160041|9972637|FG000|Overall Study|study terminated by by sponsor|1
6271094|NCT02160145|9972643|FG000|Prerandomization Single-blind Period|Placebo run-in failure|23
6271095|NCT02160145|9972644|FG001|Prerandomization Single-blind Period|Placebo run-in failure|0
6256731|NCT02003638|9948427|FG000|Overall Study|Withdrawal by Subject|1
6256732|NCT02003638|9948428|FG001|Overall Study|Withdrawal by Subject|0
6256733|NCT02003898|9948434|FG000|Overall Study|Death|3
6256734|NCT02003898|9948434|FG000|Overall Study|Lost to Follow-up|12
6256735|NCT02003898|9948434|FG000|Overall Study|Withdrawal by Subject|52
6256736|NCT02003963|9948449|FG000|Overall Study|Lost to Follow-up|2
6256737|NCT02003963|9948450|FG001|Overall Study|Lost to Follow-up|1
6256738|NCT02004093|9948460|FG000|Overall Study|Death|2
6256739|NCT02004093|9948461|FG001|Overall Study|Death|1
6256740|NCT02004093|9948460|FG000|Overall Study|Lack of Efficacy|66
6256741|NCT02004093|9948461|FG001|Overall Study|Lack of Efficacy|62
6256742|NCT02004093|9948460|FG000|Overall Study|Protocol Violation|0
6256743|NCT02004093|9948461|FG001|Overall Study|Protocol Violation|1
6256744|NCT02004093|9948460|FG000|Overall Study|Lost to Follow-up|0
6256745|NCT02004093|9948461|FG001|Overall Study|Lost to Follow-up|1
6256746|NCT02004093|9948460|FG000|Overall Study|Withdrawal by Subject|3
6256747|NCT02004093|9948461|FG001|Overall Study|Withdrawal by Subject|7
6256748|NCT02004093|9948460|FG000|Overall Study|Other|3
6256749|NCT02004093|9948461|FG001|Overall Study|Other|1
6256750|NCT02004236|9948483|FG000|Overall Study|Lack of Efficacy|0
6256751|NCT02004236|9948484|FG001|Overall Study|Lack of Efficacy|0
6256752|NCT02004236|9948485|FG002|Overall Study|Lack of Efficacy|16
6256753|NCT02004262|9948500|FG000|Overall Study|Death|67
6256754|NCT02004262|9948501|FG001|Overall Study|Death|64
6256755|NCT02004262|9948502|FG002|Overall Study|Death|66
6256756|NCT02004262|9948503|FG003|Overall Study|Death|28
6256757|NCT02004262|9948504|FG004|Overall Study|Death|29
6256758|NCT02004262|9948505|FG005|Overall Study|Death|22
6256759|NCT02004262|9948500|FG000|Overall Study|Withdrawal by Subject|1
6256760|NCT02004262|9948501|FG001|Overall Study|Withdrawal by Subject|0
6256761|NCT02004262|9948502|FG002|Overall Study|Withdrawal by Subject|4
6256762|NCT02004262|9948503|FG003|Overall Study|Withdrawal by Subject|0
6256763|NCT02004262|9948504|FG004|Overall Study|Withdrawal by Subject|1
6256764|NCT02004262|9948505|FG005|Overall Study|Withdrawal by Subject|3
6256765|NCT02004262|9948500|FG000|Overall Study|Lost to Follow-up|1
6256766|NCT02004262|9948501|FG001|Overall Study|Lost to Follow-up|1
6256767|NCT02004262|9948502|FG002|Overall Study|Lost to Follow-up|0
6256768|NCT02004262|9948503|FG003|Overall Study|Lost to Follow-up|0
6256769|NCT02004262|9948504|FG004|Overall Study|Lost to Follow-up|0
6256770|NCT02004262|9948505|FG005|Overall Study|Lost to Follow-up|0
6256771|NCT02004262|9948500|FG000|Overall Study|Study Terminated by Sponsor|4
6256772|NCT02004262|9948501|FG001|Overall Study|Study Terminated by Sponsor|3
6256773|NCT02004262|9948502|FG002|Overall Study|Study Terminated by Sponsor|2
6256774|NCT02004262|9948503|FG003|Overall Study|Study Terminated by Sponsor|1
6256775|NCT02004262|9948504|FG004|Overall Study|Study Terminated by Sponsor|1
6256776|NCT02004262|9948505|FG005|Overall Study|Study Terminated by Sponsor|5
6256777|NCT02004353|9948528|FG000|Overall Study|Voluntary participation|1334
6256778|NCT02004847|9948565|FG000|Overall Study|Protocol Violation|1
6256779|NCT02004847|9948566|FG001|Overall Study|Protocol Violation|1
6256780|NCT02004873|9948581|FG000|Overall Study|Implant unsuccessful|6
6256781|NCT02004873|9948581|FG000|Overall Study|Awaiting 6-month visit|390
6256782|NCT02004873|9948581|FG000|Overall Study|Missed 6-month visit|4
6256783|NCT02004873|9948581|FG000|Overall Study|Death|23
6256784|NCT02004873|9948581|FG000|Overall Study|Withdrawal by Subject|1
6256785|NCT02004886|9948592|FG000|Overall Study|Adverse Event|0
6256786|NCT02004886|9948593|FG001|Overall Study|Adverse Event|1
6256787|NCT02004886|9948594|FG002|Overall Study|Adverse Event|0
6256788|NCT02004886|9948595|FG003|Overall Study|Adverse Event|0
6256789|NCT02004886|9948592|FG000|Overall Study|Unable to attend future visits|1
6256790|NCT02004886|9948593|FG001|Overall Study|Unable to attend future visits|0
6256791|NCT02004886|9948594|FG002|Overall Study|Unable to attend future visits|0
6256792|NCT02004886|9948595|FG003|Overall Study|Unable to attend future visits|0
6256793|NCT02005029|9948624|FG000|First Intervention (1 Day)|participant withdrawn for noncompliance|1
6256794|NCT02005029|9948625|FG001|First Intervention (1 Day)|participant withdrawn for noncompliance|0
6256795|NCT02005211|9948656|FG000|Part 2 - Elderly Subjects Cohorts 4 & 5|Withdrawal by Subject|0
6256796|NCT02005211|9948657|FG001|Part 2 - Elderly Subjects Cohorts 4 & 5|Withdrawal by Subject|0
6256797|NCT02005211|9948658|FG002|Part 2 - Elderly Subjects Cohorts 4 & 5|Withdrawal by Subject|0
6256798|NCT02005211|9948659|FG003|Part 2 - Elderly Subjects Cohorts 4 & 5|Withdrawal by Subject|0
6256799|NCT02005211|9948660|FG004|Part 2 - Elderly Subjects Cohorts 4 & 5|Withdrawal by Subject|1
6256800|NCT02005211|9948661|FG005|Part 2 - Elderly Subjects Cohorts 4 & 5|Withdrawal by Subject|0
6256801|NCT02005211|9948662|FG006|Part 2 - Elderly Subjects Cohorts 4 & 5|Withdrawal by Subject|0
6256802|NCT02005250|9948687|FG000|Overall Study|Lost to Follow-up|15
6256803|NCT02005250|9948688|FG001|Overall Study|Lost to Follow-up|5
6256804|NCT02005276|9948698|FG000|Overall Study|No longer interested|5
6256805|NCT02005276|9948699|FG001|Overall Study|No longer interested|2
6256806|NCT02005276|9948700|FG002|Overall Study|No longer interested|3
6256807|NCT02005276|9948701|FG003|Overall Study|No longer interested|3
6256808|NCT02005484|9948726|FG000|Overall Study|Death|1
6256809|NCT02005484|9948726|FG000|Overall Study|Disease progression|1
6256810|NCT02005484|9948726|FG000|Overall Study|Changed to a Different Study|1
6256811|NCT02005484|9948726|FG000|Overall Study|Sponsor decision|1
6256812|NCT02005562|9948749|FG000|Overall Study|Death|2
6256813|NCT02005562|9948750|FG001|Overall Study|Death|2
6256814|NCT02005562|9948749|FG000|Overall Study|Graft loss|7
6256815|NCT02005562|9948750|FG001|Overall Study|Graft loss|6
6256816|NCT02005562|9948749|FG000|Overall Study|Withdrawal by Subject|2
6256817|NCT02005562|9948750|FG001|Overall Study|Withdrawal by Subject|2
6256818|NCT02005562|9948749|FG000|Overall Study|No transplant|1
6256819|NCT02005562|9948750|FG001|Overall Study|No transplant|4
6256820|NCT02005562|9948749|FG000|Overall Study|Physician Decision|0
6256821|NCT02005562|9948750|FG001|Overall Study|Physician Decision|1
6256822|NCT02005627|9948767|FG000|Overall Study|Lost to Follow-up|1
6256823|NCT02005627|9948768|FG001|Overall Study|Lost to Follow-up|2
6256824|NCT02005627|9948767|FG000|Overall Study|Withdrawal by Subject|1
6256825|NCT02005627|9948768|FG001|Overall Study|Withdrawal by Subject|2
6256826|NCT02005692|9948788|FG000|Overall Study|Protocol Violation|1
6256827|NCT02005692|9948788|FG000|Overall Study|Withdrawal by Subject|1
6256828|NCT02005692|9948788|FG000|Overall Study|Discharged earlier than anticipated|5
6256829|NCT02005887|9948795|FG000|Overall Study|Protocol Violation|0
6256830|NCT02005887|9948796|FG001|Overall Study|Protocol Violation|2
6256831|NCT02006121|9948817|FG000|Double Blind Phase|Adverse Event|6
6256832|NCT02006121|9948818|FG001|Double Blind Phase|Adverse Event|0
6256833|NCT02006121|9948817|FG000|Double Blind Phase|Lack of Efficacy|1
6256834|NCT02006121|9948818|FG001|Double Blind Phase|Lack of Efficacy|16
6256835|NCT02006121|9948817|FG000|Double Blind Phase|Withdrawal by Subject|3
6256836|NCT02006121|9948818|FG001|Double Blind Phase|Withdrawal by Subject|4
6256837|NCT02006121|9948817|FG000|Double Blind Phase|Non-compliance with study drug|1
6256838|NCT02006121|9948818|FG001|Double Blind Phase|Non-compliance with study drug|3
6256839|NCT02006121|9948817|FG000|Double Blind Phase|Minimum infusion rate poorly tolerated|1
6256840|NCT02006121|9948818|FG001|Double Blind Phase|Minimum infusion rate poorly tolerated|0
6256841|NCT02006121|9948817|FG000|Double Blind Phase|Inconvenience of infusion system|0
6256842|NCT02006121|9948818|FG001|Double Blind Phase|Inconvenience of infusion system|1
6256843|NCT02006121|9948817|FG000|Open Label Phase|Adverse Event|15
6256844|NCT02006121|9948818|FG001|Open Label Phase|Adverse Event|0
6256845|NCT02006121|9948817|FG000|Open Label Phase|Lack of Efficacy|2
6256846|NCT02006121|9948818|FG001|Open Label Phase|Lack of Efficacy|0
6256847|NCT02006121|9948817|FG000|Open Label Phase|Protocol Violation|2
6256848|NCT02006121|9948818|FG001|Open Label Phase|Protocol Violation|0
6256849|NCT02006121|9948817|FG000|Open Label Phase|Withdrawal by Subject|3
6256850|NCT02006121|9948818|FG001|Open Label Phase|Withdrawal by Subject|0
6256851|NCT02006121|9948817|FG000|Open Label Phase|Non-compliance with study drug|3
6256852|NCT02006121|9948818|FG001|Open Label Phase|Non-compliance with study drug|0
6256853|NCT02006472|9948875|FG000|Period 1 (Through Week 26)|Protocol Violation|1
6256854|NCT02006472|9948876|FG001|Period 1 (Through Week 26)|Protocol Violation|1
6256855|NCT02006472|9948877|FG002|Period 1 (Through Week 26)|Protocol Violation|1
6256856|NCT02006472|9948878|FG003|Period 1 (Through Week 26)|Protocol Violation|1
6256857|NCT02006472|9948879|FG004|Period 1 (Through Week 26)|Protocol Violation|0
6256858|NCT02006472|9948875|FG000|Period 1 (Through Week 26)|Lack of Efficacy|0
6256859|NCT02006472|9948876|FG001|Period 1 (Through Week 26)|Lack of Efficacy|0
6256860|NCT02006472|9948877|FG002|Period 1 (Through Week 26)|Lack of Efficacy|1
6256861|NCT02006472|9948878|FG003|Period 1 (Through Week 26)|Lack of Efficacy|0
6256862|NCT02006472|9948879|FG004|Period 1 (Through Week 26)|Lack of Efficacy|0
6256863|NCT02006472|9948875|FG000|Period 1 (Through Week 26)|Noncompliance|2
6256864|NCT02006472|9948876|FG001|Period 1 (Through Week 26)|Noncompliance|1
6256865|NCT02006472|9948877|FG002|Period 1 (Through Week 26)|Noncompliance|1
6256866|NCT02006472|9948878|FG003|Period 1 (Through Week 26)|Noncompliance|0
6256867|NCT02006472|9948879|FG004|Period 1 (Through Week 26)|Noncompliance|0
6256868|NCT02006472|9948875|FG000|Period 1 (Through Week 26)|Other|1
6256869|NCT02006472|9948876|FG001|Period 1 (Through Week 26)|Other|5
6256870|NCT02006472|9948877|FG002|Period 1 (Through Week 26)|Other|0
6256871|NCT02006472|9948878|FG003|Period 1 (Through Week 26)|Other|2
6256872|NCT02006472|9948879|FG004|Period 1 (Through Week 26)|Other|3
6256873|NCT02006472|9948875|FG000|Period 1 (Through Week 26)|Adverse Event|5
6256874|NCT02006472|9948876|FG001|Period 1 (Through Week 26)|Adverse Event|6
6256875|NCT02006472|9948877|FG002|Period 1 (Through Week 26)|Adverse Event|11
6256876|NCT02006472|9948878|FG003|Period 1 (Through Week 26)|Adverse Event|11
6256877|NCT02006472|9948879|FG004|Period 1 (Through Week 26)|Adverse Event|14
6256878|NCT02006472|9948875|FG000|Period 1 (Through Week 26)|Withdrawal by Subject|3
6256879|NCT02006472|9948876|FG001|Period 1 (Through Week 26)|Withdrawal by Subject|9
6256880|NCT02006472|9948877|FG002|Period 1 (Through Week 26)|Withdrawal by Subject|3
6256881|NCT02006472|9948878|FG003|Period 1 (Through Week 26)|Withdrawal by Subject|0
6256882|NCT02006472|9948879|FG004|Period 1 (Through Week 26)|Withdrawal by Subject|3
6256883|NCT02006472|9948875|FG000|Period 2 (Through Week 52)|Lack of Efficacy|1
6256884|NCT02006472|9948876|FG001|Period 2 (Through Week 52)|Lack of Efficacy|0
6256885|NCT02006472|9948877|FG002|Period 2 (Through Week 52)|Lack of Efficacy|0
6256886|NCT02006472|9948878|FG003|Period 2 (Through Week 52)|Lack of Efficacy|1
6256887|NCT02006472|9948879|FG004|Period 2 (Through Week 52)|Lack of Efficacy|1
6256888|NCT02006472|9948875|FG000|Period 2 (Through Week 52)|Noncompliance|1
6256889|NCT02006472|9948876|FG001|Period 2 (Through Week 52)|Noncompliance|0
6256890|NCT02006472|9948877|FG002|Period 2 (Through Week 52)|Noncompliance|0
6256891|NCT02006472|9948878|FG003|Period 2 (Through Week 52)|Noncompliance|0
6256892|NCT02006472|9948879|FG004|Period 2 (Through Week 52)|Noncompliance|0
6256893|NCT02006472|9948875|FG000|Period 2 (Through Week 52)|Adverse Event|1
6256894|NCT02006472|9948876|FG001|Period 2 (Through Week 52)|Adverse Event|4
6256895|NCT02006472|9948877|FG002|Period 2 (Through Week 52)|Adverse Event|5
6256896|NCT02006472|9948878|FG003|Period 2 (Through Week 52)|Adverse Event|1
6256897|NCT02006472|9948879|FG004|Period 2 (Through Week 52)|Adverse Event|1
6256898|NCT02006472|9948875|FG000|Period 2 (Through Week 52)|Other|0
6256899|NCT02006472|9948876|FG001|Period 2 (Through Week 52)|Other|1
6256900|NCT02006472|9948877|FG002|Period 2 (Through Week 52)|Other|0
6256901|NCT02006472|9948878|FG003|Period 2 (Through Week 52)|Other|1
6256902|NCT02006472|9948879|FG004|Period 2 (Through Week 52)|Other|0
6256903|NCT02006472|9948875|FG000|Period 2 (Through Week 52)|Not treated|0
6256904|NCT02006472|9948876|FG001|Period 2 (Through Week 52)|Not treated|0
6256905|NCT02006472|9948877|FG002|Period 2 (Through Week 52)|Not treated|2
6256906|NCT02006472|9948878|FG003|Period 2 (Through Week 52)|Not treated|0
6256907|NCT02006472|9948879|FG004|Period 2 (Through Week 52)|Not treated|0
6256908|NCT02006472|9948875|FG000|Period 2 (Through Week 52)|Withdrawal by Subject|2
6256909|NCT02006472|9948876|FG001|Period 2 (Through Week 52)|Withdrawal by Subject|1
6256910|NCT02006472|9948877|FG002|Period 2 (Through Week 52)|Withdrawal by Subject|2
6256911|NCT02006472|9948878|FG003|Period 2 (Through Week 52)|Withdrawal by Subject|0
6256912|NCT02006472|9948879|FG004|Period 2 (Through Week 52)|Withdrawal by Subject|0
6256913|NCT02006472|9948875|FG000|Period 2 (Through Week 52)|Sponsor decision|0
6256914|NCT02006472|9948876|FG001|Period 2 (Through Week 52)|Sponsor decision|0
6256915|NCT02006472|9948877|FG002|Period 2 (Through Week 52)|Sponsor decision|1
6256916|NCT02006472|9948878|FG003|Period 2 (Through Week 52)|Sponsor decision|0
6256917|NCT02006472|9948879|FG004|Period 2 (Through Week 52)|Sponsor decision|0
6256918|NCT02006576|9948899|FG000|Overall Study|Withdrawal by Subject|4
6256919|NCT02006576|9948900|FG001|Overall Study|Withdrawal by Subject|6
6256920|NCT02006576|9948901|FG002|Overall Study|Withdrawal by Subject|2
6256921|NCT02006576|9948899|FG000|Overall Study|Death|0
6256922|NCT02006576|9948900|FG001|Overall Study|Death|0
6256923|NCT02006576|9948901|FG002|Overall Study|Death|1
6256924|NCT02006576|9948899|FG000|Overall Study|Lost to Follow-up|1
6256925|NCT02006576|9948900|FG001|Overall Study|Lost to Follow-up|0
6256926|NCT02006576|9948901|FG002|Overall Study|Lost to Follow-up|1
6256927|NCT02006576|9948899|FG000|Overall Study|Screen Failure, too sick, other|13
6256928|NCT02006576|9948900|FG001|Overall Study|Screen Failure, too sick, other|1
6256929|NCT02006576|9948901|FG002|Overall Study|Screen Failure, too sick, other|13
6256930|NCT02006628|9948911|FG000|Overall Study|Adverse Event|1
6256931|NCT02006628|9948912|FG001|Overall Study|Adverse Event|1
6256932|NCT02006628|9948911|FG000|Overall Study|Withdrawal by Subject|2
6256933|NCT02006628|9948912|FG001|Overall Study|Withdrawal by Subject|1
6256934|NCT02006641|9948921|FG000|Overall Study|Withdrawal before treatment|2
6256935|NCT02006641|9948922|FG001|Overall Study|Withdrawal before treatment|5
6256936|NCT02006641|9948923|FG002|Overall Study|Withdrawal before treatment|3
6256937|NCT02006641|9948921|FG000|Overall Study|Adverse Event|15
6256938|NCT02006641|9948922|FG001|Overall Study|Adverse Event|11
6256939|NCT02006641|9948923|FG002|Overall Study|Adverse Event|15
6256940|NCT02006641|9948921|FG000|Overall Study|Protocol Violation|0
6256941|NCT02006641|9948922|FG001|Overall Study|Protocol Violation|2
6256942|NCT02006641|9948923|FG002|Overall Study|Protocol Violation|2
6086642|NCT00662649|9696713|FG004|Extension Study (Month 24 to 60)|Abnormal laboratory value(s)|3
6086643|NCT00662649|9696709|FG000|Extension Study (Month 24 to 60)|Abnormal test procedure result(s)|3
6086644|NCT00662649|9696710|FG001|Extension Study (Month 24 to 60)|Abnormal test procedure result(s)|1
6086645|NCT00662649|9696711|FG002|Extension Study (Month 24 to 60)|Abnormal test procedure result(s)|0
6086646|NCT00662649|9696712|FG003|Extension Study (Month 24 to 60)|Abnormal test procedure result(s)|1
6086647|NCT00662649|9696713|FG004|Extension Study (Month 24 to 60)|Abnormal test procedure result(s)|3
6086648|NCT00662649|9696709|FG000|Extension Study (Month 24 to 60)|Administrative problems|0
6086649|NCT00662649|9696710|FG001|Extension Study (Month 24 to 60)|Administrative problems|0
6256943|NCT02006641|9948921|FG000|Overall Study|Lost to Follow-up|0
6256944|NCT02006641|9948922|FG001|Overall Study|Lost to Follow-up|1
6256945|NCT02006641|9948923|FG002|Overall Study|Lost to Follow-up|0
6256946|NCT02006641|9948921|FG000|Overall Study|Withdrawal by Subject|7
6256947|NCT02006641|9948922|FG001|Overall Study|Withdrawal by Subject|12
6256948|NCT02006641|9948923|FG002|Overall Study|Withdrawal by Subject|11
6256949|NCT02006641|9948921|FG000|Overall Study|Other reason: patient didn't show up|1
6256950|NCT02006641|9948922|FG001|Overall Study|Other reason: patient didn't show up|0
6256951|NCT02006641|9948923|FG002|Overall Study|Other reason: patient didn't show up|0
6256952|NCT02006641|9948921|FG000|Overall Study|Other reason:patient didn't want to come|0
6256953|NCT02006641|9948922|FG001|Overall Study|Other reason:patient didn't want to come|0
6256954|NCT02006641|9948923|FG002|Overall Study|Other reason:patient didn't want to come|1
6256955|NCT02006641|9948921|FG000|Overall Study|Other reason: patient has moved|1
6256956|NCT02006641|9948922|FG001|Overall Study|Other reason: patient has moved|0
6256957|NCT02006641|9948923|FG002|Overall Study|Other reason: patient has moved|1
6256958|NCT02006641|9948921|FG000|Overall Study|Other reason: caregiver in hospital|0
6256959|NCT02006641|9948922|FG001|Overall Study|Other reason: caregiver in hospital|1
6256960|NCT02006641|9948923|FG002|Overall Study|Other reason: caregiver in hospital|0
6256961|NCT02006641|9948921|FG000|Overall Study|Other reason: patient's wife has died|0
6256962|NCT02006641|9948922|FG001|Overall Study|Other reason: patient's wife has died|0
6256963|NCT02006641|9948923|FG002|Overall Study|Other reason: patient's wife has died|1
6256964|NCT02006641|9948921|FG000|Overall Study|Other reason: hospitalisation|0
6256965|NCT02006641|9948922|FG001|Overall Study|Other reason: hospitalisation|1
6256966|NCT02006641|9948923|FG002|Overall Study|Other reason: hospitalisation|0
6256967|NCT02006641|9948921|FG000|Overall Study|Other reason: caregiver impossibility|0
6256968|NCT02006641|9948922|FG001|Overall Study|Other reason: caregiver impossibility|0
6256969|NCT02006641|9948923|FG002|Overall Study|Other reason: caregiver impossibility|1
6256970|NCT02006641|9948921|FG000|Overall Study|Other reason: protocol non-compliance|0
6256971|NCT02006641|9948922|FG001|Overall Study|Other reason: protocol non-compliance|0
6256972|NCT02006641|9948923|FG002|Overall Study|Other reason: protocol non-compliance|1
6256973|NCT02006654|9948933|FG000|Overall Study|Withdrawal before treatment|4
6256974|NCT02006654|9948934|FG001|Overall Study|Withdrawal before treatment|2
6256975|NCT02006654|9948933|FG000|Overall Study|Adverse Event|16
6256976|NCT02006654|9948934|FG001|Overall Study|Adverse Event|17
6256977|NCT02006654|9948933|FG000|Overall Study|Death|1
6256978|NCT02006654|9948934|FG001|Overall Study|Death|0
6256979|NCT02006654|9948933|FG000|Overall Study|Withdrawal by Subject|14
6256980|NCT02006654|9948934|FG001|Overall Study|Withdrawal by Subject|12
6256981|NCT02006654|9948933|FG000|Overall Study|Protocol Violation|5
6256982|NCT02006654|9948934|FG001|Overall Study|Protocol Violation|8
6256983|NCT02006654|9948933|FG000|Overall Study|Lost to Follow-up|1
6256984|NCT02006654|9948934|FG001|Overall Study|Lost to Follow-up|0
6256985|NCT02006654|9948933|FG000|Overall Study|patient's will|2
6256986|NCT02006654|9948934|FG001|Overall Study|patient's will|1
6256987|NCT02006654|9948933|FG000|Overall Study|insufficient compliance|1
6256988|NCT02006654|9948934|FG001|Overall Study|insufficient compliance|0
6256989|NCT02006654|9948933|FG000|Overall Study|worsening cognitive condition|0
6256990|NCT02006654|9948934|FG001|Overall Study|worsening cognitive condition|1
6256991|NCT02006654|9948933|FG000|Overall Study|faecal incontinence|0
6256992|NCT02006654|9948934|FG001|Overall Study|faecal incontinence|1
6256993|NCT02006654|9948933|FG000|Overall Study|mood disorder|0
6256994|NCT02006654|9948934|FG001|Overall Study|mood disorder|1
6256995|NCT02006654|9948933|FG000|Overall Study|disallowed medication|1
6256996|NCT02006654|9948934|FG001|Overall Study|disallowed medication|0
6256997|NCT02006654|9948933|FG000|Overall Study|moving out of state|0
6256998|NCT02006654|9948934|FG001|Overall Study|moving out of state|1
6256999|NCT02006667|9948941|FG000|Overall Study|Adverse Event|3
6257000|NCT02006667|9948941|FG000|Overall Study|Death|2
6257001|NCT02006667|9948941|FG000|Overall Study|Withdrawal by Subject|1
6257002|NCT02006693|9948947|FG000|Overall Study|No Reason Specified|6
6257003|NCT02006693|9948948|FG001|Overall Study|No Reason Specified|8
6257004|NCT02006693|9948947|FG000|Overall Study|Another Glaucoma-related Surgery|12
6257005|NCT02006693|9948948|FG001|Overall Study|Another Glaucoma-related Surgery|1
6257006|NCT02006693|9948947|FG000|Overall Study|XEN Implant Explantation|0
6257007|NCT02006693|9948948|FG001|Overall Study|XEN Implant Explantation|1
6257008|NCT02006693|9948947|FG000|Overall Study|Death|2
6257009|NCT02006693|9948948|FG001|Overall Study|Death|2
6257010|NCT02006693|9948947|FG000|Overall Study|Lost to Follow-up|4
6257011|NCT02006693|9948948|FG001|Overall Study|Lost to Follow-up|1
6257012|NCT02006693|9948947|FG000|Overall Study|Patient Decision|4
6257013|NCT02006693|9948948|FG001|Overall Study|Patient Decision|0
6257014|NCT02006706|9948954|FG000|Overall Study|Lost to Follow-up|1
6257015|NCT02006719|9948960|FG000|Overall Study|Withdrawal by Subject|10
6257016|NCT02006719|9948961|FG001|Overall Study|Withdrawal by Subject|2
6257017|NCT02006719|9948960|FG000|Overall Study|Lost to Follow-up|5
6257018|NCT02006719|9948961|FG001|Overall Study|Lost to Follow-up|1
6257019|NCT02006719|9948960|FG000|Overall Study|Protocol Violation|2
6257020|NCT02006719|9948961|FG001|Overall Study|Protocol Violation|0
6257021|NCT02006719|9948960|FG000|Overall Study|Adverse Event|1
6257022|NCT02006719|9948961|FG001|Overall Study|Adverse Event|1
6257023|NCT02006719|9948960|FG000|Overall Study|Other/Unknown|0
6257024|NCT02006719|9948961|FG001|Overall Study|Other/Unknown|1
6257025|NCT02006732|9948971|FG000|Overall Study|Adverse Event|10
6257026|NCT02006732|9948972|FG001|Overall Study|Adverse Event|7
6257027|NCT02006732|9948973|FG002|Overall Study|Adverse Event|4
6257028|NCT02006732|9948974|FG003|Overall Study|Adverse Event|2
6257029|NCT02006732|9948971|FG000|Overall Study|Lack of Efficacy|6
6257030|NCT02006732|9948972|FG001|Overall Study|Lack of Efficacy|3
6257031|NCT02006732|9948973|FG002|Overall Study|Lack of Efficacy|1
6257032|NCT02006732|9948974|FG003|Overall Study|Lack of Efficacy|1
6257033|NCT02006732|9948971|FG000|Overall Study|Protocol Violation|1
6257034|NCT02006732|9948972|FG001|Overall Study|Protocol Violation|1
6257035|NCT02006732|9948973|FG002|Overall Study|Protocol Violation|0
6257036|NCT02006732|9948974|FG003|Overall Study|Protocol Violation|0
6257037|NCT02006732|9948971|FG000|Overall Study|Lost to Follow-up|0
6257038|NCT02006732|9948972|FG001|Overall Study|Lost to Follow-up|1
6257039|NCT02006732|9948973|FG002|Overall Study|Lost to Follow-up|0
6257040|NCT02006732|9948974|FG003|Overall Study|Lost to Follow-up|0
6257041|NCT02006732|9948971|FG000|Overall Study|Withdrawal by Subject|3
6257042|NCT02006732|9948972|FG001|Overall Study|Withdrawal by Subject|0
6257043|NCT02006732|9948973|FG002|Overall Study|Withdrawal by Subject|4
6257044|NCT02006732|9948974|FG003|Overall Study|Withdrawal by Subject|1
6257045|NCT02006758|9948984|FG000|Overall Study|Protocol Violation|1
6257046|NCT02006758|9948984|FG000|Overall Study|Death|1
6257047|NCT02006758|9948984|FG000|Overall Study|Lost to Follow-up|4
6257048|NCT02006758|9948984|FG000|Overall Study|Withdrawal by Subject|4
6257049|NCT02006758|9948984|FG000|Overall Study|Procedurally excluded|1
6257050|NCT02006758|9948984|FG000|Overall Study|Other|2
6257051|NCT02006979|9949019|FG000|Overall Study|Withdrawal by Subject|1
6257052|NCT02006979|9949020|FG001|Overall Study|Withdrawal by Subject|1
6257053|NCT02006979|9949019|FG000|Overall Study|Protocol Violation|0
6257054|NCT02006979|9949020|FG001|Overall Study|Protocol Violation|1
6257055|NCT02007070|9949026|FG000|Overall Study|Adverse Event|4
6257056|NCT02007070|9949026|FG000|Overall Study|Clinical Progression|4
6257057|NCT02007070|9949026|FG000|Overall Study|Death|1
6257058|NCT02007070|9949026|FG000|Overall Study|Protocol Violation|2
6257059|NCT02007070|9949026|FG000|Overall Study|Physician Decision|1
6257060|NCT02007070|9949026|FG000|Overall Study|Progressive Disease|21
6257061|NCT02007096|9949032|FG000|Overall Study|medication not available|2
6257062|NCT02007096|9949033|FG001|Overall Study|medication not available|0
6257063|NCT02007096|9949032|FG000|Overall Study|did not inject saline|0
6257064|NCT02007096|9949033|FG001|Overall Study|did not inject saline|3
6257065|NCT02007096|9949032|FG000|Overall Study|did not follow postoperative protocol|8
6257066|NCT02007096|9949033|FG001|Overall Study|did not follow postoperative protocol|11
6257067|NCT02007096|9949032|FG000|Overall Study|converted to open surgery|1
6257068|NCT02007096|9949033|FG001|Overall Study|converted to open surgery|1
6257069|NCT02007096|9949032|FG000|Overall Study|no mesh placed|0
6257070|NCT02007096|9949033|FG001|Overall Study|no mesh placed|1
6257071|NCT02007109|9949039|FG000|Overall Study|Diary not returned or excluded|102
6257072|NCT02007109|9949039|FG000|Overall Study|Excluded - Age<7yo|9
6257073|NCT02007252|9949052|FG000|Overall Study|Administrative problems|3
6257074|NCT02007252|9949053|FG001|Overall Study|Administrative problems|7
6257075|NCT02007252|9949052|FG000|Overall Study|Abnormal laboratory value(s)|1
6257076|NCT02007252|9949053|FG001|Overall Study|Abnormal laboratory value(s)|0
6257077|NCT02007252|9949052|FG000|Overall Study|Adverse Event|7
6257078|NCT02007252|9949053|FG001|Overall Study|Adverse Event|4
6257079|NCT02007278|9949061|FG000|Overall Study|Failure to comply with an eligibility|0
6257080|NCT02007278|9949062|FG001|Overall Study|Failure to comply with an eligibility|1
6257081|NCT02007278|9949061|FG000|Overall Study|Ingestion of drugs not allowed in study|0
6257082|NCT02007278|9949062|FG001|Overall Study|Ingestion of drugs not allowed in study|1
6257083|NCT02007278|9949061|FG000|Overall Study|Incorrect medication administration|1
6257084|NCT02007278|9949062|FG001|Overall Study|Incorrect medication administration|0
6257085|NCT02007278|9949061|FG000|Overall Study|Mis-randomization|1
6257086|NCT02007278|9949062|FG001|Overall Study|Mis-randomization|1
6257087|NCT02007434|9949096|FG000|Overall Study|Lost to Follow-up|0
6257088|NCT02007434|9949097|FG001|Overall Study|Lost to Follow-up|1
6257089|NCT02007434|9949098|FG002|Overall Study|Lost to Follow-up|0
6257090|NCT02007434|9949099|FG003|Overall Study|Lost to Follow-up|0
6257091|NCT02007434|9949100|FG004|Overall Study|Lost to Follow-up|0
6257092|NCT02007434|9949101|FG005|Overall Study|Lost to Follow-up|0
6257093|NCT02007434|9949102|FG006|Overall Study|Lost to Follow-up|0
6257094|NCT02007434|9949103|FG007|Overall Study|Lost to Follow-up|0
6257095|NCT02007434|9949096|FG000|Overall Study|Non-compliance|1
6257096|NCT02007434|9949097|FG001|Overall Study|Non-compliance|0
6257097|NCT02007434|9949098|FG002|Overall Study|Non-compliance|1
6257098|NCT02007434|9949099|FG003|Overall Study|Non-compliance|0
6257099|NCT02007434|9949100|FG004|Overall Study|Non-compliance|0
6257100|NCT02007434|9949101|FG005|Overall Study|Non-compliance|0
6257101|NCT02007434|9949102|FG006|Overall Study|Non-compliance|0
6257102|NCT02007434|9949103|FG007|Overall Study|Non-compliance|0
6257103|NCT02007577|9949124|FG000|Overall Study|Adverse Event|1
6257104|NCT02007577|9949125|FG001|Overall Study|Adverse Event|0
6257105|NCT02007577|9949124|FG000|Overall Study|Withdrawal by Subject|0
6257106|NCT02007577|9949125|FG001|Overall Study|Withdrawal by Subject|1
6257107|NCT02007720|9949133|FG000|Overall Study|Withdrawal by Subject|9
6257108|NCT02007720|9949134|FG001|Overall Study|Withdrawal by Subject|11
6257109|NCT02007720|9949133|FG000|Overall Study|study terminated by sponsor|58
6257110|NCT02007720|9949134|FG001|Overall Study|study terminated by sponsor|54
6257111|NCT02007720|9949133|FG000|Overall Study|technical problem|4
6257112|NCT02007720|9949134|FG001|Overall Study|technical problem|2
6257113|NCT02007720|9949133|FG000|Overall Study|patient followd less than 165 days|11
6257114|NCT02007720|9949134|FG001|Overall Study|patient followd less than 165 days|5
6257115|NCT02007954|9949145|FG000|Overall Study|Received liver transplant|3
6257116|NCT02007954|9949145|FG000|Overall Study|Switch in treatment modality|2
6257117|NCT02007954|9949145|FG000|Overall Study|Disease progression and unrelated AE|1
6257118|NCT02007954|9949145|FG000|Overall Study|Death|1
6257119|NCT02008227|9949164|FG000|Overall Study|Lost to Follow-up|7
6257120|NCT02008227|9949165|FG001|Overall Study|Lost to Follow-up|9
6257121|NCT02008227|9949164|FG000|Overall Study|Death|494
6257122|NCT02008227|9949165|FG001|Overall Study|Death|485
6257123|NCT02008227|9949164|FG000|Overall Study|Withdrawal by Subject|67
6257124|NCT02008227|9949165|FG001|Overall Study|Withdrawal by Subject|36
6257125|NCT02008227|9949164|FG000|Overall Study|Study Terminated By Sponsor|44
6257126|NCT02008227|9949165|FG001|Overall Study|Study Terminated By Sponsor|83
6257127|NCT02008318|9949174|FG000|Overall Study|Adverse Event|4
6257128|NCT02008318|9949175|FG001|Overall Study|Adverse Event|0
6257129|NCT02008318|9949174|FG000|Overall Study|Physician Decision|2
6257130|NCT02008318|9949175|FG001|Overall Study|Physician Decision|0
6257131|NCT02008318|9949174|FG000|Overall Study|Progressive Disease|2
6257132|NCT02008318|9949175|FG001|Overall Study|Progressive Disease|0
6257133|NCT02008318|9949174|FG000|Overall Study|Protocol Violation|1
6257134|NCT02008318|9949175|FG001|Overall Study|Protocol Violation|1
6257135|NCT02008318|9949174|FG000|Overall Study|Withdrawal by Subject|3
6257136|NCT02008318|9949175|FG001|Overall Study|Withdrawal by Subject|0
6257137|NCT02008526|9949187|FG000|Overall Study|Death|0
6257138|NCT02008526|9949188|FG001|Overall Study|Death|2
6257139|NCT02008526|9949189|FG002|Overall Study|Death|1
6257140|NCT02008526|9949187|FG000|Overall Study|Withdrawal by Subject|3
6257141|NCT02008526|9949188|FG001|Overall Study|Withdrawal by Subject|3
6257142|NCT02008526|9949189|FG002|Overall Study|Withdrawal by Subject|2
6257143|NCT02008526|9949187|FG000|Overall Study|Lost to Follow-up|5
6257144|NCT02008526|9949188|FG001|Overall Study|Lost to Follow-up|9
6257145|NCT02008526|9949189|FG002|Overall Study|Lost to Follow-up|6
6257146|NCT02008565|9949201|FG000|Overall Study|Protocol Violation|1
6257147|NCT02008565|9949202|FG001|Overall Study|Protocol Violation|1
6257148|NCT02008565|9949203|FG002|Overall Study|Protocol Violation|2
6257149|NCT02008565|9949204|FG003|Overall Study|Protocol Violation|0
6257150|NCT02008773|9949238|FG000|Overall Study|Adverse Event|3
6257151|NCT02008773|9949239|FG001|Overall Study|Adverse Event|3
6257152|NCT02008773|9949240|FG002|Overall Study|Adverse Event|1
6257153|NCT02008773|9949241|FG003|Overall Study|Adverse Event|2
6257154|NCT02008773|9949238|FG000|Overall Study|Medication Non-compliance|2
6257155|NCT02008773|9949239|FG001|Overall Study|Medication Non-compliance|1
6086650|NCT00662649|9696711|FG002|Extension Study (Month 24 to 60)|Administrative problems|0
6086651|NCT00662649|9696712|FG003|Extension Study (Month 24 to 60)|Administrative problems|1
6086652|NCT00662649|9696713|FG004|Extension Study (Month 24 to 60)|Administrative problems|0
6086653|NCT00662649|9696709|FG000|Extension Study (Month 24 to 60)|Adverse Event|6
6086654|NCT00662649|9696710|FG001|Extension Study (Month 24 to 60)|Adverse Event|9
6086655|NCT00662649|9696711|FG002|Extension Study (Month 24 to 60)|Adverse Event|0
6086656|NCT00662649|9696712|FG003|Extension Study (Month 24 to 60)|Adverse Event|6
6086657|NCT00662649|9696713|FG004|Extension Study (Month 24 to 60)|Adverse Event|10
6257156|NCT02008773|9949240|FG002|Overall Study|Medication Non-compliance|3
6257157|NCT02008773|9949241|FG003|Overall Study|Medication Non-compliance|2
6257158|NCT02008773|9949238|FG000|Overall Study|Withdrawal by Subject|8
6257159|NCT02008773|9949239|FG001|Overall Study|Withdrawal by Subject|4
6257160|NCT02008773|9949240|FG002|Overall Study|Withdrawal by Subject|7
6257161|NCT02008773|9949241|FG003|Overall Study|Withdrawal by Subject|6
6257162|NCT02008773|9949238|FG000|Overall Study|Lost to Follow-up|0
6257163|NCT02008773|9949239|FG001|Overall Study|Lost to Follow-up|1
6257164|NCT02008773|9949240|FG002|Overall Study|Lost to Follow-up|3
6257165|NCT02008773|9949241|FG003|Overall Study|Lost to Follow-up|2
6257166|NCT02008877|9949249|FG000|Overall Study|Inevaluable|0
6257167|NCT02008877|9949250|FG001|Overall Study|Inevaluable|1
6257168|NCT02008877|9949251|FG002|Overall Study|Inevaluable|0
6257169|NCT02008890|9949263|FG000|Period 1|Withdrawal by Subject|7
6257170|NCT02008890|9949264|FG001|Period 1|Withdrawal by Subject|7
6257171|NCT02008890|9949265|FG002|Period 1|Withdrawal by Subject|5
6257172|NCT02008890|9949266|FG003|Period 1|Withdrawal by Subject|0
6257173|NCT02008890|9949267|FG004|Period 1|Withdrawal by Subject|0
6257174|NCT02008890|9949263|FG000|Period 1|Pregnancy|1
6257175|NCT02008890|9949264|FG001|Period 1|Pregnancy|0
6257176|NCT02008890|9949265|FG002|Period 1|Pregnancy|0
6257177|NCT02008890|9949266|FG003|Period 1|Pregnancy|0
6257178|NCT02008890|9949267|FG004|Period 1|Pregnancy|0
6257179|NCT02008890|9949263|FG000|Period 1|Physician Decision|1
6257180|NCT02008890|9949264|FG001|Period 1|Physician Decision|0
6257181|NCT02008890|9949265|FG002|Period 1|Physician Decision|1
6257182|NCT02008890|9949266|FG003|Period 1|Physician Decision|0
6257183|NCT02008890|9949267|FG004|Period 1|Physician Decision|0
6257184|NCT02008890|9949263|FG000|Period 1|Adverse Event|6
6257185|NCT02008890|9949264|FG001|Period 1|Adverse Event|8
6257186|NCT02008890|9949265|FG002|Period 1|Adverse Event|6
6257187|NCT02008890|9949266|FG003|Period 1|Adverse Event|0
6257188|NCT02008890|9949267|FG004|Period 1|Adverse Event|0
6257189|NCT02008890|9949263|FG000|Period 2|Adverse Event|12
6257190|NCT02008890|9949264|FG001|Period 2|Adverse Event|7
6257191|NCT02008890|9949265|FG002|Period 2|Adverse Event|0
6257192|NCT02008890|9949266|FG003|Period 2|Adverse Event|5
6257193|NCT02008890|9949267|FG004|Period 2|Adverse Event|5
6257194|NCT02008890|9949263|FG000|Period 2|Withdrawal by Subject|11
6190918|NCT01416805|9847402|FG001|Overall Study|Lost to Follow-up|4
6257195|NCT02008890|9949264|FG001|Period 2|Withdrawal by Subject|8
6257196|NCT02008890|9949265|FG002|Period 2|Withdrawal by Subject|0
6257197|NCT02008890|9949266|FG003|Period 2|Withdrawal by Subject|7
6257198|NCT02008890|9949267|FG004|Period 2|Withdrawal by Subject|2
6257199|NCT02008890|9949263|FG000|Period 2|Physician Decision|4
6257200|NCT02008890|9949264|FG001|Period 2|Physician Decision|0
6257201|NCT02008890|9949265|FG002|Period 2|Physician Decision|0
6257202|NCT02008890|9949266|FG003|Period 2|Physician Decision|2
6257203|NCT02008890|9949267|FG004|Period 2|Physician Decision|1
6257204|NCT02008890|9949263|FG000|Period 2|Lost to Follow-up|0
6257205|NCT02008890|9949264|FG001|Period 2|Lost to Follow-up|0
6257206|NCT02008890|9949265|FG002|Period 2|Lost to Follow-up|1
6257207|NCT02008890|9949266|FG003|Period 2|Lost to Follow-up|0
6257208|NCT02008890|9949267|FG004|Period 2|Lost to Follow-up|0
6257209|NCT02008890|9949263|FG000|Extension Period|Withdrawal by Subject|3
6257210|NCT02008890|9949264|FG001|Extension Period|Withdrawal by Subject|2
6257211|NCT02008890|9949265|FG002|Extension Period|Withdrawal by Subject|0
6257212|NCT02008890|9949266|FG003|Extension Period|Withdrawal by Subject|4
6257213|NCT02008890|9949267|FG004|Extension Period|Withdrawal by Subject|2
6257214|NCT02008890|9949263|FG000|Extension Period|Lost to Follow-up|1
6257215|NCT02008890|9949264|FG001|Extension Period|Lost to Follow-up|0
6257216|NCT02008890|9949265|FG002|Extension Period|Lost to Follow-up|0
6257217|NCT02008890|9949266|FG003|Extension Period|Lost to Follow-up|0
6257218|NCT02008890|9949267|FG004|Extension Period|Lost to Follow-up|0
6257219|NCT02008890|9949263|FG000|Extension Period|Adverse Event|1
6257220|NCT02008890|9949264|FG001|Extension Period|Adverse Event|3
6257221|NCT02008890|9949265|FG002|Extension Period|Adverse Event|0
6257222|NCT02008890|9949266|FG003|Extension Period|Adverse Event|0
6257223|NCT02008890|9949267|FG004|Extension Period|Adverse Event|2
6257224|NCT02008916|9949285|FG000|Primary Assessment (up to Week 16)|Withdrawal by Subject|0
6257225|NCT02008916|9949286|FG001|Primary Assessment (up to Week 16)|Withdrawal by Subject|1
6257226|NCT02008916|9949287|FG002|Primary Assessment (up to Week 16)|Withdrawal by Subject|3
6257227|NCT02008916|9949285|FG000|Week 16 - 156|Adverse Event|4
6257228|NCT02008916|9949286|FG001|Week 16 - 156|Adverse Event|2
6257229|NCT02008916|9949287|FG002|Week 16 - 156|Adverse Event|3
6257230|NCT02008916|9949285|FG000|Week 16 - 156|Withdrawal by Subject|7
6257231|NCT02008916|9949286|FG001|Week 16 - 156|Withdrawal by Subject|3
6257232|NCT02008916|9949287|FG002|Week 16 - 156|Withdrawal by Subject|5
6257233|NCT02008916|9949285|FG000|Week 16 - 156|No longer requires treatment|0
6257234|NCT02008916|9949286|FG001|Week 16 - 156|No longer requires treatment|1
6257235|NCT02008916|9949287|FG002|Week 16 - 156|No longer requires treatment|0
6257236|NCT02008916|9949285|FG000|Week 16 - 156|Lost to Follow-up|5
6257237|NCT02008916|9949286|FG001|Week 16 - 156|Lost to Follow-up|0
6257238|NCT02008916|9949287|FG002|Week 16 - 156|Lost to Follow-up|0
6257239|NCT02008916|9949285|FG000|Week 16 - 156|Lack of Efficacy|3
6257240|NCT02008916|9949286|FG001|Week 16 - 156|Lack of Efficacy|5
6257241|NCT02008916|9949287|FG002|Week 16 - 156|Lack of Efficacy|2
6257242|NCT02008916|9949285|FG000|Week 16 - 156|Pregnancy|0
6257243|NCT02008916|9949286|FG001|Week 16 - 156|Pregnancy|1
6257244|NCT02008916|9949287|FG002|Week 16 - 156|Pregnancy|0
6257245|NCT02008916|9949285|FG000|Week 16 - 156|Physician Decision|0
6257246|NCT02008916|9949286|FG001|Week 16 - 156|Physician Decision|1
6257247|NCT02008916|9949287|FG002|Week 16 - 156|Physician Decision|0
6257248|NCT02009046|9949305|FG000|Overall Study|Lost to Follow-up|256
6257249|NCT02009046|9949306|FG001|Overall Study|Lost to Follow-up|206
6257250|NCT02009163|9949320|FG000|Open-label Period (Non-randomized)|Failure to Meet Randomization Criteria|48
6257251|NCT02009163|9949321|FG001|Open-label Period (Non-randomized)|Failure to Meet Randomization Criteria|0
6257252|NCT02009163|9949322|FG002|Open-label Period (Non-randomized)|Failure to Meet Randomization Criteria|0
6257253|NCT02009163|9949320|FG000|Open-label Period (Non-randomized)|Withdrawal by Subject|29
6257254|NCT02009163|9949321|FG001|Open-label Period (Non-randomized)|Withdrawal by Subject|0
6257255|NCT02009163|9949322|FG002|Open-label Period (Non-randomized)|Withdrawal by Subject|0
6257256|NCT02009163|9949320|FG000|Open-label Period (Non-randomized)|Adverse Event|22
6257257|NCT02009163|9949321|FG001|Open-label Period (Non-randomized)|Adverse Event|0
6257258|NCT02009163|9949322|FG002|Open-label Period (Non-randomized)|Adverse Event|0
6257259|NCT02009163|9949320|FG000|Open-label Period (Non-randomized)|Lost to Follow-up|20
6257260|NCT02009163|9949321|FG001|Open-label Period (Non-randomized)|Lost to Follow-up|0
6257261|NCT02009163|9949322|FG002|Open-label Period (Non-randomized)|Lost to Follow-up|0
6257262|NCT02009163|9949320|FG000|Open-label Period (Non-randomized)|Protocol Violation|10
6257263|NCT02009163|9949321|FG001|Open-label Period (Non-randomized)|Protocol Violation|0
6257264|NCT02009163|9949322|FG002|Open-label Period (Non-randomized)|Protocol Violation|0
6257265|NCT02009163|9949320|FG000|Open-label Period (Non-randomized)|Pregnancy|1
6257266|NCT02009163|9949321|FG001|Open-label Period (Non-randomized)|Pregnancy|0
6257267|NCT02009163|9949322|FG002|Open-label Period (Non-randomized)|Pregnancy|0
6257268|NCT02009163|9949320|FG000|Open-label Period (Non-randomized)|Other|13
6257269|NCT02009163|9949321|FG001|Open-label Period (Non-randomized)|Other|0
6257270|NCT02009163|9949322|FG002|Open-label Period (Non-randomized)|Other|0
6257271|NCT02009163|9949320|FG000|Randomized-withdrawal Period|Withdrawal by Subject|0
6257272|NCT02009163|9949321|FG001|Randomized-withdrawal Period|Withdrawal by Subject|25
6257273|NCT02009163|9949322|FG002|Randomized-withdrawal Period|Withdrawal by Subject|9
6257274|NCT02009163|9949320|FG000|Randomized-withdrawal Period|Lost to Follow-up|0
6257275|NCT02009163|9949321|FG001|Randomized-withdrawal Period|Lost to Follow-up|13
6257276|NCT02009163|9949322|FG002|Randomized-withdrawal Period|Lost to Follow-up|6
6257277|NCT02009163|9949320|FG000|Randomized-withdrawal Period|Adverse Event|0
6257278|NCT02009163|9949321|FG001|Randomized-withdrawal Period|Adverse Event|0
6257279|NCT02009163|9949322|FG002|Randomized-withdrawal Period|Adverse Event|6
6257280|NCT02009163|9949320|FG000|Randomized-withdrawal Period|Relapse Criteria Met|0
6257281|NCT02009163|9949321|FG001|Randomized-withdrawal Period|Relapse Criteria Met|40
6257282|NCT02009163|9949322|FG002|Randomized-withdrawal Period|Relapse Criteria Met|5
6257283|NCT02009163|9949320|FG000|Randomized-withdrawal Period|Protocol Violation|0
6257284|NCT02009163|9949321|FG001|Randomized-withdrawal Period|Protocol Violation|1
6257285|NCT02009163|9949322|FG002|Randomized-withdrawal Period|Protocol Violation|2
6257286|NCT02009163|9949320|FG000|Randomized-withdrawal Period|Pregnancy|0
6257287|NCT02009163|9949321|FG001|Randomized-withdrawal Period|Pregnancy|0
6257288|NCT02009163|9949322|FG002|Randomized-withdrawal Period|Pregnancy|2
6257289|NCT02009163|9949320|FG000|Randomized-withdrawal Period|Other|0
6257290|NCT02009163|9949321|FG001|Randomized-withdrawal Period|Other|9
6257291|NCT02009163|9949322|FG002|Randomized-withdrawal Period|Other|5
6257292|NCT02009332|9949338|FG000|Phase 1: Dose Level 2/2b (Wks 11-29)|Physician Decision|0
6257293|NCT02009332|9949339|FG001|Phase 1: Dose Level 2/2b (Wks 11-29)|Physician Decision|1
6257294|NCT02009332|9949340|FG002|Phase 1: Dose Level 2/2b (Wks 11-29)|Physician Decision|0
6257295|NCT02009332|9949341|FG003|Phase 1: Dose Level 2/2b (Wks 11-29)|Physician Decision|0
6257296|NCT02009332|9949342|FG004|Phase 1: Dose Level 2/2b (Wks 11-29)|Physician Decision|0
6257297|NCT02009332|9949343|FG005|Phase 1: Dose Level 2/2b (Wks 11-29)|Physician Decision|0
6257298|NCT02009332|9949338|FG000|Phase 1: Dose Level 4 (Weeks 48-77)|Withdrawal by Subject|0
6257299|NCT02009332|9949339|FG001|Phase 1: Dose Level 4 (Weeks 48-77)|Withdrawal by Subject|0
6257300|NCT02009332|9949340|FG002|Phase 1: Dose Level 4 (Weeks 48-77)|Withdrawal by Subject|0
6257301|NCT02009332|9949341|FG003|Phase 1: Dose Level 4 (Weeks 48-77)|Withdrawal by Subject|0
6257302|NCT02009332|9949342|FG004|Phase 1: Dose Level 4 (Weeks 48-77)|Withdrawal by Subject|1
6257303|NCT02009332|9949343|FG005|Phase 1: Dose Level 4 (Weeks 48-77)|Withdrawal by Subject|0
6257304|NCT02009332|9949338|FG000|Phase 2 (Weeks 206-252)|Withdrawal by Subject|0
6257305|NCT02009332|9949339|FG001|Phase 2 (Weeks 206-252)|Withdrawal by Subject|0
6257306|NCT02009332|9949340|FG002|Phase 2 (Weeks 206-252)|Withdrawal by Subject|0
6257307|NCT02009332|9949341|FG003|Phase 2 (Weeks 206-252)|Withdrawal by Subject|0
6257308|NCT02009332|9949342|FG004|Phase 2 (Weeks 206-252)|Withdrawal by Subject|0
6257309|NCT02009332|9949343|FG005|Phase 2 (Weeks 206-252)|Withdrawal by Subject|1
6257310|NCT02009397|9949357|FG000|Overall Study|Protocol Violation|6
6257311|NCT02009397|9949357|FG000|Overall Study|Death|8
6257312|NCT02009397|9949357|FG000|Overall Study|Lost to Follow-up|6
6257313|NCT02009696|9949370|FG000|Overall Study|Withdrawal by Subject|2
6257314|NCT02009722|9949376|FG000|Overall Study|Protocol Violation|1
6257315|NCT02009722|9949377|FG001|Overall Study|Protocol Violation|2
6257316|NCT02009722|9949376|FG000|Overall Study|Did not receive intervention|0
6257317|NCT02009722|9949377|FG001|Overall Study|Did not receive intervention|1
6257318|NCT02009865|9949385|FG000|Overall Study|Adverse Event|0
6257319|NCT02009865|9949386|FG001|Overall Study|Adverse Event|2
6257320|NCT02009865|9949385|FG000|Overall Study|Protocol Violation|0
6257321|NCT02009865|9949386|FG001|Overall Study|Protocol Violation|2
6257322|NCT02009865|9949385|FG000|Overall Study|Withdrawal by Subject|1
6257323|NCT02009865|9949386|FG001|Overall Study|Withdrawal by Subject|1
6257324|NCT02009878|9949395|FG000|Overall Study|Participant Met Withdrawal Criteria|0
6257325|NCT02009878|9949396|FG001|Overall Study|Participant Met Withdrawal Criteria|1
6257326|NCT02009878|9949397|FG002|Overall Study|Participant Met Withdrawal Criteria|0
6257327|NCT02009930|9949405|FG000|Overall Study|withdrawn|5
6257328|NCT02010255|9949473|FG000|Overall Study|Death|0
6257329|NCT02010255|9949474|FG001|Overall Study|Death|1
6257330|NCT02010255|9949475|FG002|Overall Study|Death|4
6257331|NCT02010255|9949476|FG003|Overall Study|Death|4
6257332|NCT02010255|9949477|FG004|Overall Study|Death|2
6257333|NCT02010255|9949478|FG005|Overall Study|Death|0
6257334|NCT02010255|9949479|FG006|Overall Study|Death|1
6257335|NCT02010255|9949480|FG007|Overall Study|Death|1
6257336|NCT02010255|9949481|FG008|Overall Study|Death|1
6257337|NCT02010255|9949482|FG009|Overall Study|Death|0
6257338|NCT02010255|9949483|FG010|Overall Study|Death|1
6257339|NCT02010255|9949484|FG011|Overall Study|Death|1
6257340|NCT02010255|9949485|FG012|Overall Study|Death|0
6257341|NCT02010255|9949486|FG013|Overall Study|Death|0
6257342|NCT02010255|9949473|FG000|Overall Study|Lack of Efficacy|4
6257343|NCT02010255|9949474|FG001|Overall Study|Lack of Efficacy|1
6257344|NCT02010255|9949475|FG002|Overall Study|Lack of Efficacy|2
6257345|NCT02010255|9949476|FG003|Overall Study|Lack of Efficacy|1
6257346|NCT02010255|9949477|FG004|Overall Study|Lack of Efficacy|1
6257347|NCT02010255|9949478|FG005|Overall Study|Lack of Efficacy|0
6257348|NCT02010255|9949479|FG006|Overall Study|Lack of Efficacy|0
6257349|NCT02010255|9949480|FG007|Overall Study|Lack of Efficacy|0
6257350|NCT02010255|9949481|FG008|Overall Study|Lack of Efficacy|0
6257351|NCT02010255|9949482|FG009|Overall Study|Lack of Efficacy|0
6257352|NCT02010255|9949483|FG010|Overall Study|Lack of Efficacy|1
6257353|NCT02010255|9949484|FG011|Overall Study|Lack of Efficacy|0
6257354|NCT02010255|9949485|FG012|Overall Study|Lack of Efficacy|0
6257355|NCT02010255|9949486|FG013|Overall Study|Lack of Efficacy|0
6257356|NCT02010255|9949473|FG000|Overall Study|Withdrew Consent|1
6257357|NCT02010255|9949474|FG001|Overall Study|Withdrew Consent|0
6257358|NCT02010255|9949475|FG002|Overall Study|Withdrew Consent|0
6257359|NCT02010255|9949476|FG003|Overall Study|Withdrew Consent|1
6257360|NCT02010255|9949477|FG004|Overall Study|Withdrew Consent|0
6257361|NCT02010255|9949478|FG005|Overall Study|Withdrew Consent|0
6257362|NCT02010255|9949479|FG006|Overall Study|Withdrew Consent|0
6257363|NCT02010255|9949480|FG007|Overall Study|Withdrew Consent|0
6257364|NCT02010255|9949481|FG008|Overall Study|Withdrew Consent|0
6257365|NCT02010255|9949482|FG009|Overall Study|Withdrew Consent|0
6257366|NCT02010255|9949483|FG010|Overall Study|Withdrew Consent|0
6257367|NCT02010255|9949484|FG011|Overall Study|Withdrew Consent|0
6257368|NCT02010255|9949485|FG012|Overall Study|Withdrew Consent|0
6257369|NCT02010255|9949486|FG013|Overall Study|Withdrew Consent|0
6257370|NCT02010255|9949473|FG000|Overall Study|Adverse Event|1
6257371|NCT02010255|9949474|FG001|Overall Study|Adverse Event|0
6257372|NCT02010255|9949475|FG002|Overall Study|Adverse Event|0
6257373|NCT02010255|9949476|FG003|Overall Study|Adverse Event|0
6257374|NCT02010255|9949477|FG004|Overall Study|Adverse Event|0
6257375|NCT02010255|9949478|FG005|Overall Study|Adverse Event|0
6257376|NCT02010255|9949479|FG006|Overall Study|Adverse Event|0
6257377|NCT02010255|9949480|FG007|Overall Study|Adverse Event|0
6257378|NCT02010255|9949481|FG008|Overall Study|Adverse Event|0
6257379|NCT02010255|9949482|FG009|Overall Study|Adverse Event|0
6257380|NCT02010255|9949483|FG010|Overall Study|Adverse Event|0
6257381|NCT02010255|9949484|FG011|Overall Study|Adverse Event|0
6257382|NCT02010255|9949485|FG012|Overall Study|Adverse Event|0
6257383|NCT02010255|9949486|FG013|Overall Study|Adverse Event|0
6257384|NCT02010255|9949473|FG000|Overall Study|Lost to Follow-up|0
6257385|NCT02010255|9949474|FG001|Overall Study|Lost to Follow-up|0
6257386|NCT02010255|9949475|FG002|Overall Study|Lost to Follow-up|1
6257387|NCT02010255|9949476|FG003|Overall Study|Lost to Follow-up|0
6257388|NCT02010255|9949477|FG004|Overall Study|Lost to Follow-up|1
6257389|NCT02010255|9949478|FG005|Overall Study|Lost to Follow-up|0
6257390|NCT02010255|9949479|FG006|Overall Study|Lost to Follow-up|0
6257391|NCT02010255|9949480|FG007|Overall Study|Lost to Follow-up|0
6257392|NCT02010255|9949481|FG008|Overall Study|Lost to Follow-up|0
6257393|NCT02010255|9949482|FG009|Overall Study|Lost to Follow-up|0
6257394|NCT02010255|9949483|FG010|Overall Study|Lost to Follow-up|0
6257395|NCT02010255|9949484|FG011|Overall Study|Lost to Follow-up|0
6257396|NCT02010255|9949485|FG012|Overall Study|Lost to Follow-up|0
6257397|NCT02010255|9949486|FG013|Overall Study|Lost to Follow-up|0
6257398|NCT02010255|9949473|FG000|Overall Study|Randomized but Not Treated|0
6257399|NCT02010255|9949474|FG001|Overall Study|Randomized but Not Treated|0
6257400|NCT02010255|9949475|FG002|Overall Study|Randomized but Not Treated|0
6257401|NCT02010255|9949476|FG003|Overall Study|Randomized but Not Treated|0
6257402|NCT02010255|9949477|FG004|Overall Study|Randomized but Not Treated|0
6257403|NCT02010255|9949478|FG005|Overall Study|Randomized but Not Treated|0
6257404|NCT02010255|9949479|FG006|Overall Study|Randomized but Not Treated|0
6257405|NCT02010255|9949480|FG007|Overall Study|Randomized but Not Treated|0
6257406|NCT02010255|9949481|FG008|Overall Study|Randomized but Not Treated|0
6257407|NCT02010255|9949482|FG009|Overall Study|Randomized but Not Treated|0
6257408|NCT02010255|9949483|FG010|Overall Study|Randomized but Not Treated|0
6257409|NCT02010255|9949484|FG011|Overall Study|Randomized but Not Treated|0
6257410|NCT02010255|9949485|FG012|Overall Study|Randomized but Not Treated|0
6257411|NCT02010255|9949486|FG013|Overall Study|Randomized but Not Treated|1
6257412|NCT02010567|9949555|FG000|Overall Study|Adverse Event|0
6257413|NCT02010567|9949556|FG001|Overall Study|Adverse Event|0
6257414|NCT02010567|9949557|FG002|Overall Study|Adverse Event|1
6257415|NCT02010567|9949558|FG003|Overall Study|Adverse Event|0
6257416|NCT02010567|9949559|FG004|Overall Study|Adverse Event|1
6257417|NCT02010632|9949569|FG000|Second Intervention (7 Days)|Withdrawal by Subject|1
6257418|NCT02010632|9949570|FG001|Second Intervention (7 Days)|Withdrawal by Subject|0
6271096|NCT02160145|9972645|FG002|Prerandomization Single-blind Period|Placebo run-in failure|0
6271097|NCT02160145|9972643|FG000|Prerandomization Single-blind Period|Tolvaptan titration/run-in failure|126
6271098|NCT02160145|9972644|FG001|Prerandomization Single-blind Period|Tolvaptan titration/run-in failure|0
6271099|NCT02160145|9972645|FG002|Prerandomization Single-blind Period|Tolvaptan titration/run-in failure|0
6271100|NCT02160145|9972643|FG000|Randomized Double-blind Period|Subject decision|0
6271101|NCT02160145|9972644|FG001|Randomized Double-blind Period|Subject decision|21
6271102|NCT02160145|9972645|FG002|Randomized Double-blind Period|Subject decision|20
6271103|NCT02160145|9972643|FG000|Randomized Double-blind Period|Lost to Follow-up|0
6271104|NCT02160145|9972644|FG001|Randomized Double-blind Period|Lost to Follow-up|1
6271105|NCT02160145|9972645|FG002|Randomized Double-blind Period|Lost to Follow-up|3
6271106|NCT02160145|9972643|FG000|Randomized Double-blind Period|Physician Decision|0
6271107|NCT02160145|9972644|FG001|Randomized Double-blind Period|Physician Decision|7
6271108|NCT02160145|9972645|FG002|Randomized Double-blind Period|Physician Decision|5
6271886|NCT02168803|9973923|FG000|Overall Study|Death|0
6271887|NCT02168803|9973924|FG001|Overall Study|Death|0
6271888|NCT02168803|9973925|FG002|Overall Study|Death|1
6271889|NCT02168803|9973923|FG000|Overall Study|Sponsor Decision|0
6271890|NCT02168803|9973924|FG001|Overall Study|Sponsor Decision|0
6271891|NCT02168803|9973925|FG002|Overall Study|Sponsor Decision|1
6271892|NCT02168816|9973942|FG000|Overall Study|Lost to Follow-up|2
6271893|NCT02168816|9973943|FG001|Overall Study|Lost to Follow-up|2
6271894|NCT02168842|9973951|FG000|Overall Study|Withdrawal by Subject|5
6271895|NCT02168842|9973952|FG001|Overall Study|Withdrawal by Subject|3
6271896|NCT02168842|9973951|FG000|Overall Study|Lost to Follow-up|0
6271897|NCT02168842|9973952|FG001|Overall Study|Lost to Follow-up|2
6271898|NCT02168842|9973951|FG000|Overall Study|Death|2
6271899|NCT02168842|9973952|FG001|Overall Study|Death|1
6271900|NCT02168842|9973951|FG000|Overall Study|Physician Decision|1
6271901|NCT02168842|9973952|FG001|Overall Study|Physician Decision|2
6271902|NCT02168946|9973981|FG000|Overall Study|Adverse Event|8
6271903|NCT02168946|9973982|FG001|Overall Study|Adverse Event|5
6271904|NCT02168946|9973981|FG000|Overall Study|Lost to Follow-up|3
6271905|NCT02168946|9973982|FG001|Overall Study|Lost to Follow-up|0
6271906|NCT02168946|9973981|FG000|Overall Study|Subject unable to come back for visits|1
6271907|NCT02168946|9973982|FG001|Overall Study|Subject unable to come back for visits|0
6257419|NCT02010684|9949582|FG000|Overall Study|Lost to Follow-up|8
6257420|NCT02010684|9949583|FG001|Overall Study|Lost to Follow-up|18
6257421|NCT02010684|9949582|FG000|Overall Study|Withdrawal by Subject|4
6257422|NCT02010684|9949583|FG001|Overall Study|Withdrawal by Subject|5
6257423|NCT02010775|9949607|FG000|Overall Study|Adverse Event|0
6257424|NCT02010775|9949608|FG001|Overall Study|Adverse Event|0
6257425|NCT02010775|9949609|FG002|Overall Study|Adverse Event|0
6257426|NCT02010775|9949610|FG003|Overall Study|Adverse Event|0
6257427|NCT02010775|9949611|FG004|Overall Study|Adverse Event|1
6257428|NCT02010775|9949607|FG000|Overall Study|Pregnancy|0
6257429|NCT02010775|9949608|FG001|Overall Study|Pregnancy|0
6257430|NCT02010775|9949609|FG002|Overall Study|Pregnancy|2
6257431|NCT02010775|9949610|FG003|Overall Study|Pregnancy|0
6257432|NCT02010775|9949611|FG004|Overall Study|Pregnancy|0
6257433|NCT02010775|9949607|FG000|Overall Study|Lost to Follow-up|2
6257434|NCT02010775|9949608|FG001|Overall Study|Lost to Follow-up|0
6257435|NCT02010775|9949609|FG002|Overall Study|Lost to Follow-up|0
6257436|NCT02010775|9949610|FG003|Overall Study|Lost to Follow-up|1
6257437|NCT02010775|9949611|FG004|Overall Study|Lost to Follow-up|1
6257438|NCT02010775|9949607|FG000|Overall Study|Personal Reasons|3
6257439|NCT02010775|9949608|FG001|Overall Study|Personal Reasons|3
6257440|NCT02010775|9949609|FG002|Overall Study|Personal Reasons|1
6257441|NCT02010775|9949610|FG003|Overall Study|Personal Reasons|2
6257442|NCT02010775|9949611|FG004|Overall Study|Personal Reasons|4
6257443|NCT02011113|9949636|FG000|Overall Study|Adverse Event|4
6257444|NCT02011113|9949636|FG000|Overall Study|Disease Progression (DP)|16
6257445|NCT02011113|9949636|FG000|Overall Study|Death|1
6257446|NCT02011113|9949636|FG000|Overall Study|Insufficient effect of Pomalidomide|1
6257447|NCT02011113|9949636|FG000|Overall Study|Investigator's judgement- DP|3
6257448|NCT02011113|9949636|FG000|Overall Study|Study terminated by sponsor|11
6257449|NCT02011386|9949641|FG000|Overall Study|Non-compliance|2
6257450|NCT02011386|9949641|FG000|Overall Study|Lack of Efficacy|3
6257451|NCT02011893|9949697|FG000|Enrollment to Randomization|Adverse Event|2
6257452|NCT02011893|9949698|FG001|Enrollment to Randomization|Adverse Event|0
6257453|NCT02011893|9949699|FG002|Enrollment to Randomization|Adverse Event|0
6257454|NCT02011893|9949697|FG000|Enrollment to Randomization|Physician Decision|10
6257455|NCT02011893|9949698|FG001|Enrollment to Randomization|Physician Decision|0
6257456|NCT02011893|9949699|FG002|Enrollment to Randomization|Physician Decision|0
6257457|NCT02011893|9949697|FG000|Enrollment to Randomization|Withdrawal by Subject|21
6257458|NCT02011893|9949698|FG001|Enrollment to Randomization|Withdrawal by Subject|0
6257459|NCT02011893|9949699|FG002|Enrollment to Randomization|Withdrawal by Subject|0
6257460|NCT02011893|9949697|FG000|Enrollment to Randomization|Screening Failure|29
6257461|NCT02011893|9949698|FG001|Enrollment to Randomization|Screening Failure|0
6257462|NCT02011893|9949699|FG002|Enrollment to Randomization|Screening Failure|0
6257463|NCT02011893|9949697|FG000|Enrollment to Randomization|Temporary Trial Stimulation Failure|9
6257464|NCT02011893|9949698|FG001|Enrollment to Randomization|Temporary Trial Stimulation Failure|0
6257465|NCT02011893|9949699|FG002|Enrollment to Randomization|Temporary Trial Stimulation Failure|0
6257466|NCT02011893|9949697|FG000|Enrollment to Randomization|Insurance/Financial Reasons|2
6257467|NCT02011893|9949698|FG001|Enrollment to Randomization|Insurance/Financial Reasons|0
6257468|NCT02011893|9949699|FG002|Enrollment to Randomization|Insurance/Financial Reasons|0
6257469|NCT02011893|9949697|FG000|Period 1 (Randomization to 12 Weeks)|Physician Decision|0
6257470|NCT02011893|9949698|FG001|Period 1 (Randomization to 12 Weeks)|Physician Decision|0
6257471|NCT02011893|9949699|FG002|Period 1 (Randomization to 12 Weeks)|Physician Decision|1
6257472|NCT02011893|9949697|FG000|Period 1 (Randomization to 12 Weeks)|Withdrawal by Subject|0
6257473|NCT02011893|9949698|FG001|Period 1 (Randomization to 12 Weeks)|Withdrawal by Subject|0
6257474|NCT02011893|9949699|FG002|Period 1 (Randomization to 12 Weeks)|Withdrawal by Subject|2
6257475|NCT02011893|9949697|FG000|Period 2 (12 Weeks to 24 Weeks)|Physician Decision|0
6257476|NCT02011893|9949698|FG001|Period 2 (12 Weeks to 24 Weeks)|Physician Decision|0
6257477|NCT02011893|9949699|FG002|Period 2 (12 Weeks to 24 Weeks)|Physician Decision|1
6257478|NCT02011945|9949707|FG000|Overall Study|Participant requested to Discontinue|0
6257479|NCT02011945|9949708|FG001|Overall Study|Participant requested to Discontinue|1
6257480|NCT02011945|9949709|FG002|Overall Study|Participant requested to Discontinue|1
6257481|NCT02011945|9949707|FG000|Overall Study|Adverse Event unrelated to Drug|0
6257482|NCT02011945|9949708|FG001|Overall Study|Adverse Event unrelated to Drug|2
6257483|NCT02011945|9949709|FG002|Overall Study|Adverse Event unrelated to Drug|1
6257484|NCT02011945|9949707|FG000|Overall Study|Study Drug Toxicity|0
6257485|NCT02011945|9949708|FG001|Overall Study|Study Drug Toxicity|0
6257486|NCT02011945|9949709|FG002|Overall Study|Study Drug Toxicity|1
6257487|NCT02011945|9949707|FG000|Overall Study|Treatment Failure|0
6257488|NCT02011945|9949708|FG001|Overall Study|Treatment Failure|7
6257489|NCT02011945|9949709|FG002|Overall Study|Treatment Failure|6
6257490|NCT02011945|9949707|FG000|Overall Study|No Longer Meets Study Criteria|1
6257491|NCT02011945|9949708|FG001|Overall Study|No Longer Meets Study Criteria|0
6257492|NCT02011945|9949709|FG002|Overall Study|No Longer Meets Study Criteria|0
6257493|NCT02011945|9949707|FG000|Overall Study|Proceeded to stem cell transplant|0
6257494|NCT02011945|9949708|FG001|Overall Study|Proceeded to stem cell transplant|0
6257495|NCT02011945|9949709|FG002|Overall Study|Proceeded to stem cell transplant|1
6257496|NCT02011945|9949707|FG000|Overall Study|Sub-Optimal Response to dasatinib|1
6257497|NCT02011945|9949708|FG001|Overall Study|Sub-Optimal Response to dasatinib|0
6257498|NCT02011945|9949709|FG002|Overall Study|Sub-Optimal Response to dasatinib|0
6257499|NCT02012218|9949731|FG000|Overall Study|Withdrawal by Subject|1
6257500|NCT02012218|9949732|FG001|Overall Study|Withdrawal by Subject|0
6257501|NCT02012218|9949733|FG002|Overall Study|Withdrawal by Subject|1
6257502|NCT02012218|9949734|FG003|Overall Study|Withdrawal by Subject|1
6257503|NCT02012218|9949735|FG004|Overall Study|Withdrawal by Subject|1
6257504|NCT02012218|9949731|FG000|Overall Study|Adverse Event|1
6257505|NCT02012218|9949732|FG001|Overall Study|Adverse Event|0
6257506|NCT02012218|9949733|FG002|Overall Study|Adverse Event|0
6257507|NCT02012218|9949734|FG003|Overall Study|Adverse Event|1
6257508|NCT02012218|9949735|FG004|Overall Study|Adverse Event|0
6257509|NCT02012218|9949731|FG000|Overall Study|Lost to Follow-up|0
6257510|NCT02012218|9949732|FG001|Overall Study|Lost to Follow-up|1
6257511|NCT02012218|9949733|FG002|Overall Study|Lost to Follow-up|1
6257512|NCT02012218|9949734|FG003|Overall Study|Lost to Follow-up|0
6257513|NCT02012218|9949735|FG004|Overall Study|Lost to Follow-up|0
6257514|NCT02012218|9949731|FG000|Overall Study|Protocol Specified|1
6257515|NCT02012218|9949732|FG001|Overall Study|Protocol Specified|0
6257516|NCT02012218|9949733|FG002|Overall Study|Protocol Specified|0
6257517|NCT02012218|9949734|FG003|Overall Study|Protocol Specified|0
6257518|NCT02012218|9949735|FG004|Overall Study|Protocol Specified|0
6257519|NCT02012218|9949731|FG000|Overall Study|Protocol Deviation|1
6257520|NCT02012218|9949732|FG001|Overall Study|Protocol Deviation|0
6257521|NCT02012218|9949733|FG002|Overall Study|Protocol Deviation|0
6257522|NCT02012218|9949734|FG003|Overall Study|Protocol Deviation|0
6257523|NCT02012218|9949735|FG004|Overall Study|Protocol Deviation|0
6257524|NCT02012452|9949776|FG000|Overall Study|Lost to Follow-up|2
6257525|NCT02012452|9949777|FG001|Overall Study|Lost to Follow-up|1
6257526|NCT02012452|9949776|FG000|Overall Study|Withdrawal by Subject|4
6257527|NCT02012452|9949777|FG001|Overall Study|Withdrawal by Subject|0
6257528|NCT02012491|9949785|FG000|Overall Study|Lost to Follow-up|1
6257529|NCT02012491|9949786|FG001|Overall Study|Lost to Follow-up|0
6257530|NCT02012491|9949785|FG000|Overall Study|Protocol Violation|0
6257531|NCT02012491|9949786|FG001|Overall Study|Protocol Violation|1
6257532|NCT02012491|9949785|FG000|Overall Study|Withdrawal by Subject|1
6257533|NCT02012491|9949786|FG001|Overall Study|Withdrawal by Subject|0
6257534|NCT02012686|9949815|FG000|Overall Study|muscle contraction|0
6257535|NCT02012686|9949816|FG001|Overall Study|muscle contraction|1
6257536|NCT02012686|9949815|FG000|Overall Study|electrocardiography monitoring noise|0
6257537|NCT02012686|9949816|FG001|Overall Study|electrocardiography monitoring noise|1
6257538|NCT02012959|9949822|FG000|Treatment Phase A|Adverse Event|2
6257539|NCT02012959|9949823|FG001|Treatment Phase A|Adverse Event|0
6257540|NCT02012959|9949824|FG002|Treatment Phase A|Adverse Event|0
6257541|NCT02012959|9949825|FG003|Treatment Phase A|Adverse Event|0
6257542|NCT02012959|9949826|FG004|Treatment Phase A|Adverse Event|0
6257543|NCT02013037|9949836|FG000|Overall Study|Death|6
6257544|NCT02013037|9949836|FG000|Overall Study|Withdrawal by Subject|1
6257545|NCT02013037|9949836|FG000|Overall Study|Awaiting Transplantation|7
6257546|NCT02013037|9949836|FG000|Overall Study|Transplanted without DSA|2
6257547|NCT02013206|9949869|FG000|Overall Study|Progressive disease (PD)|14
6257548|NCT02013206|9949870|FG001|Overall Study|Progressive disease (PD)|17
6257549|NCT02013206|9949869|FG000|Overall Study|Symptomatic deterioration|3
6257550|NCT02013206|9949870|FG001|Overall Study|Symptomatic deterioration|1
6257551|NCT02013206|9949869|FG000|Overall Study|Adverse Event|1
6257552|NCT02013206|9949870|FG001|Overall Study|Adverse Event|0
6257553|NCT02013206|9949869|FG000|Overall Study|Patient refusal|2
6257554|NCT02013206|9949870|FG001|Overall Study|Patient refusal|0
6257555|NCT02013206|9949869|FG000|Overall Study|Patient non-compliance|1
6257556|NCT02013206|9949870|FG001|Overall Study|Patient non-compliance|0
6257557|NCT02013206|9949869|FG000|Overall Study|Death|1
6257558|NCT02013206|9949870|FG001|Overall Study|Death|2
6257559|NCT02013206|9949869|FG000|Overall Study|Other reasons off treatment|5
6257560|NCT02013206|9949870|FG001|Overall Study|Other reasons off treatment|2
6257561|NCT02013375|9949893|FG000|Overall Study|Did not engraft|1
6257562|NCT02013375|9949893|FG000|Overall Study|Did not engraft|1
6257563|NCT02013388|9949906|FG000|Overall Study|work emergency|1
6257564|NCT02013388|9949907|FG001|Overall Study|work emergency|0
6257565|NCT02013388|9949908|FG002|Overall Study|work emergency|0
6257566|NCT02013388|9949909|FG003|Overall Study|work emergency|0
6257567|NCT02013388|9949910|FG004|Overall Study|work emergency|1
6257568|NCT02013388|9949911|FG005|Overall Study|work emergency|0
6257569|NCT02013388|9949912|FG006|Overall Study|work emergency|0
6257570|NCT02013388|9949913|FG007|Overall Study|work emergency|0
6257571|NCT02013531|9949935|FG000|Overall Study|Lost to Follow-up|3
6257572|NCT02013531|9949935|FG000|Overall Study|Met Withdrawal Criteria|1
6257573|NCT02013531|9949935|FG000|Overall Study|Withdrawal by Subject|1
6257574|NCT02013544|9949941|FG000|Overall Study|Adverse Event|5
6257575|NCT02013544|9949942|FG001|Overall Study|Adverse Event|5
6257576|NCT02013544|9949941|FG000|Overall Study|Lost to Follow-up|2
6257577|NCT02013544|9949942|FG001|Overall Study|Lost to Follow-up|3
6257578|NCT02013544|9949941|FG000|Overall Study|Withdrawal by Subject|2
6257579|NCT02013544|9949942|FG001|Overall Study|Withdrawal by Subject|8
6257580|NCT02013544|9949941|FG000|Overall Study|Physician Decision|0
6257581|NCT02013544|9949942|FG001|Overall Study|Physician Decision|1
6257582|NCT02013544|9949941|FG000|Overall Study|Entry criteria not met/non-compliance|2
6257583|NCT02013544|9949942|FG001|Overall Study|Entry criteria not met/non-compliance|3
6257584|NCT02013609|9949948|FG000|Overall Study|Withdrawal by Subject|9
6257585|NCT02013609|9949948|FG000|Overall Study|Lost to Follow-up|3
6257586|NCT02013609|9949948|FG000|Overall Study|Adverse Event|3
6257587|NCT02013609|9949948|FG000|Overall Study|Met Withdrawal Criteria|3
6257588|NCT02013622|9949952|FG000|Overall Study|Lost to Follow-up|10
6257589|NCT02013622|9949952|FG000|Overall Study|Adverse Event|3
6257590|NCT02013622|9949952|FG000|Overall Study|Met Withdrawal Criteria|3
6257591|NCT02013622|9949952|FG000|Overall Study|Withdrawal by Subject|6
6257592|NCT02013622|9949952|FG000|Overall Study|Protocol Deviation|1
6257593|NCT02013622|9949952|FG000|Overall Study|Lack of Efficacy|1
6257594|NCT02013674|9949958|FG000|Overall Study|Death|0
6257595|NCT02013674|9949959|FG001|Overall Study|Death|1
6257596|NCT02013674|9949958|FG000|Overall Study|Lost to Follow-up|1
6257597|NCT02013674|9949959|FG001|Overall Study|Lost to Follow-up|0
6257598|NCT02013687|9949969|FG000|Overall Study|Lost to Follow-up|0
6257599|NCT02013687|9949970|FG001|Overall Study|Lost to Follow-up|0
6257600|NCT02013687|9949971|FG002|Overall Study|Lost to Follow-up|1
6257601|NCT02013687|9949972|FG003|Overall Study|Lost to Follow-up|0
6257602|NCT02013687|9949969|FG000|Overall Study|Protocol Violation|0
6257603|NCT02013687|9949970|FG001|Overall Study|Protocol Violation|0
6257604|NCT02013687|9949971|FG002|Overall Study|Protocol Violation|0
6257605|NCT02013687|9949972|FG003|Overall Study|Protocol Violation|1
6257606|NCT02013687|9949969|FG000|Overall Study|Withdrawal by Subject|0
6257607|NCT02013687|9949970|FG001|Overall Study|Withdrawal by Subject|0
6257608|NCT02013687|9949971|FG002|Overall Study|Withdrawal by Subject|0
6257609|NCT02013687|9949972|FG003|Overall Study|Withdrawal by Subject|1
6257610|NCT02013687|9949969|FG000|Overall Study|Missed visits due to patient travel|0
6257611|NCT02013687|9949970|FG001|Overall Study|Missed visits due to patient travel|0
6257612|NCT02013687|9949971|FG002|Overall Study|Missed visits due to patient travel|1
6257613|NCT02013687|9949972|FG003|Overall Study|Missed visits due to patient travel|0
6257614|NCT02013765|9949986|FG000|Overall Study|Trial was terminated by sponsor|1
6257615|NCT02013778|9949990|FG000|Overall Study|Death|4
6257616|NCT02013778|9949990|FG000|Overall Study|Withdrawal by Subject|1
6257617|NCT02013778|9949990|FG000|Overall Study|Physician Decision|1
6257618|NCT02013778|9949990|FG000|Overall Study|Adverse Event|1
6257619|NCT02013791|9950003|FG000|Period 1|Lost to Follow-up|0
6257620|NCT02013791|9950004|FG001|Period 1|Lost to Follow-up|0
6257621|NCT02013791|9950005|FG002|Period 1|Lost to Follow-up|0
6257622|NCT02013791|9950006|FG003|Period 1|Lost to Follow-up|1
6257623|NCT02013791|9950007|FG004|Period 1|Lost to Follow-up|0
6257624|NCT02013791|9950008|FG005|Period 1|Lost to Follow-up|0
6257625|NCT02013791|9950009|FG006|Period 1|Lost to Follow-up|1
6257626|NCT02013791|9950010|FG007|Period 1|Lost to Follow-up|1
6257627|NCT02013791|9950011|FG008|Period 1|Lost to Follow-up|0
6257628|NCT02013791|9950003|FG000|Period 1|Other Miscellaneous Reasons|0
6257629|NCT02013791|9950004|FG001|Period 1|Other Miscellaneous Reasons|2
6257630|NCT02013791|9950005|FG002|Period 1|Other Miscellaneous Reasons|0
6257631|NCT02013791|9950006|FG003|Period 1|Other Miscellaneous Reasons|0
6257632|NCT02013791|9950007|FG004|Period 1|Other Miscellaneous Reasons|0
6257633|NCT02013791|9950008|FG005|Period 1|Other Miscellaneous Reasons|0
6257634|NCT02013791|9950009|FG006|Period 1|Other Miscellaneous Reasons|0
6257635|NCT02013791|9950010|FG007|Period 1|Other Miscellaneous Reasons|0
6257636|NCT02013791|9950011|FG008|Period 1|Other Miscellaneous Reasons|0
6257637|NCT02013817|9950032|FG000|Overall Study|Adverse Event|12
6257638|NCT02013817|9950032|FG000|Overall Study|Withdrawal by Subject|4
6257639|NCT02013817|9950032|FG000|Overall Study|Death|2
6257640|NCT02013817|9950032|FG000|Overall Study|Other|9
6257641|NCT02013830|9950036|FG000|Overall Study|Adverse Event|3
6257642|NCT02013830|9950036|FG000|Overall Study|Death|1
6257643|NCT02013830|9950036|FG000|Overall Study|Insufficient therapeutic response|25
6257644|NCT02013830|9950036|FG000|Overall Study|Refused treatment|1
6257645|NCT02014116|9950057|FG000|Overall Study|Progressive Disease|3
6257646|NCT02014116|9950058|FG001|Overall Study|Progressive Disease|4
6257647|NCT02014116|9950059|FG002|Overall Study|Progressive Disease|2
6257648|NCT02014116|9950060|FG003|Overall Study|Progressive Disease|6
6257649|NCT02014116|9950061|FG004|Overall Study|Progressive Disease|1
6257650|NCT02014116|9950062|FG005|Overall Study|Progressive Disease|13
6257651|NCT02014116|9950063|FG006|Overall Study|Progressive Disease|1
6257652|NCT02014116|9950064|FG007|Overall Study|Progressive Disease|3
6257653|NCT02014116|9950065|FG008|Overall Study|Progressive Disease|7
6257654|NCT02014116|9950057|FG000|Overall Study|Adverse Event|0
6257655|NCT02014116|9950058|FG001|Overall Study|Adverse Event|0
6257656|NCT02014116|9950059|FG002|Overall Study|Adverse Event|0
6257657|NCT02014116|9950060|FG003|Overall Study|Adverse Event|0
6257658|NCT02014116|9950061|FG004|Overall Study|Adverse Event|1
6257659|NCT02014116|9950062|FG005|Overall Study|Adverse Event|0
6257660|NCT02014116|9950063|FG006|Overall Study|Adverse Event|0
6257661|NCT02014116|9950064|FG007|Overall Study|Adverse Event|1
6257662|NCT02014116|9950065|FG008|Overall Study|Adverse Event|0
6257663|NCT02014116|9950057|FG000|Overall Study|Lost to Follow-up|0
6257664|NCT02014116|9950058|FG001|Overall Study|Lost to Follow-up|0
6257665|NCT02014116|9950059|FG002|Overall Study|Lost to Follow-up|0
6257666|NCT02014116|9950060|FG003|Overall Study|Lost to Follow-up|0
6257667|NCT02014116|9950061|FG004|Overall Study|Lost to Follow-up|0
6257668|NCT02014116|9950062|FG005|Overall Study|Lost to Follow-up|1
6257669|NCT02014116|9950063|FG006|Overall Study|Lost to Follow-up|0
6257670|NCT02014116|9950064|FG007|Overall Study|Lost to Follow-up|0
6257671|NCT02014116|9950065|FG008|Overall Study|Lost to Follow-up|1
6257672|NCT02014116|9950057|FG000|Overall Study|Death|0
6257673|NCT02014116|9950058|FG001|Overall Study|Death|0
6257674|NCT02014116|9950059|FG002|Overall Study|Death|0
6257675|NCT02014116|9950060|FG003|Overall Study|Death|0
6257676|NCT02014116|9950061|FG004|Overall Study|Death|0
6257677|NCT02014116|9950062|FG005|Overall Study|Death|0
6257678|NCT02014116|9950063|FG006|Overall Study|Death|0
6257679|NCT02014116|9950064|FG007|Overall Study|Death|1
6257680|NCT02014116|9950065|FG008|Overall Study|Death|1
6257681|NCT02014116|9950057|FG000|Overall Study|Withdrawal by Subject|0
6257682|NCT02014116|9950058|FG001|Overall Study|Withdrawal by Subject|0
6257683|NCT02014116|9950059|FG002|Overall Study|Withdrawal by Subject|1
6257684|NCT02014116|9950060|FG003|Overall Study|Withdrawal by Subject|1
6257685|NCT02014116|9950061|FG004|Overall Study|Withdrawal by Subject|0
6257686|NCT02014116|9950062|FG005|Overall Study|Withdrawal by Subject|1
6257687|NCT02014116|9950063|FG006|Overall Study|Withdrawal by Subject|0
6257688|NCT02014116|9950064|FG007|Overall Study|Withdrawal by Subject|0
6257689|NCT02014116|9950065|FG008|Overall Study|Withdrawal by Subject|0
6257690|NCT02014116|9950057|FG000|Overall Study|Withdrawal Caregiver Decision|0
6257691|NCT02014116|9950058|FG001|Overall Study|Withdrawal Caregiver Decision|0
6257692|NCT02014116|9950059|FG002|Overall Study|Withdrawal Caregiver Decision|0
6257693|NCT02014116|9950060|FG003|Overall Study|Withdrawal Caregiver Decision|0
6257694|NCT02014116|9950061|FG004|Overall Study|Withdrawal Caregiver Decision|0
6257695|NCT02014116|9950062|FG005|Overall Study|Withdrawal Caregiver Decision|1
6257696|NCT02014116|9950063|FG006|Overall Study|Withdrawal Caregiver Decision|0
6257697|NCT02014116|9950064|FG007|Overall Study|Withdrawal Caregiver Decision|0
6257698|NCT02014116|9950065|FG008|Overall Study|Withdrawal Caregiver Decision|0
6257699|NCT02014116|9950057|FG000|Overall Study|Physician Decision|0
6257700|NCT02014116|9950058|FG001|Overall Study|Physician Decision|0
6257701|NCT02014116|9950059|FG002|Overall Study|Physician Decision|0
6257702|NCT02014116|9950060|FG003|Overall Study|Physician Decision|0
6257703|NCT02014116|9950061|FG004|Overall Study|Physician Decision|0
6257704|NCT02014116|9950062|FG005|Overall Study|Physician Decision|0
6257705|NCT02014116|9950063|FG006|Overall Study|Physician Decision|0
6257706|NCT02014116|9950064|FG007|Overall Study|Physician Decision|0
6257707|NCT02014116|9950065|FG008|Overall Study|Physician Decision|1
6257708|NCT02014272|9950101|FG000|Intervention Period 1|Withdrawal by Subject|1
6257709|NCT02014272|9950102|FG001|Intervention Period 1|Withdrawal by Subject|0
6257710|NCT02014272|9950101|FG000|Intervention Period 1|Adverse Event|0
6257711|NCT02014272|9950102|FG001|Intervention Period 1|Adverse Event|1
6257712|NCT02014376|9950124|FG000|Overall Study|Adverse Event|1
6257713|NCT02014376|9950125|FG001|Overall Study|Adverse Event|1
6257714|NCT02014376|9950126|FG002|Overall Study|Adverse Event|0
6257715|NCT02014376|9950124|FG000|Overall Study|Lost to Follow-up|2
6257716|NCT02014376|9950125|FG001|Overall Study|Lost to Follow-up|0
6257717|NCT02014376|9950126|FG002|Overall Study|Lost to Follow-up|0
6257718|NCT02014402|9950138|FG000|Overall Study|Adverse Event|1
6257719|NCT02014402|9950139|FG001|Overall Study|Adverse Event|0
6257720|NCT02014402|9950140|FG002|Overall Study|Adverse Event|0
6257721|NCT02014402|9950141|FG003|Overall Study|Adverse Event|0
6257722|NCT02014402|9950138|FG000|Overall Study|Withdrawal by Subject|1
6257723|NCT02014402|9950139|FG001|Overall Study|Withdrawal by Subject|2
6257724|NCT02014402|9950140|FG002|Overall Study|Withdrawal by Subject|2
6257725|NCT02014402|9950141|FG003|Overall Study|Withdrawal by Subject|1
6257726|NCT02014402|9950138|FG000|Overall Study|Subject did not have transportation|0
6257727|NCT02014402|9950139|FG001|Overall Study|Subject did not have transportation|1
6257728|NCT02014402|9950140|FG002|Overall Study|Subject did not have transportation|0
6257729|NCT02014402|9950141|FG003|Overall Study|Subject did not have transportation|0
6257730|NCT02014402|9950138|FG000|Overall Study|Lost to Follow-up|0
6257731|NCT02014402|9950139|FG001|Overall Study|Lost to Follow-up|0
6257732|NCT02014402|9950140|FG002|Overall Study|Lost to Follow-up|1
6257733|NCT02014402|9950141|FG003|Overall Study|Lost to Follow-up|2
6257734|NCT02014441|9950158|FG000|Overall Study|Withdrawal by Subject|12
6190919|NCT01417000|9847414|FG000|Overall Study|Death|59
6190920|NCT01417000|9847415|FG001|Overall Study|Death|28
6190921|NCT01417000|9847414|FG000|Overall Study|Lost to Follow-up|1
6190922|NCT01417000|9847415|FG001|Overall Study|Lost to Follow-up|0
6190923|NCT01417000|9847414|FG000|Overall Study|Study Terminated by Sponsor|1
6190924|NCT01417000|9847415|FG001|Overall Study|Study Terminated by Sponsor|1
6190925|NCT01417078|9847430|FG000|Overall Study|Withdrawal by Subject|1
6190926|NCT01417104|9847438|FG000|Overall Study|Withdrawal by Subject|5
6190927|NCT01417104|9847439|FG001|Overall Study|Withdrawal by Subject|1
6190928|NCT01417104|9847438|FG000|Overall Study|Failure to make contact|0
6190929|NCT01417104|9847439|FG001|Overall Study|Failure to make contact|1
6190930|NCT01417104|9847438|FG000|Overall Study|Adverse Event|1
6190931|NCT01417104|9847439|FG001|Overall Study|Adverse Event|0
6190932|NCT01417156|9847445|FG000|Overall Study|Adverse Event|12
6257735|NCT02014467|9950166|FG000|Overall Study|Adverse Event|4
6257736|NCT02014467|9950167|FG001|Overall Study|Adverse Event|0
6257737|NCT02014467|9950166|FG000|Overall Study|Protocol Violation|3
6257738|NCT02014467|9950167|FG001|Overall Study|Protocol Violation|0
6257739|NCT02014467|9950166|FG000|Overall Study|Physician Decision|2
6257740|NCT02014467|9950167|FG001|Overall Study|Physician Decision|3
6257741|NCT02014467|9950166|FG000|Overall Study|Withdrawal by Subject|16
6257742|NCT02014467|9950167|FG001|Overall Study|Withdrawal by Subject|4
6257743|NCT02014480|9950173|FG000|Treatment Period 1 (14 Days)|Lack of Efficacy|0
6257744|NCT02014480|9950174|FG001|Treatment Period 1 (14 Days)|Lack of Efficacy|0
6257745|NCT02014480|9950175|FG002|Treatment Period 1 (14 Days)|Lack of Efficacy|1
6257746|NCT02014480|9950176|FG003|Treatment Period 1 (14 Days)|Lack of Efficacy|0
6257747|NCT02014480|9950177|FG004|Treatment Period 1 (14 Days)|Lack of Efficacy|0
6257748|NCT02014480|9950178|FG005|Treatment Period 1 (14 Days)|Lack of Efficacy|0
6257749|NCT02014480|9950173|FG000|Treatment Period 1 (14 Days)|Withdrawal by Subject|0
6257750|NCT02014480|9950174|FG001|Treatment Period 1 (14 Days)|Withdrawal by Subject|1
6257751|NCT02014480|9950175|FG002|Treatment Period 1 (14 Days)|Withdrawal by Subject|0
6257752|NCT02014480|9950176|FG003|Treatment Period 1 (14 Days)|Withdrawal by Subject|2
6257753|NCT02014480|9950177|FG004|Treatment Period 1 (14 Days)|Withdrawal by Subject|1
6257754|NCT02014480|9950178|FG005|Treatment Period 1 (14 Days)|Withdrawal by Subject|0
6257755|NCT02014480|9950173|FG000|Washout Period 1 (10 to 14 Days)|Lack of Efficacy|0
6257756|NCT02014480|9950174|FG001|Washout Period 1 (10 to 14 Days)|Lack of Efficacy|0
6086658|NCT00662649|9696709|FG000|Extension Study (Month 24 to 60)|Lost to Follow-up|2
6257757|NCT02014480|9950175|FG002|Washout Period 1 (10 to 14 Days)|Lack of Efficacy|1
6257758|NCT02014480|9950176|FG003|Washout Period 1 (10 to 14 Days)|Lack of Efficacy|0
6257759|NCT02014480|9950177|FG004|Washout Period 1 (10 to 14 Days)|Lack of Efficacy|0
6257760|NCT02014480|9950178|FG005|Washout Period 1 (10 to 14 Days)|Lack of Efficacy|0
6257761|NCT02014480|9950173|FG000|Treatment Period 2 (14 Days)|Protocol Violation|1
6043738|NCT00391846|9642516|FG000|Overall Study|Developed study specific DC criteria|0
6043739|NCT00391846|9642517|FG001|Overall Study|Developed study specific DC criteria|1
6043740|NCT00391872|9642525|FG000|Overall Study|Protocol Violation|7
6043741|NCT00391872|9642526|FG001|Overall Study|Protocol Violation|2
6043742|NCT00391872|9642525|FG000|Overall Study|Withdrawal by Subject|296
6043743|NCT00391872|9642526|FG001|Overall Study|Withdrawal by Subject|249
6043744|NCT00391872|9642525|FG000|Overall Study|Reason unknown|2
6257762|NCT02014480|9950174|FG001|Treatment Period 2 (14 Days)|Protocol Violation|1
6257763|NCT02014480|9950175|FG002|Treatment Period 2 (14 Days)|Protocol Violation|2
6257764|NCT02014480|9950176|FG003|Treatment Period 2 (14 Days)|Protocol Violation|1
6257765|NCT02014480|9950177|FG004|Treatment Period 2 (14 Days)|Protocol Violation|0
6257766|NCT02014480|9950178|FG005|Treatment Period 2 (14 Days)|Protocol Violation|0
6257767|NCT02014480|9950173|FG000|Treatment Period 3 (14 Days)|Withdrawal by Subject|0
6257768|NCT02014480|9950174|FG001|Treatment Period 3 (14 Days)|Withdrawal by Subject|1
6257769|NCT02014480|9950175|FG002|Treatment Period 3 (14 Days)|Withdrawal by Subject|0
6257770|NCT02014480|9950176|FG003|Treatment Period 3 (14 Days)|Withdrawal by Subject|0
6257771|NCT02014480|9950177|FG004|Treatment Period 3 (14 Days)|Withdrawal by Subject|0
6257772|NCT02014480|9950178|FG005|Treatment Period 3 (14 Days)|Withdrawal by Subject|0
6257773|NCT02014480|9950173|FG000|Treatment Period 3 (14 Days)|Adverse Event|0
6257774|NCT02014480|9950174|FG001|Treatment Period 3 (14 Days)|Adverse Event|0
6257775|NCT02014480|9950175|FG002|Treatment Period 3 (14 Days)|Adverse Event|1
6257776|NCT02014480|9950176|FG003|Treatment Period 3 (14 Days)|Adverse Event|0
6257777|NCT02014480|9950177|FG004|Treatment Period 3 (14 Days)|Adverse Event|0
6257778|NCT02014480|9950178|FG005|Treatment Period 3 (14 Days)|Adverse Event|1
6257779|NCT02014480|9950173|FG000|Treatment Period 3 (14 Days)|Lack of Efficacy|0
6257780|NCT02014480|9950174|FG001|Treatment Period 3 (14 Days)|Lack of Efficacy|0
6257781|NCT02014480|9950175|FG002|Treatment Period 3 (14 Days)|Lack of Efficacy|0
6257782|NCT02014480|9950176|FG003|Treatment Period 3 (14 Days)|Lack of Efficacy|0
6257783|NCT02014480|9950177|FG004|Treatment Period 3 (14 Days)|Lack of Efficacy|0
6257784|NCT02014480|9950178|FG005|Treatment Period 3 (14 Days)|Lack of Efficacy|1
6257785|NCT02014584|9950200|FG000|Double-Blind Period (24 Weeks)|Protocol Violation|0
6257786|NCT02014584|9950201|FG001|Double-Blind Period (24 Weeks)|Protocol Violation|1
6257787|NCT02014584|9950202|FG002|Double-Blind Period (24 Weeks)|Protocol Violation|0
6257788|NCT02014584|9950203|FG003|Double-Blind Period (24 Weeks)|Protocol Violation|0
6257789|NCT02014584|9950204|FG004|Double-Blind Period (24 Weeks)|Protocol Violation|0
6257790|NCT02014584|9950205|FG005|Double-Blind Period (24 Weeks)|Protocol Violation|0
6257791|NCT02014584|9950200|FG000|Double-Blind Period (24 Weeks)|Withdrawal by Subject|2
6257792|NCT02014584|9950201|FG001|Double-Blind Period (24 Weeks)|Withdrawal by Subject|5
6257793|NCT02014584|9950202|FG002|Double-Blind Period (24 Weeks)|Withdrawal by Subject|0
6257794|NCT02014584|9950203|FG003|Double-Blind Period (24 Weeks)|Withdrawal by Subject|0
6257795|NCT02014584|9950204|FG004|Double-Blind Period (24 Weeks)|Withdrawal by Subject|0
6257796|NCT02014584|9950205|FG005|Double-Blind Period (24 Weeks)|Withdrawal by Subject|0
6257797|NCT02014584|9950200|FG000|Open-Label Period (24 Weeks)|Lost to Follow-up|0
6257798|NCT02014584|9950201|FG001|Open-Label Period (24 Weeks)|Lost to Follow-up|0
6257799|NCT02014584|9950202|FG002|Open-Label Period (24 Weeks)|Lost to Follow-up|2
6257800|NCT02014584|9950203|FG003|Open-Label Period (24 Weeks)|Lost to Follow-up|0
6257801|NCT02014584|9950204|FG004|Open-Label Period (24 Weeks)|Lost to Follow-up|0
6257802|NCT02014584|9950205|FG005|Open-Label Period (24 Weeks)|Lost to Follow-up|0
6043745|NCT00391872|9642526|FG001|Overall Study|Reason unknown|4
6043746|NCT00391872|9642525|FG000|Overall Study|Lost to Follow-up|2
6043747|NCT00391872|9642526|FG001|Overall Study|Lost to Follow-up|0
6257803|NCT02014584|9950200|FG000|Open-Label Period (24 Weeks)|Withdrawal by Subject|0
6257804|NCT02014584|9950201|FG001|Open-Label Period (24 Weeks)|Withdrawal by Subject|0
6257805|NCT02014584|9950202|FG002|Open-Label Period (24 Weeks)|Withdrawal by Subject|3
6257806|NCT02014584|9950203|FG003|Open-Label Period (24 Weeks)|Withdrawal by Subject|1
6257807|NCT02014584|9950204|FG004|Open-Label Period (24 Weeks)|Withdrawal by Subject|0
6257808|NCT02014584|9950205|FG005|Open-Label Period (24 Weeks)|Withdrawal by Subject|0
6257809|NCT02014584|9950200|FG000|Target Follow-up (F/U) Period (24 Weeks)|Withdrawal by Subject|0
6257810|NCT02014584|9950201|FG001|Target Follow-up (F/U) Period (24 Weeks)|Withdrawal by Subject|0
6257811|NCT02014584|9950202|FG002|Target Follow-up (F/U) Period (24 Weeks)|Withdrawal by Subject|0
6257812|NCT02014584|9950203|FG003|Target Follow-up (F/U) Period (24 Weeks)|Withdrawal by Subject|0
6257813|NCT02014584|9950204|FG004|Target Follow-up (F/U) Period (24 Weeks)|Withdrawal by Subject|1
6257814|NCT02014584|9950205|FG005|Target Follow-up (F/U) Period (24 Weeks)|Withdrawal by Subject|0
6257815|NCT02014597|9950219|FG000|Overall Study|Unable to record log contrast sensitivity|2
6257816|NCT02014597|9950220|FG001|Overall Study|Unable to record log contrast sensitivity|1
6257817|NCT02014740|9950228|FG000|Overall Study|Lost to Follow-up|4
6257818|NCT02014740|9950229|FG001|Overall Study|Lost to Follow-up|4
6257819|NCT02014740|9950228|FG000|Overall Study|Withdrawal by Subject|2
6257820|NCT02014740|9950229|FG001|Overall Study|Withdrawal by Subject|1
6257821|NCT02015039|9950237|FG000|Overall Study|Not eligible|0
6257822|NCT02015039|9950238|FG001|Overall Study|Not eligible|1
6257823|NCT02015065|9950247|FG000|Overall Study|Death on study|1
6257824|NCT02015065|9950248|FG001|Overall Study|Death on study|2
6257825|NCT02015065|9950249|FG002|Overall Study|Death on study|1
6257826|NCT02015104|9950259|FG000|Overall Study|Withdrew consent after first dose drug|1
6257827|NCT02015104|9950260|FG001|Overall Study|Withdrew consent after first dose drug|0
6257828|NCT02015104|9950259|FG000|Overall Study|Withdrew consent prior to treatment|0
6257829|NCT02015104|9950260|FG001|Overall Study|Withdrew consent prior to treatment|1
6257830|NCT02015195|9950276|FG000|Overall Study|Adverse Event|0
6257831|NCT02015195|9950277|FG001|Overall Study|Adverse Event|0
6257832|NCT02015195|9950278|FG002|Overall Study|Adverse Event|0
6257833|NCT02015195|9950279|FG003|Overall Study|Adverse Event|1
6257834|NCT02015195|9950280|FG004|Overall Study|Adverse Event|0
6257835|NCT02015195|9950281|FG005|Overall Study|Adverse Event|0
6257836|NCT02015195|9950282|FG006|Overall Study|Adverse Event|0
6257837|NCT02015221|9950299|FG000|Overall Study|Withdrawal by Subject|8
6257838|NCT02015221|9950300|FG001|Overall Study|Withdrawal by Subject|6
6257839|NCT02015221|9950299|FG000|Overall Study|Lost to Follow-up|1
6257840|NCT02015221|9950300|FG001|Overall Study|Lost to Follow-up|0
6257841|NCT02015390|9950319|FG000|Overall Study|Lost to Follow-up|1
6257842|NCT02015390|9950320|FG001|Overall Study|Lost to Follow-up|0
6257843|NCT02015390|9950319|FG000|Overall Study|Adverse Event|0
6257844|NCT02015390|9950320|FG001|Overall Study|Adverse Event|3
6257845|NCT02015390|9950319|FG000|Overall Study|Physician Decision|0
6257846|NCT02015390|9950320|FG001|Overall Study|Physician Decision|1
6257847|NCT02015481|9950334|FG000|Overall Study|Death|1
6257848|NCT02015520|9950343|FG000|Overall Study|Lack of Efficacy|1
6257849|NCT02015520|9950344|FG001|Overall Study|Lack of Efficacy|0
6257850|NCT02015520|9950345|FG002|Overall Study|Lack of Efficacy|3
6257851|NCT02015520|9950346|FG003|Overall Study|Lack of Efficacy|2
6257852|NCT02015520|9950343|FG000|Overall Study|Adverse Event|0
6257853|NCT02015520|9950344|FG001|Overall Study|Adverse Event|0
6257854|NCT02015520|9950345|FG002|Overall Study|Adverse Event|0
6257855|NCT02015520|9950346|FG003|Overall Study|Adverse Event|1
6257856|NCT02015520|9950343|FG000|Overall Study|Withdrawal by Subject|2
6257857|NCT02015520|9950344|FG001|Overall Study|Withdrawal by Subject|2
6257858|NCT02015520|9950345|FG002|Overall Study|Withdrawal by Subject|1
6257859|NCT02015520|9950346|FG003|Overall Study|Withdrawal by Subject|0
6257860|NCT02015520|9950343|FG000|Overall Study|Death|1
6257861|NCT02015520|9950344|FG001|Overall Study|Death|0
6257862|NCT02015520|9950345|FG002|Overall Study|Death|0
6257863|NCT02015520|9950346|FG003|Overall Study|Death|0
6257864|NCT02015520|9950343|FG000|Overall Study|Lost to Follow-up|0
6257865|NCT02015520|9950344|FG001|Overall Study|Lost to Follow-up|0
6257866|NCT02015520|9950345|FG002|Overall Study|Lost to Follow-up|1
6257867|NCT02015520|9950346|FG003|Overall Study|Lost to Follow-up|0
6257868|NCT02015520|9950343|FG000|Overall Study|Subject Request to Discontinue Study Treatment|1
6257869|NCT02015520|9950344|FG001|Overall Study|Subject Request to Discontinue Study Treatment|1
6257870|NCT02015520|9950345|FG002|Overall Study|Subject Request to Discontinue Study Treatment|2
6257871|NCT02015520|9950346|FG003|Overall Study|Subject Request to Discontinue Study Treatment|1
6257872|NCT02015520|9950343|FG000|Overall Study|Subject no Longer Meets Study Criteria|0
6257873|NCT02015520|9950344|FG001|Overall Study|Subject no Longer Meets Study Criteria|1
6257874|NCT02015520|9950345|FG002|Overall Study|Subject no Longer Meets Study Criteria|0
6257875|NCT02015520|9950346|FG003|Overall Study|Subject no Longer Meets Study Criteria|0
6257876|NCT02015546|9950359|FG000|Overall Study|Withdrawal by Subject|1
6257877|NCT02015546|9950360|FG001|Overall Study|Withdrawal by Subject|1
6257878|NCT02015546|9950361|FG002|Overall Study|Withdrawal by Subject|1
6257879|NCT02015546|9950359|FG000|Overall Study|Screem Failure|2
6257880|NCT02015546|9950360|FG001|Overall Study|Screem Failure|1
6257881|NCT02015546|9950361|FG002|Overall Study|Screem Failure|3
6257882|NCT02015637|9950371|FG000|Overall Study|Lost to Follow-up|3
6257883|NCT02015637|9950372|FG001|Overall Study|Lost to Follow-up|5
6257884|NCT02015637|9950371|FG000|Overall Study|Adverse Event|3
6257885|NCT02015637|9950372|FG001|Overall Study|Adverse Event|0
6257886|NCT02015637|9950371|FG000|Overall Study|Did not take study drug|2
6257887|NCT02015637|9950372|FG001|Overall Study|Did not take study drug|0
6257888|NCT02015676|9950381|FG000|Overall Study|Adverse Event|2
6257889|NCT02015676|9950382|FG001|Overall Study|Adverse Event|18
6257890|NCT02015676|9950383|FG002|Overall Study|Adverse Event|0
6257891|NCT02015676|9950381|FG000|Overall Study|Lack of Efficacy|2
6257892|NCT02015676|9950382|FG001|Overall Study|Lack of Efficacy|4
6257893|NCT02015676|9950383|FG002|Overall Study|Lack of Efficacy|0
6257894|NCT02015676|9950381|FG000|Overall Study|Protocol Violation|1
6257895|NCT02015676|9950382|FG001|Overall Study|Protocol Violation|0
6257896|NCT02015676|9950383|FG002|Overall Study|Protocol Violation|0
6257897|NCT02015676|9950381|FG000|Overall Study|Withdrawal by Subject|1
6257898|NCT02015676|9950382|FG001|Overall Study|Withdrawal by Subject|7
6257899|NCT02015676|9950383|FG002|Overall Study|Withdrawal by Subject|1
6257900|NCT02015676|9950381|FG000|Overall Study|Administrative reasons|0
6257901|NCT02015676|9950382|FG001|Overall Study|Administrative reasons|3
6257902|NCT02015676|9950383|FG002|Overall Study|Administrative reasons|1
6257903|NCT02015676|9950381|FG000|Overall Study|Death|0
6257904|NCT02015676|9950382|FG001|Overall Study|Death|1
6257905|NCT02015676|9950383|FG002|Overall Study|Death|0
6257906|NCT02015676|9950381|FG000|Overall Study|Disease progression|3
6257907|NCT02015676|9950382|FG001|Overall Study|Disease progression|1
6257908|NCT02015676|9950383|FG002|Overall Study|Disease progression|1
6257909|NCT02015754|9950387|FG000|Overall Study|Disease progression|5
6257910|NCT02015754|9950387|FG000|Overall Study|Change in treatment modality|5
6257911|NCT02015754|9950387|FG000|Overall Study|Lost to Follow-up|1
6257912|NCT02015793|9950393|FG000|Overall Study|Adverse Event|3
6257913|NCT02015793|9950394|FG001|Overall Study|Adverse Event|3
6257914|NCT02015793|9950393|FG000|Overall Study|Withdrawal by Subject|1
6257915|NCT02015793|9950394|FG001|Overall Study|Withdrawal by Subject|1
6257916|NCT02015819|9950410|FG000|Overall Study|Rickham catheter was misaligned|0
6257917|NCT02015819|9950411|FG001|Overall Study|Rickham catheter was misaligned|0
6257918|NCT02015819|9950412|FG002|Overall Study|Rickham catheter was misaligned|0
6257919|NCT02015819|9950413|FG003|Overall Study|Rickham catheter was misaligned|1
6257920|NCT02016105|9950429|FG000|TREATMENT PERIOD 1|Protocol Violation|2
6257921|NCT02016105|9950430|FG001|TREATMENT PERIOD 1|Protocol Violation|8
6257922|NCT02016105|9950431|FG002|TREATMENT PERIOD 1|Protocol Violation|0
6257923|NCT02016105|9950432|FG003|TREATMENT PERIOD 1|Protocol Violation|0
6257924|NCT02016105|9950433|FG004|TREATMENT PERIOD 1|Protocol Violation|0
6257925|NCT02016105|9950434|FG005|TREATMENT PERIOD 1|Protocol Violation|0
6257926|NCT02016105|9950429|FG000|TREATMENT PERIOD 1|Physician Decision|0
6257927|NCT02016105|9950430|FG001|TREATMENT PERIOD 1|Physician Decision|2
6257928|NCT02016105|9950431|FG002|TREATMENT PERIOD 1|Physician Decision|0
6257929|NCT02016105|9950432|FG003|TREATMENT PERIOD 1|Physician Decision|0
6257930|NCT02016105|9950433|FG004|TREATMENT PERIOD 1|Physician Decision|0
6257931|NCT02016105|9950434|FG005|TREATMENT PERIOD 1|Physician Decision|0
6257932|NCT02016105|9950429|FG000|TREATMENT PERIOD 1|Lack of Efficacy|4
6257933|NCT02016105|9950430|FG001|TREATMENT PERIOD 1|Lack of Efficacy|2
6257934|NCT02016105|9950431|FG002|TREATMENT PERIOD 1|Lack of Efficacy|0
6257935|NCT02016105|9950432|FG003|TREATMENT PERIOD 1|Lack of Efficacy|0
6257936|NCT02016105|9950433|FG004|TREATMENT PERIOD 1|Lack of Efficacy|0
6257937|NCT02016105|9950434|FG005|TREATMENT PERIOD 1|Lack of Efficacy|0
6257938|NCT02016105|9950429|FG000|TREATMENT PERIOD 1|Pregnancy|0
6257939|NCT02016105|9950430|FG001|TREATMENT PERIOD 1|Pregnancy|1
6257940|NCT02016105|9950431|FG002|TREATMENT PERIOD 1|Pregnancy|0
6257941|NCT02016105|9950432|FG003|TREATMENT PERIOD 1|Pregnancy|0
6257942|NCT02016105|9950433|FG004|TREATMENT PERIOD 1|Pregnancy|0
6257943|NCT02016105|9950434|FG005|TREATMENT PERIOD 1|Pregnancy|0
6257944|NCT02016105|9950429|FG000|TREATMENT PERIOD 1|Adverse Event|3
6257945|NCT02016105|9950430|FG001|TREATMENT PERIOD 1|Adverse Event|5
6257946|NCT02016105|9950431|FG002|TREATMENT PERIOD 1|Adverse Event|0
6257947|NCT02016105|9950432|FG003|TREATMENT PERIOD 1|Adverse Event|0
6257948|NCT02016105|9950433|FG004|TREATMENT PERIOD 1|Adverse Event|0
6257949|NCT02016105|9950434|FG005|TREATMENT PERIOD 1|Adverse Event|0
6257950|NCT02016105|9950429|FG000|TREATMENT PERIOD 1|Withdrawal by Subject|15
6257951|NCT02016105|9950430|FG001|TREATMENT PERIOD 1|Withdrawal by Subject|11
6257952|NCT02016105|9950431|FG002|TREATMENT PERIOD 1|Withdrawal by Subject|0
6257953|NCT02016105|9950432|FG003|TREATMENT PERIOD 1|Withdrawal by Subject|0
6257954|NCT02016105|9950433|FG004|TREATMENT PERIOD 1|Withdrawal by Subject|0
6257955|NCT02016105|9950434|FG005|TREATMENT PERIOD 1|Withdrawal by Subject|0
6257956|NCT02016105|9950429|FG000|TREATMENT PERIOD 1|Lost to Follow-up|6
6257957|NCT02016105|9950430|FG001|TREATMENT PERIOD 1|Lost to Follow-up|4
6257958|NCT02016105|9950431|FG002|TREATMENT PERIOD 1|Lost to Follow-up|0
6257959|NCT02016105|9950432|FG003|TREATMENT PERIOD 1|Lost to Follow-up|0
6257960|NCT02016105|9950433|FG004|TREATMENT PERIOD 1|Lost to Follow-up|0
6257961|NCT02016105|9950434|FG005|TREATMENT PERIOD 1|Lost to Follow-up|0
6257962|NCT02016105|9950429|FG000|TREATMENT PERIOD 2|Non compliance study medication|0
6257963|NCT02016105|9950430|FG001|TREATMENT PERIOD 2|Non compliance study medication|0
6257964|NCT02016105|9950431|FG002|TREATMENT PERIOD 2|Non compliance study medication|0
6257965|NCT02016105|9950432|FG003|TREATMENT PERIOD 2|Non compliance study medication|0
6257966|NCT02016105|9950433|FG004|TREATMENT PERIOD 2|Non compliance study medication|0
6257967|NCT02016105|9950434|FG005|TREATMENT PERIOD 2|Non compliance study medication|1
6257968|NCT02016105|9950429|FG000|TREATMENT PERIOD 2|Lack of Efficacy|0
6257969|NCT02016105|9950430|FG001|TREATMENT PERIOD 2|Lack of Efficacy|0
6257970|NCT02016105|9950431|FG002|TREATMENT PERIOD 2|Lack of Efficacy|2
6257971|NCT02016105|9950432|FG003|TREATMENT PERIOD 2|Lack of Efficacy|6
6257972|NCT02016105|9950433|FG004|TREATMENT PERIOD 2|Lack of Efficacy|3
6257973|NCT02016105|9950434|FG005|TREATMENT PERIOD 2|Lack of Efficacy|2
6257974|NCT02016105|9950429|FG000|TREATMENT PERIOD 2|Pregnancy|0
6257975|NCT02016105|9950430|FG001|TREATMENT PERIOD 2|Pregnancy|0
6257976|NCT02016105|9950431|FG002|TREATMENT PERIOD 2|Pregnancy|0
6257977|NCT02016105|9950432|FG003|TREATMENT PERIOD 2|Pregnancy|0
6257978|NCT02016105|9950433|FG004|TREATMENT PERIOD 2|Pregnancy|0
6257979|NCT02016105|9950434|FG005|TREATMENT PERIOD 2|Pregnancy|1
6257980|NCT02016105|9950429|FG000|TREATMENT PERIOD 2|Death|0
6257981|NCT02016105|9950430|FG001|TREATMENT PERIOD 2|Death|0
6257982|NCT02016105|9950431|FG002|TREATMENT PERIOD 2|Death|0
6257983|NCT02016105|9950432|FG003|TREATMENT PERIOD 2|Death|0
6257984|NCT02016105|9950433|FG004|TREATMENT PERIOD 2|Death|0
6257985|NCT02016105|9950434|FG005|TREATMENT PERIOD 2|Death|1
6257986|NCT02016105|9950429|FG000|TREATMENT PERIOD 2|Adverse Event|0
6257987|NCT02016105|9950430|FG001|TREATMENT PERIOD 2|Adverse Event|0
6257988|NCT02016105|9950431|FG002|TREATMENT PERIOD 2|Adverse Event|0
6257989|NCT02016105|9950432|FG003|TREATMENT PERIOD 2|Adverse Event|4
6257990|NCT02016105|9950433|FG004|TREATMENT PERIOD 2|Adverse Event|0
6257991|NCT02016105|9950434|FG005|TREATMENT PERIOD 2|Adverse Event|1
6257992|NCT02016105|9950429|FG000|TREATMENT PERIOD 2|Withdrawal by Subject|0
6257993|NCT02016105|9950430|FG001|TREATMENT PERIOD 2|Withdrawal by Subject|0
6257994|NCT02016105|9950431|FG002|TREATMENT PERIOD 2|Withdrawal by Subject|3
6257995|NCT02016105|9950432|FG003|TREATMENT PERIOD 2|Withdrawal by Subject|1
6257996|NCT02016105|9950433|FG004|TREATMENT PERIOD 2|Withdrawal by Subject|1
6257997|NCT02016105|9950434|FG005|TREATMENT PERIOD 2|Withdrawal by Subject|7
6257998|NCT02016105|9950429|FG000|TREATMENT PERIOD 2|Lost to Follow-up|0
6257999|NCT02016105|9950430|FG001|TREATMENT PERIOD 2|Lost to Follow-up|0
6258000|NCT02016105|9950431|FG002|TREATMENT PERIOD 2|Lost to Follow-up|1
6258001|NCT02016105|9950432|FG003|TREATMENT PERIOD 2|Lost to Follow-up|0
6258002|NCT02016105|9950433|FG004|TREATMENT PERIOD 2|Lost to Follow-up|0
6258003|NCT02016105|9950434|FG005|TREATMENT PERIOD 2|Lost to Follow-up|1
6258004|NCT02016105|9950429|FG000|EXTENSION PERIOD|New therapy for study indication|0
6258005|NCT02016105|9950430|FG001|EXTENSION PERIOD|New therapy for study indication|0
6258006|NCT02016105|9950431|FG002|EXTENSION PERIOD|New therapy for study indication|0
6258007|NCT02016105|9950432|FG003|EXTENSION PERIOD|New therapy for study indication|0
6258008|NCT02016105|9950433|FG004|EXTENSION PERIOD|New therapy for study indication|1
6258009|NCT02016105|9950434|FG005|EXTENSION PERIOD|New therapy for study indication|1
6258010|NCT02016105|9950429|FG000|EXTENSION PERIOD|Lack of Efficacy|0
6258011|NCT02016105|9950430|FG001|EXTENSION PERIOD|Lack of Efficacy|0
6258012|NCT02016105|9950431|FG002|EXTENSION PERIOD|Lack of Efficacy|1
6258013|NCT02016105|9950432|FG003|EXTENSION PERIOD|Lack of Efficacy|3
6258014|NCT02016105|9950433|FG004|EXTENSION PERIOD|Lack of Efficacy|1
6258015|NCT02016105|9950434|FG005|EXTENSION PERIOD|Lack of Efficacy|1
6258016|NCT02016105|9950429|FG000|EXTENSION PERIOD|Adverse Event|0
6258017|NCT02016105|9950430|FG001|EXTENSION PERIOD|Adverse Event|0
6258018|NCT02016105|9950431|FG002|EXTENSION PERIOD|Adverse Event|2
6258019|NCT02016105|9950432|FG003|EXTENSION PERIOD|Adverse Event|0
6258020|NCT02016105|9950433|FG004|EXTENSION PERIOD|Adverse Event|1
6258021|NCT02016105|9950434|FG005|EXTENSION PERIOD|Adverse Event|0
6258022|NCT02016105|9950429|FG000|EXTENSION PERIOD|Withdrawal by Subject|0
6258023|NCT02016105|9950430|FG001|EXTENSION PERIOD|Withdrawal by Subject|0
6258024|NCT02016105|9950431|FG002|EXTENSION PERIOD|Withdrawal by Subject|2
6258025|NCT02016105|9950432|FG003|EXTENSION PERIOD|Withdrawal by Subject|2
6258026|NCT02016105|9950433|FG004|EXTENSION PERIOD|Withdrawal by Subject|2
6258027|NCT02016105|9950434|FG005|EXTENSION PERIOD|Withdrawal by Subject|2
6258028|NCT02016105|9950429|FG000|EXTENSION PERIOD|Non-compliance with study indication|0
6258029|NCT02016105|9950430|FG001|EXTENSION PERIOD|Non-compliance with study indication|0
6258030|NCT02016105|9950431|FG002|EXTENSION PERIOD|Non-compliance with study indication|0
6258031|NCT02016105|9950432|FG003|EXTENSION PERIOD|Non-compliance with study indication|0
6258032|NCT02016105|9950433|FG004|EXTENSION PERIOD|Non-compliance with study indication|1
6258033|NCT02016105|9950434|FG005|EXTENSION PERIOD|Non-compliance with study indication|0
6258034|NCT02016105|9950429|FG000|EXTENSION PERIOD|Lost to Follow-up|0
6258035|NCT02016105|9950430|FG001|EXTENSION PERIOD|Lost to Follow-up|0
6258036|NCT02016105|9950431|FG002|EXTENSION PERIOD|Lost to Follow-up|0
6258037|NCT02016105|9950432|FG003|EXTENSION PERIOD|Lost to Follow-up|0
6258038|NCT02016105|9950433|FG004|EXTENSION PERIOD|Lost to Follow-up|0
6258039|NCT02016105|9950434|FG005|EXTENSION PERIOD|Lost to Follow-up|2
6258040|NCT02016170|9950451|FG000|Overall Study|Adverse Event|1
6258041|NCT02016170|9950452|FG001|Overall Study|Adverse Event|1
6258042|NCT02016170|9950453|FG002|Overall Study|Adverse Event|0
6258043|NCT02016170|9950451|FG000|Overall Study|Protocol Violation|1
6258044|NCT02016170|9950452|FG001|Overall Study|Protocol Violation|0
6258045|NCT02016170|9950453|FG002|Overall Study|Protocol Violation|0
6258046|NCT02016183|9950460|FG000|Overall Study|Case Report Forms Uncollected|13
6258047|NCT02016183|9950460|FG000|Overall Study|Protocol Violation|52
6258048|NCT02016300|9950479|FG000|Overall Study|Lost to Follow-up|0
6258049|NCT02016300|9950480|FG001|Overall Study|Lost to Follow-up|3
6258050|NCT02016482|9950488|FG000|Period A|Adverse Event|3
6258051|NCT02016482|9950489|FG001|Period A|Adverse Event|5
6258052|NCT02016482|9950488|FG000|Period A|Withdrawal by Subject|3
6258053|NCT02016482|9950489|FG001|Period A|Withdrawal by Subject|4
6258054|NCT02016482|9950488|FG000|Period A|Lost to Follow-up|3
6258055|NCT02016482|9950489|FG001|Period A|Lost to Follow-up|3
6258056|NCT02016482|9950488|FG000|Period A|Lack of Efficacy|2
6258057|NCT02016482|9950489|FG001|Period A|Lack of Efficacy|1
6258058|NCT02016482|9950488|FG000|Period A|Other|3
6258059|NCT02016482|9950489|FG001|Period A|Other|0
6258060|NCT02016482|9950488|FG000|Period A|Protocol Violation|0
6258061|NCT02016482|9950489|FG001|Period A|Protocol Violation|1
6258062|NCT02016482|9950488|FG000|Period A|Required Alternative/Prohibited Therapy|0
6258063|NCT02016482|9950489|FG001|Period A|Required Alternative/Prohibited Therapy|1
6258064|NCT02016482|9950488|FG000|Period B|Withdrawal by Subject|1
6258065|NCT02016482|9950489|FG001|Period B|Withdrawal by Subject|1
6258066|NCT02016482|9950488|FG000|Period B|Lost to Follow-up|2
6258067|NCT02016482|9950489|FG001|Period B|Lost to Follow-up|0
6258068|NCT02016482|9950488|FG000|Period B|Lack of Efficacy|6
6258069|NCT02016482|9950489|FG001|Period B|Lack of Efficacy|4
6258070|NCT02016482|9950488|FG000|Period B|Other|4
6258071|NCT02016482|9950489|FG001|Period B|Other|0
6258072|NCT02016482|9950488|FG000|Period B|Required Alternative/Prohibited Therapy|0
6258073|NCT02016482|9950489|FG001|Period B|Required Alternative/Prohibited Therapy|2
6258074|NCT02016625|9950549|FG000|Cyclo or Tac (Single Dose, Day 1)|not treated|0
6258075|NCT02016625|9950550|FG001|Cyclo or Tac (Single Dose, Day 1)|not treated|1
6258076|NCT02016625|9950549|FG000|Cyclo or Tac (Day 1) + FDV (Day -7 to 7)|Adverse Event|1
6258077|NCT02016625|9950550|FG001|Cyclo or Tac (Day 1) + FDV (Day -7 to 7)|Adverse Event|0
6258078|NCT02016625|9950549|FG000|Cyclo or Tac (Day 1) + FDV (Day -7 to 7)|not specified above|2
6258079|NCT02016625|9950550|FG001|Cyclo or Tac (Day 1) + FDV (Day -7 to 7)|not specified above|0
6258080|NCT02016690|9950566|FG000|Overall Study|Excluded from SAS: Enrollment violation|2
6258081|NCT02016690|9950566|FG000|Overall Study|Excluded from SAS: Duplication|2
6258082|NCT02016690|9950566|FG000|Overall Study|Excluded from SAS: Early treatment|2
6258083|NCT02016690|9950566|FG000|Overall Study|Excluded from SAS: Ineligible for study|2
6258084|NCT02016690|9950566|FG000|Overall Study|Did not meet inclusion criteria|13
6258085|NCT02016690|9950566|FG000|Overall Study|Hospitalized for RSV at study start|3
6258086|NCT02016716|9950573|FG000|Overall Study|Withdrawal by Subject|5
6258087|NCT02016716|9950574|FG001|Overall Study|Withdrawal by Subject|5
6258088|NCT02016716|9950575|FG002|Overall Study|Withdrawal by Subject|5
6258089|NCT02016716|9950573|FG000|Overall Study|Protocol-specified Criteria|0
6258090|NCT02016716|9950574|FG001|Overall Study|Protocol-specified Criteria|1
6258091|NCT02016716|9950575|FG002|Overall Study|Protocol-specified Criteria|0
6258092|NCT02016716|9950573|FG000|Overall Study|Lost to Follow-up|1
6258093|NCT02016716|9950574|FG001|Overall Study|Lost to Follow-up|2
6258094|NCT02016716|9950575|FG002|Overall Study|Lost to Follow-up|1
6258095|NCT02016755|9950584|FG000|Overall Study|Major amputation of index limb|2
6258096|NCT02016755|9950584|FG000|Overall Study|Adverse Event|2
6258097|NCT02016755|9950584|FG000|Overall Study|Physician Decision|1
6258098|NCT02016755|9950584|FG000|Overall Study|Death|2
6258099|NCT02016898|9950611|FG000|Overall Study|Death|1
6258100|NCT02016898|9950612|FG001|Overall Study|Death|1
6258101|NCT02016898|9950611|FG000|Overall Study|Lost to Follow-up|4
6258102|NCT02016898|9950612|FG001|Overall Study|Lost to Follow-up|4
6258103|NCT02017015|9950623|FG000|Overall Study|Adverse Event|9
6258104|NCT02017015|9950623|FG000|Overall Study|Withdrawal by Subject|21
6258105|NCT02017015|9950623|FG000|Overall Study|Death|4
6258106|NCT02017015|9950623|FG000|Overall Study|Progressive Disease|31
6258107|NCT02017015|9950623|FG000|Overall Study|Non-compliance with study drug|2
6258108|NCT02017015|9950623|FG000|Overall Study|Physician Decision|2
6190933|NCT01417156|9847445|FG000|Overall Study|Protocol Violation|2
6190934|NCT01417195|9847451|FG000|Overall Study|Stimulation failure|1
6190935|NCT01417195|9847452|FG001|Overall Study|Stimulation failure|0
6190936|NCT01417195|9847451|FG000|Overall Study|No embryos for transfer|0
6190937|NCT01417195|9847452|FG001|Overall Study|No embryos for transfer|1
6190938|NCT01417195|9847451|FG000|Overall Study|No transfer due to risk of OHSS|1
6190939|NCT01417195|9847452|FG001|Overall Study|No transfer due to risk of OHSS|0
6190940|NCT01417195|9847451|FG000|Overall Study|No transfer due to elevated progesterone|1
6190941|NCT01417195|9847452|FG001|Overall Study|No transfer due to elevated progesterone|0
6190942|NCT01417234|9847459|FG000|Overall Study|Subject non-compliant|3
6258109|NCT02017171|9950641|FG000|Overall Study|Death|10
6258110|NCT02017171|9950642|FG001|Overall Study|Death|4
6258111|NCT02017171|9950641|FG000|Overall Study|Withdrawal by Subject|23
6258112|NCT02017171|9950642|FG001|Overall Study|Withdrawal by Subject|17
6258113|NCT02017171|9950641|FG000|Overall Study|Lost to Follow-up|21
6258114|NCT02017171|9950642|FG001|Overall Study|Lost to Follow-up|20
6258115|NCT02017171|9950641|FG000|Overall Study|ESKD|6
6258116|NCT02017171|9950642|FG001|Overall Study|ESKD|2
6258117|NCT02017171|9950641|FG000|Overall Study|Miscellaneous|2
6258118|NCT02017171|9950642|FG001|Overall Study|Miscellaneous|3
6258119|NCT02017223|9950665|FG000|Overall Study|Algorithm problems|2
6258120|NCT02017444|9950684|FG000|Overall Study|Physician Decision|1
6258121|NCT02017444|9950685|FG001|Overall Study|Physician Decision|0
6271109|NCT02160314|9972663|FG000|Overall Study|Adverse Event|0
6258122|NCT02017444|9950684|FG000|Overall Study|Patient withdrawn day after randomisation as found to be ineligible. Did not return for follow up.|1
6258123|NCT02017444|9950685|FG001|Overall Study|Patient withdrawn day after randomisation as found to be ineligible. Did not return for follow up.|0
6258124|NCT02017535|9950695|FG000|Overall Study|Withdrawal by Subject|1
6258125|NCT02017535|9950696|FG001|Overall Study|Withdrawal by Subject|0
6258126|NCT02017535|9950697|FG002|Overall Study|Withdrawal by Subject|0
6258127|NCT02017535|9950698|FG003|Overall Study|Withdrawal by Subject|0
6258128|NCT02017860|9950717|FG000|Overall Study|Adverse Event|1
6258129|NCT02017860|9950717|FG000|Overall Study|Withdrawal by Subject|1
6258130|NCT02017899|9950727|FG000|Overall Study|Withdrawal by Subject|0
6258131|NCT02017899|9950728|FG001|Overall Study|Withdrawal by Subject|0
6258132|NCT02017899|9950729|FG002|Overall Study|Withdrawal by Subject|0
6258133|NCT02017899|9950730|FG003|Overall Study|Withdrawal by Subject|1
6258134|NCT02017899|9950731|FG004|Overall Study|Withdrawal by Subject|1
6258135|NCT02017899|9950732|FG005|Overall Study|Withdrawal by Subject|0
6258136|NCT02018042|9950746|FG000|Overall Study|Withdrawal by Subject|1
6258137|NCT02018458|9950765|FG000|Overall Study|Death|4
6271110|NCT02160314|9972664|FG001|Overall Study|Adverse Event|6
6271111|NCT02160314|9972663|FG000|Overall Study|Protocol Violation|0
6271112|NCT02160314|9972664|FG001|Overall Study|Protocol Violation|4
6271113|NCT02160314|9972663|FG000|Overall Study|Withdrawal by Subject|1
6271114|NCT02160314|9972664|FG001|Overall Study|Withdrawal by Subject|2
6271115|NCT02160314|9972663|FG000|Overall Study|Lost to Follow-up|0
6271116|NCT02160314|9972664|FG001|Overall Study|Lost to Follow-up|1
6271117|NCT02160626|9972677|FG000|Overall Study|Adverse Event|1
6271118|NCT02160626|9972678|FG001|Overall Study|Adverse Event|0
6271119|NCT02160626|9972679|FG002|Overall Study|Adverse Event|0
6271120|NCT02160626|9972677|FG000|Overall Study|Schedule not conducive to study visits|0
6271121|NCT02160626|9972678|FG001|Overall Study|Schedule not conducive to study visits|0
6271122|NCT02160626|9972679|FG002|Overall Study|Schedule not conducive to study visits|1
6271123|NCT02160626|9972677|FG000|Overall Study|Withdrawal by Subject|0
6271124|NCT02160626|9972678|FG001|Overall Study|Withdrawal by Subject|1
6271125|NCT02160626|9972679|FG002|Overall Study|Withdrawal by Subject|0
6271126|NCT02160782|9972694|FG000|Open-label Period: Maralixibat|Adverse Event|2
6271127|NCT02160782|9972695|FG001|Open-label Period: Maralixibat|Adverse Event|0
6271128|NCT02160782|9972696|FG002|Open-label Period: Maralixibat|Adverse Event|0
6271129|NCT02160782|9972697|FG003|Open-label Period: Maralixibat|Adverse Event|0
6271130|NCT02160782|9972698|FG004|Open-label Period: Maralixibat|Adverse Event|0
6271131|NCT02160782|9972694|FG000|After Randomized Withdrawal: Maralixibat|Adverse Event|0
6271132|NCT02160782|9972695|FG001|After Randomized Withdrawal: Maralixibat|Adverse Event|0
6271133|NCT02160782|9972696|FG002|After Randomized Withdrawal: Maralixibat|Adverse Event|0
6271134|NCT02160782|9972697|FG003|After Randomized Withdrawal: Maralixibat|Adverse Event|1
6271135|NCT02160782|9972698|FG004|After Randomized Withdrawal: Maralixibat|Adverse Event|0
6271136|NCT02160782|9972694|FG000|After Randomized Withdrawal: Maralixibat|Did not consent to protocol amendment for long term extension|0
6271137|NCT02160782|9972695|FG001|After Randomized Withdrawal: Maralixibat|Did not consent to protocol amendment for long term extension|0
6271138|NCT02160782|9972696|FG002|After Randomized Withdrawal: Maralixibat|Did not consent to protocol amendment for long term extension|0
6271139|NCT02160782|9972697|FG003|After Randomized Withdrawal: Maralixibat|Did not consent to protocol amendment for long term extension|5
6271140|NCT02160782|9972698|FG004|After Randomized Withdrawal: Maralixibat|Did not consent to protocol amendment for long term extension|0
6271141|NCT02160782|9972694|FG000|Long-term Extension Period: Maralixibat|Did not consent to protocol amendment|0
6271142|NCT02160782|9972695|FG001|Long-term Extension Period: Maralixibat|Did not consent to protocol amendment|0
6271143|NCT02160782|9972696|FG002|Long-term Extension Period: Maralixibat|Did not consent to protocol amendment|0
6271144|NCT02160782|9972697|FG003|Long-term Extension Period: Maralixibat|Did not consent to protocol amendment|0
6271145|NCT02160782|9972698|FG004|Long-term Extension Period: Maralixibat|Did not consent to protocol amendment|4
6271146|NCT02160782|9972694|FG000|Long-term Extension Period: Maralixibat|Physician Decision|0
6271147|NCT02160782|9972695|FG001|Long-term Extension Period: Maralixibat|Physician Decision|0
6271148|NCT02160782|9972696|FG002|Long-term Extension Period: Maralixibat|Physician Decision|0
6271149|NCT02160782|9972697|FG003|Long-term Extension Period: Maralixibat|Physician Decision|0
6271150|NCT02160782|9972698|FG004|Long-term Extension Period: Maralixibat|Physician Decision|1
6271151|NCT02160782|9972694|FG000|Long-term Extension Period: Maralixibat|Adverse Event|0
6271152|NCT02160782|9972695|FG001|Long-term Extension Period: Maralixibat|Adverse Event|0
6271153|NCT02160782|9972696|FG002|Long-term Extension Period: Maralixibat|Adverse Event|0
6271154|NCT02160782|9972697|FG003|Long-term Extension Period: Maralixibat|Adverse Event|0
6271155|NCT02160782|9972698|FG004|Long-term Extension Period: Maralixibat|Adverse Event|3
6271156|NCT02160782|9972694|FG000|Long-term Extension Period: Maralixibat|Withdrawal by caregiver|0
6271157|NCT02160782|9972695|FG001|Long-term Extension Period: Maralixibat|Withdrawal by caregiver|0
6271158|NCT02160782|9972696|FG002|Long-term Extension Period: Maralixibat|Withdrawal by caregiver|0
6271159|NCT02160782|9972697|FG003|Long-term Extension Period: Maralixibat|Withdrawal by caregiver|0
6271160|NCT02160782|9972698|FG004|Long-term Extension Period: Maralixibat|Withdrawal by caregiver|1
6271161|NCT02160899|9972761|FG000|Overall Study|Adverse Event or Serious Adverse Event|0
6271162|NCT02160899|9972762|FG001|Overall Study|Adverse Event or Serious Adverse Event|1
6271908|NCT02169219|9974002|FG000|Overall Study|Lack of Efficacy|6
6258138|NCT02018562|9950771|FG000|Overall Study|Withdrawal by Subject|2
6258139|NCT02018562|9950772|FG001|Overall Study|Withdrawal by Subject|0
6258140|NCT02018562|9950771|FG000|Overall Study|Discharged prior to study completion|1
6258141|NCT02018562|9950772|FG001|Overall Study|Discharged prior to study completion|0
6258142|NCT02018822|9950815|FG000|Overall Study|filling replaced by crown|0
6258143|NCT02018822|9950816|FG001|Overall Study|filling replaced by crown|1
6258144|NCT02018822|9950817|FG002|Overall Study|filling replaced by crown|0
6258145|NCT02018822|9950815|FG000|Overall Study|Physician Decision|0
6258146|NCT02018822|9950816|FG001|Overall Study|Physician Decision|1
6258147|NCT02018822|9950817|FG002|Overall Study|Physician Decision|1
6258148|NCT02018822|9950815|FG000|Overall Study|Lost to Follow-up|6
6258149|NCT02018822|9950816|FG001|Overall Study|Lost to Follow-up|6
6258150|NCT02018822|9950817|FG002|Overall Study|Lost to Follow-up|5
6258151|NCT02018887|9950836|FG000|Part A: Cohorts 1-2: Period 3|Adverse Event|1
6258152|NCT02018887|9950837|FG001|Part A: Cohorts 1-2: Period 3|Adverse Event|0
6258153|NCT02018887|9950838|FG002|Part A: Cohorts 1-2: Period 3|Adverse Event|0
6258154|NCT02018887|9950839|FG003|Part A: Cohorts 1-2: Period 3|Adverse Event|0
6258155|NCT02018887|9950840|FG004|Part A: Cohorts 1-2: Period 3|Adverse Event|0
6258156|NCT02018887|9950841|FG005|Part A: Cohorts 1-2: Period 3|Adverse Event|0
6258157|NCT02018887|9950842|FG006|Part A: Cohorts 1-2: Period 3|Adverse Event|0
6258158|NCT02018887|9950843|FG007|Part A: Cohorts 1-2: Period 3|Adverse Event|0
6258159|NCT02018887|9950844|FG008|Part A: Cohorts 1-2: Period 3|Adverse Event|0
6258160|NCT02018887|9950845|FG009|Part A: Cohorts 1-2: Period 3|Adverse Event|0
6086659|NCT00662649|9696710|FG001|Extension Study (Month 24 to 60)|Lost to Follow-up|0
6086660|NCT00662649|9696711|FG002|Extension Study (Month 24 to 60)|Lost to Follow-up|0
6086661|NCT00662649|9696712|FG003|Extension Study (Month 24 to 60)|Lost to Follow-up|1
6258161|NCT02018887|9950846|FG010|Part A: Cohorts 1-2: Period 3|Adverse Event|0
6258162|NCT02018887|9950836|FG000|Part B: Cohorts 3-7 Overall|Adverse Event|0
6258163|NCT02018887|9950837|FG001|Part B: Cohorts 3-7 Overall|Adverse Event|0
6258164|NCT02018887|9950838|FG002|Part B: Cohorts 3-7 Overall|Adverse Event|0
6258165|NCT02018887|9950839|FG003|Part B: Cohorts 3-7 Overall|Adverse Event|0
6258166|NCT02018887|9950840|FG004|Part B: Cohorts 3-7 Overall|Adverse Event|1
6258167|NCT02018887|9950841|FG005|Part B: Cohorts 3-7 Overall|Adverse Event|0
6258168|NCT02018887|9950842|FG006|Part B: Cohorts 3-7 Overall|Adverse Event|1
6258169|NCT02018887|9950843|FG007|Part B: Cohorts 3-7 Overall|Adverse Event|4
6258170|NCT02018887|9950844|FG008|Part B: Cohorts 3-7 Overall|Adverse Event|0
6258171|NCT02018887|9950845|FG009|Part B: Cohorts 3-7 Overall|Adverse Event|0
6258172|NCT02018887|9950846|FG010|Part B: Cohorts 3-7 Overall|Adverse Event|0
6258173|NCT02018887|9950836|FG000|Part C: Cohort 8 Overall|Adverse Event|0
6258174|NCT02018887|9950837|FG001|Part C: Cohort 8 Overall|Adverse Event|0
6258175|NCT02018887|9950838|FG002|Part C: Cohort 8 Overall|Adverse Event|0
6258176|NCT02018887|9950839|FG003|Part C: Cohort 8 Overall|Adverse Event|0
6258177|NCT02018887|9950840|FG004|Part C: Cohort 8 Overall|Adverse Event|0
6258178|NCT02018887|9950841|FG005|Part C: Cohort 8 Overall|Adverse Event|0
6258179|NCT02018887|9950842|FG006|Part C: Cohort 8 Overall|Adverse Event|0
6258180|NCT02018887|9950843|FG007|Part C: Cohort 8 Overall|Adverse Event|0
6258181|NCT02018887|9950844|FG008|Part C: Cohort 8 Overall|Adverse Event|1
6258182|NCT02018887|9950845|FG009|Part C: Cohort 8 Overall|Adverse Event|3
6258183|NCT02018887|9950846|FG010|Part C: Cohort 8 Overall|Adverse Event|0
6258184|NCT02018887|9950836|FG000|Part C: Cohort 8 Overall|Physician Decision|0
6258185|NCT02018887|9950837|FG001|Part C: Cohort 8 Overall|Physician Decision|0
6258186|NCT02018887|9950838|FG002|Part C: Cohort 8 Overall|Physician Decision|0
6258187|NCT02018887|9950839|FG003|Part C: Cohort 8 Overall|Physician Decision|0
6258188|NCT02018887|9950840|FG004|Part C: Cohort 8 Overall|Physician Decision|0
6258189|NCT02018887|9950841|FG005|Part C: Cohort 8 Overall|Physician Decision|0
6258190|NCT02018887|9950842|FG006|Part C: Cohort 8 Overall|Physician Decision|0
6258191|NCT02018887|9950843|FG007|Part C: Cohort 8 Overall|Physician Decision|0
6258192|NCT02018887|9950844|FG008|Part C: Cohort 8 Overall|Physician Decision|2
6258193|NCT02018887|9950845|FG009|Part C: Cohort 8 Overall|Physician Decision|0
6258194|NCT02018887|9950846|FG010|Part C: Cohort 8 Overall|Physician Decision|1
6258195|NCT02019108|9950918|FG000|Overall Study|Lost to Follow-up|5
6258196|NCT02019108|9950919|FG001|Overall Study|Lost to Follow-up|7
6258197|NCT02019264|9950927|FG000|Overall Study|Not treated|6
6258198|NCT02019264|9950928|FG001|Overall Study|Not treated|4
6258199|NCT02019264|9950927|FG000|Overall Study|Lost to Follow-up|50
6258200|NCT02019264|9950928|FG001|Overall Study|Lost to Follow-up|47
6258201|NCT02019264|9950927|FG000|Overall Study|Withdrawal by Subject|142
6258202|NCT02019264|9950928|FG001|Overall Study|Withdrawal by Subject|117
6258203|NCT02019264|9950927|FG000|Overall Study|Administrative reason|36
6258204|NCT02019264|9950928|FG001|Overall Study|Administrative reason|28
6258205|NCT02019264|9950927|FG000|Overall Study|Missing|14
6258206|NCT02019264|9950928|FG001|Overall Study|Missing|11
6258207|NCT02019277|9950934|FG000|Overall Study|Withdrawal by Subject|3
6258208|NCT02019277|9950934|FG000|Overall Study|Death|7
6258209|NCT02019277|9950934|FG000|Overall Study|Did no Cooperate|1
6258210|NCT02019277|9950934|FG000|Overall Study|Adverse Event|1
6258211|NCT02019420|9950940|FG000|Overall Study|Did not receive study drug|2
6258212|NCT02019420|9950941|FG001|Overall Study|Did not receive study drug|2
6258213|NCT02019420|9950940|FG000|Overall Study|Withdrawal by Subject|1
6258214|NCT02019420|9950941|FG001|Overall Study|Withdrawal by Subject|3
6258215|NCT02019420|9950940|FG000|Overall Study|At request of sponsor or investigator|0
6258216|NCT02019420|9950941|FG001|Overall Study|At request of sponsor or investigator|1
6258217|NCT02019420|9950940|FG000|Overall Study|Death|104
6258218|NCT02019420|9950941|FG001|Overall Study|Death|99
6258219|NCT02019420|9950940|FG000|Overall Study|Transferred to other care facility|1
6258220|NCT02019420|9950941|FG001|Overall Study|Transferred to other care facility|1
6258221|NCT02019472|9950950|FG000|Overall Study|Adverse Event|14
6258222|NCT02019472|9950951|FG001|Overall Study|Adverse Event|23
6258223|NCT02019472|9950952|FG002|Overall Study|Adverse Event|17
6258224|NCT02019472|9950950|FG000|Overall Study|Death|0
6258225|NCT02019472|9950951|FG001|Overall Study|Death|1
6258226|NCT02019472|9950952|FG002|Overall Study|Death|1
6258227|NCT02019472|9950950|FG000|Overall Study|Lack of Efficacy|7
6258228|NCT02019472|9950951|FG001|Overall Study|Lack of Efficacy|4
6258229|NCT02019472|9950952|FG002|Overall Study|Lack of Efficacy|4
6258230|NCT02019472|9950950|FG000|Overall Study|Lost to Follow-up|0
6258231|NCT02019472|9950951|FG001|Overall Study|Lost to Follow-up|2
6258232|NCT02019472|9950952|FG002|Overall Study|Lost to Follow-up|1
6258233|NCT02019472|9950950|FG000|Overall Study|Physician Decision|1
6258234|NCT02019472|9950951|FG001|Overall Study|Physician Decision|2
6258235|NCT02019472|9950952|FG002|Overall Study|Physician Decision|0
6258236|NCT02019472|9950950|FG000|Overall Study|Pregnancy|1
6258237|NCT02019472|9950951|FG001|Overall Study|Pregnancy|2
6258238|NCT02019472|9950952|FG002|Overall Study|Pregnancy|2
6258239|NCT02019472|9950950|FG000|Overall Study|Withdrawal by Subject|11
6258240|NCT02019472|9950951|FG001|Overall Study|Withdrawal by Subject|10
6258241|NCT02019472|9950952|FG002|Overall Study|Withdrawal by Subject|11
6258242|NCT02019472|9950950|FG000|Overall Study|Other|3
6258243|NCT02019472|9950951|FG001|Overall Study|Other|8
6258244|NCT02019472|9950952|FG002|Overall Study|Other|6
6258245|NCT02019550|9950966|FG000|Treatment Period 1 (4 Weeks)|Adverse Event|0
6258246|NCT02019550|9950967|FG001|Treatment Period 1 (4 Weeks)|Adverse Event|1
6258247|NCT02019602|9950988|FG000|Screening Period|Ineligibility|4
6258248|NCT02019602|9950989|FG001|Screening Period|Ineligibility|0
6258249|NCT02019602|9950988|FG000|Screening Period|Adverse Event|1
6258250|NCT02019602|9950989|FG001|Screening Period|Adverse Event|0
6258251|NCT02019667|9950996|FG000|First Intervention (6 Months)|Adverse Event|0
6258252|NCT02019667|9950997|FG001|First Intervention (6 Months)|Adverse Event|1
6258253|NCT02019667|9950996|FG000|2nd Intervention (6 Months)|Adverse Event|0
6258254|NCT02019667|9950997|FG001|2nd Intervention (6 Months)|Adverse Event|1
6258255|NCT02019667|9950996|FG000|2nd Intervention (6 Months)|Physician Decision|0
6258256|NCT02019667|9950997|FG001|2nd Intervention (6 Months)|Physician Decision|1
6258257|NCT02019719|9951010|FG000|Overall Study|Adverse Event|1
6258258|NCT02019719|9951011|FG001|Overall Study|Adverse Event|0
6258259|NCT02019719|9951012|FG002|Overall Study|Adverse Event|0
6258260|NCT02019719|9951013|FG003|Overall Study|Adverse Event|1
6258261|NCT02019719|9951014|FG004|Overall Study|Adverse Event|1
6258262|NCT02019719|9951010|FG000|Overall Study|Protocol Violation|1
6258263|NCT02019719|9951011|FG001|Overall Study|Protocol Violation|1
6258264|NCT02019719|9951012|FG002|Overall Study|Protocol Violation|0
6258265|NCT02019719|9951013|FG003|Overall Study|Protocol Violation|0
6258266|NCT02019719|9951014|FG004|Overall Study|Protocol Violation|0
6258267|NCT02019719|9951010|FG000|Overall Study|Protocol defined stopping criteria|2
6258268|NCT02019719|9951011|FG001|Overall Study|Protocol defined stopping criteria|0
6258269|NCT02019719|9951012|FG002|Overall Study|Protocol defined stopping criteria|0
6258270|NCT02019719|9951013|FG003|Overall Study|Protocol defined stopping criteria|1
6258271|NCT02019719|9951014|FG004|Overall Study|Protocol defined stopping criteria|1
6258272|NCT02019719|9951010|FG000|Overall Study|Physician Decision|2
6258273|NCT02019719|9951011|FG001|Overall Study|Physician Decision|0
6258274|NCT02019719|9951012|FG002|Overall Study|Physician Decision|0
6258275|NCT02019719|9951013|FG003|Overall Study|Physician Decision|0
6258276|NCT02019719|9951014|FG004|Overall Study|Physician Decision|0
6258277|NCT02019927|9951061|FG000|Overall Study|Lost to Follow-up|2
6190943|NCT01417481|9847498|FG000|First Intervention (8 Weeks)|Withdrawal by Subject|0
6190944|NCT01417481|9847499|FG001|First Intervention (8 Weeks)|Withdrawal by Subject|2
6190945|NCT01418209|9847539|FG000|Overall Study|Withdrawal by Subject|1
6190946|NCT01418209|9847540|FG001|Overall Study|Withdrawal by Subject|0
6190947|NCT01418209|9847541|FG002|Overall Study|Withdrawal by Subject|1
6190948|NCT01418209|9847539|FG000|Overall Study|Did not provide hot flash diary data|1
6190949|NCT01418209|9847540|FG001|Overall Study|Did not provide hot flash diary data|3
6190950|NCT01418209|9847541|FG002|Overall Study|Did not provide hot flash diary data|3
6258278|NCT02019927|9951062|FG001|Overall Study|Lost to Follow-up|4
6258279|NCT02019927|9951063|FG002|Overall Study|Lost to Follow-up|1
6258280|NCT02019927|9951064|FG003|Overall Study|Lost to Follow-up|2
6258281|NCT02019927|9951065|FG004|Overall Study|Lost to Follow-up|3
6258282|NCT02019927|9951066|FG005|Overall Study|Lost to Follow-up|1
6258283|NCT02019979|9951088|FG000|Overall Study|study terminated|14
6258284|NCT02020031|9951103|FG000|Overall Study|Physician Decision|1
6258285|NCT02020031|9951104|FG001|Overall Study|Physician Decision|1
6258286|NCT02020512|9951159|FG000|Overall Study|Adverse Event|1
6190951|NCT01418339|9847551|FG000|Overall Study|Adverse Event|5
6258287|NCT02020512|9951159|FG000|Overall Study|Lost to Follow-up|3
6258288|NCT02020512|9951159|FG000|Overall Study|Protocol Violation|4
6258289|NCT02020577|9951165|FG000|Overall Study|Progressive disease|3
6258290|NCT02020577|9951166|FG001|Overall Study|Progressive disease|38
6258291|NCT02020577|9951165|FG000|Overall Study|Other AE or clinical progression|0
6258292|NCT02020577|9951166|FG001|Overall Study|Other AE or clinical progression|15
6258293|NCT02020577|9951165|FG000|Overall Study|Withdrawal by Subject|0
6258294|NCT02020577|9951166|FG001|Overall Study|Withdrawal by Subject|1
6258295|NCT02020577|9951165|FG000|Overall Study|Other than stated above|0
6258296|NCT02020577|9951166|FG001|Overall Study|Other than stated above|1
6258297|NCT02020616|9951185|FG000|Overall Study|Adverse Event|0
6258298|NCT02020616|9951186|FG001|Overall Study|Adverse Event|0
6258299|NCT02020616|9951187|FG002|Overall Study|Adverse Event|0
6258300|NCT02020616|9951188|FG003|Overall Study|Adverse Event|0
6258301|NCT02020616|9951189|FG004|Overall Study|Adverse Event|0
6258302|NCT02020616|9951190|FG005|Overall Study|Adverse Event|1
6258303|NCT02020616|9951191|FG006|Overall Study|Adverse Event|1
6258304|NCT02020616|9951185|FG000|Overall Study|Physician Decision|0
6258305|NCT02020616|9951186|FG001|Overall Study|Physician Decision|0
6258306|NCT02020616|9951187|FG002|Overall Study|Physician Decision|0
6258307|NCT02020616|9951188|FG003|Overall Study|Physician Decision|0
6258308|NCT02020616|9951189|FG004|Overall Study|Physician Decision|0
6258309|NCT02020616|9951190|FG005|Overall Study|Physician Decision|1
6258310|NCT02020616|9951191|FG006|Overall Study|Physician Decision|2
6258311|NCT02020616|9951185|FG000|Overall Study|Withdrawal by Subject|0
6258312|NCT02020616|9951186|FG001|Overall Study|Withdrawal by Subject|0
6258313|NCT02020616|9951187|FG002|Overall Study|Withdrawal by Subject|1
6258314|NCT02020616|9951188|FG003|Overall Study|Withdrawal by Subject|0
6258315|NCT02020616|9951189|FG004|Overall Study|Withdrawal by Subject|0
6258316|NCT02020616|9951190|FG005|Overall Study|Withdrawal by Subject|1
6258317|NCT02020616|9951191|FG006|Overall Study|Withdrawal by Subject|1
6258318|NCT02020616|9951185|FG000|Overall Study|Lost to Follow-up|0
6258319|NCT02020616|9951186|FG001|Overall Study|Lost to Follow-up|1
6258320|NCT02020616|9951187|FG002|Overall Study|Lost to Follow-up|0
6258321|NCT02020616|9951188|FG003|Overall Study|Lost to Follow-up|1
6258322|NCT02020616|9951189|FG004|Overall Study|Lost to Follow-up|1
6258323|NCT02020616|9951190|FG005|Overall Study|Lost to Follow-up|1
6258324|NCT02020616|9951191|FG006|Overall Study|Lost to Follow-up|0
6258325|NCT02020616|9951185|FG000|Overall Study|Early Termination Criteria Met|0
6258326|NCT02020616|9951186|FG001|Overall Study|Early Termination Criteria Met|0
6258327|NCT02020616|9951187|FG002|Overall Study|Early Termination Criteria Met|1
6258328|NCT02020616|9951188|FG003|Overall Study|Early Termination Criteria Met|0
6258329|NCT02020616|9951189|FG004|Overall Study|Early Termination Criteria Met|0
6258330|NCT02020616|9951190|FG005|Overall Study|Early Termination Criteria Met|1
6258331|NCT02020616|9951191|FG006|Overall Study|Early Termination Criteria Met|0
6258332|NCT02020616|9951185|FG000|Overall Study|Randomized in Error|0
6258333|NCT02020616|9951186|FG001|Overall Study|Randomized in Error|0
6258334|NCT02020616|9951187|FG002|Overall Study|Randomized in Error|0
6258335|NCT02020616|9951188|FG003|Overall Study|Randomized in Error|1
6258336|NCT02020616|9951189|FG004|Overall Study|Randomized in Error|0
6258337|NCT02020616|9951190|FG005|Overall Study|Randomized in Error|0
6258338|NCT02020616|9951191|FG006|Overall Study|Randomized in Error|0
6258339|NCT02020616|9951185|FG000|Overall Study|Lack of Efficacy|0
6258340|NCT02020616|9951186|FG001|Overall Study|Lack of Efficacy|0
6258341|NCT02020616|9951187|FG002|Overall Study|Lack of Efficacy|0
6258342|NCT02020616|9951188|FG003|Overall Study|Lack of Efficacy|0
6258343|NCT02020616|9951189|FG004|Overall Study|Lack of Efficacy|1
6258344|NCT02020616|9951190|FG005|Overall Study|Lack of Efficacy|0
6258345|NCT02020616|9951191|FG006|Overall Study|Lack of Efficacy|0
6258346|NCT02020863|9951230|FG000|Overall Study|Discovery of Metastatic disease|4
6258347|NCT02020863|9951230|FG000|Overall Study|Team chose not to place an a line|1
6258348|NCT02020889|9951236|FG000|Overall Study|Adverse Event|0
6258349|NCT02020889|9951237|FG001|Overall Study|Adverse Event|1
6258350|NCT02020889|9951236|FG000|Overall Study|Lack of Efficacy|1
6258351|NCT02020889|9951237|FG001|Overall Study|Lack of Efficacy|0
6258352|NCT02020889|9951236|FG000|Overall Study|Lost to Follow-up|1
6258353|NCT02020889|9951237|FG001|Overall Study|Lost to Follow-up|0
6258354|NCT02020889|9951236|FG000|Overall Study|Physician Decision|2
6258355|NCT02020889|9951237|FG001|Overall Study|Physician Decision|0
6258356|NCT02020889|9951236|FG000|Overall Study|Withdrawal by Subject|3
6258357|NCT02020889|9951237|FG001|Overall Study|Withdrawal by Subject|2
6258358|NCT02020941|9951243|FG000|Overall Study|Adverse Event|1
6258359|NCT02020941|9951243|FG000|Overall Study|Physician Decision|2
6258360|NCT02020941|9951243|FG000|Overall Study|Withdrawal by Subject|1
6258361|NCT02020941|9951243|FG000|Overall Study|Disease Progression|4
6258362|NCT02020967|9951249|FG000|Overall Study|Withdrawal by Subject|51
6258363|NCT02021292|9951257|FG000|Overall Study|Physician Decision|0
6258364|NCT02021292|9951258|FG001|Overall Study|Physician Decision|1
6258365|NCT02021292|9951257|FG000|Overall Study|Lost to Follow-up|0
6258366|NCT02021292|9951258|FG001|Overall Study|Lost to Follow-up|1
6258367|NCT02021292|9951257|FG000|Overall Study|Death|0
6258368|NCT02021292|9951258|FG001|Overall Study|Death|1
6258369|NCT02021318|9951268|FG000|Overall Study|Adverse Event|2
6258370|NCT02021318|9951269|FG001|Overall Study|Adverse Event|1
6258371|NCT02021318|9951268|FG000|Overall Study|Death|33
6258372|NCT02021318|9951269|FG001|Overall Study|Death|34
6258373|NCT02021318|9951268|FG000|Overall Study|Lost to Follow-up|3
6258374|NCT02021318|9951269|FG001|Overall Study|Lost to Follow-up|3
6258375|NCT02021318|9951268|FG000|Overall Study|Progressive Disease|0
6258376|NCT02021318|9951269|FG001|Overall Study|Progressive Disease|1
6258377|NCT02021318|9951268|FG000|Overall Study|Withdrawal by Subject|30
6258378|NCT02021318|9951269|FG001|Overall Study|Withdrawal by Subject|18
6258379|NCT02021318|9951268|FG000|Overall Study|Physician Decision|3
6258380|NCT02021318|9951269|FG001|Overall Study|Physician Decision|3
6258381|NCT02021318|9951268|FG000|Overall Study|Miscellaneous|2
6258382|NCT02021318|9951269|FG001|Overall Study|Miscellaneous|3
6258383|NCT02021331|9951278|FG000|Overall Study|Adverse Event|0
6258384|NCT02021331|9951279|FG001|Overall Study|Adverse Event|2
6258385|NCT02021565|9951293|FG000|Baseline Through Intervention|Death|0
6258386|NCT02021565|9951294|FG001|Baseline Through Intervention|Death|1
6258387|NCT02021565|9951293|FG000|Baseline Through Intervention|Withdrawal by Subject|8
6258388|NCT02021565|9951294|FG001|Baseline Through Intervention|Withdrawal by Subject|8
6258389|NCT02021565|9951293|FG000|Baseline Through Intervention|Protocol Violation|0
6258390|NCT02021565|9951294|FG001|Baseline Through Intervention|Protocol Violation|7
6258391|NCT02021565|9951293|FG000|Baseline Through Intervention|Lost to Follow-up|4
6258392|NCT02021565|9951294|FG001|Baseline Through Intervention|Lost to Follow-up|2
6258393|NCT02021565|9951293|FG000|3-month Follow-up|Death|3
6258394|NCT02021565|9951294|FG001|3-month Follow-up|Death|0
6258395|NCT02021565|9951293|FG000|3-month Follow-up|Withdrawal by Subject|4
6258396|NCT02021565|9951294|FG001|3-month Follow-up|Withdrawal by Subject|0
6258397|NCT02021565|9951293|FG000|3-month Follow-up|Protocol Violation|3
6258398|NCT02021565|9951294|FG001|3-month Follow-up|Protocol Violation|2
6258399|NCT02021643|9951308|FG000|Overall Study|Enrolled but Never Treated|1
6258400|NCT02021643|9951309|FG001|Overall Study|Enrolled but Never Treated|0
6258401|NCT02021643|9951310|FG002|Overall Study|Enrolled but Never Treated|0
6258402|NCT02021643|9951311|FG003|Overall Study|Enrolled but Never Treated|0
6258403|NCT02021643|9951308|FG000|Overall Study|Adverse Event|0
6258404|NCT02021643|9951309|FG001|Overall Study|Adverse Event|1
6258405|NCT02021643|9951310|FG002|Overall Study|Adverse Event|0
6258406|NCT02021643|9951311|FG003|Overall Study|Adverse Event|0
6258407|NCT02021643|9951308|FG000|Overall Study|Death|0
6258408|NCT02021643|9951309|FG001|Overall Study|Death|1
6258409|NCT02021643|9951310|FG002|Overall Study|Death|0
6258410|NCT02021643|9951311|FG003|Overall Study|Death|0
6258411|NCT02021643|9951308|FG000|Overall Study|Investigator's Discretion|1
6258412|NCT02021643|9951309|FG001|Overall Study|Investigator's Discretion|0
6258413|NCT02021643|9951310|FG002|Overall Study|Investigator's Discretion|0
6258414|NCT02021643|9951311|FG003|Overall Study|Investigator's Discretion|0
6258415|NCT02021643|9951308|FG000|Overall Study|Lack of Efficacy|7
6258416|NCT02021643|9951309|FG001|Overall Study|Lack of Efficacy|6
6258417|NCT02021643|9951310|FG002|Overall Study|Lack of Efficacy|0
6258418|NCT02021643|9951311|FG003|Overall Study|Lack of Efficacy|12
6258419|NCT02021643|9951308|FG000|Overall Study|Lost to Follow-up|0
6258420|NCT02021643|9951309|FG001|Overall Study|Lost to Follow-up|1
6258421|NCT02021643|9951310|FG002|Overall Study|Lost to Follow-up|0
6258422|NCT02021643|9951311|FG003|Overall Study|Lost to Follow-up|0
6258423|NCT02021643|9951308|FG000|Overall Study|Withdrew Consent|0
6258424|NCT02021643|9951309|FG001|Overall Study|Withdrew Consent|1
6258425|NCT02021643|9951310|FG002|Overall Study|Withdrew Consent|0
6258426|NCT02021643|9951311|FG003|Overall Study|Withdrew Consent|0
6258427|NCT02021656|9951327|FG000|Overall Study|Adverse Event|1
6258428|NCT02021656|9951327|FG000|Overall Study|Lack of Efficacy|2
6086662|NCT00662649|9696713|FG004|Extension Study (Month 24 to 60)|Lost to Follow-up|1
6086663|NCT00662649|9696709|FG000|Extension Study (Month 24 to 60)|Protocol Violation|1
6086664|NCT00662649|9696710|FG001|Extension Study (Month 24 to 60)|Protocol Violation|1
6086665|NCT00662649|9696711|FG002|Extension Study (Month 24 to 60)|Protocol Violation|0
6086666|NCT00662649|9696712|FG003|Extension Study (Month 24 to 60)|Protocol Violation|0
6086667|NCT00662649|9696713|FG004|Extension Study (Month 24 to 60)|Protocol Violation|0
6258429|NCT02021656|9951327|FG000|Overall Study|Lost to Follow-up|1
6258430|NCT02021656|9951327|FG000|Overall Study|Withdrew Consent|2
6258431|NCT02021812|9951344|FG000|Overall Study|Death|8
6258432|NCT02021812|9951344|FG000|Overall Study|Withdrawal by Subject|3
6258433|NCT02021812|9951344|FG000|Overall Study|Lost to Follow-up|1
6258434|NCT02021812|9951344|FG000|Overall Study|Refuse to return, COVD 19, in hospice, and didn't return for visit|4
6086668|NCT00662649|9696709|FG000|Extension Study (Month 24 to 60)|Subject withdrew consent|19
6258435|NCT02021812|9951344|FG000|Overall Study|Still in study|6
6258436|NCT02022007|9951374|FG000|Overall Study|Withdrawal by Subject|1
6258437|NCT02022007|9951375|FG001|Overall Study|Withdrawal by Subject|1
6258438|NCT02022007|9951376|FG002|Overall Study|Withdrawal by Subject|1
6258439|NCT02022007|9951374|FG000|Overall Study|Noncompliant|0
6258440|NCT02022007|9951375|FG001|Overall Study|Noncompliant|0
6258441|NCT02022007|9951376|FG002|Overall Study|Noncompliant|1
6258442|NCT02022033|9951388|FG000|Overall Study|Physician Decision|1
6258443|NCT02022657|9951407|FG000|Overall Study|Withdrawal by Subject|2
6258444|NCT02022657|9951408|FG001|Overall Study|Withdrawal by Subject|0
6258445|NCT02022657|9951409|FG002|Overall Study|Withdrawal by Subject|1
6258446|NCT02022657|9951410|FG003|Overall Study|Withdrawal by Subject|0
6258447|NCT02022657|9951411|FG004|Overall Study|Withdrawal by Subject|0
6258448|NCT02022657|9951412|FG005|Overall Study|Withdrawal by Subject|0
6258449|NCT02022657|9951407|FG000|Overall Study|Physician Decision|0
6258450|NCT02022657|9951408|FG001|Overall Study|Physician Decision|0
6258451|NCT02022657|9951409|FG002|Overall Study|Physician Decision|0
6258452|NCT02022657|9951410|FG003|Overall Study|Physician Decision|0
6258453|NCT02022657|9951411|FG004|Overall Study|Physician Decision|0
6258454|NCT02022657|9951412|FG005|Overall Study|Physician Decision|1
6258455|NCT02022670|9951421|FG000|Overall Study|Adverse Event|1
6258456|NCT02022670|9951422|FG001|Overall Study|Adverse Event|0
6258457|NCT02022670|9951423|FG002|Overall Study|Adverse Event|1
6258458|NCT02022748|9951444|FG000|Overall Study|Adverse Event|1
6258459|NCT02022748|9951445|FG001|Overall Study|Adverse Event|1
6258460|NCT02022748|9951446|FG002|Overall Study|Adverse Event|0
6258461|NCT02022748|9951444|FG000|Overall Study|Withdrawal by Subject|0
6258462|NCT02022748|9951445|FG001|Overall Study|Withdrawal by Subject|1
6258463|NCT02022748|9951446|FG002|Overall Study|Withdrawal by Subject|0
6258464|NCT02023099|9951461|FG000|Overall Study|Non-fatal Adverse Event (AE)|0
6258465|NCT02023099|9951462|FG001|Overall Study|Non-fatal Adverse Event (AE)|0
6258466|NCT02023099|9951463|FG002|Overall Study|Non-fatal Adverse Event (AE)|1
6258467|NCT02023099|9951461|FG000|Overall Study|Withdrawn Consent|3
6258468|NCT02023099|9951462|FG001|Overall Study|Withdrawn Consent|0
6258469|NCT02023099|9951463|FG002|Overall Study|Withdrawn Consent|1
6258470|NCT02023099|9951461|FG000|Overall Study|Non-treatment-emergent Fatal AE|0
6258471|NCT02023099|9951462|FG001|Overall Study|Non-treatment-emergent Fatal AE|0
6258472|NCT02023099|9951463|FG002|Overall Study|Non-treatment-emergent Fatal AE|1
6258473|NCT02023112|9951473|FG000|Overall Study|Withdrawal by Subject|2
6258474|NCT02023112|9951474|FG001|Overall Study|Withdrawal by Subject|1
6258475|NCT02023151|9951498|FG000|Overall Study|Lost to Follow-up|4
6258476|NCT02023242|9951504|FG000|Overall Study|Lost to Follow-up|3
6258477|NCT02023242|9951505|FG001|Overall Study|Lost to Follow-up|1
6258478|NCT02023242|9951504|FG000|Overall Study|Death|0
6258479|NCT02023242|9951505|FG001|Overall Study|Death|1
6258480|NCT02023268|9951513|FG000|Overall Study|Lack of Efficacy|0
6258481|NCT02023268|9951514|FG001|Overall Study|Lack of Efficacy|1
6258482|NCT02023268|9951513|FG000|Overall Study|Adverse Event|0
6258483|NCT02023268|9951514|FG001|Overall Study|Adverse Event|2
6258484|NCT02023268|9951513|FG000|Overall Study|Withdrawal by Subject|0
6258485|NCT02023268|9951514|FG001|Overall Study|Withdrawal by Subject|1
6258486|NCT02023697|9951542|FG000|Treatment Period|Radiological progression|13
6258487|NCT02023697|9951543|FG001|Treatment Period|Radiological progression|17
6258488|NCT02023697|9951544|FG002|Treatment Period|Radiological progression|26
6258489|NCT02023697|9951542|FG000|Treatment Period|Never Treated|5
6258490|NCT02023697|9951543|FG001|Treatment Period|Never Treated|6
6258491|NCT02023697|9951544|FG002|Treatment Period|Never Treated|10
6258492|NCT02023697|9951542|FG000|Treatment Period|Adverse Event|13
6258493|NCT02023697|9951543|FG001|Treatment Period|Adverse Event|25
6258494|NCT02023697|9951544|FG002|Treatment Period|Adverse Event|23
6258495|NCT02023697|9951542|FG000|Treatment Period|Logistical difficulties|1
6258496|NCT02023697|9951543|FG001|Treatment Period|Logistical difficulties|1
6258497|NCT02023697|9951544|FG002|Treatment Period|Logistical difficulties|1
6258498|NCT02023697|9951542|FG000|Treatment Period|Clinical progression|10
6258499|NCT02023697|9951543|FG001|Treatment Period|Clinical progression|8
6258500|NCT02023697|9951544|FG002|Treatment Period|Clinical progression|28
6258501|NCT02023697|9951542|FG000|Treatment Period|Withdrawal by Subject|4
6258502|NCT02023697|9951543|FG001|Treatment Period|Withdrawal by Subject|5
6258503|NCT02023697|9951544|FG002|Treatment Period|Withdrawal by Subject|13
6258504|NCT02023697|9951542|FG000|Treatment Period|Safety outcome reached|0
6258505|NCT02023697|9951543|FG001|Treatment Period|Safety outcome reached|1
6258506|NCT02023697|9951544|FG002|Treatment Period|Safety outcome reached|0
6258507|NCT02023697|9951542|FG000|Treatment Period|Physician Decision|0
6258508|NCT02023697|9951543|FG001|Treatment Period|Physician Decision|0
6258509|NCT02023697|9951544|FG002|Treatment Period|Physician Decision|1
6258510|NCT02023697|9951542|FG000|Active Follow-up Period|Withdrawal by Subject|5
6258511|NCT02023697|9951543|FG001|Active Follow-up Period|Withdrawal by Subject|13
6258512|NCT02023697|9951544|FG002|Active Follow-up Period|Withdrawal by Subject|7
6258513|NCT02023697|9951542|FG000|Active Follow-up Period|Lost to Follow-up|1
6258514|NCT02023697|9951543|FG001|Active Follow-up Period|Lost to Follow-up|1
6258515|NCT02023697|9951544|FG002|Active Follow-up Period|Lost to Follow-up|1
6258516|NCT02023697|9951542|FG000|Active Follow-up Period|Deterioration of general condition|1
6258517|NCT02023697|9951543|FG001|Active Follow-up Period|Deterioration of general condition|1
6258518|NCT02023697|9951544|FG002|Active Follow-up Period|Deterioration of general condition|1
6258519|NCT02023697|9951542|FG000|Active Follow-up Period|Other unspecified|2
6258520|NCT02023697|9951543|FG001|Active Follow-up Period|Other unspecified|0
6258521|NCT02023697|9951544|FG002|Active Follow-up Period|Other unspecified|1
6258522|NCT02023697|9951542|FG000|Active Follow-up Period|Clinical progression|0
6258523|NCT02023697|9951543|FG001|Active Follow-up Period|Clinical progression|2
6258524|NCT02023697|9951544|FG002|Active Follow-up Period|Clinical progression|1
6258525|NCT02023697|9951542|FG000|Active Follow-up Period|Radiological progression|0
6258526|NCT02023697|9951543|FG001|Active Follow-up Period|Radiological progression|0
6258527|NCT02023697|9951544|FG002|Active Follow-up Period|Radiological progression|1
6258528|NCT02023697|9951542|FG000|Active Follow-up Period|Death|83
6258529|NCT02023697|9951543|FG001|Active Follow-up Period|Death|82
6258530|NCT02023697|9951544|FG002|Active Follow-up Period|Death|87
6258531|NCT02023697|9951542|FG000|Long-term Follow-up Period|Death|9
6258532|NCT02023697|9951543|FG001|Long-term Follow-up Period|Death|6
6258533|NCT02023697|9951544|FG002|Long-term Follow-up Period|Death|4
6258534|NCT02023697|9951542|FG000|Long-term Follow-up Period|Withdrawal by Subject|6
6258535|NCT02023697|9951543|FG001|Long-term Follow-up Period|Withdrawal by Subject|3
6258536|NCT02023697|9951544|FG002|Long-term Follow-up Period|Withdrawal by Subject|0
6258537|NCT02023697|9951542|FG000|Long-term Follow-up Period|Lost to Follow-up|1
6258538|NCT02023697|9951543|FG001|Long-term Follow-up Period|Lost to Follow-up|0
6258539|NCT02023697|9951544|FG002|Long-term Follow-up Period|Lost to Follow-up|1
6258540|NCT02023697|9951542|FG000|Long-term Follow-up Period|Entered the long-term follow-up study|6
6258541|NCT02023697|9951543|FG001|Long-term Follow-up Period|Entered the long-term follow-up study|9
6258542|NCT02023697|9951544|FG002|Long-term Follow-up Period|Entered the long-term follow-up study|6
6258543|NCT02023697|9951542|FG000|Long-term Follow-up Period|Technical problems|0
6258544|NCT02023697|9951543|FG001|Long-term Follow-up Period|Technical problems|0
6258545|NCT02023697|9951544|FG002|Long-term Follow-up Period|Technical problems|1
6258546|NCT02023697|9951542|FG000|Long-term Follow-up Period|Other unspecified|6
6258547|NCT02023697|9951543|FG001|Long-term Follow-up Period|Other unspecified|3
6258548|NCT02023697|9951544|FG002|Long-term Follow-up Period|Other unspecified|5
6258549|NCT02023866|9951563|FG000|Overall Study|Non-compliance|2
6258550|NCT02023866|9951563|FG000|Overall Study|Adverse Event|3
6258551|NCT02023866|9951563|FG000|Overall Study|Withdrawal by Subject|1
6258552|NCT02023879|9951570|FG000|Period 1: 24-Week Double-blind Treatment|Adverse Event|2
6258553|NCT02023879|9951571|FG001|Period 1: 24-Week Double-blind Treatment|Adverse Event|2
6258554|NCT02023879|9951572|FG002|Period 1: 24-Week Double-blind Treatment|Adverse Event|5
6258555|NCT02023879|9951570|FG000|Period 1: 24-Week Double-blind Treatment|Poor compliance to protocol|0
6258556|NCT02023879|9951571|FG001|Period 1: 24-Week Double-blind Treatment|Poor compliance to protocol|2
6258557|NCT02023879|9951572|FG002|Period 1: 24-Week Double-blind Treatment|Poor compliance to protocol|1
6258558|NCT02023879|9951570|FG000|Period 1: 24-Week Double-blind Treatment|Physician Decision|0
6258559|NCT02023879|9951571|FG001|Period 1: 24-Week Double-blind Treatment|Physician Decision|1
6258560|NCT02023879|9951572|FG002|Period 1: 24-Week Double-blind Treatment|Physician Decision|0
6258561|NCT02023879|9951570|FG000|Period 1: 24-Week Double-blind Treatment|Consent withdrawn by participant|1
6258562|NCT02023879|9951571|FG001|Period 1: 24-Week Double-blind Treatment|Consent withdrawn by participant|0
6258563|NCT02023879|9951572|FG002|Period 1: 24-Week Double-blind Treatment|Consent withdrawn by participant|1
6258564|NCT02023879|9951570|FG000|Period 1: 24-Week Double-blind Treatment|Randomized but not treated|0
6258565|NCT02023879|9951571|FG001|Period 1: 24-Week Double-blind Treatment|Randomized but not treated|1
6258566|NCT02023879|9951572|FG002|Period 1: 24-Week Double-blind Treatment|Randomized but not treated|1
6258567|NCT02023879|9951570|FG000|Period 1: 24-Week Double-blind Treatment|Other than specified above|1
6258568|NCT02023879|9951571|FG001|Period 1: 24-Week Double-blind Treatment|Other than specified above|3
6258569|NCT02023879|9951572|FG002|Period 1: 24-Week Double-blind Treatment|Other than specified above|1
6258570|NCT02023879|9951570|FG000|Extension Open Label Treatment|Adverse Event|1
6258571|NCT02023879|9951571|FG001|Extension Open Label Treatment|Adverse Event|7
6258572|NCT02023879|9951572|FG002|Extension Open Label Treatment|Adverse Event|3
6258573|NCT02023879|9951570|FG000|Extension Open Label Treatment|Poor compliance to protocol|1
6258574|NCT02023879|9951571|FG001|Extension Open Label Treatment|Poor compliance to protocol|1
6258575|NCT02023879|9951572|FG002|Extension Open Label Treatment|Poor compliance to protocol|0
6258576|NCT02023879|9951570|FG000|Extension Open Label Treatment|Participant moved|1
6258577|NCT02023879|9951571|FG001|Extension Open Label Treatment|Participant moved|2
6258578|NCT02023879|9951572|FG002|Extension Open Label Treatment|Participant moved|0
6258579|NCT02023879|9951570|FG000|Extension Open Label Treatment|Other than specified above|2
6258580|NCT02023879|9951571|FG001|Extension Open Label Treatment|Other than specified above|7
6258581|NCT02023879|9951572|FG002|Extension Open Label Treatment|Other than specified above|2
6258582|NCT02024698|9951670|FG000|First Intervention (7 Days)|Withdrawal by Subject|0
6258583|NCT02024698|9951671|FG001|First Intervention (7 Days)|Withdrawal by Subject|1
6258584|NCT02024750|9951697|FG000|Overall Study|Withdrawal by Subject|2
6258585|NCT02024750|9951698|FG001|Overall Study|Withdrawal by Subject|1
6258586|NCT02024867|9951706|FG000|Overall Study|Protocol Violation|3
6258587|NCT02024867|9951707|FG001|Overall Study|Protocol Violation|3
6258588|NCT02024867|9951706|FG000|Overall Study|Lost to Follow-up|6
6258589|NCT02024867|9951707|FG001|Overall Study|Lost to Follow-up|4
6258590|NCT02024932|9951719|FG000|Overall Study|Adverse Event|2
6258591|NCT02024932|9951720|FG001|Overall Study|Adverse Event|3
6258592|NCT02024932|9951721|FG002|Overall Study|Adverse Event|0
6258593|NCT02024932|9951722|FG003|Overall Study|Adverse Event|0
6258594|NCT02024932|9951723|FG004|Overall Study|Adverse Event|2
6258595|NCT02024932|9951724|FG005|Overall Study|Adverse Event|0
6258596|NCT02024932|9951719|FG000|Overall Study|Abnormal laboratory value|0
6258597|NCT02024932|9951720|FG001|Overall Study|Abnormal laboratory value|0
6258598|NCT02024932|9951721|FG002|Overall Study|Abnormal laboratory value|0
6258599|NCT02024932|9951722|FG003|Overall Study|Abnormal laboratory value|2
6258600|NCT02024932|9951723|FG004|Overall Study|Abnormal laboratory value|0
6258601|NCT02024932|9951724|FG005|Overall Study|Abnormal laboratory value|0
6258602|NCT02024971|9951744|FG000|Overall Study|Data Not Available|30
6258603|NCT02024971|9951744|FG000|Overall Study|Lost to Follow-up|6
6258604|NCT02025179|9951766|FG000|Overall Study|Lost to Follow-up|0
6258605|NCT02025179|9951767|FG001|Overall Study|Lost to Follow-up|0
6258606|NCT02025179|9951768|FG002|Overall Study|Lost to Follow-up|1
6258607|NCT02025205|9951778|FG000|Overall Study|Withdrawal by Subject|1
6258608|NCT02025205|9951779|FG001|Overall Study|Withdrawal by Subject|1
6258609|NCT02025205|9951778|FG000|Overall Study|Protocol Violation|2
6258610|NCT02025205|9951779|FG001|Overall Study|Protocol Violation|1
6258611|NCT02025205|9951778|FG000|Overall Study|Death|0
6258612|NCT02025205|9951779|FG001|Overall Study|Death|1
6258613|NCT02025530|9951807|FG000|Overall Study|No longer met elligibility criteria|5
6258614|NCT02025530|9951808|FG001|Overall Study|No longer met elligibility criteria|1
6258615|NCT02025621|9951816|FG000|Overall Study|Withdrawal by Subject|1
6258616|NCT02025621|9951817|FG001|Overall Study|Withdrawal by Subject|0
6258617|NCT02025621|9951816|FG000|Overall Study|Death|0
6258618|NCT02025621|9951817|FG001|Overall Study|Death|1
6258619|NCT02025621|9951816|FG000|Overall Study|No longer eligible|10
6258620|NCT02025621|9951817|FG001|Overall Study|No longer eligible|15
6258621|NCT02025621|9951816|FG000|Overall Study|Surgery initiated before infusion|3
6258622|NCT02025621|9951817|FG001|Overall Study|Surgery initiated before infusion|3
6258623|NCT02025725|9951838|FG000|Overall Study|Adverse Event|5
6258624|NCT02025725|9951839|FG001|Overall Study|Adverse Event|0
6258625|NCT02025725|9951838|FG000|Overall Study|Lost to Follow-up|2
6258626|NCT02025725|9951839|FG001|Overall Study|Lost to Follow-up|0
6258627|NCT02025725|9951838|FG000|Overall Study|Protocol Violation|1
6258628|NCT02025725|9951839|FG001|Overall Study|Protocol Violation|1
6258629|NCT02025725|9951838|FG000|Overall Study|Withdrawal by Subject|3
6258630|NCT02025725|9951839|FG001|Overall Study|Withdrawal by Subject|2
6258631|NCT02025725|9951838|FG000|Overall Study|Post-dose QTcB > 270 msec|0
6258632|NCT02025725|9951839|FG001|Overall Study|Post-dose QTcB > 270 msec|1
6258633|NCT02025751|9951849|FG000|Overall Study|Lost to Follow-up|1
6258634|NCT02025751|9951850|FG001|Overall Study|Lost to Follow-up|0
6258635|NCT02025751|9951849|FG000|Overall Study|Adverse Event|0
6258636|NCT02025751|9951850|FG001|Overall Study|Adverse Event|1
6258637|NCT02025751|9951849|FG000|Overall Study|Physician Decision|0
6258638|NCT02025751|9951850|FG001|Overall Study|Physician Decision|1
6258639|NCT02025751|9951849|FG000|Overall Study|Withdrawal by Subject|0
6258640|NCT02025751|9951850|FG001|Overall Study|Withdrawal by Subject|1
6271163|NCT02160899|9972763|FG002|Overall Study|Adverse Event or Serious Adverse Event|0
6271164|NCT02160899|9972764|FG003|Overall Study|Adverse Event or Serious Adverse Event|1
6271165|NCT02160899|9972765|FG004|Overall Study|Adverse Event or Serious Adverse Event|2
6271166|NCT02160899|9972766|FG005|Overall Study|Adverse Event or Serious Adverse Event|0
6271167|NCT02160977|9972782|FG000|Six Weeks After Surgery|Lost to Follow-up|1
6271168|NCT02160977|9972783|FG001|Six Weeks After Surgery|Lost to Follow-up|0
6271169|NCT02160977|9972782|FG000|Three Months After Surgery|Lost to Follow-up|0
6271170|NCT02160977|9972783|FG001|Three Months After Surgery|Lost to Follow-up|2
6271171|NCT02160977|9972782|FG000|Six Months After Surgery|Lost to Follow-up|2
6271172|NCT02160977|9972783|FG001|Six Months After Surgery|Lost to Follow-up|1
6271173|NCT02161146|9972812|FG000|Overall Study|Adverse Event|1
6271174|NCT02161146|9972813|FG001|Overall Study|Adverse Event|1
6271175|NCT02161146|9972814|FG002|Overall Study|Adverse Event|0
6271176|NCT02161146|9972815|FG003|Overall Study|Adverse Event|1
6271177|NCT02161146|9972816|FG004|Overall Study|Adverse Event|0
6271178|NCT02161146|9972812|FG000|Overall Study|Lost to Follow-up|0
6271179|NCT02161146|9972813|FG001|Overall Study|Lost to Follow-up|1
6271180|NCT02161146|9972814|FG002|Overall Study|Lost to Follow-up|0
6271181|NCT02161146|9972815|FG003|Overall Study|Lost to Follow-up|0
6271182|NCT02161146|9972816|FG004|Overall Study|Lost to Follow-up|0
6271183|NCT02161146|9972812|FG000|Overall Study|Personal Reasons|0
6271184|NCT02161146|9972813|FG001|Overall Study|Personal Reasons|1
6271185|NCT02161146|9972814|FG002|Overall Study|Personal Reasons|0
6271186|NCT02161146|9972815|FG003|Overall Study|Personal Reasons|2
6271187|NCT02161146|9972816|FG004|Overall Study|Personal Reasons|1
6271188|NCT02161146|9972812|FG000|Overall Study|Other Miscellaneous Reasons|0
6271189|NCT02161146|9972813|FG001|Overall Study|Other Miscellaneous Reasons|1
6271190|NCT02161146|9972814|FG002|Overall Study|Other Miscellaneous Reasons|0
6271191|NCT02161146|9972815|FG003|Overall Study|Other Miscellaneous Reasons|0
6271192|NCT02161146|9972816|FG004|Overall Study|Other Miscellaneous Reasons|0
6271193|NCT02161185|9972826|FG000|Treatment Phase|Administrative/Other|7
6271194|NCT02161406|9972832|FG000|Overall Study|Death|2
6271195|NCT02161406|9972833|FG001|Overall Study|Death|1
6271196|NCT02161406|9972832|FG000|Overall Study|Lost to Follow-up|2
6271197|NCT02161406|9972833|FG001|Overall Study|Lost to Follow-up|1
6271198|NCT02161406|9972832|FG000|Overall Study|Withdrawal by Subject|2
6271199|NCT02161406|9972833|FG001|Overall Study|Withdrawal by Subject|4
6086669|NCT00662649|9696710|FG001|Extension Study (Month 24 to 60)|Subject withdrew consent|23
6271200|NCT02161406|9972832|FG000|Overall Study|investigator withdrew subject|3
6271201|NCT02161406|9972833|FG001|Overall Study|investigator withdrew subject|1
6271202|NCT02161406|9972832|FG000|Overall Study|Lack of Efficacy|1
6271203|NCT02161406|9972833|FG001|Overall Study|Lack of Efficacy|1
6271204|NCT02161406|9972832|FG000|Overall Study|relocation|0
6271205|NCT02161406|9972833|FG001|Overall Study|relocation|1
6271206|NCT02161458|9972843|FG000|Overall Study|Withdrawal by Subject|0
6271207|NCT02161458|9972844|FG001|Overall Study|Withdrawal by Subject|4
6271208|NCT02161458|9972845|FG002|Overall Study|Withdrawal by Subject|4
6271209|NCT02161458|9972846|FG003|Overall Study|Withdrawal by Subject|0
6271210|NCT02161458|9972843|FG000|Overall Study|Lost to Follow-up|0
6271211|NCT02161458|9972844|FG001|Overall Study|Lost to Follow-up|2
6258641|NCT02025907|9951868|FG000|Overall Study|Lack of Efficacy|1
6258642|NCT02025907|9951869|FG001|Overall Study|Lack of Efficacy|0
6258643|NCT02025907|9951868|FG000|Overall Study|Withdrawal by Subject|15
6258644|NCT02025907|9951869|FG001|Overall Study|Withdrawal by Subject|8
6258645|NCT02025907|9951868|FG000|Overall Study|Protocol Violation|2
6258646|NCT02025907|9951869|FG001|Overall Study|Protocol Violation|0
6258647|NCT02025907|9951868|FG000|Overall Study|Physician Decision|2
6258648|NCT02025907|9951869|FG001|Overall Study|Physician Decision|0
6258649|NCT02025907|9951868|FG000|Overall Study|Lost to Follow-up|2
6258650|NCT02025907|9951869|FG001|Overall Study|Lost to Follow-up|2
6258651|NCT02025907|9951868|FG000|Overall Study|Adverse Event|3
6258652|NCT02025907|9951869|FG001|Overall Study|Adverse Event|1
6258653|NCT02025907|9951868|FG000|Overall Study|Potential misconduct,GCPcompliance issue|2
6258654|NCT02025907|9951869|FG001|Overall Study|Potential misconduct,GCPcompliance issue|1
6258655|NCT02025985|9951880|FG000|Overall Study|Consent withdrawn|0
6258656|NCT02025985|9951881|FG001|Overall Study|Consent withdrawn|0
6258657|NCT02025985|9951882|FG002|Overall Study|Consent withdrawn|1
6258658|NCT02025985|9951883|FG003|Overall Study|Consent withdrawn|0
6258659|NCT02025985|9951884|FG004|Overall Study|Consent withdrawn|0
6258660|NCT02025985|9951880|FG000|Overall Study|Termination of study by Sponsor|4
6258661|NCT02025985|9951881|FG001|Overall Study|Termination of study by Sponsor|3
6258662|NCT02025985|9951882|FG002|Overall Study|Termination of study by Sponsor|1
6258663|NCT02025985|9951883|FG003|Overall Study|Termination of study by Sponsor|1
6258664|NCT02025985|9951884|FG004|Overall Study|Termination of study by Sponsor|3
6258665|NCT02025985|9951880|FG000|Overall Study|Death|21
6258666|NCT02025985|9951881|FG001|Overall Study|Death|20
6258667|NCT02025985|9951882|FG002|Overall Study|Death|23
6258668|NCT02025985|9951883|FG003|Overall Study|Death|20
6258669|NCT02025985|9951884|FG004|Overall Study|Death|17
6258670|NCT02026011|9951900|FG000|Allocation 1 (First Set of Medication)|Side Effects|6
6258671|NCT02026011|9951901|FG001|Allocation 1 (First Set of Medication)|Side Effects|0
6258672|NCT02026011|9951900|FG000|Allocation 1 (First Set of Medication)|Withdrawal by Subject|1
6258673|NCT02026011|9951901|FG001|Allocation 1 (First Set of Medication)|Withdrawal by Subject|2
6258674|NCT02026011|9951900|FG000|Allocation 1 (First Set of Medication)|Investigator Withdrawal|1
6258675|NCT02026011|9951901|FG001|Allocation 1 (First Set of Medication)|Investigator Withdrawal|0
6258676|NCT02026011|9951900|FG000|Allocation 2 (Second Set of Medication)|Withdrawal by Subject|1
6258677|NCT02026011|9951901|FG001|Allocation 2 (Second Set of Medication)|Withdrawal by Subject|2
6258678|NCT02026063|9951912|FG000|Overall Study|Physician Decision|0
6258679|NCT02026063|9951913|FG001|Overall Study|Physician Decision|10
6258680|NCT02026063|9951912|FG000|Overall Study|Noncompliance with Study Drug|1
6258681|NCT02026063|9951913|FG001|Overall Study|Noncompliance with Study Drug|1
6258682|NCT02026063|9951912|FG000|Overall Study|Withdrawal of Consent|1
6258683|NCT02026063|9951913|FG001|Overall Study|Withdrawal of Consent|6
6258684|NCT02026063|9951912|FG000|Overall Study|Adverse Event|5
6258685|NCT02026063|9951913|FG001|Overall Study|Adverse Event|20
6258686|NCT02026063|9951912|FG000|Overall Study|Lack of Efficacy|0
6258687|NCT02026063|9951913|FG001|Overall Study|Lack of Efficacy|4
6258688|NCT02026063|9951912|FG000|Overall Study|Lost to Follow-up|0
6258689|NCT02026063|9951913|FG001|Overall Study|Lost to Follow-up|1
6258690|NCT02026063|9951912|FG000|Overall Study|Reason not Specified|2
6258691|NCT02026063|9951913|FG001|Overall Study|Reason not Specified|7
6258692|NCT02026141|9951922|FG000|Overall Study|Protocol Violation|0
6258693|NCT02026141|9951923|FG001|Overall Study|Protocol Violation|1
6258694|NCT02026258|9951949|FG000|Randomized|Did not start treatment|2
6258695|NCT02026258|9951950|FG001|Randomized|Did not start treatment|1
6258696|NCT02026258|9951949|FG000|Randomized|Change in treatment plan|1
6258697|NCT02026258|9951950|FG001|Randomized|Change in treatment plan|0
6258698|NCT02026258|9951949|FG000|Randomized|Presence of periodontal disease|1
6258699|NCT02026258|9951950|FG001|Randomized|Presence of periodontal disease|1
6258700|NCT02026258|9951949|FG000|Recieved Allocated Intervention|Withdrawal by Subject|1
6258701|NCT02026258|9951950|FG001|Recieved Allocated Intervention|Withdrawal by Subject|1
6258702|NCT02026258|9951949|FG000|Recieved Allocated Intervention|Lost to Follow-up|0
6258703|NCT02026258|9951950|FG001|Recieved Allocated Intervention|Lost to Follow-up|1
6258704|NCT02027025|9951991|FG000|Overall Study|Adverse Event|0
6258705|NCT02027025|9951992|FG001|Overall Study|Adverse Event|1
6258706|NCT02027025|9951993|FG002|Overall Study|Adverse Event|1
6258707|NCT02027025|9951991|FG000|Overall Study|Protocol Violation|1
6258708|NCT02027025|9951992|FG001|Overall Study|Protocol Violation|0
6258709|NCT02027025|9951993|FG002|Overall Study|Protocol Violation|0
6258710|NCT02027025|9951991|FG000|Overall Study|Lost to Follow-up|0
6258711|NCT02027025|9951992|FG001|Overall Study|Lost to Follow-up|2
6258712|NCT02027025|9951993|FG002|Overall Study|Lost to Follow-up|0
6258713|NCT02027025|9951991|FG000|Overall Study|Withdrawal by Subject|0
6258714|NCT02027025|9951992|FG001|Overall Study|Withdrawal by Subject|1
6258715|NCT02027025|9951993|FG002|Overall Study|Withdrawal by Subject|0
6258716|NCT02027025|9951991|FG000|Overall Study|Sponsor's decision|0
6258717|NCT02027025|9951992|FG001|Overall Study|Sponsor's decision|1
6258718|NCT02027025|9951993|FG002|Overall Study|Sponsor's decision|0
6258719|NCT02027311|9952014|FG000|Overall Study|Protocol Violation|3
6258720|NCT02027311|9952015|FG001|Overall Study|Protocol Violation|2
6258721|NCT02027376|9952023|FG000|Overall Study|Death|1
6258722|NCT02027376|9952024|FG001|Overall Study|Death|0
6258723|NCT02027376|9952025|FG002|Overall Study|Death|0
6258724|NCT02027402|9952037|FG000|Overall Study|Withdrawal by Subject|4
6258725|NCT02027402|9952038|FG001|Overall Study|Withdrawal by Subject|1
6258726|NCT02027428|9952048|FG000|Induction|Never treated|7
6258727|NCT02027428|9952049|FG001|Induction|Never treated|0
6258728|NCT02027428|9952050|FG002|Induction|Never treated|0
6258729|NCT02027428|9952048|FG000|Induction|Progressive disease|77
6258730|NCT02027428|9952049|FG001|Induction|Progressive disease|0
6258731|NCT02027428|9952050|FG002|Induction|Progressive disease|0
6258732|NCT02027428|9952048|FG000|Induction|Adverse Event|51
6258733|NCT02027428|9952049|FG001|Induction|Adverse Event|0
6258734|NCT02027428|9952050|FG002|Induction|Adverse Event|0
6258735|NCT02027428|9952048|FG000|Induction|Withdrawal by Subject|22
6258736|NCT02027428|9952049|FG001|Induction|Withdrawal by Subject|0
6258737|NCT02027428|9952050|FG002|Induction|Withdrawal by Subject|0
6258738|NCT02027428|9952048|FG000|Induction|Death|21
6258739|NCT02027428|9952049|FG001|Induction|Death|0
6258740|NCT02027428|9952050|FG002|Induction|Death|0
6258741|NCT02027428|9952048|FG000|Induction|Symptomatic deterioration|16
6258742|NCT02027428|9952049|FG001|Induction|Symptomatic deterioration|0
6258743|NCT02027428|9952050|FG002|Induction|Symptomatic deterioration|0
6258744|NCT02027428|9952048|FG000|Induction|Study terminated by sponsor|12
6258745|NCT02027428|9952049|FG001|Induction|Study terminated by sponsor|0
6258746|NCT02027428|9952050|FG002|Induction|Study terminated by sponsor|0
6258747|NCT02027428|9952048|FG000|Induction|Protocol Violation|1
6258748|NCT02027428|9952049|FG001|Induction|Protocol Violation|0
6258749|NCT02027428|9952050|FG002|Induction|Protocol Violation|0
6258750|NCT02027428|9952048|FG000|Induction|Miscellaneous|14
6258751|NCT02027428|9952049|FG001|Induction|Miscellaneous|0
6258752|NCT02027428|9952050|FG002|Induction|Miscellaneous|0
6258753|NCT02027428|9952048|FG000|Induction|Induction Treatment Ongoing|4
6258754|NCT02027428|9952049|FG001|Induction|Induction Treatment Ongoing|0
6258755|NCT02027428|9952050|FG002|Induction|Induction Treatment Ongoing|0
6258756|NCT02027428|9952048|FG000|Maintenance|Death|0
6258757|NCT02027428|9952049|FG001|Maintenance|Death|3
6258758|NCT02027428|9952050|FG002|Maintenance|Death|2
6258759|NCT02027428|9952048|FG000|Maintenance|Adverse Event|0
6258760|NCT02027428|9952049|FG001|Maintenance|Adverse Event|21
6258761|NCT02027428|9952050|FG002|Maintenance|Adverse Event|1
6258762|NCT02027428|9952048|FG000|Maintenance|Progressive disease|0
6258763|NCT02027428|9952049|FG001|Maintenance|Progressive disease|84
6258764|NCT02027428|9952050|FG002|Maintenance|Progressive disease|47
6258765|NCT02027428|9952048|FG000|Maintenance|Symptomatic deterioration|0
6258766|NCT02027428|9952049|FG001|Maintenance|Symptomatic deterioration|4
6258767|NCT02027428|9952050|FG002|Maintenance|Symptomatic deterioration|1
6258768|NCT02027428|9952048|FG000|Maintenance|Withdrawal by Subject|0
6258769|NCT02027428|9952049|FG001|Maintenance|Withdrawal by Subject|6
6258770|NCT02027428|9952050|FG002|Maintenance|Withdrawal by Subject|5
6258771|NCT02027428|9952048|FG000|Maintenance|Protocol Violation|0
6258772|NCT02027428|9952049|FG001|Maintenance|Protocol Violation|0
6258773|NCT02027428|9952050|FG002|Maintenance|Protocol Violation|1
6258774|NCT02027428|9952048|FG000|Maintenance|Other|0
6258775|NCT02027428|9952049|FG001|Maintenance|Other|6
6258776|NCT02027428|9952050|FG002|Maintenance|Other|3
6258777|NCT02027428|9952048|FG000|Survival Follow-up|Death|0
6258778|NCT02027428|9952049|FG001|Survival Follow-up|Death|78
6258779|NCT02027428|9952050|FG002|Survival Follow-up|Death|45
6258780|NCT02027428|9952048|FG000|Survival Follow-up|Lost to Follow-up|0
6258781|NCT02027428|9952049|FG001|Survival Follow-up|Lost to Follow-up|1
6258782|NCT02027428|9952050|FG002|Survival Follow-up|Lost to Follow-up|1
6258783|NCT02027545|9952075|FG000|Overall Study|Failed to sign HIPAA|0
6258784|NCT02027545|9952076|FG001|Overall Study|Failed to sign HIPAA|2
6258785|NCT02027545|9952075|FG000|Overall Study|Failed to attend study visit|2
6258786|NCT02027545|9952076|FG001|Overall Study|Failed to attend study visit|0
6258787|NCT02027558|9952084|FG000|Overall Study|Death|0
6258788|NCT02027558|9952085|FG001|Overall Study|Death|1
6258789|NCT02027558|9952084|FG000|Overall Study|Withdrawal by Subject|2
6258790|NCT02027558|9952085|FG001|Overall Study|Withdrawal by Subject|0
6258791|NCT02027558|9952084|FG000|Overall Study|Lost to Follow-up|4
6258792|NCT02027558|9952085|FG001|Overall Study|Lost to Follow-up|1
6258793|NCT02027558|9952084|FG000|Overall Study|Refused assessment|3
6258794|NCT02027558|9952085|FG001|Overall Study|Refused assessment|0
6258795|NCT02027623|9952095|FG000|Overall Study|Lost to Follow-up|3
6258796|NCT02027623|9952096|FG001|Overall Study|Lost to Follow-up|3
6258797|NCT02027623|9952095|FG000|Overall Study|Withdrawal by Subject|6
6258798|NCT02027623|9952096|FG001|Overall Study|Withdrawal by Subject|9
6258799|NCT02027701|9952103|FG000|Overall Study|Adverse Event|3
6258800|NCT02027701|9952103|FG000|Overall Study|Lack of Efficacy|8
6258801|NCT02027701|9952103|FG000|Overall Study|Physician Decision|2
6258802|NCT02027701|9952103|FG000|Overall Study|Withdrawal by Subject|3
6258803|NCT02027844|9952112|FG000|Overall Study|Withdrawal by Subject|3
6258804|NCT02027844|9952113|FG001|Overall Study|Withdrawal by Subject|2
6258805|NCT02027844|9952114|FG002|Overall Study|Withdrawal by Subject|1
6258806|NCT02027844|9952112|FG000|Overall Study|Lost to Follow-up|0
6258807|NCT02027844|9952113|FG001|Overall Study|Lost to Follow-up|2
6258808|NCT02027844|9952114|FG002|Overall Study|Lost to Follow-up|1
6258809|NCT02027844|9952112|FG000|Overall Study|Protocol Violation|0
6258810|NCT02027844|9952113|FG001|Overall Study|Protocol Violation|2
6258811|NCT02027844|9952114|FG002|Overall Study|Protocol Violation|0
6258812|NCT02027844|9952112|FG000|Overall Study|Incomlete data|2
6258813|NCT02027844|9952113|FG001|Overall Study|Incomlete data|0
6258814|NCT02027844|9952114|FG002|Overall Study|Incomlete data|0
6258815|NCT02028065|9952138|FG000|Randomization Through Start Treatment|Not treated|1
6258816|NCT02028065|9952139|FG001|Randomization Through Start Treatment|Not treated|3
6258817|NCT02028065|9952140|FG002|Randomization Through Start Treatment|Not treated|3
6258818|NCT02028065|9952138|FG000|Treatment Through Study Completion|Lost to Follow-up|2
6258819|NCT02028065|9952139|FG001|Treatment Through Study Completion|Lost to Follow-up|4
6258820|NCT02028065|9952140|FG002|Treatment Through Study Completion|Lost to Follow-up|6
6258821|NCT02028065|9952138|FG000|Treatment Through Study Completion|Physician Decision|1
6258822|NCT02028065|9952139|FG001|Treatment Through Study Completion|Physician Decision|0
6258823|NCT02028065|9952140|FG002|Treatment Through Study Completion|Physician Decision|0
6258824|NCT02028065|9952138|FG000|Treatment Through Study Completion|Protocol Violation|1
6258825|NCT02028065|9952139|FG001|Treatment Through Study Completion|Protocol Violation|4
6258826|NCT02028065|9952140|FG002|Treatment Through Study Completion|Protocol Violation|0
6258827|NCT02028065|9952138|FG000|Treatment Through Study Completion|Withdrawal by Subject|5
6258828|NCT02028065|9952139|FG001|Treatment Through Study Completion|Withdrawal by Subject|4
6258829|NCT02028065|9952140|FG002|Treatment Through Study Completion|Withdrawal by Subject|3
6258830|NCT02028065|9952138|FG000|Treatment Through Study Completion|Adverse Event|3
6258831|NCT02028065|9952139|FG001|Treatment Through Study Completion|Adverse Event|3
6258832|NCT02028065|9952140|FG002|Treatment Through Study Completion|Adverse Event|5
6258833|NCT02028169|9952148|FG000|Overall Study|Lost to Follow-up|21
6258834|NCT02028169|9952148|FG000|Overall Study|Lack of Efficacy|2
6258835|NCT02028169|9952148|FG000|Overall Study|Withdrawal by Subject|2
6258836|NCT02028169|9952148|FG000|Overall Study|Adverse Event|1
6258837|NCT02028169|9952148|FG000|Overall Study|Cessation of Drug|1
6258838|NCT02028169|9952148|FG000|Overall Study|Concomitant Medication Usage|1
6258839|NCT02028182|9952152|FG000|Overall Study|Protocol Violation|2
6258840|NCT02028715|9952239|FG000|Overall Study|Adverse Event|2
6258841|NCT02028715|9952240|FG001|Overall Study|Adverse Event|2
6258842|NCT02028715|9952239|FG000|Overall Study|Physician Decision|1
6258843|NCT02028715|9952240|FG001|Overall Study|Physician Decision|0
6258844|NCT02028715|9952239|FG000|Overall Study|Did not complete satisfaction surveys|2
6258845|NCT02028715|9952240|FG001|Overall Study|Did not complete satisfaction surveys|2
6258846|NCT02028767|9952255|FG000|Treatment Period 2|Non compliant with protocol|1
6086670|NCT00662649|9696711|FG002|Extension Study (Month 24 to 60)|Subject withdrew consent|0
6086671|NCT00662649|9696712|FG003|Extension Study (Month 24 to 60)|Subject withdrew consent|15
6086672|NCT00662649|9696713|FG004|Extension Study (Month 24 to 60)|Subject withdrew consent|9
6086673|NCT00662649|9696709|FG000|Extension Study (Month 24 to 60)|Subject no longer requires study drug|0
6086674|NCT00662649|9696710|FG001|Extension Study (Month 24 to 60)|Subject no longer requires study drug|1
6086675|NCT00662649|9696711|FG002|Extension Study (Month 24 to 60)|Subject no longer requires study drug|0
6086676|NCT00662649|9696712|FG003|Extension Study (Month 24 to 60)|Subject no longer requires study drug|0
6086677|NCT00662649|9696713|FG004|Extension Study (Month 24 to 60)|Subject no longer requires study drug|0
6086678|NCT00662649|9696709|FG000|Extension Study (Month 24 to 60)|Unsatisfactory therapeutic effect|3
6086679|NCT00662649|9696710|FG001|Extension Study (Month 24 to 60)|Unsatisfactory therapeutic effect|1
6086680|NCT00662649|9696711|FG002|Extension Study (Month 24 to 60)|Unsatisfactory therapeutic effect|0
6086681|NCT00662649|9696712|FG003|Extension Study (Month 24 to 60)|Unsatisfactory therapeutic effect|1
6086682|NCT00662649|9696713|FG004|Extension Study (Month 24 to 60)|Unsatisfactory therapeutic effect|3
6086683|NCT00662831|9696749|FG000|Overall Study|Death|4
6086684|NCT00662831|9696750|FG001|Overall Study|Death|1
6086685|NCT00662831|9696749|FG000|Overall Study|Lack of Efficacy|6
6086686|NCT00662831|9696750|FG001|Overall Study|Lack of Efficacy|6
6086687|NCT00662831|9696749|FG000|Overall Study|Lost to Follow-up|1
6086688|NCT00662831|9696750|FG001|Overall Study|Lost to Follow-up|0
6086689|NCT00662831|9696749|FG000|Overall Study|Withdrawal by Subject|2
6086690|NCT00662831|9696750|FG001|Overall Study|Withdrawal by Subject|1
6086691|NCT00662831|9696749|FG000|Overall Study|Other|62
6086692|NCT00662831|9696750|FG001|Overall Study|Other|31
6086693|NCT00662831|9696749|FG000|Overall Study|Protocol Violation|8
6086694|NCT00662831|9696750|FG001|Overall Study|Protocol Violation|4
6086695|NCT00662831|9696749|FG000|Overall Study|Adverse Event|23
6086696|NCT00662831|9696750|FG001|Overall Study|Adverse Event|16
6086697|NCT00662857|9696756|FG000|Washout 1 (3 - 14 Days)|Physician Decision|0
6086698|NCT00662857|9696757|FG001|Washout 1 (3 - 14 Days)|Physician Decision|1
6086699|NCT00662857|9696756|FG000|Washout 1 (3 - 14 Days)|Withdrawal by Subject|0
6086700|NCT00662857|9696757|FG001|Washout 1 (3 - 14 Days)|Withdrawal by Subject|1
6086701|NCT00662857|9696756|FG000|Washout 2 (3 - 14 Days)|Cannot Use Clamp Data|1
6086702|NCT00662857|9696757|FG001|Washout 2 (3 - 14 Days)|Cannot Use Clamp Data|0
6086703|NCT00662909|9696769|FG000|Overall Study|Adverse Event|17
6086704|NCT00662909|9696770|FG001|Overall Study|Adverse Event|18
6086705|NCT00662909|9696771|FG002|Overall Study|Adverse Event|19
6086706|NCT00662909|9696769|FG000|Overall Study|Lack of Efficacy|9
6086707|NCT00662909|9696770|FG001|Overall Study|Lack of Efficacy|1
6258847|NCT02028767|9952256|FG001|Treatment Period 2|Non compliant with protocol|0
6258848|NCT02028767|9952255|FG000|Treatment Period 2|Reason other than those specified above|1
6086708|NCT00662909|9696771|FG002|Overall Study|Lack of Efficacy|5
6086709|NCT00662909|9696769|FG000|Overall Study|Withdrawal by Subject|29
6086710|NCT00662909|9696770|FG001|Overall Study|Withdrawal by Subject|22
6086711|NCT00662909|9696771|FG002|Overall Study|Withdrawal by Subject|16
6258849|NCT02028767|9952256|FG001|Treatment Period 2|Reason other than those specified above|0
6258850|NCT02028871|9952331|FG000|Overall Study|Positive urine drug screen|1
6258851|NCT02028871|9952332|FG001|Overall Study|Positive urine drug screen|1
6258852|NCT02028871|9952331|FG000|Overall Study|Withdrawal by Subject|1
6258853|NCT02028871|9952332|FG001|Overall Study|Withdrawal by Subject|2
6258854|NCT02028871|9952331|FG000|Overall Study|IV placement difficulty|1
6258855|NCT02028871|9952332|FG001|Overall Study|IV placement difficulty|0
6258856|NCT02028871|9952331|FG000|Overall Study|Current Illness|1
6258857|NCT02028871|9952332|FG001|Overall Study|Current Illness|0
6258858|NCT02029235|9952361|FG000|Overall Study|Non-compliance with study meds or diary|4
6258859|NCT02029235|9952362|FG001|Overall Study|Non-compliance with study meds or diary|1
6258860|NCT02029274|9952372|FG000|Overall Study|Adverse Event|1
6258861|NCT02029274|9952373|FG001|Overall Study|Adverse Event|0
6258862|NCT02029274|9952374|FG002|Overall Study|Adverse Event|2
6258863|NCT02029274|9952375|FG003|Overall Study|Adverse Event|2
6258864|NCT02029417|9952389|FG000|Overall Study|Death|1
6258865|NCT02029417|9952389|FG000|Overall Study|Adverse Event|1
6258866|NCT02029521|9952408|FG000|Overall Study|Protocol Violation|1
6258867|NCT02029521|9952409|FG001|Overall Study|Protocol Violation|0
6258868|NCT02029521|9952408|FG000|Overall Study|Withdrawal by Subject|1
6258869|NCT02029521|9952409|FG001|Overall Study|Withdrawal by Subject|1
6258870|NCT02029638|9952421|FG000|Overall Study|Death|0
6258871|NCT02029638|9952422|FG001|Overall Study|Death|0
6258872|NCT02029638|9952423|FG002|Overall Study|Death|1
6258873|NCT02029638|9952421|FG000|Overall Study|Decision by Study Sponsor or Regulatory|2
6258874|NCT02029638|9952422|FG001|Overall Study|Decision by Study Sponsor or Regulatory|0
6258875|NCT02029638|9952423|FG002|Overall Study|Decision by Study Sponsor or Regulatory|0
6258876|NCT02029976|9952468|FG000|YR-1 Post Intervention vs Baseline|Lost to Follow-up|12
6258877|NCT02029976|9952469|FG001|YR-1 Post Intervention vs Baseline|Lost to Follow-up|8
6258878|NCT02029976|9952468|FG000|YR-2 Follow Up vs Baseline|Lost to Follow-up|8
6258879|NCT02029976|9952469|FG001|YR-2 Follow Up vs Baseline|Lost to Follow-up|4
6258880|NCT02029976|9952468|FG000|YR-2 Follow Up vs Baseline|Withdrawal by Subject|2
6258881|NCT02029976|9952469|FG001|YR-2 Follow Up vs Baseline|Withdrawal by Subject|2
6258882|NCT02029976|9952468|FG000|YR-2 Follow Up vs Baseline|Moved from area|0
6258883|NCT02029976|9952469|FG001|YR-2 Follow Up vs Baseline|Moved from area|2
6258884|NCT02029989|9952477|FG000|Overall Study|Withdrawal by Subject|1
6258885|NCT02029989|9952478|FG001|Overall Study|Withdrawal by Subject|0
6258886|NCT02029989|9952477|FG000|Overall Study|Withdrawal: Fear of needles|1
6258887|NCT02029989|9952478|FG001|Overall Study|Withdrawal: Fear of needles|0
6258888|NCT02029989|9952477|FG000|Overall Study|Change of location|2
6258889|NCT02029989|9952478|FG001|Overall Study|Change of location|3
6258890|NCT02029989|9952477|FG000|Overall Study|Physician Decision|2
6258891|NCT02029989|9952478|FG001|Overall Study|Physician Decision|0
6258892|NCT02029989|9952477|FG000|Overall Study|Lost to Follow-up|9
6258893|NCT02029989|9952478|FG001|Overall Study|Lost to Follow-up|7
6258894|NCT02029989|9952477|FG000|Overall Study|Death|0
6258895|NCT02029989|9952478|FG001|Overall Study|Death|1
6258896|NCT02029989|9952477|FG000|Overall Study|Protocol Violation|1
6258897|NCT02029989|9952478|FG001|Overall Study|Protocol Violation|0
6258898|NCT02030002|9952484|FG000|Enrollment|Participant had change in treatment plan and no longer met the inclusion criteria|1
6258899|NCT02030002|9952484|FG000|Enrollment|Participants signed consent, but enrollment was completed before their treatment began.|4
6258900|NCT02030002|9952484|FG000|Follow-up|Lost to Follow-up|2
6258901|NCT02030041|9952493|FG000|Overall Study|Withdrawal by Subject|2
6258902|NCT02030041|9952494|FG001|Overall Study|Withdrawal by Subject|2
6258903|NCT02030041|9952495|FG002|Overall Study|Withdrawal by Subject|1
6258904|NCT02030119|9952524|FG000|Overall Study|Withdrawal by Subject|3
6258905|NCT02030119|9952525|FG001|Overall Study|Withdrawal by Subject|1
6258906|NCT02030119|9952526|FG002|Overall Study|Withdrawal by Subject|5
6258907|NCT02030119|9952527|FG003|Overall Study|Withdrawal by Subject|3
6258908|NCT02030119|9952524|FG000|Overall Study|Ineligible (see Pre-assignment Details)|0
6258909|NCT02030119|9952525|FG001|Overall Study|Ineligible (see Pre-assignment Details)|1
6258910|NCT02030119|9952526|FG002|Overall Study|Ineligible (see Pre-assignment Details)|1
6086712|NCT00662909|9696769|FG000|Overall Study|Lost to Follow-up|2
6086713|NCT00662909|9696770|FG001|Overall Study|Lost to Follow-up|9
6086714|NCT00662909|9696771|FG002|Overall Study|Lost to Follow-up|3
6258911|NCT02030119|9952527|FG003|Overall Study|Ineligible (see Pre-assignment Details)|0
6258912|NCT02030405|9952550|FG000|Overall Study|Withdrawal by Subject|1
6258913|NCT02030405|9952550|FG000|Overall Study|Lost to Follow-up|1
6258914|NCT02030535|9952555|FG000|Washout Period 1 (21 Days)|Adverse Event|1
6258915|NCT02030600|9952575|FG000|Treatment Period 1|Adverse Event|5
6258916|NCT02030600|9952576|FG001|Treatment Period 1|Adverse Event|7
6258917|NCT02030600|9952575|FG000|Treatment Period 1|Lack of Efficacy|0
6258918|NCT02030600|9952576|FG001|Treatment Period 1|Lack of Efficacy|1
6086715|NCT00662909|9696769|FG000|Overall Study|Protocol Violation|7
6258919|NCT02030600|9952575|FG000|Treatment Period 1|Lost to Follow-up|11
6258920|NCT02030600|9952576|FG001|Treatment Period 1|Lost to Follow-up|3
6258921|NCT02030600|9952575|FG000|Treatment Period 1|Protocol Violation|22
6258922|NCT02030600|9952576|FG001|Treatment Period 1|Protocol Violation|17
6258923|NCT02030600|9952575|FG000|Treatment Period 1|Withdrawal by Subject|13
6258924|NCT02030600|9952576|FG001|Treatment Period 1|Withdrawal by Subject|17
6258925|NCT02030600|9952575|FG000|Treatment Period 1|Casebook Unsigned|1
6258926|NCT02030600|9952576|FG001|Treatment Period 1|Casebook Unsigned|0
6258927|NCT02030600|9952575|FG000|Treatment Period 1|Unclassified|1
6258928|NCT02030600|9952576|FG001|Treatment Period 1|Unclassified|0
6258929|NCT02030600|9952575|FG000|Treatment Period 2|Adverse Event|4
6258930|NCT02030600|9952576|FG001|Treatment Period 2|Adverse Event|4
6258931|NCT02030600|9952575|FG000|Treatment Period 2|Lack of Efficacy|2
6258932|NCT02030600|9952576|FG001|Treatment Period 2|Lack of Efficacy|1
6258933|NCT02030600|9952575|FG000|Treatment Period 2|Lost to Follow-up|4
6258934|NCT02030600|9952576|FG001|Treatment Period 2|Lost to Follow-up|2
6258935|NCT02030600|9952575|FG000|Treatment Period 2|Protocol Violation|1
6258936|NCT02030600|9952576|FG001|Treatment Period 2|Protocol Violation|2
6258937|NCT02030600|9952575|FG000|Treatment Period 2|Withdrawal by Subject|13
6258938|NCT02030600|9952576|FG001|Treatment Period 2|Withdrawal by Subject|9
6258939|NCT02030600|9952575|FG000|Treatment Period 2|Unclassified|1
6258940|NCT02030600|9952576|FG001|Treatment Period 2|Unclassified|0
6258941|NCT02030821|9952588|FG000|Overall Study|Physician Decision|2
6258942|NCT02030821|9952589|FG001|Overall Study|Physician Decision|2
6258943|NCT02030821|9952590|FG002|Overall Study|Physician Decision|5
6258944|NCT02030821|9952591|FG003|Overall Study|Physician Decision|2
6258945|NCT02030834|9952604|FG000|Overall Study|Death|4
6258946|NCT02030834|9952605|FG001|Overall Study|Death|0
6258947|NCT02030834|9952606|FG002|Overall Study|Death|0
6258948|NCT02030834|9952604|FG000|Overall Study|Manufacturing failure|2
6258949|NCT02030834|9952605|FG001|Overall Study|Manufacturing failure|0
6258950|NCT02030834|9952606|FG002|Overall Study|Manufacturing failure|1
6086716|NCT00662909|9696770|FG001|Overall Study|Protocol Violation|4
6086717|NCT00662909|9696771|FG002|Overall Study|Protocol Violation|5
6086718|NCT00662909|9696769|FG000|Overall Study|Randomized- never received study drug|1
6258951|NCT02030834|9952604|FG000|Overall Study|Disease progression|2
6258952|NCT02030834|9952605|FG001|Overall Study|Disease progression|0
6258953|NCT02030834|9952606|FG002|Overall Study|Disease progression|2
6258954|NCT02030834|9952604|FG000|Overall Study|Lost to Follow-up|1
6258955|NCT02030834|9952605|FG001|Overall Study|Lost to Follow-up|0
6258956|NCT02030834|9952606|FG002|Overall Study|Lost to Follow-up|0
6258957|NCT02030834|9952604|FG000|Overall Study|Withdrawal by Subject|1
6258958|NCT02030834|9952605|FG001|Overall Study|Withdrawal by Subject|0
6258959|NCT02030834|9952606|FG002|Overall Study|Withdrawal by Subject|0
6258960|NCT02030834|9952604|FG000|Overall Study|Lack of funding|1
6258961|NCT02030834|9952605|FG001|Overall Study|Lack of funding|0
6258962|NCT02030834|9952606|FG002|Overall Study|Lack of funding|0
6258963|NCT02030847|9952614|FG000|Overall Study|Death|10
6258964|NCT02030847|9952614|FG000|Overall Study|Disease Progression|15
6258965|NCT02030847|9952614|FG000|Overall Study|New Cancer Therapy|8
6258966|NCT02030847|9952614|FG000|Overall Study|Physician Decision|3
6258967|NCT02030847|9952614|FG000|Overall Study|Withdrawal by Subject|1
6258968|NCT02031146|9952632|FG000|Overall Study|Did not meet criteria for inclusion in data analysis|0
6258969|NCT02031146|9952633|FG001|Overall Study|Did not meet criteria for inclusion in data analysis|0
6258970|NCT02031146|9952634|FG002|Overall Study|Did not meet criteria for inclusion in data analysis|0
6258971|NCT02031146|9952635|FG003|Overall Study|Did not meet criteria for inclusion in data analysis|100
6258972|NCT02031146|9952636|FG004|Overall Study|Did not meet criteria for inclusion in data analysis|26
6258973|NCT02031146|9952637|FG005|Overall Study|Did not meet criteria for inclusion in data analysis|4
6258974|NCT02031146|9952638|FG006|Overall Study|Did not meet criteria for inclusion in data analysis|5
6258975|NCT02031237|9952650|FG000|Overall Study|Death|1
6258976|NCT02031237|9952651|FG001|Overall Study|Death|5
6258977|NCT02031237|9952652|FG002|Overall Study|Death|0
6258978|NCT02031237|9952650|FG000|Overall Study|Physician Decision|0
6258979|NCT02031237|9952651|FG001|Overall Study|Physician Decision|1
6258980|NCT02031237|9952652|FG002|Overall Study|Physician Decision|0
6258981|NCT02031237|9952650|FG000|Overall Study|Withdrawal by Subject|2
6258982|NCT02031237|9952651|FG001|Overall Study|Withdrawal by Subject|2
6258983|NCT02031237|9952652|FG002|Overall Study|Withdrawal by Subject|0
6258984|NCT02031237|9952650|FG000|Overall Study|Protocol Violation|2
6258985|NCT02031237|9952651|FG001|Overall Study|Protocol Violation|6
6258986|NCT02031237|9952652|FG002|Overall Study|Protocol Violation|0
6258987|NCT02031237|9952650|FG000|Overall Study|Alternate Treatment Given|0
6258988|NCT02031237|9952651|FG001|Overall Study|Alternate Treatment Given|0
6258989|NCT02031237|9952652|FG002|Overall Study|Alternate Treatment Given|3
6258990|NCT02031276|9952662|FG000|Period 1 Double-blind IV|Adverse Event|6
6258991|NCT02031276|9952663|FG001|Period 1 Double-blind IV|Adverse Event|5
6258992|NCT02031276|9952664|FG002|Period 1 Double-blind IV|Adverse Event|1
6258993|NCT02031276|9952662|FG000|Period 1 Double-blind IV|Other|0
6258994|NCT02031276|9952663|FG001|Period 1 Double-blind IV|Other|1
6258995|NCT02031276|9952664|FG002|Period 1 Double-blind IV|Other|0
6258996|NCT02031276|9952662|FG000|Period 2 Open-label Risankizumab IV|Adverse Event|1
6258997|NCT02031276|9952663|FG001|Period 2 Open-label Risankizumab IV|Adverse Event|0
6258998|NCT02031276|9952664|FG002|Period 2 Open-label Risankizumab IV|Adverse Event|0
6258999|NCT02031276|9952662|FG000|Period 2 Open-label Risankizumab IV|Withdrawal by Subject|3
6259000|NCT02031276|9952663|FG001|Period 2 Open-label Risankizumab IV|Withdrawal by Subject|0
6259001|NCT02031276|9952664|FG002|Period 2 Open-label Risankizumab IV|Withdrawal by Subject|0
6259002|NCT02031276|9952662|FG000|Period 2 Open-label Risankizumab IV|Other|0
6259003|NCT02031276|9952663|FG001|Period 2 Open-label Risankizumab IV|Other|2
6259004|NCT02031276|9952664|FG002|Period 2 Open-label Risankizumab IV|Other|1
6259005|NCT02031276|9952662|FG000|Period 3 Open-label Risankizumab SC|Adverse Event|0
6259006|NCT02031276|9952663|FG001|Period 3 Open-label Risankizumab SC|Adverse Event|2
6259007|NCT02031276|9952664|FG002|Period 3 Open-label Risankizumab SC|Adverse Event|0
6259008|NCT02031276|9952662|FG000|Period 3 Open-label Risankizumab SC|Protocol Violation|2
6259009|NCT02031276|9952663|FG001|Period 3 Open-label Risankizumab SC|Protocol Violation|0
6259010|NCT02031276|9952664|FG002|Period 3 Open-label Risankizumab SC|Protocol Violation|0
6259011|NCT02031276|9952662|FG000|Period 3 Open-label Risankizumab SC|Withdrawal by Subject|1
6259012|NCT02031276|9952663|FG001|Period 3 Open-label Risankizumab SC|Withdrawal by Subject|1
6259013|NCT02031276|9952664|FG002|Period 3 Open-label Risankizumab SC|Withdrawal by Subject|1
6259014|NCT02031276|9952662|FG000|Period 3 Open-label Risankizumab SC|Other|0
6259015|NCT02031276|9952663|FG001|Period 3 Open-label Risankizumab SC|Other|0
6259016|NCT02031276|9952664|FG002|Period 3 Open-label Risankizumab SC|Other|1
6259017|NCT02031302|9952678|FG000|Overall Study|Death|115
6259018|NCT02031302|9952679|FG001|Overall Study|Death|0
6259019|NCT02031302|9952678|FG000|Overall Study|Not treated with study valve system|18
6259020|NCT02031302|9952679|FG001|Overall Study|Not treated with study valve system|0
6259021|NCT02031302|9952678|FG000|Overall Study|Missed Follow Up|27
6259022|NCT02031302|9952679|FG001|Overall Study|Missed Follow Up|0
6259023|NCT02031302|9952678|FG000|Overall Study|Lost to Follow-up|4
6259024|NCT02031302|9952679|FG001|Overall Study|Lost to Follow-up|0
6259025|NCT02031432|9952686|FG000|Overall Study|Protocol Violation|1
6259026|NCT02031432|9952686|FG000|Overall Study|Lack of Efficacy|5
6259027|NCT02031432|9952686|FG000|Overall Study|Cancer Progression|2
6259028|NCT02031432|9952686|FG000|Overall Study|Withdrawn as forbidden meds required|1
6259029|NCT02031432|9952686|FG000|Overall Study|Adverse Event|8
6259030|NCT02031432|9952686|FG000|Overall Study|Withdrawal by Subject|5
6259031|NCT02031432|9952686|FG000|Overall Study|Lost to Follow-up|1
6259032|NCT02031432|9952686|FG000|Overall Study|Inclusion/Exclusion criteria not met|5
6259033|NCT02031432|9952686|FG000|Overall Study|Death|10
6259034|NCT02031458|9952693|FG000|May 8, 2015 to January 11, 2019|Death|89
6259035|NCT02031458|9952694|FG001|May 8, 2015 to January 11, 2019|Death|193
6259036|NCT02031458|9952695|FG002|May 8, 2015 to January 11, 2019|Death|198
6259037|NCT02031458|9952693|FG000|May 8, 2015 to January 11, 2019|Lost to Follow-up|2
6259038|NCT02031458|9952694|FG001|May 8, 2015 to January 11, 2019|Lost to Follow-up|5
6259039|NCT02031458|9952695|FG002|May 8, 2015 to January 11, 2019|Lost to Follow-up|8
6259040|NCT02031458|9952693|FG000|May 8, 2015 to January 11, 2019|Switched over to commercial Atezolizumab|1
6259041|NCT02031458|9952694|FG001|May 8, 2015 to January 11, 2019|Switched over to commercial Atezolizumab|6
6259042|NCT02031458|9952695|FG002|May 8, 2015 to January 11, 2019|Switched over to commercial Atezolizumab|6
6259043|NCT02031458|9952693|FG000|May 8, 2015 to January 11, 2019|Physician Decision|2
6259044|NCT02031458|9952694|FG001|May 8, 2015 to January 11, 2019|Physician Decision|3
6259045|NCT02031458|9952695|FG002|May 8, 2015 to January 11, 2019|Physician Decision|3
6259046|NCT02031458|9952693|FG000|May 8, 2015 to January 11, 2019|Protocol Violation|7
6259047|NCT02031458|9952694|FG001|May 8, 2015 to January 11, 2019|Protocol Violation|4
6259048|NCT02031458|9952695|FG002|May 8, 2015 to January 11, 2019|Protocol Violation|0
6259049|NCT02031458|9952693|FG000|May 8, 2015 to January 11, 2019|Study Terminated by Sponsor|24
6259050|NCT02031458|9952694|FG001|May 8, 2015 to January 11, 2019|Study Terminated by Sponsor|42
6259051|NCT02031458|9952695|FG002|May 8, 2015 to January 11, 2019|Study Terminated by Sponsor|23
6259052|NCT02031458|9952693|FG000|May 8, 2015 to January 11, 2019|Withdrawal by Subject|13
6259053|NCT02031458|9952694|FG001|May 8, 2015 to January 11, 2019|Withdrawal by Subject|16
6259054|NCT02031458|9952695|FG002|May 8, 2015 to January 11, 2019|Withdrawal by Subject|14
6259055|NCT02031458|9952693|FG000|Baseline to May 8, 2015|Death|36
6259056|NCT02031458|9952694|FG001|Baseline to May 8, 2015|Death|87
6259057|NCT02031458|9952695|FG002|Baseline to May 8, 2015|Death|100
6259058|NCT02031458|9952693|FG000|Baseline to May 8, 2015|Protocol Violation|7
6259059|NCT02031458|9952694|FG001|Baseline to May 8, 2015|Protocol Violation|4
6259060|NCT02031458|9952695|FG002|Baseline to May 8, 2015|Protocol Violation|0
6259061|NCT02031458|9952693|FG000|Baseline to May 8, 2015|Physician Decision|0
6259062|NCT02031458|9952694|FG001|Baseline to May 8, 2015|Physician Decision|1
6259063|NCT02031458|9952695|FG002|Baseline to May 8, 2015|Physician Decision|0
6259064|NCT02031458|9952693|FG000|Baseline to May 8, 2015|Unknown Reason|0
6259065|NCT02031458|9952694|FG001|Baseline to May 8, 2015|Unknown Reason|1
6259066|NCT02031458|9952695|FG002|Baseline to May 8, 2015|Unknown Reason|2
6259067|NCT02031458|9952693|FG000|Baseline to May 8, 2015|Withdrawal by Subject|6
6259068|NCT02031458|9952694|FG001|Baseline to May 8, 2015|Withdrawal by Subject|9
6259069|NCT02031458|9952695|FG002|Baseline to May 8, 2015|Withdrawal by Subject|3
6259070|NCT02031458|9952693|FG000|Baseline to May 8, 2015|On Survival Follow-Up|46
6259071|NCT02031458|9952694|FG001|Baseline to May 8, 2015|On Survival Follow-Up|83
6259072|NCT02031458|9952695|FG002|Baseline to May 8, 2015|On Survival Follow-Up|73
6259073|NCT02031458|9952693|FG000|Baseline to May 8, 2015|On Treatment|43
6259074|NCT02031458|9952694|FG001|Baseline to May 8, 2015|On Treatment|81
6259075|NCT02031458|9952695|FG002|Baseline to May 8, 2015|On Treatment|73
6259076|NCT02031458|9952693|FG000|Baseline to May 8, 2015|Lost to Follow-up|1
6259077|NCT02031458|9952694|FG001|Baseline to May 8, 2015|Lost to Follow-up|1
6259078|NCT02031458|9952695|FG002|Baseline to May 8, 2015|Lost to Follow-up|2
6259079|NCT02031471|9952705|FG000|24 Week Treatment Period|Adverse Event|6
6259080|NCT02031471|9952705|FG000|24 Week Treatment Period|Participant Decision to Withdraw|2
6259081|NCT02031471|9952705|FG000|24 Week Treatment Period|Protocol Violation|1
6259082|NCT02031471|9952705|FG000|24 Week Treatment Period|Insufficient Therapeutic Response|1
6259083|NCT02031471|9952705|FG000|24 Week Treatment Period|Hypersensitivity Reaction|1
6259084|NCT02031471|9952705|FG000|Long Term Extension (LTE) Period|Adverse Event|1
6259085|NCT02031471|9952705|FG000|Long Term Extension (LTE) Period|Insufficient Therapeutic Response|1
6259086|NCT02031536|9952711|FG000|Overall Study|ineligible|1
6259087|NCT02031536|9952712|FG001|Overall Study|ineligible|0
6259088|NCT02031640|9952736|FG000|Screening Period|Adverse Event|1
6259089|NCT02031640|9952737|FG001|Screening Period|Adverse Event|0
6259090|NCT02031640|9952738|FG002|Screening Period|Adverse Event|0
6259091|NCT02031640|9952739|FG003|Screening Period|Adverse Event|0
6259092|NCT02031640|9952740|FG004|Screening Period|Adverse Event|0
6259093|NCT02031640|9952741|FG005|Screening Period|Adverse Event|0
6259094|NCT02031640|9952736|FG000|Screening Period|Withdrawal by Subject|29
6259095|NCT02031640|9952737|FG001|Screening Period|Withdrawal by Subject|0
6259096|NCT02031640|9952738|FG002|Screening Period|Withdrawal by Subject|0
6259097|NCT02031640|9952739|FG003|Screening Period|Withdrawal by Subject|0
6259098|NCT02031640|9952740|FG004|Screening Period|Withdrawal by Subject|0
6259099|NCT02031640|9952741|FG005|Screening Period|Withdrawal by Subject|0
6259100|NCT02031640|9952736|FG000|Screening Period|Inclusion criteria not met|312
6259101|NCT02031640|9952737|FG001|Screening Period|Inclusion criteria not met|0
6259102|NCT02031640|9952738|FG002|Screening Period|Inclusion criteria not met|0
6259103|NCT02031640|9952739|FG003|Screening Period|Inclusion criteria not met|0
6259104|NCT02031640|9952740|FG004|Screening Period|Inclusion criteria not met|0
6259105|NCT02031640|9952741|FG005|Screening Period|Inclusion criteria not met|0
6259106|NCT02031640|9952736|FG000|Screening Period|Exclusion criteria met|30
6259107|NCT02031640|9952737|FG001|Screening Period|Exclusion criteria met|0
6259108|NCT02031640|9952738|FG002|Screening Period|Exclusion criteria met|0
6259109|NCT02031640|9952739|FG003|Screening Period|Exclusion criteria met|0
6259110|NCT02031640|9952740|FG004|Screening Period|Exclusion criteria met|0
6259111|NCT02031640|9952741|FG005|Screening Period|Exclusion criteria met|0
6086719|NCT00662909|9696770|FG001|Overall Study|Randomized- never received study drug|0
6086720|NCT00662909|9696771|FG002|Overall Study|Randomized- never received study drug|0
6086721|NCT00662909|9696769|FG000|Overall Study|Non-compliance with study procedures|3
6086722|NCT00662909|9696770|FG001|Overall Study|Non-compliance with study procedures|3
6086723|NCT00662909|9696771|FG002|Overall Study|Non-compliance with study procedures|2
6086724|NCT00662909|9696769|FG000|Overall Study|Physician Decision|1
6086725|NCT00662909|9696770|FG001|Overall Study|Physician Decision|1
6086726|NCT00662909|9696771|FG002|Overall Study|Physician Decision|2
6086727|NCT00662909|9696769|FG000|Overall Study|Eligibility criterion not met|0
6086728|NCT00662909|9696770|FG001|Overall Study|Eligibility criterion not met|1
6086729|NCT00662909|9696771|FG002|Overall Study|Eligibility criterion not met|1
6086730|NCT00663026|9696782|FG000|Overall Study|Lost to Follow-up|1
6086731|NCT00663026|9696783|FG001|Overall Study|Lost to Follow-up|0
6086732|NCT00663026|9696784|FG002|Overall Study|Lost to Follow-up|0
6086733|NCT00663026|9696782|FG000|Overall Study|Other|1
6086734|NCT00663026|9696783|FG001|Overall Study|Other|2
6086735|NCT00663026|9696784|FG002|Overall Study|Other|0
6086736|NCT00663026|9696782|FG000|Overall Study|Adverse Event|0
6086737|NCT00663026|9696783|FG001|Overall Study|Adverse Event|2
6086738|NCT00663026|9696784|FG002|Overall Study|Adverse Event|3
6086739|NCT00663026|9696782|FG000|Overall Study|Caregiver Request|0
6086740|NCT00663026|9696783|FG001|Overall Study|Caregiver Request|2
6086741|NCT00663026|9696784|FG002|Overall Study|Caregiver Request|0
6086742|NCT00663026|9696782|FG000|Overall Study|Withdrawal by Subject|0
6086743|NCT00663026|9696783|FG001|Overall Study|Withdrawal by Subject|0
6086744|NCT00663026|9696784|FG002|Overall Study|Withdrawal by Subject|1
6086745|NCT00663117|9696803|FG000|Overall Study|Lack of Efficacy|1
6086746|NCT00663117|9696804|FG001|Overall Study|Lack of Efficacy|0
6086747|NCT00663208|9696832|FG000|Treatment Period|Lost to Follow-up|0
6086748|NCT00663208|9696833|FG001|Treatment Period|Lost to Follow-up|1
6086749|NCT00663208|9696834|FG002|Treatment Period|Lost to Follow-up|0
6086750|NCT00663208|9696835|FG003|Treatment Period|Lost to Follow-up|0
6086751|NCT00663208|9696836|FG004|Treatment Period|Lost to Follow-up|0
6086752|NCT00663208|9696837|FG005|Treatment Period|Lost to Follow-up|0
6259112|NCT02031640|9952736|FG000|Screening Period|Lost to Follow-up|14
6259113|NCT02031640|9952737|FG001|Screening Period|Lost to Follow-up|0
6259114|NCT02031640|9952738|FG002|Screening Period|Lost to Follow-up|0
6086753|NCT00663208|9696838|FG006|Treatment Period|Lost to Follow-up|0
6086754|NCT00663208|9696832|FG000|Follow-up Period|Lost to Follow-up|2
6086755|NCT00663208|9696833|FG001|Follow-up Period|Lost to Follow-up|0
6086756|NCT00663208|9696834|FG002|Follow-up Period|Lost to Follow-up|3
6086757|NCT00663208|9696835|FG003|Follow-up Period|Lost to Follow-up|2
6259115|NCT02031640|9952739|FG003|Screening Period|Lost to Follow-up|0
6259116|NCT02031640|9952740|FG004|Screening Period|Lost to Follow-up|0
6259117|NCT02031640|9952741|FG005|Screening Period|Lost to Follow-up|0
6259118|NCT02031640|9952736|FG000|Screening Period|Enrollment closed|26
6259119|NCT02031640|9952737|FG001|Screening Period|Enrollment closed|0
6259120|NCT02031640|9952738|FG002|Screening Period|Enrollment closed|0
6259121|NCT02031640|9952739|FG003|Screening Period|Enrollment closed|0
6259122|NCT02031640|9952740|FG004|Screening Period|Enrollment closed|0
6259123|NCT02031640|9952741|FG005|Screening Period|Enrollment closed|0
6259124|NCT02031640|9952736|FG000|Run-In Period|Adverse Event|4
6259125|NCT02031640|9952737|FG001|Run-In Period|Adverse Event|0
6259126|NCT02031640|9952738|FG002|Run-In Period|Adverse Event|0
6259127|NCT02031640|9952739|FG003|Run-In Period|Adverse Event|0
6259128|NCT02031640|9952740|FG004|Run-In Period|Adverse Event|0
6259129|NCT02031640|9952741|FG005|Run-In Period|Adverse Event|0
6259130|NCT02031640|9952736|FG000|Run-In Period|Withdrawal by Subject|17
6259131|NCT02031640|9952737|FG001|Run-In Period|Withdrawal by Subject|0
6259132|NCT02031640|9952738|FG002|Run-In Period|Withdrawal by Subject|0
6259133|NCT02031640|9952739|FG003|Run-In Period|Withdrawal by Subject|0
6259134|NCT02031640|9952740|FG004|Run-In Period|Withdrawal by Subject|0
6259135|NCT02031640|9952741|FG005|Run-In Period|Withdrawal by Subject|0
6259136|NCT02031640|9952736|FG000|Run-In Period|Inclusion criteria not met|38
6259137|NCT02031640|9952737|FG001|Run-In Period|Inclusion criteria not met|0
6259138|NCT02031640|9952738|FG002|Run-In Period|Inclusion criteria not met|0
6259139|NCT02031640|9952739|FG003|Run-In Period|Inclusion criteria not met|0
6259140|NCT02031640|9952740|FG004|Run-In Period|Inclusion criteria not met|0
6259141|NCT02031640|9952741|FG005|Run-In Period|Inclusion criteria not met|0
6259142|NCT02031640|9952736|FG000|Run-In Period|Exclusion criteria met|8
6259143|NCT02031640|9952737|FG001|Run-In Period|Exclusion criteria met|0
6259144|NCT02031640|9952738|FG002|Run-In Period|Exclusion criteria met|0
6259145|NCT02031640|9952739|FG003|Run-In Period|Exclusion criteria met|0
6259146|NCT02031640|9952740|FG004|Run-In Period|Exclusion criteria met|0
6259147|NCT02031640|9952741|FG005|Run-In Period|Exclusion criteria met|0
6259148|NCT02031640|9952736|FG000|Run-In Period|Randomization criteria not met|85
6259149|NCT02031640|9952737|FG001|Run-In Period|Randomization criteria not met|0
6259150|NCT02031640|9952738|FG002|Run-In Period|Randomization criteria not met|0
6259151|NCT02031640|9952739|FG003|Run-In Period|Randomization criteria not met|0
6259152|NCT02031640|9952740|FG004|Run-In Period|Randomization criteria not met|0
6086758|NCT00663208|9696836|FG004|Follow-up Period|Lost to Follow-up|0
6259153|NCT02031640|9952741|FG005|Run-In Period|Randomization criteria not met|0
6259154|NCT02031640|9952736|FG000|Run-In Period|Various administrative reasons|17
6259155|NCT02031640|9952737|FG001|Run-In Period|Various administrative reasons|0
6259156|NCT02031640|9952738|FG002|Run-In Period|Various administrative reasons|0
6259157|NCT02031640|9952739|FG003|Run-In Period|Various administrative reasons|0
6259158|NCT02031640|9952740|FG004|Run-In Period|Various administrative reasons|0
6259159|NCT02031640|9952741|FG005|Run-In Period|Various administrative reasons|0
6259160|NCT02031640|9952736|FG000|Double-blind Treatment Period|Protocol deviation|0
6259161|NCT02031640|9952737|FG001|Double-blind Treatment Period|Protocol deviation|2
6259162|NCT02031640|9952738|FG002|Double-blind Treatment Period|Protocol deviation|0
6259163|NCT02031640|9952739|FG003|Double-blind Treatment Period|Protocol deviation|1
6259164|NCT02031640|9952740|FG004|Double-blind Treatment Period|Protocol deviation|3
6259165|NCT02031640|9952741|FG005|Double-blind Treatment Period|Protocol deviation|1
6259166|NCT02031640|9952736|FG000|Double-blind Treatment Period|Lack of Efficacy|0
6259167|NCT02031640|9952737|FG001|Double-blind Treatment Period|Lack of Efficacy|14
6259168|NCT02031640|9952738|FG002|Double-blind Treatment Period|Lack of Efficacy|3
6259169|NCT02031640|9952739|FG003|Double-blind Treatment Period|Lack of Efficacy|2
6259170|NCT02031640|9952740|FG004|Double-blind Treatment Period|Lack of Efficacy|5
6259171|NCT02031640|9952741|FG005|Double-blind Treatment Period|Lack of Efficacy|1
6259172|NCT02031640|9952736|FG000|Double-blind Treatment Period|Non-compliance|0
6259173|NCT02031640|9952737|FG001|Double-blind Treatment Period|Non-compliance|1
6259174|NCT02031640|9952738|FG002|Double-blind Treatment Period|Non-compliance|0
6259175|NCT02031640|9952739|FG003|Double-blind Treatment Period|Non-compliance|1
6259176|NCT02031640|9952740|FG004|Double-blind Treatment Period|Non-compliance|1
6259177|NCT02031640|9952741|FG005|Double-blind Treatment Period|Non-compliance|0
6259178|NCT02031640|9952736|FG000|Double-blind Treatment Period|Adverse Event|0
6259179|NCT02031640|9952737|FG001|Double-blind Treatment Period|Adverse Event|0
6259180|NCT02031640|9952738|FG002|Double-blind Treatment Period|Adverse Event|0
6259181|NCT02031640|9952739|FG003|Double-blind Treatment Period|Adverse Event|2
6259182|NCT02031640|9952740|FG004|Double-blind Treatment Period|Adverse Event|0
6259183|NCT02031640|9952741|FG005|Double-blind Treatment Period|Adverse Event|0
6086759|NCT00663208|9696837|FG005|Follow-up Period|Lost to Follow-up|0
6259184|NCT02031640|9952736|FG000|Double-blind Treatment Period|Withdrawal by Subject|0
6259185|NCT02031640|9952737|FG001|Double-blind Treatment Period|Withdrawal by Subject|2
6259186|NCT02031640|9952738|FG002|Double-blind Treatment Period|Withdrawal by Subject|3
6259187|NCT02031640|9952739|FG003|Double-blind Treatment Period|Withdrawal by Subject|1
6259188|NCT02031640|9952740|FG004|Double-blind Treatment Period|Withdrawal by Subject|1
6259189|NCT02031640|9952741|FG005|Double-blind Treatment Period|Withdrawal by Subject|1
6259190|NCT02031640|9952736|FG000|Double-blind Treatment Period|Lost to Follow-up|0
6259191|NCT02031640|9952737|FG001|Double-blind Treatment Period|Lost to Follow-up|3
6259192|NCT02031640|9952738|FG002|Double-blind Treatment Period|Lost to Follow-up|0
6259193|NCT02031640|9952739|FG003|Double-blind Treatment Period|Lost to Follow-up|0
6259194|NCT02031640|9952740|FG004|Double-blind Treatment Period|Lost to Follow-up|1
6259195|NCT02031640|9952741|FG005|Double-blind Treatment Period|Lost to Follow-up|0
6259196|NCT02031679|9952762|FG000|Overall Study|Protocol Violation|0
6259197|NCT02031679|9952763|FG001|Overall Study|Protocol Violation|1
6259198|NCT02031679|9952762|FG000|Overall Study|Lack of Efficacy|0
6259199|NCT02031679|9952763|FG001|Overall Study|Lack of Efficacy|1
6259200|NCT02032173|9952780|FG000|Overall Study|Discontinuation due to sponsor decision|31
6259201|NCT02032238|9952803|FG000|Overall Study|Lost to Follow-up|2
6259202|NCT02032238|9952804|FG001|Overall Study|Lost to Follow-up|0
6259203|NCT02032407|9952810|FG000|Overall Study|Lost to Follow-up|2
6259204|NCT02032407|9952810|FG000|Overall Study|Pregnancy|1
6259205|NCT02032407|9952810|FG000|Overall Study|Other Miscellaneous Reasons|2
6259206|NCT02032706|9952856|FG000|Overall Study|Did not qualify|5
6259207|NCT02032706|9952856|FG000|Overall Study|Protocol Violation|1
6259208|NCT02032875|9952871|FG000|Treatment Period|Adverse Event|1
6259209|NCT02032875|9952872|FG001|Treatment Period|Adverse Event|0
6259210|NCT02032875|9952871|FG000|Treatment Period|Liver transplant, No extension needed|0
6259211|NCT02032875|9952872|FG001|Treatment Period|Liver transplant, No extension needed|1
6259212|NCT02032875|9952871|FG000|Treatment Period|Liver transplant, Treatment extension|0
6259213|NCT02032875|9952872|FG001|Treatment Period|Liver transplant, Treatment extension|3
6259214|NCT02032875|9952871|FG000|Follow-up Period|Death|0
6259215|NCT02032875|9952872|FG001|Follow-up Period|Death|1
6259216|NCT02032875|9952871|FG000|Follow-up Period|Virologic Relapse|3
6259217|NCT02032875|9952872|FG001|Follow-up Period|Virologic Relapse|10
6259218|NCT02032888|9952882|FG000|Treatment Period|Poor compliance/noncompliance|1
6259219|NCT02032888|9952883|FG001|Treatment Period|Poor compliance/noncompliance|1
6259220|NCT02032888|9952884|FG002|Treatment Period|Poor compliance/noncompliance|0
6259221|NCT02032888|9952882|FG000|Treatment Period|Other|1
6259222|NCT02032888|9952883|FG001|Treatment Period|Other|1
6259223|NCT02032888|9952884|FG002|Treatment Period|Other|0
6259224|NCT02032888|9952882|FG000|Follow-up Period|Lost to Follow-up|1
6259225|NCT02032888|9952883|FG001|Follow-up Period|Lost to Follow-up|1
6259226|NCT02032888|9952884|FG002|Follow-up Period|Lost to Follow-up|0
6259227|NCT02032888|9952882|FG000|Follow-up Period|Death|1
6259228|NCT02032888|9952883|FG001|Follow-up Period|Death|1
6259229|NCT02032888|9952884|FG002|Follow-up Period|Death|0
6259230|NCT02032888|9952882|FG000|Follow-up Period|Other|1
6259231|NCT02032888|9952883|FG001|Follow-up Period|Other|0
6259232|NCT02032888|9952884|FG002|Follow-up Period|Other|0
6259233|NCT02032901|9952903|FG000|Treatment Period (12 Weeks)|Pregnancy|1
6259234|NCT02032901|9952904|FG001|Treatment Period (12 Weeks)|Pregnancy|0
6259235|NCT02032901|9952903|FG000|Follow-Up Period (24 Weeks)|Lost to Follow-up|0
6259236|NCT02032901|9952904|FG001|Follow-Up Period (24 Weeks)|Lost to Follow-up|1
6259237|NCT02033369|9952968|FG000|Overall Study|Physician Decision|1
6259238|NCT02033369|9952969|FG001|Overall Study|Physician Decision|2
6259239|NCT02033369|9952968|FG000|Overall Study|Not a good demographic match|0
6259240|NCT02033369|9952969|FG001|Overall Study|Not a good demographic match|2
6259241|NCT02033369|9952968|FG000|Overall Study|Withdrawal by Subject|1
6259242|NCT02033369|9952969|FG001|Overall Study|Withdrawal by Subject|1
6259243|NCT02033369|9952968|FG000|Overall Study|Lost to Follow-up|1
6259244|NCT02033369|9952969|FG001|Overall Study|Lost to Follow-up|0
6259245|NCT02033369|9952968|FG000|Overall Study|Protocol Violation|2
6259246|NCT02033369|9952969|FG001|Overall Study|Protocol Violation|0
6271212|NCT02161458|9972845|FG002|Overall Study|Lost to Follow-up|1
6271213|NCT02161458|9972846|FG003|Overall Study|Lost to Follow-up|0
6271214|NCT02161549|9972880|FG000|Overall Study|Physician Decision|6
6271215|NCT02161549|9972881|FG001|Overall Study|Physician Decision|2
6271216|NCT02161562|9972889|FG000|Overall Study|Withdrawal by Subject|5
6271217|NCT02161562|9972890|FG001|Overall Study|Withdrawal by Subject|8
6271218|NCT02161562|9972889|FG000|Overall Study|Protocol Violation|9
6271219|NCT02161562|9972890|FG001|Overall Study|Protocol Violation|4
6271220|NCT02161562|9972889|FG000|Overall Study|Pregnancy|1
6271221|NCT02161562|9972890|FG001|Overall Study|Pregnancy|2
6271222|NCT02161562|9972889|FG000|Overall Study|Lost to Follow-up|3
6271223|NCT02161562|9972890|FG001|Overall Study|Lost to Follow-up|1
6271224|NCT02161562|9972889|FG000|Overall Study|Lack of Efficacy|4
6271225|NCT02161562|9972890|FG001|Overall Study|Lack of Efficacy|1
6271226|NCT02161562|9972889|FG000|Overall Study|Adverse Event|1
6271227|NCT02161562|9972890|FG001|Overall Study|Adverse Event|1
6271228|NCT02161562|9972889|FG000|Overall Study|Participant moved back to home country|1
6271229|NCT02161562|9972890|FG001|Overall Study|Participant moved back to home country|0
6271230|NCT02161562|9972889|FG000|Overall Study|Withdrew due to being out of the country|1
6271231|NCT02161562|9972890|FG001|Overall Study|Withdrew due to being out of the country|0
6271232|NCT02161562|9972889|FG000|Overall Study|Participant moved out of province|1
6271233|NCT02161562|9972890|FG001|Overall Study|Participant moved out of province|0
6271234|NCT02161575|9972909|FG000|Overall Study|Protocol Violation|8
6271235|NCT02161575|9972909|FG000|Overall Study|Lack of Efficacy|1
6271236|NCT02161575|9972909|FG000|Overall Study|Adverse Event|2
6271237|NCT02161718|9972924|FG000|Open-Label ALKS 3831 Period|Protocol Violation|2
6271238|NCT02161718|9972925|FG001|Open-Label ALKS 3831 Period|Protocol Violation|0
6271239|NCT02161718|9972926|FG002|Open-Label ALKS 3831 Period|Protocol Violation|0
6271240|NCT02161718|9972924|FG000|Open-Label ALKS 3831 Period|Physician Decision|1
6271241|NCT02161718|9972925|FG001|Open-Label ALKS 3831 Period|Physician Decision|0
6259247|NCT02033759|9953007|FG000|Overall Study|Withdrawal by Subject|2
6259248|NCT02033759|9953008|FG001|Overall Study|Withdrawal by Subject|1
6259249|NCT02033759|9953007|FG000|Overall Study|Protocol Violation|1
6259250|NCT02033759|9953008|FG001|Overall Study|Protocol Violation|1
6259251|NCT02033850|9953016|FG000|Overall Study|Death|1
6259252|NCT02033850|9953017|FG001|Overall Study|Death|0
6259253|NCT02033850|9953016|FG000|Overall Study|unrelated medical reason|1
6259254|NCT02033850|9953017|FG001|Overall Study|unrelated medical reason|1
6259255|NCT02033889|9953035|FG000|Overall Study|Adverse Event|3
6259256|NCT02033889|9953036|FG001|Overall Study|Adverse Event|1
6259257|NCT02033889|9953037|FG002|Overall Study|Adverse Event|3
6259258|NCT02033889|9953035|FG000|Overall Study|Death|3
6259259|NCT02033889|9953036|FG001|Overall Study|Death|1
6259260|NCT02033889|9953037|FG002|Overall Study|Death|2
6259261|NCT02033889|9953035|FG000|Overall Study|Excluded Medication|1
6259262|NCT02033889|9953036|FG001|Overall Study|Excluded Medication|1
6259263|NCT02033889|9953037|FG002|Overall Study|Excluded Medication|0
6259264|NCT02033889|9953035|FG000|Overall Study|Lost to Follow-up|8
6259265|NCT02033889|9953036|FG001|Overall Study|Lost to Follow-up|5
6259266|NCT02033889|9953037|FG002|Overall Study|Lost to Follow-up|6
6259267|NCT02033889|9953035|FG000|Overall Study|Non-Compliance With Study Drug|1
6259268|NCT02033889|9953036|FG001|Overall Study|Non-Compliance With Study Drug|0
6259269|NCT02033889|9953037|FG002|Overall Study|Non-Compliance With Study Drug|0
6259270|NCT02033889|9953035|FG000|Overall Study|Physician Decision|0
6259271|NCT02033889|9953036|FG001|Overall Study|Physician Decision|1
6259272|NCT02033889|9953037|FG002|Overall Study|Physician Decision|1
6259273|NCT02033889|9953035|FG000|Overall Study|Participant moved|0
6259274|NCT02033889|9953036|FG001|Overall Study|Participant moved|1
6259275|NCT02033889|9953037|FG002|Overall Study|Participant moved|0
6259276|NCT02033889|9953035|FG000|Overall Study|Withdrawal by Subject|18
6259277|NCT02033889|9953036|FG001|Overall Study|Withdrawal by Subject|10
6259278|NCT02033889|9953037|FG002|Overall Study|Withdrawal by Subject|13
6259279|NCT02034006|9953056|FG000|Overall Study|Withdrawal by Subject|7
6259280|NCT02034006|9953056|FG000|Overall Study|Lost to Follow-up|5
6259281|NCT02034006|9953056|FG000|Overall Study|Death|1
6259282|NCT02034006|9953056|FG000|Overall Study|Pregnancy|1
6259283|NCT02034058|9953072|FG000|Overall Study|Death|3
6259284|NCT02034162|9953078|FG000|Double-blind|Lost to Follow-up|3
6259285|NCT02034162|9953079|FG001|Double-blind|Lost to Follow-up|0
6259286|NCT02034162|9953080|FG002|Double-blind|Lost to Follow-up|0
6259287|NCT02034162|9953078|FG000|Double-blind|Physician Decision|1
6259288|NCT02034162|9953079|FG001|Double-blind|Physician Decision|0
6259289|NCT02034162|9953080|FG002|Double-blind|Physician Decision|0
6259290|NCT02034162|9953078|FG000|Double-blind|Protocol Violation|0
6259291|NCT02034162|9953079|FG001|Double-blind|Protocol Violation|1
6259292|NCT02034162|9953080|FG002|Double-blind|Protocol Violation|0
6259293|NCT02034162|9953078|FG000|Double-blind|Withdrawal by Subject|5
6259294|NCT02034162|9953079|FG001|Double-blind|Withdrawal by Subject|7
6259295|NCT02034162|9953080|FG002|Double-blind|Withdrawal by Subject|0
6259296|NCT02034409|9953097|FG000|Sham Run-in Period|Participants withdrawn per protocol because less than 80% treatment compliance|4
6259297|NCT02034409|9953098|FG001|Sham Run-in Period|Participants withdrawn per protocol because less than 80% treatment compliance|0
6259298|NCT02034409|9953097|FG000|Sham-Controlled Treatment Period|Adverse Event|1
6259299|NCT02034409|9953098|FG001|Sham-Controlled Treatment Period|Adverse Event|1
6259300|NCT02034409|9953097|FG000|Sham-Controlled Treatment Period|Lost to Follow-up|0
6259301|NCT02034409|9953098|FG001|Sham-Controlled Treatment Period|Lost to Follow-up|1
6259302|NCT02034409|9953097|FG000|Sham-Controlled Treatment Period|Withdrawal by Subject|8
6259303|NCT02034409|9953098|FG001|Sham-Controlled Treatment Period|Withdrawal by Subject|8
6259304|NCT02034409|9953097|FG000|Sham-Controlled Treatment Period|Physician Decision|1
6259305|NCT02034409|9953098|FG001|Sham-Controlled Treatment Period|Physician Decision|3
6259306|NCT02034409|9953097|FG000|Sham-Controlled Treatment Period|misrandomized|2
6259307|NCT02034409|9953098|FG001|Sham-Controlled Treatment Period|misrandomized|2
6259308|NCT02034435|9953106|FG000|Overall Study|Withdrawal by Subject|1
6259309|NCT02034435|9953107|FG001|Overall Study|Withdrawal by Subject|0
6259310|NCT02034435|9953108|FG002|Overall Study|Withdrawal by Subject|0
6259311|NCT02034435|9953109|FG003|Overall Study|Withdrawal by Subject|0
6259312|NCT02034435|9953106|FG000|Overall Study|Illness|0
6259313|NCT02034435|9953107|FG001|Overall Study|Illness|2
6259314|NCT02034435|9953108|FG002|Overall Study|Illness|0
6259315|NCT02034435|9953109|FG003|Overall Study|Illness|0
6259316|NCT02034435|9953106|FG000|Overall Study|Inadequate IV access|1
6259317|NCT02034435|9953107|FG001|Overall Study|Inadequate IV access|0
6259318|NCT02034435|9953108|FG002|Overall Study|Inadequate IV access|0
6259319|NCT02034435|9953109|FG003|Overall Study|Inadequate IV access|1
6259320|NCT02034474|9953121|FG000|Overall Study|Adverse Event|3
6259321|NCT02034474|9953122|FG001|Overall Study|Adverse Event|2
6259322|NCT02034474|9953121|FG000|Overall Study|Withdrawal by Subject|1
6259323|NCT02034474|9953122|FG001|Overall Study|Withdrawal by Subject|2
6259324|NCT02034513|9953132|FG000|Overall Study|Adverse Event|11
6259325|NCT02034513|9953133|FG001|Overall Study|Adverse Event|10
6259326|NCT02034513|9953132|FG000|Overall Study|Lack of Efficacy|0
6259327|NCT02034513|9953133|FG001|Overall Study|Lack of Efficacy|1
6259328|NCT02034513|9953132|FG000|Overall Study|Lost to Follow-up|6
6259329|NCT02034513|9953133|FG001|Overall Study|Lost to Follow-up|7
6259330|NCT02034513|9953132|FG000|Overall Study|Pregnancy|0
6259331|NCT02034513|9953133|FG001|Overall Study|Pregnancy|3
6259332|NCT02034513|9953132|FG000|Overall Study|Protocol Violation|7
6259333|NCT02034513|9953133|FG001|Overall Study|Protocol Violation|10
6259334|NCT02034513|9953132|FG000|Overall Study|Withdrawal by Subject|25
6259335|NCT02034513|9953133|FG001|Overall Study|Withdrawal by Subject|25
6259336|NCT02034513|9953132|FG000|Overall Study|Unclassified|0
6259337|NCT02034513|9953133|FG001|Overall Study|Unclassified|1
6259338|NCT02034552|9953144|FG000|Overall Study|Never treated|3
6259339|NCT02034552|9953145|FG001|Overall Study|Never treated|2
6259340|NCT02034552|9953146|FG002|Overall Study|Never treated|0
6259341|NCT02034552|9953144|FG000|Overall Study|Radiological progression|3
6259342|NCT02034552|9953145|FG001|Overall Study|Radiological progression|5
6259343|NCT02034552|9953146|FG002|Overall Study|Radiological progression|4
6259344|NCT02034552|9953144|FG000|Overall Study|AE not assoc. with disease progression|1
6259345|NCT02034552|9953145|FG001|Overall Study|AE not assoc. with disease progression|4
6259346|NCT02034552|9953146|FG002|Overall Study|AE not assoc. with disease progression|2
6259347|NCT02034552|9953144|FG000|Overall Study|AE associated with disease progression|0
6259348|NCT02034552|9953145|FG001|Overall Study|AE associated with disease progression|1
6259349|NCT02034552|9953146|FG002|Overall Study|AE associated with disease progression|0
6259350|NCT02034552|9953144|FG000|Overall Study|Withdrawal by Subject|2
6259351|NCT02034552|9953145|FG001|Overall Study|Withdrawal by Subject|1
6259352|NCT02034552|9953146|FG002|Overall Study|Withdrawal by Subject|1
6259353|NCT02034552|9953144|FG000|Overall Study|Non-compliance with study drug|0
6259354|NCT02034552|9953145|FG001|Overall Study|Non-compliance with study drug|0
6259355|NCT02034552|9953146|FG002|Overall Study|Non-compliance with study drug|1
6259356|NCT02034552|9953144|FG000|Overall Study|Clinical progression|5
6259357|NCT02034552|9953145|FG001|Overall Study|Clinical progression|7
6259358|NCT02034552|9953146|FG002|Overall Study|Clinical progression|9
6259359|NCT02034565|9953154|FG000|Overall Study|Adverse Event|1
6259360|NCT02034565|9953155|FG001|Overall Study|Adverse Event|0
6259361|NCT02034591|9953177|FG000|Overall Study|Withdrawal by Subject|0
6259362|NCT02034591|9953178|FG001|Overall Study|Withdrawal by Subject|0
6259363|NCT02034591|9953179|FG002|Overall Study|Withdrawal by Subject|0
6259364|NCT02034591|9953180|FG003|Overall Study|Withdrawal by Subject|0
6259365|NCT02034591|9953181|FG004|Overall Study|Withdrawal by Subject|1
6259366|NCT02034591|9953182|FG005|Overall Study|Withdrawal by Subject|0
6259367|NCT02034708|9953193|FG000|Wash-out (From 2 Days up to 14 Days)|Withdrawal by Subject|2
6259368|NCT02034708|9953194|FG001|Wash-out (From 2 Days up to 14 Days)|Withdrawal by Subject|5
6259369|NCT02034708|9953193|FG000|Wash-out (From 2 Days up to 14 Days)|Adverse Event|1
6259370|NCT02034708|9953194|FG001|Wash-out (From 2 Days up to 14 Days)|Adverse Event|0
6259371|NCT02034708|9953193|FG000|Wash-out (From 2 Days up to 14 Days)|Protocol Violation|3
6259372|NCT02034708|9953194|FG001|Wash-out (From 2 Days up to 14 Days)|Protocol Violation|3
6259373|NCT02034708|9953193|FG000|Wash-out (From 2 Days up to 14 Days)|other reason|3
6259374|NCT02034708|9953194|FG001|Wash-out (From 2 Days up to 14 Days)|other reason|2
6259375|NCT02034799|9953207|FG000|Overall Study|Withdrawal by Subject|0
6259376|NCT02034799|9953208|FG001|Overall Study|Withdrawal by Subject|2
6259377|NCT02034799|9953207|FG000|Overall Study|Lost to Follow-up|0
6259378|NCT02034799|9953208|FG001|Overall Study|Lost to Follow-up|1
6259379|NCT02034799|9953207|FG000|Overall Study|Death|2
6259380|NCT02034799|9953208|FG001|Overall Study|Death|1
6259381|NCT02034877|9953216|FG000|Overall Study|Lost to Follow-up|0
6259382|NCT02034877|9953217|FG001|Overall Study|Lost to Follow-up|3
6259383|NCT02034877|9953216|FG000|Overall Study|No Longer Willing to Participate|0
6259384|NCT02034877|9953217|FG001|Overall Study|No Longer Willing to Participate|3
6259385|NCT02034916|9953225|FG000|Overall Study|Death|39
6259386|NCT02034916|9953226|FG001|Overall Study|Death|28
6259387|NCT02034916|9953225|FG000|Overall Study|Withdrawal by Subject|2
6259388|NCT02034916|9953226|FG001|Overall Study|Withdrawal by Subject|1
6259389|NCT02034916|9953225|FG000|Overall Study|Lost to Follow-up|4
6259390|NCT02034916|9953226|FG001|Overall Study|Lost to Follow-up|1
6259391|NCT02034916|9953225|FG000|Overall Study|Study terminated by sponsor|4
6259392|NCT02034916|9953226|FG001|Overall Study|Study terminated by sponsor|5
6259393|NCT02035202|9953236|FG000|Overall Study|Lost to Follow-up|8
6259394|NCT02035202|9953237|FG001|Overall Study|Lost to Follow-up|16
6259395|NCT02035202|9953238|FG002|Overall Study|Lost to Follow-up|2
6086760|NCT00663208|9696838|FG006|Follow-up Period|Lost to Follow-up|0
6086761|NCT00663208|9696832|FG000|Follow-up Period|Other reason|1
6259396|NCT02035267|9953250|FG000|Overall Study|Withdrawal consent-subject convenience|0
6259397|NCT02035267|9953251|FG001|Overall Study|Withdrawal consent-subject convenience|0
6259398|NCT02035267|9953252|FG002|Overall Study|Withdrawal consent-subject convenience|1
6259399|NCT02035267|9953253|FG003|Overall Study|Withdrawal consent-subject convenience|0
6259400|NCT02035267|9953250|FG000|Overall Study|Adverse Event|0
6259401|NCT02035267|9953251|FG001|Overall Study|Adverse Event|0
6259402|NCT02035267|9953252|FG002|Overall Study|Adverse Event|1
6259403|NCT02035267|9953253|FG003|Overall Study|Adverse Event|0
6259404|NCT02035267|9953250|FG000|Overall Study|Lost to Follow-up|0
6259405|NCT02035267|9953251|FG001|Overall Study|Lost to Follow-up|0
6259406|NCT02035267|9953252|FG002|Overall Study|Lost to Follow-up|0
6259407|NCT02035267|9953253|FG003|Overall Study|Lost to Follow-up|1
6259408|NCT02035267|9953250|FG000|Overall Study|Other unspecified|0
6259409|NCT02035267|9953251|FG001|Overall Study|Other unspecified|1
6259410|NCT02035267|9953252|FG002|Overall Study|Other unspecified|0
6259411|NCT02035267|9953253|FG003|Overall Study|Other unspecified|0
6259412|NCT02035332|9953265|FG000|Overall Study|Procedure Aborted due to Uterine Width|1
6259413|NCT02035475|9953274|FG000|Overall Study|Withdrawal by Subject|4
6259414|NCT02035475|9953274|FG000|Overall Study|Physician Decision|1
6259415|NCT02035475|9953274|FG000|Overall Study|Equipment Error|1
6259416|NCT02035553|9953282|FG000|Overall Study|Death (See All-Cause Mortality Table)|0
6259417|NCT02035553|9953283|FG001|Overall Study|Death (See All-Cause Mortality Table)|1
6259418|NCT02035553|9953282|FG000|Overall Study|Adverse Event|10
6259419|NCT02035553|9953283|FG001|Overall Study|Adverse Event|6
6259420|NCT02035553|9953282|FG000|Overall Study|Physician Decision|3
6259421|NCT02035553|9953283|FG001|Overall Study|Physician Decision|2
6259422|NCT02035553|9953282|FG000|Overall Study|Lack of Efficacy|1
6259423|NCT02035553|9953283|FG001|Overall Study|Lack of Efficacy|1
6259424|NCT02035553|9953282|FG000|Overall Study|Withdrawal by Subject|4
6259425|NCT02035553|9953283|FG001|Overall Study|Withdrawal by Subject|7
6259426|NCT02035553|9953282|FG000|Overall Study|Non-compliance with Study Drug|0
6259427|NCT02035553|9953283|FG001|Overall Study|Non-compliance with Study Drug|1
6259428|NCT02035553|9953282|FG000|Overall Study|Lost to Follow-up|0
6259429|NCT02035553|9953283|FG001|Overall Study|Lost to Follow-up|1
6259430|NCT02035553|9953282|FG000|Overall Study|Other Reason|0
6259431|NCT02035553|9953283|FG001|Overall Study|Other Reason|4
6259432|NCT02035696|9953293|FG000|Overall Study|Lost to Follow-up|0
6259433|NCT02035696|9953294|FG001|Overall Study|Lost to Follow-up|3
6259434|NCT02035696|9953295|FG002|Overall Study|Lost to Follow-up|1
6259435|NCT02035696|9953296|FG003|Overall Study|Lost to Follow-up|2
6259436|NCT02035696|9953293|FG000|Overall Study|Withdrawal by Subject|3
6259437|NCT02035696|9953294|FG001|Overall Study|Withdrawal by Subject|0
6259438|NCT02035696|9953295|FG002|Overall Study|Withdrawal by Subject|2
6259439|NCT02035696|9953296|FG003|Overall Study|Withdrawal by Subject|1
6259440|NCT02035748|9953310|FG000|Overall Study|Adverse Event|5
6259441|NCT02035748|9953310|FG000|Overall Study|Death|3
6259442|NCT02035748|9953310|FG000|Overall Study|Lost to Follow-up|2
6259443|NCT02035748|9953310|FG000|Overall Study|Physician Decision|3
6259444|NCT02035748|9953310|FG000|Overall Study|Withdrawal by Subject|6
6086762|NCT00663208|9696833|FG001|Follow-up Period|Other reason|0
6086763|NCT00663208|9696834|FG002|Follow-up Period|Other reason|0
6086764|NCT00663208|9696835|FG003|Follow-up Period|Other reason|0
6086765|NCT00663208|9696836|FG004|Follow-up Period|Other reason|0
6086766|NCT00663208|9696837|FG005|Follow-up Period|Other reason|0
6259445|NCT02035748|9953310|FG000|Overall Study|Progressive Disease|1
6259446|NCT02036294|9953317|FG000|Overall Study|Death|7
6259447|NCT02036294|9953318|FG001|Overall Study|Death|8
6259448|NCT02036294|9953317|FG000|Overall Study|Withdrawal by Subject|2
6259449|NCT02036294|9953318|FG001|Overall Study|Withdrawal by Subject|3
6259450|NCT02036502|9953348|FG000|Part 1:Dose Determination/Escalation|Death|3
6259451|NCT02036502|9953349|FG001|Part 1:Dose Determination/Escalation|Death|2
6259452|NCT02036502|9953350|FG002|Part 1:Dose Determination/Escalation|Death|0
6259453|NCT02036502|9953351|FG003|Part 1:Dose Determination/Escalation|Death|0
6259454|NCT02036502|9953352|FG004|Part 1:Dose Determination/Escalation|Death|0
6259455|NCT02036502|9953353|FG005|Part 1:Dose Determination/Escalation|Death|0
6259456|NCT02036502|9953354|FG006|Part 1:Dose Determination/Escalation|Death|0
6259457|NCT02036502|9953355|FG007|Part 1:Dose Determination/Escalation|Death|0
6259458|NCT02036502|9953348|FG000|Part 1:Dose Determination/Escalation|Study Terminated by Sponsor|3
6259459|NCT02036502|9953349|FG001|Part 1:Dose Determination/Escalation|Study Terminated by Sponsor|0
6259460|NCT02036502|9953350|FG002|Part 1:Dose Determination/Escalation|Study Terminated by Sponsor|0
6259461|NCT02036502|9953351|FG003|Part 1:Dose Determination/Escalation|Study Terminated by Sponsor|0
6259462|NCT02036502|9953352|FG004|Part 1:Dose Determination/Escalation|Study Terminated by Sponsor|0
6259463|NCT02036502|9953353|FG005|Part 1:Dose Determination/Escalation|Study Terminated by Sponsor|0
6259464|NCT02036502|9953354|FG006|Part 1:Dose Determination/Escalation|Study Terminated by Sponsor|0
6259465|NCT02036502|9953355|FG007|Part 1:Dose Determination/Escalation|Study Terminated by Sponsor|0
6259466|NCT02036502|9953348|FG000|Part 1:Dose Determination/Escalation|Adverse Event|0
6259467|NCT02036502|9953349|FG001|Part 1:Dose Determination/Escalation|Adverse Event|1
6259468|NCT02036502|9953350|FG002|Part 1:Dose Determination/Escalation|Adverse Event|0
6259469|NCT02036502|9953351|FG003|Part 1:Dose Determination/Escalation|Adverse Event|0
6259470|NCT02036502|9953352|FG004|Part 1:Dose Determination/Escalation|Adverse Event|0
6259471|NCT02036502|9953353|FG005|Part 1:Dose Determination/Escalation|Adverse Event|0
6259472|NCT02036502|9953354|FG006|Part 1:Dose Determination/Escalation|Adverse Event|0
6259473|NCT02036502|9953355|FG007|Part 1:Dose Determination/Escalation|Adverse Event|0
6259474|NCT02036502|9953348|FG000|Part 1:Dose Determination/Escalation|Not treated|0
6259475|NCT02036502|9953349|FG001|Part 1:Dose Determination/Escalation|Not treated|1
6259476|NCT02036502|9953350|FG002|Part 1:Dose Determination/Escalation|Not treated|0
6259477|NCT02036502|9953351|FG003|Part 1:Dose Determination/Escalation|Not treated|0
6259478|NCT02036502|9953352|FG004|Part 1:Dose Determination/Escalation|Not treated|0
6259479|NCT02036502|9953353|FG005|Part 1:Dose Determination/Escalation|Not treated|0
6086767|NCT00663208|9696838|FG006|Follow-up Period|Other reason|1
6086768|NCT00663234|9696856|FG000|Overall Study|Not willing to adhere to requirements|1
6259480|NCT02036502|9953354|FG006|Part 1:Dose Determination/Escalation|Not treated|0
6259481|NCT02036502|9953355|FG007|Part 1:Dose Determination/Escalation|Not treated|0
6259482|NCT02036502|9953348|FG000|Part 2:Dose Confirmation|Study Terminated by Sponsor|0
6259483|NCT02036502|9953349|FG001|Part 2:Dose Confirmation|Study Terminated by Sponsor|0
6259484|NCT02036502|9953350|FG002|Part 2:Dose Confirmation|Study Terminated by Sponsor|2
6259485|NCT02036502|9953351|FG003|Part 2:Dose Confirmation|Study Terminated by Sponsor|1
6259486|NCT02036502|9953352|FG004|Part 2:Dose Confirmation|Study Terminated by Sponsor|1
6259487|NCT02036502|9953353|FG005|Part 2:Dose Confirmation|Study Terminated by Sponsor|0
6259488|NCT02036502|9953354|FG006|Part 2:Dose Confirmation|Study Terminated by Sponsor|0
6259489|NCT02036502|9953355|FG007|Part 2:Dose Confirmation|Study Terminated by Sponsor|0
6259490|NCT02036502|9953348|FG000|Part 2:Dose Confirmation|Withdrawal by Subject|0
6259491|NCT02036502|9953349|FG001|Part 2:Dose Confirmation|Withdrawal by Subject|0
6259492|NCT02036502|9953350|FG002|Part 2:Dose Confirmation|Withdrawal by Subject|3
6259493|NCT02036502|9953351|FG003|Part 2:Dose Confirmation|Withdrawal by Subject|0
6259494|NCT02036502|9953352|FG004|Part 2:Dose Confirmation|Withdrawal by Subject|0
6259495|NCT02036502|9953353|FG005|Part 2:Dose Confirmation|Withdrawal by Subject|0
6259496|NCT02036502|9953354|FG006|Part 2:Dose Confirmation|Withdrawal by Subject|0
6259497|NCT02036502|9953355|FG007|Part 2:Dose Confirmation|Withdrawal by Subject|0
6259498|NCT02036502|9953348|FG000|Part 2:Dose Confirmation|Death|0
6259499|NCT02036502|9953349|FG001|Part 2:Dose Confirmation|Death|0
6259500|NCT02036502|9953350|FG002|Part 2:Dose Confirmation|Death|1
6259501|NCT02036502|9953351|FG003|Part 2:Dose Confirmation|Death|0
6259502|NCT02036502|9953352|FG004|Part 2:Dose Confirmation|Death|0
6259503|NCT02036502|9953353|FG005|Part 2:Dose Confirmation|Death|0
6259504|NCT02036502|9953354|FG006|Part 2:Dose Confirmation|Death|0
6259505|NCT02036502|9953355|FG007|Part 2:Dose Confirmation|Death|0
6259506|NCT02036502|9953348|FG000|Part 2:Dose Confirmation|Not treated|0
6259507|NCT02036502|9953349|FG001|Part 2:Dose Confirmation|Not treated|0
6259508|NCT02036502|9953350|FG002|Part 2:Dose Confirmation|Not treated|0
6259509|NCT02036502|9953351|FG003|Part 2:Dose Confirmation|Not treated|1
6259510|NCT02036502|9953352|FG004|Part 2:Dose Confirmation|Not treated|0
6259511|NCT02036502|9953353|FG005|Part 2:Dose Confirmation|Not treated|0
6259512|NCT02036502|9953354|FG006|Part 2:Dose Confirmation|Not treated|0
6259513|NCT02036502|9953355|FG007|Part 2:Dose Confirmation|Not treated|0
6259514|NCT02036502|9953348|FG000|Part 3:Dose Expansion|Adverse Event|0
6259515|NCT02036502|9953349|FG001|Part 3:Dose Expansion|Adverse Event|0
6259516|NCT02036502|9953350|FG002|Part 3:Dose Expansion|Adverse Event|0
6259517|NCT02036502|9953351|FG003|Part 3:Dose Expansion|Adverse Event|0
6259518|NCT02036502|9953352|FG004|Part 3:Dose Expansion|Adverse Event|0
6259519|NCT02036502|9953353|FG005|Part 3:Dose Expansion|Adverse Event|4
6259520|NCT02036502|9953354|FG006|Part 3:Dose Expansion|Adverse Event|0
6259521|NCT02036502|9953355|FG007|Part 3:Dose Expansion|Adverse Event|2
6259522|NCT02036502|9953348|FG000|Part 3:Dose Expansion|Death|0
6259523|NCT02036502|9953349|FG001|Part 3:Dose Expansion|Death|0
6259524|NCT02036502|9953350|FG002|Part 3:Dose Expansion|Death|0
6259525|NCT02036502|9953351|FG003|Part 3:Dose Expansion|Death|0
6259526|NCT02036502|9953352|FG004|Part 3:Dose Expansion|Death|0
6259527|NCT02036502|9953353|FG005|Part 3:Dose Expansion|Death|24
6259528|NCT02036502|9953354|FG006|Part 3:Dose Expansion|Death|0
6259529|NCT02036502|9953355|FG007|Part 3:Dose Expansion|Death|3
6259530|NCT02036502|9953348|FG000|Part 3:Dose Expansion|Lost to Follow-up|0
6259531|NCT02036502|9953349|FG001|Part 3:Dose Expansion|Lost to Follow-up|0
6259532|NCT02036502|9953350|FG002|Part 3:Dose Expansion|Lost to Follow-up|0
6259533|NCT02036502|9953351|FG003|Part 3:Dose Expansion|Lost to Follow-up|0
6259534|NCT02036502|9953352|FG004|Part 3:Dose Expansion|Lost to Follow-up|0
6259535|NCT02036502|9953353|FG005|Part 3:Dose Expansion|Lost to Follow-up|0
6259536|NCT02036502|9953354|FG006|Part 3:Dose Expansion|Lost to Follow-up|0
6259537|NCT02036502|9953355|FG007|Part 3:Dose Expansion|Lost to Follow-up|1
6259538|NCT02036502|9953348|FG000|Part 3:Dose Expansion|Physician Decision|0
6259539|NCT02036502|9953349|FG001|Part 3:Dose Expansion|Physician Decision|0
6259540|NCT02036502|9953350|FG002|Part 3:Dose Expansion|Physician Decision|0
6259541|NCT02036502|9953351|FG003|Part 3:Dose Expansion|Physician Decision|0
6259542|NCT02036502|9953352|FG004|Part 3:Dose Expansion|Physician Decision|0
6259543|NCT02036502|9953353|FG005|Part 3:Dose Expansion|Physician Decision|1
6259544|NCT02036502|9953354|FG006|Part 3:Dose Expansion|Physician Decision|0
6259545|NCT02036502|9953355|FG007|Part 3:Dose Expansion|Physician Decision|0
6259546|NCT02036502|9953348|FG000|Part 3:Dose Expansion|Progressive Disease|0
6259547|NCT02036502|9953349|FG001|Part 3:Dose Expansion|Progressive Disease|0
6259548|NCT02036502|9953350|FG002|Part 3:Dose Expansion|Progressive Disease|0
6259549|NCT02036502|9953351|FG003|Part 3:Dose Expansion|Progressive Disease|0
6259550|NCT02036502|9953352|FG004|Part 3:Dose Expansion|Progressive Disease|0
6259551|NCT02036502|9953353|FG005|Part 3:Dose Expansion|Progressive Disease|1
6259552|NCT02036502|9953354|FG006|Part 3:Dose Expansion|Progressive Disease|0
6259553|NCT02036502|9953355|FG007|Part 3:Dose Expansion|Progressive Disease|0
6259554|NCT02036502|9953348|FG000|Part 3:Dose Expansion|Study Terminated by Sponsor|0
6259555|NCT02036502|9953349|FG001|Part 3:Dose Expansion|Study Terminated by Sponsor|0
6259556|NCT02036502|9953350|FG002|Part 3:Dose Expansion|Study Terminated by Sponsor|0
6259557|NCT02036502|9953351|FG003|Part 3:Dose Expansion|Study Terminated by Sponsor|0
6259558|NCT02036502|9953352|FG004|Part 3:Dose Expansion|Study Terminated by Sponsor|0
6259559|NCT02036502|9953353|FG005|Part 3:Dose Expansion|Study Terminated by Sponsor|11
6259560|NCT02036502|9953354|FG006|Part 3:Dose Expansion|Study Terminated by Sponsor|0
6259561|NCT02036502|9953355|FG007|Part 3:Dose Expansion|Study Terminated by Sponsor|2
6259562|NCT02036502|9953348|FG000|Part 3:Dose Expansion|Withdrawal by Subject|0
6259563|NCT02036502|9953349|FG001|Part 3:Dose Expansion|Withdrawal by Subject|0
6259564|NCT02036502|9953350|FG002|Part 3:Dose Expansion|Withdrawal by Subject|0
6259565|NCT02036502|9953351|FG003|Part 3:Dose Expansion|Withdrawal by Subject|0
6259566|NCT02036502|9953352|FG004|Part 3:Dose Expansion|Withdrawal by Subject|0
6259567|NCT02036502|9953353|FG005|Part 3:Dose Expansion|Withdrawal by Subject|4
6086769|NCT00663260|9696867|FG000|Overall Study|Lack of Efficacy|2
6259568|NCT02036502|9953354|FG006|Part 3:Dose Expansion|Withdrawal by Subject|1
6259569|NCT02036502|9953355|FG007|Part 3:Dose Expansion|Withdrawal by Subject|2
6259570|NCT02036502|9953348|FG000|Part 3:Dose Expansion|Not Treated|0
6259571|NCT02036502|9953349|FG001|Part 3:Dose Expansion|Not Treated|0
6259572|NCT02036502|9953350|FG002|Part 3:Dose Expansion|Not Treated|0
6259573|NCT02036502|9953351|FG003|Part 3:Dose Expansion|Not Treated|0
6259574|NCT02036502|9953352|FG004|Part 3:Dose Expansion|Not Treated|0
6259575|NCT02036502|9953353|FG005|Part 3:Dose Expansion|Not Treated|2
6259576|NCT02036502|9953354|FG006|Part 3:Dose Expansion|Not Treated|0
6259577|NCT02036502|9953355|FG007|Part 3:Dose Expansion|Not Treated|0
6259578|NCT02036515|9953378|FG000|Overall Study|Adverse Event|1
6259579|NCT02036515|9953379|FG001|Overall Study|Adverse Event|1
6259580|NCT02036515|9953380|FG002|Overall Study|Adverse Event|2
6259581|NCT02036515|9953378|FG000|Overall Study|Lost to Follow-up|0
6259582|NCT02036515|9953379|FG001|Overall Study|Lost to Follow-up|2
6259583|NCT02036515|9953380|FG002|Overall Study|Lost to Follow-up|0
6259584|NCT02036515|9953378|FG000|Overall Study|Non-compliance with study drug|0
6259585|NCT02036515|9953379|FG001|Overall Study|Non-compliance with study drug|0
6259586|NCT02036515|9953380|FG002|Overall Study|Non-compliance with study drug|2
6259587|NCT02036515|9953378|FG000|Overall Study|Screen failure|0
6259588|NCT02036515|9953379|FG001|Overall Study|Screen failure|2
6259589|NCT02036515|9953380|FG002|Overall Study|Screen failure|0
6259590|NCT02036515|9953378|FG000|Overall Study|Withdrawal by Subject|4
6259591|NCT02036515|9953379|FG001|Overall Study|Withdrawal by Subject|7
6259592|NCT02036515|9953380|FG002|Overall Study|Withdrawal by Subject|9
6259593|NCT02036515|9953378|FG000|Overall Study|Hyperglycemia|0
6259594|NCT02036515|9953379|FG001|Overall Study|Hyperglycemia|0
6259595|NCT02036515|9953380|FG002|Overall Study|Hyperglycemia|1
6259596|NCT02036580|9953395|FG000|Overall Study|Withdrawal by Subject|0
6259597|NCT02036580|9953396|FG001|Overall Study|Withdrawal by Subject|1
6259598|NCT02036580|9953397|FG002|Overall Study|Withdrawal by Subject|0
6259599|NCT02036580|9953395|FG000|Overall Study|Adverse Event|1
6259600|NCT02036580|9953396|FG001|Overall Study|Adverse Event|0
6259601|NCT02036580|9953397|FG002|Overall Study|Adverse Event|0
6259602|NCT02036645|9953417|FG000|SAD Cohorts : Study Part 1|Lost to Follow-up|0
6259603|NCT02036645|9953418|FG001|SAD Cohorts : Study Part 1|Lost to Follow-up|0
6259604|NCT02036645|9953419|FG002|SAD Cohorts : Study Part 1|Lost to Follow-up|0
6259605|NCT02036645|9953420|FG003|SAD Cohorts : Study Part 1|Lost to Follow-up|0
6259606|NCT02036645|9953421|FG004|SAD Cohorts : Study Part 1|Lost to Follow-up|0
6259607|NCT02036645|9953422|FG005|SAD Cohorts : Study Part 1|Lost to Follow-up|0
6259608|NCT02036645|9953423|FG006|SAD Cohorts : Study Part 1|Lost to Follow-up|1
6259609|NCT02036645|9953424|FG007|SAD Cohorts : Study Part 1|Lost to Follow-up|0
6259610|NCT02036645|9953425|FG008|SAD Cohorts : Study Part 1|Lost to Follow-up|0
6259611|NCT02036645|9953426|FG009|SAD Cohorts : Study Part 1|Lost to Follow-up|0
6259612|NCT02036645|9953427|FG010|SAD Cohorts : Study Part 1|Lost to Follow-up|0
6259613|NCT02036645|9953428|FG011|SAD Cohorts : Study Part 1|Lost to Follow-up|0
6259614|NCT02036645|9953417|FG000|SAD Cohorts : Study Part 1|Withdrawal by Subject|0
6259615|NCT02036645|9953418|FG001|SAD Cohorts : Study Part 1|Withdrawal by Subject|0
6259616|NCT02036645|9953419|FG002|SAD Cohorts : Study Part 1|Withdrawal by Subject|0
6259617|NCT02036645|9953420|FG003|SAD Cohorts : Study Part 1|Withdrawal by Subject|1
6259618|NCT02036645|9953421|FG004|SAD Cohorts : Study Part 1|Withdrawal by Subject|0
6259619|NCT02036645|9953422|FG005|SAD Cohorts : Study Part 1|Withdrawal by Subject|0
6259620|NCT02036645|9953423|FG006|SAD Cohorts : Study Part 1|Withdrawal by Subject|0
6259621|NCT02036645|9953424|FG007|SAD Cohorts : Study Part 1|Withdrawal by Subject|0
6259622|NCT02036645|9953425|FG008|SAD Cohorts : Study Part 1|Withdrawal by Subject|0
6259623|NCT02036645|9953426|FG009|SAD Cohorts : Study Part 1|Withdrawal by Subject|0
6259624|NCT02036645|9953427|FG010|SAD Cohorts : Study Part 1|Withdrawal by Subject|0
6259625|NCT02036645|9953428|FG011|SAD Cohorts : Study Part 1|Withdrawal by Subject|0
6259626|NCT02036775|9953466|FG000|Treatment Period 2 (6 Days)|Withdrawal by Subject|0
6259627|NCT02036775|9953467|FG001|Treatment Period 2 (6 Days)|Withdrawal by Subject|0
6259628|NCT02036775|9953468|FG002|Treatment Period 2 (6 Days)|Withdrawal by Subject|0
6259629|NCT02036775|9953469|FG003|Treatment Period 2 (6 Days)|Withdrawal by Subject|0
6259630|NCT02036775|9953470|FG004|Treatment Period 2 (6 Days)|Withdrawal by Subject|0
6259631|NCT02036775|9953471|FG005|Treatment Period 2 (6 Days)|Withdrawal by Subject|1
6259632|NCT02036853|9953485|FG000|Overall Study|Adverse Event|0
6259633|NCT02036853|9953486|FG001|Overall Study|Adverse Event|2
6259634|NCT02036853|9953485|FG000|Overall Study|Lack of Efficacy|0
6259635|NCT02036853|9953486|FG001|Overall Study|Lack of Efficacy|2
6259636|NCT02036853|9953485|FG000|Overall Study|Physician Decision|0
6259637|NCT02036853|9953486|FG001|Overall Study|Physician Decision|1
6086770|NCT00663260|9696868|FG001|Overall Study|Lack of Efficacy|0
6259638|NCT02036853|9953485|FG000|Overall Study|Withdrawal by Subject|0
6259639|NCT02036853|9953486|FG001|Overall Study|Withdrawal by Subject|1
6259640|NCT02037165|9953508|FG000|Washout Period 4 (6 Days)|Withdrawal by Subject|0
6259641|NCT02037165|9953509|FG001|Washout Period 4 (6 Days)|Withdrawal by Subject|0
6259642|NCT02037165|9953510|FG002|Washout Period 4 (6 Days)|Withdrawal by Subject|0
6259643|NCT02037165|9953511|FG003|Washout Period 4 (6 Days)|Withdrawal by Subject|0
6259644|NCT02037165|9953512|FG004|Washout Period 4 (6 Days)|Withdrawal by Subject|1
6259645|NCT02037256|9953553|FG000|Overall Study|Protocol Violation|0
6259646|NCT02037256|9953554|FG001|Overall Study|Protocol Violation|1
6259647|NCT02037256|9953553|FG000|Overall Study|Withdrawn prior to Velcade|0
6259648|NCT02037256|9953554|FG001|Overall Study|Withdrawn prior to Velcade|2
6259649|NCT02037295|9953566|FG000|Phase 2: Vancomycin and Placebo|Withdrawal by Subject|1
6086771|NCT00663260|9696869|FG002|Overall Study|Lack of Efficacy|0
6259650|NCT02037295|9953567|FG001|Phase 2: Vancomycin and Placebo|Withdrawal by Subject|0
6259651|NCT02037295|9953568|FG002|Phase 2: Vancomycin and Placebo|Withdrawal by Subject|0
6259652|NCT02037295|9953569|FG003|Phase 2: Vancomycin and Placebo|Withdrawal by Subject|1
6259653|NCT02037477|9953604|FG000|Treatment Period 1|Pre-treatment Event/Adverse Event|0
6259654|NCT02037477|9953605|FG001|Treatment Period 1|Pre-treatment Event/Adverse Event|0
6259655|NCT02037477|9953606|FG002|Treatment Period 1|Pre-treatment Event/Adverse Event|1
6259656|NCT02037477|9953607|FG003|Treatment Period 1|Pre-treatment Event/Adverse Event|0
6259657|NCT02037568|9953628|FG000|Overall Study|Withdrawal by Subject|17
6259658|NCT02037568|9953629|FG001|Overall Study|Withdrawal by Subject|24
6259659|NCT02037568|9953628|FG000|Overall Study|Lost to Follow-up|16
6259660|NCT02037568|9953629|FG001|Overall Study|Lost to Follow-up|13
6259661|NCT02037568|9953628|FG000|Overall Study|Screen Failure|3
6259662|NCT02037568|9953629|FG001|Overall Study|Screen Failure|1
6259663|NCT02037568|9953628|FG000|Overall Study|Patient did not receive transplant|0
6259664|NCT02037568|9953629|FG001|Overall Study|Patient did not receive transplant|1
6259665|NCT02037984|9953673|FG000|Overall Study|Lack of Efficacy|0
6259666|NCT02037984|9953674|FG001|Overall Study|Lack of Efficacy|0
6259667|NCT02037984|9953675|FG002|Overall Study|Lack of Efficacy|3
6259668|NCT02037984|9953676|FG003|Overall Study|Lack of Efficacy|10
6259669|NCT02037984|9953677|FG004|Overall Study|Lack of Efficacy|2
6259670|NCT02037984|9953678|FG005|Overall Study|Lack of Efficacy|2
6259671|NCT02037984|9953679|FG006|Overall Study|Lack of Efficacy|4
6259672|NCT02037984|9953680|FG007|Overall Study|Lack of Efficacy|3
6259673|NCT02037984|9953673|FG000|Overall Study|Lost to Follow-up|1
6259674|NCT02037984|9953674|FG001|Overall Study|Lost to Follow-up|0
6259675|NCT02037984|9953675|FG002|Overall Study|Lost to Follow-up|3
6259676|NCT02037984|9953676|FG003|Overall Study|Lost to Follow-up|5
6259677|NCT02037984|9953677|FG004|Overall Study|Lost to Follow-up|2
6259678|NCT02037984|9953678|FG005|Overall Study|Lost to Follow-up|2
6259679|NCT02037984|9953679|FG006|Overall Study|Lost to Follow-up|2
6259680|NCT02037984|9953680|FG007|Overall Study|Lost to Follow-up|4
6259681|NCT02037984|9953673|FG000|Overall Study|Physician Decision|0
6259682|NCT02037984|9953674|FG001|Overall Study|Physician Decision|0
6259683|NCT02037984|9953675|FG002|Overall Study|Physician Decision|0
6259684|NCT02037984|9953676|FG003|Overall Study|Physician Decision|0
6259685|NCT02037984|9953677|FG004|Overall Study|Physician Decision|0
6259686|NCT02037984|9953678|FG005|Overall Study|Physician Decision|0
6259687|NCT02037984|9953679|FG006|Overall Study|Physician Decision|1
6259688|NCT02037984|9953680|FG007|Overall Study|Physician Decision|0
6259689|NCT02037984|9953673|FG000|Overall Study|Protocol Violation|0
6259690|NCT02037984|9953674|FG001|Overall Study|Protocol Violation|0
6259691|NCT02037984|9953675|FG002|Overall Study|Protocol Violation|0
6259692|NCT02037984|9953676|FG003|Overall Study|Protocol Violation|0
6259693|NCT02037984|9953677|FG004|Overall Study|Protocol Violation|0
6259694|NCT02037984|9953678|FG005|Overall Study|Protocol Violation|1
6259695|NCT02037984|9953679|FG006|Overall Study|Protocol Violation|2
6259696|NCT02037984|9953680|FG007|Overall Study|Protocol Violation|0
6259697|NCT02037984|9953673|FG000|Overall Study|Technical Problems|0
6259698|NCT02037984|9953674|FG001|Overall Study|Technical Problems|0
6259699|NCT02037984|9953675|FG002|Overall Study|Technical Problems|3
6259700|NCT02037984|9953676|FG003|Overall Study|Technical Problems|3
6259701|NCT02037984|9953677|FG004|Overall Study|Technical Problems|2
6259702|NCT02037984|9953678|FG005|Overall Study|Technical Problems|3
6259703|NCT02037984|9953679|FG006|Overall Study|Technical Problems|4
6259704|NCT02037984|9953680|FG007|Overall Study|Technical Problems|2
6259705|NCT02037984|9953673|FG000|Overall Study|Withdrawal by Parent/Guardian|0
6259706|NCT02037984|9953674|FG001|Overall Study|Withdrawal by Parent/Guardian|0
6259707|NCT02037984|9953675|FG002|Overall Study|Withdrawal by Parent/Guardian|3
6259708|NCT02037984|9953676|FG003|Overall Study|Withdrawal by Parent/Guardian|2
6259709|NCT02037984|9953677|FG004|Overall Study|Withdrawal by Parent/Guardian|5
6259710|NCT02037984|9953678|FG005|Overall Study|Withdrawal by Parent/Guardian|1
6259711|NCT02037984|9953679|FG006|Overall Study|Withdrawal by Parent/Guardian|4
6259712|NCT02037984|9953680|FG007|Overall Study|Withdrawal by Parent/Guardian|2
6259713|NCT02037984|9953673|FG000|Overall Study|Withdrawal by Subject|0
6259714|NCT02037984|9953674|FG001|Overall Study|Withdrawal by Subject|0
6259715|NCT02037984|9953675|FG002|Overall Study|Withdrawal by Subject|0
6259716|NCT02037984|9953676|FG003|Overall Study|Withdrawal by Subject|1
6259717|NCT02037984|9953677|FG004|Overall Study|Withdrawal by Subject|1
6086772|NCT00663260|9696867|FG000|Overall Study|Adverse Event|12
6259718|NCT02037984|9953678|FG005|Overall Study|Withdrawal by Subject|3
6259719|NCT02037984|9953679|FG006|Overall Study|Withdrawal by Subject|0
6259720|NCT02037984|9953680|FG007|Overall Study|Withdrawal by Subject|1
6259721|NCT02038010|9953708|FG000|Completed 1st Cycle and Started Cycle 2|Progressive Disease|0
6259722|NCT02038010|9953709|FG001|Completed 1st Cycle and Started Cycle 2|Progressive Disease|1
6259723|NCT02038010|9953710|FG002|Completed 1st Cycle and Started Cycle 2|Progressive Disease|0
6259724|NCT02038010|9953711|FG003|Completed 1st Cycle and Started Cycle 2|Progressive Disease|0
6259725|NCT02038010|9953708|FG000|Completed 1st Cycle and Started Cycle 2|Patient Non Compliance|1
6259726|NCT02038010|9953709|FG001|Completed 1st Cycle and Started Cycle 2|Patient Non Compliance|0
6259727|NCT02038010|9953710|FG002|Completed 1st Cycle and Started Cycle 2|Patient Non Compliance|0
6259728|NCT02038010|9953711|FG003|Completed 1st Cycle and Started Cycle 2|Patient Non Compliance|0
6259729|NCT02038010|9953708|FG000|Completed 1st Cycle and Started Cycle 2|Withdrawal by Subject|0
6259730|NCT02038010|9953709|FG001|Completed 1st Cycle and Started Cycle 2|Withdrawal by Subject|1
6259731|NCT02038010|9953710|FG002|Completed 1st Cycle and Started Cycle 2|Withdrawal by Subject|0
6259732|NCT02038010|9953711|FG003|Completed 1st Cycle and Started Cycle 2|Withdrawal by Subject|0
6259733|NCT02038010|9953708|FG000|Completed 3 Cycles/Reached 1st Response|Progressive Disease|1
6259734|NCT02038010|9953709|FG001|Completed 3 Cycles/Reached 1st Response|Progressive Disease|1
6259735|NCT02038010|9953710|FG002|Completed 3 Cycles/Reached 1st Response|Progressive Disease|0
6259736|NCT02038010|9953711|FG003|Completed 3 Cycles/Reached 1st Response|Progressive Disease|0
6259737|NCT02038010|9953708|FG000|Follow Up|Death|4
6259738|NCT02038010|9953709|FG001|Follow Up|Death|3
6259739|NCT02038010|9953710|FG002|Follow Up|Death|0
6259740|NCT02038010|9953711|FG003|Follow Up|Death|0
6259741|NCT02038010|9953708|FG000|Follow Up|Other|3
6259742|NCT02038010|9953709|FG001|Follow Up|Other|0
6259743|NCT02038010|9953710|FG002|Follow Up|Other|0
6259744|NCT02038010|9953711|FG003|Follow Up|Other|0
6259745|NCT02038036|9953727|FG000|Core Study|Adverse Event|7
6259746|NCT02038036|9953728|FG001|Core Study|Adverse Event|7
6259747|NCT02038036|9953727|FG000|Core Study|Death|1
6259748|NCT02038036|9953728|FG001|Core Study|Death|1
6259749|NCT02038036|9953727|FG000|Core Study|Disease progression|2
6259750|NCT02038036|9953728|FG001|Core Study|Disease progression|2
6259751|NCT02038036|9953727|FG000|Core Study|Lost to Follow-up|0
6259752|NCT02038036|9953728|FG001|Core Study|Lost to Follow-up|1
6259753|NCT02038036|9953727|FG000|Core Study|Physician Decision|2
6259754|NCT02038036|9953728|FG001|Core Study|Physician Decision|1
6259755|NCT02038036|9953727|FG000|Core Study|Subject/guardian decision|0
6259756|NCT02038036|9953728|FG001|Core Study|Subject/guardian decision|1
6259757|NCT02038036|9953727|FG000|Core Study|Withdrawal by Subject|3
6259758|NCT02038036|9953728|FG001|Core Study|Withdrawal by Subject|1
6259759|NCT02038036|9953727|FG000|Crossover Period|Withdrawal by Subject|0
6259760|NCT02038036|9953728|FG001|Crossover Period|Withdrawal by Subject|3
6259761|NCT02038036|9953727|FG000|Crossover Period|Adverse Event|0
6259762|NCT02038036|9953728|FG001|Crossover Period|Adverse Event|9
6259763|NCT02038036|9953727|FG000|Crossover Period|Death|0
6259764|NCT02038036|9953728|FG001|Crossover Period|Death|2
6259765|NCT02038036|9953727|FG000|Crossover Period|Disease progression|0
6259766|NCT02038036|9953728|FG001|Crossover Period|Disease progression|3
6259767|NCT02038036|9953727|FG000|Crossover Period|Lost to Follow-up|0
6259768|NCT02038036|9953728|FG001|Crossover Period|Lost to Follow-up|1
6259769|NCT02038036|9953727|FG000|Crossover Period|Physician Decision|0
6259770|NCT02038036|9953728|FG001|Crossover Period|Physician Decision|2
6259771|NCT02038049|9953739|FG000|Overall Study|Lost to Follow-up|1
6259772|NCT02038049|9953740|FG001|Overall Study|Lost to Follow-up|0
6259773|NCT02038075|9953752|FG000|Overall Study|Withdrawal by Subject|3
6259774|NCT02038075|9953753|FG001|Overall Study|Withdrawal by Subject|0
6259775|NCT02038543|9953779|FG000|Overall Study|Screen Failure|0
6259776|NCT02038543|9953780|FG001|Overall Study|Screen Failure|0
6259777|NCT02038543|9953781|FG002|Overall Study|Screen Failure|0
6259778|NCT02038543|9953782|FG003|Overall Study|Screen Failure|1
6259779|NCT02038543|9953779|FG000|Overall Study|Withdrawal by Subject|0
6259780|NCT02038543|9953780|FG001|Overall Study|Withdrawal by Subject|0
6259781|NCT02038543|9953781|FG002|Overall Study|Withdrawal by Subject|0
6259782|NCT02038543|9953782|FG003|Overall Study|Withdrawal by Subject|1
6259783|NCT02038647|9953799|FG000|Overall Study|Progressive Disease|50
6259784|NCT02038647|9953800|FG001|Overall Study|Progressive Disease|59
6259785|NCT02038647|9953799|FG000|Overall Study|Adverse Event|18
6259786|NCT02038647|9953800|FG001|Overall Study|Adverse Event|10
6259787|NCT02038647|9953799|FG000|Overall Study|Symptomatic Deterioration|7
6259788|NCT02038647|9953800|FG001|Overall Study|Symptomatic Deterioration|7
6259789|NCT02038647|9953799|FG000|Overall Study|Withdrawal by Subject|5
6259790|NCT02038647|9953800|FG001|Overall Study|Withdrawal by Subject|2
6259791|NCT02038647|9953799|FG000|Overall Study|Not Reported|0
6259792|NCT02038647|9953800|FG001|Overall Study|Not Reported|1
6259793|NCT02038647|9953799|FG000|Overall Study|Ongoing at Datacut|9
6259794|NCT02038647|9953800|FG001|Overall Study|Ongoing at Datacut|10
6259795|NCT02038764|9953811|FG000|Overall Study|Adverse Event|0
6259796|NCT02038764|9953812|FG001|Overall Study|Adverse Event|0
6259797|NCT02038764|9953813|FG002|Overall Study|Adverse Event|1
6259798|NCT02038764|9953814|FG003|Overall Study|Adverse Event|0
6259799|NCT02038764|9953815|FG004|Overall Study|Adverse Event|0
6259800|NCT02038764|9953811|FG000|Overall Study|Lost to Follow-up|0
6259801|NCT02038764|9953812|FG001|Overall Study|Lost to Follow-up|1
6259802|NCT02038764|9953813|FG002|Overall Study|Lost to Follow-up|0
6259803|NCT02038764|9953814|FG003|Overall Study|Lost to Follow-up|0
6259804|NCT02038764|9953815|FG004|Overall Study|Lost to Follow-up|0
6259805|NCT02038764|9953811|FG000|Overall Study|Withdrawal by Subject|0
6259806|NCT02038764|9953812|FG001|Overall Study|Withdrawal by Subject|0
6259807|NCT02038764|9953813|FG002|Overall Study|Withdrawal by Subject|0
6259808|NCT02038764|9953814|FG003|Overall Study|Withdrawal by Subject|0
6259809|NCT02038764|9953815|FG004|Overall Study|Withdrawal by Subject|1
6259810|NCT02038764|9953811|FG000|Overall Study|Other|1
6259811|NCT02038764|9953812|FG001|Overall Study|Other|0
6259812|NCT02038764|9953813|FG002|Overall Study|Other|1
6259813|NCT02038764|9953814|FG003|Overall Study|Other|0
6259814|NCT02038764|9953815|FG004|Overall Study|Other|0
6259815|NCT02038790|9953831|FG000|Day 0 - First Treatment|Withdrawal by Subject|1
6259816|NCT02038790|9953832|FG001|Day 0 - First Treatment|Withdrawal by Subject|1
6259817|NCT02038829|9953839|FG000|Washout Period 1|Death|0
6259818|NCT02038829|9953840|FG001|Washout Period 1|Death|0
6259819|NCT02038829|9953841|FG002|Washout Period 1|Death|0
6259820|NCT02038829|9953842|FG003|Washout Period 1|Death|0
6259821|NCT02038829|9953843|FG004|Washout Period 1|Death|1
6259822|NCT02038829|9953844|FG005|Washout Period 1|Death|0
6259823|NCT02038829|9953845|FG006|Washout Period 1|Death|0
6259824|NCT02038829|9953846|FG007|Washout Period 1|Death|0
6259825|NCT02038829|9953847|FG008|Washout Period 1|Death|0
6259826|NCT02038829|9953848|FG009|Washout Period 1|Death|0
6259827|NCT02038829|9953849|FG010|Washout Period 1|Death|0
6259828|NCT02038829|9953850|FG011|Washout Period 1|Death|0
6259829|NCT02038829|9953839|FG000|Treatment Period 2|Adverse Event|0
6259830|NCT02038829|9953840|FG001|Treatment Period 2|Adverse Event|0
6259831|NCT02038829|9953841|FG002|Treatment Period 2|Adverse Event|0
6259832|NCT02038829|9953842|FG003|Treatment Period 2|Adverse Event|0
6259833|NCT02038829|9953843|FG004|Treatment Period 2|Adverse Event|0
6259834|NCT02038829|9953844|FG005|Treatment Period 2|Adverse Event|0
6259835|NCT02038829|9953845|FG006|Treatment Period 2|Adverse Event|0
6259836|NCT02038829|9953846|FG007|Treatment Period 2|Adverse Event|0
6259837|NCT02038829|9953847|FG008|Treatment Period 2|Adverse Event|0
6259838|NCT02038829|9953848|FG009|Treatment Period 2|Adverse Event|0
6259839|NCT02038829|9953849|FG010|Treatment Period 2|Adverse Event|1
6259840|NCT02038829|9953850|FG011|Treatment Period 2|Adverse Event|0
6259841|NCT02038829|9953839|FG000|Treatment Period 2|Withdrawal by Subject|1
6259842|NCT02038829|9953840|FG001|Treatment Period 2|Withdrawal by Subject|0
6259843|NCT02038829|9953841|FG002|Treatment Period 2|Withdrawal by Subject|0
6259844|NCT02038829|9953842|FG003|Treatment Period 2|Withdrawal by Subject|0
6259845|NCT02038829|9953843|FG004|Treatment Period 2|Withdrawal by Subject|0
6259846|NCT02038829|9953844|FG005|Treatment Period 2|Withdrawal by Subject|0
6259847|NCT02038829|9953845|FG006|Treatment Period 2|Withdrawal by Subject|0
6259848|NCT02038829|9953846|FG007|Treatment Period 2|Withdrawal by Subject|0
6259849|NCT02038829|9953847|FG008|Treatment Period 2|Withdrawal by Subject|0
6259850|NCT02038829|9953848|FG009|Treatment Period 2|Withdrawal by Subject|0
6259851|NCT02038829|9953849|FG010|Treatment Period 2|Withdrawal by Subject|0
6259852|NCT02038829|9953850|FG011|Treatment Period 2|Withdrawal by Subject|0
6259853|NCT02038829|9953839|FG000|Washout Period 2|Adverse Event|0
6259854|NCT02038829|9953840|FG001|Washout Period 2|Adverse Event|0
6259855|NCT02038829|9953841|FG002|Washout Period 2|Adverse Event|0
6259856|NCT02038829|9953842|FG003|Washout Period 2|Adverse Event|0
6259857|NCT02038829|9953843|FG004|Washout Period 2|Adverse Event|0
6259858|NCT02038829|9953844|FG005|Washout Period 2|Adverse Event|0
6259859|NCT02038829|9953845|FG006|Washout Period 2|Adverse Event|0
6259860|NCT02038829|9953846|FG007|Washout Period 2|Adverse Event|0
6259861|NCT02038829|9953847|FG008|Washout Period 2|Adverse Event|1
6259862|NCT02038829|9953848|FG009|Washout Period 2|Adverse Event|0
6259863|NCT02038829|9953849|FG010|Washout Period 2|Adverse Event|0
6259864|NCT02038829|9953850|FG011|Washout Period 2|Adverse Event|0
6259865|NCT02038829|9953839|FG000|Washout Period 2|Withdrawal by Subject|0
6259866|NCT02038829|9953840|FG001|Washout Period 2|Withdrawal by Subject|0
6259867|NCT02038829|9953841|FG002|Washout Period 2|Withdrawal by Subject|0
6259868|NCT02038829|9953842|FG003|Washout Period 2|Withdrawal by Subject|0
6259869|NCT02038829|9953843|FG004|Washout Period 2|Withdrawal by Subject|0
6259870|NCT02038829|9953844|FG005|Washout Period 2|Withdrawal by Subject|1
6259871|NCT02038829|9953845|FG006|Washout Period 2|Withdrawal by Subject|0
6259872|NCT02038829|9953846|FG007|Washout Period 2|Withdrawal by Subject|0
6259873|NCT02038829|9953847|FG008|Washout Period 2|Withdrawal by Subject|0
6259874|NCT02038829|9953848|FG009|Washout Period 2|Withdrawal by Subject|0
6259875|NCT02038829|9953849|FG010|Washout Period 2|Withdrawal by Subject|0
6259876|NCT02038829|9953850|FG011|Washout Period 2|Withdrawal by Subject|0
6259877|NCT02038829|9953839|FG000|Treatment Period 4|Adverse Event|0
6259878|NCT02038829|9953840|FG001|Treatment Period 4|Adverse Event|1
6259879|NCT02038829|9953841|FG002|Treatment Period 4|Adverse Event|0
6259880|NCT02038829|9953842|FG003|Treatment Period 4|Adverse Event|0
6259881|NCT02038829|9953843|FG004|Treatment Period 4|Adverse Event|0
6259882|NCT02038829|9953844|FG005|Treatment Period 4|Adverse Event|0
6259883|NCT02038829|9953845|FG006|Treatment Period 4|Adverse Event|0
6259884|NCT02038829|9953846|FG007|Treatment Period 4|Adverse Event|0
6259885|NCT02038829|9953847|FG008|Treatment Period 4|Adverse Event|0
6259886|NCT02038829|9953848|FG009|Treatment Period 4|Adverse Event|0
6259887|NCT02038829|9953849|FG010|Treatment Period 4|Adverse Event|0
6259888|NCT02038829|9953850|FG011|Treatment Period 4|Adverse Event|0
6259889|NCT02038829|9953839|FG000|Washout Period 4|Adverse Event|0
6259890|NCT02038829|9953840|FG001|Washout Period 4|Adverse Event|0
6259891|NCT02038829|9953841|FG002|Washout Period 4|Adverse Event|0
6259892|NCT02038829|9953842|FG003|Washout Period 4|Adverse Event|0
6259893|NCT02038829|9953843|FG004|Washout Period 4|Adverse Event|0
6259894|NCT02038829|9953844|FG005|Washout Period 4|Adverse Event|0
6259895|NCT02038829|9953845|FG006|Washout Period 4|Adverse Event|1
6259896|NCT02038829|9953846|FG007|Washout Period 4|Adverse Event|0
6259897|NCT02038829|9953847|FG008|Washout Period 4|Adverse Event|0
6259898|NCT02038829|9953848|FG009|Washout Period 4|Adverse Event|0
6259899|NCT02038829|9953849|FG010|Washout Period 4|Adverse Event|0
6259900|NCT02038829|9953850|FG011|Washout Period 4|Adverse Event|0
6259901|NCT02038829|9953839|FG000|Treatment Period 6|Adverse Event|0
6259902|NCT02038829|9953840|FG001|Treatment Period 6|Adverse Event|0
6259903|NCT02038829|9953841|FG002|Treatment Period 6|Adverse Event|1
6259904|NCT02038829|9953842|FG003|Treatment Period 6|Adverse Event|0
6259905|NCT02038829|9953843|FG004|Treatment Period 6|Adverse Event|0
6259906|NCT02038829|9953844|FG005|Treatment Period 6|Adverse Event|0
6259907|NCT02038829|9953845|FG006|Treatment Period 6|Adverse Event|0
6259908|NCT02038829|9953846|FG007|Treatment Period 6|Adverse Event|0
6259909|NCT02038829|9953847|FG008|Treatment Period 6|Adverse Event|0
6259910|NCT02038829|9953848|FG009|Treatment Period 6|Adverse Event|0
6259911|NCT02038829|9953849|FG010|Treatment Period 6|Adverse Event|0
6259912|NCT02038829|9953850|FG011|Treatment Period 6|Adverse Event|0
6259913|NCT02038881|9953868|FG000|Overall Study|Withdrawal by Subject|0
6259914|NCT02038881|9953869|FG001|Overall Study|Withdrawal by Subject|0
6259915|NCT02038881|9953870|FG002|Overall Study|Withdrawal by Subject|1
6259916|NCT02038881|9953868|FG000|Overall Study|Lost to Follow-up|2
6259917|NCT02038881|9953869|FG001|Overall Study|Lost to Follow-up|0
6259918|NCT02038881|9953870|FG002|Overall Study|Lost to Follow-up|0
6259919|NCT02038881|9953868|FG000|Overall Study|incarcerated|1
6259920|NCT02038881|9953869|FG001|Overall Study|incarcerated|0
6259921|NCT02038881|9953870|FG002|Overall Study|incarcerated|0
6259922|NCT02038907|9953911|FG000|Overall Study|Protocol Violation|0
6259923|NCT02038907|9953912|FG001|Overall Study|Protocol Violation|0
6259924|NCT02038907|9953913|FG002|Overall Study|Protocol Violation|0
6259925|NCT02038907|9953914|FG003|Overall Study|Protocol Violation|0
6259926|NCT02038907|9953915|FG004|Overall Study|Protocol Violation|0
6259927|NCT02038907|9953916|FG005|Overall Study|Protocol Violation|0
6259928|NCT02038907|9953917|FG006|Overall Study|Protocol Violation|0
6259929|NCT02038907|9953918|FG007|Overall Study|Protocol Violation|0
6259930|NCT02038907|9953919|FG008|Overall Study|Protocol Violation|0
6259931|NCT02038907|9953920|FG009|Overall Study|Protocol Violation|0
6259932|NCT02038907|9953921|FG010|Overall Study|Protocol Violation|1
6259933|NCT02038907|9953922|FG011|Overall Study|Protocol Violation|0
6259934|NCT02038907|9953923|FG012|Overall Study|Protocol Violation|0
6259935|NCT02038907|9953924|FG013|Overall Study|Protocol Violation|0
6259936|NCT02038907|9953911|FG000|Overall Study|Withdrawal by Subject|0
6259937|NCT02038907|9953912|FG001|Overall Study|Withdrawal by Subject|0
6259938|NCT02038907|9953913|FG002|Overall Study|Withdrawal by Subject|0
6259939|NCT02038907|9953914|FG003|Overall Study|Withdrawal by Subject|0
6259940|NCT02038907|9953915|FG004|Overall Study|Withdrawal by Subject|0
6259941|NCT02038907|9953916|FG005|Overall Study|Withdrawal by Subject|0
6259942|NCT02038907|9953917|FG006|Overall Study|Withdrawal by Subject|0
6259943|NCT02038907|9953918|FG007|Overall Study|Withdrawal by Subject|0
6259944|NCT02038907|9953919|FG008|Overall Study|Withdrawal by Subject|0
6259945|NCT02038907|9953920|FG009|Overall Study|Withdrawal by Subject|0
6259946|NCT02038907|9953921|FG010|Overall Study|Withdrawal by Subject|1
6259947|NCT02038907|9953922|FG011|Overall Study|Withdrawal by Subject|0
6259948|NCT02038907|9953923|FG012|Overall Study|Withdrawal by Subject|0
6259949|NCT02038907|9953924|FG013|Overall Study|Withdrawal by Subject|0
6259950|NCT02038920|9953958|FG000|Induction Phase (Week 0 to 14)|Pretreatment Event/Adverse Event|3
6259951|NCT02038920|9953959|FG001|Induction Phase (Week 0 to 14)|Pretreatment Event/Adverse Event|11
6259952|NCT02038920|9953960|FG002|Induction Phase (Week 0 to 14)|Pretreatment Event/Adverse Event|0
6259953|NCT02038920|9953961|FG003|Induction Phase (Week 0 to 14)|Pretreatment Event/Adverse Event|0
6259954|NCT02038920|9953962|FG004|Induction Phase (Week 0 to 14)|Pretreatment Event/Adverse Event|0
6259955|NCT02038920|9953963|FG005|Induction Phase (Week 0 to 14)|Pretreatment Event/Adverse Event|0
6259956|NCT02038920|9953958|FG000|Induction Phase (Week 0 to 14)|Voluntary Withdrawal|2
6259957|NCT02038920|9953959|FG001|Induction Phase (Week 0 to 14)|Voluntary Withdrawal|0
6259958|NCT02038920|9953960|FG002|Induction Phase (Week 0 to 14)|Voluntary Withdrawal|0
6259959|NCT02038920|9953961|FG003|Induction Phase (Week 0 to 14)|Voluntary Withdrawal|0
6259960|NCT02038920|9953962|FG004|Induction Phase (Week 0 to 14)|Voluntary Withdrawal|0
6259961|NCT02038920|9953963|FG005|Induction Phase (Week 0 to 14)|Voluntary Withdrawal|0
6259962|NCT02038920|9953958|FG000|Induction Phase (Week 0 to 14)|Lack of Efficacy|1
6259963|NCT02038920|9953959|FG001|Induction Phase (Week 0 to 14)|Lack of Efficacy|1
6259964|NCT02038920|9953960|FG002|Induction Phase (Week 0 to 14)|Lack of Efficacy|0
6259965|NCT02038920|9953961|FG003|Induction Phase (Week 0 to 14)|Lack of Efficacy|0
6259966|NCT02038920|9953962|FG004|Induction Phase (Week 0 to 14)|Lack of Efficacy|0
6259967|NCT02038920|9953963|FG005|Induction Phase (Week 0 to 14)|Lack of Efficacy|0
6271909|NCT02169271|9974013|FG000|Overall Study|Protocol Violation|1
6259968|NCT02038920|9953958|FG000|Maintenance Phase (Week 14 to 60)|Pretreatment Event/Adverse Event|0
6259969|NCT02038920|9953959|FG001|Maintenance Phase (Week 14 to 60)|Pretreatment Event/Adverse Event|0
6259970|NCT02038920|9953960|FG002|Maintenance Phase (Week 14 to 60)|Pretreatment Event/Adverse Event|2
6259971|NCT02038920|9953961|FG003|Maintenance Phase (Week 14 to 60)|Pretreatment Event/Adverse Event|4
6259972|NCT02038920|9953962|FG004|Maintenance Phase (Week 14 to 60)|Pretreatment Event/Adverse Event|2
6259973|NCT02038920|9953963|FG005|Maintenance Phase (Week 14 to 60)|Pretreatment Event/Adverse Event|0
6259974|NCT02038920|9953958|FG000|Maintenance Phase (Week 14 to 60)|Lost to Follow-up|0
6259975|NCT02038920|9953959|FG001|Maintenance Phase (Week 14 to 60)|Lost to Follow-up|0
6259976|NCT02038920|9953960|FG002|Maintenance Phase (Week 14 to 60)|Lost to Follow-up|1
6259977|NCT02038920|9953961|FG003|Maintenance Phase (Week 14 to 60)|Lost to Follow-up|0
6259978|NCT02038920|9953962|FG004|Maintenance Phase (Week 14 to 60)|Lost to Follow-up|0
6259979|NCT02038920|9953963|FG005|Maintenance Phase (Week 14 to 60)|Lost to Follow-up|0
6259980|NCT02038920|9953958|FG000|Maintenance Phase (Week 14 to 60)|Lack of Efficacy|0
6259981|NCT02038920|9953959|FG001|Maintenance Phase (Week 14 to 60)|Lack of Efficacy|0
6259982|NCT02038920|9953960|FG002|Maintenance Phase (Week 14 to 60)|Lack of Efficacy|2
6259983|NCT02038920|9953961|FG003|Maintenance Phase (Week 14 to 60)|Lack of Efficacy|4
6259984|NCT02038920|9953962|FG004|Maintenance Phase (Week 14 to 60)|Lack of Efficacy|10
6259985|NCT02038920|9953963|FG005|Maintenance Phase (Week 14 to 60)|Lack of Efficacy|0
6259986|NCT02038920|9953958|FG000|Open Label Cohort (Week 10 to 154)|Pretreatment Event/Adverse Event|0
6259987|NCT02038920|9953959|FG001|Open Label Cohort (Week 10 to 154)|Pretreatment Event/Adverse Event|0
6259988|NCT02038920|9953960|FG002|Open Label Cohort (Week 10 to 154)|Pretreatment Event/Adverse Event|0
6259989|NCT02038920|9953961|FG003|Open Label Cohort (Week 10 to 154)|Pretreatment Event/Adverse Event|0
6259990|NCT02038920|9953962|FG004|Open Label Cohort (Week 10 to 154)|Pretreatment Event/Adverse Event|0
6259991|NCT02038920|9953963|FG005|Open Label Cohort (Week 10 to 154)|Pretreatment Event/Adverse Event|43
6259992|NCT02038920|9953958|FG000|Open Label Cohort (Week 10 to 154)|Lost to Follow-up|0
6259993|NCT02038920|9953959|FG001|Open Label Cohort (Week 10 to 154)|Lost to Follow-up|0
6259994|NCT02038920|9953960|FG002|Open Label Cohort (Week 10 to 154)|Lost to Follow-up|0
6259995|NCT02038920|9953961|FG003|Open Label Cohort (Week 10 to 154)|Lost to Follow-up|0
6259996|NCT02038920|9953962|FG004|Open Label Cohort (Week 10 to 154)|Lost to Follow-up|0
6259997|NCT02038920|9953963|FG005|Open Label Cohort (Week 10 to 154)|Lost to Follow-up|1
6259998|NCT02038920|9953958|FG000|Open Label Cohort (Week 10 to 154)|Voluntary Withdrawal|0
6259999|NCT02038920|9953959|FG001|Open Label Cohort (Week 10 to 154)|Voluntary Withdrawal|0
6260000|NCT02038920|9953960|FG002|Open Label Cohort (Week 10 to 154)|Voluntary Withdrawal|0
6260001|NCT02038920|9953961|FG003|Open Label Cohort (Week 10 to 154)|Voluntary Withdrawal|0
6260002|NCT02038920|9953962|FG004|Open Label Cohort (Week 10 to 154)|Voluntary Withdrawal|0
6260003|NCT02038920|9953963|FG005|Open Label Cohort (Week 10 to 154)|Voluntary Withdrawal|7
6260004|NCT02038920|9953958|FG000|Open Label Cohort (Week 10 to 154)|Pregnancy|0
6260005|NCT02038920|9953959|FG001|Open Label Cohort (Week 10 to 154)|Pregnancy|0
6260006|NCT02038920|9953960|FG002|Open Label Cohort (Week 10 to 154)|Pregnancy|0
6260007|NCT02038920|9953961|FG003|Open Label Cohort (Week 10 to 154)|Pregnancy|0
6260008|NCT02038920|9953962|FG004|Open Label Cohort (Week 10 to 154)|Pregnancy|0
6260009|NCT02038920|9953963|FG005|Open Label Cohort (Week 10 to 154)|Pregnancy|1
6260010|NCT02038920|9953958|FG000|Open Label Cohort (Week 10 to 154)|Lack of Efficacy|0
6260011|NCT02038920|9953959|FG001|Open Label Cohort (Week 10 to 154)|Lack of Efficacy|0
6260012|NCT02038920|9953960|FG002|Open Label Cohort (Week 10 to 154)|Lack of Efficacy|0
6260013|NCT02038920|9953961|FG003|Open Label Cohort (Week 10 to 154)|Lack of Efficacy|0
6260014|NCT02038920|9953962|FG004|Open Label Cohort (Week 10 to 154)|Lack of Efficacy|0
6260015|NCT02038920|9953963|FG005|Open Label Cohort (Week 10 to 154)|Lack of Efficacy|23
6260016|NCT02038920|9953958|FG000|Open Label Cohort (Week 10 to 154)|Reason Not Specified|0
6260017|NCT02038920|9953959|FG001|Open Label Cohort (Week 10 to 154)|Reason Not Specified|0
6260018|NCT02038920|9953960|FG002|Open Label Cohort (Week 10 to 154)|Reason Not Specified|0
6260019|NCT02038920|9953961|FG003|Open Label Cohort (Week 10 to 154)|Reason Not Specified|0
6260020|NCT02038920|9953962|FG004|Open Label Cohort (Week 10 to 154)|Reason Not Specified|0
6260021|NCT02038920|9953963|FG005|Open Label Cohort (Week 10 to 154)|Reason Not Specified|2
6260022|NCT02038933|9953982|FG000|Overall Study|Disease progression|104
6260023|NCT02038933|9953982|FG000|Overall Study|Study drug toxicity|6
6260024|NCT02038933|9953982|FG000|Overall Study|Adverse event unrelated to study drug|6
6260025|NCT02038933|9953982|FG000|Overall Study|Participant request to discontinue treatment|2
6260026|NCT02038933|9953982|FG000|Overall Study|Lost to Follow-up|1
6260027|NCT02038933|9953982|FG000|Overall Study|Other reasons|2
6260028|NCT02038959|9953989|FG000|Overall Study|Withdrawal by Subject|6
6260029|NCT02038959|9953990|FG001|Overall Study|Withdrawal by Subject|8
6260030|NCT02039219|9954007|FG000|Treatment|Withdrawal by Subject|1
6260031|NCT02039219|9954008|FG001|Treatment|Withdrawal by Subject|0
6260032|NCT02039219|9954007|FG000|Treatment|Adverse Event|0
6260033|NCT02039219|9954008|FG001|Treatment|Adverse Event|1
6260034|NCT02039219|9954007|FG000|Treatment|Physician Decision|1
6260035|NCT02039219|9954008|FG001|Treatment|Physician Decision|0
6260036|NCT02039219|9954007|FG000|Treatment|Lost to Follow-up|0
6260037|NCT02039219|9954008|FG001|Treatment|Lost to Follow-up|1
6260038|NCT02039219|9954007|FG000|Treatment|Protocol Violation|1
6260039|NCT02039219|9954008|FG001|Treatment|Protocol Violation|0
6260040|NCT02039219|9954007|FG000|Treatment|Death|1
6260041|NCT02039219|9954008|FG001|Treatment|Death|0
6260042|NCT02039219|9954007|FG000|Follow up|Adverse Event|0
6260043|NCT02039219|9954008|FG001|Follow up|Adverse Event|1
6260044|NCT02039375|9954014|FG000|Overall Study|Lost to Follow-up|2
6260045|NCT02039414|9954020|FG000|Overall Study|Delivered|1
6260046|NCT02039414|9954021|FG001|Overall Study|Delivered|1
6260047|NCT02039414|9954020|FG000|Overall Study|Lost to Follow-up|2
6260048|NCT02039414|9954021|FG001|Overall Study|Lost to Follow-up|0
6260049|NCT02039414|9954020|FG000|Overall Study|Protocol Violation|3
6260050|NCT02039414|9954021|FG001|Overall Study|Protocol Violation|1
6260051|NCT02039427|9954031|FG000|Overall Study|Duration of surgery > 3h|1
6260052|NCT02039427|9954032|FG001|Overall Study|Duration of surgery > 3h|1
6260053|NCT02039427|9954033|FG002|Overall Study|Duration of surgery > 3h|0
6260054|NCT02039427|9954034|FG003|Overall Study|Duration of surgery > 3h|0
6260055|NCT02039427|9954031|FG000|Overall Study|Withdrawal on concent|0
6260056|NCT02039427|9954032|FG001|Overall Study|Withdrawal on concent|0
6260057|NCT02039427|9954033|FG002|Overall Study|Withdrawal on concent|0
6260058|NCT02039427|9954034|FG003|Overall Study|Withdrawal on concent|1
6260059|NCT02039427|9954031|FG000|Overall Study|Cancellation of surgery|0
6260060|NCT02039427|9954032|FG001|Overall Study|Cancellation of surgery|0
6260061|NCT02039427|9954033|FG002|Overall Study|Cancellation of surgery|1
6260062|NCT02039427|9954034|FG003|Overall Study|Cancellation of surgery|0
6260063|NCT02039427|9954031|FG000|Overall Study|Loss of follow - up|1
6260064|NCT02039427|9954032|FG001|Overall Study|Loss of follow - up|0
6260065|NCT02039427|9954033|FG002|Overall Study|Loss of follow - up|2
6260066|NCT02039427|9954034|FG003|Overall Study|Loss of follow - up|4
6260067|NCT02039427|9954031|FG000|Overall Study|Steroid Use|1
6260068|NCT02039427|9954032|FG001|Overall Study|Steroid Use|0
6260069|NCT02039427|9954033|FG002|Overall Study|Steroid Use|0
6260070|NCT02039427|9954034|FG003|Overall Study|Steroid Use|0
6260071|NCT02039505|9954051|FG000|Induction Phase (Week 0 to Week 14)|Pretreatment Event/Adverse Event|2
6260072|NCT02039505|9954052|FG001|Induction Phase (Week 0 to Week 14)|Pretreatment Event/Adverse Event|8
6260073|NCT02039505|9954053|FG002|Induction Phase (Week 0 to Week 14)|Pretreatment Event/Adverse Event|7
6260074|NCT02039505|9954054|FG003|Induction Phase (Week 0 to Week 14)|Pretreatment Event/Adverse Event|0
6260075|NCT02039505|9954055|FG004|Induction Phase (Week 0 to Week 14)|Pretreatment Event/Adverse Event|0
6260076|NCT02039505|9954056|FG005|Induction Phase (Week 0 to Week 14)|Pretreatment Event/Adverse Event|0
6260077|NCT02039505|9954057|FG006|Induction Phase (Week 0 to Week 14)|Pretreatment Event/Adverse Event|0
6260078|NCT02039505|9954051|FG000|Induction Phase (Week 0 to Week 14)|Lack of Efficacy|1
6260079|NCT02039505|9954052|FG001|Induction Phase (Week 0 to Week 14)|Lack of Efficacy|1
6260080|NCT02039505|9954053|FG002|Induction Phase (Week 0 to Week 14)|Lack of Efficacy|3
6260081|NCT02039505|9954054|FG003|Induction Phase (Week 0 to Week 14)|Lack of Efficacy|0
6260082|NCT02039505|9954055|FG004|Induction Phase (Week 0 to Week 14)|Lack of Efficacy|0
6260083|NCT02039505|9954056|FG005|Induction Phase (Week 0 to Week 14)|Lack of Efficacy|0
6260084|NCT02039505|9954057|FG006|Induction Phase (Week 0 to Week 14)|Lack of Efficacy|0
6260085|NCT02039505|9954051|FG000|Induction Phase (Week 0 to Week 14)|Major Protocol Deviation|1
6260086|NCT02039505|9954052|FG001|Induction Phase (Week 0 to Week 14)|Major Protocol Deviation|0
6260087|NCT02039505|9954053|FG002|Induction Phase (Week 0 to Week 14)|Major Protocol Deviation|0
6260088|NCT02039505|9954054|FG003|Induction Phase (Week 0 to Week 14)|Major Protocol Deviation|0
6260089|NCT02039505|9954055|FG004|Induction Phase (Week 0 to Week 14)|Major Protocol Deviation|0
6260090|NCT02039505|9954056|FG005|Induction Phase (Week 0 to Week 14)|Major Protocol Deviation|0
6260091|NCT02039505|9954057|FG006|Induction Phase (Week 0 to Week 14)|Major Protocol Deviation|0
6260092|NCT02039505|9954051|FG000|Maintenance Phase (Week 14 to Week 60)|Lack of Efficacy|0
6260093|NCT02039505|9954052|FG001|Maintenance Phase (Week 14 to Week 60)|Lack of Efficacy|0
6260094|NCT02039505|9954053|FG002|Maintenance Phase (Week 14 to Week 60)|Lack of Efficacy|0
6260095|NCT02039505|9954054|FG003|Maintenance Phase (Week 14 to Week 60)|Lack of Efficacy|13
6260096|NCT02039505|9954055|FG004|Maintenance Phase (Week 14 to Week 60)|Lack of Efficacy|8
6260097|NCT02039505|9954056|FG005|Maintenance Phase (Week 14 to Week 60)|Lack of Efficacy|12
6260098|NCT02039505|9954057|FG006|Maintenance Phase (Week 14 to Week 60)|Lack of Efficacy|0
6260099|NCT02039505|9954051|FG000|Maintenance Phase (Week 14 to Week 60)|Pretreatment Event/Adverse Event|0
6260100|NCT02039505|9954052|FG001|Maintenance Phase (Week 14 to Week 60)|Pretreatment Event/Adverse Event|0
6260101|NCT02039505|9954053|FG002|Maintenance Phase (Week 14 to Week 60)|Pretreatment Event/Adverse Event|0
6260102|NCT02039505|9954054|FG003|Maintenance Phase (Week 14 to Week 60)|Pretreatment Event/Adverse Event|6
6260103|NCT02039505|9954055|FG004|Maintenance Phase (Week 14 to Week 60)|Pretreatment Event/Adverse Event|1
6260104|NCT02039505|9954056|FG005|Maintenance Phase (Week 14 to Week 60)|Pretreatment Event/Adverse Event|1
6260105|NCT02039505|9954057|FG006|Maintenance Phase (Week 14 to Week 60)|Pretreatment Event/Adverse Event|0
6260106|NCT02039505|9954051|FG000|Maintenance Phase (Week 14 to Week 60)|Voluntary Withdrawal|0
6260107|NCT02039505|9954052|FG001|Maintenance Phase (Week 14 to Week 60)|Voluntary Withdrawal|0
6086773|NCT00663260|9696868|FG001|Overall Study|Adverse Event|7
6086774|NCT00663260|9696869|FG002|Overall Study|Adverse Event|6
6260108|NCT02039505|9954053|FG002|Maintenance Phase (Week 14 to Week 60)|Voluntary Withdrawal|0
6260109|NCT02039505|9954054|FG003|Maintenance Phase (Week 14 to Week 60)|Voluntary Withdrawal|3
6086775|NCT00663260|9696867|FG000|Overall Study|Withdrawal by Subject|3
6260110|NCT02039505|9954055|FG004|Maintenance Phase (Week 14 to Week 60)|Voluntary Withdrawal|2
6260111|NCT02039505|9954056|FG005|Maintenance Phase (Week 14 to Week 60)|Voluntary Withdrawal|1
6260112|NCT02039505|9954057|FG006|Maintenance Phase (Week 14 to Week 60)|Voluntary Withdrawal|0
6260113|NCT02039505|9954051|FG000|Maintenance Phase (Week 14 to Week 60)|Pregnancy|0
6260114|NCT02039505|9954052|FG001|Maintenance Phase (Week 14 to Week 60)|Pregnancy|0
6260115|NCT02039505|9954053|FG002|Maintenance Phase (Week 14 to Week 60)|Pregnancy|0
6260116|NCT02039505|9954054|FG003|Maintenance Phase (Week 14 to Week 60)|Pregnancy|2
6260117|NCT02039505|9954055|FG004|Maintenance Phase (Week 14 to Week 60)|Pregnancy|0
6260118|NCT02039505|9954056|FG005|Maintenance Phase (Week 14 to Week 60)|Pregnancy|0
6260119|NCT02039505|9954057|FG006|Maintenance Phase (Week 14 to Week 60)|Pregnancy|0
6260120|NCT02039505|9954051|FG000|Open-Label (Week 10 up to Week 154)|Lack of Efficacy|0
6260121|NCT02039505|9954052|FG001|Open-Label (Week 10 up to Week 154)|Lack of Efficacy|0
6260122|NCT02039505|9954053|FG002|Open-Label (Week 10 up to Week 154)|Lack of Efficacy|0
6260123|NCT02039505|9954054|FG003|Open-Label (Week 10 up to Week 154)|Lack of Efficacy|0
6086776|NCT00663260|9696868|FG001|Overall Study|Withdrawal by Subject|1
6260124|NCT02039505|9954055|FG004|Open-Label (Week 10 up to Week 154)|Lack of Efficacy|0
6260125|NCT02039505|9954056|FG005|Open-Label (Week 10 up to Week 154)|Lack of Efficacy|0
6260126|NCT02039505|9954057|FG006|Open-Label (Week 10 up to Week 154)|Lack of Efficacy|44
6260127|NCT02039505|9954051|FG000|Open-Label (Week 10 up to Week 154)|Pretreatment Event/Adverse Event|0
6260128|NCT02039505|9954052|FG001|Open-Label (Week 10 up to Week 154)|Pretreatment Event/Adverse Event|0
6260129|NCT02039505|9954053|FG002|Open-Label (Week 10 up to Week 154)|Pretreatment Event/Adverse Event|0
6260130|NCT02039505|9954054|FG003|Open-Label (Week 10 up to Week 154)|Pretreatment Event/Adverse Event|0
6260131|NCT02039505|9954055|FG004|Open-Label (Week 10 up to Week 154)|Pretreatment Event/Adverse Event|0
6260132|NCT02039505|9954056|FG005|Open-Label (Week 10 up to Week 154)|Pretreatment Event/Adverse Event|0
6260133|NCT02039505|9954057|FG006|Open-Label (Week 10 up to Week 154)|Pretreatment Event/Adverse Event|19
6260134|NCT02039505|9954051|FG000|Open-Label (Week 10 up to Week 154)|Voluntary Withdrawal|0
6260135|NCT02039505|9954052|FG001|Open-Label (Week 10 up to Week 154)|Voluntary Withdrawal|0
6260136|NCT02039505|9954053|FG002|Open-Label (Week 10 up to Week 154)|Voluntary Withdrawal|0
6260137|NCT02039505|9954054|FG003|Open-Label (Week 10 up to Week 154)|Voluntary Withdrawal|0
6260138|NCT02039505|9954055|FG004|Open-Label (Week 10 up to Week 154)|Voluntary Withdrawal|0
6260139|NCT02039505|9954056|FG005|Open-Label (Week 10 up to Week 154)|Voluntary Withdrawal|0
6260140|NCT02039505|9954057|FG006|Open-Label (Week 10 up to Week 154)|Voluntary Withdrawal|7
6260141|NCT02039505|9954051|FG000|Open-Label (Week 10 up to Week 154)|Major Protocol Deviation|0
6260142|NCT02039505|9954052|FG001|Open-Label (Week 10 up to Week 154)|Major Protocol Deviation|0
6260143|NCT02039505|9954053|FG002|Open-Label (Week 10 up to Week 154)|Major Protocol Deviation|0
6260144|NCT02039505|9954054|FG003|Open-Label (Week 10 up to Week 154)|Major Protocol Deviation|0
6260145|NCT02039505|9954055|FG004|Open-Label (Week 10 up to Week 154)|Major Protocol Deviation|0
6260146|NCT02039505|9954056|FG005|Open-Label (Week 10 up to Week 154)|Major Protocol Deviation|0
6260147|NCT02039505|9954057|FG006|Open-Label (Week 10 up to Week 154)|Major Protocol Deviation|1
6260148|NCT02039674|9954091|FG000|Overall Study|Adverse Event|0
6260149|NCT02039674|9954092|FG001|Overall Study|Adverse Event|0
6260150|NCT02039674|9954093|FG002|Overall Study|Adverse Event|1
6260151|NCT02039674|9954094|FG003|Overall Study|Adverse Event|1
6260152|NCT02039674|9954095|FG004|Overall Study|Adverse Event|0
6260153|NCT02039674|9954096|FG005|Overall Study|Adverse Event|0
6260154|NCT02039674|9954097|FG006|Overall Study|Adverse Event|0
6260155|NCT02039674|9954098|FG007|Overall Study|Adverse Event|0
6260156|NCT02039674|9954099|FG008|Overall Study|Adverse Event|2
6260157|NCT02039674|9954100|FG009|Overall Study|Adverse Event|0
6260158|NCT02039674|9954101|FG010|Overall Study|Adverse Event|0
6260159|NCT02039674|9954102|FG011|Overall Study|Adverse Event|2
6260160|NCT02039674|9954103|FG012|Overall Study|Adverse Event|2
6260161|NCT02039674|9954104|FG013|Overall Study|Adverse Event|1
6260162|NCT02039674|9954091|FG000|Overall Study|Death|0
6260163|NCT02039674|9954092|FG001|Overall Study|Death|0
6260164|NCT02039674|9954093|FG002|Overall Study|Death|1
6260165|NCT02039674|9954094|FG003|Overall Study|Death|2
6260166|NCT02039674|9954095|FG004|Overall Study|Death|0
6260167|NCT02039674|9954096|FG005|Overall Study|Death|0
6260168|NCT02039674|9954097|FG006|Overall Study|Death|0
6260169|NCT02039674|9954098|FG007|Overall Study|Death|0
6260170|NCT02039674|9954099|FG008|Overall Study|Death|0
6260171|NCT02039674|9954100|FG009|Overall Study|Death|0
6260172|NCT02039674|9954101|FG010|Overall Study|Death|1
6260173|NCT02039674|9954102|FG011|Overall Study|Death|1
6260174|NCT02039674|9954103|FG012|Overall Study|Death|0
6260175|NCT02039674|9954104|FG013|Overall Study|Death|8
6260176|NCT02039674|9954091|FG000|Overall Study|Excluded Medication|1
6260177|NCT02039674|9954092|FG001|Overall Study|Excluded Medication|1
6260178|NCT02039674|9954093|FG002|Overall Study|Excluded Medication|0
6260179|NCT02039674|9954094|FG003|Overall Study|Excluded Medication|1
6260180|NCT02039674|9954095|FG004|Overall Study|Excluded Medication|0
6260181|NCT02039674|9954096|FG005|Overall Study|Excluded Medication|1
6260182|NCT02039674|9954097|FG006|Overall Study|Excluded Medication|0
6260183|NCT02039674|9954098|FG007|Overall Study|Excluded Medication|0
6260184|NCT02039674|9954099|FG008|Overall Study|Excluded Medication|2
6260185|NCT02039674|9954100|FG009|Overall Study|Excluded Medication|2
6086777|NCT00663260|9696869|FG002|Overall Study|Withdrawal by Subject|6
6260186|NCT02039674|9954101|FG010|Overall Study|Excluded Medication|4
6260187|NCT02039674|9954102|FG011|Overall Study|Excluded Medication|2
6260188|NCT02039674|9954103|FG012|Overall Study|Excluded Medication|4
6260189|NCT02039674|9954104|FG013|Overall Study|Excluded Medication|3
6260190|NCT02039674|9954091|FG000|Overall Study|Lost to Follow-up|0
6260191|NCT02039674|9954092|FG001|Overall Study|Lost to Follow-up|0
6260192|NCT02039674|9954093|FG002|Overall Study|Lost to Follow-up|0
6260193|NCT02039674|9954094|FG003|Overall Study|Lost to Follow-up|0
6260194|NCT02039674|9954095|FG004|Overall Study|Lost to Follow-up|0
6260195|NCT02039674|9954096|FG005|Overall Study|Lost to Follow-up|0
6260196|NCT02039674|9954097|FG006|Overall Study|Lost to Follow-up|0
6260197|NCT02039674|9954098|FG007|Overall Study|Lost to Follow-up|0
6260198|NCT02039674|9954099|FG008|Overall Study|Lost to Follow-up|0
6260199|NCT02039674|9954100|FG009|Overall Study|Lost to Follow-up|0
6260200|NCT02039674|9954101|FG010|Overall Study|Lost to Follow-up|0
6260201|NCT02039674|9954102|FG011|Overall Study|Lost to Follow-up|0
6260202|NCT02039674|9954103|FG012|Overall Study|Lost to Follow-up|1
6260203|NCT02039674|9954104|FG013|Overall Study|Lost to Follow-up|0
6260204|NCT02039674|9954091|FG000|Overall Study|Physician Decision|0
6260205|NCT02039674|9954092|FG001|Overall Study|Physician Decision|0
6260206|NCT02039674|9954093|FG002|Overall Study|Physician Decision|0
6260207|NCT02039674|9954094|FG003|Overall Study|Physician Decision|0
6260208|NCT02039674|9954095|FG004|Overall Study|Physician Decision|0
6260209|NCT02039674|9954096|FG005|Overall Study|Physician Decision|0
6260210|NCT02039674|9954097|FG006|Overall Study|Physician Decision|0
6260211|NCT02039674|9954098|FG007|Overall Study|Physician Decision|0
6260212|NCT02039674|9954099|FG008|Overall Study|Physician Decision|0
6260213|NCT02039674|9954100|FG009|Overall Study|Physician Decision|0
6260214|NCT02039674|9954101|FG010|Overall Study|Physician Decision|0
6260215|NCT02039674|9954102|FG011|Overall Study|Physician Decision|1
6260216|NCT02039674|9954103|FG012|Overall Study|Physician Decision|0
6260217|NCT02039674|9954104|FG013|Overall Study|Physician Decision|0
6260218|NCT02039674|9954091|FG000|Overall Study|Progressive Disease|6
6260219|NCT02039674|9954092|FG001|Overall Study|Progressive Disease|7
6260220|NCT02039674|9954093|FG002|Overall Study|Progressive Disease|6
6260221|NCT02039674|9954094|FG003|Overall Study|Progressive Disease|7
6260222|NCT02039674|9954095|FG004|Overall Study|Progressive Disease|8
6260223|NCT02039674|9954096|FG005|Overall Study|Progressive Disease|10
6260224|NCT02039674|9954097|FG006|Overall Study|Progressive Disease|1
6260225|NCT02039674|9954098|FG007|Overall Study|Progressive Disease|3
6260226|NCT02039674|9954099|FG008|Overall Study|Progressive Disease|7
6260227|NCT02039674|9954100|FG009|Overall Study|Progressive Disease|2
6260228|NCT02039674|9954101|FG010|Overall Study|Progressive Disease|0
6260229|NCT02039674|9954102|FG011|Overall Study|Progressive Disease|17
6260230|NCT02039674|9954103|FG012|Overall Study|Progressive Disease|18
6260231|NCT02039674|9954104|FG013|Overall Study|Progressive Disease|16
6260232|NCT02039674|9954091|FG000|Overall Study|Withdrawal by Subject|0
6260233|NCT02039674|9954092|FG001|Overall Study|Withdrawal by Subject|2
6260234|NCT02039674|9954093|FG002|Overall Study|Withdrawal by Subject|1
6260235|NCT02039674|9954094|FG003|Overall Study|Withdrawal by Subject|0
6260236|NCT02039674|9954095|FG004|Overall Study|Withdrawal by Subject|1
6260237|NCT02039674|9954096|FG005|Overall Study|Withdrawal by Subject|0
6260238|NCT02039674|9954097|FG006|Overall Study|Withdrawal by Subject|0
6260239|NCT02039674|9954098|FG007|Overall Study|Withdrawal by Subject|0
6260240|NCT02039674|9954099|FG008|Overall Study|Withdrawal by Subject|0
6260241|NCT02039674|9954100|FG009|Overall Study|Withdrawal by Subject|2
6260242|NCT02039674|9954101|FG010|Overall Study|Withdrawal by Subject|1
6260243|NCT02039674|9954102|FG011|Overall Study|Withdrawal by Subject|3
6260244|NCT02039674|9954103|FG012|Overall Study|Withdrawal by Subject|5
6260245|NCT02039674|9954104|FG013|Overall Study|Withdrawal by Subject|2
6260246|NCT02039674|9954091|FG000|Overall Study|Ongoing in Study|5
6260247|NCT02039674|9954092|FG001|Overall Study|Ongoing in Study|2
6260248|NCT02039674|9954093|FG002|Overall Study|Ongoing in Study|3
6260249|NCT02039674|9954094|FG003|Overall Study|Ongoing in Study|2
6260250|NCT02039674|9954095|FG004|Overall Study|Ongoing in Study|3
6260251|NCT02039674|9954096|FG005|Overall Study|Ongoing in Study|1
6260252|NCT02039674|9954097|FG006|Overall Study|Ongoing in Study|2
6260253|NCT02039674|9954098|FG007|Overall Study|Ongoing in Study|0
6260254|NCT02039674|9954099|FG008|Overall Study|Ongoing in Study|1
6260255|NCT02039674|9954100|FG009|Overall Study|Ongoing in Study|6
6260256|NCT02039674|9954101|FG010|Overall Study|Ongoing in Study|1
6260257|NCT02039674|9954102|FG011|Overall Study|Ongoing in Study|34
6260258|NCT02039674|9954103|FG012|Overall Study|Ongoing in Study|33
6260259|NCT02039674|9954104|FG013|Overall Study|Ongoing in Study|3
6260260|NCT02039687|9954141|FG000|Overall Study|Adverse Event|0
6260261|NCT02039687|9954142|FG001|Overall Study|Adverse Event|0
6260262|NCT02039687|9954143|FG002|Overall Study|Adverse Event|1
6260263|NCT02039687|9954144|FG003|Overall Study|Adverse Event|0
6260264|NCT02039687|9954141|FG000|Overall Study|Withdrawal by Subject|0
6260265|NCT02039687|9954142|FG001|Overall Study|Withdrawal by Subject|1
6260266|NCT02039687|9954143|FG002|Overall Study|Withdrawal by Subject|0
6260267|NCT02039687|9954144|FG003|Overall Study|Withdrawal by Subject|0
6260268|NCT02039687|9954141|FG000|Overall Study|treatment assignment could not be confir|0
6260269|NCT02039687|9954142|FG001|Overall Study|treatment assignment could not be confir|0
6260270|NCT02039687|9954143|FG002|Overall Study|treatment assignment could not be confir|2
6271910|NCT02169271|9974014|FG001|Overall Study|Protocol Violation|2
6260271|NCT02039687|9954144|FG003|Overall Study|treatment assignment could not be confir|0
6260272|NCT02039778|9954163|FG000|Overall Study|Death|2
6260273|NCT02039778|9954163|FG000|Overall Study|Withdrawal by Subject|1
6260274|NCT02039778|9954163|FG000|Overall Study|Never started the protocol treatment|1
6260275|NCT02039856|9954177|FG000|Overall Study|Death|5
6260276|NCT02039856|9954178|FG001|Overall Study|Death|3
6260277|NCT02039856|9954177|FG000|Overall Study|Partial survey completion|61
6260278|NCT02039856|9954178|FG001|Overall Study|Partial survey completion|26
6260279|NCT02039856|9954177|FG000|Overall Study|Lost to Follow-up|388
6260280|NCT02039856|9954178|FG001|Overall Study|Lost to Follow-up|206
6260281|NCT02039856|9954177|FG000|Overall Study|Withdrawal by Subject|1573
6260282|NCT02039856|9954178|FG001|Overall Study|Withdrawal by Subject|618
6260283|NCT02039908|9954186|FG000|Phase 1-Summer|Withdrawal by Subject|7
6260284|NCT02039908|9954187|FG001|Phase 1-Summer|Withdrawal by Subject|6
6260285|NCT02039908|9954188|FG002|Phase 1-Summer|Withdrawal by Subject|0
6260286|NCT02039908|9954189|FG003|Phase 1-Summer|Withdrawal by Subject|0
6260287|NCT02039908|9954186|FG000|Phase 1-Summer|Protocol Violation|6
6260288|NCT02039908|9954187|FG001|Phase 1-Summer|Protocol Violation|0
6260289|NCT02039908|9954188|FG002|Phase 1-Summer|Protocol Violation|0
6260290|NCT02039908|9954189|FG003|Phase 1-Summer|Protocol Violation|0
6260291|NCT02039908|9954186|FG000|Phase 2-School Year|Lost to Follow-up|0
6260292|NCT02039908|9954187|FG001|Phase 2-School Year|Lost to Follow-up|0
6260293|NCT02039908|9954188|FG002|Phase 2-School Year|Lost to Follow-up|1
6260294|NCT02039908|9954189|FG003|Phase 2-School Year|Lost to Follow-up|3
6260295|NCT02039908|9954186|FG000|Phase 2-School Year|Protocol Violation|0
6260296|NCT02039908|9954187|FG001|Phase 2-School Year|Protocol Violation|0
6260297|NCT02039908|9954188|FG002|Phase 2-School Year|Protocol Violation|3
6260298|NCT02039908|9954189|FG003|Phase 2-School Year|Protocol Violation|0
6260299|NCT02039908|9954186|FG000|Phase 2-School Year|Withdrawal by Subject|0
6260300|NCT02039908|9954187|FG001|Phase 2-School Year|Withdrawal by Subject|0
6260301|NCT02039908|9954188|FG002|Phase 2-School Year|Withdrawal by Subject|8
6260302|NCT02039908|9954189|FG003|Phase 2-School Year|Withdrawal by Subject|5
6260303|NCT02040090|9954234|FG000|Overall Study|Adverse Event|2
6260304|NCT02040090|9954235|FG001|Overall Study|Adverse Event|0
6260305|NCT02040090|9954234|FG000|Overall Study|Physician Decision|1
6260306|NCT02040090|9954235|FG001|Overall Study|Physician Decision|0
6260307|NCT02040090|9954234|FG000|Overall Study|Withdrawal by Subject|0
6260308|NCT02040090|9954235|FG001|Overall Study|Withdrawal by Subject|1
6260309|NCT02040090|9954234|FG000|Overall Study|Lost to Follow-up|0
6260310|NCT02040090|9954235|FG001|Overall Study|Lost to Follow-up|1
6260311|NCT02040259|9954249|FG000|Overall Study|Death|280
6260312|NCT02040259|9954249|FG000|Overall Study|Lost to Follow-up|76
6260313|NCT02040259|9954249|FG000|Overall Study|Assessment not completed|3
6260314|NCT02040259|9954249|FG000|Overall Study|Withdrawal by Subject|4
6260315|NCT02040428|9954272|FG000|Overall Study|Death|4
6260316|NCT02040428|9954273|FG001|Overall Study|Death|3
6260317|NCT02040428|9954272|FG000|Overall Study|Withdrawal by Subject|1
6260318|NCT02040428|9954273|FG001|Overall Study|Withdrawal by Subject|1
6260319|NCT02040532|9954279|FG000|Overall Study|Lost to Follow-up|1
6260320|NCT02040532|9954279|FG000|Overall Study|Physician Decision|4
6260321|NCT02040532|9954279|FG000|Overall Study|Adverse Event|4
6260322|NCT02040532|9954279|FG000|Overall Study|Withdrawal by Subject|3
6260323|NCT02040766|9954301|FG000|Overall Study|Adverse Event|1
6260324|NCT02040766|9954302|FG001|Overall Study|Adverse Event|1
6260325|NCT02040766|9954303|FG002|Overall Study|Adverse Event|1
6260326|NCT02040766|9954304|FG003|Overall Study|Adverse Event|0
6260327|NCT02040766|9954305|FG004|Overall Study|Adverse Event|2
6260328|NCT02040766|9954301|FG000|Overall Study|Withdrawal by Subject|4
6260329|NCT02040766|9954302|FG001|Overall Study|Withdrawal by Subject|3
6260330|NCT02040766|9954303|FG002|Overall Study|Withdrawal by Subject|2
6260331|NCT02040766|9954304|FG003|Overall Study|Withdrawal by Subject|3
6260332|NCT02040766|9954305|FG004|Overall Study|Withdrawal by Subject|2
6260333|NCT02040766|9954301|FG000|Overall Study|Non-compliance|0
6260334|NCT02040766|9954302|FG001|Overall Study|Non-compliance|1
6260335|NCT02040766|9954303|FG002|Overall Study|Non-compliance|0
6260336|NCT02040766|9954304|FG003|Overall Study|Non-compliance|0
6260337|NCT02040766|9954305|FG004|Overall Study|Non-compliance|0
6260338|NCT02040766|9954301|FG000|Overall Study|Protocol Violation|2
6260339|NCT02040766|9954302|FG001|Overall Study|Protocol Violation|1
6260340|NCT02040766|9954303|FG002|Overall Study|Protocol Violation|2
6260341|NCT02040766|9954304|FG003|Overall Study|Protocol Violation|3
6260342|NCT02040766|9954305|FG004|Overall Study|Protocol Violation|0
6260343|NCT02040766|9954301|FG000|Overall Study|Lost to Follow-up|4
6260344|NCT02040766|9954302|FG001|Overall Study|Lost to Follow-up|1
6260345|NCT02040766|9954303|FG002|Overall Study|Lost to Follow-up|3
6260346|NCT02040766|9954304|FG003|Overall Study|Lost to Follow-up|1
6260347|NCT02040766|9954305|FG004|Overall Study|Lost to Follow-up|4
6260348|NCT02040766|9954301|FG000|Overall Study|Not reported|1
6260349|NCT02040766|9954302|FG001|Overall Study|Not reported|0
6260350|NCT02040766|9954303|FG002|Overall Study|Not reported|0
6260351|NCT02040766|9954304|FG003|Overall Study|Not reported|0
6260352|NCT02040766|9954305|FG004|Overall Study|Not reported|0
6260353|NCT02040766|9954301|FG000|Overall Study|Lack of Efficacy|6
6260354|NCT02040766|9954302|FG001|Overall Study|Lack of Efficacy|3
6260355|NCT02040766|9954303|FG002|Overall Study|Lack of Efficacy|4
6260356|NCT02040766|9954304|FG003|Overall Study|Lack of Efficacy|6
6260357|NCT02040766|9954305|FG004|Overall Study|Lack of Efficacy|5
6260358|NCT02040779|9954321|FG000|Overall Study|Adverse Event|1
6260359|NCT02040779|9954322|FG001|Overall Study|Adverse Event|0
6260360|NCT02040779|9954323|FG002|Overall Study|Adverse Event|0
6260361|NCT02040779|9954321|FG000|Overall Study|Withdrawal by Subject|4
6260362|NCT02040779|9954322|FG001|Overall Study|Withdrawal by Subject|1
6260363|NCT02040779|9954323|FG002|Overall Study|Withdrawal by Subject|3
6260364|NCT02040779|9954321|FG000|Overall Study|Non-compliance|0
6260365|NCT02040779|9954322|FG001|Overall Study|Non-compliance|1
6260366|NCT02040779|9954323|FG002|Overall Study|Non-compliance|0
6260367|NCT02040779|9954321|FG000|Overall Study|Protocol Violation|2
6260368|NCT02040779|9954322|FG001|Overall Study|Protocol Violation|1
6260369|NCT02040779|9954323|FG002|Overall Study|Protocol Violation|0
6260370|NCT02040779|9954321|FG000|Overall Study|Lost to Follow-up|1
6260371|NCT02040779|9954322|FG001|Overall Study|Lost to Follow-up|2
6260372|NCT02040779|9954323|FG002|Overall Study|Lost to Follow-up|1
6260373|NCT02040779|9954321|FG000|Overall Study|Lack of Efficacy|4
6260374|NCT02040779|9954322|FG001|Overall Study|Lack of Efficacy|2
6260375|NCT02040779|9954323|FG002|Overall Study|Lack of Efficacy|0
6271242|NCT02161718|9972926|FG002|Open-Label ALKS 3831 Period|Physician Decision|0
6271243|NCT02161718|9972924|FG000|Open-Label ALKS 3831 Period|Non-compliance with study drug|1
6271244|NCT02161718|9972925|FG001|Open-Label ALKS 3831 Period|Non-compliance with study drug|0
6271245|NCT02161718|9972926|FG002|Open-Label ALKS 3831 Period|Non-compliance with study drug|0
6271246|NCT02161718|9972924|FG000|Open-Label ALKS 3831 Period|Lack of Efficacy|1
6271247|NCT02161718|9972925|FG001|Open-Label ALKS 3831 Period|Lack of Efficacy|0
6271248|NCT02161718|9972926|FG002|Open-Label ALKS 3831 Period|Lack of Efficacy|0
6271249|NCT02161718|9972924|FG000|Open-Label ALKS 3831 Period|Adverse Event|3
6271250|NCT02161718|9972925|FG001|Open-Label ALKS 3831 Period|Adverse Event|0
6271251|NCT02161718|9972926|FG002|Open-Label ALKS 3831 Period|Adverse Event|0
6271252|NCT02161718|9972924|FG000|Open-Label ALKS 3831 Period|Withdrawal by Subject|4
6271253|NCT02161718|9972925|FG001|Open-Label ALKS 3831 Period|Withdrawal by Subject|0
6271254|NCT02161718|9972926|FG002|Open-Label ALKS 3831 Period|Withdrawal by Subject|0
6271255|NCT02161718|9972924|FG000|Open-Label ALKS 3831 Period|Lost to Follow-up|3
6271256|NCT02161718|9972925|FG001|Open-Label ALKS 3831 Period|Lost to Follow-up|0
6271257|NCT02161718|9972926|FG002|Open-Label ALKS 3831 Period|Lost to Follow-up|0
6271258|NCT02161718|9972924|FG000|Open-Label ALKS 3831 Period|Failure to meet randomization criteria|6
6271259|NCT02161718|9972925|FG001|Open-Label ALKS 3831 Period|Failure to meet randomization criteria|0
6271260|NCT02161718|9972926|FG002|Open-Label ALKS 3831 Period|Failure to meet randomization criteria|0
6271261|NCT02161718|9972924|FG000|Post- Randomization Period|Withdrawal by Subject|0
6271262|NCT02161718|9972925|FG001|Post- Randomization Period|Withdrawal by Subject|23
6271263|NCT02161718|9972926|FG002|Post- Randomization Period|Withdrawal by Subject|18
6271264|NCT02161718|9972924|FG000|Post- Randomization Period|Lost to Follow-up|0
6086778|NCT00663260|9696867|FG000|Overall Study|Death|1
6086779|NCT00663260|9696868|FG001|Overall Study|Death|0
6086780|NCT00663260|9696869|FG002|Overall Study|Death|1
6086781|NCT00663260|9696867|FG000|Overall Study|Lost to Follow-up|0
6086782|NCT00663260|9696868|FG001|Overall Study|Lost to Follow-up|1
6086783|NCT00663260|9696869|FG002|Overall Study|Lost to Follow-up|0
6086784|NCT00663260|9696867|FG000|Overall Study|non-compliance, not met criteria, etc.|3
6271265|NCT02161718|9972925|FG001|Post- Randomization Period|Lost to Follow-up|9
6271266|NCT02161718|9972926|FG002|Post- Randomization Period|Lost to Follow-up|15
6271267|NCT02161718|9972924|FG000|Post- Randomization Period|Adverse Event|0
6271268|NCT02161718|9972925|FG001|Post- Randomization Period|Adverse Event|9
6271269|NCT02161718|9972926|FG002|Post- Randomization Period|Adverse Event|10
6271270|NCT02161718|9972924|FG000|Post- Randomization Period|Non- compliance with study drug|0
6271271|NCT02161718|9972925|FG001|Post- Randomization Period|Non- compliance with study drug|8
6271272|NCT02161718|9972926|FG002|Post- Randomization Period|Non- compliance with study drug|2
6271273|NCT02161718|9972924|FG000|Post- Randomization Period|Physician Decision|0
6271274|NCT02161718|9972925|FG001|Post- Randomization Period|Physician Decision|2
6271275|NCT02161718|9972926|FG002|Post- Randomization Period|Physician Decision|4
6271276|NCT02161718|9972924|FG000|Post- Randomization Period|Protocol Violation|0
6271277|NCT02161718|9972925|FG001|Post- Randomization Period|Protocol Violation|2
6271278|NCT02161718|9972926|FG002|Post- Randomization Period|Protocol Violation|3
6271279|NCT02161718|9972924|FG000|Post- Randomization Period|Lack of Efficacy|0
6271280|NCT02161718|9972925|FG001|Post- Randomization Period|Lack of Efficacy|0
6271281|NCT02161718|9972926|FG002|Post- Randomization Period|Lack of Efficacy|1
6271282|NCT02161718|9972924|FG000|Post- Randomization Period|Non-compliance with study procedures|0
6271283|NCT02161718|9972925|FG001|Post- Randomization Period|Non-compliance with study procedures|2
6271284|NCT02161718|9972926|FG002|Post- Randomization Period|Non-compliance with study procedures|4
6271285|NCT02161718|9972924|FG000|Post- Randomization Period|Received prohibitive treatment|0
6271286|NCT02161718|9972925|FG001|Post- Randomization Period|Received prohibitive treatment|1
6271287|NCT02161718|9972926|FG002|Post- Randomization Period|Received prohibitive treatment|2
6271288|NCT02161718|9972924|FG000|Post- Randomization Period|Relocation|0
6086785|NCT00663260|9696868|FG001|Overall Study|non-compliance, not met criteria, etc.|2
6086786|NCT00663260|9696869|FG002|Overall Study|non-compliance, not met criteria, etc.|3
6086787|NCT00663702|9696883|FG000|Overall Study|Adverse Event|8
6260376|NCT02040805|9954333|FG000|Overall Study|Lost to Follow-up|14
6260377|NCT02040805|9954334|FG001|Overall Study|Lost to Follow-up|9
6260378|NCT02040805|9954333|FG000|Overall Study|Withdrawal by Subject|28
6260379|NCT02040805|9954334|FG001|Overall Study|Withdrawal by Subject|41
6260380|NCT02040844|9954343|FG000|Overall Study|Adverse Event|0
6260381|NCT02040844|9954344|FG001|Overall Study|Adverse Event|0
6260382|NCT02040844|9954345|FG002|Overall Study|Adverse Event|1
6260383|NCT02040844|9954343|FG000|Overall Study|Withdrawal by Subject|16
6260384|NCT02040844|9954344|FG001|Overall Study|Withdrawal by Subject|22
6260385|NCT02040844|9954345|FG002|Overall Study|Withdrawal by Subject|25
6260386|NCT02040844|9954343|FG000|Overall Study|Lost to Follow-up|12
6260387|NCT02040844|9954344|FG001|Overall Study|Lost to Follow-up|9
6260388|NCT02040844|9954345|FG002|Overall Study|Lost to Follow-up|13
6260389|NCT02040844|9954343|FG000|Overall Study|Missing|13
6260390|NCT02040844|9954344|FG001|Overall Study|Missing|3
6260391|NCT02040844|9954345|FG002|Overall Study|Missing|2
6260392|NCT02040844|9954343|FG000|Overall Study|Non-specified|8
6260393|NCT02040844|9954344|FG001|Overall Study|Non-specified|2
6260394|NCT02040844|9954345|FG002|Overall Study|Non-specified|5
6260395|NCT02040844|9954343|FG000|Overall Study|Concomitant medication|1
6086788|NCT00663702|9696884|FG001|Overall Study|Adverse Event|4
6086789|NCT00663702|9696883|FG000|Overall Study|Withdrawal by Subject|3
6086790|NCT00663702|9696884|FG001|Overall Study|Withdrawal by Subject|1
6086791|NCT00663702|9696883|FG000|Overall Study|Pregnancy|0
6086792|NCT00663702|9696884|FG001|Overall Study|Pregnancy|1
6086793|NCT00663702|9696883|FG000|Overall Study|Lost to Follow-up|3
6086794|NCT00663702|9696884|FG001|Overall Study|Lost to Follow-up|0
6086795|NCT00663702|9696883|FG000|Overall Study|Death|1
6086796|NCT00663702|9696884|FG001|Overall Study|Death|1
6086797|NCT00663702|9696883|FG000|Overall Study|Lack of Efficacy|3
6086798|NCT00663702|9696884|FG001|Overall Study|Lack of Efficacy|3
6086799|NCT00663858|9696913|FG000|Overall Study|Adverse Event|9
6086800|NCT00663858|9696914|FG001|Overall Study|Adverse Event|1
6086801|NCT00663858|9696915|FG002|Overall Study|Adverse Event|6
6086802|NCT00663858|9696913|FG000|Overall Study|Lack of Efficacy|5
6086803|NCT00663858|9696914|FG001|Overall Study|Lack of Efficacy|1
6086804|NCT00663858|9696915|FG002|Overall Study|Lack of Efficacy|3
6086805|NCT00663858|9696913|FG000|Overall Study|Withdrawal by Subject|7
6086806|NCT00663858|9696914|FG001|Overall Study|Withdrawal by Subject|3
6086807|NCT00663858|9696915|FG002|Overall Study|Withdrawal by Subject|3
6086808|NCT00663858|9696913|FG000|Overall Study|Protocol Violation|5
6086809|NCT00663858|9696914|FG001|Overall Study|Protocol Violation|3
6086810|NCT00663858|9696915|FG002|Overall Study|Protocol Violation|4
6086811|NCT00663858|9696913|FG000|Overall Study|Other|8
6086812|NCT00663858|9696914|FG001|Overall Study|Other|2
6086813|NCT00663858|9696915|FG002|Overall Study|Other|4
6086814|NCT00663871|9696925|FG000|Overall Study|Lost to Follow-up|5
6086815|NCT00663871|9696926|FG001|Overall Study|Lost to Follow-up|5
6086816|NCT00663871|9696925|FG000|Overall Study|Withdrawal by Subject|5
6086817|NCT00663871|9696926|FG001|Overall Study|Withdrawal by Subject|2
6086818|NCT00663923|9696934|FG000|Overall Study|Lost to Follow-up|2
6086819|NCT00663962|9696942|FG000|Overall Study|somnolence|1
6086820|NCT00663962|9696943|FG001|Overall Study|somnolence|0
6086821|NCT00664105|9696949|FG000|Overall Study|Death|3
6086822|NCT00664105|9696949|FG000|Overall Study|Withdrawal by Subject|5
6086823|NCT00664105|9696949|FG000|Overall Study|Adverse Event|9
6086824|NCT00664105|9696949|FG000|Overall Study|Disease progression|7
6086825|NCT00664209|9696954|FG000|Motor Fluctuations Screen|Negative for motor fluctuation|7
6086826|NCT00664209|9696954|FG000|Study Treatment Period|Physician Decision|4
6086827|NCT00664209|9696954|FG000|Study Treatment Period|Withdrawal by Subject|2
6086828|NCT00664326|9696959|FG000|Overall Study|Adverse Event|14
6086829|NCT00664326|9696959|FG000|Overall Study|Noncompliance with study medication|3
6086830|NCT00664326|9696959|FG000|Overall Study|Withdrawal by Subject|1
6086831|NCT00664326|9696959|FG000|Overall Study|Physician Decision|1
6086832|NCT00664326|9696959|FG000|Overall Study|Other Reasons|3
6086833|NCT00664326|9696959|FG000|Overall Study|Death|2
6086834|NCT00664326|9696959|FG000|Overall Study|Disease Progression/Recurrence/Relapse|24
6086835|NCT00664521|9696969|FG000|Overall Study|Adverse Event|4
6086836|NCT00664521|9696970|FG001|Overall Study|Adverse Event|1
6086837|NCT00664521|9696969|FG000|Overall Study|Lost to Follow-up|1
6086838|NCT00664521|9696970|FG001|Overall Study|Lost to Follow-up|0
6086839|NCT00664521|9696969|FG000|Overall Study|Other|1
6086840|NCT00664521|9696970|FG001|Overall Study|Other|0
6260396|NCT02040844|9954344|FG001|Overall Study|Concomitant medication|3
6260397|NCT02040844|9954345|FG002|Overall Study|Concomitant medication|1
6260398|NCT02040870|9954353|FG000|Overall Study|Completed treatment phase|6
6260399|NCT02040870|9954353|FG000|Overall Study|Adverse Event|7
6086841|NCT00664534|9696978|FG000|Overall Study|Adverse Event|2
6086842|NCT00664534|9696979|FG001|Overall Study|Adverse Event|3
6086843|NCT00664534|9696978|FG000|Overall Study|Lost to Follow-up|6
6086844|NCT00664534|9696979|FG001|Overall Study|Lost to Follow-up|10
6086845|NCT00664534|9696978|FG000|Overall Study|Protocol Violation|10
6086846|NCT00664534|9696979|FG001|Overall Study|Protocol Violation|8
6086847|NCT00664534|9696978|FG000|Overall Study|Withdrawal by Subject|7
6260400|NCT02040870|9954353|FG000|Overall Study|Progressive disease|58
6260401|NCT02040870|9954353|FG000|Overall Study|Physician Decision|6
6260402|NCT02040870|9954353|FG000|Overall Study|Subject/guardian decision|10
6086848|NCT00664534|9696979|FG001|Overall Study|Withdrawal by Subject|6
6086849|NCT00664534|9696978|FG000|Overall Study|Physician Decision|8
6086850|NCT00664534|9696979|FG001|Overall Study|Physician Decision|0
6086851|NCT00664534|9696978|FG000|Overall Study|Sponsor decision|8
6086852|NCT00664534|9696979|FG001|Overall Study|Sponsor decision|6
6086853|NCT00664560|9696988|FG000|Overall Study|Adverse Event|19
6086854|NCT00664560|9696989|FG001|Overall Study|Adverse Event|16
6086855|NCT00664560|9696990|FG002|Overall Study|Adverse Event|7
6086856|NCT00664560|9696988|FG000|Overall Study|Withdrawal by Subject|9
6086857|NCT00664560|9696989|FG001|Overall Study|Withdrawal by Subject|13
6086858|NCT00664560|9696990|FG002|Overall Study|Withdrawal by Subject|7
6086859|NCT00664560|9696988|FG000|Overall Study|Lost to Follow-up|0
6086860|NCT00664560|9696989|FG001|Overall Study|Lost to Follow-up|2
6086861|NCT00664560|9696990|FG002|Overall Study|Lost to Follow-up|0
6086862|NCT00664560|9696988|FG000|Overall Study|Other|11
6086863|NCT00664560|9696989|FG001|Overall Study|Other|4
6086864|NCT00664560|9696990|FG002|Overall Study|Other|5
6086865|NCT00664742|9696998|FG000|Overall Study|Withdrawn due to adverse events|3
6086866|NCT00664742|9696998|FG000|Overall Study|Withdrawal by Subject|31
6086867|NCT00664742|9696998|FG000|Overall Study|Lost to Follow-up|92
6260403|NCT02040870|9954353|FG000|Overall Study|Lost to Follow-up|3
6260404|NCT02040870|9954353|FG000|Overall Study|Death|13
6260405|NCT02041091|9954359|FG000|Treatment|Adverse Event|3
6260406|NCT02041091|9954360|FG001|Treatment|Adverse Event|3
6260407|NCT02041091|9954359|FG000|Treatment|Withdrawal by Subject|2
6260408|NCT02041091|9954360|FG001|Treatment|Withdrawal by Subject|4
6260409|NCT02041091|9954359|FG000|Treatment|Physician Decision|1
6260410|NCT02041091|9954360|FG001|Treatment|Physician Decision|0
6260411|NCT02041091|9954359|FG000|Treatment|Sponsor Decision|15
6260412|NCT02041091|9954360|FG001|Treatment|Sponsor Decision|16
6260413|NCT02041091|9954359|FG000|Treatment|Lost to Follow-up|1
6260414|NCT02041091|9954360|FG001|Treatment|Lost to Follow-up|0
6260415|NCT02041091|9954359|FG000|Optional Safety Extension Period|Adverse Event|4
6260416|NCT02041091|9954360|FG001|Optional Safety Extension Period|Adverse Event|2
6086868|NCT00664859|9697014|FG000|Overall Study|Adverse Event|2
6190952|NCT01418339|9847552|FG001|Overall Study|Adverse Event|2
6260417|NCT02041091|9954359|FG000|Optional Safety Extension Period|Withdrawal by Subject|5
6260418|NCT02041091|9954360|FG001|Optional Safety Extension Period|Withdrawal by Subject|2
6260419|NCT02041091|9954359|FG000|Optional Safety Extension Period|Protocol Violation|2
6260420|NCT02041091|9954360|FG001|Optional Safety Extension Period|Protocol Violation|0
6260421|NCT02041091|9954359|FG000|Optional Safety Extension Period|Physician Decision|2
6260422|NCT02041091|9954360|FG001|Optional Safety Extension Period|Physician Decision|1
6260423|NCT02041091|9954359|FG000|Optional Safety Extension Period|Sponsor Decision|70
6260424|NCT02041091|9954360|FG001|Optional Safety Extension Period|Sponsor Decision|74
6260425|NCT02041091|9954359|FG000|Optional Safety Extension Period|Lost to Follow-up|2
6260426|NCT02041091|9954360|FG001|Optional Safety Extension Period|Lost to Follow-up|3
6260427|NCT02041104|9954374|FG000|Overall Study|Lost to Follow-up|1
6260428|NCT02041104|9954375|FG001|Overall Study|Lost to Follow-up|4
6260429|NCT02041104|9954374|FG000|Overall Study|discomfort during OGTT|0
6260430|NCT02041104|9954375|FG001|Overall Study|discomfort during OGTT|3
6260431|NCT02041286|9954408|FG000|Overall Study|Adverse Event|1
6260432|NCT02041299|9954416|FG000|Overall Study|Adverse Event|9
6260433|NCT02041299|9954417|FG001|Overall Study|Adverse Event|3
6260434|NCT02041299|9954416|FG000|Overall Study|Lost to Follow-up|4
6190953|NCT01418339|9847551|FG000|Overall Study|Subject Withdrew Consent|1
6190954|NCT01418339|9847552|FG001|Overall Study|Subject Withdrew Consent|2
6190955|NCT01418339|9847551|FG000|Overall Study|Lack of Efficacy as Determined by the Investigator|6
6190956|NCT01418339|9847552|FG001|Overall Study|Lack of Efficacy as Determined by the Investigator|6
6190957|NCT01418352|9847562|FG000|Overall Study|Lost to Follow-up|2
6190958|NCT01418352|9847563|FG001|Overall Study|Lost to Follow-up|0
6190959|NCT01418352|9847564|FG002|Overall Study|Lost to Follow-up|0
6190960|NCT01418352|9847565|FG003|Overall Study|Lost to Follow-up|0
6190961|NCT01418352|9847562|FG000|Overall Study|Adverse Event|0
6190962|NCT01418352|9847563|FG001|Overall Study|Adverse Event|1
6190963|NCT01418352|9847564|FG002|Overall Study|Adverse Event|0
6190964|NCT01418352|9847565|FG003|Overall Study|Adverse Event|0
6190965|NCT01418352|9847562|FG000|Overall Study|Sponsor Discontinued Trial Site|0
6190966|NCT01418352|9847563|FG001|Overall Study|Sponsor Discontinued Trial Site|2
6190967|NCT01418352|9847564|FG002|Overall Study|Sponsor Discontinued Trial Site|2
6260435|NCT02041299|9954417|FG001|Overall Study|Lost to Follow-up|1
6260436|NCT02041299|9954416|FG000|Overall Study|Physician Decision|1
6260437|NCT02041299|9954417|FG001|Overall Study|Physician Decision|1
6260438|NCT02041299|9954416|FG000|Overall Study|Withdrawal by Subject|13
6260439|NCT02041299|9954417|FG001|Overall Study|Withdrawal by Subject|7
6086869|NCT00664859|9697015|FG001|Overall Study|Adverse Event|1
6086870|NCT00664859|9697016|FG002|Overall Study|Adverse Event|3
6086871|NCT00664859|9697014|FG000|Overall Study|DB Study (LCP-AtorFen-2001) AE|6
6086872|NCT00664859|9697015|FG001|Overall Study|DB Study (LCP-AtorFen-2001) AE|4
6086873|NCT00664859|9697016|FG002|Overall Study|DB Study (LCP-AtorFen-2001) AE|4
6086874|NCT00664859|9697014|FG000|Overall Study|Noncompliance with protocol|1
6260440|NCT02041299|9954416|FG000|Overall Study|Protocol Violation|11
6260441|NCT02041299|9954417|FG001|Overall Study|Protocol Violation|4
6260442|NCT02041299|9954416|FG000|Overall Study|Termination of the study|7
6260443|NCT02041299|9954417|FG001|Overall Study|Termination of the study|3
6260444|NCT02041299|9954416|FG000|Overall Study|Required bone marrow transplant|0
6260445|NCT02041299|9954417|FG001|Overall Study|Required bone marrow transplant|1
6260446|NCT02041299|9954416|FG000|Overall Study|Patient stopped dosing on unknown date|1
6260447|NCT02041299|9954417|FG001|Overall Study|Patient stopped dosing on unknown date|0
6260448|NCT02041429|9954448|FG000|Overall Study|Progressive Disease|2
6260449|NCT02041429|9954449|FG001|Overall Study|Progressive Disease|2
6260450|NCT02041429|9954450|FG002|Overall Study|Progressive Disease|3
6260451|NCT02041429|9954451|FG003|Overall Study|Progressive Disease|2
6260452|NCT02041429|9954448|FG000|Overall Study|Toxicity|0
6260453|NCT02041429|9954449|FG001|Overall Study|Toxicity|1
6260454|NCT02041429|9954450|FG002|Overall Study|Toxicity|4
6260455|NCT02041429|9954451|FG003|Overall Study|Toxicity|2
6260456|NCT02041429|9954448|FG000|Overall Study|Withdrawal by Subject|0
6260457|NCT02041429|9954449|FG001|Overall Study|Withdrawal by Subject|1
6260458|NCT02041429|9954450|FG002|Overall Study|Withdrawal by Subject|0
6260459|NCT02041429|9954451|FG003|Overall Study|Withdrawal by Subject|0
6260460|NCT02041429|9954448|FG000|Overall Study|On Maintenance Therapy|1
6260461|NCT02041429|9954449|FG001|Overall Study|On Maintenance Therapy|0
6260462|NCT02041429|9954450|FG002|Overall Study|On Maintenance Therapy|0
6260463|NCT02041429|9954451|FG003|Overall Study|On Maintenance Therapy|2
6260464|NCT02041494|9954468|FG000|Overall Study|Death|1
6260465|NCT02041494|9954469|FG001|Overall Study|Death|3
6260466|NCT02041494|9954468|FG000|Overall Study|Lost to Follow-up|2
6260467|NCT02041494|9954469|FG001|Overall Study|Lost to Follow-up|6
6086875|NCT00664859|9697015|FG001|Overall Study|Noncompliance with protocol|0
6260468|NCT02041494|9954468|FG000|Overall Study|study terminated|16
6260469|NCT02041494|9954469|FG001|Overall Study|study terminated|11
6260470|NCT02041520|9954478|FG000|Overall Study|Adverse Event|2
6260471|NCT02041520|9954479|FG001|Overall Study|Adverse Event|1
6260472|NCT02041520|9954478|FG000|Overall Study|Withdrawal by Subject|3
6260473|NCT02041520|9954479|FG001|Overall Study|Withdrawal by Subject|4
6260474|NCT02041520|9954478|FG000|Overall Study|Protocol Violation|1
6260475|NCT02041520|9954479|FG001|Overall Study|Protocol Violation|0
6260476|NCT02041520|9954478|FG000|Overall Study|Lost to Follow-up|0
6260477|NCT02041520|9954479|FG001|Overall Study|Lost to Follow-up|1
6260478|NCT02041520|9954478|FG000|Overall Study|Hypothiroidism identified during follow-|0
6260479|NCT02041520|9954479|FG001|Overall Study|Hypothiroidism identified during follow-|1
6260480|NCT02041702|9954489|FG000|Overall Study|Lost to Follow-up|1
6260481|NCT02041702|9954490|FG001|Overall Study|Lost to Follow-up|6
6260482|NCT02041702|9954489|FG000|Overall Study|Death|4
6260483|NCT02041702|9954490|FG001|Overall Study|Death|0
6260484|NCT02041702|9954489|FG000|Overall Study|Withdrawal by Subject|4
6260485|NCT02041702|9954490|FG001|Overall Study|Withdrawal by Subject|3
6260486|NCT02041702|9954489|FG000|Overall Study|Patient not confirmed as MRI compatible|1
6260487|NCT02041702|9954490|FG001|Overall Study|Patient not confirmed as MRI compatible|0
6260488|NCT02041702|9954489|FG000|Overall Study|Cardiac Resynchronization Therapy|1
6260489|NCT02041702|9954490|FG001|Overall Study|Cardiac Resynchronization Therapy|0
6260490|NCT02041923|9954498|FG000|Overall Study|Lost to Follow-up|26
6260491|NCT02041923|9954499|FG001|Overall Study|Lost to Follow-up|30
6260492|NCT02041962|9954509|FG000|Overall Study|Lost Aetna Coverage|43
6260493|NCT02041962|9954510|FG001|Overall Study|Lost Aetna Coverage|40
6260494|NCT02041962|9954509|FG000|Overall Study|Death|1
6260495|NCT02041962|9954510|FG001|Overall Study|Death|1
6260496|NCT02041962|9954509|FG000|Overall Study|Lost to Follow-up|37
6260497|NCT02041962|9954510|FG001|Overall Study|Lost to Follow-up|32
6260498|NCT02041962|9954509|FG000|Overall Study|Withdrawal by Subject|0
6260499|NCT02041962|9954510|FG001|Overall Study|Withdrawal by Subject|11
6260500|NCT02042014|9954516|FG000|Overall Study|Adverse Event|1
6086876|NCT00664859|9697016|FG002|Overall Study|Noncompliance with protocol|4
6260501|NCT02042014|9954516|FG000|Overall Study|Physician Decision|7
6260502|NCT02042183|9954537|FG000|Overall Study|Physician Decision|7
6260503|NCT02042183|9954538|FG001|Overall Study|Physician Decision|2
6260504|NCT02042183|9954537|FG000|Overall Study|Lack of Efficacy|4
6260505|NCT02042183|9954538|FG001|Overall Study|Lack of Efficacy|3
6260506|NCT02042183|9954537|FG000|Overall Study|Non-compliance with Study Drug|2
6260507|NCT02042183|9954538|FG001|Overall Study|Non-compliance with Study Drug|3
6260508|NCT02042183|9954537|FG000|Overall Study|Adverse Event|17
6260509|NCT02042183|9954538|FG001|Overall Study|Adverse Event|6
6260510|NCT02042183|9954537|FG000|Overall Study|Other|3
6260511|NCT02042183|9954538|FG001|Overall Study|Other|3
6260512|NCT02042183|9954537|FG000|Overall Study|Withdrawal by Subject|21
6260513|NCT02042183|9954538|FG001|Overall Study|Withdrawal by Subject|16
6260514|NCT02042183|9954537|FG000|Overall Study|Site Terminated by Sponsor|2
6260515|NCT02042183|9954538|FG001|Overall Study|Site Terminated by Sponsor|1
6260516|NCT02042183|9954537|FG000|Overall Study|Lost to Follow-up|9
6260517|NCT02042183|9954538|FG001|Overall Study|Lost to Follow-up|2
6260518|NCT02042404|9954550|FG000|Overall Study|Death|1
6260519|NCT02042404|9954551|FG001|Overall Study|Death|0
6260520|NCT02042404|9954550|FG000|Overall Study|Unrelated Adverse Event|3
6260521|NCT02042404|9954551|FG001|Overall Study|Unrelated Adverse Event|0
6260522|NCT02042404|9954550|FG000|Overall Study|Inability to meet time requirements|1
6086877|NCT00664859|9697014|FG000|Overall Study|Laboratory abnormality|2
6260523|NCT02042404|9954551|FG001|Overall Study|Inability to meet time requirements|0
6260524|NCT02042443|9954560|FG000|Overall Study|Adverse Event|2
6260525|NCT02042443|9954561|FG001|Overall Study|Adverse Event|1
6260526|NCT02042443|9954560|FG000|Overall Study|Withdrawal by Subject|0
6260527|NCT02042443|9954561|FG001|Overall Study|Withdrawal by Subject|1
6260528|NCT02042443|9954560|FG000|Overall Study|Progression|21
6260529|NCT02042443|9954561|FG001|Overall Study|Progression|17
6260530|NCT02042443|9954560|FG000|Overall Study|not protocol specified|1
6260531|NCT02042443|9954561|FG001|Overall Study|not protocol specified|1
6260532|NCT02042443|9954560|FG000|Overall Study|Not eligible/not analyzable|3
6260533|NCT02042443|9954561|FG001|Overall Study|Not eligible/not analyzable|6
6260534|NCT02043015|9954590|FG000|Overall Study|Lost to Follow-up|4
6260535|NCT02043015|9954590|FG000|Overall Study|Withdrawal by Subject|4
6260536|NCT02043015|9954590|FG000|Overall Study|Removed once target enrollment reached|15
6260537|NCT02043015|9954590|FG000|Overall Study|Participant moved away from study city|4
6260538|NCT02043015|9954590|FG000|Overall Study|Incarceration|1
6260539|NCT02043132|9954598|FG000|Overall Study|Lost to Follow-up|1
6260540|NCT02043132|9954599|FG001|Overall Study|Lost to Follow-up|1
6260541|NCT02043132|9954598|FG000|Overall Study|screen failures|4
6260542|NCT02043132|9954599|FG001|Overall Study|screen failures|8
6260543|NCT02043301|9954627|FG000|Overall Study|Discontinued|0
6260544|NCT02043301|9954628|FG001|Overall Study|Discontinued|1
6260545|NCT02043301|9954629|FG002|Overall Study|Discontinued|0
6260546|NCT02043366|9954643|FG000|Overall Study|Lost to Follow-up|2
6260547|NCT02043366|9954644|FG001|Overall Study|Lost to Follow-up|2
6260548|NCT02043366|9954645|FG002|Overall Study|Lost to Follow-up|2
6260549|NCT02043366|9954646|FG003|Overall Study|Lost to Follow-up|2
6260550|NCT02043366|9954647|FG004|Overall Study|Lost to Follow-up|2
6260551|NCT02043366|9954648|FG005|Overall Study|Lost to Follow-up|2
6260552|NCT02043509|9954675|FG000|Baseline to 1st Follow-up|Lost to Follow-up|61
6260553|NCT02043509|9954676|FG001|Baseline to 1st Follow-up|Lost to Follow-up|47
6260554|NCT02043509|9954675|FG000|Baseline to 1st Follow-up|Withdrawal by Subject|4
6260555|NCT02043509|9954676|FG001|Baseline to 1st Follow-up|Withdrawal by Subject|0
6260556|NCT02043509|9954675|FG000|Baseline to 2nd Follow-up|Lost to Follow-up|67
6260557|NCT02043509|9954676|FG001|Baseline to 2nd Follow-up|Lost to Follow-up|67
6260558|NCT02043509|9954675|FG000|Baseline to 2nd Follow-up|Withdrawal by Subject|7
6260559|NCT02043509|9954676|FG001|Baseline to 2nd Follow-up|Withdrawal by Subject|5
6260560|NCT02043548|9954684|FG000|Overall Study|Lack of Efficacy|1
6260561|NCT02043548|9954685|FG001|Overall Study|Lack of Efficacy|0
6190968|NCT01418352|9847565|FG003|Overall Study|Sponsor Discontinued Trial Site|2
6190969|NCT01418352|9847562|FG000|Overall Study|Subject Withdrew Consent|0
6190970|NCT01418352|9847563|FG001|Overall Study|Subject Withdrew Consent|1
6190971|NCT01418352|9847564|FG002|Overall Study|Subject Withdrew Consent|2
6190972|NCT01418352|9847565|FG003|Overall Study|Subject Withdrew Consent|1
6190973|NCT01418352|9847562|FG000|Overall Study|Protocol Deviation|0
6190974|NCT01418352|9847563|FG001|Overall Study|Protocol Deviation|0
6190975|NCT01418352|9847564|FG002|Overall Study|Protocol Deviation|1
6190976|NCT01418352|9847565|FG003|Overall Study|Protocol Deviation|0
6190977|NCT01418352|9847562|FG000|Overall Study|Lack of Efficacy as Determined by the Investigator|1
6190978|NCT01418352|9847563|FG001|Overall Study|Lack of Efficacy as Determined by the Investigator|0
6190979|NCT01418352|9847564|FG002|Overall Study|Lack of Efficacy as Determined by the Investigator|0
6190980|NCT01418352|9847565|FG003|Overall Study|Lack of Efficacy as Determined by the Investigator|0
6190981|NCT01418365|9847577|FG000|First Intervention|Withdrawal by Subject|0
6190982|NCT01418365|9847578|FG001|First Intervention|Withdrawal by Subject|1
6190983|NCT01418365|9847577|FG000|First Intervention|Non-compliance|1
6190984|NCT01418365|9847578|FG001|First Intervention|Non-compliance|0
6190985|NCT01418365|9847577|FG000|Second Intervention|Withdrawal by Subject|0
6190986|NCT01418365|9847578|FG001|Second Intervention|Withdrawal by Subject|1
6190987|NCT01418378|9847586|FG000|Overall Study|Death|1
6190988|NCT01418378|9847587|FG001|Overall Study|Death|2
6190989|NCT01418378|9847586|FG000|Overall Study|Physician Decision|0
6190990|NCT01418378|9847587|FG001|Overall Study|Physician Decision|1
6190991|NCT01418378|9847586|FG000|Overall Study|ligament imbalance|0
6190992|NCT01418378|9847587|FG001|Overall Study|ligament imbalance|1
6190993|NCT01418378|9847586|FG000|Overall Study|developed chronic myopathy|0
6190994|NCT01418378|9847587|FG001|Overall Study|developed chronic myopathy|1
6190995|NCT01418937|9847609|FG000|Overall Study|Lost to Follow-up|5
6190996|NCT01418937|9847609|FG000|Overall Study|Protocol Violation|1
6190997|NCT01418937|9847609|FG000|Overall Study|Pregnancy|1
6190998|NCT01418937|9847609|FG000|Overall Study|Withdrawal by Subject|1
6190999|NCT01419015|9847613|FG000|Overall Study|Death|2
6193337|NCT01437397|9850966|FG000|Overall Study|Lack of Efficacy|5
6260562|NCT02043548|9954684|FG000|Overall Study|Adverse Event|0
6260563|NCT02043548|9954685|FG001|Overall Study|Adverse Event|1
6260564|NCT02043782|9954714|FG000|Period 1|Adverse Event|0
6260565|NCT02043782|9954715|FG001|Period 1|Adverse Event|0
6260566|NCT02043782|9954716|FG002|Period 1|Adverse Event|1
6193338|NCT01437397|9850967|FG001|Overall Study|Lack of Efficacy|4
6193339|NCT01437397|9850968|FG002|Overall Study|Lack of Efficacy|8
6193340|NCT01437397|9850969|FG003|Overall Study|Lack of Efficacy|10
6193341|NCT01437397|9850970|FG004|Overall Study|Lack of Efficacy|20
6260567|NCT02043782|9954717|FG003|Period 1|Adverse Event|0
6260568|NCT02043782|9954718|FG004|Period 1|Adverse Event|0
6260569|NCT02043782|9954719|FG005|Period 1|Adverse Event|0
6260570|NCT02043899|9954736|FG000|Overall Study|Adverse Event|3
6260571|NCT02043899|9954736|FG000|Overall Study|Physician Decision|1
6260572|NCT02043899|9954736|FG000|Overall Study|Withdrawal by Subject|2
6260573|NCT02043899|9954736|FG000|Overall Study|Failure to meet the clinical criteria for [124I]mIBG imaging|5
6260574|NCT02043899|9954736|FG000|Overall Study|Technical manufacturing issue or logistical difficulties of [123I]mIBG or [124I]mIBG supply|12
6260575|NCT02043899|9954736|FG000|Overall Study|Temporary halt due to out of specification radioactivity|2
6260576|NCT02043899|9954736|FG000|Overall Study|Clinical progression necessitating urgent treatment|1
6260577|NCT02043899|9954736|FG000|Overall Study|Treatment delayed|1
6260578|NCT02043938|9954740|FG000|Overall Study|Withdrawal by Subject|7
6260579|NCT02043938|9954740|FG000|Overall Study|Unable to place EEG sensors on patient|1
6260580|NCT02043938|9954740|FG000|Overall Study|No show by subject|1
6260581|NCT02043938|9954740|FG000|Overall Study|Investigator decision|1
6260582|NCT02044094|9954747|FG000|RBP-6000 Injection 1 (Day 1 to Day 28)|Lost to Follow-up|3
6260583|NCT02044094|9954747|FG000|RBP-6000 Injection 1 (Day 1 to Day 28)|Physician Decision|3
6260584|NCT02044094|9954747|FG000|RBP-6000 Injection 1 (Day 1 to Day 28)|Withdrawal by Subject|3
6260585|NCT02044094|9954747|FG000|RBP-6000 Injection 2 (Day 29 to Week 12)|Adverse Event|4
6260586|NCT02044094|9954747|FG000|RBP-6000 Injection 2 (Day 29 to Week 12)|Lost to Follow-up|5
6260587|NCT02044094|9954747|FG000|RBP-6000 Injection 2 (Day 29 to Week 12)|Withdrawal by Subject|2
6086878|NCT00664859|9697015|FG001|Overall Study|Laboratory abnormality|1
6086879|NCT00664859|9697016|FG002|Overall Study|Laboratory abnormality|4
6086880|NCT00664859|9697014|FG000|Overall Study|Withdrawal by Subject|4
6086881|NCT00664859|9697015|FG001|Overall Study|Withdrawal by Subject|1
6086882|NCT00664859|9697016|FG002|Overall Study|Withdrawal by Subject|3
6086883|NCT00664859|9697014|FG000|Overall Study|Lost to Follow-up|2
6086884|NCT00664859|9697015|FG001|Overall Study|Lost to Follow-up|2
6086885|NCT00664859|9697016|FG002|Overall Study|Lost to Follow-up|1
6086886|NCT00664859|9697014|FG000|Overall Study|Other|0
6086887|NCT00664859|9697015|FG001|Overall Study|Other|1
6086888|NCT00664859|9697016|FG002|Overall Study|Other|2
6260588|NCT02044094|9954747|FG000|RBP-6000 Injection 2 (Day 29 to Week 12)|Physician Decision|1
6260589|NCT02044094|9954747|FG000|RBP-6000 Injection 2 (Day 29 to Week 12)|Noncompliance|1
6260590|NCT02044159|9954764|FG000|Overall Study|Consent declined (deferred consent)|2
6260591|NCT02044159|9954765|FG001|Overall Study|Consent declined (deferred consent)|4
6260592|NCT02044159|9954764|FG000|Overall Study|No longer eligible, drug not given|1
6260593|NCT02044159|9954765|FG001|Overall Study|No longer eligible, drug not given|0
6260594|NCT02044159|9954764|FG000|Overall Study|Nurse declined to give study drug|1
6260595|NCT02044159|9954765|FG001|Overall Study|Nurse declined to give study drug|0
6260596|NCT02044458|9954823|FG000|Overall Study|Protocol Violation|3
6260597|NCT02044458|9954824|FG001|Overall Study|Protocol Violation|8
6260598|NCT02044510|9954832|FG000|Overall Study|Adverse Event|1
6260599|NCT02044510|9954833|FG001|Overall Study|Adverse Event|2
6260600|NCT02044874|9954871|FG000|Overall Study|Adverse Event|5
6260601|NCT02044874|9954872|FG001|Overall Study|Adverse Event|6
6260602|NCT02044874|9954873|FG002|Overall Study|Adverse Event|6
6260603|NCT02044874|9954871|FG000|Overall Study|Withdrawal by Subject|8
6260604|NCT02044874|9954872|FG001|Overall Study|Withdrawal by Subject|16
6260605|NCT02044874|9954873|FG002|Overall Study|Withdrawal by Subject|23
6260606|NCT02044874|9954871|FG000|Overall Study|Physician Decision|0
6260607|NCT02044874|9954872|FG001|Overall Study|Physician Decision|2
6260608|NCT02044874|9954873|FG002|Overall Study|Physician Decision|1
6260609|NCT02044874|9954871|FG000|Overall Study|Lost to Follow-up|10
6260610|NCT02044874|9954872|FG001|Overall Study|Lost to Follow-up|27
6260611|NCT02044874|9954873|FG002|Overall Study|Lost to Follow-up|21
6260612|NCT02044874|9954871|FG000|Overall Study|Sponsor Decision|0
6260613|NCT02044874|9954872|FG001|Overall Study|Sponsor Decision|1
6260614|NCT02044874|9954873|FG002|Overall Study|Sponsor Decision|1
6260615|NCT02044874|9954871|FG000|Overall Study|Other|7
6260616|NCT02044874|9954872|FG001|Overall Study|Other|3
6260617|NCT02044874|9954873|FG002|Overall Study|Other|8
6260618|NCT02045095|9954892|FG000|Overall Study|Other|0
6260619|NCT02045095|9954893|FG001|Overall Study|Other|0
6260620|NCT02045095|9954894|FG002|Overall Study|Other|1
6260621|NCT02045095|9954895|FG003|Overall Study|Other|0
6260622|NCT02045095|9954896|FG004|Overall Study|Other|0
6260623|NCT02045095|9954897|FG005|Overall Study|Other|2
6260624|NCT02045095|9954898|FG006|Overall Study|Other|0
6260625|NCT02045095|9954892|FG000|Overall Study|Progressive Disease|3
6086889|NCT00665002|9697024|FG000|Overall Study|Progression/relapse during treatment|11
6086890|NCT00665002|9697024|FG000|Overall Study|Cytogenetic resistance|1
6087772|NCT00670449|9698233|FG002|Overall Study|Abnormal Laboratory Value(s)|0
6260626|NCT02045095|9954893|FG001|Overall Study|Progressive Disease|3
6260627|NCT02045095|9954894|FG002|Overall Study|Progressive Disease|2
6260628|NCT02045095|9954895|FG003|Overall Study|Progressive Disease|4
6260629|NCT02045095|9954896|FG004|Overall Study|Progressive Disease|2
6260630|NCT02045095|9954897|FG005|Overall Study|Progressive Disease|4
6260631|NCT02045095|9954898|FG006|Overall Study|Progressive Disease|1
6260632|NCT02045095|9954892|FG000|Overall Study|Withdrawal by Subject|0
6260633|NCT02045095|9954893|FG001|Overall Study|Withdrawal by Subject|0
6260634|NCT02045095|9954894|FG002|Overall Study|Withdrawal by Subject|0
6260635|NCT02045095|9954895|FG003|Overall Study|Withdrawal by Subject|0
6260636|NCT02045095|9954896|FG004|Overall Study|Withdrawal by Subject|3
6260637|NCT02045095|9954897|FG005|Overall Study|Withdrawal by Subject|0
6260638|NCT02045095|9954898|FG006|Overall Study|Withdrawal by Subject|0
6260639|NCT02045095|9954892|FG000|Overall Study|Adverse Event|0
6260640|NCT02045095|9954893|FG001|Overall Study|Adverse Event|1
6260641|NCT02045095|9954894|FG002|Overall Study|Adverse Event|1
6260642|NCT02045095|9954895|FG003|Overall Study|Adverse Event|0
6260643|NCT02045095|9954896|FG004|Overall Study|Adverse Event|0
6260644|NCT02045095|9954897|FG005|Overall Study|Adverse Event|2
6260645|NCT02045095|9954898|FG006|Overall Study|Adverse Event|0
6260646|NCT02045212|9954933|FG000|Overall Study|Adverse Event|0
6260647|NCT02045212|9954934|FG001|Overall Study|Adverse Event|1
6260648|NCT02045212|9954933|FG000|Overall Study|Withdrawal by Subject|1
6260649|NCT02045212|9954934|FG001|Overall Study|Withdrawal by Subject|0
6260650|NCT02045212|9954933|FG000|Overall Study|Finished 13 weeks, chose not to extend|1
6260651|NCT02045212|9954934|FG001|Overall Study|Finished 13 weeks, chose not to extend|0
6260652|NCT02045433|9954974|FG000|Overall Study|Withdrawal by Subject|1
6260653|NCT02045732|9954989|FG000|Overall Study|At the discretion of the investigator|1
6260654|NCT02045732|9954990|FG001|Overall Study|At the discretion of the investigator|1
6260655|NCT02045836|9954998|FG000|Overall Study|Adverse Event|4
6260656|NCT02045836|9954999|FG001|Overall Study|Adverse Event|4
6260657|NCT02045836|9954998|FG000|Overall Study|Withdrawal by Subject|1
6260658|NCT02045836|9954999|FG001|Overall Study|Withdrawal by Subject|1
6260659|NCT02045836|9954998|FG000|Overall Study|Lost to Follow-up|4
6260660|NCT02045836|9954999|FG001|Overall Study|Lost to Follow-up|7
6260661|NCT02045836|9954998|FG000|Overall Study|Migrated from study area|0
6260662|NCT02045836|9954999|FG001|Overall Study|Migrated from study area|2
6260663|NCT02045862|9955009|FG000|Overall Study|Death|0
6260664|NCT02045862|9955010|FG001|Overall Study|Death|0
6260665|NCT02045862|9955011|FG002|Overall Study|Death|1
6260666|NCT02045862|9955009|FG000|Overall Study|Miscellaneous|5
6260667|NCT02045862|9955010|FG001|Overall Study|Miscellaneous|0
6260668|NCT02045862|9955011|FG002|Overall Study|Miscellaneous|8
6260669|NCT02045862|9955009|FG000|Overall Study|Withdrawal by Patient|18
6260670|NCT02045862|9955010|FG001|Overall Study|Withdrawal by Patient|27
6260671|NCT02045862|9955011|FG002|Overall Study|Withdrawal by Patient|57
6260672|NCT02045862|9955009|FG000|Overall Study|Protocol Violation|0
6260673|NCT02045862|9955010|FG001|Overall Study|Protocol Violation|0
6260674|NCT02045862|9955011|FG002|Overall Study|Protocol Violation|6
6260675|NCT02045862|9955009|FG000|Overall Study|Lack of Efficacy|8
6260676|NCT02045862|9955010|FG001|Overall Study|Lack of Efficacy|4
6260677|NCT02045862|9955011|FG002|Overall Study|Lack of Efficacy|13
6260678|NCT02045862|9955009|FG000|Overall Study|Randomized but not Received Study Drug|0
6260679|NCT02045862|9955010|FG001|Overall Study|Randomized but not Received Study Drug|2
6260680|NCT02045862|9955011|FG002|Overall Study|Randomized but not Received Study Drug|8
6260681|NCT02045862|9955009|FG000|Overall Study|Adverse Event|7
6260682|NCT02045862|9955010|FG001|Overall Study|Adverse Event|5
6260683|NCT02045862|9955011|FG002|Overall Study|Adverse Event|27
6260684|NCT02045862|9955009|FG000|Overall Study|Lost to Follow-up|1
6260685|NCT02045862|9955010|FG001|Overall Study|Lost to Follow-up|2
6260686|NCT02045862|9955011|FG002|Overall Study|Lost to Follow-up|6
6260687|NCT02045875|9955021|FG000|Overall Study|Lost to Follow-up|3
6260688|NCT02045875|9955022|FG001|Overall Study|Lost to Follow-up|0
6260689|NCT02045875|9955021|FG000|Overall Study|Withdrawal by Subject|4
6260690|NCT02045875|9955022|FG001|Overall Study|Withdrawal by Subject|3
6260691|NCT02045979|9955031|FG000|Overall Study|Informed Consent Withdrawn|2
6260692|NCT02045979|9955032|FG001|Overall Study|Informed Consent Withdrawn|0
6260693|NCT02045979|9955033|FG002|Overall Study|Informed Consent Withdrawn|1
6260694|NCT02045979|9955031|FG000|Overall Study|not specified above|0
6260695|NCT02045979|9955032|FG001|Overall Study|not specified above|1
6260696|NCT02045979|9955033|FG002|Overall Study|not specified above|0
6260697|NCT02046070|9955057|FG000|Overall Study|Progressive Disease|18
6260698|NCT02046070|9955058|FG001|Overall Study|Progressive Disease|11
6260699|NCT02046070|9955059|FG002|Overall Study|Progressive Disease|40
6260700|NCT02046070|9955057|FG000|Overall Study|Adverse Event|8
6260701|NCT02046070|9955058|FG001|Overall Study|Adverse Event|10
6260702|NCT02046070|9955059|FG002|Overall Study|Adverse Event|17
6260703|NCT02046070|9955057|FG000|Overall Study|Withdrawal by Subject|1
6260704|NCT02046070|9955058|FG001|Overall Study|Withdrawal by Subject|2
6260705|NCT02046070|9955059|FG002|Overall Study|Withdrawal by Subject|6
6260706|NCT02046070|9955057|FG000|Overall Study|Study Terminated by Sponsor|1
6260707|NCT02046070|9955058|FG001|Overall Study|Study Terminated by Sponsor|1
6260708|NCT02046070|9955059|FG002|Overall Study|Study Terminated by Sponsor|1
6260709|NCT02046070|9955057|FG000|Overall Study|Reason not Specified|4
6260710|NCT02046070|9955058|FG001|Overall Study|Reason not Specified|4
6260711|NCT02046070|9955059|FG002|Overall Study|Reason not Specified|6
6260712|NCT02046122|9955067|FG000|Overall Study|Physician Decision|8
6260713|NCT02046122|9955067|FG000|Overall Study|Withdrawal by Subject|1
6260714|NCT02046148|9955082|FG000|Overall Study|Lost to Follow-up|1
6260715|NCT02046148|9955083|FG001|Overall Study|Lost to Follow-up|1
6260716|NCT02046148|9955082|FG000|Overall Study|Withdrawal by Subject|0
6260717|NCT02046148|9955083|FG001|Overall Study|Withdrawal by Subject|2
6260718|NCT02046174|9955089|FG000|Overall Study|Too many adhesions to receive implant (at time of surgery).|1
6260719|NCT02046174|9955090|FG001|Overall Study|Too many adhesions to receive implant (at time of surgery).|0
6260720|NCT02046369|9955218|FG000|Overall Study|Adverse Event|3
6260721|NCT02046369|9955219|FG001|Overall Study|Adverse Event|3
6260722|NCT02046369|9955218|FG000|Overall Study|Lack of Efficacy|3
6260723|NCT02046369|9955219|FG001|Overall Study|Lack of Efficacy|3
6260724|NCT02046369|9955218|FG000|Overall Study|Lost to Follow-up|3
6260725|NCT02046369|9955219|FG001|Overall Study|Lost to Follow-up|3
6260726|NCT02046369|9955218|FG000|Overall Study|Protocol Violation|1
6260727|NCT02046369|9955219|FG001|Overall Study|Protocol Violation|2
6260728|NCT02046369|9955218|FG000|Overall Study|Withdrawal by Subject|3
6260729|NCT02046369|9955219|FG001|Overall Study|Withdrawal by Subject|6
6260730|NCT02046369|9955218|FG000|Overall Study|never received study drug|0
6260731|NCT02046369|9955219|FG001|Overall Study|never received study drug|1
6260732|NCT02046369|9955218|FG000|Overall Study|non compliance|1
6260733|NCT02046369|9955219|FG001|Overall Study|non compliance|0
6260734|NCT02046564|9955245|FG000|Overall Study|Adverse Event|6
6260735|NCT02046564|9955246|FG001|Overall Study|Adverse Event|3
6260736|NCT02046564|9955245|FG000|Overall Study|Physician Decision|0
6260737|NCT02046564|9955246|FG001|Overall Study|Physician Decision|1
6260738|NCT02046564|9955245|FG000|Overall Study|Protocol Violation|3
6260739|NCT02046564|9955246|FG001|Overall Study|Protocol Violation|1
6260740|NCT02046564|9955245|FG000|Overall Study|Withdrawal by Subject|4
6260741|NCT02046564|9955246|FG001|Overall Study|Withdrawal by Subject|10
6260742|NCT02046564|9955245|FG000|Overall Study|Subject met withdrawal criteria|2
6260743|NCT02046564|9955246|FG001|Overall Study|Subject met withdrawal criteria|5
6260744|NCT02046603|9955254|FG000|Overall Study|Other|11
6260745|NCT02046603|9955255|FG001|Overall Study|Other|66
6260746|NCT02046603|9955254|FG000|Overall Study|Protocol Violation|0
6260747|NCT02046603|9955255|FG001|Overall Study|Protocol Violation|1
6260748|NCT02046603|9955254|FG000|Overall Study|Participant/legal guardian decision|1
6260749|NCT02046603|9955255|FG001|Overall Study|Participant/legal guardian decision|3
6260750|NCT02046603|9955254|FG000|Overall Study|Physician Decision|2
6260751|NCT02046603|9955255|FG001|Overall Study|Physician Decision|1
6260752|NCT02046603|9955254|FG000|Overall Study|Lost to Follow-up|1
6260753|NCT02046603|9955255|FG001|Overall Study|Lost to Follow-up|2
6260754|NCT02046603|9955254|FG000|Overall Study|Death|0
6260755|NCT02046603|9955255|FG001|Overall Study|Death|1
6260756|NCT02046603|9955254|FG000|Overall Study|Adverse Event|0
6260757|NCT02046603|9955255|FG001|Overall Study|Adverse Event|1
6260758|NCT02046616|9955262|FG000|24-Week Treatment Period|Anaphylaxis/Serious Hypersensitivity|1
6260759|NCT02046616|9955262|FG000|24-Week Treatment Period|Any Other Adverse Event|13
6260760|NCT02046616|9955262|FG000|24-Week Treatment Period|Insufficient Therapeutic Response|1
6260761|NCT02046616|9955262|FG000|24-Week Treatment Period|Physician Decision|3
6260762|NCT02046616|9955262|FG000|24-Week Treatment Period|Other|1
6260763|NCT02046616|9955262|FG000|8-Week FU Period|Lost to Follow-up|1
6260764|NCT02046993|9955311|FG000|Overall Study|Withdrawal by Subject|2
6260765|NCT02046993|9955312|FG001|Overall Study|Withdrawal by Subject|10
6260766|NCT02046993|9955311|FG000|Overall Study|Lost to Follow-up|1
6260767|NCT02046993|9955312|FG001|Overall Study|Lost to Follow-up|1
6260768|NCT02047045|9955333|FG000|Baseline|Withdrawal by Subject|3
6260769|NCT02047045|9955334|FG001|Baseline|Withdrawal by Subject|2
6260770|NCT02047045|9955333|FG000|Treatment Period (8 Weeks )|Adverse Event|3
6260771|NCT02047045|9955334|FG001|Treatment Period (8 Weeks )|Adverse Event|1
6260772|NCT02047045|9955333|FG000|Treatment Period (8 Weeks )|Lost to Follow-up|1
6260773|NCT02047045|9955334|FG001|Treatment Period (8 Weeks )|Lost to Follow-up|3
6260774|NCT02047045|9955333|FG000|Treatment Period (8 Weeks )|Withdrawal by Subject|3
6260775|NCT02047045|9955334|FG001|Treatment Period (8 Weeks )|Withdrawal by Subject|5
6260776|NCT02047045|9955333|FG000|Treatment Period (8 Weeks )|moved far away out of work|3
6260777|NCT02047045|9955334|FG001|Treatment Period (8 Weeks )|moved far away out of work|0
6260778|NCT02047045|9955333|FG000|Treatment Period (8 Weeks )|no reason was given|1
6260779|NCT02047045|9955334|FG001|Treatment Period (8 Weeks )|no reason was given|0
6260780|NCT02047045|9955333|FG000|Treatment Period (8 Weeks )|refused to take drugs|0
6260781|NCT02047045|9955334|FG001|Treatment Period (8 Weeks )|refused to take drugs|5
6260782|NCT02047045|9955333|FG000|Treatment Period (8 Weeks )|for safety considerations|0
6260783|NCT02047045|9955334|FG001|Treatment Period (8 Weeks )|for safety considerations|1
6260784|NCT02047045|9955333|FG000|Follow-up Period (24 Weeks)|Adverse Event|1
6260785|NCT02047045|9955334|FG001|Follow-up Period (24 Weeks)|Adverse Event|1
6260786|NCT02047110|9955344|FG000|DB Treatment Period up to Week 24|Adverse Event|1
6260787|NCT02047110|9955345|FG001|DB Treatment Period up to Week 24|Adverse Event|0
6260788|NCT02047110|9955346|FG002|DB Treatment Period up to Week 24|Adverse Event|0
6260789|NCT02047110|9955347|FG003|DB Treatment Period up to Week 24|Adverse Event|0
6260790|NCT02047110|9955344|FG000|DB Treatment Period up to Week 24|Lost to Follow-up|1
6260791|NCT02047110|9955345|FG001|DB Treatment Period up to Week 24|Lost to Follow-up|0
6260792|NCT02047110|9955346|FG002|DB Treatment Period up to Week 24|Lost to Follow-up|0
6260793|NCT02047110|9955347|FG003|DB Treatment Period up to Week 24|Lost to Follow-up|0
6260794|NCT02047110|9955344|FG000|DB Treatment Period up to Week 24|Protocol Violation|1
6260795|NCT02047110|9955345|FG001|DB Treatment Period up to Week 24|Protocol Violation|0
6260796|NCT02047110|9955346|FG002|DB Treatment Period up to Week 24|Protocol Violation|0
6260797|NCT02047110|9955347|FG003|DB Treatment Period up to Week 24|Protocol Violation|0
6260798|NCT02047110|9955344|FG000|DB Treatment Period up to Week 24|Withdrawal by Subject|1
6260799|NCT02047110|9955345|FG001|DB Treatment Period up to Week 24|Withdrawal by Subject|0
6260800|NCT02047110|9955346|FG002|DB Treatment Period up to Week 24|Withdrawal by Subject|0
6260801|NCT02047110|9955347|FG003|DB Treatment Period up to Week 24|Withdrawal by Subject|1
6260802|NCT02047110|9955344|FG000|DB Treatment Period up to Week 24|Other than specified|1
6260803|NCT02047110|9955345|FG001|DB Treatment Period up to Week 24|Other than specified|2
6260804|NCT02047110|9955346|FG002|DB Treatment Period up to Week 24|Other than specified|3
6260805|NCT02047110|9955347|FG003|DB Treatment Period up to Week 24|Other than specified|1
6260806|NCT02047110|9955344|FG000|DB (Week 12 up to Week 24)|Withdrawal by Subject|0
6260807|NCT02047110|9955345|FG001|DB (Week 12 up to Week 24)|Withdrawal by Subject|1
6260808|NCT02047110|9955346|FG002|DB (Week 12 up to Week 24)|Withdrawal by Subject|0
6260809|NCT02047110|9955347|FG003|DB (Week 12 up to Week 24)|Withdrawal by Subject|0
6260810|NCT02047110|9955344|FG000|DB (Week 12 up to Week 24)|Other than specified|0
6260811|NCT02047110|9955345|FG001|DB (Week 12 up to Week 24)|Other than specified|1
6260812|NCT02047110|9955346|FG002|DB (Week 12 up to Week 24)|Other than specified|1
6260813|NCT02047110|9955347|FG003|DB (Week 12 up to Week 24)|Other than specified|0
6260814|NCT02047110|9955344|FG000|Escape Treatment Period|Withdrawal by Subject|1
6260815|NCT02047110|9955345|FG001|Escape Treatment Period|Withdrawal by Subject|2
6260816|NCT02047110|9955346|FG002|Escape Treatment Period|Withdrawal by Subject|1
6260817|NCT02047110|9955347|FG003|Escape Treatment Period|Withdrawal by Subject|1
6260818|NCT02047110|9955344|FG000|Escape Treatment Period|Adverse Event|1
6260819|NCT02047110|9955345|FG001|Escape Treatment Period|Adverse Event|2
6260820|NCT02047110|9955346|FG002|Escape Treatment Period|Adverse Event|2
6260821|NCT02047110|9955347|FG003|Escape Treatment Period|Adverse Event|0
6260822|NCT02047110|9955344|FG000|Escape Treatment Period|Other than specified|1
6260823|NCT02047110|9955345|FG001|Escape Treatment Period|Other than specified|2
6260824|NCT02047110|9955346|FG002|Escape Treatment Period|Other than specified|0
6260825|NCT02047110|9955347|FG003|Escape Treatment Period|Other than specified|1
6260826|NCT02047110|9955344|FG000|OLE Treatment Period|Other than specified|0
6260827|NCT02047110|9955345|FG001|OLE Treatment Period|Other than specified|0
6260828|NCT02047110|9955346|FG002|OLE Treatment Period|Other than specified|1
6260829|NCT02047110|9955347|FG003|OLE Treatment Period|Other than specified|0
6260830|NCT02047227|9955366|FG000|Overall Study|Adverse Event|2
6260831|NCT02047227|9955367|FG001|Overall Study|Adverse Event|4
6260832|NCT02047227|9955366|FG000|Overall Study|Lost to Follow-up|0
6260833|NCT02047227|9955367|FG001|Overall Study|Lost to Follow-up|3
6260834|NCT02047227|9955366|FG000|Overall Study|Protocol Violation|1
6260835|NCT02047227|9955367|FG001|Overall Study|Protocol Violation|0
6260836|NCT02047227|9955366|FG000|Overall Study|Spontaneous pregnancy|1
6260837|NCT02047227|9955367|FG001|Overall Study|Spontaneous pregnancy|0
6260838|NCT02047227|9955366|FG000|Overall Study|Lack of ovarian response to stimulation|35
6260839|NCT02047227|9955367|FG001|Overall Study|Lack of ovarian response to stimulation|32
6260840|NCT02047227|9955366|FG000|Overall Study|No oocytes retrieved|21
6260841|NCT02047227|9955367|FG001|Overall Study|No oocytes retrieved|20
6260842|NCT02047227|9955366|FG000|Overall Study|No fertilization|61
6260843|NCT02047227|9955367|FG001|Overall Study|No fertilization|51
6260844|NCT02047227|9955366|FG000|Overall Study|Intention to freeze all embryos|1
6260845|NCT02047227|9955367|FG001|Overall Study|Intention to freeze all embryos|0
6260846|NCT02047227|9955366|FG000|Overall Study|All embryos discarded|12
6260847|NCT02047227|9955367|FG001|Overall Study|All embryos discarded|11
6260848|NCT02047227|9955366|FG000|Overall Study|Other|10
6260849|NCT02047227|9955367|FG001|Overall Study|Other|9
6260850|NCT02047253|9955373|FG000|Overall Study|Lost to Follow-up|8
6260851|NCT02047318|9955381|FG000|Core Study Period|Did not consent to 52-week follow- up|8
6260852|NCT02047318|9955381|FG000|Core Study Period|Adverse Event|1
6260853|NCT02047318|9955381|FG000|Core Study Period|Withdrawal by caregiver|3
6260854|NCT02047318|9955381|FG000|Long-term Follow-up Treatment Period|consent withdrawn by subject|1
6260855|NCT02047604|9955421|FG000|Overall Study|Withdrawal by Subject|0
6260856|NCT02047604|9955422|FG001|Overall Study|Withdrawal by Subject|0
6260857|NCT02047604|9955423|FG002|Overall Study|Withdrawal by Subject|0
6260858|NCT02047604|9955424|FG003|Overall Study|Withdrawal by Subject|0
6260859|NCT02047604|9955425|FG004|Overall Study|Withdrawal by Subject|1
6260860|NCT02047604|9955426|FG005|Overall Study|Withdrawal by Subject|1
6260861|NCT02047734|9955450|FG000|Overall Study|Adverse Event|18
6260862|NCT02047734|9955451|FG001|Overall Study|Adverse Event|13
6260863|NCT02047734|9955452|FG002|Overall Study|Adverse Event|13
6260864|NCT02047734|9955450|FG000|Overall Study|Lack of Efficacy|4
6260865|NCT02047734|9955451|FG001|Overall Study|Lack of Efficacy|5
6260866|NCT02047734|9955452|FG002|Overall Study|Lack of Efficacy|1
6260867|NCT02047734|9955450|FG000|Overall Study|Protocol Violation|3
6260868|NCT02047734|9955451|FG001|Overall Study|Protocol Violation|1
6260869|NCT02047734|9955452|FG002|Overall Study|Protocol Violation|1
6260870|NCT02047734|9955450|FG000|Overall Study|Lost to Follow-up|1
6260871|NCT02047734|9955451|FG001|Overall Study|Lost to Follow-up|4
6260872|NCT02047734|9955452|FG002|Overall Study|Lost to Follow-up|0
6260873|NCT02047734|9955450|FG000|Overall Study|Death|0
6260874|NCT02047734|9955451|FG001|Overall Study|Death|1
6260875|NCT02047734|9955452|FG002|Overall Study|Death|0
6260876|NCT02047734|9955450|FG000|Overall Study|Withdrawal by Subject|30
6260877|NCT02047734|9955451|FG001|Overall Study|Withdrawal by Subject|31
6260878|NCT02047734|9955452|FG002|Overall Study|Withdrawal by Subject|19
6260879|NCT02047734|9955450|FG000|Overall Study|Physician Decision|7
6260880|NCT02047734|9955451|FG001|Overall Study|Physician Decision|6
6260881|NCT02047734|9955452|FG002|Overall Study|Physician Decision|5
6260882|NCT02047734|9955450|FG000|Overall Study|Miscellaneous|2
6260883|NCT02047734|9955451|FG001|Overall Study|Miscellaneous|4
6260884|NCT02047734|9955452|FG002|Overall Study|Miscellaneous|6
6260885|NCT02047734|9955450|FG000|Overall Study|Did Not Receive Study Drug|2
6260886|NCT02047734|9955451|FG001|Overall Study|Did Not Receive Study Drug|4
6260887|NCT02047734|9955452|FG002|Overall Study|Did Not Receive Study Drug|1
6260888|NCT02047903|9955460|FG000|Overall Study|Adverse Event|14
6260889|NCT02047903|9955460|FG000|Overall Study|Serious adverse event|10
6260890|NCT02047903|9955460|FG000|Overall Study|Withdrawal by Subject|16
6260891|NCT02047903|9955460|FG000|Overall Study|Lost to Follow-up|4
6260892|NCT02047903|9955460|FG000|Overall Study|Reason not listed|6
6260893|NCT02047903|9955460|FG000|Overall Study|Not Treated|9
6271289|NCT02161718|9972925|FG001|Post- Randomization Period|Relocation|3
6271290|NCT02161718|9972926|FG002|Post- Randomization Period|Relocation|0
6271291|NCT02161731|9972933|FG000|Period 2 (Day 7 Dosing to Day 23)|Withdrawal by Subject|0
6271292|NCT02161731|9972934|FG001|Period 2 (Day 7 Dosing to Day 23)|Withdrawal by Subject|1
6271293|NCT02161731|9972933|FG000|Period 2 (Day 7 Dosing to Day 23)|Adverse Event|0
6271294|NCT02161731|9972934|FG001|Period 2 (Day 7 Dosing to Day 23)|Adverse Event|1
6271295|NCT02161757|9972944|FG000|Randomised Through Start Treatment|Did not receive treatment|3
6271296|NCT02161757|9972945|FG001|Randomised Through Start Treatment|Did not receive treatment|2
6271297|NCT02161757|9972946|FG002|Randomised Through Start Treatment|Did not receive treatment|0
6271298|NCT02161757|9972944|FG000|Treatment Through Study Completion|Adverse Event|1
6271299|NCT02161757|9972945|FG001|Treatment Through Study Completion|Adverse Event|1
6271300|NCT02161757|9972946|FG002|Treatment Through Study Completion|Adverse Event|0
6271301|NCT02161757|9972944|FG000|Treatment Through Study Completion|Protocol Violation|0
6271302|NCT02161757|9972945|FG001|Treatment Through Study Completion|Protocol Violation|1
6271303|NCT02161757|9972946|FG002|Treatment Through Study Completion|Protocol Violation|2
6271304|NCT02161757|9972944|FG000|Treatment Through Study Completion|Withdrawal by Subject|27
6271305|NCT02161757|9972945|FG001|Treatment Through Study Completion|Withdrawal by Subject|19
6271306|NCT02161757|9972946|FG002|Treatment Through Study Completion|Withdrawal by Subject|20
6271307|NCT02161757|9972944|FG000|Treatment Through Study Completion|Lost to Follow-up|7
6271308|NCT02161757|9972945|FG001|Treatment Through Study Completion|Lost to Follow-up|2
6271309|NCT02161757|9972946|FG002|Treatment Through Study Completion|Lost to Follow-up|4
6271310|NCT02161757|9972944|FG000|Treatment Through Study Completion|Other|20
6271311|NCT02161757|9972945|FG001|Treatment Through Study Completion|Other|19
6271312|NCT02161757|9972946|FG002|Treatment Through Study Completion|Other|12
6271313|NCT02161757|9972944|FG000|Treatment Through Study Completion|Death|2
6271314|NCT02161757|9972945|FG001|Treatment Through Study Completion|Death|1
6271315|NCT02161757|9972946|FG002|Treatment Through Study Completion|Death|1
6271316|NCT02162719|9973013|FG000|Overall Study|Death|41
6271317|NCT02162719|9973014|FG001|Overall Study|Death|46
6271318|NCT02162719|9973013|FG000|Overall Study|Lost to Follow-up|1
6271319|NCT02162719|9973014|FG001|Overall Study|Lost to Follow-up|3
6271320|NCT02162719|9973013|FG000|Overall Study|Disease Progression|2
6271321|NCT02162719|9973014|FG001|Overall Study|Disease Progression|1
6271322|NCT02162719|9973013|FG000|Overall Study|Withdrawal by Subject|8
6271323|NCT02162719|9973014|FG001|Overall Study|Withdrawal by Subject|2
6271324|NCT02162719|9973013|FG000|Overall Study|Discontinuation of Overall Survival Follow-up|10
6271325|NCT02162719|9973014|FG001|Overall Study|Discontinuation of Overall Survival Follow-up|10
6271326|NCT02162758|9973022|FG000|Overall Study|Study termination|0
6271327|NCT02162758|9973023|FG001|Overall Study|Study termination|1
6271328|NCT02162771|9973031|FG000|Core Study Period (Part 2)|Progressive Disease|2
6271329|NCT02162771|9973032|FG001|Core Study Period (Part 2)|Progressive Disease|3
6271330|NCT02162771|9973031|FG000|Core Study Period (Part 2)|Adverse Event|4
6271331|NCT02162771|9973032|FG001|Core Study Period (Part 2)|Adverse Event|1
6271332|NCT02162771|9973031|FG000|Core Study Period (Part 2)|Withdrawal by Subject|1
6271333|NCT02162771|9973032|FG001|Core Study Period (Part 2)|Withdrawal by Subject|2
6271334|NCT02162771|9973031|FG000|Core Study Period (Part 2)|Physician Decision|0
6271335|NCT02162771|9973032|FG001|Core Study Period (Part 2)|Physician Decision|2
6271336|NCT02162771|9973031|FG000|Core Study Period (Part 2)|Death|1
6271337|NCT02162771|9973032|FG001|Core Study Period (Part 2)|Death|0
6271338|NCT02162771|9973031|FG000|Maintenance Study Period (Part 2)|Progressive Disease|11
6271339|NCT02162771|9973032|FG001|Maintenance Study Period (Part 2)|Progressive Disease|13
6271340|NCT02162771|9973031|FG000|Maintenance Study Period (Part 2)|Adverse Event|3
6271341|NCT02162771|9973032|FG001|Maintenance Study Period (Part 2)|Adverse Event|3
6271342|NCT02162771|9973031|FG000|Maintenance Study Period (Part 2)|Death|2
6271343|NCT02162771|9973032|FG001|Maintenance Study Period (Part 2)|Death|1
6271344|NCT02162771|9973031|FG000|Maintenance Study Period (Part 2)|Withdrawal by Subject|0
6271345|NCT02162771|9973032|FG001|Maintenance Study Period (Part 2)|Withdrawal by Subject|3
6271346|NCT02162771|9973031|FG000|Maintenance Study Period (Part 2)|Protocol Violation|0
6271347|NCT02162771|9973032|FG001|Maintenance Study Period (Part 2)|Protocol Violation|1
6271348|NCT02162771|9973031|FG000|Maintenance Study Period (Part 2)|Stable Disease|0
6271349|NCT02162771|9973032|FG001|Maintenance Study Period (Part 2)|Stable Disease|1
6271350|NCT02162862|9973041|FG000|Overall Study|Lost to Follow-up|0
6271351|NCT02162862|9973042|FG001|Overall Study|Lost to Follow-up|11
6260894|NCT02048072|9955473|FG000|Overall Study|Adverse Event|3
6260895|NCT02048072|9955473|FG000|Overall Study|Lost to Follow-up|1
6260896|NCT02048241|9955479|FG000|Overall Study|Withdrawal by Subject|0
6260897|NCT02048241|9955480|FG001|Overall Study|Withdrawal by Subject|1
6260898|NCT02048826|9955497|FG000|Overall Study|Withdrawal by Subject|1
6260899|NCT02048826|9955498|FG001|Overall Study|Withdrawal by Subject|0
6260900|NCT02049437|9955551|FG000|Period 1|Adverse Event|1
6260901|NCT02049437|9955552|FG001|Period 1|Adverse Event|1
6260902|NCT02049437|9955551|FG000|Period 1|Adverse Event|1
6260903|NCT02049437|9955552|FG001|Period 1|Adverse Event|0
6260904|NCT02049450|9955558|FG000|Overall Study|Adverse Event|2
6260905|NCT02049450|9955558|FG000|Overall Study|Withdrawal by Subject|1
6260906|NCT02049450|9955558|FG000|Overall Study|Patients/guardian decision|1
6260907|NCT02049814|9955589|FG000|Overall Study|Reason not Specified|4
6086891|NCT00665353|9697032|FG000|Study Step 1|Adverse Event|1
6086892|NCT00665353|9697032|FG000|Study Step 1|Withdrawal by Subject|2
6260908|NCT02049814|9955590|FG001|Overall Study|Reason not Specified|3
6260909|NCT02049814|9955589|FG000|Overall Study|Pregnancy|1
6260910|NCT02049814|9955590|FG001|Overall Study|Pregnancy|0
6260911|NCT02049814|9955589|FG000|Overall Study|Lost to Follow-up|2
6260912|NCT02049814|9955590|FG001|Overall Study|Lost to Follow-up|3
6260913|NCT02049814|9955589|FG000|Overall Study|Serious Protocol Violation|5
6260914|NCT02049814|9955590|FG001|Overall Study|Serious Protocol Violation|7
6260915|NCT02049814|9955589|FG000|Overall Study|Study Termination|0
6260916|NCT02049814|9955590|FG001|Overall Study|Study Termination|1
6260917|NCT02049814|9955589|FG000|Overall Study|Pretreatment event/Adverse Event (AE)|8
6260918|NCT02049814|9955590|FG001|Overall Study|Pretreatment event/Adverse Event (AE)|5
6260919|NCT02049814|9955589|FG000|Overall Study|Voluntary withdrawal|9
6260920|NCT02049814|9955590|FG001|Overall Study|Voluntary withdrawal|8
6260921|NCT02049866|9955596|FG000|Overall Study|Withdrawal by Subject|1
6260922|NCT02049944|9955613|FG000|Overall Study|Protocol Violation|2
6260923|NCT02049957|9955626|FG000|Overall Study|Progressive Disease|5
6260924|NCT02049957|9955627|FG001|Overall Study|Progressive Disease|4
6260925|NCT02049957|9955628|FG002|Overall Study|Progressive Disease|2
6260926|NCT02049957|9955629|FG003|Overall Study|Progressive Disease|2
6260927|NCT02049957|9955630|FG004|Overall Study|Progressive Disease|6
6260928|NCT02049957|9955631|FG005|Overall Study|Progressive Disease|35
6260929|NCT02049957|9955632|FG006|Overall Study|Progressive Disease|7
6260930|NCT02049957|9955633|FG007|Overall Study|Progressive Disease|26
6260931|NCT02049957|9955634|FG008|Overall Study|Progressive Disease|6
6260932|NCT02049957|9955626|FG000|Overall Study|Adverse Event|1
6260933|NCT02049957|9955627|FG001|Overall Study|Adverse Event|1
6260934|NCT02049957|9955628|FG002|Overall Study|Adverse Event|1
6260935|NCT02049957|9955629|FG003|Overall Study|Adverse Event|0
6260936|NCT02049957|9955630|FG004|Overall Study|Adverse Event|0
6260937|NCT02049957|9955631|FG005|Overall Study|Adverse Event|5
6260938|NCT02049957|9955632|FG006|Overall Study|Adverse Event|0
6260939|NCT02049957|9955633|FG007|Overall Study|Adverse Event|6
6260940|NCT02049957|9955634|FG008|Overall Study|Adverse Event|1
6260941|NCT02049957|9955626|FG000|Overall Study|Study Terminated by Sponsor|0
6260942|NCT02049957|9955627|FG001|Overall Study|Study Terminated by Sponsor|1
6260943|NCT02049957|9955628|FG002|Overall Study|Study Terminated by Sponsor|0
6260944|NCT02049957|9955629|FG003|Overall Study|Study Terminated by Sponsor|0
6260945|NCT02049957|9955630|FG004|Overall Study|Study Terminated by Sponsor|0
6260946|NCT02049957|9955631|FG005|Overall Study|Study Terminated by Sponsor|0
6260947|NCT02049957|9955632|FG006|Overall Study|Study Terminated by Sponsor|1
6260948|NCT02049957|9955633|FG007|Overall Study|Study Terminated by Sponsor|0
6260949|NCT02049957|9955634|FG008|Overall Study|Study Terminated by Sponsor|0
6260950|NCT02049957|9955626|FG000|Overall Study|Withdrawal by Subject|0
6260951|NCT02049957|9955627|FG001|Overall Study|Withdrawal by Subject|0
6260952|NCT02049957|9955628|FG002|Overall Study|Withdrawal by Subject|0
6260953|NCT02049957|9955629|FG003|Overall Study|Withdrawal by Subject|1
6260954|NCT02049957|9955630|FG004|Overall Study|Withdrawal by Subject|0
6260955|NCT02049957|9955631|FG005|Overall Study|Withdrawal by Subject|2
6260956|NCT02049957|9955632|FG006|Overall Study|Withdrawal by Subject|0
6260957|NCT02049957|9955633|FG007|Overall Study|Withdrawal by Subject|3
6260958|NCT02049957|9955634|FG008|Overall Study|Withdrawal by Subject|1
6086893|NCT00665353|9697032|FG000|Study Step 2|Lost to Follow-up|2
6260959|NCT02049957|9955626|FG000|Overall Study|Physician Decision|0
6260960|NCT02049957|9955627|FG001|Overall Study|Physician Decision|0
6260961|NCT02049957|9955628|FG002|Overall Study|Physician Decision|0
6260962|NCT02049957|9955629|FG003|Overall Study|Physician Decision|0
6260963|NCT02049957|9955630|FG004|Overall Study|Physician Decision|0
6260964|NCT02049957|9955631|FG005|Overall Study|Physician Decision|1
6260965|NCT02049957|9955632|FG006|Overall Study|Physician Decision|0
6260966|NCT02049957|9955633|FG007|Overall Study|Physician Decision|0
6260967|NCT02049957|9955634|FG008|Overall Study|Physician Decision|0
6260968|NCT02050048|9955656|FG000|Overall Study|Lost to Follow-up|0
6086894|NCT00665353|9697032|FG000|Study Step 2|Lack of Efficacy|12
6260969|NCT02050048|9955657|FG001|Overall Study|Lost to Follow-up|1
6260970|NCT02050048|9955656|FG000|Overall Study|Death|1
6260971|NCT02050048|9955657|FG001|Overall Study|Death|0
6260972|NCT02050048|9955656|FG000|Overall Study|Ineligible after ERCP|4
6260973|NCT02050048|9955657|FG001|Overall Study|Ineligible after ERCP|1
6260974|NCT02050321|9955663|FG000|Overall Study|Withdrawal by Subject|1
6260975|NCT02050321|9955663|FG000|Overall Study|Adverse Event|1
6260976|NCT02050373|9955679|FG000|Overall Study|Adverse Event|4
6260977|NCT02050373|9955680|FG001|Overall Study|Adverse Event|7
6260978|NCT02050373|9955679|FG000|Overall Study|Death|3
6260979|NCT02050373|9955680|FG001|Overall Study|Death|3
6260980|NCT02051296|9955699|FG000|Overall Study|Lost to Follow-up|1
6260981|NCT02051296|9955700|FG001|Overall Study|Lost to Follow-up|2
6260982|NCT02051296|9955699|FG000|Overall Study|withdraw prior to treatment|7
6260983|NCT02051296|9955700|FG001|Overall Study|withdraw prior to treatment|7
6260984|NCT02051764|9955756|FG000|Overall Study|Study terminated by sponsor|0
6260985|NCT02051764|9955757|FG001|Overall Study|Study terminated by sponsor|7
6260986|NCT02052011|9955790|FG000|Overall Study|Lost to Follow-up|3
6260987|NCT02052011|9955791|FG001|Overall Study|Lost to Follow-up|0
6260988|NCT02052011|9955790|FG000|Overall Study|Withdrawal by Subject|1
6260989|NCT02052011|9955791|FG001|Overall Study|Withdrawal by Subject|2
6260990|NCT02052310|9955808|FG000|Overall Study|Death|64
6260991|NCT02052310|9955809|FG001|Overall Study|Death|54
6260992|NCT02052310|9955808|FG000|Overall Study|Withdrawal by Subject|37
6260993|NCT02052310|9955809|FG001|Overall Study|Withdrawal by Subject|49
6260994|NCT02052310|9955808|FG000|Overall Study|Other than specified|32
6260995|NCT02052310|9955809|FG001|Overall Study|Other than specified|29
6260996|NCT02052310|9955808|FG000|Overall Study|Adverse Event|29
6086895|NCT00665366|9697038|FG000|Overall Study|Lack of Efficacy|11
6086896|NCT00665366|9697039|FG001|Overall Study|Lack of Efficacy|10
6086897|NCT00665366|9697038|FG000|Overall Study|Adverse Event|25
6260997|NCT02052310|9955809|FG001|Overall Study|Adverse Event|22
6260998|NCT02052310|9955808|FG000|Overall Study|Kidney Transplant|23
6260999|NCT02052310|9955809|FG001|Overall Study|Kidney Transplant|29
6261000|NCT02052310|9955808|FG000|Overall Study|Physician Decision|14
6261001|NCT02052310|9955809|FG001|Overall Study|Physician Decision|7
6261002|NCT02052310|9955808|FG000|Overall Study|Lack of Efficacy|6
6261003|NCT02052310|9955809|FG001|Overall Study|Lack of Efficacy|1
6261004|NCT02052310|9955808|FG000|Overall Study|Site Terminated by Sponsor|5
6261005|NCT02052310|9955809|FG001|Overall Study|Site Terminated by Sponsor|13
6261006|NCT02052310|9955808|FG000|Overall Study|Lost to Follow-up|4
6261007|NCT02052310|9955809|FG001|Overall Study|Lost to Follow-up|2
6261008|NCT02052310|9955808|FG000|Overall Study|Protocol Violation|1
6261009|NCT02052310|9955809|FG001|Overall Study|Protocol Violation|6
6261010|NCT02052414|9955815|FG000|Overall Study|Adverse Event|12
6261011|NCT02052414|9955815|FG000|Overall Study|Lack of Efficacy|2
6261012|NCT02052414|9955815|FG000|Overall Study|Withdrawal by Subject|3
6261013|NCT02052440|9955822|FG000|Overall Study|Withdrawal by Subject|0
6261014|NCT02052440|9955823|FG001|Overall Study|Withdrawal by Subject|1
6261015|NCT02052466|9955829|FG000|Overall Study|Withdrawal by Subject|1
6261016|NCT02052466|9955829|FG000|Overall Study|Acromial fracture|1
6261017|NCT02052596|9955851|FG000|Active Phase|Adverse Event|3
6261018|NCT02052596|9955852|FG001|Active Phase|Adverse Event|2
6261019|NCT02052596|9955851|FG000|Active Phase|Lost to Follow-up|8
6261020|NCT02052596|9955852|FG001|Active Phase|Lost to Follow-up|11
6261021|NCT02052596|9955851|FG000|Active Phase|Protocol Violation|1
6261022|NCT02052596|9955852|FG001|Active Phase|Protocol Violation|2
6261023|NCT02052596|9955851|FG000|Active Phase|Withdrawal by Subject|3
6261024|NCT02052596|9955852|FG001|Active Phase|Withdrawal by Subject|4
6261025|NCT02052596|9955851|FG000|Active Phase|Enrolled in error|1
6261026|NCT02052596|9955852|FG001|Active Phase|Enrolled in error|0
6261027|NCT02052596|9955851|FG000|Active Phase|Lost due to Crohn's disease|0
6261028|NCT02052596|9955852|FG001|Active Phase|Lost due to Crohn's disease|1
6261029|NCT02052596|9955851|FG000|Safety Phase|Adverse Event|6
6261030|NCT02052596|9955852|FG001|Safety Phase|Adverse Event|3
6261031|NCT02052596|9955851|FG000|Safety Phase|Lost to Follow-up|11
6261032|NCT02052596|9955852|FG001|Safety Phase|Lost to Follow-up|18
6261033|NCT02052596|9955851|FG000|Safety Phase|Protocol Violation|1
6261034|NCT02052596|9955852|FG001|Safety Phase|Protocol Violation|2
6261035|NCT02052596|9955851|FG000|Safety Phase|Withdrawal by Subject|8
6261036|NCT02052596|9955852|FG001|Safety Phase|Withdrawal by Subject|11
6261037|NCT02052596|9955851|FG000|Safety Phase|Enrolled in error|1
6261038|NCT02052596|9955852|FG001|Safety Phase|Enrolled in error|0
6261039|NCT02052596|9955851|FG000|Safety Phase|Lost due to Crohn's disease|0
6086898|NCT00665366|9697039|FG001|Overall Study|Adverse Event|23
6086899|NCT00665366|9697038|FG000|Overall Study|Withdrawal by Subject|11
6261040|NCT02052596|9955852|FG001|Safety Phase|Lost due to Crohn's disease|1
6261041|NCT02052960|9955899|FG000|Overall Study|Adverse Event|19
6261042|NCT02052960|9955900|FG001|Overall Study|Adverse Event|17
6261043|NCT02052960|9955899|FG000|Overall Study|Protocol Violation|4
6261044|NCT02052960|9955900|FG001|Overall Study|Protocol Violation|3
6261045|NCT02052960|9955899|FG000|Overall Study|Withdrawal by Subject|6
6261046|NCT02052960|9955900|FG001|Overall Study|Withdrawal by Subject|11
6261047|NCT02052960|9955899|FG000|Overall Study|Other|25
6261048|NCT02052960|9955900|FG001|Overall Study|Other|15
6261049|NCT02053168|9955913|FG000|Overall Study|Withdrawal by Subject|1
6261050|NCT02053168|9955913|FG000|Overall Study|Physician Decision|1
6261051|NCT02053168|9955913|FG000|Overall Study|Lost to Follow-up|1
6261052|NCT02053493|9955940|FG000|Overall Study|Withdrawal by Subject|1
6261053|NCT02053493|9955941|FG001|Overall Study|Withdrawal by Subject|1
6261054|NCT02053610|9955949|FG000|Overall Study|Adverse Event/Intercurrent Illness|25
6261055|NCT02053610|9955950|FG001|Overall Study|Adverse Event/Intercurrent Illness|43
6261056|NCT02053610|9955949|FG000|Overall Study|Withdrew Consent|2
6261057|NCT02053610|9955950|FG001|Overall Study|Withdrew Consent|9
6261058|NCT02053610|9955949|FG000|Overall Study|Death|5
6261059|NCT02053610|9955950|FG001|Overall Study|Death|5
6261060|NCT02053610|9955949|FG000|Overall Study|Administrative/Other|1
6261061|NCT02053610|9955950|FG001|Overall Study|Administrative/Other|1
6261062|NCT02053610|9955949|FG000|Overall Study|Disease Progression|2
6261063|NCT02053610|9955950|FG001|Overall Study|Disease Progression|3
6261064|NCT02053610|9955949|FG000|Overall Study|Refused treatment/Did not cooperate|1
6261065|NCT02053610|9955950|FG001|Overall Study|Refused treatment/Did not cooperate|3
6261066|NCT02053610|9955949|FG000|Overall Study|Did not Receive Treatment|4
6261067|NCT02053610|9955950|FG001|Overall Study|Did not Receive Treatment|2
6261068|NCT02053610|9955949|FG000|Overall Study|Insufficient Therapeutic Response|1
6261069|NCT02053610|9955950|FG001|Overall Study|Insufficient Therapeutic Response|1
6261070|NCT02053610|9955949|FG000|Overall Study|Violation of Selection Criteria|1
6261071|NCT02053610|9955950|FG001|Overall Study|Violation of Selection Criteria|0
6261072|NCT02053753|9955958|FG000|Overall Study|Withdrawal by Subject|2
6261073|NCT02053753|9955959|FG001|Overall Study|Withdrawal by Subject|4
6261074|NCT02053753|9955958|FG000|Overall Study|Decision by Sponsor|1
6261075|NCT02053753|9955959|FG001|Overall Study|Decision by Sponsor|1
6261076|NCT02053753|9955958|FG000|Overall Study|Lost to Follow-up|4
6261077|NCT02053753|9955959|FG001|Overall Study|Lost to Follow-up|3
6261078|NCT02054130|9955969|FG000|Overall Study|Withdrawal by Subject|4
6261079|NCT02054130|9955970|FG001|Overall Study|Withdrawal by Subject|4
6261080|NCT02054130|9955971|FG002|Overall Study|Withdrawal by Subject|7
6261081|NCT02054130|9955972|FG003|Overall Study|Withdrawal by Subject|10
6261082|NCT02054130|9955969|FG000|Overall Study|Death|0
6261083|NCT02054130|9955970|FG001|Overall Study|Death|1
6261084|NCT02054130|9955971|FG002|Overall Study|Death|0
6261085|NCT02054130|9955972|FG003|Overall Study|Death|0
6261086|NCT02054130|9955969|FG000|Overall Study|Lost to Follow-up|0
6261087|NCT02054130|9955970|FG001|Overall Study|Lost to Follow-up|0
6261088|NCT02054130|9955971|FG002|Overall Study|Lost to Follow-up|1
6261089|NCT02054130|9955972|FG003|Overall Study|Lost to Follow-up|2
6261090|NCT02054130|9955969|FG000|Overall Study|Missed dose|4
6261091|NCT02054130|9955970|FG001|Overall Study|Missed dose|6
6261092|NCT02054130|9955971|FG002|Overall Study|Missed dose|7
6261093|NCT02054130|9955972|FG003|Overall Study|Missed dose|10
6261094|NCT02054325|9955996|FG000|Overall Study|Lost to Follow-up|8
6261095|NCT02054325|9955997|FG001|Overall Study|Lost to Follow-up|5
6261096|NCT02054481|9956016|FG000|Overall Study|Adverse Event|1
6261097|NCT02054481|9956017|FG001|Overall Study|Adverse Event|1
6261098|NCT02054481|9956018|FG002|Overall Study|Adverse Event|0
6261099|NCT02054481|9956019|FG003|Overall Study|Adverse Event|1
6261100|NCT02054481|9956016|FG000|Overall Study|Lost to Follow-up|1
6261101|NCT02054481|9956017|FG001|Overall Study|Lost to Follow-up|0
6261102|NCT02054481|9956018|FG002|Overall Study|Lost to Follow-up|0
6261103|NCT02054481|9956019|FG003|Overall Study|Lost to Follow-up|0
6261104|NCT02054481|9956016|FG000|Overall Study|Other reason|2
6261105|NCT02054481|9956017|FG001|Overall Study|Other reason|1
6261106|NCT02054481|9956018|FG002|Overall Study|Other reason|2
6261107|NCT02054481|9956019|FG003|Overall Study|Other reason|0
6261108|NCT02054520|9956036|FG000|Overall Study|Adverse Event|1
6261109|NCT02054520|9956037|FG001|Overall Study|Adverse Event|4
6261110|NCT02054520|9956038|FG002|Overall Study|Adverse Event|2
6261111|NCT02054520|9956039|FG003|Overall Study|Adverse Event|1
6261112|NCT02054520|9956040|FG004|Overall Study|Adverse Event|1
6261113|NCT02054520|9956041|FG005|Overall Study|Adverse Event|0
6261114|NCT02054520|9956036|FG000|Overall Study|Lack of Efficacy|7
6191000|NCT01419184|9847627|FG000|Overall Study|Site data not available|3
6191001|NCT01419184|9847628|FG001|Overall Study|Site data not available|2
6191002|NCT01419184|9847627|FG000|Overall Study|No IRLOS-No in-patient end date reported|3
6191003|NCT01419184|9847628|FG001|Overall Study|No IRLOS-No in-patient end date reported|6
6191004|NCT01419184|9847627|FG000|Overall Study|No IRLOS-randomized, not treated|2
6191005|NCT01419184|9847628|FG001|Overall Study|No IRLOS-randomized, not treated|4
6191006|NCT01419184|9847627|FG000|Overall Study|No IRLOS-non trial antibiotic used|1
6191007|NCT01419184|9847628|FG001|Overall Study|No IRLOS-non trial antibiotic used|2
6261115|NCT02054520|9956037|FG001|Overall Study|Lack of Efficacy|0
6261116|NCT02054520|9956038|FG002|Overall Study|Lack of Efficacy|2
6261117|NCT02054520|9956039|FG003|Overall Study|Lack of Efficacy|1
6261118|NCT02054520|9956040|FG004|Overall Study|Lack of Efficacy|3
6261119|NCT02054520|9956041|FG005|Overall Study|Lack of Efficacy|2
6261120|NCT02054520|9956036|FG000|Overall Study|Withdrawal by Subject|1
6261121|NCT02054520|9956037|FG001|Overall Study|Withdrawal by Subject|0
6261122|NCT02054520|9956038|FG002|Overall Study|Withdrawal by Subject|0
6261123|NCT02054520|9956039|FG003|Overall Study|Withdrawal by Subject|2
6261124|NCT02054520|9956040|FG004|Overall Study|Withdrawal by Subject|1
6261125|NCT02054520|9956041|FG005|Overall Study|Withdrawal by Subject|0
6261126|NCT02054520|9956036|FG000|Overall Study|Physician Decision|0
6261127|NCT02054520|9956037|FG001|Overall Study|Physician Decision|1
6261128|NCT02054520|9956038|FG002|Overall Study|Physician Decision|0
6261129|NCT02054520|9956039|FG003|Overall Study|Physician Decision|1
6261130|NCT02054520|9956040|FG004|Overall Study|Physician Decision|0
6261131|NCT02054520|9956041|FG005|Overall Study|Physician Decision|1
6261132|NCT02054520|9956036|FG000|Overall Study|Study terminated by Sponsor|0
6261133|NCT02054520|9956037|FG001|Overall Study|Study terminated by Sponsor|0
6261134|NCT02054520|9956038|FG002|Overall Study|Study terminated by Sponsor|2
6261135|NCT02054520|9956039|FG003|Overall Study|Study terminated by Sponsor|1
6261136|NCT02054520|9956040|FG004|Overall Study|Study terminated by Sponsor|0
6261137|NCT02054520|9956041|FG005|Overall Study|Study terminated by Sponsor|0
6261138|NCT02054702|9956061|FG000|Overall Study|Lost to Follow-up|3
6261139|NCT02054702|9956062|FG001|Overall Study|Lost to Follow-up|5
6261140|NCT02054702|9956061|FG000|Overall Study|Adverse Event|3
6261141|NCT02054702|9956062|FG001|Overall Study|Adverse Event|1
6261142|NCT02054702|9956061|FG000|Overall Study|Met Withdrawal Criteria|4
6261143|NCT02054702|9956062|FG001|Overall Study|Met Withdrawal Criteria|1
6261144|NCT02054702|9956061|FG000|Overall Study|Physician Decision|0
6261145|NCT02054702|9956062|FG001|Overall Study|Physician Decision|1
6261146|NCT02054702|9956061|FG000|Overall Study|Withdrawal by Subject|14
6261147|NCT02054702|9956062|FG001|Overall Study|Withdrawal by Subject|4
6261148|NCT02054715|9956070|FG000|Baseline/Follow-up 1|Refused|1
6261149|NCT02054715|9956071|FG001|Baseline/Follow-up 1|Refused|3
6261150|NCT02054715|9956070|FG000|Baseline/Follow-up 1|Medical|0
6261151|NCT02054715|9956071|FG001|Baseline/Follow-up 1|Medical|1
6261152|NCT02054715|9956070|FG000|Baseline/Follow-up 1|Changed MD/Facility|0
6261153|NCT02054715|9956071|FG001|Baseline/Follow-up 1|Changed MD/Facility|1
6261154|NCT02054715|9956070|FG000|Baseline/Follow-up 1|Disliked Procedure|0
6261155|NCT02054715|9956071|FG001|Baseline/Follow-up 1|Disliked Procedure|1
6261156|NCT02054715|9956070|FG000|Baseline/Follow-up 1|No Reason|0
6261157|NCT02054715|9956071|FG001|Baseline/Follow-up 1|No Reason|1
6261158|NCT02054715|9956070|FG000|Baseline/Follow-up 1|Overwhelmed|2
6261159|NCT02054715|9956071|FG001|Baseline/Follow-up 1|Overwhelmed|0
6261160|NCT02054715|9956070|FG000|Baseline/Follow-up 1|Ineligible|3
6261161|NCT02054715|9956071|FG001|Baseline/Follow-up 1|Ineligible|0
6261162|NCT02054715|9956070|FG000|Baseline/Follow-up 1|Hospitalization|1
6261163|NCT02054715|9956071|FG001|Baseline/Follow-up 1|Hospitalization|0
6261164|NCT02054715|9956070|FG000|Baseline/Follow-up 1|Changed Mind|1
6261165|NCT02054715|9956071|FG001|Baseline/Follow-up 1|Changed Mind|0
6261166|NCT02054715|9956070|FG000|Follow-up 2|Lost to Followup|3
6261167|NCT02054715|9956071|FG001|Follow-up 2|Lost to Followup|1
6261168|NCT02054715|9956070|FG000|Follow-up 2|Refused|3
6261169|NCT02054715|9956071|FG001|Follow-up 2|Refused|2
6261170|NCT02054715|9956070|FG000|Follow-up 2|Followup Not Completed|3
6261171|NCT02054715|9956071|FG001|Follow-up 2|Followup Not Completed|4
6261172|NCT02054715|9956070|FG000|Follow-up 2|Ineligible|4
6261173|NCT02054715|9956071|FG001|Follow-up 2|Ineligible|5
6261174|NCT02054715|9956070|FG000|Follow-up 2|Death|3
6261175|NCT02054715|9956071|FG001|Follow-up 2|Death|3
6261176|NCT02054715|9956070|FG000|Follow-up 2|Hospitalization|0
6261177|NCT02054715|9956071|FG001|Follow-up 2|Hospitalization|2
6261178|NCT02054715|9956070|FG000|Follow-up 2|Changed MD/Facility|0
6261179|NCT02054715|9956071|FG001|Follow-up 2|Changed MD/Facility|1
6261180|NCT02054715|9956070|FG000|Follow-up 2|Changed Mind|0
6261181|NCT02054715|9956071|FG001|Follow-up 2|Changed Mind|1
6261182|NCT02054715|9956070|FG000|Follow-up 2|No Reason|2
6261183|NCT02054715|9956071|FG001|Follow-up 2|No Reason|0
6261184|NCT02054715|9956070|FG000|Follow-up 2|Treatment Change or Delay|1
6261185|NCT02054715|9956071|FG001|Follow-up 2|Treatment Change or Delay|0
6261186|NCT02054897|9956102|FG000|Overall Study|Withdrawal by Subject|2
6261187|NCT02054897|9956103|FG001|Overall Study|Withdrawal by Subject|0
6261188|NCT02054897|9956104|FG002|Overall Study|Withdrawal by Subject|2
6261189|NCT02054897|9956102|FG000|Overall Study|Missing follow-up information|3
6261190|NCT02054897|9956103|FG001|Overall Study|Missing follow-up information|5
6261191|NCT02054897|9956104|FG002|Overall Study|Missing follow-up information|3
6261192|NCT02054897|9956102|FG000|Overall Study|Lost to Follow-up|4
6261193|NCT02054897|9956103|FG001|Overall Study|Lost to Follow-up|2
6261194|NCT02054897|9956104|FG002|Overall Study|Lost to Follow-up|7
6261195|NCT02054897|9956102|FG000|Overall Study|Randomized but not exposed|1
6261196|NCT02054897|9956103|FG001|Overall Study|Randomized but not exposed|0
6261197|NCT02054897|9956104|FG002|Overall Study|Randomized but not exposed|0
6261198|NCT02055118|9956115|FG000|Overall Study|Withdrawal by Subject|0
6261199|NCT02055118|9956116|FG001|Overall Study|Withdrawal by Subject|2
6261200|NCT02055118|9956117|FG002|Overall Study|Withdrawal by Subject|0
6261201|NCT02055157|9956130|FG000|Initial 6 Months|Subject discontinued due to NeedlePhobia|0
6261202|NCT02055157|9956131|FG001|Initial 6 Months|Subject discontinued due to NeedlePhobia|1
6261203|NCT02055157|9956132|FG002|Initial 6 Months|Subject discontinued due to NeedlePhobia|0
6261204|NCT02055157|9956133|FG003|Initial 6 Months|Subject discontinued due to NeedlePhobia|0
6261205|NCT02055157|9956130|FG000|Initial 6 Months|Adverse Event|0
6261206|NCT02055157|9956131|FG001|Initial 6 Months|Adverse Event|0
6261207|NCT02055157|9956132|FG002|Initial 6 Months|Adverse Event|0
6261208|NCT02055157|9956133|FG003|Initial 6 Months|Adverse Event|1
6261209|NCT02055157|9956130|FG000|Initial 6 Months|Consent withdrawn by subject|1
6261210|NCT02055157|9956131|FG001|Initial 6 Months|Consent withdrawn by subject|0
6261211|NCT02055157|9956132|FG002|Initial 6 Months|Consent withdrawn by subject|0
6261212|NCT02055157|9956133|FG003|Initial 6 Months|Consent withdrawn by subject|0
6261213|NCT02055157|9956130|FG000|18-month Extension|Investigator decision|0
6261214|NCT02055157|9956131|FG001|18-month Extension|Investigator decision|1
6261215|NCT02055157|9956132|FG002|18-month Extension|Investigator decision|0
6261216|NCT02055157|9956133|FG003|18-month Extension|Investigator decision|0
6261217|NCT02055157|9956130|FG000|18-month Extension|Subject discontinued due to NeedlePhobia|1
6261218|NCT02055157|9956131|FG001|18-month Extension|Subject discontinued due to NeedlePhobia|0
6261219|NCT02055157|9956132|FG002|18-month Extension|Subject discontinued due to NeedlePhobia|0
6261220|NCT02055157|9956133|FG003|18-month Extension|Subject discontinued due to NeedlePhobia|0
6261221|NCT02055352|9956156|FG000|Overall Study|Adverse Event|0
6261222|NCT02055352|9956157|FG001|Overall Study|Adverse Event|1
6261223|NCT02055352|9956156|FG000|Overall Study|Non-eligible|0
6261224|NCT02055352|9956157|FG001|Overall Study|Non-eligible|1
6261225|NCT02055352|9956156|FG000|Overall Study|Poor compliance|1
6261226|NCT02055352|9956157|FG001|Overall Study|Poor compliance|1
6261227|NCT02055352|9956156|FG000|Overall Study|Death|1
6261228|NCT02055352|9956157|FG001|Overall Study|Death|2
6261229|NCT02055352|9956156|FG000|Overall Study|Patient decision|1
6261230|NCT02055352|9956157|FG001|Overall Study|Patient decision|1
6261231|NCT02055352|9956156|FG000|Overall Study|Use of prohibited treatment|0
6261232|NCT02055352|9956157|FG001|Overall Study|Use of prohibited treatment|3
6261233|NCT02055352|9956156|FG000|Overall Study|AE, study drug would be detrimental|1
6261234|NCT02055352|9956157|FG001|Overall Study|AE, study drug would be detrimental|3
6261235|NCT02055352|9956156|FG000|Overall Study|Withdrawal of informed consent|1
6261236|NCT02055352|9956157|FG001|Overall Study|Withdrawal of informed consent|0
6261237|NCT02055352|9956156|FG000|Overall Study|Reason unknown|1
6261238|NCT02055352|9956157|FG001|Overall Study|Reason unknown|5
6261239|NCT02055365|9956163|FG000|Overall Study|Prematurely Withdrawn|1
6261240|NCT02055820|9956228|FG000|Phase I: Dose-Finding|Death|1
6261241|NCT02055820|9956229|FG001|Phase I: Dose-Finding|Death|0
6261242|NCT02055820|9956230|FG002|Phase I: Dose-Finding|Death|1
6261243|NCT02055820|9956231|FG003|Phase I: Dose-Finding|Death|2
6261244|NCT02055820|9956232|FG004|Phase I: Dose-Finding|Death|0
6261245|NCT02055820|9956233|FG005|Phase I: Dose-Finding|Death|1
6261246|NCT02055820|9956234|FG006|Phase I: Dose-Finding|Death|1
6261247|NCT02055820|9956235|FG007|Phase I: Dose-Finding|Death|0
6261248|NCT02055820|9956236|FG008|Phase I: Dose-Finding|Death|0
6261249|NCT02055820|9956237|FG009|Phase I: Dose-Finding|Death|0
6261250|NCT02055820|9956228|FG000|Phase I: Dose-Finding|Withdrawal by Subject|0
6261251|NCT02055820|9956229|FG001|Phase I: Dose-Finding|Withdrawal by Subject|0
6261252|NCT02055820|9956230|FG002|Phase I: Dose-Finding|Withdrawal by Subject|0
6261253|NCT02055820|9956231|FG003|Phase I: Dose-Finding|Withdrawal by Subject|0
6261254|NCT02055820|9956232|FG004|Phase I: Dose-Finding|Withdrawal by Subject|0
6261255|NCT02055820|9956233|FG005|Phase I: Dose-Finding|Withdrawal by Subject|1
6261256|NCT02055820|9956234|FG006|Phase I: Dose-Finding|Withdrawal by Subject|0
6261257|NCT02055820|9956235|FG007|Phase I: Dose-Finding|Withdrawal by Subject|0
6261258|NCT02055820|9956236|FG008|Phase I: Dose-Finding|Withdrawal by Subject|0
6261259|NCT02055820|9956237|FG009|Phase I: Dose-Finding|Withdrawal by Subject|0
6261260|NCT02055820|9956228|FG000|Phase I: Dose-Finding|Lost to Follow-up|0
6261261|NCT02055820|9956229|FG001|Phase I: Dose-Finding|Lost to Follow-up|0
6261262|NCT02055820|9956230|FG002|Phase I: Dose-Finding|Lost to Follow-up|0
6261263|NCT02055820|9956231|FG003|Phase I: Dose-Finding|Lost to Follow-up|1
6261264|NCT02055820|9956232|FG004|Phase I: Dose-Finding|Lost to Follow-up|0
6261265|NCT02055820|9956233|FG005|Phase I: Dose-Finding|Lost to Follow-up|0
6261266|NCT02055820|9956234|FG006|Phase I: Dose-Finding|Lost to Follow-up|1
6261267|NCT02055820|9956235|FG007|Phase I: Dose-Finding|Lost to Follow-up|0
6261268|NCT02055820|9956236|FG008|Phase I: Dose-Finding|Lost to Follow-up|0
6261269|NCT02055820|9956237|FG009|Phase I: Dose-Finding|Lost to Follow-up|0
6261270|NCT02055820|9956228|FG000|Phase II: Expansion|Death|0
6261271|NCT02055820|9956229|FG001|Phase II: Expansion|Death|0
6261272|NCT02055820|9956230|FG002|Phase II: Expansion|Death|0
6261273|NCT02055820|9956231|FG003|Phase II: Expansion|Death|0
6261274|NCT02055820|9956232|FG004|Phase II: Expansion|Death|33
6261275|NCT02055820|9956233|FG005|Phase II: Expansion|Death|0
6261276|NCT02055820|9956234|FG006|Phase II: Expansion|Death|0
6261277|NCT02055820|9956235|FG007|Phase II: Expansion|Death|0
6261278|NCT02055820|9956236|FG008|Phase II: Expansion|Death|0
6261279|NCT02055820|9956237|FG009|Phase II: Expansion|Death|0
6261280|NCT02055820|9956228|FG000|Phase II: Expansion|Lost to Follow-up|0
6261281|NCT02055820|9956229|FG001|Phase II: Expansion|Lost to Follow-up|0
6261282|NCT02055820|9956230|FG002|Phase II: Expansion|Lost to Follow-up|0
6261283|NCT02055820|9956231|FG003|Phase II: Expansion|Lost to Follow-up|0
6261284|NCT02055820|9956232|FG004|Phase II: Expansion|Lost to Follow-up|4
6261285|NCT02055820|9956233|FG005|Phase II: Expansion|Lost to Follow-up|0
6261286|NCT02055820|9956234|FG006|Phase II: Expansion|Lost to Follow-up|0
6261287|NCT02055820|9956235|FG007|Phase II: Expansion|Lost to Follow-up|0
6261288|NCT02055820|9956236|FG008|Phase II: Expansion|Lost to Follow-up|0
6261289|NCT02055820|9956237|FG009|Phase II: Expansion|Lost to Follow-up|0
6261290|NCT02055820|9956228|FG000|Phase II: Expansion|Withdrawal by Subject|0
6261291|NCT02055820|9956229|FG001|Phase II: Expansion|Withdrawal by Subject|0
6261292|NCT02055820|9956230|FG002|Phase II: Expansion|Withdrawal by Subject|0
6261293|NCT02055820|9956231|FG003|Phase II: Expansion|Withdrawal by Subject|0
6261294|NCT02055820|9956232|FG004|Phase II: Expansion|Withdrawal by Subject|12
6261295|NCT02055820|9956233|FG005|Phase II: Expansion|Withdrawal by Subject|0
6261296|NCT02055820|9956234|FG006|Phase II: Expansion|Withdrawal by Subject|0
6261297|NCT02055820|9956235|FG007|Phase II: Expansion|Withdrawal by Subject|0
6261298|NCT02055820|9956236|FG008|Phase II: Expansion|Withdrawal by Subject|0
6261299|NCT02055820|9956237|FG009|Phase II: Expansion|Withdrawal by Subject|0
6261300|NCT02055898|9956281|FG000|First Intervention (5 Days)|Physician Decision|2
6261301|NCT02055898|9956282|FG001|First Intervention (5 Days)|Physician Decision|0
6261302|NCT02055898|9956281|FG000|First Intervention (5 Days)|Withdrawal by Subject|0
6261303|NCT02055898|9956282|FG001|First Intervention (5 Days)|Withdrawal by Subject|1
6261304|NCT02055976|9956297|FG000|Overall Study|Other|0
6261305|NCT02055976|9956298|FG001|Overall Study|Other|0
6261306|NCT02055976|9956299|FG002|Overall Study|Other|1
6261307|NCT02055976|9956300|FG003|Overall Study|Other|0
6261308|NCT02055976|9956301|FG004|Overall Study|Other|0
6261309|NCT02055976|9956302|FG005|Overall Study|Other|0
6261310|NCT02055976|9956303|FG006|Overall Study|Other|0
6261311|NCT02055976|9956304|FG007|Overall Study|Other|0
6261312|NCT02055976|9956305|FG008|Overall Study|Other|0
6261313|NCT02055976|9956297|FG000|Overall Study|Adverse Event|0
6261314|NCT02055976|9956298|FG001|Overall Study|Adverse Event|0
6261315|NCT02055976|9956299|FG002|Overall Study|Adverse Event|0
6261316|NCT02055976|9956300|FG003|Overall Study|Adverse Event|0
6261317|NCT02055976|9956301|FG004|Overall Study|Adverse Event|0
6261318|NCT02055976|9956302|FG005|Overall Study|Adverse Event|1
6261319|NCT02055976|9956303|FG006|Overall Study|Adverse Event|1
6261320|NCT02055976|9956304|FG007|Overall Study|Adverse Event|0
6261321|NCT02055976|9956305|FG008|Overall Study|Adverse Event|0
6191008|NCT01419184|9847627|FG000|Overall Study|No IRLOS-No adverse event treatment date|0
6191009|NCT01419184|9847628|FG001|Overall Study|No IRLOS-No adverse event treatment date|1
6191010|NCT01419184|9847627|FG000|Overall Study|Participant randomized, not treated|1
6191011|NCT01419184|9847628|FG001|Overall Study|Participant randomized, not treated|0
6191012|NCT01419197|9847636|FG000|Overall Study|Death|247
6191013|NCT01419197|9847637|FG001|Overall Study|Death|122
6191014|NCT01419197|9847636|FG000|Overall Study|Physician Decision|4
6191015|NCT01419197|9847637|FG001|Overall Study|Physician Decision|4
6191016|NCT01419197|9847636|FG000|Overall Study|Non-compliance|3
6191017|NCT01419197|9847637|FG001|Overall Study|Non-compliance|1
6191018|NCT01419197|9847636|FG000|Overall Study|Withdrawal by Subject|33
6191019|NCT01419197|9847637|FG001|Overall Study|Withdrawal by Subject|32
6191020|NCT01419197|9847636|FG000|Overall Study|Study Completed by Sponsor|103
6191021|NCT01419197|9847637|FG001|Overall Study|Study Completed by Sponsor|34
6191022|NCT01419197|9847636|FG000|Overall Study|Reason Not Specified|0
6191023|NCT01419197|9847637|FG001|Overall Study|Reason Not Specified|1
6191024|NCT01419197|9847636|FG000|Overall Study|Lost to Follow-up|14
6191025|NCT01419197|9847637|FG001|Overall Study|Lost to Follow-up|4
6191026|NCT01419236|9847646|FG000|Overall Study|Adverse Event|1
6191027|NCT01419236|9847647|FG001|Overall Study|Adverse Event|0
6191028|NCT01419236|9847646|FG000|Overall Study|Lack of Efficacy|0
6191029|NCT01419236|9847647|FG001|Overall Study|Lack of Efficacy|1
6191030|NCT01419236|9847646|FG000|Overall Study|Lost to Follow-up|1
6191031|NCT01419236|9847647|FG001|Overall Study|Lost to Follow-up|0
6191032|NCT01419236|9847646|FG000|Overall Study|Physician Decision|1
6191033|NCT01419236|9847647|FG001|Overall Study|Physician Decision|0
6191034|NCT01419236|9847646|FG000|Overall Study|Withdrawal by Subject|1
6191035|NCT01419236|9847647|FG001|Overall Study|Withdrawal by Subject|4
6191036|NCT01419236|9847646|FG000|Overall Study|Entry Criteria Not Met|1
6191037|NCT01419236|9847647|FG001|Overall Study|Entry Criteria Not Met|0
6191038|NCT01419314|9847669|FG000|Follow-up at Week 3 of the Trial|Withdrawal by Subject|3
6191039|NCT01419314|9847670|FG001|Follow-up at Week 3 of the Trial|Withdrawal by Subject|1
6191040|NCT01419314|9847669|FG000|Follow-up at Week 3 of the Trial|Lost to Follow-up|3
6191041|NCT01419314|9847670|FG001|Follow-up at Week 3 of the Trial|Lost to Follow-up|0
6191042|NCT01419314|9847669|FG000|Follow-up at Week 6 of the Trial|Lost to Follow-up|1
6191043|NCT01419314|9847670|FG001|Follow-up at Week 6 of the Trial|Lost to Follow-up|2
6191044|NCT01419535|9847682|FG000|Overall Study|could not maintain iv line|1
6191045|NCT01419535|9847683|FG001|Overall Study|could not maintain iv line|1
6191046|NCT01419535|9847682|FG000|Overall Study|Withdrawal by Subject|0
6191047|NCT01419535|9847683|FG001|Overall Study|Withdrawal by Subject|1
6191048|NCT01419626|9847692|FG000|Overall Study|Protocol Violation|3
6191049|NCT01419626|9847693|FG001|Overall Study|Protocol Violation|2
6191050|NCT01419626|9847694|FG002|Overall Study|Protocol Violation|2
6191051|NCT01419626|9847692|FG000|Overall Study|Withdrawal by Subject|1
6191052|NCT01419626|9847693|FG001|Overall Study|Withdrawal by Subject|0
6191053|NCT01419626|9847694|FG002|Overall Study|Withdrawal by Subject|0
6191054|NCT01419626|9847692|FG000|Overall Study|Lost to Follow-up|0
6191055|NCT01419626|9847693|FG001|Overall Study|Lost to Follow-up|1
6191056|NCT01419626|9847694|FG002|Overall Study|Lost to Follow-up|1
6191057|NCT01419665|9847708|FG000|Combination Treatment|Adverse Event|7
6191058|NCT01419665|9847709|FG001|Combination Treatment|Adverse Event|10
6191059|NCT01419665|9847708|FG000|Combination Treatment|Physician Decision|5
6191060|NCT01419665|9847709|FG001|Combination Treatment|Physician Decision|8
6261322|NCT02055976|9956297|FG000|Overall Study|Does not meet entrance criteria|0
6261323|NCT02055976|9956298|FG001|Overall Study|Does not meet entrance criteria|0
6261324|NCT02055976|9956299|FG002|Overall Study|Does not meet entrance criteria|0
6261325|NCT02055976|9956300|FG003|Overall Study|Does not meet entrance criteria|0
6261326|NCT02055976|9956301|FG004|Overall Study|Does not meet entrance criteria|0
6261327|NCT02055976|9956302|FG005|Overall Study|Does not meet entrance criteria|0
6261328|NCT02055976|9956303|FG006|Overall Study|Does not meet entrance criteria|1
6261329|NCT02055976|9956304|FG007|Overall Study|Does not meet entrance criteria|0
6261330|NCT02055976|9956305|FG008|Overall Study|Does not meet entrance criteria|0
6261331|NCT02055976|9956297|FG000|Overall Study|Lost to Follow-up|0
6261332|NCT02055976|9956298|FG001|Overall Study|Lost to Follow-up|0
6261333|NCT02055976|9956299|FG002|Overall Study|Lost to Follow-up|0
6261334|NCT02055976|9956300|FG003|Overall Study|Lost to Follow-up|1
6261335|NCT02055976|9956301|FG004|Overall Study|Lost to Follow-up|0
6261336|NCT02055976|9956302|FG005|Overall Study|Lost to Follow-up|0
6261337|NCT02055976|9956303|FG006|Overall Study|Lost to Follow-up|0
6261338|NCT02055976|9956304|FG007|Overall Study|Lost to Follow-up|0
6261339|NCT02055976|9956305|FG008|Overall Study|Lost to Follow-up|0
6261340|NCT02056288|9956343|FG000|In-Hospital Data|Surgery cancelled|1
6261341|NCT02056288|9956344|FG001|In-Hospital Data|Surgery cancelled|0
6261342|NCT02056288|9956343|FG000|In-Hospital Data|Protocol Violation|3
6261343|NCT02056288|9956344|FG001|In-Hospital Data|Protocol Violation|0
6261344|NCT02056288|9956343|FG000|In-Hospital Data|Physician Decision|1
6261345|NCT02056288|9956344|FG001|In-Hospital Data|Physician Decision|0
6261346|NCT02056288|9956343|FG000|48-Hour Post-Discharge Data|Did not return diary|14
6261347|NCT02056288|9956344|FG001|48-Hour Post-Discharge Data|Did not return diary|20
6261348|NCT02056301|9956352|FG000|Overall Study|Protocol Violation|1
6261349|NCT02056301|9956353|FG001|Overall Study|Protocol Violation|2
6261350|NCT02056301|9956352|FG000|Overall Study|Surgical complications req. 2nd surgery|1
6261351|NCT02056301|9956353|FG001|Overall Study|Surgical complications req. 2nd surgery|0
6261352|NCT02056301|9956352|FG000|Overall Study|Withdrawal by Subject|0
6261353|NCT02056301|9956353|FG001|Overall Study|Withdrawal by Subject|1
6261354|NCT02056301|9956352|FG000|Overall Study|Issues with epidural|0
6261355|NCT02056301|9956353|FG001|Overall Study|Issues with epidural|3
6261356|NCT02056340|9956361|FG000|Overall Study|Lost to Follow-up|5
6261357|NCT02056340|9956362|FG001|Overall Study|Lost to Follow-up|5
6261358|NCT02056340|9956361|FG000|Overall Study|Withdrawal by Subject|2
6261359|NCT02056340|9956362|FG001|Overall Study|Withdrawal by Subject|6
6261360|NCT02056392|9956374|FG000|Overall Study|Lost to Follow-up|0
6261361|NCT02056392|9956375|FG001|Overall Study|Lost to Follow-up|1
6261362|NCT02056392|9956376|FG002|Overall Study|Lost to Follow-up|2
6261363|NCT02056392|9956377|FG003|Overall Study|Lost to Follow-up|0
6261364|NCT02056392|9956378|FG004|Overall Study|Lost to Follow-up|0
6261365|NCT02056392|9956379|FG005|Overall Study|Lost to Follow-up|0
6261366|NCT02056392|9956374|FG000|Overall Study|Protocol Violation|1
6261367|NCT02056392|9956375|FG001|Overall Study|Protocol Violation|0
6261368|NCT02056392|9956376|FG002|Overall Study|Protocol Violation|1
6261369|NCT02056392|9956377|FG003|Overall Study|Protocol Violation|0
6261370|NCT02056392|9956378|FG004|Overall Study|Protocol Violation|0
6261371|NCT02056392|9956379|FG005|Overall Study|Protocol Violation|0
6261372|NCT02056392|9956374|FG000|Overall Study|Withdrawal by Subject|1
6261373|NCT02056392|9956375|FG001|Overall Study|Withdrawal by Subject|0
6261374|NCT02056392|9956376|FG002|Overall Study|Withdrawal by Subject|0
6261375|NCT02056392|9956377|FG003|Overall Study|Withdrawal by Subject|0
6261376|NCT02056392|9956378|FG004|Overall Study|Withdrawal by Subject|1
6261377|NCT02056392|9956379|FG005|Overall Study|Withdrawal by Subject|0
6261378|NCT02056626|9956402|FG000|Overall Study|patient did not follow directions|3
6261379|NCT02056626|9956403|FG001|Overall Study|patient did not follow directions|1
6261380|NCT02056626|9956404|FG002|Overall Study|patient did not follow directions|0
6261381|NCT02056626|9956405|FG003|Overall Study|patient did not follow directions|0
6261382|NCT02056652|9956428|FG000|Overall Study|Withdrawal by Subject|1
6261383|NCT02056652|9956429|FG001|Overall Study|Withdrawal by Subject|0
6261384|NCT02056652|9956428|FG000|Overall Study|Lost to Follow-up|0
6261385|NCT02056652|9956429|FG001|Overall Study|Lost to Follow-up|3
6261386|NCT02056834|9956435|FG000|Overall Study|Lost to Follow-up|7
6261387|NCT02057068|9956451|FG000|Overall Study|Withdrawal by Subject|2
6261388|NCT02057068|9956452|FG001|Overall Study|Withdrawal by Subject|2
6261389|NCT02057068|9956451|FG000|Overall Study|Caregiver (CG) Health|0
6261390|NCT02057068|9956452|FG001|Overall Study|Caregiver (CG) Health|2
6261391|NCT02057068|9956451|FG000|Overall Study|Carepartner (CP) Health|4
6261392|NCT02057068|9956452|FG001|Overall Study|Carepartner (CP) Health|2
6261393|NCT02057068|9956451|FG000|Overall Study|Lost to Follow-up|2
6261394|NCT02057068|9956452|FG001|Overall Study|Lost to Follow-up|2
6261395|NCT02057198|9956472|FG000|Overall Study|Death|0
6261396|NCT02057198|9956473|FG001|Overall Study|Death|0
6261397|NCT02057198|9956474|FG002|Overall Study|Death|1
6261398|NCT02057198|9956472|FG000|Overall Study|Discharged early; lost to followup|0
6261399|NCT02057198|9956473|FG001|Overall Study|Discharged early; lost to followup|1
6261400|NCT02057198|9956474|FG002|Overall Study|Discharged early; lost to followup|0
6261401|NCT02057250|9956486|FG000|AID Assessment Phase|Adverse Event|3
6261402|NCT02057250|9956487|FG001|AID Assessment Phase|Adverse Event|2
6261403|NCT02057250|9956488|FG002|AID Assessment Phase|Adverse Event|6
6261404|NCT02057250|9956489|FG003|AID Assessment Phase|Adverse Event|1
6261405|NCT02057250|9956490|FG004|AID Assessment Phase|Adverse Event|0
6261406|NCT02057250|9956486|FG000|AID Assessment Phase|Other than specified above|1
6261407|NCT02057250|9956487|FG001|AID Assessment Phase|Other than specified above|1
6261408|NCT02057250|9956488|FG002|AID Assessment Phase|Other than specified above|1
6261409|NCT02057250|9956489|FG003|AID Assessment Phase|Other than specified above|1
6261410|NCT02057250|9956490|FG004|AID Assessment Phase|Other than specified above|0
6261411|NCT02057250|9956486|FG000|Extension Phase|Adverse Event|0
6261412|NCT02057250|9956487|FG001|Extension Phase|Adverse Event|0
6261413|NCT02057250|9956488|FG002|Extension Phase|Adverse Event|0
6261414|NCT02057250|9956489|FG003|Extension Phase|Adverse Event|0
6261415|NCT02057250|9956490|FG004|Extension Phase|Adverse Event|15
6261416|NCT02057250|9956486|FG000|Extension Phase|Lack of Efficacy|0
6261417|NCT02057250|9956487|FG001|Extension Phase|Lack of Efficacy|0
6261418|NCT02057250|9956488|FG002|Extension Phase|Lack of Efficacy|0
6261419|NCT02057250|9956489|FG003|Extension Phase|Lack of Efficacy|0
6261420|NCT02057250|9956490|FG004|Extension Phase|Lack of Efficacy|10
6261421|NCT02057250|9956486|FG000|Extension Phase|Entered in this period but not treated|0
6261422|NCT02057250|9956487|FG001|Extension Phase|Entered in this period but not treated|0
6261423|NCT02057250|9956488|FG002|Extension Phase|Entered in this period but not treated|0
6261424|NCT02057250|9956489|FG003|Extension Phase|Entered in this period but not treated|0
6261425|NCT02057250|9956490|FG004|Extension Phase|Entered in this period but not treated|4
6261426|NCT02057250|9956486|FG000|Extension Phase|Other than specified above|0
6261427|NCT02057250|9956487|FG001|Extension Phase|Other than specified above|0
6261428|NCT02057250|9956488|FG002|Extension Phase|Other than specified above|0
6261429|NCT02057250|9956489|FG003|Extension Phase|Other than specified above|0
6261430|NCT02057250|9956490|FG004|Extension Phase|Other than specified above|7
6261431|NCT02057393|9956502|FG000|Overall Study|Withdrawal by Subject|1
6261432|NCT02057393|9956502|FG000|Overall Study|Patient did not meet criteria|1
6261433|NCT02057406|9956509|FG000|Overall Study|Physician Decision|0
6261434|NCT02057406|9956510|FG001|Overall Study|Physician Decision|0
6261435|NCT02057406|9956511|FG002|Overall Study|Physician Decision|2
6261436|NCT02057406|9956509|FG000|Overall Study|Withdrawal by Subject|0
6261437|NCT02057406|9956510|FG001|Overall Study|Withdrawal by Subject|2
6261438|NCT02057406|9956511|FG002|Overall Study|Withdrawal by Subject|0
6261439|NCT02057406|9956509|FG000|Overall Study|Lost to Follow-up|0
6261440|NCT02057406|9956510|FG001|Overall Study|Lost to Follow-up|0
6261441|NCT02057406|9956511|FG002|Overall Study|Lost to Follow-up|1
6261442|NCT02057406|9956509|FG000|Overall Study|Death|1
6261443|NCT02057406|9956510|FG001|Overall Study|Death|0
6261444|NCT02057406|9956511|FG002|Overall Study|Death|0
6261445|NCT02057406|9956509|FG000|Overall Study|Protocol Violation|0
6261446|NCT02057406|9956510|FG001|Overall Study|Protocol Violation|1
6261447|NCT02057406|9956511|FG002|Overall Study|Protocol Violation|0
6261448|NCT02057406|9956509|FG000|Overall Study|Patient transportation issues|0
6261449|NCT02057406|9956510|FG001|Overall Study|Patient transportation issues|0
6261450|NCT02057406|9956511|FG002|Overall Study|Patient transportation issues|1
6261451|NCT02057458|9956519|FG000|Met Inclusion Criteria|Prior history of migraine headaches|0
6261452|NCT02057458|9956520|FG001|Met Inclusion Criteria|Prior history of migraine headaches|1
6261453|NCT02057458|9956521|FG002|Met Inclusion Criteria|Prior history of migraine headaches|0
6261454|NCT02057458|9956519|FG000|Acute Study (1 Hour): First Intervention|Lost to Follow-up|2
6261455|NCT02057458|9956520|FG001|Acute Study (1 Hour): First Intervention|Lost to Follow-up|0
6261456|NCT02057458|9956521|FG002|Acute Study (1 Hour): First Intervention|Lost to Follow-up|0
6261457|NCT02057458|9956519|FG000|Sub-Chronic Study (4 Weeks)|Lost to Follow-up|1
6261458|NCT02057458|9956520|FG001|Sub-Chronic Study (4 Weeks)|Lost to Follow-up|0
6261459|NCT02057458|9956521|FG002|Sub-Chronic Study (4 Weeks)|Lost to Follow-up|0
6261460|NCT02057523|9956551|FG000|Overall Study|Withdrawal by Subject|1
6261461|NCT02057523|9956551|FG000|Overall Study|Lack of Efficacy|1
6261462|NCT02057549|9956557|FG000|Overall Study|Lost to Follow-up|1
6261463|NCT02057549|9956558|FG001|Overall Study|Lost to Follow-up|0
6261464|NCT02057549|9956557|FG000|Overall Study|Physician Decision|1
6261465|NCT02057549|9956558|FG001|Overall Study|Physician Decision|0
6261466|NCT02057549|9956557|FG000|Overall Study|Withdrawal by Subject|1
6261467|NCT02057549|9956558|FG001|Overall Study|Withdrawal by Subject|0
6261468|NCT02057575|9956568|FG000|Overall Study|Adverse Event|0
6261469|NCT02057575|9956569|FG001|Overall Study|Adverse Event|2
6261470|NCT02057575|9956570|FG002|Overall Study|Adverse Event|0
6261471|NCT02057575|9956571|FG003|Overall Study|Adverse Event|1
6261472|NCT02057575|9956568|FG000|Overall Study|Withdrawal by Subject|1
6261473|NCT02057575|9956569|FG001|Overall Study|Withdrawal by Subject|0
6261474|NCT02057575|9956570|FG002|Overall Study|Withdrawal by Subject|0
6261475|NCT02057575|9956571|FG003|Overall Study|Withdrawal by Subject|0
6261476|NCT02057575|9956568|FG000|Overall Study|Dissallowed Concurrent Medication|0
6261477|NCT02057575|9956569|FG001|Overall Study|Dissallowed Concurrent Medication|1
6261478|NCT02057575|9956570|FG002|Overall Study|Dissallowed Concurrent Medication|0
6261479|NCT02057575|9956571|FG003|Overall Study|Dissallowed Concurrent Medication|0
6261480|NCT02057575|9956568|FG000|Overall Study|Protocol Violation|0
6261481|NCT02057575|9956569|FG001|Overall Study|Protocol Violation|1
6261482|NCT02057575|9956570|FG002|Overall Study|Protocol Violation|0
6261483|NCT02057575|9956571|FG003|Overall Study|Protocol Violation|0
6261484|NCT02057666|9956593|FG000|Double Blind Treatment Period|Withdrawal by Subject|8
6261485|NCT02057666|9956594|FG001|Double Blind Treatment Period|Withdrawal by Subject|5
6261486|NCT02057666|9956593|FG000|Double Blind Treatment Period|Poor tolerability|7
6261487|NCT02057666|9956594|FG001|Double Blind Treatment Period|Poor tolerability|2
6261488|NCT02057666|9956593|FG000|Double Blind Treatment Period|Symptomatic disease progression|8
6271352|NCT02162862|9973043|FG002|Overall Study|Lost to Follow-up|0
6261489|NCT02057666|9956594|FG001|Double Blind Treatment Period|Symptomatic disease progression|3
6261490|NCT02057666|9956593|FG000|Double Blind Treatment Period|Physician Decision|1
6261491|NCT02057666|9956594|FG001|Double Blind Treatment Period|Physician Decision|0
6261492|NCT02057666|9956593|FG000|Double Blind Treatment Period|Progressive disease for bone lesion|1
6261493|NCT02057666|9956594|FG001|Double Blind Treatment Period|Progressive disease for bone lesion|0
6261494|NCT02057666|9956593|FG000|Double Blind Treatment Period|Subject planning to withdraw|1
6261495|NCT02057666|9956594|FG001|Double Blind Treatment Period|Subject planning to withdraw|0
6261496|NCT02057666|9956593|FG000|Double Blind Treatment Period|Sponsor's request|70
6261497|NCT02057666|9956594|FG001|Double Blind Treatment Period|Sponsor's request|34
6261498|NCT02057666|9956593|FG000|Open-Label Treatment Period|Poor tolerability|0
6261499|NCT02057666|9956594|FG001|Open-Label Treatment Period|Poor tolerability|1
6261500|NCT02057666|9956593|FG000|Open-Label Treatment Period|Symptomatic disease progression|0
6261501|NCT02057666|9956594|FG001|Open-Label Treatment Period|Symptomatic disease progression|1
6261502|NCT02057666|9956593|FG000|Open-Label Treatment Period|Sponsor's request|0
6261503|NCT02057666|9956594|FG001|Open-Label Treatment Period|Sponsor's request|4
6261504|NCT02057692|9956604|FG000|Overall Study|Adverse Event|1
6261505|NCT02057692|9956605|FG001|Overall Study|Adverse Event|0
6261506|NCT02057692|9956606|FG002|Overall Study|Adverse Event|0
6261507|NCT02057692|9956607|FG003|Overall Study|Adverse Event|0
6261508|NCT02057692|9956604|FG000|Overall Study|Lost to Follow-up|0
6261509|NCT02057692|9956605|FG001|Overall Study|Lost to Follow-up|0
6261510|NCT02057692|9956606|FG002|Overall Study|Lost to Follow-up|0
6261511|NCT02057692|9956607|FG003|Overall Study|Lost to Follow-up|1
6271353|NCT02162862|9973041|FG000|Overall Study|Subject did not feel the med was needed|0
6271354|NCT02162862|9973042|FG001|Overall Study|Subject did not feel the med was needed|0
6271355|NCT02162862|9973043|FG002|Overall Study|Subject did not feel the med was needed|4
6271356|NCT02163057|9973064|FG000|Overall Study|Participant Refusal to Continue|2
6271357|NCT02163057|9973065|FG001|Overall Study|Participant Refusal to Continue|2
6271358|NCT02163057|9973064|FG000|Overall Study|Participant Significant Noncompliance|0
6271359|NCT02163057|9973065|FG001|Overall Study|Participant Significant Noncompliance|1
6271360|NCT02163057|9973064|FG000|Overall Study|Progression of Disease|1
6271361|NCT02163057|9973065|FG001|Overall Study|Progression of Disease|2
6271362|NCT02163226|9973075|FG000|Overall Study|Death|2
6271363|NCT02163226|9973076|FG001|Overall Study|Death|1
6271364|NCT02163226|9973075|FG000|Overall Study|Withdrawal by Subject|5
6271365|NCT02163226|9973076|FG001|Overall Study|Withdrawal by Subject|2
6271366|NCT02163226|9973075|FG000|Overall Study|Returned home, local radiotherapy|3
6271367|NCT02163226|9973076|FG001|Overall Study|Returned home, local radiotherapy|0
6271368|NCT02163226|9973075|FG000|Overall Study|Repeat imaging showed no disease|2
6086900|NCT00665366|9697039|FG001|Overall Study|Withdrawal by Subject|14
6271369|NCT02163226|9973076|FG001|Overall Study|Repeat imaging showed no disease|0
6271370|NCT02163226|9973075|FG000|Overall Study|Incomplete radiotherapy|3
6271371|NCT02163226|9973076|FG001|Overall Study|Incomplete radiotherapy|0
6271372|NCT02163226|9973075|FG000|Overall Study|Treatment was to >3 radiotherapy fields|1
6271373|NCT02163226|9973076|FG001|Overall Study|Treatment was to >3 radiotherapy fields|0
6271374|NCT02163226|9973075|FG000|Overall Study|"Insurance denied for single-fraction treatment"|0
6271375|NCT02163226|9973076|FG001|Overall Study|"Insurance denied for single-fraction treatment"|5
6271376|NCT02163226|9973075|FG000|Overall Study|ineligible|0
6271377|NCT02163226|9973076|FG001|Overall Study|ineligible|3
6271378|NCT02163395|9973082|FG000|Overall Study|Withdrawal by Subject|1
6271379|NCT02163395|9973082|FG000|Overall Study|Lost to Follow-up|3
6271380|NCT02163395|9973082|FG000|Overall Study|Adverse Event|1
6271381|NCT02163447|9973112|FG000|Overall Study|Withdrawal by Subject|2
6271382|NCT02163447|9973113|FG001|Overall Study|Withdrawal by Subject|0
6271383|NCT02163447|9973114|FG002|Overall Study|Withdrawal by Subject|1
6271384|NCT02163447|9973112|FG000|Overall Study|Lost to Follow-up|1
6271385|NCT02163447|9973113|FG001|Overall Study|Lost to Follow-up|3
6271386|NCT02163447|9973114|FG002|Overall Study|Lost to Follow-up|0
6271387|NCT02163447|9973112|FG000|Overall Study|Moved out of study area|2
6271388|NCT02163447|9973113|FG001|Overall Study|Moved out of study area|3
6271389|NCT02163447|9973114|FG002|Overall Study|Moved out of study area|2
6271390|NCT02163447|9973112|FG000|Overall Study|Became HIV infected at time of delivery|1
6271391|NCT02163447|9973113|FG001|Overall Study|Became HIV infected at time of delivery|0
6271392|NCT02163447|9973114|FG002|Overall Study|Became HIV infected at time of delivery|0
6271393|NCT02163499|9973141|FG000|Acute Phase: ZS 10 g TID|Participant's Compliance|1
6271394|NCT02163499|9973141|FG000|Acute Phase: ZS 10 g TID|Hypo- or Hyperkalemia|1
6271395|NCT02163499|9973141|FG000|Acute Phase: ZS 10 g TID|Protocol Violation|1
6271396|NCT02163499|9973141|FG000|Acute Phase: ZS 10 g TID|Physician Decision|1
6271397|NCT02163499|9973141|FG000|Acute Phase: ZS 10 g TID|Withdrawal by Subject|1
6271398|NCT02163499|9973141|FG000|Extended Dosing Phase: ZS|Adverse Event|51
6271399|NCT02163499|9973141|FG000|Extended Dosing Phase: ZS|Expected Progression of CKD|40
6271400|NCT02163499|9973141|FG000|Extended Dosing Phase: ZS|Hypokalemia|9
6271401|NCT02163499|9973141|FG000|Extended Dosing Phase: ZS|Sponsor's Decision|5
6271402|NCT02163499|9973141|FG000|Extended Dosing Phase: ZS|Met ECG Withdrawal Criteria|7
6271403|NCT02163499|9973141|FG000|Extended Dosing Phase: ZS|Withdrawal by Subject|81
6271404|NCT02163499|9973141|FG000|Extended Dosing Phase: ZS|Physician Decision|8
6261512|NCT02057718|9956625|FG000|Completed Study Treatment Through Wk. 72|Progressive disease|0
6261513|NCT02057718|9956626|FG001|Completed Study Treatment Through Wk. 72|Progressive disease|2
6261514|NCT02057718|9956625|FG000|Completed Study Treatment Through Wk. 72|Physician Decision|1
6261515|NCT02057718|9956626|FG001|Completed Study Treatment Through Wk. 72|Physician Decision|0
6261516|NCT02057718|9956625|FG000|Completed Study Treatment Through Wk. 72|Non-compliance with study drug|0
6261517|NCT02057718|9956626|FG001|Completed Study Treatment Through Wk. 72|Non-compliance with study drug|1
6261518|NCT02057718|9956625|FG000|Completed Study Treatment Through Wk. 72|Adverse Event|0
6261519|NCT02057718|9956626|FG001|Completed Study Treatment Through Wk. 72|Adverse Event|3
6261520|NCT02057718|9956625|FG000|Completed Study Treatment Through Wk. 72|Consent withdrawn by caregiver|1
6261521|NCT02057718|9956626|FG001|Completed Study Treatment Through Wk. 72|Consent withdrawn by caregiver|1
6261522|NCT02057718|9956625|FG000|Completed Study Treatment Through Wk. 72|Consent withdrawn by subject|0
6261523|NCT02057718|9956626|FG001|Completed Study Treatment Through Wk. 72|Consent withdrawn by subject|1
6261524|NCT02057718|9956625|FG000|Completed Study Treatment Through Wk. 72|Liver Transplant|0
6261525|NCT02057718|9956626|FG001|Completed Study Treatment Through Wk. 72|Liver Transplant|1
6261526|NCT02057718|9956625|FG000|Optional Follow-up Treatment Period|Did not consent to protocol amendment|1
6261527|NCT02057718|9956626|FG001|Optional Follow-up Treatment Period|Did not consent to protocol amendment|3
6261528|NCT02057718|9956625|FG000|Optional Follow-up Treatment Period|Progressive disease|0
6261529|NCT02057718|9956626|FG001|Optional Follow-up Treatment Period|Progressive disease|1
6261530|NCT02057718|9956625|FG000|Optional Follow-up Treatment Period|Adverse Event|1
6261531|NCT02057718|9956626|FG001|Optional Follow-up Treatment Period|Adverse Event|2
6261532|NCT02057718|9956625|FG000|Optional Follow-up Treatment Period|Liver Transplant|0
6261533|NCT02057718|9956626|FG001|Optional Follow-up Treatment Period|Liver Transplant|2
6261534|NCT02057757|9956634|FG000|Overall Study|Withdrawal by Subject|3
6261535|NCT02057757|9956635|FG001|Overall Study|Withdrawal by Subject|5
6261536|NCT02057757|9956634|FG000|Overall Study|Death|2
6261537|NCT02057757|9956635|FG001|Overall Study|Death|0
6261538|NCT02057757|9956634|FG000|Overall Study|Lost to Follow-up|8
6261539|NCT02057757|9956635|FG001|Overall Study|Lost to Follow-up|3
6261540|NCT02057757|9956634|FG000|Overall Study|Non-compliance|1
6261541|NCT02057757|9956635|FG001|Overall Study|Non-compliance|0
6261542|NCT02057835|9956655|FG000|Overall Study|Withdrawal by Subject|0
6261543|NCT02057835|9956656|FG001|Overall Study|Withdrawal by Subject|2
6261544|NCT02057835|9956657|FG002|Overall Study|Withdrawal by Subject|0
6261545|NCT02057835|9956658|FG003|Overall Study|Withdrawal by Subject|0
6261546|NCT02057835|9956659|FG004|Overall Study|Withdrawal by Subject|0
6261547|NCT02057835|9956660|FG005|Overall Study|Withdrawal by Subject|0
6261548|NCT02057835|9956661|FG006|Overall Study|Withdrawal by Subject|0
6261549|NCT02057835|9956662|FG007|Overall Study|Withdrawal by Subject|0
6261550|NCT02057835|9956663|FG008|Overall Study|Withdrawal by Subject|0
6261551|NCT02057835|9956664|FG009|Overall Study|Withdrawal by Subject|0
6261552|NCT02058069|9956710|FG000|Overall Study|Exclusion due to implant size|5
6261553|NCT02058069|9956710|FG000|Overall Study|Withdrawal by Subject|6
6261554|NCT02058095|9956716|FG000|Overall Study|Adverse Event|1
6261555|NCT02058095|9956717|FG001|Overall Study|Adverse Event|0
6261556|NCT02058108|9956725|FG000|Overall Study|Abnormal Laboratory Values|0
6261557|NCT02058108|9956726|FG001|Overall Study|Abnormal Laboratory Values|1
6261558|NCT02058108|9956725|FG000|Overall Study|Unsatisfactory therapeutic effect|37
6261559|NCT02058108|9956726|FG001|Overall Study|Unsatisfactory therapeutic effect|4
6261560|NCT02058108|9956725|FG000|Overall Study|No longer requires study drug|0
6261561|NCT02058108|9956726|FG001|Overall Study|No longer requires study drug|1
6261562|NCT02058108|9956725|FG000|Overall Study|Withdrawal by Subject|1
6261563|NCT02058108|9956726|FG001|Overall Study|Withdrawal by Subject|0
6261564|NCT02058108|9956725|FG000|Overall Study|Administrative problems|3
6261565|NCT02058108|9956726|FG001|Overall Study|Administrative problems|3
6261566|NCT02058108|9956725|FG000|Overall Study|Protocol Violation|0
6261567|NCT02058108|9956726|FG001|Overall Study|Protocol Violation|1
6261568|NCT02058147|9956737|FG000|Overall Study|Randomized but not treated|0
6261569|NCT02058147|9956738|FG001|Overall Study|Randomized but not treated|0
6261570|NCT02058147|9956739|FG002|Overall Study|Randomized but not treated|1
6261571|NCT02058147|9956737|FG000|Overall Study|Adverse Event|12
6261572|NCT02058147|9956738|FG001|Overall Study|Adverse Event|9
6261573|NCT02058147|9956739|FG002|Overall Study|Adverse Event|21
6261574|NCT02058147|9956737|FG000|Overall Study|Lack of Efficacy|1
6261575|NCT02058147|9956738|FG001|Overall Study|Lack of Efficacy|0
6261576|NCT02058147|9956739|FG002|Overall Study|Lack of Efficacy|3
6261577|NCT02058147|9956737|FG000|Overall Study|Poor compliance to protocol|8
6261578|NCT02058147|9956738|FG001|Overall Study|Poor compliance to protocol|9
6261579|NCT02058147|9956739|FG002|Overall Study|Poor compliance to protocol|4
6261580|NCT02058147|9956737|FG000|Overall Study|Other than specified|8
6261581|NCT02058147|9956738|FG001|Overall Study|Other than specified|9
6261582|NCT02058147|9956739|FG002|Overall Study|Other than specified|0
6261583|NCT02058160|9956749|FG000|Overall Study|Randomized but not treated|2
6261584|NCT02058160|9956750|FG001|Overall Study|Randomized but not treated|4
6261585|NCT02058160|9956749|FG000|Overall Study|Poor compliance to protocol|4
6261586|NCT02058160|9956750|FG001|Overall Study|Poor compliance to protocol|1
6261587|NCT02058160|9956749|FG000|Overall Study|Adverse Event|12
6261588|NCT02058160|9956750|FG001|Overall Study|Adverse Event|3
6261589|NCT02058160|9956749|FG000|Overall Study|Lost to Follow-up|1
6261590|NCT02058160|9956750|FG001|Overall Study|Lost to Follow-up|0
6261591|NCT02058160|9956749|FG000|Overall Study|Other than specified above|12
6261592|NCT02058160|9956750|FG001|Overall Study|Other than specified above|6
6261593|NCT02058290|9956767|FG000|Overall Study|Protocol Violation|2
6261594|NCT02058290|9956768|FG001|Overall Study|Protocol Violation|1
6261595|NCT02058290|9956767|FG000|Overall Study|Physician Decision|1
6261596|NCT02058290|9956768|FG001|Overall Study|Physician Decision|0
6261597|NCT02058290|9956767|FG000|Overall Study|Didn't meet intraoperative criteria|8
6261598|NCT02058290|9956768|FG001|Overall Study|Didn't meet intraoperative criteria|7
6261599|NCT02058290|9956767|FG000|Overall Study|Withdrawal by Subject|0
6261600|NCT02058290|9956768|FG001|Overall Study|Withdrawal by Subject|1
6261601|NCT02058368|9956776|FG000|Overall Study|Adverse Event|15
6261602|NCT02058368|9956777|FG001|Overall Study|Adverse Event|20
6261603|NCT02058368|9956776|FG000|Overall Study|Lack of Efficacy|0
6261604|NCT02058368|9956777|FG001|Overall Study|Lack of Efficacy|1
6261605|NCT02058368|9956776|FG000|Overall Study|Protocol Violation|0
6261606|NCT02058368|9956777|FG001|Overall Study|Protocol Violation|4
6261607|NCT02058368|9956776|FG000|Overall Study|Lost to Follow-up|2
6261608|NCT02058368|9956777|FG001|Overall Study|Lost to Follow-up|0
6261609|NCT02058368|9956776|FG000|Overall Study|Physician Decision|2
6261610|NCT02058368|9956777|FG001|Overall Study|Physician Decision|3
6261611|NCT02058368|9956776|FG000|Overall Study|Withdrawal by Subject|22
6261612|NCT02058368|9956777|FG001|Overall Study|Withdrawal by Subject|26
6261613|NCT02058498|9956783|FG000|Overall Study|Withdrawal by Subject|4
6261614|NCT02058563|9956793|FG000|Overall Study|Lost to Follow-up|26
6261615|NCT02058563|9956794|FG001|Overall Study|Lost to Follow-up|22
6261616|NCT02058563|9956793|FG000|Overall Study|Other (vaccinated later as new subject)|1
6261617|NCT02058563|9956794|FG001|Overall Study|Other (vaccinated later as new subject)|0
6261618|NCT02058563|9956793|FG000|Overall Study|Consent Withdrawal|1
6261619|NCT02058563|9956794|FG001|Overall Study|Consent Withdrawal|1
6261620|NCT02058563|9956793|FG000|Overall Study|Other (patient incarcerated)|0
6261621|NCT02058563|9956794|FG001|Overall Study|Other (patient incarcerated)|1
6261622|NCT02058589|9956802|FG000|Overall Study|Serious Adverse Event|1
6261623|NCT02058589|9956803|FG001|Overall Study|Serious Adverse Event|1
6261624|NCT02058589|9956802|FG000|Overall Study|Non-Serious Adverse Event|1
6261625|NCT02058589|9956803|FG001|Overall Study|Non-Serious Adverse Event|0
6261626|NCT02058589|9956802|FG000|Overall Study|Withdrawal by Subject|0
6261627|NCT02058589|9956803|FG001|Overall Study|Withdrawal by Subject|1
6261628|NCT02058628|9956813|FG000|Overall Study|Adverse Event|1
6261629|NCT02058628|9956814|FG001|Overall Study|Adverse Event|0
6261630|NCT02058628|9956813|FG000|Overall Study|Withdrawal by Subject|2
6261631|NCT02058628|9956814|FG001|Overall Study|Withdrawal by Subject|2
6261632|NCT02058628|9956813|FG000|Overall Study|Lost to Follow-up|2
6261633|NCT02058628|9956814|FG001|Overall Study|Lost to Follow-up|4
6261634|NCT02058628|9956813|FG000|Overall Study|Not in time schedule|0
6261635|NCT02058628|9956814|FG001|Overall Study|Not in time schedule|1
6261636|NCT02058628|9956813|FG000|Overall Study|The visit date was not in timeline|0
6261637|NCT02058628|9956814|FG001|Overall Study|The visit date was not in timeline|1
6261638|NCT02058628|9956813|FG000|Overall Study|A lot of time for study for participant|1
6261639|NCT02058628|9956814|FG001|Overall Study|A lot of time for study for participant|0
6261640|NCT02058628|9956813|FG000|Overall Study|Non compliance|1
6261641|NCT02058628|9956814|FG001|Overall Study|Non compliance|0
6261642|NCT02058836|9956825|FG000|Overall Study|Withdrawal by Subject|1
6261643|NCT02058836|9956826|FG001|Overall Study|Withdrawal by Subject|1
6261644|NCT02058849|9956834|FG000|Overall Study|Hospitalization|1
6261645|NCT02058849|9956835|FG001|Overall Study|Hospitalization|1
6261646|NCT02058849|9956834|FG000|Overall Study|Death|1
6261647|NCT02058849|9956835|FG001|Overall Study|Death|0
6261648|NCT02058849|9956834|FG000|Overall Study|Lost to Follow-up|1
6261649|NCT02058849|9956835|FG001|Overall Study|Lost to Follow-up|0
6261650|NCT02058849|9956834|FG000|Overall Study|Withdrawal by Subject|4
6261651|NCT02058849|9956835|FG001|Overall Study|Withdrawal by Subject|0
6261652|NCT02058940|9956841|FG000|Overall Study|Discharged from Critical Care Unit|1
6261653|NCT02058966|9956845|FG000|Open-Label Methamphetamine|Adverse Event|1
6261654|NCT02058966|9956845|FG000|First Intervention|Withdrawal by Subject|1
6261655|NCT02058992|9956857|FG000|Overall Study|Lost to Follow-up|4
6261656|NCT02058992|9956857|FG000|Overall Study|Protocol Violation|92
6261657|NCT02058992|9956857|FG000|Overall Study|CRF Uncollected|20
6261658|NCT02059005|9956863|FG000|Overall Study|Death|1
6261659|NCT02059005|9956864|FG001|Overall Study|Death|3
6261660|NCT02059005|9956863|FG000|Overall Study|Lost to Follow-up|19
6261661|NCT02059005|9956864|FG001|Overall Study|Lost to Follow-up|19
6261662|NCT02059005|9956863|FG000|Overall Study|Incarceration|0
6261663|NCT02059005|9956864|FG001|Overall Study|Incarceration|1
6261664|NCT02059005|9956863|FG000|Overall Study|Inpatient|0
6261665|NCT02059005|9956864|FG001|Overall Study|Inpatient|1
6261666|NCT02059135|9956888|FG000|Maternal Follow-up (ITT Population)|Withdrawal by Subject|3
6261667|NCT02059135|9956889|FG001|Maternal Follow-up (ITT Population)|Withdrawal by Subject|2
6261668|NCT02059135|9956888|FG000|Maternal Follow-up (ITT Population)|Lost to Follow-up|0
6261669|NCT02059135|9956889|FG001|Maternal Follow-up (ITT Population)|Lost to Follow-up|3
6261670|NCT02059135|9956888|FG000|Maternal Follow-up (ITT Population)|declined to see site staff|0
6261671|NCT02059135|9956889|FG001|Maternal Follow-up (ITT Population)|declined to see site staff|1
6261672|NCT02059135|9956888|FG000|Maternal Follow-up (ITT Population)|didn't return to site (f/u elsewhere)|0
6261673|NCT02059135|9956889|FG001|Maternal Follow-up (ITT Population)|didn't return to site (f/u elsewhere)|1
6261674|NCT02059135|9956888|FG000|Neonatal Follow-up (Safety Population)|Lost to Follow-up|1
6261675|NCT02059135|9956889|FG001|Neonatal Follow-up (Safety Population)|Lost to Follow-up|0
6261676|NCT02059135|9956888|FG000|Neonatal Follow-up (Safety Population)|Death|3
6261677|NCT02059135|9956889|FG001|Neonatal Follow-up (Safety Population)|Death|2
6261678|NCT02059135|9956888|FG000|Neonatal Follow-up (Safety Population)|delivered at another hospital|0
6261679|NCT02059135|9956889|FG001|Neonatal Follow-up (Safety Population)|delivered at another hospital|1
6261680|NCT02059135|9956888|FG000|Neonatal Follow-up (Safety Population)|Withdrawal by Subject|0
6261681|NCT02059135|9956889|FG001|Neonatal Follow-up (Safety Population)|Withdrawal by Subject|1
6261682|NCT02059148|9956897|FG000|Treatment 1|Protocol Violation|0
6261683|NCT02059148|9956898|FG001|Treatment 1|Protocol Violation|0
6261684|NCT02059148|9956899|FG002|Treatment 1|Protocol Violation|0
6261685|NCT02059148|9956900|FG003|Treatment 1|Protocol Violation|0
6261686|NCT02059148|9956901|FG004|Treatment 1|Protocol Violation|0
6261687|NCT02059148|9956902|FG005|Treatment 1|Protocol Violation|1
6261688|NCT02059161|9956915|FG000|Overall Study|Pregnancy|0
6261689|NCT02059161|9956916|FG001|Overall Study|Pregnancy|2
6261690|NCT02059161|9956915|FG000|Overall Study|Adverse Event|2
6261691|NCT02059161|9956916|FG001|Overall Study|Adverse Event|6
6261692|NCT02059161|9956915|FG000|Overall Study|Lost to Follow-up|20
6261693|NCT02059161|9956916|FG001|Overall Study|Lost to Follow-up|12
6261694|NCT02059161|9956915|FG000|Overall Study|Physician Decision|4
6261695|NCT02059161|9956916|FG001|Overall Study|Physician Decision|4
6261696|NCT02059161|9956915|FG000|Overall Study|Protocol Violation|1
6261697|NCT02059161|9956916|FG001|Overall Study|Protocol Violation|1
6261698|NCT02059161|9956915|FG000|Overall Study|Withdrawal by Subject|16
6261699|NCT02059161|9956916|FG001|Overall Study|Withdrawal by Subject|13
6261700|NCT02059161|9956915|FG000|Overall Study|Randomized in error, no study drug|0
6261701|NCT02059161|9956916|FG001|Overall Study|Randomized in error, no study drug|1
6261702|NCT02059161|9956915|FG000|Overall Study|Non-compliance with study drug|6
6261703|NCT02059161|9956916|FG001|Overall Study|Non-compliance with study drug|2
6261704|NCT02059174|9956922|FG000|Period 1|Withdrawal by Subject|0
6261705|NCT02059174|9956923|FG001|Period 1|Withdrawal by Subject|2
6261706|NCT02059174|9956922|FG000|Period 2|Withdrawal by Subject|0
6261707|NCT02059174|9956923|FG001|Period 2|Withdrawal by Subject|2
6261708|NCT02059174|9956922|FG000|Period 2|Protocol Violation|1
6261709|NCT02059174|9956923|FG001|Period 2|Protocol Violation|0
6261710|NCT02059174|9956922|FG000|Period 3|Physician Decision|1
6261711|NCT02059174|9956923|FG001|Period 3|Physician Decision|0
6261712|NCT02059187|9956931|FG000|Overall Study|Adverse Event|0
6261713|NCT02059187|9956932|FG001|Overall Study|Adverse Event|3
6261714|NCT02059187|9956931|FG000|Overall Study|Death|1
6261715|NCT02059187|9956932|FG001|Overall Study|Death|1
6261716|NCT02059187|9956931|FG000|Overall Study|Lost to Follow-up|9
6261717|NCT02059187|9956932|FG001|Overall Study|Lost to Follow-up|8
6261718|NCT02059187|9956931|FG000|Overall Study|Non-compliance with study drug|1
6261719|NCT02059187|9956932|FG001|Overall Study|Non-compliance with study drug|0
6261720|NCT02059187|9956931|FG000|Overall Study|Physician Decision|1
6261721|NCT02059187|9956932|FG001|Overall Study|Physician Decision|2
6261722|NCT02059187|9956931|FG000|Overall Study|Protocol Violation|1
6261723|NCT02059187|9956932|FG001|Overall Study|Protocol Violation|0
6261724|NCT02059187|9956931|FG000|Overall Study|Withdrawal by Subject|12
6261725|NCT02059187|9956932|FG001|Overall Study|Withdrawal by Subject|8
6261726|NCT02059239|9956952|FG000|Overall Study|Progressive Disease after Bendamustine|1
6261727|NCT02059239|9956953|FG001|Overall Study|Progressive Disease after Bendamustine|3
6261728|NCT02059239|9956952|FG000|Overall Study|Physician Decision|1
6261729|NCT02059239|9956953|FG001|Overall Study|Physician Decision|0
6261730|NCT02059278|9956962|FG000|Overall Study|Adverse Event|1
6261731|NCT02059278|9956963|FG001|Overall Study|Adverse Event|1
6261732|NCT02059278|9956962|FG000|Overall Study|Lost to Follow-up|1
6261733|NCT02059278|9956963|FG001|Overall Study|Lost to Follow-up|0
6261734|NCT02059278|9956962|FG000|Overall Study|Withdrawal by Subject|0
6261735|NCT02059278|9956963|FG001|Overall Study|Withdrawal by Subject|3
6261736|NCT02059278|9956962|FG000|Overall Study|Ran out of IP and decided to discontinue|1
6261737|NCT02059278|9956963|FG001|Overall Study|Ran out of IP and decided to discontinue|0
6261738|NCT02059291|9956978|FG000|Epoch 2|Lack of Efficacy|0
6261739|NCT02059291|9956979|FG001|Epoch 2|Lack of Efficacy|0
6261740|NCT02059291|9956980|FG002|Epoch 2|Lack of Efficacy|0
6261741|NCT02059291|9956981|FG003|Epoch 2|Lack of Efficacy|1
6261742|NCT02059291|9956982|FG004|Epoch 2|Lack of Efficacy|0
6261743|NCT02059291|9956983|FG005|Epoch 2|Lack of Efficacy|1
6261744|NCT02059291|9956984|FG006|Epoch 2|Lack of Efficacy|0
6261745|NCT02059291|9956985|FG007|Epoch 2|Lack of Efficacy|0
6261746|NCT02059291|9956986|FG008|Epoch 2|Lack of Efficacy|0
6261747|NCT02059291|9956987|FG009|Epoch 2|Lack of Efficacy|0
6261748|NCT02059291|9956988|FG010|Epoch 2|Lack of Efficacy|0
6261749|NCT02059291|9956989|FG011|Epoch 2|Lack of Efficacy|0
6261750|NCT02059291|9956990|FG012|Epoch 2|Lack of Efficacy|0
6261751|NCT02059291|9956991|FG013|Epoch 2|Lack of Efficacy|0
6261752|NCT02059291|9956992|FG014|Epoch 2|Lack of Efficacy|0
6261753|NCT02059291|9956993|FG015|Epoch 2|Lack of Efficacy|0
6261754|NCT02059291|9956994|FG016|Epoch 2|Lack of Efficacy|0
6261755|NCT02059291|9956995|FG017|Epoch 2|Lack of Efficacy|0
6261756|NCT02059291|9956996|FG018|Epoch 2|Lack of Efficacy|0
6261757|NCT02059291|9956997|FG019|Epoch 2|Lack of Efficacy|0
6261758|NCT02059291|9956998|FG020|Epoch 2|Lack of Efficacy|0
6261759|NCT02059291|9956999|FG021|Epoch 2|Lack of Efficacy|0
6261760|NCT02059291|9957000|FG022|Epoch 2|Lack of Efficacy|0
6261761|NCT02059291|9957001|FG023|Epoch 2|Lack of Efficacy|0
6261762|NCT02059291|9957002|FG024|Epoch 2|Lack of Efficacy|0
6261763|NCT02059291|9956978|FG000|Epoch 2|Adverse Event|0
6261764|NCT02059291|9956979|FG001|Epoch 2|Adverse Event|0
6261765|NCT02059291|9956980|FG002|Epoch 2|Adverse Event|1
6261766|NCT02059291|9956981|FG003|Epoch 2|Adverse Event|1
6261767|NCT02059291|9956982|FG004|Epoch 2|Adverse Event|0
6261768|NCT02059291|9956983|FG005|Epoch 2|Adverse Event|0
6261769|NCT02059291|9956984|FG006|Epoch 2|Adverse Event|0
6261770|NCT02059291|9956985|FG007|Epoch 2|Adverse Event|1
6261771|NCT02059291|9956986|FG008|Epoch 2|Adverse Event|1
6261772|NCT02059291|9956987|FG009|Epoch 2|Adverse Event|0
6261773|NCT02059291|9956988|FG010|Epoch 2|Adverse Event|0
6261774|NCT02059291|9956989|FG011|Epoch 2|Adverse Event|0
6261775|NCT02059291|9956990|FG012|Epoch 2|Adverse Event|0
6261776|NCT02059291|9956991|FG013|Epoch 2|Adverse Event|0
6261777|NCT02059291|9956992|FG014|Epoch 2|Adverse Event|0
6261778|NCT02059291|9956993|FG015|Epoch 2|Adverse Event|0
6261779|NCT02059291|9956994|FG016|Epoch 2|Adverse Event|0
6261780|NCT02059291|9956995|FG017|Epoch 2|Adverse Event|0
6261781|NCT02059291|9956996|FG018|Epoch 2|Adverse Event|0
6261782|NCT02059291|9956997|FG019|Epoch 2|Adverse Event|0
6261783|NCT02059291|9956998|FG020|Epoch 2|Adverse Event|0
6261784|NCT02059291|9956999|FG021|Epoch 2|Adverse Event|0
6261785|NCT02059291|9957000|FG022|Epoch 2|Adverse Event|0
6261786|NCT02059291|9957001|FG023|Epoch 2|Adverse Event|0
6261787|NCT02059291|9957002|FG024|Epoch 2|Adverse Event|0
6261788|NCT02059291|9956978|FG000|Epoch 2|Withdrawal by Subject|0
6261789|NCT02059291|9956979|FG001|Epoch 2|Withdrawal by Subject|1
6261790|NCT02059291|9956980|FG002|Epoch 2|Withdrawal by Subject|0
6261791|NCT02059291|9956981|FG003|Epoch 2|Withdrawal by Subject|0
6261792|NCT02059291|9956982|FG004|Epoch 2|Withdrawal by Subject|0
6261793|NCT02059291|9956983|FG005|Epoch 2|Withdrawal by Subject|1
6261794|NCT02059291|9956984|FG006|Epoch 2|Withdrawal by Subject|0
6261795|NCT02059291|9956985|FG007|Epoch 2|Withdrawal by Subject|0
6261796|NCT02059291|9956986|FG008|Epoch 2|Withdrawal by Subject|1
6261797|NCT02059291|9956987|FG009|Epoch 2|Withdrawal by Subject|0
6261798|NCT02059291|9956988|FG010|Epoch 2|Withdrawal by Subject|0
6261799|NCT02059291|9956989|FG011|Epoch 2|Withdrawal by Subject|0
6261800|NCT02059291|9956990|FG012|Epoch 2|Withdrawal by Subject|0
6261801|NCT02059291|9956991|FG013|Epoch 2|Withdrawal by Subject|0
6261802|NCT02059291|9956992|FG014|Epoch 2|Withdrawal by Subject|0
6261803|NCT02059291|9956993|FG015|Epoch 2|Withdrawal by Subject|0
6261804|NCT02059291|9956994|FG016|Epoch 2|Withdrawal by Subject|0
6261805|NCT02059291|9956995|FG017|Epoch 2|Withdrawal by Subject|0
6261806|NCT02059291|9956996|FG018|Epoch 2|Withdrawal by Subject|0
6261807|NCT02059291|9956997|FG019|Epoch 2|Withdrawal by Subject|0
6261808|NCT02059291|9956998|FG020|Epoch 2|Withdrawal by Subject|0
6261809|NCT02059291|9956999|FG021|Epoch 2|Withdrawal by Subject|0
6261810|NCT02059291|9957000|FG022|Epoch 2|Withdrawal by Subject|0
6261811|NCT02059291|9957001|FG023|Epoch 2|Withdrawal by Subject|0
6261812|NCT02059291|9957002|FG024|Epoch 2|Withdrawal by Subject|0
6261813|NCT02059291|9956978|FG000|Epoch 3|Physician Decision|0
6261814|NCT02059291|9956979|FG001|Epoch 3|Physician Decision|0
6261815|NCT02059291|9956980|FG002|Epoch 3|Physician Decision|0
6261816|NCT02059291|9956981|FG003|Epoch 3|Physician Decision|0
6261817|NCT02059291|9956982|FG004|Epoch 3|Physician Decision|0
6261818|NCT02059291|9956983|FG005|Epoch 3|Physician Decision|0
6261819|NCT02059291|9956984|FG006|Epoch 3|Physician Decision|0
6261820|NCT02059291|9956985|FG007|Epoch 3|Physician Decision|0
6261821|NCT02059291|9956986|FG008|Epoch 3|Physician Decision|0
6261822|NCT02059291|9956987|FG009|Epoch 3|Physician Decision|0
6261823|NCT02059291|9956988|FG010|Epoch 3|Physician Decision|0
6261824|NCT02059291|9956989|FG011|Epoch 3|Physician Decision|0
6261825|NCT02059291|9956990|FG012|Epoch 3|Physician Decision|0
6261826|NCT02059291|9956991|FG013|Epoch 3|Physician Decision|1
6261827|NCT02059291|9956992|FG014|Epoch 3|Physician Decision|0
6261828|NCT02059291|9956993|FG015|Epoch 3|Physician Decision|1
6261829|NCT02059291|9956994|FG016|Epoch 3|Physician Decision|0
6261830|NCT02059291|9956995|FG017|Epoch 3|Physician Decision|0
6261831|NCT02059291|9956996|FG018|Epoch 3|Physician Decision|0
6261832|NCT02059291|9956997|FG019|Epoch 3|Physician Decision|0
6261833|NCT02059291|9956998|FG020|Epoch 3|Physician Decision|0
6261834|NCT02059291|9956999|FG021|Epoch 3|Physician Decision|0
6261835|NCT02059291|9957000|FG022|Epoch 3|Physician Decision|0
6261836|NCT02059291|9957001|FG023|Epoch 3|Physician Decision|0
6261837|NCT02059291|9957002|FG024|Epoch 3|Physician Decision|0
6261838|NCT02059291|9956978|FG000|Epoch 3|Adverse Event|0
6261839|NCT02059291|9956979|FG001|Epoch 3|Adverse Event|0
6261840|NCT02059291|9956980|FG002|Epoch 3|Adverse Event|0
6261841|NCT02059291|9956981|FG003|Epoch 3|Adverse Event|0
6261842|NCT02059291|9956982|FG004|Epoch 3|Adverse Event|0
6261843|NCT02059291|9956983|FG005|Epoch 3|Adverse Event|0
6261844|NCT02059291|9956984|FG006|Epoch 3|Adverse Event|0
6261845|NCT02059291|9956985|FG007|Epoch 3|Adverse Event|0
6261846|NCT02059291|9956986|FG008|Epoch 3|Adverse Event|0
6261847|NCT02059291|9956987|FG009|Epoch 3|Adverse Event|0
6261848|NCT02059291|9956988|FG010|Epoch 3|Adverse Event|0
6261849|NCT02059291|9956989|FG011|Epoch 3|Adverse Event|0
6261850|NCT02059291|9956990|FG012|Epoch 3|Adverse Event|0
6261851|NCT02059291|9956991|FG013|Epoch 3|Adverse Event|0
6261852|NCT02059291|9956992|FG014|Epoch 3|Adverse Event|0
6261853|NCT02059291|9956993|FG015|Epoch 3|Adverse Event|1
6261854|NCT02059291|9956994|FG016|Epoch 3|Adverse Event|0
6261855|NCT02059291|9956995|FG017|Epoch 3|Adverse Event|0
6261856|NCT02059291|9956996|FG018|Epoch 3|Adverse Event|0
6261857|NCT02059291|9956997|FG019|Epoch 3|Adverse Event|0
6261858|NCT02059291|9956998|FG020|Epoch 3|Adverse Event|0
6261859|NCT02059291|9956999|FG021|Epoch 3|Adverse Event|0
6261860|NCT02059291|9957000|FG022|Epoch 3|Adverse Event|0
6261861|NCT02059291|9957001|FG023|Epoch 3|Adverse Event|0
6261862|NCT02059291|9957002|FG024|Epoch 3|Adverse Event|0
6261863|NCT02059291|9956978|FG000|Epoch 3|Lack of Efficacy|0
6261864|NCT02059291|9956979|FG001|Epoch 3|Lack of Efficacy|0
6261865|NCT02059291|9956980|FG002|Epoch 3|Lack of Efficacy|0
6261866|NCT02059291|9956981|FG003|Epoch 3|Lack of Efficacy|0
6261867|NCT02059291|9956982|FG004|Epoch 3|Lack of Efficacy|0
6261868|NCT02059291|9956983|FG005|Epoch 3|Lack of Efficacy|0
6261869|NCT02059291|9956984|FG006|Epoch 3|Lack of Efficacy|0
6261870|NCT02059291|9956985|FG007|Epoch 3|Lack of Efficacy|0
6261871|NCT02059291|9956986|FG008|Epoch 3|Lack of Efficacy|0
6261872|NCT02059291|9956987|FG009|Epoch 3|Lack of Efficacy|0
6261873|NCT02059291|9956988|FG010|Epoch 3|Lack of Efficacy|0
6261874|NCT02059291|9956989|FG011|Epoch 3|Lack of Efficacy|0
6261875|NCT02059291|9956990|FG012|Epoch 3|Lack of Efficacy|0
6261876|NCT02059291|9956991|FG013|Epoch 3|Lack of Efficacy|0
6261877|NCT02059291|9956992|FG014|Epoch 3|Lack of Efficacy|0
6261878|NCT02059291|9956993|FG015|Epoch 3|Lack of Efficacy|3
6261879|NCT02059291|9956994|FG016|Epoch 3|Lack of Efficacy|0
6261880|NCT02059291|9956995|FG017|Epoch 3|Lack of Efficacy|0
6261881|NCT02059291|9956996|FG018|Epoch 3|Lack of Efficacy|0
6261882|NCT02059291|9956997|FG019|Epoch 3|Lack of Efficacy|0
6261883|NCT02059291|9956998|FG020|Epoch 3|Lack of Efficacy|0
6261884|NCT02059291|9956999|FG021|Epoch 3|Lack of Efficacy|0
6261885|NCT02059291|9957000|FG022|Epoch 3|Lack of Efficacy|0
6261886|NCT02059291|9957001|FG023|Epoch 3|Lack of Efficacy|0
6261887|NCT02059291|9957002|FG024|Epoch 3|Lack of Efficacy|0
6261888|NCT02059291|9956978|FG000|Epoch 3|Withdrawal by Subject|0
6261889|NCT02059291|9956979|FG001|Epoch 3|Withdrawal by Subject|0
6261890|NCT02059291|9956980|FG002|Epoch 3|Withdrawal by Subject|0
6261891|NCT02059291|9956981|FG003|Epoch 3|Withdrawal by Subject|0
6261892|NCT02059291|9956982|FG004|Epoch 3|Withdrawal by Subject|0
6261893|NCT02059291|9956983|FG005|Epoch 3|Withdrawal by Subject|0
6261894|NCT02059291|9956984|FG006|Epoch 3|Withdrawal by Subject|0
6261895|NCT02059291|9956985|FG007|Epoch 3|Withdrawal by Subject|0
6261896|NCT02059291|9956986|FG008|Epoch 3|Withdrawal by Subject|0
6261897|NCT02059291|9956987|FG009|Epoch 3|Withdrawal by Subject|0
6261898|NCT02059291|9956988|FG010|Epoch 3|Withdrawal by Subject|0
6261899|NCT02059291|9956989|FG011|Epoch 3|Withdrawal by Subject|0
6261900|NCT02059291|9956990|FG012|Epoch 3|Withdrawal by Subject|0
6261901|NCT02059291|9956991|FG013|Epoch 3|Withdrawal by Subject|0
6261902|NCT02059291|9956992|FG014|Epoch 3|Withdrawal by Subject|0
6261903|NCT02059291|9956993|FG015|Epoch 3|Withdrawal by Subject|1
6261904|NCT02059291|9956994|FG016|Epoch 3|Withdrawal by Subject|0
6261905|NCT02059291|9956995|FG017|Epoch 3|Withdrawal by Subject|0
6261906|NCT02059291|9956996|FG018|Epoch 3|Withdrawal by Subject|0
6261907|NCT02059291|9956997|FG019|Epoch 3|Withdrawal by Subject|0
6261908|NCT02059291|9956998|FG020|Epoch 3|Withdrawal by Subject|0
6261909|NCT02059291|9956999|FG021|Epoch 3|Withdrawal by Subject|0
6261910|NCT02059291|9957000|FG022|Epoch 3|Withdrawal by Subject|0
6261911|NCT02059291|9957001|FG023|Epoch 3|Withdrawal by Subject|0
6261912|NCT02059291|9957002|FG024|Epoch 3|Withdrawal by Subject|0
6261913|NCT02059291|9956978|FG000|Epoch 4|Adverse Event|0
6261914|NCT02059291|9956979|FG001|Epoch 4|Adverse Event|0
6261915|NCT02059291|9956980|FG002|Epoch 4|Adverse Event|0
6261916|NCT02059291|9956981|FG003|Epoch 4|Adverse Event|0
6086901|NCT00665366|9697038|FG000|Overall Study|Lost to Follow-up|3
6086902|NCT00665366|9697039|FG001|Overall Study|Lost to Follow-up|5
6261917|NCT02059291|9956982|FG004|Epoch 4|Adverse Event|0
6261918|NCT02059291|9956983|FG005|Epoch 4|Adverse Event|0
6261919|NCT02059291|9956984|FG006|Epoch 4|Adverse Event|0
6261920|NCT02059291|9956985|FG007|Epoch 4|Adverse Event|0
6261921|NCT02059291|9956986|FG008|Epoch 4|Adverse Event|0
6261922|NCT02059291|9956987|FG009|Epoch 4|Adverse Event|0
6261923|NCT02059291|9956988|FG010|Epoch 4|Adverse Event|0
6261924|NCT02059291|9956989|FG011|Epoch 4|Adverse Event|0
6261925|NCT02059291|9956990|FG012|Epoch 4|Adverse Event|0
6261926|NCT02059291|9956991|FG013|Epoch 4|Adverse Event|0
6261927|NCT02059291|9956992|FG014|Epoch 4|Adverse Event|0
6261928|NCT02059291|9956993|FG015|Epoch 4|Adverse Event|0
6261929|NCT02059291|9956994|FG016|Epoch 4|Adverse Event|1
6261930|NCT02059291|9956995|FG017|Epoch 4|Adverse Event|0
6261931|NCT02059291|9956996|FG018|Epoch 4|Adverse Event|0
6261932|NCT02059291|9956997|FG019|Epoch 4|Adverse Event|0
6261933|NCT02059291|9956998|FG020|Epoch 4|Adverse Event|0
6261934|NCT02059291|9956999|FG021|Epoch 4|Adverse Event|0
6261935|NCT02059291|9957000|FG022|Epoch 4|Adverse Event|1
6261936|NCT02059291|9957001|FG023|Epoch 4|Adverse Event|0
6261937|NCT02059291|9957002|FG024|Epoch 4|Adverse Event|0
6261938|NCT02059291|9956978|FG000|Epoch 4|Pregnancy|0
6261939|NCT02059291|9956979|FG001|Epoch 4|Pregnancy|0
6261940|NCT02059291|9956980|FG002|Epoch 4|Pregnancy|0
6261941|NCT02059291|9956981|FG003|Epoch 4|Pregnancy|0
6261942|NCT02059291|9956982|FG004|Epoch 4|Pregnancy|0
6261943|NCT02059291|9956983|FG005|Epoch 4|Pregnancy|0
6261944|NCT02059291|9956984|FG006|Epoch 4|Pregnancy|0
6261945|NCT02059291|9956985|FG007|Epoch 4|Pregnancy|0
6261946|NCT02059291|9956986|FG008|Epoch 4|Pregnancy|0
6261947|NCT02059291|9956987|FG009|Epoch 4|Pregnancy|0
6261948|NCT02059291|9956988|FG010|Epoch 4|Pregnancy|0
6261949|NCT02059291|9956989|FG011|Epoch 4|Pregnancy|0
6261950|NCT02059291|9956990|FG012|Epoch 4|Pregnancy|0
6261951|NCT02059291|9956991|FG013|Epoch 4|Pregnancy|0
6261952|NCT02059291|9956992|FG014|Epoch 4|Pregnancy|0
6261953|NCT02059291|9956993|FG015|Epoch 4|Pregnancy|0
6261954|NCT02059291|9956994|FG016|Epoch 4|Pregnancy|1
6261955|NCT02059291|9956995|FG017|Epoch 4|Pregnancy|0
6261956|NCT02059291|9956996|FG018|Epoch 4|Pregnancy|0
6261957|NCT02059291|9956997|FG019|Epoch 4|Pregnancy|0
6261958|NCT02059291|9956998|FG020|Epoch 4|Pregnancy|0
6261959|NCT02059291|9956999|FG021|Epoch 4|Pregnancy|0
6261960|NCT02059291|9957000|FG022|Epoch 4|Pregnancy|0
6261961|NCT02059291|9957001|FG023|Epoch 4|Pregnancy|0
6261962|NCT02059291|9957002|FG024|Epoch 4|Pregnancy|0
6261963|NCT02059291|9956978|FG000|Epoch 4|Withdrawal by Subject|0
6086903|NCT00665366|9697038|FG000|Overall Study|Poor compliance/noncompliance|3
6261964|NCT02059291|9956979|FG001|Epoch 4|Withdrawal by Subject|0
6261965|NCT02059291|9956980|FG002|Epoch 4|Withdrawal by Subject|0
6261966|NCT02059291|9956981|FG003|Epoch 4|Withdrawal by Subject|0
6261967|NCT02059291|9956982|FG004|Epoch 4|Withdrawal by Subject|0
6261968|NCT02059291|9956983|FG005|Epoch 4|Withdrawal by Subject|0
6261969|NCT02059291|9956984|FG006|Epoch 4|Withdrawal by Subject|0
6261970|NCT02059291|9956985|FG007|Epoch 4|Withdrawal by Subject|0
6261971|NCT02059291|9956986|FG008|Epoch 4|Withdrawal by Subject|0
6261972|NCT02059291|9956987|FG009|Epoch 4|Withdrawal by Subject|0
6261973|NCT02059291|9956988|FG010|Epoch 4|Withdrawal by Subject|0
6261974|NCT02059291|9956989|FG011|Epoch 4|Withdrawal by Subject|0
6261975|NCT02059291|9956990|FG012|Epoch 4|Withdrawal by Subject|0
6261976|NCT02059291|9956991|FG013|Epoch 4|Withdrawal by Subject|0
6261977|NCT02059291|9956992|FG014|Epoch 4|Withdrawal by Subject|0
6261978|NCT02059291|9956993|FG015|Epoch 4|Withdrawal by Subject|0
6261979|NCT02059291|9956994|FG016|Epoch 4|Withdrawal by Subject|0
6261980|NCT02059291|9956995|FG017|Epoch 4|Withdrawal by Subject|0
6261981|NCT02059291|9956996|FG018|Epoch 4|Withdrawal by Subject|0
6261982|NCT02059291|9956997|FG019|Epoch 4|Withdrawal by Subject|0
6261983|NCT02059291|9956998|FG020|Epoch 4|Withdrawal by Subject|1
6261984|NCT02059291|9956999|FG021|Epoch 4|Withdrawal by Subject|0
6261985|NCT02059291|9957000|FG022|Epoch 4|Withdrawal by Subject|0
6261986|NCT02059291|9957001|FG023|Epoch 4|Withdrawal by Subject|0
6261987|NCT02059291|9957002|FG024|Epoch 4|Withdrawal by Subject|0
6261988|NCT02059291|9956978|FG000|Epoch 4|Lack of Efficacy|0
6261989|NCT02059291|9956979|FG001|Epoch 4|Lack of Efficacy|0
6261990|NCT02059291|9956980|FG002|Epoch 4|Lack of Efficacy|0
6261991|NCT02059291|9956981|FG003|Epoch 4|Lack of Efficacy|0
6261992|NCT02059291|9956982|FG004|Epoch 4|Lack of Efficacy|0
6261993|NCT02059291|9956983|FG005|Epoch 4|Lack of Efficacy|0
6261994|NCT02059291|9956984|FG006|Epoch 4|Lack of Efficacy|0
6261995|NCT02059291|9956985|FG007|Epoch 4|Lack of Efficacy|0
6261996|NCT02059291|9956986|FG008|Epoch 4|Lack of Efficacy|0
6261997|NCT02059291|9956987|FG009|Epoch 4|Lack of Efficacy|0
6261998|NCT02059291|9956988|FG010|Epoch 4|Lack of Efficacy|0
6261999|NCT02059291|9956989|FG011|Epoch 4|Lack of Efficacy|0
6262000|NCT02059291|9956990|FG012|Epoch 4|Lack of Efficacy|0
6262001|NCT02059291|9956991|FG013|Epoch 4|Lack of Efficacy|0
6262002|NCT02059291|9956992|FG014|Epoch 4|Lack of Efficacy|0
6262003|NCT02059291|9956993|FG015|Epoch 4|Lack of Efficacy|0
6262004|NCT02059291|9956994|FG016|Epoch 4|Lack of Efficacy|0
6262005|NCT02059291|9956995|FG017|Epoch 4|Lack of Efficacy|0
6262006|NCT02059291|9956996|FG018|Epoch 4|Lack of Efficacy|0
6262007|NCT02059291|9956997|FG019|Epoch 4|Lack of Efficacy|0
6262008|NCT02059291|9956998|FG020|Epoch 4|Lack of Efficacy|0
6262009|NCT02059291|9956999|FG021|Epoch 4|Lack of Efficacy|0
6262010|NCT02059291|9957000|FG022|Epoch 4|Lack of Efficacy|0
6262011|NCT02059291|9957001|FG023|Epoch 4|Lack of Efficacy|1
6262012|NCT02059291|9957002|FG024|Epoch 4|Lack of Efficacy|0
6262013|NCT02059395|9957032|FG000|Overall Study|Lost to Follow-up|2
6262014|NCT02059395|9957033|FG001|Overall Study|Lost to Follow-up|4
6262015|NCT02059408|9957042|FG000|Overall Study|Did not get tested|0
6262016|NCT02059408|9957043|FG001|Overall Study|Did not get tested|330
6262017|NCT02059408|9957044|FG002|Overall Study|Did not get tested|358
6262018|NCT02059434|9957063|FG000|Washout Between Periods 1 and 2|Physician Decision|0
6262019|NCT02059434|9957064|FG001|Washout Between Periods 1 and 2|Physician Decision|0
6262020|NCT02059434|9957065|FG002|Washout Between Periods 1 and 2|Physician Decision|0
6262021|NCT02059434|9957066|FG003|Washout Between Periods 1 and 2|Physician Decision|0
6262022|NCT02059434|9957067|FG004|Washout Between Periods 1 and 2|Physician Decision|0
6262023|NCT02059434|9957068|FG005|Washout Between Periods 1 and 2|Physician Decision|0
6262024|NCT02059434|9957069|FG006|Washout Between Periods 1 and 2|Physician Decision|0
6262025|NCT02059434|9957070|FG007|Washout Between Periods 1 and 2|Physician Decision|1
6262026|NCT02059434|9957071|FG008|Washout Between Periods 1 and 2|Physician Decision|0
6262027|NCT02059434|9957063|FG000|Washout Between Periods 4 and 5|Adverse Event|0
6262028|NCT02059434|9957064|FG001|Washout Between Periods 4 and 5|Adverse Event|0
6262029|NCT02059434|9957065|FG002|Washout Between Periods 4 and 5|Adverse Event|0
6262030|NCT02059434|9957066|FG003|Washout Between Periods 4 and 5|Adverse Event|0
6262031|NCT02059434|9957067|FG004|Washout Between Periods 4 and 5|Adverse Event|0
6262032|NCT02059434|9957068|FG005|Washout Between Periods 4 and 5|Adverse Event|0
6262033|NCT02059434|9957069|FG006|Washout Between Periods 4 and 5|Adverse Event|0
6262034|NCT02059434|9957070|FG007|Washout Between Periods 4 and 5|Adverse Event|0
6262035|NCT02059434|9957071|FG008|Washout Between Periods 4 and 5|Adverse Event|1
6262036|NCT02059434|9957063|FG000|Washout Between Periods 6 and 7|Physician Decision|0
6262037|NCT02059434|9957064|FG001|Washout Between Periods 6 and 7|Physician Decision|0
6262038|NCT02059434|9957065|FG002|Washout Between Periods 6 and 7|Physician Decision|0
6262039|NCT02059434|9957066|FG003|Washout Between Periods 6 and 7|Physician Decision|0
6262040|NCT02059434|9957067|FG004|Washout Between Periods 6 and 7|Physician Decision|0
6262041|NCT02059434|9957068|FG005|Washout Between Periods 6 and 7|Physician Decision|0
6262042|NCT02059434|9957069|FG006|Washout Between Periods 6 and 7|Physician Decision|0
6262043|NCT02059434|9957070|FG007|Washout Between Periods 6 and 7|Physician Decision|0
6262044|NCT02059434|9957071|FG008|Washout Between Periods 6 and 7|Physician Decision|1
6262045|NCT02059434|9957063|FG000|Washout Between Periods 7 and 8|Adverse Event|0
6262046|NCT02059434|9957064|FG001|Washout Between Periods 7 and 8|Adverse Event|0
6262047|NCT02059434|9957065|FG002|Washout Between Periods 7 and 8|Adverse Event|0
6262048|NCT02059434|9957066|FG003|Washout Between Periods 7 and 8|Adverse Event|0
6262049|NCT02059434|9957067|FG004|Washout Between Periods 7 and 8|Adverse Event|0
6262050|NCT02059434|9957068|FG005|Washout Between Periods 7 and 8|Adverse Event|0
6262051|NCT02059434|9957069|FG006|Washout Between Periods 7 and 8|Adverse Event|0
6262052|NCT02059434|9957070|FG007|Washout Between Periods 7 and 8|Adverse Event|0
6262053|NCT02059434|9957071|FG008|Washout Between Periods 7 and 8|Adverse Event|1
6262054|NCT02059434|9957063|FG000|Washout Between Periods 7 and 8|Withdrawal by Subject|0
6262055|NCT02059434|9957064|FG001|Washout Between Periods 7 and 8|Withdrawal by Subject|0
6262056|NCT02059434|9957065|FG002|Washout Between Periods 7 and 8|Withdrawal by Subject|0
6262057|NCT02059434|9957066|FG003|Washout Between Periods 7 and 8|Withdrawal by Subject|0
6262058|NCT02059434|9957067|FG004|Washout Between Periods 7 and 8|Withdrawal by Subject|0
6262059|NCT02059434|9957068|FG005|Washout Between Periods 7 and 8|Withdrawal by Subject|0
6271911|NCT02169284|9974022|FG000|Overall Study|Physician Decision|0
6262060|NCT02059434|9957069|FG006|Washout Between Periods 7 and 8|Withdrawal by Subject|0
6262061|NCT02059434|9957070|FG007|Washout Between Periods 7 and 8|Withdrawal by Subject|0
6262062|NCT02059434|9957071|FG008|Washout Between Periods 7 and 8|Withdrawal by Subject|1
6262063|NCT02059980|9957152|FG000|Overall Study|Lost to Follow-up|2
6262064|NCT02059980|9957153|FG001|Overall Study|Lost to Follow-up|1
6262065|NCT02060370|9957182|FG000|Overall Study|Physician Decision|1
6262066|NCT02060383|9957191|FG000|Core Phase|Unsatisfactory therapeutic effect|1
6262067|NCT02060383|9957192|FG001|Core Phase|Unsatisfactory therapeutic effect|5
6262068|NCT02060383|9957193|FG002|Core Phase|Unsatisfactory therapeutic effect|0
6262069|NCT02060383|9957194|FG003|Core Phase|Unsatisfactory therapeutic effect|0
6262070|NCT02060383|9957195|FG004|Core Phase|Unsatisfactory therapeutic effect|0
6262071|NCT02060383|9957191|FG000|Core Phase|Adverse Event|2
6262072|NCT02060383|9957192|FG001|Core Phase|Adverse Event|0
6262073|NCT02060383|9957193|FG002|Core Phase|Adverse Event|0
6262074|NCT02060383|9957194|FG003|Core Phase|Adverse Event|2
6262075|NCT02060383|9957195|FG004|Core Phase|Adverse Event|6
6262076|NCT02060383|9957191|FG000|Core Phase|Administrative problems|0
6262077|NCT02060383|9957192|FG001|Core Phase|Administrative problems|1
6262078|NCT02060383|9957193|FG002|Core Phase|Administrative problems|0
6262079|NCT02060383|9957194|FG003|Core Phase|Administrative problems|0
6262080|NCT02060383|9957195|FG004|Core Phase|Administrative problems|0
6262081|NCT02060383|9957191|FG000|Core Phase|Protocol Violation|0
6262082|NCT02060383|9957192|FG001|Core Phase|Protocol Violation|0
6262083|NCT02060383|9957193|FG002|Core Phase|Protocol Violation|0
6262084|NCT02060383|9957194|FG003|Core Phase|Protocol Violation|1
6262085|NCT02060383|9957195|FG004|Core Phase|Protocol Violation|0
6262086|NCT02060383|9957191|FG000|Core Phase|Withdrawal by Subject|0
6262087|NCT02060383|9957192|FG001|Core Phase|Withdrawal by Subject|0
6262088|NCT02060383|9957193|FG002|Core Phase|Withdrawal by Subject|0
6262089|NCT02060383|9957194|FG003|Core Phase|Withdrawal by Subject|4
6262090|NCT02060383|9957195|FG004|Core Phase|Withdrawal by Subject|2
6262091|NCT02060383|9957191|FG000|Extension Phase|Unsatisfactory therapeutic effect|1
6262092|NCT02060383|9957192|FG001|Extension Phase|Unsatisfactory therapeutic effect|1
6262093|NCT02060383|9957193|FG002|Extension Phase|Unsatisfactory therapeutic effect|0
6262094|NCT02060383|9957194|FG003|Extension Phase|Unsatisfactory therapeutic effect|2
6262095|NCT02060383|9957195|FG004|Extension Phase|Unsatisfactory therapeutic effect|2
6262096|NCT02060383|9957191|FG000|Extension Phase|Adverse Event|1
6262097|NCT02060383|9957192|FG001|Extension Phase|Adverse Event|1
6262098|NCT02060383|9957193|FG002|Extension Phase|Adverse Event|2
6262099|NCT02060383|9957194|FG003|Extension Phase|Adverse Event|0
6262100|NCT02060383|9957195|FG004|Extension Phase|Adverse Event|1
6262101|NCT02060383|9957191|FG000|Extension Phase|Withdrawal by Subject|0
6262102|NCT02060383|9957192|FG001|Extension Phase|Withdrawal by Subject|1
6262103|NCT02060383|9957193|FG002|Extension Phase|Withdrawal by Subject|0
6262104|NCT02060383|9957194|FG003|Extension Phase|Withdrawal by Subject|0
6262105|NCT02060383|9957195|FG004|Extension Phase|Withdrawal by Subject|2
6262106|NCT02060383|9957191|FG000|Extension Phase|Administrative problems|1
6262107|NCT02060383|9957192|FG001|Extension Phase|Administrative problems|0
6262108|NCT02060383|9957193|FG002|Extension Phase|Administrative problems|0
6262109|NCT02060383|9957194|FG003|Extension Phase|Administrative problems|0
6262110|NCT02060383|9957195|FG004|Extension Phase|Administrative problems|0
6262111|NCT02060383|9957191|FG000|Extension Phase|Death|0
6262112|NCT02060383|9957192|FG001|Extension Phase|Death|0
6262113|NCT02060383|9957193|FG002|Extension Phase|Death|1
6262114|NCT02060383|9957194|FG003|Extension Phase|Death|0
6262115|NCT02060383|9957195|FG004|Extension Phase|Death|1
6262116|NCT02060383|9957191|FG000|Extension Phase|Protocol Violation|0
6262117|NCT02060383|9957192|FG001|Extension Phase|Protocol Violation|0
6262118|NCT02060383|9957193|FG002|Extension Phase|Protocol Violation|0
6262119|NCT02060383|9957194|FG003|Extension Phase|Protocol Violation|0
6262120|NCT02060383|9957195|FG004|Extension Phase|Protocol Violation|1
6262121|NCT02060903|9957248|FG000|Overall Study|Lost to Follow-up|4
6262122|NCT02060903|9957249|FG001|Overall Study|Lost to Follow-up|0
6262123|NCT02060903|9957248|FG000|Overall Study|Withdrawal by Subject|0
6262124|NCT02060903|9957249|FG001|Overall Study|Withdrawal by Subject|7
6262125|NCT02061202|9957257|FG000|Overall Study|Lost to Follow-up|1
6262126|NCT02061202|9957258|FG001|Overall Study|Lost to Follow-up|1
6262127|NCT02061280|9957266|FG000|Overall Study|Protocol Violation|12
6262128|NCT02061280|9957267|FG001|Overall Study|Protocol Violation|8
6262129|NCT02061280|9957266|FG000|Overall Study|moved out of state|0
6262130|NCT02061280|9957267|FG001|Overall Study|moved out of state|1
6262131|NCT02061280|9957266|FG000|Overall Study|Withdrawal by Subject|1
6262132|NCT02061280|9957267|FG001|Overall Study|Withdrawal by Subject|2
6262133|NCT02061280|9957266|FG000|Overall Study|Lost to Follow-up|5
6262134|NCT02061280|9957267|FG001|Overall Study|Lost to Follow-up|1
6262135|NCT02061540|9957326|FG000|Overall Study|Adverse Event|2
6262136|NCT02061540|9957326|FG000|Overall Study|Withdrawal by Subject|2
6262137|NCT02061592|9957337|FG000|Period 1|Withdrawal by Subject|1
6262138|NCT02061592|9957338|FG001|Period 1|Withdrawal by Subject|0
6262139|NCT02061592|9957337|FG000|Period 1|Protocol Violation|1
6262140|NCT02061592|9957338|FG001|Period 1|Protocol Violation|0
6262141|NCT02061592|9957337|FG000|Period 2|Lost to Follow-up|0
6262142|NCT02061592|9957338|FG001|Period 2|Lost to Follow-up|1
6262143|NCT02061813|9957377|FG000|Overall Study|Withdrawal by Subject|1
6262144|NCT02061813|9957377|FG000|Overall Study|Protocol Violation|2
6262145|NCT02062151|9957397|FG000|Overall Study|screen failure|1
6262146|NCT02062385|9957422|FG000|Overall Study|Adverse Event|19
6262147|NCT02062385|9957423|FG001|Overall Study|Adverse Event|13
6262148|NCT02062385|9957424|FG002|Overall Study|Adverse Event|1
6262149|NCT02062385|9957425|FG003|Overall Study|Adverse Event|0
6262150|NCT02062385|9957422|FG000|Overall Study|Protocol Violation|1
6262151|NCT02062385|9957423|FG001|Overall Study|Protocol Violation|0
6262152|NCT02062385|9957424|FG002|Overall Study|Protocol Violation|0
6262153|NCT02062385|9957425|FG003|Overall Study|Protocol Violation|0
6262154|NCT02062385|9957422|FG000|Overall Study|Incomplete EPI by database lock|2
6262155|NCT02062385|9957423|FG001|Overall Study|Incomplete EPI by database lock|0
6262156|NCT02062385|9957424|FG002|Overall Study|Incomplete EPI by database lock|0
6262157|NCT02062385|9957425|FG003|Overall Study|Incomplete EPI by database lock|0
6262158|NCT02062385|9957422|FG000|Overall Study|Moved|10
6262159|NCT02062385|9957423|FG001|Overall Study|Moved|11
6262160|NCT02062385|9957424|FG002|Overall Study|Moved|1
6262161|NCT02062385|9957425|FG003|Overall Study|Moved|0
6262162|NCT02062385|9957422|FG000|Overall Study|Withdrawn by parent/guardian|46
6262163|NCT02062385|9957423|FG001|Overall Study|Withdrawn by parent/guardian|41
6262164|NCT02062385|9957424|FG002|Overall Study|Withdrawn by parent/guardian|9
6262165|NCT02062385|9957425|FG003|Overall Study|Withdrawn by parent/guardian|8
6262166|NCT02062385|9957422|FG000|Overall Study|Death|0
6262167|NCT02062385|9957423|FG001|Overall Study|Death|0
6262168|NCT02062385|9957424|FG002|Overall Study|Death|0
6262169|NCT02062385|9957425|FG003|Overall Study|Death|1
6262170|NCT02062385|9957422|FG000|Overall Study|Lost to Follow-up|0
6262171|NCT02062385|9957423|FG001|Overall Study|Lost to Follow-up|0
6262172|NCT02062385|9957424|FG002|Overall Study|Lost to Follow-up|1
6262173|NCT02062385|9957425|FG003|Overall Study|Lost to Follow-up|0
6262174|NCT02062398|9957433|FG000|Overall Study|Implant removal|1
6262175|NCT02062437|9957437|FG000|Overall Study|Pt. didn't want to come for the 2y visit|31
6262176|NCT02062437|9957437|FG000|Overall Study|Patient not available for the 2y visit|18
6262177|NCT02062437|9957437|FG000|Overall Study|Death|2
6262178|NCT02062437|9957437|FG000|Overall Study|Pt. couldn't come due to med. condition|1
6262179|NCT02062450|9957443|FG000|Overall Study|No follow-up visit|124
6262180|NCT02062632|9957511|FG000|Overall Study|No treatment data|1
6262181|NCT02062645|9957515|FG000|Overall Study|Adverse Event|2
6262182|NCT02062645|9957515|FG000|Overall Study|Protocol Violation|8
6262183|NCT02062645|9957515|FG000|Overall Study|Lost to Follow-up|5
6262184|NCT02062658|9957519|FG000|Overall Study|Withdrawal by Subject|1
6262185|NCT02062658|9957519|FG000|Overall Study|Lack of Efficacy|1
6262186|NCT02062879|9957547|FG000|Overall Study|Withdrawal by Subject|4
6262187|NCT02062879|9957548|FG001|Overall Study|Withdrawal by Subject|1
6262188|NCT02063217|9957597|FG000|Overall Study|Withdrawal by Subject|1
6262189|NCT02063217|9957598|FG001|Overall Study|Withdrawal by Subject|0
6262190|NCT02063217|9957599|FG002|Overall Study|Withdrawal by Subject|0
6262191|NCT02063659|9957636|FG000|Double-Blind Treatment Period|Adverse Event|1
6262192|NCT02063659|9957637|FG001|Double-Blind Treatment Period|Adverse Event|2
6262193|NCT02063659|9957638|FG002|Double-Blind Treatment Period|Adverse Event|0
6262194|NCT02063659|9957639|FG003|Double-Blind Treatment Period|Adverse Event|0
6262195|NCT02063659|9957636|FG000|Double-Blind Treatment Period|Physician Decision|1
6262196|NCT02063659|9957637|FG001|Double-Blind Treatment Period|Physician Decision|0
6262197|NCT02063659|9957638|FG002|Double-Blind Treatment Period|Physician Decision|0
6262198|NCT02063659|9957639|FG003|Double-Blind Treatment Period|Physician Decision|0
6262199|NCT02063659|9957636|FG000|Double-Blind Treatment Period|Withdrawal of consent|0
6262200|NCT02063659|9957637|FG001|Double-Blind Treatment Period|Withdrawal of consent|1
6262201|NCT02063659|9957638|FG002|Double-Blind Treatment Period|Withdrawal of consent|3
6262202|NCT02063659|9957639|FG003|Double-Blind Treatment Period|Withdrawal of consent|0
6262203|NCT02063659|9957636|FG000|Open-Label Extension Period (OLE)|Physician Decision|0
6262204|NCT02063659|9957637|FG001|Open-Label Extension Period (OLE)|Physician Decision|0
6262205|NCT02063659|9957638|FG002|Open-Label Extension Period (OLE)|Physician Decision|0
6262206|NCT02063659|9957639|FG003|Open-Label Extension Period (OLE)|Physician Decision|1
6262207|NCT02063659|9957636|FG000|Open-Label Extension Period (OLE)|Withdrawal of Consent|0
6262208|NCT02063659|9957637|FG001|Open-Label Extension Period (OLE)|Withdrawal of Consent|0
6262209|NCT02063659|9957638|FG002|Open-Label Extension Period (OLE)|Withdrawal of Consent|0
6262210|NCT02063659|9957639|FG003|Open-Label Extension Period (OLE)|Withdrawal of Consent|9
6262211|NCT02063659|9957636|FG000|Open-Label Extension Period (OLE)|Lack of Efficacy|0
6262212|NCT02063659|9957637|FG001|Open-Label Extension Period (OLE)|Lack of Efficacy|0
6262213|NCT02063659|9957638|FG002|Open-Label Extension Period (OLE)|Lack of Efficacy|0
6262214|NCT02063659|9957639|FG003|Open-Label Extension Period (OLE)|Lack of Efficacy|1
6262215|NCT02063659|9957636|FG000|Open-Label Extension Period (OLE)|Adverse Event|0
6262216|NCT02063659|9957637|FG001|Open-Label Extension Period (OLE)|Adverse Event|0
6262217|NCT02063659|9957638|FG002|Open-Label Extension Period (OLE)|Adverse Event|0
6262218|NCT02063659|9957639|FG003|Open-Label Extension Period (OLE)|Adverse Event|7
6262219|NCT02063659|9957636|FG000|Open-Label Extension Period (OLE)|Reason not Specified|0
6262220|NCT02063659|9957637|FG001|Open-Label Extension Period (OLE)|Reason not Specified|0
6262221|NCT02063659|9957638|FG002|Open-Label Extension Period (OLE)|Reason not Specified|0
6262222|NCT02063659|9957639|FG003|Open-Label Extension Period (OLE)|Reason not Specified|2
6262223|NCT02063672|9957655|FG000|Overall Study|Ongoing Follow-up|27
6262224|NCT02063672|9957656|FG001|Overall Study|Ongoing Follow-up|14
6262225|NCT02063672|9957655|FG000|Overall Study|Death|5
6262226|NCT02063672|9957656|FG001|Overall Study|Death|3
6262227|NCT02063672|9957655|FG000|Overall Study|Lost to Follow-up|1
6262228|NCT02063672|9957656|FG001|Overall Study|Lost to Follow-up|3
6262229|NCT02063672|9957655|FG000|Overall Study|Withdrawal by Subject|2
6262230|NCT02063672|9957656|FG001|Overall Study|Withdrawal by Subject|2
6262231|NCT02063698|9957664|FG000|Overall Study|did not complete booklet for days 2-8|1
6262232|NCT02063698|9957665|FG001|Overall Study|did not complete booklet for days 2-8|2
6262233|NCT02063737|9957673|FG000|Overall Study|Lost to Follow-up|11
6262234|NCT02063737|9957674|FG001|Overall Study|Lost to Follow-up|4
6262235|NCT02063828|9957683|FG000|Overall Study|Withdrawal by Subject|4
6262236|NCT02063828|9957684|FG001|Overall Study|Withdrawal by Subject|6
6262237|NCT02063828|9957685|FG002|Overall Study|Withdrawal by Subject|3
6262238|NCT02063828|9957683|FG000|Overall Study|Death|0
6262239|NCT02063828|9957684|FG001|Overall Study|Death|0
6262240|NCT02063828|9957685|FG002|Overall Study|Death|1
6262241|NCT02063854|9957700|FG000|Overall Study|Pretreatment Event/Adverse Event|13
6262242|NCT02063854|9957701|FG001|Overall Study|Pretreatment Event/Adverse Event|10
6262243|NCT02063854|9957702|FG002|Overall Study|Pretreatment Event/Adverse Event|13
6262244|NCT02063854|9957703|FG003|Overall Study|Pretreatment Event/Adverse Event|8
6262245|NCT02063854|9957704|FG004|Overall Study|Pretreatment Event/Adverse Event|7
6262246|NCT02063854|9957705|FG005|Overall Study|Pretreatment Event/Adverse Event|18
6262247|NCT02063854|9957706|FG006|Overall Study|Pretreatment Event/Adverse Event|4
6262248|NCT02063854|9957700|FG000|Overall Study|Major Protocol Deviation|0
6262249|NCT02063854|9957701|FG001|Overall Study|Major Protocol Deviation|0
6262250|NCT02063854|9957702|FG002|Overall Study|Major Protocol Deviation|3
6262251|NCT02063854|9957703|FG003|Overall Study|Major Protocol Deviation|0
6262252|NCT02063854|9957704|FG004|Overall Study|Major Protocol Deviation|0
6262253|NCT02063854|9957705|FG005|Overall Study|Major Protocol Deviation|0
6262254|NCT02063854|9957706|FG006|Overall Study|Major Protocol Deviation|0
6262255|NCT02063854|9957700|FG000|Overall Study|Voluntary Withdrawal|2
6262256|NCT02063854|9957701|FG001|Overall Study|Voluntary Withdrawal|0
6262257|NCT02063854|9957702|FG002|Overall Study|Voluntary Withdrawal|8
6262258|NCT02063854|9957703|FG003|Overall Study|Voluntary Withdrawal|1
6262259|NCT02063854|9957704|FG004|Overall Study|Voluntary Withdrawal|3
6262260|NCT02063854|9957705|FG005|Overall Study|Voluntary Withdrawal|6
6262261|NCT02063854|9957706|FG006|Overall Study|Voluntary Withdrawal|1
6262262|NCT02063854|9957700|FG000|Overall Study|Surgical Dental Work Performed/Planned|5
6262263|NCT02063854|9957701|FG001|Overall Study|Surgical Dental Work Performed/Planned|2
6262264|NCT02063854|9957702|FG002|Overall Study|Surgical Dental Work Performed/Planned|6
6262265|NCT02063854|9957703|FG003|Overall Study|Surgical Dental Work Performed/Planned|1
6262266|NCT02063854|9957704|FG004|Overall Study|Surgical Dental Work Performed/Planned|1
6262267|NCT02063854|9957705|FG005|Overall Study|Surgical Dental Work Performed/Planned|6
6262268|NCT02063854|9957706|FG006|Overall Study|Surgical Dental Work Performed/Planned|1
6262269|NCT02063854|9957700|FG000|Overall Study|Reason Not Specified|1
6262270|NCT02063854|9957701|FG001|Overall Study|Reason Not Specified|0
6262271|NCT02063854|9957702|FG002|Overall Study|Reason Not Specified|0
6262272|NCT02063854|9957703|FG003|Overall Study|Reason Not Specified|0
6262273|NCT02063854|9957704|FG004|Overall Study|Reason Not Specified|0
6262274|NCT02063854|9957705|FG005|Overall Study|Reason Not Specified|0
6262275|NCT02063854|9957706|FG006|Overall Study|Reason Not Specified|0
6262276|NCT02063854|9957700|FG000|Overall Study|Did Not Receive Study Drug|0
6262277|NCT02063854|9957701|FG001|Overall Study|Did Not Receive Study Drug|0
6262278|NCT02063854|9957702|FG002|Overall Study|Did Not Receive Study Drug|0
6262279|NCT02063854|9957703|FG003|Overall Study|Did Not Receive Study Drug|0
6262280|NCT02063854|9957704|FG004|Overall Study|Did Not Receive Study Drug|0
6262281|NCT02063854|9957705|FG005|Overall Study|Did Not Receive Study Drug|1
6262282|NCT02063854|9957706|FG006|Overall Study|Did Not Receive Study Drug|0
6262283|NCT02063880|9957735|FG000|Overall Study|Death|21
6262284|NCT02063880|9957736|FG001|Overall Study|Death|18
6262285|NCT02063880|9957735|FG000|Overall Study|Lost to Follow-up|7
6262286|NCT02063880|9957736|FG001|Overall Study|Lost to Follow-up|7
6262287|NCT02063880|9957735|FG000|Overall Study|Ineligible|0
6262288|NCT02063880|9957736|FG001|Overall Study|Ineligible|2
6271405|NCT02163499|9973141|FG000|Extended Dosing Phase: ZS|Lost to Follow-up|31
6271406|NCT02163499|9973141|FG000|Extended Dosing Phase: ZS|Protocol Violation|2
6271407|NCT02163499|9973141|FG000|Extended Dosing Phase: ZS|Death|8
6271408|NCT02163499|9973141|FG000|Extended Dosing Phase: ZS|Subject Compliance|17
6271409|NCT02163499|9973141|FG000|Extended Dosing Phase: ZS|Hyperkalemia|5
6271410|NCT02163499|9973141|FG000|Extended Dosing Phase: ZS|Various reasons|16
6271411|NCT02163538|9973151|FG000|Overall Study|Protocol Violation|1
6271412|NCT02163538|9973152|FG001|Overall Study|Protocol Violation|0
6271413|NCT02163538|9973151|FG000|Overall Study|Physician Decision|0
6271414|NCT02163538|9973152|FG001|Overall Study|Physician Decision|1
6271415|NCT02163759|9973170|FG000|Overall Study|Withdrawal by Subject|1
6271416|NCT02163759|9973171|FG001|Overall Study|Withdrawal by Subject|5
6271417|NCT02163759|9973172|FG002|Overall Study|Withdrawal by Subject|1
6271418|NCT02163759|9973170|FG000|Overall Study|Adverse Event|0
6271419|NCT02163759|9973171|FG001|Overall Study|Adverse Event|0
6262289|NCT02063984|9957744|FG000|Overall Study|Lost to Follow-up|6
6262290|NCT02063984|9957745|FG001|Overall Study|Lost to Follow-up|5
6262291|NCT02064166|9957757|FG000|Overall Study|Adverse Event|1
6262292|NCT02064166|9957758|FG001|Overall Study|Adverse Event|0
6262293|NCT02064205|9957786|FG000|Overall Study|Withdrawal by Subject|1
6262294|NCT02064231|9957802|FG000|First Test Period (Test A or Test C)|Lack of Efficacy|5
6262295|NCT02064231|9957803|FG001|First Test Period (Test A or Test C)|Lack of Efficacy|3
6262296|NCT02064231|9957804|FG002|First Test Period (Test A or Test C)|Lack of Efficacy|0
6262297|NCT02064231|9957805|FG003|First Test Period (Test A or Test C)|Lack of Efficacy|0
6262298|NCT02064231|9957802|FG000|First Test Period (Test A or Test C)|Withdrawal by Subject|1
6262299|NCT02064231|9957803|FG001|First Test Period (Test A or Test C)|Withdrawal by Subject|1
6262300|NCT02064231|9957804|FG002|First Test Period (Test A or Test C)|Withdrawal by Subject|0
6262301|NCT02064231|9957805|FG003|First Test Period (Test A or Test C)|Withdrawal by Subject|0
6262302|NCT02064231|9957802|FG000|First Test Period (Test A or Test C)|Adverse Event|1
6262303|NCT02064231|9957803|FG001|First Test Period (Test A or Test C)|Adverse Event|0
6262304|NCT02064231|9957804|FG002|First Test Period (Test A or Test C)|Adverse Event|1
6262305|NCT02064231|9957805|FG003|First Test Period (Test A or Test C)|Adverse Event|0
6262306|NCT02064231|9957802|FG000|Second Test Period (Test B or Test D)|Lack of Efficacy|1
6262307|NCT02064231|9957803|FG001|Second Test Period (Test B or Test D)|Lack of Efficacy|1
6262308|NCT02064231|9957804|FG002|Second Test Period (Test B or Test D)|Lack of Efficacy|0
6262309|NCT02064231|9957805|FG003|Second Test Period (Test B or Test D)|Lack of Efficacy|0
6262310|NCT02064439|9957829|FG000|Overall Study|Adverse Event|51
6262311|NCT02064439|9957830|FG001|Overall Study|Adverse Event|47
6262312|NCT02064439|9957831|FG002|Overall Study|Adverse Event|46
6262313|NCT02064439|9957829|FG000|Overall Study|Death|0
6262314|NCT02064439|9957830|FG001|Overall Study|Death|2
6262315|NCT02064439|9957831|FG002|Overall Study|Death|3
6262316|NCT02064439|9957829|FG000|Overall Study|Withdrawal by Subject|29
6262317|NCT02064439|9957830|FG001|Overall Study|Withdrawal by Subject|18
6262318|NCT02064439|9957831|FG002|Overall Study|Withdrawal by Subject|26
6262319|NCT02064439|9957829|FG000|Overall Study|Protocol Violation|3
6262320|NCT02064439|9957830|FG001|Overall Study|Protocol Violation|5
6262321|NCT02064439|9957831|FG002|Overall Study|Protocol Violation|3
6262322|NCT02064439|9957829|FG000|Overall Study|Lost to Follow-up|1
6262323|NCT02064439|9957830|FG001|Overall Study|Lost to Follow-up|3
6262324|NCT02064439|9957831|FG002|Overall Study|Lost to Follow-up|4
6262325|NCT02064439|9957829|FG000|Overall Study|Non-compliance with study medication|21
6262326|NCT02064439|9957830|FG001|Overall Study|Non-compliance with study medication|19
6262327|NCT02064439|9957831|FG002|Overall Study|Non-compliance with study medication|23
6262328|NCT02064439|9957829|FG000|Overall Study|Physician Decision|0
6262329|NCT02064439|9957830|FG001|Overall Study|Physician Decision|1
6262330|NCT02064439|9957831|FG002|Overall Study|Physician Decision|1
6262331|NCT02064439|9957829|FG000|Overall Study|Logistical difficulties|6
6262332|NCT02064439|9957830|FG001|Overall Study|Logistical difficulties|5
6262333|NCT02064439|9957831|FG002|Overall Study|Logistical difficulties|2
6262334|NCT02064439|9957829|FG000|Overall Study|Efficacy outcome reached|18
6262335|NCT02064439|9957830|FG001|Overall Study|Efficacy outcome reached|16
6262336|NCT02064439|9957831|FG002|Overall Study|Efficacy outcome reached|57
6262337|NCT02064439|9957829|FG000|Overall Study|Safety outcome reached|12
6262338|NCT02064439|9957830|FG001|Overall Study|Safety outcome reached|20
6262339|NCT02064439|9957831|FG002|Overall Study|Safety outcome reached|10
6262340|NCT02064439|9957829|FG000|Overall Study|Other|2
6262341|NCT02064439|9957830|FG001|Overall Study|Other|2
6262342|NCT02064439|9957831|FG002|Overall Study|Other|7
6262343|NCT02064816|9957845|FG000|Overall Study|Adverse Event|3
6262344|NCT02064816|9957846|FG001|Overall Study|Adverse Event|2
6262345|NCT02064816|9957845|FG000|Overall Study|Withdrawal by Subject|2
6262346|NCT02064816|9957846|FG001|Overall Study|Withdrawal by Subject|1
6262347|NCT02064816|9957845|FG000|Overall Study|Lost to Follow-up|2
6262348|NCT02064816|9957846|FG001|Overall Study|Lost to Follow-up|1
6262349|NCT02064816|9957845|FG000|Overall Study|Therapeutic failure|0
6262350|NCT02064816|9957846|FG001|Overall Study|Therapeutic failure|1
6262351|NCT02064816|9957845|FG000|Overall Study|Other|1
6262352|NCT02064816|9957846|FG001|Overall Study|Other|3
6262353|NCT02064868|9957901|FG000|Overall Study|Lost to Follow-up|14
6262354|NCT02064868|9957902|FG001|Overall Study|Lost to Follow-up|8
6262355|NCT02064868|9957901|FG000|Overall Study|Physician Decision|1
6262356|NCT02064868|9957902|FG001|Overall Study|Physician Decision|0
6262357|NCT02064868|9957901|FG000|Overall Study|Withdrawal by Subject|14
6262358|NCT02064868|9957902|FG001|Overall Study|Withdrawal by Subject|3
6262359|NCT02064868|9957901|FG000|Overall Study|Technical Problems or Missing|5
6262360|NCT02064868|9957902|FG001|Overall Study|Technical Problems or Missing|2
6262361|NCT02064894|9957911|FG000|Overall Study|Withdrawal by Subject|43
6262362|NCT02064894|9957912|FG001|Overall Study|Withdrawal by Subject|102
6262363|NCT02064894|9957913|FG002|Overall Study|Withdrawal by Subject|115
6262364|NCT02064920|9957932|FG000|Overall Study|Adverse Event|0
6262365|NCT02064920|9957933|FG001|Overall Study|Adverse Event|4
6262366|NCT02064920|9957932|FG000|Overall Study|Physician Decision|0
6262367|NCT02064920|9957933|FG001|Overall Study|Physician Decision|1
6262368|NCT02064920|9957932|FG000|Overall Study|Technical Problems|0
6262369|NCT02064920|9957933|FG001|Overall Study|Technical Problems|1
6262370|NCT02064920|9957932|FG000|Overall Study|Withdrawal by Subject|1
6262371|NCT02064920|9957933|FG001|Overall Study|Withdrawal by Subject|3
6262372|NCT02065245|9957968|FG000|Infusion 1|Lost to Follow-up|0
6262373|NCT02065245|9957969|FG001|Infusion 1|Lost to Follow-up|0
6262374|NCT02065245|9957970|FG002|Infusion 1|Lost to Follow-up|0
6262375|NCT02065245|9957971|FG003|Infusion 1|Lost to Follow-up|0
6262376|NCT02065245|9957972|FG004|Infusion 1|Lost to Follow-up|0
6262377|NCT02065245|9957973|FG005|Infusion 1|Lost to Follow-up|0
6262378|NCT02065245|9957974|FG006|Infusion 1|Lost to Follow-up|1
6262379|NCT02065245|9957968|FG000|Infusion 1|Death|0
6262380|NCT02065245|9957969|FG001|Infusion 1|Death|0
6262381|NCT02065245|9957970|FG002|Infusion 1|Death|1
6262382|NCT02065245|9957971|FG003|Infusion 1|Death|0
6262383|NCT02065245|9957972|FG004|Infusion 1|Death|1
6262384|NCT02065245|9957973|FG005|Infusion 1|Death|0
6262385|NCT02065245|9957974|FG006|Infusion 1|Death|0
6262386|NCT02065245|9957968|FG000|Infusion 2|Death|0
6262387|NCT02065245|9957969|FG001|Infusion 2|Death|0
6262388|NCT02065245|9957970|FG002|Infusion 2|Death|0
6262389|NCT02065245|9957971|FG003|Infusion 2|Death|0
6262390|NCT02065245|9957972|FG004|Infusion 2|Death|0
6262391|NCT02065245|9957973|FG005|Infusion 2|Death|0
6262392|NCT02065245|9957974|FG006|Infusion 2|Death|1
6262393|NCT02065245|9957968|FG000|Infusion 3|Lost to Follow-up|1
6262394|NCT02065245|9957969|FG001|Infusion 3|Lost to Follow-up|1
6262395|NCT02065245|9957970|FG002|Infusion 3|Lost to Follow-up|0
6262396|NCT02065245|9957971|FG003|Infusion 3|Lost to Follow-up|0
6262397|NCT02065245|9957972|FG004|Infusion 3|Lost to Follow-up|0
6262398|NCT02065245|9957973|FG005|Infusion 3|Lost to Follow-up|0
6262399|NCT02065245|9957974|FG006|Infusion 3|Lost to Follow-up|0
6262400|NCT02065336|9957998|FG000|Extension Phase|Study Terminated by Sponsor|0
6262401|NCT02065336|9957999|FG001|Extension Phase|Study Terminated by Sponsor|0
6262402|NCT02065336|9958000|FG002|Extension Phase|Study Terminated by Sponsor|0
6262403|NCT02065336|9958001|FG003|Extension Phase|Study Terminated by Sponsor|0
6262404|NCT02065336|9958002|FG004|Extension Phase|Study Terminated by Sponsor|0
6262405|NCT02065336|9958003|FG005|Extension Phase|Study Terminated by Sponsor|0
6262406|NCT02065336|9958004|FG006|Extension Phase|Study Terminated by Sponsor|0
6262407|NCT02065336|9958005|FG007|Extension Phase|Study Terminated by Sponsor|0
6262408|NCT02065336|9958006|FG008|Extension Phase|Study Terminated by Sponsor|2
6262409|NCT02065336|9958007|FG009|Extension Phase|Study Terminated by Sponsor|8
6262410|NCT02065518|9958059|FG000|Overall Study|Lost to Follow-up|3
6262411|NCT02065518|9958060|FG001|Overall Study|Lost to Follow-up|4
6262412|NCT02065518|9958061|FG002|Overall Study|Lost to Follow-up|0
6262413|NCT02065518|9958062|FG003|Overall Study|Lost to Follow-up|3
6262414|NCT02065518|9958059|FG000|Overall Study|Withdrawal by Subject|3
6262415|NCT02065518|9958060|FG001|Overall Study|Withdrawal by Subject|4
6262416|NCT02065518|9958061|FG002|Overall Study|Withdrawal by Subject|9
6262417|NCT02065518|9958062|FG003|Overall Study|Withdrawal by Subject|2
6262418|NCT02065557|9958075|FG000|Induction Period|Withdrawal by Subject|2
6262419|NCT02065557|9958076|FG001|Induction Period|Withdrawal by Subject|1
6262420|NCT02065557|9958077|FG002|Induction Period|Withdrawal by Subject|0
6262421|NCT02065557|9958078|FG003|Induction Period|Withdrawal by Subject|0
6262422|NCT02065557|9958079|FG004|Induction Period|Withdrawal by Subject|0
6262423|NCT02065557|9958080|FG005|Induction Period|Withdrawal by Subject|0
6262424|NCT02065557|9958075|FG000|Induction Period|Lack of Efficacy|2
6262425|NCT02065557|9958076|FG001|Induction Period|Lack of Efficacy|1
6262426|NCT02065557|9958077|FG002|Induction Period|Lack of Efficacy|1
6262427|NCT02065557|9958078|FG003|Induction Period|Lack of Efficacy|0
6262428|NCT02065557|9958079|FG004|Induction Period|Lack of Efficacy|0
6262429|NCT02065557|9958080|FG005|Induction Period|Lack of Efficacy|0
6262430|NCT02065557|9958075|FG000|Induction Period|Requires Alternative/Prohibited Therapy|1
6262431|NCT02065557|9958076|FG001|Induction Period|Requires Alternative/Prohibited Therapy|1
6262432|NCT02065557|9958077|FG002|Induction Period|Requires Alternative/Prohibited Therapy|1
6262433|NCT02065557|9958078|FG003|Induction Period|Requires Alternative/Prohibited Therapy|0
6262434|NCT02065557|9958079|FG004|Induction Period|Requires Alternative/Prohibited Therapy|0
6262435|NCT02065557|9958080|FG005|Induction Period|Requires Alternative/Prohibited Therapy|0
6262436|NCT02065557|9958075|FG000|Induction Period|Non-Responder at Week 8|4
6262437|NCT02065557|9958076|FG001|Induction Period|Non-Responder at Week 8|4
6262438|NCT02065557|9958077|FG002|Induction Period|Non-Responder at Week 8|0
6262439|NCT02065557|9958078|FG003|Induction Period|Non-Responder at Week 8|0
6262440|NCT02065557|9958079|FG004|Induction Period|Non-Responder at Week 8|0
6262441|NCT02065557|9958080|FG005|Induction Period|Non-Responder at Week 8|0
6262442|NCT02065557|9958075|FG000|Induction Period|Adverse Event|1
6262443|NCT02065557|9958076|FG001|Induction Period|Adverse Event|1
6262444|NCT02065557|9958077|FG002|Induction Period|Adverse Event|0
6262445|NCT02065557|9958078|FG003|Induction Period|Adverse Event|0
6262446|NCT02065557|9958079|FG004|Induction Period|Adverse Event|0
6262447|NCT02065557|9958080|FG005|Induction Period|Adverse Event|0
6262448|NCT02065557|9958075|FG000|Maintenance Period|Requires Alternative/Prohibited Therapy|0
6262449|NCT02065557|9958076|FG001|Maintenance Period|Requires Alternative/Prohibited Therapy|0
6262450|NCT02065557|9958077|FG002|Maintenance Period|Requires Alternative/Prohibited Therapy|0
6262451|NCT02065557|9958078|FG003|Maintenance Period|Requires Alternative/Prohibited Therapy|1
6262452|NCT02065557|9958079|FG004|Maintenance Period|Requires Alternative/Prohibited Therapy|1
6271420|NCT02163759|9973172|FG002|Overall Study|Adverse Event|1
6262453|NCT02065557|9958080|FG005|Maintenance Period|Requires Alternative/Prohibited Therapy|0
6262454|NCT02065557|9958075|FG000|Maintenance Period|Withdrawal by Subject|0
6262455|NCT02065557|9958076|FG001|Maintenance Period|Withdrawal by Subject|0
6262456|NCT02065557|9958077|FG002|Maintenance Period|Withdrawal by Subject|0
6262457|NCT02065557|9958078|FG003|Maintenance Period|Withdrawal by Subject|0
6262458|NCT02065557|9958079|FG004|Maintenance Period|Withdrawal by Subject|2
6262459|NCT02065557|9958080|FG005|Maintenance Period|Withdrawal by Subject|1
6262460|NCT02065557|9958075|FG000|Maintenance Period|Lack of Efficacy|0
6262461|NCT02065557|9958076|FG001|Maintenance Period|Lack of Efficacy|0
6262462|NCT02065557|9958077|FG002|Maintenance Period|Lack of Efficacy|0
6262463|NCT02065557|9958078|FG003|Maintenance Period|Lack of Efficacy|0
6262464|NCT02065557|9958079|FG004|Maintenance Period|Lack of Efficacy|5
6262465|NCT02065557|9958080|FG005|Maintenance Period|Lack of Efficacy|2
6262466|NCT02065557|9958075|FG000|Maintenance Period|Subject Non-Compliance|0
6262467|NCT02065557|9958076|FG001|Maintenance Period|Subject Non-Compliance|0
6262468|NCT02065557|9958077|FG002|Maintenance Period|Subject Non-Compliance|0
6262469|NCT02065557|9958078|FG003|Maintenance Period|Subject Non-Compliance|0
6262470|NCT02065557|9958079|FG004|Maintenance Period|Subject Non-Compliance|0
6262471|NCT02065557|9958080|FG005|Maintenance Period|Subject Non-Compliance|1
6262472|NCT02065570|9958107|FG000|Induction Study|Adverse Event|5
6262473|NCT02065570|9958108|FG001|Induction Study|Adverse Event|12
6262474|NCT02065570|9958109|FG002|Induction Study|Adverse Event|0
6262475|NCT02065570|9958110|FG003|Induction Study|Adverse Event|0
6262476|NCT02065570|9958107|FG000|Induction Study|Withdrawal by Subject|2
6262477|NCT02065570|9958108|FG001|Induction Study|Withdrawal by Subject|3
6262478|NCT02065570|9958109|FG002|Induction Study|Withdrawal by Subject|0
6262479|NCT02065570|9958110|FG003|Induction Study|Withdrawal by Subject|0
6262480|NCT02065570|9958107|FG000|Induction Study|Lost to Follow-up|1
6262481|NCT02065570|9958108|FG001|Induction Study|Lost to Follow-up|1
6262482|NCT02065570|9958109|FG002|Induction Study|Lost to Follow-up|0
6262483|NCT02065570|9958110|FG003|Induction Study|Lost to Follow-up|0
6262484|NCT02065570|9958107|FG000|Induction Study|Other, Not Specified|6
6262485|NCT02065570|9958108|FG001|Induction Study|Other, Not Specified|5
6262486|NCT02065570|9958109|FG002|Induction Study|Other, Not Specified|0
6262487|NCT02065570|9958110|FG003|Induction Study|Other, Not Specified|0
6262488|NCT02065570|9958107|FG000|Maintenance Study|Adverse Event|0
6262489|NCT02065570|9958108|FG001|Maintenance Study|Adverse Event|0
6262490|NCT02065570|9958109|FG002|Maintenance Study|Adverse Event|8
6262491|NCT02065570|9958110|FG003|Maintenance Study|Adverse Event|8
6262492|NCT02065570|9958107|FG000|Maintenance Study|Withdrawal by Subject|0
6262493|NCT02065570|9958108|FG001|Maintenance Study|Withdrawal by Subject|0
6262494|NCT02065570|9958109|FG002|Maintenance Study|Withdrawal by Subject|1
6262495|NCT02065570|9958110|FG003|Maintenance Study|Withdrawal by Subject|4
6262496|NCT02065570|9958107|FG000|Maintenance Study|Lost to Follow-up|0
6262497|NCT02065570|9958108|FG001|Maintenance Study|Lost to Follow-up|0
6262498|NCT02065570|9958109|FG002|Maintenance Study|Lost to Follow-up|2
6262499|NCT02065570|9958110|FG003|Maintenance Study|Lost to Follow-up|2
6262500|NCT02065570|9958107|FG000|Maintenance Study|Other, Not Specified|0
6262501|NCT02065570|9958108|FG001|Maintenance Study|Other, Not Specified|0
6262502|NCT02065570|9958109|FG002|Maintenance Study|Other, Not Specified|11
6262503|NCT02065570|9958110|FG003|Maintenance Study|Other, Not Specified|5
6262504|NCT02065622|9958123|FG000|Induction Study|Adverse Event|13
6262505|NCT02065622|9958124|FG001|Induction Study|Adverse Event|19
6262506|NCT02065622|9958125|FG002|Induction Study|Adverse Event|0
6262507|NCT02065622|9958126|FG003|Induction Study|Adverse Event|0
6262508|NCT02065622|9958127|FG004|Induction Study|Adverse Event|0
6262509|NCT02065622|9958123|FG000|Induction Study|Withdrawal by Subject|3
6262510|NCT02065622|9958124|FG001|Induction Study|Withdrawal by Subject|5
6262511|NCT02065622|9958125|FG002|Induction Study|Withdrawal by Subject|0
6262512|NCT02065622|9958126|FG003|Induction Study|Withdrawal by Subject|0
6262513|NCT02065622|9958127|FG004|Induction Study|Withdrawal by Subject|0
6262514|NCT02065622|9958123|FG000|Induction Study|Lost to Follow-up|1
6262515|NCT02065622|9958124|FG001|Induction Study|Lost to Follow-up|0
6262516|NCT02065622|9958125|FG002|Induction Study|Lost to Follow-up|0
6262517|NCT02065622|9958126|FG003|Induction Study|Lost to Follow-up|0
6262518|NCT02065622|9958127|FG004|Induction Study|Lost to Follow-up|0
6262519|NCT02065622|9958123|FG000|Induction Study|Lack of Efficacy|22
6262520|NCT02065622|9958124|FG001|Induction Study|Lack of Efficacy|27
6262521|NCT02065622|9958125|FG002|Induction Study|Lack of Efficacy|0
6262522|NCT02065622|9958126|FG003|Induction Study|Lack of Efficacy|0
6262523|NCT02065622|9958127|FG004|Induction Study|Lack of Efficacy|0
6262524|NCT02065622|9958123|FG000|Induction Study|Requires Alternative/Prohibited Therapy|4
6262525|NCT02065622|9958124|FG001|Induction Study|Requires Alternative/Prohibited Therapy|5
6262526|NCT02065622|9958125|FG002|Induction Study|Requires Alternative/Prohibited Therapy|0
6262527|NCT02065622|9958126|FG003|Induction Study|Requires Alternative/Prohibited Therapy|0
6262528|NCT02065622|9958127|FG004|Induction Study|Requires Alternative/Prohibited Therapy|0
6262529|NCT02065622|9958123|FG000|Induction Study|Subject Noncompliance|1
6262530|NCT02065622|9958124|FG001|Induction Study|Subject Noncompliance|1
6262531|NCT02065622|9958125|FG002|Induction Study|Subject Noncompliance|0
6262532|NCT02065622|9958126|FG003|Induction Study|Subject Noncompliance|0
6262533|NCT02065622|9958127|FG004|Induction Study|Subject Noncompliance|0
6262534|NCT02065622|9958123|FG000|Induction Study|Other, Not Specified|3
6262535|NCT02065622|9958124|FG001|Induction Study|Other, Not Specified|2
6262536|NCT02065622|9958125|FG002|Induction Study|Other, Not Specified|0
6262537|NCT02065622|9958126|FG003|Induction Study|Other, Not Specified|0
6262538|NCT02065622|9958127|FG004|Induction Study|Other, Not Specified|0
6262539|NCT02065622|9958123|FG000|Maintenance Study|Adverse Event|0
6262540|NCT02065622|9958124|FG001|Maintenance Study|Adverse Event|0
6262541|NCT02065622|9958125|FG002|Maintenance Study|Adverse Event|25
6262542|NCT02065622|9958126|FG003|Maintenance Study|Adverse Event|22
6262543|NCT02065622|9958127|FG004|Maintenance Study|Adverse Event|11
6262544|NCT02065622|9958123|FG000|Maintenance Study|Withdrawal by Subject|0
6262545|NCT02065622|9958124|FG001|Maintenance Study|Withdrawal by Subject|0
6262546|NCT02065622|9958125|FG002|Maintenance Study|Withdrawal by Subject|11
6262547|NCT02065622|9958126|FG003|Maintenance Study|Withdrawal by Subject|5
6262548|NCT02065622|9958127|FG004|Maintenance Study|Withdrawal by Subject|7
6262549|NCT02065622|9958123|FG000|Maintenance Study|Lost to Follow-up|0
6262550|NCT02065622|9958124|FG001|Maintenance Study|Lost to Follow-up|0
6262551|NCT02065622|9958125|FG002|Maintenance Study|Lost to Follow-up|4
6262552|NCT02065622|9958126|FG003|Maintenance Study|Lost to Follow-up|1
6262553|NCT02065622|9958127|FG004|Maintenance Study|Lost to Follow-up|1
6262554|NCT02065622|9958123|FG000|Maintenance Study|Lack of Efficacy|0
6262555|NCT02065622|9958124|FG001|Maintenance Study|Lack of Efficacy|0
6262556|NCT02065622|9958125|FG002|Maintenance Study|Lack of Efficacy|70
6262557|NCT02065622|9958126|FG003|Maintenance Study|Lack of Efficacy|55
6262558|NCT02065622|9958127|FG004|Maintenance Study|Lack of Efficacy|19
6262559|NCT02065622|9958123|FG000|Maintenance Study|Requires Alternative/Prohibited Therapy|0
6262560|NCT02065622|9958124|FG001|Maintenance Study|Requires Alternative/Prohibited Therapy|0
6262561|NCT02065622|9958125|FG002|Maintenance Study|Requires Alternative/Prohibited Therapy|7
6262562|NCT02065622|9958126|FG003|Maintenance Study|Requires Alternative/Prohibited Therapy|3
6262563|NCT02065622|9958127|FG004|Maintenance Study|Requires Alternative/Prohibited Therapy|4
6262564|NCT02065622|9958123|FG000|Maintenance Study|Subject Non-Compliance|0
6262565|NCT02065622|9958124|FG001|Maintenance Study|Subject Non-Compliance|0
6262566|NCT02065622|9958125|FG002|Maintenance Study|Subject Non-Compliance|1
6262567|NCT02065622|9958126|FG003|Maintenance Study|Subject Non-Compliance|3
6262568|NCT02065622|9958127|FG004|Maintenance Study|Subject Non-Compliance|2
6262569|NCT02065622|9958123|FG000|Maintenance Study|Other, Not Specified|0
6262570|NCT02065622|9958124|FG001|Maintenance Study|Other, Not Specified|0
6262571|NCT02065622|9958125|FG002|Maintenance Study|Other, Not Specified|6
6262572|NCT02065622|9958126|FG003|Maintenance Study|Other, Not Specified|14
6262573|NCT02065622|9958127|FG004|Maintenance Study|Other, Not Specified|2
6262574|NCT02065622|9958123|FG000|Maintenance Study|Unknown Reason|0
6262575|NCT02065622|9958124|FG001|Maintenance Study|Unknown Reason|0
6262576|NCT02065622|9958125|FG002|Maintenance Study|Unknown Reason|0
6262577|NCT02065622|9958126|FG003|Maintenance Study|Unknown Reason|1
6262578|NCT02065622|9958127|FG004|Maintenance Study|Unknown Reason|0
6262579|NCT02065713|9958153|FG000|Overall Study|Adverse Event|0
6262580|NCT02065713|9958154|FG001|Overall Study|Adverse Event|1
6262581|NCT02065713|9958153|FG000|Overall Study|Unsatisfactory therapeutic effect|1
6262582|NCT02065713|9958154|FG001|Overall Study|Unsatisfactory therapeutic effect|0
6262583|NCT02065791|9958162|FG000|Overall Study|Closed Site|1
6262584|NCT02065791|9958163|FG001|Overall Study|Closed Site|1
6262585|NCT02065791|9958162|FG000|Overall Study|Withdrawal by Subject|11
6262586|NCT02065791|9958163|FG001|Overall Study|Withdrawal by Subject|5
6262587|NCT02065791|9958162|FG000|Overall Study|Lost to Follow-up|13
6262588|NCT02065791|9958163|FG001|Overall Study|Lost to Follow-up|9
6262589|NCT02065895|9958169|FG000|Overall Study|Protocol Violation|1
6262590|NCT02065895|9958170|FG001|Overall Study|Protocol Violation|0
6262591|NCT02065895|9958171|FG002|Overall Study|Protocol Violation|0
6262592|NCT02065895|9958172|FG003|Overall Study|Protocol Violation|1
6262593|NCT02065895|9958173|FG004|Overall Study|Protocol Violation|0
6262594|NCT02065895|9958174|FG005|Overall Study|Protocol Violation|0
6262595|NCT02065895|9958169|FG000|Overall Study|Scheduling conflicts|0
6262596|NCT02065895|9958170|FG001|Overall Study|Scheduling conflicts|1
6262597|NCT02065895|9958171|FG002|Overall Study|Scheduling conflicts|0
6262598|NCT02065895|9958172|FG003|Overall Study|Scheduling conflicts|0
6262599|NCT02065895|9958173|FG004|Overall Study|Scheduling conflicts|0
6262600|NCT02065895|9958174|FG005|Overall Study|Scheduling conflicts|0
6262601|NCT02066051|9958191|FG000|Overall Study|Subject developed active GVHD|1
6262602|NCT02066129|9958197|FG000|Overall Study|Lost to Follow-up|13
6262603|NCT02066129|9958198|FG001|Overall Study|Lost to Follow-up|12
6262604|NCT02066129|9958197|FG000|Overall Study|Withdrawal by Subject|7
6262605|NCT02066129|9958198|FG001|Overall Study|Withdrawal by Subject|10
6262606|NCT02066129|9958197|FG000|Overall Study|Lack of Efficacy|8
6262607|NCT02066129|9958198|FG001|Overall Study|Lack of Efficacy|10
6262608|NCT02066129|9958197|FG000|Overall Study|Physician Decision|1
6262609|NCT02066129|9958198|FG001|Overall Study|Physician Decision|1
6262610|NCT02066233|9958206|FG000|EG Scan II (Day 1)|difficulty intubating subject|6
6262611|NCT02066233|9958207|FG001|EG Scan II (Day 1)|difficulty intubating subject|6
6262612|NCT02066298|9958219|FG000|Overall Study|Lost to Follow-up|3
6262613|NCT02066298|9958220|FG001|Overall Study|Lost to Follow-up|2
6262614|NCT02066298|9958221|FG002|Overall Study|Lost to Follow-up|3
6262615|NCT02066298|9958222|FG003|Overall Study|Lost to Follow-up|2
6262616|NCT02066298|9958223|FG004|Overall Study|Lost to Follow-up|3
6262617|NCT02066298|9958224|FG005|Overall Study|Lost to Follow-up|4
6262618|NCT02066298|9958219|FG000|Overall Study|Withdrawal by Subject|6
6262619|NCT02066298|9958220|FG001|Overall Study|Withdrawal by Subject|6
6262620|NCT02066298|9958221|FG002|Overall Study|Withdrawal by Subject|6
6262621|NCT02066298|9958222|FG003|Overall Study|Withdrawal by Subject|4
6262622|NCT02066298|9958223|FG004|Overall Study|Withdrawal by Subject|5
6262623|NCT02066298|9958224|FG005|Overall Study|Withdrawal by Subject|8
6262624|NCT02066298|9958219|FG000|Overall Study|Physician Decision|0
6262625|NCT02066298|9958220|FG001|Overall Study|Physician Decision|0
6262626|NCT02066298|9958221|FG002|Overall Study|Physician Decision|1
6262627|NCT02066298|9958222|FG003|Overall Study|Physician Decision|0
6262628|NCT02066298|9958223|FG004|Overall Study|Physician Decision|1
6262629|NCT02066298|9958224|FG005|Overall Study|Physician Decision|0
6262630|NCT02066311|9958236|FG000|Overall Study|Adverse Event|4
6262631|NCT02066311|9958236|FG000|Overall Study|Withdrawal by Subject|1
6262632|NCT02066389|9958246|FG000|Overall Study|Adverse Event|1
6262633|NCT02066389|9958247|FG001|Overall Study|Adverse Event|1
6262634|NCT02066389|9958248|FG002|Overall Study|Adverse Event|1
6262635|NCT02066389|9958249|FG003|Overall Study|Adverse Event|1
6262636|NCT02066389|9958250|FG004|Overall Study|Adverse Event|5
6262637|NCT02066389|9958251|FG005|Overall Study|Adverse Event|1
6262638|NCT02066389|9958246|FG000|Overall Study|Withdrawal by Subject|4
6262639|NCT02066389|9958247|FG001|Overall Study|Withdrawal by Subject|0
6262640|NCT02066389|9958248|FG002|Overall Study|Withdrawal by Subject|5
6262641|NCT02066389|9958249|FG003|Overall Study|Withdrawal by Subject|1
6262642|NCT02066389|9958250|FG004|Overall Study|Withdrawal by Subject|1
6262643|NCT02066389|9958251|FG005|Overall Study|Withdrawal by Subject|2
6262644|NCT02066389|9958246|FG000|Overall Study|Lost to Follow-up|0
6262645|NCT02066389|9958247|FG001|Overall Study|Lost to Follow-up|0
6262646|NCT02066389|9958248|FG002|Overall Study|Lost to Follow-up|0
6262647|NCT02066389|9958249|FG003|Overall Study|Lost to Follow-up|1
6262648|NCT02066389|9958250|FG004|Overall Study|Lost to Follow-up|1
6262649|NCT02066389|9958251|FG005|Overall Study|Lost to Follow-up|1
6262650|NCT02066389|9958246|FG000|Overall Study|Randomized in Error|0
6262651|NCT02066389|9958247|FG001|Overall Study|Randomized in Error|0
6262652|NCT02066389|9958248|FG002|Overall Study|Randomized in Error|0
6262653|NCT02066389|9958249|FG003|Overall Study|Randomized in Error|0
6262654|NCT02066389|9958250|FG004|Overall Study|Randomized in Error|0
6262655|NCT02066389|9958251|FG005|Overall Study|Randomized in Error|1
6262656|NCT02066402|9958267|FG000|Overall Study|Adverse Event|1
6262657|NCT02066402|9958268|FG001|Overall Study|Adverse Event|2
6262658|NCT02066402|9958267|FG000|Overall Study|Lost to Follow-up|11
6262659|NCT02066402|9958268|FG001|Overall Study|Lost to Follow-up|8
6262660|NCT02066402|9958267|FG000|Overall Study|Withdrawal by Subject|14
6262661|NCT02066402|9958268|FG001|Overall Study|Withdrawal by Subject|11
6262662|NCT02066402|9958267|FG000|Overall Study|Progressive disease-clinical progression|0
6262663|NCT02066402|9958268|FG001|Overall Study|Progressive disease-clinical progression|1
6262664|NCT02066402|9958267|FG000|Overall Study|Protocol driven decision point|0
6262665|NCT02066402|9958268|FG001|Overall Study|Protocol driven decision point|1
6262666|NCT02066467|9958274|FG000|Overall Study|Did not undergo implant procedure|24
6262667|NCT02066467|9958274|FG000|Overall Study|Attempted to implant withoput success|43
6262668|NCT02066467|9958274|FG000|Overall Study|Consent ineligible|1
6262669|NCT02066467|9958274|FG000|Overall Study|Death|54
6262670|NCT02066467|9958274|FG000|Overall Study|Lost to Follow-up|51
6262671|NCT02066467|9958274|FG000|Overall Study|Adverse Event|20
6262672|NCT02066467|9958274|FG000|Overall Study|Withdrawal by Subject|16
6262673|NCT02066467|9958274|FG000|Overall Study|Physician Decision|2
6262674|NCT02066467|9958274|FG000|Overall Study|Not defined|4
6262675|NCT02066922|9958327|FG000|Overall Study|Adverse Event|1
6262676|NCT02067533|9958373|FG000|Overall Study|Lost to Follow-up|4
6262677|NCT02067533|9958374|FG001|Overall Study|Lost to Follow-up|2
6262678|NCT02067663|9958395|FG000|Overall Study|Lost to Follow-up|13
6262679|NCT02067663|9958396|FG001|Overall Study|Lost to Follow-up|14
6262680|NCT02067676|9958408|FG000|Overall Study|Withdrawal by Subject|1
6262681|NCT02067676|9958409|FG001|Overall Study|Withdrawal by Subject|0
6262682|NCT02067676|9958410|FG002|Overall Study|Withdrawal by Subject|0
6262683|NCT02067676|9958411|FG003|Overall Study|Withdrawal by Subject|0
6262684|NCT02067676|9958412|FG004|Overall Study|Withdrawal by Subject|0
6262685|NCT02067676|9958413|FG005|Overall Study|Withdrawal by Subject|0
6262686|NCT02067728|9958434|FG000|Baseline - 1 Month Follow up Survey|Lost to Follow-up|7
6262687|NCT02067728|9958435|FG001|Baseline - 1 Month Follow up Survey|Lost to Follow-up|28
6262688|NCT02067728|9958434|FG000|6 Month Follow up Survey|Lost to Follow-up|48
6262689|NCT02067728|9958435|FG001|6 Month Follow up Survey|Lost to Follow-up|60
6262690|NCT02067728|9958434|FG000|6 Month Measurements|Unable to attend|114
6262691|NCT02067728|9958435|FG001|6 Month Measurements|Unable to attend|97
6262692|NCT02068118|9958461|FG000|18-month Comparative Study Period|Death|90
6262693|NCT02068118|9958462|FG001|18-month Comparative Study Period|Death|97
6262694|NCT02068118|9958461|FG000|18-month Comparative Study Period|Withdrawal by Subject|23
6262695|NCT02068118|9958462|FG001|18-month Comparative Study Period|Withdrawal by Subject|52
6262696|NCT02068118|9958461|FG000|18-month Comparative Study Period|Lost to Follow-up|6
6262697|NCT02068118|9958462|FG001|18-month Comparative Study Period|Lost to Follow-up|7
6262698|NCT02068118|9958461|FG000|18-month Comparative Study Period|Heart transplant|9
6262699|NCT02068118|9958462|FG001|18-month Comparative Study Period|Heart transplant|15
6262700|NCT02068118|9958461|FG000|18-month Comparative Study Period|Inclusion in another protocol|0
6262701|NCT02068118|9958462|FG001|18-month Comparative Study Period|Inclusion in another protocol|2
6262702|NCT02068118|9958461|FG000|18-month Comparative Study Period|Hemiplegia|0
6262703|NCT02068118|9958462|FG001|18-month Comparative Study Period|Hemiplegia|1
6262704|NCT02068118|9958461|FG000|18-month Comparative Study Period|Alzheimer's disease|0
6262705|NCT02068118|9958462|FG001|18-month Comparative Study Period|Alzheimer's disease|1
6262706|NCT02068118|9958461|FG000|18-month Comparative Study Period|Move|0
6262707|NCT02068118|9958462|FG001|18-month Comparative Study Period|Move|1
6262708|NCT02068118|9958461|FG000|18-month Comparative Study Period|Hearing loss|0
6262709|NCT02068118|9958462|FG001|18-month Comparative Study Period|Hearing loss|1
6262710|NCT02068118|9958461|FG000|Extension Period|Death|0
6262711|NCT02068118|9958462|FG001|Extension Period|Death|2
6262712|NCT02068118|9958461|FG000|Extension Period|Withdrawal by Subject|1
6262713|NCT02068118|9958462|FG001|Extension Period|Withdrawal by Subject|0
6262714|NCT02068118|9958461|FG000|Extension Period|Heart transplant|1
6262715|NCT02068118|9958462|FG001|Extension Period|Heart transplant|0
6262716|NCT02068118|9958461|FG000|Extension Period|Wrong device use|0
6262717|NCT02068118|9958462|FG001|Extension Period|Wrong device use|1
6262718|NCT02068222|9958474|FG000|Overall Study|Lost to Follow-up|1
6262719|NCT02068352|9958481|FG000|Overall Study|Lost to Follow-up|0
6262720|NCT02068352|9958482|FG001|Overall Study|Lost to Follow-up|2
6262721|NCT02068352|9958483|FG002|Overall Study|Lost to Follow-up|0
6262722|NCT02068352|9958481|FG000|Overall Study|Adverse Event|4
6262723|NCT02068352|9958482|FG001|Overall Study|Adverse Event|2
6262724|NCT02068352|9958483|FG002|Overall Study|Adverse Event|7
6262725|NCT02068352|9958481|FG000|Overall Study|Participant met (Protocol Specified) Withdrawal Criteria|0
6262726|NCT02068352|9958482|FG001|Overall Study|Participant met (Protocol Specified) Withdrawal Criteria|1
6262727|NCT02068352|9958483|FG002|Overall Study|Participant met (Protocol Specified) Withdrawal Criteria|0
6262728|NCT02068352|9958481|FG000|Overall Study|Participant Withdrew Consent to Participate|6
6262729|NCT02068352|9958482|FG001|Overall Study|Participant Withdrew Consent to Participate|3
6262730|NCT02068352|9958483|FG002|Overall Study|Participant Withdrew Consent to Participate|1
6262731|NCT02068352|9958481|FG000|Overall Study|Protocol Deviation|0
6262732|NCT02068352|9958482|FG001|Overall Study|Protocol Deviation|0
6262733|NCT02068352|9958483|FG002|Overall Study|Protocol Deviation|1
6262734|NCT02068443|9958494|FG000|Overall Study|Pretreatment Event/Adverse Event|0
6262735|NCT02068443|9958495|FG001|Overall Study|Pretreatment Event/Adverse Event|5
6262736|NCT02068443|9958496|FG002|Overall Study|Pretreatment Event/Adverse Event|2
6262737|NCT02068443|9958494|FG000|Overall Study|Voluntary Withdrawal|4
6262738|NCT02068443|9958495|FG001|Overall Study|Voluntary Withdrawal|0
6262739|NCT02068443|9958496|FG002|Overall Study|Voluntary Withdrawal|1
6262740|NCT02068443|9958494|FG000|Overall Study|Lack of Efficacy|2
6262741|NCT02068443|9958495|FG001|Overall Study|Lack of Efficacy|1
6262742|NCT02068443|9958496|FG002|Overall Study|Lack of Efficacy|0
6262743|NCT02068443|9958494|FG000|Overall Study|Other Reason Not Specified|1
6262744|NCT02068443|9958495|FG001|Overall Study|Other Reason Not Specified|0
6262745|NCT02068443|9958496|FG002|Overall Study|Other Reason Not Specified|0
6262746|NCT02068495|9958504|FG000|Overall Study|Case Report Forms Uncollected|60
6262747|NCT02068495|9958504|FG000|Overall Study|Protocol Deviation|49
6262748|NCT02068508|9958508|FG000|Overall Study|Case report forms uncollected|27
6262749|NCT02068508|9958508|FG000|Overall Study|Patient did not visit the study site|1
6262750|NCT02068508|9958508|FG000|Overall Study|Protocol Violation|4
6262751|NCT02068599|9958515|FG000|Overall Study|Adverse Event|4
6262752|NCT02068599|9958516|FG001|Overall Study|Adverse Event|1
6262753|NCT02068599|9958517|FG002|Overall Study|Adverse Event|1
6262754|NCT02068599|9958515|FG000|Overall Study|Withdrawal by Subject|2
6262755|NCT02068599|9958516|FG001|Overall Study|Withdrawal by Subject|7
6262756|NCT02068599|9958517|FG002|Overall Study|Withdrawal by Subject|5
6262757|NCT02068599|9958515|FG000|Overall Study|Protocol Violation|4
6262758|NCT02068599|9958516|FG001|Overall Study|Protocol Violation|2
6262759|NCT02068599|9958517|FG002|Overall Study|Protocol Violation|3
6262760|NCT02068599|9958515|FG000|Overall Study|Lost to Follow-up|1
6262761|NCT02068599|9958516|FG001|Overall Study|Lost to Follow-up|0
6262762|NCT02068599|9958517|FG002|Overall Study|Lost to Follow-up|0
6262763|NCT02068599|9958515|FG000|Overall Study|Lack of Efficacy|0
6262764|NCT02068599|9958516|FG001|Overall Study|Lack of Efficacy|0
6262765|NCT02068599|9958517|FG002|Overall Study|Lack of Efficacy|3
6262766|NCT02068599|9958515|FG000|Overall Study|Noncompliance|0
6262767|NCT02068599|9958516|FG001|Overall Study|Noncompliance|0
6262768|NCT02068599|9958517|FG002|Overall Study|Noncompliance|1
6262769|NCT02068768|9958584|FG000|Overall Study|Lost to Follow-up|5
6262770|NCT02068768|9958584|FG000|Overall Study|Early Termination by Sponsor|2
6262771|NCT02068885|9958614|FG000|Overall Study|Withdrew|3
6262772|NCT02068885|9958615|FG001|Overall Study|Withdrew|5
6262773|NCT02068885|9958616|FG002|Overall Study|Withdrew|8
6262774|NCT02069015|9958627|FG000|Overall Study|Lost to Follow-up|39
6262775|NCT02069015|9958628|FG001|Overall Study|Lost to Follow-up|32
6262776|NCT02069015|9958627|FG000|Overall Study|Withdrawal by Subject|1
6262777|NCT02069015|9958628|FG001|Overall Study|Withdrawal by Subject|1
6262778|NCT02069093|9958639|FG000|Overall Study|Disease progression|14
6262779|NCT02069093|9958639|FG000|Overall Study|New cancer therapy|1
6262780|NCT02069093|9958639|FG000|Overall Study|Death|1
6262781|NCT02069093|9958639|FG000|Overall Study|Administrative problems|1
6262782|NCT02069093|9958639|FG000|Overall Study|Withdrawal by Subject|2
6262783|NCT02069093|9958639|FG000|Overall Study|Abnormal laboratory values|1
6262784|NCT02069093|9958639|FG000|Overall Study|Adverse Event|10
6262785|NCT02069379|9958677|FG000|Baseline Measurements|Lost to Follow-up|1
6262786|NCT02069379|9958678|FG001|Baseline Measurements|Lost to Follow-up|0
6262787|NCT02069379|9958679|FG002|Baseline Measurements|Lost to Follow-up|0
6262788|NCT02069379|9958680|FG003|Baseline Measurements|Lost to Follow-up|0
6262789|NCT02069379|9958677|FG000|Baseline Measurements|Ineligible based on initial assessments|2
6262790|NCT02069379|9958678|FG001|Baseline Measurements|Ineligible based on initial assessments|0
6262791|NCT02069379|9958679|FG002|Baseline Measurements|Ineligible based on initial assessments|0
6262792|NCT02069379|9958680|FG003|Baseline Measurements|Ineligible based on initial assessments|2
6262793|NCT02069379|9958677|FG000|First Treatment Arm|Lost to Follow-up|0
6262794|NCT02069379|9958678|FG001|First Treatment Arm|Lost to Follow-up|1
6262795|NCT02069379|9958679|FG002|First Treatment Arm|Lost to Follow-up|1
6262796|NCT02069379|9958680|FG003|First Treatment Arm|Lost to Follow-up|0
6262797|NCT02069379|9958677|FG000|Washout Period (4 Weeks)|Lost to Follow-up|0
6262798|NCT02069379|9958678|FG001|Washout Period (4 Weeks)|Lost to Follow-up|1
6262799|NCT02069379|9958679|FG002|Washout Period (4 Weeks)|Lost to Follow-up|0
6262800|NCT02069379|9958680|FG003|Washout Period (4 Weeks)|Lost to Follow-up|0
6086904|NCT00665366|9697039|FG001|Overall Study|Poor compliance/noncompliance|5
6086905|NCT00665366|9697038|FG000|Overall Study|Pregnancy|1
6086906|NCT00665366|9697039|FG001|Overall Study|Pregnancy|0
6086907|NCT00665366|9697038|FG000|Overall Study|No longer meets study criteria|0
6086908|NCT00665366|9697039|FG001|Overall Study|No longer meets study criteria|1
6262801|NCT02069379|9958677|FG000|Washout Period (4 Weeks)|Unrelated event|0
6262802|NCT02069379|9958678|FG001|Washout Period (4 Weeks)|Unrelated event|1
6262803|NCT02069379|9958679|FG002|Washout Period (4 Weeks)|Unrelated event|0
6262804|NCT02069379|9958680|FG003|Washout Period (4 Weeks)|Unrelated event|0
6262805|NCT02069379|9958677|FG000|Second Treatment Arm|Lost to Follow-up|0
6262806|NCT02069379|9958678|FG001|Second Treatment Arm|Lost to Follow-up|0
6262807|NCT02069379|9958679|FG002|Second Treatment Arm|Lost to Follow-up|1
6262808|NCT02069379|9958680|FG003|Second Treatment Arm|Lost to Follow-up|0
6262809|NCT02069392|9958692|FG000|Overall Study|Withdrawal by Subject|4
6262810|NCT02069392|9958693|FG001|Overall Study|Withdrawal by Subject|2
6262811|NCT02070380|9958760|FG000|Washout (no Second Injection/MRI)|Withdrawal by Subject|0
6262812|NCT02070380|9958761|FG001|Washout (no Second Injection/MRI)|Withdrawal by Subject|5
6262813|NCT02070380|9958762|FG002|Washout (no Second Injection/MRI)|Withdrawal by Subject|2
6262814|NCT02070380|9958763|FG003|Washout (no Second Injection/MRI)|Withdrawal by Subject|3
6262815|NCT02070380|9958760|FG000|Second Injection|Image sets missing or technically inadeq|0
6262816|NCT02070380|9958761|FG001|Second Injection|Image sets missing or technically inadeq|1
6262817|NCT02070380|9958762|FG002|Second Injection|Image sets missing or technically inadeq|0
6262818|NCT02070380|9958763|FG003|Second Injection|Image sets missing or technically inadeq|0
6262819|NCT02070380|9958760|FG000|Second Injection|Protocol Violation|0
6262820|NCT02070380|9958761|FG001|Second Injection|Protocol Violation|1
6262821|NCT02070380|9958762|FG002|Second Injection|Protocol Violation|1
6262822|NCT02070380|9958763|FG003|Second Injection|Protocol Violation|5
6262823|NCT02070484|9958777|FG000|Overall Study|Withdrawal by Subject|1
6262824|NCT02070484|9958778|FG001|Overall Study|Withdrawal by Subject|0
6262825|NCT02070588|9958787|FG000|Overall Study|Withdrawal by Subject|29
6262826|NCT02070588|9958788|FG001|Overall Study|Withdrawal by Subject|1
6262827|NCT02070588|9958789|FG002|Overall Study|Withdrawal by Subject|0
6262828|NCT02070588|9958787|FG000|Overall Study|Writhdrawal due to early termination|9
6262829|NCT02070588|9958788|FG001|Overall Study|Writhdrawal due to early termination|0
6262830|NCT02070588|9958789|FG002|Overall Study|Writhdrawal due to early termination|0
6262831|NCT02070588|9958787|FG000|Overall Study|Adverse Event|1
6262832|NCT02070588|9958788|FG001|Overall Study|Adverse Event|0
6262833|NCT02070588|9958789|FG002|Overall Study|Adverse Event|0
6262834|NCT02070744|9958820|FG000|PC Phase (12 Weeks)|Randomized, but not treated|0
6262835|NCT02070744|9958821|FG001|PC Phase (12 Weeks)|Randomized, but not treated|0
6262836|NCT02070744|9958822|FG002|PC Phase (12 Weeks)|Randomized, but not treated|0
6262837|NCT02070744|9958823|FG003|PC Phase (12 Weeks)|Randomized, but not treated|1
6262838|NCT02070744|9958824|FG004|PC Phase (12 Weeks)|Randomized, but not treated|0
6262839|NCT02070744|9958820|FG000|OLE Phase (48 Weeks)|Withdrawal by Subject|0
6262840|NCT02070744|9958821|FG001|OLE Phase (48 Weeks)|Withdrawal by Subject|0
6086909|NCT00665366|9697038|FG000|Overall Study|Other reasons|4
6262841|NCT02070744|9958822|FG002|OLE Phase (48 Weeks)|Withdrawal by Subject|0
6262842|NCT02070744|9958823|FG003|OLE Phase (48 Weeks)|Withdrawal by Subject|0
6262843|NCT02070744|9958824|FG004|OLE Phase (48 Weeks)|Withdrawal by Subject|2
6262844|NCT02070744|9958820|FG000|OLE Phase (48 Weeks)|Other|0
6262845|NCT02070744|9958821|FG001|OLE Phase (48 Weeks)|Other|0
6262846|NCT02070744|9958822|FG002|OLE Phase (48 Weeks)|Other|0
6262847|NCT02070744|9958823|FG003|OLE Phase (48 Weeks)|Other|0
6262848|NCT02070744|9958824|FG004|OLE Phase (48 Weeks)|Other|1
6086910|NCT00665366|9697039|FG001|Overall Study|Other reasons|1
6262849|NCT02070757|9958841|FG000|Overall Study|Adverse Event|107
6262850|NCT02070757|9958842|FG001|Overall Study|Adverse Event|99
6262851|NCT02070757|9958841|FG000|Overall Study|Lost to Follow-up|7
6262852|NCT02070757|9958842|FG001|Overall Study|Lost to Follow-up|4
6262853|NCT02070757|9958841|FG000|Overall Study|Protocol Violation|0
6262854|NCT02070757|9958842|FG001|Overall Study|Protocol Violation|4
6262855|NCT02070757|9958841|FG000|Overall Study|Withdrawal by Subject|1
6262856|NCT02070757|9958842|FG001|Overall Study|Withdrawal by Subject|3
6262857|NCT02070757|9958841|FG000|Overall Study|Investigator Decision|0
6262858|NCT02070757|9958842|FG001|Overall Study|Investigator Decision|2
6262859|NCT02070757|9958841|FG000|Overall Study|Discharged from Study Hospital|2
6262860|NCT02070757|9958842|FG001|Overall Study|Discharged from Study Hospital|2
6262861|NCT02070965|9958851|FG000|Overall Study|Lost to Follow-up|0
6262862|NCT02070965|9958852|FG001|Overall Study|Lost to Follow-up|1
6262863|NCT02070965|9958853|FG002|Overall Study|Lost to Follow-up|0
6262864|NCT02070965|9958851|FG000|Overall Study|Withdrawal by Subject|1
6262865|NCT02070965|9958852|FG001|Overall Study|Withdrawal by Subject|1
6262866|NCT02070965|9958853|FG002|Overall Study|Withdrawal by Subject|1
6262867|NCT02070965|9958851|FG000|Overall Study|Subject moved|1
6262868|NCT02070965|9958852|FG001|Overall Study|Subject moved|0
6262869|NCT02070965|9958853|FG002|Overall Study|Subject moved|0
6262870|NCT02070978|9958864|FG000|Overall Study|Adverse Event|6
6262871|NCT02070978|9958865|FG001|Overall Study|Adverse Event|2
6262872|NCT02070978|9958866|FG002|Overall Study|Adverse Event|0
6262873|NCT02070978|9958864|FG000|Overall Study|Lost to Follow-up|1
6262874|NCT02070978|9958865|FG001|Overall Study|Lost to Follow-up|3
6262875|NCT02070978|9958866|FG002|Overall Study|Lost to Follow-up|4
6262876|NCT02070978|9958864|FG000|Overall Study|Withdrawal by Subject|3
6262877|NCT02070978|9958865|FG001|Overall Study|Withdrawal by Subject|5
6262878|NCT02070978|9958866|FG002|Overall Study|Withdrawal by Subject|3
6262879|NCT02070978|9958864|FG000|Overall Study|Protocol Violation|1
6262880|NCT02070978|9958865|FG001|Overall Study|Protocol Violation|0
6262881|NCT02070978|9958866|FG002|Overall Study|Protocol Violation|3
6262882|NCT02070978|9958864|FG000|Overall Study|Lack of Efficacy|0
6262883|NCT02070978|9958865|FG001|Overall Study|Lack of Efficacy|1
6262884|NCT02070978|9958866|FG002|Overall Study|Lack of Efficacy|0
6262885|NCT02070978|9958864|FG000|Overall Study|Death|0
6262886|NCT02070978|9958865|FG001|Overall Study|Death|0
6262887|NCT02070978|9958866|FG002|Overall Study|Death|2
6262888|NCT02070978|9958864|FG000|Overall Study|Un-specified|3
6262889|NCT02070978|9958865|FG001|Overall Study|Un-specified|2
6262890|NCT02070978|9958866|FG002|Overall Study|Un-specified|2
6262891|NCT02070978|9958864|FG000|Overall Study|Terminated by Sponsor|33
6262892|NCT02070978|9958865|FG001|Overall Study|Terminated by Sponsor|40
6262893|NCT02070978|9958866|FG002|Overall Study|Terminated by Sponsor|39
6262894|NCT02070991|9958876|FG000|Overall Study|Death|2
6262895|NCT02070991|9958877|FG001|Overall Study|Death|0
6262896|NCT02070991|9958876|FG000|Overall Study|Withdrawal by Subject|1
6262897|NCT02070991|9958877|FG001|Overall Study|Withdrawal by Subject|0
6262898|NCT02071082|9958885|FG000|Overall Study|Enrolled and Never Treated|1
6262899|NCT02071082|9958886|FG001|Overall Study|Enrolled and Never Treated|1
6262900|NCT02071082|9958885|FG000|Overall Study|Adverse Event|0
6262901|NCT02071082|9958886|FG001|Overall Study|Adverse Event|1
6262902|NCT02071082|9958885|FG000|Overall Study|Withdrew Consent|0
6262903|NCT02071082|9958886|FG001|Overall Study|Withdrew Consent|4
6262904|NCT02071082|9958885|FG000|Overall Study|Lost to Follow-up|1
6262905|NCT02071082|9958886|FG001|Overall Study|Lost to Follow-up|1
6262906|NCT02071225|9958910|FG000|Overall Study|Withdrawal of Consent|2
6262907|NCT02071225|9958910|FG000|Overall Study|Protocol Deviation|1
6262908|NCT02071225|9958910|FG000|Overall Study|Lost to Follow-up|2
6262909|NCT02071225|9958910|FG000|Overall Study|Death|25
6262910|NCT02071290|9958916|FG000|Overall Study|Death|1
6262911|NCT02071290|9958917|FG001|Overall Study|Death|0
6262912|NCT02071290|9958916|FG000|Overall Study|Withdrawal by Subject|0
6262913|NCT02071290|9958917|FG001|Overall Study|Withdrawal by Subject|1
6262914|NCT02071290|9958916|FG000|Overall Study|Protocol Violation|3
6262915|NCT02071290|9958917|FG001|Overall Study|Protocol Violation|5
6262916|NCT02071290|9958916|FG000|Overall Study|Physician Decision|0
6262917|NCT02071290|9958917|FG001|Overall Study|Physician Decision|1
6262918|NCT02071706|9958932|FG000|Overall Study|Adverse Event|1
6262919|NCT02071706|9958932|FG000|Overall Study|Withdrawal by Subject|2
6262920|NCT02071771|9958936|FG000|Period 1: First 10 Days|Unacceptable lens fit|1
6262921|NCT02071771|9958937|FG001|Period 1: First 10 Days|Unacceptable lens fit|0
6262922|NCT02071771|9958936|FG000|Period 1: First 10 Days|Unavailable lens power|1
6262923|NCT02071771|9958937|FG001|Period 1: First 10 Days|Unavailable lens power|0
6271421|NCT02163759|9973170|FG000|Overall Study|Death|0
6271422|NCT02163759|9973171|FG001|Overall Study|Death|0
6271423|NCT02163759|9973172|FG002|Overall Study|Death|1
6271424|NCT02163902|9973211|FG000|Overall Study|Subject's Request|3
6271425|NCT02163902|9973212|FG001|Overall Study|Subject's Request|4
6271426|NCT02163902|9973211|FG000|Overall Study|Lost to Follow-up|6
6271427|NCT02163902|9973212|FG001|Overall Study|Lost to Follow-up|7
6271428|NCT02163902|9973211|FG000|Overall Study|Administrative Decision|2
6262924|NCT02071849|9958975|FG000|6-month Primary Endpoint|Did not receive device|4
6262925|NCT02071849|9958975|FG000|6-month Primary Endpoint|Adverse Event|1
6262926|NCT02071849|9958975|FG000|2-year Extended Follow-up|Adverse Event|1
6262927|NCT02072096|9958994|FG000|Overall Study|Lack of Efficacy|18
6262928|NCT02072096|9958995|FG001|Overall Study|Lack of Efficacy|29
6262929|NCT02072096|9958994|FG000|Overall Study|Protocol Violation|7
6262930|NCT02072096|9958995|FG001|Overall Study|Protocol Violation|7
6262931|NCT02072096|9958994|FG000|Overall Study|Withdrawal by Subject|5
6262932|NCT02072096|9958995|FG001|Overall Study|Withdrawal by Subject|7
6262933|NCT02072096|9958994|FG000|Overall Study|Adverse Event|5
6262934|NCT02072096|9958995|FG001|Overall Study|Adverse Event|2
6262935|NCT02072096|9958994|FG000|Overall Study|No Reason Provided|4
6262936|NCT02072096|9958995|FG001|Overall Study|No Reason Provided|2
6262937|NCT02072096|9958994|FG000|Overall Study|Death|2
6262938|NCT02072096|9958995|FG001|Overall Study|Death|0
6262939|NCT02072096|9958994|FG000|Overall Study|Physician Decision|0
6262940|NCT02072096|9958995|FG001|Overall Study|Physician Decision|1
6262941|NCT02072096|9958994|FG000|Overall Study|Study Terminated by Sponsor|43
6262942|NCT02072096|9958995|FG001|Overall Study|Study Terminated by Sponsor|30
6086911|NCT00665392|9697045|FG000|Overall Study|not treated|1
6086912|NCT00665431|9697053|FG000|Overall Study|Adverse Event|16
6086913|NCT00665431|9697054|FG001|Overall Study|Adverse Event|22
6086914|NCT00665431|9697055|FG002|Overall Study|Adverse Event|6
6191061|NCT01419665|9847708|FG000|Combination Treatment|Protocol Violation|6
6191062|NCT01419665|9847709|FG001|Combination Treatment|Protocol Violation|2
6191063|NCT01419665|9847708|FG000|Combination Treatment|disease progression|10
6191064|NCT01419665|9847709|FG001|Combination Treatment|disease progression|9
6191065|NCT01419665|9847708|FG000|Combination Treatment|Death|5
6262943|NCT02072096|9958994|FG000|Overall Study|Lost to Follow-up|1
6086915|NCT00665431|9697053|FG000|Overall Study|Withdrawal by Subject|17
6086916|NCT00665431|9697054|FG001|Overall Study|Withdrawal by Subject|25
6086917|NCT00665431|9697055|FG002|Overall Study|Withdrawal by Subject|15
6086918|NCT00665431|9697053|FG000|Overall Study|Lost to Follow-up|3
6086919|NCT00665431|9697054|FG001|Overall Study|Lost to Follow-up|3
6086920|NCT00665431|9697055|FG002|Overall Study|Lost to Follow-up|1
6086921|NCT00665431|9697053|FG000|Overall Study|Other|4
6086922|NCT00665431|9697054|FG001|Overall Study|Other|7
6086923|NCT00665431|9697055|FG002|Overall Study|Other|2
6262944|NCT02072096|9958995|FG001|Overall Study|Lost to Follow-up|0
6262945|NCT02072174|9959004|FG000|Overall Study|Did Not Meet In-/Exclusion Criteria|14
6262946|NCT02072174|9959005|FG001|Overall Study|Did Not Meet In-/Exclusion Criteria|15
6262947|NCT02072174|9959004|FG000|Overall Study|Protocol Violation|16
6262948|NCT02072174|9959005|FG001|Overall Study|Protocol Violation|23
6262949|NCT02072174|9959004|FG000|Overall Study|Physician Decision|0
6262950|NCT02072174|9959005|FG001|Overall Study|Physician Decision|1
6262951|NCT02072174|9959004|FG000|Overall Study|Non-compliance with protocol requirement|2
6262952|NCT02072174|9959005|FG001|Overall Study|Non-compliance with protocol requirement|0
6262953|NCT02072226|9959019|FG000|Overall Study|Lost to Follow-up|11
6262954|NCT02072226|9959020|FG001|Overall Study|Lost to Follow-up|7
6262955|NCT02072226|9959019|FG000|Overall Study|Patient Non-compliance|2
6262956|NCT02072226|9959020|FG001|Overall Study|Patient Non-compliance|3
6262957|NCT02072226|9959019|FG000|Overall Study|Death|1
6262958|NCT02072226|9959020|FG001|Overall Study|Death|0
6262959|NCT02072226|9959019|FG000|Overall Study|Patient Withdrawal of Consent|1
6262960|NCT02072226|9959020|FG001|Overall Study|Patient Withdrawal of Consent|0
6262961|NCT02072434|9959033|FG000|Overall Study|Protocol Violation|10
6262962|NCT02072434|9959034|FG001|Overall Study|Protocol Violation|9
6262963|NCT02072434|9959033|FG000|Overall Study|Physician Decision|5
6262964|NCT02072434|9959034|FG001|Overall Study|Physician Decision|10
6262965|NCT02072434|9959033|FG000|Overall Study|Adverse event, serious fatal|1
6262966|NCT02072434|9959034|FG001|Overall Study|Adverse event, serious fatal|6
6262967|NCT02072434|9959033|FG000|Overall Study|Adverse Event|7
6262968|NCT02072434|9959034|FG001|Overall Study|Adverse Event|6
6262969|NCT02072434|9959033|FG000|Overall Study|Withdrawal by Subject|17
6262970|NCT02072434|9959034|FG001|Overall Study|Withdrawal by Subject|29
6262971|NCT02072434|9959033|FG000|Overall Study|Other|14
6262972|NCT02072434|9959034|FG001|Overall Study|Other|29
6262973|NCT02072434|9959033|FG000|Overall Study|Lost to Follow-up|0
6262974|NCT02072434|9959034|FG001|Overall Study|Lost to Follow-up|1
6262975|NCT02072668|9959040|FG000|Second Intervention|Lost to Follow-up|1
6262976|NCT02072668|9959041|FG001|Second Intervention|Lost to Follow-up|0
6262977|NCT02072824|9959052|FG000|Overall Study|Insufficient clinical response|1
6086924|NCT00665561|9697078|FG000|Overall Study|Death recorded on subject summary pages|75
6191066|NCT01419665|9847709|FG001|Combination Treatment|Death|7
6191067|NCT01419665|9847708|FG000|Combination Treatment|administrative problems|0
6262978|NCT02072824|9959053|FG001|Overall Study|Insufficient clinical response|0
6086925|NCT00665561|9697079|FG001|Overall Study|Death recorded on subject summary pages|75
6191068|NCT01419665|9847709|FG001|Combination Treatment|administrative problems|1
6191069|NCT01419665|9847708|FG000|Combination Treatment|Withdrawal by Subject|5
6191070|NCT01419665|9847709|FG001|Combination Treatment|Withdrawal by Subject|4
6191071|NCT01419665|9847708|FG000|Maintenance Treatment and/or Follow up|switch to open label|44
6191072|NCT01419665|9847709|FG001|Maintenance Treatment and/or Follow up|switch to open label|39
6262979|NCT02072824|9959054|FG002|Overall Study|Insufficient clinical response|1
6262980|NCT02072824|9959052|FG000|Overall Study|No longer willing to participate|1
6262981|NCT02072824|9959053|FG001|Overall Study|No longer willing to participate|0
6262982|NCT02072824|9959054|FG002|Overall Study|No longer willing to participate|1
6262983|NCT02072824|9959052|FG000|Overall Study|Medication error|0
6262984|NCT02072824|9959053|FG001|Overall Study|Medication error|1
6262985|NCT02072824|9959054|FG002|Overall Study|Medication error|0
6262986|NCT02072824|9959052|FG000|Overall Study|Adverse Event|0
6262987|NCT02072824|9959053|FG001|Overall Study|Adverse Event|0
6262988|NCT02072824|9959054|FG002|Overall Study|Adverse Event|1
6262989|NCT02072941|9959068|FG000|Overall Study|Withdrawal by Subject|29
6262990|NCT02072941|9959069|FG001|Overall Study|Withdrawal by Subject|21
6262991|NCT02072941|9959068|FG000|Overall Study|Lost to Follow-up|4
6262992|NCT02072941|9959069|FG001|Overall Study|Lost to Follow-up|4
6262993|NCT02072941|9959068|FG000|Overall Study|Death|3
6262994|NCT02072941|9959069|FG001|Overall Study|Death|2
6262995|NCT02072941|9959068|FG000|Overall Study|Removed by Study Staff|2
6262996|NCT02072941|9959069|FG001|Overall Study|Removed by Study Staff|2
6262997|NCT02072980|9959075|FG000|Period 2, Second Wear|Adverse Event|0
6262998|NCT02072980|9959076|FG001|Period 2, Second Wear|Adverse Event|1
6262999|NCT02073643|9959142|FG000|Overall Study|Lost to Follow-up|24
6263000|NCT02073656|9959146|FG000|Primary Study|Lost to Follow-up|6
6263001|NCT02073656|9959146|FG000|Primary Study|Death|1
6263002|NCT02073656|9959146|FG000|Primary Study|Withdrew Consent|1
6263003|NCT02073682|9959154|FG000|Overall Study|Low Creatinine Clearance|1
6263004|NCT02073682|9959155|FG001|Overall Study|Low Creatinine Clearance|2
6263005|NCT02073682|9959154|FG000|Overall Study|Death|86
6263006|NCT02073682|9959155|FG001|Overall Study|Death|100
6263007|NCT02073682|9959154|FG000|Overall Study|Cancer Cured|10
6263008|NCT02073682|9959155|FG001|Overall Study|Cancer Cured|15
6263009|NCT02073682|9959154|FG000|Overall Study|ID: Patient Noncompliance|1
6263010|NCT02073682|9959155|FG001|Overall Study|ID: Patient Noncompliance|2
6263011|NCT02073682|9959154|FG000|Overall Study|ID: Palliative Treatment Only|10
6263012|NCT02073682|9959155|FG001|Overall Study|ID: Palliative Treatment Only|7
6263013|NCT02073682|9959154|FG000|Overall Study|Prohibited Concomitant Medication Use|0
6263014|NCT02073682|9959155|FG001|Overall Study|Prohibited Concomitant Medication Use|1
6263015|NCT02073682|9959154|FG000|Overall Study|Platelet Count <50,000/mL|1
6263016|NCT02073682|9959155|FG001|Overall Study|Platelet Count <50,000/mL|2
6263017|NCT02073682|9959154|FG000|Overall Study|Surgery/Medical Procedure|3
6263018|NCT02073682|9959155|FG001|Overall Study|Surgery/Medical Procedure|1
6263019|NCT02073682|9959154|FG000|Overall Study|Withdrawal by Subject|6
6263020|NCT02073682|9959155|FG001|Overall Study|Withdrawal by Subject|8
6263021|NCT02073682|9959154|FG000|Overall Study|Start of New Chemotherapy Regimen|6
6263022|NCT02073682|9959155|FG001|Overall Study|Start of New Chemotherapy Regimen|3
6263023|NCT02073682|9959154|FG000|Overall Study|Cancer Progression|53
6263024|NCT02073682|9959155|FG001|Overall Study|Cancer Progression|33
6263025|NCT02073682|9959154|FG000|Overall Study|Protocol Violation|1
6263026|NCT02073682|9959155|FG001|Overall Study|Protocol Violation|0
6263027|NCT02073682|9959154|FG000|Overall Study|Adverse Event|79
6263028|NCT02073682|9959155|FG001|Overall Study|Adverse Event|62
6263029|NCT02073682|9959154|FG000|Overall Study|No reason provided|11
6263030|NCT02073682|9959155|FG001|Overall Study|No reason provided|9
6263031|NCT02073682|9959154|FG000|Overall Study|PD: Inconvenience of Dosing|21
6263032|NCT02073682|9959155|FG001|Overall Study|PD: Inconvenience of Dosing|78
6263033|NCT02073682|9959154|FG000|Overall Study|Lost to Follow-up|1
6263034|NCT02073682|9959155|FG001|Overall Study|Lost to Follow-up|1
6191073|NCT01419665|9847708|FG000|Maintenance Treatment and/or Follow up|administrative problems|0
6191074|NCT01419665|9847709|FG001|Maintenance Treatment and/or Follow up|administrative problems|6
6191075|NCT01419665|9847708|FG000|Maintenance Treatment and/or Follow up|Withdrawal by Subject|6
6191076|NCT01419665|9847709|FG001|Maintenance Treatment and/or Follow up|Withdrawal by Subject|6
6191077|NCT01419665|9847708|FG000|Maintenance Treatment and/or Follow up|Protocol Violation|1
6191078|NCT01419665|9847709|FG001|Maintenance Treatment and/or Follow up|Protocol Violation|1
6191079|NCT01419665|9847708|FG000|Maintenance Treatment and/or Follow up|Physician Decision|5
6191080|NCT01419665|9847709|FG001|Maintenance Treatment and/or Follow up|Physician Decision|2
6191081|NCT01419665|9847708|FG000|Maintenance Treatment and/or Follow up|disease progression|53
6191082|NCT01419665|9847709|FG001|Maintenance Treatment and/or Follow up|disease progression|37
6191083|NCT01419665|9847708|FG000|Maintenance Treatment and/or Follow up|Death|1
6191084|NCT01419665|9847709|FG001|Maintenance Treatment and/or Follow up|Death|2
6191085|NCT01419665|9847708|FG000|Maintenance Treatment and/or Follow up|Adverse Event|11
6191086|NCT01419665|9847709|FG001|Maintenance Treatment and/or Follow up|Adverse Event|7
6191087|NCT01419665|9847708|FG000|Maintenance Treatment and/or Follow up|Lost to Follow-up|1
6263035|NCT02073682|9959154|FG000|Overall Study|ID: Benefit/Risk Judgment|32
6263036|NCT02073682|9959155|FG001|Overall Study|ID: Benefit/Risk Judgment|46
6263037|NCT02073929|9959172|FG000|Overall Study|Lost to Follow-up|2
6263038|NCT02073929|9959173|FG001|Overall Study|Lost to Follow-up|1
6263039|NCT02073929|9959172|FG000|Overall Study|Adverse Event|2
6263040|NCT02073929|9959173|FG001|Overall Study|Adverse Event|1
6263041|NCT02073929|9959172|FG000|Overall Study|Withdrawal by Subject|0
6263042|NCT02073929|9959173|FG001|Overall Study|Withdrawal by Subject|1
6263043|NCT02074059|9959185|FG000|Overall Study|Death|0
6263044|NCT02074059|9959186|FG001|Overall Study|Death|0
6263045|NCT02074059|9959187|FG002|Overall Study|Death|0
6263046|NCT02074059|9959188|FG003|Overall Study|Death|0
6263047|NCT02074059|9959189|FG004|Overall Study|Death|1
6263048|NCT02074059|9959190|FG005|Overall Study|Death|1
6263049|NCT02074514|9959239|FG000|Overall Study|Lack of Efficacy|3
6263050|NCT02074514|9959240|FG001|Overall Study|Lack of Efficacy|2
6263051|NCT02074514|9959239|FG000|Overall Study|Lost to Follow-up|0
6263052|NCT02074514|9959240|FG001|Overall Study|Lost to Follow-up|1
6263053|NCT02074514|9959239|FG000|Overall Study|Withdrew Consent|0
6263054|NCT02074514|9959240|FG001|Overall Study|Withdrew Consent|1
6263055|NCT02074553|9959252|FG000|Intervention Period 1|Family Emergency|0
6263056|NCT02074553|9959253|FG001|Intervention Period 1|Family Emergency|0
6263057|NCT02074553|9959254|FG002|Intervention Period 1|Family Emergency|0
6263058|NCT02074553|9959255|FG003|Intervention Period 1|Family Emergency|1
6263059|NCT02074553|9959256|FG004|Intervention Period 1|Family Emergency|0
6263060|NCT02074553|9959257|FG005|Intervention Period 1|Family Emergency|0
6263061|NCT02074553|9959258|FG006|Intervention Period 1|Family Emergency|0
6263062|NCT02074553|9959259|FG007|Intervention Period 1|Family Emergency|0
6263063|NCT02074553|9959252|FG000|Washout Period 1|Adverse Event|1
6263064|NCT02074553|9959253|FG001|Washout Period 1|Adverse Event|0
6263065|NCT02074553|9959254|FG002|Washout Period 1|Adverse Event|0
6263066|NCT02074553|9959255|FG003|Washout Period 1|Adverse Event|0
6263067|NCT02074553|9959256|FG004|Washout Period 1|Adverse Event|0
6263068|NCT02074553|9959257|FG005|Washout Period 1|Adverse Event|0
6263069|NCT02074553|9959258|FG006|Washout Period 1|Adverse Event|0
6263070|NCT02074553|9959259|FG007|Washout Period 1|Adverse Event|0
6263071|NCT02074553|9959252|FG000|Washout Period 1|Physician Decision|0
6263072|NCT02074553|9959253|FG001|Washout Period 1|Physician Decision|0
6263073|NCT02074553|9959254|FG002|Washout Period 1|Physician Decision|0
6263074|NCT02074553|9959255|FG003|Washout Period 1|Physician Decision|1
6263075|NCT02074553|9959256|FG004|Washout Period 1|Physician Decision|0
6263076|NCT02074553|9959257|FG005|Washout Period 1|Physician Decision|0
6263077|NCT02074553|9959258|FG006|Washout Period 1|Physician Decision|0
6263078|NCT02074553|9959259|FG007|Washout Period 1|Physician Decision|0
6263079|NCT02074553|9959252|FG000|Washout Period 1|Other|0
6263080|NCT02074553|9959253|FG001|Washout Period 1|Other|0
6263081|NCT02074553|9959254|FG002|Washout Period 1|Other|0
6263082|NCT02074553|9959255|FG003|Washout Period 1|Other|0
6263083|NCT02074553|9959256|FG004|Washout Period 1|Other|0
6263084|NCT02074553|9959257|FG005|Washout Period 1|Other|1
6263085|NCT02074553|9959258|FG006|Washout Period 1|Other|0
6263086|NCT02074553|9959259|FG007|Washout Period 1|Other|0
6263087|NCT02074553|9959252|FG000|Washout Period 2|Adverse Event|0
6263088|NCT02074553|9959253|FG001|Washout Period 2|Adverse Event|0
6263089|NCT02074553|9959254|FG002|Washout Period 2|Adverse Event|0
6263090|NCT02074553|9959255|FG003|Washout Period 2|Adverse Event|0
6263091|NCT02074553|9959256|FG004|Washout Period 2|Adverse Event|0
6263092|NCT02074553|9959257|FG005|Washout Period 2|Adverse Event|0
6263093|NCT02074553|9959258|FG006|Washout Period 2|Adverse Event|1
6263094|NCT02074553|9959259|FG007|Washout Period 2|Adverse Event|0
6263095|NCT02074553|9959252|FG000|Washout Period 2|Physician Decision|0
6263096|NCT02074553|9959253|FG001|Washout Period 2|Physician Decision|0
6263097|NCT02074553|9959254|FG002|Washout Period 2|Physician Decision|0
6263098|NCT02074553|9959255|FG003|Washout Period 2|Physician Decision|0
6263099|NCT02074553|9959256|FG004|Washout Period 2|Physician Decision|0
6263100|NCT02074553|9959257|FG005|Washout Period 2|Physician Decision|1
6263101|NCT02074553|9959258|FG006|Washout Period 2|Physician Decision|0
6263102|NCT02074553|9959259|FG007|Washout Period 2|Physician Decision|0
6263103|NCT02074553|9959252|FG000|Washout Period 2|Lost to Follow-up|0
6263104|NCT02074553|9959253|FG001|Washout Period 2|Lost to Follow-up|0
6263105|NCT02074553|9959254|FG002|Washout Period 2|Lost to Follow-up|1
6263106|NCT02074553|9959255|FG003|Washout Period 2|Lost to Follow-up|0
6263107|NCT02074553|9959256|FG004|Washout Period 2|Lost to Follow-up|0
6263108|NCT02074553|9959257|FG005|Washout Period 2|Lost to Follow-up|0
6263109|NCT02074553|9959258|FG006|Washout Period 2|Lost to Follow-up|0
6263110|NCT02074553|9959259|FG007|Washout Period 2|Lost to Follow-up|0
6263111|NCT02074553|9959252|FG000|Washout Period 3|Physician Decision|0
6263112|NCT02074553|9959253|FG001|Washout Period 3|Physician Decision|0
6263113|NCT02074553|9959254|FG002|Washout Period 3|Physician Decision|0
6263114|NCT02074553|9959255|FG003|Washout Period 3|Physician Decision|0
6263115|NCT02074553|9959256|FG004|Washout Period 3|Physician Decision|0
6263116|NCT02074553|9959257|FG005|Washout Period 3|Physician Decision|0
6263117|NCT02074553|9959258|FG006|Washout Period 3|Physician Decision|0
6263118|NCT02074553|9959259|FG007|Washout Period 3|Physician Decision|1
6263119|NCT02074982|9959297|FG000|Overall Study|Adverse Event|15
6263120|NCT02074982|9959298|FG001|Overall Study|Adverse Event|7
6263121|NCT02074982|9959297|FG000|Overall Study|Lack of Efficacy|6
6263122|NCT02074982|9959298|FG001|Overall Study|Lack of Efficacy|1
6263123|NCT02074982|9959297|FG000|Overall Study|Lost to Follow-up|9
6263124|NCT02074982|9959298|FG001|Overall Study|Lost to Follow-up|10
6263125|NCT02074982|9959297|FG000|Overall Study|Non-compliance with study treatment|0
6263126|NCT02074982|9959298|FG001|Overall Study|Non-compliance with study treatment|2
6263127|NCT02074982|9959297|FG000|Overall Study|Physician Decision|1
6263128|NCT02074982|9959298|FG001|Overall Study|Physician Decision|1
6263129|NCT02074982|9959297|FG000|Overall Study|Pregnancy|1
6263130|NCT02074982|9959298|FG001|Overall Study|Pregnancy|2
6263131|NCT02074982|9959297|FG000|Overall Study|Protocol deviation|4
6263132|NCT02074982|9959298|FG001|Overall Study|Protocol deviation|3
6263133|NCT02074982|9959297|FG000|Overall Study|Technical problems|0
6263134|NCT02074982|9959298|FG001|Overall Study|Technical problems|2
6263135|NCT02074982|9959297|FG000|Overall Study|Subject/guardian decision|15
6263136|NCT02074982|9959298|FG001|Overall Study|Subject/guardian decision|24
6263137|NCT02074982|9959297|FG000|Overall Study|Death|0
6263138|NCT02074982|9959298|FG001|Overall Study|Death|2
6263139|NCT02075008|9959310|FG000|Overall Study|Technical problems|1
6263140|NCT02075008|9959310|FG000|Overall Study|Pregnancy|1
6263141|NCT02075008|9959310|FG000|Overall Study|Physician Decision|1
6263142|NCT02075008|9959310|FG000|Overall Study|Lost to Follow-up|1
6263143|NCT02075008|9959310|FG000|Overall Study|Lack of Efficacy|1
6263144|NCT02075008|9959310|FG000|Overall Study|Death|1
6263145|NCT02075008|9959310|FG000|Overall Study|Adverse Event|5
6263146|NCT02075008|9959310|FG000|Overall Study|Withdrawal by Subject|6
6263147|NCT02075008|9959310|FG000|Overall Study|Study terminated by Sponsor|159
6263148|NCT02075047|9959316|FG000|Treatment Phase (4 Weeks)|Adverse Event|14
6263149|NCT02075047|9959317|FG001|Treatment Phase (4 Weeks)|Adverse Event|4
6263150|NCT02075047|9959316|FG000|Treatment Phase (4 Weeks)|Lack of Efficacy|2
6263151|NCT02075047|9959317|FG001|Treatment Phase (4 Weeks)|Lack of Efficacy|2
6263152|NCT02075047|9959316|FG000|Treatment Phase (4 Weeks)|Lost to Follow-up|0
6263153|NCT02075047|9959317|FG001|Treatment Phase (4 Weeks)|Lost to Follow-up|1
6263154|NCT02075047|9959316|FG000|Treatment Phase (4 Weeks)|Medication Error Without Associated Adverse Event|1
6263155|NCT02075047|9959317|FG001|Treatment Phase (4 Weeks)|Medication Error Without Associated Adverse Event|0
6263156|NCT02075047|9959316|FG000|Treatment Phase (4 Weeks)|Screen Failure|1
6263157|NCT02075047|9959317|FG001|Treatment Phase (4 Weeks)|Screen Failure|0
6263158|NCT02075047|9959316|FG000|Treatment Phase (4 Weeks)|Other|1
6263159|NCT02075047|9959317|FG001|Treatment Phase (4 Weeks)|Other|1
6263160|NCT02075047|9959316|FG000|Treatment Phase (4 Weeks)|Withdrawal By Parent/Guardian|4
6263161|NCT02075047|9959317|FG001|Treatment Phase (4 Weeks)|Withdrawal By Parent/Guardian|2
6263162|NCT02075047|9959316|FG000|Follow up Phase (5 Weeks)|Adverse Event|14
6263163|NCT02075047|9959317|FG001|Follow up Phase (5 Weeks)|Adverse Event|4
6263164|NCT02075047|9959316|FG000|Follow up Phase (5 Weeks)|Lack of Efficacy|2
6263165|NCT02075047|9959317|FG001|Follow up Phase (5 Weeks)|Lack of Efficacy|2
6263166|NCT02075047|9959316|FG000|Follow up Phase (5 Weeks)|Lost to Follow-up|0
6263167|NCT02075047|9959317|FG001|Follow up Phase (5 Weeks)|Lost to Follow-up|1
6263168|NCT02075047|9959316|FG000|Follow up Phase (5 Weeks)|Medication Error Without Associated Adverse Event|1
6263169|NCT02075047|9959317|FG001|Follow up Phase (5 Weeks)|Medication Error Without Associated Adverse Event|0
6263170|NCT02075047|9959316|FG000|Follow up Phase (5 Weeks)|Screen Failure|1
6263171|NCT02075047|9959317|FG001|Follow up Phase (5 Weeks)|Screen Failure|0
6263172|NCT02075047|9959316|FG000|Follow up Phase (5 Weeks)|Other|1
6263173|NCT02075047|9959317|FG001|Follow up Phase (5 Weeks)|Other|2
6263174|NCT02075047|9959316|FG000|Follow up Phase (5 Weeks)|Withdrawal By Parent/Guardian|7
6263175|NCT02075047|9959317|FG001|Follow up Phase (5 Weeks)|Withdrawal By Parent/Guardian|4
6263176|NCT02075073|9959326|FG000|Overall Study|Withdrawal by Subject|0
6263177|NCT02075073|9959327|FG001|Overall Study|Withdrawal by Subject|1
6263178|NCT02075073|9959328|FG002|Overall Study|Withdrawal by Subject|0
6263179|NCT02075203|9959348|FG000|Overall Study|Withdrawal by Subject|1
6263180|NCT02075203|9959349|FG001|Overall Study|Withdrawal by Subject|0
6263181|NCT02075203|9959350|FG002|Overall Study|Withdrawal by Subject|1
6263182|NCT02075203|9959348|FG000|Overall Study|Adverse Event|1
6263183|NCT02075203|9959349|FG001|Overall Study|Adverse Event|0
6263184|NCT02075203|9959350|FG002|Overall Study|Adverse Event|0
6263185|NCT02075203|9959348|FG000|Overall Study|participant refused to use contraception|1
6263186|NCT02075203|9959349|FG001|Overall Study|participant refused to use contraception|0
6263187|NCT02075203|9959350|FG002|Overall Study|participant refused to use contraception|0
6263188|NCT02075255|9959361|FG000|Overall Study|Study specific withdrawal criteria|0
6263189|NCT02075255|9959362|FG001|Overall Study|Study specific withdrawal criteria|1
6263190|NCT02075255|9959363|FG002|Overall Study|Study specific withdrawal criteria|1
6263191|NCT02075255|9959361|FG000|Overall Study|Withdrawal by Subject|4
6263192|NCT02075255|9959362|FG001|Overall Study|Withdrawal by Subject|1
6263193|NCT02075255|9959363|FG002|Overall Study|Withdrawal by Subject|0
6263194|NCT02075255|9959361|FG000|Overall Study|Lost to Follow-up|0
6263195|NCT02075255|9959362|FG001|Overall Study|Lost to Follow-up|0
6263196|NCT02075255|9959363|FG002|Overall Study|Lost to Follow-up|1
6263197|NCT02075255|9959361|FG000|Overall Study|Adverse Event|0
6263198|NCT02075255|9959362|FG001|Overall Study|Adverse Event|0
6263199|NCT02075255|9959363|FG002|Overall Study|Adverse Event|1
6263200|NCT02075255|9959361|FG000|Overall Study|Death|0
6263201|NCT02075255|9959362|FG001|Overall Study|Death|2
6263202|NCT02075255|9959363|FG002|Overall Study|Death|0
6263203|NCT02075463|9959371|FG000|Overall Study|Adverse Event|3
6263204|NCT02075463|9959371|FG000|Overall Study|Par. reached stopping criteria|4
6263205|NCT02075463|9959371|FG000|Overall Study|Withdrawal by Subject|1
6263206|NCT02075476|9959378|FG000|Overall Study|Death|2
6263207|NCT02075476|9959379|FG001|Overall Study|Death|2
6263208|NCT02075476|9959378|FG000|Overall Study|Lost to Follow-up|1
6263209|NCT02075476|9959379|FG001|Overall Study|Lost to Follow-up|3
6263210|NCT02075515|9959388|FG000|Overall Study|Serious Adverse Event|1
6263211|NCT02075515|9959389|FG001|Overall Study|Serious Adverse Event|1
6263212|NCT02075515|9959390|FG002|Overall Study|Serious Adverse Event|1
6263213|NCT02075515|9959388|FG000|Overall Study|Non-Serious Adverse Event|0
6263214|NCT02075515|9959389|FG001|Overall Study|Non-Serious Adverse Event|1
6263215|NCT02075515|9959390|FG002|Overall Study|Non-Serious Adverse Event|0
6263216|NCT02075515|9959388|FG000|Overall Study|Withdrawal by Subject|2
6263217|NCT02075515|9959389|FG001|Overall Study|Withdrawal by Subject|0
6263218|NCT02075515|9959390|FG002|Overall Study|Withdrawal by Subject|1
6263219|NCT02075515|9959388|FG000|Overall Study|Lost to Follow-up|1
6263220|NCT02075515|9959389|FG001|Overall Study|Lost to Follow-up|3
6263221|NCT02075515|9959390|FG002|Overall Study|Lost to Follow-up|6
6263222|NCT02075541|9959401|FG000|Overall Study|Serious Adverse Event|1
6263223|NCT02075541|9959402|FG001|Overall Study|Serious Adverse Event|4
6263224|NCT02075541|9959401|FG000|Overall Study|Protocol Violation|1
6263225|NCT02075541|9959402|FG001|Overall Study|Protocol Violation|0
6263226|NCT02075541|9959401|FG000|Overall Study|Withdrawal by Subject|1
6263227|NCT02075541|9959402|FG001|Overall Study|Withdrawal by Subject|3
6263228|NCT02075541|9959401|FG000|Overall Study|Sponsor study termination|0
6263229|NCT02075541|9959402|FG001|Overall Study|Sponsor study termination|1
6263230|NCT02075541|9959401|FG000|Overall Study|Other- unable to perform study procedure|1
6263231|NCT02075541|9959402|FG001|Overall Study|Other- unable to perform study procedure|0
6263232|NCT02075554|9959408|FG000|Overall Study|Lost to Follow-up|7
6263233|NCT02075554|9959408|FG000|Overall Study|Withdrawal by Subject|5
6263234|NCT02075554|9959408|FG000|Overall Study|Physician Decision|3
6263235|NCT02075606|9959412|FG000|Overall Study|Adverse Event|5
6263236|NCT02075606|9959412|FG000|Overall Study|Withdrawal by Subject|1
6263237|NCT02075606|9959412|FG000|Overall Study|Death|1
6263238|NCT02075606|9959412|FG000|Overall Study|Investigator's decision|1
6263239|NCT02075606|9959412|FG000|Overall Study|Symptom management|1
6263240|NCT02075606|9959412|FG000|Overall Study|Increasing Symptoms|1
6263241|NCT02075632|9959423|FG000|Overall Study|Adverse Event|1
6263242|NCT02075632|9959424|FG001|Overall Study|Adverse Event|1
6263243|NCT02075632|9959423|FG000|Overall Study|Lost to Follow-up|0
6263244|NCT02075632|9959424|FG001|Overall Study|Lost to Follow-up|3
6263245|NCT02075632|9959423|FG000|Overall Study|Withdrawal by Subject|0
6263246|NCT02075632|9959424|FG001|Overall Study|Withdrawal by Subject|1
6263247|NCT02075658|9959432|FG000|Overall Study|Physician Decision|2
6263248|NCT02075658|9959433|FG001|Overall Study|Physician Decision|2
6263249|NCT02076022|9959441|FG000|Overall Study|Withdrawal by Subject|2
6263250|NCT02076022|9959442|FG001|Overall Study|Withdrawal by Subject|0
6263251|NCT02076113|9959483|FG000|Overall Study|Lost to Follow-up|4
6263252|NCT02076113|9959484|FG001|Overall Study|Lost to Follow-up|1
6263253|NCT02076113|9959483|FG000|Overall Study|Withdrawal by Subject|2
6263254|NCT02076113|9959484|FG001|Overall Study|Withdrawal by Subject|3
6263255|NCT02076113|9959483|FG000|Overall Study|Death|1
6263256|NCT02076113|9959484|FG001|Overall Study|Death|3
6263257|NCT02076165|9959503|FG000|Overall Study|Lost to Follow-up|7
6263258|NCT02076165|9959504|FG001|Overall Study|Lost to Follow-up|5
6263259|NCT02076165|9959503|FG000|Overall Study|Refused follow-up assessment|1
6263260|NCT02076165|9959504|FG001|Overall Study|Refused follow-up assessment|1
6263261|NCT02076334|9959527|FG000|Overall Study|Protocol Violation|1
6263262|NCT02076334|9959528|FG001|Overall Study|Protocol Violation|0
6263263|NCT02076334|9959529|FG002|Overall Study|Protocol Violation|0
6263264|NCT02076334|9959530|FG003|Overall Study|Protocol Violation|0
6263265|NCT02076334|9959527|FG000|Overall Study|Lost to Follow-up|0
6263266|NCT02076334|9959528|FG001|Overall Study|Lost to Follow-up|1
6263267|NCT02076334|9959529|FG002|Overall Study|Lost to Follow-up|1
6263268|NCT02076334|9959530|FG003|Overall Study|Lost to Follow-up|0
6263269|NCT02076334|9959527|FG000|Overall Study|muscle soreness|0
6263270|NCT02076334|9959528|FG001|Overall Study|muscle soreness|0
6263271|NCT02076334|9959529|FG002|Overall Study|muscle soreness|0
6263272|NCT02076334|9959530|FG003|Overall Study|muscle soreness|1
6263273|NCT02077140|9959631|FG000|Overall Study|Lost to Follow-up|4
6263274|NCT02077140|9959632|FG001|Overall Study|Lost to Follow-up|1
6263275|NCT02077140|9959633|FG002|Overall Study|Lost to Follow-up|2
6263276|NCT02077140|9959634|FG003|Overall Study|Lost to Follow-up|2
6263277|NCT02077140|9959635|FG004|Overall Study|Lost to Follow-up|3
6263278|NCT02077140|9959631|FG000|Overall Study|Withdrawal by Subject|0
6263279|NCT02077140|9959632|FG001|Overall Study|Withdrawal by Subject|1
6263280|NCT02077140|9959633|FG002|Overall Study|Withdrawal by Subject|0
6263281|NCT02077140|9959634|FG003|Overall Study|Withdrawal by Subject|2
6263282|NCT02077140|9959635|FG004|Overall Study|Withdrawal by Subject|2
6263283|NCT02077374|9959652|FG000|Overall Study|Withdrawal by Subject|0
6263284|NCT02077374|9959653|FG001|Overall Study|Withdrawal by Subject|1
6263285|NCT02077374|9959652|FG000|Overall Study|Protocol Violation|0
6263286|NCT02077374|9959653|FG001|Overall Study|Protocol Violation|1
6263287|NCT02077465|9959664|FG000|Overall Study|Withdrew Consent|0
6263288|NCT02077465|9959665|FG001|Overall Study|Withdrew Consent|1
6263289|NCT02077465|9959664|FG000|Overall Study|Lost to Follow-up|1
6263290|NCT02077465|9959665|FG001|Overall Study|Lost to Follow-up|0
6263291|NCT02078102|9959673|FG000|Overall Study|Adverse Event|1
6263292|NCT02078102|9959674|FG001|Overall Study|Adverse Event|0
6263293|NCT02078102|9959673|FG000|Overall Study|Withdrawal by Subject|1
6263294|NCT02078102|9959674|FG001|Overall Study|Withdrawal by Subject|0
6263295|NCT02078102|9959673|FG000|Overall Study|Physician Decision|0
6263296|NCT02078102|9959674|FG001|Overall Study|Physician Decision|1
6191088|NCT01419665|9847709|FG001|Maintenance Treatment and/or Follow up|Lost to Follow-up|2
6191089|NCT01419665|9847708|FG000|Open Label Phase|Death|1
6191090|NCT01419665|9847709|FG001|Open Label Phase|Death|0
6191091|NCT01419665|9847708|FG000|Open Label Phase|disease progression|0
6191092|NCT01419665|9847709|FG001|Open Label Phase|disease progression|1
6191093|NCT01419717|9847717|FG000|Overall Study|Protocol-specified Criteria|62
6191094|NCT01419717|9847717|FG000|Overall Study|Adverse Event|19
6191095|NCT01419717|9847717|FG000|Overall Study|Death|17
6191096|NCT01419717|9847717|FG000|Overall Study|Withdrawal by Subject|10
6191097|NCT01419717|9847717|FG000|Overall Study|Disease Progression|9
6191098|NCT01419717|9847717|FG000|Overall Study|Other|4
6191099|NCT01419717|9847717|FG000|Overall Study|Lost to Follow-up|2
6191100|NCT01419717|9847717|FG000|Overall Study|Administrative Decision|1
6191101|NCT01419717|9847717|FG000|Overall Study|Noncompliance|1
6191102|NCT01419769|9847721|FG000|Overall Study|Did not receive the AXIOS stent|3
6191103|NCT01419769|9847721|FG000|Overall Study|Not evaluable due to pigtail stents|1
6191104|NCT01420068|9847756|FG000|Overall Study|Administrative problems|1
6191105|NCT01420068|9847757|FG001|Overall Study|Administrative problems|3
6191106|NCT01420068|9847756|FG000|Overall Study|Withdrawal by Subject|1
6191107|NCT01420068|9847757|FG001|Overall Study|Withdrawal by Subject|2
6191108|NCT01420081|9847772|FG000|Overall Study|Death|1
6263297|NCT02078219|9959700|FG000|Overall Study|Other|2
6263298|NCT02078219|9959701|FG001|Overall Study|Other|2
6263299|NCT02078219|9959702|FG002|Overall Study|Other|3
6263300|NCT02078219|9959703|FG003|Overall Study|Other|0
6263301|NCT02078219|9959704|FG004|Overall Study|Other|1
6263302|NCT02078219|9959700|FG000|Overall Study|Withdrawal by Subject|0
6263303|NCT02078219|9959701|FG001|Overall Study|Withdrawal by Subject|1
6263304|NCT02078219|9959702|FG002|Overall Study|Withdrawal by Subject|0
6263305|NCT02078219|9959703|FG003|Overall Study|Withdrawal by Subject|1
6263306|NCT02078219|9959704|FG004|Overall Study|Withdrawal by Subject|1
6263307|NCT02078219|9959700|FG000|Overall Study|Protocol Violation|0
6263308|NCT02078219|9959701|FG001|Overall Study|Protocol Violation|0
6263309|NCT02078219|9959702|FG002|Overall Study|Protocol Violation|0
6263310|NCT02078219|9959703|FG003|Overall Study|Protocol Violation|1
6263311|NCT02078219|9959704|FG004|Overall Study|Protocol Violation|0
6263312|NCT02078219|9959700|FG000|Overall Study|Death|0
6263313|NCT02078219|9959701|FG001|Overall Study|Death|0
6263314|NCT02078219|9959702|FG002|Overall Study|Death|0
6263315|NCT02078219|9959703|FG003|Overall Study|Death|1
6263316|NCT02078219|9959704|FG004|Overall Study|Death|0
6263317|NCT02078219|9959700|FG000|Overall Study|Adverse Event|1
6263318|NCT02078219|9959701|FG001|Overall Study|Adverse Event|1
6263319|NCT02078219|9959702|FG002|Overall Study|Adverse Event|3
6263320|NCT02078219|9959703|FG003|Overall Study|Adverse Event|1
6263321|NCT02078219|9959704|FG004|Overall Study|Adverse Event|0
6263322|NCT02078713|9959758|FG000|Overall Study|Lost to Follow-up|49
6263323|NCT02078713|9959759|FG001|Overall Study|Lost to Follow-up|55
6263324|NCT02078713|9959760|FG002|Overall Study|Lost to Follow-up|0
6086926|NCT00665561|9697078|FG000|Overall Study|Does not meet entrance criteria|19
6263325|NCT02078713|9959761|FG003|Overall Study|Lost to Follow-up|0
6263326|NCT02078713|9959758|FG000|Overall Study|Pregnant at baseline|3
6263327|NCT02078713|9959759|FG001|Overall Study|Pregnant at baseline|5
6263328|NCT02078713|9959760|FG002|Overall Study|Pregnant at baseline|0
6263329|NCT02078713|9959761|FG003|Overall Study|Pregnant at baseline|0
6263330|NCT02078713|9959758|FG000|Overall Study|Enrolled twice|0
6263331|NCT02078713|9959759|FG001|Overall Study|Enrolled twice|1
6263332|NCT02078713|9959760|FG002|Overall Study|Enrolled twice|0
6263333|NCT02078713|9959761|FG003|Overall Study|Enrolled twice|0
6263334|NCT02078752|9959792|FG000|Overall Study|Death|0
6263335|NCT02078752|9959793|FG001|Overall Study|Death|3
6263336|NCT02078752|9959794|FG002|Overall Study|Death|0
6263337|NCT02078752|9959795|FG003|Overall Study|Death|0
6263338|NCT02078752|9959796|FG004|Overall Study|Death|0
6263339|NCT02078752|9959797|FG005|Overall Study|Death|1
6263340|NCT02078752|9959798|FG006|Overall Study|Death|0
6263341|NCT02078752|9959799|FG007|Overall Study|Death|1
6263342|NCT02078752|9959800|FG008|Overall Study|Death|0
6263343|NCT02078752|9959801|FG009|Overall Study|Death|4
6263344|NCT02078752|9959792|FG000|Overall Study|Lost to Follow-up|1
6263345|NCT02078752|9959793|FG001|Overall Study|Lost to Follow-up|0
6263346|NCT02078752|9959794|FG002|Overall Study|Lost to Follow-up|0
6263347|NCT02078752|9959795|FG003|Overall Study|Lost to Follow-up|1
6086927|NCT00665561|9697079|FG001|Overall Study|Does not meet entrance criteria|21
6191109|NCT01420081|9847773|FG001|Overall Study|Death|0
6263348|NCT02078752|9959796|FG004|Overall Study|Lost to Follow-up|0
6263349|NCT02078752|9959797|FG005|Overall Study|Lost to Follow-up|0
6263350|NCT02078752|9959798|FG006|Overall Study|Lost to Follow-up|0
6263351|NCT02078752|9959799|FG007|Overall Study|Lost to Follow-up|0
6263352|NCT02078752|9959800|FG008|Overall Study|Lost to Follow-up|0
6191110|NCT01420081|9847774|FG002|Overall Study|Death|8
6191111|NCT01420081|9847775|FG003|Overall Study|Death|0
6263353|NCT02078752|9959801|FG009|Overall Study|Lost to Follow-up|0
6263354|NCT02078752|9959792|FG000|Overall Study|Withdrawal by Subject|1
6263355|NCT02078752|9959793|FG001|Overall Study|Withdrawal by Subject|1
6263356|NCT02078752|9959794|FG002|Overall Study|Withdrawal by Subject|1
6263357|NCT02078752|9959795|FG003|Overall Study|Withdrawal by Subject|1
6263358|NCT02078752|9959796|FG004|Overall Study|Withdrawal by Subject|0
6263359|NCT02078752|9959797|FG005|Overall Study|Withdrawal by Subject|3
6263360|NCT02078752|9959798|FG006|Overall Study|Withdrawal by Subject|2
6263361|NCT02078752|9959799|FG007|Overall Study|Withdrawal by Subject|1
6263362|NCT02078752|9959800|FG008|Overall Study|Withdrawal by Subject|0
6263363|NCT02078752|9959801|FG009|Overall Study|Withdrawal by Subject|1
6263364|NCT02078752|9959792|FG000|Overall Study|Other|0
6263365|NCT02078752|9959793|FG001|Overall Study|Other|3
6263366|NCT02078752|9959794|FG002|Overall Study|Other|0
6263367|NCT02078752|9959795|FG003|Overall Study|Other|0
6263368|NCT02078752|9959796|FG004|Overall Study|Other|1
6263369|NCT02078752|9959797|FG005|Overall Study|Other|0
6263370|NCT02078752|9959798|FG006|Overall Study|Other|0
6263371|NCT02078752|9959799|FG007|Overall Study|Other|1
6263372|NCT02078752|9959800|FG008|Overall Study|Other|0
6263373|NCT02078752|9959801|FG009|Overall Study|Other|0
6263374|NCT02078752|9959792|FG000|Overall Study|Study terminated by sponsor|0
6263375|NCT02078752|9959793|FG001|Overall Study|Study terminated by sponsor|0
6263376|NCT02078752|9959794|FG002|Overall Study|Study terminated by sponsor|0
6263377|NCT02078752|9959795|FG003|Overall Study|Study terminated by sponsor|0
6263378|NCT02078752|9959796|FG004|Overall Study|Study terminated by sponsor|0
6263379|NCT02078752|9959797|FG005|Overall Study|Study terminated by sponsor|0
6263380|NCT02078752|9959798|FG006|Overall Study|Study terminated by sponsor|0
6263381|NCT02078752|9959799|FG007|Overall Study|Study terminated by sponsor|0
6263382|NCT02078752|9959800|FG008|Overall Study|Study terminated by sponsor|0
6263383|NCT02078752|9959801|FG009|Overall Study|Study terminated by sponsor|5
6263384|NCT02078817|9959832|FG000|Overall Study|Withdrawal by Subject|1
6263385|NCT02078960|9959843|FG000|Treatment Period|Other|0
6263386|NCT02078960|9959844|FG001|Treatment Period|Other|0
6263387|NCT02078960|9959845|FG002|Treatment Period|Other|1
6263388|NCT02078960|9959843|FG000|Treatment Period|Lack of Efficacy|0
6263389|NCT02078960|9959844|FG001|Treatment Period|Lack of Efficacy|1
6263390|NCT02078960|9959845|FG002|Treatment Period|Lack of Efficacy|0
6263391|NCT02078960|9959843|FG000|Treatment Period|Disease progression - accelerated phase|0
6263392|NCT02078960|9959844|FG001|Treatment Period|Disease progression - accelerated phase|1
6263393|NCT02078960|9959845|FG002|Treatment Period|Disease progression - accelerated phase|0
6263394|NCT02078960|9959843|FG000|Treatment Period|Disease progression - blast phase|1
6263395|NCT02078960|9959844|FG001|Treatment Period|Disease progression - blast phase|0
6263396|NCT02078960|9959845|FG002|Treatment Period|Disease progression - blast phase|0
6263397|NCT02078960|9959843|FG000|Treatment Period|Withdrawal by Subject|0
6263398|NCT02078960|9959844|FG001|Treatment Period|Withdrawal by Subject|1
6263399|NCT02078960|9959845|FG002|Treatment Period|Withdrawal by Subject|1
6263400|NCT02078960|9959843|FG000|Treatment Period|Adverse Event|1
6263401|NCT02078960|9959844|FG001|Treatment Period|Adverse Event|0
6263402|NCT02078960|9959845|FG002|Treatment Period|Adverse Event|0
6263403|NCT02078960|9959843|FG000|Treatment Period|Death|0
6263404|NCT02078960|9959844|FG001|Treatment Period|Death|0
6263405|NCT02078960|9959845|FG002|Treatment Period|Death|1
6263406|NCT02078960|9959843|FG000|Follow-up Period|Death|2
6263407|NCT02078960|9959844|FG001|Follow-up Period|Death|0
6263408|NCT02078960|9959845|FG002|Follow-up Period|Death|0
6263409|NCT02078960|9959843|FG000|Follow-up Period|Lost to Follow-up|0
6263410|NCT02078960|9959844|FG001|Follow-up Period|Lost to Follow-up|1
6263411|NCT02078960|9959845|FG002|Follow-up Period|Lost to Follow-up|0
6263412|NCT02079038|9959867|FG000|Modified Intent to Treat Population|Withdrawal by Subject|6
6263413|NCT02079038|9959868|FG001|Modified Intent to Treat Population|Withdrawal by Subject|5
6263414|NCT02079038|9959867|FG000|Modified Intent to Treat Population|Death|1
6263415|NCT02079038|9959868|FG001|Modified Intent to Treat Population|Death|0
6263416|NCT02079038|9959867|FG000|Completed 6 Months|Lost to Follow-up|2
6263417|NCT02079038|9959868|FG001|Completed 6 Months|Lost to Follow-up|1
6263418|NCT02079077|9959876|FG000|Overall Study|Lost to Follow-up|5
6263419|NCT02079077|9959877|FG001|Overall Study|Lost to Follow-up|7
6263420|NCT02079077|9959876|FG000|Overall Study|Became STIs Positive|1
6263421|NCT02079077|9959877|FG001|Overall Study|Became STIs Positive|2
6263422|NCT02079246|9959883|FG000|OLEX|Withdrawal before treatment|1
6263423|NCT02079246|9959884|FG001|OLEX|Withdrawal before treatment|0
6263424|NCT02079246|9959883|FG000|OLEX|Death|11
6263425|NCT02079246|9959884|FG001|OLEX|Death|0
6263426|NCT02079246|9959883|FG000|OLEX|Adverse Event|66
6263427|NCT02079246|9959884|FG001|OLEX|Adverse Event|0
6263428|NCT02079246|9959883|FG000|OLEX|Withdrawal by Subject|60
6263429|NCT02079246|9959884|FG001|OLEX|Withdrawal by Subject|0
6263430|NCT02079246|9959883|FG000|OLEX|Lost to Follow-up|6
6263431|NCT02079246|9959884|FG001|OLEX|Lost to Follow-up|0
6263432|NCT02079246|9959883|FG000|OLEX|Protocol Violation|6
6263433|NCT02079246|9959884|FG001|OLEX|Protocol Violation|0
6263434|NCT02079246|9959883|FG000|OLEX|Lack of Efficacy|3
6263435|NCT02079246|9959884|FG001|OLEX|Lack of Efficacy|0
6263436|NCT02079246|9959883|FG000|OLEX|Results of the lead-in studies|58
6263437|NCT02079246|9959884|FG001|OLEX|Results of the lead-in studies|0
6263438|NCT02079246|9959883|FG000|OLEX|Other: Disallowed medication|8
6263439|NCT02079246|9959884|FG001|OLEX|Other: Disallowed medication|0
6263440|NCT02079246|9959883|FG000|OLEX|Other: Insufficient compliance|2
6263441|NCT02079246|9959884|FG001|OLEX|Other: Insufficient compliance|0
6263442|NCT02079246|9959883|FG000|OLEX|Other: Caregiver unavailable|3
6263443|NCT02079246|9959884|FG001|OLEX|Other: Caregiver unavailable|0
6263444|NCT02079246|9959883|FG000|OLEX|Other: Coordinator decision|1
6263445|NCT02079246|9959884|FG001|OLEX|Other: Coordinator decision|0
6263446|NCT02079246|9959883|FG000|OLEX|Other: Worsening of condition|1
6263447|NCT02079246|9959884|FG001|OLEX|Other: Worsening of condition|0
6263448|NCT02079246|9959883|FG000|OLEX|Other: Moved to nursing home|1
6263449|NCT02079246|9959884|FG001|OLEX|Other: Moved to nursing home|0
6263450|NCT02079246|9959883|FG000|OLEX|Other: Withdrawal of caregiver consent|1
6263451|NCT02079246|9959884|FG001|OLEX|Other: Withdrawal of caregiver consent|0
6263452|NCT02079246|9959883|FG000|OLEX-MEM|Adverse Event|0
6263453|NCT02079246|9959884|FG001|OLEX-MEM|Adverse Event|6
6263454|NCT02079246|9959883|FG000|OLEX-MEM|Withdrawal by Subject|0
6263455|NCT02079246|9959884|FG001|OLEX-MEM|Withdrawal by Subject|7
6263456|NCT02079246|9959883|FG000|OLEX-MEM|Protocol Violation|0
6263457|NCT02079246|9959884|FG001|OLEX-MEM|Protocol Violation|2
6263458|NCT02079246|9959883|FG000|OLEX-MEM|Lost to Follow-up|0
6263459|NCT02079246|9959884|FG001|OLEX-MEM|Lost to Follow-up|1
6263460|NCT02079246|9959883|FG000|OLEX-MEM|Other: Moved to nursing home|0
6263461|NCT02079246|9959884|FG001|OLEX-MEM|Other: Moved to nursing home|3
6263462|NCT02079519|9959902|FG000|Overall Study|Disease Progression|9
6263463|NCT02079519|9959902|FG000|Overall Study|Adverse Event|1
6263464|NCT02079532|9959906|FG000|Overall Study|Adverse Event|7
6263465|NCT02079532|9959906|FG000|Overall Study|Additional or changed therapy|2
6263466|NCT02079532|9959906|FG000|Overall Study|Lack of Efficacy|9
6263467|NCT02079532|9959906|FG000|Overall Study|Protocol Violation|3
6263468|NCT02079532|9959906|FG000|Overall Study|Withdrawal by Subject|1
6263469|NCT02079532|9959906|FG000|Overall Study|Administrative problems|1
6263470|NCT02079532|9959906|FG000|Overall Study|Inclusion into ReFIRST|3
6263471|NCT02079532|9959906|FG000|Overall Study|Other|3
6263472|NCT02079610|9959912|FG000|Overall Study|Withdrawal by Subject|1
6263473|NCT02079610|9959913|FG001|Overall Study|Withdrawal by Subject|1
6263474|NCT02079636|9959934|FG000|Overall Study|Death|2
6263475|NCT02079636|9959935|FG001|Overall Study|Death|1
6263476|NCT02079636|9959936|FG002|Overall Study|Death|0
6263477|NCT02079636|9959937|FG003|Overall Study|Death|5
6263478|NCT02079636|9959938|FG004|Overall Study|Death|1
6263479|NCT02079636|9959939|FG005|Overall Study|Death|2
6263480|NCT02079636|9959940|FG006|Overall Study|Death|1
6263481|NCT02079636|9959941|FG007|Overall Study|Death|0
6263482|NCT02079636|9959942|FG008|Overall Study|Death|0
6263483|NCT02079636|9959943|FG009|Overall Study|Death|0
6263484|NCT02079636|9959944|FG010|Overall Study|Death|0
6263485|NCT02079636|9959945|FG011|Overall Study|Death|1
6263486|NCT02079636|9959946|FG012|Overall Study|Death|1
6263487|NCT02079636|9959947|FG013|Overall Study|Death|0
6263488|NCT02079636|9959948|FG014|Overall Study|Death|2
6263489|NCT02079636|9959934|FG000|Overall Study|Adverse Event|1
6263490|NCT02079636|9959935|FG001|Overall Study|Adverse Event|1
6263491|NCT02079636|9959936|FG002|Overall Study|Adverse Event|0
6263492|NCT02079636|9959937|FG003|Overall Study|Adverse Event|1
6263493|NCT02079636|9959938|FG004|Overall Study|Adverse Event|1
6263494|NCT02079636|9959939|FG005|Overall Study|Adverse Event|2
6263495|NCT02079636|9959940|FG006|Overall Study|Adverse Event|0
6263496|NCT02079636|9959941|FG007|Overall Study|Adverse Event|0
6263497|NCT02079636|9959942|FG008|Overall Study|Adverse Event|0
6263498|NCT02079636|9959943|FG009|Overall Study|Adverse Event|0
6263499|NCT02079636|9959944|FG010|Overall Study|Adverse Event|0
6263500|NCT02079636|9959945|FG011|Overall Study|Adverse Event|0
6263501|NCT02079636|9959946|FG012|Overall Study|Adverse Event|0
6263502|NCT02079636|9959947|FG013|Overall Study|Adverse Event|0
6263503|NCT02079636|9959948|FG014|Overall Study|Adverse Event|0
6263504|NCT02079636|9959934|FG000|Overall Study|Progressive disease|0
6263505|NCT02079636|9959935|FG001|Overall Study|Progressive disease|0
6263506|NCT02079636|9959936|FG002|Overall Study|Progressive disease|0
6263507|NCT02079636|9959937|FG003|Overall Study|Progressive disease|2
6263508|NCT02079636|9959938|FG004|Overall Study|Progressive disease|0
6263509|NCT02079636|9959939|FG005|Overall Study|Progressive disease|0
6263510|NCT02079636|9959940|FG006|Overall Study|Progressive disease|0
6263511|NCT02079636|9959941|FG007|Overall Study|Progressive disease|0
6263512|NCT02079636|9959942|FG008|Overall Study|Progressive disease|0
6263513|NCT02079636|9959943|FG009|Overall Study|Progressive disease|0
6263514|NCT02079636|9959944|FG010|Overall Study|Progressive disease|0
6263515|NCT02079636|9959945|FG011|Overall Study|Progressive disease|0
6263516|NCT02079636|9959946|FG012|Overall Study|Progressive disease|1
6263517|NCT02079636|9959947|FG013|Overall Study|Progressive disease|0
6263518|NCT02079636|9959948|FG014|Overall Study|Progressive disease|0
6263519|NCT02079636|9959934|FG000|Overall Study|Withdrawal by Subject|0
6263520|NCT02079636|9959935|FG001|Overall Study|Withdrawal by Subject|0
6263521|NCT02079636|9959936|FG002|Overall Study|Withdrawal by Subject|0
6263522|NCT02079636|9959937|FG003|Overall Study|Withdrawal by Subject|4
6263523|NCT02079636|9959938|FG004|Overall Study|Withdrawal by Subject|0
6263524|NCT02079636|9959939|FG005|Overall Study|Withdrawal by Subject|1
6263525|NCT02079636|9959940|FG006|Overall Study|Withdrawal by Subject|0
6263526|NCT02079636|9959941|FG007|Overall Study|Withdrawal by Subject|0
6263527|NCT02079636|9959942|FG008|Overall Study|Withdrawal by Subject|0
6263528|NCT02079636|9959943|FG009|Overall Study|Withdrawal by Subject|2
6263529|NCT02079636|9959944|FG010|Overall Study|Withdrawal by Subject|1
6263530|NCT02079636|9959945|FG011|Overall Study|Withdrawal by Subject|1
6263531|NCT02079636|9959946|FG012|Overall Study|Withdrawal by Subject|1
6263532|NCT02079636|9959947|FG013|Overall Study|Withdrawal by Subject|0
6263533|NCT02079636|9959948|FG014|Overall Study|Withdrawal by Subject|2
6263534|NCT02079636|9959934|FG000|Overall Study|Physician Decision|0
6263535|NCT02079636|9959935|FG001|Overall Study|Physician Decision|0
6263536|NCT02079636|9959936|FG002|Overall Study|Physician Decision|0
6263537|NCT02079636|9959937|FG003|Overall Study|Physician Decision|0
6263538|NCT02079636|9959938|FG004|Overall Study|Physician Decision|0
6263539|NCT02079636|9959939|FG005|Overall Study|Physician Decision|1
6263540|NCT02079636|9959940|FG006|Overall Study|Physician Decision|0
6263541|NCT02079636|9959941|FG007|Overall Study|Physician Decision|0
6263542|NCT02079636|9959942|FG008|Overall Study|Physician Decision|0
6263543|NCT02079636|9959943|FG009|Overall Study|Physician Decision|1
6263544|NCT02079636|9959944|FG010|Overall Study|Physician Decision|1
6263545|NCT02079636|9959945|FG011|Overall Study|Physician Decision|0
6263546|NCT02079636|9959946|FG012|Overall Study|Physician Decision|0
6263547|NCT02079636|9959947|FG013|Overall Study|Physician Decision|0
6263548|NCT02079636|9959948|FG014|Overall Study|Physician Decision|1
6263549|NCT02079636|9959934|FG000|Overall Study|Lost to Follow-up|0
6263550|NCT02079636|9959935|FG001|Overall Study|Lost to Follow-up|0
6263551|NCT02079636|9959936|FG002|Overall Study|Lost to Follow-up|0
6263552|NCT02079636|9959937|FG003|Overall Study|Lost to Follow-up|0
6263553|NCT02079636|9959938|FG004|Overall Study|Lost to Follow-up|0
6263554|NCT02079636|9959939|FG005|Overall Study|Lost to Follow-up|0
6263555|NCT02079636|9959940|FG006|Overall Study|Lost to Follow-up|0
6263556|NCT02079636|9959941|FG007|Overall Study|Lost to Follow-up|1
6263557|NCT02079636|9959942|FG008|Overall Study|Lost to Follow-up|0
6263558|NCT02079636|9959943|FG009|Overall Study|Lost to Follow-up|0
6263559|NCT02079636|9959944|FG010|Overall Study|Lost to Follow-up|0
6263560|NCT02079636|9959945|FG011|Overall Study|Lost to Follow-up|0
6263561|NCT02079636|9959946|FG012|Overall Study|Lost to Follow-up|0
6263562|NCT02079636|9959947|FG013|Overall Study|Lost to Follow-up|0
6263563|NCT02079636|9959948|FG014|Overall Study|Lost to Follow-up|0
6263564|NCT02079649|9960016|FG000|Overall Study|Lost to Follow-up|0
6263565|NCT02079649|9960017|FG001|Overall Study|Lost to Follow-up|0
6263566|NCT02079649|9960018|FG002|Overall Study|Lost to Follow-up|0
6263567|NCT02079649|9960019|FG003|Overall Study|Lost to Follow-up|1
6263568|NCT02079649|9960016|FG000|Overall Study|Withdrawal by Subject|0
6263569|NCT02079649|9960017|FG001|Overall Study|Withdrawal by Subject|0
6263570|NCT02079649|9960018|FG002|Overall Study|Withdrawal by Subject|0
6263571|NCT02079649|9960019|FG003|Overall Study|Withdrawal by Subject|1
6263572|NCT02079649|9960016|FG000|Overall Study|Randomization error (prior to treatment)|1
6263573|NCT02079649|9960017|FG001|Overall Study|Randomization error (prior to treatment)|0
6263574|NCT02079649|9960018|FG002|Overall Study|Randomization error (prior to treatment)|1
6263575|NCT02079649|9960019|FG003|Overall Study|Randomization error (prior to treatment)|0
6263576|NCT02079805|9960032|FG000|Overall Study|Pretreatment Event/Adverse Event|0
6263577|NCT02079805|9960033|FG001|Overall Study|Pretreatment Event/Adverse Event|1
6263578|NCT02079805|9960032|FG000|Overall Study|Voluntary Withdrawal|0
6263579|NCT02079805|9960033|FG001|Overall Study|Voluntary Withdrawal|1
6263580|NCT02079844|9960042|FG000|Treatment Period 1|Voluntary Withdrawal|0
6263581|NCT02079844|9960043|FG001|Treatment Period 1|Voluntary Withdrawal|0
6263582|NCT02079844|9960044|FG002|Treatment Period 1|Voluntary Withdrawal|2
6263583|NCT02079844|9960042|FG000|Treatment Period 2|Voluntary Withdrawal|0
6263584|NCT02079844|9960043|FG001|Treatment Period 2|Voluntary Withdrawal|1
6263585|NCT02079844|9960044|FG002|Treatment Period 2|Voluntary Withdrawal|0
6263586|NCT02079909|9960058|FG000|Overall Study|Adverse Event|23
6263587|NCT02079909|9960059|FG001|Overall Study|Adverse Event|23
6263588|NCT02079909|9960060|FG002|Overall Study|Adverse Event|7
6263589|NCT02079909|9960058|FG000|Overall Study|Withdrawal by Subject|9
6263590|NCT02079909|9960059|FG001|Overall Study|Withdrawal by Subject|17
6263591|NCT02079909|9960060|FG002|Overall Study|Withdrawal by Subject|4
6263592|NCT02079909|9960058|FG000|Overall Study|Lost to Follow-up|2
6263593|NCT02079909|9960059|FG001|Overall Study|Lost to Follow-up|3
6263594|NCT02079909|9960060|FG002|Overall Study|Lost to Follow-up|1
6263595|NCT02079909|9960058|FG000|Overall Study|Death|2
6263596|NCT02079909|9960059|FG001|Overall Study|Death|2
6263597|NCT02079909|9960060|FG002|Overall Study|Death|0
6263598|NCT02079909|9960058|FG000|Overall Study|Lack of Efficacy|0
6263599|NCT02079909|9960059|FG001|Overall Study|Lack of Efficacy|0
6263600|NCT02079909|9960060|FG002|Overall Study|Lack of Efficacy|1
6263601|NCT02079909|9960058|FG000|Overall Study|Protocol Violation|0
6263602|NCT02079909|9960059|FG001|Overall Study|Protocol Violation|1
6263603|NCT02079909|9960060|FG002|Overall Study|Protocol Violation|1
6263604|NCT02079909|9960058|FG000|Overall Study|Physician Decision|0
6263605|NCT02079909|9960059|FG001|Overall Study|Physician Decision|1
6263606|NCT02079909|9960060|FG002|Overall Study|Physician Decision|1
6263607|NCT02079909|9960058|FG000|Overall Study|Relocation etc.|2
6263608|NCT02079909|9960059|FG001|Overall Study|Relocation etc.|2
6263609|NCT02079909|9960060|FG002|Overall Study|Relocation etc.|3
6263610|NCT02080091|9960078|FG000|Overall Study|Study Terminated|22
6263611|NCT02080091|9960078|FG000|Overall Study|Death|1
6263612|NCT02080091|9960078|FG000|Overall Study|Withdrawal by Subject|1
6263613|NCT02080091|9960078|FG000|Overall Study|Other|1
6263614|NCT02080221|9960086|FG000|Overall Study|Withdrawal by Subject|1
6263615|NCT02080221|9960086|FG000|Overall Study|Clinical Progression of Disease|1
6263616|NCT02080364|9960112|FG000|Baseline Period|Protocol Violation|2
6263617|NCT02080364|9960113|FG001|Baseline Period|Protocol Violation|1
6263618|NCT02080364|9960114|FG002|Baseline Period|Protocol Violation|0
6263619|NCT02080364|9960115|FG003|Baseline Period|Protocol Violation|0
6263620|NCT02080364|9960112|FG000|Baseline Period|Other|0
6263621|NCT02080364|9960113|FG001|Baseline Period|Other|1
6263622|NCT02080364|9960114|FG002|Baseline Period|Other|1
6263623|NCT02080364|9960115|FG003|Baseline Period|Other|0
6263624|NCT02080364|9960112|FG000|Treatment Period|Adverse Event|10
6263625|NCT02080364|9960113|FG001|Treatment Period|Adverse Event|15
6263626|NCT02080364|9960114|FG002|Treatment Period|Adverse Event|11
6263627|NCT02080364|9960115|FG003|Treatment Period|Adverse Event|14
6263628|NCT02080364|9960112|FG000|Treatment Period|Lost to Follow-up|2
6263629|NCT02080364|9960113|FG001|Treatment Period|Lost to Follow-up|3
6263630|NCT02080364|9960114|FG002|Treatment Period|Lost to Follow-up|5
6263631|NCT02080364|9960115|FG003|Treatment Period|Lost to Follow-up|0
6263632|NCT02080364|9960112|FG000|Treatment Period|Protocol Violation|5
6263633|NCT02080364|9960113|FG001|Treatment Period|Protocol Violation|3
6263634|NCT02080364|9960114|FG002|Treatment Period|Protocol Violation|5
6263635|NCT02080364|9960115|FG003|Treatment Period|Protocol Violation|1
6263636|NCT02080364|9960112|FG000|Treatment Period|Withdrawal by Subject|16
6263637|NCT02080364|9960113|FG001|Treatment Period|Withdrawal by Subject|16
6263638|NCT02080364|9960114|FG002|Treatment Period|Withdrawal by Subject|15
6263639|NCT02080364|9960115|FG003|Treatment Period|Withdrawal by Subject|10
6263640|NCT02080364|9960112|FG000|Treatment Period|Study Terminated by Sponsor|0
6263641|NCT02080364|9960113|FG001|Treatment Period|Study Terminated by Sponsor|0
6263642|NCT02080364|9960114|FG002|Treatment Period|Study Terminated by Sponsor|180
6263643|NCT02080364|9960115|FG003|Treatment Period|Study Terminated by Sponsor|183
6263644|NCT02080364|9960112|FG000|Treatment Period|Other|14
6263645|NCT02080364|9960113|FG001|Treatment Period|Other|12
6263646|NCT02080364|9960114|FG002|Treatment Period|Other|21
6263647|NCT02080364|9960115|FG003|Treatment Period|Other|16
6263648|NCT02080403|9960127|FG000|Overall Study|Adverse Event|5
6263649|NCT02080403|9960128|FG001|Overall Study|Adverse Event|1
6263650|NCT02080403|9960127|FG000|Overall Study|Death|0
6263651|NCT02080403|9960128|FG001|Overall Study|Death|2
6263652|NCT02080403|9960127|FG000|Overall Study|Lost to Follow-up|2
6263653|NCT02080403|9960128|FG001|Overall Study|Lost to Follow-up|0
6263654|NCT02080403|9960127|FG000|Overall Study|Pregnancy|0
6263655|NCT02080403|9960128|FG001|Overall Study|Pregnancy|1
6263656|NCT02080403|9960127|FG000|Overall Study|Protocol Violation|3
6263657|NCT02080403|9960128|FG001|Overall Study|Protocol Violation|7
6263658|NCT02080403|9960127|FG000|Overall Study|Withdrawal by Subject|5
6263659|NCT02080403|9960128|FG001|Overall Study|Withdrawal by Subject|1
6271429|NCT02163902|9973212|FG001|Overall Study|Administrative Decision|2
6271430|NCT02163915|9973223|FG000|Overall Study|Withdrawal by Subject|2
6271431|NCT02163915|9973224|FG001|Overall Study|Withdrawal by Subject|0
6271432|NCT02163915|9973225|FG002|Overall Study|Withdrawal by Subject|2
6271433|NCT02163915|9973226|FG003|Overall Study|Withdrawal by Subject|2
6271434|NCT02163915|9973227|FG004|Overall Study|Withdrawal by Subject|2
6271435|NCT02163915|9973223|FG000|Overall Study|Study termination|1
6271436|NCT02163915|9973224|FG001|Overall Study|Study termination|0
6271437|NCT02163915|9973225|FG002|Overall Study|Study termination|0
6271438|NCT02163915|9973226|FG003|Overall Study|Study termination|0
6271439|NCT02163915|9973227|FG004|Overall Study|Study termination|2
6271440|NCT02163915|9973223|FG000|Overall Study|Physician Decision|0
6271441|NCT02163915|9973224|FG001|Overall Study|Physician Decision|0
6271442|NCT02163915|9973225|FG002|Overall Study|Physician Decision|0
6271443|NCT02163915|9973226|FG003|Overall Study|Physician Decision|1
6271444|NCT02163915|9973227|FG004|Overall Study|Physician Decision|0
6271445|NCT02163993|9973264|FG000|Treatment Period|Adverse Event|0
6271446|NCT02163993|9973265|FG001|Treatment Period|Adverse Event|1
6271447|NCT02163993|9973266|FG002|Treatment Period|Adverse Event|0
6271448|NCT02163993|9973267|FG003|Treatment Period|Adverse Event|0
6271449|NCT02163993|9973268|FG004|Treatment Period|Adverse Event|1
6271450|NCT02163993|9973264|FG000|Treatment Period|Lost to Follow-up|2
6271451|NCT02163993|9973265|FG001|Treatment Period|Lost to Follow-up|3
6271452|NCT02163993|9973266|FG002|Treatment Period|Lost to Follow-up|1
6271453|NCT02163993|9973267|FG003|Treatment Period|Lost to Follow-up|3
6271454|NCT02163993|9973268|FG004|Treatment Period|Lost to Follow-up|1
6271455|NCT02163993|9973264|FG000|Treatment Period|Physician Decision|1
6271456|NCT02163993|9973265|FG001|Treatment Period|Physician Decision|0
6271457|NCT02163993|9973266|FG002|Treatment Period|Physician Decision|0
6271458|NCT02163993|9973267|FG003|Treatment Period|Physician Decision|0
6271459|NCT02163993|9973268|FG004|Treatment Period|Physician Decision|0
6271460|NCT02163993|9973264|FG000|Treatment Period|Protocol Violation|2
6271461|NCT02163993|9973265|FG001|Treatment Period|Protocol Violation|1
6271462|NCT02163993|9973266|FG002|Treatment Period|Protocol Violation|0
6271463|NCT02163993|9973267|FG003|Treatment Period|Protocol Violation|1
6271464|NCT02163993|9973268|FG004|Treatment Period|Protocol Violation|2
6271465|NCT02163993|9973264|FG000|Treatment Period|Withdrawal by Subject|6
6271466|NCT02163993|9973265|FG001|Treatment Period|Withdrawal by Subject|4
6271467|NCT02163993|9973266|FG002|Treatment Period|Withdrawal by Subject|1
6271468|NCT02163993|9973267|FG003|Treatment Period|Withdrawal by Subject|4
6263660|NCT02080481|9960169|FG000|Overall Study|Never received a block.|1
6263661|NCT02080481|9960170|FG001|Overall Study|Never received a block.|0
6263662|NCT02080832|9960226|FG000|Overall Study|Excluded from analysis by MRI|9
6263663|NCT02080832|9960227|FG001|Overall Study|Excluded from analysis by MRI|10
6263664|NCT02080832|9960228|FG002|Overall Study|Excluded from analysis by MRI|14
6263665|NCT02080832|9960226|FG000|Overall Study|Lost to Follow-up|0
6263666|NCT02080832|9960227|FG001|Overall Study|Lost to Follow-up|2
6263667|NCT02080832|9960228|FG002|Overall Study|Lost to Follow-up|2
6263668|NCT02080871|9960238|FG000|Overall Study|Death|1
6263669|NCT02080871|9960238|FG000|Overall Study|Lost to Follow-up|1
6263670|NCT02081001|9960244|FG000|Overall Study|Adverse Event|0
6263671|NCT02081001|9960245|FG001|Overall Study|Adverse Event|0
6263672|NCT02081001|9960246|FG002|Overall Study|Adverse Event|0
6263673|NCT02081001|9960247|FG003|Overall Study|Adverse Event|0
6263674|NCT02081001|9960248|FG004|Overall Study|Adverse Event|1
6263675|NCT02081001|9960249|FG005|Overall Study|Adverse Event|0
6263676|NCT02081001|9960250|FG006|Overall Study|Adverse Event|0
6263677|NCT02081001|9960251|FG007|Overall Study|Adverse Event|0
6263678|NCT02081001|9960252|FG008|Overall Study|Adverse Event|0
6263679|NCT02081001|9960253|FG009|Overall Study|Adverse Event|0
6263680|NCT02081001|9960254|FG010|Overall Study|Adverse Event|0
6263681|NCT02081001|9960255|FG011|Overall Study|Adverse Event|0
6263682|NCT02081079|9960292|FG000|Overall Study|Lack of Efficacy|3
6263683|NCT02081079|9960293|FG001|Overall Study|Lack of Efficacy|2
6263684|NCT02081079|9960292|FG000|Overall Study|Lost to Follow-up|1
6263685|NCT02081079|9960293|FG001|Overall Study|Lost to Follow-up|0
6263686|NCT02081196|9960303|FG000|Overall Study|Lost to Follow-up|1
6263687|NCT02081417|9960329|FG000|Overall Study|Lost to Follow-up|26
6263688|NCT02081417|9960330|FG001|Overall Study|Lost to Follow-up|23
6263689|NCT02081417|9960329|FG000|Overall Study|Moved Away|1
6263690|NCT02081417|9960330|FG001|Overall Study|Moved Away|2
6263691|NCT02081417|9960329|FG000|Overall Study|Incarcerated|2
6263692|NCT02081417|9960330|FG001|Overall Study|Incarcerated|2
6263693|NCT02081417|9960329|FG000|Overall Study|Death|4
6263694|NCT02081417|9960330|FG001|Overall Study|Death|3
6263695|NCT02081417|9960329|FG000|Overall Study|Withdrawal by Subject|4
6263696|NCT02081417|9960330|FG001|Overall Study|Withdrawal by Subject|0
6263697|NCT02081417|9960329|FG000|Overall Study|Admitted to Residential Treatment|2
6263698|NCT02081417|9960330|FG001|Overall Study|Admitted to Residential Treatment|0
6263699|NCT02081417|9960329|FG000|Overall Study|Did not start treatment|17
6263700|NCT02081417|9960330|FG001|Overall Study|Did not start treatment|21
6263701|NCT02081534|9960361|FG000|Overall Study|Adverse Event|5
6263702|NCT02081534|9960362|FG001|Overall Study|Adverse Event|4
6263703|NCT02081534|9960363|FG002|Overall Study|Adverse Event|3
6263704|NCT02081534|9960364|FG003|Overall Study|Adverse Event|10
6263705|NCT02081534|9960365|FG004|Overall Study|Adverse Event|2
6263706|NCT02081534|9960366|FG005|Overall Study|Adverse Event|8
6263707|NCT02081534|9960367|FG006|Overall Study|Adverse Event|2
6263708|NCT02081534|9960361|FG000|Overall Study|Withdrawal by Subject|0
6263709|NCT02081534|9960362|FG001|Overall Study|Withdrawal by Subject|1
6263710|NCT02081534|9960363|FG002|Overall Study|Withdrawal by Subject|1
6263711|NCT02081534|9960364|FG003|Overall Study|Withdrawal by Subject|1
6263712|NCT02081534|9960365|FG004|Overall Study|Withdrawal by Subject|1
6263713|NCT02081534|9960366|FG005|Overall Study|Withdrawal by Subject|0
6263714|NCT02081534|9960367|FG006|Overall Study|Withdrawal by Subject|1
6263715|NCT02081534|9960361|FG000|Overall Study|Protocol Violation|0
6263716|NCT02081534|9960362|FG001|Overall Study|Protocol Violation|3
6263717|NCT02081534|9960363|FG002|Overall Study|Protocol Violation|0
6263718|NCT02081534|9960364|FG003|Overall Study|Protocol Violation|0
6263719|NCT02081534|9960365|FG004|Overall Study|Protocol Violation|0
6263720|NCT02081534|9960366|FG005|Overall Study|Protocol Violation|0
6263721|NCT02081534|9960367|FG006|Overall Study|Protocol Violation|1
6263722|NCT02081534|9960361|FG000|Overall Study|Lost to Follow-up|0
6263723|NCT02081534|9960362|FG001|Overall Study|Lost to Follow-up|0
6263724|NCT02081534|9960363|FG002|Overall Study|Lost to Follow-up|0
6263725|NCT02081534|9960364|FG003|Overall Study|Lost to Follow-up|2
6263726|NCT02081534|9960365|FG004|Overall Study|Lost to Follow-up|1
6263727|NCT02081534|9960366|FG005|Overall Study|Lost to Follow-up|1
6263728|NCT02081534|9960367|FG006|Overall Study|Lost to Follow-up|0
6263729|NCT02081586|9960391|FG000|Overall Study|Lost to Follow-up|0
6263730|NCT02081586|9960392|FG001|Overall Study|Lost to Follow-up|1
6263731|NCT02081586|9960393|FG002|Overall Study|Lost to Follow-up|0
6263732|NCT02081586|9960394|FG003|Overall Study|Lost to Follow-up|1
6263733|NCT02081586|9960391|FG000|Overall Study|Head injury not related to study|0
6263734|NCT02081586|9960392|FG001|Overall Study|Head injury not related to study|0
6263735|NCT02081586|9960393|FG002|Overall Study|Head injury not related to study|1
6263736|NCT02081586|9960394|FG003|Overall Study|Head injury not related to study|0
6263737|NCT02081599|9960408|FG000|Period 1：Double-blind Period|Adverse Event|3
6263738|NCT02081599|9960409|FG001|Period 1：Double-blind Period|Adverse Event|0
6263739|NCT02081599|9960408|FG000|Period 1：Double-blind Period|Lack of Efficacy|2
6263740|NCT02081599|9960409|FG001|Period 1：Double-blind Period|Lack of Efficacy|1
6263741|NCT02081599|9960408|FG000|Period 1：Double-blind Period|Physician Decision|1
6263742|NCT02081599|9960409|FG001|Period 1：Double-blind Period|Physician Decision|0
6263743|NCT02081599|9960408|FG000|Period 1：Double-blind Period|Protocol Violation|0
6271469|NCT02163993|9973268|FG004|Treatment Period|Withdrawal by Subject|1
6263744|NCT02081599|9960409|FG001|Period 1：Double-blind Period|Protocol Violation|1
6263745|NCT02081599|9960408|FG000|Period 1：Double-blind Period|Withdrawal by Subject|1
6263746|NCT02081599|9960409|FG001|Period 1：Double-blind Period|Withdrawal by Subject|0
6263747|NCT02081599|9960408|FG000|Period 1：Double-blind Period|stopping criteria|1
6263748|NCT02081599|9960409|FG001|Period 1：Double-blind Period|stopping criteria|0
6263749|NCT02081599|9960408|FG000|Period 2：Open-label Period|Adverse Event|1
6263750|NCT02081599|9960409|FG001|Period 2：Open-label Period|Adverse Event|0
6263751|NCT02081599|9960408|FG000|Period 2：Open-label Period|Lack of Efficacy|2
6263752|NCT02081599|9960409|FG001|Period 2：Open-label Period|Lack of Efficacy|4
6263753|NCT02081599|9960408|FG000|Period 2：Open-label Period|Physician Decision|1
6263754|NCT02081599|9960409|FG001|Period 2：Open-label Period|Physician Decision|0
6263755|NCT02081599|9960408|FG000|Period 2：Open-label Period|Withdrawal by Subject|2
6263756|NCT02081599|9960409|FG001|Period 2：Open-label Period|Withdrawal by Subject|0
6263757|NCT02081677|9960434|FG000|Overall Study|Adverse Event|0
6263758|NCT02081677|9960435|FG001|Overall Study|Adverse Event|0
6263759|NCT02081677|9960436|FG002|Overall Study|Adverse Event|1
6263760|NCT02081677|9960437|FG003|Overall Study|Adverse Event|0
6263761|NCT02081677|9960434|FG000|Overall Study|No Longer Meets Eligibility Criteria|0
6263762|NCT02081677|9960435|FG001|Overall Study|No Longer Meets Eligibility Criteria|0
6263763|NCT02081677|9960436|FG002|Overall Study|No Longer Meets Eligibility Criteria|1
6263764|NCT02081677|9960437|FG003|Overall Study|No Longer Meets Eligibility Criteria|0
6263765|NCT02081677|9960434|FG000|Overall Study|Not comfortable with lens care system|1
6263766|NCT02081677|9960435|FG001|Overall Study|Not comfortable with lens care system|0
6263767|NCT02081677|9960436|FG002|Overall Study|Not comfortable with lens care system|0
6263768|NCT02081677|9960437|FG003|Overall Study|Not comfortable with lens care system|0
6263769|NCT02081677|9960434|FG000|Overall Study|Unsatisfactory Lens Fitting|0
6263770|NCT02081677|9960435|FG001|Overall Study|Unsatisfactory Lens Fitting|1
6263771|NCT02081677|9960436|FG002|Overall Study|Unsatisfactory Lens Fitting|0
6263772|NCT02081677|9960437|FG003|Overall Study|Unsatisfactory Lens Fitting|0
6263773|NCT02081690|9960447|FG000|Overall Study|Death|3
6263774|NCT02081690|9960447|FG000|Overall Study|Physician Decision|3
6263775|NCT02081690|9960447|FG000|Overall Study|Withdrawal by Subject|1
6263776|NCT02081846|9960496|FG000|Overall Study|Withdrawal by Subject|1
6263777|NCT02081846|9960497|FG001|Overall Study|Withdrawal by Subject|0
6263778|NCT02081846|9960496|FG000|Overall Study|invalid consent|1
6263779|NCT02081846|9960497|FG001|Overall Study|invalid consent|0
6263780|NCT02081859|9960505|FG000|Overall Study|No fertilization|2
6263781|NCT02081859|9960506|FG001|Overall Study|No fertilization|2
6263782|NCT02081859|9960505|FG000|Overall Study|No sperm|1
6263783|NCT02081859|9960506|FG001|Overall Study|No sperm|0
6263784|NCT02081859|9960505|FG000|Overall Study|Unanticipated freeze all cycle|2
6263785|NCT02081859|9960506|FG001|Overall Study|Unanticipated freeze all cycle|6
6263786|NCT02081859|9960505|FG000|Overall Study|< 4 embryos|27
6263787|NCT02081859|9960506|FG001|Overall Study|< 4 embryos|23
6263788|NCT02081859|9960505|FG000|Overall Study|Other reasons|2
6263789|NCT02081859|9960506|FG001|Overall Study|Other reasons|0
6263790|NCT02082158|9960548|FG000|Overall Study|Withdrawal by Subject|0
6263791|NCT02082158|9960549|FG001|Overall Study|Withdrawal by Subject|0
6263792|NCT02082158|9960550|FG002|Overall Study|Withdrawal by Subject|0
6263793|NCT02082158|9960551|FG003|Overall Study|Withdrawal by Subject|0
6263794|NCT02082158|9960552|FG004|Overall Study|Withdrawal by Subject|1
6263795|NCT02082158|9960553|FG005|Overall Study|Withdrawal by Subject|0
6263796|NCT02082158|9960548|FG000|Overall Study|Failed Fit-testing|8
6263797|NCT02082158|9960549|FG001|Overall Study|Failed Fit-testing|8
6263798|NCT02082158|9960550|FG002|Overall Study|Failed Fit-testing|14
6263799|NCT02082158|9960551|FG003|Overall Study|Failed Fit-testing|4
6263800|NCT02082158|9960552|FG004|Overall Study|Failed Fit-testing|3
6263801|NCT02082158|9960553|FG005|Overall Study|Failed Fit-testing|7
6263802|NCT02082184|9960575|FG000|Overall Study|Adverse Event|1
6263803|NCT02082184|9960576|FG001|Overall Study|Adverse Event|0
6263804|NCT02082184|9960575|FG000|Overall Study|Medical diagnosis|1
6263805|NCT02082184|9960576|FG001|Overall Study|Medical diagnosis|2
6263806|NCT02082184|9960575|FG000|Overall Study|Device associated symptoms|5
6263807|NCT02082184|9960576|FG001|Overall Study|Device associated symptoms|0
6263808|NCT02082184|9960575|FG000|Overall Study|Withdrawal by Subject|3
6263809|NCT02082184|9960576|FG001|Overall Study|Withdrawal by Subject|2
6263810|NCT02082184|9960575|FG000|Overall Study|Protocol Violation|0
6263811|NCT02082184|9960576|FG001|Overall Study|Protocol Violation|6
6263812|NCT02082184|9960575|FG000|Overall Study|Lost to Follow-up|0
6263813|NCT02082184|9960576|FG001|Overall Study|Lost to Follow-up|2
6263814|NCT02082184|9960575|FG000|Overall Study|Subject non-compliance|0
6263815|NCT02082184|9960576|FG001|Overall Study|Subject non-compliance|1
6263816|NCT02082210|9960588|FG000|Overall Study|Death|0
6263817|NCT02082210|9960589|FG001|Overall Study|Death|0
6263818|NCT02082210|9960590|FG002|Overall Study|Death|1
6263819|NCT02082210|9960591|FG003|Overall Study|Death|1
6263820|NCT02082210|9960592|FG004|Overall Study|Death|1
6263821|NCT02082210|9960593|FG005|Overall Study|Death|0
6263822|NCT02082210|9960588|FG000|Overall Study|Withdrawal by Subject|0
6263823|NCT02082210|9960589|FG001|Overall Study|Withdrawal by Subject|0
6263824|NCT02082210|9960590|FG002|Overall Study|Withdrawal by Subject|0
6263825|NCT02082210|9960591|FG003|Overall Study|Withdrawal by Subject|1
6263826|NCT02082210|9960592|FG004|Overall Study|Withdrawal by Subject|2
6263827|NCT02082210|9960593|FG005|Overall Study|Withdrawal by Subject|2
6263828|NCT02082210|9960588|FG000|Overall Study|Clinical Progression|0
6263829|NCT02082210|9960589|FG001|Overall Study|Clinical Progression|0
6263830|NCT02082210|9960590|FG002|Overall Study|Clinical Progression|0
6263831|NCT02082210|9960591|FG003|Overall Study|Clinical Progression|1
6263832|NCT02082210|9960592|FG004|Overall Study|Clinical Progression|0
6263833|NCT02082210|9960593|FG005|Overall Study|Clinical Progression|0
6263834|NCT02082210|9960588|FG000|Overall Study|No Post-Baseline Tumor Assesment|0
6263835|NCT02082210|9960589|FG001|Overall Study|No Post-Baseline Tumor Assesment|0
6263836|NCT02082210|9960590|FG002|Overall Study|No Post-Baseline Tumor Assesment|1
6263837|NCT02082210|9960591|FG003|Overall Study|No Post-Baseline Tumor Assesment|2
6263838|NCT02082210|9960592|FG004|Overall Study|No Post-Baseline Tumor Assesment|0
6263839|NCT02082210|9960593|FG005|Overall Study|No Post-Baseline Tumor Assesment|0
6263840|NCT02082210|9960588|FG000|Overall Study|Physician Decision|0
6263841|NCT02082210|9960589|FG001|Overall Study|Physician Decision|0
6263842|NCT02082210|9960590|FG002|Overall Study|Physician Decision|1
6263843|NCT02082210|9960591|FG003|Overall Study|Physician Decision|1
6263844|NCT02082210|9960592|FG004|Overall Study|Physician Decision|0
6263845|NCT02082210|9960593|FG005|Overall Study|Physician Decision|0
6263846|NCT02082262|9960619|FG000|Overall Study|Withdrawal by Subject|3
6263847|NCT02082262|9960619|FG000|Overall Study|Adverse Event|48
6263848|NCT02082340|9960629|FG000|Overall Study|Lost to Follow-up|1
6263849|NCT02082340|9960630|FG001|Overall Study|Lost to Follow-up|1
6263850|NCT02082483|9960647|FG000|Overall Study|Lost to Follow-up|1
6263851|NCT02082483|9960648|FG001|Overall Study|Lost to Follow-up|1
6263852|NCT02082483|9960647|FG000|Overall Study|Withdrawal by Subject|2
6263853|NCT02082483|9960648|FG001|Overall Study|Withdrawal by Subject|1
6263854|NCT02082483|9960647|FG000|Overall Study|Physician Decision|1
6263855|NCT02082483|9960648|FG001|Overall Study|Physician Decision|1
6263856|NCT02082483|9960647|FG000|Overall Study|Death|2
6263857|NCT02082483|9960648|FG001|Overall Study|Death|3
6263858|NCT02082522|9960657|FG000|Overall Study|Sponsor termination|5
6263859|NCT02082522|9960658|FG001|Overall Study|Sponsor termination|3
6263860|NCT02082522|9960657|FG000|Overall Study|Withdrawal by Subject|2
6263861|NCT02082522|9960658|FG001|Overall Study|Withdrawal by Subject|4
6263862|NCT02082522|9960657|FG000|Overall Study|Death|1
6263863|NCT02082522|9960658|FG001|Overall Study|Death|0
6263864|NCT02082522|9960657|FG000|Overall Study|Lost to Follow-up|1
6263865|NCT02082522|9960658|FG001|Overall Study|Lost to Follow-up|0
6263866|NCT02082522|9960657|FG000|Overall Study|Physician Decision|3
6263867|NCT02082522|9960658|FG001|Overall Study|Physician Decision|1
6263868|NCT02082522|9960657|FG000|Overall Study|Disease progression|2
6263869|NCT02082522|9960658|FG001|Overall Study|Disease progression|2
6263870|NCT02082522|9960657|FG000|Overall Study|Chemotherapy change|1
6263871|NCT02082522|9960658|FG001|Overall Study|Chemotherapy change|3
6263872|NCT02082912|9960701|FG000|Overall Study|Physician Decision|0
6263873|NCT02082912|9960702|FG001|Overall Study|Physician Decision|1
6263874|NCT02082977|9960718|FG000|Part 1 (Up to 3.2 Years)|Death|1
6263875|NCT02082977|9960719|FG001|Part 1 (Up to 3.2 Years)|Death|0
6263876|NCT02082977|9960720|FG002|Part 1 (Up to 3.2 Years)|Death|0
6263877|NCT02082977|9960721|FG003|Part 1 (Up to 3.2 Years)|Death|0
6263878|NCT02082977|9960722|FG004|Part 1 (Up to 3.2 Years)|Death|0
6263879|NCT02082977|9960723|FG005|Part 1 (Up to 3.2 Years)|Death|1
6263880|NCT02082977|9960724|FG006|Part 1 (Up to 3.2 Years)|Death|2
6263881|NCT02082977|9960725|FG007|Part 1 (Up to 3.2 Years)|Death|0
6263882|NCT02082977|9960726|FG008|Part 1 (Up to 3.2 Years)|Death|1
6263883|NCT02082977|9960727|FG009|Part 1 (Up to 3.2 Years)|Death|0
6263884|NCT02082977|9960718|FG000|Part 1 (Up to 3.2 Years)|Study closed/terminated|0
6263885|NCT02082977|9960719|FG001|Part 1 (Up to 3.2 Years)|Study closed/terminated|0
6263886|NCT02082977|9960720|FG002|Part 1 (Up to 3.2 Years)|Study closed/terminated|0
6263887|NCT02082977|9960721|FG003|Part 1 (Up to 3.2 Years)|Study closed/terminated|0
6263888|NCT02082977|9960722|FG004|Part 1 (Up to 3.2 Years)|Study closed/terminated|0
6263889|NCT02082977|9960723|FG005|Part 1 (Up to 3.2 Years)|Study closed/terminated|0
6263890|NCT02082977|9960724|FG006|Part 1 (Up to 3.2 Years)|Study closed/terminated|0
6263891|NCT02082977|9960725|FG007|Part 1 (Up to 3.2 Years)|Study closed/terminated|2
6263892|NCT02082977|9960726|FG008|Part 1 (Up to 3.2 Years)|Study closed/terminated|0
6263893|NCT02082977|9960727|FG009|Part 1 (Up to 3.2 Years)|Study closed/terminated|0
6263894|NCT02082977|9960718|FG000|Part 1 (Up to 3.2 Years)|Lost to Follow-up|0
6263895|NCT02082977|9960719|FG001|Part 1 (Up to 3.2 Years)|Lost to Follow-up|0
6263896|NCT02082977|9960720|FG002|Part 1 (Up to 3.2 Years)|Lost to Follow-up|0
6263897|NCT02082977|9960721|FG003|Part 1 (Up to 3.2 Years)|Lost to Follow-up|0
6263898|NCT02082977|9960722|FG004|Part 1 (Up to 3.2 Years)|Lost to Follow-up|0
6263899|NCT02082977|9960723|FG005|Part 1 (Up to 3.2 Years)|Lost to Follow-up|1
6263900|NCT02082977|9960724|FG006|Part 1 (Up to 3.2 Years)|Lost to Follow-up|0
6263901|NCT02082977|9960725|FG007|Part 1 (Up to 3.2 Years)|Lost to Follow-up|0
6263902|NCT02082977|9960726|FG008|Part 1 (Up to 3.2 Years)|Lost to Follow-up|0
6263903|NCT02082977|9960727|FG009|Part 1 (Up to 3.2 Years)|Lost to Follow-up|0
6263904|NCT02082977|9960718|FG000|Part 1 (Up to 3.2 Years)|Physician Decision|0
6263905|NCT02082977|9960719|FG001|Part 1 (Up to 3.2 Years)|Physician Decision|0
6263906|NCT02082977|9960720|FG002|Part 1 (Up to 3.2 Years)|Physician Decision|0
6263907|NCT02082977|9960721|FG003|Part 1 (Up to 3.2 Years)|Physician Decision|0
6263908|NCT02082977|9960722|FG004|Part 1 (Up to 3.2 Years)|Physician Decision|1
6263909|NCT02082977|9960723|FG005|Part 1 (Up to 3.2 Years)|Physician Decision|1
6263910|NCT02082977|9960724|FG006|Part 1 (Up to 3.2 Years)|Physician Decision|4
6263911|NCT02082977|9960725|FG007|Part 1 (Up to 3.2 Years)|Physician Decision|1
6263912|NCT02082977|9960726|FG008|Part 1 (Up to 3.2 Years)|Physician Decision|2
6263913|NCT02082977|9960727|FG009|Part 1 (Up to 3.2 Years)|Physician Decision|0
6263914|NCT02082977|9960718|FG000|Part 1 (Up to 3.2 Years)|Withdrawal by Subject|0
6263915|NCT02082977|9960719|FG001|Part 1 (Up to 3.2 Years)|Withdrawal by Subject|0
6263916|NCT02082977|9960720|FG002|Part 1 (Up to 3.2 Years)|Withdrawal by Subject|0
6263917|NCT02082977|9960721|FG003|Part 1 (Up to 3.2 Years)|Withdrawal by Subject|0
6263918|NCT02082977|9960722|FG004|Part 1 (Up to 3.2 Years)|Withdrawal by Subject|0
6263919|NCT02082977|9960723|FG005|Part 1 (Up to 3.2 Years)|Withdrawal by Subject|0
6263920|NCT02082977|9960724|FG006|Part 1 (Up to 3.2 Years)|Withdrawal by Subject|0
6263921|NCT02082977|9960725|FG007|Part 1 (Up to 3.2 Years)|Withdrawal by Subject|2
6263922|NCT02082977|9960726|FG008|Part 1 (Up to 3.2 Years)|Withdrawal by Subject|0
6263923|NCT02082977|9960727|FG009|Part 1 (Up to 3.2 Years)|Withdrawal by Subject|0
6263924|NCT02083185|9960775|FG000|Overall Study|Lost to Follow-up|0
6263925|NCT02083185|9960776|FG001|Overall Study|Lost to Follow-up|3
6263926|NCT02083185|9960777|FG002|Overall Study|Lost to Follow-up|0
6263927|NCT02083185|9960775|FG000|Overall Study|Withdrawal by Subject|9
6263928|NCT02083185|9960776|FG001|Overall Study|Withdrawal by Subject|15
6263929|NCT02083185|9960777|FG002|Overall Study|Withdrawal by Subject|1
6263930|NCT02083185|9960775|FG000|Overall Study|Death|2
6263931|NCT02083185|9960776|FG001|Overall Study|Death|2
6263932|NCT02083185|9960777|FG002|Overall Study|Death|1
6263933|NCT02083185|9960775|FG000|Overall Study|Reason not Specified|9
6263934|NCT02083185|9960776|FG001|Overall Study|Reason not Specified|6
6263935|NCT02083185|9960777|FG002|Overall Study|Reason not Specified|5
6263936|NCT02083185|9960775|FG000|Overall Study|Study Terminated by Sponsor|0
6263937|NCT02083185|9960776|FG001|Overall Study|Study Terminated by Sponsor|1
6263938|NCT02083185|9960777|FG002|Overall Study|Study Terminated by Sponsor|0
6263939|NCT02083185|9960775|FG000|Overall Study|Did not Receive Study Drug|0
6263940|NCT02083185|9960776|FG001|Overall Study|Did not Receive Study Drug|2
6263941|NCT02083185|9960777|FG002|Overall Study|Did not Receive Study Drug|0
6263942|NCT02083380|9960797|FG000|Overall Study|Lack of Efficacy|68
6263943|NCT02083380|9960798|FG001|Overall Study|Lack of Efficacy|79
6263944|NCT02083380|9960799|FG002|Overall Study|Lack of Efficacy|64
6263945|NCT02083380|9960797|FG000|Overall Study|Withdrawal by Subject|9
6263946|NCT02083380|9960798|FG001|Overall Study|Withdrawal by Subject|3
6263947|NCT02083380|9960799|FG002|Overall Study|Withdrawal by Subject|7
6263948|NCT02083380|9960797|FG000|Overall Study|Physician Decision|1
6263949|NCT02083380|9960798|FG001|Overall Study|Physician Decision|6
6263950|NCT02083380|9960799|FG002|Overall Study|Physician Decision|3
6263951|NCT02083380|9960797|FG000|Overall Study|Adverse Event|0
6263952|NCT02083380|9960798|FG001|Overall Study|Adverse Event|0
6263953|NCT02083380|9960799|FG002|Overall Study|Adverse Event|1
6263954|NCT02083380|9960797|FG000|Overall Study|Lost to Follow-up|5
6263955|NCT02083380|9960798|FG001|Overall Study|Lost to Follow-up|3
6263956|NCT02083380|9960799|FG002|Overall Study|Lost to Follow-up|3
6263957|NCT02083380|9960797|FG000|Overall Study|Other|8
6263958|NCT02083380|9960798|FG001|Overall Study|Other|4
6263959|NCT02083380|9960799|FG002|Overall Study|Other|6
6263960|NCT02083653|9960828|FG000|Overall Study|Randomized but not Treated|0
6263961|NCT02083653|9960829|FG001|Overall Study|Randomized but not Treated|2
6263962|NCT02083653|9960830|FG002|Overall Study|Randomized but not Treated|7
6263963|NCT02083653|9960828|FG000|Overall Study|Adverse Event|12
6263964|NCT02083653|9960829|FG001|Overall Study|Adverse Event|5
6263965|NCT02083653|9960830|FG002|Overall Study|Adverse Event|4
6263966|NCT02083653|9960828|FG000|Overall Study|Lost to Follow-up|1
6263967|NCT02083653|9960829|FG001|Overall Study|Lost to Follow-up|0
6263968|NCT02083653|9960830|FG002|Overall Study|Lost to Follow-up|0
6263969|NCT02083653|9960828|FG000|Overall Study|Death|2
6263970|NCT02083653|9960829|FG001|Overall Study|Death|2
6263971|NCT02083653|9960830|FG002|Overall Study|Death|2
6263972|NCT02083653|9960828|FG000|Overall Study|Progressive Disease|65
6263973|NCT02083653|9960829|FG001|Overall Study|Progressive Disease|73
6263974|NCT02083653|9960830|FG002|Overall Study|Progressive Disease|63
6263975|NCT02083653|9960828|FG000|Overall Study|Withdrawal by Subject|2
6263976|NCT02083653|9960829|FG001|Overall Study|Withdrawal by Subject|1
6263977|NCT02083653|9960830|FG002|Overall Study|Withdrawal by Subject|2
6263978|NCT02083653|9960828|FG000|Overall Study|Other Events|0
6263979|NCT02083653|9960829|FG001|Overall Study|Other Events|2
6263980|NCT02083653|9960830|FG002|Overall Study|Other Events|2
6263981|NCT02083653|9960828|FG000|Overall Study|Reason Missing|0
6263982|NCT02083653|9960829|FG001|Overall Study|Reason Missing|0
6263983|NCT02083653|9960830|FG002|Overall Study|Reason Missing|4
6263984|NCT02083783|9960857|FG000|Overall Study|Withdrawal by Subject|1
6263985|NCT02083783|9960858|FG001|Overall Study|Withdrawal by Subject|0
6263986|NCT02083926|9960888|FG000|Overall Study|Withdrawal by Subject|1
6263987|NCT02083926|9960889|FG001|Overall Study|Withdrawal by Subject|0
6263988|NCT02083965|9960898|FG000|Treatment Period|Other|1
6263989|NCT02083965|9960899|FG001|Treatment Period|Other|0
6263990|NCT02084056|9960909|FG000|Treatment Period 1 (4 Days)|Withdrawal by Subject|1
6263991|NCT02084056|9960910|FG001|Treatment Period 1 (4 Days)|Withdrawal by Subject|0
6263992|NCT02084056|9960911|FG002|Treatment Period 1 (4 Days)|Withdrawal by Subject|0
6263993|NCT02084056|9960912|FG003|Treatment Period 1 (4 Days)|Withdrawal by Subject|0
6263994|NCT02084056|9960909|FG000|Washout Period 1 (35 Days)|Withdrawal by Subject|1
6263995|NCT02084056|9960910|FG001|Washout Period 1 (35 Days)|Withdrawal by Subject|0
6263996|NCT02084056|9960911|FG002|Washout Period 1 (35 Days)|Withdrawal by Subject|0
6263997|NCT02084056|9960912|FG003|Washout Period 1 (35 Days)|Withdrawal by Subject|0
6263998|NCT02084082|9960933|FG000|Washout Period 1 (35 Days)|Adverse Event|0
6263999|NCT02084082|9960934|FG001|Washout Period 1 (35 Days)|Adverse Event|0
6264000|NCT02084082|9960935|FG002|Washout Period 1 (35 Days)|Adverse Event|1
6264001|NCT02084082|9960936|FG003|Washout Period 1 (35 Days)|Adverse Event|1
6264002|NCT02084082|9960933|FG000|Washout Period 1 (35 Days)|Withdrawal by Subject|0
6264003|NCT02084082|9960934|FG001|Washout Period 1 (35 Days)|Withdrawal by Subject|0
6264004|NCT02084082|9960935|FG002|Washout Period 1 (35 Days)|Withdrawal by Subject|0
6264005|NCT02084082|9960936|FG003|Washout Period 1 (35 Days)|Withdrawal by Subject|1
6264006|NCT02084134|9960948|FG000|Overall Study|Protocol Violation|4
6264007|NCT02084134|9960949|FG001|Overall Study|Protocol Violation|2
6264008|NCT02084134|9960948|FG000|Overall Study|Death|0
6264009|NCT02084134|9960949|FG001|Overall Study|Death|1
6264010|NCT02084238|9960959|FG000|Overall Study|Lost to Follow-up|2
6264011|NCT02085135|9961015|FG000|Overall Study|Adverse Event|4
6264012|NCT02085135|9961016|FG001|Overall Study|Adverse Event|7
6264013|NCT02085135|9961015|FG000|Overall Study|Lost to Follow-up|2
6264014|NCT02085135|9961016|FG001|Overall Study|Lost to Follow-up|2
6264015|NCT02085135|9961015|FG000|Overall Study|Withdrawal by Subject|3
6264016|NCT02085135|9961016|FG001|Overall Study|Withdrawal by Subject|0
6264017|NCT02085135|9961015|FG000|Overall Study|Lack of Efficacy|2
6264018|NCT02085135|9961016|FG001|Overall Study|Lack of Efficacy|0
6264019|NCT02085161|9961026|FG000|Overall Study|Not Treated|1
6264020|NCT02085161|9961027|FG001|Overall Study|Not Treated|0
6264021|NCT02085161|9961028|FG002|Overall Study|Not Treated|0
6264022|NCT02085161|9961029|FG003|Overall Study|Not Treated|0
6264023|NCT02085161|9961026|FG000|Overall Study|Adverse Event|8
6264024|NCT02085161|9961027|FG001|Overall Study|Adverse Event|5
6264025|NCT02085161|9961028|FG002|Overall Study|Adverse Event|4
6264026|NCT02085161|9961029|FG003|Overall Study|Adverse Event|5
6264027|NCT02085161|9961026|FG000|Overall Study|Protocol Violation|0
6264028|NCT02085161|9961027|FG001|Overall Study|Protocol Violation|1
6264029|NCT02085161|9961028|FG002|Overall Study|Protocol Violation|0
6264030|NCT02085161|9961029|FG003|Overall Study|Protocol Violation|1
6264031|NCT02085161|9961026|FG000|Overall Study|Withdrawal by Subject|2
6264032|NCT02085161|9961027|FG001|Overall Study|Withdrawal by Subject|4
6264033|NCT02085161|9961028|FG002|Overall Study|Withdrawal by Subject|0
6264034|NCT02085161|9961029|FG003|Overall Study|Withdrawal by Subject|3
6264035|NCT02085161|9961026|FG000|Overall Study|Other Reason|1
6264036|NCT02085161|9961027|FG001|Overall Study|Other Reason|0
6264037|NCT02085161|9961028|FG002|Overall Study|Other Reason|1
6264038|NCT02085161|9961029|FG003|Overall Study|Other Reason|1
6264039|NCT02085252|9961042|FG000|Overall Study|Withdrawal of Consent|1
6264040|NCT02085252|9961043|FG001|Overall Study|Withdrawal of Consent|0
6264041|NCT02085252|9961042|FG000|Overall Study|Adverse Event|0
6264042|NCT02085252|9961043|FG001|Overall Study|Adverse Event|1
6264043|NCT02085252|9961042|FG000|Overall Study|Discontinuation Due to Patient Decision|0
6264044|NCT02085252|9961043|FG001|Overall Study|Discontinuation Due to Patient Decision|1
6264045|NCT02085252|9961042|FG000|Overall Study|Reason Not Specified|0
6264046|NCT02085252|9961043|FG001|Overall Study|Reason Not Specified|1
6264047|NCT02085252|9961042|FG000|Overall Study|Reason Unknown|0
6264048|NCT02085252|9961043|FG001|Overall Study|Reason Unknown|1
6264049|NCT02085460|9961074|FG000|Overall Study|Adverse Event|2
6264050|NCT02085460|9961075|FG001|Overall Study|Adverse Event|2
6264051|NCT02085460|9961076|FG002|Overall Study|Adverse Event|1
6264052|NCT02085460|9961074|FG000|Overall Study|Physician Decision|1
6264053|NCT02085460|9961075|FG001|Overall Study|Physician Decision|1
6264054|NCT02085460|9961076|FG002|Overall Study|Physician Decision|2
6264055|NCT02085460|9961074|FG000|Overall Study|Withdrawal by Subject|11
6264056|NCT02085460|9961075|FG001|Overall Study|Withdrawal by Subject|5
6264057|NCT02085460|9961076|FG002|Overall Study|Withdrawal by Subject|7
6264058|NCT02085785|9961115|FG000|Overall Study|Withdrawal by Subject|2
6264059|NCT02085785|9961116|FG001|Overall Study|Withdrawal by Subject|1
6264060|NCT02085785|9961115|FG000|Overall Study|Lost to Follow-up|0
6264061|NCT02085785|9961116|FG001|Overall Study|Lost to Follow-up|1
6264062|NCT02086110|9961130|FG000|Overall Study|Withdrawal by Subject|1
6264063|NCT02086110|9961131|FG001|Overall Study|Withdrawal by Subject|1
6264064|NCT02086162|9961140|FG000|Overall Study|Withdrawal by Subject|4
6264065|NCT02086162|9961141|FG001|Overall Study|Withdrawal by Subject|4
6264066|NCT02086162|9961140|FG000|Overall Study|moved|1
6264067|NCT02086162|9961141|FG001|Overall Study|moved|1
6264068|NCT02086162|9961140|FG000|Overall Study|Lost to Follow-up|4
6264069|NCT02086162|9961141|FG001|Overall Study|Lost to Follow-up|2
6264070|NCT02086162|9961140|FG000|Overall Study|Death|1
6264071|NCT02086162|9961141|FG001|Overall Study|Death|0
6264072|NCT02086565|9961175|FG000|Overall Study|Lost to Follow-up|9
6264073|NCT02086565|9961176|FG001|Overall Study|Lost to Follow-up|7
6264074|NCT02086565|9961175|FG000|Overall Study|Withdrawal by Subject|2
6264075|NCT02086565|9961176|FG001|Overall Study|Withdrawal by Subject|1
6264076|NCT02086565|9961175|FG000|Overall Study|Death|3
6264077|NCT02086565|9961176|FG001|Overall Study|Death|2
6264078|NCT02086565|9961175|FG000|Overall Study|withdrawn by research team|2
6264079|NCT02086565|9961176|FG001|Overall Study|withdrawn by research team|2
6264080|NCT02086591|9961182|FG000|Overall Study|Adverse Event|1
6264081|NCT02086591|9961182|FG000|Overall Study|Withdrawal by Subject|1
6264082|NCT02086591|9961182|FG000|Overall Study|protocol terminated|3
6264083|NCT02086968|9961220|FG000|Overall Study|Adverse Event|1
6264084|NCT02086968|9961221|FG001|Overall Study|Adverse Event|5
6264085|NCT02086968|9961220|FG000|Overall Study|Lost to Follow-up|2
6264086|NCT02086968|9961221|FG001|Overall Study|Lost to Follow-up|3
6264087|NCT02086968|9961220|FG000|Overall Study|Study drug received outside protocol|0
6264088|NCT02086968|9961221|FG001|Overall Study|Study drug received outside protocol|1
6264089|NCT02086968|9961220|FG000|Overall Study|Physician Decision|4
6264090|NCT02086968|9961221|FG001|Overall Study|Physician Decision|0
6264091|NCT02086968|9961220|FG000|Overall Study|Withdrawal by Subject|1
6264092|NCT02086968|9961221|FG001|Overall Study|Withdrawal by Subject|4
6264093|NCT02087046|9961227|FG000|Overall Study|Adverse Event|4
6264094|NCT02087046|9961227|FG000|Overall Study|Death|1
6264095|NCT02087046|9961227|FG000|Overall Study|Lost to Follow-up|3
6264096|NCT02087046|9961227|FG000|Overall Study|Withdrawal by Subject|2
6264097|NCT02087046|9961227|FG000|Overall Study|Physician Decision|1
6264098|NCT02087059|9961232|FG000|Overall Study|Disease Progression|1
6264099|NCT02087059|9961232|FG000|Overall Study|Adverse Event|5
6264100|NCT02087059|9961232|FG000|Overall Study|Lost to Follow-up|1
6264101|NCT02087085|9961238|FG000|Overall Study|Adverse Event|10
6264102|NCT02087085|9961239|FG001|Overall Study|Adverse Event|14
6264103|NCT02087085|9961238|FG000|Overall Study|Lack of Efficacy|4
6264104|NCT02087085|9961239|FG001|Overall Study|Lack of Efficacy|3
6264105|NCT02087085|9961238|FG000|Overall Study|Lost to Follow-up|6
6264106|NCT02087085|9961239|FG001|Overall Study|Lost to Follow-up|4
6264107|NCT02087085|9961238|FG000|Overall Study|Withdrawal by Subject|9
6264108|NCT02087085|9961239|FG001|Overall Study|Withdrawal by Subject|11
6264109|NCT02087085|9961238|FG000|Overall Study|Protocol Violation|1
6264110|NCT02087085|9961239|FG001|Overall Study|Protocol Violation|0
6264111|NCT02087085|9961238|FG000|Overall Study|Study Terminated by Sponsor|87
6264112|NCT02087085|9961239|FG001|Overall Study|Study Terminated by Sponsor|80
6264113|NCT02087085|9961238|FG000|Overall Study|Other Miscellaneous Reasons|3
6264114|NCT02087085|9961239|FG001|Overall Study|Other Miscellaneous Reasons|4
6264115|NCT02087150|9961248|FG000|Overall Study|Death|0
6264116|NCT02087150|9961249|FG001|Overall Study|Death|1
6264117|NCT02087150|9961250|FG002|Overall Study|Death|0
6264118|NCT02087150|9961248|FG000|Overall Study|Lost to Follow-up|6
6264119|NCT02087150|9961249|FG001|Overall Study|Lost to Follow-up|13
6264120|NCT02087150|9961250|FG002|Overall Study|Lost to Follow-up|7
6264121|NCT02087150|9961248|FG000|Overall Study|Withdrawal by Subject|2
6264122|NCT02087150|9961249|FG001|Overall Study|Withdrawal by Subject|5
6264123|NCT02087150|9961250|FG002|Overall Study|Withdrawal by Subject|3
6264124|NCT02087150|9961248|FG000|Overall Study|Physician Decision|0
6264125|NCT02087150|9961249|FG001|Overall Study|Physician Decision|1
6264126|NCT02087150|9961250|FG002|Overall Study|Physician Decision|0
6264127|NCT02087150|9961248|FG000|Overall Study|Procedure not done|1
6264128|NCT02087150|9961249|FG001|Overall Study|Procedure not done|13
6264129|NCT02087150|9961250|FG002|Overall Study|Procedure not done|0
6264130|NCT02087150|9961248|FG000|Overall Study|F/U not completed w/in study window|0
6264131|NCT02087150|9961249|FG001|Overall Study|F/U not completed w/in study window|0
6264132|NCT02087150|9961250|FG002|Overall Study|F/U not completed w/in study window|1
6264133|NCT02087150|9961248|FG000|Overall Study|Other|1
6264134|NCT02087150|9961249|FG001|Overall Study|Other|0
6264135|NCT02087150|9961250|FG002|Overall Study|Other|0
6264136|NCT02087150|9961248|FG000|Overall Study|Pt moved out of town|0
6264137|NCT02087150|9961249|FG001|Overall Study|Pt moved out of town|1
6191112|NCT01420081|9847776|FG004|Overall Study|Death|7
6191113|NCT01420081|9847777|FG005|Overall Study|Death|12
6191114|NCT01420081|9847778|FG006|Overall Study|Death|0
6191115|NCT01420081|9847779|FG007|Overall Study|Death|1
6191116|NCT01420081|9847780|FG008|Overall Study|Death|1
6191117|NCT01420081|9847772|FG000|Overall Study|Lost to Follow-up|0
6191118|NCT01420081|9847773|FG001|Overall Study|Lost to Follow-up|0
6191119|NCT01420081|9847774|FG002|Overall Study|Lost to Follow-up|0
6191120|NCT01420081|9847775|FG003|Overall Study|Lost to Follow-up|0
6191121|NCT01420081|9847776|FG004|Overall Study|Lost to Follow-up|1
6191122|NCT01420081|9847777|FG005|Overall Study|Lost to Follow-up|1
6191123|NCT01420081|9847778|FG006|Overall Study|Lost to Follow-up|0
6191124|NCT01420081|9847779|FG007|Overall Study|Lost to Follow-up|0
6191125|NCT01420081|9847780|FG008|Overall Study|Lost to Follow-up|0
6191126|NCT01420081|9847772|FG000|Overall Study|Study Terminated by Sponsor|2
6191127|NCT01420081|9847773|FG001|Overall Study|Study Terminated by Sponsor|1
6264138|NCT02087150|9961250|FG002|Overall Study|Pt moved out of town|0
6264139|NCT02087176|9961263|FG000|Overall Study|Withdrawal by Subject|1
6264140|NCT02087176|9961263|FG000|Overall Study|Death|10
6264141|NCT02087176|9961263|FG000|Overall Study|Censored|19
6264142|NCT02087176|9961263|FG000|Overall Study|Study Terminated by Sponsor|2
6264143|NCT02087241|9961271|FG000|Overall Study|Death|2
6264144|NCT02087241|9961272|FG001|Overall Study|Death|1
6264145|NCT02087241|9961273|FG002|Overall Study|Death|1
6264146|NCT02087241|9961274|FG003|Overall Study|Death|1
6264147|NCT02087241|9961271|FG000|Overall Study|Withdrawal by Subject|1
6264148|NCT02087241|9961272|FG001|Overall Study|Withdrawal by Subject|0
6264149|NCT02087241|9961273|FG002|Overall Study|Withdrawal by Subject|0
6264150|NCT02087241|9961274|FG003|Overall Study|Withdrawal by Subject|1
6264151|NCT02087241|9961271|FG000|Overall Study|Progressive Disease|0
6264152|NCT02087241|9961272|FG001|Overall Study|Progressive Disease|0
6264153|NCT02087241|9961273|FG002|Overall Study|Progressive Disease|0
6264154|NCT02087241|9961274|FG003|Overall Study|Progressive Disease|1
6264155|NCT02087241|9961271|FG000|Overall Study|Study Terminated by Sponsor|0
6264156|NCT02087241|9961272|FG001|Overall Study|Study Terminated by Sponsor|2
6264157|NCT02087241|9961273|FG002|Overall Study|Study Terminated by Sponsor|0
6264158|NCT02087241|9961274|FG003|Overall Study|Study Terminated by Sponsor|4
6264159|NCT02087670|9961327|FG000|Overall Study|Withdrawal by Subject|3
6264160|NCT02087670|9961328|FG001|Overall Study|Withdrawal by Subject|2
6271470|NCT02163993|9973264|FG000|Treatment Period|Not treated|1
6271471|NCT02163993|9973265|FG001|Treatment Period|Not treated|0
6271472|NCT02163993|9973266|FG002|Treatment Period|Not treated|0
6271473|NCT02163993|9973267|FG003|Treatment Period|Not treated|1
6271474|NCT02163993|9973268|FG004|Treatment Period|Not treated|2
6271475|NCT02163993|9973264|FG000|Post-treatment Period|Adverse Event|0
6271476|NCT02163993|9973265|FG001|Post-treatment Period|Adverse Event|0
6271477|NCT02163993|9973266|FG002|Post-treatment Period|Adverse Event|1
6271478|NCT02163993|9973267|FG003|Post-treatment Period|Adverse Event|0
6271479|NCT02163993|9973268|FG004|Post-treatment Period|Adverse Event|0
6271480|NCT02163993|9973264|FG000|Post-treatment Period|Lost to Follow-up|2
6271481|NCT02163993|9973265|FG001|Post-treatment Period|Lost to Follow-up|2
6271482|NCT02163993|9973266|FG002|Post-treatment Period|Lost to Follow-up|3
6271483|NCT02163993|9973267|FG003|Post-treatment Period|Lost to Follow-up|1
6271484|NCT02163993|9973268|FG004|Post-treatment Period|Lost to Follow-up|0
6271485|NCT02163993|9973264|FG000|Post-treatment Period|Protocol Violation|0
6271486|NCT02163993|9973265|FG001|Post-treatment Period|Protocol Violation|0
6271487|NCT02163993|9973266|FG002|Post-treatment Period|Protocol Violation|0
6271488|NCT02163993|9973267|FG003|Post-treatment Period|Protocol Violation|0
6271489|NCT02163993|9973268|FG004|Post-treatment Period|Protocol Violation|1
6271490|NCT02163993|9973264|FG000|Post-treatment Period|Withdrawal by Subject|2
6271491|NCT02163993|9973265|FG001|Post-treatment Period|Withdrawal by Subject|4
6271492|NCT02163993|9973266|FG002|Post-treatment Period|Withdrawal by Subject|0
6271493|NCT02163993|9973267|FG003|Post-treatment Period|Withdrawal by Subject|1
6271494|NCT02163993|9973268|FG004|Post-treatment Period|Withdrawal by Subject|2
6271495|NCT02164318|9973304|FG000|Overall Study|Withdrawal by Subject|0
6271496|NCT02164318|9973305|FG001|Overall Study|Withdrawal by Subject|1
6271497|NCT02164318|9973306|FG002|Overall Study|Withdrawal by Subject|0
6271498|NCT02164318|9973307|FG003|Overall Study|Withdrawal by Subject|1
6271499|NCT02164383|9973319|FG000|Overall Study|Lost to Follow-up|1
6271500|NCT02164383|9973320|FG001|Overall Study|Lost to Follow-up|0
6271501|NCT02164513|9973355|FG000|Overall Study|Adverse Event|162
6271502|NCT02164513|9973356|FG001|Overall Study|Adverse Event|180
6271503|NCT02164513|9973357|FG002|Overall Study|Adverse Event|111
6271504|NCT02164513|9973355|FG000|Overall Study|Other: Study Closed or terminated|5
6271505|NCT02164513|9973356|FG001|Overall Study|Other: Study Closed or terminated|2
6271506|NCT02164513|9973357|FG002|Overall Study|Other: Study Closed or terminated|4
6271507|NCT02164513|9973355|FG000|Overall Study|Lost to Follow-up|30
6271508|NCT02164513|9973356|FG001|Overall Study|Lost to Follow-up|36
6271509|NCT02164513|9973357|FG002|Overall Study|Lost to Follow-up|22
6271510|NCT02164513|9973355|FG000|Overall Study|Physician Decision|47
6271511|NCT02164513|9973356|FG001|Overall Study|Physician Decision|57
6271512|NCT02164513|9973357|FG002|Overall Study|Physician Decision|28
6271513|NCT02164513|9973355|FG000|Overall Study|Withdrawal by Subject|192
6271514|NCT02164513|9973356|FG001|Overall Study|Withdrawal by Subject|261
6271515|NCT02164513|9973357|FG002|Overall Study|Withdrawal by Subject|130
6271516|NCT02164513|9973355|FG000|Overall Study|Other: Reason not provided by site|1
6271517|NCT02164513|9973356|FG001|Overall Study|Other: Reason not provided by site|0
6271518|NCT02164513|9973357|FG002|Overall Study|Other: Reason not provided by site|0
6271519|NCT02164539|9973372|FG000|Treatment Phase A (4 Weeks)|Withdrawal by Subject|2
6271520|NCT02164539|9973373|FG001|Treatment Phase A (4 Weeks)|Withdrawal by Subject|0
6271521|NCT02164539|9973374|FG002|Treatment Phase A (4 Weeks)|Withdrawal by Subject|1
6271522|NCT02164539|9973375|FG003|Treatment Phase A (4 Weeks)|Withdrawal by Subject|2
6271523|NCT02164539|9973376|FG004|Treatment Phase A (4 Weeks)|Withdrawal by Subject|3
6271524|NCT02164539|9973377|FG005|Treatment Phase A (4 Weeks)|Withdrawal by Subject|1
6271525|NCT02164539|9973378|FG006|Treatment Phase A (4 Weeks)|Withdrawal by Subject|0
6271526|NCT02164539|9973372|FG000|Treatment Phase B (1 Week)|Adverse Event|0
6271527|NCT02164539|9973373|FG001|Treatment Phase B (1 Week)|Adverse Event|0
6271528|NCT02164539|9973374|FG002|Treatment Phase B (1 Week)|Adverse Event|0
6271529|NCT02164539|9973375|FG003|Treatment Phase B (1 Week)|Adverse Event|0
6271530|NCT02164539|9973376|FG004|Treatment Phase B (1 Week)|Adverse Event|2
6271531|NCT02164539|9973377|FG005|Treatment Phase B (1 Week)|Adverse Event|0
6271532|NCT02164539|9973378|FG006|Treatment Phase B (1 Week)|Adverse Event|0
6271533|NCT02164539|9973372|FG000|Treatment Phase B (1 Week)|Physician Decision|0
6271534|NCT02164539|9973373|FG001|Treatment Phase B (1 Week)|Physician Decision|0
6271535|NCT02164539|9973374|FG002|Treatment Phase B (1 Week)|Physician Decision|0
6271536|NCT02164539|9973375|FG003|Treatment Phase B (1 Week)|Physician Decision|0
6271537|NCT02164539|9973376|FG004|Treatment Phase B (1 Week)|Physician Decision|1
6264161|NCT02087774|9961344|FG000|Overall Study|Were absent day of data collection|8
6264162|NCT02087774|9961345|FG001|Overall Study|Were absent day of data collection|20
6264163|NCT02087904|9961355|FG000|Overall Study|Did Not Receive Study Drug|0
6264164|NCT02087904|9961356|FG001|Overall Study|Did Not Receive Study Drug|0
6264165|NCT02087904|9961357|FG002|Overall Study|Did Not Receive Study Drug|2
6264166|NCT02087904|9961358|FG003|Overall Study|Did Not Receive Study Drug|1
6264167|NCT02087904|9961355|FG000|Overall Study|Adverse Event|8
6264168|NCT02087904|9961356|FG001|Overall Study|Adverse Event|4
6264169|NCT02087904|9961357|FG002|Overall Study|Adverse Event|4
6264170|NCT02087904|9961358|FG003|Overall Study|Adverse Event|12
6264171|NCT02087904|9961355|FG000|Overall Study|Lack of Efficacy|3
6264172|NCT02087904|9961356|FG001|Overall Study|Lack of Efficacy|6
6264173|NCT02087904|9961357|FG002|Overall Study|Lack of Efficacy|3
6264174|NCT02087904|9961358|FG003|Overall Study|Lack of Efficacy|2
6264175|NCT02087904|9961355|FG000|Overall Study|Other|6
6264176|NCT02087904|9961356|FG001|Overall Study|Other|2
6264177|NCT02087904|9961357|FG002|Overall Study|Other|4
6264178|NCT02087904|9961358|FG003|Overall Study|Other|4
6264179|NCT02087904|9961355|FG000|Overall Study|Withdrawal by Subject|8
6264180|NCT02087904|9961356|FG001|Overall Study|Withdrawal by Subject|3
6264181|NCT02087904|9961357|FG002|Overall Study|Withdrawal by Subject|7
6264182|NCT02087904|9961358|FG003|Overall Study|Withdrawal by Subject|4
6264183|NCT02087904|9961355|FG000|Overall Study|Lost to Follow-up|0
6264184|NCT02087904|9961356|FG001|Overall Study|Lost to Follow-up|4
6264185|NCT02087904|9961357|FG002|Overall Study|Lost to Follow-up|2
6264186|NCT02087904|9961358|FG003|Overall Study|Lost to Follow-up|2
6264187|NCT02087943|9961371|FG000|Placebo-Controlled Phase Week 0-12|Adverse Event|1
6264188|NCT02087943|9961372|FG001|Placebo-Controlled Phase Week 0-12|Adverse Event|2
6086928|NCT00665561|9697078|FG000|Overall Study|Lost to Follow-up|203
6086929|NCT00665561|9697079|FG001|Overall Study|Lost to Follow-up|264
6086930|NCT00665561|9697078|FG000|Overall Study|Withdrawal by Subject|74
6086931|NCT00665561|9697079|FG001|Overall Study|Withdrawal by Subject|65
6264189|NCT02087943|9961373|FG002|Placebo-Controlled Phase Week 0-12|Adverse Event|6
6264190|NCT02087943|9961374|FG003|Placebo-Controlled Phase Week 0-12|Adverse Event|0
6264191|NCT02087943|9961375|FG004|Placebo-Controlled Phase Week 0-12|Adverse Event|0
6264192|NCT02087943|9961371|FG000|Placebo-Controlled Phase Week 0-12|Lack of Efficacy|8
6264193|NCT02087943|9961372|FG001|Placebo-Controlled Phase Week 0-12|Lack of Efficacy|7
6264194|NCT02087943|9961373|FG002|Placebo-Controlled Phase Week 0-12|Lack of Efficacy|4
6264195|NCT02087943|9961374|FG003|Placebo-Controlled Phase Week 0-12|Lack of Efficacy|0
6264196|NCT02087943|9961375|FG004|Placebo-Controlled Phase Week 0-12|Lack of Efficacy|0
6264197|NCT02087943|9961371|FG000|Placebo-Controlled Phase Week 0-12|Withdrawal by Subject|4
6264198|NCT02087943|9961372|FG001|Placebo-Controlled Phase Week 0-12|Withdrawal by Subject|2
6264199|NCT02087943|9961373|FG002|Placebo-Controlled Phase Week 0-12|Withdrawal by Subject|2
6264200|NCT02087943|9961374|FG003|Placebo-Controlled Phase Week 0-12|Withdrawal by Subject|0
6264201|NCT02087943|9961375|FG004|Placebo-Controlled Phase Week 0-12|Withdrawal by Subject|0
6264202|NCT02087943|9961371|FG000|Placebo-Controlled Phase Week 0-12|Lost to Follow-up|1
6264203|NCT02087943|9961372|FG001|Placebo-Controlled Phase Week 0-12|Lost to Follow-up|0
6264204|NCT02087943|9961373|FG002|Placebo-Controlled Phase Week 0-12|Lost to Follow-up|1
6264205|NCT02087943|9961374|FG003|Placebo-Controlled Phase Week 0-12|Lost to Follow-up|0
6264206|NCT02087943|9961375|FG004|Placebo-Controlled Phase Week 0-12|Lost to Follow-up|0
6264207|NCT02087943|9961371|FG000|Placebo-Controlled Phase Week 0-12|Protocol Violation|0
6264208|NCT02087943|9961372|FG001|Placebo-Controlled Phase Week 0-12|Protocol Violation|1
6264209|NCT02087943|9961373|FG002|Placebo-Controlled Phase Week 0-12|Protocol Violation|0
6264210|NCT02087943|9961374|FG003|Placebo-Controlled Phase Week 0-12|Protocol Violation|0
6264211|NCT02087943|9961375|FG004|Placebo-Controlled Phase Week 0-12|Protocol Violation|0
6264212|NCT02087943|9961371|FG000|Active Treatment Phase Week 12-24|Adverse Event|0
6264213|NCT02087943|9961372|FG001|Active Treatment Phase Week 12-24|Adverse Event|1
6264214|NCT02087943|9961373|FG002|Active Treatment Phase Week 12-24|Adverse Event|2
6264215|NCT02087943|9961374|FG003|Active Treatment Phase Week 12-24|Adverse Event|0
6264216|NCT02087943|9961375|FG004|Active Treatment Phase Week 12-24|Adverse Event|1
6264217|NCT02087943|9961371|FG000|Active Treatment Phase Week 12-24|Lack of Efficacy|0
6264218|NCT02087943|9961372|FG001|Active Treatment Phase Week 12-24|Lack of Efficacy|3
6264219|NCT02087943|9961373|FG002|Active Treatment Phase Week 12-24|Lack of Efficacy|1
6264220|NCT02087943|9961374|FG003|Active Treatment Phase Week 12-24|Lack of Efficacy|1
6264221|NCT02087943|9961375|FG004|Active Treatment Phase Week 12-24|Lack of Efficacy|0
6264222|NCT02087943|9961371|FG000|Active Treatment Phase Week 12-24|Withdrawal by Subject|0
6264223|NCT02087943|9961372|FG001|Active Treatment Phase Week 12-24|Withdrawal by Subject|0
6264224|NCT02087943|9961373|FG002|Active Treatment Phase Week 12-24|Withdrawal by Subject|1
6264225|NCT02087943|9961374|FG003|Active Treatment Phase Week 12-24|Withdrawal by Subject|0
6264226|NCT02087943|9961375|FG004|Active Treatment Phase Week 12-24|Withdrawal by Subject|0
6264227|NCT02087943|9961371|FG000|Active Treatment Phase Week 12-24|Lost to Follow-up|0
6264228|NCT02087943|9961372|FG001|Active Treatment Phase Week 12-24|Lost to Follow-up|0
6086932|NCT00665561|9697078|FG000|Overall Study|Other|123
6086933|NCT00665561|9697079|FG001|Overall Study|Other|108
6264229|NCT02087943|9961373|FG002|Active Treatment Phase Week 12-24|Lost to Follow-up|0
6086934|NCT00665561|9697078|FG000|Overall Study|Site closed|8
6086935|NCT00665561|9697079|FG001|Overall Study|Site closed|0
6264230|NCT02087943|9961374|FG003|Active Treatment Phase Week 12-24|Lost to Follow-up|0
6264231|NCT02087943|9961375|FG004|Active Treatment Phase Week 12-24|Lost to Follow-up|1
6264232|NCT02087943|9961371|FG000|Active Treatment Phase Week 12-24|Other-Unspecified|0
6264233|NCT02087943|9961372|FG001|Active Treatment Phase Week 12-24|Other-Unspecified|0
6264234|NCT02087943|9961373|FG002|Active Treatment Phase Week 12-24|Other-Unspecified|1
6264235|NCT02087943|9961374|FG003|Active Treatment Phase Week 12-24|Other-Unspecified|1
6264236|NCT02087943|9961375|FG004|Active Treatment Phase Week 12-24|Other-Unspecified|0
6264237|NCT02088034|9961405|FG000|Overall Study|Lost to Follow-up|1
6264238|NCT02088034|9961406|FG001|Overall Study|Lost to Follow-up|1
6264239|NCT02088034|9961407|FG002|Overall Study|Lost to Follow-up|0
6264240|NCT02088034|9961405|FG000|Overall Study|Pregnancy|2
6264241|NCT02088034|9961406|FG001|Overall Study|Pregnancy|1
6264242|NCT02088034|9961407|FG002|Overall Study|Pregnancy|2
6264243|NCT02088047|9961417|FG000|Overall Study|Withdrawal by Subject|1
6264244|NCT02088047|9961418|FG001|Overall Study|Withdrawal by Subject|0
6264245|NCT02088073|9961429|FG000|Acute Phase|Withdrawal by Subject|5
6264246|NCT02088073|9961430|FG001|Acute Phase|Withdrawal by Subject|0
6264247|NCT02088073|9961431|FG002|Acute Phase|Withdrawal by Subject|0
6264248|NCT02088073|9961432|FG003|Acute Phase|Withdrawal by Subject|0
6264249|NCT02088073|9961433|FG004|Acute Phase|Withdrawal by Subject|0
6264250|NCT02088073|9961429|FG000|Acute Phase|Hyperkalemia|2
6264251|NCT02088073|9961430|FG001|Acute Phase|Hyperkalemia|0
6264252|NCT02088073|9961431|FG002|Acute Phase|Hyperkalemia|0
6264253|NCT02088073|9961432|FG003|Acute Phase|Hyperkalemia|0
6264254|NCT02088073|9961433|FG004|Acute Phase|Hyperkalemia|0
6264255|NCT02088073|9961429|FG000|Maintanance Phase|Withdrawal by Subject|0
6264256|NCT02088073|9961430|FG001|Maintanance Phase|Withdrawal by Subject|2
6264257|NCT02088073|9961431|FG002|Maintanance Phase|Withdrawal by Subject|0
6264258|NCT02088073|9961432|FG003|Maintanance Phase|Withdrawal by Subject|0
6264259|NCT02088073|9961433|FG004|Maintanance Phase|Withdrawal by Subject|0
6264260|NCT02088073|9961429|FG000|Maintanance Phase|Adverse Event|0
6264261|NCT02088073|9961430|FG001|Maintanance Phase|Adverse Event|0
6264262|NCT02088073|9961431|FG002|Maintanance Phase|Adverse Event|3
6264263|NCT02088073|9961432|FG003|Maintanance Phase|Adverse Event|0
6264264|NCT02088073|9961433|FG004|Maintanance Phase|Adverse Event|1
6264265|NCT02088073|9961429|FG000|Maintanance Phase|Physician Decision|0
6264266|NCT02088073|9961430|FG001|Maintanance Phase|Physician Decision|0
6264267|NCT02088073|9961431|FG002|Maintanance Phase|Physician Decision|0
6264268|NCT02088073|9961432|FG003|Maintanance Phase|Physician Decision|0
6264269|NCT02088073|9961433|FG004|Maintanance Phase|Physician Decision|1
6264270|NCT02088073|9961429|FG000|Maintanance Phase|Sponsor's decision|0
6264271|NCT02088073|9961430|FG001|Maintanance Phase|Sponsor's decision|2
6264272|NCT02088073|9961431|FG002|Maintanance Phase|Sponsor's decision|0
6264273|NCT02088073|9961432|FG003|Maintanance Phase|Sponsor's decision|2
6264274|NCT02088073|9961433|FG004|Maintanance Phase|Sponsor's decision|1
6264275|NCT02088073|9961429|FG000|Maintanance Phase|Hypo- or hyperkalemia|0
6264276|NCT02088073|9961430|FG001|Maintanance Phase|Hypo- or hyperkalemia|3
6264277|NCT02088073|9961431|FG002|Maintanance Phase|Hypo- or hyperkalemia|0
6264278|NCT02088073|9961432|FG003|Maintanance Phase|Hypo- or hyperkalemia|3
6264279|NCT02088073|9961433|FG004|Maintanance Phase|Hypo- or hyperkalemia|1
6264280|NCT02088073|9961429|FG000|Maintanance Phase|Miscellaneous|0
6264281|NCT02088073|9961430|FG001|Maintanance Phase|Miscellaneous|2
6264282|NCT02088073|9961431|FG002|Maintanance Phase|Miscellaneous|1
6264283|NCT02088073|9961432|FG003|Maintanance Phase|Miscellaneous|2
6264284|NCT02088073|9961433|FG004|Maintanance Phase|Miscellaneous|1
6264285|NCT02088073|9961429|FG000|Maintanance Phase|Met ECG withdrawal criteria|0
6264286|NCT02088073|9961430|FG001|Maintanance Phase|Met ECG withdrawal criteria|0
6264287|NCT02088073|9961431|FG002|Maintanance Phase|Met ECG withdrawal criteria|1
6264288|NCT02088073|9961432|FG003|Maintanance Phase|Met ECG withdrawal criteria|0
6264289|NCT02088073|9961433|FG004|Maintanance Phase|Met ECG withdrawal criteria|2
6264290|NCT02088073|9961429|FG000|Maintanance Phase|Subject compliance|0
6264291|NCT02088073|9961430|FG001|Maintanance Phase|Subject compliance|1
6264292|NCT02088073|9961431|FG002|Maintanance Phase|Subject compliance|0
6264293|NCT02088073|9961432|FG003|Maintanance Phase|Subject compliance|0
6264294|NCT02088073|9961433|FG004|Maintanance Phase|Subject compliance|0
6264295|NCT02088177|9961446|FG000|Overall Study|Lost to Follow-up|3
6264296|NCT02088541|9961473|FG000|Overall Study|Adverse Event|3
6264297|NCT02088541|9961474|FG001|Overall Study|Adverse Event|0
6264298|NCT02088541|9961475|FG002|Overall Study|Adverse Event|3
6264299|NCT02088541|9961476|FG003|Overall Study|Adverse Event|3
6264300|NCT02088541|9961477|FG004|Overall Study|Adverse Event|0
6264301|NCT02088541|9961473|FG000|Overall Study|Death|51
6264302|NCT02088541|9961474|FG001|Overall Study|Death|21
6264303|NCT02088541|9961475|FG002|Overall Study|Death|85
6264304|NCT02088541|9961476|FG003|Overall Study|Death|28
6264305|NCT02088541|9961477|FG004|Overall Study|Death|38
6264306|NCT02088541|9961473|FG000|Overall Study|Lost to Follow-up|2
6264307|NCT02088541|9961474|FG001|Overall Study|Lost to Follow-up|0
6264308|NCT02088541|9961475|FG002|Overall Study|Lost to Follow-up|1
6264309|NCT02088541|9961476|FG003|Overall Study|Lost to Follow-up|0
6264310|NCT02088541|9961477|FG004|Overall Study|Lost to Follow-up|0
6264311|NCT02088541|9961473|FG000|Overall Study|Physician Decision|2
6264312|NCT02088541|9961474|FG001|Overall Study|Physician Decision|1
6264313|NCT02088541|9961475|FG002|Overall Study|Physician Decision|2
6264314|NCT02088541|9961476|FG003|Overall Study|Physician Decision|0
6264315|NCT02088541|9961477|FG004|Overall Study|Physician Decision|2
6264316|NCT02088541|9961473|FG000|Overall Study|Disease progression|7
6264317|NCT02088541|9961474|FG001|Overall Study|Disease progression|1
6264318|NCT02088541|9961475|FG002|Overall Study|Disease progression|2
6264319|NCT02088541|9961476|FG003|Overall Study|Disease progression|3
6264320|NCT02088541|9961477|FG004|Overall Study|Disease progression|1
6264321|NCT02088541|9961473|FG000|Overall Study|Study terminated by sponsor|1
6264322|NCT02088541|9961474|FG001|Overall Study|Study terminated by sponsor|1
6264323|NCT02088541|9961475|FG002|Overall Study|Study terminated by sponsor|12
6264324|NCT02088541|9961476|FG003|Overall Study|Study terminated by sponsor|2
6264325|NCT02088541|9961477|FG004|Overall Study|Study terminated by sponsor|6
6264326|NCT02088541|9961473|FG000|Overall Study|Withdrawal by Subject|3
6264327|NCT02088541|9961474|FG001|Overall Study|Withdrawal by Subject|2
6264328|NCT02088541|9961475|FG002|Overall Study|Withdrawal by Subject|9
6264329|NCT02088541|9961476|FG003|Overall Study|Withdrawal by Subject|7
6264330|NCT02088541|9961477|FG004|Overall Study|Withdrawal by Subject|10
6264331|NCT02088541|9961473|FG000|Overall Study|Other|2
6264332|NCT02088541|9961474|FG001|Overall Study|Other|1
6264333|NCT02088541|9961475|FG002|Overall Study|Other|3
6264334|NCT02088541|9961476|FG003|Overall Study|Other|1
6264335|NCT02088541|9961477|FG004|Overall Study|Other|1
6264336|NCT02088697|9961489|FG000|Period I|Physician Decision|1
6264337|NCT02088697|9961490|FG001|Period I|Physician Decision|4
6264338|NCT02088697|9961489|FG000|Wash-out Period (at Least 10 Days)|Adverse Event|1
6264339|NCT02088697|9961490|FG001|Wash-out Period (at Least 10 Days)|Adverse Event|0
6264340|NCT02088905|9961507|FG000|Overall Study|Withdrawal by Subject|5
6264341|NCT02088905|9961508|FG001|Overall Study|Withdrawal by Subject|1
6264342|NCT02089230|9961533|FG000|Overall Study|Death|0
6264343|NCT02089230|9961534|FG001|Overall Study|Death|0
6264344|NCT02089230|9961535|FG002|Overall Study|Death|2
6264345|NCT02089230|9961533|FG000|Overall Study|Seeking Alternative Therapy|0
6264346|NCT02089230|9961534|FG001|Overall Study|Seeking Alternative Therapy|0
6264347|NCT02089230|9961535|FG002|Overall Study|Seeking Alternative Therapy|4
6264348|NCT02089334|9961547|FG000|Overall Study|Withdrawal by Subject|0
6264349|NCT02089334|9961548|FG001|Overall Study|Withdrawal by Subject|0
6264350|NCT02089334|9961549|FG002|Overall Study|Withdrawal by Subject|0
6264351|NCT02089334|9961550|FG003|Overall Study|Withdrawal by Subject|2
6264352|NCT02089334|9961547|FG000|Overall Study|Adverse Event|0
6264353|NCT02089334|9961548|FG001|Overall Study|Adverse Event|0
6264354|NCT02089334|9961549|FG002|Overall Study|Adverse Event|0
6264355|NCT02089334|9961550|FG003|Overall Study|Adverse Event|2
6264356|NCT02089334|9961547|FG000|Overall Study|Progressive disease|0
6264357|NCT02089334|9961548|FG001|Overall Study|Progressive disease|0
6264358|NCT02089334|9961549|FG002|Overall Study|Progressive disease|0
6264359|NCT02089334|9961550|FG003|Overall Study|Progressive disease|2
6264360|NCT02089334|9961547|FG000|Overall Study|Physician Decision|0
6264361|NCT02089334|9961548|FG001|Overall Study|Physician Decision|0
6264362|NCT02089334|9961549|FG002|Overall Study|Physician Decision|1
6264363|NCT02089334|9961550|FG003|Overall Study|Physician Decision|1
6264364|NCT02089347|9961565|FG000|Overall Study|Protocol Violation|1
6264365|NCT02089347|9961566|FG001|Overall Study|Protocol Violation|0
6264366|NCT02089737|9961591|FG000|Overall Study|Survey form not completed|5
6264367|NCT02089737|9961591|FG000|Overall Study|Not treated|1
6264368|NCT02089997|9961596|FG000|Overall Study|Case report forms uncollected|99
6264369|NCT02089997|9961596|FG000|Overall Study|Protocol Violation|147
6264370|NCT02090283|9961617|FG000|Overall Study|Withdrawal by Subject|6
6264371|NCT02090283|9961618|FG001|Overall Study|Withdrawal by Subject|6
6264372|NCT02090283|9961619|FG002|Overall Study|Withdrawal by Subject|6
6264373|NCT02090283|9961617|FG000|Overall Study|Sponsor Terminated Study|6
6264374|NCT02090283|9961618|FG001|Overall Study|Sponsor Terminated Study|6
6264375|NCT02090283|9961619|FG002|Overall Study|Sponsor Terminated Study|1
6264376|NCT02090283|9961617|FG000|Overall Study|Lost to Follow-up|2
6264377|NCT02090283|9961618|FG001|Overall Study|Lost to Follow-up|2
6264378|NCT02090283|9961619|FG002|Overall Study|Lost to Follow-up|3
6264379|NCT02090283|9961617|FG000|Overall Study|Adverse Event|1
6264380|NCT02090283|9961618|FG001|Overall Study|Adverse Event|1
6264381|NCT02090283|9961619|FG002|Overall Study|Adverse Event|0
6264382|NCT02090283|9961617|FG000|Overall Study|Protocol Violation|2
6264383|NCT02090283|9961618|FG001|Overall Study|Protocol Violation|0
6264384|NCT02090283|9961619|FG002|Overall Study|Protocol Violation|0
6264385|NCT02090413|9961663|FG000|Overall Study|Adverse Event|11
6264386|NCT02090413|9961664|FG001|Overall Study|Adverse Event|15
6264387|NCT02090413|9961665|FG002|Overall Study|Adverse Event|20
6264388|NCT02090413|9961663|FG000|Overall Study|Flushing event|2
6264389|NCT02090413|9961664|FG001|Overall Study|Flushing event|0
6264390|NCT02090413|9961665|FG002|Overall Study|Flushing event|1
6264391|NCT02090413|9961663|FG000|Overall Study|Withdrawal by Subject|2
6264392|NCT02090413|9961664|FG001|Overall Study|Withdrawal by Subject|2
6264393|NCT02090413|9961665|FG002|Overall Study|Withdrawal by Subject|2
6264394|NCT02090413|9961663|FG000|Overall Study|Investigator Decision|1
6264395|NCT02090413|9961664|FG001|Overall Study|Investigator Decision|1
6264396|NCT02090413|9961665|FG002|Overall Study|Investigator Decision|0
6264397|NCT02090413|9961663|FG000|Overall Study|Other|2
6264398|NCT02090413|9961664|FG001|Overall Study|Other|1
6264399|NCT02090413|9961665|FG002|Overall Study|Other|0
6264400|NCT02090413|9961663|FG000|Overall Study|Lost to Follow-up|1
6264401|NCT02090413|9961664|FG001|Overall Study|Lost to Follow-up|1
6264402|NCT02090413|9961665|FG002|Overall Study|Lost to Follow-up|0
6264403|NCT02090426|9961676|FG000|Overall Study|Lost to Follow-up|12
6264404|NCT02090426|9961677|FG001|Overall Study|Lost to Follow-up|6
6264405|NCT02090634|9961685|FG000|Overall Study|Lost to Follow-up|0
6264406|NCT02090634|9961686|FG001|Overall Study|Lost to Follow-up|1
6264407|NCT02090634|9961685|FG000|Overall Study|Death|0
6264408|NCT02090634|9961686|FG001|Overall Study|Death|1
6264409|NCT02090634|9961685|FG000|Overall Study|Protocol Violation|3
6264410|NCT02090634|9961686|FG001|Overall Study|Protocol Violation|1
6264411|NCT02090634|9961685|FG000|Overall Study|Adverse Event|2
6264412|NCT02090634|9961686|FG001|Overall Study|Adverse Event|0
6264413|NCT02090725|9961692|FG000|Overall Study|Withdrawal by Subject|1
6264414|NCT02090725|9961692|FG000|Overall Study|participants moved from area|3
6264415|NCT02090764|9961698|FG000|Overall Study|Adverse Event|1
6264416|NCT02090764|9961699|FG001|Overall Study|Adverse Event|3
6264417|NCT02090764|9961698|FG000|Overall Study|Lack of Efficacy|0
6264418|NCT02090764|9961699|FG001|Overall Study|Lack of Efficacy|13
6264419|NCT02090764|9961698|FG000|Overall Study|Withdrawal by Subject|2
6264420|NCT02090764|9961699|FG001|Overall Study|Withdrawal by Subject|1
6264421|NCT02090764|9961698|FG000|Overall Study|Intercurrent illness and other|1
6264422|NCT02090764|9961699|FG001|Overall Study|Intercurrent illness and other|1
6264423|NCT02090764|9961698|FG000|Overall Study|Lost to Follow-up|2
6264424|NCT02090764|9961699|FG001|Overall Study|Lost to Follow-up|2
6264425|NCT02090855|9961709|FG000|Overall Study|no evaluable Standard of Truth results|2
6264426|NCT02090959|9961720|FG000|Overall Study|Withdrawal by Subject|10
6264427|NCT02090959|9961720|FG000|Overall Study|Adverse Event|1
6264428|NCT02090959|9961720|FG000|Overall Study|Investigator decision|2
6264429|NCT02090959|9961720|FG000|Overall Study|Study termination|6
6264430|NCT02090959|9961720|FG000|Overall Study|Enrolled but not treated|1
6264431|NCT02090959|9961720|FG000|Overall Study|Transfer for compassionate use medicine|4
6264432|NCT02090959|9961720|FG000|Overall Study|Move to medical need program|3
6264433|NCT02090959|9961720|FG000|Overall Study|Entered in to other study|34
6264434|NCT02090959|9961720|FG000|Overall Study|Switched to commercial supply|88
6264435|NCT02090959|9961720|FG000|Overall Study|Other than specified|2
6264436|NCT02091089|9961724|FG000|Overall Study|Lost to Follow-up|2
6264437|NCT02091167|9961734|FG000|Overall Study|Lost to Follow-up|0
6264438|NCT02091167|9961735|FG001|Overall Study|Lost to Follow-up|2
6264439|NCT02091206|9961745|FG000|Treatment Period|Adverse Event|0
6264440|NCT02091206|9961746|FG001|Treatment Period|Adverse Event|1
6264441|NCT02091206|9961747|FG002|Treatment Period|Adverse Event|0
6264442|NCT02091206|9961748|FG003|Treatment Period|Adverse Event|0
6264443|NCT02091206|9961745|FG000|Treatment Period|Met withdrawal criteria|0
6264444|NCT02091206|9961746|FG001|Treatment Period|Met withdrawal criteria|0
6264445|NCT02091206|9961747|FG002|Treatment Period|Met withdrawal criteria|1
6264446|NCT02091206|9961748|FG003|Treatment Period|Met withdrawal criteria|0
6264447|NCT02091206|9961745|FG000|Taper Period|Participant refused study drug|1
6264448|NCT02091206|9961746|FG001|Taper Period|Participant refused study drug|0
6264449|NCT02091206|9961747|FG002|Taper Period|Participant refused study drug|0
6264450|NCT02091206|9961748|FG003|Taper Period|Participant refused study drug|1
6264451|NCT02091206|9961745|FG000|Taper Period|Lost to Follow-up|0
6264452|NCT02091206|9961746|FG001|Taper Period|Lost to Follow-up|0
6264453|NCT02091206|9961747|FG002|Taper Period|Lost to Follow-up|0
6264454|NCT02091206|9961748|FG003|Taper Period|Lost to Follow-up|1
6264455|NCT02091284|9961760|FG000|Overall Study|Withdrawal by Subject|2
6264456|NCT02091284|9961761|FG001|Overall Study|Withdrawal by Subject|1
6264457|NCT02091284|9961760|FG000|Overall Study|unreliable data|1
6264458|NCT02091284|9961761|FG001|Overall Study|unreliable data|0
6264459|NCT02091362|9961771|FG000|Period 1|Protocol Violation|1
6264460|NCT02091362|9961772|FG001|Period 1|Protocol Violation|0
6264461|NCT02091362|9961771|FG000|Period 1|Withdrawal by Subject|2
6264462|NCT02091362|9961772|FG001|Period 1|Withdrawal by Subject|3
6264463|NCT02091362|9961771|FG000|Period 1|Lost to Follow-up|0
6264464|NCT02091362|9961772|FG001|Period 1|Lost to Follow-up|1
6264465|NCT02091362|9961771|FG000|Period 1|Adverse Event|2
6264466|NCT02091362|9961772|FG001|Period 1|Adverse Event|0
6264467|NCT02091362|9961771|FG000|Wash-out|Lost to Follow-up|1
6264468|NCT02091362|9961772|FG001|Wash-out|Lost to Follow-up|1
6264469|NCT02091362|9961771|FG000|Wash-out|Withdrawal by Subject|0
6264470|NCT02091362|9961772|FG001|Wash-out|Withdrawal by Subject|2
6264471|NCT02091362|9961771|FG000|Period 2|Adverse Event|1
6264472|NCT02091362|9961772|FG001|Period 2|Adverse Event|0
6264473|NCT02091362|9961771|FG000|Period 2|Lost to Follow-up|0
6264474|NCT02091362|9961772|FG001|Period 2|Lost to Follow-up|1
6264475|NCT02091362|9961771|FG000|Period 2|Withdrawal by Subject|1
6264476|NCT02091362|9961772|FG001|Period 2|Withdrawal by Subject|1
6264477|NCT02091375|9961784|FG000|Overall Study|Adverse Event|8
6264478|NCT02091375|9961785|FG001|Overall Study|Adverse Event|1
6264479|NCT02091375|9961784|FG000|Overall Study|Lost to Follow-up|0
6264480|NCT02091375|9961785|FG001|Overall Study|Lost to Follow-up|1
6264481|NCT02091375|9961784|FG000|Overall Study|Withdrawal by Subject|0
6264482|NCT02091375|9961785|FG001|Overall Study|Withdrawal by Subject|1
6264483|NCT02091375|9961784|FG000|Overall Study|Withdrawn by the investigator|1
6264484|NCT02091375|9961785|FG001|Overall Study|Withdrawn by the investigator|0
6264485|NCT02091414|9961791|FG000|Overall Study|Withdrawal by Subject|2
6264486|NCT02091414|9961791|FG000|Overall Study|Death|2
6264487|NCT02091440|9961795|FG000|Overall Study|Death|2
6264488|NCT02091726|9961812|FG000|Overall Study|Lost to Follow-up|6
6264489|NCT02091739|9961819|FG000|MP: 16 Weeks|Adverse Event|1
6264490|NCT02091739|9961820|FG001|MP: 16 Weeks|Adverse Event|1
6264491|NCT02091739|9961821|FG002|MP: 16 Weeks|Adverse Event|1
6264492|NCT02091739|9961822|FG003|MP: 16 Weeks|Adverse Event|0
6264493|NCT02091739|9961823|FG004|MP: 16 Weeks|Adverse Event|0
6264494|NCT02091739|9961819|FG000|MP: 16 Weeks|Withdrawal by Subject|3
6264495|NCT02091739|9961820|FG001|MP: 16 Weeks|Withdrawal by Subject|4
6264496|NCT02091739|9961821|FG002|MP: 16 Weeks|Withdrawal by Subject|0
6264497|NCT02091739|9961822|FG003|MP: 16 Weeks|Withdrawal by Subject|0
6264498|NCT02091739|9961823|FG004|MP: 16 Weeks|Withdrawal by Subject|0
6264499|NCT02091739|9961819|FG000|MP: 16 Weeks|Lost to Follow-up|0
6264500|NCT02091739|9961820|FG001|MP: 16 Weeks|Lost to Follow-up|0
6264501|NCT02091739|9961821|FG002|MP: 16 Weeks|Lost to Follow-up|1
6264502|NCT02091739|9961822|FG003|MP: 16 Weeks|Lost to Follow-up|0
6264503|NCT02091739|9961823|FG004|MP: 16 Weeks|Lost to Follow-up|0
6264504|NCT02091739|9961819|FG000|EP: 48 Weeks|Other|0
6264505|NCT02091739|9961820|FG001|EP: 48 Weeks|Other|0
6264506|NCT02091739|9961821|FG002|EP: 48 Weeks|Other|0
6264507|NCT02091739|9961822|FG003|EP: 48 Weeks|Other|1
6264508|NCT02091739|9961823|FG004|EP: 48 Weeks|Other|0
6264509|NCT02091739|9961819|FG000|EP: 48 Weeks|Death|0
6264510|NCT02091739|9961820|FG001|EP: 48 Weeks|Death|0
6264511|NCT02091739|9961821|FG002|EP: 48 Weeks|Death|0
6264512|NCT02091739|9961822|FG003|EP: 48 Weeks|Death|3
6264513|NCT02091739|9961823|FG004|EP: 48 Weeks|Death|2
6264514|NCT02091739|9961819|FG000|EP: 48 Weeks|Adverse Event|0
6264515|NCT02091739|9961820|FG001|EP: 48 Weeks|Adverse Event|0
6264516|NCT02091739|9961821|FG002|EP: 48 Weeks|Adverse Event|0
6264517|NCT02091739|9961822|FG003|EP: 48 Weeks|Adverse Event|2
6264518|NCT02091739|9961823|FG004|EP: 48 Weeks|Adverse Event|6
6264519|NCT02091739|9961819|FG000|EP: 48 Weeks|Withdrawal by Subject|0
6264520|NCT02091739|9961820|FG001|EP: 48 Weeks|Withdrawal by Subject|0
6264521|NCT02091739|9961821|FG002|EP: 48 Weeks|Withdrawal by Subject|0
6264522|NCT02091739|9961822|FG003|EP: 48 Weeks|Withdrawal by Subject|2
6264523|NCT02091739|9961823|FG004|EP: 48 Weeks|Withdrawal by Subject|6
6264524|NCT02091869|9961852|FG000|Overall Study|Withdrawal by Subject|0
6264525|NCT02091869|9961853|FG001|Overall Study|Withdrawal by Subject|3
6264526|NCT02091921|9961863|FG000|Overall Study|Adverse Event|3
6264527|NCT02091986|9961873|FG000|Overall Study|7 rand in error 1 patient decision|2
6264528|NCT02091986|9961874|FG001|Overall Study|7 rand in error 1 patient decision|3
6264529|NCT02091986|9961875|FG002|Overall Study|7 rand in error 1 patient decision|3
6264530|NCT02091986|9961873|FG000|Overall Study|Lost to Follow-up|1
6264531|NCT02091986|9961874|FG001|Overall Study|Lost to Follow-up|0
6264532|NCT02091986|9961875|FG002|Overall Study|Lost to Follow-up|0
6264533|NCT02091986|9961873|FG000|Overall Study|Withdrawal by Subject|4
6264534|NCT02091986|9961874|FG001|Overall Study|Withdrawal by Subject|8
6264535|NCT02091986|9961875|FG002|Overall Study|Withdrawal by Subject|3
6264536|NCT02091986|9961873|FG000|Overall Study|Adverse Event|0
6264537|NCT02091986|9961874|FG001|Overall Study|Adverse Event|0
6264538|NCT02091986|9961875|FG002|Overall Study|Adverse Event|2
6264539|NCT02092025|9961883|FG000|Overall Study|Case Report Forms Uncollected|44
6264540|NCT02092025|9961883|FG000|Overall Study|Protocol Deviation|24
6264541|NCT02092116|9961889|FG000|Overall Study|Withdrawal by Subject|0
6264542|NCT02092116|9961890|FG001|Overall Study|Withdrawal by Subject|3
6264543|NCT02092116|9961889|FG000|Overall Study|Adverse Event|0
6264544|NCT02092116|9961890|FG001|Overall Study|Adverse Event|1
6264545|NCT02092220|9961914|FG000|Period 1|Unrelated Illness|0
6264546|NCT02092220|9961915|FG001|Period 1|Unrelated Illness|2
6264547|NCT02092220|9961914|FG000|Period 2|Severe Hypoglycaemia|1
6264548|NCT02092220|9961915|FG001|Period 2|Severe Hypoglycaemia|0
6264549|NCT02092220|9961914|FG000|Period 2|Nausea, Anxiety, Inconvenience|0
6264550|NCT02092220|9961915|FG001|Period 2|Nausea, Anxiety, Inconvenience|1
6264551|NCT02092285|9961923|FG000|Induction Phase|Adverse Event|7
6264552|NCT02092285|9961923|FG000|Induction Phase|Physician Decision|4
6264553|NCT02092285|9961923|FG000|Induction Phase|Pregnancy|1
6264554|NCT02092285|9961923|FG000|Induction Phase|Relapse/Recurrence|7
6264555|NCT02092285|9961923|FG000|Induction Phase|Withdrawal by Subject|2
6086936|NCT00665561|9697078|FG000|Overall Study|Withdrawn due to pregnancy|0
6264556|NCT02092285|9961923|FG000|Induction Phase|Lack of Efficacy|14
6264557|NCT02092285|9961923|FG000|Maintenance Phase & Follow-up|Adverse Event|22
6264558|NCT02092285|9961923|FG000|Maintenance Phase & Follow-up|Lost to Follow-up|1
6264559|NCT02092285|9961923|FG000|Maintenance Phase & Follow-up|Non-compliance with study drug|2
6264560|NCT02092285|9961923|FG000|Maintenance Phase & Follow-up|Physician Decision|10
6264561|NCT02092285|9961923|FG000|Maintenance Phase & Follow-up|Pregnancy|1
6264562|NCT02092285|9961923|FG000|Maintenance Phase & Follow-up|Protocol Violation|11
6264563|NCT02092285|9961923|FG000|Maintenance Phase & Follow-up|Relapse/recurrence|29
6264564|NCT02092285|9961923|FG000|Maintenance Phase & Follow-up|Withdrawal by Subject|11
6264565|NCT02092285|9961923|FG000|Maintenance Phase & Follow-up|Lack of Efficacy|23
6264566|NCT02092324|9961942|FG000|Overall Study|Adverse Event|1
6264567|NCT02092324|9961942|FG000|Overall Study|Lack of Efficacy|6
6264568|NCT02092324|9961942|FG000|Overall Study|Proceed to Transplant|3
6264569|NCT02092324|9961942|FG000|Overall Study|Physician Decision|7
6264570|NCT02092324|9961942|FG000|Overall Study|Misdiagnosis|2
6264571|NCT02092350|9961951|FG000|Overall Study|Adverse Event|0
6264572|NCT02092350|9961952|FG001|Overall Study|Adverse Event|3
6264573|NCT02092350|9961951|FG000|Overall Study|Death|2
6264574|NCT02092350|9961952|FG001|Overall Study|Death|5
6264575|NCT02092350|9961951|FG000|Overall Study|Lost to Follow-up|3
6264576|NCT02092350|9961952|FG001|Overall Study|Lost to Follow-up|1
6264577|NCT02092350|9961951|FG000|Overall Study|Protocol Violation|1
6264578|NCT02092350|9961952|FG001|Overall Study|Protocol Violation|0
6264579|NCT02092350|9961951|FG000|Overall Study|Physician Decision|1
6264580|NCT02092350|9961952|FG001|Overall Study|Physician Decision|1
6264581|NCT02092350|9961951|FG000|Overall Study|Screen Failure|1
6264582|NCT02092350|9961952|FG001|Overall Study|Screen Failure|0
6264583|NCT02092350|9961951|FG000|Overall Study|Withdrawal by Subject|2
6264584|NCT02092350|9961952|FG001|Overall Study|Withdrawal by Subject|2
6264585|NCT02092389|9961960|FG000|Overall Study|Adverse Event|1
6264586|NCT02092389|9961960|FG000|Overall Study|Other|5
6264587|NCT02092467|9961981|FG000|Overall Study|Death|49
6264588|NCT02092467|9961982|FG001|Overall Study|Death|66
6264589|NCT02092467|9961983|FG002|Overall Study|Death|38
6264590|NCT02092467|9961981|FG000|Overall Study|Lost to Follow-up|38
6264591|NCT02092467|9961982|FG001|Overall Study|Lost to Follow-up|35
6264592|NCT02092467|9961983|FG002|Overall Study|Lost to Follow-up|40
6264593|NCT02092467|9961981|FG000|Overall Study|Global Deterioration of Health Status|1
6264594|NCT02092467|9961982|FG001|Overall Study|Global Deterioration of Health Status|0
6264595|NCT02092467|9961983|FG002|Overall Study|Global Deterioration of Health Status|0
6264596|NCT02092467|9961981|FG000|Overall Study|Other|32
6264597|NCT02092467|9961982|FG001|Overall Study|Other|30
6264598|NCT02092467|9961983|FG002|Overall Study|Other|24
6264599|NCT02092467|9961981|FG000|Overall Study|Withdrawal by Subject|282
6264600|NCT02092467|9961982|FG001|Overall Study|Withdrawal by Subject|327
6264601|NCT02092467|9961983|FG002|Overall Study|Withdrawal by Subject|289
6264602|NCT02092467|9961981|FG000|Overall Study|Randomized but not treated|2
6264603|NCT02092467|9961982|FG001|Overall Study|Randomized but not treated|1
6264604|NCT02092467|9961983|FG002|Overall Study|Randomized but not treated|7
6191128|NCT01420081|9847774|FG002|Overall Study|Study Terminated by Sponsor|1
6191129|NCT01420081|9847775|FG003|Overall Study|Study Terminated by Sponsor|3
6191130|NCT01420081|9847776|FG004|Overall Study|Study Terminated by Sponsor|11
6191131|NCT01420081|9847777|FG005|Overall Study|Study Terminated by Sponsor|7
6191132|NCT01420081|9847778|FG006|Overall Study|Study Terminated by Sponsor|3
6191133|NCT01420081|9847779|FG007|Overall Study|Study Terminated by Sponsor|2
6191134|NCT01420081|9847780|FG008|Overall Study|Study Terminated by Sponsor|2
6191135|NCT01420081|9847772|FG000|Overall Study|Subject Refused Futher Follow-up|0
6191136|NCT01420081|9847773|FG001|Overall Study|Subject Refused Futher Follow-up|0
6191137|NCT01420081|9847774|FG002|Overall Study|Subject Refused Futher Follow-up|1
6191138|NCT01420081|9847775|FG003|Overall Study|Subject Refused Futher Follow-up|0
6191139|NCT01420081|9847776|FG004|Overall Study|Subject Refused Futher Follow-up|1
6191140|NCT01420081|9847777|FG005|Overall Study|Subject Refused Futher Follow-up|0
6191141|NCT01420081|9847778|FG006|Overall Study|Subject Refused Futher Follow-up|0
6191142|NCT01420081|9847779|FG007|Overall Study|Subject Refused Futher Follow-up|0
6191143|NCT01420081|9847780|FG008|Overall Study|Subject Refused Futher Follow-up|0
6191144|NCT01420081|9847772|FG000|Overall Study|Other Reasons|0
6191145|NCT01420081|9847773|FG001|Overall Study|Other Reasons|0
6191146|NCT01420081|9847774|FG002|Overall Study|Other Reasons|1
6191147|NCT01420081|9847775|FG003|Overall Study|Other Reasons|0
6191148|NCT01420081|9847776|FG004|Overall Study|Other Reasons|0
6191149|NCT01420081|9847777|FG005|Overall Study|Other Reasons|0
6191150|NCT01420081|9847778|FG006|Overall Study|Other Reasons|0
6191151|NCT01420081|9847779|FG007|Overall Study|Other Reasons|0
6191152|NCT01420081|9847780|FG008|Overall Study|Other Reasons|0
6191153|NCT01420536|9847811|FG000|Period 1 (30 Days)|Withdrawal by Subject|3
6191154|NCT01420536|9847812|FG001|Period 1 (30 Days)|Withdrawal by Subject|0
6191155|NCT01420549|9847822|FG000|Overall Study|Adverse Event|1
6191156|NCT01420549|9847823|FG001|Overall Study|Adverse Event|1
6191157|NCT01420549|9847822|FG000|Overall Study|Lost to Follow-up|2
6191158|NCT01420549|9847823|FG001|Overall Study|Lost to Follow-up|2
6191159|NCT01420549|9847822|FG000|Overall Study|Protocol Violation|0
6191160|NCT01420549|9847823|FG001|Overall Study|Protocol Violation|1
6191161|NCT01420549|9847822|FG000|Overall Study|Non-adherence to medication|4
6191162|NCT01420549|9847823|FG001|Overall Study|Non-adherence to medication|1
6191163|NCT01420627|9847829|FG000|EZN-2279 Treatment Period|Adverse Event|1
6191164|NCT01420679|9847856|FG000|Overall Study|Disease Progression|3
6191165|NCT01420679|9847857|FG001|Overall Study|Disease Progression|2
6191166|NCT01420679|9847856|FG000|Overall Study|Adverse Event|4
6191167|NCT01420679|9847857|FG001|Overall Study|Adverse Event|0
6191168|NCT01420679|9847856|FG000|Overall Study|More Than 28 Days Between Doses of Drug|1
6191169|NCT01420679|9847857|FG001|Overall Study|More Than 28 Days Between Doses of Drug|0
6191170|NCT01420679|9847856|FG000|Overall Study|Patient Decision|1
6191171|NCT01420679|9847857|FG001|Overall Study|Patient Decision|0
6264605|NCT02092662|9962013|FG000|Overall Study|Lost to Follow-up|13
6264606|NCT02092662|9962014|FG001|Overall Study|Lost to Follow-up|0
6264607|NCT02092909|9962038|FG000|Overall Study|Adverse Event|0
6264608|NCT02092909|9962039|FG001|Overall Study|Adverse Event|0
6264609|NCT02092909|9962040|FG002|Overall Study|Adverse Event|4
6264610|NCT02092909|9962041|FG003|Overall Study|Adverse Event|2
6264611|NCT02092909|9962038|FG000|Overall Study|Lack of Efficacy|0
6264612|NCT02092909|9962039|FG001|Overall Study|Lack of Efficacy|2
6264613|NCT02092909|9962040|FG002|Overall Study|Lack of Efficacy|1
6264614|NCT02092909|9962041|FG003|Overall Study|Lack of Efficacy|0
6264615|NCT02092909|9962038|FG000|Overall Study|Withdrawal by Subject|0
6264616|NCT02092909|9962039|FG001|Overall Study|Withdrawal by Subject|0
6264617|NCT02092909|9962040|FG002|Overall Study|Withdrawal by Subject|2
6264618|NCT02092909|9962041|FG003|Overall Study|Withdrawal by Subject|1
6264619|NCT02092909|9962038|FG000|Overall Study|Study terminated by Sponsor|0
6264620|NCT02092909|9962039|FG001|Overall Study|Study terminated by Sponsor|0
6086937|NCT00665561|9697079|FG001|Overall Study|Withdrawn due to pregnancy|1
6264621|NCT02092909|9962040|FG002|Overall Study|Study terminated by Sponsor|0
6086938|NCT00665626|9697087|FG000|Overall Study|Lack of Efficacy|8
6086939|NCT00665626|9697088|FG001|Overall Study|Lack of Efficacy|5
6086940|NCT00665626|9697087|FG000|Overall Study|Lost to Follow-up|0
6086941|NCT00665626|9697088|FG001|Overall Study|Lost to Follow-up|2
6086942|NCT00665626|9697087|FG000|Overall Study|Withdrawal by Subject|0
6264622|NCT02092909|9962041|FG003|Overall Study|Study terminated by Sponsor|2
6264623|NCT02092909|9962038|FG000|Overall Study|Miscellaneous|1
6264624|NCT02092909|9962039|FG001|Overall Study|Miscellaneous|1
6264625|NCT02092909|9962040|FG002|Overall Study|Miscellaneous|2
6264626|NCT02092909|9962041|FG003|Overall Study|Miscellaneous|1
6264627|NCT02092961|9962054|FG000|Overall Study|Not reported|1
6264628|NCT02092961|9962055|FG001|Overall Study|Not reported|0
6264629|NCT02092961|9962056|FG002|Overall Study|Not reported|1
6264630|NCT02092961|9962054|FG000|Overall Study|Study stopped|13
6264631|NCT02092961|9962055|FG001|Overall Study|Study stopped|9
6264632|NCT02092961|9962056|FG002|Overall Study|Study stopped|12
6264633|NCT02092961|9962054|FG000|Overall Study|Lack of therapeutic response|2
6264634|NCT02092961|9962055|FG001|Overall Study|Lack of therapeutic response|1
6264635|NCT02092961|9962056|FG002|Overall Study|Lack of therapeutic response|3
6264636|NCT02092961|9962054|FG000|Overall Study|Dev. of study specific discont. criteria|3
6264637|NCT02092961|9962055|FG001|Overall Study|Dev. of study specific discont. criteria|0
6264638|NCT02092961|9962056|FG002|Overall Study|Dev. of study specific discont. criteria|0
6264639|NCT02092961|9962054|FG000|Overall Study|Adverse Event|2
6264640|NCT02092961|9962055|FG001|Overall Study|Adverse Event|4
6264641|NCT02092961|9962056|FG002|Overall Study|Adverse Event|0
6264642|NCT02093026|9962077|FG000|Overall Study|Adverse Event|26
6264643|NCT02093026|9962077|FG000|Overall Study|Death|10
6264644|NCT02093026|9962077|FG000|Overall Study|Other|157
6264645|NCT02093221|9962087|FG000|Overall Study|Adverse Event|1
6264646|NCT02093221|9962088|FG001|Overall Study|Adverse Event|0
6264647|NCT02093221|9962089|FG002|Overall Study|Adverse Event|0
6264648|NCT02093221|9962090|FG003|Overall Study|Adverse Event|0
6264649|NCT02093221|9962091|FG004|Overall Study|Adverse Event|0
6264650|NCT02093221|9962087|FG000|Overall Study|Withdrawal by Subject|1
6264651|NCT02093221|9962088|FG001|Overall Study|Withdrawal by Subject|1
6264652|NCT02093221|9962089|FG002|Overall Study|Withdrawal by Subject|4
6264653|NCT02093221|9962090|FG003|Overall Study|Withdrawal by Subject|1
6264654|NCT02093221|9962091|FG004|Overall Study|Withdrawal by Subject|1
6264655|NCT02093221|9962087|FG000|Overall Study|Lost to Follow-up|2
6264656|NCT02093221|9962088|FG001|Overall Study|Lost to Follow-up|0
6264657|NCT02093221|9962089|FG002|Overall Study|Lost to Follow-up|1
6264658|NCT02093221|9962090|FG003|Overall Study|Lost to Follow-up|1
6264659|NCT02093221|9962091|FG004|Overall Study|Lost to Follow-up|0
6264660|NCT02093221|9962087|FG000|Overall Study|Death|0
6264661|NCT02093221|9962088|FG001|Overall Study|Death|1
6264662|NCT02093221|9962089|FG002|Overall Study|Death|0
6264663|NCT02093221|9962090|FG003|Overall Study|Death|0
6264664|NCT02093221|9962091|FG004|Overall Study|Death|0
6264665|NCT02093221|9962087|FG000|Overall Study|Protocol Violation|0
6264666|NCT02093221|9962088|FG001|Overall Study|Protocol Violation|1
6264667|NCT02093221|9962089|FG002|Overall Study|Protocol Violation|0
6264668|NCT02093221|9962090|FG003|Overall Study|Protocol Violation|0
6264669|NCT02093221|9962091|FG004|Overall Study|Protocol Violation|0
6264670|NCT02093221|9962087|FG000|Overall Study|Study termination|6
6264671|NCT02093221|9962088|FG001|Overall Study|Study termination|5
6264672|NCT02093221|9962089|FG002|Overall Study|Study termination|4
6264673|NCT02093221|9962090|FG003|Overall Study|Study termination|6
6264674|NCT02093221|9962091|FG004|Overall Study|Study termination|7
6264675|NCT02093351|9962119|FG000|Part A|Adverse Event|0
6086943|NCT00665626|9697088|FG001|Overall Study|Withdrawal by Subject|1
6264676|NCT02093351|9962120|FG001|Part A|Adverse Event|1
6264677|NCT02093351|9962121|FG002|Part A|Adverse Event|1
6264678|NCT02093351|9962122|FG003|Part A|Adverse Event|0
6264679|NCT02093351|9962119|FG000|Part A|Condition under investigation worsened|2
6264680|NCT02093351|9962120|FG001|Part A|Condition under investigation worsened|0
6086944|NCT00665626|9697087|FG000|Overall Study|Protocol Violation|0
6086945|NCT00665626|9697088|FG001|Overall Study|Protocol Violation|2
6264681|NCT02093351|9962121|FG002|Part A|Condition under investigation worsened|2
6264682|NCT02093351|9962122|FG003|Part A|Condition under investigation worsened|0
6264683|NCT02093351|9962119|FG000|Part A|Death|0
6264684|NCT02093351|9962120|FG001|Part A|Death|1
6264685|NCT02093351|9962121|FG002|Part A|Death|0
6264686|NCT02093351|9962122|FG003|Part A|Death|0
6264687|NCT02093351|9962119|FG000|Part B|Patient decision|0
6264688|NCT02093351|9962120|FG001|Part B|Patient decision|0
6264689|NCT02093351|9962121|FG002|Part B|Patient decision|0
6264690|NCT02093351|9962122|FG003|Part B|Patient decision|3
6264691|NCT02093351|9962119|FG000|Part B|Disease progression|0
6264692|NCT02093351|9962120|FG001|Part B|Disease progression|0
6264693|NCT02093351|9962121|FG002|Part B|Disease progression|0
6264694|NCT02093351|9962122|FG003|Part B|Disease progression|4
6264695|NCT02093351|9962119|FG000|Part B|Complete response|0
6264696|NCT02093351|9962120|FG001|Part B|Complete response|0
6264697|NCT02093351|9962121|FG002|Part B|Complete response|0
6264698|NCT02093351|9962122|FG003|Part B|Complete response|1
6264699|NCT02093351|9962119|FG000|Part B|Adverse event + disease progression|0
6264700|NCT02093351|9962120|FG001|Part B|Adverse event + disease progression|0
6264701|NCT02093351|9962121|FG002|Part B|Adverse event + disease progression|0
6264702|NCT02093351|9962122|FG003|Part B|Adverse event + disease progression|1
6264703|NCT02093351|9962119|FG000|Part B|Lack of therapeutic response|0
6264704|NCT02093351|9962120|FG001|Part B|Lack of therapeutic response|0
6264705|NCT02093351|9962121|FG002|Part B|Lack of therapeutic response|0
6264706|NCT02093351|9962122|FG003|Part B|Lack of therapeutic response|12
6264707|NCT02093351|9962119|FG000|Part B|Condition under investigation worsened|0
6264708|NCT02093351|9962120|FG001|Part B|Condition under investigation worsened|0
6264709|NCT02093351|9962121|FG002|Part B|Condition under investigation worsened|0
6264710|NCT02093351|9962122|FG003|Part B|Condition under investigation worsened|39
6264711|NCT02093351|9962119|FG000|Part B|Adverse Event|0
6086946|NCT00665626|9697087|FG000|Overall Study|Adverse Event|1
6086947|NCT00665626|9697088|FG001|Overall Study|Adverse Event|9
6264712|NCT02093351|9962120|FG001|Part B|Adverse Event|0
6264713|NCT02093351|9962121|FG002|Part B|Adverse Event|0
6264714|NCT02093351|9962122|FG003|Part B|Adverse Event|2
6264715|NCT02093351|9962119|FG000|Part B|Death|0
6264716|NCT02093351|9962120|FG001|Part B|Death|0
6264717|NCT02093351|9962121|FG002|Part B|Death|0
6264718|NCT02093351|9962122|FG003|Part B|Death|1
6264719|NCT02093390|9962139|FG000|Overall Study|Withdrawal by Subject|0
6086948|NCT00665626|9697087|FG000|Overall Study|Due to exclusion criteria|0
6086949|NCT00665626|9697088|FG001|Overall Study|Due to exclusion criteria|1
6086950|NCT00665626|9697087|FG000|Overall Study|Did not fulfil inclusion criteria|0
6086951|NCT00665626|9697088|FG001|Overall Study|Did not fulfil inclusion criteria|1
6264720|NCT02093390|9962140|FG001|Overall Study|Withdrawal by Subject|1
6264721|NCT02093520|9962149|FG000|Overall Study|Not treated|6
6264722|NCT02093520|9962150|FG001|Overall Study|Not treated|22
6264723|NCT02093663|9962156|FG000|Double Blind Acute Phase (8 Weeks)|Adverse Event|1
6264724|NCT02093663|9962157|FG001|Double Blind Acute Phase (8 Weeks)|Adverse Event|0
6264725|NCT02093663|9962158|FG002|Double Blind Acute Phase (8 Weeks)|Adverse Event|0
6264726|NCT02093663|9962159|FG003|Double Blind Acute Phase (8 Weeks)|Adverse Event|0
6264727|NCT02093663|9962160|FG004|Double Blind Acute Phase (8 Weeks)|Adverse Event|0
6264728|NCT02093663|9962156|FG000|Double Blind Acute Phase (8 Weeks)|Lack of Efficacy|5
6264729|NCT02093663|9962157|FG001|Double Blind Acute Phase (8 Weeks)|Lack of Efficacy|0
6264730|NCT02093663|9962158|FG002|Double Blind Acute Phase (8 Weeks)|Lack of Efficacy|0
6264731|NCT02093663|9962159|FG003|Double Blind Acute Phase (8 Weeks)|Lack of Efficacy|0
6264732|NCT02093663|9962160|FG004|Double Blind Acute Phase (8 Weeks)|Lack of Efficacy|0
6264733|NCT02093663|9962156|FG000|Double Blind Acute Phase (8 Weeks)|Subjects who Continued in the Study|2
6264734|NCT02093663|9962157|FG001|Double Blind Acute Phase (8 Weeks)|Subjects who Continued in the Study|4
6264735|NCT02093663|9962158|FG002|Double Blind Acute Phase (8 Weeks)|Subjects who Continued in the Study|0
6264736|NCT02093663|9962159|FG003|Double Blind Acute Phase (8 Weeks)|Subjects who Continued in the Study|0
6264737|NCT02093663|9962160|FG004|Double Blind Acute Phase (8 Weeks)|Subjects who Continued in the Study|0
6264738|NCT02093663|9962156|FG000|Open Label Acute Phase (8 Weeks)|Adverse Event|0
6264739|NCT02093663|9962157|FG001|Open Label Acute Phase (8 Weeks)|Adverse Event|0
6264740|NCT02093663|9962158|FG002|Open Label Acute Phase (8 Weeks)|Adverse Event|1
6264741|NCT02093663|9962159|FG003|Open Label Acute Phase (8 Weeks)|Adverse Event|0
6264742|NCT02093663|9962160|FG004|Open Label Acute Phase (8 Weeks)|Adverse Event|0
6264743|NCT02093663|9962156|FG000|Open Label Acute Phase (8 Weeks)|Lack of Efficacy|0
6264744|NCT02093663|9962157|FG001|Open Label Acute Phase (8 Weeks)|Lack of Efficacy|0
6264745|NCT02093663|9962158|FG002|Open Label Acute Phase (8 Weeks)|Lack of Efficacy|5
6264746|NCT02093663|9962159|FG003|Open Label Acute Phase (8 Weeks)|Lack of Efficacy|0
6264747|NCT02093663|9962160|FG004|Open Label Acute Phase (8 Weeks)|Lack of Efficacy|0
6264748|NCT02093663|9962156|FG000|Double Blind Maintenance Phase(26 Weeks)|Adverse Event|0
6264749|NCT02093663|9962157|FG001|Double Blind Maintenance Phase(26 Weeks)|Adverse Event|0
6264750|NCT02093663|9962158|FG002|Double Blind Maintenance Phase(26 Weeks)|Adverse Event|0
6264751|NCT02093663|9962159|FG003|Double Blind Maintenance Phase(26 Weeks)|Adverse Event|3
6086952|NCT00665626|9697087|FG000|Overall Study|Unably to comply with dosing regimen|0
6086953|NCT00665626|9697088|FG001|Overall Study|Unably to comply with dosing regimen|1
6264752|NCT02093663|9962160|FG004|Double Blind Maintenance Phase(26 Weeks)|Adverse Event|2
6264753|NCT02093663|9962156|FG000|Double Blind Maintenance Phase(26 Weeks)|Lack of Efficacy|0
6264754|NCT02093663|9962157|FG001|Double Blind Maintenance Phase(26 Weeks)|Lack of Efficacy|0
6086954|NCT00665626|9697087|FG000|Overall Study|Death|1
6264755|NCT02093663|9962158|FG002|Double Blind Maintenance Phase(26 Weeks)|Lack of Efficacy|0
6264756|NCT02093663|9962159|FG003|Double Blind Maintenance Phase(26 Weeks)|Lack of Efficacy|6
6264757|NCT02093663|9962160|FG004|Double Blind Maintenance Phase(26 Weeks)|Lack of Efficacy|7
6264758|NCT02093663|9962156|FG000|Double Blind Maintenance Phase(26 Weeks)|Other (unspecified)|0
6264759|NCT02093663|9962157|FG001|Double Blind Maintenance Phase(26 Weeks)|Other (unspecified)|0
6264760|NCT02093663|9962158|FG002|Double Blind Maintenance Phase(26 Weeks)|Other (unspecified)|0
6264761|NCT02093663|9962159|FG003|Double Blind Maintenance Phase(26 Weeks)|Other (unspecified)|1
6264762|NCT02093663|9962160|FG004|Double Blind Maintenance Phase(26 Weeks)|Other (unspecified)|1
6264763|NCT02093663|9962156|FG000|Double Blind Maintenance Phase(26 Weeks)|Missing|0
6264764|NCT02093663|9962157|FG001|Double Blind Maintenance Phase(26 Weeks)|Missing|0
6264765|NCT02093663|9962158|FG002|Double Blind Maintenance Phase(26 Weeks)|Missing|0
6264766|NCT02093663|9962159|FG003|Double Blind Maintenance Phase(26 Weeks)|Missing|0
6264767|NCT02093663|9962160|FG004|Double Blind Maintenance Phase(26 Weeks)|Missing|1
6264768|NCT02093897|9962242|FG000|Overall Study|Physician Decision|1
6264769|NCT02093897|9962242|FG000|Overall Study|Planned age group closure - no's reached|17
6264770|NCT02093897|9962242|FG000|Overall Study|Adverse event, non-fatal|1
6264771|NCT02093923|9962258|FG000|Overall Study|Lost to Follow-up|0
6264772|NCT02093923|9962259|FG001|Overall Study|Lost to Follow-up|0
6264773|NCT02093923|9962260|FG002|Overall Study|Lost to Follow-up|0
6264774|NCT02093923|9962261|FG003|Overall Study|Lost to Follow-up|1
6264775|NCT02093923|9962262|FG004|Overall Study|Lost to Follow-up|0
6264776|NCT02093923|9962258|FG000|Overall Study|Screen failure after randomization|0
6264777|NCT02093923|9962259|FG001|Overall Study|Screen failure after randomization|0
6264778|NCT02093923|9962260|FG002|Overall Study|Screen failure after randomization|0
6264779|NCT02093923|9962261|FG003|Overall Study|Screen failure after randomization|1
6264780|NCT02093923|9962262|FG004|Overall Study|Screen failure after randomization|0
6264781|NCT02094300|9962317|FG000|Overall Study|Death|7
6264782|NCT02094300|9962317|FG000|Overall Study|Lost to Follow-up|10
6264783|NCT02094300|9962317|FG000|Overall Study|Still be eligible for follow-up|3
6264784|NCT02094417|9962330|FG000|Overall Study|Adverse Event|0
6264785|NCT02094417|9962331|FG001|Overall Study|Adverse Event|0
6264786|NCT02094417|9962332|FG002|Overall Study|Adverse Event|0
6264787|NCT02094417|9962333|FG003|Overall Study|Adverse Event|1
6264788|NCT02094417|9962330|FG000|Overall Study|Eligibility criteria|0
6264789|NCT02094417|9962331|FG001|Overall Study|Eligibility criteria|1
6264790|NCT02094417|9962332|FG002|Overall Study|Eligibility criteria|0
6086955|NCT00665626|9697088|FG001|Overall Study|Death|0
6086956|NCT00665652|9697094|FG000|Overall Study|Adverse Event|4
6086957|NCT00665652|9697094|FG000|Overall Study|Death|1
6086958|NCT00665652|9697094|FG000|Overall Study|No longer met inclusion criteria.|1
6086959|NCT00665847|9697102|FG000|Overall Study|Adverse Event|8
6086960|NCT00665847|9697102|FG000|Overall Study|Withdrawal by Subject|2
6086961|NCT00665847|9697102|FG000|Overall Study|Subject non-compliant|8
6086962|NCT00665847|9697102|FG000|Overall Study|Subject reached a virologic endpoint|4
6086963|NCT00665847|9697102|FG000|Overall Study|Resistance to TMC125|1
6086964|NCT00665847|9697102|FG000|Overall Study|Subject ineligible to continue the trial|1
6086965|NCT00665847|9697102|FG000|Overall Study|Switch to Commercial Medication|1
6086966|NCT00665925|9697110|FG000|Overall Study|Lack of Efficacy|10
6086967|NCT00665925|9697111|FG001|Overall Study|Lack of Efficacy|8
6264791|NCT02094417|9962333|FG003|Overall Study|Eligibility criteria|0
6264792|NCT02094417|9962330|FG000|Overall Study|No responder|4
6264793|NCT02094417|9962331|FG001|Overall Study|No responder|4
6264794|NCT02094417|9962332|FG002|Overall Study|No responder|4
6264795|NCT02094417|9962333|FG003|Overall Study|No responder|3
6264796|NCT02094417|9962330|FG000|Overall Study|Unable to conduct observations or assess|0
6264797|NCT02094417|9962331|FG001|Overall Study|Unable to conduct observations or assess|1
6264798|NCT02094417|9962332|FG002|Overall Study|Unable to conduct observations or assess|0
6264799|NCT02094417|9962333|FG003|Overall Study|Unable to conduct observations or assess|0
6264800|NCT02094417|9962330|FG000|Overall Study|Withdrawal by Subject|1
6264801|NCT02094417|9962331|FG001|Overall Study|Withdrawal by Subject|2
6264802|NCT02094417|9962332|FG002|Overall Study|Withdrawal by Subject|1
6264803|NCT02094417|9962333|FG003|Overall Study|Withdrawal by Subject|3
6264804|NCT02094573|9962363|FG000|Overall Study|Adverse Event|4
6264805|NCT02094573|9962364|FG001|Overall Study|Adverse Event|14
6264806|NCT02094573|9962363|FG000|Overall Study|Clinical Progressive Disease|9
6264807|NCT02094573|9962364|FG001|Overall Study|Clinical Progressive Disease|13
6264808|NCT02094573|9962363|FG000|Overall Study|Death|11
6264809|NCT02094573|9962364|FG001|Overall Study|Death|3
6264810|NCT02094573|9962363|FG000|Overall Study|Documented Progressive Disease (RECIST 1.1)|63
6264811|NCT02094573|9962364|FG001|Overall Study|Documented Progressive Disease (RECIST 1.1)|50
6264812|NCT02094573|9962363|FG000|Overall Study|Non-compliance with Study Drug|1
6264813|NCT02094573|9962364|FG001|Overall Study|Non-compliance with Study Drug|1
6264814|NCT02094573|9962363|FG000|Overall Study|Subject Received a New Systemic Anticancer Therapy|1
6264815|NCT02094573|9962364|FG001|Overall Study|Subject Received a New Systemic Anticancer Therapy|0
6264816|NCT02094573|9962363|FG000|Overall Study|Physician Decision|4
6264817|NCT02094573|9962364|FG001|Overall Study|Physician Decision|4
6086968|NCT00665925|9697112|FG002|Overall Study|Lack of Efficacy|9
6086969|NCT00665925|9697113|FG003|Overall Study|Lack of Efficacy|8
6086970|NCT00665925|9697110|FG000|Overall Study|Lost to Follow-up|1
6264818|NCT02094573|9962363|FG000|Overall Study|Site Terminated by Sponsor|10
6264819|NCT02094573|9962364|FG001|Overall Study|Site Terminated by Sponsor|17
6264820|NCT02094573|9962363|FG000|Overall Study|Withdrawal by Subject|6
6264821|NCT02094573|9962364|FG001|Overall Study|Withdrawal by Subject|8
6264822|NCT02094573|9962363|FG000|Overall Study|Randomized but not Treated|3
6264823|NCT02094573|9962364|FG001|Overall Study|Randomized but not Treated|0
6271538|NCT02164539|9973377|FG005|Treatment Phase B (1 Week)|Physician Decision|0
6271539|NCT02164539|9973378|FG006|Treatment Phase B (1 Week)|Physician Decision|1
6271540|NCT02164539|9973372|FG000|Treatment Phase C (1 Week)|Withdrawal by Subject|1
6271541|NCT02164539|9973373|FG001|Treatment Phase C (1 Week)|Withdrawal by Subject|0
6271542|NCT02164539|9973374|FG002|Treatment Phase C (1 Week)|Withdrawal by Subject|0
6271543|NCT02164539|9973375|FG003|Treatment Phase C (1 Week)|Withdrawal by Subject|0
6271544|NCT02164539|9973376|FG004|Treatment Phase C (1 Week)|Withdrawal by Subject|0
6271545|NCT02164539|9973377|FG005|Treatment Phase C (1 Week)|Withdrawal by Subject|0
6271546|NCT02164539|9973378|FG006|Treatment Phase C (1 Week)|Withdrawal by Subject|0
6271547|NCT02164539|9973372|FG000|Treatment Phase C (1 Week)|Adverse Event|0
6271548|NCT02164539|9973373|FG001|Treatment Phase C (1 Week)|Adverse Event|0
6271549|NCT02164539|9973374|FG002|Treatment Phase C (1 Week)|Adverse Event|0
6271550|NCT02164539|9973375|FG003|Treatment Phase C (1 Week)|Adverse Event|0
6271551|NCT02164539|9973376|FG004|Treatment Phase C (1 Week)|Adverse Event|0
6271552|NCT02164539|9973377|FG005|Treatment Phase C (1 Week)|Adverse Event|0
6271553|NCT02164539|9973378|FG006|Treatment Phase C (1 Week)|Adverse Event|1
6271554|NCT02164539|9973372|FG000|Treatment Phase C (1 Week)|Physician Decision|0
6271555|NCT02164539|9973373|FG001|Treatment Phase C (1 Week)|Physician Decision|0
6271556|NCT02164539|9973374|FG002|Treatment Phase C (1 Week)|Physician Decision|0
6271557|NCT02164539|9973375|FG003|Treatment Phase C (1 Week)|Physician Decision|0
6271558|NCT02164539|9973376|FG004|Treatment Phase C (1 Week)|Physician Decision|0
6271559|NCT02164539|9973377|FG005|Treatment Phase C (1 Week)|Physician Decision|0
6271560|NCT02164539|9973378|FG006|Treatment Phase C (1 Week)|Physician Decision|1
6271561|NCT02164864|9973401|FG000|Overall Study|Trial disease worsening|7
6271562|NCT02164864|9973402|FG001|Overall Study|Trial disease worsening|5
6271563|NCT02164864|9973403|FG002|Overall Study|Trial disease worsening|1
6271564|NCT02164864|9973401|FG000|Overall Study|Other pre-existing disease worsening|6
6271565|NCT02164864|9973402|FG001|Overall Study|Other pre-existing disease worsening|4
6271566|NCT02164864|9973403|FG002|Overall Study|Other pre-existing disease worsening|9
6271567|NCT02164864|9973401|FG000|Overall Study|Other Adverse Event (AE)|52
6271568|NCT02164864|9973402|FG001|Overall Study|Other Adverse Event (AE)|32
6271569|NCT02164864|9973403|FG002|Overall Study|Other Adverse Event (AE)|49
6271570|NCT02164864|9973401|FG000|Overall Study|Protocol Violation|2
6271571|NCT02164864|9973402|FG001|Overall Study|Protocol Violation|4
6271572|NCT02164864|9973403|FG002|Overall Study|Protocol Violation|1
6271573|NCT02164864|9973401|FG000|Overall Study|Lost to Follow-up|4
6271574|NCT02164864|9973402|FG001|Overall Study|Lost to Follow-up|3
6271575|NCT02164864|9973403|FG002|Overall Study|Lost to Follow-up|2
6271576|NCT02164864|9973401|FG000|Overall Study|Consent withdrawn, not due to AE|21
6271577|NCT02164864|9973402|FG001|Overall Study|Consent withdrawn, not due to AE|8
6271578|NCT02164864|9973403|FG002|Overall Study|Consent withdrawn, not due to AE|56
6271579|NCT02164864|9973401|FG000|Overall Study|Other than stated|3
6271580|NCT02164864|9973402|FG001|Overall Study|Other than stated|4
6271581|NCT02164864|9973403|FG002|Overall Study|Other than stated|14
6271582|NCT02164916|9973416|FG000|Overall Study|Adverse Event|3
6271583|NCT02164916|9973417|FG001|Overall Study|Adverse Event|8
6271584|NCT02164916|9973416|FG000|Overall Study|Death|1
6271585|NCT02164916|9973417|FG001|Overall Study|Death|1
6271586|NCT02164916|9973416|FG000|Overall Study|Refusal unrelated to adverse event|3
6271587|NCT02164916|9973417|FG001|Overall Study|Refusal unrelated to adverse event|7
6271588|NCT02164916|9973416|FG000|Overall Study|Progression|37
6271589|NCT02164916|9973417|FG001|Overall Study|Progression|26
6271590|NCT02164916|9973416|FG000|Overall Study|Not protocol specified|5
6271591|NCT02164916|9973417|FG001|Overall Study|Not protocol specified|1
6271592|NCT02164916|9973416|FG000|Overall Study|Reason under review|1
6271593|NCT02164916|9973417|FG001|Overall Study|Reason under review|6
6271594|NCT02164916|9973416|FG000|Overall Study|Not eligible|2
6271595|NCT02164916|9973417|FG001|Overall Study|Not eligible|5
6271596|NCT02164929|9973432|FG000|Overall Study|Converted to open procedure|1
6271597|NCT02164929|9973433|FG001|Overall Study|Converted to open procedure|0
6271598|NCT02164929|9973434|FG002|Overall Study|Converted to open procedure|0
6271599|NCT02164929|9973435|FG003|Overall Study|Converted to open procedure|2
6271600|NCT02164929|9973432|FG000|Overall Study|Failed regional block|0
6271601|NCT02164929|9973433|FG001|Overall Study|Failed regional block|0
6271602|NCT02164929|9973434|FG002|Overall Study|Failed regional block|1
6271603|NCT02164929|9973435|FG003|Overall Study|Failed regional block|0
6271604|NCT02164981|9973448|FG000|Started|Withdrawal by Subject|2
6271605|NCT02164981|9973449|FG001|Started|Withdrawal by Subject|1
6271606|NCT02164981|9973450|FG002|Started|Withdrawal by Subject|0
6271607|NCT02164981|9973448|FG000|Started|Protocol Violation|2
6271608|NCT02164981|9973449|FG001|Started|Protocol Violation|0
6271609|NCT02164981|9973450|FG002|Started|Protocol Violation|0
6271610|NCT02164981|9973448|FG000|Started|Adverse Event|1
6271611|NCT02164981|9973449|FG001|Started|Adverse Event|2
6271612|NCT02164981|9973450|FG002|Started|Adverse Event|0
6264824|NCT02094612|9962401|FG000|Overall Study|Lost to Follow-up|47
6264825|NCT02094612|9962402|FG001|Overall Study|Lost to Follow-up|47
6264826|NCT02094612|9962401|FG000|Overall Study|Never started ADHD medication|32
6264827|NCT02094612|9962402|FG001|Overall Study|Never started ADHD medication|23
6264828|NCT02094677|9962419|FG000|Overall Study|Screening|3
6264829|NCT02094677|9962420|FG001|Overall Study|Screening|1
6264830|NCT02094885|9962443|FG000|Overall Study|Death|1
6264831|NCT02094885|9962444|FG001|Overall Study|Death|5
6264832|NCT02094885|9962443|FG000|Overall Study|Withdrawn due to age|1
6264833|NCT02094885|9962444|FG001|Overall Study|Withdrawn due to age|0
6264834|NCT02094898|9962450|FG000|Overall Study|Clinical Worsening|2
6264835|NCT02094898|9962450|FG000|Overall Study|Adverse Event|2
6264836|NCT02094898|9962450|FG000|Overall Study|Lack of Efficacy|1
6264837|NCT02094937|9962456|FG000|8 Weeks in Period 1|Adverse Event|9
6264838|NCT02094937|9962457|FG001|8 Weeks in Period 1|Adverse Event|0
6264839|NCT02094937|9962458|FG002|8 Weeks in Period 1|Adverse Event|0
6264840|NCT02094937|9962459|FG003|8 Weeks in Period 1|Adverse Event|0
6264841|NCT02094937|9962456|FG000|8 Weeks in Period 1|Lack of Efficacy|3
6264842|NCT02094937|9962457|FG001|8 Weeks in Period 1|Lack of Efficacy|0
6264843|NCT02094937|9962458|FG002|8 Weeks in Period 1|Lack of Efficacy|0
6264844|NCT02094937|9962459|FG003|8 Weeks in Period 1|Lack of Efficacy|0
6264845|NCT02094937|9962456|FG000|8 Weeks in Period 1|Protocol Violation|2
6264846|NCT02094937|9962457|FG001|8 Weeks in Period 1|Protocol Violation|0
6264847|NCT02094937|9962458|FG002|8 Weeks in Period 1|Protocol Violation|0
6264848|NCT02094937|9962459|FG003|8 Weeks in Period 1|Protocol Violation|0
6264849|NCT02094937|9962456|FG000|8 Weeks in Period 1|Protocol defined stopping criteria|41
6264850|NCT02094937|9962457|FG001|8 Weeks in Period 1|Protocol defined stopping criteria|0
6264851|NCT02094937|9962458|FG002|8 Weeks in Period 1|Protocol defined stopping criteria|0
6264852|NCT02094937|9962459|FG003|8 Weeks in Period 1|Protocol defined stopping criteria|0
6264853|NCT02094937|9962456|FG000|8 Weeks in Period 1|Physician Decision|1
6264854|NCT02094937|9962457|FG001|8 Weeks in Period 1|Physician Decision|0
6264855|NCT02094937|9962458|FG002|8 Weeks in Period 1|Physician Decision|0
6264856|NCT02094937|9962459|FG003|8 Weeks in Period 1|Physician Decision|0
6264857|NCT02094937|9962456|FG000|8 Weeks in Period 1|Withdrawal by Subject|4
6264858|NCT02094937|9962457|FG001|8 Weeks in Period 1|Withdrawal by Subject|0
6264859|NCT02094937|9962458|FG002|8 Weeks in Period 1|Withdrawal by Subject|0
6264860|NCT02094937|9962459|FG003|8 Weeks in Period 1|Withdrawal by Subject|0
6264861|NCT02094937|9962456|FG000|12 Weeks in Period 2|Adverse Event|0
6264862|NCT02094937|9962457|FG001|12 Weeks in Period 2|Adverse Event|2
6264863|NCT02094937|9962458|FG002|12 Weeks in Period 2|Adverse Event|4
6264864|NCT02094937|9962459|FG003|12 Weeks in Period 2|Adverse Event|1
6264865|NCT02094937|9962456|FG000|12 Weeks in Period 2|Lack of Efficacy|0
6264866|NCT02094937|9962457|FG001|12 Weeks in Period 2|Lack of Efficacy|1
6264867|NCT02094937|9962458|FG002|12 Weeks in Period 2|Lack of Efficacy|0
6264868|NCT02094937|9962459|FG003|12 Weeks in Period 2|Lack of Efficacy|0
6264869|NCT02094937|9962456|FG000|12 Weeks in Period 2|Protocol defined stopping criteria|0
6264870|NCT02094937|9962457|FG001|12 Weeks in Period 2|Protocol defined stopping criteria|5
6264871|NCT02094937|9962458|FG002|12 Weeks in Period 2|Protocol defined stopping criteria|6
6264872|NCT02094937|9962459|FG003|12 Weeks in Period 2|Protocol defined stopping criteria|11
6264873|NCT02094937|9962456|FG000|12 Weeks in Period 2|Withdrawal by Subject|0
6264874|NCT02094937|9962457|FG001|12 Weeks in Period 2|Withdrawal by Subject|2
6264875|NCT02094937|9962458|FG002|12 Weeks in Period 2|Withdrawal by Subject|2
6264876|NCT02094937|9962459|FG003|12 Weeks in Period 2|Withdrawal by Subject|0
6264877|NCT02094937|9962456|FG000|12 Weeks in Period 2|Randomized incorrectly|0
6264878|NCT02094937|9962457|FG001|12 Weeks in Period 2|Randomized incorrectly|1
6264879|NCT02094937|9962458|FG002|12 Weeks in Period 2|Randomized incorrectly|0
6264880|NCT02094937|9962459|FG003|12 Weeks in Period 2|Randomized incorrectly|0
6264881|NCT02095106|9962470|FG000|Second Intervention (14 Days)|Withdrawal by Subject|0
6264882|NCT02095106|9962471|FG001|Second Intervention (14 Days)|Withdrawal by Subject|1
6264883|NCT02095145|9962483|FG000|Overall Study|Withdrawal by Subject|1
6264884|NCT02095145|9962484|FG001|Overall Study|Withdrawal by Subject|0
6264885|NCT02095158|9962492|FG000|Overall Study|Adverse Event|14
6264886|NCT02095158|9962492|FG000|Overall Study|Lack of Efficacy|3
6264887|NCT02095158|9962492|FG000|Overall Study|Pregnancy|1
6264888|NCT02095158|9962492|FG000|Overall Study|Lost to Follow-up|20
6264889|NCT02095158|9962492|FG000|Overall Study|Personal Reasons|35
6264890|NCT02095158|9962492|FG000|Overall Study|Protocol Violation|1
6264891|NCT02095158|9962492|FG000|Overall Study|Other Miscellaneous Reasons|1
6264892|NCT02095197|9962498|FG000|Overall Study|Lost to Follow-up|0
6264893|NCT02095197|9962499|FG001|Overall Study|Lost to Follow-up|3
6264894|NCT02095223|9962507|FG000|Overall Study|Withdrawal by Subject|1
6264895|NCT02095223|9962508|FG001|Overall Study|Withdrawal by Subject|0
6264896|NCT02095535|9962528|FG000|Recruitment|Protocol Violation|2
6264897|NCT02095678|9962543|FG000|Overall Study|Withdrawal by Subject|0
6264898|NCT02095678|9962544|FG001|Overall Study|Withdrawal by Subject|1
6264899|NCT02095678|9962543|FG000|Overall Study|Omitted for Severe Image Artifacts or Patient Non-compliance|11
6264900|NCT02095678|9962544|FG001|Overall Study|Omitted for Severe Image Artifacts or Patient Non-compliance|12
6264901|NCT02095678|9962543|FG000|Overall Study|lesion impacted by previous treatment|1
6264902|NCT02095678|9962544|FG001|Overall Study|lesion impacted by previous treatment|1
6264903|NCT02095678|9962543|FG000|Overall Study|No Confirmed Diagnosis|0
6264904|NCT02095678|9962544|FG001|Overall Study|No Confirmed Diagnosis|3
6264905|NCT02095678|9962543|FG000|Overall Study|Malignant lesions not HCC nor Metastatic|1
6264906|NCT02095678|9962544|FG001|Overall Study|Malignant lesions not HCC nor Metastatic|1
6264907|NCT02095678|9962543|FG000|Overall Study|No Visible Lesion or Pathological Finding|4
6264908|NCT02095678|9962544|FG001|Overall Study|No Visible Lesion or Pathological Finding|0
6264909|NCT02095691|9962553|FG000|Overall Study|Physician Decision|1
6264910|NCT02095873|9962571|FG000|First Intervention (8 Weeks)|Withdrawal by Subject|1
6264911|NCT02095873|9962572|FG001|First Intervention (8 Weeks)|Withdrawal by Subject|0
6264912|NCT02095873|9962571|FG000|Second Intervention (8 Weeks)|Withdrawal by Subject|1
6264913|NCT02095873|9962572|FG001|Second Intervention (8 Weeks)|Withdrawal by Subject|0
6264914|NCT02095873|9962571|FG000|Second Intervention (8 Weeks)|Protocol Violation|1
6264915|NCT02095873|9962572|FG001|Second Intervention (8 Weeks)|Protocol Violation|0
6264916|NCT02095951|9962582|FG000|Overall Study|NO POSITIVE BLOOD CULTURE|9
6264917|NCT02095951|9962583|FG001|Overall Study|NO POSITIVE BLOOD CULTURE|6
6264918|NCT02096003|9962595|FG000|Overall Study|Protocol Violation|0
6264919|NCT02096003|9962596|FG001|Overall Study|Protocol Violation|2
6264920|NCT02096003|9962595|FG000|Overall Study|additional surgery|2
6264921|NCT02096003|9962596|FG001|Overall Study|additional surgery|1
6264922|NCT02096263|9962632|FG000|Overall Study|Adverse Event|1
6264923|NCT02096263|9962633|FG001|Overall Study|Adverse Event|0
6264924|NCT02096263|9962634|FG002|Overall Study|Adverse Event|1
6264925|NCT02096263|9962632|FG000|Overall Study|Lost to Follow-up|14
6264926|NCT02096263|9962633|FG001|Overall Study|Lost to Follow-up|18
6264927|NCT02096263|9962634|FG002|Overall Study|Lost to Follow-up|15
6264928|NCT02096263|9962632|FG000|Overall Study|Other|7
6264929|NCT02096263|9962633|FG001|Overall Study|Other|9
6264930|NCT02096263|9962634|FG002|Overall Study|Other|6
6191172|NCT01420679|9847856|FG000|Overall Study|Investigator Decision|1
6191173|NCT01420679|9847857|FG001|Overall Study|Investigator Decision|2
6191174|NCT01420679|9847856|FG000|Overall Study|Sponsor Decision|3
6191175|NCT01420679|9847857|FG001|Overall Study|Sponsor Decision|3
6191176|NCT01420679|9847856|FG000|Overall Study|Other|1
6191177|NCT01420679|9847857|FG001|Overall Study|Other|0
6264931|NCT02096263|9962632|FG000|Overall Study|Sponsor study termination|0
6264932|NCT02096263|9962633|FG001|Overall Study|Sponsor study termination|0
6264933|NCT02096263|9962634|FG002|Overall Study|Sponsor study termination|1
6264934|NCT02096263|9962632|FG000|Overall Study|Protocol Violation|7
6264935|NCT02096263|9962633|FG001|Overall Study|Protocol Violation|2
6264936|NCT02096263|9962634|FG002|Overall Study|Protocol Violation|8
6264937|NCT02096263|9962632|FG000|Overall Study|Withdrawal by Subject|5
6264938|NCT02096263|9962633|FG001|Overall Study|Withdrawal by Subject|7
6264939|NCT02096263|9962634|FG002|Overall Study|Withdrawal by Subject|8
6264940|NCT02096471|9962655|FG000|Overall Study|Adverse Event|1
6264941|NCT02096471|9962655|FG000|Overall Study|Lack of Efficacy|7
6264942|NCT02096471|9962655|FG000|Overall Study|Withdrawal by Subject|3
6264943|NCT02096471|9962655|FG000|Overall Study|Non-Compliant|2
6264944|NCT02096588|9962672|FG000|Overall Study|Lack of Efficacy|2
6264945|NCT02096588|9962673|FG001|Overall Study|Lack of Efficacy|0
6264946|NCT02096588|9962672|FG000|Overall Study|Withdrawal by Subject|0
6264947|NCT02096588|9962673|FG001|Overall Study|Withdrawal by Subject|1
6264948|NCT02096705|9962689|FG000|Treatment|Adverse Event|6
6264949|NCT02096705|9962690|FG001|Treatment|Adverse Event|3
6191178|NCT01421017|9847879|FG000|Overall Study|Withdrawal by Subject|2
6191179|NCT01421017|9847880|FG001|Overall Study|Withdrawal by Subject|0
6191180|NCT01421017|9847881|FG002|Overall Study|Withdrawal by Subject|0
6191181|NCT01421017|9847879|FG000|Overall Study|POD|0
6191182|NCT01421017|9847880|FG001|Overall Study|POD|6
6191183|NCT01421017|9847881|FG002|Overall Study|POD|3
6191184|NCT01421134|9847891|FG000|Overall Study|Adverse Event|3
6191185|NCT01421134|9847892|FG001|Overall Study|Adverse Event|5
6191186|NCT01421134|9847891|FG000|Overall Study|Lack of Efficacy|2
6191187|NCT01421134|9847892|FG001|Overall Study|Lack of Efficacy|4
6191188|NCT01421134|9847891|FG000|Overall Study|Protocol Violation|0
6191189|NCT01421134|9847892|FG001|Overall Study|Protocol Violation|3
6191190|NCT01421134|9847891|FG000|Overall Study|Withdrawal by Subject|1
6191191|NCT01421134|9847892|FG001|Overall Study|Withdrawal by Subject|1
6191192|NCT01421134|9847891|FG000|Overall Study|Administrative|0
6191193|NCT01421134|9847892|FG001|Overall Study|Administrative|1
6191194|NCT01421134|9847891|FG000|Overall Study|Lost to Follow-up|1
6191195|NCT01421134|9847892|FG001|Overall Study|Lost to Follow-up|1
6191196|NCT01421147|9847900|FG000|Treatment Period|Adverse Event|2
6191197|NCT01421147|9847901|FG001|Treatment Period|Adverse Event|3
6191198|NCT01421147|9847900|FG000|Treatment Period|Lost to Follow-up|2
6191199|NCT01421147|9847901|FG001|Treatment Period|Lost to Follow-up|1
6264950|NCT02096705|9962689|FG000|Treatment|Subject request to discontinue treatment|1
6191200|NCT01421147|9847900|FG000|Treatment Period|Physician Decision|2
6191201|NCT01421147|9847901|FG001|Treatment Period|Physician Decision|2
6264951|NCT02096705|9962690|FG001|Treatment|Subject request to discontinue treatment|1
6264952|NCT02096705|9962689|FG000|Treatment|Withdrawal by Subject|1
6191202|NCT01421147|9847900|FG000|Treatment Period|Withdrawal by Subject|10
6191203|NCT01421147|9847901|FG001|Treatment Period|Withdrawal by Subject|5
6191204|NCT01421147|9847900|FG000|Extension Period|Adverse Event|0
6264953|NCT02096705|9962690|FG001|Treatment|Withdrawal by Subject|0
6264954|NCT02096705|9962689|FG000|Treatment|Other|1
6264955|NCT02096705|9962690|FG001|Treatment|Other|1
6264956|NCT02096705|9962689|FG000|Follow-up|Withdrawal by Subject|1
6264957|NCT02096705|9962690|FG001|Follow-up|Withdrawal by Subject|0
6264958|NCT02096705|9962689|FG000|Follow-up|Adverse Event|2
6264959|NCT02096705|9962690|FG001|Follow-up|Adverse Event|2
6264960|NCT02096705|9962689|FG000|Follow-up|Subjects not reporting status|1
6264961|NCT02096705|9962690|FG001|Follow-up|Subjects not reporting status|2
6264962|NCT02096744|9962722|FG000|Treatment Period 1(7 Days)|Accidental early removal of the patch|0
6264963|NCT02096744|9962723|FG001|Treatment Period 1(7 Days)|Accidental early removal of the patch|1
6264964|NCT02096744|9962722|FG000|Treatment Period 1(7 Days)|Non compliance with the site rule|1
6264965|NCT02096744|9962723|FG001|Treatment Period 1(7 Days)|Non compliance with the site rule|0
6264966|NCT02096744|9962722|FG000|Treatment Period 3 (7 Days)|Withdrawal by Subject|0
6264967|NCT02096744|9962723|FG001|Treatment Period 3 (7 Days)|Withdrawal by Subject|1
6264968|NCT02096835|9962734|FG000|Overall Study|Withdrawal by Subject|1
6264969|NCT02096835|9962735|FG001|Overall Study|Withdrawal by Subject|0
6264970|NCT02096835|9962736|FG002|Overall Study|Withdrawal by Subject|0
6264971|NCT02096835|9962734|FG000|Overall Study|converted to open procedures|1
6264972|NCT02096835|9962735|FG001|Overall Study|converted to open procedures|0
6264973|NCT02096835|9962736|FG002|Overall Study|converted to open procedures|0
6264974|NCT02096835|9962734|FG000|Overall Study|Lost to Follow-up|1
6264975|NCT02096835|9962735|FG001|Overall Study|Lost to Follow-up|0
6264976|NCT02096835|9962736|FG002|Overall Study|Lost to Follow-up|1
6264977|NCT02096900|9962765|FG000|Overall Study|Did not receive medication|3
6264978|NCT02096900|9962766|FG001|Overall Study|Did not receive medication|1
6264979|NCT02096900|9962765|FG000|Overall Study|Surgery cancelled- medication received|1
6264980|NCT02096900|9962766|FG001|Overall Study|Surgery cancelled- medication received|1
6264981|NCT02096952|9962772|FG000|Overall Study|Adverse Event|1
6264982|NCT02097030|9962778|FG000|First Intervention (3 Days)|Lost to Follow-up|1
6264983|NCT02097030|9962779|FG001|First Intervention (3 Days)|Lost to Follow-up|0
6264984|NCT02097030|9962778|FG000|First Intervention (3 Days)|Visual Acuity|0
6264985|NCT02097030|9962779|FG001|First Intervention (3 Days)|Visual Acuity|1
6264986|NCT02097056|9962789|FG000|Overall Study|Protocol Violation|2
6264987|NCT02097056|9962789|FG000|Overall Study|Withdrawal by Subject|15
6264988|NCT02097056|9962789|FG000|Overall Study|Lost to Follow-up|2
6264989|NCT02097056|9962789|FG000|Overall Study|Adverse Event|37
6264990|NCT02097056|9962789|FG000|Overall Study|Other|2
6264991|NCT02097108|9962793|FG000|Overall Study|Adverse Event|1
6264992|NCT02097108|9962793|FG000|Overall Study|patient was abroad for 6 months|1
6264993|NCT02097238|9962797|FG000|Overall Study|Death|1
6264994|NCT02097238|9962797|FG000|Overall Study|Physician Decision|1
6264995|NCT02097238|9962797|FG000|Overall Study|Progressive Disease|17
6264996|NCT02097277|9962807|FG000|Overall Study|Subject no longer meets study criteria|0
6086971|NCT00665925|9697111|FG001|Overall Study|Lost to Follow-up|2
6086972|NCT00665925|9697112|FG002|Overall Study|Lost to Follow-up|2
6264997|NCT02097277|9962808|FG001|Overall Study|Subject no longer meets study criteria|1
6264998|NCT02097277|9962809|FG002|Overall Study|Subject no longer meets study criteria|0
6264999|NCT02097277|9962810|FG003|Overall Study|Subject no longer meets study criteria|1
6265000|NCT02097277|9962811|FG004|Overall Study|Subject no longer meets study criteria|0
6265001|NCT02097277|9962807|FG000|Overall Study|Subject request to discontinue treatment|0
6265002|NCT02097277|9962808|FG001|Overall Study|Subject request to discontinue treatment|0
6265003|NCT02097277|9962809|FG002|Overall Study|Subject request to discontinue treatment|0
6265004|NCT02097277|9962810|FG003|Overall Study|Subject request to discontinue treatment|0
6265005|NCT02097277|9962811|FG004|Overall Study|Subject request to discontinue treatment|1
6265006|NCT02097277|9962807|FG000|Overall Study|Lost to Follow-up|0
6265007|NCT02097277|9962808|FG001|Overall Study|Lost to Follow-up|1
6265008|NCT02097277|9962809|FG002|Overall Study|Lost to Follow-up|1
6265009|NCT02097277|9962810|FG003|Overall Study|Lost to Follow-up|0
6265010|NCT02097277|9962811|FG004|Overall Study|Lost to Follow-up|0
6265011|NCT02097277|9962807|FG000|Overall Study|Withdrawal by Subject|2
6265012|NCT02097277|9962808|FG001|Overall Study|Withdrawal by Subject|1
6265013|NCT02097277|9962809|FG002|Overall Study|Withdrawal by Subject|0
6265014|NCT02097277|9962810|FG003|Overall Study|Withdrawal by Subject|1
6265015|NCT02097277|9962811|FG004|Overall Study|Withdrawal by Subject|0
6265016|NCT02097277|9962807|FG000|Overall Study|Adverse Event|0
6265017|NCT02097277|9962808|FG001|Overall Study|Adverse Event|0
6265018|NCT02097277|9962809|FG002|Overall Study|Adverse Event|1
6265019|NCT02097277|9962810|FG003|Overall Study|Adverse Event|2
6265020|NCT02097277|9962811|FG004|Overall Study|Adverse Event|0
6265021|NCT02097290|9962827|FG000|Overall Study|Death|6
6265022|NCT02097290|9962827|FG000|Overall Study|Total Withdrawals|3
6265023|NCT02097290|9962827|FG000|Overall Study|Attempt|8
6265024|NCT02097472|9962843|FG000|Received Vaccination 2|Adverse Event|0
6265025|NCT02097472|9962844|FG001|Received Vaccination 2|Adverse Event|0
6265026|NCT02097472|9962845|FG002|Received Vaccination 2|Adverse Event|0
6265027|NCT02097472|9962846|FG003|Received Vaccination 2|Adverse Event|0
6265028|NCT02097472|9962847|FG004|Received Vaccination 2|Adverse Event|0
6265029|NCT02097472|9962848|FG005|Received Vaccination 2|Adverse Event|0
6265030|NCT02097472|9962849|FG006|Received Vaccination 2|Adverse Event|1
6265031|NCT02097472|9962850|FG007|Received Vaccination 2|Adverse Event|0
6265032|NCT02097719|9962960|FG000|Overall Study|Subject Withdrew Consent|1
6265033|NCT02097719|9962961|FG001|Overall Study|Subject Withdrew Consent|0
6265034|NCT02097719|9962960|FG000|Overall Study|Lost to Follow-up|0
6265035|NCT02097719|9962961|FG001|Overall Study|Lost to Follow-up|1
6265036|NCT02097719|9962960|FG000|Overall Study|Adverse Event|2
6265037|NCT02097719|9962961|FG001|Overall Study|Adverse Event|0
6265038|NCT02097745|9962977|FG000|Overall Study|Adverse Event|25
6265039|NCT02097745|9962977|FG000|Overall Study|Death|16
6265040|NCT02097745|9962977|FG000|Overall Study|Failure to Return|14
6265041|NCT02097745|9962977|FG000|Overall Study|Administrative/Other|27
6265042|NCT02097745|9962977|FG000|Overall Study|Reason Not Specified|96
6265043|NCT02097823|9962986|FG000|Overall Study|Withdrawal by Subject|1
6265044|NCT02097823|9962987|FG001|Overall Study|Withdrawal by Subject|1
6265045|NCT02098109|9963020|FG000|Overall Study|Protocol Violation|3
6265046|NCT02098109|9963021|FG001|Overall Study|Protocol Violation|0
6265047|NCT02098369|9963036|FG000|Overall Study|Withdrawal by Subject|1
6265048|NCT02098369|9963037|FG001|Overall Study|Withdrawal by Subject|5
6265049|NCT02098369|9963038|FG002|Overall Study|Withdrawal by Subject|0
6265050|NCT02098369|9963036|FG000|Overall Study|Lost to Follow-up|5
6265051|NCT02098369|9963037|FG001|Overall Study|Lost to Follow-up|1
6265052|NCT02098369|9963038|FG002|Overall Study|Lost to Follow-up|3
6265053|NCT02098369|9963036|FG000|Overall Study|Death|1
6265054|NCT02098369|9963037|FG001|Overall Study|Death|1
6265055|NCT02098369|9963038|FG002|Overall Study|Death|1
6265056|NCT02098369|9963036|FG000|Overall Study|Other|0
6265057|NCT02098369|9963037|FG001|Overall Study|Other|2
6265058|NCT02098369|9963038|FG002|Overall Study|Other|1
6265059|NCT02098395|9963050|FG000|Overall Study|Protocol Violation|2
6265060|NCT02098395|9963051|FG001|Overall Study|Protocol Violation|2
6265061|NCT02098395|9963052|FG002|Overall Study|Protocol Violation|0
6265062|NCT02098395|9963053|FG003|Overall Study|Protocol Violation|7
6265063|NCT02098395|9963050|FG000|Overall Study|Withdrawal by Subject|10
6265064|NCT02098395|9963051|FG001|Overall Study|Withdrawal by Subject|10
6265065|NCT02098395|9963052|FG002|Overall Study|Withdrawal by Subject|5
6265066|NCT02098395|9963053|FG003|Overall Study|Withdrawal by Subject|13
6265067|NCT02098395|9963050|FG000|Overall Study|Adverse Event|12
6265068|NCT02098395|9963051|FG001|Overall Study|Adverse Event|19
6265069|NCT02098395|9963052|FG002|Overall Study|Adverse Event|34
6265070|NCT02098395|9963053|FG003|Overall Study|Adverse Event|2
6265071|NCT02098395|9963050|FG000|Overall Study|Lost to Follow-up|2
6265072|NCT02098395|9963051|FG001|Overall Study|Lost to Follow-up|1
6265073|NCT02098395|9963052|FG002|Overall Study|Lost to Follow-up|0
6265074|NCT02098395|9963053|FG003|Overall Study|Lost to Follow-up|3
6265075|NCT02098395|9963050|FG000|Overall Study|Unclassified|0
6265076|NCT02098395|9963051|FG001|Overall Study|Unclassified|0
6265077|NCT02098395|9963052|FG002|Overall Study|Unclassified|3
6265078|NCT02098395|9963053|FG003|Overall Study|Unclassified|2
6265079|NCT02098733|9963063|FG000|Overall Study|Data Not Available|5
6265080|NCT02098733|9963063|FG000|Overall Study|Lost to Follow-up|5
6265081|NCT02098746|9963067|FG000|Overall Study|Changes of Investigator|2
6265082|NCT02098746|9963067|FG000|Overall Study|Other Miscellaneous Reasons|1
6265083|NCT02098746|9963067|FG000|Overall Study|Enrolled 15 Days After the First Dose|1
6265084|NCT02098746|9963067|FG000|Overall Study|Data Not Available After Treatment|1
6265085|NCT02099110|9963098|FG000|Overall Study|Protocol Violation|2
6265086|NCT02099110|9963099|FG001|Overall Study|Protocol Violation|1
6265087|NCT02099110|9963100|FG002|Overall Study|Protocol Violation|0
6265088|NCT02099110|9963101|FG003|Overall Study|Protocol Violation|3
6265089|NCT02099110|9963102|FG004|Overall Study|Protocol Violation|1
6265090|NCT02099110|9963098|FG000|Overall Study|Participant moved|1
6265091|NCT02099110|9963099|FG001|Overall Study|Participant moved|1
6265092|NCT02099110|9963100|FG002|Overall Study|Participant moved|1
6265093|NCT02099110|9963101|FG003|Overall Study|Participant moved|0
6265094|NCT02099110|9963102|FG004|Overall Study|Participant moved|2
6265095|NCT02099110|9963098|FG000|Overall Study|Withdrawal by Subject|7
6265096|NCT02099110|9963099|FG001|Overall Study|Withdrawal by Subject|11
6265097|NCT02099110|9963100|FG002|Overall Study|Withdrawal by Subject|13
6265098|NCT02099110|9963101|FG003|Overall Study|Withdrawal by Subject|9
6265099|NCT02099110|9963102|FG004|Overall Study|Withdrawal by Subject|13
6265100|NCT02099110|9963098|FG000|Overall Study|Adverse Event|3
6265101|NCT02099110|9963099|FG001|Overall Study|Adverse Event|5
6265102|NCT02099110|9963100|FG002|Overall Study|Adverse Event|2
6265103|NCT02099110|9963101|FG003|Overall Study|Adverse Event|3
6265104|NCT02099110|9963102|FG004|Overall Study|Adverse Event|2
6265105|NCT02099110|9963098|FG000|Overall Study|Lost to Follow-up|6
6265106|NCT02099110|9963099|FG001|Overall Study|Lost to Follow-up|12
6265107|NCT02099110|9963100|FG002|Overall Study|Lost to Follow-up|11
6265108|NCT02099110|9963101|FG003|Overall Study|Lost to Follow-up|5
6265109|NCT02099110|9963102|FG004|Overall Study|Lost to Follow-up|6
6265110|NCT02099110|9963098|FG000|Overall Study|Death|0
6265111|NCT02099110|9963099|FG001|Overall Study|Death|1
6265112|NCT02099110|9963100|FG002|Overall Study|Death|0
6265113|NCT02099110|9963101|FG003|Overall Study|Death|0
6265114|NCT02099110|9963102|FG004|Overall Study|Death|0
6265115|NCT02099110|9963098|FG000|Overall Study|Screen failure|0
6265116|NCT02099110|9963099|FG001|Overall Study|Screen failure|0
6265117|NCT02099110|9963100|FG002|Overall Study|Screen failure|0
6265118|NCT02099110|9963101|FG003|Overall Study|Screen failure|0
6265119|NCT02099110|9963102|FG004|Overall Study|Screen failure|1
6265120|NCT02099110|9963098|FG000|Overall Study|Non-compliance with study drug|2
6265121|NCT02099110|9963099|FG001|Overall Study|Non-compliance with study drug|0
6265122|NCT02099110|9963100|FG002|Overall Study|Non-compliance with study drug|0
6265123|NCT02099110|9963101|FG003|Overall Study|Non-compliance with study drug|0
6265124|NCT02099110|9963102|FG004|Overall Study|Non-compliance with study drug|1
6265125|NCT02099110|9963098|FG000|Overall Study|Physician Decision|3
6265126|NCT02099110|9963099|FG001|Overall Study|Physician Decision|0
6265127|NCT02099110|9963100|FG002|Overall Study|Physician Decision|1
6265128|NCT02099110|9963101|FG003|Overall Study|Physician Decision|2
6265129|NCT02099110|9963102|FG004|Overall Study|Physician Decision|1
6265130|NCT02099682|9963134|FG000|Overall Study|Data Not Available|51
6265131|NCT02099682|9963134|FG000|Overall Study|Lost to Follow-up|31
6265132|NCT02099682|9963134|FG000|Overall Study|Other|29
6265133|NCT02099708|9963138|FG000|Overall Study|Data Not Available|30
6265134|NCT02099708|9963138|FG000|Overall Study|Lost to Follow-up|141
6265135|NCT02099708|9963138|FG000|Overall Study|Other|29
6265136|NCT02099838|9963188|FG000|Overall Study|Death|1
6265137|NCT02099838|9963189|FG001|Overall Study|Death|0
6265138|NCT02099838|9963188|FG000|Overall Study|Lost to Follow-up|3
6265139|NCT02099838|9963189|FG001|Overall Study|Lost to Follow-up|1
6265140|NCT02099838|9963188|FG000|Overall Study|Withdrawal by Subject|0
6265141|NCT02099838|9963189|FG001|Overall Study|Withdrawal by Subject|1
6086973|NCT00665925|9697113|FG003|Overall Study|Lost to Follow-up|2
6191205|NCT01421147|9847901|FG001|Extension Period|Adverse Event|2
6265142|NCT02100124|9963215|FG000|Overall Study|Lost to Follow-up|5
6265143|NCT02100124|9963216|FG001|Overall Study|Lost to Follow-up|11
6265144|NCT02100124|9963217|FG002|Overall Study|Lost to Follow-up|3
6265145|NCT02100124|9963215|FG000|Overall Study|Withdrawal by Subject|1
6265146|NCT02100124|9963216|FG001|Overall Study|Withdrawal by Subject|0
6265147|NCT02100124|9963217|FG002|Overall Study|Withdrawal by Subject|0
6265148|NCT02100228|9963231|FG000|Overall Study|Other|19
6265149|NCT02100228|9963232|FG001|Overall Study|Other|19
6265150|NCT02100228|9963231|FG000|Overall Study|Administrative reason|0
6265151|NCT02100228|9963232|FG001|Overall Study|Administrative reason|1
6265152|NCT02100228|9963231|FG000|Overall Study|Inclusion/Exclusion criteria not met|12
6265153|NCT02100228|9963232|FG001|Overall Study|Inclusion/Exclusion criteria not met|16
6265154|NCT02100228|9963231|FG000|Overall Study|Non-compliance|0
6265155|NCT02100228|9963232|FG001|Overall Study|Non-compliance|3
6265156|NCT02100228|9963231|FG000|Overall Study|Lost to Follow-up|0
6265157|NCT02100228|9963232|FG001|Overall Study|Lost to Follow-up|1
6265158|NCT02100228|9963231|FG000|Overall Study|Withdrawal by Subject|27
6265159|NCT02100228|9963232|FG001|Overall Study|Withdrawal by Subject|37
6265160|NCT02100228|9963231|FG000|Overall Study|Adverse Event|16
6265161|NCT02100228|9963232|FG001|Overall Study|Adverse Event|12
6265162|NCT02100228|9963231|FG000|Overall Study|Death|1
6265163|NCT02100228|9963232|FG001|Overall Study|Death|1
6265164|NCT02100319|9963249|FG000|Overall Study|Case Report Forms Uncollected|11
6265165|NCT02100319|9963249|FG000|Overall Study|Protocol Deviation|5
6265166|NCT02100475|9963272|FG000|Overall Study|Unclassified|1
6265167|NCT02100475|9963273|FG001|Overall Study|Unclassified|2
6265168|NCT02100475|9963272|FG000|Overall Study|Withdrawal criteria|1
6265169|NCT02100475|9963273|FG001|Overall Study|Withdrawal criteria|0
6265170|NCT02100514|9963281|FG000|Treatment Period|Adverse Event|0
6265171|NCT02100514|9963282|FG001|Treatment Period|Adverse Event|5
6265172|NCT02100514|9963283|FG002|Treatment Period|Adverse Event|0
6265173|NCT02100514|9963284|FG003|Treatment Period|Adverse Event|0
6265174|NCT02100514|9963285|FG004|Treatment Period|Adverse Event|0
6265175|NCT02100514|9963281|FG000|Treatment Period|Death|2
6265176|NCT02100514|9963282|FG001|Treatment Period|Death|2
6265177|NCT02100514|9963283|FG002|Treatment Period|Death|0
6265178|NCT02100514|9963284|FG003|Treatment Period|Death|0
6265179|NCT02100514|9963285|FG004|Treatment Period|Death|0
6265180|NCT02100514|9963281|FG000|Treatment Period|Lost to Follow-up|5
6191206|NCT01421147|9847900|FG000|Extension Period|Death|0
6191207|NCT01421147|9847901|FG001|Extension Period|Death|1
6191208|NCT01421147|9847900|FG000|Extension Period|Lost to Follow-up|2
6191209|NCT01421147|9847901|FG001|Extension Period|Lost to Follow-up|5
6191210|NCT01421147|9847900|FG000|Extension Period|Physician Decision|1
6191211|NCT01421147|9847901|FG001|Extension Period|Physician Decision|0
6191212|NCT01421147|9847900|FG000|Extension Period|Withdrawal by Subject|5
6191213|NCT01421147|9847901|FG001|Extension Period|Withdrawal by Subject|3
6191214|NCT01421225|9847936|FG000|Overall Study|Withdrawal by Subject|0
6191215|NCT01421225|9847937|FG001|Overall Study|Withdrawal by Subject|1
6191216|NCT01421277|9847946|FG000|Overall Study|Lack of qualifying event|0
6191217|NCT01421277|9847947|FG001|Overall Study|Lack of qualifying event|61
6191218|NCT01421277|9847946|FG000|Overall Study|Incomplete baseline data|0
6265181|NCT02100514|9963282|FG001|Treatment Period|Lost to Follow-up|17
6265182|NCT02100514|9963283|FG002|Treatment Period|Lost to Follow-up|0
6265183|NCT02100514|9963284|FG003|Treatment Period|Lost to Follow-up|0
6265184|NCT02100514|9963285|FG004|Treatment Period|Lost to Follow-up|0
6265185|NCT02100514|9963281|FG000|Treatment Period|Did Not Meet Entrance Criteria|0
6265186|NCT02100514|9963282|FG001|Treatment Period|Did Not Meet Entrance Criteria|1
6265187|NCT02100514|9963283|FG002|Treatment Period|Did Not Meet Entrance Criteria|0
6265188|NCT02100514|9963284|FG003|Treatment Period|Did Not Meet Entrance Criteria|0
6265189|NCT02100514|9963285|FG004|Treatment Period|Did Not Meet Entrance Criteria|0
6265190|NCT02100514|9963281|FG000|Treatment Period|Protocol Violation|1
6265191|NCT02100514|9963282|FG001|Treatment Period|Protocol Violation|1
6265192|NCT02100514|9963283|FG002|Treatment Period|Protocol Violation|0
6265193|NCT02100514|9963284|FG003|Treatment Period|Protocol Violation|0
6265194|NCT02100514|9963285|FG004|Treatment Period|Protocol Violation|0
6265195|NCT02100514|9963281|FG000|Treatment Period|Withdrawal by Subject|12
6265196|NCT02100514|9963282|FG001|Treatment Period|Withdrawal by Subject|37
6265197|NCT02100514|9963283|FG002|Treatment Period|Withdrawal by Subject|0
6265198|NCT02100514|9963284|FG003|Treatment Period|Withdrawal by Subject|0
6265199|NCT02100514|9963285|FG004|Treatment Period|Withdrawal by Subject|0
6265200|NCT02100514|9963281|FG000|Treatment Period|Other|9
6265201|NCT02100514|9963282|FG001|Treatment Period|Other|11
6265202|NCT02100514|9963283|FG002|Treatment Period|Other|0
6265203|NCT02100514|9963284|FG003|Treatment Period|Other|0
6265204|NCT02100514|9963285|FG004|Treatment Period|Other|0
6265205|NCT02100514|9963281|FG000|Extension Period|Withdrew consent|0
6265206|NCT02100514|9963282|FG001|Extension Period|Withdrew consent|0
6265207|NCT02100514|9963283|FG002|Extension Period|Withdrew consent|2
6265208|NCT02100514|9963284|FG003|Extension Period|Withdrew consent|0
6265209|NCT02100514|9963285|FG004|Extension Period|Withdrew consent|0
6265210|NCT02100631|9963311|FG000|Overall Study|Withdrawal by Subject|1
6265211|NCT02100631|9963312|FG001|Overall Study|Withdrawal by Subject|0
6265212|NCT02100631|9963313|FG002|Overall Study|Withdrawal by Subject|0
6265213|NCT02100631|9963311|FG000|Overall Study|Lost to Follow-up|3
6265214|NCT02100631|9963312|FG001|Overall Study|Lost to Follow-up|4
6265215|NCT02100631|9963313|FG002|Overall Study|Lost to Follow-up|0
6265216|NCT02100631|9963311|FG000|Overall Study|3 subjects randomized to treatment unable to receive vaccine as product not available,|3
6265217|NCT02100631|9963312|FG001|Overall Study|3 subjects randomized to treatment unable to receive vaccine as product not available,|0
6265218|NCT02100631|9963313|FG002|Overall Study|3 subjects randomized to treatment unable to receive vaccine as product not available,|0
6265219|NCT02100644|9963321|FG000|LTG Escalation Phase|Adverse Event|9
6265220|NCT02100644|9963322|FG001|LTG Escalation Phase|Adverse Event|0
6265221|NCT02100644|9963323|FG002|LTG Escalation Phase|Adverse Event|0
6265222|NCT02100644|9963321|FG000|LTG Escalation Phase|Protocol-defined Stopping Criteria|1
6265223|NCT02100644|9963322|FG001|LTG Escalation Phase|Protocol-defined Stopping Criteria|0
6265224|NCT02100644|9963323|FG002|LTG Escalation Phase|Protocol-defined Stopping Criteria|0
6265225|NCT02100644|9963321|FG000|LTG Escalation Phase|Withdrawal by Subject|3
6265226|NCT02100644|9963322|FG001|LTG Escalation Phase|Withdrawal by Subject|0
6265227|NCT02100644|9963323|FG002|LTG Escalation Phase|Withdrawal by Subject|0
6265228|NCT02100657|9963330|FG000|Cohort 1: Dose Level 1|Progressive disease|6
6265229|NCT02100657|9963331|FG001|Cohort 1: Dose Level 1|Progressive disease|0
6265230|NCT02100657|9963332|FG002|Cohort 1: Dose Level 1|Progressive disease|0
6265231|NCT02100657|9963330|FG000|Cohort 1: Dose Level 1|Treatment-related adverse event|1
6265232|NCT02100657|9963331|FG001|Cohort 1: Dose Level 1|Treatment-related adverse event|0
6265233|NCT02100657|9963332|FG002|Cohort 1: Dose Level 1|Treatment-related adverse event|0
6265234|NCT02100657|9963330|FG000|Cohort 1: Dose Level 1|Withdrawal by Subject|1
6265235|NCT02100657|9963331|FG001|Cohort 1: Dose Level 1|Withdrawal by Subject|0
6265236|NCT02100657|9963332|FG002|Cohort 1: Dose Level 1|Withdrawal by Subject|0
6265237|NCT02100657|9963330|FG000|Cohort 2: Dose Level 2|Progressive disease|0
6265238|NCT02100657|9963331|FG001|Cohort 2: Dose Level 2|Progressive disease|2
6265239|NCT02100657|9963332|FG002|Cohort 2: Dose Level 2|Progressive disease|0
6265240|NCT02100657|9963330|FG000|Cohort 2: Dose Level 2|Physician Decision|0
6265241|NCT02100657|9963331|FG001|Cohort 2: Dose Level 2|Physician Decision|1
6265242|NCT02100657|9963332|FG002|Cohort 2: Dose Level 2|Physician Decision|0
6265243|NCT02100657|9963330|FG000|Cohort 2: Dose Level 2|Treatment-related adverse event|0
6265244|NCT02100657|9963331|FG001|Cohort 2: Dose Level 2|Treatment-related adverse event|1
6265245|NCT02100657|9963332|FG002|Cohort 2: Dose Level 2|Treatment-related adverse event|0
6265246|NCT02100657|9963330|FG000|Cohort 3: Dose Level 3|Progressive disease|0
6265247|NCT02100657|9963331|FG001|Cohort 3: Dose Level 3|Progressive disease|0
6265248|NCT02100657|9963332|FG002|Cohort 3: Dose Level 3|Progressive disease|15
6265249|NCT02100657|9963330|FG000|Cohort 3: Dose Level 3|Death|0
6265250|NCT02100657|9963331|FG001|Cohort 3: Dose Level 3|Death|0
6265251|NCT02100657|9963332|FG002|Cohort 3: Dose Level 3|Death|1
6265252|NCT02100657|9963330|FG000|Cohort 3: Dose Level 3|Non-treatment related adverse event|0
6265253|NCT02100657|9963331|FG001|Cohort 3: Dose Level 3|Non-treatment related adverse event|0
6265254|NCT02100657|9963332|FG002|Cohort 3: Dose Level 3|Non-treatment related adverse event|1
6265255|NCT02100657|9963330|FG000|Cohort 3: Dose Level 3|Physician Decision|0
6265256|NCT02100657|9963331|FG001|Cohort 3: Dose Level 3|Physician Decision|0
6265257|NCT02100657|9963332|FG002|Cohort 3: Dose Level 3|Physician Decision|1
6265258|NCT02100657|9963330|FG000|Cohort 3: Dose Level 3|Never were treated|0
6265259|NCT02100657|9963331|FG001|Cohort 3: Dose Level 3|Never were treated|0
6265260|NCT02100657|9963332|FG002|Cohort 3: Dose Level 3|Never were treated|3
6265261|NCT02100657|9963330|FG000|Cohort 3: Dose Level 3|Treatment-related adverse event|0
6265262|NCT02100657|9963331|FG001|Cohort 3: Dose Level 3|Treatment-related adverse event|0
6265263|NCT02100657|9963332|FG002|Cohort 3: Dose Level 3|Treatment-related adverse event|3
6265264|NCT02100657|9963330|FG000|Cohort 3: Dose Level 3|Withdrawal by Subject|0
6271613|NCT02164981|9973448|FG000|Phase 1 (Day 0 - Day 14)|Adverse Event|0
6265265|NCT02100657|9963331|FG001|Cohort 3: Dose Level 3|Withdrawal by Subject|0
6265266|NCT02100657|9963332|FG002|Cohort 3: Dose Level 3|Withdrawal by Subject|3
6265267|NCT02100670|9963345|FG000|Overall Study|Adverse Event|10
6265268|NCT02100670|9963346|FG001|Overall Study|Adverse Event|3
6265269|NCT02100670|9963347|FG002|Overall Study|Adverse Event|3
6265270|NCT02100670|9963348|FG003|Overall Study|Adverse Event|0
6265271|NCT02100670|9963345|FG000|Overall Study|Lost to Follow-up|1
6265272|NCT02100670|9963346|FG001|Overall Study|Lost to Follow-up|0
6265273|NCT02100670|9963347|FG002|Overall Study|Lost to Follow-up|0
6265274|NCT02100670|9963348|FG003|Overall Study|Lost to Follow-up|0
6265275|NCT02100670|9963345|FG000|Overall Study|Protocol Violation|0
6265276|NCT02100670|9963346|FG001|Overall Study|Protocol Violation|1
6265277|NCT02100670|9963347|FG002|Overall Study|Protocol Violation|0
6265278|NCT02100670|9963348|FG003|Overall Study|Protocol Violation|1
6265279|NCT02100670|9963345|FG000|Overall Study|Withdrawal of Consent|0
6265280|NCT02100670|9963346|FG001|Overall Study|Withdrawal of Consent|1
6265281|NCT02100670|9963347|FG002|Overall Study|Withdrawal of Consent|1
6265282|NCT02100670|9963348|FG003|Overall Study|Withdrawal of Consent|0
6265283|NCT02100670|9963345|FG000|Overall Study|No swelling no pain|1
6265284|NCT02100670|9963346|FG001|Overall Study|No swelling no pain|0
6265285|NCT02100670|9963347|FG002|Overall Study|No swelling no pain|0
6265286|NCT02100670|9963348|FG003|Overall Study|No swelling no pain|0
6265287|NCT02100670|9963345|FG000|Overall Study|Poor Efficacy|0
6265288|NCT02100670|9963346|FG001|Overall Study|Poor Efficacy|1
6265289|NCT02100670|9963347|FG002|Overall Study|Poor Efficacy|0
6265290|NCT02100670|9963348|FG003|Overall Study|Poor Efficacy|0
6265291|NCT02100670|9963345|FG000|Overall Study|Physician Decision|0
6265292|NCT02100670|9963346|FG001|Overall Study|Physician Decision|1
6265293|NCT02100670|9963347|FG002|Overall Study|Physician Decision|0
6265294|NCT02100670|9963348|FG003|Overall Study|Physician Decision|0
6265295|NCT02100670|9963345|FG000|Overall Study|Withdrawal by Subject|1
6265296|NCT02100670|9963346|FG001|Overall Study|Withdrawal by Subject|0
6265297|NCT02100670|9963347|FG002|Overall Study|Withdrawal by Subject|0
6265298|NCT02100670|9963348|FG003|Overall Study|Withdrawal by Subject|0
6265299|NCT02100696|9963371|FG000|Induction Phase|Adverse Event|0
6265300|NCT02100696|9963372|FG001|Induction Phase|Adverse Event|0
6265301|NCT02100696|9963373|FG002|Induction Phase|Adverse Event|1
6265302|NCT02100696|9963374|FG003|Induction Phase|Adverse Event|0
6265303|NCT02100696|9963375|FG004|Induction Phase|Adverse Event|0
6265304|NCT02100696|9963376|FG005|Induction Phase|Adverse Event|0
6265305|NCT02100696|9963371|FG000|Induction Phase|Lost to Follow-up|1
6265306|NCT02100696|9963372|FG001|Induction Phase|Lost to Follow-up|0
6265307|NCT02100696|9963373|FG002|Induction Phase|Lost to Follow-up|1
6265308|NCT02100696|9963374|FG003|Induction Phase|Lost to Follow-up|0
6265309|NCT02100696|9963375|FG004|Induction Phase|Lost to Follow-up|0
6265310|NCT02100696|9963376|FG005|Induction Phase|Lost to Follow-up|0
6265311|NCT02100696|9963371|FG000|Induction Phase|Protocol Violation|0
6265312|NCT02100696|9963372|FG001|Induction Phase|Protocol Violation|1
6265313|NCT02100696|9963373|FG002|Induction Phase|Protocol Violation|1
6265314|NCT02100696|9963374|FG003|Induction Phase|Protocol Violation|0
6265315|NCT02100696|9963375|FG004|Induction Phase|Protocol Violation|0
6265316|NCT02100696|9963376|FG005|Induction Phase|Protocol Violation|0
6265317|NCT02100696|9963371|FG000|Induction Phase|Withdrawal by Subject|8
6265318|NCT02100696|9963372|FG001|Induction Phase|Withdrawal by Subject|2
6265319|NCT02100696|9963373|FG002|Induction Phase|Withdrawal by Subject|13
6265320|NCT02100696|9963374|FG003|Induction Phase|Withdrawal by Subject|0
6265321|NCT02100696|9963375|FG004|Induction Phase|Withdrawal by Subject|0
6265322|NCT02100696|9963376|FG005|Induction Phase|Withdrawal by Subject|0
6265323|NCT02100696|9963371|FG000|Induction Phase|Physician Decision|1
6265324|NCT02100696|9963372|FG001|Induction Phase|Physician Decision|0
6265325|NCT02100696|9963373|FG002|Induction Phase|Physician Decision|2
6265326|NCT02100696|9963374|FG003|Induction Phase|Physician Decision|0
6265327|NCT02100696|9963375|FG004|Induction Phase|Physician Decision|0
6265328|NCT02100696|9963376|FG005|Induction Phase|Physician Decision|0
6265329|NCT02100696|9963371|FG000|Induction Phase|Multiple Reasons|5
6265330|NCT02100696|9963372|FG001|Induction Phase|Multiple Reasons|2
6265331|NCT02100696|9963373|FG002|Induction Phase|Multiple Reasons|8
6265332|NCT02100696|9963374|FG003|Induction Phase|Multiple Reasons|0
6265333|NCT02100696|9963375|FG004|Induction Phase|Multiple Reasons|0
6265334|NCT02100696|9963376|FG005|Induction Phase|Multiple Reasons|0
6265335|NCT02100696|9963371|FG000|Maintenance Phase|Adverse Event|0
6265336|NCT02100696|9963372|FG001|Maintenance Phase|Adverse Event|0
6265337|NCT02100696|9963373|FG002|Maintenance Phase|Adverse Event|0
6265338|NCT02100696|9963374|FG003|Maintenance Phase|Adverse Event|0
6265339|NCT02100696|9963375|FG004|Maintenance Phase|Adverse Event|0
6265340|NCT02100696|9963376|FG005|Maintenance Phase|Adverse Event|2
6265341|NCT02100696|9963371|FG000|Maintenance Phase|Lost to Follow-up|0
6265342|NCT02100696|9963372|FG001|Maintenance Phase|Lost to Follow-up|0
6265343|NCT02100696|9963373|FG002|Maintenance Phase|Lost to Follow-up|0
6265344|NCT02100696|9963374|FG003|Maintenance Phase|Lost to Follow-up|0
6265345|NCT02100696|9963375|FG004|Maintenance Phase|Lost to Follow-up|1
6265346|NCT02100696|9963376|FG005|Maintenance Phase|Lost to Follow-up|0
6265347|NCT02100696|9963371|FG000|Maintenance Phase|Protocol Violation|0
6265348|NCT02100696|9963372|FG001|Maintenance Phase|Protocol Violation|0
6265349|NCT02100696|9963373|FG002|Maintenance Phase|Protocol Violation|0
6191219|NCT01421277|9847947|FG001|Overall Study|Incomplete baseline data|31
6191220|NCT01421303|9847953|FG000|Overall Study|Lost to Follow-up|13
6191221|NCT01421303|9847953|FG000|Overall Study|Non compliance with study procedure|1
6191222|NCT01421303|9847953|FG000|Overall Study|Other|7
6265350|NCT02100696|9963374|FG003|Maintenance Phase|Protocol Violation|0
6265351|NCT02100696|9963375|FG004|Maintenance Phase|Protocol Violation|1
6265352|NCT02100696|9963376|FG005|Maintenance Phase|Protocol Violation|0
6265353|NCT02100696|9963371|FG000|Maintenance Phase|Withdrawal by Subject|0
6265354|NCT02100696|9963372|FG001|Maintenance Phase|Withdrawal by Subject|0
6265355|NCT02100696|9963373|FG002|Maintenance Phase|Withdrawal by Subject|0
6265356|NCT02100696|9963374|FG003|Maintenance Phase|Withdrawal by Subject|1
6265357|NCT02100696|9963375|FG004|Maintenance Phase|Withdrawal by Subject|4
6265358|NCT02100696|9963376|FG005|Maintenance Phase|Withdrawal by Subject|2
6265359|NCT02100696|9963371|FG000|Maintenance Phase|Physician Decision|0
6265360|NCT02100696|9963372|FG001|Maintenance Phase|Physician Decision|0
6265361|NCT02100696|9963373|FG002|Maintenance Phase|Physician Decision|0
6265362|NCT02100696|9963374|FG003|Maintenance Phase|Physician Decision|0
6086974|NCT00665925|9697110|FG000|Overall Study|Withdrawal by Subject|2
6086975|NCT00665925|9697111|FG001|Overall Study|Withdrawal by Subject|2
6265363|NCT02100696|9963375|FG004|Maintenance Phase|Physician Decision|1
6086976|NCT00665925|9697112|FG002|Overall Study|Withdrawal by Subject|3
6086977|NCT00665925|9697113|FG003|Overall Study|Withdrawal by Subject|2
6086978|NCT00665925|9697110|FG000|Overall Study|Physician Decision|0
6191223|NCT01421303|9847953|FG000|Overall Study|Withdrawal by Subject|1
6265364|NCT02100696|9963376|FG005|Maintenance Phase|Physician Decision|0
6265365|NCT02100696|9963371|FG000|Maintenance Phase|Multiple Reasons|0
6265366|NCT02100696|9963372|FG001|Maintenance Phase|Multiple Reasons|0
6265367|NCT02100696|9963373|FG002|Maintenance Phase|Multiple Reasons|0
6265368|NCT02100696|9963374|FG003|Maintenance Phase|Multiple Reasons|0
6265369|NCT02100696|9963375|FG004|Maintenance Phase|Multiple Reasons|2
6265370|NCT02100696|9963376|FG005|Maintenance Phase|Multiple Reasons|1
6265371|NCT02100813|9963454|FG000|Overall Study|Adverse Event|0
6265372|NCT02100813|9963455|FG001|Overall Study|Adverse Event|0
6265373|NCT02100813|9963456|FG002|Overall Study|Adverse Event|0
6265374|NCT02100813|9963457|FG003|Overall Study|Adverse Event|0
6265375|NCT02100813|9963458|FG004|Overall Study|Adverse Event|0
6265376|NCT02100813|9963459|FG005|Overall Study|Adverse Event|0
6265377|NCT02100813|9963460|FG006|Overall Study|Adverse Event|0
6265378|NCT02100813|9963461|FG007|Overall Study|Adverse Event|1
6265379|NCT02100839|9963488|FG000|Multiple Ascending Dose|Adverse Event|2
6265380|NCT02100839|9963489|FG001|Multiple Ascending Dose|Adverse Event|0
6265381|NCT02100839|9963488|FG000|Multiple Ascending Dose|Withdrawal by Subject|2
6265382|NCT02100839|9963489|FG001|Multiple Ascending Dose|Withdrawal by Subject|0
6265383|NCT02100969|9963499|FG000|Overall Study|Did not pass screening phase|1
6265384|NCT02101021|9963513|FG000|Overall Study|Death|4
6265385|NCT02101021|9963514|FG001|Overall Study|Death|3
6265386|NCT02101021|9963515|FG002|Overall Study|Death|6
6265387|NCT02101021|9963516|FG003|Overall Study|Death|0
6265388|NCT02101021|9963517|FG004|Overall Study|Death|3
6265389|NCT02101021|9963513|FG000|Overall Study|Withdrew Consent from study|1
6265390|NCT02101021|9963514|FG001|Overall Study|Withdrew Consent from study|1
6265391|NCT02101021|9963515|FG002|Overall Study|Withdrew Consent from study|0
6265392|NCT02101021|9963516|FG003|Overall Study|Withdrew Consent from study|2
6265393|NCT02101021|9963517|FG004|Overall Study|Withdrew Consent from study|0
6265394|NCT02101021|9963513|FG000|Overall Study|Lost to Follow-up|1
6265395|NCT02101021|9963514|FG001|Overall Study|Lost to Follow-up|0
6265396|NCT02101021|9963515|FG002|Overall Study|Lost to Follow-up|0
6265397|NCT02101021|9963516|FG003|Overall Study|Lost to Follow-up|0
6265398|NCT02101021|9963517|FG004|Overall Study|Lost to Follow-up|0
6265399|NCT02101021|9963513|FG000|Overall Study|Study Terminated by Sponsor|1
6265400|NCT02101021|9963514|FG001|Overall Study|Study Terminated by Sponsor|0
6265401|NCT02101021|9963515|FG002|Overall Study|Study Terminated by Sponsor|1
6265402|NCT02101021|9963516|FG003|Overall Study|Study Terminated by Sponsor|1
6265403|NCT02101021|9963517|FG004|Overall Study|Study Terminated by Sponsor|1
6191224|NCT01421342|9847960|FG000|Acute Treatment Phase (12 Weeks)|Lack of Efficacy|49
6191225|NCT01421342|9847961|FG001|Acute Treatment Phase (12 Weeks)|Lack of Efficacy|28
6191226|NCT01421342|9847962|FG002|Acute Treatment Phase (12 Weeks)|Lack of Efficacy|13
6191227|NCT01421342|9847960|FG000|Acute Treatment Phase (12 Weeks)|Adverse Event|53
6191228|NCT01421342|9847961|FG001|Acute Treatment Phase (12 Weeks)|Adverse Event|38
6191229|NCT01421342|9847962|FG002|Acute Treatment Phase (12 Weeks)|Adverse Event|27
6191230|NCT01421342|9847960|FG000|Acute Treatment Phase (12 Weeks)|Withdrawal by Subject|23
6191231|NCT01421342|9847961|FG001|Acute Treatment Phase (12 Weeks)|Withdrawal by Subject|20
6191232|NCT01421342|9847962|FG002|Acute Treatment Phase (12 Weeks)|Withdrawal by Subject|13
6271614|NCT02164981|9973449|FG001|Phase 1 (Day 0 - Day 14)|Adverse Event|2
6271615|NCT02164981|9973450|FG002|Phase 1 (Day 0 - Day 14)|Adverse Event|0
6086979|NCT00665925|9697111|FG001|Overall Study|Physician Decision|0
6191233|NCT01421342|9847960|FG000|Acute Treatment Phase (12 Weeks)|Death|0
6191234|NCT01421342|9847961|FG001|Acute Treatment Phase (12 Weeks)|Death|0
6271616|NCT02164981|9973448|FG000|Phase 2 (Day 14 - Day 28)|Adverse Event|2
6271617|NCT02164981|9973449|FG001|Phase 2 (Day 14 - Day 28)|Adverse Event|1
6271618|NCT02164981|9973450|FG002|Phase 2 (Day 14 - Day 28)|Adverse Event|0
6265404|NCT02101060|9963531|FG000|Overall Study|Adverse Event|1
6265405|NCT02101060|9963532|FG001|Overall Study|Adverse Event|0
6265406|NCT02101060|9963531|FG000|Overall Study|Withdrawal by Subject|1
6265407|NCT02101060|9963532|FG001|Overall Study|Withdrawal by Subject|1
6265408|NCT02101060|9963531|FG000|Overall Study|Lost to Follow-up|3
6265409|NCT02101060|9963532|FG001|Overall Study|Lost to Follow-up|3
6265410|NCT02101112|9963538|FG000|Overall Study|Adverse Event|0
6265411|NCT02101112|9963539|FG001|Overall Study|Adverse Event|0
6265412|NCT02101112|9963540|FG002|Overall Study|Adverse Event|1
6265413|NCT02101112|9963541|FG003|Overall Study|Adverse Event|0
6265414|NCT02101112|9963542|FG004|Overall Study|Adverse Event|0
6265415|NCT02101112|9963543|FG005|Overall Study|Adverse Event|0
6265416|NCT02101112|9963538|FG000|Overall Study|Withdrawal by Subject|0
6265417|NCT02101112|9963539|FG001|Overall Study|Withdrawal by Subject|0
6265418|NCT02101112|9963540|FG002|Overall Study|Withdrawal by Subject|0
6265419|NCT02101112|9963541|FG003|Overall Study|Withdrawal by Subject|0
6265420|NCT02101112|9963542|FG004|Overall Study|Withdrawal by Subject|1
6265421|NCT02101112|9963543|FG005|Overall Study|Withdrawal by Subject|0
6265422|NCT02101281|9963564|FG000|Overall Study|Adverse Event|0
6265423|NCT02101281|9963565|FG001|Overall Study|Adverse Event|1
6265424|NCT02101294|9963577|FG000|Overall Study|Withdrawal by Subject|5
6265425|NCT02101294|9963577|FG000|Overall Study|Lost to Follow-up|6
6265426|NCT02101359|9963586|FG000|Overall Study|Not included|23
6265427|NCT02101359|9963587|FG001|Overall Study|Not included|13
6265428|NCT02101359|9963586|FG000|Overall Study|Withdrawal by Subject|5
6265429|NCT02101359|9963587|FG001|Overall Study|Withdrawal by Subject|4
6265430|NCT02101359|9963586|FG000|Overall Study|Lost to Follow-up|1
6265431|NCT02101359|9963587|FG001|Overall Study|Lost to Follow-up|0
6265432|NCT02101359|9963586|FG000|Overall Study|Protocol Violation|0
6265433|NCT02101359|9963587|FG001|Overall Study|Protocol Violation|2
6265434|NCT02101554|9963635|FG000|Overall Study|Protocol Violation|0
6265435|NCT02101554|9963636|FG001|Overall Study|Protocol Violation|1
6265436|NCT02101554|9963637|FG002|Overall Study|Protocol Violation|0
6265437|NCT02101554|9963635|FG000|Overall Study|Insufficient Clinical Response|0
6265438|NCT02101554|9963636|FG001|Overall Study|Insufficient Clinical Response|2
6265439|NCT02101554|9963637|FG002|Overall Study|Insufficient Clinical Response|0
6265440|NCT02101554|9963635|FG000|Overall Study|Adverse Event|2
6265441|NCT02101554|9963636|FG001|Overall Study|Adverse Event|1
6265442|NCT02101554|9963637|FG002|Overall Study|Adverse Event|1
6265443|NCT02101554|9963635|FG000|Overall Study|Lost to Follow-up|0
6265444|NCT02101554|9963636|FG001|Overall Study|Lost to Follow-up|1
6265445|NCT02101554|9963637|FG002|Overall Study|Lost to Follow-up|0
6265446|NCT02101554|9963635|FG000|Overall Study|Withdrawl by Parents/Guardians|1
6265447|NCT02101554|9963636|FG001|Overall Study|Withdrawl by Parents/Guardians|0
6265448|NCT02101554|9963637|FG002|Overall Study|Withdrawl by Parents/Guardians|0
6265449|NCT02101983|9963651|FG000|Overall Study|Physician Decision|1
6265450|NCT02101983|9963652|FG001|Overall Study|Physician Decision|0
6265451|NCT02102204|9963667|FG000|Overall Study|Withdrawal by Subject|137
6265452|NCT02102204|9963667|FG000|Overall Study|Death|92
6265453|NCT02102204|9963667|FG000|Overall Study|Lost to Follow-up|65
6265454|NCT02102204|9963667|FG000|Overall Study|Sponsor Decision|5
6265455|NCT02102204|9963667|FG000|Overall Study|Ongoing|5
6265456|NCT02102399|9963687|FG000|Overall Study|Withdrawal by Subject|6
6265457|NCT02102399|9963688|FG001|Overall Study|Withdrawal by Subject|4
6265458|NCT02102464|9963701|FG000|Randomized Study|Withdrawal by Subject|0
6265459|NCT02102464|9963702|FG001|Randomized Study|Withdrawal by Subject|1
6265460|NCT02102464|9963703|FG002|Randomized Study|Withdrawal by Subject|0
6265461|NCT02102490|9963712|FG000|Overall Study|Death|6
6265462|NCT02102490|9963712|FG000|Overall Study|Lost to Follow-up|1
6265463|NCT02102724|9963718|FG000|Overall Study|Lost to Follow-up|1
6265464|NCT02102724|9963719|FG001|Overall Study|Lost to Follow-up|0
6265465|NCT02102724|9963718|FG000|Overall Study|surgery for brain aneurysm|1
6086980|NCT00665925|9697112|FG002|Overall Study|Physician Decision|1
6086981|NCT00665925|9697113|FG003|Overall Study|Physician Decision|2
6086982|NCT00665925|9697110|FG000|Overall Study|Severe Non-Compliance to Protocol|0
6086983|NCT00665925|9697111|FG001|Overall Study|Severe Non-Compliance to Protocol|0
6086984|NCT00665925|9697112|FG002|Overall Study|Severe Non-Compliance to Protocol|1
6265466|NCT02102724|9963719|FG001|Overall Study|surgery for brain aneurysm|1
6265467|NCT02103062|9963760|FG000|Overall Study|Adverse Event|1
6265468|NCT02103062|9963761|FG001|Overall Study|Adverse Event|2
6265469|NCT02103062|9963760|FG000|Overall Study|Progressive Disease|17
6265470|NCT02103062|9963761|FG001|Overall Study|Progressive Disease|20
6265471|NCT02103062|9963760|FG000|Overall Study|Death|0
6265472|NCT02103062|9963761|FG001|Overall Study|Death|1
6265473|NCT02103439|9963830|FG000|Overall Study|Adverse Event|0
6265474|NCT02103439|9963831|FG001|Overall Study|Adverse Event|2
6265475|NCT02103439|9963830|FG000|Overall Study|Withdrawal by Subject|3
6086985|NCT00665925|9697113|FG003|Overall Study|Severe Non-Compliance to Protocol|1
6265476|NCT02103439|9963831|FG001|Overall Study|Withdrawal by Subject|1
6265477|NCT02103478|9963848|FG000|Overall Study|Adverse Event|0
6086986|NCT00665925|9697110|FG000|Overall Study|Adverse Event|1
6265478|NCT02103478|9963849|FG001|Overall Study|Adverse Event|0
6265479|NCT02103478|9963850|FG002|Overall Study|Adverse Event|1
6265480|NCT02103478|9963851|FG003|Overall Study|Adverse Event|1
6265481|NCT02103478|9963852|FG004|Overall Study|Adverse Event|2
6265482|NCT02103478|9963853|FG005|Overall Study|Adverse Event|1
6265483|NCT02103478|9963854|FG006|Overall Study|Adverse Event|0
6265484|NCT02103478|9963855|FG007|Overall Study|Adverse Event|0
6265485|NCT02103478|9963856|FG008|Overall Study|Adverse Event|0
6265486|NCT02103478|9963848|FG000|Overall Study|Death|2
6265487|NCT02103478|9963849|FG001|Overall Study|Death|2
6265488|NCT02103478|9963850|FG002|Overall Study|Death|1
6265489|NCT02103478|9963851|FG003|Overall Study|Death|1
6265490|NCT02103478|9963852|FG004|Overall Study|Death|5
6265491|NCT02103478|9963853|FG005|Overall Study|Death|15
6265492|NCT02103478|9963854|FG006|Overall Study|Death|14
6265493|NCT02103478|9963855|FG007|Overall Study|Death|10
6265494|NCT02103478|9963856|FG008|Overall Study|Death|11
6265495|NCT02103478|9963848|FG000|Overall Study|Progressive Disease|2
6265496|NCT02103478|9963849|FG001|Overall Study|Progressive Disease|1
6265497|NCT02103478|9963850|FG002|Overall Study|Progressive Disease|2
6265498|NCT02103478|9963851|FG003|Overall Study|Progressive Disease|0
6265499|NCT02103478|9963852|FG004|Overall Study|Progressive Disease|9
6265500|NCT02103478|9963853|FG005|Overall Study|Progressive Disease|1
6265501|NCT02103478|9963854|FG006|Overall Study|Progressive Disease|2
6265502|NCT02103478|9963855|FG007|Overall Study|Progressive Disease|0
6265503|NCT02103478|9963856|FG008|Overall Study|Progressive Disease|1
6265504|NCT02103478|9963848|FG000|Overall Study|Withdrawal by Subject|2
6265505|NCT02103478|9963849|FG001|Overall Study|Withdrawal by Subject|0
6265506|NCT02103478|9963850|FG002|Overall Study|Withdrawal by Subject|0
6265507|NCT02103478|9963851|FG003|Overall Study|Withdrawal by Subject|4
6265508|NCT02103478|9963852|FG004|Overall Study|Withdrawal by Subject|0
6265509|NCT02103478|9963853|FG005|Overall Study|Withdrawal by Subject|0
6265510|NCT02103478|9963854|FG006|Overall Study|Withdrawal by Subject|1
6265511|NCT02103478|9963855|FG007|Overall Study|Withdrawal by Subject|1
6265512|NCT02103478|9963856|FG008|Overall Study|Withdrawal by Subject|0
6265513|NCT02103478|9963848|FG000|Overall Study|Lost to Follow-up|0
6265514|NCT02103478|9963849|FG001|Overall Study|Lost to Follow-up|0
6265515|NCT02103478|9963850|FG002|Overall Study|Lost to Follow-up|0
6265516|NCT02103478|9963851|FG003|Overall Study|Lost to Follow-up|0
6265517|NCT02103478|9963852|FG004|Overall Study|Lost to Follow-up|0
6265518|NCT02103478|9963853|FG005|Overall Study|Lost to Follow-up|0
6265519|NCT02103478|9963854|FG006|Overall Study|Lost to Follow-up|0
6265520|NCT02103478|9963855|FG007|Overall Study|Lost to Follow-up|1
6265521|NCT02103478|9963856|FG008|Overall Study|Lost to Follow-up|0
6265522|NCT02103478|9963848|FG000|Overall Study|Other|1
6265523|NCT02103478|9963849|FG001|Overall Study|Other|3
6265524|NCT02103478|9963850|FG002|Overall Study|Other|2
6265525|NCT02103478|9963851|FG003|Overall Study|Other|0
6265526|NCT02103478|9963852|FG004|Overall Study|Other|3
6265527|NCT02103478|9963853|FG005|Overall Study|Other|8
6265528|NCT02103478|9963854|FG006|Overall Study|Other|8
6265529|NCT02103478|9963855|FG007|Overall Study|Other|4
6265530|NCT02103478|9963856|FG008|Overall Study|Other|2
6265531|NCT02104505|9963947|FG000|First Intervention (14 Days)|Adverse Event|2
6265532|NCT02104505|9963948|FG001|First Intervention (14 Days)|Adverse Event|0
6086987|NCT00665925|9697111|FG001|Overall Study|Adverse Event|5
6086988|NCT00665925|9697112|FG002|Overall Study|Adverse Event|10
6086989|NCT00665925|9697113|FG003|Overall Study|Adverse Event|5
6265533|NCT02104505|9963947|FG000|First Intervention (14 Days)|Withdrawal by Subject|0
6265534|NCT02104505|9963948|FG001|First Intervention (14 Days)|Withdrawal by Subject|1
6265535|NCT02104505|9963947|FG000|First Intervention (14 Days)|Lost to Follow-up|0
6265536|NCT02104505|9963948|FG001|First Intervention (14 Days)|Lost to Follow-up|1
6265537|NCT02104505|9963947|FG000|First Intervention (14 Days)|exclusionary condition|0
6265538|NCT02104505|9963948|FG001|First Intervention (14 Days)|exclusionary condition|1
6265539|NCT02104505|9963947|FG000|Second Intervention (14 Days)|Withdrawal by Subject|0
6265540|NCT02104505|9963948|FG001|Second Intervention (14 Days)|Withdrawal by Subject|1
6265541|NCT02104505|9963947|FG000|Second Intervention (14 Days)|Adverse Event|2
6265542|NCT02104505|9963948|FG001|Second Intervention (14 Days)|Adverse Event|0
6265543|NCT02104557|9963955|FG000|Overall Study|Adverse Event|24
6265544|NCT02104557|9963955|FG000|Overall Study|Lost to Follow-up|34
6265545|NCT02104557|9963955|FG000|Overall Study|Violated the usage and dosage|14
6265546|NCT02104557|9963955|FG000|Overall Study|No longer met inclusion/exclusion criteria|1
6265547|NCT02104557|9963955|FG000|Overall Study|Administered Sayana prior to the contract|1
6265548|NCT02104557|9963955|FG000|Overall Study|Other|17
6265549|NCT02104557|9963955|FG000|Overall Study|Change to other contraception methods|5
6265550|NCT02104557|9963955|FG000|Overall Study|Discontinuation due to no pain|1
6265551|NCT02104557|9963955|FG000|Overall Study|Withdrawal consent|2
6265552|NCT02104557|9963955|FG000|Overall Study|Refusal of administration due to unknown reasons|69
6265553|NCT02104557|9963955|FG000|Overall Study|Discontinuation of contraception|9
6265554|NCT02104583|9963964|FG000|Overall Study|New ICD or CRT-D implanted|2
6265555|NCT02104583|9963965|FG001|Overall Study|New ICD or CRT-D implanted|0
6265556|NCT02104583|9963966|FG002|Overall Study|New ICD or CRT-D implanted|1
6265557|NCT02104583|9963967|FG003|Overall Study|New ICD or CRT-D implanted|0
6265558|NCT02104583|9963968|FG004|Overall Study|New ICD or CRT-D implanted|0
6265559|NCT02104583|9963964|FG000|Overall Study|Death|2
6265560|NCT02104583|9963965|FG001|Overall Study|Death|1
6265561|NCT02104583|9963966|FG002|Overall Study|Death|3
6265562|NCT02104583|9963967|FG003|Overall Study|Death|3
6265563|NCT02104583|9963968|FG004|Overall Study|Death|5
6265564|NCT02104583|9963964|FG000|Overall Study|Subject required cardiac ablation|6
6265565|NCT02104583|9963965|FG001|Overall Study|Subject required cardiac ablation|4
6265566|NCT02104583|9963966|FG002|Overall Study|Subject required cardiac ablation|4
6265567|NCT02104583|9963967|FG003|Overall Study|Subject required cardiac ablation|5
6265568|NCT02104583|9963968|FG004|Overall Study|Subject required cardiac ablation|4
6265569|NCT02104583|9963964|FG000|Overall Study|Subject required prohibited medication|0
6265570|NCT02104583|9963965|FG001|Overall Study|Subject required prohibited medication|1
6265571|NCT02104583|9963966|FG002|Overall Study|Subject required prohibited medication|1
6265572|NCT02104583|9963967|FG003|Overall Study|Subject required prohibited medication|0
6265573|NCT02104583|9963968|FG004|Overall Study|Subject required prohibited medication|1
6265574|NCT02104583|9963964|FG000|Overall Study|Withdrew Consent|3
6265575|NCT02104583|9963965|FG001|Overall Study|Withdrew Consent|2
6265576|NCT02104583|9963966|FG002|Overall Study|Withdrew Consent|0
6265577|NCT02104583|9963967|FG003|Overall Study|Withdrew Consent|2
6191235|NCT01421342|9847962|FG002|Acute Treatment Phase (12 Weeks)|Death|3
6265578|NCT02104583|9963968|FG004|Overall Study|Withdrew Consent|1
6265579|NCT02104583|9963964|FG000|Overall Study|Investigator's Discretion|1
6265580|NCT02104583|9963965|FG001|Overall Study|Investigator's Discretion|0
6265581|NCT02104583|9963966|FG002|Overall Study|Investigator's Discretion|0
6265582|NCT02104583|9963967|FG003|Overall Study|Investigator's Discretion|0
6265583|NCT02104583|9963968|FG004|Overall Study|Investigator's Discretion|0
6265584|NCT02104583|9963964|FG000|Overall Study|Protocol Violation|0
6265585|NCT02104583|9963965|FG001|Overall Study|Protocol Violation|0
6265586|NCT02104583|9963966|FG002|Overall Study|Protocol Violation|1
6265587|NCT02104583|9963967|FG003|Overall Study|Protocol Violation|0
6265588|NCT02104583|9963968|FG004|Overall Study|Protocol Violation|0
6265589|NCT02104583|9963964|FG000|Overall Study|Adverse Event|3
6265590|NCT02104583|9963965|FG001|Overall Study|Adverse Event|3
6265591|NCT02104583|9963966|FG002|Overall Study|Adverse Event|6
6265592|NCT02104583|9963967|FG003|Overall Study|Adverse Event|6
6265593|NCT02104583|9963968|FG004|Overall Study|Adverse Event|1
6265594|NCT02104583|9963964|FG000|Overall Study|Lost to Follow-up|1
6265595|NCT02104583|9963965|FG001|Overall Study|Lost to Follow-up|0
6265596|NCT02104583|9963966|FG002|Overall Study|Lost to Follow-up|0
6265597|NCT02104583|9963967|FG003|Overall Study|Lost to Follow-up|0
6265598|NCT02104583|9963968|FG004|Overall Study|Lost to Follow-up|0
6265599|NCT02104583|9963964|FG000|Overall Study|Randomized but Never Treated|0
6265600|NCT02104583|9963965|FG001|Overall Study|Randomized but Never Treated|0
6265601|NCT02104583|9963966|FG002|Overall Study|Randomized but Never Treated|0
6265602|NCT02104583|9963967|FG003|Overall Study|Randomized but Never Treated|1
6265603|NCT02104583|9963968|FG004|Overall Study|Randomized but Never Treated|0
6265604|NCT02104752|9964007|FG000|Overall Study|Withdrawal by Subject|1
6265605|NCT02104752|9964008|FG001|Overall Study|Withdrawal by Subject|0
6265606|NCT02104752|9964007|FG000|Overall Study|Weight gain; unrelated anxiety|0
6265607|NCT02104752|9964008|FG001|Overall Study|Weight gain; unrelated anxiety|2
6265608|NCT02104765|9964021|FG000|Overall Study|Lost to Follow-up|0
6265609|NCT02104765|9964022|FG001|Overall Study|Lost to Follow-up|0
6265610|NCT02104765|9964023|FG002|Overall Study|Lost to Follow-up|1
6265611|NCT02104765|9964024|FG003|Overall Study|Lost to Follow-up|0
6265612|NCT02104765|9964025|FG004|Overall Study|Lost to Follow-up|0
6265613|NCT02104765|9964026|FG005|Overall Study|Lost to Follow-up|0
6265614|NCT02104765|9964027|FG006|Overall Study|Lost to Follow-up|0
6265615|NCT02104765|9964021|FG000|Overall Study|Withdrawal by Subject|0
6265616|NCT02104765|9964022|FG001|Overall Study|Withdrawal by Subject|0
6265617|NCT02104765|9964023|FG002|Overall Study|Withdrawal by Subject|0
6265618|NCT02104765|9964024|FG003|Overall Study|Withdrawal by Subject|1
6265619|NCT02104765|9964025|FG004|Overall Study|Withdrawal by Subject|1
6265620|NCT02104765|9964026|FG005|Overall Study|Withdrawal by Subject|0
6265621|NCT02104765|9964027|FG006|Overall Study|Withdrawal by Subject|1
6265622|NCT02104804|9964051|FG000|Overall Study|Did not take study medication|0
6265623|NCT02104804|9964052|FG001|Overall Study|Did not take study medication|1
6191236|NCT01421342|9847960|FG000|Acute Treatment Phase (12 Weeks)|Lost to Follow-up|6
6191237|NCT01421342|9847961|FG001|Acute Treatment Phase (12 Weeks)|Lost to Follow-up|18
6191238|NCT01421342|9847962|FG002|Acute Treatment Phase (12 Weeks)|Lost to Follow-up|21
6191239|NCT01421342|9847960|FG000|Acute Treatment Phase (12 Weeks)|Non-adherence|15
6191240|NCT01421342|9847961|FG001|Acute Treatment Phase (12 Weeks)|Non-adherence|7
6191241|NCT01421342|9847962|FG002|Acute Treatment Phase (12 Weeks)|Non-adherence|13
6191242|NCT01421342|9847960|FG000|Acute Treatment Phase (12 Weeks)|Dure to other illness|3
6191243|NCT01421342|9847961|FG001|Acute Treatment Phase (12 Weeks)|Dure to other illness|2
6191244|NCT01421342|9847962|FG002|Acute Treatment Phase (12 Weeks)|Dure to other illness|4
6191245|NCT01421342|9847960|FG000|Acute Treatment Phase (12 Weeks)|Participant moved away|1
6191246|NCT01421342|9847961|FG001|Acute Treatment Phase (12 Weeks)|Participant moved away|6
6191247|NCT01421342|9847962|FG002|Acute Treatment Phase (12 Weeks)|Participant moved away|1
6191248|NCT01421342|9847960|FG000|Acute Treatment Phase (12 Weeks)|Other reason for withdrawal|8
6191249|NCT01421342|9847961|FG001|Acute Treatment Phase (12 Weeks)|Other reason for withdrawal|9
6191250|NCT01421342|9847962|FG002|Acute Treatment Phase (12 Weeks)|Other reason for withdrawal|4
6265624|NCT02104804|9964051|FG000|Overall Study|Study specific discontinuation criteria|6
6265625|NCT02104804|9964052|FG001|Overall Study|Study specific discontinuation criteria|1
6265626|NCT02104804|9964051|FG000|Overall Study|Other listed|2
6265627|NCT02104804|9964052|FG001|Overall Study|Other listed|1
6265628|NCT02104804|9964051|FG000|Overall Study|Protocol Violation|0
6265629|NCT02104804|9964052|FG001|Overall Study|Protocol Violation|1
6265630|NCT02104804|9964051|FG000|Overall Study|Adverse Event|4
6265631|NCT02104804|9964052|FG001|Overall Study|Adverse Event|3
6265632|NCT02104804|9964051|FG000|Overall Study|Withdrawal by Subject|4
6265633|NCT02104804|9964052|FG001|Overall Study|Withdrawal by Subject|12
6265634|NCT02104817|9964060|FG000|Overall Study|Death|363
6265635|NCT02104817|9964061|FG001|Overall Study|Death|330
6265636|NCT02104817|9964060|FG000|Overall Study|Lost to Follow-up|3
6265637|NCT02104817|9964061|FG001|Overall Study|Lost to Follow-up|2
6265638|NCT02104817|9964060|FG000|Overall Study|Protocol Violation|0
6265639|NCT02104817|9964061|FG001|Overall Study|Protocol Violation|1
6265640|NCT02104817|9964060|FG000|Overall Study|Study terminated by sponsor|5854
6265641|NCT02104817|9964061|FG001|Overall Study|Study terminated by sponsor|5901
6265642|NCT02104817|9964060|FG000|Overall Study|Withdrawal by Subject|111
6265643|NCT02104817|9964061|FG001|Overall Study|Withdrawal by Subject|78
6265644|NCT02104817|9964060|FG000|Overall Study|Other reasons|128
6265645|NCT02104817|9964061|FG001|Overall Study|Other reasons|135
6265646|NCT02104895|9964082|FG000|Overall Study|Withdrawal by Subject|0
6265647|NCT02104895|9964083|FG001|Overall Study|Withdrawal by Subject|14
6265648|NCT02104947|9964091|FG000|Overall Study|Withdrawal by Subject|10
6265649|NCT02104947|9964092|FG001|Overall Study|Withdrawal by Subject|3
6265650|NCT02104947|9964091|FG000|Overall Study|Lost to Follow-up|4
6265651|NCT02104947|9964092|FG001|Overall Study|Lost to Follow-up|4
6265652|NCT02104947|9964091|FG000|Overall Study|Protocol Violation|6
6265653|NCT02104947|9964092|FG001|Overall Study|Protocol Violation|8
6265654|NCT02104947|9964091|FG000|Overall Study|Adverse Event|57
6265655|NCT02104947|9964092|FG001|Overall Study|Adverse Event|38
6265656|NCT02104947|9964091|FG000|Overall Study|Other than stated above|2
6265657|NCT02104947|9964092|FG001|Overall Study|Other than stated above|3
6265658|NCT02105012|9964102|FG000|Overall Study|Withdrawal by Subject|11
6265659|NCT02105012|9964102|FG000|Overall Study|Protocol Specified Criteria|9
6265660|NCT02105012|9964102|FG000|Overall Study|Lost to Follow-up|4
6265661|NCT02105012|9964102|FG000|Overall Study|Protocol Violation|4
6265662|NCT02105012|9964102|FG000|Overall Study|Physician Decision|3
6265663|NCT02105012|9964102|FG000|Overall Study|Adverse Event|1
6265664|NCT02105012|9964102|FG000|Overall Study|Lack of Efficacy|1
6265665|NCT02105272|9964129|FG000|Overall Study|Adverse Event|1
6265666|NCT02105272|9964130|FG001|Overall Study|Adverse Event|2
6265667|NCT02105272|9964129|FG000|Overall Study|Physician Decision|0
6265668|NCT02105272|9964130|FG001|Overall Study|Physician Decision|1
6265669|NCT02105272|9964129|FG000|Overall Study|Protocol Violation|2
6265670|NCT02105272|9964130|FG001|Overall Study|Protocol Violation|0
6265671|NCT02105272|9964129|FG000|Overall Study|Withdrawal by Subject|2
6265672|NCT02105272|9964130|FG001|Overall Study|Withdrawal by Subject|0
6265673|NCT02105285|9964139|FG000|Overall Study|Adverse Event|1
6265674|NCT02105285|9964140|FG001|Overall Study|Adverse Event|1
6265675|NCT02105285|9964141|FG002|Overall Study|Adverse Event|0
6265676|NCT02105285|9964139|FG000|Overall Study|Protocol Violation|0
6265677|NCT02105285|9964140|FG001|Overall Study|Protocol Violation|1
6265678|NCT02105285|9964141|FG002|Overall Study|Protocol Violation|0
6265679|NCT02105285|9964139|FG000|Overall Study|Withdrawal by Subject|1
6265680|NCT02105285|9964140|FG001|Overall Study|Withdrawal by Subject|0
6265681|NCT02105285|9964141|FG002|Overall Study|Withdrawal by Subject|0
6265682|NCT02105454|9964172|FG000|Overall Study|Withdrawal by Subject|1
6265683|NCT02105467|9964178|FG000|Period 1|Lost to Follow-up|1
6265684|NCT02105467|9964179|FG001|Period 1|Lost to Follow-up|0
6265685|NCT02105467|9964178|FG000|Period 1|Death|1
6265686|NCT02105467|9964179|FG001|Period 1|Death|0
6265687|NCT02105467|9964178|FG000|Period 2|Lost to Follow-up|1
6265688|NCT02105467|9964179|FG001|Period 2|Lost to Follow-up|0
6265689|NCT02105467|9964178|FG000|Period 2|Death|1
6265690|NCT02105467|9964179|FG001|Period 2|Death|0
6265691|NCT02105467|9964178|FG000|Period 2|Withdrawal by Subject|0
6265692|NCT02105467|9964179|FG001|Period 2|Withdrawal by Subject|2
6265693|NCT02105467|9964178|FG000|Period 3|Lost to Follow-up|0
6265694|NCT02105467|9964179|FG001|Period 3|Lost to Follow-up|1
6265695|NCT02105662|9964195|FG000|Overall Study|Lost to Follow-up|5
6265696|NCT02105662|9964195|FG000|Overall Study|Withdrawal by Subject|1
6265697|NCT02105688|9964201|FG000|Part A: Double-Blind|Adverse Event|1
6265698|NCT02105688|9964202|FG001|Part A: Double-Blind|Adverse Event|0
6265699|NCT02105688|9964201|FG000|Part A: Double-Blind|Death|0
6265700|NCT02105688|9964202|FG001|Part A: Double-Blind|Death|1
6265701|NCT02105688|9964201|FG000|Part A: Double-Blind|Lost to Follow-up|15
6265702|NCT02105688|9964202|FG001|Part A: Double-Blind|Lost to Follow-up|11
6265703|NCT02105688|9964201|FG000|Part A: Double-Blind|Physician Decision|0
6265704|NCT02105688|9964202|FG001|Part A: Double-Blind|Physician Decision|1
6265705|NCT02105688|9964201|FG000|Part A: Double-Blind|Status Unknown|0
6265706|NCT02105688|9964202|FG001|Part A: Double-Blind|Status Unknown|2
6265707|NCT02105688|9964201|FG000|Part A: Double-Blind|Withdrawal by Subject|4
6265708|NCT02105688|9964202|FG001|Part A: Double-Blind|Withdrawal by Subject|2
6265709|NCT02105688|9964201|FG000|Part B: Observational Follow-up|Death|2
6265710|NCT02105688|9964202|FG001|Part B: Observational Follow-up|Death|1
6265711|NCT02105688|9964201|FG000|Part B: Observational Follow-up|Lost to Follow-up|23
6265712|NCT02105688|9964202|FG001|Part B: Observational Follow-up|Lost to Follow-up|15
6265713|NCT02105688|9964201|FG000|Part B: Observational Follow-up|Withdrawal by Subject|9
6265714|NCT02105688|9964202|FG001|Part B: Observational Follow-up|Withdrawal by Subject|3
6265715|NCT02105688|9964201|FG000|Part B: Observational Follow-up|Physician Decision|3
6265716|NCT02105688|9964202|FG001|Part B: Observational Follow-up|Physician Decision|1
6265717|NCT02105701|9964213|FG000|Overall Study|Lost to Follow-up|1
6265718|NCT02105701|9964214|FG001|Overall Study|Lost to Follow-up|0
6265719|NCT02105701|9964215|FG002|Overall Study|Lost to Follow-up|2
6265720|NCT02105701|9964216|FG003|Overall Study|Lost to Follow-up|1
6265721|NCT02105701|9964213|FG000|Overall Study|Protocol Violation|0
6265722|NCT02105701|9964214|FG001|Overall Study|Protocol Violation|0
6265723|NCT02105701|9964215|FG002|Overall Study|Protocol Violation|1
6265724|NCT02105701|9964216|FG003|Overall Study|Protocol Violation|0
6265725|NCT02105701|9964213|FG000|Overall Study|Withdrawal by Subject|2
6265726|NCT02105701|9964214|FG001|Overall Study|Withdrawal by Subject|1
6265727|NCT02105701|9964215|FG002|Overall Study|Withdrawal by Subject|0
6265728|NCT02105701|9964216|FG003|Overall Study|Withdrawal by Subject|1
6265729|NCT02105701|9964213|FG000|Overall Study|Death|1
6265730|NCT02105701|9964214|FG001|Overall Study|Death|0
6265731|NCT02105701|9964215|FG002|Overall Study|Death|0
6265732|NCT02105701|9964216|FG003|Overall Study|Death|0
6265733|NCT02105948|9964241|FG000|Overall Study|Adverse Event|10
6265734|NCT02105948|9964242|FG001|Overall Study|Adverse Event|7
6265735|NCT02105948|9964243|FG002|Overall Study|Adverse Event|11
6265736|NCT02105948|9964244|FG003|Overall Study|Adverse Event|11
6265737|NCT02105948|9964241|FG000|Overall Study|Lack of Efficacy|0
6265738|NCT02105948|9964242|FG001|Overall Study|Lack of Efficacy|1
6265739|NCT02105948|9964243|FG002|Overall Study|Lack of Efficacy|3
6265740|NCT02105948|9964244|FG003|Overall Study|Lack of Efficacy|2
6265741|NCT02105948|9964241|FG000|Overall Study|Lost to Follow-up|0
6265742|NCT02105948|9964242|FG001|Overall Study|Lost to Follow-up|0
6265743|NCT02105948|9964243|FG002|Overall Study|Lost to Follow-up|2
6265744|NCT02105948|9964244|FG003|Overall Study|Lost to Follow-up|1
6265745|NCT02105948|9964241|FG000|Overall Study|Physician Decision|2
6265746|NCT02105948|9964242|FG001|Overall Study|Physician Decision|2
6265747|NCT02105948|9964243|FG002|Overall Study|Physician Decision|2
6265748|NCT02105948|9964244|FG003|Overall Study|Physician Decision|2
6265749|NCT02105948|9964241|FG000|Overall Study|Withdrawal by Subject|15
6265750|NCT02105948|9964242|FG001|Overall Study|Withdrawal by Subject|10
6265751|NCT02105948|9964243|FG002|Overall Study|Withdrawal by Subject|10
6265752|NCT02105948|9964244|FG003|Overall Study|Withdrawal by Subject|11
6265753|NCT02105961|9964258|FG000|Overall Study|Adverse Event|18
6265754|NCT02105961|9964259|FG001|Overall Study|Adverse Event|7
6265755|NCT02105961|9964260|FG002|Overall Study|Adverse Event|13
6265756|NCT02105961|9964258|FG000|Overall Study|Lack of Efficacy|3
6265757|NCT02105961|9964259|FG001|Overall Study|Lack of Efficacy|0
6265758|NCT02105961|9964260|FG002|Overall Study|Lack of Efficacy|3
6265759|NCT02105961|9964258|FG000|Overall Study|Lost to Follow-up|2
6265760|NCT02105961|9964259|FG001|Overall Study|Lost to Follow-up|0
6265761|NCT02105961|9964260|FG002|Overall Study|Lost to Follow-up|1
6265762|NCT02105961|9964258|FG000|Overall Study|Physician Decision|3
6265763|NCT02105961|9964259|FG001|Overall Study|Physician Decision|3
6265764|NCT02105961|9964260|FG002|Overall Study|Physician Decision|2
6265765|NCT02105961|9964258|FG000|Overall Study|Withdrawal by Subject|15
6265766|NCT02105961|9964259|FG001|Overall Study|Withdrawal by Subject|7
6265767|NCT02105961|9964260|FG002|Overall Study|Withdrawal by Subject|11
6265768|NCT02105974|9964271|FG000|2 Week Run-in Period|Withdrew during pre-screen period|158
6265769|NCT02105974|9964272|FG001|2 Week Run-in Period|Withdrew during pre-screen period|0
6265770|NCT02105974|9964273|FG002|2 Week Run-in Period|Withdrew during pre-screen period|0
6265771|NCT02105974|9964271|FG000|2 Week Run-in Period|Did not meet inclusion/exclusion criteri|603
6265772|NCT02105974|9964272|FG001|2 Week Run-in Period|Did not meet inclusion/exclusion criteri|0
6265773|NCT02105974|9964273|FG002|2 Week Run-in Period|Did not meet inclusion/exclusion criteri|0
6265774|NCT02105974|9964271|FG000|2 Week Run-in Period|Adverse Event|6
6265775|NCT02105974|9964272|FG001|2 Week Run-in Period|Adverse Event|0
6265776|NCT02105974|9964273|FG002|2 Week Run-in Period|Adverse Event|0
6265777|NCT02105974|9964271|FG000|2 Week Run-in Period|Study closed/terminated|1
6265778|NCT02105974|9964272|FG001|2 Week Run-in Period|Study closed/terminated|0
6265779|NCT02105974|9964273|FG002|2 Week Run-in Period|Study closed/terminated|0
6265780|NCT02105974|9964271|FG000|2 Week Run-in Period|Lost to Follow-up|2
6265781|NCT02105974|9964272|FG001|2 Week Run-in Period|Lost to Follow-up|0
6265782|NCT02105974|9964273|FG002|2 Week Run-in Period|Lost to Follow-up|0
6265783|NCT02105974|9964271|FG000|2 Week Run-in Period|Withdrew consent|23
6265784|NCT02105974|9964272|FG001|2 Week Run-in Period|Withdrew consent|0
6265785|NCT02105974|9964273|FG002|2 Week Run-in Period|Withdrew consent|0
6265786|NCT02105974|9964271|FG000|2 Week Run-in Period|Investigator discretion|8
6265787|NCT02105974|9964272|FG001|2 Week Run-in Period|Investigator discretion|0
6265788|NCT02105974|9964273|FG002|2 Week Run-in Period|Investigator discretion|0
6265789|NCT02105974|9964271|FG000|12 Week (Wk) Treatment Period (TP)|Adverse Event|0
6265790|NCT02105974|9964272|FG001|12 Week (Wk) Treatment Period (TP)|Adverse Event|14
6265791|NCT02105974|9964273|FG002|12 Week (Wk) Treatment Period (TP)|Adverse Event|18
6265792|NCT02105974|9964271|FG000|12 Week (Wk) Treatment Period (TP)|Lack of Efficacy|0
6265793|NCT02105974|9964272|FG001|12 Week (Wk) Treatment Period (TP)|Lack of Efficacy|6
6265794|NCT02105974|9964273|FG002|12 Week (Wk) Treatment Period (TP)|Lack of Efficacy|9
6265795|NCT02105974|9964271|FG000|12 Week (Wk) Treatment Period (TP)|Protocol deviation|0
6265796|NCT02105974|9964272|FG001|12 Week (Wk) Treatment Period (TP)|Protocol deviation|2
6265797|NCT02105974|9964273|FG002|12 Week (Wk) Treatment Period (TP)|Protocol deviation|6
6265798|NCT02105974|9964271|FG000|12 Week (Wk) Treatment Period (TP)|Participant reached stopping criteria|0
6265799|NCT02105974|9964272|FG001|12 Week (Wk) Treatment Period (TP)|Participant reached stopping criteria|1
6265800|NCT02105974|9964273|FG002|12 Week (Wk) Treatment Period (TP)|Participant reached stopping criteria|2
6265801|NCT02105974|9964271|FG000|12 Week (Wk) Treatment Period (TP)|Lost to Follow-up|0
6265802|NCT02105974|9964272|FG001|12 Week (Wk) Treatment Period (TP)|Lost to Follow-up|0
6265803|NCT02105974|9964273|FG002|12 Week (Wk) Treatment Period (TP)|Lost to Follow-up|1
6265804|NCT02105974|9964271|FG000|12 Week (Wk) Treatment Period (TP)|Physician Decision|0
6265805|NCT02105974|9964272|FG001|12 Week (Wk) Treatment Period (TP)|Physician Decision|7
6265806|NCT02105974|9964273|FG002|12 Week (Wk) Treatment Period (TP)|Physician Decision|4
6265807|NCT02105974|9964271|FG000|12 Week (Wk) Treatment Period (TP)|Withdrawal by Subject|0
6265808|NCT02105974|9964272|FG001|12 Week (Wk) Treatment Period (TP)|Withdrawal by Subject|12
6265809|NCT02105974|9964273|FG002|12 Week (Wk) Treatment Period (TP)|Withdrawal by Subject|18
6265810|NCT02105987|9964281|FG000|Early Switch Phase (24 Weeks)|Adverse Event|10
6265811|NCT02105987|9964282|FG001|Early Switch Phase (24 Weeks)|Adverse Event|0
6265812|NCT02105987|9964283|FG002|Early Switch Phase (24 Weeks)|Adverse Event|0
6265813|NCT02105987|9964284|FG003|Early Switch Phase (24 Weeks)|Adverse Event|0
6265814|NCT02105987|9964285|FG004|Early Switch Phase (24 Weeks)|Adverse Event|0
6265815|NCT02105987|9964286|FG005|Early Switch Phase (24 Weeks)|Adverse Event|0
6265816|NCT02105987|9964281|FG000|Early Switch Phase (24 Weeks)|Protocol Violation|15
6265817|NCT02105987|9964282|FG001|Early Switch Phase (24 Weeks)|Protocol Violation|17
6265818|NCT02105987|9964283|FG002|Early Switch Phase (24 Weeks)|Protocol Violation|0
6265819|NCT02105987|9964284|FG003|Early Switch Phase (24 Weeks)|Protocol Violation|0
6265820|NCT02105987|9964285|FG004|Early Switch Phase (24 Weeks)|Protocol Violation|0
6265821|NCT02105987|9964286|FG005|Early Switch Phase (24 Weeks)|Protocol Violation|0
6265822|NCT02105987|9964281|FG000|Early Switch Phase (24 Weeks)|Withdrawal by Subject|4
6265823|NCT02105987|9964282|FG001|Early Switch Phase (24 Weeks)|Withdrawal by Subject|10
6265824|NCT02105987|9964283|FG002|Early Switch Phase (24 Weeks)|Withdrawal by Subject|0
6265825|NCT02105987|9964284|FG003|Early Switch Phase (24 Weeks)|Withdrawal by Subject|0
6265826|NCT02105987|9964285|FG004|Early Switch Phase (24 Weeks)|Withdrawal by Subject|0
6265827|NCT02105987|9964286|FG005|Early Switch Phase (24 Weeks)|Withdrawal by Subject|0
6265828|NCT02105987|9964281|FG000|Early Switch Phase (24 Weeks)|Lost to Follow-up|3
6265829|NCT02105987|9964282|FG001|Early Switch Phase (24 Weeks)|Lost to Follow-up|3
6265830|NCT02105987|9964283|FG002|Early Switch Phase (24 Weeks)|Lost to Follow-up|0
6265831|NCT02105987|9964284|FG003|Early Switch Phase (24 Weeks)|Lost to Follow-up|0
6265832|NCT02105987|9964285|FG004|Early Switch Phase (24 Weeks)|Lost to Follow-up|0
6265833|NCT02105987|9964286|FG005|Early Switch Phase (24 Weeks)|Lost to Follow-up|0
6265834|NCT02105987|9964281|FG000|Early Switch Phase (24 Weeks)|Physician Decision|4
6265835|NCT02105987|9964282|FG001|Early Switch Phase (24 Weeks)|Physician Decision|3
6265836|NCT02105987|9964283|FG002|Early Switch Phase (24 Weeks)|Physician Decision|0
6265837|NCT02105987|9964284|FG003|Early Switch Phase (24 Weeks)|Physician Decision|0
6265838|NCT02105987|9964285|FG004|Early Switch Phase (24 Weeks)|Physician Decision|0
6265839|NCT02105987|9964286|FG005|Early Switch Phase (24 Weeks)|Physician Decision|0
6265840|NCT02105987|9964281|FG000|Early Switch Phase (24 Weeks)|Missing Disposition Data|0
6265841|NCT02105987|9964282|FG001|Early Switch Phase (24 Weeks)|Missing Disposition Data|1
6265842|NCT02105987|9964283|FG002|Early Switch Phase (24 Weeks)|Missing Disposition Data|0
6265843|NCT02105987|9964284|FG003|Early Switch Phase (24 Weeks)|Missing Disposition Data|0
6265844|NCT02105987|9964285|FG004|Early Switch Phase (24 Weeks)|Missing Disposition Data|0
6265845|NCT02105987|9964286|FG005|Early Switch Phase (24 Weeks)|Missing Disposition Data|0
6265846|NCT02105987|9964281|FG000|Late Switch Phase (24 Weeks)|Adverse Event|0
6265847|NCT02105987|9964282|FG001|Late Switch Phase (24 Weeks)|Adverse Event|0
6265848|NCT02105987|9964283|FG002|Late Switch Phase (24 Weeks)|Adverse Event|10
6265849|NCT02105987|9964284|FG003|Late Switch Phase (24 Weeks)|Adverse Event|4
6265850|NCT02105987|9964285|FG004|Late Switch Phase (24 Weeks)|Adverse Event|0
6265851|NCT02105987|9964286|FG005|Late Switch Phase (24 Weeks)|Adverse Event|0
6265852|NCT02105987|9964281|FG000|Late Switch Phase (24 Weeks)|Protocol Violation|0
6265853|NCT02105987|9964282|FG001|Late Switch Phase (24 Weeks)|Protocol Violation|0
6265854|NCT02105987|9964283|FG002|Late Switch Phase (24 Weeks)|Protocol Violation|15
6265855|NCT02105987|9964284|FG003|Late Switch Phase (24 Weeks)|Protocol Violation|1
6265856|NCT02105987|9964285|FG004|Late Switch Phase (24 Weeks)|Protocol Violation|0
6265857|NCT02105987|9964286|FG005|Late Switch Phase (24 Weeks)|Protocol Violation|0
6265858|NCT02105987|9964281|FG000|Late Switch Phase (24 Weeks)|Withdrawal by Subject|0
6265859|NCT02105987|9964282|FG001|Late Switch Phase (24 Weeks)|Withdrawal by Subject|0
6265860|NCT02105987|9964283|FG002|Late Switch Phase (24 Weeks)|Withdrawal by Subject|6
6265861|NCT02105987|9964284|FG003|Late Switch Phase (24 Weeks)|Withdrawal by Subject|5
6265862|NCT02105987|9964285|FG004|Late Switch Phase (24 Weeks)|Withdrawal by Subject|0
6265863|NCT02105987|9964286|FG005|Late Switch Phase (24 Weeks)|Withdrawal by Subject|0
6265864|NCT02105987|9964281|FG000|Late Switch Phase (24 Weeks)|Lost to Follow-up|0
6271912|NCT02169284|9974023|FG001|Overall Study|Physician Decision|1
6265865|NCT02105987|9964282|FG001|Late Switch Phase (24 Weeks)|Lost to Follow-up|0
6265866|NCT02105987|9964283|FG002|Late Switch Phase (24 Weeks)|Lost to Follow-up|8
6265867|NCT02105987|9964284|FG003|Late Switch Phase (24 Weeks)|Lost to Follow-up|3
6265868|NCT02105987|9964285|FG004|Late Switch Phase (24 Weeks)|Lost to Follow-up|0
6265869|NCT02105987|9964286|FG005|Late Switch Phase (24 Weeks)|Lost to Follow-up|0
6265870|NCT02105987|9964281|FG000|Late Switch Phase (24 Weeks)|Physician Decision|0
6265871|NCT02105987|9964282|FG001|Late Switch Phase (24 Weeks)|Physician Decision|0
6265872|NCT02105987|9964283|FG002|Late Switch Phase (24 Weeks)|Physician Decision|5
6265873|NCT02105987|9964284|FG003|Late Switch Phase (24 Weeks)|Physician Decision|0
6265874|NCT02105987|9964285|FG004|Late Switch Phase (24 Weeks)|Physician Decision|0
6265875|NCT02105987|9964286|FG005|Late Switch Phase (24 Weeks)|Physician Decision|0
6265876|NCT02105987|9964281|FG000|Late Switch Phase (24 Weeks)|met protocol defined stopping criteria|0
6265877|NCT02105987|9964282|FG001|Late Switch Phase (24 Weeks)|met protocol defined stopping criteria|0
6265878|NCT02105987|9964283|FG002|Late Switch Phase (24 Weeks)|met protocol defined stopping criteria|0
6265879|NCT02105987|9964284|FG003|Late Switch Phase (24 Weeks)|met protocol defined stopping criteria|1
6265880|NCT02105987|9964285|FG004|Late Switch Phase (24 Weeks)|met protocol defined stopping criteria|0
6265881|NCT02105987|9964286|FG005|Late Switch Phase (24 Weeks)|met protocol defined stopping criteria|0
6265882|NCT02105987|9964281|FG000|Late Switch Phase (24 Weeks)|Per sponsor request|0
6265883|NCT02105987|9964282|FG001|Late Switch Phase (24 Weeks)|Per sponsor request|0
6265884|NCT02105987|9964283|FG002|Late Switch Phase (24 Weeks)|Per sponsor request|1
6265885|NCT02105987|9964284|FG003|Late Switch Phase (24 Weeks)|Per sponsor request|0
6265886|NCT02105987|9964285|FG004|Late Switch Phase (24 Weeks)|Per sponsor request|0
6265887|NCT02105987|9964286|FG005|Late Switch Phase (24 Weeks)|Per sponsor request|0
6265888|NCT02105987|9964281|FG000|Continuation Phase|Protocol Violation|0
6265889|NCT02105987|9964282|FG001|Continuation Phase|Protocol Violation|0
6265890|NCT02105987|9964283|FG002|Continuation Phase|Protocol Violation|0
6265891|NCT02105987|9964284|FG003|Continuation Phase|Protocol Violation|0
6265892|NCT02105987|9964285|FG004|Continuation Phase|Protocol Violation|1
6265893|NCT02105987|9964286|FG005|Continuation Phase|Protocol Violation|0
6265894|NCT02106156|9964308|FG000|Overall Study|Patient Died|19
6265895|NCT02106156|9964309|FG001|Overall Study|Patient Died|0
6265896|NCT02106156|9964310|FG002|Overall Study|Patient Died|0
6265897|NCT02106156|9964308|FG000|Overall Study|Lack of Tolerability|305
6265898|NCT02106156|9964309|FG001|Overall Study|Lack of Tolerability|3
6265899|NCT02106156|9964310|FG002|Overall Study|Lack of Tolerability|0
6265900|NCT02106156|9964308|FG000|Overall Study|Lack of Virological Response|1044
6265901|NCT02106156|9964309|FG001|Overall Study|Lack of Virological Response|8
6265902|NCT02106156|9964310|FG002|Overall Study|Lack of Virological Response|0
6265903|NCT02106156|9964308|FG000|Overall Study|Concomitant Disease|74
6265904|NCT02106156|9964309|FG001|Overall Study|Concomitant Disease|2
6265905|NCT02106156|9964310|FG002|Overall Study|Concomitant Disease|0
6265906|NCT02106156|9964308|FG000|Overall Study|Lack of Compliance|211
6265907|NCT02106156|9964309|FG001|Overall Study|Lack of Compliance|7
6265908|NCT02106156|9964310|FG002|Overall Study|Lack of Compliance|0
6265909|NCT02106156|9964308|FG000|Overall Study|Patients Request|307
6265910|NCT02106156|9964309|FG001|Overall Study|Patients Request|9
6265911|NCT02106156|9964310|FG002|Overall Study|Patients Request|0
6265912|NCT02106156|9964308|FG000|Overall Study|Lost to Follow-up|451
6265913|NCT02106156|9964309|FG001|Overall Study|Lost to Follow-up|8
6265914|NCT02106156|9964310|FG002|Overall Study|Lost to Follow-up|0
6265915|NCT02106156|9964308|FG000|Overall Study|Unplanned Event|82
6265916|NCT02106156|9964309|FG001|Overall Study|Unplanned Event|2
6265917|NCT02106156|9964310|FG002|Overall Study|Unplanned Event|0
6265918|NCT02106156|9964308|FG000|Overall Study|Change of Laboratory Parameter|10
6265919|NCT02106156|9964309|FG001|Overall Study|Change of Laboratory Parameter|0
6265920|NCT02106156|9964310|FG002|Overall Study|Change of Laboratory Parameter|0
6265921|NCT02106156|9964308|FG000|Overall Study|Hospitalization/Surgical Intervention|6
6265922|NCT02106156|9964309|FG001|Overall Study|Hospitalization/Surgical Intervention|0
6265923|NCT02106156|9964310|FG002|Overall Study|Hospitalization/Surgical Intervention|0
6265924|NCT02106156|9964308|FG000|Overall Study|Relocation/Change of Physician|40
6265925|NCT02106156|9964309|FG001|Overall Study|Relocation/Change of Physician|1
6265926|NCT02106156|9964310|FG002|Overall Study|Relocation/Change of Physician|0
6265927|NCT02106325|9964319|FG000|Phase 1|Lost to Follow-up|2
6265928|NCT02106325|9964320|FG001|Phase 1|Lost to Follow-up|2
6265929|NCT02106325|9964319|FG000|Phase 2|Lost to Follow-up|2
6265930|NCT02106325|9964320|FG001|Phase 2|Lost to Follow-up|3
6265931|NCT02106325|9964319|FG000|Phase 3|Lost to Follow-up|2
6265932|NCT02106325|9964320|FG001|Phase 3|Lost to Follow-up|1
6265933|NCT02106351|9964329|FG000|Treatment Cycle 1|Adverse Event|2
6265934|NCT02106351|9964330|FG001|Treatment Cycle 1|Adverse Event|0
6265935|NCT02106351|9964331|FG002|Treatment Cycle 1|Adverse Event|0
6265936|NCT02106351|9964329|FG000|Treatment Cycle 1|Consent withdrawn|1
6265937|NCT02106351|9964330|FG001|Treatment Cycle 1|Consent withdrawn|0
6265938|NCT02106351|9964331|FG002|Treatment Cycle 1|Consent withdrawn|2
6265939|NCT02106351|9964329|FG000|Treatment Cycle 1|Lost to Follow-up|1
6265940|NCT02106351|9964330|FG001|Treatment Cycle 1|Lost to Follow-up|0
6265941|NCT02106351|9964331|FG002|Treatment Cycle 1|Lost to Follow-up|0
6265942|NCT02106351|9964329|FG000|Treatment Cycle 1|Other|0
6265943|NCT02106351|9964330|FG001|Treatment Cycle 1|Other|3
6265944|NCT02106351|9964331|FG002|Treatment Cycle 1|Other|1
6265945|NCT02106351|9964329|FG000|Treatment Cycle 1|Randomised but not treated|1
6265946|NCT02106351|9964330|FG001|Treatment Cycle 1|Randomised but not treated|0
6265947|NCT02106351|9964331|FG002|Treatment Cycle 1|Randomised but not treated|1
6265948|NCT02106351|9964329|FG000|Treatment Cycle 2|Adverse Event|0
6265949|NCT02106351|9964330|FG001|Treatment Cycle 2|Adverse Event|2
6265950|NCT02106351|9964331|FG002|Treatment Cycle 2|Adverse Event|0
6265951|NCT02106351|9964329|FG000|Treatment Cycle 2|Consent withdrawn|0
6265952|NCT02106351|9964330|FG001|Treatment Cycle 2|Consent withdrawn|1
6265953|NCT02106351|9964331|FG002|Treatment Cycle 2|Consent withdrawn|1
6265954|NCT02106351|9964329|FG000|Treatment Cycle 2|Other|0
6265955|NCT02106351|9964330|FG001|Treatment Cycle 2|Other|2
6265956|NCT02106351|9964331|FG002|Treatment Cycle 2|Other|2
6265957|NCT02106351|9964329|FG000|Treatment Cycle 3|Adverse Event|0
6265958|NCT02106351|9964330|FG001|Treatment Cycle 3|Adverse Event|1
6265959|NCT02106351|9964331|FG002|Treatment Cycle 3|Adverse Event|0
6265960|NCT02106351|9964329|FG000|Treatment Cycle 3|Consent withdrawn|0
6265961|NCT02106351|9964330|FG001|Treatment Cycle 3|Consent withdrawn|0
6265962|NCT02106351|9964331|FG002|Treatment Cycle 3|Consent withdrawn|2
6265963|NCT02106351|9964329|FG000|Treatment Cycle 3|Lost to Follow-up|0
6265964|NCT02106351|9964330|FG001|Treatment Cycle 3|Lost to Follow-up|1
6265965|NCT02106351|9964331|FG002|Treatment Cycle 3|Lost to Follow-up|0
6265966|NCT02106351|9964329|FG000|Treatment Cycle 3|Other|0
6265967|NCT02106351|9964330|FG001|Treatment Cycle 3|Other|2
6265968|NCT02106351|9964331|FG002|Treatment Cycle 3|Other|3
6265969|NCT02106351|9964329|FG000|Treatment Cycle 4|Consent withdrawn|0
6265970|NCT02106351|9964330|FG001|Treatment Cycle 4|Consent withdrawn|0
6265971|NCT02106351|9964331|FG002|Treatment Cycle 4|Consent withdrawn|2
6265972|NCT02106351|9964329|FG000|Treatment Cycle 4|Other|0
6265973|NCT02106351|9964330|FG001|Treatment Cycle 4|Other|1
6265974|NCT02106351|9964331|FG002|Treatment Cycle 4|Other|0
6265975|NCT02106390|9964348|FG000|Overall Study|Withdrawal by Subject|15
6265976|NCT02106390|9964349|FG001|Overall Study|Withdrawal by Subject|16
6265977|NCT02106390|9964350|FG002|Overall Study|Withdrawal by Subject|15
6265978|NCT02106390|9964348|FG000|Overall Study|Lost to Follow-up|25
6265979|NCT02106390|9964349|FG001|Overall Study|Lost to Follow-up|20
6265980|NCT02106390|9964350|FG002|Overall Study|Lost to Follow-up|13
6265981|NCT02106390|9964348|FG000|Overall Study|Other: Administrative Reason|8
6265982|NCT02106390|9964349|FG001|Overall Study|Other: Administrative Reason|5
6265983|NCT02106390|9964350|FG002|Overall Study|Other: Administrative Reason|12
6265984|NCT02106390|9964348|FG000|Overall Study|Other: Unspecified|1
6265985|NCT02106390|9964349|FG001|Overall Study|Other: Unspecified|4
6265986|NCT02106390|9964350|FG002|Overall Study|Other: Unspecified|2
6265987|NCT02106390|9964348|FG000|Overall Study|Adverse Event|0
6265988|NCT02106390|9964349|FG001|Overall Study|Adverse Event|2
6265989|NCT02106390|9964350|FG002|Overall Study|Adverse Event|1
6265990|NCT02106390|9964348|FG000|Overall Study|Protocol Violation|0
6265991|NCT02106390|9964349|FG001|Overall Study|Protocol Violation|1
6265992|NCT02106390|9964350|FG002|Overall Study|Protocol Violation|0
6265993|NCT02106403|9964361|FG000|Follow-Up Visit 3|Other Reason|0
6265994|NCT02106403|9964362|FG001|Follow-Up Visit 3|Other Reason|0
6265995|NCT02106403|9964363|FG002|Follow-Up Visit 3|Other Reason|0
6265996|NCT02106403|9964364|FG003|Follow-Up Visit 3|Other Reason|0
6265997|NCT02106403|9964365|FG004|Follow-Up Visit 3|Other Reason|0
6265998|NCT02106403|9964366|FG005|Follow-Up Visit 3|Other Reason|1
6265999|NCT02106442|9964376|FG000|Overall Study|Case Report Forms Uncollected|7
6266000|NCT02106442|9964376|FG000|Overall Study|Protocol Deviation|30
6266001|NCT02106455|9964380|FG000|Overall Study|Case Report Form Uncollected|6
6266002|NCT02106455|9964380|FG000|Overall Study|Protocol Deviation|2
6266003|NCT02106832|9964414|FG000|Overall Study|Adverse Event|1
6266004|NCT02106832|9964415|FG001|Overall Study|Adverse Event|2
6266005|NCT02106832|9964416|FG002|Overall Study|Adverse Event|3
6266006|NCT02106832|9964417|FG003|Overall Study|Adverse Event|0
6266007|NCT02106832|9964414|FG000|Overall Study|Death|4
6266008|NCT02106832|9964415|FG001|Overall Study|Death|4
6266009|NCT02106832|9964416|FG002|Overall Study|Death|1
6266010|NCT02106832|9964417|FG003|Overall Study|Death|4
6266011|NCT02106832|9964414|FG000|Overall Study|Deterioration of general conditions|0
6266012|NCT02106832|9964415|FG001|Overall Study|Deterioration of general conditions|0
6266013|NCT02106832|9964416|FG002|Overall Study|Deterioration of general conditions|1
6266014|NCT02106832|9964417|FG003|Overall Study|Deterioration of general conditions|0
6266015|NCT02106832|9964414|FG000|Overall Study|Lost to Follow-up|0
6266016|NCT02106832|9964415|FG001|Overall Study|Lost to Follow-up|1
6266017|NCT02106832|9964416|FG002|Overall Study|Lost to Follow-up|1
6266018|NCT02106832|9964417|FG003|Overall Study|Lost to Follow-up|3
6266019|NCT02106832|9964414|FG000|Overall Study|Physician Decision|1
6266020|NCT02106832|9964415|FG001|Overall Study|Physician Decision|0
6266021|NCT02106832|9964416|FG002|Overall Study|Physician Decision|0
6266022|NCT02106832|9964417|FG003|Overall Study|Physician Decision|0
6266023|NCT02106832|9964414|FG000|Overall Study|Protocol Violation|0
6266024|NCT02106832|9964415|FG001|Overall Study|Protocol Violation|0
6266025|NCT02106832|9964416|FG002|Overall Study|Protocol Violation|0
6266026|NCT02106832|9964417|FG003|Overall Study|Protocol Violation|1
6266027|NCT02106832|9964414|FG000|Overall Study|Withdrawal by Subject|17
6266028|NCT02106832|9964415|FG001|Overall Study|Withdrawal by Subject|17
6266029|NCT02106832|9964416|FG002|Overall Study|Withdrawal by Subject|10
6266030|NCT02106832|9964417|FG003|Overall Study|Withdrawal by Subject|7
6266031|NCT02106832|9964414|FG000|Overall Study|Technical problems|0
6266032|NCT02106832|9964415|FG001|Overall Study|Technical problems|1
6266033|NCT02106832|9964416|FG002|Overall Study|Technical problems|0
6266034|NCT02106832|9964417|FG003|Overall Study|Technical problems|0
6266035|NCT02106884|9964431|FG000|Overall Study|Change of diagnosis/exclusion|0
6266036|NCT02106884|9964432|FG001|Overall Study|Change of diagnosis/exclusion|1
6266037|NCT02106910|9964443|FG000|Overall Study|Lost to Follow-up|1
6266038|NCT02106910|9964444|FG001|Overall Study|Lost to Follow-up|1
6266039|NCT02106923|9964454|FG000|Overall Study|Protocol Violation|0
6266040|NCT02106923|9964455|FG001|Overall Study|Protocol Violation|0
6266041|NCT02106923|9964456|FG002|Overall Study|Protocol Violation|0
6266042|NCT02106923|9964457|FG003|Overall Study|Protocol Violation|0
6266043|NCT02106923|9964458|FG004|Overall Study|Protocol Violation|0
6266044|NCT02106923|9964459|FG005|Overall Study|Protocol Violation|1
6266045|NCT02106975|9964486|FG000|Overall Study|Death|25
6266046|NCT02106975|9964487|FG001|Overall Study|Death|39
6266047|NCT02107014|9964493|FG000|Overall Study|Withdrew before drug: moving interstate|1
6266048|NCT02107092|9964497|FG000|Overall Study|Miscellaneous|3
6266049|NCT02107092|9964497|FG000|Overall Study|Subject compliance|3
6266050|NCT02107092|9964497|FG000|Overall Study|Hypo-or hyperkalemia|2
6266051|NCT02107092|9964497|FG000|Overall Study|Met ECG withdrawal criteria|3
6266052|NCT02107092|9964497|FG000|Overall Study|Physician Decision|3
6266053|NCT02107092|9964497|FG000|Overall Study|Lost to Follow-up|2
6266054|NCT02107092|9964497|FG000|Overall Study|Withdrawal by Subject|9
6266055|NCT02107092|9964497|FG000|Overall Study|Adverse Event|7
6266056|NCT02107092|9964497|FG000|Overall Study|Expected progression of CKD|12
6266057|NCT02107131|9964503|FG000|Overall Study|Lost to Follow-up|4
6266058|NCT02107131|9964504|FG001|Overall Study|Lost to Follow-up|4
6266059|NCT02107131|9964503|FG000|Overall Study|Physician Decision|1
6266060|NCT02107131|9964504|FG001|Overall Study|Physician Decision|0
6266061|NCT02107131|9964503|FG000|Overall Study|Withdrawal by Subject|2
6266062|NCT02107131|9964504|FG001|Overall Study|Withdrawal by Subject|0
6266063|NCT02107131|9964503|FG000|Overall Study|mental instability|1
6266064|NCT02107131|9964504|FG001|Overall Study|mental instability|0
6266065|NCT02107131|9964503|FG000|Overall Study|Death|0
6266066|NCT02107131|9964504|FG001|Overall Study|Death|1
6266067|NCT02107131|9964503|FG000|Overall Study|Protocol Violation|0
6266068|NCT02107131|9964504|FG001|Overall Study|Protocol Violation|4
6266069|NCT02107196|9964527|FG000|12-week Treatment Period|Adverse Event|6
6266070|NCT02107196|9964528|FG001|12-week Treatment Period|Adverse Event|3
6266071|NCT02107196|9964527|FG000|12-week Treatment Period|Lack of Efficacy|2
6266072|NCT02107196|9964528|FG001|12-week Treatment Period|Lack of Efficacy|1
6266073|NCT02107196|9964527|FG000|12-week Treatment Period|Lost to Follow-up|3
6266074|NCT02107196|9964528|FG001|12-week Treatment Period|Lost to Follow-up|6
6266075|NCT02107196|9964527|FG000|12-week Treatment Period|Physician Decision|0
6266076|NCT02107196|9964528|FG001|12-week Treatment Period|Physician Decision|1
6266077|NCT02107196|9964527|FG000|12-week Treatment Period|Withdrawal by Subject|15
6266078|NCT02107196|9964528|FG001|12-week Treatment Period|Withdrawal by Subject|12
6266079|NCT02107196|9964527|FG000|12-week Treatment Period|Protocol Violation|7
6266080|NCT02107196|9964528|FG001|12-week Treatment Period|Protocol Violation|8
6266081|NCT02107196|9964527|FG000|12-week Treatment Period|Reason Missing|11
6266082|NCT02107196|9964528|FG001|12-week Treatment Period|Reason Missing|8
6266083|NCT02107196|9964527|FG000|4-week Randomized Withdrawal (RW) Period|Adverse Event|2
6266084|NCT02107196|9964528|FG001|4-week Randomized Withdrawal (RW) Period|Adverse Event|0
6266085|NCT02107196|9964527|FG000|4-week Randomized Withdrawal (RW) Period|Withdrawal by Subject|1
6266086|NCT02107196|9964528|FG001|4-week Randomized Withdrawal (RW) Period|Withdrawal by Subject|0
6266087|NCT02107196|9964527|FG000|4-week Randomized Withdrawal (RW) Period|Protocol Violation|2
6266088|NCT02107196|9964528|FG001|4-week Randomized Withdrawal (RW) Period|Protocol Violation|0
6266089|NCT02107196|9964527|FG000|4-week Randomized Withdrawal (RW) Period|Reason Missing|18
6266090|NCT02107196|9964528|FG001|4-week Randomized Withdrawal (RW) Period|Reason Missing|5
6266091|NCT02107274|9964536|FG000|Treatment vs. Placebo|Adverse Event|3
6266092|NCT02107274|9964537|FG001|Treatment vs. Placebo|Adverse Event|0
6266093|NCT02107274|9964536|FG000|Treatment vs. Placebo|Lost to Follow-up|0
6266094|NCT02107274|9964537|FG001|Treatment vs. Placebo|Lost to Follow-up|2
6266095|NCT02107274|9964536|FG000|Control Phase|Lost to Follow-up|1
6266096|NCT02107274|9964537|FG001|Control Phase|Lost to Follow-up|1
6266097|NCT02107274|9964536|FG000|Control Phase|Death|2
6266098|NCT02107274|9964537|FG001|Control Phase|Death|0
6266099|NCT02107274|9964536|FG000|Control Phase|Adverse Event|0
6266100|NCT02107274|9964537|FG001|Control Phase|Adverse Event|1
6266101|NCT02107313|9964552|FG000|Overall Study|One participant did not do the FED cohor|0
6266102|NCT02107313|9964553|FG001|Overall Study|One participant did not do the FED cohor|1
6266103|NCT02107443|9964570|FG000|Overall Study|Death|42
6266104|NCT02107443|9964571|FG001|Overall Study|Death|30
6266105|NCT02107443|9964570|FG000|Overall Study|Study Protocol Violation|3
6266106|NCT02107443|9964571|FG001|Overall Study|Study Protocol Violation|1
6266107|NCT02107443|9964570|FG000|Overall Study|Registered but Not Eligible|0
6266108|NCT02107443|9964571|FG001|Overall Study|Registered but Not Eligible|1
6266109|NCT02107443|9964570|FG000|Overall Study|Withdrawal: Hospitalization/Hospice|28
6266110|NCT02107443|9964571|FG001|Overall Study|Withdrawal: Hospitalization/Hospice|28
6266111|NCT02107443|9964570|FG000|Overall Study|Withdrawal: Disliked Study Procedures|1
6266112|NCT02107443|9964571|FG001|Overall Study|Withdrawal: Disliked Study Procedures|2
6266113|NCT02107443|9964570|FG000|Overall Study|Withdrawal: Changed Mind|2
6266114|NCT02107443|9964571|FG001|Overall Study|Withdrawal: Changed Mind|0
6266115|NCT02107443|9964570|FG000|Overall Study|Withdrawal: Changed MD/Facility|1
6266116|NCT02107443|9964571|FG001|Overall Study|Withdrawal: Changed MD/Facility|3
6266117|NCT02107443|9964570|FG000|Overall Study|Withdrawal: Too Many Forms|3
6266118|NCT02107443|9964571|FG001|Overall Study|Withdrawal: Too Many Forms|1
6266119|NCT02107443|9964570|FG000|Overall Study|Withdrawal: Too Time Consuming|3
6266120|NCT02107443|9964571|FG001|Overall Study|Withdrawal: Too Time Consuming|6
6266121|NCT02107443|9964570|FG000|Overall Study|Withdrawal: Feeling Overwhelmed|2
6266122|NCT02107443|9964571|FG001|Overall Study|Withdrawal: Feeling Overwhelmed|1
6266123|NCT02107443|9964570|FG000|Overall Study|Withdrawal: Other Medical|9
6266124|NCT02107443|9964571|FG001|Overall Study|Withdrawal: Other Medical|5
6266125|NCT02107443|9964570|FG000|Overall Study|Withdrawal: Disease Progression|4
6266126|NCT02107443|9964571|FG001|Overall Study|Withdrawal: Disease Progression|2
6266127|NCT02107443|9964570|FG000|Overall Study|Withdrawal: Personal Issues|0
6266128|NCT02107443|9964571|FG001|Overall Study|Withdrawal: Personal Issues|3
6266129|NCT02107482|9964578|FG000|Overall Study|inconveinence|2
6266130|NCT02107482|9964578|FG000|Overall Study|Lost to Follow-up|1
6266131|NCT02107482|9964578|FG000|Overall Study|Lack of Efficacy|1
6266132|NCT02107703|9964591|FG000|Overall Study|Withdrawal by Subject|36
6266133|NCT02107703|9964592|FG001|Overall Study|Withdrawal by Subject|19
6266134|NCT02107703|9964591|FG000|Overall Study|Lost to Follow-up|6
6266135|NCT02107703|9964592|FG001|Overall Study|Lost to Follow-up|4
6266136|NCT02107703|9964591|FG000|Overall Study|On study treatment/follow up|319
6266137|NCT02107703|9964592|FG001|Overall Study|On study treatment/follow up|152
6266138|NCT02107859|9964601|FG000|Overall Study|Withdrawal by Subject|14
6266139|NCT02107859|9964601|FG000|Overall Study|Adverse Event|3
6266140|NCT02107859|9964601|FG000|Overall Study|Study closure|41
6266141|NCT02107859|9964601|FG000|Overall Study|Other than specified|3
6266142|NCT02107898|9964607|FG000|Overall Study|Adverse Event|4
6266143|NCT02107898|9964608|FG001|Overall Study|Adverse Event|7
6266144|NCT02107898|9964607|FG000|Overall Study|Poor compliance to protocol|0
6266145|NCT02107898|9964608|FG001|Overall Study|Poor compliance to protocol|1
6266146|NCT02107898|9964607|FG000|Overall Study|Participant moved|0
6266147|NCT02107898|9964608|FG001|Overall Study|Participant moved|2
6266148|NCT02107898|9964607|FG000|Overall Study|Consent withdrawn by participant|2
6266149|NCT02107898|9964608|FG001|Overall Study|Consent withdrawn by participant|1
6266150|NCT02107898|9964607|FG000|Overall Study|Randomized but not treated|0
6266151|NCT02107898|9964608|FG001|Overall Study|Randomized but not treated|1
6266152|NCT02108262|9964644|FG000|Overall Study|Non-compliance|0
6266153|NCT02108262|9964645|FG001|Overall Study|Non-compliance|2
6266154|NCT02108262|9964646|FG002|Overall Study|Non-compliance|1
6266155|NCT02108262|9964647|FG003|Overall Study|Non-compliance|1
6266156|NCT02108262|9964644|FG000|Overall Study|Randomized by error/screen failure|0
6266157|NCT02108262|9964645|FG001|Overall Study|Randomized by error/screen failure|0
6266158|NCT02108262|9964646|FG002|Overall Study|Randomized by error/screen failure|1
6266159|NCT02108262|9964647|FG003|Overall Study|Randomized by error/screen failure|0
6266160|NCT02108262|9964644|FG000|Overall Study|Distance to center|0
6266161|NCT02108262|9964645|FG001|Overall Study|Distance to center|1
6266162|NCT02108262|9964646|FG002|Overall Study|Distance to center|1
6266163|NCT02108262|9964647|FG003|Overall Study|Distance to center|0
6266164|NCT02108262|9964644|FG000|Overall Study|Adverse Event|0
6266165|NCT02108262|9964645|FG001|Overall Study|Adverse Event|11
6266166|NCT02108262|9964646|FG002|Overall Study|Adverse Event|6
6266167|NCT02108262|9964647|FG003|Overall Study|Adverse Event|12
6266168|NCT02108262|9964644|FG000|Overall Study|Death|0
6266169|NCT02108262|9964645|FG001|Overall Study|Death|2
6266170|NCT02108262|9964646|FG002|Overall Study|Death|2
6266171|NCT02108262|9964647|FG003|Overall Study|Death|1
6266172|NCT02108262|9964644|FG000|Overall Study|Lost to Follow-up|0
6266173|NCT02108262|9964645|FG001|Overall Study|Lost to Follow-up|0
6266174|NCT02108262|9964646|FG002|Overall Study|Lost to Follow-up|1
6266175|NCT02108262|9964647|FG003|Overall Study|Lost to Follow-up|0
6266176|NCT02108262|9964644|FG000|Overall Study|Physician Decision|0
6266177|NCT02108262|9964645|FG001|Overall Study|Physician Decision|0
6266178|NCT02108262|9964646|FG002|Overall Study|Physician Decision|2
6266179|NCT02108262|9964647|FG003|Overall Study|Physician Decision|0
6266180|NCT02108262|9964644|FG000|Overall Study|Withdrawal by Subject|0
6266181|NCT02108262|9964645|FG001|Overall Study|Withdrawal by Subject|7
6266182|NCT02108262|9964646|FG002|Overall Study|Withdrawal by Subject|3
6266183|NCT02108262|9964647|FG003|Overall Study|Withdrawal by Subject|4
6266184|NCT02108262|9964644|FG000|Overall Study|Due to key hepatic values|0
6266185|NCT02108262|9964645|FG001|Overall Study|Due to key hepatic values|1
6266186|NCT02108262|9964646|FG002|Overall Study|Due to key hepatic values|0
6266187|NCT02108262|9964647|FG003|Overall Study|Due to key hepatic values|0
6266188|NCT02108262|9964644|FG000|Overall Study|Unable to contact patient|0
6266189|NCT02108262|9964645|FG001|Overall Study|Unable to contact patient|3
6266190|NCT02108262|9964646|FG002|Overall Study|Unable to contact patient|1
6266191|NCT02108262|9964647|FG003|Overall Study|Unable to contact patient|2
6266192|NCT02108262|9964644|FG000|Overall Study|Patient unable to come to site/attend visit|0
6266193|NCT02108262|9964645|FG001|Overall Study|Patient unable to come to site/attend visit|6
6266194|NCT02108262|9964646|FG002|Overall Study|Patient unable to come to site/attend visit|11
6266195|NCT02108262|9964647|FG003|Overall Study|Patient unable to come to site/attend visit|6
6266196|NCT02108262|9964644|FG000|Overall Study|Patient did not want another infusion|0
6266197|NCT02108262|9964645|FG001|Overall Study|Patient did not want another infusion|3
6266198|NCT02108262|9964646|FG002|Overall Study|Patient did not want another infusion|3
6266199|NCT02108262|9964647|FG003|Overall Study|Patient did not want another infusion|2
6266200|NCT02108262|9964644|FG000|Overall Study|Vacation|0
6266201|NCT02108262|9964645|FG001|Overall Study|Vacation|1
6266202|NCT02108262|9964646|FG002|Overall Study|Vacation|0
6266203|NCT02108262|9964647|FG003|Overall Study|Vacation|0
6266204|NCT02108262|9964644|FG000|Overall Study|Patient decision|0
6266205|NCT02108262|9964645|FG001|Overall Study|Patient decision|7
6266206|NCT02108262|9964646|FG002|Overall Study|Patient decision|9
6266207|NCT02108262|9964647|FG003|Overall Study|Patient decision|14
6266208|NCT02108262|9964644|FG000|Overall Study|Missed IV due to pharmacy error|0
6266209|NCT02108262|9964645|FG001|Overall Study|Missed IV due to pharmacy error|0
6266210|NCT02108262|9964646|FG002|Overall Study|Missed IV due to pharmacy error|1
6266211|NCT02108262|9964647|FG003|Overall Study|Missed IV due to pharmacy error|0
6271619|NCT02164981|9973448|FG000|Phase 2 (Day 14 - Day 28)|Protocol Violation|0
6271620|NCT02164981|9973449|FG001|Phase 2 (Day 14 - Day 28)|Protocol Violation|1
6271621|NCT02164981|9973450|FG002|Phase 2 (Day 14 - Day 28)|Protocol Violation|0
6271622|NCT02165202|9973492|FG000|Oral Phase|Refused further participation|5
6271623|NCT02165202|9973493|FG001|Oral Phase|Refused further participation|1
6271624|NCT02165202|9973492|FG000|Oral Phase|Study product Related Toxicity|1
6271625|NCT02165202|9973493|FG001|Oral Phase|Study product Related Toxicity|0
6271626|NCT02165202|9973492|FG000|Oral Phase|Unable to contact Participant|1
6271627|NCT02165202|9973493|FG001|Oral Phase|Unable to contact Participant|1
6271628|NCT02165202|9973492|FG000|Oral Phase|Clinical reasons|1
6271629|NCT02165202|9973493|FG001|Oral Phase|Clinical reasons|0
6271630|NCT02165202|9973492|FG000|Oral Phase|QTcF>500 ms or increase of>60 ms|1
6271631|NCT02165202|9973493|FG001|Oral Phase|QTcF>500 ms or increase of>60 ms|0
6271632|NCT02165202|9973492|FG000|Oral Phase|CMC advised termination|1
6271633|NCT02165202|9973493|FG001|Oral Phase|CMC advised termination|0
6271634|NCT02165202|9973492|FG000|Oral Phase|Relocated, no follow-up planned|1
6271635|NCT02165202|9973493|FG001|Oral Phase|Relocated, no follow-up planned|0
6271636|NCT02165202|9973492|FG000|Oral Phase|Abnormal EKG|0
6271637|NCT02165202|9973493|FG001|Oral Phase|Abnormal EKG|1
6271638|NCT02165202|9973492|FG000|Injection Phase|Abnormal Lab Value|5
6271639|NCT02165202|9973493|FG001|Injection Phase|Abnormal Lab Value|1
6271640|NCT02165202|9973492|FG000|Injection Phase|Reactive HIV or HIV Suspected|0
6271641|NCT02165202|9973493|FG001|Injection Phase|Reactive HIV or HIV Suspected|2
6271642|NCT02165202|9973492|FG000|Injection Phase|Unable to attend within Visit Window|1
6271643|NCT02165202|9973493|FG001|Injection Phase|Unable to attend within Visit Window|0
6271644|NCT02165202|9973492|FG000|Injection Phase|QTcF>500 ms or increase of>60 ms|0
6271645|NCT02165202|9973493|FG001|Injection Phase|QTcF>500 ms or increase of>60 ms|1
6271646|NCT02165202|9973492|FG000|Injection Phase|End of Study|2
6271647|NCT02165202|9973493|FG001|Injection Phase|End of Study|1
6271648|NCT02165202|9973492|FG000|Injection Phase|Study Product related Toxicity|1
6271649|NCT02165202|9973493|FG001|Injection Phase|Study Product related Toxicity|0
6271650|NCT02165202|9973492|FG000|Injection Phase|No longer interested|0
6271651|NCT02165202|9973493|FG001|Injection Phase|No longer interested|1
6271652|NCT02165202|9973492|FG000|Injection Phase|Participant unwilling to comply|1
6271653|NCT02165202|9973493|FG001|Injection Phase|Participant unwilling to comply|0
6271654|NCT02165397|9973506|FG000|Overall Study|Death|7
6271655|NCT02165397|9973507|FG001|Overall Study|Death|10
6271656|NCT02165397|9973508|FG002|Overall Study|Death|8
6271657|NCT02165397|9973506|FG000|Overall Study|Lost to Follow-up|1
6271658|NCT02165397|9973507|FG001|Overall Study|Lost to Follow-up|3
6271659|NCT02165397|9973508|FG002|Overall Study|Lost to Follow-up|0
6271660|NCT02165397|9973506|FG000|Overall Study|Withdrawal by Subject|6
6271661|NCT02165397|9973507|FG001|Overall Study|Withdrawal by Subject|6
6271662|NCT02165397|9973508|FG002|Overall Study|Withdrawal by Subject|1
6271663|NCT02165397|9973506|FG000|Overall Study|Other, Not Specified|0
6271664|NCT02165397|9973507|FG001|Overall Study|Other, Not Specified|0
6271665|NCT02165397|9973508|FG002|Overall Study|Other, Not Specified|1
6271666|NCT02165735|9973546|FG000|Overall Study|Lost to Follow-up|12
6271667|NCT02165735|9973547|FG001|Overall Study|Lost to Follow-up|10
6271668|NCT02165735|9973546|FG000|Overall Study|Withdrawal by Subject|3
6271669|NCT02165735|9973547|FG001|Overall Study|Withdrawal by Subject|0
6271670|NCT02165735|9973546|FG000|Overall Study|Participant indicated lack of time|1
6271671|NCT02165735|9973547|FG001|Overall Study|Participant indicated lack of time|3
6271672|NCT02165735|9973546|FG000|Overall Study|Protocol Violation|0
6271673|NCT02165735|9973547|FG001|Overall Study|Protocol Violation|1
6271674|NCT02165826|9973565|FG000|Main Treatment Period|Pre-treatment Event/Adverse Event|44
6271675|NCT02165826|9973566|FG001|Main Treatment Period|Pre-treatment Event/Adverse Event|57
6271676|NCT02165826|9973567|FG002|Main Treatment Period|Pre-treatment Event/Adverse Event|68
6271677|NCT02165826|9973565|FG000|Main Treatment Period|Major/Significant Protocol Deviation|0
6271678|NCT02165826|9973566|FG001|Main Treatment Period|Major/Significant Protocol Deviation|1
6266212|NCT02108600|9964684|FG000|Overall Study|Withdrawal by Subject|2
6266213|NCT02108600|9964685|FG001|Overall Study|Withdrawal by Subject|0
6266214|NCT02108600|9964684|FG000|Overall Study|Lost to Follow-up|1
6266215|NCT02108600|9964685|FG001|Overall Study|Lost to Follow-up|1
6266216|NCT02108912|9964708|FG000|Overall Study|Lost to Follow-up|1
6266217|NCT02108912|9964709|FG001|Overall Study|Lost to Follow-up|1
6266218|NCT02108912|9964708|FG000|Overall Study|lack of transportation|1
6266219|NCT02108912|9964709|FG001|Overall Study|lack of transportation|0
6266220|NCT02108912|9964708|FG000|Overall Study|high blood pressure|1
6266221|NCT02108912|9964709|FG001|Overall Study|high blood pressure|0
6266222|NCT02108951|9964715|FG000|Overall Study|Lost to Follow-up|1
6266223|NCT02108951|9964715|FG000|Overall Study|Patient's/guardian's decision|1
6266224|NCT02108951|9964715|FG000|Overall Study|Study Terminated by Sponsor|14
6266225|NCT02109029|9964733|FG000|Part B|Adverse Event|0
6266226|NCT02109029|9964734|FG001|Part B|Adverse Event|0
6266227|NCT02109029|9964735|FG002|Part B|Adverse Event|0
6266228|NCT02109029|9964736|FG003|Part B|Adverse Event|0
6266229|NCT02109029|9964737|FG004|Part B|Adverse Event|1
6266230|NCT02109029|9964738|FG005|Part B|Adverse Event|1
6266231|NCT02109042|9964749|FG000|Overall Study|Sponsor Decision|15
6266232|NCT02109107|9964754|FG000|Overall Study|Lost to Follow-up|2
6266233|NCT02109133|9964760|FG000|Overall Study|Lost to Follow-up|1
6266234|NCT02109133|9964761|FG001|Overall Study|Lost to Follow-up|0
6266235|NCT02109432|9964784|FG000|Overall Study|Withdrawal by Subject|1
6266236|NCT02109445|9964788|FG000|Overall Study|Symptomatic deterioration|2
6266237|NCT02109445|9964788|FG000|Overall Study|Adverse Event|1
6086990|NCT00665925|9697110|FG000|Overall Study|Enrolled by mistake|0
6086991|NCT00665925|9697111|FG001|Overall Study|Enrolled by mistake|0
6086992|NCT00665925|9697112|FG002|Overall Study|Enrolled by mistake|0
6191251|NCT01421342|9847960|FG000|Completed to Week 12 But Then Withdrawn|Lack of Efficacy|111
6266238|NCT02109484|9964804|FG000|Overall Study|Lost to Follow-up|0
6266239|NCT02109484|9964805|FG001|Overall Study|Lost to Follow-up|0
6266240|NCT02109484|9964806|FG002|Overall Study|Lost to Follow-up|0
6266241|NCT02109484|9964807|FG003|Overall Study|Lost to Follow-up|1
6266242|NCT02109484|9964808|FG004|Overall Study|Lost to Follow-up|1
6266243|NCT02109484|9964809|FG005|Overall Study|Lost to Follow-up|0
6266244|NCT02109484|9964810|FG006|Overall Study|Lost to Follow-up|1
6266245|NCT02109484|9964811|FG007|Overall Study|Lost to Follow-up|0
6266246|NCT02109484|9964804|FG000|Overall Study|Withdrawal by Subject|0
6266247|NCT02109484|9964805|FG001|Overall Study|Withdrawal by Subject|0
6266248|NCT02109484|9964806|FG002|Overall Study|Withdrawal by Subject|0
6266249|NCT02109484|9964807|FG003|Overall Study|Withdrawal by Subject|0
6266250|NCT02109484|9964808|FG004|Overall Study|Withdrawal by Subject|1
6266251|NCT02109484|9964809|FG005|Overall Study|Withdrawal by Subject|1
6266252|NCT02109484|9964810|FG006|Overall Study|Withdrawal by Subject|1
6266253|NCT02109484|9964811|FG007|Overall Study|Withdrawal by Subject|0
6266254|NCT02109484|9964804|FG000|Overall Study|Physician Decision|0
6266255|NCT02109484|9964805|FG001|Overall Study|Physician Decision|0
6266256|NCT02109484|9964806|FG002|Overall Study|Physician Decision|0
6266257|NCT02109484|9964807|FG003|Overall Study|Physician Decision|0
6266258|NCT02109484|9964808|FG004|Overall Study|Physician Decision|2
6266259|NCT02109484|9964809|FG005|Overall Study|Physician Decision|0
6266260|NCT02109484|9964810|FG006|Overall Study|Physician Decision|0
6266261|NCT02109484|9964811|FG007|Overall Study|Physician Decision|0
6266262|NCT02109484|9964804|FG000|Overall Study|Death|0
6266263|NCT02109484|9964805|FG001|Overall Study|Death|0
6086993|NCT00665925|9697113|FG003|Overall Study|Enrolled by mistake|1
6086994|NCT00665925|9697110|FG000|Overall Study|Due to exclusion criteria|1
6191252|NCT01421342|9847961|FG001|Completed to Week 12 But Then Withdrawn|Lack of Efficacy|93
6191253|NCT01421342|9847962|FG002|Completed to Week 12 But Then Withdrawn|Lack of Efficacy|88
6191254|NCT01421342|9847960|FG000|Completed to Week 12 But Then Withdrawn|QIDS Score >=11|7
6191255|NCT01421342|9847961|FG001|Completed to Week 12 But Then Withdrawn|QIDS Score >=11|10
6191256|NCT01421342|9847962|FG002|Completed to Week 12 But Then Withdrawn|QIDS Score >=11|12
6191257|NCT01421342|9847960|FG000|Completed to Week 12 But Then Withdrawn|Adverse Event|4
6191258|NCT01421342|9847961|FG001|Completed to Week 12 But Then Withdrawn|Adverse Event|3
6191259|NCT01421342|9847962|FG002|Completed to Week 12 But Then Withdrawn|Adverse Event|6
6191260|NCT01421342|9847960|FG000|Completed to Week 12 But Then Withdrawn|Withdrawal by Subject|13
6191261|NCT01421342|9847961|FG001|Completed to Week 12 But Then Withdrawn|Withdrawal by Subject|4
6191262|NCT01421342|9847962|FG002|Completed to Week 12 But Then Withdrawn|Withdrawal by Subject|11
6191263|NCT01421342|9847960|FG000|Completed to Week 12 But Then Withdrawn|Lost to Follow-up|4
6191264|NCT01421342|9847961|FG001|Completed to Week 12 But Then Withdrawn|Lost to Follow-up|3
6191265|NCT01421342|9847962|FG002|Completed to Week 12 But Then Withdrawn|Lost to Follow-up|3
6191266|NCT01421342|9847960|FG000|Completed to Week 12 But Then Withdrawn|Non-adherence|5
6191267|NCT01421342|9847961|FG001|Completed to Week 12 But Then Withdrawn|Non-adherence|4
6266264|NCT02109484|9964806|FG002|Overall Study|Death|0
6266265|NCT02109484|9964807|FG003|Overall Study|Death|0
6266266|NCT02109484|9964808|FG004|Overall Study|Death|0
6266267|NCT02109484|9964809|FG005|Overall Study|Death|0
6266268|NCT02109484|9964810|FG006|Overall Study|Death|0
6266269|NCT02109484|9964811|FG007|Overall Study|Death|2
6266270|NCT02109484|9964804|FG000|Overall Study|Moved away from study area|0
6266271|NCT02109484|9964805|FG001|Overall Study|Moved away from study area|0
6266272|NCT02109484|9964806|FG002|Overall Study|Moved away from study area|0
6266273|NCT02109484|9964807|FG003|Overall Study|Moved away from study area|0
6266274|NCT02109484|9964808|FG004|Overall Study|Moved away from study area|0
6266275|NCT02109484|9964809|FG005|Overall Study|Moved away from study area|0
6266276|NCT02109484|9964810|FG006|Overall Study|Moved away from study area|1
6266277|NCT02109484|9964811|FG007|Overall Study|Moved away from study area|1
6266278|NCT02109562|9964853|FG000|Overall Study|Insufficient clinical response|2
6266279|NCT02109562|9964854|FG001|Overall Study|Insufficient clinical response|0
6266280|NCT02109562|9964855|FG002|Overall Study|Insufficient clinical response|4
6266281|NCT02109562|9964853|FG000|Overall Study|Adverse Event|0
6266282|NCT02109562|9964854|FG001|Overall Study|Adverse Event|2
6266283|NCT02109562|9964855|FG002|Overall Study|Adverse Event|3
6266284|NCT02109562|9964853|FG000|Overall Study|Lost to Follow-up|1
6266285|NCT02109562|9964854|FG001|Overall Study|Lost to Follow-up|0
6266286|NCT02109562|9964855|FG002|Overall Study|Lost to Follow-up|1
6266287|NCT02109562|9964853|FG000|Overall Study|Protocol Violation|0
6266288|NCT02109562|9964854|FG001|Overall Study|Protocol Violation|3
6266289|NCT02109562|9964855|FG002|Overall Study|Protocol Violation|1
6266290|NCT02109562|9964853|FG000|Overall Study|Withdrawal by Subject|20
6266291|NCT02109562|9964854|FG001|Overall Study|Withdrawal by Subject|25
6266292|NCT02109562|9964855|FG002|Overall Study|Withdrawal by Subject|21
6266293|NCT02109562|9964853|FG000|Overall Study|Physician Decision|3
6266294|NCT02109562|9964854|FG001|Overall Study|Physician Decision|4
6266295|NCT02109562|9964855|FG002|Overall Study|Physician Decision|5
6266296|NCT02110225|9964917|FG000|Overall Study|Lost to Follow-up|0
6266297|NCT02110225|9964918|FG001|Overall Study|Lost to Follow-up|1
6266298|NCT02110225|9964919|FG002|Overall Study|Lost to Follow-up|0
6266299|NCT02110238|9964930|FG000|12 Week Pivotal Phase|Adverse Event|3
6266300|NCT02110238|9964931|FG001|12 Week Pivotal Phase|Adverse Event|0
6266301|NCT02110238|9964930|FG000|12 Week Pivotal Phase|Lack of Efficacy|2
6266302|NCT02110238|9964931|FG001|12 Week Pivotal Phase|Lack of Efficacy|3
6266303|NCT02110238|9964930|FG000|12 Week Pivotal Phase|Lost to Follow-up|2
6266304|NCT02110238|9964931|FG001|12 Week Pivotal Phase|Lost to Follow-up|0
6266305|NCT02110238|9964930|FG000|12 Week Pivotal Phase|Physician Decision|0
6266306|NCT02110238|9964931|FG001|12 Week Pivotal Phase|Physician Decision|2
6266307|NCT02110238|9964930|FG000|12 Week Pivotal Phase|Protocol Violation|0
6266308|NCT02110238|9964931|FG001|12 Week Pivotal Phase|Protocol Violation|1
6266309|NCT02110238|9964930|FG000|12 Week Pivotal Phase|Withdrawal by Subject|3
6266310|NCT02110238|9964931|FG001|12 Week Pivotal Phase|Withdrawal by Subject|3
6266311|NCT02110238|9964930|FG000|14 Week Blinded Extension Phase|Adverse Event|1
6266312|NCT02110238|9964931|FG001|14 Week Blinded Extension Phase|Adverse Event|1
6266313|NCT02110238|9964930|FG000|14 Week Blinded Extension Phase|Lack of Efficacy|2
6266314|NCT02110238|9964931|FG001|14 Week Blinded Extension Phase|Lack of Efficacy|4
6266315|NCT02110238|9964930|FG000|14 Week Blinded Extension Phase|Lost to Follow-up|3
6266316|NCT02110238|9964931|FG001|14 Week Blinded Extension Phase|Lost to Follow-up|1
6266317|NCT02110238|9964930|FG000|14 Week Blinded Extension Phase|Protocol Violation|2
6266318|NCT02110238|9964931|FG001|14 Week Blinded Extension Phase|Protocol Violation|3
6266319|NCT02110238|9964930|FG000|14 Week Blinded Extension Phase|Withdrawal by Subject|4
6266320|NCT02110238|9964931|FG001|14 Week Blinded Extension Phase|Withdrawal by Subject|3
6266321|NCT02110693|9964969|FG000|Overall Study|Withdrawal by Subject|6
6266322|NCT02110693|9964970|FG001|Overall Study|Withdrawal by Subject|7
6266323|NCT02110693|9964969|FG000|Overall Study|skipped assessment|15
6266324|NCT02110693|9964970|FG001|Overall Study|skipped assessment|18
6266325|NCT02110693|9964969|FG000|Overall Study|technical difficulties|6
6266326|NCT02110693|9964970|FG001|Overall Study|technical difficulties|4
6266327|NCT02110693|9964969|FG000|Overall Study|Other|1
6266328|NCT02110693|9964970|FG001|Overall Study|Other|0
6266329|NCT02110706|9964992|FG000|Overall Study|Adverse Event|2
6266330|NCT02110706|9964993|FG001|Overall Study|Adverse Event|3
6266331|NCT02110706|9964992|FG000|Overall Study|Patients who didn't receive 2nd infusion|3
6266332|NCT02110706|9964993|FG001|Overall Study|Patients who didn't receive 2nd infusion|1
6266333|NCT02110732|9965003|FG000|Overall Study|Physician Decision|5
6266334|NCT02110732|9965004|FG001|Overall Study|Physician Decision|2
6266335|NCT02110732|9965003|FG000|Overall Study|Lost to Follow-up|1
6266336|NCT02110732|9965004|FG001|Overall Study|Lost to Follow-up|1
6266337|NCT02110901|9965033|FG000|Overall Study|Death|6
6266338|NCT02110901|9965034|FG001|Overall Study|Death|3
6266339|NCT02110901|9965033|FG000|Overall Study|Lost to Follow-up|12
6266340|NCT02110901|9965034|FG001|Overall Study|Lost to Follow-up|8
6266341|NCT02110901|9965033|FG000|Overall Study|Withdrawal by Subject|7
6266342|NCT02110901|9965034|FG001|Overall Study|Withdrawal by Subject|3
6266343|NCT02110901|9965033|FG000|Overall Study|received a kidney transplant|5
6266344|NCT02110901|9965034|FG001|Overall Study|received a kidney transplant|0
6266345|NCT02111083|9965043|FG000|Interval Between Dosing (7-8 Days)|Adverse Event|1
6266346|NCT02111083|9965044|FG001|Interval Between Dosing (7-8 Days)|Adverse Event|1
6266347|NCT02111096|9965053|FG000|Overall Study|Adverse Event|4
6266348|NCT02111096|9965054|FG001|Overall Study|Adverse Event|1
6266349|NCT02111096|9965055|FG002|Overall Study|Adverse Event|2
6266350|NCT02111096|9965053|FG000|Overall Study|Non-Compliance with Study Drug|1
6266351|NCT02111096|9965054|FG001|Overall Study|Non-Compliance with Study Drug|1
6266352|NCT02111096|9965055|FG002|Overall Study|Non-Compliance with Study Drug|0
6266353|NCT02111096|9965053|FG000|Overall Study|Lost to Follow Up|1
6266354|NCT02111096|9965054|FG001|Overall Study|Lost to Follow Up|1
6266355|NCT02111096|9965055|FG002|Overall Study|Lost to Follow Up|1
6266356|NCT02111096|9965053|FG000|Overall Study|Physician Decision|0
6266357|NCT02111096|9965054|FG001|Overall Study|Physician Decision|1
6266358|NCT02111096|9965055|FG002|Overall Study|Physician Decision|0
6266359|NCT02111096|9965053|FG000|Overall Study|Protocol Violation|1
6266360|NCT02111096|9965054|FG001|Overall Study|Protocol Violation|0
6266361|NCT02111096|9965055|FG002|Overall Study|Protocol Violation|1
6266362|NCT02111096|9965053|FG000|Overall Study|Terminated by Sponsor|53
6266363|NCT02111096|9965054|FG001|Overall Study|Terminated by Sponsor|35
6266364|NCT02111096|9965055|FG002|Overall Study|Terminated by Sponsor|54
6266365|NCT02111096|9965053|FG000|Overall Study|Withdrawal by Subject|4
6266366|NCT02111096|9965054|FG001|Overall Study|Withdrawal by Subject|2
6266367|NCT02111096|9965055|FG002|Overall Study|Withdrawal by Subject|8
6266368|NCT02111174|9965068|FG000|Treatment and Primary Outcome|Ineligible (not used in analysis)|1
6266369|NCT02111174|9965069|FG001|Treatment and Primary Outcome|Ineligible (not used in analysis)|0
6266370|NCT02111174|9965068|FG000|Treatment and Primary Outcome|Withdrawal by Subject|2
6266371|NCT02111174|9965069|FG001|Treatment and Primary Outcome|Withdrawal by Subject|2
6266372|NCT02111174|9965068|FG000|Secondary Outcomes (2 and 3 Month f/u)|Lost to Follow-up|8
6266373|NCT02111174|9965069|FG001|Secondary Outcomes (2 and 3 Month f/u)|Lost to Follow-up|6
6266374|NCT02111174|9965068|FG000|Secondary Outcomes (2 and 3 Month f/u)|Death|0
6266375|NCT02111174|9965069|FG001|Secondary Outcomes (2 and 3 Month f/u)|Death|1
6266376|NCT02111213|9965101|FG000|Overall Study|Withdrawal by Subject|3
6266377|NCT02111213|9965102|FG001|Overall Study|Withdrawal by Subject|2
6266378|NCT02111213|9965101|FG000|Overall Study|Lost to Follow-up|3
6266379|NCT02111213|9965102|FG001|Overall Study|Lost to Follow-up|4
6266380|NCT02111369|9965112|FG000|Overall Study|Lost to Follow-up|2
6266381|NCT02111369|9965112|FG000|Overall Study|Withdrawal by Subject|1
6266382|NCT02111564|9965135|FG000|Overall Study|Death|109
6266383|NCT02111564|9965136|FG001|Overall Study|Death|120
6266384|NCT02111564|9965135|FG000|Overall Study|Lost to Follow-up|2
6266385|NCT02111564|9965136|FG001|Overall Study|Lost to Follow-up|3
6266386|NCT02111564|9965135|FG000|Overall Study|Withdrawal by Subject|20
6266387|NCT02111564|9965136|FG001|Overall Study|Withdrawal by Subject|20
6266388|NCT02111577|9965144|FG000|Overall Study|Protocol Violation|2
6266389|NCT02111577|9965145|FG001|Overall Study|Protocol Violation|0
6266390|NCT02111577|9965144|FG000|Overall Study|Unable to tolerate leukapheresis|1
6266391|NCT02111577|9965145|FG001|Overall Study|Unable to tolerate leukapheresis|0
6266392|NCT02111577|9965144|FG000|Overall Study|Failure to produce study treatment|6
6266393|NCT02111577|9965145|FG001|Overall Study|Failure to produce study treatment|0
6266394|NCT02111577|9965144|FG000|Overall Study|Death|518
6266395|NCT02111577|9965145|FG001|Overall Study|Death|254
6266396|NCT02111577|9965144|FG000|Overall Study|Medical monitor's decision (active hepatitis B)|1
6266397|NCT02111577|9965145|FG001|Overall Study|Medical monitor's decision (active hepatitis B)|0
6266398|NCT02111577|9965144|FG000|Overall Study|Adverse Event|1
6266399|NCT02111577|9965145|FG001|Overall Study|Adverse Event|1
6266400|NCT02111577|9965144|FG000|Overall Study|Withdrawal by Subject|51
6266401|NCT02111577|9965145|FG001|Overall Study|Withdrawal by Subject|23
6266402|NCT02111577|9965144|FG000|Overall Study|Disease progression|0
6266403|NCT02111577|9965145|FG001|Overall Study|Disease progression|1
6266404|NCT02111577|9965144|FG000|Overall Study|Lost to Follow-up|19
6266405|NCT02111577|9965145|FG001|Overall Study|Lost to Follow-up|10
6266406|NCT02111603|9965153|FG000|Overall Study|Withdrawal by Subject|1
6266407|NCT02111785|9965179|FG000|Overall Study|Death|0
6266408|NCT02111785|9965180|FG001|Overall Study|Death|1
6266409|NCT02111785|9965181|FG002|Overall Study|Death|0
6266410|NCT02111785|9965182|FG003|Overall Study|Death|0
6266411|NCT02111811|9965216|FG000|Treatment Phase|Lost to Follow-up|22
6266412|NCT02111811|9965217|FG001|Treatment Phase|Lost to Follow-up|18
6266413|NCT02111811|9965216|FG000|Treatment Phase|Death|2
6266414|NCT02111811|9965217|FG001|Treatment Phase|Death|0
6266415|NCT02111811|9965216|FG000|Follow up Period (Aim 2)|Lost to Follow-up|26
6266416|NCT02111811|9965217|FG001|Follow up Period (Aim 2)|Lost to Follow-up|17
6266417|NCT02111811|9965216|FG000|Follow up Period (Aim 2)|Death|2
6266418|NCT02111811|9965217|FG001|Follow up Period (Aim 2)|Death|0
6266419|NCT02111993|9965236|FG000|Overall Study|Physician Decision|5
6266420|NCT02111993|9965237|FG001|Overall Study|Physician Decision|4
6266421|NCT02112045|9965247|FG000|Overall Study|Withdrawal by Subject|1
6266422|NCT02112045|9965248|FG001|Overall Study|Withdrawal by Subject|0
6266423|NCT02112448|9965265|FG000|Overall Study|lab values precluding use of ketorolac|2
6266424|NCT02112448|9965266|FG001|Overall Study|lab values precluding use of ketorolac|2
6266425|NCT02112448|9965265|FG000|Overall Study|Protocol Violation|1
6266426|NCT02112448|9965266|FG001|Overall Study|Protocol Violation|2
6266427|NCT02112448|9965265|FG000|Overall Study|Physician Decision|4
6266428|NCT02112448|9965266|FG001|Overall Study|Physician Decision|6
6266429|NCT02112448|9965265|FG000|Overall Study|required heparin so could not use ketoro|1
6266430|NCT02112448|9965266|FG001|Overall Study|required heparin so could not use ketoro|0
6266431|NCT02112877|9965289|FG000|Overall Study|Withdrawal by Subject|1
6266432|NCT02112877|9965290|FG001|Overall Study|Withdrawal by Subject|7
6266433|NCT02112877|9965289|FG000|Overall Study|Visit Missed|1
6266434|NCT02112877|9965290|FG001|Overall Study|Visit Missed|6
6266435|NCT02112994|9965298|FG000|Overall Study|Progressive Disease|0
6266436|NCT02112994|9965299|FG001|Overall Study|Progressive Disease|0
6266437|NCT02112994|9965300|FG002|Overall Study|Progressive Disease|1
6266438|NCT02112994|9965298|FG000|Overall Study|Pregnancy|0
6266439|NCT02112994|9965299|FG001|Overall Study|Pregnancy|1
6266440|NCT02112994|9965300|FG002|Overall Study|Pregnancy|1
6266441|NCT02112994|9965298|FG000|Overall Study|Liver Transplant|0
6266442|NCT02112994|9965299|FG001|Overall Study|Liver Transplant|1
6266443|NCT02112994|9965300|FG002|Overall Study|Liver Transplant|0
6266444|NCT02112994|9965298|FG000|Overall Study|Withdrawal by Subject|0
6266445|NCT02112994|9965299|FG001|Overall Study|Withdrawal by Subject|0
6266446|NCT02112994|9965300|FG002|Overall Study|Withdrawal by Subject|1
6266447|NCT02113007|9965312|FG000|Overall Study|Progressive disease|2
6266448|NCT02113124|9965318|FG000|Overall Study|Unable to retrieve blood sample|1
6266449|NCT02113124|9965319|FG001|Overall Study|Unable to retrieve blood sample|1
6266450|NCT02113189|9965328|FG000|Overall Study|Lost to follow up|2
6266451|NCT02113189|9965329|FG001|Overall Study|Lost to follow up|1
6266452|NCT02113189|9965330|FG002|Overall Study|Lost to follow up|3
6266453|NCT02113436|9965363|FG000|Period 1: 8 Weeks|Adverse Event|1
6266454|NCT02113436|9965364|FG001|Period 1: 8 Weeks|Adverse Event|0
6266455|NCT02113436|9965365|FG002|Period 1: 8 Weeks|Adverse Event|0
6266456|NCT02113436|9965366|FG003|Period 1: 8 Weeks|Adverse Event|0
6266457|NCT02113436|9965363|FG000|Period 1: 8 Weeks|Protocol Violation|1
6266458|NCT02113436|9965364|FG001|Period 1: 8 Weeks|Protocol Violation|0
6266459|NCT02113436|9965365|FG002|Period 1: 8 Weeks|Protocol Violation|0
6266460|NCT02113436|9965366|FG003|Period 1: 8 Weeks|Protocol Violation|0
6266461|NCT02113436|9965363|FG000|Period 1: 8 Weeks|Par. Reached Stopping Criteria|5
6266462|NCT02113436|9965364|FG001|Period 1: 8 Weeks|Par. Reached Stopping Criteria|2
6266463|NCT02113436|9965365|FG002|Period 1: 8 Weeks|Par. Reached Stopping Criteria|0
6266464|NCT02113436|9965366|FG003|Period 1: 8 Weeks|Par. Reached Stopping Criteria|0
6266465|NCT02113436|9965363|FG000|Period 1: 8 Weeks|Withdrawal by Subject|1
6266466|NCT02113436|9965364|FG001|Period 1: 8 Weeks|Withdrawal by Subject|0
6266467|NCT02113436|9965365|FG002|Period 1: 8 Weeks|Withdrawal by Subject|0
6266468|NCT02113436|9965366|FG003|Period 1: 8 Weeks|Withdrawal by Subject|0
6266469|NCT02113436|9965363|FG000|Period 2: 16 Weeks|Adverse Event|0
6266470|NCT02113436|9965364|FG001|Period 2: 16 Weeks|Adverse Event|0
6266471|NCT02113436|9965365|FG002|Period 2: 16 Weeks|Adverse Event|4
6266472|NCT02113436|9965366|FG003|Period 2: 16 Weeks|Adverse Event|5
6266473|NCT02113436|9965363|FG000|Period 2: 16 Weeks|Par. Reached Stopping Criteria|0
6266474|NCT02113436|9965364|FG001|Period 2: 16 Weeks|Par. Reached Stopping Criteria|0
6266475|NCT02113436|9965365|FG002|Period 2: 16 Weeks|Par. Reached Stopping Criteria|2
6266476|NCT02113436|9965366|FG003|Period 2: 16 Weeks|Par. Reached Stopping Criteria|5
6266477|NCT02113436|9965363|FG000|Period 2: 16 Weeks|Physician Decision|0
6266478|NCT02113436|9965364|FG001|Period 2: 16 Weeks|Physician Decision|0
6266479|NCT02113436|9965365|FG002|Period 2: 16 Weeks|Physician Decision|2
6266480|NCT02113436|9965366|FG003|Period 2: 16 Weeks|Physician Decision|0
6266481|NCT02113436|9965363|FG000|Period 2: 16 Weeks|Withdrawal by Subject|0
6266482|NCT02113436|9965364|FG001|Period 2: 16 Weeks|Withdrawal by Subject|0
6266483|NCT02113436|9965365|FG002|Period 2: 16 Weeks|Withdrawal by Subject|1
6266484|NCT02113436|9965366|FG003|Period 2: 16 Weeks|Withdrawal by Subject|1
6266485|NCT02113449|9965375|FG000|Overall Study|Adverse Event|4
6266486|NCT02113579|9965385|FG000|Overall Study|Adverse Event|1
6266487|NCT02113579|9965386|FG001|Overall Study|Adverse Event|0
6266488|NCT02113579|9965385|FG000|Overall Study|Withdrawal by Subject|3
6266489|NCT02113579|9965386|FG001|Overall Study|Withdrawal by Subject|2
6266490|NCT02113579|9965385|FG000|Overall Study|Lost to Follow-up|6
6266491|NCT02113579|9965386|FG001|Overall Study|Lost to Follow-up|2
6266492|NCT02113956|9965394|FG000|Intervention End (5 Weeks Post Baseline)|Withdrawal by Subject|5
6266493|NCT02113956|9965395|FG001|Intervention End (5 Weeks Post Baseline)|Withdrawal by Subject|1
6266494|NCT02113956|9965394|FG000|Intervention End (5 Weeks Post Baseline)|Lost to Follow-up|4
6266495|NCT02113956|9965395|FG001|Intervention End (5 Weeks Post Baseline)|Lost to Follow-up|3
6266496|NCT02113956|9965394|FG000|3 Month Post-intervention|Lost to Follow-up|4
6266497|NCT02113956|9965395|FG001|3 Month Post-intervention|Lost to Follow-up|2
6266498|NCT02114151|9965401|FG000|Overall Study|Death|1
6266499|NCT02114151|9965401|FG000|Overall Study|Lost to Follow-up|1
6266500|NCT02114151|9965401|FG000|Overall Study|Withdrawal by Subject|5
6266501|NCT02114177|9965416|FG000|Overall Study|Lost to Follow-up|1
6266502|NCT02114177|9965417|FG001|Overall Study|Lost to Follow-up|2
6266503|NCT02114177|9965416|FG000|Overall Study|Withdrawal by Subject|6
6266504|NCT02114177|9965417|FG001|Overall Study|Withdrawal by Subject|1
6266505|NCT02114177|9965416|FG000|Overall Study|Other|2
6266506|NCT02114177|9965417|FG001|Overall Study|Other|1
6266507|NCT02114203|9965426|FG000|Overall Study|Adverse Event|0
6266508|NCT02114203|9965427|FG001|Overall Study|Adverse Event|1
6266509|NCT02114203|9965428|FG002|Overall Study|Adverse Event|0
6266510|NCT02114203|9965426|FG000|Overall Study|Withdrawal by Subject|0
6266511|NCT02114203|9965427|FG001|Overall Study|Withdrawal by Subject|1
6266512|NCT02114203|9965428|FG002|Overall Study|Withdrawal by Subject|0
6266513|NCT02114268|9965458|FG000|Overall Study|Lost to Follow-up|4
6266514|NCT02114268|9965459|FG001|Overall Study|Lost to Follow-up|1
6266515|NCT02114268|9965460|FG002|Overall Study|Lost to Follow-up|1
6266516|NCT02114268|9965461|FG003|Overall Study|Lost to Follow-up|0
6266517|NCT02114268|9965462|FG004|Overall Study|Lost to Follow-up|0
6266518|NCT02114268|9965463|FG005|Overall Study|Lost to Follow-up|2
6266519|NCT02114268|9965458|FG000|Overall Study|Withdrawal by Subject|1
6266520|NCT02114268|9965459|FG001|Overall Study|Withdrawal by Subject|0
6266521|NCT02114268|9965460|FG002|Overall Study|Withdrawal by Subject|0
6266522|NCT02114268|9965461|FG003|Overall Study|Withdrawal by Subject|0
6266523|NCT02114268|9965462|FG004|Overall Study|Withdrawal by Subject|0
6266524|NCT02114268|9965463|FG005|Overall Study|Withdrawal by Subject|1
6266525|NCT02114268|9965458|FG000|Overall Study|Withdrawn by site due to noncompliance|1
6266526|NCT02114268|9965459|FG001|Overall Study|Withdrawn by site due to noncompliance|0
6266527|NCT02114268|9965460|FG002|Overall Study|Withdrawn by site due to noncompliance|0
6266528|NCT02114268|9965461|FG003|Overall Study|Withdrawn by site due to noncompliance|0
6266529|NCT02114268|9965462|FG004|Overall Study|Withdrawn by site due to noncompliance|0
6266530|NCT02114268|9965463|FG005|Overall Study|Withdrawn by site due to noncompliance|0
6266531|NCT02114385|9965495|FG000|Overall Study|Withdrawal by Subject|3
6266532|NCT02114385|9965496|FG001|Overall Study|Withdrawal by Subject|2
6266533|NCT02114385|9965495|FG000|Overall Study|Lost to Follow-up|0
6266534|NCT02114385|9965496|FG001|Overall Study|Lost to Follow-up|6
6266535|NCT02114515|9965504|FG000|Overall Study|Lost to Follow-up|52
6266536|NCT02114515|9965505|FG001|Overall Study|Lost to Follow-up|55
6266537|NCT02114515|9965504|FG000|Overall Study|Death|12
6266538|NCT02114515|9965505|FG001|Overall Study|Death|12
6266539|NCT02114515|9965504|FG000|Overall Study|Withdrawal by Subject|4
6266540|NCT02114515|9965505|FG001|Overall Study|Withdrawal by Subject|22
6266541|NCT02114515|9965504|FG000|Overall Study|Other|65
6266542|NCT02114515|9965505|FG001|Overall Study|Other|61
6266543|NCT02114606|9965511|FG000|Overall Study|Unable to swallow Cytosponge|6
6266544|NCT02114684|9965517|FG000|Overall Study|Death|6
6266545|NCT02114684|9965518|FG001|Overall Study|Death|4
6266546|NCT02114684|9965517|FG000|Overall Study|Lost to Follow-up|1
6266547|NCT02114684|9965518|FG001|Overall Study|Lost to Follow-up|2
6266548|NCT02114684|9965517|FG000|Overall Study|Withdrawal by Subject|1
6266549|NCT02114684|9965518|FG001|Overall Study|Withdrawal by Subject|2
6266550|NCT02114684|9965517|FG000|Overall Study|Relocation|3
6266551|NCT02114684|9965518|FG001|Overall Study|Relocation|1
6266552|NCT02114684|9965517|FG000|Overall Study|Rifampicin resistant on culture|0
6266553|NCT02114684|9965518|FG001|Overall Study|Rifampicin resistant on culture|1
6266554|NCT02114684|9965517|FG000|Overall Study|Patient Incarcerated|1
6266555|NCT02114684|9965518|FG001|Overall Study|Patient Incarcerated|0
6266556|NCT02114879|9965530|FG000|Overall Study|Withdrawal by Subject|9
6266557|NCT02114879|9965531|FG001|Overall Study|Withdrawal by Subject|5
6266558|NCT02114879|9965530|FG000|Overall Study|Death|6
6266559|NCT02114879|9965531|FG001|Overall Study|Death|11
6266560|NCT02114879|9965530|FG000|Overall Study|Lost to Follow-up|4
6266561|NCT02114879|9965531|FG001|Overall Study|Lost to Follow-up|6
6266562|NCT02114879|9965530|FG000|Overall Study|Physician Decision|0
6266563|NCT02114879|9965531|FG001|Overall Study|Physician Decision|2
6266564|NCT02114892|9965539|FG000|Overall Study|Lost to Follow-up|1
6266565|NCT02114892|9965540|FG001|Overall Study|Lost to Follow-up|2
6266566|NCT02114931|9965548|FG000|Overall Study|Withdrawal by Subject|15
6266567|NCT02114931|9965549|FG001|Overall Study|Withdrawal by Subject|18
6266568|NCT02114931|9965548|FG000|Overall Study|Adverse Event|4
6266569|NCT02114931|9965549|FG001|Overall Study|Adverse Event|6
6266570|NCT02114931|9965548|FG000|Overall Study|Lost to Follow-up|3
6266571|NCT02114931|9965549|FG001|Overall Study|Lost to Follow-up|3
6266572|NCT02114931|9965548|FG000|Overall Study|Physician Decision|1
6266573|NCT02114931|9965549|FG001|Overall Study|Physician Decision|2
6266574|NCT02114931|9965548|FG000|Overall Study|Other|2
6266575|NCT02114931|9965549|FG001|Overall Study|Other|1
6266576|NCT02115113|9965564|FG000|Participants in Run-in Period|Death|0
6266577|NCT02115113|9965565|FG001|Participants in Run-in Period|Death|0
6266578|NCT02115113|9965566|FG002|Participants in Run-in Period|Death|1
6266579|NCT02115113|9965564|FG000|Participants in Run-in Period|Administrative problems|0
6266580|NCT02115113|9965565|FG001|Participants in Run-in Period|Administrative problems|0
6266581|NCT02115113|9965566|FG002|Participants in Run-in Period|Administrative problems|1
6266582|NCT02115113|9965564|FG000|Participants in Run-in Period|Lost to Follow-up|0
6266583|NCT02115113|9965565|FG001|Participants in Run-in Period|Lost to Follow-up|0
6266584|NCT02115113|9965566|FG002|Participants in Run-in Period|Lost to Follow-up|5
6266585|NCT02115113|9965564|FG000|Participants in Run-in Period|Withdrawal by Subject|0
6266586|NCT02115113|9965565|FG001|Participants in Run-in Period|Withdrawal by Subject|0
6266587|NCT02115113|9965566|FG002|Participants in Run-in Period|Withdrawal by Subject|3
6266588|NCT02115113|9965564|FG000|Participants Randomized|Lost to Follow-up|1
6266589|NCT02115113|9965565|FG001|Participants Randomized|Lost to Follow-up|0
6266590|NCT02115113|9965566|FG002|Participants Randomized|Lost to Follow-up|0
6266591|NCT02115113|9965564|FG000|Participants Randomized|Death|1
6266592|NCT02115113|9965565|FG001|Participants Randomized|Death|0
6266593|NCT02115113|9965566|FG002|Participants Randomized|Death|0
6266594|NCT02115139|9965575|FG000|Overall Study|Protocol Violation|1
6266595|NCT02115139|9965575|FG000|Overall Study|treatment discontinuation|6
6266596|NCT02115256|9965581|FG000|Overall Study|Withdrawal by Subject|0
6266597|NCT02115256|9965582|FG001|Overall Study|Withdrawal by Subject|1
6266598|NCT02115269|9965588|FG000|Overall Study|Lost to Follow-up|43
6266599|NCT02115269|9965588|FG000|Overall Study|Did not complete patient diary|3
6266600|NCT02115269|9965588|FG000|Overall Study|Moved to another city|7
6266601|NCT02115269|9965588|FG000|Overall Study|Withdrawal by Subject|2
6266602|NCT02115269|9965588|FG000|Overall Study|Didn't take study drug|2
6266603|NCT02115282|9965605|FG000|Overall Study|Disease progression during treatment|216
6266604|NCT02115282|9965606|FG001|Overall Study|Disease progression during treatment|229
6266605|NCT02115282|9965605|FG000|Overall Study|Adverse Event|49
6266606|NCT02115282|9965606|FG001|Overall Study|Adverse Event|23
6266607|NCT02115282|9965605|FG000|Overall Study|Death|1
6266608|NCT02115282|9965606|FG001|Overall Study|Death|3
6266609|NCT02115282|9965605|FG000|Overall Study|Alternative therapy|1
6266610|NCT02115282|9965606|FG001|Overall Study|Alternative therapy|1
6266611|NCT02115282|9965605|FG000|Overall Study|Complicating disease|0
6266612|NCT02115282|9965606|FG001|Overall Study|Complicating disease|3
6266613|NCT02115282|9965605|FG000|Overall Study|Withdrawal by Subject|12
6266614|NCT02115282|9965606|FG001|Overall Study|Withdrawal by Subject|10
6266615|NCT02115282|9965605|FG000|Overall Study|Symptomatic progression/deterioration|7
6266616|NCT02115282|9965606|FG001|Overall Study|Symptomatic progression/deterioration|18
6266617|NCT02115282|9965605|FG000|Overall Study|Non-compliance|5
6266618|NCT02115282|9965606|FG001|Overall Study|Non-compliance|1
6266619|NCT02115282|9965605|FG000|Overall Study|Protocol Violation|2
6266620|NCT02115282|9965606|FG001|Overall Study|Protocol Violation|2
6266621|NCT02115282|9965605|FG000|Overall Study|Study termination (stop treatment due to the release of the results)|3
6266622|NCT02115282|9965606|FG001|Overall Study|Study termination (stop treatment due to the release of the results)|3
6266623|NCT02115282|9965605|FG000|Overall Study|Not start protocol therapy|9
6266624|NCT02115282|9965606|FG001|Overall Study|Not start protocol therapy|10
6266625|NCT02115308|9965616|FG000|Overall Study|Safety Screening|2
6266626|NCT02115308|9965617|FG001|Overall Study|Safety Screening|2
6266627|NCT02115321|9965629|FG000|Overall Study|Death|1
6266628|NCT02115321|9965630|FG001|Overall Study|Death|0
6266629|NCT02115386|9965666|FG000|Overall Study|Protocol Violation|1
6266630|NCT02115386|9965666|FG000|Overall Study|Administrative - trial was terminated|6
6266631|NCT02115607|9965683|FG000|Overall Study|Withdrawal by Subject|1
6271679|NCT02165826|9973567|FG002|Main Treatment Period|Major/Significant Protocol Deviation|3
6271680|NCT02165826|9973565|FG000|Main Treatment Period|Lost to Follow-up|4
6271681|NCT02165826|9973566|FG001|Main Treatment Period|Lost to Follow-up|2
6271682|NCT02165826|9973567|FG002|Main Treatment Period|Lost to Follow-up|1
6271683|NCT02165826|9973565|FG000|Main Treatment Period|Voluntary Withdrawal|23
6271684|NCT02165826|9973566|FG001|Main Treatment Period|Voluntary Withdrawal|23
6271685|NCT02165826|9973567|FG002|Main Treatment Period|Voluntary Withdrawal|21
6271686|NCT02165826|9973565|FG000|Main Treatment Period|Lack of Efficacy|2
6271687|NCT02165826|9973566|FG001|Main Treatment Period|Lack of Efficacy|0
6271688|NCT02165826|9973567|FG002|Main Treatment Period|Lack of Efficacy|0
6271689|NCT02165826|9973565|FG000|Main Treatment Period|Reason Not Specified|8
6271690|NCT02165826|9973566|FG001|Main Treatment Period|Reason Not Specified|5
6271691|NCT02165826|9973567|FG002|Main Treatment Period|Reason Not Specified|16
6271692|NCT02165826|9973565|FG000|Main Treatment Period|Did Not Receive Study Drug|0
6271693|NCT02165826|9973566|FG001|Main Treatment Period|Did Not Receive Study Drug|2
6271694|NCT02165826|9973567|FG002|Main Treatment Period|Did Not Receive Study Drug|0
6271695|NCT02165826|9973565|FG000|Down-Titration Period|Pre-treatment Event/Adverse Event|4
6271696|NCT02165826|9973566|FG001|Down-Titration Period|Pre-treatment Event/Adverse Event|10
6271697|NCT02165826|9973567|FG002|Down-Titration Period|Pre-treatment Event/Adverse Event|3
6271698|NCT02165826|9973565|FG000|Down-Titration Period|Voluntary Withdrawal|2
6271699|NCT02165826|9973566|FG001|Down-Titration Period|Voluntary Withdrawal|1
6271700|NCT02165826|9973567|FG002|Down-Titration Period|Voluntary Withdrawal|2
6271701|NCT02165826|9973565|FG000|Down-Titration Period|Reason Not Specified|1
6271702|NCT02165826|9973566|FG001|Down-Titration Period|Reason Not Specified|0
6271703|NCT02165826|9973567|FG002|Down-Titration Period|Reason Not Specified|2
6271704|NCT02166047|9973618|FG000|Overall Study|Withdrawal by Participant|0
6271705|NCT02166047|9973619|FG001|Overall Study|Withdrawal by Participant|1
6271706|NCT02166047|9973620|FG002|Overall Study|Withdrawal by Participant|2
6271707|NCT02166047|9973621|FG003|Overall Study|Withdrawal by Participant|0
6271708|NCT02166047|9973622|FG004|Overall Study|Withdrawal by Participant|0
6271709|NCT02166047|9973623|FG005|Overall Study|Withdrawal by Participant|0
6271710|NCT02166047|9973624|FG006|Overall Study|Withdrawal by Participant|1
6271711|NCT02166047|9973625|FG007|Overall Study|Withdrawal by Participant|0
6271712|NCT02166047|9973626|FG008|Overall Study|Withdrawal by Participant|0
6271713|NCT02166047|9973627|FG009|Overall Study|Withdrawal by Participant|0
6271714|NCT02166047|9973628|FG010|Overall Study|Withdrawal by Participant|0
6271715|NCT02166047|9973629|FG011|Overall Study|Withdrawal by Participant|0
6271716|NCT02166047|9973618|FG000|Overall Study|Adverse Event|0
6271717|NCT02166047|9973619|FG001|Overall Study|Adverse Event|0
6271718|NCT02166047|9973620|FG002|Overall Study|Adverse Event|0
6271719|NCT02166047|9973621|FG003|Overall Study|Adverse Event|0
6271720|NCT02166047|9973622|FG004|Overall Study|Adverse Event|1
6271721|NCT02166047|9973623|FG005|Overall Study|Adverse Event|0
6271722|NCT02166047|9973624|FG006|Overall Study|Adverse Event|1
6271723|NCT02166047|9973625|FG007|Overall Study|Adverse Event|0
6271724|NCT02166047|9973626|FG008|Overall Study|Adverse Event|0
6271725|NCT02166047|9973627|FG009|Overall Study|Adverse Event|0
6271726|NCT02166047|9973628|FG010|Overall Study|Adverse Event|2
6271727|NCT02166047|9973629|FG011|Overall Study|Adverse Event|0
6271913|NCT02169336|9974034|FG000|Overall Study|Lack of Efficacy|1
6266632|NCT02115815|9965726|FG000|Overall Study|Withdrawal by Subject|2
6266633|NCT02115815|9965727|FG001|Overall Study|Withdrawal by Subject|0
6266634|NCT02115815|9965728|FG002|Overall Study|Withdrawal by Subject|0
6266635|NCT02115815|9965729|FG003|Overall Study|Withdrawal by Subject|0
6266636|NCT02115815|9965730|FG004|Overall Study|Withdrawal by Subject|0
6266637|NCT02115815|9965731|FG005|Overall Study|Withdrawal by Subject|0
6266638|NCT02115815|9965732|FG006|Overall Study|Withdrawal by Subject|0
6266639|NCT02115815|9965726|FG000|Overall Study|Not enough drug to dose participant|0
6266640|NCT02115815|9965727|FG001|Overall Study|Not enough drug to dose participant|0
6266641|NCT02115815|9965728|FG002|Overall Study|Not enough drug to dose participant|0
6266642|NCT02115815|9965729|FG003|Overall Study|Not enough drug to dose participant|0
6266643|NCT02115815|9965730|FG004|Overall Study|Not enough drug to dose participant|0
6266644|NCT02115815|9965731|FG005|Overall Study|Not enough drug to dose participant|1
6266645|NCT02115815|9965732|FG006|Overall Study|Not enough drug to dose participant|0
6266646|NCT02115815|9965726|FG000|Overall Study|Missed appointment, randomized in error|0
6266647|NCT02115815|9965727|FG001|Overall Study|Missed appointment, randomized in error|0
6266648|NCT02115815|9965728|FG002|Overall Study|Missed appointment, randomized in error|0
6266649|NCT02115815|9965729|FG003|Overall Study|Missed appointment, randomized in error|0
6266650|NCT02115815|9965730|FG004|Overall Study|Missed appointment, randomized in error|0
6266651|NCT02115815|9965731|FG005|Overall Study|Missed appointment, randomized in error|1
6266652|NCT02115815|9965732|FG006|Overall Study|Missed appointment, randomized in error|0
6266653|NCT02116205|9965765|FG000|Overall Study|Withdrawal by Subject|2
6266654|NCT02116205|9965766|FG001|Overall Study|Withdrawal by Subject|4
6266655|NCT02116205|9965767|FG002|Overall Study|Withdrawal by Subject|1
6266656|NCT02116205|9965768|FG003|Overall Study|Withdrawal by Subject|3
6266657|NCT02116205|9965765|FG000|Overall Study|Lost to Follow-up|0
6266658|NCT02116205|9965766|FG001|Overall Study|Lost to Follow-up|2
6266659|NCT02116205|9965767|FG002|Overall Study|Lost to Follow-up|1
6266660|NCT02116205|9965768|FG003|Overall Study|Lost to Follow-up|2
6266661|NCT02116205|9965765|FG000|Overall Study|Physician Decision|0
6266662|NCT02116205|9965766|FG001|Overall Study|Physician Decision|1
6266663|NCT02116205|9965767|FG002|Overall Study|Physician Decision|1
6266664|NCT02116205|9965768|FG003|Overall Study|Physician Decision|1
6266665|NCT02116205|9965765|FG000|Overall Study|Exclusion criteria|0
6266666|NCT02116205|9965766|FG001|Overall Study|Exclusion criteria|0
6266667|NCT02116205|9965767|FG002|Overall Study|Exclusion criteria|1
6266668|NCT02116205|9965768|FG003|Overall Study|Exclusion criteria|0
6266669|NCT02116309|9965780|FG000|Overall Study|Lost to Follow-up|0
6266670|NCT02116309|9965781|FG001|Overall Study|Lost to Follow-up|1
6266671|NCT02116361|9965795|FG000|Overall Study|Pregnancy|0
6266672|NCT02116361|9965796|FG001|Overall Study|Pregnancy|0
6266673|NCT02116361|9965797|FG002|Overall Study|Pregnancy|0
6266674|NCT02116361|9965798|FG003|Overall Study|Pregnancy|1
6266675|NCT02116361|9965795|FG000|Overall Study|Protocol Violation|1
6266676|NCT02116361|9965796|FG001|Overall Study|Protocol Violation|0
6266677|NCT02116361|9965797|FG002|Overall Study|Protocol Violation|0
6266678|NCT02116361|9965798|FG003|Overall Study|Protocol Violation|2
6266679|NCT02116361|9965795|FG000|Overall Study|Physician Decision|2
6266680|NCT02116361|9965796|FG001|Overall Study|Physician Decision|3
6266681|NCT02116361|9965797|FG002|Overall Study|Physician Decision|0
6266682|NCT02116361|9965798|FG003|Overall Study|Physician Decision|0
6266683|NCT02116361|9965795|FG000|Overall Study|Adverse Event|1
6266684|NCT02116361|9965796|FG001|Overall Study|Adverse Event|0
6266685|NCT02116361|9965797|FG002|Overall Study|Adverse Event|0
6266686|NCT02116361|9965798|FG003|Overall Study|Adverse Event|3
6266687|NCT02116361|9965795|FG000|Overall Study|Other Reasons|3
6266688|NCT02116361|9965796|FG001|Overall Study|Other Reasons|3
6266689|NCT02116361|9965797|FG002|Overall Study|Other Reasons|3
6266690|NCT02116361|9965798|FG003|Overall Study|Other Reasons|3
6266691|NCT02116361|9965795|FG000|Overall Study|Lack of Efficacy|5
6266692|NCT02116361|9965796|FG001|Overall Study|Lack of Efficacy|7
6266693|NCT02116361|9965797|FG002|Overall Study|Lack of Efficacy|4
6266694|NCT02116361|9965798|FG003|Overall Study|Lack of Efficacy|3
6266695|NCT02116361|9965795|FG000|Overall Study|Lost to Follow-up|4
6266696|NCT02116361|9965796|FG001|Overall Study|Lost to Follow-up|5
6266697|NCT02116361|9965797|FG002|Overall Study|Lost to Follow-up|7
6266698|NCT02116361|9965798|FG003|Overall Study|Lost to Follow-up|5
6266699|NCT02116361|9965795|FG000|Overall Study|Personal Reasons|6
6266700|NCT02116361|9965796|FG001|Overall Study|Personal Reasons|6
6266701|NCT02116361|9965797|FG002|Overall Study|Personal Reasons|4
6266702|NCT02116361|9965798|FG003|Overall Study|Personal Reasons|9
6266703|NCT02116361|9965795|FG000|Overall Study|Investigator Decision - Relapse|9
6266704|NCT02116361|9965796|FG001|Overall Study|Investigator Decision - Relapse|7
6266705|NCT02116361|9965797|FG002|Overall Study|Investigator Decision - Relapse|8
6266706|NCT02116361|9965798|FG003|Overall Study|Investigator Decision - Relapse|5
6266707|NCT02116530|9965810|FG000|Overall Study|Withdrawal by Subject|1
6266708|NCT02116530|9965811|FG001|Overall Study|Withdrawal by Subject|2
6266709|NCT02116530|9965810|FG000|Overall Study|Adverse Event|4
6266710|NCT02116530|9965811|FG001|Overall Study|Adverse Event|0
6266711|NCT02116530|9965810|FG000|Overall Study|Physician Decision|1
6266712|NCT02116530|9965811|FG001|Overall Study|Physician Decision|0
6266713|NCT02116530|9965810|FG000|Overall Study|Lost to Follow-up|1
6266714|NCT02116530|9965811|FG001|Overall Study|Lost to Follow-up|0
6266715|NCT02116530|9965810|FG000|Overall Study|Other Medical Problems|2
6266716|NCT02116530|9965811|FG001|Overall Study|Other Medical Problems|2
6266717|NCT02116582|9965817|FG000|Overall Study|Enrolled but Never Received Study Drug|1
6266718|NCT02116582|9965817|FG000|Overall Study|Adverse Event|22
6266719|NCT02116582|9965817|FG000|Overall Study|Death|9
6266720|NCT02116582|9965817|FG000|Overall Study|Progressive Disease|148
6266721|NCT02116582|9965817|FG000|Overall Study|Protocol Violation|3
6266722|NCT02116582|9965817|FG000|Overall Study|Withdrawal by Subject|8
6266723|NCT02116582|9965817|FG000|Overall Study|Other: Miscellaneous|11
6266724|NCT02116582|9965817|FG000|Overall Study|Lost to Follow-up|1
6266725|NCT02116582|9965817|FG000|Overall Study|Other: Transitioned to 9785-CL-0123|12
6266726|NCT02116608|9965824|FG000|Overall Study|Lost to Follow-up|0
6266727|NCT02116608|9965825|FG001|Overall Study|Lost to Follow-up|0
6266728|NCT02116608|9965826|FG002|Overall Study|Lost to Follow-up|1
6266729|NCT02116608|9965824|FG000|Overall Study|Physician Decision|0
6266730|NCT02116608|9965825|FG001|Overall Study|Physician Decision|1
6266731|NCT02116608|9965826|FG002|Overall Study|Physician Decision|0
6266732|NCT02116608|9965824|FG000|Overall Study|Death|0
6266733|NCT02116608|9965825|FG001|Overall Study|Death|1
6266734|NCT02116608|9965826|FG002|Overall Study|Death|0
6266735|NCT02116621|9965836|FG000|Baseline|Withdrawal by Subject|0
6266736|NCT02116621|9965837|FG001|Baseline|Withdrawal by Subject|4
6266737|NCT02116621|9965836|FG000|Three Month Follow-up|Death|1
6266738|NCT02116621|9965837|FG001|Three Month Follow-up|Death|1
6266739|NCT02116621|9965836|FG000|Three Month Follow-up|Withdrawal by Subject|4
6266740|NCT02116621|9965837|FG001|Three Month Follow-up|Withdrawal by Subject|1
6266741|NCT02116621|9965836|FG000|Three Month Follow-up|Lost to Follow-up|0
6266742|NCT02116621|9965837|FG001|Three Month Follow-up|Lost to Follow-up|1
6266743|NCT02116621|9965836|FG000|Three Month Follow-up|Did not complete follow-up survey|14
6266744|NCT02116621|9965837|FG001|Three Month Follow-up|Did not complete follow-up survey|4
6266745|NCT02116621|9965836|FG000|Six Month Follow-up|Withdrawal by Subject|1
6266746|NCT02116621|9965837|FG001|Six Month Follow-up|Withdrawal by Subject|1
6266747|NCT02116621|9965836|FG000|Six Month Follow-up|Lost to Follow-up|2
6266748|NCT02116621|9965837|FG001|Six Month Follow-up|Lost to Follow-up|1
6266749|NCT02116621|9965836|FG000|Six Month Follow-up|Did not complete follow-up survey|1
6266750|NCT02116621|9965837|FG001|Six Month Follow-up|Did not complete follow-up survey|1
6266751|NCT02116621|9965836|FG000|Twelve Month Follow-up|Withdrawal by Subject|1
6266752|NCT02116621|9965837|FG001|Twelve Month Follow-up|Withdrawal by Subject|0
6266753|NCT02116621|9965836|FG000|Twelve Month Follow-up|Lost to Follow-up|0
6266754|NCT02116621|9965837|FG001|Twelve Month Follow-up|Lost to Follow-up|1
6266755|NCT02116621|9965836|FG000|Twelve Month Follow-up|Did not complete follow-up survey|1
6266756|NCT02116621|9965837|FG001|Twelve Month Follow-up|Did not complete follow-up survey|3
6266757|NCT02116621|9965836|FG000|Twelve Month Follow-up|Enrolled within 12 months of study end|14
6266758|NCT02116621|9965837|FG001|Twelve Month Follow-up|Enrolled within 12 months of study end|8
6266759|NCT02116660|9965845|FG000|Overall Study|Deteriorating renal function|0
6266760|NCT02116660|9965846|FG001|Overall Study|Deteriorating renal function|1
6266761|NCT02116660|9965845|FG000|Overall Study|Adverse Event|1
6266762|NCT02116660|9965846|FG001|Overall Study|Adverse Event|1
6266763|NCT02116660|9965845|FG000|Overall Study|Withdrawal by Subject|0
6266764|NCT02116660|9965846|FG001|Overall Study|Withdrawal by Subject|2
6266765|NCT02116660|9965845|FG000|Overall Study|Organization reason|1
6266766|NCT02116660|9965846|FG001|Overall Study|Organization reason|0
6266767|NCT02116777|9965861|FG000|Overall Study|Adverse Event|0
6266768|NCT02116777|9965862|FG001|Overall Study|Adverse Event|0
6266769|NCT02116777|9965863|FG002|Overall Study|Adverse Event|0
6266770|NCT02116777|9965864|FG003|Overall Study|Adverse Event|0
6266771|NCT02116777|9965865|FG004|Overall Study|Adverse Event|2
6266772|NCT02116777|9965866|FG005|Overall Study|Adverse Event|2
6266773|NCT02116777|9965867|FG006|Overall Study|Adverse Event|0
6266774|NCT02116777|9965861|FG000|Overall Study|Death|0
6266775|NCT02116777|9965862|FG001|Overall Study|Death|0
6266776|NCT02116777|9965863|FG002|Overall Study|Death|0
6266777|NCT02116777|9965864|FG003|Overall Study|Death|1
6266778|NCT02116777|9965865|FG004|Overall Study|Death|0
6266779|NCT02116777|9965866|FG005|Overall Study|Death|0
6266780|NCT02116777|9965867|FG006|Overall Study|Death|0
6266781|NCT02116777|9965861|FG000|Overall Study|Lack of Efficacy|3
6266782|NCT02116777|9965862|FG001|Overall Study|Lack of Efficacy|3
6266783|NCT02116777|9965863|FG002|Overall Study|Lack of Efficacy|3
6266784|NCT02116777|9965864|FG003|Overall Study|Lack of Efficacy|8
6266785|NCT02116777|9965865|FG004|Overall Study|Lack of Efficacy|4
6266786|NCT02116777|9965866|FG005|Overall Study|Lack of Efficacy|1
6266787|NCT02116777|9965867|FG006|Overall Study|Lack of Efficacy|9
6266788|NCT02116777|9965861|FG000|Overall Study|Physician Decision|0
6266789|NCT02116777|9965862|FG001|Overall Study|Physician Decision|0
6266790|NCT02116777|9965863|FG002|Overall Study|Physician Decision|0
6266791|NCT02116777|9965864|FG003|Overall Study|Physician Decision|2
6266792|NCT02116777|9965865|FG004|Overall Study|Physician Decision|0
6266793|NCT02116777|9965866|FG005|Overall Study|Physician Decision|0
6266794|NCT02116777|9965867|FG006|Overall Study|Physician Decision|0
6266795|NCT02116777|9965861|FG000|Overall Study|Protocol Violation|0
6266796|NCT02116777|9965862|FG001|Overall Study|Protocol Violation|0
6266797|NCT02116777|9965863|FG002|Overall Study|Protocol Violation|0
6266798|NCT02116777|9965864|FG003|Overall Study|Protocol Violation|1
6266799|NCT02116777|9965865|FG004|Overall Study|Protocol Violation|0
6266800|NCT02116777|9965866|FG005|Overall Study|Protocol Violation|0
6266801|NCT02116777|9965867|FG006|Overall Study|Protocol Violation|0
6266802|NCT02116777|9965861|FG000|Overall Study|Withdrawal by Subject|0
6266803|NCT02116777|9965862|FG001|Overall Study|Withdrawal by Subject|0
6266804|NCT02116777|9965863|FG002|Overall Study|Withdrawal by Subject|0
6266805|NCT02116777|9965864|FG003|Overall Study|Withdrawal by Subject|1
6266806|NCT02116777|9965865|FG004|Overall Study|Withdrawal by Subject|0
6266807|NCT02116777|9965866|FG005|Overall Study|Withdrawal by Subject|0
6266808|NCT02116777|9965867|FG006|Overall Study|Withdrawal by Subject|0
6266809|NCT02116803|9965888|FG000|Overall Study|Adverse Event|2
6086995|NCT00665925|9697111|FG001|Overall Study|Due to exclusion criteria|0
6266810|NCT02116803|9965889|FG001|Overall Study|Adverse Event|1
6266811|NCT02116803|9965888|FG000|Overall Study|Physician Decision|1
6266812|NCT02116803|9965889|FG001|Overall Study|Physician Decision|0
6266813|NCT02116803|9965888|FG000|Overall Study|Progressive disease|4
6266814|NCT02116803|9965889|FG001|Overall Study|Progressive disease|0
6266815|NCT02116803|9965888|FG000|Overall Study|Study terminated by sponsor|2
6266816|NCT02116803|9965889|FG001|Overall Study|Study terminated by sponsor|1
6266817|NCT02116803|9965888|FG000|Overall Study|Death|1
6266818|NCT02116803|9965889|FG001|Overall Study|Death|0
6266819|NCT02116972|9965898|FG000|Overall Study|Adverse Event|4
6266820|NCT02116972|9965899|FG001|Overall Study|Adverse Event|4
6266821|NCT02116972|9965900|FG002|Overall Study|Adverse Event|1
6266822|NCT02116972|9965898|FG000|Overall Study|Withdrawal by Subject|1
6266823|NCT02116972|9965899|FG001|Overall Study|Withdrawal by Subject|1
6266824|NCT02116972|9965900|FG002|Overall Study|Withdrawal by Subject|5
6266825|NCT02116972|9965898|FG000|Overall Study|Protocol Violation|1
6266826|NCT02116972|9965899|FG001|Overall Study|Protocol Violation|0
6266827|NCT02116972|9965900|FG002|Overall Study|Protocol Violation|1
6266828|NCT02116972|9965898|FG000|Overall Study|Lost to Follow-up|4
6266829|NCT02116972|9965899|FG001|Overall Study|Lost to Follow-up|3
6266830|NCT02116972|9965900|FG002|Overall Study|Lost to Follow-up|1
6266831|NCT02116972|9965898|FG000|Overall Study|Lack of Efficacy|6
6266832|NCT02116972|9965899|FG001|Overall Study|Lack of Efficacy|6
6266833|NCT02116972|9965900|FG002|Overall Study|Lack of Efficacy|5
6266834|NCT02116972|9965898|FG000|Overall Study|scheduling conflicts and relocation|3
6266835|NCT02116972|9965899|FG001|Overall Study|scheduling conflicts and relocation|3
6266836|NCT02116972|9965900|FG002|Overall Study|scheduling conflicts and relocation|6
6266837|NCT02117024|9965912|FG000|Overall Study|Progressive Disease|26
6266838|NCT02117024|9965913|FG001|Overall Study|Progressive Disease|9
6266839|NCT02117024|9965912|FG000|Overall Study|Significant Clinical Progression|7
6266840|NCT02117024|9965913|FG001|Overall Study|Significant Clinical Progression|4
6266841|NCT02117024|9965912|FG000|Overall Study|Death|5
6266842|NCT02117024|9965913|FG001|Overall Study|Death|0
6266843|NCT02117024|9965912|FG000|Overall Study|Withdrawal by Subject|3
6266844|NCT02117024|9965913|FG001|Overall Study|Withdrawal by Subject|1
6266845|NCT02117024|9965912|FG000|Overall Study|Protocol Violation|1
6266846|NCT02117024|9965913|FG001|Overall Study|Protocol Violation|0
6266847|NCT02117024|9965912|FG000|Overall Study|Adverse Event|1
6266848|NCT02117024|9965913|FG001|Overall Study|Adverse Event|2
6266849|NCT02117024|9965912|FG000|Overall Study|Randomized in Error|1
6266850|NCT02117024|9965913|FG001|Overall Study|Randomized in Error|0
6266851|NCT02117024|9965912|FG000|Overall Study|Patient returned to primary oncologist|0
6266852|NCT02117024|9965913|FG001|Overall Study|Patient returned to primary oncologist|1
6266853|NCT02117024|9965912|FG000|Overall Study|Patient took treatment break|0
6266854|NCT02117024|9965913|FG001|Overall Study|Patient took treatment break|1
6266855|NCT02117024|9965912|FG000|Overall Study|Physician Decision|0
6266856|NCT02117024|9965913|FG001|Overall Study|Physician Decision|2
6266857|NCT02117349|9965944|FG000|Overall Study|Withdrawal by Subject|1
6266858|NCT02117349|9965945|FG001|Overall Study|Withdrawal by Subject|0
6266859|NCT02117349|9965944|FG000|Overall Study|Lost to Follow-up|1
6266860|NCT02117349|9965945|FG001|Overall Study|Lost to Follow-up|1
6266861|NCT02117349|9965944|FG000|Overall Study|Death|1
6266862|NCT02117349|9965945|FG001|Overall Study|Death|0
6266863|NCT02117414|9965953|FG000|Overall Study|Death|5
6266864|NCT02117414|9965954|FG001|Overall Study|Death|2
6266865|NCT02117414|9965953|FG000|Overall Study|Withdrawal by Subject|10
6266866|NCT02117414|9965954|FG001|Overall Study|Withdrawal by Subject|4
6266867|NCT02117427|9965965|FG000|Overall Study|Permanent need for exogenous EPO Tx|2
6266868|NCT02117427|9965966|FG001|Overall Study|Permanent need for exogenous EPO Tx|0
6266869|NCT02117427|9965967|FG002|Overall Study|Permanent need for exogenous EPO Tx|0
6266870|NCT02117427|9965965|FG000|Overall Study|Permanent need for exogenous ESA Tx|3
6266871|NCT02117427|9965966|FG001|Overall Study|Permanent need for exogenous ESA Tx|1
6266872|NCT02117427|9965967|FG002|Overall Study|Permanent need for exogenous ESA Tx|0
6266873|NCT02117427|9965965|FG000|Overall Study|Physician Decision|0
6086996|NCT00665925|9697112|FG002|Overall Study|Due to exclusion criteria|0
6266874|NCT02117427|9965966|FG001|Overall Study|Physician Decision|2
6266875|NCT02117427|9965967|FG002|Overall Study|Physician Decision|0
6266876|NCT02117427|9965965|FG000|Overall Study|No longer meets inclusion criteria|0
6266877|NCT02117427|9965966|FG001|Overall Study|No longer meets inclusion criteria|1
6266878|NCT02117427|9965967|FG002|Overall Study|No longer meets inclusion criteria|0
6266879|NCT02117427|9965965|FG000|Overall Study|Death|0
6266880|NCT02117427|9965966|FG001|Overall Study|Death|1
6266881|NCT02117427|9965967|FG002|Overall Study|Death|0
6266882|NCT02117479|9965975|FG000|Overall Study|Death|13
6266883|NCT02117479|9965976|FG001|Overall Study|Death|8
6266884|NCT02117479|9965975|FG000|Overall Study|Adverse Event|8
6266885|NCT02117479|9965976|FG001|Overall Study|Adverse Event|16
6266886|NCT02117479|9965975|FG000|Overall Study|Subject decision|8
6266887|NCT02117479|9965976|FG001|Overall Study|Subject decision|9
6266888|NCT02117479|9965975|FG000|Overall Study|Disease progression|104
6266889|NCT02117479|9965976|FG001|Overall Study|Disease progression|108
6266890|NCT02117479|9965975|FG000|Overall Study|Noncompliance with study treatment|1
6266891|NCT02117479|9965976|FG001|Overall Study|Noncompliance with study treatment|0
6266892|NCT02117479|9965975|FG000|Overall Study|Study terminated by the sponsor|4
6266893|NCT02117479|9965976|FG001|Overall Study|Study terminated by the sponsor|6
6266894|NCT02117479|9965975|FG000|Overall Study|Physician Decision|7
6266895|NCT02117479|9965976|FG001|Overall Study|Physician Decision|2
6266896|NCT02117479|9965975|FG000|Overall Study|Other unspecified|11
6266897|NCT02117479|9965976|FG001|Overall Study|Other unspecified|7
6266898|NCT02117544|9965982|FG000|Period 1|Lost to follow-up (prior to treatment)|2
6266899|NCT02117544|9965983|FG001|Period 1|Lost to follow-up (prior to treatment)|0
6266900|NCT02117570|9965993|FG000|Stage 1 Participants Aged 50 to 64 Years|Withdrawal by Subject|0
6266901|NCT02117570|9965994|FG001|Stage 1 Participants Aged 50 to 64 Years|Withdrawal by Subject|2
6266902|NCT02117570|9965995|FG002|Stage 1 Participants Aged 50 to 64 Years|Withdrawal by Subject|1
6266903|NCT02117570|9965993|FG000|Stage 1 Participants Aged 50 to 64 Years|Lost to Follow-up|1
6266904|NCT02117570|9965994|FG001|Stage 1 Participants Aged 50 to 64 Years|Lost to Follow-up|1
6266905|NCT02117570|9965995|FG002|Stage 1 Participants Aged 50 to 64 Years|Lost to Follow-up|0
6266906|NCT02117570|9965993|FG000|Stage 2 Participants Aged 65 to 85 Years|Withdrawal by Subject|0
6266907|NCT02117570|9965994|FG001|Stage 2 Participants Aged 65 to 85 Years|Withdrawal by Subject|0
6266908|NCT02117570|9965995|FG002|Stage 2 Participants Aged 65 to 85 Years|Withdrawal by Subject|2
6266909|NCT02117570|9965993|FG000|Stage 2 Participants Aged 65 to 85 Years|Death|0
6266910|NCT02117570|9965994|FG001|Stage 2 Participants Aged 65 to 85 Years|Death|0
6266911|NCT02117570|9965995|FG002|Stage 2 Participants Aged 65 to 85 Years|Death|1
6266912|NCT02117570|9965993|FG000|Stage 2 Participants Aged 65 to 85 Years|Protocol Violation|0
6266913|NCT02117570|9965994|FG001|Stage 2 Participants Aged 65 to 85 Years|Protocol Violation|0
6266914|NCT02117570|9965995|FG002|Stage 2 Participants Aged 65 to 85 Years|Protocol Violation|1
6266915|NCT02117570|9965993|FG000|Stage 2 Participants Aged 65 to 85 Years|Lost to Follow-up|1
6266916|NCT02117570|9965994|FG001|Stage 2 Participants Aged 65 to 85 Years|Lost to Follow-up|2
6266917|NCT02117570|9965995|FG002|Stage 2 Participants Aged 65 to 85 Years|Lost to Follow-up|2
6266918|NCT02117570|9965993|FG000|Stage 2 Participants Aged 65 to 85 Years|Withdrew before vaccination|0
6266919|NCT02117570|9965994|FG001|Stage 2 Participants Aged 65 to 85 Years|Withdrew before vaccination|1
6266920|NCT02117570|9965995|FG002|Stage 2 Participants Aged 65 to 85 Years|Withdrew before vaccination|0
6266921|NCT02117648|9966006|FG000|Abemaciclib Alone Period 1|Withdrawal by Subject|1
6266922|NCT02117648|9966006|FG000|Abemaciclib Alone Period 1|Adverse Event|1
6266923|NCT02117648|9966006|FG000|Abemaciclib + Clarithromycin Period 2|Progressive Disease|1
6266924|NCT02117648|9966006|FG000|Abemaciclib + Clarithromycin Period 2|Death|1
6266925|NCT02117648|9966006|FG000|Abemaciclib + Clarithromycin Period 2|Adverse Event|1
6266926|NCT02117648|9966006|FG000|Abemaciclib + Clarithromycin Period 2|Withdrawal by Subject|1
6266927|NCT02117648|9966006|FG000|Abemaciclib Safety-Extension Phase|Progressive Disease|12
6266928|NCT02117648|9966006|FG000|Abemaciclib Safety-Extension Phase|Physician Decision|1
6266929|NCT02117648|9966006|FG000|Abemaciclib Safety-Extension Phase|Death|3
6266930|NCT02117648|9966006|FG000|Abemaciclib Safety-Extension Phase|Withdrawal by Subject|2
6266931|NCT02117648|9966006|FG000|Abemaciclib Safety-Extension Phase|Adverse Event|2
6266932|NCT02117687|9966016|FG000|Overall Study|Lost to Follow-up|0
6266933|NCT02117687|9966017|FG001|Overall Study|Lost to Follow-up|1
6266934|NCT02117687|9966016|FG000|Overall Study|Adverse Event|0
6266935|NCT02117687|9966017|FG001|Overall Study|Adverse Event|2
6266936|NCT02117687|9966016|FG000|Overall Study|Other Reasons|1
6266937|NCT02117687|9966017|FG001|Overall Study|Other Reasons|1
6266938|NCT02117713|9966023|FG000|Week 48|Adverse Event|4
6266939|NCT02117713|9966023|FG000|Week 48|Withdrawal by caregiver|2
6266940|NCT02117713|9966023|FG000|Week 48|Did not consent to Protocol Amendment 4|2
6266941|NCT02117713|9966023|FG000|Long Term Follow-up Treatment|Adverse Event|3
6266942|NCT02117713|9966023|FG000|Long Term Follow-up Treatment|Progressive Disease|2
6266943|NCT02117713|9966023|FG000|Long Term Follow-up Treatment|Non-Compliance with study drug|1
6266944|NCT02118012|9966057|FG000|Overall Study|Adverse Event|0
6266945|NCT02118012|9966058|FG001|Overall Study|Adverse Event|1
6266946|NCT02118012|9966057|FG000|Overall Study|Physician Decision|0
6266947|NCT02118012|9966058|FG001|Overall Study|Physician Decision|1
6266948|NCT02118337|9966073|FG000|Overall Study|Other|1
6266949|NCT02118337|9966074|FG001|Overall Study|Other|0
6266950|NCT02118337|9966075|FG002|Overall Study|Other|0
6266951|NCT02118337|9966076|FG003|Overall Study|Other|0
6266952|NCT02118337|9966077|FG004|Overall Study|Other|2
6266953|NCT02118337|9966078|FG005|Overall Study|Other|3
6266954|NCT02118337|9966079|FG006|Overall Study|Other|1
6086997|NCT00665925|9697113|FG003|Overall Study|Due to exclusion criteria|0
6266955|NCT02118337|9966080|FG007|Overall Study|Other|28
6266956|NCT02118337|9966081|FG008|Overall Study|Other|15
6266957|NCT02118337|9966073|FG000|Overall Study|Lost to Follow-up|0
6266958|NCT02118337|9966074|FG001|Overall Study|Lost to Follow-up|0
6266959|NCT02118337|9966075|FG002|Overall Study|Lost to Follow-up|0
6266960|NCT02118337|9966076|FG003|Overall Study|Lost to Follow-up|0
6266961|NCT02118337|9966077|FG004|Overall Study|Lost to Follow-up|0
6266962|NCT02118337|9966078|FG005|Overall Study|Lost to Follow-up|0
6266963|NCT02118337|9966079|FG006|Overall Study|Lost to Follow-up|0
6266964|NCT02118337|9966080|FG007|Overall Study|Lost to Follow-up|1
6266965|NCT02118337|9966081|FG008|Overall Study|Lost to Follow-up|0
6266966|NCT02118337|9966073|FG000|Overall Study|Withdrawal by Subject|1
6266967|NCT02118337|9966074|FG001|Overall Study|Withdrawal by Subject|3
6266968|NCT02118337|9966075|FG002|Overall Study|Withdrawal by Subject|2
6266969|NCT02118337|9966076|FG003|Overall Study|Withdrawal by Subject|1
6266970|NCT02118337|9966077|FG004|Overall Study|Withdrawal by Subject|2
6266971|NCT02118337|9966078|FG005|Overall Study|Withdrawal by Subject|2
6266972|NCT02118337|9966079|FG006|Overall Study|Withdrawal by Subject|1
6266973|NCT02118337|9966080|FG007|Overall Study|Withdrawal by Subject|4
6266974|NCT02118337|9966081|FG008|Overall Study|Withdrawal by Subject|2
6266975|NCT02118337|9966073|FG000|Overall Study|Death|2
6266976|NCT02118337|9966074|FG001|Overall Study|Death|2
6266977|NCT02118337|9966075|FG002|Overall Study|Death|1
6266978|NCT02118337|9966076|FG003|Overall Study|Death|2
6266979|NCT02118337|9966077|FG004|Overall Study|Death|5
6266980|NCT02118337|9966078|FG005|Overall Study|Death|1
6266981|NCT02118337|9966079|FG006|Overall Study|Death|2
6266982|NCT02118337|9966080|FG007|Overall Study|Death|9
6266983|NCT02118337|9966081|FG008|Overall Study|Death|4
6266984|NCT02118428|9966107|FG000|Overall Study|Physician Decision|0
6266985|NCT02118428|9966108|FG001|Overall Study|Physician Decision|1
6266986|NCT02118428|9966109|FG002|Overall Study|Physician Decision|0
6266987|NCT02118428|9966107|FG000|Overall Study|Withdrawal by Subject|2
6266988|NCT02118428|9966108|FG001|Overall Study|Withdrawal by Subject|2
6266989|NCT02118428|9966109|FG002|Overall Study|Withdrawal by Subject|0
6266990|NCT02118428|9966107|FG000|Overall Study|Death|7
6266991|NCT02118428|9966108|FG001|Overall Study|Death|5
6266992|NCT02118428|9966109|FG002|Overall Study|Death|0
6266993|NCT02118428|9966107|FG000|Overall Study|Lost to Follow-up|3
6266994|NCT02118428|9966108|FG001|Overall Study|Lost to Follow-up|1
6266995|NCT02118428|9966109|FG002|Overall Study|Lost to Follow-up|0
6266996|NCT02118428|9966107|FG000|Overall Study|Screen Failure or Became Inelegible|1
6266997|NCT02118428|9966108|FG001|Overall Study|Screen Failure or Became Inelegible|0
6266998|NCT02118428|9966109|FG002|Overall Study|Screen Failure or Became Inelegible|1
6266999|NCT02118597|9966125|FG000|Overall Study|Sponsor terminated the study|14
6267000|NCT02118597|9966125|FG000|Overall Study|Serious Adverse Event|1
6267001|NCT02118597|9966125|FG000|Overall Study|Investigator's decision|1
6267002|NCT02118714|9966129|FG000|Overall Study|Lost to Follow-up|2
6267003|NCT02118714|9966129|FG000|Overall Study|Protocol Violation|1
6267004|NCT02118766|9966135|FG000|Overall Study|Adverse Event|7
6267005|NCT02118766|9966136|FG001|Overall Study|Adverse Event|2
6267006|NCT02118766|9966135|FG000|Overall Study|Withdrawal by Subject|3
6267007|NCT02118766|9966136|FG001|Overall Study|Withdrawal by Subject|6
6267008|NCT02118766|9966135|FG000|Overall Study|Lost to Follow-up|5
6086998|NCT00666198|9697134|FG000|Overall Study|Protocol Violation|10
6086999|NCT00666198|9697134|FG000|Overall Study|No Visit After First Day of Treatment|13
6267009|NCT02118766|9966136|FG001|Overall Study|Lost to Follow-up|4
6267010|NCT02118766|9966135|FG000|Overall Study|Withdrawal by parent/guardian|12
6267011|NCT02118766|9966136|FG001|Overall Study|Withdrawal by parent/guardian|18
6267012|NCT02118766|9966135|FG000|Overall Study|Other|3
6267013|NCT02118766|9966136|FG001|Overall Study|Other|1
6267014|NCT02118792|9966144|FG000|Overall Study|Withdrawal by Subject|6
6267015|NCT02118792|9966145|FG001|Overall Study|Withdrawal by Subject|3
6267016|NCT02118792|9966144|FG000|Overall Study|Lost to Follow-up|4
6267017|NCT02118792|9966145|FG001|Overall Study|Lost to Follow-up|4
6267018|NCT02118792|9966144|FG000|Overall Study|Adverse Event|5
6267019|NCT02118792|9966145|FG001|Overall Study|Adverse Event|4
6267020|NCT02118792|9966144|FG000|Overall Study|Withdrawal by parent/guardian|14
6267021|NCT02118792|9966145|FG001|Overall Study|Withdrawal by parent/guardian|20
6267022|NCT02118792|9966144|FG000|Overall Study|Other|1
6267023|NCT02118792|9966145|FG001|Overall Study|Other|6
6267024|NCT02118792|9966144|FG000|Overall Study|Randomised but not treated|1
6267025|NCT02118792|9966145|FG001|Overall Study|Randomised but not treated|0
6267026|NCT02118896|9966176|FG000|Overall Study|Death|4
6267027|NCT02118896|9966177|FG001|Overall Study|Death|0
6267028|NCT02118896|9966178|FG002|Overall Study|Death|4
6267029|NCT02118896|9966179|FG003|Overall Study|Death|6
6267030|NCT02118896|9966180|FG004|Overall Study|Death|3
6267031|NCT02118896|9966181|FG005|Overall Study|Death|1
6267032|NCT02118896|9966182|FG006|Overall Study|Death|0
6267033|NCT02118896|9966183|FG007|Overall Study|Death|0
6267034|NCT02118896|9966184|FG008|Overall Study|Death|0
6267035|NCT02118896|9966185|FG009|Overall Study|Death|0
6267036|NCT02118896|9966176|FG000|Overall Study|Adverse Event|5
6267037|NCT02118896|9966177|FG001|Overall Study|Adverse Event|4
6267038|NCT02118896|9966178|FG002|Overall Study|Adverse Event|4
6267039|NCT02118896|9966179|FG003|Overall Study|Adverse Event|5
6267040|NCT02118896|9966180|FG004|Overall Study|Adverse Event|5
6267041|NCT02118896|9966181|FG005|Overall Study|Adverse Event|9
6267042|NCT02118896|9966182|FG006|Overall Study|Adverse Event|1
6267043|NCT02118896|9966183|FG007|Overall Study|Adverse Event|1
6267044|NCT02118896|9966184|FG008|Overall Study|Adverse Event|4
6267045|NCT02118896|9966185|FG009|Overall Study|Adverse Event|0
6267046|NCT02118896|9966176|FG000|Overall Study|Consent withdrawn|2
6267047|NCT02118896|9966177|FG001|Overall Study|Consent withdrawn|0
6267048|NCT02118896|9966178|FG002|Overall Study|Consent withdrawn|3
6267049|NCT02118896|9966179|FG003|Overall Study|Consent withdrawn|4
6267050|NCT02118896|9966180|FG004|Overall Study|Consent withdrawn|1
6267051|NCT02118896|9966181|FG005|Overall Study|Consent withdrawn|4
6267052|NCT02118896|9966182|FG006|Overall Study|Consent withdrawn|0
6267053|NCT02118896|9966183|FG007|Overall Study|Consent withdrawn|0
6267054|NCT02118896|9966184|FG008|Overall Study|Consent withdrawn|0
6267055|NCT02118896|9966185|FG009|Overall Study|Consent withdrawn|0
6267056|NCT02118896|9966176|FG000|Overall Study|Non-compliance|2
6267057|NCT02118896|9966177|FG001|Overall Study|Non-compliance|1
6267058|NCT02118896|9966178|FG002|Overall Study|Non-compliance|1
6267059|NCT02118896|9966179|FG003|Overall Study|Non-compliance|5
6267060|NCT02118896|9966180|FG004|Overall Study|Non-compliance|0
6267061|NCT02118896|9966181|FG005|Overall Study|Non-compliance|1
6267062|NCT02118896|9966182|FG006|Overall Study|Non-compliance|0
6267063|NCT02118896|9966183|FG007|Overall Study|Non-compliance|1
6267064|NCT02118896|9966184|FG008|Overall Study|Non-compliance|0
6267065|NCT02118896|9966185|FG009|Overall Study|Non-compliance|0
6267066|NCT02118896|9966176|FG000|Overall Study|Pregnancy|1
6267067|NCT02118896|9966177|FG001|Overall Study|Pregnancy|1
6267068|NCT02118896|9966178|FG002|Overall Study|Pregnancy|0
6267069|NCT02118896|9966179|FG003|Overall Study|Pregnancy|0
6267070|NCT02118896|9966180|FG004|Overall Study|Pregnancy|1
6267071|NCT02118896|9966181|FG005|Overall Study|Pregnancy|3
6267072|NCT02118896|9966182|FG006|Overall Study|Pregnancy|1
6267073|NCT02118896|9966183|FG007|Overall Study|Pregnancy|0
6267074|NCT02118896|9966184|FG008|Overall Study|Pregnancy|0
6267075|NCT02118896|9966185|FG009|Overall Study|Pregnancy|0
6267076|NCT02118896|9966176|FG000|Overall Study|Lost to Follow-up|1
6267077|NCT02118896|9966177|FG001|Overall Study|Lost to Follow-up|2
6267078|NCT02118896|9966178|FG002|Overall Study|Lost to Follow-up|1
6267079|NCT02118896|9966179|FG003|Overall Study|Lost to Follow-up|0
6267080|NCT02118896|9966180|FG004|Overall Study|Lost to Follow-up|2
6267081|NCT02118896|9966181|FG005|Overall Study|Lost to Follow-up|1
6267082|NCT02118896|9966182|FG006|Overall Study|Lost to Follow-up|0
6267083|NCT02118896|9966183|FG007|Overall Study|Lost to Follow-up|0
6267084|NCT02118896|9966184|FG008|Overall Study|Lost to Follow-up|0
6267085|NCT02118896|9966185|FG009|Overall Study|Lost to Follow-up|0
6267086|NCT02118896|9966176|FG000|Overall Study|Immunosuppressive regimen (not MR4)|1
6267087|NCT02118896|9966177|FG001|Overall Study|Immunosuppressive regimen (not MR4)|5
6267088|NCT02118896|9966178|FG002|Overall Study|Immunosuppressive regimen (not MR4)|1
6267089|NCT02118896|9966179|FG003|Overall Study|Immunosuppressive regimen (not MR4)|2
6267090|NCT02118896|9966180|FG004|Overall Study|Immunosuppressive regimen (not MR4)|4
6267091|NCT02118896|9966181|FG005|Overall Study|Immunosuppressive regimen (not MR4)|2
6267092|NCT02118896|9966182|FG006|Overall Study|Immunosuppressive regimen (not MR4)|0
6267093|NCT02118896|9966183|FG007|Overall Study|Immunosuppressive regimen (not MR4)|0
6267094|NCT02118896|9966184|FG008|Overall Study|Immunosuppressive regimen (not MR4)|0
6267095|NCT02118896|9966185|FG009|Overall Study|Immunosuppressive regimen (not MR4)|2
6267096|NCT02118896|9966176|FG000|Overall Study|Prohibited medication|0
6267097|NCT02118896|9966177|FG001|Overall Study|Prohibited medication|0
6267098|NCT02118896|9966178|FG002|Overall Study|Prohibited medication|0
6267099|NCT02118896|9966179|FG003|Overall Study|Prohibited medication|0
6267100|NCT02118896|9966180|FG004|Overall Study|Prohibited medication|1
6267101|NCT02118896|9966181|FG005|Overall Study|Prohibited medication|3
6267102|NCT02118896|9966182|FG006|Overall Study|Prohibited medication|0
6267103|NCT02118896|9966183|FG007|Overall Study|Prohibited medication|0
6267104|NCT02118896|9966184|FG008|Overall Study|Prohibited medication|0
6267105|NCT02118896|9966185|FG009|Overall Study|Prohibited medication|0
6267106|NCT02118896|9966176|FG000|Overall Study|Miscellaneous|1
6267107|NCT02118896|9966177|FG001|Overall Study|Miscellaneous|2
6267108|NCT02118896|9966178|FG002|Overall Study|Miscellaneous|0
6267109|NCT02118896|9966179|FG003|Overall Study|Miscellaneous|2
6267110|NCT02118896|9966180|FG004|Overall Study|Miscellaneous|0
6267111|NCT02118896|9966181|FG005|Overall Study|Miscellaneous|4
6267112|NCT02118896|9966182|FG006|Overall Study|Miscellaneous|0
6267113|NCT02118896|9966183|FG007|Overall Study|Miscellaneous|0
6267114|NCT02118896|9966184|FG008|Overall Study|Miscellaneous|0
6267115|NCT02118896|9966185|FG009|Overall Study|Miscellaneous|0
6267116|NCT02118961|9966210|FG000|Overall Study|Withdrawal by Subject|1
6267117|NCT02118961|9966211|FG001|Overall Study|Withdrawal by Subject|0
6267118|NCT02119026|9966219|FG000|1st-line Treatment|Adverse Event|9
6267119|NCT02119026|9966220|FG001|1st-line Treatment|Adverse Event|14
6267120|NCT02119026|9966219|FG000|1st-line Treatment|Physician Decision|3
6267121|NCT02119026|9966220|FG001|1st-line Treatment|Physician Decision|8
6267122|NCT02119026|9966219|FG000|1st-line Treatment|Withdrawal by Subject|4
6267123|NCT02119026|9966220|FG001|1st-line Treatment|Withdrawal by Subject|10
6267124|NCT02119026|9966219|FG000|1st-line Treatment|Patient condition or compliance|6
6267125|NCT02119026|9966220|FG001|1st-line Treatment|Patient condition or compliance|4
6267126|NCT02119026|9966219|FG000|1st-line Treatment|Surgery of metastases|2
6267127|NCT02119026|9966220|FG001|1st-line Treatment|Surgery of metastases|1
6267128|NCT02119026|9966219|FG000|1st-line Treatment|Death|2
6267129|NCT02119026|9966220|FG001|1st-line Treatment|Death|1
6267130|NCT02119026|9966219|FG000|2nd-line Treatment|Lost to Follow-up|2
6267131|NCT02119026|9966220|FG001|2nd-line Treatment|Lost to Follow-up|0
6267132|NCT02119026|9966219|FG000|2nd-line Treatment|Withdrawal by Subject|3
6267133|NCT02119026|9966220|FG001|2nd-line Treatment|Withdrawal by Subject|1
6267134|NCT02119026|9966219|FG000|2nd-line Treatment|Adverse Event|4
6267135|NCT02119026|9966220|FG001|2nd-line Treatment|Adverse Event|1
6267136|NCT02119104|9966226|FG000|Overall Study|Protocol Violation|16
6267137|NCT02119156|9966233|FG000|Treatment Phase (Up to 52 Weeks)|Study Terminated By Sponsor|0
6267138|NCT02119156|9966234|FG001|Treatment Phase (Up to 52 Weeks)|Study Terminated By Sponsor|0
6267139|NCT02119156|9966235|FG002|Treatment Phase (Up to 52 Weeks)|Study Terminated By Sponsor|1
6267140|NCT02119156|9966233|FG000|Treatment Phase (Up to 52 Weeks)|Withdrawal by Subject|4
6267141|NCT02119156|9966234|FG001|Treatment Phase (Up to 52 Weeks)|Withdrawal by Subject|0
6267142|NCT02119156|9966235|FG002|Treatment Phase (Up to 52 Weeks)|Withdrawal by Subject|0
6267143|NCT02119156|9966233|FG000|Treatment Phase (Up to 52 Weeks)|Protocol Violation|1
6267144|NCT02119156|9966234|FG001|Treatment Phase (Up to 52 Weeks)|Protocol Violation|2
6267145|NCT02119156|9966235|FG002|Treatment Phase (Up to 52 Weeks)|Protocol Violation|0
6267146|NCT02119156|9966233|FG000|Treatment Phase (Up to 52 Weeks)|Physician Decision|1
6267147|NCT02119156|9966234|FG001|Treatment Phase (Up to 52 Weeks)|Physician Decision|0
6267148|NCT02119156|9966235|FG002|Treatment Phase (Up to 52 Weeks)|Physician Decision|0
6267149|NCT02119156|9966233|FG000|Maintenance (Up to 48 Weeks of Year 2-4)|Study Terminated By Sponsor|0
6267150|NCT02119156|9966234|FG001|Maintenance (Up to 48 Weeks of Year 2-4)|Study Terminated By Sponsor|10
6267151|NCT02119156|9966235|FG002|Maintenance (Up to 48 Weeks of Year 2-4)|Study Terminated By Sponsor|7
6267152|NCT02119260|9966257|FG000|Overall Study|Adverse Event|1
6267153|NCT02119260|9966258|FG001|Overall Study|Adverse Event|0
6267154|NCT02119260|9966259|FG002|Overall Study|Adverse Event|0
6267155|NCT02119260|9966260|FG003|Overall Study|Adverse Event|0
6267156|NCT02119260|9966261|FG004|Overall Study|Adverse Event|0
6267157|NCT02119260|9966262|FG005|Overall Study|Adverse Event|0
6267158|NCT02119260|9966263|FG006|Overall Study|Adverse Event|0
6267159|NCT02119260|9966257|FG000|Overall Study|Withdrew consent|0
6267160|NCT02119260|9966258|FG001|Overall Study|Withdrew consent|1
6267161|NCT02119260|9966259|FG002|Overall Study|Withdrew consent|1
6267162|NCT02119260|9966260|FG003|Overall Study|Withdrew consent|0
6267163|NCT02119260|9966261|FG004|Overall Study|Withdrew consent|0
6267164|NCT02119260|9966262|FG005|Overall Study|Withdrew consent|0
6267165|NCT02119260|9966263|FG006|Overall Study|Withdrew consent|0
6267166|NCT02119286|9966291|FG000|Overall Study|Adverse Event|9
6267167|NCT02119286|9966292|FG001|Overall Study|Adverse Event|7
6267168|NCT02119286|9966293|FG002|Overall Study|Adverse Event|2
6267169|NCT02119286|9966291|FG000|Overall Study|Lack of Efficacy|11
6267170|NCT02119286|9966292|FG001|Overall Study|Lack of Efficacy|3
6267171|NCT02119286|9966293|FG002|Overall Study|Lack of Efficacy|4
6267172|NCT02119286|9966291|FG000|Overall Study|Lost to Follow-up|2
6267173|NCT02119286|9966292|FG001|Overall Study|Lost to Follow-up|0
6267174|NCT02119286|9966293|FG002|Overall Study|Lost to Follow-up|1
6267175|NCT02119286|9966291|FG000|Overall Study|Withdrawal by Subject|4
6267176|NCT02119286|9966292|FG001|Overall Study|Withdrawal by Subject|1
6267177|NCT02119286|9966293|FG002|Overall Study|Withdrawal by Subject|0
6267178|NCT02119299|9966301|FG000|Overall Study|Withdrawal by Subject|7
6267179|NCT02119299|9966301|FG000|Overall Study|Lack of Efficacy|1
6267180|NCT02119299|9966301|FG000|Overall Study|Pregnancy|1
6267181|NCT02119325|9966305|FG000|Washout Period 1|Adverse Event|0
6267182|NCT02119325|9966306|FG001|Washout Period 1|Adverse Event|1
6267183|NCT02119650|9966329|FG000|Overall Study|Adverse Event|3
6267184|NCT02119650|9966330|FG001|Overall Study|Adverse Event|4
6267185|NCT02119650|9966329|FG000|Overall Study|Subject decision|2
6267186|NCT02119650|9966330|FG001|Overall Study|Subject decision|3
6267187|NCT02119650|9966329|FG000|Overall Study|Disease progression|11
6267188|NCT02119650|9966330|FG001|Overall Study|Disease progression|14
6267189|NCT02119650|9966329|FG000|Overall Study|Death|5
6267190|NCT02119650|9966330|FG001|Overall Study|Death|1
6267191|NCT02119650|9966329|FG000|Overall Study|Noncompliance with study treatment|1
6267192|NCT02119650|9966330|FG001|Overall Study|Noncompliance with study treatment|1
6267193|NCT02119650|9966329|FG000|Overall Study|Study terminated by the sponsor|1
6267194|NCT02119650|9966330|FG001|Overall Study|Study terminated by the sponsor|0
6267195|NCT02119650|9966329|FG000|Overall Study|Physician Decision|0
6267196|NCT02119650|9966330|FG001|Overall Study|Physician Decision|2
6267197|NCT02119650|9966329|FG000|Overall Study|Multiple reasons for termination|2
6267198|NCT02119650|9966330|FG001|Overall Study|Multiple reasons for termination|1
6267199|NCT02119663|9966338|FG000|Overall Study|Disease progression|26
6267200|NCT02119663|9966339|FG001|Overall Study|Disease progression|27
6267201|NCT02119663|9966338|FG000|Overall Study|Adverse Event|5
6267202|NCT02119663|9966339|FG001|Overall Study|Adverse Event|5
6267203|NCT02119663|9966338|FG000|Overall Study|Death|3
6267204|NCT02119663|9966339|FG001|Overall Study|Death|2
6267205|NCT02119663|9966338|FG000|Overall Study|Physician Decision|1
6267206|NCT02119663|9966339|FG001|Overall Study|Physician Decision|2
6267207|NCT02119663|9966338|FG000|Overall Study|Other unspecified|2
6267208|NCT02119663|9966339|FG001|Overall Study|Other unspecified|0
6267209|NCT02119663|9966338|FG000|Overall Study|Subject decision|0
6267210|NCT02119663|9966339|FG001|Overall Study|Subject decision|1
6267211|NCT02119663|9966338|FG000|Overall Study|Study Terminated by the Sponsor|3
6267212|NCT02119663|9966339|FG001|Overall Study|Study Terminated by the Sponsor|4
6267213|NCT02119676|9966349|FG000|Overall Study|Adverse Event|9
6267214|NCT02119676|9966350|FG001|Overall Study|Adverse Event|17
6267215|NCT02119676|9966351|FG002|Overall Study|Adverse Event|10
6267216|NCT02119676|9966352|FG003|Overall Study|Adverse Event|10
6267217|NCT02119676|9966349|FG000|Overall Study|Disease progression|53
6267218|NCT02119676|9966350|FG001|Overall Study|Disease progression|55
6267219|NCT02119676|9966351|FG002|Overall Study|Disease progression|68
6267220|NCT02119676|9966352|FG003|Overall Study|Disease progression|73
6267221|NCT02119676|9966349|FG000|Overall Study|Patient decision, inc. consent withdrawn|4
6267222|NCT02119676|9966350|FG001|Overall Study|Patient decision, inc. consent withdrawn|5
6267223|NCT02119676|9966351|FG002|Overall Study|Patient decision, inc. consent withdrawn|5
6267224|NCT02119676|9966352|FG003|Overall Study|Patient decision, inc. consent withdrawn|6
6267225|NCT02119676|9966349|FG000|Overall Study|Physician Decision|4
6267226|NCT02119676|9966350|FG001|Overall Study|Physician Decision|2
6267227|NCT02119676|9966351|FG002|Overall Study|Physician Decision|3
6267228|NCT02119676|9966352|FG003|Overall Study|Physician Decision|2
6267229|NCT02119676|9966349|FG000|Overall Study|Death|9
6267230|NCT02119676|9966350|FG001|Overall Study|Death|3
6267231|NCT02119676|9966351|FG002|Overall Study|Death|2
6267232|NCT02119676|9966352|FG003|Overall Study|Death|1
6267233|NCT02119676|9966349|FG000|Overall Study|Noncompliance|0
6267234|NCT02119676|9966350|FG001|Overall Study|Noncompliance|1
6267235|NCT02119676|9966351|FG002|Overall Study|Noncompliance|0
6267236|NCT02119676|9966352|FG003|Overall Study|Noncompliance|0
6087000|NCT00666198|9697134|FG000|Overall Study|Safety Not Assessable|6
6087001|NCT00666198|9697134|FG000|Overall Study|No Drug Administration|4
6087002|NCT00666211|9697140|FG000|Overall Study|Withdrawal by Subject|10
6087003|NCT00666211|9697141|FG001|Overall Study|Withdrawal by Subject|13
6087004|NCT00666211|9697140|FG000|Overall Study|went off medication, no more pain|1
6087005|NCT00666211|9697141|FG001|Overall Study|went off medication, no more pain|0
6087006|NCT00666211|9697140|FG000|Overall Study|patient non-compliant|6
6087007|NCT00666211|9697141|FG001|Overall Study|patient non-compliant|6
6087008|NCT00666211|9697140|FG000|Overall Study|disease progression|1
6087009|NCT00666211|9697141|FG001|Overall Study|disease progression|8
6191268|NCT01421342|9847962|FG002|Completed to Week 12 But Then Withdrawn|Non-adherence|5
6267237|NCT02119676|9966349|FG000|Overall Study|Lost to Follow-up|0
6267238|NCT02119676|9966350|FG001|Overall Study|Lost to Follow-up|0
6267239|NCT02119676|9966351|FG002|Overall Study|Lost to Follow-up|1
6267240|NCT02119676|9966352|FG003|Overall Study|Lost to Follow-up|0
6267241|NCT02119676|9966349|FG000|Overall Study|Protocol deviation|0
6267242|NCT02119676|9966350|FG001|Overall Study|Protocol deviation|0
6267243|NCT02119676|9966351|FG002|Overall Study|Protocol deviation|1
6267244|NCT02119676|9966352|FG003|Overall Study|Protocol deviation|0
6267245|NCT02119676|9966349|FG000|Overall Study|Other, unspecified|2
6267246|NCT02119676|9966350|FG001|Overall Study|Other, unspecified|1
6267247|NCT02119676|9966351|FG002|Overall Study|Other, unspecified|3
6267248|NCT02119676|9966352|FG003|Overall Study|Other, unspecified|4
6267249|NCT02119676|9966349|FG000|Overall Study|Did not receive study med|2
6267250|NCT02119676|9966350|FG001|Overall Study|Did not receive study med|2
6267251|NCT02119676|9966351|FG002|Overall Study|Did not receive study med|4
6267252|NCT02119676|9966352|FG003|Overall Study|Did not receive study med|5
6267253|NCT02119819|9966368|FG000|Overall Study|Adverse Event|3
6267254|NCT02119819|9966369|FG001|Overall Study|Adverse Event|1
6267255|NCT02119819|9966370|FG002|Overall Study|Adverse Event|2
6267256|NCT02119819|9966371|FG003|Overall Study|Adverse Event|3
6267257|NCT02119819|9966372|FG004|Overall Study|Adverse Event|0
6191269|NCT01421342|9847960|FG000|Completed to Week 12 But Then Withdrawn|Due to Other Illness|1
6191270|NCT01421342|9847961|FG001|Completed to Week 12 But Then Withdrawn|Due to Other Illness|0
6191271|NCT01421342|9847962|FG002|Completed to Week 12 But Then Withdrawn|Due to Other Illness|2
6191272|NCT01421342|9847960|FG000|Completed to Week 12 But Then Withdrawn|Participant Moved Away|1
6191273|NCT01421342|9847961|FG001|Completed to Week 12 But Then Withdrawn|Participant Moved Away|5
6191274|NCT01421342|9847962|FG002|Completed to Week 12 But Then Withdrawn|Participant Moved Away|5
6191275|NCT01421342|9847960|FG000|Completed to Week 12 But Then Withdrawn|Oher reason for withdrawal|3
6191276|NCT01421342|9847961|FG001|Completed to Week 12 But Then Withdrawn|Oher reason for withdrawal|3
6191277|NCT01421342|9847962|FG002|Completed to Week 12 But Then Withdrawn|Oher reason for withdrawal|4
6191278|NCT01421342|9847960|FG000|Completed to Week 12 But Then Withdrawn|End of Study Time|0
6191279|NCT01421342|9847961|FG001|Completed to Week 12 But Then Withdrawn|End of Study Time|0
6191280|NCT01421342|9847962|FG002|Completed to Week 12 But Then Withdrawn|End of Study Time|2
6267258|NCT02119819|9966373|FG005|Overall Study|Adverse Event|1
6267259|NCT02119819|9966368|FG000|Overall Study|Lack of Efficacy|0
6267260|NCT02119819|9966369|FG001|Overall Study|Lack of Efficacy|0
6267261|NCT02119819|9966370|FG002|Overall Study|Lack of Efficacy|0
6267262|NCT02119819|9966371|FG003|Overall Study|Lack of Efficacy|0
6267263|NCT02119819|9966372|FG004|Overall Study|Lack of Efficacy|0
6267264|NCT02119819|9966373|FG005|Overall Study|Lack of Efficacy|1
6267265|NCT02119819|9966368|FG000|Overall Study|Lost to Follow-up|0
6267266|NCT02119819|9966369|FG001|Overall Study|Lost to Follow-up|0
6267267|NCT02119819|9966370|FG002|Overall Study|Lost to Follow-up|1
6267268|NCT02119819|9966371|FG003|Overall Study|Lost to Follow-up|2
6267269|NCT02119819|9966372|FG004|Overall Study|Lost to Follow-up|1
6267270|NCT02119819|9966373|FG005|Overall Study|Lost to Follow-up|2
6267271|NCT02119819|9966368|FG000|Overall Study|Physician Decision|1
6267272|NCT02119819|9966369|FG001|Overall Study|Physician Decision|1
6267273|NCT02119819|9966370|FG002|Overall Study|Physician Decision|0
6267274|NCT02119819|9966371|FG003|Overall Study|Physician Decision|0
6267275|NCT02119819|9966372|FG004|Overall Study|Physician Decision|0
6267276|NCT02119819|9966373|FG005|Overall Study|Physician Decision|1
6267277|NCT02119819|9966368|FG000|Overall Study|Withdrawal by Subject|5
6267278|NCT02119819|9966369|FG001|Overall Study|Withdrawal by Subject|3
6267279|NCT02119819|9966370|FG002|Overall Study|Withdrawal by Subject|0
6267280|NCT02119819|9966371|FG003|Overall Study|Withdrawal by Subject|0
6267281|NCT02119819|9966372|FG004|Overall Study|Withdrawal by Subject|6
6267282|NCT02119819|9966373|FG005|Overall Study|Withdrawal by Subject|10
6267283|NCT02119819|9966368|FG000|Overall Study|Jury Duty|0
6267284|NCT02119819|9966369|FG001|Overall Study|Jury Duty|0
6267285|NCT02119819|9966370|FG002|Overall Study|Jury Duty|1
6267286|NCT02119819|9966371|FG003|Overall Study|Jury Duty|0
6267287|NCT02119819|9966372|FG004|Overall Study|Jury Duty|0
6267288|NCT02119819|9966373|FG005|Overall Study|Jury Duty|0
6267289|NCT02119819|9966368|FG000|Overall Study|Protocol Violation|0
6267290|NCT02119819|9966369|FG001|Overall Study|Protocol Violation|0
6267291|NCT02119819|9966370|FG002|Overall Study|Protocol Violation|0
6267292|NCT02119819|9966371|FG003|Overall Study|Protocol Violation|1
6267293|NCT02119819|9966372|FG004|Overall Study|Protocol Violation|0
6267294|NCT02119819|9966373|FG005|Overall Study|Protocol Violation|0
6267295|NCT02119819|9966368|FG000|Overall Study|Left the city to get a job|0
6267296|NCT02119819|9966369|FG001|Overall Study|Left the city to get a job|0
6267297|NCT02119819|9966370|FG002|Overall Study|Left the city to get a job|0
6267298|NCT02119819|9966371|FG003|Overall Study|Left the city to get a job|1
6267299|NCT02119819|9966372|FG004|Overall Study|Left the city to get a job|0
6267300|NCT02119819|9966373|FG005|Overall Study|Left the city to get a job|0
6267301|NCT02119936|9966396|FG000|Overall Study|Lost to Follow-up|10
6267302|NCT02120027|9966411|FG000|Overall Study|Adverse Event|4
6267303|NCT02120027|9966412|FG001|Overall Study|Adverse Event|5
6267304|NCT02120027|9966411|FG000|Overall Study|Lack of Efficacy|3
6267305|NCT02120027|9966412|FG001|Overall Study|Lack of Efficacy|5
6267306|NCT02120027|9966411|FG000|Overall Study|Lost to Follow-up|5
6267307|NCT02120027|9966412|FG001|Overall Study|Lost to Follow-up|13
6267308|NCT02120027|9966411|FG000|Overall Study|Other|4
6267309|NCT02120027|9966412|FG001|Overall Study|Other|0
6267310|NCT02120027|9966411|FG000|Overall Study|Physician Decision|4
6267311|NCT02120027|9966412|FG001|Overall Study|Physician Decision|3
6267312|NCT02120027|9966411|FG000|Overall Study|Protocol Violation|18
6267313|NCT02120027|9966412|FG001|Overall Study|Protocol Violation|21
6267314|NCT02120027|9966411|FG000|Overall Study|Study terminated by Sponsor|45
6267315|NCT02120027|9966412|FG001|Overall Study|Study terminated by Sponsor|47
6267316|NCT02120027|9966411|FG000|Overall Study|Withdrawal by Subject|33
6267317|NCT02120027|9966412|FG001|Overall Study|Withdrawal by Subject|25
6267318|NCT02120157|9966418|FG000|Overall Study|Death|8
6267319|NCT02120300|9966441|FG000|Overall Study|Enrolled but Never Treated|2
6267320|NCT02120300|9966442|FG001|Overall Study|Enrolled but Never Treated|0
6267321|NCT02120300|9966443|FG002|Overall Study|Enrolled but Never Treated|0
6267322|NCT02120300|9966444|FG003|Overall Study|Enrolled but Never Treated|0
6267323|NCT02120300|9966441|FG000|Overall Study|Lack of Efficacy|0
6267324|NCT02120300|9966442|FG001|Overall Study|Lack of Efficacy|0
6267325|NCT02120300|9966443|FG002|Overall Study|Lack of Efficacy|0
6267326|NCT02120300|9966444|FG003|Overall Study|Lack of Efficacy|1
6267327|NCT02120300|9966441|FG000|Overall Study|Lost to Follow-up|1
6267328|NCT02120300|9966442|FG001|Overall Study|Lost to Follow-up|0
6267329|NCT02120300|9966443|FG002|Overall Study|Lost to Follow-up|0
6267330|NCT02120300|9966444|FG003|Overall Study|Lost to Follow-up|0
6267331|NCT02120417|9966458|FG000|Overall Study|Death|5
6267332|NCT02120417|9966459|FG001|Overall Study|Death|1
6267333|NCT02120417|9966458|FG000|Overall Study|Adverse Event|3
6267334|NCT02120417|9966459|FG001|Overall Study|Adverse Event|9
6267335|NCT02120417|9966458|FG000|Overall Study|Participant decision|4
6267336|NCT02120417|9966459|FG001|Overall Study|Participant decision|4
6267337|NCT02120417|9966458|FG000|Overall Study|Disease progression|41
6267338|NCT02120417|9966459|FG001|Overall Study|Disease progression|45
6267339|NCT02120417|9966458|FG000|Overall Study|Noncompliance with study treatment|0
6267340|NCT02120417|9966459|FG001|Overall Study|Noncompliance with study treatment|2
6267341|NCT02120417|9966458|FG000|Overall Study|Physician Decision|2
6267342|NCT02120417|9966459|FG001|Overall Study|Physician Decision|3
6267343|NCT02120417|9966458|FG000|Overall Study|Other unspecified|5
6267344|NCT02120417|9966459|FG001|Overall Study|Other unspecified|4
6267345|NCT02120456|9966478|FG000|Part 2 Double-blind Phase|Lost to Follow-up|0
6267346|NCT02120456|9966479|FG001|Part 2 Double-blind Phase|Lost to Follow-up|0
6267347|NCT02120456|9966480|FG002|Part 2 Double-blind Phase|Lost to Follow-up|0
6267348|NCT02120456|9966481|FG003|Part 2 Double-blind Phase|Lost to Follow-up|0
6267349|NCT02120456|9966482|FG004|Part 2 Double-blind Phase|Lost to Follow-up|0
6267350|NCT02120456|9966483|FG005|Part 2 Double-blind Phase|Lost to Follow-up|0
6267351|NCT02120456|9966484|FG006|Part 2 Double-blind Phase|Lost to Follow-up|1
6267352|NCT02120456|9966485|FG007|Part 2 Double-blind Phase|Lost to Follow-up|0
6267353|NCT02120456|9966486|FG008|Part 2 Double-blind Phase|Lost to Follow-up|0
6267354|NCT02120456|9966478|FG000|Part 2 Double-blind Phase|Withdrawal of consent|0
6267355|NCT02120456|9966479|FG001|Part 2 Double-blind Phase|Withdrawal of consent|0
6267356|NCT02120456|9966480|FG002|Part 2 Double-blind Phase|Withdrawal of consent|0
6267357|NCT02120456|9966481|FG003|Part 2 Double-blind Phase|Withdrawal of consent|0
6267358|NCT02120456|9966482|FG004|Part 2 Double-blind Phase|Withdrawal of consent|0
6267359|NCT02120456|9966483|FG005|Part 2 Double-blind Phase|Withdrawal of consent|0
6267360|NCT02120456|9966484|FG006|Part 2 Double-blind Phase|Withdrawal of consent|1
6267361|NCT02120456|9966485|FG007|Part 2 Double-blind Phase|Withdrawal of consent|0
6267362|NCT02120456|9966486|FG008|Part 2 Double-blind Phase|Withdrawal of consent|0
6267363|NCT02120456|9966478|FG000|Part 2 Double-blind Phase|Unable to attend visit due to work|0
6267364|NCT02120456|9966479|FG001|Part 2 Double-blind Phase|Unable to attend visit due to work|0
6267365|NCT02120456|9966480|FG002|Part 2 Double-blind Phase|Unable to attend visit due to work|0
6267366|NCT02120456|9966481|FG003|Part 2 Double-blind Phase|Unable to attend visit due to work|0
6267367|NCT02120456|9966482|FG004|Part 2 Double-blind Phase|Unable to attend visit due to work|0
6267368|NCT02120456|9966483|FG005|Part 2 Double-blind Phase|Unable to attend visit due to work|0
6267369|NCT02120456|9966484|FG006|Part 2 Double-blind Phase|Unable to attend visit due to work|0
6267370|NCT02120456|9966485|FG007|Part 2 Double-blind Phase|Unable to attend visit due to work|0
6267371|NCT02120456|9966486|FG008|Part 2 Double-blind Phase|Unable to attend visit due to work|1
6267372|NCT02120625|9966506|FG000|Overall Study|Physician Decision|2
6267373|NCT02120664|9966515|FG000|Overall Study|Withdrawal by Subject|0
6267374|NCT02120664|9966516|FG001|Overall Study|Withdrawal by Subject|0
6267375|NCT02120664|9966517|FG002|Overall Study|Withdrawal by Subject|0
6267376|NCT02120664|9966518|FG003|Overall Study|Withdrawal by Subject|1
6267377|NCT02120664|9966519|FG004|Overall Study|Withdrawal by Subject|0
6267378|NCT02120781|9966543|FG000|Overall Study|Physician Decision|2
6267379|NCT02120781|9966544|FG001|Overall Study|Physician Decision|0
6267380|NCT02120781|9966543|FG000|Overall Study|Completion not documented|2
6267381|NCT02120781|9966544|FG001|Overall Study|Completion not documented|1
6267382|NCT02120794|9966550|FG000|Overall Study|Withdrawal by Subject|43
6267383|NCT02120794|9966550|FG000|Overall Study|Adverse Event|10
6267384|NCT02120794|9966550|FG000|Overall Study|Physician Decision|4
6267385|NCT02120794|9966550|FG000|Overall Study|Due to insurance coverage|1
6267386|NCT02120833|9966556|FG000|Overall Study|Adverse Event|1
6267387|NCT02120833|9966557|FG001|Overall Study|Adverse Event|0
6267388|NCT02120833|9966556|FG000|Overall Study|Withdrawal by Subject|2
6267389|NCT02120833|9966557|FG001|Overall Study|Withdrawal by Subject|0
6267390|NCT02120833|9966556|FG000|Overall Study|Lost to Follow-up|1
6267391|NCT02120833|9966557|FG001|Overall Study|Lost to Follow-up|1
6267392|NCT02120898|9966566|FG000|Overall Study|Withdrawal by Subject|4
6267393|NCT02120898|9966567|FG001|Overall Study|Withdrawal by Subject|2
6267394|NCT02120898|9966568|FG002|Overall Study|Withdrawal by Subject|2
6267395|NCT02120898|9966566|FG000|Overall Study|Non-compliance with study drug|3
6267396|NCT02120898|9966567|FG001|Overall Study|Non-compliance with study drug|0
6267397|NCT02120898|9966568|FG002|Overall Study|Non-compliance with study drug|0
6267398|NCT02120898|9966566|FG000|Overall Study|Adverse Event|1
6267399|NCT02120898|9966567|FG001|Overall Study|Adverse Event|2
6267400|NCT02120898|9966568|FG002|Overall Study|Adverse Event|1
6267401|NCT02120898|9966566|FG000|Overall Study|Protocol Violation|1
6267402|NCT02120898|9966567|FG001|Overall Study|Protocol Violation|2
6267403|NCT02120898|9966568|FG002|Overall Study|Protocol Violation|0
6267404|NCT02120898|9966566|FG000|Overall Study|Lost to Follow-up|0
6267405|NCT02120898|9966567|FG001|Overall Study|Lost to Follow-up|0
6267406|NCT02120898|9966568|FG002|Overall Study|Lost to Follow-up|1
6267407|NCT02120924|9966579|FG000|Overall Study|Lack of Efficacy|1
6267408|NCT02120924|9966580|FG001|Overall Study|Lack of Efficacy|2
6267409|NCT02120924|9966581|FG002|Overall Study|Lack of Efficacy|3
6267410|NCT02120924|9966579|FG000|Overall Study|Adverse Event|0
6267411|NCT02120924|9966580|FG001|Overall Study|Adverse Event|1
6267412|NCT02120924|9966581|FG002|Overall Study|Adverse Event|3
6267413|NCT02120924|9966579|FG000|Overall Study|Withdrawal by Subject|16
6267414|NCT02120924|9966580|FG001|Overall Study|Withdrawal by Subject|20
6267415|NCT02120924|9966581|FG002|Overall Study|Withdrawal by Subject|8
6267416|NCT02120924|9966579|FG000|Overall Study|Lost to Follow-up|14
6267417|NCT02120924|9966580|FG001|Overall Study|Lost to Follow-up|14
6267418|NCT02120924|9966581|FG002|Overall Study|Lost to Follow-up|11
6267419|NCT02120924|9966579|FG000|Overall Study|Pregnancy|2
6267420|NCT02120924|9966580|FG001|Overall Study|Pregnancy|0
6267421|NCT02120924|9966581|FG002|Overall Study|Pregnancy|0
6267422|NCT02120924|9966579|FG000|Overall Study|Protocol Violation|3
6267423|NCT02120924|9966580|FG001|Overall Study|Protocol Violation|7
6267424|NCT02120924|9966581|FG002|Overall Study|Protocol Violation|2
6267425|NCT02120924|9966579|FG000|Overall Study|Physician Decision|0
6267426|NCT02120924|9966580|FG001|Overall Study|Physician Decision|1
6267427|NCT02120924|9966581|FG002|Overall Study|Physician Decision|1
6267428|NCT02120924|9966579|FG000|Overall Study|Death|1
6267429|NCT02120924|9966580|FG001|Overall Study|Death|0
6267430|NCT02120924|9966581|FG002|Overall Study|Death|0
6267431|NCT02120924|9966579|FG000|Overall Study|Compliance with IP|5
6267432|NCT02120924|9966580|FG001|Overall Study|Compliance with IP|1
6267433|NCT02120924|9966581|FG002|Overall Study|Compliance with IP|1
6267434|NCT02120950|9966592|FG000|Overall Study|Adverse Event|5
6267435|NCT02120950|9966593|FG001|Overall Study|Adverse Event|4
6267436|NCT02120950|9966594|FG002|Overall Study|Adverse Event|3
6267437|NCT02120950|9966592|FG000|Overall Study|Death|3
6267438|NCT02120950|9966593|FG001|Overall Study|Death|0
6267439|NCT02120950|9966594|FG002|Overall Study|Death|1
6267440|NCT02120950|9966592|FG000|Overall Study|Withdrawal by Subject|6
6267441|NCT02120950|9966593|FG001|Overall Study|Withdrawal by Subject|3
6267442|NCT02120950|9966594|FG002|Overall Study|Withdrawal by Subject|2
6267443|NCT02120950|9966592|FG000|Overall Study|Protocol Violation|1
6267444|NCT02120950|9966593|FG001|Overall Study|Protocol Violation|1
6267445|NCT02120950|9966594|FG002|Overall Study|Protocol Violation|7
6267446|NCT02120950|9966592|FG000|Overall Study|Other reasons|5
6267447|NCT02120950|9966593|FG001|Overall Study|Other reasons|4
6267448|NCT02120950|9966594|FG002|Overall Study|Other reasons|1
6267449|NCT02120950|9966592|FG000|Overall Study|Lost to Follow-up|0
6267450|NCT02120950|9966593|FG001|Overall Study|Lost to Follow-up|2
6267451|NCT02120950|9966594|FG002|Overall Study|Lost to Follow-up|1
6267452|NCT02121002|9966604|FG000|Overall Study|Physician Decision|2
6267453|NCT02121002|9966605|FG001|Overall Study|Physician Decision|0
6267454|NCT02121002|9966606|FG002|Overall Study|Physician Decision|0
6267455|NCT02121002|9966604|FG000|Overall Study|Withdrawal by Subject|3
6267456|NCT02121002|9966605|FG001|Overall Study|Withdrawal by Subject|1
6267457|NCT02121002|9966606|FG002|Overall Study|Withdrawal by Subject|4
6267458|NCT02121002|9966604|FG000|Overall Study|Protocol Violation|1
6267459|NCT02121002|9966605|FG001|Overall Study|Protocol Violation|2
6267460|NCT02121002|9966606|FG002|Overall Study|Protocol Violation|4
6267461|NCT02121002|9966604|FG000|Overall Study|Concomitant therapy|0
6267462|NCT02121002|9966605|FG001|Overall Study|Concomitant therapy|1
6267463|NCT02121002|9966606|FG002|Overall Study|Concomitant therapy|1
6267464|NCT02121002|9966604|FG000|Overall Study|Others|1
6267465|NCT02121002|9966605|FG001|Overall Study|Others|0
6267466|NCT02121002|9966606|FG002|Overall Study|Others|1
6267467|NCT02121210|9966630|FG000|Overall Study|Adverse Event|5
6267468|NCT02121210|9966631|FG001|Overall Study|Adverse Event|7
6267469|NCT02121210|9966630|FG000|Overall Study|Lack of Efficacy|2
6267470|NCT02121210|9966631|FG001|Overall Study|Lack of Efficacy|0
6267471|NCT02121210|9966630|FG000|Overall Study|Other than specified above|0
6267472|NCT02121210|9966631|FG001|Overall Study|Other than specified above|2
6267473|NCT02121262|9966639|FG000|Overall Study|Adverse Event|6
6267474|NCT02121262|9966640|FG001|Overall Study|Adverse Event|3
6267475|NCT02121262|9966639|FG000|Overall Study|Lack of Efficacy|3
6267476|NCT02121262|9966640|FG001|Overall Study|Lack of Efficacy|0
6267477|NCT02121262|9966639|FG000|Overall Study|Personal Reasons|19
6267478|NCT02121262|9966640|FG001|Overall Study|Personal Reasons|5
6267479|NCT02121262|9966639|FG000|Overall Study|Protocol Violation|1
6267480|NCT02121262|9966640|FG001|Overall Study|Protocol Violation|1
6267481|NCT02121262|9966639|FG000|Overall Study|Participant Dropped-out|0
6267482|NCT02121262|9966640|FG001|Overall Study|Participant Dropped-out|1
6267483|NCT02121262|9966639|FG000|Overall Study|Participant was Deemed Unsuitable|1
6267484|NCT02121262|9966640|FG001|Overall Study|Participant was Deemed Unsuitable|0
6267485|NCT02121262|9966639|FG000|Overall Study|Consent Withdrawn|1
6267486|NCT02121262|9966640|FG001|Overall Study|Consent Withdrawn|0
6267487|NCT02121301|9966649|FG000|Overall Study|Protocol Violation|1
6267488|NCT02121301|9966650|FG001|Overall Study|Protocol Violation|4
6267489|NCT02121301|9966651|FG002|Overall Study|Protocol Violation|1
6267490|NCT02121392|9966661|FG000|Prior to Intervention|Protocol Violation|40
6267491|NCT02121392|9966662|FG001|Prior to Intervention|Protocol Violation|35
6267492|NCT02121392|9966661|FG000|Prior to Intervention|Withdrawal by Subject|8
6267493|NCT02121392|9966662|FG001|Prior to Intervention|Withdrawal by Subject|6
6267494|NCT02121392|9966661|FG000|After Placement of AC Block vs Sham|Protocol Violation|3
6267495|NCT02121392|9966662|FG001|After Placement of AC Block vs Sham|Protocol Violation|2
6267496|NCT02121392|9966661|FG000|After Placement of AC Block vs Sham|Lost to Follow-up|0
6267497|NCT02121392|9966662|FG001|After Placement of AC Block vs Sham|Lost to Follow-up|1
6267498|NCT02121509|9966687|FG000|Washout Period (35 Days)|Adverse Event|1
6267499|NCT02121509|9966688|FG001|Washout Period (35 Days)|Adverse Event|1
6267500|NCT02121509|9966689|FG002|Washout Period (35 Days)|Adverse Event|0
6267501|NCT02121509|9966690|FG003|Washout Period (35 Days)|Adverse Event|0
6087010|NCT00666211|9697140|FG000|Overall Study|Lost to Follow-up|2
6087011|NCT00666211|9697141|FG001|Overall Study|Lost to Follow-up|0
6267502|NCT02121509|9966687|FG000|Washout Period (35 Days)|Withdrawal by Subject|0
6267503|NCT02121509|9966688|FG001|Washout Period (35 Days)|Withdrawal by Subject|3
6267504|NCT02121509|9966689|FG002|Washout Period (35 Days)|Withdrawal by Subject|0
6267505|NCT02121509|9966690|FG003|Washout Period (35 Days)|Withdrawal by Subject|0
6267506|NCT02121509|9966687|FG000|Washout Period (35 Days)|elevated AST and ALT levels|1
6087012|NCT00666211|9697140|FG000|Overall Study|toxicity|0
6267507|NCT02121509|9966688|FG001|Washout Period (35 Days)|elevated AST and ALT levels|0
6267508|NCT02121509|9966689|FG002|Washout Period (35 Days)|elevated AST and ALT levels|0
6267509|NCT02121509|9966690|FG003|Washout Period (35 Days)|elevated AST and ALT levels|0
6267510|NCT02121522|9966700|FG000|Overall Study|Adverse Event|1
6267511|NCT02121535|9966706|FG000|Period 1 (8 Trial Days)|Withdrawal by Subject|0
6267512|NCT02121535|9966707|FG001|Period 1 (8 Trial Days)|Withdrawal by Subject|1
6267513|NCT02121535|9966706|FG000|Period 3 (8 Trial Days)|Withdrawal by Subject|1
6267514|NCT02121535|9966707|FG001|Period 3 (8 Trial Days)|Withdrawal by Subject|0
6267515|NCT02121756|9966716|FG000|Overall Study|Adverse Event|3
6087013|NCT00666211|9697141|FG001|Overall Study|toxicity|2
6087014|NCT00666211|9697140|FG000|Overall Study|hospital admission|0
6087015|NCT00666211|9697141|FG001|Overall Study|hospital admission|5
6267516|NCT02121756|9966717|FG001|Overall Study|Adverse Event|0
6267517|NCT02121756|9966716|FG000|Overall Study|Protocol Violation|1
6267518|NCT02121756|9966717|FG001|Overall Study|Protocol Violation|1
6267519|NCT02121756|9966716|FG000|Overall Study|Physician Decision|2
6267520|NCT02121756|9966717|FG001|Overall Study|Physician Decision|1
6267521|NCT02121795|9966728|FG000|Double-Blind Phase|Randomized but Never Treated|1
6267522|NCT02121795|9966729|FG001|Double-Blind Phase|Randomized but Never Treated|4
6267523|NCT02121795|9966728|FG000|Double-Blind Phase|Withdrawal by Subject|19
6267524|NCT02121795|9966729|FG001|Double-Blind Phase|Withdrawal by Subject|16
6267525|NCT02121795|9966728|FG000|Double-Blind Phase|Lost to Follow-up|7
6267526|NCT02121795|9966729|FG001|Double-Blind Phase|Lost to Follow-up|4
6267527|NCT02121795|9966728|FG000|Double-Blind Phase|Physician Decision|2
6267528|NCT02121795|9966729|FG001|Double-Blind Phase|Physician Decision|5
6267529|NCT02121795|9966728|FG000|Double-Blind Phase|Adverse Event|5
6267530|NCT02121795|9966729|FG001|Double-Blind Phase|Adverse Event|0
6267531|NCT02121795|9966728|FG000|Double-Blind Phase|Non-Compliance with Study Drug|3
6267532|NCT02121795|9966729|FG001|Double-Blind Phase|Non-Compliance with Study Drug|1
6267533|NCT02121795|9966728|FG000|Double-Blind Phase|Protocol Violation|0
6267534|NCT02121795|9966729|FG001|Double-Blind Phase|Protocol Violation|3
6267535|NCT02121795|9966728|FG000|Double-Blind Phase|Death|1
6267536|NCT02121795|9966729|FG001|Double-Blind Phase|Death|1
6267537|NCT02121795|9966728|FG000|Open-Label Phase|Physician Decision|8
6267538|NCT02121795|9966729|FG001|Open-Label Phase|Physician Decision|8
6267539|NCT02121795|9966728|FG000|Open-Label Phase|Withdrawal by Subject|3
6267540|NCT02121795|9966729|FG001|Open-Label Phase|Withdrawal by Subject|2
6267541|NCT02121795|9966728|FG000|Open-Label Phase|Lost to Follow-up|1
6267542|NCT02121795|9966729|FG001|Open-Label Phase|Lost to Follow-up|0
6267543|NCT02121808|9966737|FG000|Overall Study|Technical problem|3
6267544|NCT02121834|9966753|FG000|Overall Study|Protocol Violation|0
6267545|NCT02121834|9966754|FG001|Overall Study|Protocol Violation|1
6267546|NCT02121834|9966755|FG002|Overall Study|Protocol Violation|0
6267547|NCT02121834|9966756|FG003|Overall Study|Protocol Violation|0
6267548|NCT02121834|9966757|FG004|Overall Study|Protocol Violation|0
6267549|NCT02121834|9966758|FG005|Overall Study|Protocol Violation|0
6267550|NCT02121834|9966759|FG006|Overall Study|Protocol Violation|0
6267551|NCT02121834|9966753|FG000|Overall Study|Withdrawal by Subject|0
6267552|NCT02121834|9966754|FG001|Overall Study|Withdrawal by Subject|1
6267553|NCT02121834|9966755|FG002|Overall Study|Withdrawal by Subject|1
6267554|NCT02121834|9966756|FG003|Overall Study|Withdrawal by Subject|0
6267555|NCT02121834|9966757|FG004|Overall Study|Withdrawal by Subject|0
6267556|NCT02121834|9966758|FG005|Overall Study|Withdrawal by Subject|0
6267557|NCT02121834|9966759|FG006|Overall Study|Withdrawal by Subject|0
6267558|NCT02121834|9966753|FG000|Overall Study|Lost to Follow-up|0
6267559|NCT02121834|9966754|FG001|Overall Study|Lost to Follow-up|0
6267560|NCT02121834|9966755|FG002|Overall Study|Lost to Follow-up|1
6267561|NCT02121834|9966756|FG003|Overall Study|Lost to Follow-up|0
6267562|NCT02121834|9966757|FG004|Overall Study|Lost to Follow-up|0
6267563|NCT02121834|9966758|FG005|Overall Study|Lost to Follow-up|0
6267564|NCT02121834|9966759|FG006|Overall Study|Lost to Follow-up|0
6267565|NCT02121847|9966785|FG000|Overall Study|Administrative Reasons|1
6267566|NCT02121847|9966785|FG000|Overall Study|Adverse Event|2
6267567|NCT02122146|9966820|FG000|Part 1: Dose Escalation|Death|0
6267568|NCT02122146|9966821|FG001|Part 1: Dose Escalation|Death|1
6267569|NCT02122146|9966822|FG002|Part 1: Dose Escalation|Death|1
6267570|NCT02122146|9966823|FG003|Part 1: Dose Escalation|Death|0
6267571|NCT02122146|9966824|FG004|Part 1: Dose Escalation|Death|0
6267572|NCT02122146|9966825|FG005|Part 1: Dose Escalation|Death|0
6267573|NCT02122146|9966826|FG006|Part 1: Dose Escalation|Death|0
6267574|NCT02122146|9966827|FG007|Part 1: Dose Escalation|Death|0
6267575|NCT02122146|9966820|FG000|Part 1: Dose Escalation|Lost to Follow-up|0
6267576|NCT02122146|9966821|FG001|Part 1: Dose Escalation|Lost to Follow-up|0
6267577|NCT02122146|9966822|FG002|Part 1: Dose Escalation|Lost to Follow-up|1
6267578|NCT02122146|9966823|FG003|Part 1: Dose Escalation|Lost to Follow-up|0
6267579|NCT02122146|9966824|FG004|Part 1: Dose Escalation|Lost to Follow-up|1
6267580|NCT02122146|9966825|FG005|Part 1: Dose Escalation|Lost to Follow-up|0
6267581|NCT02122146|9966826|FG006|Part 1: Dose Escalation|Lost to Follow-up|0
6267582|NCT02122146|9966827|FG007|Part 1: Dose Escalation|Lost to Follow-up|0
6267583|NCT02122146|9966820|FG000|Part 1: Dose Escalation|Withdrawal by Subject|0
6267584|NCT02122146|9966821|FG001|Part 1: Dose Escalation|Withdrawal by Subject|0
6267585|NCT02122146|9966822|FG002|Part 1: Dose Escalation|Withdrawal by Subject|0
6267586|NCT02122146|9966823|FG003|Part 1: Dose Escalation|Withdrawal by Subject|1
6267587|NCT02122146|9966824|FG004|Part 1: Dose Escalation|Withdrawal by Subject|0
6267588|NCT02122146|9966825|FG005|Part 1: Dose Escalation|Withdrawal by Subject|0
6087016|NCT00666211|9697140|FG000|Overall Study|Death|0
6087017|NCT00666211|9697141|FG001|Overall Study|Death|2
6267589|NCT02122146|9966826|FG006|Part 1: Dose Escalation|Withdrawal by Subject|0
6267590|NCT02122146|9966827|FG007|Part 1: Dose Escalation|Withdrawal by Subject|0
6267591|NCT02122146|9966820|FG000|Part 1: Dose Escalation|Other|1
6267592|NCT02122146|9966821|FG001|Part 1: Dose Escalation|Other|0
6267593|NCT02122146|9966822|FG002|Part 1: Dose Escalation|Other|0
6267594|NCT02122146|9966823|FG003|Part 1: Dose Escalation|Other|0
6267595|NCT02122146|9966824|FG004|Part 1: Dose Escalation|Other|0
6267596|NCT02122146|9966825|FG005|Part 1: Dose Escalation|Other|1
6267597|NCT02122146|9966826|FG006|Part 1: Dose Escalation|Other|1
6267598|NCT02122146|9966827|FG007|Part 1: Dose Escalation|Other|2
6267599|NCT02122380|9966857|FG000|First Intervention (30 Days)|Adverse Event|1
6267600|NCT02122380|9966858|FG001|First Intervention (30 Days)|Adverse Event|0
6267601|NCT02122380|9966857|FG000|First Intervention (30 Days)|Physician Decision|0
6267602|NCT02122380|9966858|FG001|First Intervention (30 Days)|Physician Decision|1
6267603|NCT02122380|9966857|FG000|Washout (8 Weeks)|Lost to Follow-up|1
6267604|NCT02122380|9966858|FG001|Washout (8 Weeks)|Lost to Follow-up|0
6267605|NCT02122380|9966857|FG000|Washout (8 Weeks)|No Longer Met Inclusion Criteria|0
6267606|NCT02122380|9966858|FG001|Washout (8 Weeks)|No Longer Met Inclusion Criteria|2
6267607|NCT02122380|9966857|FG000|Second Intervention (30 Days)|2 did not complete all of inpatient day|0
6267608|NCT02122380|9966858|FG001|Second Intervention (30 Days)|2 did not complete all of inpatient day|2
6271728|NCT02166333|9973659|FG000|Stage 1|Finished the trial (did the 2 year visit) during Stage 1 and did not advance to Stage 2|4
6271729|NCT02166333|9973660|FG001|Stage 1|Finished the trial (did the 2 year visit) during Stage 1 and did not advance to Stage 2|0
6271730|NCT02166333|9973661|FG002|Stage 1|Finished the trial (did the 2 year visit) during Stage 1 and did not advance to Stage 2|0
6271731|NCT02166333|9973662|FG003|Stage 1|Finished the trial (did the 2 year visit) during Stage 1 and did not advance to Stage 2|0
6271732|NCT02166333|9973663|FG004|Stage 1|Finished the trial (did the 2 year visit) during Stage 1 and did not advance to Stage 2|3
6271733|NCT02166333|9973664|FG005|Stage 1|Finished the trial (did the 2 year visit) during Stage 1 and did not advance to Stage 2|1
6271734|NCT02166333|9973659|FG000|Stage 1|Death|4
6271735|NCT02166333|9973660|FG001|Stage 1|Death|0
6271736|NCT02166333|9973661|FG002|Stage 1|Death|2
6271737|NCT02166333|9973662|FG003|Stage 1|Death|0
6271738|NCT02166333|9973663|FG004|Stage 1|Death|3
6271739|NCT02166333|9973664|FG005|Stage 1|Death|2
6271740|NCT02166333|9973659|FG000|Stage 1|Lost to Follow-up|12
6271741|NCT02166333|9973660|FG001|Stage 1|Lost to Follow-up|0
6271742|NCT02166333|9973661|FG002|Stage 1|Lost to Follow-up|6
6271743|NCT02166333|9973662|FG003|Stage 1|Lost to Follow-up|0
6271744|NCT02166333|9973663|FG004|Stage 1|Lost to Follow-up|3
6271745|NCT02166333|9973664|FG005|Stage 1|Lost to Follow-up|3
6271746|NCT02166333|9973659|FG000|Stage 2|Finished the trial (did the 2 year visit) prior to or during trial closeout|180
6271747|NCT02166333|9973660|FG001|Stage 2|Finished the trial (did the 2 year visit) prior to or during trial closeout|0
6271748|NCT02166333|9973661|FG002|Stage 2|Finished the trial (did the 2 year visit) prior to or during trial closeout|63
6271749|NCT02166333|9973662|FG003|Stage 2|Finished the trial (did the 2 year visit) prior to or during trial closeout|0
6271750|NCT02166333|9973663|FG004|Stage 2|Finished the trial (did the 2 year visit) prior to or during trial closeout|54
6271751|NCT02166333|9973664|FG005|Stage 2|Finished the trial (did the 2 year visit) prior to or during trial closeout|52
6271752|NCT02166333|9973659|FG000|Stage 2|Death|4
6271753|NCT02166333|9973660|FG001|Stage 2|Death|2
6271754|NCT02166333|9973661|FG002|Stage 2|Death|1
6271755|NCT02166333|9973662|FG003|Stage 2|Death|0
6271756|NCT02166333|9973663|FG004|Stage 2|Death|0
6271757|NCT02166333|9973664|FG005|Stage 2|Death|1
6271758|NCT02166333|9973659|FG000|Stage 2|Lost to Follow-up|23
6271759|NCT02166333|9973660|FG001|Stage 2|Lost to Follow-up|4
6271760|NCT02166333|9973661|FG002|Stage 2|Lost to Follow-up|11
6271761|NCT02166333|9973662|FG003|Stage 2|Lost to Follow-up|9
6271762|NCT02166333|9973663|FG004|Stage 2|Lost to Follow-up|3
6271763|NCT02166333|9973664|FG005|Stage 2|Lost to Follow-up|6
6271764|NCT02166476|9973685|FG000|Overall Study|Withdrawal by Subject|5
6271765|NCT02166476|9973686|FG001|Overall Study|Withdrawal by Subject|7
6271766|NCT02166476|9973685|FG000|Overall Study|Adverse Event|3
6271767|NCT02166476|9973686|FG001|Overall Study|Adverse Event|3
6271768|NCT02166476|9973685|FG000|Overall Study|Lost to Follow-up|5
6271769|NCT02166476|9973686|FG001|Overall Study|Lost to Follow-up|10
6271770|NCT02166476|9973685|FG000|Overall Study|Physician Decision|1
6271771|NCT02166476|9973686|FG001|Overall Study|Physician Decision|0
6271772|NCT02166476|9973685|FG000|Overall Study|Unable to Come for Visit|0
6271773|NCT02166476|9973686|FG001|Overall Study|Unable to Come for Visit|3
6271774|NCT02166606|9973695|FG000|Overall Study|Adverse Event|3
6271775|NCT02166606|9973695|FG000|Overall Study|Death|31
6271776|NCT02166606|9973695|FG000|Overall Study|Protocol Violation|7
6271777|NCT02166606|9973695|FG000|Overall Study|Lost to Follow-up|30
6271778|NCT02166606|9973695|FG000|Overall Study|Withdrawal by Subject|1
6271779|NCT02166606|9973695|FG000|Overall Study|Physician Decision|1
6271780|NCT02166606|9973695|FG000|Overall Study|Device upgrade|1
6271781|NCT02166606|9973695|FG000|Overall Study|Enrolled after End of Enrollment|4
6271782|NCT02166697|9973699|FG000|Overall Study|Protocol Violation|347
6271783|NCT02167035|9973705|FG000|Overall Study|Adverse Event|2
6271784|NCT02167035|9973706|FG001|Overall Study|Adverse Event|2
6271785|NCT02167035|9973705|FG000|Overall Study|Lost to Follow-up|3
6271786|NCT02167035|9973706|FG001|Overall Study|Lost to Follow-up|3
6271787|NCT02167035|9973705|FG000|Overall Study|Randomized to incorrect Study Medication|0
6267609|NCT02122770|9966895|FG000|Part A: Drug-drug Interaction 2|Adverse Event|3
6267610|NCT02122770|9966896|FG001|Part A: Drug-drug Interaction 2|Adverse Event|0
6267611|NCT02122770|9966897|FG002|Part A: Drug-drug Interaction 2|Adverse Event|1
6267612|NCT02122770|9966898|FG003|Part A: Drug-drug Interaction 2|Adverse Event|2
6267613|NCT02122770|9966899|FG004|Part A: Drug-drug Interaction 2|Adverse Event|0
6267614|NCT02122770|9966900|FG005|Part A: Drug-drug Interaction 2|Adverse Event|0
6267615|NCT02122770|9966895|FG000|Part A: Drug-drug Interaction 2|Other|0
6267616|NCT02122770|9966896|FG001|Part A: Drug-drug Interaction 2|Other|0
6267617|NCT02122770|9966897|FG002|Part A: Drug-drug Interaction 2|Other|1
6267618|NCT02122770|9966898|FG003|Part A: Drug-drug Interaction 2|Other|0
6267619|NCT02122770|9966899|FG004|Part A: Drug-drug Interaction 2|Other|0
6267620|NCT02122770|9966900|FG005|Part A: Drug-drug Interaction 2|Other|0
6267621|NCT02122770|9966895|FG000|Part A: Drug-drug Interaction 2|Withdrawal by Subject|0
6267622|NCT02122770|9966896|FG001|Part A: Drug-drug Interaction 2|Withdrawal by Subject|1
6267623|NCT02122770|9966897|FG002|Part A: Drug-drug Interaction 2|Withdrawal by Subject|0
6267624|NCT02122770|9966898|FG003|Part A: Drug-drug Interaction 2|Withdrawal by Subject|0
6267625|NCT02122770|9966899|FG004|Part A: Drug-drug Interaction 2|Withdrawal by Subject|0
6267626|NCT02122770|9966900|FG005|Part A: Drug-drug Interaction 2|Withdrawal by Subject|0
6267627|NCT02122770|9966895|FG000|Part A: Drug-drug Interaction 2|Symptomatic Deterioration|1
6267628|NCT02122770|9966896|FG001|Part A: Drug-drug Interaction 2|Symptomatic Deterioration|5
6267629|NCT02122770|9966897|FG002|Part A: Drug-drug Interaction 2|Symptomatic Deterioration|0
6267630|NCT02122770|9966898|FG003|Part A: Drug-drug Interaction 2|Symptomatic Deterioration|1
6267631|NCT02122770|9966899|FG004|Part A: Drug-drug Interaction 2|Symptomatic Deterioration|0
6267632|NCT02122770|9966900|FG005|Part A: Drug-drug Interaction 2|Symptomatic Deterioration|0
6267633|NCT02122770|9966895|FG000|Part B: Standard of Care|Adverse Event|0
6267634|NCT02122770|9966896|FG001|Part B: Standard of Care|Adverse Event|0
6267635|NCT02122770|9966897|FG002|Part B: Standard of Care|Adverse Event|0
6267636|NCT02122770|9966898|FG003|Part B: Standard of Care|Adverse Event|0
6267637|NCT02122770|9966899|FG004|Part B: Standard of Care|Adverse Event|4
6267638|NCT02122770|9966900|FG005|Part B: Standard of Care|Adverse Event|1
6267639|NCT02122770|9966895|FG000|Part B: Standard of Care|Other|0
6267640|NCT02122770|9966896|FG001|Part B: Standard of Care|Other|0
6267641|NCT02122770|9966897|FG002|Part B: Standard of Care|Other|0
6267642|NCT02122770|9966898|FG003|Part B: Standard of Care|Other|0
6267643|NCT02122770|9966899|FG004|Part B: Standard of Care|Other|0
6267644|NCT02122770|9966900|FG005|Part B: Standard of Care|Other|2
6267645|NCT02122770|9966895|FG000|Part B: Standard of Care|Withdrawal by Subject|0
6267646|NCT02122770|9966896|FG001|Part B: Standard of Care|Withdrawal by Subject|0
6267647|NCT02122770|9966897|FG002|Part B: Standard of Care|Withdrawal by Subject|0
6267648|NCT02122770|9966898|FG003|Part B: Standard of Care|Withdrawal by Subject|0
6267649|NCT02122770|9966899|FG004|Part B: Standard of Care|Withdrawal by Subject|4
6267650|NCT02122770|9966900|FG005|Part B: Standard of Care|Withdrawal by Subject|2
6267651|NCT02122770|9966895|FG000|Part B: Standard of Care|Symptomatic Deterioration|0
6267652|NCT02122770|9966896|FG001|Part B: Standard of Care|Symptomatic Deterioration|0
6267653|NCT02122770|9966897|FG002|Part B: Standard of Care|Symptomatic Deterioration|0
6267654|NCT02122770|9966898|FG003|Part B: Standard of Care|Symptomatic Deterioration|0
6267655|NCT02122770|9966899|FG004|Part B: Standard of Care|Symptomatic Deterioration|5
6267656|NCT02122770|9966900|FG005|Part B: Standard of Care|Symptomatic Deterioration|0
6267657|NCT02122770|9966895|FG000|Part B: Standard of Care|Progressive Disease|0
6267658|NCT02122770|9966896|FG001|Part B: Standard of Care|Progressive Disease|0
6267659|NCT02122770|9966897|FG002|Part B: Standard of Care|Progressive Disease|0
6267660|NCT02122770|9966898|FG003|Part B: Standard of Care|Progressive Disease|0
6267661|NCT02122770|9966899|FG004|Part B: Standard of Care|Progressive Disease|10
6267662|NCT02122770|9966900|FG005|Part B: Standard of Care|Progressive Disease|8
6267663|NCT02122783|9966925|FG000|Overall Study|Adverse Event|0
6267664|NCT02122783|9966926|FG001|Overall Study|Adverse Event|1
6267665|NCT02122887|9966947|FG000|Overall Study|Withdrawal by Subject|20
6267666|NCT02122887|9966948|FG001|Overall Study|Withdrawal by Subject|2
6267667|NCT02123134|9966978|FG000|Overall Study|Withdrawal of consent|3
6267668|NCT02123134|9966979|FG001|Overall Study|Withdrawal of consent|2
6191281|NCT01421342|9847960|FG000|Continuation of Treatment (Week 12 - 36)|Lack of Efficacy|11
6191282|NCT01421342|9847961|FG001|Continuation of Treatment (Week 12 - 36)|Lack of Efficacy|5
6191283|NCT01421342|9847962|FG002|Continuation of Treatment (Week 12 - 36)|Lack of Efficacy|11
6191284|NCT01421342|9847960|FG000|Continuation of Treatment (Week 12 - 36)|Adverse Event|0
6191285|NCT01421342|9847961|FG001|Continuation of Treatment (Week 12 - 36)|Adverse Event|6
6191286|NCT01421342|9847962|FG002|Continuation of Treatment (Week 12 - 36)|Adverse Event|11
6191287|NCT01421342|9847960|FG000|Continuation of Treatment (Week 12 - 36)|Withdrawal by Subject|7
6191288|NCT01421342|9847961|FG001|Continuation of Treatment (Week 12 - 36)|Withdrawal by Subject|6
6191289|NCT01421342|9847962|FG002|Continuation of Treatment (Week 12 - 36)|Withdrawal by Subject|4
6191290|NCT01421342|9847960|FG000|Continuation of Treatment (Week 12 - 36)|Lost to Follow-up|4
6191291|NCT01421342|9847961|FG001|Continuation of Treatment (Week 12 - 36)|Lost to Follow-up|11
6191292|NCT01421342|9847962|FG002|Continuation of Treatment (Week 12 - 36)|Lost to Follow-up|9
6191293|NCT01421342|9847960|FG000|Continuation of Treatment (Week 12 - 36)|Non-adherence|3
6191294|NCT01421342|9847961|FG001|Continuation of Treatment (Week 12 - 36)|Non-adherence|8
6267669|NCT02123134|9966978|FG000|Overall Study|Administrative decision|0
6267670|NCT02123134|9966979|FG001|Overall Study|Administrative decision|1
6267671|NCT02123251|9966987|FG000|Overall Study|Death|1
6267672|NCT02123251|9966988|FG001|Overall Study|Death|1
6267673|NCT02123251|9966987|FG000|Overall Study|Withdrawal by Subject|0
6267674|NCT02123251|9966988|FG001|Overall Study|Withdrawal by Subject|3
6267675|NCT02123251|9966987|FG000|Overall Study|Lost Medicaid eligibility|29
6267676|NCT02123251|9966988|FG001|Overall Study|Lost Medicaid eligibility|22
6267677|NCT02123251|9966987|FG000|Overall Study|Switched Managed Care Organization (MCO)|4
6267678|NCT02123251|9966988|FG001|Overall Study|Switched Managed Care Organization (MCO)|4
6267679|NCT02123446|9967004|FG000|Washout Period (1 Day)|Physician Decision|1
6267680|NCT02123446|9967005|FG001|Washout Period (1 Day)|Physician Decision|0
6267681|NCT02123459|9967011|FG000|Washout Period (1 Day)|Adverse Event|1
6267682|NCT02123459|9967012|FG001|Washout Period (1 Day)|Adverse Event|0
6267683|NCT02123472|9967018|FG000|Period 2 (7 Days)|Withdrawal by Subject|0
6267684|NCT02123472|9967019|FG001|Period 2 (7 Days)|Withdrawal by Subject|1
6267685|NCT02123511|9967036|FG000|Overall Study|Cancelled treatment|1
6267686|NCT02123511|9967037|FG001|Overall Study|Cancelled treatment|0
6267687|NCT02123511|9967036|FG000|Overall Study|Incomplete data|1
6267688|NCT02123511|9967037|FG001|Overall Study|Incomplete data|3
6267689|NCT02123511|9967036|FG000|Overall Study|Ineligible|0
6267690|NCT02123511|9967037|FG001|Overall Study|Ineligible|1
6267691|NCT02123576|9967045|FG000|Overall Study|Adverse Event|1
6267692|NCT02123576|9967046|FG001|Overall Study|Adverse Event|0
6267693|NCT02123797|9967058|FG000|Baseline Intervention|Death|9
6267694|NCT02123797|9967059|FG001|Baseline Intervention|Death|16
6267695|NCT02123797|9967060|FG002|Baseline Intervention|Death|0
6267696|NCT02123797|9967061|FG003|Baseline Intervention|Death|0
6267697|NCT02123797|9967062|FG004|Baseline Intervention|Death|0
6267698|NCT02123797|9967058|FG000|Baseline Intervention|Withdrawal by Subject|2
6267699|NCT02123797|9967059|FG001|Baseline Intervention|Withdrawal by Subject|8
6267700|NCT02123797|9967060|FG002|Baseline Intervention|Withdrawal by Subject|0
6267701|NCT02123797|9967061|FG003|Baseline Intervention|Withdrawal by Subject|0
6267702|NCT02123797|9967062|FG004|Baseline Intervention|Withdrawal by Subject|0
6267703|NCT02123797|9967058|FG000|Baseline Intervention|Relocation|2
6267704|NCT02123797|9967059|FG001|Baseline Intervention|Relocation|0
6267705|NCT02123797|9967060|FG002|Baseline Intervention|Relocation|0
6267706|NCT02123797|9967061|FG003|Baseline Intervention|Relocation|0
6267707|NCT02123797|9967062|FG004|Baseline Intervention|Relocation|0
6267708|NCT02123797|9967058|FG000|Baseline Intervention|Out of window for initial survey|6
6267709|NCT02123797|9967059|FG001|Baseline Intervention|Out of window for initial survey|13
6267710|NCT02123797|9967060|FG002|Baseline Intervention|Out of window for initial survey|0
6267711|NCT02123797|9967061|FG003|Baseline Intervention|Out of window for initial survey|0
6267712|NCT02123797|9967062|FG004|Baseline Intervention|Out of window for initial survey|0
6267713|NCT02123797|9967058|FG000|Baseline Intervention|Lost to Follow-up|0
6267714|NCT02123797|9967059|FG001|Baseline Intervention|Lost to Follow-up|5
6267715|NCT02123797|9967060|FG002|Baseline Intervention|Lost to Follow-up|0
6267716|NCT02123797|9967061|FG003|Baseline Intervention|Lost to Follow-up|0
6267717|NCT02123797|9967062|FG004|Baseline Intervention|Lost to Follow-up|0
6267718|NCT02123797|9967058|FG000|Baseline Intervention|Other Disease|3
6267719|NCT02123797|9967059|FG001|Baseline Intervention|Other Disease|0
6267720|NCT02123797|9967060|FG002|Baseline Intervention|Other Disease|0
6267721|NCT02123797|9967061|FG003|Baseline Intervention|Other Disease|0
6267722|NCT02123797|9967062|FG004|Baseline Intervention|Other Disease|0
6267723|NCT02123797|9967058|FG000|3-month Follow up (Cumulative Counts)|Death|33
6267724|NCT02123797|9967059|FG001|3-month Follow up (Cumulative Counts)|Death|57
6267725|NCT02123797|9967060|FG002|3-month Follow up (Cumulative Counts)|Death|0
6267726|NCT02123797|9967061|FG003|3-month Follow up (Cumulative Counts)|Death|0
6267727|NCT02123797|9967062|FG004|3-month Follow up (Cumulative Counts)|Death|0
6267728|NCT02123797|9967058|FG000|3-month Follow up (Cumulative Counts)|Lost to Follow-up|2
6267729|NCT02123797|9967059|FG001|3-month Follow up (Cumulative Counts)|Lost to Follow-up|7
6267730|NCT02123797|9967060|FG002|3-month Follow up (Cumulative Counts)|Lost to Follow-up|50
6267731|NCT02123797|9967061|FG003|3-month Follow up (Cumulative Counts)|Lost to Follow-up|82
6267732|NCT02123797|9967062|FG004|3-month Follow up (Cumulative Counts)|Lost to Follow-up|3
6267733|NCT02123797|9967058|FG000|3-month Follow up (Cumulative Counts)|Withdrawal by Subject|6
6267734|NCT02123797|9967059|FG001|3-month Follow up (Cumulative Counts)|Withdrawal by Subject|16
6267735|NCT02123797|9967060|FG002|3-month Follow up (Cumulative Counts)|Withdrawal by Subject|0
6267736|NCT02123797|9967061|FG003|3-month Follow up (Cumulative Counts)|Withdrawal by Subject|0
6267737|NCT02123797|9967062|FG004|3-month Follow up (Cumulative Counts)|Withdrawal by Subject|0
6267738|NCT02123797|9967058|FG000|3-month Follow up (Cumulative Counts)|Relocation|0
6267739|NCT02123797|9967059|FG001|3-month Follow up (Cumulative Counts)|Relocation|1
6267740|NCT02123797|9967060|FG002|3-month Follow up (Cumulative Counts)|Relocation|0
6267741|NCT02123797|9967061|FG003|3-month Follow up (Cumulative Counts)|Relocation|0
6267742|NCT02123797|9967062|FG004|3-month Follow up (Cumulative Counts)|Relocation|0
6267743|NCT02123797|9967058|FG000|3-month Follow up (Cumulative Counts)|Out of window for follow-up survey|16
6267744|NCT02123797|9967059|FG001|3-month Follow up (Cumulative Counts)|Out of window for follow-up survey|36
6267745|NCT02123797|9967060|FG002|3-month Follow up (Cumulative Counts)|Out of window for follow-up survey|0
6267746|NCT02123797|9967061|FG003|3-month Follow up (Cumulative Counts)|Out of window for follow-up survey|0
6267747|NCT02123797|9967062|FG004|3-month Follow up (Cumulative Counts)|Out of window for follow-up survey|0
6267748|NCT02123797|9967058|FG000|6-month Follow up (Cumulative Counts)|Death|51
6267749|NCT02123797|9967059|FG001|6-month Follow up (Cumulative Counts)|Death|97
6267750|NCT02123797|9967060|FG002|6-month Follow up (Cumulative Counts)|Death|0
6267751|NCT02123797|9967061|FG003|6-month Follow up (Cumulative Counts)|Death|0
6267752|NCT02123797|9967062|FG004|6-month Follow up (Cumulative Counts)|Death|0
6267753|NCT02123797|9967058|FG000|6-month Follow up (Cumulative Counts)|Lost to Follow-up|3
6267754|NCT02123797|9967059|FG001|6-month Follow up (Cumulative Counts)|Lost to Follow-up|20
6267755|NCT02123797|9967060|FG002|6-month Follow up (Cumulative Counts)|Lost to Follow-up|66
6267756|NCT02123797|9967061|FG003|6-month Follow up (Cumulative Counts)|Lost to Follow-up|113
6267757|NCT02123797|9967062|FG004|6-month Follow up (Cumulative Counts)|Lost to Follow-up|3
6267758|NCT02123797|9967058|FG000|6-month Follow up (Cumulative Counts)|Withdrawal by Subject|1
6267759|NCT02123797|9967059|FG001|6-month Follow up (Cumulative Counts)|Withdrawal by Subject|9
6267760|NCT02123797|9967060|FG002|6-month Follow up (Cumulative Counts)|Withdrawal by Subject|0
6267761|NCT02123797|9967061|FG003|6-month Follow up (Cumulative Counts)|Withdrawal by Subject|0
6267762|NCT02123797|9967062|FG004|6-month Follow up (Cumulative Counts)|Withdrawal by Subject|0
6267763|NCT02123797|9967058|FG000|6-month Follow up (Cumulative Counts)|Relocation|0
6267764|NCT02123797|9967059|FG001|6-month Follow up (Cumulative Counts)|Relocation|2
6267765|NCT02123797|9967060|FG002|6-month Follow up (Cumulative Counts)|Relocation|0
6267766|NCT02123797|9967061|FG003|6-month Follow up (Cumulative Counts)|Relocation|0
6267767|NCT02123797|9967062|FG004|6-month Follow up (Cumulative Counts)|Relocation|0
6267768|NCT02123966|9967093|FG000|Overall Study|Intercurrent Illness|1
6267769|NCT02124161|9967137|FG000|Overall Study|Other unspecified|0
6267770|NCT02124161|9967138|FG001|Overall Study|Other unspecified|1
6267771|NCT02124161|9967137|FG000|Overall Study|Death|1
6267772|NCT02124161|9967138|FG001|Overall Study|Death|0
6267773|NCT02124161|9967137|FG000|Overall Study|Protocol Violation|2
6267774|NCT02124161|9967138|FG001|Overall Study|Protocol Violation|1
6267775|NCT02124161|9967137|FG000|Overall Study|Withdrawal by Subject|1
6267776|NCT02124161|9967138|FG001|Overall Study|Withdrawal by Subject|2
6267777|NCT02124161|9967137|FG000|Overall Study|Adverse Event|2
6267778|NCT02124161|9967138|FG001|Overall Study|Adverse Event|0
6267779|NCT02124161|9967137|FG000|Overall Study|Does not meet entrance criteria|2
6267780|NCT02124161|9967138|FG001|Overall Study|Does not meet entrance criteria|3
6267781|NCT02124161|9967137|FG000|Overall Study|No longer meets eligibility criteria|5
6267782|NCT02124161|9967138|FG001|Overall Study|No longer meets eligibility criteria|4
6267783|NCT02124161|9967137|FG000|Overall Study|Lost to Follow-up|3
6267784|NCT02124161|9967138|FG001|Overall Study|Lost to Follow-up|4
6267785|NCT02124265|9967151|FG000|Overall Study|Adverse Event|1
6267786|NCT02124564|9967183|FG000|Treatment Period|Adverse Event|2
6267787|NCT02124564|9967183|FG000|Treatment Period|Lack of Efficacy|3
6267788|NCT02124564|9967183|FG000|Treatment Period|Withdrawal by Subject|2
6267789|NCT02124707|9967193|FG000|Overall Study|Adverse Event|5
6267790|NCT02124707|9967193|FG000|Overall Study|Physician Decision|1
6267791|NCT02124707|9967193|FG000|Overall Study|Death|1
6267792|NCT02124746|9967201|FG000|Overall Study|Adverse Event|2
6267793|NCT02124746|9967202|FG001|Overall Study|Adverse Event|1
6267794|NCT02124746|9967203|FG002|Overall Study|Adverse Event|2
6267795|NCT02124746|9967201|FG000|Overall Study|Death|2
6267796|NCT02124746|9967202|FG001|Overall Study|Death|1
6267797|NCT02124746|9967203|FG002|Overall Study|Death|3
6267798|NCT02124746|9967201|FG000|Overall Study|Lack of Efficacy|3
6267799|NCT02124746|9967202|FG001|Overall Study|Lack of Efficacy|2
6267800|NCT02124746|9967203|FG002|Overall Study|Lack of Efficacy|2
6267801|NCT02124746|9967201|FG000|Overall Study|Physician Decision|6
6267802|NCT02124746|9967202|FG001|Overall Study|Physician Decision|4
6267803|NCT02124746|9967203|FG002|Overall Study|Physician Decision|5
6267804|NCT02124746|9967201|FG000|Overall Study|Non-Compliance with Study Drug|0
6267805|NCT02124746|9967202|FG001|Overall Study|Non-Compliance with Study Drug|1
6267806|NCT02124746|9967203|FG002|Overall Study|Non-Compliance with Study Drug|0
6267807|NCT02124746|9967201|FG000|Overall Study|Withdrawal by Subject|3
6267808|NCT02124746|9967202|FG001|Overall Study|Withdrawal by Subject|3
6267809|NCT02124746|9967203|FG002|Overall Study|Withdrawal by Subject|0
6267810|NCT02124746|9967201|FG000|Overall Study|Study Terminated by Sponsor|0
6267811|NCT02124746|9967202|FG001|Overall Study|Study Terminated by Sponsor|0
6267812|NCT02124746|9967203|FG002|Overall Study|Study Terminated by Sponsor|6
6267813|NCT02124746|9967201|FG000|Overall Study|Disease Progression|3
6267814|NCT02124746|9967202|FG001|Overall Study|Disease Progression|6
6267815|NCT02124746|9967203|FG002|Overall Study|Disease Progression|4
6267816|NCT02124759|9967214|FG000|Overall Study|Withdrawal by Subject|3
6267817|NCT02124759|9967215|FG001|Overall Study|Withdrawal by Subject|1
6267818|NCT02124759|9967216|FG002|Overall Study|Withdrawal by Subject|1
6267819|NCT02124759|9967214|FG000|Overall Study|Screen Fail|2
6267820|NCT02124759|9967215|FG001|Overall Study|Screen Fail|2
6267821|NCT02124759|9967216|FG002|Overall Study|Screen Fail|3
6267822|NCT02124772|9967242|FG000|Overall Study|Lack of Efficacy|2
6267823|NCT02124772|9967243|FG001|Overall Study|Lack of Efficacy|0
6267824|NCT02124772|9967244|FG002|Overall Study|Lack of Efficacy|0
6267825|NCT02124772|9967245|FG003|Overall Study|Lack of Efficacy|1
6267826|NCT02124772|9967246|FG004|Overall Study|Lack of Efficacy|2
6267827|NCT02124772|9967247|FG005|Overall Study|Lack of Efficacy|3
6267828|NCT02124772|9967248|FG006|Overall Study|Lack of Efficacy|0
6267829|NCT02124772|9967249|FG007|Overall Study|Lack of Efficacy|2
6267830|NCT02124772|9967250|FG008|Overall Study|Lack of Efficacy|0
6267831|NCT02124772|9967251|FG009|Overall Study|Lack of Efficacy|1
6267832|NCT02124772|9967252|FG010|Overall Study|Lack of Efficacy|0
6267833|NCT02124772|9967253|FG011|Overall Study|Lack of Efficacy|0
6267834|NCT02124772|9967254|FG012|Overall Study|Lack of Efficacy|1
6267835|NCT02124772|9967242|FG000|Overall Study|Adverse Event|1
6267836|NCT02124772|9967243|FG001|Overall Study|Adverse Event|4
6267837|NCT02124772|9967244|FG002|Overall Study|Adverse Event|1
6267838|NCT02124772|9967245|FG003|Overall Study|Adverse Event|5
6267839|NCT02124772|9967246|FG004|Overall Study|Adverse Event|2
6267840|NCT02124772|9967247|FG005|Overall Study|Adverse Event|1
6267841|NCT02124772|9967248|FG006|Overall Study|Adverse Event|1
6267842|NCT02124772|9967249|FG007|Overall Study|Adverse Event|5
6267843|NCT02124772|9967250|FG008|Overall Study|Adverse Event|0
6267844|NCT02124772|9967251|FG009|Overall Study|Adverse Event|3
6267845|NCT02124772|9967252|FG010|Overall Study|Adverse Event|1
6267846|NCT02124772|9967253|FG011|Overall Study|Adverse Event|3
6267847|NCT02124772|9967254|FG012|Overall Study|Adverse Event|1
6267848|NCT02124772|9967242|FG000|Overall Study|Withdrawal consent|0
6267849|NCT02124772|9967243|FG001|Overall Study|Withdrawal consent|1
6267850|NCT02124772|9967244|FG002|Overall Study|Withdrawal consent|1
6267851|NCT02124772|9967245|FG003|Overall Study|Withdrawal consent|1
6267852|NCT02124772|9967246|FG004|Overall Study|Withdrawal consent|0
6267853|NCT02124772|9967247|FG005|Overall Study|Withdrawal consent|1
6267854|NCT02124772|9967248|FG006|Overall Study|Withdrawal consent|1
6267855|NCT02124772|9967249|FG007|Overall Study|Withdrawal consent|0
6267856|NCT02124772|9967250|FG008|Overall Study|Withdrawal consent|0
6267857|NCT02124772|9967251|FG009|Overall Study|Withdrawal consent|1
6267858|NCT02124772|9967252|FG010|Overall Study|Withdrawal consent|0
6267859|NCT02124772|9967253|FG011|Overall Study|Withdrawal consent|1
6267860|NCT02124772|9967254|FG012|Overall Study|Withdrawal consent|0
6267861|NCT02124772|9967242|FG000|Overall Study|Investigator discretion|0
6267862|NCT02124772|9967243|FG001|Overall Study|Investigator discretion|2
6267863|NCT02124772|9967244|FG002|Overall Study|Investigator discretion|2
6267864|NCT02124772|9967245|FG003|Overall Study|Investigator discretion|1
6267865|NCT02124772|9967246|FG004|Overall Study|Investigator discretion|1
6267866|NCT02124772|9967247|FG005|Overall Study|Investigator discretion|0
6267867|NCT02124772|9967248|FG006|Overall Study|Investigator discretion|1
6267868|NCT02124772|9967249|FG007|Overall Study|Investigator discretion|0
6267869|NCT02124772|9967250|FG008|Overall Study|Investigator discretion|0
6267870|NCT02124772|9967251|FG009|Overall Study|Investigator discretion|1
6267871|NCT02124772|9967252|FG010|Overall Study|Investigator discretion|0
6267872|NCT02124772|9967253|FG011|Overall Study|Investigator discretion|1
6267873|NCT02124772|9967254|FG012|Overall Study|Investigator discretion|0
6267874|NCT02124772|9967242|FG000|Overall Study|Progressive disease|0
6267875|NCT02124772|9967243|FG001|Overall Study|Progressive disease|0
6267876|NCT02124772|9967244|FG002|Overall Study|Progressive disease|0
6267877|NCT02124772|9967245|FG003|Overall Study|Progressive disease|0
6267878|NCT02124772|9967246|FG004|Overall Study|Progressive disease|0
6267879|NCT02124772|9967247|FG005|Overall Study|Progressive disease|0
6267880|NCT02124772|9967248|FG006|Overall Study|Progressive disease|1
6267881|NCT02124772|9967249|FG007|Overall Study|Progressive disease|1
6267882|NCT02124772|9967250|FG008|Overall Study|Progressive disease|0
6267883|NCT02124772|9967251|FG009|Overall Study|Progressive disease|0
6267884|NCT02124772|9967252|FG010|Overall Study|Progressive disease|0
6267885|NCT02124772|9967253|FG011|Overall Study|Progressive disease|0
6267886|NCT02124772|9967254|FG012|Overall Study|Progressive disease|0
6267887|NCT02124772|9967242|FG000|Overall Study|Other|0
6267888|NCT02124772|9967243|FG001|Overall Study|Other|7
6267889|NCT02124772|9967244|FG002|Overall Study|Other|2
6267890|NCT02124772|9967245|FG003|Overall Study|Other|5
6267891|NCT02124772|9967246|FG004|Overall Study|Other|4
6267892|NCT02124772|9967247|FG005|Overall Study|Other|3
6267893|NCT02124772|9967248|FG006|Overall Study|Other|4
6267894|NCT02124772|9967249|FG007|Overall Study|Other|1
6267895|NCT02124772|9967250|FG008|Overall Study|Other|1
6267896|NCT02124772|9967251|FG009|Overall Study|Other|1
6267897|NCT02124772|9967252|FG010|Overall Study|Other|1
6267898|NCT02124772|9967253|FG011|Overall Study|Other|1
6267899|NCT02124772|9967254|FG012|Overall Study|Other|0
6267900|NCT02124798|9967306|FG000|Overall Study|Adverse Event|3
6267901|NCT02124798|9967306|FG000|Overall Study|Lost to Follow-up|1
6267902|NCT02124811|9967312|FG000|Overall Study|Early termination|2
6267903|NCT02124811|9967313|FG001|Overall Study|Early termination|2
6267904|NCT02124811|9967312|FG000|Overall Study|Withdrawal by Subject|1
6267905|NCT02124811|9967313|FG001|Overall Study|Withdrawal by Subject|0
6267906|NCT02125279|9967334|FG000|Overall Study|Lack of Efficacy|2
6267907|NCT02125279|9967334|FG000|Overall Study|Withdrawal by Subject|6
6267908|NCT02125279|9967334|FG000|Overall Study|Protocol Violation|1
6267909|NCT02125279|9967334|FG000|Overall Study|Lost to Follow-up|4
6267910|NCT02125331|9967356|FG000|Overall Study|Protocol Violation|1
6267911|NCT02125331|9967357|FG001|Overall Study|Protocol Violation|0
6267912|NCT02125331|9967356|FG000|Overall Study|technical problem|2
6267913|NCT02125331|9967357|FG001|Overall Study|technical problem|0
6267914|NCT02125331|9967356|FG000|Overall Study|screen failure|2
6267915|NCT02125331|9967357|FG001|Overall Study|screen failure|0
6267916|NCT02125604|9967363|FG000|Overall Study|Other|4
6267917|NCT02125604|9967363|FG000|Overall Study|Investigator Decision|1
6267918|NCT02125604|9967363|FG000|Overall Study|Lost to Follow-up|2
6267919|NCT02125604|9967363|FG000|Overall Study|Consent Withdrawn|4
6267920|NCT02125604|9967363|FG000|Overall Study|Adverse Event|20
6267921|NCT02125734|9967373|FG000|Period 2|Adverse Event|0
6267922|NCT02125734|9967374|FG001|Period 2|Adverse Event|1
6267923|NCT02125838|9967382|FG000|Overall Study|Lost to Follow-up|4
6087018|NCT00666211|9697140|FG000|Overall Study|off tx for other complicating disease|0
6267924|NCT02125838|9967383|FG001|Overall Study|Lost to Follow-up|4
6267925|NCT02125877|9967391|FG000|Overall Study|Physician Decision|1
6267926|NCT02125877|9967392|FG001|Overall Study|Physician Decision|0
6267927|NCT02125877|9967391|FG000|Overall Study|Death|0
6267928|NCT02125877|9967392|FG001|Overall Study|Death|1
6267929|NCT02125877|9967391|FG000|Overall Study|Administrative problems|0
6267930|NCT02125877|9967392|FG001|Overall Study|Administrative problems|1
6267931|NCT02125877|9967391|FG000|Overall Study|Participant/guardian decision|0
6267932|NCT02125877|9967392|FG001|Overall Study|Participant/guardian decision|2
6267933|NCT02125877|9967391|FG000|Overall Study|Withdrawal by Subject|2
6267934|NCT02125877|9967392|FG001|Overall Study|Withdrawal by Subject|1
6267935|NCT02125877|9967391|FG000|Overall Study|Protocol deviation|4
6267936|NCT02125877|9967392|FG001|Overall Study|Protocol deviation|1
6267937|NCT02125877|9967391|FG000|Overall Study|Adverse Event|6
6267938|NCT02125877|9967392|FG001|Overall Study|Adverse Event|4
6267939|NCT02126670|9967422|FG000|Overall Study|Withdrawal by Subject|1
6267940|NCT02126670|9967423|FG001|Overall Study|Withdrawal by Subject|0
6267941|NCT02126670|9967424|FG002|Overall Study|Withdrawal by Subject|0
6267942|NCT02126670|9967425|FG003|Overall Study|Withdrawal by Subject|1
6267943|NCT02126826|9967455|FG000|Overall Study|Withdrawal by Subject|0
6267944|NCT02126826|9967456|FG001|Overall Study|Withdrawal by Subject|0
6267945|NCT02126826|9967457|FG002|Overall Study|Withdrawal by Subject|0
6267946|NCT02126826|9967458|FG003|Overall Study|Withdrawal by Subject|1
6267947|NCT02126826|9967459|FG004|Overall Study|Withdrawal by Subject|0
6267948|NCT02126826|9967460|FG005|Overall Study|Withdrawal by Subject|0
6267949|NCT02126826|9967461|FG006|Overall Study|Withdrawal by Subject|0
6267950|NCT02126839|9967484|FG000|Overall Study|Adverse Event|0
6267951|NCT02126839|9967485|FG001|Overall Study|Adverse Event|1
6267952|NCT02126839|9967484|FG000|Overall Study|Withdrawal by Subject|1
6267953|NCT02126839|9967485|FG001|Overall Study|Withdrawal by Subject|0
6267954|NCT02126839|9967484|FG000|Overall Study|Withdrawal by parent/guardian|1
6267955|NCT02126839|9967485|FG001|Overall Study|Withdrawal by parent/guardian|0
6267956|NCT02126839|9967484|FG000|Overall Study|Protocol Violation|2
6267957|NCT02126839|9967485|FG001|Overall Study|Protocol Violation|3
6267958|NCT02126839|9967484|FG000|Overall Study|Sponsor request|0
6267959|NCT02126839|9967485|FG001|Overall Study|Sponsor request|1
6267960|NCT02126839|9967484|FG000|Overall Study|Lost to Follow-up|1
6267961|NCT02126839|9967485|FG001|Overall Study|Lost to Follow-up|4
6267962|NCT02126839|9967484|FG000|Overall Study|Other|5
6267963|NCT02126839|9967485|FG001|Overall Study|Other|5
6267964|NCT02126969|9967493|FG000|Overall Study|Withdrawal by Subject|1
6267965|NCT02126969|9967494|FG001|Overall Study|Withdrawal by Subject|2
6087019|NCT00666211|9697141|FG001|Overall Study|off tx for other complicating disease|1
6087020|NCT00666211|9697140|FG000|Overall Study|Physician Decision|0
6087021|NCT00666211|9697141|FG001|Overall Study|Physician Decision|1
6087022|NCT00666224|9697149|FG000|Double-Blind|Adverse Event|15
6087023|NCT00666224|9697150|FG001|Double-Blind|Adverse Event|5
6087024|NCT00666224|9697149|FG000|Double-Blind|Lost to Follow-up|2
6087025|NCT00666224|9697150|FG001|Double-Blind|Lost to Follow-up|2
6087026|NCT00666224|9697149|FG000|Double-Blind|Withdrawal by Subject|18
6087027|NCT00666224|9697150|FG001|Double-Blind|Withdrawal by Subject|14
6087028|NCT00666224|9697149|FG000|Double-Blind|Physician Decision|0
6087029|NCT00666224|9697150|FG001|Double-Blind|Physician Decision|3
6087030|NCT00666224|9697149|FG000|Double-Blind|Sponsor decision|1
6087031|NCT00666224|9697150|FG001|Double-Blind|Sponsor decision|0
6087032|NCT00666224|9697149|FG000|Double-Blind|Pregnancy|3
6087033|NCT00666224|9697150|FG001|Double-Blind|Pregnancy|2
6087034|NCT00666224|9697149|FG000|Double-Blind|Noncompliance|1
6087035|NCT00666224|9697150|FG001|Double-Blind|Noncompliance|0
6087036|NCT00666224|9697149|FG000|Double-Blind|Death|1
6087037|NCT00666224|9697150|FG001|Double-Blind|Death|0
6267966|NCT02127125|9967509|FG000|Overall Study|Lost to Follow-up|0
6267967|NCT02127125|9967510|FG001|Overall Study|Lost to Follow-up|0
6267968|NCT02127125|9967511|FG002|Overall Study|Lost to Follow-up|0
6267969|NCT02127125|9967512|FG003|Overall Study|Lost to Follow-up|0
6267970|NCT02127125|9967513|FG004|Overall Study|Lost to Follow-up|2
6267971|NCT02127125|9967514|FG005|Overall Study|Lost to Follow-up|1
6267972|NCT02127125|9967515|FG006|Overall Study|Lost to Follow-up|0
6267973|NCT02127125|9967516|FG007|Overall Study|Lost to Follow-up|0
6267974|NCT02127125|9967517|FG008|Overall Study|Lost to Follow-up|0
6267975|NCT02127125|9967509|FG000|Overall Study|Withdrawal by Subject|0
6267976|NCT02127125|9967510|FG001|Overall Study|Withdrawal by Subject|0
6267977|NCT02127125|9967511|FG002|Overall Study|Withdrawal by Subject|0
6267978|NCT02127125|9967512|FG003|Overall Study|Withdrawal by Subject|1
6267979|NCT02127125|9967513|FG004|Overall Study|Withdrawal by Subject|0
6267980|NCT02127125|9967514|FG005|Overall Study|Withdrawal by Subject|0
6267981|NCT02127125|9967515|FG006|Overall Study|Withdrawal by Subject|0
6267982|NCT02127125|9967516|FG007|Overall Study|Withdrawal by Subject|0
6267983|NCT02127125|9967517|FG008|Overall Study|Withdrawal by Subject|0
6267984|NCT02127125|9967509|FG000|Overall Study|Physician Decision|0
6267985|NCT02127125|9967510|FG001|Overall Study|Physician Decision|0
6267986|NCT02127125|9967511|FG002|Overall Study|Physician Decision|1
6267987|NCT02127125|9967512|FG003|Overall Study|Physician Decision|0
6267988|NCT02127125|9967513|FG004|Overall Study|Physician Decision|1
6267989|NCT02127125|9967514|FG005|Overall Study|Physician Decision|2
6267990|NCT02127125|9967515|FG006|Overall Study|Physician Decision|0
6267991|NCT02127125|9967516|FG007|Overall Study|Physician Decision|0
6267992|NCT02127125|9967517|FG008|Overall Study|Physician Decision|0
6267993|NCT02127281|9967539|FG000|Overall Study|Lost to Follow-up|1
6267994|NCT02127281|9967540|FG001|Overall Study|Lost to Follow-up|0
6267995|NCT02127307|9967546|FG000|Overall Study|Protocol Violation|36
6267996|NCT02127307|9967546|FG000|Overall Study|Lost to Follow-up|2
6267997|NCT02127307|9967546|FG000|Overall Study|Death|101
6267998|NCT02127307|9967546|FG000|Overall Study|Other than specified above|169
6267999|NCT02127372|9967552|FG000|Overall Study|Withdrawal by Subject|1
6268000|NCT02127372|9967553|FG001|Overall Study|Withdrawal by Subject|0
6268001|NCT02127931|9967614|FG000|Overall Study|Glitch in Game|1
6268002|NCT02127970|9967621|FG000|Overall Study|Adverse Event|2
6268003|NCT02127970|9967622|FG001|Overall Study|Adverse Event|1
6268004|NCT02127970|9967621|FG000|Overall Study|Death|1
6268005|NCT02127970|9967622|FG001|Overall Study|Death|1
6268006|NCT02127970|9967621|FG000|Overall Study|Lost to Follow-up|14
6268007|NCT02127970|9967622|FG001|Overall Study|Lost to Follow-up|14
6268008|NCT02127970|9967621|FG000|Overall Study|Reason not Specified|4
6268009|NCT02127970|9967622|FG001|Overall Study|Reason not Specified|7
6268010|NCT02127970|9967621|FG000|Overall Study|Pregnancy|0
6268011|NCT02127970|9967622|FG001|Overall Study|Pregnancy|1
6268012|NCT02127970|9967621|FG000|Overall Study|Subject Withdrew Consent|5
6268013|NCT02127970|9967622|FG001|Overall Study|Subject Withdrew Consent|3
6268014|NCT02128217|9967634|FG000|Overall Study|Lost to Follow-up|0
6268015|NCT02128217|9967635|FG001|Overall Study|Lost to Follow-up|1
6268016|NCT02128269|9967650|FG000|Treatment Period|Adverse Event|1
6268017|NCT02128269|9967650|FG000|Treatment Period|Physician Decision|1
6268018|NCT02128490|9967659|FG000|Overall Study|Pretreatment Event/Adverse Event|1
6268019|NCT02128490|9967660|FG001|Overall Study|Pretreatment Event/Adverse Event|0
6268020|NCT02128490|9967661|FG002|Overall Study|Pretreatment Event/Adverse Event|1
6268021|NCT02128490|9967662|FG003|Overall Study|Pretreatment Event/Adverse Event|1
6268022|NCT02128490|9967663|FG004|Overall Study|Pretreatment Event/Adverse Event|0
6268023|NCT02128490|9967659|FG000|Overall Study|Major Protocol Deviation|1
6268024|NCT02128490|9967660|FG001|Overall Study|Major Protocol Deviation|2
6268025|NCT02128490|9967661|FG002|Overall Study|Major Protocol Deviation|0
6268026|NCT02128490|9967662|FG003|Overall Study|Major Protocol Deviation|2
6268027|NCT02128490|9967663|FG004|Overall Study|Major Protocol Deviation|2
6268028|NCT02128490|9967659|FG000|Overall Study|Lost to Follow-up|0
6268029|NCT02128490|9967660|FG001|Overall Study|Lost to Follow-up|0
6268030|NCT02128490|9967661|FG002|Overall Study|Lost to Follow-up|1
6268031|NCT02128490|9967662|FG003|Overall Study|Lost to Follow-up|1
6268032|NCT02128490|9967663|FG004|Overall Study|Lost to Follow-up|1
6268033|NCT02128490|9967659|FG000|Overall Study|Voluntary Withdrawal|3
6268034|NCT02128490|9967660|FG001|Overall Study|Voluntary Withdrawal|3
6268035|NCT02128490|9967661|FG002|Overall Study|Voluntary Withdrawal|1
6268036|NCT02128490|9967662|FG003|Overall Study|Voluntary Withdrawal|1
6268037|NCT02128490|9967663|FG004|Overall Study|Voluntary Withdrawal|2
6268038|NCT02128490|9967659|FG000|Overall Study|Lack of Efficacy|0
6268039|NCT02128490|9967660|FG001|Overall Study|Lack of Efficacy|1
6268040|NCT02128490|9967661|FG002|Overall Study|Lack of Efficacy|0
6268041|NCT02128490|9967662|FG003|Overall Study|Lack of Efficacy|0
6268042|NCT02128490|9967663|FG004|Overall Study|Lack of Efficacy|0
6268043|NCT02128490|9967659|FG000|Overall Study|Withdraw from Study Drug, Gout Flare|0
6268044|NCT02128490|9967660|FG001|Overall Study|Withdraw from Study Drug, Gout Flare|0
6268045|NCT02128490|9967661|FG002|Overall Study|Withdraw from Study Drug, Gout Flare|0
6268046|NCT02128490|9967662|FG003|Overall Study|Withdraw from Study Drug, Gout Flare|0
6268047|NCT02128490|9967663|FG004|Overall Study|Withdraw from Study Drug, Gout Flare|1
6268048|NCT02128490|9967659|FG000|Overall Study|Other Miscellaneous Reasons|0
6268049|NCT02128490|9967660|FG001|Overall Study|Other Miscellaneous Reasons|0
6268050|NCT02128490|9967661|FG002|Overall Study|Other Miscellaneous Reasons|2
6268051|NCT02128490|9967662|FG003|Overall Study|Other Miscellaneous Reasons|1
6268052|NCT02128490|9967663|FG004|Overall Study|Other Miscellaneous Reasons|1
6268053|NCT02128542|9967677|FG000|Overall Study|Lost to Follow-up|3
6268054|NCT02128542|9967678|FG001|Overall Study|Lost to Follow-up|0
6268055|NCT02128542|9967677|FG000|Overall Study|Withdrew Consent|1
6268056|NCT02128542|9967678|FG001|Overall Study|Withdrew Consent|0
6268057|NCT02128724|9967690|FG000|Overall Study|Death|1
6268058|NCT02128724|9967691|FG001|Overall Study|Death|0
6268059|NCT02128724|9967692|FG002|Overall Study|Death|0
6268060|NCT02128724|9967693|FG003|Overall Study|Death|0
6268061|NCT02128724|9967690|FG000|Overall Study|Adverse Event|0
6268062|NCT02128724|9967691|FG001|Overall Study|Adverse Event|1
6268063|NCT02128724|9967692|FG002|Overall Study|Adverse Event|0
6268064|NCT02128724|9967693|FG003|Overall Study|Adverse Event|0
6268065|NCT02128724|9967690|FG000|Overall Study|Physician Decision|0
6268066|NCT02128724|9967691|FG001|Overall Study|Physician Decision|0
6268067|NCT02128724|9967692|FG002|Overall Study|Physician Decision|0
6268068|NCT02128724|9967693|FG003|Overall Study|Physician Decision|2
6268069|NCT02128724|9967690|FG000|Overall Study|Withdrawal by Subject|0
6268070|NCT02128724|9967691|FG001|Overall Study|Withdrawal by Subject|0
6268071|NCT02128724|9967692|FG002|Overall Study|Withdrawal by Subject|0
6268072|NCT02128724|9967693|FG003|Overall Study|Withdrawal by Subject|1
6268073|NCT02128763|9967704|FG000|Overall Study|Death|1
6268074|NCT02128763|9967705|FG001|Overall Study|Death|0
6268075|NCT02128763|9967704|FG000|Overall Study|Lost to Follow-up|19
6268076|NCT02128763|9967705|FG001|Overall Study|Lost to Follow-up|16
6268077|NCT02128932|9967744|FG000|Overall Study|Withdrawal by Subject|11
6268078|NCT02128932|9967745|FG001|Overall Study|Withdrawal by Subject|7
6268079|NCT02128932|9967746|FG002|Overall Study|Withdrawal by Subject|8
6268080|NCT02128932|9967744|FG000|Overall Study|Death|2
6268081|NCT02128932|9967745|FG001|Overall Study|Death|0
6268082|NCT02128932|9967746|FG002|Overall Study|Death|2
6268083|NCT02128932|9967744|FG000|Overall Study|Lost to Follow-up|2
6268084|NCT02128932|9967745|FG001|Overall Study|Lost to Follow-up|1
6268085|NCT02128932|9967746|FG002|Overall Study|Lost to Follow-up|1
6268086|NCT02128932|9967744|FG000|Overall Study|No reason for withdrawal|12
6268087|NCT02128932|9967745|FG001|Overall Study|No reason for withdrawal|11
6268088|NCT02128932|9967746|FG002|Overall Study|No reason for withdrawal|7
6268089|NCT02128997|9967756|FG000|Overall Study|Lost to Follow-up|6
6268090|NCT02128997|9967757|FG001|Overall Study|Lost to Follow-up|11
6268091|NCT02129062|9967763|FG000|Overall Study|Death|1
6268092|NCT02129062|9967763|FG000|Overall Study|Disease Progression|2
6268093|NCT02129192|9967780|FG000|Period 1 Including Washout Period|Withdrawal by Subject|0
6268094|NCT02129192|9967781|FG001|Period 1 Including Washout Period|Withdrawal by Subject|1
6268095|NCT02129205|9967800|FG000|Overall Study|Withdrawal by Subject|0
6268096|NCT02129205|9967801|FG001|Overall Study|Withdrawal by Subject|0
6268097|NCT02129205|9967802|FG002|Overall Study|Withdrawal by Subject|0
6268098|NCT02129205|9967803|FG003|Overall Study|Withdrawal by Subject|0
6268099|NCT02129205|9967804|FG004|Overall Study|Withdrawal by Subject|1
6268100|NCT02129205|9967805|FG005|Overall Study|Withdrawal by Subject|1
6268101|NCT02129205|9967806|FG006|Overall Study|Withdrawal by Subject|1
6268102|NCT02129205|9967807|FG007|Overall Study|Withdrawal by Subject|0
6268103|NCT02129205|9967808|FG008|Overall Study|Withdrawal by Subject|1
6268104|NCT02129205|9967809|FG009|Overall Study|Withdrawal by Subject|0
6268105|NCT02129205|9967800|FG000|Overall Study|Other|1
6268106|NCT02129205|9967801|FG001|Overall Study|Other|0
6268107|NCT02129205|9967802|FG002|Overall Study|Other|0
6268108|NCT02129205|9967803|FG003|Overall Study|Other|0
6268109|NCT02129205|9967804|FG004|Overall Study|Other|2
6268110|NCT02129205|9967805|FG005|Overall Study|Other|3
6268111|NCT02129205|9967806|FG006|Overall Study|Other|3
6268112|NCT02129205|9967807|FG007|Overall Study|Other|2
6268113|NCT02129205|9967808|FG008|Overall Study|Other|1
6268114|NCT02129205|9967809|FG009|Overall Study|Other|0
6268115|NCT02129608|9967864|FG000|Overall Study|Lost to Follow-up|0
6268116|NCT02129608|9967865|FG001|Overall Study|Lost to Follow-up|1
6268117|NCT02129608|9967866|FG002|Overall Study|Lost to Follow-up|1
6268118|NCT02129608|9967864|FG000|Overall Study|Withdrawal by Subject|0
6268119|NCT02129608|9967865|FG001|Overall Study|Withdrawal by Subject|0
6268120|NCT02129608|9967866|FG002|Overall Study|Withdrawal by Subject|2
6268121|NCT02129777|9967910|FG000|Double-Blind Period|Adverse Event|0
6268122|NCT02129777|9967911|FG001|Double-Blind Period|Adverse Event|0
6087038|NCT00666224|9697149|FG000|Double-Blind|Undefined/Unknown|4
6268123|NCT02129777|9967912|FG002|Double-Blind Period|Adverse Event|0
6268124|NCT02129777|9967913|FG003|Double-Blind Period|Adverse Event|0
6268125|NCT02129777|9967914|FG004|Double-Blind Period|Adverse Event|1
6268126|NCT02129777|9967915|FG005|Double-Blind Period|Adverse Event|0
6268127|NCT02129777|9967916|FG006|Double-Blind Period|Adverse Event|0
6268128|NCT02129777|9967910|FG000|Double-Blind Period|Lost to Follow-up|1
6268129|NCT02129777|9967911|FG001|Double-Blind Period|Lost to Follow-up|1
6087039|NCT00666224|9697150|FG001|Double-Blind|Undefined/Unknown|1
6087040|NCT00666224|9697149|FG000|Open-Label|Adverse Event|8
6268130|NCT02129777|9967912|FG002|Double-Blind Period|Lost to Follow-up|1
6268131|NCT02129777|9967913|FG003|Double-Blind Period|Lost to Follow-up|2
6268132|NCT02129777|9967914|FG004|Double-Blind Period|Lost to Follow-up|0
6268133|NCT02129777|9967915|FG005|Double-Blind Period|Lost to Follow-up|0
6268134|NCT02129777|9967916|FG006|Double-Blind Period|Lost to Follow-up|0
6268135|NCT02129777|9967910|FG000|Double-Blind Period|Withdrawal by Subject|2
6268136|NCT02129777|9967911|FG001|Double-Blind Period|Withdrawal by Subject|4
6268137|NCT02129777|9967912|FG002|Double-Blind Period|Withdrawal by Subject|3
6268138|NCT02129777|9967913|FG003|Double-Blind Period|Withdrawal by Subject|2
6268139|NCT02129777|9967914|FG004|Double-Blind Period|Withdrawal by Subject|3
6268140|NCT02129777|9967915|FG005|Double-Blind Period|Withdrawal by Subject|0
6268141|NCT02129777|9967916|FG006|Double-Blind Period|Withdrawal by Subject|0
6268142|NCT02129777|9967910|FG000|Double-Blind Period|Pregnancy|0
6268143|NCT02129777|9967911|FG001|Double-Blind Period|Pregnancy|0
6268144|NCT02129777|9967912|FG002|Double-Blind Period|Pregnancy|0
6268145|NCT02129777|9967913|FG003|Double-Blind Period|Pregnancy|0
6268146|NCT02129777|9967914|FG004|Double-Blind Period|Pregnancy|1
6268147|NCT02129777|9967915|FG005|Double-Blind Period|Pregnancy|0
6268148|NCT02129777|9967916|FG006|Double-Blind Period|Pregnancy|0
6268149|NCT02129777|9967910|FG000|Double-Blind Period|Lack of Efficacy|3
6268150|NCT02129777|9967911|FG001|Double-Blind Period|Lack of Efficacy|1
6268151|NCT02129777|9967912|FG002|Double-Blind Period|Lack of Efficacy|0
6268152|NCT02129777|9967913|FG003|Double-Blind Period|Lack of Efficacy|3
6268153|NCT02129777|9967914|FG004|Double-Blind Period|Lack of Efficacy|2
6268154|NCT02129777|9967915|FG005|Double-Blind Period|Lack of Efficacy|0
6268155|NCT02129777|9967916|FG006|Double-Blind Period|Lack of Efficacy|0
6268156|NCT02129777|9967910|FG000|Double-Blind Period|Other|1
6268157|NCT02129777|9967911|FG001|Double-Blind Period|Other|2
6268158|NCT02129777|9967912|FG002|Double-Blind Period|Other|0
6268159|NCT02129777|9967913|FG003|Double-Blind Period|Other|0
6268160|NCT02129777|9967914|FG004|Double-Blind Period|Other|0
6268161|NCT02129777|9967915|FG005|Double-Blind Period|Other|0
6268162|NCT02129777|9967916|FG006|Double-Blind Period|Other|0
6268163|NCT02129777|9967910|FG000|Open-Label Period|Lack of Efficacy|0
6268164|NCT02129777|9967911|FG001|Open-Label Period|Lack of Efficacy|0
6268165|NCT02129777|9967912|FG002|Open-Label Period|Lack of Efficacy|0
6268166|NCT02129777|9967913|FG003|Open-Label Period|Lack of Efficacy|0
6268167|NCT02129777|9967914|FG004|Open-Label Period|Lack of Efficacy|0
6268168|NCT02129777|9967915|FG005|Open-Label Period|Lack of Efficacy|0
6268169|NCT02129777|9967916|FG006|Open-Label Period|Lack of Efficacy|5
6268170|NCT02129777|9967910|FG000|Open-Label Period|Lost to Follow-up|0
6268171|NCT02129777|9967911|FG001|Open-Label Period|Lost to Follow-up|0
6268172|NCT02129777|9967912|FG002|Open-Label Period|Lost to Follow-up|0
6268173|NCT02129777|9967913|FG003|Open-Label Period|Lost to Follow-up|0
6268174|NCT02129777|9967914|FG004|Open-Label Period|Lost to Follow-up|0
6268175|NCT02129777|9967915|FG005|Open-Label Period|Lost to Follow-up|1
6268176|NCT02129777|9967916|FG006|Open-Label Period|Lost to Follow-up|1
6268177|NCT02129777|9967910|FG000|Open-Label Period|Withdrawal by Subject|0
6268178|NCT02129777|9967911|FG001|Open-Label Period|Withdrawal by Subject|0
6268179|NCT02129777|9967912|FG002|Open-Label Period|Withdrawal by Subject|0
6268180|NCT02129777|9967913|FG003|Open-Label Period|Withdrawal by Subject|0
6268181|NCT02129777|9967914|FG004|Open-Label Period|Withdrawal by Subject|0
6268182|NCT02129777|9967915|FG005|Open-Label Period|Withdrawal by Subject|1
6268183|NCT02129777|9967916|FG006|Open-Label Period|Withdrawal by Subject|3
6268184|NCT02129777|9967910|FG000|Open-Label Period|Study Termination|0
6268185|NCT02129777|9967911|FG001|Open-Label Period|Study Termination|0
6268186|NCT02129777|9967912|FG002|Open-Label Period|Study Termination|0
6268187|NCT02129777|9967913|FG003|Open-Label Period|Study Termination|0
6268188|NCT02129777|9967914|FG004|Open-Label Period|Study Termination|0
6268189|NCT02129777|9967915|FG005|Open-Label Period|Study Termination|10
6268190|NCT02129777|9967916|FG006|Open-Label Period|Study Termination|39
6268191|NCT02129803|9967937|FG000|Overall Study|Protocol Violation|4
6268192|NCT02129803|9967938|FG001|Overall Study|Protocol Violation|0
6268193|NCT02129803|9967937|FG000|Overall Study|Physician Decision|0
6268194|NCT02129803|9967938|FG001|Overall Study|Physician Decision|1
6268195|NCT02129803|9967937|FG000|Overall Study|Difficulty sleeping|1
6268196|NCT02129803|9967938|FG001|Overall Study|Difficulty sleeping|0
6268197|NCT02129803|9967937|FG000|Overall Study|Morning headache|0
6268198|NCT02129803|9967938|FG001|Overall Study|Morning headache|1
6268199|NCT02129803|9967937|FG000|Overall Study|Withdrawal by Subject|1
6087041|NCT00666224|9697150|FG001|Open-Label|Adverse Event|43
6087042|NCT00666224|9697149|FG000|Open-Label|Lost to Follow-up|4
6087043|NCT00666224|9697150|FG001|Open-Label|Lost to Follow-up|5
6087044|NCT00666224|9697149|FG000|Open-Label|Withdrawal by Subject|12
6087045|NCT00666224|9697150|FG001|Open-Label|Withdrawal by Subject|25
6087046|NCT00666224|9697149|FG000|Open-Label|Physician Decision|7
6087047|NCT00666224|9697150|FG001|Open-Label|Physician Decision|5
6087048|NCT00666224|9697149|FG000|Open-Label|Pregnancy|1
6087049|NCT00666224|9697150|FG001|Open-Label|Pregnancy|5
6087050|NCT00666224|9697149|FG000|Open-Label|Noncompliance|2
6087051|NCT00666224|9697150|FG001|Open-Label|Noncompliance|1
6087052|NCT00666224|9697149|FG000|Open-Label|Undefined/Unknown|1
6087053|NCT00666224|9697150|FG001|Open-Label|Undefined/Unknown|1
6087054|NCT00666263|9697157|FG000|Study Part 1 (Stabilization Phase 1)|Adverse Event|0
6087055|NCT00666263|9697158|FG001|Study Part 1 (Stabilization Phase 1)|Adverse Event|1
6087056|NCT00666263|9697157|FG000|Study Part 4 (Cross-over Period 2)|Adverse Event|1
6087057|NCT00666263|9697158|FG001|Study Part 4 (Cross-over Period 2)|Adverse Event|0
6268200|NCT02129803|9967938|FG001|Overall Study|Withdrawal by Subject|1
6268201|NCT02130024|9967946|FG000|Overall Study|Adverse Event|10
6268202|NCT02130024|9967947|FG001|Overall Study|Adverse Event|11
6268203|NCT02130024|9967946|FG000|Overall Study|Death|2
6087058|NCT00666263|9697157|FG000|Study Part 5 (Stabilization Phase 3)|Withdrawal by Subject|0
6087059|NCT00666263|9697158|FG001|Study Part 5 (Stabilization Phase 3)|Withdrawal by Subject|1
6268204|NCT02130024|9967947|FG001|Overall Study|Death|2
6268205|NCT02130024|9967946|FG000|Overall Study|Lost to Follow-up|1
6268206|NCT02130024|9967947|FG001|Overall Study|Lost to Follow-up|1
6268207|NCT02130024|9967946|FG000|Overall Study|Physician Decision|1
6087060|NCT00666276|9697203|FG000|Overall Study|Protocol Violation|34
6087061|NCT00666328|9697226|FG000|Overall Study|Death|2
6087062|NCT00666328|9697226|FG000|Overall Study|Lost to Follow-up|2
6087063|NCT00666328|9697226|FG000|Overall Study|No longer met eligibility criteria|1
6087064|NCT00666458|9697240|FG000|Overall Study|Adverse Event|8
6087065|NCT00666458|9697241|FG001|Overall Study|Adverse Event|7
6268208|NCT02130024|9967947|FG001|Overall Study|Physician Decision|3
6268209|NCT02130024|9967946|FG000|Overall Study|Protocol Deviation|4
6268210|NCT02130024|9967947|FG001|Overall Study|Protocol Deviation|0
6268211|NCT02130024|9967946|FG000|Overall Study|Site Administration Problems|1
6268212|NCT02130024|9967947|FG001|Overall Study|Site Administration Problems|0
6268213|NCT02130024|9967946|FG000|Overall Study|Subject Withdrew Consent|6
6268214|NCT02130024|9967947|FG001|Overall Study|Subject Withdrew Consent|14
6268215|NCT02130193|9967964|FG000|Part B: 52-week Double-blind Period|Adverse Event|0
6268216|NCT02130193|9967965|FG001|Part B: 52-week Double-blind Period|Adverse Event|5
6268217|NCT02130193|9967966|FG002|Part B: 52-week Double-blind Period|Adverse Event|3
6268218|NCT02130193|9967964|FG000|Part B: 52-week Double-blind Period|Protocol Violation|0
6268219|NCT02130193|9967965|FG001|Part B: 52-week Double-blind Period|Protocol Violation|2
6268220|NCT02130193|9967966|FG002|Part B: 52-week Double-blind Period|Protocol Violation|1
6268221|NCT02130193|9967964|FG000|Part B: 52-week Double-blind Period|Physician Decision|0
6268222|NCT02130193|9967965|FG001|Part B: 52-week Double-blind Period|Physician Decision|0
6268223|NCT02130193|9967966|FG002|Part B: 52-week Double-blind Period|Physician Decision|1
6268224|NCT02130193|9967964|FG000|Part B: 52-week Double-blind Period|Withdrawal by Subject|0
6268225|NCT02130193|9967965|FG001|Part B: 52-week Double-blind Period|Withdrawal by Subject|3
6268226|NCT02130193|9967966|FG002|Part B: 52-week Double-blind Period|Withdrawal by Subject|3
6268227|NCT02130284|9967984|FG000|Overall Study|Withdrawal by Subject|3
6268228|NCT02130284|9967984|FG000|Overall Study|Subject Withdrew Consent|1
6268229|NCT02130284|9967984|FG000|Overall Study|Subject's sensor failed at Visit 2, Day|1
6268230|NCT02130284|9967984|FG000|Overall Study|Subject was screened as backup for study|3
6268231|NCT02130284|9967984|FG000|Overall Study|Screen Failure|1
6268232|NCT02130297|9967988|FG000|Overall Study|Lost to Follow-up|4
6268233|NCT02130427|9967992|FG000|Overall Study|Imaging results not interpretable|30
6268234|NCT02130557|9967998|FG000|Overall Study|Withdrawal by Subject|12
6268235|NCT02130557|9967999|FG001|Overall Study|Withdrawal by Subject|12
6268236|NCT02130557|9967998|FG000|Overall Study|Investigator Request|0
6268237|NCT02130557|9967999|FG001|Overall Study|Investigator Request|2
6268238|NCT02130557|9967998|FG000|Overall Study|Deceased|14
6268239|NCT02130557|9967999|FG001|Overall Study|Deceased|14
6268240|NCT02130557|9967998|FG000|Overall Study|Lost to Follow-up|6
6268241|NCT02130557|9967999|FG001|Overall Study|Lost to Follow-up|7
6268242|NCT02130557|9967998|FG000|Overall Study|Other|2
6268243|NCT02130557|9967999|FG001|Overall Study|Other|1
6268244|NCT02130557|9967998|FG000|Overall Study|Missing|2
6268245|NCT02130557|9967999|FG001|Overall Study|Missing|1
6268246|NCT02130570|9968007|FG000|Overall Study|Death|3
6268247|NCT02130570|9968008|FG001|Overall Study|Death|5
6268248|NCT02130570|9968007|FG000|Overall Study|Withdrawal by Subject|6
6268249|NCT02130570|9968008|FG001|Overall Study|Withdrawal by Subject|3
6268250|NCT02130570|9968007|FG000|Overall Study|Part of practice that discontinued study|0
6268251|NCT02130570|9968008|FG001|Overall Study|Part of practice that discontinued study|5
6271788|NCT02167035|9973706|FG001|Overall Study|Randomized to incorrect Study Medication|1
6271789|NCT02167139|9973725|FG000|Randomised, Double-blind|Withdrawal by Subject|11
6271790|NCT02167139|9973726|FG001|Randomised, Double-blind|Withdrawal by Subject|8
6271791|NCT02167139|9973727|FG002|Randomised, Double-blind|Withdrawal by Subject|0
6271792|NCT02167139|9973728|FG003|Randomised, Double-blind|Withdrawal by Subject|0
6271793|NCT02167139|9973725|FG000|Randomised, Double-blind|Adverse Event|2
6271794|NCT02167139|9973726|FG001|Randomised, Double-blind|Adverse Event|9
6271795|NCT02167139|9973727|FG002|Randomised, Double-blind|Adverse Event|0
6271796|NCT02167139|9973728|FG003|Randomised, Double-blind|Adverse Event|0
6271797|NCT02167139|9973725|FG000|Randomised, Double-blind|Lack of Efficacy|1
6271798|NCT02167139|9973726|FG001|Randomised, Double-blind|Lack of Efficacy|2
6271799|NCT02167139|9973727|FG002|Randomised, Double-blind|Lack of Efficacy|0
6271800|NCT02167139|9973728|FG003|Randomised, Double-blind|Lack of Efficacy|0
6271801|NCT02167139|9973725|FG000|Randomised, Double-blind|Other|3
6271802|NCT02167139|9973726|FG001|Randomised, Double-blind|Other|0
6271803|NCT02167139|9973727|FG002|Randomised, Double-blind|Other|0
6271804|NCT02167139|9973728|FG003|Randomised, Double-blind|Other|0
6271805|NCT02167139|9973725|FG000|Transition-extension|Adverse Event|2
6271806|NCT02167139|9973726|FG001|Transition-extension|Adverse Event|0
6271807|NCT02167139|9973727|FG002|Transition-extension|Adverse Event|2
6271808|NCT02167139|9973728|FG003|Transition-extension|Adverse Event|3
6271809|NCT02167139|9973725|FG000|Transition-extension|Withdrawal by Subject|2
6271810|NCT02167139|9973726|FG001|Transition-extension|Withdrawal by Subject|0
6271811|NCT02167139|9973727|FG002|Transition-extension|Withdrawal by Subject|4
6271812|NCT02167139|9973728|FG003|Transition-extension|Withdrawal by Subject|1
6087066|NCT00666458|9697240|FG000|Overall Study|Withdrawal by Subject|5
6271813|NCT02167139|9973725|FG000|Transition-extension|Lack of Efficacy|0
6271814|NCT02167139|9973726|FG001|Transition-extension|Lack of Efficacy|0
6271815|NCT02167139|9973727|FG002|Transition-extension|Lack of Efficacy|1
6268252|NCT02130765|9968072|FG000|Overall Study|Did not receive treatment|4
6268253|NCT02130765|9968073|FG001|Overall Study|Did not receive treatment|0
6268254|NCT02130765|9968074|FG002|Overall Study|Did not receive treatment|0
6268255|NCT02130765|9968075|FG003|Overall Study|Did not receive treatment|0
6268256|NCT02130986|9968089|FG000|Overall Study|Withdrawal by Subject|4
6268257|NCT02130986|9968090|FG001|Overall Study|Withdrawal by Subject|4
6268258|NCT02130986|9968089|FG000|Overall Study|Lost to Follow-up|151
6268259|NCT02130986|9968090|FG001|Overall Study|Lost to Follow-up|160
6268260|NCT02131064|9968112|FG000|Overall Study|Death|5
6268261|NCT02131064|9968113|FG001|Overall Study|Death|6
6268262|NCT02131064|9968112|FG000|Overall Study|Lost to Follow-up|4
6268263|NCT02131064|9968113|FG001|Overall Study|Lost to Follow-up|8
6268264|NCT02131064|9968112|FG000|Overall Study|Withdrawal by Subject|14
6268265|NCT02131064|9968113|FG001|Overall Study|Withdrawal by Subject|18
6268266|NCT02131064|9968112|FG000|Overall Study|Other|2
6268267|NCT02131064|9968113|FG001|Overall Study|Other|2
6268268|NCT02131129|9968122|FG000|Overall Study|Withdrawal by Subject|1
6268269|NCT02131129|9968123|FG001|Overall Study|Withdrawal by Subject|0
6268270|NCT02131233|9968131|FG000|Overall Study|Not Treated|2
6268271|NCT02131233|9968132|FG001|Overall Study|Not Treated|3
6268272|NCT02131233|9968131|FG000|Overall Study|Adverse Event|7
6268273|NCT02131233|9968132|FG001|Overall Study|Adverse Event|6
6268274|NCT02131233|9968131|FG000|Overall Study|Death|0
6268275|NCT02131233|9968132|FG001|Overall Study|Death|1
6268276|NCT02131233|9968131|FG000|Overall Study|Lack of Efficacy|6
6268277|NCT02131233|9968132|FG001|Overall Study|Lack of Efficacy|3
6268278|NCT02131233|9968131|FG000|Overall Study|Lost to Follow-up|14
6268279|NCT02131233|9968132|FG001|Overall Study|Lost to Follow-up|13
6268280|NCT02131233|9968131|FG000|Overall Study|Non-Compliance With Study Drug|8
6268281|NCT02131233|9968132|FG001|Overall Study|Non-Compliance With Study Drug|5
6268282|NCT02131233|9968131|FG000|Overall Study|Physician Decision|7
6268283|NCT02131233|9968132|FG001|Overall Study|Physician Decision|0
6268284|NCT02131233|9968131|FG000|Overall Study|Pregnancy|4
6268285|NCT02131233|9968132|FG001|Overall Study|Pregnancy|0
6268286|NCT02131233|9968131|FG000|Overall Study|Withdrawal by Subject|18
6268287|NCT02131233|9968132|FG001|Overall Study|Withdrawal by Subject|11
6268288|NCT02131259|9968138|FG000|Overall Study|Progressive disease|751
6268289|NCT02131259|9968138|FG000|Overall Study|Adverse Event|341
6268290|NCT02131259|9968138|FG000|Overall Study|Lost to Follow-up|7
6268291|NCT02131259|9968138|FG000|Overall Study|Relocation|32
6268292|NCT02131259|9968138|FG000|Overall Study|Other|63
6268293|NCT02131259|9968138|FG000|Overall Study|Progressive disease/Adverse Event (AE)|22
6268294|NCT02131259|9968138|FG000|Overall Study|Progressive disease/relocation|1
6268295|NCT02131259|9968138|FG000|Overall Study|Progressive disease/other|2
6268296|NCT02131259|9968138|FG000|Overall Study|AE/lost to follow-up|1
6268297|NCT02131259|9968138|FG000|Overall Study|AE/other|1
6268298|NCT02131259|9968138|FG000|Overall Study|Progressive disease/AE/other|1
6268299|NCT02131259|9968138|FG000|Overall Study|Missing|3
6268300|NCT02131272|9968144|FG000|Overall Study|Withdrawal by parent|0
6268301|NCT02131272|9968145|FG001|Overall Study|Withdrawal by parent|1
6268302|NCT02131272|9968144|FG000|Overall Study|Withdrawal by Subject|0
6268303|NCT02131272|9968145|FG001|Overall Study|Withdrawal by Subject|1
6268304|NCT02131272|9968144|FG000|Overall Study|Withdrawal Criteria|1
6268305|NCT02131272|9968145|FG001|Overall Study|Withdrawal Criteria|0
6268306|NCT02131311|9968151|FG000|Overall Study|Adverse Event|2
6268307|NCT02131311|9968151|FG000|Overall Study|Protocol Violation|1
6268308|NCT02131311|9968151|FG000|Overall Study|Lost to Follow-up|1
6268309|NCT02131324|9968158|FG000|Overall Study|Withdrawal by Subject|1
6268310|NCT02131324|9968159|FG001|Overall Study|Withdrawal by Subject|2
6268311|NCT02131324|9968158|FG000|Overall Study|Lost to Follow-up|1
6268312|NCT02131324|9968159|FG001|Overall Study|Lost to Follow-up|1
6268313|NCT02131532|9968228|FG000|Overall Study|Withdrawal by Subject|1
6268314|NCT02131532|9968228|FG000|Overall Study|Physician Decision|1
6268315|NCT02131532|9968228|FG000|Overall Study|Other health conditions|2
6268316|NCT02131636|9968235|FG000|Overall Study|Personal Reasons|4
6268317|NCT02131636|9968236|FG001|Overall Study|Personal Reasons|4
6268318|NCT02131636|9968235|FG000|Overall Study|Lost to Follow-up|4
6268319|NCT02131636|9968236|FG001|Overall Study|Lost to Follow-up|0
6268320|NCT02131636|9968235|FG000|Overall Study|Adverse Event|4
6268321|NCT02131636|9968236|FG001|Overall Study|Adverse Event|1
6268322|NCT02131662|9968247|FG000|Overall Study|Protocol Violation|1
6268323|NCT02131662|9968248|FG001|Overall Study|Protocol Violation|0
6268324|NCT02131662|9968249|FG002|Overall Study|Protocol Violation|0
6268325|NCT02131662|9968250|FG003|Overall Study|Protocol Violation|0
6268326|NCT02131662|9968251|FG004|Overall Study|Protocol Violation|0
6268327|NCT02131662|9968247|FG000|Overall Study|Other|2
6268328|NCT02131662|9968248|FG001|Overall Study|Other|4
6268329|NCT02131662|9968249|FG002|Overall Study|Other|3
6268330|NCT02131662|9968250|FG003|Overall Study|Other|3
6268331|NCT02131662|9968251|FG004|Overall Study|Other|4
6268332|NCT02131662|9968247|FG000|Overall Study|Adverse Event|0
6268333|NCT02131662|9968248|FG001|Overall Study|Adverse Event|1
6268334|NCT02131662|9968249|FG002|Overall Study|Adverse Event|1
6268335|NCT02131662|9968250|FG003|Overall Study|Adverse Event|1
6268336|NCT02131662|9968251|FG004|Overall Study|Adverse Event|3
6268337|NCT02131662|9968247|FG000|Overall Study|Pregnancy|0
6268338|NCT02131662|9968248|FG001|Overall Study|Pregnancy|1
6268339|NCT02131662|9968249|FG002|Overall Study|Pregnancy|0
6268340|NCT02131662|9968250|FG003|Overall Study|Pregnancy|1
6268341|NCT02131662|9968251|FG004|Overall Study|Pregnancy|0
6268342|NCT02131662|9968247|FG000|Overall Study|Wish for pregnancy|0
6268343|NCT02131662|9968248|FG001|Overall Study|Wish for pregnancy|0
6268344|NCT02131662|9968249|FG002|Overall Study|Wish for pregnancy|0
6268345|NCT02131662|9968250|FG003|Overall Study|Wish for pregnancy|0
6268346|NCT02131662|9968251|FG004|Overall Study|Wish for pregnancy|1
6268347|NCT02131662|9968247|FG000|Overall Study|Lack of Efficacy|1
6268348|NCT02131662|9968248|FG001|Overall Study|Lack of Efficacy|0
6268349|NCT02131662|9968249|FG002|Overall Study|Lack of Efficacy|0
6268350|NCT02131662|9968250|FG003|Overall Study|Lack of Efficacy|0
6268351|NCT02131662|9968251|FG004|Overall Study|Lack of Efficacy|1
6268352|NCT02131662|9968247|FG000|Overall Study|Withdrawal by Subject|1
6268353|NCT02131662|9968248|FG001|Overall Study|Withdrawal by Subject|5
6268354|NCT02131662|9968249|FG002|Overall Study|Withdrawal by Subject|1
6268355|NCT02131662|9968250|FG003|Overall Study|Withdrawal by Subject|5
6268356|NCT02131662|9968251|FG004|Overall Study|Withdrawal by Subject|6
6268357|NCT02131662|9968247|FG000|Overall Study|Lost to Follow-up|1
6268358|NCT02131662|9968248|FG001|Overall Study|Lost to Follow-up|3
6268359|NCT02131662|9968249|FG002|Overall Study|Lost to Follow-up|0
6268360|NCT02131662|9968250|FG003|Overall Study|Lost to Follow-up|9
6268361|NCT02131662|9968251|FG004|Overall Study|Lost to Follow-up|0
6268362|NCT02131662|9968247|FG000|Overall Study|Not treated|2
6268363|NCT02131662|9968248|FG001|Overall Study|Not treated|0
6268364|NCT02131662|9968249|FG002|Overall Study|Not treated|2
6268365|NCT02131662|9968250|FG003|Overall Study|Not treated|2
6268366|NCT02131662|9968251|FG004|Overall Study|Not treated|3
6268367|NCT02131766|9968267|FG000|Overall Study|Withdrawal by Subject|4
6268368|NCT02132117|9968276|FG000|Overall Study|Adverse Event|6
6268369|NCT02132117|9968277|FG001|Overall Study|Adverse Event|1
6268370|NCT02132117|9968276|FG000|Overall Study|Lost to Follow-up|2
6268371|NCT02132117|9968277|FG001|Overall Study|Lost to Follow-up|2
6268372|NCT02132117|9968276|FG000|Overall Study|Personal Reasons|1
6268373|NCT02132117|9968277|FG001|Overall Study|Personal Reasons|2
6268374|NCT02132117|9968276|FG000|Overall Study|Other Miscellaneous Reasons|2
6268375|NCT02132117|9968277|FG001|Overall Study|Other Miscellaneous Reasons|0
6268376|NCT02132130|9968287|FG000|Overall Study|Lost to Follow-up|0
6268377|NCT02132130|9968288|FG001|Overall Study|Lost to Follow-up|2
6268378|NCT02132130|9968289|FG002|Overall Study|Lost to Follow-up|0
6268379|NCT02132130|9968290|FG003|Overall Study|Lost to Follow-up|0
6268380|NCT02132130|9968287|FG000|Overall Study|Withdrawal by Subject|0
6268381|NCT02132130|9968288|FG001|Overall Study|Withdrawal by Subject|0
6268382|NCT02132130|9968289|FG002|Overall Study|Withdrawal by Subject|0
6268383|NCT02132130|9968290|FG003|Overall Study|Withdrawal by Subject|1
6268384|NCT02132195|9968316|FG000|Initial Assignment|Relapsed|14
6268385|NCT02132195|9968317|FG001|Initial Assignment|Relapsed|0
6268386|NCT02132195|9968318|FG002|Initial Assignment|Relapsed|0
6268387|NCT02132195|9968316|FG000|Rescue Therapy|Relapsed|0
6268388|NCT02132195|9968317|FG001|Rescue Therapy|Relapsed|0
6268389|NCT02132195|9968318|FG002|Rescue Therapy|Relapsed|7
6268390|NCT02132195|9968316|FG000|Rescue Therapy|Physician Decision|0
6268391|NCT02132195|9968317|FG001|Rescue Therapy|Physician Decision|0
6268392|NCT02132195|9968318|FG002|Rescue Therapy|Physician Decision|1
6268393|NCT02132195|9968316|FG000|Rescue Therapy|Withdrawal by Subject|0
6268394|NCT02132195|9968317|FG001|Rescue Therapy|Withdrawal by Subject|0
6268395|NCT02132195|9968318|FG002|Rescue Therapy|Withdrawal by Subject|1
6268396|NCT02132195|9968316|FG000|Rescue Therapy|Adverse Event|0
6268397|NCT02132195|9968317|FG001|Rescue Therapy|Adverse Event|0
6268398|NCT02132195|9968318|FG002|Rescue Therapy|Adverse Event|2
6268399|NCT02132247|9968328|FG000|Overall Study|Protocol Violation|1
6268400|NCT02132247|9968329|FG001|Overall Study|Protocol Violation|0
6268401|NCT02132312|9968337|FG000|Overall Study|Adverse Event|2
6268402|NCT02132312|9968338|FG001|Overall Study|Adverse Event|0
6268403|NCT02132312|9968337|FG000|Overall Study|Physician Decision|1
6268404|NCT02132312|9968338|FG001|Overall Study|Physician Decision|1
6268405|NCT02132312|9968337|FG000|Overall Study|Protocol Violation|0
6268406|NCT02132312|9968338|FG001|Overall Study|Protocol Violation|1
6268407|NCT02132312|9968337|FG000|Overall Study|Withdrawal by Subject|1
6268408|NCT02132312|9968338|FG001|Overall Study|Withdrawal by Subject|0
6268409|NCT02132312|9968337|FG000|Overall Study|Lost to Follow-up|2
6268410|NCT02132312|9968338|FG001|Overall Study|Lost to Follow-up|1
6268411|NCT02132637|9968379|FG000|Study Period 1|Withdrawal by Subject|0
6268412|NCT02132637|9968380|FG001|Study Period 1|Withdrawal by Subject|4
6268413|NCT02132637|9968379|FG000|Study Period 1|Physician Decision|1
6268414|NCT02132637|9968380|FG001|Study Period 1|Physician Decision|0
6268415|NCT02132637|9968379|FG000|Study Period 2 (Crossover)|Adverse Event|0
6268416|NCT02132637|9968380|FG001|Study Period 2 (Crossover)|Adverse Event|1
6268417|NCT02132637|9968379|FG000|Study Period 2 (Crossover)|Physician Decision|2
6268418|NCT02132637|9968380|FG001|Study Period 2 (Crossover)|Physician Decision|0
6268419|NCT02132754|9968430|FG000|Overall Study|Adverse Event|0
6268420|NCT02132754|9968431|FG001|Overall Study|Adverse Event|0
6268421|NCT02132754|9968432|FG002|Overall Study|Adverse Event|0
6268422|NCT02132754|9968433|FG003|Overall Study|Adverse Event|0
6268423|NCT02132754|9968434|FG004|Overall Study|Adverse Event|0
6268424|NCT02132754|9968435|FG005|Overall Study|Adverse Event|0
6268425|NCT02132754|9968436|FG006|Overall Study|Adverse Event|0
6191295|NCT01421342|9847962|FG002|Continuation of Treatment (Week 12 - 36)|Non-adherence|4
6191296|NCT01421342|9847960|FG000|Continuation of Treatment (Week 12 - 36)|End of Study Time|15
6191297|NCT01421342|9847961|FG001|Continuation of Treatment (Week 12 - 36)|End of Study Time|20
6191298|NCT01421342|9847962|FG002|Continuation of Treatment (Week 12 - 36)|End of Study Time|14
6191299|NCT01421342|9847960|FG000|Continuation of Treatment (Week 12 - 36)|Participant moved away|4
6191300|NCT01421342|9847961|FG001|Continuation of Treatment (Week 12 - 36)|Participant moved away|1
6191301|NCT01421342|9847962|FG002|Continuation of Treatment (Week 12 - 36)|Participant moved away|3
6191302|NCT01421342|9847960|FG000|Continuation of Treatment (Week 12 - 36)|Due to Other Illness|2
6268426|NCT02132754|9968437|FG007|Overall Study|Adverse Event|0
6268427|NCT02132754|9968438|FG008|Overall Study|Adverse Event|0
6268428|NCT02132754|9968439|FG009|Overall Study|Adverse Event|0
6268429|NCT02132754|9968440|FG010|Overall Study|Adverse Event|0
6268430|NCT02132754|9968441|FG011|Overall Study|Adverse Event|0
6268431|NCT02132754|9968442|FG012|Overall Study|Adverse Event|0
6268432|NCT02132754|9968443|FG013|Overall Study|Adverse Event|0
6268433|NCT02132754|9968444|FG014|Overall Study|Adverse Event|0
6268434|NCT02132754|9968445|FG015|Overall Study|Adverse Event|0
6268435|NCT02132754|9968446|FG016|Overall Study|Adverse Event|0
6268436|NCT02132754|9968447|FG017|Overall Study|Adverse Event|1
6268437|NCT02132754|9968448|FG018|Overall Study|Adverse Event|0
6268438|NCT02132754|9968449|FG019|Overall Study|Adverse Event|0
6268439|NCT02132754|9968450|FG020|Overall Study|Adverse Event|0
6268440|NCT02132754|9968451|FG021|Overall Study|Adverse Event|0
6268441|NCT02132754|9968452|FG022|Overall Study|Adverse Event|0
6268442|NCT02132754|9968453|FG023|Overall Study|Adverse Event|0
6268443|NCT02132754|9968454|FG024|Overall Study|Adverse Event|0
6268444|NCT02132754|9968455|FG025|Overall Study|Adverse Event|1
6268445|NCT02132754|9968456|FG026|Overall Study|Adverse Event|1
6268446|NCT02132754|9968457|FG027|Overall Study|Adverse Event|0
6268447|NCT02132754|9968458|FG028|Overall Study|Adverse Event|0
6268448|NCT02132754|9968459|FG029|Overall Study|Adverse Event|0
6268449|NCT02132754|9968460|FG030|Overall Study|Adverse Event|1
6268450|NCT02132754|9968461|FG031|Overall Study|Adverse Event|0
6268451|NCT02132754|9968462|FG032|Overall Study|Adverse Event|1
6268452|NCT02132754|9968463|FG033|Overall Study|Adverse Event|1
6268453|NCT02132754|9968430|FG000|Overall Study|Clinical Progression|0
6268454|NCT02132754|9968431|FG001|Overall Study|Clinical Progression|0
6268455|NCT02132754|9968432|FG002|Overall Study|Clinical Progression|0
6268456|NCT02132754|9968433|FG003|Overall Study|Clinical Progression|0
6268457|NCT02132754|9968434|FG004|Overall Study|Clinical Progression|0
6268458|NCT02132754|9968435|FG005|Overall Study|Clinical Progression|0
6268459|NCT02132754|9968436|FG006|Overall Study|Clinical Progression|0
6268460|NCT02132754|9968437|FG007|Overall Study|Clinical Progression|0
6268461|NCT02132754|9968438|FG008|Overall Study|Clinical Progression|0
6268462|NCT02132754|9968439|FG009|Overall Study|Clinical Progression|1
6268463|NCT02132754|9968440|FG010|Overall Study|Clinical Progression|0
6268464|NCT02132754|9968441|FG011|Overall Study|Clinical Progression|0
6268465|NCT02132754|9968442|FG012|Overall Study|Clinical Progression|0
6268466|NCT02132754|9968443|FG013|Overall Study|Clinical Progression|0
6268467|NCT02132754|9968444|FG014|Overall Study|Clinical Progression|0
6268468|NCT02132754|9968445|FG015|Overall Study|Clinical Progression|0
6268469|NCT02132754|9968446|FG016|Overall Study|Clinical Progression|1
6268470|NCT02132754|9968447|FG017|Overall Study|Clinical Progression|1
6268471|NCT02132754|9968448|FG018|Overall Study|Clinical Progression|0
6268472|NCT02132754|9968449|FG019|Overall Study|Clinical Progression|1
6268473|NCT02132754|9968450|FG020|Overall Study|Clinical Progression|0
6268474|NCT02132754|9968451|FG021|Overall Study|Clinical Progression|0
6268475|NCT02132754|9968452|FG022|Overall Study|Clinical Progression|1
6268476|NCT02132754|9968453|FG023|Overall Study|Clinical Progression|0
6268477|NCT02132754|9968454|FG024|Overall Study|Clinical Progression|1
6268478|NCT02132754|9968455|FG025|Overall Study|Clinical Progression|1
6268479|NCT02132754|9968456|FG026|Overall Study|Clinical Progression|0
6268480|NCT02132754|9968457|FG027|Overall Study|Clinical Progression|1
6268481|NCT02132754|9968458|FG028|Overall Study|Clinical Progression|1
6268482|NCT02132754|9968459|FG029|Overall Study|Clinical Progression|0
6268483|NCT02132754|9968460|FG030|Overall Study|Clinical Progression|1
6268484|NCT02132754|9968461|FG031|Overall Study|Clinical Progression|0
6268485|NCT02132754|9968462|FG032|Overall Study|Clinical Progression|0
6268486|NCT02132754|9968463|FG033|Overall Study|Clinical Progression|2
6268487|NCT02132754|9968430|FG000|Overall Study|Death|0
6268488|NCT02132754|9968431|FG001|Overall Study|Death|0
6268489|NCT02132754|9968432|FG002|Overall Study|Death|0
6268490|NCT02132754|9968433|FG003|Overall Study|Death|0
6268491|NCT02132754|9968434|FG004|Overall Study|Death|0
6268492|NCT02132754|9968435|FG005|Overall Study|Death|0
6268493|NCT02132754|9968436|FG006|Overall Study|Death|0
6268494|NCT02132754|9968437|FG007|Overall Study|Death|0
6268495|NCT02132754|9968438|FG008|Overall Study|Death|0
6268496|NCT02132754|9968439|FG009|Overall Study|Death|0
6268497|NCT02132754|9968440|FG010|Overall Study|Death|0
6268498|NCT02132754|9968441|FG011|Overall Study|Death|0
6268499|NCT02132754|9968442|FG012|Overall Study|Death|0
6268500|NCT02132754|9968443|FG013|Overall Study|Death|0
6268501|NCT02132754|9968444|FG014|Overall Study|Death|0
6268502|NCT02132754|9968445|FG015|Overall Study|Death|1
6268503|NCT02132754|9968446|FG016|Overall Study|Death|0
6268504|NCT02132754|9968447|FG017|Overall Study|Death|0
6268505|NCT02132754|9968448|FG018|Overall Study|Death|0
6268506|NCT02132754|9968449|FG019|Overall Study|Death|1
6268507|NCT02132754|9968450|FG020|Overall Study|Death|0
6268508|NCT02132754|9968451|FG021|Overall Study|Death|1
6268509|NCT02132754|9968452|FG022|Overall Study|Death|0
6268510|NCT02132754|9968453|FG023|Overall Study|Death|0
6268511|NCT02132754|9968454|FG024|Overall Study|Death|0
6268512|NCT02132754|9968455|FG025|Overall Study|Death|0
6268513|NCT02132754|9968456|FG026|Overall Study|Death|1
6268514|NCT02132754|9968457|FG027|Overall Study|Death|0
6268515|NCT02132754|9968458|FG028|Overall Study|Death|0
6268516|NCT02132754|9968459|FG029|Overall Study|Death|0
6268517|NCT02132754|9968460|FG030|Overall Study|Death|0
6268518|NCT02132754|9968461|FG031|Overall Study|Death|0
6268519|NCT02132754|9968462|FG032|Overall Study|Death|0
6268520|NCT02132754|9968463|FG033|Overall Study|Death|2
6268521|NCT02132754|9968430|FG000|Overall Study|Excluded Medication|0
6268522|NCT02132754|9968431|FG001|Overall Study|Excluded Medication|0
6268523|NCT02132754|9968432|FG002|Overall Study|Excluded Medication|0
6268524|NCT02132754|9968433|FG003|Overall Study|Excluded Medication|0
6268525|NCT02132754|9968434|FG004|Overall Study|Excluded Medication|0
6268526|NCT02132754|9968435|FG005|Overall Study|Excluded Medication|0
6268527|NCT02132754|9968436|FG006|Overall Study|Excluded Medication|0
6268528|NCT02132754|9968437|FG007|Overall Study|Excluded Medication|0
6268529|NCT02132754|9968438|FG008|Overall Study|Excluded Medication|0
6268530|NCT02132754|9968439|FG009|Overall Study|Excluded Medication|0
6268531|NCT02132754|9968440|FG010|Overall Study|Excluded Medication|0
6268532|NCT02132754|9968441|FG011|Overall Study|Excluded Medication|0
6268533|NCT02132754|9968442|FG012|Overall Study|Excluded Medication|0
6268534|NCT02132754|9968443|FG013|Overall Study|Excluded Medication|0
6268535|NCT02132754|9968444|FG014|Overall Study|Excluded Medication|0
6268536|NCT02132754|9968445|FG015|Overall Study|Excluded Medication|0
6268537|NCT02132754|9968446|FG016|Overall Study|Excluded Medication|0
6268538|NCT02132754|9968447|FG017|Overall Study|Excluded Medication|0
6268539|NCT02132754|9968448|FG018|Overall Study|Excluded Medication|0
6268540|NCT02132754|9968449|FG019|Overall Study|Excluded Medication|0
6268541|NCT02132754|9968450|FG020|Overall Study|Excluded Medication|1
6268542|NCT02132754|9968451|FG021|Overall Study|Excluded Medication|0
6268543|NCT02132754|9968452|FG022|Overall Study|Excluded Medication|0
6268544|NCT02132754|9968453|FG023|Overall Study|Excluded Medication|0
6268545|NCT02132754|9968454|FG024|Overall Study|Excluded Medication|0
6268546|NCT02132754|9968455|FG025|Overall Study|Excluded Medication|0
6268547|NCT02132754|9968456|FG026|Overall Study|Excluded Medication|0
6268548|NCT02132754|9968457|FG027|Overall Study|Excluded Medication|0
6268549|NCT02132754|9968458|FG028|Overall Study|Excluded Medication|0
6268550|NCT02132754|9968459|FG029|Overall Study|Excluded Medication|0
6268551|NCT02132754|9968460|FG030|Overall Study|Excluded Medication|0
6268552|NCT02132754|9968461|FG031|Overall Study|Excluded Medication|0
6268553|NCT02132754|9968462|FG032|Overall Study|Excluded Medication|0
6268554|NCT02132754|9968463|FG033|Overall Study|Excluded Medication|1
6268555|NCT02132754|9968430|FG000|Overall Study|Physician Decision|0
6268556|NCT02132754|9968431|FG001|Overall Study|Physician Decision|0
6268557|NCT02132754|9968432|FG002|Overall Study|Physician Decision|0
6268558|NCT02132754|9968433|FG003|Overall Study|Physician Decision|0
6268559|NCT02132754|9968434|FG004|Overall Study|Physician Decision|0
6268560|NCT02132754|9968435|FG005|Overall Study|Physician Decision|0
6268561|NCT02132754|9968436|FG006|Overall Study|Physician Decision|0
6268562|NCT02132754|9968437|FG007|Overall Study|Physician Decision|0
6268563|NCT02132754|9968438|FG008|Overall Study|Physician Decision|0
6268564|NCT02132754|9968439|FG009|Overall Study|Physician Decision|1
6268565|NCT02132754|9968440|FG010|Overall Study|Physician Decision|0
6268566|NCT02132754|9968441|FG011|Overall Study|Physician Decision|1
6268567|NCT02132754|9968442|FG012|Overall Study|Physician Decision|1
6268568|NCT02132754|9968443|FG013|Overall Study|Physician Decision|0
6268569|NCT02132754|9968444|FG014|Overall Study|Physician Decision|0
6268570|NCT02132754|9968445|FG015|Overall Study|Physician Decision|1
6268571|NCT02132754|9968446|FG016|Overall Study|Physician Decision|0
6268572|NCT02132754|9968447|FG017|Overall Study|Physician Decision|0
6268573|NCT02132754|9968448|FG018|Overall Study|Physician Decision|0
6268574|NCT02132754|9968449|FG019|Overall Study|Physician Decision|0
6268575|NCT02132754|9968450|FG020|Overall Study|Physician Decision|0
6268576|NCT02132754|9968451|FG021|Overall Study|Physician Decision|0
6268577|NCT02132754|9968452|FG022|Overall Study|Physician Decision|0
6268578|NCT02132754|9968453|FG023|Overall Study|Physician Decision|0
6268579|NCT02132754|9968454|FG024|Overall Study|Physician Decision|1
6268580|NCT02132754|9968455|FG025|Overall Study|Physician Decision|0
6268581|NCT02132754|9968456|FG026|Overall Study|Physician Decision|0
6268582|NCT02132754|9968457|FG027|Overall Study|Physician Decision|0
6268583|NCT02132754|9968458|FG028|Overall Study|Physician Decision|0
6268584|NCT02132754|9968459|FG029|Overall Study|Physician Decision|0
6268585|NCT02132754|9968460|FG030|Overall Study|Physician Decision|0
6268586|NCT02132754|9968461|FG031|Overall Study|Physician Decision|1
6268587|NCT02132754|9968462|FG032|Overall Study|Physician Decision|0
6268588|NCT02132754|9968463|FG033|Overall Study|Physician Decision|3
6268589|NCT02132754|9968430|FG000|Overall Study|Progressive Disease|1
6268590|NCT02132754|9968431|FG001|Overall Study|Progressive Disease|1
6268591|NCT02132754|9968432|FG002|Overall Study|Progressive Disease|1
6268592|NCT02132754|9968433|FG003|Overall Study|Progressive Disease|1
6268593|NCT02132754|9968434|FG004|Overall Study|Progressive Disease|1
6268594|NCT02132754|9968435|FG005|Overall Study|Progressive Disease|1
6268595|NCT02132754|9968436|FG006|Overall Study|Progressive Disease|1
6268596|NCT02132754|9968437|FG007|Overall Study|Progressive Disease|1
6268597|NCT02132754|9968438|FG008|Overall Study|Progressive Disease|1
6268598|NCT02132754|9968439|FG009|Overall Study|Progressive Disease|3
6268599|NCT02132754|9968440|FG010|Overall Study|Progressive Disease|3
6268600|NCT02132754|9968441|FG011|Overall Study|Progressive Disease|2
6268601|NCT02132754|9968442|FG012|Overall Study|Progressive Disease|2
6268602|NCT02132754|9968443|FG013|Overall Study|Progressive Disease|3
6268603|NCT02132754|9968444|FG014|Overall Study|Progressive Disease|2
6268604|NCT02132754|9968445|FG015|Overall Study|Progressive Disease|1
6268605|NCT02132754|9968446|FG016|Overall Study|Progressive Disease|2
6268606|NCT02132754|9968447|FG017|Overall Study|Progressive Disease|1
6268607|NCT02132754|9968448|FG018|Overall Study|Progressive Disease|3
6268608|NCT02132754|9968449|FG019|Overall Study|Progressive Disease|1
6268609|NCT02132754|9968450|FG020|Overall Study|Progressive Disease|1
6087067|NCT00666458|9697241|FG001|Overall Study|Withdrawal by Subject|4
6087068|NCT00666458|9697240|FG000|Overall Study|Lost to Follow-up|0
6087069|NCT00666458|9697241|FG001|Overall Study|Lost to Follow-up|3
6087070|NCT00666458|9697240|FG000|Overall Study|Administrative reason by sponsor|1
6087071|NCT00666458|9697241|FG001|Overall Study|Administrative reason by sponsor|1
6268610|NCT02132754|9968451|FG021|Overall Study|Progressive Disease|3
6268611|NCT02132754|9968452|FG022|Overall Study|Progressive Disease|2
6268612|NCT02132754|9968453|FG023|Overall Study|Progressive Disease|3
6268613|NCT02132754|9968454|FG024|Overall Study|Progressive Disease|0
6268614|NCT02132754|9968455|FG025|Overall Study|Progressive Disease|1
6268615|NCT02132754|9968456|FG026|Overall Study|Progressive Disease|2
6268616|NCT02132754|9968457|FG027|Overall Study|Progressive Disease|1
6268617|NCT02132754|9968458|FG028|Overall Study|Progressive Disease|2
6268618|NCT02132754|9968459|FG029|Overall Study|Progressive Disease|3
6268619|NCT02132754|9968460|FG030|Overall Study|Progressive Disease|1
6268620|NCT02132754|9968461|FG031|Overall Study|Progressive Disease|1
6268621|NCT02132754|9968462|FG032|Overall Study|Progressive Disease|3
6268622|NCT02132754|9968463|FG033|Overall Study|Progressive Disease|6
6268623|NCT02132754|9968430|FG000|Overall Study|Screen Failure|0
6268624|NCT02132754|9968431|FG001|Overall Study|Screen Failure|0
6268625|NCT02132754|9968432|FG002|Overall Study|Screen Failure|0
6268626|NCT02132754|9968433|FG003|Overall Study|Screen Failure|0
6268627|NCT02132754|9968434|FG004|Overall Study|Screen Failure|0
6268628|NCT02132754|9968435|FG005|Overall Study|Screen Failure|0
6268629|NCT02132754|9968436|FG006|Overall Study|Screen Failure|0
6268630|NCT02132754|9968437|FG007|Overall Study|Screen Failure|0
6268631|NCT02132754|9968438|FG008|Overall Study|Screen Failure|0
6268632|NCT02132754|9968439|FG009|Overall Study|Screen Failure|0
6268633|NCT02132754|9968440|FG010|Overall Study|Screen Failure|0
6268634|NCT02132754|9968441|FG011|Overall Study|Screen Failure|0
6268635|NCT02132754|9968442|FG012|Overall Study|Screen Failure|0
6268636|NCT02132754|9968443|FG013|Overall Study|Screen Failure|0
6268637|NCT02132754|9968444|FG014|Overall Study|Screen Failure|0
6268638|NCT02132754|9968445|FG015|Overall Study|Screen Failure|0
6268639|NCT02132754|9968446|FG016|Overall Study|Screen Failure|0
6268640|NCT02132754|9968447|FG017|Overall Study|Screen Failure|0
6268641|NCT02132754|9968448|FG018|Overall Study|Screen Failure|0
6268642|NCT02132754|9968449|FG019|Overall Study|Screen Failure|1
6268643|NCT02132754|9968450|FG020|Overall Study|Screen Failure|0
6268644|NCT02132754|9968451|FG021|Overall Study|Screen Failure|1
6268645|NCT02132754|9968452|FG022|Overall Study|Screen Failure|0
6268646|NCT02132754|9968453|FG023|Overall Study|Screen Failure|0
6268647|NCT02132754|9968454|FG024|Overall Study|Screen Failure|0
6268648|NCT02132754|9968455|FG025|Overall Study|Screen Failure|0
6268649|NCT02132754|9968456|FG026|Overall Study|Screen Failure|0
6268650|NCT02132754|9968457|FG027|Overall Study|Screen Failure|0
6268651|NCT02132754|9968458|FG028|Overall Study|Screen Failure|0
6268652|NCT02132754|9968459|FG029|Overall Study|Screen Failure|0
6268653|NCT02132754|9968460|FG030|Overall Study|Screen Failure|0
6268654|NCT02132754|9968461|FG031|Overall Study|Screen Failure|0
6268655|NCT02132754|9968462|FG032|Overall Study|Screen Failure|0
6268656|NCT02132754|9968463|FG033|Overall Study|Screen Failure|0
6268657|NCT02132754|9968430|FG000|Overall Study|Transferred to Extension Study|0
6268658|NCT02132754|9968431|FG001|Overall Study|Transferred to Extension Study|0
6268659|NCT02132754|9968432|FG002|Overall Study|Transferred to Extension Study|0
6268660|NCT02132754|9968433|FG003|Overall Study|Transferred to Extension Study|0
6268661|NCT02132754|9968434|FG004|Overall Study|Transferred to Extension Study|0
6268662|NCT02132754|9968435|FG005|Overall Study|Transferred to Extension Study|0
6268663|NCT02132754|9968436|FG006|Overall Study|Transferred to Extension Study|0
6268664|NCT02132754|9968437|FG007|Overall Study|Transferred to Extension Study|0
6087072|NCT00666458|9697240|FG000|Overall Study|Incorrect enrollment|7
6087073|NCT00666458|9697241|FG001|Overall Study|Incorrect enrollment|1
6268665|NCT02132754|9968438|FG008|Overall Study|Transferred to Extension Study|0
6268666|NCT02132754|9968439|FG009|Overall Study|Transferred to Extension Study|0
6268667|NCT02132754|9968440|FG010|Overall Study|Transferred to Extension Study|0
6268668|NCT02132754|9968441|FG011|Overall Study|Transferred to Extension Study|0
6268669|NCT02132754|9968442|FG012|Overall Study|Transferred to Extension Study|0
6268670|NCT02132754|9968443|FG013|Overall Study|Transferred to Extension Study|0
6268671|NCT02132754|9968444|FG014|Overall Study|Transferred to Extension Study|0
6268672|NCT02132754|9968445|FG015|Overall Study|Transferred to Extension Study|0
6268673|NCT02132754|9968446|FG016|Overall Study|Transferred to Extension Study|0
6268674|NCT02132754|9968447|FG017|Overall Study|Transferred to Extension Study|0
6268675|NCT02132754|9968448|FG018|Overall Study|Transferred to Extension Study|0
6268676|NCT02132754|9968449|FG019|Overall Study|Transferred to Extension Study|0
6268677|NCT02132754|9968450|FG020|Overall Study|Transferred to Extension Study|0
6268678|NCT02132754|9968451|FG021|Overall Study|Transferred to Extension Study|0
6268679|NCT02132754|9968452|FG022|Overall Study|Transferred to Extension Study|0
6268680|NCT02132754|9968453|FG023|Overall Study|Transferred to Extension Study|0
6268681|NCT02132754|9968454|FG024|Overall Study|Transferred to Extension Study|0
6268682|NCT02132754|9968455|FG025|Overall Study|Transferred to Extension Study|0
6268683|NCT02132754|9968456|FG026|Overall Study|Transferred to Extension Study|0
6268684|NCT02132754|9968457|FG027|Overall Study|Transferred to Extension Study|0
6268685|NCT02132754|9968458|FG028|Overall Study|Transferred to Extension Study|0
6268686|NCT02132754|9968459|FG029|Overall Study|Transferred to Extension Study|0
6268687|NCT02132754|9968460|FG030|Overall Study|Transferred to Extension Study|0
6268688|NCT02132754|9968461|FG031|Overall Study|Transferred to Extension Study|0
6268689|NCT02132754|9968462|FG032|Overall Study|Transferred to Extension Study|0
6268690|NCT02132754|9968463|FG033|Overall Study|Transferred to Extension Study|6
6268691|NCT02132754|9968430|FG000|Overall Study|Withdrawal by Subject|0
6268692|NCT02132754|9968431|FG001|Overall Study|Withdrawal by Subject|0
6268693|NCT02132754|9968432|FG002|Overall Study|Withdrawal by Subject|0
6268694|NCT02132754|9968433|FG003|Overall Study|Withdrawal by Subject|0
6268695|NCT02132754|9968434|FG004|Overall Study|Withdrawal by Subject|0
6268696|NCT02132754|9968435|FG005|Overall Study|Withdrawal by Subject|0
6268697|NCT02132754|9968436|FG006|Overall Study|Withdrawal by Subject|0
6268698|NCT02132754|9968437|FG007|Overall Study|Withdrawal by Subject|0
6268699|NCT02132754|9968438|FG008|Overall Study|Withdrawal by Subject|0
6268700|NCT02132754|9968439|FG009|Overall Study|Withdrawal by Subject|1
6268701|NCT02132754|9968440|FG010|Overall Study|Withdrawal by Subject|0
6268702|NCT02132754|9968441|FG011|Overall Study|Withdrawal by Subject|0
6268703|NCT02132754|9968442|FG012|Overall Study|Withdrawal by Subject|1
6268704|NCT02132754|9968443|FG013|Overall Study|Withdrawal by Subject|0
6268705|NCT02132754|9968444|FG014|Overall Study|Withdrawal by Subject|1
6268706|NCT02132754|9968445|FG015|Overall Study|Withdrawal by Subject|2
6268707|NCT02132754|9968446|FG016|Overall Study|Withdrawal by Subject|1
6268708|NCT02132754|9968447|FG017|Overall Study|Withdrawal by Subject|0
6268709|NCT02132754|9968448|FG018|Overall Study|Withdrawal by Subject|0
6268710|NCT02132754|9968449|FG019|Overall Study|Withdrawal by Subject|0
6268711|NCT02132754|9968450|FG020|Overall Study|Withdrawal by Subject|1
6268712|NCT02132754|9968451|FG021|Overall Study|Withdrawal by Subject|0
6268713|NCT02132754|9968452|FG022|Overall Study|Withdrawal by Subject|0
6268714|NCT02132754|9968453|FG023|Overall Study|Withdrawal by Subject|0
6268715|NCT02132754|9968454|FG024|Overall Study|Withdrawal by Subject|1
6268716|NCT02132754|9968455|FG025|Overall Study|Withdrawal by Subject|0
6268717|NCT02132754|9968456|FG026|Overall Study|Withdrawal by Subject|0
6268718|NCT02132754|9968457|FG027|Overall Study|Withdrawal by Subject|1
6268719|NCT02132754|9968458|FG028|Overall Study|Withdrawal by Subject|0
6268720|NCT02132754|9968459|FG029|Overall Study|Withdrawal by Subject|0
6268721|NCT02132754|9968460|FG030|Overall Study|Withdrawal by Subject|0
6268722|NCT02132754|9968461|FG031|Overall Study|Withdrawal by Subject|1
6268723|NCT02132754|9968462|FG032|Overall Study|Withdrawal by Subject|0
6268724|NCT02132754|9968463|FG033|Overall Study|Withdrawal by Subject|2
6268725|NCT02132767|9968575|FG000|Overall Study|Death|3
6268726|NCT02132767|9968576|FG001|Overall Study|Death|2
6268727|NCT02132767|9968575|FG000|Overall Study|Withdrawal by Subject|10
6268728|NCT02132767|9968576|FG001|Overall Study|Withdrawal by Subject|9
6268729|NCT02132767|9968575|FG000|Overall Study|Lost to Follow-up|4
6268730|NCT02132767|9968576|FG001|Overall Study|Lost to Follow-up|4
6268731|NCT02132949|9968620|FG000|Overall Study|Death|7
6268732|NCT02132949|9968621|FG001|Overall Study|Death|13
6268733|NCT02132949|9968620|FG000|Overall Study|Lost to Follow-up|14
6268734|NCT02132949|9968621|FG001|Overall Study|Lost to Follow-up|4
6268735|NCT02132949|9968620|FG000|Overall Study|Withdrawal by Subject|6
6268736|NCT02132949|9968621|FG001|Overall Study|Withdrawal by Subject|5
6268737|NCT02132949|9968620|FG000|Overall Study|Noncompliance|5
6268738|NCT02132949|9968621|FG001|Overall Study|Noncompliance|1
6268739|NCT02132949|9968620|FG000|Overall Study|Physician Decision|3
6268740|NCT02132949|9968621|FG001|Overall Study|Physician Decision|1
6268741|NCT02132949|9968620|FG000|Overall Study|Disease Progression|3
6268742|NCT02132949|9968621|FG001|Overall Study|Disease Progression|0
6268743|NCT02132949|9968620|FG000|Overall Study|Adverse Event|2
6268744|NCT02132949|9968621|FG001|Overall Study|Adverse Event|1
6268745|NCT02132949|9968620|FG000|Overall Study|Withdrew Prior to Treatment|1
6268746|NCT02132949|9968621|FG001|Overall Study|Withdrew Prior to Treatment|2
6268747|NCT02132949|9968620|FG000|Overall Study|Reason Unspecified|0
6268748|NCT02132949|9968621|FG001|Overall Study|Reason Unspecified|1
6268749|NCT02133001|9968629|FG000|Double Blind (Day 1-25)|Adverse Event|1
6268750|NCT02133001|9968630|FG001|Double Blind (Day 1-25)|Adverse Event|5
6268751|NCT02133001|9968629|FG000|Double Blind (Day 1-25)|Lack of Efficacy|4
6268752|NCT02133001|9968630|FG001|Double Blind (Day 1-25)|Lack of Efficacy|1
6268753|NCT02133001|9968629|FG000|Double Blind (Day 1-25)|Lost to Follow-up|2
6268754|NCT02133001|9968630|FG001|Double Blind (Day 1-25)|Lost to Follow-up|0
6268755|NCT02133001|9968629|FG000|Double Blind (Day 1-25)|Other|2
6268756|NCT02133001|9968630|FG001|Double Blind (Day 1-25)|Other|2
6268757|NCT02133001|9968629|FG000|Double Blind (Day 1-25)|Withdrawal by Subject|1
6268758|NCT02133001|9968630|FG001|Double Blind (Day 1-25)|Withdrawal by Subject|1
6268759|NCT02133001|9968629|FG000|Follow-Up Phase (Day 26-81)|Lost to Follow-up|1
6268760|NCT02133001|9968630|FG001|Follow-Up Phase (Day 26-81)|Lost to Follow-up|1
6268761|NCT02133001|9968629|FG000|Follow-Up Phase (Day 26-81)|Withdrawal by Subject|1
6268762|NCT02133001|9968630|FG001|Follow-Up Phase (Day 26-81)|Withdrawal by Subject|1
6268763|NCT02133001|9968629|FG000|Follow-Up Phase (Day 26-81)|Other|0
6268764|NCT02133001|9968630|FG001|Follow-Up Phase (Day 26-81)|Other|1
6268765|NCT02133131|9968654|FG000|Overall Study|Adverse Event|0
6268766|NCT02133131|9968655|FG001|Overall Study|Adverse Event|0
6268767|NCT02133131|9968656|FG002|Overall Study|Adverse Event|0
6268768|NCT02133131|9968657|FG003|Overall Study|Adverse Event|1
6268769|NCT02133131|9968658|FG004|Overall Study|Adverse Event|0
6268770|NCT02133131|9968659|FG005|Overall Study|Adverse Event|0
6268771|NCT02133131|9968660|FG006|Overall Study|Adverse Event|0
6268772|NCT02133131|9968654|FG000|Overall Study|Lost to Follow-up|1
6268773|NCT02133131|9968655|FG001|Overall Study|Lost to Follow-up|0
6268774|NCT02133131|9968656|FG002|Overall Study|Lost to Follow-up|0
6268775|NCT02133131|9968657|FG003|Overall Study|Lost to Follow-up|1
6268776|NCT02133131|9968658|FG004|Overall Study|Lost to Follow-up|0
6268777|NCT02133131|9968659|FG005|Overall Study|Lost to Follow-up|0
6268778|NCT02133131|9968660|FG006|Overall Study|Lost to Follow-up|0
6268779|NCT02133131|9968654|FG000|Overall Study|Status not recorded|4
6268780|NCT02133131|9968655|FG001|Overall Study|Status not recorded|5
6268781|NCT02133131|9968656|FG002|Overall Study|Status not recorded|1
6268782|NCT02133131|9968657|FG003|Overall Study|Status not recorded|4
6268783|NCT02133131|9968658|FG004|Overall Study|Status not recorded|0
6268784|NCT02133131|9968659|FG005|Overall Study|Status not recorded|0
6268785|NCT02133131|9968660|FG006|Overall Study|Status not recorded|0
6268786|NCT02133131|9968654|FG000|Overall Study|Ongoing in study|0
6268787|NCT02133131|9968655|FG001|Overall Study|Ongoing in study|0
6268788|NCT02133131|9968656|FG002|Overall Study|Ongoing in study|0
6268789|NCT02133131|9968657|FG003|Overall Study|Ongoing in study|0
6268790|NCT02133131|9968658|FG004|Overall Study|Ongoing in study|15
6268791|NCT02133131|9968659|FG005|Overall Study|Ongoing in study|14
6268792|NCT02133131|9968660|FG006|Overall Study|Ongoing in study|11
6268793|NCT02133131|9968654|FG000|Overall Study|Protocol Violation|0
6268794|NCT02133131|9968655|FG001|Overall Study|Protocol Violation|0
6268795|NCT02133131|9968656|FG002|Overall Study|Protocol Violation|0
6268796|NCT02133131|9968657|FG003|Overall Study|Protocol Violation|0
6268797|NCT02133131|9968658|FG004|Overall Study|Protocol Violation|0
6268798|NCT02133131|9968659|FG005|Overall Study|Protocol Violation|0
6268799|NCT02133131|9968660|FG006|Overall Study|Protocol Violation|1
6268800|NCT02133352|9968691|FG000|Longer Term Extension|4 of the initial 10 subjects agreed/cons|6
6268801|NCT02133508|9968695|FG000|Overall Study|Decision of Investigator or Sponsor|1
6268802|NCT02133508|9968695|FG000|Overall Study|Death|12
6268803|NCT02133508|9968695|FG000|Overall Study|Lost to Follow-up|2
6268804|NCT02133664|9968701|FG000|Overall Study|Lost to Follow-up|2
6268805|NCT02133664|9968702|FG001|Overall Study|Lost to Follow-up|1
6268806|NCT02133664|9968701|FG000|Overall Study|Adverse Event|3
6268807|NCT02133664|9968702|FG001|Overall Study|Adverse Event|6
6268808|NCT02133742|9968708|FG000|Period 2:Dose Expansion Phase (1344days)|Lost to Follow-up|2
6268809|NCT02133742|9968708|FG000|Period 2:Dose Expansion Phase (1344days)|End of survival follow-up/treatment|31
6268810|NCT02133742|9968708|FG000|Period 2:Dose Expansion Phase (1344days)|Death|13
6268811|NCT02133742|9968708|FG000|Period 2:Dose Expansion Phase (1344days)|Participant refused further follow-up|5
6268812|NCT02133742|9968708|FG000|Period 2:Dose Expansion Phase (1344days)|Adverse Event|1
6268813|NCT02134015|9968729|FG000|Overall Study|Protocol Violation|0
6268814|NCT02134015|9968730|FG001|Overall Study|Protocol Violation|1
6268815|NCT02134015|9968729|FG000|Overall Study|Death|2
6268816|NCT02134015|9968730|FG001|Overall Study|Death|1
6268817|NCT02134015|9968729|FG000|Overall Study|Reason not provided|1
6268818|NCT02134015|9968730|FG001|Overall Study|Reason not provided|2
6268819|NCT02134015|9968729|FG000|Overall Study|Clinical progression|14
6268820|NCT02134015|9968730|FG001|Overall Study|Clinical progression|7
6268821|NCT02134015|9968729|FG000|Overall Study|Progressive disease (per RECIST 1.1)|40
6268822|NCT02134015|9968730|FG001|Overall Study|Progressive disease (per RECIST 1.1)|43
6268823|NCT02134015|9968729|FG000|Overall Study|Study terminated by sponsor|2
6268824|NCT02134015|9968730|FG001|Overall Study|Study terminated by sponsor|3
6268825|NCT02134015|9968729|FG000|Overall Study|Adverse Event|9
6268826|NCT02134015|9968730|FG001|Overall Study|Adverse Event|10
6268827|NCT02134015|9968729|FG000|Overall Study|Withdrawal by Subject|3
6268828|NCT02134015|9968730|FG001|Overall Study|Withdrawal by Subject|7
6268829|NCT02134353|9968779|FG000|Overall Study|Adverse Event|10
6268830|NCT02134353|9968780|FG001|Overall Study|Adverse Event|6
6268831|NCT02134353|9968779|FG000|Overall Study|Lost to Follow-up|1
6268832|NCT02134353|9968780|FG001|Overall Study|Lost to Follow-up|1
6268833|NCT02134353|9968779|FG000|Overall Study|Lack of Efficacy|2
6268834|NCT02134353|9968780|FG001|Overall Study|Lack of Efficacy|1
6268835|NCT02134353|9968779|FG000|Overall Study|Withdrawal by Subject|12
6268836|NCT02134353|9968780|FG001|Overall Study|Withdrawal by Subject|13
6268837|NCT02134353|9968779|FG000|Overall Study|Death|0
6268838|NCT02134353|9968780|FG001|Overall Study|Death|1
6268839|NCT02134353|9968779|FG000|Overall Study|Pregnancy|0
6268840|NCT02134353|9968780|FG001|Overall Study|Pregnancy|1
6268841|NCT02134353|9968779|FG000|Overall Study|Relocation|1
6268842|NCT02134353|9968780|FG001|Overall Study|Relocation|0
6268843|NCT02134353|9968779|FG000|Overall Study|Other - Patient's Choice|0
6268844|NCT02134353|9968780|FG001|Overall Study|Other - Patient's Choice|1
6268845|NCT02134587|9968790|FG000|Overall Study|Did not completed all meetings|30
6268846|NCT02134977|9968817|FG000|Overall Study|Protocol Deviation|102
6268847|NCT02135107|9968845|FG000|Treatment Period|Withdrawal by Subject|11
6268848|NCT02135107|9968846|FG001|Treatment Period|Withdrawal by Subject|0
6268849|NCT02135107|9968847|FG002|Treatment Period|Withdrawal by Subject|0
6268850|NCT02135107|9968848|FG003|Treatment Period|Withdrawal by Subject|0
6268851|NCT02135107|9968845|FG000|Treatment Period|Adverse Event|5
6268852|NCT02135107|9968846|FG001|Treatment Period|Adverse Event|2
6268853|NCT02135107|9968847|FG002|Treatment Period|Adverse Event|0
6268854|NCT02135107|9968848|FG003|Treatment Period|Adverse Event|0
6268855|NCT02135107|9968845|FG000|Treatment Period|Pregnancy|1
6268856|NCT02135107|9968846|FG001|Treatment Period|Pregnancy|0
6268857|NCT02135107|9968847|FG002|Treatment Period|Pregnancy|0
6268858|NCT02135107|9968848|FG003|Treatment Period|Pregnancy|0
6268859|NCT02135107|9968845|FG000|Treatment Period|Other|115
6268860|NCT02135107|9968846|FG001|Treatment Period|Other|24
6268861|NCT02135107|9968847|FG002|Treatment Period|Other|0
6268862|NCT02135107|9968848|FG003|Treatment Period|Other|0
6268863|NCT02135107|9968845|FG000|Maintenance Therapy Period|Adverse Event|0
6268864|NCT02135107|9968846|FG001|Maintenance Therapy Period|Adverse Event|0
6268865|NCT02135107|9968847|FG002|Maintenance Therapy Period|Adverse Event|3
6268866|NCT02135107|9968848|FG003|Maintenance Therapy Period|Adverse Event|7
6268867|NCT02135107|9968845|FG000|Maintenance Therapy Period|Withdrawal by Subject|0
6268868|NCT02135107|9968846|FG001|Maintenance Therapy Period|Withdrawal by Subject|0
6268869|NCT02135107|9968847|FG002|Maintenance Therapy Period|Withdrawal by Subject|5
6268870|NCT02135107|9968848|FG003|Maintenance Therapy Period|Withdrawal by Subject|4
6268871|NCT02135107|9968845|FG000|Maintenance Therapy Period|Pregnancy|0
6268872|NCT02135107|9968846|FG001|Maintenance Therapy Period|Pregnancy|0
6268873|NCT02135107|9968847|FG002|Maintenance Therapy Period|Pregnancy|0
6268874|NCT02135107|9968848|FG003|Maintenance Therapy Period|Pregnancy|1
6268875|NCT02135107|9968845|FG000|Maintenance Therapy Period|Other|0
6268876|NCT02135107|9968846|FG001|Maintenance Therapy Period|Other|0
6268877|NCT02135107|9968847|FG002|Maintenance Therapy Period|Other|7
6268878|NCT02135107|9968848|FG003|Maintenance Therapy Period|Other|8
6268879|NCT02135445|9968881|FG000|Overall Study|Lost to Follow-up|1
6268880|NCT02135445|9968882|FG001|Overall Study|Lost to Follow-up|0
6268881|NCT02135445|9968881|FG000|Overall Study|Withdrawal by Subject|1
6268882|NCT02135445|9968882|FG001|Overall Study|Withdrawal by Subject|0
6268883|NCT02135614|9968890|FG000|Overall Study|Randomized but Not Treated|2
6268884|NCT02135614|9968891|FG001|Overall Study|Randomized but Not Treated|1
6268885|NCT02135614|9968890|FG000|Overall Study|Adverse Event|0
6268886|NCT02135614|9968891|FG001|Overall Study|Adverse Event|1
6268887|NCT02135614|9968890|FG000|Overall Study|Death|1
6268888|NCT02135614|9968891|FG001|Overall Study|Death|0
6268889|NCT02135614|9968890|FG000|Overall Study|Investigator's Discretion|0
6268890|NCT02135614|9968891|FG001|Overall Study|Investigator's Discretion|1
6268891|NCT02135614|9968890|FG000|Overall Study|Withdrew Consent|2
6268892|NCT02135614|9968891|FG001|Overall Study|Withdrew Consent|2
6268893|NCT02135614|9968890|FG000|Overall Study|Lost to Follow-up|3
6268894|NCT02135614|9968891|FG001|Overall Study|Lost to Follow-up|0
6268895|NCT02135692|9968908|FG000|Overall Study|Adverse Event|3
6268896|NCT02135692|9968908|FG000|Overall Study|Lack of Efficacy|2
6268897|NCT02135692|9968908|FG000|Overall Study|Protocol Violation|2
6268898|NCT02135692|9968908|FG000|Overall Study|Subject met Liver Stopping Criteria|1
6268899|NCT02135692|9968908|FG000|Overall Study|Product commercially available|159
6268900|NCT02135692|9968908|FG000|Overall Study|Study closed/terminated|153
6268901|NCT02135692|9968908|FG000|Overall Study|Lost to Follow-up|4
6268902|NCT02135692|9968908|FG000|Overall Study|Withdrawal by Subject|15
6268903|NCT02135848|9968914|FG000|Overall Study|Adverse Event|2
6268904|NCT02135848|9968915|FG001|Overall Study|Adverse Event|0
6268905|NCT02135848|9968914|FG000|Overall Study|Withdrawal by Subject|1
6268906|NCT02135848|9968915|FG001|Overall Study|Withdrawal by Subject|1
6268907|NCT02136576|9969008|FG000|Overall Study|Lost to Follow-up|2
6268908|NCT02136576|9969009|FG001|Overall Study|Lost to Follow-up|0
6268909|NCT02136576|9969010|FG002|Overall Study|Lost to Follow-up|0
6268910|NCT02136680|9969020|FG000|Overall Study|No Longer Interested|1
6268911|NCT02136680|9969021|FG001|Overall Study|No Longer Interested|1
6268912|NCT02136680|9969020|FG000|Overall Study|No longer receiving care at clinic|3
6268913|NCT02136680|9969021|FG001|Overall Study|No longer receiving care at clinic|5
6268914|NCT02136680|9969020|FG000|Overall Study|Moved away|5
6268915|NCT02136680|9969021|FG001|Overall Study|Moved away|4
6268916|NCT02136680|9969020|FG000|Overall Study|Unable to schedule|17
6268917|NCT02136680|9969021|FG001|Overall Study|Unable to schedule|16
6268918|NCT02136680|9969020|FG000|Overall Study|Study ended before interview due|6
6268919|NCT02136680|9969021|FG001|Overall Study|Study ended before interview due|3
6268920|NCT02136914|9969033|FG000|Overall Study|Sponsor's Decision to Stop the Study|7
6268921|NCT02136914|9969034|FG001|Overall Study|Sponsor's Decision to Stop the Study|7
6268922|NCT02136914|9969033|FG000|Overall Study|Withdrawal by Subject|3
6268923|NCT02136914|9969034|FG001|Overall Study|Withdrawal by Subject|10
6268924|NCT02136914|9969033|FG000|Overall Study|Subject Unwilling to Proceed|7
6268925|NCT02136914|9969034|FG001|Overall Study|Subject Unwilling to Proceed|2
6268926|NCT02136914|9969033|FG000|Overall Study|Lost to Follow-up|1
6268927|NCT02136914|9969034|FG001|Overall Study|Lost to Follow-up|1
6268928|NCT02136914|9969033|FG000|Overall Study|Did Not Receive Study Drug|2
6268929|NCT02136914|9969034|FG001|Overall Study|Did Not Receive Study Drug|0
6268930|NCT02136914|9969033|FG000|Overall Study|Lack of Efficacy|1
6268931|NCT02136914|9969034|FG001|Overall Study|Lack of Efficacy|0
6268932|NCT02136914|9969033|FG000|Overall Study|Death|0
6268933|NCT02136914|9969034|FG001|Overall Study|Death|1
6268934|NCT02137226|9969042|FG000|Period 1 (Initial Randomization)|Adverse Event|3
6268935|NCT02137226|9969043|FG001|Period 1 (Initial Randomization)|Adverse Event|3
6268936|NCT02137226|9969044|FG002|Period 1 (Initial Randomization)|Adverse Event|0
6268937|NCT02137226|9969045|FG003|Period 1 (Initial Randomization)|Adverse Event|0
6268938|NCT02137226|9969046|FG004|Period 1 (Initial Randomization)|Adverse Event|0
6268939|NCT02137226|9969042|FG000|Period 1 (Initial Randomization)|Withdrawal by Subject|11
6268940|NCT02137226|9969043|FG001|Period 1 (Initial Randomization)|Withdrawal by Subject|5
6268941|NCT02137226|9969044|FG002|Period 1 (Initial Randomization)|Withdrawal by Subject|0
6268942|NCT02137226|9969045|FG003|Period 1 (Initial Randomization)|Withdrawal by Subject|0
6268943|NCT02137226|9969046|FG004|Period 1 (Initial Randomization)|Withdrawal by Subject|0
6268944|NCT02137226|9969042|FG000|Period 1 (Initial Randomization)|Physician Decision|1
6268945|NCT02137226|9969043|FG001|Period 1 (Initial Randomization)|Physician Decision|3
6268946|NCT02137226|9969044|FG002|Period 1 (Initial Randomization)|Physician Decision|0
6268947|NCT02137226|9969045|FG003|Period 1 (Initial Randomization)|Physician Decision|0
6268948|NCT02137226|9969046|FG004|Period 1 (Initial Randomization)|Physician Decision|0
6268949|NCT02137226|9969042|FG000|Period 1 (Initial Randomization)|Lost to Follow-up|3
6268950|NCT02137226|9969043|FG001|Period 1 (Initial Randomization)|Lost to Follow-up|2
6268951|NCT02137226|9969044|FG002|Period 1 (Initial Randomization)|Lost to Follow-up|0
6268952|NCT02137226|9969045|FG003|Period 1 (Initial Randomization)|Lost to Follow-up|0
6268953|NCT02137226|9969046|FG004|Period 1 (Initial Randomization)|Lost to Follow-up|0
6268954|NCT02137226|9969042|FG000|Period 1 (Initial Randomization)|Lack of Efficacy|1
6268955|NCT02137226|9969043|FG001|Period 1 (Initial Randomization)|Lack of Efficacy|0
6268956|NCT02137226|9969044|FG002|Period 1 (Initial Randomization)|Lack of Efficacy|0
6268957|NCT02137226|9969045|FG003|Period 1 (Initial Randomization)|Lack of Efficacy|0
6268958|NCT02137226|9969046|FG004|Period 1 (Initial Randomization)|Lack of Efficacy|0
6268959|NCT02137226|9969042|FG000|Period 1 (Initial Randomization)|Other Reason|1
6268960|NCT02137226|9969043|FG001|Period 1 (Initial Randomization)|Other Reason|3
6268961|NCT02137226|9969044|FG002|Period 1 (Initial Randomization)|Other Reason|0
6268962|NCT02137226|9969045|FG003|Period 1 (Initial Randomization)|Other Reason|0
6268963|NCT02137226|9969046|FG004|Period 1 (Initial Randomization)|Other Reason|0
6268964|NCT02137226|9969042|FG000|Period 2 (Re - Randomization)|Adverse Event|0
6268965|NCT02137226|9969043|FG001|Period 2 (Re - Randomization)|Adverse Event|0
6268966|NCT02137226|9969044|FG002|Period 2 (Re - Randomization)|Adverse Event|3
6268967|NCT02137226|9969045|FG003|Period 2 (Re - Randomization)|Adverse Event|1
6268968|NCT02137226|9969046|FG004|Period 2 (Re - Randomization)|Adverse Event|4
6268969|NCT02137226|9969042|FG000|Period 2 (Re - Randomization)|Withdrawal by Subject|0
6268970|NCT02137226|9969043|FG001|Period 2 (Re - Randomization)|Withdrawal by Subject|0
6268971|NCT02137226|9969044|FG002|Period 2 (Re - Randomization)|Withdrawal by Subject|8
6268972|NCT02137226|9969045|FG003|Period 2 (Re - Randomization)|Withdrawal by Subject|5
6268973|NCT02137226|9969046|FG004|Period 2 (Re - Randomization)|Withdrawal by Subject|4
6268974|NCT02137226|9969042|FG000|Period 2 (Re - Randomization)|Physician Decision|0
6268975|NCT02137226|9969043|FG001|Period 2 (Re - Randomization)|Physician Decision|0
6268976|NCT02137226|9969044|FG002|Period 2 (Re - Randomization)|Physician Decision|0
6268977|NCT02137226|9969045|FG003|Period 2 (Re - Randomization)|Physician Decision|1
6268978|NCT02137226|9969046|FG004|Period 2 (Re - Randomization)|Physician Decision|0
6268979|NCT02137226|9969042|FG000|Period 2 (Re - Randomization)|Lost to Follow-up|0
6268980|NCT02137226|9969043|FG001|Period 2 (Re - Randomization)|Lost to Follow-up|0
6268981|NCT02137226|9969044|FG002|Period 2 (Re - Randomization)|Lost to Follow-up|3
6268982|NCT02137226|9969045|FG003|Period 2 (Re - Randomization)|Lost to Follow-up|0
6268983|NCT02137226|9969046|FG004|Period 2 (Re - Randomization)|Lost to Follow-up|0
6268984|NCT02137226|9969042|FG000|Period 2 (Re - Randomization)|Lack of Efficacy|0
6268985|NCT02137226|9969043|FG001|Period 2 (Re - Randomization)|Lack of Efficacy|0
6268986|NCT02137226|9969044|FG002|Period 2 (Re - Randomization)|Lack of Efficacy|2
6268987|NCT02137226|9969045|FG003|Period 2 (Re - Randomization)|Lack of Efficacy|0
6268988|NCT02137226|9969046|FG004|Period 2 (Re - Randomization)|Lack of Efficacy|0
6268989|NCT02137226|9969042|FG000|Period 2 (Re - Randomization)|Other Reason|0
6268990|NCT02137226|9969043|FG001|Period 2 (Re - Randomization)|Other Reason|0
6268991|NCT02137226|9969044|FG002|Period 2 (Re - Randomization)|Other Reason|1
6268992|NCT02137226|9969045|FG003|Period 2 (Re - Randomization)|Other Reason|1
6268993|NCT02137226|9969046|FG004|Period 2 (Re - Randomization)|Other Reason|1
6268994|NCT02137369|9969056|FG000|Overall Study|Withdrawal by Subject|3
6268995|NCT02137369|9969057|FG001|Overall Study|Withdrawal by Subject|2
6268996|NCT02137369|9969056|FG000|Overall Study|Adverse Event|2
6268997|NCT02137369|9969057|FG001|Overall Study|Adverse Event|0
6268998|NCT02137369|9969056|FG000|Overall Study|Lost to Follow-up|1
6268999|NCT02137369|9969057|FG001|Overall Study|Lost to Follow-up|0
6269000|NCT02137369|9969056|FG000|Overall Study|Moved away|2
6269001|NCT02137369|9969057|FG001|Overall Study|Moved away|0
6269002|NCT02137772|9969134|FG000|Overall Study|Adverse Event|6
6269003|NCT02137772|9969135|FG001|Overall Study|Adverse Event|3
6269004|NCT02137772|9969134|FG000|Overall Study|Death|71
6269005|NCT02137772|9969135|FG001|Overall Study|Death|44
6269006|NCT02137772|9969134|FG000|Overall Study|Lost to Follow-up|8
6269007|NCT02137772|9969135|FG001|Overall Study|Lost to Follow-up|4
6269008|NCT02137772|9969134|FG000|Overall Study|Physician Decision|15
6269009|NCT02137772|9969135|FG001|Overall Study|Physician Decision|5
6269010|NCT02137772|9969134|FG000|Overall Study|Withdrawal by Subject|28
6269011|NCT02137772|9969135|FG001|Overall Study|Withdrawal by Subject|17
6269012|NCT02137772|9969134|FG000|Overall Study|Non-compliance with study drug|1
6269013|NCT02137772|9969135|FG001|Overall Study|Non-compliance with study drug|0
6269014|NCT02137772|9969134|FG000|Overall Study|Not treated|3
6269015|NCT02137772|9969135|FG001|Overall Study|Not treated|2
6269016|NCT02137785|9969143|FG000|Overall Study|Lost to Follow-up|1
6269017|NCT02137785|9969144|FG001|Overall Study|Lost to Follow-up|0
6269018|NCT02137785|9969143|FG000|Overall Study|Withdrawal by Subject|1
6269019|NCT02137785|9969144|FG001|Overall Study|Withdrawal by Subject|4
6269020|NCT02137785|9969143|FG000|Overall Study|subject moved out of state|1
6269021|NCT02137785|9969144|FG001|Overall Study|subject moved out of state|0
6269022|NCT02137837|9969153|FG000|Overall Study|Adverse Event|0
6269023|NCT02137837|9969154|FG001|Overall Study|Adverse Event|2
6269024|NCT02137837|9969155|FG002|Overall Study|Adverse Event|1
6269025|NCT02137837|9969153|FG000|Overall Study|Refusal unrelated to adverse event|2
6269026|NCT02137837|9969154|FG001|Overall Study|Refusal unrelated to adverse event|2
6269027|NCT02137837|9969155|FG002|Overall Study|Refusal unrelated to adverse event|1
6269028|NCT02137837|9969153|FG000|Overall Study|Progression/relapse|9
6269029|NCT02137837|9969154|FG001|Overall Study|Progression/relapse|7
6269030|NCT02137837|9969155|FG002|Overall Study|Progression/relapse|7
6269031|NCT02137837|9969153|FG000|Overall Study|Not protocol specified|2
6269032|NCT02137837|9969154|FG001|Overall Study|Not protocol specified|1
6269033|NCT02137837|9969155|FG002|Overall Study|Not protocol specified|3
6269034|NCT02138110|9969220|FG000|Enrolled for Scaffold Implantation|Physician Decision|1
6269035|NCT02138110|9969220|FG000|Overall Scaffold Implantation|Death|3
6269036|NCT02138136|9969224|FG000|Overall Study|Protocol Violation|4
6269037|NCT02138136|9969224|FG000|Overall Study|Physician Decision|7
6269038|NCT02138136|9969224|FG000|Overall Study|Lack of Efficacy|35
6269039|NCT02138136|9969224|FG000|Overall Study|Pregnancy|2
6269040|NCT02138136|9969224|FG000|Overall Study|Adverse Event|18
6269041|NCT02138136|9969224|FG000|Overall Study|Withdrawal by Subject|36
6269042|NCT02138136|9969224|FG000|Overall Study|Lost to Follow-up|32
6269043|NCT02138136|9969224|FG000|Overall Study|Withdrawn by Sponsor|5
6269044|NCT02138214|9969232|FG000|Overall Study|Withdrawal by Subject|0
6269045|NCT02138214|9969233|FG001|Overall Study|Withdrawal by Subject|1
6269046|NCT02138214|9969234|FG002|Overall Study|Withdrawal by Subject|0
6269047|NCT02138214|9969232|FG000|Overall Study|Lost to Follow-up|0
6269048|NCT02138214|9969233|FG001|Overall Study|Lost to Follow-up|2
6269049|NCT02138214|9969234|FG002|Overall Study|Lost to Follow-up|4
6269050|NCT02138214|9969232|FG000|Overall Study|Screen Failure|0
6269051|NCT02138214|9969233|FG001|Overall Study|Screen Failure|1
6269052|NCT02138214|9969234|FG002|Overall Study|Screen Failure|0
6269053|NCT02138253|9969281|FG000|Overall Study|Adverse Event|3
6269054|NCT02138253|9969282|FG001|Overall Study|Adverse Event|3
6269055|NCT02138253|9969281|FG000|Overall Study|Lost to Follow-up|2
6087074|NCT00666458|9697240|FG000|Overall Study|Study specific discontinuation criteria|14
6087075|NCT00666458|9697241|FG001|Overall Study|Study specific discontinuation criteria|7
6269056|NCT02138253|9969282|FG001|Overall Study|Lost to Follow-up|1
6269057|NCT02138253|9969281|FG000|Overall Study|Physician Decision|2
6269058|NCT02138253|9969282|FG001|Overall Study|Physician Decision|0
6269059|NCT02138253|9969281|FG000|Overall Study|Non compliance|1
6269060|NCT02138253|9969282|FG001|Overall Study|Non compliance|0
6269061|NCT02138253|9969281|FG000|Overall Study|Withdrawal by Subject|1
6269062|NCT02138253|9969282|FG001|Overall Study|Withdrawal by Subject|0
6269063|NCT02138747|9969314|FG000|Treatment Period 1|Adverse Event|10
6269064|NCT02138747|9969315|FG001|Treatment Period 1|Adverse Event|14
6269065|NCT02138747|9969316|FG002|Treatment Period 1|Adverse Event|2
6269066|NCT02138747|9969317|FG003|Treatment Period 1|Adverse Event|1
6269067|NCT02138747|9969314|FG000|Treatment Period 1|Lost to Follow-up|0
6269068|NCT02138747|9969315|FG001|Treatment Period 1|Lost to Follow-up|1
6269069|NCT02138747|9969316|FG002|Treatment Period 1|Lost to Follow-up|1
6269070|NCT02138747|9969317|FG003|Treatment Period 1|Lost to Follow-up|0
6269071|NCT02138747|9969314|FG000|Treatment Period 1|Protocol Violation|0
6269072|NCT02138747|9969315|FG001|Treatment Period 1|Protocol Violation|2
6269073|NCT02138747|9969316|FG002|Treatment Period 1|Protocol Violation|0
6269074|NCT02138747|9969317|FG003|Treatment Period 1|Protocol Violation|0
6269075|NCT02138747|9969314|FG000|Treatment Period 1|Withdrawal by Subject|8
6269076|NCT02138747|9969315|FG001|Treatment Period 1|Withdrawal by Subject|4
6269077|NCT02138747|9969316|FG002|Treatment Period 1|Withdrawal by Subject|1
6269078|NCT02138747|9969317|FG003|Treatment Period 1|Withdrawal by Subject|3
6269079|NCT02138747|9969314|FG000|Treatment Period 1|Other - Miscellaneous|2
6269080|NCT02138747|9969315|FG001|Treatment Period 1|Other - Miscellaneous|4
6269081|NCT02138747|9969316|FG002|Treatment Period 1|Other - Miscellaneous|0
6269082|NCT02138747|9969317|FG003|Treatment Period 1|Other - Miscellaneous|0
6269083|NCT02138747|9969314|FG000|Treatment Period 2|Adverse Event|6
6269084|NCT02138747|9969315|FG001|Treatment Period 2|Adverse Event|3
6269085|NCT02138747|9969316|FG002|Treatment Period 2|Adverse Event|1
6269086|NCT02138747|9969317|FG003|Treatment Period 2|Adverse Event|1
6269087|NCT02138747|9969314|FG000|Treatment Period 2|Lost to Follow-up|2
6269088|NCT02138747|9969315|FG001|Treatment Period 2|Lost to Follow-up|0
6269089|NCT02138747|9969316|FG002|Treatment Period 2|Lost to Follow-up|0
6269090|NCT02138747|9969317|FG003|Treatment Period 2|Lost to Follow-up|0
6269091|NCT02138747|9969314|FG000|Treatment Period 2|Protocol Violation|1
6269092|NCT02138747|9969315|FG001|Treatment Period 2|Protocol Violation|0
6269093|NCT02138747|9969316|FG002|Treatment Period 2|Protocol Violation|0
6269094|NCT02138747|9969317|FG003|Treatment Period 2|Protocol Violation|0
6269095|NCT02138747|9969314|FG000|Treatment Period 2|Withdrawal by Subject|5
6269096|NCT02138747|9969315|FG001|Treatment Period 2|Withdrawal by Subject|4
6269097|NCT02138747|9969316|FG002|Treatment Period 2|Withdrawal by Subject|1
6269098|NCT02138747|9969317|FG003|Treatment Period 2|Withdrawal by Subject|2
6269099|NCT02138747|9969314|FG000|Treatment Period 2|Other - Miscellaneous|3
6269100|NCT02138747|9969315|FG001|Treatment Period 2|Other - Miscellaneous|0
6269101|NCT02138747|9969316|FG002|Treatment Period 2|Other - Miscellaneous|0
6269102|NCT02138747|9969317|FG003|Treatment Period 2|Other - Miscellaneous|0
6269103|NCT02138786|9969330|FG000|Overall Study|Adverse Event|0
6269104|NCT02138786|9969331|FG001|Overall Study|Adverse Event|2
6269105|NCT02138786|9969332|FG002|Overall Study|Adverse Event|1
6269106|NCT02138786|9969330|FG000|Overall Study|Death|1
6269107|NCT02138786|9969331|FG001|Overall Study|Death|7
6269108|NCT02138786|9969332|FG002|Overall Study|Death|2
6269109|NCT02138786|9969330|FG000|Overall Study|Disease Progression|1
6269110|NCT02138786|9969331|FG001|Overall Study|Disease Progression|1
6269111|NCT02138786|9969332|FG002|Overall Study|Disease Progression|3
6269112|NCT02138786|9969330|FG000|Overall Study|Withdrawal by Subject|1
6269113|NCT02138786|9969331|FG001|Overall Study|Withdrawal by Subject|2
6269114|NCT02138786|9969332|FG002|Overall Study|Withdrawal by Subject|0
6269115|NCT02138786|9969330|FG000|Overall Study|Patient's Wish|0
6269116|NCT02138786|9969331|FG001|Overall Study|Patient's Wish|2
6269117|NCT02138786|9969332|FG002|Overall Study|Patient's Wish|0
6269118|NCT02138786|9969330|FG000|Overall Study|Sponsor Terminated Study|0
6269119|NCT02138786|9969331|FG001|Overall Study|Sponsor Terminated Study|1
6269120|NCT02138786|9969332|FG002|Overall Study|Sponsor Terminated Study|1
6269121|NCT02138786|9969330|FG000|Overall Study|Non-Compliance|0
6269122|NCT02138786|9969331|FG001|Overall Study|Non-Compliance|0
6269123|NCT02138786|9969332|FG002|Overall Study|Non-Compliance|1
6271816|NCT02167139|9973728|FG003|Transition-extension|Lack of Efficacy|1
6271817|NCT02167139|9973725|FG000|Transition-extension|Other|1
6271818|NCT02167139|9973726|FG001|Transition-extension|Other|0
6271819|NCT02167139|9973727|FG002|Transition-extension|Other|1
6271820|NCT02167139|9973728|FG003|Transition-extension|Other|0
6271821|NCT02167139|9973725|FG000|Transition-extension|Lost to Follow-up|1
6271822|NCT02167139|9973726|FG001|Transition-extension|Lost to Follow-up|0
6271823|NCT02167139|9973727|FG002|Transition-extension|Lost to Follow-up|0
6271824|NCT02167139|9973728|FG003|Transition-extension|Lost to Follow-up|0
6271825|NCT02167256|9973758|FG000|Overall Study|Adverse Event|13
6271826|NCT02167256|9973759|FG001|Overall Study|Adverse Event|6
6271827|NCT02167256|9973758|FG000|Overall Study|Withdrawal by Subject|4
6271828|NCT02167256|9973759|FG001|Overall Study|Withdrawal by Subject|4
6271829|NCT02167256|9973758|FG000|Overall Study|non-compliance|3
6271830|NCT02167256|9973759|FG001|Overall Study|non-compliance|0
6271831|NCT02167256|9973758|FG000|Overall Study|Study partner unable to participate|1
6271832|NCT02167256|9973759|FG001|Overall Study|Study partner unable to participate|0
6271833|NCT02167451|9973765|FG000|Overall Study|Withdrawal by Subject|1
6271834|NCT02167594|9973772|FG000|Overall Study|Withdrawal by Subject|2
6271835|NCT02167594|9973773|FG001|Overall Study|Withdrawal by Subject|0
6271836|NCT02167594|9973774|FG002|Overall Study|Withdrawal by Subject|0
6271837|NCT02167594|9973772|FG000|Overall Study|Death|0
6271838|NCT02167594|9973773|FG001|Overall Study|Death|1
6271839|NCT02167594|9973774|FG002|Overall Study|Death|0
6271840|NCT02167893|9973802|FG000|Overall Study|Investigator transferred|85
6271841|NCT02167893|9973802|FG000|Overall Study|Investigator health reasons|10
6271842|NCT02167893|9973802|FG000|Overall Study|Case report forms not collected|68
6271843|NCT02168101|9973824|FG000|Overall Study|Death|2
6271844|NCT02168101|9973825|FG001|Overall Study|Death|2
6271845|NCT02168101|9973826|FG002|Overall Study|Death|1
6271914|NCT02169336|9974035|FG001|Overall Study|Lack of Efficacy|1
6271915|NCT02169336|9974036|FG002|Overall Study|Lack of Efficacy|0
6271916|NCT02169336|9974034|FG000|Overall Study|Adverse Event|2
6271917|NCT02169336|9974035|FG001|Overall Study|Adverse Event|3
6271918|NCT02169336|9974036|FG002|Overall Study|Adverse Event|1
6271919|NCT02169336|9974034|FG000|Overall Study|Withdrawal by Subject|1
6271920|NCT02169336|9974035|FG001|Overall Study|Withdrawal by Subject|0
6269124|NCT02138825|9969340|FG000|Main Study Treatment|Adverse Event|11
6269125|NCT02138825|9969341|FG001|Main Study Treatment|Adverse Event|3
6269126|NCT02138825|9969340|FG000|Main Study Treatment|Death|1
6269127|NCT02138825|9969341|FG001|Main Study Treatment|Death|2
6269128|NCT02138825|9969340|FG000|Main Study Treatment|Protocol Violation|2
6269129|NCT02138825|9969341|FG001|Main Study Treatment|Protocol Violation|2
6269130|NCT02138825|9969340|FG000|Main Study Treatment|Sponsor decision|12
6269131|NCT02138825|9969341|FG001|Main Study Treatment|Sponsor decision|18
6269132|NCT02138825|9969340|FG000|Main Study Treatment|Study terminated by sponsor|10
6269133|NCT02138825|9969341|FG001|Main Study Treatment|Study terminated by sponsor|9
6269134|NCT02138825|9969340|FG000|Main Study Treatment|Withdrawal by Subject|3
6269135|NCT02138825|9969341|FG001|Main Study Treatment|Withdrawal by Subject|1
6269136|NCT02138825|9969340|FG000|Main Study Treatment|Medical decision|1
6269137|NCT02138825|9969341|FG001|Main Study Treatment|Medical decision|0
6269138|NCT02138825|9969340|FG000|Long-term Extension|Study termination by sponsor|32
6269139|NCT02138825|9969341|FG001|Long-term Extension|Study termination by sponsor|38
6269140|NCT02138825|9969340|FG000|Safety Follow-up|Adverse Event|4
6269141|NCT02138825|9969341|FG001|Safety Follow-up|Adverse Event|3
6269142|NCT02138825|9969340|FG000|Safety Follow-up|Death|11
6269143|NCT02138825|9969341|FG001|Safety Follow-up|Death|5
6269144|NCT02138825|9969340|FG000|Safety Follow-up|Withdrawal by Subject|5
6269145|NCT02138825|9969341|FG001|Safety Follow-up|Withdrawal by Subject|3
6269146|NCT02138825|9969340|FG000|Safety Follow-up|clinic worsening|1
6269147|NCT02138825|9969341|FG001|Safety Follow-up|clinic worsening|0
6269148|NCT02138825|9969340|FG000|Safety Follow-up|withdrawal by PI|1
6269149|NCT02138825|9969341|FG001|Safety Follow-up|withdrawal by PI|0
6269150|NCT02138825|9969340|FG000|Safety Follow-up|logistical difficulties|0
6269151|NCT02138825|9969341|FG001|Safety Follow-up|logistical difficulties|1
6269152|NCT02138825|9969340|FG000|Safety Follow-up|progressive disease|0
6269153|NCT02138825|9969341|FG001|Safety Follow-up|progressive disease|2
6269154|NCT02138825|9969340|FG000|Safety Follow-up|too unwell to attend the visit|0
6269155|NCT02138825|9969341|FG001|Safety Follow-up|too unwell to attend the visit|1
6269156|NCT02138825|9969340|FG000|Safety Follow-up|treatment unblinded|0
6269157|NCT02138825|9969341|FG001|Safety Follow-up|treatment unblinded|1
6269158|NCT02138825|9969340|FG000|Safety Follow-up|withdrawn due to lung transplant|0
6269159|NCT02138825|9969341|FG001|Safety Follow-up|withdrawn due to lung transplant|1
6269160|NCT02138838|9969354|FG000|Overall Study|Study Closure|7
6269161|NCT02138838|9969355|FG001|Overall Study|Study Closure|6
6269162|NCT02138838|9969354|FG000|Overall Study|Withdrawal by Subject|1
6269163|NCT02138838|9969355|FG001|Overall Study|Withdrawal by Subject|5
6269164|NCT02138890|9969363|FG000|Overall Study|Adverse Event|1
6269165|NCT02138890|9969364|FG001|Overall Study|Adverse Event|0
6269166|NCT02138916|9969374|FG000|Overall Study|eg., meds change, lack of efficacy, etc.|6
6269167|NCT02138916|9969375|FG001|Overall Study|eg., meds change, lack of efficacy, etc.|9
6269168|NCT02138916|9969376|FG002|Overall Study|eg., meds change, lack of efficacy, etc.|7
6269169|NCT02138916|9969374|FG000|Overall Study|Death|14
6269170|NCT02138916|9969375|FG001|Overall Study|Death|11
6269171|NCT02138916|9969376|FG002|Overall Study|Death|12
6269172|NCT02138916|9969374|FG000|Overall Study|Withdrawal by Subject|27
6269173|NCT02138916|9969375|FG001|Overall Study|Withdrawal by Subject|31
6269174|NCT02138916|9969376|FG002|Overall Study|Withdrawal by Subject|32
6269175|NCT02138916|9969374|FG000|Overall Study|Study specific withdrawal criteria|0
6269176|NCT02138916|9969375|FG001|Overall Study|Study specific withdrawal criteria|0
6269177|NCT02138916|9969376|FG002|Overall Study|Study specific withdrawal criteria|1
6269178|NCT02138916|9969374|FG000|Overall Study|incorrect enrolment|1
6269179|NCT02138916|9969375|FG001|Overall Study|incorrect enrolment|1
6269180|NCT02138916|9969376|FG002|Overall Study|incorrect enrolment|0
6269181|NCT02138916|9969374|FG000|Overall Study|Severe non-compliance|1
6269182|NCT02138916|9969375|FG001|Overall Study|Severe non-compliance|2
6269183|NCT02138916|9969376|FG002|Overall Study|Severe non-compliance|1
6269184|NCT02138916|9969374|FG000|Overall Study|Lost to Follow-up|4
6269185|NCT02138916|9969375|FG001|Overall Study|Lost to Follow-up|2
6269186|NCT02138916|9969376|FG002|Overall Study|Lost to Follow-up|3
6269187|NCT02138916|9969374|FG000|Overall Study|Adverse Event|4
6269188|NCT02138916|9969375|FG001|Overall Study|Adverse Event|4
6269189|NCT02138916|9969376|FG002|Overall Study|Adverse Event|3
6269190|NCT02139046|9969401|FG000|Overall Study|Pretreatment Event/Adverse Event|9
6269191|NCT02139046|9969402|FG001|Overall Study|Pretreatment Event/Adverse Event|9
6269192|NCT02139046|9969403|FG002|Overall Study|Pretreatment Event/Adverse Event|10
6269193|NCT02139046|9969404|FG003|Overall Study|Pretreatment Event/Adverse Event|13
6269194|NCT02139046|9969405|FG004|Overall Study|Pretreatment Event/Adverse Event|7
6269195|NCT02139046|9969401|FG000|Overall Study|Major Protocol Deviation|9
6269196|NCT02139046|9969402|FG001|Overall Study|Major Protocol Deviation|10
6269197|NCT02139046|9969403|FG002|Overall Study|Major Protocol Deviation|16
6269198|NCT02139046|9969404|FG003|Overall Study|Major Protocol Deviation|12
6269199|NCT02139046|9969405|FG004|Overall Study|Major Protocol Deviation|6
6269200|NCT02139046|9969401|FG000|Overall Study|Lost to Follow-up|13
6269201|NCT02139046|9969402|FG001|Overall Study|Lost to Follow-up|16
6269202|NCT02139046|9969403|FG002|Overall Study|Lost to Follow-up|16
6269203|NCT02139046|9969404|FG003|Overall Study|Lost to Follow-up|18
6269204|NCT02139046|9969405|FG004|Overall Study|Lost to Follow-up|13
6269205|NCT02139046|9969401|FG000|Overall Study|Voluntary Withdrawal|20
6269206|NCT02139046|9969402|FG001|Overall Study|Voluntary Withdrawal|8
6269207|NCT02139046|9969403|FG002|Overall Study|Voluntary Withdrawal|10
6269208|NCT02139046|9969404|FG003|Overall Study|Voluntary Withdrawal|15
6269209|NCT02139046|9969405|FG004|Overall Study|Voluntary Withdrawal|16
6269210|NCT02139046|9969401|FG000|Overall Study|Lack of Efficacy|0
6269211|NCT02139046|9969402|FG001|Overall Study|Lack of Efficacy|1
6269212|NCT02139046|9969403|FG002|Overall Study|Lack of Efficacy|2
6269213|NCT02139046|9969404|FG003|Overall Study|Lack of Efficacy|1
6269214|NCT02139046|9969405|FG004|Overall Study|Lack of Efficacy|2
6269215|NCT02139046|9969401|FG000|Overall Study|Withdrawal due to a Gout Flare|1
6269216|NCT02139046|9969402|FG001|Overall Study|Withdrawal due to a Gout Flare|1
6269217|NCT02139046|9969403|FG002|Overall Study|Withdrawal due to a Gout Flare|1
6269218|NCT02139046|9969404|FG003|Overall Study|Withdrawal due to a Gout Flare|0
6269219|NCT02139046|9969405|FG004|Overall Study|Withdrawal due to a Gout Flare|1
6269220|NCT02139046|9969401|FG000|Overall Study|Other Miscellaneous Reasons|10
6269221|NCT02139046|9969402|FG001|Overall Study|Other Miscellaneous Reasons|9
6269222|NCT02139046|9969403|FG002|Overall Study|Other Miscellaneous Reasons|4
6269223|NCT02139046|9969404|FG003|Overall Study|Other Miscellaneous Reasons|9
6269224|NCT02139046|9969405|FG004|Overall Study|Other Miscellaneous Reasons|12
6269225|NCT02139124|9969422|FG000|Overall Study|Adverse Event|2
6269226|NCT02139124|9969423|FG001|Overall Study|Adverse Event|0
6269227|NCT02139124|9969424|FG002|Overall Study|Adverse Event|1
6269228|NCT02139124|9969425|FG003|Overall Study|Adverse Event|2
6269229|NCT02139124|9969426|FG004|Overall Study|Adverse Event|5
6269230|NCT02139124|9969422|FG000|Overall Study|Withdrawal by Subject|2
6269231|NCT02139124|9969423|FG001|Overall Study|Withdrawal by Subject|2
6269232|NCT02139124|9969424|FG002|Overall Study|Withdrawal by Subject|2
6269233|NCT02139124|9969425|FG003|Overall Study|Withdrawal by Subject|2
6269234|NCT02139124|9969426|FG004|Overall Study|Withdrawal by Subject|3
6269235|NCT02139124|9969422|FG000|Overall Study|Protocol Violation|0
6269236|NCT02139124|9969423|FG001|Overall Study|Protocol Violation|0
6269237|NCT02139124|9969424|FG002|Overall Study|Protocol Violation|0
6269238|NCT02139124|9969425|FG003|Overall Study|Protocol Violation|1
6269239|NCT02139124|9969426|FG004|Overall Study|Protocol Violation|1
6269240|NCT02139124|9969422|FG000|Overall Study|non-compliant|1
6269241|NCT02139124|9969423|FG001|Overall Study|non-compliant|0
6269242|NCT02139124|9969424|FG002|Overall Study|non-compliant|0
6269243|NCT02139124|9969425|FG003|Overall Study|non-compliant|2
6269244|NCT02139124|9969426|FG004|Overall Study|non-compliant|0
6269245|NCT02139124|9969422|FG000|Overall Study|incarceration|0
6269246|NCT02139124|9969423|FG001|Overall Study|incarceration|0
6269247|NCT02139124|9969424|FG002|Overall Study|incarceration|1
6269248|NCT02139124|9969425|FG003|Overall Study|incarceration|0
6269249|NCT02139124|9969426|FG004|Overall Study|incarceration|0
6087076|NCT00666458|9697240|FG000|Overall Study|Severe non-compliance to the protocol|1
6087077|NCT00666458|9697241|FG001|Overall Study|Severe non-compliance to the protocol|1
6087078|NCT00666458|9697240|FG000|Overall Study|Safety reasons|1
6269250|NCT02139124|9969422|FG000|Overall Study|subject moved|1
6269251|NCT02139124|9969423|FG001|Overall Study|subject moved|0
6269252|NCT02139124|9969424|FG002|Overall Study|subject moved|0
6269253|NCT02139124|9969425|FG003|Overall Study|subject moved|0
6269254|NCT02139124|9969426|FG004|Overall Study|subject moved|0
6269255|NCT02139124|9969422|FG000|Overall Study|Lost to Follow-up|3
6269256|NCT02139124|9969423|FG001|Overall Study|Lost to Follow-up|2
6269257|NCT02139124|9969424|FG002|Overall Study|Lost to Follow-up|0
6269258|NCT02139124|9969425|FG003|Overall Study|Lost to Follow-up|5
6269259|NCT02139124|9969426|FG004|Overall Study|Lost to Follow-up|4
6269260|NCT02139280|9969468|FG000|Overall Study|No longer eligible|2
6269261|NCT02139280|9969469|FG001|Overall Study|No longer eligible|0
6269262|NCT02139306|9969477|FG000|Overall Study|Withdrawal by Subject|4
6269263|NCT02139306|9969478|FG001|Overall Study|Withdrawal by Subject|6
6269264|NCT02139306|9969477|FG000|Overall Study|Adverse Event|3
6269265|NCT02139306|9969478|FG001|Overall Study|Adverse Event|4
6269266|NCT02139306|9969477|FG000|Overall Study|Physician Decision|0
6269267|NCT02139306|9969478|FG001|Overall Study|Physician Decision|1
6269268|NCT02139306|9969477|FG000|Overall Study|Other Unspecified|2
6269269|NCT02139306|9969478|FG001|Overall Study|Other Unspecified|3
6269270|NCT02139306|9969477|FG000|Overall Study|Protocol Violation|4
6269271|NCT02139306|9969478|FG001|Overall Study|Protocol Violation|0
6269272|NCT02139592|9969489|FG000|Overall Study|Case Report Forms Uncollected|8
6269273|NCT02139644|9969498|FG000|Run-In Period (Pre-assignment)|Randomization criteria not met|70
6269274|NCT02139644|9969499|FG001|Run-In Period (Pre-assignment)|Randomization criteria not met|0
6269275|NCT02139644|9969500|FG002|Run-In Period (Pre-assignment)|Randomization criteria not met|0
6269276|NCT02139644|9969501|FG003|Run-In Period (Pre-assignment)|Randomization criteria not met|0
6269277|NCT02139644|9969502|FG004|Run-In Period (Pre-assignment)|Randomization criteria not met|0
6269278|NCT02139644|9969503|FG005|Run-In Period (Pre-assignment)|Randomization criteria not met|0
6269279|NCT02139644|9969498|FG000|Run-In Period (Pre-assignment)|Inclusion criteria not met|30
6269280|NCT02139644|9969499|FG001|Run-In Period (Pre-assignment)|Inclusion criteria not met|0
6269281|NCT02139644|9969500|FG002|Run-In Period (Pre-assignment)|Inclusion criteria not met|0
6269282|NCT02139644|9969501|FG003|Run-In Period (Pre-assignment)|Inclusion criteria not met|0
6269283|NCT02139644|9969502|FG004|Run-In Period (Pre-assignment)|Inclusion criteria not met|0
6271846|NCT02168387|9973864|FG000|Overall Study|Planned exubation|6
6269284|NCT02139644|9969503|FG005|Run-In Period (Pre-assignment)|Inclusion criteria not met|0
6269285|NCT02139644|9969498|FG000|Run-In Period (Pre-assignment)|Withdrawal by Subject|12
6269286|NCT02139644|9969499|FG001|Run-In Period (Pre-assignment)|Withdrawal by Subject|0
6269287|NCT02139644|9969500|FG002|Run-In Period (Pre-assignment)|Withdrawal by Subject|0
6269288|NCT02139644|9969501|FG003|Run-In Period (Pre-assignment)|Withdrawal by Subject|0
6269289|NCT02139644|9969502|FG004|Run-In Period (Pre-assignment)|Withdrawal by Subject|0
6269290|NCT02139644|9969503|FG005|Run-In Period (Pre-assignment)|Withdrawal by Subject|0
6269291|NCT02139644|9969498|FG000|Run-In Period (Pre-assignment)|Exclusion criteria met|11
6269292|NCT02139644|9969499|FG001|Run-In Period (Pre-assignment)|Exclusion criteria met|0
6269293|NCT02139644|9969500|FG002|Run-In Period (Pre-assignment)|Exclusion criteria met|0
6269294|NCT02139644|9969501|FG003|Run-In Period (Pre-assignment)|Exclusion criteria met|0
6269295|NCT02139644|9969502|FG004|Run-In Period (Pre-assignment)|Exclusion criteria met|0
6269296|NCT02139644|9969503|FG005|Run-In Period (Pre-assignment)|Exclusion criteria met|0
6269297|NCT02139644|9969498|FG000|Run-In Period (Pre-assignment)|Lost to Follow-up|8
6269298|NCT02139644|9969499|FG001|Run-In Period (Pre-assignment)|Lost to Follow-up|0
6269299|NCT02139644|9969500|FG002|Run-In Period (Pre-assignment)|Lost to Follow-up|0
6269300|NCT02139644|9969501|FG003|Run-In Period (Pre-assignment)|Lost to Follow-up|0
6269301|NCT02139644|9969502|FG004|Run-In Period (Pre-assignment)|Lost to Follow-up|0
6269302|NCT02139644|9969503|FG005|Run-In Period (Pre-assignment)|Lost to Follow-up|0
6269303|NCT02139644|9969498|FG000|Run-In Period (Pre-assignment)|Adverse Event|3
6269304|NCT02139644|9969499|FG001|Run-In Period (Pre-assignment)|Adverse Event|0
6269305|NCT02139644|9969500|FG002|Run-In Period (Pre-assignment)|Adverse Event|0
6269306|NCT02139644|9969501|FG003|Run-In Period (Pre-assignment)|Adverse Event|0
6269307|NCT02139644|9969502|FG004|Run-In Period (Pre-assignment)|Adverse Event|0
6269308|NCT02139644|9969503|FG005|Run-In Period (Pre-assignment)|Adverse Event|0
6269309|NCT02139644|9969498|FG000|Run-In Period (Pre-assignment)|Other|6
6269310|NCT02139644|9969499|FG001|Run-In Period (Pre-assignment)|Other|0
6269311|NCT02139644|9969500|FG002|Run-In Period (Pre-assignment)|Other|0
6269312|NCT02139644|9969501|FG003|Run-In Period (Pre-assignment)|Other|0
6269313|NCT02139644|9969502|FG004|Run-In Period (Pre-assignment)|Other|0
6269314|NCT02139644|9969503|FG005|Run-In Period (Pre-assignment)|Other|0
6269315|NCT02139644|9969498|FG000|Treatment Period|Adverse Event|0
6269316|NCT02139644|9969499|FG001|Treatment Period|Adverse Event|0
6269317|NCT02139644|9969500|FG002|Treatment Period|Adverse Event|3
6269318|NCT02139644|9969501|FG003|Treatment Period|Adverse Event|2
6269319|NCT02139644|9969502|FG004|Treatment Period|Adverse Event|1
6269320|NCT02139644|9969503|FG005|Treatment Period|Adverse Event|6
6269321|NCT02139644|9969498|FG000|Treatment Period|Withdrawal by Subject|0
6269322|NCT02139644|9969499|FG001|Treatment Period|Withdrawal by Subject|0
6269323|NCT02139644|9969500|FG002|Treatment Period|Withdrawal by Subject|2
6269324|NCT02139644|9969501|FG003|Treatment Period|Withdrawal by Subject|2
6269325|NCT02139644|9969502|FG004|Treatment Period|Withdrawal by Subject|3
6269326|NCT02139644|9969503|FG005|Treatment Period|Withdrawal by Subject|2
6269327|NCT02139644|9969498|FG000|Treatment Period|Non-compliance|0
6269328|NCT02139644|9969499|FG001|Treatment Period|Non-compliance|0
6269329|NCT02139644|9969500|FG002|Treatment Period|Non-compliance|0
6269330|NCT02139644|9969501|FG003|Treatment Period|Non-compliance|1
6269331|NCT02139644|9969502|FG004|Treatment Period|Non-compliance|0
6269332|NCT02139644|9969503|FG005|Treatment Period|Non-compliance|0
6269333|NCT02139644|9969498|FG000|Treatment Period|Protocol Violation|0
6269334|NCT02139644|9969499|FG001|Treatment Period|Protocol Violation|0
6269335|NCT02139644|9969500|FG002|Treatment Period|Protocol Violation|0
6269336|NCT02139644|9969501|FG003|Treatment Period|Protocol Violation|1
6269337|NCT02139644|9969502|FG004|Treatment Period|Protocol Violation|1
6269338|NCT02139644|9969503|FG005|Treatment Period|Protocol Violation|1
6269339|NCT02139644|9969498|FG000|Treatment Period|Disease progression|0
6269340|NCT02139644|9969499|FG001|Treatment Period|Disease progression|0
6269341|NCT02139644|9969500|FG002|Treatment Period|Disease progression|0
6269342|NCT02139644|9969501|FG003|Treatment Period|Disease progression|1
6269343|NCT02139644|9969502|FG004|Treatment Period|Disease progression|1
6269344|NCT02139644|9969503|FG005|Treatment Period|Disease progression|2
6269345|NCT02139644|9969498|FG000|Treatment Period|Lost to Follow-up|0
6269346|NCT02139644|9969499|FG001|Treatment Period|Lost to Follow-up|0
6269347|NCT02139644|9969500|FG002|Treatment Period|Lost to Follow-up|1
6269348|NCT02139644|9969501|FG003|Treatment Period|Lost to Follow-up|1
6269349|NCT02139644|9969502|FG004|Treatment Period|Lost to Follow-up|1
6269350|NCT02139644|9969503|FG005|Treatment Period|Lost to Follow-up|1
6269351|NCT02139644|9969498|FG000|Treatment Period|Lack of Efficacy|0
6269352|NCT02139644|9969499|FG001|Treatment Period|Lack of Efficacy|0
6269353|NCT02139644|9969500|FG002|Treatment Period|Lack of Efficacy|1
6269354|NCT02139644|9969501|FG003|Treatment Period|Lack of Efficacy|0
6269355|NCT02139644|9969502|FG004|Treatment Period|Lack of Efficacy|1
6269356|NCT02139644|9969503|FG005|Treatment Period|Lack of Efficacy|4
6269357|NCT02139644|9969498|FG000|Treatment Period|Other|0
6269358|NCT02139644|9969499|FG001|Treatment Period|Other|3
6269359|NCT02139644|9969500|FG002|Treatment Period|Other|1
6269360|NCT02139644|9969501|FG003|Treatment Period|Other|1
6269361|NCT02139644|9969502|FG004|Treatment Period|Other|0
6269362|NCT02139644|9969503|FG005|Treatment Period|Other|1
6269363|NCT02139826|9969524|FG000|Overall Study|Adverse Event|1
6269364|NCT02139943|9969544|FG000|Overall Study|Adverse Event|0
6269365|NCT02139943|9969545|FG001|Overall Study|Adverse Event|1
6269366|NCT02139943|9969546|FG002|Overall Study|Adverse Event|2
6269367|NCT02139943|9969544|FG000|Overall Study|Lost to Follow-up|3
6043748|NCT00391898|9642534|FG000|Overall Study|Adverse Event|3
6043749|NCT00391898|9642535|FG001|Overall Study|Adverse Event|0
6043750|NCT00391898|9642534|FG000|Overall Study|Other|8
6043751|NCT00391898|9642535|FG001|Overall Study|Other|10
6043752|NCT00391976|9642544|FG000|Overall Study|Adverse Event|0
6043753|NCT00391976|9642545|FG001|Overall Study|Adverse Event|0
6043754|NCT00391976|9642546|FG002|Overall Study|Adverse Event|1
6043755|NCT00391976|9642544|FG000|Overall Study|Withdrawal of consent|0
6043756|NCT00391976|9642545|FG001|Overall Study|Withdrawal of consent|1
6043757|NCT00391976|9642546|FG002|Overall Study|Withdrawal of consent|1
6043758|NCT00391976|9642544|FG000|Overall Study|Lost to Follow-up|1
6043759|NCT00391976|9642545|FG001|Overall Study|Lost to Follow-up|2
6043760|NCT00391976|9642546|FG002|Overall Study|Lost to Follow-up|0
6043761|NCT00391976|9642544|FG000|Overall Study|Inappropriate enrollment|1
6043762|NCT00391976|9642545|FG001|Overall Study|Inappropriate enrollment|1
6043763|NCT00391976|9642546|FG002|Overall Study|Inappropriate enrollment|0
6043764|NCT00391976|9642544|FG000|Overall Study|Protocol deviation/violation|4
6043765|NCT00391976|9642545|FG001|Overall Study|Protocol deviation/violation|2
6043766|NCT00391976|9642546|FG002|Overall Study|Protocol deviation/violation|1
6269368|NCT02139943|9969545|FG001|Overall Study|Lost to Follow-up|2
6269369|NCT02139943|9969546|FG002|Overall Study|Lost to Follow-up|2
6269370|NCT02139943|9969544|FG000|Overall Study|Withdrawal by Subject|4
6269371|NCT02139943|9969545|FG001|Overall Study|Withdrawal by Subject|3
6269372|NCT02139943|9969546|FG002|Overall Study|Withdrawal by Subject|0
6269373|NCT02139943|9969544|FG000|Overall Study|Other|0
6269374|NCT02139943|9969545|FG001|Overall Study|Other|0
6269375|NCT02139943|9969546|FG002|Overall Study|Other|1
6269376|NCT02139943|9969544|FG000|Overall Study|Participant wishes to discontinue|2
6269377|NCT02139943|9969545|FG001|Overall Study|Participant wishes to discontinue|0
6269378|NCT02139943|9969546|FG002|Overall Study|Participant wishes to discontinue|0
6269379|NCT02139943|9969544|FG000|Overall Study|Participant in Poor Compliance|1
6269380|NCT02139943|9969545|FG001|Overall Study|Participant in Poor Compliance|0
6269381|NCT02139943|9969546|FG002|Overall Study|Participant in Poor Compliance|1
6269382|NCT02139943|9969544|FG000|Overall Study|eGFR Withdrawal Criteria|0
6269383|NCT02139943|9969545|FG001|Overall Study|eGFR Withdrawal Criteria|0
6269384|NCT02139943|9969546|FG002|Overall Study|eGFR Withdrawal Criteria|1
6269385|NCT02139982|9969568|FG000|Overall Study|Lack of Efficacy|0
6269386|NCT02139982|9969569|FG001|Overall Study|Lack of Efficacy|1
6269387|NCT02139982|9969570|FG002|Overall Study|Lack of Efficacy|0
6269388|NCT02139982|9969571|FG003|Overall Study|Lack of Efficacy|1
6269389|NCT02139982|9969572|FG004|Overall Study|Lack of Efficacy|0
6269390|NCT02139982|9969573|FG005|Overall Study|Lack of Efficacy|0
6269391|NCT02139982|9969574|FG006|Overall Study|Lack of Efficacy|0
6269392|NCT02139982|9969575|FG007|Overall Study|Lack of Efficacy|0
6269393|NCT02139982|9969576|FG008|Overall Study|Lack of Efficacy|0
6269394|NCT02139982|9969577|FG009|Overall Study|Lack of Efficacy|0
6269395|NCT02140060|9969605|FG000|Overall Study|Adverse Event|0
6269396|NCT02140060|9969606|FG001|Overall Study|Adverse Event|0
6269397|NCT02140060|9969607|FG002|Overall Study|Adverse Event|0
6269398|NCT02140060|9969608|FG003|Overall Study|Adverse Event|1
6269399|NCT02140060|9969609|FG004|Overall Study|Adverse Event|1
6269400|NCT02140060|9969610|FG005|Overall Study|Adverse Event|1
6269401|NCT02140060|9969605|FG000|Overall Study|Lack of Efficacy|0
6269402|NCT02140060|9969606|FG001|Overall Study|Lack of Efficacy|0
6269403|NCT02140060|9969607|FG002|Overall Study|Lack of Efficacy|0
6269404|NCT02140060|9969608|FG003|Overall Study|Lack of Efficacy|1
6269405|NCT02140060|9969609|FG004|Overall Study|Lack of Efficacy|0
6269406|NCT02140060|9969610|FG005|Overall Study|Lack of Efficacy|0
6269407|NCT02140164|9969625|FG000|Overall Study|Cystoid Macular Edema (CME) resolved|2
6269408|NCT02140411|9969633|FG000|Overall Study|Adverse Event|1
6269409|NCT02140567|9969637|FG000|Overall Study|Problems with recording equipment|6
6269410|NCT02140645|9969657|FG000|Overall Study|Not linked|5489
6269411|NCT02140645|9969658|FG001|Overall Study|Not linked|61654
6269412|NCT02140645|9969659|FG002|Overall Study|Not linked|4236
6269413|NCT02140645|9969660|FG003|Overall Study|Not linked|13833
6269414|NCT02140645|9969661|FG004|Overall Study|Not linked|3286
6043767|NCT00391976|9642544|FG000|Overall Study|Recurrence/no eradication of infection|21
6087079|NCT00666458|9697241|FG001|Overall Study|Safety reasons|0
6087080|NCT00666458|9697240|FG000|Overall Study|Medical history of anemia|1
6269415|NCT02140645|9969662|FG005|Overall Study|Not linked|70896
6269416|NCT02140762|9969673|FG000|Overall Study|Adverse Event|1
6269417|NCT02140762|9969674|FG001|Overall Study|Adverse Event|1
6269418|NCT02140762|9969673|FG000|Overall Study|Lost to Follow-up|9
6269419|NCT02140762|9969674|FG001|Overall Study|Lost to Follow-up|5
6269420|NCT02140762|9969673|FG000|Overall Study|Protocol Violation|1
6043768|NCT00391976|9642545|FG001|Overall Study|Recurrence/no eradication of infection|19
6043769|NCT00391976|9642546|FG002|Overall Study|Recurrence/no eradication of infection|0
6269421|NCT02140762|9969674|FG001|Overall Study|Protocol Violation|1
6269422|NCT02140762|9969673|FG000|Overall Study|Withdrawal by Subject|6
6269423|NCT02140762|9969674|FG001|Overall Study|Withdrawal by Subject|4
6269424|NCT02140762|9969673|FG000|Overall Study|Other|0
6269425|NCT02140762|9969674|FG001|Overall Study|Other|1
6269426|NCT02140775|9969687|FG000|Overall Study|Withdrawal by Subject|30
6269427|NCT02140775|9969688|FG001|Overall Study|Withdrawal by Subject|7
6269428|NCT02140970|9969707|FG000|Overall Study|Lost to Follow-up|1
6269429|NCT02140970|9969708|FG001|Overall Study|Lost to Follow-up|2
6269430|NCT02140970|9969707|FG000|Overall Study|Misplaced consent, subject withdrawn|1
6269431|NCT02140970|9969708|FG001|Overall Study|Misplaced consent, subject withdrawn|0
6269432|NCT02140970|9969707|FG000|Overall Study|Did not meet inclusion criteria|0
6269433|NCT02140970|9969708|FG001|Overall Study|Did not meet inclusion criteria|1
6269434|NCT02141204|9969716|FG000|Overall Study|Lost to Follow-up|2
6269435|NCT02141204|9969717|FG001|Overall Study|Lost to Follow-up|1
6269436|NCT02141204|9969716|FG000|Overall Study|CONSENT WITHDRAWAL NOT DUE TO AE|1
6269437|NCT02141204|9969717|FG001|Overall Study|CONSENT WITHDRAWAL NOT DUE TO AE|2
6269438|NCT02141204|9969716|FG000|Overall Study|MIGRATED / MOVED FROM THE STUDY AREA|3
6269439|NCT02141204|9969717|FG001|Overall Study|MIGRATED / MOVED FROM THE STUDY AREA|5
6269440|NCT02141204|9969716|FG000|Overall Study|NOT WILLING TO PARTICIPATE THIS VISIT|9
6269441|NCT02141204|9969717|FG001|Overall Study|NOT WILLING TO PARTICIPATE THIS VISIT|7
6269442|NCT02141217|9969725|FG000|Overall Study|Adverse Event|1
6269443|NCT02141217|9969726|FG001|Overall Study|Adverse Event|2
6269444|NCT02141217|9969725|FG000|Overall Study|Protocol Violation|1
6269445|NCT02141217|9969726|FG001|Overall Study|Protocol Violation|4
6269446|NCT02141217|9969725|FG000|Overall Study|Withdrawal by Subject|6
6269447|NCT02141217|9969726|FG001|Overall Study|Withdrawal by Subject|0
6269448|NCT02141217|9969725|FG000|Overall Study|Lost to Follow-up|1
6269449|NCT02141217|9969726|FG001|Overall Study|Lost to Follow-up|1
6269450|NCT02141217|9969725|FG000|Overall Study|Physician Decision|1
6269451|NCT02141217|9969726|FG001|Overall Study|Physician Decision|0
6269452|NCT02141217|9969725|FG000|Overall Study|Surgical Intervention|1
6269453|NCT02141217|9969726|FG001|Overall Study|Surgical Intervention|1
6269454|NCT02141295|9969738|FG000|Overall Study|Adverse Event|1
6269455|NCT02141295|9969739|FG001|Overall Study|Adverse Event|18
6269456|NCT02141295|9969740|FG002|Overall Study|Adverse Event|11
6269457|NCT02141295|9969738|FG000|Overall Study|Physician Decision|2
6269458|NCT02141295|9969739|FG001|Overall Study|Physician Decision|19
6269459|NCT02141295|9969740|FG002|Overall Study|Physician Decision|14
6269460|NCT02141295|9969738|FG000|Overall Study|Study terminated by sponsor|0
6269461|NCT02141295|9969739|FG001|Overall Study|Study terminated by sponsor|6
6269462|NCT02141295|9969740|FG002|Overall Study|Study terminated by sponsor|6
6269463|NCT02141295|9969738|FG000|Overall Study|Non-compliance|0
6269464|NCT02141295|9969739|FG001|Overall Study|Non-compliance|1
6269465|NCT02141295|9969740|FG002|Overall Study|Non-compliance|0
6269466|NCT02141295|9969738|FG000|Overall Study|Progressive disease|3
6269467|NCT02141295|9969739|FG001|Overall Study|Progressive disease|32
6269468|NCT02141295|9969740|FG002|Overall Study|Progressive disease|50
6269469|NCT02141295|9969738|FG000|Overall Study|Reason not specified|0
6269470|NCT02141295|9969739|FG001|Overall Study|Reason not specified|9
6269471|NCT02141295|9969740|FG002|Overall Study|Reason not specified|10
6269472|NCT02141295|9969738|FG000|Overall Study|Withdrawal by Subject|0
6269473|NCT02141295|9969739|FG001|Overall Study|Withdrawal by Subject|9
6269474|NCT02141295|9969740|FG002|Overall Study|Withdrawal by Subject|4
6269475|NCT02141360|9969752|FG000|Overall Study|Withdrawal by Subject|6
6269476|NCT02141360|9969753|FG001|Overall Study|Withdrawal by Subject|0
6269477|NCT02141360|9969754|FG002|Overall Study|Withdrawal by Subject|0
6269478|NCT02141360|9969752|FG000|Overall Study|Study Terminated before Visit|1
6269479|NCT02141360|9969753|FG001|Overall Study|Study Terminated before Visit|0
6269480|NCT02141360|9969754|FG002|Overall Study|Study Terminated before Visit|0
6269481|NCT02141399|9969762|FG000|Overall Study|Adverse Event|158
6269482|NCT02141399|9969762|FG000|Overall Study|Lack of Efficacy|62
6269483|NCT02141399|9969762|FG000|Overall Study|Lost to Follow-up|151
6269484|NCT02141399|9969762|FG000|Overall Study|Non-compliance with study drug|18
6269485|NCT02141399|9969762|FG000|Overall Study|Other|45
6269486|NCT02141399|9969762|FG000|Overall Study|Physician Decision|17
6269487|NCT02141399|9969762|FG000|Overall Study|Pregnancy|3
6269488|NCT02141399|9969762|FG000|Overall Study|Protocol Violation|38
6269489|NCT02141399|9969762|FG000|Overall Study|Withdrawal by Subject|238
6269490|NCT02141399|9969762|FG000|Overall Study|Failure to meet eligibility criteria|14
6269491|NCT02141490|9969789|FG000|Overall Study|Screening failures|4
6269492|NCT02141490|9969790|FG001|Overall Study|Screening failures|0
6269493|NCT02141490|9969791|FG002|Overall Study|Screening failures|0
6269494|NCT02141516|9969804|FG000|Overall Study|Adverse Event|0
6269495|NCT02141516|9969805|FG001|Overall Study|Adverse Event|1
6269496|NCT02141516|9969806|FG002|Overall Study|Adverse Event|0
6269497|NCT02141516|9969804|FG000|Overall Study|Lost to Follow-up|0
6269498|NCT02141516|9969805|FG001|Overall Study|Lost to Follow-up|1
6269499|NCT02141516|9969806|FG002|Overall Study|Lost to Follow-up|0
6269500|NCT02141516|9969804|FG000|Overall Study|Other|0
6269501|NCT02141516|9969805|FG001|Overall Study|Other|3
6269502|NCT02141516|9969806|FG002|Overall Study|Other|0
6269503|NCT02141620|9969840|FG000|Treatment Condition 1 (7 Days)|Adverse Event|1
6269504|NCT02141620|9969841|FG001|Treatment Condition 1 (7 Days)|Adverse Event|0
6269505|NCT02141633|9969849|FG000|Overall Study|Physician Decision|1
6269506|NCT02141633|9969850|FG001|Overall Study|Physician Decision|0
6269507|NCT02141659|9969862|FG000|Overall Study|Major Protocol Deviation|0
6271925|NCT02169336|9974034|FG000|Overall Study|Subject declined to continue dosing|0
6271926|NCT02169336|9974035|FG001|Overall Study|Subject declined to continue dosing|0
6271927|NCT02169336|9974036|FG002|Overall Study|Subject declined to continue dosing|1
6271928|NCT02169414|9974048|FG000|Overall Study|Withdrawal by Subject|1
6271929|NCT02169414|9974049|FG001|Overall Study|Withdrawal by Subject|0
6271930|NCT02169414|9974050|FG002|Overall Study|Withdrawal by Subject|0
6271931|NCT02169414|9974051|FG003|Overall Study|Withdrawal by Subject|0
6271932|NCT02169414|9974048|FG000|Overall Study|Adverse Event|0
6271933|NCT02169414|9974049|FG001|Overall Study|Adverse Event|1
6271934|NCT02169414|9974050|FG002|Overall Study|Adverse Event|0
6271935|NCT02169414|9974051|FG003|Overall Study|Adverse Event|0
6271936|NCT02169505|9974134|FG000|Overall Study|Withdrawal by Subject|1
6271937|NCT02169674|9974140|FG000|Overall Study|Withdrawal by Subject|2
6271938|NCT02169674|9974141|FG001|Overall Study|Withdrawal by Subject|1
6271939|NCT02169674|9974140|FG000|Overall Study|Seroprotected|30
6271940|NCT02169674|9974141|FG001|Overall Study|Seroprotected|76
6271941|NCT02169674|9974140|FG000|Overall Study|Lost to Follow-up|0
6271942|NCT02169674|9974141|FG001|Overall Study|Lost to Follow-up|1
6271943|NCT02169739|9974149|FG000|Overall Study|Lost to Follow-up|0
6271944|NCT02169739|9974150|FG001|Overall Study|Lost to Follow-up|4
6271945|NCT02169791|9974157|FG000|Overall Study|Death|6
6271946|NCT02169791|9974157|FG000|Overall Study|patient withdrew consent|1
6271947|NCT02170025|9974189|FG000|Overall Study|Adverse Event|2
6271948|NCT02170025|9974190|FG001|Overall Study|Adverse Event|0
6271949|NCT02170051|9974198|FG000|Overall Study|Withdrawal by Subject|10
6271950|NCT02170051|9974199|FG001|Overall Study|Withdrawal by Subject|10
6271951|NCT02170051|9974198|FG000|Overall Study|Lost to Follow-up|1
6271952|NCT02170051|9974199|FG001|Overall Study|Lost to Follow-up|3
6271953|NCT02170064|9974208|FG000|Overall Study|Withdrawal by Subject|5
6271954|NCT02170064|9974209|FG001|Overall Study|Withdrawal by Subject|1
6271955|NCT02170064|9974210|FG002|Overall Study|Withdrawal by Subject|1
6271956|NCT02170064|9974208|FG000|Overall Study|Physician Decision|1
6271957|NCT02170064|9974209|FG001|Overall Study|Physician Decision|1
6271958|NCT02170064|9974210|FG002|Overall Study|Physician Decision|0
6271959|NCT02170077|9974221|FG000|Overall Study|Withdrawal by Subject|3
6271960|NCT02170077|9974222|FG001|Overall Study|Withdrawal by Subject|4
6271961|NCT02170077|9974223|FG002|Overall Study|Withdrawal by Subject|2
6271962|NCT02170077|9974221|FG000|Overall Study|Adverse Event|4
6271963|NCT02170077|9974222|FG001|Overall Study|Adverse Event|4
6271964|NCT02170077|9974223|FG002|Overall Study|Adverse Event|4
6271965|NCT02170077|9974221|FG000|Overall Study|Lost to Follow-up|0
6271966|NCT02170077|9974222|FG001|Overall Study|Lost to Follow-up|1
6271967|NCT02170077|9974223|FG002|Overall Study|Lost to Follow-up|0
6271968|NCT02170077|9974221|FG000|Overall Study|Exclusion criteria|2
6271969|NCT02170077|9974222|FG001|Overall Study|Exclusion criteria|2
6271970|NCT02170077|9974223|FG002|Overall Study|Exclusion criteria|5
6271971|NCT02170077|9974221|FG000|Overall Study|Exacerbation of seizures|0
6271972|NCT02170077|9974222|FG001|Overall Study|Exacerbation of seizures|2
6271973|NCT02170077|9974223|FG002|Overall Study|Exacerbation of seizures|1
6271974|NCT02170207|9974231|FG000|Overall Study|Case report forms unavailable|5
6271975|NCT02170389|9974271|FG000|Overall Study|Study terminated prior to start of treat|1
6271976|NCT02170688|9974314|FG000|Overall Study|Exclusion Criteria: Fatty Liver|4
6271977|NCT02170688|9974315|FG001|Overall Study|Exclusion Criteria: Fatty Liver|2
6271978|NCT02170688|9974316|FG002|Overall Study|Exclusion Criteria: Fatty Liver|3
6271979|NCT02170688|9974317|FG003|Overall Study|Exclusion Criteria: Fatty Liver|2
6271980|NCT02170688|9974318|FG004|Overall Study|Exclusion Criteria: Fatty Liver|0
6271981|NCT02170688|9974314|FG000|Overall Study|Full dose not received|0
6271982|NCT02170688|9974315|FG001|Overall Study|Full dose not received|1
6271983|NCT02170688|9974316|FG002|Overall Study|Full dose not received|0
6271984|NCT02170688|9974317|FG003|Overall Study|Full dose not received|0
6271985|NCT02170688|9974318|FG004|Overall Study|Full dose not received|0
6271986|NCT02170688|9974314|FG000|Overall Study|Physician Decision|0
6271987|NCT02170688|9974315|FG001|Overall Study|Physician Decision|0
6271988|NCT02170688|9974316|FG002|Overall Study|Physician Decision|1
6271989|NCT02170688|9974317|FG003|Overall Study|Physician Decision|0
6271990|NCT02170688|9974318|FG004|Overall Study|Physician Decision|0
6271991|NCT02170727|9974332|FG000|Overall Study|Lost to Follow-up|1
6271992|NCT02170727|9974333|FG001|Overall Study|Lost to Follow-up|0
6271993|NCT02170727|9974332|FG000|Overall Study|Withdrawal by Subject|2
6271994|NCT02170727|9974333|FG001|Overall Study|Withdrawal by Subject|0
6271995|NCT02170779|9974344|FG000|Overall Study|Withdrawal by Subject|1
6271996|NCT02170779|9974345|FG001|Overall Study|Withdrawal by Subject|0
6271997|NCT02170779|9974344|FG000|Overall Study|Lost to Follow-up|0
6271998|NCT02170779|9974345|FG001|Overall Study|Lost to Follow-up|1
6271999|NCT02171065|9974382|FG000|Overall Study|Withdrawal by Subject|1
6272000|NCT02171065|9974383|FG001|Overall Study|Withdrawal by Subject|0
6272001|NCT02171065|9974384|FG002|Overall Study|Withdrawal by Subject|0
6272002|NCT02171065|9974382|FG000|Overall Study|Lost to Follow-up|0
6272003|NCT02171065|9974383|FG001|Overall Study|Lost to Follow-up|0
6272004|NCT02171065|9974384|FG002|Overall Study|Lost to Follow-up|1
6272005|NCT02171130|9974394|FG000|Overall Study|Death|1
6272006|NCT02171130|9974394|FG000|Overall Study|Discontinued; Clinical Material Issue|16
6272007|NCT02171130|9974394|FG000|Overall Study|Discontinued; Site Termination|5
6272008|NCT02171130|9974394|FG000|Overall Study|Withdrawal by Subject|3
6272009|NCT02171130|9974394|FG000|Overall Study|Physician Decision|1
6272010|NCT02171130|9974394|FG000|Overall Study|Lost to Follow-up|1
6272011|NCT02171130|9974394|FG000|Overall Study|Met Exclusion Criteria|1
6272012|NCT02171260|9974469|FG000|Overall Study|Death|0
6087773|NCT00670449|9698234|FG003|Overall Study|Abnormal Laboratory Value(s)|0
6087774|NCT00670488|9698264|FG000|Overall Study|Adverse Event|0
6087775|NCT00670488|9698265|FG001|Overall Study|Adverse Event|7
6087776|NCT00670488|9698266|FG002|Overall Study|Adverse Event|0
6087777|NCT00670488|9698267|FG003|Overall Study|Adverse Event|3
6087778|NCT00670488|9698268|FG004|Overall Study|Adverse Event|1
6272013|NCT02171260|9974470|FG001|Overall Study|Death|0
6272014|NCT02171260|9974471|FG002|Overall Study|Death|0
6272015|NCT02171260|9974472|FG003|Overall Study|Death|1
6272016|NCT02171260|9974469|FG000|Overall Study|Physician Decision|1
6272017|NCT02171260|9974470|FG001|Overall Study|Physician Decision|0
6272018|NCT02171260|9974471|FG002|Overall Study|Physician Decision|1
6087779|NCT00670488|9698269|FG005|Overall Study|Adverse Event|1
6087780|NCT00670488|9698270|FG006|Overall Study|Adverse Event|5
6272019|NCT02171260|9974472|FG003|Overall Study|Physician Decision|0
6272020|NCT02171260|9974469|FG000|Overall Study|Withdrawal by Subject|1
6272021|NCT02171260|9974470|FG001|Overall Study|Withdrawal by Subject|0
6272022|NCT02171260|9974471|FG002|Overall Study|Withdrawal by Subject|0
6272023|NCT02171260|9974472|FG003|Overall Study|Withdrawal by Subject|0
6272024|NCT02171260|9974469|FG000|Overall Study|Evidence of progressive disease|4
6272025|NCT02171260|9974470|FG001|Overall Study|Evidence of progressive disease|6
6272026|NCT02171260|9974471|FG002|Overall Study|Evidence of progressive disease|4
6272027|NCT02171260|9974472|FG003|Overall Study|Evidence of progressive disease|4
6272028|NCT02171429|9974491|FG000|Overall Study|Other|0
6272029|NCT02171429|9974492|FG001|Overall Study|Other|1
6272030|NCT02171429|9974493|FG002|Overall Study|Other|1
6272031|NCT02171429|9974491|FG000|Overall Study|Non-Compliance|0
6272032|NCT02171429|9974492|FG001|Overall Study|Non-Compliance|0
6272033|NCT02171429|9974493|FG002|Overall Study|Non-Compliance|1
6272034|NCT02171429|9974491|FG000|Overall Study|Physician Decision|0
6272035|NCT02171429|9974492|FG001|Overall Study|Physician Decision|0
6272036|NCT02171429|9974493|FG002|Overall Study|Physician Decision|1
6272037|NCT02171429|9974491|FG000|Overall Study|Withdrawal by Subject|1
6272038|NCT02171429|9974492|FG001|Overall Study|Withdrawal by Subject|1
6272039|NCT02171429|9974493|FG002|Overall Study|Withdrawal by Subject|1
6272040|NCT02171429|9974491|FG000|Overall Study|Lost to Follow-up|0
6272041|NCT02171429|9974492|FG001|Overall Study|Lost to Follow-up|1
6272042|NCT02171429|9974493|FG002|Overall Study|Lost to Follow-up|0
6272043|NCT02171429|9974491|FG000|Overall Study|Death|0
6272044|NCT02171429|9974492|FG001|Overall Study|Death|0
6272045|NCT02171429|9974493|FG002|Overall Study|Death|1
6272046|NCT02172040|9974538|FG000|Overall Study|Adverse Event|0
5972298|NCT03730662|9558038|FG003|Treatment Period (52 Weeks)|Protocol Violation|1
5972299|NCT03730662|9558035|FG000|Treatment Period (52 Weeks)|Withdrawal by Subject|5
5972300|NCT03730662|9558036|FG001|Treatment Period (52 Weeks)|Withdrawal by Subject|0
5972301|NCT03730662|9558037|FG002|Treatment Period (52 Weeks)|Withdrawal by Subject|5
5972302|NCT03730662|9558038|FG003|Treatment Period (52 Weeks)|Withdrawal by Subject|23
5972303|NCT03730662|9558035|FG000|Treatment Period (52 Weeks)|Personal Reason|2
5972304|NCT03730662|9558036|FG001|Treatment Period (52 Weeks)|Personal Reason|2
5972305|NCT03730662|9558037|FG002|Treatment Period (52 Weeks)|Personal Reason|0
5972306|NCT03730662|9558038|FG003|Treatment Period (52 Weeks)|Personal Reason|2
5972307|NCT03730662|9558035|FG000|Variable Treatment Period|Adverse Event|1
5972308|NCT03730662|9558036|FG001|Variable Treatment Period|Adverse Event|2
5972309|NCT03730662|9558037|FG002|Variable Treatment Period|Adverse Event|0
5972310|NCT03730662|9558038|FG003|Variable Treatment Period|Adverse Event|7
5972311|NCT03730662|9558035|FG000|Variable Treatment Period|Death|9
5972312|NCT03730662|9558036|FG001|Variable Treatment Period|Death|0
5972313|NCT03730662|9558037|FG002|Variable Treatment Period|Death|6
5972314|NCT03730662|9558038|FG003|Variable Treatment Period|Death|26
5972315|NCT03730662|9558035|FG000|Variable Treatment Period|Lost to Follow-up|2
5972316|NCT03730662|9558036|FG001|Variable Treatment Period|Lost to Follow-up|1
5972317|NCT03730662|9558037|FG002|Variable Treatment Period|Lost to Follow-up|4
5972318|NCT03730662|9558038|FG003|Variable Treatment Period|Lost to Follow-up|11
5972319|NCT03730662|9558035|FG000|Variable Treatment Period|Personal Reason|0
5972320|NCT03730662|9558036|FG001|Variable Treatment Period|Personal Reason|2
5972321|NCT03730662|9558037|FG002|Variable Treatment Period|Personal Reason|1
5972322|NCT03730662|9558038|FG003|Variable Treatment Period|Personal Reason|6
5972323|NCT03730662|9558035|FG000|Variable Treatment Period|Physician Decision|0
5972324|NCT03730662|9558036|FG001|Variable Treatment Period|Physician Decision|0
5972325|NCT03730662|9558037|FG002|Variable Treatment Period|Physician Decision|0
5972326|NCT03730662|9558038|FG003|Variable Treatment Period|Physician Decision|3
5972327|NCT03730662|9558035|FG000|Variable Treatment Period|Protocol Violation|0
5972328|NCT03730662|9558036|FG001|Variable Treatment Period|Protocol Violation|1
5972329|NCT03730662|9558037|FG002|Variable Treatment Period|Protocol Violation|1
5972330|NCT03730662|9558038|FG003|Variable Treatment Period|Protocol Violation|1
5972331|NCT03730662|9558035|FG000|Variable Treatment Period|Withdrawal by Subject|2
5972332|NCT03730662|9558036|FG001|Variable Treatment Period|Withdrawal by Subject|1
5972333|NCT03730662|9558037|FG002|Variable Treatment Period|Withdrawal by Subject|4
5972334|NCT03730662|9558038|FG003|Variable Treatment Period|Withdrawal by Subject|17
5972335|NCT03538444|9558054|FG000|Overall Study|opioid withdrawal|1
5972336|NCT03538444|9558055|FG001|Overall Study|opioid withdrawal|0
5972337|NCT03410693|9558063|FG000|Overall Study|Disc trt: Withdrawal by participant|6
5972338|NCT03410693|9558064|FG001|Overall Study|Disc trt: Withdrawal by participant|4
5972339|NCT03410693|9558063|FG000|Overall Study|Disc trt: Lost to follow up|0
5972340|NCT03410693|9558064|FG001|Overall Study|Disc trt: Lost to follow up|1
5972341|NCT03410693|9558063|FG000|Overall Study|Disc trt: radiological progression|58
5972342|NCT03410693|9558064|FG001|Overall Study|Disc trt: radiological progression|50
5972343|NCT03410693|9558063|FG000|Overall Study|Disc trt: Other|1
5972344|NCT03410693|9558064|FG001|Overall Study|Disc trt: Other|0
5972345|NCT03410693|9558063|FG000|Overall Study|Study drug never administered|1
5972346|NCT03410693|9558064|FG001|Overall Study|Study drug never administered|6
5972347|NCT03410693|9558063|FG000|Overall Study|Discontinued (disc) treatment (trt): Death|6
5972348|NCT03410693|9558064|FG001|Overall Study|Discontinued (disc) treatment (trt): Death|4
5972349|NCT03410693|9558063|FG000|Overall Study|Disc trt: Adverse Event (AE)|13
5972350|NCT03410693|9558064|FG001|Overall Study|Disc trt: Adverse Event (AE)|9
5972351|NCT03410693|9558063|FG000|Overall Study|Disc trt: Physician decision|0
5972352|NCT03410693|9558064|FG001|Overall Study|Disc trt: Physician decision|5
6049111|NCT00421304|9648324|FG002|Overall Study|Did not attend Day 360 visit|1
6049112|NCT00421343|9648334|FG000|Overall Study|Death|1
6049113|NCT00421343|9648334|FG000|Overall Study|Withdrawal by Subject|2
6272047|NCT02172040|9974539|FG001|Overall Study|Adverse Event|2
6272048|NCT02172040|9974540|FG002|Overall Study|Adverse Event|0
6272049|NCT02172040|9974541|FG003|Overall Study|Adverse Event|0
6272050|NCT02172040|9974538|FG000|Overall Study|Protocol Violation|0
6272051|NCT02172040|9974539|FG001|Overall Study|Protocol Violation|1
6272052|NCT02172040|9974540|FG002|Overall Study|Protocol Violation|0
6087781|NCT00670488|9698271|FG007|Overall Study|Adverse Event|1
6087782|NCT00670488|9698272|FG008|Overall Study|Adverse Event|0
6272053|NCT02172040|9974541|FG003|Overall Study|Protocol Violation|0
6272054|NCT02172040|9974538|FG000|Overall Study|Withdrawal by Subject|0
6272055|NCT02172040|9974539|FG001|Overall Study|Withdrawal by Subject|0
6272056|NCT02172040|9974540|FG002|Overall Study|Withdrawal by Subject|1
6272057|NCT02172040|9974541|FG003|Overall Study|Withdrawal by Subject|0
6272058|NCT02172040|9974538|FG000|Overall Study|Not available for Day 13 & 14 visits|0
6272059|NCT02172040|9974539|FG001|Overall Study|Not available for Day 13 & 14 visits|0
6272060|NCT02172040|9974540|FG002|Overall Study|Not available for Day 13 & 14 visits|1
6272061|NCT02172040|9974541|FG003|Overall Study|Not available for Day 13 & 14 visits|0
6272062|NCT02172040|9974538|FG000|Overall Study|Family emergency abroad|0
6272063|NCT02172040|9974539|FG001|Overall Study|Family emergency abroad|0
6272064|NCT02172040|9974540|FG002|Overall Study|Family emergency abroad|0
6272065|NCT02172040|9974541|FG003|Overall Study|Family emergency abroad|1
6272066|NCT02172625|9974554|FG000|Overall Study|Adverse Event|0
6272067|NCT02172625|9974555|FG001|Overall Study|Adverse Event|1
6272068|NCT02172625|9974554|FG000|Overall Study|Pregnancy|0
6272069|NCT02172625|9974555|FG001|Overall Study|Pregnancy|1
6272070|NCT02172625|9974554|FG000|Overall Study|car accident|0
6272071|NCT02172625|9974555|FG001|Overall Study|car accident|1
6272072|NCT02172664|9974565|FG000|Overall Study|Lost to Follow-up|4
6272073|NCT02172664|9974566|FG001|Overall Study|Lost to Follow-up|4
6272074|NCT02172664|9974565|FG000|Overall Study|Death|1
6272075|NCT02172664|9974566|FG001|Overall Study|Death|1
6272076|NCT02172664|9974565|FG000|Overall Study|Moved out of area|1
6272077|NCT02172664|9974566|FG001|Overall Study|Moved out of area|1
6272078|NCT02172911|9974599|FG000|Overall Study|Serious Adverse Event|0
6272079|NCT02172911|9974600|FG001|Overall Study|Serious Adverse Event|1
6272080|NCT02172911|9974599|FG000|Overall Study|Progression of Disease|0
6272081|NCT02172911|9974600|FG001|Overall Study|Progression of Disease|1
6272082|NCT02172911|9974599|FG000|Overall Study|Loss of insurance coverage|1
6272083|NCT02172911|9974600|FG001|Overall Study|Loss of insurance coverage|0
6272084|NCT02172950|9974608|FG000|Overall Study|Physician Decision|3
6272085|NCT02172950|9974609|FG001|Overall Study|Physician Decision|3
6272086|NCT02172950|9974608|FG000|Overall Study|Lack of Efficacy|1
6272087|NCT02172950|9974609|FG001|Overall Study|Lack of Efficacy|0
6272088|NCT02172950|9974608|FG000|Overall Study|Adverse Event|4
6272089|NCT02172950|9974609|FG001|Overall Study|Adverse Event|1
6272090|NCT02172950|9974608|FG000|Overall Study|Withdrawal by Subject|10
6272091|NCT02172950|9974609|FG001|Overall Study|Withdrawal by Subject|0
6272092|NCT02172950|9974608|FG000|Overall Study|Protocol Violation|1
6272093|NCT02172950|9974609|FG001|Overall Study|Protocol Violation|0
6272094|NCT02172950|9974608|FG000|Overall Study|Lost to Follow-up|1
6272095|NCT02172950|9974609|FG001|Overall Study|Lost to Follow-up|0
6272096|NCT02172950|9974608|FG000|Overall Study|Death|1
6272097|NCT02172950|9974609|FG001|Overall Study|Death|0
6272098|NCT02172950|9974608|FG000|Overall Study|Patient traveling|1
6272099|NCT02172950|9974609|FG001|Overall Study|Patient traveling|0
6272100|NCT02172950|9974608|FG000|Overall Study|Patient went to other country|1
6272101|NCT02172950|9974609|FG001|Overall Study|Patient went to other country|0
6272102|NCT02172950|9974608|FG000|Overall Study|Patient relocated overseas|1
6272103|NCT02172950|9974609|FG001|Overall Study|Patient relocated overseas|1
6272104|NCT02172950|9974608|FG000|Overall Study|Patient moving|1
6272105|NCT02172950|9974609|FG001|Overall Study|Patient moving|0
6272106|NCT02173054|9974619|FG000|Overall Study|lack of compliance|1
6272107|NCT02173054|9974620|FG001|Overall Study|lack of compliance|0
6272108|NCT02173054|9974621|FG002|Overall Study|lack of compliance|0
6272109|NCT02173054|9974619|FG000|Overall Study|Withdrawal by Subject|0
6272110|NCT02173054|9974620|FG001|Overall Study|Withdrawal by Subject|0
6272111|NCT02173054|9974621|FG002|Overall Study|Withdrawal by Subject|1
6272112|NCT02173158|9974629|FG000|Efficacy Phase|Adverse Event|1
6272113|NCT02173548|9974720|FG000|Overall Study|Lost to Follow-up|0
6272114|NCT02173548|9974721|FG001|Overall Study|Lost to Follow-up|2
6272115|NCT02173548|9974720|FG000|Overall Study|Withdrawal by Subject|1
6272116|NCT02173548|9974721|FG001|Overall Study|Withdrawal by Subject|0
6272117|NCT02173704|9974729|FG000|Overall Study|Adverse Event|1
6272118|NCT02173704|9974730|FG001|Overall Study|Adverse Event|0
6272119|NCT02173704|9974729|FG000|Overall Study|Lost to Follow-up|1
6272120|NCT02173704|9974730|FG001|Overall Study|Lost to Follow-up|0
6272121|NCT02173704|9974729|FG000|Overall Study|Other|1
6272122|NCT02173704|9974730|FG001|Overall Study|Other|0
6272123|NCT02173704|9974729|FG000|Overall Study|Protocol Violation|1
6272124|NCT02173704|9974730|FG001|Overall Study|Protocol Violation|0
6272125|NCT02173704|9974729|FG000|Overall Study|Withdrawal by Subject|9
6272126|NCT02173704|9974730|FG001|Overall Study|Withdrawal by Subject|4
6272127|NCT02173769|9974736|FG000|Overall Study|Protocol Violation|4
6272128|NCT02174276|9974754|FG000|Study Treatment Phase (Weeks 1 to 48)|Lost to Follow-up|1
6272129|NCT02174276|9974755|FG001|Study Treatment Phase (Weeks 1 to 48)|Lost to Follow-up|0
6272130|NCT02174276|9974756|FG002|Study Treatment Phase (Weeks 1 to 48)|Lost to Follow-up|0
6272131|NCT02174276|9974757|FG003|Study Treatment Phase (Weeks 1 to 48)|Lost to Follow-up|0
6272132|NCT02174276|9974754|FG000|Study Treatment Phase (Weeks 1 to 48)|Pregnancy|0
6272133|NCT02174276|9974755|FG001|Study Treatment Phase (Weeks 1 to 48)|Pregnancy|0
6272134|NCT02174276|9974756|FG002|Study Treatment Phase (Weeks 1 to 48)|Pregnancy|1
6272135|NCT02174276|9974757|FG003|Study Treatment Phase (Weeks 1 to 48)|Pregnancy|0
6272136|NCT02174276|9974754|FG000|Study Treatment Phase (Weeks 1 to 48)|Withdrawal by Subject|0
6272137|NCT02174276|9974755|FG001|Study Treatment Phase (Weeks 1 to 48)|Withdrawal by Subject|1
6272138|NCT02174276|9974756|FG002|Study Treatment Phase (Weeks 1 to 48)|Withdrawal by Subject|2
6272139|NCT02174276|9974757|FG003|Study Treatment Phase (Weeks 1 to 48)|Withdrawal by Subject|0
6272140|NCT02174276|9974754|FG000|OTEP (Weeks 48 to 144)|Lost to Follow-up|0
6272141|NCT02174276|9974755|FG001|OTEP (Weeks 48 to 144)|Lost to Follow-up|0
6272142|NCT02174276|9974756|FG002|OTEP (Weeks 48 to 144)|Lost to Follow-up|1
6272143|NCT02174276|9974757|FG003|OTEP (Weeks 48 to 144)|Lost to Follow-up|0
6272144|NCT02174276|9974754|FG000|OTEP (Weeks 48 to 144)|Pregnancy|0
6272145|NCT02174276|9974755|FG001|OTEP (Weeks 48 to 144)|Pregnancy|0
6272146|NCT02174276|9974756|FG002|OTEP (Weeks 48 to 144)|Pregnancy|1
6272147|NCT02174276|9974757|FG003|OTEP (Weeks 48 to 144)|Pregnancy|0
6272148|NCT02174276|9974754|FG000|OTEP (Weeks 48 to 144)|Withdrew Consent|1
6272149|NCT02174276|9974755|FG001|OTEP (Weeks 48 to 144)|Withdrew Consent|0
6272150|NCT02174276|9974756|FG002|OTEP (Weeks 48 to 144)|Withdrew Consent|1
6272151|NCT02174276|9974757|FG003|OTEP (Weeks 48 to 144)|Withdrew Consent|2
6272152|NCT02174523|9974802|FG000|Overall Study|Withdrawal by Subject|1
6272153|NCT02174523|9974803|FG001|Overall Study|Withdrawal by Subject|0
6272154|NCT02174562|9974810|FG000|Overall Study|Withdrawal by Subject|7
6272155|NCT02174562|9974811|FG001|Overall Study|Withdrawal by Subject|2
6272156|NCT02174562|9974810|FG000|Overall Study|Death|2
6272157|NCT02174562|9974811|FG001|Overall Study|Death|0
6272158|NCT02174562|9974810|FG000|Overall Study|Lost to Follow-up|0
6272159|NCT02174562|9974811|FG001|Overall Study|Lost to Follow-up|3
6272160|NCT02174627|9974819|FG000|Overall Study|Missing|0
6272161|NCT02174627|9974820|FG001|Overall Study|Missing|1
6272162|NCT02174627|9974819|FG000|Overall Study|Incorrect enrolment before randomization|0
6272163|NCT02174627|9974820|FG001|Overall Study|Incorrect enrolment before randomization|1
6272164|NCT02174627|9974819|FG000|Overall Study|Participant decision|84
6272165|NCT02174627|9974820|FG001|Overall Study|Participant decision|128
6272166|NCT02174731|9974828|FG000|Overall Study|Participant decision|67
6272167|NCT02174731|9974829|FG001|Overall Study|Participant decision|64
6272168|NCT02174731|9974828|FG000|Overall Study|Incorrect enrolment before randomization|0
6272169|NCT02174731|9974829|FG001|Overall Study|Incorrect enrolment before randomization|1
6272170|NCT02174731|9974828|FG000|Overall Study|Missing|2
6272171|NCT02174731|9974829|FG001|Overall Study|Missing|0
6272172|NCT02174848|9974837|FG000|Overall Study|Adverse Event|2
6272173|NCT02174848|9974838|FG001|Overall Study|Adverse Event|1
6272174|NCT02174848|9974837|FG000|Overall Study|Withdrawal by Subject|3
6272175|NCT02174848|9974838|FG001|Overall Study|Withdrawal by Subject|3
5972353|NCT03410693|9558063|FG000|Overall Study|Disc trt: clinical progression|1
5972354|NCT03410693|9558064|FG001|Overall Study|Disc trt: clinical progression|5
5972355|NCT03410693|9558063|FG000|Overall Study|Disc trt:AE not asso. w/ clinical disease progress|1
5972356|NCT03410693|9558064|FG001|Overall Study|Disc trt:AE not asso. w/ clinical disease progress|4
5972357|NCT03252925|9558091|FG000|Overall Study|Withdrawal by Subject|1
5972358|NCT03252925|9558092|FG001|Overall Study|Withdrawal by Subject|0
5972359|NCT03252925|9558091|FG000|Overall Study|Protocol Violation|6
5972360|NCT03252925|9558092|FG001|Overall Study|Protocol Violation|0
5972361|NCT03252925|9558091|FG000|Overall Study|Adverse Event|1
5972362|NCT03252925|9558092|FG001|Overall Study|Adverse Event|0
5972363|NCT03252925|9558091|FG000|Overall Study|Lost to Follow-up|6
5972364|NCT03252925|9558092|FG001|Overall Study|Lost to Follow-up|6
5972365|NCT03185832|9558102|FG000|Overall Study|Death|9
5972366|NCT03185832|9558103|FG001|Overall Study|Death|14
5972367|NCT03185832|9558104|FG002|Overall Study|Death|9
5972368|NCT03185832|9558105|FG003|Overall Study|Death|7
5972369|NCT03185832|9558102|FG000|Overall Study|Withdrawn - vital status available|0
5972370|NCT03185832|9558103|FG001|Overall Study|Withdrawn - vital status available|1
5972371|NCT03185832|9558104|FG002|Overall Study|Withdrawn - vital status available|1
5972372|NCT03185832|9558105|FG003|Overall Study|Withdrawn - vital status available|4
5972373|NCT02959918|9558136|FG000|Overall Study|Adverse Event|1
5972374|NCT02959918|9558137|FG001|Overall Study|Adverse Event|1
5972375|NCT02959918|9558138|FG002|Overall Study|Adverse Event|2
5972376|NCT02959918|9558139|FG003|Overall Study|Adverse Event|0
5972377|NCT02959918|9558140|FG004|Overall Study|Adverse Event|0
5972378|NCT02959918|9558141|FG005|Overall Study|Adverse Event|2
5972379|NCT02959918|9558142|FG006|Overall Study|Adverse Event|2
5972380|NCT02959918|9558143|FG007|Overall Study|Adverse Event|1
5972381|NCT02959918|9558144|FG008|Overall Study|Adverse Event|2
5972382|NCT02959918|9558145|FG009|Overall Study|Adverse Event|1
5972383|NCT02959918|9558146|FG010|Overall Study|Adverse Event|1
5972384|NCT02959918|9558147|FG011|Overall Study|Adverse Event|3
5972385|NCT02959918|9558148|FG012|Overall Study|Adverse Event|2
5972386|NCT02959918|9558149|FG013|Overall Study|Adverse Event|4
6272176|NCT02174848|9974837|FG000|Overall Study|Lost to Follow-up|0
6272177|NCT02174848|9974838|FG001|Overall Study|Lost to Follow-up|1
6272178|NCT02174848|9974837|FG000|Overall Study|Worsening of disease|1
6272179|NCT02174848|9974838|FG001|Overall Study|Worsening of disease|1
6272180|NCT02174848|9974837|FG000|Overall Study|Unable to comply with study requirements|1
5972387|NCT02959918|9558136|FG000|Overall Study|Lost to Follow-up|0
5972388|NCT02959918|9558137|FG001|Overall Study|Lost to Follow-up|0
5972389|NCT02959918|9558138|FG002|Overall Study|Lost to Follow-up|0
5972390|NCT02959918|9558139|FG003|Overall Study|Lost to Follow-up|0
5972391|NCT02959918|9558140|FG004|Overall Study|Lost to Follow-up|0
5972392|NCT02959918|9558141|FG005|Overall Study|Lost to Follow-up|0
5972393|NCT02959918|9558142|FG006|Overall Study|Lost to Follow-up|0
5972394|NCT02959918|9558143|FG007|Overall Study|Lost to Follow-up|0
6272181|NCT02174848|9974838|FG001|Overall Study|Unable to comply with study requirements|0
6272182|NCT02175121|9974863|FG000|Overall Study|Lack of Efficacy|1
6272183|NCT02175121|9974864|FG001|Overall Study|Lack of Efficacy|0
6272184|NCT02175121|9974865|FG002|Overall Study|Lack of Efficacy|0
6272185|NCT02175121|9974866|FG003|Overall Study|Lack of Efficacy|0
6272186|NCT02175121|9974867|FG004|Overall Study|Lack of Efficacy|0
6272187|NCT02175121|9974863|FG000|Overall Study|Lost to Follow-up|0
6272188|NCT02175121|9974864|FG001|Overall Study|Lost to Follow-up|1
6272189|NCT02175121|9974865|FG002|Overall Study|Lost to Follow-up|0
6272190|NCT02175121|9974866|FG003|Overall Study|Lost to Follow-up|1
6272191|NCT02175121|9974867|FG004|Overall Study|Lost to Follow-up|0
6272192|NCT02175121|9974863|FG000|Overall Study|Personal emergency|0
6272193|NCT02175121|9974864|FG001|Overall Study|Personal emergency|0
6272194|NCT02175121|9974865|FG002|Overall Study|Personal emergency|0
6272195|NCT02175121|9974866|FG003|Overall Study|Personal emergency|0
6272196|NCT02175121|9974867|FG004|Overall Study|Personal emergency|1
6272197|NCT02175121|9974863|FG000|Overall Study|Schedule conflict|0
6272198|NCT02175121|9974864|FG001|Overall Study|Schedule conflict|0
6272199|NCT02175121|9974865|FG002|Overall Study|Schedule conflict|1
6272200|NCT02175121|9974866|FG003|Overall Study|Schedule conflict|0
6272201|NCT02175121|9974867|FG004|Overall Study|Schedule conflict|0
6272202|NCT02175121|9974863|FG000|Overall Study|Time issues|0
6272203|NCT02175121|9974864|FG001|Overall Study|Time issues|0
6272204|NCT02175121|9974865|FG002|Overall Study|Time issues|1
6272205|NCT02175121|9974866|FG003|Overall Study|Time issues|0
6272206|NCT02175121|9974867|FG004|Overall Study|Time issues|0
6272207|NCT02175199|9974885|FG000|Overall Study|Withdrawal by Subject|1
6272208|NCT02175199|9974886|FG001|Overall Study|Withdrawal by Subject|5
6272209|NCT02175199|9974885|FG000|Overall Study|Randomized in Error|1
6272210|NCT02175199|9974886|FG001|Overall Study|Randomized in Error|0
6272211|NCT02175199|9974885|FG000|Overall Study|Sponsor Decision|1
6272212|NCT02175199|9974886|FG001|Overall Study|Sponsor Decision|0
6272213|NCT02175225|9974904|FG000|Overall Study|Withdrawal by Subject|1
6272214|NCT02175225|9974905|FG001|Overall Study|Withdrawal by Subject|2
6272215|NCT02175225|9974904|FG000|Overall Study|Lost to Follow-up|6
6272216|NCT02175225|9974905|FG001|Overall Study|Lost to Follow-up|7
6272217|NCT02175225|9974904|FG000|Overall Study|Study drug not administered|1
6272218|NCT02175225|9974905|FG001|Overall Study|Study drug not administered|2
6272219|NCT02175277|9974911|FG000|Overall Study|Protocol-specified Criteria|1
6272220|NCT02175368|9974915|FG000|Overall Study|Lost to Follow-up|1
6272221|NCT02175641|9974930|FG000|Overall Study|Death|3
6272222|NCT02175641|9974931|FG001|Overall Study|Death|4
6272223|NCT02175641|9974930|FG000|Overall Study|Lost to Follow-up|4
6272224|NCT02175641|9974931|FG001|Overall Study|Lost to Follow-up|4
6272225|NCT02175641|9974930|FG000|Overall Study|Withdrawal by Subject|7
6272226|NCT02175641|9974931|FG001|Overall Study|Withdrawal by Subject|4
6272227|NCT02175641|9974930|FG000|Overall Study|Discharged from Supportive Housing Agenc|13
6272228|NCT02175641|9974931|FG001|Overall Study|Discharged from Supportive Housing Agenc|15
6272229|NCT02175641|9974930|FG000|Overall Study|Developed Contraindicated Condition|8
6272230|NCT02175641|9974931|FG001|Overall Study|Developed Contraindicated Condition|0
6272231|NCT02175745|9974937|FG000|Overall Study|Not Eligible|1
6272232|NCT02175758|9974947|FG000|Treatment Phase|Lost to Follow-up|0
6272233|NCT02175758|9974948|FG001|Treatment Phase|Lost to Follow-up|1
6272234|NCT02175758|9974949|FG002|Treatment Phase|Lost to Follow-up|0
6272235|NCT02175758|9974950|FG003|Treatment Phase|Lost to Follow-up|0
6272236|NCT02175758|9974951|FG004|Treatment Phase|Lost to Follow-up|0
6272237|NCT02175758|9974952|FG005|Treatment Phase|Lost to Follow-up|0
6272238|NCT02175758|9974947|FG000|Treatment Phase|Adverse Event|0
6272239|NCT02175758|9974948|FG001|Treatment Phase|Adverse Event|0
6272240|NCT02175758|9974949|FG002|Treatment Phase|Adverse Event|0
5972395|NCT02959918|9558144|FG008|Overall Study|Lost to Follow-up|0
5972396|NCT02959918|9558145|FG009|Overall Study|Lost to Follow-up|1
5972397|NCT02959918|9558146|FG010|Overall Study|Lost to Follow-up|0
5972398|NCT02959918|9558147|FG011|Overall Study|Lost to Follow-up|0
5972399|NCT02959918|9558148|FG012|Overall Study|Lost to Follow-up|1
5972400|NCT02959918|9558149|FG013|Overall Study|Lost to Follow-up|0
5972401|NCT02959918|9558136|FG000|Overall Study|Withdrawal by Subject|0
5972402|NCT02959918|9558137|FG001|Overall Study|Withdrawal by Subject|0
5972403|NCT02959918|9558138|FG002|Overall Study|Withdrawal by Subject|1
5972404|NCT02959918|9558139|FG003|Overall Study|Withdrawal by Subject|2
5972405|NCT02959918|9558140|FG004|Overall Study|Withdrawal by Subject|0
5972406|NCT02959918|9558141|FG005|Overall Study|Withdrawal by Subject|0
5972407|NCT02959918|9558142|FG006|Overall Study|Withdrawal by Subject|1
5972408|NCT02959918|9558143|FG007|Overall Study|Withdrawal by Subject|0
5972409|NCT02959918|9558144|FG008|Overall Study|Withdrawal by Subject|1
5972410|NCT02959918|9558145|FG009|Overall Study|Withdrawal by Subject|1
5972411|NCT02959918|9558146|FG010|Overall Study|Withdrawal by Subject|2
6272241|NCT02175758|9974950|FG003|Treatment Phase|Adverse Event|0
6272242|NCT02175758|9974951|FG004|Treatment Phase|Adverse Event|1
6272243|NCT02175758|9974952|FG005|Treatment Phase|Adverse Event|0
6272244|NCT02175771|9975000|FG000|Run-In Period (Pre-assignment)|Randomization criteria not met|23
6272245|NCT02175771|9975001|FG001|Run-In Period (Pre-assignment)|Randomization criteria not met|0
6272246|NCT02175771|9975002|FG002|Run-In Period (Pre-assignment)|Randomization criteria not met|0
6272247|NCT02175771|9975003|FG003|Run-In Period (Pre-assignment)|Randomization criteria not met|0
6272248|NCT02175771|9975004|FG004|Run-In Period (Pre-assignment)|Randomization criteria not met|0
6272249|NCT02175771|9975005|FG005|Run-In Period (Pre-assignment)|Randomization criteria not met|0
6272250|NCT02175771|9975006|FG006|Run-In Period (Pre-assignment)|Randomization criteria not met|0
6272251|NCT02175771|9975007|FG007|Run-In Period (Pre-assignment)|Randomization criteria not met|0
6272252|NCT02175771|9975008|FG008|Run-In Period (Pre-assignment)|Randomization criteria not met|0
6272253|NCT02175771|9975000|FG000|Run-In Period (Pre-assignment)|Exclusion criteria met|20
6272254|NCT02175771|9975001|FG001|Run-In Period (Pre-assignment)|Exclusion criteria met|0
6272255|NCT02175771|9975002|FG002|Run-In Period (Pre-assignment)|Exclusion criteria met|0
6272256|NCT02175771|9975003|FG003|Run-In Period (Pre-assignment)|Exclusion criteria met|0
6272257|NCT02175771|9975004|FG004|Run-In Period (Pre-assignment)|Exclusion criteria met|0
6272258|NCT02175771|9975005|FG005|Run-In Period (Pre-assignment)|Exclusion criteria met|0
6272259|NCT02175771|9975006|FG006|Run-In Period (Pre-assignment)|Exclusion criteria met|0
6272260|NCT02175771|9975007|FG007|Run-In Period (Pre-assignment)|Exclusion criteria met|0
6272261|NCT02175771|9975008|FG008|Run-In Period (Pre-assignment)|Exclusion criteria met|0
6272262|NCT02175771|9975000|FG000|Run-In Period (Pre-assignment)|Withdrawal by Subject|11
6272263|NCT02175771|9975001|FG001|Run-In Period (Pre-assignment)|Withdrawal by Subject|0
6272264|NCT02175771|9975002|FG002|Run-In Period (Pre-assignment)|Withdrawal by Subject|0
6272265|NCT02175771|9975003|FG003|Run-In Period (Pre-assignment)|Withdrawal by Subject|0
6272266|NCT02175771|9975004|FG004|Run-In Period (Pre-assignment)|Withdrawal by Subject|0
6272267|NCT02175771|9975005|FG005|Run-In Period (Pre-assignment)|Withdrawal by Subject|0
6272268|NCT02175771|9975006|FG006|Run-In Period (Pre-assignment)|Withdrawal by Subject|0
6272269|NCT02175771|9975007|FG007|Run-In Period (Pre-assignment)|Withdrawal by Subject|0
6272270|NCT02175771|9975008|FG008|Run-In Period (Pre-assignment)|Withdrawal by Subject|0
6272271|NCT02175771|9975000|FG000|Run-In Period (Pre-assignment)|Adverse Event|9
6272272|NCT02175771|9975001|FG001|Run-In Period (Pre-assignment)|Adverse Event|0
6272273|NCT02175771|9975002|FG002|Run-In Period (Pre-assignment)|Adverse Event|0
6272274|NCT02175771|9975003|FG003|Run-In Period (Pre-assignment)|Adverse Event|0
6272275|NCT02175771|9975004|FG004|Run-In Period (Pre-assignment)|Adverse Event|0
6272276|NCT02175771|9975005|FG005|Run-In Period (Pre-assignment)|Adverse Event|0
6272277|NCT02175771|9975006|FG006|Run-In Period (Pre-assignment)|Adverse Event|0
6272278|NCT02175771|9975007|FG007|Run-In Period (Pre-assignment)|Adverse Event|0
6272279|NCT02175771|9975008|FG008|Run-In Period (Pre-assignment)|Adverse Event|0
6272280|NCT02175771|9975000|FG000|Run-In Period (Pre-assignment)|Inclusion criteria not met|7
6272281|NCT02175771|9975001|FG001|Run-In Period (Pre-assignment)|Inclusion criteria not met|0
6272282|NCT02175771|9975002|FG002|Run-In Period (Pre-assignment)|Inclusion criteria not met|0
6272283|NCT02175771|9975003|FG003|Run-In Period (Pre-assignment)|Inclusion criteria not met|0
6272284|NCT02175771|9975004|FG004|Run-In Period (Pre-assignment)|Inclusion criteria not met|0
6272285|NCT02175771|9975005|FG005|Run-In Period (Pre-assignment)|Inclusion criteria not met|0
6272286|NCT02175771|9975006|FG006|Run-In Period (Pre-assignment)|Inclusion criteria not met|0
6272287|NCT02175771|9975007|FG007|Run-In Period (Pre-assignment)|Inclusion criteria not met|0
6272288|NCT02175771|9975008|FG008|Run-In Period (Pre-assignment)|Inclusion criteria not met|0
6272289|NCT02175771|9975000|FG000|Run-In Period (Pre-assignment)|Lost to Follow-up|6
6272290|NCT02175771|9975001|FG001|Run-In Period (Pre-assignment)|Lost to Follow-up|0
6272291|NCT02175771|9975002|FG002|Run-In Period (Pre-assignment)|Lost to Follow-up|0
6272292|NCT02175771|9975003|FG003|Run-In Period (Pre-assignment)|Lost to Follow-up|0
6272293|NCT02175771|9975004|FG004|Run-In Period (Pre-assignment)|Lost to Follow-up|0
6272294|NCT02175771|9975005|FG005|Run-In Period (Pre-assignment)|Lost to Follow-up|0
6272295|NCT02175771|9975006|FG006|Run-In Period (Pre-assignment)|Lost to Follow-up|0
6272296|NCT02175771|9975007|FG007|Run-In Period (Pre-assignment)|Lost to Follow-up|0
6272297|NCT02175771|9975008|FG008|Run-In Period (Pre-assignment)|Lost to Follow-up|0
6272298|NCT02175771|9975000|FG000|Run-In Period (Pre-assignment)|Other|8
6272299|NCT02175771|9975001|FG001|Run-In Period (Pre-assignment)|Other|0
6272300|NCT02175771|9975002|FG002|Run-In Period (Pre-assignment)|Other|0
6272301|NCT02175771|9975003|FG003|Run-In Period (Pre-assignment)|Other|0
6272302|NCT02175771|9975004|FG004|Run-In Period (Pre-assignment)|Other|0
6272303|NCT02175771|9975005|FG005|Run-In Period (Pre-assignment)|Other|0
6272304|NCT02175771|9975006|FG006|Run-In Period (Pre-assignment)|Other|0
6272305|NCT02175771|9975007|FG007|Run-In Period (Pre-assignment)|Other|0
6272306|NCT02175771|9975008|FG008|Run-In Period (Pre-assignment)|Other|0
6272307|NCT02175771|9975000|FG000|Treatment Period|Adverse Event|0
6272308|NCT02175771|9975001|FG001|Treatment Period|Adverse Event|2
6272309|NCT02175771|9975002|FG002|Treatment Period|Adverse Event|1
6272310|NCT02175771|9975003|FG003|Treatment Period|Adverse Event|1
6272311|NCT02175771|9975004|FG004|Treatment Period|Adverse Event|1
6272312|NCT02175771|9975005|FG005|Treatment Period|Adverse Event|3
6272313|NCT02175771|9975006|FG006|Treatment Period|Adverse Event|2
6272314|NCT02175771|9975007|FG007|Treatment Period|Adverse Event|0
5972412|NCT02959918|9558147|FG011|Overall Study|Withdrawal by Subject|3
6272315|NCT02175771|9975008|FG008|Treatment Period|Adverse Event|1
6272316|NCT02175771|9975000|FG000|Treatment Period|Withdrawal by Subject|0
6272317|NCT02175771|9975001|FG001|Treatment Period|Withdrawal by Subject|9
6272318|NCT02175771|9975002|FG002|Treatment Period|Withdrawal by Subject|3
6272319|NCT02175771|9975003|FG003|Treatment Period|Withdrawal by Subject|6
6272320|NCT02175771|9975004|FG004|Treatment Period|Withdrawal by Subject|2
6272321|NCT02175771|9975005|FG005|Treatment Period|Withdrawal by Subject|4
6272322|NCT02175771|9975006|FG006|Treatment Period|Withdrawal by Subject|2
6272323|NCT02175771|9975007|FG007|Treatment Period|Withdrawal by Subject|9
6272324|NCT02175771|9975008|FG008|Treatment Period|Withdrawal by Subject|2
6272325|NCT02175771|9975000|FG000|Treatment Period|Noncompliance|0
6272326|NCT02175771|9975001|FG001|Treatment Period|Noncompliance|1
6272327|NCT02175771|9975002|FG002|Treatment Period|Noncompliance|2
6272328|NCT02175771|9975003|FG003|Treatment Period|Noncompliance|0
6272329|NCT02175771|9975004|FG004|Treatment Period|Noncompliance|0
6272330|NCT02175771|9975005|FG005|Treatment Period|Noncompliance|0
6272331|NCT02175771|9975006|FG006|Treatment Period|Noncompliance|0
6272332|NCT02175771|9975007|FG007|Treatment Period|Noncompliance|0
6272333|NCT02175771|9975008|FG008|Treatment Period|Noncompliance|1
6272334|NCT02175771|9975000|FG000|Treatment Period|Protocol Violation|0
6272335|NCT02175771|9975001|FG001|Treatment Period|Protocol Violation|0
6272336|NCT02175771|9975002|FG002|Treatment Period|Protocol Violation|0
6272337|NCT02175771|9975003|FG003|Treatment Period|Protocol Violation|0
6272338|NCT02175771|9975004|FG004|Treatment Period|Protocol Violation|0
6272339|NCT02175771|9975005|FG005|Treatment Period|Protocol Violation|0
6272340|NCT02175771|9975006|FG006|Treatment Period|Protocol Violation|0
6272341|NCT02175771|9975007|FG007|Treatment Period|Protocol Violation|1
6272342|NCT02175771|9975008|FG008|Treatment Period|Protocol Violation|0
6272343|NCT02175771|9975000|FG000|Treatment Period|Disease progression|0
6272344|NCT02175771|9975001|FG001|Treatment Period|Disease progression|0
6272345|NCT02175771|9975002|FG002|Treatment Period|Disease progression|0
6272346|NCT02175771|9975003|FG003|Treatment Period|Disease progression|0
6272347|NCT02175771|9975004|FG004|Treatment Period|Disease progression|0
6272348|NCT02175771|9975005|FG005|Treatment Period|Disease progression|0
6272349|NCT02175771|9975006|FG006|Treatment Period|Disease progression|0
6272350|NCT02175771|9975007|FG007|Treatment Period|Disease progression|2
6272351|NCT02175771|9975008|FG008|Treatment Period|Disease progression|0
6272352|NCT02175771|9975000|FG000|Treatment Period|Lost to Follow-up|0
6272353|NCT02175771|9975001|FG001|Treatment Period|Lost to Follow-up|3
6272354|NCT02175771|9975002|FG002|Treatment Period|Lost to Follow-up|1
5972413|NCT02959918|9558148|FG012|Overall Study|Withdrawal by Subject|1
5972414|NCT02959918|9558149|FG013|Overall Study|Withdrawal by Subject|1
5972415|NCT02959918|9558136|FG000|Overall Study|Protocol Violation|0
5972416|NCT02959918|9558137|FG001|Overall Study|Protocol Violation|0
5972417|NCT02959918|9558138|FG002|Overall Study|Protocol Violation|1
5972418|NCT02959918|9558139|FG003|Overall Study|Protocol Violation|0
5972419|NCT02959918|9558140|FG004|Overall Study|Protocol Violation|0
5972420|NCT02959918|9558141|FG005|Overall Study|Protocol Violation|1
5972421|NCT02959918|9558142|FG006|Overall Study|Protocol Violation|0
5972422|NCT02959918|9558143|FG007|Overall Study|Protocol Violation|0
5972423|NCT02959918|9558144|FG008|Overall Study|Protocol Violation|2
5972424|NCT02959918|9558145|FG009|Overall Study|Protocol Violation|1
5972425|NCT02959918|9558146|FG010|Overall Study|Protocol Violation|0
5972426|NCT02959918|9558147|FG011|Overall Study|Protocol Violation|1
5972427|NCT02959918|9558148|FG012|Overall Study|Protocol Violation|1
5972428|NCT02959918|9558149|FG013|Overall Study|Protocol Violation|0
5972429|NCT02959918|9558136|FG000|Overall Study|Stopping Rule Met|1
5972430|NCT02959918|9558137|FG001|Overall Study|Stopping Rule Met|0
5972431|NCT02959918|9558138|FG002|Overall Study|Stopping Rule Met|3
5972432|NCT02959918|9558139|FG003|Overall Study|Stopping Rule Met|4
5972433|NCT02959918|9558140|FG004|Overall Study|Stopping Rule Met|5
5972434|NCT02959918|9558141|FG005|Overall Study|Stopping Rule Met|3
5972435|NCT02959918|9558142|FG006|Overall Study|Stopping Rule Met|2
5972436|NCT02959918|9558143|FG007|Overall Study|Stopping Rule Met|4
5972437|NCT02959918|9558144|FG008|Overall Study|Stopping Rule Met|1
5972438|NCT02959918|9558145|FG009|Overall Study|Stopping Rule Met|1
5972439|NCT02959918|9558146|FG010|Overall Study|Stopping Rule Met|3
5972440|NCT02959918|9558147|FG011|Overall Study|Stopping Rule Met|5
5972441|NCT02959918|9558148|FG012|Overall Study|Stopping Rule Met|2
5972442|NCT02959918|9558149|FG013|Overall Study|Stopping Rule Met|1
6272355|NCT02175771|9975003|FG003|Treatment Period|Lost to Follow-up|3
6272356|NCT02175771|9975004|FG004|Treatment Period|Lost to Follow-up|1
6272357|NCT02175771|9975005|FG005|Treatment Period|Lost to Follow-up|2
6272358|NCT02175771|9975006|FG006|Treatment Period|Lost to Follow-up|1
6272359|NCT02175771|9975007|FG007|Treatment Period|Lost to Follow-up|2
6272360|NCT02175771|9975008|FG008|Treatment Period|Lost to Follow-up|2
6272361|NCT02175771|9975000|FG000|Treatment Period|Lack of Efficacy|0
5972443|NCT02959918|9558136|FG000|Overall Study|Sponsor Decision, Pause in Clinical Trial|1
5972444|NCT02959918|9558137|FG001|Overall Study|Sponsor Decision, Pause in Clinical Trial|2
6272362|NCT02175771|9975001|FG001|Treatment Period|Lack of Efficacy|0
6272363|NCT02175771|9975002|FG002|Treatment Period|Lack of Efficacy|0
6272364|NCT02175771|9975003|FG003|Treatment Period|Lack of Efficacy|0
6272365|NCT02175771|9975004|FG004|Treatment Period|Lack of Efficacy|0
6272366|NCT02175771|9975005|FG005|Treatment Period|Lack of Efficacy|1
6272367|NCT02175771|9975006|FG006|Treatment Period|Lack of Efficacy|0
6272368|NCT02175771|9975007|FG007|Treatment Period|Lack of Efficacy|1
6272369|NCT02175771|9975008|FG008|Treatment Period|Lack of Efficacy|0
6272370|NCT02175771|9975000|FG000|Treatment Period|Other|0
6272371|NCT02175771|9975001|FG001|Treatment Period|Other|1
6272372|NCT02175771|9975002|FG002|Treatment Period|Other|0
6272373|NCT02175771|9975003|FG003|Treatment Period|Other|3
6272374|NCT02175771|9975004|FG004|Treatment Period|Other|1
6272375|NCT02175771|9975005|FG005|Treatment Period|Other|0
6272376|NCT02175771|9975006|FG006|Treatment Period|Other|0
6272377|NCT02175771|9975007|FG007|Treatment Period|Other|2
6272378|NCT02175771|9975008|FG008|Treatment Period|Other|0
6272379|NCT02175966|9975028|FG000|Follow-up Period|Lack of Efficacy|10
6272380|NCT02175966|9975029|FG001|Follow-up Period|Lack of Efficacy|6
6272381|NCT02176018|9975063|FG000|Overall Study|Adverse Event|0
6272382|NCT02176018|9975064|FG001|Overall Study|Adverse Event|2
6272383|NCT02176018|9975063|FG000|Overall Study|Lost to Follow-up|3
6272384|NCT02176018|9975064|FG001|Overall Study|Lost to Follow-up|1
6272385|NCT02176018|9975063|FG000|Overall Study|Protocol Violation|1
6272386|NCT02176018|9975064|FG001|Overall Study|Protocol Violation|1
6272387|NCT02176018|9975063|FG000|Overall Study|Withdrawal by Subject|1
6272388|NCT02176018|9975064|FG001|Overall Study|Withdrawal by Subject|2
6272389|NCT02176226|9975084|FG000|Overall Study|Lost to Follow-up|3
6272390|NCT02176226|9975084|FG000|Overall Study|Withdrew prior to treatment|6
6272391|NCT02176291|9975090|FG000|Overall Study|Death|1
6272392|NCT02176291|9975091|FG001|Overall Study|Death|0
6272393|NCT02176291|9975090|FG000|Overall Study|non compliance with protocol|2
6272394|NCT02176291|9975091|FG001|Overall Study|non compliance with protocol|0
6272395|NCT02176291|9975090|FG000|Overall Study|Withdrawal by Subject|2
6272396|NCT02176291|9975091|FG001|Overall Study|Withdrawal by Subject|0
6272397|NCT02176356|9975101|FG000|Overall Study|Screen Failure|14
6272398|NCT02176356|9975101|FG000|Overall Study|Lost to Follow-up|4
6272399|NCT02176356|9975101|FG000|Overall Study|Personal Reasons|3
6272400|NCT02176356|9975101|FG000|Overall Study|Other Miscellaneous Reasons|2
6272401|NCT02176421|9975123|FG000|Overall Study|Lost to Follow-up|4
6272402|NCT02176421|9975123|FG000|Overall Study|Adverse Event|1
6272403|NCT02176525|9975150|FG000|Overall Study|Adverse Event|0
6272404|NCT02176525|9975151|FG001|Overall Study|Adverse Event|0
6272405|NCT02176525|9975152|FG002|Overall Study|Adverse Event|0
6272406|NCT02176525|9975153|FG003|Overall Study|Adverse Event|1
6272407|NCT02176525|9975154|FG004|Overall Study|Adverse Event|1
6272408|NCT02176525|9975155|FG005|Overall Study|Adverse Event|0
6272409|NCT02176525|9975156|FG006|Overall Study|Adverse Event|1
6272410|NCT02176525|9975157|FG007|Overall Study|Adverse Event|0
6272411|NCT02176525|9975150|FG000|Overall Study|not treated|1
6272412|NCT02176525|9975151|FG001|Overall Study|not treated|0
6272413|NCT02176525|9975152|FG002|Overall Study|not treated|0
6272414|NCT02176525|9975153|FG003|Overall Study|not treated|0
6272415|NCT02176525|9975154|FG004|Overall Study|not treated|0
6272416|NCT02176525|9975155|FG005|Overall Study|not treated|1
6272417|NCT02176525|9975156|FG006|Overall Study|not treated|0
6272418|NCT02176525|9975157|FG007|Overall Study|not treated|0
6272419|NCT02176642|9975185|FG000|Overall Study|Withdrawal by Subject|0
6272420|NCT02176642|9975186|FG001|Overall Study|Withdrawal by Subject|1
6272421|NCT02176655|9975192|FG000|Overall Study|Subjects did not treat|6
6272422|NCT02176928|9975203|FG000|Overall Study|Lost to Follow-up|2
6272423|NCT02176928|9975204|FG001|Overall Study|Lost to Follow-up|4
6272424|NCT02177032|9975214|FG000|Overall Study|ADMINISTRATIVE REASON|2
6272425|NCT02177032|9975215|FG001|Overall Study|ADMINISTRATIVE REASON|0
5972445|NCT02959918|9558138|FG002|Overall Study|Sponsor Decision, Pause in Clinical Trial|1
5972446|NCT02959918|9558139|FG003|Overall Study|Sponsor Decision, Pause in Clinical Trial|3
6049114|NCT00421343|9648334|FG000|Overall Study|Lost to Follow-up|3
6049115|NCT00421408|9648340|FG000|Overall Study|Lost to Follow-up|30
6049116|NCT00421408|9648341|FG001|Overall Study|Lost to Follow-up|20
6087783|NCT00670488|9698273|FG009|Overall Study|Adverse Event|1
6087784|NCT00670488|9698264|FG000|Overall Study|Physician Decision|1
6087785|NCT00670488|9698265|FG001|Overall Study|Physician Decision|9
6087786|NCT00670488|9698266|FG002|Overall Study|Physician Decision|0
6087787|NCT00670488|9698267|FG003|Overall Study|Physician Decision|1
6272426|NCT02177032|9975216|FG002|Overall Study|ADMINISTRATIVE REASON|1
6272427|NCT02177032|9975217|FG003|Overall Study|ADMINISTRATIVE REASON|0
6272428|NCT02177032|9975214|FG000|Overall Study|Lost to Follow-up|0
6272429|NCT02177032|9975215|FG001|Overall Study|Lost to Follow-up|2
6272430|NCT02177032|9975216|FG002|Overall Study|Lost to Follow-up|0
6272431|NCT02177032|9975217|FG003|Overall Study|Lost to Follow-up|0
6272432|NCT02177032|9975214|FG000|Overall Study|OTHER|2
6272433|NCT02177032|9975215|FG001|Overall Study|OTHER|0
6272434|NCT02177032|9975216|FG002|Overall Study|OTHER|1
6272435|NCT02177032|9975217|FG003|Overall Study|OTHER|0
6272436|NCT02177032|9975214|FG000|Overall Study|Withdrawal by Subject|1
6087788|NCT00670488|9698268|FG004|Overall Study|Physician Decision|0
6087789|NCT00670488|9698269|FG005|Overall Study|Physician Decision|0
6087790|NCT00670488|9698270|FG006|Overall Study|Physician Decision|0
6087791|NCT00670488|9698271|FG007|Overall Study|Physician Decision|0
6087792|NCT00670488|9698272|FG008|Overall Study|Physician Decision|0
6087793|NCT00670488|9698273|FG009|Overall Study|Physician Decision|0
6087794|NCT00670488|9698264|FG000|Overall Study|Progressive Disease|2
6087795|NCT00670488|9698265|FG001|Overall Study|Progressive Disease|41
6087796|NCT00670488|9698266|FG002|Overall Study|Progressive Disease|3
6087797|NCT00670488|9698267|FG003|Overall Study|Progressive Disease|2
6087798|NCT00670488|9698268|FG004|Overall Study|Progressive Disease|2
6087799|NCT00670488|9698269|FG005|Overall Study|Progressive Disease|4
6087800|NCT00670488|9698270|FG006|Overall Study|Progressive Disease|11
6087801|NCT00670488|9698271|FG007|Overall Study|Progressive Disease|2
6087802|NCT00670488|9698272|FG008|Overall Study|Progressive Disease|2
6087803|NCT00670488|9698273|FG009|Overall Study|Progressive Disease|1
6087804|NCT00670488|9698264|FG000|Overall Study|Withdrawal by Subject|0
6087805|NCT00670488|9698265|FG001|Overall Study|Withdrawal by Subject|1
6272437|NCT02177032|9975215|FG001|Overall Study|Withdrawal by Subject|0
6272438|NCT02177032|9975216|FG002|Overall Study|Withdrawal by Subject|1
6087806|NCT00670488|9698266|FG002|Overall Study|Withdrawal by Subject|0
6087807|NCT00670488|9698267|FG003|Overall Study|Withdrawal by Subject|1
6087808|NCT00670488|9698268|FG004|Overall Study|Withdrawal by Subject|0
6272439|NCT02177032|9975217|FG003|Overall Study|Withdrawal by Subject|0
6272440|NCT02177123|9975238|FG000|Overall Study|Lost to Follow-up|6
6272441|NCT02177123|9975238|FG000|Overall Study|Withdrawal by Subject|4
6272442|NCT02177123|9975238|FG000|Overall Study|Adverse Event|4
6272443|NCT02177123|9975238|FG000|Overall Study|Physician Decision|3
6272444|NCT02177123|9975238|FG000|Overall Study|Excluded by Sponsor - other reason|2
6272445|NCT02177123|9975238|FG000|Overall Study|Excluded for medical reasons|2
6272446|NCT02177123|9975238|FG000|Overall Study|Death|1
6272447|NCT02177123|9975238|FG000|Overall Study|Other|1
6272448|NCT02177123|9975238|FG000|Overall Study|Excl. #31 Ocular pathology or medical condition which would place subject at increased risk|1
6272449|NCT02177136|9975248|FG000|DB Phase|Withdrawal by Subject|2
6272450|NCT02177136|9975249|FG001|DB Phase|Withdrawal by Subject|0
6272451|NCT02177136|9975250|FG002|DB Phase|Withdrawal by Subject|0
6272452|NCT02177136|9975251|FG003|DB Phase|Withdrawal by Subject|0
6272453|NCT02177136|9975248|FG000|DB Phase|Discontinued Due to Pruritus|1
6272454|NCT02177136|9975249|FG001|DB Phase|Discontinued Due to Pruritus|3
6272455|NCT02177136|9975250|FG002|DB Phase|Discontinued Due to Pruritus|0
6272456|NCT02177136|9975251|FG003|DB Phase|Discontinued Due to Pruritus|0
6272457|NCT02177136|9975248|FG000|DB Phase|Adverse Event|3
6272458|NCT02177136|9975249|FG001|DB Phase|Adverse Event|2
6272459|NCT02177136|9975250|FG002|DB Phase|Adverse Event|3
6272460|NCT02177136|9975251|FG003|DB Phase|Adverse Event|0
6272461|NCT02177136|9975248|FG000|DB Phase|Protocol Violation|0
6272462|NCT02177136|9975249|FG001|DB Phase|Protocol Violation|0
6272463|NCT02177136|9975250|FG002|DB Phase|Protocol Violation|1
6272464|NCT02177136|9975251|FG003|DB Phase|Protocol Violation|0
6272465|NCT02177136|9975248|FG000|DB Phase|Withdrew Consent Prior to Dosing|1
6272466|NCT02177136|9975249|FG001|DB Phase|Withdrew Consent Prior to Dosing|0
6272467|NCT02177136|9975250|FG002|DB Phase|Withdrew Consent Prior to Dosing|0
6272468|NCT02177136|9975251|FG003|DB Phase|Withdrew Consent Prior to Dosing|0
6272469|NCT02177136|9975248|FG000|LTSE Phase|Withdrawal by Subject|0
6272470|NCT02177136|9975249|FG001|LTSE Phase|Withdrawal by Subject|0
6272471|NCT02177136|9975250|FG002|LTSE Phase|Withdrawal by Subject|0
6272472|NCT02177136|9975251|FG003|LTSE Phase|Withdrawal by Subject|6
6272473|NCT02177136|9975248|FG000|LTSE Phase|Adverse Event|0
6272474|NCT02177136|9975249|FG001|LTSE Phase|Adverse Event|0
6272475|NCT02177136|9975250|FG002|LTSE Phase|Adverse Event|0
6272476|NCT02177136|9975251|FG003|LTSE Phase|Adverse Event|10
6272477|NCT02177136|9975248|FG000|LTSE Phase|Discontinued Due to Pruritus|0
6272478|NCT02177136|9975249|FG001|LTSE Phase|Discontinued Due to Pruritus|0
6272479|NCT02177136|9975250|FG002|LTSE Phase|Discontinued Due to Pruritus|0
6272480|NCT02177136|9975251|FG003|LTSE Phase|Discontinued Due to Pruritus|4
6272481|NCT02177136|9975248|FG000|LTSE Phase|Physician Decision|0
6272482|NCT02177136|9975249|FG001|LTSE Phase|Physician Decision|0
6272483|NCT02177136|9975250|FG002|LTSE Phase|Physician Decision|0
6272484|NCT02177136|9975251|FG003|LTSE Phase|Physician Decision|2
6272485|NCT02177136|9975248|FG000|LTSE Phase|Lost to Follow-up|0
6272486|NCT02177136|9975249|FG001|LTSE Phase|Lost to Follow-up|0
6272487|NCT02177136|9975250|FG002|LTSE Phase|Lost to Follow-up|0
6272488|NCT02177136|9975251|FG003|LTSE Phase|Lost to Follow-up|1
6272489|NCT02177136|9975248|FG000|LTSE Phase|Participant Moved|0
6272490|NCT02177136|9975249|FG001|LTSE Phase|Participant Moved|0
6272491|NCT02177136|9975250|FG002|LTSE Phase|Participant Moved|0
6272492|NCT02177136|9975251|FG003|LTSE Phase|Participant Moved|1
6272493|NCT02177786|9975275|FG000|Overall Study|Withdrew Consent|2
6272494|NCT02177786|9975276|FG001|Overall Study|Withdrew Consent|6
6272495|NCT02177786|9975277|FG002|Overall Study|Withdrew Consent|9
6272496|NCT02177786|9975278|FG003|Overall Study|Withdrew Consent|5
6272497|NCT02177786|9975275|FG000|Overall Study|Progression to End Stage Renal Disease|2
6272498|NCT02177786|9975276|FG001|Overall Study|Progression to End Stage Renal Disease|3
6272499|NCT02177786|9975277|FG002|Overall Study|Progression to End Stage Renal Disease|2
6272500|NCT02177786|9975278|FG003|Overall Study|Progression to End Stage Renal Disease|1
6272501|NCT02177786|9975275|FG000|Overall Study|Adverse Event|1
6272502|NCT02177786|9975276|FG001|Overall Study|Adverse Event|1
6272503|NCT02177786|9975277|FG002|Overall Study|Adverse Event|2
6272504|NCT02177786|9975278|FG003|Overall Study|Adverse Event|3
6272505|NCT02177786|9975275|FG000|Overall Study|Death|1
6272506|NCT02177786|9975276|FG001|Overall Study|Death|1
6272507|NCT02177786|9975277|FG002|Overall Study|Death|1
6272508|NCT02177786|9975278|FG003|Overall Study|Death|1
6272509|NCT02177786|9975275|FG000|Overall Study|Lost to Follow-up|0
6272510|NCT02177786|9975276|FG001|Overall Study|Lost to Follow-up|0
6272511|NCT02177786|9975277|FG002|Overall Study|Lost to Follow-up|2
6272512|NCT02177786|9975278|FG003|Overall Study|Lost to Follow-up|2
6272513|NCT02177786|9975275|FG000|Overall Study|Non-Compliance with Study Drug|0
6272514|NCT02177786|9975276|FG001|Overall Study|Non-Compliance with Study Drug|1
6272515|NCT02177786|9975277|FG002|Overall Study|Non-Compliance with Study Drug|0
6272516|NCT02177786|9975278|FG003|Overall Study|Non-Compliance with Study Drug|1
6272517|NCT02177786|9975275|FG000|Overall Study|Protocol Violation|0
6272518|NCT02177786|9975276|FG001|Overall Study|Protocol Violation|0
6272519|NCT02177786|9975277|FG002|Overall Study|Protocol Violation|2
6272520|NCT02177786|9975278|FG003|Overall Study|Protocol Violation|0
6272521|NCT02177786|9975275|FG000|Overall Study|Progressive Disease|0
6272522|NCT02177786|9975276|FG001|Overall Study|Progressive Disease|1
6272523|NCT02177786|9975277|FG002|Overall Study|Progressive Disease|0
6272524|NCT02177786|9975278|FG003|Overall Study|Progressive Disease|0
6272525|NCT02177786|9975275|FG000|Overall Study|Missing study completion status|0
6272526|NCT02177786|9975276|FG001|Overall Study|Missing study completion status|1
6272527|NCT02177786|9975277|FG002|Overall Study|Missing study completion status|0
6272528|NCT02177786|9975278|FG003|Overall Study|Missing study completion status|0
6272529|NCT02177812|9975297|FG000|Part 1 (Median of 4 Weeks)|Withdrawal by Subject|0
6272530|NCT02177812|9975298|FG001|Part 1 (Median of 4 Weeks)|Withdrawal by Subject|0
6272531|NCT02177812|9975299|FG002|Part 1 (Median of 4 Weeks)|Withdrawal by Subject|0
6272532|NCT02177812|9975300|FG003|Part 1 (Median of 4 Weeks)|Withdrawal by Subject|0
6272533|NCT02177812|9975301|FG004|Part 1 (Median of 4 Weeks)|Withdrawal by Subject|0
6272534|NCT02177812|9975302|FG005|Part 1 (Median of 4 Weeks)|Withdrawal by Subject|1
6272535|NCT02177812|9975303|FG006|Part 1 (Median of 4 Weeks)|Withdrawal by Subject|2
6272536|NCT02177812|9975304|FG007|Part 1 (Median of 4 Weeks)|Withdrawal by Subject|1
6272537|NCT02177812|9975305|FG008|Part 1 (Median of 4 Weeks)|Withdrawal by Subject|0
6272538|NCT02177812|9975297|FG000|Part 1 (Median of 4 Weeks)|Physician Decision|0
6272539|NCT02177812|9975298|FG001|Part 1 (Median of 4 Weeks)|Physician Decision|0
6272540|NCT02177812|9975299|FG002|Part 1 (Median of 4 Weeks)|Physician Decision|0
6272541|NCT02177812|9975300|FG003|Part 1 (Median of 4 Weeks)|Physician Decision|0
6272542|NCT02177812|9975301|FG004|Part 1 (Median of 4 Weeks)|Physician Decision|0
6272543|NCT02177812|9975302|FG005|Part 1 (Median of 4 Weeks)|Physician Decision|1
6272544|NCT02177812|9975303|FG006|Part 1 (Median of 4 Weeks)|Physician Decision|1
6272545|NCT02177812|9975304|FG007|Part 1 (Median of 4 Weeks)|Physician Decision|0
6272546|NCT02177812|9975305|FG008|Part 1 (Median of 4 Weeks)|Physician Decision|0
6272547|NCT02177812|9975297|FG000|Part 1 (Median of 4 Weeks)|Adverse Event|0
6272548|NCT02177812|9975298|FG001|Part 1 (Median of 4 Weeks)|Adverse Event|0
6272549|NCT02177812|9975299|FG002|Part 1 (Median of 4 Weeks)|Adverse Event|0
6272550|NCT02177812|9975300|FG003|Part 1 (Median of 4 Weeks)|Adverse Event|1
6272551|NCT02177812|9975301|FG004|Part 1 (Median of 4 Weeks)|Adverse Event|1
6272552|NCT02177812|9975302|FG005|Part 1 (Median of 4 Weeks)|Adverse Event|1
6272553|NCT02177812|9975303|FG006|Part 1 (Median of 4 Weeks)|Adverse Event|6
6272554|NCT02177812|9975304|FG007|Part 1 (Median of 4 Weeks)|Adverse Event|1
6272555|NCT02177812|9975305|FG008|Part 1 (Median of 4 Weeks)|Adverse Event|0
6272556|NCT02177838|9975334|FG000|Overall Study|Withdrawal by Subject|1
6272557|NCT02177838|9975334|FG000|Overall Study|Physician Decision|1
6272558|NCT02177838|9975334|FG000|Overall Study|Death|1
6272559|NCT02177942|9975340|FG000|Overall Study|Adverse Event|1
6272560|NCT02177942|9975341|FG001|Overall Study|Adverse Event|0
6272561|NCT02177942|9975340|FG000|Overall Study|Lost to Follow-up|1
6272562|NCT02177942|9975341|FG001|Overall Study|Lost to Follow-up|1
6272563|NCT02177942|9975340|FG000|Overall Study|Protocol Violation|4
6272564|NCT02177942|9975341|FG001|Overall Study|Protocol Violation|6
6272565|NCT02177942|9975340|FG000|Overall Study|Withdrawal by Subject|71
6272566|NCT02177942|9975341|FG001|Overall Study|Withdrawal by Subject|81
6272567|NCT02178059|9975351|FG000|Washout|Physician Decision|1
6272568|NCT02178059|9975352|FG001|Washout|Physician Decision|0
6272569|NCT02178475|9975362|FG000|Overall Study|Withdrawal by Subject|7
6272570|NCT02178475|9975362|FG000|Overall Study|Lost to Follow-up|10
6272571|NCT02178475|9975362|FG000|Overall Study|Death|13
6272572|NCT02178475|9975362|FG000|Overall Study|Protocol-specified Criteria|99
6272573|NCT02178553|9975375|FG000|Overall Study|Did not proceed to open thoracotomy|7
6272574|NCT02178553|9975376|FG001|Overall Study|Did not proceed to open thoracotomy|3
6272575|NCT02178553|9975375|FG000|Overall Study|Physician Decision|0
6272576|NCT02178553|9975376|FG001|Overall Study|Physician Decision|4
6272577|NCT02178553|9975375|FG000|Overall Study|Technical problem with injection|1
6272578|NCT02178553|9975376|FG001|Overall Study|Technical problem with injection|3
5972447|NCT02959918|9558140|FG004|Overall Study|Sponsor Decision, Pause in Clinical Trial|0
5972448|NCT02959918|9558141|FG005|Overall Study|Sponsor Decision, Pause in Clinical Trial|0
5972449|NCT02959918|9558142|FG006|Overall Study|Sponsor Decision, Pause in Clinical Trial|0
6087809|NCT00670488|9698269|FG005|Overall Study|Withdrawal by Subject|0
5972450|NCT02959918|9558143|FG007|Overall Study|Sponsor Decision, Pause in Clinical Trial|0
5972451|NCT02959918|9558144|FG008|Overall Study|Sponsor Decision, Pause in Clinical Trial|0
5972452|NCT02959918|9558145|FG009|Overall Study|Sponsor Decision, Pause in Clinical Trial|0
5972453|NCT02959918|9558146|FG010|Overall Study|Sponsor Decision, Pause in Clinical Trial|0
5972454|NCT02959918|9558147|FG011|Overall Study|Sponsor Decision, Pause in Clinical Trial|0
5972455|NCT02959918|9558148|FG012|Overall Study|Sponsor Decision, Pause in Clinical Trial|0
5972456|NCT02959918|9558149|FG013|Overall Study|Sponsor Decision, Pause in Clinical Trial|0
5972457|NCT02959918|9558136|FG000|Overall Study|Subject Hospitalized, out of window for next dosing period|0
5972458|NCT02959918|9558137|FG001|Overall Study|Subject Hospitalized, out of window for next dosing period|0
5972459|NCT02959918|9558138|FG002|Overall Study|Subject Hospitalized, out of window for next dosing period|0
5972460|NCT02959918|9558139|FG003|Overall Study|Subject Hospitalized, out of window for next dosing period|0
5972461|NCT02959918|9558140|FG004|Overall Study|Subject Hospitalized, out of window for next dosing period|0
5972462|NCT02959918|9558141|FG005|Overall Study|Subject Hospitalized, out of window for next dosing period|0
5972463|NCT02959918|9558142|FG006|Overall Study|Subject Hospitalized, out of window for next dosing period|0
5972464|NCT02959918|9558143|FG007|Overall Study|Subject Hospitalized, out of window for next dosing period|1
5972465|NCT02959918|9558144|FG008|Overall Study|Subject Hospitalized, out of window for next dosing period|0
5972466|NCT02959918|9558145|FG009|Overall Study|Subject Hospitalized, out of window for next dosing period|0
6272579|NCT02178592|9975384|FG000|Randomized Phase (Up to Week 52)|Adverse Event|0
6272580|NCT02178592|9975385|FG001|Randomized Phase (Up to Week 52)|Adverse Event|2
6272581|NCT02178592|9975384|FG000|Randomized Phase (Up to Week 52)|Lack of Efficacy|1
6272582|NCT02178592|9975385|FG001|Randomized Phase (Up to Week 52)|Lack of Efficacy|1
6272583|NCT02178592|9975384|FG000|Randomized Phase (Up to Week 52)|Protocol Violation|3
6272584|NCT02178592|9975385|FG001|Randomized Phase (Up to Week 52)|Protocol Violation|2
6272585|NCT02178592|9975384|FG000|Randomized Phase (Up to Week 52)|Withdrawal by Subject|3
6272586|NCT02178592|9975385|FG001|Randomized Phase (Up to Week 52)|Withdrawal by Subject|1
6272587|NCT02178592|9975384|FG000|Randomized Phase (Up to Week 52)|Lost to Follow-up|11
5972467|NCT02959918|9558146|FG010|Overall Study|Subject Hospitalized, out of window for next dosing period|0
5972468|NCT02959918|9558147|FG011|Overall Study|Subject Hospitalized, out of window for next dosing period|0
5972469|NCT02959918|9558148|FG012|Overall Study|Subject Hospitalized, out of window for next dosing period|0
5972470|NCT02959918|9558149|FG013|Overall Study|Subject Hospitalized, out of window for next dosing period|0
5972471|NCT02959918|9558136|FG000|Overall Study|PI Discretion due to abnormal Hgb results|0
5972472|NCT02959918|9558137|FG001|Overall Study|PI Discretion due to abnormal Hgb results|0
5972473|NCT02959918|9558138|FG002|Overall Study|PI Discretion due to abnormal Hgb results|0
5972474|NCT02959918|9558139|FG003|Overall Study|PI Discretion due to abnormal Hgb results|0
5972475|NCT02959918|9558140|FG004|Overall Study|PI Discretion due to abnormal Hgb results|0
5972476|NCT02959918|9558141|FG005|Overall Study|PI Discretion due to abnormal Hgb results|0
5972477|NCT02959918|9558142|FG006|Overall Study|PI Discretion due to abnormal Hgb results|0
5972478|NCT02959918|9558143|FG007|Overall Study|PI Discretion due to abnormal Hgb results|0
5972479|NCT02959918|9558144|FG008|Overall Study|PI Discretion due to abnormal Hgb results|1
5972480|NCT02959918|9558145|FG009|Overall Study|PI Discretion due to abnormal Hgb results|0
5972481|NCT02959918|9558146|FG010|Overall Study|PI Discretion due to abnormal Hgb results|0
5972482|NCT02959918|9558147|FG011|Overall Study|PI Discretion due to abnormal Hgb results|0
5972483|NCT02959918|9558148|FG012|Overall Study|PI Discretion due to abnormal Hgb results|0
5972484|NCT02959918|9558149|FG013|Overall Study|PI Discretion due to abnormal Hgb results|0
5972485|NCT02959918|9558136|FG000|Overall Study|Subject under-dosed with study drug and removed by Sponsor|0
5972486|NCT02959918|9558137|FG001|Overall Study|Subject under-dosed with study drug and removed by Sponsor|0
5972487|NCT02959918|9558138|FG002|Overall Study|Subject under-dosed with study drug and removed by Sponsor|0
5972488|NCT02959918|9558139|FG003|Overall Study|Subject under-dosed with study drug and removed by Sponsor|0
5972489|NCT02959918|9558140|FG004|Overall Study|Subject under-dosed with study drug and removed by Sponsor|0
5972490|NCT02959918|9558141|FG005|Overall Study|Subject under-dosed with study drug and removed by Sponsor|0
5972491|NCT02959918|9558142|FG006|Overall Study|Subject under-dosed with study drug and removed by Sponsor|0
6193383|NCT01438060|9851069|FG000|Acute Phase: Double-blind, 10 Weeks|Lost to Follow-up|1
6193384|NCT01438060|9851070|FG001|Acute Phase: Double-blind, 10 Weeks|Lost to Follow-up|0
6193385|NCT01438060|9851069|FG000|Acute Phase: Double-blind, 10 Weeks|Death|0
6193386|NCT01438060|9851070|FG001|Acute Phase: Double-blind, 10 Weeks|Death|2
6193387|NCT01438060|9851069|FG000|Acute Phase: Double-blind, 10 Weeks|Other Reason|1
6193388|NCT01438060|9851070|FG001|Acute Phase: Double-blind, 10 Weeks|Other Reason|0
6193389|NCT01438060|9851069|FG000|Extension Phase: Week 10 to Week 130|Adverse Event|15
6193390|NCT01438060|9851070|FG001|Extension Phase: Week 10 to Week 130|Adverse Event|16
6193391|NCT01438060|9851069|FG000|Extension Phase: Week 10 to Week 130|Lack of Efficacy|8
6193392|NCT01438060|9851070|FG001|Extension Phase: Week 10 to Week 130|Lack of Efficacy|8
6193393|NCT01438060|9851069|FG000|Extension Phase: Week 10 to Week 130|Withdrawal by Subject|3
6193394|NCT01438060|9851070|FG001|Extension Phase: Week 10 to Week 130|Withdrawal by Subject|5
6193395|NCT01438060|9851069|FG000|Extension Phase: Week 10 to Week 130|Participant Unreliability|1
6193396|NCT01438060|9851070|FG001|Extension Phase: Week 10 to Week 130|Participant Unreliability|0
6193397|NCT01438060|9851069|FG000|Extension Phase: Week 10 to Week 130|Lost to Follow-up|2
6193398|NCT01438060|9851070|FG001|Extension Phase: Week 10 to Week 130|Lost to Follow-up|0
6193399|NCT01438060|9851069|FG000|Extension Phase: Week 10 to Week 130|Death|22
6193400|NCT01438060|9851070|FG001|Extension Phase: Week 10 to Week 130|Death|12
6193401|NCT01438060|9851069|FG000|Extension Phase: Week 10 to Week 130|Other Reason|7
6193402|NCT01438060|9851070|FG001|Extension Phase: Week 10 to Week 130|Other Reason|15
6193403|NCT01438060|9851069|FG000|On Study Beyond Week 140|Adverse Event|0
6193404|NCT01438060|9851070|FG001|On Study Beyond Week 140|Adverse Event|2
6193405|NCT01438060|9851069|FG000|On Study Beyond Week 140|Lack of Efficacy|0
6193406|NCT01438060|9851070|FG001|On Study Beyond Week 140|Lack of Efficacy|1
6193407|NCT01438060|9851069|FG000|On Study Beyond Week 140|Withdrawal by Subject|0
6193408|NCT01438060|9851070|FG001|On Study Beyond Week 140|Withdrawal by Subject|1
6193409|NCT01438060|9851069|FG000|On Study Beyond Week 140|Death|0
6193410|NCT01438060|9851070|FG001|On Study Beyond Week 140|Death|1
6193411|NCT01438060|9851069|FG000|On Study Beyond Week 140|Other Reason|0
6193412|NCT01438060|9851070|FG001|On Study Beyond Week 140|Other Reason|3
6193413|NCT01438151|9851081|FG000|Overall Study|study terminated|8
6193414|NCT01438177|9851085|FG000|Overall Study|Withdrawal by Subject|1
6193415|NCT01438177|9851085|FG000|Overall Study|Initiation of new therapy|1
6193416|NCT01438294|9851095|FG000|Overall Study|Lost to Follow-up|3
6193417|NCT01438294|9851096|FG001|Overall Study|Lost to Follow-up|7
6193418|NCT01438307|9851104|FG000|Overall Study|Death|1
6193419|NCT01438307|9851105|FG001|Overall Study|Death|1
6193420|NCT01438411|9851111|FG000|Overall Study|Adverse Event|8
6193421|NCT01438411|9851111|FG000|Overall Study|Lost to Follow-up|1
6193422|NCT01438411|9851111|FG000|Overall Study|Lack of Efficacy|1
6272588|NCT02178592|9975385|FG001|Randomized Phase (Up to Week 52)|Lost to Follow-up|3
6272589|NCT02178592|9975384|FG000|Randomized Phase (Up to Week 52)|Physician Decision|1
6272590|NCT02178592|9975385|FG001|Randomized Phase (Up to Week 52)|Physician Decision|0
6272591|NCT02178592|9975384|FG000|OLE Phase (Week 52 to Week 252)|Adverse Event|1
6272592|NCT02178592|9975385|FG001|OLE Phase (Week 52 to Week 252)|Adverse Event|0
6272593|NCT02178592|9975384|FG000|OLE Phase (Week 52 to Week 252)|Lack of Efficacy|0
6272594|NCT02178592|9975385|FG001|OLE Phase (Week 52 to Week 252)|Lack of Efficacy|1
6272595|NCT02178592|9975384|FG000|OLE Phase (Week 52 to Week 252)|Protocol Violation|2
6272596|NCT02178592|9975385|FG001|OLE Phase (Week 52 to Week 252)|Protocol Violation|0
6272597|NCT02178592|9975384|FG000|OLE Phase (Week 52 to Week 252)|Withdrawal by Subject|4
6272598|NCT02178592|9975385|FG001|OLE Phase (Week 52 to Week 252)|Withdrawal by Subject|1
6272599|NCT02178592|9975384|FG000|OLE Phase (Week 52 to Week 252)|Reached Protocol defined stopping criteria|2
6272600|NCT02178592|9975385|FG001|OLE Phase (Week 52 to Week 252)|Reached Protocol defined stopping criteria|0
5972492|NCT02959918|9558143|FG007|Overall Study|Subject under-dosed with study drug and removed by Sponsor|0
5972493|NCT02959918|9558144|FG008|Overall Study|Subject under-dosed with study drug and removed by Sponsor|0
5972494|NCT02959918|9558145|FG009|Overall Study|Subject under-dosed with study drug and removed by Sponsor|1
5972495|NCT02959918|9558146|FG010|Overall Study|Subject under-dosed with study drug and removed by Sponsor|0
5972496|NCT02959918|9558147|FG011|Overall Study|Subject under-dosed with study drug and removed by Sponsor|0
5972497|NCT02959918|9558148|FG012|Overall Study|Subject under-dosed with study drug and removed by Sponsor|0
5972498|NCT02959918|9558149|FG013|Overall Study|Subject under-dosed with study drug and removed by Sponsor|0
6049117|NCT00421408|9648340|FG000|Overall Study|Discountinued from treatment/ f/u cont.|12
6049118|NCT00421408|9648341|FG001|Overall Study|Discountinued from treatment/ f/u cont.|25
6087810|NCT00670488|9698270|FG006|Overall Study|Withdrawal by Subject|1
6087811|NCT00670488|9698271|FG007|Overall Study|Withdrawal by Subject|0
6087812|NCT00670488|9698272|FG008|Overall Study|Withdrawal by Subject|1
6087813|NCT00670488|9698273|FG009|Overall Study|Withdrawal by Subject|0
6087814|NCT00670540|9698295|FG000|Overall Study|ineligible|17
6087815|NCT00670540|9698295|FG000|Overall Study|not living in France|348
6087816|NCT00670540|9698295|FG000|Overall Study|refused to participate|189
6087817|NCT00670540|9698295|FG000|Overall Study|controls randomised for no follow up|2770
6087818|NCT00670540|9698295|FG000|Overall Study|missing information inclusion criteria|1
6087819|NCT00670748|9698312|FG000|Overall Study|Death during treatment|1
6087820|NCT00670748|9698313|FG001|Overall Study|Death during treatment|1
6087821|NCT00670748|9698314|FG002|Overall Study|Death during treatment|1
6087822|NCT00670748|9698315|FG003|Overall Study|Death during treatment|0
6087823|NCT00670748|9698312|FG000|Overall Study|Not off study|2
6087824|NCT00670748|9698313|FG001|Overall Study|Not off study|1
6087825|NCT00670748|9698314|FG002|Overall Study|Not off study|1
6087826|NCT00670748|9698315|FG003|Overall Study|Not off study|1
6087827|NCT00670800|9698331|FG000|Overall Study|2 controls were insulin resistant|0
6087828|NCT00670800|9698332|FG001|Overall Study|2 controls were insulin resistant|2
6087829|NCT00670930|9698342|FG000|Overall Study|Adminstrative Problem|0
6087830|NCT00670930|9698343|FG001|Overall Study|Adminstrative Problem|1
6087831|NCT00670930|9698342|FG000|Overall Study|Lost to Follow-up|1
6087832|NCT00670930|9698343|FG001|Overall Study|Lost to Follow-up|0
6087833|NCT00671034|9698364|FG000|Overall Study|Adverse Event|5
6087834|NCT00671034|9698365|FG001|Overall Study|Adverse Event|7
6193423|NCT01438411|9851111|FG000|Overall Study|Withdrawal by Subject|3
6193424|NCT01438424|9851115|FG000|Overall Study|Continuing treatment|29
6193425|NCT01438424|9851115|FG000|Overall Study|Minimal virologic response|95
6193426|NCT01438424|9851115|FG000|Overall Study|Not identified|55
6193427|NCT01438424|9851115|FG000|Overall Study|Withdrawal by Subject|104
6193428|NCT01438424|9851115|FG000|Overall Study|Progression of chronic hepatitis B|22
6193429|NCT01438424|9851115|FG000|Overall Study|Death|22
6193430|NCT01438424|9851115|FG000|Overall Study|Adverse Event|17
6193431|NCT01438424|9851115|FG000|Overall Study|Lost to Follow-up|17
6193432|NCT01438424|9851115|FG000|Overall Study|Abnormal laboratory test result|14
6193433|NCT01438424|9851115|FG000|Overall Study|Need for drug prohibited by protocol|14
6193434|NCT01438424|9851115|FG000|Overall Study|Pregnancy|7
6193435|NCT01438424|9851115|FG000|Overall Study|No longer met inclusion criteria|1
6193436|NCT01438424|9851115|FG000|Overall Study|Participant noncompliance|20
6193437|NCT01438476|9851131|FG000|Overall Study|Protocol Violation|1
6193438|NCT01438476|9851132|FG001|Overall Study|Protocol Violation|0
6193439|NCT01438476|9851131|FG000|Overall Study|Withdrawal by Subject|1
6193440|NCT01438476|9851132|FG001|Overall Study|Withdrawal by Subject|0
6193441|NCT01438476|9851131|FG000|Overall Study|No Surgery- Disease|8
6193442|NCT01438476|9851132|FG001|Overall Study|No Surgery- Disease|10
6272601|NCT02178592|9975384|FG000|OLE Phase (Week 52 to Week 252)|Lost to Follow-up|3
6272602|NCT02178592|9975385|FG001|OLE Phase (Week 52 to Week 252)|Lost to Follow-up|1
6272603|NCT02178787|9975408|FG000|Overall Study|Lost to Follow-up|1
6272604|NCT02178787|9975409|FG001|Overall Study|Lost to Follow-up|0
6272605|NCT02178787|9975408|FG000|Overall Study|Withdrawal by Subject|0
6272606|NCT02178787|9975409|FG001|Overall Study|Withdrawal by Subject|2
6272607|NCT02178787|9975408|FG000|Overall Study|No TCD window|3
6272608|NCT02178787|9975409|FG001|Overall Study|No TCD window|7
6272609|NCT02178787|9975408|FG000|Overall Study|Physician Decision|1
6272610|NCT02178787|9975409|FG001|Overall Study|Physician Decision|0
6272611|NCT02178995|9975436|FG000|Double Blind|Adverse Event|0
6272612|NCT02178995|9975437|FG001|Double Blind|Adverse Event|0
6272613|NCT02178995|9975438|FG002|Double Blind|Adverse Event|0
6272614|NCT02178995|9975439|FG003|Double Blind|Adverse Event|0
6272615|NCT02178995|9975440|FG004|Double Blind|Adverse Event|0
6272616|NCT02178995|9975441|FG005|Double Blind|Adverse Event|1
6272617|NCT02178995|9975442|FG006|Double Blind|Adverse Event|0
6272618|NCT02178995|9975443|FG007|Double Blind|Adverse Event|1
6272619|NCT02178995|9975444|FG008|Double Blind|Adverse Event|1
6272620|NCT02178995|9975436|FG000|Double Blind|Lost to Follow-up|0
6272621|NCT02178995|9975437|FG001|Double Blind|Lost to Follow-up|1
6272622|NCT02178995|9975438|FG002|Double Blind|Lost to Follow-up|0
6272623|NCT02178995|9975439|FG003|Double Blind|Lost to Follow-up|0
6272624|NCT02178995|9975440|FG004|Double Blind|Lost to Follow-up|0
6272625|NCT02178995|9975441|FG005|Double Blind|Lost to Follow-up|0
6272626|NCT02178995|9975442|FG006|Double Blind|Lost to Follow-up|0
6272627|NCT02178995|9975443|FG007|Double Blind|Lost to Follow-up|1
6272628|NCT02178995|9975444|FG008|Double Blind|Lost to Follow-up|0
6272629|NCT02178995|9975436|FG000|Open Label|Adverse Event|2
6272630|NCT02178995|9975437|FG001|Open Label|Adverse Event|0
6272631|NCT02178995|9975438|FG002|Open Label|Adverse Event|0
6272632|NCT02178995|9975439|FG003|Open Label|Adverse Event|0
6272633|NCT02178995|9975440|FG004|Open Label|Adverse Event|0
6272634|NCT02178995|9975441|FG005|Open Label|Adverse Event|0
6272635|NCT02178995|9975442|FG006|Open Label|Adverse Event|0
6272636|NCT02178995|9975443|FG007|Open Label|Adverse Event|0
6272637|NCT02178995|9975444|FG008|Open Label|Adverse Event|0
6272638|NCT02179177|9975490|FG000|Overall Study|Lost to Follow-up|1
6272639|NCT02179177|9975491|FG001|Overall Study|Lost to Follow-up|1
6272640|NCT02179177|9975490|FG000|Overall Study|Withdrawal by Subject|1
6272641|NCT02179177|9975491|FG001|Overall Study|Withdrawal by Subject|1
6272642|NCT02179190|9975497|FG000|Enrollment|Exit Prior to Device Attempt|11
6272643|NCT02179190|9975497|FG000|Index Procedure With Barrel VRD Attempt|Did not receive Barrel VRD|7
6272644|NCT02179190|9975497|FG000|Follow-Up Post Barrel VRD Implanted|Death|3
6272645|NCT02179190|9975497|FG000|Follow-Up Post Barrel VRD Implanted|Withdrawal by Subject|3
6272646|NCT02179190|9975497|FG000|Follow-Up Post Barrel VRD Implanted|Physician Decision|2
6272647|NCT02179190|9975497|FG000|Follow-Up Post Barrel VRD Implanted|Lost to Follow-up|1
6272648|NCT02179398|9975503|FG000|Overall Study|Lack of obligatory data|3
6272649|NCT02179398|9975504|FG001|Overall Study|Lack of obligatory data|3
6272650|NCT02179398|9975503|FG000|Overall Study|Lost to Follow-up|0
6272651|NCT02179398|9975504|FG001|Overall Study|Lost to Follow-up|1
6272652|NCT02179515|9975535|FG000|Overall Study|switched to alternative treatment|0
6272653|NCT02179515|9975536|FG001|Overall Study|switched to alternative treatment|1
6272654|NCT02179515|9975537|FG002|Overall Study|switched to alternative treatment|1
6272655|NCT02179515|9975535|FG000|Overall Study|Death|0
6272656|NCT02179515|9975536|FG001|Overall Study|Death|1
6272657|NCT02179515|9975537|FG002|Overall Study|Death|1
6272658|NCT02179515|9975535|FG000|Overall Study|refused further treatment|0
6272659|NCT02179515|9975536|FG001|Overall Study|refused further treatment|3
6272660|NCT02179515|9975537|FG002|Overall Study|refused further treatment|4
6272661|NCT02179515|9975535|FG000|Overall Study|Disease progression on study|2
6193443|NCT01438476|9851131|FG000|Overall Study|Communication barrier|0
6193444|NCT01438476|9851132|FG001|Overall Study|Communication barrier|1
6193445|NCT01438489|9851141|FG000|Overall Study|Lost to Follow-up|4
6193446|NCT01438489|9851142|FG001|Overall Study|Lost to Follow-up|2
6193447|NCT01438489|9851143|FG002|Overall Study|Lost to Follow-up|2
6193448|NCT01438489|9851141|FG000|Overall Study|Withdrawal by Subject|11
6193449|NCT01438489|9851142|FG001|Overall Study|Withdrawal by Subject|3
6193450|NCT01438489|9851143|FG002|Overall Study|Withdrawal by Subject|8
6193451|NCT01438489|9851141|FG000|Overall Study|Death|0
6193452|NCT01438489|9851142|FG001|Overall Study|Death|0
6272662|NCT02179515|9975536|FG001|Overall Study|Disease progression on study|11
6272663|NCT02179515|9975537|FG002|Overall Study|Disease progression on study|8
6272664|NCT02179918|9975593|FG000|Overall Study|Death|0
6272665|NCT02179918|9975594|FG001|Overall Study|Death|0
6272666|NCT02179918|9975595|FG002|Overall Study|Death|0
6272667|NCT02179918|9975596|FG003|Overall Study|Death|1
6272668|NCT02179918|9975597|FG004|Overall Study|Death|0
6272669|NCT02179918|9975593|FG000|Overall Study|Lost to Follow-up|0
6272670|NCT02179918|9975594|FG001|Overall Study|Lost to Follow-up|0
6272671|NCT02179918|9975595|FG002|Overall Study|Lost to Follow-up|1
6272672|NCT02179918|9975596|FG003|Overall Study|Lost to Follow-up|0
6193453|NCT01438489|9851143|FG002|Overall Study|Death|1
6193454|NCT01438489|9851141|FG000|Overall Study|Sponsor decision|4
6272673|NCT02179918|9975597|FG004|Overall Study|Lost to Follow-up|0
6272674|NCT02179918|9975593|FG000|Overall Study|Progressive Disease|4
6272675|NCT02179918|9975594|FG001|Overall Study|Progressive Disease|1
6272676|NCT02179918|9975595|FG002|Overall Study|Progressive Disease|1
6272677|NCT02179918|9975596|FG003|Overall Study|Progressive Disease|2
6272678|NCT02179918|9975597|FG004|Overall Study|Progressive Disease|6
6272679|NCT02179918|9975593|FG000|Overall Study|Other|0
6272680|NCT02179918|9975594|FG001|Overall Study|Other|1
6272681|NCT02179918|9975595|FG002|Overall Study|Other|0
6272682|NCT02179918|9975596|FG003|Overall Study|Other|0
6272683|NCT02179918|9975597|FG004|Overall Study|Other|1
6272684|NCT02179918|9975593|FG000|Overall Study|Subject refused further follow-up|0
6272685|NCT02179918|9975594|FG001|Overall Study|Subject refused further follow-up|1
6272686|NCT02179918|9975595|FG002|Overall Study|Subject refused further follow-up|0
6272687|NCT02179918|9975596|FG003|Overall Study|Subject refused further follow-up|0
6272688|NCT02179918|9975597|FG004|Overall Study|Subject refused further follow-up|1
6272689|NCT02180061|9975612|FG000|Overall Study|Adverse Event|4
6272690|NCT02180061|9975613|FG001|Overall Study|Adverse Event|2
6272691|NCT02180061|9975612|FG000|Overall Study|Clinical Progression|5
6193455|NCT01438489|9851142|FG001|Overall Study|Sponsor decision|1
6193456|NCT01438489|9851143|FG002|Overall Study|Sponsor decision|4
5972513|NCT02472964|9558194|FG000|Part 1 (up to Week 24)|Adverse Event|2
5972514|NCT02472964|9558195|FG001|Part 1 (up to Week 24)|Adverse Event|4
5972515|NCT02472964|9558194|FG000|Part 1 (up to Week 24)|disease progression|58
5972516|NCT02472964|9558195|FG001|Part 1 (up to Week 24)|disease progression|47
5972517|NCT02472964|9558194|FG000|Part 1 (up to Week 24)|Death|3
5972518|NCT02472964|9558195|FG001|Part 1 (up to Week 24)|Death|6
5972519|NCT02472964|9558194|FG000|Part 1 (up to Week 24)|Physician Decision|3
5972520|NCT02472964|9558195|FG001|Part 1 (up to Week 24)|Physician Decision|1
5972521|NCT02472964|9558194|FG000|Part 1 (up to Week 24)|Lost to Follow-up|0
5972522|NCT02472964|9558195|FG001|Part 1 (up to Week 24)|Lost to Follow-up|1
5972523|NCT02472964|9558194|FG000|Part 1 (up to Week 24)|Withdrawal by Subject|7
5972524|NCT02472964|9558195|FG001|Part 1 (up to Week 24)|Withdrawal by Subject|2
5972525|NCT02472964|9558194|FG000|Part 1 (up to Week 24)|Other|2
5972526|NCT02472964|9558195|FG001|Part 1 (up to Week 24)|Other|1
5972527|NCT02472964|9558194|FG000|Part 2 (Week 24-week 48)|Adverse Event|4
5972528|NCT02472964|9558195|FG001|Part 2 (Week 24-week 48)|Adverse Event|2
5972529|NCT02472964|9558194|FG000|Part 2 (Week 24-week 48)|Disease Progression|52
5972530|NCT02472964|9558195|FG001|Part 2 (Week 24-week 48)|Disease Progression|56
5972531|NCT02472964|9558194|FG000|Part 2 (Week 24-week 48)|Death|0
5972532|NCT02472964|9558195|FG001|Part 2 (Week 24-week 48)|Death|1
5972533|NCT02472964|9558194|FG000|Part 2 (Week 24-week 48)|Physician Decision|1
5972534|NCT02472964|9558195|FG001|Part 2 (Week 24-week 48)|Physician Decision|1
5972535|NCT02472964|9558194|FG000|Part 2 (Week 24-week 48)|Lost to Follow-up|2
5972536|NCT02472964|9558195|FG001|Part 2 (Week 24-week 48)|Lost to Follow-up|1
6193457|NCT01438489|9851141|FG000|Overall Study|Subject choice/Subject moved|2
6193458|NCT01438489|9851142|FG001|Overall Study|Subject choice/Subject moved|1
6193459|NCT01438489|9851143|FG002|Overall Study|Subject choice/Subject moved|1
6193460|NCT01438489|9851141|FG000|Overall Study|Investigator decision|0
6193461|NCT01438489|9851142|FG001|Overall Study|Investigator decision|1
6193462|NCT01438489|9851143|FG002|Overall Study|Investigator decision|0
6193463|NCT01438489|9851141|FG000|Overall Study|AE/SAEs|2
6193464|NCT01438489|9851142|FG001|Overall Study|AE/SAEs|1
6193465|NCT01438489|9851143|FG002|Overall Study|AE/SAEs|1
6193466|NCT01438489|9851141|FG000|Overall Study|Received prohibited medication|1
6193467|NCT01438489|9851142|FG001|Overall Study|Received prohibited medication|0
6193468|NCT01438489|9851143|FG002|Overall Study|Received prohibited medication|0
6193469|NCT01438489|9851141|FG000|Overall Study|Did not complete all 3 follow-up visits|2
6193470|NCT01438489|9851142|FG001|Overall Study|Did not complete all 3 follow-up visits|5
6193471|NCT01438489|9851143|FG002|Overall Study|Did not complete all 3 follow-up visits|2
6193472|NCT01438489|9851141|FG000|Overall Study|Inadequate venous access|0
6193473|NCT01438489|9851142|FG001|Overall Study|Inadequate venous access|2
6193474|NCT01438489|9851143|FG002|Overall Study|Inadequate venous access|0
6193475|NCT01438541|9851153|FG000|Overall Study|Physician Decision|1
6193476|NCT01438541|9851153|FG000|Overall Study|Withdrawal by Subject|1
6193477|NCT01438541|9851153|FG000|Overall Study|discharge from the hospital|5
6193478|NCT01438814|9851165|FG000|Overall Study|Adverse Event|3
6193479|NCT01438814|9851166|FG001|Overall Study|Adverse Event|3
6193480|NCT01438814|9851165|FG000|Overall Study|Protocol Violation|1
6193481|NCT01438814|9851166|FG001|Overall Study|Protocol Violation|2
6193482|NCT01438814|9851165|FG000|Overall Study|Lost to Follow-up|4
6193483|NCT01438814|9851166|FG001|Overall Study|Lost to Follow-up|3
6193484|NCT01438814|9851165|FG000|Overall Study|Withdrawal by Subject|4
6193485|NCT01438814|9851166|FG001|Overall Study|Withdrawal by Subject|2
6193486|NCT01438814|9851165|FG000|Overall Study|Other|2
6193487|NCT01438814|9851166|FG001|Overall Study|Other|4
6193488|NCT01438840|9851174|FG000|Core Study|Adverse Event|0
6193489|NCT01438840|9851175|FG001|Core Study|Adverse Event|3
6193490|NCT01438840|9851176|FG002|Core Study|Adverse Event|0
6193491|NCT01438840|9851174|FG000|Core Study|Lack of Efficacy|15
6193492|NCT01438840|9851175|FG001|Core Study|Lack of Efficacy|7
6193493|NCT01438840|9851176|FG002|Core Study|Lack of Efficacy|0
6193494|NCT01438840|9851174|FG000|Core Study|Withdrawal of consent|1
6193495|NCT01438840|9851175|FG001|Core Study|Withdrawal of consent|0
6272692|NCT02180061|9975613|FG001|Overall Study|Clinical Progression|1
6272693|NCT02180061|9975612|FG000|Overall Study|Progressive Disease|15
6272694|NCT02180061|9975613|FG001|Overall Study|Progressive Disease|5
6272695|NCT02180061|9975612|FG000|Overall Study|Physician Decision|1
6272696|NCT02180061|9975613|FG001|Overall Study|Physician Decision|0
6272697|NCT02180165|9975632|FG000|Overall Study|Not Treated|0
6272698|NCT02180165|9975633|FG001|Overall Study|Not Treated|0
6272699|NCT02180165|9975634|FG002|Overall Study|Not Treated|1
6272700|NCT02180165|9975635|FG003|Overall Study|Not Treated|0
6272701|NCT02180165|9975632|FG000|Overall Study|Adverse Event|7
6272702|NCT02180165|9975633|FG001|Overall Study|Adverse Event|0
6272703|NCT02180165|9975634|FG002|Overall Study|Adverse Event|18
6272704|NCT02180165|9975635|FG003|Overall Study|Adverse Event|3
5972537|NCT02472964|9558194|FG000|Part 2 (Week 24-week 48)|Withdrawal by Subject|3
5972538|NCT02472964|9558195|FG001|Part 2 (Week 24-week 48)|Withdrawal by Subject|1
5972539|NCT02472964|9558194|FG000|Part 2 (Week 24-week 48)|Protocol Violation|3
5972540|NCT02472964|9558195|FG001|Part 2 (Week 24-week 48)|Protocol Violation|1
5972541|NCT02178722|9558206|FG000|Overall Study|Withdrawal by Subject|0
5972542|NCT02178722|9558207|FG001|Overall Study|Withdrawal by Subject|0
5972543|NCT02178722|9558208|FG002|Overall Study|Withdrawal by Subject|0
5972544|NCT02178722|9558209|FG003|Overall Study|Withdrawal by Subject|2
5972545|NCT02178722|9558210|FG004|Overall Study|Withdrawal by Subject|33
5972546|NCT02178722|9558206|FG000|Overall Study|Death|2
5972547|NCT02178722|9558207|FG001|Overall Study|Death|13
5972548|NCT02178722|9558208|FG002|Overall Study|Death|12
5972549|NCT02178722|9558209|FG003|Overall Study|Death|12
5972550|NCT02178722|9558210|FG004|Overall Study|Death|205
5972551|NCT02178722|9558206|FG000|Overall Study|Lost to Follow-up|0
5972552|NCT02178722|9558207|FG001|Overall Study|Lost to Follow-up|0
5972553|NCT02178722|9558208|FG002|Overall Study|Lost to Follow-up|0
5972554|NCT02178722|9558209|FG003|Overall Study|Lost to Follow-up|2
5972555|NCT02178722|9558210|FG004|Overall Study|Lost to Follow-up|11
5972556|NCT02178722|9558206|FG000|Overall Study|Study terminated by Sponsor|2
5972557|NCT02178722|9558207|FG001|Overall Study|Study terminated by Sponsor|7
5972558|NCT02178722|9558208|FG002|Overall Study|Study terminated by Sponsor|6
5972559|NCT02178722|9558209|FG003|Overall Study|Study terminated by Sponsor|4
5972560|NCT02178722|9558210|FG004|Overall Study|Study terminated by Sponsor|128
5972561|NCT02178722|9558206|FG000|Overall Study|Physician Decision|0
5972562|NCT02178722|9558207|FG001|Overall Study|Physician Decision|0
5972563|NCT02178722|9558208|FG002|Overall Study|Physician Decision|0
5972564|NCT02178722|9558209|FG003|Overall Study|Physician Decision|0
5972565|NCT02178722|9558210|FG004|Overall Study|Physician Decision|3
5972566|NCT02178722|9558206|FG000|Overall Study|Other|0
5972567|NCT02178722|9558207|FG001|Overall Study|Other|0
6049119|NCT00421707|9648358|FG000|Period 1: Treatment Period 1|Withdrawal by Subject|1
6049120|NCT00421707|9648359|FG001|Period 1: Treatment Period 1|Withdrawal by Subject|5
6049121|NCT00421707|9648358|FG000|Period 1: Treatment Period 1|Adverse Event|7
6049122|NCT00421707|9648359|FG001|Period 1: Treatment Period 1|Adverse Event|2
6049123|NCT00421707|9648358|FG000|Period 1: Treatment Period 1|Lost to Follow-up|2
6049124|NCT00421707|9648359|FG001|Period 1: Treatment Period 1|Lost to Follow-up|2
6049125|NCT00421707|9648358|FG000|Period 1: Treatment Period 1|Protocol Violation|1
6049126|NCT00421707|9648359|FG001|Period 1: Treatment Period 1|Protocol Violation|0
6049127|NCT00421707|9648358|FG000|Period 2: Washout|Adverse Event|1
6049128|NCT00421707|9648359|FG001|Period 2: Washout|Adverse Event|1
6049129|NCT00421707|9648358|FG000|Period 2: Washout|Withdrawal by Subject|0
6049130|NCT00421707|9648359|FG001|Period 2: Washout|Withdrawal by Subject|1
6049131|NCT00421707|9648358|FG000|Period 2: Washout|Lost to Follow-up|0
6049132|NCT00421707|9648359|FG001|Period 2: Washout|Lost to Follow-up|1
6049133|NCT00421707|9648358|FG000|Period 2: Washout|Other: Pregnancy|0
6049134|NCT00421707|9648359|FG001|Period 2: Washout|Other: Pregnancy|1
6049135|NCT00421707|9648358|FG000|Period 3:Treatment Period 2|Withdrawal by Subject|1
6049136|NCT00421707|9648359|FG001|Period 3:Treatment Period 2|Withdrawal by Subject|1
6049137|NCT00421707|9648358|FG000|Period 3:Treatment Period 2|Protocol Violation|1
6049138|NCT00421707|9648359|FG001|Period 3:Treatment Period 2|Protocol Violation|0
6049139|NCT00421707|9648358|FG000|Period 3:Treatment Period 2|Adverse Event|0
6049140|NCT00421707|9648359|FG001|Period 3:Treatment Period 2|Adverse Event|2
6049141|NCT00421733|9648371|FG000|Overall Study|Adverse Event|4
6049142|NCT00421733|9648372|FG001|Overall Study|Adverse Event|9
6049143|NCT00421733|9648373|FG002|Overall Study|Adverse Event|2
6049144|NCT00421733|9648371|FG000|Overall Study|Lost to Follow-up|1
6049145|NCT00421733|9648372|FG001|Overall Study|Lost to Follow-up|2
6049146|NCT00421733|9648373|FG002|Overall Study|Lost to Follow-up|4
6272705|NCT02180165|9975632|FG000|Overall Study|Lack of Efficacy|0
6272706|NCT02180165|9975633|FG001|Overall Study|Lack of Efficacy|1
6272707|NCT02180165|9975634|FG002|Overall Study|Lack of Efficacy|3
6272708|NCT02180165|9975635|FG003|Overall Study|Lack of Efficacy|2
6272709|NCT02180165|9975632|FG000|Overall Study|Physician Decision|1
6272710|NCT02180165|9975633|FG001|Overall Study|Physician Decision|0
5972568|NCT02178722|9558208|FG002|Overall Study|Other|0
6049147|NCT00421733|9648371|FG000|Overall Study|Withdrawal by Subject|1
6049148|NCT00421733|9648372|FG001|Overall Study|Withdrawal by Subject|2
6049149|NCT00421733|9648373|FG002|Overall Study|Withdrawal by Subject|7
6049150|NCT00421733|9648371|FG000|Overall Study|Death|0
6272711|NCT02180165|9975634|FG002|Overall Study|Physician Decision|5
6272712|NCT02180165|9975635|FG003|Overall Study|Physician Decision|0
6272713|NCT02180165|9975632|FG000|Overall Study|Withdrawal by Subject|3
6272714|NCT02180165|9975633|FG001|Overall Study|Withdrawal by Subject|0
6272715|NCT02180165|9975634|FG002|Overall Study|Withdrawal by Subject|2
6272716|NCT02180165|9975635|FG003|Overall Study|Withdrawal by Subject|1
6272717|NCT02180438|9975651|FG000|Overall Study|Lost to Follow-up|1
6272718|NCT02180659|9975668|FG000|Overall Study|Adverse Event|1
6272719|NCT02180659|9975669|FG001|Overall Study|Adverse Event|0
6272720|NCT02180659|9975668|FG000|Overall Study|Lost to Follow-up|4
6272721|NCT02180659|9975669|FG001|Overall Study|Lost to Follow-up|2
6272722|NCT02180659|9975668|FG000|Overall Study|Subject incarcerated during conduct|1
6272723|NCT02180659|9975669|FG001|Overall Study|Subject incarcerated during conduct|0
6272724|NCT02180659|9975668|FG000|Overall Study|Withdrawal by Subject|0
6272725|NCT02180659|9975669|FG001|Overall Study|Withdrawal by Subject|2
6272726|NCT02180659|9975668|FG000|Overall Study|AT REQUEST OF THE SPONSOR|0
6272727|NCT02180659|9975669|FG001|Overall Study|AT REQUEST OF THE SPONSOR|1
6272728|NCT02180672|9975677|FG000|Overall Study|Lost to Follow-up|5
6272729|NCT02180672|9975678|FG001|Overall Study|Lost to Follow-up|7
6272730|NCT02181296|9975739|FG000|Overall Study|Lost to Follow-up|7
6272731|NCT02181296|9975740|FG001|Overall Study|Lost to Follow-up|6
6272732|NCT02181504|9975788|FG000|Overall Study|Adverse Event|1
6272733|NCT02181504|9975789|FG001|Overall Study|Adverse Event|1
6272734|NCT02181504|9975790|FG002|Overall Study|Adverse Event|1
6272735|NCT02181556|9975816|FG000|Overall Study|Withdrawal by Subject|1
6272736|NCT02181634|9975820|FG000|Overall Study|Lack of Efficacy|33
6272737|NCT02181634|9975820|FG000|Overall Study|Adverse Event|17
6272738|NCT02181634|9975820|FG000|Overall Study|Physician Decision|8
6272739|NCT02181634|9975820|FG000|Overall Study|Withdrawal by Subject|5
6272740|NCT02181634|9975820|FG000|Overall Study|Death|2
6272741|NCT02181634|9975820|FG000|Overall Study|Treatment delayed greater than 4 weeks|3
6272742|NCT02181634|9975820|FG000|Overall Study|Ineligible|1
6272743|NCT02181634|9975820|FG000|Overall Study|Max number of dose reduction|1
6272744|NCT02181634|9975820|FG000|Overall Study|Symptomatic progression|1
6272745|NCT02181634|9975820|FG000|Overall Study|Patient opted to proceed to surgery|1
6272746|NCT02181673|9975826|FG000|Up to Week 24|Adverse Event|2
6272747|NCT02181673|9975827|FG001|Up to Week 24|Adverse Event|0
6272748|NCT02181673|9975828|FG002|Up to Week 24|Adverse Event|3
6272749|NCT02181673|9975826|FG000|Up to Week 24|Death|1
6272750|NCT02181673|9975827|FG001|Up to Week 24|Death|0
6272751|NCT02181673|9975828|FG002|Up to Week 24|Death|0
6272752|NCT02181673|9975826|FG000|Up to Week 24|Lack of Efficacy|1
6272753|NCT02181673|9975827|FG001|Up to Week 24|Lack of Efficacy|0
6272754|NCT02181673|9975828|FG002|Up to Week 24|Lack of Efficacy|0
6272755|NCT02181673|9975826|FG000|Up to Week 24|Lost to Follow-up|1
6272756|NCT02181673|9975827|FG001|Up to Week 24|Lost to Follow-up|0
6272757|NCT02181673|9975828|FG002|Up to Week 24|Lost to Follow-up|0
6272758|NCT02181673|9975826|FG000|Up to Week 24|Physician Decision|0
6272759|NCT02181673|9975827|FG001|Up to Week 24|Physician Decision|0
6272760|NCT02181673|9975828|FG002|Up to Week 24|Physician Decision|3
6272761|NCT02181673|9975826|FG000|Up to Week 24|Withdrawal by Subject|10
6272762|NCT02181673|9975827|FG001|Up to Week 24|Withdrawal by Subject|0
6272763|NCT02181673|9975828|FG002|Up to Week 24|Withdrawal by Subject|1
6272764|NCT02181673|9975826|FG000|Up to Week 24|Other|2
6272765|NCT02181673|9975827|FG001|Up to Week 24|Other|0
6272766|NCT02181673|9975828|FG002|Up to Week 24|Other|3
6272767|NCT02181673|9975826|FG000|Up to Week 24|Randomized not Treated|0
6272768|NCT02181673|9975827|FG001|Up to Week 24|Randomized not Treated|0
6272769|NCT02181673|9975828|FG002|Up to Week 24|Randomized not Treated|1
6272770|NCT02181673|9975826|FG000|Week 24-Week 60|Adverse Event|0
6272771|NCT02181673|9975827|FG001|Week 24-Week 60|Adverse Event|4
6272772|NCT02181673|9975828|FG002|Week 24-Week 60|Adverse Event|10
6272773|NCT02181673|9975826|FG000|Week 24-Week 60|Other|0
6272774|NCT02181673|9975827|FG001|Week 24-Week 60|Other|2
6272775|NCT02181673|9975828|FG002|Week 24-Week 60|Other|1
6272776|NCT02181673|9975826|FG000|Week 24-Week 60|Withdrawal by Subject|0
6272777|NCT02181673|9975827|FG001|Week 24-Week 60|Withdrawal by Subject|2
6272778|NCT02181673|9975828|FG002|Week 24-Week 60|Withdrawal by Subject|2
6272779|NCT02181673|9975826|FG000|Week 24-Week 60|Pregnancy|0
6272780|NCT02181673|9975827|FG001|Week 24-Week 60|Pregnancy|0
6272781|NCT02181673|9975828|FG002|Week 24-Week 60|Pregnancy|1
6272782|NCT02181673|9975826|FG000|Week 24-Week 60|Lack of Efficacy|0
6272783|NCT02181673|9975827|FG001|Week 24-Week 60|Lack of Efficacy|0
6272784|NCT02181673|9975828|FG002|Week 24-Week 60|Lack of Efficacy|1
6272785|NCT02181673|9975826|FG000|Week 24-Week 60|Lost to Follow-up|0
6272786|NCT02181673|9975827|FG001|Week 24-Week 60|Lost to Follow-up|0
6272787|NCT02181673|9975828|FG002|Week 24-Week 60|Lost to Follow-up|1
6272788|NCT02181673|9975826|FG000|Week 24-Week 60|Physician Decision|0
6272789|NCT02181673|9975827|FG001|Week 24-Week 60|Physician Decision|0
6272790|NCT02181673|9975828|FG002|Week 24-Week 60|Physician Decision|1
6272791|NCT02181738|9975839|FG000|Overall Study|Death|1
6272792|NCT02181738|9975840|FG001|Overall Study|Death|1
6272793|NCT02181738|9975841|FG002|Overall Study|Death|6
6272794|NCT02181738|9975842|FG003|Overall Study|Death|1
6272795|NCT02181738|9975839|FG000|Overall Study|Subject Withdrew Consent|1
6272796|NCT02181738|9975840|FG001|Overall Study|Subject Withdrew Consent|3
6272797|NCT02181738|9975841|FG002|Overall Study|Subject Withdrew Consent|2
6272798|NCT02181738|9975842|FG003|Overall Study|Subject Withdrew Consent|1
6272799|NCT02181738|9975839|FG000|Overall Study|Lost to Follow-up|0
6272800|NCT02181738|9975840|FG001|Overall Study|Lost to Follow-up|4
6272801|NCT02181738|9975841|FG002|Overall Study|Lost to Follow-up|2
6272802|NCT02181738|9975842|FG003|Overall Study|Lost to Follow-up|0
6087835|NCT00671034|9698366|FG002|Overall Study|Adverse Event|1
6087836|NCT00671034|9698364|FG000|Overall Study|Death|3
6087837|NCT00671034|9698365|FG001|Overall Study|Death|2
6087838|NCT00671034|9698366|FG002|Overall Study|Death|1
6087839|NCT00671034|9698364|FG000|Overall Study|Physician Decision|12
6087840|NCT00671034|9698365|FG001|Overall Study|Physician Decision|4
6087841|NCT00671034|9698366|FG002|Overall Study|Physician Decision|5
6087842|NCT00671034|9698364|FG000|Overall Study|VHR ALL feature|8
6087843|NCT00671034|9698365|FG001|Overall Study|VHR ALL feature|3
6087844|NCT00671034|9698366|FG002|Overall Study|VHR ALL feature|5
6087845|NCT00671034|9698364|FG000|Overall Study|Refusal|5
6272803|NCT02181738|9975839|FG000|Overall Study|Patient Return to Home Country|0
6272804|NCT02181738|9975840|FG001|Overall Study|Patient Return to Home Country|1
6272805|NCT02181738|9975841|FG002|Overall Study|Patient Return to Home Country|0
6272806|NCT02181738|9975842|FG003|Overall Study|Patient Return to Home Country|0
6272807|NCT02181803|9975861|FG000|Overall Study|Withdrawal by Subject|0
6272808|NCT02181803|9975862|FG001|Overall Study|Withdrawal by Subject|2
6272809|NCT02181803|9975863|FG002|Overall Study|Withdrawal by Subject|0
6272810|NCT02181803|9975864|FG003|Overall Study|Withdrawal by Subject|0
6272811|NCT02181803|9975865|FG004|Overall Study|Withdrawal by Subject|0
6272812|NCT02181803|9975866|FG005|Overall Study|Withdrawal by Subject|0
6272813|NCT02181803|9975867|FG006|Overall Study|Withdrawal by Subject|0
6272814|NCT02181803|9975868|FG007|Overall Study|Withdrawal by Subject|0
6272815|NCT02181803|9975869|FG008|Overall Study|Withdrawal by Subject|0
6272816|NCT02181803|9975861|FG000|Overall Study|Physician Decision|0
6272817|NCT02181803|9975862|FG001|Overall Study|Physician Decision|0
6272818|NCT02181803|9975863|FG002|Overall Study|Physician Decision|0
6272819|NCT02181803|9975864|FG003|Overall Study|Physician Decision|1
5972569|NCT02178722|9558209|FG003|Overall Study|Other|0
5972570|NCT02178722|9558210|FG004|Overall Study|Other|2
5972571|NCT01258803|9558225|FG000|Treatment Period 2 (1 Dose)|Protocol Violation|1
5972572|NCT01258803|9558226|FG001|Treatment Period 2 (1 Dose)|Protocol Violation|1
5972573|NCT01258803|9558227|FG002|Treatment Period 2 (1 Dose)|Protocol Violation|0
5972574|NCT01258803|9558228|FG003|Treatment Period 2 (1 Dose)|Protocol Violation|0
5972575|NCT01258803|9558229|FG004|Treatment Period 2 (1 Dose)|Protocol Violation|0
5972576|NCT01258803|9558230|FG005|Treatment Period 2 (1 Dose)|Protocol Violation|1
5972577|NCT01258803|9558225|FG000|Treatment Period 2 (1 Dose)|Withdrawal by Subject|0
5972578|NCT01258803|9558226|FG001|Treatment Period 2 (1 Dose)|Withdrawal by Subject|1
5972579|NCT01258803|9558227|FG002|Treatment Period 2 (1 Dose)|Withdrawal by Subject|0
5972580|NCT01258803|9558228|FG003|Treatment Period 2 (1 Dose)|Withdrawal by Subject|0
5972581|NCT01258803|9558229|FG004|Treatment Period 2 (1 Dose)|Withdrawal by Subject|0
5972582|NCT01258803|9558230|FG005|Treatment Period 2 (1 Dose)|Withdrawal by Subject|0
5972583|NCT01258803|9558225|FG000|Treatment Period 3 (1 Dose)|Protocol Violation|0
5972584|NCT01258803|9558226|FG001|Treatment Period 3 (1 Dose)|Protocol Violation|0
6087846|NCT00671034|9698365|FG001|Overall Study|Refusal|3
6087847|NCT00671034|9698366|FG002|Overall Study|Refusal|5
6193496|NCT01438840|9851176|FG002|Core Study|Withdrawal of consent|0
6193497|NCT01438840|9851174|FG000|Extension Phase|Adverse Event|0
6193498|NCT01438840|9851175|FG001|Extension Phase|Adverse Event|0
6193499|NCT01438840|9851176|FG002|Extension Phase|Adverse Event|3
6193500|NCT01438840|9851174|FG000|Extension Phase|Lost to Follow-up|0
6193501|NCT01438840|9851175|FG001|Extension Phase|Lost to Follow-up|0
6193502|NCT01438840|9851176|FG002|Extension Phase|Lost to Follow-up|1
6193503|NCT01438840|9851174|FG000|Extension Phase|Withdrawal by Subject|0
6193504|NCT01438840|9851175|FG001|Extension Phase|Withdrawal by Subject|0
6193505|NCT01438840|9851176|FG002|Extension Phase|Withdrawal by Subject|3
6193506|NCT01438840|9851174|FG000|Extension Phase|Lack of Efficacy|0
6193507|NCT01438840|9851175|FG001|Extension Phase|Lack of Efficacy|0
6193508|NCT01438840|9851176|FG002|Extension Phase|Lack of Efficacy|2
6193509|NCT01438840|9851174|FG000|Extension Phase|Other|0
6193510|NCT01438840|9851175|FG001|Extension Phase|Other|0
6193511|NCT01438840|9851176|FG002|Extension Phase|Other|1
6193512|NCT01438957|9851188|FG000|Overall Study|Physician Decision|1
6193513|NCT01438957|9851189|FG001|Overall Study|Physician Decision|1
6193514|NCT01438957|9851190|FG002|Overall Study|Physician Decision|0
6193515|NCT01438957|9851191|FG003|Overall Study|Physician Decision|1
6193516|NCT01438957|9851192|FG004|Overall Study|Physician Decision|0
6272820|NCT02181803|9975865|FG004|Overall Study|Physician Decision|0
6272821|NCT02181803|9975866|FG005|Overall Study|Physician Decision|0
6272822|NCT02181803|9975867|FG006|Overall Study|Physician Decision|0
6193517|NCT01438996|9851207|FG000|Overall Study|Not meeting Inclusion Criteria|4
6193518|NCT01438996|9851208|FG001|Overall Study|Not meeting Inclusion Criteria|1
6193519|NCT01438996|9851209|FG002|Overall Study|Not meeting Inclusion Criteria|0
6193520|NCT01439009|9851219|FG000|Overall Study|Physician Decision|5
6272823|NCT02181803|9975868|FG007|Overall Study|Physician Decision|1
6272824|NCT02181803|9975869|FG008|Overall Study|Physician Decision|0
6272825|NCT02181803|9975861|FG000|Overall Study|Adverse Event|0
6272826|NCT02181803|9975862|FG001|Overall Study|Adverse Event|2
6272827|NCT02181803|9975863|FG002|Overall Study|Adverse Event|0
6272828|NCT02181803|9975864|FG003|Overall Study|Adverse Event|1
6272829|NCT02181803|9975865|FG004|Overall Study|Adverse Event|0
6272830|NCT02181803|9975866|FG005|Overall Study|Adverse Event|0
6272831|NCT02181803|9975867|FG006|Overall Study|Adverse Event|1
6272832|NCT02181803|9975868|FG007|Overall Study|Adverse Event|0
6272833|NCT02181803|9975869|FG008|Overall Study|Adverse Event|0
6272834|NCT02181816|9975914|FG000|Overall Study|Case Report Forms Uncollected|38
5972585|NCT01258803|9558227|FG002|Treatment Period 3 (1 Dose)|Protocol Violation|1
5972586|NCT01258803|9558228|FG003|Treatment Period 3 (1 Dose)|Protocol Violation|0
5972587|NCT01258803|9558229|FG004|Treatment Period 3 (1 Dose)|Protocol Violation|0
5972588|NCT01258803|9558230|FG005|Treatment Period 3 (1 Dose)|Protocol Violation|0
5972589|NCT00862251|9558251|FG000|Overall Study|Adverse Event|8
5972590|NCT00862251|9558252|FG001|Overall Study|Adverse Event|3
5972591|NCT00862251|9558253|FG002|Overall Study|Adverse Event|1
5972592|NCT00862251|9558251|FG000|Overall Study|Lost to Follow-up|0
5972593|NCT00862251|9558252|FG001|Overall Study|Lost to Follow-up|0
5972594|NCT00862251|9558253|FG002|Overall Study|Lost to Follow-up|1
5972595|NCT00862251|9558251|FG000|Overall Study|Protocol Violation|2
5972596|NCT00862251|9558252|FG001|Overall Study|Protocol Violation|0
5972597|NCT00862251|9558253|FG002|Overall Study|Protocol Violation|1
5972598|NCT00862251|9558251|FG000|Overall Study|Withdrawal by Subject|9
5972599|NCT00862251|9558252|FG001|Overall Study|Withdrawal by Subject|2
5972600|NCT00862251|9558253|FG002|Overall Study|Withdrawal by Subject|6
5972601|NCT00783263|9558268|FG000|Overall Study|Adverse Event|3
5972602|NCT00783263|9558269|FG001|Overall Study|Adverse Event|0
5972603|NCT00783263|9558270|FG002|Overall Study|Adverse Event|2
5972604|NCT00783263|9558271|FG003|Overall Study|Adverse Event|1
5972605|NCT00783263|9558268|FG000|Overall Study|Lost to Follow-up|1
5972606|NCT00783263|9558269|FG001|Overall Study|Lost to Follow-up|1
5972607|NCT00783263|9558270|FG002|Overall Study|Lost to Follow-up|0
5972608|NCT00783263|9558271|FG003|Overall Study|Lost to Follow-up|0
5972609|NCT00783263|9558268|FG000|Overall Study|Withdrawal by Subject|0
5972610|NCT00783263|9558269|FG001|Overall Study|Withdrawal by Subject|1
5972611|NCT00783263|9558270|FG002|Overall Study|Withdrawal by Subject|1
5972612|NCT00783263|9558271|FG003|Overall Study|Withdrawal by Subject|2
5972613|NCT00782184|9558296|FG000|Overall Study|Adverse Event|1
5972614|NCT00782184|9558297|FG001|Overall Study|Adverse Event|2
5972615|NCT00782184|9558296|FG000|Overall Study|Protocol Violation|0
5972616|NCT00782184|9558297|FG001|Overall Study|Protocol Violation|1
5972617|NCT00782184|9558296|FG000|Overall Study|Withdrawal by Subject|3
5972618|NCT00782184|9558297|FG001|Overall Study|Withdrawal by Subject|2
5972619|NCT00635882|9558310|FG000|Overall Study|Protocol Violation|1
5972620|NCT00635882|9558311|FG001|Overall Study|Protocol Violation|0
5972621|NCT00635882|9558312|FG002|Overall Study|Protocol Violation|0
5972622|NCT00635882|9558313|FG003|Overall Study|Protocol Violation|0
5972623|NCT00635882|9558314|FG004|Overall Study|Protocol Violation|0
5972624|NCT00635882|9558315|FG005|Overall Study|Protocol Violation|0
5972625|NCT00535405|9558343|FG000|Overall Study|Adverse Event|6
5972626|NCT00535405|9558344|FG001|Overall Study|Adverse Event|8
5972627|NCT00535405|9558345|FG002|Overall Study|Adverse Event|3
5972628|NCT00535405|9558346|FG003|Overall Study|Adverse Event|8
5972629|NCT00535405|9558347|FG004|Overall Study|Adverse Event|6
5972630|NCT00535405|9558343|FG000|Overall Study|Lost to Follow-up|1
5972631|NCT00535405|9558344|FG001|Overall Study|Lost to Follow-up|3
5972632|NCT00535405|9558345|FG002|Overall Study|Lost to Follow-up|3
5972633|NCT00535405|9558346|FG003|Overall Study|Lost to Follow-up|2
5972634|NCT00535405|9558347|FG004|Overall Study|Lost to Follow-up|1
5972635|NCT00535405|9558343|FG000|Overall Study|Physician Decision|3
5972636|NCT00535405|9558344|FG001|Overall Study|Physician Decision|2
5972637|NCT00535405|9558345|FG002|Overall Study|Physician Decision|0
5972638|NCT00535405|9558346|FG003|Overall Study|Physician Decision|1
5972639|NCT00535405|9558347|FG004|Overall Study|Physician Decision|1
5972640|NCT00535405|9558343|FG000|Overall Study|Protocol Violation|2
5972641|NCT00535405|9558344|FG001|Overall Study|Protocol Violation|2
5972642|NCT00535405|9558345|FG002|Overall Study|Protocol Violation|2
6272835|NCT02181816|9975914|FG000|Overall Study|Protocol Deviation|21
6272836|NCT02181842|9975922|FG000|Overall Study|Case Report Forms Uncollected|2
6272837|NCT02182440|9975939|FG000|Overall Study|Adverse Event|0
6272838|NCT02182440|9975940|FG001|Overall Study|Adverse Event|1
6272839|NCT02182440|9975941|FG002|Overall Study|Adverse Event|0
6272840|NCT02182440|9975942|FG003|Overall Study|Adverse Event|0
6272841|NCT02182440|9975939|FG000|Overall Study|Death|31
6272842|NCT02182440|9975940|FG001|Overall Study|Death|8
6272843|NCT02182440|9975941|FG002|Overall Study|Death|5
6272844|NCT02182440|9975942|FG003|Overall Study|Death|16
6272845|NCT02182440|9975939|FG000|Overall Study|Protocol Violation|0
6272846|NCT02182440|9975940|FG001|Overall Study|Protocol Violation|1
6272847|NCT02182440|9975941|FG002|Overall Study|Protocol Violation|0
6272848|NCT02182440|9975942|FG003|Overall Study|Protocol Violation|0
6272849|NCT02182440|9975939|FG000|Overall Study|Physician Decision|1
6272850|NCT02182440|9975940|FG001|Overall Study|Physician Decision|0
6272851|NCT02182440|9975941|FG002|Overall Study|Physician Decision|0
6272852|NCT02182440|9975942|FG003|Overall Study|Physician Decision|0
6272853|NCT02182440|9975939|FG000|Overall Study|Withdrawal by Subject|1
6272854|NCT02182440|9975940|FG001|Overall Study|Withdrawal by Subject|1
6272855|NCT02182440|9975941|FG002|Overall Study|Withdrawal by Subject|3
6272856|NCT02182440|9975942|FG003|Overall Study|Withdrawal by Subject|4
6272857|NCT02182440|9975939|FG000|Overall Study|different, e.g adm other hospital|12
6272858|NCT02182440|9975940|FG001|Overall Study|different, e.g adm other hospital|3
6272859|NCT02182440|9975941|FG002|Overall Study|different, e.g adm other hospital|3
6272860|NCT02182440|9975942|FG003|Overall Study|different, e.g adm other hospital|10
6272861|NCT02182830|9975969|FG000|Overall Study|Not Treated|1
6272862|NCT02182830|9975970|FG001|Overall Study|Not Treated|1
6272863|NCT02182830|9975969|FG000|Overall Study|Trial stopped, reason missing|3
6272864|NCT02182830|9975970|FG001|Overall Study|Trial stopped, reason missing|3
6272865|NCT02182830|9975969|FG000|Overall Study|Consent withdrawn|8
6272866|NCT02182830|9975970|FG001|Overall Study|Consent withdrawn|8
5972643|NCT00535405|9558346|FG003|Overall Study|Protocol Violation|1
5972644|NCT00535405|9558347|FG004|Overall Study|Protocol Violation|0
5972645|NCT00535405|9558343|FG000|Overall Study|Withdrawal by Subject|5
5972646|NCT00535405|9558344|FG001|Overall Study|Withdrawal by Subject|11
5972647|NCT00535405|9558345|FG002|Overall Study|Withdrawal by Subject|10
5972648|NCT00535405|9558346|FG003|Overall Study|Withdrawal by Subject|10
5972649|NCT00535405|9558347|FG004|Overall Study|Withdrawal by Subject|8
5972650|NCT00496730|9558361|FG000|Overall Study|Lost to Follow-up|4
5972651|NCT00496730|9558362|FG001|Overall Study|Lost to Follow-up|3
5972652|NCT00496730|9558361|FG000|Overall Study|Withdrawal by Subject|2
5972653|NCT00496730|9558362|FG001|Overall Study|Withdrawal by Subject|2
5972654|NCT00462748|9558371|FG000|Overall Study|Adverse Event|7
5972655|NCT00462748|9558372|FG001|Overall Study|Adverse Event|5
5972656|NCT00462748|9558373|FG002|Overall Study|Adverse Event|9
5972657|NCT00462748|9558371|FG000|Overall Study|Protocol Violation|0
5972658|NCT00462748|9558372|FG001|Overall Study|Protocol Violation|2
5972659|NCT00462748|9558373|FG002|Overall Study|Protocol Violation|1
5972660|NCT00462748|9558371|FG000|Overall Study|Withdrew consent|3
5972661|NCT00462748|9558372|FG001|Overall Study|Withdrew consent|3
5972662|NCT00462748|9558373|FG002|Overall Study|Withdrew consent|0
5972663|NCT00462748|9558371|FG000|Overall Study|Lost to Follow-up|1
5972664|NCT00462748|9558372|FG001|Overall Study|Lost to Follow-up|1
5972665|NCT00462748|9558373|FG002|Overall Study|Lost to Follow-up|1
5972666|NCT00462748|9558371|FG000|Overall Study|Discontinued after 41 days Rx|1
5972667|NCT00462748|9558372|FG001|Overall Study|Discontinued after 41 days Rx|0
5972668|NCT00462748|9558373|FG002|Overall Study|Discontinued after 41 days Rx|0
5972669|NCT00418834|9558383|FG000|Overall Study|Adverse Event|16
5972670|NCT00418834|9558384|FG001|Overall Study|Adverse Event|9
5972671|NCT00418834|9558383|FG000|Overall Study|Lost to Follow-up|0
5972672|NCT00418834|9558384|FG001|Overall Study|Lost to Follow-up|1
5972673|NCT00418834|9558383|FG000|Overall Study|Protocol Violation|4
5972674|NCT00418834|9558384|FG001|Overall Study|Protocol Violation|3
5972675|NCT00418834|9558383|FG000|Overall Study|Withdrawal by Subject|3
5972676|NCT00418834|9558384|FG001|Overall Study|Withdrawal by Subject|7
5972677|NCT00409773|9558395|FG000|Overall Study|Adverse Event|3
5972678|NCT00409773|9558396|FG001|Overall Study|Adverse Event|4
5972679|NCT00409773|9558397|FG002|Overall Study|Adverse Event|4
5972680|NCT00409773|9558398|FG003|Overall Study|Adverse Event|2
5972681|NCT00409773|9558399|FG004|Overall Study|Adverse Event|6
5972682|NCT00409773|9558395|FG000|Overall Study|Lost to Follow-up|6
6272867|NCT02182830|9975969|FG000|Overall Study|Lost to Follow-up|3
6272868|NCT02182830|9975970|FG001|Overall Study|Lost to Follow-up|3
6272869|NCT02182843|9975976|FG000|Overall Study|Withdrawal by Subject|7
6272870|NCT02182843|9975976|FG000|Overall Study|Lost to Follow-up|2
6272871|NCT02182843|9975976|FG000|Overall Study|Adverse Event|1
6272872|NCT02182895|9975982|FG000|Overall Study|Discharged from hospital within 24 hours|2
6272873|NCT02182895|9975983|FG001|Overall Study|Discharged from hospital within 24 hours|4
6272874|NCT02182947|9975989|FG000|Overall Study|Withdrawal by Subject|7
5972683|NCT00409773|9558396|FG001|Overall Study|Lost to Follow-up|1
5972684|NCT00409773|9558397|FG002|Overall Study|Lost to Follow-up|2
5972685|NCT00409773|9558398|FG003|Overall Study|Lost to Follow-up|3
5972686|NCT00409773|9558399|FG004|Overall Study|Lost to Follow-up|1
5972687|NCT00409773|9558395|FG000|Overall Study|Physician Decision|0
6272875|NCT02182947|9975989|FG000|Overall Study|Lost to Follow-up|3
6272876|NCT02182947|9975989|FG000|Overall Study|Failed screening activities|8
6272877|NCT02182973|9975995|FG000|Overall Study|Withdrawal by Subject|3
6272878|NCT02182973|9975996|FG001|Overall Study|Withdrawal by Subject|0
6272879|NCT02182999|9976005|FG000|Overall Study|Adverse Event|4
6272880|NCT02182999|9976006|FG001|Overall Study|Adverse Event|3
6272881|NCT02182999|9976005|FG000|Overall Study|Physician Decision|1
6272882|NCT02182999|9976006|FG001|Overall Study|Physician Decision|0
6272883|NCT02183519|9976014|FG000|Overall Study|computer error|3
6272884|NCT02183519|9976015|FG001|Overall Study|computer error|0
6272885|NCT02183519|9976014|FG000|Overall Study|Did not respond to cough inducter|0
6272886|NCT02183519|9976015|FG001|Overall Study|Did not respond to cough inducter|3
6193521|NCT01439009|9851220|FG001|Overall Study|Physician Decision|3
6193522|NCT01439009|9851219|FG000|Overall Study|Protocol Violation|2
6193523|NCT01439009|9851220|FG001|Overall Study|Protocol Violation|0
6193524|NCT01439009|9851219|FG000|Overall Study|Deviation of exclusion criteria|1
6193525|NCT01439009|9851220|FG001|Overall Study|Deviation of exclusion criteria|0
6193526|NCT01439074|9851232|FG000|Overall Study|Lost to Follow-up|3
6193527|NCT01439074|9851233|FG001|Overall Study|Lost to Follow-up|4
6193528|NCT01439074|9851232|FG000|Overall Study|Subject shedding|1
6193529|NCT01439074|9851233|FG001|Overall Study|Subject shedding|0
6193530|NCT01439074|9851232|FG000|Overall Study|Withdrawal by Subject|1
6193531|NCT01439074|9851233|FG001|Overall Study|Withdrawal by Subject|5
6193532|NCT01439074|9851232|FG000|Overall Study|Other|4
6193533|NCT01439074|9851233|FG001|Overall Study|Other|4
6193534|NCT01439126|9851245|FG000|Overall Study|Adverse Event|2
6193535|NCT01439126|9851246|FG001|Overall Study|Adverse Event|0
6193536|NCT01439126|9851245|FG000|Overall Study|Withdrawal by Subject|5
6193537|NCT01439126|9851246|FG001|Overall Study|Withdrawal by Subject|21
6193538|NCT01439126|9851245|FG000|Overall Study|Protocol Violation|6
6193539|NCT01439126|9851246|FG001|Overall Study|Protocol Violation|4
6272887|NCT02183675|9976027|FG000|Treatment Period 2 (10 Days)|Adverse Event|0
6272888|NCT02183675|9976028|FG001|Treatment Period 2 (10 Days)|Adverse Event|0
6272889|NCT02183675|9976029|FG002|Treatment Period 2 (10 Days)|Adverse Event|0
6272890|NCT02183675|9976030|FG003|Treatment Period 2 (10 Days)|Adverse Event|0
6272891|NCT02183675|9976031|FG004|Treatment Period 2 (10 Days)|Adverse Event|0
6272892|NCT02183675|9976032|FG005|Treatment Period 2 (10 Days)|Adverse Event|2
6272893|NCT02184143|9976053|FG000|Overall Study|Withdrawal by Subject|4
6272894|NCT02184143|9976054|FG001|Overall Study|Withdrawal by Subject|4
6272895|NCT02184143|9976053|FG000|Overall Study|Lost to Follow-up|5
6272896|NCT02184143|9976054|FG001|Overall Study|Lost to Follow-up|3
5972688|NCT00409773|9558396|FG001|Overall Study|Physician Decision|0
5972689|NCT00409773|9558397|FG002|Overall Study|Physician Decision|0
5972690|NCT00409773|9558398|FG003|Overall Study|Physician Decision|2
5972691|NCT00409773|9558399|FG004|Overall Study|Physician Decision|0
5972692|NCT00409773|9558395|FG000|Overall Study|Protocol Violation|0
5972693|NCT00409773|9558396|FG001|Overall Study|Protocol Violation|2
5972694|NCT00409773|9558397|FG002|Overall Study|Protocol Violation|3
5972695|NCT00409773|9558398|FG003|Overall Study|Protocol Violation|3
5972696|NCT00409773|9558399|FG004|Overall Study|Protocol Violation|1
5972697|NCT00409773|9558395|FG000|Overall Study|Withdrawal by Subject|0
5972698|NCT00409773|9558396|FG001|Overall Study|Withdrawal by Subject|0
5972699|NCT00409773|9558397|FG002|Overall Study|Withdrawal by Subject|0
5972700|NCT00409773|9558398|FG003|Overall Study|Withdrawal by Subject|2
5972701|NCT00409773|9558399|FG004|Overall Study|Withdrawal by Subject|1
5972702|NCT00409773|9558395|FG000|Overall Study|Lack of Eligibility|0
5972703|NCT00409773|9558396|FG001|Overall Study|Lack of Eligibility|0
5972704|NCT00409773|9558397|FG002|Overall Study|Lack of Eligibility|0
5972705|NCT00409773|9558398|FG003|Overall Study|Lack of Eligibility|0
6272897|NCT02184143|9976053|FG000|Overall Study|Death|1
6272898|NCT02184143|9976054|FG001|Overall Study|Death|0
6272899|NCT02184442|9976081|FG000|Overall Study|Death|61
6272900|NCT02184442|9976082|FG001|Overall Study|Death|65
6272901|NCT02184442|9976081|FG000|Overall Study|Withdrawal by Subject|3
5972706|NCT00409773|9558399|FG004|Overall Study|Lack of Eligibility|1
5972707|NCT00276484|9558413|FG000|Overall Study|Adverse Event|4
5972708|NCT00276484|9558414|FG001|Overall Study|Adverse Event|7
6193540|NCT01439126|9851245|FG000|Overall Study|Lost to Follow-up|6
6193541|NCT01439126|9851246|FG001|Overall Study|Lost to Follow-up|3
6193542|NCT01439126|9851245|FG000|Overall Study|Other-Use of prohibited treatment|0
6193543|NCT01439126|9851246|FG001|Overall Study|Other-Use of prohibited treatment|2
6272902|NCT02184442|9976082|FG001|Overall Study|Withdrawal by Subject|11
6272903|NCT02184455|9976088|FG000|Overall Study|Lost to Follow-up|1
6272904|NCT02184572|9976107|FG000|Overall Study|Lost to Follow-up|29
6272905|NCT02184572|9976108|FG001|Overall Study|Lost to Follow-up|21
6272906|NCT02184572|9976107|FG000|Overall Study|Family Out Of Country Until 9/29/2015|1
6272907|NCT02184572|9976108|FG001|Overall Study|Family Out Of Country Until 9/29/2015|0
6272908|NCT02184572|9976107|FG000|Overall Study|Loss Of Kaiser Insurance|1
6272909|NCT02184572|9976108|FG001|Overall Study|Loss Of Kaiser Insurance|0
6272910|NCT02184572|9976107|FG000|Overall Study|2nd blooddraw & diary card incomplete|1
6272911|NCT02184572|9976108|FG001|Overall Study|2nd blooddraw & diary card incomplete|0
6272912|NCT02184572|9976107|FG000|Overall Study|Traveling Outside The Country|1
6272913|NCT02184572|9976108|FG001|Overall Study|Traveling Outside The Country|0
6272914|NCT02184572|9976107|FG000|Overall Study|Withdrawal by Subject|14
6272915|NCT02184572|9976108|FG001|Overall Study|Withdrawal by Subject|9
6272916|NCT02184611|9976118|FG000|Overall Study|Lack of Efficacy|11
6272917|NCT02184611|9976119|FG001|Overall Study|Lack of Efficacy|15
6272918|NCT02184611|9976118|FG000|Overall Study|Withdrawal by Subject|5
6272919|NCT02184611|9976119|FG001|Overall Study|Withdrawal by Subject|6
6272920|NCT02184611|9976118|FG000|Overall Study|Adverse Event|4
5972709|NCT00276484|9558413|FG000|Overall Study|Lost to Follow-up|1
5972710|NCT00276484|9558414|FG001|Overall Study|Lost to Follow-up|1
5972711|NCT00276484|9558413|FG000|Overall Study|Protocol Violation|0
5972712|NCT00276484|9558414|FG001|Overall Study|Protocol Violation|1
5972713|NCT00276484|9558413|FG000|Overall Study|Withdrawal by Subject|4
6049151|NCT00421733|9648372|FG001|Overall Study|Death|3
6049152|NCT00421733|9648373|FG002|Overall Study|Death|0
6049153|NCT00421733|9648371|FG000|Overall Study|Required dialysis|1
6049154|NCT00421733|9648372|FG001|Overall Study|Required dialysis|0
6049155|NCT00421733|9648373|FG002|Overall Study|Required dialysis|0
6049156|NCT00421733|9648371|FG000|Overall Study|Administrative|2
6049157|NCT00421733|9648372|FG001|Overall Study|Administrative|0
6049158|NCT00421733|9648373|FG002|Overall Study|Administrative|0
6049159|NCT00421733|9648371|FG000|Overall Study|Did not satisfy entry criteria|1
6049160|NCT00421733|9648372|FG001|Overall Study|Did not satisfy entry criteria|3
6049161|NCT00421733|9648373|FG002|Overall Study|Did not satisfy entry criteria|2
6049162|NCT00421733|9648371|FG000|Overall Study|Sponsor request|1
6049163|NCT00421733|9648372|FG001|Overall Study|Sponsor request|0
6049164|NCT00421733|9648373|FG002|Overall Study|Sponsor request|3
6049165|NCT00421733|9648371|FG000|Overall Study|Protocol deviation|4
6049166|NCT00421733|9648372|FG001|Overall Study|Protocol deviation|7
6049167|NCT00421733|9648373|FG002|Overall Study|Protocol deviation|2
6087848|NCT00671034|9698364|FG000|Overall Study|includes Alternative therapy, etc.|6
6087849|NCT00671034|9698365|FG001|Overall Study|includes Alternative therapy, etc.|1
6087850|NCT00671034|9698366|FG002|Overall Study|includes Alternative therapy, etc.|7
6087851|NCT00671060|9698377|FG000|Overall Study|Protocol Violation|1
6087852|NCT00671060|9698378|FG001|Overall Study|Protocol Violation|0
6087853|NCT00671060|9698377|FG000|Overall Study|Physician Decision|0
6087854|NCT00671060|9698378|FG001|Overall Study|Physician Decision|1
6193544|NCT01439126|9851245|FG000|Overall Study|Other-Miscellaneous|12
5972714|NCT00276484|9558414|FG001|Overall Study|Withdrawal by Subject|3
5972715|NCT00276484|9558413|FG000|Overall Study|Could not take time off work|0
5972716|NCT00276484|9558414|FG001|Overall Study|Could not take time off work|1
5972717|NCT00276458|9558422|FG000|Overall Study|Adverse Event|0
5972718|NCT00276458|9558423|FG001|Overall Study|Adverse Event|2
5972719|NCT00276458|9558422|FG000|Overall Study|Lost to Follow-up|2
5972720|NCT00276458|9558423|FG001|Overall Study|Lost to Follow-up|2
5972721|NCT00276458|9558422|FG000|Overall Study|Protocol Violation|4
5972722|NCT00276458|9558423|FG001|Overall Study|Protocol Violation|3
5972723|NCT00271817|9558432|FG000|Part 1|Adverse Event|68
5972724|NCT00271817|9558433|FG001|Part 1|Adverse Event|25
5972725|NCT00271817|9558434|FG002|Part 1|Adverse Event|156
5972726|NCT00271817|9558432|FG000|Part 1|Lost to Follow-up|6
5972727|NCT00271817|9558433|FG001|Part 1|Lost to Follow-up|8
5972728|NCT00271817|9558434|FG002|Part 1|Lost to Follow-up|24
5972729|NCT00271817|9558432|FG000|Part 1|Protocol Violation|5
5972730|NCT00271817|9558433|FG001|Part 1|Protocol Violation|4
5972731|NCT00271817|9558434|FG002|Part 1|Protocol Violation|7
5972732|NCT00271817|9558432|FG000|Part 1|Patient Moved|3
5972733|NCT00271817|9558433|FG001|Part 1|Patient Moved|1
5972734|NCT00271817|9558434|FG002|Part 1|Patient Moved|5
5972735|NCT00271817|9558432|FG000|Part 1|Withdrawal by Subject|23
5972736|NCT00271817|9558433|FG001|Part 1|Withdrawal by Subject|17
5972737|NCT00271817|9558434|FG002|Part 1|Withdrawal by Subject|45
5972738|NCT00271817|9558432|FG000|Part 1|LDL < 50 mg/dL|1
5972739|NCT00271817|9558433|FG001|Part 1|LDL < 50 mg/dL|4
5972740|NCT00271817|9558434|FG002|Part 1|LDL < 50 mg/dL|48
6193545|NCT01439126|9851246|FG001|Overall Study|Other-Miscellaneous|12
6193546|NCT01439204|9851254|FG000|Overall Study|Withdrawal by Subject|0
6193547|NCT01439204|9851255|FG001|Overall Study|Withdrawal by Subject|1
6193548|NCT01439204|9851254|FG000|Overall Study|Lost to Follow-up|0
6193549|NCT01439204|9851255|FG001|Overall Study|Lost to Follow-up|2
6193550|NCT01439204|9851254|FG000|Overall Study|No longer meets study criteria|1
6193551|NCT01439204|9851255|FG001|Overall Study|No longer meets study criteria|0
6193552|NCT01439204|9851254|FG000|Overall Study|poor/non-compliance|3
6193553|NCT01439204|9851255|FG001|Overall Study|poor/non-compliance|0
6272921|NCT02184611|9976119|FG001|Overall Study|Adverse Event|5
6272922|NCT02184611|9976118|FG000|Overall Study|Protocol Violation|1
6272923|NCT02184611|9976119|FG001|Overall Study|Protocol Violation|1
6272924|NCT02184611|9976118|FG000|Overall Study|Protocol defined stopping criteria|0
6272925|NCT02184611|9976119|FG001|Overall Study|Protocol defined stopping criteria|1
6272926|NCT02184988|9976146|FG000|Overall Study|Pregnancy|2
6272927|NCT02184988|9976146|FG000|Overall Study|Adverse Event|2
6272928|NCT02184988|9976146|FG000|Overall Study|moving away/travelling/unable to complet|6
6272929|NCT02184988|9976146|FG000|Overall Study|work scheduling issues|4
6272930|NCT02184988|9976146|FG000|Overall Study|various other reasons|9
6272931|NCT02184988|9976146|FG000|Overall Study|Lost to Follow-up|32
6272932|NCT02185014|9976150|FG000|Overall Study|Adverse Event|18
6272933|NCT02185014|9976150|FG000|Overall Study|Withdrew Consent|8
6272934|NCT02185014|9976150|FG000|Overall Study|Lost to Follow-up|4
6272935|NCT02185014|9976150|FG000|Overall Study|Lack of Efficacy|14
6272936|NCT02185014|9976150|FG000|Overall Study|Requires Alternative/Prohibited Therapy|5
6272937|NCT02185014|9976150|FG000|Overall Study|Subject Noncompliance|1
6272938|NCT02185014|9976150|FG000|Overall Study|Other|4
6272939|NCT02185040|9976159|FG000|Part 1 Treatment Phase|Miscellaneous|0
6272940|NCT02185040|9976160|FG001|Part 1 Treatment Phase|Miscellaneous|0
6272941|NCT02185040|9976161|FG002|Part 1 Treatment Phase|Miscellaneous|1
6272942|NCT02185040|9976162|FG003|Part 1 Treatment Phase|Miscellaneous|0
5972741|NCT00271817|9558432|FG000|Part 2|Adverse Event|0
5972742|NCT00271817|9558433|FG001|Part 2|Adverse Event|17
5972743|NCT00271817|9558434|FG002|Part 2|Adverse Event|33
5972744|NCT00271817|9558432|FG000|Part 2|Lack of Efficacy|0
5972745|NCT00271817|9558433|FG001|Part 2|Lack of Efficacy|1
5972746|NCT00271817|9558434|FG002|Part 2|Lack of Efficacy|6
5972747|NCT00271817|9558432|FG000|Part 2|Lost to Follow-up|0
5972748|NCT00271817|9558433|FG001|Part 2|Lost to Follow-up|6
5972749|NCT00271817|9558434|FG002|Part 2|Lost to Follow-up|18
5972750|NCT00271817|9558432|FG000|Part 2|Protocol Violation|0
5972751|NCT00271817|9558433|FG001|Part 2|Protocol Violation|3
5972752|NCT00271817|9558434|FG002|Part 2|Protocol Violation|5
5972753|NCT00271817|9558432|FG000|Part 2|Patient Moved|0
5972754|NCT00271817|9558433|FG001|Part 2|Patient Moved|0
6272943|NCT02185040|9976163|FG004|Part 1 Treatment Phase|Miscellaneous|0
5972755|NCT00271817|9558434|FG002|Part 2|Patient Moved|5
6272944|NCT02185040|9976164|FG005|Part 1 Treatment Phase|Miscellaneous|0
6272945|NCT02185040|9976165|FG006|Part 1 Treatment Phase|Miscellaneous|0
6272946|NCT02185040|9976159|FG000|Part 1 Treatment Phase|Adverse Event|1
6272947|NCT02185040|9976160|FG001|Part 1 Treatment Phase|Adverse Event|0
6272948|NCT02185040|9976161|FG002|Part 1 Treatment Phase|Adverse Event|0
6272949|NCT02185040|9976162|FG003|Part 1 Treatment Phase|Adverse Event|2
6272950|NCT02185040|9976163|FG004|Part 1 Treatment Phase|Adverse Event|3
6272951|NCT02185040|9976164|FG005|Part 1 Treatment Phase|Adverse Event|0
6272952|NCT02185040|9976165|FG006|Part 1 Treatment Phase|Adverse Event|0
6272953|NCT02185040|9976159|FG000|Part 1 Treatment Phase|Withdrawal by Subject|0
6272954|NCT02185040|9976160|FG001|Part 1 Treatment Phase|Withdrawal by Subject|1
6272955|NCT02185040|9976161|FG002|Part 1 Treatment Phase|Withdrawal by Subject|0
6272956|NCT02185040|9976162|FG003|Part 1 Treatment Phase|Withdrawal by Subject|0
6272957|NCT02185040|9976163|FG004|Part 1 Treatment Phase|Withdrawal by Subject|0
6272958|NCT02185040|9976164|FG005|Part 1 Treatment Phase|Withdrawal by Subject|0
6272959|NCT02185040|9976165|FG006|Part 1 Treatment Phase|Withdrawal by Subject|0
6272960|NCT02185040|9976159|FG000|Part 1 Treatment Phase|Lost to Follow-up|0
6272961|NCT02185040|9976160|FG001|Part 1 Treatment Phase|Lost to Follow-up|1
6272962|NCT02185040|9976161|FG002|Part 1 Treatment Phase|Lost to Follow-up|0
6272963|NCT02185040|9976162|FG003|Part 1 Treatment Phase|Lost to Follow-up|0
6272964|NCT02185040|9976163|FG004|Part 1 Treatment Phase|Lost to Follow-up|0
6272965|NCT02185040|9976164|FG005|Part 1 Treatment Phase|Lost to Follow-up|0
6272966|NCT02185040|9976165|FG006|Part 1 Treatment Phase|Lost to Follow-up|0
6272967|NCT02185040|9976159|FG000|Active Treatment Extension Phase|Miscellaneous|0
6272968|NCT02185040|9976160|FG001|Active Treatment Extension Phase|Miscellaneous|0
6272969|NCT02185040|9976161|FG002|Active Treatment Extension Phase|Miscellaneous|0
6272970|NCT02185040|9976162|FG003|Active Treatment Extension Phase|Miscellaneous|0
6272971|NCT02185040|9976163|FG004|Active Treatment Extension Phase|Miscellaneous|0
6272972|NCT02185040|9976164|FG005|Active Treatment Extension Phase|Miscellaneous|1
6272973|NCT02185040|9976165|FG006|Active Treatment Extension Phase|Miscellaneous|0
6272974|NCT02185040|9976159|FG000|Active Treatment Extension Phase|Adverse Event|0
6272975|NCT02185040|9976160|FG001|Active Treatment Extension Phase|Adverse Event|0
6272976|NCT02185040|9976161|FG002|Active Treatment Extension Phase|Adverse Event|0
6272977|NCT02185040|9976162|FG003|Active Treatment Extension Phase|Adverse Event|0
6272978|NCT02185040|9976163|FG004|Active Treatment Extension Phase|Adverse Event|0
6272979|NCT02185040|9976164|FG005|Active Treatment Extension Phase|Adverse Event|1
6272980|NCT02185040|9976165|FG006|Active Treatment Extension Phase|Adverse Event|4
6272981|NCT02185040|9976159|FG000|Active Treatment Extension Phase|Withdrawal by Subject|0
6272982|NCT02185040|9976160|FG001|Active Treatment Extension Phase|Withdrawal by Subject|0
6272983|NCT02185040|9976161|FG002|Active Treatment Extension Phase|Withdrawal by Subject|0
6272984|NCT02185040|9976162|FG003|Active Treatment Extension Phase|Withdrawal by Subject|0
6272985|NCT02185040|9976163|FG004|Active Treatment Extension Phase|Withdrawal by Subject|0
6272986|NCT02185040|9976164|FG005|Active Treatment Extension Phase|Withdrawal by Subject|1
6272987|NCT02185040|9976165|FG006|Active Treatment Extension Phase|Withdrawal by Subject|1
6272988|NCT02185040|9976159|FG000|Active Treatment Extension Phase|Lost to Follow-up|0
6272989|NCT02185040|9976160|FG001|Active Treatment Extension Phase|Lost to Follow-up|0
6272990|NCT02185040|9976161|FG002|Active Treatment Extension Phase|Lost to Follow-up|0
6272991|NCT02185040|9976162|FG003|Active Treatment Extension Phase|Lost to Follow-up|0
6272992|NCT02185040|9976163|FG004|Active Treatment Extension Phase|Lost to Follow-up|0
6272993|NCT02185040|9976164|FG005|Active Treatment Extension Phase|Lost to Follow-up|0
6272994|NCT02185040|9976165|FG006|Active Treatment Extension Phase|Lost to Follow-up|2
6272995|NCT02185053|9976185|FG000|Solifenacin Dose Escalation Phase|Cardiac symptoms|1
6272996|NCT02185053|9976186|FG001|Solifenacin Dose Escalation Phase|Cardiac symptoms|0
6272997|NCT02185053|9976187|FG002|Solifenacin Dose Escalation Phase|Cardiac symptoms|0
6272998|NCT02185053|9976185|FG000|Solifenacin Dose Escalation Phase|No longer meeting eligibility criteria|2
6272999|NCT02185053|9976186|FG001|Solifenacin Dose Escalation Phase|No longer meeting eligibility criteria|0
6273000|NCT02185053|9976187|FG002|Solifenacin Dose Escalation Phase|No longer meeting eligibility criteria|0
6273001|NCT02185053|9976185|FG000|Donepezil Dose Escalation Phase|Cardiac symptoms|0
6273002|NCT02185053|9976186|FG001|Donepezil Dose Escalation Phase|Cardiac symptoms|1
6273003|NCT02185053|9976187|FG002|Donepezil Dose Escalation Phase|Cardiac symptoms|0
6273004|NCT02185053|9976185|FG000|Donepezil Dose Escalation Phase|Adverse Event|0
6273005|NCT02185053|9976186|FG001|Donepezil Dose Escalation Phase|Adverse Event|1
6273006|NCT02185053|9976187|FG002|Donepezil Dose Escalation Phase|Adverse Event|0
6273007|NCT02185053|9976185|FG000|Donepezil Dose Escalation Phase|No longer meeting eligibility criteria|0
6273008|NCT02185053|9976186|FG001|Donepezil Dose Escalation Phase|No longer meeting eligibility criteria|2
6273009|NCT02185053|9976187|FG002|Donepezil Dose Escalation Phase|No longer meeting eligibility criteria|0
6273010|NCT02185053|9976185|FG000|Donepezil Dose Escalation Phase|Withdrawal by Subject|0
6273011|NCT02185053|9976186|FG001|Donepezil Dose Escalation Phase|Withdrawal by Subject|1
6273012|NCT02185053|9976187|FG002|Donepezil Dose Escalation Phase|Withdrawal by Subject|0
6273013|NCT02185053|9976185|FG000|Donepezil Dose Maintenance Phase|Cardiac symptoms|0
6273014|NCT02185053|9976186|FG001|Donepezil Dose Maintenance Phase|Cardiac symptoms|0
6273015|NCT02185053|9976187|FG002|Donepezil Dose Maintenance Phase|Cardiac symptoms|1
6273016|NCT02185053|9976185|FG000|Donepezil Dose Maintenance Phase|Withdrawal by Subject|0
6273017|NCT02185053|9976186|FG001|Donepezil Dose Maintenance Phase|Withdrawal by Subject|0
6273018|NCT02185053|9976187|FG002|Donepezil Dose Maintenance Phase|Withdrawal by Subject|2
5972756|NCT00271817|9558432|FG000|Part 2|Withdrawal by Subject|0
5972757|NCT00271817|9558433|FG001|Part 2|Withdrawal by Subject|2
5972758|NCT00271817|9558434|FG002|Part 2|Withdrawal by Subject|13
5972759|NCT00271817|9558432|FG000|Part 2|LDL < 50 mg/dL|0
5972760|NCT00271817|9558433|FG001|Part 2|LDL < 50 mg/dL|3
5972761|NCT00271817|9558434|FG002|Part 2|LDL < 50 mg/dL|4
6049168|NCT00421889|9648394|FG000|Overall Study|Adverse Event|1
6193554|NCT01439282|9851263|FG000|Overall Study|Adverse Event|5
6193555|NCT01439282|9851264|FG001|Overall Study|Adverse Event|0
6193556|NCT01439282|9851263|FG000|Overall Study|Withdrawal by Subject|2
6193557|NCT01439282|9851264|FG001|Overall Study|Withdrawal by Subject|0
6193558|NCT01439282|9851263|FG000|Overall Study|Other|1
6193559|NCT01439282|9851264|FG001|Overall Study|Other|1
6193560|NCT01439360|9851273|FG000|Overall Study|Adverse Event|4
6193561|NCT01439360|9851274|FG001|Overall Study|Adverse Event|16
6193562|NCT01439360|9851273|FG000|Overall Study|Lost to Follow-up|43
6193563|NCT01439360|9851274|FG001|Overall Study|Lost to Follow-up|58
6049169|NCT00421889|9648395|FG001|Overall Study|Adverse Event|0
6049170|NCT00421889|9648396|FG002|Overall Study|Adverse Event|1
6049171|NCT00421889|9648397|FG003|Overall Study|Adverse Event|1
6193564|NCT01439360|9851273|FG000|Overall Study|Others|10
6193565|NCT01439360|9851274|FG001|Overall Study|Others|5
6049172|NCT00421889|9648398|FG004|Overall Study|Adverse Event|1
6049173|NCT00421889|9648399|FG005|Overall Study|Adverse Event|4
6193566|NCT01439360|9851273|FG000|Overall Study|Protocol Violation|1
6193567|NCT01439360|9851274|FG001|Overall Study|Protocol Violation|0
6273019|NCT02185521|9976233|FG000|Overall Study|Withdrawal by Subject|1
6273020|NCT02185521|9976233|FG000|Overall Study|Protocol Violation|1
6273021|NCT02185534|9976244|FG000|First Period|Withdrawal by Subject|0
6273022|NCT02185534|9976245|FG001|First Period|Withdrawal by Subject|0
6273023|NCT02185534|9976246|FG002|First Period|Withdrawal by Subject|0
6273024|NCT02185534|9976247|FG003|First Period|Withdrawal by Subject|1
6273025|NCT02185534|9976248|FG004|First Period|Withdrawal by Subject|0
6273026|NCT02185534|9976249|FG005|First Period|Withdrawal by Subject|0
6273027|NCT02185534|9976244|FG000|First Washout Period|Withdrawal by Subject|1
6273028|NCT02185534|9976245|FG001|First Washout Period|Withdrawal by Subject|0
6273029|NCT02185534|9976246|FG002|First Washout Period|Withdrawal by Subject|0
6273030|NCT02185534|9976247|FG003|First Washout Period|Withdrawal by Subject|0
6273031|NCT02185534|9976248|FG004|First Washout Period|Withdrawal by Subject|1
6273032|NCT02185534|9976249|FG005|First Washout Period|Withdrawal by Subject|0
6273033|NCT02185534|9976244|FG000|First Washout Period|Protocol Violation|0
6273034|NCT02185534|9976245|FG001|First Washout Period|Protocol Violation|0
6273035|NCT02185534|9976246|FG002|First Washout Period|Protocol Violation|0
6273036|NCT02185534|9976247|FG003|First Washout Period|Protocol Violation|0
6273037|NCT02185534|9976248|FG004|First Washout Period|Protocol Violation|0
6273038|NCT02185534|9976249|FG005|First Washout Period|Protocol Violation|1
6273039|NCT02185794|9976271|FG000|Overall Study|Enrolled but Never Dosed|1
6273040|NCT02185794|9976272|FG001|Overall Study|Enrolled but Never Dosed|6
6273041|NCT02185794|9976273|FG002|Overall Study|Enrolled but Never Dosed|3
6273042|NCT02185794|9976274|FG003|Overall Study|Enrolled but Never Dosed|1
6273043|NCT02185794|9976275|FG004|Overall Study|Enrolled but Never Dosed|1
6273044|NCT02185794|9976276|FG005|Overall Study|Enrolled but Never Dosed|0
6273045|NCT02185794|9976271|FG000|Overall Study|Investigator's Discretion|1
6273046|NCT02185794|9976272|FG001|Overall Study|Investigator's Discretion|0
6273047|NCT02185794|9976273|FG002|Overall Study|Investigator's Discretion|1
6273048|NCT02185794|9976274|FG003|Overall Study|Investigator's Discretion|2
6273049|NCT02185794|9976275|FG004|Overall Study|Investigator's Discretion|2
6273050|NCT02185794|9976276|FG005|Overall Study|Investigator's Discretion|15
6273051|NCT02185794|9976271|FG000|Overall Study|Withdrew Consent|2
5972762|NCT03420781|9558466|FG000|Treatment Period (40 Weeks)|Adverse Event|1
5972763|NCT03420781|9558467|FG001|Treatment Period (40 Weeks)|Adverse Event|6
5972764|NCT03420781|9558468|FG002|Treatment Period (40 Weeks)|Adverse Event|0
5972765|NCT03420781|9558469|FG003|Treatment Period (40 Weeks)|Adverse Event|0
5972766|NCT03420781|9558470|FG004|Treatment Period (40 Weeks)|Adverse Event|0
5972767|NCT03420781|9558466|FG000|Treatment Period (40 Weeks)|Lack of Efficacy|1
6049174|NCT00421889|9648400|FG006|Overall Study|Adverse Event|1
6049175|NCT00421889|9648401|FG007|Overall Study|Adverse Event|0
6049176|NCT00421889|9648402|FG008|Overall Study|Adverse Event|2
6049177|NCT00421889|9648394|FG000|Overall Study|Withdrawal by Subject|1
6049178|NCT00421889|9648395|FG001|Overall Study|Withdrawal by Subject|3
6049179|NCT00421889|9648396|FG002|Overall Study|Withdrawal by Subject|0
6049180|NCT00421889|9648397|FG003|Overall Study|Withdrawal by Subject|0
6049181|NCT00421889|9648398|FG004|Overall Study|Withdrawal by Subject|2
6049182|NCT00421889|9648399|FG005|Overall Study|Withdrawal by Subject|0
6049183|NCT00421889|9648400|FG006|Overall Study|Withdrawal by Subject|0
6049184|NCT00421889|9648401|FG007|Overall Study|Withdrawal by Subject|0
6087855|NCT00671437|9698393|FG000|Overall Study|Progressive disease before C1 week 8|8
6087856|NCT00671437|9698393|FG000|Overall Study|Cutaneous SCC of head and neck|3
6087857|NCT00671437|9698393|FG000|Overall Study|Adverse Event|3
6087858|NCT00671437|9698393|FG000|Overall Study|Ineligible post-hoc|1
6087859|NCT00671554|9698422|FG000|Overall Study|Disease progression|3
6087860|NCT00671658|9698427|FG000|Overall Study|Physician Decision|5
6087861|NCT00671749|9698454|FG000|Overall Study|Adverse Event|2
6087862|NCT00671749|9698454|FG000|Overall Study|Withdrawal by Subject|4
6087863|NCT00671749|9698454|FG000|Overall Study|Protocol Violation|1
6087864|NCT00671749|9698454|FG000|Overall Study|Lost to Follow-up|1
6087865|NCT00671788|9698458|FG000|Overall Study|Adverse Event|8
6087866|NCT00671788|9698458|FG000|Overall Study|Refused further treatment|3
6087867|NCT00671788|9698458|FG000|Overall Study|Ineligible|1
6087868|NCT00671788|9698458|FG000|Overall Study|MD Decision|1
6087869|NCT00671788|9698458|FG000|Overall Study|Other|1
6087870|NCT00671853|9698464|FG000|Overall Study|Lack of Efficacy|3
6087871|NCT00671853|9698465|FG001|Overall Study|Lack of Efficacy|7
6087872|NCT00671853|9698464|FG000|Overall Study|Adverse Event|7
6273052|NCT02185794|9976272|FG001|Overall Study|Withdrew Consent|5
6273053|NCT02185794|9976273|FG002|Overall Study|Withdrew Consent|10
6087873|NCT00671853|9698465|FG001|Overall Study|Adverse Event|1
5972768|NCT03420781|9558467|FG001|Treatment Period (40 Weeks)|Lack of Efficacy|1
5972769|NCT03420781|9558468|FG002|Treatment Period (40 Weeks)|Lack of Efficacy|0
6087874|NCT00671853|9698464|FG000|Overall Study|Withdrawal by Subject|1
6087875|NCT00671853|9698465|FG001|Overall Study|Withdrawal by Subject|5
6087876|NCT00671853|9698464|FG000|Overall Study|Lost to Follow-up|8
5972770|NCT03420781|9558469|FG003|Treatment Period (40 Weeks)|Lack of Efficacy|0
5972771|NCT03420781|9558470|FG004|Treatment Period (40 Weeks)|Lack of Efficacy|0
5972772|NCT03420781|9558466|FG000|Treatment Period (40 Weeks)|Withdrawal by Subject|22
6087877|NCT00671853|9698465|FG001|Overall Study|Lost to Follow-up|8
6273054|NCT02185794|9976274|FG003|Overall Study|Withdrew Consent|2
6273055|NCT02185794|9976275|FG004|Overall Study|Withdrew Consent|0
6273056|NCT02185794|9976276|FG005|Overall Study|Withdrew Consent|0
6273057|NCT02185794|9976271|FG000|Overall Study|Lost to Follow-up|1
6273058|NCT02185794|9976272|FG001|Overall Study|Lost to Follow-up|2
6273059|NCT02185794|9976273|FG002|Overall Study|Lost to Follow-up|2
6273060|NCT02185794|9976274|FG003|Overall Study|Lost to Follow-up|3
6273061|NCT02185794|9976275|FG004|Overall Study|Lost to Follow-up|0
6273062|NCT02185794|9976276|FG005|Overall Study|Lost to Follow-up|1
6273063|NCT02186015|9976306|FG000|Overall Study|Physician Decision|1
6273064|NCT02186015|9976307|FG001|Overall Study|Physician Decision|0
6273065|NCT02186171|9976316|FG000|Overall Study|Withdrawal by Subject|1
6273066|NCT02186171|9976317|FG001|Overall Study|Withdrawal by Subject|9
6273067|NCT02186171|9976316|FG000|Overall Study|Lost to Follow-up|2
6273068|NCT02186171|9976317|FG001|Overall Study|Lost to Follow-up|2
6273069|NCT02186171|9976316|FG000|Overall Study|Death|1
6273070|NCT02186171|9976317|FG001|Overall Study|Death|2
6273071|NCT02186171|9976316|FG000|Overall Study|Protocol-specified Criteria|0
6273072|NCT02186171|9976317|FG001|Overall Study|Protocol-specified Criteria|2
6273073|NCT02186223|9976334|FG000|Overall Study|Not eligible for device placement|6
6273074|NCT02186223|9976334|FG000|Overall Study|Unable to obtain femoral access|3
6273075|NCT02186223|9976334|FG000|Overall Study|Death|3
6273076|NCT02186223|9976334|FG000|Overall Study|Device in place less than 48 hours|9
6273077|NCT02186301|9976342|FG000|Overall Study|Progressive Disease|7
6273078|NCT02186301|9976343|FG001|Overall Study|Progressive Disease|22
6273079|NCT02186301|9976344|FG002|Overall Study|Progressive Disease|27
6273080|NCT02186301|9976342|FG000|Overall Study|Adverse Event|5
6273081|NCT02186301|9976343|FG001|Overall Study|Adverse Event|5
6273082|NCT02186301|9976344|FG002|Overall Study|Adverse Event|5
6273083|NCT02186301|9976342|FG000|Overall Study|Death|1
6273084|NCT02186301|9976343|FG001|Overall Study|Death|0
6273085|NCT02186301|9976344|FG002|Overall Study|Death|0
6273086|NCT02186301|9976342|FG000|Overall Study|Withdrawal by Subject|5
6273087|NCT02186301|9976343|FG001|Overall Study|Withdrawal by Subject|1
6273088|NCT02186301|9976344|FG002|Overall Study|Withdrawal by Subject|3
6273089|NCT02186301|9976342|FG000|Overall Study|Physician Decision|1
5972773|NCT03420781|9558467|FG001|Treatment Period (40 Weeks)|Withdrawal by Subject|16
5972774|NCT03420781|9558468|FG002|Treatment Period (40 Weeks)|Withdrawal by Subject|0
5972775|NCT03420781|9558469|FG003|Treatment Period (40 Weeks)|Withdrawal by Subject|0
5972776|NCT03420781|9558470|FG004|Treatment Period (40 Weeks)|Withdrawal by Subject|0
5972777|NCT03420781|9558466|FG000|Treatment Period (40 Weeks)|Lost to Follow-up|10
5972778|NCT03420781|9558467|FG001|Treatment Period (40 Weeks)|Lost to Follow-up|6
5972779|NCT03420781|9558468|FG002|Treatment Period (40 Weeks)|Lost to Follow-up|0
5972780|NCT03420781|9558469|FG003|Treatment Period (40 Weeks)|Lost to Follow-up|0
5972781|NCT03420781|9558470|FG004|Treatment Period (40 Weeks)|Lost to Follow-up|0
5972782|NCT03420781|9558466|FG000|Treatment Period (40 Weeks)|Death|2
5972783|NCT03420781|9558467|FG001|Treatment Period (40 Weeks)|Death|2
5972784|NCT03420781|9558468|FG002|Treatment Period (40 Weeks)|Death|0
5972785|NCT03420781|9558469|FG003|Treatment Period (40 Weeks)|Death|0
5972786|NCT03420781|9558470|FG004|Treatment Period (40 Weeks)|Death|0
5972787|NCT03420781|9558466|FG000|Treatment Period (40 Weeks)|Physician Decision|3
5972788|NCT03420781|9558467|FG001|Treatment Period (40 Weeks)|Physician Decision|4
5972789|NCT03420781|9558468|FG002|Treatment Period (40 Weeks)|Physician Decision|0
5972790|NCT03420781|9558469|FG003|Treatment Period (40 Weeks)|Physician Decision|0
5972791|NCT03420781|9558470|FG004|Treatment Period (40 Weeks)|Physician Decision|0
5972792|NCT03420781|9558466|FG000|Treatment Period (40 Weeks)|Protocol Deviation|0
5972793|NCT03420781|9558467|FG001|Treatment Period (40 Weeks)|Protocol Deviation|2
5972794|NCT03420781|9558468|FG002|Treatment Period (40 Weeks)|Protocol Deviation|0
5972795|NCT03420781|9558469|FG003|Treatment Period (40 Weeks)|Protocol Deviation|0
5972796|NCT03420781|9558470|FG004|Treatment Period (40 Weeks)|Protocol Deviation|0
5972797|NCT03420781|9558466|FG000|Treatment Period (40 Weeks)|Study Terminated by the Sponsor|101
5972798|NCT03420781|9558467|FG001|Treatment Period (40 Weeks)|Study Terminated by the Sponsor|89
5972799|NCT03420781|9558468|FG002|Treatment Period (40 Weeks)|Study Terminated by the Sponsor|0
5972800|NCT03420781|9558469|FG003|Treatment Period (40 Weeks)|Study Terminated by the Sponsor|0
6273090|NCT02186301|9976343|FG001|Overall Study|Physician Decision|0
6273091|NCT02186301|9976344|FG002|Overall Study|Physician Decision|1
6273092|NCT02186301|9976342|FG000|Overall Study|Study Terminated by Sponsor|1
6273093|NCT02186301|9976343|FG001|Overall Study|Study Terminated by Sponsor|0
6273094|NCT02186301|9976344|FG002|Overall Study|Study Terminated by Sponsor|11
5972801|NCT03420781|9558470|FG004|Treatment Period (40 Weeks)|Study Terminated by the Sponsor|0
5972802|NCT03420781|9558466|FG000|Treatment Period (40 Weeks)|Site Terminated by the Sponsor|1
5972803|NCT03420781|9558467|FG001|Treatment Period (40 Weeks)|Site Terminated by the Sponsor|0
5972804|NCT03420781|9558468|FG002|Treatment Period (40 Weeks)|Site Terminated by the Sponsor|0
5972805|NCT03420781|9558469|FG003|Treatment Period (40 Weeks)|Site Terminated by the Sponsor|0
5972806|NCT03420781|9558470|FG004|Treatment Period (40 Weeks)|Site Terminated by the Sponsor|0
5972807|NCT03420781|9558466|FG000|Treatment Period (40 Weeks)|Reason Not Specified|3
5972808|NCT03420781|9558467|FG001|Treatment Period (40 Weeks)|Reason Not Specified|0
5972809|NCT03420781|9558468|FG002|Treatment Period (40 Weeks)|Reason Not Specified|0
5972810|NCT03420781|9558469|FG003|Treatment Period (40 Weeks)|Reason Not Specified|0
5972811|NCT03420781|9558470|FG004|Treatment Period (40 Weeks)|Reason Not Specified|0
5972812|NCT03420781|9558466|FG000|RW Period: 6 Weeks (Week 41 to Week 46)|Adverse Event|0
5972813|NCT03420781|9558467|FG001|RW Period: 6 Weeks (Week 41 to Week 46)|Adverse Event|0
5972814|NCT03420781|9558468|FG002|RW Period: 6 Weeks (Week 41 to Week 46)|Adverse Event|0
5972815|NCT03420781|9558469|FG003|RW Period: 6 Weeks (Week 41 to Week 46)|Adverse Event|2
5972816|NCT03420781|9558470|FG004|RW Period: 6 Weeks (Week 41 to Week 46)|Adverse Event|0
5972817|NCT03420781|9558466|FG000|RW Period: 6 Weeks (Week 41 to Week 46)|Withdrawal by Subject|0
5972818|NCT03420781|9558467|FG001|RW Period: 6 Weeks (Week 41 to Week 46)|Withdrawal by Subject|0
5972819|NCT03420781|9558468|FG002|RW Period: 6 Weeks (Week 41 to Week 46)|Withdrawal by Subject|0
5972820|NCT03420781|9558469|FG003|RW Period: 6 Weeks (Week 41 to Week 46)|Withdrawal by Subject|0
5972821|NCT03420781|9558470|FG004|RW Period: 6 Weeks (Week 41 to Week 46)|Withdrawal by Subject|2
5972822|NCT03420781|9558466|FG000|RW Period: 6 Weeks (Week 41 to Week 46)|Study Terminated by the Sponsor|0
5972823|NCT03420781|9558467|FG001|RW Period: 6 Weeks (Week 41 to Week 46)|Study Terminated by the Sponsor|0
5972824|NCT03420781|9558468|FG002|RW Period: 6 Weeks (Week 41 to Week 46)|Study Terminated by the Sponsor|6
5972825|NCT03420781|9558469|FG003|RW Period: 6 Weeks (Week 41 to Week 46)|Study Terminated by the Sponsor|3
5972826|NCT03420781|9558470|FG004|RW Period: 6 Weeks (Week 41 to Week 46)|Study Terminated by the Sponsor|3
5972827|NCT03316586|9558486|FG000|Overall Study|Adverse Event|2
5972828|NCT03316586|9558486|FG000|Overall Study|Physician Decision|3
5972829|NCT03316586|9558486|FG000|Overall Study|Lack of Efficacy|10
5972830|NCT03316586|9558486|FG000|Overall Study|still on treatment|1
5972831|NCT03316586|9558486|FG000|Overall Study|Patient needed radiation therapy|1
5972832|NCT03316586|9558486|FG000|Overall Study|Physician Decision to send patient for breast surgery|1
5972833|NCT03269695|9558505|FG000|Overall Study|Adverse Event|2
5972834|NCT03269695|9558506|FG001|Overall Study|Adverse Event|1
5972835|NCT03269695|9558505|FG000|Overall Study|Lack of Efficacy|0
5972836|NCT03269695|9558506|FG001|Overall Study|Lack of Efficacy|1
5972837|NCT03269695|9558505|FG000|Overall Study|Withdrawal by Subject|0
5972838|NCT03269695|9558506|FG001|Overall Study|Withdrawal by Subject|1
5972839|NCT03268811|9558515|FG000|Overall Study|Adverse Event|0
5972840|NCT03268811|9558516|FG001|Overall Study|Adverse Event|1
5972841|NCT03227757|9558523|FG000|Overall Study|Death|7
5972842|NCT03227757|9558523|FG000|Overall Study|Withdrawal|5
5972843|NCT03227757|9558523|FG000|Overall Study|Missed visits|4
5972844|NCT03142334|9558533|FG000|Overall Study|Death|18
5972845|NCT03142334|9558534|FG001|Overall Study|Death|33
5972846|NCT03142334|9558533|FG000|Overall Study|Withdrawal by Subject|15
5972847|NCT03142334|9558534|FG001|Overall Study|Withdrawal by Subject|11
5972848|NCT03142334|9558533|FG000|Overall Study|Ongoing on trial follow up|463
5972849|NCT03142334|9558534|FG001|Overall Study|Ongoing on trial follow up|454
6049185|NCT00421889|9648402|FG008|Overall Study|Withdrawal by Subject|0
6049186|NCT00421889|9648394|FG000|Overall Study|Death|0
6049187|NCT00421889|9648395|FG001|Overall Study|Death|0
6049188|NCT00421889|9648396|FG002|Overall Study|Death|0
6049189|NCT00421889|9648397|FG003|Overall Study|Death|0
6049190|NCT00421889|9648398|FG004|Overall Study|Death|1
6049191|NCT00421889|9648399|FG005|Overall Study|Death|1
6049192|NCT00421889|9648400|FG006|Overall Study|Death|0
6049193|NCT00421889|9648401|FG007|Overall Study|Death|0
6049194|NCT00421889|9648402|FG008|Overall Study|Death|0
6049195|NCT00421889|9648394|FG000|Overall Study|Progressive disease|3
6049196|NCT00421889|9648395|FG001|Overall Study|Progressive disease|2
6049197|NCT00421889|9648396|FG002|Overall Study|Progressive disease|2
6049198|NCT00421889|9648397|FG003|Overall Study|Progressive disease|3
6049199|NCT00421889|9648398|FG004|Overall Study|Progressive disease|2
6049200|NCT00421889|9648399|FG005|Overall Study|Progressive disease|21
6049201|NCT00421889|9648400|FG006|Overall Study|Progressive disease|3
6049202|NCT00421889|9648401|FG007|Overall Study|Progressive disease|1
6049203|NCT00421889|9648402|FG008|Overall Study|Progressive disease|5
6049204|NCT00421889|9648394|FG000|Overall Study|Patient/Investigator request|0
6049205|NCT00421889|9648395|FG001|Overall Study|Patient/Investigator request|0
6049206|NCT00421889|9648396|FG002|Overall Study|Patient/Investigator request|0
6049207|NCT00421889|9648397|FG003|Overall Study|Patient/Investigator request|0
6049208|NCT00421889|9648398|FG004|Overall Study|Patient/Investigator request|0
6049209|NCT00421889|9648399|FG005|Overall Study|Patient/Investigator request|9
6049210|NCT00421889|9648400|FG006|Overall Study|Patient/Investigator request|0
6049211|NCT00421889|9648401|FG007|Overall Study|Patient/Investigator request|1
6049212|NCT00421889|9648402|FG008|Overall Study|Patient/Investigator request|3
6049213|NCT00421889|9648394|FG000|Overall Study|Lost to Follow-up|0
5972850|NCT02857426|9558614|FG000|Overall Study|Disease progression|34
5972851|NCT02857426|9558615|FG001|Overall Study|Disease progression|13
5972852|NCT02857426|9558614|FG000|Overall Study|Study drug toxicity|4
5972853|NCT02857426|9558615|FG001|Overall Study|Study drug toxicity|1
5972854|NCT02857426|9558614|FG000|Overall Study|Death|1
5972855|NCT02857426|9558615|FG001|Overall Study|Death|0
5972856|NCT02857426|9558614|FG000|Overall Study|Adverse event unrelated to study drug|6
5972857|NCT02857426|9558615|FG001|Overall Study|Adverse event unrelated to study drug|2
5972858|NCT02857426|9558614|FG000|Overall Study|Participant withdrew consent|1
5972859|NCT02857426|9558615|FG001|Overall Study|Participant withdrew consent|1
5972860|NCT02857426|9558614|FG000|Overall Study|Maximum clinical benefit|1
5972861|NCT02857426|9558615|FG001|Overall Study|Maximum clinical benefit|0
5972862|NCT02857426|9558614|FG000|Overall Study|Completed treatment|0
5972863|NCT02857426|9558615|FG001|Overall Study|Completed treatment|2
5972864|NCT02855125|9558623|FG000|Overall Study|Withdrawal by Subject|2
5972865|NCT02855125|9558624|FG001|Overall Study|Withdrawal by Subject|2
5972866|NCT02855125|9558623|FG000|Overall Study|Clinical Disease Progression|5
5972867|NCT02855125|9558624|FG001|Overall Study|Clinical Disease Progression|4
5972868|NCT02855125|9558623|FG000|Overall Study|Radiologic Disease Progression|36
5972869|NCT02855125|9558624|FG001|Overall Study|Radiologic Disease Progression|39
5972870|NCT02855125|9558623|FG000|Overall Study|Adverse Event|11
5972871|NCT02855125|9558624|FG001|Overall Study|Adverse Event|7
5972872|NCT02855125|9558623|FG000|Overall Study|Physician Decision|1
5972873|NCT02855125|9558624|FG001|Overall Study|Physician Decision|0
5972874|NCT02855125|9558623|FG000|Overall Study|On Treatment|9
5972875|NCT02855125|9558624|FG001|Overall Study|On Treatment|11
5972876|NCT02855125|9558623|FG000|Overall Study|Randomized but not treated|0
5972877|NCT02855125|9558624|FG001|Overall Study|Randomized but not treated|1
5972878|NCT02836236|9558632|FG000|Overall Study|Randomized but Never Treated|1
5972879|NCT02836236|9558633|FG001|Overall Study|Randomized but Never Treated|0
5972880|NCT02836236|9558632|FG000|Overall Study|Withdrew Consent|2
5972881|NCT02836236|9558633|FG001|Overall Study|Withdrew Consent|0
5972882|NCT02836236|9558632|FG000|Overall Study|Adverse Event|0
5972883|NCT02836236|9558633|FG001|Overall Study|Adverse Event|1
5972884|NCT02836236|9558632|FG000|Overall Study|Investigator's Discretion|1
5972885|NCT02836236|9558633|FG001|Overall Study|Investigator's Discretion|0
5972886|NCT02836236|9558632|FG000|Overall Study|Still on Study|101
5972887|NCT02836236|9558633|FG001|Overall Study|Still on Study|49
5972888|NCT02680587|9558651|FG000|Overall Study|Withdrawal by Subject|1
5972889|NCT02680587|9558652|FG001|Overall Study|Withdrawal by Subject|0
6087878|NCT00671853|9698464|FG000|Overall Study|Physician Decision|0
6087879|NCT00671853|9698465|FG001|Overall Study|Physician Decision|2
6087880|NCT00671853|9698464|FG000|Overall Study|Non-adherence with study procedures|1
6087881|NCT00671853|9698465|FG001|Overall Study|Non-adherence with study procedures|4
6087882|NCT00671879|9698476|FG000|Overall Study|Withdrawal by Subject|0
6087883|NCT00671879|9698477|FG001|Overall Study|Withdrawal by Subject|4
6087884|NCT00671879|9698478|FG002|Overall Study|Withdrawal by Subject|6
6087885|NCT00671931|9698497|FG000|Overall Study|Physician Decision|1
6087886|NCT00671931|9698498|FG001|Overall Study|Physician Decision|0
6087887|NCT00671931|9698499|FG002|Overall Study|Physician Decision|0
5972900|NCT02574455|9558685|FG000|Overall Study|Death|197
5972901|NCT02574455|9558686|FG001|Overall Study|Death|210
5972902|NCT02574455|9558685|FG000|Overall Study|Withdrawal of Consent|11
5972903|NCT02574455|9558686|FG001|Overall Study|Withdrawal of Consent|28
5972904|NCT02574455|9558685|FG000|Overall Study|Lost to Follow-up|4
5972905|NCT02574455|9558686|FG001|Overall Study|Lost to Follow-up|4
5972906|NCT02574455|9558685|FG000|Overall Study|Sponsor's Decision|55
5972907|NCT02574455|9558686|FG001|Overall Study|Sponsor's Decision|20
5972908|NCT02527798|9558698|FG000|Overall Study|Physician Decision|1
5972909|NCT02527798|9558699|FG001|Overall Study|Physician Decision|0
5972910|NCT02527798|9558700|FG002|Overall Study|Physician Decision|1
5972911|NCT02527798|9558701|FG003|Overall Study|Physician Decision|1
5972912|NCT02527798|9558702|FG004|Overall Study|Physician Decision|0
5972913|NCT02527798|9558703|FG005|Overall Study|Physician Decision|0
5972914|NCT02527798|9558698|FG000|Overall Study|Death|0
5972915|NCT02527798|9558699|FG001|Overall Study|Death|0
5972916|NCT02527798|9558700|FG002|Overall Study|Death|1
5972917|NCT02527798|9558701|FG003|Overall Study|Death|0
5972918|NCT02527798|9558702|FG004|Overall Study|Death|0
5972919|NCT02527798|9558703|FG005|Overall Study|Death|0
5972920|NCT02527798|9558698|FG000|Overall Study|Withdrawal by Subject|0
5972921|NCT02527798|9558699|FG001|Overall Study|Withdrawal by Subject|1
5972922|NCT02527798|9558700|FG002|Overall Study|Withdrawal by Subject|2
5972923|NCT02527798|9558701|FG003|Overall Study|Withdrawal by Subject|0
5972924|NCT02527798|9558702|FG004|Overall Study|Withdrawal by Subject|0
5972925|NCT02527798|9558703|FG005|Overall Study|Withdrawal by Subject|0
5972926|NCT02527798|9558698|FG000|Overall Study|Reason undisclosed|1
5972927|NCT02527798|9558699|FG001|Overall Study|Reason undisclosed|0
5972928|NCT02527798|9558700|FG002|Overall Study|Reason undisclosed|1
5972929|NCT02527798|9558701|FG003|Overall Study|Reason undisclosed|0
5972930|NCT02527798|9558702|FG004|Overall Study|Reason undisclosed|0
5972931|NCT02527798|9558703|FG005|Overall Study|Reason undisclosed|0
6087888|NCT00671931|9698500|FG003|Overall Study|Physician Decision|2
6087889|NCT00671931|9698501|FG004|Overall Study|Physician Decision|1
6087890|NCT00672139|9698553|FG000|Overall Study|Death|14
5972932|NCT02527798|9558698|FG000|Overall Study|Did not receive intervention|1
5972933|NCT02527798|9558699|FG001|Overall Study|Did not receive intervention|1
5972934|NCT02527798|9558700|FG002|Overall Study|Did not receive intervention|0
5972935|NCT02527798|9558701|FG003|Overall Study|Did not receive intervention|0
5972936|NCT02527798|9558702|FG004|Overall Study|Did not receive intervention|0
5972937|NCT02527798|9558703|FG005|Overall Study|Did not receive intervention|0
5972938|NCT02279745|9558754|FG000|Overall Study|Adverse Event|7
5972939|NCT02279745|9558754|FG000|Overall Study|Death|6
5972940|NCT02279745|9558754|FG000|Overall Study|Clinical Worsening as Defined by Protocol|2
5972941|NCT02279745|9558754|FG000|Overall Study|Withdrawal by Subject|2
5972942|NCT02279745|9558754|FG000|Overall Study|Pregnancy|1
5972943|NCT02279745|9558754|FG000|Overall Study|Study Non-compliance|1
5972944|NCT02279745|9558754|FG000|Overall Study|Did Not Transition to Study ROR-PH-303|1
5972945|NCT02030938|9558777|FG000|Overall Study|Lost to Follow-up|4
5972946|NCT02030938|9558777|FG000|Overall Study|Withdrawal by Subject|1
5972947|NCT02006147|9558789|FG000|Overall Study|Protocol Violation|1
5972948|NCT02006147|9558790|FG001|Overall Study|Protocol Violation|1
5972949|NCT02006147|9558791|FG002|Overall Study|Protocol Violation|0
5972950|NCT02006147|9558792|FG003|Overall Study|Protocol Violation|0
5972951|NCT02006147|9558789|FG000|Overall Study|Withdrawal by Subject|0
5972952|NCT02006147|9558790|FG001|Overall Study|Withdrawal by Subject|1
5972953|NCT02006147|9558791|FG002|Overall Study|Withdrawal by Subject|0
5972954|NCT02006147|9558792|FG003|Overall Study|Withdrawal by Subject|0
5972955|NCT02006147|9558789|FG000|Overall Study|Withdrawal by Sponsor|1
5972956|NCT02006147|9558790|FG001|Overall Study|Withdrawal by Sponsor|0
5972957|NCT02006147|9558791|FG002|Overall Study|Withdrawal by Sponsor|0
5972958|NCT02006147|9558792|FG003|Overall Study|Withdrawal by Sponsor|0
6049214|NCT00421889|9648395|FG001|Overall Study|Lost to Follow-up|0
6049215|NCT00421889|9648396|FG002|Overall Study|Lost to Follow-up|0
6049216|NCT00421889|9648397|FG003|Overall Study|Lost to Follow-up|0
6049217|NCT00421889|9648398|FG004|Overall Study|Lost to Follow-up|0
6049218|NCT00421889|9648399|FG005|Overall Study|Lost to Follow-up|0
6049219|NCT00421889|9648400|FG006|Overall Study|Lost to Follow-up|0
6049220|NCT00421889|9648401|FG007|Overall Study|Lost to Follow-up|0
6049221|NCT00421889|9648402|FG008|Overall Study|Lost to Follow-up|1
6049222|NCT00421928|9648429|FG000|Overall Study|Adverse Event|61
6049223|NCT00421928|9648430|FG001|Overall Study|Adverse Event|140
6049224|NCT00421928|9648431|FG002|Overall Study|Adverse Event|22
6049225|NCT00421928|9648429|FG000|Overall Study|Lost to Follow-up|5
6049226|NCT00421928|9648430|FG001|Overall Study|Lost to Follow-up|0
6049227|NCT00421928|9648431|FG002|Overall Study|Lost to Follow-up|3
6049228|NCT00421928|9648429|FG000|Overall Study|Withdrawal by Subject|50
6049229|NCT00421928|9648430|FG001|Overall Study|Withdrawal by Subject|48
6049230|NCT00421928|9648431|FG002|Overall Study|Withdrawal by Subject|43
6049231|NCT00421928|9648429|FG000|Overall Study|Lack of Efficacy|15
6049232|NCT00421928|9648430|FG001|Overall Study|Lack of Efficacy|7
6049233|NCT00421928|9648431|FG002|Overall Study|Lack of Efficacy|35
6049234|NCT00421928|9648429|FG000|Overall Study|Study drug non-compliant|6
6049235|NCT00421928|9648430|FG001|Overall Study|Study drug non-compliant|7
6049236|NCT00421928|9648431|FG002|Overall Study|Study drug non-compliant|4
6049237|NCT00421928|9648429|FG000|Overall Study|All other|26
6049238|NCT00421928|9648430|FG001|Overall Study|All other|21
6049239|NCT00421928|9648431|FG002|Overall Study|All other|27
6049240|NCT00421928|9648429|FG000|Overall Study|Death|0
6049241|NCT00421928|9648430|FG001|Overall Study|Death|1
6049242|NCT00421928|9648431|FG002|Overall Study|Death|0
6049243|NCT00421993|9648443|FG000|Overall Study|Withdrawal by Subject|22
6049244|NCT00421993|9648444|FG001|Overall Study|Withdrawal by Subject|23
6049245|NCT00421993|9648445|FG002|Overall Study|Withdrawal by Subject|23
6049246|NCT00421993|9648446|FG003|Overall Study|Withdrawal by Subject|24
6049247|NCT00421993|9648443|FG000|Overall Study|Lost to Follow-up|18
6049248|NCT00421993|9648444|FG001|Overall Study|Lost to Follow-up|19
6049249|NCT00421993|9648445|FG002|Overall Study|Lost to Follow-up|22
6049250|NCT00421993|9648446|FG003|Overall Study|Lost to Follow-up|20
6049251|NCT00421993|9648443|FG000|Overall Study|Adverse Event|11
6049252|NCT00421993|9648444|FG001|Overall Study|Adverse Event|1
6049253|NCT00421993|9648445|FG002|Overall Study|Adverse Event|6
6049254|NCT00421993|9648446|FG003|Overall Study|Adverse Event|4
6049255|NCT00421993|9648443|FG000|Overall Study|Protocol Violation|2
6049256|NCT00421993|9648444|FG001|Overall Study|Protocol Violation|2
6049257|NCT00421993|9648445|FG002|Overall Study|Protocol Violation|0
6049258|NCT00421993|9648446|FG003|Overall Study|Protocol Violation|1
6049259|NCT00421993|9648443|FG000|Overall Study|Lack of Efficacy|0
6049260|NCT00421993|9648444|FG001|Overall Study|Lack of Efficacy|3
6049261|NCT00421993|9648445|FG002|Overall Study|Lack of Efficacy|0
6049262|NCT00421993|9648446|FG003|Overall Study|Lack of Efficacy|5
6049263|NCT00421993|9648443|FG000|Overall Study|Pregnancy|0
6049264|NCT00421993|9648444|FG001|Overall Study|Pregnancy|1
6049265|NCT00421993|9648445|FG002|Overall Study|Pregnancy|1
6049266|NCT00421993|9648446|FG003|Overall Study|Pregnancy|2
6049267|NCT00421993|9648443|FG000|Overall Study|Subject transportation issues|0
6049268|NCT00421993|9648444|FG001|Overall Study|Subject transportation issues|0
6049269|NCT00421993|9648445|FG002|Overall Study|Subject transportation issues|0
6049270|NCT00421993|9648446|FG003|Overall Study|Subject transportation issues|1
6049271|NCT00422058|9648471|FG000|Double-Blind, Week 0-20|Adverse Event|3
5972959|NCT01940341|9558800|FG000|Double-Blind Phase|Randomized but Never Treated|0
5972960|NCT01940341|9558801|FG001|Double-Blind Phase|Randomized but Never Treated|1
5972961|NCT01940341|9558800|FG000|Double-Blind Phase|Adverse Event|3
5972962|NCT01940341|9558801|FG001|Double-Blind Phase|Adverse Event|2
5972963|NCT01940341|9558800|FG000|Double-Blind Phase|Withdrew Consent|3
5972964|NCT01940341|9558801|FG001|Double-Blind Phase|Withdrew Consent|2
5972965|NCT01940341|9558800|FG000|Double-Blind Phase|Lost to Follow-up|4
5972966|NCT01940341|9558801|FG001|Double-Blind Phase|Lost to Follow-up|1
5972967|NCT01940341|9558800|FG000|Double-Blind Phase|Pregnancy|0
5972968|NCT01940341|9558801|FG001|Double-Blind Phase|Pregnancy|1
5972969|NCT01940341|9558800|FG000|Double-Blind Phase|Investigator's Discretion|1
5972970|NCT01940341|9558801|FG001|Double-Blind Phase|Investigator's Discretion|0
5972971|NCT01940341|9558800|FG000|Double-Blind Phase|Non-Compliance with Study Drug|0
5972972|NCT01940341|9558801|FG001|Double-Blind Phase|Non-Compliance with Study Drug|1
6049272|NCT00422058|9648472|FG001|Double-Blind, Week 0-20|Adverse Event|4
6049273|NCT00422058|9648473|FG002|Double-Blind, Week 0-20|Adverse Event|5
6049274|NCT00422058|9648474|FG003|Double-Blind, Week 0-20|Adverse Event|9
6049275|NCT00422058|9648475|FG004|Double-Blind, Week 0-20|Adverse Event|5
6049276|NCT00422058|9648476|FG005|Double-Blind, Week 0-20|Adverse Event|3
6049277|NCT00422058|9648471|FG000|Double-Blind, Week 0-20|Protocol Violation|3
6049278|NCT00422058|9648472|FG001|Double-Blind, Week 0-20|Protocol Violation|2
6049279|NCT00422058|9648473|FG002|Double-Blind, Week 0-20|Protocol Violation|2
6049280|NCT00422058|9648474|FG003|Double-Blind, Week 0-20|Protocol Violation|3
6049281|NCT00422058|9648475|FG004|Double-Blind, Week 0-20|Protocol Violation|2
6049282|NCT00422058|9648476|FG005|Double-Blind, Week 0-20|Protocol Violation|2
6049283|NCT00422058|9648471|FG000|Double-Blind, Week 0-20|Lack of Efficacy|2
6049284|NCT00422058|9648472|FG001|Double-Blind, Week 0-20|Lack of Efficacy|1
6049285|NCT00422058|9648473|FG002|Double-Blind, Week 0-20|Lack of Efficacy|1
6049286|NCT00422058|9648474|FG003|Double-Blind, Week 0-20|Lack of Efficacy|0
6049287|NCT00422058|9648475|FG004|Double-Blind, Week 0-20|Lack of Efficacy|0
6049288|NCT00422058|9648476|FG005|Double-Blind, Week 0-20|Lack of Efficacy|1
6049289|NCT00422058|9648471|FG000|Double-Blind, Week 0-20|Other|11
6049290|NCT00422058|9648472|FG001|Double-Blind, Week 0-20|Other|3
6049291|NCT00422058|9648473|FG002|Double-Blind, Week 0-20|Other|8
6049292|NCT00422058|9648474|FG003|Double-Blind, Week 0-20|Other|8
6049293|NCT00422058|9648475|FG004|Double-Blind, Week 0-20|Other|4
6049294|NCT00422058|9648476|FG005|Double-Blind, Week 0-20|Other|10
6049295|NCT00422058|9648471|FG000|Open-Label Extension, Week 20-104|Not giving consent for extension|12
6049296|NCT00422058|9648472|FG001|Open-Label Extension, Week 20-104|Not giving consent for extension|17
6049297|NCT00422058|9648473|FG002|Open-Label Extension, Week 20-104|Not giving consent for extension|15
6049298|NCT00422058|9648474|FG003|Open-Label Extension, Week 20-104|Not giving consent for extension|8
6049299|NCT00422058|9648475|FG004|Open-Label Extension, Week 20-104|Not giving consent for extension|10
6049300|NCT00422058|9648476|FG005|Open-Label Extension, Week 20-104|Not giving consent for extension|12
6049301|NCT00422058|9648471|FG000|Open-Label Extension, Week 20-104|Adverse Event|3
6049302|NCT00422058|9648472|FG001|Open-Label Extension, Week 20-104|Adverse Event|4
6049303|NCT00422058|9648473|FG002|Open-Label Extension, Week 20-104|Adverse Event|7
6049304|NCT00422058|9648474|FG003|Open-Label Extension, Week 20-104|Adverse Event|4
6049305|NCT00422058|9648475|FG004|Open-Label Extension, Week 20-104|Adverse Event|4
6049306|NCT00422058|9648476|FG005|Open-Label Extension, Week 20-104|Adverse Event|0
6049307|NCT00422058|9648471|FG000|Open-Label Extension, Week 20-104|Protocol Violation|1
6049308|NCT00422058|9648472|FG001|Open-Label Extension, Week 20-104|Protocol Violation|2
6049309|NCT00422058|9648473|FG002|Open-Label Extension, Week 20-104|Protocol Violation|3
6049310|NCT00422058|9648474|FG003|Open-Label Extension, Week 20-104|Protocol Violation|1
6049311|NCT00422058|9648475|FG004|Open-Label Extension, Week 20-104|Protocol Violation|5
6049312|NCT00422058|9648476|FG005|Open-Label Extension, Week 20-104|Protocol Violation|3
6049313|NCT00422058|9648471|FG000|Open-Label Extension, Week 20-104|Lack of Efficacy|3
6049314|NCT00422058|9648472|FG001|Open-Label Extension, Week 20-104|Lack of Efficacy|2
5972973|NCT01940341|9558800|FG000|Double-Blind Phase|Protocol Specified Criteria|1
5972974|NCT01940341|9558801|FG001|Double-Blind Phase|Protocol Specified Criteria|0
5972975|NCT01940341|9558800|FG000|Double-Blind Phase|Still on Double-Blind Treatment|269
5972976|NCT01940341|9558801|FG001|Double-Blind Phase|Still on Double-Blind Treatment|132
5972977|NCT01940341|9558800|FG000|Open-label Extension Phase|Still on Study|4
5972978|NCT01940341|9558801|FG001|Open-label Extension Phase|Still on Study|1
5972979|NCT01925794|9558809|FG000|180 Days|Death|2
5972980|NCT01925794|9558809|FG000|180 Days|Withdrawal by Subject|2
5972981|NCT01925794|9558809|FG000|270 Days|Death|2
5972982|NCT01925794|9558809|FG000|270 Days|Protocol Violation|3
5972983|NCT01849250|9558832|FG000|Overall Study|Withdrawal by Subject|1
5972984|NCT01849250|9558833|FG001|Overall Study|Withdrawal by Subject|0
5972985|NCT01849250|9558832|FG000|Overall Study|Not Evaluable|5
5972986|NCT01849250|9558833|FG001|Overall Study|Not Evaluable|3
5972987|NCT01849250|9558832|FG000|Overall Study|Screen Failure|1
5972988|NCT01849250|9558833|FG001|Overall Study|Screen Failure|0
5972989|NCT01441115|9558844|FG000|Overall Study|Taken off study - Principal Investigator discretion|1
5972990|NCT01199302|9558855|FG000|Overall Study|Adverse Event|1
5972991|NCT01199302|9558856|FG001|Overall Study|Adverse Event|1
5972992|NCT01199302|9558857|FG002|Overall Study|Adverse Event|2
5972993|NCT01199302|9558858|FG003|Overall Study|Adverse Event|0
5972994|NCT01199302|9558855|FG000|Overall Study|Withdrawal by Subject|2
5972995|NCT01199302|9558856|FG001|Overall Study|Withdrawal by Subject|2
5972996|NCT01199302|9558857|FG002|Overall Study|Withdrawal by Subject|3
5972997|NCT01199302|9558858|FG003|Overall Study|Withdrawal by Subject|0
5972998|NCT01199302|9558855|FG000|Overall Study|Disease Progression|3
5972999|NCT01199302|9558856|FG001|Overall Study|Disease Progression|4
5973000|NCT01199302|9558857|FG002|Overall Study|Disease Progression|4
5973001|NCT01199302|9558858|FG003|Overall Study|Disease Progression|2
5973002|NCT01199302|9558855|FG000|Overall Study|Study Termination|13
5973003|NCT01199302|9558856|FG001|Overall Study|Study Termination|8
6087891|NCT00672139|9698554|FG001|Overall Study|Death|23
5973004|NCT01199302|9558857|FG002|Overall Study|Study Termination|11
5973005|NCT01199302|9558858|FG003|Overall Study|Study Termination|9
5973006|NCT01199302|9558855|FG000|Overall Study|Lost to Follow-up|0
5973007|NCT01199302|9558856|FG001|Overall Study|Lost to Follow-up|1
5973008|NCT01199302|9558857|FG002|Overall Study|Lost to Follow-up|0
5973009|NCT01199302|9558858|FG003|Overall Study|Lost to Follow-up|0
5973010|NCT01199302|9558855|FG000|Overall Study|Other|1
5973011|NCT01199302|9558856|FG001|Overall Study|Other|0
5973012|NCT01199302|9558857|FG002|Overall Study|Other|0
6049315|NCT00422058|9648473|FG002|Open-Label Extension, Week 20-104|Lack of Efficacy|5
6049316|NCT00422058|9648474|FG003|Open-Label Extension, Week 20-104|Lack of Efficacy|2
6049317|NCT00422058|9648475|FG004|Open-Label Extension, Week 20-104|Lack of Efficacy|0
6049318|NCT00422058|9648476|FG005|Open-Label Extension, Week 20-104|Lack of Efficacy|1
6049319|NCT00422058|9648471|FG000|Open-Label Extension, Week 20-104|Other|13
6049320|NCT00422058|9648472|FG001|Open-Label Extension, Week 20-104|Other|14
6049321|NCT00422058|9648473|FG002|Open-Label Extension, Week 20-104|Other|6
6049322|NCT00422058|9648474|FG003|Open-Label Extension, Week 20-104|Other|13
6049323|NCT00422058|9648475|FG004|Open-Label Extension, Week 20-104|Other|16
6049324|NCT00422058|9648476|FG005|Open-Label Extension, Week 20-104|Other|18
6049325|NCT00422084|9648492|FG000|Overall Study|Adverse Event|21
6049326|NCT00422084|9648493|FG001|Overall Study|Adverse Event|7
6049327|NCT00422084|9648492|FG000|Overall Study|Withdrawal by Subject|12
6049328|NCT00422084|9648493|FG001|Overall Study|Withdrawal by Subject|9
6049329|NCT00422084|9648492|FG000|Overall Study|Lost to Follow-up|14
6049330|NCT00422084|9648493|FG001|Overall Study|Lost to Follow-up|9
6049331|NCT00422084|9648492|FG000|Overall Study|Protocol Violation|4
6049332|NCT00422084|9648493|FG001|Overall Study|Protocol Violation|1
6049333|NCT00422084|9648492|FG000|Overall Study|Lack of Efficacy|40
6049334|NCT00422084|9648493|FG001|Overall Study|Lack of Efficacy|42
6049335|NCT00422084|9648492|FG000|Overall Study|P. vivax infection|3
6049336|NCT00422084|9648493|FG001|Overall Study|P. vivax infection|6
6049337|NCT00422084|9648492|FG000|Overall Study|Cyesis|1
6049338|NCT00422084|9648493|FG001|Overall Study|Cyesis|0
6049339|NCT00422084|9648492|FG000|Overall Study|Withdrawn from study accidentally|1
6049340|NCT00422084|9648493|FG001|Overall Study|Withdrawn from study accidentally|0
6049341|NCT00422084|9648492|FG000|Overall Study|Non-compliance|1
6049342|NCT00422084|9648493|FG001|Overall Study|Non-compliance|0
6049343|NCT00422084|9648492|FG000|Overall Study|Re-location|0
6049344|NCT00422084|9648493|FG001|Overall Study|Re-location|1
6049345|NCT00422084|9648492|FG000|Overall Study|Not defined|1
6049346|NCT00422084|9648493|FG001|Overall Study|Not defined|1
6049347|NCT00422097|9648505|FG000|Dose Level 2|Still on treatment|0
6049348|NCT00422097|9648506|FG001|Dose Level 2|Still on treatment|1
6049349|NCT00422097|9648507|FG002|Dose Level 2|Still on treatment|0
6049350|NCT00422097|9648508|FG003|Dose Level 2|Still on treatment|0
6049351|NCT00422097|9648509|FG004|Dose Level 2|Still on treatment|0
6049352|NCT00422097|9648510|FG005|Dose Level 2|Still on treatment|0
6049353|NCT00422097|9648511|FG006|Dose Level 2|Still on treatment|0
6049354|NCT00422097|9648512|FG007|Dose Level 2|Still on treatment|0
6049355|NCT00422162|9648538|FG000|Overall Study|Adverse Event|11
6049356|NCT00422162|9648539|FG001|Overall Study|Adverse Event|9
6049357|NCT00422162|9648538|FG000|Overall Study|Lack of Efficacy|4
6049358|NCT00422162|9648539|FG001|Overall Study|Lack of Efficacy|10
6049359|NCT00422162|9648538|FG000|Overall Study|Withdrawal by Subject|7
6049360|NCT00422162|9648539|FG001|Overall Study|Withdrawal by Subject|6
6049361|NCT00422162|9648538|FG000|Overall Study|Lost to Follow-up|1
6049362|NCT00422162|9648539|FG001|Overall Study|Lost to Follow-up|2
6049363|NCT00422162|9648538|FG000|Overall Study|Non-Compliant with Protocol|1
6049364|NCT00422162|9648539|FG001|Overall Study|Non-Compliant with Protocol|1
6049365|NCT00422162|9648538|FG000|Overall Study|Other|0
6049366|NCT00422162|9648539|FG001|Overall Study|Other|1
6049367|NCT00422162|9648538|FG000|Overall Study|Didn't Receive Treatment|0
6049368|NCT00422162|9648539|FG001|Overall Study|Didn't Receive Treatment|1
6049369|NCT00422227|9648562|FG000|Overall Study|Adverse Event|3
6049370|NCT00422227|9648563|FG001|Overall Study|Adverse Event|8
6049371|NCT00422227|9648562|FG000|Overall Study|Lost to Follow-up|1
6049372|NCT00422227|9648563|FG001|Overall Study|Lost to Follow-up|3
5973013|NCT01199302|9558858|FG003|Overall Study|Other|0
6049373|NCT00422227|9648562|FG000|Overall Study|Withdrawal by Subject|0
6087892|NCT00672139|9698553|FG000|Overall Study|Withdrawal by Subject|2
6087893|NCT00672139|9698554|FG001|Overall Study|Withdrawal by Subject|11
6087894|NCT00672139|9698553|FG000|Overall Study|Adverse Event|4
6087895|NCT00672139|9698554|FG001|Overall Study|Adverse Event|7
6087896|NCT00672139|9698553|FG000|Overall Study|Physician Decision|2
5973014|NCT01123707|9558869|FG000|Overall Study|Lost to Follow-up|3
5973015|NCT01123707|9558870|FG001|Overall Study|Lost to Follow-up|1
5973016|NCT01123707|9558871|FG002|Overall Study|Lost to Follow-up|3
5973017|NCT01123707|9558872|FG003|Overall Study|Lost to Follow-up|2
5973018|NCT01123707|9558869|FG000|Overall Study|Adverse Event|5
5973019|NCT01123707|9558870|FG001|Overall Study|Adverse Event|7
5973020|NCT01123707|9558871|FG002|Overall Study|Adverse Event|5
5973021|NCT01123707|9558872|FG003|Overall Study|Adverse Event|3
5973022|NCT01123707|9558869|FG000|Overall Study|Sponsor Discontinued Study|30
5973023|NCT01123707|9558870|FG001|Overall Study|Sponsor Discontinued Study|24
5973024|NCT01123707|9558871|FG002|Overall Study|Sponsor Discontinued Study|25
5973025|NCT01123707|9558872|FG003|Overall Study|Sponsor Discontinued Study|40
5973026|NCT01123707|9558869|FG000|Overall Study|Participant Met Withdrawal Criteria|1
5973027|NCT01123707|9558870|FG001|Overall Study|Participant Met Withdrawal Criteria|1
5973028|NCT01123707|9558871|FG002|Overall Study|Participant Met Withdrawal Criteria|0
5973029|NCT01123707|9558872|FG003|Overall Study|Participant Met Withdrawal Criteria|1
5973030|NCT01123707|9558869|FG000|Overall Study|Investigator Withdrew Participant|0
5973031|NCT01123707|9558870|FG001|Overall Study|Investigator Withdrew Participant|1
5973032|NCT01123707|9558871|FG002|Overall Study|Investigator Withdrew Participant|1
5973033|NCT01123707|9558872|FG003|Overall Study|Investigator Withdrew Participant|1
5973034|NCT01123707|9558869|FG000|Overall Study|Subject Withdrew Consent|4
5973035|NCT01123707|9558870|FG001|Overall Study|Subject Withdrew Consent|5
5973036|NCT01123707|9558871|FG002|Overall Study|Subject Withdrew Consent|1
5973037|NCT01123707|9558872|FG003|Overall Study|Subject Withdrew Consent|2
5973038|NCT01123707|9558869|FG000|Overall Study|Lack of Efficacy|1
5973039|NCT01123707|9558870|FG001|Overall Study|Lack of Efficacy|2
5973040|NCT01123707|9558871|FG002|Overall Study|Lack of Efficacy|1
5973041|NCT01123707|9558872|FG003|Overall Study|Lack of Efficacy|0
5973042|NCT01123707|9558869|FG000|Overall Study|Subject Met Exclusion Criteria|0
5973043|NCT01123707|9558870|FG001|Overall Study|Subject Met Exclusion Criteria|0
5973044|NCT01123707|9558871|FG002|Overall Study|Subject Met Exclusion Criteria|2
5973045|NCT01123707|9558872|FG003|Overall Study|Subject Met Exclusion Criteria|1
5973046|NCT00462943|9558889|FG000|Overall Study|Failure to achieve a response|5
5973047|NCT00462943|9558890|FG001|Overall Study|Failure to achieve a response|5
5973048|NCT00462943|9558891|FG002|Overall Study|Failure to achieve a response|1
5973049|NCT00462943|9558889|FG000|Overall Study|Adverse Event|6
5973050|NCT00462943|9558890|FG001|Overall Study|Adverse Event|4
5973051|NCT00462943|9558891|FG002|Overall Study|Adverse Event|1
5973052|NCT00462943|9558889|FG000|Overall Study|Protocol Violation|1
5973053|NCT00462943|9558890|FG001|Overall Study|Protocol Violation|0
5973054|NCT00462943|9558891|FG002|Overall Study|Protocol Violation|0
5973055|NCT00462943|9558889|FG000|Overall Study|Request of Patient, PI, Sponsor or RA|8
5973056|NCT00462943|9558890|FG001|Overall Study|Request of Patient, PI, Sponsor or RA|2
5973057|NCT00462943|9558891|FG002|Overall Study|Request of Patient, PI, Sponsor or RA|4
5973058|NCT00462943|9558889|FG000|Overall Study|Disease Progression|15
5973059|NCT00462943|9558890|FG001|Overall Study|Disease Progression|15
5973060|NCT00462943|9558891|FG002|Overall Study|Disease Progression|9
5973061|NCT00462943|9558889|FG000|Overall Study|Death|5
5973062|NCT00462943|9558890|FG001|Overall Study|Death|2
5973063|NCT00462943|9558891|FG002|Overall Study|Death|7
5973064|NCT00462943|9558889|FG000|Overall Study|Stem Cell Transplant|1
5973065|NCT00462943|9558890|FG001|Overall Study|Stem Cell Transplant|1
5973066|NCT00462943|9558891|FG002|Overall Study|Stem Cell Transplant|0
5973067|NCT00462943|9558889|FG000|Overall Study|Bone Marrow Transplant|1
5973068|NCT00462943|9558890|FG001|Overall Study|Bone Marrow Transplant|0
5973069|NCT00462943|9558891|FG002|Overall Study|Bone Marrow Transplant|0
5973070|NCT00462943|9558889|FG000|Overall Study|Required Lymphocyte Infusion|1
5973071|NCT00462943|9558890|FG001|Overall Study|Required Lymphocyte Infusion|0
5973072|NCT00462943|9558891|FG002|Overall Study|Required Lymphocyte Infusion|0
5973073|NCT00462943|9558889|FG000|Overall Study|Transplant - not specified|1
5973074|NCT00462943|9558890|FG001|Overall Study|Transplant - not specified|0
5973075|NCT00462943|9558891|FG002|Overall Study|Transplant - not specified|1
5973076|NCT00462943|9558889|FG000|Overall Study|Physician Decision|1
5973077|NCT00462943|9558890|FG001|Overall Study|Physician Decision|0
5973078|NCT00462943|9558891|FG002|Overall Study|Physician Decision|0
5973079|NCT00462943|9558889|FG000|Overall Study|Withdrawal by Subject|0
5973080|NCT00462943|9558890|FG001|Overall Study|Withdrawal by Subject|1
5973081|NCT00462943|9558891|FG002|Overall Study|Withdrawal by Subject|0
5973082|NCT00248287|9558901|FG000|Overall Study|Adverse Event|11
5973083|NCT00248287|9558902|FG001|Overall Study|Adverse Event|10
6193568|NCT01439360|9851273|FG000|Overall Study|Withdrawal by Subject|140
6193569|NCT01439360|9851274|FG001|Overall Study|Withdrawal by Subject|129
6193570|NCT01439373|9851282|FG000|Monotherapy (Day 1)|Participant Dropped-out at Day 1 visit|0
6193571|NCT01439373|9851283|FG001|Monotherapy (Day 1)|Participant Dropped-out at Day 1 visit|1
6273095|NCT02186301|9976342|FG000|Overall Study|Protocol Deviation|0
5973084|NCT00248287|9558901|FG000|Overall Study|Death|1
5973085|NCT00248287|9558902|FG001|Overall Study|Death|0
5973086|NCT00248287|9558901|FG000|Overall Study|Lost to Follow-up|0
5973087|NCT00248287|9558902|FG001|Overall Study|Lost to Follow-up|1
5973088|NCT00248287|9558901|FG000|Overall Study|Investigator Request|4
5973089|NCT00248287|9558902|FG001|Overall Study|Investigator Request|3
5973090|NCT00248287|9558901|FG000|Overall Study|Patient Request|5
5973091|NCT00248287|9558902|FG001|Overall Study|Patient Request|3
5973092|NCT00248287|9558901|FG000|Overall Study|Other|3
5973093|NCT00248287|9558902|FG001|Overall Study|Other|2
5973094|NCT00105560|9558912|FG000|Overall Study|Lost to Follow-up|1
6049374|NCT00422227|9648563|FG001|Overall Study|Withdrawal by Subject|4
6049375|NCT00422292|9648584|FG000|Overall Study|Serious adverse events|1
6049376|NCT00422292|9648585|FG001|Overall Study|Serious adverse events|4
6049377|NCT00422292|9648586|FG002|Overall Study|Serious adverse events|0
6049378|NCT00422292|9648587|FG003|Overall Study|Serious adverse events|0
6049379|NCT00422292|9648584|FG000|Overall Study|Adverse Event|1
6049380|NCT00422292|9648585|FG001|Overall Study|Adverse Event|0
6049381|NCT00422292|9648586|FG002|Overall Study|Adverse Event|1
6049382|NCT00422292|9648587|FG003|Overall Study|Adverse Event|0
6049383|NCT00422292|9648584|FG000|Overall Study|Protocol Violation|4
6049384|NCT00422292|9648585|FG001|Overall Study|Protocol Violation|25
6049385|NCT00422292|9648586|FG002|Overall Study|Protocol Violation|8
6049386|NCT00422292|9648587|FG003|Overall Study|Protocol Violation|5
6049387|NCT00422292|9648584|FG000|Overall Study|Lost to Follow-up|6
6049388|NCT00422292|9648585|FG001|Overall Study|Lost to Follow-up|12
6049389|NCT00422292|9648586|FG002|Overall Study|Lost to Follow-up|6
6049390|NCT00422292|9648587|FG003|Overall Study|Lost to Follow-up|6
6049391|NCT00422292|9648584|FG000|Overall Study|Withdrawal by Subject|6
6049392|NCT00422292|9648585|FG001|Overall Study|Withdrawal by Subject|25
6049393|NCT00422292|9648586|FG002|Overall Study|Withdrawal by Subject|7
6049394|NCT00422292|9648587|FG003|Overall Study|Withdrawal by Subject|13
6049395|NCT00422383|9648602|FG000|Overall Study|Adverse Event|5
6049396|NCT00422383|9648603|FG001|Overall Study|Adverse Event|3
6049397|NCT00422383|9648604|FG002|Overall Study|Adverse Event|1
6049398|NCT00422383|9648605|FG003|Overall Study|Adverse Event|1
6049399|NCT00422383|9648606|FG004|Overall Study|Adverse Event|0
6049400|NCT00422383|9648602|FG000|Overall Study|Lack of Efficacy|4
6049401|NCT00422383|9648603|FG001|Overall Study|Lack of Efficacy|4
6049402|NCT00422383|9648604|FG002|Overall Study|Lack of Efficacy|2
6049403|NCT00422383|9648605|FG003|Overall Study|Lack of Efficacy|1
6049404|NCT00422383|9648606|FG004|Overall Study|Lack of Efficacy|1
6049405|NCT00422383|9648602|FG000|Overall Study|Lost to Follow-up|0
6049406|NCT00422383|9648603|FG001|Overall Study|Lost to Follow-up|1
6049407|NCT00422383|9648604|FG002|Overall Study|Lost to Follow-up|0
6049408|NCT00422383|9648605|FG003|Overall Study|Lost to Follow-up|0
6049409|NCT00422383|9648606|FG004|Overall Study|Lost to Follow-up|1
6049410|NCT00422383|9648602|FG000|Overall Study|Protocol Violation|1
6049411|NCT00422383|9648603|FG001|Overall Study|Protocol Violation|1
6049412|NCT00422383|9648604|FG002|Overall Study|Protocol Violation|1
6049413|NCT00422383|9648605|FG003|Overall Study|Protocol Violation|0
6049414|NCT00422383|9648606|FG004|Overall Study|Protocol Violation|0
6049415|NCT00422383|9648602|FG000|Overall Study|Withdrawal by Subject|5
6049416|NCT00422383|9648603|FG001|Overall Study|Withdrawal by Subject|5
6049417|NCT00422383|9648604|FG002|Overall Study|Withdrawal by Subject|0
6049418|NCT00422383|9648605|FG003|Overall Study|Withdrawal by Subject|0
6049419|NCT00422383|9648606|FG004|Overall Study|Withdrawal by Subject|1
6049420|NCT00422422|9648624|FG000|Overall Study|Lack of Efficacy|1
6049421|NCT00422422|9648624|FG000|Overall Study|Protocol Violation|1
6049422|NCT00422422|9648624|FG000|Overall Study|Withdrawal by Subject|2
6049423|NCT00422422|9648624|FG000|Overall Study|SAE, non-fatal|1
6049424|NCT00422422|9648624|FG000|Overall Study|AE, non-serious non-fatal|5
6049425|NCT00422461|9648638|FG000|Overall Study|Adverse Event|1
6049426|NCT00422461|9648639|FG001|Overall Study|Adverse Event|2
6049427|NCT00422461|9648640|FG002|Overall Study|Adverse Event|1
6049428|NCT00422461|9648641|FG003|Overall Study|Adverse Event|1
6049429|NCT00422461|9648638|FG000|Overall Study|Other|0
6049430|NCT00422461|9648639|FG001|Overall Study|Other|0
6049431|NCT00422461|9648640|FG002|Overall Study|Other|0
6049432|NCT00422461|9648641|FG003|Overall Study|Other|2
6049433|NCT00422461|9648638|FG000|Overall Study|Participants no longer willing to participate in study|1
6049434|NCT00422461|9648639|FG001|Overall Study|Participants no longer willing to participate in study|0
6049435|NCT00422461|9648640|FG002|Overall Study|Participants no longer willing to participate in study|0
6049436|NCT00422461|9648641|FG003|Overall Study|Participants no longer willing to participate in study|0
6049437|NCT00422461|9648638|FG000|Overall Study|Randomized but not treated|1
6049438|NCT00422461|9648639|FG001|Overall Study|Randomized but not treated|1
6049439|NCT00422461|9648640|FG002|Overall Study|Randomized but not treated|0
6049440|NCT00422461|9648641|FG003|Overall Study|Randomized but not treated|0
6049441|NCT00422513|9648653|FG000|Overall Study|Lack of Efficacy|4
6049442|NCT00422513|9648654|FG001|Overall Study|Lack of Efficacy|5
6049443|NCT00422513|9648653|FG000|Overall Study|Protocol Violation|23
6049444|NCT00422513|9648654|FG001|Overall Study|Protocol Violation|7
6049445|NCT00422513|9648653|FG000|Overall Study|Refused Treatment|4
6049446|NCT00422513|9648654|FG001|Overall Study|Refused Treatment|2
6049447|NCT00422513|9648653|FG000|Overall Study|Withdrawal by Subject|2
6049448|NCT00422513|9648654|FG001|Overall Study|Withdrawal by Subject|1
6049449|NCT00422513|9648653|FG000|Overall Study|early termination of the study|67
6049450|NCT00422513|9648654|FG001|Overall Study|early termination of the study|80
6049451|NCT00422513|9648653|FG000|Overall Study|Adverse Event|4
6049452|NCT00422513|9648654|FG001|Overall Study|Adverse Event|4
6049453|NCT00422513|9648653|FG000|Overall Study|Death|3
6049454|NCT00422513|9648654|FG001|Overall Study|Death|7
5973095|NCT04569786|9558946|FG000|Overall Study|Lost to Follow-up|1
5973096|NCT04569786|9558947|FG001|Overall Study|Lost to Follow-up|0
5973097|NCT04569786|9558948|FG002|Overall Study|Lost to Follow-up|4
5973098|NCT04569786|9558949|FG003|Overall Study|Lost to Follow-up|1
5973099|NCT04569786|9558950|FG004|Overall Study|Lost to Follow-up|0
5973100|NCT04569786|9558946|FG000|Overall Study|Withdrawal by Subject|0
5973101|NCT04569786|9558947|FG001|Overall Study|Withdrawal by Subject|0
5973102|NCT04569786|9558948|FG002|Overall Study|Withdrawal by Subject|0
5973103|NCT04569786|9558949|FG003|Overall Study|Withdrawal by Subject|5
5973104|NCT04569786|9558950|FG004|Overall Study|Withdrawal by Subject|1
5973105|NCT04569786|9558946|FG000|Overall Study|Physician Decision|0
5973106|NCT04569786|9558947|FG001|Overall Study|Physician Decision|0
5973107|NCT04569786|9558948|FG002|Overall Study|Physician Decision|0
5973108|NCT04569786|9558949|FG003|Overall Study|Physician Decision|1
5973109|NCT04569786|9558950|FG004|Overall Study|Physician Decision|0
5973110|NCT04129944|9558971|FG000|Overall Study|Death|0
5973111|NCT04129944|9558972|FG001|Overall Study|Death|0
5973112|NCT04129944|9558973|FG002|Overall Study|Death|0
5973113|NCT04129944|9558974|FG003|Overall Study|Death|1
5973114|NCT04129944|9558971|FG000|Overall Study|Lost to Follow-up|1
5973115|NCT04129944|9558972|FG001|Overall Study|Lost to Follow-up|0
5973116|NCT04129944|9558973|FG002|Overall Study|Lost to Follow-up|0
5973117|NCT04129944|9558974|FG003|Overall Study|Lost to Follow-up|0
5973118|NCT04129944|9558971|FG000|Overall Study|Withdrawal by Subject|1
5973119|NCT04129944|9558972|FG001|Overall Study|Withdrawal by Subject|0
5973120|NCT04129944|9558973|FG002|Overall Study|Withdrawal by Subject|1
5973121|NCT04129944|9558974|FG003|Overall Study|Withdrawal by Subject|2
5973122|NCT03857542|9558995|FG000|Overall Study|Adverse Event|1
5973123|NCT03857542|9558996|FG001|Overall Study|Adverse Event|3
5973124|NCT03857542|9558995|FG000|Overall Study|Withdrawal by Subject|2
5973125|NCT03857542|9558996|FG001|Overall Study|Withdrawal by Subject|1
5973126|NCT03857542|9558995|FG000|Overall Study|Lost to Follow-up|2
5973127|NCT03857542|9558996|FG001|Overall Study|Lost to Follow-up|1
5973128|NCT03857542|9558995|FG000|Overall Study|Reason not Specified|1
5973129|NCT03857542|9558996|FG001|Overall Study|Reason not Specified|0
5973130|NCT03848832|9559006|FG000|Overall Study|Withdrawal of Consent Due To Covid-19|0
5973131|NCT03848832|9559007|FG001|Overall Study|Withdrawal of Consent Due To Covid-19|0
5973132|NCT03848832|9559008|FG002|Overall Study|Withdrawal of Consent Due To Covid-19|1
5973133|NCT03848832|9559006|FG000|Overall Study|Withdrawal by Subject|0
5973134|NCT03848832|9559007|FG001|Overall Study|Withdrawal by Subject|0
5973135|NCT03848832|9559008|FG002|Overall Study|Withdrawal by Subject|1
5973136|NCT03848832|9559006|FG000|Overall Study|Withdrawal (Covid-19)|0
5973137|NCT03848832|9559007|FG001|Overall Study|Withdrawal (Covid-19)|2
5973138|NCT03848832|9559008|FG002|Overall Study|Withdrawal (Covid-19)|0
5973139|NCT03848832|9559006|FG000|Overall Study|Physician Decision|2
5973140|NCT03848832|9559007|FG001|Overall Study|Physician Decision|1
5973141|NCT03848832|9559008|FG002|Overall Study|Physician Decision|3
5973142|NCT03848832|9559006|FG000|Overall Study|Sponsor Decision - Covid-19 Precaution|0
5973143|NCT03848832|9559007|FG001|Overall Study|Sponsor Decision - Covid-19 Precaution|0
5973144|NCT03848832|9559008|FG002|Overall Study|Sponsor Decision - Covid-19 Precaution|1
5973145|NCT03848832|9559006|FG000|Overall Study|Adverse Event|1
5973146|NCT03848832|9559007|FG001|Overall Study|Adverse Event|0
5973147|NCT03848832|9559008|FG002|Overall Study|Adverse Event|0
5973148|NCT03656744|9559030|FG000|Overall Study|Adverse Event|1
5973149|NCT03656744|9559031|FG001|Overall Study|Adverse Event|4
5973150|NCT03656744|9559032|FG002|Overall Study|Adverse Event|1
6193572|NCT01439373|9851282|FG000|Combined With PEG and RIBA (Day 2 to 28)|Adverse Event|2
6193573|NCT01439373|9851283|FG001|Combined With PEG and RIBA (Day 2 to 28)|Adverse Event|0
6193574|NCT01439555|9851293|FG000|Overall Study|Protocol Violation|1
6087897|NCT00672139|9698554|FG001|Overall Study|Physician Decision|0
6087898|NCT00672139|9698553|FG000|Overall Study|Lack of Efficacy|4
6087899|NCT00672139|9698554|FG001|Overall Study|Lack of Efficacy|1
6087900|NCT00672139|9698553|FG000|Overall Study|Protocol Violation|1
6087901|NCT00672139|9698554|FG001|Overall Study|Protocol Violation|1
6087902|NCT00672139|9698553|FG000|Overall Study|hospice discharge, caregiver requests|3
6087903|NCT00672139|9698554|FG001|Overall Study|hospice discharge, caregiver requests|2
6087904|NCT00672256|9698569|FG000|Overall Study|PI dropped, bad data|44
6087905|NCT00672477|9698593|FG000|Overall Study|Adverse Event|10
6087906|NCT00672477|9698594|FG001|Overall Study|Adverse Event|7
6087907|NCT00672477|9698593|FG000|Overall Study|Death|7
6087908|NCT00672477|9698594|FG001|Overall Study|Death|11
6087909|NCT00672477|9698593|FG000|Overall Study|Physician Decision|2
6087910|NCT00672477|9698594|FG001|Overall Study|Physician Decision|0
6087911|NCT00672477|9698593|FG000|Overall Study|Protocol Violation|1
5973151|NCT03656744|9559030|FG000|Overall Study|Protocol Violation|1
5973152|NCT03656744|9559031|FG001|Overall Study|Protocol Violation|0
5973153|NCT03656744|9559032|FG002|Overall Study|Protocol Violation|0
5973154|NCT03656744|9559030|FG000|Overall Study|Lost to Follow-up|2
6087912|NCT00672477|9698594|FG001|Overall Study|Protocol Violation|1
6087913|NCT00672477|9698593|FG000|Overall Study|Withdrawal by Subject|5
6087914|NCT00672477|9698594|FG001|Overall Study|Withdrawal by Subject|3
6193575|NCT01439568|9851299|FG000|Overall Study|Lost to Follow-up|1
5973155|NCT03656744|9559031|FG001|Overall Study|Lost to Follow-up|2
5973156|NCT03656744|9559032|FG002|Overall Study|Lost to Follow-up|0
5973157|NCT03656744|9559030|FG000|Overall Study|Withdrawal by Subject|0
5973158|NCT03656744|9559031|FG001|Overall Study|Withdrawal by Subject|1
5973159|NCT03656744|9559032|FG002|Overall Study|Withdrawal by Subject|0
5973160|NCT03656744|9559030|FG000|Overall Study|Randomized in error. Did not start investigational product. Considered an ET.|1
5973161|NCT03656744|9559031|FG001|Overall Study|Randomized in error. Did not start investigational product. Considered an ET.|0
5973162|NCT03656744|9559032|FG002|Overall Study|Randomized in error. Did not start investigational product. Considered an ET.|0
5973163|NCT03510598|9559040|FG000|Overall Study|Withdrawal by Subject|1
5973164|NCT03487796|9559048|FG000|Overall Study|Lost to Follow-up|18
5973165|NCT03487796|9559049|FG001|Overall Study|Lost to Follow-up|6
5973166|NCT03446612|9559063|FG000|Overall Study|Protocol defined stopping criteria|0
5973167|NCT03446612|9559064|FG001|Overall Study|Protocol defined stopping criteria|1
5973168|NCT03370120|9559085|FG000|Overall Study|Adverse event, non-fatal|24
5973169|NCT03370120|9559085|FG000|Overall Study|Withdrawal by Subject|6
5973170|NCT03370120|9559085|FG000|Overall Study|Lost to Follow-up|1
5973171|NCT03370120|9559085|FG000|Overall Study|Lack of Efficacy|37
5973172|NCT03370120|9559085|FG000|Overall Study|Per sponsor's instructions|1
5973173|NCT03370120|9559085|FG000|Overall Study|Study was terminated by parent company UCB|2
5973174|NCT03370120|9559085|FG000|Overall Study|The study was ended by the promoter|3
5973175|NCT03370120|9559085|FG000|Overall Study|Discontinuation of drug development|3
5973176|NCT03370120|9559085|FG000|Overall Study|End of project|2
5973177|NCT03370120|9559085|FG000|Overall Study|Premature study closure|2
5973178|NCT03370120|9559085|FG000|Overall Study|Premature program termination|1
5973179|NCT03370120|9559085|FG000|Overall Study|Premature study termination|7
5973180|NCT03370120|9559085|FG000|Overall Study|Trial terminated by sponsor|2
5973181|NCT03370120|9559085|FG000|Overall Study|Trial discontinued by sponsor|2
5973182|NCT03370120|9559085|FG000|Overall Study|Study ended|15
5973183|NCT03370120|9559085|FG000|Overall Study|Clinical trial has been cancelled|1
5973184|NCT03370120|9559085|FG000|Overall Study|End of study per sponsor decision|2
5973185|NCT03370120|9559085|FG000|Overall Study|Promoter's decision|2
5973186|NCT03370120|9559085|FG000|Overall Study|The trial has been suspended|3
5973187|NCT03370120|9559085|FG000|Overall Study|Sponsor stopped PSL development based on data|3
5973188|NCT03370120|9559085|FG000|Overall Study|Early termination by order of sponsor|2
5973189|NCT03370120|9559085|FG000|Overall Study|Discontinuation of the study|5
5973190|NCT03370120|9559085|FG000|Overall Study|End of clinical trial discontinuation|1
5973191|NCT03370120|9559085|FG000|Overall Study|Because the clinical trial ended halfway|4
5973192|NCT03370120|9559085|FG000|Overall Study|Development discontinued|5
5973193|NCT03370120|9559085|FG000|Overall Study|Padsenovil program closed|3
5973194|NCT03370120|9559085|FG000|Overall Study|End of project|2
5973195|NCT03370120|9559085|FG000|Overall Study|Termination of project|1
5973196|NCT03370120|9559085|FG000|Overall Study|The study was interrupted by sponsor|4
5973197|NCT03370120|9559085|FG000|Overall Study|The protocol was interrupted by sponsor|1
5973198|NCT03370120|9559085|FG000|Overall Study|End of sponsor decision|1
5973199|NCT03370120|9559085|FG000|Overall Study|The study was terminated prematurely by study lead|1
5973200|NCT03370120|9559085|FG000|Overall Study|Early termination of studies|5
5973201|NCT03370120|9559085|FG000|Overall Study|This study is ended early|1
5973202|NCT03370120|9559085|FG000|Overall Study|End of padsevonil program|2
5973203|NCT03370120|9559085|FG000|Overall Study|Decision of sponsor|6
5973204|NCT03370120|9559085|FG000|Overall Study|Asked by the sponsor|3
5973205|NCT03370120|9559085|FG000|Overall Study|Sponsor decision to stop the protocol|1
5973206|NCT03370120|9559085|FG000|Overall Study|PI decision poor compliance from participant|1
5973207|NCT03370120|9559085|FG000|Overall Study|Promoter ended the study|3
5973208|NCT03370120|9559085|FG000|Overall Study|Premature study close by sponsor's decision|4
5973209|NCT03370120|9559085|FG000|Overall Study|Study terminated by sponsor|33
5973210|NCT03370120|9559085|FG000|Overall Study|Sponsor prematurely terminated this study|2
5973211|NCT03370120|9559085|FG000|Overall Study|Sponsor decision to terminate study|63
5973212|NCT03370120|9559085|FG000|Overall Study|Program closure|3
5973213|NCT03370120|9559085|FG000|Overall Study|Study ended prematurely|1
5973214|NCT03370120|9559085|FG000|Overall Study|Study stopped by sponsor|2
5973215|NCT03370120|9559085|FG000|Overall Study|Program termination|55
5973216|NCT03370120|9559085|FG000|Overall Study|Sponsor decision|62
5973217|NCT03370120|9559085|FG000|Overall Study|Sponsor study closure|10
5973218|NCT03143829|9559108|FG000|Overall Study|Withdrawal by Subject|2
5973219|NCT03143829|9559109|FG001|Overall Study|Withdrawal by Subject|5
5973220|NCT03143829|9559108|FG000|Overall Study|Lost to Follow-up|0
5973221|NCT03143829|9559109|FG001|Overall Study|Lost to Follow-up|2
5973222|NCT03143829|9559108|FG000|Overall Study|Death|1
5973223|NCT03143829|9559109|FG001|Overall Study|Death|1
5973224|NCT03143829|9559108|FG000|Overall Study|changed treatment, no longer eligible|2
5973225|NCT03143829|9559109|FG001|Overall Study|changed treatment, no longer eligible|2
6049455|NCT00422591|9648660|FG000|Overall Study|Physician Decision|4
6049456|NCT00422591|9648660|FG000|Overall Study|Withdrawal by Subject|2
6049457|NCT00422734|9648679|FG000|Overall Study|Physician Decision|1
6049458|NCT00422734|9648680|FG001|Overall Study|Physician Decision|1
6049459|NCT00422734|9648679|FG000|Overall Study|Protocol Violation|1
6049460|NCT00422734|9648680|FG001|Overall Study|Protocol Violation|6
6049461|NCT00422734|9648679|FG000|Overall Study|Withdrawal by Subject|12
6049462|NCT00422734|9648680|FG001|Overall Study|Withdrawal by Subject|8
5973226|NCT02963610|9559124|FG000|Overall Study|Study terminated prematurely due to funding/support being withdrawn by grantor. No analyses occurred|3
5973227|NCT02766335|9559131|FG000|Initial Registration|Adverse Event|6
5973228|NCT02766335|9559132|FG001|Initial Registration|Adverse Event|3
5973229|NCT02766335|9559133|FG002|Initial Registration|Adverse Event|0
5973230|NCT02766335|9559131|FG000|Initial Registration|Refusal unrelated to adverse event|1
5973231|NCT02766335|9559132|FG001|Initial Registration|Refusal unrelated to adverse event|0
5973232|NCT02766335|9559133|FG002|Initial Registration|Refusal unrelated to adverse event|0
5973233|NCT02766335|9559131|FG000|Initial Registration|Progression/relapse|49
5973234|NCT02766335|9559132|FG001|Initial Registration|Progression/relapse|15
5973235|NCT02766335|9559133|FG002|Initial Registration|Progression/relapse|0
5973236|NCT02766335|9559131|FG000|Initial Registration|Death|1
5973237|NCT02766335|9559132|FG001|Initial Registration|Death|3
5973238|NCT02766335|9559133|FG002|Initial Registration|Death|0
5973239|NCT02766335|9559131|FG000|Initial Registration|not protocol specified|1
5973240|NCT02766335|9559132|FG001|Initial Registration|not protocol specified|9
5973241|NCT02766335|9559133|FG002|Initial Registration|not protocol specified|0
5973242|NCT02766335|9559131|FG000|Re-registration of Arm I to MEDI4738|Death|0
5973243|NCT02766335|9559132|FG001|Re-registration of Arm I to MEDI4738|Death|0
5973244|NCT02766335|9559133|FG002|Re-registration of Arm I to MEDI4738|Death|1
5973245|NCT02766335|9559131|FG000|Re-registration of Arm I to MEDI4738|Progression/relapse|0
5973246|NCT02766335|9559132|FG001|Re-registration of Arm I to MEDI4738|Progression/relapse|0
5973247|NCT02766335|9559133|FG002|Re-registration of Arm I to MEDI4738|Progression/relapse|1
5973248|NCT02606136|9559139|FG000|Overall Study|Participant/Legal Guardian Decision|5
5973249|NCT02606136|9559139|FG000|Overall Study|Withdrawal by Subject|1
5973250|NCT02228382|9559148|FG000|Overall Study|Death|5
5973251|NCT02228382|9559149|FG001|Overall Study|Death|7
5973252|NCT02228382|9559150|FG002|Overall Study|Death|5
5973253|NCT02228382|9559151|FG003|Overall Study|Death|0
5973254|NCT02228382|9559152|FG004|Overall Study|Death|2
5973255|NCT02228382|9559148|FG000|Overall Study|Participant refused further follow-up|0
5973256|NCT02228382|9559149|FG001|Overall Study|Participant refused further follow-up|0
5973257|NCT02228382|9559150|FG002|Overall Study|Participant refused further follow-up|1
5973258|NCT02228382|9559151|FG003|Overall Study|Participant refused further follow-up|0
5973259|NCT02228382|9559152|FG004|Overall Study|Participant refused further follow-up|0
5973260|NCT02228382|9559148|FG000|Overall Study|Study terminated by sponsor|3
5973261|NCT02228382|9559149|FG001|Overall Study|Study terminated by sponsor|5
5973262|NCT02228382|9559150|FG002|Overall Study|Study terminated by sponsor|7
5973263|NCT02228382|9559151|FG003|Overall Study|Study terminated by sponsor|0
5973264|NCT02228382|9559152|FG004|Overall Study|Study terminated by sponsor|0
5973265|NCT02228382|9559148|FG000|Overall Study|Lost to Follow-up|0
5973266|NCT02228382|9559149|FG001|Overall Study|Lost to Follow-up|0
5973267|NCT02228382|9559150|FG002|Overall Study|Lost to Follow-up|3
5973268|NCT02228382|9559151|FG003|Overall Study|Lost to Follow-up|1
5973269|NCT02228382|9559152|FG004|Overall Study|Lost to Follow-up|0
5973270|NCT02228382|9559148|FG000|Overall Study|Withdrawal by Subject|0
5973271|NCT02228382|9559149|FG001|Overall Study|Withdrawal by Subject|3
5973272|NCT02228382|9559150|FG002|Overall Study|Withdrawal by Subject|2
5973273|NCT02228382|9559151|FG003|Overall Study|Withdrawal by Subject|1
5973274|NCT02228382|9559152|FG004|Overall Study|Withdrawal by Subject|0
5973275|NCT02228382|9559148|FG000|Overall Study|Other|2
6049463|NCT00422734|9648679|FG000|Overall Study|Adverse Event|0
6049464|NCT00422734|9648680|FG001|Overall Study|Adverse Event|3
6049465|NCT00422734|9648679|FG000|Overall Study|Partner Decision|0
6049466|NCT00422734|9648680|FG001|Overall Study|Partner Decision|3
6049467|NCT00422799|9648686|FG000|Overall Study|Withdrawal by Subject|6
6049468|NCT00422799|9648686|FG000|Overall Study|Adverse Event|7
6049469|NCT00422903|9648709|FG000|Overall Study|Disease Progression|3
6049470|NCT00422903|9648710|FG001|Overall Study|Disease Progression|1
6049471|NCT00422903|9648709|FG000|Overall Study|Adverse Event|0
6049472|NCT00422903|9648710|FG001|Overall Study|Adverse Event|2
6049473|NCT00422903|9648709|FG000|Overall Study|Informed Consent Withdrawn|1
6049474|NCT00422903|9648710|FG001|Overall Study|Informed Consent Withdrawn|2
6049475|NCT00423046|9648718|FG000|Overall Study|Other|340
6049476|NCT00423046|9648719|FG001|Overall Study|Other|345
6049477|NCT00423085|9648730|FG000|24-Week Double-Blind Treatment Phase|Adverse Event|21
6049478|NCT00423085|9648731|FG001|24-Week Double-Blind Treatment Phase|Adverse Event|38
6049479|NCT00423085|9648732|FG002|24-Week Double-Blind Treatment Phase|Adverse Event|34
6049480|NCT00423085|9648733|FG003|24-Week Double-Blind Treatment Phase|Adverse Event|0
6049481|NCT00423085|9648730|FG000|24-Week Double-Blind Treatment Phase|Withdrawal by Subject|8
6049482|NCT00423085|9648731|FG001|24-Week Double-Blind Treatment Phase|Withdrawal by Subject|16
6049483|NCT00423085|9648732|FG002|24-Week Double-Blind Treatment Phase|Withdrawal by Subject|11
6049484|NCT00423085|9648733|FG003|24-Week Double-Blind Treatment Phase|Withdrawal by Subject|0
6049485|NCT00423085|9648730|FG000|24-Week Double-Blind Treatment Phase|Unsatisfactory therapeutic effect|7
6049486|NCT00423085|9648731|FG001|24-Week Double-Blind Treatment Phase|Unsatisfactory therapeutic effect|6
6049487|NCT00423085|9648732|FG002|24-Week Double-Blind Treatment Phase|Unsatisfactory therapeutic effect|7
5973276|NCT02228382|9559149|FG001|Overall Study|Other|3
5973277|NCT02228382|9559150|FG002|Overall Study|Other|3
5973278|NCT02228382|9559151|FG003|Overall Study|Other|0
5973279|NCT02228382|9559152|FG004|Overall Study|Other|0
5973280|NCT02001623|9559202|FG000|Overall Study|Disease Progression|2
5973281|NCT02001623|9559203|FG001|Overall Study|Disease Progression|2
5973282|NCT02001623|9559204|FG002|Overall Study|Disease Progression|3
5973283|NCT02001623|9559205|FG003|Overall Study|Disease Progression|2
5973284|NCT02001623|9559206|FG004|Overall Study|Disease Progression|3
5973285|NCT02001623|9559207|FG005|Overall Study|Disease Progression|2
5973286|NCT02001623|9559208|FG006|Overall Study|Disease Progression|3
5973287|NCT02001623|9559209|FG007|Overall Study|Disease Progression|3
5973288|NCT02001623|9559210|FG008|Overall Study|Disease Progression|7
5973289|NCT02001623|9559211|FG009|Overall Study|Disease Progression|40
5973290|NCT02001623|9559212|FG010|Overall Study|Disease Progression|5
5973291|NCT02001623|9559213|FG011|Overall Study|Disease Progression|9
5973292|NCT02001623|9559214|FG012|Overall Study|Disease Progression|9
5973293|NCT02001623|9559215|FG013|Overall Study|Disease Progression|20
5973294|NCT02001623|9559216|FG014|Overall Study|Disease Progression|9
5973295|NCT02001623|9559202|FG000|Overall Study|Physician Decision|0
5973296|NCT02001623|9559203|FG001|Overall Study|Physician Decision|0
5973297|NCT02001623|9559204|FG002|Overall Study|Physician Decision|0
5973298|NCT02001623|9559205|FG003|Overall Study|Physician Decision|0
5973299|NCT02001623|9559206|FG004|Overall Study|Physician Decision|0
5973300|NCT02001623|9559207|FG005|Overall Study|Physician Decision|0
5973301|NCT02001623|9559208|FG006|Overall Study|Physician Decision|0
5973302|NCT02001623|9559209|FG007|Overall Study|Physician Decision|0
5973303|NCT02001623|9559210|FG008|Overall Study|Physician Decision|3
5973304|NCT02001623|9559211|FG009|Overall Study|Physician Decision|2
5973305|NCT02001623|9559212|FG010|Overall Study|Physician Decision|3
5973306|NCT02001623|9559213|FG011|Overall Study|Physician Decision|3
5973307|NCT02001623|9559214|FG012|Overall Study|Physician Decision|1
5973308|NCT02001623|9559215|FG013|Overall Study|Physician Decision|2
5973309|NCT02001623|9559216|FG014|Overall Study|Physician Decision|1
5973310|NCT02001623|9559202|FG000|Overall Study|Death|0
5973311|NCT02001623|9559203|FG001|Overall Study|Death|1
5973312|NCT02001623|9559204|FG002|Overall Study|Death|0
5973313|NCT02001623|9559205|FG003|Overall Study|Death|0
5973314|NCT02001623|9559206|FG004|Overall Study|Death|0
5973315|NCT02001623|9559207|FG005|Overall Study|Death|0
5973316|NCT02001623|9559208|FG006|Overall Study|Death|0
5973317|NCT02001623|9559209|FG007|Overall Study|Death|0
5973318|NCT02001623|9559210|FG008|Overall Study|Death|0
5973319|NCT02001623|9559211|FG009|Overall Study|Death|0
5973320|NCT02001623|9559212|FG010|Overall Study|Death|0
5973321|NCT02001623|9559213|FG011|Overall Study|Death|0
5973322|NCT02001623|9559214|FG012|Overall Study|Death|0
5973323|NCT02001623|9559215|FG013|Overall Study|Death|0
5973324|NCT02001623|9559216|FG014|Overall Study|Death|0
5973325|NCT02001623|9559202|FG000|Overall Study|Adverse Event|0
5973326|NCT02001623|9559203|FG001|Overall Study|Adverse Event|0
5973327|NCT02001623|9559204|FG002|Overall Study|Adverse Event|0
5973328|NCT02001623|9559205|FG003|Overall Study|Adverse Event|0
5973329|NCT02001623|9559206|FG004|Overall Study|Adverse Event|0
5973330|NCT02001623|9559207|FG005|Overall Study|Adverse Event|1
5973331|NCT02001623|9559208|FG006|Overall Study|Adverse Event|0
5973332|NCT02001623|9559209|FG007|Overall Study|Adverse Event|3
5973333|NCT02001623|9559210|FG008|Overall Study|Adverse Event|4
5973334|NCT02001623|9559211|FG009|Overall Study|Adverse Event|6
5973335|NCT02001623|9559212|FG010|Overall Study|Adverse Event|4
5973336|NCT02001623|9559213|FG011|Overall Study|Adverse Event|0
5973337|NCT02001623|9559214|FG012|Overall Study|Adverse Event|3
5973338|NCT02001623|9559215|FG013|Overall Study|Adverse Event|5
5973339|NCT02001623|9559216|FG014|Overall Study|Adverse Event|6
5973340|NCT02001623|9559202|FG000|Overall Study|Other - Miscellaneous|0
5973341|NCT02001623|9559203|FG001|Overall Study|Other - Miscellaneous|0
5973342|NCT02001623|9559204|FG002|Overall Study|Other - Miscellaneous|0
5973343|NCT02001623|9559205|FG003|Overall Study|Other - Miscellaneous|0
5973344|NCT02001623|9559206|FG004|Overall Study|Other - Miscellaneous|0
5973345|NCT02001623|9559207|FG005|Overall Study|Other - Miscellaneous|0
5973346|NCT02001623|9559208|FG006|Overall Study|Other - Miscellaneous|0
5973347|NCT02001623|9559209|FG007|Overall Study|Other - Miscellaneous|0
5973348|NCT02001623|9559210|FG008|Overall Study|Other - Miscellaneous|0
5973349|NCT02001623|9559211|FG009|Overall Study|Other - Miscellaneous|1
5973350|NCT02001623|9559212|FG010|Overall Study|Other - Miscellaneous|0
5973351|NCT02001623|9559213|FG011|Overall Study|Other - Miscellaneous|0
5973352|NCT02001623|9559214|FG012|Overall Study|Other - Miscellaneous|0
5973353|NCT02001623|9559215|FG013|Overall Study|Other - Miscellaneous|1
5973354|NCT02001623|9559216|FG014|Overall Study|Other - Miscellaneous|0
5973355|NCT02001623|9559202|FG000|Overall Study|Withdrawal by Subject|1
5973356|NCT02001623|9559203|FG001|Overall Study|Withdrawal by Subject|0
5973357|NCT02001623|9559204|FG002|Overall Study|Withdrawal by Subject|0
5973358|NCT02001623|9559205|FG003|Overall Study|Withdrawal by Subject|0
5973359|NCT02001623|9559206|FG004|Overall Study|Withdrawal by Subject|0
5973360|NCT02001623|9559207|FG005|Overall Study|Withdrawal by Subject|0
5973361|NCT02001623|9559208|FG006|Overall Study|Withdrawal by Subject|0
5973362|NCT02001623|9559209|FG007|Overall Study|Withdrawal by Subject|0
5973363|NCT02001623|9559210|FG008|Overall Study|Withdrawal by Subject|1
5973364|NCT02001623|9559211|FG009|Overall Study|Withdrawal by Subject|3
5973365|NCT02001623|9559212|FG010|Overall Study|Withdrawal by Subject|2
5973366|NCT02001623|9559213|FG011|Overall Study|Withdrawal by Subject|2
5973367|NCT02001623|9559214|FG012|Overall Study|Withdrawal by Subject|1
5973368|NCT02001623|9559215|FG013|Overall Study|Withdrawal by Subject|5
5973369|NCT02001623|9559216|FG014|Overall Study|Withdrawal by Subject|2
5973370|NCT02001623|9559202|FG000|Overall Study|Lost to Follow-up|0
5973371|NCT02001623|9559203|FG001|Overall Study|Lost to Follow-up|0
5973372|NCT02001623|9559204|FG002|Overall Study|Lost to Follow-up|0
5973373|NCT02001623|9559205|FG003|Overall Study|Lost to Follow-up|0
5973374|NCT02001623|9559206|FG004|Overall Study|Lost to Follow-up|0
5973375|NCT02001623|9559207|FG005|Overall Study|Lost to Follow-up|0
5973376|NCT02001623|9559208|FG006|Overall Study|Lost to Follow-up|0
5973377|NCT02001623|9559209|FG007|Overall Study|Lost to Follow-up|0
5973378|NCT02001623|9559210|FG008|Overall Study|Lost to Follow-up|0
5973379|NCT02001623|9559211|FG009|Overall Study|Lost to Follow-up|1
5973380|NCT02001623|9559212|FG010|Overall Study|Lost to Follow-up|0
5973381|NCT02001623|9559213|FG011|Overall Study|Lost to Follow-up|0
5973382|NCT02001623|9559214|FG012|Overall Study|Lost to Follow-up|0
5973383|NCT02001623|9559215|FG013|Overall Study|Lost to Follow-up|0
5973384|NCT02001623|9559216|FG014|Overall Study|Lost to Follow-up|0
5973385|NCT02001623|9559202|FG000|Overall Study|Start of New Anti-cancer Treatment|0
5973386|NCT02001623|9559203|FG001|Overall Study|Start of New Anti-cancer Treatment|0
5973387|NCT02001623|9559204|FG002|Overall Study|Start of New Anti-cancer Treatment|0
5973388|NCT02001623|9559205|FG003|Overall Study|Start of New Anti-cancer Treatment|0
5973389|NCT02001623|9559206|FG004|Overall Study|Start of New Anti-cancer Treatment|0
5973390|NCT02001623|9559207|FG005|Overall Study|Start of New Anti-cancer Treatment|0
5973391|NCT02001623|9559208|FG006|Overall Study|Start of New Anti-cancer Treatment|0
5973392|NCT02001623|9559209|FG007|Overall Study|Start of New Anti-cancer Treatment|0
5973393|NCT02001623|9559210|FG008|Overall Study|Start of New Anti-cancer Treatment|0
5973394|NCT02001623|9559211|FG009|Overall Study|Start of New Anti-cancer Treatment|0
5973395|NCT02001623|9559212|FG010|Overall Study|Start of New Anti-cancer Treatment|0
5973396|NCT02001623|9559213|FG011|Overall Study|Start of New Anti-cancer Treatment|1
5973397|NCT02001623|9559214|FG012|Overall Study|Start of New Anti-cancer Treatment|0
5973398|NCT02001623|9559215|FG013|Overall Study|Start of New Anti-cancer Treatment|1
5973399|NCT02001623|9559216|FG014|Overall Study|Start of New Anti-cancer Treatment|0
5973400|NCT02001623|9559202|FG000|Overall Study|Dose Delay Due to Toxicity|0
5973401|NCT02001623|9559203|FG001|Overall Study|Dose Delay Due to Toxicity|0
5973402|NCT02001623|9559204|FG002|Overall Study|Dose Delay Due to Toxicity|0
5973403|NCT02001623|9559205|FG003|Overall Study|Dose Delay Due to Toxicity|0
5973404|NCT02001623|9559206|FG004|Overall Study|Dose Delay Due to Toxicity|0
5973405|NCT02001623|9559207|FG005|Overall Study|Dose Delay Due to Toxicity|0
5973406|NCT02001623|9559208|FG006|Overall Study|Dose Delay Due to Toxicity|0
5973407|NCT02001623|9559209|FG007|Overall Study|Dose Delay Due to Toxicity|0
5973408|NCT02001623|9559210|FG008|Overall Study|Dose Delay Due to Toxicity|0
5973409|NCT02001623|9559211|FG009|Overall Study|Dose Delay Due to Toxicity|0
5973410|NCT02001623|9559212|FG010|Overall Study|Dose Delay Due to Toxicity|0
5973411|NCT02001623|9559213|FG011|Overall Study|Dose Delay Due to Toxicity|0
5973412|NCT02001623|9559214|FG012|Overall Study|Dose Delay Due to Toxicity|0
5973413|NCT02001623|9559215|FG013|Overall Study|Dose Delay Due to Toxicity|1
5973414|NCT02001623|9559216|FG014|Overall Study|Dose Delay Due to Toxicity|0
5973415|NCT01900002|9559265|FG000|Overall Study|Withdrawal by Subject|2
5973416|NCT01900002|9559265|FG000|Overall Study|ineligible for Y-90|4
5973417|NCT01595061|9559269|FG000|Overall Study|Never Treated|3
5973418|NCT01595061|9559269|FG000|Overall Study|Inadequate Pathology|1
6049488|NCT00423085|9648733|FG003|24-Week Double-Blind Treatment Phase|Unsatisfactory therapeutic effect|0
6049489|NCT00423085|9648730|FG000|24-Week Double-Blind Treatment Phase|Protocol Violation|8
6049490|NCT00423085|9648731|FG001|24-Week Double-Blind Treatment Phase|Protocol Violation|3
6049491|NCT00423085|9648732|FG002|24-Week Double-Blind Treatment Phase|Protocol Violation|7
6049492|NCT00423085|9648733|FG003|24-Week Double-Blind Treatment Phase|Protocol Violation|0
6049493|NCT00423085|9648730|FG000|24-Week Double-Blind Treatment Phase|Death|1
6049494|NCT00423085|9648731|FG001|24-Week Double-Blind Treatment Phase|Death|1
6049495|NCT00423085|9648732|FG002|24-Week Double-Blind Treatment Phase|Death|0
6049496|NCT00423085|9648733|FG003|24-Week Double-Blind Treatment Phase|Death|0
6049497|NCT00423085|9648730|FG000|24-Week Double-Blind Treatment Phase|Lost to Follow-up|1
6049498|NCT00423085|9648731|FG001|24-Week Double-Blind Treatment Phase|Lost to Follow-up|0
6049499|NCT00423085|9648732|FG002|24-Week Double-Blind Treatment Phase|Lost to Follow-up|0
6049500|NCT00423085|9648733|FG003|24-Week Double-Blind Treatment Phase|Lost to Follow-up|0
6049501|NCT00423085|9648730|FG000|52-Week Open-Label Extension Phase|Adverse Event|0
6049502|NCT00423085|9648731|FG001|52-Week Open-Label Extension Phase|Adverse Event|0
6049503|NCT00423085|9648732|FG002|52-Week Open-Label Extension Phase|Adverse Event|0
6049504|NCT00423085|9648733|FG003|52-Week Open-Label Extension Phase|Adverse Event|97
6049505|NCT00423085|9648730|FG000|52-Week Open-Label Extension Phase|Withdrawal by Subject|0
6049506|NCT00423085|9648731|FG001|52-Week Open-Label Extension Phase|Withdrawal by Subject|0
6049507|NCT00423085|9648732|FG002|52-Week Open-Label Extension Phase|Withdrawal by Subject|0
6049508|NCT00423085|9648733|FG003|52-Week Open-Label Extension Phase|Withdrawal by Subject|37
6049509|NCT00423085|9648730|FG000|52-Week Open-Label Extension Phase|Unsatisfactory therapeutic effect|0
6049510|NCT00423085|9648731|FG001|52-Week Open-Label Extension Phase|Unsatisfactory therapeutic effect|0
6049511|NCT00423085|9648732|FG002|52-Week Open-Label Extension Phase|Unsatisfactory therapeutic effect|0
5973419|NCT04794803|9559284|FG000|Overall Study|Death|1
5973420|NCT04794803|9559285|FG001|Overall Study|Death|3
5973421|NCT04794803|9559284|FG000|Overall Study|Lost to Follow-up|2
5973422|NCT04794803|9559285|FG001|Overall Study|Lost to Follow-up|2
5973423|NCT04794803|9559284|FG000|Overall Study|Withdrawal by Subject|1
5973424|NCT04794803|9559285|FG001|Overall Study|Withdrawal by Subject|0
5973425|NCT04794803|9559284|FG000|Overall Study|Physician Decision|1
5973426|NCT04794803|9559285|FG001|Overall Study|Physician Decision|1
5973427|NCT04794803|9559284|FG000|Overall Study|Patient transferred to another centre for oxygen rehabilitation|4
5973428|NCT04794803|9559285|FG001|Overall Study|Patient transferred to another centre for oxygen rehabilitation|1
5973429|NCT04794803|9559284|FG000|Overall Study|Refused to continue the treatment|1
5973430|NCT04794803|9559285|FG001|Overall Study|Refused to continue the treatment|0
5973431|NCT04794803|9559284|FG000|Overall Study|Patient admitted to ICU|0
5973432|NCT04794803|9559285|FG001|Overall Study|Patient admitted to ICU|1
5973433|NCT04706403|9559296|FG000|Overall Study|Participants did not provide respond to the question re-assessing vaccination intent|0
5973434|NCT04706403|9559297|FG001|Overall Study|Participants did not provide respond to the question re-assessing vaccination intent|0
5973435|NCT04706403|9559298|FG002|Overall Study|Participants did not provide respond to the question re-assessing vaccination intent|1
5973436|NCT04706403|9559299|FG003|Overall Study|Participants did not provide respond to the question re-assessing vaccination intent|1
5973437|NCT04706403|9559300|FG004|Overall Study|Participants did not provide respond to the question re-assessing vaccination intent|2
5973438|NCT04440449|9559314|FG000|Overall Study|Lost to Follow-up|2
5973439|NCT04440449|9559315|FG001|Overall Study|Lost to Follow-up|0
5973440|NCT04369469|9559324|FG000|Overall Study|Lost to Follow-up|2
5973441|NCT04369469|9559325|FG001|Overall Study|Lost to Follow-up|4
5973442|NCT04369469|9559324|FG000|Overall Study|Physician Decision|2
5973443|NCT04369469|9559325|FG001|Overall Study|Physician Decision|1
5973444|NCT04369469|9559324|FG000|Overall Study|Withdrawal by Subject|2
5973445|NCT04369469|9559325|FG001|Overall Study|Withdrawal by Subject|3
5973446|NCT04369469|9559324|FG000|Overall Study|Adverse Event|1
5973447|NCT04369469|9559325|FG001|Overall Study|Adverse Event|0
5973448|NCT04369469|9559324|FG000|Overall Study|Did Not Meet Inclusion/Exclusion Criteria|2
5973449|NCT04369469|9559325|FG001|Overall Study|Did Not Meet Inclusion/Exclusion Criteria|0
5973450|NCT04369469|9559324|FG000|Overall Study|Not Qualified due to History of Anaphylaxis|1
5973451|NCT04369469|9559325|FG001|Overall Study|Not Qualified due to History of Anaphylaxis|0
5973452|NCT04369469|9559324|FG000|Overall Study|Unable to Provide Consent|0
5973453|NCT04369469|9559325|FG001|Overall Study|Unable to Provide Consent|1
5973454|NCT04128696|9559333|FG000|Overall Study|Lost to Follow-up|0
5973455|NCT04128696|9559334|FG001|Overall Study|Lost to Follow-up|1
5973456|NCT04128696|9559333|FG000|Overall Study|Withdrawal by Subject|8
5973457|NCT04128696|9559334|FG001|Overall Study|Withdrawal by Subject|5
5973458|NCT04128696|9559333|FG000|Overall Study|In Follow-up|47
5973459|NCT04128696|9559334|FG001|Overall Study|In Follow-up|51
5973460|NCT04128696|9559333|FG000|Overall Study|On Study Treatment (pembrolizumab) All participants discontinued feladilimab/placebo|52
5973461|NCT04128696|9559334|FG001|Overall Study|On Study Treatment (pembrolizumab) All participants discontinued feladilimab/placebo|62
5973462|NCT03965962|9559348|FG000|Overall Study|Adverse Event|1
5973463|NCT03965962|9559349|FG001|Overall Study|Adverse Event|0
5973464|NCT03965962|9559350|FG002|Overall Study|Adverse Event|0
5973465|NCT03965962|9559351|FG003|Overall Study|Adverse Event|0
5973466|NCT03965962|9559348|FG000|Overall Study|Protocol Violation|21
5973467|NCT03965962|9559349|FG001|Overall Study|Protocol Violation|4
5973468|NCT03965962|9559350|FG002|Overall Study|Protocol Violation|10
5973469|NCT03965962|9559351|FG003|Overall Study|Protocol Violation|5
5973470|NCT03965962|9559348|FG000|Overall Study|Lost to Follow-up|0
5973471|NCT03965962|9559349|FG001|Overall Study|Lost to Follow-up|1
5973472|NCT03965962|9559350|FG002|Overall Study|Lost to Follow-up|0
5973473|NCT03965962|9559351|FG003|Overall Study|Lost to Follow-up|0
5973474|NCT03965962|9559348|FG000|Overall Study|Withdrawal by Subject|3
5973475|NCT03965962|9559349|FG001|Overall Study|Withdrawal by Subject|0
5973476|NCT03965962|9559350|FG002|Overall Study|Withdrawal by Subject|0
5973477|NCT03965962|9559351|FG003|Overall Study|Withdrawal by Subject|1
5973478|NCT03772574|9559364|FG000|Overall Study|Protocol Violation|2
5973479|NCT03772574|9559365|FG001|Overall Study|Protocol Violation|0
5973480|NCT03772574|9559366|FG002|Overall Study|Protocol Violation|0
5973481|NCT03772574|9559364|FG000|Overall Study|Discomfort|0
5973482|NCT03772574|9559365|FG001|Overall Study|Discomfort|5
5973483|NCT03772574|9559366|FG002|Overall Study|Discomfort|4
5973484|NCT03694522|9559376|FG000|Overall Study|Ongoing|42
5973485|NCT03694522|9559377|FG001|Overall Study|Ongoing|27
5973486|NCT03694522|9559376|FG000|Overall Study|Withdrawal by Subject|6
5973487|NCT03694522|9559377|FG001|Overall Study|Withdrawal by Subject|10
5973488|NCT03694522|9559376|FG000|Overall Study|Death|28
5973489|NCT03694522|9559377|FG001|Overall Study|Death|40
5973490|NCT03694522|9559376|FG000|Overall Study|Other|1
5973491|NCT03694522|9559377|FG001|Overall Study|Other|1
5973492|NCT03615040|9559385|FG000|Overall Study|Withdrawal by Subject|2
5973493|NCT03615040|9559386|FG001|Overall Study|Withdrawal by Subject|1
5973494|NCT03615040|9559385|FG000|Overall Study|Physician Decision|2
5973495|NCT03615040|9559386|FG001|Overall Study|Physician Decision|2
5973496|NCT03615040|9559385|FG000|Overall Study|Clinical diagnosis of lung cancer|1
5973497|NCT03615040|9559386|FG001|Overall Study|Clinical diagnosis of lung cancer|0
5973498|NCT03615040|9559385|FG000|Overall Study|Clinical diagnosis of oesophageal cancer|1
5973499|NCT03615040|9559386|FG001|Overall Study|Clinical diagnosis of oesophageal cancer|0
5973500|NCT03615040|9559385|FG000|Overall Study|Death|0
5973501|NCT03615040|9559386|FG001|Overall Study|Death|2
5973502|NCT03594955|9559392|FG000|Overall Study|Adverse Event|1
5973503|NCT03594955|9559392|FG000|Overall Study|Progressive disease|5
5973504|NCT03594955|9559392|FG000|Overall Study|Sponsor's decision|1
5973505|NCT03548220|9559400|FG000|Overall Study|Lost to Follow-up|1
5973506|NCT03548220|9559401|FG001|Overall Study|Lost to Follow-up|0
5973507|NCT03548220|9559402|FG002|Overall Study|Lost to Follow-up|0
5973508|NCT03548220|9559403|FG003|Overall Study|Lost to Follow-up|0
5973509|NCT03474107|9559425|FG000|Overall Study|Adverse Event|42
5973510|NCT03474107|9559426|FG001|Overall Study|Adverse Event|46
5973511|NCT03474107|9559425|FG000|Overall Study|Death|2
5973512|NCT03474107|9559426|FG001|Overall Study|Death|2
5973513|NCT03474107|9559425|FG000|Overall Study|Lost to Follow-up|0
5973514|NCT03474107|9559426|FG001|Overall Study|Lost to Follow-up|1
5973515|NCT03474107|9559425|FG000|Overall Study|Progressive Disease|177
5973516|NCT03474107|9559426|FG001|Overall Study|Progressive Disease|180
5973517|NCT03474107|9559425|FG000|Overall Study|Protocol Violation|1
5973518|NCT03474107|9559426|FG001|Overall Study|Protocol Violation|1
5973519|NCT03474107|9559425|FG000|Overall Study|Withdrawal by Subject|15
5973520|NCT03474107|9559426|FG001|Overall Study|Withdrawal by Subject|27
5973521|NCT03474107|9559425|FG000|Overall Study|Physician Decision|7
5973522|NCT03474107|9559426|FG001|Overall Study|Physician Decision|22
5973523|NCT03474107|9559425|FG000|Overall Study|Miscellaneous|1
5973524|NCT03474107|9559426|FG001|Overall Study|Miscellaneous|6
5973525|NCT03434041|9559438|FG000|Double Blind Treatment Phase (4 Weeks)|Lost to Follow-up|1
5973526|NCT03434041|9559439|FG001|Double Blind Treatment Phase (4 Weeks)|Lost to Follow-up|0
5973527|NCT03434041|9559438|FG000|Double Blind Treatment Phase (4 Weeks)|Withdrawal by Subject|2
5973528|NCT03434041|9559439|FG001|Double Blind Treatment Phase (4 Weeks)|Withdrawal by Subject|1
5973529|NCT03434041|9559438|FG000|Double Blind Treatment Phase (4 Weeks)|Lack of Efficacy|3
5973530|NCT03434041|9559439|FG001|Double Blind Treatment Phase (4 Weeks)|Lack of Efficacy|14
5973531|NCT03434041|9559438|FG000|Double Blind Treatment Phase (4 Weeks)|Adverse Event|7
5973532|NCT03434041|9559439|FG001|Double Blind Treatment Phase (4 Weeks)|Adverse Event|2
5973533|NCT03434041|9559438|FG000|Double Blind Treatment Phase (4 Weeks)|Death|1
5973534|NCT03434041|9559439|FG001|Double Blind Treatment Phase (4 Weeks)|Death|0
5973535|NCT03434041|9559438|FG000|Double Blind Treatment Phase (4 Weeks)|Covid-19 related|2
5973536|NCT03434041|9559439|FG001|Double Blind Treatment Phase (4 Weeks)|Covid-19 related|2
5973537|NCT03434041|9559438|FG000|Double Blind Treatment Phase (4 Weeks)|Non-compliance with study drug|0
5973538|NCT03434041|9559439|FG001|Double Blind Treatment Phase (4 Weeks)|Non-compliance with study drug|1
5973539|NCT03434041|9559438|FG000|Double Blind Treatment Phase (4 Weeks)|Other|2
5973540|NCT03434041|9559439|FG001|Double Blind Treatment Phase (4 Weeks)|Other|0
5973541|NCT03434041|9559438|FG000|Follow-up Phase (Up to 8 Weeks)|Withdrawal by Subject|4
5973542|NCT03434041|9559439|FG001|Follow-up Phase (Up to 8 Weeks)|Withdrawal by Subject|3
5973543|NCT03434041|9559438|FG000|Follow-up Phase (Up to 8 Weeks)|Adverse Event|2
5973544|NCT03434041|9559439|FG001|Follow-up Phase (Up to 8 Weeks)|Adverse Event|0
5973545|NCT03434041|9559438|FG000|Follow-up Phase (Up to 8 Weeks)|Investigator decision to discontinue follow-up and proceed to 54135419TRD3008 (NCT02782104)|1
5973546|NCT03434041|9559439|FG001|Follow-up Phase (Up to 8 Weeks)|Investigator decision to discontinue follow-up and proceed to 54135419TRD3008 (NCT02782104)|0
5973547|NCT03420222|9559449|FG000|Overall Study|Withdrawal by Subject|5
5973548|NCT03420222|9559450|FG001|Overall Study|Withdrawal by Subject|0
5973549|NCT03420222|9559449|FG000|Overall Study|Physician Decision|0
5973550|NCT03420222|9559450|FG001|Overall Study|Physician Decision|1
5973551|NCT03409796|9559458|FG000|Overall Study|Adverse Event|2
5973552|NCT03409796|9559459|FG001|Overall Study|Adverse Event|0
5973553|NCT03409796|9559458|FG000|Overall Study|Other|0
5973554|NCT03409796|9559459|FG001|Overall Study|Other|1
5973555|NCT03215706|9559467|FG000|Randomization|Adverse Event unrelated to study drug|1
5973556|NCT03215706|9559468|FG001|Randomization|Adverse Event unrelated to study drug|0
5973557|NCT03215706|9559467|FG000|Randomization|participant withdrew consent|1
5973558|NCT03215706|9559468|FG001|Randomization|participant withdrew consent|3
6049512|NCT00423085|9648733|FG003|52-Week Open-Label Extension Phase|Unsatisfactory therapeutic effect|18
6049513|NCT00423085|9648730|FG000|52-Week Open-Label Extension Phase|Protocol deviation|0
6087915|NCT00672477|9698593|FG000|Overall Study|Lack of Efficacy|1
5973559|NCT03215706|9559467|FG000|Randomization|no longer meets study criteria|1
5973560|NCT03215706|9559468|FG001|Randomization|no longer meets study criteria|4
5973561|NCT03215706|9559467|FG000|Randomization|other reasons|0
5973562|NCT03215706|9559468|FG001|Randomization|other reasons|2
5973563|NCT03215706|9559467|FG000|Treatment Period|Disease Progression|150
5973564|NCT03215706|9559468|FG001|Treatment Period|Disease Progression|142
5973565|NCT03215706|9559467|FG000|Treatment Period|Study Drug Toxicity|53
5973566|NCT03215706|9559468|FG001|Treatment Period|Study Drug Toxicity|21
5973567|NCT03215706|9559467|FG000|Treatment Period|Death|2
5973568|NCT03215706|9559468|FG001|Treatment Period|Death|1
5973569|NCT03215706|9559467|FG000|Treatment Period|Adverse event unrelated to study drug|24
5973570|NCT03215706|9559468|FG001|Treatment Period|Adverse event unrelated to study drug|23
5973571|NCT03215706|9559467|FG000|Treatment Period|Request to D/C treatment|1
5973572|NCT03215706|9559468|FG001|Treatment Period|Request to D/C treatment|6
5973573|NCT03215706|9559467|FG000|Treatment Period|Participant withdrew consent|3
5973574|NCT03215706|9559468|FG001|Treatment Period|Participant withdrew consent|4
5973575|NCT03215706|9559467|FG000|Treatment Period|Lost to Follow-up|0
5973576|NCT03215706|9559468|FG001|Treatment Period|Lost to Follow-up|1
5973577|NCT03215706|9559467|FG000|Treatment Period|Other Reasons|4
5973578|NCT03215706|9559468|FG001|Treatment Period|Other Reasons|5
5973579|NCT03215706|9559467|FG000|Treatment Period|Ongoing in the treatment period|105
5973580|NCT03215706|9559468|FG001|Treatment Period|Ongoing in the treatment period|43
5973581|NCT03144674|9559491|FG000|Overall Study|Participants Still Ongoing in the Study|1
5973582|NCT03144674|9559492|FG001|Overall Study|Participants Still Ongoing in the Study|4
5973583|NCT03144674|9559493|FG002|Overall Study|Participants Still Ongoing in the Study|24
5973584|NCT03144674|9559494|FG003|Overall Study|Participants Still Ongoing in the Study|54
5973585|NCT03144674|9559491|FG000|Overall Study|Death|3
5973586|NCT03144674|9559492|FG001|Overall Study|Death|1
5973587|NCT03144674|9559493|FG002|Overall Study|Death|1
5973588|NCT03144674|9559494|FG003|Overall Study|Death|10
5973589|NCT03144674|9559491|FG000|Overall Study|Lost to Follow-up|0
5973590|NCT03144674|9559492|FG001|Overall Study|Lost to Follow-up|1
5973591|NCT03144674|9559493|FG002|Overall Study|Lost to Follow-up|1
5973592|NCT03144674|9559494|FG003|Overall Study|Lost to Follow-up|1
5973593|NCT03144674|9559491|FG000|Overall Study|Withdrawal by Participant|0
5973594|NCT03144674|9559492|FG001|Overall Study|Withdrawal by Participant|0
5973595|NCT03144674|9559493|FG002|Overall Study|Withdrawal by Participant|0
5973596|NCT03144674|9559494|FG003|Overall Study|Withdrawal by Participant|3
5973597|NCT03144674|9559491|FG000|Overall Study|Reason not Specified|0
5973598|NCT03144674|9559492|FG001|Overall Study|Reason not Specified|0
5973599|NCT03144674|9559493|FG002|Overall Study|Reason not Specified|2
5973600|NCT03144674|9559494|FG003|Overall Study|Reason not Specified|4
5973601|NCT03143153|9559512|FG000|Pre-Treatment|Participant request to discontinue study treatment|0
5973602|NCT03143153|9559513|FG001|Pre-Treatment|Participant request to discontinue study treatment|0
5973603|NCT03143153|9559514|FG002|Pre-Treatment|Participant request to discontinue study treatment|2
5973604|NCT03143153|9559512|FG000|Pre-Treatment|Participant withdrew consent|0
5973605|NCT03143153|9559513|FG001|Pre-Treatment|Participant withdrew consent|1
5973606|NCT03143153|9559514|FG002|Pre-Treatment|Participant withdrew consent|12
5973607|NCT03143153|9559512|FG000|Pre-Treatment|Participant no longer meets study criteria|0
5973608|NCT03143153|9559513|FG001|Pre-Treatment|Participant no longer meets study criteria|4
5973609|NCT03143153|9559514|FG002|Pre-Treatment|Participant no longer meets study criteria|2
5973610|NCT03143153|9559512|FG000|Pre-Treatment|Other Reasons|1
5973611|NCT03143153|9559513|FG001|Pre-Treatment|Other Reasons|2
5973612|NCT03143153|9559514|FG002|Pre-Treatment|Other Reasons|1
5973613|NCT03143153|9559512|FG000|Pre-Treatment|Disease Progression|1
5973614|NCT03143153|9559513|FG001|Pre-Treatment|Disease Progression|1
5973615|NCT03143153|9559514|FG002|Pre-Treatment|Disease Progression|2
5973616|NCT03143153|9559512|FG000|Pre-Treatment|Adverse event unrelated to study drug|1
5973617|NCT03143153|9559513|FG001|Pre-Treatment|Adverse event unrelated to study drug|3
5973618|NCT03143153|9559514|FG002|Pre-Treatment|Adverse event unrelated to study drug|1
5973619|NCT03143153|9559512|FG000|Treatment|Disease progression|174
5973620|NCT03143153|9559513|FG001|Treatment|Disease progression|184
5973621|NCT03143153|9559514|FG002|Treatment|Disease progression|193
5973622|NCT03143153|9559512|FG000|Treatment|Study drug toxicity|59
5973623|NCT03143153|9559513|FG001|Treatment|Study drug toxicity|33
5973624|NCT03143153|9559514|FG002|Treatment|Study drug toxicity|40
5973625|NCT03143153|9559512|FG000|Treatment|Death|5
5973626|NCT03143153|9559513|FG001|Treatment|Death|3
5973627|NCT03143153|9559514|FG002|Treatment|Death|4
5973628|NCT03143153|9559512|FG000|Treatment|Adverse event unrelated to study drug|19
5973629|NCT03143153|9559513|FG001|Treatment|Adverse event unrelated to study drug|28
5973630|NCT03143153|9559514|FG002|Treatment|Adverse event unrelated to study drug|12
5973631|NCT03143153|9559512|FG000|Treatment|Participant request to discontinue study treatment|13
5973632|NCT03143153|9559513|FG001|Treatment|Participant request to discontinue study treatment|15
5973633|NCT03143153|9559514|FG002|Treatment|Participant request to discontinue study treatment|20
5973634|NCT03143153|9559512|FG000|Treatment|Participant withdrew consent|3
5973635|NCT03143153|9559513|FG001|Treatment|Participant withdrew consent|4
5973636|NCT03143153|9559514|FG002|Treatment|Participant withdrew consent|12
5973637|NCT03143153|9559512|FG000|Treatment|Pregnancy|1
5973638|NCT03143153|9559513|FG001|Treatment|Pregnancy|0
5973639|NCT03143153|9559514|FG002|Treatment|Pregnancy|0
5973640|NCT03143153|9559512|FG000|Treatment|Maximum clinical benefit|1
5973641|NCT03143153|9559513|FG001|Treatment|Maximum clinical benefit|3
5973642|NCT03143153|9559514|FG002|Treatment|Maximum clinical benefit|4
5973643|NCT03143153|9559512|FG000|Treatment|Completed treatment as per Protocol|13
5973644|NCT03143153|9559513|FG001|Treatment|Completed treatment as per Protocol|8
5973645|NCT03143153|9559514|FG002|Treatment|Completed treatment as per Protocol|0
5973646|NCT03143153|9559512|FG000|Treatment|Other reasons|12
5973647|NCT03143153|9559513|FG001|Treatment|Other reasons|7
5973648|NCT03143153|9559514|FG002|Treatment|Other reasons|15
5973649|NCT03143153|9559512|FG000|Treatment|Not reported|1
5973650|NCT03143153|9559513|FG001|Treatment|Not reported|0
5973651|NCT03143153|9559514|FG002|Treatment|Not reported|0
5973652|NCT03093350|9559522|FG000|Overall Study|Death|1
5973653|NCT03093350|9559522|FG000|Overall Study|Signed consent, never began treartment|1
5973654|NCT02999854|9559535|FG000|Active Study Phase (up to 18 Months)|Screen failures|7
5973655|NCT02999854|9559536|FG001|Active Study Phase (up to 18 Months)|Screen failures|2
5973656|NCT02999854|9559535|FG000|Active Study Phase (up to 18 Months)|Discontinued before HSCT|8
5973657|NCT02999854|9559536|FG001|Active Study Phase (up to 18 Months)|Discontinued before HSCT|2
5973658|NCT02999854|9559535|FG000|Active Study Phase (up to 18 Months)|Death|7
5973659|NCT02999854|9559536|FG001|Active Study Phase (up to 18 Months)|Death|5
5973660|NCT02999854|9559535|FG000|Active Study Phase (up to 18 Months)|Completed 2 year follow-up|1
5973661|NCT02999854|9559536|FG001|Active Study Phase (up to 18 Months)|Completed 2 year follow-up|0
5973662|NCT02999854|9559535|FG000|Active Study Phase (up to 18 Months)|End of study after HSCT but before treatment|1
5973663|NCT02999854|9559536|FG001|Active Study Phase (up to 18 Months)|End of study after HSCT but before treatment|0
5973664|NCT02999854|9559535|FG000|Long Term Safety FU (up to 24 Months)|Death|1
5973665|NCT02999854|9559536|FG001|Long Term Safety FU (up to 24 Months)|Death|1
5973666|NCT02999854|9559535|FG000|Long Term Safety FU (up to 24 Months)|Withdrawal by Subject|1
5973667|NCT02999854|9559536|FG001|Long Term Safety FU (up to 24 Months)|Withdrawal by Subject|1
5973668|NCT02999854|9559535|FG000|Long Term Safety FU (up to 24 Months)|Lost to Follow-up|1
5973669|NCT02999854|9559536|FG001|Long Term Safety FU (up to 24 Months)|Lost to Follow-up|1
5973670|NCT02960763|9559547|FG000|Step 1|Withdrawal by Subject|10
5973671|NCT02960763|9559548|FG001|Step 1|Withdrawal by Subject|8
5973672|NCT02960763|9559549|FG002|Step 1|Withdrawal by Subject|13
5973673|NCT02960763|9559550|FG003|Step 1|Withdrawal by Subject|0
5973674|NCT02960763|9559551|FG004|Step 1|Withdrawal by Subject|0
5973675|NCT02960763|9559547|FG000|Step 1|Lost to Follow-up|7
5973676|NCT02960763|9559548|FG001|Step 1|Lost to Follow-up|9
5973677|NCT02960763|9559549|FG002|Step 1|Lost to Follow-up|13
5973678|NCT02960763|9559550|FG003|Step 1|Lost to Follow-up|0
5973679|NCT02960763|9559551|FG004|Step 1|Lost to Follow-up|0
5973680|NCT02960763|9559547|FG000|Step 1|Death|1
5973681|NCT02960763|9559548|FG001|Step 1|Death|1
5973682|NCT02960763|9559549|FG002|Step 1|Death|1
5973683|NCT02960763|9559550|FG003|Step 1|Death|0
5973684|NCT02960763|9559551|FG004|Step 1|Death|0
5973685|NCT02960763|9559547|FG000|Step 1|Investigator discretion|1
5973686|NCT02960763|9559548|FG001|Step 1|Investigator discretion|0
5973687|NCT02960763|9559549|FG002|Step 1|Investigator discretion|1
5973688|NCT02960763|9559550|FG003|Step 1|Investigator discretion|0
5973689|NCT02960763|9559551|FG004|Step 1|Investigator discretion|0
5973690|NCT02960763|9559547|FG000|Step 2|Withdrawal by Subject|0
5973691|NCT02960763|9559548|FG001|Step 2|Withdrawal by Subject|0
5973692|NCT02960763|9559549|FG002|Step 2|Withdrawal by Subject|0
5973693|NCT02960763|9559550|FG003|Step 2|Withdrawal by Subject|7
5973694|NCT02960763|9559551|FG004|Step 2|Withdrawal by Subject|3
5973695|NCT02960763|9559547|FG000|Step 2|Lost to Follow-up|0
5973696|NCT02960763|9559548|FG001|Step 2|Lost to Follow-up|0
5973697|NCT02960763|9559549|FG002|Step 2|Lost to Follow-up|0
6049514|NCT00423085|9648731|FG001|52-Week Open-Label Extension Phase|Protocol deviation|0
6049515|NCT00423085|9648732|FG002|52-Week Open-Label Extension Phase|Protocol deviation|0
6049516|NCT00423085|9648733|FG003|52-Week Open-Label Extension Phase|Protocol deviation|9
6049517|NCT00423085|9648730|FG000|52-Week Open-Label Extension Phase|Death|0
6049518|NCT00423085|9648731|FG001|52-Week Open-Label Extension Phase|Death|0
6049519|NCT00423085|9648732|FG002|52-Week Open-Label Extension Phase|Death|0
6049520|NCT00423085|9648733|FG003|52-Week Open-Label Extension Phase|Death|2
6049521|NCT00423098|9648745|FG000|Overall Study|Adverse Event|1
6049522|NCT00423098|9648746|FG001|Overall Study|Adverse Event|2
6049523|NCT00423098|9648745|FG000|Overall Study|Unsatisfactory therapeutic effect|0
6049524|NCT00423098|9648746|FG001|Overall Study|Unsatisfactory therapeutic effect|1
6049525|NCT00423098|9648745|FG000|Overall Study|Administrative problems|0
6049526|NCT00423098|9648746|FG001|Overall Study|Administrative problems|1
6087916|NCT00672477|9698594|FG001|Overall Study|Lack of Efficacy|1
6193576|NCT01439568|9851300|FG001|Overall Study|Lost to Follow-up|0
5973698|NCT02960763|9559550|FG003|Step 2|Lost to Follow-up|4
5973699|NCT02960763|9559551|FG004|Step 2|Lost to Follow-up|1
5973700|NCT02960763|9559547|FG000|Step 2|Investigator discretion|0
5973701|NCT02960763|9559548|FG001|Step 2|Investigator discretion|0
5973702|NCT02960763|9559549|FG002|Step 2|Investigator discretion|0
5973703|NCT02960763|9559550|FG003|Step 2|Investigator discretion|0
5973704|NCT02960763|9559551|FG004|Step 2|Investigator discretion|1
5973705|NCT02839343|9559565|FG000|Overall Study|Withdrawal by Subject|3
6049527|NCT00423098|9648745|FG000|Overall Study|Death|2
5973706|NCT02839343|9559566|FG001|Overall Study|Withdrawal by Subject|1
5973707|NCT02839343|9559565|FG000|Overall Study|Disease Progression Prior to Treatment|1
5973708|NCT02839343|9559566|FG001|Overall Study|Disease Progression Prior to Treatment|0
5973709|NCT02839343|9559565|FG000|Overall Study|Adverse Event|1
5973710|NCT02839343|9559566|FG001|Overall Study|Adverse Event|0
5973711|NCT02819479|9559572|FG000|Overall Study|Adverse Event|2
5973712|NCT02601313|9559580|FG000|Overall Study|Death|2
5973713|NCT02601313|9559581|FG001|Overall Study|Death|16
5973714|NCT02601313|9559582|FG002|Overall Study|Death|4
5973715|NCT02601313|9559580|FG000|Overall Study|Enrolled, did not initiate CTE/KTE-X19|0
5973716|NCT02601313|9559581|FG001|Overall Study|Enrolled, did not initiate CTE/KTE-X19|5
5973717|NCT02601313|9559582|FG002|Overall Study|Enrolled, did not initiate CTE/KTE-X19|2
5973718|NCT02601313|9559580|FG000|Overall Study|Enrolled, did not initiate KTE-X19|0
5973719|NCT02601313|9559581|FG001|Overall Study|Enrolled, did not initiate KTE-X19|1
5973720|NCT02601313|9559582|FG002|Overall Study|Enrolled, did not initiate KTE-X19|1
5973721|NCT02601313|9559580|FG000|Overall Study|Still on study|0
5973722|NCT02601313|9559581|FG001|Overall Study|Still on study|52
5973723|NCT02601313|9559582|FG002|Overall Study|Still on study|10
5973724|NCT02601313|9559580|FG000|Overall Study|Enrolled, did not initiate AC|4
5973725|NCT02601313|9559581|FG001|Overall Study|Enrolled, did not initiate AC|0
5973726|NCT02601313|9559582|FG002|Overall Study|Enrolled, did not initiate AC|0
5973727|NCT02581930|9559590|FG000|Overall Study|Withdrawal by Subject|1
5973728|NCT02581930|9559590|FG000|Overall Study|patient declined further treatment|1
5973729|NCT02542293|9559596|FG000|Overall Study|Death|367
5973730|NCT02542293|9559597|FG001|Overall Study|Death|377
5973731|NCT02542293|9559596|FG000|Overall Study|Withdrawal by Subject|8
5973732|NCT02542293|9559597|FG001|Overall Study|Withdrawal by Subject|19
5973733|NCT02438722|9559616|FG000|Overall Study|Adverse Event|12
5973734|NCT02438722|9559617|FG001|Overall Study|Adverse Event|9
5973735|NCT02438722|9559616|FG000|Overall Study|Refusal unrelated to AE|2
5973736|NCT02438722|9559617|FG001|Overall Study|Refusal unrelated to AE|5
5973737|NCT02438722|9559616|FG000|Overall Study|Disease progression/relapse|46
5973738|NCT02438722|9559617|FG001|Overall Study|Disease progression/relapse|51
5973739|NCT02438722|9559616|FG000|Overall Study|Death|0
5973740|NCT02438722|9559617|FG001|Overall Study|Death|3
5973741|NCT02438722|9559616|FG000|Overall Study|Physician Decision|2
5973742|NCT02438722|9559617|FG001|Overall Study|Physician Decision|2
5973743|NCT02438722|9559616|FG000|Overall Study|Exceeded protocol-specified maximum treatment delay unrelated to AE|1
5973744|NCT02438722|9559617|FG001|Overall Study|Exceeded protocol-specified maximum treatment delay unrelated to AE|0
5973745|NCT02438722|9559616|FG000|Overall Study|Withdrawal by Subject|0
5973746|NCT02438722|9559617|FG001|Overall Study|Withdrawal by Subject|1
5973747|NCT02438722|9559616|FG000|Overall Study|On protocol treatment|15
5973748|NCT02438722|9559617|FG001|Overall Study|On protocol treatment|14
5973749|NCT02438722|9559616|FG000|Overall Study|Did not receive protocol treatment|5
5973750|NCT02438722|9559617|FG001|Overall Study|Did not receive protocol treatment|0
5973751|NCT02278120|9559642|FG000|Overall Study|Progressive disease|122
5973752|NCT02278120|9559643|FG001|Overall Study|Progressive disease|174
5973753|NCT02278120|9559642|FG000|Overall Study|Patient/guardian decision|14
5973754|NCT02278120|9559643|FG001|Overall Study|Patient/guardian decision|8
5973755|NCT02278120|9559642|FG000|Overall Study|Adverse Event|12
5973756|NCT02278120|9559643|FG001|Overall Study|Adverse Event|10
5973757|NCT02278120|9559642|FG000|Overall Study|Physician Decision|8
5973758|NCT02278120|9559643|FG001|Overall Study|Physician Decision|19
5973759|NCT02278120|9559642|FG000|Overall Study|Death|3
5973760|NCT02278120|9559643|FG001|Overall Study|Death|3
5973761|NCT02278120|9559642|FG000|Overall Study|Lost to Follow-up|2
5973762|NCT02278120|9559643|FG001|Overall Study|Lost to Follow-up|0
5973763|NCT02278120|9559642|FG000|Overall Study|Protocol Violation|0
5973764|NCT02278120|9559643|FG001|Overall Study|Protocol Violation|2
5973765|NCT02258451|9559651|FG000|Overall Study|Discontinuation all treatment due to progressive disease - radiological progression|88
6049528|NCT00423098|9648746|FG001|Overall Study|Death|0
5973766|NCT02258451|9559652|FG001|Overall Study|Discontinuation all treatment due to progressive disease - radiological progression|95
5973767|NCT02258451|9559651|FG000|Overall Study|Discontinuation all treatment due to progressive disease - clinical progression|6
5973768|NCT02258451|9559652|FG001|Overall Study|Discontinuation all treatment due to progressive disease - clinical progression|7
5973769|NCT02258451|9559651|FG000|Overall Study|Discontinuation all treatment due to adverse event not associated with clinical disease progression|8
5973770|NCT02258451|9559652|FG001|Overall Study|Discontinuation all treatment due to adverse event not associated with clinical disease progression|1
5973771|NCT02258451|9559651|FG000|Overall Study|Discontinuation all treatment due to adverse event associated with clinical disease progression|8
5973772|NCT02258451|9559652|FG001|Overall Study|Discontinuation all treatment due to adverse event associated with clinical disease progression|6
5973773|NCT02258451|9559651|FG000|Overall Study|Death|4
5973774|NCT02258451|9559652|FG001|Overall Study|Death|3
5973775|NCT02258451|9559651|FG000|Overall Study|Withdrawal by Subject|21
5973776|NCT02258451|9559652|FG001|Overall Study|Withdrawal by Subject|12
5973777|NCT02258451|9559651|FG000|Overall Study|Discontinuation all treatment due to TS-1 started|1
5973778|NCT02258451|9559652|FG001|Overall Study|Discontinuation all treatment due to TS-1 started|0
5973779|NCT02258451|9559651|FG000|Overall Study|Discontinuation all treatment due to event point reached|1
6049529|NCT00423137|9648756|FG000|Overall Study|Lost to Follow-up|0
5973780|NCT02258451|9559652|FG001|Overall Study|Discontinuation all treatment due to event point reached|1
5973781|NCT02258451|9559651|FG000|Overall Study|Physician Decision|0
5973782|NCT02258451|9559652|FG001|Overall Study|Physician Decision|2
5973783|NCT02258451|9559651|FG000|Overall Study|Never treated|2
5973784|NCT02258451|9559652|FG001|Overall Study|Never treated|3
5973785|NCT02258451|9559651|FG000|Overall Study|Ongoing with any Treatment of radium 223 or placebo, exemestane, or everolimus|3
5973786|NCT02258451|9559652|FG001|Overall Study|Ongoing with any Treatment of radium 223 or placebo, exemestane, or everolimus|11
5973787|NCT02120352|9559660|FG000|Induction Period (20 Weeks)|Adverse Event|3
5973788|NCT02120352|9559661|FG001|Induction Period (20 Weeks)|Adverse Event|0
5973789|NCT02120352|9559662|FG002|Induction Period (20 Weeks)|Adverse Event|0
5973790|NCT02120352|9559663|FG003|Induction Period (20 Weeks)|Adverse Event|0
5973791|NCT02120352|9559660|FG000|Induction Period (20 Weeks)|Lack of Efficacy|5
5973792|NCT02120352|9559661|FG001|Induction Period (20 Weeks)|Lack of Efficacy|0
5973793|NCT02120352|9559662|FG002|Induction Period (20 Weeks)|Lack of Efficacy|0
5973794|NCT02120352|9559663|FG003|Induction Period (20 Weeks)|Lack of Efficacy|0
5973795|NCT02120352|9559660|FG000|Induction Period (20 Weeks)|Protocol Violation|2
5973796|NCT02120352|9559661|FG001|Induction Period (20 Weeks)|Protocol Violation|0
5973797|NCT02120352|9559662|FG002|Induction Period (20 Weeks)|Protocol Violation|0
5973798|NCT02120352|9559663|FG003|Induction Period (20 Weeks)|Protocol Violation|0
5973799|NCT02120352|9559660|FG000|Induction Period (20 Weeks)|Met protocol-defined stopping criteria|3
5973800|NCT02120352|9559661|FG001|Induction Period (20 Weeks)|Met protocol-defined stopping criteria|0
5973801|NCT02120352|9559662|FG002|Induction Period (20 Weeks)|Met protocol-defined stopping criteria|0
5973802|NCT02120352|9559663|FG003|Induction Period (20 Weeks)|Met protocol-defined stopping criteria|0
5973803|NCT02120352|9559660|FG000|Induction Period (20 Weeks)|Lost to Follow-up|2
5973804|NCT02120352|9559661|FG001|Induction Period (20 Weeks)|Lost to Follow-up|0
5973805|NCT02120352|9559662|FG002|Induction Period (20 Weeks)|Lost to Follow-up|0
5973806|NCT02120352|9559663|FG003|Induction Period (20 Weeks)|Lost to Follow-up|0
5973807|NCT02120352|9559660|FG000|Induction Period (20 Weeks)|Withdrawal by Subject|5
5973808|NCT02120352|9559661|FG001|Induction Period (20 Weeks)|Withdrawal by Subject|0
5973809|NCT02120352|9559662|FG002|Induction Period (20 Weeks)|Withdrawal by Subject|0
5973810|NCT02120352|9559663|FG003|Induction Period (20 Weeks)|Withdrawal by Subject|0
6087917|NCT00672477|9698593|FG000|Overall Study|no study drug for low GFR, health cond.|1
6087918|NCT00672477|9698594|FG001|Overall Study|no study drug for low GFR, health cond.|3
6087919|NCT00672490|9698602|FG000|Overall Study|Withdrawal by Subject|8
6087920|NCT00672490|9698603|FG001|Overall Study|Withdrawal by Subject|8
6087921|NCT00672490|9698602|FG000|Overall Study|Lack of Compliance|2
6087922|NCT00672490|9698603|FG001|Overall Study|Lack of Compliance|7
6087923|NCT00672490|9698602|FG000|Overall Study|Mismatch Include/Exclude Criteria|1
6087924|NCT00672490|9698603|FG001|Overall Study|Mismatch Include/Exclude Criteria|0
6087925|NCT00672490|9698602|FG000|Overall Study|Adverse Event|5
6087926|NCT00672490|9698603|FG001|Overall Study|Adverse Event|8
6087927|NCT00672490|9698602|FG000|Overall Study|Violation of Concomitant Medicine|1
5973811|NCT02120352|9559660|FG000|Induction Period (20 Weeks)|Physician Decision|1
5973812|NCT02120352|9559661|FG001|Induction Period (20 Weeks)|Physician Decision|0
6049530|NCT00423137|9648757|FG001|Overall Study|Lost to Follow-up|0
6049531|NCT00423137|9648758|FG002|Overall Study|Lost to Follow-up|1
6049532|NCT00423137|9648759|FG003|Overall Study|Lost to Follow-up|0
6049533|NCT00423137|9648756|FG000|Overall Study|Protocol Violation|0
6049534|NCT00423137|9648757|FG001|Overall Study|Protocol Violation|0
6049535|NCT00423137|9648758|FG002|Overall Study|Protocol Violation|0
6049536|NCT00423137|9648759|FG003|Overall Study|Protocol Violation|1
6049537|NCT00423137|9648756|FG000|Overall Study|Adverse Event Study disease worse|1
6049538|NCT00423137|9648757|FG001|Overall Study|Adverse Event Study disease worse|0
6049539|NCT00423137|9648758|FG002|Overall Study|Adverse Event Study disease worse|3
6049540|NCT00423137|9648759|FG003|Overall Study|Adverse Event Study disease worse|1
6049541|NCT00423137|9648756|FG000|Overall Study|Adverse Event Other|0
6049542|NCT00423137|9648757|FG001|Overall Study|Adverse Event Other|0
6049543|NCT00423137|9648758|FG002|Overall Study|Adverse Event Other|2
6049544|NCT00423137|9648759|FG003|Overall Study|Adverse Event Other|0
6049545|NCT00423150|9648772|FG000|Overall Study|Adverse Event|11
6049546|NCT00423150|9648772|FG000|Overall Study|Progression of disease being studied|69
6049547|NCT00423150|9648772|FG000|Overall Study|Withdrawal by Subject|1
6049548|NCT00423150|9648772|FG000|Overall Study|Non-compliance with protocol|1
6049549|NCT00423150|9648772|FG000|Overall Study|Administrative|4
6049550|NCT00423189|9648779|FG000|Overall Study|Death|0
6049551|NCT00423189|9648780|FG001|Overall Study|Death|1
6049552|NCT00423189|9648781|FG002|Overall Study|Death|0
6049553|NCT00423267|9648796|FG000|Period A|Withdrawal by Subject|0
6049554|NCT00423267|9648797|FG001|Period A|Withdrawal by Subject|1
6049555|NCT00423267|9648796|FG000|Period A|Non-compliance with protocol|1
6049556|NCT00423267|9648797|FG001|Period A|Non-compliance with protocol|0
6049557|NCT00423267|9648796|FG000|Period A|Administrative|1
6049558|NCT00423267|9648797|FG001|Period A|Administrative|0
6049559|NCT00423293|9648805|FG000|Overall Study|Ineligible / No protocol treatment|11
6049560|NCT00423319|9648811|FG000|Overall Study|Death|2
6049561|NCT00423319|9648812|FG001|Overall Study|Death|0
6049562|NCT00423319|9648811|FG000|Overall Study|Adverse Event|93
6049563|NCT00423319|9648812|FG001|Overall Study|Adverse Event|112
5973813|NCT02120352|9559662|FG002|Induction Period (20 Weeks)|Physician Decision|0
5973814|NCT02120352|9559663|FG003|Induction Period (20 Weeks)|Physician Decision|0
5973815|NCT02120352|9559660|FG000|Maintenance Period (32 Weeks)|Adverse Event|0
5973816|NCT02120352|9559661|FG001|Maintenance Period (32 Weeks)|Adverse Event|0
5973817|NCT02120352|9559662|FG002|Maintenance Period (32 Weeks)|Adverse Event|6
5973818|NCT02120352|9559663|FG003|Maintenance Period (32 Weeks)|Adverse Event|1
5973819|NCT02120352|9559660|FG000|Maintenance Period (32 Weeks)|Lack of Efficacy|0
5973820|NCT02120352|9559661|FG001|Maintenance Period (32 Weeks)|Lack of Efficacy|1
5973821|NCT02120352|9559662|FG002|Maintenance Period (32 Weeks)|Lack of Efficacy|0
5973822|NCT02120352|9559663|FG003|Maintenance Period (32 Weeks)|Lack of Efficacy|1
5973823|NCT02120352|9559660|FG000|Maintenance Period (32 Weeks)|Protocol Violation|0
5973824|NCT02120352|9559661|FG001|Maintenance Period (32 Weeks)|Protocol Violation|0
5973825|NCT02120352|9559662|FG002|Maintenance Period (32 Weeks)|Protocol Violation|2
5973826|NCT02120352|9559663|FG003|Maintenance Period (32 Weeks)|Protocol Violation|0
5973827|NCT02120352|9559660|FG000|Maintenance Period (32 Weeks)|Met protocol-defined stopping criteria|0
5973828|NCT02120352|9559661|FG001|Maintenance Period (32 Weeks)|Met protocol-defined stopping criteria|0
5973829|NCT02120352|9559662|FG002|Maintenance Period (32 Weeks)|Met protocol-defined stopping criteria|1
5973830|NCT02120352|9559663|FG003|Maintenance Period (32 Weeks)|Met protocol-defined stopping criteria|1
5973831|NCT02120352|9559660|FG000|Maintenance Period (32 Weeks)|Lost to Follow-up|0
5973832|NCT02120352|9559661|FG001|Maintenance Period (32 Weeks)|Lost to Follow-up|0
5973833|NCT02120352|9559662|FG002|Maintenance Period (32 Weeks)|Lost to Follow-up|0
5973834|NCT02120352|9559663|FG003|Maintenance Period (32 Weeks)|Lost to Follow-up|1
5973835|NCT02120352|9559660|FG000|Maintenance Period (32 Weeks)|Withdrawal by Subject|0
5973836|NCT02120352|9559661|FG001|Maintenance Period (32 Weeks)|Withdrawal by Subject|2
5973837|NCT02120352|9559662|FG002|Maintenance Period (32 Weeks)|Withdrawal by Subject|1
5973838|NCT02120352|9559663|FG003|Maintenance Period (32 Weeks)|Withdrawal by Subject|2
5973839|NCT02120352|9559660|FG000|Maintenance Period (32 Weeks)|Ongoing at the time of interim analysis|0
5973840|NCT02120352|9559661|FG001|Maintenance Period (32 Weeks)|Ongoing at the time of interim analysis|112
5973841|NCT02120352|9559662|FG002|Maintenance Period (32 Weeks)|Ongoing at the time of interim analysis|105
5973842|NCT02120352|9559663|FG003|Maintenance Period (32 Weeks)|Ongoing at the time of interim analysis|50
5973843|NCT02004691|9559701|FG000|PAP: Up to 52 Weeks|Poor compliance|1
5973844|NCT02004691|9559702|FG001|PAP: Up to 52 Weeks|Poor compliance|0
5973845|NCT02004691|9559701|FG000|ETP: Ongoing From Week 52|Related to Coronavirus Disease (COVID-19)|1
5973846|NCT02004691|9559702|FG001|ETP: Ongoing From Week 52|Related to Coronavirus Disease (COVID-19)|0
5973847|NCT02004691|9559701|FG000|ETP: Ongoing From Week 52|Withdrawal by Subject|0
5973848|NCT02004691|9559702|FG001|ETP: Ongoing From Week 52|Withdrawal by Subject|1
5973849|NCT02004691|9559701|FG000|ETP: Ongoing From Week 52|Other|0
5973850|NCT02004691|9559702|FG001|ETP: Ongoing From Week 52|Other|1
5973851|NCT02004691|9559701|FG000|ETP: Ongoing From Week 52|Ongoing|16
5973852|NCT02004691|9559702|FG001|ETP: Ongoing From Week 52|Ongoing|16
5973853|NCT01886872|9559711|FG000|Overall Study|Ineligible|7
5973854|NCT01886872|9559712|FG001|Overall Study|Ineligible|4
5973855|NCT01886872|9559713|FG002|Overall Study|Ineligible|12
5973856|NCT01835145|9559724|FG000|Overall Study|Ineligible prior to treatment|1
5973857|NCT01835145|9559725|FG001|Overall Study|Ineligible prior to treatment|0
5973858|NCT01802632|9559739|FG000|Overall Study|Death|28
5973859|NCT01802632|9559740|FG001|Overall Study|Death|1
5973860|NCT01802632|9559741|FG002|Overall Study|Death|38
5973861|NCT01802632|9559742|FG003|Overall Study|Death|0
5973862|NCT01802632|9559743|FG004|Overall Study|Death|2
5973863|NCT01802632|9559744|FG005|Overall Study|Death|0
5973864|NCT01802632|9559739|FG000|Overall Study|Withdrawal by Subject|4
5973865|NCT01802632|9559740|FG001|Overall Study|Withdrawal by Subject|2
5973866|NCT01802632|9559741|FG002|Overall Study|Withdrawal by Subject|7
5973867|NCT01802632|9559742|FG003|Overall Study|Withdrawal by Subject|3
5973868|NCT01802632|9559743|FG004|Overall Study|Withdrawal by Subject|0
5973869|NCT01802632|9559744|FG005|Overall Study|Withdrawal by Subject|1
5973870|NCT01802632|9559739|FG000|Overall Study|Objective Disease Progression|1
5973871|NCT01802632|9559740|FG001|Overall Study|Objective Disease Progression|12
5973872|NCT01802632|9559741|FG002|Overall Study|Objective Disease Progression|104
5973873|NCT01802632|9559742|FG003|Overall Study|Objective Disease Progression|6
5973874|NCT01802632|9559743|FG004|Overall Study|Objective Disease Progression|4
5973875|NCT01802632|9559744|FG005|Overall Study|Objective Disease Progression|4
5973876|NCT01802632|9559739|FG000|Overall Study|Ongoing Study at Data Cut-off|168
5973877|NCT01802632|9559740|FG001|Overall Study|Ongoing Study at Data Cut-off|16
5973878|NCT01802632|9559741|FG002|Overall Study|Ongoing Study at Data Cut-off|115
5973879|NCT01802632|9559742|FG003|Overall Study|Ongoing Study at Data Cut-off|50
5973880|NCT01802632|9559743|FG004|Overall Study|Ongoing Study at Data Cut-off|6
5973881|NCT01802632|9559744|FG005|Overall Study|Ongoing Study at Data Cut-off|22
5973882|NCT01802632|9559739|FG000|Overall Study|Other (not specified)|0
5973883|NCT01802632|9559740|FG001|Overall Study|Other (not specified)|0
5973884|NCT01802632|9559741|FG002|Overall Study|Other (not specified)|7
5973885|NCT01802632|9559742|FG003|Overall Study|Other (not specified)|1
5973886|NCT01802632|9559743|FG004|Overall Study|Other (not specified)|0
5973887|NCT01802632|9559744|FG005|Overall Study|Other (not specified)|1
5973888|NCT01668719|9559759|FG000|Phase I|On treatment|1
5973889|NCT01668719|9559760|FG001|Phase I|On treatment|0
5973890|NCT01668719|9559761|FG002|Phase I|On treatment|0
5973891|NCT01668719|9559759|FG000|Phase I|Adverse Event|2
5973892|NCT01668719|9559760|FG001|Phase I|Adverse Event|0
5973893|NCT01668719|9559761|FG002|Phase I|Adverse Event|0
5973894|NCT01668719|9559759|FG000|Phase I|Progression/relapse|1
5973895|NCT01668719|9559760|FG001|Phase I|Progression/relapse|0
5973896|NCT01668719|9559761|FG002|Phase I|Progression/relapse|0
5973897|NCT01668719|9559759|FG000|Phase I|not protocol specified|2
5973898|NCT01668719|9559760|FG001|Phase I|not protocol specified|0
5973899|NCT01668719|9559761|FG002|Phase I|not protocol specified|0
5973900|NCT01668719|9559759|FG000|Phase II|On treatment|0
5973901|NCT01668719|9559760|FG001|Phase II|On treatment|4
5973902|NCT01668719|9559761|FG002|Phase II|On treatment|3
5973903|NCT01668719|9559759|FG000|Phase II|Adverse Event|0
5973904|NCT01668719|9559760|FG001|Phase II|Adverse Event|18
5973905|NCT01668719|9559761|FG002|Phase II|Adverse Event|18
5973906|NCT01668719|9559759|FG000|Phase II|Refusal unrelated to adverse event|0
5973907|NCT01668719|9559760|FG001|Phase II|Refusal unrelated to adverse event|4
5973908|NCT01668719|9559761|FG002|Phase II|Refusal unrelated to adverse event|1
5973909|NCT01668719|9559759|FG000|Phase II|Progression/relapse|0
5973910|NCT01668719|9559760|FG001|Phase II|Progression/relapse|13
5973911|NCT01668719|9559761|FG002|Phase II|Progression/relapse|17
5973912|NCT01668719|9559759|FG000|Phase II|Death|0
5973913|NCT01668719|9559760|FG001|Phase II|Death|0
5973914|NCT01668719|9559761|FG002|Phase II|Death|2
5973915|NCT01668719|9559759|FG000|Phase II|not protocol specified|0
5973916|NCT01668719|9559760|FG001|Phase II|not protocol specified|13
5973917|NCT01668719|9559761|FG002|Phase II|not protocol specified|7
5973918|NCT01625286|9559778|FG000|Overall Study|Adverse Event|0
5973919|NCT01625286|9559779|FG001|Overall Study|Adverse Event|0
5973920|NCT01625286|9559780|FG002|Overall Study|Adverse Event|0
5973921|NCT01625286|9559781|FG003|Overall Study|Adverse Event|0
5973922|NCT01625286|9559782|FG004|Overall Study|Adverse Event|1
5973923|NCT01625286|9559783|FG005|Overall Study|Adverse Event|2
5973924|NCT01625286|9559784|FG006|Overall Study|Adverse Event|1
5973925|NCT01625286|9559778|FG000|Overall Study|Death|0
5973926|NCT01625286|9559779|FG001|Overall Study|Death|0
5973927|NCT01625286|9559780|FG002|Overall Study|Death|1
5973928|NCT01625286|9559781|FG003|Overall Study|Death|1
5973929|NCT01625286|9559782|FG004|Overall Study|Death|0
5973930|NCT01625286|9559783|FG005|Overall Study|Death|11
5973931|NCT01625286|9559784|FG006|Overall Study|Death|16
5973932|NCT01625286|9559778|FG000|Overall Study|Withdrawal by Subject|0
5973933|NCT01625286|9559779|FG001|Overall Study|Withdrawal by Subject|1
5973934|NCT01625286|9559780|FG002|Overall Study|Withdrawal by Subject|0
5973935|NCT01625286|9559781|FG003|Overall Study|Withdrawal by Subject|1
5973936|NCT01625286|9559782|FG004|Overall Study|Withdrawal by Subject|0
5973937|NCT01625286|9559783|FG005|Overall Study|Withdrawal by Subject|0
5973938|NCT01625286|9559784|FG006|Overall Study|Withdrawal by Subject|1
5973939|NCT01625286|9559778|FG000|Overall Study|Any reason not specifically recorded|0
5973940|NCT01625286|9559779|FG001|Overall Study|Any reason not specifically recorded|0
5973941|NCT01625286|9559780|FG002|Overall Study|Any reason not specifically recorded|0
5973942|NCT01625286|9559781|FG003|Overall Study|Any reason not specifically recorded|0
5973943|NCT01625286|9559782|FG004|Overall Study|Any reason not specifically recorded|0
5973944|NCT01625286|9559783|FG005|Overall Study|Any reason not specifically recorded|1
5973945|NCT01625286|9559784|FG006|Overall Study|Any reason not specifically recorded|0
5973946|NCT01625286|9559778|FG000|Overall Study|Progressive disease|6
5973947|NCT01625286|9559779|FG001|Overall Study|Progressive disease|3
5973948|NCT01625286|9559780|FG002|Overall Study|Progressive disease|4
5973949|NCT01625286|9559781|FG003|Overall Study|Progressive disease|5
5973950|NCT01625286|9559782|FG004|Overall Study|Progressive disease|5
5973951|NCT01625286|9559783|FG005|Overall Study|Progressive disease|0
5973952|NCT01625286|9559784|FG006|Overall Study|Progressive disease|0
5973953|NCT01625286|9559778|FG000|Overall Study|Lost to Follow-up|0
5973954|NCT01625286|9559779|FG001|Overall Study|Lost to Follow-up|0
5973955|NCT01625286|9559780|FG002|Overall Study|Lost to Follow-up|0
5973956|NCT01625286|9559781|FG003|Overall Study|Lost to Follow-up|0
5973957|NCT01625286|9559782|FG004|Overall Study|Lost to Follow-up|0
5973958|NCT01625286|9559783|FG005|Overall Study|Lost to Follow-up|0
5973959|NCT01625286|9559784|FG006|Overall Study|Lost to Follow-up|1
5973960|NCT01625286|9559778|FG000|Overall Study|Ongoing off-treatment at DCO|0
5973961|NCT01625286|9559779|FG001|Overall Study|Ongoing off-treatment at DCO|0
5973962|NCT01625286|9559780|FG002|Overall Study|Ongoing off-treatment at DCO|0
5973963|NCT01625286|9559781|FG003|Overall Study|Ongoing off-treatment at DCO|0
5973964|NCT01625286|9559782|FG004|Overall Study|Ongoing off-treatment at DCO|0
5973965|NCT01625286|9559783|FG005|Overall Study|Ongoing off-treatment at DCO|32
5973966|NCT01625286|9559784|FG006|Overall Study|Ongoing off-treatment at DCO|31
5973967|NCT01625286|9559778|FG000|Overall Study|Ongoing on-treatment at DCO|6
5973968|NCT01625286|9559779|FG001|Overall Study|Ongoing on-treatment at DCO|4
5973969|NCT01625286|9559780|FG002|Overall Study|Ongoing on-treatment at DCO|0
5973970|NCT01625286|9559781|FG003|Overall Study|Ongoing on-treatment at DCO|0
5973971|NCT01625286|9559782|FG004|Overall Study|Ongoing on-treatment at DCO|0
5973972|NCT01625286|9559783|FG005|Overall Study|Ongoing on-treatment at DCO|8
5973973|NCT01625286|9559784|FG006|Overall Study|Ongoing on-treatment at DCO|6
5973974|NCT01515748|9559802|FG000|Overall Study|Withdrawal by Subject|32
5973975|NCT01515748|9559803|FG001|Overall Study|Withdrawal by Subject|41
5973976|NCT01515748|9559802|FG000|Overall Study|Lost to Follow-up|2
5973977|NCT01515748|9559803|FG001|Overall Study|Lost to Follow-up|4
5973978|NCT01515748|9559802|FG000|Overall Study|Ongoing|86
5973979|NCT01515748|9559803|FG001|Overall Study|Ongoing|90
5973980|NCT01261247|9559810|FG000|Overall Study|Ineligible|2
5973981|NCT00790933|9559842|FG000|Overall Study|Adverse Event|94
5973982|NCT00790933|9559843|FG001|Overall Study|Adverse Event|119
5973983|NCT00790933|9559844|FG002|Overall Study|Adverse Event|65
5973984|NCT00790933|9559845|FG003|Overall Study|Adverse Event|5
5973985|NCT00790933|9559846|FG004|Overall Study|Adverse Event|69
5973986|NCT00790933|9559842|FG000|Overall Study|Protocol Violation(s)|8
5973987|NCT00790933|9559843|FG001|Overall Study|Protocol Violation(s)|18
5973988|NCT00790933|9559844|FG002|Overall Study|Protocol Violation(s)|7
5973989|NCT00790933|9559845|FG003|Overall Study|Protocol Violation(s)|0
5973990|NCT00790933|9559846|FG004|Overall Study|Protocol Violation(s)|12
5973991|NCT00790933|9559842|FG000|Overall Study|Lack of Efficacy|192
5973992|NCT00790933|9559843|FG001|Overall Study|Lack of Efficacy|176
5973993|NCT00790933|9559844|FG002|Overall Study|Lack of Efficacy|130
5973994|NCT00790933|9559845|FG003|Overall Study|Lack of Efficacy|1
5973995|NCT00790933|9559846|FG004|Overall Study|Lack of Efficacy|121
5973996|NCT00790933|9559842|FG000|Overall Study|Study Terminated by Sponsor|0
5973997|NCT00790933|9559843|FG001|Overall Study|Study Terminated by Sponsor|0
5973998|NCT00790933|9559844|FG002|Overall Study|Study Terminated by Sponsor|1
5973999|NCT00790933|9559845|FG003|Overall Study|Study Terminated by Sponsor|0
5974000|NCT00790933|9559846|FG004|Overall Study|Study Terminated by Sponsor|0
5974001|NCT00790933|9559842|FG000|Overall Study|Withdrawal by Subject|123
5974002|NCT00790933|9559843|FG001|Overall Study|Withdrawal by Subject|120
5974003|NCT00790933|9559844|FG002|Overall Study|Withdrawal by Subject|52
5974004|NCT00790933|9559845|FG003|Overall Study|Withdrawal by Subject|6
5974005|NCT00790933|9559846|FG004|Overall Study|Withdrawal by Subject|50
5974006|NCT00790933|9559842|FG000|Overall Study|Lost to Follow-up|13
5974007|NCT00790933|9559843|FG001|Overall Study|Lost to Follow-up|31
5974008|NCT00790933|9559844|FG002|Overall Study|Lost to Follow-up|10
5974009|NCT00790933|9559845|FG003|Overall Study|Lost to Follow-up|1
5974010|NCT00790933|9559846|FG004|Overall Study|Lost to Follow-up|15
5974011|NCT00790933|9559842|FG000|Overall Study|Reason Not Specified|8
5974012|NCT00790933|9559843|FG001|Overall Study|Reason Not Specified|16
5974013|NCT00790933|9559844|FG002|Overall Study|Reason Not Specified|4
5974014|NCT00790933|9559845|FG003|Overall Study|Reason Not Specified|1
5974015|NCT00790933|9559846|FG004|Overall Study|Reason Not Specified|9
6049564|NCT00423319|9648811|FG000|Overall Study|Withdrawal by Subject|86
6049565|NCT00423319|9648812|FG001|Overall Study|Withdrawal by Subject|99
6049566|NCT00423319|9648811|FG000|Overall Study|Lost to Follow-up|4
6049567|NCT00423319|9648812|FG001|Overall Study|Lost to Follow-up|3
6049568|NCT00423319|9648811|FG000|Overall Study|Poor compliance or noncompliance|1
6049569|NCT00423319|9648812|FG001|Overall Study|Poor compliance or noncompliance|1
6049570|NCT00423319|9648811|FG000|Overall Study|No longer meets study criteria|15
6049571|NCT00423319|9648812|FG001|Overall Study|No longer meets study criteria|15
6049572|NCT00423319|9648811|FG000|Overall Study|Other|23
6049573|NCT00423319|9648812|FG001|Overall Study|Other|22
6049574|NCT00423332|9648821|FG000|Overall Study|Adverse Event|6
6049575|NCT00423332|9648822|FG001|Overall Study|Adverse Event|2
6049576|NCT00423332|9648821|FG000|Overall Study|Withdrawal by Subject|1
6049577|NCT00423332|9648822|FG001|Overall Study|Withdrawal by Subject|0
6049578|NCT00423332|9648821|FG000|Overall Study|Condition under investigation worsened|1
6049579|NCT00423332|9648822|FG001|Overall Study|Condition under investigation worsened|1
6049580|NCT00423332|9648821|FG000|Overall Study|Progressive at Week 6|0
6049581|NCT00423332|9648822|FG001|Overall Study|Progressive at Week 6|1
6049582|NCT00423332|9648821|FG000|Overall Study|Unblinded before 12 weeks|1
6049583|NCT00423332|9648822|FG001|Overall Study|Unblinded before 12 weeks|3
6049584|NCT00423449|9648847|FG000|Overall Study|Clinical Adverse Event|1
6049585|NCT00423449|9648848|FG001|Overall Study|Clinical Adverse Event|0
6049586|NCT00423449|9648849|FG002|Overall Study|Clinical Adverse Event|1
6049587|NCT00423449|9648850|FG003|Overall Study|Clinical Adverse Event|8
6049588|NCT00423449|9648851|FG004|Overall Study|Clinical Adverse Event|2
6049589|NCT00423449|9648847|FG000|Overall Study|Death|1
6049590|NCT00423449|9648848|FG001|Overall Study|Death|0
6049591|NCT00423449|9648849|FG002|Overall Study|Death|2
6049592|NCT00423449|9648850|FG003|Overall Study|Death|1
6049593|NCT00423449|9648851|FG004|Overall Study|Death|1
6049594|NCT00423449|9648847|FG000|Overall Study|Progressive Disease|1
6049595|NCT00423449|9648848|FG001|Overall Study|Progressive Disease|3
6049596|NCT00423449|9648849|FG002|Overall Study|Progressive Disease|8
6049597|NCT00423449|9648850|FG003|Overall Study|Progressive Disease|11
6049598|NCT00423449|9648851|FG004|Overall Study|Progressive Disease|4
6049599|NCT00423449|9648847|FG000|Overall Study|Laboratory Adverse Event|0
6049600|NCT00423449|9648848|FG001|Overall Study|Laboratory Adverse Event|1
6049601|NCT00423449|9648849|FG002|Overall Study|Laboratory Adverse Event|2
6049602|NCT00423449|9648850|FG003|Overall Study|Laboratory Adverse Event|0
6049603|NCT00423449|9648851|FG004|Overall Study|Laboratory Adverse Event|0
6049604|NCT00423449|9648847|FG000|Overall Study|Other|0
6049605|NCT00423449|9648848|FG001|Overall Study|Other|0
5974016|NCT04388527|9559931|FG000|Overall Study|Death|14
5974017|NCT04388527|9559931|FG000|Overall Study|Withdrawal by Subject|2
5974018|NCT04388527|9559931|FG000|Overall Study|Lost to Follow-up|1
5974019|NCT04126083|9559948|FG000|Overall Study|Withdrawal by Subject|1
5974020|NCT03444038|9560071|FG000|Overall Study|Adverse Event|12
5974021|NCT03444038|9560071|FG000|Overall Study|Withdrawal by Subject|7
5974022|NCT03444038|9560071|FG000|Overall Study|Lost to Follow-up|1
5974023|NCT03444038|9560071|FG000|Overall Study|Physician Decision|2
5974024|NCT03444038|9560071|FG000|Overall Study|Lack of Efficacy|7
5974025|NCT03265665|9560081|FG000|24-week Data Collection|Withdrawal by Subject|2
5974026|NCT03265665|9560082|FG001|24-week Data Collection|Withdrawal by Subject|2
5974027|NCT03265665|9560081|FG000|24-week Data Collection|Lost to Follow-up|4
5974028|NCT03265665|9560082|FG001|24-week Data Collection|Lost to Follow-up|5
6193577|NCT01439568|9851299|FG000|Overall Study|Withdrawal by Subject|2
5974029|NCT03265665|9560081|FG000|36-week Data Collection|Lost to Follow-up|6
5974030|NCT03265665|9560082|FG001|36-week Data Collection|Lost to Follow-up|8
5974031|NCT02725593|9560096|FG000|Blinded Treatment Period|Withdrawal by Subject|4
5974032|NCT02725593|9560097|FG001|Blinded Treatment Period|Withdrawal by Subject|3
5974033|NCT02725593|9560096|FG000|Blinded Treatment Period|Withdrawal by Parent/Guardian|0
5974034|NCT02725593|9560097|FG001|Blinded Treatment Period|Withdrawal by Parent/Guardian|2
5974035|NCT02725593|9560096|FG000|Blinded Treatment Period|Lost to Follow-up|1
5974036|NCT02725593|9560097|FG001|Blinded Treatment Period|Lost to Follow-up|1
5974037|NCT02725593|9560096|FG000|Long Term Extension|Withdrawal by Subject|1
5974038|NCT02725593|9560097|FG001|Long Term Extension|Withdrawal by Subject|3
5974039|NCT02716675|9560106|FG000|Overall Study|Death|2
5974040|NCT02716675|9560107|FG001|Overall Study|Death|3
5974041|NCT02716675|9560108|FG002|Overall Study|Death|0
5974042|NCT02716675|9560106|FG000|Overall Study|Physician Decision|2
5974043|NCT02716675|9560107|FG001|Overall Study|Physician Decision|1
5974044|NCT02716675|9560108|FG002|Overall Study|Physician Decision|1
5974045|NCT02716675|9560106|FG000|Overall Study|Lost to Follow-up|100
5974046|NCT02716675|9560107|FG001|Overall Study|Lost to Follow-up|87
5974047|NCT02716675|9560108|FG002|Overall Study|Lost to Follow-up|99
6049606|NCT00423449|9648849|FG002|Overall Study|Other|0
6049607|NCT00423449|9648850|FG003|Overall Study|Other|1
6049608|NCT00423449|9648851|FG004|Overall Study|Other|0
6049609|NCT00423449|9648847|FG000|Overall Study|Protocol Violation|0
6049610|NCT00423449|9648848|FG001|Overall Study|Protocol Violation|0
6049611|NCT00423449|9648849|FG002|Overall Study|Protocol Violation|2
6049612|NCT00423449|9648850|FG003|Overall Study|Protocol Violation|1
6049613|NCT00423449|9648851|FG004|Overall Study|Protocol Violation|0
6049614|NCT00423592|9648864|FG000|Overall Study|Adverse Event (through Week 12)|2
6049615|NCT00423592|9648864|FG000|Overall Study|Adverse Event (post Week 12)|5
6049616|NCT00423605|9648868|FG000|Overall Study|Adverse Event|129
6049617|NCT00423605|9648868|FG000|Overall Study|Withdrawal by Subject|36
6049618|NCT00423605|9648868|FG000|Overall Study|Lost to Follow-up|15
6049619|NCT00423605|9648868|FG000|Overall Study|Lack of Efficacy|38
6049620|NCT00423605|9648868|FG000|Overall Study|Sponsor Decision|3
6049621|NCT00423605|9648868|FG000|Overall Study|Physician Decision|8
6049622|NCT00423605|9648868|FG000|Overall Study|Protocol Violation|7
6049623|NCT00423605|9648868|FG000|Overall Study|Not one of the pre-specified options|5
6049624|NCT00423657|9648874|FG000|Overall Study|Withdrew consent|10
6049625|NCT00423657|9648875|FG001|Overall Study|Withdrew consent|8
6049626|NCT00423657|9648874|FG000|Overall Study|Non-compliance|0
6049627|NCT00423657|9648875|FG001|Overall Study|Non-compliance|1
6049628|NCT00423657|9648874|FG000|Overall Study|Other|15
6049629|NCT00423657|9648875|FG001|Overall Study|Other|16
6049630|NCT00423657|9648874|FG000|Overall Study|Request of sponsor/investigator|1
6049631|NCT00423657|9648875|FG001|Overall Study|Request of sponsor/investigator|0
6049632|NCT00423670|9648888|FG000|Treatment Period|Switched to Arm 8 at TW 24|36
6049633|NCT00423670|9648889|FG001|Treatment Period|Switched to Arm 8 at TW 24|0
6049634|NCT00423670|9648890|FG002|Treatment Period|Switched to Arm 8 at TW 24|0
6049635|NCT00423670|9648891|FG003|Treatment Period|Switched to Arm 8 at TW 24|0
6049636|NCT00423670|9648892|FG004|Treatment Period|Switched to Arm 8 at TW 24|0
6049637|NCT00423670|9648893|FG005|Treatment Period|Switched to Arm 8 at TW 24|0
6049638|NCT00423670|9648894|FG006|Treatment Period|Switched to Arm 8 at TW 24|0
6049639|NCT00423670|9648895|FG007|Treatment Period|Switched to Arm 8 at TW 24|0
6049640|NCT00423670|9648888|FG000|Treatment Period|Adverse Event|8
6049641|NCT00423670|9648889|FG001|Treatment Period|Adverse Event|12
6049642|NCT00423670|9648890|FG002|Treatment Period|Adverse Event|15
6049643|NCT00423670|9648891|FG003|Treatment Period|Adverse Event|20
6049644|NCT00423670|9648892|FG004|Treatment Period|Adverse Event|9
6049645|NCT00423670|9648893|FG005|Treatment Period|Adverse Event|4
6049646|NCT00423670|9648894|FG006|Treatment Period|Adverse Event|7
6049647|NCT00423670|9648895|FG007|Treatment Period|Adverse Event|2
6049648|NCT00423670|9648888|FG000|Treatment Period|Protocol-defined clinical event|0
6049649|NCT00423670|9648889|FG001|Treatment Period|Protocol-defined clinical event|7
6049650|NCT00423670|9648890|FG002|Treatment Period|Protocol-defined clinical event|4
6049651|NCT00423670|9648891|FG003|Treatment Period|Protocol-defined clinical event|12
6049652|NCT00423670|9648892|FG004|Treatment Period|Protocol-defined clinical event|5
6193578|NCT01439568|9851300|FG001|Overall Study|Withdrawal by Subject|2
5974048|NCT02716675|9560106|FG000|Overall Study|Withdrawal by Subject|22
6049653|NCT00423670|9648893|FG005|Treatment Period|Protocol-defined clinical event|4
5974049|NCT02716675|9560107|FG001|Overall Study|Withdrawal by Subject|25
5974050|NCT02716675|9560108|FG002|Overall Study|Withdrawal by Subject|20
5974051|NCT02716675|9560106|FG000|Overall Study|Protocol Violation|0
5974052|NCT02716675|9560107|FG001|Overall Study|Protocol Violation|3
5974053|NCT02716675|9560108|FG002|Overall Study|Protocol Violation|1
5974054|NCT02716675|9560106|FG000|Overall Study|Participant Unable to Adhere to Visit Schedule|36
5974055|NCT02716675|9560107|FG001|Overall Study|Participant Unable to Adhere to Visit Schedule|31
5974056|NCT02716675|9560108|FG002|Overall Study|Participant Unable to Adhere to Visit Schedule|42
5974057|NCT02716675|9560106|FG000|Overall Study|Other|38
5974058|NCT02716675|9560107|FG001|Overall Study|Other|47
5974059|NCT02716675|9560108|FG002|Overall Study|Other|48
5974060|NCT02636946|9560123|FG000|Cycle 1 (Day 1 to Week 15)|Withdrawal of Consent|0
5974061|NCT02636946|9560124|FG001|Cycle 1 (Day 1 to Week 15)|Withdrawal of Consent|1
5974062|NCT02636946|9560123|FG000|Cycle 1 (Day 1 to Week 15)|Lost to Follow-up|1
5974063|NCT02636946|9560124|FG001|Cycle 1 (Day 1 to Week 15)|Lost to Follow-up|0
5974064|NCT02636946|9560123|FG000|Cycle 1 (Day 1 to Week 15)|Protocol Violation|0
5974065|NCT02636946|9560124|FG001|Cycle 1 (Day 1 to Week 15)|Protocol Violation|1
5974066|NCT02636946|9560123|FG000|Cycle 1 (Day 1 to Week 15)|Reason not Specified|0
5974067|NCT02636946|9560124|FG001|Cycle 1 (Day 1 to Week 15)|Reason not Specified|1
5974068|NCT02636946|9560123|FG000|Cycle 1 (Day 1 to Week 15)|Randomized but not Treated|0
5974069|NCT02636946|9560124|FG001|Cycle 1 (Day 1 to Week 15)|Randomized but not Treated|2
5974070|NCT02636946|9560123|FG000|Cycle 2 (Week 16 to Week 31)|Adverse Event|2
5974071|NCT02636946|9560124|FG001|Cycle 2 (Week 16 to Week 31)|Adverse Event|1
5974072|NCT02631941|9560140|FG000|Overall Study|Physician Decision|0
5974073|NCT02631941|9560141|FG001|Overall Study|Physician Decision|1
5974074|NCT02631941|9560142|FG002|Overall Study|Physician Decision|0
6193579|NCT01439711|9851331|FG000|Overall Study|Ineligible|13
5974075|NCT02631941|9560143|FG003|Overall Study|Physician Decision|0
5974076|NCT02631941|9560144|FG004|Overall Study|Physician Decision|0
5974077|NCT02631941|9560145|FG005|Overall Study|Physician Decision|0
5974078|NCT02631941|9560146|FG006|Overall Study|Physician Decision|0
5974079|NCT02631941|9560147|FG007|Overall Study|Physician Decision|0
5974080|NCT02631941|9560148|FG008|Overall Study|Physician Decision|0
5974081|NCT02631941|9560149|FG009|Overall Study|Physician Decision|0
5974082|NCT02631941|9560140|FG000|Overall Study|Adverse Event|0
5974083|NCT02631941|9560141|FG001|Overall Study|Adverse Event|1
5974084|NCT02631941|9560142|FG002|Overall Study|Adverse Event|0
5974085|NCT02631941|9560143|FG003|Overall Study|Adverse Event|0
5974086|NCT02631941|9560144|FG004|Overall Study|Adverse Event|0
5974087|NCT02631941|9560145|FG005|Overall Study|Adverse Event|0
5974088|NCT02631941|9560146|FG006|Overall Study|Adverse Event|0
5974089|NCT02631941|9560147|FG007|Overall Study|Adverse Event|0
5974090|NCT02631941|9560148|FG008|Overall Study|Adverse Event|0
5974091|NCT02631941|9560149|FG009|Overall Study|Adverse Event|0
5974092|NCT02631941|9560140|FG000|Overall Study|Withdrawal by Subject|0
5974093|NCT02631941|9560141|FG001|Overall Study|Withdrawal by Subject|0
5974094|NCT02631941|9560142|FG002|Overall Study|Withdrawal by Subject|0
5974095|NCT02631941|9560143|FG003|Overall Study|Withdrawal by Subject|0
5974096|NCT02631941|9560144|FG004|Overall Study|Withdrawal by Subject|1
5974097|NCT02631941|9560145|FG005|Overall Study|Withdrawal by Subject|0
5974098|NCT02631941|9560146|FG006|Overall Study|Withdrawal by Subject|0
5974099|NCT02631941|9560147|FG007|Overall Study|Withdrawal by Subject|1
5974100|NCT02631941|9560148|FG008|Overall Study|Withdrawal by Subject|0
5974101|NCT02631941|9560149|FG009|Overall Study|Withdrawal by Subject|0
5974102|NCT02631941|9560140|FG000|Overall Study|Lost to Follow-up|0
5974103|NCT02631941|9560141|FG001|Overall Study|Lost to Follow-up|0
5974104|NCT02631941|9560142|FG002|Overall Study|Lost to Follow-up|0
5974105|NCT02631941|9560143|FG003|Overall Study|Lost to Follow-up|0
5974106|NCT02631941|9560144|FG004|Overall Study|Lost to Follow-up|0
5974107|NCT02631941|9560145|FG005|Overall Study|Lost to Follow-up|0
5974108|NCT02631941|9560146|FG006|Overall Study|Lost to Follow-up|0
5974109|NCT02631941|9560147|FG007|Overall Study|Lost to Follow-up|0
5974110|NCT02631941|9560148|FG008|Overall Study|Lost to Follow-up|1
5974111|NCT02631941|9560149|FG009|Overall Study|Lost to Follow-up|0
5974112|NCT02568215|9560162|FG000|Overall Study|Death|1
5974113|NCT02568215|9560163|FG001|Overall Study|Death|2
5974114|NCT02568215|9560164|FG002|Overall Study|Death|0
5974115|NCT02568215|9560162|FG000|Overall Study|Physician Decision|2
5974116|NCT02568215|9560163|FG001|Overall Study|Physician Decision|2
5974117|NCT02568215|9560164|FG002|Overall Study|Physician Decision|2
5974118|NCT02568215|9560162|FG000|Overall Study|Lost to Follow-up|29
5974119|NCT02568215|9560163|FG001|Overall Study|Lost to Follow-up|32
5974120|NCT02568215|9560164|FG002|Overall Study|Lost to Follow-up|41
5974121|NCT02568215|9560162|FG000|Overall Study|Withdrawal by Subject|21
5974122|NCT02568215|9560163|FG001|Overall Study|Withdrawal by Subject|19
5974123|NCT02568215|9560164|FG002|Overall Study|Withdrawal by Subject|22
5974124|NCT02568215|9560162|FG000|Overall Study|Protocol Violation|1
5974125|NCT02568215|9560163|FG001|Overall Study|Protocol Violation|1
5974126|NCT02568215|9560164|FG002|Overall Study|Protocol Violation|0
5974127|NCT02568215|9560162|FG000|Overall Study|Participant Unable to Adhere to Visit Schedule|25
5974128|NCT02568215|9560163|FG001|Overall Study|Participant Unable to Adhere to Visit Schedule|23
5974129|NCT02568215|9560164|FG002|Overall Study|Participant Unable to Adhere to Visit Schedule|21
5974130|NCT02568215|9560162|FG000|Overall Study|Other|0
5974131|NCT02568215|9560163|FG001|Overall Study|Other|1
5974132|NCT02568215|9560164|FG002|Overall Study|Other|4
5974133|NCT02528643|9560192|FG000|DB (Median Duration up to 14.65 Months)|Adverse Event|5
5974134|NCT02528643|9560193|FG001|DB (Median Duration up to 14.65 Months)|Adverse Event|8
5974135|NCT02528643|9560192|FG000|DB (Median Duration up to 14.65 Months)|Death|1
5974136|NCT02528643|9560193|FG001|DB (Median Duration up to 14.65 Months)|Death|6
5974137|NCT02528643|9560192|FG000|DB (Median Duration up to 14.65 Months)|Lost to Follow-up|0
5974138|NCT02528643|9560193|FG001|DB (Median Duration up to 14.65 Months)|Lost to Follow-up|1
5974139|NCT02528643|9560192|FG000|DB (Median Duration up to 14.65 Months)|Progressive Disease|44
5974140|NCT02528643|9560193|FG001|DB (Median Duration up to 14.65 Months)|Progressive Disease|82
5974141|NCT02528643|9560192|FG000|DB (Median Duration up to 14.65 Months)|Withdrawal by Subject|2
5974142|NCT02528643|9560193|FG001|DB (Median Duration up to 14.65 Months)|Withdrawal by Subject|8
5974143|NCT02528643|9560192|FG000|DB (Median Duration up to 14.65 Months)|Miscellaneous|3
5974144|NCT02528643|9560193|FG001|DB (Median Duration up to 14.65 Months)|Miscellaneous|5
5974145|NCT02528643|9560192|FG000|OL (Median Duration up to 27.56 Months)|Progressive Disease|0
5974146|NCT02528643|9560193|FG001|OL (Median Duration up to 27.56 Months)|Progressive Disease|1
5974147|NCT02237508|9560237|FG000|Overall Study|Withdrawal by Subject|0
5974148|NCT02237508|9560238|FG001|Overall Study|Withdrawal by Subject|2
5974149|NCT02237508|9560239|FG002|Overall Study|Withdrawal by Subject|0
5974150|NCT02237508|9560240|FG003|Overall Study|Withdrawal by Subject|1
5974151|NCT02237508|9560241|FG004|Overall Study|Withdrawal by Subject|0
5974152|NCT02237508|9560242|FG005|Overall Study|Withdrawal by Subject|1
5974153|NCT02237508|9560243|FG006|Overall Study|Withdrawal by Subject|1
5974154|NCT02237508|9560244|FG007|Overall Study|Withdrawal by Subject|0
6193580|NCT01439711|9851331|FG000|Overall Study|Cancel|3
6193581|NCT01439711|9851331|FG000|Overall Study|Progression Prior to Beginning Tx|1
5974155|NCT02237508|9560245|FG008|Overall Study|Withdrawal by Subject|1
6193582|NCT01439711|9851331|FG000|Overall Study|Adverse Event|5
6193583|NCT01439711|9851331|FG000|Overall Study|Withdrawal by Subject|3
6193584|NCT01439711|9851331|FG000|Overall Study|Progression During Active Tx|3
6193585|NCT01439711|9851331|FG000|Overall Study|Noncompliance|3
6193586|NCT01439711|9851331|FG000|Overall Study|No MRI|9
6193587|NCT01439724|9851337|FG000|Overall Study|missing consultation|9
6193588|NCT01439724|9851338|FG001|Overall Study|missing consultation|8
5974156|NCT02237508|9560246|FG009|Overall Study|Withdrawal by Subject|0
5974157|NCT02237508|9560237|FG000|Overall Study|Physician Decision|0
5974158|NCT02237508|9560238|FG001|Overall Study|Physician Decision|1
5974159|NCT02237508|9560239|FG002|Overall Study|Physician Decision|0
5974160|NCT02237508|9560240|FG003|Overall Study|Physician Decision|0
5974161|NCT02237508|9560241|FG004|Overall Study|Physician Decision|0
5974162|NCT02237508|9560242|FG005|Overall Study|Physician Decision|0
5974163|NCT02237508|9560243|FG006|Overall Study|Physician Decision|0
5974164|NCT02237508|9560244|FG007|Overall Study|Physician Decision|0
5974165|NCT02237508|9560245|FG008|Overall Study|Physician Decision|0
5974166|NCT02237508|9560246|FG009|Overall Study|Physician Decision|0
5974167|NCT02237508|9560237|FG000|Overall Study|Protocol Violation|0
5974168|NCT02237508|9560238|FG001|Overall Study|Protocol Violation|0
5974169|NCT02237508|9560239|FG002|Overall Study|Protocol Violation|1
5974170|NCT02237508|9560240|FG003|Overall Study|Protocol Violation|0
5974171|NCT02237508|9560241|FG004|Overall Study|Protocol Violation|0
5974172|NCT02237508|9560242|FG005|Overall Study|Protocol Violation|0
5974173|NCT02237508|9560243|FG006|Overall Study|Protocol Violation|0
5974174|NCT02237508|9560244|FG007|Overall Study|Protocol Violation|0
5974175|NCT02237508|9560245|FG008|Overall Study|Protocol Violation|0
5974176|NCT02237508|9560246|FG009|Overall Study|Protocol Violation|0
5974177|NCT02197234|9560264|FG000|Part A: Day 3-30 (AZD9291 Alone)|Condition under investigation worsened|1
5974178|NCT02197234|9560264|FG000|Part A: Day 3-30 (AZD9291 Alone)|Adverse Event|1
5974179|NCT02197234|9560264|FG000|Part A: Day 3-30 (AZD9291 Alone)|Withdrawal by Subject|1
5974180|NCT02197234|9560264|FG000|Part B: Day 33 to End Part B (AZD9291)|Adverse Event|1
5974181|NCT02197234|9560264|FG000|Part B: Day 33 to End Part B (AZD9291)|Withdrawal by Subject|1
5974182|NCT02197234|9560264|FG000|Part B: Day 33 to End Part B (AZD9291)|Death|6
5974183|NCT02197234|9560264|FG000|Part B: Day 33 to End Part B (AZD9291)|Condition under investigation worsened|22
5974184|NCT02163733|9560273|FG000|Part B: Day 15 to End Part B (AZD9291)|Death|0
5974185|NCT02163733|9560274|FG001|Part B: Day 15 to End Part B (AZD9291)|Death|0
5974186|NCT02163733|9560275|FG002|Part B: Day 15 to End Part B (AZD9291)|Death|5
5974187|NCT02163733|9560273|FG000|Part B: Day 15 to End Part B (AZD9291)|Disease progression|0
5974188|NCT02163733|9560274|FG001|Part B: Day 15 to End Part B (AZD9291)|Disease progression|0
5974189|NCT02163733|9560275|FG002|Part B: Day 15 to End Part B (AZD9291)|Disease progression|19
6193589|NCT01439867|9851364|FG000|Overall Study|Non-compliance|0
5974190|NCT02157883|9560282|FG000|Part A: Day 6-18 (AZD9291+Itraconozole)|Adverse Event|1
5974191|NCT02157883|9560282|FG000|Part B: Day 19 to End Part B (AZD9291)|Adverse Event|3
5974192|NCT02157883|9560282|FG000|Part B: Day 19 to End Part B (AZD9291)|Disease progression|15
5974193|NCT02157883|9560282|FG000|Part B: Day 19 to End Part B (AZD9291)|Withdrawal by Subject|1
5974194|NCT02157883|9560282|FG000|Part B: Day 19 to End Part B (AZD9291)|Death|3
5974195|NCT01706705|9560289|FG000|Overall Study|Death|1
5974196|NCT01706705|9560289|FG000|Overall Study|Lack of Efficacy|13
6193590|NCT01439867|9851365|FG001|Overall Study|Non-compliance|1
6193591|NCT01439867|9851364|FG000|Overall Study|Withdrawal by Subject|1
5974197|NCT01706705|9560289|FG000|Overall Study|Non-clinical|6
5974198|NCT01609842|9560298|FG000|Concurrent Intervention Control|pharmacy data not available|2
5974199|NCT01609842|9560299|FG001|Concurrent Intervention Control|pharmacy data not available|0
5974200|NCT00288080|9560333|FG000|Overall Study|Withdrawal by Subject|1
5974201|NCT00288080|9560334|FG001|Overall Study|Withdrawal by Subject|3
5974202|NCT00288080|9560333|FG000|Overall Study|Protocol Violation|25
5974203|NCT00288080|9560334|FG001|Overall Study|Protocol Violation|20
5974204|NCT00099437|9560342|FG000|Overall Study|Lost to Follow-up|30
5974205|NCT00099437|9560343|FG001|Overall Study|Lost to Follow-up|33
5974206|NCT00099437|9560342|FG000|Overall Study|Death|293
6087928|NCT00672490|9698603|FG001|Overall Study|Violation of Concomitant Medicine|0
6087929|NCT00672490|9698602|FG000|Overall Study|Intolerance|0
5974207|NCT00099437|9560343|FG001|Overall Study|Death|261
5974208|NCT00099437|9560342|FG000|Overall Study|Withdrawal by Subject|6
5974209|NCT00099437|9560343|FG001|Overall Study|Withdrawal by Subject|10
5974210|NCT00099437|9560342|FG000|Overall Study|Ongoing in FU but not on treatment|37
5974211|NCT00099437|9560343|FG001|Overall Study|Ongoing in FU but not on treatment|45
5974212|NCT00003479|9560349|FG000|Overall Study|Not evaluable|3
6049654|NCT00423670|9648894|FG006|Treatment Period|Protocol-defined clinical event|16
6049655|NCT00423670|9648895|FG007|Treatment Period|Protocol-defined clinical event|15
6049656|NCT00423670|9648888|FG000|Treatment Period|Lost to Follow-up|2
6049657|NCT00423670|9648889|FG001|Treatment Period|Lost to Follow-up|1
6049658|NCT00423670|9648890|FG002|Treatment Period|Lost to Follow-up|3
6049659|NCT00423670|9648891|FG003|Treatment Period|Lost to Follow-up|1
6049660|NCT00423670|9648892|FG004|Treatment Period|Lost to Follow-up|6
6049661|NCT00423670|9648893|FG005|Treatment Period|Lost to Follow-up|0
6049662|NCT00423670|9648894|FG006|Treatment Period|Lost to Follow-up|3
6049663|NCT00423670|9648895|FG007|Treatment Period|Lost to Follow-up|1
6049664|NCT00423670|9648888|FG000|Treatment Period|Subject withdrew (not treatment related)|3
6049665|NCT00423670|9648889|FG001|Treatment Period|Subject withdrew (not treatment related)|9
6049666|NCT00423670|9648890|FG002|Treatment Period|Subject withdrew (not treatment related)|4
6049667|NCT00423670|9648891|FG003|Treatment Period|Subject withdrew (not treatment related)|4
6049668|NCT00423670|9648892|FG004|Treatment Period|Subject withdrew (not treatment related)|5
6049669|NCT00423670|9648893|FG005|Treatment Period|Subject withdrew (not treatment related)|0
6049670|NCT00423670|9648894|FG006|Treatment Period|Subject withdrew (not treatment related)|3
6049671|NCT00423670|9648895|FG007|Treatment Period|Subject withdrew (not treatment related)|0
6049672|NCT00423670|9648888|FG000|Treatment Period|Investigator decision|0
6049673|NCT00423670|9648889|FG001|Treatment Period|Investigator decision|0
6049674|NCT00423670|9648890|FG002|Treatment Period|Investigator decision|0
6049675|NCT00423670|9648891|FG003|Treatment Period|Investigator decision|0
6049676|NCT00423670|9648892|FG004|Treatment Period|Investigator decision|0
6049677|NCT00423670|9648893|FG005|Treatment Period|Investigator decision|0
6049678|NCT00423670|9648894|FG006|Treatment Period|Investigator decision|0
6049679|NCT00423670|9648895|FG007|Treatment Period|Investigator decision|1
6049680|NCT00423670|9648888|FG000|Treatment Period|Non-compliance with protocol|3
6049681|NCT00423670|9648889|FG001|Treatment Period|Non-compliance with protocol|1
6049682|NCT00423670|9648890|FG002|Treatment Period|Non-compliance with protocol|1
6049683|NCT00423670|9648891|FG003|Treatment Period|Non-compliance with protocol|3
6049684|NCT00423670|9648892|FG004|Treatment Period|Non-compliance with protocol|2
6049685|NCT00423670|9648893|FG005|Treatment Period|Non-compliance with protocol|0
6049686|NCT00423670|9648894|FG006|Treatment Period|Non-compliance with protocol|2
6049687|NCT00423670|9648895|FG007|Treatment Period|Non-compliance with protocol|2
6049688|NCT00423670|9648888|FG000|Follow-up Period|Lost to Follow-up|0
6049689|NCT00423670|9648889|FG001|Follow-up Period|Lost to Follow-up|12
6049690|NCT00423670|9648890|FG002|Follow-up Period|Lost to Follow-up|8
6049691|NCT00423670|9648891|FG003|Follow-up Period|Lost to Follow-up|3
6049692|NCT00423670|9648892|FG004|Follow-up Period|Lost to Follow-up|1
6049693|NCT00423670|9648893|FG005|Follow-up Period|Lost to Follow-up|0
6049694|NCT00423670|9648894|FG006|Follow-up Period|Lost to Follow-up|5
6049695|NCT00423670|9648895|FG007|Follow-up Period|Lost to Follow-up|0
6049696|NCT00423670|9648888|FG000|Follow-up Period|Subject withdrew (not treatment related)|1
6049697|NCT00423670|9648889|FG001|Follow-up Period|Subject withdrew (not treatment related)|4
6049698|NCT00423670|9648890|FG002|Follow-up Period|Subject withdrew (not treatment related)|2
6049699|NCT00423670|9648891|FG003|Follow-up Period|Subject withdrew (not treatment related)|1
6049700|NCT00423670|9648892|FG004|Follow-up Period|Subject withdrew (not treatment related)|1
6049701|NCT00423670|9648893|FG005|Follow-up Period|Subject withdrew (not treatment related)|0
6049702|NCT00423670|9648894|FG006|Follow-up Period|Subject withdrew (not treatment related)|1
6049703|NCT00423670|9648895|FG007|Follow-up Period|Subject withdrew (not treatment related)|1
6049704|NCT00423670|9648888|FG000|Follow-up Period|Non-compliance with protocol|2
6049705|NCT00423670|9648889|FG001|Follow-up Period|Non-compliance with protocol|0
6049706|NCT00423670|9648890|FG002|Follow-up Period|Non-compliance with protocol|1
6049707|NCT00423670|9648891|FG003|Follow-up Period|Non-compliance with protocol|1
6049708|NCT00423670|9648892|FG004|Follow-up Period|Non-compliance with protocol|0
6049709|NCT00423670|9648893|FG005|Follow-up Period|Non-compliance with protocol|0
6049710|NCT00423670|9648894|FG006|Follow-up Period|Non-compliance with protocol|3
6049711|NCT00423670|9648895|FG007|Follow-up Period|Non-compliance with protocol|2
6087930|NCT00672490|9698603|FG001|Overall Study|Intolerance|2
5974213|NCT04160195|9560355|FG000|Overall Study|Principal investigator stopped study due to instability of chimeric antigen receptor gene.|1
5974214|NCT04160195|9560356|FG001|Overall Study|Principal investigator stopped study due to instability of chimeric antigen receptor gene.|0
5974215|NCT04159701|9560366|FG000|Period 1: Treatment Period|Pregnancy|1
5974216|NCT04159701|9560367|FG001|Period 1: Treatment Period|Pregnancy|0
5974217|NCT04159701|9560366|FG000|Period 1: Treatment Period|Study Terminated by sponsor|4
5974218|NCT04159701|9560367|FG001|Period 1: Treatment Period|Study Terminated by sponsor|1
5974219|NCT04159701|9560366|FG000|Period 1: Treatment Period|Withdrawal by Subject|3
5974220|NCT04159701|9560367|FG001|Period 1: Treatment Period|Withdrawal by Subject|0
5974221|NCT04159701|9560366|FG000|Washout Period|site terminated by sponsor|0
5974222|NCT04159701|9560367|FG001|Washout Period|site terminated by sponsor|1
5974223|NCT04159701|9560366|FG000|Washout Period|study terminated by sponsor|10
5974224|NCT04159701|9560367|FG001|Washout Period|study terminated by sponsor|3
5974225|NCT04159701|9560366|FG000|Washout Period|Withdrawal by Subject|1
5974226|NCT04159701|9560367|FG001|Washout Period|Withdrawal by Subject|0
5974227|NCT04159701|9560366|FG000|Washout Period|Inadvertent Enrollment|1
5974228|NCT04159701|9560367|FG001|Washout Period|Inadvertent Enrollment|0
5974229|NCT04159701|9560366|FG000|Washout Period|Miscellaneous|1
5974230|NCT04159701|9560367|FG001|Washout Period|Miscellaneous|0
5974231|NCT04159701|9560366|FG000|Period 2: Treatment Period (Crossover)|Study Terminated by Sponsor|0
5974232|NCT04159701|9560367|FG001|Period 2: Treatment Period (Crossover)|Study Terminated by Sponsor|2
5974233|NCT04159701|9560366|FG000|Period 2: Treatment Period (Crossover)|Withdrawal by Subject|0
5974234|NCT04159701|9560367|FG001|Period 2: Treatment Period (Crossover)|Withdrawal by Subject|1
5974235|NCT04159701|9560366|FG000|Post-treatment Follow-up|Study Terminated by Sponsor|6
5974236|NCT04159701|9560367|FG001|Post-treatment Follow-up|Study Terminated by Sponsor|3
5974237|NCT04159701|9560366|FG000|Post-treatment Follow-up|Withdrawal by Subject|3
5974238|NCT04159701|9560367|FG001|Post-treatment Follow-up|Withdrawal by Subject|0
5974239|NCT04159701|9560366|FG000|Post-treatment Follow-up|Inadvertent Enrollment|1
5974240|NCT04159701|9560367|FG001|Post-treatment Follow-up|Inadvertent Enrollment|0
5974241|NCT04152447|9560379|FG000|Overall Study|Lost to Follow-up|1
5974242|NCT04152447|9560380|FG001|Overall Study|Lost to Follow-up|0
5974243|NCT04152447|9560379|FG000|Overall Study|Treatment plan switched to an ineligible criteria|1
5974244|NCT04152447|9560380|FG001|Overall Study|Treatment plan switched to an ineligible criteria|1
5974245|NCT04152447|9560379|FG000|Overall Study|Withdrawal by Subject|0
5974246|NCT04152447|9560380|FG001|Overall Study|Withdrawal by Subject|1
5974247|NCT04152447|9560379|FG000|Overall Study|Found ineligible after enrolling|1
5974248|NCT04152447|9560380|FG001|Overall Study|Found ineligible after enrolling|1
5974249|NCT04152447|9560379|FG000|Overall Study|Did not receive VR headset in time.|0
5974250|NCT04152447|9560380|FG001|Overall Study|Did not receive VR headset in time.|2
5974251|NCT04097925|9560386|FG000|Overall Study|Withdrawal by Subject|1
6087931|NCT00672490|9698602|FG000|Overall Study|Lost to Follow-up|1
6087932|NCT00672490|9698603|FG001|Overall Study|Lost to Follow-up|5
6087933|NCT00672490|9698602|FG000|Overall Study|No reason was provided|6
6087934|NCT00672490|9698603|FG001|Overall Study|No reason was provided|2
6087935|NCT00672555|9698609|FG000|Overall Study|Lost to Follow-up|4
6087936|NCT00672555|9698609|FG000|Overall Study|Did not want to answer questionnaire|2
6087937|NCT00672620|9698621|FG000|Overall Study|Adverse Event|7
6087938|NCT00672620|9698622|FG001|Overall Study|Adverse Event|7
6087939|NCT00672620|9698623|FG002|Overall Study|Adverse Event|12
5974261|NCT03794544|9560451|FG000|Overall Study|Withdrawal by Subject|1
5974262|NCT03794544|9560452|FG001|Overall Study|Withdrawal by Subject|1
5974263|NCT03794544|9560453|FG002|Overall Study|Withdrawal by Subject|0
5974264|NCT03794544|9560454|FG003|Overall Study|Withdrawal by Subject|0
5974265|NCT03794544|9560451|FG000|Overall Study|Death|0
5974266|NCT03794544|9560452|FG001|Overall Study|Death|0
5974267|NCT03794544|9560453|FG002|Overall Study|Death|0
5974268|NCT03794544|9560454|FG003|Overall Study|Death|1
5974269|NCT03794544|9560451|FG000|Overall Study|Lost to Follow-up|0
5974270|NCT03794544|9560452|FG001|Overall Study|Lost to Follow-up|1
5974271|NCT03794544|9560453|FG002|Overall Study|Lost to Follow-up|1
5974272|NCT03794544|9560454|FG003|Overall Study|Lost to Follow-up|0
5974273|NCT03794544|9560451|FG000|Overall Study|Other|0
5974274|NCT03794544|9560452|FG001|Overall Study|Other|1
5974275|NCT03794544|9560453|FG002|Overall Study|Other|0
5974276|NCT03794544|9560454|FG003|Overall Study|Other|0
5974277|NCT03732807|9560471|FG000|Treatment Period (up to Week 24)|Adverse Event|3
5974278|NCT03732807|9560472|FG001|Treatment Period (up to Week 24)|Adverse Event|0
5974279|NCT03732807|9560473|FG002|Treatment Period (up to Week 24)|Adverse Event|2
5974280|NCT03732807|9560474|FG003|Treatment Period (up to Week 24)|Adverse Event|4
5974281|NCT03732807|9560475|FG004|Treatment Period (up to Week 24)|Adverse Event|2
5974282|NCT03732807|9560476|FG005|Treatment Period (up to Week 24)|Adverse Event|0
5974283|NCT03732807|9560477|FG006|Treatment Period (up to Week 24)|Adverse Event|1
5974284|NCT03732807|9560471|FG000|Treatment Period (up to Week 24)|Lost to Follow-up|1
5974285|NCT03732807|9560472|FG001|Treatment Period (up to Week 24)|Lost to Follow-up|0
5974286|NCT03732807|9560473|FG002|Treatment Period (up to Week 24)|Lost to Follow-up|1
5974287|NCT03732807|9560474|FG003|Treatment Period (up to Week 24)|Lost to Follow-up|2
5974288|NCT03732807|9560475|FG004|Treatment Period (up to Week 24)|Lost to Follow-up|1
5974289|NCT03732807|9560476|FG005|Treatment Period (up to Week 24)|Lost to Follow-up|0
5974290|NCT03732807|9560477|FG006|Treatment Period (up to Week 24)|Lost to Follow-up|0
5974291|NCT03732807|9560471|FG000|Treatment Period (up to Week 24)|Physician Decision|0
5974292|NCT03732807|9560472|FG001|Treatment Period (up to Week 24)|Physician Decision|1
5974293|NCT03732807|9560473|FG002|Treatment Period (up to Week 24)|Physician Decision|2
5974294|NCT03732807|9560474|FG003|Treatment Period (up to Week 24)|Physician Decision|5
5974295|NCT03732807|9560475|FG004|Treatment Period (up to Week 24)|Physician Decision|0
5974296|NCT03732807|9560476|FG005|Treatment Period (up to Week 24)|Physician Decision|0
5974297|NCT03732807|9560477|FG006|Treatment Period (up to Week 24)|Physician Decision|1
5974298|NCT03732807|9560471|FG000|Treatment Period (up to Week 24)|Pregnancy|1
5974299|NCT03732807|9560472|FG001|Treatment Period (up to Week 24)|Pregnancy|0
6049712|NCT00423722|9648929|FG000|Overall Study|Death|4
6049713|NCT00423722|9648930|FG001|Overall Study|Death|4
6193592|NCT01439867|9851365|FG001|Overall Study|Withdrawal by Subject|2
6049714|NCT00423722|9648929|FG000|Overall Study|Declined to participate|2
6049715|NCT00423722|9648930|FG001|Overall Study|Declined to participate|3
6049716|NCT00423722|9648929|FG000|Overall Study|Unable to complete questionnaires|4
6049717|NCT00423722|9648930|FG001|Overall Study|Unable to complete questionnaires|4
6049718|NCT00423722|9648929|FG000|Overall Study|Withdrawal by Subject|4
6049719|NCT00423722|9648930|FG001|Overall Study|Withdrawal by Subject|2
6049720|NCT00423735|9648945|FG000|Overall Study|Ineligible / No protocol treatment|8
6049721|NCT00423735|9648946|FG001|Overall Study|Ineligible / No protocol treatment|6
6049722|NCT00423735|9648947|FG002|Overall Study|Ineligible / No protocol treatment|0
6049723|NCT00423800|9648959|FG000|Overall Study|Protocol Violation|0
6049724|NCT00423800|9648960|FG001|Overall Study|Protocol Violation|1
6049725|NCT00423813|9648970|FG000|Overall Study|Adverse Event|11
6049726|NCT00423813|9648971|FG001|Overall Study|Adverse Event|30
6049727|NCT00423813|9648972|FG002|Overall Study|Adverse Event|40
6049728|NCT00423813|9648970|FG000|Overall Study|Withdrawal by Subject|6
6049729|NCT00423813|9648971|FG001|Overall Study|Withdrawal by Subject|8
6049730|NCT00423813|9648972|FG002|Overall Study|Withdrawal by Subject|5
6049731|NCT00423813|9648970|FG000|Overall Study|Lost to Follow-up|5
6049732|NCT00423813|9648971|FG001|Overall Study|Lost to Follow-up|4
6049733|NCT00423813|9648972|FG002|Overall Study|Lost to Follow-up|4
6049734|NCT00423813|9648970|FG000|Overall Study|Lack of Efficacy|23
6049735|NCT00423813|9648971|FG001|Overall Study|Lack of Efficacy|18
6049736|NCT00423813|9648972|FG002|Overall Study|Lack of Efficacy|19
6049737|NCT00423813|9648970|FG000|Overall Study|Physician Decision|2
6049738|NCT00423813|9648971|FG001|Overall Study|Physician Decision|0
6049739|NCT00423813|9648972|FG002|Overall Study|Physician Decision|0
6049740|NCT00423813|9648970|FG000|Overall Study|Sponsor Decision|0
6049741|NCT00423813|9648971|FG001|Overall Study|Sponsor Decision|1
6049742|NCT00423813|9648972|FG002|Overall Study|Sponsor Decision|0
6049743|NCT00423813|9648970|FG000|Overall Study|Protocol Violation|9
6049744|NCT00423813|9648971|FG001|Overall Study|Protocol Violation|4
6049745|NCT00423813|9648972|FG002|Overall Study|Protocol Violation|4
6049746|NCT00423813|9648970|FG000|Overall Study|Pregnancy|0
6049747|NCT00423813|9648971|FG001|Overall Study|Pregnancy|0
6049748|NCT00423813|9648972|FG002|Overall Study|Pregnancy|1
6049749|NCT00423813|9648970|FG000|Overall Study|Subject started night shift work|1
6049750|NCT00423813|9648971|FG001|Overall Study|Subject started night shift work|0
6049751|NCT00423813|9648972|FG002|Overall Study|Subject started night shift work|0
6049752|NCT00423813|9648970|FG000|Overall Study|Will start exclusionary medications|0
6049753|NCT00423813|9648971|FG001|Overall Study|Will start exclusionary medications|1
6049754|NCT00423813|9648972|FG002|Overall Study|Will start exclusionary medications|0
6049755|NCT00423813|9648970|FG000|Overall Study|Undergoing tests for Cushings Syndrome|0
6049756|NCT00423813|9648971|FG001|Overall Study|Undergoing tests for Cushings Syndrome|0
6049757|NCT00423813|9648972|FG002|Overall Study|Undergoing tests for Cushings Syndrome|1
6049758|NCT00423852|9648980|FG000|Overall Study|Removed pior to the high-dose portion|3
6049759|NCT00423891|9648996|FG000|Enrolled|Withdrawal by Subject|0
6049760|NCT00423891|9648997|FG001|Enrolled|Withdrawal by Subject|0
6049761|NCT00423891|9648998|FG002|Enrolled|Withdrawal by Subject|1
6049762|NCT00423891|9648996|FG000|Enrolled|Lost to Follow-up|0
6049763|NCT00423891|9648997|FG001|Enrolled|Lost to Follow-up|0
6049764|NCT00423891|9648998|FG002|Enrolled|Lost to Follow-up|1
6193593|NCT01439867|9851364|FG000|Overall Study|Administrative Decision|4
6193594|NCT01439867|9851365|FG001|Overall Study|Administrative Decision|5
6193595|NCT01439867|9851364|FG000|Overall Study|Protocol-specified Criteria|1
6193596|NCT01439867|9851365|FG001|Overall Study|Protocol-specified Criteria|0
6273096|NCT02186301|9976343|FG001|Overall Study|Protocol Deviation|2
6273097|NCT02186301|9976344|FG002|Overall Study|Protocol Deviation|0
6273098|NCT02186301|9976342|FG000|Overall Study|Missing|0
6273099|NCT02186301|9976343|FG001|Overall Study|Missing|0
6273100|NCT02186301|9976344|FG002|Overall Study|Missing|2
6273101|NCT02186301|9976342|FG000|Overall Study|Other|0
6273102|NCT02186301|9976343|FG001|Overall Study|Other|0
6273103|NCT02186301|9976344|FG002|Overall Study|Other|1
6273104|NCT02186561|9976358|FG000|Enrollment|Did Not Meet Inclusion Criteria|46
6273105|NCT02186561|9976358|FG000|Enrollment|Enrollment Cap Reached|5
6273106|NCT02186561|9976358|FG000|Enrollment|Insurance Denial|2
6273107|NCT02186561|9976358|FG000|Enrollment|Withdrawal by Subject|2
6273108|NCT02186561|9976358|FG000|Enrollment|Investigator Withdrew Consent|1
6273109|NCT02186561|9976358|FG000|30-Day Post Index Procedure Visit|Death|1
5974300|NCT03732807|9560473|FG002|Treatment Period (up to Week 24)|Pregnancy|0
5974301|NCT03732807|9560474|FG003|Treatment Period (up to Week 24)|Pregnancy|0
5974302|NCT03732807|9560475|FG004|Treatment Period (up to Week 24)|Pregnancy|1
5974303|NCT03732807|9560476|FG005|Treatment Period (up to Week 24)|Pregnancy|0
5974304|NCT03732807|9560477|FG006|Treatment Period (up to Week 24)|Pregnancy|1
5974305|NCT03732807|9560471|FG000|Treatment Period (up to Week 24)|Protocol Violation|1
5974306|NCT03732807|9560472|FG001|Treatment Period (up to Week 24)|Protocol Violation|1
5974307|NCT03732807|9560473|FG002|Treatment Period (up to Week 24)|Protocol Violation|0
5974308|NCT03732807|9560474|FG003|Treatment Period (up to Week 24)|Protocol Violation|0
5974309|NCT03732807|9560475|FG004|Treatment Period (up to Week 24)|Protocol Violation|0
5974310|NCT03732807|9560476|FG005|Treatment Period (up to Week 24)|Protocol Violation|0
5974311|NCT03732807|9560477|FG006|Treatment Period (up to Week 24)|Protocol Violation|0
5974312|NCT03732807|9560471|FG000|Treatment Period (up to Week 24)|Withdrawal by Subject|4
5974313|NCT03732807|9560472|FG001|Treatment Period (up to Week 24)|Withdrawal by Subject|4
5974314|NCT03732807|9560473|FG002|Treatment Period (up to Week 24)|Withdrawal by Subject|4
5974315|NCT03732807|9560474|FG003|Treatment Period (up to Week 24)|Withdrawal by Subject|4
5974316|NCT03732807|9560475|FG004|Treatment Period (up to Week 24)|Withdrawal by Subject|1
5974317|NCT03732807|9560476|FG005|Treatment Period (up to Week 24)|Withdrawal by Subject|1
5974318|NCT03732807|9560477|FG006|Treatment Period (up to Week 24)|Withdrawal by Subject|2
5974319|NCT03732807|9560471|FG000|Treatment Period (up to Week 24)|Lack of Efficacy|0
6049765|NCT00423891|9648996|FG000|Enrolled|No longer met criteria|11
6049766|NCT00423891|9648997|FG001|Enrolled|No longer met criteria|2
6049767|NCT00423891|9648998|FG002|Enrolled|No longer met criteria|1
6049768|NCT00423891|9648996|FG000|Treatment|Withdrawal by Subject|1
6049769|NCT00423891|9648997|FG001|Treatment|Withdrawal by Subject|0
6049770|NCT00423891|9648998|FG002|Treatment|Withdrawal by Subject|0
5974320|NCT03732807|9560472|FG001|Treatment Period (up to Week 24)|Lack of Efficacy|0
5974321|NCT03732807|9560473|FG002|Treatment Period (up to Week 24)|Lack of Efficacy|0
5974322|NCT03732807|9560474|FG003|Treatment Period (up to Week 24)|Lack of Efficacy|0
5974323|NCT03732807|9560475|FG004|Treatment Period (up to Week 24)|Lack of Efficacy|0
5974324|NCT03732807|9560476|FG005|Treatment Period (up to Week 24)|Lack of Efficacy|1
5974325|NCT03732807|9560477|FG006|Treatment Period (up to Week 24)|Lack of Efficacy|0
5974326|NCT03732807|9560471|FG000|Treatment Extension (Week 25 up to 48)|Adverse Event|0
5974327|NCT03732807|9560472|FG001|Treatment Extension (Week 25 up to 48)|Adverse Event|2
5974328|NCT03732807|9560473|FG002|Treatment Extension (Week 25 up to 48)|Adverse Event|2
5974329|NCT03732807|9560474|FG003|Treatment Extension (Week 25 up to 48)|Adverse Event|1
5974330|NCT03732807|9560475|FG004|Treatment Extension (Week 25 up to 48)|Adverse Event|0
5974331|NCT03732807|9560476|FG005|Treatment Extension (Week 25 up to 48)|Adverse Event|0
5974332|NCT03732807|9560477|FG006|Treatment Extension (Week 25 up to 48)|Adverse Event|2
5974333|NCT03732807|9560471|FG000|Treatment Extension (Week 25 up to 48)|Lack of Efficacy|2
5974334|NCT03732807|9560472|FG001|Treatment Extension (Week 25 up to 48)|Lack of Efficacy|1
5974335|NCT03732807|9560473|FG002|Treatment Extension (Week 25 up to 48)|Lack of Efficacy|0
5974336|NCT03732807|9560474|FG003|Treatment Extension (Week 25 up to 48)|Lack of Efficacy|3
5974337|NCT03732807|9560475|FG004|Treatment Extension (Week 25 up to 48)|Lack of Efficacy|3
5974338|NCT03732807|9560476|FG005|Treatment Extension (Week 25 up to 48)|Lack of Efficacy|0
5974339|NCT03732807|9560477|FG006|Treatment Extension (Week 25 up to 48)|Lack of Efficacy|1
5974340|NCT03732807|9560471|FG000|Treatment Extension (Week 25 up to 48)|Lost to Follow-up|0
5974341|NCT03732807|9560472|FG001|Treatment Extension (Week 25 up to 48)|Lost to Follow-up|0
5974342|NCT03732807|9560473|FG002|Treatment Extension (Week 25 up to 48)|Lost to Follow-up|2
5974343|NCT03732807|9560474|FG003|Treatment Extension (Week 25 up to 48)|Lost to Follow-up|1
5974344|NCT03732807|9560475|FG004|Treatment Extension (Week 25 up to 48)|Lost to Follow-up|1
5974345|NCT03732807|9560476|FG005|Treatment Extension (Week 25 up to 48)|Lost to Follow-up|2
6049771|NCT00423891|9648996|FG000|Treatment|Lost to Follow-up|1
6049772|NCT00423891|9648997|FG001|Treatment|Lost to Follow-up|0
6049773|NCT00423891|9648998|FG002|Treatment|Lost to Follow-up|0
6049774|NCT00423891|9648996|FG000|Post-Dosing Follow Up|Withdrawal by Subject|0
6049775|NCT00423891|9648997|FG001|Post-Dosing Follow Up|Withdrawal by Subject|3
6049776|NCT00423891|9648998|FG002|Post-Dosing Follow Up|Withdrawal by Subject|2
6049777|NCT00423891|9648996|FG000|Post-Dosing Follow Up|Lost to Follow-up|2
6049778|NCT00423891|9648997|FG001|Post-Dosing Follow Up|Lost to Follow-up|0
6049779|NCT00423891|9648998|FG002|Post-Dosing Follow Up|Lost to Follow-up|0
6049780|NCT00423917|9649008|FG000|Overall Study|Cancel|2
6049781|NCT00423917|9649008|FG000|Overall Study|Ineligible|1
6049782|NCT00423930|9649012|FG000|Overall Study|Withdrawal by Subject|2
6049783|NCT00423943|9649018|FG000|Overall Study|Withdrawal by Subject|3
6049784|NCT00423943|9649019|FG001|Overall Study|Withdrawal by Subject|1
6049785|NCT00424021|9649029|FG000|NCT00046319 Study Period|Adverse Event|1
6049786|NCT00424021|9649030|FG001|NCT00046319 Study Period|Adverse Event|0
6049787|NCT00424021|9649031|FG002|NCT00046319 Study Period|Adverse Event|1
6049788|NCT00424021|9649032|FG003|NCT00046319 Study Period|Adverse Event|1
6049789|NCT00424021|9649029|FG000|NCT00046319 Study Period|Withdrawal by Subject|0
6049790|NCT00424021|9649030|FG001|NCT00046319 Study Period|Withdrawal by Subject|1
6049791|NCT00424021|9649031|FG002|NCT00046319 Study Period|Withdrawal by Subject|0
6049792|NCT00424021|9649032|FG003|NCT00046319 Study Period|Withdrawal by Subject|0
6049793|NCT00424021|9649029|FG000|NCT00046319 Study Period|Sponsor discretion|0
5974346|NCT03732807|9560477|FG006|Treatment Extension (Week 25 up to 48)|Lost to Follow-up|0
5974347|NCT03732807|9560471|FG000|Treatment Extension (Week 25 up to 48)|Non-Compliant with study drug|0
5974348|NCT03732807|9560472|FG001|Treatment Extension (Week 25 up to 48)|Non-Compliant with study drug|1
5974349|NCT03732807|9560473|FG002|Treatment Extension (Week 25 up to 48)|Non-Compliant with study drug|0
5974350|NCT03732807|9560474|FG003|Treatment Extension (Week 25 up to 48)|Non-Compliant with study drug|0
5974351|NCT03732807|9560475|FG004|Treatment Extension (Week 25 up to 48)|Non-Compliant with study drug|0
5974352|NCT03732807|9560476|FG005|Treatment Extension (Week 25 up to 48)|Non-Compliant with study drug|0
5974353|NCT03732807|9560477|FG006|Treatment Extension (Week 25 up to 48)|Non-Compliant with study drug|0
5974354|NCT03732807|9560471|FG000|Treatment Extension (Week 25 up to 48)|Physician Decision|0
5974355|NCT03732807|9560472|FG001|Treatment Extension (Week 25 up to 48)|Physician Decision|1
5974356|NCT03732807|9560473|FG002|Treatment Extension (Week 25 up to 48)|Physician Decision|0
5974357|NCT03732807|9560474|FG003|Treatment Extension (Week 25 up to 48)|Physician Decision|1
5974358|NCT03732807|9560475|FG004|Treatment Extension (Week 25 up to 48)|Physician Decision|1
5974359|NCT03732807|9560476|FG005|Treatment Extension (Week 25 up to 48)|Physician Decision|0
5974360|NCT03732807|9560477|FG006|Treatment Extension (Week 25 up to 48)|Physician Decision|0
5974361|NCT03732807|9560471|FG000|Treatment Extension (Week 25 up to 48)|Withdrawal by Subject|3
5974362|NCT03732807|9560472|FG001|Treatment Extension (Week 25 up to 48)|Withdrawal by Subject|2
5974363|NCT03732807|9560473|FG002|Treatment Extension (Week 25 up to 48)|Withdrawal by Subject|1
5974364|NCT03732807|9560474|FG003|Treatment Extension (Week 25 up to 48)|Withdrawal by Subject|1
5974365|NCT03732807|9560475|FG004|Treatment Extension (Week 25 up to 48)|Withdrawal by Subject|0
5974366|NCT03732807|9560476|FG005|Treatment Extension (Week 25 up to 48)|Withdrawal by Subject|1
5974367|NCT03732807|9560477|FG006|Treatment Extension (Week 25 up to 48)|Withdrawal by Subject|1
5974368|NCT03732807|9560471|FG000|Treatment Extension (Week 25 up to 48)|Other|1
5974369|NCT03732807|9560472|FG001|Treatment Extension (Week 25 up to 48)|Other|4
5974370|NCT03732807|9560473|FG002|Treatment Extension (Week 25 up to 48)|Other|0
5974371|NCT03732807|9560474|FG003|Treatment Extension (Week 25 up to 48)|Other|2
5974372|NCT03732807|9560475|FG004|Treatment Extension (Week 25 up to 48)|Other|0
5974373|NCT03732807|9560476|FG005|Treatment Extension (Week 25 up to 48)|Other|0
5974374|NCT03732807|9560477|FG006|Treatment Extension (Week 25 up to 48)|Other|0
6049794|NCT00424021|9649030|FG001|NCT00046319 Study Period|Sponsor discretion|1
6049795|NCT00424021|9649031|FG002|NCT00046319 Study Period|Sponsor discretion|0
6049796|NCT00424021|9649032|FG003|NCT00046319 Study Period|Sponsor discretion|0
6049797|NCT00424021|9649029|FG000|NCT00046319 Study Period|Lost to Follow-up|0
6049798|NCT00424021|9649030|FG001|NCT00046319 Study Period|Lost to Follow-up|1
6049799|NCT00424021|9649031|FG002|NCT00046319 Study Period|Lost to Follow-up|0
6049800|NCT00424021|9649032|FG003|NCT00046319 Study Period|Lost to Follow-up|0
6049801|NCT00424021|9649029|FG000|AMB-220-E Study Period|Adverse Event|1
6049802|NCT00424021|9649030|FG001|AMB-220-E Study Period|Adverse Event|1
6049803|NCT00424021|9649031|FG002|AMB-220-E Study Period|Adverse Event|3
6049804|NCT00424021|9649032|FG003|AMB-220-E Study Period|Adverse Event|7
6049805|NCT00424021|9649029|FG000|AMB-220-E Study Period|Death|0
6049806|NCT00424021|9649030|FG001|AMB-220-E Study Period|Death|0
6049807|NCT00424021|9649031|FG002|AMB-220-E Study Period|Death|1
6049808|NCT00424021|9649032|FG003|AMB-220-E Study Period|Death|1
6049809|NCT00424021|9649029|FG000|AMB-220-E Study Period|Lost to Follow-up|0
6049810|NCT00424021|9649030|FG001|AMB-220-E Study Period|Lost to Follow-up|1
6049811|NCT00424021|9649031|FG002|AMB-220-E Study Period|Lost to Follow-up|1
6049812|NCT00424021|9649032|FG003|AMB-220-E Study Period|Lost to Follow-up|1
6049813|NCT00424021|9649029|FG000|AMB-220-E Study Period|Physician Decision|0
6049814|NCT00424021|9649030|FG001|AMB-220-E Study Period|Physician Decision|0
6049815|NCT00424021|9649031|FG002|AMB-220-E Study Period|Physician Decision|0
6049816|NCT00424021|9649032|FG003|AMB-220-E Study Period|Physician Decision|1
6193597|NCT01439880|9851375|FG000|SOC-controlled Period (Year 1)|Withdrawal by Subject|24
6193598|NCT01439880|9851376|FG001|SOC-controlled Period (Year 1)|Withdrawal by Subject|38
6193599|NCT01439880|9851375|FG000|SOC-controlled Period (Year 1)|Death|2
6193600|NCT01439880|9851376|FG001|SOC-controlled Period (Year 1)|Death|1
6193601|NCT01439880|9851375|FG000|SOC-controlled Period (Year 1)|Sponsor Decision|0
6193602|NCT01439880|9851376|FG001|SOC-controlled Period (Year 1)|Sponsor Decision|1
6273110|NCT02186561|9976358|FG000|1- Year Post Index Procedure Visit|Death|1
6273111|NCT02186561|9976358|FG000|1- Year Post Index Procedure Visit|Missed|1
6273112|NCT02186652|9976374|FG000|Overall Study|Lost to Follow-up|2
6273113|NCT02186652|9976375|FG001|Overall Study|Lost to Follow-up|0
6273114|NCT02186821|9976410|FG000|Overall Study|Adverse Event|9
6273115|NCT02186821|9976410|FG000|Overall Study|Death|2
6273116|NCT02186821|9976410|FG000|Overall Study|Disease progression|32
6273117|NCT02186821|9976410|FG000|Overall Study|Protocol Violation|1
6273118|NCT02186821|9976410|FG000|Overall Study|Physician Decision|1
6193603|NCT01439880|9851375|FG000|SOC-controlled Period (Year 1)|Lost to Follow-up|10
6193604|NCT01439880|9851376|FG001|SOC-controlled Period (Year 1)|Lost to Follow-up|5
6193605|NCT01439880|9851375|FG000|SOC-controlled Period (Year 1)|Other|8
6193606|NCT01439880|9851376|FG001|SOC-controlled Period (Year 1)|Other|13
6193607|NCT01439880|9851375|FG000|SOC-controlled Period (Year 1)|Reason Missing|0
6273119|NCT02186821|9976410|FG000|Overall Study|Study terminated by sponsor|2
6273120|NCT02186873|9976416|FG000|Overall Study|Adverse Event|1
5974375|NCT03731364|9560499|FG000|Overall Study|Adverse Event|0
5974376|NCT03731364|9560500|FG001|Overall Study|Adverse Event|0
5974377|NCT03731364|9560501|FG002|Overall Study|Adverse Event|1
5974378|NCT03731364|9560502|FG003|Overall Study|Adverse Event|2
5974379|NCT03731364|9560503|FG004|Overall Study|Adverse Event|1
6049817|NCT00424047|9649051|FG000|Blinded Treatment (Up to 03 Aug 2005)|Adverse Event|18
6049818|NCT00424047|9649052|FG001|Blinded Treatment (Up to 03 Aug 2005)|Adverse Event|12
6049819|NCT00424047|9649051|FG000|Blinded Treatment (Up to 03 Aug 2005)|Progression of disease|67
6049820|NCT00424047|9649052|FG001|Blinded Treatment (Up to 03 Aug 2005)|Progression of disease|122
6049821|NCT00424047|9649051|FG000|Blinded Treatment (Up to 03 Aug 2005)|Lack of therapeutic effect|1
6049822|NCT00424047|9649052|FG001|Blinded Treatment (Up to 03 Aug 2005)|Lack of therapeutic effect|3
6049823|NCT00424047|9649051|FG000|Blinded Treatment (Up to 03 Aug 2005)|Withdrawal by Subject|23
6049824|NCT00424047|9649052|FG001|Blinded Treatment (Up to 03 Aug 2005)|Withdrawal by Subject|8
6049825|NCT00424047|9649051|FG000|Blinded Treatment (Up to 03 Aug 2005)|Death|11
6049826|NCT00424047|9649052|FG001|Blinded Treatment (Up to 03 Aug 2005)|Death|10
6049827|NCT00424047|9649051|FG000|Blinded Treatment (Up to 03 Aug 2005)|Other|2
6049828|NCT00424047|9649052|FG001|Blinded Treatment (Up to 03 Aug 2005)|Other|1
6049829|NCT00424047|9649051|FG000|On Study at Time of Unblinding|Adverse Event|22
6049830|NCT00424047|9649052|FG001|On Study at Time of Unblinding|Adverse Event|12
6049831|NCT00424047|9649051|FG000|On Study at Time of Unblinding|Progression of disease|92
6049832|NCT00424047|9649052|FG001|On Study at Time of Unblinding|Progression of disease|128
6049833|NCT00424047|9649051|FG000|On Study at Time of Unblinding|Lack of Efficacy|1
6049834|NCT00424047|9649052|FG001|On Study at Time of Unblinding|Lack of Efficacy|3
6049835|NCT00424047|9649051|FG000|On Study at Time of Unblinding|Withdrawal by Subject|24
6049836|NCT00424047|9649052|FG001|On Study at Time of Unblinding|Withdrawal by Subject|9
6049837|NCT00424047|9649051|FG000|On Study at Time of Unblinding|Death|11
6049838|NCT00424047|9649052|FG001|On Study at Time of Unblinding|Death|11
6049839|NCT00424047|9649051|FG000|On Study at Time of Unblinding|Other|5
6049840|NCT00424047|9649052|FG001|On Study at Time of Unblinding|Other|4
6049841|NCT00424047|9649051|FG000|Long Term Extension (Up to 25 Jun 2013)|Adverse Event|1
6049842|NCT00424047|9649052|FG001|Long Term Extension (Up to 25 Jun 2013)|Adverse Event|0
6049843|NCT00424047|9649051|FG000|Long Term Extension (Up to 25 Jun 2013)|Death|0
6049844|NCT00424047|9649052|FG001|Long Term Extension (Up to 25 Jun 2013)|Death|1
6049845|NCT00424047|9649051|FG000|Long Term Extension (Up to 25 Jun 2013)|Other|12
6049846|NCT00424047|9649052|FG001|Long Term Extension (Up to 25 Jun 2013)|Other|4
6049847|NCT00424047|9649051|FG000|Long Term Extension (Up to 25 Jun 2013)|Progression of Disease|7
6049848|NCT00424047|9649052|FG001|Long Term Extension (Up to 25 Jun 2013)|Progression of Disease|3
6049849|NCT00424047|9649051|FG000|Long Term Extension (Up to 25 Jun 2013)|Withdrawal by Subject|1
6049850|NCT00424047|9649052|FG001|Long Term Extension (Up to 25 Jun 2013)|Withdrawal by Subject|0
6049851|NCT00424177|9649063|FG000|Cycle 1: Eltrombopag 50 mg Starting Dose|Lack of Efficacy|8
6049852|NCT00424177|9649063|FG000|Cycle 1: Eltrombopag 50 mg Starting Dose|Adverse Event|1
6049853|NCT00424177|9649063|FG000|Cycle 1: Eltrombopag 50 mg Starting Dose|Prolonged Response|1
6049854|NCT00424177|9649063|FG000|Cycle 1: Eltrombopag 50 mg Starting Dose|Relocation|1
6049855|NCT00424177|9649063|FG000|Cycle 2: Eltrombopag 50 or 75 mg|Lack of Efficacy|2
6049856|NCT00424177|9649063|FG000|Cycle 2: Eltrombopag 50 or 75 mg|Prolonged Response|1
6049857|NCT00424177|9649063|FG000|Cycle 2: Eltrombopag 50 or 75 mg|Withdrawal by Subject|1
6049858|NCT00424177|9649063|FG000|Cycle 3: Eltrombopag 50 or 75 mg|Lack of Efficacy|1
6049859|NCT00424177|9649063|FG000|Cycle 3: Eltrombopag 50 or 75 mg|Withdrawal by Subject|1
6049860|NCT00424177|9649063|FG000|Cycle 3: Eltrombopag 50 or 75 mg|Physician Decision|1
6049861|NCT00424190|9649077|FG000|Overall Study|Withdrew consent|3
6049862|NCT00424190|9649078|FG001|Overall Study|Withdrew consent|4
6049863|NCT00424190|9649077|FG000|Overall Study|Death|3
6049864|NCT00424190|9649078|FG001|Overall Study|Death|0
6049865|NCT00424190|9649077|FG000|Overall Study|Noncompliance|1
6049866|NCT00424190|9649078|FG001|Overall Study|Noncompliance|2
6049867|NCT00424190|9649077|FG000|Overall Study|Request of sponsor or investigator|0
6049868|NCT00424190|9649078|FG001|Overall Study|Request of sponsor or investigator|2
6049869|NCT00424190|9649077|FG000|Overall Study|Diagnosis of osteomyelitis|0
6049870|NCT00424190|9649078|FG001|Overall Study|Diagnosis of osteomyelitis|1
6049871|NCT00424190|9649077|FG000|Overall Study|Other|15
6049872|NCT00424190|9649078|FG001|Overall Study|Other|21
6049873|NCT00424255|9649086|FG000|Overall Study|Death|115
6049874|NCT00424255|9649087|FG001|Overall Study|Death|111
6049875|NCT00424255|9649086|FG000|Overall Study|Lost to Follow-up|26
6049876|NCT00424255|9649087|FG001|Overall Study|Lost to Follow-up|20
6049877|NCT00424255|9649086|FG000|Overall Study|Protocol Violation|0
6049878|NCT00424255|9649087|FG001|Overall Study|Protocol Violation|1
6049879|NCT00424255|9649086|FG000|Overall Study|Withdrawal by Subject|34
6049880|NCT00424255|9649087|FG001|Overall Study|Withdrawal by Subject|38
6049881|NCT00424255|9649086|FG000|Overall Study|Physician Decision|3
6049882|NCT00424255|9649087|FG001|Overall Study|Physician Decision|7
6049883|NCT00424255|9649086|FG000|Overall Study|Cognitive Disturbance|1
6049884|NCT00424255|9649087|FG001|Overall Study|Cognitive Disturbance|0
6049885|NCT00424255|9649086|FG000|Overall Study|Non-compliance by Participants|1
6049886|NCT00424255|9649087|FG001|Overall Study|Non-compliance by Participants|0
6049887|NCT00424255|9649086|FG000|Overall Study|Fatigue|1
6049888|NCT00424255|9649087|FG001|Overall Study|Fatigue|0
5974380|NCT04598152|9560555|FG000|Overall Study|Lost to Follow-up|0
5974381|NCT04598152|9560556|FG001|Overall Study|Lost to Follow-up|1
5974382|NCT04570670|9560590|FG000|Overall Study|Withdrawal by Subject|1
5974383|NCT04570670|9560591|FG001|Overall Study|Withdrawal by Subject|0
5974384|NCT04546581|9560607|FG000|Overall Study|Adverse Event|9
5974385|NCT04546581|9560608|FG001|Overall Study|Adverse Event|3
5974386|NCT04546581|9560607|FG000|Overall Study|Physician Decision|0
5974387|NCT04546581|9560608|FG001|Overall Study|Physician Decision|1
5974388|NCT04546581|9560607|FG000|Overall Study|Protocol Violation|1
5974389|NCT04546581|9560608|FG001|Overall Study|Protocol Violation|2
5974390|NCT04546581|9560607|FG000|Overall Study|Withdrawal by Subject|3
5974391|NCT04546581|9560608|FG001|Overall Study|Withdrawal by Subject|7
5974392|NCT03915626|9560618|FG000|Overall Study|study was halted due to COVID-19; once started again volunteer could no longer participate|1
5974393|NCT03698279|9560634|FG000|Overall Study|Withdrawal by parent/guardian|1
5974394|NCT03698279|9560635|FG001|Overall Study|Withdrawal by parent/guardian|1
5974395|NCT03698279|9560636|FG002|Overall Study|Withdrawal by parent/guardian|1
5974396|NCT03698279|9560637|FG003|Overall Study|Withdrawal by parent/guardian|1
5974397|NCT03698279|9560638|FG004|Overall Study|Withdrawal by parent/guardian|0
5974398|NCT03698279|9560639|FG005|Overall Study|Withdrawal by parent/guardian|0
5974399|NCT03698279|9560634|FG000|Overall Study|Protocol deviation|1
5974400|NCT03698279|9560635|FG001|Overall Study|Protocol deviation|0
5974401|NCT03698279|9560636|FG002|Overall Study|Protocol deviation|1
5974402|NCT03698279|9560637|FG003|Overall Study|Protocol deviation|0
5974403|NCT03698279|9560638|FG004|Overall Study|Protocol deviation|0
5974404|NCT03698279|9560639|FG005|Overall Study|Protocol deviation|0
5974405|NCT03698279|9560634|FG000|Overall Study|Withdrawal by Subject|0
5974406|NCT03698279|9560635|FG001|Overall Study|Withdrawal by Subject|0
5974407|NCT03698279|9560636|FG002|Overall Study|Withdrawal by Subject|1
5974408|NCT03698279|9560637|FG003|Overall Study|Withdrawal by Subject|0
5974409|NCT03698279|9560638|FG004|Overall Study|Withdrawal by Subject|0
5974410|NCT03698279|9560639|FG005|Overall Study|Withdrawal by Subject|0
5974411|NCT03698279|9560634|FG000|Overall Study|Lost to Follow-up|3
5974412|NCT03698279|9560635|FG001|Overall Study|Lost to Follow-up|1
5974413|NCT03698279|9560636|FG002|Overall Study|Lost to Follow-up|4
5974414|NCT03698279|9560637|FG003|Overall Study|Lost to Follow-up|5
5974415|NCT03698279|9560638|FG004|Overall Study|Lost to Follow-up|0
5974416|NCT03698279|9560639|FG005|Overall Study|Lost to Follow-up|0
6193608|NCT01439880|9851376|FG001|SOC-controlled Period (Year 1)|Reason Missing|2
6193609|NCT01439880|9851375|FG000|All-IP Period (Years 2 to 5)|Lost to Follow-up|21
6193610|NCT01439880|9851376|FG001|All-IP Period (Years 2 to 5)|Lost to Follow-up|30
6193611|NCT01439880|9851375|FG000|All-IP Period (Years 2 to 5)|Withdrawal by Subject|30
5974417|NCT03478930|9560669|FG000|Overall Study|Adverse Event|0
5974418|NCT03478930|9560670|FG001|Overall Study|Adverse Event|1
5974419|NCT03478930|9560669|FG000|Overall Study|Lack of Efficacy|3
5974420|NCT03478930|9560670|FG001|Overall Study|Lack of Efficacy|3
5974421|NCT03478930|9560669|FG000|Overall Study|Withdrawal by Subject|6
5974422|NCT03478930|9560670|FG001|Overall Study|Withdrawal by Subject|5
5974423|NCT03434353|9560681|FG000|Overall Study|Started commercial Hepatitis B virus therapy|10
5974424|NCT03434353|9560682|FG001|Overall Study|Started commercial Hepatitis B virus therapy|3
5974425|NCT03434353|9560683|FG002|Overall Study|Started commercial Hepatitis B virus therapy|11
5974426|NCT03434353|9560684|FG003|Overall Study|Started commercial Hepatitis B virus therapy|3
5974427|NCT03434353|9560685|FG004|Overall Study|Started commercial Hepatitis B virus therapy|17
5974428|NCT03434353|9560681|FG000|Overall Study|Withdrew consent|1
5974429|NCT03434353|9560682|FG001|Overall Study|Withdrew consent|0
5974430|NCT03434353|9560683|FG002|Overall Study|Withdrew consent|3
5974431|NCT03434353|9560684|FG003|Overall Study|Withdrew consent|0
5974432|NCT03434353|9560685|FG004|Overall Study|Withdrew consent|0
5974433|NCT03434353|9560681|FG000|Overall Study|Adverse Event|1
6193612|NCT01439880|9851376|FG001|All-IP Period (Years 2 to 5)|Withdrawal by Subject|66
6193613|NCT01439880|9851375|FG000|All-IP Period (Years 2 to 5)|Death|3
6193614|NCT01439880|9851376|FG001|All-IP Period (Years 2 to 5)|Death|13
6193615|NCT01439880|9851375|FG000|All-IP Period (Years 2 to 5)|Sponsor Decision|1
6193616|NCT01439880|9851376|FG001|All-IP Period (Years 2 to 5)|Sponsor Decision|0
6193617|NCT01439880|9851375|FG000|All-IP Period (Years 2 to 5)|Other|14
6193618|NCT01439880|9851376|FG001|All-IP Period (Years 2 to 5)|Other|31
6193619|NCT01439880|9851375|FG000|All-IP Period (Years 2 to 5)|Reason Missing|1
6193620|NCT01439880|9851376|FG001|All-IP Period (Years 2 to 5)|Reason Missing|0
6193621|NCT01439945|9851396|FG000|Double-Blind Treatment Phase|Withdrawal by Subject|3
6193622|NCT01439945|9851397|FG001|Double-Blind Treatment Phase|Withdrawal by Subject|3
6193623|NCT01439945|9851398|FG002|Double-Blind Treatment Phase|Withdrawal by Subject|3
5974434|NCT03434353|9560682|FG001|Overall Study|Adverse Event|0
5974435|NCT03434353|9560683|FG002|Overall Study|Adverse Event|0
5974436|NCT03434353|9560684|FG003|Overall Study|Adverse Event|0
5974437|NCT03434353|9560685|FG004|Overall Study|Adverse Event|1
5974438|NCT03434353|9560681|FG000|Overall Study|Lost to Follow-up|2
6049889|NCT00424255|9649086|FG000|Overall Study|Disease Progression|0
6049890|NCT00424255|9649087|FG001|Overall Study|Disease Progression|2
6049891|NCT00424255|9649086|FG000|Overall Study|Sponsor Terminated Study|161
6049892|NCT00424255|9649087|FG001|Overall Study|Sponsor Terminated Study|167
6049893|NCT00424294|9649104|FG000|Overall Study|Adverse Event|4
5974439|NCT03434353|9560682|FG001|Overall Study|Lost to Follow-up|0
5974440|NCT03434353|9560683|FG002|Overall Study|Lost to Follow-up|0
5974441|NCT03434353|9560684|FG003|Overall Study|Lost to Follow-up|0
5974442|NCT03434353|9560685|FG004|Overall Study|Lost to Follow-up|0
5974443|NCT03415022|9560699|FG000|Overall Study|Withdrawal by Subject|1
5974444|NCT03415022|9560700|FG001|Overall Study|Withdrawal by Subject|2
5974445|NCT03415022|9560699|FG000|Overall Study|COVID-19 Suspension|2
5974446|NCT03415022|9560700|FG001|Overall Study|COVID-19 Suspension|3
5974447|NCT03415022|9560699|FG000|Overall Study|Lost to Follow-up|2
5974448|NCT03415022|9560700|FG001|Overall Study|Lost to Follow-up|0
6049894|NCT00424294|9649105|FG001|Overall Study|Adverse Event|10
6049895|NCT00424294|9649104|FG000|Overall Study|Lack of Efficacy|2
6049896|NCT00424294|9649105|FG001|Overall Study|Lack of Efficacy|1
6049897|NCT00424294|9649104|FG000|Overall Study|Withdrawal by Subject|1
6049898|NCT00424294|9649105|FG001|Overall Study|Withdrawal by Subject|2
6049899|NCT00424294|9649104|FG000|Overall Study|Other|0
6049900|NCT00424294|9649105|FG001|Overall Study|Other|2
6049901|NCT00424294|9649104|FG000|Overall Study|Randomized but not Treated|1
6049902|NCT00424294|9649105|FG001|Overall Study|Randomized but not Treated|0
6049903|NCT00424346|9649115|FG000|Core Study|Adverse Event|5
6049904|NCT00424346|9649116|FG001|Core Study|Adverse Event|3
6087940|NCT00672620|9698624|FG003|Overall Study|Adverse Event|17
6087941|NCT00672620|9698621|FG000|Overall Study|Lack of Efficacy|1
6087942|NCT00672620|9698622|FG001|Overall Study|Lack of Efficacy|2
6087943|NCT00672620|9698623|FG002|Overall Study|Lack of Efficacy|2
6087944|NCT00672620|9698624|FG003|Overall Study|Lack of Efficacy|0
6087945|NCT00672620|9698621|FG000|Overall Study|Noncompliance with Study Drug|3
6087946|NCT00672620|9698622|FG001|Overall Study|Noncompliance with Study Drug|4
6087947|NCT00672620|9698623|FG002|Overall Study|Noncompliance with Study Drug|0
6087948|NCT00672620|9698624|FG003|Overall Study|Noncompliance with Study Drug|2
6087949|NCT00672620|9698621|FG000|Overall Study|Protocol Deviations|5
6087950|NCT00672620|9698622|FG001|Overall Study|Protocol Deviations|7
6087951|NCT00672620|9698623|FG002|Overall Study|Protocol Deviations|2
6087952|NCT00672620|9698624|FG003|Overall Study|Protocol Deviations|5
6087953|NCT00672620|9698621|FG000|Overall Study|Withdrawal of Consent|6
6087954|NCT00672620|9698622|FG001|Overall Study|Withdrawal of Consent|12
6087955|NCT00672620|9698623|FG002|Overall Study|Withdrawal of Consent|5
6087956|NCT00672620|9698624|FG003|Overall Study|Withdrawal of Consent|6
6087957|NCT00672620|9698621|FG000|Overall Study|Lost to Follow-up|8
6087958|NCT00672620|9698622|FG001|Overall Study|Lost to Follow-up|19
6049905|NCT00424346|9649117|FG002|Core Study|Adverse Event|1
6049906|NCT00424346|9649118|FG003|Core Study|Adverse Event|1
6049907|NCT00424346|9649115|FG000|Core Study|Abnormal Laboratory Values|0
6049908|NCT00424346|9649116|FG001|Core Study|Abnormal Laboratory Values|1
6049909|NCT00424346|9649117|FG002|Core Study|Abnormal Laboratory Values|0
6049910|NCT00424346|9649118|FG003|Core Study|Abnormal Laboratory Values|0
6049911|NCT00424346|9649115|FG000|Core Study|Lack of Efficacy|1
6049912|NCT00424346|9649116|FG001|Core Study|Lack of Efficacy|3
6049913|NCT00424346|9649117|FG002|Core Study|Lack of Efficacy|0
6049914|NCT00424346|9649118|FG003|Core Study|Lack of Efficacy|4
6049915|NCT00424346|9649115|FG000|Core Study|Withdrawal by Subject|1
6049916|NCT00424346|9649116|FG001|Core Study|Withdrawal by Subject|0
6049917|NCT00424346|9649117|FG002|Core Study|Withdrawal by Subject|0
6049918|NCT00424346|9649118|FG003|Core Study|Withdrawal by Subject|2
6049919|NCT00424346|9649115|FG000|Core Study|Lost to Follow-up|1
6049920|NCT00424346|9649116|FG001|Core Study|Lost to Follow-up|1
6049921|NCT00424346|9649117|FG002|Core Study|Lost to Follow-up|0
6049922|NCT00424346|9649118|FG003|Core Study|Lost to Follow-up|0
6049923|NCT00424346|9649115|FG000|Core Study|Administrative Problems|1
6049924|NCT00424346|9649116|FG001|Core Study|Administrative Problems|0
6049925|NCT00424346|9649117|FG002|Core Study|Administrative Problems|1
6049926|NCT00424346|9649118|FG003|Core Study|Administrative Problems|0
6049927|NCT00424346|9649115|FG000|Core Study|Protocol Violation|0
6049928|NCT00424346|9649116|FG001|Core Study|Protocol Violation|0
6049929|NCT00424346|9649117|FG002|Core Study|Protocol Violation|2
6049930|NCT00424346|9649118|FG003|Core Study|Protocol Violation|0
6049931|NCT00424346|9649115|FG000|Extension Phase|Adverse Event|0
6049932|NCT00424346|9649116|FG001|Extension Phase|Adverse Event|9
6049933|NCT00424346|9649117|FG002|Extension Phase|Adverse Event|5
6049934|NCT00424346|9649118|FG003|Extension Phase|Adverse Event|4
6049935|NCT00424346|9649115|FG000|Extension Phase|Lack of Efficacy|0
6049936|NCT00424346|9649116|FG001|Extension Phase|Lack of Efficacy|16
6049937|NCT00424346|9649117|FG002|Extension Phase|Lack of Efficacy|14
6049938|NCT00424346|9649118|FG003|Extension Phase|Lack of Efficacy|11
6049939|NCT00424346|9649115|FG000|Extension Phase|Withdrawal by Subject|0
6049940|NCT00424346|9649116|FG001|Extension Phase|Withdrawal by Subject|5
6049941|NCT00424346|9649117|FG002|Extension Phase|Withdrawal by Subject|3
6049942|NCT00424346|9649118|FG003|Extension Phase|Withdrawal by Subject|4
6049943|NCT00424346|9649115|FG000|Extension Phase|Lost to Follow-up|0
6049944|NCT00424346|9649116|FG001|Extension Phase|Lost to Follow-up|2
6049945|NCT00424346|9649117|FG002|Extension Phase|Lost to Follow-up|0
6049946|NCT00424346|9649118|FG003|Extension Phase|Lost to Follow-up|0
6049947|NCT00424346|9649115|FG000|Extension Phase|Administrative Problems|0
6049948|NCT00424346|9649116|FG001|Extension Phase|Administrative Problems|69
6087959|NCT00672620|9698623|FG002|Overall Study|Lost to Follow-up|8
5974449|NCT03283670|9560706|FG000|Placebo Gas|Withdrawal by Subject|2
5974450|NCT03283670|9560706|FG000|25% Nitrous Oxide|Withdrawal by Subject|4
5974451|NCT03283670|9560706|FG000|50% Nitrous Oxide|Withdrawal by Subject|1
5974452|NCT03219567|9560737|FG000|Overall Study|Withdrawal by Subject|0
5974453|NCT03219567|9560738|FG001|Overall Study|Withdrawal by Subject|1
5974454|NCT03153111|9560756|FG000|Overall Study|Death|2
5974455|NCT03153111|9560757|FG001|Overall Study|Death|5
5974456|NCT03153111|9560756|FG000|Overall Study|Lost to Follow-up|1
5974457|NCT03153111|9560757|FG001|Overall Study|Lost to Follow-up|0
5974458|NCT03153111|9560756|FG000|Overall Study|Physician Decision|5
5974459|NCT03153111|9560757|FG001|Overall Study|Physician Decision|1
5974460|NCT03153111|9560756|FG000|Overall Study|Withdrawal by Subject|3
5974461|NCT03153111|9560757|FG001|Overall Study|Withdrawal by Subject|3
5974462|NCT03073733|9560766|FG000|Overall Study|Lost to Follow-up|1
5974463|NCT03073733|9560767|FG001|Overall Study|Lost to Follow-up|0
5974464|NCT03073733|9560768|FG002|Overall Study|Lost to Follow-up|0
5974465|NCT03073733|9560766|FG000|Overall Study|Physician Decision|0
5974466|NCT03073733|9560767|FG001|Overall Study|Physician Decision|1
5974467|NCT03073733|9560768|FG002|Overall Study|Physician Decision|0
5974468|NCT03073733|9560766|FG000|Overall Study|Withdrawal by Subject|0
5974469|NCT03073733|9560767|FG001|Overall Study|Withdrawal by Subject|0
5974470|NCT03073733|9560768|FG002|Overall Study|Withdrawal by Subject|1
5974471|NCT02821000|9560778|FG000|Overall Study|Death|44
5974472|NCT02821000|9560778|FG000|Overall Study|Withdrawal by Subject|1
6087960|NCT00672620|9698624|FG003|Overall Study|Lost to Follow-up|11
6087961|NCT00672620|9698621|FG000|Overall Study|Reason not Specified|3
6087962|NCT00672620|9698622|FG001|Overall Study|Reason not Specified|3
6087963|NCT00672620|9698623|FG002|Overall Study|Reason not Specified|2
5974473|NCT02821000|9560778|FG000|Overall Study|Ongoing in Study|58
5974474|NCT02702414|9560806|FG000|Overall Study|Death|77
5974475|NCT02702414|9560807|FG001|Overall Study|Death|34
5974476|NCT02702414|9560806|FG000|Overall Study|Lost to Follow-up|0
5974477|NCT02702414|9560807|FG001|Overall Study|Lost to Follow-up|1
5974478|NCT02702414|9560806|FG000|Overall Study|Withdrawal by Subject|0
5974479|NCT02702414|9560807|FG001|Overall Study|Withdrawal by Subject|1
5974480|NCT02702414|9560806|FG000|Overall Study|Participants Ongoing in Study|27
5974481|NCT02702414|9560807|FG001|Overall Study|Participants Ongoing in Study|15
5974482|NCT02702414|9560806|FG000|Overall Study|Not Treated|1
5974483|NCT02702414|9560807|FG001|Overall Study|Not Treated|0
5974484|NCT02425904|9560836|FG000|Overall Study|Lost to Follow-up|1
5974485|NCT02425904|9560837|FG001|Overall Study|Lost to Follow-up|0
5974486|NCT02425904|9560836|FG000|Overall Study|Withdrawal by Subject|2
5974487|NCT02425904|9560837|FG001|Overall Study|Withdrawal by Subject|0
5974488|NCT02425904|9560836|FG000|Overall Study|Death|0
5974489|NCT02425904|9560837|FG001|Overall Study|Death|3
5974490|NCT02420795|9560847|FG000|Overall Study|Withdrawal by Subject|1
5974491|NCT02420795|9560848|FG001|Overall Study|Withdrawal by Subject|0
5974492|NCT02420795|9560849|FG002|Overall Study|Withdrawal by Subject|0
5974493|NCT02420795|9560847|FG000|Overall Study|Adverse Event|1
5974494|NCT02420795|9560848|FG001|Overall Study|Adverse Event|0
5974495|NCT02420795|9560849|FG002|Overall Study|Adverse Event|0
5974496|NCT02420795|9560847|FG000|Overall Study|Progressive disease|2
5974497|NCT02420795|9560848|FG001|Overall Study|Progressive disease|2
5974498|NCT02420795|9560849|FG002|Overall Study|Progressive disease|4
5974499|NCT02420795|9560847|FG000|Overall Study|Death|0
5974500|NCT02420795|9560848|FG001|Overall Study|Death|0
5974501|NCT02420795|9560849|FG002|Overall Study|Death|1
5974502|NCT02240485|9560861|FG000|3 Months Post-admission|Lost to Follow-up|1
5974503|NCT02240485|9560862|FG001|3 Months Post-admission|Lost to Follow-up|5
5974504|NCT02240485|9560861|FG000|3 Months Post-admission|Withdrawal by Subject|2
5974505|NCT02240485|9560862|FG001|3 Months Post-admission|Withdrawal by Subject|1
6087964|NCT00672620|9698624|FG003|Overall Study|Reason not Specified|1
6087965|NCT00672633|9698636|FG000|Overall Study|Withdrawal by Subject|0
6087966|NCT00672633|9698637|FG001|Overall Study|Withdrawal by Subject|1
6087967|NCT00672646|9698646|FG000|Overall Study|Lost to Follow-up|0
6087968|NCT00672646|9698647|FG001|Overall Study|Lost to Follow-up|1
6087969|NCT00672646|9698648|FG002|Overall Study|Lost to Follow-up|2
6087970|NCT00672646|9698646|FG000|Overall Study|Withdrawal by Subject|0
6087971|NCT00672646|9698647|FG001|Overall Study|Withdrawal by Subject|0
5974506|NCT02240485|9560861|FG000|9 Months Post-admission|Lost to Follow-up|3
5974507|NCT02240485|9560862|FG001|9 Months Post-admission|Lost to Follow-up|1
5974508|NCT02240485|9560861|FG000|9 Months Post-admission|Withdrawal by Subject|0
5974509|NCT02240485|9560862|FG001|9 Months Post-admission|Withdrawal by Subject|3
5974510|NCT02240485|9560861|FG000|18 Months Post-admission|Lost to Follow-up|1
5974511|NCT02240485|9560862|FG001|18 Months Post-admission|Lost to Follow-up|1
5974512|NCT02240485|9560861|FG000|18 Months Post-admission|Withdrawal by Subject|2
6087972|NCT00672646|9698648|FG002|Overall Study|Withdrawal by Subject|1
6087973|NCT00672841|9698663|FG000|Overall Study|Comfort care|1
6087974|NCT00672841|9698664|FG001|Overall Study|Comfort care|4
5974513|NCT02240485|9560862|FG001|18 Months Post-admission|Withdrawal by Subject|4
5974514|NCT02227147|9560874|FG000|Controlled Treatment Period|Adverse Event|4
5974515|NCT02227147|9560875|FG001|Controlled Treatment Period|Adverse Event|3
5974516|NCT02227147|9560874|FG000|Controlled Treatment Period|Other|2
5974517|NCT02227147|9560875|FG001|Controlled Treatment Period|Other|0
5974518|NCT02227147|9560874|FG000|Follow-up Period|Other|3
5974519|NCT02227147|9560875|FG001|Follow-up Period|Other|5
5974520|NCT02199691|9560889|FG000|Overall Study|Protocol Violation|3
5974521|NCT02199691|9560890|FG001|Overall Study|Protocol Violation|3
5974522|NCT02199691|9560891|FG002|Overall Study|Protocol Violation|6
5974523|NCT02199691|9560892|FG003|Overall Study|Protocol Violation|7
5974524|NCT02199691|9560889|FG000|Overall Study|Withdrawal by Subject|5
5974525|NCT02199691|9560890|FG001|Overall Study|Withdrawal by Subject|3
5974526|NCT02199691|9560891|FG002|Overall Study|Withdrawal by Subject|12
5974527|NCT02199691|9560892|FG003|Overall Study|Withdrawal by Subject|13
5974528|NCT02199691|9560889|FG000|Overall Study|Lost to Follow-up|2
5974529|NCT02199691|9560890|FG001|Overall Study|Lost to Follow-up|1
5974530|NCT02199691|9560891|FG002|Overall Study|Lost to Follow-up|9
5974531|NCT02199691|9560892|FG003|Overall Study|Lost to Follow-up|10
5974532|NCT02163694|9560906|FG000|Overall Study|Adverse event- related to progression|3
5974533|NCT02163694|9560907|FG001|Overall Study|Adverse event- related to progression|8
5974534|NCT02163694|9560906|FG000|Overall Study|Adverse event- not related to progression|7
5974535|NCT02163694|9560907|FG001|Overall Study|Adverse event- not related to progression|17
5974536|NCT02163694|9560906|FG000|Overall Study|Withdrew consent|8
5974537|NCT02163694|9560907|FG001|Overall Study|Withdrew consent|21
5974538|NCT02163694|9560906|FG000|Overall Study|Lost to Follow-up|1
5974539|NCT02163694|9560907|FG001|Overall Study|Lost to Follow-up|2
5974540|NCT02163694|9560906|FG000|Overall Study|Progressive disease per protocol|122
5974541|NCT02163694|9560907|FG001|Overall Study|Progressive disease per protocol|197
6049949|NCT00424346|9649117|FG002|Extension Phase|Administrative Problems|32
6049950|NCT00424346|9649118|FG003|Extension Phase|Administrative Problems|35
6049951|NCT00424346|9649115|FG000|Extension Phase|Death|0
6049952|NCT00424346|9649116|FG001|Extension Phase|Death|0
6049953|NCT00424346|9649117|FG002|Extension Phase|Death|0
6049954|NCT00424346|9649118|FG003|Extension Phase|Death|1
6049955|NCT00424346|9649115|FG000|Extension Phase|Protocol Violation|0
6049956|NCT00424346|9649116|FG001|Extension Phase|Protocol Violation|1
6049957|NCT00424346|9649117|FG002|Extension Phase|Protocol Violation|1
6049958|NCT00424346|9649118|FG003|Extension Phase|Protocol Violation|0
6049959|NCT00424372|9649131|FG000|Overall Study|Death|1
6049960|NCT00424372|9649131|FG000|Overall Study|Adverse Event|18
6049961|NCT00424372|9649131|FG000|Overall Study|Lack of Efficacy|6
6049962|NCT00424372|9649131|FG000|Overall Study|Withdrawal by Subject|4
6049963|NCT00424372|9649131|FG000|Overall Study|Protocol Violation|1
6049964|NCT00424372|9649131|FG000|Overall Study|Health deterioration|1
6049965|NCT00424385|9649135|FG000|Cohort 0|Withdrawal by Subject|5
6049966|NCT00424385|9649135|FG000|Cohort 0|Physician Decision|1
6049967|NCT00424385|9649135|FG000|Cohort 1|Withdrawal by Subject|1
6049968|NCT00424398|9649144|FG000|Overall Study|Withdrawal by Subject|2
6049969|NCT00424398|9649145|FG001|Overall Study|Withdrawal by Subject|1
6049970|NCT00424398|9649146|FG002|Overall Study|Withdrawal by Subject|0
6049971|NCT00424398|9649144|FG000|Overall Study|Subject met exclusion criteria|1
6049972|NCT00424398|9649145|FG001|Overall Study|Subject met exclusion criteria|0
6049973|NCT00424398|9649146|FG002|Overall Study|Subject met exclusion criteria|0
6049974|NCT00424463|9649157|FG000|Overall Study|Adverse Event|2
6049975|NCT00424463|9649158|FG001|Overall Study|Adverse Event|3
6049976|NCT00424463|9649159|FG002|Overall Study|Adverse Event|2
6049977|NCT00424463|9649157|FG000|Overall Study|Physician Decision|0
6049978|NCT00424463|9649158|FG001|Overall Study|Physician Decision|2
6049979|NCT00424463|9649159|FG002|Overall Study|Physician Decision|2
6049980|NCT00424463|9649157|FG000|Overall Study|Withdrawal by Subject|4
6049981|NCT00424463|9649158|FG001|Overall Study|Withdrawal by Subject|2
6049982|NCT00424463|9649159|FG002|Overall Study|Withdrawal by Subject|5
6049983|NCT00424463|9649157|FG000|Overall Study|Tracheotomy due to worsening of ALS|1
6049984|NCT00424463|9649158|FG001|Overall Study|Tracheotomy due to worsening of ALS|7
6049985|NCT00424463|9649159|FG002|Overall Study|Tracheotomy due to worsening of ALS|6
6049986|NCT00424463|9649157|FG000|Overall Study|Patient's convenience|0
6049987|NCT00424463|9649158|FG001|Overall Study|Patient's convenience|0
6049988|NCT00424463|9649159|FG002|Overall Study|Patient's convenience|1
6049989|NCT00424476|9649170|FG000|Overall Study|Withdrawal by Subject|7
6049990|NCT00424476|9649171|FG001|Overall Study|Withdrawal by Subject|6
6049991|NCT00424476|9649172|FG002|Overall Study|Withdrawal by Subject|3
6049992|NCT00424476|9649170|FG000|Overall Study|Adverse Event|19
6049993|NCT00424476|9649171|FG001|Overall Study|Adverse Event|16
6049994|NCT00424476|9649172|FG002|Overall Study|Adverse Event|15
6049995|NCT00424476|9649170|FG000|Overall Study|Lack of Efficacy|16
6049996|NCT00424476|9649171|FG001|Overall Study|Lack of Efficacy|12
6049997|NCT00424476|9649172|FG002|Overall Study|Lack of Efficacy|12
6049998|NCT00424476|9649170|FG000|Overall Study|Lack of Compliance|1
6049999|NCT00424476|9649171|FG001|Overall Study|Lack of Compliance|1
6050000|NCT00424476|9649172|FG002|Overall Study|Lack of Compliance|1
5974542|NCT02163694|9560906|FG000|Overall Study|Other, not specified|13
5974543|NCT02163694|9560907|FG001|Overall Study|Other, not specified|22
6050001|NCT00424476|9649170|FG000|Overall Study|Lost to Follow-up|4
6050002|NCT00424476|9649171|FG001|Overall Study|Lost to Follow-up|6
6050003|NCT00424476|9649172|FG002|Overall Study|Lost to Follow-up|3
6050004|NCT00424476|9649170|FG000|Overall Study|Protocol Violation|7
6050005|NCT00424476|9649171|FG001|Overall Study|Protocol Violation|2
6050006|NCT00424476|9649172|FG002|Overall Study|Protocol Violation|3
6050007|NCT00424476|9649170|FG000|Overall Study|Physician Decision|3
5974544|NCT01751984|9560948|FG000|Overall Study|Adverse Event|5
5974545|NCT01751984|9560949|FG001|Overall Study|Adverse Event|3
5974546|NCT01751984|9560948|FG000|Overall Study|Withdrawal by Subject|0
5974547|NCT01751984|9560949|FG001|Overall Study|Withdrawal by Subject|1
5974548|NCT01751984|9560948|FG000|Overall Study|Per Investigator/Sponsor/Regulatory Body|1
5974549|NCT01751984|9560949|FG001|Overall Study|Per Investigator/Sponsor/Regulatory Body|0
5974550|NCT01732627|9560957|FG000|Overall Study|Withdrawal by Subject|1
5974551|NCT01732627|9560958|FG001|Overall Study|Withdrawal by Subject|0
5974552|NCT01702571|9560966|FG000|Overall Study|Death|1067
5974553|NCT01702571|9560967|FG001|Overall Study|Death|76
5974554|NCT01702571|9560966|FG000|Overall Study|Lost to Follow-up|144
5974555|NCT01702571|9560967|FG001|Overall Study|Lost to Follow-up|10
5974556|NCT01702571|9560966|FG000|Overall Study|Adverse Event/Unacceptable Toxicity|4
5974557|NCT01702571|9560967|FG001|Overall Study|Adverse Event/Unacceptable Toxicity|0
5974558|NCT01702571|9560966|FG000|Overall Study|Investigator Decision|5
5974559|NCT01702571|9560967|FG001|Overall Study|Investigator Decision|0
5974560|NCT01702571|9560966|FG000|Overall Study|Not Classifiable|1
5974561|NCT01702571|9560967|FG001|Overall Study|Not Classifiable|0
5974562|NCT01702571|9560966|FG000|Overall Study|On Study Treatment At Lplv/Cohort 1|93
5974563|NCT01702571|9560967|FG001|Overall Study|On Study Treatment At Lplv/Cohort 1|0
5974564|NCT01702571|9560966|FG000|Overall Study|On Study Treatment At Lplv/Cohort 2|0
5974565|NCT01702571|9560967|FG001|Overall Study|On Study Treatment At Lplv/Cohort 2|1
5974566|NCT01702571|9560966|FG000|Overall Study|Progressive Disease|3
5974567|NCT01702571|9560967|FG001|Overall Study|Progressive Disease|0
5974568|NCT01702571|9560966|FG000|Overall Study|Protocol Violation|2
5974569|NCT01702571|9560967|FG001|Overall Study|Protocol Violation|0
5974570|NCT01702571|9560966|FG000|Overall Study|Safety FU Done < 3 Months Prior To CCOD|9
5974571|NCT01702571|9560967|FG001|Overall Study|Safety FU Done < 3 Months Prior To CCOD|1
5974572|NCT01702571|9560966|FG000|Overall Study|Termination By Sponsor|4
5974573|NCT01702571|9560967|FG001|Overall Study|Termination By Sponsor|0
5974574|NCT01702571|9560966|FG000|Overall Study|Withdrawal by Subject|177
5974575|NCT01702571|9560967|FG001|Overall Study|Withdrawal by Subject|29
6050008|NCT00424476|9649171|FG001|Overall Study|Physician Decision|2
6050009|NCT00424476|9649172|FG002|Overall Study|Physician Decision|3
6050010|NCT00424476|9649170|FG000|Overall Study|Other|4
6050011|NCT00424476|9649171|FG001|Overall Study|Other|3
6050012|NCT00424476|9649172|FG002|Overall Study|Other|9
6050013|NCT00424489|9649180|FG000|Overall Study|Death|3
6050014|NCT00424515|9649190|FG000|Overall Study|Progressive Disease|10
6050015|NCT00424515|9649191|FG001|Overall Study|Progressive Disease|11
6050016|NCT00424515|9649190|FG000|Overall Study|Adverse Event|0
6050017|NCT00424515|9649191|FG001|Overall Study|Adverse Event|1
6050018|NCT00424515|9649190|FG000|Overall Study|Intercurrent Illness|0
6050019|NCT00424515|9649191|FG001|Overall Study|Intercurrent Illness|1
6050020|NCT00424515|9649190|FG000|Overall Study|Withdrawal by Subject|1
6050021|NCT00424515|9649191|FG001|Overall Study|Withdrawal by Subject|0
6050022|NCT00424528|9649200|FG000|Overall Study|Adverse Event|2
6050023|NCT00424528|9649201|FG001|Overall Study|Adverse Event|1
6050024|NCT00424528|9649202|FG002|Overall Study|Adverse Event|2
6050025|NCT00424528|9649200|FG000|Overall Study|Protocol Violation|1
6050026|NCT00424528|9649201|FG001|Overall Study|Protocol Violation|1
6050027|NCT00424528|9649202|FG002|Overall Study|Protocol Violation|0
6050028|NCT00424528|9649200|FG000|Overall Study|Lost to Follow-up|0
6050029|NCT00424528|9649201|FG001|Overall Study|Lost to Follow-up|1
6050030|NCT00424528|9649202|FG002|Overall Study|Lost to Follow-up|0
6050031|NCT00424528|9649200|FG000|Overall Study|noncompliance with study requirements|2
6050032|NCT00424528|9649201|FG001|Overall Study|noncompliance with study requirements|1
6050033|NCT00424528|9649202|FG002|Overall Study|noncompliance with study requirements|2
6087975|NCT00672841|9698663|FG000|Overall Study|icteric specimens|0
6087976|NCT00672841|9698664|FG001|Overall Study|icteric specimens|3
6087977|NCT00672841|9698663|FG000|Overall Study|Antifungal therapy, negative glucan|0
6087978|NCT00672841|9698664|FG001|Overall Study|Antifungal therapy, negative glucan|4
6087979|NCT00672841|9698663|FG000|Overall Study|Adverse Event|0
6087980|NCT00672841|9698664|FG001|Overall Study|Adverse Event|3
6087981|NCT00672841|9698663|FG000|Overall Study|Pregnancy|0
6087982|NCT00672841|9698664|FG001|Overall Study|Pregnancy|1
6087983|NCT00672958|9698695|FG000|Overall Study|Adverse Event|11
6087984|NCT00672958|9698696|FG001|Overall Study|Adverse Event|9
6087985|NCT00672958|9698695|FG000|Overall Study|Lack of Efficacy|6
6087986|NCT00672958|9698696|FG001|Overall Study|Lack of Efficacy|11
6087987|NCT00672958|9698695|FG000|Overall Study|Non-compliance with study drug|2
6087988|NCT00672958|9698696|FG001|Overall Study|Non-compliance with study drug|3
6087989|NCT00672958|9698695|FG000|Overall Study|Protocol deviations|11
6087990|NCT00672958|9698696|FG001|Overall Study|Protocol deviations|5
6087991|NCT00672958|9698695|FG000|Overall Study|Voluntary withdrawal|12
6193624|NCT01439945|9851399|FG003|Double-Blind Treatment Phase|Withdrawal by Subject|1
6087992|NCT00672958|9698696|FG001|Overall Study|Voluntary withdrawal|8
6087993|NCT00672958|9698695|FG000|Overall Study|Lost to Follow-up|22
6087994|NCT00672958|9698696|FG001|Overall Study|Lost to Follow-up|17
6087995|NCT00672958|9698695|FG000|Overall Study|Reason not specified|0
6087996|NCT00672958|9698696|FG001|Overall Study|Reason not specified|3
6087997|NCT00672984|9698705|FG000|First Intervention|Adverse Event|5
6087998|NCT00672984|9698706|FG001|First Intervention|Adverse Event|0
5974576|NCT01578239|9560975|FG000|Treatment Period|Progressive Disease|19
5974577|NCT01578239|9560976|FG001|Treatment Period|Progressive Disease|64
5974578|NCT01578239|9560975|FG000|Treatment Period|Physician Decision|17
5974579|NCT01578239|9560976|FG001|Treatment Period|Physician Decision|17
5974580|NCT01578239|9560975|FG000|Treatment Period|Adverse Event|13
5974581|NCT01578239|9560976|FG001|Treatment Period|Adverse Event|10
5974582|NCT01578239|9560975|FG000|Treatment Period|Non-compliance|2
5974583|NCT01578239|9560976|FG001|Treatment Period|Non-compliance|0
5974584|NCT01578239|9560975|FG000|Treatment Period|Withdrawal by Subject|10
5974585|NCT01578239|9560976|FG001|Treatment Period|Withdrawal by Subject|9
5974586|NCT01578239|9560975|FG000|Treatment Period|Other|6
5974587|NCT01578239|9560976|FG001|Treatment Period|Other|1
5974588|NCT01578239|9560975|FG000|Long-term Follow-Up Period|Death|69
5974589|NCT01578239|9560976|FG001|Long-term Follow-Up Period|Death|64
5974590|NCT01578239|9560975|FG000|Long-term Follow-Up Period|Consent withdrawal|4
5974591|NCT01578239|9560976|FG001|Long-term Follow-Up Period|Consent withdrawal|10
5974592|NCT01578239|9560975|FG000|Long-term Follow-Up Period|Lost to Follow-up|2
5974593|NCT01578239|9560976|FG001|Long-term Follow-Up Period|Lost to Follow-up|4
5974594|NCT01578239|9560975|FG000|Long-term Follow-Up Period|Other|2
5974595|NCT01578239|9560976|FG001|Long-term Follow-Up Period|Other|2
5974596|NCT01458340|9560985|FG000|Overall Study|Adverse Event|5
5974597|NCT01458340|9560986|FG001|Overall Study|Adverse Event|4
5974598|NCT01458340|9560987|FG002|Overall Study|Adverse Event|2
5974599|NCT01458340|9560985|FG000|Overall Study|Lost to Follow-up|3
5974600|NCT01458340|9560986|FG001|Overall Study|Lost to Follow-up|3
5974601|NCT01458340|9560987|FG002|Overall Study|Lost to Follow-up|10
5974602|NCT01458340|9560985|FG000|Overall Study|Miscellaneous|0
5974603|NCT01458340|9560986|FG001|Overall Study|Miscellaneous|1
5974604|NCT01458340|9560987|FG002|Overall Study|Miscellaneous|0
5974605|NCT01458340|9560985|FG000|Overall Study|Physician Decision|1
5974606|NCT01458340|9560986|FG001|Overall Study|Physician Decision|1
5974607|NCT01458340|9560987|FG002|Overall Study|Physician Decision|2
5974608|NCT01458340|9560985|FG000|Overall Study|Protocol Violation|6
5974609|NCT01458340|9560986|FG001|Overall Study|Protocol Violation|6
5974610|NCT01458340|9560987|FG002|Overall Study|Protocol Violation|5
5974611|NCT01458340|9560985|FG000|Overall Study|Withdrawal by Subject|12
5974612|NCT01458340|9560986|FG001|Overall Study|Withdrawal by Subject|6
5974613|NCT01458340|9560987|FG002|Overall Study|Withdrawal by Subject|4
5974614|NCT01336634|9561035|FG000|Overall Study|Study closed/terminated|5
5974615|NCT01336634|9561036|FG001|Overall Study|Study closed/terminated|6
5974616|NCT01336634|9561037|FG002|Overall Study|Study closed/terminated|6
5974617|NCT01336634|9561035|FG000|Overall Study|Lost to Follow-up|2
5974618|NCT01336634|9561036|FG001|Overall Study|Lost to Follow-up|1
5974619|NCT01336634|9561037|FG002|Overall Study|Lost to Follow-up|1
5974620|NCT01336634|9561035|FG000|Overall Study|Physician Decision|1
5974621|NCT01336634|9561036|FG001|Overall Study|Physician Decision|1
5974622|NCT01336634|9561037|FG002|Overall Study|Physician Decision|0
5974623|NCT01336634|9561035|FG000|Overall Study|Withdrawal by Subject|6
5974624|NCT01336634|9561036|FG001|Overall Study|Withdrawal by Subject|0
5974625|NCT01336634|9561037|FG002|Overall Study|Withdrawal by Subject|2
5974626|NCT01155375|9561050|FG000|Overall Study|Adverse Event|1
5974627|NCT01155375|9561051|FG001|Overall Study|Adverse Event|0
5974628|NCT00628095|9561064|FG000|Overall Study|Adverse Event|5
5974629|NCT00628095|9561065|FG001|Overall Study|Adverse Event|3
5974630|NCT00628095|9561064|FG000|Overall Study|Lack of Efficacy|0
5974631|NCT00628095|9561065|FG001|Overall Study|Lack of Efficacy|3
5974632|NCT00628095|9561064|FG000|Overall Study|Withdrawal by Subject|2
5974633|NCT00628095|9561065|FG001|Overall Study|Withdrawal by Subject|0
5974634|NCT00628095|9561064|FG000|Overall Study|Other|0
5974635|NCT00628095|9561065|FG001|Overall Study|Other|1
6050034|NCT00424593|9649221|FG000|Acute Double-Blind Period|Adverse Event|16
6050035|NCT00424593|9649222|FG001|Acute Double-Blind Period|Adverse Event|7
6050036|NCT00424593|9649221|FG000|Acute Double-Blind Period|Withdrawal by Subject|11
6050037|NCT00424593|9649222|FG001|Acute Double-Blind Period|Withdrawal by Subject|10
6050038|NCT00424593|9649221|FG000|Acute Double-Blind Period|Protocol Violation|2
6050039|NCT00424593|9649222|FG001|Acute Double-Blind Period|Protocol Violation|2
6050040|NCT00424593|9649221|FG000|Acute Double-Blind Period|Physician Decision|1
6050041|NCT00424593|9649222|FG001|Acute Double-Blind Period|Physician Decision|2
6050042|NCT00424593|9649221|FG000|Acute Double-Blind Period|Lost to Follow-up|1
6050043|NCT00424593|9649222|FG001|Acute Double-Blind Period|Lost to Follow-up|1
6050044|NCT00424593|9649221|FG000|Acute Double-Blind Period|Lack of Efficacy|0
6050045|NCT00424593|9649222|FG001|Acute Double-Blind Period|Lack of Efficacy|1
6050046|NCT00424593|9649221|FG000|Dose-Blind Extension Period|Withdrawal by Subject|19
6050047|NCT00424593|9649222|FG001|Dose-Blind Extension Period|Withdrawal by Subject|0
6050048|NCT00424593|9649221|FG000|Dose-Blind Extension Period|Adverse Event|18
6050049|NCT00424593|9649222|FG001|Dose-Blind Extension Period|Adverse Event|0
6050050|NCT00424593|9649221|FG000|Dose-Blind Extension Period|Lack of Efficacy|9
6050051|NCT00424593|9649222|FG001|Dose-Blind Extension Period|Lack of Efficacy|0
6050052|NCT00424593|9649221|FG000|Dose-Blind Extension Period|Protocol Violation|9
6050053|NCT00424593|9649222|FG001|Dose-Blind Extension Period|Protocol Violation|0
6050054|NCT00424593|9649221|FG000|Dose-Blind Extension Period|Lost to Follow-up|6
6050055|NCT00424593|9649222|FG001|Dose-Blind Extension Period|Lost to Follow-up|0
5974636|NCT03945825|9561097|FG000|Overall Study|Enrolled but treatment not administered|0
5974637|NCT03945825|9561098|FG001|Overall Study|Enrolled but treatment not administered|0
5974638|NCT03945825|9561099|FG002|Overall Study|Enrolled but treatment not administered|0
5974639|NCT03945825|9561100|FG003|Overall Study|Enrolled but treatment not administered|0
6050056|NCT00424593|9649221|FG000|Dose-Blind Extension Period|Physician Decision|3
6050057|NCT00424593|9649222|FG001|Dose-Blind Extension Period|Physician Decision|0
6050058|NCT00424632|9649243|FG000|Overall Study|Death|0
6050059|NCT00424632|9649244|FG001|Overall Study|Death|0
6050060|NCT00424632|9649245|FG002|Overall Study|Death|0
6050061|NCT00424632|9649246|FG003|Overall Study|Death|0
6050062|NCT00424632|9649247|FG004|Overall Study|Death|0
6050063|NCT00424632|9649248|FG005|Overall Study|Death|2
6050064|NCT00424632|9649249|FG006|Overall Study|Death|0
6050065|NCT00424632|9649250|FG007|Overall Study|Death|0
6050066|NCT00424632|9649251|FG008|Overall Study|Death|0
6087999|NCT00672984|9698707|FG002|First Intervention|Adverse Event|0
6088000|NCT00672984|9698705|FG000|First Intervention|Withdrawal by Subject|1
6088001|NCT00672984|9698706|FG001|First Intervention|Withdrawal by Subject|2
6088002|NCT00672984|9698707|FG002|First Intervention|Withdrawal by Subject|2
6088003|NCT00672984|9698705|FG000|First Intervention|Sponsor decision|3
6088004|NCT00672984|9698706|FG001|First Intervention|Sponsor decision|0
6088005|NCT00672984|9698707|FG002|First Intervention|Sponsor decision|0
6088006|NCT00672984|9698705|FG000|Second Intervention|Non-compliance with facility policies|0
6088007|NCT00672984|9698706|FG001|Second Intervention|Non-compliance with facility policies|2
6088008|NCT00672984|9698707|FG002|Second Intervention|Non-compliance with facility policies|0
6088009|NCT00672984|9698705|FG000|Second Intervention|Withdrawal by Subject|0
6088010|NCT00672984|9698706|FG001|Second Intervention|Withdrawal by Subject|3
6088011|NCT00672984|9698707|FG002|Second Intervention|Withdrawal by Subject|0
6088012|NCT00672984|9698705|FG000|Second Intervention|Protocol Violation|0
6088013|NCT00672984|9698706|FG001|Second Intervention|Protocol Violation|1
6088014|NCT00672984|9698707|FG002|Second Intervention|Protocol Violation|1
6088015|NCT00672984|9698705|FG000|Third Intervention|Adverse Event|1
6088016|NCT00672984|9698706|FG001|Third Intervention|Adverse Event|0
6088017|NCT00672984|9698707|FG002|Third Intervention|Adverse Event|1
6088018|NCT00673049|9698719|FG000|Before Progression on Erlotinib|Randomized but not treated|3
6088019|NCT00673049|9698720|FG001|Before Progression on Erlotinib|Randomized but not treated|1
6088020|NCT00673049|9698721|FG002|Before Progression on Erlotinib|Randomized but not treated|0
6088021|NCT00673049|9698722|FG003|Before Progression on Erlotinib|Randomized but not treated|0
6088022|NCT00673049|9698719|FG000|Before Progression on Erlotinib|Death|235
6088023|NCT00673049|9698720|FG001|Before Progression on Erlotinib|Death|167
6088024|NCT00673049|9698721|FG002|Before Progression on Erlotinib|Death|1
6088025|NCT00673049|9698722|FG003|Before Progression on Erlotinib|Death|0
6088026|NCT00673049|9698719|FG000|Before Progression on Erlotinib|Lost to Follow-up|9
6088027|NCT00673049|9698720|FG001|Before Progression on Erlotinib|Lost to Follow-up|5
6088028|NCT00673049|9698721|FG002|Before Progression on Erlotinib|Lost to Follow-up|0
6088029|NCT00673049|9698722|FG003|Before Progression on Erlotinib|Lost to Follow-up|0
6088030|NCT00673049|9698719|FG000|Before Progression on Erlotinib|Withdrawal by Subject|26
6088031|NCT00673049|9698720|FG001|Before Progression on Erlotinib|Withdrawal by Subject|18
6088032|NCT00673049|9698721|FG002|Before Progression on Erlotinib|Withdrawal by Subject|0
6088033|NCT00673049|9698722|FG003|Before Progression on Erlotinib|Withdrawal by Subject|0
6088034|NCT00673049|9698719|FG000|Before Progression on Erlotinib|Other|1
6088035|NCT00673049|9698720|FG001|Before Progression on Erlotinib|Other|2
6088036|NCT00673049|9698721|FG002|Before Progression on Erlotinib|Other|0
6088037|NCT00673049|9698722|FG003|Before Progression on Erlotinib|Other|0
6088038|NCT00673049|9698719|FG000|Before Progression on Erlotinib|study terminated by sponsor|18
6088039|NCT00673049|9698720|FG001|Before Progression on Erlotinib|study terminated by sponsor|14
6088040|NCT00673049|9698721|FG002|Before Progression on Erlotinib|study terminated by sponsor|0
6088041|NCT00673049|9698722|FG003|Before Progression on Erlotinib|study terminated by sponsor|0
6088042|NCT00673049|9698719|FG000|Before Progression on Erlotinib|Switched to figitumumab|0
6088043|NCT00673049|9698720|FG001|Before Progression on Erlotinib|Switched to figitumumab|83
6088044|NCT00673049|9698721|FG002|Before Progression on Erlotinib|Switched to figitumumab|0
5974640|NCT03945825|9561101|FG004|Overall Study|Enrolled but treatment not administered|1
5974641|NCT03945825|9561102|FG005|Overall Study|Enrolled but treatment not administered|0
5974642|NCT03945825|9561097|FG000|Overall Study|Lost to Follow-up|1
5974643|NCT03945825|9561098|FG001|Overall Study|Lost to Follow-up|5
5974644|NCT03945825|9561099|FG002|Overall Study|Lost to Follow-up|0
5974645|NCT03945825|9561100|FG003|Overall Study|Lost to Follow-up|1
5974646|NCT03945825|9561101|FG004|Overall Study|Lost to Follow-up|2
5974647|NCT03945825|9561102|FG005|Overall Study|Lost to Follow-up|2
5974648|NCT03945825|9561097|FG000|Overall Study|Withdrawal by Subject|1
5974649|NCT03945825|9561098|FG001|Overall Study|Withdrawal by Subject|0
6050067|NCT00424632|9649252|FG009|Overall Study|Death|0
6050068|NCT00424632|9649243|FG000|Overall Study|Adverse Event|0
6050069|NCT00424632|9649244|FG001|Overall Study|Adverse Event|0
6050070|NCT00424632|9649245|FG002|Overall Study|Adverse Event|0
6050071|NCT00424632|9649246|FG003|Overall Study|Adverse Event|0
6050072|NCT00424632|9649247|FG004|Overall Study|Adverse Event|0
6050073|NCT00424632|9649248|FG005|Overall Study|Adverse Event|0
6050074|NCT00424632|9649249|FG006|Overall Study|Adverse Event|0
5974650|NCT03945825|9561099|FG002|Overall Study|Withdrawal by Subject|1
5974651|NCT03945825|9561100|FG003|Overall Study|Withdrawal by Subject|1
5974652|NCT03945825|9561101|FG004|Overall Study|Withdrawal by Subject|0
5974653|NCT03945825|9561102|FG005|Overall Study|Withdrawal by Subject|1
5974654|NCT03562767|9561149|FG000|Overall Study|Physician Decision|2
5974655|NCT03562767|9561150|FG001|Overall Study|Physician Decision|0
5974656|NCT03562767|9561151|FG002|Overall Study|Physician Decision|0
5974657|NCT03562767|9561149|FG000|Overall Study|Logistic Reason|1
5974658|NCT03562767|9561150|FG001|Overall Study|Logistic Reason|3
5974659|NCT03562767|9561151|FG002|Overall Study|Logistic Reason|0
5974660|NCT03559699|9561163|FG000|Overall Study|Withdrawal by Subject|6
5974661|NCT03559699|9561163|FG000|Overall Study|Lost to Follow-up|1
5974662|NCT03305016|9561180|FG000|Overall Study|Withdrawal by Subject|2
5974663|NCT03291067|9561197|FG000|Overall Study|Adverse Event|0
5974664|NCT03291067|9561198|FG001|Overall Study|Adverse Event|2
5974665|NCT03291067|9561199|FG002|Overall Study|Adverse Event|17
5974666|NCT03291067|9561200|FG003|Overall Study|Adverse Event|3
5974667|NCT03291067|9561197|FG000|Overall Study|Lost to Follow-up|2
5974668|NCT03291067|9561198|FG001|Overall Study|Lost to Follow-up|1
5974669|NCT03291067|9561199|FG002|Overall Study|Lost to Follow-up|0
5974670|NCT03291067|9561200|FG003|Overall Study|Lost to Follow-up|1
5974671|NCT03291067|9561197|FG000|Overall Study|Physician Decision|0
5974672|NCT03291067|9561198|FG001|Overall Study|Physician Decision|0
5974673|NCT03291067|9561199|FG002|Overall Study|Physician Decision|1
5974674|NCT03291067|9561200|FG003|Overall Study|Physician Decision|0
5974675|NCT03291067|9561197|FG000|Overall Study|Protocol Violation|5
5974676|NCT03291067|9561198|FG001|Overall Study|Protocol Violation|3
5974677|NCT03291067|9561199|FG002|Overall Study|Protocol Violation|4
5974678|NCT03291067|9561200|FG003|Overall Study|Protocol Violation|2
5974679|NCT03291067|9561197|FG000|Overall Study|Withdrawal by Subject|3
5974680|NCT03291067|9561198|FG001|Overall Study|Withdrawal by Subject|4
5974681|NCT03291067|9561199|FG002|Overall Study|Withdrawal by Subject|7
5974682|NCT03291067|9561200|FG003|Overall Study|Withdrawal by Subject|5
5974683|NCT03291067|9561197|FG000|Overall Study|Other|0
5974684|NCT03291067|9561198|FG001|Overall Study|Other|4
5974685|NCT03291067|9561199|FG002|Overall Study|Other|4
5974686|NCT03291067|9561200|FG003|Overall Study|Other|6
5974687|NCT03271047|9561214|FG000|Phase 1b: Dose Finding Period|Death|8
5974688|NCT03271047|9561215|FG001|Phase 1b: Dose Finding Period|Death|8
5974689|NCT03271047|9561216|FG002|Phase 1b: Dose Finding Period|Death|0
5974690|NCT03271047|9561217|FG003|Phase 1b: Dose Finding Period|Death|0
5974691|NCT03271047|9561214|FG000|Phase 1b: Dose Finding Period|Lost to Follow-up|1
5974692|NCT03271047|9561215|FG001|Phase 1b: Dose Finding Period|Lost to Follow-up|0
6050075|NCT00424632|9649250|FG007|Overall Study|Adverse Event|0
6050076|NCT00424632|9649251|FG008|Overall Study|Adverse Event|3
6050077|NCT00424632|9649252|FG009|Overall Study|Adverse Event|2
6050078|NCT00424632|9649243|FG000|Overall Study|Global deterioration of health status|0
6050079|NCT00424632|9649244|FG001|Overall Study|Global deterioration of health status|0
6050080|NCT00424632|9649245|FG002|Overall Study|Global deterioration of health status|0
6050081|NCT00424632|9649246|FG003|Overall Study|Global deterioration of health status|1
6050082|NCT00424632|9649247|FG004|Overall Study|Global deterioration of health status|1
6050083|NCT00424632|9649248|FG005|Overall Study|Global deterioration of health status|0
6050084|NCT00424632|9649249|FG006|Overall Study|Global deterioration of health status|0
6050085|NCT00424632|9649250|FG007|Overall Study|Global deterioration of health status|0
6050086|NCT00424632|9649251|FG008|Overall Study|Global deterioration of health status|0
6050087|NCT00424632|9649252|FG009|Overall Study|Global deterioration of health status|0
6050088|NCT00424632|9649243|FG000|Overall Study|Objective progression or relapse|1
6050089|NCT00424632|9649244|FG001|Overall Study|Objective progression or relapse|1
6050090|NCT00424632|9649245|FG002|Overall Study|Objective progression or relapse|1
6050091|NCT00424632|9649246|FG003|Overall Study|Objective progression or relapse|2
6050092|NCT00424632|9649247|FG004|Overall Study|Objective progression or relapse|2
6050093|NCT00424632|9649248|FG005|Overall Study|Objective progression or relapse|13
6050094|NCT00424632|9649249|FG006|Overall Study|Objective progression or relapse|7
6050095|NCT00424632|9649250|FG007|Overall Study|Objective progression or relapse|3
6050096|NCT00424632|9649251|FG008|Overall Study|Objective progression or relapse|12
6050097|NCT00424632|9649252|FG009|Overall Study|Objective progression or relapse|4
6050098|NCT00424632|9649243|FG000|Overall Study|Other|0
6050099|NCT00424632|9649244|FG001|Overall Study|Other|0
6050100|NCT00424632|9649245|FG002|Overall Study|Other|0
6050101|NCT00424632|9649246|FG003|Overall Study|Other|1
6050102|NCT00424632|9649247|FG004|Overall Study|Other|0
6050103|NCT00424632|9649248|FG005|Overall Study|Other|0
6050104|NCT00424632|9649249|FG006|Overall Study|Other|0
6050105|NCT00424632|9649250|FG007|Overall Study|Other|0
6050106|NCT00424632|9649251|FG008|Overall Study|Other|1
6050107|NCT00424632|9649252|FG009|Overall Study|Other|0
6050108|NCT00424749|9649283|FG000|Overall Study|Withdrawal by Subject|1
6050109|NCT00424762|9649289|FG000|Overall Study|Withdrawal by Subject|18
6050110|NCT00424762|9649290|FG001|Overall Study|Withdrawal by Subject|19
6050111|NCT00424762|9649289|FG000|Overall Study|Lost to Follow-up|2
6050112|NCT00424762|9649290|FG001|Overall Study|Lost to Follow-up|3
6050113|NCT00424775|9649296|FG000|Overall Study|Adverse Event|2
6050114|NCT00424775|9649297|FG001|Overall Study|Adverse Event|0
5974693|NCT03271047|9561216|FG002|Phase 1b: Dose Finding Period|Lost to Follow-up|0
5974694|NCT03271047|9561217|FG003|Phase 1b: Dose Finding Period|Lost to Follow-up|0
5974695|NCT03271047|9561214|FG000|Phase 1b: Dose Finding Period|Withdrawal by Subject|0
5974696|NCT03271047|9561215|FG001|Phase 1b: Dose Finding Period|Withdrawal by Subject|2
5974697|NCT03271047|9561216|FG002|Phase 1b: Dose Finding Period|Withdrawal by Subject|0
5974698|NCT03271047|9561217|FG003|Phase 1b: Dose Finding Period|Withdrawal by Subject|0
5974699|NCT03271047|9561214|FG000|Phase 1b: Dose Finding Period|Completed follow-up per protocol|1
5974700|NCT03271047|9561215|FG001|Phase 1b: Dose Finding Period|Completed follow-up per protocol|1
5974701|NCT03271047|9561216|FG002|Phase 1b: Dose Finding Period|Completed follow-up per protocol|0
5974702|NCT03271047|9561217|FG003|Phase 1b: Dose Finding Period|Completed follow-up per protocol|0
5974703|NCT03271047|9561214|FG000|Randomized Phase 2 Period|Other|0
5974704|NCT03271047|9561215|FG001|Randomized Phase 2 Period|Other|0
5974705|NCT03271047|9561216|FG002|Randomized Phase 2 Period|Other|0
5974706|NCT03271047|9561217|FG003|Randomized Phase 2 Period|Other|1
5974707|NCT03271047|9561214|FG000|Randomized Phase 2 Period|Death|0
5974708|NCT03271047|9561215|FG001|Randomized Phase 2 Period|Death|0
5974709|NCT03271047|9561216|FG002|Randomized Phase 2 Period|Death|20
5974710|NCT03271047|9561217|FG003|Randomized Phase 2 Period|Death|21
5974711|NCT03271047|9561214|FG000|Randomized Phase 2 Period|Lost to Follow-up|0
5974712|NCT03271047|9561215|FG001|Randomized Phase 2 Period|Lost to Follow-up|0
5974713|NCT03271047|9561216|FG002|Randomized Phase 2 Period|Lost to Follow-up|2
5974714|NCT03271047|9561217|FG003|Randomized Phase 2 Period|Lost to Follow-up|1
5974715|NCT03271047|9561214|FG000|Randomized Phase 2 Period|Withdrawal by Subject|0
5974716|NCT03271047|9561215|FG001|Randomized Phase 2 Period|Withdrawal by Subject|0
5974717|NCT03271047|9561216|FG002|Randomized Phase 2 Period|Withdrawal by Subject|5
5974718|NCT03271047|9561217|FG003|Randomized Phase 2 Period|Withdrawal by Subject|0
6088045|NCT00673049|9698722|FG003|Before Progression on Erlotinib|Switched to figitumumab|0
6088046|NCT00673049|9698719|FG000|After Progression on Erlotinib|Death|0
6088047|NCT00673049|9698720|FG001|After Progression on Erlotinib|Death|0
6088048|NCT00673049|9698721|FG002|After Progression on Erlotinib|Death|0
6088049|NCT00673049|9698722|FG003|After Progression on Erlotinib|Death|71
6088050|NCT00673049|9698719|FG000|After Progression on Erlotinib|Lost to Follow-up|0
6088051|NCT00673049|9698720|FG001|After Progression on Erlotinib|Lost to Follow-up|0
6088052|NCT00673049|9698721|FG002|After Progression on Erlotinib|Lost to Follow-up|0
6088053|NCT00673049|9698722|FG003|After Progression on Erlotinib|Lost to Follow-up|3
6088054|NCT00673049|9698719|FG000|After Progression on Erlotinib|Withdrawal by Subject|0
6088055|NCT00673049|9698720|FG001|After Progression on Erlotinib|Withdrawal by Subject|0
6088056|NCT00673049|9698721|FG002|After Progression on Erlotinib|Withdrawal by Subject|0
6088057|NCT00673049|9698722|FG003|After Progression on Erlotinib|Withdrawal by Subject|5
6088058|NCT00673049|9698719|FG000|After Progression on Erlotinib|study terminated by sponsor|0
6088059|NCT00673049|9698720|FG001|After Progression on Erlotinib|study terminated by sponsor|0
6088060|NCT00673049|9698721|FG002|After Progression on Erlotinib|study terminated by sponsor|0
6088061|NCT00673049|9698722|FG003|After Progression on Erlotinib|study terminated by sponsor|4
6088062|NCT00673231|9698758|FG000|Overall Study|Withdrawal by Subject|14
6088063|NCT00673231|9698759|FG001|Overall Study|Withdrawal by Subject|10
6088064|NCT00673231|9698760|FG002|Overall Study|Withdrawal by Subject|8
6088065|NCT00673231|9698761|FG003|Overall Study|Withdrawal by Subject|6
6088066|NCT00673231|9698758|FG000|Overall Study|Adverse Event|6
5974719|NCT03271047|9561214|FG000|Randomized Phase 2 Period|Completed follow-up per protocol|0
5974720|NCT03271047|9561215|FG001|Randomized Phase 2 Period|Completed follow-up per protocol|0
5974721|NCT03271047|9561216|FG002|Randomized Phase 2 Period|Completed follow-up per protocol|0
5974722|NCT03271047|9561217|FG003|Randomized Phase 2 Period|Completed follow-up per protocol|4
5974723|NCT03257436|9561229|FG000|Overall Study|Withdrawal by Subject|76
5974724|NCT03257436|9561229|FG000|Overall Study|Death|19
6050115|NCT00424775|9649296|FG000|Overall Study|Lack of Efficacy|1
6050116|NCT00424775|9649297|FG001|Overall Study|Lack of Efficacy|0
6050117|NCT00424827|9649301|FG000|Overall Study|Adverse Event|1
6050118|NCT00425061|9649321|FG000|Overall Study|Adverse Event|1
6050119|NCT00425061|9649322|FG001|Overall Study|Adverse Event|0
6050120|NCT00425061|9649323|FG002|Overall Study|Adverse Event|0
6050121|NCT00425061|9649324|FG003|Overall Study|Adverse Event|2
6050122|NCT00425061|9649325|FG004|Overall Study|Adverse Event|2
6050123|NCT00425061|9649326|FG005|Overall Study|Adverse Event|0
6050124|NCT00425061|9649327|FG006|Overall Study|Adverse Event|0
6050125|NCT00425061|9649321|FG000|Overall Study|Lost to Follow-up|0
6050126|NCT00425061|9649322|FG001|Overall Study|Lost to Follow-up|1
6050127|NCT00425061|9649323|FG002|Overall Study|Lost to Follow-up|0
6050128|NCT00425061|9649324|FG003|Overall Study|Lost to Follow-up|0
6050129|NCT00425061|9649325|FG004|Overall Study|Lost to Follow-up|0
6050130|NCT00425061|9649326|FG005|Overall Study|Lost to Follow-up|0
6050131|NCT00425061|9649327|FG006|Overall Study|Lost to Follow-up|0
6050132|NCT00425061|9649321|FG000|Overall Study|Protocol Violation|1
6050133|NCT00425061|9649322|FG001|Overall Study|Protocol Violation|0
6088067|NCT00673231|9698759|FG001|Overall Study|Adverse Event|5
6088068|NCT00673231|9698760|FG002|Overall Study|Adverse Event|9
6050134|NCT00425061|9649323|FG002|Overall Study|Protocol Violation|0
6050135|NCT00425061|9649324|FG003|Overall Study|Protocol Violation|0
6050136|NCT00425061|9649325|FG004|Overall Study|Protocol Violation|0
5974725|NCT03158285|9561246|FG000|Placebo-controlled Period: Week 0 - 24|Adverse Event|4
5974726|NCT03158285|9561247|FG001|Placebo-controlled Period: Week 0 - 24|Adverse Event|2
5974727|NCT03158285|9561248|FG002|Placebo-controlled Period: Week 0 - 24|Adverse Event|6
5974728|NCT03158285|9561246|FG000|Placebo-controlled Period: Week 0 - 24|Lack of Efficacy|0
5974729|NCT03158285|9561247|FG001|Placebo-controlled Period: Week 0 - 24|Lack of Efficacy|3
5974730|NCT03158285|9561248|FG002|Placebo-controlled Period: Week 0 - 24|Lack of Efficacy|3
5974731|NCT03158285|9561246|FG000|Placebo-controlled Period: Week 0 - 24|Withdrawal by Subject|1
5974732|NCT03158285|9561247|FG001|Placebo-controlled Period: Week 0 - 24|Withdrawal by Subject|1
5974733|NCT03158285|9561248|FG002|Placebo-controlled Period: Week 0 - 24|Withdrawal by Subject|0
5974734|NCT03158285|9561246|FG000|Placebo-controlled Period: Week 0 - 24|Lost to Follow-up|0
5974735|NCT03158285|9561247|FG001|Placebo-controlled Period: Week 0 - 24|Lost to Follow-up|1
5974736|NCT03158285|9561248|FG002|Placebo-controlled Period: Week 0 - 24|Lost to Follow-up|0
5974737|NCT03158285|9561246|FG000|Placebo-controlled Period: Week 0 - 24|Other|1
5974738|NCT03158285|9561247|FG001|Placebo-controlled Period: Week 0 - 24|Other|1
5974739|NCT03158285|9561248|FG002|Placebo-controlled Period: Week 0 - 24|Other|0
5974740|NCT03158285|9561246|FG000|Active Treatment Period: Week 24 - 52|Adverse Event|3
5974741|NCT03158285|9561247|FG001|Active Treatment Period: Week 24 - 52|Adverse Event|0
5974742|NCT03158285|9561248|FG002|Active Treatment Period: Week 24 - 52|Adverse Event|1
5974743|NCT03158285|9561246|FG000|Active Treatment Period: Week 24 - 52|Lack of Efficacy|5
5974744|NCT03158285|9561247|FG001|Active Treatment Period: Week 24 - 52|Lack of Efficacy|3
5974745|NCT03158285|9561248|FG002|Active Treatment Period: Week 24 - 52|Lack of Efficacy|4
5974746|NCT03158285|9561246|FG000|Active Treatment Period: Week 24 - 52|Withdrawal by Subject|1
5974747|NCT03158285|9561247|FG001|Active Treatment Period: Week 24 - 52|Withdrawal by Subject|2
5974748|NCT03158285|9561248|FG002|Active Treatment Period: Week 24 - 52|Withdrawal by Subject|1
5974749|NCT03158285|9561246|FG000|Active Treatment Period: Week 24 - 52|Pregnancy|0
5974750|NCT03158285|9561247|FG001|Active Treatment Period: Week 24 - 52|Pregnancy|0
5974751|NCT03158285|9561248|FG002|Active Treatment Period: Week 24 - 52|Pregnancy|1
5974752|NCT03158285|9561246|FG000|Active Treatment Period: Week 24 - 52|Other|1
5974753|NCT03158285|9561247|FG001|Active Treatment Period: Week 24 - 52|Other|1
5974754|NCT03158285|9561248|FG002|Active Treatment Period: Week 24 - 52|Other|0
5974755|NCT03158285|9561246|FG000|Active Treatment Period: Week 52-100|Adverse Event|7
5974756|NCT03158285|9561247|FG001|Active Treatment Period: Week 52-100|Adverse Event|5
5974757|NCT03158285|9561248|FG002|Active Treatment Period: Week 52-100|Adverse Event|3
5974758|NCT03158285|9561246|FG000|Active Treatment Period: Week 52-100|Lack of Efficacy|1
5974759|NCT03158285|9561247|FG001|Active Treatment Period: Week 52-100|Lack of Efficacy|1
5974760|NCT03158285|9561248|FG002|Active Treatment Period: Week 52-100|Lack of Efficacy|3
5974761|NCT03158285|9561246|FG000|Active Treatment Period: Week 52-100|Withdrawal by Subject|5
5974762|NCT03158285|9561247|FG001|Active Treatment Period: Week 52-100|Withdrawal by Subject|2
5974763|NCT03158285|9561248|FG002|Active Treatment Period: Week 52-100|Withdrawal by Subject|1
5974764|NCT03158285|9561246|FG000|Active Treatment Period: Week 52-100|Pregnancy|0
5974765|NCT03158285|9561247|FG001|Active Treatment Period: Week 52-100|Pregnancy|0
5974766|NCT03158285|9561248|FG002|Active Treatment Period: Week 52-100|Pregnancy|1
5974767|NCT03158285|9561246|FG000|Active Treatment Period: Week 52-100|Death|1
5974768|NCT03158285|9561247|FG001|Active Treatment Period: Week 52-100|Death|0
5974769|NCT03158285|9561248|FG002|Active Treatment Period: Week 52-100|Death|0
5974770|NCT03158285|9561246|FG000|Active Treatment Period: Week 52-100|Other|4
5974771|NCT03158285|9561247|FG001|Active Treatment Period: Week 52-100|Other|1
5974772|NCT03158285|9561248|FG002|Active Treatment Period: Week 52-100|Other|0
5974773|NCT04723173|9561261|FG000|Subjective Listening Effort Scaling|One participant was not able to perform the test as required by the study protocol.|1
5974774|NCT03683823|9561305|FG000|Post-treatment Assessment|Withdrawal by Subject|1
5974775|NCT03683823|9561306|FG001|Post-treatment Assessment|Withdrawal by Subject|1
5974776|NCT03683823|9561305|FG000|Post-treatment Assessment|Lost to Follow-up|0
5974777|NCT03683823|9561306|FG001|Post-treatment Assessment|Lost to Follow-up|1
5974778|NCT03683823|9561305|FG000|1-week Follow-up|Research halted due to COVID-19 pandemic|1
5974779|NCT03683823|9561306|FG001|1-week Follow-up|Research halted due to COVID-19 pandemic|1
5974780|NCT03515551|9561332|FG000|Overall Study|Death|4
5974781|NCT03515551|9561333|FG001|Overall Study|Death|1
5974782|NCT03515551|9561334|FG002|Overall Study|Death|2
5974783|NCT03515551|9561335|FG003|Overall Study|Death|2
5974784|NCT03515551|9561336|FG004|Overall Study|Death|2
5974785|NCT03515551|9561337|FG005|Overall Study|Death|4
5974786|NCT03515551|9561338|FG006|Overall Study|Death|1
5974787|NCT03515551|9561332|FG000|Overall Study|Lost to Follow-up|0
5974788|NCT03515551|9561333|FG001|Overall Study|Lost to Follow-up|0
5974789|NCT03515551|9561334|FG002|Overall Study|Lost to Follow-up|1
5974790|NCT03515551|9561335|FG003|Overall Study|Lost to Follow-up|0
5974791|NCT03515551|9561336|FG004|Overall Study|Lost to Follow-up|0
5974792|NCT03515551|9561337|FG005|Overall Study|Lost to Follow-up|0
5974793|NCT03515551|9561338|FG006|Overall Study|Lost to Follow-up|0
5974794|NCT03515551|9561332|FG000|Overall Study|Withdrawal by Subject|0
5974795|NCT03515551|9561333|FG001|Overall Study|Withdrawal by Subject|1
5974796|NCT03515551|9561334|FG002|Overall Study|Withdrawal by Subject|0
5974797|NCT03515551|9561335|FG003|Overall Study|Withdrawal by Subject|0
5974798|NCT03515551|9561336|FG004|Overall Study|Withdrawal by Subject|0
5974799|NCT03515551|9561337|FG005|Overall Study|Withdrawal by Subject|0
5974800|NCT03515551|9561338|FG006|Overall Study|Withdrawal by Subject|1
5974801|NCT03515551|9561332|FG000|Overall Study|Study ended by sponsor|0
5974802|NCT03515551|9561333|FG001|Overall Study|Study ended by sponsor|0
5974803|NCT03515551|9561334|FG002|Overall Study|Study ended by sponsor|2
5974804|NCT03515551|9561335|FG003|Overall Study|Study ended by sponsor|1
5974805|NCT03515551|9561336|FG004|Overall Study|Study ended by sponsor|3
5974806|NCT03515551|9561337|FG005|Overall Study|Study ended by sponsor|0
5974807|NCT03515551|9561338|FG006|Overall Study|Study ended by sponsor|3
5974808|NCT03515551|9561332|FG000|Overall Study|Sequential enrollment in 30-100 mcg cohort|0
5974809|NCT03515551|9561333|FG001|Overall Study|Sequential enrollment in 30-100 mcg cohort|1
5974810|NCT03515551|9561334|FG002|Overall Study|Sequential enrollment in 30-100 mcg cohort|0
5974811|NCT03515551|9561335|FG003|Overall Study|Sequential enrollment in 30-100 mcg cohort|0
5974812|NCT03515551|9561336|FG004|Overall Study|Sequential enrollment in 30-100 mcg cohort|0
5974813|NCT03515551|9561337|FG005|Overall Study|Sequential enrollment in 30-100 mcg cohort|0
5974814|NCT03515551|9561338|FG006|Overall Study|Sequential enrollment in 30-100 mcg cohort|0
5974815|NCT03385265|9561363|FG000|Overall Study|Withdrawal by Subject|5
5974816|NCT03385265|9561364|FG001|Overall Study|Withdrawal by Subject|2
5974817|NCT03385265|9561365|FG002|Overall Study|Withdrawal by Subject|5
5974818|NCT03385265|9561366|FG003|Overall Study|Withdrawal by Subject|2
5974819|NCT02987543|9561421|FG000|Overall Study|Ongoing study at data cut off|49
5974820|NCT02987543|9561422|FG001|Overall Study|Ongoing study at data cut off|21
5974821|NCT02987543|9561423|FG002|Overall Study|Ongoing study at data cut off|19
5974822|NCT02987543|9561424|FG003|Overall Study|Ongoing study at data cut off|12
5974823|NCT02987543|9561421|FG000|Overall Study|Death|88
5974824|NCT02987543|9561422|FG001|Overall Study|Death|54
5974825|NCT02987543|9561423|FG002|Overall Study|Death|67
5974826|NCT02987543|9561424|FG003|Overall Study|Death|28
5974827|NCT02987543|9561421|FG000|Overall Study|Lost to Follow-up|3
5974828|NCT02987543|9561422|FG001|Overall Study|Lost to Follow-up|0
5974829|NCT02987543|9561423|FG002|Overall Study|Lost to Follow-up|1
5974830|NCT02987543|9561424|FG003|Overall Study|Lost to Follow-up|0
5974831|NCT02987543|9561421|FG000|Overall Study|Screen failure|0
5974832|NCT02987543|9561422|FG001|Overall Study|Screen failure|0
5974833|NCT02987543|9561423|FG002|Overall Study|Screen failure|0
5974834|NCT02987543|9561424|FG003|Overall Study|Screen failure|1
5974835|NCT02987543|9561421|FG000|Overall Study|Withdrawal by Subject|21
5974836|NCT02987543|9561422|FG001|Overall Study|Withdrawal by Subject|7
5974837|NCT02987543|9561423|FG002|Overall Study|Withdrawal by Subject|7
5974838|NCT02987543|9561424|FG003|Overall Study|Withdrawal by Subject|6
5974839|NCT02987543|9561421|FG000|Overall Study|Study terminated by sponsor|1
5974840|NCT02987543|9561422|FG001|Overall Study|Study terminated by sponsor|0
5974841|NCT02987543|9561423|FG002|Overall Study|Study terminated by sponsor|0
5974842|NCT02987543|9561424|FG003|Overall Study|Study terminated by sponsor|0
5974843|NCT02987543|9561421|FG000|Overall Study|Investigator decision|0
6050137|NCT00425061|9649326|FG005|Overall Study|Protocol Violation|0
6050138|NCT00425061|9649327|FG006|Overall Study|Protocol Violation|0
6050139|NCT00425061|9649321|FG000|Overall Study|Withdrawal by Subject|0
6050140|NCT00425061|9649322|FG001|Overall Study|Withdrawal by Subject|1
6050141|NCT00425061|9649323|FG002|Overall Study|Withdrawal by Subject|0
6050142|NCT00425061|9649324|FG003|Overall Study|Withdrawal by Subject|0
6050143|NCT00425061|9649325|FG004|Overall Study|Withdrawal by Subject|1
6050144|NCT00425061|9649326|FG005|Overall Study|Withdrawal by Subject|0
6050145|NCT00425061|9649327|FG006|Overall Study|Withdrawal by Subject|3
6050146|NCT00425061|9649321|FG000|Overall Study|Sponsor's request|0
6050147|NCT00425061|9649322|FG001|Overall Study|Sponsor's request|0
6050148|NCT00425061|9649323|FG002|Overall Study|Sponsor's request|0
6050149|NCT00425061|9649324|FG003|Overall Study|Sponsor's request|0
6050150|NCT00425061|9649325|FG004|Overall Study|Sponsor's request|19
6050151|NCT00425061|9649326|FG005|Overall Study|Sponsor's request|4
6050152|NCT00425061|9649327|FG006|Overall Study|Sponsor's request|15
6050153|NCT00425061|9649321|FG000|Overall Study|Physician Decision|0
6050154|NCT00425061|9649322|FG001|Overall Study|Physician Decision|0
6050155|NCT00425061|9649323|FG002|Overall Study|Physician Decision|0
6050156|NCT00425061|9649324|FG003|Overall Study|Physician Decision|0
6050157|NCT00425061|9649325|FG004|Overall Study|Physician Decision|1
6050158|NCT00425061|9649326|FG005|Overall Study|Physician Decision|0
6050159|NCT00425061|9649327|FG006|Overall Study|Physician Decision|0
6050160|NCT00425061|9649321|FG000|Overall Study|Other|0
6050161|NCT00425061|9649322|FG001|Overall Study|Other|0
6050162|NCT00425061|9649323|FG002|Overall Study|Other|0
6050163|NCT00425061|9649324|FG003|Overall Study|Other|0
6050164|NCT00425061|9649325|FG004|Overall Study|Other|3
6050165|NCT00425061|9649326|FG005|Overall Study|Other|0
6050166|NCT00425061|9649327|FG006|Overall Study|Other|1
6050167|NCT00425113|9649347|FG000|Overall Study|uncontrolled diabetes mellitus|1
6050168|NCT00425113|9649348|FG001|Overall Study|uncontrolled diabetes mellitus|0
6050169|NCT00425113|9649347|FG000|Overall Study|diagnosis of abdominal TB|0
6050170|NCT00425113|9649348|FG001|Overall Study|diagnosis of abdominal TB|1
6050171|NCT00425113|9649347|FG000|Overall Study|missing study drug more than 14 days|0
6050172|NCT00425113|9649348|FG001|Overall Study|missing study drug more than 14 days|1
5974844|NCT02987543|9561422|FG001|Overall Study|Investigator decision|1
5974845|NCT02987543|9561423|FG002|Overall Study|Investigator decision|0
5974846|NCT02987543|9561424|FG003|Overall Study|Investigator decision|0
5974847|NCT02987543|9561421|FG000|Overall Study|Disease progression|0
5974848|NCT02987543|9561422|FG001|Overall Study|Disease progression|0
5974849|NCT02987543|9561423|FG002|Overall Study|Disease progression|0
5974850|NCT02987543|9561424|FG003|Overall Study|Disease progression|1
6050173|NCT00425113|9649347|FG000|Overall Study|Withdrawal by Subject|1
6050174|NCT00425113|9649348|FG001|Overall Study|Withdrawal by Subject|0
6050175|NCT00425269|9649357|FG000|Overall Study|Pregnancy|5
6050176|NCT00425269|9649358|FG001|Overall Study|Pregnancy|7
6050177|NCT00425269|9649357|FG000|Overall Study|Lost to Follow-up|9
6050178|NCT00425269|9649358|FG001|Overall Study|Lost to Follow-up|9
6050179|NCT00425269|9649357|FG000|Overall Study|moved or medical reason|5
6050180|NCT00425269|9649358|FG001|Overall Study|moved or medical reason|4
6050181|NCT00425308|9649366|FG000|Overall Study|Adverse Event|2
6050182|NCT00425308|9649367|FG001|Overall Study|Adverse Event|1
6050183|NCT00425308|9649366|FG000|Overall Study|Withdrawal by Subject|1
6050184|NCT00425308|9649367|FG001|Overall Study|Withdrawal by Subject|0
6050185|NCT00425308|9649366|FG000|Overall Study|Death|1
6050186|NCT00425308|9649367|FG001|Overall Study|Death|0
6050187|NCT00425373|9649382|FG000|Overall Study|Adverse Event|2
6050188|NCT00425373|9649383|FG001|Overall Study|Adverse Event|2
6050189|NCT00425373|9649384|FG002|Overall Study|Adverse Event|0
6050190|NCT00425373|9649385|FG003|Overall Study|Adverse Event|1
6050191|NCT00425373|9649386|FG004|Overall Study|Adverse Event|4
6050192|NCT00425373|9649387|FG005|Overall Study|Adverse Event|6
6050193|NCT00425373|9649388|FG006|Overall Study|Adverse Event|2
6050194|NCT00425373|9649389|FG007|Overall Study|Adverse Event|3
6050195|NCT00425373|9649390|FG008|Overall Study|Adverse Event|8
6050196|NCT00425373|9649382|FG000|Overall Study|Lost to Follow-up|0
6050197|NCT00425373|9649383|FG001|Overall Study|Lost to Follow-up|1
6050198|NCT00425373|9649384|FG002|Overall Study|Lost to Follow-up|0
6050199|NCT00425373|9649385|FG003|Overall Study|Lost to Follow-up|0
6050200|NCT00425373|9649386|FG004|Overall Study|Lost to Follow-up|1
6050201|NCT00425373|9649387|FG005|Overall Study|Lost to Follow-up|0
6050202|NCT00425373|9649388|FG006|Overall Study|Lost to Follow-up|0
6050203|NCT00425373|9649389|FG007|Overall Study|Lost to Follow-up|0
6050204|NCT00425373|9649390|FG008|Overall Study|Lost to Follow-up|0
6050205|NCT00425373|9649382|FG000|Overall Study|Protocol Violation|1
6050206|NCT00425373|9649383|FG001|Overall Study|Protocol Violation|0
6050207|NCT00425373|9649384|FG002|Overall Study|Protocol Violation|1
6050208|NCT00425373|9649385|FG003|Overall Study|Protocol Violation|0
6050209|NCT00425373|9649386|FG004|Overall Study|Protocol Violation|0
6050210|NCT00425373|9649387|FG005|Overall Study|Protocol Violation|0
6050211|NCT00425373|9649388|FG006|Overall Study|Protocol Violation|0
6050212|NCT00425373|9649389|FG007|Overall Study|Protocol Violation|5
6050213|NCT00425373|9649390|FG008|Overall Study|Protocol Violation|3
6050214|NCT00425373|9649382|FG000|Overall Study|Withdrawal by Subject|2
6050215|NCT00425373|9649383|FG001|Overall Study|Withdrawal by Subject|0
6050216|NCT00425373|9649384|FG002|Overall Study|Withdrawal by Subject|2
6050217|NCT00425373|9649385|FG003|Overall Study|Withdrawal by Subject|1
6050218|NCT00425373|9649386|FG004|Overall Study|Withdrawal by Subject|4
6193625|NCT01439945|9851396|FG000|Double-Blind Treatment Phase|Ineligible|1
6193626|NCT01439945|9851397|FG001|Double-Blind Treatment Phase|Ineligible|2
6193627|NCT01439945|9851398|FG002|Double-Blind Treatment Phase|Ineligible|0
6193628|NCT01439945|9851399|FG003|Double-Blind Treatment Phase|Ineligible|1
6193629|NCT01439971|9851415|FG000|Overall Study|Required number in cohort dosed|0
6193630|NCT01439971|9851416|FG001|Overall Study|Required number in cohort dosed|1
6193631|NCT01439971|9851417|FG002|Overall Study|Required number in cohort dosed|2
6193632|NCT01439971|9851418|FG003|Overall Study|Required number in cohort dosed|0
6193633|NCT01439971|9851419|FG004|Overall Study|Required number in cohort dosed|1
6193634|NCT01440049|9851431|FG000|Overall Study|Adverse Event|5
6193635|NCT01440101|9851438|FG000|Overall Study|Adverse Event|2
6193636|NCT01440101|9851439|FG001|Overall Study|Adverse Event|0
6193637|NCT01440101|9851440|FG002|Overall Study|Adverse Event|0
6193638|NCT01440101|9851438|FG000|Overall Study|Withdrawal by Subject|0
6193639|NCT01440101|9851439|FG001|Overall Study|Withdrawal by Subject|3
6193640|NCT01440101|9851440|FG002|Overall Study|Withdrawal by Subject|1
6193641|NCT01440101|9851438|FG000|Overall Study|Other|0
6193642|NCT01440101|9851439|FG001|Overall Study|Other|1
6193643|NCT01440101|9851440|FG002|Overall Study|Other|0
6193644|NCT01440283|9851449|FG000|Overall Study|Death|3
6193645|NCT01440283|9851449|FG000|Overall Study|Withdrawal by Subject|4
6050219|NCT00425373|9649387|FG005|Overall Study|Withdrawal by Subject|0
6050220|NCT00425373|9649388|FG006|Overall Study|Withdrawal by Subject|2
6050221|NCT00425373|9649389|FG007|Overall Study|Withdrawal by Subject|2
6050222|NCT00425373|9649390|FG008|Overall Study|Withdrawal by Subject|2
6050223|NCT00425373|9649382|FG000|Overall Study|Lack of Efficacy|0
6050224|NCT00425373|9649383|FG001|Overall Study|Lack of Efficacy|0
6050225|NCT00425373|9649384|FG002|Overall Study|Lack of Efficacy|0
6050226|NCT00425373|9649385|FG003|Overall Study|Lack of Efficacy|0
6193646|NCT01440283|9851449|FG000|Overall Study|Physician Decision|3
6193647|NCT01440322|9851461|FG000|Overall Study|Discomfort|2
6193648|NCT01440322|9851462|FG001|Overall Study|Discomfort|0
5974851|NCT02919306|9561432|FG000|Overall Study|Withdrawal by Subject|1
5974852|NCT02919306|9561433|FG001|Overall Study|Withdrawal by Subject|0
5974853|NCT02919306|9561432|FG000|Overall Study|Protocol Violation|1
5974854|NCT02919306|9561433|FG001|Overall Study|Protocol Violation|0
5974855|NCT02763189|9561441|FG000|Overall Study|Device failure|0
5974856|NCT02763189|9561442|FG001|Overall Study|Device failure|2
5974857|NCT02659514|9561459|FG000|Overall Study|Adverse Event|3
5974858|NCT02659514|9561460|FG001|Overall Study|Adverse Event|12
5974859|NCT02659514|9561459|FG000|Overall Study|Disease Progression|23
5974860|NCT02659514|9561460|FG001|Overall Study|Disease Progression|13
5974861|NCT02659514|9561459|FG000|Overall Study|Withdrawal by Subject|0
5974862|NCT02659514|9561460|FG001|Overall Study|Withdrawal by Subject|4
5974863|NCT02659514|9561459|FG000|Overall Study|Lost to Follow-up|0
5974864|NCT02659514|9561460|FG001|Overall Study|Lost to Follow-up|1
5974865|NCT02659514|9561459|FG000|Overall Study|Death|6
5974866|NCT02659514|9561460|FG001|Overall Study|Death|1
5974867|NCT02659514|9561459|FG000|Overall Study|Reason Unspecified|0
5974868|NCT02659514|9561460|FG001|Overall Study|Reason Unspecified|3
5974869|NCT02390245|9561485|FG000|Phase 2. Randomization Into 2 Groups|Lost to Follow-up|0
5974870|NCT02390245|9561486|FG001|Phase 2. Randomization Into 2 Groups|Lost to Follow-up|104
5974871|NCT02390245|9561487|FG002|Phase 2. Randomization Into 2 Groups|Lost to Follow-up|105
5974872|NCT02390245|9561485|FG000|Phase 3. Ophthalmic Follow-up Adherence|Lost to Follow-up|0
5974873|NCT02390245|9561486|FG001|Phase 3. Ophthalmic Follow-up Adherence|Lost to Follow-up|94
5974874|NCT02390245|9561487|FG002|Phase 3. Ophthalmic Follow-up Adherence|Lost to Follow-up|105
5974875|NCT02254278|9561496|FG000|Overall Study|Protocol Violation|1
5974876|NCT02254278|9561497|FG001|Overall Study|Protocol Violation|1
5974877|NCT01850524|9561508|FG000|Overall Study|Ongoing on Treatment|57
5974878|NCT01850524|9561509|FG001|Overall Study|Ongoing on Treatment|54
5974879|NCT01850524|9561508|FG000|Overall Study|Adverse Event|96
5974880|NCT01850524|9561509|FG001|Overall Study|Adverse Event|122
5974881|NCT01850524|9561508|FG000|Overall Study|Lost to Follow-up|2
5974882|NCT01850524|9561509|FG001|Overall Study|Lost to Follow-up|0
5974883|NCT01850524|9561508|FG000|Overall Study|Progressive Disease|166
5974884|NCT01850524|9561509|FG001|Overall Study|Progressive Disease|123
5974885|NCT01850524|9561508|FG000|Overall Study|Protocol Violation|1
5974886|NCT01850524|9561509|FG001|Overall Study|Protocol Violation|2
5974887|NCT01850524|9561508|FG000|Overall Study|Withdrawal by Subject|8
5974888|NCT01850524|9561509|FG001|Overall Study|Withdrawal by Subject|19
5974889|NCT01850524|9561508|FG000|Overall Study|Participant Wished to Discontinue Treatment|15
5974890|NCT01850524|9561509|FG001|Overall Study|Participant Wished to Discontinue Treatment|22
5974891|NCT01850524|9561508|FG000|Overall Study|Investigator Decision|4
5974892|NCT01850524|9561509|FG001|Overall Study|Investigator Decision|4
5974893|NCT01850524|9561508|FG000|Overall Study|Participants Removed From Study|0
5974894|NCT01850524|9561509|FG001|Overall Study|Participants Removed From Study|1
5974895|NCT01850524|9561508|FG000|Overall Study|Medical Monitor Decision|0
5974896|NCT01850524|9561509|FG001|Overall Study|Medical Monitor Decision|1
5974897|NCT01850524|9561508|FG000|Overall Study|Participants Decision|2
5974898|NCT01850524|9561509|FG001|Overall Study|Participants Decision|2
5974899|NCT01850524|9561508|FG000|Overall Study|Progressive Disease Per Local Lab|1
5974900|NCT01850524|9561509|FG001|Overall Study|Progressive Disease Per Local Lab|0
5974901|NCT01850524|9561508|FG000|Overall Study|Lack of Improvement|0
5974902|NCT01850524|9561509|FG001|Overall Study|Lack of Improvement|1
5974903|NCT01850524|9561508|FG000|Overall Study|Minimal Response|1
5974904|NCT01850524|9561509|FG001|Overall Study|Minimal Response|0
5974905|NCT01850524|9561508|FG000|Overall Study|Comorbidities|1
5974906|NCT01850524|9561509|FG001|Overall Study|Comorbidities|0
5974907|NCT01673867|9561519|FG000|Randomization|AE unrelated to study drug|1
5974908|NCT01673867|9561520|FG001|Randomization|AE unrelated to study drug|0
5974909|NCT01673867|9561519|FG000|Randomization|Requested treatment discontinuation|0
5974910|NCT01673867|9561520|FG001|Randomization|Requested treatment discontinuation|4
6193649|NCT01440322|9851461|FG000|Overall Study|Biomicroscopy|1
6193650|NCT01440322|9851462|FG001|Overall Study|Biomicroscopy|0
6193651|NCT01440322|9851461|FG000|Overall Study|Symptoms and Problems|1
6193652|NCT01440322|9851462|FG001|Overall Study|Symptoms and Problems|0
6193653|NCT01440322|9851461|FG000|Overall Study|Unacceptable Subjective Vision|1
6193654|NCT01440322|9851462|FG001|Overall Study|Unacceptable Subjective Vision|0
6193655|NCT01440322|9851461|FG000|Overall Study|Other Product Related|1
6193656|NCT01440322|9851462|FG001|Overall Study|Other Product Related|0
6193657|NCT01440322|9851461|FG000|Overall Study|Unrelated Medical Problem|0
6193658|NCT01440322|9851462|FG001|Overall Study|Unrelated Medical Problem|1
6193659|NCT01440322|9851461|FG000|Overall Study|Other Non-Product Related|1
6193660|NCT01440322|9851462|FG001|Overall Study|Other Non-Product Related|0
6193661|NCT01440374|9851471|FG000|Part 1: Open-label Phase|Adverse Event|5
6193662|NCT01440374|9851472|FG001|Part 1: Open-label Phase|Adverse Event|0
6193663|NCT01440374|9851473|FG002|Part 1: Open-label Phase|Adverse Event|0
6193664|NCT01440374|9851474|FG003|Part 1: Open-label Phase|Adverse Event|0
5974911|NCT01673867|9561519|FG000|Randomization|Withdrawal by Subject|0
5974912|NCT01673867|9561520|FG001|Randomization|Withdrawal by Subject|12
5974913|NCT01673867|9561519|FG000|Randomization|Lost to Follow-up|0
6193665|NCT01440374|9851471|FG000|Part 1: Open-label Phase|Physician Decision|1
6193666|NCT01440374|9851472|FG001|Part 1: Open-label Phase|Physician Decision|0
5974914|NCT01673867|9561520|FG001|Randomization|Lost to Follow-up|1
5974915|NCT01673867|9561519|FG000|Randomization|No longer meets criteria|4
5974916|NCT01673867|9561520|FG001|Randomization|No longer meets criteria|5
5974917|NCT01673867|9561519|FG000|Treatment|Disease Progression|194
5974918|NCT01673867|9561520|FG001|Treatment|Disease Progression|179
5974919|NCT01673867|9561519|FG000|Treatment|Study Drug Toxicity|17
5974920|NCT01673867|9561520|FG001|Treatment|Study Drug Toxicity|42
5974921|NCT01673867|9561519|FG000|Treatment|Death|1
5974922|NCT01673867|9561520|FG001|Treatment|Death|1
5974923|NCT01673867|9561519|FG000|Treatment|AE unrelated to study drug|19
5974924|NCT01673867|9561520|FG001|Treatment|AE unrelated to study drug|11
5974925|NCT01673867|9561519|FG000|Treatment|Requested treatment discontinuation|5
5974926|NCT01673867|9561520|FG001|Treatment|Requested treatment discontinuation|16
5974927|NCT01673867|9561519|FG000|Treatment|Withdrawal by Subject|4
5974928|NCT01673867|9561520|FG001|Treatment|Withdrawal by Subject|6
5974929|NCT01673867|9561519|FG000|Treatment|Maximum clinical benefit|0
5974930|NCT01673867|9561520|FG001|Treatment|Maximum clinical benefit|10
5974931|NCT01673867|9561519|FG000|Treatment|No longer meets criteria|2
5974932|NCT01673867|9561520|FG001|Treatment|No longer meets criteria|0
5974933|NCT01673867|9561519|FG000|Treatment|Required steroid therapy|1
5974934|NCT01673867|9561520|FG001|Treatment|Required steroid therapy|0
5974935|NCT01673867|9561519|FG000|Treatment|Health status not improved|1
5974936|NCT01673867|9561520|FG001|Treatment|Health status not improved|0
5974937|NCT01673867|9561519|FG000|Treatment|Required prolonged hospitalization|0
5974938|NCT01673867|9561520|FG001|Treatment|Required prolonged hospitalization|1
5974939|NCT01673867|9561519|FG000|Treatment|Symptomatic deterioration|0
5974940|NCT01673867|9561520|FG001|Treatment|Symptomatic deterioration|1
5974941|NCT01673867|9561519|FG000|Treatment|Physician Decision|0
6050227|NCT00425373|9649386|FG004|Overall Study|Lack of Efficacy|1
6088069|NCT00673231|9698761|FG003|Overall Study|Adverse Event|6
6088070|NCT00673231|9698758|FG000|Overall Study|Lost to Follow-up|1
6088071|NCT00673231|9698759|FG001|Overall Study|Lost to Follow-up|2
6088072|NCT00673231|9698760|FG002|Overall Study|Lost to Follow-up|1
6088073|NCT00673231|9698761|FG003|Overall Study|Lost to Follow-up|2
6088074|NCT00673231|9698758|FG000|Overall Study|Death|0
6088075|NCT00673231|9698759|FG001|Overall Study|Death|0
6088076|NCT00673231|9698760|FG002|Overall Study|Death|1
6088077|NCT00673231|9698761|FG003|Overall Study|Death|0
6088078|NCT00673231|9698758|FG000|Overall Study|Study criteria,compliance,safety, other|8
6088079|NCT00673231|9698759|FG001|Overall Study|Study criteria,compliance,safety, other|5
6088080|NCT00673231|9698760|FG002|Overall Study|Study criteria,compliance,safety, other|7
6088081|NCT00673231|9698761|FG003|Overall Study|Study criteria,compliance,safety, other|4
6193667|NCT01440374|9851473|FG002|Part 1: Open-label Phase|Physician Decision|0
6193668|NCT01440374|9851474|FG003|Part 1: Open-label Phase|Physician Decision|0
6193669|NCT01440374|9851471|FG000|Part 2; Double-blind Phase|Physician Decision|0
6193670|NCT01440374|9851472|FG001|Part 2; Double-blind Phase|Physician Decision|8
6193671|NCT01440374|9851473|FG002|Part 2; Double-blind Phase|Physician Decision|17
6193672|NCT01440374|9851474|FG003|Part 2; Double-blind Phase|Physician Decision|0
6193673|NCT01440374|9851471|FG000|Part 2; Double-blind Phase|Withdrawal by Subject|0
6193674|NCT01440374|9851472|FG001|Part 2; Double-blind Phase|Withdrawal by Subject|4
6193675|NCT01440374|9851473|FG002|Part 2; Double-blind Phase|Withdrawal by Subject|5
6193676|NCT01440374|9851474|FG003|Part 2; Double-blind Phase|Withdrawal by Subject|0
6193677|NCT01440374|9851471|FG000|Part 2; Double-blind Phase|Protocol Violation|0
6193678|NCT01440374|9851472|FG001|Part 2; Double-blind Phase|Protocol Violation|0
6193679|NCT01440374|9851473|FG002|Part 2; Double-blind Phase|Protocol Violation|1
6193680|NCT01440374|9851474|FG003|Part 2; Double-blind Phase|Protocol Violation|0
6273121|NCT02186873|9976417|FG001|Overall Study|Adverse Event|3
6273122|NCT02186873|9976416|FG000|Overall Study|Lack of Efficacy|0
5974942|NCT01673867|9561520|FG001|Treatment|Physician Decision|1
5974943|NCT00335777|9561530|FG000|Enrolled and Dispensed Study Medication|Lost to Follow-up|5
5974944|NCT00335777|9561530|FG000|Enrolled and Dispensed Study Medication|Withdrawal by Subject|6
6050228|NCT00425373|9649387|FG005|Overall Study|Lack of Efficacy|3
6050229|NCT00425373|9649388|FG006|Overall Study|Lack of Efficacy|3
6050230|NCT00425373|9649389|FG007|Overall Study|Lack of Efficacy|0
6050231|NCT00425373|9649390|FG008|Overall Study|Lack of Efficacy|5
6050232|NCT00425503|9649418|FG000|Overall Study|Adverse Event|2
6050233|NCT00425503|9649418|FG000|Overall Study|Protocol Violation|1
6050234|NCT00425555|9649424|FG000|Overall Study|Withdrawal by Subject|11
6050235|NCT00425555|9649425|FG001|Overall Study|Withdrawal by Subject|8
6050236|NCT00425555|9649424|FG000|Overall Study|Lost to Follow-up|0
6050237|NCT00425555|9649425|FG001|Overall Study|Lost to Follow-up|1
6050238|NCT00425555|9649424|FG000|Overall Study|Administrative problems|3
6050239|NCT00425555|9649425|FG001|Overall Study|Administrative problems|0
6050240|NCT00425555|9649424|FG000|Overall Study|Death|1
6050241|NCT00425555|9649425|FG001|Overall Study|Death|2
6050242|NCT00425555|9649424|FG000|Overall Study|New cancer therapy|2
6050243|NCT00425555|9649425|FG001|Overall Study|New cancer therapy|1
6050244|NCT00425555|9649424|FG000|Overall Study|Disease progression|36
6050245|NCT00425555|9649425|FG001|Overall Study|Disease progression|33
6050246|NCT00425555|9649424|FG000|Overall Study|Adverse Event|25
6050247|NCT00425555|9649425|FG001|Overall Study|Adverse Event|15
6050248|NCT00425555|9649424|FG000|Overall Study|Protocol Violation|1
5974945|NCT00335777|9561530|FG000|Enrolled and Dispensed Study Medication|Treated only 1 or no headaches|18
5974946|NCT00335777|9561530|FG000|Treated 2 Headaches Per Protocol|Treated 2 early or 2 late headaches|1
5974947|NCT00335777|9561530|FG000|Treated 2 Headaches Per Protocol|Treated out of protocol for early and late|12
5974948|NCT00159588|9561538|FG000|5 Month Follow-up|Withdrawal by Subject|2
5974949|NCT00159588|9561539|FG001|5 Month Follow-up|Withdrawal by Subject|4
5974950|NCT00159588|9561540|FG002|5 Month Follow-up|Withdrawal by Subject|2
5974951|NCT03051217|9561554|FG000|Initial Period (Week 0 to Week 16)|Adverse Event|2
5974952|NCT03051217|9561555|FG001|Initial Period (Week 0 to Week 16)|Adverse Event|0
5974953|NCT03051217|9561556|FG002|Initial Period (Week 0 to Week 16)|Adverse Event|1
5974954|NCT03051217|9561557|FG003|Initial Period (Week 0 to Week 16)|Adverse Event|0
5974955|NCT03051217|9561558|FG004|Initial Period (Week 0 to Week 16)|Adverse Event|0
5974956|NCT03051217|9561559|FG005|Initial Period (Week 0 to Week 16)|Adverse Event|0
5974957|NCT03051217|9561560|FG006|Initial Period (Week 0 to Week 16)|Adverse Event|0
5974958|NCT03051217|9561554|FG000|Initial Period (Week 0 to Week 16)|Protocol Violation|0
5974959|NCT03051217|9561555|FG001|Initial Period (Week 0 to Week 16)|Protocol Violation|1
5974960|NCT03051217|9561556|FG002|Initial Period (Week 0 to Week 16)|Protocol Violation|0
5974961|NCT03051217|9561557|FG003|Initial Period (Week 0 to Week 16)|Protocol Violation|0
5974962|NCT03051217|9561558|FG004|Initial Period (Week 0 to Week 16)|Protocol Violation|0
5974963|NCT03051217|9561559|FG005|Initial Period (Week 0 to Week 16)|Protocol Violation|0
5974964|NCT03051217|9561560|FG006|Initial Period (Week 0 to Week 16)|Protocol Violation|0
5974965|NCT03051217|9561554|FG000|Initial Period (Week 0 to Week 16)|Withdrawal by Subject|1
5974966|NCT03051217|9561555|FG001|Initial Period (Week 0 to Week 16)|Withdrawal by Subject|1
5974967|NCT03051217|9561556|FG002|Initial Period (Week 0 to Week 16)|Withdrawal by Subject|1
5974968|NCT03051217|9561557|FG003|Initial Period (Week 0 to Week 16)|Withdrawal by Subject|0
5974969|NCT03051217|9561558|FG004|Initial Period (Week 0 to Week 16)|Withdrawal by Subject|0
5974970|NCT03051217|9561559|FG005|Initial Period (Week 0 to Week 16)|Withdrawal by Subject|0
5974971|NCT03051217|9561560|FG006|Initial Period (Week 0 to Week 16)|Withdrawal by Subject|0
5974972|NCT03051217|9561554|FG000|Maintenance Period (Week 16 to Week 52)|Adverse Event|0
5974973|NCT03051217|9561555|FG001|Maintenance Period (Week 16 to Week 52)|Adverse Event|0
5974974|NCT03051217|9561556|FG002|Maintenance Period (Week 16 to Week 52)|Adverse Event|0
5974975|NCT03051217|9561557|FG003|Maintenance Period (Week 16 to Week 52)|Adverse Event|1
5974976|NCT03051217|9561558|FG004|Maintenance Period (Week 16 to Week 52)|Adverse Event|2
5974977|NCT03051217|9561559|FG005|Maintenance Period (Week 16 to Week 52)|Adverse Event|1
5974978|NCT03051217|9561560|FG006|Maintenance Period (Week 16 to Week 52)|Adverse Event|1
5974979|NCT03051217|9561554|FG000|Maintenance Period (Week 16 to Week 52)|Lack of Efficacy|0
5974980|NCT03051217|9561555|FG001|Maintenance Period (Week 16 to Week 52)|Lack of Efficacy|0
5974981|NCT03051217|9561556|FG002|Maintenance Period (Week 16 to Week 52)|Lack of Efficacy|0
5974982|NCT03051217|9561557|FG003|Maintenance Period (Week 16 to Week 52)|Lack of Efficacy|1
5974983|NCT03051217|9561558|FG004|Maintenance Period (Week 16 to Week 52)|Lack of Efficacy|0
5974984|NCT03051217|9561559|FG005|Maintenance Period (Week 16 to Week 52)|Lack of Efficacy|0
5974985|NCT03051217|9561560|FG006|Maintenance Period (Week 16 to Week 52)|Lack of Efficacy|0
5974986|NCT03051217|9561554|FG000|Maintenance Period (Week 16 to Week 52)|Protocol Violation|0
5974987|NCT03051217|9561555|FG001|Maintenance Period (Week 16 to Week 52)|Protocol Violation|0
5974988|NCT03051217|9561556|FG002|Maintenance Period (Week 16 to Week 52)|Protocol Violation|0
5974989|NCT03051217|9561557|FG003|Maintenance Period (Week 16 to Week 52)|Protocol Violation|1
5974990|NCT03051217|9561558|FG004|Maintenance Period (Week 16 to Week 52)|Protocol Violation|0
5974991|NCT03051217|9561559|FG005|Maintenance Period (Week 16 to Week 52)|Protocol Violation|0
5974992|NCT03051217|9561560|FG006|Maintenance Period (Week 16 to Week 52)|Protocol Violation|0
5974993|NCT03051217|9561554|FG000|Maintenance Period (Week 16 to Week 52)|Withdrawal by Subject|0
5974994|NCT03051217|9561555|FG001|Maintenance Period (Week 16 to Week 52)|Withdrawal by Subject|0
5974995|NCT03051217|9561556|FG002|Maintenance Period (Week 16 to Week 52)|Withdrawal by Subject|0
5974996|NCT03051217|9561557|FG003|Maintenance Period (Week 16 to Week 52)|Withdrawal by Subject|0
5974997|NCT03051217|9561558|FG004|Maintenance Period (Week 16 to Week 52)|Withdrawal by Subject|1
5974998|NCT03051217|9561559|FG005|Maintenance Period (Week 16 to Week 52)|Withdrawal by Subject|0
5974999|NCT03051217|9561560|FG006|Maintenance Period (Week 16 to Week 52)|Withdrawal by Subject|0
5975000|NCT03051217|9561554|FG000|Maintenance Period (Week 16 to Week 52)|Difficulty in going to hospital|0
5975001|NCT03051217|9561555|FG001|Maintenance Period (Week 16 to Week 52)|Difficulty in going to hospital|0
5975002|NCT03051217|9561556|FG002|Maintenance Period (Week 16 to Week 52)|Difficulty in going to hospital|0
5975003|NCT03051217|9561557|FG003|Maintenance Period (Week 16 to Week 52)|Difficulty in going to hospital|0
5975004|NCT03051217|9561558|FG004|Maintenance Period (Week 16 to Week 52)|Difficulty in going to hospital|0
5975005|NCT03051217|9561559|FG005|Maintenance Period (Week 16 to Week 52)|Difficulty in going to hospital|1
5975006|NCT03051217|9561560|FG006|Maintenance Period (Week 16 to Week 52)|Difficulty in going to hospital|0
5975007|NCT03025542|9561576|FG000|Overall Study|Adverse Event|0
5975008|NCT03025542|9561577|FG001|Overall Study|Adverse Event|2
5975009|NCT03025542|9561576|FG000|Overall Study|Lost to Follow-up|1
5975010|NCT03025542|9561577|FG001|Overall Study|Lost to Follow-up|0
5975011|NCT03025542|9561576|FG000|Overall Study|Withdrawal by Subject|1
6088082|NCT00673257|9698780|FG000|Overall Study|Withdrawal by Subject|4
6088083|NCT00673257|9698780|FG000|Overall Study|Unable to obtain specimen|1
5975012|NCT03025542|9561577|FG001|Overall Study|Withdrawal by Subject|0
5975013|NCT02889809|9561613|FG000|Overall Study|Withdrawal by Subject|30
5975014|NCT02889809|9561614|FG001|Overall Study|Withdrawal by Subject|21
5975015|NCT02889809|9561613|FG000|Overall Study|Lost to Follow-up|1
5975016|NCT02889809|9561614|FG001|Overall Study|Lost to Follow-up|1
5975017|NCT02889809|9561613|FG000|Overall Study|Site Closed|12
5975018|NCT02889809|9561614|FG001|Overall Study|Site Closed|11
5975019|NCT02849587|9561623|FG000|Overall Study|Oral THC > 5ng/mL prior to treatment (indicating likely recent use)|2
5975020|NCT02849587|9561624|FG001|Overall Study|Oral THC > 5ng/mL prior to treatment (indicating likely recent use)|3
5975021|NCT02849587|9561625|FG002|Overall Study|Oral THC > 5ng/mL prior to treatment (indicating likely recent use)|2
5975022|NCT02849587|9561623|FG000|Overall Study|Withdrawal by Subject|0
5975023|NCT02849587|9561624|FG001|Overall Study|Withdrawal by Subject|1
5975024|NCT02849587|9561625|FG002|Overall Study|Withdrawal by Subject|0
5975025|NCT02815540|9561637|FG000|Overall Study|Physician left institution and study was discontinued. No other PI was available.|2
5975026|NCT02781727|9561672|FG000|Pre-dosing Period|Withdrawal by Subject|1
5975027|NCT02781727|9561673|FG001|Pre-dosing Period|Withdrawal by Subject|0
5975028|NCT02781727|9561672|FG000|Treatment Period|Withdrawal by Subject|1
5975029|NCT02781727|9561673|FG001|Treatment Period|Withdrawal by Subject|0
6088084|NCT00673387|9698792|FG000|Overall Study|Withdrawal by Subject|15
6088085|NCT00673387|9698793|FG001|Overall Study|Withdrawal by Subject|16
5975030|NCT02781727|9561672|FG000|Treatment Period|Lost to Follow-up|0
5975031|NCT02781727|9561673|FG001|Treatment Period|Lost to Follow-up|1
5975032|NCT02778204|9561683|FG000|Overall Study|Adverse Event|1
5975033|NCT02778204|9561684|FG001|Overall Study|Adverse Event|0
5975034|NCT02778204|9561685|FG002|Overall Study|Adverse Event|0
5975035|NCT02778204|9561686|FG003|Overall Study|Adverse Event|0
5975036|NCT02778204|9561683|FG000|Overall Study|Withdrawal by Subject|0
5975037|NCT02778204|9561684|FG001|Overall Study|Withdrawal by Subject|0
5975038|NCT02778204|9561685|FG002|Overall Study|Withdrawal by Subject|1
5975039|NCT02778204|9561686|FG003|Overall Study|Withdrawal by Subject|2
5975040|NCT02778204|9561683|FG000|Overall Study|Lost to Follow-up|1
5975041|NCT02778204|9561684|FG001|Overall Study|Lost to Follow-up|0
5975042|NCT02778204|9561685|FG002|Overall Study|Lost to Follow-up|2
5975043|NCT02778204|9561686|FG003|Overall Study|Lost to Follow-up|1
5975044|NCT02778204|9561683|FG000|Overall Study|Protocol Violation|0
5975045|NCT02778204|9561684|FG001|Overall Study|Protocol Violation|0
6088086|NCT00673387|9698794|FG002|Overall Study|Withdrawal by Subject|20
6088087|NCT00673387|9698795|FG003|Overall Study|Withdrawal by Subject|16
6088088|NCT00673387|9698796|FG004|Overall Study|Withdrawal by Subject|18
6088089|NCT00673387|9698797|FG005|Overall Study|Withdrawal by Subject|21
6088090|NCT00673387|9698798|FG006|Overall Study|Withdrawal by Subject|15
6088091|NCT00673387|9698799|FG007|Overall Study|Withdrawal by Subject|21
6088092|NCT00673387|9698792|FG000|Overall Study|Adverse Event|3
6088093|NCT00673387|9698793|FG001|Overall Study|Adverse Event|1
6088094|NCT00673387|9698794|FG002|Overall Study|Adverse Event|5
6088095|NCT00673387|9698795|FG003|Overall Study|Adverse Event|2
6088096|NCT00673387|9698796|FG004|Overall Study|Adverse Event|6
6088097|NCT00673387|9698797|FG005|Overall Study|Adverse Event|2
6088098|NCT00673387|9698798|FG006|Overall Study|Adverse Event|5
6088099|NCT00673387|9698799|FG007|Overall Study|Adverse Event|5
6088100|NCT00673387|9698792|FG000|Overall Study|Physician Decision|0
6088101|NCT00673387|9698793|FG001|Overall Study|Physician Decision|0
6088102|NCT00673387|9698794|FG002|Overall Study|Physician Decision|0
6088103|NCT00673387|9698795|FG003|Overall Study|Physician Decision|0
6088104|NCT00673387|9698796|FG004|Overall Study|Physician Decision|0
6088105|NCT00673387|9698797|FG005|Overall Study|Physician Decision|5
6088106|NCT00673387|9698798|FG006|Overall Study|Physician Decision|1
6088107|NCT00673387|9698799|FG007|Overall Study|Physician Decision|1
6088108|NCT00673387|9698792|FG000|Overall Study|Protocol Violation|3
6088109|NCT00673387|9698793|FG001|Overall Study|Protocol Violation|0
5975046|NCT02778204|9561685|FG002|Overall Study|Protocol Violation|1
5975047|NCT02778204|9561686|FG003|Overall Study|Protocol Violation|0
5975048|NCT02778204|9561683|FG000|Overall Study|Eligibility Violation|0
5975049|NCT02778204|9561684|FG001|Overall Study|Eligibility Violation|0
5975050|NCT02778204|9561685|FG002|Overall Study|Eligibility Violation|0
5975051|NCT02778204|9561686|FG003|Overall Study|Eligibility Violation|1
6050249|NCT00425555|9649425|FG001|Overall Study|Protocol Violation|0
6050250|NCT00425607|9649434|FG000|Overall Study|Death|1
6050251|NCT00425607|9649434|FG000|Overall Study|Withdrawal by Subject|1
6050252|NCT00425698|9649444|FG000|Overall Study|Adverse Event|3
6050253|NCT00425698|9649445|FG001|Overall Study|Adverse Event|1
6050254|NCT00425698|9649444|FG000|Overall Study|Withdrawal by Subject|0
6050255|NCT00425698|9649445|FG001|Overall Study|Withdrawal by Subject|1
6050256|NCT00425750|9649451|FG000|Overall Study|Death|1
6050257|NCT00425750|9649451|FG000|Overall Study|Withdrawal by Subject|3
6050258|NCT00425750|9649451|FG000|Overall Study|Adverse Event|3
6088110|NCT00673387|9698794|FG002|Overall Study|Protocol Violation|1
6050259|NCT00425750|9649451|FG000|Overall Study|Progression of disease|18
6050260|NCT00425854|9649461|FG000|Overall Study|Progressive Disease|19
6050261|NCT00425854|9649462|FG001|Overall Study|Progressive Disease|12
6050262|NCT00425854|9649461|FG000|Overall Study|Dose reduction toxicity AE|8
6050263|NCT00425854|9649462|FG001|Overall Study|Dose reduction toxicity AE|7
6088111|NCT00673387|9698795|FG003|Overall Study|Protocol Violation|2
5975052|NCT02496611|9561709|FG000|Overall Study|Lost to Follow-up|2
5975053|NCT02496611|9561710|FG001|Overall Study|Lost to Follow-up|1
5975054|NCT02496611|9561709|FG000|Overall Study|Withdrawal by Subject|5
5975055|NCT02496611|9561710|FG001|Overall Study|Withdrawal by Subject|2
5975056|NCT02227199|9561729|FG000|Overall Study|Physician Decision|0
5975057|NCT02227199|9561730|FG001|Overall Study|Physician Decision|0
5975058|NCT02227199|9561731|FG002|Overall Study|Physician Decision|1
5975059|NCT02227199|9561729|FG000|Overall Study|Adverse Event|0
5975060|NCT02227199|9561730|FG001|Overall Study|Adverse Event|0
5975061|NCT02227199|9561731|FG002|Overall Study|Adverse Event|3
5975062|NCT02177695|9561745|FG000|ITT Analysis|Ineligible|5
5975063|NCT02177695|9561746|FG001|ITT Analysis|Ineligible|5
5975064|NCT02177695|9561745|FG000|Primary COXEN Analysis|inadequate tissue submitted|5
5975065|NCT02177695|9561746|FG001|Primary COXEN Analysis|inadequate tissue submitted|6
5975066|NCT02177695|9561745|FG000|Primary COXEN Analysis|insufficient amount of chemotherapy received|15
5975067|NCT02177695|9561746|FG001|Primary COXEN Analysis|insufficient amount of chemotherapy received|8
5975068|NCT02177695|9561745|FG000|Primary COXEN Analysis|Pathologic response not evaluated|13
5975069|NCT02177695|9561746|FG001|Primary COXEN Analysis|Pathologic response not evaluated|13
5975070|NCT02105636|9561776|FG000|Overall Study|Disease Progression|162
5975071|NCT02105636|9561777|FG001|Overall Study|Disease Progression|83
5975072|NCT02105636|9561776|FG000|Overall Study|Study Drug Toxicity|9
5975073|NCT02105636|9561777|FG001|Overall Study|Study Drug Toxicity|11
5975074|NCT02105636|9561776|FG000|Overall Study|Adverse Event Unrelated to Study Drug|12
5975075|NCT02105636|9561777|FG001|Overall Study|Adverse Event Unrelated to Study Drug|3
5975076|NCT02105636|9561776|FG000|Overall Study|Subject Request to Discontinue Treatment|4
5975077|NCT02105636|9561777|FG001|Overall Study|Subject Request to Discontinue Treatment|6
5975078|NCT02105636|9561776|FG000|Overall Study|Subject Withdrew Consent|4
5975079|NCT02105636|9561777|FG001|Overall Study|Subject Withdrew Consent|1
5975080|NCT02105636|9561776|FG000|Overall Study|Maximum Clinical Benefit|1
5975081|NCT02105636|9561777|FG001|Overall Study|Maximum Clinical Benefit|1
5975082|NCT02105636|9561776|FG000|Overall Study|Poor/Non-compliance|0
5975083|NCT02105636|9561777|FG001|Overall Study|Poor/Non-compliance|1
5975084|NCT02105636|9561776|FG000|Overall Study|Reason Not Specified|0
5975085|NCT02105636|9561777|FG001|Overall Study|Reason Not Specified|2
5975086|NCT02105636|9561776|FG000|Overall Study|Not Reported|3
5975087|NCT02105636|9561777|FG001|Overall Study|Not Reported|0
5975088|NCT02038946|9561784|FG000|Overall Study|Death|5
5975089|NCT02038946|9561784|FG000|Overall Study|Withdrawal by Subject|3
5975090|NCT02038946|9561784|FG000|Overall Study|Lost to Follow-up|2
5975091|NCT02038946|9561784|FG000|Overall Study|Other reasons|2
5975092|NCT01988571|9561790|FG000|Overall Study|Death|3
5975093|NCT01988571|9561791|FG001|Overall Study|Death|1
5975094|NCT01988571|9561790|FG000|Overall Study|Physician Decision|2
5975095|NCT01988571|9561791|FG001|Overall Study|Physician Decision|1
5975096|NCT01988571|9561790|FG000|Overall Study|Lost to Follow-up|3
5975097|NCT01988571|9561791|FG001|Overall Study|Lost to Follow-up|0
5975098|NCT01988571|9561790|FG000|Overall Study|Withdrawal by Subject|31
5975099|NCT01988571|9561791|FG001|Overall Study|Withdrawal by Subject|33
5975100|NCT01332266|9561806|FG000|Phase 1b|Death|3
5975101|NCT01332266|9561807|FG001|Phase 1b|Death|3
5975102|NCT01332266|9561808|FG002|Phase 1b|Death|2
5975103|NCT01332266|9561809|FG003|Phase 1b|Death|0
5975104|NCT01332266|9561810|FG004|Phase 1b|Death|0
5975105|NCT01332266|9561806|FG000|Phase 1b|Lost to Follow-up|0
5975106|NCT01332266|9561807|FG001|Phase 1b|Lost to Follow-up|1
5975107|NCT01332266|9561808|FG002|Phase 1b|Lost to Follow-up|0
5975108|NCT01332266|9561809|FG003|Phase 1b|Lost to Follow-up|0
5975109|NCT01332266|9561810|FG004|Phase 1b|Lost to Follow-up|0
5975110|NCT01332266|9561806|FG000|Phase 1b|Withdrawal by Subject|1
5975111|NCT01332266|9561807|FG001|Phase 1b|Withdrawal by Subject|1
5975112|NCT01332266|9561808|FG002|Phase 1b|Withdrawal by Subject|1
5975113|NCT01332266|9561809|FG003|Phase 1b|Withdrawal by Subject|0
5975114|NCT01332266|9561810|FG004|Phase 1b|Withdrawal by Subject|0
5975115|NCT01332266|9561806|FG000|Phase 2|Death|0
5975116|NCT01332266|9561807|FG001|Phase 2|Death|0
5975117|NCT01332266|9561808|FG002|Phase 2|Death|0
6050264|NCT00425854|9649461|FG000|Overall Study|Other Adverse Event|2
6050265|NCT00425854|9649462|FG001|Overall Study|Other Adverse Event|2
6050266|NCT00425945|9649471|FG000|Overall Study|Concern about Supplement|2
6050267|NCT00425945|9649472|FG001|Overall Study|Concern about Supplement|0
6050268|NCT00425945|9649471|FG000|Overall Study|Inconvenience|0
6050269|NCT00425945|9649472|FG001|Overall Study|Inconvenience|2
6050270|NCT00425945|9649471|FG000|Overall Study|Lost to Follow-up|0
6050271|NCT00425945|9649472|FG001|Overall Study|Lost to Follow-up|2
6050272|NCT00425945|9649471|FG000|Overall Study|Began hypertension medication|1
6050273|NCT00425945|9649472|FG001|Overall Study|Began hypertension medication|0
6193681|NCT01440374|9851471|FG000|Part 2; Double-blind Phase|Lack of Efficacy|0
5975118|NCT01332266|9561809|FG003|Phase 2|Death|33
5975119|NCT01332266|9561810|FG004|Phase 2|Death|36
5975120|NCT01332266|9561806|FG000|Phase 2|Lost to Follow-up|0
5975121|NCT01332266|9561807|FG001|Phase 2|Lost to Follow-up|0
5975122|NCT01332266|9561808|FG002|Phase 2|Lost to Follow-up|0
5975123|NCT01332266|9561809|FG003|Phase 2|Lost to Follow-up|2
5975124|NCT01332266|9561810|FG004|Phase 2|Lost to Follow-up|0
5975125|NCT01332266|9561806|FG000|Phase 2|Physician Decision|0
5975126|NCT01332266|9561807|FG001|Phase 2|Physician Decision|0
5975127|NCT01332266|9561808|FG002|Phase 2|Physician Decision|0
5975128|NCT01332266|9561809|FG003|Phase 2|Physician Decision|3
5975129|NCT01332266|9561810|FG004|Phase 2|Physician Decision|1
5975130|NCT01332266|9561806|FG000|Phase 2|Symptomatic deterioration|0
5975131|NCT01332266|9561807|FG001|Phase 2|Symptomatic deterioration|0
5975132|NCT01332266|9561808|FG002|Phase 2|Symptomatic deterioration|0
5975133|NCT01332266|9561809|FG003|Phase 2|Symptomatic deterioration|0
5975134|NCT01332266|9561810|FG004|Phase 2|Symptomatic deterioration|1
5975135|NCT01332266|9561806|FG000|Phase 2|Progression Disease|0
5975136|NCT01332266|9561807|FG001|Phase 2|Progression Disease|0
5975137|NCT01332266|9561808|FG002|Phase 2|Progression Disease|0
5975138|NCT01332266|9561809|FG003|Phase 2|Progression Disease|2
5975139|NCT01332266|9561810|FG004|Phase 2|Progression Disease|1
5975140|NCT01332266|9561806|FG000|Phase 2|Withdrawal by Subject|0
5975141|NCT01332266|9561807|FG001|Phase 2|Withdrawal by Subject|0
5975142|NCT01332266|9561808|FG002|Phase 2|Withdrawal by Subject|0
5975143|NCT01332266|9561809|FG003|Phase 2|Withdrawal by Subject|2
5975144|NCT01332266|9561810|FG004|Phase 2|Withdrawal by Subject|2
5975145|NCT01150890|9561827|FG000|Overall Study|Other|0
5975146|NCT01150890|9561828|FG001|Overall Study|Other|1
5975147|NCT01150890|9561829|FG002|Overall Study|Other|0
5975148|NCT01150890|9561830|FG003|Overall Study|Other|2
5975149|NCT01150890|9561827|FG000|Overall Study|Pregnancy|0
5975150|NCT01150890|9561828|FG001|Overall Study|Pregnancy|0
5975151|NCT01150890|9561829|FG002|Overall Study|Pregnancy|0
5975152|NCT01150890|9561830|FG003|Overall Study|Pregnancy|1
5975153|NCT01150890|9561827|FG000|Overall Study|Administrative Decision|4
5975154|NCT01150890|9561828|FG001|Overall Study|Administrative Decision|4
5975155|NCT01150890|9561829|FG002|Overall Study|Administrative Decision|5
5975156|NCT01150890|9561830|FG003|Overall Study|Administrative Decision|6
5975157|NCT01150890|9561827|FG000|Overall Study|Ineligibility determined|0
5975158|NCT01150890|9561828|FG001|Overall Study|Ineligibility determined|1
5975159|NCT01150890|9561829|FG002|Overall Study|Ineligibility determined|0
5975160|NCT01150890|9561830|FG003|Overall Study|Ineligibility determined|0
5975161|NCT01150890|9561827|FG000|Overall Study|Adverse Event|0
5975162|NCT01150890|9561828|FG001|Overall Study|Adverse Event|0
5975163|NCT01150890|9561829|FG002|Overall Study|Adverse Event|2
5975164|NCT01150890|9561830|FG003|Overall Study|Adverse Event|0
5975165|NCT01150890|9561827|FG000|Overall Study|Withdrawal by Subject|0
5975166|NCT01150890|9561828|FG001|Overall Study|Withdrawal by Subject|0
5975167|NCT01150890|9561829|FG002|Overall Study|Withdrawal by Subject|2
5975168|NCT01150890|9561830|FG003|Overall Study|Withdrawal by Subject|1
5975169|NCT01150890|9561827|FG000|Overall Study|Disease progression|0
5975170|NCT01150890|9561828|FG001|Overall Study|Disease progression|7
5975171|NCT01150890|9561829|FG002|Overall Study|Disease progression|3
5975172|NCT01150890|9561830|FG003|Overall Study|Disease progression|7
5975173|NCT01140867|9561843|FG000|Overall Study|Adverse Event|22
5975174|NCT01140867|9561843|FG000|Overall Study|Lack of Efficacy|3
5975175|NCT01140867|9561843|FG000|Overall Study|Lost to Follow-up|2
5975176|NCT01140867|9561843|FG000|Overall Study|Withdrawal by Subject|1
5975177|NCT01140867|9561843|FG000|Overall Study|Protocol Violation|1
5975178|NCT01140867|9561843|FG000|Overall Study|Uncooperative patient|2
5975179|NCT01140867|9561843|FG000|Overall Study|Medication Noncompliance|2
5975180|NCT01137773|9561849|FG000|Overall Study|Death|3
5975181|NCT01137773|9561850|FG001|Overall Study|Death|3
5975182|NCT01137773|9561849|FG000|Overall Study|Lost to Follow-up|6
5975183|NCT01137773|9561850|FG001|Overall Study|Lost to Follow-up|0
5975184|NCT01127256|9561860|FG000|Overall Study|Adverse Event|13
5975185|NCT01127256|9561861|FG001|Overall Study|Adverse Event|13
5975186|NCT01127256|9561860|FG000|Overall Study|Lack of Efficacy|4
5975187|NCT01127256|9561861|FG001|Overall Study|Lack of Efficacy|0
5975188|NCT01127256|9561860|FG000|Overall Study|Lost to Follow-up|16
5975189|NCT01127256|9561861|FG001|Overall Study|Lost to Follow-up|17
5975190|NCT01127256|9561860|FG000|Overall Study|Withdrawal by Subject|5
5975191|NCT01127256|9561861|FG001|Overall Study|Withdrawal by Subject|9
5975192|NCT01127256|9561860|FG000|Overall Study|Protocol Violation|1
5975193|NCT01127256|9561861|FG001|Overall Study|Protocol Violation|0
5975194|NCT01004861|9561880|FG000|Overall Study|Disease progression|3
5975195|NCT01004861|9561881|FG001|Overall Study|Disease progression|4
5975196|NCT01004861|9561882|FG002|Overall Study|Disease progression|5
5975197|NCT01004861|9561883|FG003|Overall Study|Disease progression|4
5975198|NCT01004861|9561884|FG004|Overall Study|Disease progression|4
5975199|NCT01004861|9561885|FG005|Overall Study|Disease progression|4
5975200|NCT01004861|9561886|FG006|Overall Study|Disease progression|5
5975201|NCT01004861|9561887|FG007|Overall Study|Disease progression|1
5975202|NCT01004861|9561888|FG008|Overall Study|Disease progression|4
5975203|NCT01004861|9561889|FG009|Overall Study|Disease progression|7
5975204|NCT01004861|9561890|FG010|Overall Study|Disease progression|6
5975205|NCT01004861|9561891|FG011|Overall Study|Disease progression|3
5975206|NCT01004861|9561892|FG012|Overall Study|Disease progression|8
6050274|NCT00425945|9649471|FG000|Overall Study|Began cancer treatments|1
5975207|NCT01004861|9561880|FG000|Overall Study|Physician Decision|0
5975208|NCT01004861|9561881|FG001|Overall Study|Physician Decision|2
5975209|NCT01004861|9561882|FG002|Overall Study|Physician Decision|1
5975210|NCT01004861|9561883|FG003|Overall Study|Physician Decision|1
5975211|NCT01004861|9561884|FG004|Overall Study|Physician Decision|1
5975212|NCT01004861|9561885|FG005|Overall Study|Physician Decision|0
5975213|NCT01004861|9561886|FG006|Overall Study|Physician Decision|0
5975214|NCT01004861|9561887|FG007|Overall Study|Physician Decision|1
5975215|NCT01004861|9561888|FG008|Overall Study|Physician Decision|0
5975216|NCT01004861|9561889|FG009|Overall Study|Physician Decision|0
5975217|NCT01004861|9561890|FG010|Overall Study|Physician Decision|0
5975218|NCT01004861|9561891|FG011|Overall Study|Physician Decision|0
5975219|NCT01004861|9561892|FG012|Overall Study|Physician Decision|3
5975220|NCT01004861|9561880|FG000|Overall Study|Adverse Event|0
5975221|NCT01004861|9561881|FG001|Overall Study|Adverse Event|0
5975222|NCT01004861|9561882|FG002|Overall Study|Adverse Event|0
5975223|NCT01004861|9561883|FG003|Overall Study|Adverse Event|1
5975224|NCT01004861|9561884|FG004|Overall Study|Adverse Event|0
5975225|NCT01004861|9561885|FG005|Overall Study|Adverse Event|2
5975226|NCT01004861|9561886|FG006|Overall Study|Adverse Event|1
5975227|NCT01004861|9561887|FG007|Overall Study|Adverse Event|1
5975228|NCT01004861|9561888|FG008|Overall Study|Adverse Event|13
5975229|NCT01004861|9561889|FG009|Overall Study|Adverse Event|1
5975230|NCT01004861|9561890|FG010|Overall Study|Adverse Event|1
5975231|NCT01004861|9561891|FG011|Overall Study|Adverse Event|0
5975232|NCT01004861|9561892|FG012|Overall Study|Adverse Event|2
5975233|NCT01004861|9561880|FG000|Overall Study|Protocol Violation|0
5975234|NCT01004861|9561881|FG001|Overall Study|Protocol Violation|0
5975235|NCT01004861|9561882|FG002|Overall Study|Protocol Violation|0
5975236|NCT01004861|9561883|FG003|Overall Study|Protocol Violation|0
5975237|NCT01004861|9561884|FG004|Overall Study|Protocol Violation|1
5975238|NCT01004861|9561885|FG005|Overall Study|Protocol Violation|0
5975239|NCT01004861|9561886|FG006|Overall Study|Protocol Violation|0
5975240|NCT01004861|9561887|FG007|Overall Study|Protocol Violation|0
5975241|NCT01004861|9561888|FG008|Overall Study|Protocol Violation|0
5975242|NCT01004861|9561889|FG009|Overall Study|Protocol Violation|0
5975243|NCT01004861|9561890|FG010|Overall Study|Protocol Violation|0
5975244|NCT01004861|9561891|FG011|Overall Study|Protocol Violation|0
5975245|NCT01004861|9561892|FG012|Overall Study|Protocol Violation|0
5975246|NCT01004861|9561880|FG000|Overall Study|Lost to Follow-up|0
5975247|NCT01004861|9561881|FG001|Overall Study|Lost to Follow-up|0
5975248|NCT01004861|9561882|FG002|Overall Study|Lost to Follow-up|0
5975249|NCT01004861|9561883|FG003|Overall Study|Lost to Follow-up|0
5975250|NCT01004861|9561884|FG004|Overall Study|Lost to Follow-up|0
5975251|NCT01004861|9561885|FG005|Overall Study|Lost to Follow-up|0
5975252|NCT01004861|9561886|FG006|Overall Study|Lost to Follow-up|0
5975253|NCT01004861|9561887|FG007|Overall Study|Lost to Follow-up|1
5975254|NCT01004861|9561888|FG008|Overall Study|Lost to Follow-up|3
5975255|NCT01004861|9561889|FG009|Overall Study|Lost to Follow-up|0
5975256|NCT01004861|9561890|FG010|Overall Study|Lost to Follow-up|0
5975257|NCT01004861|9561891|FG011|Overall Study|Lost to Follow-up|1
5975258|NCT01004861|9561892|FG012|Overall Study|Lost to Follow-up|0
5975259|NCT01004861|9561880|FG000|Overall Study|Non-compliance|0
5975260|NCT01004861|9561881|FG001|Overall Study|Non-compliance|0
6088112|NCT00673387|9698796|FG004|Overall Study|Protocol Violation|0
6088113|NCT00673387|9698797|FG005|Overall Study|Protocol Violation|1
6088114|NCT00673387|9698798|FG006|Overall Study|Protocol Violation|1
6088115|NCT00673387|9698799|FG007|Overall Study|Protocol Violation|3
6088116|NCT00673387|9698792|FG000|Overall Study|Lost to Follow-up|8
6088117|NCT00673387|9698793|FG001|Overall Study|Lost to Follow-up|6
6088118|NCT00673387|9698794|FG002|Overall Study|Lost to Follow-up|5
6088119|NCT00673387|9698795|FG003|Overall Study|Lost to Follow-up|6
6088120|NCT00673387|9698796|FG004|Overall Study|Lost to Follow-up|6
5975261|NCT01004861|9561882|FG002|Overall Study|Non-compliance|0
5975262|NCT01004861|9561883|FG003|Overall Study|Non-compliance|0
5975263|NCT01004861|9561884|FG004|Overall Study|Non-compliance|0
5975264|NCT01004861|9561885|FG005|Overall Study|Non-compliance|0
5975265|NCT01004861|9561886|FG006|Overall Study|Non-compliance|0
5975266|NCT01004861|9561887|FG007|Overall Study|Non-compliance|0
5975267|NCT01004861|9561888|FG008|Overall Study|Non-compliance|5
5975268|NCT01004861|9561889|FG009|Overall Study|Non-compliance|0
5975269|NCT01004861|9561890|FG010|Overall Study|Non-compliance|0
5975270|NCT01004861|9561891|FG011|Overall Study|Non-compliance|0
5975271|NCT01004861|9561892|FG012|Overall Study|Non-compliance|1
5975272|NCT01004861|9561880|FG000|Overall Study|Other|0
5975273|NCT01004861|9561881|FG001|Overall Study|Other|0
5975274|NCT01004861|9561882|FG002|Overall Study|Other|0
5975275|NCT01004861|9561883|FG003|Overall Study|Other|0
5975276|NCT01004861|9561884|FG004|Overall Study|Other|0
5975277|NCT01004861|9561885|FG005|Overall Study|Other|0
5975278|NCT01004861|9561886|FG006|Overall Study|Other|0
6088121|NCT00673387|9698797|FG005|Overall Study|Lost to Follow-up|5
6088122|NCT00673387|9698798|FG006|Overall Study|Lost to Follow-up|8
5975279|NCT01004861|9561887|FG007|Overall Study|Other|0
5975280|NCT01004861|9561888|FG008|Overall Study|Other|0
5975281|NCT01004861|9561889|FG009|Overall Study|Other|2
5975282|NCT01004861|9561890|FG010|Overall Study|Other|1
5975283|NCT01004861|9561891|FG011|Overall Study|Other|2
5975284|NCT01004861|9561892|FG012|Overall Study|Other|3
5975285|NCT01004861|9561880|FG000|Overall Study|Patient decision|0
5975286|NCT01004861|9561881|FG001|Overall Study|Patient decision|0
6088123|NCT00673387|9698799|FG007|Overall Study|Lost to Follow-up|5
6088124|NCT00673452|9698844|FG000|Acute Double-Blind Phase|Adverse Event|41
5975287|NCT01004861|9561882|FG002|Overall Study|Patient decision|0
6088125|NCT00673452|9698845|FG001|Acute Double-Blind Phase|Adverse Event|24
5975288|NCT01004861|9561883|FG003|Overall Study|Patient decision|0
5975289|NCT01004861|9561884|FG004|Overall Study|Patient decision|1
5975290|NCT01004861|9561885|FG005|Overall Study|Patient decision|0
5975291|NCT01004861|9561886|FG006|Overall Study|Patient decision|1
5975292|NCT01004861|9561887|FG007|Overall Study|Patient decision|0
5975293|NCT01004861|9561888|FG008|Overall Study|Patient decision|7
5975294|NCT01004861|9561889|FG009|Overall Study|Patient decision|1
5975295|NCT01004861|9561890|FG010|Overall Study|Patient decision|1
5975296|NCT01004861|9561891|FG011|Overall Study|Patient decision|2
5975297|NCT01004861|9561892|FG012|Overall Study|Patient decision|3
5975298|NCT01004861|9561880|FG000|Overall Study|Transitioned to Phase 4 study|0
5975299|NCT01004861|9561881|FG001|Overall Study|Transitioned to Phase 4 study|0
5975300|NCT01004861|9561882|FG002|Overall Study|Transitioned to Phase 4 study|0
5975301|NCT01004861|9561883|FG003|Overall Study|Transitioned to Phase 4 study|0
5975302|NCT01004861|9561884|FG004|Overall Study|Transitioned to Phase 4 study|0
5975303|NCT01004861|9561885|FG005|Overall Study|Transitioned to Phase 4 study|0
5975304|NCT01004861|9561886|FG006|Overall Study|Transitioned to Phase 4 study|0
5975305|NCT01004861|9561887|FG007|Overall Study|Transitioned to Phase 4 study|0
5975306|NCT01004861|9561888|FG008|Overall Study|Transitioned to Phase 4 study|2
5975307|NCT01004861|9561889|FG009|Overall Study|Transitioned to Phase 4 study|0
5975308|NCT01004861|9561890|FG010|Overall Study|Transitioned to Phase 4 study|0
5975309|NCT01004861|9561891|FG011|Overall Study|Transitioned to Phase 4 study|0
5975310|NCT01004861|9561892|FG012|Overall Study|Transitioned to Phase 4 study|0
5975311|NCT01004861|9561880|FG000|Overall Study|Patient completed 12-week follow-up and continued on commercially approved drug|0
5975312|NCT01004861|9561881|FG001|Overall Study|Patient completed 12-week follow-up and continued on commercially approved drug|0
5975313|NCT01004861|9561882|FG002|Overall Study|Patient completed 12-week follow-up and continued on commercially approved drug|0
5975314|NCT01004861|9561883|FG003|Overall Study|Patient completed 12-week follow-up and continued on commercially approved drug|0
5975315|NCT01004861|9561884|FG004|Overall Study|Patient completed 12-week follow-up and continued on commercially approved drug|0
5975316|NCT01004861|9561885|FG005|Overall Study|Patient completed 12-week follow-up and continued on commercially approved drug|0
5975317|NCT01004861|9561886|FG006|Overall Study|Patient completed 12-week follow-up and continued on commercially approved drug|0
5975318|NCT01004861|9561887|FG007|Overall Study|Patient completed 12-week follow-up and continued on commercially approved drug|0
5975319|NCT01004861|9561888|FG008|Overall Study|Patient completed 12-week follow-up and continued on commercially approved drug|1
5975320|NCT01004861|9561889|FG009|Overall Study|Patient completed 12-week follow-up and continued on commercially approved drug|0
5975321|NCT01004861|9561890|FG010|Overall Study|Patient completed 12-week follow-up and continued on commercially approved drug|0
5975322|NCT01004861|9561891|FG011|Overall Study|Patient completed 12-week follow-up and continued on commercially approved drug|0
5975323|NCT01004861|9561892|FG012|Overall Study|Patient completed 12-week follow-up and continued on commercially approved drug|0
5975324|NCT01004861|9561880|FG000|Overall Study|Patient withdrew|0
5975325|NCT01004861|9561881|FG001|Overall Study|Patient withdrew|0
5975326|NCT01004861|9561882|FG002|Overall Study|Patient withdrew|0
5975327|NCT01004861|9561883|FG003|Overall Study|Patient withdrew|0
5975328|NCT01004861|9561884|FG004|Overall Study|Patient withdrew|0
5975329|NCT01004861|9561885|FG005|Overall Study|Patient withdrew|0
5975330|NCT01004861|9561886|FG006|Overall Study|Patient withdrew|0
5975331|NCT01004861|9561887|FG007|Overall Study|Patient withdrew|0
5975332|NCT01004861|9561888|FG008|Overall Study|Patient withdrew|1
5975333|NCT01004861|9561889|FG009|Overall Study|Patient withdrew|0
5975334|NCT01004861|9561890|FG010|Overall Study|Patient withdrew|0
5975335|NCT01004861|9561891|FG011|Overall Study|Patient withdrew|0
5975336|NCT01004861|9561892|FG012|Overall Study|Patient withdrew|0
5975337|NCT01004861|9561880|FG000|Overall Study|Surgical resection|0
5975338|NCT01004861|9561881|FG001|Overall Study|Surgical resection|0
5975339|NCT01004861|9561882|FG002|Overall Study|Surgical resection|0
5975340|NCT01004861|9561883|FG003|Overall Study|Surgical resection|0
5975341|NCT01004861|9561884|FG004|Overall Study|Surgical resection|0
5975342|NCT01004861|9561885|FG005|Overall Study|Surgical resection|0
5975343|NCT01004861|9561886|FG006|Overall Study|Surgical resection|0
5975344|NCT01004861|9561887|FG007|Overall Study|Surgical resection|0
5975345|NCT01004861|9561888|FG008|Overall Study|Surgical resection|1
5975346|NCT01004861|9561889|FG009|Overall Study|Surgical resection|0
5975347|NCT01004861|9561890|FG010|Overall Study|Surgical resection|0
5975348|NCT01004861|9561891|FG011|Overall Study|Surgical resection|0
5975349|NCT01004861|9561892|FG012|Overall Study|Surgical resection|0
5975350|NCT01004861|9561880|FG000|Overall Study|Patient maintained complete response status throughout drug holiday|0
5975351|NCT01004861|9561881|FG001|Overall Study|Patient maintained complete response status throughout drug holiday|0
5975352|NCT01004861|9561882|FG002|Overall Study|Patient maintained complete response status throughout drug holiday|0
5975353|NCT01004861|9561883|FG003|Overall Study|Patient maintained complete response status throughout drug holiday|0
5975354|NCT01004861|9561884|FG004|Overall Study|Patient maintained complete response status throughout drug holiday|0
5975355|NCT01004861|9561885|FG005|Overall Study|Patient maintained complete response status throughout drug holiday|0
5975356|NCT01004861|9561886|FG006|Overall Study|Patient maintained complete response status throughout drug holiday|0
5975357|NCT01004861|9561887|FG007|Overall Study|Patient maintained complete response status throughout drug holiday|0
6273123|NCT02186873|9976417|FG001|Overall Study|Lack of Efficacy|1
5975358|NCT01004861|9561888|FG008|Overall Study|Patient maintained complete response status throughout drug holiday|1
5975359|NCT01004861|9561889|FG009|Overall Study|Patient maintained complete response status throughout drug holiday|0
5975360|NCT01004861|9561890|FG010|Overall Study|Patient maintained complete response status throughout drug holiday|0
5975361|NCT01004861|9561891|FG011|Overall Study|Patient maintained complete response status throughout drug holiday|0
5975362|NCT01004861|9561892|FG012|Overall Study|Patient maintained complete response status throughout drug holiday|0
5975363|NCT01004861|9561880|FG000|Overall Study|Study termination by Sponsor|0
5975364|NCT01004861|9561881|FG001|Overall Study|Study termination by Sponsor|0
5975365|NCT01004861|9561882|FG002|Overall Study|Study termination by Sponsor|0
5975366|NCT01004861|9561883|FG003|Overall Study|Study termination by Sponsor|0
5975367|NCT01004861|9561884|FG004|Overall Study|Study termination by Sponsor|0
5975368|NCT01004861|9561885|FG005|Overall Study|Study termination by Sponsor|0
5975369|NCT01004861|9561886|FG006|Overall Study|Study termination by Sponsor|0
5975370|NCT01004861|9561887|FG007|Overall Study|Study termination by Sponsor|0
5975371|NCT01004861|9561888|FG008|Overall Study|Study termination by Sponsor|1
5975372|NCT01004861|9561889|FG009|Overall Study|Study termination by Sponsor|0
5975373|NCT01004861|9561890|FG010|Overall Study|Study termination by Sponsor|0
5975374|NCT01004861|9561891|FG011|Overall Study|Study termination by Sponsor|0
5975375|NCT01004861|9561892|FG012|Overall Study|Study termination by Sponsor|0
5975376|NCT00912223|9561924|FG000|Overall Study|Withdrawal by Subject|1
5975377|NCT00912223|9561924|FG000|Overall Study|Not transplanted|1
5975378|NCT00912223|9561924|FG000|Overall Study|Transformed disease|1
5975379|NCT00381381|9561928|FG000|Overall Study|Adverse Event|3
5975380|NCT00381381|9561928|FG000|Overall Study|Lost to Follow-up|52
5975381|NCT00381381|9561928|FG000|Overall Study|Withdrawal by Subject|9
6050275|NCT00425945|9649472|FG001|Overall Study|Began cancer treatments|0
6050276|NCT00425945|9649471|FG000|Overall Study|Moved from area|0
6050277|NCT00425945|9649472|FG001|Overall Study|Moved from area|1
6050278|NCT00426127|9649480|FG000|Overall Study|Adverse Event|1
6050279|NCT00426127|9649480|FG000|Overall Study|Removed due to disease progression|1
6050280|NCT00426231|9649495|FG000|Overall Study|Withdrawal by Subject|9
6050281|NCT00426231|9649496|FG001|Overall Study|Withdrawal by Subject|12
6088126|NCT00673452|9698844|FG000|Acute Double-Blind Phase|Lack of Efficacy|9
6088127|NCT00673452|9698845|FG001|Acute Double-Blind Phase|Lack of Efficacy|14
6088128|NCT00673452|9698844|FG000|Acute Double-Blind Phase|Lost to Follow-up|16
6088129|NCT00673452|9698845|FG001|Acute Double-Blind Phase|Lost to Follow-up|19
6088130|NCT00673452|9698844|FG000|Acute Double-Blind Phase|Physician Decision|0
6088131|NCT00673452|9698845|FG001|Acute Double-Blind Phase|Physician Decision|6
6088132|NCT00673452|9698844|FG000|Acute Double-Blind Phase|Protocol Violation|5
6088133|NCT00673452|9698845|FG001|Acute Double-Blind Phase|Protocol Violation|3
6088134|NCT00673452|9698844|FG000|Acute Double-Blind Phase|Sponsor Decision|0
6088135|NCT00673452|9698845|FG001|Acute Double-Blind Phase|Sponsor Decision|1
6088136|NCT00673452|9698844|FG000|Acute Double-Blind Phase|Withdrawal by Subject|16
6088137|NCT00673452|9698845|FG001|Acute Double-Blind Phase|Withdrawal by Subject|13
6088138|NCT00673452|9698844|FG000|Continuation Double-Blind Phase|Adverse Event|5
6088139|NCT00673452|9698845|FG001|Continuation Double-Blind Phase|Adverse Event|13
6088140|NCT00673452|9698844|FG000|Continuation Double-Blind Phase|Withdrawal by Subject|9
6088141|NCT00673452|9698845|FG001|Continuation Double-Blind Phase|Withdrawal by Subject|5
6088142|NCT00673452|9698844|FG000|Continuation Double-Blind Phase|Lost to Follow-up|4
6088143|NCT00673452|9698845|FG001|Continuation Double-Blind Phase|Lost to Follow-up|5
6088144|NCT00673452|9698844|FG000|Continuation Double-Blind Phase|Lack of Efficacy|2
6088145|NCT00673452|9698845|FG001|Continuation Double-Blind Phase|Lack of Efficacy|5
6088146|NCT00673452|9698844|FG000|Continuation Double-Blind Phase|Protocol Violation|2
6088147|NCT00673452|9698845|FG001|Continuation Double-Blind Phase|Protocol Violation|3
6088148|NCT00673452|9698844|FG000|Continuation Double-Blind Phase|Sponsor Decision|0
6088149|NCT00673452|9698845|FG001|Continuation Double-Blind Phase|Sponsor Decision|3
6088150|NCT00673452|9698844|FG000|Continuation Double-Blind Phase|Physician Decision|2
6088151|NCT00673452|9698845|FG001|Continuation Double-Blind Phase|Physician Decision|0
6088152|NCT00673452|9698844|FG000|Continuation Double-Blind Phase|Death - Cervical vertebral fracture|1
6088153|NCT00673452|9698845|FG001|Continuation Double-Blind Phase|Death - Cervical vertebral fracture|0
6088154|NCT00673465|9698851|FG000|Part 1/Period 1 (United States)|Protocol Violation|0
6088155|NCT00673465|9698852|FG001|Part 1/Period 1 (United States)|Protocol Violation|0
6088156|NCT00673465|9698853|FG002|Part 1/Period 1 (United States)|Protocol Violation|0
6088157|NCT00673465|9698854|FG003|Part 1/Period 1 (United States)|Protocol Violation|0
6088158|NCT00673465|9698855|FG004|Part 1/Period 1 (United States)|Protocol Violation|1
6088159|NCT00673465|9698856|FG005|Part 1/Period 1 (United States)|Protocol Violation|1
6088160|NCT00673465|9698857|FG006|Part 1/Period 1 (United States)|Protocol Violation|0
6088161|NCT00673465|9698858|FG007|Part 1/Period 1 (United States)|Protocol Violation|0
6088162|NCT00673465|9698859|FG008|Part 1/Period 1 (United States)|Protocol Violation|0
6088163|NCT00673465|9698860|FG009|Part 1/Period 1 (United States)|Protocol Violation|0
6088164|NCT00673465|9698861|FG010|Part 1/Period 1 (United States)|Protocol Violation|0
6088165|NCT00673465|9698862|FG011|Part 1/Period 1 (United States)|Protocol Violation|0
6088166|NCT00673465|9698851|FG000|Part 1/Period 2 (United States)|Protocol Violation|0
6088167|NCT00673465|9698852|FG001|Part 1/Period 2 (United States)|Protocol Violation|0
6088168|NCT00673465|9698853|FG002|Part 1/Period 2 (United States)|Protocol Violation|0
5975382|NCT03712124|9561959|FG000|Overall Study|Protocol Violation|1
5975383|NCT03712124|9561960|FG001|Overall Study|Protocol Violation|0
5975384|NCT03535740|9561972|FG000|Overall Study|Ongoing at Data Cut-off Date: 30 September 2020|55
5975385|NCT03535740|9561972|FG000|Overall Study|Death|34
5975386|NCT03535740|9561972|FG000|Overall Study|Lost to Follow-up|1
5975387|NCT03535740|9561972|FG000|Overall Study|Withdrawal by Subject|13
5975388|NCT02921789|9561997|FG000|Overall Study|Adverse Event|0
5975389|NCT02921789|9561998|FG001|Overall Study|Adverse Event|1
5975390|NCT02921789|9561997|FG000|Overall Study|Lost to Follow-up|1
5975391|NCT02921789|9561998|FG001|Overall Study|Lost to Follow-up|0
5975392|NCT02921789|9561997|FG000|Overall Study|Protocol Deviation|2
5975393|NCT02921789|9561998|FG001|Overall Study|Protocol Deviation|0
5975394|NCT02921789|9561997|FG000|Overall Study|Withdrawal by Subject|2
5975395|NCT02921789|9561998|FG001|Overall Study|Withdrawal by Subject|1
5975396|NCT02921789|9561997|FG000|Overall Study|Miscellaneous|3
5975397|NCT02921789|9561998|FG001|Overall Study|Miscellaneous|2
5975398|NCT02896257|9562018|FG000|Providers|Without eligible patients|21
5975399|NCT02896257|9562019|FG001|Providers|Without eligible patients|28
5975400|NCT02896257|9562018|FG000|Patients|PFT entry criteria not met|43
5975401|NCT02896257|9562019|FG001|Patients|PFT entry criteria not met|50
5975402|NCT02896257|9562018|FG000|Patients|No capacity to review|8
5975403|NCT02896257|9562019|FG001|Patients|No capacity to review|11
5975404|NCT02896257|9562018|FG000|Patients|Appointment rescheduled/cancelled|5
5975405|NCT02896257|9562019|FG001|Patients|Appointment rescheduled/cancelled|7
5975406|NCT02896257|9562018|FG000|Patients|PCP not assigned a clinic|4
5975407|NCT02896257|9562019|FG001|Patients|PCP not assigned a clinic|0
5975408|NCT02896257|9562018|FG000|Patients|No history of COPD|0
5975409|NCT02896257|9562019|FG001|Patients|No history of COPD|1
5975410|NCT02896257|9562018|FG000|Patients|Deceased between review and index date|0
5975411|NCT02896257|9562019|FG001|Patients|Deceased between review and index date|1
5975412|NCT02896257|9562018|FG000|Patients|No ICS Rx upon review|1
5975413|NCT02896257|9562019|FG001|Patients|No ICS Rx upon review|1
5975414|NCT02896257|9562018|FG000|Patients|Protocol Violation|2
5975415|NCT02896257|9562019|FG001|Patients|Protocol Violation|1
5975416|NCT02896257|9562018|FG000|Patients|Hospice care|0
5975417|NCT02896257|9562019|FG001|Patients|Hospice care|1
6050282|NCT00426270|9649502|FG000|Overall Study|Incorrectly Enrolled in the Study|1
6050283|NCT00426270|9649502|FG000|Overall Study|Adverse Event|5
6050284|NCT00426361|9649522|FG000|Overall Study|Lost to Follow-up|3
6050285|NCT00426361|9649523|FG001|Overall Study|Lost to Follow-up|2
6050286|NCT00426361|9649524|FG002|Overall Study|Lost to Follow-up|5
6050287|NCT00426361|9649522|FG000|Overall Study|Withdrawal by Subject|1
6050288|NCT00426361|9649523|FG001|Overall Study|Withdrawal by Subject|3
6050289|NCT00426361|9649524|FG002|Overall Study|Withdrawal by Subject|0
6050290|NCT00426556|9649553|FG000|Phase I - Core Phase|Disease Progression|0
6050291|NCT00426556|9649554|FG001|Phase I - Core Phase|Disease Progression|6
6050292|NCT00426556|9649555|FG002|Phase I - Core Phase|Disease Progression|2
6050293|NCT00426556|9649556|FG003|Phase I - Core Phase|Disease Progression|0
6050294|NCT00426556|9649553|FG000|Phase I - Core Phase|Adverse Event|1
6050295|NCT00426556|9649554|FG001|Phase I - Core Phase|Adverse Event|3
6050296|NCT00426556|9649555|FG002|Phase I - Core Phase|Adverse Event|1
6050297|NCT00426556|9649556|FG003|Phase I - Core Phase|Adverse Event|0
6050298|NCT00426556|9649553|FG000|Phase I - Core Phase|Death|0
6050299|NCT00426556|9649554|FG001|Phase I - Core Phase|Death|1
6050300|NCT00426556|9649555|FG002|Phase I - Core Phase|Death|0
6050301|NCT00426556|9649556|FG003|Phase I - Core Phase|Death|0
6050302|NCT00426556|9649553|FG000|Phase I - Extension Phase|Adverse Event|0
6050303|NCT00426556|9649554|FG001|Phase I - Extension Phase|Adverse Event|1
6050304|NCT00426556|9649555|FG002|Phase I - Extension Phase|Adverse Event|1
6050305|NCT00426556|9649556|FG003|Phase I - Extension Phase|Adverse Event|0
6050306|NCT00426556|9649553|FG000|Phase I - Extension Phase|Disease Progression|5
6050307|NCT00426556|9649554|FG001|Phase I - Extension Phase|Disease Progression|5
6050308|NCT00426556|9649555|FG002|Phase I - Extension Phase|Disease Progression|6
6050309|NCT00426556|9649556|FG003|Phase I - Extension Phase|Disease Progression|0
6050310|NCT00426556|9649553|FG000|Phase II - Core Phase|Withdrawal by Subject|0
6050311|NCT00426556|9649554|FG001|Phase II - Core Phase|Withdrawal by Subject|0
6050312|NCT00426556|9649555|FG002|Phase II - Core Phase|Withdrawal by Subject|0
6050313|NCT00426556|9649556|FG003|Phase II - Core Phase|Withdrawal by Subject|3
6050314|NCT00426556|9649553|FG000|Phase II - Core Phase|Disease Progression|0
6050315|NCT00426556|9649554|FG001|Phase II - Core Phase|Disease Progression|0
6050316|NCT00426556|9649555|FG002|Phase II - Core Phase|Disease Progression|0
6050317|NCT00426556|9649556|FG003|Phase II - Core Phase|Disease Progression|16
6050318|NCT00426556|9649553|FG000|Phase II - Core Phase|Adverse Event|0
6050319|NCT00426556|9649554|FG001|Phase II - Core Phase|Adverse Event|0
6050320|NCT00426556|9649555|FG002|Phase II - Core Phase|Adverse Event|0
6050321|NCT00426556|9649556|FG003|Phase II - Core Phase|Adverse Event|8
6273124|NCT02186873|9976416|FG000|Overall Study|Lost to Follow-up|1
5975418|NCT02736617|9562035|FG000|Treatment|Adverse Event|1
5975419|NCT02736617|9562035|FG000|Treatment|Lack of Efficacy|1
5975420|NCT02736617|9562035|FG000|Treatment|Withdrawal by Subject|1
5975421|NCT02736617|9562035|FG000|Maintenance|Lack of Efficacy|4
5975422|NCT02736617|9562035|FG000|Maintenance|Physician Decision|1
5975423|NCT02579265|9562046|FG000|Overall Study|Weaned off earlier than 28 days|44
5975424|NCT02579265|9562047|FG001|Overall Study|Weaned off earlier than 28 days|43
5975425|NCT02579265|9562046|FG000|Overall Study|Adverse Event|2
5975426|NCT02579265|9562047|FG001|Overall Study|Adverse Event|0
5975427|NCT02579265|9562046|FG000|Overall Study|Any other reason not specified|0
5975428|NCT02579265|9562047|FG001|Overall Study|Any other reason not specified|2
5975429|NCT02579265|9562046|FG000|Overall Study|Withdrawal by Subject|2
5975430|NCT02579265|9562047|FG001|Overall Study|Withdrawal by Subject|0
5975431|NCT02579265|9562046|FG000|Overall Study|Physician Decision|1
5975432|NCT02579265|9562047|FG001|Overall Study|Physician Decision|0
5975433|NCT02579265|9562046|FG000|Overall Study|Withdrawal due to increased conjugated bilirubin|1
5975434|NCT02579265|9562047|FG001|Overall Study|Withdrawal due to increased conjugated bilirubin|0
6050322|NCT00426556|9649553|FG000|Phase II - Extension Phase|Disease Progression|0
6050323|NCT00426556|9649554|FG001|Phase II - Extension Phase|Disease Progression|0
6050324|NCT00426556|9649555|FG002|Phase II - Extension Phase|Disease Progression|0
6050325|NCT00426556|9649556|FG003|Phase II - Extension Phase|Disease Progression|21
6050326|NCT00426556|9649553|FG000|Phase II - Extension Phase|Adverse Event|0
6050327|NCT00426556|9649554|FG001|Phase II - Extension Phase|Adverse Event|0
6050328|NCT00426556|9649555|FG002|Phase II - Extension Phase|Adverse Event|0
6050329|NCT00426556|9649556|FG003|Phase II - Extension Phase|Adverse Event|2
6050330|NCT00426660|9649566|FG000|Overall Study|Death|14
6050331|NCT00426660|9649566|FG000|Overall Study|Adverse Event|23
6050332|NCT00426660|9649566|FG000|Overall Study|Insufficient Clinical Response|22
6050333|NCT00426660|9649566|FG000|Overall Study|Lost to Follow-up|15
6050334|NCT00426660|9649566|FG000|Overall Study|Other|23
6050335|NCT00426660|9649566|FG000|Overall Study|Withdrawal by Subject|18
6050336|NCT00426660|9649566|FG000|Overall Study|Protocol Violation|1
6050337|NCT00426660|9649566|FG000|Overall Study|Enrolled Not Treated|15
6050338|NCT00426751|9649572|FG000|Overall Study|Adverse Event|8
6050339|NCT00426751|9649573|FG001|Overall Study|Adverse Event|1
6050340|NCT00426751|9649572|FG000|Overall Study|Lost to Follow-up|7
6050341|NCT00426751|9649573|FG001|Overall Study|Lost to Follow-up|6
6050342|NCT00426751|9649572|FG000|Overall Study|Consent Withdrawn|0
6050343|NCT00426751|9649573|FG001|Overall Study|Consent Withdrawn|1
6050344|NCT00426751|9649572|FG000|Overall Study|Other Reasons|7
6050345|NCT00426751|9649573|FG001|Overall Study|Other Reasons|12
6050346|NCT00426764|9649579|FG000|Overall Study|Protocol Violation|1
6050347|NCT00426764|9649579|FG000|Overall Study|Withdrawal by Subject|4
6050348|NCT00426764|9649579|FG000|Overall Study|Physician Decision|6
6050349|NCT00426764|9649579|FG000|Overall Study|Compassionate Use|1
6050350|NCT00426764|9649579|FG000|Overall Study|Progressive Disease|83
6050351|NCT00426764|9649579|FG000|Overall Study|Adverse Event|24
6050352|NCT00426764|9649579|FG000|Overall Study|Other|1
6050353|NCT00426764|9649579|FG000|Overall Study|Death|1
6050354|NCT00426764|9649579|FG000|Overall Study|Other Reasons (Miscellaneous)|10
6050355|NCT00426842|9649589|FG000|Overall Study|Lost to Follow-up|1
6050356|NCT00427011|9649599|FG000|Overall Study|Adverse Event|10
6050357|NCT00427011|9649599|FG000|Overall Study|Withdrawal by Subject|1
6050358|NCT00427011|9649599|FG000|Overall Study|Lack of Efficacy|2
6050359|NCT00427011|9649599|FG000|Overall Study|Other|12
6050360|NCT00427349|9649628|FG000|Overall Study|Lack of Efficacy|23
6050361|NCT00427349|9649628|FG000|Overall Study|Adverse Event|14
6050362|NCT00427349|9649628|FG000|Overall Study|Death|1
6050363|NCT00427349|9649628|FG000|Overall Study|Withdrawal by Subject|3
6050364|NCT00427349|9649628|FG000|Overall Study|Alternative therapy|1
6050365|NCT00427349|9649628|FG000|Overall Study|Other|2
6050366|NCT00427349|9649628|FG000|Overall Study|Ineligible|1
6050367|NCT00427349|9649628|FG000|Overall Study|Never started therapy|1
6050368|NCT00427635|9649638|FG000|Treatment Phase|Withdrawal by Subject|1
6050369|NCT00427635|9649639|FG001|Treatment Phase|Withdrawal by Subject|0
6050370|NCT00427635|9649638|FG000|Study Completion to Safety Follow-up|Lost to Follow-up|0
6050371|NCT00427635|9649639|FG001|Study Completion to Safety Follow-up|Lost to Follow-up|1
6050372|NCT00427648|9649647|FG000|Overall Study|Protocol Violation|1
6050373|NCT00427648|9649648|FG001|Overall Study|Protocol Violation|2
6050374|NCT00427648|9649647|FG000|Overall Study|Adverse Event|0
6050375|NCT00427648|9649648|FG001|Overall Study|Adverse Event|1
6193682|NCT01440374|9851472|FG001|Part 2; Double-blind Phase|Lack of Efficacy|1
6193683|NCT01440374|9851473|FG002|Part 2; Double-blind Phase|Lack of Efficacy|0
6193684|NCT01440374|9851474|FG003|Part 2; Double-blind Phase|Lack of Efficacy|0
6193685|NCT01440374|9851471|FG000|Part 2; Double-blind Phase|Adverse Event|0
6193686|NCT01440374|9851472|FG001|Part 2; Double-blind Phase|Adverse Event|7
6193687|NCT01440374|9851473|FG002|Part 2; Double-blind Phase|Adverse Event|31
6193688|NCT01440374|9851474|FG003|Part 2; Double-blind Phase|Adverse Event|0
6193689|NCT01440374|9851471|FG000|Part 2; Double-blind Phase|Not treated|0
6193690|NCT01440374|9851472|FG001|Part 2; Double-blind Phase|Not treated|0
6193691|NCT01440374|9851473|FG002|Part 2; Double-blind Phase|Not treated|1
6193692|NCT01440374|9851474|FG003|Part 2; Double-blind Phase|Not treated|0
6050376|NCT00427700|9649663|FG000|Overall Study|Lost to Follow-up|2
6050377|NCT00427700|9649664|FG001|Overall Study|Lost to Follow-up|5
6050378|NCT00427700|9649663|FG000|Overall Study|no induction of menses|1
6050379|NCT00427700|9649664|FG001|Overall Study|no induction of menses|4
6050380|NCT00427700|9649663|FG000|Overall Study|Pregnancy|0
6050381|NCT00427700|9649664|FG001|Overall Study|Pregnancy|2
6050382|NCT00427778|9649675|FG000|First Intervention (4 Weeks)|no longer interested|1
5975435|NCT02013167|9562055|FG000|Overall Study|Withdrawal by Subject|15
5975436|NCT02013167|9562056|FG001|Overall Study|Withdrawal by Subject|14
5975437|NCT02013167|9562055|FG000|Overall Study|Sponsor Decision|1
5975438|NCT02013167|9562056|FG001|Overall Study|Sponsor Decision|3
5975439|NCT02013167|9562055|FG000|Overall Study|Lost to Follow-up|0
5975440|NCT02013167|9562056|FG001|Overall Study|Lost to Follow-up|1
5975441|NCT02013167|9562055|FG000|Overall Study|Death|85
5975442|NCT02013167|9562056|FG001|Overall Study|Death|160
5975443|NCT02004522|9562065|FG000|Overall Study|Adverse Event|55
5975444|NCT02004522|9562066|FG001|Overall Study|Adverse Event|6
5975445|NCT02004522|9562065|FG000|Overall Study|Withdrawal by Subject|13
5975446|NCT02004522|9562066|FG001|Overall Study|Withdrawal by Subject|7
5975447|NCT02004522|9562065|FG000|Overall Study|Death|12
5975448|NCT02004522|9562066|FG001|Overall Study|Death|3
5975449|NCT02004522|9562065|FG000|Overall Study|Physician Decision|3
5975450|NCT02004522|9562066|FG001|Overall Study|Physician Decision|4
5975451|NCT02004522|9562065|FG000|Overall Study|Protocol Violation|1
5975452|NCT02004522|9562066|FG001|Overall Study|Protocol Violation|0
5975453|NCT02004522|9562065|FG000|Overall Study|Other is reason listed by PI.|4
5975454|NCT02004522|9562066|FG001|Overall Study|Other is reason listed by PI.|1
5975455|NCT02004522|9562065|FG000|Overall Study|Never Dosed|2
5975456|NCT02004522|9562066|FG001|Overall Study|Never Dosed|4
5975457|NCT02004522|9562065|FG000|Overall Study|Disease Progression|35
5975458|NCT02004522|9562066|FG001|Overall Study|Disease Progression|31
5975459|NCT02004522|9562065|FG000|Overall Study|Completed Treatrment Cycles Per Protocol|1
5975460|NCT02004522|9562066|FG001|Overall Study|Completed Treatrment Cycles Per Protocol|103
6088169|NCT00673465|9698854|FG003|Part 1/Period 2 (United States)|Protocol Violation|0
6088170|NCT00673465|9698855|FG004|Part 1/Period 2 (United States)|Protocol Violation|1
6088171|NCT00673465|9698856|FG005|Part 1/Period 2 (United States)|Protocol Violation|0
5975461|NCT02000427|9562072|FG000|Overall Study|Death|22
5975462|NCT01981850|9562083|FG000|Main Phase Stage 1|Death|2
5975463|NCT01981850|9562084|FG001|Main Phase Stage 1|Death|0
5975464|NCT01981850|9562085|FG002|Main Phase Stage 1|Death|0
5975465|NCT01981850|9562086|FG003|Main Phase Stage 1|Death|0
5975466|NCT01981850|9562087|FG004|Main Phase Stage 1|Death|0
5975467|NCT01981850|9562088|FG005|Main Phase Stage 1|Death|0
5975468|NCT01981850|9562089|FG006|Main Phase Stage 1|Death|0
5975469|NCT01981850|9562090|FG007|Main Phase Stage 1|Death|0
5975470|NCT01981850|9562091|FG008|Main Phase Stage 1|Death|0
5975471|NCT01981850|9562092|FG009|Main Phase Stage 1|Death|0
5975472|NCT01981850|9562083|FG000|Main Phase Stage 1|Informed Consent Withdrawn|1
5975473|NCT01981850|9562084|FG001|Main Phase Stage 1|Informed Consent Withdrawn|0
5975474|NCT01981850|9562085|FG002|Main Phase Stage 1|Informed Consent Withdrawn|0
5975475|NCT01981850|9562086|FG003|Main Phase Stage 1|Informed Consent Withdrawn|0
5975476|NCT01981850|9562087|FG004|Main Phase Stage 1|Informed Consent Withdrawn|0
5975477|NCT01981850|9562088|FG005|Main Phase Stage 1|Informed Consent Withdrawn|0
5975478|NCT01981850|9562089|FG006|Main Phase Stage 1|Informed Consent Withdrawn|0
5975479|NCT01981850|9562090|FG007|Main Phase Stage 1|Informed Consent Withdrawn|0
5975480|NCT01981850|9562091|FG008|Main Phase Stage 1|Informed Consent Withdrawn|0
5975481|NCT01981850|9562092|FG009|Main Phase Stage 1|Informed Consent Withdrawn|0
5975482|NCT01981850|9562083|FG000|Main Phase Stage 1|Lack of Efficacy|0
5975483|NCT01981850|9562084|FG001|Main Phase Stage 1|Lack of Efficacy|2
5975484|NCT01981850|9562085|FG002|Main Phase Stage 1|Lack of Efficacy|0
5975485|NCT01981850|9562086|FG003|Main Phase Stage 1|Lack of Efficacy|0
5975486|NCT01981850|9562087|FG004|Main Phase Stage 1|Lack of Efficacy|0
5975487|NCT01981850|9562088|FG005|Main Phase Stage 1|Lack of Efficacy|0
5975488|NCT01981850|9562089|FG006|Main Phase Stage 1|Lack of Efficacy|0
6088172|NCT00673465|9698857|FG006|Part 1/Period 2 (United States)|Protocol Violation|0
6088173|NCT00673465|9698858|FG007|Part 1/Period 2 (United States)|Protocol Violation|0
6088174|NCT00673465|9698859|FG008|Part 1/Period 2 (United States)|Protocol Violation|0
6088175|NCT00673465|9698860|FG009|Part 1/Period 2 (United States)|Protocol Violation|0
6088176|NCT00673465|9698861|FG010|Part 1/Period 2 (United States)|Protocol Violation|0
6088177|NCT00673465|9698862|FG011|Part 1/Period 2 (United States)|Protocol Violation|0
6088178|NCT00673660|9698870|FG000|Overall Study|Lost to Follow-up|107
6088179|NCT00673673|9698879|FG000|Overall Study|Progressive disease|27
6088180|NCT00673673|9698879|FG000|Overall Study|Adverse Event|4
6193693|NCT01440374|9851471|FG000|Part 3: Extension|Withdrawal by Subject|0
6193694|NCT01440374|9851472|FG001|Part 3: Extension|Withdrawal by Subject|0
6193695|NCT01440374|9851473|FG002|Part 3: Extension|Withdrawal by Subject|0
6193696|NCT01440374|9851474|FG003|Part 3: Extension|Withdrawal by Subject|5
6193697|NCT01440374|9851471|FG000|Part 3: Extension|Adverse Event|0
6193698|NCT01440374|9851472|FG001|Part 3: Extension|Adverse Event|0
6193699|NCT01440374|9851473|FG002|Part 3: Extension|Adverse Event|0
6193700|NCT01440374|9851474|FG003|Part 3: Extension|Adverse Event|13
6193701|NCT01440374|9851471|FG000|Part 3: Extension|Physician Decision|0
6193702|NCT01440374|9851472|FG001|Part 3: Extension|Physician Decision|0
5975489|NCT01981850|9562090|FG007|Main Phase Stage 1|Lack of Efficacy|0
5975490|NCT01981850|9562091|FG008|Main Phase Stage 1|Lack of Efficacy|0
5975491|NCT01981850|9562092|FG009|Main Phase Stage 1|Lack of Efficacy|0
6193703|NCT01440374|9851473|FG002|Part 3: Extension|Physician Decision|0
6193704|NCT01440374|9851474|FG003|Part 3: Extension|Physician Decision|14
5975492|NCT01981850|9562083|FG000|Main Phase Stage 1|Various reasons|0
5975493|NCT01981850|9562084|FG001|Main Phase Stage 1|Various reasons|0
6088181|NCT00673673|9698879|FG000|Overall Study|Withdrawal by Subject|3
6088182|NCT00673673|9698879|FG000|Overall Study|Investigators' discretion|2
6088183|NCT00673790|9698906|FG000|Overall Study|Adverse Event|23
6088184|NCT00673790|9698907|FG001|Overall Study|Adverse Event|14
6088185|NCT00673790|9698908|FG002|Overall Study|Adverse Event|2
6088186|NCT00673790|9698906|FG000|Overall Study|Lack of Efficacy|2
6088187|NCT00673790|9698907|FG001|Overall Study|Lack of Efficacy|2
6088188|NCT00673790|9698908|FG002|Overall Study|Lack of Efficacy|2
6088189|NCT00673790|9698906|FG000|Overall Study|Protocol Violation|6
6088190|NCT00673790|9698907|FG001|Overall Study|Protocol Violation|9
5975494|NCT01981850|9562085|FG002|Main Phase Stage 1|Various reasons|2
5975495|NCT01981850|9562086|FG003|Main Phase Stage 1|Various reasons|0
5975496|NCT01981850|9562087|FG004|Main Phase Stage 1|Various reasons|0
5975497|NCT01981850|9562088|FG005|Main Phase Stage 1|Various reasons|0
5975498|NCT01981850|9562089|FG006|Main Phase Stage 1|Various reasons|0
5975499|NCT01981850|9562090|FG007|Main Phase Stage 1|Various reasons|0
5975500|NCT01981850|9562091|FG008|Main Phase Stage 1|Various reasons|0
5975501|NCT01981850|9562092|FG009|Main Phase Stage 1|Various reasons|0
5975502|NCT01981850|9562083|FG000|Main Phase Stage 2|Adverse Event|0
5975503|NCT01981850|9562084|FG001|Main Phase Stage 2|Adverse Event|0
5975504|NCT01981850|9562085|FG002|Main Phase Stage 2|Adverse Event|0
5975505|NCT01981850|9562086|FG003|Main Phase Stage 2|Adverse Event|0
5975506|NCT01981850|9562087|FG004|Main Phase Stage 2|Adverse Event|6
5975507|NCT01981850|9562088|FG005|Main Phase Stage 2|Adverse Event|5
5975508|NCT01981850|9562089|FG006|Main Phase Stage 2|Adverse Event|7
5975509|NCT01981850|9562090|FG007|Main Phase Stage 2|Adverse Event|0
5975510|NCT01981850|9562091|FG008|Main Phase Stage 2|Adverse Event|0
6050383|NCT00427778|9649676|FG001|First Intervention (4 Weeks)|no longer interested|0
6050384|NCT00427778|9649675|FG000|First Intervention (4 Weeks)|Not successfully fitted with ring|2
6050385|NCT00427778|9649676|FG001|First Intervention (4 Weeks)|Not successfully fitted with ring|0
6050386|NCT00427778|9649675|FG000|First Intervention (4 Weeks)|unable to manipulate ring due to OA|0
6050387|NCT00427778|9649676|FG001|First Intervention (4 Weeks)|unable to manipulate ring due to OA|1
6050388|NCT00427778|9649675|FG000|First Intervention (4 Weeks)|anxious about using ring|1
6050389|NCT00427778|9649676|FG001|First Intervention (4 Weeks)|anxious about using ring|0
6050390|NCT00427895|9649717|FG000|Between 6-Month Follow-up - Year 1|Did not enter 1-year blood draw|0
6050391|NCT00427895|9649718|FG001|Between 6-Month Follow-up - Year 1|Did not enter 1-year blood draw|0
6050392|NCT00427895|9649719|FG002|Between 6-Month Follow-up - Year 1|Did not enter 1-year blood draw|0
6050393|NCT00427895|9649720|FG003|Between 6-Month Follow-up - Year 1|Did not enter 1-year blood draw|352
6050394|NCT00427895|9649721|FG004|Between 6-Month Follow-up - Year 1|Did not enter 1-year blood draw|0
6050395|NCT00427895|9649722|FG005|Between 6-Month Follow-up - Year 1|Did not enter 1-year blood draw|0
6050396|NCT00427895|9649723|FG006|Between 6-Month Follow-up - Year 1|Did not enter 1-year blood draw|0
6050397|NCT00427895|9649724|FG007|Between 6-Month Follow-up - Year 1|Did not enter 1-year blood draw|0
6050398|NCT00427895|9649717|FG000|Vax 2/Year 3 to 4|Lost to Follow-up|0
6050399|NCT00427895|9649718|FG001|Vax 2/Year 3 to 4|Lost to Follow-up|0
6050400|NCT00427895|9649719|FG002|Vax 2/Year 3 to 4|Lost to Follow-up|0
6050401|NCT00427895|9649720|FG003|Vax 2/Year 3 to 4|Lost to Follow-up|0
6050402|NCT00427895|9649721|FG004|Vax 2/Year 3 to 4|Lost to Follow-up|0
6050403|NCT00427895|9649722|FG005|Vax 2/Year 3 to 4|Lost to Follow-up|0
6050404|NCT00427895|9649723|FG006|Vax 2/Year 3 to 4|Lost to Follow-up|0
6050405|NCT00427895|9649724|FG007|Vax 2/Year 3 to 4|Lost to Follow-up|1
6088191|NCT00673790|9698908|FG002|Overall Study|Protocol Violation|1
6088192|NCT00673790|9698906|FG000|Overall Study|Withdrawal by Subject|7
6088193|NCT00673790|9698907|FG001|Overall Study|Withdrawal by Subject|4
6088194|NCT00673790|9698908|FG002|Overall Study|Withdrawal by Subject|1
6088195|NCT00673790|9698906|FG000|Overall Study|Lost to Follow-up|6
6088196|NCT00673790|9698907|FG001|Overall Study|Lost to Follow-up|6
6088197|NCT00673790|9698908|FG002|Overall Study|Lost to Follow-up|5
6088198|NCT00673790|9698906|FG000|Overall Study|Sponsor Terminated due to PI oversight|0
6088199|NCT00673790|9698907|FG001|Overall Study|Sponsor Terminated due to PI oversight|1
6088200|NCT00673790|9698908|FG002|Overall Study|Sponsor Terminated due to PI oversight|0
6088201|NCT00673790|9698906|FG000|Overall Study|Poor compliance|1
6088202|NCT00673790|9698907|FG001|Overall Study|Poor compliance|0
6088203|NCT00673790|9698908|FG002|Overall Study|Poor compliance|0
6088204|NCT00673790|9698906|FG000|Overall Study|Participated in two Nebivolol studies|0
6088205|NCT00673790|9698907|FG001|Overall Study|Participated in two Nebivolol studies|0
6088206|NCT00673790|9698908|FG002|Overall Study|Participated in two Nebivolol studies|1
6088207|NCT00673790|9698906|FG000|Overall Study|Unconfirmed pregnancy|0
6088208|NCT00673790|9698907|FG001|Overall Study|Unconfirmed pregnancy|1
6088209|NCT00673790|9698908|FG002|Overall Study|Unconfirmed pregnancy|0
6088210|NCT00673790|9698906|FG000|Overall Study|Randomization criteria not met|0
6088211|NCT00673790|9698907|FG001|Overall Study|Randomization criteria not met|1
6088212|NCT00673790|9698908|FG002|Overall Study|Randomization criteria not met|0
6088213|NCT00673816|9698917|FG000|Overall Study|Adverse Event|1
6088214|NCT00673816|9698917|FG000|Overall Study|Withdrawal by Subject|1
6088215|NCT00673881|9698929|FG000|Overall Study|Withdrawal by Subject|1
6088216|NCT00673894|9698935|FG000|First Intervention 4 Weeks|Withdrawal by Subject|1
6193705|NCT01440569|9851514|FG000|Main Study|Enrolled but not treated|1
5975511|NCT01981850|9562092|FG009|Main Phase Stage 2|Adverse Event|0
5975512|NCT01981850|9562083|FG000|Main Phase Stage 2|Informed Consent Withdrawn|0
5975513|NCT01981850|9562084|FG001|Main Phase Stage 2|Informed Consent Withdrawn|0
5975514|NCT01981850|9562085|FG002|Main Phase Stage 2|Informed Consent Withdrawn|0
5975515|NCT01981850|9562086|FG003|Main Phase Stage 2|Informed Consent Withdrawn|0
5975516|NCT01981850|9562087|FG004|Main Phase Stage 2|Informed Consent Withdrawn|4
5975517|NCT01981850|9562088|FG005|Main Phase Stage 2|Informed Consent Withdrawn|3
5975518|NCT01981850|9562089|FG006|Main Phase Stage 2|Informed Consent Withdrawn|3
5975519|NCT01981850|9562090|FG007|Main Phase Stage 2|Informed Consent Withdrawn|0
5975520|NCT01981850|9562091|FG008|Main Phase Stage 2|Informed Consent Withdrawn|0
5975521|NCT01981850|9562092|FG009|Main Phase Stage 2|Informed Consent Withdrawn|0
5975522|NCT01981850|9562083|FG000|Main Phase Stage 2|Lack of Efficacy|0
5975523|NCT01981850|9562084|FG001|Main Phase Stage 2|Lack of Efficacy|0
5975524|NCT01981850|9562085|FG002|Main Phase Stage 2|Lack of Efficacy|0
5975525|NCT01981850|9562086|FG003|Main Phase Stage 2|Lack of Efficacy|0
5975526|NCT01981850|9562087|FG004|Main Phase Stage 2|Lack of Efficacy|1
5975527|NCT01981850|9562088|FG005|Main Phase Stage 2|Lack of Efficacy|2
5975528|NCT01981850|9562089|FG006|Main Phase Stage 2|Lack of Efficacy|0
5975529|NCT01981850|9562090|FG007|Main Phase Stage 2|Lack of Efficacy|0
5975530|NCT01981850|9562091|FG008|Main Phase Stage 2|Lack of Efficacy|0
5975531|NCT01981850|9562092|FG009|Main Phase Stage 2|Lack of Efficacy|0
5975532|NCT01981850|9562083|FG000|Main Phase Stage 2|Various reasons|0
5975533|NCT01981850|9562084|FG001|Main Phase Stage 2|Various reasons|0
5975534|NCT01981850|9562085|FG002|Main Phase Stage 2|Various reasons|0
5975535|NCT01981850|9562086|FG003|Main Phase Stage 2|Various reasons|0
5975536|NCT01981850|9562087|FG004|Main Phase Stage 2|Various reasons|2
5975537|NCT01981850|9562088|FG005|Main Phase Stage 2|Various reasons|0
5975538|NCT01981850|9562089|FG006|Main Phase Stage 2|Various reasons|1
5975539|NCT01981850|9562090|FG007|Main Phase Stage 2|Various reasons|0
5975540|NCT01981850|9562091|FG008|Main Phase Stage 2|Various reasons|0
5975541|NCT01981850|9562092|FG009|Main Phase Stage 2|Various reasons|0
5975542|NCT01981850|9562083|FG000|Main Phase Stage 2|Progressive Disease|0
5975543|NCT01981850|9562084|FG001|Main Phase Stage 2|Progressive Disease|0
5975544|NCT01981850|9562085|FG002|Main Phase Stage 2|Progressive Disease|0
5975545|NCT01981850|9562086|FG003|Main Phase Stage 2|Progressive Disease|0
5975546|NCT01981850|9562087|FG004|Main Phase Stage 2|Progressive Disease|0
5975547|NCT01981850|9562088|FG005|Main Phase Stage 2|Progressive Disease|6
5975548|NCT01981850|9562089|FG006|Main Phase Stage 2|Progressive Disease|6
5975549|NCT01981850|9562090|FG007|Main Phase Stage 2|Progressive Disease|0
5975550|NCT01981850|9562091|FG008|Main Phase Stage 2|Progressive Disease|0
5975551|NCT01981850|9562092|FG009|Main Phase Stage 2|Progressive Disease|0
5975552|NCT01981850|9562083|FG000|Open Label Extension (OLE)|Adverse Event|0
5975553|NCT01981850|9562084|FG001|Open Label Extension (OLE)|Adverse Event|0
5975554|NCT01981850|9562085|FG002|Open Label Extension (OLE)|Adverse Event|0
5975555|NCT01981850|9562086|FG003|Open Label Extension (OLE)|Adverse Event|0
5975556|NCT01981850|9562087|FG004|Open Label Extension (OLE)|Adverse Event|0
5975557|NCT01981850|9562088|FG005|Open Label Extension (OLE)|Adverse Event|0
5975558|NCT01981850|9562089|FG006|Open Label Extension (OLE)|Adverse Event|0
5975559|NCT01981850|9562090|FG007|Open Label Extension (OLE)|Adverse Event|2
5975560|NCT01981850|9562091|FG008|Open Label Extension (OLE)|Adverse Event|1
5975561|NCT01981850|9562092|FG009|Open Label Extension (OLE)|Adverse Event|8
5975562|NCT01981850|9562083|FG000|Open Label Extension (OLE)|Lack of Efficacy|0
5975563|NCT01981850|9562084|FG001|Open Label Extension (OLE)|Lack of Efficacy|0
5975564|NCT01981850|9562085|FG002|Open Label Extension (OLE)|Lack of Efficacy|0
5975565|NCT01981850|9562086|FG003|Open Label Extension (OLE)|Lack of Efficacy|0
5975566|NCT01981850|9562087|FG004|Open Label Extension (OLE)|Lack of Efficacy|0
5975567|NCT01981850|9562088|FG005|Open Label Extension (OLE)|Lack of Efficacy|0
5975568|NCT01981850|9562089|FG006|Open Label Extension (OLE)|Lack of Efficacy|0
5975569|NCT01981850|9562090|FG007|Open Label Extension (OLE)|Lack of Efficacy|4
5975570|NCT01981850|9562091|FG008|Open Label Extension (OLE)|Lack of Efficacy|1
5975571|NCT01981850|9562092|FG009|Open Label Extension (OLE)|Lack of Efficacy|19
5975572|NCT01981850|9562083|FG000|Open Label Extension (OLE)|Various reasons|0
5975573|NCT01981850|9562084|FG001|Open Label Extension (OLE)|Various reasons|0
5975574|NCT01981850|9562085|FG002|Open Label Extension (OLE)|Various reasons|0
5975575|NCT01981850|9562086|FG003|Open Label Extension (OLE)|Various reasons|0
5975576|NCT01981850|9562087|FG004|Open Label Extension (OLE)|Various reasons|0
5975577|NCT01981850|9562088|FG005|Open Label Extension (OLE)|Various reasons|0
5975578|NCT01981850|9562089|FG006|Open Label Extension (OLE)|Various reasons|0
5975579|NCT01981850|9562090|FG007|Open Label Extension (OLE)|Various reasons|3
5975580|NCT01981850|9562091|FG008|Open Label Extension (OLE)|Various reasons|1
5975581|NCT01981850|9562092|FG009|Open Label Extension (OLE)|Various reasons|3
5975582|NCT01981850|9562083|FG000|Open Label Extension (OLE)|Progressive Disease|0
5975583|NCT01981850|9562084|FG001|Open Label Extension (OLE)|Progressive Disease|0
5975584|NCT01981850|9562085|FG002|Open Label Extension (OLE)|Progressive Disease|0
5975585|NCT01981850|9562086|FG003|Open Label Extension (OLE)|Progressive Disease|0
5975586|NCT01981850|9562087|FG004|Open Label Extension (OLE)|Progressive Disease|0
5975587|NCT01981850|9562088|FG005|Open Label Extension (OLE)|Progressive Disease|0
5975588|NCT01981850|9562089|FG006|Open Label Extension (OLE)|Progressive Disease|0
5975589|NCT01981850|9562090|FG007|Open Label Extension (OLE)|Progressive Disease|3
5975590|NCT01981850|9562091|FG008|Open Label Extension (OLE)|Progressive Disease|2
5975591|NCT01981850|9562092|FG009|Open Label Extension (OLE)|Progressive Disease|9
5975592|NCT01981850|9562083|FG000|Open Label Extension (OLE)|Informed Consent Withdrawn|0
5975593|NCT01981850|9562084|FG001|Open Label Extension (OLE)|Informed Consent Withdrawn|0
5975594|NCT01981850|9562085|FG002|Open Label Extension (OLE)|Informed Consent Withdrawn|0
5975595|NCT01981850|9562086|FG003|Open Label Extension (OLE)|Informed Consent Withdrawn|0
5975596|NCT01981850|9562087|FG004|Open Label Extension (OLE)|Informed Consent Withdrawn|0
5975597|NCT01981850|9562088|FG005|Open Label Extension (OLE)|Informed Consent Withdrawn|0
5975598|NCT01981850|9562089|FG006|Open Label Extension (OLE)|Informed Consent Withdrawn|0
5975599|NCT01981850|9562090|FG007|Open Label Extension (OLE)|Informed Consent Withdrawn|0
5975600|NCT01981850|9562091|FG008|Open Label Extension (OLE)|Informed Consent Withdrawn|0
5975601|NCT01981850|9562092|FG009|Open Label Extension (OLE)|Informed Consent Withdrawn|8
5975602|NCT01981850|9562083|FG000|Open Label Extension (OLE)|Lost to Follow-up|0
5975603|NCT01981850|9562084|FG001|Open Label Extension (OLE)|Lost to Follow-up|0
5975604|NCT01981850|9562085|FG002|Open Label Extension (OLE)|Lost to Follow-up|0
5975605|NCT01981850|9562086|FG003|Open Label Extension (OLE)|Lost to Follow-up|0
6273125|NCT02186873|9976417|FG001|Overall Study|Lost to Follow-up|2
6273126|NCT02186873|9976416|FG000|Overall Study|Withdrawal by Subject|7
5975606|NCT01981850|9562087|FG004|Open Label Extension (OLE)|Lost to Follow-up|0
5975607|NCT01981850|9562088|FG005|Open Label Extension (OLE)|Lost to Follow-up|0
5975608|NCT01981850|9562089|FG006|Open Label Extension (OLE)|Lost to Follow-up|0
5975609|NCT01981850|9562090|FG007|Open Label Extension (OLE)|Lost to Follow-up|0
5975610|NCT01981850|9562091|FG008|Open Label Extension (OLE)|Lost to Follow-up|0
5975611|NCT01981850|9562092|FG009|Open Label Extension (OLE)|Lost to Follow-up|1
5975612|NCT01804816|9562124|FG000|No Acupuncture (Initial 5 Weeks)|Withdrawal by Subject|3
5975613|NCT01804816|9562124|FG000|Acupuncture (Second 5 Weeks)|Physician Decision|1
5975614|NCT01519960|9562158|FG000|Overall Study|Ongoing in Follow-Up|101
5975615|NCT01519960|9562159|FG001|Overall Study|Ongoing in Follow-Up|11
5975616|NCT01519960|9562160|FG002|Overall Study|Ongoing in Follow-Up|10
5975617|NCT01519960|9562158|FG000|Overall Study|Ongoing/Switched to PEG-IFN|0
5975618|NCT01519960|9562159|FG001|Overall Study|Ongoing/Switched to PEG-IFN|33
6193706|NCT01440569|9851515|FG001|Main Study|Enrolled but not treated|0
6193707|NCT01440569|9851514|FG000|Main Study|Adverse Event|9
6193708|NCT01440569|9851515|FG001|Main Study|Adverse Event|0
6193709|NCT01440569|9851514|FG000|Main Study|Pregnancy|1
6193710|NCT01440569|9851515|FG001|Main Study|Pregnancy|0
6193711|NCT01440569|9851514|FG000|Main Study|Investigator's Discretion|1
6193712|NCT01440569|9851515|FG001|Main Study|Investigator's Discretion|1
6193713|NCT01440569|9851514|FG000|Main Study|Withdrew Consent|7
6193714|NCT01440569|9851515|FG001|Main Study|Withdrew Consent|1
6193715|NCT01440569|9851514|FG000|Main Study|Lost to Follow-up|13
6273127|NCT02186873|9976417|FG001|Overall Study|Withdrawal by Subject|2
6273128|NCT02187029|9976454|FG000|Overall Study|Adverse Event|0
6273129|NCT02187029|9976455|FG001|Overall Study|Adverse Event|1
6273130|NCT02187029|9976456|FG002|Overall Study|Adverse Event|1
6273131|NCT02187029|9976457|FG003|Overall Study|Adverse Event|0
6273132|NCT02187029|9976454|FG000|Overall Study|Study Terminated by Sponsor|0
6273133|NCT02187029|9976455|FG001|Overall Study|Study Terminated by Sponsor|0
6273134|NCT02187029|9976456|FG002|Overall Study|Study Terminated by Sponsor|10
6273135|NCT02187029|9976457|FG003|Overall Study|Study Terminated by Sponsor|3
6273136|NCT02187029|9976454|FG000|Overall Study|Withdrawal by Subject|1
6273137|NCT02187029|9976455|FG001|Overall Study|Withdrawal by Subject|0
6273138|NCT02187029|9976456|FG002|Overall Study|Withdrawal by Subject|0
6273139|NCT02187029|9976457|FG003|Overall Study|Withdrawal by Subject|0
6273140|NCT02187042|9976469|FG000|Overall Study|Death|1
6273141|NCT02187042|9976470|FG001|Overall Study|Death|1
6273142|NCT02187042|9976469|FG000|Overall Study|Toxicity|6
6273143|NCT02187042|9976470|FG001|Overall Study|Toxicity|5
6273144|NCT02187042|9976469|FG000|Overall Study|Participant choice|1
6273145|NCT02187042|9976470|FG001|Overall Study|Participant choice|0
6273146|NCT02187042|9976469|FG000|Overall Study|Doctor choice|1
6273147|NCT02187042|9976470|FG001|Overall Study|Doctor choice|0
6273148|NCT02187042|9976469|FG000|Overall Study|Progressive disease|4
6273149|NCT02187042|9976470|FG001|Overall Study|Progressive disease|8
5975619|NCT01519960|9562160|FG002|Overall Study|Ongoing/Switched to PEG-IFN|0
5975620|NCT01519960|9562158|FG000|Overall Study|Adverse Event|0
5975621|NCT01519960|9562159|FG001|Overall Study|Adverse Event|1
5975622|NCT01519960|9562160|FG002|Overall Study|Adverse Event|0
5975623|NCT01519960|9562158|FG000|Overall Study|Withdrawal by Subject|0
5975624|NCT01519960|9562159|FG001|Overall Study|Withdrawal by Subject|4
5975625|NCT01519960|9562160|FG002|Overall Study|Withdrawal by Subject|0
5975626|NCT01519960|9562158|FG000|Overall Study|Lost to Follow-up|0
5975627|NCT01519960|9562159|FG001|Overall Study|Lost to Follow-up|1
5975628|NCT01519960|9562160|FG002|Overall Study|Lost to Follow-up|0
5975629|NCT00688376|9562173|FG000|Double-Blind Phase|Adverse Event|4
5975630|NCT00688376|9562174|FG001|Double-Blind Phase|Adverse Event|4
5975631|NCT00688376|9562173|FG000|Double-Blind Phase|Protocol Violation|1
5975632|NCT00688376|9562174|FG001|Double-Blind Phase|Protocol Violation|2
5975633|NCT00688376|9562173|FG000|Double-Blind Phase|Withdrawal by Subject|1
5975634|NCT00688376|9562174|FG001|Double-Blind Phase|Withdrawal by Subject|0
5975635|NCT00688376|9562173|FG000|Double-Blind Phase|Not treated|0
5975636|NCT00688376|9562174|FG001|Double-Blind Phase|Not treated|1
5975637|NCT00688376|9562173|FG000|Blinded Extension Phase|Adverse Event|3
5975638|NCT00688376|9562174|FG001|Blinded Extension Phase|Adverse Event|4
5975639|NCT00688376|9562173|FG000|Blinded Extension Phase|Withdrawal by Subject|0
5975640|NCT00688376|9562174|FG001|Blinded Extension Phase|Withdrawal by Subject|1
5975641|NCT00688376|9562173|FG000|Blinded Extension Phase|Physician Decision|1
5975642|NCT00688376|9562174|FG001|Blinded Extension Phase|Physician Decision|0
5975643|NCT00688376|9562173|FG000|Blinded Extension Phase|Other|1
5975644|NCT00688376|9562174|FG001|Blinded Extension Phase|Other|0
5975645|NCT00121108|9562201|FG000|Overall Study|Lost to Follow-up|10
5975646|NCT00121108|9562202|FG001|Overall Study|Lost to Follow-up|22
5975647|NCT00121108|9562201|FG000|Overall Study|Withdrawal by Subject|106
5975648|NCT00121108|9562202|FG001|Overall Study|Withdrawal by Subject|195
5975649|NCT00121108|9562201|FG000|Overall Study|Death|5
5975650|NCT00121108|9562202|FG001|Overall Study|Death|8
5975651|NCT00003102|9562212|FG000|Overall Study|Physician Decision|1
5975652|NCT00003102|9562213|FG001|Overall Study|Physician Decision|1
5975653|NCT00003102|9562214|FG002|Overall Study|Physician Decision|0
5975654|NCT00003102|9562212|FG000|Overall Study|Progressive Disease|0
5975655|NCT00003102|9562213|FG001|Overall Study|Progressive Disease|1
5975656|NCT00003102|9562214|FG002|Overall Study|Progressive Disease|0
5975657|NCT00003102|9562212|FG000|Overall Study|Adverse Event|0
5975658|NCT00003102|9562213|FG001|Overall Study|Adverse Event|1
5975659|NCT00003102|9562214|FG002|Overall Study|Adverse Event|1
5975660|NCT00003102|9562212|FG000|Overall Study|Death|0
5975661|NCT00003102|9562213|FG001|Overall Study|Death|0
5975662|NCT00003102|9562214|FG002|Overall Study|Death|1
6050406|NCT00427895|9649717|FG000|Vax 2/Year 3 to 4|Protocol Violation|0
6050407|NCT00427895|9649718|FG001|Vax 2/Year 3 to 4|Protocol Violation|0
6050408|NCT00427895|9649719|FG002|Vax 2/Year 3 to 4|Protocol Violation|0
6050409|NCT00427895|9649720|FG003|Vax 2/Year 3 to 4|Protocol Violation|0
6050410|NCT00427895|9649721|FG004|Vax 2/Year 3 to 4|Protocol Violation|0
6088217|NCT00673894|9698936|FG001|First Intervention 4 Weeks|Withdrawal by Subject|0
6193716|NCT01440569|9851515|FG001|Main Study|Lost to Follow-up|2
6193717|NCT01440569|9851514|FG000|Main Study|Subject Non-Compliance|3
6193718|NCT01440569|9851515|FG001|Main Study|Subject Non-Compliance|0
6193719|NCT01440569|9851514|FG000|Main Study|Protocol Violation|1
6193720|NCT01440569|9851515|FG001|Main Study|Protocol Violation|0
6193721|NCT01440569|9851514|FG000|Open-Label Rollover Phase|Adverse Event|3
6193722|NCT01440569|9851515|FG001|Open-Label Rollover Phase|Adverse Event|0
6050411|NCT00427895|9649722|FG005|Vax 2/Year 3 to 4|Protocol Violation|0
6050412|NCT00427895|9649723|FG006|Vax 2/Year 3 to 4|Protocol Violation|0
6088218|NCT00673894|9698935|FG000|First Intervention 4 Weeks|Adverse Event|1
6088219|NCT00673894|9698936|FG001|First Intervention 4 Weeks|Adverse Event|0
6088220|NCT00673920|9698950|FG000|Baseline up to Week 48|Withdrew consent|1
6088221|NCT00673920|9698951|FG001|Baseline up to Week 48|Withdrew consent|0
6088222|NCT00673920|9698952|FG002|Baseline up to Week 48|Withdrew consent|2
6088223|NCT00673920|9698953|FG003|Baseline up to Week 48|Withdrew consent|0
6088224|NCT00673920|9698954|FG004|Baseline up to Week 48|Withdrew consent|0
6088225|NCT00673920|9698955|FG005|Baseline up to Week 48|Withdrew consent|0
6088226|NCT00673920|9698956|FG006|Baseline up to Week 48|Withdrew consent|0
6088227|NCT00673920|9698957|FG007|Baseline up to Week 48|Withdrew consent|0
6088228|NCT00673920|9698950|FG000|Baseline up to Week 48|Refused treatment|1
6088229|NCT00673920|9698951|FG001|Baseline up to Week 48|Refused treatment|0
6088230|NCT00673920|9698952|FG002|Baseline up to Week 48|Refused treatment|0
6088231|NCT00673920|9698953|FG003|Baseline up to Week 48|Refused treatment|0
6088232|NCT00673920|9698954|FG004|Baseline up to Week 48|Refused treatment|0
6088233|NCT00673920|9698955|FG005|Baseline up to Week 48|Refused treatment|0
6088234|NCT00673920|9698956|FG006|Baseline up to Week 48|Refused treatment|0
6088235|NCT00673920|9698957|FG007|Baseline up to Week 48|Refused treatment|0
6088236|NCT00673920|9698950|FG000|Baseline up to Week 48|Insufficient therapeutic response|2
6193723|NCT01440569|9851514|FG000|Open-Label Rollover Phase|Pregnancy|1
6050413|NCT00427895|9649724|FG007|Vax 2/Year 3 to 4|Protocol Violation|1
6050414|NCT00427895|9649717|FG000|Vax 2/Year 3 to 4|Failed to Return|0
6193724|NCT01440569|9851515|FG001|Open-Label Rollover Phase|Pregnancy|0
6193725|NCT01440569|9851514|FG000|Open-Label Rollover Phase|Lack of Efficacy|2
5975663|NCT04633837|9562224|FG000|Overall Study|Participant outcomes data not collected due to technical errors.|5
5975664|NCT04633837|9562225|FG001|Overall Study|Participant outcomes data not collected due to technical errors.|0
5975665|NCT04352127|9562234|FG000|Overall Study|Unable to obtain readings|4
5975666|NCT04352127|9562235|FG001|Overall Study|Unable to obtain readings|1
5975667|NCT04352127|9562236|FG002|Overall Study|Unable to obtain readings|0
5975668|NCT04057937|9562246|FG000|Placebo-controlled Phase|Adverse Event|3
5975669|NCT04057937|9562247|FG001|Placebo-controlled Phase|Adverse Event|0
5975670|NCT04057937|9562246|FG000|Active-treatment Phase|Withdrawal by Subject|1
5975671|NCT04057937|9562247|FG001|Active-treatment Phase|Withdrawal by Subject|0
5975672|NCT04057937|9562246|FG000|Active-treatment Phase|Pregnancy|0
5975673|NCT04057937|9562247|FG001|Active-treatment Phase|Pregnancy|1
5975674|NCT04057937|9562246|FG000|Active-treatment Phase|Physician Decision|0
5975675|NCT04057937|9562247|FG001|Active-treatment Phase|Physician Decision|1
5975676|NCT03032510|9562260|FG000|Overall Study|Adverse Event|5
5975677|NCT03032510|9562261|FG001|Overall Study|Adverse Event|2
5975678|NCT03032510|9562260|FG000|Overall Study|Lost to Follow-up|8
5975679|NCT03032510|9562261|FG001|Overall Study|Lost to Follow-up|7
5975680|NCT03032510|9562260|FG000|Overall Study|Withdrawal by Subject|8
5975681|NCT03032510|9562261|FG001|Overall Study|Withdrawal by Subject|7
5975682|NCT03032510|9562260|FG000|Overall Study|Subject noncompliance|4
6050415|NCT00427895|9649718|FG001|Vax 2/Year 3 to 4|Failed to Return|0
6050416|NCT00427895|9649719|FG002|Vax 2/Year 3 to 4|Failed to Return|0
6050417|NCT00427895|9649720|FG003|Vax 2/Year 3 to 4|Failed to Return|0
6050418|NCT00427895|9649721|FG004|Vax 2/Year 3 to 4|Failed to Return|1
6050419|NCT00427895|9649722|FG005|Vax 2/Year 3 to 4|Failed to Return|0
6050420|NCT00427895|9649723|FG006|Vax 2/Year 3 to 4|Failed to Return|0
6050421|NCT00427895|9649724|FG007|Vax 2/Year 3 to 4|Failed to Return|0
6050422|NCT00427895|9649717|FG000|Vax 1 Baseline/6-Month Follow-up|Lost to Follow-up|0
6050423|NCT00427895|9649718|FG001|Vax 1 Baseline/6-Month Follow-up|Lost to Follow-up|1
6050424|NCT00427895|9649719|FG002|Vax 1 Baseline/6-Month Follow-up|Lost to Follow-up|4
6050425|NCT00427895|9649720|FG003|Vax 1 Baseline/6-Month Follow-up|Lost to Follow-up|32
6050426|NCT00427895|9649721|FG004|Vax 1 Baseline/6-Month Follow-up|Lost to Follow-up|0
6050427|NCT00427895|9649722|FG005|Vax 1 Baseline/6-Month Follow-up|Lost to Follow-up|0
6050428|NCT00427895|9649723|FG006|Vax 1 Baseline/6-Month Follow-up|Lost to Follow-up|0
6050429|NCT00427895|9649724|FG007|Vax 1 Baseline/6-Month Follow-up|Lost to Follow-up|0
6050430|NCT00427895|9649717|FG000|Vax 1 Baseline/6-Month Follow-up|Protocol Violation|4
6050431|NCT00427895|9649718|FG001|Vax 1 Baseline/6-Month Follow-up|Protocol Violation|0
6050432|NCT00427895|9649719|FG002|Vax 1 Baseline/6-Month Follow-up|Protocol Violation|3
6050433|NCT00427895|9649720|FG003|Vax 1 Baseline/6-Month Follow-up|Protocol Violation|2
6050434|NCT00427895|9649721|FG004|Vax 1 Baseline/6-Month Follow-up|Protocol Violation|0
6050435|NCT00427895|9649722|FG005|Vax 1 Baseline/6-Month Follow-up|Protocol Violation|0
6050436|NCT00427895|9649723|FG006|Vax 1 Baseline/6-Month Follow-up|Protocol Violation|0
6050437|NCT00427895|9649724|FG007|Vax 1 Baseline/6-Month Follow-up|Protocol Violation|0
6050438|NCT00427895|9649717|FG000|Vax 1 Baseline/6-Month Follow-up|Physician Decision|1
6050439|NCT00427895|9649718|FG001|Vax 1 Baseline/6-Month Follow-up|Physician Decision|1
6050440|NCT00427895|9649719|FG002|Vax 1 Baseline/6-Month Follow-up|Physician Decision|0
6050441|NCT00427895|9649720|FG003|Vax 1 Baseline/6-Month Follow-up|Physician Decision|0
6050442|NCT00427895|9649721|FG004|Vax 1 Baseline/6-Month Follow-up|Physician Decision|0
6050443|NCT00427895|9649722|FG005|Vax 1 Baseline/6-Month Follow-up|Physician Decision|0
6050444|NCT00427895|9649723|FG006|Vax 1 Baseline/6-Month Follow-up|Physician Decision|0
6050445|NCT00427895|9649724|FG007|Vax 1 Baseline/6-Month Follow-up|Physician Decision|0
6050446|NCT00427895|9649717|FG000|Vax 1 Baseline/6-Month Follow-up|Withdrawal by Subject|1
6050447|NCT00427895|9649718|FG001|Vax 1 Baseline/6-Month Follow-up|Withdrawal by Subject|1
6050448|NCT00427895|9649719|FG002|Vax 1 Baseline/6-Month Follow-up|Withdrawal by Subject|4
6050449|NCT00427895|9649720|FG003|Vax 1 Baseline/6-Month Follow-up|Withdrawal by Subject|7
6050450|NCT00427895|9649721|FG004|Vax 1 Baseline/6-Month Follow-up|Withdrawal by Subject|0
6050451|NCT00427895|9649722|FG005|Vax 1 Baseline/6-Month Follow-up|Withdrawal by Subject|0
6050452|NCT00427895|9649723|FG006|Vax 1 Baseline/6-Month Follow-up|Withdrawal by Subject|0
6050453|NCT00427895|9649724|FG007|Vax 1 Baseline/6-Month Follow-up|Withdrawal by Subject|0
6050454|NCT00427895|9649717|FG000|Vax 1 Baseline/6-Month Follow-up|Failed to Return|0
6050455|NCT00427895|9649718|FG001|Vax 1 Baseline/6-Month Follow-up|Failed to Return|0
6050456|NCT00427895|9649719|FG002|Vax 1 Baseline/6-Month Follow-up|Failed to Return|0
6050457|NCT00427895|9649720|FG003|Vax 1 Baseline/6-Month Follow-up|Failed to Return|2
6050458|NCT00427895|9649721|FG004|Vax 1 Baseline/6-Month Follow-up|Failed to Return|0
6050459|NCT00427895|9649722|FG005|Vax 1 Baseline/6-Month Follow-up|Failed to Return|0
6050460|NCT00427895|9649723|FG006|Vax 1 Baseline/6-Month Follow-up|Failed to Return|0
6050461|NCT00427895|9649724|FG007|Vax 1 Baseline/6-Month Follow-up|Failed to Return|0
6050462|NCT00427895|9649717|FG000|Vax 1 Baseline/6-Month Follow-up|Randomized, Not Vaccinated|1
6050463|NCT00427895|9649718|FG001|Vax 1 Baseline/6-Month Follow-up|Randomized, Not Vaccinated|3
6050464|NCT00427895|9649719|FG002|Vax 1 Baseline/6-Month Follow-up|Randomized, Not Vaccinated|2
6050465|NCT00427895|9649720|FG003|Vax 1 Baseline/6-Month Follow-up|Randomized, Not Vaccinated|1
6273150|NCT02187055|9976480|FG000|Overall Study|Lack of Efficacy|10
6273151|NCT02187055|9976481|FG001|Overall Study|Lack of Efficacy|3
5975683|NCT03032510|9562261|FG001|Overall Study|Subject noncompliance|2
5975684|NCT03032510|9562260|FG000|Overall Study|Physician Decision|2
5975685|NCT03032510|9562261|FG001|Overall Study|Physician Decision|0
5975686|NCT02946047|9562292|FG000|Overall Study|Adverse Event|1
5975687|NCT02946047|9562293|FG001|Overall Study|Adverse Event|0
5975688|NCT02946047|9562294|FG002|Overall Study|Adverse Event|0
5975689|NCT02946047|9562295|FG003|Overall Study|Adverse Event|0
5975690|NCT02784704|9562313|FG000|Overall Study|Adverse Event|4
5975691|NCT02784704|9562314|FG001|Overall Study|Adverse Event|2
5975692|NCT02784704|9562313|FG000|Overall Study|Lost to Follow-up|6
5975693|NCT02784704|9562314|FG001|Overall Study|Lost to Follow-up|4
5975694|NCT02784704|9562313|FG000|Overall Study|Withdrawal by Subject|1
5975695|NCT02784704|9562314|FG001|Overall Study|Withdrawal by Subject|3
5975696|NCT02784704|9562313|FG000|Overall Study|Subject Non Compliance|2
5975697|NCT02784704|9562314|FG001|Overall Study|Subject Non Compliance|0
6050466|NCT00427895|9649721|FG004|Vax 1 Baseline/6-Month Follow-up|Randomized, Not Vaccinated|0
6050467|NCT00427895|9649722|FG005|Vax 1 Baseline/6-Month Follow-up|Randomized, Not Vaccinated|0
6050468|NCT00427895|9649723|FG006|Vax 1 Baseline/6-Month Follow-up|Randomized, Not Vaccinated|0
6050469|NCT00427895|9649724|FG007|Vax 1 Baseline/6-Month Follow-up|Randomized, Not Vaccinated|0
6050470|NCT00427895|9649717|FG000|Vax 1 Baseline/6-Month Follow-up|Other|0
6050471|NCT00427895|9649718|FG001|Vax 1 Baseline/6-Month Follow-up|Other|0
6050472|NCT00427895|9649719|FG002|Vax 1 Baseline/6-Month Follow-up|Other|1
6050473|NCT00427895|9649720|FG003|Vax 1 Baseline/6-Month Follow-up|Other|2
6050474|NCT00427895|9649721|FG004|Vax 1 Baseline/6-Month Follow-up|Other|0
6050475|NCT00427895|9649722|FG005|Vax 1 Baseline/6-Month Follow-up|Other|0
6050476|NCT00427895|9649723|FG006|Vax 1 Baseline/6-Month Follow-up|Other|0
6050477|NCT00427895|9649724|FG007|Vax 1 Baseline/6-Month Follow-up|Other|0
6050478|NCT00427895|9649717|FG000|Vax 1/Year 1 Follow-up|Lost to Follow-up|0
6050479|NCT00427895|9649718|FG001|Vax 1/Year 1 Follow-up|Lost to Follow-up|5
6050480|NCT00427895|9649719|FG002|Vax 1/Year 1 Follow-up|Lost to Follow-up|2
6050481|NCT00427895|9649720|FG003|Vax 1/Year 1 Follow-up|Lost to Follow-up|21
6050482|NCT00427895|9649721|FG004|Vax 1/Year 1 Follow-up|Lost to Follow-up|0
6050483|NCT00427895|9649722|FG005|Vax 1/Year 1 Follow-up|Lost to Follow-up|0
6050484|NCT00427895|9649723|FG006|Vax 1/Year 1 Follow-up|Lost to Follow-up|0
6050485|NCT00427895|9649724|FG007|Vax 1/Year 1 Follow-up|Lost to Follow-up|0
6050486|NCT00427895|9649717|FG000|Vax 1/Year 1 Follow-up|Protocol Violation|3
6050487|NCT00427895|9649718|FG001|Vax 1/Year 1 Follow-up|Protocol Violation|3
6050488|NCT00427895|9649719|FG002|Vax 1/Year 1 Follow-up|Protocol Violation|0
6050489|NCT00427895|9649720|FG003|Vax 1/Year 1 Follow-up|Protocol Violation|1
6050490|NCT00427895|9649721|FG004|Vax 1/Year 1 Follow-up|Protocol Violation|0
6050491|NCT00427895|9649722|FG005|Vax 1/Year 1 Follow-up|Protocol Violation|0
6050492|NCT00427895|9649723|FG006|Vax 1/Year 1 Follow-up|Protocol Violation|0
6050493|NCT00427895|9649724|FG007|Vax 1/Year 1 Follow-up|Protocol Violation|0
6050494|NCT00427895|9649717|FG000|Vax 1/Year 1 Follow-up|Withdrawal by Subject|3
6050495|NCT00427895|9649718|FG001|Vax 1/Year 1 Follow-up|Withdrawal by Subject|6
6050496|NCT00427895|9649719|FG002|Vax 1/Year 1 Follow-up|Withdrawal by Subject|5
6050497|NCT00427895|9649720|FG003|Vax 1/Year 1 Follow-up|Withdrawal by Subject|4
6050498|NCT00427895|9649721|FG004|Vax 1/Year 1 Follow-up|Withdrawal by Subject|0
6050499|NCT00427895|9649722|FG005|Vax 1/Year 1 Follow-up|Withdrawal by Subject|0
6050500|NCT00427895|9649723|FG006|Vax 1/Year 1 Follow-up|Withdrawal by Subject|0
6050501|NCT00427895|9649724|FG007|Vax 1/Year 1 Follow-up|Withdrawal by Subject|0
6050502|NCT00427895|9649717|FG000|Vax 1/Year 1 Follow-up|Adverse Event|0
6050503|NCT00427895|9649718|FG001|Vax 1/Year 1 Follow-up|Adverse Event|1
6050504|NCT00427895|9649719|FG002|Vax 1/Year 1 Follow-up|Adverse Event|0
6050505|NCT00427895|9649720|FG003|Vax 1/Year 1 Follow-up|Adverse Event|0
6050506|NCT00427895|9649721|FG004|Vax 1/Year 1 Follow-up|Adverse Event|0
6050507|NCT00427895|9649722|FG005|Vax 1/Year 1 Follow-up|Adverse Event|0
6050508|NCT00427895|9649723|FG006|Vax 1/Year 1 Follow-up|Adverse Event|0
6050509|NCT00427895|9649724|FG007|Vax 1/Year 1 Follow-up|Adverse Event|0
6050510|NCT00427895|9649717|FG000|Vax 1/Year 1 Follow-up|Death|1
6050511|NCT00427895|9649718|FG001|Vax 1/Year 1 Follow-up|Death|0
6050512|NCT00427895|9649719|FG002|Vax 1/Year 1 Follow-up|Death|0
6050513|NCT00427895|9649720|FG003|Vax 1/Year 1 Follow-up|Death|0
6050514|NCT00427895|9649721|FG004|Vax 1/Year 1 Follow-up|Death|0
6050515|NCT00427895|9649722|FG005|Vax 1/Year 1 Follow-up|Death|0
6050516|NCT00427895|9649723|FG006|Vax 1/Year 1 Follow-up|Death|0
6050517|NCT00427895|9649724|FG007|Vax 1/Year 1 Follow-up|Death|0
6050518|NCT00427895|9649717|FG000|Vax 1/Year 1 Follow-up|Failed to Return|0
6050519|NCT00427895|9649718|FG001|Vax 1/Year 1 Follow-up|Failed to Return|0
6050520|NCT00427895|9649719|FG002|Vax 1/Year 1 Follow-up|Failed to Return|12
6050521|NCT00427895|9649720|FG003|Vax 1/Year 1 Follow-up|Failed to Return|5
6050522|NCT00427895|9649721|FG004|Vax 1/Year 1 Follow-up|Failed to Return|0
6050523|NCT00427895|9649722|FG005|Vax 1/Year 1 Follow-up|Failed to Return|0
6050524|NCT00427895|9649723|FG006|Vax 1/Year 1 Follow-up|Failed to Return|0
6050525|NCT00427895|9649724|FG007|Vax 1/Year 1 Follow-up|Failed to Return|0
6050526|NCT00427895|9649717|FG000|Vax 1/Year 1 Follow-up|Other|0
6050527|NCT00427895|9649718|FG001|Vax 1/Year 1 Follow-up|Other|0
6050528|NCT00427895|9649719|FG002|Vax 1/Year 1 Follow-up|Other|0
6050529|NCT00427895|9649720|FG003|Vax 1/Year 1 Follow-up|Other|2
6050530|NCT00427895|9649721|FG004|Vax 1/Year 1 Follow-up|Other|0
6050531|NCT00427895|9649722|FG005|Vax 1/Year 1 Follow-up|Other|0
6050532|NCT00427895|9649723|FG006|Vax 1/Year 1 Follow-up|Other|0
5975698|NCT04831515|9562322|FG000|First Intervention|Adverse Event|0
5975699|NCT04831515|9562323|FG001|First Intervention|Adverse Event|1
5975700|NCT03881059|9562354|FG000|Treatment Period - Part A|Adverse Event|1
5975701|NCT03881059|9562355|FG001|Treatment Period - Part A|Adverse Event|3
5975702|NCT03881059|9562356|FG002|Treatment Period - Part A|Adverse Event|4
5975703|NCT03881059|9562354|FG000|Treatment Period - Part A|Randomized by mistake with study treatment|0
5975704|NCT03881059|9562355|FG001|Treatment Period - Part A|Randomized by mistake with study treatment|1
5975705|NCT03881059|9562356|FG002|Treatment Period - Part A|Randomized by mistake with study treatment|1
5975706|NCT03881059|9562354|FG000|Treatment Period - Part A|Withdrawal by Subject|5
5975707|NCT03881059|9562355|FG001|Treatment Period - Part A|Withdrawal by Subject|2
5975708|NCT03881059|9562356|FG002|Treatment Period - Part A|Withdrawal by Subject|3
5975709|NCT03881059|9562354|FG000|Treatment Period - Part A|Other reasons|2
5975710|NCT03881059|9562355|FG001|Treatment Period - Part A|Other reasons|1
5975711|NCT03881059|9562356|FG002|Treatment Period - Part A|Other reasons|0
5975712|NCT03881059|9562354|FG000|Treatment Period - Part B|Adverse Event|0
5975713|NCT03881059|9562355|FG001|Treatment Period - Part B|Adverse Event|0
5975714|NCT03881059|9562356|FG002|Treatment Period - Part B|Adverse Event|3
5975715|NCT03881059|9562354|FG000|Treatment Period - Part B|Death|0
5975716|NCT03881059|9562355|FG001|Treatment Period - Part B|Death|1
5975717|NCT03881059|9562356|FG002|Treatment Period - Part B|Death|1
5975718|NCT03881059|9562354|FG000|Treatment Period - Part B|Lack of Efficacy|1
5975719|NCT03881059|9562355|FG001|Treatment Period - Part B|Lack of Efficacy|1
5975720|NCT03881059|9562356|FG002|Treatment Period - Part B|Lack of Efficacy|0
5975721|NCT03881059|9562354|FG000|Treatment Period - Part B|Lost to Follow-up|1
5975722|NCT03881059|9562355|FG001|Treatment Period - Part B|Lost to Follow-up|1
5975723|NCT03881059|9562356|FG002|Treatment Period - Part B|Lost to Follow-up|0
5975724|NCT03881059|9562354|FG000|Treatment Period - Part B|Site terminated by sponsor|1
5975725|NCT03881059|9562355|FG001|Treatment Period - Part B|Site terminated by sponsor|0
5975726|NCT03881059|9562356|FG002|Treatment Period - Part B|Site terminated by sponsor|3
5975727|NCT03881059|9562354|FG000|Treatment Period - Part B|Withdrawal by Subject|1
5975728|NCT03881059|9562355|FG001|Treatment Period - Part B|Withdrawal by Subject|0
5975729|NCT03881059|9562356|FG002|Treatment Period - Part B|Withdrawal by Subject|1
5975730|NCT03881059|9562354|FG000|Treatment Period - Part B|Other reasons|4
5975731|NCT03881059|9562355|FG001|Treatment Period - Part B|Other reasons|3
5975732|NCT03881059|9562356|FG002|Treatment Period - Part B|Other reasons|3
5975733|NCT03450629|9562375|FG000|Overall Study|Adverse Event|15
5975734|NCT03450629|9562376|FG001|Overall Study|Adverse Event|14
5975735|NCT03450629|9562375|FG000|Overall Study|Physician Decision|2
5975736|NCT03450629|9562376|FG001|Overall Study|Physician Decision|2
5975737|NCT03450629|9562375|FG000|Overall Study|Lack of Efficacy|2
5975738|NCT03450629|9562376|FG001|Overall Study|Lack of Efficacy|0
5975739|NCT03450629|9562375|FG000|Overall Study|Lost to Follow-up|4
5975740|NCT03450629|9562376|FG001|Overall Study|Lost to Follow-up|2
5975741|NCT03450629|9562375|FG000|Overall Study|No Longer Meets Eligibility Criteria|0
5975742|NCT03450629|9562376|FG001|Overall Study|No Longer Meets Eligibility Criteria|1
5975743|NCT03450629|9562375|FG000|Overall Study|Non-Compliance With Study Drug|2
5975744|NCT03450629|9562376|FG001|Overall Study|Non-Compliance With Study Drug|1
5975745|NCT03450629|9562375|FG000|Overall Study|Protocol Violation|11
5975746|NCT03450629|9562376|FG001|Overall Study|Protocol Violation|8
5975747|NCT03450629|9562375|FG000|Overall Study|Withdrawal by Subject|12
5975748|NCT03450629|9562376|FG001|Overall Study|Withdrawal by Subject|6
5975749|NCT03367403|9562385|FG000|Overall Study|Adverse Event|20
5975750|NCT03367403|9562386|FG001|Overall Study|Adverse Event|6
5975751|NCT03367403|9562387|FG002|Overall Study|Adverse Event|2
5975752|NCT03367403|9562385|FG000|Overall Study|Withdrawal by Subject|12
5975753|NCT03367403|9562386|FG001|Overall Study|Withdrawal by Subject|12
5975754|NCT03367403|9562387|FG002|Overall Study|Withdrawal by Subject|1
5975755|NCT03367403|9562385|FG000|Overall Study|Death|1
5975756|NCT03367403|9562386|FG001|Overall Study|Death|2
5975757|NCT03367403|9562387|FG002|Overall Study|Death|0
5975758|NCT03367403|9562385|FG000|Overall Study|Physician Decision|0
5975759|NCT03367403|9562386|FG001|Overall Study|Physician Decision|1
5975760|NCT03367403|9562387|FG002|Overall Study|Physician Decision|0
5975761|NCT03367403|9562385|FG000|Overall Study|Protocol Violation|1
5975762|NCT03367403|9562386|FG001|Overall Study|Protocol Violation|1
5975763|NCT03367403|9562387|FG002|Overall Study|Protocol Violation|0
5975764|NCT03367403|9562385|FG000|Overall Study|Withdrawal Due to Caregiver Circumstances|0
5975765|NCT03367403|9562386|FG001|Overall Study|Withdrawal Due to Caregiver Circumstances|2
5975766|NCT03367403|9562387|FG002|Overall Study|Withdrawal Due to Caregiver Circumstances|0
5975767|NCT03367403|9562385|FG000|Overall Study|COVID-19|3
5975768|NCT03367403|9562386|FG001|Overall Study|COVID-19|7
5975769|NCT03367403|9562387|FG002|Overall Study|COVID-19|0
5975770|NCT03367403|9562385|FG000|Overall Study|Abuse of Alcohol Intake|0
5975771|NCT03367403|9562386|FG001|Overall Study|Abuse of Alcohol Intake|1
5975772|NCT03367403|9562387|FG002|Overall Study|Abuse of Alcohol Intake|0
5975773|NCT03367403|9562385|FG000|Overall Study|Subject and Study Partner do not believe study has been Beneficial and Cognition has Declined|0
5975774|NCT03367403|9562386|FG001|Overall Study|Subject and Study Partner do not believe study has been Beneficial and Cognition has Declined|1
5975775|NCT03367403|9562387|FG002|Overall Study|Subject and Study Partner do not believe study has been Beneficial and Cognition has Declined|0
5975776|NCT03286426|9562395|FG000|Overall Study|Physician Decision|3
6050533|NCT00427895|9649724|FG007|Vax 1/Year 1 Follow-up|Other|0
6050534|NCT00427895|9649717|FG000|Between Year 1 - Vax 2/Year 3 to 4|Did Not Consent to Receive Vax 2|188
6050535|NCT00427895|9649718|FG001|Between Year 1 - Vax 2/Year 3 to 4|Did Not Consent to Receive Vax 2|207
6050536|NCT00427895|9649719|FG002|Between Year 1 - Vax 2/Year 3 to 4|Did Not Consent to Receive Vax 2|159
6050537|NCT00427895|9649720|FG003|Between Year 1 - Vax 2/Year 3 to 4|Did Not Consent to Receive Vax 2|469
6050538|NCT00427895|9649721|FG004|Between Year 1 - Vax 2/Year 3 to 4|Did Not Consent to Receive Vax 2|0
6050539|NCT00427895|9649722|FG005|Between Year 1 - Vax 2/Year 3 to 4|Did Not Consent to Receive Vax 2|0
6050540|NCT00427895|9649723|FG006|Between Year 1 - Vax 2/Year 3 to 4|Did Not Consent to Receive Vax 2|0
6050541|NCT00427895|9649724|FG007|Between Year 1 - Vax 2/Year 3 to 4|Did Not Consent to Receive Vax 2|0
6050542|NCT00427908|9649767|FG000|Primary Phase|Lost to Follow-up|4
6050543|NCT00427908|9649768|FG001|Primary Phase|Lost to Follow-up|0
6050544|NCT00427908|9649769|FG002|Primary Phase|Lost to Follow-up|2
6050545|NCT00427908|9649770|FG003|Primary Phase|Lost to Follow-up|0
6050546|NCT00427908|9649767|FG000|Primary Phase|Withdrawal by Subject|1
6050547|NCT00427908|9649768|FG001|Primary Phase|Withdrawal by Subject|2
6050548|NCT00427908|9649769|FG002|Primary Phase|Withdrawal by Subject|1
6050549|NCT00427908|9649770|FG003|Primary Phase|Withdrawal by Subject|0
6050550|NCT00427908|9649767|FG000|Primary Phase|Adverse Event|0
6050551|NCT00427908|9649768|FG001|Primary Phase|Adverse Event|1
6050552|NCT00427908|9649769|FG002|Primary Phase|Adverse Event|0
6050553|NCT00427908|9649770|FG003|Primary Phase|Adverse Event|0
6050554|NCT00427921|9649805|FG000|Overall Study|Adverse Event|26
6050555|NCT00427921|9649805|FG000|Overall Study|Withdrawal by Subject|4
6050556|NCT00427921|9649805|FG000|Overall Study|Lost to Follow-up|2
6050557|NCT00427921|9649805|FG000|Overall Study|Other reason not specified|10
6050558|NCT00427921|9649805|FG000|Overall Study|Adverse Event + Hospitalization|1
6050559|NCT00427921|9649805|FG000|Overall Study|Adverse Event + Withdrew Consent|1
6050560|NCT00427921|9649805|FG000|Overall Study|Adverse Event + No Response|1
6050561|NCT00427921|9649805|FG000|Overall Study|Adverse Event + Worsening of CD|1
6050562|NCT00427921|9649805|FG000|Overall Study|Adverse Event + No Therapeutic Benefit|1
6050563|NCT00427921|9649805|FG000|Overall Study|Adverse Event + Lost Response|1
6050564|NCT00427921|9649805|FG000|Overall Study|Adverse Event + Withdrawn from Study|1
6050565|NCT00427921|9649805|FG000|Overall Study|Withdrew Consent + Lack of Efficacy|1
6050566|NCT00427934|9649813|FG000|Overall Study|Adverse Event|1
6050567|NCT00427934|9649814|FG001|Overall Study|Adverse Event|0
6050568|NCT00427934|9649815|FG002|Overall Study|Adverse Event|5
6050569|NCT00427934|9649816|FG003|Overall Study|Adverse Event|4
6050570|NCT00427934|9649813|FG000|Overall Study|Lack of Efficacy|0
6050571|NCT00427934|9649814|FG001|Overall Study|Lack of Efficacy|0
6050572|NCT00427934|9649815|FG002|Overall Study|Lack of Efficacy|5
6050573|NCT00427934|9649816|FG003|Overall Study|Lack of Efficacy|2
6050574|NCT00427934|9649813|FG000|Overall Study|Randomized But Did Not Receive Treatment|0
6050575|NCT00427934|9649814|FG001|Overall Study|Randomized But Did Not Receive Treatment|0
6193726|NCT01440569|9851515|FG001|Open-Label Rollover Phase|Lack of Efficacy|0
6193727|NCT01440569|9851514|FG000|Open-Label Rollover Phase|Investigator's Discretion|3
6193728|NCT01440569|9851515|FG001|Open-Label Rollover Phase|Investigator's Discretion|1
6193729|NCT01440569|9851514|FG000|Open-Label Rollover Phase|Withdrew Consent|11
6193730|NCT01440569|9851515|FG001|Open-Label Rollover Phase|Withdrew Consent|1
6193731|NCT01440569|9851514|FG000|Open-Label Rollover Phase|Lost to Follow-up|26
6193732|NCT01440569|9851515|FG001|Open-Label Rollover Phase|Lost to Follow-up|3
6193733|NCT01440569|9851514|FG000|Open-Label Rollover Phase|Subject Non-Compliance|1
6193734|NCT01440569|9851515|FG001|Open-Label Rollover Phase|Subject Non-Compliance|1
6193735|NCT01440647|9851532|FG000|Overall Study|Death|2
6193736|NCT01440647|9851533|FG001|Overall Study|Death|3
6193737|NCT01440803|9851567|FG000|Overall Study|Met study stopping rule|2
6193738|NCT01440803|9851568|FG001|Overall Study|Met study stopping rule|1
6193739|NCT01440803|9851567|FG000|Overall Study|Lost to Follow-up|0
6193740|NCT01440803|9851568|FG001|Overall Study|Lost to Follow-up|2
6193741|NCT01440803|9851567|FG000|Overall Study|Withdrawal by Subject|0
6193742|NCT01440803|9851568|FG001|Overall Study|Withdrawal by Subject|1
6193743|NCT01440816|9851577|FG000|Overall Study|Disease Progression|0
6193744|NCT01440816|9851578|FG001|Overall Study|Disease Progression|9
6193745|NCT01440816|9851577|FG000|Overall Study|To Be Seen By Local Oncologist|1
6193746|NCT01440816|9851578|FG001|Overall Study|To Be Seen By Local Oncologist|2
6273152|NCT02187055|9976482|FG002|Overall Study|Lack of Efficacy|7
6050576|NCT00427934|9649815|FG002|Overall Study|Randomized But Did Not Receive Treatment|1
6050577|NCT00427934|9649816|FG003|Overall Study|Randomized But Did Not Receive Treatment|1
6050578|NCT00427934|9649813|FG000|Overall Study|Other|0
6050579|NCT00427934|9649814|FG001|Overall Study|Other|0
6050580|NCT00427934|9649815|FG002|Overall Study|Other|11
6050581|NCT00427934|9649816|FG003|Overall Study|Other|5
6193747|NCT01440881|9851588|FG000|Overall Study|Death|0
6193748|NCT01440881|9851589|FG001|Overall Study|Death|1
6193749|NCT01440946|9851611|FG000|Overall Study|Lost to Follow-up|1
6193750|NCT01440946|9851612|FG001|Overall Study|Lost to Follow-up|1
6193751|NCT01440946|9851611|FG000|Overall Study|Physician Decision|1
6050582|NCT00427934|9649813|FG000|Overall Study|Withdrawal by Subject|0
5975777|NCT02809677|9562412|FG000|Overall Study|Withdrawal by Subject|8
5975778|NCT02554253|9562423|FG000|Overall Study|ineligible after enrollment|1
5975779|NCT02554253|9562424|FG001|Overall Study|ineligible after enrollment|0
5975780|NCT02554253|9562423|FG000|Overall Study|converted to transcatheter procedure|0
5975781|NCT02554253|9562424|FG001|Overall Study|converted to transcatheter procedure|1
5975782|NCT02554253|9562423|FG000|Overall Study|received both drugs|0
5975783|NCT02554253|9562424|FG001|Overall Study|received both drugs|1
5975784|NCT01307046|9562443|FG000|Overall Study|Adverse Event|3
5975785|NCT01307046|9562444|FG001|Overall Study|Adverse Event|3
5975786|NCT01307046|9562443|FG000|Overall Study|Lack of Efficacy|0
5975787|NCT01307046|9562444|FG001|Overall Study|Lack of Efficacy|2
5975788|NCT01307046|9562443|FG000|Overall Study|Physician Decision|2
5975789|NCT01307046|9562444|FG001|Overall Study|Physician Decision|0
5975790|NCT01307046|9562443|FG000|Overall Study|Withdrawal by Subject|1
5975791|NCT01307046|9562444|FG001|Overall Study|Withdrawal by Subject|1
5975792|NCT01307046|9562443|FG000|Overall Study|Serum Potassium Withdrawal Criteria Met|4
5975793|NCT01307046|9562444|FG001|Overall Study|Serum Potassium Withdrawal Criteria Met|2
5975794|NCT01307046|9562443|FG000|Overall Study|Blood Pressure Withdrawal Criteria Met|2
5975795|NCT01307046|9562444|FG001|Overall Study|Blood Pressure Withdrawal Criteria Met|3
5975796|NCT01307033|9562452|FG000|8-week Double-blind Period|Adverse Event|2
5975797|NCT01307033|9562453|FG001|8-week Double-blind Period|Adverse Event|0
5975798|NCT01307033|9562454|FG002|8-week Double-blind Period|Adverse Event|0
5975799|NCT01307033|9562455|FG003|8-week Double-blind Period|Adverse Event|0
5975800|NCT01307033|9562452|FG000|8-week Double-blind Period|Withdrawal by Subject|4
5975801|NCT01307033|9562453|FG001|8-week Double-blind Period|Withdrawal by Subject|1
5975802|NCT01307033|9562454|FG002|8-week Double-blind Period|Withdrawal by Subject|0
5975803|NCT01307033|9562455|FG003|8-week Double-blind Period|Withdrawal by Subject|0
5975804|NCT01307033|9562452|FG000|8-week Double-blind Period|Lack of Efficacy|1
5975805|NCT01307033|9562453|FG001|8-week Double-blind Period|Lack of Efficacy|0
5975806|NCT01307033|9562454|FG002|8-week Double-blind Period|Lack of Efficacy|0
5975807|NCT01307033|9562455|FG003|8-week Double-blind Period|Lack of Efficacy|0
5975808|NCT01307033|9562452|FG000|8-week Double-blind Period|Blood Pressure Withdrawal Criteria Met|0
5975809|NCT01307033|9562453|FG001|8-week Double-blind Period|Blood Pressure Withdrawal Criteria Met|3
5975810|NCT01307033|9562454|FG002|8-week Double-blind Period|Blood Pressure Withdrawal Criteria Met|0
5975811|NCT01307033|9562455|FG003|8-week Double-blind Period|Blood Pressure Withdrawal Criteria Met|0
5975812|NCT01307033|9562452|FG000|8-week Double-blind Period|Potassium Withdrawal Criteria Met|6
5975813|NCT01307033|9562453|FG001|8-week Double-blind Period|Potassium Withdrawal Criteria Met|3
5975814|NCT01307033|9562454|FG002|8-week Double-blind Period|Potassium Withdrawal Criteria Met|0
5975815|NCT01307033|9562455|FG003|8-week Double-blind Period|Potassium Withdrawal Criteria Met|0
5975816|NCT01307033|9562452|FG000|44-week Open-label Extension|Adverse Event|0
5975817|NCT01307033|9562453|FG001|44-week Open-label Extension|Adverse Event|0
5975818|NCT01307033|9562454|FG002|44-week Open-label Extension|Adverse Event|2
5975819|NCT01307033|9562455|FG003|44-week Open-label Extension|Adverse Event|1
5975820|NCT01307033|9562452|FG000|44-week Open-label Extension|Withdrawal by Subject|0
5975821|NCT01307033|9562453|FG001|44-week Open-label Extension|Withdrawal by Subject|0
5975822|NCT01307033|9562454|FG002|44-week Open-label Extension|Withdrawal by Subject|2
5975823|NCT01307033|9562455|FG003|44-week Open-label Extension|Withdrawal by Subject|1
5975824|NCT01307033|9562452|FG000|44-week Open-label Extension|Physician Decision|0
5975825|NCT01307033|9562453|FG001|44-week Open-label Extension|Physician Decision|0
5975826|NCT01307033|9562454|FG002|44-week Open-label Extension|Physician Decision|1
5975827|NCT01307033|9562455|FG003|44-week Open-label Extension|Physician Decision|0
5975828|NCT01307033|9562452|FG000|44-week Open-label Extension|Blood Pressure Withdrawal Criteria Met|0
5975829|NCT01307033|9562453|FG001|44-week Open-label Extension|Blood Pressure Withdrawal Criteria Met|0
5975830|NCT01307033|9562454|FG002|44-week Open-label Extension|Blood Pressure Withdrawal Criteria Met|0
5975831|NCT01307033|9562455|FG003|44-week Open-label Extension|Blood Pressure Withdrawal Criteria Met|2
5975832|NCT01307033|9562452|FG000|44-week Open-label Extension|Potassium Withdrawal Criteria Met|0
5975833|NCT01307033|9562453|FG001|44-week Open-label Extension|Potassium Withdrawal Criteria Met|0
5975834|NCT01307033|9562454|FG002|44-week Open-label Extension|Potassium Withdrawal Criteria Met|6
5975835|NCT01307033|9562455|FG003|44-week Open-label Extension|Potassium Withdrawal Criteria Met|7
5975836|NCT01307033|9562452|FG000|44-week Open-label Extension|Death|0
5975837|NCT01307033|9562453|FG001|44-week Open-label Extension|Death|0
5975838|NCT01307033|9562454|FG002|44-week Open-label Extension|Death|0
5975839|NCT01307033|9562455|FG003|44-week Open-label Extension|Death|1
5975840|NCT00739674|9562469|FG000|Overall Study|Screening failures|19
5975841|NCT00739674|9562470|FG001|Overall Study|Screening failures|17
5975842|NCT00739674|9562469|FG000|Overall Study|Site 212 removal|19
5975843|NCT00739674|9562470|FG001|Overall Study|Site 212 removal|13
5975844|NCT00739674|9562469|FG000|Overall Study|No follow-up data|33
5975845|NCT00739674|9562470|FG001|Overall Study|No follow-up data|18
5975846|NCT00739674|9562469|FG000|Overall Study|Dietician consultation >30 days|1
5975847|NCT00739674|9562470|FG001|Overall Study|Dietician consultation >30 days|9
5975848|NCT00739674|9562469|FG000|Overall Study|Adverse Event|22
5975849|NCT00739674|9562470|FG001|Overall Study|Adverse Event|13
5975850|NCT00739674|9562469|FG000|Overall Study|Death|1
5975851|NCT00739674|9562470|FG001|Overall Study|Death|0
5975852|NCT00739674|9562469|FG000|Overall Study|Lack of Efficacy|1
5975853|NCT00739674|9562470|FG001|Overall Study|Lack of Efficacy|0
5975854|NCT00739674|9562469|FG000|Overall Study|Lost to Follow-up|52
5975855|NCT00739674|9562470|FG001|Overall Study|Lost to Follow-up|30
5975856|NCT00739674|9562469|FG000|Overall Study|Protocol Violation|5
5975857|NCT00739674|9562470|FG001|Overall Study|Protocol Violation|5
5975858|NCT00739674|9562469|FG000|Overall Study|Withdrawal by Subject|9
5975859|NCT00739674|9562470|FG001|Overall Study|Withdrawal by Subject|9
5975860|NCT00739674|9562469|FG000|Overall Study|Reason missing|2
6050583|NCT00427934|9649814|FG001|Overall Study|Withdrawal by Subject|0
6050584|NCT00427934|9649815|FG002|Overall Study|Withdrawal by Subject|1
6050585|NCT00427934|9649816|FG003|Overall Study|Withdrawal by Subject|3
6050586|NCT00427960|9649830|FG000|Overall Study|Adverse Event|2
6050587|NCT00427960|9649831|FG001|Overall Study|Adverse Event|0
6050588|NCT00427960|9649830|FG000|Overall Study|Withdrawal by Subject|0
6050589|NCT00427960|9649831|FG001|Overall Study|Withdrawal by Subject|3
6050590|NCT00427960|9649830|FG000|Overall Study|Other|0
6050591|NCT00427960|9649831|FG001|Overall Study|Other|1
6050592|NCT00427999|9649841|FG000|Overall Study|Adverse Event|6
6050593|NCT00427999|9649841|FG000|Overall Study|Abnormal laboratory values|1
6050594|NCT00427999|9649841|FG000|Overall Study|Unsatisfactory therapeutic effect|13
6050595|NCT00427999|9649841|FG000|Overall Study|Protocol Violation|2
6050596|NCT00427999|9649841|FG000|Overall Study|Withdrawal by Subject|9
6050597|NCT00427999|9649841|FG000|Overall Study|Death|1
6050598|NCT00428090|9649854|FG000|Overall Study|Adverse Event|10
6050599|NCT00428090|9649855|FG001|Overall Study|Adverse Event|8
6050600|NCT00428090|9649856|FG002|Overall Study|Adverse Event|10
6050601|NCT00428090|9649857|FG003|Overall Study|Adverse Event|11
6050602|NCT00428090|9649854|FG000|Overall Study|Lost to Follow-up|3
6050603|NCT00428090|9649855|FG001|Overall Study|Lost to Follow-up|6
6050604|NCT00428090|9649856|FG002|Overall Study|Lost to Follow-up|1
6050605|NCT00428090|9649857|FG003|Overall Study|Lost to Follow-up|4
6050606|NCT00428090|9649854|FG000|Overall Study|Protocol Violation|3
6050607|NCT00428090|9649855|FG001|Overall Study|Protocol Violation|1
6050608|NCT00428090|9649856|FG002|Overall Study|Protocol Violation|3
6050609|NCT00428090|9649857|FG003|Overall Study|Protocol Violation|3
6050610|NCT00428090|9649854|FG000|Overall Study|Withdrawal by Subject|10
6050611|NCT00428090|9649855|FG001|Overall Study|Withdrawal by Subject|12
6050612|NCT00428090|9649856|FG002|Overall Study|Withdrawal by Subject|15
6050613|NCT00428090|9649857|FG003|Overall Study|Withdrawal by Subject|5
6050614|NCT00428090|9649854|FG000|Overall Study|Sponsor terminated study|0
6050615|NCT00428090|9649855|FG001|Overall Study|Sponsor terminated study|1
6050616|NCT00428090|9649856|FG002|Overall Study|Sponsor terminated study|0
6050617|NCT00428090|9649857|FG003|Overall Study|Sponsor terminated study|0
6050618|NCT00428090|9649854|FG000|Overall Study|Non-compliance|4
6050619|NCT00428090|9649855|FG001|Overall Study|Non-compliance|0
6193752|NCT01440946|9851612|FG001|Overall Study|Physician Decision|0
6193753|NCT01440972|9851625|FG000|Overall Study|Withdrawal by Subject|3
6193754|NCT01440972|9851626|FG001|Overall Study|Withdrawal by Subject|2
6193755|NCT01441063|9851636|FG000|Tocilizumab Alone|Required AZT/VGC addition|3
6193756|NCT01441063|9851636|FG000|Tocilizumab + Zidovudine /Valganciclovir|Worsening KSHV-MCD symptoms|1
6193757|NCT01441102|9851647|FG000|Overall Study|Adverse Event|1
6193758|NCT01441102|9851647|FG000|Overall Study|Withdrawal by Subject|2
6193759|NCT01441180|9851654|FG000|Overall Study|Lost to Follow-up|1
6193760|NCT01441180|9851655|FG001|Overall Study|Lost to Follow-up|1
6193761|NCT01441180|9851656|FG002|Overall Study|Lost to Follow-up|1
6193762|NCT01441180|9851654|FG000|Overall Study|Discontinued|0
6273153|NCT02187055|9976480|FG000|Overall Study|Lost to Follow-up|2
6273154|NCT02187055|9976481|FG001|Overall Study|Lost to Follow-up|7
6273155|NCT02187055|9976482|FG002|Overall Study|Lost to Follow-up|3
6273156|NCT02187055|9976480|FG000|Overall Study|No longer meets eligibility criteria|0
6273157|NCT02187055|9976481|FG001|Overall Study|No longer meets eligibility criteria|2
6273158|NCT02187055|9976482|FG002|Overall Study|No longer meets eligibility criteria|0
6273159|NCT02187055|9976480|FG000|Overall Study|No longer willing to participate|6
6273160|NCT02187055|9976481|FG001|Overall Study|No longer willing to participate|8
6273161|NCT02187055|9976482|FG002|Overall Study|No longer willing to participate|10
6273162|NCT02187055|9976480|FG000|Overall Study|Other|5
6273163|NCT02187055|9976481|FG001|Overall Study|Other|6
6273164|NCT02187055|9976482|FG002|Overall Study|Other|3
6273165|NCT02187055|9976480|FG000|Overall Study|Protocol Violation|9
6273166|NCT02187055|9976481|FG001|Overall Study|Protocol Violation|9
6273167|NCT02187055|9976482|FG002|Overall Study|Protocol Violation|4
6273168|NCT02187055|9976480|FG000|Overall Study|Pregnancy|3
6050620|NCT00428090|9649856|FG002|Overall Study|Non-compliance|1
6050621|NCT00428090|9649857|FG003|Overall Study|Non-compliance|3
6050622|NCT00428090|9649854|FG000|Overall Study|Par. did not returned to visit|1
6050623|NCT00428090|9649855|FG001|Overall Study|Par. did not returned to visit|0
6193763|NCT01441180|9851655|FG001|Overall Study|Discontinued|0
6193764|NCT01441180|9851656|FG002|Overall Study|Discontinued|2
6193765|NCT01441414|9851710|FG000|Overall Study|Participant died|9
6273169|NCT02187055|9976481|FG001|Overall Study|Pregnancy|1
6273170|NCT02187055|9976482|FG002|Overall Study|Pregnancy|0
5975861|NCT00739674|9562470|FG001|Overall Study|Reason missing|0
6050624|NCT00428090|9649856|FG002|Overall Study|Par. did not returned to visit|0
6273171|NCT02187055|9976480|FG000|Overall Study|Withdrawal by Subject|11
5975862|NCT00739674|9562469|FG000|Overall Study|Clinic closed|6
5975863|NCT00739674|9562470|FG001|Overall Study|Clinic closed|4
5975864|NCT00739674|9562469|FG000|Overall Study|Patient moved|3
5975865|NCT00739674|9562470|FG001|Overall Study|Patient moved|2
5975866|NCT00739674|9562469|FG000|Overall Study|Non compliant|4
5975867|NCT00739674|9562470|FG001|Overall Study|Non compliant|0
5975868|NCT00739674|9562469|FG000|Overall Study|Unable to attend visit|3
5975869|NCT00739674|9562470|FG001|Overall Study|Unable to attend visit|1
5975870|NCT00739674|9562469|FG000|Overall Study|Home monitoring off meds|1
5975871|NCT00739674|9562470|FG001|Overall Study|Home monitoring off meds|0
5975872|NCT00739674|9562469|FG000|Overall Study|Erectile dysfunction|0
5975873|NCT00739674|9562470|FG001|Overall Study|Erectile dysfunction|1
5975874|NCT00546754|9562478|FG000|Overall Study|Serious Adverse Event|1
5975875|NCT00546754|9562479|FG001|Overall Study|Serious Adverse Event|1
5975876|NCT00546754|9562478|FG000|Overall Study|Adverse Event|11
5975877|NCT00546754|9562479|FG001|Overall Study|Adverse Event|16
5975878|NCT00546754|9562478|FG000|Overall Study|Lack of Efficacy|1
5975879|NCT00546754|9562479|FG001|Overall Study|Lack of Efficacy|1
5975880|NCT00546754|9562478|FG000|Overall Study|Lost to Follow-up|9
5975881|NCT00546754|9562479|FG001|Overall Study|Lost to Follow-up|15
5975882|NCT00546754|9562478|FG000|Overall Study|Protocol Violation|3
5975883|NCT00546754|9562479|FG001|Overall Study|Protocol Violation|0
5975884|NCT00546754|9562478|FG000|Overall Study|Withdrawal by Subject|6
5975885|NCT00546754|9562479|FG001|Overall Study|Withdrawal by Subject|7
5975886|NCT00546754|9562478|FG000|Overall Study|Dyspnea|1
5975887|NCT00546754|9562479|FG001|Overall Study|Dyspnea|0
5975888|NCT00546754|9562478|FG000|Overall Study|Per Data Query, Less Than 4 Wks Coversyl|1
5975889|NCT00546754|9562479|FG001|Overall Study|Per Data Query, Less Than 4 Wks Coversyl|0
5975890|NCT00546754|9562478|FG000|Overall Study|Hip Replacement|1
5975891|NCT00546754|9562479|FG001|Overall Study|Hip Replacement|0
5975892|NCT00546754|9562478|FG000|Overall Study|Suicide|1
5975893|NCT00546754|9562479|FG001|Overall Study|Suicide|0
5975894|NCT00546754|9562478|FG000|Overall Study|Missing Cooperation|1
5975895|NCT00546754|9562479|FG001|Overall Study|Missing Cooperation|0
5975896|NCT00546754|9562478|FG000|Overall Study|Elevated Creatinine and Potassium levels|0
5975897|NCT00546754|9562479|FG001|Overall Study|Elevated Creatinine and Potassium levels|1
5975898|NCT00546754|9562478|FG000|Overall Study|Patient's Decision|0
5975899|NCT00546754|9562479|FG001|Overall Study|Patient's Decision|1
5975900|NCT00546754|9562478|FG000|Overall Study|Missing|14
5975901|NCT00546754|9562479|FG001|Overall Study|Missing|7
6193766|NCT01441414|9851710|FG000|Overall Study|Other reasons|3
6193767|NCT01441414|9851710|FG000|Overall Study|Study terminated by sponsor|2
6193768|NCT01441414|9851710|FG000|Overall Study|Subject refused further follow-up|1
6193769|NCT01441440|9851729|FG000|Overall Study|Death|1
6193770|NCT01441440|9851730|FG001|Overall Study|Death|0
6193771|NCT01441440|9851731|FG002|Overall Study|Death|1
6193772|NCT01441440|9851729|FG000|Overall Study|Adverse Event|2
6193773|NCT01441440|9851730|FG001|Overall Study|Adverse Event|9
6193774|NCT01441440|9851731|FG002|Overall Study|Adverse Event|9
6193775|NCT01441440|9851729|FG000|Overall Study|Lost to Follow-up|0
6193776|NCT01441440|9851730|FG001|Overall Study|Lost to Follow-up|2
6193777|NCT01441440|9851731|FG002|Overall Study|Lost to Follow-up|1
6193778|NCT01441440|9851729|FG000|Overall Study|Withdrawal by Subject|11
6193779|NCT01441440|9851730|FG001|Overall Study|Withdrawal by Subject|9
6193780|NCT01441440|9851731|FG002|Overall Study|Withdrawal by Subject|9
6193781|NCT01441440|9851729|FG000|Overall Study|Pregnancy|1
6193782|NCT01441440|9851730|FG001|Overall Study|Pregnancy|0
6193783|NCT01441440|9851731|FG002|Overall Study|Pregnancy|0
5975902|NCT00479713|9562487|FG000|Overall Study|Adverse Event|8
5975903|NCT00479713|9562488|FG001|Overall Study|Adverse Event|6
5975904|NCT00479713|9562487|FG000|Overall Study|Death|1
5975905|NCT00479713|9562488|FG001|Overall Study|Death|0
5975906|NCT00479713|9562487|FG000|Overall Study|Lost to Follow-up|0
5975907|NCT00479713|9562488|FG001|Overall Study|Lost to Follow-up|1
5975908|NCT00479713|9562487|FG000|Overall Study|Protocol Violation|0
5975909|NCT00479713|9562488|FG001|Overall Study|Protocol Violation|1
5975910|NCT00479713|9562487|FG000|Overall Study|Withdrawal by Subject|4
5975911|NCT00479713|9562488|FG001|Overall Study|Withdrawal by Subject|1
5975912|NCT00406783|9562496|FG000|Overall Study|Adverse Event|4
5975913|NCT00406783|9562497|FG001|Overall Study|Adverse Event|4
5975914|NCT00406783|9562496|FG000|Overall Study|Treatment Failure|2
5975915|NCT00406783|9562497|FG001|Overall Study|Treatment Failure|3
5975916|NCT00406783|9562496|FG000|Overall Study|Lost to Follow-up|3
5975917|NCT00406783|9562497|FG001|Overall Study|Lost to Follow-up|0
5975918|NCT00406783|9562496|FG000|Overall Study|Withdrawal by Subject|1
5975919|NCT00406783|9562497|FG001|Overall Study|Withdrawal by Subject|4
5975920|NCT00406783|9562496|FG000|Overall Study|Protocol Violation|4
5975921|NCT00406783|9562497|FG001|Overall Study|Protocol Violation|4
5975922|NCT00405964|9562505|FG000|Overall Study|Treatment Failure|17
6193784|NCT01441440|9851729|FG000|Overall Study|Lack of Efficacy|1
6193785|NCT01441440|9851730|FG001|Overall Study|Lack of Efficacy|0
6193786|NCT01441440|9851731|FG002|Overall Study|Lack of Efficacy|1
6193787|NCT01441440|9851729|FG000|Overall Study|Moving|0
6193788|NCT01441440|9851730|FG001|Overall Study|Moving|1
6193789|NCT01441440|9851731|FG002|Overall Study|Moving|1
6193790|NCT01441440|9851729|FG000|Overall Study|Work-related matter|0
5975923|NCT00405964|9562506|FG001|Overall Study|Treatment Failure|45
5975924|NCT00405964|9562505|FG000|Overall Study|Adverse Event|7
5975925|NCT00405964|9562506|FG001|Overall Study|Adverse Event|16
5975926|NCT00405964|9562505|FG000|Overall Study|Lost to Follow-up|5
5975927|NCT00405964|9562506|FG001|Overall Study|Lost to Follow-up|5
5975928|NCT00405964|9562505|FG000|Overall Study|Withdrawal by Subject|19
5975929|NCT00405964|9562506|FG001|Overall Study|Withdrawal by Subject|23
5975930|NCT00405964|9562505|FG000|Overall Study|Protocol Violation|11
5975931|NCT00405964|9562506|FG001|Overall Study|Protocol Violation|6
5975932|NCT00383721|9562517|FG000|26-Week Double-Blind Treatment Period|Adverse Event|11
5975933|NCT00383721|9562518|FG001|26-Week Double-Blind Treatment Period|Adverse Event|5
5975934|NCT00383721|9562519|FG002|26-Week Double-Blind Treatment Period|Adverse Event|7
5975935|NCT00383721|9562520|FG003|26-Week Double-Blind Treatment Period|Adverse Event|14
5975936|NCT00383721|9562521|FG004|26-Week Double-Blind Treatment Period|Adverse Event|13
5975937|NCT00383721|9562517|FG000|26-Week Double-Blind Treatment Period|Lack of Efficacy|1
5975938|NCT00383721|9562518|FG001|26-Week Double-Blind Treatment Period|Lack of Efficacy|3
5975939|NCT00383721|9562519|FG002|26-Week Double-Blind Treatment Period|Lack of Efficacy|3
5975940|NCT00383721|9562520|FG003|26-Week Double-Blind Treatment Period|Lack of Efficacy|4
5975941|NCT00383721|9562521|FG004|26-Week Double-Blind Treatment Period|Lack of Efficacy|8
5975942|NCT00383721|9562517|FG000|26-Week Double-Blind Treatment Period|Lost to Follow-up|0
5975943|NCT00383721|9562518|FG001|26-Week Double-Blind Treatment Period|Lost to Follow-up|0
5975944|NCT00383721|9562519|FG002|26-Week Double-Blind Treatment Period|Lost to Follow-up|2
5975945|NCT00383721|9562520|FG003|26-Week Double-Blind Treatment Period|Lost to Follow-up|1
5975946|NCT00383721|9562521|FG004|26-Week Double-Blind Treatment Period|Lost to Follow-up|4
5975947|NCT00383721|9562517|FG000|26-Week Double-Blind Treatment Period|Participant withdrawal unrelated|4
5975948|NCT00383721|9562518|FG001|26-Week Double-Blind Treatment Period|Participant withdrawal unrelated|12
5975949|NCT00383721|9562519|FG002|26-Week Double-Blind Treatment Period|Participant withdrawal unrelated|15
5975950|NCT00383721|9562520|FG003|26-Week Double-Blind Treatment Period|Participant withdrawal unrelated|10
5975951|NCT00383721|9562521|FG004|26-Week Double-Blind Treatment Period|Participant withdrawal unrelated|11
5975952|NCT00383721|9562517|FG000|26-Week Double-Blind Treatment Period|Participant withdrawal related|5
5975953|NCT00383721|9562518|FG001|26-Week Double-Blind Treatment Period|Participant withdrawal related|3
5975954|NCT00383721|9562519|FG002|26-Week Double-Blind Treatment Period|Participant withdrawal related|6
5975955|NCT00383721|9562520|FG003|26-Week Double-Blind Treatment Period|Participant withdrawal related|8
5975956|NCT00383721|9562521|FG004|26-Week Double-Blind Treatment Period|Participant withdrawal related|9
5975957|NCT00383721|9562517|FG000|26-Week Double-Blind Treatment Period|Non-compliance with protocol|7
5975958|NCT00383721|9562518|FG001|26-Week Double-Blind Treatment Period|Non-compliance with protocol|5
5975959|NCT00383721|9562519|FG002|26-Week Double-Blind Treatment Period|Non-compliance with protocol|4
5975960|NCT00383721|9562520|FG003|26-Week Double-Blind Treatment Period|Non-compliance with protocol|6
5975961|NCT00383721|9562521|FG004|26-Week Double-Blind Treatment Period|Non-compliance with protocol|6
5975962|NCT00383721|9562517|FG000|26-Week Double-Blind Treatment Period|Did not meet protocol eligibility|5
5975963|NCT00383721|9562518|FG001|26-Week Double-Blind Treatment Period|Did not meet protocol eligibility|6
5975964|NCT00383721|9562519|FG002|26-Week Double-Blind Treatment Period|Did not meet protocol eligibility|11
5975965|NCT00383721|9562520|FG003|26-Week Double-Blind Treatment Period|Did not meet protocol eligibility|4
5975966|NCT00383721|9562521|FG004|26-Week Double-Blind Treatment Period|Did not meet protocol eligibility|13
5975967|NCT00383721|9562517|FG000|26-Week Double-Blind Treatment Period|Administrative|1
5975968|NCT00383721|9562518|FG001|26-Week Double-Blind Treatment Period|Administrative|3
5975969|NCT00383721|9562519|FG002|26-Week Double-Blind Treatment Period|Administrative|3
5975970|NCT00383721|9562520|FG003|26-Week Double-Blind Treatment Period|Administrative|3
5975971|NCT00383721|9562521|FG004|26-Week Double-Blind Treatment Period|Administrative|3
5975972|NCT00383721|9562517|FG000|26-Week Double-Blind Treatment Period|Ongoing|1
5975973|NCT00383721|9562518|FG001|26-Week Double-Blind Treatment Period|Ongoing|0
5975974|NCT00383721|9562519|FG002|26-Week Double-Blind Treatment Period|Ongoing|0
5975975|NCT00383721|9562520|FG003|26-Week Double-Blind Treatment Period|Ongoing|0
5975976|NCT00383721|9562521|FG004|26-Week Double-Blind Treatment Period|Ongoing|0
5975977|NCT00383721|9562517|FG000|26-Week Treatment Safety Extension|Adverse Event|6
5975978|NCT00383721|9562518|FG001|26-Week Treatment Safety Extension|Adverse Event|7
5975979|NCT00383721|9562519|FG002|26-Week Treatment Safety Extension|Adverse Event|10
5975980|NCT00383721|9562520|FG003|26-Week Treatment Safety Extension|Adverse Event|1
5975981|NCT00383721|9562521|FG004|26-Week Treatment Safety Extension|Adverse Event|0
5975982|NCT00383721|9562517|FG000|26-Week Treatment Safety Extension|Lack of Efficacy|0
5975983|NCT00383721|9562518|FG001|26-Week Treatment Safety Extension|Lack of Efficacy|2
5975984|NCT00383721|9562519|FG002|26-Week Treatment Safety Extension|Lack of Efficacy|4
5975985|NCT00383721|9562520|FG003|26-Week Treatment Safety Extension|Lack of Efficacy|1
5975986|NCT00383721|9562521|FG004|26-Week Treatment Safety Extension|Lack of Efficacy|0
5975987|NCT00383721|9562517|FG000|26-Week Treatment Safety Extension|Lost to Follow-up|2
5975988|NCT00383721|9562518|FG001|26-Week Treatment Safety Extension|Lost to Follow-up|0
5975989|NCT00383721|9562519|FG002|26-Week Treatment Safety Extension|Lost to Follow-up|1
5975990|NCT00383721|9562520|FG003|26-Week Treatment Safety Extension|Lost to Follow-up|1
5975991|NCT00383721|9562521|FG004|26-Week Treatment Safety Extension|Lost to Follow-up|0
5975992|NCT00383721|9562517|FG000|26-Week Treatment Safety Extension|Participant withdrawal unrelated|6
5975993|NCT00383721|9562518|FG001|26-Week Treatment Safety Extension|Participant withdrawal unrelated|4
5975994|NCT00383721|9562519|FG002|26-Week Treatment Safety Extension|Participant withdrawal unrelated|2
6193791|NCT01441440|9851730|FG001|Overall Study|Work-related matter|1
6193792|NCT01441440|9851731|FG002|Overall Study|Work-related matter|0
6193793|NCT01441440|9851729|FG000|Overall Study|Difficllty in keeping the schedule|1
6193794|NCT01441440|9851730|FG001|Overall Study|Difficllty in keeping the schedule|1
6193795|NCT01441440|9851731|FG002|Overall Study|Difficllty in keeping the schedule|0
6193796|NCT01441596|9851772|FG000|Overall Study|Other reason not defined below|0
6193797|NCT01441596|9851773|FG001|Overall Study|Other reason not defined below|2
6193798|NCT01441596|9851774|FG002|Overall Study|Other reason not defined below|1
6193799|NCT01441596|9851772|FG000|Overall Study|Withdrawal by Subject|4
6193800|NCT01441596|9851773|FG001|Overall Study|Withdrawal by Subject|0
6193801|NCT01441596|9851774|FG002|Overall Study|Withdrawal by Subject|2
6193802|NCT01441596|9851772|FG000|Overall Study|Not treated|0
6193803|NCT01441596|9851773|FG001|Overall Study|Not treated|1
6193804|NCT01441596|9851774|FG002|Overall Study|Not treated|1
6193805|NCT01441635|9851792|FG000|Overall Study|Adverse Event|4
6193806|NCT01441635|9851793|FG001|Overall Study|Adverse Event|3
6193807|NCT01441635|9851794|FG002|Overall Study|Adverse Event|1
6193808|NCT01441635|9851795|FG003|Overall Study|Adverse Event|5
6193809|NCT01441635|9851796|FG004|Overall Study|Adverse Event|1
6193810|NCT01441635|9851797|FG005|Overall Study|Adverse Event|2
6193811|NCT01441635|9851798|FG006|Overall Study|Adverse Event|2
6193812|NCT01441635|9851799|FG007|Overall Study|Adverse Event|2
6193813|NCT01441635|9851800|FG008|Overall Study|Adverse Event|1
6193814|NCT01441635|9851801|FG009|Overall Study|Adverse Event|0
6193815|NCT01441635|9851792|FG000|Overall Study|Withdrawal by Subject|1
6193816|NCT01441635|9851793|FG001|Overall Study|Withdrawal by Subject|1
6193817|NCT01441635|9851794|FG002|Overall Study|Withdrawal by Subject|0
6193818|NCT01441635|9851795|FG003|Overall Study|Withdrawal by Subject|1
6193819|NCT01441635|9851796|FG004|Overall Study|Withdrawal by Subject|0
6273172|NCT02187055|9976481|FG001|Overall Study|Withdrawal by Subject|11
6273173|NCT02187055|9976482|FG002|Overall Study|Withdrawal by Subject|11
6273174|NCT02187055|9976480|FG000|Overall Study|Adverse Event|21
6273175|NCT02187055|9976481|FG001|Overall Study|Adverse Event|26
6273176|NCT02187055|9976482|FG002|Overall Study|Adverse Event|36
6273177|NCT02187055|9976480|FG000|Overall Study|Death|2
6273178|NCT02187055|9976481|FG001|Overall Study|Death|0
6273179|NCT02187055|9976482|FG002|Overall Study|Death|0
6273180|NCT02187159|9976494|FG000|Overall Study|Protocol Violation|4
6273181|NCT02187159|9976495|FG001|Overall Study|Protocol Violation|6
6273182|NCT02187159|9976496|FG002|Overall Study|Protocol Violation|3
6273183|NCT02187159|9976497|FG003|Overall Study|Protocol Violation|4
6273184|NCT02187159|9976494|FG000|Overall Study|Lack of Efficacy|10
6273185|NCT02187159|9976495|FG001|Overall Study|Lack of Efficacy|5
6273186|NCT02187159|9976496|FG002|Overall Study|Lack of Efficacy|4
6273187|NCT02187159|9976497|FG003|Overall Study|Lack of Efficacy|7
6273188|NCT02187159|9976494|FG000|Overall Study|Adverse Event|28
6273189|NCT02187159|9976495|FG001|Overall Study|Adverse Event|33
5975995|NCT00383721|9562520|FG003|26-Week Treatment Safety Extension|Participant withdrawal unrelated|7
5975996|NCT00383721|9562521|FG004|26-Week Treatment Safety Extension|Participant withdrawal unrelated|0
5975997|NCT00383721|9562517|FG000|26-Week Treatment Safety Extension|Participant withdrawal related|1
5975998|NCT00383721|9562518|FG001|26-Week Treatment Safety Extension|Participant withdrawal related|1
5975999|NCT00383721|9562519|FG002|26-Week Treatment Safety Extension|Participant withdrawal related|1
5976000|NCT00383721|9562520|FG003|26-Week Treatment Safety Extension|Participant withdrawal related|1
5976001|NCT00383721|9562521|FG004|26-Week Treatment Safety Extension|Participant withdrawal related|0
6050625|NCT00428090|9649857|FG003|Overall Study|Par. did not returned to visit|1
6193820|NCT01441635|9851797|FG005|Overall Study|Withdrawal by Subject|0
6193821|NCT01441635|9851798|FG006|Overall Study|Withdrawal by Subject|2
6193822|NCT01441635|9851799|FG007|Overall Study|Withdrawal by Subject|0
6193823|NCT01441635|9851800|FG008|Overall Study|Withdrawal by Subject|1
6193824|NCT01441635|9851801|FG009|Overall Study|Withdrawal by Subject|1
6273190|NCT02187159|9976496|FG002|Overall Study|Adverse Event|42
6273191|NCT02187159|9976497|FG003|Overall Study|Adverse Event|50
6273192|NCT02187159|9976494|FG000|Overall Study|Withdrawal by Subject|24
6273193|NCT02187159|9976495|FG001|Overall Study|Withdrawal by Subject|28
6273194|NCT02187159|9976496|FG002|Overall Study|Withdrawal by Subject|25
6273195|NCT02187159|9976497|FG003|Overall Study|Withdrawal by Subject|26
6273196|NCT02187159|9976494|FG000|Overall Study|Other|3
6273197|NCT02187159|9976495|FG001|Overall Study|Other|7
6273198|NCT02187159|9976496|FG002|Overall Study|Other|3
6273199|NCT02187159|9976497|FG003|Overall Study|Other|9
6273200|NCT02187172|9976509|FG000|Overall Study|Lost to Follow-up|1
6273201|NCT02187172|9976510|FG001|Overall Study|Lost to Follow-up|2
6273202|NCT02187172|9976509|FG000|Overall Study|Lack of Efficacy|1
6273203|NCT02187172|9976510|FG001|Overall Study|Lack of Efficacy|2
6273204|NCT02187172|9976509|FG000|Overall Study|Adverse Event|0
6273205|NCT02187172|9976510|FG001|Overall Study|Adverse Event|1
6273206|NCT02187172|9976509|FG000|Overall Study|Physician Decision|1
6273207|NCT02187172|9976510|FG001|Overall Study|Physician Decision|1
6273208|NCT02187471|9976522|FG000|Overall Study|Protocol Violation|4
6273209|NCT02187471|9976523|FG001|Overall Study|Protocol Violation|5
6273210|NCT02187471|9976524|FG002|Overall Study|Protocol Violation|4
6273211|NCT02187471|9976525|FG003|Overall Study|Protocol Violation|4
6273212|NCT02187471|9976522|FG000|Overall Study|Missing|0
6273213|NCT02187471|9976523|FG001|Overall Study|Missing|0
6273214|NCT02187471|9976524|FG002|Overall Study|Missing|0
6273215|NCT02187471|9976525|FG003|Overall Study|Missing|1
6273216|NCT02187471|9976522|FG000|Overall Study|Lack of Efficacy|18
6273217|NCT02187471|9976523|FG001|Overall Study|Lack of Efficacy|9
6273218|NCT02187471|9976524|FG002|Overall Study|Lack of Efficacy|13
6273219|NCT02187471|9976525|FG003|Overall Study|Lack of Efficacy|11
6273220|NCT02187471|9976522|FG000|Overall Study|Adverse Event|24
6273221|NCT02187471|9976523|FG001|Overall Study|Adverse Event|34
6273222|NCT02187471|9976524|FG002|Overall Study|Adverse Event|44
6273223|NCT02187471|9976525|FG003|Overall Study|Adverse Event|36
6273224|NCT02187471|9976522|FG000|Overall Study|Withdrawal by Subject|23
6273225|NCT02187471|9976523|FG001|Overall Study|Withdrawal by Subject|29
6273226|NCT02187471|9976524|FG002|Overall Study|Withdrawal by Subject|22
6273227|NCT02187471|9976525|FG003|Overall Study|Withdrawal by Subject|24
6273228|NCT02187471|9976522|FG000|Overall Study|Other|7
6273229|NCT02187471|9976523|FG001|Overall Study|Other|5
6273230|NCT02187471|9976524|FG002|Overall Study|Other|3
6273231|NCT02187471|9976525|FG003|Overall Study|Other|4
6273232|NCT02187744|9976538|FG000|Study|Participant refused further follow-up|1
6273233|NCT02187744|9976539|FG001|Study|Participant refused further follow-up|0
6273234|NCT02187744|9976538|FG000|Study|Other|2
6273235|NCT02187744|9976539|FG001|Study|Other|1
6273236|NCT02187744|9976538|FG000|Study|Lost to Follow-up|0
6273237|NCT02187744|9976539|FG001|Study|Lost to Follow-up|2
6273238|NCT02187744|9976538|FG000|Study|Related adverse event, not serious|0
6273239|NCT02187744|9976539|FG001|Study|Related adverse event, not serious|2
6050626|NCT00428090|9649854|FG000|Overall Study|Follow-Up visit not possible|1
6050627|NCT00428090|9649855|FG001|Overall Study|Follow-Up visit not possible|0
6050628|NCT00428090|9649856|FG002|Overall Study|Follow-Up visit not possible|0
6050629|NCT00428090|9649857|FG003|Overall Study|Follow-Up visit not possible|0
6050630|NCT00428090|9649854|FG000|Overall Study|Prohibited medication used for SAE|1
6193825|NCT01441635|9851792|FG000|Overall Study|Lost to Follow-up|0
6193826|NCT01441635|9851793|FG001|Overall Study|Lost to Follow-up|1
6193827|NCT01441635|9851794|FG002|Overall Study|Lost to Follow-up|1
6193828|NCT01441635|9851795|FG003|Overall Study|Lost to Follow-up|1
6193829|NCT01441635|9851796|FG004|Overall Study|Lost to Follow-up|1
6273240|NCT02187744|9976538|FG000|Study|Death|1
6273241|NCT02187744|9976539|FG001|Study|Death|0
6273242|NCT02187744|9976538|FG000|Study|Related adverse event, serious non-fatal|0
6273243|NCT02187744|9976539|FG001|Study|Related adverse event, serious non-fatal|1
6273244|NCT02187744|9976538|FG000|Treatment|Death|1
6273245|NCT02187744|9976539|FG001|Treatment|Death|0
6273246|NCT02187744|9976538|FG000|Treatment|Related adverse event, serious non-fatal|0
6273247|NCT02187744|9976539|FG001|Treatment|Related adverse event, serious non-fatal|1
6273248|NCT02187744|9976538|FG000|Treatment|Related adverse event, not serious|0
6273249|NCT02187744|9976539|FG001|Treatment|Related adverse event, not serious|2
6273250|NCT02187744|9976538|FG000|Treatment|Lost to Follow-up|0
5976002|NCT00383721|9562517|FG000|26-Week Treatment Safety Extension|Non-compliance with protocol|2
5976003|NCT00383721|9562518|FG001|26-Week Treatment Safety Extension|Non-compliance with protocol|1
5976004|NCT00383721|9562519|FG002|26-Week Treatment Safety Extension|Non-compliance with protocol|1
5976005|NCT00383721|9562520|FG003|26-Week Treatment Safety Extension|Non-compliance with protocol|4
5976006|NCT00383721|9562521|FG004|26-Week Treatment Safety Extension|Non-compliance with protocol|0
5976007|NCT00383721|9562517|FG000|26-Week Treatment Safety Extension|Did not meet protocol eligibility|1
5976008|NCT00383721|9562518|FG001|26-Week Treatment Safety Extension|Did not meet protocol eligibility|0
5976009|NCT00383721|9562519|FG002|26-Week Treatment Safety Extension|Did not meet protocol eligibility|1
5976010|NCT00383721|9562520|FG003|26-Week Treatment Safety Extension|Did not meet protocol eligibility|1
5976011|NCT00383721|9562521|FG004|26-Week Treatment Safety Extension|Did not meet protocol eligibility|0
5976012|NCT00383721|9562517|FG000|26-Week Treatment Safety Extension|Administrative|1
5976013|NCT00383721|9562518|FG001|26-Week Treatment Safety Extension|Administrative|2
5976014|NCT00383721|9562519|FG002|26-Week Treatment Safety Extension|Administrative|3
5976015|NCT00383721|9562520|FG003|26-Week Treatment Safety Extension|Administrative|1
5976016|NCT00383721|9562521|FG004|26-Week Treatment Safety Extension|Administrative|0
5976017|NCT00383552|9562537|FG000|Overall Study|Adverse Event|7
5976018|NCT00383552|9562538|FG001|Overall Study|Adverse Event|6
5976019|NCT00383552|9562539|FG002|Overall Study|Adverse Event|9
5976020|NCT00383552|9562540|FG003|Overall Study|Adverse Event|6
5976021|NCT00383552|9562537|FG000|Overall Study|Lack of Efficacy|4
5976022|NCT00383552|9562538|FG001|Overall Study|Lack of Efficacy|13
5976023|NCT00383552|9562539|FG002|Overall Study|Lack of Efficacy|29
5976024|NCT00383552|9562540|FG003|Overall Study|Lack of Efficacy|42
5976025|NCT00383552|9562537|FG000|Overall Study|Lost to Follow-up|0
5976026|NCT00383552|9562538|FG001|Overall Study|Lost to Follow-up|1
5976027|NCT00383552|9562539|FG002|Overall Study|Lost to Follow-up|5
5976028|NCT00383552|9562540|FG003|Overall Study|Lost to Follow-up|1
5976029|NCT00383552|9562537|FG000|Overall Study|Did not wish to continue (unrelated)|4
5976030|NCT00383552|9562538|FG001|Overall Study|Did not wish to continue (unrelated)|9
5976031|NCT00383552|9562539|FG002|Overall Study|Did not wish to continue (unrelated)|5
5976032|NCT00383552|9562540|FG003|Overall Study|Did not wish to continue (unrelated)|6
5976033|NCT00383552|9562537|FG000|Overall Study|Did not wish to continue (related)|1
5976034|NCT00383552|9562538|FG001|Overall Study|Did not wish to continue (related)|0
5976035|NCT00383552|9562539|FG002|Overall Study|Did not wish to continue (related)|2
5976036|NCT00383552|9562540|FG003|Overall Study|Did not wish to continue (related)|3
5976037|NCT00383552|9562537|FG000|Overall Study|Noncompliance with the protocol|11
5976038|NCT00383552|9562538|FG001|Overall Study|Noncompliance with the protocol|6
5976039|NCT00383552|9562539|FG002|Overall Study|Noncompliance with the protocol|8
5976040|NCT00383552|9562540|FG003|Overall Study|Noncompliance with the protocol|10
5976041|NCT00383552|9562537|FG000|Overall Study|Did not meet protocol eligibility|8
5976042|NCT00383552|9562538|FG001|Overall Study|Did not meet protocol eligibility|6
5976043|NCT00383552|9562539|FG002|Overall Study|Did not meet protocol eligibility|2
5976044|NCT00383552|9562540|FG003|Overall Study|Did not meet protocol eligibility|3
5976045|NCT00383552|9562537|FG000|Overall Study|Administrative|1
5976046|NCT00383552|9562538|FG001|Overall Study|Administrative|0
6193830|NCT01441635|9851797|FG005|Overall Study|Lost to Follow-up|3
6193831|NCT01441635|9851798|FG006|Overall Study|Lost to Follow-up|1
6193832|NCT01441635|9851799|FG007|Overall Study|Lost to Follow-up|1
6193833|NCT01441635|9851800|FG008|Overall Study|Lost to Follow-up|0
6193834|NCT01441635|9851801|FG009|Overall Study|Lost to Follow-up|1
6193835|NCT01441635|9851792|FG000|Overall Study|Noncompliance|0
6193836|NCT01441635|9851793|FG001|Overall Study|Noncompliance|1
6193837|NCT01441635|9851794|FG002|Overall Study|Noncompliance|0
6193838|NCT01441635|9851795|FG003|Overall Study|Noncompliance|0
6193839|NCT01441635|9851796|FG004|Overall Study|Noncompliance|0
6193840|NCT01441635|9851797|FG005|Overall Study|Noncompliance|0
6193841|NCT01441635|9851798|FG006|Overall Study|Noncompliance|1
6193842|NCT01441635|9851799|FG007|Overall Study|Noncompliance|0
6193843|NCT01441635|9851800|FG008|Overall Study|Noncompliance|0
6193844|NCT01441635|9851801|FG009|Overall Study|Noncompliance|0
6193845|NCT01441635|9851792|FG000|Overall Study|Surgery or Invasive Intervention|0
6193846|NCT01441635|9851793|FG001|Overall Study|Surgery or Invasive Intervention|0
6193847|NCT01441635|9851794|FG002|Overall Study|Surgery or Invasive Intervention|1
6273251|NCT02187744|9976539|FG001|Treatment|Lost to Follow-up|1
6273252|NCT02187744|9976538|FG000|Treatment|Other|2
6193848|NCT01441635|9851795|FG003|Overall Study|Surgery or Invasive Intervention|0
6273253|NCT02187744|9976539|FG001|Treatment|Other|0
6273254|NCT02187744|9976538|FG000|Treatment|Participant refused continued treatment|1
6273255|NCT02187744|9976539|FG001|Treatment|Participant refused continued treatment|1
6273256|NCT02187783|9976545|FG000|Overall Study|Adverse Event|8
6273257|NCT02187783|9976545|FG000|Overall Study|Death|3
6273258|NCT02187783|9976545|FG000|Overall Study|Progressive disease|80
6273259|NCT02187783|9976545|FG000|Overall Study|Protocol Violation|3
6273260|NCT02187783|9976545|FG000|Overall Study|Physician Decision|2
6273261|NCT02187783|9976545|FG000|Overall Study|Withdrawal by Subject|9
6273262|NCT02187783|9976545|FG000|Overall Study|Study terminated by sponsor|1
6273263|NCT02187809|9976549|FG000|Overall Study|The study was terminated|3
6273264|NCT02187861|9976557|FG000|Overall Study|Adverse Event|2
6273265|NCT02187861|9976558|FG001|Overall Study|Adverse Event|1
5976047|NCT00383552|9562539|FG002|Overall Study|Administrative|1
5976048|NCT00383552|9562540|FG003|Overall Study|Administrative|1
5976049|NCT00383435|9562560|FG000|26-Week Double-Blind Treatment Period|Adverse Event|10
5976050|NCT00383435|9562561|FG001|26-Week Double-Blind Treatment Period|Adverse Event|2
5976051|NCT00383435|9562562|FG002|26-Week Double-Blind Treatment Period|Adverse Event|8
5976052|NCT00383435|9562563|FG003|26-Week Double-Blind Treatment Period|Adverse Event|6
5976053|NCT00383435|9562564|FG004|26-Week Double-Blind Treatment Period|Adverse Event|8
5976054|NCT00383435|9562560|FG000|26-Week Double-Blind Treatment Period|Lack of Efficacy|3
6193849|NCT01441635|9851796|FG004|Overall Study|Surgery or Invasive Intervention|0
6193850|NCT01441635|9851797|FG005|Overall Study|Surgery or Invasive Intervention|0
6193851|NCT01441635|9851798|FG006|Overall Study|Surgery or Invasive Intervention|0
6193852|NCT01441635|9851799|FG007|Overall Study|Surgery or Invasive Intervention|0
6193853|NCT01441635|9851800|FG008|Overall Study|Surgery or Invasive Intervention|0
6193854|NCT01441635|9851801|FG009|Overall Study|Surgery or Invasive Intervention|0
6193855|NCT01441635|9851792|FG000|Overall Study|Received Exclusionary Medication|1
6193856|NCT01441635|9851793|FG001|Overall Study|Received Exclusionary Medication|0
6193857|NCT01441635|9851794|FG002|Overall Study|Received Exclusionary Medication|0
6193858|NCT01441635|9851795|FG003|Overall Study|Received Exclusionary Medication|0
6193859|NCT01441635|9851796|FG004|Overall Study|Received Exclusionary Medication|0
6193860|NCT01441635|9851797|FG005|Overall Study|Received Exclusionary Medication|0
6193861|NCT01441635|9851798|FG006|Overall Study|Received Exclusionary Medication|0
6193862|NCT01441635|9851799|FG007|Overall Study|Received Exclusionary Medication|0
6193863|NCT01441635|9851800|FG008|Overall Study|Received Exclusionary Medication|0
6193864|NCT01441635|9851801|FG009|Overall Study|Received Exclusionary Medication|0
6193865|NCT01441635|9851792|FG000|Overall Study|Other|0
6193866|NCT01441635|9851793|FG001|Overall Study|Other|0
6193867|NCT01441635|9851794|FG002|Overall Study|Other|0
6193868|NCT01441635|9851795|FG003|Overall Study|Other|0
6193869|NCT01441635|9851796|FG004|Overall Study|Other|0
6193870|NCT01441635|9851797|FG005|Overall Study|Other|0
6193871|NCT01441635|9851798|FG006|Overall Study|Other|0
6193872|NCT01441635|9851799|FG007|Overall Study|Other|1
6193873|NCT01441635|9851800|FG008|Overall Study|Other|0
6193874|NCT01441635|9851801|FG009|Overall Study|Other|0
6193875|NCT01441765|9851825|FG000|Overall Study|Death|1
6193876|NCT01441765|9851826|FG001|Overall Study|Death|0
6193877|NCT01441960|9851845|FG000|First Neuromuscular Blocking Agent:|Technical error or incomplete ECT series|6
6193878|NCT01441960|9851846|FG001|First Neuromuscular Blocking Agent:|Technical error or incomplete ECT series|5
6193879|NCT01441960|9851845|FG000|First Neuromuscular Blocking Agent:|Protocol Violation|1
6193880|NCT01441960|9851846|FG001|First Neuromuscular Blocking Agent:|Protocol Violation|1
6193881|NCT01441960|9851845|FG000|First Neuromuscular Blocking Agent:|Withdrawal by Subject|1
6273266|NCT02187861|9976559|FG002|Overall Study|Adverse Event|2
6273267|NCT02187861|9976560|FG003|Overall Study|Adverse Event|1
6273268|NCT02187861|9976557|FG000|Overall Study|Death|0
6273269|NCT02187861|9976558|FG001|Overall Study|Death|3
6273270|NCT02187861|9976559|FG002|Overall Study|Death|1
6273271|NCT02187861|9976560|FG003|Overall Study|Death|2
6273272|NCT02187861|9976557|FG000|Overall Study|Physician Decision|0
6273273|NCT02187861|9976558|FG001|Overall Study|Physician Decision|1
6273274|NCT02187861|9976559|FG002|Overall Study|Physician Decision|0
6273275|NCT02187861|9976560|FG003|Overall Study|Physician Decision|3
6273276|NCT02187861|9976557|FG000|Overall Study|Progressive Disease|4
6273277|NCT02187861|9976558|FG001|Overall Study|Progressive Disease|42
6273278|NCT02187861|9976559|FG002|Overall Study|Progressive Disease|19
6273279|NCT02187861|9976560|FG003|Overall Study|Progressive Disease|22
6273280|NCT02187861|9976557|FG000|Overall Study|Withdrawal by Subject|0
6273281|NCT02187861|9976558|FG001|Overall Study|Withdrawal by Subject|0
6273282|NCT02187861|9976559|FG002|Overall Study|Withdrawal by Subject|3
6273283|NCT02187861|9976560|FG003|Overall Study|Withdrawal by Subject|3
6273284|NCT02187861|9976557|FG000|Overall Study|Other|0
6273285|NCT02187861|9976558|FG001|Overall Study|Other|1
6273286|NCT02187861|9976559|FG002|Overall Study|Other|7
6273287|NCT02187861|9976560|FG003|Overall Study|Other|1
6273288|NCT02188160|9976581|FG000|Overall Study|Adverse Event|1
6273289|NCT02188160|9976582|FG001|Overall Study|Adverse Event|0
6273290|NCT02188160|9976581|FG000|Overall Study|Use of an excluded medication|0
6273291|NCT02188160|9976582|FG001|Overall Study|Use of an excluded medication|1
6273292|NCT02188303|9976596|FG000|Overall Study|Adverse Event|0
6273293|NCT02188303|9976597|FG001|Overall Study|Adverse Event|0
6273294|NCT02188303|9976598|FG002|Overall Study|Adverse Event|0
6193882|NCT01441960|9851846|FG001|First Neuromuscular Blocking Agent:|Withdrawal by Subject|0
6193883|NCT01441973|9851858|FG000|Overall Study|Disease progression|8
6193884|NCT01441973|9851859|FG001|Overall Study|Disease progression|6
6193885|NCT01441973|9851858|FG000|Overall Study|Adverse event unrelated to study drug|3
6273295|NCT02188303|9976599|FG003|Overall Study|Adverse Event|0
6273296|NCT02188303|9976600|FG004|Overall Study|Adverse Event|0
6273297|NCT02188303|9976601|FG005|Overall Study|Adverse Event|2
6273298|NCT02188303|9976602|FG006|Overall Study|Adverse Event|0
6273299|NCT02188303|9976603|FG007|Overall Study|Adverse Event|2
6273300|NCT02188303|9976596|FG000|Overall Study|Dose Termination Criteria Met|0
6273301|NCT02188303|9976597|FG001|Overall Study|Dose Termination Criteria Met|0
5976055|NCT00383435|9562561|FG001|26-Week Double-Blind Treatment Period|Lack of Efficacy|2
5976056|NCT00383435|9562562|FG002|26-Week Double-Blind Treatment Period|Lack of Efficacy|3
5976057|NCT00383435|9562563|FG003|26-Week Double-Blind Treatment Period|Lack of Efficacy|5
5976058|NCT00383435|9562564|FG004|26-Week Double-Blind Treatment Period|Lack of Efficacy|8
5976059|NCT00383435|9562560|FG000|26-Week Double-Blind Treatment Period|Lost to Follow-up|3
6050631|NCT00428090|9649855|FG001|Overall Study|Prohibited medication used for SAE|0
6050632|NCT00428090|9649856|FG002|Overall Study|Prohibited medication used for SAE|0
6193886|NCT01441973|9851859|FG001|Overall Study|Adverse event unrelated to study drug|2
6193887|NCT01441973|9851858|FG000|Overall Study|Participant request to discontinue|1
6193888|NCT01441973|9851859|FG001|Overall Study|Participant request to discontinue|1
6193889|NCT01441973|9851858|FG000|Overall Study|Poor compliance/noncompliance|0
6273302|NCT02188303|9976598|FG002|Overall Study|Dose Termination Criteria Met|0
6273303|NCT02188303|9976599|FG003|Overall Study|Dose Termination Criteria Met|0
6273304|NCT02188303|9976600|FG004|Overall Study|Dose Termination Criteria Met|0
6273305|NCT02188303|9976601|FG005|Overall Study|Dose Termination Criteria Met|0
6273306|NCT02188303|9976602|FG006|Overall Study|Dose Termination Criteria Met|2
6273307|NCT02188303|9976603|FG007|Overall Study|Dose Termination Criteria Met|4
6273308|NCT02188459|9976629|FG000|Overall Study|Lost to Follow-up|3
6273309|NCT02188459|9976630|FG001|Overall Study|Lost to Follow-up|4
6273310|NCT02188459|9976629|FG000|Overall Study|Early Termination|0
6273311|NCT02188459|9976630|FG001|Overall Study|Early Termination|3
6273312|NCT02188485|9976642|FG000|Overall Study|Withdrawal by Subject|2
6273313|NCT02188485|9976643|FG001|Overall Study|Withdrawal by Subject|1
6273314|NCT02188485|9976642|FG000|Overall Study|PI withdrew, lack of capacity|0
6273315|NCT02188485|9976643|FG001|Overall Study|PI withdrew, lack of capacity|2
6273316|NCT02188589|9976658|FG000|Overall Study|Withdrawal by Subject|5
6273317|NCT02188719|9976667|FG000|Overall Study|Screen B Ineligible (Page 55, Protocol)|0
6273318|NCT02188719|9976668|FG001|Overall Study|Screen B Ineligible (Page 55, Protocol)|1
6273319|NCT02188719|9976669|FG002|Overall Study|Screen B Ineligible (Page 55, Protocol)|0
6273320|NCT02188719|9976670|FG003|Overall Study|Screen B Ineligible (Page 55, Protocol)|0
6273321|NCT02188784|9976680|FG000|Overall Study|Death|3
6273322|NCT02188784|9976681|FG001|Overall Study|Death|1
6273323|NCT02188784|9976680|FG000|Overall Study|Lost to Follow-up|1
6273324|NCT02188784|9976681|FG001|Overall Study|Lost to Follow-up|0
6273325|NCT02188784|9976680|FG000|Overall Study|Withdrawal by Subject|3
6273326|NCT02188784|9976681|FG001|Overall Study|Withdrawal by Subject|9
6273327|NCT02188784|9976680|FG000|Overall Study|Physician Decision|2
6273328|NCT02188784|9976681|FG001|Overall Study|Physician Decision|3
6273329|NCT02188849|9976689|FG000|Overall Study|Lost to Follow-up|3
6273330|NCT02188849|9976690|FG001|Overall Study|Lost to Follow-up|8
6273331|NCT02189252|9976724|FG000|Period 1 (Visit 4b, Week 4)|Withdrawal by Subject|0
6273332|NCT02189252|9976725|FG001|Period 1 (Visit 4b, Week 4)|Withdrawal by Subject|1
6273333|NCT02189252|9976726|FG002|Period 1 (Visit 4b, Week 4)|Withdrawal by Subject|0
6273334|NCT02189252|9976727|FG003|Period 1 (Visit 4b, Week 4)|Withdrawal by Subject|0
6273335|NCT02189252|9976724|FG000|Period 1 (Visit 4b, Week 4)|Adverse Event|0
6273336|NCT02189252|9976725|FG001|Period 1 (Visit 4b, Week 4)|Adverse Event|1
6273337|NCT02189252|9976726|FG002|Period 1 (Visit 4b, Week 4)|Adverse Event|0
6273338|NCT02189252|9976727|FG003|Period 1 (Visit 4b, Week 4)|Adverse Event|0
6273339|NCT02189473|9976758|FG000|Overall Study|Death|22
6273340|NCT02189473|9976759|FG001|Overall Study|Death|23
6273341|NCT02189473|9976758|FG000|Overall Study|Lost to Follow-up|1
6273342|NCT02189473|9976759|FG001|Overall Study|Lost to Follow-up|2
6273343|NCT02189759|9976782|FG000|Overall Study|Lost to Follow-up|0
6273344|NCT02189759|9976783|FG001|Overall Study|Lost to Follow-up|0
6273345|NCT02189759|9976784|FG002|Overall Study|Lost to Follow-up|2
6273346|NCT02189759|9976785|FG003|Overall Study|Lost to Follow-up|5
6273347|NCT02189837|9976801|FG000|Overall Study|Withdrawal by Subject|2
6273348|NCT02189837|9976802|FG001|Overall Study|Withdrawal by Subject|1
6273349|NCT02189837|9976803|FG002|Overall Study|Withdrawal by Subject|3
6273350|NCT02189837|9976804|FG003|Overall Study|Withdrawal by Subject|1
5976060|NCT00383435|9562561|FG001|26-Week Double-Blind Treatment Period|Lost to Follow-up|3
5976061|NCT00383435|9562562|FG002|26-Week Double-Blind Treatment Period|Lost to Follow-up|1
5976062|NCT00383435|9562563|FG003|26-Week Double-Blind Treatment Period|Lost to Follow-up|2
5976063|NCT00383435|9562564|FG004|26-Week Double-Blind Treatment Period|Lost to Follow-up|2
6193890|NCT01441973|9851859|FG001|Overall Study|Poor compliance/noncompliance|1
6193891|NCT01441973|9851858|FG000|Overall Study|Administrative reason by sponsor|3
6193892|NCT01441973|9851859|FG001|Overall Study|Administrative reason by sponsor|5
6193893|NCT01441973|9851858|FG000|Overall Study|Participant withdrew consent|0
6193894|NCT01441973|9851859|FG001|Overall Study|Participant withdrew consent|1
6193895|NCT01442038|9851868|FG000|Overall Study|Death|35
6193896|NCT01442038|9851869|FG001|Overall Study|Death|29
6193897|NCT01442038|9851868|FG000|Overall Study|Investigator-Initiated Early Closure|44
6193898|NCT01442038|9851869|FG001|Overall Study|Investigator-Initiated Early Closure|43
6193899|NCT01442038|9851868|FG000|Overall Study|Participant Withdrew Consent|137
6193900|NCT01442038|9851869|FG001|Overall Study|Participant Withdrew Consent|102
6193901|NCT01442038|9851868|FG000|Overall Study|Lost to Follow-up|37
6193902|NCT01442038|9851869|FG001|Overall Study|Lost to Follow-up|51
6193903|NCT01442038|9851868|FG000|Overall Study|Adverse Event|26
5976064|NCT00383435|9562560|FG000|26-Week Double-Blind Treatment Period|Participant withdrawal unrelated|7
5976065|NCT00383435|9562561|FG001|26-Week Double-Blind Treatment Period|Participant withdrawal unrelated|12
5976066|NCT00383435|9562562|FG002|26-Week Double-Blind Treatment Period|Participant withdrawal unrelated|14
5976067|NCT00383435|9562563|FG003|26-Week Double-Blind Treatment Period|Participant withdrawal unrelated|10
5976068|NCT00383435|9562564|FG004|26-Week Double-Blind Treatment Period|Participant withdrawal unrelated|17
5976069|NCT00383435|9562560|FG000|26-Week Double-Blind Treatment Period|Participant withdrawal related|2
5976070|NCT00383435|9562561|FG001|26-Week Double-Blind Treatment Period|Participant withdrawal related|3
5976071|NCT00383435|9562562|FG002|26-Week Double-Blind Treatment Period|Participant withdrawal related|7
5976072|NCT00383435|9562563|FG003|26-Week Double-Blind Treatment Period|Participant withdrawal related|3
5976073|NCT00383435|9562564|FG004|26-Week Double-Blind Treatment Period|Participant withdrawal related|7
5976074|NCT00383435|9562560|FG000|26-Week Double-Blind Treatment Period|Non-compliance with protocol|1
5976075|NCT00383435|9562561|FG001|26-Week Double-Blind Treatment Period|Non-compliance with protocol|5
5976076|NCT00383435|9562562|FG002|26-Week Double-Blind Treatment Period|Non-compliance with protocol|3
5976077|NCT00383435|9562563|FG003|26-Week Double-Blind Treatment Period|Non-compliance with protocol|5
5976078|NCT00383435|9562564|FG004|26-Week Double-Blind Treatment Period|Non-compliance with protocol|4
5976079|NCT00383435|9562560|FG000|26-Week Double-Blind Treatment Period|Did not meet protocol eligibility|10
5976080|NCT00383435|9562561|FG001|26-Week Double-Blind Treatment Period|Did not meet protocol eligibility|8
5976081|NCT00383435|9562562|FG002|26-Week Double-Blind Treatment Period|Did not meet protocol eligibility|9
5976082|NCT00383435|9562563|FG003|26-Week Double-Blind Treatment Period|Did not meet protocol eligibility|5
5976083|NCT00383435|9562564|FG004|26-Week Double-Blind Treatment Period|Did not meet protocol eligibility|6
5976084|NCT00383435|9562560|FG000|26-Week Double-Blind Treatment Period|Administrative|5
5976085|NCT00383435|9562561|FG001|26-Week Double-Blind Treatment Period|Administrative|3
5976086|NCT00383435|9562562|FG002|26-Week Double-Blind Treatment Period|Administrative|1
5976087|NCT00383435|9562563|FG003|26-Week Double-Blind Treatment Period|Administrative|1
5976088|NCT00383435|9562564|FG004|26-Week Double-Blind Treatment Period|Administrative|1
5976089|NCT00383435|9562560|FG000|26-Week Treatment Safety Extension|Adverse Event|4
6193904|NCT01442038|9851869|FG001|Overall Study|Adverse Event|15
6193905|NCT01442038|9851868|FG000|Overall Study|Protocol Deviation|9
6193906|NCT01442038|9851869|FG001|Overall Study|Protocol Deviation|20
6193907|NCT01442038|9851868|FG000|Overall Study|Investigator's Discretion|13
6193908|NCT01442038|9851869|FG001|Overall Study|Investigator's Discretion|16
6193909|NCT01442038|9851868|FG000|Overall Study|Study Terminated By Sponsor|2
6193910|NCT01442038|9851869|FG001|Overall Study|Study Terminated By Sponsor|3
6193911|NCT01442064|9851881|FG000|Overall Study|Adverse Event|2
6193912|NCT01442064|9851882|FG001|Overall Study|Adverse Event|2
6193913|NCT01442064|9851883|FG002|Overall Study|Adverse Event|2
6193914|NCT01442064|9851884|FG003|Overall Study|Adverse Event|1
6193915|NCT01442064|9851885|FG004|Overall Study|Adverse Event|2
6193916|NCT01442064|9851886|FG005|Overall Study|Adverse Event|0
6193917|NCT01442064|9851881|FG000|Overall Study|Death|0
6193918|NCT01442064|9851882|FG001|Overall Study|Death|1
6193919|NCT01442064|9851883|FG002|Overall Study|Death|3
6193920|NCT01442064|9851884|FG003|Overall Study|Death|3
6193921|NCT01442064|9851885|FG004|Overall Study|Death|1
6193922|NCT01442064|9851886|FG005|Overall Study|Death|3
6193923|NCT01442064|9851881|FG000|Overall Study|Lost to Follow-up|5
6193924|NCT01442064|9851882|FG001|Overall Study|Lost to Follow-up|5
6193925|NCT01442064|9851883|FG002|Overall Study|Lost to Follow-up|1
6193926|NCT01442064|9851884|FG003|Overall Study|Lost to Follow-up|1
6193927|NCT01442064|9851885|FG004|Overall Study|Lost to Follow-up|3
6193928|NCT01442064|9851886|FG005|Overall Study|Lost to Follow-up|3
6193929|NCT01442064|9851881|FG000|Overall Study|Physician Decision|1
6193930|NCT01442064|9851882|FG001|Overall Study|Physician Decision|1
6273351|NCT02189837|9976801|FG000|Overall Study|Sponsor Decision|0
6273352|NCT02189837|9976802|FG001|Overall Study|Sponsor Decision|0
6273353|NCT02189837|9976803|FG002|Overall Study|Sponsor Decision|0
6273354|NCT02189837|9976804|FG003|Overall Study|Sponsor Decision|1
6273355|NCT02189863|9976823|FG000|First 2 Weeks|Motion Sickness|4
6273356|NCT02189863|9976824|FG001|First 2 Weeks|Motion Sickness|2
6273357|NCT02189941|9976846|FG000|Overall Study|Non-compliance|0
6273358|NCT02189941|9976847|FG001|Overall Study|Non-compliance|0
6273359|NCT02189941|9976848|FG002|Overall Study|Non-compliance|1
6273360|NCT02190279|9976877|FG000|Overall Study|Withdrawal consent|1
6273361|NCT02190279|9976878|FG001|Overall Study|Withdrawal consent|0
6273362|NCT02190279|9976879|FG002|Overall Study|Withdrawal consent|1
6273363|NCT02190279|9976877|FG000|Overall Study|Lost to Follow-up|2
6273364|NCT02190279|9976878|FG001|Overall Study|Lost to Follow-up|0
6273365|NCT02190279|9976879|FG002|Overall Study|Lost to Follow-up|0
6273366|NCT02190279|9976877|FG000|Overall Study|Refused further treatment|0
6273367|NCT02190279|9976878|FG001|Overall Study|Refused further treatment|0
6273368|NCT02190279|9976879|FG002|Overall Study|Refused further treatment|1
6273369|NCT02190279|9976877|FG000|Overall Study|Screening failure|0
6273370|NCT02190279|9976878|FG001|Overall Study|Screening failure|0
6273371|NCT02190279|9976879|FG002|Overall Study|Screening failure|1
6193931|NCT01442064|9851883|FG002|Overall Study|Physician Decision|2
6193932|NCT01442064|9851884|FG003|Overall Study|Physician Decision|3
6273372|NCT02190435|9976891|FG000|Overall Study|First 12 patients were lead-ins|12
5976090|NCT00383435|9562561|FG001|26-Week Treatment Safety Extension|Adverse Event|2
5976091|NCT00383435|9562562|FG002|26-Week Treatment Safety Extension|Adverse Event|5
5976092|NCT00383435|9562563|FG003|26-Week Treatment Safety Extension|Adverse Event|5
5976093|NCT00383435|9562564|FG004|26-Week Treatment Safety Extension|Adverse Event|1
5976094|NCT00383435|9562560|FG000|26-Week Treatment Safety Extension|Lack of Efficacy|1
5976095|NCT00383435|9562561|FG001|26-Week Treatment Safety Extension|Lack of Efficacy|1
5976096|NCT00383435|9562562|FG002|26-Week Treatment Safety Extension|Lack of Efficacy|1
5976097|NCT00383435|9562563|FG003|26-Week Treatment Safety Extension|Lack of Efficacy|1
5976098|NCT00383435|9562564|FG004|26-Week Treatment Safety Extension|Lack of Efficacy|0
5976099|NCT00383435|9562560|FG000|26-Week Treatment Safety Extension|Lost to Follow-up|0
5976100|NCT00383435|9562561|FG001|26-Week Treatment Safety Extension|Lost to Follow-up|2
5976101|NCT00383435|9562562|FG002|26-Week Treatment Safety Extension|Lost to Follow-up|1
5976102|NCT00383435|9562563|FG003|26-Week Treatment Safety Extension|Lost to Follow-up|0
5976103|NCT00383435|9562564|FG004|26-Week Treatment Safety Extension|Lost to Follow-up|1
5976104|NCT00383435|9562560|FG000|26-Week Treatment Safety Extension|Participant withdrawal unrelated|2
5976105|NCT00383435|9562561|FG001|26-Week Treatment Safety Extension|Participant withdrawal unrelated|2
5976106|NCT00383435|9562562|FG002|26-Week Treatment Safety Extension|Participant withdrawal unrelated|6
5976107|NCT00383435|9562563|FG003|26-Week Treatment Safety Extension|Participant withdrawal unrelated|6
5976108|NCT00383435|9562564|FG004|26-Week Treatment Safety Extension|Participant withdrawal unrelated|0
5976109|NCT00383435|9562560|FG000|26-Week Treatment Safety Extension|Participant withdrawal related|1
5976110|NCT00383435|9562561|FG001|26-Week Treatment Safety Extension|Participant withdrawal related|0
5976111|NCT00383435|9562562|FG002|26-Week Treatment Safety Extension|Participant withdrawal related|2
5976112|NCT00383435|9562563|FG003|26-Week Treatment Safety Extension|Participant withdrawal related|0
5976113|NCT00383435|9562564|FG004|26-Week Treatment Safety Extension|Participant withdrawal related|1
5976114|NCT00383435|9562560|FG000|26-Week Treatment Safety Extension|Non-compliance with protocol|4
5976115|NCT00383435|9562561|FG001|26-Week Treatment Safety Extension|Non-compliance with protocol|1
5976116|NCT00383435|9562562|FG002|26-Week Treatment Safety Extension|Non-compliance with protocol|1
5976117|NCT00383435|9562563|FG003|26-Week Treatment Safety Extension|Non-compliance with protocol|1
5976118|NCT00383435|9562564|FG004|26-Week Treatment Safety Extension|Non-compliance with protocol|0
5976119|NCT00383435|9562560|FG000|26-Week Treatment Safety Extension|Did not meet protocol eligibility|1
5976120|NCT00383435|9562561|FG001|26-Week Treatment Safety Extension|Did not meet protocol eligibility|0
5976121|NCT00383435|9562562|FG002|26-Week Treatment Safety Extension|Did not meet protocol eligibility|0
5976122|NCT00383435|9562563|FG003|26-Week Treatment Safety Extension|Did not meet protocol eligibility|1
5976123|NCT00383435|9562564|FG004|26-Week Treatment Safety Extension|Did not meet protocol eligibility|0
5976124|NCT00383435|9562560|FG000|26-Week Treatment Safety Extension|Administrative|1
5976125|NCT00383435|9562561|FG001|26-Week Treatment Safety Extension|Administrative|1
6193933|NCT01442064|9851885|FG004|Overall Study|Physician Decision|3
6193934|NCT01442064|9851886|FG005|Overall Study|Physician Decision|1
6193935|NCT01442064|9851881|FG000|Overall Study|Withdrawal by Subject|6
6193936|NCT01442064|9851882|FG001|Overall Study|Withdrawal by Subject|3
6193937|NCT01442064|9851883|FG002|Overall Study|Withdrawal by Subject|2
6273373|NCT02190435|9976892|FG001|Overall Study|First 12 patients were lead-ins|0
6273374|NCT02190435|9976891|FG000|Overall Study|3 consented screen fails|3
6273375|NCT02190435|9976892|FG001|Overall Study|3 consented screen fails|0
6273376|NCT02190591|9976905|FG000|Overall Study|Withdrawal by Subject|1
6273377|NCT02190591|9976906|FG001|Overall Study|Withdrawal by Subject|8
6273378|NCT02190591|9976905|FG000|Overall Study|Protocol Violation|1
6273379|NCT02190591|9976906|FG001|Overall Study|Protocol Violation|0
6273380|NCT02190591|9976905|FG000|Overall Study|did not use peanut ball as instructed|0
6273381|NCT02190591|9976906|FG001|Overall Study|did not use peanut ball as instructed|2
6273382|NCT02190591|9976905|FG000|Overall Study|face presentation so she was ineligible|0
6273383|NCT02190591|9976906|FG001|Overall Study|face presentation so she was ineligible|1
6273384|NCT02190604|9976931|FG000|Part 1 and 2 (Healthy Volunteers)|Adverse Event|0
6273385|NCT02190604|9976932|FG001|Part 1 and 2 (Healthy Volunteers)|Adverse Event|0
6273386|NCT02190604|9976933|FG002|Part 1 and 2 (Healthy Volunteers)|Adverse Event|0
5976126|NCT00383435|9562562|FG002|26-Week Treatment Safety Extension|Administrative|0
5976127|NCT00383435|9562563|FG003|26-Week Treatment Safety Extension|Administrative|1
5976128|NCT00383435|9562564|FG004|26-Week Treatment Safety Extension|Administrative|0
5976129|NCT00381485|9562579|FG000|Open-Label Run-In Period|Adverse Event|9
5976130|NCT00381485|9562580|FG001|Open-Label Run-In Period|Adverse Event|0
6193938|NCT01442064|9851884|FG003|Overall Study|Withdrawal by Subject|2
6193939|NCT01442064|9851885|FG004|Overall Study|Withdrawal by Subject|2
6193940|NCT01442064|9851886|FG005|Overall Study|Withdrawal by Subject|1
6193941|NCT01442064|9851881|FG000|Overall Study|Sponsor decision|82
6193942|NCT01442064|9851882|FG001|Overall Study|Sponsor decision|88
6193943|NCT01442064|9851883|FG002|Overall Study|Sponsor decision|92
6193944|NCT01442064|9851884|FG003|Overall Study|Sponsor decision|88
6193945|NCT01442064|9851885|FG004|Overall Study|Sponsor decision|95
6193946|NCT01442064|9851886|FG005|Overall Study|Sponsor decision|87
6193947|NCT01442064|9851881|FG000|Overall Study|Subject non-compliance|0
6193948|NCT01442064|9851882|FG001|Overall Study|Subject non-compliance|0
6193949|NCT01442064|9851883|FG002|Overall Study|Subject non-compliance|0
6193950|NCT01442064|9851884|FG003|Overall Study|Subject non-compliance|0
5976131|NCT00381485|9562581|FG002|Open-Label Run-In Period|Adverse Event|0
5976132|NCT00381485|9562582|FG003|Open-Label Run-In Period|Adverse Event|0
5976133|NCT00381485|9562579|FG000|Open-Label Run-In Period|Did not meet protocol eligibility|76
5976134|NCT00381485|9562580|FG001|Open-Label Run-In Period|Did not meet protocol eligibility|0
5976135|NCT00381485|9562581|FG002|Open-Label Run-In Period|Did not meet protocol eligibility|0
5976136|NCT00381485|9562582|FG003|Open-Label Run-In Period|Did not meet protocol eligibility|0
5976137|NCT00381485|9562579|FG000|Open-Label Run-In Period|Withdrawal by Subject-reasons related|16
5976138|NCT00381485|9562580|FG001|Open-Label Run-In Period|Withdrawal by Subject-reasons related|0
5976139|NCT00381485|9562581|FG002|Open-Label Run-In Period|Withdrawal by Subject-reasons related|0
5976140|NCT00381485|9562582|FG003|Open-Label Run-In Period|Withdrawal by Subject-reasons related|0
5976141|NCT00381485|9562579|FG000|Open-Label Run-In Period|Withdrawal by Subject-reasons unrelated|1
5976142|NCT00381485|9562580|FG001|Open-Label Run-In Period|Withdrawal by Subject-reasons unrelated|0
5976143|NCT00381485|9562581|FG002|Open-Label Run-In Period|Withdrawal by Subject-reasons unrelated|0
5976144|NCT00381485|9562582|FG003|Open-Label Run-In Period|Withdrawal by Subject-reasons unrelated|0
5976145|NCT00381485|9562579|FG000|Open-Label Run-In Period|Lost to Follow-up|3
5976146|NCT00381485|9562580|FG001|Open-Label Run-In Period|Lost to Follow-up|0
5976147|NCT00381485|9562581|FG002|Open-Label Run-In Period|Lost to Follow-up|0
5976148|NCT00381485|9562582|FG003|Open-Label Run-In Period|Lost to Follow-up|0
5976149|NCT00381485|9562579|FG000|Open-Label Run-In Period|Treatment failure|1
5976150|NCT00381485|9562580|FG001|Open-Label Run-In Period|Treatment failure|0
5976151|NCT00381485|9562581|FG002|Open-Label Run-In Period|Treatment failure|0
5976152|NCT00381485|9562582|FG003|Open-Label Run-In Period|Treatment failure|0
6050633|NCT00428090|9649857|FG003|Overall Study|Prohibited medication used for SAE|0
6050634|NCT00428090|9649854|FG000|Overall Study|Death of par.|1
6050635|NCT00428090|9649855|FG001|Overall Study|Death of par.|0
6193951|NCT01442064|9851885|FG004|Overall Study|Subject non-compliance|0
6193952|NCT01442064|9851886|FG005|Overall Study|Subject non-compliance|2
6193953|NCT01442064|9851881|FG000|Overall Study|Condition mandated other intervention|1
6193954|NCT01442064|9851882|FG001|Overall Study|Condition mandated other intervention|1
6193955|NCT01442064|9851883|FG002|Overall Study|Condition mandated other intervention|2
6193956|NCT01442064|9851884|FG003|Overall Study|Condition mandated other intervention|0
6193957|NCT01442064|9851885|FG004|Overall Study|Condition mandated other intervention|0
6193958|NCT01442064|9851886|FG005|Overall Study|Condition mandated other intervention|2
6193959|NCT01442103|9851903|FG000|Overall Study|Lost to Follow-up|2
6193960|NCT01442155|9851916|FG000|Overall Study|Complete remission|35
6193961|NCT01442155|9851916|FG000|Overall Study|Recurrence|26
6193962|NCT01442155|9851916|FG000|Overall Study|Adverse Event|2
6193963|NCT01442155|9851916|FG000|Overall Study|Lost to Follow-up|2
6273387|NCT02190604|9976934|FG003|Part 1 and 2 (Healthy Volunteers)|Adverse Event|0
6273388|NCT02190604|9976935|FG004|Part 1 and 2 (Healthy Volunteers)|Adverse Event|0
6273389|NCT02190604|9976936|FG005|Part 1 and 2 (Healthy Volunteers)|Adverse Event|0
6273390|NCT02190604|9976937|FG006|Part 1 and 2 (Healthy Volunteers)|Adverse Event|0
6273391|NCT02190604|9976938|FG007|Part 1 and 2 (Healthy Volunteers)|Adverse Event|0
6273392|NCT02190604|9976939|FG008|Part 1 and 2 (Healthy Volunteers)|Adverse Event|0
6273393|NCT02190604|9976940|FG009|Part 1 and 2 (Healthy Volunteers)|Adverse Event|0
6273394|NCT02190604|9976941|FG010|Part 1 and 2 (Healthy Volunteers)|Adverse Event|0
6273395|NCT02190604|9976942|FG011|Part 1 and 2 (Healthy Volunteers)|Adverse Event|0
6273396|NCT02190604|9976943|FG012|Part 1 and 2 (Healthy Volunteers)|Adverse Event|0
6273397|NCT02190604|9976944|FG013|Part 1 and 2 (Healthy Volunteers)|Adverse Event|0
6273398|NCT02190604|9976945|FG014|Part 1 and 2 (Healthy Volunteers)|Adverse Event|2
6273399|NCT02190604|9976946|FG015|Part 1 and 2 (Healthy Volunteers)|Adverse Event|0
6273400|NCT02190604|9976947|FG016|Part 1 and 2 (Healthy Volunteers)|Adverse Event|0
6273401|NCT02190604|9976948|FG017|Part 1 and 2 (Healthy Volunteers)|Adverse Event|0
6273402|NCT02190604|9976949|FG018|Part 1 and 2 (Healthy Volunteers)|Adverse Event|0
6273403|NCT02190604|9976931|FG000|Part 1 and 2 (Healthy Volunteers)|Lost to Follow-up|0
6273404|NCT02190604|9976932|FG001|Part 1 and 2 (Healthy Volunteers)|Lost to Follow-up|0
6273405|NCT02190604|9976933|FG002|Part 1 and 2 (Healthy Volunteers)|Lost to Follow-up|0
6273406|NCT02190604|9976934|FG003|Part 1 and 2 (Healthy Volunteers)|Lost to Follow-up|0
6273407|NCT02190604|9976935|FG004|Part 1 and 2 (Healthy Volunteers)|Lost to Follow-up|0
6273408|NCT02190604|9976936|FG005|Part 1 and 2 (Healthy Volunteers)|Lost to Follow-up|0
6273409|NCT02190604|9976937|FG006|Part 1 and 2 (Healthy Volunteers)|Lost to Follow-up|0
6273410|NCT02190604|9976938|FG007|Part 1 and 2 (Healthy Volunteers)|Lost to Follow-up|0
6273411|NCT02190604|9976939|FG008|Part 1 and 2 (Healthy Volunteers)|Lost to Follow-up|0
6273412|NCT02190604|9976940|FG009|Part 1 and 2 (Healthy Volunteers)|Lost to Follow-up|0
6273413|NCT02190604|9976941|FG010|Part 1 and 2 (Healthy Volunteers)|Lost to Follow-up|0
6273414|NCT02190604|9976942|FG011|Part 1 and 2 (Healthy Volunteers)|Lost to Follow-up|0
6273415|NCT02190604|9976943|FG012|Part 1 and 2 (Healthy Volunteers)|Lost to Follow-up|0
6273416|NCT02190604|9976944|FG013|Part 1 and 2 (Healthy Volunteers)|Lost to Follow-up|1
6273417|NCT02190604|9976945|FG014|Part 1 and 2 (Healthy Volunteers)|Lost to Follow-up|0
6273418|NCT02190604|9976946|FG015|Part 1 and 2 (Healthy Volunteers)|Lost to Follow-up|0
6273419|NCT02190604|9976947|FG016|Part 1 and 2 (Healthy Volunteers)|Lost to Follow-up|0
6273420|NCT02190604|9976948|FG017|Part 1 and 2 (Healthy Volunteers)|Lost to Follow-up|0
5976153|NCT00381485|9562579|FG000|Double-Blind Treatment Period|Adverse Event|0
5976154|NCT00381485|9562580|FG001|Double-Blind Treatment Period|Adverse Event|2
5976155|NCT00381485|9562581|FG002|Double-Blind Treatment Period|Adverse Event|2
5976156|NCT00381485|9562582|FG003|Double-Blind Treatment Period|Adverse Event|5
5976157|NCT00381485|9562579|FG000|Double-Blind Treatment Period|Lack of Efficacy|0
5976158|NCT00381485|9562580|FG001|Double-Blind Treatment Period|Lack of Efficacy|8
5976159|NCT00381485|9562581|FG002|Double-Blind Treatment Period|Lack of Efficacy|11
5976160|NCT00381485|9562582|FG003|Double-Blind Treatment Period|Lack of Efficacy|13
5976161|NCT00381485|9562579|FG000|Double-Blind Treatment Period|Lost to Follow-up|0
5976162|NCT00381485|9562580|FG001|Double-Blind Treatment Period|Lost to Follow-up|0
5976163|NCT00381485|9562581|FG002|Double-Blind Treatment Period|Lost to Follow-up|1
5976164|NCT00381485|9562582|FG003|Double-Blind Treatment Period|Lost to Follow-up|1
5976165|NCT00381485|9562579|FG000|Double-Blind Treatment Period|Noncompliance with protocol|0
5976166|NCT00381485|9562580|FG001|Double-Blind Treatment Period|Noncompliance with protocol|9
5976167|NCT00381485|9562581|FG002|Double-Blind Treatment Period|Noncompliance with protocol|3
5976168|NCT00381485|9562582|FG003|Double-Blind Treatment Period|Noncompliance with protocol|3
5976169|NCT00381485|9562579|FG000|Double-Blind Treatment Period|Did not meet protocol eligibility|0
5976170|NCT00381485|9562580|FG001|Double-Blind Treatment Period|Did not meet protocol eligibility|5
5976171|NCT00381485|9562581|FG002|Double-Blind Treatment Period|Did not meet protocol eligibility|7
5976172|NCT00381485|9562582|FG003|Double-Blind Treatment Period|Did not meet protocol eligibility|5
5976173|NCT00381485|9562579|FG000|Double-Blind Treatment Period|Withdrawal by Subject-reasons unrelated|0
5976174|NCT00381485|9562580|FG001|Double-Blind Treatment Period|Withdrawal by Subject-reasons unrelated|2
5976175|NCT00381485|9562581|FG002|Double-Blind Treatment Period|Withdrawal by Subject-reasons unrelated|1
5976176|NCT00381485|9562582|FG003|Double-Blind Treatment Period|Withdrawal by Subject-reasons unrelated|4
5976177|NCT00381485|9562579|FG000|Double-Blind Treatment Period|Withdrawal by Subject-reasons related|0
5976178|NCT00381485|9562580|FG001|Double-Blind Treatment Period|Withdrawal by Subject-reasons related|0
5976179|NCT00381485|9562581|FG002|Double-Blind Treatment Period|Withdrawal by Subject-reasons related|0
5976180|NCT00381485|9562582|FG003|Double-Blind Treatment Period|Withdrawal by Subject-reasons related|1
5976181|NCT00381485|9562579|FG000|Double-Blind Treatment Period|Administrative|0
5976182|NCT00381485|9562580|FG001|Double-Blind Treatment Period|Administrative|1
5976183|NCT00381485|9562581|FG002|Double-Blind Treatment Period|Administrative|0
5976184|NCT00381485|9562582|FG003|Double-Blind Treatment Period|Administrative|1
5976185|NCT00379288|9562595|FG000|Overall Study|Adverse Event|5
5976186|NCT00379288|9562596|FG001|Overall Study|Adverse Event|6
5976187|NCT00379288|9562597|FG002|Overall Study|Adverse Event|2
5976188|NCT00379288|9562598|FG003|Overall Study|Adverse Event|0
5976189|NCT00379288|9562595|FG000|Overall Study|Treatment Failure|0
6088237|NCT00673920|9698951|FG001|Baseline up to Week 48|Insufficient therapeutic response|1
6088238|NCT00673920|9698952|FG002|Baseline up to Week 48|Insufficient therapeutic response|0
5976190|NCT00379288|9562596|FG001|Overall Study|Treatment Failure|1
5976191|NCT00379288|9562597|FG002|Overall Study|Treatment Failure|0
5976192|NCT00379288|9562598|FG003|Overall Study|Treatment Failure|1
5976193|NCT00379288|9562595|FG000|Overall Study|Lost to Follow-up|3
5976194|NCT00379288|9562596|FG001|Overall Study|Lost to Follow-up|3
5976195|NCT00379288|9562597|FG002|Overall Study|Lost to Follow-up|2
5976196|NCT00379288|9562598|FG003|Overall Study|Lost to Follow-up|0
5976197|NCT00379288|9562595|FG000|Overall Study|Subject withdrew-unrelated to study drug|0
5976198|NCT00379288|9562596|FG001|Overall Study|Subject withdrew-unrelated to study drug|3
5976199|NCT00379288|9562597|FG002|Overall Study|Subject withdrew-unrelated to study drug|4
5976200|NCT00379288|9562598|FG003|Overall Study|Subject withdrew-unrelated to study drug|2
5976201|NCT00379288|9562595|FG000|Overall Study|Subject withdrew-related to study drug|1
5976202|NCT00379288|9562596|FG001|Overall Study|Subject withdrew-related to study drug|0
6193964|NCT01442181|9851922|FG000|Overall Study|patient refused surgery|1
6193965|NCT01442181|9851923|FG001|Overall Study|patient refused surgery|0
6193966|NCT01442181|9851922|FG000|Overall Study|no insurance for surgery|1
6193967|NCT01442181|9851923|FG001|Overall Study|no insurance for surgery|0
6193968|NCT01442181|9851922|FG000|Overall Study|low ejection factor|0
6193969|NCT01442181|9851923|FG001|Overall Study|low ejection factor|1
6193970|NCT01442181|9851922|FG000|Overall Study|Lost to Follow-up|1
6193971|NCT01442181|9851923|FG001|Overall Study|Lost to Follow-up|1
6193972|NCT01442181|9851922|FG000|Overall Study|patient in an additional study|1
6193973|NCT01442181|9851923|FG001|Overall Study|patient in an additional study|0
6193974|NCT01442181|9851922|FG000|Overall Study|atrial fibrillation not noted|0
6193975|NCT01442181|9851923|FG001|Overall Study|atrial fibrillation not noted|1
6193976|NCT01442376|9851933|FG000|Overall Study|Adverse Event|0
6193977|NCT01442376|9851934|FG001|Overall Study|Adverse Event|3
6193978|NCT01442376|9851935|FG002|Overall Study|Adverse Event|2
6193979|NCT01442376|9851933|FG000|Overall Study|Death|0
6193980|NCT01442376|9851934|FG001|Overall Study|Death|1
6193981|NCT01442376|9851935|FG002|Overall Study|Death|1
5976203|NCT00379288|9562597|FG002|Overall Study|Subject withdrew-related to study drug|0
5976204|NCT00379288|9562598|FG003|Overall Study|Subject withdrew-related to study drug|1
5976205|NCT00379288|9562595|FG000|Overall Study|Noncompliance with protocol|8
5976206|NCT00379288|9562596|FG001|Overall Study|Noncompliance with protocol|6
5976207|NCT00379288|9562597|FG002|Overall Study|Noncompliance with protocol|2
5976208|NCT00379288|9562598|FG003|Overall Study|Noncompliance with protocol|1
6088239|NCT00673920|9698953|FG003|Baseline up to Week 48|Insufficient therapeutic response|0
6088240|NCT00673920|9698954|FG004|Baseline up to Week 48|Insufficient therapeutic response|0
6088241|NCT00673920|9698955|FG005|Baseline up to Week 48|Insufficient therapeutic response|0
6088242|NCT00673920|9698956|FG006|Baseline up to Week 48|Insufficient therapeutic response|0
6193982|NCT01442376|9851933|FG000|Overall Study|Withdrawal of consent|0
6193983|NCT01442376|9851934|FG001|Overall Study|Withdrawal of consent|0
5976209|NCT00379288|9562595|FG000|Overall Study|Did not meet protocol eligibility|0
6193984|NCT01442376|9851935|FG002|Overall Study|Withdrawal of consent|1
6193985|NCT01442376|9851933|FG000|Overall Study|Patients not treated|2
6193986|NCT01442376|9851934|FG001|Overall Study|Patients not treated|3
6193987|NCT01442376|9851935|FG002|Overall Study|Patients not treated|1
6193988|NCT01442376|9851933|FG000|Overall Study|Not eligible for subsequent cycles|1
6193989|NCT01442376|9851934|FG001|Overall Study|Not eligible for subsequent cycles|2
6193990|NCT01442376|9851935|FG002|Overall Study|Not eligible for subsequent cycles|0
6193991|NCT01442493|9851945|FG000|Overall Study|withdrawn from study|3
6193992|NCT01442493|9851946|FG001|Overall Study|withdrawn from study|2
6193993|NCT01442675|9851952|FG000|Overall Study|Protocol Violation|6
6193994|NCT01442675|9851952|FG000|Overall Study|Lost to Follow-up|2
6193995|NCT01442675|9851952|FG000|Overall Study|Withdrawal by Subject|4
6193996|NCT01442688|9851959|FG000|First Intervention|Withdrawal by Subject|1
6193997|NCT01442688|9851960|FG001|First Intervention|Withdrawal by Subject|0
6193998|NCT01442688|9851959|FG000|First Intervention|subject incarcerated|1
6193999|NCT01442688|9851960|FG001|First Intervention|subject incarcerated|0
6194000|NCT01442688|9851959|FG000|Second Intervention|Adverse Event|1
6194001|NCT01442688|9851960|FG001|Second Intervention|Adverse Event|0
6194002|NCT01442714|9851966|FG000|Overall Study|Death|11
6194003|NCT01442714|9851966|FG000|Overall Study|Withdrawal by Subject|1
6194004|NCT01442779|9851972|FG000|Overall Study|Withdrawal by Subject|3
6194005|NCT01442779|9851972|FG000|Overall Study|Death|3
6194006|NCT01442779|9851972|FG000|Overall Study|Non-compliance|1
6194007|NCT01443026|9851987|FG000|Overall Study|Physician Decision|1
6273421|NCT02190604|9976949|FG018|Part 1 and 2 (Healthy Volunteers)|Lost to Follow-up|0
6273422|NCT02191046|9977039|FG000|Overall Study|low compliance|5
6273423|NCT02191046|9977040|FG001|Overall Study|low compliance|1
6273424|NCT02191137|9977046|FG000|Treatment|Death|4
6273425|NCT02191137|9977046|FG000|Treatment|Withdrawal by Subject|3
6273426|NCT02191137|9977046|FG000|Treatment|Adverse Event|2
6273427|NCT02191137|9977046|FG000|Treatment|Other|1
6273428|NCT02191137|9977046|FG000|Follow-up|Lost to Follow-up|2
6273429|NCT02191137|9977046|FG000|Follow-up|Ongoing/unknown|2
6273430|NCT02191137|9977046|FG000|Follow-up|Adverse Event|1
6273431|NCT02191267|9977053|FG000|Overall Study|Withdrawal by Subject|1
6273432|NCT02191267|9977054|FG001|Overall Study|Withdrawal by Subject|0
6273433|NCT02191267|9977055|FG002|Overall Study|Withdrawal by Subject|0
6273434|NCT02191397|9977065|FG000|Overall Study|Adverse Event|28
6273435|NCT02191397|9977066|FG001|Overall Study|Adverse Event|17
6273436|NCT02191397|9977065|FG000|Overall Study|Lack of Efficacy|10
6273437|NCT02191397|9977066|FG001|Overall Study|Lack of Efficacy|5
6273438|NCT02191397|9977065|FG000|Overall Study|Protocol Violation|0
6273439|NCT02191397|9977066|FG001|Overall Study|Protocol Violation|3
6273440|NCT02191397|9977065|FG000|Overall Study|Met protocol-defined stopping criteria|5
6273441|NCT02191397|9977066|FG001|Overall Study|Met protocol-defined stopping criteria|4
6273442|NCT02191397|9977065|FG000|Overall Study|Lost to Follow-up|10
6273443|NCT02191397|9977066|FG001|Overall Study|Lost to Follow-up|11
6273444|NCT02191397|9977065|FG000|Overall Study|Physician Decision|8
6273445|NCT02191397|9977066|FG001|Overall Study|Physician Decision|3
6273446|NCT02191397|9977065|FG000|Overall Study|Withdrawal by Subject|22
6273447|NCT02191397|9977066|FG001|Overall Study|Withdrawal by Subject|27
6273448|NCT02191579|9977074|FG000|Treatment 1|Multiple Reasons Specified|27
6273449|NCT02191579|9977075|FG001|Treatment 1|Multiple Reasons Specified|58
6273450|NCT02191579|9977074|FG000|Treatment 2|Multiple Reasons Specified|0
6273451|NCT02191579|9977075|FG001|Treatment 2|Multiple Reasons Specified|25
6273452|NCT02191605|9977086|FG000|Overall Study|Lost to Follow-up|9
6273453|NCT02191605|9977087|FG001|Overall Study|Lost to Follow-up|4
6273454|NCT02191605|9977088|FG002|Overall Study|Lost to Follow-up|7
6273455|NCT02191605|9977089|FG003|Overall Study|Lost to Follow-up|3
6273456|NCT02191605|9977090|FG004|Overall Study|Lost to Follow-up|4
6273457|NCT02191618|9977102|FG000|Overall Study|Withdrawal by Subject|3
6273458|NCT02191618|9977102|FG000|Overall Study|Missed Visit|4
6273459|NCT02192099|9977122|FG000|Overall Study|Adverse Event|1
6273460|NCT02192099|9977122|FG000|Overall Study|Lost to Follow-up|2
6273461|NCT02192099|9977122|FG000|Overall Study|Physician Decision|1
6273462|NCT02192099|9977122|FG000|Overall Study|Pregnancy|1
6273463|NCT02192099|9977122|FG000|Overall Study|Protocol Violation|8
6273464|NCT02192099|9977122|FG000|Overall Study|Study Terminated by Sponsor|32
5976210|NCT00379288|9562596|FG001|Overall Study|Did not meet protocol eligibility|1
6194008|NCT01443026|9851988|FG001|Overall Study|Physician Decision|0
6194009|NCT01443026|9851987|FG000|Overall Study|Death|0
6194010|NCT01443026|9851988|FG001|Overall Study|Death|1
6194011|NCT01443026|9851987|FG000|Overall Study|Withdrawal by Subject|0
6194012|NCT01443026|9851988|FG001|Overall Study|Withdrawal by Subject|3
6194013|NCT01443026|9851987|FG000|Overall Study|Lost to Follow-up|2
5976211|NCT00379288|9562597|FG002|Overall Study|Did not meet protocol eligibility|0
5976212|NCT00379288|9562598|FG003|Overall Study|Did not meet protocol eligibility|2
5976213|NCT00379288|9562595|FG000|Overall Study|Administrative|2
5976214|NCT00379288|9562596|FG001|Overall Study|Administrative|2
5976215|NCT00379288|9562597|FG002|Overall Study|Administrative|0
5976216|NCT00379288|9562598|FG003|Overall Study|Administrative|1
5976217|NCT00378378|9562611|FG000|Overall Study|Withdrawal by Subject|0
5976218|NCT00378378|9562612|FG001|Overall Study|Withdrawal by Subject|1
5976219|NCT00378378|9562613|FG002|Overall Study|Withdrawal by Subject|0
5976220|NCT00378378|9562611|FG000|Overall Study|Treatment Failure|0
5976221|NCT00378378|9562612|FG001|Overall Study|Treatment Failure|0
5976222|NCT00378378|9562613|FG002|Overall Study|Treatment Failure|1
5976223|NCT00378378|9562611|FG000|Overall Study|Non-compliance with protocol|0
5976224|NCT00378378|9562612|FG001|Overall Study|Non-compliance with protocol|0
5976225|NCT00378378|9562613|FG002|Overall Study|Non-compliance with protocol|1
5976226|NCT00089895|9562623|FG000|Overall Study|Consent Withdrawn|11
5976227|NCT00089895|9562624|FG001|Overall Study|Consent Withdrawn|14
5976228|NCT00089895|9562623|FG000|Overall Study|Technical reason|7
5976229|NCT00089895|9562624|FG001|Overall Study|Technical reason|2
5976230|NCT00089895|9562623|FG000|Overall Study|Surgery|0
5976231|NCT00089895|9562624|FG001|Overall Study|Surgery|1
5976232|NCT00089895|9562623|FG000|Overall Study|Bleeding|0
5976233|NCT00089895|9562624|FG001|Overall Study|Bleeding|2
5976234|NCT00089895|9562623|FG000|Overall Study|Physician Decision|3
5976235|NCT00089895|9562624|FG001|Overall Study|Physician Decision|7
5976236|NCT00089895|9562623|FG000|Overall Study|Exclusion criteria met|6
5976237|NCT00089895|9562624|FG001|Overall Study|Exclusion criteria met|6
5976238|NCT00089895|9562623|FG000|Overall Study|Not otherwise specified|4
5976239|NCT00089895|9562624|FG001|Overall Study|Not otherwise specified|8
5976240|NCT00089895|9562623|FG000|Overall Study|Missing|4
5976241|NCT00089895|9562624|FG001|Overall Study|Missing|2
5976242|NCT02577354|9562632|FG000|Overall Study|Lack of Efficacy|4
5976243|NCT02577354|9562633|FG001|Overall Study|Lack of Efficacy|4
5976244|NCT02577354|9562632|FG000|Overall Study|Lost to Follow-up|3
5976245|NCT02577354|9562633|FG001|Overall Study|Lost to Follow-up|1
5976246|NCT02577354|9562632|FG000|Overall Study|Missed Visit|4
5976247|NCT02577354|9562633|FG001|Overall Study|Missed Visit|3
5976248|NCT02577354|9562632|FG000|Overall Study|Adverse Event|4
5976249|NCT02577354|9562633|FG001|Overall Study|Adverse Event|5
5976250|NCT02471807|9562653|FG000|Overall Study|Death|14
5976251|NCT02471807|9562653|FG000|Overall Study|Withdrawal by Subject|1
5976252|NCT02471807|9562653|FG000|Overall Study|Explant|5
6194014|NCT01443026|9851988|FG001|Overall Study|Lost to Follow-up|1
6194015|NCT01443078|9851994|FG000|Overall Study|Responded to neoadjuvant platinum txt|27
6194016|NCT01443078|9851994|FG000|Overall Study|Withdrawal by Subject|1
6194017|NCT01443078|9851994|FG000|Overall Study|Patient had brain mets|1
6194018|NCT01443130|9852004|FG000|Overall Study|Lost to Follow-up|44
6194019|NCT01443130|9852005|FG001|Overall Study|Lost to Follow-up|42
6194020|NCT01443130|9852006|FG002|Overall Study|Lost to Follow-up|50
6194021|NCT01443130|9852007|FG003|Overall Study|Lost to Follow-up|23
6194022|NCT01443130|9852008|FG004|Overall Study|Lost to Follow-up|25
6194023|NCT01443130|9852009|FG005|Overall Study|Lost to Follow-up|21
6194024|NCT01443130|9852004|FG000|Overall Study|Death|0
6194025|NCT01443130|9852005|FG001|Overall Study|Death|1
6194026|NCT01443130|9852006|FG002|Overall Study|Death|0
6194027|NCT01443130|9852007|FG003|Overall Study|Death|7
6194028|NCT01443130|9852008|FG004|Overall Study|Death|10
6194029|NCT01443130|9852009|FG005|Overall Study|Death|8
6194030|NCT01443130|9852004|FG000|Overall Study|Adverse Event|2
6194031|NCT01443130|9852005|FG001|Overall Study|Adverse Event|1
6194032|NCT01443130|9852006|FG002|Overall Study|Adverse Event|1
6194033|NCT01443130|9852007|FG003|Overall Study|Adverse Event|0
6194034|NCT01443130|9852008|FG004|Overall Study|Adverse Event|0
6194035|NCT01443130|9852009|FG005|Overall Study|Adverse Event|0
6194036|NCT01443130|9852004|FG000|Overall Study|Protocol Violation|2
6194037|NCT01443130|9852005|FG001|Overall Study|Protocol Violation|1
6273465|NCT02192099|9977122|FG000|Overall Study|Withdrawal by Subject|11
5976253|NCT02471807|9562653|FG000|Overall Study|Visits not yet due|2
5976254|NCT02471807|9562653|FG000|Overall Study|Missed Visit|1
5976255|NCT02321514|9562657|FG000|Overall Study|Death|15
5976256|NCT02321514|9562657|FG000|Overall Study|Missed Visit|7
5976257|NCT02321514|9562657|FG000|Overall Study|Study Exit|3
5976258|NCT01453946|9562679|FG000|Overall Study|Did not receive drug for the taper phase|1
5976259|NCT01453946|9562679|FG000|Overall Study|Protocol Violation|2
5976260|NCT01453946|9562679|FG000|Overall Study|Lack of Efficacy|3
5976261|NCT01453946|9562679|FG000|Overall Study|Adverse Event|3
5976262|NCT01444092|9562683|FG000|Overall Study|Adverse Event|8
5976263|NCT01444092|9562683|FG000|Overall Study|Protocol Violation|1
5976264|NCT01444092|9562683|FG000|Overall Study|Withdrawal by Subject|1
5976265|NCT01444092|9562683|FG000|Overall Study|Other Eligibility criteria|7
5976266|NCT01265784|9562690|FG000|Overall Study|Lost to Follow-up|5
5976267|NCT01265784|9562691|FG001|Overall Study|Lost to Follow-up|3
5976268|NCT01265784|9562692|FG002|Overall Study|Lost to Follow-up|2
5976269|NCT01265784|9562690|FG000|Overall Study|Withdrawal by Subject|0
5976270|NCT01265784|9562691|FG001|Overall Study|Withdrawal by Subject|5
5976271|NCT01265784|9562692|FG002|Overall Study|Withdrawal by Subject|0
5976272|NCT01265784|9562690|FG000|Overall Study|Physician Decision|1
6194038|NCT01443130|9852006|FG002|Overall Study|Protocol Violation|3
5976273|NCT01265784|9562691|FG001|Overall Study|Physician Decision|0
5976274|NCT01265784|9562692|FG002|Overall Study|Physician Decision|1
5976275|NCT01265784|9562690|FG000|Overall Study|Adverse Event|1
5976276|NCT01265784|9562691|FG001|Overall Study|Adverse Event|0
5976277|NCT01265784|9562692|FG002|Overall Study|Adverse Event|0
5976278|NCT01265784|9562690|FG000|Overall Study|Death|3
5976279|NCT01265784|9562691|FG001|Overall Study|Death|0
5976280|NCT01265784|9562692|FG002|Overall Study|Death|0
5976281|NCT01265784|9562690|FG000|Overall Study|Protocol Violation|2
5976282|NCT01265784|9562691|FG001|Overall Study|Protocol Violation|0
5976283|NCT01265784|9562692|FG002|Overall Study|Protocol Violation|0
5976284|NCT01265784|9562690|FG000|Overall Study|Incorrectly Randomized|0
5976285|NCT01265784|9562691|FG001|Overall Study|Incorrectly Randomized|0
5976286|NCT01265784|9562692|FG002|Overall Study|Incorrectly Randomized|1
5976287|NCT00577577|9562702|FG000|Overall Study|Adverse Event|3
5976288|NCT00577577|9562703|FG001|Overall Study|Adverse Event|2
5976289|NCT00577577|9562702|FG000|Overall Study|Lost to Follow-up|1
5976290|NCT00577577|9562703|FG001|Overall Study|Lost to Follow-up|0
5976291|NCT00577577|9562702|FG000|Overall Study|Protocol Violation|0
5976292|NCT00577577|9562703|FG001|Overall Study|Protocol Violation|3
6088243|NCT00673920|9698957|FG007|Baseline up to Week 48|Insufficient therapeutic response|0
6088244|NCT00673920|9698950|FG000|Baseline up to Week 48|Protocol Violation|0
6088245|NCT00673920|9698951|FG001|Baseline up to Week 48|Protocol Violation|0
6194039|NCT01443130|9852007|FG003|Overall Study|Protocol Violation|2
6194040|NCT01443130|9852008|FG004|Overall Study|Protocol Violation|2
6194041|NCT01443130|9852009|FG005|Overall Study|Protocol Violation|3
6194042|NCT01443130|9852004|FG000|Overall Study|Withdrawal by Subject|15
6194043|NCT01443130|9852005|FG001|Overall Study|Withdrawal by Subject|14
6194044|NCT01443130|9852006|FG002|Overall Study|Withdrawal by Subject|12
6194045|NCT01443130|9852007|FG003|Overall Study|Withdrawal by Subject|7
6194046|NCT01443130|9852008|FG004|Overall Study|Withdrawal by Subject|7
6194047|NCT01443130|9852009|FG005|Overall Study|Withdrawal by Subject|2
6194048|NCT01443130|9852004|FG000|Overall Study|Death of Subject's Infant|5
6194049|NCT01443130|9852005|FG001|Overall Study|Death of Subject's Infant|10
6194050|NCT01443130|9852006|FG002|Overall Study|Death of Subject's Infant|11
6194051|NCT01443130|9852007|FG003|Overall Study|Death of Subject's Infant|0
6194052|NCT01443130|9852008|FG004|Overall Study|Death of Subject's Infant|0
6194053|NCT01443130|9852009|FG005|Overall Study|Death of Subject's Infant|0
6194054|NCT01443364|9852023|FG000|Overall Study|Lack of Efficacy|14
6194055|NCT01443364|9852023|FG000|Overall Study|Lost to Follow-up|3
6194056|NCT01443364|9852023|FG000|Overall Study|Withdrawal by Subject|5
6194057|NCT01443364|9852023|FG000|Overall Study|Other Reason|4
6194058|NCT01443364|9852023|FG000|Overall Study|SAE, non-fatal|6
6194059|NCT01443364|9852023|FG000|Overall Study|AE, non-serious non-fatal|8
6194060|NCT01443364|9852023|FG000|Overall Study|SAE, non-fatal+AE, non-serious non-fatal|1
6194061|NCT01443403|9852031|FG000|Overall Study|Adverse Event|1
6194062|NCT01443403|9852032|FG001|Overall Study|Adverse Event|1
6194063|NCT01443403|9852033|FG002|Overall Study|Adverse Event|4
6194064|NCT01443403|9852034|FG003|Overall Study|Adverse Event|5
6194065|NCT01443403|9852031|FG000|Overall Study|Withdrawal by Subject|0
6194066|NCT01443403|9852032|FG001|Overall Study|Withdrawal by Subject|1
6194067|NCT01443403|9852033|FG002|Overall Study|Withdrawal by Subject|2
6194068|NCT01443403|9852034|FG003|Overall Study|Withdrawal by Subject|1
6194069|NCT01443403|9852031|FG000|Overall Study|Lost to Follow-up|0
6194070|NCT01443403|9852032|FG001|Overall Study|Lost to Follow-up|0
6194071|NCT01443403|9852033|FG002|Overall Study|Lost to Follow-up|0
6194072|NCT01443403|9852034|FG003|Overall Study|Lost to Follow-up|1
6194073|NCT01443403|9852031|FG000|Overall Study|Protocol Violation|2
6194074|NCT01443403|9852032|FG001|Overall Study|Protocol Violation|1
6194075|NCT01443403|9852033|FG002|Overall Study|Protocol Violation|1
6194076|NCT01443403|9852034|FG003|Overall Study|Protocol Violation|1
6194077|NCT01443403|9852031|FG000|Overall Study|Use of Prohibited Treatment|2
6194078|NCT01443403|9852032|FG001|Overall Study|Use of Prohibited Treatment|3
6194079|NCT01443403|9852033|FG002|Overall Study|Use of Prohibited Treatment|0
6194080|NCT01443403|9852034|FG003|Overall Study|Use of Prohibited Treatment|0
6194081|NCT01443403|9852031|FG000|Overall Study|Other - Miscellaneous|1
6194082|NCT01443403|9852032|FG001|Overall Study|Other - Miscellaneous|0
6194083|NCT01443403|9852033|FG002|Overall Study|Other - Miscellaneous|0
6194084|NCT01443403|9852034|FG003|Overall Study|Other - Miscellaneous|1
6194085|NCT01443845|9852077|FG000|Overall Study|Protocol Violation|43
6194086|NCT01443845|9852078|FG001|Overall Study|Protocol Violation|45
6194087|NCT01443845|9852077|FG000|Overall Study|Other reasons, such as COPD exacerbation|44
6194088|NCT01443845|9852078|FG001|Overall Study|Other reasons, such as COPD exacerbation|44
6273466|NCT02192099|9977122|FG000|Overall Study|Miscellaneous Reasons|5
6194089|NCT01443845|9852077|FG000|Overall Study|Deterioration in pulmonary function|1
6194090|NCT01443845|9852078|FG001|Overall Study|Deterioration in pulmonary function|4
6194091|NCT01443845|9852077|FG000|Overall Study|Lack of Efficacy|10
5976293|NCT00577577|9562702|FG000|Overall Study|Transportation|1
5976294|NCT00577577|9562703|FG001|Overall Study|Transportation|0
5976295|NCT00392327|9562717|FG000|Overall Study|Death|1
5976296|NCT00392327|9562718|FG001|Overall Study|Death|0
5976297|NCT00392327|9562719|FG002|Overall Study|Death|1
5976298|NCT00392327|9562720|FG003|Overall Study|Death|0
5976299|NCT00392327|9562721|FG004|Overall Study|Death|0
5976300|NCT00392327|9562722|FG005|Overall Study|Death|0
5976301|NCT00392327|9562723|FG006|Overall Study|Death|0
5976302|NCT00392327|9562724|FG007|Overall Study|Death|0
5976303|NCT00392327|9562717|FG000|Overall Study|Lack of Efficacy|8
5976304|NCT00392327|9562718|FG001|Overall Study|Lack of Efficacy|8
5976305|NCT00392327|9562719|FG002|Overall Study|Lack of Efficacy|9
5976306|NCT00392327|9562720|FG003|Overall Study|Lack of Efficacy|6
5976307|NCT00392327|9562721|FG004|Overall Study|Lack of Efficacy|3
5976308|NCT00392327|9562722|FG005|Overall Study|Lack of Efficacy|3
5976309|NCT00392327|9562723|FG006|Overall Study|Lack of Efficacy|3
5976310|NCT00392327|9562724|FG007|Overall Study|Lack of Efficacy|3
5976311|NCT00392327|9562717|FG000|Overall Study|Physician Decision|3
5976312|NCT00392327|9562718|FG001|Overall Study|Physician Decision|5
5976313|NCT00392327|9562719|FG002|Overall Study|Physician Decision|2
5976314|NCT00392327|9562720|FG003|Overall Study|Physician Decision|2
5976315|NCT00392327|9562721|FG004|Overall Study|Physician Decision|0
5976316|NCT00392327|9562722|FG005|Overall Study|Physician Decision|1
6088246|NCT00673920|9698952|FG002|Baseline up to Week 48|Protocol Violation|1
6088247|NCT00673920|9698953|FG003|Baseline up to Week 48|Protocol Violation|0
6088248|NCT00673920|9698954|FG004|Baseline up to Week 48|Protocol Violation|0
6088249|NCT00673920|9698955|FG005|Baseline up to Week 48|Protocol Violation|0
6194092|NCT01443845|9852078|FG001|Overall Study|Lack of Efficacy|5
6194093|NCT01443845|9852077|FG000|Overall Study|Adverse Event|64
6194094|NCT01443845|9852078|FG001|Overall Study|Adverse Event|138
6194095|NCT01443845|9852077|FG000|Overall Study|Withdrawal by Subject|63
6194096|NCT01443845|9852078|FG001|Overall Study|Withdrawal by Subject|67
6194097|NCT01443845|9852077|FG000|Overall Study|Military Conflict - Site Terminated|20
6194098|NCT01443845|9852078|FG001|Overall Study|Military Conflict - Site Terminated|21
6194099|NCT01443845|9852077|FG000|Overall Study|Lost to Follow-up|9
6194100|NCT01443845|9852078|FG001|Overall Study|Lost to Follow-up|13
6194101|NCT01443858|9852087|FG000|Overall Study|Withdrawal by Subject|9
6194102|NCT01443858|9852088|FG001|Overall Study|Withdrawal by Subject|8
6194103|NCT01443858|9852089|FG002|Overall Study|Withdrawal by Subject|5
6273467|NCT02192164|9977126|FG000|Overall Study|Other|8
6273468|NCT02192164|9977126|FG000|Overall Study|Withdrawal by Subject|1
6273469|NCT02192164|9977126|FG000|Overall Study|Physician Decision|4
6273470|NCT02192164|9977126|FG000|Overall Study|Did not meet the exclusion criteria|1
6273471|NCT02192190|9977139|FG000|Overall Study|Adverse Event|1
6273472|NCT02192190|9977140|FG001|Overall Study|Adverse Event|1
6273473|NCT02192190|9977141|FG002|Overall Study|Adverse Event|0
6273474|NCT02192190|9977142|FG003|Overall Study|Adverse Event|0
6273475|NCT02192190|9977143|FG004|Overall Study|Adverse Event|0
6273476|NCT02192190|9977144|FG005|Overall Study|Adverse Event|0
6273477|NCT02192190|9977139|FG000|Overall Study|Lost to Follow-up|3
6273478|NCT02192190|9977140|FG001|Overall Study|Lost to Follow-up|3
6273479|NCT02192190|9977141|FG002|Overall Study|Lost to Follow-up|2
6273480|NCT02192190|9977142|FG003|Overall Study|Lost to Follow-up|1
6273481|NCT02192190|9977143|FG004|Overall Study|Lost to Follow-up|4
6273482|NCT02192190|9977144|FG005|Overall Study|Lost to Follow-up|3
6273483|NCT02192190|9977139|FG000|Overall Study|Physician Decision|2
6273484|NCT02192190|9977140|FG001|Overall Study|Physician Decision|0
6273485|NCT02192190|9977141|FG002|Overall Study|Physician Decision|0
6273486|NCT02192190|9977142|FG003|Overall Study|Physician Decision|0
6273487|NCT02192190|9977143|FG004|Overall Study|Physician Decision|0
6273488|NCT02192190|9977144|FG005|Overall Study|Physician Decision|0
6273489|NCT02192190|9977139|FG000|Overall Study|Terminated by Sponsor|43
6273490|NCT02192190|9977140|FG001|Overall Study|Terminated by Sponsor|23
6273491|NCT02192190|9977141|FG002|Overall Study|Terminated by Sponsor|20
6273492|NCT02192190|9977142|FG003|Overall Study|Terminated by Sponsor|23
6273493|NCT02192190|9977143|FG004|Overall Study|Terminated by Sponsor|21
6273494|NCT02192190|9977144|FG005|Overall Study|Terminated by Sponsor|23
6273495|NCT02192190|9977139|FG000|Overall Study|Withdrawal by Subject|4
6273496|NCT02192190|9977140|FG001|Overall Study|Withdrawal by Subject|1
6273497|NCT02192190|9977141|FG002|Overall Study|Withdrawal by Subject|2
6273498|NCT02192190|9977142|FG003|Overall Study|Withdrawal by Subject|1
6273499|NCT02192190|9977143|FG004|Overall Study|Withdrawal by Subject|5
6273500|NCT02192190|9977144|FG005|Overall Study|Withdrawal by Subject|3
5976317|NCT00392327|9562723|FG006|Overall Study|Physician Decision|5
5976318|NCT00392327|9562724|FG007|Overall Study|Physician Decision|3
5976319|NCT00392327|9562717|FG000|Overall Study|Protocol Violation|0
5976320|NCT00392327|9562718|FG001|Overall Study|Protocol Violation|0
5976321|NCT00392327|9562719|FG002|Overall Study|Protocol Violation|1
5976322|NCT00392327|9562720|FG003|Overall Study|Protocol Violation|0
6088250|NCT00673920|9698956|FG006|Baseline up to Week 48|Protocol Violation|0
6273501|NCT02192190|9977139|FG000|Overall Study|Could not Keep Visit Schedule|1
6273502|NCT02192190|9977140|FG001|Overall Study|Could not Keep Visit Schedule|0
6273503|NCT02192190|9977141|FG002|Overall Study|Could not Keep Visit Schedule|0
6273504|NCT02192190|9977142|FG003|Overall Study|Could not Keep Visit Schedule|0
6273505|NCT02192190|9977143|FG004|Overall Study|Could not Keep Visit Schedule|0
5976323|NCT00392327|9562721|FG004|Overall Study|Protocol Violation|0
5976324|NCT00392327|9562722|FG005|Overall Study|Protocol Violation|0
5976325|NCT00392327|9562723|FG006|Overall Study|Protocol Violation|0
5976326|NCT00392327|9562724|FG007|Overall Study|Protocol Violation|0
5976327|NCT00392327|9562717|FG000|Overall Study|Withdrawal by Subject|3
5976328|NCT00392327|9562718|FG001|Overall Study|Withdrawal by Subject|2
5976329|NCT00392327|9562719|FG002|Overall Study|Withdrawal by Subject|4
5976330|NCT00392327|9562720|FG003|Overall Study|Withdrawal by Subject|6
5976331|NCT00392327|9562721|FG004|Overall Study|Withdrawal by Subject|0
5976332|NCT00392327|9562722|FG005|Overall Study|Withdrawal by Subject|1
5976333|NCT00392327|9562723|FG006|Overall Study|Withdrawal by Subject|1
6194104|NCT01443858|9852087|FG000|Overall Study|Lack of Efficacy|1
6194105|NCT01443858|9852088|FG001|Overall Study|Lack of Efficacy|0
6194106|NCT01443858|9852089|FG002|Overall Study|Lack of Efficacy|0
6194107|NCT01443858|9852087|FG000|Overall Study|Lost to Follow-up|5
6194108|NCT01443858|9852088|FG001|Overall Study|Lost to Follow-up|5
6194109|NCT01443858|9852089|FG002|Overall Study|Lost to Follow-up|2
6194110|NCT01444027|9852100|FG000|Overall Study|Withdrawal by Subject|4
6194111|NCT01444027|9852101|FG001|Overall Study|Withdrawal by Subject|10
6194112|NCT01444027|9852102|FG002|Overall Study|Withdrawal by Subject|24
6194113|NCT01444027|9852100|FG000|Overall Study|Lost to Follow-up|26
6194114|NCT01444027|9852101|FG001|Overall Study|Lost to Follow-up|20
6194115|NCT01444027|9852102|FG002|Overall Study|Lost to Follow-up|14
6194116|NCT01444300|9852126|FG000|Overall Study|Adverse Event|4
6194117|NCT01444300|9852127|FG001|Overall Study|Adverse Event|0
6194118|NCT01444378|9852134|FG000|Overall Study|Lost to Follow-up|1
6194119|NCT01444378|9852134|FG000|Overall Study|Withdrawal by Subject|1
6194120|NCT01444378|9852134|FG000|Overall Study|Death|3
6194121|NCT01444378|9852134|FG000|Overall Study|Administrative Closure Of The Study|2
6194122|NCT01444378|9852134|FG000|Overall Study|Missed Visits|10
6194123|NCT01444391|9852141|FG000|Overall Study|Death|1
6194124|NCT01444417|9852147|FG000|Overall Study|Ineligibility Determined|0
6194125|NCT01444417|9852148|FG001|Overall Study|Ineligibility Determined|1
6194126|NCT01444417|9852147|FG000|Overall Study|Withdrawal by Subject|2
6194127|NCT01444417|9852148|FG001|Overall Study|Withdrawal by Subject|0
6194128|NCT01444430|9852156|FG000|Overall Study|Withdrawal by Subject|53
6194129|NCT01444430|9852157|FG001|Overall Study|Withdrawal by Subject|72
6194130|NCT01444430|9852156|FG000|Overall Study|Death|6
6194131|NCT01444430|9852157|FG001|Overall Study|Death|8
6194132|NCT01444430|9852156|FG000|Overall Study|Lost to Follow-up|2
6194133|NCT01444430|9852157|FG001|Overall Study|Lost to Follow-up|0
6194134|NCT01444430|9852156|FG000|Overall Study|CRF termination module not completed.|0
6194135|NCT01444430|9852157|FG001|Overall Study|CRF termination module not completed.|1
6194136|NCT01444456|9852163|FG000|Overall Study|Withdrawal by Subject|21
6194137|NCT01444456|9852163|FG000|Overall Study|Physician Decision|9
6194138|NCT01444456|9852163|FG000|Overall Study|Lost to Follow-up|37
6194139|NCT01444456|9852163|FG000|Overall Study|Death|73
6194140|NCT01444456|9852163|FG000|Overall Study|Ineligibility determined|23
6194141|NCT01444456|9852163|FG000|Overall Study|Other|18
6194142|NCT01444456|9852163|FG000|Overall Study|Not treated|104
6194143|NCT01444651|9852169|FG000|Overall Study|Adverse Event|3
6194144|NCT01444651|9852170|FG001|Overall Study|Adverse Event|2
6194145|NCT01444651|9852169|FG000|Overall Study|Lost to Follow-up|5
6194146|NCT01444651|9852170|FG001|Overall Study|Lost to Follow-up|5
6194147|NCT01444651|9852169|FG000|Overall Study|Non-fasting|2
6194148|NCT01444651|9852170|FG001|Overall Study|Non-fasting|1
6194149|NCT01444651|9852169|FG000|Overall Study|Missing data|1
6194150|NCT01444651|9852170|FG001|Overall Study|Missing data|1
6194151|NCT01444742|9852180|FG000|Overall Study|Death|1
6194152|NCT01444781|9852187|FG000|Overall Study|Lost to Follow-up|0
6194153|NCT01444781|9852188|FG001|Overall Study|Lost to Follow-up|3
6194154|NCT01444781|9852189|FG002|Overall Study|Lost to Follow-up|1
6194155|NCT01444781|9852187|FG000|Overall Study|Withdrawal by Subject|3
6194156|NCT01444781|9852188|FG001|Overall Study|Withdrawal by Subject|1
6194157|NCT01444781|9852189|FG002|Overall Study|Withdrawal by Subject|2
6194158|NCT01444898|9852204|FG000|Overall Study|Withdrawal by Subject|1
6194159|NCT01445080|9852244|FG000|Overall Study|Adverse Event|5
6194160|NCT01445080|9852245|FG001|Overall Study|Adverse Event|3
6194161|NCT01445080|9852246|FG002|Overall Study|Adverse Event|11
6194162|NCT01445080|9852247|FG003|Overall Study|Adverse Event|6
6194163|NCT01445080|9852248|FG004|Overall Study|Adverse Event|2
6194164|NCT01445080|9852249|FG005|Overall Study|Adverse Event|3
6194165|NCT01445080|9852250|FG006|Overall Study|Adverse Event|0
6194166|NCT01445080|9852251|FG007|Overall Study|Adverse Event|3
6194167|NCT01445080|9852252|FG008|Overall Study|Adverse Event|10
6194168|NCT01445080|9852244|FG000|Overall Study|Physician Decision|0
6273506|NCT02192190|9977144|FG005|Overall Study|Could not Keep Visit Schedule|0
6273507|NCT02192190|9977139|FG000|Overall Study|Positive Drug Screen|0
5976334|NCT00392327|9562724|FG007|Overall Study|Withdrawal by Subject|5
6194169|NCT01445080|9852245|FG001|Overall Study|Physician Decision|0
6194170|NCT01445080|9852246|FG002|Overall Study|Physician Decision|1
6194171|NCT01445080|9852247|FG003|Overall Study|Physician Decision|0
6194172|NCT01445080|9852248|FG004|Overall Study|Physician Decision|0
6194173|NCT01445080|9852249|FG005|Overall Study|Physician Decision|3
6194174|NCT01445080|9852250|FG006|Overall Study|Physician Decision|2
6194175|NCT01445080|9852251|FG007|Overall Study|Physician Decision|2
6194176|NCT01445080|9852252|FG008|Overall Study|Physician Decision|0
6194177|NCT01445080|9852244|FG000|Overall Study|Withdrawal by Subject|1
6194178|NCT01445080|9852245|FG001|Overall Study|Withdrawal by Subject|0
6194179|NCT01445080|9852246|FG002|Overall Study|Withdrawal by Subject|0
6194180|NCT01445080|9852247|FG003|Overall Study|Withdrawal by Subject|1
6194181|NCT01445080|9852248|FG004|Overall Study|Withdrawal by Subject|0
6194182|NCT01445080|9852249|FG005|Overall Study|Withdrawal by Subject|0
5976335|NCT00392327|9562717|FG000|Overall Study|Ineligible|0
5976336|NCT00392327|9562718|FG001|Overall Study|Ineligible|4
5976337|NCT00392327|9562719|FG002|Overall Study|Ineligible|3
6088251|NCT00673920|9698957|FG007|Baseline up to Week 48|Protocol Violation|0
6088252|NCT00673920|9698950|FG000|Baseline up to Week 48|Violation of selection criteria at entry|0
6088253|NCT00673920|9698951|FG001|Baseline up to Week 48|Violation of selection criteria at entry|0
6088254|NCT00673920|9698952|FG002|Baseline up to Week 48|Violation of selection criteria at entry|1
6088255|NCT00673920|9698953|FG003|Baseline up to Week 48|Violation of selection criteria at entry|0
6088256|NCT00673920|9698954|FG004|Baseline up to Week 48|Violation of selection criteria at entry|0
6088257|NCT00673920|9698955|FG005|Baseline up to Week 48|Violation of selection criteria at entry|0
6088258|NCT00673920|9698956|FG006|Baseline up to Week 48|Violation of selection criteria at entry|0
6088259|NCT00673920|9698957|FG007|Baseline up to Week 48|Violation of selection criteria at entry|0
6194183|NCT01445080|9852250|FG006|Overall Study|Withdrawal by Subject|0
6194184|NCT01445080|9852251|FG007|Overall Study|Withdrawal by Subject|0
6194185|NCT01445080|9852252|FG008|Overall Study|Withdrawal by Subject|2
6194186|NCT01445080|9852244|FG000|Overall Study|Ineligible/Inevaluable|1
6194187|NCT01445080|9852245|FG001|Overall Study|Ineligible/Inevaluable|2
6194188|NCT01445080|9852246|FG002|Overall Study|Ineligible/Inevaluable|0
6194189|NCT01445080|9852247|FG003|Overall Study|Ineligible/Inevaluable|1
6273508|NCT02192190|9977140|FG001|Overall Study|Positive Drug Screen|0
6273509|NCT02192190|9977141|FG002|Overall Study|Positive Drug Screen|0
6273510|NCT02192190|9977142|FG003|Overall Study|Positive Drug Screen|1
6273511|NCT02192190|9977143|FG004|Overall Study|Positive Drug Screen|0
6273512|NCT02192190|9977144|FG005|Overall Study|Positive Drug Screen|0
6273513|NCT02192190|9977139|FG000|Overall Study|Inadequate Pain Relief|0
6273514|NCT02192190|9977140|FG001|Overall Study|Inadequate Pain Relief|1
6273515|NCT02192190|9977141|FG002|Overall Study|Inadequate Pain Relief|1
6273516|NCT02192190|9977142|FG003|Overall Study|Inadequate Pain Relief|0
6273517|NCT02192190|9977143|FG004|Overall Study|Inadequate Pain Relief|0
6273518|NCT02192190|9977144|FG005|Overall Study|Inadequate Pain Relief|0
6273519|NCT02192606|9977180|FG000|Overall Study|surgery type was changed|1
6273520|NCT02192606|9977181|FG001|Overall Study|surgery type was changed|1
6273521|NCT02192606|9977180|FG000|Overall Study|Physician Decision|1
6273522|NCT02192606|9977181|FG001|Overall Study|Physician Decision|2
6273523|NCT02192606|9977180|FG000|Overall Study|3D equipment rep unable to join|0
6273524|NCT02192606|9977181|FG001|Overall Study|3D equipment rep unable to join|1
6273525|NCT02192905|9977213|FG000|Overall Study|Lost to Follow-up|1
6273526|NCT02192970|9977220|FG000|Overall Study|Lost to Follow-up|6
6273527|NCT02192970|9977221|FG001|Overall Study|Lost to Follow-up|0
6273528|NCT02193074|9977229|FG000|Overall Study|Withdrawal by Subject|1
6273529|NCT02193074|9977230|FG001|Overall Study|Withdrawal by Subject|2
6273530|NCT02193074|9977229|FG000|Overall Study|Adverse Event|16
6273531|NCT02193074|9977230|FG001|Overall Study|Adverse Event|13
6273532|NCT02193087|9977240|FG000|Overall Study|Adverse Event|2
6273533|NCT02193087|9977241|FG001|Overall Study|Adverse Event|0
6273534|NCT02193087|9977242|FG002|Overall Study|Adverse Event|0
6273535|NCT02193087|9977243|FG003|Overall Study|Adverse Event|11
6273536|NCT02193087|9977240|FG000|Overall Study|Lost to Follow-up|14
6273537|NCT02193087|9977241|FG001|Overall Study|Lost to Follow-up|6
6273538|NCT02193087|9977242|FG002|Overall Study|Lost to Follow-up|4
6273539|NCT02193087|9977243|FG003|Overall Study|Lost to Follow-up|37
6273540|NCT02193087|9977240|FG000|Overall Study|Protocol Violation|2
6273541|NCT02193087|9977241|FG001|Overall Study|Protocol Violation|0
6273542|NCT02193087|9977242|FG002|Overall Study|Protocol Violation|1
6273543|NCT02193087|9977243|FG003|Overall Study|Protocol Violation|2
6273544|NCT02193087|9977240|FG000|Overall Study|Withdrawal by Subject|10
6273545|NCT02193087|9977241|FG001|Overall Study|Withdrawal by Subject|3
6273546|NCT02193087|9977242|FG002|Overall Study|Withdrawal by Subject|1
6273547|NCT02193087|9977243|FG003|Overall Study|Withdrawal by Subject|19
6273548|NCT02193087|9977240|FG000|Overall Study|Other Reason Not Specified|7
6088260|NCT00673920|9698950|FG000|Baseline up to Week 48|Administrative/Other|0
6088261|NCT00673920|9698951|FG001|Baseline up to Week 48|Administrative/Other|1
6088262|NCT00673920|9698952|FG002|Baseline up to Week 48|Administrative/Other|2
6088263|NCT00673920|9698953|FG003|Baseline up to Week 48|Administrative/Other|0
6194190|NCT01445080|9852248|FG004|Overall Study|Ineligible/Inevaluable|2
6194191|NCT01445080|9852249|FG005|Overall Study|Ineligible/Inevaluable|3
6273549|NCT02193087|9977241|FG001|Overall Study|Other Reason Not Specified|2
6273550|NCT02193087|9977242|FG002|Overall Study|Other Reason Not Specified|1
6273551|NCT02193087|9977243|FG003|Overall Study|Other Reason Not Specified|9
6273552|NCT02193087|9977240|FG000|Overall Study|Did Not Receive Any Vaccination|2
6273553|NCT02193087|9977241|FG001|Overall Study|Did Not Receive Any Vaccination|3
6273554|NCT02193087|9977242|FG002|Overall Study|Did Not Receive Any Vaccination|0
6273555|NCT02193087|9977243|FG003|Overall Study|Did Not Receive Any Vaccination|1
6273556|NCT02193165|9977267|FG000|4 Week Product Use|Lost to Follow-up|1
6273557|NCT02193165|9977268|FG001|4 Week Product Use|Lost to Follow-up|1
6273558|NCT02193165|9977269|FG002|4 Week Product Use|Lost to Follow-up|1
6273559|NCT02193165|9977267|FG000|6 Week Product Use|Lost to Follow-up|0
6273560|NCT02193165|9977268|FG001|6 Week Product Use|Lost to Follow-up|1
5976338|NCT00392327|9562720|FG003|Overall Study|Ineligible|2
5976339|NCT00392327|9562721|FG004|Overall Study|Ineligible|0
5976340|NCT00392327|9562722|FG005|Overall Study|Ineligible|0
5976341|NCT00392327|9562723|FG006|Overall Study|Ineligible|0
5976342|NCT00392327|9562724|FG007|Overall Study|Ineligible|0
5976343|NCT00085202|9562744|FG000|Overall Study|Still on therapy|2
5976344|NCT00085202|9562745|FG001|Overall Study|Still on therapy|0
5976345|NCT00085202|9562744|FG000|Overall Study|Bone involvement confirmed by bone scan|0
5976346|NCT00085202|9562745|FG001|Overall Study|Bone involvement confirmed by bone scan|1
5976347|NCT00085202|9562744|FG000|Overall Study|Excessive toxicity|6
5976348|NCT00085202|9562745|FG001|Overall Study|Excessive toxicity|5
5976349|NCT00085202|9562744|FG000|Overall Study|Non-specified|3
5976350|NCT00085202|9562745|FG001|Overall Study|Non-specified|5
5976351|NCT00085202|9562744|FG000|Overall Study|Withdrawal by Subject|2
6088264|NCT00673920|9698954|FG004|Baseline up to Week 48|Administrative/Other|0
6088265|NCT00673920|9698955|FG005|Baseline up to Week 48|Administrative/Other|0
6088266|NCT00673920|9698956|FG006|Baseline up to Week 48|Administrative/Other|0
6194192|NCT01445080|9852250|FG006|Overall Study|Ineligible/Inevaluable|0
6194193|NCT01445080|9852251|FG007|Overall Study|Ineligible/Inevaluable|0
6194194|NCT01445080|9852252|FG008|Overall Study|Ineligible/Inevaluable|6
6194195|NCT01445171|9852287|FG000|Overall Study|Lost to Follow-up|11
6194196|NCT01445171|9852287|FG000|Overall Study|Withdrawal by Subject|16
6194197|NCT01445171|9852287|FG000|Overall Study|Death|51
6194198|NCT01445171|9852287|FG000|Overall Study|Subjects declined to return for followup|9
6194199|NCT01445171|9852287|FG000|Overall Study|Consented but did not receive device|8
6194200|NCT01445301|9852296|FG000|Overall Study|Adverse Event|15
6194201|NCT01445301|9852297|FG001|Overall Study|Adverse Event|25
6194202|NCT01445301|9852298|FG002|Overall Study|Adverse Event|4
6194203|NCT01445301|9852296|FG000|Overall Study|Lack of Efficacy|0
6194204|NCT01445301|9852297|FG001|Overall Study|Lack of Efficacy|1
6194205|NCT01445301|9852298|FG002|Overall Study|Lack of Efficacy|0
6194206|NCT01445301|9852296|FG000|Overall Study|Protocol Violation|1
6194207|NCT01445301|9852297|FG001|Overall Study|Protocol Violation|0
6194208|NCT01445301|9852298|FG002|Overall Study|Protocol Violation|0
6194209|NCT01445301|9852296|FG000|Overall Study|Protocol-Defined Stopping Criteria|0
6194210|NCT01445301|9852297|FG001|Overall Study|Protocol-Defined Stopping Criteria|1
6194211|NCT01445301|9852298|FG002|Overall Study|Protocol-Defined Stopping Criteria|1
6194212|NCT01445301|9852296|FG000|Overall Study|Physician Decision|0
6194213|NCT01445301|9852297|FG001|Overall Study|Physician Decision|2
6194214|NCT01445301|9852298|FG002|Overall Study|Physician Decision|0
6194215|NCT01445301|9852296|FG000|Overall Study|Withdrawal by Subject|5
6194216|NCT01445301|9852297|FG001|Overall Study|Withdrawal by Subject|6
6194217|NCT01445301|9852298|FG002|Overall Study|Withdrawal by Subject|4
6194218|NCT01445535|9852310|FG000|Overall Study|Enrolled/taken off study, no drug avail.|0
6194219|NCT01445535|9852311|FG001|Overall Study|Enrolled/taken off study, no drug avail.|0
6194220|NCT01445535|9852312|FG002|Overall Study|Enrolled/taken off study, no drug avail.|0
6194221|NCT01445535|9852313|FG003|Overall Study|Enrolled/taken off study, no drug avail.|1
6194222|NCT01445535|9852310|FG000|Overall Study|Disease progression|1
6194223|NCT01445535|9852311|FG001|Overall Study|Disease progression|0
6194224|NCT01445535|9852312|FG002|Overall Study|Disease progression|1
6194225|NCT01445535|9852313|FG003|Overall Study|Disease progression|0
6194226|NCT01445535|9852310|FG000|Overall Study|PI discretion|0
6194227|NCT01445535|9852311|FG001|Overall Study|PI discretion|0
6194228|NCT01445535|9852312|FG002|Overall Study|PI discretion|0
6194229|NCT01445535|9852313|FG003|Overall Study|PI discretion|1
6194230|NCT01445548|9852324|FG000|Overall Study|Adverse Event|1
6194231|NCT01445613|9852328|FG000|30-day Follow-up|Withdrawal by Subject|6
6194232|NCT01445613|9852328|FG000|30-day Follow-up|Physician Decision|3
6194233|NCT01445613|9852328|FG000|30-day Follow-up|Missed visit|23
6194234|NCT01445613|9852328|FG000|30-day Follow-up|Death|3
6194235|NCT01445613|9852328|FG000|1-year Follow-up|Withdrawal by Subject|12
6194236|NCT01445613|9852328|FG000|1-year Follow-up|Missed visit|29
6194237|NCT01445613|9852328|FG000|1-year Follow-up|Lost to Follow-up|2
6194238|NCT01445613|9852328|FG000|1-year Follow-up|Death|30
6194239|NCT01445613|9852328|FG000|1-year Follow-up|Physician Decision|2
6194240|NCT01445613|9852328|FG000|1-year Follow-up|Received a non-study stent|2
6194241|NCT01445652|9852344|FG000|Overall Study|Not comfortable in lenses|5
6194242|NCT01445652|9852345|FG001|Overall Study|Not comfortable in lenses|0
6194243|NCT01445652|9852344|FG000|Overall Study|Failed to attend scheduled visit|2
6194244|NCT01445652|9852345|FG001|Overall Study|Failed to attend scheduled visit|3
6194245|NCT01445652|9852344|FG000|Overall Study|Failed teach session|2
5976352|NCT00085202|9562745|FG001|Overall Study|Withdrawal by Subject|1
5976353|NCT00085202|9562744|FG000|Overall Study|Physician Decision|4
5976354|NCT00085202|9562745|FG001|Overall Study|Physician Decision|1
5976355|NCT00085202|9562744|FG000|Overall Study|Progressive disease|1
5976356|NCT00085202|9562745|FG001|Overall Study|Progressive disease|11
6050636|NCT00428090|9649856|FG002|Overall Study|Death of par.|1
6050637|NCT00428090|9649857|FG003|Overall Study|Death of par.|0
6050638|NCT00428090|9649854|FG000|Overall Study|Visit 7 exceed the visit window|0
6194246|NCT01445652|9852345|FG001|Overall Study|Failed teach session|0
6194247|NCT01445652|9852344|FG000|Overall Study|Adverse Event|1
6194248|NCT01445652|9852345|FG001|Overall Study|Adverse Event|0
6194249|NCT01445678|9852353|FG000|Overall Study|Adverse Event|12
6194250|NCT01445678|9852354|FG001|Overall Study|Adverse Event|8
6194251|NCT01445678|9852353|FG000|Overall Study|Lack of Efficacy|0
6194252|NCT01445678|9852354|FG001|Overall Study|Lack of Efficacy|2
5976357|NCT04386616|9562846|FG000|Overall Study|Death|22
5976358|NCT04386616|9562847|FG001|Overall Study|Death|22
5976359|NCT04386616|9562848|FG002|Overall Study|Death|21
5976360|NCT04386616|9562846|FG000|Overall Study|Lost to Follow-up|5
5976361|NCT04386616|9562847|FG001|Overall Study|Lost to Follow-up|8
5976362|NCT04386616|9562848|FG002|Overall Study|Lost to Follow-up|6
5976363|NCT04386616|9562846|FG000|Overall Study|Withdrawal by Subject|2
5976364|NCT04386616|9562847|FG001|Overall Study|Withdrawal by Subject|4
5976365|NCT04386616|9562848|FG002|Overall Study|Withdrawal by Subject|1
5976366|NCT04386616|9562846|FG000|Overall Study|Adverse Event|1
5976367|NCT04386616|9562847|FG001|Overall Study|Adverse Event|1
5976368|NCT04386616|9562848|FG002|Overall Study|Adverse Event|0
5976369|NCT04296942|9562881|FG000|Overall Study|Study closure by sponsor|1
5976370|NCT04296942|9562882|FG001|Overall Study|Study closure by sponsor|0
6088267|NCT00673920|9698957|FG007|Baseline up to Week 48|Administrative/Other|0
6088268|NCT00673920|9698950|FG000|Baseline up to Week 48|Adverse event/intercurrent illness|0
6088269|NCT00673920|9698951|FG001|Baseline up to Week 48|Adverse event/intercurrent illness|1
6088270|NCT00673920|9698952|FG002|Baseline up to Week 48|Adverse event/intercurrent illness|1
6088271|NCT00673920|9698953|FG003|Baseline up to Week 48|Adverse event/intercurrent illness|0
6088272|NCT00673920|9698954|FG004|Baseline up to Week 48|Adverse event/intercurrent illness|0
6088273|NCT00673920|9698955|FG005|Baseline up to Week 48|Adverse event/intercurrent illness|0
6088274|NCT00673920|9698956|FG006|Baseline up to Week 48|Adverse event/intercurrent illness|0
6088275|NCT00673920|9698957|FG007|Baseline up to Week 48|Adverse event/intercurrent illness|0
6088276|NCT00673920|9698950|FG000|Week 24 to Week 48|Adverse event/intercurrent illness|0
6088277|NCT00673920|9698951|FG001|Week 24 to Week 48|Adverse event/intercurrent illness|0
6194253|NCT01445678|9852353|FG000|Overall Study|Lost to Follow-up|8
6194254|NCT01445678|9852354|FG001|Overall Study|Lost to Follow-up|5
6194255|NCT01445678|9852353|FG000|Overall Study|Protocol Violation|1
6194256|NCT01445678|9852354|FG001|Overall Study|Protocol Violation|1
6194257|NCT01445678|9852353|FG000|Overall Study|Withdrawal by Subject|9
6194258|NCT01445678|9852354|FG001|Overall Study|Withdrawal by Subject|5
6194259|NCT01445730|9852360|FG000|Overall Study|Adverse Event|1
6194260|NCT01445730|9852360|FG000|Overall Study|For the advice of a dentist|1
6194261|NCT01445730|9852360|FG000|Overall Study|The data from magnetic resonance examinations were not sufficient|9
6194262|NCT01445769|9852364|FG000|Overall Study|Consent Withdrawn|2
6194263|NCT01445769|9852364|FG000|Overall Study|Disease Progression|1
6194264|NCT01445769|9852364|FG000|Overall Study|Lost to Follow-up|5
6194265|NCT01445847|9852381|FG000|Overall Study|Protocol Violation|13
6194266|NCT01445847|9852382|FG001|Overall Study|Protocol Violation|14
6194267|NCT01445847|9852381|FG000|Overall Study|Missed Data|1
6194268|NCT01445847|9852382|FG001|Overall Study|Missed Data|0
6194269|NCT01445886|9852392|FG000|Overall Study|Lost to Follow-up|2
6194270|NCT01445886|9852392|FG000|Overall Study|Protocol Violation|3
6194271|NCT01445951|9852401|FG000|Overall Study|Adverse Event|16
6194272|NCT01445951|9852402|FG001|Overall Study|Adverse Event|9
6273561|NCT02193165|9977269|FG002|6 Week Product Use|Lost to Follow-up|0
6273562|NCT02193178|9977277|FG000|Overall Study|Lost to Follow-up|1
6273563|NCT02193178|9977277|FG000|Overall Study|Dry eyes|1
6273564|NCT02193776|9977312|FG000|Overall Study|Consent withdrawn|1
6273565|NCT02193776|9977313|FG001|Overall Study|Consent withdrawn|0
6273566|NCT02193776|9977314|FG002|Overall Study|Consent withdrawn|0
6273567|NCT02193776|9977315|FG003|Overall Study|Consent withdrawn|0
6273568|NCT02193776|9977312|FG000|Overall Study|Failure to comply with protocol|0
6273569|NCT02193776|9977313|FG001|Overall Study|Failure to comply with protocol|1
6273570|NCT02193776|9977314|FG002|Overall Study|Failure to comply with protocol|0
6273571|NCT02193776|9977315|FG003|Overall Study|Failure to comply with protocol|0
6273572|NCT02193776|9977312|FG000|Overall Study|Investigator/Sponsor decision|1
6273573|NCT02193776|9977313|FG001|Overall Study|Investigator/Sponsor decision|1
6273574|NCT02193776|9977314|FG002|Overall Study|Investigator/Sponsor decision|0
6273575|NCT02193776|9977315|FG003|Overall Study|Investigator/Sponsor decision|0
6194273|NCT01445951|9852403|FG002|Overall Study|Adverse Event|0
6194274|NCT01445951|9852401|FG000|Overall Study|Protocol Violation|2
6194275|NCT01445951|9852402|FG001|Overall Study|Protocol Violation|2
6194276|NCT01445951|9852403|FG002|Overall Study|Protocol Violation|2
6194277|NCT01445951|9852401|FG000|Overall Study|Withdrawal by Subject|21
6194278|NCT01445951|9852402|FG001|Overall Study|Withdrawal by Subject|16
6194279|NCT01445951|9852403|FG002|Overall Study|Withdrawal by Subject|8
6273576|NCT02193776|9977312|FG000|Overall Study|Death|1
6273577|NCT02193776|9977313|FG001|Overall Study|Death|0
5976371|NCT04296942|9562883|FG002|Overall Study|Study closure by sponsor|0
6050639|NCT00428090|9649855|FG001|Overall Study|Visit 7 exceed the visit window|1
6050640|NCT00428090|9649856|FG002|Overall Study|Visit 7 exceed the visit window|0
6050641|NCT00428090|9649857|FG003|Overall Study|Visit 7 exceed the visit window|0
6050642|NCT00428090|9649854|FG000|Overall Study|Medical monitor terminated par.|0
6050643|NCT00428090|9649855|FG001|Overall Study|Medical monitor terminated par.|1
6050644|NCT00428090|9649856|FG002|Overall Study|Medical monitor terminated par.|0
6050645|NCT00428090|9649857|FG003|Overall Study|Medical monitor terminated par.|0
5976372|NCT04278872|9562895|FG000|Overall Study|Adverse Event|1
5976373|NCT04278872|9562896|FG001|Overall Study|Adverse Event|0
5976374|NCT04278872|9562895|FG000|Overall Study|Protocol Violation|0
5976375|NCT04278872|9562896|FG001|Overall Study|Protocol Violation|1
6088278|NCT00673920|9698952|FG002|Week 24 to Week 48|Adverse event/intercurrent illness|0
6088279|NCT00673920|9698953|FG003|Week 24 to Week 48|Adverse event/intercurrent illness|0
6088280|NCT00673920|9698954|FG004|Week 24 to Week 48|Adverse event/intercurrent illness|0
6088281|NCT00673920|9698955|FG005|Week 24 to Week 48|Adverse event/intercurrent illness|0
6088282|NCT00673920|9698956|FG006|Week 24 to Week 48|Adverse event/intercurrent illness|1
6088283|NCT00673920|9698957|FG007|Week 24 to Week 48|Adverse event/intercurrent illness|0
6088284|NCT00673920|9698950|FG000|Week 24 to Week 48|Failure to return|0
6088285|NCT00673920|9698951|FG001|Week 24 to Week 48|Failure to return|0
6088286|NCT00673920|9698952|FG002|Week 24 to Week 48|Failure to return|0
6088287|NCT00673920|9698953|FG003|Week 24 to Week 48|Failure to return|0
6088288|NCT00673920|9698954|FG004|Week 24 to Week 48|Failure to return|0
6088289|NCT00673920|9698955|FG005|Week 24 to Week 48|Failure to return|1
6088290|NCT00673920|9698956|FG006|Week 24 to Week 48|Failure to return|0
6088291|NCT00673920|9698957|FG007|Week 24 to Week 48|Failure to return|0
6088292|NCT00673920|9698950|FG000|Week 24 to Week 48|Insufficient therapeutic response|0
6088293|NCT00673920|9698951|FG001|Week 24 to Week 48|Insufficient therapeutic response|0
6088294|NCT00673920|9698952|FG002|Week 24 to Week 48|Insufficient therapeutic response|0
6088295|NCT00673920|9698953|FG003|Week 24 to Week 48|Insufficient therapeutic response|0
6088296|NCT00673920|9698954|FG004|Week 24 to Week 48|Insufficient therapeutic response|0
6088297|NCT00673920|9698955|FG005|Week 24 to Week 48|Insufficient therapeutic response|1
6088298|NCT00673920|9698956|FG006|Week 24 to Week 48|Insufficient therapeutic response|0
6088299|NCT00673920|9698957|FG007|Week 24 to Week 48|Insufficient therapeutic response|0
6088300|NCT00673920|9698950|FG000|Week 24 to Week 48|Death|0
6088301|NCT00673920|9698951|FG001|Week 24 to Week 48|Death|0
6088302|NCT00673920|9698952|FG002|Week 24 to Week 48|Death|0
6088303|NCT00673920|9698953|FG003|Week 24 to Week 48|Death|0
6088304|NCT00673920|9698954|FG004|Week 24 to Week 48|Death|0
6088305|NCT00673920|9698955|FG005|Week 24 to Week 48|Death|1
6088306|NCT00673920|9698956|FG006|Week 24 to Week 48|Death|0
6088307|NCT00673920|9698957|FG007|Week 24 to Week 48|Death|0
6088308|NCT00673920|9698950|FG000|Week 24 to Week 48|Adminstrative/Other|0
6088309|NCT00673920|9698951|FG001|Week 24 to Week 48|Adminstrative/Other|0
6088310|NCT00673920|9698952|FG002|Week 24 to Week 48|Adminstrative/Other|0
6088311|NCT00673920|9698953|FG003|Week 24 to Week 48|Adminstrative/Other|1
6194280|NCT01445951|9852401|FG000|Overall Study|Physician Decision|3
6194281|NCT01445951|9852402|FG001|Overall Study|Physician Decision|1
6194282|NCT01445951|9852403|FG002|Overall Study|Physician Decision|0
6194283|NCT01445951|9852401|FG000|Overall Study|Lost to Follow-up|1
6194284|NCT01445951|9852402|FG001|Overall Study|Lost to Follow-up|2
6194285|NCT01445951|9852403|FG002|Overall Study|Lost to Follow-up|4
6194286|NCT01445951|9852401|FG000|Overall Study|Pregnancy|0
6194287|NCT01445951|9852402|FG001|Overall Study|Pregnancy|1
6194288|NCT01445951|9852403|FG002|Overall Study|Pregnancy|4
6194289|NCT01445951|9852401|FG000|Overall Study|Death|0
6194290|NCT01445951|9852402|FG001|Overall Study|Death|0
6194291|NCT01445951|9852403|FG002|Overall Study|Death|1
6194292|NCT01445951|9852401|FG000|Overall Study|Non-compliance with study drug|1
6194293|NCT01445951|9852402|FG001|Overall Study|Non-compliance with study drug|2
6194294|NCT01445951|9852403|FG002|Overall Study|Non-compliance with study drug|0
6273578|NCT02193776|9977314|FG002|Overall Study|Death|0
6273579|NCT02193776|9977315|FG003|Overall Study|Death|0
6273580|NCT02193776|9977312|FG000|Overall Study|Adverse event/Specific toxicity|5
6273581|NCT02193776|9977313|FG001|Overall Study|Adverse event/Specific toxicity|5
6273582|NCT02193776|9977314|FG002|Overall Study|Adverse event/Specific toxicity|2
6273583|NCT02193776|9977315|FG003|Overall Study|Adverse event/Specific toxicity|2
6088312|NCT00673920|9698954|FG004|Week 24 to Week 48|Adminstrative/Other|0
6194295|NCT01445951|9852401|FG000|Overall Study|Non-compliance with protocol|0
5976376|NCT04278872|9562895|FG000|Overall Study|Study Termination|2
5976377|NCT04278872|9562896|FG001|Overall Study|Study Termination|0
6194296|NCT01445951|9852402|FG001|Overall Study|Non-compliance with protocol|1
5976378|NCT04213807|9562905|FG000|Overall Study|Physician Decision|0
5976379|NCT04213807|9562906|FG001|Overall Study|Physician Decision|0
5976380|NCT04213807|9562907|FG002|Overall Study|Physician Decision|1
6050646|NCT00428090|9649854|FG000|Overall Study|Mental status of par. was|0
6050647|NCT00428090|9649855|FG001|Overall Study|Mental status of par. was|1
6050648|NCT00428090|9649856|FG002|Overall Study|Mental status of par. was|0
6050649|NCT00428090|9649857|FG003|Overall Study|Mental status of par. was|0
6050650|NCT00428090|9649854|FG000|Overall Study|Worsening of AD|0
6050651|NCT00428090|9649855|FG001|Overall Study|Worsening of AD|0
6194297|NCT01445951|9852403|FG002|Overall Study|Non-compliance with protocol|0
6194298|NCT01445951|9852401|FG000|Overall Study|Sponsor decision - subject travel|0
6194299|NCT01445951|9852402|FG001|Overall Study|Sponsor decision - subject travel|1
6194300|NCT01445951|9852403|FG002|Overall Study|Sponsor decision - subject travel|0
6194301|NCT01445951|9852401|FG000|Overall Study|Cough|0
6194302|NCT01445951|9852402|FG001|Overall Study|Cough|1
6194303|NCT01445951|9852403|FG002|Overall Study|Cough|0
6194304|NCT01446003|9852411|FG000|Period 1|Protocol Violation|2
6194305|NCT01446003|9852412|FG001|Period 1|Protocol Violation|0
6194306|NCT01446003|9852411|FG000|Period 2|Adverse Event|1
6194307|NCT01446003|9852412|FG001|Period 2|Adverse Event|0
6194308|NCT01446042|9852421|FG000|Overall Study|Withdrawal by Subject|12
6194309|NCT01446042|9852422|FG001|Overall Study|Withdrawal by Subject|2
6194310|NCT01446042|9852423|FG002|Overall Study|Withdrawal by Subject|4
6194311|NCT01446042|9852421|FG000|Overall Study|Adverse Event|1
6194312|NCT01446042|9852422|FG001|Overall Study|Adverse Event|0
6194313|NCT01446042|9852423|FG002|Overall Study|Adverse Event|4
6194314|NCT01446042|9852421|FG000|Overall Study|Lost to Follow-up|5
6194315|NCT01446042|9852422|FG001|Overall Study|Lost to Follow-up|0
6194316|NCT01446042|9852423|FG002|Overall Study|Lost to Follow-up|0
6194317|NCT01446042|9852421|FG000|Overall Study|Other reasons|2
6194318|NCT01446042|9852422|FG001|Overall Study|Other reasons|1
6194319|NCT01446042|9852423|FG002|Overall Study|Other reasons|1
6194320|NCT01446159|9852435|FG000|Overall Study|Withdrawal by Subject|1
6194321|NCT01446159|9852436|FG001|Overall Study|Withdrawal by Subject|0
6194322|NCT01446159|9852437|FG002|Overall Study|Withdrawal by Subject|14
6194323|NCT01446159|9852438|FG003|Overall Study|Withdrawal by Subject|11
6194324|NCT01446159|9852435|FG000|Overall Study|Lost to Follow-up|0
6194325|NCT01446159|9852436|FG001|Overall Study|Lost to Follow-up|0
6194326|NCT01446159|9852437|FG002|Overall Study|Lost to Follow-up|1
6194327|NCT01446159|9852438|FG003|Overall Study|Lost to Follow-up|2
6194328|NCT01446159|9852435|FG000|Overall Study|Death|2
6194329|NCT01446159|9852436|FG001|Overall Study|Death|3
6194330|NCT01446159|9852437|FG002|Overall Study|Death|43
6194331|NCT01446159|9852438|FG003|Overall Study|Death|36
6194332|NCT01446159|9852435|FG000|Overall Study|Other|0
6194333|NCT01446159|9852436|FG001|Overall Study|Other|0
6194334|NCT01446159|9852437|FG002|Overall Study|Other|13
6194335|NCT01446159|9852438|FG003|Overall Study|Other|13
6194336|NCT01446237|9852450|FG000|Overall Study|Adverse Event|1
6194337|NCT01446237|9852450|FG000|Overall Study|Lost to Follow-up|2
6194338|NCT01446237|9852450|FG000|Overall Study|Withdrawal by Subject|7
6194339|NCT01446289|9852458|FG000|Overall Study|Withdrawal by Subject|1
6194340|NCT01446289|9852459|FG001|Overall Study|Withdrawal by Subject|0
6194341|NCT01446289|9852460|FG002|Overall Study|Withdrawal by Subject|1
6194342|NCT01446289|9852461|FG003|Overall Study|Withdrawal by Subject|0
6194343|NCT01446419|9852475|FG000|Overall Study|Death|1
6194344|NCT01446419|9852476|FG001|Overall Study|Death|0
6194345|NCT01446419|9852475|FG000|Overall Study|Withdrawal by Subject|1
6194346|NCT01446419|9852476|FG001|Overall Study|Withdrawal by Subject|1
6194347|NCT01446419|9852475|FG000|Overall Study|Terminated per protocol|3
6194348|NCT01446419|9852476|FG001|Overall Study|Terminated per protocol|0
6194349|NCT01446809|9852508|FG000|Overall Study|Adverse Event|0
6194350|NCT01446809|9852509|FG001|Overall Study|Adverse Event|0
6194351|NCT01446809|9852510|FG002|Overall Study|Adverse Event|1
6194352|NCT01446809|9852508|FG000|Overall Study|Failure to complete study procedures|0
6194353|NCT01446809|9852509|FG001|Overall Study|Failure to complete study procedures|0
6194354|NCT01446809|9852510|FG002|Overall Study|Failure to complete study procedures|1
6194355|NCT01446874|9852522|FG000|Overall Study|Not eligible|1
6194356|NCT01446874|9852523|FG001|Overall Study|Not eligible|0
6194357|NCT01446874|9852524|FG002|Overall Study|Not eligible|0
6194358|NCT01446874|9852522|FG000|Overall Study|No surgery/No qualifying surgery|1
6194359|NCT01446874|9852523|FG001|Overall Study|No surgery/No qualifying surgery|0
6194360|NCT01446874|9852524|FG002|Overall Study|No surgery/No qualifying surgery|12
6194361|NCT01446874|9852522|FG000|Overall Study|Non-compliance|0
6194362|NCT01446874|9852523|FG001|Overall Study|Non-compliance|4
6194363|NCT01446874|9852524|FG002|Overall Study|Non-compliance|0
6194364|NCT01446874|9852522|FG000|Overall Study|Antibiotics for pre-op infection|0
6194365|NCT01446874|9852523|FG001|Overall Study|Antibiotics for pre-op infection|0
6050652|NCT00428090|9649856|FG002|Overall Study|Worsening of AD|1
6050653|NCT00428090|9649857|FG003|Overall Study|Worsening of AD|0
6050654|NCT00428090|9649854|FG000|Overall Study|Excluded for concerning QTc value|0
6194366|NCT01446874|9852524|FG002|Overall Study|Antibiotics for pre-op infection|2
6194367|NCT01446874|9852522|FG000|Overall Study|Withdrawal by Subject|0
6194368|NCT01446874|9852523|FG001|Overall Study|Withdrawal by Subject|0
6194369|NCT01446874|9852524|FG002|Overall Study|Withdrawal by Subject|4
5976381|NCT03721107|9562989|FG000|Overall Study|Adverse Event|1
5976382|NCT03721107|9562990|FG001|Overall Study|Adverse Event|1
5976383|NCT03721107|9562991|FG002|Overall Study|Adverse Event|6
5976384|NCT03721107|9562992|FG003|Overall Study|Adverse Event|5
5976385|NCT03721107|9562989|FG000|Overall Study|Lost to Follow-up|2
5976386|NCT03721107|9562990|FG001|Overall Study|Lost to Follow-up|0
5976387|NCT03721107|9562991|FG002|Overall Study|Lost to Follow-up|3
5976388|NCT03721107|9562992|FG003|Overall Study|Lost to Follow-up|0
5976389|NCT03721107|9562989|FG000|Overall Study|Inclusion/Exclusion Criteria not Met|0
5976390|NCT03721107|9562990|FG001|Overall Study|Inclusion/Exclusion Criteria not Met|0
5976391|NCT03721107|9562991|FG002|Overall Study|Inclusion/Exclusion Criteria not Met|0
5976392|NCT03721107|9562992|FG003|Overall Study|Inclusion/Exclusion Criteria not Met|1
6088313|NCT00673920|9698955|FG005|Week 24 to Week 48|Adminstrative/Other|0
6088314|NCT00673920|9698956|FG006|Week 24 to Week 48|Adminstrative/Other|0
6273584|NCT02193828|9977343|FG000|Overall Study|Withdrawal by Subject|0
6273585|NCT02193828|9977344|FG001|Overall Study|Withdrawal by Subject|0
6273586|NCT02193828|9977345|FG002|Overall Study|Withdrawal by Subject|1
6273587|NCT02193828|9977346|FG003|Overall Study|Withdrawal by Subject|1
6273588|NCT02193880|9977356|FG000|Overall Study|patients did not collect enough HPC|3
6273589|NCT02194062|9977363|FG000|Overall Study|Lost to Follow-up|2
6273590|NCT02194062|9977364|FG001|Overall Study|Lost to Follow-up|2
6273591|NCT02194062|9977365|FG002|Overall Study|Lost to Follow-up|5
5976393|NCT03721107|9562989|FG000|Overall Study|Physician Decision|0
6088315|NCT00673920|9698957|FG007|Week 24 to Week 48|Adminstrative/Other|0
6088316|NCT00673933|9698979|FG000|Overall Study|Withdrawal by Subject|2
5976394|NCT03721107|9562990|FG001|Overall Study|Physician Decision|1
5976395|NCT03721107|9562991|FG002|Overall Study|Physician Decision|0
5976396|NCT03721107|9562992|FG003|Overall Study|Physician Decision|0
5976397|NCT03721107|9562989|FG000|Overall Study|Pregnancy|0
5976398|NCT03721107|9562990|FG001|Overall Study|Pregnancy|0
5976399|NCT03721107|9562991|FG002|Overall Study|Pregnancy|1
5976400|NCT03721107|9562992|FG003|Overall Study|Pregnancy|0
6088317|NCT00673933|9698979|FG000|Overall Study|Lost to Follow-up|1
5976401|NCT03721107|9562989|FG000|Overall Study|Withdrawal by Subject|1
5976402|NCT03721107|9562990|FG001|Overall Study|Withdrawal by Subject|1
5976403|NCT03721107|9562991|FG002|Overall Study|Withdrawal by Subject|5
5976404|NCT03721107|9562992|FG003|Overall Study|Withdrawal by Subject|5
5976405|NCT03721107|9562989|FG000|Overall Study|Other|1
6194370|NCT01446913|9852535|FG000|Overall Study|Significant illness|1
6194371|NCT01446913|9852536|FG001|Overall Study|Significant illness|1
6194372|NCT01446913|9852537|FG002|Overall Study|Significant illness|1
6194373|NCT01446913|9852535|FG000|Overall Study|Withdrawal by Subject|5
6194374|NCT01446913|9852536|FG001|Overall Study|Withdrawal by Subject|3
6194375|NCT01446913|9852537|FG002|Overall Study|Withdrawal by Subject|5
6194376|NCT01446913|9852535|FG000|Overall Study|Physician Decision|0
6194377|NCT01446913|9852536|FG001|Overall Study|Physician Decision|0
6194378|NCT01446913|9852537|FG002|Overall Study|Physician Decision|2
6194379|NCT01446913|9852535|FG000|Overall Study|Lost to Follow-up|3
6194380|NCT01446913|9852536|FG001|Overall Study|Lost to Follow-up|5
6194381|NCT01446913|9852537|FG002|Overall Study|Lost to Follow-up|3
6194382|NCT01446965|9852553|FG000|Randominization|One site was dismissed due to IRB irregularity|30
6194383|NCT01446965|9852554|FG001|Randominization|One site was dismissed due to IRB irregularity|16
6194384|NCT01446965|9852553|FG000|Participants Followed and Analyzed|Lost to Follow-up|10
6194385|NCT01446965|9852554|FG001|Participants Followed and Analyzed|Lost to Follow-up|12
6194386|NCT01447407|9852623|FG000|Overall Study|Withdrawal by Subject|2
6194387|NCT01447407|9852624|FG001|Overall Study|Withdrawal by Subject|0
6194388|NCT01447407|9852625|FG002|Overall Study|Withdrawal by Subject|0
6194389|NCT01447407|9852626|FG003|Overall Study|Withdrawal by Subject|1
6194390|NCT01447407|9852623|FG000|Overall Study|Physician Decision|0
6194391|NCT01447407|9852624|FG001|Overall Study|Physician Decision|0
6194392|NCT01447407|9852625|FG002|Overall Study|Physician Decision|1
6194393|NCT01447407|9852626|FG003|Overall Study|Physician Decision|1
6194394|NCT01447420|9852639|FG000|Overall Study|Adverse Event|2
6194395|NCT01447420|9852640|FG001|Overall Study|Adverse Event|4
6194396|NCT01447420|9852641|FG002|Overall Study|Adverse Event|2
6194397|NCT01447420|9852639|FG000|Overall Study|Protocol Violation|3
6194398|NCT01447420|9852640|FG001|Overall Study|Protocol Violation|3
6194399|NCT01447420|9852641|FG002|Overall Study|Protocol Violation|0
6194400|NCT01447420|9852639|FG000|Overall Study|Withdrawal by Subject|4
6194401|NCT01447420|9852640|FG001|Overall Study|Withdrawal by Subject|1
6194402|NCT01447420|9852641|FG002|Overall Study|Withdrawal by Subject|0
6194403|NCT01447420|9852639|FG000|Overall Study|Lack of Efficacy|1
6194404|NCT01447420|9852640|FG001|Overall Study|Lack of Efficacy|19
6194405|NCT01447420|9852641|FG002|Overall Study|Lack of Efficacy|8
6194406|NCT01447433|9852650|FG000|Overall Study|Lost to Follow-up|0
6194407|NCT01447433|9852651|FG001|Overall Study|Lost to Follow-up|2
6194408|NCT01447433|9852650|FG000|Overall Study|Withdrawal by Subject|3
6194409|NCT01447433|9852651|FG001|Overall Study|Withdrawal by Subject|3
6194410|NCT01447433|9852650|FG000|Overall Study|Protocol Violation|1
6194411|NCT01447433|9852651|FG001|Overall Study|Protocol Violation|1
6273592|NCT02194465|9977395|FG000|Overall Study|Adverse Event|6
6273593|NCT02194465|9977396|FG001|Overall Study|Adverse Event|1
6273594|NCT02194465|9977397|FG002|Overall Study|Adverse Event|4
6273595|NCT02194465|9977398|FG003|Overall Study|Adverse Event|4
6273596|NCT02194465|9977399|FG004|Overall Study|Adverse Event|4
6273597|NCT02194465|9977400|FG005|Overall Study|Adverse Event|2
6273598|NCT02194465|9977401|FG006|Overall Study|Adverse Event|0
6273599|NCT02194465|9977395|FG000|Overall Study|Lost to Follow-up|0
6273600|NCT02194465|9977396|FG001|Overall Study|Lost to Follow-up|0
6273601|NCT02194465|9977397|FG002|Overall Study|Lost to Follow-up|0
6273602|NCT02194465|9977398|FG003|Overall Study|Lost to Follow-up|1
6273603|NCT02194465|9977399|FG004|Overall Study|Lost to Follow-up|0
6273604|NCT02194465|9977400|FG005|Overall Study|Lost to Follow-up|1
6273605|NCT02194465|9977401|FG006|Overall Study|Lost to Follow-up|0
6273606|NCT02194465|9977395|FG000|Overall Study|Physician Decision|1
6273607|NCT02194465|9977396|FG001|Overall Study|Physician Decision|0
6273608|NCT02194465|9977397|FG002|Overall Study|Physician Decision|0
6273609|NCT02194465|9977398|FG003|Overall Study|Physician Decision|0
6273610|NCT02194465|9977399|FG004|Overall Study|Physician Decision|0
6273611|NCT02194465|9977400|FG005|Overall Study|Physician Decision|0
6273612|NCT02194465|9977401|FG006|Overall Study|Physician Decision|0
6273613|NCT02194465|9977395|FG000|Overall Study|Protocol Violation|1
6273614|NCT02194465|9977396|FG001|Overall Study|Protocol Violation|1
6273615|NCT02194465|9977397|FG002|Overall Study|Protocol Violation|2
6273616|NCT02194465|9977398|FG003|Overall Study|Protocol Violation|1
6273617|NCT02194465|9977399|FG004|Overall Study|Protocol Violation|1
6273618|NCT02194465|9977400|FG005|Overall Study|Protocol Violation|0
6273619|NCT02194465|9977401|FG006|Overall Study|Protocol Violation|0
6273620|NCT02194465|9977395|FG000|Overall Study|Withdrawal by Subject|1
5976406|NCT03721107|9562990|FG001|Overall Study|Other|0
5976407|NCT03721107|9562991|FG002|Overall Study|Other|0
5976408|NCT03721107|9562992|FG003|Overall Study|Other|1
5976409|NCT03644849|9563032|FG000|Overall Study|Lost to Follow-up|1
6273621|NCT02194465|9977396|FG001|Overall Study|Withdrawal by Subject|3
6273622|NCT02194465|9977397|FG002|Overall Study|Withdrawal by Subject|1
6273623|NCT02194465|9977398|FG003|Overall Study|Withdrawal by Subject|2
6273624|NCT02194465|9977399|FG004|Overall Study|Withdrawal by Subject|2
6273625|NCT02194465|9977400|FG005|Overall Study|Withdrawal by Subject|1
5976410|NCT03644849|9563033|FG001|Overall Study|Lost to Follow-up|3
5976411|NCT03604159|9563041|FG000|Overall Study|Lost to Follow-up|6
5976412|NCT03604159|9563042|FG001|Overall Study|Lost to Follow-up|7
5976413|NCT03602885|9563050|FG000|Overall Study|Lost to Follow-up|3
5976414|NCT03602885|9563051|FG001|Overall Study|Lost to Follow-up|0
5976415|NCT03539601|9563061|FG000|Overall Study|Withdraw by parent/guardian|1
5976416|NCT03539601|9563062|FG001|Overall Study|Withdraw by parent/guardian|0
6194412|NCT01447446|9852663|FG000|Overall Study|Death|6
6194413|NCT01447446|9852664|FG001|Overall Study|Death|3
6194414|NCT01447446|9852665|FG002|Overall Study|Death|2
6194415|NCT01447446|9852666|FG003|Overall Study|Death|1
6194416|NCT01447446|9852667|FG004|Overall Study|Death|7
6194417|NCT01447446|9852668|FG005|Overall Study|Death|0
6194418|NCT01447446|9852663|FG000|Overall Study|Adverse Event|3
6194419|NCT01447446|9852664|FG001|Overall Study|Adverse Event|0
6194420|NCT01447446|9852665|FG002|Overall Study|Adverse Event|1
6194421|NCT01447446|9852666|FG003|Overall Study|Adverse Event|0
6194422|NCT01447446|9852667|FG004|Overall Study|Adverse Event|2
6194423|NCT01447446|9852668|FG005|Overall Study|Adverse Event|0
6194424|NCT01447446|9852663|FG000|Overall Study|Failure to Return/Consent Withdrawn|357
6194425|NCT01447446|9852664|FG001|Overall Study|Failure to Return/Consent Withdrawn|78
6194426|NCT01447446|9852665|FG002|Overall Study|Failure to Return/Consent Withdrawn|31
6194427|NCT01447446|9852666|FG003|Overall Study|Failure to Return/Consent Withdrawn|7
6194428|NCT01447446|9852667|FG004|Overall Study|Failure to Return/Consent Withdrawn|69
6194429|NCT01447446|9852668|FG005|Overall Study|Failure to Return/Consent Withdrawn|9
6194430|NCT01447446|9852663|FG000|Overall Study|Insuff. VR/TRT too Short to Expect VR|300
6194431|NCT01447446|9852664|FG001|Overall Study|Insuff. VR/TRT too Short to Expect VR|71
6194432|NCT01447446|9852665|FG002|Overall Study|Insuff. VR/TRT too Short to Expect VR|52
6194433|NCT01447446|9852666|FG003|Overall Study|Insuff. VR/TRT too Short to Expect VR|21
6194434|NCT01447446|9852667|FG004|Overall Study|Insuff. VR/TRT too Short to Expect VR|92
6194435|NCT01447446|9852668|FG005|Overall Study|Insuff. VR/TRT too Short to Expect VR|14
6194436|NCT01447446|9852663|FG000|Overall Study|Administrative/Other|34
6194437|NCT01447446|9852664|FG001|Overall Study|Administrative/Other|9
6194438|NCT01447446|9852665|FG002|Overall Study|Administrative/Other|10
6194439|NCT01447446|9852666|FG003|Overall Study|Administrative/Other|2
6194440|NCT01447446|9852667|FG004|Overall Study|Administrative/Other|33
6194441|NCT01447446|9852668|FG005|Overall Study|Administrative/Other|4
6194442|NCT01447446|9852663|FG000|Overall Study|SVR12 Assessment|13
6273626|NCT02194465|9977401|FG006|Overall Study|Withdrawal by Subject|2
6273627|NCT02194465|9977395|FG000|Overall Study|Discontinued follow-up period|0
6273628|NCT02194465|9977396|FG001|Overall Study|Discontinued follow-up period|2
6273629|NCT02194465|9977397|FG002|Overall Study|Discontinued follow-up period|1
6273630|NCT02194465|9977398|FG003|Overall Study|Discontinued follow-up period|0
6273631|NCT02194465|9977399|FG004|Overall Study|Discontinued follow-up period|2
6273632|NCT02194465|9977400|FG005|Overall Study|Discontinued follow-up period|0
6273633|NCT02194465|9977401|FG006|Overall Study|Discontinued follow-up period|0
6194443|NCT01447446|9852664|FG001|Overall Study|SVR12 Assessment|1
6194444|NCT01447446|9852665|FG002|Overall Study|SVR12 Assessment|2
6194445|NCT01447446|9852666|FG003|Overall Study|SVR12 Assessment|1
6194446|NCT01447446|9852667|FG004|Overall Study|SVR12 Assessment|5
6194447|NCT01447446|9852668|FG005|Overall Study|SVR12 Assessment|5
6194448|NCT01447446|9852663|FG000|Overall Study|New Treatment Started|8
6194449|NCT01447446|9852664|FG001|Overall Study|New Treatment Started|2
6194450|NCT01447446|9852665|FG002|Overall Study|New Treatment Started|1
6194451|NCT01447446|9852666|FG003|Overall Study|New Treatment Started|0
6194452|NCT01447446|9852667|FG004|Overall Study|New Treatment Started|2
6194453|NCT01447446|9852668|FG005|Overall Study|New Treatment Started|0
6194454|NCT01447446|9852663|FG000|Overall Study|Reason not Specified|1
6194455|NCT01447446|9852664|FG001|Overall Study|Reason not Specified|1
6194456|NCT01447446|9852665|FG002|Overall Study|Reason not Specified|1
6194457|NCT01447446|9852666|FG003|Overall Study|Reason not Specified|1
6194458|NCT01447446|9852667|FG004|Overall Study|Reason not Specified|1
6194459|NCT01447446|9852668|FG005|Overall Study|Reason not Specified|0
6194460|NCT01447576|9852709|FG000|Overall Study|Lost to Follow-up|52
6194461|NCT01447576|9852709|FG000|Overall Study|Adverse Event|127
6194462|NCT01447576|9852709|FG000|Overall Study|Participant met withdrawal criteria|40
6194463|NCT01447576|9852709|FG000|Overall Study|Withdrawal by Subject|100
6194464|NCT01447576|9852709|FG000|Overall Study|Protocol deviation|83
6194465|NCT01447576|9852709|FG000|Overall Study|Lack of Efficacy|68
6194466|NCT01447576|9852709|FG000|Overall Study|Physician Decision|6
6194467|NCT01447719|9852726|FG000|Overall Study|Image acquisition failure|2
6194468|NCT01447719|9852726|FG000|Overall Study|Invalid image or not imaged|3
6194469|NCT01447719|9852726|FG000|Overall Study|Subject still living at end of study|79
6194470|NCT01447719|9852726|FG000|Overall Study|Withdrawal by Subject|2
6194471|NCT01447719|9852726|FG000|Overall Study|Family withdrew autopsy consent|7
6194472|NCT01447927|9852767|FG000|Overall Study|Adverse Event|4
6194473|NCT01447927|9852768|FG001|Overall Study|Adverse Event|3
6194474|NCT01447927|9852767|FG000|Overall Study|Withdrawal by Subject|1
5976417|NCT03539601|9563063|FG002|Overall Study|Withdraw by parent/guardian|1
6194475|NCT01447927|9852768|FG001|Overall Study|Withdrawal by Subject|0
6194476|NCT01448044|9852776|FG000|Treatment Period|Adverse Event|4
6194477|NCT01448044|9852777|FG001|Treatment Period|Adverse Event|3
6194478|NCT01448044|9852776|FG000|Treatment Period|Lack of Efficacy|5
6194479|NCT01448044|9852777|FG001|Treatment Period|Lack of Efficacy|12
6273634|NCT02194621|9977424|FG000|Overall Study|6 withdrew prior to randomization|2
5976418|NCT03539601|9563064|FG003|Overall Study|Withdraw by parent/guardian|0
5976419|NCT03539601|9563061|FG000|Overall Study|Adverse Event|0
5976420|NCT03539601|9563062|FG001|Overall Study|Adverse Event|2
6273635|NCT02194621|9977425|FG001|Overall Study|6 withdrew prior to randomization|2
6273636|NCT02194621|9977426|FG002|Overall Study|6 withdrew prior to randomization|2
6273637|NCT02194621|9977424|FG000|Overall Study|Withdrawal by Subject|4
6273638|NCT02194621|9977425|FG001|Overall Study|Withdrawal by Subject|4
6273639|NCT02194621|9977426|FG002|Overall Study|Withdrawal by Subject|7
6273640|NCT02194699|9977436|FG000|Randomised|Did not receive treatment|1
6273641|NCT02194699|9977437|FG001|Randomised|Did not receive treatment|5
6273642|NCT02194699|9977436|FG000|Randomised|Without potential for 52 weeks of IP|5
6273643|NCT02194699|9977437|FG001|Randomised|Without potential for 52 weeks of IP|5
6273644|NCT02194699|9977436|FG000|Randomised|Duplicate patient|2
6273645|NCT02194699|9977437|FG001|Randomised|Duplicate patient|1
6273646|NCT02194699|9977436|FG000|With Potential to Receive 52 Weeks of IP|Adverse Event|4
6273647|NCT02194699|9977437|FG001|With Potential to Receive 52 Weeks of IP|Adverse Event|3
6273648|NCT02194699|9977436|FG000|With Potential to Receive 52 Weeks of IP|Death|1
6273649|NCT02194699|9977437|FG001|With Potential to Receive 52 Weeks of IP|Death|3
6273650|NCT02194699|9977436|FG000|With Potential to Receive 52 Weeks of IP|Lost to Follow-up|5
6273651|NCT02194699|9977437|FG001|With Potential to Receive 52 Weeks of IP|Lost to Follow-up|8
6273652|NCT02194699|9977436|FG000|With Potential to Receive 52 Weeks of IP|Protocol Violation|2
6273653|NCT02194699|9977437|FG001|With Potential to Receive 52 Weeks of IP|Protocol Violation|2
6273654|NCT02194699|9977436|FG000|With Potential to Receive 52 Weeks of IP|Withdrawal by Subject|14
6273655|NCT02194699|9977437|FG001|With Potential to Receive 52 Weeks of IP|Withdrawal by Subject|20
6273656|NCT02194699|9977436|FG000|With Potential to Receive 52 Weeks of IP|Other|24
6273657|NCT02194699|9977437|FG001|With Potential to Receive 52 Weeks of IP|Other|16
6273658|NCT02194933|9977453|FG000|Overall Study|Lost to Follow-up|1
6273659|NCT02194933|9977454|FG001|Overall Study|Lost to Follow-up|2
6273660|NCT02194933|9977453|FG000|Overall Study|Participant met withdrawal criteria|1
6273661|NCT02194933|9977454|FG001|Overall Study|Participant met withdrawal criteria|3
6273662|NCT02194933|9977453|FG000|Overall Study|Withdrawal by Subject|0
6273663|NCT02194933|9977454|FG001|Overall Study|Withdrawal by Subject|2
6273664|NCT02194933|9977453|FG000|Overall Study|Lack of Efficacy|1
6273665|NCT02194933|9977454|FG001|Overall Study|Lack of Efficacy|2
6273666|NCT02194985|9977462|FG000|Overall Study|Adverse Event|1
6273667|NCT02194985|9977462|FG000|Overall Study|Met Protocol Defined Stopping Criteria|3
6273668|NCT02194985|9977462|FG000|Overall Study|Physician Decision|4
6273669|NCT02194985|9977462|FG000|Overall Study|Lost to Follow-up|1
6273670|NCT02194985|9977462|FG000|Overall Study|Withdrawal by Subject|2
5976421|NCT03539601|9563063|FG002|Overall Study|Adverse Event|0
5976422|NCT03539601|9563064|FG003|Overall Study|Adverse Event|0
5976423|NCT03539601|9563061|FG000|Overall Study|Lost to Follow-up|2
5976424|NCT03539601|9563062|FG001|Overall Study|Lost to Follow-up|4
5976425|NCT03539601|9563063|FG002|Overall Study|Lost to Follow-up|5
5976426|NCT03539601|9563064|FG003|Overall Study|Lost to Follow-up|0
5976427|NCT03539601|9563061|FG000|Overall Study|Withdrawal by Subject|2
5976428|NCT03539601|9563062|FG001|Overall Study|Withdrawal by Subject|0
5976429|NCT03539601|9563063|FG002|Overall Study|Withdrawal by Subject|0
5976430|NCT03539601|9563064|FG003|Overall Study|Withdrawal by Subject|1
5976431|NCT03539601|9563061|FG000|Overall Study|Randomized but not treated|1
5976432|NCT03539601|9563062|FG001|Overall Study|Randomized but not treated|1
6050655|NCT00428090|9649855|FG001|Overall Study|Excluded for concerning QTc value|0
6050656|NCT00428090|9649856|FG002|Overall Study|Excluded for concerning QTc value|1
6050657|NCT00428090|9649857|FG003|Overall Study|Excluded for concerning QTc value|0
6050658|NCT00428090|9649854|FG000|Overall Study|Insufficient AD documentation|0
6050659|NCT00428090|9649855|FG001|Overall Study|Insufficient AD documentation|0
6050660|NCT00428090|9649856|FG002|Overall Study|Insufficient AD documentation|1
6050661|NCT00428090|9649857|FG003|Overall Study|Insufficient AD documentation|0
6050662|NCT00428090|9649854|FG000|Overall Study|High MMSE scores|0
6050663|NCT00428090|9649855|FG001|Overall Study|High MMSE scores|0
6050664|NCT00428090|9649856|FG002|Overall Study|High MMSE scores|1
6050665|NCT00428090|9649857|FG003|Overall Study|High MMSE scores|0
6050666|NCT00428090|9649854|FG000|Overall Study|Deterioration of cognitive status|0
6050667|NCT00428090|9649855|FG001|Overall Study|Deterioration of cognitive status|0
6194480|NCT01448044|9852776|FG000|Treatment Period|Subject requested discontinue study drug|1
6194481|NCT01448044|9852777|FG001|Treatment Period|Subject requested discontinue study drug|0
6194482|NCT01448044|9852776|FG000|Treatment Period|Completed 24 weeks treatment period only|8
6194483|NCT01448044|9852777|FG001|Treatment Period|Completed 24 weeks treatment period only|0
6194484|NCT01448044|9852776|FG000|Treatment Period|Participant does not meet study criteria|1
6194485|NCT01448044|9852777|FG001|Treatment Period|Participant does not meet study criteria|0
6194486|NCT01448044|9852776|FG000|Treatment Period|Lost to Follow-up|2
5976433|NCT03539601|9563063|FG002|Overall Study|Randomized but not treated|0
6050668|NCT00428090|9649856|FG002|Overall Study|Deterioration of cognitive status|1
6194487|NCT01448044|9852777|FG001|Treatment Period|Lost to Follow-up|1
5976434|NCT03539601|9563064|FG003|Overall Study|Randomized but not treated|0
5976435|NCT03539458|9563082|FG000|Overall Study|Death|1
5976436|NCT03532451|9563088|FG000|Overall Study|Withdrawal by Subject|0
5976437|NCT03532451|9563089|FG001|Overall Study|Withdrawal by Subject|1
5976438|NCT03532451|9563088|FG000|Overall Study|Progression prior to the surgery|1
5976439|NCT03532451|9563089|FG001|Overall Study|Progression prior to the surgery|0
6050669|NCT00428090|9649857|FG003|Overall Study|Deterioration of cognitive status|0
6050670|NCT00428090|9649854|FG000|Overall Study|Serious adverse event|0
6194488|NCT01448044|9852776|FG000|Treatment Period|Other reason|2
6194489|NCT01448044|9852777|FG001|Treatment Period|Other reason|0
6194490|NCT01448044|9852776|FG000|Follow Up Period|Withdrawal by Subject|1
6194491|NCT01448044|9852777|FG001|Follow Up Period|Withdrawal by Subject|1
6194492|NCT01448044|9852776|FG000|Follow Up Period|Lost to Follow-up|6
6194493|NCT01448044|9852777|FG001|Follow Up Period|Lost to Follow-up|2
6194494|NCT01448044|9852776|FG000|Follow Up Period|Other|5
6194495|NCT01448044|9852777|FG001|Follow Up Period|Other|11
6194496|NCT01448057|9852785|FG000|Overall Study|Protocol Violation|3
6194497|NCT01448057|9852786|FG001|Overall Study|Protocol Violation|2
6194498|NCT01448057|9852785|FG000|Overall Study|Lost to Follow-up|3
6194499|NCT01448057|9852786|FG001|Overall Study|Lost to Follow-up|0
6194500|NCT01448057|9852785|FG000|Overall Study|Adverse Event|0
6194501|NCT01448057|9852786|FG001|Overall Study|Adverse Event|2
6273671|NCT02194998|9977470|FG000|On-HCV Treatment|Did not pick up study medication|0
6273672|NCT02194998|9977471|FG001|On-HCV Treatment|Did not pick up study medication|1
6273673|NCT02194998|9977472|FG002|On-HCV Treatment|Did not pick up study medication|0
6273674|NCT02194998|9977473|FG003|On-HCV Treatment|Did not pick up study medication|0
6273675|NCT02194998|9977470|FG000|Post-HCV Treatment Follow-Up|Lost to Follow-up|1
6273676|NCT02194998|9977471|FG001|Post-HCV Treatment Follow-Up|Lost to Follow-up|0
6273677|NCT02194998|9977472|FG002|Post-HCV Treatment Follow-Up|Lost to Follow-up|1
6273678|NCT02194998|9977473|FG003|Post-HCV Treatment Follow-Up|Lost to Follow-up|0
6273679|NCT02195011|9977485|FG000|Overall Study|Adverse Event|4
6273680|NCT02195011|9977486|FG001|Overall Study|Adverse Event|0
6273681|NCT02195011|9977485|FG000|Overall Study|Progressive Disease|18
6273682|NCT02195011|9977486|FG001|Overall Study|Progressive Disease|1
6273683|NCT02195011|9977485|FG000|Overall Study|Withdrawal by Subject|3
6273684|NCT02195011|9977486|FG001|Overall Study|Withdrawal by Subject|0
6273685|NCT02195427|9977581|FG000|Overall Study|Did not consent to study extension|13
6273686|NCT02195427|9977582|FG001|Overall Study|Did not consent to study extension|9
6273687|NCT02195427|9977581|FG000|Overall Study|Withdrawal by Subject|4
6273688|NCT02195427|9977582|FG001|Overall Study|Withdrawal by Subject|2
6273689|NCT02195427|9977581|FG000|Overall Study|Lost to Follow-up|0
6273690|NCT02195427|9977582|FG001|Overall Study|Lost to Follow-up|1
6273691|NCT02195427|9977581|FG000|Overall Study|Protocol Violation|7
6273692|NCT02195427|9977582|FG001|Overall Study|Protocol Violation|14
6273693|NCT02195427|9977581|FG000|Overall Study|Conditional re-treatment at W52|2
6273694|NCT02195427|9977582|FG001|Overall Study|Conditional re-treatment at W52|1
6273695|NCT02195518|9977592|FG000|Overall Study|Adverse Event|1
6273696|NCT02195518|9977592|FG000|Overall Study|Protocol Violation|4
6273697|NCT02195518|9977592|FG000|Overall Study|Pregnancy|2
6273698|NCT02195518|9977592|FG000|Overall Study|Withdrawal by Subject|1
6273699|NCT02195518|9977592|FG000|Overall Study|Lost to Follow-up|1
6273700|NCT02195531|9977599|FG000|Overall Study|Withdrawal by Subject|1
6273701|NCT02195531|9977600|FG001|Overall Study|Withdrawal by Subject|1
6273702|NCT02195531|9977601|FG002|Overall Study|Withdrawal by Subject|1
6273703|NCT02195583|9977609|FG000|Overall Study|Lost to Follow-up|1
6273704|NCT02195583|9977609|FG000|Overall Study|Withdrawal by Subject|4
6273705|NCT02195583|9977609|FG000|Overall Study|Adverse Event|2
6273706|NCT02195583|9977609|FG000|Overall Study|Other Reason|2
6273707|NCT02195687|9977635|FG000|Overall Study|Personal Reasons|1
6273708|NCT02195687|9977636|FG001|Overall Study|Personal Reasons|1
6273709|NCT02195687|9977635|FG000|Overall Study|Lost to Follow-up|4
6273710|NCT02195687|9977636|FG001|Overall Study|Lost to Follow-up|1
6273711|NCT02195700|9977644|FG000|Overall Study|Protocol Violation|0
6273712|NCT02195700|9977645|FG001|Overall Study|Protocol Violation|2
6273713|NCT02195700|9977644|FG000|Overall Study|Noncompliance|1
6273714|NCT02195700|9977645|FG001|Overall Study|Noncompliance|0
6273715|NCT02195700|9977644|FG000|Overall Study|Adverse Event|1
6273716|NCT02195700|9977645|FG001|Overall Study|Adverse Event|2
6273717|NCT02195700|9977644|FG000|Overall Study|Withdrawal by Subject|3
6273718|NCT02195700|9977645|FG001|Overall Study|Withdrawal by Subject|2
6273719|NCT02195700|9977644|FG000|Overall Study|Lost to Follow-up|1
6273720|NCT02195700|9977645|FG001|Overall Study|Lost to Follow-up|1
6273721|NCT02195869|9977660|FG000|Overall Study|cGVHD Progression|5
6273722|NCT02195869|9977660|FG000|Overall Study|Malignancy Progression/relapse|2
6273723|NCT02195869|9977660|FG000|Overall Study|Adverse Event|15
6273724|NCT02195869|9977660|FG000|Overall Study|Withdrawal by Subject|7
6050671|NCT00428090|9649855|FG001|Overall Study|Serious adverse event|0
6273725|NCT02195869|9977660|FG000|Overall Study|Physician Decision|4
6273726|NCT02195869|9977660|FG000|Overall Study|Study Terminated by Sponsor|7
6050672|NCT00428090|9649856|FG002|Overall Study|Serious adverse event|1
6050673|NCT00428090|9649857|FG003|Overall Study|Serious adverse event|0
6194502|NCT01448057|9852785|FG000|Overall Study|Withdrawal by Subject|2
6194503|NCT01448057|9852786|FG001|Overall Study|Withdrawal by Subject|0
6194504|NCT01448213|9852794|FG000|Overall Study|Lost to Follow-up|12
6194505|NCT01448213|9852795|FG001|Overall Study|Lost to Follow-up|10
6194506|NCT01448213|9852794|FG000|Overall Study|Adverse Event|4
6194507|NCT01448213|9852795|FG001|Overall Study|Adverse Event|10
6194508|NCT01448213|9852794|FG000|Overall Study|Protocol Violation|1
6194509|NCT01448213|9852795|FG001|Overall Study|Protocol Violation|2
6194510|NCT01448616|9852840|FG000|Lead-In (Observational Phase)|Collected no genital swabs|3
6194511|NCT01448616|9852841|FG001|Lead-In (Observational Phase)|Collected no genital swabs|0
6194512|NCT01448616|9852842|FG002|Lead-In (Observational Phase)|Collected no genital swabs|0
6194513|NCT01448616|9852843|FG003|Lead-In (Observational Phase)|Collected no genital swabs|0
6194514|NCT01448616|9852840|FG000|Lead-In (Observational Phase)|Collected <90% of required swabs|6
6194515|NCT01448616|9852841|FG001|Lead-In (Observational Phase)|Collected <90% of required swabs|0
6194516|NCT01448616|9852842|FG002|Lead-In (Observational Phase)|Collected <90% of required swabs|0
6194517|NCT01448616|9852843|FG003|Lead-In (Observational Phase)|Collected <90% of required swabs|0
6194518|NCT01448616|9852840|FG000|Study Drug (Treatment Phase)|Adverse Event|0
6194519|NCT01448616|9852841|FG001|Study Drug (Treatment Phase)|Adverse Event|1
6194520|NCT01448616|9852842|FG002|Study Drug (Treatment Phase)|Adverse Event|1
6194521|NCT01448616|9852843|FG003|Study Drug (Treatment Phase)|Adverse Event|0
6194522|NCT01448616|9852840|FG000|Study Drug (Treatment Phase)|Never initiated study drug|0
6194523|NCT01448616|9852841|FG001|Study Drug (Treatment Phase)|Never initiated study drug|0
6194524|NCT01448616|9852842|FG002|Study Drug (Treatment Phase)|Never initiated study drug|1
6194525|NCT01448616|9852843|FG003|Study Drug (Treatment Phase)|Never initiated study drug|2
6194526|NCT01448616|9852840|FG000|Study Drug (Treatment Phase)|Withdrawal by Subject|0
6194527|NCT01448616|9852841|FG001|Study Drug (Treatment Phase)|Withdrawal by Subject|1
6194528|NCT01448616|9852842|FG002|Study Drug (Treatment Phase)|Withdrawal by Subject|2
6194529|NCT01448616|9852843|FG003|Study Drug (Treatment Phase)|Withdrawal by Subject|2
6194530|NCT01448707|9852858|FG000|Overall Study|Adverse Event|3
6194531|NCT01448707|9852859|FG001|Overall Study|Adverse Event|1
6273727|NCT02195869|9977660|FG000|Overall Study|Noncompliance with study drug|2
6273728|NCT02196038|9977695|FG000|Overall Study|Death|16
6273729|NCT02196038|9977696|FG001|Overall Study|Death|21
6273730|NCT02196038|9977695|FG000|Overall Study|Withdrawal by Subject|0
6273731|NCT02196038|9977696|FG001|Overall Study|Withdrawal by Subject|1
6273732|NCT02196038|9977695|FG000|Overall Study|Lost to Follow-up|1
6273733|NCT02196038|9977696|FG001|Overall Study|Lost to Follow-up|0
6273734|NCT02196077|9977702|FG000|Overall Study|Adverse Event|4
6273735|NCT02196077|9977702|FG000|Overall Study|Lack of Efficacy|1
6273736|NCT02196077|9977702|FG000|Overall Study|Withdrawal by Subject|14
6273737|NCT02196077|9977702|FG000|Overall Study|Physician Decision|1
6273738|NCT02196077|9977702|FG000|Overall Study|Lost to Follow-up|3
6273739|NCT02196077|9977702|FG000|Overall Study|Protocol Violation|24
6273740|NCT02196259|9977726|FG000|Overall Study|Researcher choice|0
6273741|NCT02196259|9977727|FG001|Overall Study|Researcher choice|0
6273742|NCT02196259|9977728|FG002|Overall Study|Researcher choice|1
6273743|NCT02196259|9977726|FG000|Overall Study|Partial data analysis|0
6273744|NCT02196259|9977727|FG001|Overall Study|Partial data analysis|3
6273745|NCT02196259|9977728|FG002|Overall Study|Partial data analysis|0
6273746|NCT02196324|9977737|FG000|Overall Study|Withdrawal by Subject|8
6273747|NCT02196324|9977738|FG001|Overall Study|Withdrawal by Subject|4
6273748|NCT02196324|9977737|FG000|Overall Study|Adverse Event or Serious Adverse Event|6
6273749|NCT02196324|9977738|FG001|Overall Study|Adverse Event or Serious Adverse Event|3
6273750|NCT02196324|9977737|FG000|Overall Study|Occurrence of an Exclusion Criterion|0
6273751|NCT02196324|9977738|FG001|Overall Study|Occurrence of an Exclusion Criterion|1
6273752|NCT02196324|9977737|FG000|Overall Study|Other|1
6273753|NCT02196324|9977738|FG001|Overall Study|Other|0
6273754|NCT02196506|9977746|FG000|Phase A|Participant Met Withdrawal Criteria|34
6273755|NCT02196506|9977747|FG001|Phase A|Participant Met Withdrawal Criteria|0
6273756|NCT02196506|9977748|FG002|Phase A|Participant Met Withdrawal Criteria|0
6273757|NCT02196506|9977749|FG003|Phase A|Participant Met Withdrawal Criteria|0
6273758|NCT02196506|9977746|FG000|Phase A|Withdrawal by Subject|34
6273759|NCT02196506|9977747|FG001|Phase A|Withdrawal by Subject|0
6273760|NCT02196506|9977748|FG002|Phase A|Withdrawal by Subject|0
6273761|NCT02196506|9977749|FG003|Phase A|Withdrawal by Subject|0
6273762|NCT02196506|9977746|FG000|Phase A|Adverse Event|22
6273763|NCT02196506|9977747|FG001|Phase A|Adverse Event|0
6273764|NCT02196506|9977748|FG002|Phase A|Adverse Event|0
6273765|NCT02196506|9977749|FG003|Phase A|Adverse Event|0
6273766|NCT02196506|9977746|FG000|Phase A|Lost to Follow-up|9
6273767|NCT02196506|9977747|FG001|Phase A|Lost to Follow-up|0
6273768|NCT02196506|9977748|FG002|Phase A|Lost to Follow-up|0
6273769|NCT02196506|9977749|FG003|Phase A|Lost to Follow-up|0
6273770|NCT02196506|9977746|FG000|Phase A|Protocol deviation|12
6273771|NCT02196506|9977747|FG001|Phase A|Protocol deviation|0
6273772|NCT02196506|9977748|FG002|Phase A|Protocol deviation|0
6273773|NCT02196506|9977749|FG003|Phase A|Protocol deviation|0
6273774|NCT02196506|9977746|FG000|Phase A|Participant withdrawn by investigator|10
6273775|NCT02196506|9977747|FG001|Phase A|Participant withdrawn by investigator|0
6194532|NCT01448707|9852858|FG000|Overall Study|Lost to Follow-up|2
6194533|NCT01448707|9852859|FG001|Overall Study|Lost to Follow-up|6
6194534|NCT01448707|9852858|FG000|Overall Study|Withdrawal by Subject|6
6194535|NCT01448707|9852859|FG001|Overall Study|Withdrawal by Subject|7
6194536|NCT01448707|9852858|FG000|Overall Study|Other|7
6194537|NCT01448707|9852859|FG001|Overall Study|Other|4
6194538|NCT01448824|9852873|FG000|Part 1 Period 1: Multiple Ascending Dose|Adverse Event|0
6194539|NCT01448824|9852874|FG001|Part 1 Period 1: Multiple Ascending Dose|Adverse Event|0
6194540|NCT01448824|9852875|FG002|Part 1 Period 1: Multiple Ascending Dose|Adverse Event|0
6194541|NCT01448824|9852876|FG003|Part 1 Period 1: Multiple Ascending Dose|Adverse Event|0
6194542|NCT01448824|9852877|FG004|Part 1 Period 1: Multiple Ascending Dose|Adverse Event|0
6194543|NCT01448824|9852878|FG005|Part 1 Period 1: Multiple Ascending Dose|Adverse Event|0
6194544|NCT01448824|9852879|FG006|Part 1 Period 1: Multiple Ascending Dose|Adverse Event|1
6194545|NCT01448824|9852880|FG007|Part 1 Period 1: Multiple Ascending Dose|Adverse Event|0
6194546|NCT01448824|9852873|FG000|Part 1 Period 1: Multiple Ascending Dose|Withdrawal by Subject|0
6194547|NCT01448824|9852874|FG001|Part 1 Period 1: Multiple Ascending Dose|Withdrawal by Subject|0
6194548|NCT01448824|9852875|FG002|Part 1 Period 1: Multiple Ascending Dose|Withdrawal by Subject|0
6194549|NCT01448824|9852876|FG003|Part 1 Period 1: Multiple Ascending Dose|Withdrawal by Subject|1
6194550|NCT01448824|9852877|FG004|Part 1 Period 1: Multiple Ascending Dose|Withdrawal by Subject|2
6194551|NCT01448824|9852878|FG005|Part 1 Period 1: Multiple Ascending Dose|Withdrawal by Subject|1
6194552|NCT01448824|9852879|FG006|Part 1 Period 1: Multiple Ascending Dose|Withdrawal by Subject|0
6194553|NCT01448824|9852880|FG007|Part 1 Period 1: Multiple Ascending Dose|Withdrawal by Subject|0
6194554|NCT01448824|9852873|FG000|Part 1 Period 1: Multiple Ascending Dose|Lost to Follow-up|0
6194555|NCT01448824|9852874|FG001|Part 1 Period 1: Multiple Ascending Dose|Lost to Follow-up|0
6194556|NCT01448824|9852875|FG002|Part 1 Period 1: Multiple Ascending Dose|Lost to Follow-up|0
6194557|NCT01448824|9852876|FG003|Part 1 Period 1: Multiple Ascending Dose|Lost to Follow-up|0
6194558|NCT01448824|9852877|FG004|Part 1 Period 1: Multiple Ascending Dose|Lost to Follow-up|0
6194559|NCT01448824|9852878|FG005|Part 1 Period 1: Multiple Ascending Dose|Lost to Follow-up|1
6194560|NCT01448824|9852879|FG006|Part 1 Period 1: Multiple Ascending Dose|Lost to Follow-up|0
6194561|NCT01448824|9852880|FG007|Part 1 Period 1: Multiple Ascending Dose|Lost to Follow-up|0
6194562|NCT01448824|9852873|FG000|Part 1: Washout Period|Lost to Follow-up|1
6194563|NCT01448824|9852874|FG001|Part 1: Washout Period|Lost to Follow-up|0
6194564|NCT01448824|9852875|FG002|Part 1: Washout Period|Lost to Follow-up|0
6194565|NCT01448824|9852876|FG003|Part 1: Washout Period|Lost to Follow-up|0
6194566|NCT01448824|9852877|FG004|Part 1: Washout Period|Lost to Follow-up|0
6194567|NCT01448824|9852878|FG005|Part 1: Washout Period|Lost to Follow-up|0
6194568|NCT01448824|9852879|FG006|Part 1: Washout Period|Lost to Follow-up|0
6194569|NCT01448824|9852880|FG007|Part 1: Washout Period|Lost to Follow-up|0
6194570|NCT01448824|9852873|FG000|Part 2 Period 1: Drug-drug Interaction|Adverse Event|0
6194571|NCT01448824|9852874|FG001|Part 2 Period 1: Drug-drug Interaction|Adverse Event|0
6194572|NCT01448824|9852875|FG002|Part 2 Period 1: Drug-drug Interaction|Adverse Event|0
6194573|NCT01448824|9852876|FG003|Part 2 Period 1: Drug-drug Interaction|Adverse Event|0
6194574|NCT01448824|9852877|FG004|Part 2 Period 1: Drug-drug Interaction|Adverse Event|0
6273776|NCT02196506|9977748|FG002|Phase A|Participant withdrawn by investigator|0
6273777|NCT02196506|9977749|FG003|Phase A|Participant withdrawn by investigator|0
6273778|NCT02196506|9977746|FG000|Phase B|Participant Met Withdrawal Criteria|0
6273779|NCT02196506|9977747|FG001|Phase B|Participant Met Withdrawal Criteria|0
6273780|NCT02196506|9977748|FG002|Phase B|Participant Met Withdrawal Criteria|1
6273781|NCT02196506|9977749|FG003|Phase B|Participant Met Withdrawal Criteria|0
6273782|NCT02196506|9977746|FG000|Phase B|Lack of Efficacy|0
6273783|NCT02196506|9977747|FG001|Phase B|Lack of Efficacy|1
6273784|NCT02196506|9977748|FG002|Phase B|Lack of Efficacy|2
6273785|NCT02196506|9977749|FG003|Phase B|Lack of Efficacy|0
6273786|NCT02196506|9977746|FG000|Phase B|Withdrawal by Participant|0
6273787|NCT02196506|9977747|FG001|Phase B|Withdrawal by Participant|8
6273788|NCT02196506|9977748|FG002|Phase B|Withdrawal by Participant|1
5976440|NCT03464136|9563115|FG000|Overall Study|Lost to Follow-up|5
5976441|NCT03464136|9563116|FG001|Overall Study|Lost to Follow-up|8
5976442|NCT03464136|9563115|FG000|Overall Study|Withdrawal by Subject|16
5976443|NCT03464136|9563116|FG001|Overall Study|Withdrawal by Subject|13
5976444|NCT03464136|9563115|FG000|Overall Study|Death|1
5976445|NCT03464136|9563116|FG001|Overall Study|Death|0
5976446|NCT03464136|9563115|FG000|Overall Study|Other|8
5976447|NCT03464136|9563116|FG001|Overall Study|Other|4
5976448|NCT03439657|9563124|FG000|Overall Study|Adverse Event|2
5976449|NCT03439657|9563125|FG001|Overall Study|Adverse Event|3
5976450|NCT03439657|9563124|FG000|Overall Study|Lost to Follow-up|1
5976451|NCT03439657|9563125|FG001|Overall Study|Lost to Follow-up|0
5976452|NCT03439657|9563124|FG000|Overall Study|Protocol Violation|1
5976453|NCT03439657|9563125|FG001|Overall Study|Protocol Violation|1
5976454|NCT03439657|9563124|FG000|Overall Study|Consent withdrawal, not due to an Adverse Event|3
5976455|NCT03439657|9563125|FG001|Overall Study|Consent withdrawal, not due to an Adverse Event|0
5976456|NCT03377790|9563135|FG000|Overall Study|Withdrawal by Subject|1
5976457|NCT03377790|9563136|FG001|Overall Study|Withdrawal by Subject|0
5976458|NCT03377790|9563135|FG000|Overall Study|Adverse Event|1
5976459|NCT03377790|9563136|FG001|Overall Study|Adverse Event|0
6273789|NCT02196506|9977749|FG003|Phase B|Withdrawal by Participant|0
6273790|NCT02196506|9977746|FG000|Phase B|Adverse Event|0
5976460|NCT03377790|9563135|FG000|Overall Study|Lost to Follow-up|0
5976461|NCT03377790|9563136|FG001|Overall Study|Lost to Follow-up|2
5976462|NCT03377790|9563135|FG000|Overall Study|Randomized but not treated|1
6194575|NCT01448824|9852878|FG005|Part 2 Period 1: Drug-drug Interaction|Adverse Event|0
6194576|NCT01448824|9852879|FG006|Part 2 Period 1: Drug-drug Interaction|Adverse Event|0
6194577|NCT01448824|9852880|FG007|Part 2 Period 1: Drug-drug Interaction|Adverse Event|1
6088318|NCT00674128|9699006|FG000|Overall Study|Withdrawal by Subject|25
6088319|NCT00674128|9699007|FG001|Overall Study|Withdrawal by Subject|23
6088320|NCT00674154|9699015|FG000|Overall Study|Withdrawal by Subject|3
6088321|NCT00674154|9699016|FG001|Overall Study|Withdrawal by Subject|1
6194578|NCT01448824|9852873|FG000|Part 2 Period 2: Drug-drug Interaction|Adverse Event|0
6194579|NCT01448824|9852874|FG001|Part 2 Period 2: Drug-drug Interaction|Adverse Event|0
6194580|NCT01448824|9852875|FG002|Part 2 Period 2: Drug-drug Interaction|Adverse Event|0
6194581|NCT01448824|9852876|FG003|Part 2 Period 2: Drug-drug Interaction|Adverse Event|0
6194582|NCT01448824|9852877|FG004|Part 2 Period 2: Drug-drug Interaction|Adverse Event|0
6194583|NCT01448824|9852878|FG005|Part 2 Period 2: Drug-drug Interaction|Adverse Event|0
6194584|NCT01448824|9852879|FG006|Part 2 Period 2: Drug-drug Interaction|Adverse Event|0
6194585|NCT01448824|9852880|FG007|Part 2 Period 2: Drug-drug Interaction|Adverse Event|1
6194586|NCT01448824|9852873|FG000|Part 2 Period 2: Drug-drug Interaction|Lost to Follow-up|0
6194587|NCT01448824|9852874|FG001|Part 2 Period 2: Drug-drug Interaction|Lost to Follow-up|0
6194588|NCT01448824|9852875|FG002|Part 2 Period 2: Drug-drug Interaction|Lost to Follow-up|0
6194589|NCT01448824|9852876|FG003|Part 2 Period 2: Drug-drug Interaction|Lost to Follow-up|0
6194590|NCT01448824|9852877|FG004|Part 2 Period 2: Drug-drug Interaction|Lost to Follow-up|0
6194591|NCT01448824|9852878|FG005|Part 2 Period 2: Drug-drug Interaction|Lost to Follow-up|0
6194592|NCT01448824|9852879|FG006|Part 2 Period 2: Drug-drug Interaction|Lost to Follow-up|0
6194593|NCT01448824|9852880|FG007|Part 2 Period 2: Drug-drug Interaction|Lost to Follow-up|1
6194594|NCT01448824|9852873|FG000|Part 2 Period 2: Drug-drug Interaction|Withdrawal by Subject|0
6194595|NCT01448824|9852874|FG001|Part 2 Period 2: Drug-drug Interaction|Withdrawal by Subject|0
6194596|NCT01448824|9852875|FG002|Part 2 Period 2: Drug-drug Interaction|Withdrawal by Subject|0
6194597|NCT01448824|9852876|FG003|Part 2 Period 2: Drug-drug Interaction|Withdrawal by Subject|0
6194598|NCT01448824|9852877|FG004|Part 2 Period 2: Drug-drug Interaction|Withdrawal by Subject|0
6194599|NCT01448824|9852878|FG005|Part 2 Period 2: Drug-drug Interaction|Withdrawal by Subject|0
6194600|NCT01448824|9852879|FG006|Part 2 Period 2: Drug-drug Interaction|Withdrawal by Subject|0
6194601|NCT01448824|9852880|FG007|Part 2 Period 2: Drug-drug Interaction|Withdrawal by Subject|1
6194602|NCT01448850|9852910|FG000|Overall Study|Death|3
6194603|NCT01448850|9852911|FG001|Overall Study|Death|6
6194604|NCT01448850|9852910|FG000|Overall Study|Withdrawal by Subject|13
6194605|NCT01448850|9852911|FG001|Overall Study|Withdrawal by Subject|21
6194606|NCT01448850|9852910|FG000|Overall Study|Lost to Follow-up|3
6194607|NCT01448850|9852911|FG001|Overall Study|Lost to Follow-up|1
6194608|NCT01448850|9852910|FG000|Overall Study|Other|15
6194609|NCT01448850|9852911|FG001|Overall Study|Other|12
6194610|NCT01449006|9852920|FG000|Overall Study|Lost to Follow-up|1
6194611|NCT01449006|9852921|FG001|Overall Study|Lost to Follow-up|0
6194612|NCT01449006|9852920|FG000|Overall Study|Withdrawal by Subject|1
6194613|NCT01449006|9852921|FG001|Overall Study|Withdrawal by Subject|0
6194614|NCT01449006|9852920|FG000|Overall Study|Protocol Violation|1
6194615|NCT01449006|9852921|FG001|Overall Study|Protocol Violation|0
6194616|NCT01449279|9852935|FG000|Overall Study|Lack of Efficacy|5
6194617|NCT01449279|9852935|FG000|Overall Study|Toxicity|2
6194618|NCT01449370|9852968|FG000|Overall Study|Disease Progression|5
6194619|NCT01449370|9852969|FG001|Overall Study|Disease Progression|4
6194620|NCT01449370|9852970|FG002|Overall Study|Disease Progression|8
6194621|NCT01449370|9852971|FG003|Overall Study|Disease Progression|3
6194622|NCT01449370|9852972|FG004|Overall Study|Disease Progression|3
6194623|NCT01449370|9852973|FG005|Overall Study|Disease Progression|3
6194624|NCT01449370|9852974|FG006|Overall Study|Disease Progression|3
6194625|NCT01449370|9852975|FG007|Overall Study|Disease Progression|2
6194626|NCT01449370|9852976|FG008|Overall Study|Disease Progression|9
6194627|NCT01449370|9852977|FG009|Overall Study|Disease Progression|1
6194628|NCT01449370|9852978|FG010|Overall Study|Disease Progression|3
6194629|NCT01449370|9852979|FG011|Overall Study|Disease Progression|3
6194630|NCT01449370|9852980|FG012|Overall Study|Disease Progression|2
6194631|NCT01449370|9852981|FG013|Overall Study|Disease Progression|8
6194632|NCT01449370|9852982|FG014|Overall Study|Disease Progression|3
6194633|NCT01449370|9852983|FG015|Overall Study|Disease Progression|1
6194634|NCT01449370|9852984|FG016|Overall Study|Disease Progression|4
6194635|NCT01449370|9852985|FG017|Overall Study|Disease Progression|3
6194636|NCT01449370|9852986|FG018|Overall Study|Disease Progression|1
6194637|NCT01449370|9852987|FG019|Overall Study|Disease Progression|2
6194638|NCT01449370|9852988|FG020|Overall Study|Disease Progression|5
6194639|NCT01449370|9852989|FG021|Overall Study|Disease Progression|2
6194640|NCT01449370|9852990|FG022|Overall Study|Disease Progression|3
6194641|NCT01449370|9852991|FG023|Overall Study|Disease Progression|7
6194642|NCT01449370|9852992|FG024|Overall Study|Disease Progression|3
6194643|NCT01449370|9852968|FG000|Overall Study|Adverse Event|1
6194644|NCT01449370|9852969|FG001|Overall Study|Adverse Event|2
6194645|NCT01449370|9852970|FG002|Overall Study|Adverse Event|0
6194646|NCT01449370|9852971|FG003|Overall Study|Adverse Event|1
6194647|NCT01449370|9852972|FG004|Overall Study|Adverse Event|0
6194648|NCT01449370|9852973|FG005|Overall Study|Adverse Event|0
5976463|NCT03377790|9563136|FG001|Overall Study|Randomized but not treated|0
5976464|NCT03377790|9563135|FG000|Overall Study|Withdrawn by Parent/Guardian|7
6194649|NCT01449370|9852974|FG006|Overall Study|Adverse Event|0
6194650|NCT01449370|9852975|FG007|Overall Study|Adverse Event|0
6194651|NCT01449370|9852976|FG008|Overall Study|Adverse Event|1
6194652|NCT01449370|9852977|FG009|Overall Study|Adverse Event|1
6194653|NCT01449370|9852978|FG010|Overall Study|Adverse Event|0
6194654|NCT01449370|9852979|FG011|Overall Study|Adverse Event|0
6194655|NCT01449370|9852980|FG012|Overall Study|Adverse Event|0
6194656|NCT01449370|9852981|FG013|Overall Study|Adverse Event|2
6194657|NCT01449370|9852982|FG014|Overall Study|Adverse Event|0
6194658|NCT01449370|9852983|FG015|Overall Study|Adverse Event|1
6194659|NCT01449370|9852984|FG016|Overall Study|Adverse Event|0
6194660|NCT01449370|9852985|FG017|Overall Study|Adverse Event|0
6194661|NCT01449370|9852986|FG018|Overall Study|Adverse Event|1
6194662|NCT01449370|9852987|FG019|Overall Study|Adverse Event|1
6194663|NCT01449370|9852988|FG020|Overall Study|Adverse Event|0
6194664|NCT01449370|9852989|FG021|Overall Study|Adverse Event|1
6194665|NCT01449370|9852990|FG022|Overall Study|Adverse Event|0
6194666|NCT01449370|9852991|FG023|Overall Study|Adverse Event|1
6194667|NCT01449370|9852992|FG024|Overall Study|Adverse Event|3
6194668|NCT01449370|9852968|FG000|Overall Study|Participant Decision|0
6194669|NCT01449370|9852969|FG001|Overall Study|Participant Decision|0
6194670|NCT01449370|9852970|FG002|Overall Study|Participant Decision|0
6194671|NCT01449370|9852971|FG003|Overall Study|Participant Decision|0
6194672|NCT01449370|9852972|FG004|Overall Study|Participant Decision|0
6194673|NCT01449370|9852973|FG005|Overall Study|Participant Decision|0
6194674|NCT01449370|9852974|FG006|Overall Study|Participant Decision|0
6194675|NCT01449370|9852975|FG007|Overall Study|Participant Decision|1
6194676|NCT01449370|9852976|FG008|Overall Study|Participant Decision|1
6194677|NCT01449370|9852977|FG009|Overall Study|Participant Decision|0
6194678|NCT01449370|9852978|FG010|Overall Study|Participant Decision|0
6194679|NCT01449370|9852979|FG011|Overall Study|Participant Decision|0
6194680|NCT01449370|9852980|FG012|Overall Study|Participant Decision|1
6194681|NCT01449370|9852981|FG013|Overall Study|Participant Decision|1
6194682|NCT01449370|9852982|FG014|Overall Study|Participant Decision|0
6194683|NCT01449370|9852983|FG015|Overall Study|Participant Decision|1
6194684|NCT01449370|9852984|FG016|Overall Study|Participant Decision|3
6194685|NCT01449370|9852985|FG017|Overall Study|Participant Decision|0
6194686|NCT01449370|9852986|FG018|Overall Study|Participant Decision|1
6194687|NCT01449370|9852987|FG019|Overall Study|Participant Decision|0
6194688|NCT01449370|9852988|FG020|Overall Study|Participant Decision|0
6194689|NCT01449370|9852989|FG021|Overall Study|Participant Decision|1
6194690|NCT01449370|9852990|FG022|Overall Study|Participant Decision|0
6194691|NCT01449370|9852991|FG023|Overall Study|Participant Decision|0
6194692|NCT01449370|9852992|FG024|Overall Study|Participant Decision|1
6194693|NCT01449370|9852968|FG000|Overall Study|Lost to Follow-up|0
6194694|NCT01449370|9852969|FG001|Overall Study|Lost to Follow-up|0
6194695|NCT01449370|9852970|FG002|Overall Study|Lost to Follow-up|0
6194696|NCT01449370|9852971|FG003|Overall Study|Lost to Follow-up|0
6194697|NCT01449370|9852972|FG004|Overall Study|Lost to Follow-up|0
6194698|NCT01449370|9852973|FG005|Overall Study|Lost to Follow-up|0
6194699|NCT01449370|9852974|FG006|Overall Study|Lost to Follow-up|0
6194700|NCT01449370|9852975|FG007|Overall Study|Lost to Follow-up|0
6194701|NCT01449370|9852976|FG008|Overall Study|Lost to Follow-up|0
6194702|NCT01449370|9852977|FG009|Overall Study|Lost to Follow-up|0
6194703|NCT01449370|9852978|FG010|Overall Study|Lost to Follow-up|0
6194704|NCT01449370|9852979|FG011|Overall Study|Lost to Follow-up|0
6194705|NCT01449370|9852980|FG012|Overall Study|Lost to Follow-up|0
6194706|NCT01449370|9852981|FG013|Overall Study|Lost to Follow-up|0
6194707|NCT01449370|9852982|FG014|Overall Study|Lost to Follow-up|0
6194708|NCT01449370|9852983|FG015|Overall Study|Lost to Follow-up|0
6273791|NCT02196506|9977747|FG001|Phase B|Adverse Event|4
6273792|NCT02196506|9977748|FG002|Phase B|Adverse Event|1
6273793|NCT02196506|9977749|FG003|Phase B|Adverse Event|0
6273794|NCT02196506|9977746|FG000|Phase B|Lost to Follow-up|0
6273795|NCT02196506|9977747|FG001|Phase B|Lost to Follow-up|2
6273796|NCT02196506|9977748|FG002|Phase B|Lost to Follow-up|1
6273797|NCT02196506|9977749|FG003|Phase B|Lost to Follow-up|0
6273798|NCT02196506|9977746|FG000|Phase A+|Participant Met Withdrawal Criteria|0
6273799|NCT02196506|9977747|FG001|Phase A+|Participant Met Withdrawal Criteria|0
6273800|NCT02196506|9977748|FG002|Phase A+|Participant Met Withdrawal Criteria|0
6273801|NCT02196506|9977749|FG003|Phase A+|Participant Met Withdrawal Criteria|1
6273802|NCT02196506|9977746|FG000|Phase A+|Withdrawal by Participant|0
6273803|NCT02196506|9977747|FG001|Phase A+|Withdrawal by Participant|0
6273804|NCT02196506|9977748|FG002|Phase A+|Withdrawal by Participant|0
6273805|NCT02196506|9977749|FG003|Phase A+|Withdrawal by Participant|5
5976465|NCT03377790|9563136|FG001|Overall Study|Withdrawn by Parent/Guardian|4
5976466|NCT03353675|9563142|FG000|Overall Study|Adverse Event|4
6273806|NCT02196506|9977746|FG000|Phase A+|Adverse Event|0
6273807|NCT02196506|9977747|FG001|Phase A+|Adverse Event|0
6273808|NCT02196506|9977748|FG002|Phase A+|Adverse Event|0
6273809|NCT02196506|9977749|FG003|Phase A+|Adverse Event|1
6273810|NCT02196506|9977746|FG000|Phase A+|Lost to Follow-up|0
6273811|NCT02196506|9977747|FG001|Phase A+|Lost to Follow-up|0
5976467|NCT03294109|9563148|FG000|Overall Study|Withdrawal by Subject|6
5976468|NCT03294109|9563149|FG001|Overall Study|Withdrawal by Subject|5
6194709|NCT01449370|9852984|FG016|Overall Study|Lost to Follow-up|0
6194710|NCT01449370|9852985|FG017|Overall Study|Lost to Follow-up|0
6194711|NCT01449370|9852986|FG018|Overall Study|Lost to Follow-up|0
6194712|NCT01449370|9852987|FG019|Overall Study|Lost to Follow-up|0
6194713|NCT01449370|9852988|FG020|Overall Study|Lost to Follow-up|1
6194714|NCT01449370|9852989|FG021|Overall Study|Lost to Follow-up|0
6194715|NCT01449370|9852990|FG022|Overall Study|Lost to Follow-up|0
6194716|NCT01449370|9852991|FG023|Overall Study|Lost to Follow-up|0
6194717|NCT01449370|9852992|FG024|Overall Study|Lost to Follow-up|0
6194718|NCT01449370|9852968|FG000|Overall Study|Other|0
6194719|NCT01449370|9852969|FG001|Overall Study|Other|0
6194720|NCT01449370|9852970|FG002|Overall Study|Other|0
6194721|NCT01449370|9852971|FG003|Overall Study|Other|0
6194722|NCT01449370|9852972|FG004|Overall Study|Other|0
6194723|NCT01449370|9852973|FG005|Overall Study|Other|0
6194724|NCT01449370|9852974|FG006|Overall Study|Other|0
6194725|NCT01449370|9852975|FG007|Overall Study|Other|0
6194726|NCT01449370|9852976|FG008|Overall Study|Other|1
6194727|NCT01449370|9852977|FG009|Overall Study|Other|1
6194728|NCT01449370|9852978|FG010|Overall Study|Other|0
6194729|NCT01449370|9852979|FG011|Overall Study|Other|0
6194730|NCT01449370|9852980|FG012|Overall Study|Other|0
6194731|NCT01449370|9852981|FG013|Overall Study|Other|0
6194732|NCT01449370|9852982|FG014|Overall Study|Other|0
6194733|NCT01449370|9852983|FG015|Overall Study|Other|0
6194734|NCT01449370|9852984|FG016|Overall Study|Other|0
6194735|NCT01449370|9852985|FG017|Overall Study|Other|0
6194736|NCT01449370|9852986|FG018|Overall Study|Other|0
6194737|NCT01449370|9852987|FG019|Overall Study|Other|0
6194738|NCT01449370|9852988|FG020|Overall Study|Other|0
6194739|NCT01449370|9852989|FG021|Overall Study|Other|0
6194740|NCT01449370|9852990|FG022|Overall Study|Other|1
6194741|NCT01449370|9852991|FG023|Overall Study|Other|1
6194742|NCT01449370|9852992|FG024|Overall Study|Other|0
6194743|NCT01449370|9852968|FG000|Overall Study|Medication Prohibited by Protocol|0
6194744|NCT01449370|9852969|FG001|Overall Study|Medication Prohibited by Protocol|0
6194745|NCT01449370|9852970|FG002|Overall Study|Medication Prohibited by Protocol|0
6194746|NCT01449370|9852971|FG003|Overall Study|Medication Prohibited by Protocol|0
6194747|NCT01449370|9852972|FG004|Overall Study|Medication Prohibited by Protocol|0
6194748|NCT01449370|9852973|FG005|Overall Study|Medication Prohibited by Protocol|0
6194749|NCT01449370|9852974|FG006|Overall Study|Medication Prohibited by Protocol|0
6194750|NCT01449370|9852975|FG007|Overall Study|Medication Prohibited by Protocol|0
6194751|NCT01449370|9852976|FG008|Overall Study|Medication Prohibited by Protocol|0
6194752|NCT01449370|9852977|FG009|Overall Study|Medication Prohibited by Protocol|0
6194753|NCT01449370|9852978|FG010|Overall Study|Medication Prohibited by Protocol|0
6194754|NCT01449370|9852979|FG011|Overall Study|Medication Prohibited by Protocol|0
6194755|NCT01449370|9852980|FG012|Overall Study|Medication Prohibited by Protocol|0
6194756|NCT01449370|9852981|FG013|Overall Study|Medication Prohibited by Protocol|0
6194757|NCT01449370|9852982|FG014|Overall Study|Medication Prohibited by Protocol|0
6194758|NCT01449370|9852983|FG015|Overall Study|Medication Prohibited by Protocol|0
6194759|NCT01449370|9852984|FG016|Overall Study|Medication Prohibited by Protocol|0
6194760|NCT01449370|9852985|FG017|Overall Study|Medication Prohibited by Protocol|0
5976469|NCT03268005|9563158|FG000|Overall Study|Death|2
5976470|NCT03268005|9563159|FG001|Overall Study|Death|1
5976471|NCT03268005|9563158|FG000|Overall Study|Lost to Follow-up|2
5976472|NCT03268005|9563159|FG001|Overall Study|Lost to Follow-up|2
5976473|NCT03268005|9563158|FG000|Overall Study|Withdrawal by Subject|11
5976474|NCT03268005|9563159|FG001|Overall Study|Withdrawal by Subject|11
6194761|NCT01449370|9852986|FG018|Overall Study|Medication Prohibited by Protocol|0
6194762|NCT01449370|9852987|FG019|Overall Study|Medication Prohibited by Protocol|0
6194763|NCT01449370|9852988|FG020|Overall Study|Medication Prohibited by Protocol|0
6194764|NCT01449370|9852989|FG021|Overall Study|Medication Prohibited by Protocol|0
6194765|NCT01449370|9852990|FG022|Overall Study|Medication Prohibited by Protocol|0
6194766|NCT01449370|9852991|FG023|Overall Study|Medication Prohibited by Protocol|1
6194767|NCT01449370|9852992|FG024|Overall Study|Medication Prohibited by Protocol|0
6194768|NCT01449370|9852968|FG000|Overall Study|Death|0
6194769|NCT01449370|9852969|FG001|Overall Study|Death|0
6194770|NCT01449370|9852970|FG002|Overall Study|Death|0
6194771|NCT01449370|9852971|FG003|Overall Study|Death|0
6194772|NCT01449370|9852972|FG004|Overall Study|Death|0
6194773|NCT01449370|9852973|FG005|Overall Study|Death|0
6194774|NCT01449370|9852974|FG006|Overall Study|Death|0
6194775|NCT01449370|9852975|FG007|Overall Study|Death|0
6194776|NCT01449370|9852976|FG008|Overall Study|Death|0
6194777|NCT01449370|9852977|FG009|Overall Study|Death|0
6273812|NCT02196506|9977748|FG002|Phase A+|Lost to Follow-up|0
5976475|NCT03225170|9563168|FG000|Overall Study|Lost to Follow-up|4
6194778|NCT01449370|9852978|FG010|Overall Study|Death|0
6194779|NCT01449370|9852979|FG011|Overall Study|Death|0
6194780|NCT01449370|9852980|FG012|Overall Study|Death|0
6194781|NCT01449370|9852981|FG013|Overall Study|Death|0
6194782|NCT01449370|9852982|FG014|Overall Study|Death|0
6194783|NCT01449370|9852983|FG015|Overall Study|Death|0
6194784|NCT01449370|9852984|FG016|Overall Study|Death|0
6194785|NCT01449370|9852985|FG017|Overall Study|Death|0
6194786|NCT01449370|9852986|FG018|Overall Study|Death|0
6194787|NCT01449370|9852987|FG019|Overall Study|Death|0
6194788|NCT01449370|9852988|FG020|Overall Study|Death|0
6194789|NCT01449370|9852989|FG021|Overall Study|Death|0
6194790|NCT01449370|9852990|FG022|Overall Study|Death|0
6194791|NCT01449370|9852991|FG023|Overall Study|Death|0
6194792|NCT01449370|9852992|FG024|Overall Study|Death|1
6194793|NCT01449461|9853071|FG000|Overall Study|Adverse Event|0
6194794|NCT01449461|9853072|FG001|Overall Study|Adverse Event|3
6194795|NCT01449461|9853073|FG002|Overall Study|Adverse Event|2
6194796|NCT01449461|9853074|FG003|Overall Study|Adverse Event|3
6194797|NCT01449461|9853075|FG004|Overall Study|Adverse Event|4
6194798|NCT01449461|9853076|FG005|Overall Study|Adverse Event|4
6194799|NCT01449461|9853071|FG000|Overall Study|Death|0
6194800|NCT01449461|9853072|FG001|Overall Study|Death|2
6194801|NCT01449461|9853073|FG002|Overall Study|Death|0
6194802|NCT01449461|9853074|FG003|Overall Study|Death|0
6194803|NCT01449461|9853075|FG004|Overall Study|Death|7
6194804|NCT01449461|9853076|FG005|Overall Study|Death|1
6194805|NCT01449461|9853071|FG000|Overall Study|Physician Decision|0
6194806|NCT01449461|9853072|FG001|Overall Study|Physician Decision|1
6194807|NCT01449461|9853073|FG002|Overall Study|Physician Decision|0
6194808|NCT01449461|9853074|FG003|Overall Study|Physician Decision|4
6194809|NCT01449461|9853075|FG004|Overall Study|Physician Decision|1
6194810|NCT01449461|9853076|FG005|Overall Study|Physician Decision|0
6194811|NCT01449461|9853071|FG000|Overall Study|Documented Progressive Disease|4
6194812|NCT01449461|9853072|FG001|Overall Study|Documented Progressive Disease|7
6194813|NCT01449461|9853073|FG002|Overall Study|Documented Progressive Disease|14
6194814|NCT01449461|9853074|FG003|Overall Study|Documented Progressive Disease|15
6194815|NCT01449461|9853075|FG004|Overall Study|Documented Progressive Disease|24
6194816|NCT01449461|9853076|FG005|Overall Study|Documented Progressive Disease|5
6194817|NCT01449461|9853071|FG000|Overall Study|Clinical Progressive Disease|2
6194818|NCT01449461|9853072|FG001|Overall Study|Clinical Progressive Disease|2
6194819|NCT01449461|9853073|FG002|Overall Study|Clinical Progressive Disease|0
6194820|NCT01449461|9853074|FG003|Overall Study|Clinical Progressive Disease|3
6194821|NCT01449461|9853075|FG004|Overall Study|Clinical Progressive Disease|4
6194822|NCT01449461|9853076|FG005|Overall Study|Clinical Progressive Disease|2
6273813|NCT02196506|9977749|FG003|Phase A+|Lost to Follow-up|6
6273814|NCT02196506|9977746|FG000|Phase A+|Participant withdrawn by investigator|0
6273815|NCT02196506|9977747|FG001|Phase A+|Participant withdrawn by investigator|0
6273816|NCT02196506|9977748|FG002|Phase A+|Participant withdrawn by investigator|0
6273817|NCT02196506|9977749|FG003|Phase A+|Participant withdrawn by investigator|1
6273818|NCT02196558|9977758|FG000|Treatment Phase (12 Weeks)|Adverse Event|0
6273819|NCT02196558|9977759|FG001|Treatment Phase (12 Weeks)|Adverse Event|2
6273820|NCT02196558|9977760|FG002|Treatment Phase (12 Weeks)|Adverse Event|0
6273821|NCT02196558|9977758|FG000|Treatment Phase (12 Weeks)|Participant Choice|0
6273822|NCT02196558|9977759|FG001|Treatment Phase (12 Weeks)|Participant Choice|1
6273823|NCT02196558|9977760|FG002|Treatment Phase (12 Weeks)|Participant Choice|1
6273824|NCT02196558|9977758|FG000|Treatment Phase (12 Weeks)|Progression of Disease|0
6273825|NCT02196558|9977759|FG001|Treatment Phase (12 Weeks)|Progression of Disease|0
6273826|NCT02196558|9977760|FG002|Treatment Phase (12 Weeks)|Progression of Disease|1
6273827|NCT02196558|9977758|FG000|Extension Phase (40 Weeks)|Adverse Event|1
6273828|NCT02196558|9977759|FG001|Extension Phase (40 Weeks)|Adverse Event|2
6273829|NCT02196558|9977760|FG002|Extension Phase (40 Weeks)|Adverse Event|0
6273830|NCT02196558|9977758|FG000|Extension Phase (40 Weeks)|Inadequate therapeutic effect|1
6273831|NCT02196558|9977759|FG001|Extension Phase (40 Weeks)|Inadequate therapeutic effect|1
6273832|NCT02196558|9977760|FG002|Extension Phase (40 Weeks)|Inadequate therapeutic effect|1
6273833|NCT02196675|9977771|FG000|Overall Study|Withdrawal by Subject|1
6273834|NCT02196675|9977772|FG001|Overall Study|Withdrawal by Subject|0
6273835|NCT02196675|9977773|FG002|Overall Study|Withdrawal by Subject|0
6273836|NCT02196675|9977771|FG000|Overall Study|Intra-operative surgical exclusion|1
5976476|NCT03225170|9563169|FG001|Overall Study|Lost to Follow-up|4
5976477|NCT03225170|9563170|FG002|Overall Study|Lost to Follow-up|0
5976478|NCT03225170|9563168|FG000|Overall Study|Did not complete intervention/control writing exercise|0
5976479|NCT03225170|9563169|FG001|Overall Study|Did not complete intervention/control writing exercise|1
5976480|NCT03225170|9563170|FG002|Overall Study|Did not complete intervention/control writing exercise|0
5976481|NCT03219034|9563194|FG000|Overall Study|Lost to Follow-up|9
5976482|NCT03219034|9563195|FG001|Overall Study|Lost to Follow-up|13
6194823|NCT01449461|9853071|FG000|Overall Study|Protocol Violation|0
6194824|NCT01449461|9853072|FG001|Overall Study|Protocol Violation|0
6194825|NCT01449461|9853073|FG002|Overall Study|Protocol Violation|0
6194826|NCT01449461|9853074|FG003|Overall Study|Protocol Violation|1
6194827|NCT01449461|9853075|FG004|Overall Study|Protocol Violation|0
6194828|NCT01449461|9853076|FG005|Overall Study|Protocol Violation|0
6194829|NCT01449461|9853071|FG000|Overall Study|Site Terminated by Sponsor|0
6194830|NCT01449461|9853072|FG001|Overall Study|Site Terminated by Sponsor|1
6194831|NCT01449461|9853073|FG002|Overall Study|Site Terminated by Sponsor|2
6194832|NCT01449461|9853074|FG003|Overall Study|Site Terminated by Sponsor|3
6194833|NCT01449461|9853075|FG004|Overall Study|Site Terminated by Sponsor|4
6194834|NCT01449461|9853076|FG005|Overall Study|Site Terminated by Sponsor|1
6194835|NCT01449461|9853071|FG000|Overall Study|Withdrawal by Subject|0
6194836|NCT01449461|9853072|FG001|Overall Study|Withdrawal by Subject|1
6194837|NCT01449461|9853073|FG002|Overall Study|Withdrawal by Subject|0
6194838|NCT01449461|9853074|FG003|Overall Study|Withdrawal by Subject|0
6194839|NCT01449461|9853075|FG004|Overall Study|Withdrawal by Subject|2
6194840|NCT01449461|9853076|FG005|Overall Study|Withdrawal by Subject|1
6194841|NCT01449461|9853071|FG000|Overall Study|Reason not Specified|0
6194842|NCT01449461|9853072|FG001|Overall Study|Reason not Specified|1
6194843|NCT01449461|9853073|FG002|Overall Study|Reason not Specified|0
6194844|NCT01449461|9853074|FG003|Overall Study|Reason not Specified|3
6194845|NCT01449461|9853075|FG004|Overall Study|Reason not Specified|2
6194846|NCT01449461|9853076|FG005|Overall Study|Reason not Specified|1
6194847|NCT01449526|9853110|FG000|Overall Study|Lost to Follow-up|1
6194848|NCT01449526|9853111|FG001|Overall Study|Lost to Follow-up|2
6194849|NCT01449526|9853110|FG000|Overall Study|Withdrawal by Subject|1
6194850|NCT01449526|9853111|FG001|Overall Study|Withdrawal by Subject|1
6194851|NCT01449526|9853110|FG000|Overall Study|Symptoms/complaints|0
6194852|NCT01449526|9853111|FG001|Overall Study|Symptoms/complaints|1
6194853|NCT01449526|9853110|FG000|Overall Study|Lack of Motivation|0
6194854|NCT01449526|9853111|FG001|Overall Study|Lack of Motivation|1
6194855|NCT01449526|9853110|FG000|Overall Study|Cannot maintain visits|0
6194856|NCT01449526|9853111|FG001|Overall Study|Cannot maintain visits|1
6194857|NCT01449539|9853117|FG000|Overall Study|Withdrawal by Subject|3
6194858|NCT01449539|9853117|FG000|Overall Study|Toxicity not study related|1
6194859|NCT01449630|9853130|FG000|Period 1|Physician Decision|1
6194860|NCT01449630|9853131|FG001|Period 1|Physician Decision|0
6194861|NCT01449630|9853132|FG002|Period 1|Physician Decision|0
6194862|NCT01449630|9853133|FG003|Period 1|Physician Decision|1
6194863|NCT01449630|9853134|FG004|Period 1|Physician Decision|0
6194864|NCT01449630|9853135|FG005|Period 1|Physician Decision|0
6194865|NCT01449630|9853136|FG006|Period 1|Physician Decision|0
6194866|NCT01449630|9853137|FG007|Period 1|Physician Decision|0
6194867|NCT01449630|9853138|FG008|Period 1|Physician Decision|0
6194868|NCT01449630|9853130|FG000|Period 1|Sponsor Decision|0
6194869|NCT01449630|9853131|FG001|Period 1|Sponsor Decision|0
6273837|NCT02196675|9977772|FG001|Overall Study|Intra-operative surgical exclusion|1
6273838|NCT02196675|9977773|FG002|Overall Study|Intra-operative surgical exclusion|0
6273839|NCT02196675|9977771|FG000|Overall Study|Protocol Violation|0
6273840|NCT02196675|9977772|FG001|Overall Study|Protocol Violation|1
6273841|NCT02196675|9977773|FG002|Overall Study|Protocol Violation|0
6273842|NCT02196675|9977771|FG000|Overall Study|Death|0
6273843|NCT02196675|9977772|FG001|Overall Study|Death|0
6273844|NCT02196675|9977773|FG002|Overall Study|Death|1
6273845|NCT02196701|9977792|FG000|Overall Study|Adverse Event|1
6273846|NCT02196701|9977792|FG000|Overall Study|Lost to Follow-up|1
6273847|NCT02196701|9977792|FG000|Overall Study|Non-adherence to Protocol|1
6273848|NCT02196714|9977799|FG000|Overall Study|Protocol Violation|0
6273849|NCT02196714|9977800|FG001|Overall Study|Protocol Violation|0
6273850|NCT02196714|9977801|FG002|Overall Study|Protocol Violation|1
6273851|NCT02196714|9977802|FG003|Overall Study|Protocol Violation|0
6273852|NCT02197130|9977910|FG000|Overall Study|Adverse Event|13
6273853|NCT02197130|9977911|FG001|Overall Study|Adverse Event|4
6273854|NCT02197130|9977912|FG002|Overall Study|Adverse Event|23
6273855|NCT02197130|9977910|FG000|Overall Study|Death|0
6273856|NCT02197130|9977911|FG001|Overall Study|Death|1
6273857|NCT02197130|9977912|FG002|Overall Study|Death|0
6273858|NCT02197130|9977910|FG000|Overall Study|Lost to Follow-up|2
6273859|NCT02197130|9977911|FG001|Overall Study|Lost to Follow-up|0
6273860|NCT02197130|9977912|FG002|Overall Study|Lost to Follow-up|1
6273861|NCT02197130|9977910|FG000|Overall Study|Does not meet entrance criteria|0
6273862|NCT02197130|9977911|FG001|Overall Study|Does not meet entrance criteria|0
6273863|NCT02197130|9977912|FG002|Overall Study|Does not meet entrance criteria|1
5976483|NCT03219034|9563194|FG000|Overall Study|Additional dental work needed|1
5976484|NCT03219034|9563195|FG001|Overall Study|Additional dental work needed|0
5976485|NCT03219034|9563194|FG000|Overall Study|UPPP Surgery|1
5976486|NCT03219034|9563195|FG001|Overall Study|UPPP Surgery|0
5976487|NCT03219034|9563194|FG000|Overall Study|Dental sensitivity|0
5976488|NCT03219034|9563195|FG001|Overall Study|Dental sensitivity|1
5976489|NCT03219034|9563194|FG000|Overall Study|Death in family|0
5976490|NCT03219034|9563195|FG001|Overall Study|Death in family|1
5976491|NCT03168438|9563205|FG000|Overall Study|Long term follow-up declined, study terminated by sponsor|0
5976492|NCT03168438|9563206|FG001|Overall Study|Long term follow-up declined, study terminated by sponsor|1
6050674|NCT00428090|9649854|FG000|Overall Study|Excluded for heart insufficiency|0
6050675|NCT00428090|9649855|FG001|Overall Study|Excluded for heart insufficiency|0
6050676|NCT00428090|9649856|FG002|Overall Study|Excluded for heart insufficiency|1
6050677|NCT00428090|9649857|FG003|Overall Study|Excluded for heart insufficiency|0
6050678|NCT00428090|9649854|FG000|Overall Study|Raised Creatinine Value|0
6050679|NCT00428090|9649855|FG001|Overall Study|Raised Creatinine Value|0
6194870|NCT01449630|9853132|FG002|Period 1|Sponsor Decision|0
6273864|NCT02197130|9977910|FG000|Overall Study|Withdrawal by Subject|0
6273865|NCT02197130|9977911|FG001|Overall Study|Withdrawal by Subject|3
6273866|NCT02197130|9977912|FG002|Overall Study|Withdrawal by Subject|4
6273867|NCT02197130|9977910|FG000|Overall Study|Other|1
6194871|NCT01449630|9853133|FG003|Period 1|Sponsor Decision|0
6194872|NCT01449630|9853134|FG004|Period 1|Sponsor Decision|0
6194873|NCT01449630|9853135|FG005|Period 1|Sponsor Decision|1
6194874|NCT01449630|9853136|FG006|Period 1|Sponsor Decision|0
6194875|NCT01449630|9853137|FG007|Period 1|Sponsor Decision|0
6194876|NCT01449630|9853138|FG008|Period 1|Sponsor Decision|0
6194877|NCT01449630|9853130|FG000|Period 2|Sponsor Decision|0
6194878|NCT01449630|9853131|FG001|Period 2|Sponsor Decision|0
6194879|NCT01449630|9853132|FG002|Period 2|Sponsor Decision|0
6194880|NCT01449630|9853133|FG003|Period 2|Sponsor Decision|0
6194881|NCT01449630|9853134|FG004|Period 2|Sponsor Decision|0
6194882|NCT01449630|9853135|FG005|Period 2|Sponsor Decision|0
6194883|NCT01449630|9853136|FG006|Period 2|Sponsor Decision|1
6194884|NCT01449630|9853137|FG007|Period 2|Sponsor Decision|0
6194885|NCT01449630|9853138|FG008|Period 2|Sponsor Decision|0
6273868|NCT02197130|9977911|FG001|Overall Study|Other|0
6273869|NCT02197130|9977912|FG002|Overall Study|Other|3
6273870|NCT02197247|9977920|FG000|Part A: Day 29-49 (AZD9291+Rifampicin)|Adverse Event|2
6273871|NCT02197247|9977920|FG000|Part A: Day 29-49 (AZD9291+Rifampicin)|Condition under investigation worsened|2
6273872|NCT02197247|9977920|FG000|Part A: Day 50-77 (AZD9291 Alone)|Condition under investigation worsened|5
6273873|NCT02197247|9977920|FG000|Part B: Day 78 to End Part B (AZD9291)|Adverse Event|2
6273874|NCT02197247|9977920|FG000|Part B: Day 78 to End Part B (AZD9291)|Withdrawal by Subject|2
6273875|NCT02197247|9977920|FG000|Part B: Day 78 to End Part B (AZD9291)|Newly discovered brain metastases|1
6273876|NCT02197247|9977920|FG000|Part B: Day 78 to End Part B (AZD9291)|Death|1
6273877|NCT02197247|9977920|FG000|Part B: Day 78 to End Part B (AZD9291)|Condition under investigation worsened|9
6273878|NCT02197377|9977941|FG000|Overall Study|Insertion Failure|0
6273879|NCT02197377|9977942|FG001|Overall Study|Insertion Failure|3
6273880|NCT02197416|9977951|FG000|Overall Study|Other reasons|0
6273881|NCT02197416|9977952|FG001|Overall Study|Other reasons|2
6273882|NCT02197416|9977953|FG002|Overall Study|Other reasons|5
6273883|NCT02197416|9977951|FG000|Overall Study|Withdrawal by Subject|0
6273884|NCT02197416|9977952|FG001|Overall Study|Withdrawal by Subject|2
6273885|NCT02197416|9977953|FG002|Overall Study|Withdrawal by Subject|1
6273886|NCT02197416|9977951|FG000|Overall Study|Protocol Violation|1
6273887|NCT02197416|9977952|FG001|Overall Study|Protocol Violation|0
6273888|NCT02197416|9977953|FG002|Overall Study|Protocol Violation|1
6273889|NCT02197416|9977951|FG000|Overall Study|Adverse Event|0
6273890|NCT02197416|9977952|FG001|Overall Study|Adverse Event|0
6273891|NCT02197416|9977953|FG002|Overall Study|Adverse Event|1
6273892|NCT02197520|9977972|FG000|Period 1|Withdrawal by Subject|1
6273893|NCT02197520|9977973|FG001|Period 1|Withdrawal by Subject|0
6273894|NCT02197520|9977972|FG000|Period 2|Adverse Event|0
6273895|NCT02197520|9977973|FG001|Period 2|Adverse Event|2
6273896|NCT02197520|9977972|FG000|Period 2|Withdrawal by Subject|1
6273897|NCT02197520|9977973|FG001|Period 2|Withdrawal by Subject|0
6273898|NCT02197572|9977981|FG000|Overall Study|Progressive Disease|28
6273899|NCT02197572|9977981|FG000|Overall Study|Withdrawal by Subject|9
6273900|NCT02197572|9977981|FG000|Overall Study|Adverse Event|3
6273901|NCT02197572|9977981|FG000|Overall Study|Reason Not Specified|4
6273902|NCT02197806|9977993|FG000|Overall Study|Adverse Event|0
6273903|NCT02197806|9977994|FG001|Overall Study|Adverse Event|1
6273904|NCT02197806|9977995|FG002|Overall Study|Adverse Event|0
6273905|NCT02197806|9977996|FG003|Overall Study|Adverse Event|1
6273906|NCT02197897|9978006|FG000|Overall Study|not eligible|1
6273907|NCT02198040|9978013|FG000|Overall Study|Work reasons|0
6273908|NCT02198040|9978014|FG001|Overall Study|Work reasons|1
6273909|NCT02198040|9978015|FG002|Overall Study|Work reasons|0
6273910|NCT02198040|9978013|FG000|Overall Study|Withdrawal by Subject|0
6273911|NCT02198040|9978014|FG001|Overall Study|Withdrawal by Subject|0
6273912|NCT02198040|9978015|FG002|Overall Study|Withdrawal by Subject|1
6273913|NCT02198235|9978028|FG000|Overall Study|Lost to Follow-up|3
6273914|NCT02198235|9978029|FG001|Overall Study|Lost to Follow-up|2
6273915|NCT02198235|9978030|FG002|Overall Study|Lost to Follow-up|2
6273916|NCT02198651|9978047|FG000|Lead-in Period|Withdrew consent|13
6273917|NCT02198651|9978048|FG001|Lead-in Period|Withdrew consent|0
6273918|NCT02198651|9978049|FG002|Lead-in Period|Withdrew consent|0
6273919|NCT02198651|9978050|FG003|Lead-in Period|Withdrew consent|0
6273920|NCT02198651|9978051|FG004|Lead-in Period|Withdrew consent|0
6273921|NCT02198651|9978047|FG000|Lead-in Period|Adverse Event|2
6273922|NCT02198651|9978048|FG001|Lead-in Period|Adverse Event|0
6273923|NCT02198651|9978049|FG002|Lead-in Period|Adverse Event|0
6273924|NCT02198651|9978050|FG003|Lead-in Period|Adverse Event|0
6273925|NCT02198651|9978051|FG004|Lead-in Period|Adverse Event|0
6273926|NCT02198651|9978047|FG000|Lead-in Period|Other, not specified|22
6273927|NCT02198651|9978048|FG001|Lead-in Period|Other, not specified|0
6273928|NCT02198651|9978049|FG002|Lead-in Period|Other, not specified|0
6273929|NCT02198651|9978050|FG003|Lead-in Period|Other, not specified|0
6273930|NCT02198651|9978051|FG004|Lead-in Period|Other, not specified|0
6273931|NCT02198651|9978047|FG000|Double-blind Period|Withdrew consent|0
6273932|NCT02198651|9978048|FG001|Double-blind Period|Withdrew consent|4
6273933|NCT02198651|9978049|FG002|Double-blind Period|Withdrew consent|0
6273934|NCT02198651|9978050|FG003|Double-blind Period|Withdrew consent|0
6273935|NCT02198651|9978051|FG004|Double-blind Period|Withdrew consent|0
6273936|NCT02198651|9978047|FG000|Double-blind Period|Adverse Event|0
6273937|NCT02198651|9978048|FG001|Double-blind Period|Adverse Event|1
6273938|NCT02198651|9978049|FG002|Double-blind Period|Adverse Event|0
6273939|NCT02198651|9978050|FG003|Double-blind Period|Adverse Event|0
6273940|NCT02198651|9978051|FG004|Double-blind Period|Adverse Event|0
6273941|NCT02198651|9978047|FG000|Double-blind Period|Other, not specified|0
6273942|NCT02198651|9978048|FG001|Double-blind Period|Other, not specified|4
6194886|NCT01449682|9853162|FG000|Overall Study|Death|0
6194887|NCT01449682|9853163|FG001|Overall Study|Death|1
6273943|NCT02198651|9978049|FG002|Double-blind Period|Other, not specified|1
6273944|NCT02198651|9978050|FG003|Double-blind Period|Other, not specified|0
6273945|NCT02198651|9978051|FG004|Double-blind Period|Other, not specified|0
6273946|NCT02198651|9978047|FG000|Open-label Rescue Period|Withdrew consent|0
6273947|NCT02198651|9978048|FG001|Open-label Rescue Period|Withdrew consent|0
6273948|NCT02198651|9978049|FG002|Open-label Rescue Period|Withdrew consent|0
6273949|NCT02198651|9978050|FG003|Open-label Rescue Period|Withdrew consent|2
6273950|NCT02198651|9978051|FG004|Open-label Rescue Period|Withdrew consent|0
6273951|NCT02198651|9978047|FG000|Open-label Rescue Period|Incorrectly entered Open-label Rescue|0
6273952|NCT02198651|9978048|FG001|Open-label Rescue Period|Incorrectly entered Open-label Rescue|0
6273953|NCT02198651|9978049|FG002|Open-label Rescue Period|Incorrectly entered Open-label Rescue|0
5976493|NCT03110380|9563215|FG000|Double-Blind Treatment Phase|Withdrew Consent|10
5976494|NCT03110380|9563216|FG001|Double-Blind Treatment Phase|Withdrew Consent|16
5976495|NCT03110380|9563217|FG002|Double-Blind Treatment Phase|Withdrew Consent|0
5976496|NCT03110380|9563218|FG003|Double-Blind Treatment Phase|Withdrew Consent|0
5976497|NCT03110380|9563215|FG000|Double-Blind Treatment Phase|Lost to Follow-up|4
5976498|NCT03110380|9563216|FG001|Double-Blind Treatment Phase|Lost to Follow-up|3
5976499|NCT03110380|9563217|FG002|Double-Blind Treatment Phase|Lost to Follow-up|0
5976500|NCT03110380|9563218|FG003|Double-Blind Treatment Phase|Lost to Follow-up|0
5976501|NCT03110380|9563215|FG000|Double-Blind Treatment Phase|Adverse Event|3
5976502|NCT03110380|9563216|FG001|Double-Blind Treatment Phase|Adverse Event|3
5976503|NCT03110380|9563217|FG002|Double-Blind Treatment Phase|Adverse Event|0
5976504|NCT03110380|9563218|FG003|Double-Blind Treatment Phase|Adverse Event|0
5976505|NCT03110380|9563215|FG000|Double-Blind Treatment Phase|Investigator's Discretion|1
5976506|NCT03110380|9563216|FG001|Double-Blind Treatment Phase|Investigator's Discretion|3
5976507|NCT03110380|9563217|FG002|Double-Blind Treatment Phase|Investigator's Discretion|0
5976508|NCT03110380|9563218|FG003|Double-Blind Treatment Phase|Investigator's Discretion|0
5976509|NCT03110380|9563215|FG000|Double-Blind Treatment Phase|Death|2
5976510|NCT03110380|9563216|FG001|Double-Blind Treatment Phase|Death|1
5976511|NCT03110380|9563217|FG002|Double-Blind Treatment Phase|Death|0
5976512|NCT03110380|9563218|FG003|Double-Blind Treatment Phase|Death|0
5976513|NCT03110380|9563215|FG000|Double-Blind Treatment Phase|Non-Compliance with Study Drug|1
5976514|NCT03110380|9563216|FG001|Double-Blind Treatment Phase|Non-Compliance with Study Drug|1
5976515|NCT03110380|9563217|FG002|Double-Blind Treatment Phase|Non-Compliance with Study Drug|0
5976516|NCT03110380|9563218|FG003|Double-Blind Treatment Phase|Non-Compliance with Study Drug|0
5976517|NCT03110380|9563215|FG000|Double-Blind Treatment Phase|Protocol Violation|0
5976518|NCT03110380|9563216|FG001|Double-Blind Treatment Phase|Protocol Violation|1
5976519|NCT03110380|9563217|FG002|Double-Blind Treatment Phase|Protocol Violation|0
5976520|NCT03110380|9563218|FG003|Double-Blind Treatment Phase|Protocol Violation|0
5976521|NCT03110380|9563215|FG000|Double-Blind Treatment Phase|Randomized but not Treated|0
5976522|NCT03110380|9563216|FG001|Double-Blind Treatment Phase|Randomized but not Treated|2
5976523|NCT03110380|9563217|FG002|Double-Blind Treatment Phase|Randomized but not Treated|0
5976524|NCT03110380|9563218|FG003|Double-Blind Treatment Phase|Randomized but not Treated|0
5976525|NCT03110380|9563215|FG000|Open-label B/F/TAF Extension Phase|Lost to Follow-up|0
5976526|NCT03110380|9563216|FG001|Open-label B/F/TAF Extension Phase|Lost to Follow-up|0
5976527|NCT03110380|9563217|FG002|Open-label B/F/TAF Extension Phase|Lost to Follow-up|3
5976528|NCT03110380|9563218|FG003|Open-label B/F/TAF Extension Phase|Lost to Follow-up|1
5976529|NCT03110380|9563215|FG000|Open-label B/F/TAF Extension Phase|Withdrew Consent|0
5976530|NCT03110380|9563216|FG001|Open-label B/F/TAF Extension Phase|Withdrew Consent|0
5976531|NCT03110380|9563217|FG002|Open-label B/F/TAF Extension Phase|Withdrew Consent|1
6194888|NCT01449682|9853162|FG000|Overall Study|Adverse Event|1
6194889|NCT01449682|9853163|FG001|Overall Study|Adverse Event|0
6194890|NCT01449708|9853171|FG000|Overall Study|Protocol Violation|0
6194891|NCT01449708|9853172|FG001|Overall Study|Protocol Violation|1
6194892|NCT01449708|9853171|FG000|Overall Study|surgical complication|1
6194893|NCT01449708|9853172|FG001|Overall Study|surgical complication|2
6194894|NCT01449708|9853171|FG000|Overall Study|respiratory failure|1
6194895|NCT01449708|9853172|FG001|Overall Study|respiratory failure|0
6194896|NCT01449721|9853183|FG000|Overall Study|Physician Decision|0
6194897|NCT01449721|9853184|FG001|Overall Study|Physician Decision|1
6194898|NCT01449721|9853183|FG000|Overall Study|Physician Decision|0
6194899|NCT01449721|9853184|FG001|Overall Study|Physician Decision|1
6194900|NCT01449812|9853206|FG000|Overall Study|Migrated/moved from study area|1
6194901|NCT01449812|9853207|FG001|Overall Study|Migrated/moved from study area|0
6194902|NCT01449812|9853208|FG002|Overall Study|Migrated/moved from study area|0
6194903|NCT01449812|9853206|FG000|Overall Study|Withdrawal by Subject|0
6194904|NCT01449812|9853207|FG001|Overall Study|Withdrawal by Subject|0
6194905|NCT01449812|9853208|FG002|Overall Study|Withdrawal by Subject|1
6194906|NCT01449812|9853206|FG000|Overall Study|Lost to Follow-up|1
6194907|NCT01449812|9853207|FG001|Overall Study|Lost to Follow-up|0
6194908|NCT01449812|9853208|FG002|Overall Study|Lost to Follow-up|0
6194909|NCT01449929|9853222|FG000|Randomization Phase 96 Week|Adverse Event|5
6194910|NCT01449929|9853223|FG001|Randomization Phase 96 Week|Adverse Event|13
6194911|NCT01449929|9853224|FG002|Randomization Phase 96 Week|Adverse Event|0
6194912|NCT01449929|9853222|FG000|Randomization Phase 96 Week|Lack of Efficacy|3
6194913|NCT01449929|9853223|FG001|Randomization Phase 96 Week|Lack of Efficacy|4
6194914|NCT01449929|9853224|FG002|Randomization Phase 96 Week|Lack of Efficacy|0
6194915|NCT01449929|9853222|FG000|Randomization Phase 96 Week|Protocol Violation|5
6194916|NCT01449929|9853223|FG001|Randomization Phase 96 Week|Protocol Violation|6
6194917|NCT01449929|9853224|FG002|Randomization Phase 96 Week|Protocol Violation|0
6194918|NCT01449929|9853222|FG000|Randomization Phase 96 Week|Protocol-defined Stopping Criteria|1
6194919|NCT01449929|9853223|FG001|Randomization Phase 96 Week|Protocol-defined Stopping Criteria|0
6194920|NCT01449929|9853224|FG002|Randomization Phase 96 Week|Protocol-defined Stopping Criteria|0
6194921|NCT01449929|9853222|FG000|Randomization Phase 96 Week|Lost to Follow-up|15
6194922|NCT01449929|9853223|FG001|Randomization Phase 96 Week|Lost to Follow-up|18
6194923|NCT01449929|9853224|FG002|Randomization Phase 96 Week|Lost to Follow-up|0
6194924|NCT01449929|9853222|FG000|Randomization Phase 96 Week|Withdrawal by Subject|2
6194925|NCT01449929|9853223|FG001|Randomization Phase 96 Week|Withdrawal by Subject|8
6194926|NCT01449929|9853224|FG002|Randomization Phase 96 Week|Withdrawal by Subject|0
6194927|NCT01449929|9853222|FG000|Randomization Phase 96 Week|Physician Decision|2
6194928|NCT01449929|9853223|FG001|Randomization Phase 96 Week|Physician Decision|3
6273954|NCT02198651|9978050|FG003|Open-label Rescue Period|Incorrectly entered Open-label Rescue|1
6273955|NCT02198651|9978051|FG004|Open-label Rescue Period|Incorrectly entered Open-label Rescue|0
6273956|NCT02198664|9978066|FG000|Overall Study|Adverse Event|2
6273957|NCT02198664|9978067|FG001|Overall Study|Adverse Event|0
6273958|NCT02198664|9978066|FG000|Overall Study|Withdrawal by Subject|11
6273959|NCT02198664|9978067|FG001|Overall Study|Withdrawal by Subject|8
6273960|NCT02198664|9978066|FG000|Overall Study|Failure to tolerate|2
6273961|NCT02198664|9978067|FG001|Overall Study|Failure to tolerate|0
6273962|NCT02198664|9978066|FG000|Overall Study|Not stated|1
6273963|NCT02198664|9978067|FG001|Overall Study|Not stated|0
6273964|NCT02198963|9978075|FG000|Overall Study|Adverse Event|1
6273965|NCT02198963|9978075|FG000|Overall Study|Withdrawal by Subject|6
6273966|NCT02199028|9978086|FG000|Week 1|Adverse Event|1
6273967|NCT02199028|9978087|FG001|Week 1|Adverse Event|0
6273968|NCT02199028|9978086|FG000|Week 3|Adverse Event|1
6273969|NCT02199028|9978087|FG001|Week 3|Adverse Event|0
6273970|NCT02199080|9978099|FG000|Overall Study|Protocol Violation|12
6273971|NCT02199314|9978115|FG000|Overall Study|Withdrawal by Subject|6
6273972|NCT02199314|9978115|FG000|Overall Study|Physician Decision|10
6273973|NCT02199509|9978130|FG000|Overall Study|Suicidal Ideation|0
6273974|NCT02199509|9978131|FG001|Overall Study|Suicidal Ideation|1
6273975|NCT02199509|9978130|FG000|Overall Study|Misunderstood titration schedule|1
6273976|NCT02199509|9978131|FG001|Overall Study|Misunderstood titration schedule|0
6273977|NCT02199795|9978174|FG000|Overall Study|no longer met inclusion criteria|1
6273978|NCT02199795|9978175|FG001|Overall Study|no longer met inclusion criteria|0
6273979|NCT02199795|9978174|FG000|Overall Study|withdrew due to shoulder pain|1
6273980|NCT02199795|9978175|FG001|Overall Study|withdrew due to shoulder pain|0
6273981|NCT02200211|9978200|FG000|Overall Study|Lost to Follow-up|7
6273982|NCT02200211|9978201|FG001|Overall Study|Lost to Follow-up|7
6273983|NCT02200211|9978202|FG002|Overall Study|Lost to Follow-up|1
6273984|NCT02200211|9978203|FG003|Overall Study|Lost to Follow-up|2
6273985|NCT02200211|9978200|FG000|Overall Study|Withdrawal by Subject|1
6273986|NCT02200211|9978201|FG001|Overall Study|Withdrawal by Subject|0
6273987|NCT02200211|9978202|FG002|Overall Study|Withdrawal by Subject|0
6273988|NCT02200211|9978203|FG003|Overall Study|Withdrawal by Subject|0
6273989|NCT02200445|9978224|FG000|Overall Study|Lack of Efficacy|1
6273990|NCT02200445|9978225|FG001|Overall Study|Lack of Efficacy|2
6273991|NCT02200445|9978226|FG002|Overall Study|Lack of Efficacy|2
6273992|NCT02200445|9978224|FG000|Overall Study|Adverse Event|0
6273993|NCT02200445|9978225|FG001|Overall Study|Adverse Event|2
6273994|NCT02200445|9978226|FG002|Overall Study|Adverse Event|0
6273995|NCT02200510|9978240|FG000|Overall Study|Death|1
6273996|NCT02200510|9978241|FG001|Overall Study|Death|1
6273997|NCT02200510|9978240|FG000|Overall Study|Protocol Violation|0
6273998|NCT02200510|9978241|FG001|Overall Study|Protocol Violation|1
6273999|NCT02200510|9978240|FG000|Overall Study|Lost to Follow-up|7
6274000|NCT02200510|9978241|FG001|Overall Study|Lost to Follow-up|1
5976532|NCT03110380|9563218|FG003|Open-label B/F/TAF Extension Phase|Withdrew Consent|1
5976533|NCT03110380|9563215|FG000|Open-label B/F/TAF Extension Phase|Adverse Event|0
5976534|NCT03110380|9563216|FG001|Open-label B/F/TAF Extension Phase|Adverse Event|0
5976535|NCT03110380|9563217|FG002|Open-label B/F/TAF Extension Phase|Adverse Event|0
5976536|NCT03110380|9563218|FG003|Open-label B/F/TAF Extension Phase|Adverse Event|1
5976537|NCT03078478|9563234|FG000|Maintenance Period 1 (36 Weeks)|Withdrawal by Subject|36
5976538|NCT03078478|9563235|FG001|Maintenance Period 1 (36 Weeks)|Withdrawal by Subject|36
5976539|NCT03078478|9563234|FG000|Maintenance Period 1 (36 Weeks)|Lost to Follow-up|7
5976540|NCT03078478|9563235|FG001|Maintenance Period 1 (36 Weeks)|Lost to Follow-up|4
5976541|NCT03078478|9563234|FG000|Maintenance Period 1 (36 Weeks)|Death|3
6194929|NCT01449929|9853224|FG002|Randomization Phase 96 Week|Physician Decision|0
6274001|NCT02200510|9978240|FG000|Overall Study|potential COI - joined study team|1
6274002|NCT02200510|9978241|FG001|Overall Study|potential COI - joined study team|0
6274003|NCT02200614|9978271|FG000|Double Blind Treatment|Adverse Event|86
6274004|NCT02200614|9978272|FG001|Double Blind Treatment|Adverse Event|48
6274005|NCT02200614|9978271|FG000|Double Blind Treatment|Confirmed metastasis|119
6194930|NCT01449929|9853222|FG000|Randomization Phase 96 Week|Other: study closed/terminated|0
6194931|NCT01449929|9853223|FG001|Randomization Phase 96 Week|Other: study closed/terminated|1
6194932|NCT01449929|9853224|FG002|Randomization Phase 96 Week|Other: study closed/terminated|0
6194933|NCT01449929|9853222|FG000|Extension Phase Approximately 3 Years|Adverse Event|0
6194934|NCT01449929|9853223|FG001|Extension Phase Approximately 3 Years|Adverse Event|0
6194935|NCT01449929|9853224|FG002|Extension Phase Approximately 3 Years|Adverse Event|2
6194936|NCT01449929|9853222|FG000|Extension Phase Approximately 3 Years|Lack of Efficacy|0
6194937|NCT01449929|9853223|FG001|Extension Phase Approximately 3 Years|Lack of Efficacy|0
6194938|NCT01449929|9853224|FG002|Extension Phase Approximately 3 Years|Lack of Efficacy|2
6194939|NCT01449929|9853222|FG000|Extension Phase Approximately 3 Years|Lost to Follow-up|0
6194940|NCT01449929|9853223|FG001|Extension Phase Approximately 3 Years|Lost to Follow-up|0
6194941|NCT01449929|9853224|FG002|Extension Phase Approximately 3 Years|Lost to Follow-up|4
6194942|NCT01449955|9853236|FG000|Overall Study|Withdrawal by Subject|1
6194943|NCT01449955|9853237|FG001|Overall Study|Withdrawal by Subject|2
6194944|NCT01450007|9853253|FG000|Overall Study|Late exclusion before treatment|2
6194945|NCT01450007|9853254|FG001|Overall Study|Late exclusion before treatment|3
6194946|NCT01450007|9853255|FG002|Overall Study|Late exclusion before treatment|2
6194947|NCT01450007|9853253|FG000|Overall Study|Protocol Violation|0
6194948|NCT01450007|9853254|FG001|Overall Study|Protocol Violation|1
6194949|NCT01450007|9853255|FG002|Overall Study|Protocol Violation|1
6194950|NCT01450007|9853253|FG000|Overall Study|Adverse Event|0
6194951|NCT01450007|9853254|FG001|Overall Study|Adverse Event|1
6194952|NCT01450007|9853255|FG002|Overall Study|Adverse Event|0
6194953|NCT01450098|9853265|FG000|Period 3|Protocol Violation|0
6274006|NCT02200614|9978272|FG001|Double Blind Treatment|Confirmed metastasis|140
6274007|NCT02200614|9978271|FG000|Double Blind Treatment|Judgment of the investigator|60
6274008|NCT02200614|9978272|FG001|Double Blind Treatment|Judgment of the investigator|99
6274009|NCT02200614|9978271|FG000|Double Blind Treatment|Metastasis by local reading|1
6274010|NCT02200614|9978272|FG001|Double Blind Treatment|Metastasis by local reading|3
6274011|NCT02200614|9978271|FG000|Double Blind Treatment|Other reason|6
6274012|NCT02200614|9978272|FG001|Double Blind Treatment|Other reason|2
6274013|NCT02200614|9978271|FG000|Double Blind Treatment|Personal reason|77
6274014|NCT02200614|9978272|FG001|Double Blind Treatment|Personal reason|85
5976542|NCT03078478|9563235|FG001|Maintenance Period 1 (36 Weeks)|Death|3
5976543|NCT03078478|9563234|FG000|Maintenance Period 1 (36 Weeks)|Subject withdrawal reason not collected|1
5976544|NCT03078478|9563235|FG001|Maintenance Period 1 (36 Weeks)|Subject withdrawal reason not collected|0
5976545|NCT03078478|9563234|FG000|Maintencance Period 2 (36 Weeks)|Withdrawal by Subject|18
5976546|NCT03078478|9563235|FG001|Maintencance Period 2 (36 Weeks)|Withdrawal by Subject|13
5976547|NCT03078478|9563234|FG000|Maintencance Period 2 (36 Weeks)|Lost to Follow-up|3
5976548|NCT03078478|9563235|FG001|Maintencance Period 2 (36 Weeks)|Lost to Follow-up|6
5976549|NCT03078478|9563234|FG000|Maintencance Period 2 (36 Weeks)|Death|4
5976550|NCT03078478|9563235|FG001|Maintencance Period 2 (36 Weeks)|Death|6
5976551|NCT03078478|9563234|FG000|Maintencance Period 2 (36 Weeks)|Not reconsenting|0
5976552|NCT03078478|9563235|FG001|Maintencance Period 2 (36 Weeks)|Not reconsenting|2
5976553|NCT02993263|9563250|FG000|Overall Study|Equipment Software failed and results were lost.|323
5976554|NCT02985684|9563254|FG000|6-Month Clinical Success Evaluation|Missed Echocardiograph|5
5976555|NCT02985684|9563254|FG000|6-Month Closure Success Evaluation|Technical Failure (No Device)|5
5976556|NCT02985684|9563254|FG000|6-Month Closure Success Evaluation|Device Removal|3
5976557|NCT02873195|9563269|FG000|Overall Study|Ineligible|5
5976558|NCT02873195|9563270|FG001|Overall Study|Ineligible|0
5976559|NCT02785952|9563287|FG000|Overall Study|Adverse Event|31
5976560|NCT02785952|9563288|FG001|Overall Study|Adverse Event|19
5976561|NCT02785952|9563287|FG000|Overall Study|Refusal unrelated to adverse events|10
5976562|NCT02785952|9563288|FG001|Overall Study|Refusal unrelated to adverse events|5
5976563|NCT02785952|9563287|FG000|Overall Study|Disease progression/relapse|61
5976564|NCT02785952|9563288|FG001|Overall Study|Disease progression/relapse|89
5976565|NCT02785952|9563287|FG000|Overall Study|Death|11
5976566|NCT02785952|9563288|FG001|Overall Study|Death|7
5976567|NCT02785952|9563287|FG000|Overall Study|Other- not protocol specified|6
5976568|NCT02785952|9563288|FG001|Overall Study|Other- not protocol specified|4
6194954|NCT01450098|9853266|FG001|Period 3|Protocol Violation|1
6194955|NCT01450098|9853265|FG000|Period 3|Withdrawal by Subject|0
6194956|NCT01450098|9853266|FG001|Period 3|Withdrawal by Subject|2
6194957|NCT01450137|9853281|FG000|Up to Week 12|Adverse Event|2
6194958|NCT01450137|9853282|FG001|Up to Week 12|Adverse Event|1
6194959|NCT01450137|9853281|FG000|Up to Week 12|Withdrawal by Subject|0
6194960|NCT01450137|9853282|FG001|Up to Week 12|Withdrawal by Subject|2
6194961|NCT01450137|9853281|FG000|Week 12 to Study End|Death|0
6194962|NCT01450137|9853282|FG001|Week 12 to Study End|Death|1
6194963|NCT01450137|9853281|FG000|Week 12 to Study End|Withdrawal by Subject|0
6194964|NCT01450137|9853282|FG001|Week 12 to Study End|Withdrawal by Subject|1
6194965|NCT01450540|9853327|FG000|Overall Study|Withdrawal by Subject|19
6194966|NCT01450540|9853328|FG001|Overall Study|Withdrawal by Subject|13
6194967|NCT01450540|9853327|FG000|Overall Study|protocol deviation|3
6194968|NCT01450540|9853328|FG001|Overall Study|protocol deviation|23
6274015|NCT02200614|9978271|FG000|Double Blind Treatment|Protocol deviation|14
6274016|NCT02200614|9978272|FG001|Double Blind Treatment|Protocol deviation|7
6194969|NCT01450631|9853338|FG000|Overall Study|Lost to Follow-up|2
6194970|NCT01450631|9853339|FG001|Overall Study|Lost to Follow-up|4
6194971|NCT01450631|9853338|FG000|Overall Study|Withdrawal by Subject|1
6194972|NCT01450631|9853339|FG001|Overall Study|Withdrawal by Subject|0
6194973|NCT01450683|9853345|FG000|Overall Study|Adverse Event|2
6194974|NCT01450696|9853351|FG000|Overall Study|Never Treated|1
6194975|NCT01450696|9853352|FG001|Overall Study|Never Treated|1
6194976|NCT01450696|9853351|FG000|Overall Study|Death|77
6194977|NCT01450696|9853352|FG001|Overall Study|Death|84
6194978|NCT01450696|9853351|FG000|Overall Study|Lost to Follow-up|3
6194979|NCT01450696|9853352|FG001|Overall Study|Lost to Follow-up|3
6194980|NCT01450696|9853351|FG000|Overall Study|Non-Compliance|1
6194981|NCT01450696|9853352|FG001|Overall Study|Non-Compliance|0
6274017|NCT02200614|9978271|FG000|Double Blind Treatment|Not treated|1
6274018|NCT02200614|9978272|FG001|Double Blind Treatment|Not treated|0
6274019|NCT02200614|9978271|FG000|Open Label|Adverse Event|15
6274020|NCT02200614|9978272|FG001|Open Label|Adverse Event|8
6274021|NCT02200614|9978271|FG000|Open Label|Confirmed metastasis|1
6274022|NCT02200614|9978272|FG001|Open Label|Confirmed metastasis|0
6274023|NCT02200614|9978271|FG000|Open Label|Judgment of the investigator|15
6274024|NCT02200614|9978272|FG001|Open Label|Judgment of the investigator|0
6274025|NCT02200614|9978271|FG000|Open Label|Metastasis by local reading|58
6274026|NCT02200614|9978272|FG001|Open Label|Metastasis by local reading|10
6274027|NCT02200614|9978271|FG000|Open Label|Other reason|6
6274028|NCT02200614|9978272|FG001|Open Label|Other reason|1
6274029|NCT02200614|9978271|FG000|Open Label|Personal reason|29
6274030|NCT02200614|9978272|FG001|Open Label|Personal reason|3
6274031|NCT02200614|9978271|FG000|Open Label|Protocol deviation|1
6274032|NCT02200614|9978272|FG001|Open Label|Protocol deviation|1
6274033|NCT02201108|9978317|FG000|Overall Study|Adverse Event|0
6274034|NCT02201108|9978318|FG001|Overall Study|Adverse Event|6
6274035|NCT02201108|9978317|FG000|Overall Study|Lack of Efficacy|2
6274036|NCT02201108|9978318|FG001|Overall Study|Lack of Efficacy|1
6274037|NCT02201108|9978317|FG000|Overall Study|Withdrawal by Subject|2
6274038|NCT02201108|9978318|FG001|Overall Study|Withdrawal by Subject|0
6274039|NCT02201277|9978333|FG000|Overall Study|Death|3
6274040|NCT02201277|9978334|FG001|Overall Study|Death|4
6274041|NCT02201277|9978333|FG000|Overall Study|Lost to Follow-up|2
6274042|NCT02201277|9978334|FG001|Overall Study|Lost to Follow-up|1
6274043|NCT02201277|9978333|FG000|Overall Study|Failed retrieval|1
6274044|NCT02201277|9978334|FG001|Overall Study|Failed retrieval|0
6274045|NCT02201277|9978333|FG000|Overall Study|Physician Decision|1
6274046|NCT02201277|9978334|FG001|Overall Study|Physician Decision|0
6274047|NCT02201290|9978344|FG000|Overall Study|Withdrawal by Subject|2
6274048|NCT02201290|9978344|FG000|Overall Study|Lack of Efficacy|2
6274049|NCT02201290|9978344|FG000|Overall Study|Adverse Event|1
6274050|NCT02201329|9978348|FG000|Overall Study|Progressive Dis./Relapse/Clinical Prog.|3
6274051|NCT02201329|9978348|FG000|Overall Study|Withdrawal by Subject|2
6274052|NCT02201524|9978374|FG000|Overall Study|Adverse Event|0
6274053|NCT02201524|9978375|FG001|Overall Study|Adverse Event|2
6274054|NCT02201524|9978376|FG002|Overall Study|Adverse Event|1
6274055|NCT02201524|9978377|FG003|Overall Study|Adverse Event|0
6274056|NCT02201524|9978374|FG000|Overall Study|Insufficient clinical response|1
6274057|NCT02201524|9978375|FG001|Overall Study|Insufficient clinical response|0
6274058|NCT02201524|9978376|FG002|Overall Study|Insufficient clinical response|0
6274059|NCT02201524|9978377|FG003|Overall Study|Insufficient clinical response|0
6274060|NCT02201524|9978374|FG000|Overall Study|Lost to Follow-up|0
6274061|NCT02201524|9978375|FG001|Overall Study|Lost to Follow-up|0
6274062|NCT02201524|9978376|FG002|Overall Study|Lost to Follow-up|2
6274063|NCT02201524|9978377|FG003|Overall Study|Lost to Follow-up|0
6274064|NCT02201524|9978374|FG000|Overall Study|No longer meets eligibility criteria|0
6274065|NCT02201524|9978375|FG001|Overall Study|No longer meets eligibility criteria|0
6274066|NCT02201524|9978376|FG002|Overall Study|No longer meets eligibility criteria|0
6274067|NCT02201524|9978377|FG003|Overall Study|No longer meets eligibility criteria|2
6274068|NCT02201524|9978374|FG000|Overall Study|Protocol Violation|0
6274069|NCT02201524|9978375|FG001|Overall Study|Protocol Violation|0
6274070|NCT02201524|9978376|FG002|Overall Study|Protocol Violation|0
6274071|NCT02201524|9978377|FG003|Overall Study|Protocol Violation|1
6274072|NCT02201524|9978374|FG000|Overall Study|Withdrawal by Subject|0
6274073|NCT02201524|9978375|FG001|Overall Study|Withdrawal by Subject|0
6274074|NCT02201524|9978376|FG002|Overall Study|Withdrawal by Subject|1
6274075|NCT02201524|9978377|FG003|Overall Study|Withdrawal by Subject|1
6274076|NCT02201524|9978374|FG000|Overall Study|Other|1
6274077|NCT02201524|9978375|FG001|Overall Study|Other|1
6274078|NCT02201524|9978376|FG002|Overall Study|Other|0
5976569|NCT02785952|9563287|FG000|Overall Study|On protocol treatment|6
6194982|NCT01450696|9853351|FG000|Overall Study|Withdrawal by Subject|13
6194983|NCT01450696|9853352|FG001|Overall Study|Withdrawal by Subject|2
6194984|NCT01450696|9853351|FG000|Overall Study|Study Terminated by Sponsor|53
6194985|NCT01450696|9853352|FG001|Overall Study|Study Terminated by Sponsor|58
6274079|NCT02201524|9978377|FG003|Overall Study|Other|0
6274080|NCT02201771|9978390|FG000|Overall Study|Death|3
6274081|NCT02201771|9978391|FG001|Overall Study|Death|2
6274082|NCT02201771|9978392|FG002|Overall Study|Death|0
6274083|NCT02201771|9978390|FG000|Overall Study|Protocol Violation|10
6274084|NCT02201771|9978391|FG001|Overall Study|Protocol Violation|8
6194986|NCT01450761|9853360|FG000|Randomization|Subject no longer meets study criteria|1
6194987|NCT01450761|9853361|FG001|Randomization|Subject no longer meets study criteria|2
6194988|NCT01450761|9853360|FG000|Randomization|Withdrawal by Subject|2
6194989|NCT01450761|9853361|FG001|Randomization|Withdrawal by Subject|0
6194990|NCT01450761|9853360|FG000|Randomization|Disease progression|0
6194991|NCT01450761|9853361|FG001|Randomization|Disease progression|2
6194992|NCT01450761|9853360|FG000|Randomization|Adverse Event unrelated to study drug|1
6194993|NCT01450761|9853361|FG001|Randomization|Adverse Event unrelated to study drug|0
6194994|NCT01450761|9853360|FG000|Randomization|Other|0
6194995|NCT01450761|9853361|FG001|Randomization|Other|1
6194996|NCT01450761|9853360|FG000|Lead-in Chemotherapy|Disease progression|33
6194997|NCT01450761|9853361|FG001|Lead-in Chemotherapy|Disease progression|32
6194998|NCT01450761|9853360|FG000|Lead-in Chemotherapy|Adverse event unrelated to study drug|21
6194999|NCT01450761|9853361|FG001|Lead-in Chemotherapy|Adverse event unrelated to study drug|19
6195000|NCT01450761|9853360|FG000|Lead-in Chemotherapy|Withdrawal by Subject|14
6195001|NCT01450761|9853361|FG001|Lead-in Chemotherapy|Withdrawal by Subject|12
6195002|NCT01450761|9853360|FG000|Lead-in Chemotherapy|Study drug toxicity|6
6195003|NCT01450761|9853361|FG001|Lead-in Chemotherapy|Study drug toxicity|10
6195004|NCT01450761|9853360|FG000|Lead-in Chemotherapy|No longer meets study criteria|3
6195005|NCT01450761|9853361|FG001|Lead-in Chemotherapy|No longer meets study criteria|7
6195006|NCT01450761|9853360|FG000|Lead-in Chemotherapy|Death|3
6195007|NCT01450761|9853361|FG001|Lead-in Chemotherapy|Death|3
6195008|NCT01450761|9853360|FG000|Lead-in Chemotherapy|Other|2
6195009|NCT01450761|9853361|FG001|Lead-in Chemotherapy|Other|2
6195010|NCT01450761|9853360|FG000|Lead-in Chemotherapy|Lost to Follow-up|2
6195011|NCT01450761|9853361|FG001|Lead-in Chemotherapy|Lost to Follow-up|0
6195012|NCT01450761|9853360|FG000|Treatment With Blinded Study Therapy|Disease progression|318
6195013|NCT01450761|9853361|FG001|Treatment With Blinded Study Therapy|Disease progression|415
6195014|NCT01450761|9853360|FG000|Treatment With Blinded Study Therapy|Study drug toxicity|87
6195015|NCT01450761|9853361|FG001|Treatment With Blinded Study Therapy|Study drug toxicity|9
6195016|NCT01450761|9853360|FG000|Treatment With Blinded Study Therapy|Adverse event unrelated to study drug|27
6195017|NCT01450761|9853361|FG001|Treatment With Blinded Study Therapy|Adverse event unrelated to study drug|19
6195018|NCT01450761|9853360|FG000|Treatment With Blinded Study Therapy|Subject request to discontinue treatment|15
6195019|NCT01450761|9853361|FG001|Treatment With Blinded Study Therapy|Subject request to discontinue treatment|8
6195020|NCT01450761|9853360|FG000|Treatment With Blinded Study Therapy|Withdrawal by Subject|12
6195021|NCT01450761|9853361|FG001|Treatment With Blinded Study Therapy|Withdrawal by Subject|5
6195022|NCT01450761|9853360|FG000|Treatment With Blinded Study Therapy|Death|5
6274085|NCT02201771|9978392|FG002|Overall Study|Protocol Violation|10
6274086|NCT02201784|9978402|FG000|Overall Study|Failure to achieve adequate block|2
6274087|NCT02201784|9978403|FG001|Overall Study|Failure to achieve adequate block|0
6274088|NCT02201901|9978412|FG000|Overall Study|Randomized but never treated|0
6274089|NCT02201901|9978413|FG001|Overall Study|Randomized but never treated|1
6274090|NCT02201901|9978414|FG002|Overall Study|Randomized but never treated|0
6274091|NCT02201901|9978412|FG000|Overall Study|Lack of Efficacy|7
6274092|NCT02201901|9978413|FG001|Overall Study|Lack of Efficacy|1
6274093|NCT02201901|9978414|FG002|Overall Study|Lack of Efficacy|6
6274094|NCT02201901|9978412|FG000|Overall Study|Death|3
6274095|NCT02201901|9978413|FG001|Overall Study|Death|3
6274096|NCT02201901|9978414|FG002|Overall Study|Death|3
6274097|NCT02201901|9978412|FG000|Overall Study|Lost to Follow-up|2
6274098|NCT02201901|9978413|FG001|Overall Study|Lost to Follow-up|3
6274099|NCT02201901|9978414|FG002|Overall Study|Lost to Follow-up|2
6274100|NCT02201901|9978412|FG000|Overall Study|Withdrew Consent|2
6274101|NCT02201901|9978413|FG001|Overall Study|Withdrew Consent|0
6274102|NCT02201901|9978414|FG002|Overall Study|Withdrew Consent|2
6274103|NCT02201901|9978412|FG000|Overall Study|Adverse Event|1
6274104|NCT02201901|9978413|FG001|Overall Study|Adverse Event|1
6274105|NCT02201901|9978414|FG002|Overall Study|Adverse Event|0
6274106|NCT02201940|9978425|FG000|Overall Study|Randomized/Enrolled but Never Treated|1
6274107|NCT02201940|9978426|FG001|Overall Study|Randomized/Enrolled but Never Treated|0
6274108|NCT02201940|9978425|FG000|Overall Study|Lack of Efficacy|2
6274109|NCT02201940|9978426|FG001|Overall Study|Lack of Efficacy|113
6274110|NCT02201940|9978425|FG000|Overall Study|Lost to Follow-up|5
6274111|NCT02201940|9978426|FG001|Overall Study|Lost to Follow-up|0
6274112|NCT02201940|9978425|FG000|Overall Study|Withdrew Consent|2
6274113|NCT02201940|9978426|FG001|Overall Study|Withdrew Consent|1
6274114|NCT02201940|9978425|FG000|Overall Study|Investigator's Discretion|1
6274115|NCT02201940|9978426|FG001|Overall Study|Investigator's Discretion|1
6274116|NCT02201940|9978425|FG000|Overall Study|Death|1
6274117|NCT02201940|9978426|FG001|Overall Study|Death|0
6274118|NCT02201940|9978425|FG000|Overall Study|Adverse Event|0
6274119|NCT02201940|9978426|FG001|Overall Study|Adverse Event|1
6274120|NCT02201953|9978434|FG000|Overall Study|Randomized but Never Treated|1
6274121|NCT02201953|9978435|FG001|Overall Study|Randomized but Never Treated|5
6274122|NCT02201953|9978434|FG000|Overall Study|Lack of Efficacy|9
6274123|NCT02201953|9978435|FG001|Overall Study|Lack of Efficacy|30
6274124|NCT02201953|9978434|FG000|Overall Study|Lost to Follow-up|8
6274125|NCT02201953|9978435|FG001|Overall Study|Lost to Follow-up|8
6274126|NCT02201953|9978434|FG000|Overall Study|Withdrew Consent|2
6195023|NCT01450761|9853361|FG001|Treatment With Blinded Study Therapy|Death|6
6195024|NCT01450761|9853360|FG000|Treatment With Blinded Study Therapy|Other/Unspecified|5
6195025|NCT01450761|9853361|FG001|Treatment With Blinded Study Therapy|Other/Unspecified|4
6195026|NCT01450761|9853360|FG000|Treatment With Blinded Study Therapy|Lost to Follow-up|2
6195027|NCT01450761|9853361|FG001|Treatment With Blinded Study Therapy|Lost to Follow-up|1
6195028|NCT01450761|9853360|FG000|Treatment With Blinded Study Therapy|Maximum clinical benefit|1
6195029|NCT01450761|9853361|FG001|Treatment With Blinded Study Therapy|Maximum clinical benefit|2
6195030|NCT01450761|9853360|FG000|Treatment With Blinded Study Therapy|No longer meets study criteria|1
6195031|NCT01450761|9853361|FG001|Treatment With Blinded Study Therapy|No longer meets study criteria|2
6195032|NCT01450761|9853360|FG000|Treatment With Blinded Study Therapy|Not reported|2
6195033|NCT01450761|9853361|FG001|Treatment With Blinded Study Therapy|Not reported|2
6195034|NCT01450761|9853360|FG000|Treatment With Blinded Study Therapy|Poor/non-compliance|1
6195035|NCT01450761|9853361|FG001|Treatment With Blinded Study Therapy|Poor/non-compliance|0
6195036|NCT01450761|9853360|FG000|Treatment With Blinded Study Therapy|Administrative reason by sponsor|2
6195037|NCT01450761|9853361|FG001|Treatment With Blinded Study Therapy|Administrative reason by sponsor|3
6195038|NCT01450800|9853378|FG000|Overall Study|Protocol Violation|1
6195039|NCT01450800|9853379|FG001|Overall Study|Protocol Violation|3
6195040|NCT01450813|9853391|FG000|Overall Study|Physician Decision|1
6195041|NCT01450813|9853392|FG001|Overall Study|Physician Decision|1
6195042|NCT01450813|9853393|FG002|Overall Study|Physician Decision|0
6195043|NCT01450813|9853394|FG003|Overall Study|Physician Decision|3
6195044|NCT01450943|9853418|FG000|Overall Study|Screen failure, loss to follow-up|2
6195045|NCT01450943|9853419|FG001|Overall Study|Screen failure, loss to follow-up|7
6195046|NCT01450943|9853420|FG002|Overall Study|Screen failure, loss to follow-up|6
6195047|NCT01451164|9853436|FG000|Overall Study|Adverse Event|19
6195048|NCT01451164|9853437|FG001|Overall Study|Adverse Event|12
6195049|NCT01451164|9853438|FG002|Overall Study|Adverse Event|18
6195050|NCT01451164|9853439|FG003|Overall Study|Adverse Event|21
6195051|NCT01451164|9853436|FG000|Overall Study|Withdrawal Criteria|1
6195052|NCT01451164|9853437|FG001|Overall Study|Withdrawal Criteria|1
6195053|NCT01451164|9853438|FG002|Overall Study|Withdrawal Criteria|1
6195054|NCT01451164|9853439|FG003|Overall Study|Withdrawal Criteria|1
6195055|NCT01451164|9853436|FG000|Overall Study|Physician Decision|2
6195056|NCT01451164|9853437|FG001|Overall Study|Physician Decision|0
6195057|NCT01451164|9853438|FG002|Overall Study|Physician Decision|1
6195058|NCT01451164|9853439|FG003|Overall Study|Physician Decision|0
6195059|NCT01451164|9853436|FG000|Overall Study|Withdrawal by Subject|14
6195060|NCT01451164|9853437|FG001|Overall Study|Withdrawal by Subject|11
6195061|NCT01451164|9853438|FG002|Overall Study|Withdrawal by Subject|16
6274127|NCT02201953|9978435|FG001|Overall Study|Withdrew Consent|5
6274128|NCT02201953|9978434|FG000|Overall Study|Adverse Event|0
6274129|NCT02201953|9978435|FG001|Overall Study|Adverse Event|5
6274130|NCT02201953|9978434|FG000|Overall Study|Death|0
6274131|NCT02201953|9978435|FG001|Overall Study|Death|3
6274132|NCT02202031|9978443|FG000|Overall Study|Lost to Follow-up|1
6274133|NCT02202031|9978444|FG001|Overall Study|Lost to Follow-up|0
6274134|NCT02202031|9978443|FG000|Overall Study|Too Busy|1
6274135|NCT02202031|9978444|FG001|Overall Study|Too Busy|3
6274136|NCT02202031|9978443|FG000|Overall Study|Illness/Medical Reason|0
6274137|NCT02202031|9978444|FG001|Overall Study|Illness/Medical Reason|2
6274138|NCT02202031|9978443|FG000|Overall Study|Intolerance/Lack of Improvement|3
6274139|NCT02202031|9978444|FG001|Overall Study|Intolerance/Lack of Improvement|0
6274140|NCT02202109|9978452|FG000|Overall Study|Lost to Follow-up|88
6274141|NCT02202109|9978453|FG001|Overall Study|Lost to Follow-up|87
6274142|NCT02202109|9978452|FG000|Overall Study|Withdrawal by Subject|2
6274143|NCT02202109|9978453|FG001|Overall Study|Withdrawal by Subject|0
6274144|NCT02202161|9978471|FG000|Overall Study|Adverse Event|1
6274145|NCT02202161|9978472|FG001|Overall Study|Adverse Event|1
6274146|NCT02202161|9978473|FG002|Overall Study|Adverse Event|0
6274147|NCT02202161|9978474|FG003|Overall Study|Adverse Event|0
5976570|NCT02785952|9563288|FG001|Overall Study|On protocol treatment|3
5976571|NCT02748616|9563300|FG000|Overall Study|Lost to Follow-up|1
5976572|NCT02748616|9563300|FG000|Overall Study|Withdrawal by Subject|2
5976573|NCT02748616|9563300|FG000|Overall Study|Physician Decision|2
5976574|NCT02748616|9563300|FG000|Overall Study|Did Not Complete Ursodial Course|2
5976575|NCT02719522|9563304|FG000|Overall Study|Implant Failure|4
5976576|NCT02719522|9563304|FG000|Overall Study|Death|2
5976577|NCT02719522|9563304|FG000|Overall Study|Lost to Follow-up|5
5976578|NCT02585232|9563325|FG000|Overall Study|Lost to Follow-up|8
5976579|NCT02585232|9563326|FG001|Overall Study|Lost to Follow-up|8
5976580|NCT02585232|9563325|FG000|Overall Study|Withdrawal by Subject|4
5976581|NCT02585232|9563326|FG001|Overall Study|Withdrawal by Subject|8
5976582|NCT02583269|9563337|FG000|Overall Study|Patient hospitalized prior to start|1
5976583|NCT02583269|9563338|FG001|Overall Study|Patient hospitalized prior to start|0
5976584|NCT02583269|9563339|FG002|Overall Study|Patient hospitalized prior to start|0
5976585|NCT02583269|9563340|FG003|Overall Study|Patient hospitalized prior to start|0
5976586|NCT02583269|9563341|FG004|Overall Study|Patient hospitalized prior to start|0
6050680|NCT00428090|9649856|FG002|Overall Study|Raised Creatinine Value|0
6274148|NCT02202161|9978475|FG004|Overall Study|Adverse Event|0
6274149|NCT02202161|9978476|FG005|Overall Study|Adverse Event|1
6274150|NCT02202161|9978477|FG006|Overall Study|Adverse Event|0
6195062|NCT01451164|9853439|FG003|Overall Study|Withdrawal by Subject|17
6195063|NCT01451164|9853436|FG000|Overall Study|Protocol Violation|0
6195064|NCT01451164|9853437|FG001|Overall Study|Protocol Violation|1
6195065|NCT01451164|9853438|FG002|Overall Study|Protocol Violation|0
6195066|NCT01451164|9853439|FG003|Overall Study|Protocol Violation|0
6195067|NCT01451164|9853436|FG000|Overall Study|Lack of Efficacy|7
6195068|NCT01451164|9853437|FG001|Overall Study|Lack of Efficacy|9
6195069|NCT01451164|9853438|FG002|Overall Study|Lack of Efficacy|9
6195070|NCT01451164|9853439|FG003|Overall Study|Lack of Efficacy|7
6195071|NCT01451203|9853451|FG000|Double-blind Treatment Period|Did not receive treatment|1
6195072|NCT01451203|9853452|FG001|Double-blind Treatment Period|Did not receive treatment|2
6195073|NCT01451203|9853451|FG000|Double-blind Treatment Period|Consent Withdrawn|3
6195074|NCT01451203|9853452|FG001|Double-blind Treatment Period|Consent Withdrawn|2
6195075|NCT01451203|9853451|FG000|Double-blind Treatment Period|Lack of Efficacy|71
6195076|NCT01451203|9853452|FG001|Double-blind Treatment Period|Lack of Efficacy|36
6195077|NCT01451203|9853451|FG000|Double-blind Treatment Period|HBV-DNA positive (during the DB Period)|0
6195078|NCT01451203|9853452|FG001|Double-blind Treatment Period|HBV-DNA positive (during the DB Period)|1
6195079|NCT01451203|9853451|FG000|Double-blind Treatment Period|Adverse Event|6
6195080|NCT01451203|9853452|FG001|Double-blind Treatment Period|Adverse Event|9
6195081|NCT01451203|9853451|FG000|Double-blind Treatment Period|Missing study medication ≥6 times|1
6195082|NCT01451203|9853452|FG001|Double-blind Treatment Period|Missing study medication ≥6 times|0
6195083|NCT01451203|9853451|FG000|Double-blind Treatment Period|Violation of eligibility criteria|1
6195084|NCT01451203|9853452|FG001|Double-blind Treatment Period|Violation of eligibility criteria|0
6195085|NCT01451203|9853451|FG000|Double-blind Treatment Period|Investigator decision|2
6195086|NCT01451203|9853452|FG001|Double-blind Treatment Period|Investigator decision|0
6195087|NCT01451203|9853451|FG000|Post-treatment Period|Consent withdrawn|2
6274151|NCT02202161|9978478|FG007|Overall Study|Adverse Event|0
6274152|NCT02202161|9978471|FG000|Overall Study|Did not meet continuation criteria|0
6274153|NCT02202161|9978472|FG001|Overall Study|Did not meet continuation criteria|0
6274154|NCT02202161|9978473|FG002|Overall Study|Did not meet continuation criteria|0
6274155|NCT02202161|9978474|FG003|Overall Study|Did not meet continuation criteria|0
6274156|NCT02202161|9978475|FG004|Overall Study|Did not meet continuation criteria|0
6274157|NCT02202161|9978476|FG005|Overall Study|Did not meet continuation criteria|0
6274158|NCT02202161|9978477|FG006|Overall Study|Did not meet continuation criteria|0
6274159|NCT02202161|9978478|FG007|Overall Study|Did not meet continuation criteria|3
6274160|NCT02202161|9978471|FG000|Overall Study|Physician Decision|0
6274161|NCT02202161|9978472|FG001|Overall Study|Physician Decision|0
6274162|NCT02202161|9978473|FG002|Overall Study|Physician Decision|0
6274163|NCT02202161|9978474|FG003|Overall Study|Physician Decision|0
5976587|NCT02545283|9563377|FG000|Overall Study|Lost to Follow-up|2
5976588|NCT02545283|9563378|FG001|Overall Study|Lost to Follow-up|4
5976589|NCT02545283|9563377|FG000|Overall Study|Withdrawal by Subject|5
5976590|NCT02545283|9563378|FG001|Overall Study|Withdrawal by Subject|9
5976591|NCT02545283|9563377|FG000|Overall Study|Death|109
5976592|NCT02545283|9563378|FG001|Overall Study|Death|211
5976593|NCT02545283|9563377|FG000|Overall Study|Did not complete due to 2 ineligibilities and physician's decision|0
5976594|NCT02545283|9563378|FG001|Overall Study|Did not complete due to 2 ineligibilities and physician's decision|3
5976595|NCT02545283|9563377|FG000|Overall Study|Study Terminated By Sponsor|33
5976596|NCT02545283|9563378|FG001|Overall Study|Study Terminated By Sponsor|71
5976597|NCT02524171|9563388|FG000|6-month Follow-up|Lost to Follow-up|53
5976598|NCT02524171|9563389|FG001|6-month Follow-up|Lost to Follow-up|45
5976599|NCT02524171|9563388|FG000|12-month Follow-up Interview|Lost to Follow-up|45
5976600|NCT02524171|9563389|FG001|12-month Follow-up Interview|Lost to Follow-up|41
5976601|NCT02476968|9563425|FG000|Overall Study|Other|0
5976602|NCT02476968|9563426|FG001|Overall Study|Other|2
5976603|NCT02476968|9563427|FG002|Overall Study|Other|0
5976604|NCT02476968|9563425|FG000|Overall Study|Lost to Follow-up|10
5976605|NCT02476968|9563426|FG001|Overall Study|Lost to Follow-up|0
5976606|NCT02476968|9563427|FG002|Overall Study|Lost to Follow-up|1
5976607|NCT02476968|9563425|FG000|Overall Study|Death|34
5976608|NCT02476968|9563426|FG001|Overall Study|Death|6
5976609|NCT02476968|9563427|FG002|Overall Study|Death|0
5976610|NCT02476968|9563425|FG000|Overall Study|Eligibility criteria not fulfilled|0
5976611|NCT02476968|9563426|FG001|Overall Study|Eligibility criteria not fulfilled|0
5976612|NCT02476968|9563427|FG002|Overall Study|Eligibility criteria not fulfilled|1
5976613|NCT02476968|9563425|FG000|Overall Study|Patient decision|30
5976614|NCT02476968|9563426|FG001|Overall Study|Patient decision|7
5976615|NCT02476968|9563427|FG002|Overall Study|Patient decision|0
5976616|NCT02306122|9563444|FG000|Initial Physician Randomization|Physician Decision|0
5976617|NCT02306122|9563445|FG001|Initial Physician Randomization|Physician Decision|0
5976618|NCT02306122|9563446|FG002|Initial Physician Randomization|Physician Decision|0
5976619|NCT02306122|9563447|FG003|Initial Physician Randomization|Physician Decision|0
5976620|NCT02306122|9563448|FG004|Initial Physician Randomization|Physician Decision|0
5976621|NCT02306122|9563449|FG005|Initial Physician Randomization|Physician Decision|0
5976622|NCT02306122|9563450|FG006|Initial Physician Randomization|Physician Decision|0
5976623|NCT02306122|9563451|FG007|Initial Physician Randomization|Physician Decision|0
5976624|NCT02306122|9563452|FG008|Initial Physician Randomization|Physician Decision|1
6274164|NCT02202161|9978475|FG004|Overall Study|Physician Decision|0
6195088|NCT01451203|9853452|FG001|Post-treatment Period|Consent withdrawn|4
6195089|NCT01451203|9853451|FG000|Post-treatment Period|Lack of Efficacy|12
6195090|NCT01451203|9853452|FG001|Post-treatment Period|Lack of Efficacy|28
6195091|NCT01451203|9853451|FG000|Post-treatment Period|Adverse Event|0
6195092|NCT01451203|9853452|FG001|Post-treatment Period|Adverse Event|1
6195093|NCT01451203|9853451|FG000|Post-treatment Period|Investigator decision|0
6195094|NCT01451203|9853452|FG001|Post-treatment Period|Investigator decision|1
6195095|NCT01451398|9853468|FG000|Overall Study|Adverse Event|7
6195096|NCT01451398|9853469|FG001|Overall Study|Adverse Event|9
6195097|NCT01451398|9853468|FG000|Overall Study|Protocol Violation|1
6195098|NCT01451398|9853469|FG001|Overall Study|Protocol Violation|2
6195099|NCT01451398|9853468|FG000|Overall Study|Physician Decision|1
6195100|NCT01451398|9853469|FG001|Overall Study|Physician Decision|1
6195101|NCT01451398|9853468|FG000|Overall Study|Withdrawal by Subject|10
6195102|NCT01451398|9853469|FG001|Overall Study|Withdrawal by Subject|14
6195103|NCT01451398|9853468|FG000|Overall Study|Lost to Follow-up|6
6195104|NCT01451398|9853469|FG001|Overall Study|Lost to Follow-up|4
6195105|NCT01451398|9853468|FG000|Overall Study|Non-compliance with study drug|1
6195106|NCT01451398|9853469|FG001|Overall Study|Non-compliance with study drug|3
6195107|NCT01451398|9853468|FG000|Overall Study|Non-compliance with protocol|1
6195108|NCT01451398|9853469|FG001|Overall Study|Non-compliance with protocol|1
6195109|NCT01451398|9853468|FG000|Overall Study|Moved out of country|0
6195110|NCT01451398|9853469|FG001|Overall Study|Moved out of country|1
6195111|NCT01451398|9853468|FG000|Overall Study|Adverse Event + Elevated Fasting Glucose|0
6195112|NCT01451398|9853469|FG001|Overall Study|Adverse Event + Elevated Fasting Glucose|1
6195113|NCT01451398|9853468|FG000|Overall Study|Lack of Efficacy|0
6195114|NCT01451398|9853469|FG001|Overall Study|Lack of Efficacy|1
6195115|NCT01451424|9853488|FG000|Overall Study|Withdrawal by Subject|1
6195116|NCT01451424|9853489|FG001|Overall Study|Withdrawal by Subject|1
6195117|NCT01451424|9853490|FG002|Overall Study|Withdrawal by Subject|0
6195118|NCT01451424|9853491|FG003|Overall Study|Withdrawal by Subject|2
6195119|NCT01451424|9853488|FG000|Overall Study|Lost to Follow-up|0
6195120|NCT01451424|9853489|FG001|Overall Study|Lost to Follow-up|1
6195121|NCT01451424|9853490|FG002|Overall Study|Lost to Follow-up|0
6195122|NCT01451424|9853491|FG003|Overall Study|Lost to Follow-up|1
6195123|NCT01451424|9853488|FG000|Overall Study|Physician Decision|0
6195124|NCT01451424|9853489|FG001|Overall Study|Physician Decision|0
6195125|NCT01451424|9853490|FG002|Overall Study|Physician Decision|1
6195126|NCT01451424|9853491|FG003|Overall Study|Physician Decision|1
6195127|NCT01451424|9853488|FG000|Overall Study|Adverse Event|0
6195128|NCT01451424|9853489|FG001|Overall Study|Adverse Event|0
6195129|NCT01451424|9853490|FG002|Overall Study|Adverse Event|0
6195130|NCT01451424|9853491|FG003|Overall Study|Adverse Event|1
6274165|NCT02202161|9978476|FG005|Overall Study|Physician Decision|0
6274166|NCT02202161|9978477|FG006|Overall Study|Physician Decision|0
6274167|NCT02202161|9978478|FG007|Overall Study|Physician Decision|3
6274168|NCT02202161|9978471|FG000|Overall Study|Withdrawal by Subject|0
6274169|NCT02202161|9978472|FG001|Overall Study|Withdrawal by Subject|0
6274170|NCT02202161|9978473|FG002|Overall Study|Withdrawal by Subject|0
6274171|NCT02202161|9978474|FG003|Overall Study|Withdrawal by Subject|0
6274172|NCT02202161|9978475|FG004|Overall Study|Withdrawal by Subject|1
6274173|NCT02202161|9978476|FG005|Overall Study|Withdrawal by Subject|0
6274174|NCT02202161|9978477|FG006|Overall Study|Withdrawal by Subject|0
6274175|NCT02202161|9978478|FG007|Overall Study|Withdrawal by Subject|0
6274176|NCT02202317|9978506|FG000|Overall Study|Lost to Follow-up|1
6088322|NCT00674154|9699015|FG000|Overall Study|Did not want parathyroidectomy|0
6088323|NCT00674154|9699016|FG001|Overall Study|Did not want parathyroidectomy|2
6088324|NCT00674323|9699048|FG000|Overall Study|Adverse Event|0
6195131|NCT01451437|9853515|FG000|Overall Study|Adverse Event|0
6274177|NCT02202499|9978513|FG000|Overall Study|Cancer diagnosis|0
6274178|NCT02202499|9978514|FG001|Overall Study|Cancer diagnosis|0
6274179|NCT02202499|9978515|FG002|Overall Study|Cancer diagnosis|1
6274180|NCT02202499|9978513|FG000|Overall Study|Moved from area|0
6274181|NCT02202499|9978514|FG001|Overall Study|Moved from area|0
6274182|NCT02202499|9978515|FG002|Overall Study|Moved from area|1
6274183|NCT02202499|9978513|FG000|Overall Study|Declined before randomization|1
6274184|NCT02202499|9978514|FG001|Overall Study|Declined before randomization|0
6274185|NCT02202499|9978515|FG002|Overall Study|Declined before randomization|0
6274186|NCT02202499|9978513|FG000|Overall Study|Auto accident|1
6274187|NCT02202499|9978514|FG001|Overall Study|Auto accident|0
6274188|NCT02202499|9978515|FG002|Overall Study|Auto accident|0
6195132|NCT01451437|9853516|FG001|Overall Study|Adverse Event|0
6195133|NCT01451437|9853517|FG002|Overall Study|Adverse Event|0
6195134|NCT01451437|9853518|FG003|Overall Study|Adverse Event|0
6195135|NCT01451437|9853519|FG004|Overall Study|Adverse Event|0
6088325|NCT00674323|9699049|FG001|Overall Study|Adverse Event|1
6195136|NCT01451437|9853520|FG005|Overall Study|Adverse Event|1
6195137|NCT01451437|9853521|FG006|Overall Study|Adverse Event|1
6195138|NCT01451437|9853522|FG007|Overall Study|Adverse Event|2
6195139|NCT01451437|9853523|FG008|Overall Study|Adverse Event|1
6195140|NCT01451437|9853515|FG000|Overall Study|Physician Decision|1
6195141|NCT01451437|9853516|FG001|Overall Study|Physician Decision|1
6195142|NCT01451437|9853517|FG002|Overall Study|Physician Decision|2
6195143|NCT01451437|9853518|FG003|Overall Study|Physician Decision|0
6195144|NCT01451437|9853519|FG004|Overall Study|Physician Decision|0
6195145|NCT01451437|9853520|FG005|Overall Study|Physician Decision|0
6195146|NCT01451437|9853521|FG006|Overall Study|Physician Decision|0
6195147|NCT01451437|9853522|FG007|Overall Study|Physician Decision|0
6195148|NCT01451437|9853523|FG008|Overall Study|Physician Decision|0
6195149|NCT01451437|9853515|FG000|Overall Study|Disease Progression|0
6195150|NCT01451437|9853516|FG001|Overall Study|Disease Progression|0
6195151|NCT01451437|9853517|FG002|Overall Study|Disease Progression|1
6195152|NCT01451437|9853518|FG003|Overall Study|Disease Progression|1
6195153|NCT01451437|9853519|FG004|Overall Study|Disease Progression|3
6195154|NCT01451437|9853520|FG005|Overall Study|Disease Progression|2
6195155|NCT01451437|9853521|FG006|Overall Study|Disease Progression|3
6195156|NCT01451437|9853522|FG007|Overall Study|Disease Progression|1
6195157|NCT01451437|9853523|FG008|Overall Study|Disease Progression|3
6195158|NCT01451437|9853515|FG000|Overall Study|Protocol Violation|0
6195159|NCT01451437|9853516|FG001|Overall Study|Protocol Violation|0
6195160|NCT01451437|9853517|FG002|Overall Study|Protocol Violation|0
6195161|NCT01451437|9853518|FG003|Overall Study|Protocol Violation|0
6195162|NCT01451437|9853519|FG004|Overall Study|Protocol Violation|0
6195163|NCT01451437|9853520|FG005|Overall Study|Protocol Violation|0
6195164|NCT01451437|9853521|FG006|Overall Study|Protocol Violation|1
6195165|NCT01451437|9853522|FG007|Overall Study|Protocol Violation|0
6195166|NCT01451437|9853523|FG008|Overall Study|Protocol Violation|0
6195167|NCT01451437|9853515|FG000|Overall Study|Withdrawal by Subject|0
6195168|NCT01451437|9853516|FG001|Overall Study|Withdrawal by Subject|0
6195169|NCT01451437|9853517|FG002|Overall Study|Withdrawal by Subject|0
6195170|NCT01451437|9853518|FG003|Overall Study|Withdrawal by Subject|0
6195171|NCT01451437|9853519|FG004|Overall Study|Withdrawal by Subject|1
6195172|NCT01451437|9853520|FG005|Overall Study|Withdrawal by Subject|0
6195173|NCT01451437|9853521|FG006|Overall Study|Withdrawal by Subject|1
6195174|NCT01451437|9853522|FG007|Overall Study|Withdrawal by Subject|0
6195175|NCT01451437|9853523|FG008|Overall Study|Withdrawal by Subject|0
6195176|NCT01451541|9853564|FG000|Overall Study|Adverse Event|4
6195177|NCT01451541|9853565|FG001|Overall Study|Adverse Event|3
6195178|NCT01451541|9853566|FG002|Overall Study|Adverse Event|6
6195179|NCT01451541|9853564|FG000|Overall Study|Lack of Efficacy|2
6195180|NCT01451541|9853565|FG001|Overall Study|Lack of Efficacy|0
6195181|NCT01451541|9853566|FG002|Overall Study|Lack of Efficacy|0
6195182|NCT01451541|9853564|FG000|Overall Study|Lost to Follow-up|4
6195183|NCT01451541|9853565|FG001|Overall Study|Lost to Follow-up|4
6195184|NCT01451541|9853566|FG002|Overall Study|Lost to Follow-up|7
6195185|NCT01451541|9853564|FG000|Overall Study|Withdrawal by Subject|15
6195186|NCT01451541|9853565|FG001|Overall Study|Withdrawal by Subject|8
6195187|NCT01451541|9853566|FG002|Overall Study|Withdrawal by Subject|6
6195188|NCT01451541|9853564|FG000|Overall Study|randomization error, noncompliance|11
6195189|NCT01451541|9853565|FG001|Overall Study|randomization error, noncompliance|10
6195190|NCT01451541|9853566|FG002|Overall Study|randomization error, noncompliance|8
6195191|NCT01451554|9853578|FG000|Overall Study|Withdrawal by Subject|14
6195192|NCT01451554|9853579|FG001|Overall Study|Withdrawal by Subject|9
6195193|NCT01451606|9853587|FG000|Overall Study|Withdrawal by Subject|4
6195194|NCT01451606|9853588|FG001|Overall Study|Withdrawal by Subject|3
6195195|NCT01451645|9853632|FG000|Overall Study|Protocol Violation|1
6195196|NCT01451645|9853633|FG001|Overall Study|Protocol Violation|0
6195197|NCT01451645|9853632|FG000|Overall Study|Adverse Event|0
6195198|NCT01451645|9853633|FG001|Overall Study|Adverse Event|3
6195199|NCT01451645|9853632|FG000|Overall Study|Withdrawal by Subject|4
6195200|NCT01451645|9853633|FG001|Overall Study|Withdrawal by Subject|2
6195201|NCT01451645|9853632|FG000|Overall Study|Lost to Follow-up|4
6195202|NCT01451645|9853633|FG001|Overall Study|Lost to Follow-up|3
6274189|NCT02202538|9978528|FG000|Overall Study|Withdrawal by Subject|5
6274190|NCT02202538|9978528|FG000|Overall Study|Did not meet all inclusion criteria|2
6274191|NCT02202538|9978528|FG000|Overall Study|Investigator Decision|1
6274192|NCT02202551|9978536|FG000|Overall Study|Adverse Event|8
6274193|NCT02202551|9978537|FG001|Overall Study|Adverse Event|19
6274194|NCT02202551|9978538|FG002|Overall Study|Adverse Event|5
6274195|NCT02202551|9978539|FG003|Overall Study|Adverse Event|9
6274196|NCT02202551|9978536|FG000|Overall Study|Death|3
6195203|NCT01451749|9853641|FG000|Overall Study|Protocol Violation|14
6195204|NCT01451749|9853642|FG001|Overall Study|Protocol Violation|7
6195205|NCT01451749|9853641|FG000|Overall Study|Lost to Follow-up|15
6195206|NCT01451749|9853642|FG001|Overall Study|Lost to Follow-up|5
6195207|NCT01451749|9853641|FG000|Overall Study|Meet the exclusion criteria,and|1
6195208|NCT01451749|9853642|FG001|Overall Study|Meet the exclusion criteria,and|1
6195209|NCT01451749|9853641|FG000|Overall Study|Adverse Event|2
6274197|NCT02202551|9978537|FG001|Overall Study|Death|2
6195210|NCT01451749|9853642|FG001|Overall Study|Adverse Event|0
6195211|NCT01451749|9853641|FG000|Overall Study|Withdrawal by Subject|0
6274198|NCT02202551|9978538|FG002|Overall Study|Death|1
6195212|NCT01451749|9853642|FG001|Overall Study|Withdrawal by Subject|1
6195213|NCT01451762|9853653|FG000|Overall Study|Lost to Follow-up|3
6195214|NCT01451762|9853654|FG001|Overall Study|Lost to Follow-up|6
6195215|NCT01451762|9853655|FG002|Overall Study|Lost to Follow-up|6
6195216|NCT01451814|9853678|FG000|Overall Study|Withdrawal by Subject|1
6195217|NCT01451814|9853679|FG001|Overall Study|Withdrawal by Subject|1
6195218|NCT01451814|9853678|FG000|Overall Study|Lost to Follow-up|5
6195219|NCT01451814|9853679|FG001|Overall Study|Lost to Follow-up|4
6195220|NCT01451827|9853689|FG000|Overall Study|Adverse Event|2
6195221|NCT01451827|9853690|FG001|Overall Study|Adverse Event|0
6195222|NCT01451827|9853691|FG002|Overall Study|Adverse Event|1
6195223|NCT01451827|9853692|FG003|Overall Study|Adverse Event|1
6195224|NCT01451827|9853689|FG000|Overall Study|Protocol deviation|1
6195225|NCT01451827|9853690|FG001|Overall Study|Protocol deviation|0
6195226|NCT01451827|9853691|FG002|Overall Study|Protocol deviation|0
6195227|NCT01451827|9853692|FG003|Overall Study|Protocol deviation|0
6195228|NCT01451827|9853689|FG000|Overall Study|Lost to Follow-up|0
6195229|NCT01451827|9853690|FG001|Overall Study|Lost to Follow-up|3
6195230|NCT01451827|9853691|FG002|Overall Study|Lost to Follow-up|0
6195231|NCT01451827|9853692|FG003|Overall Study|Lost to Follow-up|2
6195232|NCT01451827|9853689|FG000|Overall Study|Participant met withdrawal criteria|0
6195233|NCT01451827|9853690|FG001|Overall Study|Participant met withdrawal criteria|2
6195234|NCT01451827|9853691|FG002|Overall Study|Participant met withdrawal criteria|0
6195235|NCT01451827|9853692|FG003|Overall Study|Participant met withdrawal criteria|0
6195236|NCT01451827|9853689|FG000|Overall Study|Withdrawal by Subject|0
6195237|NCT01451827|9853690|FG001|Overall Study|Withdrawal by Subject|0
6195238|NCT01451827|9853691|FG002|Overall Study|Withdrawal by Subject|1
6195239|NCT01451827|9853692|FG003|Overall Study|Withdrawal by Subject|1
6195240|NCT01451931|9853705|FG000|Overall Study|Lost to Follow-up|17
6195241|NCT01451931|9853706|FG001|Overall Study|Lost to Follow-up|36
6195242|NCT01451931|9853707|FG002|Overall Study|Lost to Follow-up|21
6195243|NCT01451931|9853705|FG000|Overall Study|Withdrawal by Subject|16
6195244|NCT01451931|9853706|FG001|Overall Study|Withdrawal by Subject|22
6195245|NCT01451931|9853707|FG002|Overall Study|Withdrawal by Subject|22
6195246|NCT01452347|9853782|FG000|Overall Study|Adverse Event|2
6195247|NCT01452347|9853783|FG001|Overall Study|Adverse Event|1
6195248|NCT01452347|9853782|FG000|Overall Study|Non compliance protocol|2
6195249|NCT01452347|9853783|FG001|Overall Study|Non compliance protocol|0
6195250|NCT01452347|9853782|FG000|Overall Study|Lost to Follow-up|2
6195251|NCT01452347|9853783|FG001|Overall Study|Lost to Follow-up|0
6195252|NCT01452347|9853782|FG000|Overall Study|Withdrawal by Subject|3
6195253|NCT01452347|9853783|FG001|Overall Study|Withdrawal by Subject|3
6195254|NCT01452347|9853782|FG000|Overall Study|Not treated|6
6195255|NCT01452347|9853783|FG001|Overall Study|Not treated|3
6195256|NCT01452347|9853782|FG000|Overall Study|Other reason not defined above|2
6195257|NCT01452347|9853783|FG001|Overall Study|Other reason not defined above|0
6195258|NCT01452412|9853793|FG000|Overall Study|Withdrawal by Subject|15
6195259|NCT01452412|9853794|FG001|Overall Study|Withdrawal by Subject|11
6195260|NCT01452412|9853793|FG000|Overall Study|Adverse Event|4
6195261|NCT01452412|9853794|FG001|Overall Study|Adverse Event|3
6195262|NCT01452412|9853793|FG000|Overall Study|Lost to Follow-up|5
6195263|NCT01452412|9853794|FG001|Overall Study|Lost to Follow-up|3
6195264|NCT01452412|9853793|FG000|Overall Study|Death|1
6088326|NCT00674323|9699050|FG002|Overall Study|Adverse Event|0
6195265|NCT01452412|9853794|FG001|Overall Study|Death|0
6195266|NCT01452412|9853793|FG000|Overall Study|Initiated dialysis|1
6195267|NCT01452412|9853794|FG001|Overall Study|Initiated dialysis|0
6195268|NCT01452412|9853793|FG000|Overall Study|Other|2
6195269|NCT01452412|9853794|FG001|Overall Study|Other|0
6195270|NCT01452529|9853807|FG000|Run-in Period|Adverse Event|96
6088327|NCT00674323|9699048|FG000|Overall Study|Protocol Violation|1
6088328|NCT00674323|9699049|FG001|Overall Study|Protocol Violation|0
6088329|NCT00674323|9699050|FG002|Overall Study|Protocol Violation|0
6088330|NCT00674362|9699060|FG000|Double Blind|Adverse Event|6
6088331|NCT00674362|9699061|FG001|Double Blind|Adverse Event|6
6088332|NCT00674362|9699060|FG000|Double Blind|Lack of Efficacy|2
6088333|NCT00674362|9699061|FG001|Double Blind|Lack of Efficacy|6
6088334|NCT00674362|9699060|FG000|Double Blind|Loss of efficacy|0
6088335|NCT00674362|9699061|FG001|Double Blind|Loss of efficacy|1
6088336|NCT00674362|9699060|FG000|Double Blind|Withdrawal by Subject|4
6195271|NCT01452529|9853808|FG001|Run-in Period|Adverse Event|0
6195272|NCT01452529|9853809|FG002|Run-in Period|Adverse Event|0
6195273|NCT01452529|9853807|FG000|Run-in Period|Withdrawal by Subject|49
6195274|NCT01452529|9853808|FG001|Run-in Period|Withdrawal by Subject|0
6088337|NCT00674362|9699061|FG001|Double Blind|Withdrawal by Subject|3
6195275|NCT01452529|9853809|FG002|Run-in Period|Withdrawal by Subject|0
6195276|NCT01452529|9853807|FG000|Run-in Period|Lost to Follow-up|19
6195277|NCT01452529|9853808|FG001|Run-in Period|Lost to Follow-up|0
6195278|NCT01452529|9853809|FG002|Run-in Period|Lost to Follow-up|0
6195279|NCT01452529|9853807|FG000|Run-in Period|Lack of Efficacy|46
6195280|NCT01452529|9853808|FG001|Run-in Period|Lack of Efficacy|0
6195281|NCT01452529|9853809|FG002|Run-in Period|Lack of Efficacy|0
6195282|NCT01452529|9853807|FG000|Run-in Period|Confirmed or suspected diversion|23
6195283|NCT01452529|9853808|FG001|Run-in Period|Confirmed or suspected diversion|0
6088338|NCT00674362|9699060|FG000|Double Blind|Other: Loss of Patient Compliance|0
6195284|NCT01452529|9853809|FG002|Run-in Period|Confirmed or suspected diversion|0
6195285|NCT01452529|9853807|FG000|Run-in Period|Administrative|21
6195286|NCT01452529|9853808|FG001|Run-in Period|Administrative|0
6195287|NCT01452529|9853809|FG002|Run-in Period|Administrative|0
6195288|NCT01452529|9853807|FG000|Run-in Period|Did not qualify for Double-Blind Phase|59
6195289|NCT01452529|9853808|FG001|Run-in Period|Did not qualify for Double-Blind Phase|0
6195290|NCT01452529|9853809|FG002|Run-in Period|Did not qualify for Double-Blind Phase|0
6195291|NCT01452529|9853807|FG000|Double-blind (DB) Period|Adverse Event|0
6195292|NCT01452529|9853808|FG001|Double-blind (DB) Period|Adverse Event|18
6195293|NCT01452529|9853809|FG002|Double-blind (DB) Period|Adverse Event|11
6195294|NCT01452529|9853807|FG000|Double-blind (DB) Period|Withdrawal by Subject|0
6195295|NCT01452529|9853808|FG001|Double-blind (DB) Period|Withdrawal by Subject|15
6195296|NCT01452529|9853809|FG002|Double-blind (DB) Period|Withdrawal by Subject|14
6195297|NCT01452529|9853807|FG000|Double-blind (DB) Period|Lost to Follow-up|0
6195298|NCT01452529|9853808|FG001|Double-blind (DB) Period|Lost to Follow-up|5
6195299|NCT01452529|9853809|FG002|Double-blind (DB) Period|Lost to Follow-up|3
6195300|NCT01452529|9853807|FG000|Double-blind (DB) Period|Lack of Efficacy|0
6195301|NCT01452529|9853808|FG001|Double-blind (DB) Period|Lack of Efficacy|16
6195302|NCT01452529|9853809|FG002|Double-blind (DB) Period|Lack of Efficacy|44
6195303|NCT01452529|9853807|FG000|Double-blind (DB) Period|Confirmed or suspected diversion|0
6195304|NCT01452529|9853808|FG001|Double-blind (DB) Period|Confirmed or suspected diversion|2
6195305|NCT01452529|9853809|FG002|Double-blind (DB) Period|Confirmed or suspected diversion|3
6195306|NCT01452529|9853807|FG000|Double-blind (DB) Period|Administrative|0
6195307|NCT01452529|9853808|FG001|Double-blind (DB) Period|Administrative|11
6195308|NCT01452529|9853809|FG002|Double-blind (DB) Period|Administrative|7
6195309|NCT01452789|9853818|FG000|Overall Study|Withdrawal by Subject|3
6195310|NCT01452789|9853819|FG001|Overall Study|Withdrawal by Subject|2
6195311|NCT01452919|9853825|FG000|Open-Label Treatment|Adverse Event|5
6195312|NCT01452919|9853826|FG001|Open-Label Treatment|Adverse Event|0
6195313|NCT01452919|9853827|FG002|Open-Label Treatment|Adverse Event|0
6195314|NCT01452919|9853825|FG000|Open-Label Treatment|Lost to Follow-up|4
6195315|NCT01452919|9853826|FG001|Open-Label Treatment|Lost to Follow-up|0
6195316|NCT01452919|9853827|FG002|Open-Label Treatment|Lost to Follow-up|0
6195317|NCT01452919|9853825|FG000|Open-Label Treatment|Perceived lack of efficacy|3
6195318|NCT01452919|9853826|FG001|Open-Label Treatment|Perceived lack of efficacy|0
6195319|NCT01452919|9853827|FG002|Open-Label Treatment|Perceived lack of efficacy|0
6195320|NCT01452919|9853825|FG000|Open-Label Treatment|Protocol Violation|4
6195321|NCT01452919|9853826|FG001|Open-Label Treatment|Protocol Violation|0
6195322|NCT01452919|9853827|FG002|Open-Label Treatment|Protocol Violation|0
6195323|NCT01452919|9853825|FG000|Open-Label Treatment|Sponsor Decision|1
6195324|NCT01452919|9853826|FG001|Open-Label Treatment|Sponsor Decision|0
6195325|NCT01452919|9853827|FG002|Open-Label Treatment|Sponsor Decision|0
6195326|NCT01452919|9853825|FG000|Open-Label Treatment|Withdrawal by Subject|2
6195327|NCT01452919|9853826|FG001|Open-Label Treatment|Withdrawal by Subject|0
6195328|NCT01452919|9853827|FG002|Open-Label Treatment|Withdrawal by Subject|0
6195329|NCT01452919|9853825|FG000|Open-Label Treatment|Subject is moving or has moved|1
6195330|NCT01452919|9853826|FG001|Open-Label Treatment|Subject is moving or has moved|0
6274199|NCT02202551|9978539|FG003|Overall Study|Death|1
6274200|NCT02202551|9978536|FG000|Overall Study|Lost to Follow-up|0
6274201|NCT02202551|9978537|FG001|Overall Study|Lost to Follow-up|1
6274202|NCT02202551|9978538|FG002|Overall Study|Lost to Follow-up|0
6274203|NCT02202551|9978539|FG003|Overall Study|Lost to Follow-up|1
6274204|NCT02202551|9978536|FG000|Overall Study|Needed to take excluded medication|0
5976625|NCT02306122|9563453|FG009|Initial Physician Randomization|Physician Decision|0
6195331|NCT01452919|9853827|FG002|Open-Label Treatment|Subject is moving or has moved|0
6195332|NCT01452919|9853825|FG000|Randomization Treatment|Adverse Event|0
6195333|NCT01452919|9853826|FG001|Randomization Treatment|Adverse Event|0
6195334|NCT01452919|9853827|FG002|Randomization Treatment|Adverse Event|2
6195335|NCT01452919|9853825|FG000|Randomization Treatment|Sponsor Decision|0
6195336|NCT01452919|9853826|FG001|Randomization Treatment|Sponsor Decision|1
6195337|NCT01452919|9853827|FG002|Randomization Treatment|Sponsor Decision|0
6195338|NCT01452919|9853825|FG000|Randomization Treatment|Withdrawal by Subject|0
6195339|NCT01452919|9853826|FG001|Randomization Treatment|Withdrawal by Subject|1
6195340|NCT01452919|9853827|FG002|Randomization Treatment|Withdrawal by Subject|0
6195341|NCT01452919|9853825|FG000|Randomization Treatment|Subject is moving or has moved|0
6195342|NCT01452919|9853826|FG001|Randomization Treatment|Subject is moving or has moved|1
6195343|NCT01452919|9853827|FG002|Randomization Treatment|Subject is moving or has moved|0
6195344|NCT01453023|9853837|FG000|Treatment Period (TP) 1|Protocol Violation|1
6195345|NCT01453023|9853838|FG001|Treatment Period (TP) 1|Protocol Violation|0
6195346|NCT01453023|9853837|FG000|Treatment Period (TP) 1|Met Protocol-defined Stopping Criteria|0
6195347|NCT01453023|9853838|FG001|Treatment Period (TP) 1|Met Protocol-defined Stopping Criteria|1
6195348|NCT01453023|9853837|FG000|Treatment Period 2|Protocol Violation|0
6195349|NCT01453023|9853838|FG001|Treatment Period 2|Protocol Violation|1
6195350|NCT01453036|9853847|FG000|Overall Study|Lost to Follow-up|26
6195351|NCT01453036|9853848|FG001|Overall Study|Lost to Follow-up|115
6274205|NCT02202551|9978537|FG001|Overall Study|Needed to take excluded medication|2
6274206|NCT02202551|9978538|FG002|Overall Study|Needed to take excluded medication|0
6274207|NCT02202551|9978539|FG003|Overall Study|Needed to take excluded medication|1
6274208|NCT02202551|9978536|FG000|Overall Study|Subject moved away|0
6274209|NCT02202551|9978537|FG001|Overall Study|Subject moved away|1
6274210|NCT02202551|9978538|FG002|Overall Study|Subject moved away|0
6274211|NCT02202551|9978539|FG003|Overall Study|Subject moved away|0
6274212|NCT02202551|9978536|FG000|Overall Study|DBS surgery|3
6274213|NCT02202551|9978537|FG001|Overall Study|DBS surgery|0
6274214|NCT02202551|9978538|FG002|Overall Study|DBS surgery|0
6274215|NCT02202551|9978539|FG003|Overall Study|DBS surgery|0
6274216|NCT02202551|9978536|FG000|Overall Study|Dyskinesia upon taper|1
6274217|NCT02202551|9978537|FG001|Overall Study|Dyskinesia upon taper|0
6274218|NCT02202551|9978538|FG002|Overall Study|Dyskinesia upon taper|0
6274219|NCT02202551|9978539|FG003|Overall Study|Dyskinesia upon taper|0
6274220|NCT02202551|9978536|FG000|Overall Study|Lack of Efficacy|0
6274221|NCT02202551|9978537|FG001|Overall Study|Lack of Efficacy|1
6274222|NCT02202551|9978538|FG002|Overall Study|Lack of Efficacy|0
6274223|NCT02202551|9978539|FG003|Overall Study|Lack of Efficacy|0
6274224|NCT02202551|9978536|FG000|Overall Study|Physician Decision|1
6274225|NCT02202551|9978537|FG001|Overall Study|Physician Decision|0
6274226|NCT02202551|9978538|FG002|Overall Study|Physician Decision|0
6274227|NCT02202551|9978539|FG003|Overall Study|Physician Decision|0
6274228|NCT02202551|9978536|FG000|Overall Study|Site closure|3
6274229|NCT02202551|9978537|FG001|Overall Study|Site closure|0
6274230|NCT02202551|9978538|FG002|Overall Study|Site closure|0
6274231|NCT02202551|9978539|FG003|Overall Study|Site closure|1
6274232|NCT02202551|9978536|FG000|Overall Study|Unable to complete visits per protocol|1
6274233|NCT02202551|9978537|FG001|Overall Study|Unable to complete visits per protocol|0
6274234|NCT02202551|9978538|FG002|Overall Study|Unable to complete visits per protocol|0
6274235|NCT02202551|9978539|FG003|Overall Study|Unable to complete visits per protocol|0
6274236|NCT02202551|9978536|FG000|Overall Study|Worsening Dyskinesia|0
6195352|NCT01453036|9853849|FG002|Overall Study|Lost to Follow-up|31
6195353|NCT01453049|9853859|FG000|Overall Study|Protocol Violation|2
6195354|NCT01453049|9853860|FG001|Overall Study|Protocol Violation|5
6195355|NCT01453049|9853859|FG000|Overall Study|Lost to Follow-up|2
6195356|NCT01453049|9853860|FG001|Overall Study|Lost to Follow-up|1
6195357|NCT01453049|9853859|FG000|Overall Study|Withdrawn When Sponsor Terminated Study|35
6195358|NCT01453049|9853860|FG001|Overall Study|Withdrawn When Sponsor Terminated Study|36
6195359|NCT01453049|9853859|FG000|Overall Study|Withdrawal by Subject|1
6195360|NCT01453049|9853860|FG001|Overall Study|Withdrawal by Subject|0
6195361|NCT01453049|9853859|FG000|Overall Study|Randomized in Error|1
6195362|NCT01453049|9853860|FG001|Overall Study|Randomized in Error|0
6195363|NCT01453153|9853878|FG000|Overall Study|Physician Decision|0
6195364|NCT01453153|9853879|FG001|Overall Study|Physician Decision|0
6195365|NCT01453153|9853880|FG002|Overall Study|Physician Decision|1
6195366|NCT01453153|9853878|FG000|Overall Study|Progressive Disease|3
6195367|NCT01453153|9853879|FG001|Overall Study|Progressive Disease|2
6195368|NCT01453153|9853880|FG002|Overall Study|Progressive Disease|16
6195369|NCT01453153|9853878|FG000|Overall Study|Withdrawal by Subject|0
6274237|NCT02202551|9978537|FG001|Overall Study|Worsening Dyskinesia|0
6274238|NCT02202551|9978538|FG002|Overall Study|Worsening Dyskinesia|0
6274239|NCT02202551|9978539|FG003|Overall Study|Worsening Dyskinesia|1
6274240|NCT02202551|9978536|FG000|Overall Study|Protocol Violation|0
6274241|NCT02202551|9978537|FG001|Overall Study|Protocol Violation|1
6274242|NCT02202551|9978538|FG002|Overall Study|Protocol Violation|0
6274243|NCT02202551|9978539|FG003|Overall Study|Protocol Violation|0
6274244|NCT02202551|9978536|FG000|Overall Study|Sponsor's decision|2
6274245|NCT02202551|9978537|FG001|Overall Study|Sponsor's decision|0
6274246|NCT02202551|9978538|FG002|Overall Study|Sponsor's decision|0
6274247|NCT02202551|9978539|FG003|Overall Study|Sponsor's decision|0
6274248|NCT02202551|9978536|FG000|Overall Study|Subject unwilling to proceed|1
6274249|NCT02202551|9978537|FG001|Overall Study|Subject unwilling to proceed|5
6274250|NCT02202551|9978538|FG002|Overall Study|Subject unwilling to proceed|3
6274251|NCT02202551|9978539|FG003|Overall Study|Subject unwilling to proceed|5
6274252|NCT02202551|9978536|FG000|Overall Study|Subject consent withdrawn|0
6274253|NCT02202551|9978537|FG001|Overall Study|Subject consent withdrawn|3
6274254|NCT02202551|9978538|FG002|Overall Study|Subject consent withdrawn|1
6274255|NCT02202551|9978539|FG003|Overall Study|Subject consent withdrawn|2
6274256|NCT02202551|9978536|FG000|Overall Study|eGFR<50mL/min/m2|2
6274257|NCT02202551|9978537|FG001|Overall Study|eGFR<50mL/min/m2|2
6274258|NCT02202551|9978538|FG002|Overall Study|eGFR<50mL/min/m2|0
6274259|NCT02202551|9978539|FG003|Overall Study|eGFR<50mL/min/m2|1
6274260|NCT02202616|9978553|FG000|Overall Study|Screen failed|24
6274261|NCT02202616|9978553|FG000|Overall Study|Adverse Event|32
6274262|NCT02202616|9978553|FG000|Overall Study|Protocol deviation|18
6274263|NCT02202616|9978553|FG000|Overall Study|Patient withdrew consent|12
6274264|NCT02202616|9978553|FG000|Overall Study|Lost to Follow-up|6
6274265|NCT02202616|9978553|FG000|Overall Study|Administrative problems|6
6274266|NCT02202616|9978553|FG000|Overall Study|Abnormal test procedure result|1
6274267|NCT02202616|9978553|FG000|Overall Study|Unsatisfactory therapeutic effect|1
6274268|NCT02202759|9978573|FG000|Overall Study|Study Terminated by Sponsor|3
6274269|NCT02202759|9978574|FG001|Overall Study|Study Terminated by Sponsor|3
6274270|NCT02202759|9978575|FG002|Overall Study|Study Terminated by Sponsor|3
6274271|NCT02202759|9978573|FG000|Overall Study|Withdrawal by Subject|2
6274272|NCT02202759|9978574|FG001|Overall Study|Withdrawal by Subject|1
6274273|NCT02202759|9978575|FG002|Overall Study|Withdrawal by Subject|1
6274274|NCT02202759|9978573|FG000|Overall Study|Reason not Specified|4
6274275|NCT02202759|9978574|FG001|Overall Study|Reason not Specified|11
6274276|NCT02202759|9978575|FG002|Overall Study|Reason not Specified|10
6274277|NCT02202785|9978585|FG000|Overall Study|Study Terminated by Sponsor|1
6274278|NCT02202785|9978586|FG001|Overall Study|Study Terminated by Sponsor|6
6274279|NCT02202785|9978587|FG002|Overall Study|Study Terminated by Sponsor|4
6274280|NCT02202785|9978585|FG000|Overall Study|Withdrawal by Subject|0
6274281|NCT02202785|9978586|FG001|Overall Study|Withdrawal by Subject|1
6274282|NCT02202785|9978587|FG002|Overall Study|Withdrawal by Subject|0
6274283|NCT02202785|9978585|FG000|Overall Study|Lost to Follow-up|0
6274284|NCT02202785|9978586|FG001|Overall Study|Lost to Follow-up|1
6274285|NCT02202785|9978587|FG002|Overall Study|Lost to Follow-up|0
6274286|NCT02202785|9978585|FG000|Overall Study|Reason not Specified|10
6274287|NCT02202785|9978586|FG001|Overall Study|Reason not Specified|7
6274288|NCT02202785|9978587|FG002|Overall Study|Reason not Specified|13
6274289|NCT02202837|9978597|FG000|Overall Study|Enbrel treatment discontinued|36
6274290|NCT02202837|9978598|FG001|Overall Study|Enbrel treatment discontinued|4
6274291|NCT02202837|9978597|FG000|Overall Study|Other|10
6274292|NCT02202837|9978598|FG001|Overall Study|Other|0
6274293|NCT02202837|9978597|FG000|Overall Study|Lost to Follow-up|7
6274294|NCT02202837|9978598|FG001|Overall Study|Lost to Follow-up|1
6274295|NCT02202850|9978606|FG000|Overall Study|Other|2
6274296|NCT02202850|9978607|FG001|Overall Study|Other|2
6274297|NCT02202850|9978606|FG000|Overall Study|Enbrel treatment discontinued|15
6274298|NCT02202850|9978607|FG001|Overall Study|Enbrel treatment discontinued|3
6274299|NCT02202850|9978606|FG000|Overall Study|Lost to Follow-up|7
6274300|NCT02202850|9978607|FG001|Overall Study|Lost to Follow-up|1
6274301|NCT02202980|9978627|FG000|Overall Study|Lack of Efficacy|1
6195370|NCT01453153|9853879|FG001|Overall Study|Withdrawal by Subject|1
6195371|NCT01453153|9853880|FG002|Overall Study|Withdrawal by Subject|2
6274302|NCT02202980|9978628|FG001|Overall Study|Lack of Efficacy|0
6195372|NCT01453153|9853878|FG000|Overall Study|Adverse Event|1
6195373|NCT01453153|9853879|FG001|Overall Study|Adverse Event|1
6195374|NCT01453153|9853880|FG002|Overall Study|Adverse Event|1
6195375|NCT01453205|9853908|FG000|Overall Study|Lost to Follow-up|3
6195376|NCT01453205|9853909|FG001|Overall Study|Lost to Follow-up|0
6195377|NCT01453205|9853910|FG002|Overall Study|Lost to Follow-up|1
6195378|NCT01453205|9853908|FG000|Overall Study|Withdrawal by Subject|8
6195379|NCT01453205|9853909|FG001|Overall Study|Withdrawal by Subject|3
6195380|NCT01453205|9853910|FG002|Overall Study|Withdrawal by Subject|0
6195381|NCT01453205|9853908|FG000|Overall Study|Death|24
6195382|NCT01453205|9853909|FG001|Overall Study|Death|22
6195383|NCT01453205|9853910|FG002|Overall Study|Death|18
6195384|NCT01453205|9853908|FG000|Overall Study|Other|45
6088339|NCT00674362|9699061|FG001|Double Blind|Other: Loss of Patient Compliance|1
6195385|NCT01453205|9853909|FG001|Overall Study|Other|27
6195386|NCT01453205|9853910|FG002|Overall Study|Other|35
6195387|NCT01453296|9853921|FG000|Treatment Period 1|Adverse Event|0
6195388|NCT01453296|9853922|FG001|Treatment Period 1|Adverse Event|1
6195389|NCT01453296|9853921|FG000|Treatment Period 1|Met Protocol-Defined Stopping Criteria|1
6195390|NCT01453296|9853922|FG001|Treatment Period 1|Met Protocol-Defined Stopping Criteria|0
6195391|NCT01453296|9853921|FG000|Treatment Period 2|Adverse Event|1
6088340|NCT00674362|9699060|FG000|Double Blind|Other: Surgery|0
6195392|NCT01453296|9853922|FG001|Treatment Period 2|Adverse Event|0
6195393|NCT01453296|9853921|FG000|Treatment Period 2|Withdrawal by Subject|1
6195394|NCT01453296|9853922|FG001|Treatment Period 2|Withdrawal by Subject|0
6195395|NCT01453348|9853931|FG000|Overall Study|Death|0
6195396|NCT01453348|9853932|FG001|Overall Study|Death|0
6195397|NCT01453348|9853933|FG002|Overall Study|Death|1
6195398|NCT01453348|9853931|FG000|Overall Study|Withdrawal by Subject|0
6195399|NCT01453348|9853932|FG001|Overall Study|Withdrawal by Subject|1
6195400|NCT01453348|9853933|FG002|Overall Study|Withdrawal by Subject|0
6195401|NCT01453348|9853931|FG000|Overall Study|Protocol Violation|1
6195402|NCT01453348|9853932|FG001|Overall Study|Protocol Violation|0
6195403|NCT01453348|9853933|FG002|Overall Study|Protocol Violation|0
6195404|NCT01453361|9853944|FG000|Overall Study|Disease Progression|6
6195405|NCT01453361|9853944|FG000|Overall Study|Screen-Failures|10
6195406|NCT01453374|9853948|FG000|Overall Study|Adverse Event|7
6195407|NCT01453374|9853948|FG000|Overall Study|Lack of Efficacy|1
6195408|NCT01453374|9853948|FG000|Overall Study|Lost to Follow-up|3
6195409|NCT01453374|9853948|FG000|Overall Study|Withdrawal by Subject|5
6195410|NCT01453374|9853948|FG000|Overall Study|Incarcerated|2
6195411|NCT01453439|9853986|FG000|Treatment Phase|Withdrawal by Subject|13
6195412|NCT01453439|9853987|FG001|Treatment Phase|Withdrawal by Subject|10
6195413|NCT01453439|9853986|FG000|Treatment Phase|Suicidal Ideation|2
6195414|NCT01453439|9853987|FG001|Treatment Phase|Suicidal Ideation|0
6195415|NCT01453439|9853986|FG000|Treatment Phase|Need for higher level of care|1
6195416|NCT01453439|9853987|FG001|Treatment Phase|Need for higher level of care|1
6195417|NCT01453439|9853986|FG000|Treatment Phase|Therapist conflict of interest|1
6195418|NCT01453439|9853987|FG001|Treatment Phase|Therapist conflict of interest|0
6195419|NCT01453439|9853986|FG000|Follow-up|Withdrawal by Subject|0
6195420|NCT01453439|9853987|FG001|Follow-up|Withdrawal by Subject|1
6195421|NCT01453439|9853986|FG000|Follow-up|Lost to Follow-up|5
6195422|NCT01453439|9853987|FG001|Follow-up|Lost to Follow-up|10
6195423|NCT01453595|9854009|FG000|Overall Study|Dose Limiting Toxicity (DLT)|2
6195424|NCT01453595|9854010|FG001|Overall Study|Dose Limiting Toxicity (DLT)|1
6195425|NCT01453595|9854011|FG002|Overall Study|Dose Limiting Toxicity (DLT)|2
6195426|NCT01453725|9854019|FG000|Overall Study|Adverse Event|3
6195427|NCT01453725|9854020|FG001|Overall Study|Adverse Event|3
6195428|NCT01453725|9854019|FG000|Overall Study|Lost to Follow-up|4
6195429|NCT01453725|9854020|FG001|Overall Study|Lost to Follow-up|0
6195430|NCT01453725|9854019|FG000|Overall Study|Non-compliance With Protocol|1
6195431|NCT01453725|9854020|FG001|Overall Study|Non-compliance With Protocol|2
6195432|NCT01453725|9854019|FG000|Overall Study|Protocol Violation|1
6195433|NCT01453725|9854020|FG001|Overall Study|Protocol Violation|0
6195434|NCT01453725|9854019|FG000|Overall Study|Withdrawal by Subject|2
6195435|NCT01453725|9854020|FG001|Overall Study|Withdrawal by Subject|3
6195436|NCT01453725|9854019|FG000|Overall Study|Pregnancy Wish|0
6195437|NCT01453725|9854020|FG001|Overall Study|Pregnancy Wish|2
6195438|NCT01453725|9854019|FG000|Overall Study|Pregnancy|1
6195439|NCT01453725|9854020|FG001|Overall Study|Pregnancy|0
6195440|NCT01453725|9854019|FG000|Overall Study|Physician Decision|1
6195441|NCT01453725|9854020|FG001|Overall Study|Physician Decision|1
6195442|NCT01453855|9854030|FG000|Overall Study|Adverse Event|3
6195443|NCT01453855|9854031|FG001|Overall Study|Adverse Event|4
6195444|NCT01453855|9854030|FG000|Overall Study|Lost to Follow-up|2
6274303|NCT02202980|9978629|FG002|Overall Study|Lack of Efficacy|7
6274304|NCT02202980|9978630|FG003|Overall Study|Lack of Efficacy|0
6195445|NCT01453855|9854031|FG001|Overall Study|Lost to Follow-up|1
6195446|NCT01453855|9854030|FG000|Overall Study|Patient Decision Unrel to Adverse Event|3
6088341|NCT00674362|9699061|FG001|Double Blind|Other: Surgery|1
6195447|NCT01453855|9854031|FG001|Overall Study|Patient Decision Unrel to Adverse Event|3
6195448|NCT01453855|9854030|FG000|Overall Study|Noncompliance|1
6195449|NCT01453855|9854031|FG001|Overall Study|Noncompliance|0
6195450|NCT01453855|9854030|FG000|Overall Study|Inadequate Control of IOP|1
6195451|NCT01453855|9854031|FG001|Overall Study|Inadequate Control of IOP|5
6195452|NCT01453855|9854030|FG000|Overall Study|Other|0
6195453|NCT01453855|9854031|FG001|Overall Study|Other|1
6195454|NCT01453998|9854049|FG000|After Protocol Amendment 2.|Withdrawal by Subject|1
6195455|NCT01453998|9854050|FG001|After Protocol Amendment 2.|Withdrawal by Subject|0
6195456|NCT01453998|9854051|FG002|After Protocol Amendment 2.|Withdrawal by Subject|0
6195457|NCT01454063|9854064|FG000|Randomized|Adverse Event|1
6195458|NCT01454063|9854065|FG001|Randomized|Adverse Event|1
6195459|NCT01454063|9854064|FG000|Randomized|Protocol Violation|0
6195460|NCT01454063|9854065|FG001|Randomized|Protocol Violation|1
6195461|NCT01454076|9854076|FG000|Overall Study|Other|2
6195462|NCT01454076|9854077|FG001|Overall Study|Other|0
6195463|NCT01454076|9854078|FG002|Overall Study|Other|0
6195464|NCT01454076|9854079|FG003|Overall Study|Other|1
6195465|NCT01454076|9854080|FG004|Overall Study|Other|2
6195466|NCT01454076|9854076|FG000|Overall Study|Withdrawal by Subject|3
6195467|NCT01454076|9854077|FG001|Overall Study|Withdrawal by Subject|4
6195468|NCT01454076|9854078|FG002|Overall Study|Withdrawal by Subject|2
6195469|NCT01454076|9854079|FG003|Overall Study|Withdrawal by Subject|1
6195470|NCT01454076|9854080|FG004|Overall Study|Withdrawal by Subject|2
6195471|NCT01454076|9854076|FG000|Overall Study|Adverse Event|8
6195472|NCT01454076|9854077|FG001|Overall Study|Adverse Event|2
6195473|NCT01454076|9854078|FG002|Overall Study|Adverse Event|7
6195474|NCT01454076|9854079|FG003|Overall Study|Adverse Event|0
6195475|NCT01454076|9854080|FG004|Overall Study|Adverse Event|2
6195476|NCT01454102|9854117|FG000|Overall Study|Continuing in the treatment period|0
6195477|NCT01454102|9854118|FG001|Overall Study|Continuing in the treatment period|0
6195478|NCT01454102|9854119|FG002|Overall Study|Continuing in the treatment period|0
6195479|NCT01454102|9854120|FG003|Overall Study|Continuing in the treatment period|0
6195480|NCT01454102|9854121|FG004|Overall Study|Continuing in the treatment period|3
6195481|NCT01454102|9854122|FG005|Overall Study|Continuing in the treatment period|3
6195482|NCT01454102|9854123|FG006|Overall Study|Continuing in the treatment period|2
6195483|NCT01454102|9854124|FG007|Overall Study|Continuing in the treatment period|0
6195484|NCT01454102|9854125|FG008|Overall Study|Continuing in the treatment period|1
6195485|NCT01454102|9854126|FG009|Overall Study|Continuing in the treatment period|0
6195486|NCT01454102|9854127|FG010|Overall Study|Continuing in the treatment period|0
6195487|NCT01454102|9854128|FG011|Overall Study|Continuing in the treatment period|4
6195488|NCT01454102|9854129|FG012|Overall Study|Continuing in the treatment period|7
6195489|NCT01454102|9854130|FG013|Overall Study|Continuing in the treatment period|4
6195490|NCT01454102|9854131|FG014|Overall Study|Continuing in the treatment period|3
6195491|NCT01454102|9854132|FG015|Overall Study|Continuing in the treatment period|1
6195492|NCT01454284|9854175|FG000|Overall Study|Adverse Event|20
6195493|NCT01454284|9854176|FG001|Overall Study|Adverse Event|7
6195494|NCT01454284|9854175|FG000|Overall Study|Death|0
6195495|NCT01454284|9854176|FG001|Overall Study|Death|3
6274305|NCT02202980|9978631|FG004|Overall Study|Lack of Efficacy|3
6274306|NCT02202980|9978632|FG005|Overall Study|Lack of Efficacy|1
6274307|NCT02202980|9978633|FG006|Overall Study|Lack of Efficacy|11
6274308|NCT02202980|9978634|FG007|Overall Study|Lack of Efficacy|2
6274309|NCT02202980|9978635|FG008|Overall Study|Lack of Efficacy|2
6274310|NCT02202980|9978636|FG009|Overall Study|Lack of Efficacy|0
6274311|NCT02202980|9978637|FG010|Overall Study|Lack of Efficacy|0
6274312|NCT02202980|9978638|FG011|Overall Study|Lack of Efficacy|3
6274313|NCT02202980|9978639|FG012|Overall Study|Lack of Efficacy|10
6274314|NCT02202980|9978640|FG013|Overall Study|Lack of Efficacy|0
6274315|NCT02202980|9978627|FG000|Overall Study|Protocol Violation|0
6274316|NCT02202980|9978628|FG001|Overall Study|Protocol Violation|0
6274317|NCT02202980|9978629|FG002|Overall Study|Protocol Violation|0
6274318|NCT02202980|9978630|FG003|Overall Study|Protocol Violation|3
6274319|NCT02202980|9978631|FG004|Overall Study|Protocol Violation|3
6274320|NCT02202980|9978632|FG005|Overall Study|Protocol Violation|0
6195496|NCT01454284|9854175|FG000|Overall Study|Lost to Follow-up|13
6195497|NCT01454284|9854176|FG001|Overall Study|Lost to Follow-up|8
6195498|NCT01454284|9854175|FG000|Overall Study|Protocol Violation|9
6195499|NCT01454284|9854176|FG001|Overall Study|Protocol Violation|6
6195500|NCT01454284|9854175|FG000|Overall Study|Withdrawal by Subject|58
6195501|NCT01454284|9854176|FG001|Overall Study|Withdrawal by Subject|36
6195502|NCT01454284|9854175|FG000|Overall Study|Physician Decision|16
6195503|NCT01454284|9854176|FG001|Overall Study|Physician Decision|11
6274321|NCT02202980|9978633|FG006|Overall Study|Protocol Violation|0
6274322|NCT02202980|9978634|FG007|Overall Study|Protocol Violation|0
6274323|NCT02202980|9978635|FG008|Overall Study|Protocol Violation|0
6274324|NCT02202980|9978636|FG009|Overall Study|Protocol Violation|0
6195504|NCT01454284|9854175|FG000|Overall Study|Sponsor Decision|0
6195505|NCT01454284|9854176|FG001|Overall Study|Sponsor Decision|2
6195506|NCT01454401|9854193|FG000|Overall Study|Death|1
6195507|NCT01454401|9854193|FG000|Overall Study|hospitalised|1
6195508|NCT01454401|9854193|FG000|Overall Study|osteomyelitis|2
6274325|NCT02202980|9978637|FG010|Overall Study|Protocol Violation|0
6274326|NCT02202980|9978638|FG011|Overall Study|Protocol Violation|0
6274327|NCT02202980|9978639|FG012|Overall Study|Protocol Violation|0
6274328|NCT02202980|9978640|FG013|Overall Study|Protocol Violation|0
6274329|NCT02202980|9978627|FG000|Overall Study|Lost to Follow-up|0
6274330|NCT02202980|9978628|FG001|Overall Study|Lost to Follow-up|1
6274331|NCT02202980|9978629|FG002|Overall Study|Lost to Follow-up|1
6274332|NCT02202980|9978630|FG003|Overall Study|Lost to Follow-up|1
6274333|NCT02202980|9978631|FG004|Overall Study|Lost to Follow-up|0
6274334|NCT02202980|9978632|FG005|Overall Study|Lost to Follow-up|0
6274335|NCT02202980|9978633|FG006|Overall Study|Lost to Follow-up|0
6274336|NCT02202980|9978634|FG007|Overall Study|Lost to Follow-up|1
6274337|NCT02202980|9978635|FG008|Overall Study|Lost to Follow-up|1
6274338|NCT02202980|9978636|FG009|Overall Study|Lost to Follow-up|0
6274339|NCT02202980|9978637|FG010|Overall Study|Lost to Follow-up|0
6274340|NCT02202980|9978638|FG011|Overall Study|Lost to Follow-up|0
6274341|NCT02202980|9978639|FG012|Overall Study|Lost to Follow-up|1
6274342|NCT02202980|9978640|FG013|Overall Study|Lost to Follow-up|0
6274343|NCT02202980|9978627|FG000|Overall Study|Withdrew Consent|0
6274344|NCT02202980|9978628|FG001|Overall Study|Withdrew Consent|1
6274345|NCT02202980|9978629|FG002|Overall Study|Withdrew Consent|2
6274346|NCT02202980|9978630|FG003|Overall Study|Withdrew Consent|0
6274347|NCT02202980|9978631|FG004|Overall Study|Withdrew Consent|0
6274348|NCT02202980|9978632|FG005|Overall Study|Withdrew Consent|0
6274349|NCT02202980|9978633|FG006|Overall Study|Withdrew Consent|0
6274350|NCT02202980|9978634|FG007|Overall Study|Withdrew Consent|0
6274351|NCT02202980|9978635|FG008|Overall Study|Withdrew Consent|1
6274352|NCT02202980|9978636|FG009|Overall Study|Withdrew Consent|0
6274353|NCT02202980|9978637|FG010|Overall Study|Withdrew Consent|0
6274354|NCT02202980|9978638|FG011|Overall Study|Withdrew Consent|0
6274355|NCT02202980|9978639|FG012|Overall Study|Withdrew Consent|0
6274356|NCT02202980|9978640|FG013|Overall Study|Withdrew Consent|0
6274357|NCT02203032|9978679|FG000|Open Label Run-in (Week 0 to Week 16)|Adverse Event|2
6274358|NCT02203032|9978680|FG001|Open Label Run-in (Week 0 to Week 16)|Adverse Event|0
6274359|NCT02203032|9978681|FG002|Open Label Run-in (Week 0 to Week 16)|Adverse Event|0
6274360|NCT02203032|9978682|FG003|Open Label Run-in (Week 0 to Week 16)|Adverse Event|0
6274361|NCT02203032|9978679|FG000|Open Label Run-in (Week 0 to Week 16)|Lack of Efficacy|1
6274362|NCT02203032|9978680|FG001|Open Label Run-in (Week 0 to Week 16)|Lack of Efficacy|0
6274363|NCT02203032|9978681|FG002|Open Label Run-in (Week 0 to Week 16)|Lack of Efficacy|0
6274364|NCT02203032|9978682|FG003|Open Label Run-in (Week 0 to Week 16)|Lack of Efficacy|0
6274365|NCT02203032|9978679|FG000|Open Label Run-in (Week 0 to Week 16)|Lost to Follow-up|3
6274366|NCT02203032|9978680|FG001|Open Label Run-in (Week 0 to Week 16)|Lost to Follow-up|0
6274367|NCT02203032|9978681|FG002|Open Label Run-in (Week 0 to Week 16)|Lost to Follow-up|0
6274368|NCT02203032|9978682|FG003|Open Label Run-in (Week 0 to Week 16)|Lost to Follow-up|0
6274369|NCT02203032|9978679|FG000|Open Label Run-in (Week 0 to Week 16)|Withdrawal by Subject|6
6274370|NCT02203032|9978680|FG001|Open Label Run-in (Week 0 to Week 16)|Withdrawal by Subject|0
6274371|NCT02203032|9978681|FG002|Open Label Run-in (Week 0 to Week 16)|Withdrawal by Subject|0
6274372|NCT02203032|9978682|FG003|Open Label Run-in (Week 0 to Week 16)|Withdrawal by Subject|0
6274373|NCT02203032|9978679|FG000|Open Label Run-in (Week 0 to Week 16)|Protocol Violation|4
6274374|NCT02203032|9978680|FG001|Open Label Run-in (Week 0 to Week 16)|Protocol Violation|0
6274375|NCT02203032|9978681|FG002|Open Label Run-in (Week 0 to Week 16)|Protocol Violation|0
6274376|NCT02203032|9978682|FG003|Open Label Run-in (Week 0 to Week 16)|Protocol Violation|0
6274377|NCT02203032|9978679|FG000|Open Label Run-in (Week 0 to Week 16)|Other|2
6274378|NCT02203032|9978680|FG001|Open Label Run-in (Week 0 to Week 16)|Other|0
6274379|NCT02203032|9978681|FG002|Open Label Run-in (Week 0 to Week 16)|Other|0
6274380|NCT02203032|9978682|FG003|Open Label Run-in (Week 0 to Week 16)|Other|0
6274381|NCT02203032|9978679|FG000|Open Label Run-in (Week 0 to Week 16)|Enrolled but not treated|1
6274382|NCT02203032|9978680|FG001|Open Label Run-in (Week 0 to Week 16)|Enrolled but not treated|0
6274383|NCT02203032|9978681|FG002|Open Label Run-in (Week 0 to Week 16)|Enrolled but not treated|0
6274384|NCT02203032|9978682|FG003|Open Label Run-in (Week 0 to Week 16)|Enrolled but not treated|0
6274385|NCT02203032|9978679|FG000|Blinded Phase (Week 16 to Week 44)|Lost to Follow-up|0
6274386|NCT02203032|9978680|FG001|Blinded Phase (Week 16 to Week 44)|Lost to Follow-up|2
6274387|NCT02203032|9978681|FG002|Blinded Phase (Week 16 to Week 44)|Lost to Follow-up|3
6274388|NCT02203032|9978682|FG003|Blinded Phase (Week 16 to Week 44)|Lost to Follow-up|8
6274389|NCT02203032|9978679|FG000|Blinded Phase (Week 16 to Week 44)|Withdrawal by Subject|0
6274390|NCT02203032|9978680|FG001|Blinded Phase (Week 16 to Week 44)|Withdrawal by Subject|8
6274391|NCT02203032|9978681|FG002|Blinded Phase (Week 16 to Week 44)|Withdrawal by Subject|19
6195509|NCT01454401|9854193|FG000|Overall Study|non-adherence|1
6195510|NCT01454531|9854222|FG000|Overall Study|Adverse Event|14
6195511|NCT01454531|9854222|FG000|Overall Study|Withdrawal by Subject|5
6195512|NCT01454531|9854222|FG000|Overall Study|Lost to Follow-up|1
6195513|NCT01454531|9854222|FG000|Overall Study|Physician Decision|1
6195514|NCT01454531|9854222|FG000|Overall Study|Delay in IMP administration|1
6195515|NCT01454531|9854222|FG000|Overall Study|Other|1
6195516|NCT01454570|9854226|FG000|Overall Study|Withdrawal by Subject|2
6195517|NCT01454570|9854226|FG000|Overall Study|Screen Failure|7
6195518|NCT01454583|9854233|FG000|1st Year|Lost to Follow-up|1057
6195519|NCT01454583|9854234|FG001|1st Year|Lost to Follow-up|318
6195520|NCT01454583|9854235|FG002|1st Year|Lost to Follow-up|180
6088342|NCT00674362|9699060|FG000|Open Label|Adverse Event|1
6088343|NCT00674362|9699061|FG001|Open Label|Adverse Event|0
6195521|NCT01454583|9854233|FG000|2nd Year|Lost to Follow-up|3965
6195522|NCT01454583|9854234|FG001|2nd Year|Lost to Follow-up|1049
6195523|NCT01454583|9854235|FG002|2nd Year|Lost to Follow-up|737
6195524|NCT01454583|9854233|FG000|3rd Year|Lost to Follow-up|1959
6195525|NCT01454583|9854234|FG001|3rd Year|Lost to Follow-up|512
6195526|NCT01454583|9854235|FG002|3rd Year|Lost to Follow-up|297
6195527|NCT01454596|9854255|FG000|Overall Study|Death|0
6195528|NCT01454596|9854256|FG001|Overall Study|Death|0
6195529|NCT01454596|9854257|FG002|Overall Study|Death|0
6195530|NCT01454596|9854258|FG003|Overall Study|Death|0
6195531|NCT01454596|9854259|FG004|Overall Study|Death|0
6195532|NCT01454596|9854260|FG005|Overall Study|Death|0
6195533|NCT01454596|9854261|FG006|Overall Study|Death|0
6195534|NCT01454596|9854262|FG007|Overall Study|Death|0
6195535|NCT01454596|9854263|FG008|Overall Study|Death|0
6195536|NCT01454596|9854264|FG009|Overall Study|Death|1
6195537|NCT01454596|9854265|FG010|Overall Study|Death|1
6195538|NCT01454596|9854266|FG011|Overall Study|Death|0
6195539|NCT01454726|9854294|FG000|Overall Study|Withdrawal by Subject|0
6195540|NCT01454726|9854295|FG001|Overall Study|Withdrawal by Subject|1
6195541|NCT01454739|9854303|FG000|Overall Study|Protocol Violation|2
6195542|NCT01454739|9854304|FG001|Overall Study|Protocol Violation|3
6195543|NCT01454739|9854303|FG000|Overall Study|Withdrawal by Subject|2
6195544|NCT01454739|9854304|FG001|Overall Study|Withdrawal by Subject|6
6195545|NCT01454739|9854303|FG000|Overall Study|Other|3
6195546|NCT01454739|9854304|FG001|Overall Study|Other|5
6195547|NCT01454739|9854303|FG000|Overall Study|Physician Decision|0
6195548|NCT01454739|9854304|FG001|Overall Study|Physician Decision|5
6195549|NCT01454739|9854303|FG000|Overall Study|Lost to Follow-up|0
6195550|NCT01454739|9854304|FG001|Overall Study|Lost to Follow-up|1
6195551|NCT01454739|9854303|FG000|Overall Study|Adverse Event|0
6195552|NCT01454739|9854304|FG001|Overall Study|Adverse Event|1
6195553|NCT01454778|9854317|FG000|Overall Study|Lost to Follow-up|2
6195554|NCT01454778|9854317|FG000|Overall Study|Death|1
6195555|NCT01454830|9854334|FG000|Overall Study|Withdrawal by Subject|4
6195556|NCT01454830|9854335|FG001|Overall Study|Withdrawal by Subject|4
6195557|NCT01454830|9854334|FG000|Overall Study|Post-allocation Exclude- AHI<10|18
6195558|NCT01454830|9854335|FG001|Overall Study|Post-allocation Exclude- AHI<10|12
6195559|NCT01454830|9854334|FG000|Overall Study|Post-allocation Exclude-refused PAP|0
6195560|NCT01454830|9854335|FG001|Overall Study|Post-allocation Exclude-refused PAP|2
6195561|NCT01454830|9854334|FG000|Overall Study|Post-allocation Exclude-other treatment|6
6195562|NCT01454830|9854335|FG001|Overall Study|Post-allocation Exclude-other treatment|7
6195563|NCT01454830|9854334|FG000|Overall Study|Withdrawal - no polysomnography|3
6195564|NCT01454830|9854335|FG001|Overall Study|Withdrawal - no polysomnography|2
6195565|NCT01454934|9854343|FG000|Overall Study|Clinical progression|28
6195566|NCT01454934|9854344|FG001|Overall Study|Clinical progression|25
6088344|NCT00674362|9699060|FG000|Open Label|Other: Subject moved to extension study|1
6088345|NCT00674362|9699061|FG001|Open Label|Other: Subject moved to extension study|0
6088346|NCT00674570|9699092|FG000|Overall Study|Withdrawal by Subject|0
6088347|NCT00674570|9699093|FG001|Overall Study|Withdrawal by Subject|2
6088348|NCT00674570|9699094|FG002|Overall Study|Withdrawal by Subject|0
6088349|NCT00674661|9699143|FG000|Overall Study|Other|5
6088350|NCT00674661|9699144|FG001|Overall Study|Other|7
6088351|NCT00674661|9699143|FG000|Overall Study|Lost to Follow-up|6
6088352|NCT00674661|9699144|FG001|Overall Study|Lost to Follow-up|3
6088353|NCT00674661|9699143|FG000|Overall Study|Withdrawal by Subject|0
6088354|NCT00674661|9699144|FG001|Overall Study|Withdrawal by Subject|5
6195567|NCT01454934|9854343|FG000|Overall Study|Other|6
6195568|NCT01454934|9854344|FG001|Overall Study|Other|17
6195569|NCT01454934|9854343|FG000|Overall Study|Adverse Event|28
6195570|NCT01454934|9854344|FG001|Overall Study|Adverse Event|24
6195571|NCT01454934|9854343|FG000|Overall Study|Withdrawn consent|2
6195572|NCT01454934|9854344|FG001|Overall Study|Withdrawn consent|5
6195573|NCT01454934|9854343|FG000|Overall Study|Withdrawal by Subject|11
6195574|NCT01454934|9854344|FG001|Overall Study|Withdrawal by Subject|15
6195575|NCT01454934|9854343|FG000|Overall Study|Disease progression|194
6195576|NCT01454934|9854344|FG001|Overall Study|Disease progression|181
6195577|NCT01454934|9854343|FG000|Overall Study|Lost to Follow-up|0
6195578|NCT01454934|9854344|FG001|Overall Study|Lost to Follow-up|1
6195579|NCT01454934|9854343|FG000|Overall Study|Not treated|1
6195580|NCT01454934|9854344|FG001|Overall Study|Not treated|2
6195581|NCT01455012|9854385|FG000|Overall Study|Adverse Event|0
6195582|NCT01455012|9854386|FG001|Overall Study|Adverse Event|2
6195583|NCT01455012|9854385|FG000|Overall Study|Lack of Efficacy|6
6195584|NCT01455012|9854386|FG001|Overall Study|Lack of Efficacy|1
6195585|NCT01455012|9854385|FG000|Overall Study|Withdrawal by Subject|3
6195586|NCT01455012|9854386|FG001|Overall Study|Withdrawal by Subject|1
6195587|NCT01455012|9854385|FG000|Overall Study|Unknown reason|2
6195588|NCT01455012|9854386|FG001|Overall Study|Unknown reason|0
6274392|NCT02203032|9978682|FG003|Blinded Phase (Week 16 to Week 44)|Withdrawal by Subject|20
6274393|NCT02203032|9978679|FG000|Blinded Phase (Week 16 to Week 44)|Other|0
6274394|NCT02203032|9978680|FG001|Blinded Phase (Week 16 to Week 44)|Other|4
6274395|NCT02203032|9978681|FG002|Blinded Phase (Week 16 to Week 44)|Other|1
6274396|NCT02203032|9978682|FG003|Blinded Phase (Week 16 to Week 44)|Other|15
6274397|NCT02203032|9978679|FG000|Blinded Phase (Week 16 to Week 44)|Death|0
6274398|NCT02203032|9978680|FG001|Blinded Phase (Week 16 to Week 44)|Death|0
6274399|NCT02203032|9978681|FG002|Blinded Phase (Week 16 to Week 44)|Death|0
6274400|NCT02203032|9978682|FG003|Blinded Phase (Week 16 to Week 44)|Death|1
6274401|NCT02203032|9978679|FG000|Blinded Phase (Week 16 to Week 44)|Completed Safety follow-up|0
6274402|NCT02203032|9978680|FG001|Blinded Phase (Week 16 to Week 44)|Completed Safety follow-up|1
6274403|NCT02203032|9978681|FG002|Blinded Phase (Week 16 to Week 44)|Completed Safety follow-up|3
6274404|NCT02203032|9978682|FG003|Blinded Phase (Week 16 to Week 44)|Completed Safety follow-up|2
6274405|NCT02203071|9978692|FG000|Overall Study|Lost to Follow-up|3
6274406|NCT02203071|9978693|FG001|Overall Study|Lost to Follow-up|1
6274407|NCT02203149|9978704|FG000|Part 1|Adverse Event|0
6274408|NCT02203149|9978705|FG001|Part 1|Adverse Event|1
6274409|NCT02203149|9978706|FG002|Part 1|Adverse Event|0
6274410|NCT02203149|9978707|FG003|Part 1|Adverse Event|0
6274411|NCT02203149|9978708|FG004|Part 1|Adverse Event|0
6274412|NCT02203149|9978704|FG000|Part 2|Death|0
6274413|NCT02203149|9978705|FG001|Part 2|Death|0
6274414|NCT02203149|9978706|FG002|Part 2|Death|1
6274415|NCT02203149|9978707|FG003|Part 2|Death|1
6274416|NCT02203149|9978708|FG004|Part 2|Death|0
6274417|NCT02203149|9978704|FG000|Part 2|Withdrawal by Subject|0
6274418|NCT02203149|9978705|FG001|Part 2|Withdrawal by Subject|0
6274419|NCT02203149|9978706|FG002|Part 2|Withdrawal by Subject|0
6274420|NCT02203149|9978707|FG003|Part 2|Withdrawal by Subject|1
6274421|NCT02203149|9978708|FG004|Part 2|Withdrawal by Subject|0
6274422|NCT02203149|9978704|FG000|Part 2|Adverse Event|0
6274423|NCT02203149|9978705|FG001|Part 2|Adverse Event|0
6274424|NCT02203149|9978706|FG002|Part 2|Adverse Event|0
6274425|NCT02203149|9978707|FG003|Part 2|Adverse Event|1
6274426|NCT02203149|9978708|FG004|Part 2|Adverse Event|1
6274427|NCT02203331|9978740|FG000|Overall Study|Pregnancy|1
5976626|NCT02306122|9563454|FG010|Initial Physician Randomization|Physician Decision|0
6274428|NCT02203331|9978741|FG001|Overall Study|Pregnancy|0
6274429|NCT02203331|9978742|FG002|Overall Study|Pregnancy|0
6274430|NCT02203331|9978743|FG003|Overall Study|Pregnancy|0
6274431|NCT02203331|9978744|FG004|Overall Study|Pregnancy|2
6274432|NCT02203331|9978745|FG005|Overall Study|Pregnancy|0
6274433|NCT02203331|9978740|FG000|Overall Study|Withdrawal by Subject|1
6274434|NCT02203331|9978741|FG001|Overall Study|Withdrawal by Subject|0
6274435|NCT02203331|9978742|FG002|Overall Study|Withdrawal by Subject|1
6274436|NCT02203331|9978743|FG003|Overall Study|Withdrawal by Subject|0
6274437|NCT02203331|9978744|FG004|Overall Study|Withdrawal by Subject|0
6274438|NCT02203331|9978745|FG005|Overall Study|Withdrawal by Subject|3
6274439|NCT02203331|9978740|FG000|Overall Study|Adverse Event|4
6274440|NCT02203331|9978741|FG001|Overall Study|Adverse Event|8
6274441|NCT02203331|9978742|FG002|Overall Study|Adverse Event|3
6274442|NCT02203331|9978743|FG003|Overall Study|Adverse Event|4
6274443|NCT02203331|9978744|FG004|Overall Study|Adverse Event|3
6274444|NCT02203331|9978745|FG005|Overall Study|Adverse Event|3
6274445|NCT02203331|9978740|FG000|Overall Study|Other Reasons|1
6274446|NCT02203331|9978741|FG001|Overall Study|Other Reasons|2
6274447|NCT02203331|9978742|FG002|Overall Study|Other Reasons|0
6274448|NCT02203331|9978743|FG003|Overall Study|Other Reasons|2
6274449|NCT02203331|9978744|FG004|Overall Study|Other Reasons|0
6274450|NCT02203331|9978745|FG005|Overall Study|Other Reasons|0
6274451|NCT02203331|9978740|FG000|Overall Study|Lack of Efficacy|0
6274452|NCT02203331|9978741|FG001|Overall Study|Lack of Efficacy|2
6274453|NCT02203331|9978742|FG002|Overall Study|Lack of Efficacy|1
6274454|NCT02203331|9978743|FG003|Overall Study|Lack of Efficacy|0
6274455|NCT02203331|9978744|FG004|Overall Study|Lack of Efficacy|0
6274456|NCT02203331|9978745|FG005|Overall Study|Lack of Efficacy|1
6274457|NCT02203331|9978740|FG000|Overall Study|Protocol Violation|0
6274458|NCT02203331|9978741|FG001|Overall Study|Protocol Violation|2
6274459|NCT02203331|9978742|FG002|Overall Study|Protocol Violation|0
6274460|NCT02203331|9978743|FG003|Overall Study|Protocol Violation|1
6274461|NCT02203331|9978744|FG004|Overall Study|Protocol Violation|1
6274462|NCT02203331|9978745|FG005|Overall Study|Protocol Violation|0
6274463|NCT02203331|9978740|FG000|Overall Study|Lost to Follow-up|0
6274464|NCT02203331|9978741|FG001|Overall Study|Lost to Follow-up|0
6274465|NCT02203331|9978742|FG002|Overall Study|Lost to Follow-up|0
6274466|NCT02203331|9978743|FG003|Overall Study|Lost to Follow-up|0
6274467|NCT02203331|9978744|FG004|Overall Study|Lost to Follow-up|1
6274468|NCT02203331|9978745|FG005|Overall Study|Lost to Follow-up|0
6195589|NCT01455194|9854403|FG000|Overall Study|Screen Failure|20
6195590|NCT01455194|9854404|FG001|Overall Study|Screen Failure|0
6195591|NCT01455194|9854405|FG002|Overall Study|Screen Failure|0
6274469|NCT02203357|9978762|FG000|Overall Study|Lost to Follow-up|58
6274470|NCT02203357|9978763|FG001|Overall Study|Lost to Follow-up|66
6274471|NCT02203357|9978764|FG002|Overall Study|Lost to Follow-up|70
6274472|NCT02203591|9978791|FG000|Overall Study|Did not meet treatment day baseline|147
6274473|NCT02203591|9978792|FG001|Overall Study|Did not meet treatment day baseline|141
6274474|NCT02203591|9978793|FG002|Overall Study|Did not meet treatment day baseline|150
6274475|NCT02203591|9978794|FG003|Overall Study|Did not meet treatment day baseline|45
6274476|NCT02203591|9978795|FG004|Overall Study|Did not meet treatment day baseline|33
6274477|NCT02203591|9978796|FG005|Overall Study|Did not meet treatment day baseline|35
6274478|NCT02203591|9978797|FG006|Overall Study|Did not meet treatment day baseline|29
6274479|NCT02203591|9978798|FG007|Overall Study|Did not meet treatment day baseline|12
6274480|NCT02203591|9978791|FG000|Overall Study|Discontinued early due to compromised test sites|0
6274481|NCT02203591|9978792|FG001|Overall Study|Discontinued early due to compromised test sites|1
6274482|NCT02203591|9978793|FG002|Overall Study|Discontinued early due to compromised test sites|1
6274483|NCT02203591|9978794|FG003|Overall Study|Discontinued early due to compromised test sites|0
6274484|NCT02203591|9978795|FG004|Overall Study|Discontinued early due to compromised test sites|1
6274485|NCT02203591|9978796|FG005|Overall Study|Discontinued early due to compromised test sites|0
6274486|NCT02203591|9978797|FG006|Overall Study|Discontinued early due to compromised test sites|0
6274487|NCT02203591|9978798|FG007|Overall Study|Discontinued early due to compromised test sites|1
6274488|NCT02203721|9978831|FG000|Overall Study|Lost to Follow-up|1
6088355|NCT00674700|9699153|FG000|Year 1|Adverse Event|17
6088356|NCT00674700|9699154|FG001|Year 1|Adverse Event|20
6088357|NCT00674700|9699155|FG002|Year 1|Adverse Event|5
6088358|NCT00674700|9699153|FG000|Year 1|Withdrawal by Subject|7
6088359|NCT00674700|9699154|FG001|Year 1|Withdrawal by Subject|7
6088360|NCT00674700|9699155|FG002|Year 1|Withdrawal by Subject|6
6088361|NCT00674700|9699153|FG000|Year 1|Any other reason not above-mentioned|7
6088362|NCT00674700|9699154|FG001|Year 1|Any other reason not above-mentioned|7
6088363|NCT00674700|9699155|FG002|Year 1|Any other reason not above-mentioned|6
6088364|NCT00674700|9699153|FG000|Year 2 Follow-up Without Treatment|Adverse Event|0
6088365|NCT00674700|9699154|FG001|Year 2 Follow-up Without Treatment|Adverse Event|1
6088366|NCT00674700|9699155|FG002|Year 2 Follow-up Without Treatment|Adverse Event|1
6088367|NCT00674700|9699153|FG000|Year 2 Follow-up Without Treatment|Withdrawal by Subject|1
6088368|NCT00674700|9699154|FG001|Year 2 Follow-up Without Treatment|Withdrawal by Subject|1
6088369|NCT00674700|9699155|FG002|Year 2 Follow-up Without Treatment|Withdrawal by Subject|4
6088370|NCT00674700|9699153|FG000|Year 2 Follow-up Without Treatment|Any other reason not above-mentioned|5
6195592|NCT01455194|9854406|FG003|Overall Study|Screen Failure|0
6274489|NCT02203721|9978832|FG001|Overall Study|Lost to Follow-up|0
6274490|NCT02203721|9978831|FG000|Overall Study|Death|0
6274491|NCT02203721|9978832|FG001|Overall Study|Death|2
6274492|NCT02203721|9978831|FG000|Overall Study|Illness|0
6274493|NCT02203721|9978832|FG001|Overall Study|Illness|1
6274494|NCT02203838|9978870|FG000|Overall Study|Lack of Efficacy|7
6274495|NCT02203838|9978871|FG001|Overall Study|Lack of Efficacy|0
6274496|NCT02203838|9978872|FG002|Overall Study|Lack of Efficacy|1
6274497|NCT02203838|9978873|FG003|Overall Study|Lack of Efficacy|1
6274498|NCT02203838|9978870|FG000|Overall Study|Adverse Event|46
6274499|NCT02203838|9978871|FG001|Overall Study|Adverse Event|6
6274500|NCT02203838|9978872|FG002|Overall Study|Adverse Event|3
6274501|NCT02203838|9978873|FG003|Overall Study|Adverse Event|2
5976627|NCT02147184|9563492|FG000|Overall Study|Lost to Follow-up|28
6195593|NCT01455194|9854403|FG000|Overall Study|Randomisation Failure|90
6195594|NCT01455194|9854404|FG001|Overall Study|Randomisation Failure|0
6195595|NCT01455194|9854405|FG002|Overall Study|Randomisation Failure|0
6195596|NCT01455194|9854406|FG003|Overall Study|Randomisation Failure|0
6195597|NCT01455194|9854403|FG000|Overall Study|Deterioration in asthma|12
6195598|NCT01455194|9854404|FG001|Overall Study|Deterioration in asthma|6
6195599|NCT01455194|9854405|FG002|Overall Study|Deterioration in asthma|14
6195600|NCT01455194|9854406|FG003|Overall Study|Deterioration in asthma|9
6195601|NCT01455194|9854403|FG000|Overall Study|Adverse Event|1
6195602|NCT01455194|9854404|FG001|Overall Study|Adverse Event|1
6195603|NCT01455194|9854405|FG002|Overall Study|Adverse Event|1
6195604|NCT01455194|9854406|FG003|Overall Study|Adverse Event|3
6195605|NCT01455194|9854403|FG000|Overall Study|Withdrawal by Subject|21
6195606|NCT01455194|9854404|FG001|Overall Study|Withdrawal by Subject|16
6195607|NCT01455194|9854405|FG002|Overall Study|Withdrawal by Subject|12
6195608|NCT01455194|9854406|FG003|Overall Study|Withdrawal by Subject|9
6195609|NCT01455194|9854403|FG000|Overall Study|Lost to Follow-up|2
6195610|NCT01455194|9854404|FG001|Overall Study|Lost to Follow-up|0
6195611|NCT01455194|9854405|FG002|Overall Study|Lost to Follow-up|1
6195612|NCT01455194|9854406|FG003|Overall Study|Lost to Follow-up|1
6195613|NCT01455194|9854403|FG000|Overall Study|Pregnancy|0
6195614|NCT01455194|9854404|FG001|Overall Study|Pregnancy|1
6195615|NCT01455194|9854405|FG002|Overall Study|Pregnancy|1
6195616|NCT01455194|9854406|FG003|Overall Study|Pregnancy|0
6195617|NCT01455194|9854403|FG000|Overall Study|Discontinuation criterion fulfilled|3
6195618|NCT01455194|9854404|FG001|Overall Study|Discontinuation criterion fulfilled|2
6195619|NCT01455194|9854405|FG002|Overall Study|Discontinuation criterion fulfilled|0
6195620|NCT01455194|9854406|FG003|Overall Study|Discontinuation criterion fulfilled|2
6195621|NCT01455194|9854403|FG000|Overall Study|Miscellaneous|4
6195622|NCT01455194|9854404|FG001|Overall Study|Miscellaneous|5
6195623|NCT01455194|9854405|FG002|Overall Study|Miscellaneous|1
6195624|NCT01455194|9854406|FG003|Overall Study|Miscellaneous|4
6195625|NCT01455220|9854419|FG000|Overall Study|screen fail|30
6195626|NCT01455415|9854428|FG000|Period 1|Adverse Event (AE) Related to Study Drug|9
6195627|NCT01455415|9854429|FG001|Period 1|Adverse Event (AE) Related to Study Drug|6
6195628|NCT01455415|9854428|FG000|Period 1|Lost To Follow-up Related to Study Drug|3
6195629|NCT01455415|9854429|FG001|Period 1|Lost To Follow-up Related to Study Drug|3
6195630|NCT01455415|9854428|FG000|Period 1|Drug Error not Associated to AE|0
6195631|NCT01455415|9854429|FG001|Period 1|Drug Error not Associated to AE|1
6195632|NCT01455415|9854428|FG000|Period 1|AE Not Related to Study Drug|2
6195633|NCT01455415|9854429|FG001|Period 1|AE Not Related to Study Drug|6
6195634|NCT01455415|9854428|FG000|Period 1|Withdrawal by Subject|4
6195635|NCT01455415|9854429|FG001|Period 1|Withdrawal by Subject|5
6195636|NCT01455415|9854428|FG000|Period 1|Unspecified Reason|1
6195637|NCT01455415|9854429|FG001|Period 1|Unspecified Reason|1
6195638|NCT01455415|9854428|FG000|Period 1|Protocol Violation|0
6195639|NCT01455415|9854429|FG001|Period 1|Protocol Violation|2
6195640|NCT01455415|9854428|FG000|Washout|AE Related to Study Drug|2
6195641|NCT01455415|9854429|FG001|Washout|AE Related to Study Drug|0
6195642|NCT01455415|9854428|FG000|Washout|Lost to Follow-up|1
6195643|NCT01455415|9854429|FG001|Washout|Lost to Follow-up|0
6195644|NCT01455415|9854428|FG000|Washout|Drug Error not Associated to AE|2
6195645|NCT01455415|9854429|FG001|Washout|Drug Error not Associated to AE|1
6195646|NCT01455415|9854428|FG000|Washout|AE Not Related to Study Drug|2
6195647|NCT01455415|9854429|FG001|Washout|AE Not Related to Study Drug|3
6195648|NCT01455415|9854428|FG000|Washout|Unspecified Reason|1
6195649|NCT01455415|9854429|FG001|Washout|Unspecified Reason|2
6195650|NCT01455415|9854428|FG000|Washout|Protocol Violation|0
6195651|NCT01455415|9854429|FG001|Washout|Protocol Violation|1
6195652|NCT01455415|9854428|FG000|Period 2|AE Related to Study Drug|1
6195653|NCT01455415|9854429|FG001|Period 2|AE Related to Study Drug|2
6195654|NCT01455415|9854428|FG000|Period 2|Lost to Follow-up|2
6195655|NCT01455415|9854429|FG001|Period 2|Lost to Follow-up|1
6195656|NCT01455415|9854428|FG000|Period 2|AE Not Related to Study Drug|2
6195657|NCT01455415|9854429|FG001|Period 2|AE Not Related to Study Drug|1
6195658|NCT01455415|9854428|FG000|Period 2|Lack of Efficacy|2
6195659|NCT01455415|9854429|FG001|Period 2|Lack of Efficacy|0
6195660|NCT01455415|9854428|FG000|Period 2|Withdrawal by Subject|2
6195661|NCT01455415|9854429|FG001|Period 2|Withdrawal by Subject|3
6195662|NCT01455415|9854428|FG000|Period 2|Unspecified Reason|2
6195663|NCT01455415|9854429|FG001|Period 2|Unspecified Reason|3
6195664|NCT01455415|9854428|FG000|Period 2|Protocol Violation|2
6195665|NCT01455415|9854429|FG001|Period 2|Protocol Violation|0
6195666|NCT01455415|9854428|FG000|Follow-up|AE Related to Study Drug|0
6195667|NCT01455415|9854429|FG001|Follow-up|AE Related to Study Drug|1
6195668|NCT01455415|9854428|FG000|Follow-up|Lack of Efficacy|0
6195669|NCT01455415|9854429|FG001|Follow-up|Lack of Efficacy|1
6195670|NCT01455415|9854428|FG000|Follow-up|Withdrawal by Subject|2
6195671|NCT01455415|9854429|FG001|Follow-up|Withdrawal by Subject|0
6195672|NCT01455415|9854428|FG000|Follow-up|Unspecified Reason|1
6195673|NCT01455415|9854429|FG001|Follow-up|Unspecified Reason|0
6195674|NCT01455428|9854437|FG000|Overall Study|Protocol Violation|2
6195675|NCT01455428|9854438|FG001|Overall Study|Protocol Violation|1
6195676|NCT01455428|9854437|FG000|Overall Study|Adverse Event|6
6195677|NCT01455428|9854438|FG001|Overall Study|Adverse Event|2
6195678|NCT01455428|9854437|FG000|Overall Study|Lost to Follow-up|1
6195679|NCT01455428|9854438|FG001|Overall Study|Lost to Follow-up|1
6195680|NCT01455428|9854437|FG000|Overall Study|Withdrawal by Subject|2
6195681|NCT01455428|9854438|FG001|Overall Study|Withdrawal by Subject|5
6195682|NCT01455428|9854437|FG000|Overall Study|Did not meet entrance criteria|0
6195683|NCT01455428|9854438|FG001|Overall Study|Did not meet entrance criteria|2
6195684|NCT01455428|9854437|FG000|Overall Study|Insufficient clinical response|0
6195685|NCT01455428|9854438|FG001|Overall Study|Insufficient clinical response|2
6195686|NCT01455428|9854437|FG000|Overall Study|Did not receive treatment|1
6195687|NCT01455428|9854438|FG001|Overall Study|Did not receive treatment|1
6195688|NCT01455428|9854437|FG000|Overall Study|Other|2
6195689|NCT01455428|9854438|FG001|Overall Study|Other|4
6195690|NCT01456039|9854481|FG000|Phase 1 (First Step)|Disease Progression|1
6195691|NCT01456039|9854482|FG001|Phase 1 (First Step)|Disease Progression|1
6195692|NCT01456039|9854483|FG002|Phase 1 (First Step)|Disease Progression|0
6195693|NCT01456039|9854481|FG000|Phase 1 (First Step)|Withdrawal by Subject|1
6195694|NCT01456039|9854482|FG001|Phase 1 (First Step)|Withdrawal by Subject|2
6195695|NCT01456039|9854483|FG002|Phase 1 (First Step)|Withdrawal by Subject|0
6195696|NCT01456039|9854481|FG000|Phase 1 (First Step)|Adverse Event|0
6195697|NCT01456039|9854482|FG001|Phase 1 (First Step)|Adverse Event|3
6195698|NCT01456039|9854483|FG002|Phase 1 (First Step)|Adverse Event|0
6195699|NCT01456039|9854481|FG000|Phase 1 (First Step)|Other|0
6195700|NCT01456039|9854482|FG001|Phase 1 (First Step)|Other|1
6195701|NCT01456039|9854483|FG002|Phase 1 (First Step)|Other|0
6195702|NCT01456039|9854481|FG000|Phase 2 (Second Step)|Disease Progression|0
6195703|NCT01456039|9854482|FG001|Phase 2 (Second Step)|Disease Progression|0
6195704|NCT01456039|9854483|FG002|Phase 2 (Second Step)|Disease Progression|17
6195705|NCT01456039|9854481|FG000|Phase 2 (Second Step)|Adverse Event|0
6195706|NCT01456039|9854482|FG001|Phase 2 (Second Step)|Adverse Event|0
6195707|NCT01456039|9854483|FG002|Phase 2 (Second Step)|Adverse Event|10
6195708|NCT01456039|9854481|FG000|Phase 2 (Second Step)|Withdrawal by Subject|0
6195709|NCT01456039|9854482|FG001|Phase 2 (Second Step)|Withdrawal by Subject|0
6195710|NCT01456039|9854483|FG002|Phase 2 (Second Step)|Withdrawal by Subject|4
6195711|NCT01456039|9854481|FG000|Phase 2 (Second Step)|Protocol Violation|0
6274502|NCT02203838|9978870|FG000|Overall Study|Lost to Follow-up|39
6274503|NCT02203838|9978871|FG001|Overall Study|Lost to Follow-up|3
6274504|NCT02203838|9978872|FG002|Overall Study|Lost to Follow-up|2
5976628|NCT02147184|9563493|FG001|Overall Study|Lost to Follow-up|15
5976629|NCT02147184|9563492|FG000|Overall Study|Study Burden|11
5976630|NCT02147184|9563493|FG001|Overall Study|Study Burden|7
5976631|NCT02147184|9563492|FG000|Overall Study|Pregnancy|6
5976632|NCT02147184|9563493|FG001|Overall Study|Pregnancy|0
5976633|NCT02147184|9563492|FG000|Overall Study|Moved out of state|3
5976634|NCT02147184|9563493|FG001|Overall Study|Moved out of state|3
5976635|NCT02147184|9563492|FG000|Overall Study|Physician Decision|0
5976636|NCT02147184|9563493|FG001|Overall Study|Physician Decision|2
5976637|NCT02147184|9563492|FG000|Overall Study|Other|1
5976638|NCT02147184|9563493|FG001|Overall Study|Other|0
5976639|NCT02000219|9563518|FG000|14-Week Study Period|Physician Decision|1
5976640|NCT02000219|9563518|FG000|14-Week Study Period|Adverse Event|1
5976641|NCT02000219|9563518|FG000|14-Week Study Period|Underwent transplantation|1
5976642|NCT02000219|9563518|FG000|Continuation Period|Withdrawal by Subject|1
5976643|NCT02000219|9563518|FG000|Continuation Period|Had liver transplant|2
5976644|NCT02000219|9563518|FG000|Continuation Period|Non-compliance with study drug|2
5976645|NCT01978938|9563524|FG000|Overall Study|Lost to Follow-up|12
5976646|NCT01978938|9563525|FG001|Overall Study|Lost to Follow-up|6
6050681|NCT00428090|9649857|FG003|Overall Study|Raised Creatinine Value|1
6050682|NCT00428116|9649877|FG000|Overall Study|Death|1
6050683|NCT00428116|9649878|FG001|Overall Study|Death|0
6050684|NCT00428116|9649877|FG000|Overall Study|Withdrawal by Subject|1
6050685|NCT00428116|9649878|FG001|Overall Study|Withdrawal by Subject|0
6050686|NCT00428116|9649877|FG000|Overall Study|Lost to Follow-up|1
6050687|NCT00428116|9649878|FG001|Overall Study|Lost to Follow-up|0
6050688|NCT00428220|9649885|FG000|Overall Study|Participant died|8
6050689|NCT00428220|9649885|FG000|Overall Study|Global deterioration of health status|7
6050690|NCT00428220|9649885|FG000|Overall Study|Lost to Follow-up|4
6050691|NCT00428220|9649885|FG000|Overall Study|Objective progression or relapse|123
6195712|NCT01456039|9854482|FG001|Phase 2 (Second Step)|Protocol Violation|0
6195713|NCT01456039|9854483|FG002|Phase 2 (Second Step)|Protocol Violation|1
6195714|NCT01456039|9854481|FG000|Phase 2 (Second Step)|Other|0
6195715|NCT01456039|9854482|FG001|Phase 2 (Second Step)|Other|0
6195716|NCT01456039|9854483|FG002|Phase 2 (Second Step)|Other|1
6195717|NCT01456052|9854502|FG000|Overall Study|Adverse Event|1
6195718|NCT01456052|9854503|FG001|Overall Study|Adverse Event|1
6195719|NCT01456052|9854504|FG002|Overall Study|Adverse Event|2
6195720|NCT01456052|9854502|FG000|Overall Study|Consent withdrawn|0
6195721|NCT01456052|9854503|FG001|Overall Study|Consent withdrawn|2
6195722|NCT01456052|9854504|FG002|Overall Study|Consent withdrawn|1
6195723|NCT01456052|9854502|FG000|Overall Study|Protocol Violation|0
6195724|NCT01456052|9854503|FG001|Overall Study|Protocol Violation|1
6195725|NCT01456052|9854504|FG002|Overall Study|Protocol Violation|0
6195726|NCT01456052|9854502|FG000|Overall Study|Physician Decision|1
6195727|NCT01456052|9854503|FG001|Overall Study|Physician Decision|0
6195728|NCT01456052|9854504|FG002|Overall Study|Physician Decision|1
6195729|NCT01456052|9854502|FG000|Overall Study|Treatment Failure|0
6195730|NCT01456052|9854503|FG001|Overall Study|Treatment Failure|1
6195731|NCT01456052|9854504|FG002|Overall Study|Treatment Failure|1
6195732|NCT01456130|9854513|FG000|Overall Study|Adverse Event|4
6195733|NCT01456130|9854513|FG000|Overall Study|Voluntary Withdrawal|1
6195734|NCT01456130|9854513|FG000|Overall Study|Lack of Efficacy|4
6195735|NCT01456130|9854513|FG000|Overall Study|Other|1
6195736|NCT01456169|9854524|FG000|Overall Study|Adverse Event|1
6195737|NCT01456169|9854525|FG001|Overall Study|Adverse Event|2
6195738|NCT01456169|9854526|FG002|Overall Study|Adverse Event|7
6274505|NCT02203838|9978873|FG003|Overall Study|Lost to Follow-up|1
5976647|NCT01978938|9563524|FG000|Overall Study|Withdrawal by Subject|8
5976648|NCT01978938|9563525|FG001|Overall Study|Withdrawal by Subject|4
5976649|NCT01978938|9563524|FG000|Overall Study|Adverse Event, non-fatal|2
5976650|NCT01978938|9563525|FG001|Overall Study|Adverse Event, non-fatal|1
5976651|NCT01978938|9563524|FG000|Overall Study|Participant noncompliance|1
5976652|NCT01978938|9563525|FG001|Overall Study|Participant noncompliance|1
6050692|NCT00428220|9649885|FG000|Overall Study|Participant refused continued treatment|7
6050693|NCT00428220|9649885|FG000|Overall Study|Adverse Event|51
6195739|NCT01456169|9854524|FG000|Overall Study|Major Protocol Deviation|3
6195740|NCT01456169|9854525|FG001|Overall Study|Major Protocol Deviation|2
6195741|NCT01456169|9854526|FG002|Overall Study|Major Protocol Deviation|3
6195742|NCT01456169|9854524|FG000|Overall Study|Voluntary Withdrawal|3
6195743|NCT01456169|9854525|FG001|Overall Study|Voluntary Withdrawal|0
6195744|NCT01456169|9854526|FG002|Overall Study|Voluntary Withdrawal|2
6195745|NCT01456169|9854524|FG000|Overall Study|Lack of Efficacy|2
6088371|NCT00674700|9699154|FG001|Year 2 Follow-up Without Treatment|Any other reason not above-mentioned|10
6088372|NCT00674700|9699155|FG002|Year 2 Follow-up Without Treatment|Any other reason not above-mentioned|7
6088373|NCT00674817|9699185|FG000|Period 1|Withdrawal by Subject|2
6088374|NCT00674817|9699185|FG000|Period 1|Protocol Violation|1
6088375|NCT00674817|9699185|FG000|Period 3|Adverse Event|1
6088376|NCT00674817|9699185|FG000|Period 3|Protocol Violation|1
6088377|NCT00674817|9699185|FG000|Period 4|Adverse Event|1
6088378|NCT00674973|9699201|FG000|Overall Study|Insufficient Therapeutic Response|77
6088379|NCT00674973|9699202|FG001|Overall Study|Insufficient Therapeutic Response|72
6088380|NCT00674973|9699201|FG000|Overall Study|Refused Treatment|1
6088381|NCT00674973|9699202|FG001|Overall Study|Refused Treatment|5
6088382|NCT00674973|9699201|FG000|Overall Study|Failure to Return|1
6088383|NCT00674973|9699202|FG001|Overall Study|Failure to Return|0
6088384|NCT00674973|9699201|FG000|Overall Study|Adverse Event|2
6088385|NCT00674973|9699202|FG001|Overall Study|Adverse Event|9
6088386|NCT00674973|9699201|FG000|Overall Study|Death|19
6088387|NCT00674973|9699202|FG001|Overall Study|Death|15
6088388|NCT00674973|9699201|FG000|Overall Study|Protocol Violation|0
6088389|NCT00674973|9699202|FG001|Overall Study|Protocol Violation|1
6088390|NCT00674986|9699210|FG000|Overall Study|Adverse Event|2
6088391|NCT00674986|9699211|FG001|Overall Study|Adverse Event|1
6088392|NCT00674986|9699210|FG000|Overall Study|Subject withdrew consent|12
6088393|NCT00674986|9699211|FG001|Overall Study|Subject withdrew consent|19
6088394|NCT00674986|9699210|FG000|Overall Study|Lost to Follow-up|25
6088395|NCT00674986|9699211|FG001|Overall Study|Lost to Follow-up|53
6088396|NCT00674986|9699210|FG000|Overall Study|Other reasons|4
6088397|NCT00674986|9699211|FG001|Overall Study|Other reasons|8
6088398|NCT00675025|9699220|FG000|Overall Study|Study Terminated by Sponsor|38
6088399|NCT00675025|9699221|FG001|Overall Study|Study Terminated by Sponsor|42
6088400|NCT00675025|9699220|FG000|Overall Study|Adverse Event|6
6088401|NCT00675025|9699221|FG001|Overall Study|Adverse Event|11
6088402|NCT00675025|9699220|FG000|Overall Study|Lost to Follow-up|6
6088403|NCT00675025|9699221|FG001|Overall Study|Lost to Follow-up|4
6088404|NCT00675025|9699220|FG000|Overall Study|Withdrawal by Subject|4
6088405|NCT00675025|9699221|FG001|Overall Study|Withdrawal by Subject|6
6088406|NCT00675103|9699227|FG000|Overall Study|Lack of Efficacy|2
6088407|NCT00675103|9699227|FG000|Overall Study|Adverse Event|1
6088408|NCT00675428|9699250|FG000|Overall Study|Disease Progression|2
6088409|NCT00675428|9699251|FG001|Overall Study|Disease Progression|2
6088410|NCT00675428|9699250|FG000|Overall Study|No Disease Response After Cycle 6|0
6088411|NCT00675428|9699251|FG001|Overall Study|No Disease Response After Cycle 6|1
6088412|NCT00675428|9699250|FG000|Overall Study|Physician Decision|1
6088413|NCT00675428|9699251|FG001|Overall Study|Physician Decision|0
6088414|NCT00675441|9699257|FG000|Overall Study|Withdrawal by Subject|2
6088415|NCT00675441|9699257|FG000|Overall Study|Death|1
6088416|NCT00675506|9699263|FG000|Overall Study|Lost to Follow-up|1
6088417|NCT00675506|9699264|FG001|Overall Study|Lost to Follow-up|5
6088418|NCT00675506|9699263|FG000|Overall Study|Lost interest|3
6088419|NCT00675506|9699264|FG001|Overall Study|Lost interest|5
6088420|NCT00675506|9699263|FG000|Overall Study|Elevated fasting glucose|2
6088421|NCT00675506|9699264|FG001|Overall Study|Elevated fasting glucose|1
6088422|NCT00675506|9699263|FG000|Overall Study|Elevated IGF-1 prior to treatment|1
6088423|NCT00675506|9699264|FG001|Overall Study|Elevated IGF-1 prior to treatment|0
6088424|NCT00675506|9699263|FG000|Overall Study|Elevated IGF-1|2
6088425|NCT00675506|9699264|FG001|Overall Study|Elevated IGF-1|0
6088426|NCT00675506|9699263|FG000|Overall Study|Hypersensitivity Reaction|1
6088427|NCT00675506|9699264|FG001|Overall Study|Hypersensitivity Reaction|0
6088428|NCT00675506|9699263|FG000|Overall Study|Disclosed history of cancer|1
6088429|NCT00675506|9699264|FG001|Overall Study|Disclosed history of cancer|0
6088430|NCT00675506|9699263|FG000|Overall Study|Declined participation|1
6088431|NCT00675506|9699264|FG001|Overall Study|Declined participation|0
6088432|NCT00675506|9699263|FG000|Overall Study|Schedule conflict|0
6088433|NCT00675506|9699264|FG001|Overall Study|Schedule conflict|1
6088434|NCT00675597|9699293|FG000|Overall Study|Withdrawal by Subject|3
6088435|NCT00675766|9699301|FG000|Overall Study|Lost to Follow-up|6
6088436|NCT00675766|9699302|FG001|Overall Study|Lost to Follow-up|5
6088437|NCT00675766|9699303|FG002|Overall Study|Lost to Follow-up|21
6088438|NCT00675766|9699304|FG003|Overall Study|Lost to Follow-up|26
6088439|NCT00675948|9699343|FG000|Overall Study|Adverse Event|23
6088440|NCT00675948|9699344|FG001|Overall Study|Adverse Event|1
6088441|NCT00675948|9699343|FG000|Overall Study|Lack of Efficacy|3
6088442|NCT00675948|9699344|FG001|Overall Study|Lack of Efficacy|0
6088443|NCT00675948|9699343|FG000|Overall Study|Withdrawal by Subject|7
6088444|NCT00675948|9699344|FG001|Overall Study|Withdrawal by Subject|0
6088445|NCT00675948|9699343|FG000|Overall Study|Lost to Follow-up|2
6088446|NCT00675948|9699344|FG001|Overall Study|Lost to Follow-up|0
6088447|NCT00675948|9699343|FG000|Overall Study|Protocol Violation|1
6088448|NCT00675948|9699344|FG001|Overall Study|Protocol Violation|0
6088449|NCT00675948|9699343|FG000|Overall Study|Pain under control|1
6088450|NCT00675948|9699344|FG001|Overall Study|Pain under control|0
6088451|NCT00675948|9699343|FG000|Overall Study|Sponsor decision|0
6088452|NCT00675948|9699344|FG001|Overall Study|Sponsor decision|1
6195746|NCT01456169|9854525|FG001|Overall Study|Lack of Efficacy|0
6195747|NCT01456169|9854526|FG002|Overall Study|Lack of Efficacy|0
6195748|NCT01456169|9854524|FG000|Overall Study|Other|1
6195749|NCT01456169|9854525|FG001|Overall Study|Other|1
6195750|NCT01456169|9854526|FG002|Overall Study|Other|0
6195751|NCT01456195|9854538|FG000|Overall Study|Pretreatment Event/Adverse Event|1
6195752|NCT01456195|9854539|FG001|Overall Study|Pretreatment Event/Adverse Event|4
6195753|NCT01456195|9854540|FG002|Overall Study|Pretreatment Event/Adverse Event|1
6195754|NCT01456195|9854538|FG000|Overall Study|Lost to Follow-up|3
6195755|NCT01456195|9854539|FG001|Overall Study|Lost to Follow-up|1
6195756|NCT01456195|9854540|FG002|Overall Study|Lost to Follow-up|3
6195757|NCT01456195|9854538|FG000|Overall Study|Voluntary Withdrawal|5
6195758|NCT01456195|9854539|FG001|Overall Study|Voluntary Withdrawal|3
6195759|NCT01456195|9854540|FG002|Overall Study|Voluntary Withdrawal|7
6195760|NCT01456195|9854538|FG000|Overall Study|Lack of Efficacy|0
6195761|NCT01456195|9854539|FG001|Overall Study|Lack of Efficacy|1
6195762|NCT01456195|9854540|FG002|Overall Study|Lack of Efficacy|0
6195763|NCT01456195|9854538|FG000|Overall Study|Other Reasons|2
6195764|NCT01456195|9854539|FG001|Overall Study|Other Reasons|1
6195765|NCT01456195|9854540|FG002|Overall Study|Other Reasons|3
6195766|NCT01456221|9854550|FG000|Overall Study|Withdrawal by Subject|56
6195767|NCT01456221|9854551|FG001|Overall Study|Withdrawal by Subject|49
6195768|NCT01456221|9854550|FG000|Overall Study|Lost to Follow-up|1
6195769|NCT01456221|9854551|FG001|Overall Study|Lost to Follow-up|4
6195770|NCT01456221|9854550|FG000|Overall Study|Received medication|3
6195771|NCT01456221|9854551|FG001|Overall Study|Received medication|2
6195772|NCT01456221|9854550|FG000|Overall Study|Incomplete data|4
6195773|NCT01456221|9854551|FG001|Overall Study|Incomplete data|2
6195774|NCT01456780|9854582|FG000|Overall Study|Lost to Follow-up|3
6195775|NCT01456780|9854583|FG001|Overall Study|Lost to Follow-up|3
6195776|NCT01456780|9854584|FG002|Overall Study|Lost to Follow-up|0
6195777|NCT01456897|9854594|FG000|Overall Study|Adverse Event|19
6274506|NCT02203838|9978870|FG000|Overall Study|Protocol Violation|7
6274507|NCT02203838|9978871|FG001|Overall Study|Protocol Violation|3
6274508|NCT02203838|9978872|FG002|Overall Study|Protocol Violation|0
6274509|NCT02203838|9978873|FG003|Overall Study|Protocol Violation|0
6274510|NCT02203838|9978870|FG000|Overall Study|Withdrawal by Subject|83
6274511|NCT02203838|9978871|FG001|Overall Study|Withdrawal by Subject|10
6274512|NCT02203838|9978872|FG002|Overall Study|Withdrawal by Subject|8
6274513|NCT02203838|9978873|FG003|Overall Study|Withdrawal by Subject|11
6274514|NCT02203838|9978870|FG000|Overall Study|Physician Decision|27
6274515|NCT02203838|9978871|FG001|Overall Study|Physician Decision|0
6274516|NCT02203838|9978872|FG002|Overall Study|Physician Decision|2
6274517|NCT02203838|9978873|FG003|Overall Study|Physician Decision|3
6274518|NCT02203838|9978870|FG000|Overall Study|Other|1
6274519|NCT02203838|9978871|FG001|Overall Study|Other|0
6274520|NCT02203838|9978872|FG002|Overall Study|Other|0
6274521|NCT02203838|9978873|FG003|Overall Study|Other|0
6274522|NCT02203851|9978883|FG000|Overall Study|Lost to Follow-up|4
6274523|NCT02203851|9978883|FG000|Overall Study|Withdrawal by Subject|6
6274524|NCT02203851|9978883|FG000|Overall Study|Other|1
6274525|NCT02203916|9978897|FG000|Overall Study|Pretreatment Event/Adverse Event|1
6274526|NCT02203916|9978898|FG001|Overall Study|Pretreatment Event/Adverse Event|3
6274527|NCT02203916|9978899|FG002|Overall Study|Pretreatment Event/Adverse Event|2
6274528|NCT02203916|9978897|FG000|Overall Study|Major Protocol Deviation|1
6274529|NCT02203916|9978898|FG001|Overall Study|Major Protocol Deviation|1
6274530|NCT02203916|9978899|FG002|Overall Study|Major Protocol Deviation|0
6274531|NCT02203916|9978897|FG000|Overall Study|Lost to Follow-up|0
6274532|NCT02203916|9978898|FG001|Overall Study|Lost to Follow-up|1
6274533|NCT02203916|9978899|FG002|Overall Study|Lost to Follow-up|0
6274534|NCT02203916|9978897|FG000|Overall Study|Voluntary Withdrawal|3
6274535|NCT02203916|9978898|FG001|Overall Study|Voluntary Withdrawal|3
6274536|NCT02203916|9978899|FG002|Overall Study|Voluntary Withdrawal|8
6274537|NCT02203916|9978897|FG000|Overall Study|Lack of Efficacy|3
6274538|NCT02203916|9978898|FG001|Overall Study|Lack of Efficacy|0
6274539|NCT02203916|9978899|FG002|Overall Study|Lack of Efficacy|0
6274540|NCT02203916|9978897|FG000|Overall Study|Reason Not Specified|0
6274541|NCT02203916|9978898|FG001|Overall Study|Reason Not Specified|2
6274542|NCT02203916|9978899|FG002|Overall Study|Reason Not Specified|1
6274543|NCT02204007|9978909|FG000|Overall Study|Surgery Canceled|1
6274544|NCT02204007|9978910|FG001|Overall Study|Surgery Canceled|1
6274545|NCT02204293|9978944|FG000|Core Study Part I|Met one or more exclusion criteria|1
6274546|NCT02204293|9978945|FG001|Core Study Part I|Met one or more exclusion criteria|0
6274547|NCT02204293|9978946|FG002|Core Study Part I|Met one or more exclusion criteria|0
6274548|NCT02204293|9978947|FG003|Core Study Part I|Met one or more exclusion criteria|0
6274549|NCT02204293|9978948|FG004|Core Study Part I|Met one or more exclusion criteria|0
6195778|NCT01456897|9854595|FG001|Overall Study|Adverse Event|22
6195779|NCT01456897|9854594|FG000|Overall Study|Protocol Violation|3
6195780|NCT01456897|9854595|FG001|Overall Study|Protocol Violation|4
6195781|NCT01456897|9854594|FG000|Overall Study|Physician Decision|5
6195782|NCT01456897|9854595|FG001|Overall Study|Physician Decision|3
6195783|NCT01456897|9854594|FG000|Overall Study|Withdrawal by Subject|44
6195784|NCT01456897|9854595|FG001|Overall Study|Withdrawal by Subject|17
6195785|NCT01456897|9854594|FG000|Overall Study|Lack of Efficacy|4
6195786|NCT01456897|9854595|FG001|Overall Study|Lack of Efficacy|11
6195787|NCT01456936|9854605|FG000|Overall Study|Other reason|41
6195788|NCT01456936|9854606|FG001|Overall Study|Other reason|30
6195789|NCT01456936|9854607|FG002|Overall Study|Other reason|36
6195790|NCT01456936|9854608|FG003|Overall Study|Other reason|33
6195791|NCT01456936|9854605|FG000|Overall Study|No longer meets eligibility criteria|4
6195792|NCT01456936|9854606|FG001|Overall Study|No longer meets eligibility criteria|8
6195793|NCT01456936|9854607|FG002|Overall Study|No longer meets eligibility criteria|6
6195794|NCT01456936|9854608|FG003|Overall Study|No longer meets eligibility criteria|5
6195795|NCT01456936|9854605|FG000|Overall Study|Protocol Violation|4
6195796|NCT01456936|9854606|FG001|Overall Study|Protocol Violation|2
6195797|NCT01456936|9854607|FG002|Overall Study|Protocol Violation|5
6274550|NCT02204293|9978949|FG005|Core Study Part I|Met one or more exclusion criteria|0
6274551|NCT02204293|9978944|FG000|Core Study Part I|Adverse Event|1
6274552|NCT02204293|9978945|FG001|Core Study Part I|Adverse Event|0
6274553|NCT02204293|9978946|FG002|Core Study Part I|Adverse Event|0
6274554|NCT02204293|9978947|FG003|Core Study Part I|Adverse Event|0
6274555|NCT02204293|9978948|FG004|Core Study Part I|Adverse Event|0
6274556|NCT02204293|9978949|FG005|Core Study Part I|Adverse Event|0
6274557|NCT02204293|9978944|FG000|Core Study Part I|Physician Decision|0
6274558|NCT02204293|9978945|FG001|Core Study Part I|Physician Decision|3
6274559|NCT02204293|9978946|FG002|Core Study Part I|Physician Decision|0
6274560|NCT02204293|9978947|FG003|Core Study Part I|Physician Decision|0
6274561|NCT02204293|9978948|FG004|Core Study Part I|Physician Decision|0
6274562|NCT02204293|9978949|FG005|Core Study Part I|Physician Decision|0
6274563|NCT02204293|9978944|FG000|LTE Phase|Study Suspended|0
6274564|NCT02204293|9978945|FG001|LTE Phase|Study Suspended|0
6274565|NCT02204293|9978946|FG002|LTE Phase|Study Suspended|0
6274566|NCT02204293|9978947|FG003|LTE Phase|Study Suspended|0
6274567|NCT02204293|9978948|FG004|LTE Phase|Study Suspended|0
6274568|NCT02204293|9978949|FG005|LTE Phase|Study Suspended|7
6274569|NCT02204319|9978963|FG000|Overall Study|Pregnancy|1
6274570|NCT02204319|9978963|FG000|Overall Study|Withdrawal by Subject|2
6274571|NCT02204371|9978968|FG000|Overall Study|Adverse Event|1
5976653|NCT01978938|9563524|FG000|Overall Study|Did not meet inclusion criteria|0
5976654|NCT01978938|9563525|FG001|Overall Study|Did not meet inclusion criteria|1
5976655|NCT01978938|9563524|FG000|Overall Study|Previously scheduled procedure|0
5976656|NCT01978938|9563525|FG001|Overall Study|Previously scheduled procedure|1
5976657|NCT01854385|9563531|FG000|Pre-Treatment|Withdrawal by Subject|4
5976658|NCT01854385|9563531|FG000|Pre-Treatment|Did not meet criteria based on headache number|15
5976659|NCT01854385|9563531|FG000|Pre-Treatment|Disqualified based on blood pressure requirement|3
5976660|NCT01854385|9563531|FG000|Pre-Treatment|Unable to come for study visits|1
5976661|NCT01854385|9563531|FG000|Treatment|Lost to Follow-up|1
5976662|NCT01844856|9563537|FG000|Overall Study|Lost to Follow-up|15
5976663|NCT01844856|9563538|FG001|Overall Study|Lost to Follow-up|3
5976664|NCT01844856|9563537|FG000|Overall Study|Adverse Event|3
5976665|NCT01844856|9563538|FG001|Overall Study|Adverse Event|6
5976666|NCT01844856|9563537|FG000|Overall Study|Withdrawal by Subject|3
5976667|NCT01844856|9563538|FG001|Overall Study|Withdrawal by Subject|2
5976668|NCT01844856|9563537|FG000|Overall Study|Noncompliance|2
5976669|NCT01844856|9563538|FG001|Overall Study|Noncompliance|3
5976670|NCT01844856|9563537|FG000|Overall Study|Enterococcus Resistant|0
5976671|NCT01844856|9563538|FG001|Overall Study|Enterococcus Resistant|1
5976672|NCT01844856|9563537|FG000|Overall Study|Inadvertently Not Scheduled|1
5976673|NCT01844856|9563538|FG001|Overall Study|Inadvertently Not Scheduled|0
5976674|NCT01844856|9563537|FG000|Overall Study|Randomized but was a Screen Failure|0
6050694|NCT00428220|9649885|FG000|Overall Study|Other|23
6050695|NCT00428246|9649903|FG000|Overall Study|Withdrawal by Subject|0
6050696|NCT00428246|9649904|FG001|Overall Study|Withdrawal by Subject|0
6050697|NCT00428246|9649905|FG002|Overall Study|Withdrawal by Subject|1
6050698|NCT00428246|9649903|FG000|Overall Study|Adverse Event|1
6088453|NCT00675948|9699343|FG000|Overall Study|Patient died|1
6088454|NCT00675948|9699344|FG001|Overall Study|Patient died|0
6088455|NCT00675948|9699343|FG000|Overall Study|Patient unable to comply with diaries|1
6088456|NCT00675948|9699344|FG001|Overall Study|Patient unable to comply with diaries|0
6195798|NCT01456936|9854608|FG003|Overall Study|Protocol Violation|5
6195799|NCT01456936|9854605|FG000|Overall Study|Pregnancy|1
6195800|NCT01456936|9854606|FG001|Overall Study|Pregnancy|0
6195801|NCT01456936|9854607|FG002|Overall Study|Pregnancy|0
6195802|NCT01456936|9854608|FG003|Overall Study|Pregnancy|1
5976675|NCT01844856|9563538|FG001|Overall Study|Randomized but was a Screen Failure|1
6050699|NCT00428246|9649904|FG001|Overall Study|Adverse Event|0
6050700|NCT00428246|9649905|FG002|Overall Study|Adverse Event|0
6050701|NCT00428389|9649926|FG000|Core Phase|Adverse Event|6
6050702|NCT00428389|9649927|FG001|Core Phase|Adverse Event|4
6050703|NCT00428389|9649926|FG000|Core Phase|Lack of Efficacy|2
6050704|NCT00428389|9649927|FG001|Core Phase|Lack of Efficacy|0
6050705|NCT00428389|9649926|FG000|Core Phase|Abnormal test procedure result(s)|0
6274572|NCT02204410|9978972|FG000|Overall Study|Lost to Follow-up|5
6274573|NCT02204410|9978972|FG000|Overall Study|Physician Decision|2
6274574|NCT02204410|9978972|FG000|Overall Study|Protocol Violation|1
6274575|NCT02204410|9978972|FG000|Overall Study|Withdrawal by Subject|3
6274576|NCT02204449|9978978|FG000|Overall Study|Lost to Follow-up|7
6274577|NCT02204449|9978979|FG001|Overall Study|Lost to Follow-up|9
6088457|NCT00675948|9699343|FG000|Overall Study|Patient feels unable to take medication|0
6088458|NCT00675948|9699344|FG001|Overall Study|Patient feels unable to take medication|1
6088459|NCT00676052|9699375|FG000|Overall Study|Adverse Event|0
6088460|NCT00676052|9699376|FG001|Overall Study|Adverse Event|1
6088461|NCT00676052|9699377|FG002|Overall Study|Adverse Event|1
6088462|NCT00676052|9699378|FG003|Overall Study|Adverse Event|2
6088463|NCT00676052|9699379|FG004|Overall Study|Adverse Event|2
6088464|NCT00676052|9699380|FG005|Overall Study|Adverse Event|2
6088465|NCT00676052|9699375|FG000|Overall Study|Lack of Efficacy|2
6088466|NCT00676052|9699376|FG001|Overall Study|Lack of Efficacy|2
6088467|NCT00676052|9699377|FG002|Overall Study|Lack of Efficacy|1
6088468|NCT00676052|9699378|FG003|Overall Study|Lack of Efficacy|1
6088469|NCT00676052|9699379|FG004|Overall Study|Lack of Efficacy|2
6088470|NCT00676052|9699380|FG005|Overall Study|Lack of Efficacy|1
6088471|NCT00676052|9699375|FG000|Overall Study|Protocol Violation|5
6088472|NCT00676052|9699376|FG001|Overall Study|Protocol Violation|3
6088473|NCT00676052|9699377|FG002|Overall Study|Protocol Violation|2
6088474|NCT00676052|9699378|FG003|Overall Study|Protocol Violation|2
6088475|NCT00676052|9699379|FG004|Overall Study|Protocol Violation|1
6088476|NCT00676052|9699380|FG005|Overall Study|Protocol Violation|2
6088477|NCT00676052|9699375|FG000|Overall Study|Lost to Follow-up|0
6088478|NCT00676052|9699376|FG001|Overall Study|Lost to Follow-up|0
6088479|NCT00676052|9699377|FG002|Overall Study|Lost to Follow-up|0
6088480|NCT00676052|9699378|FG003|Overall Study|Lost to Follow-up|0
6088481|NCT00676052|9699379|FG004|Overall Study|Lost to Follow-up|1
6088482|NCT00676052|9699380|FG005|Overall Study|Lost to Follow-up|0
6088483|NCT00676052|9699375|FG000|Overall Study|Physician Decision|1
6088484|NCT00676052|9699376|FG001|Overall Study|Physician Decision|1
6088485|NCT00676052|9699377|FG002|Overall Study|Physician Decision|1
6088486|NCT00676052|9699378|FG003|Overall Study|Physician Decision|0
6088487|NCT00676052|9699379|FG004|Overall Study|Physician Decision|0
6088488|NCT00676052|9699380|FG005|Overall Study|Physician Decision|1
6088489|NCT00676052|9699375|FG000|Overall Study|Withdrawal by Subject|1
6088490|NCT00676052|9699376|FG001|Overall Study|Withdrawal by Subject|0
6088491|NCT00676052|9699377|FG002|Overall Study|Withdrawal by Subject|1
6195803|NCT01456936|9854605|FG000|Overall Study|Insufficient clinical response|4
6195804|NCT01456936|9854606|FG001|Overall Study|Insufficient clinical response|4
6195805|NCT01456936|9854607|FG002|Overall Study|Insufficient clinical response|14
6195806|NCT01456936|9854608|FG003|Overall Study|Insufficient clinical response|13
6195807|NCT01456936|9854605|FG000|Overall Study|No longer willing to participate|195
6195808|NCT01456936|9854606|FG001|Overall Study|No longer willing to participate|218
6195809|NCT01456936|9854607|FG002|Overall Study|No longer willing to participate|224
6195810|NCT01456936|9854608|FG003|Overall Study|No longer willing to participate|248
6195811|NCT01456936|9854605|FG000|Overall Study|Lost to Follow-up|135
6195812|NCT01456936|9854606|FG001|Overall Study|Lost to Follow-up|126
6195813|NCT01456936|9854607|FG002|Overall Study|Lost to Follow-up|144
6195814|NCT01456936|9854608|FG003|Overall Study|Lost to Follow-up|127
6195815|NCT01456936|9854605|FG000|Overall Study|Medication error|0
6195816|NCT01456936|9854606|FG001|Overall Study|Medication error|1
6195817|NCT01456936|9854607|FG002|Overall Study|Medication error|0
6195818|NCT01456936|9854608|FG003|Overall Study|Medication error|1
6195819|NCT01456936|9854605|FG000|Overall Study|Adverse event (study drug)|25
6195820|NCT01456936|9854606|FG001|Overall Study|Adverse event (study drug)|21
6195821|NCT01456936|9854607|FG002|Overall Study|Adverse event (study drug)|26
6195822|NCT01456936|9854608|FG003|Overall Study|Adverse event (study drug)|17
6195823|NCT01456936|9854605|FG000|Overall Study|Adverse event (study drug unrelated)|9
6195824|NCT01456936|9854606|FG001|Overall Study|Adverse event (study drug unrelated)|7
6195825|NCT01456936|9854607|FG002|Overall Study|Adverse event (study drug unrelated)|9
6195826|NCT01456936|9854608|FG003|Overall Study|Adverse event (study drug unrelated)|9
6195827|NCT01456936|9854605|FG000|Overall Study|Death|0
6195828|NCT01456936|9854606|FG001|Overall Study|Death|3
6195829|NCT01456936|9854607|FG002|Overall Study|Death|1
6195830|NCT01456936|9854608|FG003|Overall Study|Death|3
6195831|NCT01456936|9854605|FG000|Overall Study|Randomized but not treated|21
6195832|NCT01456936|9854606|FG001|Overall Study|Randomized but not treated|28
6195833|NCT01456936|9854607|FG002|Overall Study|Randomized but not treated|16
6195834|NCT01456936|9854608|FG003|Overall Study|Randomized but not treated|21
6195835|NCT01456949|9854618|FG000|Enrollment|PI death- incomplete data|6
6195836|NCT01456949|9854618|FG000|Enrollment|Death|1
6195837|NCT01456949|9854618|FG000|Enrollment|I/E criteria not met prior to procedure|13
6195838|NCT01456949|9854618|FG000|Enrollment|Physician Decision|10
6195839|NCT01456949|9854618|FG000|Enrollment|Withdrawal by Subject|7
6195840|NCT01456949|9854618|FG000|Study Cryoablation Procedure & Follow-up|Death|5
6088492|NCT00676052|9699378|FG003|Overall Study|Withdrawal by Subject|0
6195841|NCT01456949|9854618|FG000|Study Cryoablation Procedure & Follow-up|Withdrawal by Subject|23
6195842|NCT01456949|9854618|FG000|Study Cryoablation Procedure & Follow-up|Lost to Follow-up|11
6195843|NCT01456949|9854618|FG000|Study Cryoablation Procedure & Follow-up|Physician Decision|1
6088493|NCT00676052|9699379|FG004|Overall Study|Withdrawal by Subject|0
6088494|NCT00676052|9699380|FG005|Overall Study|Withdrawal by Subject|0
6088495|NCT00676091|9699409|FG000|Infant Series|Parent or legal guardian request|10
6088496|NCT00676091|9699410|FG001|Infant Series|Parent or legal guardian request|8
6088497|NCT00676091|9699409|FG000|Infant Series|Protocol Violation|6
6195844|NCT01456949|9854618|FG000|Study Cryoablation Procedure & Follow-up|Subject Relocation|10
6195845|NCT01456949|9854618|FG000|Study Cryoablation Procedure & Follow-up|Failure to maintain study compliance|2
6195846|NCT01456949|9854618|FG000|Study Cryoablation Procedure & Follow-up|Rollover not included in completer total|6
6195847|NCT01456949|9854618|FG000|Study Cryoablation Procedure & Follow-up|Treated did not meet I/E criteria|4
6195848|NCT01456962|9854624|FG000|Overall Study|Lost to Follow-up|2
6195849|NCT01456962|9854625|FG001|Overall Study|Lost to Follow-up|1
6195850|NCT01457014|9854631|FG000|First Night|Didn't meet inclusion/exclusion criteria|37
6195851|NCT01457014|9854632|FG001|First Night|Didn't meet inclusion/exclusion criteria|0
6195852|NCT01457014|9854633|FG002|First Night|Didn't meet inclusion/exclusion criteria|0
6195853|NCT01457014|9854634|FG003|First Night|Didn't meet inclusion/exclusion criteria|0
6195854|NCT01457014|9854631|FG000|First Night|Withdrawal by Subject|3
6195855|NCT01457014|9854632|FG001|First Night|Withdrawal by Subject|0
6195856|NCT01457014|9854633|FG002|First Night|Withdrawal by Subject|0
6195857|NCT01457014|9854634|FG003|First Night|Withdrawal by Subject|0
6195858|NCT01457118|9854646|FG000|Overall Study|Adverse Event|1
6195859|NCT01457118|9854647|FG001|Overall Study|Adverse Event|0
6195860|NCT01457118|9854648|FG002|Overall Study|Adverse Event|0
6195861|NCT01457118|9854649|FG003|Overall Study|Adverse Event|1
6195862|NCT01457118|9854646|FG000|Overall Study|Clinical Progression|0
6195863|NCT01457118|9854647|FG001|Overall Study|Clinical Progression|1
6195864|NCT01457118|9854648|FG002|Overall Study|Clinical Progression|0
6195865|NCT01457118|9854649|FG003|Overall Study|Clinical Progression|1
6274578|NCT02204449|9978978|FG000|Overall Study|Death|0
6274579|NCT02204449|9978979|FG001|Overall Study|Death|1
6274580|NCT02204449|9978978|FG000|Overall Study|Withdrawal by Subject|0
6274581|NCT02204449|9978979|FG001|Overall Study|Withdrawal by Subject|1
6274582|NCT02204579|9978989|FG000|Overall Study|Screen failures|2
6274583|NCT02204917|9979015|FG000|Overall Study|Protocol Violation|1
6274584|NCT02204982|9979024|FG000|Overall Study|Patient ineligible-medical monitor|1
6274585|NCT02204982|9979025|FG001|Overall Study|Patient ineligible-medical monitor|0
6274586|NCT02204982|9979024|FG000|Overall Study|Withdrawal by Subject|1
6274587|NCT02204982|9979025|FG001|Overall Study|Withdrawal by Subject|0
6274588|NCT02204982|9979024|FG000|Overall Study|Adverse Event|1
6274589|NCT02204982|9979025|FG001|Overall Study|Adverse Event|0
6274590|NCT02204982|9979024|FG000|Overall Study|Adverse Event and Investigator decision|1
6274591|NCT02204982|9979025|FG001|Overall Study|Adverse Event and Investigator decision|0
6274592|NCT02204982|9979024|FG000|Overall Study|Physician Decision|0
6274593|NCT02204982|9979025|FG001|Overall Study|Physician Decision|2
6274594|NCT02204982|9979024|FG000|Overall Study|Protocol-Specified Disease Progression|0
6274595|NCT02204982|9979025|FG001|Overall Study|Protocol-Specified Disease Progression|4
6274596|NCT02204982|9979024|FG000|Overall Study|Termination of Study bySponsor|0
6274597|NCT02204982|9979025|FG001|Overall Study|Termination of Study bySponsor|1
6274598|NCT02205333|9979059|FG000|Overall Study|Death|5
6274599|NCT02205333|9979060|FG001|Overall Study|Death|6
6274600|NCT02205333|9979061|FG002|Overall Study|Death|2
6274601|NCT02205333|9979062|FG003|Overall Study|Death|6
6274602|NCT02205333|9979063|FG004|Overall Study|Death|5
6274603|NCT02205333|9979064|FG005|Overall Study|Death|3
6274604|NCT02205333|9979065|FG006|Overall Study|Death|3
6274605|NCT02205333|9979066|FG007|Overall Study|Death|2
6274606|NCT02205333|9979067|FG008|Overall Study|Death|0
6274607|NCT02205333|9979059|FG000|Overall Study|Withdrawal by Subject|1
5976676|NCT01712789|9563602|FG000|Overall Study|Lack of Efficacy|2
5976677|NCT01712789|9563602|FG000|Overall Study|Lost to Follow-up|1
5976678|NCT01712789|9563602|FG000|Overall Study|Progressive Disease|504
5976679|NCT01712789|9563602|FG000|Overall Study|Death|57
5976680|NCT01712789|9563602|FG000|Overall Study|Adverse Event|52
5976681|NCT01712789|9563602|FG000|Overall Study|Miscellaneous|31
5976682|NCT01712789|9563602|FG000|Overall Study|Withdrawal by Subject|21
5976683|NCT01712789|9563602|FG000|Overall Study|Transition to Commercial Treatment|8
5976684|NCT01712789|9563602|FG000|Overall Study|Participants Did Not Receive Study Drug|6
5976685|NCT01651403|9563608|FG000|Double-Blind Period (Through Week 48/72)|Participant Noncompliance|1
5976686|NCT01651403|9563609|FG001|Double-Blind Period (Through Week 48/72)|Participant Noncompliance|1
5976687|NCT01651403|9563608|FG000|Double-Blind Period (Through Week 48/72)|Withdrew Consent/Assent|3
5976688|NCT01651403|9563609|FG001|Double-Blind Period (Through Week 48/72)|Withdrew Consent/Assent|3
5976689|NCT01651403|9563608|FG000|Double-Blind Period (Through Week 48/72)|Randomized but not Treated|0
5976690|NCT01651403|9563609|FG001|Double-Blind Period (Through Week 48/72)|Randomized but not Treated|1
6195866|NCT01457118|9854646|FG000|Overall Study|Physician Decision|2
6274608|NCT02205333|9979060|FG001|Overall Study|Withdrawal by Subject|0
6274609|NCT02205333|9979061|FG002|Overall Study|Withdrawal by Subject|0
6274610|NCT02205333|9979062|FG003|Overall Study|Withdrawal by Subject|1
6274611|NCT02205333|9979063|FG004|Overall Study|Withdrawal by Subject|0
5976691|NCT01651403|9563608|FG000|Open-Label Phase (Weeks 49/73-192)|Continuing Study|13
5976692|NCT01651403|9563609|FG001|Open-Label Phase (Weeks 49/73-192)|Continuing Study|9
5976693|NCT01651403|9563608|FG000|Open-Label Phase (Weeks 49/73-192)|Investigator decision|2
5976694|NCT01651403|9563609|FG001|Open-Label Phase (Weeks 49/73-192)|Investigator decision|1
6195867|NCT01457118|9854647|FG001|Overall Study|Physician Decision|0
6195868|NCT01457118|9854648|FG002|Overall Study|Physician Decision|0
6195869|NCT01457118|9854649|FG003|Overall Study|Physician Decision|0
6195870|NCT01457118|9854646|FG000|Overall Study|Progressive Disease by RECIST|12
6195871|NCT01457118|9854647|FG001|Overall Study|Progressive Disease by RECIST|3
6195872|NCT01457118|9854648|FG002|Overall Study|Progressive Disease by RECIST|1
6195873|NCT01457118|9854649|FG003|Overall Study|Progressive Disease by RECIST|0
6195874|NCT01457118|9854646|FG000|Overall Study|Withdrawal by Subject|5
6195875|NCT01457118|9854647|FG001|Overall Study|Withdrawal by Subject|0
6195876|NCT01457118|9854648|FG002|Overall Study|Withdrawal by Subject|0
6195877|NCT01457118|9854649|FG003|Overall Study|Withdrawal by Subject|0
6195878|NCT01457339|9854667|FG000|Period 3 (100 mg)|Adverse Event|0
6195879|NCT01457339|9854668|FG001|Period 3 (100 mg)|Adverse Event|1
6195880|NCT01457339|9854667|FG000|Period 5 (200 mg)|Met stopping criteria for PANSS score|0
6195881|NCT01457339|9854668|FG001|Period 5 (200 mg)|Met stopping criteria for PANSS score|1
6195882|NCT01457339|9854667|FG000|Period 6 (250 mg)|Family Emergency|1
6195883|NCT01457339|9854668|FG001|Period 6 (250 mg)|Family Emergency|0
6195884|NCT01457339|9854667|FG000|Period 6 (250 mg)|Personal appointment|0
6195885|NCT01457339|9854668|FG001|Period 6 (250 mg)|Personal appointment|1
6195886|NCT01457352|9854693|FG000|Period 1|Adverse Event|2
6195887|NCT01457352|9854694|FG001|Period 1|Adverse Event|0
6195888|NCT01457352|9854693|FG000|Period 1|Withdrawal by Subject|2
6195889|NCT01457352|9854694|FG001|Period 1|Withdrawal by Subject|0
6195890|NCT01457352|9854693|FG000|Period 1|Physician Decision|2
6195891|NCT01457352|9854694|FG001|Period 1|Physician Decision|0
6195892|NCT01457352|9854693|FG000|Period 1|MS related disease progression|1
6195893|NCT01457352|9854694|FG001|Period 1|MS related disease progression|0
6195894|NCT01457352|9854693|FG000|Period 1|Withdrawn|1
6195895|NCT01457352|9854694|FG001|Period 1|Withdrawn|0
6195896|NCT01457352|9854693|FG000|Period 1|withdrew per sponsor|1
6195897|NCT01457352|9854694|FG001|Period 1|withdrew per sponsor|0
6195898|NCT01457352|9854693|FG000|Period 1|Protocol Violation|4
6195899|NCT01457352|9854694|FG001|Period 1|Protocol Violation|0
6195900|NCT01457352|9854693|FG000|Period 1|Did not meet eligibility criteria|3
6195901|NCT01457352|9854694|FG001|Period 1|Did not meet eligibility criteria|0
6195902|NCT01457352|9854693|FG000|Period 2|Withdrawal by Subject|23
6195903|NCT01457352|9854694|FG001|Period 2|Withdrawal by Subject|0
6195904|NCT01457352|9854693|FG000|Period 2|Adverse Event|22
6195905|NCT01457352|9854694|FG001|Period 2|Adverse Event|0
6195906|NCT01457352|9854693|FG000|Period 2|no analysis|10
6195907|NCT01457352|9854694|FG001|Period 2|no analysis|0
6195908|NCT01457352|9854693|FG000|Period 2|Lack of Efficacy|8
6195909|NCT01457352|9854694|FG001|Period 2|Lack of Efficacy|0
6195910|NCT01457352|9854693|FG000|Period 2|Protocol Violation|4
6195911|NCT01457352|9854694|FG001|Period 2|Protocol Violation|0
6195912|NCT01457352|9854693|FG000|Period 2|Sponsor's withdrawal|7
6195913|NCT01457352|9854694|FG001|Period 2|Sponsor's withdrawal|0
6195914|NCT01457352|9854693|FG000|Period 2|Lost to Follow-up|1
6195915|NCT01457352|9854694|FG001|Period 2|Lost to Follow-up|0
6195916|NCT01457352|9854693|FG000|Period 2|dose change|1
6195917|NCT01457352|9854694|FG001|Period 2|dose change|0
6195918|NCT01457352|9854693|FG000|Period 2|Physician Decision|1
6195919|NCT01457352|9854694|FG001|Period 2|Physician Decision|0
6195920|NCT01457352|9854693|FG000|Period 2|Did not meet eligibility criteria|3
6274612|NCT02205333|9979064|FG005|Overall Study|Withdrawal by Subject|0
6274613|NCT02205333|9979065|FG006|Overall Study|Withdrawal by Subject|2
6274614|NCT02205333|9979066|FG007|Overall Study|Withdrawal by Subject|0
6274615|NCT02205333|9979067|FG008|Overall Study|Withdrawal by Subject|0
6274616|NCT02205476|9979089|FG000|Overall Study|Study termination by Sponsor|7
6274617|NCT02205476|9979090|FG001|Overall Study|Study termination by Sponsor|3
6274618|NCT02205814|9979123|FG000|Overall Study|Lost to Follow-up|0
6274619|NCT02205814|9979124|FG001|Overall Study|Lost to Follow-up|0
6274620|NCT02205814|9979125|FG002|Overall Study|Lost to Follow-up|0
6274621|NCT02205814|9979126|FG003|Overall Study|Lost to Follow-up|1
6274622|NCT02205814|9979123|FG000|Overall Study|Lack of Efficacy|1
6274623|NCT02205814|9979124|FG001|Overall Study|Lack of Efficacy|0
6274624|NCT02205814|9979125|FG002|Overall Study|Lack of Efficacy|1
6274625|NCT02205814|9979126|FG003|Overall Study|Lack of Efficacy|1
6274626|NCT02205814|9979123|FG000|Overall Study|Physician Decision|0
6274627|NCT02205814|9979124|FG001|Overall Study|Physician Decision|0
6274628|NCT02205814|9979125|FG002|Overall Study|Physician Decision|1
6274629|NCT02205814|9979126|FG003|Overall Study|Physician Decision|0
6274630|NCT02205814|9979123|FG000|Overall Study|Protocol Violation|1
6274631|NCT02205814|9979124|FG001|Overall Study|Protocol Violation|0
6274632|NCT02205814|9979125|FG002|Overall Study|Protocol Violation|0
6274633|NCT02205814|9979126|FG003|Overall Study|Protocol Violation|1
6274634|NCT02205814|9979123|FG000|Overall Study|Withdrawal by Subject|0
6274635|NCT02205814|9979124|FG001|Overall Study|Withdrawal by Subject|1
6274636|NCT02205814|9979125|FG002|Overall Study|Withdrawal by Subject|2
6195921|NCT01457352|9854694|FG001|Period 2|Did not meet eligibility criteria|0
6195922|NCT01457352|9854693|FG000|Period 3|Adverse Event|1
6195923|NCT01457352|9854694|FG001|Period 3|Adverse Event|1
6195924|NCT01457352|9854693|FG000|Period 3|Withdrawal by Subject|0
6195925|NCT01457352|9854694|FG001|Period 3|Withdrawal by Subject|2
6195926|NCT01457352|9854693|FG000|Period 3|incorrect treatment|0
6195927|NCT01457352|9854694|FG001|Period 3|incorrect treatment|1
6195928|NCT01457352|9854693|FG000|Period 3|Sponsor's withdrawal|0
6195929|NCT01457352|9854694|FG001|Period 3|Sponsor's withdrawal|1
6195930|NCT01457703|9854748|FG000|Overall Study|Screen Failure|5
6195931|NCT01457703|9854749|FG001|Overall Study|Screen Failure|7
6195932|NCT01457703|9854748|FG000|Overall Study|Withdrawal by Subject|1
6195933|NCT01457703|9854749|FG001|Overall Study|Withdrawal by Subject|4
6195934|NCT01457846|9854759|FG000|Overall Study|Death before treatment|1
6195935|NCT01457846|9854760|FG001|Overall Study|Death before treatment|2
6195936|NCT01457846|9854759|FG000|Overall Study|Did not receive treatment|0
6195937|NCT01457846|9854760|FG001|Overall Study|Did not receive treatment|1
6195938|NCT01457846|9854759|FG000|Overall Study|Death|27
6195939|NCT01457846|9854760|FG001|Overall Study|Death|16
6195940|NCT01457846|9854759|FG000|Overall Study|Unclassified reason for not completed|11
6195941|NCT01457846|9854760|FG001|Overall Study|Unclassified reason for not completed|10
6195942|NCT01457846|9854759|FG000|Overall Study|Withdrawal by Subject|1
6195943|NCT01457846|9854760|FG001|Overall Study|Withdrawal by Subject|1
6195944|NCT01457846|9854759|FG000|Overall Study|Lost to Follow-up|1
6195945|NCT01457846|9854760|FG001|Overall Study|Lost to Follow-up|0
6195946|NCT01457924|9854775|FG000|Treatment Phase (Weeks 0-24)|Adverse Event|0
6195947|NCT01457924|9854776|FG001|Treatment Phase (Weeks 0-24)|Adverse Event|4
6195948|NCT01457924|9854777|FG002|Treatment Phase (Weeks 0-24)|Adverse Event|1
6195949|NCT01457924|9854778|FG003|Treatment Phase (Weeks 0-24)|Adverse Event|0
6195950|NCT01457924|9854779|FG004|Treatment Phase (Weeks 0-24)|Adverse Event|2
6195951|NCT01457924|9854775|FG000|Treatment Phase (Weeks 0-24)|Physician Decision|0
6195952|NCT01457924|9854776|FG001|Treatment Phase (Weeks 0-24)|Physician Decision|0
6195953|NCT01457924|9854777|FG002|Treatment Phase (Weeks 0-24)|Physician Decision|0
6195954|NCT01457924|9854778|FG003|Treatment Phase (Weeks 0-24)|Physician Decision|0
6195955|NCT01457924|9854779|FG004|Treatment Phase (Weeks 0-24)|Physician Decision|1
6195956|NCT01457924|9854775|FG000|Treatment Phase (Weeks 0-24)|Lack of Efficacy|1
6195957|NCT01457924|9854776|FG001|Treatment Phase (Weeks 0-24)|Lack of Efficacy|0
6195958|NCT01457924|9854777|FG002|Treatment Phase (Weeks 0-24)|Lack of Efficacy|0
6195959|NCT01457924|9854778|FG003|Treatment Phase (Weeks 0-24)|Lack of Efficacy|0
6195960|NCT01457924|9854779|FG004|Treatment Phase (Weeks 0-24)|Lack of Efficacy|0
6195961|NCT01457924|9854775|FG000|Treatment Phase (Weeks 0-24)|Protocol Violation|1
6195962|NCT01457924|9854776|FG001|Treatment Phase (Weeks 0-24)|Protocol Violation|0
6195963|NCT01457924|9854777|FG002|Treatment Phase (Weeks 0-24)|Protocol Violation|1
6195964|NCT01457924|9854778|FG003|Treatment Phase (Weeks 0-24)|Protocol Violation|0
6195965|NCT01457924|9854779|FG004|Treatment Phase (Weeks 0-24)|Protocol Violation|0
6195966|NCT01457924|9854775|FG000|Treatment Phase (Weeks 0-24)|Withdrawal by Subject|0
6274637|NCT02205814|9979126|FG003|Overall Study|Withdrawal by Subject|1
6274638|NCT02205814|9979123|FG000|Overall Study|not compliant with study procedures|0
6274639|NCT02205814|9979124|FG001|Overall Study|not compliant with study procedures|0
6274640|NCT02205814|9979125|FG002|Overall Study|not compliant with study procedures|1
6274641|NCT02205814|9979126|FG003|Overall Study|not compliant with study procedures|0
6274642|NCT02206061|9979156|FG000|Overall Study|Withdrawal by Subject|4
6274643|NCT02206061|9979157|FG001|Overall Study|Withdrawal by Subject|7
6274644|NCT02206061|9979158|FG002|Overall Study|Withdrawal by Subject|1
6274645|NCT02206061|9979156|FG000|Overall Study|Lost to Follow-up|14
6274646|NCT02206061|9979157|FG001|Overall Study|Lost to Follow-up|7
6274647|NCT02206061|9979158|FG002|Overall Study|Lost to Follow-up|20
6274648|NCT02206152|9979166|FG000|Pre-Randomization|Withdrawal by Subject|2
6274649|NCT02206607|9979181|FG000|Open-Label Run-In|Withdrawal by Subject|3
6274650|NCT02206607|9979182|FG001|Open-Label Run-In|Withdrawal by Subject|0
6274651|NCT02206607|9979183|FG002|Open-Label Run-In|Withdrawal by Subject|0
6274652|NCT02206607|9979184|FG003|Open-Label Run-In|Withdrawal by Subject|0
6195967|NCT01457924|9854776|FG001|Treatment Phase (Weeks 0-24)|Withdrawal by Subject|0
6195968|NCT01457924|9854777|FG002|Treatment Phase (Weeks 0-24)|Withdrawal by Subject|0
6274653|NCT02206607|9979185|FG004|Open-Label Run-In|Withdrawal by Subject|0
6274654|NCT02206607|9979181|FG000|Second Intervention Period|Insufficient Clinical Response|0
6274655|NCT02206607|9979182|FG001|Second Intervention Period|Insufficient Clinical Response|0
6195969|NCT01457924|9854778|FG003|Treatment Phase (Weeks 0-24)|Withdrawal by Subject|1
6195970|NCT01457924|9854779|FG004|Treatment Phase (Weeks 0-24)|Withdrawal by Subject|1
6195971|NCT01457924|9854775|FG000|Treatment Phase (Weeks 0-24)|Other-Protocol defined stopping criteria|1
6195972|NCT01457924|9854776|FG001|Treatment Phase (Weeks 0-24)|Other-Protocol defined stopping criteria|1
6195973|NCT01457924|9854777|FG002|Treatment Phase (Weeks 0-24)|Other-Protocol defined stopping criteria|0
6195974|NCT01457924|9854778|FG003|Treatment Phase (Weeks 0-24)|Other-Protocol defined stopping criteria|0
6195975|NCT01457924|9854779|FG004|Treatment Phase (Weeks 0-24)|Other-Protocol defined stopping criteria|2
6195976|NCT01457924|9854775|FG000|FUP (Weeks 24-48)|Adverse Event|0
6195977|NCT01457924|9854776|FG001|FUP (Weeks 24-48)|Adverse Event|0
6195978|NCT01457924|9854777|FG002|FUP (Weeks 24-48)|Adverse Event|1
6195979|NCT01457924|9854778|FG003|FUP (Weeks 24-48)|Adverse Event|0
6274656|NCT02206607|9979183|FG002|Second Intervention Period|Insufficient Clinical Response|0
6274657|NCT02206607|9979184|FG003|Second Intervention Period|Insufficient Clinical Response|1
6274658|NCT02206607|9979185|FG004|Second Intervention Period|Insufficient Clinical Response|0
6274659|NCT02206620|9979201|FG000|Phase I - First Intervention (6 Weeks)|Withdrawal by Subject|1
6274660|NCT02206620|9979202|FG001|Phase I - First Intervention (6 Weeks)|Withdrawal by Subject|1
6274661|NCT02206620|9979201|FG000|Phase II - Second Intervention (6 Weeks)|Withdrawal by Subject|0
6274662|NCT02206620|9979202|FG001|Phase II - Second Intervention (6 Weeks)|Withdrawal by Subject|2
6274663|NCT02206685|9979216|FG000|Overall Study|Surgery cancelled/changed|2
6274664|NCT02206685|9979217|FG001|Overall Study|Surgery cancelled/changed|3
6274665|NCT02206685|9979216|FG000|Overall Study|Withdrawal by Subject|1
6274666|NCT02206685|9979217|FG001|Overall Study|Withdrawal by Subject|2
6274667|NCT02206685|9979216|FG000|Overall Study|Protocol Violation|2
6274668|NCT02206685|9979217|FG001|Overall Study|Protocol Violation|2
6274669|NCT02206828|9979232|FG000|Overall Study|Lost to Follow-up|7
6274670|NCT02207088|9979259|FG000|Overall Study|Adverse Event|2
6274671|NCT02207231|9979266|FG000|Placebo Controlled Period: Week 0 - 16|Adverse Event|2
6274672|NCT02207231|9979267|FG001|Placebo Controlled Period: Week 0 - 16|Adverse Event|4
6274673|NCT02207231|9979268|FG002|Placebo Controlled Period: Week 0 - 16|Adverse Event|2
6274674|NCT02207231|9979269|FG003|Placebo Controlled Period: Week 0 - 16|Adverse Event|0
6274675|NCT02207231|9979266|FG000|Placebo Controlled Period: Week 0 - 16|Lack of Efficacy|2
5976695|NCT01651403|9563608|FG000|Open-Label Phase (Weeks 49/73-192)|Withdrew consent/assent|6
5976696|NCT01651403|9563609|FG001|Open-Label Phase (Weeks 49/73-192)|Withdrew consent/assent|4
5976697|NCT01542736|9563624|FG000|Overall Study|Death|1
5976698|NCT01535807|9563630|FG000|Overall Study|Withdrawal by Subject|1
5976699|NCT01535807|9563631|FG001|Overall Study|Withdrawal by Subject|1
5976700|NCT01535807|9563630|FG000|Overall Study|Data collection error|1
5976701|NCT01535807|9563631|FG001|Overall Study|Data collection error|1
5976702|NCT01147666|9563652|FG000|Dosing Period 1: 6-Week Treatment|Adverse Event|1
5976703|NCT01147666|9563653|FG001|Dosing Period 1: 6-Week Treatment|Adverse Event|1
5976704|NCT01147666|9563654|FG002|Dosing Period 1: 6-Week Treatment|Adverse Event|1
5976705|NCT01147666|9563655|FG003|Dosing Period 1: 6-Week Treatment|Adverse Event|0
5976706|NCT01147666|9563656|FG004|Dosing Period 1: 6-Week Treatment|Adverse Event|0
6195980|NCT01457924|9854779|FG004|FUP (Weeks 24-48)|Adverse Event|0
6195981|NCT01457924|9854775|FG000|FUP (Weeks 24-48)|Physician Decision|1
6195982|NCT01457924|9854776|FG001|FUP (Weeks 24-48)|Physician Decision|0
6195983|NCT01457924|9854777|FG002|FUP (Weeks 24-48)|Physician Decision|1
6195984|NCT01457924|9854778|FG003|FUP (Weeks 24-48)|Physician Decision|0
6195985|NCT01457924|9854779|FG004|FUP (Weeks 24-48)|Physician Decision|0
6195986|NCT01457924|9854775|FG000|FUP (Weeks 24-48)|Lost to Follow-up|0
6195987|NCT01457924|9854776|FG001|FUP (Weeks 24-48)|Lost to Follow-up|0
6195988|NCT01457924|9854777|FG002|FUP (Weeks 24-48)|Lost to Follow-up|0
6195989|NCT01457924|9854778|FG003|FUP (Weeks 24-48)|Lost to Follow-up|1
6195990|NCT01457924|9854779|FG004|FUP (Weeks 24-48)|Lost to Follow-up|0
6195991|NCT01457924|9854775|FG000|FUP (Weeks 24-48)|Withdrawal by Subject|2
6195992|NCT01457924|9854776|FG001|FUP (Weeks 24-48)|Withdrawal by Subject|1
6195993|NCT01457924|9854777|FG002|FUP (Weeks 24-48)|Withdrawal by Subject|0
6195994|NCT01457924|9854778|FG003|FUP (Weeks 24-48)|Withdrawal by Subject|0
6195995|NCT01457924|9854779|FG004|FUP (Weeks 24-48)|Withdrawal by Subject|2
6195996|NCT01457924|9854775|FG000|Individualized FUP (Weeks 48+)|Lost to Follow-up|1
6195997|NCT01457924|9854776|FG001|Individualized FUP (Weeks 48+)|Lost to Follow-up|0
6195998|NCT01457924|9854777|FG002|Individualized FUP (Weeks 48+)|Lost to Follow-up|1
6195999|NCT01457924|9854778|FG003|Individualized FUP (Weeks 48+)|Lost to Follow-up|0
6196000|NCT01457924|9854779|FG004|Individualized FUP (Weeks 48+)|Lost to Follow-up|0
6196001|NCT01457924|9854775|FG000|Individualized FUP (Weeks 48+)|Other-Protocol defined stopping criteria|3
6196002|NCT01457924|9854776|FG001|Individualized FUP (Weeks 48+)|Other-Protocol defined stopping criteria|4
6196003|NCT01457924|9854777|FG002|Individualized FUP (Weeks 48+)|Other-Protocol defined stopping criteria|2
6196004|NCT01457924|9854778|FG003|Individualized FUP (Weeks 48+)|Other-Protocol defined stopping criteria|3
6196005|NCT01457924|9854779|FG004|Individualized FUP (Weeks 48+)|Other-Protocol defined stopping criteria|5
6196006|NCT01457924|9854775|FG000|Individualized FUP (Weeks 48+)|Withdrawal by Subject|1
6196007|NCT01457924|9854776|FG001|Individualized FUP (Weeks 48+)|Withdrawal by Subject|0
6196008|NCT01457924|9854777|FG002|Individualized FUP (Weeks 48+)|Withdrawal by Subject|1
6196009|NCT01457924|9854778|FG003|Individualized FUP (Weeks 48+)|Withdrawal by Subject|2
6196010|NCT01457924|9854779|FG004|Individualized FUP (Weeks 48+)|Withdrawal by Subject|1
6196011|NCT01457950|9854793|FG000|Double-Blind Phase|Continuation Criteria Not Met|1
6196012|NCT01457950|9854794|FG001|Double-Blind Phase|Continuation Criteria Not Met|0
6196013|NCT01457950|9854795|FG002|Double-Blind Phase|Continuation Criteria Not Met|0
6196014|NCT01457950|9854796|FG003|Double-Blind Phase|Continuation Criteria Not Met|0
6196015|NCT01457950|9854793|FG000|Double-Blind Phase|Protocol Violation|2
6196016|NCT01457950|9854794|FG001|Double-Blind Phase|Protocol Violation|1
6196017|NCT01457950|9854795|FG002|Double-Blind Phase|Protocol Violation|0
6274676|NCT02207231|9979267|FG001|Placebo Controlled Period: Week 0 - 16|Lack of Efficacy|0
6274677|NCT02207231|9979268|FG002|Placebo Controlled Period: Week 0 - 16|Lack of Efficacy|1
6274678|NCT02207231|9979269|FG003|Placebo Controlled Period: Week 0 - 16|Lack of Efficacy|0
6274679|NCT02207231|9979266|FG000|Placebo Controlled Period: Week 0 - 16|Lost to Follow-up|1
6274680|NCT02207231|9979267|FG001|Placebo Controlled Period: Week 0 - 16|Lost to Follow-up|1
6274681|NCT02207231|9979268|FG002|Placebo Controlled Period: Week 0 - 16|Lost to Follow-up|1
6274682|NCT02207231|9979269|FG003|Placebo Controlled Period: Week 0 - 16|Lost to Follow-up|0
6274683|NCT02207231|9979266|FG000|Placebo Controlled Period: Week 0 - 16|Withdrawal by Subject|2
6274684|NCT02207231|9979267|FG001|Placebo Controlled Period: Week 0 - 16|Withdrawal by Subject|0
6274685|NCT02207231|9979268|FG002|Placebo Controlled Period: Week 0 - 16|Withdrawal by Subject|4
6274686|NCT02207231|9979269|FG003|Placebo Controlled Period: Week 0 - 16|Withdrawal by Subject|0
6274687|NCT02207231|9979266|FG000|Placebo Controlled Period: Week 0 - 16|Protocol Violation|0
6274688|NCT02207231|9979267|FG001|Placebo Controlled Period: Week 0 - 16|Protocol Violation|0
6274689|NCT02207231|9979268|FG002|Placebo Controlled Period: Week 0 - 16|Protocol Violation|1
6274690|NCT02207231|9979269|FG003|Placebo Controlled Period: Week 0 - 16|Protocol Violation|0
6274691|NCT02207231|9979266|FG000|Placebo Controlled Period: Week 0 - 16|Noncompliance|0
6274692|NCT02207231|9979267|FG001|Placebo Controlled Period: Week 0 - 16|Noncompliance|2
6274693|NCT02207231|9979268|FG002|Placebo Controlled Period: Week 0 - 16|Noncompliance|1
6274694|NCT02207231|9979269|FG003|Placebo Controlled Period: Week 0 - 16|Noncompliance|0
6274695|NCT02207231|9979266|FG000|Active Controlled Period: Week 16 - 48|Adverse Event|1
6274696|NCT02207231|9979267|FG001|Active Controlled Period: Week 16 - 48|Adverse Event|6
6274697|NCT02207231|9979268|FG002|Active Controlled Period: Week 16 - 48|Adverse Event|10
6274698|NCT02207231|9979269|FG003|Active Controlled Period: Week 16 - 48|Adverse Event|0
6274699|NCT02207231|9979266|FG000|Active Controlled Period: Week 16 - 48|Pregnancy|0
6274700|NCT02207231|9979267|FG001|Active Controlled Period: Week 16 - 48|Pregnancy|0
6274701|NCT02207231|9979268|FG002|Active Controlled Period: Week 16 - 48|Pregnancy|1
6274702|NCT02207231|9979269|FG003|Active Controlled Period: Week 16 - 48|Pregnancy|0
6274703|NCT02207231|9979266|FG000|Active Controlled Period: Week 16 - 48|Lack of Efficacy|0
6274704|NCT02207231|9979267|FG001|Active Controlled Period: Week 16 - 48|Lack of Efficacy|3
6274705|NCT02207231|9979268|FG002|Active Controlled Period: Week 16 - 48|Lack of Efficacy|11
6274706|NCT02207231|9979269|FG003|Active Controlled Period: Week 16 - 48|Lack of Efficacy|0
6274707|NCT02207231|9979266|FG000|Active Controlled Period: Week 16 - 48|Lost to Follow-up|1
6274708|NCT02207231|9979267|FG001|Active Controlled Period: Week 16 - 48|Lost to Follow-up|2
6274709|NCT02207231|9979268|FG002|Active Controlled Period: Week 16 - 48|Lost to Follow-up|5
6196018|NCT01457950|9854796|FG003|Double-Blind Phase|Protocol Violation|0
6196019|NCT01457950|9854793|FG000|Double-Blind Phase|Withdrawal by Subject|6
6196020|NCT01457950|9854794|FG001|Double-Blind Phase|Withdrawal by Subject|2
6196021|NCT01457950|9854795|FG002|Double-Blind Phase|Withdrawal by Subject|0
6196022|NCT01457950|9854796|FG003|Double-Blind Phase|Withdrawal by Subject|0
6196023|NCT01457950|9854793|FG000|Open-Label Phase|Adverse Event|0
6196024|NCT01457950|9854794|FG001|Open-Label Phase|Adverse Event|0
6196025|NCT01457950|9854795|FG002|Open-Label Phase|Adverse Event|0
6196026|NCT01457950|9854796|FG003|Open-Label Phase|Adverse Event|1
6196027|NCT01457950|9854793|FG000|Open-Label Phase|Protocol Violation|0
6196028|NCT01457950|9854794|FG001|Open-Label Phase|Protocol Violation|0
6196029|NCT01457950|9854795|FG002|Open-Label Phase|Protocol Violation|0
6196030|NCT01457950|9854796|FG003|Open-Label Phase|Protocol Violation|1
6196031|NCT01457950|9854793|FG000|Open-Label Phase|Withdrawal by Subject|0
6196032|NCT01457950|9854794|FG001|Open-Label Phase|Withdrawal by Subject|0
6196033|NCT01457950|9854795|FG002|Open-Label Phase|Withdrawal by Subject|2
6196034|NCT01457950|9854796|FG003|Open-Label Phase|Withdrawal by Subject|0
6196035|NCT01458106|9854809|FG000|Overall Study|Withdrawal by Subject|2
6196036|NCT01458106|9854810|FG001|Overall Study|Withdrawal by Subject|0
6196037|NCT01458106|9854809|FG000|Overall Study|Pre-rFVIIIFc Adverse Event|1
6196038|NCT01458106|9854810|FG001|Overall Study|Pre-rFVIIIFc Adverse Event|0
6196039|NCT01458106|9854809|FG000|Overall Study|Withdrawn Per Protocol|0
6196040|NCT01458106|9854810|FG001|Overall Study|Withdrawn Per Protocol|1
6196041|NCT01458119|9854819|FG000|Overall Study|Physician Decision|4
6274710|NCT02207231|9979269|FG003|Active Controlled Period: Week 16 - 48|Lost to Follow-up|0
6274711|NCT02207231|9979266|FG000|Active Controlled Period: Week 16 - 48|Withdrawal by Subject|1
6274712|NCT02207231|9979267|FG001|Active Controlled Period: Week 16 - 48|Withdrawal by Subject|4
6274713|NCT02207231|9979268|FG002|Active Controlled Period: Week 16 - 48|Withdrawal by Subject|10
6274714|NCT02207231|9979269|FG003|Active Controlled Period: Week 16 - 48|Withdrawal by Subject|0
6274715|NCT02207231|9979266|FG000|Active Controlled Period: Week 16 - 48|Protocol Violation|0
6274716|NCT02207231|9979267|FG001|Active Controlled Period: Week 16 - 48|Protocol Violation|1
6274717|NCT02207231|9979268|FG002|Active Controlled Period: Week 16 - 48|Protocol Violation|0
6274718|NCT02207231|9979269|FG003|Active Controlled Period: Week 16 - 48|Protocol Violation|0
6274719|NCT02207231|9979266|FG000|Active Controlled Period: Week 16 - 48|Noncompliance|0
6274720|NCT02207231|9979267|FG001|Active Controlled Period: Week 16 - 48|Noncompliance|3
6274721|NCT02207231|9979268|FG002|Active Controlled Period: Week 16 - 48|Noncompliance|3
5976707|NCT01147666|9563657|FG005|Dosing Period 1: 6-Week Treatment|Adverse Event|0
5976708|NCT01147666|9563658|FG006|Dosing Period 1: 6-Week Treatment|Adverse Event|0
5976709|NCT01147666|9563659|FG007|Dosing Period 1: 6-Week Treatment|Adverse Event|0
5976710|NCT01147666|9563660|FG008|Dosing Period 1: 6-Week Treatment|Adverse Event|0
5976711|NCT01147666|9563661|FG009|Dosing Period 1: 6-Week Treatment|Adverse Event|0
5976712|NCT01147666|9563662|FG010|Dosing Period 1: 6-Week Treatment|Adverse Event|0
5976713|NCT01147666|9563663|FG011|Dosing Period 1: 6-Week Treatment|Adverse Event|0
5976714|NCT01147666|9563664|FG012|Dosing Period 1: 6-Week Treatment|Adverse Event|1
5976715|NCT01147666|9563665|FG013|Dosing Period 1: 6-Week Treatment|Adverse Event|0
5976716|NCT01147666|9563666|FG014|Dosing Period 1: 6-Week Treatment|Adverse Event|0
5976717|NCT01147666|9563652|FG000|Dosing Period 1: 6-Week Treatment|Lack of Efficacy|0
5976718|NCT01147666|9563653|FG001|Dosing Period 1: 6-Week Treatment|Lack of Efficacy|1
5976719|NCT01147666|9563654|FG002|Dosing Period 1: 6-Week Treatment|Lack of Efficacy|0
5976720|NCT01147666|9563655|FG003|Dosing Period 1: 6-Week Treatment|Lack of Efficacy|0
5976721|NCT01147666|9563656|FG004|Dosing Period 1: 6-Week Treatment|Lack of Efficacy|3
5976722|NCT01147666|9563657|FG005|Dosing Period 1: 6-Week Treatment|Lack of Efficacy|1
5976723|NCT01147666|9563658|FG006|Dosing Period 1: 6-Week Treatment|Lack of Efficacy|2
5976724|NCT01147666|9563659|FG007|Dosing Period 1: 6-Week Treatment|Lack of Efficacy|2
5976725|NCT01147666|9563660|FG008|Dosing Period 1: 6-Week Treatment|Lack of Efficacy|0
5976726|NCT01147666|9563661|FG009|Dosing Period 1: 6-Week Treatment|Lack of Efficacy|1
5976727|NCT01147666|9563662|FG010|Dosing Period 1: 6-Week Treatment|Lack of Efficacy|0
5976728|NCT01147666|9563663|FG011|Dosing Period 1: 6-Week Treatment|Lack of Efficacy|0
5976729|NCT01147666|9563664|FG012|Dosing Period 1: 6-Week Treatment|Lack of Efficacy|1
5976730|NCT01147666|9563665|FG013|Dosing Period 1: 6-Week Treatment|Lack of Efficacy|0
5976731|NCT01147666|9563666|FG014|Dosing Period 1: 6-Week Treatment|Lack of Efficacy|3
5976732|NCT01147666|9563652|FG000|Dosing Period 1: 6-Week Treatment|Death|0
6050706|NCT00428389|9649927|FG001|Core Phase|Abnormal test procedure result(s)|1
6050707|NCT00428389|9649926|FG000|Core Phase|Withdrawal by Subject|3
6050708|NCT00428389|9649927|FG001|Core Phase|Withdrawal by Subject|4
6050709|NCT00428389|9649926|FG000|Core Phase|Protocol deviation|0
6050710|NCT00428389|9649927|FG001|Core Phase|Protocol deviation|2
6050711|NCT00428389|9649926|FG000|Extension Phase|Adverse Event|17
6050712|NCT00428389|9649927|FG001|Extension Phase|Adverse Event|11
6050713|NCT00428389|9649926|FG000|Extension Phase|Lack of Efficacy|4
6050714|NCT00428389|9649927|FG001|Extension Phase|Lack of Efficacy|3
6050715|NCT00428389|9649926|FG000|Extension Phase|Withdrawal by Subject|6
6196042|NCT01458119|9854819|FG000|Overall Study|Withdrawal Due to Nonamenable Mutation|1
6196043|NCT01458119|9854819|FG000|Overall Study|Pregnancy|1
6196044|NCT01458119|9854819|FG000|Overall Study|Death|2
6196045|NCT01458119|9854819|FG000|Overall Study|Adverse Event|1
6196046|NCT01458119|9854819|FG000|Overall Study|Consent Withdrawn by Participant|8
6196047|NCT01458119|9854819|FG000|Overall Study|Non-compliance With Study Drug|3
6196048|NCT01458132|9854826|FG000|Overall Study|Other|15
6196049|NCT01458132|9854827|FG001|Overall Study|Other|3
6196050|NCT01458171|9854833|FG000|Overall Study|Adverse Event|1
6196051|NCT01458210|9854839|FG000|Ortho-Cyclen Alone (Period 1)|Withdrawal by Subject|2
6196052|NCT01458210|9854839|FG000|Ortho-Cyclen Alone (Period 1)|Lost to Follow-up|2
6196053|NCT01458210|9854839|FG000|Ortho-Cyclen + Dulaglutide (Period 2)|Withdrawal by Subject|2
6196054|NCT01458210|9854839|FG000|Ortho-Cyclen + Dulaglutide (Period 2)|Adverse Event|1
6196055|NCT01458249|9854848|FG000|Overall Study|Not treated|1
6196056|NCT01458249|9854848|FG000|Overall Study|Adverse Event|4
6196057|NCT01458249|9854848|FG000|Overall Study|Other|2
6196058|NCT01458249|9854848|FG000|Overall Study|Ongoing|1
6196059|NCT01458275|9854856|FG000|Overall Study|Adverse Event|3
6196060|NCT01458275|9854857|FG001|Overall Study|Adverse Event|4
6196061|NCT01458275|9854858|FG002|Overall Study|Adverse Event|1
6196062|NCT01458275|9854856|FG000|Overall Study|Lost to Follow-up|3
6196063|NCT01458275|9854857|FG001|Overall Study|Lost to Follow-up|2
6196064|NCT01458275|9854858|FG002|Overall Study|Lost to Follow-up|5
6196065|NCT01458275|9854856|FG000|Overall Study|Protocol Violation|5
6196066|NCT01458275|9854857|FG001|Overall Study|Protocol Violation|5
6196067|NCT01458275|9854858|FG002|Overall Study|Protocol Violation|2
6196068|NCT01458275|9854856|FG000|Overall Study|Withdrawal by Subject|3
6196069|NCT01458275|9854857|FG001|Overall Study|Withdrawal by Subject|2
6196070|NCT01458275|9854858|FG002|Overall Study|Withdrawal by Subject|1
6196071|NCT01458366|9854883|FG000|Period 1: 70mg/m^2|Physician Decision|2
6196072|NCT01458366|9854884|FG001|Period 1: 70mg/m^2|Physician Decision|0
6196073|NCT01458366|9854885|FG002|Period 1: 70mg/m^2|Physician Decision|0
6196074|NCT01458366|9854886|FG003|Period 1: 70mg/m^2|Physician Decision|0
6196075|NCT01458366|9854887|FG004|Period 1: 70mg/m^2|Physician Decision|0
6196076|NCT01458366|9854883|FG000|Period 5: Maximum Tolerated Dose (MTD)|Withdrawal by Subject|0
6196077|NCT01458366|9854884|FG001|Period 5: Maximum Tolerated Dose (MTD)|Withdrawal by Subject|0
6196078|NCT01458366|9854885|FG002|Period 5: Maximum Tolerated Dose (MTD)|Withdrawal by Subject|0
6196079|NCT01458366|9854886|FG003|Period 5: Maximum Tolerated Dose (MTD)|Withdrawal by Subject|0
6196080|NCT01458366|9854887|FG004|Period 5: Maximum Tolerated Dose (MTD)|Withdrawal by Subject|1
6196081|NCT01458392|9854898|FG000|Overall Study|Death|2
6196082|NCT01458392|9854899|FG001|Overall Study|Death|11
6196083|NCT01458392|9854900|FG002|Overall Study|Death|22
6196084|NCT01458392|9854898|FG000|Overall Study|At the discretion of the sponsor|0
6196085|NCT01458392|9854899|FG001|Overall Study|At the discretion of the sponsor|2
6196086|NCT01458392|9854900|FG002|Overall Study|At the discretion of the sponsor|7
6196087|NCT01458392|9854898|FG000|Overall Study|Patient unwilling to comply with protoco|0
6196088|NCT01458392|9854899|FG001|Overall Study|Patient unwilling to comply with protoco|0
6274722|NCT02207231|9979269|FG003|Active Controlled Period: Week 16 - 48|Noncompliance|0
6274723|NCT02207231|9979266|FG000|Active Controlled Period: Week 16 - 48|Other|0
6274724|NCT02207231|9979267|FG001|Active Controlled Period: Week 16 - 48|Other|2
6274725|NCT02207231|9979268|FG002|Active Controlled Period: Week 16 - 48|Other|3
6274726|NCT02207231|9979269|FG003|Active Controlled Period: Week 16 - 48|Other|0
6274727|NCT02207231|9979266|FG000|Open-label Guselkumab: Week 48 - 264|Adverse Event|0
6274728|NCT02207231|9979267|FG001|Open-label Guselkumab: Week 48 - 264|Adverse Event|0
6274729|NCT02207231|9979268|FG002|Open-label Guselkumab: Week 48 - 264|Adverse Event|12
6274730|NCT02207231|9979269|FG003|Open-label Guselkumab: Week 48 - 264|Adverse Event|19
6274731|NCT02207231|9979266|FG000|Open-label Guselkumab: Week 48 - 264|Death|0
6274732|NCT02207231|9979267|FG001|Open-label Guselkumab: Week 48 - 264|Death|0
6274733|NCT02207231|9979268|FG002|Open-label Guselkumab: Week 48 - 264|Death|1
6274734|NCT02207231|9979269|FG003|Open-label Guselkumab: Week 48 - 264|Death|3
6274735|NCT02207231|9979266|FG000|Open-label Guselkumab: Week 48 - 264|Pregnancy|0
6274736|NCT02207231|9979267|FG001|Open-label Guselkumab: Week 48 - 264|Pregnancy|0
6196089|NCT01458392|9854900|FG002|Overall Study|Patient unwilling to comply with protoco|2
6196090|NCT01458522|9854931|FG000|Overall Study|Withdrawal by Subject|2
6196091|NCT01458522|9854932|FG001|Overall Study|Withdrawal by Subject|2
6196092|NCT01458522|9854931|FG000|Overall Study|Physician Decision|1
6196093|NCT01458522|9854932|FG001|Overall Study|Physician Decision|9
6196094|NCT01458535|9854950|FG000|Overall Study|Other|0
6196095|NCT01458535|9854951|FG001|Overall Study|Other|0
6196096|NCT01458535|9854952|FG002|Overall Study|Other|0
6196097|NCT01458535|9854953|FG003|Overall Study|Other|0
6196098|NCT01458535|9854954|FG004|Overall Study|Other|1
6196099|NCT01458535|9854955|FG005|Overall Study|Other|1
6196100|NCT01458535|9854950|FG000|Overall Study|Withdrawal by Subject|0
6196101|NCT01458535|9854951|FG001|Overall Study|Withdrawal by Subject|0
6196102|NCT01458535|9854952|FG002|Overall Study|Withdrawal by Subject|2
6196103|NCT01458535|9854953|FG003|Overall Study|Withdrawal by Subject|0
6196104|NCT01458535|9854954|FG004|Overall Study|Withdrawal by Subject|1
6196105|NCT01458535|9854955|FG005|Overall Study|Withdrawal by Subject|1
6196106|NCT01458535|9854950|FG000|Overall Study|Lost to Follow-up|0
6196107|NCT01458535|9854951|FG001|Overall Study|Lost to Follow-up|2
6196108|NCT01458535|9854952|FG002|Overall Study|Lost to Follow-up|0
6274737|NCT02207231|9979268|FG002|Open-label Guselkumab: Week 48 - 264|Pregnancy|3
6196109|NCT01458535|9854953|FG003|Overall Study|Lost to Follow-up|3
6196110|NCT01458535|9854954|FG004|Overall Study|Lost to Follow-up|2
6196111|NCT01458535|9854955|FG005|Overall Study|Lost to Follow-up|2
6196112|NCT01458535|9854950|FG000|Overall Study|Adverse Event|0
6196113|NCT01458535|9854951|FG001|Overall Study|Adverse Event|0
6196114|NCT01458535|9854952|FG002|Overall Study|Adverse Event|0
6196115|NCT01458535|9854953|FG003|Overall Study|Adverse Event|1
6196116|NCT01458535|9854954|FG004|Overall Study|Adverse Event|0
6196117|NCT01458535|9854955|FG005|Overall Study|Adverse Event|0
6196118|NCT01458574|9855011|FG000|Overall Study|Adverse Event|5
6196119|NCT01458574|9855012|FG001|Overall Study|Adverse Event|9
6196120|NCT01458574|9855013|FG002|Overall Study|Adverse Event|7
6196121|NCT01458574|9855011|FG000|Overall Study|Lack of Efficacy|70
6196122|NCT01458574|9855012|FG001|Overall Study|Lack of Efficacy|53
6196123|NCT01458574|9855013|FG002|Overall Study|Lack of Efficacy|132
6274738|NCT02207231|9979269|FG003|Open-label Guselkumab: Week 48 - 264|Pregnancy|7
6274739|NCT02207231|9979266|FG000|Open-label Guselkumab: Week 48 - 264|Lack of Efficacy|0
6274740|NCT02207231|9979267|FG001|Open-label Guselkumab: Week 48 - 264|Lack of Efficacy|0
6274741|NCT02207231|9979268|FG002|Open-label Guselkumab: Week 48 - 264|Lack of Efficacy|2
6274742|NCT02207231|9979269|FG003|Open-label Guselkumab: Week 48 - 264|Lack of Efficacy|4
6274743|NCT02207231|9979266|FG000|Open-label Guselkumab: Week 48 - 264|Lost to Follow-up|0
6274744|NCT02207231|9979267|FG001|Open-label Guselkumab: Week 48 - 264|Lost to Follow-up|0
6274745|NCT02207231|9979268|FG002|Open-label Guselkumab: Week 48 - 264|Lost to Follow-up|6
6274746|NCT02207231|9979269|FG003|Open-label Guselkumab: Week 48 - 264|Lost to Follow-up|11
6274747|NCT02207231|9979266|FG000|Open-label Guselkumab: Week 48 - 264|Withdrawal by Subject|0
6274748|NCT02207231|9979267|FG001|Open-label Guselkumab: Week 48 - 264|Withdrawal by Subject|0
6274749|NCT02207231|9979268|FG002|Open-label Guselkumab: Week 48 - 264|Withdrawal by Subject|10
6274750|NCT02207231|9979269|FG003|Open-label Guselkumab: Week 48 - 264|Withdrawal by Subject|28
6274751|NCT02207231|9979266|FG000|Open-label Guselkumab: Week 48 - 264|Other|0
6274752|NCT02207231|9979267|FG001|Open-label Guselkumab: Week 48 - 264|Other|0
6274753|NCT02207231|9979268|FG002|Open-label Guselkumab: Week 48 - 264|Other|4
6274754|NCT02207231|9979269|FG003|Open-label Guselkumab: Week 48 - 264|Other|11
6274755|NCT02207244|9979290|FG000|Placebo Controlled Period: Week 0-16|Adverse Event|2
6274756|NCT02207244|9979291|FG001|Placebo Controlled Period: Week 0-16|Adverse Event|9
6274757|NCT02207244|9979292|FG002|Placebo Controlled Period: Week 0-16|Adverse Event|4
6274758|NCT02207244|9979293|FG003|Placebo Controlled Period: Week 0-16|Adverse Event|0
6274759|NCT02207244|9979294|FG004|Placebo Controlled Period: Week 0-16|Adverse Event|0
6274760|NCT02207244|9979295|FG005|Placebo Controlled Period: Week 0-16|Adverse Event|0
6274761|NCT02207244|9979296|FG006|Placebo Controlled Period: Week 0-16|Adverse Event|0
6274762|NCT02207244|9979297|FG007|Placebo Controlled Period: Week 0-16|Adverse Event|0
6274763|NCT02207244|9979298|FG008|Placebo Controlled Period: Week 0-16|Adverse Event|0
6274764|NCT02207244|9979299|FG009|Placebo Controlled Period: Week 0-16|Adverse Event|0
6274765|NCT02207244|9979300|FG010|Placebo Controlled Period: Week 0-16|Adverse Event|0
6274766|NCT02207244|9979290|FG000|Placebo Controlled Period: Week 0-16|Lack of Efficacy|4
6274767|NCT02207244|9979291|FG001|Placebo Controlled Period: Week 0-16|Lack of Efficacy|0
6274768|NCT02207244|9979292|FG002|Placebo Controlled Period: Week 0-16|Lack of Efficacy|2
6274769|NCT02207244|9979293|FG003|Placebo Controlled Period: Week 0-16|Lack of Efficacy|0
6274770|NCT02207244|9979294|FG004|Placebo Controlled Period: Week 0-16|Lack of Efficacy|0
6274771|NCT02207244|9979295|FG005|Placebo Controlled Period: Week 0-16|Lack of Efficacy|0
6274772|NCT02207244|9979296|FG006|Placebo Controlled Period: Week 0-16|Lack of Efficacy|0
6274773|NCT02207244|9979297|FG007|Placebo Controlled Period: Week 0-16|Lack of Efficacy|0
6274774|NCT02207244|9979298|FG008|Placebo Controlled Period: Week 0-16|Lack of Efficacy|0
6274775|NCT02207244|9979299|FG009|Placebo Controlled Period: Week 0-16|Lack of Efficacy|0
6274776|NCT02207244|9979300|FG010|Placebo Controlled Period: Week 0-16|Lack of Efficacy|0
6274777|NCT02207244|9979290|FG000|Placebo Controlled Period: Week 0-16|Lost to Follow-up|1
6274778|NCT02207244|9979291|FG001|Placebo Controlled Period: Week 0-16|Lost to Follow-up|3
6274779|NCT02207244|9979292|FG002|Placebo Controlled Period: Week 0-16|Lost to Follow-up|2
6274780|NCT02207244|9979293|FG003|Placebo Controlled Period: Week 0-16|Lost to Follow-up|0
6274781|NCT02207244|9979294|FG004|Placebo Controlled Period: Week 0-16|Lost to Follow-up|0
6274782|NCT02207244|9979295|FG005|Placebo Controlled Period: Week 0-16|Lost to Follow-up|0
6274783|NCT02207244|9979296|FG006|Placebo Controlled Period: Week 0-16|Lost to Follow-up|0
6274784|NCT02207244|9979297|FG007|Placebo Controlled Period: Week 0-16|Lost to Follow-up|0
6274785|NCT02207244|9979298|FG008|Placebo Controlled Period: Week 0-16|Lost to Follow-up|0
6274786|NCT02207244|9979299|FG009|Placebo Controlled Period: Week 0-16|Lost to Follow-up|0
6274787|NCT02207244|9979300|FG010|Placebo Controlled Period: Week 0-16|Lost to Follow-up|0
6274788|NCT02207244|9979290|FG000|Placebo Controlled Period: Week 0-16|Withdrawal by Subject|7
6274789|NCT02207244|9979291|FG001|Placebo Controlled Period: Week 0-16|Withdrawal by Subject|1
6274790|NCT02207244|9979292|FG002|Placebo Controlled Period: Week 0-16|Withdrawal by Subject|0
6274791|NCT02207244|9979293|FG003|Placebo Controlled Period: Week 0-16|Withdrawal by Subject|0
6274792|NCT02207244|9979294|FG004|Placebo Controlled Period: Week 0-16|Withdrawal by Subject|0
6274793|NCT02207244|9979295|FG005|Placebo Controlled Period: Week 0-16|Withdrawal by Subject|0
6196124|NCT01458574|9855011|FG000|Overall Study|Lost to Follow-up|3
6196125|NCT01458574|9855012|FG001|Overall Study|Lost to Follow-up|2
6196126|NCT01458574|9855013|FG002|Overall Study|Lost to Follow-up|1
6196127|NCT01458574|9855011|FG000|Overall Study|Pregnancy|1
6196128|NCT01458574|9855012|FG001|Overall Study|Pregnancy|1
6196129|NCT01458574|9855013|FG002|Overall Study|Pregnancy|0
6196130|NCT01458574|9855011|FG000|Overall Study|Protocol Violation|0
6274794|NCT02207244|9979296|FG006|Placebo Controlled Period: Week 0-16|Withdrawal by Subject|0
6274795|NCT02207244|9979297|FG007|Placebo Controlled Period: Week 0-16|Withdrawal by Subject|0
6274796|NCT02207244|9979298|FG008|Placebo Controlled Period: Week 0-16|Withdrawal by Subject|0
6274797|NCT02207244|9979299|FG009|Placebo Controlled Period: Week 0-16|Withdrawal by Subject|0
6274798|NCT02207244|9979300|FG010|Placebo Controlled Period: Week 0-16|Withdrawal by Subject|0
6274799|NCT02207244|9979290|FG000|Placebo Controlled Period: Week 0-16|Protocol Violation|1
6274800|NCT02207244|9979291|FG001|Placebo Controlled Period: Week 0-16|Protocol Violation|3
6274801|NCT02207244|9979292|FG002|Placebo Controlled Period: Week 0-16|Protocol Violation|1
6274802|NCT02207244|9979293|FG003|Placebo Controlled Period: Week 0-16|Protocol Violation|0
6274803|NCT02207244|9979294|FG004|Placebo Controlled Period: Week 0-16|Protocol Violation|0
6274804|NCT02207244|9979295|FG005|Placebo Controlled Period: Week 0-16|Protocol Violation|0
6274805|NCT02207244|9979296|FG006|Placebo Controlled Period: Week 0-16|Protocol Violation|0
6274806|NCT02207244|9979297|FG007|Placebo Controlled Period: Week 0-16|Protocol Violation|0
6274807|NCT02207244|9979298|FG008|Placebo Controlled Period: Week 0-16|Protocol Violation|0
6274808|NCT02207244|9979299|FG009|Placebo Controlled Period: Week 0-16|Protocol Violation|0
6274809|NCT02207244|9979300|FG010|Placebo Controlled Period: Week 0-16|Protocol Violation|0
6274810|NCT02207244|9979290|FG000|Placebo Controlled Period: Week 0-16|Noncompliance|0
6274811|NCT02207244|9979291|FG001|Placebo Controlled Period: Week 0-16|Noncompliance|1
6274812|NCT02207244|9979292|FG002|Placebo Controlled Period: Week 0-16|Noncompliance|2
6274813|NCT02207244|9979293|FG003|Placebo Controlled Period: Week 0-16|Noncompliance|0
6274814|NCT02207244|9979294|FG004|Placebo Controlled Period: Week 0-16|Noncompliance|0
6274815|NCT02207244|9979295|FG005|Placebo Controlled Period: Week 0-16|Noncompliance|0
6274816|NCT02207244|9979296|FG006|Placebo Controlled Period: Week 0-16|Noncompliance|0
6274817|NCT02207244|9979297|FG007|Placebo Controlled Period: Week 0-16|Noncompliance|0
6274818|NCT02207244|9979298|FG008|Placebo Controlled Period: Week 0-16|Noncompliance|0
6274819|NCT02207244|9979299|FG009|Placebo Controlled Period: Week 0-16|Noncompliance|0
6274820|NCT02207244|9979300|FG010|Placebo Controlled Period: Week 0-16|Noncompliance|0
6274821|NCT02207244|9979290|FG000|Placebo Controlled Period: Week 0-16|OTHER|0
6274822|NCT02207244|9979291|FG001|Placebo Controlled Period: Week 0-16|OTHER|1
6274823|NCT02207244|9979292|FG002|Placebo Controlled Period: Week 0-16|OTHER|0
6274824|NCT02207244|9979293|FG003|Placebo Controlled Period: Week 0-16|OTHER|0
6274825|NCT02207244|9979294|FG004|Placebo Controlled Period: Week 0-16|OTHER|0
6274826|NCT02207244|9979295|FG005|Placebo Controlled Period: Week 0-16|OTHER|0
6274827|NCT02207244|9979296|FG006|Placebo Controlled Period: Week 0-16|OTHER|0
6274828|NCT02207244|9979297|FG007|Placebo Controlled Period: Week 0-16|OTHER|0
6274829|NCT02207244|9979298|FG008|Placebo Controlled Period: Week 0-16|OTHER|0
6274830|NCT02207244|9979299|FG009|Placebo Controlled Period: Week 0-16|OTHER|0
6274831|NCT02207244|9979300|FG010|Placebo Controlled Period: Week 0-16|OTHER|0
6274832|NCT02207244|9979290|FG000|Placebo Crossover and ACP: Week 16-28|Adverse Event|0
6274833|NCT02207244|9979291|FG001|Placebo Crossover and ACP: Week 16-28|Adverse Event|0
6274834|NCT02207244|9979292|FG002|Placebo Crossover and ACP: Week 16-28|Adverse Event|0
6274835|NCT02207244|9979293|FG003|Placebo Crossover and ACP: Week 16-28|Adverse Event|0
6274836|NCT02207244|9979294|FG004|Placebo Crossover and ACP: Week 16-28|Adverse Event|3
6274837|NCT02207244|9979295|FG005|Placebo Crossover and ACP: Week 16-28|Adverse Event|2
6274838|NCT02207244|9979296|FG006|Placebo Crossover and ACP: Week 16-28|Adverse Event|0
6274839|NCT02207244|9979297|FG007|Placebo Crossover and ACP: Week 16-28|Adverse Event|0
6274840|NCT02207244|9979298|FG008|Placebo Crossover and ACP: Week 16-28|Adverse Event|0
6274841|NCT02207244|9979299|FG009|Placebo Crossover and ACP: Week 16-28|Adverse Event|0
6274842|NCT02207244|9979300|FG010|Placebo Crossover and ACP: Week 16-28|Adverse Event|0
6274843|NCT02207244|9979290|FG000|Placebo Crossover and ACP: Week 16-28|Lack of Efficacy|0
6274844|NCT02207244|9979291|FG001|Placebo Crossover and ACP: Week 16-28|Lack of Efficacy|0
6274845|NCT02207244|9979292|FG002|Placebo Crossover and ACP: Week 16-28|Lack of Efficacy|0
6274846|NCT02207244|9979293|FG003|Placebo Crossover and ACP: Week 16-28|Lack of Efficacy|0
6274847|NCT02207244|9979294|FG004|Placebo Crossover and ACP: Week 16-28|Lack of Efficacy|0
6274848|NCT02207244|9979295|FG005|Placebo Crossover and ACP: Week 16-28|Lack of Efficacy|2
6274849|NCT02207244|9979296|FG006|Placebo Crossover and ACP: Week 16-28|Lack of Efficacy|0
6274850|NCT02207244|9979297|FG007|Placebo Crossover and ACP: Week 16-28|Lack of Efficacy|0
6274851|NCT02207244|9979298|FG008|Placebo Crossover and ACP: Week 16-28|Lack of Efficacy|0
6274852|NCT02207244|9979299|FG009|Placebo Crossover and ACP: Week 16-28|Lack of Efficacy|0
6274853|NCT02207244|9979300|FG010|Placebo Crossover and ACP: Week 16-28|Lack of Efficacy|0
6196131|NCT01458574|9855012|FG001|Overall Study|Protocol Violation|1
6196132|NCT01458574|9855013|FG002|Overall Study|Protocol Violation|0
6196133|NCT01458574|9855011|FG000|Overall Study|Withdrawal by Subject|6
6196134|NCT01458574|9855012|FG001|Overall Study|Withdrawal by Subject|3
6196135|NCT01458574|9855013|FG002|Overall Study|Withdrawal by Subject|5
6196136|NCT01458574|9855011|FG000|Overall Study|Other|2
6196137|NCT01458574|9855012|FG001|Overall Study|Other|1
6196138|NCT01458574|9855013|FG002|Overall Study|Other|0
6196139|NCT01458574|9855011|FG000|Overall Study|Randomized but not treated|0
6196140|NCT01458574|9855012|FG001|Overall Study|Randomized but not treated|1
6196141|NCT01458574|9855013|FG002|Overall Study|Randomized but not treated|0
6196142|NCT01458587|9855023|FG000|Overall Study|Withdrawal by Subject|1
6196143|NCT01458587|9855024|FG001|Overall Study|Withdrawal by Subject|0
6196144|NCT01458639|9855032|FG000|Overall Study|Physician Decision|4
6196145|NCT01458639|9855032|FG000|Overall Study|Equipment issue|1
6196146|NCT01458639|9855032|FG000|Overall Study|Inability to obtain subject blood sample|1
6196147|NCT01458951|9855039|FG000|Overall Study|Other|1
6196148|NCT01458951|9855040|FG001|Overall Study|Other|0
6196149|NCT01458951|9855041|FG002|Overall Study|Other|0
6196150|NCT01458951|9855039|FG000|Overall Study|Protocol Violation|5
6196151|NCT01458951|9855040|FG001|Overall Study|Protocol Violation|1
6196152|NCT01458951|9855041|FG002|Overall Study|Protocol Violation|0
6196153|NCT01458951|9855039|FG000|Overall Study|Withdrawal by Subject|2
6196154|NCT01458951|9855040|FG001|Overall Study|Withdrawal by Subject|0
6274854|NCT02207244|9979290|FG000|Placebo Crossover and ACP: Week 16-28|Lost to Follow-up|0
6274855|NCT02207244|9979291|FG001|Placebo Crossover and ACP: Week 16-28|Lost to Follow-up|0
6274856|NCT02207244|9979292|FG002|Placebo Crossover and ACP: Week 16-28|Lost to Follow-up|0
6274857|NCT02207244|9979293|FG003|Placebo Crossover and ACP: Week 16-28|Lost to Follow-up|1
6274858|NCT02207244|9979294|FG004|Placebo Crossover and ACP: Week 16-28|Lost to Follow-up|2
6274859|NCT02207244|9979295|FG005|Placebo Crossover and ACP: Week 16-28|Lost to Follow-up|2
6274860|NCT02207244|9979296|FG006|Placebo Crossover and ACP: Week 16-28|Lost to Follow-up|0
6274861|NCT02207244|9979297|FG007|Placebo Crossover and ACP: Week 16-28|Lost to Follow-up|0
6274862|NCT02207244|9979298|FG008|Placebo Crossover and ACP: Week 16-28|Lost to Follow-up|0
5976733|NCT01147666|9563653|FG001|Dosing Period 1: 6-Week Treatment|Death|0
5976734|NCT01147666|9563654|FG002|Dosing Period 1: 6-Week Treatment|Death|0
5976735|NCT01147666|9563655|FG003|Dosing Period 1: 6-Week Treatment|Death|0
5976736|NCT01147666|9563656|FG004|Dosing Period 1: 6-Week Treatment|Death|1
5976737|NCT01147666|9563657|FG005|Dosing Period 1: 6-Week Treatment|Death|1
5976738|NCT01147666|9563658|FG006|Dosing Period 1: 6-Week Treatment|Death|1
5976739|NCT01147666|9563659|FG007|Dosing Period 1: 6-Week Treatment|Death|0
5976740|NCT01147666|9563660|FG008|Dosing Period 1: 6-Week Treatment|Death|0
5976741|NCT01147666|9563661|FG009|Dosing Period 1: 6-Week Treatment|Death|0
5976742|NCT01147666|9563662|FG010|Dosing Period 1: 6-Week Treatment|Death|0
5976743|NCT01147666|9563663|FG011|Dosing Period 1: 6-Week Treatment|Death|0
5976744|NCT01147666|9563664|FG012|Dosing Period 1: 6-Week Treatment|Death|1
5976745|NCT01147666|9563665|FG013|Dosing Period 1: 6-Week Treatment|Death|0
5976746|NCT01147666|9563666|FG014|Dosing Period 1: 6-Week Treatment|Death|0
5976747|NCT01147666|9563652|FG000|Dosing Period 1: 6-Week Treatment|Protocol Violation|1
5976748|NCT01147666|9563653|FG001|Dosing Period 1: 6-Week Treatment|Protocol Violation|0
5976749|NCT01147666|9563654|FG002|Dosing Period 1: 6-Week Treatment|Protocol Violation|0
5976750|NCT01147666|9563655|FG003|Dosing Period 1: 6-Week Treatment|Protocol Violation|1
5976751|NCT01147666|9563656|FG004|Dosing Period 1: 6-Week Treatment|Protocol Violation|0
5976752|NCT01147666|9563657|FG005|Dosing Period 1: 6-Week Treatment|Protocol Violation|0
5976753|NCT01147666|9563658|FG006|Dosing Period 1: 6-Week Treatment|Protocol Violation|0
5976754|NCT01147666|9563659|FG007|Dosing Period 1: 6-Week Treatment|Protocol Violation|0
5976755|NCT01147666|9563660|FG008|Dosing Period 1: 6-Week Treatment|Protocol Violation|0
5976756|NCT01147666|9563661|FG009|Dosing Period 1: 6-Week Treatment|Protocol Violation|0
5976757|NCT01147666|9563662|FG010|Dosing Period 1: 6-Week Treatment|Protocol Violation|1
5976758|NCT01147666|9563663|FG011|Dosing Period 1: 6-Week Treatment|Protocol Violation|0
5976759|NCT01147666|9563664|FG012|Dosing Period 1: 6-Week Treatment|Protocol Violation|0
5976760|NCT01147666|9563665|FG013|Dosing Period 1: 6-Week Treatment|Protocol Violation|0
5976761|NCT01147666|9563666|FG014|Dosing Period 1: 6-Week Treatment|Protocol Violation|0
5976762|NCT01147666|9563652|FG000|Dosing Period 1: 6-Week Treatment|Withdrawal by Subject|0
5976763|NCT01147666|9563653|FG001|Dosing Period 1: 6-Week Treatment|Withdrawal by Subject|0
5976764|NCT01147666|9563654|FG002|Dosing Period 1: 6-Week Treatment|Withdrawal by Subject|0
5976765|NCT01147666|9563655|FG003|Dosing Period 1: 6-Week Treatment|Withdrawal by Subject|0
5976766|NCT01147666|9563656|FG004|Dosing Period 1: 6-Week Treatment|Withdrawal by Subject|1
5976767|NCT01147666|9563657|FG005|Dosing Period 1: 6-Week Treatment|Withdrawal by Subject|1
5976768|NCT01147666|9563658|FG006|Dosing Period 1: 6-Week Treatment|Withdrawal by Subject|0
5976769|NCT01147666|9563659|FG007|Dosing Period 1: 6-Week Treatment|Withdrawal by Subject|1
5976770|NCT01147666|9563660|FG008|Dosing Period 1: 6-Week Treatment|Withdrawal by Subject|0
5976771|NCT01147666|9563661|FG009|Dosing Period 1: 6-Week Treatment|Withdrawal by Subject|1
5976772|NCT01147666|9563662|FG010|Dosing Period 1: 6-Week Treatment|Withdrawal by Subject|0
5976773|NCT01147666|9563663|FG011|Dosing Period 1: 6-Week Treatment|Withdrawal by Subject|1
5976774|NCT01147666|9563664|FG012|Dosing Period 1: 6-Week Treatment|Withdrawal by Subject|0
5976775|NCT01147666|9563665|FG013|Dosing Period 1: 6-Week Treatment|Withdrawal by Subject|1
5976776|NCT01147666|9563666|FG014|Dosing Period 1: 6-Week Treatment|Withdrawal by Subject|0
6196155|NCT01458951|9855041|FG002|Overall Study|Withdrawal by Subject|2
6196156|NCT01458951|9855039|FG000|Overall Study|Adverse Event|7
6196157|NCT01458951|9855040|FG001|Overall Study|Adverse Event|0
6196158|NCT01458951|9855041|FG002|Overall Study|Adverse Event|2
6274863|NCT02207244|9979299|FG009|Placebo Crossover and ACP: Week 16-28|Lost to Follow-up|0
6196159|NCT01458951|9855039|FG000|Overall Study|Insufficient Clinical Response|17
6196160|NCT01458951|9855040|FG001|Overall Study|Insufficient Clinical Response|0
6196161|NCT01458951|9855041|FG002|Overall Study|Insufficient Clinical Response|11
6196162|NCT01459016|9855059|FG000|Overall Study|Withdrawal by Subject|11
6196163|NCT01459016|9855059|FG000|Overall Study|Amendment Discontinuation Criteria|4
6196164|NCT01459068|9855065|FG000|Overall Study|Withdrawal by Subject|8
6196165|NCT01459068|9855066|FG001|Overall Study|Withdrawal by Subject|18
6196166|NCT01459068|9855065|FG000|Overall Study|Lost to Follow-up|31
6196167|NCT01459068|9855066|FG001|Overall Study|Lost to Follow-up|15
6196168|NCT01459068|9855065|FG000|Overall Study|Death|0
6196169|NCT01459068|9855066|FG001|Overall Study|Death|1
6196170|NCT01459614|9855091|FG000|Overall Study|Adverse Event|1
6196171|NCT01459614|9855092|FG001|Overall Study|Adverse Event|0
6196172|NCT01459718|9855182|FG000|Overall Study|Physician Decision|1
6196173|NCT01459718|9855182|FG000|Overall Study|Lost to Follow-up|1
6196174|NCT01459718|9855182|FG000|Overall Study|Adverse Event|1
6196175|NCT01459783|9855188|FG000|Baseline to 6 Months|Death|1
6196176|NCT01459783|9855189|FG001|Baseline to 6 Months|Death|0
6196177|NCT01459783|9855188|FG000|Baseline to 6 Months|Withdrawal by Subject|12
6196178|NCT01459783|9855189|FG001|Baseline to 6 Months|Withdrawal by Subject|6
6196179|NCT01459783|9855188|FG000|Baseline to 6 Months|Lost to Follow-up|19
6196180|NCT01459783|9855189|FG001|Baseline to 6 Months|Lost to Follow-up|14
6196181|NCT01459783|9855188|FG000|6 Months to 12 Months|Death|0
6196182|NCT01459783|9855189|FG001|6 Months to 12 Months|Death|1
6196183|NCT01459783|9855188|FG000|6 Months to 12 Months|Withdrawal by Subject|6
6196184|NCT01459783|9855189|FG001|6 Months to 12 Months|Withdrawal by Subject|5
6196185|NCT01459783|9855188|FG000|6 Months to 12 Months|Lost to Follow-up|2
6196186|NCT01459783|9855189|FG001|6 Months to 12 Months|Lost to Follow-up|7
6196187|NCT01459783|9855188|FG000|6 Months to 12 Months|Study ended before 12-month follow-up|11
6196188|NCT01459783|9855189|FG001|6 Months to 12 Months|Study ended before 12-month follow-up|17
6196189|NCT01459796|9855197|FG000|Overall Study|Non compliance with protocol|2
6196190|NCT01459796|9855198|FG001|Overall Study|Non compliance with protocol|4
6196191|NCT01459796|9855197|FG000|Overall Study|Adverse Event|5
6196192|NCT01459796|9855198|FG001|Overall Study|Adverse Event|5
6196193|NCT01459796|9855197|FG000|Overall Study|Withdrawal by Subject|6
6196194|NCT01459796|9855198|FG001|Overall Study|Withdrawal by Subject|3
6196195|NCT01459796|9855197|FG000|Overall Study|Lost to Follow-up|5
6088498|NCT00676091|9699410|FG001|Infant Series|Protocol Violation|3
6196196|NCT01459796|9855198|FG001|Overall Study|Lost to Follow-up|4
6196197|NCT01459796|9855197|FG000|Overall Study|Reason unspecified|1
6196198|NCT01459796|9855198|FG001|Overall Study|Reason unspecified|2
6196199|NCT01459796|9855197|FG000|Overall Study|Decision by the sponsor|75
6196200|NCT01459796|9855198|FG001|Overall Study|Decision by the sponsor|108
6196201|NCT01459913|9855208|FG000|Overall Study|Adverse Event|0
6088499|NCT00676091|9699409|FG000|Infant Series|Adverse Event|2
6088500|NCT00676091|9699410|FG001|Infant Series|Adverse Event|3
6088501|NCT00676091|9699409|FG000|Infant Series|Failed to return|1
6088502|NCT00676091|9699410|FG001|Infant Series|Failed to return|3
6088503|NCT00676091|9699409|FG000|Infant Series|Lost to Follow-up|1
6088504|NCT00676091|9699410|FG001|Infant Series|Lost to Follow-up|0
6088505|NCT00676091|9699409|FG000|Infant Series|Died prior to receiving 7vPnC|0
6088506|NCT00676091|9699410|FG001|Infant Series|Died prior to receiving 7vPnC|1
6088507|NCT00676091|9699409|FG000|After Infant Series|Adverse Event|0
6088508|NCT00676091|9699410|FG001|After Infant Series|Adverse Event|1
6088509|NCT00676091|9699409|FG000|After Infant Series|Protocol Violation|0
6088510|NCT00676091|9699410|FG001|After Infant Series|Protocol Violation|1
6088511|NCT00676091|9699409|FG000|After Infant Series|Failed to return|1
6088512|NCT00676091|9699410|FG001|After Infant Series|Failed to return|1
6088513|NCT00676091|9699409|FG000|Toddler Dose|Failed to return|2
6088514|NCT00676091|9699410|FG001|Toddler Dose|Failed to return|0
6088515|NCT00676091|9699409|FG000|Toddler Dose|Parent or legal guardian request|1
6088516|NCT00676091|9699410|FG001|Toddler Dose|Parent or legal guardian request|0
6088517|NCT00676130|9699422|FG000|Overall Study|Lost to Follow-up|0
6088518|NCT00676130|9699423|FG001|Overall Study|Lost to Follow-up|1
6088519|NCT00676130|9699422|FG000|Overall Study|Found ineligible|3
6088520|NCT00676130|9699423|FG001|Overall Study|Found ineligible|2
6088521|NCT00676130|9699422|FG000|Overall Study|Withdrawal by Subject|0
6088522|NCT00676130|9699423|FG001|Overall Study|Withdrawal by Subject|1
6088523|NCT00676143|9699431|FG000|Overall Study|Adverse Event|34
6088524|NCT00676143|9699432|FG001|Overall Study|Adverse Event|60
6088525|NCT00676143|9699431|FG000|Overall Study|Death|4
6088526|NCT00676143|9699432|FG001|Overall Study|Death|4
6196202|NCT01459913|9855209|FG001|Overall Study|Adverse Event|0
6196203|NCT01459913|9855210|FG002|Overall Study|Adverse Event|0
6196204|NCT01459913|9855211|FG003|Overall Study|Adverse Event|3
6196205|NCT01459913|9855208|FG000|Overall Study|Withdrawal by Subject|4
6196206|NCT01459913|9855209|FG001|Overall Study|Withdrawal by Subject|0
6196207|NCT01459913|9855210|FG002|Overall Study|Withdrawal by Subject|0
6088527|NCT00676143|9699431|FG000|Overall Study|Lack of Efficacy|0
6088528|NCT00676143|9699432|FG001|Overall Study|Lack of Efficacy|6
6088529|NCT00676143|9699431|FG000|Overall Study|Lost to Follow-up|0
6088530|NCT00676143|9699432|FG001|Overall Study|Lost to Follow-up|13
6088531|NCT00676143|9699431|FG000|Overall Study|Physician Decision|5
6196208|NCT01459913|9855211|FG003|Overall Study|Withdrawal by Subject|5
6196209|NCT01459913|9855208|FG000|Overall Study|Lost to Follow-up|7
6196210|NCT01459913|9855209|FG001|Overall Study|Lost to Follow-up|4
6196211|NCT01459913|9855210|FG002|Overall Study|Lost to Follow-up|1
6196212|NCT01459913|9855211|FG003|Overall Study|Lost to Follow-up|8
6196213|NCT01459913|9855208|FG000|Overall Study|Death|0
6196214|NCT01459913|9855209|FG001|Overall Study|Death|0
6196215|NCT01459913|9855210|FG002|Overall Study|Death|0
6196216|NCT01459913|9855211|FG003|Overall Study|Death|1
6196217|NCT01459913|9855208|FG000|Overall Study|Non- Compliance|0
6196218|NCT01459913|9855209|FG001|Overall Study|Non- Compliance|0
6196219|NCT01459913|9855210|FG002|Overall Study|Non- Compliance|0
6196220|NCT01459913|9855211|FG003|Overall Study|Non- Compliance|3
6196221|NCT01459913|9855208|FG000|Overall Study|Physician Decision|0
6196222|NCT01459913|9855209|FG001|Overall Study|Physician Decision|1
6196223|NCT01459913|9855210|FG002|Overall Study|Physician Decision|0
6196224|NCT01459913|9855211|FG003|Overall Study|Physician Decision|0
6196225|NCT01459913|9855208|FG000|Overall Study|Study Terminated by Sponsor|30
6196226|NCT01459913|9855209|FG001|Overall Study|Study Terminated by Sponsor|15
6196227|NCT01459913|9855210|FG002|Overall Study|Study Terminated by Sponsor|9
6196228|NCT01459913|9855211|FG003|Overall Study|Study Terminated by Sponsor|11
6196229|NCT01459913|9855208|FG000|Overall Study|Other|0
6196230|NCT01459913|9855209|FG001|Overall Study|Other|0
6196231|NCT01459913|9855210|FG002|Overall Study|Other|3
6196232|NCT01459913|9855211|FG003|Overall Study|Other|1
6196233|NCT01459913|9855208|FG000|Overall Study|Did Not Meet Inclusion Criteria|0
6196234|NCT01459913|9855209|FG001|Overall Study|Did Not Meet Inclusion Criteria|0
6196235|NCT01459913|9855210|FG002|Overall Study|Did Not Meet Inclusion Criteria|0
6196236|NCT01459913|9855211|FG003|Overall Study|Did Not Meet Inclusion Criteria|1
6196237|NCT01460290|9855228|FG000|Overall Study|Adverse Event|3
6196238|NCT01460290|9855228|FG000|Overall Study|Elevated liver function|1
6196239|NCT01460342|9855244|FG000|Overall Study|Adverse Event|5
6196240|NCT01460342|9855245|FG001|Overall Study|Adverse Event|4
6196241|NCT01460342|9855244|FG000|Overall Study|Lost to Follow-up|1
6196242|NCT01460342|9855245|FG001|Overall Study|Lost to Follow-up|2
6196243|NCT01460342|9855244|FG000|Overall Study|Protocol Violation|0
6196244|NCT01460342|9855245|FG001|Overall Study|Protocol Violation|1
6196245|NCT01460342|9855244|FG000|Overall Study|Withdrawal by Subject|3
6196246|NCT01460342|9855245|FG001|Overall Study|Withdrawal by Subject|4
6196247|NCT01460342|9855244|FG000|Overall Study|Physician Decision|1
6196248|NCT01460342|9855245|FG001|Overall Study|Physician Decision|3
6196249|NCT01460342|9855244|FG000|Overall Study|Lack of Efficacy|1
6196250|NCT01460342|9855245|FG001|Overall Study|Lack of Efficacy|0
6196251|NCT01460368|9855253|FG000|Part B: First Intervention (Period 1)|Lost to Follow-up|0
6196252|NCT01460368|9855254|FG001|Part B: First Intervention (Period 1)|Lost to Follow-up|0
6196253|NCT01460368|9855255|FG002|Part B: First Intervention (Period 1)|Lost to Follow-up|0
6196254|NCT01460368|9855256|FG003|Part B: First Intervention (Period 1)|Lost to Follow-up|0
6196255|NCT01460368|9855257|FG004|Part B: First Intervention (Period 1)|Lost to Follow-up|1
6196256|NCT01460368|9855258|FG005|Part B: First Intervention (Period 1)|Lost to Follow-up|0
6196257|NCT01460368|9855259|FG006|Part B: First Intervention (Period 1)|Lost to Follow-up|0
6196258|NCT01460368|9855253|FG000|Part B: Second Intervention (Period 2)|Withdrawal by Subject|0
6196259|NCT01460368|9855254|FG001|Part B: Second Intervention (Period 2)|Withdrawal by Subject|1
6196260|NCT01460368|9855255|FG002|Part B: Second Intervention (Period 2)|Withdrawal by Subject|0
6196261|NCT01460368|9855256|FG003|Part B: Second Intervention (Period 2)|Withdrawal by Subject|0
6196262|NCT01460368|9855257|FG004|Part B: Second Intervention (Period 2)|Withdrawal by Subject|0
6196263|NCT01460368|9855258|FG005|Part B: Second Intervention (Period 2)|Withdrawal by Subject|0
6196264|NCT01460368|9855259|FG006|Part B: Second Intervention (Period 2)|Withdrawal by Subject|1
6196265|NCT01460368|9855253|FG000|Part B: Second Intervention (Period 2)|Lost to Follow-up|0
6196266|NCT01460368|9855254|FG001|Part B: Second Intervention (Period 2)|Lost to Follow-up|1
6196267|NCT01460368|9855255|FG002|Part B: Second Intervention (Period 2)|Lost to Follow-up|0
6196268|NCT01460368|9855256|FG003|Part B: Second Intervention (Period 2)|Lost to Follow-up|0
6196269|NCT01460368|9855257|FG004|Part B: Second Intervention (Period 2)|Lost to Follow-up|0
6196270|NCT01460368|9855258|FG005|Part B: Second Intervention (Period 2)|Lost to Follow-up|0
6196271|NCT01460368|9855259|FG006|Part B: Second Intervention (Period 2)|Lost to Follow-up|0
6196272|NCT01460368|9855253|FG000|Part B: Washout (up to 15 Days)|Protocol Violation|0
6196273|NCT01460368|9855254|FG001|Part B: Washout (up to 15 Days)|Protocol Violation|0
6196274|NCT01460368|9855255|FG002|Part B: Washout (up to 15 Days)|Protocol Violation|1
6196275|NCT01460368|9855256|FG003|Part B: Washout (up to 15 Days)|Protocol Violation|0
6196276|NCT01460368|9855257|FG004|Part B: Washout (up to 15 Days)|Protocol Violation|0
6196277|NCT01460368|9855258|FG005|Part B: Washout (up to 15 Days)|Protocol Violation|0
6196278|NCT01460368|9855259|FG006|Part B: Washout (up to 15 Days)|Protocol Violation|0
6196279|NCT01460368|9855253|FG000|Part B: Third Interventions (Period 3)|Withdrawal by Subject|0
6196280|NCT01460368|9855254|FG001|Part B: Third Interventions (Period 3)|Withdrawal by Subject|0
6196281|NCT01460368|9855255|FG002|Part B: Third Interventions (Period 3)|Withdrawal by Subject|1
6196282|NCT01460368|9855256|FG003|Part B: Third Interventions (Period 3)|Withdrawal by Subject|1
6196283|NCT01460368|9855257|FG004|Part B: Third Interventions (Period 3)|Withdrawal by Subject|0
6196284|NCT01460368|9855258|FG005|Part B: Third Interventions (Period 3)|Withdrawal by Subject|1
6196285|NCT01460368|9855259|FG006|Part B: Third Interventions (Period 3)|Withdrawal by Subject|0
6196286|NCT01460381|9855270|FG000|Period 2 (Days 8-15)|Lost to Follow-up|1
6196287|NCT01460381|9855271|FG001|Period 2 (Days 8-15)|Lost to Follow-up|0
6196288|NCT01460407|9855279|FG000|Period 2: Day 6 to Day 14|Adverse Event|0
6196289|NCT01460407|9855280|FG001|Period 2: Day 6 to Day 14|Adverse Event|1
6196290|NCT01460446|9855289|FG000|Overall Study|Non-compliance|2
6196291|NCT01460446|9855290|FG001|Overall Study|Non-compliance|9
6196292|NCT01460446|9855289|FG000|Overall Study|Consent Withdrawn|0
6196293|NCT01460446|9855290|FG001|Overall Study|Consent Withdrawn|4
6196294|NCT01460446|9855289|FG000|Overall Study|Non-compliance & Consent Withdrawn|1
6196295|NCT01460446|9855290|FG001|Overall Study|Non-compliance & Consent Withdrawn|3
6196296|NCT01460446|9855289|FG000|Overall Study|Surgery/Illness|1
6196297|NCT01460446|9855290|FG001|Overall Study|Surgery/Illness|1
6196298|NCT01460446|9855289|FG000|Overall Study|Pregnancy|1
6196299|NCT01460446|9855290|FG001|Overall Study|Pregnancy|0
6196300|NCT01460446|9855289|FG000|Overall Study|Other Reasons Incl. Lost for Follow-Up|0
6196301|NCT01460446|9855290|FG001|Overall Study|Other Reasons Incl. Lost for Follow-Up|3
6196302|NCT01460628|9855297|FG000|Overall Study|Adverse Event|3
6196303|NCT01460628|9855297|FG000|Overall Study|Withdrawal by Subject|2
6196304|NCT01460719|9855301|FG000|Overall Study|Adverse Event|1
6196305|NCT01460719|9855301|FG000|Overall Study|Withdrawal by Subject|1
6196306|NCT01460901|9855315|FG000|Overall Study|Withdrawal by Subject|2
6196307|NCT01461005|9855334|FG000|Overall Study|FDA reclassified Dynamic Stabilization D|1
6196308|NCT01461044|9855341|FG000|Overall Study|Death|58
6196309|NCT01461044|9855342|FG001|Overall Study|Death|35
6196310|NCT01461044|9855341|FG000|Overall Study|Lost to Follow-up|12
6196311|NCT01461044|9855342|FG001|Overall Study|Lost to Follow-up|5
6274864|NCT02207244|9979300|FG010|Placebo Crossover and ACP: Week 16-28|Lost to Follow-up|0
6274865|NCT02207244|9979290|FG000|Placebo Crossover and ACP: Week 16-28|Withdrawal by Subject|0
6274866|NCT02207244|9979291|FG001|Placebo Crossover and ACP: Week 16-28|Withdrawal by Subject|0
6274867|NCT02207244|9979292|FG002|Placebo Crossover and ACP: Week 16-28|Withdrawal by Subject|0
6274868|NCT02207244|9979293|FG003|Placebo Crossover and ACP: Week 16-28|Withdrawal by Subject|3
6274869|NCT02207244|9979294|FG004|Placebo Crossover and ACP: Week 16-28|Withdrawal by Subject|3
6274870|NCT02207244|9979295|FG005|Placebo Crossover and ACP: Week 16-28|Withdrawal by Subject|2
6274871|NCT02207244|9979296|FG006|Placebo Crossover and ACP: Week 16-28|Withdrawal by Subject|0
6274872|NCT02207244|9979297|FG007|Placebo Crossover and ACP: Week 16-28|Withdrawal by Subject|0
6274873|NCT02207244|9979298|FG008|Placebo Crossover and ACP: Week 16-28|Withdrawal by Subject|0
6274874|NCT02207244|9979299|FG009|Placebo Crossover and ACP: Week 16-28|Withdrawal by Subject|0
6274875|NCT02207244|9979300|FG010|Placebo Crossover and ACP: Week 16-28|Withdrawal by Subject|0
6274876|NCT02207244|9979290|FG000|Placebo Crossover and ACP: Week 16-28|Protocol Violation|0
6274877|NCT02207244|9979291|FG001|Placebo Crossover and ACP: Week 16-28|Protocol Violation|0
6274878|NCT02207244|9979292|FG002|Placebo Crossover and ACP: Week 16-28|Protocol Violation|0
6274879|NCT02207244|9979293|FG003|Placebo Crossover and ACP: Week 16-28|Protocol Violation|1
6274880|NCT02207244|9979294|FG004|Placebo Crossover and ACP: Week 16-28|Protocol Violation|0
6274881|NCT02207244|9979295|FG005|Placebo Crossover and ACP: Week 16-28|Protocol Violation|1
5976777|NCT01147666|9563652|FG000|Dosing Period 1: 6-Week Treatment|Other than specified|0
5976778|NCT01147666|9563653|FG001|Dosing Period 1: 6-Week Treatment|Other than specified|0
5976779|NCT01147666|9563654|FG002|Dosing Period 1: 6-Week Treatment|Other than specified|0
5976780|NCT01147666|9563655|FG003|Dosing Period 1: 6-Week Treatment|Other than specified|1
5976781|NCT01147666|9563656|FG004|Dosing Period 1: 6-Week Treatment|Other than specified|0
5976782|NCT01147666|9563657|FG005|Dosing Period 1: 6-Week Treatment|Other than specified|0
5976783|NCT01147666|9563658|FG006|Dosing Period 1: 6-Week Treatment|Other than specified|0
5976784|NCT01147666|9563659|FG007|Dosing Period 1: 6-Week Treatment|Other than specified|0
5976785|NCT01147666|9563660|FG008|Dosing Period 1: 6-Week Treatment|Other than specified|0
5976786|NCT01147666|9563661|FG009|Dosing Period 1: 6-Week Treatment|Other than specified|0
5976787|NCT01147666|9563662|FG010|Dosing Period 1: 6-Week Treatment|Other than specified|2
5976788|NCT01147666|9563663|FG011|Dosing Period 1: 6-Week Treatment|Other than specified|0
6196312|NCT01461057|9855353|FG000|Overall Study|Death|10
6196313|NCT01461057|9855354|FG001|Overall Study|Death|9
6050716|NCT00428389|9649927|FG001|Extension Phase|Withdrawal by Subject|6
6196314|NCT01461057|9855353|FG000|Overall Study|Withdrawal by Subject|2
6196315|NCT01461057|9855354|FG001|Overall Study|Withdrawal by Subject|3
6196316|NCT01461057|9855353|FG000|Overall Study|Physician Decision|0
6196317|NCT01461057|9855354|FG001|Overall Study|Physician Decision|2
6196318|NCT01461057|9855353|FG000|Overall Study|Adverse Event|0
6196319|NCT01461057|9855354|FG001|Overall Study|Adverse Event|1
6196320|NCT01461057|9855353|FG000|Overall Study|Progression of Disease|1
6196321|NCT01461057|9855354|FG001|Overall Study|Progression of Disease|0
6196322|NCT01461057|9855353|FG000|Overall Study|Study Terminated by Sponsor|2
6196323|NCT01461057|9855354|FG001|Overall Study|Study Terminated by Sponsor|0
6196324|NCT01461096|9855362|FG000|Overall Study|Death|3
6196325|NCT01461096|9855363|FG001|Overall Study|Death|6
6196326|NCT01461096|9855362|FG000|Overall Study|Severe debilitation, unable to continue|1
6196327|NCT01461096|9855363|FG001|Overall Study|Severe debilitation, unable to continue|1
6196328|NCT01461096|9855362|FG000|Overall Study|Subj not able to get to clinic|15
6196329|NCT01461096|9855363|FG001|Overall Study|Subj not able to get to clinic|13
6196330|NCT01461096|9855362|FG000|Overall Study|Site is closing|27
6196331|NCT01461096|9855363|FG001|Overall Study|Site is closing|30
6196332|NCT01461096|9855362|FG000|Overall Study|Withdrawal by Subject|5
6196333|NCT01461096|9855363|FG001|Overall Study|Withdrawal by Subject|3
6196334|NCT01461096|9855362|FG000|Overall Study|Subj not willing to adhere to reqs|3
6196335|NCT01461096|9855363|FG001|Overall Study|Subj not willing to adhere to reqs|4
6196336|NCT01461096|9855362|FG000|Overall Study|Lost to Follow-up|8
6196337|NCT01461096|9855363|FG001|Overall Study|Lost to Follow-up|4
6196338|NCT01461369|9855373|FG000|Overall Study|Lack of Efficacy|2
6196339|NCT01461369|9855374|FG001|Overall Study|Lack of Efficacy|0
6196340|NCT01461369|9855375|FG002|Overall Study|Lack of Efficacy|6
6196341|NCT01461369|9855373|FG000|Overall Study|Lost to Follow-up|0
6274882|NCT02207244|9979296|FG006|Placebo Crossover and ACP: Week 16-28|Protocol Violation|0
6274883|NCT02207244|9979297|FG007|Placebo Crossover and ACP: Week 16-28|Protocol Violation|0
6274884|NCT02207244|9979298|FG008|Placebo Crossover and ACP: Week 16-28|Protocol Violation|0
6274885|NCT02207244|9979299|FG009|Placebo Crossover and ACP: Week 16-28|Protocol Violation|0
6274886|NCT02207244|9979300|FG010|Placebo Crossover and ACP: Week 16-28|Protocol Violation|0
6274887|NCT02207244|9979290|FG000|Placebo Crossover and ACP: Week 16-28|Other|0
6274888|NCT02207244|9979291|FG001|Placebo Crossover and ACP: Week 16-28|Other|0
6274889|NCT02207244|9979292|FG002|Placebo Crossover and ACP: Week 16-28|Other|0
6274890|NCT02207244|9979293|FG003|Placebo Crossover and ACP: Week 16-28|Other|1
6274891|NCT02207244|9979294|FG004|Placebo Crossover and ACP: Week 16-28|Other|0
6274892|NCT02207244|9979295|FG005|Placebo Crossover and ACP: Week 16-28|Other|0
6274893|NCT02207244|9979296|FG006|Placebo Crossover and ACP: Week 16-28|Other|0
6274894|NCT02207244|9979297|FG007|Placebo Crossover and ACP: Week 16-28|Other|0
6274895|NCT02207244|9979298|FG008|Placebo Crossover and ACP: Week 16-28|Other|0
6274896|NCT02207244|9979299|FG009|Placebo Crossover and ACP: Week 16-28|Other|0
6274897|NCT02207244|9979300|FG010|Placebo Crossover and ACP: Week 16-28|Other|0
6274898|NCT02207244|9979290|FG000|Withdrawal and Re-treatment: Week 28-72|Adverse Event|0
6274899|NCT02207244|9979291|FG001|Withdrawal and Re-treatment: Week 28-72|Adverse Event|0
6274900|NCT02207244|9979292|FG002|Withdrawal and Re-treatment: Week 28-72|Adverse Event|0
6274901|NCT02207244|9979293|FG003|Withdrawal and Re-treatment: Week 28-72|Adverse Event|0
6274902|NCT02207244|9979294|FG004|Withdrawal and Re-treatment: Week 28-72|Adverse Event|0
6274903|NCT02207244|9979295|FG005|Withdrawal and Re-treatment: Week 28-72|Adverse Event|0
6274904|NCT02207244|9979296|FG006|Withdrawal and Re-treatment: Week 28-72|Adverse Event|1
6274905|NCT02207244|9979297|FG007|Withdrawal and Re-treatment: Week 28-72|Adverse Event|5
6274906|NCT02207244|9979298|FG008|Withdrawal and Re-treatment: Week 28-72|Adverse Event|3
6274907|NCT02207244|9979299|FG009|Withdrawal and Re-treatment: Week 28-72|Adverse Event|2
6274908|NCT02207244|9979300|FG010|Withdrawal and Re-treatment: Week 28-72|Adverse Event|0
6274909|NCT02207244|9979290|FG000|Withdrawal and Re-treatment: Week 28-72|Pregnancy|0
6274910|NCT02207244|9979291|FG001|Withdrawal and Re-treatment: Week 28-72|Pregnancy|0
6274911|NCT02207244|9979292|FG002|Withdrawal and Re-treatment: Week 28-72|Pregnancy|0
6274912|NCT02207244|9979293|FG003|Withdrawal and Re-treatment: Week 28-72|Pregnancy|0
6274913|NCT02207244|9979294|FG004|Withdrawal and Re-treatment: Week 28-72|Pregnancy|0
6274914|NCT02207244|9979295|FG005|Withdrawal and Re-treatment: Week 28-72|Pregnancy|0
6274915|NCT02207244|9979296|FG006|Withdrawal and Re-treatment: Week 28-72|Pregnancy|0
6274916|NCT02207244|9979297|FG007|Withdrawal and Re-treatment: Week 28-72|Pregnancy|2
6274917|NCT02207244|9979298|FG008|Withdrawal and Re-treatment: Week 28-72|Pregnancy|0
6274918|NCT02207244|9979299|FG009|Withdrawal and Re-treatment: Week 28-72|Pregnancy|0
6274919|NCT02207244|9979300|FG010|Withdrawal and Re-treatment: Week 28-72|Pregnancy|0
6274920|NCT02207244|9979290|FG000|Withdrawal and Re-treatment: Week 28-72|Lack of Efficacy|0
6274921|NCT02207244|9979291|FG001|Withdrawal and Re-treatment: Week 28-72|Lack of Efficacy|0
6274922|NCT02207244|9979292|FG002|Withdrawal and Re-treatment: Week 28-72|Lack of Efficacy|0
6274923|NCT02207244|9979293|FG003|Withdrawal and Re-treatment: Week 28-72|Lack of Efficacy|0
6274924|NCT02207244|9979294|FG004|Withdrawal and Re-treatment: Week 28-72|Lack of Efficacy|0
6274925|NCT02207244|9979295|FG005|Withdrawal and Re-treatment: Week 28-72|Lack of Efficacy|0
6274926|NCT02207244|9979296|FG006|Withdrawal and Re-treatment: Week 28-72|Lack of Efficacy|1
6274927|NCT02207244|9979297|FG007|Withdrawal and Re-treatment: Week 28-72|Lack of Efficacy|3
6274928|NCT02207244|9979298|FG008|Withdrawal and Re-treatment: Week 28-72|Lack of Efficacy|2
6274929|NCT02207244|9979299|FG009|Withdrawal and Re-treatment: Week 28-72|Lack of Efficacy|2
6196342|NCT01461369|9855374|FG001|Overall Study|Lost to Follow-up|0
6196343|NCT01461369|9855375|FG002|Overall Study|Lost to Follow-up|3
6196344|NCT01461369|9855373|FG000|Overall Study|Adverse Event|9
6196345|NCT01461369|9855374|FG001|Overall Study|Adverse Event|12
6196346|NCT01461369|9855375|FG002|Overall Study|Adverse Event|4
6196347|NCT01461369|9855373|FG000|Overall Study|Protocol Violation|1
6196348|NCT01461369|9855374|FG001|Overall Study|Protocol Violation|2
6196349|NCT01461369|9855375|FG002|Overall Study|Protocol Violation|2
6196350|NCT01461369|9855373|FG000|Overall Study|Withdrawal by Subject|1
6274930|NCT02207244|9979300|FG010|Withdrawal and Re-treatment: Week 28-72|Lack of Efficacy|0
6274931|NCT02207244|9979290|FG000|Withdrawal and Re-treatment: Week 28-72|Lost to Follow-up|0
6274932|NCT02207244|9979291|FG001|Withdrawal and Re-treatment: Week 28-72|Lost to Follow-up|0
6274933|NCT02207244|9979292|FG002|Withdrawal and Re-treatment: Week 28-72|Lost to Follow-up|0
6274934|NCT02207244|9979293|FG003|Withdrawal and Re-treatment: Week 28-72|Lost to Follow-up|0
6274935|NCT02207244|9979294|FG004|Withdrawal and Re-treatment: Week 28-72|Lost to Follow-up|0
6274936|NCT02207244|9979295|FG005|Withdrawal and Re-treatment: Week 28-72|Lost to Follow-up|0
6274937|NCT02207244|9979296|FG006|Withdrawal and Re-treatment: Week 28-72|Lost to Follow-up|2
6274938|NCT02207244|9979297|FG007|Withdrawal and Re-treatment: Week 28-72|Lost to Follow-up|7
6274939|NCT02207244|9979298|FG008|Withdrawal and Re-treatment: Week 28-72|Lost to Follow-up|0
6274940|NCT02207244|9979299|FG009|Withdrawal and Re-treatment: Week 28-72|Lost to Follow-up|2
6274941|NCT02207244|9979300|FG010|Withdrawal and Re-treatment: Week 28-72|Lost to Follow-up|0
6274942|NCT02207244|9979290|FG000|Withdrawal and Re-treatment: Week 28-72|Withdrawal by Subject|0
6274943|NCT02207244|9979291|FG001|Withdrawal and Re-treatment: Week 28-72|Withdrawal by Subject|0
6274944|NCT02207244|9979292|FG002|Withdrawal and Re-treatment: Week 28-72|Withdrawal by Subject|0
6274945|NCT02207244|9979293|FG003|Withdrawal and Re-treatment: Week 28-72|Withdrawal by Subject|0
6274946|NCT02207244|9979294|FG004|Withdrawal and Re-treatment: Week 28-72|Withdrawal by Subject|0
6274947|NCT02207244|9979295|FG005|Withdrawal and Re-treatment: Week 28-72|Withdrawal by Subject|0
6274948|NCT02207244|9979296|FG006|Withdrawal and Re-treatment: Week 28-72|Withdrawal by Subject|2
6274949|NCT02207244|9979297|FG007|Withdrawal and Re-treatment: Week 28-72|Withdrawal by Subject|7
6274950|NCT02207244|9979298|FG008|Withdrawal and Re-treatment: Week 28-72|Withdrawal by Subject|2
6274951|NCT02207244|9979299|FG009|Withdrawal and Re-treatment: Week 28-72|Withdrawal by Subject|2
6274952|NCT02207244|9979300|FG010|Withdrawal and Re-treatment: Week 28-72|Withdrawal by Subject|0
6274953|NCT02207244|9979290|FG000|Withdrawal and Re-treatment: Week 28-72|Protocol Violation|0
6274954|NCT02207244|9979291|FG001|Withdrawal and Re-treatment: Week 28-72|Protocol Violation|0
6274955|NCT02207244|9979292|FG002|Withdrawal and Re-treatment: Week 28-72|Protocol Violation|0
6274956|NCT02207244|9979293|FG003|Withdrawal and Re-treatment: Week 28-72|Protocol Violation|0
6274957|NCT02207244|9979294|FG004|Withdrawal and Re-treatment: Week 28-72|Protocol Violation|0
6274958|NCT02207244|9979295|FG005|Withdrawal and Re-treatment: Week 28-72|Protocol Violation|0
6274959|NCT02207244|9979296|FG006|Withdrawal and Re-treatment: Week 28-72|Protocol Violation|0
6274960|NCT02207244|9979297|FG007|Withdrawal and Re-treatment: Week 28-72|Protocol Violation|1
6274961|NCT02207244|9979298|FG008|Withdrawal and Re-treatment: Week 28-72|Protocol Violation|1
6274962|NCT02207244|9979299|FG009|Withdrawal and Re-treatment: Week 28-72|Protocol Violation|0
6274963|NCT02207244|9979300|FG010|Withdrawal and Re-treatment: Week 28-72|Protocol Violation|0
6274964|NCT02207244|9979290|FG000|Withdrawal and Re-treatment: Week 28-72|Noncompliance|0
6274965|NCT02207244|9979291|FG001|Withdrawal and Re-treatment: Week 28-72|Noncompliance|0
6274966|NCT02207244|9979292|FG002|Withdrawal and Re-treatment: Week 28-72|Noncompliance|0
6274967|NCT02207244|9979293|FG003|Withdrawal and Re-treatment: Week 28-72|Noncompliance|0
6274968|NCT02207244|9979294|FG004|Withdrawal and Re-treatment: Week 28-72|Noncompliance|0
6274969|NCT02207244|9979295|FG005|Withdrawal and Re-treatment: Week 28-72|Noncompliance|0
6274970|NCT02207244|9979296|FG006|Withdrawal and Re-treatment: Week 28-72|Noncompliance|0
6274971|NCT02207244|9979297|FG007|Withdrawal and Re-treatment: Week 28-72|Noncompliance|0
6274972|NCT02207244|9979298|FG008|Withdrawal and Re-treatment: Week 28-72|Noncompliance|1
6274973|NCT02207244|9979299|FG009|Withdrawal and Re-treatment: Week 28-72|Noncompliance|0
6274974|NCT02207244|9979300|FG010|Withdrawal and Re-treatment: Week 28-72|Noncompliance|0
6274975|NCT02207244|9979290|FG000|Withdrawal and Re-treatment: Week 28-72|Other|0
6274976|NCT02207244|9979291|FG001|Withdrawal and Re-treatment: Week 28-72|Other|0
6274977|NCT02207244|9979292|FG002|Withdrawal and Re-treatment: Week 28-72|Other|0
6274978|NCT02207244|9979293|FG003|Withdrawal and Re-treatment: Week 28-72|Other|0
6274979|NCT02207244|9979294|FG004|Withdrawal and Re-treatment: Week 28-72|Other|0
6274980|NCT02207244|9979295|FG005|Withdrawal and Re-treatment: Week 28-72|Other|0
6274981|NCT02207244|9979296|FG006|Withdrawal and Re-treatment: Week 28-72|Other|0
6274982|NCT02207244|9979297|FG007|Withdrawal and Re-treatment: Week 28-72|Other|2
6274983|NCT02207244|9979298|FG008|Withdrawal and Re-treatment: Week 28-72|Other|0
6274984|NCT02207244|9979299|FG009|Withdrawal and Re-treatment: Week 28-72|Other|0
6274985|NCT02207244|9979300|FG010|Withdrawal and Re-treatment: Week 28-72|Other|0
6274986|NCT02207244|9979290|FG000|Withdrawal and Re-treatment: Week 28-72|Participants not retreated with guselkumab|0
6274987|NCT02207244|9979291|FG001|Withdrawal and Re-treatment: Week 28-72|Participants not retreated with guselkumab|0
6274988|NCT02207244|9979292|FG002|Withdrawal and Re-treatment: Week 28-72|Participants not retreated with guselkumab|0
6196351|NCT01461369|9855374|FG001|Overall Study|Withdrawal by Subject|3
6196352|NCT01461369|9855375|FG002|Overall Study|Withdrawal by Subject|2
6196353|NCT01461538|9855406|FG000|Overall Study|Death|15
6196354|NCT01461538|9855407|FG001|Overall Study|Death|6
6196355|NCT01461538|9855408|FG002|Overall Study|Death|2
6196356|NCT01461538|9855406|FG000|Overall Study|Study Stopped by Sponsor|2
6196357|NCT01461538|9855407|FG001|Overall Study|Study Stopped by Sponsor|1
6196358|NCT01461538|9855408|FG002|Overall Study|Study Stopped by Sponsor|0
6196359|NCT01461538|9855406|FG000|Overall Study|Withdrawal by Subject|1
6196360|NCT01461538|9855407|FG001|Overall Study|Withdrawal by Subject|1
6274989|NCT02207244|9979293|FG003|Withdrawal and Re-treatment: Week 28-72|Participants not retreated with guselkumab|0
6274990|NCT02207244|9979294|FG004|Withdrawal and Re-treatment: Week 28-72|Participants not retreated with guselkumab|0
6274991|NCT02207244|9979295|FG005|Withdrawal and Re-treatment: Week 28-72|Participants not retreated with guselkumab|0
6274992|NCT02207244|9979296|FG006|Withdrawal and Re-treatment: Week 28-72|Participants not retreated with guselkumab|8
6274993|NCT02207244|9979297|FG007|Withdrawal and Re-treatment: Week 28-72|Participants not retreated with guselkumab|0
6274994|NCT02207244|9979298|FG008|Withdrawal and Re-treatment: Week 28-72|Participants not retreated with guselkumab|0
6274995|NCT02207244|9979299|FG009|Withdrawal and Re-treatment: Week 28-72|Participants not retreated with guselkumab|0
6274996|NCT02207244|9979300|FG010|Withdrawal and Re-treatment: Week 28-72|Participants not retreated with guselkumab|0
6274997|NCT02207244|9979290|FG000|Open-label Guselkumab: Week 72-264|Withdrawal by Subject|0
6274998|NCT02207244|9979291|FG001|Open-label Guselkumab: Week 72-264|Withdrawal by Subject|0
6274999|NCT02207244|9979292|FG002|Open-label Guselkumab: Week 72-264|Withdrawal by Subject|0
6275000|NCT02207244|9979293|FG003|Open-label Guselkumab: Week 72-264|Withdrawal by Subject|0
6275001|NCT02207244|9979294|FG004|Open-label Guselkumab: Week 72-264|Withdrawal by Subject|0
6275002|NCT02207244|9979295|FG005|Open-label Guselkumab: Week 72-264|Withdrawal by Subject|0
6275003|NCT02207244|9979296|FG006|Open-label Guselkumab: Week 72-264|Withdrawal by Subject|0
6275004|NCT02207244|9979297|FG007|Open-label Guselkumab: Week 72-264|Withdrawal by Subject|0
6275005|NCT02207244|9979298|FG008|Open-label Guselkumab: Week 72-264|Withdrawal by Subject|10
6275006|NCT02207244|9979299|FG009|Open-label Guselkumab: Week 72-264|Withdrawal by Subject|0
6275007|NCT02207244|9979300|FG010|Open-label Guselkumab: Week 72-264|Withdrawal by Subject|30
6275008|NCT02207244|9979290|FG000|Open-label Guselkumab: Week 72-264|Lack of Efficacy|0
6275009|NCT02207244|9979291|FG001|Open-label Guselkumab: Week 72-264|Lack of Efficacy|0
6275010|NCT02207244|9979292|FG002|Open-label Guselkumab: Week 72-264|Lack of Efficacy|0
6275011|NCT02207244|9979293|FG003|Open-label Guselkumab: Week 72-264|Lack of Efficacy|0
6275012|NCT02207244|9979294|FG004|Open-label Guselkumab: Week 72-264|Lack of Efficacy|0
6275013|NCT02207244|9979295|FG005|Open-label Guselkumab: Week 72-264|Lack of Efficacy|0
6196361|NCT01461538|9855408|FG002|Overall Study|Withdrawal by Subject|0
6196362|NCT01461551|9855421|FG000|Overall Study|Physician Decision|2
6196363|NCT01461551|9855422|FG001|Overall Study|Physician Decision|1
6196364|NCT01461551|9855423|FG002|Overall Study|Physician Decision|2
6196365|NCT01461707|9855447|FG000|Overall Study|Withdrawal by Subject|1
6196366|NCT01461707|9855448|FG001|Overall Study|Withdrawal by Subject|0
6196367|NCT01461811|9855465|FG000|Overall Study|Adverse Event|2
6196368|NCT01461811|9855466|FG001|Overall Study|Adverse Event|1
6196369|NCT01461811|9855465|FG000|Overall Study|Subject decision unrelated to an AE|1
6196370|NCT01461811|9855466|FG001|Overall Study|Subject decision unrelated to an AE|1
6196371|NCT01461811|9855465|FG000|Overall Study|Noncompliance|1
6196372|NCT01461811|9855466|FG001|Overall Study|Noncompliance|1
6196373|NCT01461928|9855496|FG000|Induction (up to 8 Months)|Adverse Event|76
6196374|NCT01461928|9855497|FG001|Induction (up to 8 Months)|Adverse Event|0
6196375|NCT01461928|9855498|FG002|Induction (up to 8 Months)|Adverse Event|0
6196376|NCT01461928|9855496|FG000|Induction (up to 8 Months)|Death|3
6196377|NCT01461928|9855497|FG001|Induction (up to 8 Months)|Death|0
6196378|NCT01461928|9855498|FG002|Induction (up to 8 Months)|Death|0
6196379|NCT01461928|9855496|FG000|Induction (up to 8 Months)|Lost to Follow-up|5
6196380|NCT01461928|9855497|FG001|Induction (up to 8 Months)|Lost to Follow-up|0
6196381|NCT01461928|9855498|FG002|Induction (up to 8 Months)|Lost to Follow-up|0
6196382|NCT01461928|9855496|FG000|Induction (up to 8 Months)|Physician Decision|9
6196383|NCT01461928|9855497|FG001|Induction (up to 8 Months)|Physician Decision|0
6196384|NCT01461928|9855498|FG002|Induction (up to 8 Months)|Physician Decision|0
6196385|NCT01461928|9855496|FG000|Induction (up to 8 Months)|Withdrawal by Subject|18
6196386|NCT01461928|9855497|FG001|Induction (up to 8 Months)|Withdrawal by Subject|0
6196387|NCT01461928|9855498|FG002|Induction (up to 8 Months)|Withdrawal by Subject|0
6196388|NCT01461928|9855496|FG000|Induction (up to 8 Months)|Disease progression|45
6196389|NCT01461928|9855497|FG001|Induction (up to 8 Months)|Disease progression|0
6196390|NCT01461928|9855498|FG002|Induction (up to 8 Months)|Disease progression|0
6196391|NCT01461928|9855496|FG000|Induction (up to 8 Months)|Eligibility criteria deviation|10
6196392|NCT01461928|9855497|FG001|Induction (up to 8 Months)|Eligibility criteria deviation|0
6196393|NCT01461928|9855498|FG002|Induction (up to 8 Months)|Eligibility criteria deviation|0
6196394|NCT01461928|9855496|FG000|Induction (up to 8 Months)|Completed Induction, no Maint I received|11
6196395|NCT01461928|9855497|FG001|Induction (up to 8 Months)|Completed Induction, no Maint I received|0
6196396|NCT01461928|9855498|FG002|Induction (up to 8 Months)|Completed Induction, no Maint I received|0
6196397|NCT01461928|9855496|FG000|Induction (up to 8 Months)|Not responding to treatment|11
6196398|NCT01461928|9855497|FG001|Induction (up to 8 Months)|Not responding to treatment|0
6196399|NCT01461928|9855498|FG002|Induction (up to 8 Months)|Not responding to treatment|0
6196400|NCT01461928|9855496|FG000|Induction (up to 8 Months)|Termination of study in Switzerland|1
6196401|NCT01461928|9855497|FG001|Induction (up to 8 Months)|Termination of study in Switzerland|0
6196402|NCT01461928|9855498|FG002|Induction (up to 8 Months)|Termination of study in Switzerland|0
6196403|NCT01461928|9855496|FG000|Induction (up to 8 Months)|Treated before eligibility was confirmed|1
6196404|NCT01461928|9855497|FG001|Induction (up to 8 Months)|Treated before eligibility was confirmed|0
6196405|NCT01461928|9855498|FG002|Induction (up to 8 Months)|Treated before eligibility was confirmed|0
6196406|NCT01461928|9855496|FG000|Induction (up to 8 Months)|Sponsor decision|1
6196407|NCT01461928|9855497|FG001|Induction (up to 8 Months)|Sponsor decision|0
6196408|NCT01461928|9855498|FG002|Induction (up to 8 Months)|Sponsor decision|0
6196409|NCT01461928|9855496|FG000|Induction (up to 8 Months)|Protocol deviation|2
6196410|NCT01461928|9855497|FG001|Induction (up to 8 Months)|Protocol deviation|0
6196411|NCT01461928|9855498|FG002|Induction (up to 8 Months)|Protocol deviation|0
6196412|NCT01461928|9855496|FG000|Induction (up to 8 Months)|Prednisolone given prior to enrolment|1
6196413|NCT01461928|9855497|FG001|Induction (up to 8 Months)|Prednisolone given prior to enrolment|0
6196414|NCT01461928|9855498|FG002|Induction (up to 8 Months)|Prednisolone given prior to enrolment|0
6196415|NCT01461928|9855496|FG000|Induction (up to 8 Months)|Cycle 7 rituximab not given in error|1
6196416|NCT01461928|9855497|FG001|Induction (up to 8 Months)|Cycle 7 rituximab not given in error|0
6196417|NCT01461928|9855498|FG002|Induction (up to 8 Months)|Cycle 7 rituximab not given in error|0
6196418|NCT01461928|9855496|FG000|Induction (up to 8 Months)|Promotor request|1
6196419|NCT01461928|9855497|FG001|Induction (up to 8 Months)|Promotor request|0
6196420|NCT01461928|9855498|FG002|Induction (up to 8 Months)|Promotor request|0
6196421|NCT01461928|9855496|FG000|Induction (up to 8 Months)|Exceeded time limit for next cycle|1
6196422|NCT01461928|9855497|FG001|Induction (up to 8 Months)|Exceeded time limit for next cycle|0
6196423|NCT01461928|9855498|FG002|Induction (up to 8 Months)|Exceeded time limit for next cycle|0
6196424|NCT01461928|9855496|FG000|Induction (up to 8 Months)|Medical advisor request|1
6196425|NCT01461928|9855497|FG001|Induction (up to 8 Months)|Medical advisor request|0
6196426|NCT01461928|9855498|FG002|Induction (up to 8 Months)|Medical advisor request|0
6196427|NCT01461928|9855496|FG000|Maintenance I (24 Months)|Death|3
6196428|NCT01461928|9855497|FG001|Maintenance I (24 Months)|Death|0
6196429|NCT01461928|9855498|FG002|Maintenance I (24 Months)|Death|0
6196430|NCT01461928|9855496|FG000|Maintenance I (24 Months)|Withdrawal by Subject|32
6196431|NCT01461928|9855497|FG001|Maintenance I (24 Months)|Withdrawal by Subject|0
6196432|NCT01461928|9855498|FG002|Maintenance I (24 Months)|Withdrawal by Subject|0
6196433|NCT01461928|9855496|FG000|Maintenance I (24 Months)|Lost to Follow-up|2
6196434|NCT01461928|9855497|FG001|Maintenance I (24 Months)|Lost to Follow-up|0
6196435|NCT01461928|9855498|FG002|Maintenance I (24 Months)|Lost to Follow-up|0
6196436|NCT01461928|9855496|FG000|Maintenance I (24 Months)|Diseases progression|91
6196437|NCT01461928|9855497|FG001|Maintenance I (24 Months)|Diseases progression|0
6196438|NCT01461928|9855498|FG002|Maintenance I (24 Months)|Diseases progression|0
6196439|NCT01461928|9855496|FG000|Maintenance I (24 Months)|Adverse Event|70
6196440|NCT01461928|9855497|FG001|Maintenance I (24 Months)|Adverse Event|0
6196441|NCT01461928|9855498|FG002|Maintenance I (24 Months)|Adverse Event|0
6196442|NCT01461928|9855496|FG000|Maintenance I (24 Months)|Physician Decision|9
6196443|NCT01461928|9855497|FG001|Maintenance I (24 Months)|Physician Decision|0
6196444|NCT01461928|9855498|FG002|Maintenance I (24 Months)|Physician Decision|0
6196445|NCT01461928|9855496|FG000|Maintenance I (24 Months)|Did not meet randomization criteria|2
6196446|NCT01461928|9855497|FG001|Maintenance I (24 Months)|Did not meet randomization criteria|0
6196447|NCT01461928|9855498|FG002|Maintenance I (24 Months)|Did not meet randomization criteria|0
6196448|NCT01461928|9855496|FG000|Maintenance I (24 Months)|Did not perform scheduled assessment|2
6196449|NCT01461928|9855497|FG001|Maintenance I (24 Months)|Did not perform scheduled assessment|0
6196450|NCT01461928|9855498|FG002|Maintenance I (24 Months)|Did not perform scheduled assessment|0
6196451|NCT01461928|9855496|FG000|Maintenance I (24 Months)|Delay in rituximab administration|1
6196452|NCT01461928|9855497|FG001|Maintenance I (24 Months)|Delay in rituximab administration|0
6196453|NCT01461928|9855498|FG002|Maintenance I (24 Months)|Delay in rituximab administration|0
6196454|NCT01461928|9855496|FG000|Maintenance I (24 Months)|Not compliant|1
6275014|NCT02207244|9979296|FG006|Open-label Guselkumab: Week 72-264|Lack of Efficacy|0
6275015|NCT02207244|9979297|FG007|Open-label Guselkumab: Week 72-264|Lack of Efficacy|0
6275016|NCT02207244|9979298|FG008|Open-label Guselkumab: Week 72-264|Lack of Efficacy|2
6275017|NCT02207244|9979299|FG009|Open-label Guselkumab: Week 72-264|Lack of Efficacy|0
6275018|NCT02207244|9979300|FG010|Open-label Guselkumab: Week 72-264|Lack of Efficacy|3
6275019|NCT02207244|9979290|FG000|Open-label Guselkumab: Week 72-264|Lost to Follow-up|0
6275020|NCT02207244|9979291|FG001|Open-label Guselkumab: Week 72-264|Lost to Follow-up|0
6275021|NCT02207244|9979292|FG002|Open-label Guselkumab: Week 72-264|Lost to Follow-up|0
6275022|NCT02207244|9979293|FG003|Open-label Guselkumab: Week 72-264|Lost to Follow-up|0
6275023|NCT02207244|9979294|FG004|Open-label Guselkumab: Week 72-264|Lost to Follow-up|0
6275024|NCT02207244|9979295|FG005|Open-label Guselkumab: Week 72-264|Lost to Follow-up|0
6275025|NCT02207244|9979296|FG006|Open-label Guselkumab: Week 72-264|Lost to Follow-up|0
6275026|NCT02207244|9979297|FG007|Open-label Guselkumab: Week 72-264|Lost to Follow-up|0
6275027|NCT02207244|9979298|FG008|Open-label Guselkumab: Week 72-264|Lost to Follow-up|5
6275028|NCT02207244|9979299|FG009|Open-label Guselkumab: Week 72-264|Lost to Follow-up|0
6196455|NCT01461928|9855497|FG001|Maintenance I (24 Months)|Not compliant|0
6196456|NCT01461928|9855498|FG002|Maintenance I (24 Months)|Not compliant|0
6196457|NCT01461928|9855496|FG000|Maintenance I (24 Months)|Did not meet criteria|5
6196458|NCT01461928|9855497|FG001|Maintenance I (24 Months)|Did not meet criteria|0
6196459|NCT01461928|9855498|FG002|Maintenance I (24 Months)|Did not meet criteria|0
6196460|NCT01461928|9855496|FG000|Maintenance II (15 Months)|Adverse Event|0
6196461|NCT01461928|9855497|FG001|Maintenance II (15 Months)|Adverse Event|2
6196462|NCT01461928|9855498|FG002|Maintenance II (15 Months)|Adverse Event|0
6196463|NCT01461928|9855496|FG000|Maintenance II (15 Months)|Death|0
6196464|NCT01461928|9855497|FG001|Maintenance II (15 Months)|Death|10
6196465|NCT01461928|9855498|FG002|Maintenance II (15 Months)|Death|8
6275029|NCT02207244|9979300|FG010|Open-label Guselkumab: Week 72-264|Lost to Follow-up|26
6275030|NCT02207244|9979290|FG000|Open-label Guselkumab: Week 72-264|Adverse Event|0
6275031|NCT02207244|9979291|FG001|Open-label Guselkumab: Week 72-264|Adverse Event|0
6275032|NCT02207244|9979292|FG002|Open-label Guselkumab: Week 72-264|Adverse Event|0
6275033|NCT02207244|9979293|FG003|Open-label Guselkumab: Week 72-264|Adverse Event|0
6275034|NCT02207244|9979294|FG004|Open-label Guselkumab: Week 72-264|Adverse Event|0
6275035|NCT02207244|9979295|FG005|Open-label Guselkumab: Week 72-264|Adverse Event|0
6275036|NCT02207244|9979296|FG006|Open-label Guselkumab: Week 72-264|Adverse Event|0
6275037|NCT02207244|9979297|FG007|Open-label Guselkumab: Week 72-264|Adverse Event|0
6275038|NCT02207244|9979298|FG008|Open-label Guselkumab: Week 72-264|Adverse Event|12
5976789|NCT01147666|9563664|FG012|Dosing Period 1: 6-Week Treatment|Other than specified|0
5976790|NCT01147666|9563665|FG013|Dosing Period 1: 6-Week Treatment|Other than specified|0
6196466|NCT01461928|9855496|FG000|Maintenance II (15 Months)|Physician Decision|0
6196467|NCT01461928|9855497|FG001|Maintenance II (15 Months)|Physician Decision|0
6196468|NCT01461928|9855498|FG002|Maintenance II (15 Months)|Physician Decision|4
6196469|NCT01461928|9855496|FG000|Maintenance II (15 Months)|Lost to Follow-up|0
6196470|NCT01461928|9855497|FG001|Maintenance II (15 Months)|Lost to Follow-up|1
6196471|NCT01461928|9855498|FG002|Maintenance II (15 Months)|Lost to Follow-up|0
6196472|NCT01461928|9855496|FG000|Maintenance II (15 Months)|Moved to another town|0
6196473|NCT01461928|9855497|FG001|Maintenance II (15 Months)|Moved to another town|1
6196474|NCT01461928|9855498|FG002|Maintenance II (15 Months)|Moved to another town|0
6196475|NCT01461928|9855496|FG000|Maintenance II (15 Months)|Disease progression|0
6196476|NCT01461928|9855497|FG001|Maintenance II (15 Months)|Disease progression|0
6196477|NCT01461928|9855498|FG002|Maintenance II (15 Months)|Disease progression|3
6196478|NCT01461928|9855496|FG000|Maintenance II (15 Months)|Withdrawal by Subject|0
6196479|NCT01461928|9855497|FG001|Maintenance II (15 Months)|Withdrawal by Subject|9
6196480|NCT01461928|9855498|FG002|Maintenance II (15 Months)|Withdrawal by Subject|8
6196481|NCT01461928|9855496|FG000|Maintenance II (15 Months)|Changed physician in another hospital|0
6196482|NCT01461928|9855497|FG001|Maintenance II (15 Months)|Changed physician in another hospital|0
6196483|NCT01461928|9855498|FG002|Maintenance II (15 Months)|Changed physician in another hospital|1
6196484|NCT01461928|9855496|FG000|Maintenance II (15 Months)|Squamous lung carcinoma|0
6196485|NCT01461928|9855497|FG001|Maintenance II (15 Months)|Squamous lung carcinoma|0
6196486|NCT01461928|9855498|FG002|Maintenance II (15 Months)|Squamous lung carcinoma|1
6196487|NCT01461928|9855496|FG000|Maintenance II (15 Months)|Withdrew informed consent|0
6196488|NCT01461928|9855497|FG001|Maintenance II (15 Months)|Withdrew informed consent|0
6196489|NCT01461928|9855498|FG002|Maintenance II (15 Months)|Withdrew informed consent|1
6196490|NCT01461928|9855496|FG000|Maintenance II (15 Months)|Refused to be transferred to other site|0
6196491|NCT01461928|9855497|FG001|Maintenance II (15 Months)|Refused to be transferred to other site|0
6196492|NCT01461928|9855498|FG002|Maintenance II (15 Months)|Refused to be transferred to other site|1
6196493|NCT01461980|9855512|FG000|Overall Study|Other|9
6196494|NCT01461980|9855513|FG001|Overall Study|Other|8
6196495|NCT01461980|9855514|FG002|Overall Study|Other|6
6196496|NCT01461980|9855512|FG000|Overall Study|Medication error|7
6196497|NCT01461980|9855513|FG001|Overall Study|Medication error|5
6196498|NCT01461980|9855514|FG002|Overall Study|Medication error|6
6196499|NCT01461980|9855512|FG000|Overall Study|Adverse Event|12
6196500|NCT01461980|9855513|FG001|Overall Study|Adverse Event|5
6196501|NCT01461980|9855514|FG002|Overall Study|Adverse Event|6
6196502|NCT01461980|9855512|FG000|Overall Study|Protocol Violation|12
6196503|NCT01461980|9855513|FG001|Overall Study|Protocol Violation|19
6196504|NCT01461980|9855514|FG002|Overall Study|Protocol Violation|16
6196505|NCT01461980|9855512|FG000|Overall Study|No longer meets eligibility criteria|18
6196506|NCT01461980|9855513|FG001|Overall Study|No longer meets eligibility criteria|9
6196507|NCT01461980|9855514|FG002|Overall Study|No longer meets eligibility criteria|19
6196508|NCT01461980|9855512|FG000|Overall Study|Lost to Follow-up|52
6196509|NCT01461980|9855513|FG001|Overall Study|Lost to Follow-up|53
6196510|NCT01461980|9855514|FG002|Overall Study|Lost to Follow-up|51
6275039|NCT02207244|9979299|FG009|Open-label Guselkumab: Week 72-264|Adverse Event|0
6275040|NCT02207244|9979300|FG010|Open-label Guselkumab: Week 72-264|Adverse Event|21
6275041|NCT02207244|9979290|FG000|Open-label Guselkumab: Week 72-264|Death|0
6275042|NCT02207244|9979291|FG001|Open-label Guselkumab: Week 72-264|Death|0
6275043|NCT02207244|9979292|FG002|Open-label Guselkumab: Week 72-264|Death|0
6275044|NCT02207244|9979293|FG003|Open-label Guselkumab: Week 72-264|Death|0
6275045|NCT02207244|9979294|FG004|Open-label Guselkumab: Week 72-264|Death|0
6275046|NCT02207244|9979295|FG005|Open-label Guselkumab: Week 72-264|Death|0
6275047|NCT02207244|9979296|FG006|Open-label Guselkumab: Week 72-264|Death|0
6275048|NCT02207244|9979297|FG007|Open-label Guselkumab: Week 72-264|Death|0
6275049|NCT02207244|9979298|FG008|Open-label Guselkumab: Week 72-264|Death|1
6275050|NCT02207244|9979299|FG009|Open-label Guselkumab: Week 72-264|Death|0
6275051|NCT02207244|9979300|FG010|Open-label Guselkumab: Week 72-264|Death|1
6275052|NCT02207244|9979290|FG000|Open-label Guselkumab: Week 72-264|Other|0
6275053|NCT02207244|9979291|FG001|Open-label Guselkumab: Week 72-264|Other|0
6275054|NCT02207244|9979292|FG002|Open-label Guselkumab: Week 72-264|Other|0
6275055|NCT02207244|9979293|FG003|Open-label Guselkumab: Week 72-264|Other|0
6275056|NCT02207244|9979294|FG004|Open-label Guselkumab: Week 72-264|Other|0
5976791|NCT01147666|9563666|FG014|Dosing Period 1: 6-Week Treatment|Other than specified|0
5976792|NCT01147666|9563652|FG000|Dosing Period 1: 6-Week Treatment|Non-compliance with study drug|0
5976793|NCT01147666|9563653|FG001|Dosing Period 1: 6-Week Treatment|Non-compliance with study drug|0
5976794|NCT01147666|9563654|FG002|Dosing Period 1: 6-Week Treatment|Non-compliance with study drug|0
5976795|NCT01147666|9563655|FG003|Dosing Period 1: 6-Week Treatment|Non-compliance with study drug|0
5976796|NCT01147666|9563656|FG004|Dosing Period 1: 6-Week Treatment|Non-compliance with study drug|0
6196511|NCT01461980|9855512|FG000|Overall Study|No longer willing to participate|52
6196512|NCT01461980|9855513|FG001|Overall Study|No longer willing to participate|38
6275057|NCT02207244|9979295|FG005|Open-label Guselkumab: Week 72-264|Other|0
6275058|NCT02207244|9979296|FG006|Open-label Guselkumab: Week 72-264|Other|0
6275059|NCT02207244|9979297|FG007|Open-label Guselkumab: Week 72-264|Other|0
5976797|NCT01147666|9563657|FG005|Dosing Period 1: 6-Week Treatment|Non-compliance with study drug|0
6196513|NCT01461980|9855514|FG002|Overall Study|No longer willing to participate|54
6196514|NCT01461980|9855512|FG000|Overall Study|Randomized but not vaccinated|4
6196515|NCT01461980|9855513|FG001|Overall Study|Randomized but not vaccinated|8
6196516|NCT01461980|9855514|FG002|Overall Study|Randomized but not vaccinated|7
6196517|NCT01461993|9855526|FG000|Overall Study|Withdrawal by Subject|60
6196518|NCT01461993|9855527|FG001|Overall Study|Withdrawal by Subject|53
6196519|NCT01461993|9855528|FG002|Overall Study|Withdrawal by Subject|16
6196520|NCT01461993|9855526|FG000|Overall Study|Lost to Follow-up|44
6196521|NCT01461993|9855527|FG001|Overall Study|Lost to Follow-up|48
6196522|NCT01461993|9855528|FG002|Overall Study|Lost to Follow-up|22
6196523|NCT01461993|9855526|FG000|Overall Study|Protocol Violation|10
6196524|NCT01461993|9855527|FG001|Overall Study|Protocol Violation|9
6196525|NCT01461993|9855528|FG002|Overall Study|Protocol Violation|7
6196526|NCT01461993|9855526|FG000|Overall Study|Adverse Event|9
6196527|NCT01461993|9855527|FG001|Overall Study|Adverse Event|11
6196528|NCT01461993|9855528|FG002|Overall Study|Adverse Event|3
6196529|NCT01461993|9855526|FG000|Overall Study|No longer met eligibility criteria|13
6196530|NCT01461993|9855527|FG001|Overall Study|No longer met eligibility criteria|18
6196531|NCT01461993|9855528|FG002|Overall Study|No longer met eligibility criteria|10
6196532|NCT01461993|9855526|FG000|Overall Study|Did not meet entrance criteria|2
6196533|NCT01461993|9855527|FG001|Overall Study|Did not meet entrance criteria|3
6196534|NCT01461993|9855528|FG002|Overall Study|Did not meet entrance criteria|0
6196535|NCT01461993|9855526|FG000|Overall Study|Other|13
6196536|NCT01461993|9855527|FG001|Overall Study|Other|15
6196537|NCT01461993|9855528|FG002|Overall Study|Other|6
6196538|NCT01462045|9855540|FG000|Overall Study|Family matter|0
6196539|NCT01462045|9855541|FG001|Overall Study|Family matter|1
6196540|NCT01462045|9855542|FG002|Overall Study|Family matter|0
6275060|NCT02207244|9979298|FG008|Open-label Guselkumab: Week 72-264|Other|8
6275061|NCT02207244|9979299|FG009|Open-label Guselkumab: Week 72-264|Other|0
6275062|NCT02207244|9979300|FG010|Open-label Guselkumab: Week 72-264|Other|19
6275063|NCT02207244|9979290|FG000|Open-label Guselkumab: Week 72-264|Pregnancy|0
6275064|NCT02207244|9979291|FG001|Open-label Guselkumab: Week 72-264|Pregnancy|0
6275065|NCT02207244|9979292|FG002|Open-label Guselkumab: Week 72-264|Pregnancy|0
6275066|NCT02207244|9979293|FG003|Open-label Guselkumab: Week 72-264|Pregnancy|0
6275067|NCT02207244|9979294|FG004|Open-label Guselkumab: Week 72-264|Pregnancy|0
6275068|NCT02207244|9979295|FG005|Open-label Guselkumab: Week 72-264|Pregnancy|0
6275069|NCT02207244|9979296|FG006|Open-label Guselkumab: Week 72-264|Pregnancy|0
6275070|NCT02207244|9979297|FG007|Open-label Guselkumab: Week 72-264|Pregnancy|0
6275071|NCT02207244|9979298|FG008|Open-label Guselkumab: Week 72-264|Pregnancy|0
6275072|NCT02207244|9979299|FG009|Open-label Guselkumab: Week 72-264|Pregnancy|0
6275073|NCT02207244|9979300|FG010|Open-label Guselkumab: Week 72-264|Pregnancy|2
6275074|NCT02207374|9979341|FG000|Overall Study|Withdrawal by Subject|5
6275075|NCT02207374|9979342|FG001|Overall Study|Withdrawal by Subject|9
6275076|NCT02207374|9979343|FG002|Overall Study|Withdrawal by Subject|4
6275077|NCT02207374|9979341|FG000|Overall Study|Death|1
6275078|NCT02207374|9979342|FG001|Overall Study|Death|0
6275079|NCT02207374|9979343|FG002|Overall Study|Death|1
6275080|NCT02207374|9979341|FG000|Overall Study|Missing follow-up information|0
6275081|NCT02207374|9979342|FG001|Overall Study|Missing follow-up information|1
6275082|NCT02207374|9979343|FG002|Overall Study|Missing follow-up information|1
6275083|NCT02207400|9979353|FG000|Overall Study|Adverse Event|1
6275084|NCT02207400|9979354|FG001|Overall Study|Adverse Event|1
6275085|NCT02207400|9979353|FG000|Overall Study|Lost to Follow-up|6
6275086|NCT02207400|9979354|FG001|Overall Study|Lost to Follow-up|7
6275087|NCT02207400|9979353|FG000|Overall Study|Protocol Violation|1
6275088|NCT02207400|9979354|FG001|Overall Study|Protocol Violation|1
6275089|NCT02207400|9979353|FG000|Overall Study|Withdrawal by Subject|8
6275090|NCT02207400|9979354|FG001|Overall Study|Withdrawal by Subject|4
6275091|NCT02207400|9979353|FG000|Overall Study|Positive Urine Pregnancy Test|0
6275092|NCT02207400|9979354|FG001|Overall Study|Positive Urine Pregnancy Test|1
6275093|NCT02207413|9979369|FG000|Overall Study|Withdrawal by Subject|1
6275094|NCT02207413|9979370|FG001|Overall Study|Withdrawal by Subject|0
6275095|NCT02207413|9979371|FG002|Overall Study|Withdrawal by Subject|0
6275096|NCT02207413|9979372|FG003|Overall Study|Withdrawal by Subject|0
6275097|NCT02207413|9979373|FG004|Overall Study|Withdrawal by Subject|3
6275098|NCT02207413|9979374|FG005|Overall Study|Withdrawal by Subject|7
6275099|NCT02207413|9979369|FG000|Overall Study|Lost to Follow-up|0
6275100|NCT02207413|9979370|FG001|Overall Study|Lost to Follow-up|0
6275101|NCT02207413|9979371|FG002|Overall Study|Lost to Follow-up|0
6275102|NCT02207413|9979372|FG003|Overall Study|Lost to Follow-up|1
6275103|NCT02207413|9979373|FG004|Overall Study|Lost to Follow-up|1
6275104|NCT02207413|9979374|FG005|Overall Study|Lost to Follow-up|5
6275105|NCT02207413|9979369|FG000|Overall Study|Adverse Event|0
6275106|NCT02207413|9979370|FG001|Overall Study|Adverse Event|0
6275107|NCT02207413|9979371|FG002|Overall Study|Adverse Event|0
6275108|NCT02207413|9979372|FG003|Overall Study|Adverse Event|0
6275109|NCT02207413|9979373|FG004|Overall Study|Adverse Event|2
6275110|NCT02207413|9979374|FG005|Overall Study|Adverse Event|1
6275111|NCT02207413|9979369|FG000|Overall Study|Migrated/moved from study area|0
6275112|NCT02207413|9979370|FG001|Overall Study|Migrated/moved from study area|0
6275113|NCT02207413|9979371|FG002|Overall Study|Migrated/moved from study area|0
6196541|NCT01462084|9855550|FG000|Overall Study|Withdrawal by Subject|1
6196542|NCT01462084|9855551|FG001|Overall Study|Withdrawal by Subject|0
6196543|NCT01462084|9855550|FG000|Overall Study|Protocol Violation|1
6196544|NCT01462084|9855551|FG001|Overall Study|Protocol Violation|1
6196545|NCT01462110|9855560|FG000|Overall Study|Adverse Event|1
6196546|NCT01462110|9855561|FG001|Overall Study|Adverse Event|0
6196547|NCT01462162|9855567|FG000|Overall Study|Adverse Event|5
6196548|NCT01462162|9855567|FG000|Overall Study|Lack of Efficacy|4
6196549|NCT01462162|9855567|FG000|Overall Study|Abnormal laboratory parameters|1
6196550|NCT01462162|9855567|FG000|Overall Study|Other|2
6196551|NCT01462227|9855574|FG000|Second Assignment|Lost to Follow-up|1
6196552|NCT01462227|9855575|FG001|Second Assignment|Lost to Follow-up|0
6196553|NCT01462227|9855576|FG002|Second Assignment|Lost to Follow-up|0
6196554|NCT01462227|9855577|FG003|Second Assignment|Lost to Follow-up|0
6196555|NCT01462227|9855574|FG000|Second Assignment|Protocol Violation|0
6196556|NCT01462227|9855575|FG001|Second Assignment|Protocol Violation|1
6196557|NCT01462227|9855576|FG002|Second Assignment|Protocol Violation|1
6196558|NCT01462227|9855577|FG003|Second Assignment|Protocol Violation|0
6196559|NCT01462266|9855591|FG000|Overall Study|Adverse Event|7
6196560|NCT01462266|9855592|FG001|Overall Study|Adverse Event|6
6196561|NCT01462266|9855591|FG000|Overall Study|Death|2
6196562|NCT01462266|9855592|FG001|Overall Study|Death|1
6196563|NCT01462266|9855591|FG000|Overall Study|Lack of Efficacy|0
6196564|NCT01462266|9855592|FG001|Overall Study|Lack of Efficacy|2
6196565|NCT01462266|9855591|FG000|Overall Study|Lost to Follow-up|4
6196566|NCT01462266|9855592|FG001|Overall Study|Lost to Follow-up|3
6196567|NCT01462266|9855591|FG000|Overall Study|Non-compliance with study drug|3
6196568|NCT01462266|9855592|FG001|Overall Study|Non-compliance with study drug|0
6196569|NCT01462266|9855591|FG000|Overall Study|Creatinine and eGFR, excluded medication|8
6196570|NCT01462266|9855592|FG001|Overall Study|Creatinine and eGFR, excluded medication|4
6196571|NCT01462266|9855591|FG000|Overall Study|Physician Decision|2
6196572|NCT01462266|9855592|FG001|Overall Study|Physician Decision|5
6196573|NCT01462266|9855591|FG000|Overall Study|Protocol Violation|1
6196574|NCT01462266|9855592|FG001|Overall Study|Protocol Violation|3
6196575|NCT01462266|9855591|FG000|Overall Study|Withdrawal by Subject|7
6196576|NCT01462266|9855592|FG001|Overall Study|Withdrawal by Subject|2
6196577|NCT01462266|9855591|FG000|Overall Study|Screen failure|1
6196578|NCT01462266|9855592|FG001|Overall Study|Screen failure|1
6196579|NCT01462318|9855629|FG000|Main Study / TP-DI Study|Other|2
6196580|NCT01462318|9855630|FG001|Main Study / TP-DI Study|Other|0
6196581|NCT01462318|9855631|FG002|Main Study / TP-DI Study|Other|0
6275114|NCT02207413|9979372|FG003|Overall Study|Migrated/moved from study area|0
6275115|NCT02207413|9979373|FG004|Overall Study|Migrated/moved from study area|1
6275116|NCT02207413|9979374|FG005|Overall Study|Migrated/moved from study area|0
6275117|NCT02207491|9979405|FG000|Overall Study|Adverse Event|20
6275118|NCT02207491|9979406|FG001|Overall Study|Adverse Event|4
6275119|NCT02207491|9979405|FG000|Overall Study|Withdrawal by Subject|3
6275120|NCT02207491|9979406|FG001|Overall Study|Withdrawal by Subject|2
6275121|NCT02207491|9979405|FG000|Overall Study|Non-compliant|0
6275122|NCT02207491|9979406|FG001|Overall Study|Non-compliant|1
6275123|NCT02207491|9979405|FG000|Overall Study|Lost to Follow-up|0
6275124|NCT02207491|9979406|FG001|Overall Study|Lost to Follow-up|1
6275125|NCT02207491|9979405|FG000|Overall Study|Lack of Efficacy|3
6275126|NCT02207491|9979406|FG001|Overall Study|Lack of Efficacy|0
6275127|NCT02207491|9979405|FG000|Overall Study|Physician Decision|2
6275128|NCT02207491|9979406|FG001|Overall Study|Physician Decision|0
6275129|NCT02207491|9979405|FG000|Overall Study|Protocol Violation|3
6275130|NCT02207491|9979406|FG001|Overall Study|Protocol Violation|5
5976798|NCT01147666|9563658|FG006|Dosing Period 1: 6-Week Treatment|Non-compliance with study drug|0
5976799|NCT01147666|9563659|FG007|Dosing Period 1: 6-Week Treatment|Non-compliance with study drug|0
5976800|NCT01147666|9563660|FG008|Dosing Period 1: 6-Week Treatment|Non-compliance with study drug|0
5976801|NCT01147666|9563661|FG009|Dosing Period 1: 6-Week Treatment|Non-compliance with study drug|0
5976802|NCT01147666|9563662|FG010|Dosing Period 1: 6-Week Treatment|Non-compliance with study drug|0
5976803|NCT01147666|9563663|FG011|Dosing Period 1: 6-Week Treatment|Non-compliance with study drug|1
5976804|NCT01147666|9563664|FG012|Dosing Period 1: 6-Week Treatment|Non-compliance with study drug|1
6196582|NCT01462318|9855629|FG000|Main Study / TP-DI Study|Withdrawal by Subject|2
6196583|NCT01462318|9855630|FG001|Main Study / TP-DI Study|Withdrawal by Subject|0
6196584|NCT01462318|9855631|FG002|Main Study / TP-DI Study|Withdrawal by Subject|0
6196585|NCT01462318|9855629|FG000|Main Study / TP-DI Study|Adverse Event|4
6196586|NCT01462318|9855630|FG001|Main Study / TP-DI Study|Adverse Event|0
6196587|NCT01462318|9855631|FG002|Main Study / TP-DI Study|Adverse Event|0
6196588|NCT01462318|9855629|FG000|Extension Phase|Lost to Follow-up|0
6196589|NCT01462318|9855630|FG001|Extension Phase|Lost to Follow-up|0
6196590|NCT01462318|9855631|FG002|Extension Phase|Lost to Follow-up|1
6196591|NCT01462318|9855629|FG000|Extension Phase|Other|0
6196592|NCT01462318|9855630|FG001|Extension Phase|Other|0
6196593|NCT01462318|9855631|FG002|Extension Phase|Other|1
6196594|NCT01462318|9855629|FG000|Extension Phase|Disease Progression|0
6196595|NCT01462318|9855630|FG001|Extension Phase|Disease Progression|0
6196596|NCT01462318|9855631|FG002|Extension Phase|Disease Progression|1
6196597|NCT01462318|9855629|FG000|Extension Phase|Withdrawal by Subject|0
6196598|NCT01462318|9855630|FG001|Extension Phase|Withdrawal by Subject|0
6196599|NCT01462318|9855631|FG002|Extension Phase|Withdrawal by Subject|15
6196600|NCT01462318|9855629|FG000|Extension Phase|Investigator Decision|0
6196601|NCT01462318|9855630|FG001|Extension Phase|Investigator Decision|0
6196602|NCT01462318|9855631|FG002|Extension Phase|Investigator Decision|5
6196603|NCT01462318|9855629|FG000|Extension Phase|Adverse Event|0
6196604|NCT01462318|9855630|FG001|Extension Phase|Adverse Event|0
6196605|NCT01462318|9855631|FG002|Extension Phase|Adverse Event|22
6196606|NCT01462344|9855638|FG000|Overall Study|Withdrawal by Subject|245
6196607|NCT01462344|9855639|FG001|Overall Study|Withdrawal by Subject|226
6196608|NCT01462344|9855638|FG000|Overall Study|Adverse Event|24
6196609|NCT01462344|9855639|FG001|Overall Study|Adverse Event|23
6196610|NCT01462344|9855638|FG000|Overall Study|Asthma Exacerbation|34
6196611|NCT01462344|9855639|FG001|Overall Study|Asthma Exacerbation|35
6196612|NCT01462344|9855638|FG000|Overall Study|Lack of Efficacy|5
6196613|NCT01462344|9855639|FG001|Overall Study|Lack of Efficacy|6
6196614|NCT01462344|9855638|FG000|Overall Study|Protocol Violation|68
6196615|NCT01462344|9855639|FG001|Overall Study|Protocol Violation|53
6196616|NCT01462344|9855638|FG000|Overall Study|Lost to Follow-up|7
6275131|NCT02207530|9979412|FG000|Overall Study|Worsening condition under investigation|78
6275132|NCT02207530|9979412|FG000|Overall Study|Patient decision to stop study treatment|5
6275133|NCT02207530|9979412|FG000|Overall Study|Adverse Event|8
6275134|NCT02207556|9979418|FG000|Overall Study|Physician Decision|1
6275135|NCT02207556|9979419|FG001|Overall Study|Physician Decision|0
6275136|NCT02207556|9979418|FG000|Overall Study|Withdrawal by Subject|1
6275137|NCT02207556|9979419|FG001|Overall Study|Withdrawal by Subject|0
6275138|NCT02207556|9979418|FG000|Overall Study|Death|0
6275139|NCT02207556|9979419|FG001|Overall Study|Death|5
6275140|NCT02207569|9979428|FG000|Implant to 1-Month|Death|6
6275141|NCT02207569|9979428|FG000|Implant to 1-Month|Withdrawal by Subject|2
6275142|NCT02207569|9979428|FG000|Implant to 1-Month|Subject anesthetized but product not onsite, for medical justification treated w/commercial device|1
6275143|NCT02207569|9979428|FG000|1-Month to 6-Month|Death|8
6275144|NCT02207569|9979428|FG000|1-Month to 6-Month|Withdrawal by Subject|2
6275145|NCT02207569|9979428|FG000|12-Month|Death|8
6275146|NCT02207569|9979428|FG000|12-Month|Withdrawal by Subject|1
6275147|NCT02207569|9979428|FG000|6-Month to 12-Month|Death|14
6275148|NCT02207569|9979428|FG000|6-Month to 12-Month|Withdrawal by Subject|2
6275149|NCT02207569|9979428|FG000|12-Month to 24 Month|Death|23
6275150|NCT02207569|9979428|FG000|12-Month to 24 Month|Withdrawal by Subject|3
6275151|NCT02207569|9979428|FG000|24-Month to 36-Month|Death|23
6275152|NCT02207569|9979428|FG000|24-Month to 36-Month|Withdrawal by Subject|4
6275153|NCT02207569|9979428|FG000|36-Month to 48-Month|Death|25
6275154|NCT02207569|9979428|FG000|36-Month to 48-Month|Withdrawal by Subject|2
6275155|NCT02207569|9979428|FG000|36-Month to 48-Month|Lost to Follow-up|4
6275156|NCT02207569|9979428|FG000|48-Month to 60-Month|Death|1
6275157|NCT02207569|9979428|FG000|48-Month to 60-Month|Lost to Follow-up|1
6275158|NCT02207569|9979428|FG000|48-Month to 60-Month|pt 103 years old no longer traveling for MD visits|1
6275159|NCT02207569|9979428|FG000|48-Month to 60-Month|Covid-19 pt not willing to be seen|1
6275160|NCT02207608|9979434|FG000|Overall Study|Adverse Event|1
6275161|NCT02207608|9979435|FG001|Overall Study|Adverse Event|0
6275162|NCT02207621|9979444|FG000|Overall Study|Adverse Event|71
6275163|NCT02207621|9979445|FG001|Overall Study|Adverse Event|15
6275164|NCT02207621|9979446|FG002|Overall Study|Adverse Event|132
6275165|NCT02207621|9979444|FG000|Overall Study|Withdrawal by Subject|9
6275166|NCT02207621|9979445|FG001|Overall Study|Withdrawal by Subject|9
6275167|NCT02207621|9979446|FG002|Overall Study|Withdrawal by Subject|13
6275168|NCT02207621|9979444|FG000|Overall Study|Non-Compliant|3
6275169|NCT02207621|9979445|FG001|Overall Study|Non-Compliant|3
6275170|NCT02207621|9979446|FG002|Overall Study|Non-Compliant|1
6275171|NCT02207621|9979444|FG000|Overall Study|Lost to Follow-up|1
6275172|NCT02207621|9979445|FG001|Overall Study|Lost to Follow-up|0
6196617|NCT01462344|9855639|FG001|Overall Study|Lost to Follow-up|7
6196618|NCT01462357|9855648|FG000|Overall Study|Death|0
6196619|NCT01462357|9855649|FG001|Overall Study|Death|0
6196620|NCT01462357|9855650|FG002|Overall Study|Death|1
6196621|NCT01462357|9855648|FG000|Overall Study|Withdrawal by Subject|3
6275173|NCT02207621|9979446|FG002|Overall Study|Lost to Follow-up|3
6275174|NCT02207621|9979444|FG000|Overall Study|Lack of Efficacy|10
6275175|NCT02207621|9979445|FG001|Overall Study|Lack of Efficacy|2
6275176|NCT02207621|9979446|FG002|Overall Study|Lack of Efficacy|4
6275177|NCT02207621|9979444|FG000|Overall Study|Disallowed Concurrent Medication|2
6275178|NCT02207621|9979445|FG001|Overall Study|Disallowed Concurrent Medication|5
6196622|NCT01462357|9855649|FG001|Overall Study|Withdrawal by Subject|11
6196623|NCT01462357|9855650|FG002|Overall Study|Withdrawal by Subject|3
6196624|NCT01462357|9855648|FG000|Overall Study|Migrated/moved from study area|2
6196625|NCT01462357|9855649|FG001|Overall Study|Migrated/moved from study area|3
6196626|NCT01462357|9855650|FG002|Overall Study|Migrated/moved from study area|1
6196627|NCT01462357|9855648|FG000|Overall Study|Lost to Follow-up|3
6196628|NCT01462357|9855649|FG001|Overall Study|Lost to Follow-up|5
6196629|NCT01462357|9855650|FG002|Overall Study|Lost to Follow-up|7
6196630|NCT01462435|9855662|FG000|Overall Study|Lack of Efficacy|1
6196631|NCT01462435|9855663|FG001|Overall Study|Lack of Efficacy|0
6196632|NCT01462435|9855664|FG002|Overall Study|Lack of Efficacy|0
6196633|NCT01462435|9855665|FG003|Overall Study|Lack of Efficacy|3
6196634|NCT01462435|9855662|FG000|Overall Study|Physician Decision|0
6196635|NCT01462435|9855663|FG001|Overall Study|Physician Decision|0
6196636|NCT01462435|9855664|FG002|Overall Study|Physician Decision|1
6196637|NCT01462435|9855665|FG003|Overall Study|Physician Decision|0
6196638|NCT01462435|9855662|FG000|Overall Study|Withdrawal by Subject|0
6196639|NCT01462435|9855663|FG001|Overall Study|Withdrawal by Subject|0
6196640|NCT01462435|9855664|FG002|Overall Study|Withdrawal by Subject|0
6196641|NCT01462435|9855665|FG003|Overall Study|Withdrawal by Subject|1
6196642|NCT01462435|9855662|FG000|Overall Study|Lost to Follow-up|0
6196643|NCT01462435|9855663|FG001|Overall Study|Lost to Follow-up|0
6196644|NCT01462435|9855664|FG002|Overall Study|Lost to Follow-up|0
6196645|NCT01462435|9855665|FG003|Overall Study|Lost to Follow-up|1
6196646|NCT01462695|9855681|FG000|Overall Study|Adverse Event|1
6196647|NCT01462695|9855682|FG001|Overall Study|Adverse Event|1
6196648|NCT01462695|9855681|FG000|Overall Study|Death|2
6275179|NCT02207621|9979446|FG002|Overall Study|Disallowed Concurrent Medication|2
6275180|NCT02207621|9979444|FG000|Overall Study|Physician Decision|1
6275181|NCT02207621|9979445|FG001|Overall Study|Physician Decision|2
6275182|NCT02207621|9979446|FG002|Overall Study|Physician Decision|2
6275183|NCT02207621|9979444|FG000|Overall Study|Protocol Violation|4
6275184|NCT02207621|9979445|FG001|Overall Study|Protocol Violation|10
6275185|NCT02207621|9979446|FG002|Overall Study|Protocol Violation|6
6275186|NCT02207621|9979444|FG000|Overall Study|Death|2
6275187|NCT02207621|9979445|FG001|Overall Study|Death|0
6275188|NCT02207621|9979446|FG002|Overall Study|Death|0
6275189|NCT02207621|9979444|FG000|Overall Study|Other(Site,Sponsor and Subject request)|2
6275190|NCT02207621|9979445|FG001|Overall Study|Other(Site,Sponsor and Subject request)|1
6275191|NCT02207621|9979446|FG002|Overall Study|Other(Site,Sponsor and Subject request)|5
6275192|NCT02207634|9979457|FG000|Overall Study|Withdrawal by Subject|21
6275193|NCT02207634|9979458|FG001|Overall Study|Withdrawal by Subject|31
6275194|NCT02207634|9979457|FG000|Overall Study|Lost to Follow-up|1
6275195|NCT02207634|9979458|FG001|Overall Study|Lost to Follow-up|0
6275196|NCT02207725|9979468|FG000|Overall Study|Did Not Receive Treatment|0
6275197|NCT02207725|9979469|FG001|Overall Study|Did Not Receive Treatment|1
6275198|NCT02207725|9979470|FG002|Overall Study|Did Not Receive Treatment|1
6275199|NCT02207725|9979471|FG003|Overall Study|Did Not Receive Treatment|1
6275200|NCT02207816|9979495|FG000|Overall Study|Serious Adverse Event|0
6275201|NCT02207816|9979496|FG001|Overall Study|Serious Adverse Event|5
6275202|NCT02207816|9979497|FG002|Overall Study|Serious Adverse Event|2
6275203|NCT02207816|9979495|FG000|Overall Study|Eligibility Criteria Not Fulfilled|2
6275204|NCT02207816|9979496|FG001|Overall Study|Eligibility Criteria Not Fulfilled|1
6275205|NCT02207816|9979497|FG002|Overall Study|Eligibility Criteria Not Fulfilled|2
6275206|NCT02207816|9979495|FG000|Overall Study|Withdrawal by Subject|4
6275207|NCT02207816|9979496|FG001|Overall Study|Withdrawal by Subject|9
6275208|NCT02207816|9979497|FG002|Overall Study|Withdrawal by Subject|7
6275209|NCT02207816|9979495|FG000|Overall Study|Migrated/Moved From Study Area|41
6275210|NCT02207816|9979496|FG001|Overall Study|Migrated/Moved From Study Area|60
6275211|NCT02207816|9979497|FG002|Overall Study|Migrated/Moved From Study Area|51
6275212|NCT02207816|9979495|FG000|Overall Study|Lost to Follow-up|3
6275213|NCT02207816|9979496|FG001|Overall Study|Lost to Follow-up|9
6275214|NCT02207816|9979497|FG002|Overall Study|Lost to Follow-up|1
6275215|NCT02207816|9979495|FG000|Overall Study|Other|1
6275216|NCT02207816|9979496|FG001|Overall Study|Other|2
6275217|NCT02207816|9979497|FG002|Overall Study|Other|4
6275218|NCT02207829|9979510|FG000|Overall Study|Adverse Event|10
6275219|NCT02207829|9979511|FG001|Overall Study|Adverse Event|9
6275220|NCT02207829|9979510|FG000|Overall Study|Lack of Efficacy|7
6275221|NCT02207829|9979511|FG001|Overall Study|Lack of Efficacy|5
6275222|NCT02207829|9979510|FG000|Overall Study|Lost to Follow-up|2
6275223|NCT02207829|9979511|FG001|Overall Study|Lost to Follow-up|2
6275224|NCT02207829|9979510|FG000|Overall Study|Protocol deviation|5
6275225|NCT02207829|9979511|FG001|Overall Study|Protocol deviation|4
6275226|NCT02207829|9979510|FG000|Overall Study|Withdrew consent|18
6275227|NCT02207829|9979511|FG001|Overall Study|Withdrew consent|14
6196649|NCT01462695|9855682|FG001|Overall Study|Death|0
6196650|NCT01462695|9855681|FG000|Overall Study|Lack of Efficacy|6
6275228|NCT02207907|9979519|FG000|Overall Study|Lost to Follow-up|3
6275229|NCT02207907|9979520|FG001|Overall Study|Lost to Follow-up|1
6196651|NCT01462695|9855682|FG001|Overall Study|Lack of Efficacy|12
6275230|NCT02207907|9979519|FG000|Overall Study|Withdrawal by Subject|5
6275231|NCT02207907|9979520|FG001|Overall Study|Withdrawal by Subject|6
6275232|NCT02207907|9979519|FG000|Overall Study|Did not meet study criteria|3
6275233|NCT02207907|9979520|FG001|Overall Study|Did not meet study criteria|0
6275234|NCT02207907|9979519|FG000|Overall Study|Pregnancy|0
6196652|NCT01462695|9855681|FG000|Overall Study|Physician Decision|5
6196653|NCT01462695|9855682|FG001|Overall Study|Physician Decision|0
6196654|NCT01462695|9855681|FG000|Overall Study|Withdrawal by Subject|2
6196655|NCT01462695|9855682|FG001|Overall Study|Withdrawal by Subject|0
6196656|NCT01462695|9855681|FG000|Overall Study|Inevaluable (did not receive study drug)|1
6196657|NCT01462695|9855682|FG001|Overall Study|Inevaluable (did not receive study drug)|0
6196658|NCT01462929|9855709|FG000|Overall Study|Adverse Event|3
6196659|NCT01462929|9855710|FG001|Overall Study|Adverse Event|3
6196660|NCT01462929|9855711|FG002|Overall Study|Adverse Event|4
6196661|NCT01462929|9855709|FG000|Overall Study|Withdrawal by Subject|2
6196662|NCT01462929|9855710|FG001|Overall Study|Withdrawal by Subject|1
6196663|NCT01462929|9855711|FG002|Overall Study|Withdrawal by Subject|0
6196664|NCT01462929|9855709|FG000|Overall Study|Lack of Efficacy|0
6196665|NCT01462929|9855710|FG001|Overall Study|Lack of Efficacy|0
6196666|NCT01462929|9855711|FG002|Overall Study|Lack of Efficacy|1
6196667|NCT01462942|9855724|FG000|Overall Study|Adverse Event|7
6196668|NCT01462942|9855725|FG001|Overall Study|Adverse Event|12
6196669|NCT01462942|9855726|FG002|Overall Study|Adverse Event|10
6196670|NCT01462942|9855727|FG003|Overall Study|Adverse Event|11
6196671|NCT01462942|9855728|FG004|Overall Study|Adverse Event|11
6196672|NCT01462942|9855724|FG000|Overall Study|Other, including COPD exacerbation|3
6196673|NCT01462942|9855725|FG001|Overall Study|Other, including COPD exacerbation|5
6196674|NCT01462942|9855726|FG002|Overall Study|Other, including COPD exacerbation|2
6196675|NCT01462942|9855727|FG003|Overall Study|Other, including COPD exacerbation|8
6196676|NCT01462942|9855728|FG004|Overall Study|Other, including COPD exacerbation|5
6196677|NCT01462942|9855724|FG000|Overall Study|Withdrawal by Subject|14
6196678|NCT01462942|9855725|FG001|Overall Study|Withdrawal by Subject|10
6196679|NCT01462942|9855726|FG002|Overall Study|Withdrawal by Subject|14
6196680|NCT01462942|9855727|FG003|Overall Study|Withdrawal by Subject|16
6196681|NCT01462942|9855728|FG004|Overall Study|Withdrawal by Subject|19
6196682|NCT01462942|9855724|FG000|Overall Study|Lack of Efficacy|6
6196683|NCT01462942|9855725|FG001|Overall Study|Lack of Efficacy|0
6196684|NCT01462942|9855726|FG002|Overall Study|Lack of Efficacy|4
6196685|NCT01462942|9855727|FG003|Overall Study|Lack of Efficacy|5
6196686|NCT01462942|9855728|FG004|Overall Study|Lack of Efficacy|3
6196687|NCT01462942|9855724|FG000|Overall Study|Lost to Follow-up|0
6196688|NCT01462942|9855725|FG001|Overall Study|Lost to Follow-up|1
6196689|NCT01462942|9855726|FG002|Overall Study|Lost to Follow-up|1
6196690|NCT01462942|9855727|FG003|Overall Study|Lost to Follow-up|1
6196691|NCT01462942|9855728|FG004|Overall Study|Lost to Follow-up|1
6196692|NCT01462942|9855724|FG000|Overall Study|Protocol Violation|4
6196693|NCT01462942|9855725|FG001|Overall Study|Protocol Violation|6
6196694|NCT01462942|9855726|FG002|Overall Study|Protocol Violation|9
6196695|NCT01462942|9855727|FG003|Overall Study|Protocol Violation|9
6196696|NCT01462942|9855728|FG004|Overall Study|Protocol Violation|6
6196697|NCT01463007|9855740|FG000|Overall Study|Physician Decision|1
6196698|NCT01463033|9855747|FG000|Overall Study|Lost to Follow-up|4
6275235|NCT02207907|9979520|FG001|Overall Study|Pregnancy|1
6275236|NCT02207946|9979529|FG000|Overall Study|Lost to Follow-up|1
6275237|NCT02207946|9979530|FG001|Overall Study|Lost to Follow-up|0
6275238|NCT02207946|9979529|FG000|Overall Study|Adverse Event|0
6275239|NCT02207946|9979530|FG001|Overall Study|Adverse Event|1
6275240|NCT02208050|9979562|FG000|Washout Period 1: 2 Weeks|Withdrawal by Subject|1
6275241|NCT02208050|9979563|FG001|Washout Period 1: 2 Weeks|Withdrawal by Subject|0
6275242|NCT02208063|9979585|FG000|Overall Study|Death|3
6275243|NCT02208063|9979586|FG001|Overall Study|Death|5
6275244|NCT02208063|9979585|FG000|Overall Study|Not Specified in report|3
6275245|NCT02208063|9979586|FG001|Overall Study|Not Specified in report|4
6275246|NCT02208063|9979585|FG000|Overall Study|Withdrawal by Subject|5
6275247|NCT02208063|9979586|FG001|Overall Study|Withdrawal by Subject|2
6275248|NCT02208063|9979585|FG000|Overall Study|Lost to Follow-up|1
6275249|NCT02208063|9979586|FG001|Overall Study|Lost to Follow-up|0
6275250|NCT02208089|9979594|FG000|Overall Study|Withdrawal by Subject|1
6275251|NCT02208089|9979595|FG001|Overall Study|Withdrawal by Subject|0
6275252|NCT02208089|9979594|FG000|Overall Study|Lost to Follow-up|6
6275253|NCT02208089|9979595|FG001|Overall Study|Lost to Follow-up|0
6275254|NCT02208843|9979644|FG000|Overall Study|Clinical symptoms of progression|2
6275255|NCT02208843|9979644|FG000|Overall Study|Progression disease according to RECIST|24
6275256|NCT02208843|9979644|FG000|Overall Study|Adverse Event|12
6275257|NCT02208843|9979644|FG000|Overall Study|Protocol Violation|1
6275258|NCT02208843|9979644|FG000|Overall Study|Withdrawal by Subject|1
6275259|NCT02208843|9979644|FG000|Overall Study|Switched to commercial afatinib|20
6275260|NCT02208999|9979650|FG000|Overall Study|Lost to Follow-up|1
6275261|NCT02209181|9979678|FG000|Overall Study|Adverse Event|1
6196699|NCT01463033|9855748|FG001|Overall Study|Lost to Follow-up|4
6196700|NCT01463033|9855747|FG000|Overall Study|Death|3
6196701|NCT01463033|9855748|FG001|Overall Study|Death|2
6275262|NCT02209181|9979679|FG001|Overall Study|Adverse Event|0
6275263|NCT02209181|9979680|FG002|Overall Study|Adverse Event|1
6275264|NCT02209181|9979681|FG003|Overall Study|Adverse Event|0
6275265|NCT02209181|9979678|FG000|Overall Study|Withdrawal by Subject|0
6275266|NCT02209181|9979679|FG001|Overall Study|Withdrawal by Subject|1
6275267|NCT02209181|9979680|FG002|Overall Study|Withdrawal by Subject|0
6275268|NCT02209181|9979681|FG003|Overall Study|Withdrawal by Subject|0
6196702|NCT01463098|9855769|FG000|Part A (11 Days)|Participant Choice|2
6196703|NCT01463098|9855770|FG001|Part A (11 Days)|Participant Choice|0
6196704|NCT01463098|9855771|FG002|Part A (11 Days)|Participant Choice|0
6196705|NCT01463098|9855772|FG003|Part A (11 Days)|Participant Choice|0
6196706|NCT01463098|9855773|FG004|Part A (11 Days)|Participant Choice|0
6196707|NCT01463098|9855774|FG005|Part A (11 Days)|Participant Choice|0
6196708|NCT01463098|9855775|FG006|Part A (11 Days)|Participant Choice|0
6196709|NCT01463098|9855776|FG007|Part A (11 Days)|Participant Choice|0
6196710|NCT01463098|9855777|FG008|Part A (11 Days)|Participant Choice|1
6196711|NCT01463098|9855778|FG009|Part A (11 Days)|Participant Choice|0
6196712|NCT01463098|9855779|FG010|Part A (11 Days)|Participant Choice|0
6196713|NCT01463098|9855780|FG011|Part A (11 Days)|Participant Choice|0
6196714|NCT01463098|9855781|FG012|Part A (11 Days)|Participant Choice|0
6196715|NCT01463098|9855782|FG013|Part A (11 Days)|Participant Choice|0
6196716|NCT01463098|9855769|FG000|Part A (11 Days)|Lost to Follow-up|0
6196717|NCT01463098|9855770|FG001|Part A (11 Days)|Lost to Follow-up|0
6196718|NCT01463098|9855771|FG002|Part A (11 Days)|Lost to Follow-up|0
6275269|NCT02209454|9979713|FG000|Second Period|Adverse Event|1
6275270|NCT02209454|9979714|FG001|Second Period|Adverse Event|0
6275271|NCT02209506|9979725|FG000|Overall Study|Withdrawal by Subject|0
6275272|NCT02209506|9979726|FG001|Overall Study|Withdrawal by Subject|0
6275273|NCT02209506|9979727|FG002|Overall Study|Withdrawal by Subject|0
6275274|NCT02209506|9979728|FG003|Overall Study|Withdrawal by Subject|0
6275275|NCT02209506|9979729|FG004|Overall Study|Withdrawal by Subject|1
6275276|NCT02209597|9979764|FG000|Phase 1 Current Tx (Non-randomized)|Withdrawal by Subject|2
6275277|NCT02209597|9979764|FG000|Phase 1 Current Tx (Non-randomized)|Adverse Event|1
6275278|NCT02209597|9979764|FG000|Phase 2 (Randomized: 1 Brand, 3 Generic)|Withdrawal by Subject|3
6275279|NCT02209597|9979764|FG000|Phase 2 (Randomized: 1 Brand, 3 Generic)|Adverse Event|1
6275280|NCT02209766|9979788|FG000|Overall Study|Withdrawal by Subject|0
6275281|NCT02209766|9979789|FG001|Overall Study|Withdrawal by Subject|0
6275282|NCT02209766|9979790|FG002|Overall Study|Withdrawal by Subject|0
6275283|NCT02209766|9979791|FG003|Overall Study|Withdrawal by Subject|1
6275284|NCT02209766|9979792|FG004|Overall Study|Withdrawal by Subject|0
5976805|NCT01147666|9563665|FG013|Dosing Period 1: 6-Week Treatment|Non-compliance with study drug|0
5976806|NCT01147666|9563666|FG014|Dosing Period 1: 6-Week Treatment|Non-compliance with study drug|1
5976807|NCT01147666|9563652|FG000|Dosing Period 2: 19-Week Treatment|Death|0
5976808|NCT01147666|9563653|FG001|Dosing Period 2: 19-Week Treatment|Death|0
5976809|NCT01147666|9563654|FG002|Dosing Period 2: 19-Week Treatment|Death|0
5976810|NCT01147666|9563655|FG003|Dosing Period 2: 19-Week Treatment|Death|0
5976811|NCT01147666|9563656|FG004|Dosing Period 2: 19-Week Treatment|Death|1
5976812|NCT01147666|9563657|FG005|Dosing Period 2: 19-Week Treatment|Death|1
5976813|NCT01147666|9563658|FG006|Dosing Period 2: 19-Week Treatment|Death|1
5976814|NCT01147666|9563659|FG007|Dosing Period 2: 19-Week Treatment|Death|0
5976815|NCT01147666|9563660|FG008|Dosing Period 2: 19-Week Treatment|Death|0
5976816|NCT01147666|9563661|FG009|Dosing Period 2: 19-Week Treatment|Death|0
5976817|NCT01147666|9563662|FG010|Dosing Period 2: 19-Week Treatment|Death|0
5976818|NCT01147666|9563663|FG011|Dosing Period 2: 19-Week Treatment|Death|0
5976819|NCT01147666|9563664|FG012|Dosing Period 2: 19-Week Treatment|Death|1
5976820|NCT01147666|9563665|FG013|Dosing Period 2: 19-Week Treatment|Death|0
5976821|NCT01147666|9563666|FG014|Dosing Period 2: 19-Week Treatment|Death|0
5976822|NCT01147666|9563652|FG000|Dosing Period 2: 19-Week Treatment|Lack of Efficacy|0
5976823|NCT01147666|9563653|FG001|Dosing Period 2: 19-Week Treatment|Lack of Efficacy|0
5976824|NCT01147666|9563654|FG002|Dosing Period 2: 19-Week Treatment|Lack of Efficacy|0
5976825|NCT01147666|9563655|FG003|Dosing Period 2: 19-Week Treatment|Lack of Efficacy|0
5976826|NCT01147666|9563656|FG004|Dosing Period 2: 19-Week Treatment|Lack of Efficacy|3
5976827|NCT01147666|9563657|FG005|Dosing Period 2: 19-Week Treatment|Lack of Efficacy|1
5976828|NCT01147666|9563658|FG006|Dosing Period 2: 19-Week Treatment|Lack of Efficacy|2
5976829|NCT01147666|9563659|FG007|Dosing Period 2: 19-Week Treatment|Lack of Efficacy|2
5976830|NCT01147666|9563660|FG008|Dosing Period 2: 19-Week Treatment|Lack of Efficacy|0
5976831|NCT01147666|9563661|FG009|Dosing Period 2: 19-Week Treatment|Lack of Efficacy|1
5976832|NCT01147666|9563662|FG010|Dosing Period 2: 19-Week Treatment|Lack of Efficacy|0
5976833|NCT01147666|9563663|FG011|Dosing Period 2: 19-Week Treatment|Lack of Efficacy|0
5976834|NCT01147666|9563664|FG012|Dosing Period 2: 19-Week Treatment|Lack of Efficacy|1
5976835|NCT01147666|9563665|FG013|Dosing Period 2: 19-Week Treatment|Lack of Efficacy|0
5976836|NCT01147666|9563666|FG014|Dosing Period 2: 19-Week Treatment|Lack of Efficacy|2
6088532|NCT00676143|9699432|FG001|Overall Study|Physician Decision|8
6088533|NCT00676143|9699431|FG000|Overall Study|Protocol Violation|4
5976837|NCT01147666|9563652|FG000|Dosing Period 2: 19-Week Treatment|Protocol Violation|0
5976838|NCT01147666|9563653|FG001|Dosing Period 2: 19-Week Treatment|Protocol Violation|0
5976839|NCT01147666|9563654|FG002|Dosing Period 2: 19-Week Treatment|Protocol Violation|0
5976840|NCT01147666|9563655|FG003|Dosing Period 2: 19-Week Treatment|Protocol Violation|1
5976841|NCT01147666|9563656|FG004|Dosing Period 2: 19-Week Treatment|Protocol Violation|0
6196719|NCT01463098|9855772|FG003|Part A (11 Days)|Lost to Follow-up|0
5976842|NCT01147666|9563657|FG005|Dosing Period 2: 19-Week Treatment|Protocol Violation|0
6196720|NCT01463098|9855773|FG004|Part A (11 Days)|Lost to Follow-up|1
6196721|NCT01463098|9855774|FG005|Part A (11 Days)|Lost to Follow-up|0
6196722|NCT01463098|9855775|FG006|Part A (11 Days)|Lost to Follow-up|0
6196723|NCT01463098|9855776|FG007|Part A (11 Days)|Lost to Follow-up|0
6196724|NCT01463098|9855777|FG008|Part A (11 Days)|Lost to Follow-up|0
6196725|NCT01463098|9855778|FG009|Part A (11 Days)|Lost to Follow-up|0
6196726|NCT01463098|9855779|FG010|Part A (11 Days)|Lost to Follow-up|0
6196727|NCT01463098|9855780|FG011|Part A (11 Days)|Lost to Follow-up|0
6196728|NCT01463098|9855781|FG012|Part A (11 Days)|Lost to Follow-up|0
6196729|NCT01463098|9855782|FG013|Part A (11 Days)|Lost to Follow-up|0
6196730|NCT01463098|9855769|FG000|Part B (11 Days)|Participant Choice|0
6196731|NCT01463098|9855770|FG001|Part B (11 Days)|Participant Choice|0
6196732|NCT01463098|9855771|FG002|Part B (11 Days)|Participant Choice|0
6196733|NCT01463098|9855772|FG003|Part B (11 Days)|Participant Choice|0
6196734|NCT01463098|9855773|FG004|Part B (11 Days)|Participant Choice|0
6196735|NCT01463098|9855774|FG005|Part B (11 Days)|Participant Choice|0
6196736|NCT01463098|9855775|FG006|Part B (11 Days)|Participant Choice|0
6196737|NCT01463098|9855776|FG007|Part B (11 Days)|Participant Choice|0
6196738|NCT01463098|9855777|FG008|Part B (11 Days)|Participant Choice|0
6196739|NCT01463098|9855778|FG009|Part B (11 Days)|Participant Choice|0
6196740|NCT01463098|9855779|FG010|Part B (11 Days)|Participant Choice|0
6196741|NCT01463098|9855780|FG011|Part B (11 Days)|Participant Choice|1
6275285|NCT02210000|9979813|FG000|Overall Study|Study Terminated|11
6275286|NCT02210000|9979814|FG001|Overall Study|Study Terminated|12
6088534|NCT00676143|9699432|FG001|Overall Study|Protocol Violation|8
6088535|NCT00676143|9699431|FG000|Overall Study|Withdrawal by Subject|24
6088536|NCT00676143|9699432|FG001|Overall Study|Withdrawal by Subject|42
6088537|NCT00676143|9699431|FG000|Overall Study|Discontinuation of study by sponsor|65
6088538|NCT00676143|9699432|FG001|Overall Study|Discontinuation of study by sponsor|88
6275287|NCT02210000|9979813|FG000|Overall Study|Withdrawal by Subject|7
6275288|NCT02210000|9979814|FG001|Overall Study|Withdrawal by Subject|1
6275289|NCT02210000|9979813|FG000|Overall Study|Adverse Event|1
6275290|NCT02210000|9979814|FG001|Overall Study|Adverse Event|5
6275291|NCT02210000|9979813|FG000|Overall Study|Lost to Follow-up|0
6275292|NCT02210000|9979814|FG001|Overall Study|Lost to Follow-up|2
6275293|NCT02210000|9979813|FG000|Overall Study|Physician Decision|0
6275294|NCT02210000|9979814|FG001|Overall Study|Physician Decision|1
6275295|NCT02210091|9979834|FG000|Overall Study|Physician Decision|0
6275296|NCT02210091|9979835|FG001|Overall Study|Physician Decision|1
6275297|NCT02210091|9979834|FG000|Overall Study|Withdrawal by Sponsor|0
6275298|NCT02210091|9979835|FG001|Overall Study|Withdrawal by Sponsor|1
6275299|NCT02210208|9979866|FG000|Period A (Graft Site)|Withdrawal by Subject|1
6275300|NCT02210208|9979866|FG000|Period A (Graft Site)|Physician decided not to graft at OR|1
6275301|NCT02210208|9979866|FG000|Period B (Donor Site)|7 subjects healed at or before Day 14|7
6275302|NCT02210221|9979872|FG000|Overall Study|Lack of Efficacy|7
6275303|NCT02210221|9979872|FG000|Overall Study|Withdrawal by Subject|43
6275304|NCT02210689|9979918|FG000|Overall Study|Withdrawal by Subject|7
6275305|NCT02210689|9979919|FG001|Overall Study|Withdrawal by Subject|4
6275306|NCT02210689|9979920|FG002|Overall Study|Withdrawal by Subject|2
6275307|NCT02210689|9979918|FG000|Overall Study|Adverse Event|0
6275308|NCT02210689|9979919|FG001|Overall Study|Adverse Event|1
6275309|NCT02210689|9979920|FG002|Overall Study|Adverse Event|0
6275310|NCT02210689|9979918|FG000|Overall Study|Protocol Violation|1
6275311|NCT02210689|9979919|FG001|Overall Study|Protocol Violation|0
6275312|NCT02210689|9979920|FG002|Overall Study|Protocol Violation|0
6275313|NCT02210689|9979918|FG000|Overall Study|Lost to Follow-up|11
6275314|NCT02210689|9979919|FG001|Overall Study|Lost to Follow-up|9
6275315|NCT02210689|9979920|FG002|Overall Study|Lost to Follow-up|5
6275316|NCT02210689|9979918|FG000|Overall Study|Pregnancy|0
5976843|NCT01147666|9563658|FG006|Dosing Period 2: 19-Week Treatment|Protocol Violation|0
6088539|NCT00676143|9699431|FG000|Overall Study|Failed to return|2
6088540|NCT00676143|9699432|FG001|Overall Study|Failed to return|1
6088541|NCT00676143|9699431|FG000|Overall Study|Loss of caregiver|5
6088542|NCT00676143|9699432|FG001|Overall Study|Loss of caregiver|3
6088543|NCT00676143|9699431|FG000|Overall Study|Other|11
6088544|NCT00676143|9699432|FG001|Overall Study|Other|20
6088545|NCT00676143|9699431|FG000|Overall Study|Participant participation unknown|1
6088546|NCT00676143|9699432|FG001|Overall Study|Participant participation unknown|4
6088547|NCT00676143|9699431|FG000|Overall Study|Vasogenic edema recurrence|1
6088548|NCT00676143|9699432|FG001|Overall Study|Vasogenic edema recurrence|3
6088549|NCT00676195|9699451|FG000|Overall Study|Lost to Follow-up|1
6088550|NCT00676195|9699451|FG000|Overall Study|Adverse Event|1
6088551|NCT00676195|9699451|FG000|Overall Study|Physician Decision|1
6088552|NCT00676208|9699458|FG000|Overall Study|Lost to Follow-up|0
6088553|NCT00676208|9699459|FG001|Overall Study|Lost to Follow-up|2
6088554|NCT00676208|9699458|FG000|Overall Study|Incomplete data|2
6275317|NCT02210689|9979919|FG001|Overall Study|Pregnancy|1
6275318|NCT02210689|9979920|FG002|Overall Study|Pregnancy|0
6275319|NCT02210689|9979918|FG000|Overall Study|Lack of Efficacy|0
6275320|NCT02210689|9979919|FG001|Overall Study|Lack of Efficacy|1
6088555|NCT00676208|9699459|FG001|Overall Study|Incomplete data|4
6088556|NCT00676338|9699471|FG000|Overall Study|Adverse Event|6
6088557|NCT00676338|9699472|FG001|Overall Study|Adverse Event|6
6088558|NCT00676338|9699473|FG002|Overall Study|Adverse Event|5
6196742|NCT01463098|9855781|FG012|Part B (11 Days)|Participant Choice|0
6196743|NCT01463098|9855782|FG013|Part B (11 Days)|Participant Choice|0
6196744|NCT01463111|9855831|FG000|Overall Study|Withdrawal by Subject|2
6275321|NCT02210689|9979920|FG002|Overall Study|Lack of Efficacy|5
6275322|NCT02210689|9979918|FG000|Overall Study|Prohibited medication|2
6275323|NCT02210689|9979919|FG001|Overall Study|Prohibited medication|8
6275324|NCT02210689|9979920|FG002|Overall Study|Prohibited medication|1
6275325|NCT02210689|9979918|FG000|Overall Study|Negative Nugent score at baseline|6
6275326|NCT02210689|9979919|FG001|Overall Study|Negative Nugent score at baseline|2
6275327|NCT02210689|9979920|FG002|Overall Study|Negative Nugent score at baseline|2
6275328|NCT02210689|9979918|FG000|Overall Study|Other|25
6275329|NCT02210689|9979919|FG001|Overall Study|Other|21
6275330|NCT02210689|9979920|FG002|Overall Study|Other|8
6196745|NCT01463111|9855831|FG000|Overall Study|Lost to Follow-up|5
6196746|NCT01463111|9855831|FG000|Overall Study|Physician Decision|2
6196747|NCT01463306|9855864|FG000|Overall Study|Adverse Event|6
6196748|NCT01463306|9855865|FG001|Overall Study|Adverse Event|9
6196749|NCT01463306|9855866|FG002|Overall Study|Adverse Event|3
6196750|NCT01463306|9855864|FG000|Overall Study|Death|3
6196751|NCT01463306|9855865|FG001|Overall Study|Death|3
6196752|NCT01463306|9855866|FG002|Overall Study|Death|0
6196753|NCT01463306|9855864|FG000|Overall Study|Lack of Efficacy|22
6196754|NCT01463306|9855865|FG001|Overall Study|Lack of Efficacy|16
6196755|NCT01463306|9855866|FG002|Overall Study|Lack of Efficacy|1
6196756|NCT01463306|9855864|FG000|Overall Study|Lost to Follow-up|5
6196757|NCT01463306|9855865|FG001|Overall Study|Lost to Follow-up|2
6196758|NCT01463306|9855866|FG002|Overall Study|Lost to Follow-up|0
6196759|NCT01463306|9855864|FG000|Overall Study|Protocol Violation|4
6196760|NCT01463306|9855865|FG001|Overall Study|Protocol Violation|0
6196761|NCT01463306|9855866|FG002|Overall Study|Protocol Violation|0
6196762|NCT01463306|9855864|FG000|Overall Study|Withdrawal by Subject|19
6196763|NCT01463306|9855865|FG001|Overall Study|Withdrawal by Subject|9
6196764|NCT01463306|9855866|FG002|Overall Study|Withdrawal by Subject|1
6196765|NCT01463306|9855864|FG000|Overall Study|Other|26
6196766|NCT01463306|9855865|FG001|Overall Study|Other|13
6196767|NCT01463306|9855866|FG002|Overall Study|Other|0
6196768|NCT01463306|9855864|FG000|Overall Study|Approval expiry at site|1
6196769|NCT01463306|9855865|FG001|Overall Study|Approval expiry at site|0
6196770|NCT01463306|9855866|FG002|Overall Study|Approval expiry at site|0
6196771|NCT01463527|9855891|FG000|Overall Study|Protocol Violation|1
6196772|NCT01463527|9855892|FG001|Overall Study|Protocol Violation|1
6196773|NCT01463527|9855891|FG000|Overall Study|Crying >20% of sedation|5
6196774|NCT01463527|9855892|FG001|Overall Study|Crying >20% of sedation|6
6196775|NCT01463631|9855902|FG000|Overall Study|Withdrawal by Subject|0
6196776|NCT01463631|9855903|FG001|Overall Study|Withdrawal by Subject|0
6196777|NCT01463631|9855904|FG002|Overall Study|Withdrawal by Subject|0
6196778|NCT01463631|9855905|FG003|Overall Study|Withdrawal by Subject|1
6196779|NCT01463631|9855902|FG000|Overall Study|Death|0
6196780|NCT01463631|9855903|FG001|Overall Study|Death|0
6196781|NCT01463631|9855904|FG002|Overall Study|Death|1
6196782|NCT01463631|9855905|FG003|Overall Study|Death|0
6196783|NCT01463631|9855902|FG000|Overall Study|Progressive Disease|0
6196784|NCT01463631|9855903|FG001|Overall Study|Progressive Disease|0
6196785|NCT01463631|9855904|FG002|Overall Study|Progressive Disease|0
6196786|NCT01463631|9855905|FG003|Overall Study|Progressive Disease|5
6196787|NCT01463683|9855920|FG000|Overall Study|Adverse Event|2
6196788|NCT01463683|9855921|FG001|Overall Study|Adverse Event|0
6196789|NCT01463683|9855922|FG002|Overall Study|Adverse Event|0
6196790|NCT01463683|9855920|FG000|Overall Study|Lost to Follow-up|10
6196791|NCT01463683|9855921|FG001|Overall Study|Lost to Follow-up|9
6275331|NCT02210780|9979930|FG000|Overall Study|Adverse Event|0
6275332|NCT02210780|9979931|FG001|Overall Study|Adverse Event|5
6275333|NCT02210780|9979930|FG000|Overall Study|Lost to Follow-up|2
6275334|NCT02210780|9979931|FG001|Overall Study|Lost to Follow-up|1
6275335|NCT02210780|9979930|FG000|Overall Study|Withdrawal by Subject|1
6275336|NCT02210780|9979931|FG001|Overall Study|Withdrawal by Subject|1
6275337|NCT02210780|9979930|FG000|Overall Study|Physician Decision|1
6275338|NCT02210780|9979931|FG001|Overall Study|Physician Decision|0
6275339|NCT02210780|9979930|FG000|Overall Study|Protocol Violation|1
6275340|NCT02210780|9979931|FG001|Overall Study|Protocol Violation|0
6275341|NCT02210780|9979930|FG000|Overall Study|Other than specified above|0
6275342|NCT02210780|9979931|FG001|Overall Study|Other than specified above|1
6275343|NCT02211014|9979939|FG000|Overall Study|Adverse Event|0
6275344|NCT02211014|9979940|FG001|Overall Study|Adverse Event|2
6275345|NCT02211014|9979939|FG000|Overall Study|Physician Decision|1
6275346|NCT02211014|9979940|FG001|Overall Study|Physician Decision|2
6275347|NCT02211014|9979939|FG000|Overall Study|Started another cancer therapy|1
6275348|NCT02211014|9979940|FG001|Overall Study|Started another cancer therapy|0
6275349|NCT02211014|9979939|FG000|Overall Study|Withdrawal by Subject|0
6275350|NCT02211014|9979940|FG001|Overall Study|Withdrawal by Subject|1
6275351|NCT02211014|9979939|FG000|Overall Study|In agreement with patient, no benefit|0
6275352|NCT02211014|9979940|FG001|Overall Study|In agreement with patient, no benefit|1
6275353|NCT02211261|9979973|FG000|Overall Study|Withdrawal by Subject|0
6275354|NCT02211261|9979974|FG001|Overall Study|Withdrawal by Subject|0
5976844|NCT01147666|9563659|FG007|Dosing Period 2: 19-Week Treatment|Protocol Violation|0
5976845|NCT01147666|9563660|FG008|Dosing Period 2: 19-Week Treatment|Protocol Violation|0
5976846|NCT01147666|9563661|FG009|Dosing Period 2: 19-Week Treatment|Protocol Violation|0
5976847|NCT01147666|9563662|FG010|Dosing Period 2: 19-Week Treatment|Protocol Violation|0
5976848|NCT01147666|9563663|FG011|Dosing Period 2: 19-Week Treatment|Protocol Violation|0
5976849|NCT01147666|9563664|FG012|Dosing Period 2: 19-Week Treatment|Protocol Violation|0
5976850|NCT01147666|9563665|FG013|Dosing Period 2: 19-Week Treatment|Protocol Violation|0
5976851|NCT01147666|9563666|FG014|Dosing Period 2: 19-Week Treatment|Protocol Violation|0
5976852|NCT01147666|9563652|FG000|Dosing Period 2: 19-Week Treatment|Withdrawal by Subject|0
5976853|NCT01147666|9563653|FG001|Dosing Period 2: 19-Week Treatment|Withdrawal by Subject|0
5976854|NCT01147666|9563654|FG002|Dosing Period 2: 19-Week Treatment|Withdrawal by Subject|0
5976855|NCT01147666|9563655|FG003|Dosing Period 2: 19-Week Treatment|Withdrawal by Subject|0
5976856|NCT01147666|9563656|FG004|Dosing Period 2: 19-Week Treatment|Withdrawal by Subject|1
5976857|NCT01147666|9563657|FG005|Dosing Period 2: 19-Week Treatment|Withdrawal by Subject|1
5976858|NCT01147666|9563658|FG006|Dosing Period 2: 19-Week Treatment|Withdrawal by Subject|0
6196792|NCT01463683|9855922|FG002|Overall Study|Lost to Follow-up|7
6196793|NCT01463683|9855920|FG000|Overall Study|Physician Decision|0
6196794|NCT01463683|9855921|FG001|Overall Study|Physician Decision|3
6196795|NCT01463683|9855922|FG002|Overall Study|Physician Decision|1
6196796|NCT01463683|9855920|FG000|Overall Study|Pregnancy|2
6196797|NCT01463683|9855921|FG001|Overall Study|Pregnancy|2
6196798|NCT01463683|9855922|FG002|Overall Study|Pregnancy|1
6196799|NCT01463683|9855920|FG000|Overall Study|Withdrawal by Subject|5
6196800|NCT01463683|9855921|FG001|Overall Study|Withdrawal by Subject|17
6196801|NCT01463683|9855922|FG002|Overall Study|Withdrawal by Subject|2
6196802|NCT01463696|9855938|FG000|Overall Study|Adverse Event|0
6196803|NCT01463696|9855939|FG001|Overall Study|Adverse Event|1
6196804|NCT01463696|9855940|FG002|Overall Study|Adverse Event|0
6196805|NCT01463696|9855941|FG003|Overall Study|Adverse Event|2
6196806|NCT01463696|9855942|FG004|Overall Study|Adverse Event|0
6196807|NCT01463696|9855943|FG005|Overall Study|Adverse Event|1
6196808|NCT01463696|9855944|FG006|Overall Study|Adverse Event|3
6196809|NCT01463696|9855945|FG007|Overall Study|Adverse Event|2
6196810|NCT01463696|9855938|FG000|Overall Study|Lost to Follow-up|0
6196811|NCT01463696|9855939|FG001|Overall Study|Lost to Follow-up|0
6196812|NCT01463696|9855940|FG002|Overall Study|Lost to Follow-up|1
6196813|NCT01463696|9855941|FG003|Overall Study|Lost to Follow-up|0
6196814|NCT01463696|9855942|FG004|Overall Study|Lost to Follow-up|0
6196815|NCT01463696|9855943|FG005|Overall Study|Lost to Follow-up|0
6196816|NCT01463696|9855944|FG006|Overall Study|Lost to Follow-up|0
6196817|NCT01463696|9855945|FG007|Overall Study|Lost to Follow-up|0
6196818|NCT01463696|9855938|FG000|Overall Study|Progressive Disease|0
6196819|NCT01463696|9855939|FG001|Overall Study|Progressive Disease|1
6196820|NCT01463696|9855940|FG002|Overall Study|Progressive Disease|0
6196821|NCT01463696|9855941|FG003|Overall Study|Progressive Disease|1
6196822|NCT01463696|9855942|FG004|Overall Study|Progressive Disease|0
6196823|NCT01463696|9855943|FG005|Overall Study|Progressive Disease|1
6196824|NCT01463696|9855944|FG006|Overall Study|Progressive Disease|4
6196825|NCT01463696|9855945|FG007|Overall Study|Progressive Disease|2
6196826|NCT01463696|9855938|FG000|Overall Study|Withdrawal by Subject|0
6196827|NCT01463696|9855939|FG001|Overall Study|Withdrawal by Subject|0
6196828|NCT01463696|9855940|FG002|Overall Study|Withdrawal by Subject|0
6196829|NCT01463696|9855941|FG003|Overall Study|Withdrawal by Subject|1
6196830|NCT01463696|9855942|FG004|Overall Study|Withdrawal by Subject|1
6196831|NCT01463696|9855943|FG005|Overall Study|Withdrawal by Subject|1
6196832|NCT01463696|9855944|FG006|Overall Study|Withdrawal by Subject|2
6196833|NCT01463696|9855945|FG007|Overall Study|Withdrawal by Subject|0
6196834|NCT01463696|9855938|FG000|Overall Study|Not Treated|0
6196835|NCT01463696|9855939|FG001|Overall Study|Not Treated|0
6275355|NCT02211261|9979975|FG002|Overall Study|Withdrawal by Subject|1
6275356|NCT02211261|9979976|FG003|Overall Study|Withdrawal by Subject|0
6275357|NCT02211261|9979977|FG004|Overall Study|Withdrawal by Subject|2
6275358|NCT02211261|9979978|FG005|Overall Study|Withdrawal by Subject|0
6275359|NCT02211261|9979979|FG006|Overall Study|Withdrawal by Subject|0
6275360|NCT02211261|9979980|FG007|Overall Study|Withdrawal by Subject|0
6275361|NCT02211261|9979981|FG008|Overall Study|Withdrawal by Subject|0
6275362|NCT02211261|9979982|FG009|Overall Study|Withdrawal by Subject|0
6275363|NCT02211261|9979983|FG010|Overall Study|Withdrawal by Subject|0
6275364|NCT02211261|9979973|FG000|Overall Study|Other|0
6275365|NCT02211261|9979974|FG001|Overall Study|Other|0
6275366|NCT02211261|9979975|FG002|Overall Study|Other|0
6275367|NCT02211261|9979976|FG003|Overall Study|Other|0
6275368|NCT02211261|9979977|FG004|Overall Study|Other|0
6275369|NCT02211261|9979978|FG005|Overall Study|Other|1
6275370|NCT02211261|9979979|FG006|Overall Study|Other|0
6275371|NCT02211261|9979980|FG007|Overall Study|Other|0
6275372|NCT02211261|9979981|FG008|Overall Study|Other|0
6196836|NCT01463696|9855940|FG002|Overall Study|Not Treated|0
6196837|NCT01463696|9855941|FG003|Overall Study|Not Treated|0
6196838|NCT01463696|9855942|FG004|Overall Study|Not Treated|0
6196839|NCT01463696|9855943|FG005|Overall Study|Not Treated|0
6196840|NCT01463696|9855944|FG006|Overall Study|Not Treated|1
6196841|NCT01463696|9855945|FG007|Overall Study|Not Treated|0
6275373|NCT02211261|9979982|FG009|Overall Study|Other|2
6196842|NCT01463878|9855965|FG000|Overall Study|no longer met criteria for tube feed|2
6196843|NCT01463878|9855966|FG001|Overall Study|no longer met criteria for tube feed|2
6196844|NCT01463982|9855976|FG000|Overall Study|Withdrawal by Subject|0
6196845|NCT01463982|9855977|FG001|Overall Study|Withdrawal by Subject|1
6196846|NCT01463982|9855978|FG002|Overall Study|Withdrawal by Subject|1
6196847|NCT01463982|9855979|FG003|Overall Study|Withdrawal by Subject|0
6196848|NCT01463982|9855976|FG000|Overall Study|Treatment delay over 5 week|0
6196849|NCT01463982|9855977|FG001|Overall Study|Treatment delay over 5 week|0
6196850|NCT01463982|9855978|FG002|Overall Study|Treatment delay over 5 week|1
6196851|NCT01463982|9855979|FG003|Overall Study|Treatment delay over 5 week|0
6196852|NCT01464021|9855989|FG000|Overall Study|Withdrawal by Subject|13
6196853|NCT01464021|9855989|FG000|Overall Study|Lost to Follow-up|1
6196854|NCT01464021|9855989|FG000|Overall Study|Lack of Efficacy|1
6196855|NCT01464021|9855989|FG000|Overall Study|various|11
6196856|NCT01464255|9856013|FG000|Overall Study|unresolve corneal staining|0
6196857|NCT01464255|9856014|FG001|Overall Study|unresolve corneal staining|1
6196858|NCT01464307|9856023|FG000|Main Period|Death|0
6196859|NCT01464307|9856024|FG001|Main Period|Death|1
6196860|NCT01464307|9856023|FG000|Main Period|Adverse Event|6
6196861|NCT01464307|9856024|FG001|Main Period|Adverse Event|1
6196862|NCT01464307|9856023|FG000|Main Period|Lack of Efficacy|2
6196863|NCT01464307|9856024|FG001|Main Period|Lack of Efficacy|0
6196864|NCT01464307|9856023|FG000|Main Period|Withdrawal by Subject|5
6196865|NCT01464307|9856024|FG001|Main Period|Withdrawal by Subject|2
6196866|NCT01464307|9856023|FG000|Main Period|Predefined discontinuation criteria|2
6196867|NCT01464307|9856024|FG001|Main Period|Predefined discontinuation criteria|1
6196868|NCT01464307|9856023|FG000|Open-Label Extension Period|Adverse Event|15
6196869|NCT01464307|9856024|FG001|Open-Label Extension Period|Adverse Event|0
6196870|NCT01464307|9856023|FG000|Open-Label Extension Period|Withdrawal by Subject|14
6196871|NCT01464307|9856024|FG001|Open-Label Extension Period|Withdrawal by Subject|0
6196872|NCT01464307|9856023|FG000|Open-Label Extension Period|Lack of Efficacy|5
6196873|NCT01464307|9856024|FG001|Open-Label Extension Period|Lack of Efficacy|0
6196874|NCT01464307|9856023|FG000|Open-Label Extension Period|Death|1
6196875|NCT01464307|9856024|FG001|Open-Label Extension Period|Death|0
6196876|NCT01464307|9856023|FG000|Open-Label Extension Period|Lost to Follow-up|1
6196877|NCT01464307|9856024|FG001|Open-Label Extension Period|Lost to Follow-up|0
6196878|NCT01464307|9856023|FG000|Open-Label Extension Period|Non-compliance|9
6196879|NCT01464307|9856024|FG001|Open-Label Extension Period|Non-compliance|0
6196880|NCT01464307|9856023|FG000|Open-Label Extension Period|Predefined discontinuation criteria|6
6196881|NCT01464307|9856024|FG001|Open-Label Extension Period|Predefined discontinuation criteria|0
6196882|NCT01464333|9856031|FG000|Overall Study|Adverse Event|34
6196883|NCT01464333|9856031|FG000|Overall Study|Lack of Efficacy|72
6196884|NCT01464333|9856031|FG000|Overall Study|Withdrawal by Subject|11
6196885|NCT01464333|9856031|FG000|Overall Study|Other|4
6196886|NCT01464333|9856031|FG000|Overall Study|No Hospital Visit|42
6196887|NCT01464346|9856035|FG000|Overall Study|Withdrawal by Subject|0
6196888|NCT01464346|9856036|FG001|Overall Study|Withdrawal by Subject|0
6196889|NCT01464346|9856037|FG002|Overall Study|Withdrawal by Subject|1
6196890|NCT01464424|9856049|FG000|Period 1, First 6 Weeks|Adverse Event|0
6196891|NCT01464424|9856050|FG001|Period 1, First 6 Weeks|Adverse Event|1
6196892|NCT01464619|9856058|FG000|Overall Study|Lost to Follow-up|3
6196893|NCT01464619|9856059|FG001|Overall Study|Lost to Follow-up|4
6196894|NCT01464788|9856090|FG000|Overall Study|Lost to Follow-up|0
6196895|NCT01464788|9856091|FG001|Overall Study|Lost to Follow-up|1
6196896|NCT01464788|9856092|FG002|Overall Study|Lost to Follow-up|0
6196897|NCT01464788|9856090|FG000|Overall Study|Patient had hemorrhage after tPA started|0
6196898|NCT01464788|9856091|FG001|Overall Study|Patient had hemorrhage after tPA started|1
6196899|NCT01464788|9856092|FG002|Overall Study|Patient had hemorrhage after tPA started|0
6196900|NCT01464827|9856116|FG000|Overall Study|Adverse Event|0
6196901|NCT01464827|9856117|FG001|Overall Study|Adverse Event|0
6196902|NCT01464827|9856118|FG002|Overall Study|Adverse Event|0
6196903|NCT01464827|9856119|FG003|Overall Study|Adverse Event|0
6196904|NCT01464827|9856120|FG004|Overall Study|Adverse Event|0
6196905|NCT01464827|9856121|FG005|Overall Study|Adverse Event|0
6196906|NCT01464827|9856122|FG006|Overall Study|Adverse Event|0
6196907|NCT01464827|9856123|FG007|Overall Study|Adverse Event|0
6196908|NCT01464827|9856124|FG008|Overall Study|Adverse Event|0
6196909|NCT01464827|9856125|FG009|Overall Study|Adverse Event|0
6196910|NCT01464827|9856126|FG010|Overall Study|Adverse Event|0
6196911|NCT01464827|9856127|FG011|Overall Study|Adverse Event|0
6196912|NCT01464827|9856128|FG012|Overall Study|Adverse Event|1
6196913|NCT01464827|9856129|FG013|Overall Study|Adverse Event|0
6196914|NCT01464827|9856116|FG000|Overall Study|Withdrawal by Subject|1
6196915|NCT01464827|9856117|FG001|Overall Study|Withdrawal by Subject|0
6196916|NCT01464827|9856118|FG002|Overall Study|Withdrawal by Subject|0
6196917|NCT01464827|9856119|FG003|Overall Study|Withdrawal by Subject|0
6196918|NCT01464827|9856120|FG004|Overall Study|Withdrawal by Subject|1
6196919|NCT01464827|9856121|FG005|Overall Study|Withdrawal by Subject|0
6196920|NCT01464827|9856122|FG006|Overall Study|Withdrawal by Subject|0
6196921|NCT01464827|9856123|FG007|Overall Study|Withdrawal by Subject|1
6275374|NCT02211261|9979983|FG010|Overall Study|Other|0
6275375|NCT02211261|9979973|FG000|Overall Study|Lost to Follow-up|0
6196922|NCT01464827|9856124|FG008|Overall Study|Withdrawal by Subject|0
6196923|NCT01464827|9856125|FG009|Overall Study|Withdrawal by Subject|0
6196924|NCT01464827|9856126|FG010|Overall Study|Withdrawal by Subject|0
6196925|NCT01464827|9856127|FG011|Overall Study|Withdrawal by Subject|0
6196926|NCT01464827|9856128|FG012|Overall Study|Withdrawal by Subject|0
6196927|NCT01464827|9856129|FG013|Overall Study|Withdrawal by Subject|0
6196928|NCT01464827|9856116|FG000|Overall Study|Lost to Follow-up|0
6196929|NCT01464827|9856117|FG001|Overall Study|Lost to Follow-up|2
6196930|NCT01464827|9856118|FG002|Overall Study|Lost to Follow-up|0
6196931|NCT01464827|9856119|FG003|Overall Study|Lost to Follow-up|2
6196932|NCT01464827|9856120|FG004|Overall Study|Lost to Follow-up|3
6196933|NCT01464827|9856121|FG005|Overall Study|Lost to Follow-up|1
6196934|NCT01464827|9856122|FG006|Overall Study|Lost to Follow-up|2
6196935|NCT01464827|9856123|FG007|Overall Study|Lost to Follow-up|2
6196936|NCT01464827|9856124|FG008|Overall Study|Lost to Follow-up|0
6196937|NCT01464827|9856125|FG009|Overall Study|Lost to Follow-up|0
6196938|NCT01464827|9856126|FG010|Overall Study|Lost to Follow-up|0
6196939|NCT01464827|9856127|FG011|Overall Study|Lost to Follow-up|1
6196940|NCT01464827|9856128|FG012|Overall Study|Lost to Follow-up|0
6196941|NCT01464827|9856129|FG013|Overall Study|Lost to Follow-up|1
6196942|NCT01464827|9856116|FG000|Overall Study|Other|2
6196943|NCT01464827|9856117|FG001|Overall Study|Other|3
6196944|NCT01464827|9856118|FG002|Overall Study|Other|0
6196945|NCT01464827|9856119|FG003|Overall Study|Other|2
6196946|NCT01464827|9856120|FG004|Overall Study|Other|3
6196947|NCT01464827|9856121|FG005|Overall Study|Other|0
6196948|NCT01464827|9856122|FG006|Overall Study|Other|1
6196949|NCT01464827|9856123|FG007|Overall Study|Other|0
6196950|NCT01464827|9856124|FG008|Overall Study|Other|3
6196951|NCT01464827|9856125|FG009|Overall Study|Other|1
6196952|NCT01464827|9856126|FG010|Overall Study|Other|2
6196953|NCT01464827|9856127|FG011|Overall Study|Other|0
6196954|NCT01464827|9856128|FG012|Overall Study|Other|1
6196955|NCT01464827|9856129|FG013|Overall Study|Other|0
6196956|NCT01464827|9856116|FG000|Overall Study|Not Treated|0
6196957|NCT01464827|9856117|FG001|Overall Study|Not Treated|2
6196958|NCT01464827|9856118|FG002|Overall Study|Not Treated|0
6196959|NCT01464827|9856119|FG003|Overall Study|Not Treated|0
6196960|NCT01464827|9856120|FG004|Overall Study|Not Treated|1
6196961|NCT01464827|9856121|FG005|Overall Study|Not Treated|0
5976859|NCT01147666|9563659|FG007|Dosing Period 2: 19-Week Treatment|Withdrawal by Subject|1
5976860|NCT01147666|9563660|FG008|Dosing Period 2: 19-Week Treatment|Withdrawal by Subject|0
5976861|NCT01147666|9563661|FG009|Dosing Period 2: 19-Week Treatment|Withdrawal by Subject|1
5976862|NCT01147666|9563662|FG010|Dosing Period 2: 19-Week Treatment|Withdrawal by Subject|0
5976863|NCT01147666|9563663|FG011|Dosing Period 2: 19-Week Treatment|Withdrawal by Subject|0
5976864|NCT01147666|9563664|FG012|Dosing Period 2: 19-Week Treatment|Withdrawal by Subject|0
5976865|NCT01147666|9563665|FG013|Dosing Period 2: 19-Week Treatment|Withdrawal by Subject|1
5976866|NCT01147666|9563666|FG014|Dosing Period 2: 19-Week Treatment|Withdrawal by Subject|0
5976867|NCT01147666|9563652|FG000|Dosing Period 2: 19-Week Treatment|Other than specified|0
5976868|NCT01147666|9563653|FG001|Dosing Period 2: 19-Week Treatment|Other than specified|0
5976869|NCT01147666|9563654|FG002|Dosing Period 2: 19-Week Treatment|Other than specified|0
5976870|NCT01147666|9563655|FG003|Dosing Period 2: 19-Week Treatment|Other than specified|1
5976871|NCT01147666|9563656|FG004|Dosing Period 2: 19-Week Treatment|Other than specified|0
5976872|NCT01147666|9563657|FG005|Dosing Period 2: 19-Week Treatment|Other than specified|0
5976873|NCT01147666|9563658|FG006|Dosing Period 2: 19-Week Treatment|Other than specified|0
6196962|NCT01464827|9856122|FG006|Overall Study|Not Treated|1
6196963|NCT01464827|9856123|FG007|Overall Study|Not Treated|0
6196964|NCT01464827|9856124|FG008|Overall Study|Not Treated|0
6196965|NCT01464827|9856125|FG009|Overall Study|Not Treated|2
6196966|NCT01464827|9856126|FG010|Overall Study|Not Treated|0
6196967|NCT01464827|9856127|FG011|Overall Study|Not Treated|1
6196968|NCT01464827|9856128|FG012|Overall Study|Not Treated|0
6196969|NCT01464827|9856129|FG013|Overall Study|Not Treated|2
6196970|NCT01464879|9856183|FG000|Overall Study|Physician Decision|1
6196971|NCT01464879|9856183|FG000|Overall Study|Non-compliance|1
6196972|NCT01464931|9856195|FG000|Overall Study|Withdrawal by Subject|1
6196973|NCT01464931|9856196|FG001|Overall Study|Withdrawal by Subject|0
6196974|NCT01465022|9856218|FG000|Overall Study|Lost to Follow-up|15
6196975|NCT01465022|9856219|FG001|Overall Study|Lost to Follow-up|14
6196976|NCT01465022|9856220|FG002|Overall Study|Lost to Follow-up|0
6196977|NCT01465022|9856218|FG000|Overall Study|Breastfeeding discontinuation before 8 w|8
6196978|NCT01465022|9856219|FG001|Overall Study|Breastfeeding discontinuation before 8 w|9
6196979|NCT01465022|9856220|FG002|Overall Study|Breastfeeding discontinuation before 8 w|0
6196980|NCT01465022|9856218|FG000|Overall Study|Not Randomized|0
6196981|NCT01465022|9856219|FG001|Overall Study|Not Randomized|0
6196982|NCT01465022|9856220|FG002|Overall Study|Not Randomized|70
6196983|NCT01465178|9856241|FG000|Overall Study|Withdrawal by Subject|1
6196984|NCT01465178|9856242|FG001|Overall Study|Withdrawal by Subject|0
6196985|NCT01465191|9856251|FG000|Overall Study|Protocol Violation|6
6196986|NCT01465191|9856252|FG001|Overall Study|Protocol Violation|3
6196987|NCT01465191|9856253|FG002|Overall Study|Protocol Violation|3
6196988|NCT01465191|9856251|FG000|Overall Study|Lost to Follow-up|3
5976874|NCT01147666|9563659|FG007|Dosing Period 2: 19-Week Treatment|Other than specified|0
6196989|NCT01465191|9856252|FG001|Overall Study|Lost to Follow-up|6
6196990|NCT01465191|9856253|FG002|Overall Study|Lost to Follow-up|4
6196991|NCT01465334|9856266|FG000|Overall Study|Disease Progression|1
6196992|NCT01465334|9856267|FG001|Overall Study|Disease Progression|0
6196993|NCT01465334|9856266|FG000|Overall Study|Adverse Event|1
6196994|NCT01465334|9856267|FG001|Overall Study|Adverse Event|0
6196995|NCT01465334|9856266|FG000|Overall Study|Richter's transformation|0
6196996|NCT01465334|9856267|FG001|Overall Study|Richter's transformation|3
6196997|NCT01465334|9856266|FG000|Overall Study|Refractory Disease|0
6196998|NCT01465334|9856267|FG001|Overall Study|Refractory Disease|3
6196999|NCT01465347|9856273|FG000|Overall Study|Withdrawal by Subject|1
6275376|NCT02211261|9979974|FG001|Overall Study|Lost to Follow-up|0
6275377|NCT02211261|9979975|FG002|Overall Study|Lost to Follow-up|0
6275378|NCT02211261|9979976|FG003|Overall Study|Lost to Follow-up|0
6275379|NCT02211261|9979977|FG004|Overall Study|Lost to Follow-up|0
6275380|NCT02211261|9979978|FG005|Overall Study|Lost to Follow-up|0
6275381|NCT02211261|9979979|FG006|Overall Study|Lost to Follow-up|0
6275382|NCT02211261|9979980|FG007|Overall Study|Lost to Follow-up|1
6275383|NCT02211261|9979981|FG008|Overall Study|Lost to Follow-up|0
6275384|NCT02211261|9979982|FG009|Overall Study|Lost to Follow-up|0
6275385|NCT02211261|9979983|FG010|Overall Study|Lost to Follow-up|0
6275386|NCT02211313|9980018|FG000|Overall Study|Treatment Failure|5
6275387|NCT02211313|9980019|FG001|Overall Study|Treatment Failure|2
6275388|NCT02211313|9980018|FG000|Overall Study|No Follow up Questionnaires|1
6275389|NCT02211313|9980019|FG001|Overall Study|No Follow up Questionnaires|1
6275390|NCT02211638|9980051|FG000|Overall Study|Case Report Forms Uncollected|291
6275391|NCT02211638|9980051|FG000|Overall Study|Protocol Violation|692
6275392|NCT02212197|9980077|FG000|Overall Study|Need for radiotherapy|1
6275393|NCT02212197|9980078|FG001|Overall Study|Need for radiotherapy|0
5976875|NCT01147666|9563660|FG008|Dosing Period 2: 19-Week Treatment|Other than specified|0
5976876|NCT01147666|9563661|FG009|Dosing Period 2: 19-Week Treatment|Other than specified|0
5976877|NCT01147666|9563662|FG010|Dosing Period 2: 19-Week Treatment|Other than specified|2
5976878|NCT01147666|9563663|FG011|Dosing Period 2: 19-Week Treatment|Other than specified|0
5976879|NCT01147666|9563664|FG012|Dosing Period 2: 19-Week Treatment|Other than specified|0
5976880|NCT01147666|9563665|FG013|Dosing Period 2: 19-Week Treatment|Other than specified|0
5976881|NCT01147666|9563666|FG014|Dosing Period 2: 19-Week Treatment|Other than specified|0
5976882|NCT01147666|9563652|FG000|Dosing Period 2: 19-Week Treatment|Adverse Event|0
5976883|NCT01147666|9563653|FG001|Dosing Period 2: 19-Week Treatment|Adverse Event|0
5976884|NCT01147666|9563654|FG002|Dosing Period 2: 19-Week Treatment|Adverse Event|0
5976885|NCT01147666|9563655|FG003|Dosing Period 2: 19-Week Treatment|Adverse Event|0
5976886|NCT01147666|9563656|FG004|Dosing Period 2: 19-Week Treatment|Adverse Event|0
5976887|NCT01147666|9563657|FG005|Dosing Period 2: 19-Week Treatment|Adverse Event|0
5976888|NCT01147666|9563658|FG006|Dosing Period 2: 19-Week Treatment|Adverse Event|0
5976889|NCT01147666|9563659|FG007|Dosing Period 2: 19-Week Treatment|Adverse Event|0
5976890|NCT01147666|9563660|FG008|Dosing Period 2: 19-Week Treatment|Adverse Event|0
5976891|NCT01147666|9563661|FG009|Dosing Period 2: 19-Week Treatment|Adverse Event|0
5976892|NCT01147666|9563662|FG010|Dosing Period 2: 19-Week Treatment|Adverse Event|0
5976893|NCT01147666|9563663|FG011|Dosing Period 2: 19-Week Treatment|Adverse Event|0
5976894|NCT01147666|9563664|FG012|Dosing Period 2: 19-Week Treatment|Adverse Event|1
5976895|NCT01147666|9563665|FG013|Dosing Period 2: 19-Week Treatment|Adverse Event|0
5976896|NCT01147666|9563666|FG014|Dosing Period 2: 19-Week Treatment|Adverse Event|0
5976897|NCT01147666|9563652|FG000|Dosing Period 2: 19-Week Treatment|Non-compliance with study drug|0
5976898|NCT01147666|9563653|FG001|Dosing Period 2: 19-Week Treatment|Non-compliance with study drug|0
5976899|NCT01147666|9563654|FG002|Dosing Period 2: 19-Week Treatment|Non-compliance with study drug|0
5976900|NCT01147666|9563655|FG003|Dosing Period 2: 19-Week Treatment|Non-compliance with study drug|0
5976901|NCT01147666|9563656|FG004|Dosing Period 2: 19-Week Treatment|Non-compliance with study drug|0
5976902|NCT01147666|9563657|FG005|Dosing Period 2: 19-Week Treatment|Non-compliance with study drug|0
5976903|NCT01147666|9563658|FG006|Dosing Period 2: 19-Week Treatment|Non-compliance with study drug|0
5976904|NCT01147666|9563659|FG007|Dosing Period 2: 19-Week Treatment|Non-compliance with study drug|0
5976905|NCT01147666|9563660|FG008|Dosing Period 2: 19-Week Treatment|Non-compliance with study drug|0
5976906|NCT01147666|9563661|FG009|Dosing Period 2: 19-Week Treatment|Non-compliance with study drug|0
5976907|NCT01147666|9563662|FG010|Dosing Period 2: 19-Week Treatment|Non-compliance with study drug|0
5976908|NCT01147666|9563663|FG011|Dosing Period 2: 19-Week Treatment|Non-compliance with study drug|0
5976909|NCT01147666|9563664|FG012|Dosing Period 2: 19-Week Treatment|Non-compliance with study drug|1
5976910|NCT01147666|9563665|FG013|Dosing Period 2: 19-Week Treatment|Non-compliance with study drug|0
5976911|NCT01147666|9563666|FG014|Dosing Period 2: 19-Week Treatment|Non-compliance with study drug|1
5976912|NCT00982111|9563730|FG000|Overall Study|Adverse Event|1
5976913|NCT00982111|9563731|FG001|Overall Study|Adverse Event|1
6050717|NCT00428389|9649926|FG000|Extension Phase|Lost to Follow-up|0
6050718|NCT00428389|9649927|FG001|Extension Phase|Lost to Follow-up|3
6050719|NCT00428389|9649926|FG000|Extension Phase|Death|1
6050720|NCT00428389|9649927|FG001|Extension Phase|Death|0
6050721|NCT00428389|9649926|FG000|Extension Phase|Protocol Violation|3
6197000|NCT01465347|9856274|FG001|Overall Study|Withdrawal by Subject|1
6275394|NCT02212197|9980079|FG002|Overall Study|Need for radiotherapy|0
6050722|NCT00428389|9649927|FG001|Extension Phase|Protocol Violation|2
6050723|NCT00428389|9649926|FG000|Extension Phase|Administrative problems|1
6050724|NCT00428389|9649927|FG001|Extension Phase|Administrative problems|1
6197001|NCT01465347|9856273|FG000|Overall Study|Physician Decision|0
6275395|NCT02212301|9980087|FG000|Period 1|Lost to Follow-up|0
6197002|NCT01465347|9856274|FG001|Overall Study|Physician Decision|1
6197003|NCT01465347|9856273|FG000|Overall Study|Admitted to hospice|0
6088559|NCT00676338|9699474|FG003|Overall Study|Adverse Event|1
6088560|NCT00676338|9699471|FG000|Overall Study|Lost to Follow-up|4
6088561|NCT00676338|9699472|FG001|Overall Study|Lost to Follow-up|1
6088562|NCT00676338|9699473|FG002|Overall Study|Lost to Follow-up|3
6197004|NCT01465347|9856274|FG001|Overall Study|Admitted to hospice|1
6197005|NCT01465386|9856283|FG000|Overall Study|Lack of Efficacy|3
6197006|NCT01465386|9856283|FG000|Overall Study|Adverse Event|1
6197007|NCT01465464|9856306|FG000|Overall Study|Adverse Event|96
6197008|NCT01465464|9856307|FG001|Overall Study|Adverse Event|49
6197009|NCT01465464|9856306|FG000|Overall Study|Lack of Efficacy|139
6197010|NCT01465464|9856307|FG001|Overall Study|Lack of Efficacy|190
6197011|NCT01465464|9856306|FG000|Overall Study|Physician Decision|13
6197012|NCT01465464|9856307|FG001|Overall Study|Physician Decision|5
6197013|NCT01465464|9856306|FG000|Overall Study|Protocol Violation|1
6197014|NCT01465464|9856307|FG001|Overall Study|Protocol Violation|1
6197015|NCT01465464|9856306|FG000|Overall Study|Withdrawal by Subject|46
6197016|NCT01465464|9856307|FG001|Overall Study|Withdrawal by Subject|30
6197017|NCT01465464|9856306|FG000|Overall Study|Other|9
6197018|NCT01465464|9856307|FG001|Overall Study|Other|3
6197019|NCT01465464|9856306|FG000|Overall Study|Ongoing treatment at cutoff date|140
6197020|NCT01465464|9856307|FG001|Overall Study|Ongoing treatment at cutoff date|166
6197021|NCT01465659|9856317|FG000|Completed 1 Cycle of Treatment|Death|0
6197022|NCT01465659|9856318|FG001|Completed 1 Cycle of Treatment|Death|1
6197023|NCT01465659|9856319|FG002|Completed 1 Cycle of Treatment|Death|0
6197024|NCT01465659|9856320|FG003|Completed 1 Cycle of Treatment|Death|0
6197025|NCT01465659|9856317|FG000|Completed 1 Cycle of Treatment|Adverse Event|0
6197026|NCT01465659|9856318|FG001|Completed 1 Cycle of Treatment|Adverse Event|0
6197027|NCT01465659|9856319|FG002|Completed 1 Cycle of Treatment|Adverse Event|0
6197028|NCT01465659|9856320|FG003|Completed 1 Cycle of Treatment|Adverse Event|1
6197029|NCT01465659|9856317|FG000|Completed 2 Cycles/Reached 1st Response|Progressive Disease|1
6197030|NCT01465659|9856318|FG001|Completed 2 Cycles/Reached 1st Response|Progressive Disease|0
6197031|NCT01465659|9856319|FG002|Completed 2 Cycles/Reached 1st Response|Progressive Disease|1
6197032|NCT01465659|9856320|FG003|Completed 2 Cycles/Reached 1st Response|Progressive Disease|1
6197033|NCT01465659|9856317|FG000|Completed 2 Cycles/Reached 1st Response|Adverse Event|1
6197034|NCT01465659|9856318|FG001|Completed 2 Cycles/Reached 1st Response|Adverse Event|0
6197035|NCT01465659|9856319|FG002|Completed 2 Cycles/Reached 1st Response|Adverse Event|1
6197036|NCT01465659|9856320|FG003|Completed 2 Cycles/Reached 1st Response|Adverse Event|0
6197037|NCT01465659|9856317|FG000|Completed Follow for 1 Year|Death|6
6197038|NCT01465659|9856318|FG001|Completed Follow for 1 Year|Death|3
6197039|NCT01465659|9856319|FG002|Completed Follow for 1 Year|Death|2
6197040|NCT01465659|9856320|FG003|Completed Follow for 1 Year|Death|4
6197041|NCT01465763|9856336|FG000|Overall Study|Withdrawal by Subject|4
6197042|NCT01465763|9856337|FG001|Overall Study|Withdrawal by Subject|0
6197043|NCT01465763|9856338|FG002|Overall Study|Withdrawal by Subject|1
6197044|NCT01465763|9856336|FG000|Overall Study|Insufficient Clinical Response|11
6197045|NCT01465763|9856337|FG001|Overall Study|Insufficient Clinical Response|0
6197046|NCT01465763|9856338|FG002|Overall Study|Insufficient Clinical Response|1
6197047|NCT01465763|9856336|FG000|Overall Study|Adverse Event|9
6197048|NCT01465763|9856337|FG001|Overall Study|Adverse Event|0
6197049|NCT01465763|9856338|FG002|Overall Study|Adverse Event|1
6197050|NCT01465763|9856336|FG000|Overall Study|Other|2
6197051|NCT01465763|9856337|FG001|Overall Study|Other|0
6197052|NCT01465763|9856338|FG002|Overall Study|Other|0
6197053|NCT01465763|9856336|FG000|Overall Study|Protocol Violation|4
6197054|NCT01465763|9856337|FG001|Overall Study|Protocol Violation|1
6197055|NCT01465763|9856338|FG002|Overall Study|Protocol Violation|1
6197056|NCT01465763|9856336|FG000|Overall Study|Death|1
6197057|NCT01465763|9856337|FG001|Overall Study|Death|0
6197058|NCT01465763|9856338|FG002|Overall Study|Death|0
6197059|NCT01465802|9856350|FG000|Overall Study|Study terminated by sponsor|1
6197060|NCT01465802|9856351|FG001|Overall Study|Study terminated by sponsor|0
6197061|NCT01465802|9856352|FG002|Overall Study|Study terminated by sponsor|0
6197062|NCT01465802|9856353|FG003|Overall Study|Study terminated by sponsor|1
6275396|NCT02212301|9980088|FG001|Period 1|Lost to Follow-up|1
6275397|NCT02212379|9980095|FG000|From Baseline to Week 48|Lack of Efficacy|1
6275398|NCT02212379|9980095|FG000|From Baseline to Week 48|Adverse Event|7
6275399|NCT02212379|9980095|FG000|From Baseline to Week 48|Withdrawal by Subject|1
6275400|NCT02212379|9980095|FG000|From Week 48 to Week 96|Lack of Efficacy|1
6088563|NCT00676338|9699474|FG003|Overall Study|Lost to Follow-up|4
6197063|NCT01465802|9856354|FG004|Overall Study|Study terminated by sponsor|7
6197064|NCT01465802|9856350|FG000|Overall Study|Withdrawal by Subject|7
6197065|NCT01465802|9856351|FG001|Overall Study|Withdrawal by Subject|7
6197066|NCT01465802|9856352|FG002|Overall Study|Withdrawal by Subject|0
6197067|NCT01465802|9856353|FG003|Overall Study|Withdrawal by Subject|8
6197068|NCT01465802|9856354|FG004|Overall Study|Withdrawal by Subject|1
6197069|NCT01465802|9856350|FG000|Overall Study|Lost to Follow-up|1
6197070|NCT01465802|9856351|FG001|Overall Study|Lost to Follow-up|1
6197071|NCT01465802|9856352|FG002|Overall Study|Lost to Follow-up|0
6197072|NCT01465802|9856353|FG003|Overall Study|Lost to Follow-up|0
6197073|NCT01465802|9856354|FG004|Overall Study|Lost to Follow-up|0
6197074|NCT01465802|9856350|FG000|Overall Study|Reason not specified|9
6197075|NCT01465802|9856351|FG001|Overall Study|Reason not specified|4
6197076|NCT01465802|9856352|FG002|Overall Study|Reason not specified|0
6197077|NCT01465802|9856353|FG003|Overall Study|Reason not specified|10
6197078|NCT01465802|9856354|FG004|Overall Study|Reason not specified|2
6197079|NCT01465802|9856350|FG000|Overall Study|Death|15
6197080|NCT01465802|9856351|FG001|Overall Study|Death|12
6197081|NCT01465802|9856352|FG002|Overall Study|Death|0
6197082|NCT01465802|9856353|FG003|Overall Study|Death|10
6197083|NCT01465802|9856354|FG004|Overall Study|Death|2
6197084|NCT01465958|9856372|FG000|Run-in Phase|Protocol Violation|1
6197085|NCT01465958|9856373|FG001|Run-in Phase|Protocol Violation|0
6197086|NCT01465958|9856372|FG000|Subcutaneous (SC) Phase|Adverse Event|0
6197087|NCT01465958|9856373|FG001|Subcutaneous (SC) Phase|Adverse Event|1
6197088|NCT01465997|9856382|FG000|Overall Study|Adverse Event|12
6197089|NCT01465997|9856383|FG001|Overall Study|Adverse Event|22
6197090|NCT01465997|9856382|FG000|Overall Study|Lack of Efficacy|13
6197091|NCT01465997|9856383|FG001|Overall Study|Lack of Efficacy|1
6197092|NCT01465997|9856382|FG000|Overall Study|Protocol Violation|1
6197093|NCT01465997|9856383|FG001|Overall Study|Protocol Violation|4
6197094|NCT01465997|9856382|FG000|Overall Study|Lost to Follow-up|6
6197095|NCT01465997|9856383|FG001|Overall Study|Lost to Follow-up|9
6197096|NCT01465997|9856382|FG000|Overall Study|Withdrawal by Subject|32
6197097|NCT01465997|9856383|FG001|Overall Study|Withdrawal by Subject|35
6197098|NCT01465997|9856382|FG000|Overall Study|investigator's decision|1
6275401|NCT02212379|9980095|FG000|From Week 48 to Week 96|Adverse Event|1
6275402|NCT02212379|9980095|FG000|From Week 48 to Week 96|Withdrawal by Subject|2
6275403|NCT02212457|9980108|FG000|Overall Study|Adverse Event|1
6275404|NCT02212457|9980109|FG001|Overall Study|Adverse Event|2
6275405|NCT02212457|9980110|FG002|Overall Study|Adverse Event|2
6275406|NCT02212457|9980111|FG003|Overall Study|Adverse Event|2
6275407|NCT02212457|9980112|FG004|Overall Study|Adverse Event|0
6275408|NCT02212457|9980113|FG005|Overall Study|Adverse Event|1
6275409|NCT02212457|9980108|FG000|Overall Study|Withdrawal by Subject|8
6275410|NCT02212457|9980109|FG001|Overall Study|Withdrawal by Subject|10
6275411|NCT02212457|9980110|FG002|Overall Study|Withdrawal by Subject|8
6275412|NCT02212457|9980111|FG003|Overall Study|Withdrawal by Subject|6
6275413|NCT02212457|9980112|FG004|Overall Study|Withdrawal by Subject|5
6275414|NCT02212457|9980113|FG005|Overall Study|Withdrawal by Subject|4
6275415|NCT02212457|9980108|FG000|Overall Study|Lost to Follow-up|6
6275416|NCT02212457|9980109|FG001|Overall Study|Lost to Follow-up|7
6275417|NCT02212457|9980110|FG002|Overall Study|Lost to Follow-up|4
6275418|NCT02212457|9980111|FG003|Overall Study|Lost to Follow-up|1
6275419|NCT02212457|9980112|FG004|Overall Study|Lost to Follow-up|8
6275420|NCT02212457|9980113|FG005|Overall Study|Lost to Follow-up|4
6275421|NCT02212457|9980108|FG000|Overall Study|Protocol Violation|2
6275422|NCT02212457|9980109|FG001|Overall Study|Protocol Violation|1
6275423|NCT02212457|9980110|FG002|Overall Study|Protocol Violation|0
6275424|NCT02212457|9980111|FG003|Overall Study|Protocol Violation|1
6275425|NCT02212457|9980112|FG004|Overall Study|Protocol Violation|2
6275426|NCT02212457|9980113|FG005|Overall Study|Protocol Violation|3
6275427|NCT02212457|9980108|FG000|Overall Study|Other|2
6275428|NCT02212457|9980109|FG001|Overall Study|Other|1
6275429|NCT02212457|9980110|FG002|Overall Study|Other|2
6275430|NCT02212457|9980111|FG003|Overall Study|Other|1
6275431|NCT02212457|9980112|FG004|Overall Study|Other|0
6275432|NCT02212457|9980113|FG005|Overall Study|Other|1
6275433|NCT02212678|9980138|FG000|Overall Study|Adverse Event|1
6275434|NCT02212730|9980144|FG000|Overall Study|Tumor not of the required cell histology|1
6275435|NCT02212730|9980145|FG001|Overall Study|Tumor not of the required cell histology|0
6275436|NCT02212730|9980144|FG000|Overall Study|Withdrawal by Subject|1
6275437|NCT02212730|9980145|FG001|Overall Study|Withdrawal by Subject|0
6275438|NCT02212730|9980144|FG000|Overall Study|Disease progression prior to RCC surgery|0
6275439|NCT02212730|9980145|FG001|Overall Study|Disease progression prior to RCC surgery|1
6275440|NCT02213042|9980174|FG000|Overall Study|Disease progression (incl. death due to disease progression)|14
6275441|NCT02213042|9980175|FG001|Overall Study|Disease progression (incl. death due to disease progression)|13
6275442|NCT02213042|9980176|FG002|Overall Study|Disease progression (incl. death due to disease progression)|8
6275443|NCT02213042|9980174|FG000|Overall Study|Adverse Event|2
6275444|NCT02213042|9980175|FG001|Overall Study|Adverse Event|1
6275445|NCT02213042|9980176|FG002|Overall Study|Adverse Event|0
6275446|NCT02213042|9980174|FG000|Overall Study|Withdrawal by Subject|0
6275447|NCT02213042|9980175|FG001|Overall Study|Withdrawal by Subject|1
6275448|NCT02213042|9980176|FG002|Overall Study|Withdrawal by Subject|1
6275449|NCT02213042|9980174|FG000|Overall Study|Protocol Violation|1
6275450|NCT02213042|9980175|FG001|Overall Study|Protocol Violation|0
6275451|NCT02213042|9980176|FG002|Overall Study|Protocol Violation|0
6275452|NCT02213042|9980174|FG000|Overall Study|Investigator discretion|0
6275453|NCT02213042|9980175|FG001|Overall Study|Investigator discretion|0
6197099|NCT01465997|9856383|FG001|Overall Study|investigator's decision|1
6197100|NCT01465997|9856382|FG000|Overall Study|Death|0
6197101|NCT01465997|9856383|FG001|Overall Study|Death|1
6197102|NCT01465997|9856382|FG000|Overall Study|sponsor's decision|1
6197103|NCT01465997|9856383|FG001|Overall Study|sponsor's decision|1
6275454|NCT02213042|9980176|FG002|Overall Study|Investigator discretion|1
6197104|NCT01465997|9856382|FG000|Overall Study|subject withdrew consent|1
6197105|NCT01465997|9856383|FG001|Overall Study|subject withdrew consent|0
6197106|NCT01465997|9856382|FG000|Overall Study|local lab unblinded site|1
6197107|NCT01465997|9856383|FG001|Overall Study|local lab unblinded site|0
6197108|NCT01465997|9856382|FG000|Overall Study|withdrew before follow-up|0
6197109|NCT01465997|9856383|FG001|Overall Study|withdrew before follow-up|13
6197110|NCT01465997|9856382|FG000|Overall Study|decision by site staff|0
6197111|NCT01465997|9856383|FG001|Overall Study|decision by site staff|1
6197112|NCT01465997|9856382|FG000|Overall Study|subject left participation SP0993|0
6197113|NCT01465997|9856383|FG001|Overall Study|subject left participation SP0993|1
6197114|NCT01466062|9856391|FG000|Overall Study|Adverse Event|1
6197115|NCT01466062|9856391|FG000|Overall Study|Withdrawal by Subject|1
6197116|NCT01466153|9856411|FG000|Overall Study|Disease Progression|2
6197117|NCT01466153|9856412|FG001|Overall Study|Disease Progression|2
6197118|NCT01466153|9856413|FG002|Overall Study|Disease Progression|0
6197119|NCT01466153|9856411|FG000|Overall Study|Adverse Event|14
6197120|NCT01466153|9856412|FG001|Overall Study|Adverse Event|13
6197121|NCT01466153|9856413|FG002|Overall Study|Adverse Event|17
6197122|NCT01466153|9856411|FG000|Overall Study|Withdrawal of Consent|2
6197123|NCT01466153|9856412|FG001|Overall Study|Withdrawal of Consent|0
6197124|NCT01466153|9856413|FG002|Overall Study|Withdrawal of Consent|0
6197125|NCT01466153|9856411|FG000|Overall Study|Investigator Discretion|3
6197126|NCT01466153|9856412|FG001|Overall Study|Investigator Discretion|2
6197127|NCT01466153|9856413|FG002|Overall Study|Investigator Discretion|2
6197128|NCT01466153|9856411|FG000|Overall Study|Randomized-Not Treated|2
6275455|NCT02213055|9980188|FG000|Overall Study|Protocol was not Followed at Enrollment|5
6275456|NCT02213055|9980189|FG001|Overall Study|Protocol was not Followed at Enrollment|0
6275457|NCT02213055|9980188|FG000|Overall Study|Protocol was not Followed during Study|1
6275458|NCT02213055|9980189|FG001|Overall Study|Protocol was not Followed during Study|0
6275459|NCT02213055|9980188|FG000|Overall Study|Documentation Issue at Enrollment|1
6275460|NCT02213055|9980189|FG001|Overall Study|Documentation Issue at Enrollment|0
6275461|NCT02213055|9980188|FG000|Overall Study|Documentation Issue during Study|10
6275462|NCT02213055|9980189|FG001|Overall Study|Documentation Issue during Study|0
6275463|NCT02213055|9980188|FG000|Overall Study|Did not have Live Lice|8
6275464|NCT02213055|9980189|FG001|Overall Study|Did not have Live Lice|0
6275465|NCT02213055|9980188|FG000|Overall Study|Had another Treatment during the Study|3
6275466|NCT02213055|9980189|FG001|Overall Study|Had another Treatment during the Study|0
6275467|NCT02213055|9980188|FG000|Overall Study|Did not meet Inclusion Criteria|6
6275468|NCT02213055|9980189|FG001|Overall Study|Did not meet Inclusion Criteria|0
6275469|NCT02213055|9980188|FG000|Overall Study|Did not Return to School|5
6275470|NCT02213055|9980189|FG001|Overall Study|Did not Return to School|0
6275471|NCT02213094|9980210|FG000|Overall Study|Adverse Event|1
6275472|NCT02213094|9980211|FG001|Overall Study|Adverse Event|0
6275473|NCT02213133|9980220|FG000|Overall Study|Participant discontinued study therapy|2
6275474|NCT02213133|9980221|FG001|Overall Study|Participant discontinued study therapy|0
6275475|NCT02213133|9980222|FG002|Overall Study|Participant discontinued study therapy|0
6275476|NCT02213133|9980220|FG000|Overall Study|Participant withdrew informed consent|2
6275477|NCT02213133|9980221|FG001|Overall Study|Participant withdrew informed consent|1
6275478|NCT02213133|9980222|FG002|Overall Study|Participant withdrew informed consent|2
6275479|NCT02213133|9980220|FG000|Overall Study|Disease progression|11
6275480|NCT02213133|9980221|FG001|Overall Study|Disease progression|2
6275481|NCT02213133|9980222|FG002|Overall Study|Disease progression|0
6275482|NCT02213133|9980220|FG000|Overall Study|Adverse Event (AE)|1
6275483|NCT02213133|9980221|FG001|Overall Study|Adverse Event (AE)|0
6275484|NCT02213133|9980222|FG002|Overall Study|Adverse Event (AE)|0
6275485|NCT02213133|9980220|FG000|Overall Study|Death|16
6275486|NCT02213133|9980221|FG001|Overall Study|Death|2
6275487|NCT02213133|9980222|FG002|Overall Study|Death|1
6275488|NCT02213133|9980220|FG000|Overall Study|Other|5
6275489|NCT02213133|9980221|FG001|Overall Study|Other|0
6275490|NCT02213133|9980222|FG002|Overall Study|Other|0
6275491|NCT02213198|9980233|FG000|Baseline|No show for intake|7
6275492|NCT02213198|9980234|FG001|Baseline|No show for intake|9
6275493|NCT02213198|9980233|FG000|Baseline|Withdrawal by Subject|34
5976914|NCT00982111|9563730|FG000|Overall Study|Progressive Disease|46
5976915|NCT00982111|9563731|FG001|Overall Study|Progressive Disease|39
5976916|NCT00982111|9563730|FG000|Overall Study|Lost to Follow-up|9
5976917|NCT00982111|9563731|FG001|Overall Study|Lost to Follow-up|6
5976918|NCT00982111|9563730|FG000|Overall Study|New Anti-Cancer Therapy|5
5976919|NCT00982111|9563731|FG001|Overall Study|New Anti-Cancer Therapy|5
5976920|NCT00982111|9563730|FG000|Overall Study|Medical Decision|1
5976921|NCT00982111|9563731|FG001|Overall Study|Medical Decision|0
5976922|NCT00982111|9563730|FG000|Overall Study|Withdrawal by Subject|17
5976923|NCT00982111|9563731|FG001|Overall Study|Withdrawal by Subject|19
6197129|NCT01466153|9856412|FG001|Overall Study|Randomized-Not Treated|3
6197130|NCT01466153|9856413|FG002|Overall Study|Randomized-Not Treated|4
6197131|NCT01466153|9856411|FG000|Overall Study|Other-Unspecified|6
5976924|NCT00982111|9563730|FG000|Overall Study|Global Study End|0
5976925|NCT00982111|9563731|FG001|Overall Study|Global Study End|1
6197132|NCT01466153|9856412|FG001|Overall Study|Other-Unspecified|4
6197133|NCT01466153|9856413|FG002|Overall Study|Other-Unspecified|2
6275494|NCT02213198|9980234|FG001|Baseline|Withdrawal by Subject|11
6197134|NCT01466166|9856423|FG000|Overall Study|Death|1
6197135|NCT01466166|9856423|FG000|Overall Study|Lost to Follow-up|7
6197136|NCT01466166|9856423|FG000|Overall Study|Infusion Reaction (IR)|27
6197137|NCT01466166|9856423|FG000|Overall Study|Adverse Event (Other than IR)|11
6197138|NCT01466166|9856423|FG000|Overall Study|Elevated Serum Uric Acid|78
6197139|NCT01466166|9856423|FG000|Overall Study|Withdrawal by Subject|13
6197140|NCT01466166|9856423|FG000|Overall Study|Sponsor Decision|4
6197141|NCT01466166|9856423|FG000|Overall Study|Protocol Violation/Noncompliance|2
6197142|NCT01466166|9856423|FG000|Overall Study|Other|20
6197143|NCT01466179|9856427|FG000|Overall Study|Ongoing in core study|2
6197144|NCT01466179|9856427|FG000|Overall Study|Physician Decision|46
6197145|NCT01466179|9856427|FG000|Overall Study|Progressive disease|43
6197146|NCT01466179|9856427|FG000|Overall Study|Adverse Event|32
6197147|NCT01466179|9856427|FG000|Overall Study|Disease relapse|23
6197148|NCT01466179|9856427|FG000|Overall Study|Lack of Efficacy|14
6197149|NCT01466179|9856427|FG000|Overall Study|Death|7
6197150|NCT01466179|9856427|FG000|Overall Study|Withdrawal by Subject|7
6197151|NCT01466179|9856427|FG000|Overall Study|Protocol Violation|2
6197152|NCT01466179|9856427|FG000|Overall Study|Other|3
6197153|NCT01466192|9856434|FG000|Overall Study|Physician Decision|1
6197154|NCT01466192|9856434|FG000|Overall Study|Withdrawal by Subject|3
6197155|NCT01466270|9856440|FG000|Overall Study|Withdrawal by Subject|4
6197156|NCT01466270|9856441|FG001|Overall Study|Withdrawal by Subject|1
6197157|NCT01466270|9856440|FG000|Overall Study|Physician Decision|1
6197158|NCT01466270|9856441|FG001|Overall Study|Physician Decision|0
6197159|NCT01466270|9856440|FG000|Overall Study|Lost to Follow-up|1
6197160|NCT01466270|9856441|FG001|Overall Study|Lost to Follow-up|3
6197161|NCT01466270|9856440|FG000|Overall Study|Progression|1
6197162|NCT01466270|9856441|FG001|Overall Study|Progression|0
6197163|NCT01466270|9856440|FG000|Overall Study|Toxicity|4
6197164|NCT01466270|9856441|FG001|Overall Study|Toxicity|1
6197165|NCT01466270|9856440|FG000|Overall Study|Multiple|1
6197166|NCT01466270|9856441|FG001|Overall Study|Multiple|1
6197167|NCT01466348|9856449|FG000|Period I - First Intervention|Withdrawal by Subject|0
6197168|NCT01466348|9856450|FG001|Period I - First Intervention|Withdrawal by Subject|1
6197169|NCT01466387|9856486|FG000|Overall Study|Adverse Event|0
6197170|NCT01466387|9856487|FG001|Overall Study|Adverse Event|0
6197171|NCT01466387|9856488|FG002|Overall Study|Adverse Event|1
6197172|NCT01466387|9856489|FG003|Overall Study|Adverse Event|1
6197173|NCT01466387|9856490|FG004|Overall Study|Adverse Event|0
6197174|NCT01466387|9856491|FG005|Overall Study|Adverse Event|0
6197175|NCT01466387|9856486|FG000|Overall Study|Lost to Follow-up|0
6197176|NCT01466387|9856487|FG001|Overall Study|Lost to Follow-up|0
6197177|NCT01466387|9856488|FG002|Overall Study|Lost to Follow-up|0
6197178|NCT01466387|9856489|FG003|Overall Study|Lost to Follow-up|0
6197179|NCT01466387|9856490|FG004|Overall Study|Lost to Follow-up|0
6197180|NCT01466387|9856491|FG005|Overall Study|Lost to Follow-up|1
6197181|NCT01466387|9856486|FG000|Overall Study|Protocol Violation|1
6197182|NCT01466387|9856487|FG001|Overall Study|Protocol Violation|0
6197183|NCT01466387|9856488|FG002|Overall Study|Protocol Violation|0
6197184|NCT01466387|9856489|FG003|Overall Study|Protocol Violation|1
6197185|NCT01466387|9856490|FG004|Overall Study|Protocol Violation|0
6197186|NCT01466387|9856491|FG005|Overall Study|Protocol Violation|0
6197187|NCT01466491|9856518|FG000|Overall Study|Protocol Violation|0
6197188|NCT01466491|9856519|FG001|Overall Study|Protocol Violation|3
6197189|NCT01466491|9856520|FG002|Overall Study|Protocol Violation|2
6197190|NCT01466491|9856521|FG003|Overall Study|Protocol Violation|0
6197191|NCT01466491|9856518|FG000|Overall Study|Missing Data|0
6197192|NCT01466491|9856519|FG001|Overall Study|Missing Data|0
6197193|NCT01466491|9856520|FG002|Overall Study|Missing Data|1
6197194|NCT01466491|9856521|FG003|Overall Study|Missing Data|0
6275495|NCT02213198|9980233|FG000|Baseline|transferred out of clinic|7
6275496|NCT02213198|9980234|FG001|Baseline|transferred out of clinic|9
6275497|NCT02213198|9980233|FG000|Baseline|Lost to Follow-up|40
6275498|NCT02213198|9980234|FG001|Baseline|Lost to Follow-up|21
6275499|NCT02213198|9980233|FG000|Baseline|incarcerated,violent|0
6275500|NCT02213198|9980234|FG001|Baseline|incarcerated,violent|1
6275501|NCT02213198|9980233|FG000|Follow up 1 3 Mos Post BL End of TCC tx|Withdrawal by Subject|4
6275502|NCT02213198|9980234|FG001|Follow up 1 3 Mos Post BL End of TCC tx|Withdrawal by Subject|4
6275503|NCT02213198|9980233|FG000|Follow up 1 3 Mos Post BL End of TCC tx|rehab/incarceration/violence|3
6275504|NCT02213198|9980234|FG001|Follow up 1 3 Mos Post BL End of TCC tx|rehab/incarceration/violence|2
6275505|NCT02213198|9980233|FG000|Follow up 1 3 Mos Post BL End of TCC tx|Death|1
6275506|NCT02213198|9980234|FG001|Follow up 1 3 Mos Post BL End of TCC tx|Death|0
6275507|NCT02213198|9980233|FG000|Follow up 1 3 Mos Post BL End of TCC tx|Lost to Follow-up|68
6275508|NCT02213198|9980234|FG001|Follow up 1 3 Mos Post BL End of TCC tx|Lost to Follow-up|25
6275509|NCT02213198|9980233|FG000|Follow up 1 3 Mos Post BL End of TCC tx|unable to contact at 3 but got 6 post DC|17
6275510|NCT02213198|9980234|FG001|Follow up 1 3 Mos Post BL End of TCC tx|unable to contact at 3 but got 6 post DC|10
6275511|NCT02213198|9980233|FG000|Follow up 2 6 Months Post TCC Treatment|Lost to Follow-up|23
6275512|NCT02213198|9980234|FG001|Follow up 2 6 Months Post TCC Treatment|Lost to Follow-up|7
6275513|NCT02213263|9980250|FG000|Overall Study|Insufficient clinical response|4
6197195|NCT01466595|9856533|FG000|Overall Study|Withdrawal by Subject|0
6197196|NCT01466595|9856534|FG001|Overall Study|Withdrawal by Subject|1
6197197|NCT01466660|9856542|FG000|Overall Study|Progressive Disease (RECIST 1.1)|120
6197198|NCT01466660|9856543|FG001|Overall Study|Progressive Disease (RECIST 1.1)|127
6275514|NCT02213263|9980251|FG001|Overall Study|Insufficient clinical response|3
6275515|NCT02213263|9980250|FG000|Overall Study|Lost to Follow-up|0
6275516|NCT02213263|9980251|FG001|Overall Study|Lost to Follow-up|1
6275517|NCT02213263|9980250|FG000|Overall Study|No longer willing to participate|3
5976926|NCT00982111|9563730|FG000|Overall Study|Sponsor's Decision|0
5976927|NCT00982111|9563731|FG001|Overall Study|Sponsor's Decision|1
5976928|NCT00116142|9563745|FG000|Overall Study|Adverse Event|8
5976929|NCT00116142|9563746|FG001|Overall Study|Adverse Event|7
5976930|NCT00116142|9563745|FG000|Overall Study|Protocol Violation|2
5976931|NCT00116142|9563746|FG001|Overall Study|Protocol Violation|1
5976932|NCT00116142|9563745|FG000|Overall Study|Withdrawal by Subject|5
5976933|NCT00116142|9563746|FG001|Overall Study|Withdrawal by Subject|5
5976934|NCT00116142|9563745|FG000|Overall Study|Physician Decision|3
5976935|NCT00116142|9563746|FG001|Overall Study|Physician Decision|1
5976936|NCT00116142|9563745|FG000|Overall Study|Delayed Radiation Therapy|1
5976937|NCT00116142|9563746|FG001|Overall Study|Delayed Radiation Therapy|0
5976938|NCT00116142|9563745|FG000|Overall Study|Patient could not tolerate docetaxel|0
5976939|NCT00116142|9563746|FG001|Overall Study|Patient could not tolerate docetaxel|2
5976940|NCT00116142|9563745|FG000|Overall Study|Patient stopped due to depression|0
5976941|NCT00116142|9563746|FG001|Overall Study|Patient stopped due to depression|1
5976942|NCT00116142|9563745|FG000|Overall Study|Patient stopped due to bilateral ruptured tendons|0
5976943|NCT00116142|9563746|FG001|Overall Study|Patient stopped due to bilateral ruptured tendons|1
6197199|NCT01466660|9856542|FG000|Overall Study|Worsening of underlying cancer disease|5
6197200|NCT01466660|9856543|FG001|Overall Study|Worsening of underlying cancer disease|2
6197201|NCT01466660|9856542|FG000|Overall Study|Other adverse event|19
6197202|NCT01466660|9856543|FG001|Overall Study|Other adverse event|18
6197203|NCT01466660|9856542|FG000|Overall Study|Protocol Violation|2
6197204|NCT01466660|9856543|FG001|Overall Study|Protocol Violation|1
6197205|NCT01466660|9856542|FG000|Overall Study|Refused continuation of trial medication|4
6197206|NCT01466660|9856543|FG001|Overall Study|Refused continuation of trial medication|3
6197207|NCT01466660|9856542|FG000|Overall Study|Other reason not defined above|10
6197208|NCT01466660|9856543|FG001|Overall Study|Other reason not defined above|8
6197209|NCT01466673|9856551|FG000|Overall Study|Non-compliance with study treatment|2
6197210|NCT01466673|9856552|FG001|Overall Study|Non-compliance with study treatment|0
6197211|NCT01466673|9856551|FG000|Overall Study|Lost to Follow-up|3
6197212|NCT01466673|9856552|FG001|Overall Study|Lost to Follow-up|5
6197213|NCT01466673|9856551|FG000|Overall Study|Adverse Event|2
6197214|NCT01466673|9856552|FG001|Overall Study|Adverse Event|1
6197215|NCT01466790|9856586|FG000|Overall Study|Adverse Event|1
6197216|NCT01466790|9856587|FG001|Overall Study|Adverse Event|0
6197217|NCT01466790|9856588|FG002|Overall Study|Adverse Event|0
6197218|NCT01466790|9856589|FG003|Overall Study|Adverse Event|0
6197219|NCT01466790|9856590|FG004|Overall Study|Adverse Event|2
6197220|NCT01466790|9856591|FG005|Overall Study|Adverse Event|0
6197221|NCT01466790|9856592|FG006|Overall Study|Adverse Event|0
5976944|NCT00116142|9563745|FG000|Overall Study|Patient didn't start due to diagnosis of colon cancer|0
6197222|NCT01466790|9856593|FG007|Overall Study|Adverse Event|0
6197223|NCT01466790|9856586|FG000|Overall Study|Lost to Follow-up|2
6197224|NCT01466790|9856587|FG001|Overall Study|Lost to Follow-up|0
6197225|NCT01466790|9856588|FG002|Overall Study|Lost to Follow-up|0
6197226|NCT01466790|9856589|FG003|Overall Study|Lost to Follow-up|0
6197227|NCT01466790|9856590|FG004|Overall Study|Lost to Follow-up|0
6197228|NCT01466790|9856591|FG005|Overall Study|Lost to Follow-up|0
6197229|NCT01466790|9856592|FG006|Overall Study|Lost to Follow-up|0
6197230|NCT01466790|9856593|FG007|Overall Study|Lost to Follow-up|0
6197231|NCT01466790|9856586|FG000|Overall Study|Withdrawal by Subject|1
6197232|NCT01466790|9856587|FG001|Overall Study|Withdrawal by Subject|1
6197233|NCT01466790|9856588|FG002|Overall Study|Withdrawal by Subject|0
6197234|NCT01466790|9856589|FG003|Overall Study|Withdrawal by Subject|0
6197235|NCT01466790|9856590|FG004|Overall Study|Withdrawal by Subject|1
6197236|NCT01466790|9856591|FG005|Overall Study|Withdrawal by Subject|0
6197237|NCT01466790|9856592|FG006|Overall Study|Withdrawal by Subject|1
6197238|NCT01466790|9856593|FG007|Overall Study|Withdrawal by Subject|1
6197239|NCT01466881|9856607|FG000|Overall Study|Ineligible|5
6197240|NCT01466881|9856607|FG000|Overall Study|Adverse Event|6
6197241|NCT01466881|9856607|FG000|Overall Study|Progression/relapse|20
6197242|NCT01466881|9856607|FG000|Overall Study|Death|4
6197243|NCT01466881|9856607|FG000|Overall Study|Other reason not protocol specified|5
6197244|NCT01467076|9856650|FG000|Overall Study|Lost to Follow-up|1
6197245|NCT01467076|9856651|FG001|Overall Study|Lost to Follow-up|0
6197246|NCT01467076|9856652|FG002|Overall Study|Lost to Follow-up|0
6197247|NCT01467271|9856660|FG000|Overall Study|Death|84
6197248|NCT01467271|9856660|FG000|Overall Study|Lost to Follow-up|83
6197249|NCT01467271|9856660|FG000|Overall Study|Retraction of patient's consent|21
6197250|NCT01467271|9856660|FG000|Overall Study|Other reason|14
6197251|NCT01467427|9856666|FG000|Overall Study|Withdrawal by Subject|1
6197252|NCT01467427|9856667|FG001|Overall Study|Withdrawal by Subject|0
6197253|NCT01467427|9856666|FG000|Overall Study|Entered extension phase|11
6088564|NCT00676338|9699471|FG000|Overall Study|Physician Decision|3
6088565|NCT00676338|9699472|FG001|Overall Study|Physician Decision|3
6088566|NCT00676338|9699473|FG002|Overall Study|Physician Decision|2
6088567|NCT00676338|9699474|FG003|Overall Study|Physician Decision|3
6088568|NCT00676338|9699471|FG000|Overall Study|Protocol Violation|5
6088569|NCT00676338|9699472|FG001|Overall Study|Protocol Violation|9
6088570|NCT00676338|9699473|FG002|Overall Study|Protocol Violation|2
6088571|NCT00676338|9699474|FG003|Overall Study|Protocol Violation|5
6088572|NCT00676338|9699471|FG000|Overall Study|Withdrawal by Subject|17
6088573|NCT00676338|9699472|FG001|Overall Study|Withdrawal by Subject|9
6088574|NCT00676338|9699473|FG002|Overall Study|Withdrawal by Subject|12
6088575|NCT00676338|9699474|FG003|Overall Study|Withdrawal by Subject|6
6088576|NCT00676338|9699471|FG000|Overall Study|Entry Criteria Not Met|0
6088577|NCT00676338|9699472|FG001|Overall Study|Entry Criteria Not Met|2
6088578|NCT00676338|9699473|FG002|Overall Study|Entry Criteria Not Met|1
6088579|NCT00676338|9699474|FG003|Overall Study|Entry Criteria Not Met|1
6197254|NCT01467427|9856667|FG001|Overall Study|Entered extension phase|11
6197255|NCT01467427|9856666|FG000|Overall Study|Not continuing in extension phase|0
6197256|NCT01467427|9856667|FG001|Overall Study|Not continuing in extension phase|2
6197257|NCT01467466|9856677|FG000|Overall Study|Withdrawal by Subject|15
6197258|NCT01467466|9856678|FG001|Overall Study|Withdrawal by Subject|18
6197259|NCT01467466|9856679|FG002|Overall Study|Withdrawal by Subject|13
6197260|NCT01467466|9856680|FG003|Overall Study|Withdrawal by Subject|11
6197261|NCT01467466|9856677|FG000|Overall Study|Revoked Consent Prior To Procedure|10
6197262|NCT01467466|9856678|FG001|Overall Study|Revoked Consent Prior To Procedure|9
6197263|NCT01467466|9856679|FG002|Overall Study|Revoked Consent Prior To Procedure|15
6197264|NCT01467466|9856680|FG003|Overall Study|Revoked Consent Prior To Procedure|5
6197265|NCT01467466|9856677|FG000|Overall Study|Procedure Cancelled|46
6197266|NCT01467466|9856678|FG001|Overall Study|Procedure Cancelled|45
6197267|NCT01467466|9856679|FG002|Overall Study|Procedure Cancelled|25
6197268|NCT01467466|9856680|FG003|Overall Study|Procedure Cancelled|29
6197269|NCT01467466|9856677|FG000|Overall Study|No Endpoint Blood Draw|38
6197270|NCT01467466|9856678|FG001|Overall Study|No Endpoint Blood Draw|32
6197271|NCT01467466|9856679|FG002|Overall Study|No Endpoint Blood Draw|51
6197272|NCT01467466|9856680|FG003|Overall Study|No Endpoint Blood Draw|43
6197273|NCT01467479|9856693|FG000|Overall Study|No Study Medication|1
6197274|NCT01467479|9856694|FG001|Overall Study|No Study Medication|0
6197275|NCT01467479|9856695|FG002|Overall Study|No Study Medication|2
6197276|NCT01467479|9856693|FG000|Overall Study|Adverse Event|1
6197277|NCT01467479|9856694|FG001|Overall Study|Adverse Event|2
6197278|NCT01467479|9856695|FG002|Overall Study|Adverse Event|0
6197279|NCT01467479|9856693|FG000|Overall Study|Death|0
6197280|NCT01467479|9856694|FG001|Overall Study|Death|0
6197281|NCT01467479|9856695|FG002|Overall Study|Death|1
6088580|NCT00676338|9699471|FG000|Overall Study|Lack of Efficacy-Loss of Glucose Control|3
6197282|NCT01467479|9856693|FG000|Overall Study|Lost to Follow-up|2
6088581|NCT00676338|9699472|FG001|Overall Study|Lack of Efficacy-Loss of Glucose Control|3
6088582|NCT00676338|9699473|FG002|Overall Study|Lack of Efficacy-Loss of Glucose Control|5
6197283|NCT01467479|9856694|FG001|Overall Study|Lost to Follow-up|5
6197284|NCT01467479|9856695|FG002|Overall Study|Lost to Follow-up|3
6197285|NCT01467479|9856693|FG000|Overall Study|Withdrawal of Consent|3
6197286|NCT01467479|9856694|FG001|Overall Study|Withdrawal of Consent|7
6197287|NCT01467479|9856695|FG002|Overall Study|Withdrawal of Consent|7
6197288|NCT01467479|9856693|FG000|Overall Study|Study Terminated by Sponsor|1
6197289|NCT01467479|9856694|FG001|Overall Study|Study Terminated by Sponsor|3
6197290|NCT01467479|9856695|FG002|Overall Study|Study Terminated by Sponsor|3
6197291|NCT01467479|9856693|FG000|Overall Study|Other|1
6197292|NCT01467479|9856694|FG001|Overall Study|Other|0
6197293|NCT01467479|9856695|FG002|Overall Study|Other|0
6197294|NCT01467492|9856706|FG000|Overall Study|Withdrawal by Subject|6
6197295|NCT01467492|9856707|FG001|Overall Study|Withdrawal by Subject|4
6197296|NCT01467492|9856706|FG000|Overall Study|Study Terminated by Sponsor|6
6197297|NCT01467492|9856707|FG001|Overall Study|Study Terminated by Sponsor|4
6197298|NCT01467492|9856706|FG000|Overall Study|Adverse Event|4
6197299|NCT01467492|9856707|FG001|Overall Study|Adverse Event|3
6197300|NCT01467492|9856706|FG000|Overall Study|Lost to Follow-up|3
6197301|NCT01467492|9856707|FG001|Overall Study|Lost to Follow-up|2
6197302|NCT01467492|9856706|FG000|Overall Study|Undefined|2
6197303|NCT01467492|9856707|FG001|Overall Study|Undefined|0
6197304|NCT01467492|9856706|FG000|Overall Study|Enrolled But Not Treated|1
6197305|NCT01467492|9856707|FG001|Overall Study|Enrolled But Not Treated|0
6197306|NCT01467505|9856716|FG000|Overall Study|Adverse Event|1
6197307|NCT01467505|9856717|FG001|Overall Study|Adverse Event|0
6197308|NCT01467505|9856716|FG000|Overall Study|Withdrawal by Subject|4
6197309|NCT01467505|9856717|FG001|Overall Study|Withdrawal by Subject|0
6197310|NCT01467505|9856716|FG000|Overall Study|Study Terminated by Sponsor|28
6197311|NCT01467505|9856717|FG001|Overall Study|Study Terminated by Sponsor|3
6197312|NCT01467570|9856734|FG000|Overall Study|Lost to Follow-up|8
6088583|NCT00676338|9699474|FG003|Overall Study|Lack of Efficacy-Loss of Glucose Control|3
6088584|NCT00676403|9699501|FG000|Overall Study|Adverse Event|1
6088585|NCT00676403|9699502|FG001|Overall Study|Adverse Event|2
6088586|NCT00676403|9699503|FG002|Overall Study|Adverse Event|0
6088587|NCT00676403|9699504|FG003|Overall Study|Adverse Event|5
6088588|NCT00676403|9699505|FG004|Overall Study|Adverse Event|1
6088589|NCT00676403|9699506|FG005|Overall Study|Adverse Event|2
6088590|NCT00676403|9699501|FG000|Overall Study|Lost to Follow-up|0
6088591|NCT00676403|9699502|FG001|Overall Study|Lost to Follow-up|0
6088592|NCT00676403|9699503|FG002|Overall Study|Lost to Follow-up|0
6088593|NCT00676403|9699504|FG003|Overall Study|Lost to Follow-up|0
6088594|NCT00676403|9699505|FG004|Overall Study|Lost to Follow-up|0
6088595|NCT00676403|9699506|FG005|Overall Study|Lost to Follow-up|1
6088596|NCT00676403|9699501|FG000|Overall Study|Reason Unspecified|1
6088597|NCT00676403|9699502|FG001|Overall Study|Reason Unspecified|0
6088598|NCT00676403|9699503|FG002|Overall Study|Reason Unspecified|1
6088599|NCT00676403|9699504|FG003|Overall Study|Reason Unspecified|0
6088600|NCT00676403|9699505|FG004|Overall Study|Reason Unspecified|0
6197313|NCT01467570|9856735|FG001|Overall Study|Lost to Follow-up|9
6275518|NCT02213263|9980251|FG001|Overall Study|No longer willing to participate|4
6275519|NCT02213263|9980250|FG000|Overall Study|Progressive disease|20
6275520|NCT02213263|9980251|FG001|Overall Study|Progressive disease|14
6275521|NCT02213263|9980250|FG000|Overall Study|Protocol Violation|0
6275522|NCT02213263|9980251|FG001|Overall Study|Protocol Violation|1
6275523|NCT02213263|9980250|FG000|Overall Study|Adverse Event|1
6275524|NCT02213263|9980251|FG001|Overall Study|Adverse Event|3
6275525|NCT02213458|9980272|FG000|Overall Study|No longer meets criteria: caregiver deceased|4
6275526|NCT02213458|9980273|FG001|Overall Study|No longer meets criteria: caregiver deceased|0
6275527|NCT02213458|9980272|FG000|Overall Study|No longer meets criteria: caregiver no longer caregiving|4
6275528|NCT02213458|9980273|FG001|Overall Study|No longer meets criteria: caregiver no longer caregiving|0
6275529|NCT02213458|9980272|FG000|Overall Study|No longer meets criteria: caregiver too sick to participate|2
6275530|NCT02213458|9980273|FG001|Overall Study|No longer meets criteria: caregiver too sick to participate|0
6275531|NCT02213458|9980272|FG000|Overall Study|No longer meets criteria: patient moved out of state|10
6275532|NCT02213458|9980273|FG001|Overall Study|No longer meets criteria: patient moved out of state|0
6275533|NCT02213458|9980272|FG000|Overall Study|Refused re-consent|6
6275534|NCT02213458|9980273|FG001|Overall Study|Refused re-consent|0
6275535|NCT02213458|9980272|FG000|Overall Study|Lost to Follow-up|2
6275536|NCT02213458|9980273|FG001|Overall Study|Lost to Follow-up|2
6275537|NCT02213458|9980272|FG000|Overall Study|Withdrawal by Subject|26
6275538|NCT02213458|9980273|FG001|Overall Study|Withdrawal by Subject|8
6275539|NCT02213510|9980281|FG000|Overall Study|Death|0
6275540|NCT02213510|9980282|FG001|Overall Study|Death|1
6275541|NCT02213510|9980281|FG000|Overall Study|Lost to Follow-up|1
6275542|NCT02213510|9980282|FG001|Overall Study|Lost to Follow-up|0
6275543|NCT02213666|9980288|FG000|Overall Study|Withdrawal by Subject|1
6275544|NCT02214121|9980313|FG000|Part A|Patient decision|2
6088601|NCT00676403|9699506|FG005|Overall Study|Reason Unspecified|1
6088602|NCT00676403|9699501|FG000|Overall Study|Withdrawal by Subject|0
6088603|NCT00676403|9699502|FG001|Overall Study|Withdrawal by Subject|0
6088604|NCT00676403|9699503|FG002|Overall Study|Withdrawal by Subject|0
6275545|NCT02214121|9980314|FG001|Part A|Patient decision|0
6275546|NCT02214121|9980315|FG002|Part A|Patient decision|0
6275547|NCT02214121|9980313|FG000|Part A|Dev. of study-specific withdrawal crit.|4
6275548|NCT02214121|9980314|FG001|Part A|Dev. of study-specific withdrawal crit.|0
6275549|NCT02214121|9980315|FG002|Part A|Dev. of study-specific withdrawal crit.|0
6275550|NCT02214121|9980313|FG000|Part A|Other|1
6275551|NCT02214121|9980314|FG001|Part A|Other|0
6275552|NCT02214121|9980315|FG002|Part A|Other|0
6197314|NCT01467583|9856746|FG000|Overall Study|Death|1
6197315|NCT01467583|9856747|FG001|Overall Study|Death|1
6197316|NCT01467583|9856748|FG002|Overall Study|Death|0
6275553|NCT02214121|9980313|FG000|Part B|Patient decision|0
6275554|NCT02214121|9980314|FG001|Part B|Patient decision|1
6275555|NCT02214121|9980315|FG002|Part B|Patient decision|0
6275556|NCT02214121|9980313|FG000|Part B|Dev. of study-specific withdrawal crit.|0
6275557|NCT02214121|9980314|FG001|Part B|Dev. of study-specific withdrawal crit.|2
6275558|NCT02214121|9980315|FG002|Part B|Dev. of study-specific withdrawal crit.|0
5976945|NCT00116142|9563746|FG001|Overall Study|Patient didn't start due to diagnosis of colon cancer|1
5976946|NCT00116142|9563745|FG000|Overall Study|Patient didn't start due to low platelet counts|0
5976947|NCT00116142|9563746|FG001|Overall Study|Patient didn't start due to low platelet counts|1
5976948|NCT00070018|9563755|FG000|Overall Study|Adverse Event|2
5976949|NCT00070018|9563755|FG000|Overall Study|Lack of Efficacy|1
5976950|NCT00070018|9563755|FG000|Overall Study|Withdrawal by Subject|1
6050725|NCT00428441|9649933|FG000|Overall Study|Lost to Follow-up|1
6050726|NCT00428597|9649952|FG000|Overall Study|Randomized but not treated|3
6050727|NCT00428597|9649953|FG001|Overall Study|Randomized but not treated|3
6050728|NCT00428597|9649952|FG000|Overall Study|Objective Progression or Relapse|19
6050729|NCT00428597|9649953|FG001|Overall Study|Objective Progression or Relapse|47
6050730|NCT00428597|9649952|FG000|Overall Study|Study Terminated by Sponsor|41
6050731|NCT00428597|9649953|FG001|Overall Study|Study Terminated by Sponsor|16
6050732|NCT00428597|9649952|FG000|Overall Study|Adverse Event|15
6050733|NCT00428597|9649953|FG001|Overall Study|Adverse Event|7
6050734|NCT00428597|9649952|FG000|Overall Study|Global Deterioration of Health Status|1
6050735|NCT00428597|9649953|FG001|Overall Study|Global Deterioration of Health Status|5
6050736|NCT00428597|9649952|FG000|Overall Study|Protocol Violation|2
6050737|NCT00428597|9649953|FG001|Overall Study|Protocol Violation|1
6050738|NCT00428597|9649952|FG000|Overall Study|Withdrawal by Subject|2
6050739|NCT00428597|9649953|FG001|Overall Study|Withdrawal by Subject|1
6050740|NCT00428597|9649952|FG000|Overall Study|Other|1
6050741|NCT00428597|9649953|FG001|Overall Study|Other|1
6050742|NCT00428597|9649952|FG000|Overall Study|Lost to Follow-up|0
6050743|NCT00428597|9649953|FG001|Overall Study|Lost to Follow-up|1
6050744|NCT00428597|9649952|FG000|Overall Study|Pregnancy|1
6050745|NCT00428597|9649953|FG001|Overall Study|Pregnancy|0
6050746|NCT00428597|9649952|FG000|Overall Study|Death|1
6050747|NCT00428597|9649953|FG001|Overall Study|Death|3
6050748|NCT00428610|9649962|FG000|Overall Study|Death Due to Adverse Event|3
6050749|NCT00428610|9649963|FG001|Overall Study|Death Due to Adverse Event|0
6050750|NCT00428610|9649964|FG002|Overall Study|Death Due to Adverse Event|5
6050751|NCT00428610|9649962|FG000|Overall Study|Death Due to Progressive Disease|0
6050752|NCT00428610|9649963|FG001|Overall Study|Death Due to Progressive Disease|0
6050753|NCT00428610|9649964|FG002|Overall Study|Death Due to Progressive Disease|2
6050754|NCT00428610|9649962|FG000|Overall Study|Adverse Event|2
6050755|NCT00428610|9649963|FG001|Overall Study|Adverse Event|3
6050756|NCT00428610|9649964|FG002|Overall Study|Adverse Event|2
6050757|NCT00428610|9649962|FG000|Overall Study|Investigator Decision|2
6050758|NCT00428610|9649963|FG001|Overall Study|Investigator Decision|1
6050759|NCT00428610|9649964|FG002|Overall Study|Investigator Decision|1
6050760|NCT00428610|9649962|FG000|Overall Study|Progressive Disease|42
6050761|NCT00428610|9649963|FG001|Overall Study|Progressive Disease|14
6050762|NCT00428610|9649964|FG002|Overall Study|Progressive Disease|22
6050763|NCT00428610|9649962|FG000|Overall Study|Withdrawal by Subject|4
6050764|NCT00428610|9649963|FG001|Overall Study|Withdrawal by Subject|0
6050765|NCT00428610|9649964|FG002|Overall Study|Withdrawal by Subject|0
6050766|NCT00428714|9649974|FG000|Overall Study|Progressive Disease|28
6050767|NCT00428714|9649975|FG001|Overall Study|Progressive Disease|36
6050768|NCT00428714|9649974|FG000|Overall Study|Withdrawal by Subject|0
6050769|NCT00428714|9649975|FG001|Overall Study|Withdrawal by Subject|3
6050770|NCT00428714|9649974|FG000|Overall Study|Adverse Event|0
6050771|NCT00428714|9649975|FG001|Overall Study|Adverse Event|2
6197317|NCT01467583|9856746|FG000|Overall Study|Withdrawal by Subject|1
6197318|NCT01467583|9856747|FG001|Overall Study|Withdrawal by Subject|0
6197319|NCT01467583|9856748|FG002|Overall Study|Withdrawal by Subject|0
6197320|NCT01467583|9856746|FG000|Overall Study|Protocol Violation|0
6197321|NCT01467583|9856747|FG001|Overall Study|Protocol Violation|0
6197322|NCT01467583|9856748|FG002|Overall Study|Protocol Violation|2
6197323|NCT01467661|9856759|FG000|Overall Study|Adverse Event|16
6197324|NCT01467661|9856759|FG000|Overall Study|Withdrawal by Subject|1
6197325|NCT01467661|9856759|FG000|Overall Study|Lack of Efficacy|3
6197326|NCT01467661|9856759|FG000|Overall Study|Not enrolled to SPD422-309 (NCT01467661)|1
6197327|NCT01467700|9856769|FG000|Overall Study|Pretreatment Event or Adverse Event|6
6197328|NCT01467700|9856770|FG001|Overall Study|Pretreatment Event or Adverse Event|4
6197329|NCT01467700|9856771|FG002|Overall Study|Pretreatment Event or Adverse Event|2
6197330|NCT01467700|9856772|FG003|Overall Study|Pretreatment Event or Adverse Event|3
6197331|NCT01467700|9856769|FG000|Overall Study|Major Protocol Deviation|3
6197332|NCT01467700|9856770|FG001|Overall Study|Major Protocol Deviation|3
6197333|NCT01467700|9856771|FG002|Overall Study|Major Protocol Deviation|2
6197334|NCT01467700|9856772|FG003|Overall Study|Major Protocol Deviation|3
6275559|NCT02214121|9980313|FG000|Part B|Lost to Follow-up|0
6275560|NCT02214121|9980314|FG001|Part B|Lost to Follow-up|0
6275561|NCT02214121|9980315|FG002|Part B|Lost to Follow-up|1
6197335|NCT01467700|9856769|FG000|Overall Study|Lost to Follow-up|6
6197336|NCT01467700|9856770|FG001|Overall Study|Lost to Follow-up|5
6197337|NCT01467700|9856771|FG002|Overall Study|Lost to Follow-up|2
6197338|NCT01467700|9856772|FG003|Overall Study|Lost to Follow-up|3
6197339|NCT01467700|9856769|FG000|Overall Study|Voluntary Withdrawal|5
6197340|NCT01467700|9856770|FG001|Overall Study|Voluntary Withdrawal|7
6197341|NCT01467700|9856771|FG002|Overall Study|Voluntary Withdrawal|6
6197342|NCT01467700|9856772|FG003|Overall Study|Voluntary Withdrawal|2
6197343|NCT01467700|9856769|FG000|Overall Study|Study Termination|6
6197344|NCT01467700|9856770|FG001|Overall Study|Study Termination|5
6197345|NCT01467700|9856771|FG002|Overall Study|Study Termination|10
6197346|NCT01467700|9856772|FG003|Overall Study|Study Termination|7
6197347|NCT01467700|9856769|FG000|Overall Study|Pregnancy|0
6197348|NCT01467700|9856770|FG001|Overall Study|Pregnancy|1
6197349|NCT01467700|9856771|FG002|Overall Study|Pregnancy|1
6197350|NCT01467700|9856772|FG003|Overall Study|Pregnancy|0
6197351|NCT01467700|9856769|FG000|Overall Study|Lack of Efficacy|2
6197352|NCT01467700|9856770|FG001|Overall Study|Lack of Efficacy|0
6197353|NCT01467700|9856771|FG002|Overall Study|Lack of Efficacy|2
6197354|NCT01467700|9856772|FG003|Overall Study|Lack of Efficacy|1
6197355|NCT01467700|9856769|FG000|Overall Study|Reason not Specified|1
6275562|NCT02214186|9980350|FG000|Overall Study|Lost to Follow-up|1
6275563|NCT02214186|9980351|FG001|Overall Study|Lost to Follow-up|1
6275564|NCT02214186|9980350|FG000|Overall Study|Protocol Violation|1
6275565|NCT02214186|9980351|FG001|Overall Study|Protocol Violation|1
6275566|NCT02214225|9980374|FG000|Overall Study|Lost to Follow-up|46
6275567|NCT02214225|9980375|FG001|Overall Study|Lost to Follow-up|18
6275568|NCT02214225|9980376|FG002|Overall Study|Lost to Follow-up|18
6275569|NCT02214225|9980374|FG000|Overall Study|Withdrawal by Subject|2
6275570|NCT02214225|9980375|FG001|Overall Study|Withdrawal by Subject|0
6275571|NCT02214225|9980376|FG002|Overall Study|Withdrawal by Subject|2
6275572|NCT02214225|9980374|FG000|Overall Study|Death|5
6275573|NCT02214225|9980375|FG001|Overall Study|Death|0
6275574|NCT02214225|9980376|FG002|Overall Study|Death|1
6275575|NCT02214225|9980374|FG000|Overall Study|randomized in error, not vaccinated|2
6275576|NCT02214225|9980375|FG001|Overall Study|randomized in error, not vaccinated|1
5976951|NCT04447287|9563768|FG000|Period 1: Run-in Period|Adverse Event|3
5976952|NCT04447287|9563769|FG001|Period 1: Run-in Period|Adverse Event|0
5976953|NCT04447287|9563770|FG002|Period 1: Run-in Period|Adverse Event|0
5976954|NCT04447287|9563768|FG000|Period 1: Run-in Period|Withdrawal by Subject|1
5976955|NCT04447287|9563769|FG001|Period 1: Run-in Period|Withdrawal by Subject|0
5976956|NCT04447287|9563770|FG002|Period 1: Run-in Period|Withdrawal by Subject|0
5976957|NCT04447287|9563768|FG000|Period 2: Investigational Period|Completed the run-in period but discontinued before randomization due to limited samples collected.|1
5976958|NCT04447287|9563769|FG001|Period 2: Investigational Period|Completed the run-in period but discontinued before randomization due to limited samples collected.|0
5976959|NCT04447287|9563770|FG002|Period 2: Investigational Period|Completed the run-in period but discontinued before randomization due to limited samples collected.|0
5976960|NCT04039503|9563826|FG000|Overall Study|Adverse Event|3
5976961|NCT04039503|9563827|FG001|Overall Study|Adverse Event|0
5976962|NCT04039503|9563828|FG002|Overall Study|Adverse Event|2
5976963|NCT04039503|9563829|FG003|Overall Study|Adverse Event|0
5976964|NCT04039503|9563826|FG000|Overall Study|Lost to Follow-up|0
5976965|NCT04039503|9563827|FG001|Overall Study|Lost to Follow-up|0
5976966|NCT04039503|9563828|FG002|Overall Study|Lost to Follow-up|1
5976967|NCT04039503|9563829|FG003|Overall Study|Lost to Follow-up|0
5976968|NCT04039503|9563826|FG000|Overall Study|Protocol Violation|0
5976969|NCT04039503|9563827|FG001|Overall Study|Protocol Violation|1
5976970|NCT04039503|9563828|FG002|Overall Study|Protocol Violation|2
5976971|NCT04039503|9563829|FG003|Overall Study|Protocol Violation|1
5976972|NCT04039503|9563826|FG000|Overall Study|Withdrawal by Subject|4
5976973|NCT04039503|9563827|FG001|Overall Study|Withdrawal by Subject|3
5976974|NCT04039503|9563828|FG002|Overall Study|Withdrawal by Subject|5
5976975|NCT04039503|9563829|FG003|Overall Study|Withdrawal by Subject|2
5976976|NCT03695172|9563847|FG000|Overall Study|Withdrawal by Subject|1
5976977|NCT03695172|9563848|FG001|Overall Study|Withdrawal by Subject|1
5976978|NCT03695172|9563849|FG002|Overall Study|Withdrawal by Subject|0
6050772|NCT00428714|9649974|FG000|Overall Study|Physician Decision|1
6197356|NCT01467700|9856770|FG001|Overall Study|Reason not Specified|3
6275577|NCT02214225|9980376|FG002|Overall Study|randomized in error, not vaccinated|1
6275578|NCT02215252|9980504|FG000|Overall Study|Adverse Event|1
6275579|NCT02215252|9980505|FG001|Overall Study|Adverse Event|5
6275580|NCT02215252|9980506|FG002|Overall Study|Adverse Event|2
5976979|NCT03394027|9563877|FG000|Overall Study|Ineligible|3
5976980|NCT03394027|9563878|FG001|Overall Study|Ineligible|1
5976981|NCT03394027|9563879|FG002|Overall Study|Ineligible|3
5976982|NCT03394027|9563877|FG000|Overall Study|Participant declined to participate before treatment started|0
6197357|NCT01467700|9856771|FG002|Overall Study|Reason not Specified|2
6197358|NCT01467700|9856772|FG003|Overall Study|Reason not Specified|8
6050773|NCT00428714|9649975|FG001|Overall Study|Physician Decision|1
6050774|NCT00428714|9649974|FG000|Overall Study|Death due to Progressive Disease (PD)|1
6275581|NCT02215252|9980504|FG000|Overall Study|Lost to Follow-up|0
6275582|NCT02215252|9980505|FG001|Overall Study|Lost to Follow-up|0
6275583|NCT02215252|9980506|FG002|Overall Study|Lost to Follow-up|1
6197359|NCT01467713|9856786|FG000|Overall Study|Pretreatment Event or Adverse Event|9
6197360|NCT01467713|9856787|FG001|Overall Study|Pretreatment Event or Adverse Event|4
6197361|NCT01467713|9856788|FG002|Overall Study|Pretreatment Event or Adverse Event|6
6197362|NCT01467713|9856789|FG003|Overall Study|Pretreatment Event or Adverse Event|5
6197363|NCT01467713|9856786|FG000|Overall Study|Major Protocol Deviation|2
6197364|NCT01467713|9856787|FG001|Overall Study|Major Protocol Deviation|4
6197365|NCT01467713|9856788|FG002|Overall Study|Major Protocol Deviation|4
6197366|NCT01467713|9856789|FG003|Overall Study|Major Protocol Deviation|1
6197367|NCT01467713|9856786|FG000|Overall Study|Lost to Follow-up|9
6197368|NCT01467713|9856787|FG001|Overall Study|Lost to Follow-up|12
6197369|NCT01467713|9856788|FG002|Overall Study|Lost to Follow-up|6
6197370|NCT01467713|9856789|FG003|Overall Study|Lost to Follow-up|9
6197371|NCT01467713|9856786|FG000|Overall Study|Voluntary Withdrawal|18
6197372|NCT01467713|9856787|FG001|Overall Study|Voluntary Withdrawal|14
6197373|NCT01467713|9856788|FG002|Overall Study|Voluntary Withdrawal|21
6197374|NCT01467713|9856789|FG003|Overall Study|Voluntary Withdrawal|20
6197375|NCT01467713|9856786|FG000|Overall Study|Study Termination|23
6197376|NCT01467713|9856787|FG001|Overall Study|Study Termination|33
6197377|NCT01467713|9856788|FG002|Overall Study|Study Termination|28
6197378|NCT01467713|9856789|FG003|Overall Study|Study Termination|29
6275584|NCT02215252|9980504|FG000|Overall Study|Does not Meet Entrance Criteria|0
6275585|NCT02215252|9980505|FG001|Overall Study|Does not Meet Entrance Criteria|1
6275586|NCT02215252|9980506|FG002|Overall Study|Does not Meet Entrance Criteria|0
6275587|NCT02215252|9980504|FG000|Overall Study|Protocol Violation|0
6275588|NCT02215252|9980505|FG001|Overall Study|Protocol Violation|1
6275589|NCT02215252|9980506|FG002|Overall Study|Protocol Violation|0
6275590|NCT02215252|9980504|FG000|Overall Study|Withdrawal by Subject|1
6275591|NCT02215252|9980505|FG001|Overall Study|Withdrawal by Subject|0
6275592|NCT02215252|9980506|FG002|Overall Study|Withdrawal by Subject|0
6275593|NCT02215252|9980504|FG000|Overall Study|Other|0
6275594|NCT02215252|9980505|FG001|Overall Study|Other|1
6275595|NCT02215252|9980506|FG002|Overall Study|Other|1
6275596|NCT02215616|9980522|FG000|Overall Study|Sponsor requested to stop study drug|0
6275597|NCT02215616|9980523|FG001|Overall Study|Sponsor requested to stop study drug|0
6275598|NCT02215616|9980524|FG002|Overall Study|Sponsor requested to stop study drug|1
6275599|NCT02215616|9980525|FG003|Overall Study|Sponsor requested to stop study drug|4
6275600|NCT02215616|9980522|FG000|Overall Study|Death|1
6275601|NCT02215616|9980523|FG001|Overall Study|Death|0
6275602|NCT02215616|9980524|FG002|Overall Study|Death|0
6275603|NCT02215616|9980525|FG003|Overall Study|Death|0
6275604|NCT02215616|9980522|FG000|Overall Study|Adverse Event|7
6275605|NCT02215616|9980523|FG001|Overall Study|Adverse Event|4
6275606|NCT02215616|9980524|FG002|Overall Study|Adverse Event|9
6275607|NCT02215616|9980525|FG003|Overall Study|Adverse Event|2
5976983|NCT03394027|9563878|FG001|Overall Study|Participant declined to participate before treatment started|0
5976984|NCT03394027|9563879|FG002|Overall Study|Participant declined to participate before treatment started|1
5976985|NCT03357952|9563907|FG000|Overall Study|Withdrawal by Subject|0
5976986|NCT03357952|9563908|FG001|Overall Study|Withdrawal by Subject|1
5976987|NCT03357952|9563907|FG000|Overall Study|Sponsor Decision|9
5976988|NCT03357952|9563908|FG001|Overall Study|Sponsor Decision|0
5976989|NCT03170869|9563923|FG000|Overall Study|Protocol Violation|5
5976990|NCT03170869|9563923|FG000|Overall Study|Early study termination|3
5976991|NCT03066622|9563930|FG000|Overall Study|Lost to Follow-up|24
5976992|NCT03066622|9563931|FG001|Overall Study|Lost to Follow-up|25
5976993|NCT03066622|9563930|FG000|Overall Study|Withdrawal by Subject|2
5976994|NCT03066622|9563931|FG001|Overall Study|Withdrawal by Subject|1
5976995|NCT03052920|9563937|FG000|Overall Study|Withdrawal by Subject|1
5976996|NCT03016312|9563956|FG000|Overall Study|Death|194
5976997|NCT03016312|9563957|FG001|Overall Study|Death|164
6088605|NCT00676403|9699504|FG003|Overall Study|Withdrawal by Subject|0
6197379|NCT01467713|9856786|FG000|Overall Study|Pregnancy|0
6197380|NCT01467713|9856787|FG001|Overall Study|Pregnancy|1
6197381|NCT01467713|9856788|FG002|Overall Study|Pregnancy|1
6197382|NCT01467713|9856789|FG003|Overall Study|Pregnancy|3
6275608|NCT02215616|9980522|FG000|Overall Study|Withdrawal by Subject|1
6275609|NCT02215616|9980523|FG001|Overall Study|Withdrawal by Subject|8
6275610|NCT02215616|9980524|FG002|Overall Study|Withdrawal by Subject|2
6275611|NCT02215616|9980525|FG003|Overall Study|Withdrawal by Subject|5
6275612|NCT02215616|9980522|FG000|Overall Study|Non-compliance|0
6275613|NCT02215616|9980523|FG001|Overall Study|Non-compliance|2
6197383|NCT01467713|9856786|FG000|Overall Study|Relapse|35
6197384|NCT01467713|9856787|FG001|Overall Study|Relapse|25
6197385|NCT01467713|9856788|FG002|Overall Study|Relapse|28
6197386|NCT01467713|9856789|FG003|Overall Study|Relapse|35
6197387|NCT01467713|9856786|FG000|Overall Study|Reason not Specified|6
6197388|NCT01467713|9856787|FG001|Overall Study|Reason not Specified|11
6197389|NCT01467713|9856788|FG002|Overall Study|Reason not Specified|8
6197390|NCT01467713|9856789|FG003|Overall Study|Reason not Specified|7
6197391|NCT01467960|9856833|FG000|Overall Study|Enrollment of patients (PD) in 09/2013|0
6197392|NCT01467960|9856834|FG001|Overall Study|Enrollment of patients (PD) in 09/2013|0
6197393|NCT01467960|9856835|FG002|Overall Study|Enrollment of patients (PD) in 09/2013|0
6197394|NCT01467960|9856836|FG003|Overall Study|Enrollment of patients (PD) in 09/2013|30
6197395|NCT01467960|9856837|FG004|Overall Study|Enrollment of patients (PD) in 09/2013|30
6197396|NCT01467960|9856838|FG005|Overall Study|Enrollment of patients (PD) in 09/2013|30
6197397|NCT01468077|9856872|FG000|Overall Study|Adverse Event|2
6197398|NCT01468077|9856873|FG001|Overall Study|Adverse Event|2
6197399|NCT01468077|9856872|FG000|Overall Study|Lack of Efficacy|1
6197400|NCT01468077|9856873|FG001|Overall Study|Lack of Efficacy|1
6197401|NCT01468077|9856872|FG000|Overall Study|Physician Decision|1
6197402|NCT01468077|9856873|FG001|Overall Study|Physician Decision|0
6197403|NCT01468181|9856884|FG000|Overall Study|Adverse Event|8
6197404|NCT01468181|9856885|FG001|Overall Study|Adverse Event|1
6197405|NCT01468181|9856886|FG002|Overall Study|Adverse Event|6
6197406|NCT01468181|9856887|FG003|Overall Study|Adverse Event|2
6197407|NCT01468181|9856888|FG004|Overall Study|Adverse Event|2
6197408|NCT01468181|9856884|FG000|Overall Study|Protocol Violation|2
6197409|NCT01468181|9856885|FG001|Overall Study|Protocol Violation|0
6197410|NCT01468181|9856886|FG002|Overall Study|Protocol Violation|1
6197411|NCT01468181|9856887|FG003|Overall Study|Protocol Violation|0
6197412|NCT01468181|9856888|FG004|Overall Study|Protocol Violation|1
6197413|NCT01468181|9856884|FG000|Overall Study|Physician Decision|0
6197414|NCT01468181|9856885|FG001|Overall Study|Physician Decision|0
6197415|NCT01468181|9856886|FG002|Overall Study|Physician Decision|0
6197416|NCT01468181|9856887|FG003|Overall Study|Physician Decision|1
6197417|NCT01468181|9856888|FG004|Overall Study|Physician Decision|1
6197418|NCT01468181|9856884|FG000|Overall Study|Lost to Follow-up|0
6197419|NCT01468181|9856885|FG001|Overall Study|Lost to Follow-up|0
6197420|NCT01468181|9856886|FG002|Overall Study|Lost to Follow-up|1
6197421|NCT01468181|9856887|FG003|Overall Study|Lost to Follow-up|0
6197422|NCT01468181|9856888|FG004|Overall Study|Lost to Follow-up|1
6197423|NCT01468181|9856884|FG000|Overall Study|Withdrawal by Subject|0
6197424|NCT01468181|9856885|FG001|Overall Study|Withdrawal by Subject|1
6197425|NCT01468181|9856886|FG002|Overall Study|Withdrawal by Subject|0
6197426|NCT01468181|9856887|FG003|Overall Study|Withdrawal by Subject|0
6197427|NCT01468181|9856888|FG004|Overall Study|Withdrawal by Subject|0
6197428|NCT01468207|9856902|FG000|Treatment Period 1|Adverse Event|1
6197429|NCT01468207|9856903|FG001|Treatment Period 1|Adverse Event|0
6197430|NCT01468207|9856904|FG002|Treatment Period 1|Adverse Event|0
6275614|NCT02215616|9980524|FG002|Overall Study|Non-compliance|1
6275615|NCT02215616|9980525|FG003|Overall Study|Non-compliance|0
6275616|NCT02215616|9980522|FG000|Overall Study|Protocol Violation|0
6275617|NCT02215616|9980523|FG001|Overall Study|Protocol Violation|2
6275618|NCT02215616|9980524|FG002|Overall Study|Protocol Violation|0
6275619|NCT02215616|9980525|FG003|Overall Study|Protocol Violation|0
6275620|NCT02215616|9980522|FG000|Overall Study|Lost to Follow-up|1
6275621|NCT02215616|9980523|FG001|Overall Study|Lost to Follow-up|1
6275622|NCT02215616|9980524|FG002|Overall Study|Lost to Follow-up|0
6275623|NCT02215616|9980525|FG003|Overall Study|Lost to Follow-up|1
6275624|NCT02215616|9980522|FG000|Overall Study|Other than specified|1
6275625|NCT02215616|9980523|FG001|Overall Study|Other than specified|0
6275626|NCT02215616|9980524|FG002|Overall Study|Other than specified|1
6275627|NCT02215616|9980525|FG003|Overall Study|Other than specified|1
6275628|NCT02215954|9980538|FG000|Overall Study|Adverse Event|0
6275629|NCT02215954|9980539|FG001|Overall Study|Adverse Event|0
6275630|NCT02215954|9980540|FG002|Overall Study|Adverse Event|1
6275631|NCT02215954|9980538|FG000|Overall Study|Withdrawal by Subject|0
6275632|NCT02215954|9980539|FG001|Overall Study|Withdrawal by Subject|0
6275633|NCT02215954|9980540|FG002|Overall Study|Withdrawal by Subject|2
6275634|NCT02215954|9980538|FG000|Overall Study|Not exposed|1
6275635|NCT02215954|9980539|FG001|Overall Study|Not exposed|1
6275636|NCT02215954|9980540|FG002|Overall Study|Not exposed|3
6275637|NCT02215967|9980553|FG000|Overall Study|Patient became ineligible for treatment|0
6275638|NCT02215967|9980554|FG001|Overall Study|Patient became ineligible for treatment|0
6275639|NCT02215967|9980555|FG002|Overall Study|Patient became ineligible for treatment|0
6275640|NCT02215967|9980556|FG003|Overall Study|Patient became ineligible for treatment|3
6275641|NCT02215967|9980553|FG000|Overall Study|Patient did not get CAR T-Cells|0
6275642|NCT02215967|9980554|FG001|Overall Study|Patient did not get CAR T-Cells|0
6275643|NCT02215967|9980555|FG002|Overall Study|Patient did not get CAR T-Cells|1
6275644|NCT02215967|9980556|FG003|Overall Study|Patient did not get CAR T-Cells|0
6197431|NCT01468207|9856905|FG003|Treatment Period 1|Adverse Event|0
6197432|NCT01468207|9856906|FG004|Treatment Period 1|Adverse Event|0
6197433|NCT01468207|9856907|FG005|Treatment Period 1|Adverse Event|0
6275645|NCT02216071|9980568|FG000|Overall Study|Withdrawal by Subject|7
6275646|NCT02216071|9980569|FG001|Overall Study|Withdrawal by Subject|2
6197434|NCT01468207|9856902|FG000|Treatment Period 1|Protocol Violation|1
6197435|NCT01468207|9856903|FG001|Treatment Period 1|Protocol Violation|1
6197436|NCT01468207|9856904|FG002|Treatment Period 1|Protocol Violation|0
6197437|NCT01468207|9856905|FG003|Treatment Period 1|Protocol Violation|0
6197438|NCT01468207|9856906|FG004|Treatment Period 1|Protocol Violation|0
6197439|NCT01468207|9856907|FG005|Treatment Period 1|Protocol Violation|0
6197440|NCT01468207|9856902|FG000|Treatment Period 1|Withdrawal by Subject|5
6197441|NCT01468207|9856903|FG001|Treatment Period 1|Withdrawal by Subject|4
6197442|NCT01468207|9856904|FG002|Treatment Period 1|Withdrawal by Subject|0
6197443|NCT01468207|9856905|FG003|Treatment Period 1|Withdrawal by Subject|0
6197444|NCT01468207|9856906|FG004|Treatment Period 1|Withdrawal by Subject|0
6197445|NCT01468207|9856907|FG005|Treatment Period 1|Withdrawal by Subject|0
6197446|NCT01468207|9856902|FG000|Treatment Period 1|Lost to Follow-up|2
6197447|NCT01468207|9856903|FG001|Treatment Period 1|Lost to Follow-up|1
6197448|NCT01468207|9856904|FG002|Treatment Period 1|Lost to Follow-up|0
6197449|NCT01468207|9856905|FG003|Treatment Period 1|Lost to Follow-up|0
6197450|NCT01468207|9856906|FG004|Treatment Period 1|Lost to Follow-up|0
6197451|NCT01468207|9856907|FG005|Treatment Period 1|Lost to Follow-up|0
6197452|NCT01468207|9856902|FG000|Treatment Period 1|Other|0
6197453|NCT01468207|9856903|FG001|Treatment Period 1|Other|2
6275647|NCT02216071|9980568|FG000|Overall Study|Lost to Follow-up|3
6275648|NCT02216071|9980569|FG001|Overall Study|Lost to Follow-up|3
6275649|NCT02216071|9980568|FG000|Overall Study|Protocol Violation|3
6275650|NCT02216071|9980569|FG001|Overall Study|Protocol Violation|5
6275651|NCT02216071|9980568|FG000|Overall Study|Other|2
6275652|NCT02216071|9980569|FG001|Overall Study|Other|2
6275653|NCT02216123|9980586|FG000|Overall Study|Lost to Follow-up|4
6275654|NCT02216123|9980587|FG001|Overall Study|Lost to Follow-up|2
6275655|NCT02216123|9980586|FG000|Overall Study|Withdrawal by Subject|2
6275656|NCT02216123|9980587|FG001|Overall Study|Withdrawal by Subject|0
6275657|NCT02216214|9980612|FG000|Overall Study|Randomized Never Received Study Drug|1
6275658|NCT02216214|9980613|FG001|Overall Study|Randomized Never Received Study Drug|0
6275659|NCT02216214|9980612|FG000|Overall Study|Adverse Event|10
6275660|NCT02216214|9980613|FG001|Overall Study|Adverse Event|8
6275661|NCT02216214|9980612|FG000|Overall Study|Lack of Efficacy|2
6275662|NCT02216214|9980613|FG001|Overall Study|Lack of Efficacy|2
6275663|NCT02216214|9980612|FG000|Overall Study|Lost to Follow-up|3
5976998|NCT03016312|9563956|FG000|Overall Study|Lost to Follow-up|11
5976999|NCT03016312|9563957|FG001|Overall Study|Lost to Follow-up|12
5977000|NCT03016312|9563956|FG000|Overall Study|Started new therapy, loss of contact|2
5977001|NCT03016312|9563957|FG001|Overall Study|Started new therapy, loss of contact|1
5977002|NCT03016312|9563956|FG000|Overall Study|Physician Decision|0
5977003|NCT03016312|9563957|FG001|Overall Study|Physician Decision|2
5977004|NCT03016312|9563956|FG000|Overall Study|Withdrawal by Subject|34
5977005|NCT03016312|9563957|FG001|Overall Study|Withdrawal by Subject|39
5977006|NCT02722434|9563975|FG000|Overall Study|Withdrawal Prior to Beginning Treatment|1
6088606|NCT00676403|9699505|FG004|Overall Study|Withdrawal by Subject|0
6088607|NCT00676403|9699506|FG005|Overall Study|Withdrawal by Subject|1
6088608|NCT00676520|9699526|FG000|Overall Study|Withdrawal by Subject|163
6088609|NCT00676520|9699526|FG000|Overall Study|Lost to Follow-up|162
6088610|NCT00676520|9699526|FG000|Overall Study|Death|159
6088611|NCT00676520|9699526|FG000|Overall Study|Physician Decision|20
6088612|NCT00676520|9699526|FG000|Overall Study|Ineligible for Randomization to DAPT|209
5977007|NCT02722434|9563976|FG001|Overall Study|Withdrawal Prior to Beginning Treatment|0
5977008|NCT02722434|9563975|FG000|Overall Study|Withdrawal After Beginning Treatment|0
5977009|NCT02722434|9563976|FG001|Overall Study|Withdrawal After Beginning Treatment|3
6050775|NCT00428714|9649975|FG001|Overall Study|Death due to Progressive Disease (PD)|0
6050776|NCT00428714|9649974|FG000|Overall Study|Death due to other then PD|1
6050777|NCT00428714|9649975|FG001|Overall Study|Death due to other then PD|0
6050778|NCT00428792|9649984|FG000|Overall Study|Lack of Efficacy|1
6050779|NCT00428792|9649985|FG001|Overall Study|Lack of Efficacy|3
6050780|NCT00428792|9649984|FG000|Overall Study|Lost to Follow-up|0
6050781|NCT00428792|9649985|FG001|Overall Study|Lost to Follow-up|1
6050782|NCT00428844|9649994|FG000|Completed Study Drug Treatment|Adverse Event|2
6050783|NCT00428844|9649995|FG001|Completed Study Drug Treatment|Adverse Event|4
6050784|NCT00428844|9649996|FG002|Completed Study Drug Treatment|Adverse Event|4
6050785|NCT00428844|9649994|FG000|Completed Study Drug Treatment|Protocol Violation|0
6050786|NCT00428844|9649995|FG001|Completed Study Drug Treatment|Protocol Violation|1
6050787|NCT00428844|9649996|FG002|Completed Study Drug Treatment|Protocol Violation|1
6050788|NCT00428844|9649994|FG000|Completed Study Drug Treatment|Withdrawal by Subject|0
6088613|NCT00676520|9699526|FG000|Overall Study|Other Reason|18
6275664|NCT02216214|9980613|FG001|Overall Study|Lost to Follow-up|2
6275665|NCT02216214|9980612|FG000|Overall Study|Protocol Violation|4
6275666|NCT02216214|9980613|FG001|Overall Study|Protocol Violation|2
6275667|NCT02216214|9980612|FG000|Overall Study|Withdrawal by Subject|22
6275668|NCT02216214|9980613|FG001|Overall Study|Withdrawal by Subject|20
6275669|NCT02216214|9980612|FG000|Overall Study|Study Terminated By Sponsor|0
6275670|NCT02216214|9980613|FG001|Overall Study|Study Terminated By Sponsor|1
6050789|NCT00428844|9649995|FG001|Completed Study Drug Treatment|Withdrawal by Subject|1
6050790|NCT00428844|9649996|FG002|Completed Study Drug Treatment|Withdrawal by Subject|1
6088614|NCT00676650|9699555|FG000|Overall Study|Death|45
6197454|NCT01468207|9856904|FG002|Treatment Period 1|Other|0
6197455|NCT01468207|9856905|FG003|Treatment Period 1|Other|0
6197456|NCT01468207|9856906|FG004|Treatment Period 1|Other|0
6197457|NCT01468207|9856907|FG005|Treatment Period 1|Other|0
6197458|NCT01468207|9856902|FG000|Treatment Period 2|Adverse Event|0
6197459|NCT01468207|9856903|FG001|Treatment Period 2|Adverse Event|0
6197460|NCT01468207|9856904|FG002|Treatment Period 2|Adverse Event|6
6197461|NCT01468207|9856905|FG003|Treatment Period 2|Adverse Event|1
6197462|NCT01468207|9856906|FG004|Treatment Period 2|Adverse Event|2
6197463|NCT01468207|9856907|FG005|Treatment Period 2|Adverse Event|1
6197464|NCT01468207|9856902|FG000|Treatment Period 2|Lack of Efficacy|0
6197465|NCT01468207|9856903|FG001|Treatment Period 2|Lack of Efficacy|0
6197466|NCT01468207|9856904|FG002|Treatment Period 2|Lack of Efficacy|1
6197467|NCT01468207|9856905|FG003|Treatment Period 2|Lack of Efficacy|1
6197468|NCT01468207|9856906|FG004|Treatment Period 2|Lack of Efficacy|0
6197469|NCT01468207|9856907|FG005|Treatment Period 2|Lack of Efficacy|2
6275671|NCT02216214|9980612|FG000|Overall Study|Miscellaneous|1
6275672|NCT02216214|9980613|FG001|Overall Study|Miscellaneous|1
6275673|NCT02216357|9980621|FG000|Overall Study|Inclusion or exclusion criteria not met|2
6275674|NCT02216357|9980622|FG001|Overall Study|Inclusion or exclusion criteria not met|1
6275675|NCT02216526|9980635|FG000|Overall Study|Adverse Event|1
6275676|NCT02216526|9980636|FG001|Overall Study|Adverse Event|1
6275677|NCT02216526|9980637|FG002|Overall Study|Adverse Event|0
6275678|NCT02216526|9980635|FG000|Overall Study|Death|0
6275679|NCT02216526|9980636|FG001|Overall Study|Death|1
6275680|NCT02216526|9980637|FG002|Overall Study|Death|3
6275681|NCT02216526|9980635|FG000|Overall Study|Protocol Violation|2
6275682|NCT02216526|9980636|FG001|Overall Study|Protocol Violation|0
6275683|NCT02216526|9980637|FG002|Overall Study|Protocol Violation|2
6275684|NCT02216526|9980635|FG000|Overall Study|Hospitalization|2
6275685|NCT02216526|9980636|FG001|Overall Study|Hospitalization|1
6275686|NCT02216526|9980637|FG002|Overall Study|Hospitalization|3
6275687|NCT02216591|9980647|FG000|Overall Study|Lost to Follow-up|0
6275688|NCT02216591|9980648|FG001|Overall Study|Lost to Follow-up|1
6275689|NCT02216773|9980665|FG000|Overall Study|Disease progression|4
6275690|NCT02216773|9980666|FG001|Overall Study|Disease progression|2
6275691|NCT02216773|9980665|FG000|Overall Study|Insufficient FLRV|4
6275692|NCT02216773|9980666|FG001|Overall Study|Insufficient FLRV|0
6275693|NCT02216773|9980665|FG000|Overall Study|Abandoned|4
6275694|NCT02216773|9980666|FG001|Overall Study|Abandoned|3
6275695|NCT02216812|9980674|FG000|Overall Study|Lost to Follow-up|10
6275696|NCT02216812|9980675|FG001|Overall Study|Lost to Follow-up|5
6275697|NCT02217280|9980690|FG000|Overall Study|Withdrawal by Subject|2
6275698|NCT02217280|9980690|FG000|Overall Study|Post-consent sceen fail|2
6275699|NCT02217332|9980695|FG000|Overall Study|Adverse Event|3
6275700|NCT02217332|9980695|FG000|Overall Study|Dose interruption >1 month|1
6275701|NCT02217332|9980695|FG000|Overall Study|Protocol Violation (eligibility)|1
6275702|NCT02217332|9980695|FG000|Overall Study|Withdrawal by Subject|1
5977010|NCT02604511|9563986|FG000|Overall Study|Adverse Event|3
5977011|NCT02604511|9563986|FG000|Overall Study|Disease Progression|4
5977012|NCT02604511|9563986|FG000|Overall Study|Withdrawal by Subject|3
5977013|NCT02604511|9563986|FG000|Overall Study|Participant ineligible|1
5977014|NCT02604511|9563986|FG000|Overall Study|Intercurrent illness|1
5977015|NCT01963728|9564028|FG000|Overall Study|Study terminated early|0
5977016|NCT01963728|9564029|FG001|Overall Study|Study terminated early|1
5977017|NCT01248247|9564039|FG000|Overall Study|Adverse Event|2
5977018|NCT01248247|9564040|FG001|Overall Study|Adverse Event|4
5977019|NCT01248247|9564041|FG002|Overall Study|Adverse Event|4
5977020|NCT01248247|9564042|FG003|Overall Study|Adverse Event|2
5977021|NCT01248247|9564039|FG000|Overall Study|Death|0
6275703|NCT02217332|9980695|FG000|Overall Study|Lost to Follow-up|1
6275704|NCT02217410|9980702|FG000|Overall Study|Graft Loss|0
6275705|NCT02217410|9980703|FG001|Overall Study|Graft Loss|0
6275706|NCT02217410|9980704|FG002|Overall Study|Graft Loss|2
6275707|NCT02217410|9980702|FG000|Overall Study|Withdrawal by Subject|0
6275708|NCT02217410|9980703|FG001|Overall Study|Withdrawal by Subject|0
6275709|NCT02217410|9980704|FG002|Overall Study|Withdrawal by Subject|2
6275710|NCT02217410|9980702|FG000|Overall Study|Lost to Follow-up|0
6275711|NCT02217410|9980703|FG001|Overall Study|Lost to Follow-up|0
6275712|NCT02217410|9980704|FG002|Overall Study|Lost to Follow-up|1
6275713|NCT02217410|9980702|FG000|Overall Study|Lack of Efficacy|0
6275714|NCT02217410|9980703|FG001|Overall Study|Lack of Efficacy|1
6275715|NCT02217410|9980704|FG002|Overall Study|Lack of Efficacy|0
6275716|NCT02217410|9980702|FG000|Overall Study|Physician Decision|1
6275717|NCT02217410|9980703|FG001|Overall Study|Physician Decision|3
6275718|NCT02217410|9980704|FG002|Overall Study|Physician Decision|0
6275719|NCT02217436|9980719|FG000|Overall Study|Protocol Violation|1
6275720|NCT02217436|9980720|FG001|Overall Study|Protocol Violation|1
6275721|NCT02217436|9980719|FG000|Overall Study|Incomplete data|0
6275722|NCT02217436|9980720|FG001|Overall Study|Incomplete data|1
6275723|NCT02217475|9980729|FG000|Treatment Period 1 (Year 1)|Protocol Deviation (with non-compliance)|0
6275724|NCT02217475|9980730|FG001|Treatment Period 1 (Year 1)|Protocol Deviation (with non-compliance)|1
6275725|NCT02217475|9980731|FG002|Treatment Period 1 (Year 1)|Protocol Deviation (with non-compliance)|0
5977022|NCT01248247|9564040|FG001|Overall Study|Death|1
5977023|NCT01248247|9564041|FG002|Overall Study|Death|4
5977024|NCT01248247|9564042|FG003|Overall Study|Death|7
6197470|NCT01468207|9856902|FG000|Treatment Period 2|Withdrawal by Subject|0
6197471|NCT01468207|9856903|FG001|Treatment Period 2|Withdrawal by Subject|0
6197472|NCT01468207|9856904|FG002|Treatment Period 2|Withdrawal by Subject|5
6197473|NCT01468207|9856905|FG003|Treatment Period 2|Withdrawal by Subject|0
6197474|NCT01468207|9856906|FG004|Treatment Period 2|Withdrawal by Subject|0
6197475|NCT01468207|9856907|FG005|Treatment Period 2|Withdrawal by Subject|2
6197476|NCT01468207|9856902|FG000|Treatment Period 2|Loss/abscence of response (per protocol)|0
6197477|NCT01468207|9856903|FG001|Treatment Period 2|Loss/abscence of response (per protocol)|0
6197478|NCT01468207|9856904|FG002|Treatment Period 2|Loss/abscence of response (per protocol)|30
6197479|NCT01468207|9856905|FG003|Treatment Period 2|Loss/abscence of response (per protocol)|23
6197480|NCT01468207|9856906|FG004|Treatment Period 2|Loss/abscence of response (per protocol)|18
6197481|NCT01468207|9856907|FG005|Treatment Period 2|Loss/abscence of response (per protocol)|13
6197482|NCT01468207|9856902|FG000|Treatment Period 2|Lost to Follow-up|0
6197483|NCT01468207|9856903|FG001|Treatment Period 2|Lost to Follow-up|0
6197484|NCT01468207|9856904|FG002|Treatment Period 2|Lost to Follow-up|5
6197485|NCT01468207|9856905|FG003|Treatment Period 2|Lost to Follow-up|1
6197486|NCT01468207|9856906|FG004|Treatment Period 2|Lost to Follow-up|0
6197487|NCT01468207|9856907|FG005|Treatment Period 2|Lost to Follow-up|0
6197488|NCT01468207|9856902|FG000|Treatment Period 2|Other|0
6197489|NCT01468207|9856903|FG001|Treatment Period 2|Other|0
6197490|NCT01468207|9856904|FG002|Treatment Period 2|Other|5
6197491|NCT01468207|9856905|FG003|Treatment Period 2|Other|1
6197492|NCT01468207|9856906|FG004|Treatment Period 2|Other|1
6197493|NCT01468207|9856907|FG005|Treatment Period 2|Other|2
6197494|NCT01468233|9856927|FG000|Treatment Period 1|Adverse Event|5
6197495|NCT01468233|9856928|FG001|Treatment Period 1|Adverse Event|3
6197496|NCT01468233|9856929|FG002|Treatment Period 1|Adverse Event|0
6197497|NCT01468233|9856930|FG003|Treatment Period 1|Adverse Event|0
6197498|NCT01468233|9856931|FG004|Treatment Period 1|Adverse Event|0
6197499|NCT01468233|9856932|FG005|Treatment Period 1|Adverse Event|0
6197500|NCT01468233|9856927|FG000|Treatment Period 1|Withdrawal by Subject|3
6197501|NCT01468233|9856928|FG001|Treatment Period 1|Withdrawal by Subject|4
6197502|NCT01468233|9856929|FG002|Treatment Period 1|Withdrawal by Subject|0
6197503|NCT01468233|9856930|FG003|Treatment Period 1|Withdrawal by Subject|0
6197504|NCT01468233|9856931|FG004|Treatment Period 1|Withdrawal by Subject|0
6197505|NCT01468233|9856932|FG005|Treatment Period 1|Withdrawal by Subject|0
6197506|NCT01468233|9856927|FG000|Treatment Period 1|Lost to Follow-up|3
6197507|NCT01468233|9856928|FG001|Treatment Period 1|Lost to Follow-up|0
6197508|NCT01468233|9856929|FG002|Treatment Period 1|Lost to Follow-up|0
6197509|NCT01468233|9856930|FG003|Treatment Period 1|Lost to Follow-up|0
6197510|NCT01468233|9856931|FG004|Treatment Period 1|Lost to Follow-up|0
6197511|NCT01468233|9856932|FG005|Treatment Period 1|Lost to Follow-up|0
6197512|NCT01468233|9856927|FG000|Treatment Period 1|Other|1
6197513|NCT01468233|9856928|FG001|Treatment Period 1|Other|1
6197514|NCT01468233|9856929|FG002|Treatment Period 1|Other|0
6197515|NCT01468233|9856930|FG003|Treatment Period 1|Other|0
6197516|NCT01468233|9856931|FG004|Treatment Period 1|Other|0
6197517|NCT01468233|9856932|FG005|Treatment Period 1|Other|0
6197518|NCT01468233|9856927|FG000|Treatment Period 2|Adverse Event|0
6197519|NCT01468233|9856928|FG001|Treatment Period 2|Adverse Event|0
6197520|NCT01468233|9856929|FG002|Treatment Period 2|Adverse Event|3
6197521|NCT01468233|9856930|FG003|Treatment Period 2|Adverse Event|0
6197522|NCT01468233|9856931|FG004|Treatment Period 2|Adverse Event|2
6197523|NCT01468233|9856932|FG005|Treatment Period 2|Adverse Event|1
6197524|NCT01468233|9856927|FG000|Treatment Period 2|Lack of Efficacy|0
6197525|NCT01468233|9856928|FG001|Treatment Period 2|Lack of Efficacy|0
6197526|NCT01468233|9856929|FG002|Treatment Period 2|Lack of Efficacy|9
6197527|NCT01468233|9856930|FG003|Treatment Period 2|Lack of Efficacy|2
6197528|NCT01468233|9856931|FG004|Treatment Period 2|Lack of Efficacy|0
6275726|NCT02217475|9980729|FG000|Treatment Period 1 (Year 1)|Adverse Event|4
6275727|NCT02217475|9980730|FG001|Treatment Period 1 (Year 1)|Adverse Event|5
6275728|NCT02217475|9980731|FG002|Treatment Period 1 (Year 1)|Adverse Event|9
6275729|NCT02217475|9980729|FG000|Treatment Period 1 (Year 1)|Lost to Follow-up|1
6275730|NCT02217475|9980730|FG001|Treatment Period 1 (Year 1)|Lost to Follow-up|0
6275731|NCT02217475|9980731|FG002|Treatment Period 1 (Year 1)|Lost to Follow-up|0
6275732|NCT02217475|9980729|FG000|Treatment Period 1 (Year 1)|Subject Withdrew Consent|5
6275733|NCT02217475|9980730|FG001|Treatment Period 1 (Year 1)|Subject Withdrew Consent|2
6275734|NCT02217475|9980731|FG002|Treatment Period 1 (Year 1)|Subject Withdrew Consent|11
6197529|NCT01468233|9856932|FG005|Treatment Period 2|Lack of Efficacy|1
6197530|NCT01468233|9856927|FG000|Treatment Period 2|Withdrawal by Subject|0
6197531|NCT01468233|9856928|FG001|Treatment Period 2|Withdrawal by Subject|0
6197532|NCT01468233|9856929|FG002|Treatment Period 2|Withdrawal by Subject|9
6197533|NCT01468233|9856930|FG003|Treatment Period 2|Withdrawal by Subject|1
6197534|NCT01468233|9856931|FG004|Treatment Period 2|Withdrawal by Subject|1
6197535|NCT01468233|9856932|FG005|Treatment Period 2|Withdrawal by Subject|1
6197536|NCT01468233|9856927|FG000|Treatment Period 2|Loss/absence of response (per protocol)|0
6197537|NCT01468233|9856928|FG001|Treatment Period 2|Loss/absence of response (per protocol)|0
6197538|NCT01468233|9856929|FG002|Treatment Period 2|Loss/absence of response (per protocol)|84
6197539|NCT01468233|9856930|FG003|Treatment Period 2|Loss/absence of response (per protocol)|25
6197540|NCT01468233|9856931|FG004|Treatment Period 2|Loss/absence of response (per protocol)|22
6197541|NCT01468233|9856932|FG005|Treatment Period 2|Loss/absence of response (per protocol)|20
6197542|NCT01468233|9856927|FG000|Treatment Period 2|Lost to Follow-up|0
6197543|NCT01468233|9856928|FG001|Treatment Period 2|Lost to Follow-up|0
6197544|NCT01468233|9856929|FG002|Treatment Period 2|Lost to Follow-up|3
6197545|NCT01468233|9856930|FG003|Treatment Period 2|Lost to Follow-up|0
6197546|NCT01468233|9856931|FG004|Treatment Period 2|Lost to Follow-up|2
6197547|NCT01468233|9856932|FG005|Treatment Period 2|Lost to Follow-up|0
6197548|NCT01468233|9856927|FG000|Treatment Period 2|Other|0
6197549|NCT01468233|9856928|FG001|Treatment Period 2|Other|0
6197550|NCT01468233|9856929|FG002|Treatment Period 2|Other|3
6197551|NCT01468233|9856930|FG003|Treatment Period 2|Other|0
6197552|NCT01468233|9856931|FG004|Treatment Period 2|Other|1
6197553|NCT01468233|9856932|FG005|Treatment Period 2|Other|0
6197554|NCT01468311|9856950|FG000|Overall Study|mobilization failure|1
6197555|NCT01468311|9856950|FG000|Overall Study|Withdrawal by Subject|1
6197556|NCT01468454|9856975|FG000|Overall Study|Did not have surgery after PET|9
6197557|NCT01468597|9856996|FG000|Overall Study|Found ineligible|17
6197558|NCT01468597|9856996|FG000|Overall Study|concomitant valves|12
6197559|NCT01468597|9856996|FG000|Overall Study|off-pump CABG|1
6197560|NCT01468597|9856996|FG000|Overall Study|no platelet function data|5
6197561|NCT01468701|9857026|FG000|Overall Study|Not eligible|91
6197562|NCT01468701|9857027|FG001|Overall Study|Not eligible|140
6197563|NCT01468701|9857028|FG002|Overall Study|Not eligible|29
6197564|NCT01468701|9857029|FG003|Overall Study|Not eligible|12
6197565|NCT01468701|9857030|FG004|Overall Study|Not eligible|22
6197566|NCT01468701|9857031|FG005|Overall Study|Not eligible|2
6197567|NCT01468701|9857032|FG006|Overall Study|Not eligible|39
6197568|NCT01468701|9857033|FG007|Overall Study|Not eligible|1
6197569|NCT01468701|9857034|FG008|Overall Study|Not eligible|40
6197570|NCT01468701|9857035|FG009|Overall Study|Not eligible|126
6197571|NCT01468701|9857036|FG010|Overall Study|Not eligible|39
6197572|NCT01468701|9857037|FG011|Overall Study|Not eligible|33
6197573|NCT01468701|9857038|FG012|Overall Study|Not eligible|1
6197574|NCT01468701|9857039|FG013|Overall Study|Not eligible|19
6197575|NCT01468701|9857040|FG014|Overall Study|Not eligible|1
6197576|NCT01468701|9857041|FG015|Overall Study|Not eligible|32
6197577|NCT01468701|9857042|FG016|Overall Study|Not eligible|0
6088615|NCT00676650|9699556|FG001|Overall Study|Death|14
6197578|NCT01468701|9857026|FG000|Overall Study|Lost to Follow-up|306
6197579|NCT01468701|9857027|FG001|Overall Study|Lost to Follow-up|0
6197580|NCT01468701|9857028|FG002|Overall Study|Lost to Follow-up|0
6197581|NCT01468701|9857029|FG003|Overall Study|Lost to Follow-up|0
6197582|NCT01468701|9857030|FG004|Overall Study|Lost to Follow-up|0
6275735|NCT02217475|9980729|FG000|Treatment Period 1 (Year 1)|Other Miscellaneous Reasons|0
6275736|NCT02217475|9980730|FG001|Treatment Period 1 (Year 1)|Other Miscellaneous Reasons|0
6275737|NCT02217475|9980731|FG002|Treatment Period 1 (Year 1)|Other Miscellaneous Reasons|1
6275738|NCT02217475|9980729|FG000|Discontinued After Period 1|Adverse Event|1
6275739|NCT02217475|9980730|FG001|Discontinued After Period 1|Adverse Event|2
6275740|NCT02217475|9980731|FG002|Discontinued After Period 1|Adverse Event|0
6275741|NCT02217475|9980729|FG000|Discontinued After Period 1|Participant Withdrew Consent|1
6275742|NCT02217475|9980730|FG001|Discontinued After Period 1|Participant Withdrew Consent|1
6275743|NCT02217475|9980731|FG002|Discontinued After Period 1|Participant Withdrew Consent|2
6275744|NCT02217475|9980729|FG000|Discontinued After Period 1|Physician Decision|0
6275745|NCT02217475|9980730|FG001|Discontinued After Period 1|Physician Decision|0
6275746|NCT02217475|9980731|FG002|Discontinued After Period 1|Physician Decision|1
6275747|NCT02217475|9980729|FG000|Treatment Period 2 (Year 2)|Adverse Event|0
6275748|NCT02217475|9980730|FG001|Treatment Period 2 (Year 2)|Adverse Event|1
6275749|NCT02217475|9980731|FG002|Treatment Period 2 (Year 2)|Adverse Event|5
6275750|NCT02217475|9980729|FG000|Treatment Period 2 (Year 2)|Lost to Follow-up|0
6275751|NCT02217475|9980730|FG001|Treatment Period 2 (Year 2)|Lost to Follow-up|1
6275752|NCT02217475|9980731|FG002|Treatment Period 2 (Year 2)|Lost to Follow-up|2
6275753|NCT02217475|9980729|FG000|Treatment Period 2 (Year 2)|Subject Withdrew Consent|2
6275754|NCT02217475|9980730|FG001|Treatment Period 2 (Year 2)|Subject Withdrew Consent|0
5977025|NCT01248247|9564039|FG000|Overall Study|Lost to Follow-up|0
5977026|NCT01248247|9564040|FG001|Overall Study|Lost to Follow-up|1
5977027|NCT01248247|9564041|FG002|Overall Study|Lost to Follow-up|1
5977028|NCT01248247|9564042|FG003|Overall Study|Lost to Follow-up|0
5977029|NCT01248247|9564039|FG000|Overall Study|Alternative treatment|0
5977030|NCT01248247|9564040|FG001|Overall Study|Alternative treatment|1
5977031|NCT01248247|9564041|FG002|Overall Study|Alternative treatment|0
6197583|NCT01468701|9857031|FG005|Overall Study|Lost to Follow-up|0
6275755|NCT02217475|9980731|FG002|Treatment Period 2 (Year 2)|Subject Withdrew Consent|2
6275756|NCT02217475|9980729|FG000|Treatment Period 2 (Year 2)|Physician Decision|0
6197584|NCT01468701|9857032|FG006|Overall Study|Lost to Follow-up|0
6197585|NCT01468701|9857033|FG007|Overall Study|Lost to Follow-up|0
6197586|NCT01468701|9857034|FG008|Overall Study|Lost to Follow-up|215
6197587|NCT01468701|9857035|FG009|Overall Study|Lost to Follow-up|309
6197588|NCT01468701|9857036|FG010|Overall Study|Lost to Follow-up|224
6197589|NCT01468701|9857037|FG011|Overall Study|Lost to Follow-up|212
6197590|NCT01468701|9857038|FG012|Overall Study|Lost to Follow-up|11
5977032|NCT01248247|9564042|FG003|Overall Study|Alternative treatment|0
6197591|NCT01468701|9857039|FG013|Overall Study|Lost to Follow-up|164
6197592|NCT01468701|9857040|FG014|Overall Study|Lost to Follow-up|17
6197593|NCT01468701|9857041|FG015|Overall Study|Lost to Follow-up|127
6197594|NCT01468701|9857042|FG016|Overall Study|Lost to Follow-up|1
6197595|NCT01468701|9857026|FG000|Overall Study|Withdrawal by Subject|165
6197596|NCT01468701|9857027|FG001|Overall Study|Withdrawal by Subject|0
6197597|NCT01468701|9857028|FG002|Overall Study|Withdrawal by Subject|0
6197598|NCT01468701|9857029|FG003|Overall Study|Withdrawal by Subject|0
6197599|NCT01468701|9857030|FG004|Overall Study|Withdrawal by Subject|0
6197600|NCT01468701|9857031|FG005|Overall Study|Withdrawal by Subject|0
6197601|NCT01468701|9857032|FG006|Overall Study|Withdrawal by Subject|0
6197602|NCT01468701|9857033|FG007|Overall Study|Withdrawal by Subject|0
6197603|NCT01468701|9857034|FG008|Overall Study|Withdrawal by Subject|83
6197604|NCT01468701|9857035|FG009|Overall Study|Withdrawal by Subject|88
6197605|NCT01468701|9857036|FG010|Overall Study|Withdrawal by Subject|100
6197606|NCT01468701|9857037|FG011|Overall Study|Withdrawal by Subject|114
6197607|NCT01468701|9857038|FG012|Overall Study|Withdrawal by Subject|9
6197608|NCT01468701|9857039|FG013|Overall Study|Withdrawal by Subject|47
6197609|NCT01468701|9857040|FG014|Overall Study|Withdrawal by Subject|6
6197610|NCT01468701|9857041|FG015|Overall Study|Withdrawal by Subject|31
6197611|NCT01468701|9857042|FG016|Overall Study|Withdrawal by Subject|0
6197612|NCT01468701|9857026|FG000|Overall Study|Other reasons than listed|437
6197613|NCT01468701|9857027|FG001|Overall Study|Other reasons than listed|0
6197614|NCT01468701|9857028|FG002|Overall Study|Other reasons than listed|0
6197615|NCT01468701|9857029|FG003|Overall Study|Other reasons than listed|0
6197616|NCT01468701|9857030|FG004|Overall Study|Other reasons than listed|0
6197617|NCT01468701|9857031|FG005|Overall Study|Other reasons than listed|0
6197618|NCT01468701|9857032|FG006|Overall Study|Other reasons than listed|0
6197619|NCT01468701|9857033|FG007|Overall Study|Other reasons than listed|0
6197620|NCT01468701|9857034|FG008|Overall Study|Other reasons than listed|318
6197621|NCT01468701|9857035|FG009|Overall Study|Other reasons than listed|658
6197622|NCT01468701|9857036|FG010|Overall Study|Other reasons than listed|433
6197623|NCT01468701|9857037|FG011|Overall Study|Other reasons than listed|504
6197624|NCT01468701|9857038|FG012|Overall Study|Other reasons than listed|28
6197625|NCT01468701|9857039|FG013|Overall Study|Other reasons than listed|239
6197626|NCT01468701|9857040|FG014|Overall Study|Other reasons than listed|39
6197627|NCT01468701|9857041|FG015|Overall Study|Other reasons than listed|172
6197628|NCT01468701|9857042|FG016|Overall Study|Other reasons than listed|0
6197629|NCT01468701|9857026|FG000|Overall Study|No end of study case report form|0
6197630|NCT01468701|9857027|FG001|Overall Study|No end of study case report form|0
6197631|NCT01468701|9857028|FG002|Overall Study|No end of study case report form|0
6197632|NCT01468701|9857029|FG003|Overall Study|No end of study case report form|0
6197633|NCT01468701|9857030|FG004|Overall Study|No end of study case report form|0
6197634|NCT01468701|9857031|FG005|Overall Study|No end of study case report form|0
6197635|NCT01468701|9857032|FG006|Overall Study|No end of study case report form|0
6197636|NCT01468701|9857033|FG007|Overall Study|No end of study case report form|0
6197637|NCT01468701|9857034|FG008|Overall Study|No end of study case report form|4
6197638|NCT01468701|9857035|FG009|Overall Study|No end of study case report form|1
6197639|NCT01468701|9857036|FG010|Overall Study|No end of study case report form|2
6197640|NCT01468701|9857037|FG011|Overall Study|No end of study case report form|3
6197641|NCT01468701|9857038|FG012|Overall Study|No end of study case report form|0
6197642|NCT01468701|9857039|FG013|Overall Study|No end of study case report form|1
6197643|NCT01468701|9857040|FG014|Overall Study|No end of study case report form|0
6197644|NCT01468701|9857041|FG015|Overall Study|No end of study case report form|0
6197645|NCT01468701|9857042|FG016|Overall Study|No end of study case report form|0
6197646|NCT01468701|9857026|FG000|Overall Study|Not being followed up|0
6197647|NCT01468701|9857027|FG001|Overall Study|Not being followed up|4963
6197648|NCT01468701|9857028|FG002|Overall Study|Not being followed up|1755
6197649|NCT01468701|9857029|FG003|Overall Study|Not being followed up|703
6197650|NCT01468701|9857030|FG004|Overall Study|Not being followed up|1714
6197651|NCT01468701|9857031|FG005|Overall Study|Not being followed up|126
6197652|NCT01468701|9857032|FG006|Overall Study|Not being followed up|1170
6197653|NCT01468701|9857033|FG007|Overall Study|Not being followed up|4
6088616|NCT00676650|9699555|FG000|Overall Study|Adverse Event|159
6088617|NCT00676650|9699556|FG001|Overall Study|Adverse Event|21
6088618|NCT00676650|9699555|FG000|Overall Study|Global deterioration of health status|66
6088619|NCT00676650|9699556|FG001|Overall Study|Global deterioration of health status|31
6088620|NCT00676650|9699555|FG000|Overall Study|Lost to Follow-up|0
6197654|NCT01468701|9857034|FG008|Overall Study|Not being followed up|0
6197655|NCT01468701|9857035|FG009|Overall Study|Not being followed up|0
6197656|NCT01468701|9857036|FG010|Overall Study|Not being followed up|0
6197657|NCT01468701|9857037|FG011|Overall Study|Not being followed up|0
6197658|NCT01468701|9857038|FG012|Overall Study|Not being followed up|0
6197659|NCT01468701|9857039|FG013|Overall Study|Not being followed up|0
6275757|NCT02217475|9980730|FG001|Treatment Period 2 (Year 2)|Physician Decision|0
6275758|NCT02217475|9980731|FG002|Treatment Period 2 (Year 2)|Physician Decision|2
6197660|NCT01468701|9857040|FG014|Overall Study|Not being followed up|0
6197661|NCT01468701|9857041|FG015|Overall Study|Not being followed up|0
6197662|NCT01468701|9857042|FG016|Overall Study|Not being followed up|0
6275759|NCT02217475|9980729|FG000|Treatment Period 2 (Year 2)|Other Miscellaneous Reasons|0
6088621|NCT00676650|9699556|FG001|Overall Study|Lost to Follow-up|1
6197663|NCT01468818|9857055|FG000|Overall Study|Death during treatment|2
6197664|NCT01468844|9857061|FG000|Overall Study|Adverse Event|1
6197665|NCT01468844|9857062|FG001|Overall Study|Adverse Event|0
6050791|NCT00428844|9649994|FG000|Completed Study Drug Treatment|Randomized Not Treated|0
6050792|NCT00428844|9649995|FG001|Completed Study Drug Treatment|Randomized Not Treated|0
6050793|NCT00428844|9649996|FG002|Completed Study Drug Treatment|Randomized Not Treated|1
6050794|NCT00428844|9649994|FG000|Completed Test of Cure (TOC) Visit|Adverse Event|0
6050795|NCT00428844|9649995|FG001|Completed Test of Cure (TOC) Visit|Adverse Event|1
6050796|NCT00428844|9649996|FG002|Completed Test of Cure (TOC) Visit|Adverse Event|1
6088622|NCT00676650|9699555|FG000|Overall Study|Objective progression or relapse|189
6197666|NCT01468844|9857061|FG000|Overall Study|Withdrawal by Subject|1
6197667|NCT01468844|9857062|FG001|Overall Study|Withdrawal by Subject|0
6197668|NCT01468909|9857073|FG000|Overall Study|Never Treated|2
6197669|NCT01468909|9857074|FG001|Overall Study|Never Treated|2
6197670|NCT01468987|9857086|FG000|Overall Study|Adverse Event|12
6197671|NCT01468987|9857087|FG001|Overall Study|Adverse Event|9
6197672|NCT01468987|9857086|FG000|Overall Study|Death|4
6197673|NCT01468987|9857087|FG001|Overall Study|Death|1
6197674|NCT01468987|9857086|FG000|Overall Study|Lost to Follow-up|10
6197675|NCT01468987|9857087|FG001|Overall Study|Lost to Follow-up|5
6197676|NCT01468987|9857086|FG000|Overall Study|Protocol Violation|8
6197677|NCT01468987|9857087|FG001|Overall Study|Protocol Violation|2
6197678|NCT01468987|9857086|FG000|Overall Study|Withdrawal by Subject|28
6197679|NCT01468987|9857087|FG001|Overall Study|Withdrawal by Subject|28
6197680|NCT01468987|9857086|FG000|Overall Study|Physician Decision|8
6197681|NCT01468987|9857087|FG001|Overall Study|Physician Decision|15
6197682|NCT01468987|9857086|FG000|Overall Study|Sponsor Decision|1
6197683|NCT01468987|9857087|FG001|Overall Study|Sponsor Decision|0
6197684|NCT01469000|9857097|FG000|Overall Study|Withdrawal by Subject|16
6197685|NCT01469000|9857098|FG001|Overall Study|Withdrawal by Subject|3
6088623|NCT00676650|9699556|FG001|Overall Study|Objective progression or relapse|140
6088624|NCT00676650|9699555|FG000|Overall Study|Other|14
6088625|NCT00676650|9699556|FG001|Overall Study|Other|10
6088626|NCT00676650|9699555|FG000|Overall Study|Protocol Violation|3
6088627|NCT00676650|9699556|FG001|Overall Study|Protocol Violation|1
6088628|NCT00676650|9699555|FG000|Overall Study|Study terminated by sponsor|57
6088629|NCT00676650|9699556|FG001|Overall Study|Study terminated by sponsor|43
6088630|NCT00676650|9699555|FG000|Overall Study|Withdrawal by Subject|48
6088631|NCT00676650|9699556|FG001|Overall Study|Withdrawal by Subject|24
6088632|NCT00676650|9699555|FG000|Overall Study|Randomized but not treated|3
6088633|NCT00676650|9699556|FG001|Overall Study|Randomized but not treated|4
6088634|NCT00676689|9699566|FG000|Overall Study|Screen Failure|2
6088635|NCT00676689|9699566|FG000|Overall Study|Death|2
6088636|NCT00676689|9699566|FG000|Overall Study|Lost to Follow-up|4
6088637|NCT00676689|9699566|FG000|Overall Study|Physician Decision|1
6088638|NCT00676689|9699566|FG000|Overall Study|Withdrawal by Subject|3
6088639|NCT00676689|9699566|FG000|Overall Study|Continuing FU|49
6088640|NCT00677014|9699606|FG000|Overall Study|Lost to Follow-up|20
6088641|NCT00677014|9699607|FG001|Overall Study|Lost to Follow-up|12
6088642|NCT00677014|9699608|FG002|Overall Study|Lost to Follow-up|24
6088643|NCT00677014|9699606|FG000|Overall Study|Death|6
6088644|NCT00677014|9699607|FG001|Overall Study|Death|15
6088645|NCT00677014|9699608|FG002|Overall Study|Death|7
6088646|NCT00677014|9699606|FG000|Overall Study|Unavailable or unreadable 6 month LVESV|18
6088647|NCT00677014|9699607|FG001|Overall Study|Unavailable or unreadable 6 month LVESV|14
6088648|NCT00677014|9699608|FG002|Overall Study|Unavailable or unreadable 6 month LVESV|18
6088649|NCT00677092|9699621|FG000|Overall Study|Adverse Event|1
6197686|NCT01469000|9857097|FG000|Overall Study|Sponsor Decision|4
6197687|NCT01469000|9857098|FG001|Overall Study|Sponsor Decision|1
6197688|NCT01469013|9857109|FG000|Part A (Treatment Period)|Adverse Event|1
6197689|NCT01469013|9857110|FG001|Part A (Treatment Period)|Adverse Event|0
6197690|NCT01469013|9857111|FG002|Part A (Treatment Period)|Adverse Event|0
6275760|NCT02217475|9980730|FG001|Treatment Period 2 (Year 2)|Other Miscellaneous Reasons|0
6275761|NCT02217475|9980731|FG002|Treatment Period 2 (Year 2)|Other Miscellaneous Reasons|1
6275762|NCT02217501|9980750|FG000|Overall Study|Death|3
6275763|NCT02217501|9980751|FG001|Overall Study|Death|4
6275764|NCT02217527|9980759|FG000|Drug Condition 1: First Study Phase|Withdrawal by Subject|1
6275765|NCT02217527|9980760|FG001|Drug Condition 1: First Study Phase|Withdrawal by Subject|3
6275766|NCT02217527|9980759|FG000|Drug Condition 2: Second Study Phase|Withdrawal by Subject|0
6275767|NCT02217527|9980760|FG001|Drug Condition 2: Second Study Phase|Withdrawal by Subject|1
6197691|NCT01469013|9857112|FG003|Part A (Treatment Period)|Adverse Event|0
6197692|NCT01469013|9857113|FG004|Part A (Treatment Period)|Adverse Event|1
6197693|NCT01469013|9857114|FG005|Part A (Treatment Period)|Adverse Event|0
6197694|NCT01469013|9857115|FG006|Part A (Treatment Period)|Adverse Event|0
6088650|NCT00677092|9699621|FG000|Overall Study|Lost to Follow-up|1
6197695|NCT01469013|9857116|FG007|Part A (Treatment Period)|Adverse Event|0
6088651|NCT00677092|9699621|FG000|Overall Study|Withdrawal by Subject|3
6197696|NCT01469013|9857117|FG008|Part A (Treatment Period)|Adverse Event|0
6197697|NCT01469013|9857118|FG009|Part A (Treatment Period)|Adverse Event|0
6197698|NCT01469013|9857119|FG010|Part A (Treatment Period)|Adverse Event|0
6197699|NCT01469013|9857120|FG011|Part A (Treatment Period)|Adverse Event|0
6197700|NCT01469013|9857121|FG012|Part A (Treatment Period)|Adverse Event|0
6197701|NCT01469013|9857109|FG000|Part A (Treatment Period)|Withdrawal by Subject|0
6197702|NCT01469013|9857110|FG001|Part A (Treatment Period)|Withdrawal by Subject|0
6197703|NCT01469013|9857111|FG002|Part A (Treatment Period)|Withdrawal by Subject|1
6197704|NCT01469013|9857112|FG003|Part A (Treatment Period)|Withdrawal by Subject|0
6197705|NCT01469013|9857113|FG004|Part A (Treatment Period)|Withdrawal by Subject|0
6197706|NCT01469013|9857114|FG005|Part A (Treatment Period)|Withdrawal by Subject|0
6197707|NCT01469013|9857115|FG006|Part A (Treatment Period)|Withdrawal by Subject|0
6197708|NCT01469013|9857116|FG007|Part A (Treatment Period)|Withdrawal by Subject|0
6197709|NCT01469013|9857117|FG008|Part A (Treatment Period)|Withdrawal by Subject|0
6197710|NCT01469013|9857118|FG009|Part A (Treatment Period)|Withdrawal by Subject|0
6197711|NCT01469013|9857119|FG010|Part A (Treatment Period)|Withdrawal by Subject|0
6197712|NCT01469013|9857120|FG011|Part A (Treatment Period)|Withdrawal by Subject|0
6197713|NCT01469013|9857121|FG012|Part A (Treatment Period)|Withdrawal by Subject|0
6197714|NCT01469013|9857109|FG000|Part B (Extension Period)|Adverse Event|0
6197715|NCT01469013|9857110|FG001|Part B (Extension Period)|Adverse Event|0
6197716|NCT01469013|9857111|FG002|Part B (Extension Period)|Adverse Event|0
6197717|NCT01469013|9857112|FG003|Part B (Extension Period)|Adverse Event|0
6197718|NCT01469013|9857113|FG004|Part B (Extension Period)|Adverse Event|0
6197719|NCT01469013|9857114|FG005|Part B (Extension Period)|Adverse Event|2
6197720|NCT01469013|9857115|FG006|Part B (Extension Period)|Adverse Event|5
6197721|NCT01469013|9857116|FG007|Part B (Extension Period)|Adverse Event|5
6197722|NCT01469013|9857117|FG008|Part B (Extension Period)|Adverse Event|3
6197723|NCT01469013|9857118|FG009|Part B (Extension Period)|Adverse Event|3
6197724|NCT01469013|9857119|FG010|Part B (Extension Period)|Adverse Event|1
6197725|NCT01469013|9857120|FG011|Part B (Extension Period)|Adverse Event|6
6197726|NCT01469013|9857121|FG012|Part B (Extension Period)|Adverse Event|3
6197727|NCT01469013|9857109|FG000|Part B (Extension Period)|Withdrawal by Subject|0
6197728|NCT01469013|9857110|FG001|Part B (Extension Period)|Withdrawal by Subject|0
6197729|NCT01469013|9857111|FG002|Part B (Extension Period)|Withdrawal by Subject|0
6197730|NCT01469013|9857112|FG003|Part B (Extension Period)|Withdrawal by Subject|0
6197731|NCT01469013|9857113|FG004|Part B (Extension Period)|Withdrawal by Subject|0
6197732|NCT01469013|9857114|FG005|Part B (Extension Period)|Withdrawal by Subject|0
6197733|NCT01469013|9857115|FG006|Part B (Extension Period)|Withdrawal by Subject|0
6197734|NCT01469013|9857116|FG007|Part B (Extension Period)|Withdrawal by Subject|0
6197735|NCT01469013|9857117|FG008|Part B (Extension Period)|Withdrawal by Subject|1
6197736|NCT01469013|9857118|FG009|Part B (Extension Period)|Withdrawal by Subject|0
6197737|NCT01469013|9857119|FG010|Part B (Extension Period)|Withdrawal by Subject|1
6197738|NCT01469013|9857120|FG011|Part B (Extension Period)|Withdrawal by Subject|0
6197739|NCT01469013|9857121|FG012|Part B (Extension Period)|Withdrawal by Subject|3
6197740|NCT01469052|9857167|FG000|Overall Study|Adverse Event|2
6197741|NCT01469052|9857168|FG001|Overall Study|Adverse Event|3
6197742|NCT01469052|9857169|FG002|Overall Study|Adverse Event|0
6197743|NCT01469052|9857170|FG003|Overall Study|Adverse Event|2
6197744|NCT01469052|9857171|FG004|Overall Study|Adverse Event|0
6197745|NCT01469052|9857172|FG005|Overall Study|Adverse Event|1
6197746|NCT01469052|9857167|FG000|Overall Study|Progressive disease|3
6197747|NCT01469052|9857168|FG001|Overall Study|Progressive disease|0
6197748|NCT01469052|9857169|FG002|Overall Study|Progressive disease|5
6197749|NCT01469052|9857170|FG003|Overall Study|Progressive disease|3
6197750|NCT01469052|9857171|FG004|Overall Study|Progressive disease|7
6197751|NCT01469052|9857172|FG005|Overall Study|Progressive disease|2
6197752|NCT01469052|9857167|FG000|Overall Study|Lack of Efficacy|0
6197753|NCT01469052|9857168|FG001|Overall Study|Lack of Efficacy|0
6197754|NCT01469052|9857169|FG002|Overall Study|Lack of Efficacy|0
6197755|NCT01469052|9857170|FG003|Overall Study|Lack of Efficacy|0
6197756|NCT01469052|9857171|FG004|Overall Study|Lack of Efficacy|0
6197757|NCT01469052|9857172|FG005|Overall Study|Lack of Efficacy|2
6197758|NCT01469052|9857167|FG000|Overall Study|Moved to rollover protocol|1
6197759|NCT01469052|9857168|FG001|Overall Study|Moved to rollover protocol|0
6197760|NCT01469052|9857169|FG002|Overall Study|Moved to rollover protocol|1
6197761|NCT01469052|9857170|FG003|Overall Study|Moved to rollover protocol|0
6088652|NCT00677092|9699621|FG000|Overall Study|Death Prior to Receiving Treatment|1
6088653|NCT00677235|9699628|FG000|Overall Study|Withdrawal by Subject|1
6088654|NCT00677235|9699629|FG001|Overall Study|Withdrawal by Subject|1
6088655|NCT00677235|9699628|FG000|Overall Study|Lost to Follow-up|2
6197762|NCT01469052|9857171|FG004|Overall Study|Moved to rollover protocol|0
6197763|NCT01469052|9857172|FG005|Overall Study|Moved to rollover protocol|1
6197764|NCT01469052|9857167|FG000|Overall Study|Other|0
6197765|NCT01469052|9857168|FG001|Overall Study|Other|1
6197766|NCT01469052|9857169|FG002|Overall Study|Other|0
6197767|NCT01469052|9857170|FG003|Overall Study|Other|0
6197768|NCT01469052|9857171|FG004|Overall Study|Other|1
6197769|NCT01469052|9857172|FG005|Overall Study|Other|0
6275768|NCT02217566|9980766|FG000|Overall Study|Lost to Follow-up|2
6275769|NCT02217566|9980766|FG000|Overall Study|Death|3
6275770|NCT02217566|9980766|FG000|Overall Study|Early study termination|6
6275771|NCT02217878|9980788|FG000|Overall Study|required morphine due to chest pain|1
6275772|NCT02217878|9980789|FG001|Overall Study|required morphine due to chest pain|2
6275773|NCT02217878|9980788|FG000|Overall Study|initial diagnosis of STEMI not confirmed|1
6275774|NCT02217878|9980789|FG001|Overall Study|initial diagnosis of STEMI not confirmed|0
6088656|NCT00677235|9699629|FG001|Overall Study|Lost to Follow-up|1
6197770|NCT01469065|9857189|FG000|Overall Study|Lack of Efficacy|0
6197771|NCT01469065|9857190|FG001|Overall Study|Lack of Efficacy|0
6197772|NCT01469065|9857191|FG002|Overall Study|Lack of Efficacy|0
6197773|NCT01469065|9857192|FG003|Overall Study|Lack of Efficacy|0
6197774|NCT01469065|9857193|FG004|Overall Study|Lack of Efficacy|1
6197775|NCT01469065|9857189|FG000|Overall Study|Other|0
6197776|NCT01469065|9857190|FG001|Overall Study|Other|1
6197777|NCT01469065|9857191|FG002|Overall Study|Other|0
6197778|NCT01469065|9857192|FG003|Overall Study|Other|0
6197779|NCT01469065|9857193|FG004|Overall Study|Other|0
6197780|NCT01469182|9857211|FG000|Overall Study|Adverse Event|21
6197781|NCT01469182|9857212|FG001|Overall Study|Adverse Event|3
6197782|NCT01469182|9857211|FG000|Overall Study|Lost to Follow-up|3
6197783|NCT01469182|9857212|FG001|Overall Study|Lost to Follow-up|0
6197784|NCT01469182|9857211|FG000|Overall Study|Withdrawal by Subject|4
6197785|NCT01469182|9857212|FG001|Overall Study|Withdrawal by Subject|1
6197786|NCT01469182|9857211|FG000|Overall Study|Protocol Violation|4
6197787|NCT01469182|9857212|FG001|Overall Study|Protocol Violation|2
6197788|NCT01469182|9857211|FG000|Overall Study|Did not meet Protocol Eligibility|3
6197789|NCT01469182|9857212|FG001|Overall Study|Did not meet Protocol Eligibility|0
6197790|NCT01469221|9857220|FG000|Double Blind Phase|Protocol Violation|1
6197791|NCT01469221|9857221|FG001|Double Blind Phase|Protocol Violation|0
6197792|NCT01469221|9857222|FG002|Double Blind Phase|Protocol Violation|0
6197793|NCT01469221|9857220|FG000|Double Blind Phase|Physician Decision|1
6197794|NCT01469221|9857221|FG001|Double Blind Phase|Physician Decision|1
6197795|NCT01469221|9857222|FG002|Double Blind Phase|Physician Decision|0
6197796|NCT01469221|9857220|FG000|Double Blind Phase|Sponsor Terminate Study|12
6197797|NCT01469221|9857221|FG001|Double Blind Phase|Sponsor Terminate Study|16
6197798|NCT01469221|9857222|FG002|Double Blind Phase|Sponsor Terminate Study|0
6197799|NCT01469364|9857242|FG000|Overall Study|Adverse Event|1
6197800|NCT01469364|9857242|FG000|Overall Study|Withdrawal by Subject|1
6197801|NCT01469377|9857249|FG000|Overall Study|Protocol Deviation|7
6197802|NCT01469377|9857250|FG001|Overall Study|Protocol Deviation|10
6197803|NCT01469377|9857251|FG002|Overall Study|Protocol Deviation|10
6197804|NCT01469377|9857249|FG000|Overall Study|Lost to Follow-up|3
6197805|NCT01469377|9857250|FG001|Overall Study|Lost to Follow-up|2
6197806|NCT01469377|9857251|FG002|Overall Study|Lost to Follow-up|5
6197807|NCT01469377|9857249|FG000|Overall Study|Withdrawal of Consent|12
6197808|NCT01469377|9857250|FG001|Overall Study|Withdrawal of Consent|14
6197809|NCT01469377|9857251|FG002|Overall Study|Withdrawal of Consent|15
6197810|NCT01469377|9857249|FG000|Overall Study|Adverse Event|8
6197811|NCT01469377|9857250|FG001|Overall Study|Adverse Event|18
6197812|NCT01469377|9857251|FG002|Overall Study|Adverse Event|36
6197813|NCT01469377|9857249|FG000|Overall Study|Insufficient Therapeutic Response|3
6197814|NCT01469377|9857250|FG001|Overall Study|Insufficient Therapeutic Response|4
6197815|NCT01469377|9857251|FG002|Overall Study|Insufficient Therapeutic Response|0
6197816|NCT01469377|9857249|FG000|Overall Study|Other Miscellaneous Reasons|2
6197817|NCT01469377|9857250|FG001|Overall Study|Other Miscellaneous Reasons|0
6197818|NCT01469377|9857251|FG002|Overall Study|Other Miscellaneous Reasons|0
6197819|NCT01469546|9857259|FG000|Received 5 mg Dose|Adverse Event|13
6197820|NCT01469546|9857259|FG000|Received 5 mg Dose|Death|2
6197821|NCT01469546|9857259|FG000|Received 5 mg Dose|Protocol Violation|2
6197822|NCT01469546|9857259|FG000|Received 5 mg Dose|Progressive Disease|3
6197823|NCT01469546|9857259|FG000|Received 5 mg Dose|Physician Decision|3
6197824|NCT01469637|9857276|FG000|First Intervention|Unacceptable behavior|0
6197825|NCT01469637|9857277|FG001|First Intervention|Unacceptable behavior|1
6197826|NCT01469637|9857276|FG000|Second Intervention|Incarcerated|1
6197827|NCT01469637|9857277|FG001|Second Intervention|Incarcerated|0
6197828|NCT01469819|9857291|FG000|Overall Study|Withdrawal by Subject|1
6197829|NCT01469819|9857291|FG000|Overall Study|Did not meet inclusionary criteria|2
6197830|NCT01469819|9857291|FG000|Overall Study|Could not swallow SmartPill|2
6197831|NCT01469819|9857291|FG000|Overall Study|Technical malfunction of SmartPill data|3
6197832|NCT01470001|9857303|FG000|Overall Study|Lost to Follow-up|1
6197833|NCT01470001|9857304|FG001|Overall Study|Lost to Follow-up|1
6197834|NCT01470001|9857303|FG000|Overall Study|Physician Decision|2
6197835|NCT01470001|9857304|FG001|Overall Study|Physician Decision|0
6197836|NCT01470001|9857303|FG000|Overall Study|Withdrawal by Subject|2
6197837|NCT01470001|9857304|FG001|Overall Study|Withdrawal by Subject|1
6197838|NCT01470144|9857345|FG000|Overall Study|Adverse Event|2
6197839|NCT01470144|9857345|FG000|Overall Study|Death|1
6197840|NCT01470144|9857345|FG000|Overall Study|Lung transplant|6
6197841|NCT01470144|9857345|FG000|Overall Study|Patient's and investigator's decision|1
6197842|NCT01470248|9857374|FG000|Overall Study|Withdrawal by Subject|1
6197843|NCT01470417|9857380|FG000|Overall Study|Disease progression|0
6197844|NCT01470417|9857381|FG001|Overall Study|Disease progression|2
6197845|NCT01470469|9857389|FG000|Overall Study|Withdrawal by Subject|4
6197846|NCT01470469|9857390|FG001|Overall Study|Withdrawal by Subject|6
6197847|NCT01470469|9857389|FG000|Overall Study|Lack of Efficacy|1
6197848|NCT01470469|9857390|FG001|Overall Study|Lack of Efficacy|7
6197849|NCT01470469|9857389|FG000|Overall Study|Adverse Event|0
6197850|NCT01470469|9857390|FG001|Overall Study|Adverse Event|7
6197851|NCT01470469|9857389|FG000|Overall Study|Lost to Follow-up|2
6197852|NCT01470469|9857390|FG001|Overall Study|Lost to Follow-up|2
6197853|NCT01470469|9857389|FG000|Overall Study|Protocol Violation|1
6197854|NCT01470469|9857390|FG001|Overall Study|Protocol Violation|1
6197855|NCT01470469|9857389|FG000|Overall Study|Other|2
6197856|NCT01470469|9857390|FG001|Overall Study|Other|1
6197857|NCT01470599|9857398|FG000|Overall Study|Did not meet entrance criteria|1
6197858|NCT01470599|9857399|FG001|Overall Study|Did not meet entrance criteria|0
6197859|NCT01470599|9857398|FG000|Overall Study|Lost to Follow-up|2
6197860|NCT01470599|9857399|FG001|Overall Study|Lost to Follow-up|1
6197861|NCT01470599|9857398|FG000|Overall Study|Withdrawal by Subject|3
6197862|NCT01470599|9857399|FG001|Overall Study|Withdrawal by Subject|4
6197863|NCT01470599|9857398|FG000|Overall Study|Other|1
6197864|NCT01470599|9857399|FG001|Overall Study|Other|0
6197865|NCT01470599|9857398|FG000|Overall Study|Protocol Violation|3
6197866|NCT01470599|9857399|FG001|Overall Study|Protocol Violation|1
6197867|NCT01470599|9857398|FG000|Overall Study|Adverse event related to study drug|2
6197868|NCT01470599|9857399|FG001|Overall Study|Adverse event related to study drug|5
6197869|NCT01470599|9857398|FG000|Overall Study|Insufficient clinical response|6
6197870|NCT01470599|9857399|FG001|Overall Study|Insufficient clinical response|27
6197871|NCT01470599|9857398|FG000|Overall Study|Adverse event not related to study drug|1
6197872|NCT01470599|9857399|FG001|Overall Study|Adverse event not related to study drug|5
6197873|NCT01470612|9857407|FG000|Overall Study|Adverse Event|20
6197874|NCT01470612|9857408|FG001|Overall Study|Adverse Event|80
6197875|NCT01470612|9857407|FG000|Overall Study|Death|0
6197876|NCT01470612|9857408|FG001|Overall Study|Death|1
6197877|NCT01470612|9857407|FG000|Overall Study|Lack of Efficacy|20
6197878|NCT01470612|9857408|FG001|Overall Study|Lack of Efficacy|326
6197879|NCT01470612|9857407|FG000|Overall Study|Lost to Follow-up|2
6197880|NCT01470612|9857408|FG001|Overall Study|Lost to Follow-up|5
6197881|NCT01470612|9857407|FG000|Overall Study|Did not meet entrance criteria|0
6197882|NCT01470612|9857408|FG001|Overall Study|Did not meet entrance criteria|1
6197883|NCT01470612|9857407|FG000|Overall Study|Pregnancy|2
6197884|NCT01470612|9857408|FG001|Overall Study|Pregnancy|10
6197885|NCT01470612|9857407|FG000|Overall Study|Protocol Violation|2
6197886|NCT01470612|9857408|FG001|Overall Study|Protocol Violation|7
6197887|NCT01470612|9857407|FG000|Overall Study|Withdrawal by Subject|24
6197888|NCT01470612|9857408|FG001|Overall Study|Withdrawal by Subject|79
6197889|NCT01470612|9857407|FG000|Overall Study|Other|14
6197890|NCT01470612|9857408|FG001|Overall Study|Other|156
6197891|NCT01470989|9857444|FG000|Overall Study|Participants did not entered extension studies 1, 2 and 3|103
6197892|NCT01470989|9857445|FG001|Overall Study|Participants did not entered extension studies 1, 2 and 3|136
6197893|NCT01470989|9857444|FG000|Overall Study|Adverse Event|2
6197894|NCT01470989|9857445|FG001|Overall Study|Adverse Event|5
6197895|NCT01470989|9857444|FG000|Overall Study|Abnormal laboratory value|1
6197896|NCT01470989|9857445|FG001|Overall Study|Abnormal laboratory value|1
6197897|NCT01470989|9857444|FG000|Overall Study|Unsatisfactory therapeutic effect|0
6197898|NCT01470989|9857445|FG001|Overall Study|Unsatisfactory therapeutic effect|6
6197899|NCT01470989|9857444|FG000|Overall Study|Withdrawal by Subject|19
6197900|NCT01470989|9857445|FG001|Overall Study|Withdrawal by Subject|17
6197901|NCT01470989|9857444|FG000|Overall Study|Lost to Follow-up|18
6197902|NCT01470989|9857445|FG001|Overall Study|Lost to Follow-up|13
6197903|NCT01470989|9857444|FG000|Overall Study|Administrative problems|2
6197904|NCT01470989|9857445|FG001|Overall Study|Administrative problems|4
6197905|NCT01470989|9857444|FG000|Overall Study|Death|2
6197906|NCT01470989|9857445|FG001|Overall Study|Death|2
6197907|NCT01470989|9857444|FG000|Overall Study|Protocol deviation|1
6197908|NCT01470989|9857445|FG001|Overall Study|Protocol deviation|2
6197909|NCT01471015|9857456|FG000|Overall Study|Death|0
6197910|NCT01471015|9857457|FG001|Overall Study|Death|1
6197911|NCT01471015|9857458|FG002|Overall Study|Death|1
6197912|NCT01471028|9857468|FG000|VTI-208|Adverse Event|39
6197913|NCT01471028|9857469|FG001|VTI-208|Adverse Event|41
6197914|NCT01471028|9857468|FG000|VTI-208|Withdrawal by Subject|0
6197915|NCT01471028|9857469|FG001|VTI-208|Withdrawal by Subject|2
6197916|NCT01471028|9857468|FG000|VTI-208|Lost to Follow-up|1
6197917|NCT01471028|9857469|FG001|VTI-208|Lost to Follow-up|1
6197918|NCT01471028|9857468|FG000|VTI-208E|Death|7
6197919|NCT01471028|9857469|FG001|VTI-208E|Death|10
6197920|NCT01471028|9857468|FG000|VTI-208E|Withdrawal by Subject|1
6197921|NCT01471028|9857469|FG001|VTI-208E|Withdrawal by Subject|0
6197922|NCT01471028|9857468|FG000|VTI-208E|Lost to Follow-up|0
6197923|NCT01471028|9857469|FG001|VTI-208E|Lost to Follow-up|2
6197924|NCT01471054|9857484|FG000|Overall Study|Study terminated prematurely|4
6197925|NCT01471054|9857485|FG001|Overall Study|Study terminated prematurely|0
6197926|NCT01471093|9857503|FG000|Overall Study|Adverse Event|1
6197927|NCT01471093|9857504|FG001|Overall Study|Adverse Event|0
6197928|NCT01471093|9857505|FG002|Overall Study|Adverse Event|0
6197929|NCT01471093|9857506|FG003|Overall Study|Adverse Event|0
6197930|NCT01471171|9857512|FG000|Treatment Period 1|Adverse Event|4
6197931|NCT01471171|9857513|FG001|Treatment Period 1|Adverse Event|1
6197932|NCT01471171|9857512|FG000|Treatment Period 2|Adverse Event|1
6197933|NCT01471171|9857513|FG001|Treatment Period 2|Adverse Event|0
6197934|NCT01471197|9857521|FG000|Overall Study|Disease Progression|4
6197935|NCT01471197|9857522|FG001|Overall Study|Disease Progression|2
6197936|NCT01471197|9857521|FG000|Overall Study|Death|1
6197937|NCT01471197|9857522|FG001|Overall Study|Death|0
6197938|NCT01471197|9857521|FG000|Overall Study|Study Drug Toxicity|1
6197939|NCT01471197|9857522|FG001|Overall Study|Study Drug Toxicity|0
6197940|NCT01471353|9857528|FG000|Overall Study|remain on study|3
6197941|NCT01471379|9857535|FG000|Overall Study|Adverse Event|1
6197942|NCT01471379|9857536|FG001|Overall Study|Adverse Event|0
6197943|NCT01471379|9857537|FG002|Overall Study|Adverse Event|0
6197944|NCT01471379|9857535|FG000|Overall Study|Study terminated|0
6197945|NCT01471379|9857536|FG001|Overall Study|Study terminated|1
6197946|NCT01471379|9857537|FG002|Overall Study|Study terminated|0
6197947|NCT01471522|9857557|FG000|Overall Study|Withdrawal by Subject|28
6197948|NCT01471522|9857558|FG001|Overall Study|Withdrawal by Subject|22
6197949|NCT01471522|9857557|FG000|Overall Study|Lost to Follow-up|36
6197950|NCT01471522|9857558|FG001|Overall Study|Lost to Follow-up|26
6197951|NCT01471574|9857569|FG000|Treatment Period|Lack of Efficacy|12
6197952|NCT01471574|9857570|FG001|Treatment Period|Lack of Efficacy|4
6197953|NCT01471574|9857571|FG002|Treatment Period|Lack of Efficacy|14
6197954|NCT01471574|9857572|FG003|Treatment Period|Lack of Efficacy|1
6197955|NCT01471574|9857569|FG000|Treatment Period|Adverse Event|7
6197956|NCT01471574|9857570|FG001|Treatment Period|Adverse Event|3
6197957|NCT01471574|9857571|FG002|Treatment Period|Adverse Event|6
6197958|NCT01471574|9857572|FG003|Treatment Period|Adverse Event|1
6197959|NCT01471574|9857569|FG000|Treatment Period|Withdrawal by Subject|5
6197960|NCT01471574|9857570|FG001|Treatment Period|Withdrawal by Subject|1
6197961|NCT01471574|9857571|FG002|Treatment Period|Withdrawal by Subject|1
6197962|NCT01471574|9857572|FG003|Treatment Period|Withdrawal by Subject|0
6197963|NCT01471574|9857569|FG000|Treatment Period|Patient Requested Discontinue Study drug|4
6197964|NCT01471574|9857570|FG001|Treatment Period|Patient Requested Discontinue Study drug|0
6197965|NCT01471574|9857571|FG002|Treatment Period|Patient Requested Discontinue Study drug|1
6197966|NCT01471574|9857572|FG003|Treatment Period|Patient Requested Discontinue Study drug|1
6197967|NCT01471574|9857569|FG000|Treatment Period|Lost to Follow-up|1
6197968|NCT01471574|9857570|FG001|Treatment Period|Lost to Follow-up|2
6197969|NCT01471574|9857571|FG002|Treatment Period|Lost to Follow-up|2
6197970|NCT01471574|9857572|FG003|Treatment Period|Lost to Follow-up|0
6197971|NCT01471574|9857569|FG000|Treatment Period|Patient no Longer Meets Study Criteria|1
6197972|NCT01471574|9857570|FG001|Treatment Period|Patient no Longer Meets Study Criteria|0
6197973|NCT01471574|9857571|FG002|Treatment Period|Patient no Longer Meets Study Criteria|0
6197974|NCT01471574|9857572|FG003|Treatment Period|Patient no Longer Meets Study Criteria|0
6197975|NCT01471574|9857569|FG000|Treatment Period|Other|1
6197976|NCT01471574|9857570|FG001|Treatment Period|Other|0
6197977|NCT01471574|9857571|FG002|Treatment Period|Other|0
6197978|NCT01471574|9857572|FG003|Treatment Period|Other|0
6197979|NCT01471574|9857569|FG000|Follow-up Period|Withdrawal by Subject|3
6197980|NCT01471574|9857570|FG001|Follow-up Period|Withdrawal by Subject|0
6197981|NCT01471574|9857571|FG002|Follow-up Period|Withdrawal by Subject|3
6197982|NCT01471574|9857572|FG003|Follow-up Period|Withdrawal by Subject|1
6197983|NCT01471574|9857569|FG000|Follow-up Period|Lost to Follow-up|4
6197984|NCT01471574|9857570|FG001|Follow-up Period|Lost to Follow-up|1
6197985|NCT01471574|9857571|FG002|Follow-up Period|Lost to Follow-up|3
6197986|NCT01471574|9857572|FG003|Follow-up Period|Lost to Follow-up|2
6197987|NCT01471574|9857569|FG000|Follow-up Period|Death|0
6197988|NCT01471574|9857570|FG001|Follow-up Period|Death|0
6197989|NCT01471574|9857571|FG002|Follow-up Period|Death|1
6197990|NCT01471574|9857572|FG003|Follow-up Period|Death|0
6197991|NCT01471574|9857569|FG000|Follow-up Period|Follow-up no longer required|0
6197992|NCT01471574|9857570|FG001|Follow-up Period|Follow-up no longer required|1
6197993|NCT01471574|9857571|FG002|Follow-up Period|Follow-up no longer required|0
6197994|NCT01471574|9857572|FG003|Follow-up Period|Follow-up no longer required|0
6197995|NCT01471691|9857598|FG000|Overall Study|Lack of Efficacy|0
6197996|NCT01471691|9857599|FG001|Overall Study|Lack of Efficacy|1
6197997|NCT01471782|9857611|FG000|Overall Study|Hematopoietic Stem Cell Transplantation|2
6197998|NCT01471782|9857612|FG001|Overall Study|Hematopoietic Stem Cell Transplantation|2
6197999|NCT01471782|9857613|FG002|Overall Study|Hematopoietic Stem Cell Transplantation|1
6198000|NCT01471782|9857614|FG003|Overall Study|Hematopoietic Stem Cell Transplantation|0
6198001|NCT01471782|9857615|FG004|Overall Study|Hematopoietic Stem Cell Transplantation|5
6198002|NCT01471782|9857616|FG005|Overall Study|Hematopoietic Stem Cell Transplantation|3
6198003|NCT01471782|9857611|FG000|Overall Study|Lack of Efficacy|1
6198004|NCT01471782|9857612|FG001|Overall Study|Lack of Efficacy|2
6198005|NCT01471782|9857613|FG002|Overall Study|Lack of Efficacy|1
6198006|NCT01471782|9857614|FG003|Overall Study|Lack of Efficacy|1
6198007|NCT01471782|9857615|FG004|Overall Study|Lack of Efficacy|5
6198008|NCT01471782|9857616|FG005|Overall Study|Lack of Efficacy|18
6198009|NCT01471782|9857611|FG000|Overall Study|Adverse Event|1
6198010|NCT01471782|9857612|FG001|Overall Study|Adverse Event|1
6198011|NCT01471782|9857613|FG002|Overall Study|Adverse Event|2
6198012|NCT01471782|9857614|FG003|Overall Study|Adverse Event|2
6198013|NCT01471782|9857615|FG004|Overall Study|Adverse Event|3
6198014|NCT01471782|9857616|FG005|Overall Study|Adverse Event|1
6198015|NCT01471782|9857611|FG000|Overall Study|Other|0
6198016|NCT01471782|9857612|FG001|Overall Study|Other|0
6198017|NCT01471782|9857613|FG002|Overall Study|Other|1
6198018|NCT01471782|9857614|FG003|Overall Study|Other|1
6198019|NCT01471782|9857615|FG004|Overall Study|Other|6
6198020|NCT01471782|9857616|FG005|Overall Study|Other|5
6198021|NCT01471782|9857611|FG000|Overall Study|Change of Chemotherapy|1
6198022|NCT01471782|9857612|FG001|Overall Study|Change of Chemotherapy|1
6198023|NCT01471782|9857613|FG002|Overall Study|Change of Chemotherapy|0
6198024|NCT01471782|9857614|FG003|Overall Study|Change of Chemotherapy|0
6198025|NCT01471782|9857615|FG004|Overall Study|Change of Chemotherapy|1
6198026|NCT01471782|9857616|FG005|Overall Study|Change of Chemotherapy|4
6198027|NCT01471782|9857611|FG000|Overall Study|Disease Relapse|0
6198028|NCT01471782|9857612|FG001|Overall Study|Disease Relapse|0
6198029|NCT01471782|9857613|FG002|Overall Study|Disease Relapse|0
6198030|NCT01471782|9857614|FG003|Overall Study|Disease Relapse|1
6198031|NCT01471782|9857615|FG004|Overall Study|Disease Relapse|2
6198032|NCT01471782|9857616|FG005|Overall Study|Disease Relapse|1
6088657|NCT00677235|9699628|FG000|Overall Study|Death|37
6088658|NCT00677235|9699629|FG001|Overall Study|Death|36
6088659|NCT00677235|9699628|FG000|Overall Study|Adverse Experience|1
6088660|NCT00677235|9699629|FG001|Overall Study|Adverse Experience|0
6088661|NCT00677352|9699637|FG000|Treatment Phase|Adverse Event|14
6198033|NCT01471782|9857611|FG000|Overall Study|Physician Decision|0
6198034|NCT01471782|9857612|FG001|Overall Study|Physician Decision|0
6198035|NCT01471782|9857613|FG002|Overall Study|Physician Decision|0
6198036|NCT01471782|9857614|FG003|Overall Study|Physician Decision|0
6198037|NCT01471782|9857615|FG004|Overall Study|Physician Decision|3
6198038|NCT01471782|9857616|FG005|Overall Study|Physician Decision|8
6198039|NCT01471782|9857611|FG000|Overall Study|Withdrawal by Parent/Guardian|0
6198040|NCT01471782|9857612|FG001|Overall Study|Withdrawal by Parent/Guardian|0
6198041|NCT01471782|9857613|FG002|Overall Study|Withdrawal by Parent/Guardian|0
6198042|NCT01471782|9857614|FG003|Overall Study|Withdrawal by Parent/Guardian|0
6198043|NCT01471782|9857615|FG004|Overall Study|Withdrawal by Parent/Guardian|1
6198044|NCT01471782|9857616|FG005|Overall Study|Withdrawal by Parent/Guardian|0
6198045|NCT01471782|9857611|FG000|Overall Study|Death|0
6198046|NCT01471782|9857612|FG001|Overall Study|Death|0
6198047|NCT01471782|9857613|FG002|Overall Study|Death|0
6198048|NCT01471782|9857614|FG003|Overall Study|Death|0
6198049|NCT01471782|9857615|FG004|Overall Study|Death|0
6198050|NCT01471782|9857616|FG005|Overall Study|Death|1
6198051|NCT01472185|9857643|FG000|Overall Study|Randomized but Not Treated|0
6198052|NCT01472185|9857644|FG001|Overall Study|Randomized but Not Treated|1
6198053|NCT01472185|9857643|FG000|Overall Study|Adverse Event Other than Hyperglycemia|3
6198054|NCT01472185|9857644|FG001|Overall Study|Adverse Event Other than Hyperglycemia|10
6198055|NCT01472185|9857643|FG000|Overall Study|Hyperglycemia|5
6198056|NCT01472185|9857644|FG001|Overall Study|Hyperglycemia|2
6198057|NCT01472185|9857643|FG000|Overall Study|Investigator's Discretion|3
6198058|NCT01472185|9857644|FG001|Overall Study|Investigator's Discretion|1
6198059|NCT01472185|9857643|FG000|Overall Study|Lost to Follow-up|4
6198060|NCT01472185|9857644|FG001|Overall Study|Lost to Follow-up|1
6198061|NCT01472185|9857643|FG000|Overall Study|Protocol Violation|5
6198062|NCT01472185|9857644|FG001|Overall Study|Protocol Violation|1
6198063|NCT01472185|9857643|FG000|Overall Study|Subject Noncompliance|8
6198064|NCT01472185|9857644|FG001|Overall Study|Subject Noncompliance|15
6198065|NCT01472185|9857643|FG000|Overall Study|Subject Withdrew Consent|6
6198066|NCT01472185|9857644|FG001|Overall Study|Subject Withdrew Consent|3
6198067|NCT01472289|9857650|FG000|Overall Study|Death|2
6198068|NCT01472341|9857654|FG000|Overall Study|Started insulin therapy|55
6198069|NCT01472341|9857654|FG000|Overall Study|Started therapy with a DPP-IV/GLP-1|92
6198070|NCT01472341|9857654|FG000|Overall Study|Withdrawal by Subject|39
6198071|NCT01472341|9857654|FG000|Overall Study|Lost to Follow-up|52
6198072|NCT01472341|9857654|FG000|Overall Study|Laboratory parameters unavailable|25
6198073|NCT01472341|9857654|FG000|Overall Study|Death|9
6198074|NCT01472380|9857658|FG000|Efavirenz Alone|Withdrawal by Subject|1
6198075|NCT01472380|9857658|FG000|1 Day Period Between Dosing|Protocol Violation|1
6198076|NCT01472757|9857709|FG000|Overall Study|Withdrawal by Subject|1
6198077|NCT01472757|9857710|FG001|Overall Study|Withdrawal by Subject|2
6198078|NCT01472757|9857711|FG002|Overall Study|Withdrawal by Subject|2
6198079|NCT01472757|9857712|FG003|Overall Study|Withdrawal by Subject|0
6198080|NCT01472757|9857709|FG000|Overall Study|Asthma exacerbation|4
6198081|NCT01472757|9857710|FG001|Overall Study|Asthma exacerbation|1
6198082|NCT01472757|9857711|FG002|Overall Study|Asthma exacerbation|2
6198083|NCT01472757|9857712|FG003|Overall Study|Asthma exacerbation|1
6198084|NCT01472757|9857709|FG000|Overall Study|Treatment period withdrawal criteria met|21
6198085|NCT01472757|9857710|FG001|Overall Study|Treatment period withdrawal criteria met|8
6198086|NCT01472757|9857711|FG002|Overall Study|Treatment period withdrawal criteria met|9
6088662|NCT00677352|9699638|FG001|Treatment Phase|Adverse Event|22
6198087|NCT01472757|9857712|FG003|Overall Study|Treatment period withdrawal criteria met|12
6198088|NCT01472757|9857709|FG000|Overall Study|Protocol Violation|3
6198089|NCT01472757|9857710|FG001|Overall Study|Protocol Violation|2
6198090|NCT01472757|9857711|FG002|Overall Study|Protocol Violation|4
6198091|NCT01472757|9857712|FG003|Overall Study|Protocol Violation|4
6198092|NCT01472757|9857709|FG000|Overall Study|Other reasons|1
6088663|NCT00677352|9699637|FG000|Treatment Phase|Lack of Efficacy|2
6198093|NCT01472757|9857710|FG001|Overall Study|Other reasons|0
6198094|NCT01472757|9857711|FG002|Overall Study|Other reasons|2
6198095|NCT01472757|9857712|FG003|Overall Study|Other reasons|2
6198096|NCT01472835|9857733|FG000|Overall Study|Lost to Follow-up|2
6198097|NCT01472835|9857734|FG001|Overall Study|Lost to Follow-up|0
6198098|NCT01472939|9857751|FG000|Overall Study|Adverse Event|3
6198099|NCT01472939|9857752|FG001|Overall Study|Adverse Event|7
6198100|NCT01472939|9857753|FG002|Overall Study|Adverse Event|7
6198101|NCT01472939|9857754|FG003|Overall Study|Adverse Event|14
6198102|NCT01472939|9857751|FG000|Overall Study|Lack of Efficacy|1
6198103|NCT01472939|9857752|FG001|Overall Study|Lack of Efficacy|0
6198104|NCT01472939|9857753|FG002|Overall Study|Lack of Efficacy|0
6198105|NCT01472939|9857754|FG003|Overall Study|Lack of Efficacy|1
6198106|NCT01472939|9857751|FG000|Overall Study|Lost to Follow-up|3
6198107|NCT01472939|9857752|FG001|Overall Study|Lost to Follow-up|0
6198108|NCT01472939|9857753|FG002|Overall Study|Lost to Follow-up|2
6198109|NCT01472939|9857754|FG003|Overall Study|Lost to Follow-up|0
6198110|NCT01472939|9857751|FG000|Overall Study|Clinically Significant Pre-Dose ECG|0
6198111|NCT01472939|9857752|FG001|Overall Study|Clinically Significant Pre-Dose ECG|0
6198112|NCT01472939|9857753|FG002|Overall Study|Clinically Significant Pre-Dose ECG|1
6198113|NCT01472939|9857754|FG003|Overall Study|Clinically Significant Pre-Dose ECG|0
6198114|NCT01472939|9857751|FG000|Overall Study|Prohibited Medication|0
6198115|NCT01472939|9857752|FG001|Overall Study|Prohibited Medication|1
6198116|NCT01472939|9857753|FG002|Overall Study|Prohibited Medication|0
6198117|NCT01472939|9857754|FG003|Overall Study|Prohibited Medication|0
6198118|NCT01472939|9857751|FG000|Overall Study|Withdrawal By PI|1
6198119|NCT01472939|9857752|FG001|Overall Study|Withdrawal By PI|0
6198120|NCT01472939|9857753|FG002|Overall Study|Withdrawal By PI|0
6198121|NCT01472939|9857754|FG003|Overall Study|Withdrawal By PI|0
6198122|NCT01472939|9857751|FG000|Overall Study|Protocol Violation|3
6198123|NCT01472939|9857752|FG001|Overall Study|Protocol Violation|3
6198124|NCT01472939|9857753|FG002|Overall Study|Protocol Violation|0
6198125|NCT01472939|9857754|FG003|Overall Study|Protocol Violation|1
6198126|NCT01472939|9857751|FG000|Overall Study|Withdrawal by Subject|9
6198127|NCT01472939|9857752|FG001|Overall Study|Withdrawal by Subject|3
6198128|NCT01472939|9857753|FG002|Overall Study|Withdrawal by Subject|1
6198129|NCT01472939|9857754|FG003|Overall Study|Withdrawal by Subject|4
6198130|NCT01472965|9857769|FG000|Overall Study|Withdrawal by Subject|1
6198131|NCT01472965|9857770|FG001|Overall Study|Withdrawal by Subject|0
6198132|NCT01473355|9857782|FG000|Overall Study|Protocol Violation|2
6198133|NCT01473355|9857782|FG000|Overall Study|Adverse Event|2
6198134|NCT01473355|9857782|FG000|Overall Study|Lost to Follow-up|2
6198135|NCT01473381|9857823|FG000|Overall Study|Adverse Event|8
6198136|NCT01473381|9857824|FG001|Overall Study|Adverse Event|20
6198137|NCT01473381|9857825|FG002|Overall Study|Adverse Event|25
6198138|NCT01473381|9857826|FG003|Overall Study|Adverse Event|17
6198139|NCT01473381|9857823|FG000|Overall Study|Insufficient Therapeutic Response|10
6198140|NCT01473381|9857824|FG001|Overall Study|Insufficient Therapeutic Response|1
6198141|NCT01473381|9857825|FG002|Overall Study|Insufficient Therapeutic Response|2
6198142|NCT01473381|9857826|FG003|Overall Study|Insufficient Therapeutic Response|3
6198143|NCT01473381|9857823|FG000|Overall Study|Protocol Violation|17
6198144|NCT01473381|9857824|FG001|Overall Study|Protocol Violation|23
6198145|NCT01473381|9857825|FG002|Overall Study|Protocol Violation|19
6198146|NCT01473381|9857826|FG003|Overall Study|Protocol Violation|17
6198147|NCT01473381|9857823|FG000|Overall Study|Withdrawal of Consent|20
6198148|NCT01473381|9857824|FG001|Overall Study|Withdrawal of Consent|21
6198149|NCT01473381|9857825|FG002|Overall Study|Withdrawal of Consent|20
6198150|NCT01473381|9857826|FG003|Overall Study|Withdrawal of Consent|26
6198151|NCT01473381|9857823|FG000|Overall Study|Lost to Follow-up|25
6198152|NCT01473381|9857824|FG001|Overall Study|Lost to Follow-up|28
6198153|NCT01473381|9857825|FG002|Overall Study|Lost to Follow-up|35
6198154|NCT01473381|9857826|FG003|Overall Study|Lost to Follow-up|23
6198155|NCT01473381|9857823|FG000|Overall Study|Other Reasons|0
6198156|NCT01473381|9857824|FG001|Overall Study|Other Reasons|0
6198157|NCT01473381|9857825|FG002|Overall Study|Other Reasons|1
6198158|NCT01473381|9857826|FG003|Overall Study|Other Reasons|3
6198159|NCT01473394|9857839|FG000|Overall Study|Adverse Event|13
6275775|NCT02217982|9980820|FG000|Overall Study|Trial discontinued|1
6275776|NCT02217982|9980821|FG001|Overall Study|Trial discontinued|0
6275777|NCT02217982|9980820|FG000|Overall Study|Adverse Event|0
6275778|NCT02217982|9980821|FG001|Overall Study|Adverse Event|1
6275779|NCT02218008|9980830|FG000|Stage 1 (S1)|Adverse Event|6
6198160|NCT01473394|9857840|FG001|Overall Study|Adverse Event|16
6198161|NCT01473394|9857839|FG000|Overall Study|Insufficient Therapeutic Response|4
6198162|NCT01473394|9857840|FG001|Overall Study|Insufficient Therapeutic Response|1
6198163|NCT01473394|9857839|FG000|Overall Study|Protocol Violation|7
6198164|NCT01473394|9857840|FG001|Overall Study|Protocol Violation|5
6198165|NCT01473394|9857839|FG000|Overall Study|Withdrew Consent|12
6198166|NCT01473394|9857840|FG001|Overall Study|Withdrew Consent|10
6198167|NCT01473394|9857839|FG000|Overall Study|Lost to Follow-up|9
6275780|NCT02218008|9980831|FG001|Stage 1 (S1)|Adverse Event|5
6275781|NCT02218008|9980832|FG002|Stage 1 (S1)|Adverse Event|11
6198168|NCT01473394|9857840|FG001|Overall Study|Lost to Follow-up|11
6198169|NCT01473407|9857848|FG000|Overall Study|Physician Decision|1
6198170|NCT01473407|9857849|FG001|Overall Study|Physician Decision|4
6198171|NCT01473407|9857848|FG000|Overall Study|Lost to Follow-up|10
6198172|NCT01473407|9857849|FG001|Overall Study|Lost to Follow-up|4
6198173|NCT01473407|9857848|FG000|Overall Study|Adverse Event|8
6198174|NCT01473407|9857849|FG001|Overall Study|Adverse Event|8
6198175|NCT01473407|9857848|FG000|Overall Study|Randomization Error|3
6198176|NCT01473407|9857849|FG001|Overall Study|Randomization Error|1
6198177|NCT01473407|9857848|FG000|Overall Study|Withdrawal by Subject|4
6198178|NCT01473407|9857849|FG001|Overall Study|Withdrawal by Subject|7
6198179|NCT01473407|9857848|FG000|Overall Study|Kidney Transplant|7
6198180|NCT01473407|9857849|FG001|Overall Study|Kidney Transplant|6
6198181|NCT01473407|9857848|FG000|Overall Study|Vacation/Travel|1
6275782|NCT02218008|9980833|FG003|Stage 1 (S1)|Adverse Event|0
6275783|NCT02218008|9980834|FG004|Stage 1 (S1)|Adverse Event|0
6275784|NCT02218008|9980835|FG005|Stage 1 (S1)|Adverse Event|0
6275785|NCT02218008|9980830|FG000|Stage 1 (S1)|Withdrawal by Subject|6
6275786|NCT02218008|9980831|FG001|Stage 1 (S1)|Withdrawal by Subject|1
6275787|NCT02218008|9980832|FG002|Stage 1 (S1)|Withdrawal by Subject|1
6275788|NCT02218008|9980833|FG003|Stage 1 (S1)|Withdrawal by Subject|0
5977033|NCT01248247|9564039|FG000|Overall Study|Other|2
5977034|NCT01248247|9564040|FG001|Overall Study|Other|8
5977035|NCT01248247|9564041|FG002|Overall Study|Other|8
5977036|NCT01248247|9564042|FG003|Overall Study|Other|5
5977037|NCT01248247|9564039|FG000|Overall Study|Progression|18
5977038|NCT01248247|9564040|FG001|Overall Study|Progression|27
5977039|NCT01248247|9564041|FG002|Overall Study|Progression|56
5977040|NCT01248247|9564042|FG003|Overall Study|Progression|44
5977041|NCT01248247|9564039|FG000|Overall Study|Refuse further treatment|0
5977042|NCT01248247|9564040|FG001|Overall Study|Refuse further treatment|0
5977043|NCT01248247|9564041|FG002|Overall Study|Refuse further treatment|1
5977044|NCT01248247|9564042|FG003|Overall Study|Refuse further treatment|2
5977045|NCT01248247|9564039|FG000|Overall Study|Complicating disease|0
5977046|NCT01248247|9564040|FG001|Overall Study|Complicating disease|0
5977047|NCT01248247|9564041|FG002|Overall Study|Complicating disease|1
5977048|NCT01248247|9564042|FG003|Overall Study|Complicating disease|1
5977049|NCT01164228|9564054|FG000|Overall Study|Progression|24
5977050|NCT01164228|9564055|FG001|Overall Study|Progression|25
5977051|NCT01164228|9564054|FG000|Overall Study|Adverse Event|13
5977052|NCT01164228|9564055|FG001|Overall Study|Adverse Event|7
5977053|NCT01164228|9564054|FG000|Overall Study|Death|1
5977054|NCT01164228|9564055|FG001|Overall Study|Death|1
5977055|NCT01164228|9564054|FG000|Overall Study|Withdrawal by Subject|2
5977056|NCT01164228|9564055|FG001|Overall Study|Withdrawal by Subject|0
5977057|NCT01164228|9564054|FG000|Overall Study|Physician Decision|1
5977058|NCT01164228|9564055|FG001|Overall Study|Physician Decision|2
6198182|NCT01473407|9857849|FG001|Overall Study|Vacation/Travel|1
6198183|NCT01473407|9857848|FG000|Overall Study|Elevated Hemoglobin|1
6198184|NCT01473407|9857849|FG001|Overall Study|Elevated Hemoglobin|0
6198185|NCT01473407|9857848|FG000|Overall Study|Patient Received Aranesp|1
6198186|NCT01473407|9857849|FG001|Overall Study|Patient Received Aranesp|0
6198187|NCT01473407|9857848|FG000|Overall Study|Patient Lost Green Card Status|1
6198188|NCT01473407|9857849|FG001|Overall Study|Patient Lost Green Card Status|0
6198189|NCT01473407|9857848|FG000|Overall Study|Temperature Excursion|2
6198190|NCT01473407|9857849|FG001|Overall Study|Temperature Excursion|3
6198191|NCT01473407|9857848|FG000|Overall Study|Transfer to Another Facility/Unit|4
6198192|NCT01473407|9857849|FG001|Overall Study|Transfer to Another Facility/Unit|3
6198193|NCT01473407|9857848|FG000|Overall Study|Sponsor's Decision|10
6198194|NCT01473407|9857849|FG001|Overall Study|Sponsor's Decision|10
6198195|NCT01473407|9857848|FG000|Overall Study|Site Closure|1
6198196|NCT01473407|9857849|FG001|Overall Study|Site Closure|0
6198197|NCT01473420|9857857|FG000|Titration Period (18 Weeks)|Adverse Event|4
6198198|NCT01473420|9857858|FG001|Titration Period (18 Weeks)|Adverse Event|6
6198199|NCT01473420|9857857|FG000|Titration Period (18 Weeks)|Did not meet criteria|32
6198200|NCT01473420|9857858|FG001|Titration Period (18 Weeks)|Did not meet criteria|32
6198201|NCT01473420|9857857|FG000|Maintenance Period (16 Weeks)|Adverse Event|3
6198202|NCT01473420|9857858|FG001|Maintenance Period (16 Weeks)|Adverse Event|2
6198203|NCT01473420|9857857|FG000|Maintenance Period (16 Weeks)|Physician Decision|1
6198204|NCT01473420|9857858|FG001|Maintenance Period (16 Weeks)|Physician Decision|2
6198205|NCT01473420|9857857|FG000|Maintenance Period (16 Weeks)|Did not meet criteria|0
6198206|NCT01473420|9857858|FG001|Maintenance Period (16 Weeks)|Did not meet criteria|2
6198207|NCT01473420|9857857|FG000|Maintenance Period (16 Weeks)|Kidney transplant|3
6198208|NCT01473420|9857858|FG001|Maintenance Period (16 Weeks)|Kidney transplant|1
6198209|NCT01473420|9857857|FG000|Maintenance Period (16 Weeks)|Lost to Follow-up|1
6275789|NCT02218008|9980834|FG004|Stage 1 (S1)|Withdrawal by Subject|0
5977059|NCT01164228|9564054|FG000|Overall Study|Symptomatic deterioration|1
6198210|NCT01473420|9857858|FG001|Maintenance Period (16 Weeks)|Lost to Follow-up|2
6198211|NCT01473420|9857857|FG000|Maintenance Period (16 Weeks)|Withdrawal by Subject|4
6198212|NCT01473420|9857858|FG001|Maintenance Period (16 Weeks)|Withdrawal by Subject|6
6198213|NCT01473420|9857857|FG000|Maintenance Period (16 Weeks)|Site closure|3
6198214|NCT01473420|9857858|FG001|Maintenance Period (16 Weeks)|Site closure|1
6198215|NCT01473420|9857857|FG000|Maintenance Period (16 Weeks)|Started Peritoneal Dialysis|1
6198216|NCT01473420|9857858|FG001|Maintenance Period (16 Weeks)|Started Peritoneal Dialysis|0
6198217|NCT01473420|9857857|FG000|Maintenance Period (16 Weeks)|Long term hospitalization|0
6198218|NCT01473420|9857858|FG001|Maintenance Period (16 Weeks)|Long term hospitalization|1
6198219|NCT01473420|9857857|FG000|Maintenance Period (16 Weeks)|Sponsor's Decision|1
6198220|NCT01473420|9857858|FG001|Maintenance Period (16 Weeks)|Sponsor's Decision|0
6198221|NCT01473420|9857857|FG000|Maintenance Period (16 Weeks)|Elevated Hemoglobin|1
6198222|NCT01473420|9857858|FG001|Maintenance Period (16 Weeks)|Elevated Hemoglobin|0
6198223|NCT01473524|9857873|FG000|DB Phase|Adverse Event|4
6275790|NCT02218008|9980835|FG005|Stage 1 (S1)|Withdrawal by Subject|0
6275791|NCT02218008|9980830|FG000|Stage 1 (S1)|Lack of Efficacy|3
6275792|NCT02218008|9980831|FG001|Stage 1 (S1)|Lack of Efficacy|0
6275793|NCT02218008|9980832|FG002|Stage 1 (S1)|Lack of Efficacy|0
6275794|NCT02218008|9980833|FG003|Stage 1 (S1)|Lack of Efficacy|0
5977060|NCT01164228|9564055|FG001|Overall Study|Symptomatic deterioration|0
5977061|NCT01164228|9564054|FG000|Overall Study|Never started treatment|1
5977062|NCT01164228|9564055|FG001|Overall Study|Never started treatment|3
5977063|NCT01164228|9564054|FG000|Overall Study|Ineligible|1
5977064|NCT01164228|9564055|FG001|Overall Study|Ineligible|0
5977065|NCT00591318|9564122|FG000|Overall Study|Lack of Efficacy|2
5977066|NCT00591318|9564123|FG001|Overall Study|Lack of Efficacy|0
5977067|NCT00591318|9564122|FG000|Overall Study|Adverse Event|2
5977068|NCT00591318|9564123|FG001|Overall Study|Adverse Event|0
6050797|NCT00428844|9649994|FG000|Completed Test of Cure (TOC) Visit|Protocol Violation|0
6198224|NCT01473524|9857874|FG001|DB Phase|Adverse Event|8
6198225|NCT01473524|9857875|FG002|DB Phase|Adverse Event|2
6198226|NCT01473524|9857876|FG003|DB Phase|Adverse Event|0
6198227|NCT01473524|9857877|FG004|DB Phase|Adverse Event|0
6198228|NCT01473524|9857878|FG005|DB Phase|Adverse Event|0
6198229|NCT01473524|9857873|FG000|DB Phase|Death|1
6198230|NCT01473524|9857874|FG001|DB Phase|Death|0
6198231|NCT01473524|9857875|FG002|DB Phase|Death|0
6198232|NCT01473524|9857876|FG003|DB Phase|Death|0
6198233|NCT01473524|9857877|FG004|DB Phase|Death|0
6198234|NCT01473524|9857878|FG005|DB Phase|Death|0
6198235|NCT01473524|9857873|FG000|DB Phase|Withdrawal by Subject|2
6198236|NCT01473524|9857874|FG001|DB Phase|Withdrawal by Subject|1
6198237|NCT01473524|9857875|FG002|DB Phase|Withdrawal by Subject|1
6198238|NCT01473524|9857876|FG003|DB Phase|Withdrawal by Subject|0
6198239|NCT01473524|9857877|FG004|DB Phase|Withdrawal by Subject|0
6198240|NCT01473524|9857878|FG005|DB Phase|Withdrawal by Subject|0
6198241|NCT01473524|9857873|FG000|LTSE Phase|Withdrawal by Subject|0
6198242|NCT01473524|9857874|FG001|LTSE Phase|Withdrawal by Subject|0
6198243|NCT01473524|9857875|FG002|LTSE Phase|Withdrawal by Subject|0
6275795|NCT02218008|9980834|FG004|Stage 1 (S1)|Lack of Efficacy|0
6275796|NCT02218008|9980835|FG005|Stage 1 (S1)|Lack of Efficacy|0
6275797|NCT02218008|9980830|FG000|Stage 1 (S1)|Lost to Follow-up|3
6275798|NCT02218008|9980831|FG001|Stage 1 (S1)|Lost to Follow-up|0
6275799|NCT02218008|9980832|FG002|Stage 1 (S1)|Lost to Follow-up|1
6275800|NCT02218008|9980833|FG003|Stage 1 (S1)|Lost to Follow-up|0
6275801|NCT02218008|9980834|FG004|Stage 1 (S1)|Lost to Follow-up|0
6275802|NCT02218008|9980835|FG005|Stage 1 (S1)|Lost to Follow-up|0
6275803|NCT02218008|9980830|FG000|Stage 1 (S1)|Non-compliance with Study Drug|2
6275804|NCT02218008|9980831|FG001|Stage 1 (S1)|Non-compliance with Study Drug|1
6275805|NCT02218008|9980832|FG002|Stage 1 (S1)|Non-compliance with Study Drug|0
6275806|NCT02218008|9980833|FG003|Stage 1 (S1)|Non-compliance with Study Drug|0
6275807|NCT02218008|9980834|FG004|Stage 1 (S1)|Non-compliance with Study Drug|0
6275808|NCT02218008|9980835|FG005|Stage 1 (S1)|Non-compliance with Study Drug|0
6275809|NCT02218008|9980830|FG000|Stage 1 (S1)|Non-compliance; drug use|1
6275810|NCT02218008|9980831|FG001|Stage 1 (S1)|Non-compliance; drug use|0
6275811|NCT02218008|9980832|FG002|Stage 1 (S1)|Non-compliance; drug use|0
6275812|NCT02218008|9980833|FG003|Stage 1 (S1)|Non-compliance; drug use|0
6275813|NCT02218008|9980834|FG004|Stage 1 (S1)|Non-compliance; drug use|0
6275814|NCT02218008|9980835|FG005|Stage 1 (S1)|Non-compliance; drug use|0
6275815|NCT02218008|9980830|FG000|Stage 1 (S1)|Pregnancy|0
6275816|NCT02218008|9980831|FG001|Stage 1 (S1)|Pregnancy|0
6275817|NCT02218008|9980832|FG002|Stage 1 (S1)|Pregnancy|1
6275818|NCT02218008|9980833|FG003|Stage 1 (S1)|Pregnancy|0
6275819|NCT02218008|9980834|FG004|Stage 1 (S1)|Pregnancy|0
6275820|NCT02218008|9980835|FG005|Stage 1 (S1)|Pregnancy|0
6275821|NCT02218008|9980830|FG000|Stage 1 (S1)|Protocol Violation|0
6275822|NCT02218008|9980831|FG001|Stage 1 (S1)|Protocol Violation|0
6275823|NCT02218008|9980832|FG002|Stage 1 (S1)|Protocol Violation|1
6275824|NCT02218008|9980833|FG003|Stage 1 (S1)|Protocol Violation|0
6275825|NCT02218008|9980834|FG004|Stage 1 (S1)|Protocol Violation|0
6275826|NCT02218008|9980835|FG005|Stage 1 (S1)|Protocol Violation|0
6275827|NCT02218008|9980830|FG000|Stage 1 (S1)|Failure to Meet Eligibility Criteria|1
6275828|NCT02218008|9980831|FG001|Stage 1 (S1)|Failure to Meet Eligibility Criteria|0
6275829|NCT02218008|9980832|FG002|Stage 1 (S1)|Failure to Meet Eligibility Criteria|0
6275830|NCT02218008|9980833|FG003|Stage 1 (S1)|Failure to Meet Eligibility Criteria|0
6275831|NCT02218008|9980834|FG004|Stage 1 (S1)|Failure to Meet Eligibility Criteria|0
6275832|NCT02218008|9980835|FG005|Stage 1 (S1)|Failure to Meet Eligibility Criteria|0
6275833|NCT02218008|9980830|FG000|Stage 2 (S2)|Adverse Event|0
6275834|NCT02218008|9980831|FG001|Stage 2 (S2)|Adverse Event|0
6275835|NCT02218008|9980832|FG002|Stage 2 (S2)|Adverse Event|0
6275836|NCT02218008|9980833|FG003|Stage 2 (S2)|Adverse Event|2
6275837|NCT02218008|9980834|FG004|Stage 2 (S2)|Adverse Event|3
6275838|NCT02218008|9980835|FG005|Stage 2 (S2)|Adverse Event|3
6275839|NCT02218008|9980830|FG000|Stage 2 (S2)|Withdrawal by Subject|0
6275840|NCT02218008|9980831|FG001|Stage 2 (S2)|Withdrawal by Subject|0
6275841|NCT02218008|9980832|FG002|Stage 2 (S2)|Withdrawal by Subject|0
6275842|NCT02218008|9980833|FG003|Stage 2 (S2)|Withdrawal by Subject|1
6088664|NCT00677352|9699638|FG001|Treatment Phase|Lack of Efficacy|3
6088665|NCT00677352|9699637|FG000|Treatment Phase|Lost to Follow-up|0
6275843|NCT02218008|9980834|FG004|Stage 2 (S2)|Withdrawal by Subject|1
6275844|NCT02218008|9980835|FG005|Stage 2 (S2)|Withdrawal by Subject|0
6275845|NCT02218008|9980830|FG000|Stage 2 (S2)|Lack of Efficacy|0
6275846|NCT02218008|9980831|FG001|Stage 2 (S2)|Lack of Efficacy|0
5977069|NCT04534517|9564144|FG000|Overall Study|Adverse Event|1
6275847|NCT02218008|9980832|FG002|Stage 2 (S2)|Lack of Efficacy|0
6198244|NCT01473524|9857876|FG003|LTSE Phase|Withdrawal by Subject|3
6275848|NCT02218008|9980833|FG003|Stage 2 (S2)|Lack of Efficacy|0
6088666|NCT00677352|9699638|FG001|Treatment Phase|Lost to Follow-up|1
6275849|NCT02218008|9980834|FG004|Stage 2 (S2)|Lack of Efficacy|0
6275850|NCT02218008|9980835|FG005|Stage 2 (S2)|Lack of Efficacy|2
6275851|NCT02218008|9980830|FG000|Stage 2 (S2)|Failure to Meet Eligibility Criteria|0
6275852|NCT02218008|9980831|FG001|Stage 2 (S2)|Failure to Meet Eligibility Criteria|0
6275853|NCT02218008|9980832|FG002|Stage 2 (S2)|Failure to Meet Eligibility Criteria|0
6198245|NCT01473524|9857877|FG004|LTSE Phase|Withdrawal by Subject|3
6198246|NCT01473524|9857878|FG005|LTSE Phase|Withdrawal by Subject|6
6198247|NCT01473524|9857873|FG000|LTSE Phase|Death|0
6198248|NCT01473524|9857874|FG001|LTSE Phase|Death|0
6198249|NCT01473524|9857875|FG002|LTSE Phase|Death|0
6198250|NCT01473524|9857876|FG003|LTSE Phase|Death|0
6198251|NCT01473524|9857877|FG004|LTSE Phase|Death|1
6198252|NCT01473524|9857878|FG005|LTSE Phase|Death|0
6198253|NCT01473524|9857873|FG000|LTSE Phase|Adverse Event of Pruritus|0
6198254|NCT01473524|9857874|FG001|LTSE Phase|Adverse Event of Pruritus|0
6198255|NCT01473524|9857875|FG002|LTSE Phase|Adverse Event of Pruritus|0
6198256|NCT01473524|9857876|FG003|LTSE Phase|Adverse Event of Pruritus|1
6198257|NCT01473524|9857877|FG004|LTSE Phase|Adverse Event of Pruritus|5
6198258|NCT01473524|9857878|FG005|LTSE Phase|Adverse Event of Pruritus|2
6198259|NCT01473524|9857873|FG000|LTSE Phase|Other Clinical/ Laboratory Adverse Event|0
6198260|NCT01473524|9857874|FG001|LTSE Phase|Other Clinical/ Laboratory Adverse Event|0
6198261|NCT01473524|9857875|FG002|LTSE Phase|Other Clinical/ Laboratory Adverse Event|0
6198262|NCT01473524|9857876|FG003|LTSE Phase|Other Clinical/ Laboratory Adverse Event|2
6198263|NCT01473524|9857877|FG004|LTSE Phase|Other Clinical/ Laboratory Adverse Event|4
6198264|NCT01473524|9857878|FG005|LTSE Phase|Other Clinical/ Laboratory Adverse Event|6
6198265|NCT01473524|9857873|FG000|LTSE Phase|Lost to Follow-up|0
6198266|NCT01473524|9857874|FG001|LTSE Phase|Lost to Follow-up|0
6198267|NCT01473524|9857875|FG002|LTSE Phase|Lost to Follow-up|0
6198268|NCT01473524|9857876|FG003|LTSE Phase|Lost to Follow-up|1
6198269|NCT01473524|9857877|FG004|LTSE Phase|Lost to Follow-up|3
6198270|NCT01473524|9857878|FG005|LTSE Phase|Lost to Follow-up|2
6198271|NCT01473524|9857873|FG000|LTSE Phase|Principal Investigator Decision|0
6198272|NCT01473524|9857874|FG001|LTSE Phase|Principal Investigator Decision|0
6198273|NCT01473524|9857875|FG002|LTSE Phase|Principal Investigator Decision|0
6198274|NCT01473524|9857876|FG003|LTSE Phase|Principal Investigator Decision|1
6198275|NCT01473524|9857877|FG004|LTSE Phase|Principal Investigator Decision|1
6198276|NCT01473524|9857878|FG005|LTSE Phase|Principal Investigator Decision|3
6198277|NCT01473524|9857873|FG000|LTSE Phase|Liver Transplantation|0
6198278|NCT01473524|9857874|FG001|LTSE Phase|Liver Transplantation|0
6198279|NCT01473524|9857875|FG002|LTSE Phase|Liver Transplantation|0
6198280|NCT01473524|9857876|FG003|LTSE Phase|Liver Transplantation|0
6198281|NCT01473524|9857877|FG004|LTSE Phase|Liver Transplantation|0
6198282|NCT01473524|9857878|FG005|LTSE Phase|Liver Transplantation|1
6198283|NCT01473524|9857873|FG000|LTSE Phase|Pregnancy|0
6198284|NCT01473524|9857874|FG001|LTSE Phase|Pregnancy|0
6198285|NCT01473524|9857875|FG002|LTSE Phase|Pregnancy|0
6198286|NCT01473524|9857876|FG003|LTSE Phase|Pregnancy|1
6198287|NCT01473524|9857877|FG004|LTSE Phase|Pregnancy|0
6198288|NCT01473524|9857878|FG005|LTSE Phase|Pregnancy|0
6198289|NCT01473524|9857873|FG000|LTSE Phase|Protocol Violation|0
6198290|NCT01473524|9857874|FG001|LTSE Phase|Protocol Violation|0
6198291|NCT01473524|9857875|FG002|LTSE Phase|Protocol Violation|0
6198292|NCT01473524|9857876|FG003|LTSE Phase|Protocol Violation|0
6198293|NCT01473524|9857877|FG004|LTSE Phase|Protocol Violation|0
6198294|NCT01473524|9857878|FG005|LTSE Phase|Protocol Violation|1
6198295|NCT01473563|9857900|FG000|Overall Study|Lost to FU post tx discontinuation|1
6198296|NCT01473589|9857906|FG000|Overall Study|Adverse Event|1
6198297|NCT01473589|9857907|FG001|Overall Study|Adverse Event|1
6198298|NCT01473589|9857906|FG000|Overall Study|Death|2
6198299|NCT01473589|9857907|FG001|Overall Study|Death|0
6198300|NCT01473589|9857906|FG000|Overall Study|Lost to Follow-up|2
6198301|NCT01473589|9857907|FG001|Overall Study|Lost to Follow-up|2
6198302|NCT01473589|9857906|FG000|Overall Study|Protocol Violation|1
6198303|NCT01473589|9857907|FG001|Overall Study|Protocol Violation|0
6198304|NCT01473589|9857906|FG000|Overall Study|Withdrawal by Subject|5
6198305|NCT01473589|9857907|FG001|Overall Study|Withdrawal by Subject|11
6198306|NCT01473589|9857906|FG000|Overall Study|Physician Decision|0
6198307|NCT01473589|9857907|FG001|Overall Study|Physician Decision|1
6198308|NCT01473589|9857906|FG000|Overall Study|Entry criteria not met|0
6198309|NCT01473589|9857907|FG001|Overall Study|Entry criteria not met|1
6275854|NCT02218008|9980833|FG003|Stage 2 (S2)|Failure to Meet Eligibility Criteria|1
6275855|NCT02218008|9980834|FG004|Stage 2 (S2)|Failure to Meet Eligibility Criteria|0
6275856|NCT02218008|9980835|FG005|Stage 2 (S2)|Failure to Meet Eligibility Criteria|0
6275857|NCT02218008|9980830|FG000|Stage 2 (S2)|Lost to Follow-up|0
6275858|NCT02218008|9980831|FG001|Stage 2 (S2)|Lost to Follow-up|0
6275859|NCT02218008|9980832|FG002|Stage 2 (S2)|Lost to Follow-up|0
6275860|NCT02218008|9980833|FG003|Stage 2 (S2)|Lost to Follow-up|0
6275861|NCT02218008|9980834|FG004|Stage 2 (S2)|Lost to Follow-up|0
6275862|NCT02218008|9980835|FG005|Stage 2 (S2)|Lost to Follow-up|1
6275863|NCT02218216|9980882|FG000|Overall Study|Study terminated before completed|6
6275864|NCT02218216|9980883|FG001|Overall Study|Study terminated before completed|0
5977070|NCT04534517|9564144|FG000|Overall Study|Withdrawal by Subject|1
5977071|NCT04534517|9564144|FG000|Overall Study|Unsatisfactory Visual Response due to Test Article|1
6275865|NCT02218216|9980884|FG002|Overall Study|Study terminated before completed|0
6275866|NCT02218268|9980896|FG000|24 Hour Washout|Physician Decision|11
6275867|NCT02218268|9980897|FG001|24 Hour Washout|Physician Decision|9
6275868|NCT02218372|9980923|FG000|Overall Study|Adverse Event|1
6275869|NCT02218372|9980924|FG001|Overall Study|Adverse Event|1
6275870|NCT02218372|9980923|FG000|Overall Study|Miscellaneous|2
6275871|NCT02218372|9980924|FG001|Overall Study|Miscellaneous|1
6275872|NCT02218372|9980923|FG000|Overall Study|Randomized but did not receive treatment|2
6275873|NCT02218372|9980924|FG001|Overall Study|Randomized but did not receive treatment|3
6198310|NCT01473602|9857917|FG000|Overall Study|Adverse Event|1
6198311|NCT01473602|9857918|FG001|Overall Study|Adverse Event|2
6198312|NCT01473602|9857917|FG000|Overall Study|Death|0
6275874|NCT02218372|9980923|FG000|Overall Study|Withdrawal by Parent/Guardian|0
6275875|NCT02218372|9980924|FG001|Overall Study|Withdrawal by Parent/Guardian|1
6198313|NCT01473602|9857918|FG001|Overall Study|Death|1
6198314|NCT01473602|9857917|FG000|Overall Study|Lost to Follow-up|1
6198315|NCT01473602|9857918|FG001|Overall Study|Lost to Follow-up|1
6198316|NCT01473602|9857917|FG000|Overall Study|Withdrawal by Subject|5
6198317|NCT01473602|9857918|FG001|Overall Study|Withdrawal by Subject|4
6198318|NCT01473602|9857917|FG000|Overall Study|Physician Decision|1
6198319|NCT01473602|9857918|FG001|Overall Study|Physician Decision|0
6198320|NCT01473758|9857937|FG000|Cycle 1|Adverse Event|10
6198321|NCT01473758|9857938|FG001|Cycle 1|Adverse Event|2
6198322|NCT01473758|9857939|FG002|Cycle 1|Adverse Event|0
6198323|NCT01473758|9857940|FG003|Cycle 1|Adverse Event|0
6198324|NCT01473758|9857937|FG000|Cycle 1|Withdrawal by Subject|1
6198325|NCT01473758|9857938|FG001|Cycle 1|Withdrawal by Subject|1
6198326|NCT01473758|9857939|FG002|Cycle 1|Withdrawal by Subject|0
6198327|NCT01473758|9857940|FG003|Cycle 1|Withdrawal by Subject|0
6198328|NCT01473758|9857937|FG000|Cycle 2|Adverse Event|0
6198329|NCT01473758|9857938|FG001|Cycle 2|Adverse Event|0
6198330|NCT01473758|9857939|FG002|Cycle 2|Adverse Event|5
6198331|NCT01473758|9857940|FG003|Cycle 2|Adverse Event|0
6198332|NCT01473836|9857948|FG000|Overall Study|Adverse Event|4
6198333|NCT01473836|9857948|FG000|Overall Study|Lack of Efficacy|1
6198334|NCT01473836|9857948|FG000|Overall Study|Does not meet entrance criteria|1
6198335|NCT01473940|9857956|FG000|Induction Therapy|Death|0
6198336|NCT01473940|9857957|FG001|Induction Therapy|Death|0
6198337|NCT01473940|9857958|FG002|Induction Therapy|Death|1
6198338|NCT01473940|9857959|FG003|Induction Therapy|Death|1
6198339|NCT01473940|9857956|FG000|Induction Therapy|Progressive Disease|0
6198340|NCT01473940|9857957|FG001|Induction Therapy|Progressive Disease|1
6198341|NCT01473940|9857958|FG002|Induction Therapy|Progressive Disease|1
6275876|NCT02218489|9980955|FG000|Overall Study|Withdrawal by Subject|4
6275877|NCT02218489|9980956|FG001|Overall Study|Withdrawal by Subject|3
6275878|NCT02218489|9980955|FG000|Overall Study|Lost to Follow-up|1
6275879|NCT02218489|9980956|FG001|Overall Study|Lost to Follow-up|0
6275880|NCT02218541|9980965|FG000|Overall Study|Lost to Follow-up|2
6275881|NCT02218541|9980966|FG001|Overall Study|Lost to Follow-up|1
6275882|NCT02218541|9980965|FG000|Overall Study|Implant Failure|4
6275883|NCT02218541|9980966|FG001|Overall Study|Implant Failure|1
6275884|NCT02218736|9980975|FG000|Overall Study|Withdrawal by Subject|10
6275885|NCT02218736|9980976|FG001|Overall Study|Withdrawal by Subject|9
6275886|NCT02218736|9980975|FG000|Overall Study|Protocol Violation|2
6275887|NCT02218736|9980976|FG001|Overall Study|Protocol Violation|0
6275888|NCT02219009|9980984|FG000|Overall Study|Withdrawal by Subject|5
6275889|NCT02219009|9980985|FG001|Overall Study|Withdrawal by Subject|1
6275890|NCT02219009|9980984|FG000|Overall Study|Adverse Event|2
6275891|NCT02219009|9980985|FG001|Overall Study|Adverse Event|4
6275892|NCT02219009|9980984|FG000|Overall Study|Lost to Follow-up|2
6275893|NCT02219009|9980985|FG001|Overall Study|Lost to Follow-up|2
6275894|NCT02219009|9980984|FG000|Overall Study|Protocol deviation|1
6275895|NCT02219009|9980985|FG001|Overall Study|Protocol deviation|0
6275896|NCT02219009|9980984|FG000|Overall Study|Physician Decision|0
6275897|NCT02219009|9980985|FG001|Overall Study|Physician Decision|1
6275898|NCT02219048|9980993|FG000|Overall Study|Adverse Event|2
6275899|NCT02219048|9980994|FG001|Overall Study|Adverse Event|5
6275900|NCT02219048|9980993|FG000|Overall Study|No longer meets eligibility criteria|1
5977072|NCT04534517|9564144|FG000|Overall Study|COVID-19 Related|1
5977073|NCT04494646|9564150|FG000|Overall Study|Adverse Event|0
5977074|NCT04494646|9564151|FG001|Overall Study|Adverse Event|1
5977075|NCT04494646|9564150|FG000|Overall Study|Withdrawal by Subject|0
5977076|NCT04494646|9564151|FG001|Overall Study|Withdrawal by Subject|1
5977077|NCT04258020|9564159|FG000|Overall Study|Withdrawal by Subject|1
5977078|NCT04258020|9564160|FG001|Overall Study|Withdrawal by Subject|0
5977079|NCT04234464|9564168|FG000|Period 2 (Second Treatment Intervention)|Subject did not meet the pre-dose FEV₁ criterion of >70% predicted at Visit 4/Visit 4 repeat.|1
5977080|NCT04234464|9564169|FG001|Period 2 (Second Treatment Intervention)|Subject did not meet the pre-dose FEV₁ criterion of >70% predicted at Visit 4/Visit 4 repeat.|0
6050798|NCT00428844|9649995|FG001|Completed Test of Cure (TOC) Visit|Protocol Violation|0
6198342|NCT01473940|9857959|FG003|Induction Therapy|Progressive Disease|0
6198343|NCT01473940|9857956|FG000|Maintenance Therapy|Progressive Disease|1
6275901|NCT02219048|9980994|FG001|Overall Study|No longer meets eligibility criteria|0
6275902|NCT02219048|9980993|FG000|Overall Study|Study terminated by sponsor|16
6275903|NCT02219048|9980994|FG001|Overall Study|Study terminated by sponsor|15
6275904|NCT02219048|9980993|FG000|Overall Study|Withdrawal by Subject|2
6275905|NCT02219048|9980994|FG001|Overall Study|Withdrawal by Subject|0
6275906|NCT02219048|9980993|FG000|Overall Study|Other|0
6050799|NCT00428844|9649996|FG002|Completed Test of Cure (TOC) Visit|Protocol Violation|1
6050800|NCT00428844|9649994|FG000|Completed Test of Cure (TOC) Visit|Withdrawal by Subject|1
6050801|NCT00428844|9649995|FG001|Completed Test of Cure (TOC) Visit|Withdrawal by Subject|0
6050802|NCT00428844|9649996|FG002|Completed Test of Cure (TOC) Visit|Withdrawal by Subject|0
6050803|NCT00428844|9649994|FG000|Completed Test of Cure (TOC) Visit|Lack of Efficacy|2
6050804|NCT00428844|9649995|FG001|Completed Test of Cure (TOC) Visit|Lack of Efficacy|0
6050805|NCT00428844|9649996|FG002|Completed Test of Cure (TOC) Visit|Lack of Efficacy|0
6050806|NCT00428844|9649994|FG000|Completed Test of Cure (TOC) Visit|Microbiologic failure|0
6050807|NCT00428844|9649995|FG001|Completed Test of Cure (TOC) Visit|Microbiologic failure|1
6050808|NCT00428844|9649996|FG002|Completed Test of Cure (TOC) Visit|Microbiologic failure|0
6050809|NCT00428948|9650010|FG000|Overall Study|Lost to Follow-up|15
6088667|NCT00677352|9699637|FG000|Treatment Phase|Withdrawal by Subject|7
6088668|NCT00677352|9699638|FG001|Treatment Phase|Withdrawal by Subject|7
6198344|NCT01473940|9857957|FG001|Maintenance Therapy|Progressive Disease|2
6198345|NCT01473940|9857958|FG002|Maintenance Therapy|Progressive Disease|1
6275907|NCT02219048|9980994|FG001|Overall Study|Other|1
6275908|NCT02219087|9981002|FG000|Overall Study|Randomization envelope pulled out of seq|0
6198346|NCT01473940|9857959|FG003|Maintenance Therapy|Progressive Disease|4
6198347|NCT01473953|9857977|FG000|Overall Study|Other|1
6198348|NCT01473953|9857978|FG001|Overall Study|Other|0
6198349|NCT01473953|9857979|FG002|Overall Study|Other|0
6198350|NCT01473953|9857980|FG003|Overall Study|Other|0
6198351|NCT01473953|9857981|FG004|Overall Study|Other|0
6198352|NCT01474018|9858007|FG000|Overall Study|Lost to Follow-up|0
6198353|NCT01474018|9858008|FG001|Overall Study|Lost to Follow-up|1
6198354|NCT01474018|9858007|FG000|Overall Study|Withdrawal by Subject|0
6198355|NCT01474018|9858008|FG001|Overall Study|Withdrawal by Subject|2
6198356|NCT01474239|9858066|FG000|Overall Study|Disease Progression|37
6198357|NCT01474239|9858067|FG001|Overall Study|Disease Progression|25
6198358|NCT01474239|9858066|FG000|Overall Study|Adverse Event|12
6198359|NCT01474239|9858067|FG001|Overall Study|Adverse Event|3
6198360|NCT01474239|9858066|FG000|Overall Study|Withdrawal by Subject|1
6198361|NCT01474239|9858067|FG001|Overall Study|Withdrawal by Subject|2
6198362|NCT01474239|9858066|FG000|Overall Study|Death|1
6198363|NCT01474239|9858067|FG001|Overall Study|Death|1
6088669|NCT00677352|9699637|FG000|Treatment Phase|Physician Decision|1
6088670|NCT00677352|9699638|FG001|Treatment Phase|Physician Decision|0
6088671|NCT00677352|9699637|FG000|Treatment Phase|Pregnancy|0
6088672|NCT00677352|9699638|FG001|Treatment Phase|Pregnancy|1
6088673|NCT00677352|9699637|FG000|Treatment Phase|Protocol Violation|1
6088674|NCT00677352|9699638|FG001|Treatment Phase|Protocol Violation|1
6198364|NCT01474239|9858066|FG000|Overall Study|Clinical Disease Progression|7
6198365|NCT01474239|9858067|FG001|Overall Study|Clinical Disease Progression|1
6198366|NCT01474239|9858066|FG000|Overall Study|Withdrawal for Economic Reason|1
6198367|NCT01474239|9858067|FG001|Overall Study|Withdrawal for Economic Reason|0
6198368|NCT01474291|9858075|FG000|Overall Study|Not Evaluable for Efficacy|26
6198369|NCT01474291|9858075|FG000|Overall Study|Lack of Treatment Efficacy|88
6198370|NCT01474291|9858075|FG000|Overall Study|Adverse Event|53
6198371|NCT01474291|9858075|FG000|Overall Study|Lost to Follow-up|29
6198372|NCT01474291|9858075|FG000|Overall Study|Patient No Longer Wanted to Participate|12
6198373|NCT01474291|9858075|FG000|Overall Study|No Reason Reported|10
6198374|NCT01474291|9858075|FG000|Overall Study|Death|2
6198375|NCT01474317|9858082|FG000|Overall Study|Adverse Event|1
6198376|NCT01474317|9858082|FG000|Overall Study|Subject ineligible for study|1
6198377|NCT01474434|9858090|FG000|Treatment Period 1 (5 Days [Day 1 - 5])|Adverse Event|0
6198378|NCT01474434|9858091|FG001|Treatment Period 1 (5 Days [Day 1 - 5])|Adverse Event|0
6198379|NCT01474434|9858092|FG002|Treatment Period 1 (5 Days [Day 1 - 5])|Adverse Event|1
6198380|NCT01474434|9858093|FG003|Treatment Period 1 (5 Days [Day 1 - 5])|Adverse Event|1
6198381|NCT01474434|9858090|FG000|Treatment Period 1 (5 Days [Day 1 - 5])|Withdrawal by Subject|0
6198382|NCT01474434|9858091|FG001|Treatment Period 1 (5 Days [Day 1 - 5])|Withdrawal by Subject|0
6198383|NCT01474434|9858092|FG002|Treatment Period 1 (5 Days [Day 1 - 5])|Withdrawal by Subject|0
6198384|NCT01474434|9858093|FG003|Treatment Period 1 (5 Days [Day 1 - 5])|Withdrawal by Subject|1
6198385|NCT01474434|9858090|FG000|Treatment Period 1 (5 Days [Day 1 - 5])|Protocol deviation|1
6198386|NCT01474434|9858091|FG001|Treatment Period 1 (5 Days [Day 1 - 5])|Protocol deviation|0
6198387|NCT01474434|9858092|FG002|Treatment Period 1 (5 Days [Day 1 - 5])|Protocol deviation|0
6198388|NCT01474434|9858093|FG003|Treatment Period 1 (5 Days [Day 1 - 5])|Protocol deviation|0
6198389|NCT01474486|9858107|FG000|Overall Study|Death|2
6198390|NCT01474486|9858107|FG000|Overall Study|Withdrawal by Subject|4
6198391|NCT01474486|9858107|FG000|Overall Study|Withdrawn by the PI: One didn't understand what he consented for and one required surgery.|2
6198392|NCT01474512|9858118|FG000|Induction Period|Adverse Event|6
6088675|NCT00677352|9699637|FG000|Treatment Phase|Transference or work related matter|0
6088676|NCT00677352|9699638|FG001|Treatment Phase|Transference or work related matter|5
6198393|NCT01474512|9858119|FG001|Induction Period|Adverse Event|10
6198394|NCT01474512|9858120|FG002|Induction Period|Adverse Event|10
6198395|NCT01474512|9858121|FG003|Induction Period|Adverse Event|0
6198396|NCT01474512|9858122|FG004|Induction Period|Adverse Event|0
6198397|NCT01474512|9858123|FG005|Induction Period|Adverse Event|0
6198398|NCT01474512|9858124|FG006|Induction Period|Adverse Event|0
6198399|NCT01474512|9858125|FG007|Induction Period|Adverse Event|0
6198400|NCT01474512|9858126|FG008|Induction Period|Adverse Event|0
6198401|NCT01474512|9858127|FG009|Induction Period|Adverse Event|0
6198402|NCT01474512|9858128|FG010|Induction Period|Adverse Event|0
6198403|NCT01474512|9858129|FG011|Induction Period|Adverse Event|0
6198404|NCT01474512|9858130|FG012|Induction Period|Adverse Event|0
6198405|NCT01474512|9858131|FG013|Induction Period|Adverse Event|0
6198406|NCT01474512|9858132|FG014|Induction Period|Adverse Event|0
6198407|NCT01474512|9858133|FG015|Induction Period|Adverse Event|0
6198408|NCT01474512|9858134|FG016|Induction Period|Adverse Event|0
6198409|NCT01474512|9858135|FG017|Induction Period|Adverse Event|0
6198410|NCT01474512|9858118|FG000|Induction Period|Lack of Efficacy|7
6198411|NCT01474512|9858119|FG001|Induction Period|Lack of Efficacy|1
6198412|NCT01474512|9858120|FG002|Induction Period|Lack of Efficacy|0
6198413|NCT01474512|9858121|FG003|Induction Period|Lack of Efficacy|0
6198414|NCT01474512|9858122|FG004|Induction Period|Lack of Efficacy|0
6198415|NCT01474512|9858123|FG005|Induction Period|Lack of Efficacy|0
6275909|NCT02219087|9981003|FG001|Overall Study|Randomization envelope pulled out of seq|1
6088677|NCT00677352|9699637|FG000|Treatment Phase|Not treated|0
6198416|NCT01474512|9858124|FG006|Induction Period|Lack of Efficacy|0
6198417|NCT01474512|9858125|FG007|Induction Period|Lack of Efficacy|0
6198418|NCT01474512|9858126|FG008|Induction Period|Lack of Efficacy|0
6198419|NCT01474512|9858127|FG009|Induction Period|Lack of Efficacy|0
6198420|NCT01474512|9858128|FG010|Induction Period|Lack of Efficacy|0
6198421|NCT01474512|9858129|FG011|Induction Period|Lack of Efficacy|0
6198422|NCT01474512|9858130|FG012|Induction Period|Lack of Efficacy|0
6198423|NCT01474512|9858131|FG013|Induction Period|Lack of Efficacy|0
6198424|NCT01474512|9858132|FG014|Induction Period|Lack of Efficacy|0
6198425|NCT01474512|9858133|FG015|Induction Period|Lack of Efficacy|0
6198426|NCT01474512|9858134|FG016|Induction Period|Lack of Efficacy|0
6198427|NCT01474512|9858135|FG017|Induction Period|Lack of Efficacy|0
6198428|NCT01474512|9858118|FG000|Induction Period|Withdrawal by Subject|6
6198429|NCT01474512|9858119|FG001|Induction Period|Withdrawal by Subject|6
6198430|NCT01474512|9858120|FG002|Induction Period|Withdrawal by Subject|5
6198431|NCT01474512|9858121|FG003|Induction Period|Withdrawal by Subject|0
6198432|NCT01474512|9858122|FG004|Induction Period|Withdrawal by Subject|0
6275910|NCT02219308|9981073|FG000|Overall Study|Withdrawal by Subject|1
6275911|NCT02219308|9981074|FG001|Overall Study|Withdrawal by Subject|2
6275912|NCT02219334|9981091|FG000|Overall Study|Withdrawal by Subject|1
6275913|NCT02219334|9981092|FG001|Overall Study|Withdrawal by Subject|0
6275914|NCT02219334|9981091|FG000|Overall Study|Protocol Violation|7
6275915|NCT02219334|9981092|FG001|Overall Study|Protocol Violation|3
6275916|NCT02219464|9981111|FG000|Overall Study|Withdrawal by Subject|1
6275917|NCT02219464|9981112|FG001|Overall Study|Withdrawal by Subject|0
6275918|NCT02219464|9981111|FG000|Overall Study|case cancelled|1
6275919|NCT02219464|9981112|FG001|Overall Study|case cancelled|0
6275920|NCT02219464|9981111|FG000|Overall Study|catheter malfunction|1
6275921|NCT02219464|9981112|FG001|Overall Study|catheter malfunction|0
6275922|NCT02219477|9981121|FG000|Overall Study|Adverse Event|0
6275923|NCT02219477|9981122|FG001|Overall Study|Adverse Event|1
6275924|NCT02219477|9981123|FG002|Overall Study|Adverse Event|1
6275925|NCT02219477|9981121|FG000|Overall Study|Withdrawal by Subject|0
6275926|NCT02219477|9981122|FG001|Overall Study|Withdrawal by Subject|1
6275927|NCT02219477|9981123|FG002|Overall Study|Withdrawal by Subject|0
6275928|NCT02219685|9981155|FG000|Blinded Treatment Phase|Lost to Follow-up|1
6275929|NCT02219685|9981156|FG001|Blinded Treatment Phase|Lost to Follow-up|0
6275930|NCT02219685|9981155|FG000|Blinded Treatment Phase|Withdrew Consent|1
6275931|NCT02219685|9981156|FG001|Blinded Treatment Phase|Withdrew Consent|0
6275932|NCT02219932|9981175|FG000|Overall Study|Other|5
6275933|NCT02219932|9981176|FG001|Overall Study|Other|11
6275934|NCT02219932|9981175|FG000|Overall Study|Death|1
6275935|NCT02219932|9981176|FG001|Overall Study|Death|1
6275936|NCT02219932|9981175|FG000|Overall Study|Investigator Decision|0
6275937|NCT02219932|9981176|FG001|Overall Study|Investigator Decision|1
6275938|NCT02219932|9981175|FG000|Overall Study|Consent Withdrawn|11
6275939|NCT02219932|9981176|FG001|Overall Study|Consent Withdrawn|7
6275940|NCT02219932|9981175|FG000|Overall Study|Lack of Efficacy (Subject Perception)|10
6275941|NCT02219932|9981176|FG001|Overall Study|Lack of Efficacy (Subject Perception)|2
6275942|NCT02219932|9981175|FG000|Overall Study|Protocol Violation|10
6275943|NCT02219932|9981176|FG001|Overall Study|Protocol Violation|6
6275944|NCT02219932|9981175|FG000|Overall Study|Pregnancy|1
6275945|NCT02219932|9981176|FG001|Overall Study|Pregnancy|0
6275946|NCT02219932|9981175|FG000|Overall Study|Lost to Follow-up|4
6275947|NCT02219932|9981176|FG001|Overall Study|Lost to Follow-up|2
6275948|NCT02219932|9981175|FG000|Overall Study|Adverse Event|23
6275949|NCT02219932|9981176|FG001|Overall Study|Adverse Event|21
6275950|NCT02220205|9981199|FG000|Overall Study|Withdrawal by Subject|1
6275951|NCT02220205|9981200|FG001|Overall Study|Withdrawal by Subject|0
6275952|NCT02220712|9981206|FG000|Overall Study|Adverse Event|1
6275953|NCT02220712|9981206|FG000|Overall Study|Withdrawal by Subject|2
6275954|NCT02220712|9981206|FG000|Overall Study|Exacerbation of symptoms of an underlying disease|1
6275955|NCT02220725|9981218|FG000|Overall Study|Lost to Follow-up|0
6275956|NCT02220725|9981219|FG001|Overall Study|Lost to Follow-up|0
6275957|NCT02220725|9981220|FG002|Overall Study|Lost to Follow-up|0
6275958|NCT02220725|9981221|FG003|Overall Study|Lost to Follow-up|1
6275959|NCT02220725|9981218|FG000|Overall Study|Withdrawal by Subject|0
6275960|NCT02220725|9981219|FG001|Overall Study|Withdrawal by Subject|0
6275961|NCT02220725|9981220|FG002|Overall Study|Withdrawal by Subject|0
6275962|NCT02220725|9981221|FG003|Overall Study|Withdrawal by Subject|1
6275963|NCT02220764|9981236|FG000|Overall Study|Lost to Follow-up|3
6275964|NCT02220764|9981237|FG001|Overall Study|Lost to Follow-up|1
6275965|NCT02220764|9981236|FG000|Overall Study|Death|1
6275966|NCT02220764|9981237|FG001|Overall Study|Death|0
6275967|NCT02220907|9981243|FG000|Overall Study|Adverse Event|7
6275968|NCT02220907|9981243|FG000|Overall Study|Physician Decision|1
6198433|NCT01474512|9858123|FG005|Induction Period|Withdrawal by Subject|0
6198434|NCT01474512|9858124|FG006|Induction Period|Withdrawal by Subject|0
5977081|NCT03852316|9564175|FG000|Overall Study|Protocol Violation|1
6198435|NCT01474512|9858125|FG007|Induction Period|Withdrawal by Subject|0
6198436|NCT01474512|9858126|FG008|Induction Period|Withdrawal by Subject|0
6198437|NCT01474512|9858127|FG009|Induction Period|Withdrawal by Subject|0
6198438|NCT01474512|9858128|FG010|Induction Period|Withdrawal by Subject|0
6275969|NCT02220907|9981243|FG000|Overall Study|Withdrawal by Subject|2
6275970|NCT02220907|9981243|FG000|Overall Study|Conflict with the stopping criteria|1
6198439|NCT01474512|9858129|FG011|Induction Period|Withdrawal by Subject|0
6198440|NCT01474512|9858130|FG012|Induction Period|Withdrawal by Subject|0
6198441|NCT01474512|9858131|FG013|Induction Period|Withdrawal by Subject|0
6198442|NCT01474512|9858132|FG014|Induction Period|Withdrawal by Subject|0
6198443|NCT01474512|9858133|FG015|Induction Period|Withdrawal by Subject|0
6198444|NCT01474512|9858134|FG016|Induction Period|Withdrawal by Subject|0
6198445|NCT01474512|9858135|FG017|Induction Period|Withdrawal by Subject|0
6198446|NCT01474512|9858118|FG000|Induction Period|Protocol Violation|3
6198447|NCT01474512|9858119|FG001|Induction Period|Protocol Violation|6
6198448|NCT01474512|9858120|FG002|Induction Period|Protocol Violation|0
6198449|NCT01474512|9858121|FG003|Induction Period|Protocol Violation|0
6198450|NCT01474512|9858122|FG004|Induction Period|Protocol Violation|0
6198451|NCT01474512|9858123|FG005|Induction Period|Protocol Violation|0
6198452|NCT01474512|9858124|FG006|Induction Period|Protocol Violation|0
6198453|NCT01474512|9858125|FG007|Induction Period|Protocol Violation|0
6198454|NCT01474512|9858126|FG008|Induction Period|Protocol Violation|0
6198455|NCT01474512|9858127|FG009|Induction Period|Protocol Violation|0
6198456|NCT01474512|9858128|FG010|Induction Period|Protocol Violation|0
6198457|NCT01474512|9858129|FG011|Induction Period|Protocol Violation|0
6198458|NCT01474512|9858130|FG012|Induction Period|Protocol Violation|0
6198459|NCT01474512|9858131|FG013|Induction Period|Protocol Violation|0
6198460|NCT01474512|9858132|FG014|Induction Period|Protocol Violation|0
6198461|NCT01474512|9858133|FG015|Induction Period|Protocol Violation|0
6198462|NCT01474512|9858134|FG016|Induction Period|Protocol Violation|0
6198463|NCT01474512|9858135|FG017|Induction Period|Protocol Violation|0
6198464|NCT01474512|9858118|FG000|Induction Period|Sponsor Decision|1
6198465|NCT01474512|9858119|FG001|Induction Period|Sponsor Decision|1
6275971|NCT02220920|9981249|FG000|Overall Study|Adverse Event|1
6275972|NCT02220920|9981250|FG001|Overall Study|Adverse Event|0
6275973|NCT02220920|9981249|FG000|Overall Study|Lack of Efficacy|0
6275974|NCT02220920|9981250|FG001|Overall Study|Lack of Efficacy|1
6275975|NCT02220920|9981249|FG000|Overall Study|Withdrawal by Subject|1
6275976|NCT02220920|9981250|FG001|Overall Study|Withdrawal by Subject|0
6275977|NCT02220920|9981249|FG000|Overall Study|Conflict with the stopping criteria|1
6275978|NCT02220920|9981250|FG001|Overall Study|Conflict with the stopping criteria|2
6275979|NCT02220998|9981258|FG000|Overall Study|Randomized but Never Treated|1
6275980|NCT02220998|9981259|FG001|Overall Study|Randomized but Never Treated|2
6275981|NCT02220998|9981258|FG000|Overall Study|Death|2
6275982|NCT02220998|9981259|FG001|Overall Study|Death|0
6275983|NCT02220998|9981258|FG000|Overall Study|Lack of Efficacy|0
6275984|NCT02220998|9981259|FG001|Overall Study|Lack of Efficacy|5
6275985|NCT02220998|9981258|FG000|Overall Study|Lost to Follow-up|4
6275986|NCT02220998|9981259|FG001|Overall Study|Lost to Follow-up|4
6275987|NCT02221284|9981286|FG000|Overall Study|Case Report Forms Uncollected|56
6275988|NCT02221284|9981286|FG000|Overall Study|Protocol Deviation|5
6275989|NCT02221648|9981311|FG000|Overall Study|Withdrawal by Subject|3
6275990|NCT02221648|9981312|FG001|Overall Study|Withdrawal by Subject|3
6275991|NCT02221674|9981325|FG000|Overall Study|Lost to Follow-up|1
6275992|NCT02221674|9981326|FG001|Overall Study|Lost to Follow-up|0
6275993|NCT02221674|9981327|FG002|Overall Study|Lost to Follow-up|0
6275994|NCT02221882|9981359|FG000|Overall Study|Withdrawal by Subject|0
6275995|NCT02221882|9981360|FG001|Overall Study|Withdrawal by Subject|0
6275996|NCT02221882|9981361|FG002|Overall Study|Withdrawal by Subject|4
6275997|NCT02221882|9981362|FG003|Overall Study|Withdrawal by Subject|2
6275998|NCT02221882|9981363|FG004|Overall Study|Withdrawal by Subject|2
6275999|NCT02221882|9981364|FG005|Overall Study|Withdrawal by Subject|2
6276000|NCT02221882|9981359|FG000|Overall Study|Death|0
6276001|NCT02221882|9981360|FG001|Overall Study|Death|1
6276002|NCT02221882|9981361|FG002|Overall Study|Death|0
6276003|NCT02221882|9981362|FG003|Overall Study|Death|0
6276004|NCT02221882|9981363|FG004|Overall Study|Death|0
6276005|NCT02221882|9981364|FG005|Overall Study|Death|0
6276006|NCT02222207|9981408|FG000|Overall Study|Death|1
6276007|NCT02222207|9981408|FG000|Overall Study|Other reasons|2
6276008|NCT02222207|9981408|FG000|Overall Study|Adverse Event|1
6276009|NCT02222246|9981414|FG000|Overall Study|No Emergency Department Visits|27
6276010|NCT02222246|9981415|FG001|Overall Study|No Emergency Department Visits|26
6276011|NCT02222246|9981414|FG000|Overall Study|Physician Decision|0
6276012|NCT02222246|9981415|FG001|Overall Study|Physician Decision|1
6276013|NCT02222493|9981438|FG000|Period 1: First Dose-Week 30 (Pre-dose)|Death|2
6276014|NCT02222493|9981439|FG001|Period 1: First Dose-Week 30 (Pre-dose)|Death|2
6276015|NCT02222493|9981438|FG000|Period 1: First Dose-Week 30 (Pre-dose)|Lost to Follow-up|0
6276016|NCT02222493|9981439|FG001|Period 1: First Dose-Week 30 (Pre-dose)|Lost to Follow-up|1
6276017|NCT02222493|9981438|FG000|Period 1: First Dose-Week 30 (Pre-dose)|Withdrawal by Subject|11
6276018|NCT02222493|9981439|FG001|Period 1: First Dose-Week 30 (Pre-dose)|Withdrawal by Subject|9
6276019|NCT02222493|9981438|FG000|Period 1: First Dose-Week 30 (Pre-dose)|Protocol Violation|5
6198466|NCT01474512|9858120|FG002|Induction Period|Sponsor Decision|1
6198467|NCT01474512|9858121|FG003|Induction Period|Sponsor Decision|0
6198468|NCT01474512|9858122|FG004|Induction Period|Sponsor Decision|0
6198469|NCT01474512|9858123|FG005|Induction Period|Sponsor Decision|0
6198470|NCT01474512|9858124|FG006|Induction Period|Sponsor Decision|0
6276020|NCT02222493|9981439|FG001|Period 1: First Dose-Week 30 (Pre-dose)|Protocol Violation|1
6198471|NCT01474512|9858125|FG007|Induction Period|Sponsor Decision|0
6198472|NCT01474512|9858126|FG008|Induction Period|Sponsor Decision|0
6198473|NCT01474512|9858127|FG009|Induction Period|Sponsor Decision|0
6198474|NCT01474512|9858128|FG010|Induction Period|Sponsor Decision|0
6198475|NCT01474512|9858129|FG011|Induction Period|Sponsor Decision|0
6198476|NCT01474512|9858130|FG012|Induction Period|Sponsor Decision|0
6198477|NCT01474512|9858131|FG013|Induction Period|Sponsor Decision|0
6198478|NCT01474512|9858132|FG014|Induction Period|Sponsor Decision|0
6198479|NCT01474512|9858133|FG015|Induction Period|Sponsor Decision|0
6198480|NCT01474512|9858134|FG016|Induction Period|Sponsor Decision|0
6198481|NCT01474512|9858135|FG017|Induction Period|Sponsor Decision|0
6198482|NCT01474512|9858118|FG000|Induction Period|Lost to Follow-up|1
6198483|NCT01474512|9858119|FG001|Induction Period|Lost to Follow-up|0
6198484|NCT01474512|9858120|FG002|Induction Period|Lost to Follow-up|2
6198485|NCT01474512|9858121|FG003|Induction Period|Lost to Follow-up|0
6198486|NCT01474512|9858122|FG004|Induction Period|Lost to Follow-up|0
6198487|NCT01474512|9858123|FG005|Induction Period|Lost to Follow-up|0
6198488|NCT01474512|9858124|FG006|Induction Period|Lost to Follow-up|0
6198489|NCT01474512|9858125|FG007|Induction Period|Lost to Follow-up|0
6198490|NCT01474512|9858126|FG008|Induction Period|Lost to Follow-up|0
6198491|NCT01474512|9858127|FG009|Induction Period|Lost to Follow-up|0
6198492|NCT01474512|9858128|FG010|Induction Period|Lost to Follow-up|0
6198493|NCT01474512|9858129|FG011|Induction Period|Lost to Follow-up|0
6198494|NCT01474512|9858130|FG012|Induction Period|Lost to Follow-up|0
6198495|NCT01474512|9858131|FG013|Induction Period|Lost to Follow-up|0
6276021|NCT02222493|9981438|FG000|Period 1: First Dose-Week 30 (Pre-dose)|Insufficient clinical response|0
6276022|NCT02222493|9981439|FG001|Period 1: First Dose-Week 30 (Pre-dose)|Insufficient clinical response|7
6276023|NCT02222493|9981438|FG000|Period 1: First Dose-Week 30 (Pre-dose)|Non-compliance with study treatment|1
6276024|NCT02222493|9981439|FG001|Period 1: First Dose-Week 30 (Pre-dose)|Non-compliance with study treatment|0
6276025|NCT02222493|9981438|FG000|Period 1: First Dose-Week 30 (Pre-dose)|Pregnancy|2
6276026|NCT02222493|9981439|FG001|Period 1: First Dose-Week 30 (Pre-dose)|Pregnancy|0
6276027|NCT02222493|9981438|FG000|Period 1: First Dose-Week 30 (Pre-dose)|Adverse Event|18
6276028|NCT02222493|9981439|FG001|Period 1: First Dose-Week 30 (Pre-dose)|Adverse Event|20
6276029|NCT02222493|9981438|FG000|Period 1: First Dose-Week 30 (Pre-dose)|Other|4
6276030|NCT02222493|9981439|FG001|Period 1: First Dose-Week 30 (Pre-dose)|Other|0
6276031|NCT02222493|9981438|FG000|Period 1: First Dose-Week 30 (Pre-dose)|Randomized but not treated|1
6276032|NCT02222493|9981439|FG001|Period 1: First Dose-Week 30 (Pre-dose)|Randomized but not treated|0
6276033|NCT02222493|9981438|FG000|Period 2: Week30 Dosing-Week54(Pre-dose)|Death|1
6276034|NCT02222493|9981439|FG001|Period 2: Week30 Dosing-Week54(Pre-dose)|Death|0
6276035|NCT02222493|9981438|FG000|Period 2: Week30 Dosing-Week54(Pre-dose)|Adverse Event|22
6276036|NCT02222493|9981439|FG001|Period 2: Week30 Dosing-Week54(Pre-dose)|Adverse Event|9
6276037|NCT02222493|9981438|FG000|Period 2: Week30 Dosing-Week54(Pre-dose)|Other|3
6276038|NCT02222493|9981439|FG001|Period 2: Week30 Dosing-Week54(Pre-dose)|Other|0
6276039|NCT02222493|9981438|FG000|Period 2: Week30 Dosing-Week54(Pre-dose)|Non-compliance with study treatment|1
6276040|NCT02222493|9981439|FG001|Period 2: Week30 Dosing-Week54(Pre-dose)|Non-compliance with study treatment|0
6276041|NCT02222493|9981438|FG000|Period 2: Week30 Dosing-Week54(Pre-dose)|Withdrawal by Subject|6
6276042|NCT02222493|9981439|FG001|Period 2: Week30 Dosing-Week54(Pre-dose)|Withdrawal by Subject|4
6276043|NCT02222493|9981438|FG000|Period 2: Week30 Dosing-Week54(Pre-dose)|Lost to Follow-up|1
6276044|NCT02222493|9981439|FG001|Period 2: Week30 Dosing-Week54(Pre-dose)|Lost to Follow-up|1
6276045|NCT02222493|9981438|FG000|Period 2: Week30 Dosing-Week54(Pre-dose)|Insufficient clinical response|9
6276046|NCT02222493|9981439|FG001|Period 2: Week30 Dosing-Week54(Pre-dose)|Insufficient clinical response|3
6276047|NCT02222493|9981438|FG000|Period 3: Week 54 Dosing-Week 78 Visit|Insufficient clinical response|3
6276048|NCT02222493|9981439|FG001|Period 3: Week 54 Dosing-Week 78 Visit|Insufficient clinical response|0
6276049|NCT02222493|9981438|FG000|Period 3: Week 54 Dosing-Week 78 Visit|Adverse Event|14
6276050|NCT02222493|9981439|FG001|Period 3: Week 54 Dosing-Week 78 Visit|Adverse Event|0
6276051|NCT02222493|9981438|FG000|Period 3: Week 54 Dosing-Week 78 Visit|Other|4
6276052|NCT02222493|9981439|FG001|Period 3: Week 54 Dosing-Week 78 Visit|Other|0
6276053|NCT02222493|9981438|FG000|Period 3: Week 54 Dosing-Week 78 Visit|Non-compliance with study treatment|1
6276054|NCT02222493|9981439|FG001|Period 3: Week 54 Dosing-Week 78 Visit|Non-compliance with study treatment|0
5977082|NCT03852316|9564175|FG000|Overall Study|Withdrawal by Subject|2
6198496|NCT01474512|9858132|FG014|Induction Period|Lost to Follow-up|0
6198497|NCT01474512|9858133|FG015|Induction Period|Lost to Follow-up|0
6198498|NCT01474512|9858134|FG016|Induction Period|Lost to Follow-up|0
6198499|NCT01474512|9858135|FG017|Induction Period|Lost to Follow-up|0
6198500|NCT01474512|9858118|FG000|Maintenance Period|Relapsed (sPGA ≥3)|0
6198501|NCT01474512|9858119|FG001|Maintenance Period|Relapsed (sPGA ≥3)|0
6198502|NCT01474512|9858120|FG002|Maintenance Period|Relapsed (sPGA ≥3)|0
6198503|NCT01474512|9858121|FG003|Maintenance Period|Relapsed (sPGA ≥3)|186
6198504|NCT01474512|9858122|FG004|Maintenance Period|Relapsed (sPGA ≥3)|111
6198505|NCT01474512|9858123|FG005|Maintenance Period|Relapsed (sPGA ≥3)|39
6198506|NCT01474512|9858124|FG006|Maintenance Period|Relapsed (sPGA ≥3)|9
6198507|NCT01474512|9858125|FG007|Maintenance Period|Relapsed (sPGA ≥3)|0
6198508|NCT01474512|9858126|FG008|Maintenance Period|Relapsed (sPGA ≥3)|0
6198509|NCT01474512|9858127|FG009|Maintenance Period|Relapsed (sPGA ≥3)|0
6198510|NCT01474512|9858128|FG010|Maintenance Period|Relapsed (sPGA ≥3)|0
6198511|NCT01474512|9858129|FG011|Maintenance Period|Relapsed (sPGA ≥3)|0
6198512|NCT01474512|9858130|FG012|Maintenance Period|Relapsed (sPGA ≥3)|0
6198513|NCT01474512|9858131|FG013|Maintenance Period|Relapsed (sPGA ≥3)|0
6198514|NCT01474512|9858132|FG014|Maintenance Period|Relapsed (sPGA ≥3)|0
6198515|NCT01474512|9858133|FG015|Maintenance Period|Relapsed (sPGA ≥3)|0
6198516|NCT01474512|9858134|FG016|Maintenance Period|Relapsed (sPGA ≥3)|0
6198517|NCT01474512|9858135|FG017|Maintenance Period|Relapsed (sPGA ≥3)|0
6198518|NCT01474512|9858118|FG000|Maintenance Period|Adverse Event|0
6198519|NCT01474512|9858119|FG001|Maintenance Period|Adverse Event|0
6198520|NCT01474512|9858120|FG002|Maintenance Period|Adverse Event|0
6198521|NCT01474512|9858121|FG003|Maintenance Period|Adverse Event|4
6198522|NCT01474512|9858122|FG004|Maintenance Period|Adverse Event|2
6198523|NCT01474512|9858123|FG005|Maintenance Period|Adverse Event|7
6198524|NCT01474512|9858124|FG006|Maintenance Period|Adverse Event|0
6198525|NCT01474512|9858125|FG007|Maintenance Period|Adverse Event|19
6198526|NCT01474512|9858126|FG008|Maintenance Period|Adverse Event|1
6198527|NCT01474512|9858127|FG009|Maintenance Period|Adverse Event|3
6198528|NCT01474512|9858128|FG010|Maintenance Period|Adverse Event|0
6198529|NCT01474512|9858129|FG011|Maintenance Period|Adverse Event|0
6198530|NCT01474512|9858130|FG012|Maintenance Period|Adverse Event|0
6198531|NCT01474512|9858131|FG013|Maintenance Period|Adverse Event|0
6198532|NCT01474512|9858132|FG014|Maintenance Period|Adverse Event|0
6198533|NCT01474512|9858133|FG015|Maintenance Period|Adverse Event|0
6198534|NCT01474512|9858134|FG016|Maintenance Period|Adverse Event|0
6198535|NCT01474512|9858135|FG017|Maintenance Period|Adverse Event|0
6276055|NCT02222493|9981438|FG000|Period 3: Week 54 Dosing-Week 78 Visit|Withdrawal by Subject|9
6276056|NCT02222493|9981439|FG001|Period 3: Week 54 Dosing-Week 78 Visit|Withdrawal by Subject|0
6276057|NCT02222558|9981458|FG000|Period 1: Single Dose|Withdrawal by Subject|4
6276058|NCT02222558|9981459|FG001|Period 1: Single Dose|Withdrawal by Subject|0
6276059|NCT02222558|9981460|FG002|Period 1: Single Dose|Withdrawal by Subject|0
6276060|NCT02222558|9981461|FG003|Period 1: Single Dose|Withdrawal by Subject|0
6276061|NCT02222558|9981462|FG004|Period 1: Single Dose|Withdrawal by Subject|0
6276062|NCT02222558|9981463|FG005|Period 1: Single Dose|Withdrawal by Subject|0
6276063|NCT02222558|9981458|FG000|Period 3|Withdrawal by Subject|0
6276064|NCT02222558|9981459|FG001|Period 3|Withdrawal by Subject|0
6276065|NCT02222558|9981460|FG002|Period 3|Withdrawal by Subject|0
6276066|NCT02222558|9981461|FG003|Period 3|Withdrawal by Subject|0
6276067|NCT02222558|9981462|FG004|Period 3|Withdrawal by Subject|0
6276068|NCT02222558|9981463|FG005|Period 3|Withdrawal by Subject|1
6276069|NCT02222688|9981497|FG000|Overall Study|Withdrawal by Subject|0
6276070|NCT02222688|9981498|FG001|Overall Study|Withdrawal by Subject|0
6276071|NCT02222688|9981499|FG002|Overall Study|Withdrawal by Subject|0
6276072|NCT02222688|9981500|FG003|Overall Study|Withdrawal by Subject|2
6276073|NCT02222688|9981501|FG004|Overall Study|Withdrawal by Subject|1
6276074|NCT02222688|9981502|FG005|Overall Study|Withdrawal by Subject|0
6276075|NCT02222688|9981503|FG006|Overall Study|Withdrawal by Subject|1
6276076|NCT02222688|9981497|FG000|Overall Study|Disease progression|1
6276077|NCT02222688|9981498|FG001|Overall Study|Disease progression|0
6276078|NCT02222688|9981499|FG002|Overall Study|Disease progression|0
6276079|NCT02222688|9981500|FG003|Overall Study|Disease progression|0
6276080|NCT02222688|9981501|FG004|Overall Study|Disease progression|0
6276081|NCT02222688|9981502|FG005|Overall Study|Disease progression|0
6276082|NCT02222688|9981503|FG006|Overall Study|Disease progression|0
6276083|NCT02222714|9981526|FG000|Overall Study|Death|0
6276084|NCT02222714|9981527|FG001|Overall Study|Death|2
6276085|NCT02222714|9981528|FG002|Overall Study|Death|3
6276086|NCT02222714|9981529|FG003|Overall Study|Death|4
6276087|NCT02222714|9981530|FG004|Overall Study|Death|6
6276088|NCT02222714|9981526|FG000|Overall Study|Withdrawal by Subject|0
6276089|NCT02222714|9981527|FG001|Overall Study|Withdrawal by Subject|0
6276090|NCT02222714|9981528|FG002|Overall Study|Withdrawal by Subject|1
6276091|NCT02222714|9981529|FG003|Overall Study|Withdrawal by Subject|0
6276092|NCT02222714|9981530|FG004|Overall Study|Withdrawal by Subject|1
6276093|NCT02222818|9981547|FG000|Period 1|Eligibility criteria not met|0
6276094|NCT02222818|9981548|FG001|Period 1|Eligibility criteria not met|3
6276095|NCT02222896|9981562|FG000|Abdomen|Did not qualify|34
6276096|NCT02222896|9981563|FG001|Abdomen|Did not qualify|10
6276097|NCT02222896|9981564|FG002|Abdomen|Did not qualify|32
6276098|NCT02222896|9981562|FG000|Groin|Did not qualify|43
6276099|NCT02222896|9981563|FG001|Groin|Did not qualify|9
6276100|NCT02222896|9981564|FG002|Groin|Did not qualify|40
6276101|NCT02222922|9981584|FG000|Overall Study|Death|0
6276102|NCT02222922|9981585|FG001|Overall Study|Death|0
6276103|NCT02222922|9981586|FG002|Overall Study|Death|0
6276104|NCT02222922|9981587|FG003|Overall Study|Death|0
6276105|NCT02222922|9981588|FG004|Overall Study|Death|13
6276106|NCT02222922|9981589|FG005|Overall Study|Death|0
6276107|NCT02222922|9981590|FG006|Overall Study|Death|0
6276108|NCT02222922|9981591|FG007|Overall Study|Death|0
6276109|NCT02222922|9981592|FG008|Overall Study|Death|2
6276110|NCT02222922|9981584|FG000|Overall Study|Lost to Follow-up|0
6276111|NCT02222922|9981585|FG001|Overall Study|Lost to Follow-up|0
6276112|NCT02222922|9981586|FG002|Overall Study|Lost to Follow-up|1
6276113|NCT02222922|9981587|FG003|Overall Study|Lost to Follow-up|0
6276114|NCT02222922|9981588|FG004|Overall Study|Lost to Follow-up|9
6198536|NCT01474512|9858118|FG000|Maintenance Period|Withdrawal by Subject|0
6198537|NCT01474512|9858119|FG001|Maintenance Period|Withdrawal by Subject|0
6198538|NCT01474512|9858120|FG002|Maintenance Period|Withdrawal by Subject|0
6198539|NCT01474512|9858121|FG003|Maintenance Period|Withdrawal by Subject|6
6198540|NCT01474512|9858122|FG004|Maintenance Period|Withdrawal by Subject|2
6198541|NCT01474512|9858123|FG005|Maintenance Period|Withdrawal by Subject|3
6198542|NCT01474512|9858124|FG006|Maintenance Period|Withdrawal by Subject|1
6198543|NCT01474512|9858125|FG007|Maintenance Period|Withdrawal by Subject|6
6198544|NCT01474512|9858126|FG008|Maintenance Period|Withdrawal by Subject|3
6198545|NCT01474512|9858127|FG009|Maintenance Period|Withdrawal by Subject|1
6198546|NCT01474512|9858128|FG010|Maintenance Period|Withdrawal by Subject|0
6198547|NCT01474512|9858129|FG011|Maintenance Period|Withdrawal by Subject|0
6198548|NCT01474512|9858130|FG012|Maintenance Period|Withdrawal by Subject|0
6198549|NCT01474512|9858131|FG013|Maintenance Period|Withdrawal by Subject|0
6198550|NCT01474512|9858132|FG014|Maintenance Period|Withdrawal by Subject|0
6198551|NCT01474512|9858133|FG015|Maintenance Period|Withdrawal by Subject|0
6198552|NCT01474512|9858134|FG016|Maintenance Period|Withdrawal by Subject|0
6198553|NCT01474512|9858135|FG017|Maintenance Period|Withdrawal by Subject|0
6198554|NCT01474512|9858118|FG000|Maintenance Period|Lost to Follow-up|0
6198555|NCT01474512|9858119|FG001|Maintenance Period|Lost to Follow-up|0
6198556|NCT01474512|9858120|FG002|Maintenance Period|Lost to Follow-up|0
6198557|NCT01474512|9858121|FG003|Maintenance Period|Lost to Follow-up|3
6198558|NCT01474512|9858122|FG004|Maintenance Period|Lost to Follow-up|3
6198559|NCT01474512|9858123|FG005|Maintenance Period|Lost to Follow-up|0
6198560|NCT01474512|9858124|FG006|Maintenance Period|Lost to Follow-up|0
6198561|NCT01474512|9858125|FG007|Maintenance Period|Lost to Follow-up|2
6198562|NCT01474512|9858126|FG008|Maintenance Period|Lost to Follow-up|1
6198563|NCT01474512|9858127|FG009|Maintenance Period|Lost to Follow-up|1
6198564|NCT01474512|9858128|FG010|Maintenance Period|Lost to Follow-up|0
6198565|NCT01474512|9858129|FG011|Maintenance Period|Lost to Follow-up|0
6198566|NCT01474512|9858130|FG012|Maintenance Period|Lost to Follow-up|0
6198567|NCT01474512|9858131|FG013|Maintenance Period|Lost to Follow-up|0
6198568|NCT01474512|9858132|FG014|Maintenance Period|Lost to Follow-up|0
6198569|NCT01474512|9858133|FG015|Maintenance Period|Lost to Follow-up|0
6198570|NCT01474512|9858134|FG016|Maintenance Period|Lost to Follow-up|0
6198571|NCT01474512|9858135|FG017|Maintenance Period|Lost to Follow-up|0
6198572|NCT01474512|9858118|FG000|Maintenance Period|Death|0
6198573|NCT01474512|9858119|FG001|Maintenance Period|Death|0
6198574|NCT01474512|9858120|FG002|Maintenance Period|Death|0
6198575|NCT01474512|9858121|FG003|Maintenance Period|Death|0
6198576|NCT01474512|9858122|FG004|Maintenance Period|Death|0
6198577|NCT01474512|9858123|FG005|Maintenance Period|Death|2
6198578|NCT01474512|9858124|FG006|Maintenance Period|Death|0
6198579|NCT01474512|9858125|FG007|Maintenance Period|Death|0
6198580|NCT01474512|9858126|FG008|Maintenance Period|Death|0
6198581|NCT01474512|9858127|FG009|Maintenance Period|Death|0
6198582|NCT01474512|9858128|FG010|Maintenance Period|Death|0
6198583|NCT01474512|9858129|FG011|Maintenance Period|Death|0
6198584|NCT01474512|9858130|FG012|Maintenance Period|Death|0
6198585|NCT01474512|9858131|FG013|Maintenance Period|Death|0
6198586|NCT01474512|9858132|FG014|Maintenance Period|Death|0
6198587|NCT01474512|9858133|FG015|Maintenance Period|Death|0
6198588|NCT01474512|9858134|FG016|Maintenance Period|Death|0
6198589|NCT01474512|9858135|FG017|Maintenance Period|Death|0
6198590|NCT01474512|9858118|FG000|Maintenance Period|Physician Decision|0
6198591|NCT01474512|9858119|FG001|Maintenance Period|Physician Decision|0
6198592|NCT01474512|9858120|FG002|Maintenance Period|Physician Decision|0
6198593|NCT01474512|9858121|FG003|Maintenance Period|Physician Decision|0
6198594|NCT01474512|9858122|FG004|Maintenance Period|Physician Decision|0
6198595|NCT01474512|9858123|FG005|Maintenance Period|Physician Decision|1
6198596|NCT01474512|9858124|FG006|Maintenance Period|Physician Decision|0
6198597|NCT01474512|9858125|FG007|Maintenance Period|Physician Decision|2
6198598|NCT01474512|9858126|FG008|Maintenance Period|Physician Decision|0
6198599|NCT01474512|9858127|FG009|Maintenance Period|Physician Decision|0
6198600|NCT01474512|9858128|FG010|Maintenance Period|Physician Decision|0
6198601|NCT01474512|9858129|FG011|Maintenance Period|Physician Decision|0
6198602|NCT01474512|9858130|FG012|Maintenance Period|Physician Decision|0
6198603|NCT01474512|9858131|FG013|Maintenance Period|Physician Decision|0
6198604|NCT01474512|9858132|FG014|Maintenance Period|Physician Decision|0
6198605|NCT01474512|9858133|FG015|Maintenance Period|Physician Decision|0
6198606|NCT01474512|9858134|FG016|Maintenance Period|Physician Decision|0
6198607|NCT01474512|9858135|FG017|Maintenance Period|Physician Decision|0
6198608|NCT01474512|9858118|FG000|Maintenance Period|Clinical Relapse|0
6198609|NCT01474512|9858119|FG001|Maintenance Period|Clinical Relapse|0
6198610|NCT01474512|9858120|FG002|Maintenance Period|Clinical Relapse|0
6198611|NCT01474512|9858121|FG003|Maintenance Period|Clinical Relapse|1
6198612|NCT01474512|9858122|FG004|Maintenance Period|Clinical Relapse|0
6198613|NCT01474512|9858123|FG005|Maintenance Period|Clinical Relapse|0
6198614|NCT01474512|9858124|FG006|Maintenance Period|Clinical Relapse|0
6198615|NCT01474512|9858125|FG007|Maintenance Period|Clinical Relapse|0
6198616|NCT01474512|9858126|FG008|Maintenance Period|Clinical Relapse|0
6198617|NCT01474512|9858127|FG009|Maintenance Period|Clinical Relapse|0
6198618|NCT01474512|9858128|FG010|Maintenance Period|Clinical Relapse|0
6198619|NCT01474512|9858129|FG011|Maintenance Period|Clinical Relapse|0
6198620|NCT01474512|9858130|FG012|Maintenance Period|Clinical Relapse|0
6198621|NCT01474512|9858131|FG013|Maintenance Period|Clinical Relapse|0
6276115|NCT02222922|9981589|FG005|Overall Study|Lost to Follow-up|1
6276116|NCT02222922|9981590|FG006|Overall Study|Lost to Follow-up|0
6276117|NCT02222922|9981591|FG007|Overall Study|Lost to Follow-up|0
6276118|NCT02222922|9981592|FG008|Overall Study|Lost to Follow-up|0
6276119|NCT02222922|9981584|FG000|Overall Study|Other|0
6276120|NCT02222922|9981585|FG001|Overall Study|Other|0
6276121|NCT02222922|9981586|FG002|Overall Study|Other|0
6276122|NCT02222922|9981587|FG003|Overall Study|Other|2
6276123|NCT02222922|9981588|FG004|Overall Study|Other|10
6276124|NCT02222922|9981589|FG005|Overall Study|Other|2
6276125|NCT02222922|9981590|FG006|Overall Study|Other|2
6276126|NCT02222922|9981591|FG007|Overall Study|Other|4
6276127|NCT02222922|9981592|FG008|Overall Study|Other|1
6276128|NCT02222922|9981584|FG000|Overall Study|Participant refused further follow-up|1
6276129|NCT02222922|9981585|FG001|Overall Study|Participant refused further follow-up|0
5977083|NCT03852316|9564175|FG000|Overall Study|Enrolled but Device not Utilized|1
5977084|NCT03789318|9564184|FG000|Overall Study|Adverse Event|0
5977085|NCT03789318|9564185|FG001|Overall Study|Adverse Event|0
5977086|NCT03789318|9564186|FG002|Overall Study|Adverse Event|1
5977087|NCT03789318|9564187|FG003|Overall Study|Adverse Event|1
5977088|NCT03789318|9564188|FG004|Overall Study|Adverse Event|0
5977089|NCT03789318|9564184|FG000|Overall Study|Lost to Follow-up|0
5977090|NCT03789318|9564185|FG001|Overall Study|Lost to Follow-up|0
5977091|NCT03789318|9564186|FG002|Overall Study|Lost to Follow-up|1
5977092|NCT03789318|9564187|FG003|Overall Study|Lost to Follow-up|0
5977093|NCT03789318|9564188|FG004|Overall Study|Lost to Follow-up|0
5977094|NCT03789318|9564184|FG000|Overall Study|Withdrawal by Subject|0
5977095|NCT03789318|9564185|FG001|Overall Study|Withdrawal by Subject|0
5977096|NCT03789318|9564186|FG002|Overall Study|Withdrawal by Subject|1
5977097|NCT03789318|9564187|FG003|Overall Study|Withdrawal by Subject|0
5977098|NCT03789318|9564188|FG004|Overall Study|Withdrawal by Subject|0
5977099|NCT03774875|9564202|FG000|Overall Study|Adverse Event|8
5977100|NCT03774875|9564203|FG001|Overall Study|Adverse Event|16
5977101|NCT03774875|9564202|FG000|Overall Study|Lack of Efficacy|2
5977102|NCT03774875|9564203|FG001|Overall Study|Lack of Efficacy|4
5977103|NCT03774875|9564202|FG000|Overall Study|Withdrawal by Subject|12
5977104|NCT03774875|9564203|FG001|Overall Study|Withdrawal by Subject|10
5977105|NCT03774875|9564202|FG000|Overall Study|Lost to Follow-up|0
5977106|NCT03774875|9564203|FG001|Overall Study|Lost to Follow-up|2
5977107|NCT03774875|9564202|FG000|Overall Study|Protocol Deviation|0
5977108|NCT03774875|9564203|FG001|Overall Study|Protocol Deviation|1
5977109|NCT03774875|9564202|FG000|Overall Study|Reason Unknown|1
5977110|NCT03774875|9564203|FG001|Overall Study|Reason Unknown|0
5977111|NCT03158688|9564232|FG000|Overall Study|Continuing in study|107
5977112|NCT03158688|9564233|FG001|Overall Study|Continuing in study|233
5977113|NCT03158688|9564232|FG000|Overall Study|Death|36
5977114|NCT03158688|9564233|FG001|Overall Study|Death|59
5977115|NCT03158688|9564232|FG000|Overall Study|Withdrawal by Subject|9
5977116|NCT03158688|9564233|FG001|Overall Study|Withdrawal by Subject|14
5977117|NCT03158688|9564232|FG000|Overall Study|Decision by sponsor|2
5977118|NCT03158688|9564233|FG001|Overall Study|Decision by sponsor|3
5977119|NCT03158688|9564232|FG000|Overall Study|Lost to Follow-up|0
5977120|NCT03158688|9564233|FG001|Overall Study|Lost to Follow-up|3
5977121|NCT03103321|9564243|FG000|Overall Study|Protocol Violation|1
5977122|NCT03103321|9564244|FG001|Overall Study|Protocol Violation|1
5977123|NCT03103321|9564245|FG002|Overall Study|Protocol Violation|1
5977124|NCT03103321|9564246|FG003|Overall Study|Protocol Violation|0
5977125|NCT03079869|9564258|FG000|Overall Study|Adverse Event|6
5977126|NCT03079869|9564259|FG001|Overall Study|Adverse Event|8
5977127|NCT03079869|9564258|FG000|Overall Study|Withdrawal by Subject|4
5977128|NCT03079869|9564259|FG001|Overall Study|Withdrawal by Subject|1
5977129|NCT03079869|9564258|FG000|Overall Study|Protocol withdrawal criteria-off drug > 2 weeks|3
5977130|NCT03079869|9564259|FG001|Overall Study|Protocol withdrawal criteria-off drug > 2 weeks|2
5977131|NCT03033875|9564268|FG000|Overall Study|Withdrawal by Subject|5
5977132|NCT03033875|9564269|FG001|Overall Study|Withdrawal by Subject|9
5977133|NCT03033875|9564270|FG002|Overall Study|Withdrawal by Subject|4
6198622|NCT01474512|9858132|FG014|Maintenance Period|Clinical Relapse|0
6198623|NCT01474512|9858133|FG015|Maintenance Period|Clinical Relapse|0
6198624|NCT01474512|9858134|FG016|Maintenance Period|Clinical Relapse|0
6198625|NCT01474512|9858135|FG017|Maintenance Period|Clinical Relapse|0
6198626|NCT01474512|9858118|FG000|Maintenance Period|Lack of Efficacy|0
6198627|NCT01474512|9858119|FG001|Maintenance Period|Lack of Efficacy|0
6198628|NCT01474512|9858120|FG002|Maintenance Period|Lack of Efficacy|0
6198629|NCT01474512|9858121|FG003|Maintenance Period|Lack of Efficacy|1
6198630|NCT01474512|9858122|FG004|Maintenance Period|Lack of Efficacy|0
6276130|NCT02222922|9981586|FG002|Overall Study|Participant refused further follow-up|0
6276131|NCT02222922|9981587|FG003|Overall Study|Participant refused further follow-up|1
5977134|NCT03033875|9564268|FG000|Overall Study|Other|14
6276132|NCT02222922|9981588|FG004|Overall Study|Participant refused further follow-up|6
5977135|NCT03033875|9564269|FG001|Overall Study|Other|15
5977136|NCT03033875|9564270|FG002|Overall Study|Other|8
5977137|NCT02887248|9564282|FG000|Overall Study|Withdrawal by Subject|1
5977138|NCT02887248|9564282|FG000|Overall Study|Adverse Event|1
6198631|NCT01474512|9858123|FG005|Maintenance Period|Lack of Efficacy|0
6198632|NCT01474512|9858124|FG006|Maintenance Period|Lack of Efficacy|0
6198633|NCT01474512|9858125|FG007|Maintenance Period|Lack of Efficacy|11
6198634|NCT01474512|9858126|FG008|Maintenance Period|Lack of Efficacy|11
6198635|NCT01474512|9858127|FG009|Maintenance Period|Lack of Efficacy|12
6198636|NCT01474512|9858128|FG010|Maintenance Period|Lack of Efficacy|0
6198637|NCT01474512|9858129|FG011|Maintenance Period|Lack of Efficacy|0
6198638|NCT01474512|9858130|FG012|Maintenance Period|Lack of Efficacy|0
6198639|NCT01474512|9858131|FG013|Maintenance Period|Lack of Efficacy|0
6198640|NCT01474512|9858132|FG014|Maintenance Period|Lack of Efficacy|0
6198641|NCT01474512|9858133|FG015|Maintenance Period|Lack of Efficacy|0
6198642|NCT01474512|9858134|FG016|Maintenance Period|Lack of Efficacy|0
6198643|NCT01474512|9858135|FG017|Maintenance Period|Lack of Efficacy|0
6198644|NCT01474512|9858118|FG000|Maintenance Period|Protocol Violation|0
6198645|NCT01474512|9858119|FG001|Maintenance Period|Protocol Violation|0
6198646|NCT01474512|9858120|FG002|Maintenance Period|Protocol Violation|0
6198647|NCT01474512|9858121|FG003|Maintenance Period|Protocol Violation|1
6198648|NCT01474512|9858122|FG004|Maintenance Period|Protocol Violation|0
6198649|NCT01474512|9858123|FG005|Maintenance Period|Protocol Violation|0
6198650|NCT01474512|9858124|FG006|Maintenance Period|Protocol Violation|0
6198651|NCT01474512|9858125|FG007|Maintenance Period|Protocol Violation|1
6198652|NCT01474512|9858126|FG008|Maintenance Period|Protocol Violation|0
6198653|NCT01474512|9858127|FG009|Maintenance Period|Protocol Violation|1
6198654|NCT01474512|9858128|FG010|Maintenance Period|Protocol Violation|0
6198655|NCT01474512|9858129|FG011|Maintenance Period|Protocol Violation|0
6198656|NCT01474512|9858130|FG012|Maintenance Period|Protocol Violation|0
6276133|NCT02222922|9981589|FG005|Overall Study|Participant refused further follow-up|0
6276134|NCT02222922|9981590|FG006|Overall Study|Participant refused further follow-up|0
6276135|NCT02222922|9981591|FG007|Overall Study|Participant refused further follow-up|0
6276136|NCT02222922|9981592|FG008|Overall Study|Participant refused further follow-up|3
6276137|NCT02223364|9981668|FG000|Overall Study|Protocol Violation|3
6276138|NCT02223364|9981669|FG001|Overall Study|Protocol Violation|0
6276139|NCT02223364|9981670|FG002|Overall Study|Protocol Violation|3
6276140|NCT02223364|9981668|FG000|Overall Study|subject expired before surgery|1
6276141|NCT02223364|9981669|FG001|Overall Study|subject expired before surgery|0
6276142|NCT02223364|9981670|FG002|Overall Study|subject expired before surgery|0
6276143|NCT02223364|9981668|FG000|Overall Study|Physician Decision|1
6276144|NCT02223364|9981669|FG001|Overall Study|Physician Decision|0
6276145|NCT02223364|9981670|FG002|Overall Study|Physician Decision|0
6276146|NCT02223390|9981680|FG000|Overall Study|Lost to Follow-up|9
6276147|NCT02223390|9981681|FG001|Overall Study|Lost to Follow-up|4
6276148|NCT02223715|9981756|FG000|Overall Study|Death|31
6276149|NCT02223715|9981756|FG000|Overall Study|Lost to Follow-up|73
6276150|NCT02223754|9981765|FG000|Period 1|Adverse Event|1
6276151|NCT02223754|9981766|FG001|Period 1|Adverse Event|0
6276152|NCT02223754|9981765|FG000|Period 1|Lost to Follow-up|0
6276153|NCT02223754|9981766|FG001|Period 1|Lost to Follow-up|1
6276154|NCT02223754|9981765|FG000|Period 1|Protocol Violation|2
6276155|NCT02223754|9981766|FG001|Period 1|Protocol Violation|4
6276156|NCT02223754|9981765|FG000|Period 1|Withdrawal by Subject|0
6276157|NCT02223754|9981766|FG001|Period 1|Withdrawal by Subject|4
6276158|NCT02223754|9981765|FG000|Period 1|Test Article No Longer Available|1
6276159|NCT02223754|9981766|FG001|Period 1|Test Article No Longer Available|5
6276160|NCT02223754|9981765|FG000|Period 1|Unsatisfactory Visual Response|0
6276161|NCT02223754|9981766|FG001|Period 1|Unsatisfactory Visual Response|1
6276162|NCT02223754|9981765|FG000|Period 2|Adverse Event|0
6276163|NCT02223754|9981766|FG001|Period 2|Adverse Event|1
6276164|NCT02223754|9981765|FG000|Period 2|Protocol Violation|1
6276165|NCT02223754|9981766|FG001|Period 2|Protocol Violation|0
6276166|NCT02223754|9981765|FG000|Period 2|Lens Discomfort|1
6276167|NCT02223754|9981766|FG001|Period 2|Lens Discomfort|1
6276168|NCT02223754|9981765|FG000|Period 2|Lost to Follow-up|1
6276169|NCT02223754|9981766|FG001|Period 2|Lost to Follow-up|0
6276170|NCT02223754|9981765|FG000|Period 2|Test Article No Longer Available|0
6276171|NCT02223754|9981766|FG001|Period 2|Test Article No Longer Available|1
6276172|NCT02223793|9981776|FG000|Overall Study|Lost to Follow-up|10
6276173|NCT02223793|9981777|FG001|Overall Study|Lost to Follow-up|1
6276174|NCT02223793|9981778|FG002|Overall Study|Lost to Follow-up|2
6276175|NCT02223793|9981776|FG000|Overall Study|Withdrawal by Subject|3
6276176|NCT02223793|9981777|FG001|Overall Study|Withdrawal by Subject|2
6276177|NCT02223793|9981778|FG002|Overall Study|Withdrawal by Subject|3
6276178|NCT02223793|9981776|FG000|Overall Study|Moved/studycenter unable to participate|4
6276179|NCT02223793|9981777|FG001|Overall Study|Moved/studycenter unable to participate|6
6276180|NCT02223793|9981778|FG002|Overall Study|Moved/studycenter unable to participate|8
6276181|NCT02223858|9981788|FG000|Overall Study|Death|1
6276182|NCT02223858|9981789|FG001|Overall Study|Death|1
6276183|NCT02223858|9981788|FG000|Overall Study|Lost to Follow-up|6
6276184|NCT02223858|9981789|FG001|Overall Study|Lost to Follow-up|11
6276185|NCT02223858|9981788|FG000|Overall Study|Withdrawal by Subject|8
6198657|NCT01474512|9858131|FG013|Maintenance Period|Protocol Violation|0
6198658|NCT01474512|9858132|FG014|Maintenance Period|Protocol Violation|0
6198659|NCT01474512|9858133|FG015|Maintenance Period|Protocol Violation|0
6198660|NCT01474512|9858134|FG016|Maintenance Period|Protocol Violation|0
6198661|NCT01474512|9858135|FG017|Maintenance Period|Protocol Violation|0
6198662|NCT01474512|9858118|FG000|Maintenance Period|Treated but Discontinued in Induction|0
6198663|NCT01474512|9858119|FG001|Maintenance Period|Treated but Discontinued in Induction|0
6198664|NCT01474512|9858120|FG002|Maintenance Period|Treated but Discontinued in Induction|0
6198665|NCT01474512|9858121|FG003|Maintenance Period|Treated but Discontinued in Induction|0
6198666|NCT01474512|9858122|FG004|Maintenance Period|Treated but Discontinued in Induction|1
6198667|NCT01474512|9858123|FG005|Maintenance Period|Treated but Discontinued in Induction|0
6198668|NCT01474512|9858124|FG006|Maintenance Period|Treated but Discontinued in Induction|0
6198669|NCT01474512|9858125|FG007|Maintenance Period|Treated but Discontinued in Induction|0
6198670|NCT01474512|9858126|FG008|Maintenance Period|Treated but Discontinued in Induction|0
6198671|NCT01474512|9858127|FG009|Maintenance Period|Treated but Discontinued in Induction|0
6198672|NCT01474512|9858128|FG010|Maintenance Period|Treated but Discontinued in Induction|0
6198673|NCT01474512|9858129|FG011|Maintenance Period|Treated but Discontinued in Induction|0
6198674|NCT01474512|9858130|FG012|Maintenance Period|Treated but Discontinued in Induction|0
6198675|NCT01474512|9858131|FG013|Maintenance Period|Treated but Discontinued in Induction|0
6198676|NCT01474512|9858132|FG014|Maintenance Period|Treated but Discontinued in Induction|0
6198677|NCT01474512|9858133|FG015|Maintenance Period|Treated but Discontinued in Induction|0
6198678|NCT01474512|9858134|FG016|Maintenance Period|Treated but Discontinued in Induction|0
6198679|NCT01474512|9858135|FG017|Maintenance Period|Treated but Discontinued in Induction|0
6198680|NCT01474512|9858118|FG000|Long-Term Extension Period|Withdrawal by Subject|0
6198681|NCT01474512|9858119|FG001|Long-Term Extension Period|Withdrawal by Subject|0
6198682|NCT01474512|9858120|FG002|Long-Term Extension Period|Withdrawal by Subject|0
6198683|NCT01474512|9858121|FG003|Long-Term Extension Period|Withdrawal by Subject|0
6198684|NCT01474512|9858122|FG004|Long-Term Extension Period|Withdrawal by Subject|0
6198685|NCT01474512|9858123|FG005|Long-Term Extension Period|Withdrawal by Subject|0
6198686|NCT01474512|9858124|FG006|Long-Term Extension Period|Withdrawal by Subject|0
6198687|NCT01474512|9858125|FG007|Long-Term Extension Period|Withdrawal by Subject|0
6198688|NCT01474512|9858126|FG008|Long-Term Extension Period|Withdrawal by Subject|0
6198689|NCT01474512|9858127|FG009|Long-Term Extension Period|Withdrawal by Subject|0
6198690|NCT01474512|9858128|FG010|Long-Term Extension Period|Withdrawal by Subject|0
6198691|NCT01474512|9858129|FG011|Long-Term Extension Period|Withdrawal by Subject|3
6198692|NCT01474512|9858130|FG012|Long-Term Extension Period|Withdrawal by Subject|61
6198693|NCT01474512|9858131|FG013|Long-Term Extension Period|Withdrawal by Subject|61
6198694|NCT01474512|9858132|FG014|Long-Term Extension Period|Withdrawal by Subject|0
6198695|NCT01474512|9858133|FG015|Long-Term Extension Period|Withdrawal by Subject|0
6198696|NCT01474512|9858134|FG016|Long-Term Extension Period|Withdrawal by Subject|0
6198697|NCT01474512|9858135|FG017|Long-Term Extension Period|Withdrawal by Subject|0
6198698|NCT01474512|9858118|FG000|Long-Term Extension Period|Adverse Event|0
6198699|NCT01474512|9858119|FG001|Long-Term Extension Period|Adverse Event|0
6198700|NCT01474512|9858120|FG002|Long-Term Extension Period|Adverse Event|0
6276186|NCT02223858|9981789|FG001|Overall Study|Withdrawal by Subject|5
6276187|NCT02223858|9981788|FG000|Overall Study|Refused|9
6276188|NCT02223858|9981789|FG001|Overall Study|Refused|9
6276189|NCT02224053|9981799|FG000|AZD9291 and Omeprazole Co-administration|Exceeding PK limits after Period 1|11
6088678|NCT00677352|9699638|FG001|Treatment Phase|Not treated|2
6088679|NCT00677352|9699637|FG000|Tapering Phase|Adverse Event|1
6276190|NCT02224053|9981799|FG000|AZD9291 and Omeprazole Co-administration|Protocol Violation|4
6276191|NCT02224053|9981799|FG000|AZD9291 and Omeprazole Co-administration|Adverse Event|3
6276192|NCT02224053|9981799|FG000|AZD9291 and Omeprazole Co-administration|Withdrawal by Subject|1
6276193|NCT02224053|9981799|FG000|AZD9291 and Omeprazole Co-administration|Protocol non-compliance|2
6276194|NCT02224157|9981807|FG000|Overall Study|Severe non-compliance to protocol|2
6276195|NCT02224157|9981808|FG001|Overall Study|Severe non-compliance to protocol|2
6276196|NCT02224157|9981807|FG000|Overall Study|Other|13
6276197|NCT02224157|9981808|FG001|Overall Study|Other|10
6276198|NCT02224157|9981807|FG000|Overall Study|Subject decision|58
6276199|NCT02224157|9981808|FG001|Overall Study|Subject decision|50
5977139|NCT02887248|9564282|FG000|Overall Study|Progressive Disease|1
5977140|NCT02849990|9564286|FG000|Overall Study|Adverse Event|1
5977141|NCT02849990|9564286|FG000|Overall Study|Withdrawal by Subject|1
6050810|NCT00428948|9650011|FG001|Overall Study|Lost to Follow-up|8
6050811|NCT00428948|9650010|FG000|Overall Study|Adverse Event|148
6050812|NCT00428948|9650011|FG001|Overall Study|Adverse Event|24
6050813|NCT00428948|9650010|FG000|Overall Study|Subject Met Withdrawal Criteria|4
6050814|NCT00428948|9650011|FG001|Overall Study|Subject Met Withdrawal Criteria|0
6050815|NCT00428948|9650010|FG000|Overall Study|Investigator Withdrew Subject|3
6050816|NCT00428948|9650011|FG001|Overall Study|Investigator Withdrew Subject|4
6050817|NCT00428948|9650010|FG000|Overall Study|Subject Withdrew Consent|50
6050818|NCT00428948|9650011|FG001|Overall Study|Subject Withdrew Consent|30
6050819|NCT00428948|9650010|FG000|Overall Study|Protocol Deviation|1
6050820|NCT00428948|9650011|FG001|Overall Study|Protocol Deviation|1
6050821|NCT00429104|9650035|FG000|Overall Study|Protocol Violation|1
6050822|NCT00429169|9650045|FG000|Overall Study|Lost to Follow-up|0
6088680|NCT00677352|9699638|FG001|Tapering Phase|Adverse Event|5
6088681|NCT00677352|9699637|FG000|Tapering Phase|Withdrawal by Subject|5
6050823|NCT00429169|9650046|FG001|Overall Study|Lost to Follow-up|1
6088682|NCT00677352|9699638|FG001|Tapering Phase|Withdrawal by Subject|3
6198701|NCT01474512|9858121|FG003|Long-Term Extension Period|Adverse Event|0
6198702|NCT01474512|9858122|FG004|Long-Term Extension Period|Adverse Event|0
6198703|NCT01474512|9858123|FG005|Long-Term Extension Period|Adverse Event|0
6198704|NCT01474512|9858124|FG006|Long-Term Extension Period|Adverse Event|0
6198705|NCT01474512|9858125|FG007|Long-Term Extension Period|Adverse Event|0
6198706|NCT01474512|9858126|FG008|Long-Term Extension Period|Adverse Event|0
6198707|NCT01474512|9858127|FG009|Long-Term Extension Period|Adverse Event|0
6198708|NCT01474512|9858128|FG010|Long-Term Extension Period|Adverse Event|0
6198709|NCT01474512|9858129|FG011|Long-Term Extension Period|Adverse Event|1
6198710|NCT01474512|9858130|FG012|Long-Term Extension Period|Adverse Event|57
6198711|NCT01474512|9858131|FG013|Long-Term Extension Period|Adverse Event|58
6198712|NCT01474512|9858132|FG014|Long-Term Extension Period|Adverse Event|0
6198713|NCT01474512|9858133|FG015|Long-Term Extension Period|Adverse Event|0
6198714|NCT01474512|9858134|FG016|Long-Term Extension Period|Adverse Event|0
6198715|NCT01474512|9858135|FG017|Long-Term Extension Period|Adverse Event|0
6198716|NCT01474512|9858118|FG000|Long-Term Extension Period|Lost to Follow-up|0
6198717|NCT01474512|9858119|FG001|Long-Term Extension Period|Lost to Follow-up|0
6198718|NCT01474512|9858120|FG002|Long-Term Extension Period|Lost to Follow-up|0
6198719|NCT01474512|9858121|FG003|Long-Term Extension Period|Lost to Follow-up|0
6198720|NCT01474512|9858122|FG004|Long-Term Extension Period|Lost to Follow-up|0
6198721|NCT01474512|9858123|FG005|Long-Term Extension Period|Lost to Follow-up|0
6198722|NCT01474512|9858124|FG006|Long-Term Extension Period|Lost to Follow-up|0
6198723|NCT01474512|9858125|FG007|Long-Term Extension Period|Lost to Follow-up|0
6276200|NCT02224157|9981807|FG000|Overall Study|Prematurely closed site|4
6276201|NCT02224157|9981808|FG001|Overall Study|Prematurely closed site|2
6276202|NCT02224157|9981807|FG000|Overall Study|Eligibility criteria not fulfilled|4
6276203|NCT02224157|9981808|FG001|Overall Study|Eligibility criteria not fulfilled|8
6276204|NCT02224157|9981807|FG000|Overall Study|Lost to Follow-up|27
6276205|NCT02224157|9981808|FG001|Overall Study|Lost to Follow-up|35
6276206|NCT02224157|9981807|FG000|Overall Study|Death|1
6276207|NCT02224157|9981808|FG001|Overall Study|Death|1
6276208|NCT02224157|9981807|FG000|Overall Study|Adverse Event|1
6276209|NCT02224157|9981808|FG001|Overall Study|Adverse Event|3
6276210|NCT02224274|9981816|FG000|Overall Study|Death|1
6276211|NCT02224274|9981817|FG001|Overall Study|Death|0
6276212|NCT02224560|9981858|FG000|Overall Study|Protocol Deviation|1
6276213|NCT02224560|9981859|FG001|Overall Study|Protocol Deviation|0
6276214|NCT02224560|9981860|FG002|Overall Study|Protocol Deviation|0
6276215|NCT02224560|9981858|FG000|Overall Study|Withdrawal by Subject|2
6276216|NCT02224560|9981859|FG001|Overall Study|Withdrawal by Subject|0
6276217|NCT02224560|9981860|FG002|Overall Study|Withdrawal by Subject|1
6276218|NCT02224560|9981858|FG000|Overall Study|Met Withdrawal Criteria|1
6276219|NCT02224560|9981859|FG001|Overall Study|Met Withdrawal Criteria|0
6276220|NCT02224560|9981860|FG002|Overall Study|Met Withdrawal Criteria|0
6276221|NCT02224560|9981858|FG000|Overall Study|Adverse Event|4
6276222|NCT02224560|9981859|FG001|Overall Study|Adverse Event|1
6276223|NCT02224560|9981860|FG002|Overall Study|Adverse Event|1
6276224|NCT02224560|9981858|FG000|Overall Study|Withdrawn by Investigator|1
6276225|NCT02224560|9981859|FG001|Overall Study|Withdrawn by Investigator|1
6276226|NCT02224560|9981860|FG002|Overall Study|Withdrawn by Investigator|0
6276227|NCT02224625|9981877|FG000|Irritation|Adverse Event|6
6276228|NCT02224625|9981877|FG000|Sensitization|Adverse Event|55
6276229|NCT02224638|9981891|FG000|Overall Study|Adverse Event|1
6276230|NCT02224638|9981892|FG001|Overall Study|Adverse Event|1
6276231|NCT02224664|9981900|FG000|Lead-in Period (3 Days)|Does not meet entrance criteria|5
6276232|NCT02224664|9981901|FG001|Lead-in Period (3 Days)|Does not meet entrance criteria|0
6276233|NCT02224664|9981902|FG002|Lead-in Period (3 Days)|Does not meet entrance criteria|0
6276234|NCT02224664|9981903|FG003|Lead-in Period (3 Days)|Does not meet entrance criteria|0
6276235|NCT02224664|9981904|FG004|Lead-in Period (3 Days)|Does not meet entrance criteria|0
6276236|NCT02224664|9981900|FG000|Dose Escalation Period (21 Days)|Adverse Event|0
6276237|NCT02224664|9981901|FG001|Dose Escalation Period (21 Days)|Adverse Event|0
6276238|NCT02224664|9981902|FG002|Dose Escalation Period (21 Days)|Adverse Event|2
6276239|NCT02224664|9981903|FG003|Dose Escalation Period (21 Days)|Adverse Event|2
6276240|NCT02224664|9981904|FG004|Dose Escalation Period (21 Days)|Adverse Event|7
6276241|NCT02224664|9981900|FG000|Dose Escalation Period (21 Days)|Withdrawal by Subject|0
6276242|NCT02224664|9981901|FG001|Dose Escalation Period (21 Days)|Withdrawal by Subject|0
6276243|NCT02224664|9981902|FG002|Dose Escalation Period (21 Days)|Withdrawal by Subject|0
6276244|NCT02224664|9981903|FG003|Dose Escalation Period (21 Days)|Withdrawal by Subject|1
6276245|NCT02224664|9981904|FG004|Dose Escalation Period (21 Days)|Withdrawal by Subject|4
6276246|NCT02224690|9981922|FG000|Overall Study|Adverse Event|8
6276247|NCT02224690|9981923|FG001|Overall Study|Adverse Event|1
6276248|NCT02224690|9981922|FG000|Overall Study|Met Withdrawal Criteria|4
6276249|NCT02224690|9981923|FG001|Overall Study|Met Withdrawal Criteria|0
6276250|NCT02224690|9981922|FG000|Overall Study|Use of G-tube|1
6276251|NCT02224690|9981923|FG001|Overall Study|Use of G-tube|0
6276252|NCT02224690|9981922|FG000|Overall Study|Did not meet eligibility criteria|1
6276253|NCT02224690|9981923|FG001|Overall Study|Did not meet eligibility criteria|0
6276254|NCT02224703|9981932|FG000|Overall Study|Adverse Event|0
6276255|NCT02224703|9981933|FG001|Overall Study|Adverse Event|5
6198724|NCT01474512|9858126|FG008|Long-Term Extension Period|Lost to Follow-up|0
6198725|NCT01474512|9858127|FG009|Long-Term Extension Period|Lost to Follow-up|0
6198726|NCT01474512|9858128|FG010|Long-Term Extension Period|Lost to Follow-up|0
6198727|NCT01474512|9858129|FG011|Long-Term Extension Period|Lost to Follow-up|0
6198728|NCT01474512|9858130|FG012|Long-Term Extension Period|Lost to Follow-up|25
6198729|NCT01474512|9858131|FG013|Long-Term Extension Period|Lost to Follow-up|25
6198730|NCT01474512|9858132|FG014|Long-Term Extension Period|Lost to Follow-up|0
6198731|NCT01474512|9858133|FG015|Long-Term Extension Period|Lost to Follow-up|0
6198732|NCT01474512|9858134|FG016|Long-Term Extension Period|Lost to Follow-up|0
6198733|NCT01474512|9858135|FG017|Long-Term Extension Period|Lost to Follow-up|0
6198734|NCT01474512|9858118|FG000|Long-Term Extension Period|Lack of Efficacy|0
6198735|NCT01474512|9858119|FG001|Long-Term Extension Period|Lack of Efficacy|0
6198736|NCT01474512|9858120|FG002|Long-Term Extension Period|Lack of Efficacy|0
6198737|NCT01474512|9858121|FG003|Long-Term Extension Period|Lack of Efficacy|0
6198738|NCT01474512|9858122|FG004|Long-Term Extension Period|Lack of Efficacy|0
6198739|NCT01474512|9858123|FG005|Long-Term Extension Period|Lack of Efficacy|0
6198740|NCT01474512|9858124|FG006|Long-Term Extension Period|Lack of Efficacy|0
6198741|NCT01474512|9858125|FG007|Long-Term Extension Period|Lack of Efficacy|0
6198742|NCT01474512|9858126|FG008|Long-Term Extension Period|Lack of Efficacy|0
6198743|NCT01474512|9858127|FG009|Long-Term Extension Period|Lack of Efficacy|0
6198744|NCT01474512|9858128|FG010|Long-Term Extension Period|Lack of Efficacy|0
6198745|NCT01474512|9858129|FG011|Long-Term Extension Period|Lack of Efficacy|1
6198746|NCT01474512|9858130|FG012|Long-Term Extension Period|Lack of Efficacy|24
6198747|NCT01474512|9858131|FG013|Long-Term Extension Period|Lack of Efficacy|25
6198748|NCT01474512|9858132|FG014|Long-Term Extension Period|Lack of Efficacy|0
6198749|NCT01474512|9858133|FG015|Long-Term Extension Period|Lack of Efficacy|0
6198750|NCT01474512|9858134|FG016|Long-Term Extension Period|Lack of Efficacy|0
6198751|NCT01474512|9858135|FG017|Long-Term Extension Period|Lack of Efficacy|0
6198752|NCT01474512|9858118|FG000|Long-Term Extension Period|Physician Decision|0
6198753|NCT01474512|9858119|FG001|Long-Term Extension Period|Physician Decision|0
6198754|NCT01474512|9858120|FG002|Long-Term Extension Period|Physician Decision|0
6198755|NCT01474512|9858121|FG003|Long-Term Extension Period|Physician Decision|0
6198756|NCT01474512|9858122|FG004|Long-Term Extension Period|Physician Decision|0
6198757|NCT01474512|9858123|FG005|Long-Term Extension Period|Physician Decision|0
6198758|NCT01474512|9858124|FG006|Long-Term Extension Period|Physician Decision|0
6198759|NCT01474512|9858125|FG007|Long-Term Extension Period|Physician Decision|0
6198760|NCT01474512|9858126|FG008|Long-Term Extension Period|Physician Decision|0
6198761|NCT01474512|9858127|FG009|Long-Term Extension Period|Physician Decision|0
6198762|NCT01474512|9858128|FG010|Long-Term Extension Period|Physician Decision|0
6198763|NCT01474512|9858129|FG011|Long-Term Extension Period|Physician Decision|0
6198764|NCT01474512|9858130|FG012|Long-Term Extension Period|Physician Decision|21
6198765|NCT01474512|9858131|FG013|Long-Term Extension Period|Physician Decision|21
6198766|NCT01474512|9858132|FG014|Long-Term Extension Period|Physician Decision|0
6198767|NCT01474512|9858133|FG015|Long-Term Extension Period|Physician Decision|0
6198768|NCT01474512|9858134|FG016|Long-Term Extension Period|Physician Decision|0
6198769|NCT01474512|9858135|FG017|Long-Term Extension Period|Physician Decision|0
6198770|NCT01474512|9858118|FG000|Long-Term Extension Period|Clinical Relapse|0
6198771|NCT01474512|9858119|FG001|Long-Term Extension Period|Clinical Relapse|0
6198772|NCT01474512|9858120|FG002|Long-Term Extension Period|Clinical Relapse|0
6198773|NCT01474512|9858121|FG003|Long-Term Extension Period|Clinical Relapse|0
6198774|NCT01474512|9858122|FG004|Long-Term Extension Period|Clinical Relapse|0
6198775|NCT01474512|9858123|FG005|Long-Term Extension Period|Clinical Relapse|0
6198776|NCT01474512|9858124|FG006|Long-Term Extension Period|Clinical Relapse|0
6198777|NCT01474512|9858125|FG007|Long-Term Extension Period|Clinical Relapse|0
6198778|NCT01474512|9858126|FG008|Long-Term Extension Period|Clinical Relapse|0
6198779|NCT01474512|9858127|FG009|Long-Term Extension Period|Clinical Relapse|0
6198780|NCT01474512|9858128|FG010|Long-Term Extension Period|Clinical Relapse|0
6198781|NCT01474512|9858129|FG011|Long-Term Extension Period|Clinical Relapse|0
6198782|NCT01474512|9858130|FG012|Long-Term Extension Period|Clinical Relapse|9
6198783|NCT01474512|9858131|FG013|Long-Term Extension Period|Clinical Relapse|9
6198784|NCT01474512|9858132|FG014|Long-Term Extension Period|Clinical Relapse|0
6198785|NCT01474512|9858133|FG015|Long-Term Extension Period|Clinical Relapse|0
6198786|NCT01474512|9858134|FG016|Long-Term Extension Period|Clinical Relapse|0
6198787|NCT01474512|9858135|FG017|Long-Term Extension Period|Clinical Relapse|0
6198788|NCT01474512|9858118|FG000|Long-Term Extension Period|Death|0
6198789|NCT01474512|9858119|FG001|Long-Term Extension Period|Death|0
6198790|NCT01474512|9858120|FG002|Long-Term Extension Period|Death|0
6198791|NCT01474512|9858121|FG003|Long-Term Extension Period|Death|0
6198792|NCT01474512|9858122|FG004|Long-Term Extension Period|Death|0
6198793|NCT01474512|9858123|FG005|Long-Term Extension Period|Death|0
6198794|NCT01474512|9858124|FG006|Long-Term Extension Period|Death|0
6198795|NCT01474512|9858125|FG007|Long-Term Extension Period|Death|0
6198796|NCT01474512|9858126|FG008|Long-Term Extension Period|Death|0
6198797|NCT01474512|9858127|FG009|Long-Term Extension Period|Death|0
6198798|NCT01474512|9858128|FG010|Long-Term Extension Period|Death|0
6198799|NCT01474512|9858129|FG011|Long-Term Extension Period|Death|0
6198800|NCT01474512|9858130|FG012|Long-Term Extension Period|Death|9
6198801|NCT01474512|9858131|FG013|Long-Term Extension Period|Death|9
6198802|NCT01474512|9858132|FG014|Long-Term Extension Period|Death|0
6198803|NCT01474512|9858133|FG015|Long-Term Extension Period|Death|0
6198804|NCT01474512|9858134|FG016|Long-Term Extension Period|Death|0
6198805|NCT01474512|9858135|FG017|Long-Term Extension Period|Death|0
6198806|NCT01474512|9858118|FG000|Long-Term Extension Period|Sponsor Decision|0
6198807|NCT01474512|9858119|FG001|Long-Term Extension Period|Sponsor Decision|0
6198808|NCT01474512|9858120|FG002|Long-Term Extension Period|Sponsor Decision|0
6198809|NCT01474512|9858121|FG003|Long-Term Extension Period|Sponsor Decision|0
6198810|NCT01474512|9858122|FG004|Long-Term Extension Period|Sponsor Decision|0
6198811|NCT01474512|9858123|FG005|Long-Term Extension Period|Sponsor Decision|0
6198812|NCT01474512|9858124|FG006|Long-Term Extension Period|Sponsor Decision|0
6198813|NCT01474512|9858125|FG007|Long-Term Extension Period|Sponsor Decision|0
6198814|NCT01474512|9858126|FG008|Long-Term Extension Period|Sponsor Decision|0
6198815|NCT01474512|9858127|FG009|Long-Term Extension Period|Sponsor Decision|0
6198816|NCT01474512|9858128|FG010|Long-Term Extension Period|Sponsor Decision|0
6198817|NCT01474512|9858129|FG011|Long-Term Extension Period|Sponsor Decision|0
6198818|NCT01474512|9858130|FG012|Long-Term Extension Period|Sponsor Decision|6
6198819|NCT01474512|9858131|FG013|Long-Term Extension Period|Sponsor Decision|6
6198820|NCT01474512|9858132|FG014|Long-Term Extension Period|Sponsor Decision|0
6198821|NCT01474512|9858133|FG015|Long-Term Extension Period|Sponsor Decision|0
6198822|NCT01474512|9858134|FG016|Long-Term Extension Period|Sponsor Decision|0
6198823|NCT01474512|9858135|FG017|Long-Term Extension Period|Sponsor Decision|0
6198824|NCT01474512|9858118|FG000|Long-Term Extension Period|Protocol Violation|0
6198825|NCT01474512|9858119|FG001|Long-Term Extension Period|Protocol Violation|0
6198826|NCT01474512|9858120|FG002|Long-Term Extension Period|Protocol Violation|0
6198827|NCT01474512|9858121|FG003|Long-Term Extension Period|Protocol Violation|0
6198828|NCT01474512|9858122|FG004|Long-Term Extension Period|Protocol Violation|0
6198829|NCT01474512|9858123|FG005|Long-Term Extension Period|Protocol Violation|0
6198830|NCT01474512|9858124|FG006|Long-Term Extension Period|Protocol Violation|0
6198831|NCT01474512|9858125|FG007|Long-Term Extension Period|Protocol Violation|0
6198832|NCT01474512|9858126|FG008|Long-Term Extension Period|Protocol Violation|0
6276256|NCT02224703|9981934|FG002|Overall Study|Adverse Event|0
6276257|NCT02224703|9981932|FG000|Overall Study|Withdrawn by investigator|1
6276258|NCT02224703|9981933|FG001|Overall Study|Withdrawn by investigator|0
6276259|NCT02224703|9981934|FG002|Overall Study|Withdrawn by investigator|0
6276260|NCT02224703|9981932|FG000|Overall Study|Advised by medical monitor|1
6276261|NCT02224703|9981933|FG001|Overall Study|Advised by medical monitor|0
6276262|NCT02224703|9981934|FG002|Overall Study|Advised by medical monitor|0
6276263|NCT02224703|9981932|FG000|Overall Study|Withdrawn by parent/guardian|0
6276264|NCT02224703|9981933|FG001|Overall Study|Withdrawn by parent/guardian|1
6276265|NCT02224703|9981934|FG002|Overall Study|Withdrawn by parent/guardian|0
6276266|NCT02224703|9981932|FG000|Overall Study|Lack of Efficacy|1
6276267|NCT02224703|9981933|FG001|Overall Study|Lack of Efficacy|0
6276268|NCT02224703|9981934|FG002|Overall Study|Lack of Efficacy|0
6276269|NCT02224755|9981949|FG000|Randomization to Device Implant|Withdrawn prior to implant|7
6276270|NCT02224755|9981950|FG001|Randomization to Device Implant|Withdrawn prior to implant|1
6276271|NCT02224755|9981949|FG000|Two Year Follow up Post-implant|Death|103
6276272|NCT02224755|9981950|FG001|Two Year Follow up Post-implant|Death|98
6276273|NCT02224755|9981949|FG000|Two Year Follow up Post-implant|Heart transplant|137
6276274|NCT02224755|9981950|FG001|Two Year Follow up Post-implant|Heart transplant|119
6276275|NCT02224755|9981949|FG000|Two Year Follow up Post-implant|Device explant or permanent deactivation|3
6276276|NCT02224755|9981950|FG001|Two Year Follow up Post-implant|Device explant or permanent deactivation|3
6276277|NCT02224755|9981949|FG000|Two Year Follow up Post-implant|Withdrawn post-implant|15
6276278|NCT02224755|9981950|FG001|Two Year Follow up Post-implant|Withdrawn post-implant|6
6276279|NCT02224846|9981966|FG000|Period 1 (Month 3)|Adverse Event|2
6276280|NCT02224846|9981967|FG001|Period 1 (Month 3)|Adverse Event|1
6276281|NCT02224846|9981966|FG000|Period 1 (Month 3)|Lost to Follow-up|3
6276282|NCT02224846|9981967|FG001|Period 1 (Month 3)|Lost to Follow-up|8
6276283|NCT02224846|9981966|FG000|Period 1 (Month 3)|Protocol Violation|4
6276284|NCT02224846|9981967|FG001|Period 1 (Month 3)|Protocol Violation|8
6276285|NCT02224846|9981966|FG000|Period 1 (Month 3)|Withdrawal by Subject|8
6276286|NCT02224846|9981967|FG001|Period 1 (Month 3)|Withdrawal by Subject|18
6276287|NCT02224846|9981966|FG000|Period 1 (Month 3)|Sponsor Decision|2
6276288|NCT02224846|9981967|FG001|Period 1 (Month 3)|Sponsor Decision|1
6276289|NCT02224846|9981966|FG000|Period 2 (Month 3 to Month 12)|Adverse Event|1
6276290|NCT02224846|9981967|FG001|Period 2 (Month 3 to Month 12)|Adverse Event|2
6276291|NCT02224846|9981966|FG000|Period 2 (Month 3 to Month 12)|Lost to Follow-up|3
6276292|NCT02224846|9981967|FG001|Period 2 (Month 3 to Month 12)|Lost to Follow-up|5
6276293|NCT02224846|9981966|FG000|Period 2 (Month 3 to Month 12)|Protocol Violation|0
6276294|NCT02224846|9981967|FG001|Period 2 (Month 3 to Month 12)|Protocol Violation|3
6276295|NCT02224846|9981966|FG000|Period 2 (Month 3 to Month 12)|Withdrawal by Subject|15
6276296|NCT02224846|9981967|FG001|Period 2 (Month 3 to Month 12)|Withdrawal by Subject|19
6276297|NCT02224846|9981966|FG000|Period 2 (Month 3 to Month 12)|Physician Decision|0
6276298|NCT02224846|9981967|FG001|Period 2 (Month 3 to Month 12)|Physician Decision|2
6198833|NCT01474512|9858127|FG009|Long-Term Extension Period|Protocol Violation|0
6198834|NCT01474512|9858128|FG010|Long-Term Extension Period|Protocol Violation|0
6198835|NCT01474512|9858129|FG011|Long-Term Extension Period|Protocol Violation|0
6198836|NCT01474512|9858130|FG012|Long-Term Extension Period|Protocol Violation|5
6198837|NCT01474512|9858131|FG013|Long-Term Extension Period|Protocol Violation|5
6198838|NCT01474512|9858132|FG014|Long-Term Extension Period|Protocol Violation|0
6198839|NCT01474512|9858133|FG015|Long-Term Extension Period|Protocol Violation|0
6198840|NCT01474512|9858134|FG016|Long-Term Extension Period|Protocol Violation|0
6198841|NCT01474512|9858135|FG017|Long-Term Extension Period|Protocol Violation|0
6198842|NCT01474512|9858118|FG000|Long-Term Extension Period|Parent/Caregiver Decision|0
6198843|NCT01474512|9858119|FG001|Long-Term Extension Period|Parent/Caregiver Decision|0
6198844|NCT01474512|9858120|FG002|Long-Term Extension Period|Parent/Caregiver Decision|0
6198845|NCT01474512|9858121|FG003|Long-Term Extension Period|Parent/Caregiver Decision|0
6198846|NCT01474512|9858122|FG004|Long-Term Extension Period|Parent/Caregiver Decision|0
6198847|NCT01474512|9858123|FG005|Long-Term Extension Period|Parent/Caregiver Decision|0
6198848|NCT01474512|9858124|FG006|Long-Term Extension Period|Parent/Caregiver Decision|0
6198849|NCT01474512|9858125|FG007|Long-Term Extension Period|Parent/Caregiver Decision|0
6198850|NCT01474512|9858126|FG008|Long-Term Extension Period|Parent/Caregiver Decision|0
6198851|NCT01474512|9858127|FG009|Long-Term Extension Period|Parent/Caregiver Decision|0
6198852|NCT01474512|9858128|FG010|Long-Term Extension Period|Parent/Caregiver Decision|0
6198853|NCT01474512|9858129|FG011|Long-Term Extension Period|Parent/Caregiver Decision|0
6198854|NCT01474512|9858130|FG012|Long-Term Extension Period|Parent/Caregiver Decision|1
6198855|NCT01474512|9858131|FG013|Long-Term Extension Period|Parent/Caregiver Decision|1
6198856|NCT01474512|9858132|FG014|Long-Term Extension Period|Parent/Caregiver Decision|0
6198857|NCT01474512|9858133|FG015|Long-Term Extension Period|Parent/Caregiver Decision|0
6198858|NCT01474512|9858134|FG016|Long-Term Extension Period|Parent/Caregiver Decision|0
6198859|NCT01474512|9858135|FG017|Long-Term Extension Period|Parent/Caregiver Decision|0
6198860|NCT01474512|9858118|FG000|Long-Term Extension Period|Switched From PBO to Ixe|0
6198861|NCT01474512|9858119|FG001|Long-Term Extension Period|Switched From PBO to Ixe|0
6198862|NCT01474512|9858120|FG002|Long-Term Extension Period|Switched From PBO to Ixe|0
6198863|NCT01474512|9858121|FG003|Long-Term Extension Period|Switched From PBO to Ixe|0
6198864|NCT01474512|9858122|FG004|Long-Term Extension Period|Switched From PBO to Ixe|0
6198865|NCT01474512|9858123|FG005|Long-Term Extension Period|Switched From PBO to Ixe|0
6198866|NCT01474512|9858124|FG006|Long-Term Extension Period|Switched From PBO to Ixe|0
6198867|NCT01474512|9858125|FG007|Long-Term Extension Period|Switched From PBO to Ixe|0
6198868|NCT01474512|9858126|FG008|Long-Term Extension Period|Switched From PBO to Ixe|0
6198869|NCT01474512|9858127|FG009|Long-Term Extension Period|Switched From PBO to Ixe|0
6198870|NCT01474512|9858128|FG010|Long-Term Extension Period|Switched From PBO to Ixe|0
6198871|NCT01474512|9858129|FG011|Long-Term Extension Period|Switched From PBO to Ixe|21
6198872|NCT01474512|9858130|FG012|Long-Term Extension Period|Switched From PBO to Ixe|0
6198873|NCT01474512|9858131|FG013|Long-Term Extension Period|Switched From PBO to Ixe|0
6198874|NCT01474512|9858132|FG014|Long-Term Extension Period|Switched From PBO to Ixe|0
6198875|NCT01474512|9858133|FG015|Long-Term Extension Period|Switched From PBO to Ixe|0
6198876|NCT01474512|9858134|FG016|Long-Term Extension Period|Switched From PBO to Ixe|0
6198877|NCT01474512|9858135|FG017|Long-Term Extension Period|Switched From PBO to Ixe|0
6198878|NCT01474512|9858118|FG000|Post-Treatment Follow-Up|Adverse Event|0
6198879|NCT01474512|9858119|FG001|Post-Treatment Follow-Up|Adverse Event|0
6198880|NCT01474512|9858120|FG002|Post-Treatment Follow-Up|Adverse Event|0
6198881|NCT01474512|9858121|FG003|Post-Treatment Follow-Up|Adverse Event|0
6198882|NCT01474512|9858122|FG004|Post-Treatment Follow-Up|Adverse Event|0
6198883|NCT01474512|9858123|FG005|Post-Treatment Follow-Up|Adverse Event|0
6198884|NCT01474512|9858124|FG006|Post-Treatment Follow-Up|Adverse Event|0
6198885|NCT01474512|9858125|FG007|Post-Treatment Follow-Up|Adverse Event|0
6198886|NCT01474512|9858126|FG008|Post-Treatment Follow-Up|Adverse Event|0
6198887|NCT01474512|9858127|FG009|Post-Treatment Follow-Up|Adverse Event|0
6198888|NCT01474512|9858128|FG010|Post-Treatment Follow-Up|Adverse Event|0
6198889|NCT01474512|9858129|FG011|Post-Treatment Follow-Up|Adverse Event|0
6198890|NCT01474512|9858130|FG012|Post-Treatment Follow-Up|Adverse Event|0
6198891|NCT01474512|9858131|FG013|Post-Treatment Follow-Up|Adverse Event|0
6198892|NCT01474512|9858132|FG014|Post-Treatment Follow-Up|Adverse Event|8
6198893|NCT01474512|9858133|FG015|Post-Treatment Follow-Up|Adverse Event|2
6198894|NCT01474512|9858134|FG016|Post-Treatment Follow-Up|Adverse Event|58
6198895|NCT01474512|9858135|FG017|Post-Treatment Follow-Up|Adverse Event|11
6198896|NCT01474512|9858118|FG000|Post-Treatment Follow-Up|Withdrawal by Subject|0
6198897|NCT01474512|9858119|FG001|Post-Treatment Follow-Up|Withdrawal by Subject|0
6198898|NCT01474512|9858120|FG002|Post-Treatment Follow-Up|Withdrawal by Subject|0
6198899|NCT01474512|9858121|FG003|Post-Treatment Follow-Up|Withdrawal by Subject|0
6198900|NCT01474512|9858122|FG004|Post-Treatment Follow-Up|Withdrawal by Subject|0
6198901|NCT01474512|9858123|FG005|Post-Treatment Follow-Up|Withdrawal by Subject|0
6198902|NCT01474512|9858124|FG006|Post-Treatment Follow-Up|Withdrawal by Subject|0
6198903|NCT01474512|9858125|FG007|Post-Treatment Follow-Up|Withdrawal by Subject|0
6198904|NCT01474512|9858126|FG008|Post-Treatment Follow-Up|Withdrawal by Subject|0
6198905|NCT01474512|9858127|FG009|Post-Treatment Follow-Up|Withdrawal by Subject|0
6198906|NCT01474512|9858128|FG010|Post-Treatment Follow-Up|Withdrawal by Subject|0
6198907|NCT01474512|9858129|FG011|Post-Treatment Follow-Up|Withdrawal by Subject|0
6198908|NCT01474512|9858130|FG012|Post-Treatment Follow-Up|Withdrawal by Subject|0
6198909|NCT01474512|9858131|FG013|Post-Treatment Follow-Up|Withdrawal by Subject|0
6276299|NCT02224846|9981966|FG000|Period 2 (Month 12 to Month 24)|Adverse Event|3
6276300|NCT02224846|9981967|FG001|Period 2 (Month 12 to Month 24)|Adverse Event|4
6276301|NCT02224846|9981966|FG000|Period 2 (Month 12 to Month 24)|Death|1
6276302|NCT02224846|9981967|FG001|Period 2 (Month 12 to Month 24)|Death|0
6276303|NCT02224846|9981966|FG000|Period 2 (Month 12 to Month 24)|Lost to Follow-up|7
6276304|NCT02224846|9981967|FG001|Period 2 (Month 12 to Month 24)|Lost to Follow-up|13
6276305|NCT02224846|9981966|FG000|Period 2 (Month 12 to Month 24)|Protocol Violation|4
6276306|NCT02224846|9981967|FG001|Period 2 (Month 12 to Month 24)|Protocol Violation|11
6276307|NCT02224846|9981966|FG000|Period 2 (Month 12 to Month 24)|Withdrawal by Subject|25
6276308|NCT02224846|9981967|FG001|Period 2 (Month 12 to Month 24)|Withdrawal by Subject|43
6276309|NCT02224846|9981966|FG000|Period 2 (Month 12 to Month 24)|Physician Decision|0
6276310|NCT02224846|9981967|FG001|Period 2 (Month 12 to Month 24)|Physician Decision|2
6276311|NCT02224846|9981966|FG000|Period 2 (Month 12 to Month 24)|Sponsor Decision|2
6276312|NCT02224846|9981967|FG001|Period 2 (Month 12 to Month 24)|Sponsor Decision|1
6276313|NCT02225223|9981987|FG000|Overall Study|Death|10
6276314|NCT02225223|9981988|FG001|Overall Study|Death|1
6276315|NCT02225223|9981987|FG000|Overall Study|Lost to Follow-up|5
6276316|NCT02225223|9981988|FG001|Overall Study|Lost to Follow-up|0
5977142|NCT02467270|9564319|FG000|Overall Study|Participants Never Treated|0
5977143|NCT02467270|9564320|FG001|Overall Study|Participants Never Treated|1
5977144|NCT02467270|9564321|FG002|Overall Study|Participants Never Treated|0
5977145|NCT02467270|9564319|FG000|Overall Study|Ongoing|50
5977146|NCT02467270|9564320|FG001|Overall Study|Ongoing|41
5977147|NCT02467270|9564321|FG002|Overall Study|Ongoing|43
5977148|NCT02467270|9564319|FG000|Overall Study|Adverse Event|16
5977149|NCT02467270|9564320|FG001|Overall Study|Adverse Event|15
5977150|NCT02467270|9564321|FG002|Overall Study|Adverse Event|14
5977151|NCT02467270|9564319|FG000|Overall Study|Progressive Disease|7
5977152|NCT02467270|9564320|FG001|Overall Study|Progressive Disease|7
5977153|NCT02467270|9564321|FG002|Overall Study|Progressive Disease|4
5977154|NCT02467270|9564319|FG000|Overall Study|Death|2
5977155|NCT02467270|9564320|FG001|Overall Study|Death|0
5977156|NCT02467270|9564321|FG002|Overall Study|Death|2
5977157|NCT02467270|9564319|FG000|Overall Study|Lack of Efficacy|12
5977158|NCT02467270|9564320|FG001|Overall Study|Lack of Efficacy|18
5977159|NCT02467270|9564321|FG002|Overall Study|Lack of Efficacy|23
5977160|NCT02467270|9564319|FG000|Overall Study|Non-compliance With Study Drug|0
5977161|NCT02467270|9564320|FG001|Overall Study|Non-compliance With Study Drug|2
5977162|NCT02467270|9564321|FG002|Overall Study|Non-compliance With Study Drug|1
5977163|NCT02467270|9564319|FG000|Overall Study|Lost to Follow-up|2
5977164|NCT02467270|9564320|FG001|Overall Study|Lost to Follow-up|1
5977165|NCT02467270|9564321|FG002|Overall Study|Lost to Follow-up|0
5977166|NCT02467270|9564319|FG000|Overall Study|Pregnancy|0
5977167|NCT02467270|9564320|FG001|Overall Study|Pregnancy|1
5977168|NCT02467270|9564321|FG002|Overall Study|Pregnancy|0
5977169|NCT02467270|9564319|FG000|Overall Study|Physician Decision|0
5977170|NCT02467270|9564320|FG001|Overall Study|Physician Decision|4
5977171|NCT02467270|9564321|FG002|Overall Study|Physician Decision|1
5977172|NCT02467270|9564319|FG000|Overall Study|Withdrawal by Subject|4
5977173|NCT02467270|9564320|FG001|Overall Study|Withdrawal by Subject|3
5977174|NCT02467270|9564321|FG002|Overall Study|Withdrawal by Subject|5
5977175|NCT02467270|9564319|FG000|Overall Study|Reason not Specified|1
5977176|NCT02467270|9564320|FG001|Overall Study|Reason not Specified|2
5977177|NCT02467270|9564321|FG002|Overall Study|Reason not Specified|1
5977178|NCT02452554|9564335|FG000|Overall Study|Death|2
5977179|NCT02452554|9564336|FG001|Overall Study|Death|1
5977180|NCT02452554|9564337|FG002|Overall Study|Death|0
5977181|NCT02452554|9564338|FG003|Overall Study|Death|0
5977182|NCT02452554|9564339|FG004|Overall Study|Death|0
5977183|NCT02452554|9564340|FG005|Overall Study|Death|0
5977184|NCT02452554|9564335|FG000|Overall Study|Lack of Efficacy|13
5977185|NCT02452554|9564336|FG001|Overall Study|Lack of Efficacy|14
5977186|NCT02452554|9564337|FG002|Overall Study|Lack of Efficacy|9
5977187|NCT02452554|9564338|FG003|Overall Study|Lack of Efficacy|1
5977188|NCT02452554|9564339|FG004|Overall Study|Lack of Efficacy|5
5977189|NCT02452554|9564340|FG005|Overall Study|Lack of Efficacy|8
5977190|NCT02452554|9564335|FG000|Overall Study|Physician Decision|0
5977191|NCT02452554|9564336|FG001|Overall Study|Physician Decision|1
5977192|NCT02452554|9564337|FG002|Overall Study|Physician Decision|0
5977193|NCT02452554|9564338|FG003|Overall Study|Physician Decision|0
6198910|NCT01474512|9858132|FG014|Post-Treatment Follow-Up|Withdrawal by Subject|3
6198911|NCT01474512|9858133|FG015|Post-Treatment Follow-Up|Withdrawal by Subject|2
6198912|NCT01474512|9858134|FG016|Post-Treatment Follow-Up|Withdrawal by Subject|36
6198913|NCT01474512|9858135|FG017|Post-Treatment Follow-Up|Withdrawal by Subject|17
6198914|NCT01474512|9858118|FG000|Post-Treatment Follow-Up|Lack of Efficacy|0
6198915|NCT01474512|9858119|FG001|Post-Treatment Follow-Up|Lack of Efficacy|0
6198916|NCT01474512|9858120|FG002|Post-Treatment Follow-Up|Lack of Efficacy|0
6198917|NCT01474512|9858121|FG003|Post-Treatment Follow-Up|Lack of Efficacy|0
5977194|NCT02452554|9564339|FG004|Overall Study|Physician Decision|0
5977195|NCT02452554|9564340|FG005|Overall Study|Physician Decision|0
5977196|NCT02452554|9564335|FG000|Overall Study|Withdrawal by Subject|1
5977197|NCT02452554|9564336|FG001|Overall Study|Withdrawal by Subject|0
6198918|NCT01474512|9858122|FG004|Post-Treatment Follow-Up|Lack of Efficacy|0
6198919|NCT01474512|9858123|FG005|Post-Treatment Follow-Up|Lack of Efficacy|0
6198920|NCT01474512|9858124|FG006|Post-Treatment Follow-Up|Lack of Efficacy|0
6198921|NCT01474512|9858125|FG007|Post-Treatment Follow-Up|Lack of Efficacy|0
6198922|NCT01474512|9858126|FG008|Post-Treatment Follow-Up|Lack of Efficacy|0
6198923|NCT01474512|9858127|FG009|Post-Treatment Follow-Up|Lack of Efficacy|0
6198924|NCT01474512|9858128|FG010|Post-Treatment Follow-Up|Lack of Efficacy|0
6198925|NCT01474512|9858129|FG011|Post-Treatment Follow-Up|Lack of Efficacy|0
6198926|NCT01474512|9858130|FG012|Post-Treatment Follow-Up|Lack of Efficacy|0
6198927|NCT01474512|9858131|FG013|Post-Treatment Follow-Up|Lack of Efficacy|0
6198928|NCT01474512|9858132|FG014|Post-Treatment Follow-Up|Lack of Efficacy|3
6198929|NCT01474512|9858133|FG015|Post-Treatment Follow-Up|Lack of Efficacy|2
6198930|NCT01474512|9858134|FG016|Post-Treatment Follow-Up|Lack of Efficacy|31
6198931|NCT01474512|9858135|FG017|Post-Treatment Follow-Up|Lack of Efficacy|3
6198932|NCT01474512|9858118|FG000|Post-Treatment Follow-Up|Lost to Follow-up|0
6198933|NCT01474512|9858119|FG001|Post-Treatment Follow-Up|Lost to Follow-up|0
6198934|NCT01474512|9858120|FG002|Post-Treatment Follow-Up|Lost to Follow-up|0
6198935|NCT01474512|9858121|FG003|Post-Treatment Follow-Up|Lost to Follow-up|0
6198936|NCT01474512|9858122|FG004|Post-Treatment Follow-Up|Lost to Follow-up|0
6198937|NCT01474512|9858123|FG005|Post-Treatment Follow-Up|Lost to Follow-up|0
6198938|NCT01474512|9858124|FG006|Post-Treatment Follow-Up|Lost to Follow-up|0
6198939|NCT01474512|9858125|FG007|Post-Treatment Follow-Up|Lost to Follow-up|0
6198940|NCT01474512|9858126|FG008|Post-Treatment Follow-Up|Lost to Follow-up|0
6198941|NCT01474512|9858127|FG009|Post-Treatment Follow-Up|Lost to Follow-up|0
6198942|NCT01474512|9858128|FG010|Post-Treatment Follow-Up|Lost to Follow-up|0
6198943|NCT01474512|9858129|FG011|Post-Treatment Follow-Up|Lost to Follow-up|0
6198944|NCT01474512|9858130|FG012|Post-Treatment Follow-Up|Lost to Follow-up|0
6198945|NCT01474512|9858131|FG013|Post-Treatment Follow-Up|Lost to Follow-up|0
6198946|NCT01474512|9858132|FG014|Post-Treatment Follow-Up|Lost to Follow-up|0
6198947|NCT01474512|9858133|FG015|Post-Treatment Follow-Up|Lost to Follow-up|0
6198948|NCT01474512|9858134|FG016|Post-Treatment Follow-Up|Lost to Follow-up|12
6198949|NCT01474512|9858135|FG017|Post-Treatment Follow-Up|Lost to Follow-up|7
6198950|NCT01474512|9858118|FG000|Post-Treatment Follow-Up|Physician Decision|0
6198951|NCT01474512|9858119|FG001|Post-Treatment Follow-Up|Physician Decision|0
6198952|NCT01474512|9858120|FG002|Post-Treatment Follow-Up|Physician Decision|0
6276317|NCT02225223|9981987|FG000|Overall Study|Other|1
6276318|NCT02225223|9981988|FG001|Overall Study|Other|2
6276319|NCT02225223|9981987|FG000|Overall Study|Physician Decision|1
6276320|NCT02225223|9981988|FG001|Overall Study|Physician Decision|0
6276321|NCT02225223|9981987|FG000|Overall Study|Withdrawal by Subject|2
6276322|NCT02225223|9981988|FG001|Overall Study|Withdrawal by Subject|2
6276323|NCT02225353|9981997|FG000|Overall Study|Lost to Follow-up|0
6276324|NCT02225353|9981998|FG001|Overall Study|Lost to Follow-up|1
6276325|NCT02225353|9981999|FG002|Overall Study|Lost to Follow-up|3
6276326|NCT02225353|9981997|FG000|Overall Study|Protocol Violation|4
6276327|NCT02225353|9981998|FG001|Overall Study|Protocol Violation|5
6276328|NCT02225353|9981999|FG002|Overall Study|Protocol Violation|12
6276329|NCT02225587|9982012|FG000|Overall Study|Adverse Event|5
6276330|NCT02225587|9982013|FG001|Overall Study|Adverse Event|5
6276331|NCT02225587|9982012|FG000|Overall Study|Lost to Follow-up|5
6276332|NCT02225587|9982013|FG001|Overall Study|Lost to Follow-up|5
6276333|NCT02225587|9982012|FG000|Overall Study|Non-Compliance With Study Drug|1
6276334|NCT02225587|9982013|FG001|Overall Study|Non-Compliance With Study Drug|0
6276335|NCT02225587|9982012|FG000|Overall Study|Physician Decision|2
6276336|NCT02225587|9982013|FG001|Overall Study|Physician Decision|0
6276337|NCT02225587|9982012|FG000|Overall Study|Protocol Violation|1
6276338|NCT02225587|9982013|FG001|Overall Study|Protocol Violation|0
6276339|NCT02225587|9982012|FG000|Overall Study|Participant Moved|1
6276340|NCT02225587|9982013|FG001|Overall Study|Participant Moved|0
6276341|NCT02225587|9982012|FG000|Overall Study|Withdrawal by Subject|13
6276342|NCT02225587|9982013|FG001|Overall Study|Withdrawal by Subject|28
6276343|NCT02225665|9982021|FG000|Overall Study|Subject moved from area and finds it difficult to return for visits.|1
6276344|NCT02225665|9982022|FG001|Overall Study|Subject moved from area and finds it difficult to return for visits.|0
6276345|NCT02225665|9982021|FG000|Overall Study|Subject restarted HAART prior to month 18.|0
6276346|NCT02225665|9982022|FG001|Overall Study|Subject restarted HAART prior to month 18.|1
6276347|NCT02225743|9982028|FG000|Overall Study|Withdrawal by Subject|18
6276348|NCT02226003|9982049|FG000|Overall Study|Lost to Follow-up|2
6276349|NCT02226003|9982050|FG001|Overall Study|Lost to Follow-up|1
6276350|NCT02226003|9982051|FG002|Overall Study|Lost to Follow-up|3
6276351|NCT02226003|9982049|FG000|Overall Study|Withdrawal by Subject|0
6276352|NCT02226003|9982050|FG001|Overall Study|Withdrawal by Subject|0
6276353|NCT02226003|9982051|FG002|Overall Study|Withdrawal by Subject|3
6276354|NCT02226120|9982059|FG000|Overall Study|Adverse Event|60
6276355|NCT02226120|9982059|FG000|Overall Study|Death|172
6276356|NCT02226120|9982059|FG000|Overall Study|Study terminated by sponsor|1
6276357|NCT02226120|9982059|FG000|Overall Study|Technical problems|4
6276358|NCT02226120|9982059|FG000|Overall Study|Lost to Follow-up|13
6198953|NCT01474512|9858121|FG003|Post-Treatment Follow-Up|Physician Decision|0
6198954|NCT01474512|9858122|FG004|Post-Treatment Follow-Up|Physician Decision|0
6198955|NCT01474512|9858123|FG005|Post-Treatment Follow-Up|Physician Decision|0
6198956|NCT01474512|9858124|FG006|Post-Treatment Follow-Up|Physician Decision|0
6198957|NCT01474512|9858125|FG007|Post-Treatment Follow-Up|Physician Decision|0
6198958|NCT01474512|9858126|FG008|Post-Treatment Follow-Up|Physician Decision|0
6198959|NCT01474512|9858127|FG009|Post-Treatment Follow-Up|Physician Decision|0
6198960|NCT01474512|9858128|FG010|Post-Treatment Follow-Up|Physician Decision|0
6198961|NCT01474512|9858129|FG011|Post-Treatment Follow-Up|Physician Decision|0
6198962|NCT01474512|9858130|FG012|Post-Treatment Follow-Up|Physician Decision|0
6198963|NCT01474512|9858131|FG013|Post-Treatment Follow-Up|Physician Decision|0
6198964|NCT01474512|9858132|FG014|Post-Treatment Follow-Up|Physician Decision|0
6198965|NCT01474512|9858133|FG015|Post-Treatment Follow-Up|Physician Decision|0
6198966|NCT01474512|9858134|FG016|Post-Treatment Follow-Up|Physician Decision|4
6198967|NCT01474512|9858135|FG017|Post-Treatment Follow-Up|Physician Decision|5
6198968|NCT01474512|9858118|FG000|Post-Treatment Follow-Up|Clinical Relapse|0
6198969|NCT01474512|9858119|FG001|Post-Treatment Follow-Up|Clinical Relapse|0
6198970|NCT01474512|9858120|FG002|Post-Treatment Follow-Up|Clinical Relapse|0
6198971|NCT01474512|9858121|FG003|Post-Treatment Follow-Up|Clinical Relapse|0
6198972|NCT01474512|9858122|FG004|Post-Treatment Follow-Up|Clinical Relapse|0
6198973|NCT01474512|9858123|FG005|Post-Treatment Follow-Up|Clinical Relapse|0
6198974|NCT01474512|9858124|FG006|Post-Treatment Follow-Up|Clinical Relapse|0
6198975|NCT01474512|9858125|FG007|Post-Treatment Follow-Up|Clinical Relapse|0
6276359|NCT02226120|9982059|FG000|Overall Study|Physician Decision|21
6276360|NCT02226120|9982059|FG000|Overall Study|Withdrawal by parent/guardian|36
6276361|NCT02226120|9982059|FG000|Overall Study|Non-compliance with study drug|10
6276362|NCT02226120|9982059|FG000|Overall Study|Protocol deviation|1
6276363|NCT02226120|9982059|FG000|Overall Study|missing treatment disposition pages|2
6088683|NCT00677352|9699637|FG000|Tapering Phase|Pregnancy|0
6088684|NCT00677352|9699638|FG001|Tapering Phase|Pregnancy|1
6088685|NCT00677352|9699637|FG000|Tapering Phase|Job transfer|0
6088686|NCT00677352|9699638|FG001|Tapering Phase|Job transfer|1
6088687|NCT00677365|9699648|FG000|Overall Study|Adverse Event|2
6088688|NCT00677365|9699649|FG001|Overall Study|Adverse Event|1
6088689|NCT00677365|9699650|FG002|Overall Study|Adverse Event|1
6088690|NCT00677365|9699651|FG003|Overall Study|Adverse Event|2
6088691|NCT00677365|9699648|FG000|Overall Study|Withdrawal by Subject|0
6088692|NCT00677365|9699649|FG001|Overall Study|Withdrawal by Subject|0
6088693|NCT00677365|9699650|FG002|Overall Study|Withdrawal by Subject|1
6088694|NCT00677365|9699651|FG003|Overall Study|Withdrawal by Subject|0
6198976|NCT01474512|9858126|FG008|Post-Treatment Follow-Up|Clinical Relapse|0
6198977|NCT01474512|9858127|FG009|Post-Treatment Follow-Up|Clinical Relapse|0
6088695|NCT00677365|9699648|FG000|Overall Study|Other reason|0
6088696|NCT00677365|9699649|FG001|Overall Study|Other reason|0
6088697|NCT00677365|9699650|FG002|Overall Study|Other reason|0
6088698|NCT00677365|9699651|FG003|Overall Study|Other reason|1
6198978|NCT01474512|9858128|FG010|Post-Treatment Follow-Up|Clinical Relapse|0
6198979|NCT01474512|9858129|FG011|Post-Treatment Follow-Up|Clinical Relapse|0
6198980|NCT01474512|9858130|FG012|Post-Treatment Follow-Up|Clinical Relapse|0
6198981|NCT01474512|9858131|FG013|Post-Treatment Follow-Up|Clinical Relapse|0
6198982|NCT01474512|9858132|FG014|Post-Treatment Follow-Up|Clinical Relapse|0
6198983|NCT01474512|9858133|FG015|Post-Treatment Follow-Up|Clinical Relapse|0
6198984|NCT01474512|9858134|FG016|Post-Treatment Follow-Up|Clinical Relapse|6
6198985|NCT01474512|9858135|FG017|Post-Treatment Follow-Up|Clinical Relapse|2
6198986|NCT01474512|9858118|FG000|Post-Treatment Follow-Up|Protocol Violation|0
6198987|NCT01474512|9858119|FG001|Post-Treatment Follow-Up|Protocol Violation|0
6198988|NCT01474512|9858120|FG002|Post-Treatment Follow-Up|Protocol Violation|0
6198989|NCT01474512|9858121|FG003|Post-Treatment Follow-Up|Protocol Violation|0
6198990|NCT01474512|9858122|FG004|Post-Treatment Follow-Up|Protocol Violation|0
6198991|NCT01474512|9858123|FG005|Post-Treatment Follow-Up|Protocol Violation|0
6198992|NCT01474512|9858124|FG006|Post-Treatment Follow-Up|Protocol Violation|0
6198993|NCT01474512|9858125|FG007|Post-Treatment Follow-Up|Protocol Violation|0
6198994|NCT01474512|9858126|FG008|Post-Treatment Follow-Up|Protocol Violation|0
6198995|NCT01474512|9858127|FG009|Post-Treatment Follow-Up|Protocol Violation|0
6198996|NCT01474512|9858128|FG010|Post-Treatment Follow-Up|Protocol Violation|0
6198997|NCT01474512|9858129|FG011|Post-Treatment Follow-Up|Protocol Violation|0
6198998|NCT01474512|9858130|FG012|Post-Treatment Follow-Up|Protocol Violation|0
6198999|NCT01474512|9858131|FG013|Post-Treatment Follow-Up|Protocol Violation|0
6199000|NCT01474512|9858132|FG014|Post-Treatment Follow-Up|Protocol Violation|2
6199001|NCT01474512|9858133|FG015|Post-Treatment Follow-Up|Protocol Violation|2
6199002|NCT01474512|9858134|FG016|Post-Treatment Follow-Up|Protocol Violation|4
6199003|NCT01474512|9858135|FG017|Post-Treatment Follow-Up|Protocol Violation|0
6199004|NCT01474512|9858118|FG000|Post-Treatment Follow-Up|Sponsor Decision|0
6199005|NCT01474512|9858119|FG001|Post-Treatment Follow-Up|Sponsor Decision|0
6199006|NCT01474512|9858120|FG002|Post-Treatment Follow-Up|Sponsor Decision|0
6199007|NCT01474512|9858121|FG003|Post-Treatment Follow-Up|Sponsor Decision|0
6199008|NCT01474512|9858122|FG004|Post-Treatment Follow-Up|Sponsor Decision|0
6199009|NCT01474512|9858123|FG005|Post-Treatment Follow-Up|Sponsor Decision|0
6199010|NCT01474512|9858124|FG006|Post-Treatment Follow-Up|Sponsor Decision|0
6199011|NCT01474512|9858125|FG007|Post-Treatment Follow-Up|Sponsor Decision|0
6199012|NCT01474512|9858126|FG008|Post-Treatment Follow-Up|Sponsor Decision|0
6199013|NCT01474512|9858127|FG009|Post-Treatment Follow-Up|Sponsor Decision|0
6199014|NCT01474512|9858128|FG010|Post-Treatment Follow-Up|Sponsor Decision|0
6199015|NCT01474512|9858129|FG011|Post-Treatment Follow-Up|Sponsor Decision|0
6199016|NCT01474512|9858130|FG012|Post-Treatment Follow-Up|Sponsor Decision|0
6199017|NCT01474512|9858131|FG013|Post-Treatment Follow-Up|Sponsor Decision|0
6199018|NCT01474512|9858132|FG014|Post-Treatment Follow-Up|Sponsor Decision|1
6199019|NCT01474512|9858133|FG015|Post-Treatment Follow-Up|Sponsor Decision|0
6199020|NCT01474512|9858134|FG016|Post-Treatment Follow-Up|Sponsor Decision|4
6199021|NCT01474512|9858135|FG017|Post-Treatment Follow-Up|Sponsor Decision|0
6199022|NCT01474512|9858118|FG000|Post-Treatment Follow-Up|Parent/Caregiver Decision|0
6199023|NCT01474512|9858119|FG001|Post-Treatment Follow-Up|Parent/Caregiver Decision|0
6199024|NCT01474512|9858120|FG002|Post-Treatment Follow-Up|Parent/Caregiver Decision|0
6199025|NCT01474512|9858121|FG003|Post-Treatment Follow-Up|Parent/Caregiver Decision|0
6199026|NCT01474512|9858122|FG004|Post-Treatment Follow-Up|Parent/Caregiver Decision|0
6199027|NCT01474512|9858123|FG005|Post-Treatment Follow-Up|Parent/Caregiver Decision|0
6199028|NCT01474512|9858124|FG006|Post-Treatment Follow-Up|Parent/Caregiver Decision|0
6199029|NCT01474512|9858125|FG007|Post-Treatment Follow-Up|Parent/Caregiver Decision|0
6199030|NCT01474512|9858126|FG008|Post-Treatment Follow-Up|Parent/Caregiver Decision|0
6199031|NCT01474512|9858127|FG009|Post-Treatment Follow-Up|Parent/Caregiver Decision|0
6199032|NCT01474512|9858128|FG010|Post-Treatment Follow-Up|Parent/Caregiver Decision|0
6199033|NCT01474512|9858129|FG011|Post-Treatment Follow-Up|Parent/Caregiver Decision|0
6199034|NCT01474512|9858130|FG012|Post-Treatment Follow-Up|Parent/Caregiver Decision|0
6199035|NCT01474512|9858131|FG013|Post-Treatment Follow-Up|Parent/Caregiver Decision|0
6276364|NCT02226172|9982072|FG000|Overall Study|Participant refused further follow-up|4
6276365|NCT02226172|9982072|FG000|Overall Study|Other|5
6276366|NCT02226172|9982072|FG000|Overall Study|Death|1
6276367|NCT02226172|9982072|FG000|Overall Study|Study terminated by sponsor|1
6276368|NCT02226172|9982072|FG000|Overall Study|Adverse Event|6
6276369|NCT02226198|9982076|FG000|Lead-in Phase|Protocol Violation|1
6276370|NCT02226198|9982077|FG001|Lead-in Phase|Protocol Violation|0
6276371|NCT02226198|9982078|FG002|Lead-in Phase|Protocol Violation|0
6276372|NCT02226198|9982076|FG000|Cross-Over: First Intervention (6 Weeks)|No possibility to draw blood|0
6276373|NCT02226198|9982077|FG001|Cross-Over: First Intervention (6 Weeks)|No possibility to draw blood|1
5977198|NCT02452554|9564337|FG002|Overall Study|Withdrawal by Subject|2
6199036|NCT01474512|9858132|FG014|Post-Treatment Follow-Up|Parent/Caregiver Decision|1
6199037|NCT01474512|9858133|FG015|Post-Treatment Follow-Up|Parent/Caregiver Decision|0
6199038|NCT01474512|9858134|FG016|Post-Treatment Follow-Up|Parent/Caregiver Decision|0
6199039|NCT01474512|9858135|FG017|Post-Treatment Follow-Up|Parent/Caregiver Decision|1
6199040|NCT01474512|9858118|FG000|Post-Treatment Follow-Up|Death|0
6199041|NCT01474512|9858119|FG001|Post-Treatment Follow-Up|Death|0
6199042|NCT01474512|9858120|FG002|Post-Treatment Follow-Up|Death|0
6199043|NCT01474512|9858121|FG003|Post-Treatment Follow-Up|Death|0
6199044|NCT01474512|9858122|FG004|Post-Treatment Follow-Up|Death|0
6199045|NCT01474512|9858123|FG005|Post-Treatment Follow-Up|Death|0
6199046|NCT01474512|9858124|FG006|Post-Treatment Follow-Up|Death|0
6199047|NCT01474512|9858125|FG007|Post-Treatment Follow-Up|Death|0
6199048|NCT01474512|9858126|FG008|Post-Treatment Follow-Up|Death|0
6199049|NCT01474512|9858127|FG009|Post-Treatment Follow-Up|Death|0
6199050|NCT01474512|9858128|FG010|Post-Treatment Follow-Up|Death|0
6199051|NCT01474512|9858129|FG011|Post-Treatment Follow-Up|Death|0
6199052|NCT01474512|9858130|FG012|Post-Treatment Follow-Up|Death|0
6199053|NCT01474512|9858131|FG013|Post-Treatment Follow-Up|Death|0
6199054|NCT01474512|9858132|FG014|Post-Treatment Follow-Up|Death|0
6199055|NCT01474512|9858133|FG015|Post-Treatment Follow-Up|Death|0
6199056|NCT01474512|9858134|FG016|Post-Treatment Follow-Up|Death|1
6199057|NCT01474512|9858135|FG017|Post-Treatment Follow-Up|Death|0
6199058|NCT01474538|9858167|FG000|Treatment Period 1|Death|1
6199059|NCT01474538|9858168|FG001|Treatment Period 1|Death|0
6199060|NCT01474538|9858167|FG000|Treatment Period 1|Physician Decision|1
6276374|NCT02226198|9982078|FG002|Cross-Over: First Intervention (6 Weeks)|No possibility to draw blood|0
6276375|NCT02226549|9982106|FG000|Overall Study|Randomized but Never Treated|1
6276376|NCT02226549|9982107|FG001|Overall Study|Randomized but Never Treated|0
6276377|NCT02226549|9982106|FG000|Overall Study|Lost to Follow-up|0
6276378|NCT02226549|9982107|FG001|Overall Study|Lost to Follow-up|1
6276379|NCT02226562|9982115|FG000|Overall Study|Lost to Follow-up|0
6276380|NCT02226562|9982116|FG001|Overall Study|Lost to Follow-up|1
6276381|NCT02226653|9982124|FG000|Treatment Period 2 Fasted State|Lost to Follow-up|1
6276382|NCT02226653|9982125|FG001|Treatment Period 2 Fasted State|Lost to Follow-up|0
6276383|NCT02226653|9982124|FG000|Treatment Period 5 Fed State|Adverse Event|0
6276384|NCT02226653|9982125|FG001|Treatment Period 5 Fed State|Adverse Event|1
6276385|NCT02227108|9982149|FG000|Overall Study|Did not receive treatment|2
6276386|NCT02227108|9982149|FG000|Overall Study|Other|3
6276387|NCT02227108|9982149|FG000|Overall Study|Progressive disease|17
6276388|NCT02227108|9982149|FG000|Overall Study|Initiation of alternative therapy|2
6276389|NCT02227108|9982149|FG000|Overall Study|Investigator discretion|1
6276390|NCT02227108|9982149|FG000|Overall Study|Adverse Event|6
6276391|NCT02227368|9982185|FG000|Overall Study|No EVR/not PAD/PI decision/RLE bypass|0
6276392|NCT02227368|9982186|FG001|Overall Study|No EVR/not PAD/PI decision/RLE bypass|4
6276393|NCT02227368|9982185|FG000|Overall Study|Lost to Follow-up|1
6276394|NCT02227368|9982186|FG001|Overall Study|Lost to Follow-up|0
6276395|NCT02227368|9982185|FG000|Overall Study|Adverse Event|1
6276396|NCT02227368|9982186|FG001|Overall Study|Adverse Event|0
6276397|NCT02227446|9982194|FG000|Overall Study|not eligible post randomization|18
6276398|NCT02227446|9982195|FG001|Overall Study|not eligible post randomization|29
6276399|NCT02227446|9982194|FG000|Overall Study|Withdrawal by Subject|4
6276400|NCT02227446|9982195|FG001|Overall Study|Withdrawal by Subject|5
6276401|NCT02227784|9982255|FG000|Double-Blind Phase|Adverse Event|3
6276402|NCT02227784|9982256|FG001|Double-Blind Phase|Adverse Event|2
6276403|NCT02227784|9982257|FG002|Double-Blind Phase|Adverse Event|1
6276404|NCT02227784|9982258|FG003|Double-Blind Phase|Adverse Event|3
6276405|NCT02227784|9982259|FG004|Double-Blind Phase|Adverse Event|0
6276406|NCT02227784|9982255|FG000|Double-Blind Phase|Physician Decision|1
6276407|NCT02227784|9982256|FG001|Double-Blind Phase|Physician Decision|0
6276408|NCT02227784|9982257|FG002|Double-Blind Phase|Physician Decision|0
6276409|NCT02227784|9982258|FG003|Double-Blind Phase|Physician Decision|1
6276410|NCT02227784|9982259|FG004|Double-Blind Phase|Physician Decision|0
6276411|NCT02227784|9982255|FG000|Double-Blind Phase|Protocol Violation|0
6276412|NCT02227784|9982256|FG001|Double-Blind Phase|Protocol Violation|0
6276413|NCT02227784|9982257|FG002|Double-Blind Phase|Protocol Violation|1
6276414|NCT02227784|9982258|FG003|Double-Blind Phase|Protocol Violation|1
6276415|NCT02227784|9982259|FG004|Double-Blind Phase|Protocol Violation|0
6276416|NCT02227784|9982255|FG000|Double-Blind Phase|Sponsor Decision|34
6276417|NCT02227784|9982256|FG001|Double-Blind Phase|Sponsor Decision|15
6276418|NCT02227784|9982257|FG002|Double-Blind Phase|Sponsor Decision|14
6276419|NCT02227784|9982258|FG003|Double-Blind Phase|Sponsor Decision|32
6276420|NCT02227784|9982259|FG004|Double-Blind Phase|Sponsor Decision|0
6276421|NCT02227784|9982255|FG000|Double-Blind Phase|Withdrawal by Subject|2
6276422|NCT02227784|9982256|FG001|Double-Blind Phase|Withdrawal by Subject|1
6276423|NCT02227784|9982257|FG002|Double-Blind Phase|Withdrawal by Subject|5
6276424|NCT02227784|9982258|FG003|Double-Blind Phase|Withdrawal by Subject|2
6276425|NCT02227784|9982259|FG004|Double-Blind Phase|Withdrawal by Subject|0
6276426|NCT02227784|9982255|FG000|Open-Label Extension Phase (OLE)|Adverse Event|0
6276427|NCT02227784|9982256|FG001|Open-Label Extension Phase (OLE)|Adverse Event|0
6276428|NCT02227784|9982257|FG002|Open-Label Extension Phase (OLE)|Adverse Event|0
6276429|NCT02227784|9982258|FG003|Open-Label Extension Phase (OLE)|Adverse Event|0
6276430|NCT02227784|9982259|FG004|Open-Label Extension Phase (OLE)|Adverse Event|1
6276431|NCT02227784|9982255|FG000|Open-Label Extension Phase (OLE)|Death|0
6276432|NCT02227784|9982256|FG001|Open-Label Extension Phase (OLE)|Death|0
6276433|NCT02227784|9982257|FG002|Open-Label Extension Phase (OLE)|Death|0
6276434|NCT02227784|9982258|FG003|Open-Label Extension Phase (OLE)|Death|0
6199061|NCT01474538|9858168|FG001|Treatment Period 1|Physician Decision|0
6199062|NCT01474538|9858167|FG000|Treatment Period 1|Withdrawal by Subject|1
6276435|NCT02227784|9982259|FG004|Open-Label Extension Phase (OLE)|Death|1
6199063|NCT01474538|9858168|FG001|Treatment Period 1|Withdrawal by Subject|3
6199064|NCT01474538|9858167|FG000|Treatment Period 1|Protocol Violation|0
6199065|NCT01474538|9858168|FG001|Treatment Period 1|Protocol Violation|1
6199066|NCT01474538|9858167|FG000|Treatment Period 2|Death|1
6199067|NCT01474538|9858168|FG001|Treatment Period 2|Death|0
6199068|NCT01474538|9858167|FG000|Treatment Period 2|Adverse Event|1
6199069|NCT01474538|9858168|FG001|Treatment Period 2|Adverse Event|1
6199070|NCT01474538|9858167|FG000|Treatment Period 2|Withdrawal by Subject|2
6199071|NCT01474538|9858168|FG001|Treatment Period 2|Withdrawal by Subject|0
6199072|NCT01474538|9858167|FG000|Treatment Period 2|Sponsor decision|1
6199073|NCT01474538|9858168|FG001|Treatment Period 2|Sponsor decision|0
6199074|NCT01474538|9858167|FG000|Treatment Period 2|Physician Decision|0
6199075|NCT01474538|9858168|FG001|Treatment Period 2|Physician Decision|1
6199076|NCT01474538|9858167|FG000|Treatment Period 2|Protocol Violation|1
6199077|NCT01474538|9858168|FG001|Treatment Period 2|Protocol Violation|0
6199078|NCT01474551|9858174|FG000|Overall Study|Death|1
6199079|NCT01474681|9858189|FG000|Overall Study|Death|0
6199080|NCT01474681|9858190|FG001|Overall Study|Death|3
6199081|NCT01474681|9858191|FG002|Overall Study|Death|2
6199082|NCT01474681|9858192|FG003|Overall Study|Death|6
6199083|NCT01474746|9858208|FG000|Overall Study|Lost to Follow-up|1
6199084|NCT01474746|9858209|FG001|Overall Study|Lost to Follow-up|1
6199085|NCT01474746|9858208|FG000|Overall Study|Withdrawal by Subject|2
6199086|NCT01474746|9858209|FG001|Overall Study|Withdrawal by Subject|1
6199087|NCT01474772|9858217|FG000|Period 1|Adverse Event (AE) Related to Study Drug|6
6199088|NCT01474772|9858218|FG001|Period 1|Adverse Event (AE) Related to Study Drug|1
6199089|NCT01474772|9858217|FG000|Period 1|AE not Related to Study Drug|1
6199090|NCT01474772|9858218|FG001|Period 1|AE not Related to Study Drug|0
6199091|NCT01474772|9858217|FG000|Period 1|Withdrawal by Subject|3
6199092|NCT01474772|9858218|FG001|Period 1|Withdrawal by Subject|1
6199093|NCT01474772|9858217|FG000|Period 1|Lost to Follow-up|1
6199094|NCT01474772|9858218|FG001|Period 1|Lost to Follow-up|0
6199095|NCT01474772|9858217|FG000|Period 1|Reason not Specified|1
6199096|NCT01474772|9858218|FG001|Period 1|Reason not Specified|1
6199097|NCT01474772|9858217|FG000|Washout|AE not Related to Study Drug|2
6276436|NCT02227784|9982255|FG000|Open-Label Extension Phase (OLE)|Sponsor Decision|0
6276437|NCT02227784|9982256|FG001|Open-Label Extension Phase (OLE)|Sponsor Decision|0
6276438|NCT02227784|9982257|FG002|Open-Label Extension Phase (OLE)|Sponsor Decision|0
6276439|NCT02227784|9982258|FG003|Open-Label Extension Phase (OLE)|Sponsor Decision|0
6276440|NCT02227784|9982259|FG004|Open-Label Extension Phase (OLE)|Sponsor Decision|243
6276441|NCT02227784|9982255|FG000|Open-Label Extension Phase (OLE)|Withdrawal by Subject|0
6276442|NCT02227784|9982256|FG001|Open-Label Extension Phase (OLE)|Withdrawal by Subject|0
6276443|NCT02227784|9982257|FG002|Open-Label Extension Phase (OLE)|Withdrawal by Subject|0
6276444|NCT02227784|9982258|FG003|Open-Label Extension Phase (OLE)|Withdrawal by Subject|0
6276445|NCT02227784|9982259|FG004|Open-Label Extension Phase (OLE)|Withdrawal by Subject|3
6276446|NCT02227849|9982287|FG000|Overall Study|Adverse Event|4
6276447|NCT02227849|9982287|FG000|Overall Study|Physician Decision|1
6276448|NCT02227849|9982287|FG000|Overall Study|Withdrawal by Subject|3
6276449|NCT02228096|9982293|FG000|Overall Study|Study terminated by Sponsor|24
6276450|NCT02228096|9982293|FG000|Overall Study|Lack of Efficacy|18
6276451|NCT02228096|9982293|FG000|Overall Study|Death|12
6276452|NCT02228096|9982293|FG000|Overall Study|Physician Decision|3
5977199|NCT02452554|9564338|FG003|Overall Study|Withdrawal by Subject|0
5977200|NCT02452554|9564339|FG004|Overall Study|Withdrawal by Subject|0
5977201|NCT02452554|9564340|FG005|Overall Study|Withdrawal by Subject|1
5977202|NCT02452554|9564335|FG000|Overall Study|Ineligible|0
5977203|NCT02452554|9564336|FG001|Overall Study|Ineligible|1
5977204|NCT02452554|9564337|FG002|Overall Study|Ineligible|0
5977205|NCT02452554|9564338|FG003|Overall Study|Ineligible|0
5977206|NCT02452554|9564339|FG004|Overall Study|Ineligible|0
5977207|NCT02452554|9564340|FG005|Overall Study|Ineligible|0
5977208|NCT02452554|9564335|FG000|Overall Study|Never Received Treatment|1
6199098|NCT01474772|9858218|FG001|Washout|AE not Related to Study Drug|0
6199099|NCT01474772|9858217|FG000|Washout|Withdrawal by Subject|1
6199100|NCT01474772|9858218|FG001|Washout|Withdrawal by Subject|0
6199101|NCT01474772|9858217|FG000|Washout|Lost to Follow-up|0
6199102|NCT01474772|9858218|FG001|Washout|Lost to Follow-up|1
6199103|NCT01474772|9858217|FG000|Washout|Reason not Specified|0
6199104|NCT01474772|9858218|FG001|Washout|Reason not Specified|1
6199105|NCT01474772|9858217|FG000|Period 2|Death|0
5977209|NCT02452554|9564336|FG001|Overall Study|Never Received Treatment|0
6199106|NCT01474772|9858218|FG001|Period 2|Death|1
6199107|NCT01474772|9858217|FG000|Period 2|AE Related to Study Drug|0
6199108|NCT01474772|9858218|FG001|Period 2|AE Related to Study Drug|1
6199109|NCT01474772|9858217|FG000|Period 2|AE not Related to Study Drug|4
6199110|NCT01474772|9858218|FG001|Period 2|AE not Related to Study Drug|1
6199111|NCT01474772|9858217|FG000|Period 2|Lack of Efficacy|1
6199112|NCT01474772|9858218|FG001|Period 2|Lack of Efficacy|0
6199113|NCT01474772|9858217|FG000|Period 2|Withdrawal by Subject|3
6199114|NCT01474772|9858218|FG001|Period 2|Withdrawal by Subject|4
6199115|NCT01474772|9858217|FG000|Period 2|Lost to Follow-up|1
6199116|NCT01474772|9858218|FG001|Period 2|Lost to Follow-up|1
6199117|NCT01474772|9858217|FG000|Period 2|Reason not Specified|0
6199118|NCT01474772|9858218|FG001|Period 2|Reason not Specified|2
6199119|NCT01474772|9858217|FG000|Follow-up|AE not Related to Study Drug|0
6199120|NCT01474772|9858218|FG001|Follow-up|AE not Related to Study Drug|1
6199121|NCT01474876|9858240|FG000|Overall Study|Adverse Event|11
6199122|NCT01474876|9858241|FG001|Overall Study|Adverse Event|5
6199123|NCT01474876|9858242|FG002|Overall Study|Adverse Event|0
6199124|NCT01474876|9858240|FG000|Overall Study|Serious Adverse Event|2
6199125|NCT01474876|9858241|FG001|Overall Study|Serious Adverse Event|3
6199126|NCT01474876|9858242|FG002|Overall Study|Serious Adverse Event|0
6199127|NCT01474876|9858240|FG000|Overall Study|Lost to Follow-up|5
6199128|NCT01474876|9858241|FG001|Overall Study|Lost to Follow-up|4
6199129|NCT01474876|9858242|FG002|Overall Study|Lost to Follow-up|0
6199130|NCT01474876|9858240|FG000|Overall Study|Investigator's decision|28
6199131|NCT01474876|9858241|FG001|Overall Study|Investigator's decision|6
6199132|NCT01474876|9858242|FG002|Overall Study|Investigator's decision|0
6199133|NCT01474876|9858240|FG000|Overall Study|Patient's request|19
6199134|NCT01474876|9858241|FG001|Overall Study|Patient's request|5
6199135|NCT01474876|9858242|FG002|Overall Study|Patient's request|0
6276453|NCT02228096|9982293|FG000|Overall Study|Subject/guardian decision|2
6276454|NCT02228096|9982293|FG000|Overall Study|New therapy for study indication|1
6276455|NCT02228096|9982293|FG000|Overall Study|Enrolled, not infused|11
6276456|NCT02228395|9982315|FG000|First Intervention Period|No longer willing to participate|1
6276457|NCT02228395|9982316|FG001|First Intervention Period|No longer willing to participate|0
6276458|NCT02228395|9982317|FG002|First Intervention Period|No longer willing to participate|0
6276459|NCT02228395|9982315|FG000|First Intervention Period|Unable to comply with study dates|0
6276460|NCT02228395|9982316|FG001|First Intervention Period|Unable to comply with study dates|1
6276461|NCT02228395|9982317|FG002|First Intervention Period|Unable to comply with study dates|1
6276462|NCT02228460|9982336|FG000|Overall Study|Adverse Event|1
6276463|NCT02228460|9982336|FG000|Overall Study|Lost to Follow-up|1
6276464|NCT02228564|9982350|FG000|Overall Study|Withdrawal by Subject|10
6276465|NCT02228564|9982350|FG000|Overall Study|Death|11
6276466|NCT02228564|9982350|FG000|Overall Study|Physician Decision|5
6276467|NCT02228564|9982350|FG000|Overall Study|Lost to Follow-up|17
6276468|NCT02228564|9982350|FG000|Overall Study|Other|6
6276469|NCT02228590|9982354|FG000|Overall Study|Withdrawal by Subject|1
6276470|NCT02228720|9982368|FG000|Open Label - Day 30|Lost to Follow-up|1
6276471|NCT02228967|9982383|FG000|Overall Study|Lost to Follow-up|146
6276472|NCT02228967|9982384|FG001|Overall Study|Lost to Follow-up|142
6276473|NCT02228967|9982383|FG000|Overall Study|Withdrawal by Subject|13
6276474|NCT02228967|9982384|FG001|Overall Study|Withdrawal by Subject|18
6276475|NCT02228980|9982394|FG000|Overall Study|Adverse Event|14
6276476|NCT02228980|9982395|FG001|Overall Study|Adverse Event|0
6276477|NCT02228980|9982396|FG002|Overall Study|Adverse Event|0
6276478|NCT02228980|9982397|FG003|Overall Study|Adverse Event|0
6276479|NCT02228980|9982394|FG000|Overall Study|Protocol Violation|7
6276480|NCT02228980|9982395|FG001|Overall Study|Protocol Violation|0
6276481|NCT02228980|9982396|FG002|Overall Study|Protocol Violation|0
6276482|NCT02228980|9982397|FG003|Overall Study|Protocol Violation|0
6276483|NCT02228980|9982394|FG000|Overall Study|Withdrawal by Subject|3
6276484|NCT02228980|9982395|FG001|Overall Study|Withdrawal by Subject|3
6276485|NCT02228980|9982396|FG002|Overall Study|Withdrawal by Subject|2
6276486|NCT02228980|9982397|FG003|Overall Study|Withdrawal by Subject|3
6276487|NCT02229214|9982413|FG000|Overall Study|Adverse Event|2
6276488|NCT02229214|9982414|FG001|Overall Study|Adverse Event|0
6276489|NCT02229214|9982413|FG000|Overall Study|Withdrawal by Subject|4
6276490|NCT02229214|9982414|FG001|Overall Study|Withdrawal by Subject|0
6276491|NCT02229227|9982424|FG000|Overall Study|Adverse Event|14
6276492|NCT02229227|9982425|FG001|Overall Study|Adverse Event|9
6276493|NCT02229227|9982424|FG000|Overall Study|Lack of Efficacy|3
6276494|NCT02229227|9982425|FG001|Overall Study|Lack of Efficacy|3
6276495|NCT02229227|9982424|FG000|Overall Study|Protocol Violation|6
6276496|NCT02229227|9982425|FG001|Overall Study|Protocol Violation|8
6276497|NCT02229227|9982424|FG000|Overall Study|Protocol defined stopping criteria|1
6276498|NCT02229227|9982425|FG001|Overall Study|Protocol defined stopping criteria|3
6276499|NCT02229227|9982424|FG000|Overall Study|Lost to Follow-up|3
6276500|NCT02229227|9982425|FG001|Overall Study|Lost to Follow-up|3
6276501|NCT02229227|9982424|FG000|Overall Study|Study terminated by sponsor|11
6276502|NCT02229227|9982425|FG001|Overall Study|Study terminated by sponsor|11
6199136|NCT01474876|9858240|FG000|Overall Study|Investigator's decision and pt request|1
6276503|NCT02229227|9982424|FG000|Overall Study|Withdrawal by Subject|8
6276504|NCT02229227|9982425|FG001|Overall Study|Withdrawal by Subject|12
6276505|NCT02229227|9982424|FG000|Overall Study|Other|0
6276506|NCT02229227|9982425|FG001|Overall Study|Other|1
6276507|NCT02229227|9982424|FG000|Overall Study|Physician Decision|5
6276508|NCT02229227|9982425|FG001|Overall Study|Physician Decision|12
6276509|NCT02229383|9982438|FG000|Overall Study|Adverse Event|7
6199137|NCT01474876|9858241|FG001|Overall Study|Investigator's decision and pt request|0
6199138|NCT01474876|9858242|FG002|Overall Study|Investigator's decision and pt request|0
6199139|NCT01474993|9858260|FG000|Overall Study|Lost to Follow-up|1
6199140|NCT01474993|9858261|FG001|Overall Study|Lost to Follow-up|2
6199141|NCT01474993|9858260|FG000|Overall Study|Adverse Event|0
6199142|NCT01474993|9858261|FG001|Overall Study|Adverse Event|1
6199143|NCT01475071|9858269|FG000|Overall Study|Physician Decision|1
6199144|NCT01475071|9858269|FG000|Overall Study|Withdrawal by Subject|6
6199145|NCT01475071|9858269|FG000|Overall Study|Lost to Follow-up|1
6199146|NCT01475097|9858277|FG000|Overall Study|Protocol Violation|1
6199147|NCT01475097|9858278|FG001|Overall Study|Protocol Violation|1
6199148|NCT01475136|9858288|FG000|Overall Study|Sponsor Decision|0
6199149|NCT01475136|9858289|FG001|Overall Study|Sponsor Decision|1
6199150|NCT01475136|9858290|FG002|Overall Study|Sponsor Decision|0
6199151|NCT01475136|9858291|FG003|Overall Study|Sponsor Decision|0
6199152|NCT01475136|9858288|FG000|Overall Study|Entry Criteria Not Met|0
6199153|NCT01475136|9858289|FG001|Overall Study|Entry Criteria Not Met|2
6199154|NCT01475136|9858290|FG002|Overall Study|Entry Criteria Not Met|3
6199155|NCT01475136|9858291|FG003|Overall Study|Entry Criteria Not Met|1
6199156|NCT01475136|9858288|FG000|Overall Study|Withdrawal by Subject|0
6199157|NCT01475136|9858289|FG001|Overall Study|Withdrawal by Subject|0
6199158|NCT01475136|9858290|FG002|Overall Study|Withdrawal by Subject|0
6276510|NCT02229383|9982439|FG001|Overall Study|Adverse Event|4
6276511|NCT02229383|9982438|FG000|Overall Study|Death|0
6276512|NCT02229383|9982439|FG001|Overall Study|Death|1
6276513|NCT02229383|9982438|FG000|Overall Study|Lost to Follow-up|5
6276514|NCT02229383|9982439|FG001|Overall Study|Lost to Follow-up|3
6276515|NCT02229383|9982438|FG000|Overall Study|Withdrawal by Subject|4
6276516|NCT02229383|9982439|FG001|Overall Study|Withdrawal by Subject|6
6276517|NCT02229383|9982438|FG000|Overall Study|Did not receive treatment|1
6276518|NCT02229383|9982439|FG001|Overall Study|Did not receive treatment|0
6276519|NCT02229383|9982438|FG000|Overall Study|Other|3
6276520|NCT02229383|9982439|FG001|Overall Study|Other|8
6276521|NCT02229396|9982448|FG000|Overall Study|Adverse Event|6
6276522|NCT02229396|9982449|FG001|Overall Study|Adverse Event|12
6276523|NCT02229396|9982450|FG002|Overall Study|Adverse Event|12
6276524|NCT02229396|9982448|FG000|Overall Study|Death|2
6276525|NCT02229396|9982449|FG001|Overall Study|Death|3
6276526|NCT02229396|9982450|FG002|Overall Study|Death|1
6276527|NCT02229396|9982448|FG000|Overall Study|Lost to Follow-up|14
6276528|NCT02229396|9982449|FG001|Overall Study|Lost to Follow-up|14
6276529|NCT02229396|9982450|FG002|Overall Study|Lost to Follow-up|21
6276530|NCT02229396|9982448|FG000|Overall Study|Protocol Violation|2
6276531|NCT02229396|9982449|FG001|Overall Study|Protocol Violation|1
6276532|NCT02229396|9982450|FG002|Overall Study|Protocol Violation|0
6276533|NCT02229396|9982448|FG000|Overall Study|Patient Incorrectly Randomized|0
6276534|NCT02229396|9982449|FG001|Overall Study|Patient Incorrectly Randomized|0
6276535|NCT02229396|9982450|FG002|Overall Study|Patient Incorrectly Randomized|1
6276536|NCT02229396|9982448|FG000|Overall Study|Other|10
6276537|NCT02229396|9982449|FG001|Overall Study|Other|18
6276538|NCT02229396|9982450|FG002|Overall Study|Other|15
6276539|NCT02229396|9982448|FG000|Overall Study|Withdrawal by Subject|42
6276540|NCT02229396|9982449|FG001|Overall Study|Withdrawal by Subject|28
6276541|NCT02229396|9982450|FG002|Overall Study|Withdrawal by Subject|41
6276542|NCT02229396|9982448|FG000|Overall Study|Study-Specific Withdrawal Criteria|0
6276543|NCT02229396|9982449|FG001|Overall Study|Study-Specific Withdrawal Criteria|1
6276544|NCT02229396|9982450|FG002|Overall Study|Study-Specific Withdrawal Criteria|3
6276545|NCT02229396|9982448|FG000|Overall Study|Withdrew; No Record on Termination Page|2
6276546|NCT02229396|9982449|FG001|Overall Study|Withdrew; No Record on Termination Page|0
6276547|NCT02229396|9982450|FG002|Overall Study|Withdrew; No Record on Termination Page|1
6276548|NCT02229539|9982516|FG000|Cycle 1 (Treatment Per Protocol)|Withdrawal by Subject|0
6276549|NCT02229539|9982517|FG001|Cycle 1 (Treatment Per Protocol)|Withdrawal by Subject|1
6276550|NCT02229539|9982518|FG002|Cycle 1 (Treatment Per Protocol)|Withdrawal by Subject|0
6276551|NCT02229539|9982516|FG000|Cycle 1 (Treatment Per Protocol)|Alternate Therapy|0
6276552|NCT02229539|9982517|FG001|Cycle 1 (Treatment Per Protocol)|Alternate Therapy|0
6276553|NCT02229539|9982518|FG002|Cycle 1 (Treatment Per Protocol)|Alternate Therapy|1
6276554|NCT02229539|9982516|FG000|Cycle 1 (Treatment Per Protocol)|Medical Problems|0
6276555|NCT02229539|9982517|FG001|Cycle 1 (Treatment Per Protocol)|Medical Problems|0
5977210|NCT02452554|9564337|FG002|Overall Study|Never Received Treatment|0
5977211|NCT02452554|9564338|FG003|Overall Study|Never Received Treatment|0
5977212|NCT02452554|9564339|FG004|Overall Study|Never Received Treatment|0
6088699|NCT00677534|9699661|FG000|Washout (Weeks 1-4)|did not qualify after signing consent|1
6088700|NCT00677534|9699661|FG000|Washout (Weeks 1-4)|Withdrawal by Subject|1
6088701|NCT00677534|9699661|FG000|Washout (Weeks 1-4)|Withdrawal by Subject|1
6088702|NCT00677807|9699677|FG000|Overall Study|Adverse Event|4
6199159|NCT01475136|9858291|FG003|Overall Study|Withdrawal by Subject|2
6199160|NCT01475136|9858288|FG000|Overall Study|Adverse Event|1
6199161|NCT01475136|9858289|FG001|Overall Study|Adverse Event|0
6088703|NCT00677807|9699678|FG001|Overall Study|Adverse Event|1
6199162|NCT01475136|9858290|FG002|Overall Study|Adverse Event|0
6276556|NCT02229539|9982518|FG002|Cycle 1 (Treatment Per Protocol)|Medical Problems|1
6199163|NCT01475136|9858291|FG003|Overall Study|Adverse Event|1
6199164|NCT01475136|9858288|FG000|Overall Study|Death|0
6199165|NCT01475136|9858289|FG001|Overall Study|Death|0
6199166|NCT01475136|9858290|FG002|Overall Study|Death|0
6199167|NCT01475136|9858291|FG003|Overall Study|Death|1
6199168|NCT01475162|9858301|FG000|Overall Study|Physician Decision|1
6199169|NCT01475162|9858301|FG000|Overall Study|Death|10
6199170|NCT01475162|9858301|FG000|Overall Study|Study closed for safety|3
6199171|NCT01475214|9858313|FG000|Overall Study|Lost to Follow-up|1
6199172|NCT01475214|9858314|FG001|Overall Study|Lost to Follow-up|0
6199173|NCT01475214|9858315|FG002|Overall Study|Lost to Follow-up|1
6199174|NCT01475214|9858313|FG000|Overall Study|Physician Decision|2
6199175|NCT01475214|9858314|FG001|Overall Study|Physician Decision|0
6199176|NCT01475214|9858315|FG002|Overall Study|Physician Decision|0
6199177|NCT01475214|9858313|FG000|Overall Study|Withdrawal by Subject|2
6199178|NCT01475214|9858314|FG001|Overall Study|Withdrawal by Subject|4
6199179|NCT01475214|9858315|FG002|Overall Study|Withdrawal by Subject|1
6199180|NCT01475253|9858327|FG000|Randomized, Blinded Study|Withdrawal by Subject|1
6199181|NCT01475253|9858328|FG001|Randomized, Blinded Study|Withdrawal by Subject|1
6199182|NCT01475253|9858329|FG002|Randomized, Blinded Study|Withdrawal by Subject|0
6199183|NCT01475253|9858330|FG003|Randomized, Blinded Study|Withdrawal by Subject|0
6199184|NCT01475253|9858327|FG000|Randomized, Blinded Study|Lost to Follow-up|1
6199185|NCT01475253|9858328|FG001|Randomized, Blinded Study|Lost to Follow-up|0
6199186|NCT01475253|9858329|FG002|Randomized, Blinded Study|Lost to Follow-up|0
6199187|NCT01475253|9858330|FG003|Randomized, Blinded Study|Lost to Follow-up|0
6199188|NCT01475331|9858350|FG000|Overall Study|Osteophyte obstruction of the proximal|1
6199189|NCT01475331|9858351|FG001|Overall Study|Osteophyte obstruction of the proximal|0
6199190|NCT01475331|9858350|FG000|Overall Study|excessive main duct communication|1
6199191|NCT01475331|9858351|FG001|Overall Study|excessive main duct communication|1
6199192|NCT01475331|9858350|FG000|Overall Study|Loss of needle positioning due pt. cough|1
6199193|NCT01475331|9858351|FG001|Overall Study|Loss of needle positioning due pt. cough|0
6199194|NCT01475331|9858350|FG000|Overall Study|Sign of malignancy during the procedure|2
6199195|NCT01475331|9858351|FG001|Overall Study|Sign of malignancy during the procedure|0
6276557|NCT02229539|9982516|FG000|Cycle 1 (Treatment Per Protocol)|Data being queried at the time of report|3
6276558|NCT02229539|9982517|FG001|Cycle 1 (Treatment Per Protocol)|Data being queried at the time of report|4
6276559|NCT02229539|9982518|FG002|Cycle 1 (Treatment Per Protocol)|Data being queried at the time of report|1
6276560|NCT02229539|9982516|FG000|Cycle 2 (Optional Continuation Phase)|Withdrawal by Subject|5
6276561|NCT02229539|9982517|FG001|Cycle 2 (Optional Continuation Phase)|Withdrawal by Subject|5
6276562|NCT02229539|9982518|FG002|Cycle 2 (Optional Continuation Phase)|Withdrawal by Subject|6
6276563|NCT02229539|9982516|FG000|Cycle 2 (Optional Continuation Phase)|Adverse Event|2
6276564|NCT02229539|9982517|FG001|Cycle 2 (Optional Continuation Phase)|Adverse Event|0
6276565|NCT02229539|9982518|FG002|Cycle 2 (Optional Continuation Phase)|Adverse Event|0
6276566|NCT02229539|9982516|FG000|Cycle 2 (Optional Continuation Phase)|Alternative Therapy|0
6276567|NCT02229539|9982517|FG001|Cycle 2 (Optional Continuation Phase)|Alternative Therapy|1
6276568|NCT02229539|9982518|FG002|Cycle 2 (Optional Continuation Phase)|Alternative Therapy|1
6276569|NCT02229539|9982516|FG000|Cycle 2 (Optional Continuation Phase)|Other Unknown Reason|0
6276570|NCT02229539|9982517|FG001|Cycle 2 (Optional Continuation Phase)|Other Unknown Reason|0
6276571|NCT02229539|9982518|FG002|Cycle 2 (Optional Continuation Phase)|Other Unknown Reason|3
6276572|NCT02229539|9982516|FG000|Cycle 2 (Optional Continuation Phase)|Data being queried at the time of report|2
6276573|NCT02229539|9982517|FG001|Cycle 2 (Optional Continuation Phase)|Data being queried at the time of report|1
6276574|NCT02229539|9982518|FG002|Cycle 2 (Optional Continuation Phase)|Data being queried at the time of report|0
6276575|NCT02229552|9982526|FG000|Baseline|Withdrawal by Subject|6
6276576|NCT02229552|9982526|FG000|1-year Follow up|Withdrawal by Subject|7
6276577|NCT02229552|9982526|FG000|1-year Follow up|Lost to Follow-up|18
6276578|NCT02229552|9982526|FG000|2-Year Follow up|Withdrawal by Subject|9
6276579|NCT02229552|9982526|FG000|2-Year Follow up|Lost to Follow-up|17
6276580|NCT02229851|9982533|FG000|Main Phase (Double-blind Phase)|Unclassified|1
6276581|NCT02229851|9982534|FG001|Main Phase (Double-blind Phase)|Unclassified|2
6276582|NCT02229851|9982535|FG002|Main Phase (Double-blind Phase)|Unclassified|0
6276583|NCT02229851|9982536|FG003|Main Phase (Double-blind Phase)|Unclassified|0
6276584|NCT02229851|9982537|FG004|Main Phase (Double-blind Phase)|Unclassified|0
6276585|NCT02229851|9982538|FG005|Main Phase (Double-blind Phase)|Unclassified|0
6276586|NCT02229851|9982539|FG006|Main Phase (Double-blind Phase)|Unclassified|0
6276587|NCT02229851|9982533|FG000|Main Phase (Double-blind Phase)|Lost to Follow-up|0
6276588|NCT02229851|9982534|FG001|Main Phase (Double-blind Phase)|Lost to Follow-up|1
6276589|NCT02229851|9982535|FG002|Main Phase (Double-blind Phase)|Lost to Follow-up|0
6276590|NCT02229851|9982536|FG003|Main Phase (Double-blind Phase)|Lost to Follow-up|0
6276591|NCT02229851|9982537|FG004|Main Phase (Double-blind Phase)|Lost to Follow-up|0
6199196|NCT01475331|9858350|FG000|Overall Study|cyst found to be prohibitively small|0
6199197|NCT01475331|9858351|FG001|Overall Study|cyst found to be prohibitively small|1
6199198|NCT01475370|9858360|FG000|Overall Study|Exacerbation of primary disease|2
6199199|NCT01475370|9858361|FG001|Overall Study|Exacerbation of primary disease|2
6199200|NCT01475370|9858362|FG002|Overall Study|Exacerbation of primary disease|2
6199201|NCT01475370|9858360|FG000|Overall Study|Study drug administration difficult|0
6199202|NCT01475370|9858361|FG001|Overall Study|Study drug administration difficult|1
6199203|NCT01475370|9858362|FG002|Overall Study|Study drug administration difficult|1
6199204|NCT01475370|9858360|FG000|Overall Study|Other than specified|1
6199205|NCT01475370|9858361|FG001|Overall Study|Other than specified|0
6199206|NCT01475370|9858362|FG002|Overall Study|Other than specified|0
6199207|NCT01475461|9858376|FG000|Run-in Period|Not meet eligibility criteria|16
6199208|NCT01475461|9858377|FG001|Run-in Period|Not meet eligibility criteria|0
6199209|NCT01475461|9858378|FG002|Run-in Period|Not meet eligibility criteria|0
6199210|NCT01475461|9858379|FG003|Run-in Period|Not meet eligibility criteria|0
6199211|NCT01475461|9858380|FG004|Run-in Period|Not meet eligibility criteria|0
6199212|NCT01475461|9858381|FG005|Run-in Period|Not meet eligibility criteria|0
6199213|NCT01475461|9858382|FG006|Run-in Period|Not meet eligibility criteria|0
6199214|NCT01475461|9858376|FG000|Run-in Period|Lost to Follow-up|7
6199215|NCT01475461|9858377|FG001|Run-in Period|Lost to Follow-up|0
6199216|NCT01475461|9858378|FG002|Run-in Period|Lost to Follow-up|0
6199217|NCT01475461|9858379|FG003|Run-in Period|Lost to Follow-up|0
6199218|NCT01475461|9858380|FG004|Run-in Period|Lost to Follow-up|0
6199219|NCT01475461|9858381|FG005|Run-in Period|Lost to Follow-up|0
6199220|NCT01475461|9858382|FG006|Run-in Period|Lost to Follow-up|0
6199221|NCT01475461|9858376|FG000|Run-in Period|Withdrawal by Subject|11
6199222|NCT01475461|9858377|FG001|Run-in Period|Withdrawal by Subject|0
6199223|NCT01475461|9858378|FG002|Run-in Period|Withdrawal by Subject|0
6199224|NCT01475461|9858379|FG003|Run-in Period|Withdrawal by Subject|0
6199225|NCT01475461|9858380|FG004|Run-in Period|Withdrawal by Subject|0
6199226|NCT01475461|9858381|FG005|Run-in Period|Withdrawal by Subject|0
6199227|NCT01475461|9858382|FG006|Run-in Period|Withdrawal by Subject|0
6199228|NCT01475461|9858376|FG000|Run-in Period|Other|3
6199229|NCT01475461|9858377|FG001|Run-in Period|Other|0
6199230|NCT01475461|9858378|FG002|Run-in Period|Other|0
6199231|NCT01475461|9858379|FG003|Run-in Period|Other|0
6199232|NCT01475461|9858380|FG004|Run-in Period|Other|0
6199233|NCT01475461|9858381|FG005|Run-in Period|Other|0
6199234|NCT01475461|9858382|FG006|Run-in Period|Other|0
6199235|NCT01475461|9858376|FG000|Run-in Period|Protocol Violation|4
6199236|NCT01475461|9858377|FG001|Run-in Period|Protocol Violation|0
6199237|NCT01475461|9858378|FG002|Run-in Period|Protocol Violation|0
6199238|NCT01475461|9858379|FG003|Run-in Period|Protocol Violation|0
6199239|NCT01475461|9858380|FG004|Run-in Period|Protocol Violation|0
6199240|NCT01475461|9858381|FG005|Run-in Period|Protocol Violation|0
6199241|NCT01475461|9858382|FG006|Run-in Period|Protocol Violation|0
6199242|NCT01475461|9858376|FG000|Treatment Period|Death|0
6276592|NCT02229851|9982538|FG005|Main Phase (Double-blind Phase)|Lost to Follow-up|0
6276593|NCT02229851|9982539|FG006|Main Phase (Double-blind Phase)|Lost to Follow-up|0
6276594|NCT02229851|9982533|FG000|Main Phase (Double-blind Phase)|Withdrawal by Subject|4
6276595|NCT02229851|9982534|FG001|Main Phase (Double-blind Phase)|Withdrawal by Subject|12
6276596|NCT02229851|9982535|FG002|Main Phase (Double-blind Phase)|Withdrawal by Subject|4
6276597|NCT02229851|9982536|FG003|Main Phase (Double-blind Phase)|Withdrawal by Subject|0
6276598|NCT02229851|9982537|FG004|Main Phase (Double-blind Phase)|Withdrawal by Subject|0
6276599|NCT02229851|9982538|FG005|Main Phase (Double-blind Phase)|Withdrawal by Subject|0
6276600|NCT02229851|9982539|FG006|Main Phase (Double-blind Phase)|Withdrawal by Subject|0
6276601|NCT02229851|9982533|FG000|Main Phase (Double-blind Phase)|Protocol Violation|0
6276602|NCT02229851|9982534|FG001|Main Phase (Double-blind Phase)|Protocol Violation|0
6276603|NCT02229851|9982535|FG002|Main Phase (Double-blind Phase)|Protocol Violation|2
6276604|NCT02229851|9982536|FG003|Main Phase (Double-blind Phase)|Protocol Violation|0
6276605|NCT02229851|9982537|FG004|Main Phase (Double-blind Phase)|Protocol Violation|0
6276606|NCT02229851|9982538|FG005|Main Phase (Double-blind Phase)|Protocol Violation|0
5977213|NCT02452554|9564340|FG005|Overall Study|Never Received Treatment|0
5977214|NCT02318277|9564376|FG000|Overall Study|Physician Decision|0
5977215|NCT02318277|9564377|FG001|Overall Study|Physician Decision|0
5977216|NCT02318277|9564378|FG002|Overall Study|Physician Decision|0
5977217|NCT02318277|9564379|FG003|Overall Study|Physician Decision|0
5977218|NCT02318277|9564380|FG004|Overall Study|Physician Decision|0
5977219|NCT02318277|9564381|FG005|Overall Study|Physician Decision|0
5977220|NCT02318277|9564382|FG006|Overall Study|Physician Decision|0
5977221|NCT02318277|9564383|FG007|Overall Study|Physician Decision|1
5977222|NCT02318277|9564376|FG000|Overall Study|Other|0
6199243|NCT01475461|9858377|FG001|Treatment Period|Death|0
6199244|NCT01475461|9858378|FG002|Treatment Period|Death|0
6199245|NCT01475461|9858379|FG003|Treatment Period|Death|1
6199246|NCT01475461|9858380|FG004|Treatment Period|Death|0
6199247|NCT01475461|9858381|FG005|Treatment Period|Death|0
6276607|NCT02229851|9982539|FG006|Main Phase (Double-blind Phase)|Protocol Violation|0
6276608|NCT02229851|9982533|FG000|Main Phase (Double-blind Phase)|Death|1
6276609|NCT02229851|9982534|FG001|Main Phase (Double-blind Phase)|Death|1
6276610|NCT02229851|9982535|FG002|Main Phase (Double-blind Phase)|Death|0
5977223|NCT02318277|9564377|FG001|Overall Study|Other|0
5977224|NCT02318277|9564378|FG002|Overall Study|Other|0
6199248|NCT01475461|9858382|FG006|Treatment Period|Death|0
6199249|NCT01475461|9858376|FG000|Treatment Period|Lost to Follow-up|0
6199250|NCT01475461|9858377|FG001|Treatment Period|Lost to Follow-up|3
6199251|NCT01475461|9858378|FG002|Treatment Period|Lost to Follow-up|2
6199252|NCT01475461|9858379|FG003|Treatment Period|Lost to Follow-up|3
6199253|NCT01475461|9858380|FG004|Treatment Period|Lost to Follow-up|1
6199254|NCT01475461|9858381|FG005|Treatment Period|Lost to Follow-up|2
6199255|NCT01475461|9858382|FG006|Treatment Period|Lost to Follow-up|1
6199256|NCT01475461|9858376|FG000|Treatment Period|Withdrawal by Subject|0
6199257|NCT01475461|9858377|FG001|Treatment Period|Withdrawal by Subject|2
6199258|NCT01475461|9858378|FG002|Treatment Period|Withdrawal by Subject|2
6199259|NCT01475461|9858379|FG003|Treatment Period|Withdrawal by Subject|0
6199260|NCT01475461|9858380|FG004|Treatment Period|Withdrawal by Subject|2
6199261|NCT01475461|9858381|FG005|Treatment Period|Withdrawal by Subject|2
6199262|NCT01475461|9858382|FG006|Treatment Period|Withdrawal by Subject|0
6199263|NCT01475461|9858376|FG000|Treatment Period|Other|0
6199264|NCT01475461|9858377|FG001|Treatment Period|Other|1
6199265|NCT01475461|9858378|FG002|Treatment Period|Other|0
6199266|NCT01475461|9858379|FG003|Treatment Period|Other|0
6199267|NCT01475461|9858380|FG004|Treatment Period|Other|0
6199268|NCT01475461|9858381|FG005|Treatment Period|Other|0
6199269|NCT01475461|9858382|FG006|Treatment Period|Other|0
6199270|NCT01475461|9858376|FG000|Treatment Period|Protocol Violation|0
6199271|NCT01475461|9858377|FG001|Treatment Period|Protocol Violation|1
6199272|NCT01475461|9858378|FG002|Treatment Period|Protocol Violation|0
6199273|NCT01475461|9858379|FG003|Treatment Period|Protocol Violation|0
6199274|NCT01475461|9858380|FG004|Treatment Period|Protocol Violation|0
6199275|NCT01475461|9858381|FG005|Treatment Period|Protocol Violation|0
6199276|NCT01475461|9858382|FG006|Treatment Period|Protocol Violation|1
6199277|NCT01475461|9858376|FG000|Treatment Period|Lack of Efficacy|0
6199278|NCT01475461|9858377|FG001|Treatment Period|Lack of Efficacy|2
6276611|NCT02229851|9982536|FG003|Main Phase (Double-blind Phase)|Death|0
6276612|NCT02229851|9982537|FG004|Main Phase (Double-blind Phase)|Death|0
6276613|NCT02229851|9982538|FG005|Main Phase (Double-blind Phase)|Death|0
6276614|NCT02229851|9982539|FG006|Main Phase (Double-blind Phase)|Death|0
6276615|NCT02229851|9982533|FG000|Extension Phase (Open-label Phase)|Lost to Follow-up|0
6276616|NCT02229851|9982534|FG001|Extension Phase (Open-label Phase)|Lost to Follow-up|0
6276617|NCT02229851|9982535|FG002|Extension Phase (Open-label Phase)|Lost to Follow-up|0
6276618|NCT02229851|9982536|FG003|Extension Phase (Open-label Phase)|Lost to Follow-up|0
6276619|NCT02229851|9982537|FG004|Extension Phase (Open-label Phase)|Lost to Follow-up|1
6276620|NCT02229851|9982538|FG005|Extension Phase (Open-label Phase)|Lost to Follow-up|1
6276621|NCT02229851|9982539|FG006|Extension Phase (Open-label Phase)|Lost to Follow-up|1
6276622|NCT02229851|9982533|FG000|Extension Phase (Open-label Phase)|Withdrawal by Subject|0
6276623|NCT02229851|9982534|FG001|Extension Phase (Open-label Phase)|Withdrawal by Subject|0
6276624|NCT02229851|9982535|FG002|Extension Phase (Open-label Phase)|Withdrawal by Subject|0
6276625|NCT02229851|9982536|FG003|Extension Phase (Open-label Phase)|Withdrawal by Subject|1
6276626|NCT02229851|9982537|FG004|Extension Phase (Open-label Phase)|Withdrawal by Subject|4
6276627|NCT02229851|9982538|FG005|Extension Phase (Open-label Phase)|Withdrawal by Subject|3
6276628|NCT02229851|9982539|FG006|Extension Phase (Open-label Phase)|Withdrawal by Subject|1
6276629|NCT02229851|9982533|FG000|Extension Phase (Open-label Phase)|Death|0
6276630|NCT02229851|9982534|FG001|Extension Phase (Open-label Phase)|Death|0
6276631|NCT02229851|9982535|FG002|Extension Phase (Open-label Phase)|Death|0
6276632|NCT02229851|9982536|FG003|Extension Phase (Open-label Phase)|Death|1
6276633|NCT02229851|9982537|FG004|Extension Phase (Open-label Phase)|Death|0
6276634|NCT02229851|9982538|FG005|Extension Phase (Open-label Phase)|Death|1
6276635|NCT02229851|9982539|FG006|Extension Phase (Open-label Phase)|Death|1
6276636|NCT02229864|9982554|FG000|Overall Study|Death|2
6276637|NCT02229864|9982554|FG000|Overall Study|Lost to Follow-up|1
6276638|NCT02230085|9982558|FG000|Overall Study|Physician Decision|1
6276639|NCT02230085|9982558|FG000|Overall Study|Withdrawal by Subject|3
6276640|NCT02230306|9982562|FG000|Overall Study|Did not receive study treatment|1
6276641|NCT02230332|9982568|FG000|Overall Study|Adverse Event|2
6276642|NCT02230332|9982569|FG001|Overall Study|Adverse Event|1
6199279|NCT01475461|9858378|FG002|Treatment Period|Lack of Efficacy|0
6199280|NCT01475461|9858379|FG003|Treatment Period|Lack of Efficacy|2
6199281|NCT01475461|9858380|FG004|Treatment Period|Lack of Efficacy|1
6199282|NCT01475461|9858381|FG005|Treatment Period|Lack of Efficacy|1
6199283|NCT01475461|9858382|FG006|Treatment Period|Lack of Efficacy|0
6199284|NCT01475461|9858376|FG000|Treatment Period|Medication Error|0
6199285|NCT01475461|9858377|FG001|Treatment Period|Medication Error|0
6199286|NCT01475461|9858378|FG002|Treatment Period|Medication Error|0
6199287|NCT01475461|9858379|FG003|Treatment Period|Medication Error|1
6199288|NCT01475461|9858380|FG004|Treatment Period|Medication Error|0
6199289|NCT01475461|9858381|FG005|Treatment Period|Medication Error|0
6199290|NCT01475461|9858382|FG006|Treatment Period|Medication Error|0
6199291|NCT01475461|9858376|FG000|Treatment Period|Adverse Event|0
6199292|NCT01475461|9858377|FG001|Treatment Period|Adverse Event|0
6199293|NCT01475461|9858378|FG002|Treatment Period|Adverse Event|0
6199294|NCT01475461|9858379|FG003|Treatment Period|Adverse Event|1
6199295|NCT01475461|9858380|FG004|Treatment Period|Adverse Event|0
6199296|NCT01475461|9858381|FG005|Treatment Period|Adverse Event|0
6199297|NCT01475461|9858382|FG006|Treatment Period|Adverse Event|0
6276643|NCT02230332|9982568|FG000|Overall Study|Lost to Follow-up|1
6276644|NCT02230332|9982569|FG001|Overall Study|Lost to Follow-up|0
6276645|NCT02230332|9982568|FG000|Overall Study|Protocol Violation|1
6276646|NCT02230332|9982569|FG001|Overall Study|Protocol Violation|0
6276647|NCT02230384|9982577|FG000|Phase 1|Lost to Follow-up|1
6276648|NCT02230384|9982578|FG001|Phase 1|Lost to Follow-up|0
6276649|NCT02230384|9982577|FG000|Phase 1|Physician Decision|0
6276650|NCT02230384|9982578|FG001|Phase 1|Physician Decision|1
6276651|NCT02230384|9982577|FG000|Phase 2 - Switch|Withdrawal by Subject|0
6276652|NCT02230384|9982578|FG001|Phase 2 - Switch|Withdrawal by Subject|1
6276653|NCT02230384|9982577|FG000|Phase 2 - Switch|Lost to Follow-up|1
6276654|NCT02230384|9982578|FG001|Phase 2 - Switch|Lost to Follow-up|0
6276655|NCT02230384|9982577|FG000|Phase 2 - Switch|Adverse Event|2
6276656|NCT02230384|9982578|FG001|Phase 2 - Switch|Adverse Event|0
6276657|NCT02230527|9982594|FG000|Overall Study|Withdrawal by Subject|1
6276658|NCT02230527|9982595|FG001|Overall Study|Withdrawal by Subject|1
6276659|NCT02230527|9982594|FG000|Overall Study|Death|1
6276660|NCT02230527|9982595|FG001|Overall Study|Death|0
6276661|NCT02230527|9982594|FG000|Overall Study|Lost to Follow-up|2
6276662|NCT02230527|9982595|FG001|Overall Study|Lost to Follow-up|1
6276663|NCT02230527|9982594|FG000|Overall Study|Other|1
6276664|NCT02230527|9982595|FG001|Overall Study|Other|0
6276665|NCT02230670|9982649|FG000|Overall Study|Adverse Event|1
6276666|NCT02230670|9982650|FG001|Overall Study|Adverse Event|2
6276667|NCT02230670|9982649|FG000|Overall Study|Withdrawal by Subject|2
6276668|NCT02230670|9982650|FG001|Overall Study|Withdrawal by Subject|2
6276669|NCT02230670|9982649|FG000|Overall Study|Physician Decision|0
6276670|NCT02230670|9982650|FG001|Overall Study|Physician Decision|1
6276671|NCT02230670|9982649|FG000|Overall Study|Protocol Violation|0
6276672|NCT02230670|9982650|FG001|Overall Study|Protocol Violation|1
6276673|NCT02230670|9982649|FG000|Overall Study|Progression to Child-Pugh C|1
6276674|NCT02230670|9982650|FG001|Overall Study|Progression to Child-Pugh C|2
6276675|NCT02230683|9982656|FG000|Overall Study|Adverse Event|1
6276676|NCT02230904|9982690|FG000|Overall Study|Safety follow up could not take place|0
6276677|NCT02230904|9982691|FG001|Overall Study|Safety follow up could not take place|1
6276678|NCT02230956|9982702|FG000|Overall Study|Adverse Event|1
6276679|NCT02230956|9982703|FG001|Overall Study|Adverse Event|1
6276680|NCT02230956|9982704|FG002|Overall Study|Adverse Event|0
6276681|NCT02230956|9982702|FG000|Overall Study|Lack of Efficacy|1
6276682|NCT02230956|9982703|FG001|Overall Study|Lack of Efficacy|1
6276683|NCT02230956|9982704|FG002|Overall Study|Lack of Efficacy|1
6276684|NCT02230956|9982702|FG000|Overall Study|Lost to Follow-up|1
6276685|NCT02230956|9982703|FG001|Overall Study|Lost to Follow-up|1
6276686|NCT02230956|9982704|FG002|Overall Study|Lost to Follow-up|2
6276687|NCT02230956|9982702|FG000|Overall Study|Personal Reasons|2
6276688|NCT02230956|9982703|FG001|Overall Study|Personal Reasons|1
6276689|NCT02230956|9982704|FG002|Overall Study|Personal Reasons|1
6276690|NCT02230956|9982702|FG000|Overall Study|Protocol Violation|0
6276691|NCT02230956|9982703|FG001|Overall Study|Protocol Violation|1
6276692|NCT02230956|9982704|FG002|Overall Study|Protocol Violation|1
6276693|NCT02230956|9982702|FG000|Overall Study|Other Miscellaneous Reason|0
6276694|NCT02230956|9982703|FG001|Overall Study|Other Miscellaneous Reason|1
6276695|NCT02230956|9982704|FG002|Overall Study|Other Miscellaneous Reason|2
6276696|NCT02231164|9982732|FG000|Overall Study|Adverse Event|1
6276697|NCT02231164|9982733|FG001|Overall Study|Adverse Event|1
6276698|NCT02231164|9982732|FG000|Overall Study|Lack of Efficacy|4
6276699|NCT02231164|9982733|FG001|Overall Study|Lack of Efficacy|3
6276700|NCT02231164|9982732|FG000|Overall Study|Withdrawal by Subject|1
6276701|NCT02231164|9982733|FG001|Overall Study|Withdrawal by Subject|2
6276702|NCT02231580|9982755|FG000|Overall Study|Adverse Event|5
6276703|NCT02231580|9982756|FG001|Overall Study|Adverse Event|0
5977225|NCT02318277|9564379|FG003|Overall Study|Other|0
5977226|NCT02318277|9564380|FG004|Overall Study|Other|0
5977227|NCT02318277|9564381|FG005|Overall Study|Other|0
5977228|NCT02318277|9564382|FG006|Overall Study|Other|1
5977229|NCT02318277|9564383|FG007|Overall Study|Other|0
5977230|NCT02318277|9564376|FG000|Overall Study|Withdrawal by Subject|0
5977231|NCT02318277|9564377|FG001|Overall Study|Withdrawal by Subject|0
6276704|NCT02231918|9982767|FG000|Overall Study|Withdrawal by Subject|0
5977232|NCT02318277|9564378|FG002|Overall Study|Withdrawal by Subject|1
5977233|NCT02318277|9564379|FG003|Overall Study|Withdrawal by Subject|0
6276705|NCT02231918|9982768|FG001|Overall Study|Withdrawal by Subject|1
6276706|NCT02231918|9982769|FG002|Overall Study|Withdrawal by Subject|0
6199298|NCT01475474|9858415|FG000|Baseline Period - 4 Weeks|Did not meet eligibility for treatment|4
6276707|NCT02231918|9982767|FG000|Overall Study|Adverse Event|0
6199299|NCT01475474|9858415|FG000|Baseline Period - 4 Weeks|Withdrawal by Subject|2
6199300|NCT01475487|9858422|FG000|Overall Study|had to leave early for personal reasons|2
6199301|NCT01475487|9858423|FG001|Overall Study|had to leave early for personal reasons|1
6199302|NCT01475721|9858451|FG000|Overall Study|Death|3
6199303|NCT01475721|9858452|FG001|Overall Study|Death|6
6199304|NCT01475721|9858451|FG000|Overall Study|Withdrawal by Subject|8
6199305|NCT01475721|9858452|FG001|Overall Study|Withdrawal by Subject|8
6199306|NCT01475734|9858460|FG000|Overall Study|Withdrawal by Subject|1
6199307|NCT01475734|9858461|FG001|Overall Study|Withdrawal by Subject|0
6199308|NCT01475734|9858460|FG000|Overall Study|Protocol Violation|1
6199309|NCT01475734|9858461|FG001|Overall Study|Protocol Violation|0
6199310|NCT01475734|9858460|FG000|Overall Study|Physician Decision|0
6199311|NCT01475734|9858461|FG001|Overall Study|Physician Decision|1
6199312|NCT01475825|9858471|FG000|Overall Study|Adverse Event|41
6199313|NCT01475825|9858472|FG001|Overall Study|Adverse Event|15
6199314|NCT01475825|9858473|FG002|Overall Study|Adverse Event|27
6199315|NCT01475825|9858474|FG003|Overall Study|Adverse Event|11
6199316|NCT01475825|9858471|FG000|Overall Study|Death|1
6199317|NCT01475825|9858472|FG001|Overall Study|Death|0
6199318|NCT01475825|9858473|FG002|Overall Study|Death|1
6199319|NCT01475825|9858474|FG003|Overall Study|Death|0
6199320|NCT01475825|9858471|FG000|Overall Study|Lack of Efficacy|0
6199321|NCT01475825|9858472|FG001|Overall Study|Lack of Efficacy|0
6199322|NCT01475825|9858473|FG002|Overall Study|Lack of Efficacy|1
6199323|NCT01475825|9858474|FG003|Overall Study|Lack of Efficacy|0
6199324|NCT01475825|9858471|FG000|Overall Study|Lost to Follow-up|0
6199325|NCT01475825|9858472|FG001|Overall Study|Lost to Follow-up|0
6199326|NCT01475825|9858473|FG002|Overall Study|Lost to Follow-up|3
6199327|NCT01475825|9858474|FG003|Overall Study|Lost to Follow-up|1
6199328|NCT01475825|9858471|FG000|Overall Study|Non-compliance with Study Drug|1
6199329|NCT01475825|9858472|FG001|Overall Study|Non-compliance with Study Drug|2
6276708|NCT02231918|9982768|FG001|Overall Study|Adverse Event|0
6276709|NCT02231918|9982769|FG002|Overall Study|Adverse Event|1
6276710|NCT02232061|9982787|FG000|Overall Study|Administrative problems|1
6276711|NCT02232061|9982787|FG000|Overall Study|Withdrawal by Subject|1
6276712|NCT02232074|9982793|FG000|Overall Study|Withdrawal by Subject|5
6276713|NCT02232074|9982794|FG001|Overall Study|Withdrawal by Subject|3
6276714|NCT02232074|9982793|FG000|Overall Study|No legal concerns at baseline|36
6276715|NCT02232074|9982794|FG001|Overall Study|No legal concerns at baseline|41
6276716|NCT02232074|9982793|FG000|Overall Study|deemed ineligible|0
6276717|NCT02232074|9982794|FG001|Overall Study|deemed ineligible|1
6276718|NCT02232087|9982806|FG000|Overall Study|Withdrawal by Subject|2
6276719|NCT02232087|9982807|FG001|Overall Study|Withdrawal by Subject|0
6199330|NCT01475825|9858473|FG002|Overall Study|Non-compliance with Study Drug|4
6199331|NCT01475825|9858474|FG003|Overall Study|Non-compliance with Study Drug|0
6199332|NCT01475825|9858471|FG000|Overall Study|Other: Not available|0
6199333|NCT01475825|9858472|FG001|Overall Study|Other: Not available|0
6276720|NCT02232087|9982808|FG002|Overall Study|Withdrawal by Subject|0
6199334|NCT01475825|9858473|FG002|Overall Study|Other: Not available|2
6199335|NCT01475825|9858474|FG003|Overall Study|Other: Not available|0
6199336|NCT01475825|9858471|FG000|Overall Study|Protocol Violation|1
6199337|NCT01475825|9858472|FG001|Overall Study|Protocol Violation|0
6199338|NCT01475825|9858473|FG002|Overall Study|Protocol Violation|0
6199339|NCT01475825|9858474|FG003|Overall Study|Protocol Violation|0
6199340|NCT01475825|9858471|FG000|Overall Study|Physician Decision|0
6199341|NCT01475825|9858472|FG001|Overall Study|Physician Decision|1
6276721|NCT02232087|9982809|FG003|Overall Study|Withdrawal by Subject|0
6276722|NCT02232087|9982810|FG004|Overall Study|Withdrawal by Subject|0
6276723|NCT02232087|9982811|FG005|Overall Study|Withdrawal by Subject|1
6276724|NCT02232087|9982806|FG000|Overall Study|poor inhalation technique|0
6276725|NCT02232087|9982807|FG001|Overall Study|poor inhalation technique|1
6276726|NCT02232087|9982808|FG002|Overall Study|poor inhalation technique|0
6276727|NCT02232087|9982809|FG003|Overall Study|poor inhalation technique|0
6276728|NCT02232087|9982810|FG004|Overall Study|poor inhalation technique|0
6276729|NCT02232087|9982811|FG005|Overall Study|poor inhalation technique|2
6276730|NCT02232087|9982806|FG000|Overall Study|protocol stop criteria|0
6276731|NCT02232087|9982807|FG001|Overall Study|protocol stop criteria|1
6276732|NCT02232087|9982808|FG002|Overall Study|protocol stop criteria|0
6276733|NCT02232087|9982809|FG003|Overall Study|protocol stop criteria|1
6276734|NCT02232087|9982810|FG004|Overall Study|protocol stop criteria|0
6276735|NCT02232087|9982811|FG005|Overall Study|protocol stop criteria|0
6276736|NCT02232087|9982806|FG000|Overall Study|Adverse Event|0
6276737|NCT02232087|9982807|FG001|Overall Study|Adverse Event|0
6276738|NCT02232087|9982808|FG002|Overall Study|Adverse Event|0
6276739|NCT02232087|9982809|FG003|Overall Study|Adverse Event|0
6276740|NCT02232087|9982810|FG004|Overall Study|Adverse Event|1
6276741|NCT02232087|9982811|FG005|Overall Study|Adverse Event|0
6276742|NCT02232178|9982844|FG000|Overall Study|Lost to Follow-up|0
6276743|NCT02232178|9982845|FG001|Overall Study|Lost to Follow-up|1
6276744|NCT02232178|9982846|FG002|Overall Study|Lost to Follow-up|0
6276745|NCT02232178|9982844|FG000|Overall Study|ineligibility|0
6276746|NCT02232178|9982845|FG001|Overall Study|ineligibility|0
6276747|NCT02232178|9982846|FG002|Overall Study|ineligibility|1
6276748|NCT02232178|9982844|FG000|Overall Study|surgical complication|1
6276749|NCT02232178|9982845|FG001|Overall Study|surgical complication|0
6276750|NCT02232178|9982846|FG002|Overall Study|surgical complication|0
6276751|NCT02232243|9982857|FG000|Second Dose (400mg HCQ Twice Daily)|Protocol Violation|0
6276752|NCT02232243|9982858|FG001|Second Dose (400mg HCQ Twice Daily)|Protocol Violation|1
6276753|NCT02232243|9982859|FG002|Second Dose (400mg HCQ Twice Daily)|Protocol Violation|0
6276754|NCT02232425|9982870|FG000|Overall Study|Lost to Follow-up|6
6276755|NCT02232425|9982871|FG001|Overall Study|Lost to Follow-up|2
6276756|NCT02232425|9982870|FG000|Overall Study|Adverse Event|2
6276757|NCT02232425|9982871|FG001|Overall Study|Adverse Event|0
6276758|NCT02232425|9982870|FG000|Overall Study|Withdrawal by Subject|5
6276759|NCT02232425|9982871|FG001|Overall Study|Withdrawal by Subject|6
6276760|NCT02232425|9982870|FG000|Overall Study|Lack of Efficacy|1
6276761|NCT02232425|9982871|FG001|Overall Study|Lack of Efficacy|0
6276762|NCT02232698|9982879|FG000|Overall Study|Pregnancy|1
6276763|NCT02232698|9982880|FG001|Overall Study|Pregnancy|1
6276764|NCT02232698|9982879|FG000|Overall Study|Met exclusion criteria|1
6276765|NCT02232698|9982880|FG001|Overall Study|Met exclusion criteria|1
6276766|NCT02232698|9982879|FG000|Overall Study|Had device-associated symptoms|7
6276767|NCT02232698|9982880|FG001|Overall Study|Had device-associated symptoms|0
6276768|NCT02232698|9982879|FG000|Overall Study|Non-compliance with study device|1
6276769|NCT02232698|9982880|FG001|Overall Study|Non-compliance with study device|4
6276770|NCT02232698|9982879|FG000|Overall Study|Allocated to control group|0
6276771|NCT02232698|9982880|FG001|Overall Study|Allocated to control group|3
6276772|NCT02232698|9982879|FG000|Overall Study|Withdrawal by Subject|0
6276773|NCT02232698|9982880|FG001|Overall Study|Withdrawal by Subject|11
6276774|NCT02232802|9982888|FG000|Period 1|Sponsor request|1
6276775|NCT02232802|9982889|FG001|Period 1|Sponsor request|0
6276776|NCT02232802|9982888|FG000|Period 1|Adverse Event|1
6276777|NCT02232802|9982889|FG001|Period 1|Adverse Event|1
6276778|NCT02232893|9982897|FG000|Overall Study|Withdrawal by Subject|4
6276779|NCT02232893|9982898|FG001|Overall Study|Withdrawal by Subject|1
6276780|NCT02232893|9982897|FG000|Overall Study|Adverse Event|0
6276781|NCT02232893|9982898|FG001|Overall Study|Adverse Event|1
6276782|NCT02232893|9982897|FG000|Overall Study|Sponsor request early termination|0
6199342|NCT01475825|9858473|FG002|Overall Study|Physician Decision|0
6199343|NCT01475825|9858474|FG003|Overall Study|Physician Decision|0
6199344|NCT01475825|9858471|FG000|Overall Study|Withdrawal by Subject|8
6276783|NCT02232893|9982898|FG001|Overall Study|Sponsor request early termination|1
6276784|NCT02232893|9982897|FG000|Overall Study|Developed exclusion criteria|0
6276785|NCT02232893|9982898|FG001|Overall Study|Developed exclusion criteria|1
6276786|NCT02232893|9982897|FG000|Overall Study|Other|0
6276787|NCT02232893|9982898|FG001|Overall Study|Other|3
6199345|NCT01475825|9858472|FG001|Overall Study|Withdrawal by Subject|3
6276788|NCT02232984|9982904|FG000|Overall Study|Withdrawal by Subject|5
6276789|NCT02232984|9982904|FG000|Overall Study|Death|1
6276790|NCT02232984|9982904|FG000|Overall Study|Investigator withdrawal|10
6276791|NCT02232984|9982904|FG000|Overall Study|Device implant unsuccessful|53
6276792|NCT02232984|9982904|FG000|Overall Study|not disclosed by site|7
6199346|NCT01475825|9858473|FG002|Overall Study|Withdrawal by Subject|11
6199347|NCT01475825|9858474|FG003|Overall Study|Withdrawal by Subject|7
6199348|NCT01475825|9858471|FG000|Overall Study|Did not enter OLC|15
6199349|NCT01475825|9858472|FG001|Overall Study|Did not enter OLC|11
6199350|NCT01475825|9858473|FG002|Overall Study|Did not enter OLC|15
6199351|NCT01475825|9858474|FG003|Overall Study|Did not enter OLC|11
6199352|NCT01475838|9858486|FG000|Randomized Phase|Randomized but Not Treated|0
6199353|NCT01475838|9858487|FG001|Randomized Phase|Randomized but Not Treated|5
6199354|NCT01475838|9858486|FG000|Randomized Phase|Adverse Event|6
6199355|NCT01475838|9858487|FG001|Randomized Phase|Adverse Event|1
6276793|NCT02232984|9982904|FG000|Overall Study|Protocol Violation|1
6276794|NCT02233309|9982933|FG000|Overall Study|Physician Decision|5
6276795|NCT02233413|9982939|FG000|Overall Study|Lost to Follow-up|7
6276796|NCT02233413|9982940|FG001|Overall Study|Lost to Follow-up|9
6276797|NCT02233413|9982939|FG000|Overall Study|Withdrawal by Subject|4
6276798|NCT02233413|9982940|FG001|Overall Study|Withdrawal by Subject|5
6276799|NCT02233543|9982972|FG000|Period 1|Withdrawal by Subject|1
6276800|NCT02233543|9982973|FG001|Period 1|Withdrawal by Subject|0
6276801|NCT02233543|9982972|FG000|Period 1|Participants required other treatment.|2
6276802|NCT02233543|9982973|FG001|Period 1|Participants required other treatment.|3
6276803|NCT02233543|9982972|FG000|Period 2|Adverse Event|1
6276804|NCT02233543|9982973|FG001|Period 2|Adverse Event|0
6276805|NCT02233543|9982972|FG000|Period 2|Participant required other treatment.|0
6276806|NCT02233543|9982973|FG001|Period 2|Participant required other treatment.|1
6088704|NCT00677807|9699679|FG002|Overall Study|Adverse Event|6
6088705|NCT00677807|9699677|FG000|Overall Study|Lack of Efficacy|0
6088706|NCT00677807|9699678|FG001|Overall Study|Lack of Efficacy|0
6088707|NCT00677807|9699679|FG002|Overall Study|Lack of Efficacy|2
6088708|NCT00677807|9699677|FG000|Overall Study|Participant no longer needs study drug|0
6088709|NCT00677807|9699678|FG001|Overall Study|Participant no longer needs study drug|0
6088710|NCT00677807|9699679|FG002|Overall Study|Participant no longer needs study drug|1
6088711|NCT00677807|9699677|FG000|Overall Study|Withdrawal by Subject|10
6088712|NCT00677807|9699678|FG001|Overall Study|Withdrawal by Subject|3
6088713|NCT00677807|9699679|FG002|Overall Study|Withdrawal by Subject|6
6088714|NCT00677807|9699677|FG000|Overall Study|Lost to Follow-up|2
6088715|NCT00677807|9699678|FG001|Overall Study|Lost to Follow-up|2
6088716|NCT00677807|9699679|FG002|Overall Study|Lost to Follow-up|2
6088717|NCT00677807|9699677|FG000|Overall Study|Administrative problems|1
6088718|NCT00677807|9699678|FG001|Overall Study|Administrative problems|1
6088719|NCT00677807|9699679|FG002|Overall Study|Administrative problems|2
6088720|NCT00677807|9699677|FG000|Overall Study|Death|0
6088721|NCT00677807|9699678|FG001|Overall Study|Death|1
6088722|NCT00677807|9699679|FG002|Overall Study|Death|1
6088723|NCT00677807|9699677|FG000|Overall Study|Protocol Deviation|1
6088724|NCT00677807|9699678|FG001|Overall Study|Protocol Deviation|3
6088725|NCT00677807|9699679|FG002|Overall Study|Protocol Deviation|0
6088726|NCT00677820|9699689|FG000|Overall Study|Lost to Follow-up|1
6199356|NCT01475838|9858486|FG000|Randomized Phase|Pregnancy|0
6199357|NCT01475838|9858487|FG001|Randomized Phase|Pregnancy|1
6276807|NCT02233543|9982972|FG000|Period 2|COPD exacerbation|1
6276808|NCT02233543|9982973|FG001|Period 2|COPD exacerbation|0
6276809|NCT02233647|9982979|FG000|Overall Study|Adverse Event|1
6276810|NCT02233738|9982985|FG000|Overall Study|Lost to Follow-up|5
6276811|NCT02233738|9982986|FG001|Overall Study|Lost to Follow-up|12
6276812|NCT02233738|9982985|FG000|Overall Study|Death|0
6276813|NCT02233738|9982986|FG001|Overall Study|Death|1
6276814|NCT02233738|9982985|FG000|Overall Study|Withdrawal by Subject|0
6276815|NCT02233738|9982986|FG001|Overall Study|Withdrawal by Subject|1
6276816|NCT02233738|9982985|FG000|Overall Study|Did not return after Baseline|3
6276817|NCT02233738|9982986|FG001|Overall Study|Did not return after Baseline|2
6276818|NCT02233803|9983163|FG000|Treatment Period 1 (4-Wks)|Protocol-defined stopping criteria reach|1
6276819|NCT02233803|9983164|FG001|Treatment Period 1 (4-Wks)|Protocol-defined stopping criteria reach|0
6276820|NCT02233803|9983163|FG000|Treatment Period 1 (4-Wks)|Adverse Event|0
6276821|NCT02233803|9983164|FG001|Treatment Period 1 (4-Wks)|Adverse Event|1
6276822|NCT02233803|9983163|FG000|Treatment Period 1 (4-Wks)|Protocol Violation|2
6276823|NCT02233803|9983164|FG001|Treatment Period 1 (4-Wks)|Protocol Violation|2
6276824|NCT02233803|9983163|FG000|Treatment Period 1 (4-Wks)|Withdrawal by Subject|0
6276825|NCT02233803|9983164|FG001|Treatment Period 1 (4-Wks)|Withdrawal by Subject|1
6276826|NCT02233803|9983163|FG000|Washout Period (4-Wks)|Lost to Follow-up|0
6276827|NCT02233803|9983164|FG001|Washout Period (4-Wks)|Lost to Follow-up|1
6276828|NCT02233803|9983163|FG000|Washout Period (4-Wks)|Physician Decision|1
6276829|NCT02233803|9983164|FG001|Washout Period (4-Wks)|Physician Decision|0
6276830|NCT02233803|9983163|FG000|Washout Period (4-Wks)|Withdrawal by Subject|1
6276831|NCT02233803|9983164|FG001|Washout Period (4-Wks)|Withdrawal by Subject|1
6276832|NCT02233803|9983163|FG000|Treatment Period 2 (4-Wks)|Lost to Follow-up|1
6088727|NCT00677820|9699690|FG001|Overall Study|Lost to Follow-up|0
6088728|NCT00677833|9699700|FG000|Overall Study|Withdrawal by Subject|4
6088729|NCT00677833|9699701|FG001|Overall Study|Withdrawal by Subject|0
6088730|NCT00677833|9699702|FG002|Overall Study|Withdrawal by Subject|1
6088731|NCT00677833|9699703|FG003|Overall Study|Withdrawal by Subject|3
6088732|NCT00677833|9699700|FG000|Overall Study|Lost to Follow-up|0
6199358|NCT01475838|9858486|FG000|Randomized Phase|Investigators Discretion|1
6199359|NCT01475838|9858487|FG001|Randomized Phase|Investigators Discretion|2
6199360|NCT01475838|9858486|FG000|Randomized Phase|Withdrew Consent|10
6199361|NCT01475838|9858487|FG001|Randomized Phase|Withdrew Consent|14
6199362|NCT01475838|9858486|FG000|Randomized Phase|Lost to Follow-up|3
6199363|NCT01475838|9858487|FG001|Randomized Phase|Lost to Follow-up|4
6199364|NCT01475838|9858486|FG000|Randomized Phase|Participant Noncompliance|1
6199365|NCT01475838|9858487|FG001|Randomized Phase|Participant Noncompliance|5
6199366|NCT01475838|9858486|FG000|Randomized Phase|Protocol Violation|9
6199367|NCT01475838|9858487|FG001|Randomized Phase|Protocol Violation|4
6199368|NCT01475838|9858486|FG000|Extension Phase|Participant Noncompliance|1
6199369|NCT01475838|9858487|FG001|Extension Phase|Participant Noncompliance|0
6088733|NCT00677833|9699701|FG001|Overall Study|Lost to Follow-up|0
6088734|NCT00677833|9699702|FG002|Overall Study|Lost to Follow-up|1
6088735|NCT00677833|9699703|FG003|Overall Study|Lost to Follow-up|0
6199370|NCT01475851|9858496|FG000|Overall Study|Protocol defined stopping criteria|1
6199371|NCT01475851|9858497|FG001|Overall Study|Protocol defined stopping criteria|0
6199372|NCT01476475|9858581|FG000|Overall Study|Adverse Event|6
6199373|NCT01476475|9858582|FG001|Overall Study|Adverse Event|0
6199374|NCT01476475|9858581|FG000|Overall Study|Poor compliance to protocol|1
6276833|NCT02233803|9983164|FG001|Treatment Period 2 (4-Wks)|Lost to Follow-up|0
6276834|NCT02233803|9983163|FG000|Treatment Period 2 (4-Wks)|Withdrawal by Subject|1
6276835|NCT02233803|9983164|FG001|Treatment Period 2 (4-Wks)|Withdrawal by Subject|2
6276836|NCT02233946|9983179|FG000|Baseline|Withdrawal by Subject|2
6276837|NCT02233946|9983180|FG001|Baseline|Withdrawal by Subject|0
6276838|NCT02233946|9983179|FG000|3-months Follow-up|Lost to Follow-up|53
6276839|NCT02233946|9983180|FG001|3-months Follow-up|Lost to Follow-up|29
6276840|NCT02233946|9983179|FG000|6-months Follow-up|Lost to Follow-up|21
6276841|NCT02233946|9983180|FG001|6-months Follow-up|Lost to Follow-up|2
6276842|NCT02233946|9983179|FG000|9-month Follow-up|Lost to Follow-up|20
6088736|NCT00678080|9699735|FG000|Overall Study|Physician Decision|2
6088737|NCT00678080|9699736|FG001|Overall Study|Physician Decision|0
6088738|NCT00678080|9699735|FG000|Overall Study|Lost to Follow-up|1
6088739|NCT00678080|9699736|FG001|Overall Study|Lost to Follow-up|0
6088740|NCT00678080|9699735|FG000|Overall Study|Withdrawal by Subject|0
6088741|NCT00678080|9699736|FG001|Overall Study|Withdrawal by Subject|1
6088742|NCT00678210|9699746|FG000|Overall Study|Adverse Event|1
6088743|NCT00678210|9699747|FG001|Overall Study|Adverse Event|2
6088744|NCT00678210|9699748|FG002|Overall Study|Adverse Event|3
6088745|NCT00678210|9699749|FG003|Overall Study|Adverse Event|3
6088746|NCT00678210|9699746|FG000|Overall Study|Lack of Efficacy|2
6088747|NCT00678210|9699747|FG001|Overall Study|Lack of Efficacy|3
6276843|NCT02233946|9983180|FG001|9-month Follow-up|Lost to Follow-up|11
6276844|NCT02233946|9983179|FG000|12-month Follow-up|Lost to Follow-up|28
6276845|NCT02233946|9983180|FG001|12-month Follow-up|Lost to Follow-up|11
6276846|NCT02234063|9983212|FG000|Overall Study|Lost to Follow-up|235
6276847|NCT02234063|9983213|FG001|Overall Study|Lost to Follow-up|42
6088748|NCT00678210|9699748|FG002|Overall Study|Lack of Efficacy|1
6088749|NCT00678210|9699749|FG003|Overall Study|Lack of Efficacy|9
6088750|NCT00678210|9699746|FG000|Overall Study|Lost to Follow-up|4
6088751|NCT00678210|9699747|FG001|Overall Study|Lost to Follow-up|2
6088752|NCT00678210|9699748|FG002|Overall Study|Lost to Follow-up|0
6088753|NCT00678210|9699749|FG003|Overall Study|Lost to Follow-up|1
6088754|NCT00678210|9699746|FG000|Overall Study|Withdrawal by Subject|3
6088755|NCT00678210|9699747|FG001|Overall Study|Withdrawal by Subject|4
6276848|NCT02234063|9983212|FG000|Overall Study|Withdrawal by Subject|20
6276849|NCT02234063|9983213|FG001|Overall Study|Withdrawal by Subject|1
6088756|NCT00678210|9699748|FG002|Overall Study|Withdrawal by Subject|1
6088757|NCT00678210|9699749|FG003|Overall Study|Withdrawal by Subject|7
6088758|NCT00678210|9699746|FG000|Overall Study|Other|1
6088759|NCT00678210|9699747|FG001|Overall Study|Other|0
6088760|NCT00678210|9699748|FG002|Overall Study|Other|1
6088761|NCT00678210|9699749|FG003|Overall Study|Other|0
6199375|NCT01476475|9858582|FG001|Overall Study|Poor compliance to protocol|1
6199376|NCT01476475|9858581|FG000|Overall Study|Other reasons|4
6199377|NCT01476475|9858582|FG001|Overall Study|Other reasons|2
6199378|NCT01476644|9858589|FG000|Overall Study|Death|5
6199379|NCT01476644|9858589|FG000|Overall Study|moved to another state|2
6199380|NCT01476644|9858589|FG000|Overall Study|Lost to Follow-up|19
6199381|NCT01476644|9858589|FG000|Overall Study|Withdrawal by Subject|13
6199382|NCT01476696|9858594|FG000|Overall Study|Sponsor decision|2
6199383|NCT01476696|9858595|FG001|Overall Study|Sponsor decision|1
6199384|NCT01476696|9858596|FG002|Overall Study|Sponsor decision|0
6199385|NCT01476696|9858594|FG000|Overall Study|Withdrawal by Subject|1
6199386|NCT01476696|9858595|FG001|Overall Study|Withdrawal by Subject|0
6199387|NCT01476696|9858596|FG002|Overall Study|Withdrawal by Subject|0
6199388|NCT01476722|9858609|FG000|Overall Study|Adverse Event|1
6199389|NCT01477333|9858635|FG000|Overall Study|Adverse Event|1
6199390|NCT01477333|9858635|FG000|Overall Study|Withdrawal by Subject|1
6199391|NCT01477333|9858635|FG000|Overall Study|Clinical Deterioration|1
6199392|NCT01477749|9858709|FG000|Overall Study|Physician Decision|4
6199393|NCT01477853|9858733|FG000|Phase A|Adverse Event|1
6199394|NCT01477853|9858734|FG001|Phase A|Adverse Event|2
6199395|NCT01477853|9858735|FG002|Phase A|Adverse Event|2
6199396|NCT01477853|9858733|FG000|Phase A|Lost to Follow-up|4
6199397|NCT01477853|9858734|FG001|Phase A|Lost to Follow-up|3
6199398|NCT01477853|9858735|FG002|Phase A|Lost to Follow-up|2
6199399|NCT01477853|9858733|FG000|Phase A|Physician Decision|1
6199400|NCT01477853|9858734|FG001|Phase A|Physician Decision|0
6199401|NCT01477853|9858735|FG002|Phase A|Physician Decision|1
6199402|NCT01477853|9858733|FG000|Phase A|Study terminated by sponsor|37
6199403|NCT01477853|9858734|FG001|Phase A|Study terminated by sponsor|40
6199404|NCT01477853|9858735|FG002|Phase A|Study terminated by sponsor|39
6199405|NCT01477853|9858733|FG000|Phase B|Lost to Follow-up|0
6199406|NCT01477853|9858734|FG001|Phase B|Lost to Follow-up|1
6276850|NCT02234141|9983245|FG000|Treatment Period (24 Weeks)|Protocol Violation|0
6276851|NCT02234141|9983246|FG001|Treatment Period (24 Weeks)|Protocol Violation|0
6276852|NCT02234141|9983247|FG002|Treatment Period (24 Weeks)|Protocol Violation|0
6276853|NCT02234141|9983248|FG003|Treatment Period (24 Weeks)|Protocol Violation|1
6276854|NCT02234141|9983249|FG004|Treatment Period (24 Weeks)|Protocol Violation|0
6276855|NCT02234141|9983250|FG005|Treatment Period (24 Weeks)|Protocol Violation|0
6276856|NCT02234141|9983251|FG006|Treatment Period (24 Weeks)|Protocol Violation|0
6276857|NCT02234141|9983245|FG000|Treatment Period (24 Weeks)|Investigator's discretion|0
6276858|NCT02234141|9983246|FG001|Treatment Period (24 Weeks)|Investigator's discretion|2
6276859|NCT02234141|9983247|FG002|Treatment Period (24 Weeks)|Investigator's discretion|0
6276860|NCT02234141|9983248|FG003|Treatment Period (24 Weeks)|Investigator's discretion|0
6276861|NCT02234141|9983249|FG004|Treatment Period (24 Weeks)|Investigator's discretion|0
6276862|NCT02234141|9983250|FG005|Treatment Period (24 Weeks)|Investigator's discretion|0
6276863|NCT02234141|9983251|FG006|Treatment Period (24 Weeks)|Investigator's discretion|0
6276864|NCT02234141|9983245|FG000|Treatment Period (24 Weeks)|Death|1
6276865|NCT02234141|9983246|FG001|Treatment Period (24 Weeks)|Death|2
6276866|NCT02234141|9983247|FG002|Treatment Period (24 Weeks)|Death|0
6276867|NCT02234141|9983248|FG003|Treatment Period (24 Weeks)|Death|1
6276868|NCT02234141|9983249|FG004|Treatment Period (24 Weeks)|Death|0
6276869|NCT02234141|9983250|FG005|Treatment Period (24 Weeks)|Death|0
6276870|NCT02234141|9983251|FG006|Treatment Period (24 Weeks)|Death|0
6276871|NCT02234141|9983245|FG000|Treatment Period (24 Weeks)|Adverse Event|3
6276872|NCT02234141|9983246|FG001|Treatment Period (24 Weeks)|Adverse Event|1
6276873|NCT02234141|9983247|FG002|Treatment Period (24 Weeks)|Adverse Event|2
6276874|NCT02234141|9983248|FG003|Treatment Period (24 Weeks)|Adverse Event|3
6276875|NCT02234141|9983249|FG004|Treatment Period (24 Weeks)|Adverse Event|0
6276876|NCT02234141|9983250|FG005|Treatment Period (24 Weeks)|Adverse Event|0
6276877|NCT02234141|9983251|FG006|Treatment Period (24 Weeks)|Adverse Event|0
6276878|NCT02234141|9983245|FG000|Treatment Period (24 Weeks)|Randomized but not treated|0
6276879|NCT02234141|9983246|FG001|Treatment Period (24 Weeks)|Randomized but not treated|1
6276880|NCT02234141|9983247|FG002|Treatment Period (24 Weeks)|Randomized but not treated|0
6276881|NCT02234141|9983248|FG003|Treatment Period (24 Weeks)|Randomized but not treated|0
6276882|NCT02234141|9983249|FG004|Treatment Period (24 Weeks)|Randomized but not treated|0
6276883|NCT02234141|9983250|FG005|Treatment Period (24 Weeks)|Randomized but not treated|0
6276884|NCT02234141|9983251|FG006|Treatment Period (24 Weeks)|Randomized but not treated|0
6276885|NCT02234141|9983245|FG000|Long-Term Treatment Period|Death|0
6276886|NCT02234141|9983246|FG001|Long-Term Treatment Period|Death|0
6276887|NCT02234141|9983247|FG002|Long-Term Treatment Period|Death|0
6276888|NCT02234141|9983248|FG003|Long-Term Treatment Period|Death|0
6276889|NCT02234141|9983249|FG004|Long-Term Treatment Period|Death|0
6276890|NCT02234141|9983250|FG005|Long-Term Treatment Period|Death|1
6276891|NCT02234141|9983251|FG006|Long-Term Treatment Period|Death|0
6276892|NCT02234141|9983245|FG000|Long-Term Treatment Period|Investigator's discretion|1
6276893|NCT02234141|9983246|FG001|Long-Term Treatment Period|Investigator's discretion|3
5977234|NCT02318277|9564380|FG004|Overall Study|Withdrawal by Subject|1
6276894|NCT02234141|9983247|FG002|Long-Term Treatment Period|Investigator's discretion|2
6276895|NCT02234141|9983248|FG003|Long-Term Treatment Period|Investigator's discretion|0
6199407|NCT01477853|9858735|FG002|Phase B|Lost to Follow-up|0
6199408|NCT01477853|9858733|FG000|Phase B|Study terminated by sponsor|12
6199409|NCT01477853|9858734|FG001|Phase B|Study terminated by sponsor|10
6199410|NCT01477853|9858735|FG002|Phase B|Study terminated by sponsor|11
6199411|NCT01477892|9858745|FG000|Overall Study|Withdrawal by Subject|0
6199412|NCT01477892|9858746|FG001|Overall Study|Withdrawal by Subject|2
6199413|NCT01478048|9858763|FG000|Overall Study|Disease Progression|52
6199414|NCT01478048|9858764|FG001|Overall Study|Disease Progression|35
6199415|NCT01478048|9858763|FG000|Overall Study|study drug toxicity|11
6199416|NCT01478048|9858764|FG001|Overall Study|study drug toxicity|14
6199417|NCT01478048|9858763|FG000|Overall Study|Adverse Event|2
6199418|NCT01478048|9858764|FG001|Overall Study|Adverse Event|11
6199419|NCT01478048|9858763|FG000|Overall Study|subject request to discontinue treatment|3
6199420|NCT01478048|9858764|FG001|Overall Study|subject request to discontinue treatment|5
6199421|NCT01478048|9858763|FG000|Overall Study|Withdrawal by Subject|2
6199422|NCT01478048|9858764|FG001|Overall Study|Withdrawal by Subject|5
6199423|NCT01478048|9858763|FG000|Overall Study|non-specified|6
6199424|NCT01478048|9858764|FG001|Overall Study|non-specified|4
6199425|NCT01478048|9858763|FG000|Overall Study|poor/non-compliance|0
6199426|NCT01478048|9858764|FG001|Overall Study|poor/non-compliance|1
6199427|NCT01478048|9858763|FG000|Overall Study|no longer meets study criteria|1
6199428|NCT01478048|9858764|FG001|Overall Study|no longer meets study criteria|0
6199429|NCT01478087|9858770|FG000|Overall Study|due to sponsor closing study|1
6199430|NCT01478321|9858785|FG000|Concurrent Therapy (5 Weeks)|Adverse Event|4
6199431|NCT01478321|9858785|FG000|Concurrent Therapy (5 Weeks)|Death|2
6199432|NCT01478321|9858785|FG000|Concurrent Therapy (5 Weeks)|Withdrawal by Subject|5
6199433|NCT01478321|9858785|FG000|Concurrent Therapy (5 Weeks)|Progressive Disease|5
6199434|NCT01478321|9858785|FG000|Started Adjuvant Therapy|Withdrawal by Subject|1
6199435|NCT01478321|9858785|FG000|Adjuvant Therapy Until PD or Toxicity|Death|1
6199436|NCT01478321|9858785|FG000|Adjuvant Therapy Until PD or Toxicity|Withdrawal by Subject|1
6199437|NCT01478321|9858785|FG000|Adjuvant Therapy Until PD or Toxicity|Progressive Disease|8
6199438|NCT01478347|9858789|FG000|Visit 1-Visit 3 (Day 0-91) - Part I|Lost to Follow-up|1
6199439|NCT01478347|9858789|FG000|Visit 4-Visit 7 (Day 151-331) - Part II|Lost to Follow-up|4
6199440|NCT01478347|9858789|FG000|Visit 4-Visit 7 (Day 151-331) - Part II|Withdrawal by Subject|4
6199441|NCT01478360|9858795|FG000|Overall Study|Lost to Follow-up|1
6199442|NCT01478360|9858796|FG001|Overall Study|Lost to Follow-up|0
6199443|NCT01478360|9858795|FG000|Overall Study|Adverse Event|0
6199444|NCT01478360|9858796|FG001|Overall Study|Adverse Event|1
6199445|NCT01478360|9858795|FG000|Overall Study|Administrative problems|1
6199446|NCT01478360|9858796|FG001|Overall Study|Administrative problems|2
6199447|NCT01478373|9858802|FG000|Treatment Phase|Protocol Violation|1
6199448|NCT01478373|9858802|FG000|Survival Phase|Adverse Event|8
6199449|NCT01478373|9858802|FG000|Survival Phase|Protocol Violation|1
6199450|NCT01478373|9858802|FG000|Survival Phase|crossover to another study|2
6199451|NCT01478373|9858802|FG000|Survival Phase|Progressive Disease|27
6199452|NCT01478594|9858829|FG000|Overall Study|Randomized but Never Received Study Drug|0
6199453|NCT01478594|9858830|FG001|Overall Study|Randomized but Never Received Study Drug|1
6199454|NCT01478594|9858829|FG000|Overall Study|Death|45
6199455|NCT01478594|9858830|FG001|Overall Study|Death|18
6199456|NCT01478594|9858829|FG000|Overall Study|Lost to Follow-up|3
6199457|NCT01478594|9858830|FG001|Overall Study|Lost to Follow-up|1
6199458|NCT01478594|9858829|FG000|Overall Study|Withdrawal by Subject|9
6199459|NCT01478594|9858830|FG001|Overall Study|Withdrawal by Subject|3
6199460|NCT01478594|9858829|FG000|Overall Study|Study Closed by Sponsor|8
6199461|NCT01478594|9858830|FG001|Overall Study|Study Closed by Sponsor|5
6199462|NCT01478620|9858889|FG000|Overall Study|Lost to Follow-up|6
6199463|NCT01478828|9858893|FG000|Overall Study|Adverse Event|1
6199464|NCT01478958|9858905|FG000|Overall Study|Withdrawal by Subject|1
6199465|NCT01478958|9858906|FG001|Overall Study|Withdrawal by Subject|1
6199466|NCT01478958|9858907|FG002|Overall Study|Withdrawal by Subject|1
6199467|NCT01478958|9858905|FG000|Overall Study|Weight loss|1
6199468|NCT01478958|9858906|FG001|Overall Study|Weight loss|0
6199469|NCT01478958|9858907|FG002|Overall Study|Weight loss|0
6199470|NCT01478958|9858905|FG000|Overall Study|Re-located|0
6199471|NCT01478958|9858906|FG001|Overall Study|Re-located|1
6199472|NCT01478958|9858907|FG002|Overall Study|Re-located|0
6199473|NCT01478958|9858905|FG000|Overall Study|Unable to comply|0
6199474|NCT01478958|9858906|FG001|Overall Study|Unable to comply|0
6199475|NCT01478958|9858907|FG002|Overall Study|Unable to comply|2
6199476|NCT01478971|9858915|FG000|Standard of Care Period|Adverse Event|1
6199477|NCT01478971|9858915|FG000|Standard of Care Period|Withdrawal by Subject|3
6199478|NCT01478971|9858915|FG000|Standard of Care Period|Death|8
6199479|NCT01478971|9858915|FG000|Standard of Care Period|Lost to Follow-up|9
6199480|NCT01478971|9858915|FG000|Standard of Care Period|Other|4
6199481|NCT01478971|9858915|FG000|Peginesatide Treatment Period|Adverse Event|1
6199482|NCT01478971|9858915|FG000|Peginesatide Treatment Period|Withdrawal by Subject|1
6199483|NCT01478971|9858915|FG000|Peginesatide Treatment Period|Death|4
6199484|NCT01478971|9858915|FG000|Peginesatide Treatment Period|Lost to Follow-up|4
6199485|NCT01478971|9858915|FG000|Peginesatide Treatment Period|Other|4
6199486|NCT01479374|9858951|FG000|Overall Study|Adverse Event|2
6199487|NCT01479374|9858952|FG001|Overall Study|Adverse Event|1
6199488|NCT01479374|9858953|FG002|Overall Study|Adverse Event|0
6199489|NCT01479374|9858951|FG000|Overall Study|Lost to Follow-up|1
6199490|NCT01479374|9858952|FG001|Overall Study|Lost to Follow-up|2
6199491|NCT01479374|9858953|FG002|Overall Study|Lost to Follow-up|0
6199492|NCT01479374|9858951|FG000|Overall Study|Decision Unrelated to Adverse Event|0
6199493|NCT01479374|9858952|FG001|Overall Study|Decision Unrelated to Adverse Event|1
6199494|NCT01479374|9858953|FG002|Overall Study|Decision Unrelated to Adverse Event|0
6199495|NCT01479374|9858951|FG000|Overall Study|Other|0
6199496|NCT01479374|9858952|FG001|Overall Study|Other|4
6199497|NCT01479374|9858953|FG002|Overall Study|Other|5
6199498|NCT01479439|9858973|FG000|Overall Study|Adverse Event|1
6199499|NCT01479439|9858974|FG001|Overall Study|Adverse Event|0
6199500|NCT01479439|9858975|FG002|Overall Study|Adverse Event|0
6199501|NCT01479439|9858973|FG000|Overall Study|Lost to Follow-up|0
6199502|NCT01479439|9858974|FG001|Overall Study|Lost to Follow-up|1
6199503|NCT01479439|9858975|FG002|Overall Study|Lost to Follow-up|0
6199504|NCT01479439|9858973|FG000|Overall Study|Protocol Violation|0
6199505|NCT01479439|9858974|FG001|Overall Study|Protocol Violation|0
6199506|NCT01479439|9858975|FG002|Overall Study|Protocol Violation|2
6199507|NCT01479465|9858990|FG000|Overall Study|Disease Progression|9
6199508|NCT01479465|9858991|FG001|Overall Study|Disease Progression|61
6276896|NCT02234141|9983249|FG004|Long-Term Treatment Period|Investigator's discretion|0
6276897|NCT02234141|9983250|FG005|Long-Term Treatment Period|Investigator's discretion|0
6276898|NCT02234141|9983251|FG006|Long-Term Treatment Period|Investigator's discretion|1
6276899|NCT02234141|9983245|FG000|Long-Term Treatment Period|Adverse Event|4
6276900|NCT02234141|9983246|FG001|Long-Term Treatment Period|Adverse Event|0
6276901|NCT02234141|9983247|FG002|Long-Term Treatment Period|Adverse Event|5
6276902|NCT02234141|9983248|FG003|Long-Term Treatment Period|Adverse Event|0
6276903|NCT02234141|9983249|FG004|Long-Term Treatment Period|Adverse Event|1
6276904|NCT02234141|9983250|FG005|Long-Term Treatment Period|Adverse Event|1
6276905|NCT02234141|9983251|FG006|Long-Term Treatment Period|Adverse Event|1
6276906|NCT02234141|9983245|FG000|Long-Term Treatment Period|Withdrew Consent|0
6276907|NCT02234141|9983246|FG001|Long-Term Treatment Period|Withdrew Consent|1
6276908|NCT02234141|9983247|FG002|Long-Term Treatment Period|Withdrew Consent|1
6276909|NCT02234141|9983248|FG003|Long-Term Treatment Period|Withdrew Consent|0
6276910|NCT02234141|9983249|FG004|Long-Term Treatment Period|Withdrew Consent|0
6276911|NCT02234141|9983250|FG005|Long-Term Treatment Period|Withdrew Consent|0
5977235|NCT02318277|9564381|FG005|Overall Study|Withdrawal by Subject|1
5977236|NCT02318277|9564382|FG006|Overall Study|Withdrawal by Subject|6
5977237|NCT02318277|9564383|FG007|Overall Study|Withdrawal by Subject|14
5977238|NCT02318277|9564376|FG000|Overall Study|Participant trial terminated by sponsor|0
5977239|NCT02318277|9564377|FG001|Overall Study|Participant trial terminated by sponsor|0
5977240|NCT02318277|9564378|FG002|Overall Study|Participant trial terminated by sponsor|1
5977241|NCT02318277|9564379|FG003|Overall Study|Participant trial terminated by sponsor|0
5977242|NCT02318277|9564380|FG004|Overall Study|Participant trial terminated by sponsor|1
5977243|NCT02318277|9564381|FG005|Overall Study|Participant trial terminated by sponsor|2
5977244|NCT02318277|9564382|FG006|Overall Study|Participant trial terminated by sponsor|5
5977245|NCT02318277|9564383|FG007|Overall Study|Participant trial terminated by sponsor|16
5977246|NCT02318277|9564376|FG000|Overall Study|Lost to Follow-up|1
5977247|NCT02318277|9564377|FG001|Overall Study|Lost to Follow-up|0
5977248|NCT02318277|9564378|FG002|Overall Study|Lost to Follow-up|1
5977249|NCT02318277|9564379|FG003|Overall Study|Lost to Follow-up|0
5977250|NCT02318277|9564380|FG004|Overall Study|Lost to Follow-up|0
5977251|NCT02318277|9564381|FG005|Overall Study|Lost to Follow-up|0
5977252|NCT02318277|9564382|FG006|Overall Study|Lost to Follow-up|3
5977253|NCT02318277|9564383|FG007|Overall Study|Lost to Follow-up|4
5977254|NCT02318277|9564376|FG000|Overall Study|Death|5
5977255|NCT02318277|9564377|FG001|Overall Study|Death|3
5977256|NCT02318277|9564378|FG002|Overall Study|Death|1
5977257|NCT02318277|9564379|FG003|Overall Study|Death|4
5977258|NCT02318277|9564380|FG004|Overall Study|Death|6
5977259|NCT02318277|9564381|FG005|Overall Study|Death|5
5977260|NCT02318277|9564382|FG006|Overall Study|Death|34
5977261|NCT02318277|9564383|FG007|Overall Study|Death|58
5977262|NCT02318277|9564376|FG000|Overall Study|Transitioned to Hospice|0
5977263|NCT02318277|9564377|FG001|Overall Study|Transitioned to Hospice|0
5977264|NCT02318277|9564378|FG002|Overall Study|Transitioned to Hospice|0
5977265|NCT02318277|9564379|FG003|Overall Study|Transitioned to Hospice|0
5977266|NCT02318277|9564380|FG004|Overall Study|Transitioned to Hospice|0
5977267|NCT02318277|9564381|FG005|Overall Study|Transitioned to Hospice|1
6199509|NCT01479465|9858992|FG002|Overall Study|Disease Progression|65
6199510|NCT01479465|9858993|FG003|Overall Study|Disease Progression|70
6199511|NCT01479465|9858990|FG000|Overall Study|Study Discontinued by Sponsor|0
6199512|NCT01479465|9858991|FG001|Overall Study|Study Discontinued by Sponsor|7
6199513|NCT01479465|9858992|FG002|Overall Study|Study Discontinued by Sponsor|5
6199514|NCT01479465|9858993|FG003|Overall Study|Study Discontinued by Sponsor|3
6199515|NCT01479465|9858990|FG000|Overall Study|Adverse Event|0
6199516|NCT01479465|9858991|FG001|Overall Study|Adverse Event|3
6199517|NCT01479465|9858992|FG002|Overall Study|Adverse Event|6
6276912|NCT02234141|9983251|FG006|Long-Term Treatment Period|Withdrew Consent|0
6276913|NCT02234141|9983245|FG000|Long-Term Treatment Period|Study Discontinued by Sponsor|28
6199518|NCT01479465|9858993|FG003|Overall Study|Adverse Event|4
6199519|NCT01479465|9858990|FG000|Overall Study|Investigator Discretion|1
6199520|NCT01479465|9858991|FG001|Overall Study|Investigator Discretion|4
6199521|NCT01479465|9858992|FG002|Overall Study|Investigator Discretion|2
6199522|NCT01479465|9858993|FG003|Overall Study|Investigator Discretion|4
6199523|NCT01479465|9858990|FG000|Overall Study|Subject Request|1
6199524|NCT01479465|9858991|FG001|Overall Study|Subject Request|3
6199525|NCT01479465|9858992|FG002|Overall Study|Subject Request|4
6199526|NCT01479465|9858993|FG003|Overall Study|Subject Request|2
6199527|NCT01479465|9858990|FG000|Overall Study|Subject Withdrew Consent|0
6199528|NCT01479465|9858991|FG001|Overall Study|Subject Withdrew Consent|5
6199529|NCT01479465|9858992|FG002|Overall Study|Subject Withdrew Consent|2
6199530|NCT01479465|9858993|FG003|Overall Study|Subject Withdrew Consent|1
6199531|NCT01479465|9858990|FG000|Overall Study|Protocol Violation|0
6199532|NCT01479465|9858991|FG001|Overall Study|Protocol Violation|1
6199533|NCT01479465|9858992|FG002|Overall Study|Protocol Violation|1
6199534|NCT01479465|9858993|FG003|Overall Study|Protocol Violation|0
6199535|NCT01479465|9858990|FG000|Overall Study|Death|0
6199536|NCT01479465|9858991|FG001|Overall Study|Death|0
6199537|NCT01479465|9858992|FG002|Overall Study|Death|0
6199538|NCT01479465|9858993|FG003|Overall Study|Death|1
6199539|NCT01479465|9858990|FG000|Overall Study|Lost to Follow-up|0
6199540|NCT01479465|9858991|FG001|Overall Study|Lost to Follow-up|0
6199541|NCT01479465|9858992|FG002|Overall Study|Lost to Follow-up|1
6199542|NCT01479465|9858993|FG003|Overall Study|Lost to Follow-up|0
6199543|NCT01479530|9859027|FG000|Overall Study|Adverse Event|5
6199544|NCT01479530|9859028|FG001|Overall Study|Adverse Event|6
6199545|NCT01479530|9859027|FG000|Overall Study|Lack of Efficacy|0
6199546|NCT01479530|9859028|FG001|Overall Study|Lack of Efficacy|1
6199547|NCT01479530|9859027|FG000|Overall Study|Protocol Violation|2
6199548|NCT01479530|9859028|FG001|Overall Study|Protocol Violation|3
6199549|NCT01479530|9859027|FG000|Overall Study|Withdrawal of Consent|3
6199550|NCT01479530|9859028|FG001|Overall Study|Withdrawal of Consent|2
6199551|NCT01479595|9859057|FG000|Overall Study|Protocol deviation|0
6199552|NCT01479595|9859058|FG001|Overall Study|Protocol deviation|1
6199553|NCT01479595|9859057|FG000|Overall Study|Adverse Event|2
6199554|NCT01479595|9859058|FG001|Overall Study|Adverse Event|1
6199555|NCT01479621|9859070|FG000|Pre-Assignment Period (Run-In Placebo)|Inclusion/exclusion criteria|93
6199556|NCT01479621|9859071|FG001|Pre-Assignment Period (Run-In Placebo)|Inclusion/exclusion criteria|0
6199557|NCT01479621|9859072|FG002|Pre-Assignment Period (Run-In Placebo)|Inclusion/exclusion criteria|0
6199558|NCT01479621|9859073|FG003|Pre-Assignment Period (Run-In Placebo)|Inclusion/exclusion criteria|0
6199559|NCT01479621|9859074|FG004|Pre-Assignment Period (Run-In Placebo)|Inclusion/exclusion criteria|0
6199560|NCT01479621|9859075|FG005|Pre-Assignment Period (Run-In Placebo)|Inclusion/exclusion criteria|0
6199561|NCT01479621|9859076|FG006|Pre-Assignment Period (Run-In Placebo)|Inclusion/exclusion criteria|0
6199562|NCT01479621|9859070|FG000|Pre-Assignment Period (Run-In Placebo)|Withdrawal by Subject|19
6199563|NCT01479621|9859071|FG001|Pre-Assignment Period (Run-In Placebo)|Withdrawal by Subject|0
6199564|NCT01479621|9859072|FG002|Pre-Assignment Period (Run-In Placebo)|Withdrawal by Subject|0
6199565|NCT01479621|9859073|FG003|Pre-Assignment Period (Run-In Placebo)|Withdrawal by Subject|0
6199566|NCT01479621|9859074|FG004|Pre-Assignment Period (Run-In Placebo)|Withdrawal by Subject|0
6199567|NCT01479621|9859075|FG005|Pre-Assignment Period (Run-In Placebo)|Withdrawal by Subject|0
6199568|NCT01479621|9859076|FG006|Pre-Assignment Period (Run-In Placebo)|Withdrawal by Subject|0
6199569|NCT01479621|9859070|FG000|Pre-Assignment Period (Run-In Placebo)|Randomization criteria not met|153
6199570|NCT01479621|9859071|FG001|Pre-Assignment Period (Run-In Placebo)|Randomization criteria not met|0
6199571|NCT01479621|9859072|FG002|Pre-Assignment Period (Run-In Placebo)|Randomization criteria not met|0
6199572|NCT01479621|9859073|FG003|Pre-Assignment Period (Run-In Placebo)|Randomization criteria not met|0
6199573|NCT01479621|9859074|FG004|Pre-Assignment Period (Run-In Placebo)|Randomization criteria not met|0
6199574|NCT01479621|9859075|FG005|Pre-Assignment Period (Run-In Placebo)|Randomization criteria not met|0
6199575|NCT01479621|9859076|FG006|Pre-Assignment Period (Run-In Placebo)|Randomization criteria not met|0
6199576|NCT01479621|9859070|FG000|Pre-Assignment Period (Run-In Placebo)|Lost to Follow-up|7
6199577|NCT01479621|9859071|FG001|Pre-Assignment Period (Run-In Placebo)|Lost to Follow-up|0
6199578|NCT01479621|9859072|FG002|Pre-Assignment Period (Run-In Placebo)|Lost to Follow-up|0
6199579|NCT01479621|9859073|FG003|Pre-Assignment Period (Run-In Placebo)|Lost to Follow-up|0
6199580|NCT01479621|9859074|FG004|Pre-Assignment Period (Run-In Placebo)|Lost to Follow-up|0
6199581|NCT01479621|9859075|FG005|Pre-Assignment Period (Run-In Placebo)|Lost to Follow-up|0
6199582|NCT01479621|9859076|FG006|Pre-Assignment Period (Run-In Placebo)|Lost to Follow-up|0
6199583|NCT01479621|9859070|FG000|Pre-Assignment Period (Run-In Placebo)|Other|15
6199584|NCT01479621|9859071|FG001|Pre-Assignment Period (Run-In Placebo)|Other|0
6199585|NCT01479621|9859072|FG002|Pre-Assignment Period (Run-In Placebo)|Other|0
6199586|NCT01479621|9859073|FG003|Pre-Assignment Period (Run-In Placebo)|Other|0
6199587|NCT01479621|9859074|FG004|Pre-Assignment Period (Run-In Placebo)|Other|0
6199588|NCT01479621|9859075|FG005|Pre-Assignment Period (Run-In Placebo)|Other|0
6199589|NCT01479621|9859076|FG006|Pre-Assignment Period (Run-In Placebo)|Other|0
6199590|NCT01479621|9859070|FG000|Treatment Period|Adverse Event|0
6199591|NCT01479621|9859071|FG001|Treatment Period|Adverse Event|0
6199592|NCT01479621|9859072|FG002|Treatment Period|Adverse Event|0
6199593|NCT01479621|9859073|FG003|Treatment Period|Adverse Event|0
6199594|NCT01479621|9859074|FG004|Treatment Period|Adverse Event|1
6199595|NCT01479621|9859075|FG005|Treatment Period|Adverse Event|2
6199596|NCT01479621|9859076|FG006|Treatment Period|Adverse Event|2
6199597|NCT01479621|9859070|FG000|Treatment Period|Withdrawal by Subject|0
6199598|NCT01479621|9859071|FG001|Treatment Period|Withdrawal by Subject|4
6199599|NCT01479621|9859072|FG002|Treatment Period|Withdrawal by Subject|2
6199600|NCT01479621|9859073|FG003|Treatment Period|Withdrawal by Subject|2
6199601|NCT01479621|9859074|FG004|Treatment Period|Withdrawal by Subject|5
6199602|NCT01479621|9859075|FG005|Treatment Period|Withdrawal by Subject|5
6199603|NCT01479621|9859076|FG006|Treatment Period|Withdrawal by Subject|1
6199604|NCT01479621|9859070|FG000|Treatment Period|Physician Decision|0
6199605|NCT01479621|9859071|FG001|Treatment Period|Physician Decision|0
6199606|NCT01479621|9859072|FG002|Treatment Period|Physician Decision|0
6199607|NCT01479621|9859073|FG003|Treatment Period|Physician Decision|0
6199608|NCT01479621|9859074|FG004|Treatment Period|Physician Decision|1
6199609|NCT01479621|9859075|FG005|Treatment Period|Physician Decision|1
6199610|NCT01479621|9859076|FG006|Treatment Period|Physician Decision|0
6199611|NCT01479621|9859070|FG000|Treatment Period|Non-compliance to study drug|0
6199612|NCT01479621|9859071|FG001|Treatment Period|Non-compliance to study drug|1
6199613|NCT01479621|9859072|FG002|Treatment Period|Non-compliance to study drug|0
6199614|NCT01479621|9859073|FG003|Treatment Period|Non-compliance to study drug|0
6199615|NCT01479621|9859074|FG004|Treatment Period|Non-compliance to study drug|0
6199616|NCT01479621|9859075|FG005|Treatment Period|Non-compliance to study drug|0
6199617|NCT01479621|9859076|FG006|Treatment Period|Non-compliance to study drug|1
6199618|NCT01479621|9859070|FG000|Treatment Period|Protocol Violation|0
6199619|NCT01479621|9859071|FG001|Treatment Period|Protocol Violation|9
6199620|NCT01479621|9859072|FG002|Treatment Period|Protocol Violation|6
6199621|NCT01479621|9859073|FG003|Treatment Period|Protocol Violation|5
6199622|NCT01479621|9859074|FG004|Treatment Period|Protocol Violation|2
6199623|NCT01479621|9859075|FG005|Treatment Period|Protocol Violation|10
6199624|NCT01479621|9859076|FG006|Treatment Period|Protocol Violation|6
6199625|NCT01479621|9859070|FG000|Treatment Period|Pregnancy|0
6199626|NCT01479621|9859071|FG001|Treatment Period|Pregnancy|0
6199627|NCT01479621|9859072|FG002|Treatment Period|Pregnancy|2
6199628|NCT01479621|9859073|FG003|Treatment Period|Pregnancy|0
6199629|NCT01479621|9859074|FG004|Treatment Period|Pregnancy|0
6199630|NCT01479621|9859075|FG005|Treatment Period|Pregnancy|0
6199631|NCT01479621|9859076|FG006|Treatment Period|Pregnancy|0
6199632|NCT01479621|9859070|FG000|Treatment Period|Sponsor request subject to be withdrawn|0
6199633|NCT01479621|9859071|FG001|Treatment Period|Sponsor request subject to be withdrawn|2
6199634|NCT01479621|9859072|FG002|Treatment Period|Sponsor request subject to be withdrawn|3
6199635|NCT01479621|9859073|FG003|Treatment Period|Sponsor request subject to be withdrawn|1
6199636|NCT01479621|9859074|FG004|Treatment Period|Sponsor request subject to be withdrawn|1
6199637|NCT01479621|9859075|FG005|Treatment Period|Sponsor request subject to be withdrawn|1
6199638|NCT01479621|9859076|FG006|Treatment Period|Sponsor request subject to be withdrawn|3
6199639|NCT01479621|9859070|FG000|Treatment Period|Lost to Follow-up|0
6199640|NCT01479621|9859071|FG001|Treatment Period|Lost to Follow-up|0
6199641|NCT01479621|9859072|FG002|Treatment Period|Lost to Follow-up|1
6199642|NCT01479621|9859073|FG003|Treatment Period|Lost to Follow-up|0
6199643|NCT01479621|9859074|FG004|Treatment Period|Lost to Follow-up|2
6199644|NCT01479621|9859075|FG005|Treatment Period|Lost to Follow-up|2
6199645|NCT01479621|9859076|FG006|Treatment Period|Lost to Follow-up|1
6199646|NCT01479621|9859070|FG000|Treatment Period|Met stopping criteria|0
6199647|NCT01479621|9859071|FG001|Treatment Period|Met stopping criteria|8
6199648|NCT01479621|9859072|FG002|Treatment Period|Met stopping criteria|7
6199649|NCT01479621|9859073|FG003|Treatment Period|Met stopping criteria|4
6199650|NCT01479621|9859074|FG004|Treatment Period|Met stopping criteria|9
6199651|NCT01479621|9859075|FG005|Treatment Period|Met stopping criteria|20
6199652|NCT01479621|9859076|FG006|Treatment Period|Met stopping criteria|6
6199653|NCT01479764|9859101|FG000|Randomized|Adverse Event|1
6199654|NCT01479764|9859102|FG001|Randomized|Adverse Event|1
6199655|NCT01479764|9859101|FG000|Randomized|Withdrawal by Subject|1
6199656|NCT01479764|9859102|FG001|Randomized|Withdrawal by Subject|0
6199657|NCT01479764|9859101|FG000|Treated|Lost to Follow-up|0
6199658|NCT01479764|9859102|FG001|Treated|Lost to Follow-up|2
6199659|NCT01479777|9859108|FG000|Overall Study|Physician Decision|2
6199660|NCT01479868|9859112|FG000|Overall Study|Adverse Event|1
6199661|NCT01479868|9859112|FG000|Overall Study|Lost to Follow-up|4
6276914|NCT02234141|9983246|FG001|Long-Term Treatment Period|Study Discontinued by Sponsor|27
6276915|NCT02234141|9983247|FG002|Long-Term Treatment Period|Study Discontinued by Sponsor|25
6276916|NCT02234141|9983248|FG003|Long-Term Treatment Period|Study Discontinued by Sponsor|0
6276917|NCT02234141|9983249|FG004|Long-Term Treatment Period|Study Discontinued by Sponsor|9
6276918|NCT02234141|9983250|FG005|Long-Term Treatment Period|Study Discontinued by Sponsor|10
6276919|NCT02234141|9983251|FG006|Long-Term Treatment Period|Study Discontinued by Sponsor|8
6276920|NCT02234284|9983269|FG000|Overall Study|Death|4
6276921|NCT02234284|9983270|FG001|Overall Study|Death|2
6276922|NCT02234284|9983269|FG000|Overall Study|Withdrawal by Subject|1
6276923|NCT02234284|9983270|FG001|Overall Study|Withdrawal by Subject|0
6276924|NCT02234284|9983269|FG000|Overall Study|Lost to Follow-up|20
6276925|NCT02234284|9983270|FG001|Overall Study|Lost to Follow-up|7
6276926|NCT02234362|9983280|FG000|Overall Study|Not eligible after first screening visit|17
6276927|NCT02234362|9983280|FG000|Overall Study|Lost to Follow-up|6
6276928|NCT02234362|9983280|FG000|Overall Study|Withdrawal by Subject|3
6199662|NCT01479868|9859112|FG000|Overall Study|Protocol Violation|1
6199663|NCT01479868|9859112|FG000|Overall Study|Withdrawal by Subject|1
6199664|NCT01479868|9859112|FG000|Overall Study|Sponsor's Decision|1
6199665|NCT01479868|9859112|FG000|Overall Study|Initiation of new HCV Therapy|1
6276929|NCT02234479|9983290|FG000|Overall Study|Withdrawal by Subject|1
6276930|NCT02234479|9983291|FG001|Overall Study|Withdrawal by Subject|3
6276931|NCT02234583|9983332|FG000|Overall Study|Adverse Event|172
6276932|NCT02234583|9983333|FG001|Overall Study|Adverse Event|156
6276933|NCT02234583|9983332|FG000|Overall Study|Withdrawal by Subject|109
6276934|NCT02234583|9983333|FG001|Overall Study|Withdrawal by Subject|157
6276935|NCT02234583|9983332|FG000|Overall Study|Lost to Follow-up|0
6276936|NCT02234583|9983333|FG001|Overall Study|Lost to Follow-up|1
6276937|NCT02234583|9983332|FG000|Overall Study|Lack of Efficacy|58
6276938|NCT02234583|9983333|FG001|Overall Study|Lack of Efficacy|103
6276939|NCT02234583|9983332|FG000|Overall Study|Protocol Violation|35
6276940|NCT02234583|9983333|FG001|Overall Study|Protocol Violation|42
6276941|NCT02234583|9983332|FG000|Overall Study|Other|39
6276942|NCT02234583|9983333|FG001|Overall Study|Other|97
6276943|NCT02234596|9983345|FG000|Overall Study|Participant not treated|2
6088762|NCT00678301|9699774|FG000|Overall Study|Non-compliance with study procedures|0
6088763|NCT00678301|9699775|FG001|Overall Study|Non-compliance with study procedures|1
6276944|NCT02234622|9983351|FG000|Overall Study|Withdrawal by Subject|16
6276945|NCT02234622|9983352|FG001|Overall Study|Withdrawal by Subject|22
6276946|NCT02234622|9983351|FG000|Overall Study|Lost to Follow-up|27
6276947|NCT02234622|9983352|FG001|Overall Study|Lost to Follow-up|14
6276948|NCT02235077|9983388|FG000|Overall Study|Death|5
6276949|NCT02235077|9983389|FG001|Overall Study|Death|7
6276950|NCT02235077|9983388|FG000|Overall Study|Lost to Follow-up|5
6276951|NCT02235077|9983389|FG001|Overall Study|Lost to Follow-up|6
6276952|NCT02235077|9983388|FG000|Overall Study|Withdrawal by Subject|8
6276953|NCT02235077|9983389|FG001|Overall Study|Withdrawal by Subject|5
6276954|NCT02235077|9983388|FG000|Overall Study|Physician Decision|0
6276955|NCT02235077|9983389|FG001|Overall Study|Physician Decision|1
6276956|NCT02235298|9983401|FG000|Overall Study|Lost to Follow-up|6
6276957|NCT02235298|9983402|FG001|Overall Study|Lost to Follow-up|5
6276958|NCT02235298|9983401|FG000|Overall Study|Adverse Event|2
6276959|NCT02235298|9983402|FG001|Overall Study|Adverse Event|2
6276960|NCT02235298|9983401|FG000|Overall Study|Withdrawal by Subject|0
6276961|NCT02235298|9983402|FG001|Overall Study|Withdrawal by Subject|1
6276962|NCT02235311|9983410|FG000|Overall Study|Lost to Follow-up|0
6276963|NCT02235311|9983411|FG001|Overall Study|Lost to Follow-up|1
6276964|NCT02235311|9983410|FG000|Overall Study|Protocol Violation|0
6276965|NCT02235311|9983411|FG001|Overall Study|Protocol Violation|1
6276966|NCT02235454|9983417|FG000|Overall Study|Withdrawal by Subject|2
6276967|NCT02236130|9983462|FG000|Overall Study|Lost to Follow-up|7
6276968|NCT02236130|9983463|FG001|Overall Study|Lost to Follow-up|12
6276969|NCT02236520|9983482|FG000|Overall Study|Physician Decision|0
6276970|NCT02236520|9983483|FG001|Overall Study|Physician Decision|5
6276971|NCT02236520|9983484|FG002|Overall Study|Physician Decision|0
6276972|NCT02236520|9983485|FG003|Overall Study|Physician Decision|0
6276973|NCT02236520|9983482|FG000|Overall Study|Withdrawal by Subject|1
6276974|NCT02236520|9983483|FG001|Overall Study|Withdrawal by Subject|0
6276975|NCT02236520|9983484|FG002|Overall Study|Withdrawal by Subject|0
6276976|NCT02236520|9983485|FG003|Overall Study|Withdrawal by Subject|1
6276977|NCT02236520|9983482|FG000|Overall Study|Pregnancy|1
6276978|NCT02236520|9983483|FG001|Overall Study|Pregnancy|0
6276979|NCT02236520|9983484|FG002|Overall Study|Pregnancy|0
6276980|NCT02236520|9983485|FG003|Overall Study|Pregnancy|0
6276981|NCT02236559|9983497|FG000|Overall Study|Met Exclusion|3
6276982|NCT02236559|9983498|FG001|Overall Study|Met Exclusion|6
6276983|NCT02236559|9983497|FG000|Overall Study|Did not Meet Inclusion|3
6276984|NCT02236559|9983498|FG001|Overall Study|Did not Meet Inclusion|3
6276985|NCT02236559|9983497|FG000|Overall Study|Subject Did Not Consent|4
6276986|NCT02236559|9983498|FG001|Overall Study|Subject Did Not Consent|2
6276987|NCT02236559|9983497|FG000|Overall Study|Physician Decision|1
6276988|NCT02236559|9983498|FG001|Overall Study|Physician Decision|1
6276989|NCT02236559|9983497|FG000|Overall Study|Withdrawal by Subject|1
6276990|NCT02236559|9983498|FG001|Overall Study|Withdrawal by Subject|0
6276991|NCT02236598|9983506|FG000|Overall Study|Adverse Event|0
6276992|NCT02236598|9983507|FG001|Overall Study|Adverse Event|1
6276993|NCT02236598|9983506|FG000|Overall Study|Withdrawal by Subject|0
6276994|NCT02236598|9983507|FG001|Overall Study|Withdrawal by Subject|1
6276995|NCT02236611|9983515|FG000|Overall Study|Adverse Event|10
6276996|NCT02236611|9983516|FG001|Overall Study|Adverse Event|16
6276997|NCT02236611|9983515|FG000|Overall Study|Lack of Efficacy|4
6276998|NCT02236611|9983516|FG001|Overall Study|Lack of Efficacy|7
6276999|NCT02236611|9983515|FG000|Overall Study|Lost to Follow-up|0
6277000|NCT02236611|9983516|FG001|Overall Study|Lost to Follow-up|2
6277001|NCT02236611|9983515|FG000|Overall Study|Protocol deviation|3
6277002|NCT02236611|9983516|FG001|Overall Study|Protocol deviation|5
6277003|NCT02236611|9983515|FG000|Overall Study|Withdrew consent|9
6277004|NCT02236611|9983516|FG001|Overall Study|Withdrew consent|4
6277005|NCT02236988|9983530|FG000|Overall Study|Lost to Follow-up|0
6277006|NCT02236988|9983531|FG001|Overall Study|Lost to Follow-up|0
6277007|NCT02236988|9983532|FG002|Overall Study|Lost to Follow-up|0
6277008|NCT02236988|9983533|FG003|Overall Study|Lost to Follow-up|1
6277009|NCT02236988|9983530|FG000|Overall Study|Unable to Comply with Study Visits|0
6277010|NCT02236988|9983531|FG001|Overall Study|Unable to Comply with Study Visits|0
6277011|NCT02236988|9983532|FG002|Overall Study|Unable to Comply with Study Visits|0
6199666|NCT01479985|9859118|FG000|Overall Study|Tablet malfunction, no data saved|1
6199667|NCT01479985|9859119|FG001|Overall Study|Tablet malfunction, no data saved|1
6199668|NCT01479985|9859118|FG000|Overall Study|No decisional conflict scale responses|0
6199669|NCT01479985|9859119|FG001|Overall Study|No decisional conflict scale responses|2
6199670|NCT01479985|9859118|FG000|Overall Study|No post-visit survey|5
6199671|NCT01479985|9859119|FG001|Overall Study|No post-visit survey|3
6199672|NCT01480076|9859127|FG000|Overall Study|Run-in Failure|52
6199673|NCT01480076|9859127|FG000|Overall Study|Adverse Event|39
6199674|NCT01480076|9859127|FG000|Overall Study|Death|2
6199675|NCT01480076|9859127|FG000|Overall Study|Disease Progression|5
6199676|NCT01480076|9859127|FG000|Overall Study|Non-compliance With Study Protocol|15
6199677|NCT01480076|9859127|FG000|Overall Study|Withdrawal by Subject|105
6199678|NCT01480076|9859127|FG000|Overall Study|Lost to Follow-up|7
6199679|NCT01480076|9859127|FG000|Overall Study|Investigator Decision|13
6199680|NCT01480076|9859127|FG000|Overall Study|Other|52
6199681|NCT01480258|9859180|FG000|Infant Series|Protocol Violation|2
6199682|NCT01480258|9859181|FG001|Infant Series|Protocol Violation|0
6199683|NCT01480258|9859180|FG000|Infant Series|Physician Decision|0
6199684|NCT01480258|9859181|FG001|Infant Series|Physician Decision|1
6199685|NCT01480258|9859180|FG000|Infant Series|Not Vaccinated|3
6199686|NCT01480258|9859181|FG001|Infant Series|Not Vaccinated|0
6199687|NCT01480258|9859180|FG000|Infant Series|Adverse Event|1
6199688|NCT01480258|9859181|FG001|Infant Series|Adverse Event|1
6199689|NCT01480258|9859180|FG000|Infant Series|Withdrawal by Subject|1
6199690|NCT01480258|9859181|FG001|Infant Series|Withdrawal by Subject|6
6199691|NCT01480258|9859180|FG000|Interim Period|Lost to Follow-up|0
6199692|NCT01480258|9859181|FG001|Interim Period|Lost to Follow-up|2
6199693|NCT01480258|9859180|FG000|Interim Period|Physician Decision|1
6199694|NCT01480258|9859181|FG001|Interim Period|Physician Decision|0
6199695|NCT01480258|9859180|FG000|Interim Period|Protocol Violation|0
6199696|NCT01480258|9859181|FG001|Interim Period|Protocol Violation|1
6199697|NCT01480258|9859180|FG000|Interim Period|Withdrawal by Subject|9
6199698|NCT01480258|9859181|FG001|Interim Period|Withdrawal by Subject|6
6199699|NCT01480284|9859189|FG000|Overall Study|Withdrawal by Subject|2
6199700|NCT01480284|9859190|FG001|Overall Study|Withdrawal by Subject|0
6199701|NCT01480284|9859189|FG000|Overall Study|Adverse Event|1
6199702|NCT01480284|9859190|FG001|Overall Study|Adverse Event|0
6199703|NCT01480284|9859189|FG000|Overall Study|Study closed/terminated|3
6199704|NCT01480284|9859190|FG001|Overall Study|Study closed/terminated|0
6199705|NCT01480284|9859189|FG000|Overall Study|Lost to Follow-up|1
6199706|NCT01480284|9859190|FG001|Overall Study|Lost to Follow-up|0
6199707|NCT01480284|9859189|FG000|Overall Study|Physician Decision|1
6199708|NCT01480284|9859190|FG001|Overall Study|Physician Decision|0
6199709|NCT01480596|9859202|FG000|Overall Study|Adverse Event|3
6199710|NCT01480596|9859203|FG001|Overall Study|Adverse Event|0
6199711|NCT01480596|9859202|FG000|Overall Study|MG exacerbation or change in medication|2
6199712|NCT01480596|9859203|FG001|Overall Study|MG exacerbation or change in medication|2
6199713|NCT01480674|9859209|FG000|Overall Study|Death|23
6199714|NCT01480674|9859209|FG000|Overall Study|Lost to Follow-up|2
6199715|NCT01480674|9859209|FG000|Overall Study|visit not done|10
6199716|NCT01481116|9859220|FG000|Overall Study|Adverse Event|26
6199717|NCT01481116|9859221|FG001|Overall Study|Adverse Event|26
6199718|NCT01481116|9859222|FG002|Overall Study|Adverse Event|42
6199719|NCT01481116|9859220|FG000|Overall Study|Major Protocol Deviation|3
6199720|NCT01481116|9859221|FG001|Overall Study|Major Protocol Deviation|7
6199721|NCT01481116|9859222|FG002|Overall Study|Major Protocol Deviation|1
6199722|NCT01481116|9859220|FG000|Overall Study|Lost to Follow-up|8
6199723|NCT01481116|9859221|FG001|Overall Study|Lost to Follow-up|12
6199724|NCT01481116|9859222|FG002|Overall Study|Lost to Follow-up|11
6199725|NCT01481116|9859220|FG000|Overall Study|Withdrawal by Subject|37
6277012|NCT02236988|9983533|FG003|Overall Study|Unable to Comply with Study Visits|2
6277013|NCT02237001|9983584|FG000|Overall Study|Lost to Follow-up|2
6277014|NCT02237001|9983584|FG000|Overall Study|Withdrawal by Subject|1
6277015|NCT02237001|9983584|FG000|Overall Study|Eligibility criteria/Late Screen Failure|3
6277016|NCT02237001|9983584|FG000|Overall Study|Re-operation|4
6277017|NCT02237001|9983584|FG000|Overall Study|Incarceration|1
6277018|NCT02237118|9983605|FG000|Overall Study|Protocol Violation|0
6277019|NCT02237118|9983606|FG001|Overall Study|Protocol Violation|1
6277020|NCT02237118|9983605|FG000|Overall Study|consent withdrawn|1
6277021|NCT02237118|9983606|FG001|Overall Study|consent withdrawn|0
6277022|NCT02237157|9983620|FG000|Gemcitabine, Local Delivery (Dose 1)|Adverse Event|3
6277023|NCT02237157|9983621|FG001|Gemcitabine, Local Delivery (Dose 1)|Adverse Event|0
6277024|NCT02237157|9983622|FG002|Gemcitabine, Local Delivery (Dose 1)|Adverse Event|0
6277025|NCT02237157|9983623|FG003|Gemcitabine, Local Delivery (Dose 1)|Adverse Event|0
6277026|NCT02237157|9983620|FG000|Gemcitabine, Local Delivery (Dose 1)|Withdrawal by Subject|1
6277027|NCT02237157|9983621|FG001|Gemcitabine, Local Delivery (Dose 1)|Withdrawal by Subject|0
6277028|NCT02237157|9983622|FG002|Gemcitabine, Local Delivery (Dose 1)|Withdrawal by Subject|0
6199726|NCT01481116|9859221|FG001|Overall Study|Withdrawal by Subject|33
6199727|NCT01481116|9859222|FG002|Overall Study|Withdrawal by Subject|37
6199728|NCT01481116|9859220|FG000|Overall Study|Study Termination|730
6199729|NCT01481116|9859221|FG001|Overall Study|Study Termination|729
6199730|NCT01481116|9859222|FG002|Overall Study|Study Termination|713
6199731|NCT01481116|9859220|FG000|Overall Study|Pregnancy|0
6199732|NCT01481116|9859221|FG001|Overall Study|Pregnancy|0
6199733|NCT01481116|9859222|FG002|Overall Study|Pregnancy|1
6199734|NCT01481116|9859220|FG000|Overall Study|Lack of Efficacy|3
6199735|NCT01481116|9859221|FG001|Overall Study|Lack of Efficacy|3
6199736|NCT01481116|9859222|FG002|Overall Study|Lack of Efficacy|1
6199737|NCT01481116|9859220|FG000|Overall Study|Contraindications|1
6199738|NCT01481116|9859221|FG001|Overall Study|Contraindications|1
6199739|NCT01481116|9859222|FG002|Overall Study|Contraindications|0
6199740|NCT01481116|9859220|FG000|Overall Study|Other|1
6199741|NCT01481116|9859221|FG001|Overall Study|Other|1
6199742|NCT01481116|9859222|FG002|Overall Study|Other|0
6199743|NCT01481116|9859220|FG000|Overall Study|Participant Started Taking Glipizide|1
6199744|NCT01481116|9859221|FG001|Overall Study|Participant Started Taking Glipizide|0
6199745|NCT01481116|9859222|FG002|Overall Study|Participant Started Taking Glipizide|0
6199746|NCT01481116|9859220|FG000|Overall Study|Participant Moved Out of Area|2
6199747|NCT01481116|9859221|FG001|Overall Study|Participant Moved Out of Area|0
6199748|NCT01481116|9859222|FG002|Overall Study|Participant Moved Out of Area|1
6199749|NCT01481116|9859220|FG000|Overall Study|Participant Moved Out of Country|1
6199750|NCT01481116|9859221|FG001|Overall Study|Participant Moved Out of Country|0
6199751|NCT01481116|9859222|FG002|Overall Study|Participant Moved Out of Country|1
6199752|NCT01481116|9859220|FG000|Overall Study|Investigator Decision|3
6199753|NCT01481116|9859221|FG001|Overall Study|Investigator Decision|2
6199754|NCT01481116|9859222|FG002|Overall Study|Investigator Decision|1
6199755|NCT01481116|9859220|FG000|Overall Study|Sponsor Decision|0
6199756|NCT01481116|9859221|FG001|Overall Study|Sponsor Decision|1
6199757|NCT01481116|9859222|FG002|Overall Study|Sponsor Decision|3
6199758|NCT01481116|9859220|FG000|Overall Study|Non-Compliant With Study Drug|0
6199759|NCT01481116|9859221|FG001|Overall Study|Non-Compliant With Study Drug|1
6199760|NCT01481116|9859222|FG002|Overall Study|Non-Compliant With Study Drug|1
6199761|NCT01481116|9859220|FG000|Overall Study|Investigator's Discretion|2
6199762|NCT01481116|9859221|FG001|Overall Study|Investigator's Discretion|0
6199763|NCT01481116|9859222|FG002|Overall Study|Investigator's Discretion|0
6199764|NCT01481116|9859220|FG000|Overall Study|Death|2
6199765|NCT01481116|9859221|FG001|Overall Study|Death|1
6199766|NCT01481116|9859222|FG002|Overall Study|Death|0
6199767|NCT01481116|9859220|FG000|Overall Study|Hypoglycemic Event|4
6199768|NCT01481116|9859221|FG001|Overall Study|Hypoglycemic Event|0
6199769|NCT01481116|9859222|FG002|Overall Study|Hypoglycemic Event|0
6199770|NCT01481324|9859237|FG000|Overall Study|Missing Data|0
6277029|NCT02237157|9983623|FG003|Gemcitabine, Local Delivery (Dose 1)|Withdrawal by Subject|0
6277030|NCT02237196|9983634|FG000|Overall Study|Adverse Event|0
6277031|NCT02237196|9983635|FG001|Overall Study|Adverse Event|1
6277032|NCT02237196|9983636|FG002|Overall Study|Adverse Event|1
6277033|NCT02237196|9983637|FG003|Overall Study|Adverse Event|0
6277034|NCT02237196|9983634|FG000|Overall Study|Lost to Follow-up|4
6277035|NCT02237196|9983635|FG001|Overall Study|Lost to Follow-up|2
6277036|NCT02237196|9983636|FG002|Overall Study|Lost to Follow-up|4
6277037|NCT02237196|9983637|FG003|Overall Study|Lost to Follow-up|6
6277038|NCT02237196|9983634|FG000|Overall Study|Physician Decision|2
6277039|NCT02237196|9983635|FG001|Overall Study|Physician Decision|0
6277040|NCT02237196|9983636|FG002|Overall Study|Physician Decision|0
6277041|NCT02237196|9983637|FG003|Overall Study|Physician Decision|1
6277042|NCT02237196|9983634|FG000|Overall Study|Pregnancy|0
6277043|NCT02237196|9983635|FG001|Overall Study|Pregnancy|0
6277044|NCT02237196|9983636|FG002|Overall Study|Pregnancy|1
6277045|NCT02237196|9983637|FG003|Overall Study|Pregnancy|1
6277046|NCT02237196|9983634|FG000|Overall Study|Withdrawal by Subject|1
6277047|NCT02237196|9983635|FG001|Overall Study|Withdrawal by Subject|1
6277048|NCT02237196|9983636|FG002|Overall Study|Withdrawal by Subject|4
6277049|NCT02237196|9983637|FG003|Overall Study|Withdrawal by Subject|1
6277050|NCT02237196|9983634|FG000|Overall Study|Site Error|1
6277051|NCT02237196|9983635|FG001|Overall Study|Site Error|2
6277052|NCT02237196|9983636|FG002|Overall Study|Site Error|0
6277053|NCT02237196|9983637|FG003|Overall Study|Site Error|2
6277054|NCT02237911|9983674|FG000|Overall Study|Withdrawal by Subject|4
6277055|NCT02237911|9983675|FG001|Overall Study|Withdrawal by Subject|7
6277056|NCT02237911|9983676|FG002|Overall Study|Withdrawal by Subject|2
6277057|NCT02237911|9983674|FG000|Overall Study|Lost to Follow-up|3
5977268|NCT02318277|9564382|FG006|Overall Study|Transitioned to Hospice|0
6199771|NCT01481324|9859238|FG001|Overall Study|Missing Data|2
6199772|NCT01481324|9859239|FG002|Overall Study|Missing Data|2
6199773|NCT01481779|9859282|FG000|Overall Study|Adverse Event|23
6199774|NCT01481779|9859283|FG001|Overall Study|Adverse Event|5
6199775|NCT01481779|9859282|FG000|Overall Study|Lost to Follow-up|3
6199776|NCT01481779|9859283|FG001|Overall Study|Lost to Follow-up|2
6277058|NCT02237911|9983675|FG001|Overall Study|Lost to Follow-up|1
6277059|NCT02237911|9983676|FG002|Overall Study|Lost to Follow-up|1
6277060|NCT02238067|9983714|FG000|Overall Study|Not completed survey at Month 6|45
6277061|NCT02238080|9983718|FG000|Overall Study|Death|13
6277062|NCT02238080|9983718|FG000|Overall Study|Treatment interrupted|6
5977269|NCT02318277|9564383|FG007|Overall Study|Transitioned to Hospice|0
6199777|NCT01481779|9859282|FG000|Overall Study|Protocol Violation|2
6199778|NCT01481779|9859283|FG001|Overall Study|Protocol Violation|3
6199779|NCT01481779|9859282|FG000|Overall Study|Withdrawal by Subject|26
6277063|NCT02238080|9983718|FG000|Overall Study|Withdrawal by Subject|2
6199780|NCT01481779|9859283|FG001|Overall Study|Withdrawal by Subject|13
6199781|NCT01481779|9859282|FG000|Overall Study|Physician Decision|13
6199782|NCT01481779|9859283|FG001|Overall Study|Physician Decision|4
6199783|NCT01481779|9859282|FG000|Overall Study|Sponsor Decision|3
6199784|NCT01481779|9859283|FG001|Overall Study|Sponsor Decision|1
6199785|NCT01481896|9859289|FG000|Overall Study|Lost to Follow-up|12
6199786|NCT01482065|9859305|FG000|Overall Study|Withdrawal by Subject|0
6199787|NCT01482065|9859306|FG001|Overall Study|Withdrawal by Subject|1
6199788|NCT01482169|9859321|FG000|Overall Study|Physician Decision|2
6199789|NCT01482221|9859331|FG000|Overall Study|Lack of Efficacy|1
6199790|NCT01482221|9859332|FG001|Overall Study|Lack of Efficacy|0
6199791|NCT01482221|9859333|FG002|Overall Study|Lack of Efficacy|1
6199792|NCT01482221|9859331|FG000|Overall Study|Lost to Follow-up|3
6199793|NCT01482221|9859332|FG001|Overall Study|Lost to Follow-up|2
6199794|NCT01482221|9859333|FG002|Overall Study|Lost to Follow-up|1
6199795|NCT01482221|9859331|FG000|Overall Study|Study-Specific Withdrawal Criteria|2
6199796|NCT01482221|9859332|FG001|Overall Study|Study-Specific Withdrawal Criteria|0
6199797|NCT01482221|9859333|FG002|Overall Study|Study-Specific Withdrawal Criteria|1
6199798|NCT01482221|9859331|FG000|Overall Study|Condition under Investigation Worsened|3
6199799|NCT01482221|9859332|FG001|Overall Study|Condition under Investigation Worsened|2
6199800|NCT01482221|9859333|FG002|Overall Study|Condition under Investigation Worsened|4
6199801|NCT01482221|9859331|FG000|Overall Study|Severe Non-Compliance to Protocol|1
6199802|NCT01482221|9859332|FG001|Overall Study|Severe Non-Compliance to Protocol|0
6199803|NCT01482221|9859333|FG002|Overall Study|Severe Non-Compliance to Protocol|1
6199804|NCT01482221|9859331|FG000|Overall Study|Adverse Event|1
6199805|NCT01482221|9859332|FG001|Overall Study|Adverse Event|7
6199806|NCT01482221|9859333|FG002|Overall Study|Adverse Event|3
6199807|NCT01482221|9859331|FG000|Overall Study|Withdrawal by Subject|10
6199808|NCT01482221|9859332|FG001|Overall Study|Withdrawal by Subject|7
6199809|NCT01482221|9859333|FG002|Overall Study|Withdrawal by Subject|12
6199810|NCT01482221|9859331|FG000|Overall Study|Incorrect randomization|0
6199811|NCT01482221|9859332|FG001|Overall Study|Incorrect randomization|1
6199812|NCT01482221|9859333|FG002|Overall Study|Incorrect randomization|0
6199813|NCT01482221|9859331|FG000|Overall Study|Physician Decision|0
6199814|NCT01482221|9859332|FG001|Overall Study|Physician Decision|1
6199815|NCT01482221|9859333|FG002|Overall Study|Physician Decision|0
6199816|NCT01482312|9859341|FG000|Period 1, 90 Minutes of Wear|Other|1
6199817|NCT01482312|9859342|FG001|Period 1, 90 Minutes of Wear|Other|0
6199818|NCT01482312|9859343|FG002|Period 1, 90 Minutes of Wear|Other|0
6199819|NCT01482312|9859341|FG000|Period 2, 90 Minutes of Wear|Other|1
6199820|NCT01482312|9859342|FG001|Period 2, 90 Minutes of Wear|Other|0
6199821|NCT01482312|9859343|FG002|Period 2, 90 Minutes of Wear|Other|0
6199822|NCT01482429|9859363|FG000|Care Usual|Protocol Violation|0
6199823|NCT01482429|9859364|FG001|Care Usual|Protocol Violation|172
6199824|NCT01482429|9859363|FG000|Care Usual|Lost to Follow-up|0
6199825|NCT01482429|9859364|FG001|Care Usual|Lost to Follow-up|1
6199826|NCT01482429|9859363|FG000|Protocol|Protocol Violation|275
6199827|NCT01482429|9859364|FG001|Protocol|Protocol Violation|0
6199828|NCT01482767|9859438|FG000|Overall Study|Death|1
6199829|NCT01482767|9859439|FG001|Overall Study|Death|1
6199830|NCT01482767|9859438|FG000|Overall Study|Withdrawal by Subject|7
6199831|NCT01482767|9859439|FG001|Overall Study|Withdrawal by Subject|5
6199832|NCT01482767|9859438|FG000|Overall Study|Lost to Follow-up|12
6199833|NCT01482767|9859439|FG001|Overall Study|Lost to Follow-up|6
6199834|NCT01482767|9859438|FG000|Overall Study|Adverse Event|0
6199835|NCT01482767|9859439|FG001|Overall Study|Adverse Event|3
6199836|NCT01482767|9859438|FG000|Overall Study|Site closure|22
6199837|NCT01482767|9859439|FG001|Overall Study|Site closure|14
6199838|NCT01482767|9859438|FG000|Overall Study|Non-adherence to study requirements|4
6199839|NCT01482767|9859439|FG001|Overall Study|Non-adherence to study requirements|7
6199840|NCT01482767|9859438|FG000|Overall Study|Alternate HCV treatment|7
6199841|NCT01482767|9859439|FG001|Overall Study|Alternate HCV treatment|8
6199842|NCT01482767|9859438|FG000|Overall Study|Ineligible|0
6199843|NCT01482767|9859439|FG001|Overall Study|Ineligible|5
6199844|NCT01482767|9859438|FG000|Overall Study|Nurse error|1
6199845|NCT01482767|9859439|FG001|Overall Study|Nurse error|0
6199846|NCT01482819|9859445|FG000|Overall Study|Lost to Follow-up|2
6199847|NCT01482884|9859455|FG000|Overall Study|Medical decision due to lack of efficacy|0
6199848|NCT01482884|9859456|FG001|Overall Study|Medical decision due to lack of efficacy|1
6199849|NCT01482884|9859455|FG000|Overall Study|Protocol Violation|1
6199850|NCT01482884|9859456|FG001|Overall Study|Protocol Violation|0
6199851|NCT01482884|9859455|FG000|Overall Study|Lost to Follow-up|2
6199852|NCT01482884|9859456|FG001|Overall Study|Lost to Follow-up|2
6199853|NCT01482884|9859455|FG000|Overall Study|Lack of Efficacy|0
6199854|NCT01482884|9859456|FG001|Overall Study|Lack of Efficacy|1
6199855|NCT01482884|9859455|FG000|Overall Study|Adverse Event|2
6199856|NCT01482884|9859456|FG001|Overall Study|Adverse Event|1
6199857|NCT01482884|9859455|FG000|Overall Study|Withdrawal by Subject|8
6199858|NCT01482884|9859456|FG001|Overall Study|Withdrawal by Subject|13
6199859|NCT01482910|9859464|FG000|Overall Study|Adverse Event|6
6199860|NCT01482910|9859465|FG001|Overall Study|Adverse Event|5
6199861|NCT01482910|9859464|FG000|Overall Study|Lost to Follow-up|0
6199862|NCT01482910|9859465|FG001|Overall Study|Lost to Follow-up|1
6199863|NCT01482910|9859464|FG000|Overall Study|Protocol Violation|1
6199864|NCT01482910|9859465|FG001|Overall Study|Protocol Violation|1
6199865|NCT01482910|9859464|FG000|Overall Study|Withdrawal by Subject|7
5977270|NCT02143063|9564439|FG000|Overall Study|Lost to Follow-up|16
5977271|NCT02143063|9564440|FG001|Overall Study|Lost to Follow-up|28
5977272|NCT02143063|9564441|FG002|Overall Study|Lost to Follow-up|29
5977273|NCT02143063|9564439|FG000|Overall Study|Withdrawal by Subject|0
5977274|NCT02143063|9564440|FG001|Overall Study|Withdrawal by Subject|1
5977275|NCT02143063|9564441|FG002|Overall Study|Withdrawal by Subject|0
6199866|NCT01482910|9859465|FG001|Overall Study|Withdrawal by Subject|2
6199867|NCT01482910|9859464|FG000|Overall Study|Death|1
6199868|NCT01482910|9859465|FG001|Overall Study|Death|0
6199869|NCT01482962|9859475|FG000|Overall Study|Progressive Disease|65
6199870|NCT01482962|9859476|FG001|Overall Study|Progressive Disease|53
6199871|NCT01482962|9859475|FG000|Overall Study|Unsatisfactory Therapeutic Response|37
6199872|NCT01482962|9859476|FG001|Overall Study|Unsatisfactory Therapeutic Response|23
6199873|NCT01482962|9859475|FG000|Overall Study|Adverse Event|18
6199874|NCT01482962|9859476|FG001|Overall Study|Adverse Event|22
6199875|NCT01482962|9859475|FG000|Overall Study|Withdrawal by Participant|8
6199876|NCT01482962|9859476|FG001|Overall Study|Withdrawal by Participant|13
6199877|NCT01482962|9859475|FG000|Overall Study|Hematopoietic Stem Cell Transplant|3
6199878|NCT01482962|9859476|FG001|Overall Study|Hematopoietic Stem Cell Transplant|9
6199879|NCT01482962|9859475|FG000|Overall Study|Other Reason|1
6199880|NCT01482962|9859476|FG001|Overall Study|Other Reason|5
6199881|NCT01482962|9859475|FG000|Overall Study|Study Terminated by Sponsor|5
6199882|NCT01482962|9859476|FG001|Overall Study|Study Terminated by Sponsor|2
6199883|NCT01482962|9859475|FG000|Overall Study|Did not Receive Study Drug|1
6199884|NCT01482962|9859476|FG001|Overall Study|Did not Receive Study Drug|6
6199885|NCT01483118|9859486|FG000|Overall Study|Lost to Follow-up|12
6199886|NCT01483118|9859487|FG001|Overall Study|Lost to Follow-up|16
6199887|NCT01483144|9859498|FG000|Overall Study|Adverse Event|9
6199888|NCT01483144|9859499|FG001|Overall Study|Adverse Event|4
6088764|NCT00678301|9699774|FG000|Overall Study|Adverse Event|1
6199889|NCT01483144|9859500|FG002|Overall Study|Adverse Event|6
6199890|NCT01483144|9859498|FG000|Overall Study|Withdrawal by Subject|0
6199891|NCT01483144|9859499|FG001|Overall Study|Withdrawal by Subject|2
6199892|NCT01483144|9859500|FG002|Overall Study|Withdrawal by Subject|5
6199893|NCT01483144|9859498|FG000|Overall Study|Physician Decision|1
6199894|NCT01483144|9859499|FG001|Overall Study|Physician Decision|0
6199895|NCT01483144|9859500|FG002|Overall Study|Physician Decision|0
6199896|NCT01483144|9859498|FG000|Overall Study|Lost to Follow-up|2
6199897|NCT01483144|9859499|FG001|Overall Study|Lost to Follow-up|4
6088765|NCT00678301|9699775|FG001|Overall Study|Adverse Event|0
6088766|NCT00678301|9699774|FG000|Overall Study|Withdrawal by Subject|4
6088767|NCT00678301|9699775|FG001|Overall Study|Withdrawal by Subject|0
6088768|NCT00678301|9699774|FG000|Overall Study|Lost to Follow-up|3
6088769|NCT00678301|9699775|FG001|Overall Study|Lost to Follow-up|1
6088770|NCT00678379|9699784|FG000|Overall Study|Injection performed after tonsillectomy|2
6088771|NCT00678379|9699785|FG001|Overall Study|Injection performed after tonsillectomy|0
6088772|NCT00678379|9699786|FG002|Overall Study|Injection performed after tonsillectomy|1
6088773|NCT00678379|9699784|FG000|Overall Study|Incomplete Data|4
6088774|NCT00678379|9699785|FG001|Overall Study|Incomplete Data|3
6088775|NCT00678379|9699786|FG002|Overall Study|Incomplete Data|3
6088776|NCT00678392|9699796|FG000|Overall Study|Adverse Event|0
6199898|NCT01483144|9859500|FG002|Overall Study|Lost to Follow-up|1
6199899|NCT01483144|9859498|FG000|Overall Study|Protocol Violation|3
6199900|NCT01483144|9859499|FG001|Overall Study|Protocol Violation|3
6199901|NCT01483144|9859500|FG002|Overall Study|Protocol Violation|3
6199902|NCT01483183|9859518|FG000|Overall Study|Physician Decision|0
6199903|NCT01483183|9859519|FG001|Overall Study|Physician Decision|0
6199904|NCT01483183|9859520|FG002|Overall Study|Physician Decision|0
6199905|NCT01483183|9859521|FG003|Overall Study|Physician Decision|0
6199906|NCT01483183|9859522|FG004|Overall Study|Physician Decision|0
6199907|NCT01483183|9859523|FG005|Overall Study|Physician Decision|0
6199908|NCT01483183|9859524|FG006|Overall Study|Physician Decision|2
6199909|NCT01483183|9859525|FG007|Overall Study|Physician Decision|0
6199910|NCT01483183|9859526|FG008|Overall Study|Physician Decision|0
5977276|NCT02143063|9564439|FG000|Overall Study|Death|0
5977277|NCT02143063|9564440|FG001|Overall Study|Death|1
6199911|NCT01483183|9859527|FG009|Overall Study|Physician Decision|0
6199912|NCT01483183|9859518|FG000|Overall Study|Withdrawal by Subject|0
6199913|NCT01483183|9859519|FG001|Overall Study|Withdrawal by Subject|0
6199914|NCT01483183|9859520|FG002|Overall Study|Withdrawal by Subject|0
6199915|NCT01483183|9859521|FG003|Overall Study|Withdrawal by Subject|0
6199916|NCT01483183|9859522|FG004|Overall Study|Withdrawal by Subject|0
6199917|NCT01483183|9859523|FG005|Overall Study|Withdrawal by Subject|0
6199918|NCT01483183|9859524|FG006|Overall Study|Withdrawal by Subject|0
6199919|NCT01483183|9859525|FG007|Overall Study|Withdrawal by Subject|0
6199920|NCT01483183|9859526|FG008|Overall Study|Withdrawal by Subject|0
5977278|NCT02143063|9564441|FG002|Overall Study|Death|1
5977279|NCT02017964|9564449|FG000|Overall Study|Patient deemed ineligible|1
5977280|NCT01968785|9564455|FG000|Overall Study|Withdrawal by Subject|1
5977281|NCT01968785|9564456|FG001|Overall Study|Withdrawal by Subject|0
5977282|NCT01956110|9564464|FG000|Overall Study|Protocol Violation|25
5977283|NCT01956110|9564465|FG001|Overall Study|Protocol Violation|11
6088777|NCT00678392|9699797|FG001|Overall Study|Adverse Event|6
6088778|NCT00678392|9699796|FG000|Overall Study|Death|280
6088779|NCT00678392|9699797|FG001|Overall Study|Death|269
6088780|NCT00678392|9699796|FG000|Overall Study|Lost to Follow-up|15
6088781|NCT00678392|9699797|FG001|Overall Study|Lost to Follow-up|13
6088782|NCT00678392|9699796|FG000|Overall Study|Objective Progression or Relapse|3
6088783|NCT00678392|9699797|FG001|Overall Study|Objective Progression or Relapse|8
6088784|NCT00678392|9699796|FG000|Overall Study|Sponsor's Decision|1
6088785|NCT00678392|9699797|FG001|Overall Study|Sponsor's Decision|2
6088786|NCT00678392|9699796|FG000|Overall Study|Withdrawal by Subject|4
6088787|NCT00678392|9699797|FG001|Overall Study|Withdrawal by Subject|4
6088788|NCT00678392|9699796|FG000|Overall Study|Randomized But Not Treated|2
6088789|NCT00678392|9699797|FG001|Overall Study|Randomized But Not Treated|7
6088790|NCT00678392|9699796|FG000|Overall Study|Other|56
6088791|NCT00678392|9699797|FG001|Overall Study|Other|53
6088792|NCT00678561|9699853|FG000|Overall Study|Adverse Event|0
6088793|NCT00678561|9699854|FG001|Overall Study|Adverse Event|1
6088794|NCT00678561|9699855|FG002|Overall Study|Adverse Event|1
6088795|NCT00678561|9699856|FG003|Overall Study|Adverse Event|0
6199921|NCT01483183|9859527|FG009|Overall Study|Withdrawal by Subject|1
6199922|NCT01483599|9859582|FG000|Controlled Period (CP) (up to Week 16)|Adverse Event|2
6199923|NCT01483599|9859583|FG001|Controlled Period (CP) (up to Week 16)|Adverse Event|0
6199924|NCT01483599|9859584|FG002|Controlled Period (CP) (up to Week 16)|Adverse Event|0
6199925|NCT01483599|9859585|FG003|Controlled Period (CP) (up to Week 16)|Adverse Event|1
6199926|NCT01483599|9859586|FG004|Controlled Period (CP) (up to Week 16)|Adverse Event|1
6199927|NCT01483599|9859587|FG005|Controlled Period (CP) (up to Week 16)|Adverse Event|4
6199928|NCT01483599|9859588|FG006|Controlled Period (CP) (up to Week 16)|Adverse Event|3
6088796|NCT00678561|9699857|FG004|Overall Study|Adverse Event|1
6088797|NCT00678561|9699858|FG005|Overall Study|Adverse Event|0
6088798|NCT00678561|9699859|FG006|Overall Study|Adverse Event|0
6088799|NCT00678561|9699860|FG007|Overall Study|Adverse Event|0
6088800|NCT00678561|9699853|FG000|Overall Study|Protocol Violation|0
6088801|NCT00678561|9699854|FG001|Overall Study|Protocol Violation|0
6088802|NCT00678561|9699855|FG002|Overall Study|Protocol Violation|0
6088803|NCT00678561|9699856|FG003|Overall Study|Protocol Violation|0
6088804|NCT00678561|9699857|FG004|Overall Study|Protocol Violation|1
6088805|NCT00678561|9699858|FG005|Overall Study|Protocol Violation|1
6088806|NCT00678561|9699859|FG006|Overall Study|Protocol Violation|0
6088807|NCT00678561|9699860|FG007|Overall Study|Protocol Violation|0
6088808|NCT00678561|9699853|FG000|Overall Study|Withdrawal by Subject|0
6088809|NCT00678561|9699854|FG001|Overall Study|Withdrawal by Subject|0
6088810|NCT00678561|9699855|FG002|Overall Study|Withdrawal by Subject|0
6088811|NCT00678561|9699856|FG003|Overall Study|Withdrawal by Subject|0
6088812|NCT00678561|9699857|FG004|Overall Study|Withdrawal by Subject|0
6088813|NCT00678561|9699858|FG005|Overall Study|Withdrawal by Subject|0
6088814|NCT00678561|9699859|FG006|Overall Study|Withdrawal by Subject|0
6088815|NCT00678561|9699860|FG007|Overall Study|Withdrawal by Subject|1
6088816|NCT00678587|9699887|FG000|Overall Study|Adverse Event|3
6088817|NCT00678587|9699888|FG001|Overall Study|Adverse Event|3
6088818|NCT00678587|9699887|FG000|Overall Study|Lack of Efficacy|1
6088819|NCT00678587|9699888|FG001|Overall Study|Lack of Efficacy|0
6088820|NCT00678587|9699887|FG000|Overall Study|Protocol Violation|2
6088821|NCT00678587|9699888|FG001|Overall Study|Protocol Violation|1
6088822|NCT00678587|9699887|FG000|Overall Study|Study Closed/Terminated|1
6088823|NCT00678587|9699888|FG001|Overall Study|Study Closed/Terminated|0
6088824|NCT00678587|9699887|FG000|Overall Study|Lost to Follow-up|3
6088825|NCT00678587|9699888|FG001|Overall Study|Lost to Follow-up|5
6088826|NCT00678587|9699887|FG000|Overall Study|Investigator Discretion|2
6088827|NCT00678587|9699888|FG001|Overall Study|Investigator Discretion|6
6088828|NCT00678587|9699887|FG000|Overall Study|Withdrew Consent|8
6088829|NCT00678587|9699888|FG001|Overall Study|Withdrew Consent|3
6088830|NCT00678639|9699897|FG000|Overall Study|Lost to Follow-up at 30 days|2
6088831|NCT00678639|9699898|FG001|Overall Study|Lost to Follow-up at 30 days|0
6088832|NCT00678652|9699909|FG000|Overall Study|Protocol Violation|2
6088833|NCT00678652|9699910|FG001|Overall Study|Protocol Violation|0
6088834|NCT00678652|9699911|FG002|Overall Study|Protocol Violation|0
6088835|NCT00678652|9699912|FG003|Overall Study|Protocol Violation|0
6088836|NCT00678652|9699909|FG000|Overall Study|Pregnancy|0
6088837|NCT00678652|9699910|FG001|Overall Study|Pregnancy|0
6088838|NCT00678652|9699911|FG002|Overall Study|Pregnancy|1
6088839|NCT00678652|9699912|FG003|Overall Study|Pregnancy|0
6088840|NCT00678652|9699909|FG000|Overall Study|Relocation|1
6088841|NCT00678652|9699910|FG001|Overall Study|Relocation|0
6088842|NCT00678652|9699911|FG002|Overall Study|Relocation|0
6088843|NCT00678652|9699912|FG003|Overall Study|Relocation|0
6088844|NCT00678691|9699924|FG000|Overall Study|Adverse Event|6
6088845|NCT00678691|9699925|FG001|Overall Study|Adverse Event|4
6088846|NCT00678795|9699933|FG000|Overall Study|Adverse Event|7
6088847|NCT00678795|9699934|FG001|Overall Study|Adverse Event|3
6088848|NCT00678795|9699933|FG000|Overall Study|Withdrawal by Subject|3
6088849|NCT00678795|9699934|FG001|Overall Study|Withdrawal by Subject|0
6088850|NCT00678795|9699933|FG000|Overall Study|Protocol Violation|0
6088851|NCT00678795|9699934|FG001|Overall Study|Protocol Violation|1
6088852|NCT00678795|9699933|FG000|Overall Study|Lost to Follow-up|0
6199929|NCT01483599|9859589|FG007|Controlled Period (CP) (up to Week 16)|Adverse Event|0
6088853|NCT00678795|9699934|FG001|Overall Study|Lost to Follow-up|1
6088854|NCT00678795|9699933|FG000|Overall Study|Lack of Efficacy|1
6088855|NCT00678795|9699934|FG001|Overall Study|Lack of Efficacy|1
6088856|NCT00678886|9699965|FG000|Overall Study|Withdrawal by Subject|0
6088857|NCT00678886|9699966|FG001|Overall Study|Withdrawal by Subject|0
6088858|NCT00678886|9699967|FG002|Overall Study|Withdrawal by Subject|4
6088859|NCT00678886|9699968|FG003|Overall Study|Withdrawal by Subject|6
6088860|NCT00678886|9699965|FG000|Overall Study|Physician Decision|0
6088861|NCT00678886|9699966|FG001|Overall Study|Physician Decision|0
6088862|NCT00678886|9699967|FG002|Overall Study|Physician Decision|1
6088863|NCT00678886|9699968|FG003|Overall Study|Physician Decision|1
6088864|NCT00678886|9699965|FG000|Overall Study|Lost to Follow-up|0
6088865|NCT00678886|9699966|FG001|Overall Study|Lost to Follow-up|0
6088866|NCT00678886|9699967|FG002|Overall Study|Lost to Follow-up|3
6088867|NCT00678886|9699968|FG003|Overall Study|Lost to Follow-up|2
6088868|NCT00678886|9699965|FG000|Overall Study|Other|0
6088869|NCT00678886|9699966|FG001|Overall Study|Other|0
6088870|NCT00678886|9699967|FG002|Overall Study|Other|1
6088871|NCT00678886|9699968|FG003|Overall Study|Other|0
6088872|NCT00678899|9699977|FG000|Overall Study|Adverse Event|1
6088873|NCT00679029|9699982|FG000|Overall Study|Adverse Event|3
6088874|NCT00679029|9699982|FG000|Overall Study|Withdrawal by Subject|1
6088875|NCT00679029|9699982|FG000|Overall Study|Lost to Follow-up|1
6088876|NCT00679042|9699986|FG000|Transplant + 1 Year Follow Up|Withdrawal by Subject|2
6088877|NCT00679042|9699986|FG000|5-Year Follow Up|In follow-up (ongoing)|6
6088878|NCT00679042|9699986|FG000|5-Year Follow Up|Death|1
6088879|NCT00679042|9699986|FG000|5-Year Follow Up|Did not consent to continue into 10-year follow up|7
6088880|NCT00679042|9699986|FG000|10-Year Follow Up|In follow-up (ongoing)|5
6088881|NCT00679055|9699992|FG000|Overall Study|Adverse Event|0
6088882|NCT00679055|9699993|FG001|Overall Study|Adverse Event|1
6088883|NCT00679055|9699992|FG000|Overall Study|Other|0
6088884|NCT00679055|9699993|FG001|Overall Study|Other|3
6088885|NCT00679055|9699992|FG000|Overall Study|Study Terminated|2
6088886|NCT00679055|9699993|FG001|Overall Study|Study Terminated|1
6088887|NCT00679081|9699999|FG000|Overall Study|Lost to Follow-up|1
6088888|NCT00679172|9700012|FG000|Overall Study|Non-compliance|1
6088889|NCT00679172|9700013|FG001|Overall Study|Non-compliance|1
6088890|NCT00679172|9700014|FG002|Overall Study|Non-compliance|0
6088891|NCT00679172|9700015|FG003|Overall Study|Non-compliance|1
6088892|NCT00679172|9700016|FG004|Overall Study|Non-compliance|0
6088893|NCT00679172|9700012|FG000|Overall Study|Other not specified|0
6088894|NCT00679172|9700013|FG001|Overall Study|Other not specified|0
6088895|NCT00679172|9700014|FG002|Overall Study|Other not specified|1
6199930|NCT01483599|9859590|FG008|Controlled Period (CP) (up to Week 16)|Adverse Event|0
6199931|NCT01483599|9859591|FG009|Controlled Period (CP) (up to Week 16)|Adverse Event|0
6199932|NCT01483599|9859592|FG010|Controlled Period (CP) (up to Week 16)|Adverse Event|0
6199933|NCT01483599|9859593|FG011|Controlled Period (CP) (up to Week 16)|Adverse Event|0
6199934|NCT01483599|9859594|FG012|Controlled Period (CP) (up to Week 16)|Adverse Event|0
6199935|NCT01483599|9859595|FG013|Controlled Period (CP) (up to Week 16)|Adverse Event|0
6199936|NCT01483599|9859582|FG000|Controlled Period (CP) (up to Week 16)|Lost to Follow-up|0
6199937|NCT01483599|9859583|FG001|Controlled Period (CP) (up to Week 16)|Lost to Follow-up|1
6199938|NCT01483599|9859584|FG002|Controlled Period (CP) (up to Week 16)|Lost to Follow-up|0
6088896|NCT00679172|9700015|FG003|Overall Study|Other not specified|0
6088897|NCT00679172|9700016|FG004|Overall Study|Other not specified|0
6088898|NCT00679211|9700031|FG000|Overall Study|Progressive disease|82
6088899|NCT00679211|9700031|FG000|Overall Study|Adverse Event|7
6088900|NCT00679211|9700031|FG000|Overall Study|Withdrawal by Subject|2
6088901|NCT00679211|9700031|FG000|Overall Study|Physician Decision|5
6088902|NCT00679211|9700031|FG000|Overall Study|Refused to undergo protocol procedures|1
6088903|NCT00679211|9700031|FG000|Overall Study|Transferred to extension study TDM4529g|12
6088904|NCT00679211|9700031|FG000|Overall Study|Other|1
6088905|NCT00679263|9700040|FG000|Visit 2/Dose 1|Adverse Event|1
6088906|NCT00679263|9700041|FG001|Visit 2/Dose 1|Adverse Event|0
6088907|NCT00679263|9700042|FG002|Visit 2/Dose 1|Adverse Event|0
6088908|NCT00679263|9700040|FG000|Visit 2/Dose 1|subject not compliance|1
6088909|NCT00679263|9700041|FG001|Visit 2/Dose 1|subject not compliance|1
6088910|NCT00679263|9700042|FG002|Visit 2/Dose 1|subject not compliance|0
6088911|NCT00679289|9700053|FG000|Overall Study|Progressive disease|4
6088912|NCT00679289|9700054|FG001|Overall Study|Progressive disease|5
6088913|NCT00679289|9700055|FG002|Overall Study|Progressive disease|18
6088914|NCT00679289|9700053|FG000|Overall Study|Withdrawal by Subject|0
6088915|NCT00679289|9700054|FG001|Overall Study|Withdrawal by Subject|1
6088916|NCT00679289|9700055|FG002|Overall Study|Withdrawal by Subject|1
6088917|NCT00679289|9700053|FG000|Overall Study|Adverse Event|0
6088918|NCT00679289|9700054|FG001|Overall Study|Adverse Event|0
6088919|NCT00679289|9700055|FG002|Overall Study|Adverse Event|3
6088920|NCT00679289|9700053|FG000|Overall Study|Physician Decision|1
6088921|NCT00679289|9700054|FG001|Overall Study|Physician Decision|0
6088922|NCT00679289|9700055|FG002|Overall Study|Physician Decision|1
6088923|NCT00679302|9700067|FG000|Overall Study|Lost to Follow-up|8
6088924|NCT00679302|9700068|FG001|Overall Study|Lost to Follow-up|4
6088925|NCT00679341|9700076|FG000|Overall Study|Disease progression|42
6088926|NCT00679341|9700077|FG001|Overall Study|Disease progression|36
6088927|NCT00679341|9700076|FG000|Overall Study|Adverse Event|5
6088928|NCT00679341|9700077|FG001|Overall Study|Adverse Event|6
6088929|NCT00679341|9700076|FG000|Overall Study|Subject/guardian decision to discontinue|3
6088930|NCT00679341|9700077|FG001|Overall Study|Subject/guardian decision to discontinue|0
6088931|NCT00679341|9700076|FG000|Overall Study|Death|1
6088932|NCT00679341|9700077|FG001|Overall Study|Death|1
6088933|NCT00679341|9700076|FG000|Overall Study|Other|1
6088934|NCT00679341|9700077|FG001|Overall Study|Other|0
6088935|NCT00679341|9700076|FG000|Overall Study|Physician Decision|1
6088936|NCT00679341|9700077|FG001|Overall Study|Physician Decision|0
6088937|NCT00679341|9700076|FG000|Overall Study|Not treated|0
6088938|NCT00679341|9700077|FG001|Overall Study|Not treated|2
6088939|NCT00679341|9700076|FG000|Overall Study|Physician/patient decision to withdraw|0
6088940|NCT00679341|9700077|FG001|Overall Study|Physician/patient decision to withdraw|6
6088941|NCT00679354|9700084|FG000|Overall Study|Death|3
6199939|NCT01483599|9859585|FG003|Controlled Period (CP) (up to Week 16)|Lost to Follow-up|1
6199940|NCT01483599|9859586|FG004|Controlled Period (CP) (up to Week 16)|Lost to Follow-up|0
6199941|NCT01483599|9859587|FG005|Controlled Period (CP) (up to Week 16)|Lost to Follow-up|0
6199942|NCT01483599|9859588|FG006|Controlled Period (CP) (up to Week 16)|Lost to Follow-up|1
6199943|NCT01483599|9859589|FG007|Controlled Period (CP) (up to Week 16)|Lost to Follow-up|0
6199944|NCT01483599|9859590|FG008|Controlled Period (CP) (up to Week 16)|Lost to Follow-up|0
6199945|NCT01483599|9859591|FG009|Controlled Period (CP) (up to Week 16)|Lost to Follow-up|0
6199946|NCT01483599|9859592|FG010|Controlled Period (CP) (up to Week 16)|Lost to Follow-up|0
6199947|NCT01483599|9859593|FG011|Controlled Period (CP) (up to Week 16)|Lost to Follow-up|0
6199948|NCT01483599|9859594|FG012|Controlled Period (CP) (up to Week 16)|Lost to Follow-up|0
6199949|NCT01483599|9859595|FG013|Controlled Period (CP) (up to Week 16)|Lost to Follow-up|0
6199950|NCT01483599|9859582|FG000|Controlled Period (CP) (up to Week 16)|Lack of Efficacy|1
6199951|NCT01483599|9859583|FG001|Controlled Period (CP) (up to Week 16)|Lack of Efficacy|0
6199952|NCT01483599|9859584|FG002|Controlled Period (CP) (up to Week 16)|Lack of Efficacy|0
6199953|NCT01483599|9859585|FG003|Controlled Period (CP) (up to Week 16)|Lack of Efficacy|0
6199954|NCT01483599|9859586|FG004|Controlled Period (CP) (up to Week 16)|Lack of Efficacy|0
6199955|NCT01483599|9859587|FG005|Controlled Period (CP) (up to Week 16)|Lack of Efficacy|0
6199956|NCT01483599|9859588|FG006|Controlled Period (CP) (up to Week 16)|Lack of Efficacy|0
6199957|NCT01483599|9859589|FG007|Controlled Period (CP) (up to Week 16)|Lack of Efficacy|0
6199958|NCT01483599|9859590|FG008|Controlled Period (CP) (up to Week 16)|Lack of Efficacy|0
6199959|NCT01483599|9859591|FG009|Controlled Period (CP) (up to Week 16)|Lack of Efficacy|0
6199960|NCT01483599|9859592|FG010|Controlled Period (CP) (up to Week 16)|Lack of Efficacy|0
6199961|NCT01483599|9859593|FG011|Controlled Period (CP) (up to Week 16)|Lack of Efficacy|0
6199962|NCT01483599|9859594|FG012|Controlled Period (CP) (up to Week 16)|Lack of Efficacy|0
6199963|NCT01483599|9859595|FG013|Controlled Period (CP) (up to Week 16)|Lack of Efficacy|0
6277064|NCT02238080|9983718|FG000|Overall Study|Other|4
6277065|NCT02238379|9983724|FG000|Overall Study|Lost to Follow-up|1
6277066|NCT02238379|9983725|FG001|Overall Study|Lost to Follow-up|0
6277067|NCT02238483|9983733|FG000|Overall Study|Withdrawal by Subject|2
6277068|NCT02238483|9983734|FG001|Overall Study|Withdrawal by Subject|7
6277069|NCT02238483|9983733|FG000|Overall Study|Lost to Follow-up|1
6277070|NCT02238483|9983734|FG001|Overall Study|Lost to Follow-up|1
6277071|NCT02238483|9983733|FG000|Overall Study|Protocol Violation|1
6277072|NCT02238483|9983734|FG001|Overall Study|Protocol Violation|2
6277073|NCT02238483|9983733|FG000|Overall Study|Death|1
6277074|NCT02238483|9983734|FG001|Overall Study|Death|0
6277075|NCT02238483|9983733|FG000|Overall Study|Adverse Event|7
6277076|NCT02238483|9983734|FG001|Overall Study|Adverse Event|3
6277077|NCT02238483|9983733|FG000|Overall Study|Withdrawn due to physician decision|1
6277078|NCT02238483|9983734|FG001|Overall Study|Withdrawn due to physician decision|0
6277079|NCT02238483|9983733|FG000|Overall Study|Completion status not recorded|1
6277080|NCT02238483|9983734|FG001|Overall Study|Completion status not recorded|1
6277081|NCT02238483|9983733|FG000|Overall Study|Illness in family member|1
6277082|NCT02238483|9983734|FG001|Overall Study|Illness in family member|0
6277083|NCT02238626|9983744|FG000|Overall Study|Adverse Event|3
6277084|NCT02238626|9983745|FG001|Overall Study|Adverse Event|5
6277085|NCT02238626|9983746|FG002|Overall Study|Adverse Event|0
6277086|NCT02238626|9983747|FG003|Overall Study|Adverse Event|3
6277087|NCT02238626|9983744|FG000|Overall Study|Lost to Follow-up|2
6277088|NCT02238626|9983745|FG001|Overall Study|Lost to Follow-up|4
6277089|NCT02238626|9983746|FG002|Overall Study|Lost to Follow-up|2
6277090|NCT02238626|9983747|FG003|Overall Study|Lost to Follow-up|2
6277091|NCT02238626|9983744|FG000|Overall Study|Withdrawal by Subject|0
6277092|NCT02238626|9983745|FG001|Overall Study|Withdrawal by Subject|3
6277093|NCT02238626|9983746|FG002|Overall Study|Withdrawal by Subject|0
6277094|NCT02238626|9983747|FG003|Overall Study|Withdrawal by Subject|1
6277095|NCT02238626|9983744|FG000|Overall Study|Death|0
6277096|NCT02238626|9983745|FG001|Overall Study|Death|0
6277097|NCT02238626|9983746|FG002|Overall Study|Death|1
6277098|NCT02238626|9983747|FG003|Overall Study|Death|1
6277099|NCT02238626|9983744|FG000|Overall Study|Other|0
6277100|NCT02238626|9983745|FG001|Overall Study|Other|2
6277101|NCT02238626|9983746|FG002|Overall Study|Other|0
6277102|NCT02238626|9983747|FG003|Overall Study|Other|0
6088942|NCT00679354|9700084|FG000|Overall Study|Lack of Efficacy|22
6088943|NCT00679354|9700084|FG000|Overall Study|Physician Decision|4
6199964|NCT01483599|9859582|FG000|Controlled Period (CP) (up to Week 16)|Other|0
6199965|NCT01483599|9859583|FG001|Controlled Period (CP) (up to Week 16)|Other|2
6277103|NCT02239094|9983794|FG000|Overall Study|Withdrawal by Subject|1
6277104|NCT02239094|9983794|FG000|Overall Study|Remitted before started|1
6277105|NCT02239120|9983800|FG000|Overall Study|Death|56
6277106|NCT02239120|9983801|FG001|Overall Study|Death|58
6277107|NCT02239120|9983800|FG000|Overall Study|Lost to Follow-up|19
6277108|NCT02239120|9983801|FG001|Overall Study|Lost to Follow-up|14
6277109|NCT02239224|9983811|FG000|Overall Study|Administrative|0
6277110|NCT02239224|9983812|FG001|Overall Study|Administrative|0
6277111|NCT02239224|9983813|FG002|Overall Study|Administrative|3
6277112|NCT02239224|9983814|FG003|Overall Study|Administrative|1
6277113|NCT02239263|9983824|FG000|Overall Study|Protocol Violation|6
6277114|NCT02239328|9983834|FG000|Overall Study|Benign disease noted at time of surgery|6
6277115|NCT02239328|9983834|FG000|Overall Study|Equipment or website malfunction|2
6277116|NCT02239510|9983844|FG000|Overall Study|Lost to Follow-up|2
6277117|NCT02239510|9983845|FG001|Overall Study|Lost to Follow-up|1
6277118|NCT02239536|9983853|FG000|Overall Study|Non-neoplastic polyp|23
6277119|NCT02239536|9983854|FG001|Overall Study|Non-neoplastic polyp|17
6277120|NCT02239601|9983889|FG000|Overall Study|Withdrawal by Subject|3
6277121|NCT02239601|9983890|FG001|Overall Study|Withdrawal by Subject|4
6277122|NCT02239601|9983889|FG000|Overall Study|Protocol Violation|4
6277123|NCT02239601|9983890|FG001|Overall Study|Protocol Violation|2
5977284|NCT01956110|9564464|FG000|Overall Study|Adverse Event|9
5977285|NCT01956110|9564465|FG001|Overall Study|Adverse Event|10
5977286|NCT01956110|9564464|FG000|Overall Study|Personal reasons|1
5977287|NCT01956110|9564465|FG001|Overall Study|Personal reasons|1
5977288|NCT01648023|9564474|FG000|Overall Study|Screen Fail Post Randomization|1
5977289|NCT01648023|9564475|FG001|Overall Study|Screen Fail Post Randomization|2
5977290|NCT01083433|9564498|FG000|Overall Study|Lost to Follow-up|2
5977291|NCT01083433|9564499|FG001|Overall Study|Lost to Follow-up|1
5977292|NCT01083433|9564500|FG002|Overall Study|Lost to Follow-up|1
5977293|NCT01083433|9564498|FG000|Overall Study|Withdrawal by Subject|0
5977294|NCT01083433|9564499|FG001|Overall Study|Withdrawal by Subject|5
5977295|NCT01083433|9564500|FG002|Overall Study|Withdrawal by Subject|3
5977296|NCT01083433|9564498|FG000|Overall Study|Pregnancy|0
5977297|NCT01083433|9564499|FG001|Overall Study|Pregnancy|0
5977298|NCT01083433|9564500|FG002|Overall Study|Pregnancy|1
5977299|NCT00787176|9564516|FG000|Overall Study|Low quality fetal heart rate tracing|7
5977300|NCT00787176|9564517|FG001|Overall Study|Low quality fetal heart rate tracing|3
5977301|NCT00787176|9564518|FG002|Overall Study|Low quality fetal heart rate tracing|6
5977302|NCT00787176|9564519|FG003|Overall Study|Low quality fetal heart rate tracing|5
5977303|NCT00352534|9564532|FG000|Initial Staging|Ineligible|8
5977304|NCT00352534|9564533|FG001|Initial Staging|Ineligible|9
5977305|NCT00352534|9564534|FG002|Initial Staging|Ineligible|0
5977306|NCT00352534|9564535|FG003|Initial Staging|Ineligible|0
5977307|NCT00352534|9564536|FG004|Initial Staging|Ineligible|0
5977308|NCT00352534|9564537|FG005|Initial Staging|Ineligible|0
5977309|NCT00352534|9564538|FG006|Initial Staging|Ineligible|0
5977310|NCT00352534|9564532|FG000|Final Risk Group Assignment|Lack of Efficacy|0
5977311|NCT00352534|9564533|FG001|Final Risk Group Assignment|Lack of Efficacy|0
5977312|NCT00352534|9564534|FG002|Final Risk Group Assignment|Lack of Efficacy|0
5977313|NCT00352534|9564535|FG003|Final Risk Group Assignment|Lack of Efficacy|2
5977314|NCT00352534|9564536|FG004|Final Risk Group Assignment|Lack of Efficacy|1
5977315|NCT00352534|9564537|FG005|Final Risk Group Assignment|Lack of Efficacy|19
5977316|NCT00352534|9564538|FG006|Final Risk Group Assignment|Lack of Efficacy|0
5977317|NCT00352534|9564532|FG000|Final Risk Group Assignment|Physician Decision|0
5977318|NCT00352534|9564533|FG001|Final Risk Group Assignment|Physician Decision|0
5977319|NCT00352534|9564534|FG002|Final Risk Group Assignment|Physician Decision|0
5977320|NCT00352534|9564535|FG003|Final Risk Group Assignment|Physician Decision|0
6277124|NCT02239640|9983901|FG000|Overall Study|Withdrawal by Subject|3
5977321|NCT00352534|9564536|FG004|Final Risk Group Assignment|Physician Decision|0
5977322|NCT00352534|9564537|FG005|Final Risk Group Assignment|Physician Decision|8
5977323|NCT00352534|9564538|FG006|Final Risk Group Assignment|Physician Decision|0
5977324|NCT00352534|9564532|FG000|Final Risk Group Assignment|Withdrawal by Subject|0
5977325|NCT00352534|9564533|FG001|Final Risk Group Assignment|Withdrawal by Subject|0
5977326|NCT00352534|9564534|FG002|Final Risk Group Assignment|Withdrawal by Subject|0
5977327|NCT00352534|9564535|FG003|Final Risk Group Assignment|Withdrawal by Subject|0
5977328|NCT00352534|9564536|FG004|Final Risk Group Assignment|Withdrawal by Subject|0
5977329|NCT00352534|9564537|FG005|Final Risk Group Assignment|Withdrawal by Subject|3
5977330|NCT00352534|9564538|FG006|Final Risk Group Assignment|Withdrawal by Subject|0
5977331|NCT00352534|9564532|FG000|Final Risk Group Assignment|Ineligible|0
5977332|NCT00352534|9564533|FG001|Final Risk Group Assignment|Ineligible|0
6199966|NCT01483599|9859584|FG002|Controlled Period (CP) (up to Week 16)|Other|0
6199967|NCT01483599|9859585|FG003|Controlled Period (CP) (up to Week 16)|Other|1
6199968|NCT01483599|9859586|FG004|Controlled Period (CP) (up to Week 16)|Other|1
6199969|NCT01483599|9859587|FG005|Controlled Period (CP) (up to Week 16)|Other|0
6199970|NCT01483599|9859588|FG006|Controlled Period (CP) (up to Week 16)|Other|0
6199971|NCT01483599|9859589|FG007|Controlled Period (CP) (up to Week 16)|Other|0
6277125|NCT02239640|9983901|FG000|Overall Study|Lost to Follow-up|72
6199972|NCT01483599|9859590|FG008|Controlled Period (CP) (up to Week 16)|Other|0
6199973|NCT01483599|9859591|FG009|Controlled Period (CP) (up to Week 16)|Other|0
6199974|NCT01483599|9859592|FG010|Controlled Period (CP) (up to Week 16)|Other|0
6199975|NCT01483599|9859593|FG011|Controlled Period (CP) (up to Week 16)|Other|0
6199976|NCT01483599|9859594|FG012|Controlled Period (CP) (up to Week 16)|Other|0
6199977|NCT01483599|9859595|FG013|Controlled Period (CP) (up to Week 16)|Other|0
6199978|NCT01483599|9859582|FG000|After Controlled Period(Week 16-Week 40)|Death|0
6199979|NCT01483599|9859583|FG001|After Controlled Period(Week 16-Week 40)|Death|0
6199980|NCT01483599|9859584|FG002|After Controlled Period(Week 16-Week 40)|Death|0
6199981|NCT01483599|9859585|FG003|After Controlled Period(Week 16-Week 40)|Death|0
6199982|NCT01483599|9859586|FG004|After Controlled Period(Week 16-Week 40)|Death|0
6199983|NCT01483599|9859587|FG005|After Controlled Period(Week 16-Week 40)|Death|0
6199984|NCT01483599|9859588|FG006|After Controlled Period(Week 16-Week 40)|Death|0
6199985|NCT01483599|9859589|FG007|After Controlled Period(Week 16-Week 40)|Death|0
6199986|NCT01483599|9859590|FG008|After Controlled Period(Week 16-Week 40)|Death|1
6199987|NCT01483599|9859591|FG009|After Controlled Period(Week 16-Week 40)|Death|0
6199988|NCT01483599|9859592|FG010|After Controlled Period(Week 16-Week 40)|Death|0
6199989|NCT01483599|9859593|FG011|After Controlled Period(Week 16-Week 40)|Death|0
6199990|NCT01483599|9859594|FG012|After Controlled Period(Week 16-Week 40)|Death|0
6199991|NCT01483599|9859595|FG013|After Controlled Period(Week 16-Week 40)|Death|0
6199992|NCT01483599|9859582|FG000|After Controlled Period(Week 16-Week 40)|Adverse Event|0
6199993|NCT01483599|9859583|FG001|After Controlled Period(Week 16-Week 40)|Adverse Event|0
6199994|NCT01483599|9859584|FG002|After Controlled Period(Week 16-Week 40)|Adverse Event|0
6199995|NCT01483599|9859585|FG003|After Controlled Period(Week 16-Week 40)|Adverse Event|0
6199996|NCT01483599|9859586|FG004|After Controlled Period(Week 16-Week 40)|Adverse Event|0
6199997|NCT01483599|9859587|FG005|After Controlled Period(Week 16-Week 40)|Adverse Event|0
6199998|NCT01483599|9859588|FG006|After Controlled Period(Week 16-Week 40)|Adverse Event|0
6199999|NCT01483599|9859589|FG007|After Controlled Period(Week 16-Week 40)|Adverse Event|1
6200000|NCT01483599|9859590|FG008|After Controlled Period(Week 16-Week 40)|Adverse Event|1
6200001|NCT01483599|9859591|FG009|After Controlled Period(Week 16-Week 40)|Adverse Event|0
6200002|NCT01483599|9859592|FG010|After Controlled Period(Week 16-Week 40)|Adverse Event|0
6200003|NCT01483599|9859593|FG011|After Controlled Period(Week 16-Week 40)|Adverse Event|0
6200004|NCT01483599|9859594|FG012|After Controlled Period(Week 16-Week 40)|Adverse Event|1
6200005|NCT01483599|9859595|FG013|After Controlled Period(Week 16-Week 40)|Adverse Event|1
6200006|NCT01483599|9859582|FG000|After Controlled Period(Week 16-Week 40)|Lost to Follow-up|0
6200007|NCT01483599|9859583|FG001|After Controlled Period(Week 16-Week 40)|Lost to Follow-up|0
6200008|NCT01483599|9859584|FG002|After Controlled Period(Week 16-Week 40)|Lost to Follow-up|0
6200009|NCT01483599|9859585|FG003|After Controlled Period(Week 16-Week 40)|Lost to Follow-up|0
6200010|NCT01483599|9859586|FG004|After Controlled Period(Week 16-Week 40)|Lost to Follow-up|0
6200011|NCT01483599|9859587|FG005|After Controlled Period(Week 16-Week 40)|Lost to Follow-up|0
6200012|NCT01483599|9859588|FG006|After Controlled Period(Week 16-Week 40)|Lost to Follow-up|0
6200013|NCT01483599|9859589|FG007|After Controlled Period(Week 16-Week 40)|Lost to Follow-up|0
6200014|NCT01483599|9859590|FG008|After Controlled Period(Week 16-Week 40)|Lost to Follow-up|1
6200015|NCT01483599|9859591|FG009|After Controlled Period(Week 16-Week 40)|Lost to Follow-up|0
6200016|NCT01483599|9859592|FG010|After Controlled Period(Week 16-Week 40)|Lost to Follow-up|0
6200017|NCT01483599|9859593|FG011|After Controlled Period(Week 16-Week 40)|Lost to Follow-up|1
6200018|NCT01483599|9859594|FG012|After Controlled Period(Week 16-Week 40)|Lost to Follow-up|0
6200019|NCT01483599|9859595|FG013|After Controlled Period(Week 16-Week 40)|Lost to Follow-up|1
6200020|NCT01483599|9859582|FG000|After Controlled Period(Week 16-Week 40)|Withdrawal by Subject|0
6200021|NCT01483599|9859583|FG001|After Controlled Period(Week 16-Week 40)|Withdrawal by Subject|0
6200022|NCT01483599|9859584|FG002|After Controlled Period(Week 16-Week 40)|Withdrawal by Subject|0
6200023|NCT01483599|9859585|FG003|After Controlled Period(Week 16-Week 40)|Withdrawal by Subject|0
6200024|NCT01483599|9859586|FG004|After Controlled Period(Week 16-Week 40)|Withdrawal by Subject|0
6200025|NCT01483599|9859587|FG005|After Controlled Period(Week 16-Week 40)|Withdrawal by Subject|0
6200026|NCT01483599|9859588|FG006|After Controlled Period(Week 16-Week 40)|Withdrawal by Subject|0
6200027|NCT01483599|9859589|FG007|After Controlled Period(Week 16-Week 40)|Withdrawal by Subject|0
6200028|NCT01483599|9859590|FG008|After Controlled Period(Week 16-Week 40)|Withdrawal by Subject|1
6200029|NCT01483599|9859591|FG009|After Controlled Period(Week 16-Week 40)|Withdrawal by Subject|0
6200030|NCT01483599|9859592|FG010|After Controlled Period(Week 16-Week 40)|Withdrawal by Subject|2
6200031|NCT01483599|9859593|FG011|After Controlled Period(Week 16-Week 40)|Withdrawal by Subject|0
6200032|NCT01483599|9859594|FG012|After Controlled Period(Week 16-Week 40)|Withdrawal by Subject|0
6200033|NCT01483599|9859595|FG013|After Controlled Period(Week 16-Week 40)|Withdrawal by Subject|1
6200034|NCT01483599|9859582|FG000|After Controlled Period(Week 16-Week 40)|Lack of Efficacy|0
6200035|NCT01483599|9859583|FG001|After Controlled Period(Week 16-Week 40)|Lack of Efficacy|0
6200036|NCT01483599|9859584|FG002|After Controlled Period(Week 16-Week 40)|Lack of Efficacy|0
6277126|NCT02239640|9983901|FG000|Overall Study|Death|142
6277127|NCT02239679|9983914|FG000|Overall Study|Lost to Follow-up|1
6277128|NCT02239679|9983915|FG001|Overall Study|Lost to Follow-up|0
6277129|NCT02239679|9983916|FG002|Overall Study|Lost to Follow-up|0
6277130|NCT02239679|9983914|FG000|Overall Study|Withdrawal by Subject|2
6200037|NCT01483599|9859585|FG003|After Controlled Period(Week 16-Week 40)|Lack of Efficacy|0
6200038|NCT01483599|9859586|FG004|After Controlled Period(Week 16-Week 40)|Lack of Efficacy|0
6200039|NCT01483599|9859587|FG005|After Controlled Period(Week 16-Week 40)|Lack of Efficacy|0
6200040|NCT01483599|9859588|FG006|After Controlled Period(Week 16-Week 40)|Lack of Efficacy|0
6200041|NCT01483599|9859589|FG007|After Controlled Period(Week 16-Week 40)|Lack of Efficacy|0
6200042|NCT01483599|9859590|FG008|After Controlled Period(Week 16-Week 40)|Lack of Efficacy|5
6200043|NCT01483599|9859591|FG009|After Controlled Period(Week 16-Week 40)|Lack of Efficacy|0
6200044|NCT01483599|9859592|FG010|After Controlled Period(Week 16-Week 40)|Lack of Efficacy|0
6200045|NCT01483599|9859593|FG011|After Controlled Period(Week 16-Week 40)|Lack of Efficacy|0
6200046|NCT01483599|9859594|FG012|After Controlled Period(Week 16-Week 40)|Lack of Efficacy|1
6200047|NCT01483599|9859595|FG013|After Controlled Period(Week 16-Week 40)|Lack of Efficacy|4
6200048|NCT01483599|9859582|FG000|After Controlled Period(Week 16-Week 40)|Other|0
6200049|NCT01483599|9859583|FG001|After Controlled Period(Week 16-Week 40)|Other|0
6200050|NCT01483599|9859584|FG002|After Controlled Period(Week 16-Week 40)|Other|0
6200051|NCT01483599|9859585|FG003|After Controlled Period(Week 16-Week 40)|Other|0
6200052|NCT01483599|9859586|FG004|After Controlled Period(Week 16-Week 40)|Other|0
6200053|NCT01483599|9859587|FG005|After Controlled Period(Week 16-Week 40)|Other|0
6200054|NCT01483599|9859588|FG006|After Controlled Period(Week 16-Week 40)|Other|0
6200055|NCT01483599|9859589|FG007|After Controlled Period(Week 16-Week 40)|Other|1
6200056|NCT01483599|9859590|FG008|After Controlled Period(Week 16-Week 40)|Other|0
6200057|NCT01483599|9859591|FG009|After Controlled Period(Week 16-Week 40)|Other|4
6200058|NCT01483599|9859592|FG010|After Controlled Period(Week 16-Week 40)|Other|0
6200059|NCT01483599|9859593|FG011|After Controlled Period(Week 16-Week 40)|Other|0
6200060|NCT01483599|9859594|FG012|After Controlled Period(Week 16-Week 40)|Other|1
6277131|NCT02239679|9983915|FG001|Overall Study|Withdrawal by Subject|3
6277132|NCT02239679|9983916|FG002|Overall Study|Withdrawal by Subject|1
6277133|NCT02239692|9983926|FG000|Overall Study|Incomplete colonoscopy|1
6277134|NCT02239692|9983927|FG001|Overall Study|Incomplete colonoscopy|2
6277135|NCT02239692|9983926|FG000|Overall Study|Adverse Event|0
6277136|NCT02239692|9983927|FG001|Overall Study|Adverse Event|1
6277137|NCT02239692|9983926|FG000|Overall Study|Physician Decision|0
6277138|NCT02239692|9983927|FG001|Overall Study|Physician Decision|1
6277139|NCT02239692|9983926|FG000|Overall Study|Lost to Follow-up|1
6277140|NCT02239692|9983927|FG001|Overall Study|Lost to Follow-up|4
6277141|NCT02239692|9983926|FG000|Overall Study|Withdrawal by Subject|3
6277142|NCT02239692|9983927|FG001|Overall Study|Withdrawal by Subject|5
6277143|NCT02239692|9983926|FG000|Overall Study|Other reason|1
6277144|NCT02239692|9983927|FG001|Overall Study|Other reason|0
6277145|NCT02239939|9983978|FG000|Overall Study|Adverse Event|1
6277146|NCT02239939|9983979|FG001|Overall Study|Adverse Event|0
6277147|NCT02239939|9983978|FG000|Overall Study|Withdrawal by Subject|1
6277148|NCT02239939|9983979|FG001|Overall Study|Withdrawal by Subject|1
6277149|NCT02239939|9983978|FG000|Overall Study|Lost to Follow-up|0
6277150|NCT02239939|9983979|FG001|Overall Study|Lost to Follow-up|1
6277151|NCT02239978|9983989|FG000|Overall Study|Withdrawal by Subject|2
6088944|NCT00679354|9700084|FG000|Overall Study|Ineligible|1
6277152|NCT02239978|9983990|FG001|Overall Study|Withdrawal by Subject|0
6277153|NCT02240108|9984015|FG000|Overall Study|Other than specified|8
6277154|NCT02240108|9984016|FG001|Overall Study|Other than specified|6
6277155|NCT02240108|9984015|FG000|Overall Study|Adverse Event|1
6277156|NCT02240108|9984016|FG001|Overall Study|Adverse Event|9
6277157|NCT02240108|9984015|FG000|Overall Study|Pregnancy|1
6277158|NCT02240108|9984016|FG001|Overall Study|Pregnancy|0
6277159|NCT02240108|9984015|FG000|Overall Study|Withdrawal by Subject|4
6277160|NCT02240108|9984016|FG001|Overall Study|Withdrawal by Subject|9
6277161|NCT02240108|9984015|FG000|Overall Study|StudyTerminated by Sponsor|0
6277162|NCT02240108|9984016|FG001|Overall Study|StudyTerminated by Sponsor|1
6277163|NCT02240121|9984024|FG000|Overall Study|Protocol Violation|1
6277164|NCT02240121|9984025|FG001|Overall Study|Protocol Violation|2
6277165|NCT02240121|9984024|FG000|Overall Study|Physician Decision|0
6277166|NCT02240121|9984025|FG001|Overall Study|Physician Decision|1
6277167|NCT02240121|9984024|FG000|Overall Study|Change in protocol interpretation|1
6277168|NCT02240121|9984025|FG001|Overall Study|Change in protocol interpretation|0
6277169|NCT02240121|9984024|FG000|Overall Study|Lack of Efficacy|2
6277170|NCT02240121|9984025|FG001|Overall Study|Lack of Efficacy|3
5977333|NCT00352534|9564534|FG002|Final Risk Group Assignment|Ineligible|3
5977334|NCT00352534|9564535|FG003|Final Risk Group Assignment|Ineligible|1
5977335|NCT00352534|9564536|FG004|Final Risk Group Assignment|Ineligible|0
6088945|NCT00679367|9700089|FG000|Overall Study|Adverse Event|7
6088946|NCT00679367|9700089|FG000|Overall Study|inability to swallow oral drugs|1
6088947|NCT00679367|9700089|FG000|Overall Study|Lack of Efficacy|3
6088948|NCT00679367|9700089|FG000|Overall Study|Withdrawal by Subject|1
6088949|NCT00679432|9700115|FG000|Overall Study|Adverse Event|5
6088950|NCT00679432|9700116|FG001|Overall Study|Adverse Event|6
6088951|NCT00679432|9700117|FG002|Overall Study|Adverse Event|10
6200061|NCT01483599|9859595|FG013|After Controlled Period(Week 16-Week 40)|Other|0
6200062|NCT01483625|9859626|FG000|Overall Study|Adverse Event|1
6277171|NCT02240121|9984024|FG000|Overall Study|Site closed|1
6277172|NCT02240121|9984025|FG001|Overall Study|Site closed|1
6277173|NCT02240121|9984024|FG000|Overall Study|Pregnancy|1
6277174|NCT02240121|9984025|FG001|Overall Study|Pregnancy|0
5977336|NCT00352534|9564537|FG005|Final Risk Group Assignment|Ineligible|13
5977337|NCT00352534|9564538|FG006|Final Risk Group Assignment|Ineligible|0
5977338|NCT00352534|9564532|FG000|Final Risk Group Assignment|Enrollment onto another COG study|0
5977339|NCT00352534|9564533|FG001|Final Risk Group Assignment|Enrollment onto another COG study|0
5977340|NCT00352534|9564534|FG002|Final Risk Group Assignment|Enrollment onto another COG study|0
5977341|NCT00352534|9564535|FG003|Final Risk Group Assignment|Enrollment onto another COG study|0
5977342|NCT00352534|9564536|FG004|Final Risk Group Assignment|Enrollment onto another COG study|0
5977343|NCT00352534|9564537|FG005|Final Risk Group Assignment|Enrollment onto another COG study|0
5977344|NCT00352534|9564538|FG006|Final Risk Group Assignment|Enrollment onto another COG study|28
6200063|NCT01483625|9859627|FG001|Overall Study|Adverse Event|1
6200064|NCT01483625|9859626|FG000|Overall Study|Refused to continue medication|2
6200065|NCT01483625|9859627|FG001|Overall Study|Refused to continue medication|1
6200066|NCT01483625|9859626|FG000|Overall Study|Due to other reason|1
6200067|NCT01483625|9859627|FG001|Overall Study|Due to other reason|0
6200068|NCT01483651|9859633|FG000|Overall Study|Withdrawal by Subject|0
6200069|NCT01483651|9859634|FG001|Overall Study|Withdrawal by Subject|1
6200070|NCT01483651|9859635|FG002|Overall Study|Withdrawal by Subject|1
6200071|NCT01483651|9859636|FG003|Overall Study|Withdrawal by Subject|0
6200072|NCT01483651|9859637|FG004|Overall Study|Withdrawal by Subject|0
6200073|NCT01483651|9859638|FG005|Overall Study|Withdrawal by Subject|1
6200074|NCT01483690|9859648|FG000|Overall Study|Adverse Event|1
6200075|NCT01483690|9859649|FG001|Overall Study|Adverse Event|2
6200076|NCT01483690|9859648|FG000|Overall Study|clinical deterioration|1
6200077|NCT01483690|9859649|FG001|Overall Study|clinical deterioration|0
6200078|NCT01483690|9859648|FG000|Overall Study|Physician Decision|0
6200079|NCT01483690|9859649|FG001|Overall Study|Physician Decision|2
6200080|NCT01483690|9859648|FG000|Overall Study|exclusionary procedure|0
6200081|NCT01483690|9859649|FG001|Overall Study|exclusionary procedure|1
6200082|NCT01483924|9859669|FG000|Overall Study|Withdrawal by Subject|2
6200083|NCT01483924|9859670|FG001|Overall Study|Withdrawal by Subject|0
6200084|NCT01483924|9859671|FG002|Overall Study|Withdrawal by Subject|0
6200085|NCT01483924|9859672|FG003|Overall Study|Withdrawal by Subject|1
6200086|NCT01483924|9859673|FG004|Overall Study|Withdrawal by Subject|1
6200087|NCT01483924|9859669|FG000|Overall Study|Adverse Event|0
6200088|NCT01483924|9859670|FG001|Overall Study|Adverse Event|0
6200089|NCT01483924|9859671|FG002|Overall Study|Adverse Event|1
6200090|NCT01483924|9859672|FG003|Overall Study|Adverse Event|1
6200091|NCT01483924|9859673|FG004|Overall Study|Adverse Event|0
6200092|NCT01483924|9859669|FG000|Overall Study|Non-compliance|0
6200093|NCT01483924|9859670|FG001|Overall Study|Non-compliance|0
6200094|NCT01483924|9859671|FG002|Overall Study|Non-compliance|0
6200095|NCT01483924|9859672|FG003|Overall Study|Non-compliance|1
6200096|NCT01483924|9859673|FG004|Overall Study|Non-compliance|1
6200097|NCT01483924|9859669|FG000|Overall Study|Sponsor concern over ECG result|0
6200098|NCT01483924|9859670|FG001|Overall Study|Sponsor concern over ECG result|0
6200099|NCT01483924|9859671|FG002|Overall Study|Sponsor concern over ECG result|0
6200100|NCT01483924|9859672|FG003|Overall Study|Sponsor concern over ECG result|1
6200101|NCT01483924|9859673|FG004|Overall Study|Sponsor concern over ECG result|0
6200102|NCT01483937|9859696|FG000|Overall Study|Withdrawal by Subject|4
6200103|NCT01483937|9859697|FG001|Overall Study|Withdrawal by Subject|3
6200104|NCT01484028|9859728|FG000|Period 1|Lost to Follow-up|0
6200105|NCT01484028|9859729|FG001|Period 1|Lost to Follow-up|1
6200106|NCT01484028|9859730|FG002|Period 1|Lost to Follow-up|0
6200107|NCT01484028|9859731|FG003|Period 1|Lost to Follow-up|0
6200108|NCT01484028|9859728|FG000|Period 1|Non-Compliance to Protocol|0
6200109|NCT01484028|9859729|FG001|Period 1|Non-Compliance to Protocol|1
6200110|NCT01484028|9859730|FG002|Period 1|Non-Compliance to Protocol|0
6200111|NCT01484028|9859731|FG003|Period 1|Non-Compliance to Protocol|1
6277175|NCT02240121|9984024|FG000|Overall Study|Adverse Event|2
6277176|NCT02240121|9984025|FG001|Overall Study|Adverse Event|4
6277177|NCT02240121|9984024|FG000|Overall Study|Withdrawal by Subject|6
6277178|NCT02240121|9984025|FG001|Overall Study|Withdrawal by Subject|2
6277179|NCT02240121|9984024|FG000|Overall Study|Lost to Follow-up|3
6277180|NCT02240121|9984025|FG001|Overall Study|Lost to Follow-up|4
6277181|NCT02240121|9984024|FG000|Overall Study|Other than specified|1
6277182|NCT02240121|9984025|FG001|Overall Study|Other than specified|3
6277183|NCT02240368|9984045|FG000|Overall Study|Surgery lasted less then 20 minutes|1
6277184|NCT02240368|9984046|FG001|Overall Study|Surgery lasted less then 20 minutes|0
6277185|NCT02240368|9984047|FG002|Overall Study|Surgery lasted less then 20 minutes|0
6277186|NCT02240368|9984045|FG000|Overall Study|Entropy failed to detect more than 50%|0
6277187|NCT02240368|9984046|FG001|Overall Study|Entropy failed to detect more than 50%|0
6277188|NCT02240368|9984047|FG002|Overall Study|Entropy failed to detect more than 50%|1
6277189|NCT02240628|9984066|FG000|Overall Study|Physician Decision|6
6200112|NCT01484028|9859728|FG000|Period 1|Lens Discomfort|0
6200113|NCT01484028|9859729|FG001|Period 1|Lens Discomfort|1
6200114|NCT01484028|9859730|FG002|Period 1|Lens Discomfort|0
6277190|NCT02240628|9984067|FG001|Overall Study|Physician Decision|5
6277191|NCT02240680|9984105|FG000|Overall Study (Up to 24 Weeks)|Adverse Event|6
6277192|NCT02240680|9984106|FG001|Overall Study (Up to 24 Weeks)|Adverse Event|6
6277193|NCT02240680|9984107|FG002|Overall Study (Up to 24 Weeks)|Adverse Event|0
6200115|NCT01484028|9859731|FG003|Period 1|Lens Discomfort|0
6200116|NCT01484054|9859743|FG000|Period 1|Withdrawal by Subject|0
6200117|NCT01484054|9859744|FG001|Period 1|Withdrawal by Subject|1
6200118|NCT01484132|9859751|FG000|Overall Study|Lost to Follow-up|8
6200119|NCT01484132|9859751|FG000|Overall Study|Difficulty with time commitment|2
6200120|NCT01484132|9859751|FG000|Overall Study|Ineligible|1
6200121|NCT01484132|9859751|FG000|Overall Study|No pre-treatment urine sample collected|1
6200122|NCT01484132|9859751|FG000|Overall Study|No post-treatment urine sample collected|10
6200123|NCT01484197|9859755|FG000|Treatment Period 1|Adverse Event|1
6200124|NCT01484197|9859756|FG001|Treatment Period 1|Adverse Event|0
6200125|NCT01484197|9859757|FG002|Treatment Period 1|Adverse Event|0
6200126|NCT01484197|9859758|FG003|Treatment Period 1|Adverse Event|0
6200127|NCT01484197|9859755|FG000|Treatment Period 2|Subject withdrew consent|0
6200128|NCT01484197|9859756|FG001|Treatment Period 2|Subject withdrew consent|0
6200129|NCT01484197|9859757|FG002|Treatment Period 2|Subject withdrew consent|0
6200130|NCT01484197|9859758|FG003|Treatment Period 2|Subject withdrew consent|1
6200131|NCT01484275|9859770|FG000|Overall Study|Study terminated by sponsor|28
6200132|NCT01484275|9859771|FG001|Overall Study|Study terminated by sponsor|32
6200133|NCT01484275|9859770|FG000|Overall Study|Other|10
6200134|NCT01484275|9859771|FG001|Overall Study|Other|0
6200135|NCT01484275|9859770|FG000|Overall Study|Death|3
6200136|NCT01484275|9859771|FG001|Overall Study|Death|4
6200137|NCT01484275|9859770|FG000|Overall Study|Withdrawal by Subject|1
6200138|NCT01484275|9859771|FG001|Overall Study|Withdrawal by Subject|5
6200139|NCT01484275|9859770|FG000|Overall Study|Lost to Follow-up|1
6277194|NCT02240680|9984108|FG003|Overall Study (Up to 24 Weeks)|Adverse Event|0
6277195|NCT02240680|9984105|FG000|Overall Study (Up to 24 Weeks)|Protocol Violation|4
6277196|NCT02240680|9984106|FG001|Overall Study (Up to 24 Weeks)|Protocol Violation|1
6277197|NCT02240680|9984107|FG002|Overall Study (Up to 24 Weeks)|Protocol Violation|0
6277198|NCT02240680|9984108|FG003|Overall Study (Up to 24 Weeks)|Protocol Violation|0
6277199|NCT02240680|9984105|FG000|Overall Study (Up to 24 Weeks)|Lost to Follow-up|1
6277200|NCT02240680|9984106|FG001|Overall Study (Up to 24 Weeks)|Lost to Follow-up|0
6277201|NCT02240680|9984107|FG002|Overall Study (Up to 24 Weeks)|Lost to Follow-up|0
6277202|NCT02240680|9984108|FG003|Overall Study (Up to 24 Weeks)|Lost to Follow-up|0
6277203|NCT02240680|9984105|FG000|Overall Study (Up to 24 Weeks)|Withdrawal by Subject|3
6277204|NCT02240680|9984106|FG001|Overall Study (Up to 24 Weeks)|Withdrawal by Subject|1
6277205|NCT02240680|9984107|FG002|Overall Study (Up to 24 Weeks)|Withdrawal by Subject|0
6277206|NCT02240680|9984108|FG003|Overall Study (Up to 24 Weeks)|Withdrawal by Subject|0
6277207|NCT02240680|9984105|FG000|Overall Study (Up to 24 Weeks)|Other than specified|1
6277208|NCT02240680|9984106|FG001|Overall Study (Up to 24 Weeks)|Other than specified|0
6277209|NCT02240680|9984107|FG002|Overall Study (Up to 24 Weeks)|Other than specified|0
6277210|NCT02240680|9984108|FG003|Overall Study (Up to 24 Weeks)|Other than specified|0
6277211|NCT02240680|9984105|FG000|Japanese Patients (Up to 52 Weeks)|Adverse Event|0
6277212|NCT02240680|9984106|FG001|Japanese Patients (Up to 52 Weeks)|Adverse Event|0
6277213|NCT02240680|9984107|FG002|Japanese Patients (Up to 52 Weeks)|Adverse Event|6
6277214|NCT02240680|9984108|FG003|Japanese Patients (Up to 52 Weeks)|Adverse Event|7
6277215|NCT02240680|9984105|FG000|Japanese Patients (Up to 52 Weeks)|Protocol Violation|0
6277216|NCT02240680|9984106|FG001|Japanese Patients (Up to 52 Weeks)|Protocol Violation|0
6277217|NCT02240680|9984107|FG002|Japanese Patients (Up to 52 Weeks)|Protocol Violation|1
6277218|NCT02240680|9984108|FG003|Japanese Patients (Up to 52 Weeks)|Protocol Violation|0
6277219|NCT02240680|9984105|FG000|Japanese Patients (Up to 52 Weeks)|Withdrawal by Subject|0
6277220|NCT02240680|9984106|FG001|Japanese Patients (Up to 52 Weeks)|Withdrawal by Subject|0
6277221|NCT02240680|9984107|FG002|Japanese Patients (Up to 52 Weeks)|Withdrawal by Subject|1
6277222|NCT02240680|9984108|FG003|Japanese Patients (Up to 52 Weeks)|Withdrawal by Subject|0
6277223|NCT02240693|9984121|FG000|Overall Study|Adverse Event|0
6277224|NCT02240693|9984122|FG001|Overall Study|Adverse Event|0
6277225|NCT02240693|9984123|FG002|Overall Study|Adverse Event|0
6277226|NCT02240693|9984124|FG003|Overall Study|Adverse Event|0
6277227|NCT02240693|9984125|FG004|Overall Study|Adverse Event|1
6277228|NCT02240693|9984121|FG000|Overall Study|Withdrawal by Subject|0
6277229|NCT02240693|9984122|FG001|Overall Study|Withdrawal by Subject|0
6277230|NCT02240693|9984123|FG002|Overall Study|Withdrawal by Subject|2
6277231|NCT02240693|9984124|FG003|Overall Study|Withdrawal by Subject|1
6277232|NCT02240693|9984125|FG004|Overall Study|Withdrawal by Subject|0
6277233|NCT02240693|9984121|FG000|Overall Study|Other than specified|0
6277234|NCT02240693|9984122|FG001|Overall Study|Other than specified|0
6277235|NCT02240693|9984123|FG002|Overall Study|Other than specified|2
6277236|NCT02240693|9984124|FG003|Overall Study|Other than specified|0
6277237|NCT02240693|9984125|FG004|Overall Study|Other than specified|0
6277238|NCT02240706|9984144|FG000|Overall Study|Lack of Efficacy|2
6277239|NCT02240706|9984145|FG001|Overall Study|Lack of Efficacy|2
6277240|NCT02240706|9984146|FG002|Overall Study|Lack of Efficacy|2
6277241|NCT02240706|9984147|FG003|Overall Study|Lack of Efficacy|2
6277242|NCT02240706|9984148|FG004|Overall Study|Lack of Efficacy|5
6277243|NCT02240706|9984149|FG005|Overall Study|Lack of Efficacy|0
6277244|NCT02240706|9984150|FG006|Overall Study|Lack of Efficacy|0
6277245|NCT02240706|9984144|FG000|Overall Study|Adverse Event|1
6200140|NCT01484275|9859771|FG001|Overall Study|Lost to Follow-up|1
6200141|NCT01484431|9859793|FG000|Period 1: High Dose|Physician Decision|0
6200142|NCT01484431|9859794|FG001|Period 1: High Dose|Physician Decision|1
6200143|NCT01484431|9859795|FG002|Period 1: High Dose|Physician Decision|0
6200144|NCT01484431|9859793|FG000|Period 2|Death|0
6200145|NCT01484431|9859794|FG001|Period 2|Death|1
6200146|NCT01484431|9859795|FG002|Period 2|Death|1
6200147|NCT01484431|9859793|FG000|Period 2|Physician Decision|0
6200148|NCT01484431|9859794|FG001|Period 2|Physician Decision|0
6200149|NCT01484431|9859795|FG002|Period 2|Physician Decision|1
6200150|NCT01484431|9859793|FG000|Period 2|Non-Compliance with Study Drug|1
6200151|NCT01484431|9859794|FG001|Period 2|Non-Compliance with Study Drug|0
6200152|NCT01484431|9859795|FG002|Period 2|Non-Compliance with Study Drug|0
6277246|NCT02240706|9984145|FG001|Overall Study|Adverse Event|0
6277247|NCT02240706|9984146|FG002|Overall Study|Adverse Event|1
6277248|NCT02240706|9984147|FG003|Overall Study|Adverse Event|0
6277249|NCT02240706|9984148|FG004|Overall Study|Adverse Event|2
6277250|NCT02240706|9984149|FG005|Overall Study|Adverse Event|0
6277251|NCT02240706|9984150|FG006|Overall Study|Adverse Event|0
6277252|NCT02240706|9984144|FG000|Overall Study|Progressive disease|0
6277253|NCT02240706|9984145|FG001|Overall Study|Progressive disease|0
6277254|NCT02240706|9984146|FG002|Overall Study|Progressive disease|0
6277255|NCT02240706|9984147|FG003|Overall Study|Progressive disease|0
6277256|NCT02240706|9984148|FG004|Overall Study|Progressive disease|1
6277257|NCT02240706|9984149|FG005|Overall Study|Progressive disease|0
6277258|NCT02240706|9984150|FG006|Overall Study|Progressive disease|0
6277259|NCT02240706|9984144|FG000|Overall Study|Dose limiting toxicity|0
6277260|NCT02240706|9984145|FG001|Overall Study|Dose limiting toxicity|0
6277261|NCT02240706|9984146|FG002|Overall Study|Dose limiting toxicity|0
6277262|NCT02240706|9984147|FG003|Overall Study|Dose limiting toxicity|0
6277263|NCT02240706|9984148|FG004|Overall Study|Dose limiting toxicity|1
6277264|NCT02240706|9984149|FG005|Overall Study|Dose limiting toxicity|0
6277265|NCT02240706|9984150|FG006|Overall Study|Dose limiting toxicity|0
6277266|NCT02240706|9984144|FG000|Overall Study|Refused to continue taking medication|0
6277267|NCT02240706|9984145|FG001|Overall Study|Refused to continue taking medication|1
6277268|NCT02240706|9984146|FG002|Overall Study|Refused to continue taking medication|3
6277269|NCT02240706|9984147|FG003|Overall Study|Refused to continue taking medication|1
6277270|NCT02240706|9984148|FG004|Overall Study|Refused to continue taking medication|2
6277271|NCT02240706|9984149|FG005|Overall Study|Refused to continue taking medication|0
6277272|NCT02240706|9984150|FG006|Overall Study|Refused to continue taking medication|0
6277273|NCT02240706|9984144|FG000|Overall Study|Insurance billing concerns|0
6277274|NCT02240706|9984145|FG001|Overall Study|Insurance billing concerns|0
6277275|NCT02240706|9984146|FG002|Overall Study|Insurance billing concerns|0
6277276|NCT02240706|9984147|FG003|Overall Study|Insurance billing concerns|1
6277277|NCT02240706|9984148|FG004|Overall Study|Insurance billing concerns|0
6277278|NCT02240706|9984149|FG005|Overall Study|Insurance billing concerns|0
6277279|NCT02240706|9984150|FG006|Overall Study|Insurance billing concerns|0
6277280|NCT02241512|9984181|FG000|Overall Study|Pump malfunction, drug not delivered|1
6277281|NCT02241512|9984182|FG001|Overall Study|Pump malfunction, drug not delivered|0
6277282|NCT02241733|9984208|FG000|Overall Study|Lost to Follow-up|9
6277283|NCT02241733|9984209|FG001|Overall Study|Lost to Follow-up|4
6277284|NCT02241733|9984208|FG000|Overall Study|Physician Decision|6
6277285|NCT02241733|9984209|FG001|Overall Study|Physician Decision|2
6277286|NCT02241733|9984208|FG000|Overall Study|Withdrawal by Subject|0
6277287|NCT02241733|9984209|FG001|Overall Study|Withdrawal by Subject|2
6277288|NCT02241733|9984208|FG000|Overall Study|Death|0
6277289|NCT02241733|9984209|FG001|Overall Study|Death|2
6277290|NCT02241785|9984215|FG000|Overall Study|Sponsor Termination|43
6277291|NCT02241785|9984215|FG000|Overall Study|Withdrawal by Subject|1
6277292|NCT02241785|9984215|FG000|Overall Study|Lost to Follow-up|2
6277293|NCT02241785|9984215|FG000|Overall Study|Adverse Event|1
6277294|NCT02241889|9984219|FG000|Overall Study|device issues|0
6277295|NCT02241889|9984220|FG001|Overall Study|device issues|0
6277296|NCT02241889|9984221|FG002|Overall Study|device issues|1
6277297|NCT02241889|9984222|FG003|Overall Study|device issues|0
6277298|NCT02241889|9984223|FG004|Overall Study|device issues|0
6277299|NCT02241889|9984224|FG005|Overall Study|device issues|0
6277300|NCT02241889|9984219|FG000|Overall Study|Withdrawal by Subject|0
6277301|NCT02241889|9984220|FG001|Overall Study|Withdrawal by Subject|0
6277302|NCT02241889|9984221|FG002|Overall Study|Withdrawal by Subject|0
6277303|NCT02241889|9984222|FG003|Overall Study|Withdrawal by Subject|0
6277304|NCT02241889|9984223|FG004|Overall Study|Withdrawal by Subject|0
6277305|NCT02241889|9984224|FG005|Overall Study|Withdrawal by Subject|1
6277306|NCT02242045|9984253|FG000|Overall Study|Investigator's Discretion|1
6277307|NCT02242045|9984253|FG000|Overall Study|Progressive Disease|2
6277308|NCT02242045|9984253|FG000|Overall Study|Unable to tolerate rechallenge with idelalisib|1
6277309|NCT02242045|9984253|FG000|Overall Study|Initiated another anti-cancer or experimental therapy|2
6277310|NCT02242201|9984260|FG000|Overall Study|preoperative identified neuropathy|2
6277311|NCT02242201|9984261|FG001|Overall Study|preoperative identified neuropathy|0
6277312|NCT02242201|9984262|FG002|Overall Study|preoperative identified neuropathy|0
6200153|NCT01484496|9859810|FG000|Period 1|Protocol Violation|3
6200154|NCT01484496|9859811|FG001|Period 1|Protocol Violation|4
6277313|NCT02242201|9984260|FG000|Overall Study|planned post-op anticoagulation|1
6277314|NCT02242201|9984261|FG001|Overall Study|planned post-op anticoagulation|0
6277315|NCT02242201|9984262|FG002|Overall Study|planned post-op anticoagulation|0
6277316|NCT02242201|9984260|FG000|Overall Study|changed surgical procedure|1
6277317|NCT02242201|9984261|FG001|Overall Study|changed surgical procedure|0
6277318|NCT02242201|9984262|FG002|Overall Study|changed surgical procedure|0
6277319|NCT02242201|9984260|FG000|Overall Study|postponed surgery|0
6277320|NCT02242201|9984261|FG001|Overall Study|postponed surgery|0
6277321|NCT02242201|9984262|FG002|Overall Study|postponed surgery|1
6277322|NCT02242201|9984260|FG000|Overall Study|preoperative opioid consumption|0
6277323|NCT02242201|9984261|FG001|Overall Study|preoperative opioid consumption|1
6277324|NCT02242201|9984262|FG002|Overall Study|preoperative opioid consumption|0
6277325|NCT02242305|9984272|FG000|Overall Study|Without spasm-like pain during 3 weeks|1
6277326|NCT02242305|9984273|FG001|Overall Study|Without spasm-like pain during 3 weeks|4
6277327|NCT02242305|9984272|FG000|Overall Study|Adverse Event|1
5977345|NCT00352534|9564532|FG000|Final Risk Group Assignment|Stage III Wilms tumor with LOH|0
5977346|NCT00352534|9564533|FG001|Final Risk Group Assignment|Stage III Wilms tumor with LOH|0
5977347|NCT00352534|9564534|FG002|Final Risk Group Assignment|Stage III Wilms tumor with LOH|0
5977348|NCT00352534|9564535|FG003|Final Risk Group Assignment|Stage III Wilms tumor with LOH|0
5977349|NCT00352534|9564536|FG004|Final Risk Group Assignment|Stage III Wilms tumor with LOH|0
5977350|NCT00352534|9564537|FG005|Final Risk Group Assignment|Stage III Wilms tumor with LOH|0
5977351|NCT00352534|9564538|FG006|Final Risk Group Assignment|Stage III Wilms tumor with LOH|11
5977352|NCT00352534|9564532|FG000|Final Risk Group Assignment|Death|0
5977353|NCT00352534|9564533|FG001|Final Risk Group Assignment|Death|0
5977354|NCT00352534|9564534|FG002|Final Risk Group Assignment|Death|0
5977355|NCT00352534|9564535|FG003|Final Risk Group Assignment|Death|0
5977356|NCT00352534|9564536|FG004|Final Risk Group Assignment|Death|0
5977357|NCT00352534|9564537|FG005|Final Risk Group Assignment|Death|2
5977358|NCT00352534|9564538|FG006|Final Risk Group Assignment|Death|0
5977359|NCT00033293|9564550|FG000|Overall Study|Death|0
5977360|NCT00033293|9564551|FG001|Overall Study|Death|1
5977361|NCT00033293|9564550|FG000|Overall Study|Lack of Efficacy|5
5977362|NCT00033293|9564551|FG001|Overall Study|Lack of Efficacy|8
6088952|NCT00679432|9700118|FG003|Overall Study|Adverse Event|7
6088953|NCT00679432|9700115|FG000|Overall Study|Protocol Violation|1
6088954|NCT00679432|9700116|FG001|Overall Study|Protocol Violation|1
6088955|NCT00679432|9700117|FG002|Overall Study|Protocol Violation|2
6088956|NCT00679432|9700118|FG003|Overall Study|Protocol Violation|1
6088957|NCT00679432|9700115|FG000|Overall Study|Withdrawal by Subject|8
6088958|NCT00679432|9700116|FG001|Overall Study|Withdrawal by Subject|11
6088959|NCT00679432|9700117|FG002|Overall Study|Withdrawal by Subject|10
6088960|NCT00679432|9700118|FG003|Overall Study|Withdrawal by Subject|9
6088961|NCT00679432|9700115|FG000|Overall Study|Lost to Follow-up|1
6088962|NCT00679432|9700116|FG001|Overall Study|Lost to Follow-up|5
6088963|NCT00679432|9700117|FG002|Overall Study|Lost to Follow-up|4
6088964|NCT00679432|9700118|FG003|Overall Study|Lost to Follow-up|2
6088965|NCT00679432|9700115|FG000|Overall Study|Physician Decision|3
6088966|NCT00679432|9700116|FG001|Overall Study|Physician Decision|2
6088967|NCT00679432|9700117|FG002|Overall Study|Physician Decision|2
6088968|NCT00679432|9700118|FG003|Overall Study|Physician Decision|2
6088969|NCT00679432|9700115|FG000|Overall Study|Sponsor decision|1
6088970|NCT00679432|9700116|FG001|Overall Study|Sponsor decision|0
6088971|NCT00679432|9700117|FG002|Overall Study|Sponsor decision|0
6088972|NCT00679432|9700118|FG003|Overall Study|Sponsor decision|0
6088973|NCT00679432|9700115|FG000|Overall Study|Lack of Efficacy|13
6088974|NCT00679432|9700116|FG001|Overall Study|Lack of Efficacy|9
6088975|NCT00679432|9700117|FG002|Overall Study|Lack of Efficacy|14
6088976|NCT00679432|9700118|FG003|Overall Study|Lack of Efficacy|8
6088977|NCT00679432|9700115|FG000|Overall Study|Infectious colitis, normal histology|5
6088978|NCT00679432|9700116|FG001|Overall Study|Infectious colitis, normal histology|4
6088979|NCT00679432|9700117|FG002|Overall Study|Infectious colitis, normal histology|8
6088980|NCT00679432|9700118|FG003|Overall Study|Infectious colitis, normal histology|3
6088981|NCT00679432|9700115|FG000|Overall Study|Randomization error, return to prior Rx|0
6088982|NCT00679432|9700116|FG001|Overall Study|Randomization error, return to prior Rx|0
6088983|NCT00679432|9700117|FG002|Overall Study|Randomization error, return to prior Rx|3
6088984|NCT00679432|9700118|FG003|Overall Study|Randomization error, return to prior Rx|0
6088985|NCT00679549|9700130|FG000|Overall Study|dropout|2
6088986|NCT00679549|9700131|FG001|Overall Study|dropout|4
6088987|NCT00679549|9700130|FG000|Overall Study|missing outcome echocardiograms|4
6088988|NCT00679549|9700131|FG001|Overall Study|missing outcome echocardiograms|5
6088989|NCT00679627|9700139|FG000|Overall Study|Death|41
6088990|NCT00679627|9700140|FG001|Overall Study|Death|29
6088991|NCT00679627|9700139|FG000|Overall Study|Adverse Event|43
6088992|NCT00679627|9700140|FG001|Overall Study|Adverse Event|53
6088993|NCT00679627|9700139|FG000|Overall Study|Withdrawal by Subject|168
6088994|NCT00679627|9700140|FG001|Overall Study|Withdrawal by Subject|172
6088995|NCT00679627|9700139|FG000|Overall Study|Lost to Follow-up|22
6277328|NCT02242305|9984273|FG001|Overall Study|Adverse Event|0
6088996|NCT00679627|9700140|FG001|Overall Study|Lost to Follow-up|26
6088997|NCT00679627|9700139|FG000|Overall Study|Early Study Closure|425
6088998|NCT00679627|9700140|FG001|Overall Study|Early Study Closure|405
6088999|NCT00679913|9700148|FG000|Overall Study|Protocol Violation|18
6200155|NCT01484496|9859812|FG002|Period 1|Protocol Violation|0
6200156|NCT01484496|9859813|FG003|Period 1|Protocol Violation|0
6200157|NCT01484496|9859810|FG000|Period 1|Physician Decision|5
6200158|NCT01484496|9859811|FG001|Period 1|Physician Decision|1
6200159|NCT01484496|9859812|FG002|Period 1|Physician Decision|0
6200160|NCT01484496|9859813|FG003|Period 1|Physician Decision|0
6200161|NCT01484496|9859810|FG000|Period 1|Lack of Efficacy|10
6200162|NCT01484496|9859811|FG001|Period 1|Lack of Efficacy|15
6200163|NCT01484496|9859812|FG002|Period 1|Lack of Efficacy|0
6200164|NCT01484496|9859813|FG003|Period 1|Lack of Efficacy|0
6200165|NCT01484496|9859810|FG000|Period 1|Adverse Event|25
6200166|NCT01484496|9859811|FG001|Period 1|Adverse Event|40
6200167|NCT01484496|9859812|FG002|Period 1|Adverse Event|0
6200168|NCT01484496|9859813|FG003|Period 1|Adverse Event|0
6200169|NCT01484496|9859810|FG000|Period 1|Withdrawal by Subject|15
6200170|NCT01484496|9859811|FG001|Period 1|Withdrawal by Subject|12
6200171|NCT01484496|9859812|FG002|Period 1|Withdrawal by Subject|0
6200172|NCT01484496|9859813|FG003|Period 1|Withdrawal by Subject|0
6200173|NCT01484496|9859810|FG000|Period 1|Lost to Follow-up|2
6200174|NCT01484496|9859811|FG001|Period 1|Lost to Follow-up|6
6200175|NCT01484496|9859812|FG002|Period 1|Lost to Follow-up|0
6200176|NCT01484496|9859813|FG003|Period 1|Lost to Follow-up|0
6200177|NCT01484496|9859810|FG000|Period 1|Positive Pregnancy|1
6200178|NCT01484496|9859811|FG001|Period 1|Positive Pregnancy|6
6200179|NCT01484496|9859812|FG002|Period 1|Positive Pregnancy|0
6200180|NCT01484496|9859813|FG003|Period 1|Positive Pregnancy|0
6200181|NCT01484496|9859810|FG000|Period 1|Treatment Failure|3
6200182|NCT01484496|9859811|FG001|Period 1|Treatment Failure|6
6200183|NCT01484496|9859812|FG002|Period 1|Treatment Failure|0
6200184|NCT01484496|9859813|FG003|Period 1|Treatment Failure|0
6200185|NCT01484496|9859810|FG000|Period 1|Lack of Compliance|2
6200186|NCT01484496|9859811|FG001|Period 1|Lack of Compliance|1
6200187|NCT01484496|9859812|FG002|Period 1|Lack of Compliance|0
6200188|NCT01484496|9859813|FG003|Period 1|Lack of Compliance|0
6200189|NCT01484496|9859810|FG000|Period 1|Unable to Visit Site|0
6200190|NCT01484496|9859811|FG001|Period 1|Unable to Visit Site|2
6200191|NCT01484496|9859812|FG002|Period 1|Unable to Visit Site|0
6200192|NCT01484496|9859813|FG003|Period 1|Unable to Visit Site|0
6200193|NCT01484496|9859810|FG000|Period 2|Lack of Efficacy|0
6200194|NCT01484496|9859811|FG001|Period 2|Lack of Efficacy|0
6200195|NCT01484496|9859812|FG002|Period 2|Lack of Efficacy|1
6200196|NCT01484496|9859813|FG003|Period 2|Lack of Efficacy|3
6200197|NCT01484496|9859810|FG000|Period 2|Adverse Event|0
6200198|NCT01484496|9859811|FG001|Period 2|Adverse Event|0
6200199|NCT01484496|9859812|FG002|Period 2|Adverse Event|5
6200200|NCT01484496|9859813|FG003|Period 2|Adverse Event|13
6200201|NCT01484496|9859810|FG000|Period 2|Other|0
6200202|NCT01484496|9859811|FG001|Period 2|Other|0
6200203|NCT01484496|9859812|FG002|Period 2|Other|9
6200204|NCT01484496|9859813|FG003|Period 2|Other|6
6200205|NCT01484561|9859823|FG000|Overall Study|Lack of Efficacy|3
6200206|NCT01484561|9859824|FG001|Overall Study|Lack of Efficacy|1
6200207|NCT01484561|9859823|FG000|Overall Study|Lost to Follow-up|1
6200208|NCT01484561|9859824|FG001|Overall Study|Lost to Follow-up|0
6200209|NCT01484561|9859823|FG000|Overall Study|Withdrawal by Subject|3
6200210|NCT01484561|9859824|FG001|Overall Study|Withdrawal by Subject|0
6200211|NCT01484561|9859823|FG000|Overall Study|Other|1
6200212|NCT01484561|9859824|FG001|Overall Study|Other|1
6200213|NCT01484561|9859823|FG000|Overall Study|Adverse Event|1
6200214|NCT01484561|9859824|FG001|Overall Study|Adverse Event|4
6200215|NCT01484834|9859847|FG000|Overall Study|Lost to Follow-up|5
6200216|NCT01484834|9859848|FG001|Overall Study|Lost to Follow-up|8
6200217|NCT01484834|9859849|FG002|Overall Study|Lost to Follow-up|1
6200218|NCT01484834|9859850|FG003|Overall Study|Lost to Follow-up|4
6200219|NCT01484873|9859860|FG000|Overall Study|Withdrawal by Subject|2
6200220|NCT01484912|9859867|FG000|Overall Study|Withdrawal by Subject|1
6200221|NCT01484912|9859868|FG001|Overall Study|Withdrawal by Subject|0
6200222|NCT01484912|9859867|FG000|Overall Study|Physician Decision|0
6200223|NCT01484912|9859868|FG001|Overall Study|Physician Decision|1
6200224|NCT01484938|9859874|FG000|Overall Study|Adverse Event|2
6200225|NCT01484938|9859874|FG000|Overall Study|Lost to Follow-up|1
6200226|NCT01484938|9859874|FG000|Overall Study|Noncompliance|1
6200227|NCT01484951|9859878|FG000|Overall Study|Adverse Event|3
6200228|NCT01484951|9859878|FG000|Overall Study|Personal Reasons|1
6277329|NCT02242305|9984272|FG000|Overall Study|Non-compliance dosing regimen or visit|2
6277330|NCT02242305|9984273|FG001|Overall Study|Non-compliance dosing regimen or visit|2
6200229|NCT01484951|9859878|FG000|Overall Study|Non-Compliance|1
6200230|NCT01484977|9859882|FG000|Overall Study|Adverse Event|8
6200231|NCT01484977|9859882|FG000|Overall Study|Lack of Efficacy|4
6200232|NCT01484977|9859882|FG000|Overall Study|Protocol Violation|6
6200233|NCT01484977|9859882|FG000|Overall Study|Lost to Follow-up|1
6200234|NCT01484977|9859882|FG000|Overall Study|Withdrawal by Subject|4
6200235|NCT01484977|9859882|FG000|Overall Study|Subject Protocol Non-compliant|1
6200236|NCT01484977|9859882|FG000|Overall Study|Moving Overseas|1
6200237|NCT01484977|9859882|FG000|Overall Study|Low White Blood Cell Count|1
6200238|NCT01484977|9859882|FG000|Overall Study|Lack of Compliance|1
6200239|NCT01485094|9859893|FG000|Overall Study|Adverse Event|1
6200240|NCT01485094|9859894|FG001|Overall Study|Adverse Event|1
6200241|NCT01485094|9859895|FG002|Overall Study|Adverse Event|1
6200242|NCT01485094|9859893|FG000|Overall Study|Lost to Follow-up|1
6200243|NCT01485094|9859894|FG001|Overall Study|Lost to Follow-up|0
6200244|NCT01485094|9859895|FG002|Overall Study|Lost to Follow-up|0
6200245|NCT01485094|9859893|FG000|Overall Study|Withdrawal by Subject|1
6200246|NCT01485094|9859894|FG001|Overall Study|Withdrawal by Subject|1
6200247|NCT01485094|9859895|FG002|Overall Study|Withdrawal by Subject|0
6200248|NCT01485120|9859903|FG000|Overall Study|Withdrawal by Subject|2
6200249|NCT01485172|9859914|FG000|Overall Study|Adverse Event|2
6200250|NCT01485172|9859915|FG001|Overall Study|Adverse Event|1
6200251|NCT01485172|9859916|FG002|Overall Study|Adverse Event|2
6200252|NCT01485172|9859917|FG003|Overall Study|Adverse Event|2
6200253|NCT01485172|9859918|FG004|Overall Study|Adverse Event|1
6200254|NCT01485172|9859919|FG005|Overall Study|Adverse Event|2
6200255|NCT01485172|9859914|FG000|Overall Study|Lack of Efficacy|2
6200256|NCT01485172|9859915|FG001|Overall Study|Lack of Efficacy|0
6200257|NCT01485172|9859916|FG002|Overall Study|Lack of Efficacy|0
6200258|NCT01485172|9859917|FG003|Overall Study|Lack of Efficacy|0
6200259|NCT01485172|9859918|FG004|Overall Study|Lack of Efficacy|0
6200260|NCT01485172|9859919|FG005|Overall Study|Lack of Efficacy|0
6200261|NCT01485172|9859914|FG000|Overall Study|Protocol Violation|0
6200262|NCT01485172|9859915|FG001|Overall Study|Protocol Violation|0
6200263|NCT01485172|9859916|FG002|Overall Study|Protocol Violation|4
6200264|NCT01485172|9859917|FG003|Overall Study|Protocol Violation|5
6200265|NCT01485172|9859918|FG004|Overall Study|Protocol Violation|1
6200266|NCT01485172|9859919|FG005|Overall Study|Protocol Violation|0
6200267|NCT01485172|9859914|FG000|Overall Study|Protocol defined stopping criteria|1
6200268|NCT01485172|9859915|FG001|Overall Study|Protocol defined stopping criteria|0
6200269|NCT01485172|9859916|FG002|Overall Study|Protocol defined stopping criteria|0
6200270|NCT01485172|9859917|FG003|Overall Study|Protocol defined stopping criteria|0
6200271|NCT01485172|9859918|FG004|Overall Study|Protocol defined stopping criteria|1
6200272|NCT01485172|9859919|FG005|Overall Study|Protocol defined stopping criteria|0
6200273|NCT01485172|9859914|FG000|Overall Study|Lost to Follow-up|0
6200274|NCT01485172|9859915|FG001|Overall Study|Lost to Follow-up|0
6200275|NCT01485172|9859916|FG002|Overall Study|Lost to Follow-up|1
6200276|NCT01485172|9859917|FG003|Overall Study|Lost to Follow-up|0
6200277|NCT01485172|9859918|FG004|Overall Study|Lost to Follow-up|0
6277331|NCT02242305|9984272|FG000|Overall Study|Subject withdraws inform consent|0
6277332|NCT02242305|9984273|FG001|Overall Study|Subject withdraws inform consent|4
6277333|NCT02242305|9984272|FG000|Overall Study|Lost to Follow-up|2
6277334|NCT02242305|9984273|FG001|Overall Study|Lost to Follow-up|0
6277335|NCT02242487|9984281|FG000|Overall Study|Adverse Event|13
6277336|NCT02242487|9984282|FG001|Overall Study|Adverse Event|15
6277337|NCT02242487|9984281|FG000|Overall Study|Lack of Efficacy|4
6277338|NCT02242487|9984282|FG001|Overall Study|Lack of Efficacy|6
6277339|NCT02242487|9984281|FG000|Overall Study|Protocol Violation|2
6277340|NCT02242487|9984282|FG001|Overall Study|Protocol Violation|0
6277341|NCT02242487|9984281|FG000|Overall Study|Lost to Follow-up|2
6277342|NCT02242487|9984282|FG001|Overall Study|Lost to Follow-up|1
6277343|NCT02242487|9984281|FG000|Overall Study|Other - Miscellaneous|4
6277344|NCT02242487|9984282|FG001|Overall Study|Other - Miscellaneous|6
6277345|NCT02242487|9984281|FG000|Overall Study|Withdrawal by Subject|37
6277346|NCT02242487|9984282|FG001|Overall Study|Withdrawal by Subject|19
6277347|NCT02242643|9984309|FG000|Overall Study|Protocol Violation|1
6277348|NCT02242643|9984310|FG001|Overall Study|Protocol Violation|2
6277349|NCT02242643|9984309|FG000|Overall Study|Withdrawal by Subject|15
6277350|NCT02242643|9984310|FG001|Overall Study|Withdrawal by Subject|10
6277351|NCT02242643|9984309|FG000|Overall Study|Migrated/moved from study area|1
6277352|NCT02242643|9984310|FG001|Overall Study|Migrated/moved from study area|3
6277353|NCT02242643|9984309|FG000|Overall Study|Lost to Follow-up|54
6277354|NCT02242643|9984310|FG001|Overall Study|Lost to Follow-up|61
6277355|NCT02242643|9984309|FG000|Overall Study|Child placed in foster care by family|0
6277356|NCT02242643|9984310|FG001|Overall Study|Child placed in foster care by family|1
6277357|NCT02242643|9984309|FG000|Overall Study|Non-compliance|1
6277358|NCT02242643|9984310|FG001|Overall Study|Non-compliance|0
6277359|NCT02242643|9984309|FG000|Overall Study|Consent withdrawal by parent|1
6277360|NCT02242643|9984310|FG001|Overall Study|Consent withdrawal by parent|0
6277361|NCT02242643|9984309|FG000|Overall Study|Protocol requirements not followed|1
6200278|NCT01485172|9859919|FG005|Overall Study|Lost to Follow-up|1
6200279|NCT01485172|9859914|FG000|Overall Study|Physician Decision|0
6200280|NCT01485172|9859915|FG001|Overall Study|Physician Decision|0
6200281|NCT01485172|9859916|FG002|Overall Study|Physician Decision|0
6200282|NCT01485172|9859917|FG003|Overall Study|Physician Decision|0
6200283|NCT01485172|9859918|FG004|Overall Study|Physician Decision|1
6200284|NCT01485172|9859919|FG005|Overall Study|Physician Decision|0
6200285|NCT01485172|9859914|FG000|Overall Study|Withdrawal by Subject|2
6277362|NCT02242643|9984310|FG001|Overall Study|Protocol requirements not followed|0
6277363|NCT02242643|9984309|FG000|Overall Study|Language barrier|1
6277364|NCT02242643|9984310|FG001|Overall Study|Language barrier|0
6277365|NCT02242643|9984309|FG000|Overall Study|Withdrawal by subject at Visit 2|0
6277366|NCT02242643|9984310|FG001|Overall Study|Withdrawal by subject at Visit 2|1
6277367|NCT02242903|9984325|FG000|Overall Study|Withdrawal by Subject|1
6277368|NCT02242903|9984326|FG001|Overall Study|Withdrawal by Subject|0
6200286|NCT01485172|9859915|FG001|Overall Study|Withdrawal by Subject|0
6200287|NCT01485172|9859916|FG002|Overall Study|Withdrawal by Subject|0
6200288|NCT01485172|9859917|FG003|Overall Study|Withdrawal by Subject|1
6200289|NCT01485172|9859918|FG004|Overall Study|Withdrawal by Subject|1
6200290|NCT01485172|9859919|FG005|Overall Study|Withdrawal by Subject|1
6200291|NCT01485354|9859933|FG000|Overall Study|Withdrawal by Subject|5
6200292|NCT01485536|9859949|FG000|Overall Study|Withdrawal by Subject|3
6200293|NCT01485536|9859949|FG000|Overall Study|Adverse Event|1
6200294|NCT01485614|9859972|FG000|Randomization|Not Treated|1
6200295|NCT01485614|9859973|FG001|Randomization|Not Treated|0
6200296|NCT01485614|9859974|FG002|Randomization|Not Treated|0
6200297|NCT01485614|9859975|FG003|Randomization|Not Treated|0
6200298|NCT01485614|9859972|FG000|Weeks 0-20|Lost to Follow-up|2
6200299|NCT01485614|9859973|FG001|Weeks 0-20|Lost to Follow-up|0
6200300|NCT01485614|9859974|FG002|Weeks 0-20|Lost to Follow-up|0
6200301|NCT01485614|9859975|FG003|Weeks 0-20|Lost to Follow-up|0
6200302|NCT01485614|9859972|FG000|Weeks 0-20|Withdrawal by Parent/Guardian|5
6200303|NCT01485614|9859973|FG001|Weeks 0-20|Withdrawal by Parent/Guardian|2
6200304|NCT01485614|9859974|FG002|Weeks 0-20|Withdrawal by Parent/Guardian|0
6200305|NCT01485614|9859975|FG003|Weeks 0-20|Withdrawal by Parent/Guardian|0
6200306|NCT01485614|9859972|FG000|Weeks 0-20|Withdrawal by Subject|3
6200307|NCT01485614|9859973|FG001|Weeks 0-20|Withdrawal by Subject|2
6200308|NCT01485614|9859974|FG002|Weeks 0-20|Withdrawal by Subject|1
6200309|NCT01485614|9859975|FG003|Weeks 0-20|Withdrawal by Subject|0
6200310|NCT01485614|9859972|FG000|Weeks 20-54|Lost to Follow-up|4
6200311|NCT01485614|9859973|FG001|Weeks 20-54|Lost to Follow-up|3
6200312|NCT01485614|9859974|FG002|Weeks 20-54|Lost to Follow-up|1
6200313|NCT01485614|9859975|FG003|Weeks 20-54|Lost to Follow-up|0
6200314|NCT01485614|9859972|FG000|Weeks 20-54|Withdrawal by Parent/Guardian|2
6200315|NCT01485614|9859973|FG001|Weeks 20-54|Withdrawal by Parent/Guardian|2
6200316|NCT01485614|9859974|FG002|Weeks 20-54|Withdrawal by Parent/Guardian|1
6277369|NCT02242903|9984327|FG002|Overall Study|Withdrawal by Subject|0
6277370|NCT02242903|9984328|FG003|Overall Study|Withdrawal by Subject|0
6277371|NCT02242903|9984329|FG004|Overall Study|Withdrawal by Subject|0
6277372|NCT02242903|9984330|FG005|Overall Study|Withdrawal by Subject|0
6277373|NCT02242903|9984331|FG006|Overall Study|Withdrawal by Subject|0
6277374|NCT02242981|9984353|FG000|Overall Study|Withdrawal by Subject|1
6200317|NCT01485614|9859975|FG003|Weeks 20-54|Withdrawal by Parent/Guardian|0
6200318|NCT01485614|9859972|FG000|Weeks 20-54|Withdrawal by Subject|5
6200319|NCT01485614|9859973|FG001|Weeks 20-54|Withdrawal by Subject|3
6200320|NCT01485614|9859974|FG002|Weeks 20-54|Withdrawal by Subject|0
6200321|NCT01485614|9859975|FG003|Weeks 20-54|Withdrawal by Subject|0
6200322|NCT01485627|9859993|FG000|Overall Study|Patient withdrew|6
6200323|NCT01485627|9859994|FG001|Overall Study|Patient withdrew|5
6200324|NCT01485627|9859993|FG000|Overall Study|Patient died|3
6200325|NCT01485627|9859994|FG001|Overall Study|Patient died|1
6200326|NCT01485627|9859993|FG000|Overall Study|Patient lost to followup|0
6200327|NCT01485627|9859994|FG001|Overall Study|Patient lost to followup|1
6200328|NCT01485627|9859993|FG000|Overall Study|Caregiver withdrew|3
6200329|NCT01485627|9859994|FG001|Overall Study|Caregiver withdrew|3
6200330|NCT01485627|9859993|FG000|Overall Study|Caregiver lost to follow up|11
6200331|NCT01485627|9859994|FG001|Overall Study|Caregiver lost to follow up|12
6200332|NCT01485627|9859993|FG000|Overall Study|Caregiver died|1
6200333|NCT01485627|9859994|FG001|Overall Study|Caregiver died|0
6200334|NCT01485627|9859993|FG000|Overall Study|caregiver was not bereaved|42
6200335|NCT01485627|9859994|FG001|Overall Study|caregiver was not bereaved|35
6200336|NCT01485640|9860004|FG000|Overall Study|Adverse Event|10
6200337|NCT01485640|9860004|FG000|Overall Study|Lack of Efficacy|2
6200338|NCT01485640|9860004|FG000|Overall Study|Protocol Violation|1
6200339|NCT01485640|9860004|FG000|Overall Study|Withdrawal by Subject|14
6200340|NCT01485640|9860004|FG000|Overall Study|Terminated by Sponsor|95
6200341|NCT01485796|9860019|FG000|Period 1: Epoch 1 (Ramp-up)|Withdrawal by Subject|1
6200342|NCT01485796|9860019|FG000|Period 2: Epoch 2|Withdrawal by Subject|6
6200343|NCT01485796|9860019|FG000|Period 2: Epoch 2|Adverse Event|3
6200344|NCT01485796|9860019|FG000|Period 2: Epoch 2|Switch to safety follow-up|26
6200345|NCT01485796|9860019|FG000|Overall Trial (Incl. Safety Follow-up)|Withdrawal by Subject in Epoch 1|1
6200346|NCT01485796|9860019|FG000|Overall Trial (Incl. Safety Follow-up)|Withdrawal by Subject in Epoch 2|6
6200347|NCT01485796|9860019|FG000|Overall Trial (Incl. Safety Follow-up)|Adverse Event in Epoch 2|3
6200348|NCT01485796|9860019|FG000|Overall Trial (Incl. Safety Follow-up)|Withdrawal During Safety-Follow-up|2
6200349|NCT01485887|9860027|FG000|Overall Study|Withdrawal by Subject|2
6200350|NCT01485887|9860027|FG000|Overall Study|Adverse Event|8
6200351|NCT01485887|9860027|FG000|Overall Study|Deterioration of primary disease|1
6200352|NCT01485887|9860027|FG000|Overall Study|Primary disease markedly improved|1
6200353|NCT01485991|9860033|FG000|Overall Study|Adverse Event|0
6200354|NCT01485991|9860034|FG001|Overall Study|Adverse Event|4
6200355|NCT01485991|9860033|FG000|Overall Study|Lost to Follow-up|13
6200356|NCT01485991|9860034|FG001|Overall Study|Lost to Follow-up|10
6200357|NCT01485991|9860033|FG000|Overall Study|Withdrawal by Subject|13
6200358|NCT01485991|9860034|FG001|Overall Study|Withdrawal by Subject|20
6200359|NCT01485991|9860033|FG000|Overall Study|randomized but not treated|6
6200360|NCT01485991|9860034|FG001|Overall Study|randomized but not treated|2
6200361|NCT01486199|9860046|FG000|Two Year Period Between Study Days|Physician Decision|1
6200362|NCT01486199|9860047|FG001|Two Year Period Between Study Days|Physician Decision|0
6200363|NCT01486238|9860055|FG000|Overall Study|Death|0
6200364|NCT01486238|9860056|FG001|Overall Study|Death|2
6200365|NCT01486238|9860055|FG000|Overall Study|Withdrawal by Subject|2
6200366|NCT01486238|9860056|FG001|Overall Study|Withdrawal by Subject|1
6200367|NCT01486238|9860055|FG000|Overall Study|Lost to Follow-up|0
6200368|NCT01486238|9860056|FG001|Overall Study|Lost to Follow-up|3
6200369|NCT01486316|9860065|FG000|Overall Study|Device explanted with/without re-implant|3
6200370|NCT01486316|9860066|FG001|Overall Study|Device explanted with/without re-implant|2
6200371|NCT01486316|9860067|FG002|Overall Study|Device explanted with/without re-implant|0
6200372|NCT01486316|9860068|FG003|Overall Study|Device explanted with/without re-implant|2
6200373|NCT01486316|9860065|FG000|Overall Study|Not meeting eligibility criteria|0
6200374|NCT01486316|9860066|FG001|Overall Study|Not meeting eligibility criteria|0
6200375|NCT01486316|9860067|FG002|Overall Study|Not meeting eligibility criteria|1
6200376|NCT01486316|9860068|FG003|Overall Study|Not meeting eligibility criteria|0
6200377|NCT01486316|9860065|FG000|Overall Study|Withdrawal by Subject|1
6200378|NCT01486316|9860066|FG001|Overall Study|Withdrawal by Subject|0
6200379|NCT01486316|9860067|FG002|Overall Study|Withdrawal by Subject|3
6200380|NCT01486316|9860068|FG003|Overall Study|Withdrawal by Subject|0
6200381|NCT01486316|9860065|FG000|Overall Study|Physician Decision|0
6200382|NCT01486316|9860066|FG001|Overall Study|Physician Decision|0
6200383|NCT01486316|9860067|FG002|Overall Study|Physician Decision|1
6200384|NCT01486316|9860068|FG003|Overall Study|Physician Decision|0
6200385|NCT01486316|9860065|FG000|Overall Study|Death|0
6200386|NCT01486316|9860066|FG001|Overall Study|Death|1
6200387|NCT01486316|9860067|FG002|Overall Study|Death|0
6200388|NCT01486316|9860068|FG003|Overall Study|Death|0
6200389|NCT01486446|9860079|FG000|Overall Study|Adverse Event|1
6200390|NCT01486446|9860080|FG001|Overall Study|Adverse Event|0
6200391|NCT01486758|9860105|FG000|Overall Study|Lost to Follow-up|0
6200392|NCT01486758|9860106|FG001|Overall Study|Lost to Follow-up|1
6200393|NCT01486784|9860119|FG000|Overall Study|Withdrawal by Subject|0
6200394|NCT01486784|9860120|FG001|Overall Study|Withdrawal by Subject|0
6200395|NCT01486784|9860121|FG002|Overall Study|Withdrawal by Subject|1
6200396|NCT01486784|9860122|FG003|Overall Study|Withdrawal by Subject|0
6200397|NCT01486784|9860123|FG004|Overall Study|Withdrawal by Subject|1
6200398|NCT01486784|9860124|FG005|Overall Study|Withdrawal by Subject|2
6200399|NCT01486784|9860119|FG000|Overall Study|Subject did not meet entry criteria|0
6200400|NCT01486784|9860120|FG001|Overall Study|Subject did not meet entry criteria|0
6089000|NCT00679913|9700149|FG001|Overall Study|Protocol Violation|13
6200401|NCT01486784|9860121|FG002|Overall Study|Subject did not meet entry criteria|0
6200402|NCT01486784|9860122|FG003|Overall Study|Subject did not meet entry criteria|0
6200403|NCT01486784|9860123|FG004|Overall Study|Subject did not meet entry criteria|1
6200404|NCT01486784|9860124|FG005|Overall Study|Subject did not meet entry criteria|0
6200405|NCT01486784|9860119|FG000|Overall Study|Death|0
6277375|NCT02243046|9984373|FG000|Overall Study|Lost to Follow-up|1
6277376|NCT02243046|9984374|FG001|Overall Study|Lost to Follow-up|1
6277377|NCT02243046|9984375|FG002|Overall Study|Lost to Follow-up|4
6277378|NCT02243176|9984385|FG000|Overall Study|Other reason|1
6277379|NCT02243176|9984386|FG001|Overall Study|Other reason|2
6277380|NCT02243176|9984385|FG000|Overall Study|protocol specified withdrawal critera|1
6277381|NCT02243176|9984386|FG001|Overall Study|protocol specified withdrawal critera|3
6277382|NCT02243176|9984385|FG000|Overall Study|Protocol Violation|2
6277383|NCT02243176|9984386|FG001|Overall Study|Protocol Violation|1
6277384|NCT02243176|9984385|FG000|Overall Study|Withdrawal by Subject|8
6277385|NCT02243176|9984386|FG001|Overall Study|Withdrawal by Subject|7
6277386|NCT02243176|9984385|FG000|Overall Study|Adverse Event|2
6277387|NCT02243176|9984386|FG001|Overall Study|Adverse Event|2
6277388|NCT02243202|9984396|FG000|Overall Study|Adverse Event|5
6277389|NCT02243202|9984397|FG001|Overall Study|Adverse Event|6
6277390|NCT02243202|9984398|FG002|Overall Study|Adverse Event|10
5977363|NCT00033293|9564550|FG000|Overall Study|Lost to Follow-up|0
5977364|NCT00033293|9564551|FG001|Overall Study|Lost to Follow-up|1
5977365|NCT00033293|9564550|FG000|Overall Study|Physician Decision|3
5977366|NCT00033293|9564551|FG001|Overall Study|Physician Decision|1
5977367|NCT00033293|9564550|FG000|Overall Study|Withdrawal by Subject|1
5977368|NCT00033293|9564551|FG001|Overall Study|Withdrawal by Subject|0
5977369|NCT00033293|9564550|FG000|Overall Study|Could not be weaned from steroid therapy|1
5977370|NCT00033293|9564551|FG001|Overall Study|Could not be weaned from steroid therapy|1
5977371|NCT00033293|9564550|FG000|Overall Study|Treatment refused|0
5977372|NCT00033293|9564551|FG001|Overall Study|Treatment refused|6
6050824|NCT00429169|9650045|FG000|Overall Study|Ineligibility discovered after entry|2
6050825|NCT00429169|9650046|FG001|Overall Study|Ineligibility discovered after entry|1
6050826|NCT00429182|9650054|FG000|Overall Study|Not evaluable, Disease Progression|2
6050827|NCT00429182|9650054|FG000|Overall Study|Not eligible|5
6050828|NCT00429273|9650061|FG000|Overall Study|Lost to Follow-up|1
6050829|NCT00429273|9650062|FG001|Overall Study|Lost to Follow-up|2
6050830|NCT00429273|9650063|FG002|Overall Study|Lost to Follow-up|2
6050831|NCT00429273|9650061|FG000|Overall Study|Physician Decision|6
6050832|NCT00429273|9650062|FG001|Overall Study|Physician Decision|5
6050833|NCT00429273|9650063|FG002|Overall Study|Physician Decision|5
6050834|NCT00429273|9650061|FG000|Overall Study|Adverse Event|1
6050835|NCT00429273|9650062|FG001|Overall Study|Adverse Event|1
6050836|NCT00429273|9650063|FG002|Overall Study|Adverse Event|2
6050837|NCT00429299|9650074|FG000|Overall Study|Disease Progression|1
6050838|NCT00429299|9650075|FG001|Overall Study|Disease Progression|1
6050839|NCT00429299|9650076|FG002|Overall Study|Disease Progression|0
6050840|NCT00429299|9650074|FG000|Overall Study|Adverse Event|2
6050841|NCT00429299|9650075|FG001|Overall Study|Adverse Event|5
6050842|NCT00429299|9650076|FG002|Overall Study|Adverse Event|1
6050843|NCT00429299|9650074|FG000|Overall Study|Protocol Violation|1
6050844|NCT00429299|9650075|FG001|Overall Study|Protocol Violation|0
6050845|NCT00429299|9650076|FG002|Overall Study|Protocol Violation|0
6050846|NCT00429299|9650074|FG000|Overall Study|Withdrawal by Subject|0
6050847|NCT00429299|9650075|FG001|Overall Study|Withdrawal by Subject|1
6050848|NCT00429299|9650076|FG002|Overall Study|Withdrawal by Subject|3
6050849|NCT00429364|9650086|FG000|Overall Study|Withdrawal by Subject|11
6050850|NCT00429364|9650087|FG001|Overall Study|Withdrawal by Subject|5
6050851|NCT00429364|9650086|FG000|Overall Study|Physician Decision|4
6050852|NCT00429364|9650087|FG001|Overall Study|Physician Decision|2
6200406|NCT01486784|9860120|FG001|Overall Study|Death|0
6200407|NCT01486784|9860121|FG002|Overall Study|Death|0
6200408|NCT01486784|9860122|FG003|Overall Study|Death|0
6200409|NCT01486784|9860123|FG004|Overall Study|Death|0
6200410|NCT01486784|9860124|FG005|Overall Study|Death|1
6200411|NCT01486927|9860142|FG000|Overall Study|Knee surgery (prior to surgery substudy)|1
6200412|NCT01486927|9860142|FG000|Overall Study|Physician Decision|1
6200413|NCT01486927|9860142|FG000|Overall Study|50 Exposure days not reached|2
6200414|NCT01486927|9860142|FG000|Overall Study|Withdrawal by Subject|8
6200415|NCT01486927|9860142|FG000|Overall Study|Subject did not reach 6 mo of treatment|1
6200416|NCT01486966|9860155|FG000|Overall Study|Adverse Event|0
6200417|NCT01486966|9860156|FG001|Overall Study|Adverse Event|1
6200418|NCT01486966|9860155|FG000|Overall Study|Withdrawal by Subject|0
6200419|NCT01486966|9860156|FG001|Overall Study|Withdrawal by Subject|1
6200420|NCT01487161|9860166|FG000|Overall Study|Adverse Event|1
6200421|NCT01487161|9860167|FG001|Overall Study|Adverse Event|0
6200422|NCT01487161|9860168|FG002|Overall Study|Adverse Event|0
6200423|NCT01487161|9860169|FG003|Overall Study|Adverse Event|0
6200424|NCT01487161|9860166|FG000|Overall Study|Withdrawal by Subject|1
6050853|NCT00429364|9650086|FG000|Overall Study|Lost to Follow-up|7
6050854|NCT00429364|9650087|FG001|Overall Study|Lost to Follow-up|6
6050855|NCT00429364|9650086|FG000|Overall Study|Death|0
6050856|NCT00429364|9650087|FG001|Overall Study|Death|1
6050857|NCT00429364|9650086|FG000|Overall Study|Underwent aortic root surgery|10
6200425|NCT01487161|9860167|FG001|Overall Study|Withdrawal by Subject|1
6200426|NCT01487161|9860168|FG002|Overall Study|Withdrawal by Subject|1
6277391|NCT02243202|9984399|FG003|Overall Study|Adverse Event|4
6277392|NCT02243202|9984396|FG000|Overall Study|Lost to Follow-up|9
6200427|NCT01487161|9860169|FG003|Overall Study|Withdrawal by Subject|2
6200428|NCT01487161|9860166|FG000|Overall Study|missing data|0
6200429|NCT01487161|9860167|FG001|Overall Study|missing data|1
6200430|NCT01487161|9860168|FG002|Overall Study|missing data|0
6200431|NCT01487161|9860169|FG003|Overall Study|missing data|0
6200432|NCT01487200|9860188|FG000|Overall Study|Withdrawal by Subject|0
6200433|NCT01487200|9860189|FG001|Overall Study|Withdrawal by Subject|1
6200434|NCT01487200|9860190|FG002|Overall Study|Withdrawal by Subject|0
6200435|NCT01487200|9860191|FG003|Overall Study|Withdrawal by Subject|0
6200436|NCT01487265|9860202|FG000|Overall Study|Adverse Event|8
6200437|NCT01487265|9860202|FG000|Overall Study|Withdrawal by Subject|5
6200438|NCT01487265|9860202|FG000|Overall Study|Disease Progression|21
6200439|NCT01487265|9860202|FG000|Overall Study|Death|2
6200440|NCT01487265|9860202|FG000|Overall Study|Still on Treatment|1
6200441|NCT01487525|9860208|FG000|Overall Study|Withdrawal by Subject|0
6200442|NCT01487525|9860209|FG001|Overall Study|Withdrawal by Subject|1
6200443|NCT01487577|9860215|FG000|Overall Study|Became ineligible after signing consent|1
6200444|NCT01487863|9860232|FG000|Overall Study|Death|19
6200445|NCT01487863|9860233|FG001|Overall Study|Death|19
6277393|NCT02243202|9984397|FG001|Overall Study|Lost to Follow-up|9
6277394|NCT02243202|9984398|FG002|Overall Study|Lost to Follow-up|14
6277395|NCT02243202|9984399|FG003|Overall Study|Lost to Follow-up|11
6277396|NCT02243202|9984396|FG000|Overall Study|Protocol Violation|3
6277397|NCT02243202|9984397|FG001|Overall Study|Protocol Violation|1
6277398|NCT02243202|9984398|FG002|Overall Study|Protocol Violation|2
6277399|NCT02243202|9984399|FG003|Overall Study|Protocol Violation|1
6277400|NCT02243202|9984396|FG000|Overall Study|Withdrawal by Subject|7
6277401|NCT02243202|9984397|FG001|Overall Study|Withdrawal by Subject|6
6277402|NCT02243202|9984398|FG002|Overall Study|Withdrawal by Subject|4
6277403|NCT02243202|9984399|FG003|Overall Study|Withdrawal by Subject|4
6277404|NCT02243202|9984396|FG000|Overall Study|Other|1
6277405|NCT02243202|9984397|FG001|Overall Study|Other|3
6277406|NCT02243202|9984398|FG002|Overall Study|Other|1
6277407|NCT02243202|9984399|FG003|Overall Study|Other|2
6277408|NCT02243202|9984396|FG000|Overall Study|Randomized but not received treatment|0
6277409|NCT02243202|9984397|FG001|Overall Study|Randomized but not received treatment|0
6277410|NCT02243202|9984398|FG002|Overall Study|Randomized but not received treatment|0
6277411|NCT02243202|9984399|FG003|Overall Study|Randomized but not received treatment|1
6277412|NCT02243280|9984420|FG000|Treated|Adverse Event|1
6277413|NCT02243280|9984421|FG001|Treated|Adverse Event|0
6277414|NCT02243280|9984422|FG002|Treated|Adverse Event|0
6277415|NCT02243280|9984423|FG003|Treated|Adverse Event|0
6277416|NCT02243280|9984424|FG004|Treated|Adverse Event|0
6277417|NCT02243280|9984425|FG005|Treated|Adverse Event|0
6277418|NCT02243280|9984426|FG006|Treated|Adverse Event|0
6277419|NCT02243280|9984427|FG007|Treated|Adverse Event|0
6277420|NCT02243280|9984428|FG008|Treated|Adverse Event|0
6277421|NCT02243280|9984429|FG009|Treated|Adverse Event|0
6277422|NCT02243280|9984430|FG010|Treated|Adverse Event|1
6277423|NCT02243280|9984420|FG000|Treated|Lost to Follow-up|0
6277424|NCT02243280|9984421|FG001|Treated|Lost to Follow-up|0
6277425|NCT02243280|9984422|FG002|Treated|Lost to Follow-up|0
6277426|NCT02243280|9984423|FG003|Treated|Lost to Follow-up|0
6277427|NCT02243280|9984424|FG004|Treated|Lost to Follow-up|0
6277428|NCT02243280|9984425|FG005|Treated|Lost to Follow-up|0
6277429|NCT02243280|9984426|FG006|Treated|Lost to Follow-up|0
6277430|NCT02243280|9984427|FG007|Treated|Lost to Follow-up|0
6277431|NCT02243280|9984428|FG008|Treated|Lost to Follow-up|1
6277432|NCT02243280|9984429|FG009|Treated|Lost to Follow-up|0
6277433|NCT02243280|9984430|FG010|Treated|Lost to Follow-up|2
6277434|NCT02243293|9984465|FG000|Overall Study|Adverse Event|1
6277435|NCT02243293|9984466|FG001|Overall Study|Adverse Event|0
6277436|NCT02243293|9984467|FG002|Overall Study|Adverse Event|0
5977373|NCT04497415|9564561|FG000|Overall Study|Lost to Follow-up|43
5977374|NCT04497415|9564562|FG001|Overall Study|Lost to Follow-up|27
5977375|NCT04594759|9564603|FG000|Overall Study|Lost to Follow-up|3
5977376|NCT04463069|9564609|FG000|Overall Study|Withdrawal by Subject|2
5977377|NCT04463069|9564610|FG001|Overall Study|Withdrawal by Subject|10
5977378|NCT04463069|9564609|FG000|Overall Study|Participants' parents refused to participate after learning the assignment results|0
5977379|NCT04463069|9564610|FG001|Overall Study|Participants' parents refused to participate after learning the assignment results|13
6277437|NCT02243293|9984468|FG003|Overall Study|Adverse Event|0
6277438|NCT02243293|9984469|FG004|Overall Study|Adverse Event|0
6277439|NCT02243293|9984470|FG005|Overall Study|Adverse Event|0
6277440|NCT02243293|9984471|FG006|Overall Study|Adverse Event|0
6277441|NCT02243293|9984472|FG007|Overall Study|Adverse Event|0
6277442|NCT02243293|9984473|FG008|Overall Study|Adverse Event|0
6277443|NCT02243293|9984474|FG009|Overall Study|Adverse Event|0
6277444|NCT02243293|9984475|FG010|Overall Study|Adverse Event|0
6277445|NCT02243293|9984476|FG011|Overall Study|Adverse Event|0
6277446|NCT02243293|9984477|FG012|Overall Study|Adverse Event|0
6277447|NCT02243293|9984478|FG013|Overall Study|Adverse Event|0
6277448|NCT02243293|9984479|FG014|Overall Study|Adverse Event|0
6200446|NCT01488071|9860261|FG000|Overall Study|Adverse Event|15
6200447|NCT01488071|9860262|FG001|Overall Study|Adverse Event|23
6200448|NCT01488071|9860261|FG000|Overall Study|Lack of Efficacy|11
6200449|NCT01488071|9860262|FG001|Overall Study|Lack of Efficacy|17
6200450|NCT01488071|9860261|FG000|Overall Study|Non-compliance with study drug|2
6200451|NCT01488071|9860262|FG001|Overall Study|Non-compliance with study drug|0
6200452|NCT01488071|9860261|FG000|Overall Study|Protocol Violation|5
6200453|NCT01488071|9860262|FG001|Overall Study|Protocol Violation|7
6200454|NCT01488071|9860261|FG000|Overall Study|Withdrawal of Consent|14
6200455|NCT01488071|9860262|FG001|Overall Study|Withdrawal of Consent|12
6200456|NCT01488071|9860261|FG000|Overall Study|Lost to Follow-up|1
6200457|NCT01488071|9860262|FG001|Overall Study|Lost to Follow-up|0
6200458|NCT01488071|9860261|FG000|Overall Study|Administrative or Other Reason(s)|5
6200459|NCT01488071|9860262|FG001|Overall Study|Administrative or Other Reason(s)|4
6200460|NCT01488097|9860268|FG000|Overall Study|Lost to Follow-up|1
6200461|NCT01488370|9860300|FG000|Overall Study|Protocol Violation|0
6200462|NCT01488370|9860301|FG001|Overall Study|Protocol Violation|1
6200463|NCT01488370|9860302|FG002|Overall Study|Protocol Violation|1
6200464|NCT01488448|9860321|FG000|Overall Study|Withdrawal by Subject|3
6200465|NCT01488448|9860322|FG001|Overall Study|Withdrawal by Subject|1
6200466|NCT01488448|9860321|FG000|Overall Study|Adverse Event|9
6200467|NCT01488448|9860322|FG001|Overall Study|Adverse Event|4
6200468|NCT01488448|9860321|FG000|Overall Study|Physician Decision|4
6200469|NCT01488448|9860322|FG001|Overall Study|Physician Decision|9
6200470|NCT01488448|9860321|FG000|Overall Study|Protocol Violation|4
6200471|NCT01488448|9860322|FG001|Overall Study|Protocol Violation|3
6277449|NCT02243293|9984480|FG015|Overall Study|Adverse Event|1
6277450|NCT02243293|9984481|FG016|Overall Study|Adverse Event|0
6277451|NCT02243293|9984482|FG017|Overall Study|Adverse Event|0
6277452|NCT02243293|9984483|FG018|Overall Study|Adverse Event|0
6277453|NCT02243293|9984484|FG019|Overall Study|Adverse Event|0
6277454|NCT02243293|9984485|FG020|Overall Study|Adverse Event|1
6277455|NCT02243293|9984486|FG021|Overall Study|Adverse Event|0
6277456|NCT02243293|9984465|FG000|Overall Study|Withdrawal by Subject|1
6277457|NCT02243293|9984466|FG001|Overall Study|Withdrawal by Subject|0
6277458|NCT02243293|9984467|FG002|Overall Study|Withdrawal by Subject|0
6277459|NCT02243293|9984468|FG003|Overall Study|Withdrawal by Subject|0
6277460|NCT02243293|9984469|FG004|Overall Study|Withdrawal by Subject|0
6277461|NCT02243293|9984470|FG005|Overall Study|Withdrawal by Subject|0
6277462|NCT02243293|9984471|FG006|Overall Study|Withdrawal by Subject|0
6277463|NCT02243293|9984472|FG007|Overall Study|Withdrawal by Subject|0
6277464|NCT02243293|9984473|FG008|Overall Study|Withdrawal by Subject|0
6277465|NCT02243293|9984474|FG009|Overall Study|Withdrawal by Subject|1
6277466|NCT02243293|9984475|FG010|Overall Study|Withdrawal by Subject|0
6277467|NCT02243293|9984476|FG011|Overall Study|Withdrawal by Subject|1
6277468|NCT02243293|9984477|FG012|Overall Study|Withdrawal by Subject|0
6277469|NCT02243293|9984478|FG013|Overall Study|Withdrawal by Subject|0
6277470|NCT02243293|9984479|FG014|Overall Study|Withdrawal by Subject|0
6277471|NCT02243293|9984480|FG015|Overall Study|Withdrawal by Subject|0
6277472|NCT02243293|9984481|FG016|Overall Study|Withdrawal by Subject|0
6277473|NCT02243293|9984482|FG017|Overall Study|Withdrawal by Subject|0
6277474|NCT02243293|9984483|FG018|Overall Study|Withdrawal by Subject|0
6277475|NCT02243293|9984484|FG019|Overall Study|Withdrawal by Subject|0
6277476|NCT02243293|9984485|FG020|Overall Study|Withdrawal by Subject|0
5977380|NCT04250337|9564618|FG000|Overall Study|Adverse Event|0
5977381|NCT04250337|9564619|FG001|Overall Study|Adverse Event|3
5977382|NCT04250337|9564618|FG000|Overall Study|Lack of Efficacy|1
5977383|NCT04250337|9564619|FG001|Overall Study|Lack of Efficacy|3
5977384|NCT04250337|9564618|FG000|Overall Study|Physician Decision|1
5977385|NCT04250337|9564619|FG001|Overall Study|Physician Decision|0
5977386|NCT04250337|9564618|FG000|Overall Study|Protocol Deviation|2
5977387|NCT04250337|9564619|FG001|Overall Study|Protocol Deviation|2
5977388|NCT04250337|9564618|FG000|Overall Study|Withdrawal by Subject|4
5977389|NCT04250337|9564619|FG001|Overall Study|Withdrawal by Subject|3
6050858|NCT00429364|9650087|FG001|Overall Study|Underwent aortic root surgery|18
6050859|NCT00429364|9650086|FG000|Overall Study|Pregnancy|0
6200472|NCT01488487|9860330|FG000|Overall Study|Adverse Event|6
6200473|NCT01488487|9860330|FG000|Overall Study|Death|1
6200474|NCT01488487|9860330|FG000|Overall Study|Withdrawal by Subject|2
6050860|NCT00429364|9650087|FG001|Overall Study|Pregnancy|1
6050861|NCT00429416|9650102|FG000|Overall Study|Death|1
6050862|NCT00429494|9650106|FG000|Overall Study|Withdrawal by Subject|9
6050863|NCT00429494|9650106|FG000|Overall Study|Death|6
6050864|NCT00429572|9650114|FG000|Overall Study|Disease progression|1
6050865|NCT00429585|9650120|FG000|Overall Study|Death|1
6050866|NCT00429585|9650121|FG001|Overall Study|Death|0
6050867|NCT00429585|9650120|FG000|Overall Study|Lost to Follow-up|27
6050868|NCT00429585|9650121|FG001|Overall Study|Lost to Follow-up|20
6050869|NCT00429585|9650120|FG000|Overall Study|Physician Decision|2
6050870|NCT00429585|9650121|FG001|Overall Study|Physician Decision|0
6050871|NCT00429663|9650129|FG000|Overall Study|Lost to Follow-up|24
6200475|NCT01488578|9860334|FG000|Overall Study|Protocol Violation|1836
6200476|NCT01488994|9860386|FG000|Overall Study|Withdrawal by Subject|0
6200477|NCT01488994|9860387|FG001|Overall Study|Withdrawal by Subject|1
6200478|NCT01489020|9860404|FG000|Overall Study|Withdrawal by Subject|1
6200479|NCT01489020|9860405|FG001|Overall Study|Withdrawal by Subject|0
6200480|NCT01489020|9860406|FG002|Overall Study|Withdrawal by Subject|0
6200481|NCT01489020|9860407|FG003|Overall Study|Withdrawal by Subject|0
6200482|NCT01489020|9860408|FG004|Overall Study|Withdrawal by Subject|0
6200483|NCT01489020|9860409|FG005|Overall Study|Withdrawal by Subject|0
6200484|NCT01489020|9860404|FG000|Overall Study|Adverse Event|0
6200485|NCT01489020|9860405|FG001|Overall Study|Adverse Event|0
6200486|NCT01489020|9860406|FG002|Overall Study|Adverse Event|3
6200487|NCT01489020|9860407|FG003|Overall Study|Adverse Event|0
6200488|NCT01489020|9860408|FG004|Overall Study|Adverse Event|3
6200489|NCT01489020|9860409|FG005|Overall Study|Adverse Event|0
6200490|NCT01489020|9860404|FG000|Overall Study|Concomitant disease|0
6200491|NCT01489020|9860405|FG001|Overall Study|Concomitant disease|0
6200492|NCT01489020|9860406|FG002|Overall Study|Concomitant disease|0
6200493|NCT01489020|9860407|FG003|Overall Study|Concomitant disease|0
6200494|NCT01489020|9860408|FG004|Overall Study|Concomitant disease|3
6200495|NCT01489020|9860409|FG005|Overall Study|Concomitant disease|0
6200496|NCT01489111|9860429|FG000|Overall Study|Withdrawal criterion|1
6200497|NCT01489189|9860435|FG000|Overall Study|Withdrawal by Subject|20
6200498|NCT01489189|9860436|FG001|Overall Study|Withdrawal by Subject|23
6200499|NCT01489189|9860435|FG000|Overall Study|Death|10
6200500|NCT01489189|9860436|FG001|Overall Study|Death|8
6200501|NCT01489189|9860435|FG000|Overall Study|Missed Visit|1
6200502|NCT01489189|9860436|FG001|Overall Study|Missed Visit|4
6200503|NCT01489254|9860446|FG000|Double-blind Part|Adverse Event|7
6200504|NCT01489254|9860447|FG001|Double-blind Part|Adverse Event|2
6200505|NCT01489254|9860448|FG002|Double-blind Part|Adverse Event|2
6200506|NCT01489254|9860449|FG003|Double-blind Part|Adverse Event|0
6200507|NCT01489254|9860446|FG000|Double-blind Part|Pregnancy|1
6200508|NCT01489254|9860447|FG001|Double-blind Part|Pregnancy|3
6200509|NCT01489254|9860448|FG002|Double-blind Part|Pregnancy|0
6200510|NCT01489254|9860449|FG003|Double-blind Part|Pregnancy|0
6200511|NCT01489254|9860446|FG000|Double-blind Part|Withdrawal by Subject|12
6200512|NCT01489254|9860447|FG001|Double-blind Part|Withdrawal by Subject|20
6200513|NCT01489254|9860448|FG002|Double-blind Part|Withdrawal by Subject|1
6200514|NCT01489254|9860449|FG003|Double-blind Part|Withdrawal by Subject|0
6200515|NCT01489254|9860446|FG000|Double-blind Part|Lost to Follow-up|1
6200516|NCT01489254|9860447|FG001|Double-blind Part|Lost to Follow-up|2
6200517|NCT01489254|9860448|FG002|Double-blind Part|Lost to Follow-up|0
6200518|NCT01489254|9860449|FG003|Double-blind Part|Lost to Follow-up|0
6200519|NCT01489254|9860446|FG000|Double-blind Part|Other reasons for not completing study|4
6200520|NCT01489254|9860447|FG001|Double-blind Part|Other reasons for not completing study|6
6200521|NCT01489254|9860448|FG002|Double-blind Part|Other reasons for not completing study|0
6200522|NCT01489254|9860449|FG003|Double-blind Part|Other reasons for not completing study|0
6200523|NCT01489254|9860446|FG000|Open-label Extension Part|Adverse Event|0
6200524|NCT01489254|9860447|FG001|Open-label Extension Part|Adverse Event|0
6200525|NCT01489254|9860448|FG002|Open-label Extension Part|Adverse Event|0
6200526|NCT01489254|9860449|FG003|Open-label Extension Part|Adverse Event|10
6200527|NCT01489254|9860446|FG000|Open-label Extension Part|Pregnancy|0
6200528|NCT01489254|9860447|FG001|Open-label Extension Part|Pregnancy|0
6200529|NCT01489254|9860448|FG002|Open-label Extension Part|Pregnancy|0
6200530|NCT01489254|9860449|FG003|Open-label Extension Part|Pregnancy|3
6200531|NCT01489254|9860446|FG000|Open-label Extension Part|Withdrawal by Subject|0
6200532|NCT01489254|9860447|FG001|Open-label Extension Part|Withdrawal by Subject|0
6200533|NCT01489254|9860448|FG002|Open-label Extension Part|Withdrawal by Subject|0
6200534|NCT01489254|9860449|FG003|Open-label Extension Part|Withdrawal by Subject|30
6200535|NCT01489254|9860446|FG000|Open-label Extension Part|Protocol Violation|0
6200536|NCT01489254|9860447|FG001|Open-label Extension Part|Protocol Violation|0
6200537|NCT01489254|9860448|FG002|Open-label Extension Part|Protocol Violation|0
6200538|NCT01489254|9860449|FG003|Open-label Extension Part|Protocol Violation|1
6200539|NCT01489254|9860446|FG000|Open-label Extension Part|Lost to Follow-up|0
6200540|NCT01489254|9860447|FG001|Open-label Extension Part|Lost to Follow-up|0
6200541|NCT01489254|9860448|FG002|Open-label Extension Part|Lost to Follow-up|0
6200542|NCT01489254|9860449|FG003|Open-label Extension Part|Lost to Follow-up|9
6200543|NCT01489254|9860446|FG000|Open-label Extension Part|Other reasons for not completing study|0
6200544|NCT01489254|9860447|FG001|Open-label Extension Part|Other reasons for not completing study|0
6200545|NCT01489254|9860448|FG002|Open-label Extension Part|Other reasons for not completing study|0
6200546|NCT01489254|9860449|FG003|Open-label Extension Part|Other reasons for not completing study|5
6200547|NCT01489358|9860461|FG000|Overall Study|Lost to Follow-up|0
6277477|NCT02243293|9984486|FG021|Overall Study|Withdrawal by Subject|1
6277478|NCT02243293|9984465|FG000|Overall Study|Lost to Follow-up|0
6277479|NCT02243293|9984466|FG001|Overall Study|Lost to Follow-up|1
6277480|NCT02243293|9984467|FG002|Overall Study|Lost to Follow-up|1
6277481|NCT02243293|9984468|FG003|Overall Study|Lost to Follow-up|1
6277482|NCT02243293|9984469|FG004|Overall Study|Lost to Follow-up|0
6277483|NCT02243293|9984470|FG005|Overall Study|Lost to Follow-up|0
6200548|NCT01489358|9860462|FG001|Overall Study|Lost to Follow-up|0
6200549|NCT01489358|9860463|FG002|Overall Study|Lost to Follow-up|2
6200550|NCT01489527|9860473|FG000|Overall Study|Pregnancy|9
6277484|NCT02243293|9984471|FG006|Overall Study|Lost to Follow-up|3
6277485|NCT02243293|9984472|FG007|Overall Study|Lost to Follow-up|0
6200551|NCT01489527|9860474|FG001|Overall Study|Pregnancy|14
6200552|NCT01489527|9860473|FG000|Overall Study|Participant moved|6
6200553|NCT01489527|9860474|FG001|Overall Study|Participant moved|7
6200554|NCT01489527|9860473|FG000|Overall Study|Withdrawal by Subject|0
6277486|NCT02243293|9984473|FG008|Overall Study|Lost to Follow-up|0
6277487|NCT02243293|9984474|FG009|Overall Study|Lost to Follow-up|0
6277488|NCT02243293|9984475|FG010|Overall Study|Lost to Follow-up|0
6277489|NCT02243293|9984476|FG011|Overall Study|Lost to Follow-up|2
6277490|NCT02243293|9984477|FG012|Overall Study|Lost to Follow-up|0
6277491|NCT02243293|9984478|FG013|Overall Study|Lost to Follow-up|0
6277492|NCT02243293|9984479|FG014|Overall Study|Lost to Follow-up|0
6277493|NCT02243293|9984480|FG015|Overall Study|Lost to Follow-up|0
6277494|NCT02243293|9984481|FG016|Overall Study|Lost to Follow-up|3
6277495|NCT02243293|9984482|FG017|Overall Study|Lost to Follow-up|1
6277496|NCT02243293|9984483|FG018|Overall Study|Lost to Follow-up|0
6277497|NCT02243293|9984484|FG019|Overall Study|Lost to Follow-up|0
6277498|NCT02243293|9984485|FG020|Overall Study|Lost to Follow-up|1
6277499|NCT02243293|9984486|FG021|Overall Study|Lost to Follow-up|2
6277500|NCT02243293|9984465|FG000|Overall Study|Enrolled into a Re-treatment Study|0
5977390|NCT04126733|9564626|FG000|Treatment Period|Other Reason|1
6200555|NCT01489527|9860474|FG001|Overall Study|Withdrawal by Subject|4
6200556|NCT01489527|9860473|FG000|Overall Study|Lost to Follow-up|5
6200557|NCT01489527|9860474|FG001|Overall Study|Lost to Follow-up|1
6200558|NCT01489527|9860473|FG000|Overall Study|Procedures|1
6200559|NCT01489527|9860474|FG001|Overall Study|Procedures|0
6200560|NCT01489527|9860473|FG000|Overall Study|Not compliant|1
6200561|NCT01489527|9860474|FG001|Overall Study|Not compliant|0
6200562|NCT01489891|9860542|FG000|Overall Study|Endoscopy failure|1
6200563|NCT01489891|9860543|FG001|Overall Study|Endoscopy failure|0
6200564|NCT01489956|9860551|FG000|Overall Study|Lost to Follow-up|1
6200565|NCT01489956|9860552|FG001|Overall Study|Lost to Follow-up|0
6200566|NCT01489956|9860553|FG002|Overall Study|Lost to Follow-up|0
6200567|NCT01489956|9860551|FG000|Overall Study|Withdrawal by Subject|0
6200568|NCT01489956|9860552|FG001|Overall Study|Withdrawal by Subject|0
6200569|NCT01489956|9860553|FG002|Overall Study|Withdrawal by Subject|1
6200570|NCT01490060|9860576|FG000|Cycle 1|Change of Treatment|0
6200571|NCT01490060|9860577|FG001|Cycle 1|Change of Treatment|1
6200572|NCT01490060|9860578|FG002|Cycle 1|Change of Treatment|1
6200573|NCT01490060|9860579|FG003|Cycle 1|Change of Treatment|1
6200574|NCT01490060|9860576|FG000|Cycle 1|Insurance Denied|0
6200575|NCT01490060|9860577|FG001|Cycle 1|Insurance Denied|0
6200576|NCT01490060|9860578|FG002|Cycle 1|Insurance Denied|2
6200577|NCT01490060|9860579|FG003|Cycle 1|Insurance Denied|0
6200578|NCT01490060|9860576|FG000|Cycle 1|Withdrawal by Subject|0
6200579|NCT01490060|9860577|FG001|Cycle 1|Withdrawal by Subject|0
6200580|NCT01490060|9860578|FG002|Cycle 1|Withdrawal by Subject|0
6200581|NCT01490060|9860579|FG003|Cycle 1|Withdrawal by Subject|1
6200582|NCT01490060|9860576|FG000|Cycle 1|Treatment at Another Facility|0
6200583|NCT01490060|9860577|FG001|Cycle 1|Treatment at Another Facility|0
6200584|NCT01490060|9860578|FG002|Cycle 1|Treatment at Another Facility|0
6200585|NCT01490060|9860579|FG003|Cycle 1|Treatment at Another Facility|1
6200586|NCT01490060|9860576|FG000|Cycle 2|Change of Treatment|1
6200587|NCT01490060|9860577|FG001|Cycle 2|Change of Treatment|1
6200588|NCT01490060|9860578|FG002|Cycle 2|Change of Treatment|0
6200589|NCT01490060|9860579|FG003|Cycle 2|Change of Treatment|0
6200590|NCT01490060|9860576|FG000|Cycle 2|Non-Compliance|0
6200591|NCT01490060|9860577|FG001|Cycle 2|Non-Compliance|0
6200592|NCT01490060|9860578|FG002|Cycle 2|Non-Compliance|1
6200593|NCT01490060|9860579|FG003|Cycle 2|Non-Compliance|0
6200594|NCT01490060|9860576|FG000|Cycle 2|Adverse Event Related to Chemotherapy|1
6200595|NCT01490060|9860577|FG001|Cycle 2|Adverse Event Related to Chemotherapy|0
6200596|NCT01490060|9860578|FG002|Cycle 2|Adverse Event Related to Chemotherapy|0
6200597|NCT01490060|9860579|FG003|Cycle 2|Adverse Event Related to Chemotherapy|0
6200598|NCT01490086|9860601|FG000|Overall Study|Consent withdrawn|4
6200599|NCT01490086|9860602|FG001|Overall Study|Consent withdrawn|4
6200600|NCT01490086|9860603|FG002|Overall Study|Consent withdrawn|3
6277501|NCT02243293|9984466|FG001|Overall Study|Enrolled into a Re-treatment Study|0
6277502|NCT02243293|9984467|FG002|Overall Study|Enrolled into a Re-treatment Study|0
6277503|NCT02243293|9984468|FG003|Overall Study|Enrolled into a Re-treatment Study|0
6277504|NCT02243293|9984469|FG004|Overall Study|Enrolled into a Re-treatment Study|0
6277505|NCT02243293|9984470|FG005|Overall Study|Enrolled into a Re-treatment Study|0
6277506|NCT02243293|9984471|FG006|Overall Study|Enrolled into a Re-treatment Study|0
6277507|NCT02243293|9984472|FG007|Overall Study|Enrolled into a Re-treatment Study|0
6277508|NCT02243293|9984473|FG008|Overall Study|Enrolled into a Re-treatment Study|0
6277509|NCT02243293|9984474|FG009|Overall Study|Enrolled into a Re-treatment Study|0
6277510|NCT02243293|9984475|FG010|Overall Study|Enrolled into a Re-treatment Study|0
6277511|NCT02243293|9984476|FG011|Overall Study|Enrolled into a Re-treatment Study|0
6277512|NCT02243293|9984477|FG012|Overall Study|Enrolled into a Re-treatment Study|0
6277513|NCT02243293|9984478|FG013|Overall Study|Enrolled into a Re-treatment Study|0
6277514|NCT02243293|9984479|FG014|Overall Study|Enrolled into a Re-treatment Study|1
6277515|NCT02243293|9984480|FG015|Overall Study|Enrolled into a Re-treatment Study|0
6277516|NCT02243293|9984481|FG016|Overall Study|Enrolled into a Re-treatment Study|0
6277517|NCT02243293|9984482|FG017|Overall Study|Enrolled into a Re-treatment Study|0
6277518|NCT02243293|9984483|FG018|Overall Study|Enrolled into a Re-treatment Study|0
6277519|NCT02243293|9984484|FG019|Overall Study|Enrolled into a Re-treatment Study|0
6277520|NCT02243293|9984485|FG020|Overall Study|Enrolled into a Re-treatment Study|0
6277521|NCT02243293|9984486|FG021|Overall Study|Enrolled into a Re-treatment Study|0
6277522|NCT02243293|9984465|FG000|Overall Study|Randomized but did'nt receive study drug|0
6277523|NCT02243293|9984466|FG001|Overall Study|Randomized but did'nt receive study drug|0
6277524|NCT02243293|9984467|FG002|Overall Study|Randomized but did'nt receive study drug|0
5977391|NCT04126733|9564626|FG000|Treatment Period|Death|1
5977392|NCT04126733|9564626|FG000|Treatment Period|Physician Decision|3
5977393|NCT04126733|9564626|FG000|Treatment Period|Progressive Disease - Clinical Assessment|7
5977394|NCT04126733|9564626|FG000|Treatment Period|Adverse Event|7
5977395|NCT04126733|9564626|FG000|Treatment Period|Progressive Disease - Radiological Progression|44
5977396|NCT04126733|9564626|FG000|Treatment Period|Ongoing with Study Treatment|7
5977397|NCT04126733|9564626|FG000|Active Follow-up Period|Death|13
5977398|NCT04126733|9564626|FG000|Active Follow-up Period|Other Reason|1
5977399|NCT04126733|9564626|FG000|Active Follow-up Period|Progressive Disease - Clinical Assessment|4
5977400|NCT04126733|9564626|FG000|Active Follow-up Period|Withdrawal by Subject|2
5977401|NCT04126733|9564626|FG000|Long-term Follow-up Period|Withdrawal by Subject|1
5977402|NCT04126733|9564626|FG000|Long-term Follow-up Period|Death|5
5977403|NCT03662659|9564643|FG000|Pre-treatment|Participant no longer met study criteria|1
5977404|NCT03662659|9564644|FG001|Pre-treatment|Participant no longer met study criteria|1
5977405|NCT03662659|9564643|FG000|Pre-treatment|Other reasons|1
5977406|NCT03662659|9564644|FG001|Pre-treatment|Other reasons|0
5977407|NCT03662659|9564643|FG000|Treatment|Completed Treatment|0
5977408|NCT03662659|9564644|FG001|Treatment|Completed Treatment|3
5977409|NCT03662659|9564643|FG000|Treatment|Disease Progression|69
5977410|NCT03662659|9564644|FG001|Treatment|Disease Progression|78
5977411|NCT03662659|9564643|FG000|Treatment|Study Drug Toxicity|18
5977412|NCT03662659|9564644|FG001|Treatment|Study Drug Toxicity|8
5977413|NCT03662659|9564643|FG000|Treatment|Death|12
5977414|NCT03662659|9564644|FG001|Treatment|Death|7
5977415|NCT03662659|9564643|FG000|Treatment|Adverse Event unrelated to Study Drug|7
5977416|NCT03662659|9564644|FG001|Treatment|Adverse Event unrelated to Study Drug|4
5977417|NCT03662659|9564643|FG000|Treatment|Withdrawal by Subject|1
5977418|NCT03662659|9564644|FG001|Treatment|Withdrawal by Subject|1
5977419|NCT03662659|9564643|FG000|Treatment|Poor/Non-compliance|1
5977420|NCT03662659|9564644|FG001|Treatment|Poor/Non-compliance|0
5977421|NCT03662659|9564643|FG000|Treatment|Participant no longer meets study criteria|1
5977422|NCT03662659|9564644|FG001|Treatment|Participant no longer meets study criteria|0
5977423|NCT03662659|9564643|FG000|Treatment|Other reasons|6
5977424|NCT03662659|9564644|FG001|Treatment|Other reasons|5
5977425|NCT03575572|9564656|FG000|Overall Study|Withdrawal by Subject|2
5977426|NCT03575572|9564656|FG000|Overall Study|Physician Decision|2
6200601|NCT01490086|9860604|FG003|Overall Study|Consent withdrawn|0
6200602|NCT01490086|9860605|FG004|Overall Study|Consent withdrawn|1
6200603|NCT01490086|9860601|FG000|Overall Study|Non-compliance|0
6200604|NCT01490086|9860602|FG001|Overall Study|Non-compliance|1
6200605|NCT01490086|9860603|FG002|Overall Study|Non-compliance|0
6200606|NCT01490086|9860604|FG003|Overall Study|Non-compliance|0
6200607|NCT01490086|9860605|FG004|Overall Study|Non-compliance|0
6200608|NCT01490086|9860601|FG000|Overall Study|Abnormal laboratory findings|1
6200609|NCT01490086|9860602|FG001|Overall Study|Abnormal laboratory findings|0
6200610|NCT01490086|9860603|FG002|Overall Study|Abnormal laboratory findings|0
6200611|NCT01490086|9860604|FG003|Overall Study|Abnormal laboratory findings|0
6200612|NCT01490086|9860605|FG004|Overall Study|Abnormal laboratory findings|0
6200613|NCT01490086|9860601|FG000|Overall Study|Lost to Follow-up|0
6200614|NCT01490086|9860602|FG001|Overall Study|Lost to Follow-up|0
6200615|NCT01490086|9860603|FG002|Overall Study|Lost to Follow-up|0
6200616|NCT01490086|9860604|FG003|Overall Study|Lost to Follow-up|0
6200617|NCT01490086|9860605|FG004|Overall Study|Lost to Follow-up|1
6200618|NCT01490086|9860601|FG000|Overall Study|Physician Decision|3
6200619|NCT01490086|9860602|FG001|Overall Study|Physician Decision|4
6200620|NCT01490086|9860603|FG002|Overall Study|Physician Decision|2
6277525|NCT02243293|9984468|FG003|Overall Study|Randomized but did'nt receive study drug|0
6277526|NCT02243293|9984469|FG004|Overall Study|Randomized but did'nt receive study drug|1
5977427|NCT03521687|9564669|FG000|Overall Study|Adverse Event|4
5977428|NCT03521687|9564669|FG000|Overall Study|Physician Decision|1
5977429|NCT03511664|9564675|FG000|Overall Study|Treatment ongoing|49
5977430|NCT03511664|9564676|FG001|Overall Study|Treatment ongoing|5
5977431|NCT03511664|9564675|FG000|Overall Study|Entered long-term follow-up|140
5977432|NCT03511664|9564676|FG001|Overall Study|Entered long-term follow-up|50
5977433|NCT03511664|9564675|FG000|Overall Study|Withdrawal by Subject|29
5977434|NCT03511664|9564676|FG001|Overall Study|Withdrawal by Subject|53
5977435|NCT03511664|9564675|FG000|Overall Study|Lost to Follow-up|4
5977436|NCT03511664|9564676|FG001|Overall Study|Lost to Follow-up|4
5977437|NCT03511664|9564675|FG000|Overall Study|Physician Decision|0
5977438|NCT03511664|9564676|FG001|Overall Study|Physician Decision|1
6050872|NCT00429663|9650130|FG001|Overall Study|Lost to Follow-up|31
6050873|NCT00429663|9650129|FG000|Overall Study|Physician Decision|6
6089001|NCT00679939|9700158|FG000|52-Week Double-Blind (DB) Period|Withdrew Consent|17
6089002|NCT00679939|9700159|FG001|52-Week Double-Blind (DB) Period|Withdrew Consent|13
6089003|NCT00679939|9700158|FG000|52-Week Double-Blind (DB) Period|Adverse Event|14
6089004|NCT00679939|9700159|FG001|52-Week Double-Blind (DB) Period|Adverse Event|12
6089005|NCT00679939|9700158|FG000|52-Week Double-Blind (DB) Period|Investigator Discretion|5
6089006|NCT00679939|9700159|FG001|52-Week Double-Blind (DB) Period|Investigator Discretion|0
6200621|NCT01490086|9860604|FG003|Overall Study|Physician Decision|3
6200622|NCT01490086|9860605|FG004|Overall Study|Physician Decision|1
6200623|NCT01490086|9860601|FG000|Overall Study|Adverse Event|0
6200624|NCT01490086|9860602|FG001|Overall Study|Adverse Event|0
6200625|NCT01490086|9860603|FG002|Overall Study|Adverse Event|1
6200626|NCT01490086|9860604|FG003|Overall Study|Adverse Event|2
6200627|NCT01490086|9860605|FG004|Overall Study|Adverse Event|0
6200628|NCT01490086|9860601|FG000|Overall Study|Lack of Efficacy|0
6200629|NCT01490086|9860602|FG001|Overall Study|Lack of Efficacy|3
6200630|NCT01490086|9860603|FG002|Overall Study|Lack of Efficacy|1
6200631|NCT01490086|9860604|FG003|Overall Study|Lack of Efficacy|0
6200632|NCT01490086|9860605|FG004|Overall Study|Lack of Efficacy|8
6200633|NCT01490086|9860601|FG000|Overall Study|Worsening of symptoms|0
6200634|NCT01490086|9860602|FG001|Overall Study|Worsening of symptoms|1
6050874|NCT00429663|9650130|FG001|Overall Study|Physician Decision|3
6050875|NCT00429663|9650129|FG000|Overall Study|Withdrawal by Subject|2
6200635|NCT01490086|9860603|FG002|Overall Study|Worsening of symptoms|0
6200636|NCT01490086|9860604|FG003|Overall Study|Worsening of symptoms|1
6200637|NCT01490086|9860605|FG004|Overall Study|Worsening of symptoms|0
6200638|NCT01490086|9860601|FG000|Overall Study|Subject uncontrollable and abusive|0
6089007|NCT00679939|9700158|FG000|52-Week Double-Blind (DB) Period|Protocol Violation|1
6089008|NCT00679939|9700159|FG001|52-Week Double-Blind (DB) Period|Protocol Violation|0
6200639|NCT01490086|9860602|FG001|Overall Study|Subject uncontrollable and abusive|1
6200640|NCT01490086|9860603|FG002|Overall Study|Subject uncontrollable and abusive|0
6200641|NCT01490086|9860604|FG003|Overall Study|Subject uncontrollable and abusive|0
6200642|NCT01490086|9860605|FG004|Overall Study|Subject uncontrollable and abusive|0
6200643|NCT01490086|9860601|FG000|Overall Study|Subject left hospital|0
6200644|NCT01490086|9860602|FG001|Overall Study|Subject left hospital|1
6200645|NCT01490086|9860603|FG002|Overall Study|Subject left hospital|0
6200646|NCT01490086|9860604|FG003|Overall Study|Subject left hospital|1
6200647|NCT01490086|9860605|FG004|Overall Study|Subject left hospital|0
6200648|NCT01490125|9860617|FG000|Period I|Adverse Event|4
6200649|NCT01490125|9860618|FG001|Period I|Adverse Event|1
6200650|NCT01490125|9860619|FG002|Period I|Adverse Event|1
6200651|NCT01490125|9860620|FG003|Period I|Adverse Event|3
6200652|NCT01490125|9860621|FG004|Period I|Adverse Event|2
6200653|NCT01490125|9860622|FG005|Period I|Adverse Event|4
6200654|NCT01490125|9860617|FG000|Period I|Protocol Violation|1
6200655|NCT01490125|9860618|FG001|Period I|Protocol Violation|1
6200656|NCT01490125|9860619|FG002|Period I|Protocol Violation|1
6200657|NCT01490125|9860620|FG003|Period I|Protocol Violation|1
6200658|NCT01490125|9860621|FG004|Period I|Protocol Violation|0
6200659|NCT01490125|9860622|FG005|Period I|Protocol Violation|0
6200660|NCT01490125|9860617|FG000|Period I|Withdrawal by Subject|1
6200661|NCT01490125|9860618|FG001|Period I|Withdrawal by Subject|3
6200662|NCT01490125|9860619|FG002|Period I|Withdrawal by Subject|2
6200663|NCT01490125|9860620|FG003|Period I|Withdrawal by Subject|1
6200664|NCT01490125|9860621|FG004|Period I|Withdrawal by Subject|2
6200665|NCT01490125|9860622|FG005|Period I|Withdrawal by Subject|1
6200666|NCT01490125|9860617|FG000|Period II|Adverse Event|2
6200667|NCT01490125|9860618|FG001|Period II|Adverse Event|3
6200668|NCT01490125|9860619|FG002|Period II|Adverse Event|2
6200669|NCT01490125|9860620|FG003|Period II|Adverse Event|2
6200670|NCT01490125|9860621|FG004|Period II|Adverse Event|4
6200671|NCT01490125|9860622|FG005|Period II|Adverse Event|2
6200672|NCT01490125|9860617|FG000|Period II|Protocol Violation|0
6200673|NCT01490125|9860618|FG001|Period II|Protocol Violation|0
6200674|NCT01490125|9860619|FG002|Period II|Protocol Violation|1
6200675|NCT01490125|9860620|FG003|Period II|Protocol Violation|1
6200676|NCT01490125|9860621|FG004|Period II|Protocol Violation|0
6200677|NCT01490125|9860622|FG005|Period II|Protocol Violation|0
6200678|NCT01490125|9860617|FG000|Period II|Lost to Follow-up|0
6200679|NCT01490125|9860618|FG001|Period II|Lost to Follow-up|1
6200680|NCT01490125|9860619|FG002|Period II|Lost to Follow-up|0
6200681|NCT01490125|9860620|FG003|Period II|Lost to Follow-up|0
6200682|NCT01490125|9860621|FG004|Period II|Lost to Follow-up|0
6200683|NCT01490125|9860622|FG005|Period II|Lost to Follow-up|0
6200684|NCT01490125|9860617|FG000|Period II|Withdrawal by Subject|1
6200685|NCT01490125|9860618|FG001|Period II|Withdrawal by Subject|0
6200686|NCT01490125|9860619|FG002|Period II|Withdrawal by Subject|0
6200687|NCT01490125|9860620|FG003|Period II|Withdrawal by Subject|0
6200688|NCT01490125|9860621|FG004|Period II|Withdrawal by Subject|0
6200689|NCT01490125|9860622|FG005|Period II|Withdrawal by Subject|0
6200690|NCT01490125|9860617|FG000|Period III|Adverse Event|3
6200691|NCT01490125|9860618|FG001|Period III|Adverse Event|1
6200692|NCT01490125|9860619|FG002|Period III|Adverse Event|0
6200693|NCT01490125|9860620|FG003|Period III|Adverse Event|1
6200694|NCT01490125|9860621|FG004|Period III|Adverse Event|0
6200695|NCT01490125|9860622|FG005|Period III|Adverse Event|0
6200696|NCT01490125|9860617|FG000|Period III|Death|0
6200697|NCT01490125|9860618|FG001|Period III|Death|0
6200698|NCT01490125|9860619|FG002|Period III|Death|0
6200699|NCT01490125|9860620|FG003|Period III|Death|1
6200700|NCT01490125|9860621|FG004|Period III|Death|0
6200701|NCT01490125|9860622|FG005|Period III|Death|0
6200702|NCT01490125|9860617|FG000|Period III|Lack of Efficacy|0
6200703|NCT01490125|9860618|FG001|Period III|Lack of Efficacy|0
6200704|NCT01490125|9860619|FG002|Period III|Lack of Efficacy|0
6200705|NCT01490125|9860620|FG003|Period III|Lack of Efficacy|0
6200706|NCT01490125|9860621|FG004|Period III|Lack of Efficacy|1
6200707|NCT01490125|9860622|FG005|Period III|Lack of Efficacy|0
6200708|NCT01490294|9860640|FG000|Overall Study|Prematurely discontinuation|4
6200709|NCT01490294|9860641|FG001|Overall Study|Prematurely discontinuation|0
6200710|NCT01490294|9860642|FG002|Overall Study|Prematurely discontinuation|1
6277527|NCT02243293|9984470|FG005|Overall Study|Randomized but did'nt receive study drug|0
6277528|NCT02243293|9984471|FG006|Overall Study|Randomized but did'nt receive study drug|0
6277529|NCT02243293|9984472|FG007|Overall Study|Randomized but did'nt receive study drug|0
6277530|NCT02243293|9984473|FG008|Overall Study|Randomized but did'nt receive study drug|0
6277531|NCT02243293|9984474|FG009|Overall Study|Randomized but did'nt receive study drug|1
6277532|NCT02243293|9984475|FG010|Overall Study|Randomized but did'nt receive study drug|0
6200711|NCT01490294|9860643|FG003|Overall Study|Prematurely discontinuation|1
6200712|NCT01490294|9860640|FG000|Overall Study|Adverse Event|1
6200713|NCT01490294|9860641|FG001|Overall Study|Adverse Event|0
6200714|NCT01490294|9860642|FG002|Overall Study|Adverse Event|0
6200715|NCT01490294|9860643|FG003|Overall Study|Adverse Event|0
6200716|NCT01490450|9860667|FG000|Period 1|Lack of Efficacy|2
6200717|NCT01490450|9860668|FG001|Period 1|Lack of Efficacy|0
6200718|NCT01490450|9860669|FG002|Period 1|Lack of Efficacy|3
6200719|NCT01490450|9860670|FG003|Period 1|Lack of Efficacy|0
6277533|NCT02243293|9984476|FG011|Overall Study|Randomized but did'nt receive study drug|0
6277534|NCT02243293|9984477|FG012|Overall Study|Randomized but did'nt receive study drug|0
6277535|NCT02243293|9984478|FG013|Overall Study|Randomized but did'nt receive study drug|0
6277536|NCT02243293|9984479|FG014|Overall Study|Randomized but did'nt receive study drug|0
6277537|NCT02243293|9984480|FG015|Overall Study|Randomized but did'nt receive study drug|0
6277538|NCT02243293|9984481|FG016|Overall Study|Randomized but did'nt receive study drug|0
6277539|NCT02243293|9984482|FG017|Overall Study|Randomized but did'nt receive study drug|0
6277540|NCT02243293|9984483|FG018|Overall Study|Randomized but did'nt receive study drug|0
6277541|NCT02243293|9984484|FG019|Overall Study|Randomized but did'nt receive study drug|1
6277542|NCT02243293|9984485|FG020|Overall Study|Randomized but did'nt receive study drug|0
6277543|NCT02243293|9984486|FG021|Overall Study|Randomized but did'nt receive study drug|0
6277544|NCT02243371|9984525|FG000|Overall Study|Progressive Disease (clinic & radio)|35
6277545|NCT02243371|9984526|FG001|Overall Study|Progressive Disease (clinic & radio)|24
6277546|NCT02243371|9984525|FG000|Overall Study|Death (unrelated)|2
6277547|NCT02243371|9984526|FG001|Overall Study|Death (unrelated)|4
6277548|NCT02243371|9984525|FG000|Overall Study|Adverse Event (unrelated)|0
6277549|NCT02243371|9984526|FG001|Overall Study|Adverse Event (unrelated)|1
6277550|NCT02243371|9984525|FG000|Overall Study|Lack of Clinical Benefit|0
6277551|NCT02243371|9984526|FG001|Overall Study|Lack of Clinical Benefit|1
6277552|NCT02243371|9984525|FG000|Overall Study|Withdrawal by Subject|0
6277553|NCT02243371|9984526|FG001|Overall Study|Withdrawal by Subject|2
6277554|NCT02243696|9984545|FG000|Overall Study|Death|282
6277555|NCT02243696|9984545|FG000|Overall Study|Withdrawal by Subject|79
6277556|NCT02243696|9984545|FG000|Overall Study|Lost to Follow-up|57
6277557|NCT02243696|9984545|FG000|Overall Study|Subject No Longer has Study System|42
6277558|NCT02243696|9984545|FG000|Overall Study|Subject Withdrawn by Investigator|273
6277559|NCT02243696|9984545|FG000|Overall Study|Study Terminated for EP PASSION|961
6277560|NCT02243865|9984551|FG000|Overall Study|Protocol Violation|1
6277561|NCT02243865|9984552|FG001|Overall Study|Protocol Violation|3
6277562|NCT02243865|9984551|FG000|Overall Study|Lost to Follow-up|1
6277563|NCT02243865|9984552|FG001|Overall Study|Lost to Follow-up|1
6277564|NCT02243865|9984551|FG000|Overall Study|Withdrawal by Subject|1
6277565|NCT02243865|9984552|FG001|Overall Study|Withdrawal by Subject|0
6277566|NCT02243865|9984551|FG000|Overall Study|Adverse Event|1
6277567|NCT02243865|9984552|FG001|Overall Study|Adverse Event|1
6277568|NCT02244424|9984571|FG000|Overall Study|Lost to Follow-up|20
6277569|NCT02244424|9984572|FG001|Overall Study|Lost to Follow-up|10
6277570|NCT02244580|9984578|FG000|Overall Study|No cancer tissues available|241
6277571|NCT02244619|9984588|FG000|Overall Study|Did not receive study intervention|8
6277572|NCT02244619|9984589|FG001|Overall Study|Did not receive study intervention|21
6277573|NCT02244957|9984611|FG000|Overall Study|Lack of Efficacy|1
6277574|NCT02244957|9984612|FG001|Overall Study|Lack of Efficacy|0
6277575|NCT02244996|9984622|FG000|Overall Study|Lack of Efficacy|2
6277576|NCT02244996|9984623|FG001|Overall Study|Lack of Efficacy|6
6277577|NCT02245412|9984645|FG000|Treatment Period|Death|1
6277578|NCT02245412|9984646|FG001|Treatment Period|Death|1
6200720|NCT01490450|9860667|FG000|Period 1|Adverse Event|0
6200721|NCT01490450|9860668|FG001|Period 1|Adverse Event|0
6200722|NCT01490450|9860669|FG002|Period 1|Adverse Event|0
6200723|NCT01490450|9860670|FG003|Period 1|Adverse Event|5
6200724|NCT01490450|9860667|FG000|Period 1|Request to discontinue treatment|1
6200725|NCT01490450|9860668|FG001|Period 1|Request to discontinue treatment|0
6200726|NCT01490450|9860669|FG002|Period 1|Request to discontinue treatment|0
6200727|NCT01490450|9860670|FG003|Period 1|Request to discontinue treatment|0
6200728|NCT01490450|9860667|FG000|Period 1|Withdrawal by Subject|0
6200729|NCT01490450|9860668|FG001|Period 1|Withdrawal by Subject|0
6200730|NCT01490450|9860669|FG002|Period 1|Withdrawal by Subject|0
6200731|NCT01490450|9860670|FG003|Period 1|Withdrawal by Subject|3
6200732|NCT01490450|9860667|FG000|Period 1|No longer met study criteria|0
6200733|NCT01490450|9860668|FG001|Period 1|No longer met study criteria|1
6200734|NCT01490450|9860669|FG002|Period 1|No longer met study criteria|1
6200735|NCT01490450|9860670|FG003|Period 1|No longer met study criteria|0
6200736|NCT01490450|9860667|FG000|Period 2|Lack of Efficacy|0
6200737|NCT01490450|9860668|FG001|Period 2|Lack of Efficacy|0
6200738|NCT01490450|9860669|FG002|Period 2|Lack of Efficacy|0
6200739|NCT01490450|9860670|FG003|Period 2|Lack of Efficacy|1
6200740|NCT01490450|9860667|FG000|Period 2|Adverse Event|1
6200741|NCT01490450|9860668|FG001|Period 2|Adverse Event|1
6200742|NCT01490450|9860669|FG002|Period 2|Adverse Event|0
6200743|NCT01490450|9860670|FG003|Period 2|Adverse Event|1
6200744|NCT01490450|9860667|FG000|Period 2|Withdrawal by Subject|1
6200745|NCT01490450|9860668|FG001|Period 2|Withdrawal by Subject|0
6200746|NCT01490450|9860669|FG002|Period 2|Withdrawal by Subject|0
6200747|NCT01490450|9860670|FG003|Period 2|Withdrawal by Subject|0
6200748|NCT01490450|9860667|FG000|Period 2|Lost to Follow-up|0
6200749|NCT01490450|9860668|FG001|Period 2|Lost to Follow-up|0
6200750|NCT01490450|9860669|FG002|Period 2|Lost to Follow-up|0
6200751|NCT01490450|9860670|FG003|Period 2|Lost to Follow-up|2
6200752|NCT01490580|9860685|FG000|Overall Study|Parents withdrew consent|0
6200753|NCT01490580|9860686|FG001|Overall Study|Parents withdrew consent|2
6200754|NCT01490632|9860701|FG000|Part A: Initial Treatment Period|Adverse Event|0
6200755|NCT01490632|9860702|FG001|Part A: Initial Treatment Period|Adverse Event|0
6200756|NCT01490632|9860703|FG002|Part A: Initial Treatment Period|Adverse Event|2
6200757|NCT01490632|9860704|FG003|Part A: Initial Treatment Period|Adverse Event|4
6200758|NCT01490632|9860705|FG004|Part A: Initial Treatment Period|Adverse Event|4
6200759|NCT01490632|9860706|FG005|Part A: Initial Treatment Period|Adverse Event|0
6200760|NCT01490632|9860707|FG006|Part A: Initial Treatment Period|Adverse Event|0
6200761|NCT01490632|9860708|FG007|Part A: Initial Treatment Period|Adverse Event|0
6200762|NCT01490632|9860709|FG008|Part A: Initial Treatment Period|Adverse Event|0
6200763|NCT01490632|9860710|FG009|Part A: Initial Treatment Period|Adverse Event|0
6200764|NCT01490632|9860711|FG010|Part A: Initial Treatment Period|Adverse Event|0
6200765|NCT01490632|9860712|FG011|Part A: Initial Treatment Period|Adverse Event|0
6200766|NCT01490632|9860713|FG012|Part A: Initial Treatment Period|Adverse Event|0
6200767|NCT01490632|9860714|FG013|Part A: Initial Treatment Period|Adverse Event|0
6200768|NCT01490632|9860715|FG014|Part A: Initial Treatment Period|Adverse Event|0
6200769|NCT01490632|9860716|FG015|Part A: Initial Treatment Period|Adverse Event|0
6200770|NCT01490632|9860717|FG016|Part A: Initial Treatment Period|Adverse Event|0
6200771|NCT01490632|9860718|FG017|Part A: Initial Treatment Period|Adverse Event|0
6200772|NCT01490632|9860719|FG018|Part A: Initial Treatment Period|Adverse Event|0
6200773|NCT01490632|9860720|FG019|Part A: Initial Treatment Period|Adverse Event|0
6200774|NCT01490632|9860701|FG000|Part A: Initial Treatment Period|Lack of Efficacy|3
6200775|NCT01490632|9860702|FG001|Part A: Initial Treatment Period|Lack of Efficacy|1
6200776|NCT01490632|9860703|FG002|Part A: Initial Treatment Period|Lack of Efficacy|2
6200777|NCT01490632|9860704|FG003|Part A: Initial Treatment Period|Lack of Efficacy|2
6200778|NCT01490632|9860705|FG004|Part A: Initial Treatment Period|Lack of Efficacy|0
6277579|NCT02245412|9984647|FG002|Treatment Period|Death|0
6277580|NCT02245412|9984645|FG000|Treatment Period|Physician Decision|1
6277581|NCT02245412|9984646|FG001|Treatment Period|Physician Decision|1
6277582|NCT02245412|9984647|FG002|Treatment Period|Physician Decision|0
6277583|NCT02245412|9984645|FG000|Treatment Period|Withdrawal by Subject|2
6277584|NCT02245412|9984646|FG001|Treatment Period|Withdrawal by Subject|1
6277585|NCT02245412|9984647|FG002|Treatment Period|Withdrawal by Subject|0
6277586|NCT02245412|9984645|FG000|Treatment Period|Biopsy did not confirm GI GVHD|1
6277587|NCT02245412|9984646|FG001|Treatment Period|Biopsy did not confirm GI GVHD|0
6277588|NCT02245412|9984647|FG002|Treatment Period|Biopsy did not confirm GI GVHD|0
6277589|NCT02245412|9984645|FG000|Follow-Up Period|Death|4
6277590|NCT02245412|9984646|FG001|Follow-Up Period|Death|2
6277591|NCT02245412|9984647|FG002|Follow-Up Period|Death|1
6277592|NCT02245412|9984645|FG000|Follow-Up Period|Physician Decision|1
6089009|NCT00679939|9700158|FG000|52-Week Double-Blind (DB) Period|Lost to Follow-up|0
6277593|NCT02245412|9984646|FG001|Follow-Up Period|Physician Decision|0
6277594|NCT02245412|9984647|FG002|Follow-Up Period|Physician Decision|0
6277595|NCT02245412|9984645|FG000|Follow-Up Period|Other - Terminated by Sponsor|0
6277596|NCT02245412|9984646|FG001|Follow-Up Period|Other - Terminated by Sponsor|0
6277597|NCT02245412|9984647|FG002|Follow-Up Period|Other - Terminated by Sponsor|1
6277598|NCT02245568|9984664|FG000|Overall Study|Study terminated by Sponsor|346
6277599|NCT02245568|9984664|FG000|Overall Study|Adverse Event|144
6277600|NCT02245568|9984664|FG000|Overall Study|Lack of Efficacy|98
6277601|NCT02245568|9984664|FG000|Overall Study|Withdrawal by Caregiver|85
6277602|NCT02245568|9984664|FG000|Overall Study|Withdrawal by Subject|77
6277603|NCT02245568|9984664|FG000|Overall Study|Withdrawal by Legal Representative|31
6277604|NCT02245568|9984664|FG000|Overall Study|Missing (Site closure)|16
6277605|NCT02245568|9984664|FG000|Overall Study|Physician Decision|14
6277606|NCT02245568|9984664|FG000|Overall Study|Non-compliance with study drug|11
6277607|NCT02245568|9984664|FG000|Overall Study|Death|9
6277608|NCT02245568|9984664|FG000|Overall Study|Blue staining|6
6277609|NCT02245568|9984664|FG000|Overall Study|Worsening dementia/caregiver withdrawal|6
6277610|NCT02245568|9984664|FG000|Overall Study|Intolerance/dosing issues/interruption|5
6277611|NCT02245568|9984664|FG000|Overall Study|Lost to Follow-up|5
5977439|NCT03461289|9564682|FG000|Overall Study|Death|1
5977440|NCT03406507|9564688|FG000|Extension Period|Lack of Efficacy|0
5977441|NCT03406507|9564689|FG001|Extension Period|Lack of Efficacy|1
5977442|NCT03406507|9564688|FG000|Extension Period|Ongoing in Extension Period|5
5977443|NCT03406507|9564689|FG001|Extension Period|Ongoing in Extension Period|5
5977444|NCT02966301|9564713|FG000|Overall Study|Death|2
5977445|NCT02966301|9564713|FG000|Overall Study|Withdrawal by Subject|1
5977446|NCT02941926|9564717|FG000|Overall Study|Progressive disease|1109
5977447|NCT02941926|9564717|FG000|Overall Study|Adverse Event|504
5977448|NCT02941926|9564717|FG000|Overall Study|Subject/guardian decision|127
5977449|NCT02941926|9564717|FG000|Overall Study|Physician Decision|112
5977450|NCT02941926|9564717|FG000|Overall Study|Death|46
5977451|NCT02941926|9564717|FG000|Overall Study|Protocol deviation|34
5977452|NCT02941926|9564717|FG000|Overall Study|Lost to Follow-up|8
6200779|NCT01490632|9860706|FG005|Part A: Initial Treatment Period|Lack of Efficacy|0
6277612|NCT02245620|9984670|FG000|Overall Study|Physician Decision|1
6277613|NCT02245620|9984671|FG001|Overall Study|Physician Decision|1
6277614|NCT02245737|9984680|FG000|Overall Study|Adverse Event|23
6277615|NCT02245737|9984681|FG001|Overall Study|Adverse Event|26
6277616|NCT02245737|9984682|FG002|Overall Study|Adverse Event|33
6277617|NCT02245737|9984680|FG000|Overall Study|Condition Worsened|9
6200780|NCT01490632|9860707|FG006|Part A: Initial Treatment Period|Lack of Efficacy|0
6200781|NCT01490632|9860708|FG007|Part A: Initial Treatment Period|Lack of Efficacy|0
6200782|NCT01490632|9860709|FG008|Part A: Initial Treatment Period|Lack of Efficacy|0
6277618|NCT02245737|9984681|FG001|Overall Study|Condition Worsened|10
6277619|NCT02245737|9984682|FG002|Overall Study|Condition Worsened|9
6277620|NCT02245737|9984680|FG000|Overall Study|Death|2
6277621|NCT02245737|9984681|FG001|Overall Study|Death|4
6277622|NCT02245737|9984682|FG002|Overall Study|Death|4
6277623|NCT02245737|9984680|FG000|Overall Study|Eligibility Criteria No Longer Met|2
6277624|NCT02245737|9984681|FG001|Overall Study|Eligibility Criteria No Longer Met|4
6277625|NCT02245737|9984682|FG002|Overall Study|Eligibility Criteria No Longer Met|4
6277626|NCT02245737|9984680|FG000|Overall Study|Initiation of Symptomatic AD medication|2
6277627|NCT02245737|9984681|FG001|Overall Study|Initiation of Symptomatic AD medication|0
6277628|NCT02245737|9984682|FG002|Overall Study|Initiation of Symptomatic AD medication|0
6277629|NCT02245737|9984680|FG000|Overall Study|Lost to Follow-up|2
6277630|NCT02245737|9984681|FG001|Overall Study|Lost to Follow-up|5
6277631|NCT02245737|9984682|FG002|Overall Study|Lost to Follow-up|4
6277632|NCT02245737|9984680|FG000|Overall Study|Other-determined by Investigator|9
6277633|NCT02245737|9984681|FG001|Overall Study|Other-determined by Investigator|10
6277634|NCT02245737|9984682|FG002|Overall Study|Other-determined by Investigator|10
6277635|NCT02245737|9984680|FG000|Overall Study|Physician Decision|6
6277636|NCT02245737|9984681|FG001|Overall Study|Physician Decision|3
6277637|NCT02245737|9984682|FG002|Overall Study|Physician Decision|6
6277638|NCT02245737|9984680|FG000|Overall Study|Protocol Violation|3
6277639|NCT02245737|9984681|FG001|Overall Study|Protocol Violation|2
6277640|NCT02245737|9984682|FG002|Overall Study|Protocol Violation|3
6277641|NCT02245737|9984680|FG000|Overall Study|Withdrawal by Subject|40
6277642|NCT02245737|9984681|FG001|Overall Study|Withdrawal by Subject|41
6277643|NCT02245737|9984682|FG002|Overall Study|Withdrawal by Subject|44
6277644|NCT02245737|9984680|FG000|Overall Study|Withdrawal due to Caregiver Circumstance|10
6277645|NCT02245737|9984681|FG001|Overall Study|Withdrawal due to Caregiver Circumstance|20
6277646|NCT02245737|9984682|FG002|Overall Study|Withdrawal due to Caregiver Circumstance|22
6277647|NCT02245737|9984680|FG000|Overall Study|Sponsor Decision|445
6277648|NCT02245737|9984681|FG001|Overall Study|Sponsor Decision|430
6277649|NCT02245737|9984682|FG002|Overall Study|Sponsor Decision|432
6277650|NCT02246166|9984731|FG000|Overall Study|Protocol Violation|1
6277651|NCT02246166|9984732|FG001|Overall Study|Protocol Violation|0
6277652|NCT02246218|9984740|FG000|Overall Study|Withdrawal by Parent/Guardian|0
6277653|NCT02246218|9984741|FG001|Overall Study|Withdrawal by Parent/Guardian|1
6277654|NCT02246218|9984740|FG000|Overall Study|Stopping Rule: Liver Transplant|2
6277655|NCT02246218|9984741|FG001|Overall Study|Stopping Rule: Liver Transplant|4
6277656|NCT02246218|9984740|FG000|Overall Study|Adverse Event|1
6277657|NCT02246218|9984741|FG001|Overall Study|Adverse Event|1
6277658|NCT02246218|9984740|FG000|Overall Study|Lost to Follow-up|1
6277659|NCT02246218|9984741|FG001|Overall Study|Lost to Follow-up|0
6277660|NCT02246439|9984767|FG000|Overall Study|Adverse Event|3
6277661|NCT02246439|9984768|FG001|Overall Study|Adverse Event|0
6277662|NCT02246439|9984767|FG000|Overall Study|Lost to Follow-up|7
5977453|NCT02941926|9564717|FG000|Overall Study|Technical problems|5
5977454|NCT02832167|9564732|FG000|Treatment Period 1|Disease progression|90
5977455|NCT02832167|9564732|FG000|Treatment Period 1|Adverse event unrelated to study drug|12
5977456|NCT02832167|9564732|FG000|Treatment Period 1|Death|2
5977457|NCT02832167|9564732|FG000|Treatment Period 1|Study Drug Toxicity|6
5977458|NCT02832167|9564732|FG000|Treatment Period 1|Participant request to discontinue|9
5977459|NCT02832167|9564732|FG000|Treatment Period 1|No longer meet study criteria|1
5977460|NCT02832167|9564732|FG000|Treatment Period 1|Participant withdrew consent|3
5977461|NCT02832167|9564732|FG000|Treatment Period 1|Other reasons|6
5977462|NCT02832167|9564732|FG000|Transition From Period 1 to Period 2|Other reasons|1
5977463|NCT02832167|9564732|FG000|Transition From Period 1 to Period 2|Participant withdrew consent|1
5977464|NCT02832167|9564732|FG000|Transition From Period 1 to Period 2|Death|2
5977465|NCT02832167|9564732|FG000|Transition From Period 1 to Period 2|Lost to Follow-up|3
5977466|NCT02832167|9564732|FG000|Treatment Period 2|Disease progression|69
5977467|NCT02832167|9564732|FG000|Treatment Period 2|Adverse event unrelated to study drug|1
5977468|NCT02832167|9564732|FG000|Treatment Period 2|Maximum clinical benefit|1
5977469|NCT02832167|9564732|FG000|Treatment Period 2|Study Drug Toxicity|5
5977470|NCT02832167|9564732|FG000|Treatment Period 2|Participant request to discontinue|2
5977471|NCT02832167|9564732|FG000|Treatment Period 2|Participant withdrew consent|3
5977472|NCT02832167|9564732|FG000|Treatment Period 2|Other reasons|3
6050876|NCT00429663|9650130|FG001|Overall Study|Withdrawal by Subject|5
6050877|NCT00429663|9650129|FG000|Overall Study|Death|4
6200783|NCT01490632|9860710|FG009|Part A: Initial Treatment Period|Lack of Efficacy|0
6200784|NCT01490632|9860711|FG010|Part A: Initial Treatment Period|Lack of Efficacy|0
6200785|NCT01490632|9860712|FG011|Part A: Initial Treatment Period|Lack of Efficacy|0
6200786|NCT01490632|9860713|FG012|Part A: Initial Treatment Period|Lack of Efficacy|0
6277663|NCT02246439|9984768|FG001|Overall Study|Lost to Follow-up|5
6277664|NCT02246439|9984767|FG000|Overall Study|Protocol Violation|0
6277665|NCT02246439|9984768|FG001|Overall Study|Protocol Violation|2
6277666|NCT02246439|9984767|FG000|Overall Study|Physician Decision|0
6200787|NCT01490632|9860714|FG013|Part A: Initial Treatment Period|Lack of Efficacy|0
6050878|NCT00429663|9650130|FG001|Overall Study|Death|0
6200788|NCT01490632|9860715|FG014|Part A: Initial Treatment Period|Lack of Efficacy|0
6200789|NCT01490632|9860716|FG015|Part A: Initial Treatment Period|Lack of Efficacy|0
6200790|NCT01490632|9860717|FG016|Part A: Initial Treatment Period|Lack of Efficacy|0
6200791|NCT01490632|9860718|FG017|Part A: Initial Treatment Period|Lack of Efficacy|0
6200792|NCT01490632|9860719|FG018|Part A: Initial Treatment Period|Lack of Efficacy|0
6200793|NCT01490632|9860720|FG019|Part A: Initial Treatment Period|Lack of Efficacy|0
6200794|NCT01490632|9860701|FG000|Part A: Initial Treatment Period|Lost to Follow-up|0
6200795|NCT01490632|9860702|FG001|Part A: Initial Treatment Period|Lost to Follow-up|0
6200796|NCT01490632|9860703|FG002|Part A: Initial Treatment Period|Lost to Follow-up|1
6200797|NCT01490632|9860704|FG003|Part A: Initial Treatment Period|Lost to Follow-up|1
6200798|NCT01490632|9860705|FG004|Part A: Initial Treatment Period|Lost to Follow-up|2
6200799|NCT01490632|9860706|FG005|Part A: Initial Treatment Period|Lost to Follow-up|0
6200800|NCT01490632|9860707|FG006|Part A: Initial Treatment Period|Lost to Follow-up|0
6200801|NCT01490632|9860708|FG007|Part A: Initial Treatment Period|Lost to Follow-up|0
6200802|NCT01490632|9860709|FG008|Part A: Initial Treatment Period|Lost to Follow-up|0
6200803|NCT01490632|9860710|FG009|Part A: Initial Treatment Period|Lost to Follow-up|0
6200804|NCT01490632|9860711|FG010|Part A: Initial Treatment Period|Lost to Follow-up|0
6200805|NCT01490632|9860712|FG011|Part A: Initial Treatment Period|Lost to Follow-up|0
6200806|NCT01490632|9860713|FG012|Part A: Initial Treatment Period|Lost to Follow-up|0
6200807|NCT01490632|9860714|FG013|Part A: Initial Treatment Period|Lost to Follow-up|0
6200808|NCT01490632|9860715|FG014|Part A: Initial Treatment Period|Lost to Follow-up|0
6200809|NCT01490632|9860716|FG015|Part A: Initial Treatment Period|Lost to Follow-up|0
6200810|NCT01490632|9860717|FG016|Part A: Initial Treatment Period|Lost to Follow-up|0
6200811|NCT01490632|9860718|FG017|Part A: Initial Treatment Period|Lost to Follow-up|0
6277667|NCT02246439|9984768|FG001|Overall Study|Physician Decision|1
6277668|NCT02246439|9984767|FG000|Overall Study|Unkonwn|1
6277669|NCT02246439|9984768|FG001|Overall Study|Unkonwn|3
6277670|NCT02246439|9984767|FG000|Overall Study|Withdrawal by Subject|1
6277671|NCT02246439|9984768|FG001|Overall Study|Withdrawal by Subject|0
6277672|NCT02246478|9984778|FG000|Multiple-dose Phase|Protocol Violation|1
6277673|NCT02246478|9984779|FG001|Multiple-dose Phase|Protocol Violation|0
6277674|NCT02246478|9984780|FG002|Multiple-dose Phase|Protocol Violation|0
6277675|NCT02246478|9984781|FG003|Multiple-dose Phase|Protocol Violation|1
6277676|NCT02246582|9984798|FG000|Overall Study|Withdrawal by Subject|3
6277677|NCT02246582|9984799|FG001|Overall Study|Withdrawal by Subject|4
6277678|NCT02246647|9984814|FG000|Overall Study|Withdrawal by Subject|1
6277679|NCT02246647|9984815|FG001|Overall Study|Withdrawal by Subject|1
6277680|NCT02246660|9984838|FG000|Overall Study|Withdrawal by Subject|0
6277681|NCT02246660|9984839|FG001|Overall Study|Withdrawal by Subject|1
6277682|NCT02246660|9984840|FG002|Overall Study|Withdrawal by Subject|0
6277683|NCT02246660|9984838|FG000|Overall Study|Death|0
6277684|NCT02246660|9984839|FG001|Overall Study|Death|0
6277685|NCT02246660|9984840|FG002|Overall Study|Death|1
6277686|NCT02246673|9984853|FG000|Overall Study|Sponsor Decision|1
6277687|NCT02246673|9984854|FG001|Overall Study|Sponsor Decision|0
6277688|NCT02246673|9984855|FG002|Overall Study|Sponsor Decision|0
6277689|NCT02246673|9984856|FG003|Overall Study|Sponsor Decision|0
6277690|NCT02246673|9984857|FG004|Overall Study|Sponsor Decision|0
6277691|NCT02246673|9984853|FG000|Overall Study|Withdrawal by Subject|0
6277692|NCT02246673|9984854|FG001|Overall Study|Withdrawal by Subject|0
6277693|NCT02246673|9984855|FG002|Overall Study|Withdrawal by Subject|0
6277694|NCT02246673|9984856|FG003|Overall Study|Withdrawal by Subject|0
6277695|NCT02246673|9984857|FG004|Overall Study|Withdrawal by Subject|1
6277696|NCT02246673|9984853|FG000|Overall Study|Lost to Follow-up|0
6277697|NCT02246673|9984854|FG001|Overall Study|Lost to Follow-up|0
6277698|NCT02246673|9984855|FG002|Overall Study|Lost to Follow-up|0
6277699|NCT02246673|9984856|FG003|Overall Study|Lost to Follow-up|1
6277700|NCT02246673|9984857|FG004|Overall Study|Lost to Follow-up|0
6277701|NCT02246673|9984853|FG000|Overall Study|Protocol Violation|0
6277702|NCT02246673|9984854|FG001|Overall Study|Protocol Violation|0
6277703|NCT02246673|9984855|FG002|Overall Study|Protocol Violation|0
6277704|NCT02246673|9984856|FG003|Overall Study|Protocol Violation|1
6277705|NCT02246673|9984857|FG004|Overall Study|Protocol Violation|0
6277706|NCT02246764|9984902|FG000|Overall Study|Adverse Event|15
5977473|NCT02699554|9564736|FG000|Overall Study|Lost to Follow-up|9
5977474|NCT02659020|9564747|FG000|Overall Study|Adverse Event|0
5977475|NCT02659020|9564748|FG001|Overall Study|Adverse Event|0
5977476|NCT02659020|9564749|FG002|Overall Study|Adverse Event|0
5977477|NCT02659020|9564750|FG003|Overall Study|Adverse Event|2
6200812|NCT01490632|9860719|FG018|Part A: Initial Treatment Period|Lost to Follow-up|0
6200813|NCT01490632|9860720|FG019|Part A: Initial Treatment Period|Lost to Follow-up|0
6277707|NCT02246764|9984903|FG001|Overall Study|Adverse Event|29
6277708|NCT02246764|9984904|FG002|Overall Study|Adverse Event|1
6277709|NCT02246764|9984902|FG000|Overall Study|Withdrawal by Subject|0
6277710|NCT02246764|9984903|FG001|Overall Study|Withdrawal by Subject|0
6277711|NCT02246764|9984904|FG002|Overall Study|Withdrawal by Subject|1
6277712|NCT02246764|9984902|FG000|Overall Study|Disallowed Concomitant Medication|1
6277713|NCT02246764|9984903|FG001|Overall Study|Disallowed Concomitant Medication|0
6277714|NCT02246764|9984904|FG002|Overall Study|Disallowed Concomitant Medication|0
6277715|NCT02246764|9984902|FG000|Overall Study|Physician Decision|0
6200814|NCT01490632|9860701|FG000|Part A: Initial Treatment Period|Physician Decision|0
6200815|NCT01490632|9860702|FG001|Part A: Initial Treatment Period|Physician Decision|1
6200816|NCT01490632|9860703|FG002|Part A: Initial Treatment Period|Physician Decision|0
6200817|NCT01490632|9860704|FG003|Part A: Initial Treatment Period|Physician Decision|1
6200818|NCT01490632|9860705|FG004|Part A: Initial Treatment Period|Physician Decision|0
6200819|NCT01490632|9860706|FG005|Part A: Initial Treatment Period|Physician Decision|0
6200820|NCT01490632|9860707|FG006|Part A: Initial Treatment Period|Physician Decision|0
6200821|NCT01490632|9860708|FG007|Part A: Initial Treatment Period|Physician Decision|0
6200822|NCT01490632|9860709|FG008|Part A: Initial Treatment Period|Physician Decision|0
6200823|NCT01490632|9860710|FG009|Part A: Initial Treatment Period|Physician Decision|0
6200824|NCT01490632|9860711|FG010|Part A: Initial Treatment Period|Physician Decision|0
6277716|NCT02246764|9984903|FG001|Overall Study|Physician Decision|2
6277717|NCT02246764|9984904|FG002|Overall Study|Physician Decision|1
6277718|NCT02246764|9984902|FG000|Overall Study|Protocol Violation|2
6277719|NCT02246764|9984903|FG001|Overall Study|Protocol Violation|1
6277720|NCT02246764|9984904|FG002|Overall Study|Protocol Violation|1
6277721|NCT02246777|9984912|FG000|Overall Study|Adverse Event|2
6277722|NCT02246777|9984912|FG000|Overall Study|Change of residence|1
6277723|NCT02246998|9984925|FG000|Overall Study|Adverse Event|0
6277724|NCT02246998|9984926|FG001|Overall Study|Adverse Event|1
6277725|NCT02246998|9984927|FG002|Overall Study|Adverse Event|1
6277726|NCT02246998|9984928|FG003|Overall Study|Adverse Event|0
6277727|NCT02246998|9984925|FG000|Overall Study|Lost to Follow-up|1
6277728|NCT02246998|9984926|FG001|Overall Study|Lost to Follow-up|0
6277729|NCT02246998|9984927|FG002|Overall Study|Lost to Follow-up|0
6277730|NCT02246998|9984928|FG003|Overall Study|Lost to Follow-up|1
6277731|NCT02246998|9984925|FG000|Overall Study|Randomized but Never Dosed|1
6277732|NCT02246998|9984926|FG001|Overall Study|Randomized but Never Dosed|2
6277733|NCT02246998|9984927|FG002|Overall Study|Randomized but Never Dosed|2
6277734|NCT02246998|9984928|FG003|Overall Study|Randomized but Never Dosed|1
6277735|NCT02247011|9984943|FG000|Overall Study|Poor quality of radiological results|125
6277736|NCT02247401|9984997|FG000|Overall Study|Adverse Event|1
6277737|NCT02247401|9984998|FG001|Overall Study|Adverse Event|0
6277738|NCT02247401|9984999|FG002|Overall Study|Adverse Event|0
6277739|NCT02247401|9984997|FG000|Overall Study|Withdrawal by Subject|4
6277740|NCT02247401|9984998|FG001|Overall Study|Withdrawal by Subject|1
6277741|NCT02247401|9984999|FG002|Overall Study|Withdrawal by Subject|1
6277742|NCT02247401|9984997|FG000|Overall Study|Lost to Follow-up|1
6277743|NCT02247401|9984998|FG001|Overall Study|Lost to Follow-up|1
6277744|NCT02247401|9984999|FG002|Overall Study|Lost to Follow-up|1
6277745|NCT02247440|9985008|FG000|Overall Study|Withdrawal by Subject|1
6277746|NCT02247440|9985008|FG000|Overall Study|Lack of Efficacy|3
6277747|NCT02247466|9985014|FG000|Overall Study|Procedure changed to open surgery|0
6277748|NCT02247466|9985015|FG001|Overall Study|Procedure changed to open surgery|3
6277749|NCT02247479|9985024|FG000|Overall Study|Adverse Event|8
6277750|NCT02247479|9985025|FG001|Overall Study|Adverse Event|9
6277751|NCT02247479|9985026|FG002|Overall Study|Adverse Event|8
6277752|NCT02247479|9985024|FG000|Overall Study|Death|5
6277753|NCT02247479|9985025|FG001|Overall Study|Death|4
6277754|NCT02247479|9985026|FG002|Overall Study|Death|6
6277755|NCT02247479|9985024|FG000|Overall Study|Lost to Follow-up|3
6277756|NCT02247479|9985025|FG001|Overall Study|Lost to Follow-up|3
6277757|NCT02247479|9985026|FG002|Overall Study|Lost to Follow-up|1
6277758|NCT02247479|9985024|FG000|Overall Study|Non-compliance|0
6277759|NCT02247479|9985025|FG001|Overall Study|Non-compliance|0
6277760|NCT02247479|9985026|FG002|Overall Study|Non-compliance|1
6277761|NCT02247479|9985024|FG000|Overall Study|Withdrawal by Subject|25
6277762|NCT02247479|9985025|FG001|Overall Study|Withdrawal by Subject|29
6277763|NCT02247479|9985026|FG002|Overall Study|Withdrawal by Subject|24
6277764|NCT02247479|9985024|FG000|Overall Study|Study Terminated by Sponsor|98
6277765|NCT02247479|9985025|FG001|Overall Study|Study Terminated by Sponsor|88
6277766|NCT02247479|9985026|FG002|Overall Study|Study Terminated by Sponsor|94
6277767|NCT02247479|9985024|FG000|Overall Study|Physician Decision|1
6277768|NCT02247479|9985025|FG001|Overall Study|Physician Decision|0
6277769|NCT02247479|9985026|FG002|Overall Study|Physician Decision|2
6277770|NCT02247479|9985024|FG000|Overall Study|Unspecified Reason|2
6277771|NCT02247479|9985025|FG001|Overall Study|Unspecified Reason|5
6277772|NCT02247479|9985026|FG002|Overall Study|Unspecified Reason|2
6277773|NCT02247531|9985037|FG000|Overall Study|Adverse Event|3
6277774|NCT02247531|9985038|FG001|Overall Study|Adverse Event|4
6277775|NCT02247531|9985039|FG002|Overall Study|Adverse Event|9
6277776|NCT02247531|9985037|FG000|Overall Study|Death|8
6277777|NCT02247531|9985038|FG001|Overall Study|Death|9
6277778|NCT02247531|9985039|FG002|Overall Study|Death|5
6277779|NCT02247531|9985037|FG000|Overall Study|Lost to Follow-up|1
6277780|NCT02247531|9985038|FG001|Overall Study|Lost to Follow-up|8
6277781|NCT02247531|9985039|FG002|Overall Study|Lost to Follow-up|3
6277782|NCT02247531|9985037|FG000|Overall Study|Non-compliance|2
6277783|NCT02247531|9985038|FG001|Overall Study|Non-compliance|2
6277784|NCT02247531|9985039|FG002|Overall Study|Non-compliance|0
6277785|NCT02247531|9985037|FG000|Overall Study|Withdrawal by Subject|26
6277786|NCT02247531|9985038|FG001|Overall Study|Withdrawal by Subject|31
6277787|NCT02247531|9985039|FG002|Overall Study|Withdrawal by Subject|25
6277788|NCT02247531|9985037|FG000|Overall Study|Study Terminated by Sponsor|64
6200825|NCT01490632|9860712|FG011|Part A: Initial Treatment Period|Physician Decision|0
6200826|NCT01490632|9860713|FG012|Part A: Initial Treatment Period|Physician Decision|0
6200827|NCT01490632|9860714|FG013|Part A: Initial Treatment Period|Physician Decision|0
6200828|NCT01490632|9860715|FG014|Part A: Initial Treatment Period|Physician Decision|0
6200829|NCT01490632|9860716|FG015|Part A: Initial Treatment Period|Physician Decision|0
6200830|NCT01490632|9860717|FG016|Part A: Initial Treatment Period|Physician Decision|0
6200831|NCT01490632|9860718|FG017|Part A: Initial Treatment Period|Physician Decision|0
6200832|NCT01490632|9860719|FG018|Part A: Initial Treatment Period|Physician Decision|0
6089010|NCT00679939|9700159|FG001|52-Week Double-Blind (DB) Period|Lost to Follow-up|2
6200833|NCT01490632|9860720|FG019|Part A: Initial Treatment Period|Physician Decision|0
6200834|NCT01490632|9860701|FG000|Part A: Initial Treatment Period|Sponsor Decision|2
6200835|NCT01490632|9860702|FG001|Part A: Initial Treatment Period|Sponsor Decision|0
6200836|NCT01490632|9860703|FG002|Part A: Initial Treatment Period|Sponsor Decision|0
6200837|NCT01490632|9860704|FG003|Part A: Initial Treatment Period|Sponsor Decision|0
6200838|NCT01490632|9860705|FG004|Part A: Initial Treatment Period|Sponsor Decision|0
6200839|NCT01490632|9860706|FG005|Part A: Initial Treatment Period|Sponsor Decision|0
6200840|NCT01490632|9860707|FG006|Part A: Initial Treatment Period|Sponsor Decision|0
6200841|NCT01490632|9860708|FG007|Part A: Initial Treatment Period|Sponsor Decision|0
6200842|NCT01490632|9860709|FG008|Part A: Initial Treatment Period|Sponsor Decision|0
6200843|NCT01490632|9860710|FG009|Part A: Initial Treatment Period|Sponsor Decision|0
6200844|NCT01490632|9860711|FG010|Part A: Initial Treatment Period|Sponsor Decision|0
6200845|NCT01490632|9860712|FG011|Part A: Initial Treatment Period|Sponsor Decision|0
6200846|NCT01490632|9860713|FG012|Part A: Initial Treatment Period|Sponsor Decision|0
6200847|NCT01490632|9860714|FG013|Part A: Initial Treatment Period|Sponsor Decision|0
6277789|NCT02247531|9985038|FG001|Overall Study|Study Terminated by Sponsor|66
6089011|NCT00679939|9700158|FG000|24-Week Open-Label (OL) Period|Adverse Event|0
6089012|NCT00679939|9700159|FG001|24-Week Open-Label (OL) Period|Adverse Event|1
6089013|NCT00679939|9700158|FG000|24-Week Open-Label (OL) Period|Protocol Violation|1
6089014|NCT00679939|9700159|FG001|24-Week Open-Label (OL) Period|Protocol Violation|1
6089015|NCT00679939|9700158|FG000|24-Week Open-Label (OL) Period|Met Stopping Criteria|3
6089016|NCT00679939|9700159|FG001|24-Week Open-Label (OL) Period|Met Stopping Criteria|1
6089017|NCT00679939|9700158|FG000|24-Week Open-Label (OL) Period|Physician Decision|1
6089018|NCT00679939|9700159|FG001|24-Week Open-Label (OL) Period|Physician Decision|0
6089019|NCT00679939|9700158|FG000|24-Week Open-Label (OL) Period|Withdrawal by Subject|2
6089020|NCT00679939|9700159|FG001|24-Week Open-Label (OL) Period|Withdrawal by Subject|1
6089021|NCT00680017|9700180|FG000|Overall Study|Adverse Event|13
6089022|NCT00680017|9700181|FG001|Overall Study|Adverse Event|7
6089023|NCT00680017|9700180|FG000|Overall Study|Withdrawal by Subject|2
6089024|NCT00680017|9700181|FG001|Overall Study|Withdrawal by Subject|5
6089025|NCT00680017|9700180|FG000|Overall Study|Lost to Follow-up|2
6277790|NCT02247531|9985039|FG002|Overall Study|Study Terminated by Sponsor|62
6277791|NCT02247531|9985037|FG000|Overall Study|Physician Decision|0
6277792|NCT02247531|9985038|FG001|Overall Study|Physician Decision|2
6277793|NCT02247531|9985039|FG002|Overall Study|Physician Decision|2
6277794|NCT02247531|9985037|FG000|Overall Study|Unspecified Reason|2
6277795|NCT02247531|9985038|FG001|Overall Study|Unspecified Reason|3
6277796|NCT02247531|9985039|FG002|Overall Study|Unspecified Reason|4
6277797|NCT02247804|9985069|FG000|Treatment Period 1|Adverse Event|9
6277798|NCT02247804|9985070|FG001|Treatment Period 1|Adverse Event|2
6277799|NCT02247804|9985071|FG002|Treatment Period 1|Adverse Event|0
5977478|NCT02659020|9564751|FG004|Overall Study|Adverse Event|0
5977479|NCT02659020|9564752|FG005|Overall Study|Adverse Event|0
5977480|NCT02659020|9564753|FG006|Overall Study|Adverse Event|2
5977481|NCT02659020|9564747|FG000|Overall Study|Lost to Follow-up|1
5977482|NCT02659020|9564748|FG001|Overall Study|Lost to Follow-up|2
5977483|NCT02659020|9564749|FG002|Overall Study|Lost to Follow-up|1
5977484|NCT02659020|9564750|FG003|Overall Study|Lost to Follow-up|6
5977485|NCT02659020|9564751|FG004|Overall Study|Lost to Follow-up|1
5977486|NCT02659020|9564752|FG005|Overall Study|Lost to Follow-up|5
5977487|NCT02659020|9564753|FG006|Overall Study|Lost to Follow-up|0
5977488|NCT02659020|9564747|FG000|Overall Study|Physician Decision|0
5977489|NCT02659020|9564748|FG001|Overall Study|Physician Decision|0
5977490|NCT02659020|9564749|FG002|Overall Study|Physician Decision|0
5977491|NCT02659020|9564750|FG003|Overall Study|Physician Decision|1
5977492|NCT02659020|9564751|FG004|Overall Study|Physician Decision|1
5977493|NCT02659020|9564752|FG005|Overall Study|Physician Decision|0
5977494|NCT02659020|9564753|FG006|Overall Study|Physician Decision|1
5977495|NCT02659020|9564747|FG000|Overall Study|Withdrawal by Subject|2
5977496|NCT02659020|9564748|FG001|Overall Study|Withdrawal by Subject|1
6089026|NCT00680017|9700181|FG001|Overall Study|Lost to Follow-up|0
6089027|NCT00680043|9700190|FG000|Overall Study|Withdrawal by Subject|1
6200848|NCT01490632|9860715|FG014|Part A: Initial Treatment Period|Sponsor Decision|0
6277800|NCT02247804|9985069|FG000|Treatment Period 1|Lack of Efficacy|0
6277801|NCT02247804|9985070|FG001|Treatment Period 1|Lack of Efficacy|0
6277802|NCT02247804|9985071|FG002|Treatment Period 1|Lack of Efficacy|2
6277803|NCT02247804|9985069|FG000|Treatment Period 1|Lost to Follow-up|1
6277804|NCT02247804|9985070|FG001|Treatment Period 1|Lost to Follow-up|0
5977497|NCT02659020|9564749|FG002|Overall Study|Withdrawal by Subject|0
5977498|NCT02659020|9564750|FG003|Overall Study|Withdrawal by Subject|3
6200849|NCT01490632|9860716|FG015|Part A: Initial Treatment Period|Sponsor Decision|0
6200850|NCT01490632|9860717|FG016|Part A: Initial Treatment Period|Sponsor Decision|0
6200851|NCT01490632|9860718|FG017|Part A: Initial Treatment Period|Sponsor Decision|0
6200852|NCT01490632|9860719|FG018|Part A: Initial Treatment Period|Sponsor Decision|0
6200853|NCT01490632|9860720|FG019|Part A: Initial Treatment Period|Sponsor Decision|0
6200854|NCT01490632|9860701|FG000|Part A: Initial Treatment Period|Withdrawal by Subject|2
6200855|NCT01490632|9860702|FG001|Part A: Initial Treatment Period|Withdrawal by Subject|2
6200856|NCT01490632|9860703|FG002|Part A: Initial Treatment Period|Withdrawal by Subject|0
6200857|NCT01490632|9860704|FG003|Part A: Initial Treatment Period|Withdrawal by Subject|1
6200858|NCT01490632|9860705|FG004|Part A: Initial Treatment Period|Withdrawal by Subject|2
6200859|NCT01490632|9860706|FG005|Part A: Initial Treatment Period|Withdrawal by Subject|0
6200860|NCT01490632|9860707|FG006|Part A: Initial Treatment Period|Withdrawal by Subject|0
6200861|NCT01490632|9860708|FG007|Part A: Initial Treatment Period|Withdrawal by Subject|0
6200862|NCT01490632|9860709|FG008|Part A: Initial Treatment Period|Withdrawal by Subject|0
6200863|NCT01490632|9860710|FG009|Part A: Initial Treatment Period|Withdrawal by Subject|0
6200864|NCT01490632|9860711|FG010|Part A: Initial Treatment Period|Withdrawal by Subject|0
6200865|NCT01490632|9860712|FG011|Part A: Initial Treatment Period|Withdrawal by Subject|0
6200866|NCT01490632|9860713|FG012|Part A: Initial Treatment Period|Withdrawal by Subject|0
6200867|NCT01490632|9860714|FG013|Part A: Initial Treatment Period|Withdrawal by Subject|0
6200868|NCT01490632|9860715|FG014|Part A: Initial Treatment Period|Withdrawal by Subject|0
6200869|NCT01490632|9860716|FG015|Part A: Initial Treatment Period|Withdrawal by Subject|0
6200870|NCT01490632|9860717|FG016|Part A: Initial Treatment Period|Withdrawal by Subject|0
6200871|NCT01490632|9860718|FG017|Part A: Initial Treatment Period|Withdrawal by Subject|0
6200872|NCT01490632|9860719|FG018|Part A: Initial Treatment Period|Withdrawal by Subject|0
6200873|NCT01490632|9860720|FG019|Part A: Initial Treatment Period|Withdrawal by Subject|0
6200874|NCT01490632|9860701|FG000|Part A: Initial Treatment Period|Discontinued at Week 12 per protocol|0
6200875|NCT01490632|9860702|FG001|Part A: Initial Treatment Period|Discontinued at Week 12 per protocol|0
6200876|NCT01490632|9860703|FG002|Part A: Initial Treatment Period|Discontinued at Week 12 per protocol|0
6200877|NCT01490632|9860704|FG003|Part A: Initial Treatment Period|Discontinued at Week 12 per protocol|0
6200878|NCT01490632|9860705|FG004|Part A: Initial Treatment Period|Discontinued at Week 12 per protocol|9
6200879|NCT01490632|9860706|FG005|Part A: Initial Treatment Period|Discontinued at Week 12 per protocol|0
6200880|NCT01490632|9860707|FG006|Part A: Initial Treatment Period|Discontinued at Week 12 per protocol|0
6200881|NCT01490632|9860708|FG007|Part A: Initial Treatment Period|Discontinued at Week 12 per protocol|0
6200882|NCT01490632|9860709|FG008|Part A: Initial Treatment Period|Discontinued at Week 12 per protocol|0
6200883|NCT01490632|9860710|FG009|Part A: Initial Treatment Period|Discontinued at Week 12 per protocol|0
6200884|NCT01490632|9860711|FG010|Part A: Initial Treatment Period|Discontinued at Week 12 per protocol|0
6200885|NCT01490632|9860712|FG011|Part A: Initial Treatment Period|Discontinued at Week 12 per protocol|0
6200886|NCT01490632|9860713|FG012|Part A: Initial Treatment Period|Discontinued at Week 12 per protocol|0
6200887|NCT01490632|9860714|FG013|Part A: Initial Treatment Period|Discontinued at Week 12 per protocol|0
6200888|NCT01490632|9860715|FG014|Part A: Initial Treatment Period|Discontinued at Week 12 per protocol|0
6200889|NCT01490632|9860716|FG015|Part A: Initial Treatment Period|Discontinued at Week 12 per protocol|0
6200890|NCT01490632|9860717|FG016|Part A: Initial Treatment Period|Discontinued at Week 12 per protocol|0
6200891|NCT01490632|9860718|FG017|Part A: Initial Treatment Period|Discontinued at Week 12 per protocol|0
6200892|NCT01490632|9860719|FG018|Part A: Initial Treatment Period|Discontinued at Week 12 per protocol|0
6200893|NCT01490632|9860720|FG019|Part A: Initial Treatment Period|Discontinued at Week 12 per protocol|0
6200894|NCT01490632|9860701|FG000|Part B: Extension or Step-Up Period|Adverse Event|0
6200895|NCT01490632|9860702|FG001|Part B: Extension or Step-Up Period|Adverse Event|0
6200896|NCT01490632|9860703|FG002|Part B: Extension or Step-Up Period|Adverse Event|0
6200897|NCT01490632|9860704|FG003|Part B: Extension or Step-Up Period|Adverse Event|0
6200898|NCT01490632|9860705|FG004|Part B: Extension or Step-Up Period|Adverse Event|0
6200899|NCT01490632|9860706|FG005|Part B: Extension or Step-Up Period|Adverse Event|2
6200900|NCT01490632|9860707|FG006|Part B: Extension or Step-Up Period|Adverse Event|2
6200901|NCT01490632|9860708|FG007|Part B: Extension or Step-Up Period|Adverse Event|0
6200902|NCT01490632|9860709|FG008|Part B: Extension or Step-Up Period|Adverse Event|0
6200903|NCT01490632|9860710|FG009|Part B: Extension or Step-Up Period|Adverse Event|2
6200904|NCT01490632|9860711|FG010|Part B: Extension or Step-Up Period|Adverse Event|3
6200905|NCT01490632|9860712|FG011|Part B: Extension or Step-Up Period|Adverse Event|1
6200906|NCT01490632|9860713|FG012|Part B: Extension or Step-Up Period|Adverse Event|0
6200907|NCT01490632|9860714|FG013|Part B: Extension or Step-Up Period|Adverse Event|0
6200908|NCT01490632|9860715|FG014|Part B: Extension or Step-Up Period|Adverse Event|0
6200909|NCT01490632|9860716|FG015|Part B: Extension or Step-Up Period|Adverse Event|0
6200910|NCT01490632|9860717|FG016|Part B: Extension or Step-Up Period|Adverse Event|0
6200911|NCT01490632|9860718|FG017|Part B: Extension or Step-Up Period|Adverse Event|0
6200912|NCT01490632|9860719|FG018|Part B: Extension or Step-Up Period|Adverse Event|0
6200913|NCT01490632|9860720|FG019|Part B: Extension or Step-Up Period|Adverse Event|0
6200914|NCT01490632|9860701|FG000|Part B: Extension or Step-Up Period|Lack of Efficacy|0
6200915|NCT01490632|9860702|FG001|Part B: Extension or Step-Up Period|Lack of Efficacy|0
6200916|NCT01490632|9860703|FG002|Part B: Extension or Step-Up Period|Lack of Efficacy|0
6200917|NCT01490632|9860704|FG003|Part B: Extension or Step-Up Period|Lack of Efficacy|0
6200918|NCT01490632|9860705|FG004|Part B: Extension or Step-Up Period|Lack of Efficacy|0
6200919|NCT01490632|9860706|FG005|Part B: Extension or Step-Up Period|Lack of Efficacy|0
6200920|NCT01490632|9860707|FG006|Part B: Extension or Step-Up Period|Lack of Efficacy|1
6200921|NCT01490632|9860708|FG007|Part B: Extension or Step-Up Period|Lack of Efficacy|0
6200922|NCT01490632|9860709|FG008|Part B: Extension or Step-Up Period|Lack of Efficacy|1
6200923|NCT01490632|9860710|FG009|Part B: Extension or Step-Up Period|Lack of Efficacy|3
6200924|NCT01490632|9860711|FG010|Part B: Extension or Step-Up Period|Lack of Efficacy|1
6200925|NCT01490632|9860712|FG011|Part B: Extension or Step-Up Period|Lack of Efficacy|0
6200926|NCT01490632|9860713|FG012|Part B: Extension or Step-Up Period|Lack of Efficacy|0
6200927|NCT01490632|9860714|FG013|Part B: Extension or Step-Up Period|Lack of Efficacy|0
6200928|NCT01490632|9860715|FG014|Part B: Extension or Step-Up Period|Lack of Efficacy|0
6200929|NCT01490632|9860716|FG015|Part B: Extension or Step-Up Period|Lack of Efficacy|0
6200930|NCT01490632|9860717|FG016|Part B: Extension or Step-Up Period|Lack of Efficacy|0
6200931|NCT01490632|9860718|FG017|Part B: Extension or Step-Up Period|Lack of Efficacy|0
6200932|NCT01490632|9860719|FG018|Part B: Extension or Step-Up Period|Lack of Efficacy|0
6200933|NCT01490632|9860720|FG019|Part B: Extension or Step-Up Period|Lack of Efficacy|0
6200934|NCT01490632|9860701|FG000|Part B: Extension or Step-Up Period|Lost to Follow-up|0
6200935|NCT01490632|9860702|FG001|Part B: Extension or Step-Up Period|Lost to Follow-up|0
6200936|NCT01490632|9860703|FG002|Part B: Extension or Step-Up Period|Lost to Follow-up|0
6089028|NCT00680043|9700191|FG001|Overall Study|Withdrawal by Subject|0
6089029|NCT00680043|9700192|FG002|Overall Study|Withdrawal by Subject|0
6200937|NCT01490632|9860704|FG003|Part B: Extension or Step-Up Period|Lost to Follow-up|0
6200938|NCT01490632|9860705|FG004|Part B: Extension or Step-Up Period|Lost to Follow-up|0
6200939|NCT01490632|9860706|FG005|Part B: Extension or Step-Up Period|Lost to Follow-up|0
6200940|NCT01490632|9860707|FG006|Part B: Extension or Step-Up Period|Lost to Follow-up|2
6200941|NCT01490632|9860708|FG007|Part B: Extension or Step-Up Period|Lost to Follow-up|0
6200942|NCT01490632|9860709|FG008|Part B: Extension or Step-Up Period|Lost to Follow-up|0
6200943|NCT01490632|9860710|FG009|Part B: Extension or Step-Up Period|Lost to Follow-up|1
6277805|NCT02247804|9985071|FG002|Treatment Period 1|Lost to Follow-up|2
6277806|NCT02247804|9985069|FG000|Treatment Period 1|Personal Reasons|7
6277807|NCT02247804|9985070|FG001|Treatment Period 1|Personal Reasons|1
6277808|NCT02247804|9985071|FG002|Treatment Period 1|Personal Reasons|2
6277809|NCT02247804|9985069|FG000|Treatment Period 1|Protocol Deviation|0
6277810|NCT02247804|9985070|FG001|Treatment Period 1|Protocol Deviation|0
6277811|NCT02247804|9985071|FG002|Treatment Period 1|Protocol Deviation|1
6277812|NCT02247804|9985069|FG000|Treatment Period 1|Randomized but not Treated|5
6277813|NCT02247804|9985070|FG001|Treatment Period 1|Randomized but not Treated|1
6277814|NCT02247804|9985071|FG002|Treatment Period 1|Randomized but not Treated|1
6277815|NCT02247804|9985069|FG000|Treatment Period 2|Adverse Event|6
6277816|NCT02247804|9985070|FG001|Treatment Period 2|Adverse Event|3
6277817|NCT02247804|9985071|FG002|Treatment Period 2|Adverse Event|3
6277818|NCT02247804|9985069|FG000|Treatment Period 2|Lack of Efficacy|0
6277819|NCT02247804|9985070|FG001|Treatment Period 2|Lack of Efficacy|0
6277820|NCT02247804|9985071|FG002|Treatment Period 2|Lack of Efficacy|1
6277821|NCT02247804|9985069|FG000|Treatment Period 2|Lost to Follow-up|0
6277822|NCT02247804|9985070|FG001|Treatment Period 2|Lost to Follow-up|1
6277823|NCT02247804|9985071|FG002|Treatment Period 2|Lost to Follow-up|1
6277824|NCT02247804|9985069|FG000|Treatment Period 2|Personal Reasons|2
6277825|NCT02247804|9985070|FG001|Treatment Period 2|Personal Reasons|1
6277826|NCT02247804|9985071|FG002|Treatment Period 2|Personal Reasons|1
6277827|NCT02247804|9985069|FG000|Treatment Period 2|Reason not Specified|0
6277828|NCT02247804|9985070|FG001|Treatment Period 2|Reason not Specified|0
6277829|NCT02247804|9985071|FG002|Treatment Period 2|Reason not Specified|2
6277830|NCT02247804|9985069|FG000|Treatment Period 3|Adverse Event|4
6277831|NCT02247804|9985070|FG001|Treatment Period 3|Adverse Event|3
6277832|NCT02247804|9985071|FG002|Treatment Period 3|Adverse Event|3
6277833|NCT02247804|9985069|FG000|Treatment Period 3|Lack of Efficacy|0
6277834|NCT02247804|9985070|FG001|Treatment Period 3|Lack of Efficacy|1
6277835|NCT02247804|9985071|FG002|Treatment Period 3|Lack of Efficacy|0
6277836|NCT02247804|9985069|FG000|Treatment Period 3|Lost to Follow-up|1
6277837|NCT02247804|9985070|FG001|Treatment Period 3|Lost to Follow-up|2
6277838|NCT02247804|9985071|FG002|Treatment Period 3|Lost to Follow-up|2
6277839|NCT02247804|9985069|FG000|Treatment Period 3|Personal Reasons|4
6277840|NCT02247804|9985070|FG001|Treatment Period 3|Personal Reasons|3
6277841|NCT02247804|9985071|FG002|Treatment Period 3|Personal Reasons|2
6277842|NCT02247804|9985069|FG000|Treatment Period 3|Reason not Specified|2
6277843|NCT02247804|9985070|FG001|Treatment Period 3|Reason not Specified|1
6277844|NCT02247804|9985071|FG002|Treatment Period 3|Reason not Specified|3
6277845|NCT02247960|9985081|FG000|Patient Consent and Randomization|Physician Decision|2
6277846|NCT02247960|9985082|FG001|Patient Consent and Randomization|Physician Decision|2
6277847|NCT02247960|9985081|FG000|Patient Consent and Randomization|Withdrawal by Subject|0
6277848|NCT02247960|9985082|FG001|Patient Consent and Randomization|Withdrawal by Subject|4
6277849|NCT02247960|9985081|FG000|Catheter Removed|Lost to Follow-up|7
6277850|NCT02247960|9985082|FG001|Catheter Removed|Lost to Follow-up|10
6277851|NCT02248480|9985112|FG000|Overall Study|Lack of Efficacy|4
6200944|NCT01490632|9860711|FG010|Part B: Extension or Step-Up Period|Lost to Follow-up|0
6200945|NCT01490632|9860712|FG011|Part B: Extension or Step-Up Period|Lost to Follow-up|0
6200946|NCT01490632|9860713|FG012|Part B: Extension or Step-Up Period|Lost to Follow-up|0
6200947|NCT01490632|9860714|FG013|Part B: Extension or Step-Up Period|Lost to Follow-up|0
6200948|NCT01490632|9860715|FG014|Part B: Extension or Step-Up Period|Lost to Follow-up|0
6200949|NCT01490632|9860716|FG015|Part B: Extension or Step-Up Period|Lost to Follow-up|0
6200950|NCT01490632|9860717|FG016|Part B: Extension or Step-Up Period|Lost to Follow-up|0
6200951|NCT01490632|9860718|FG017|Part B: Extension or Step-Up Period|Lost to Follow-up|0
6200952|NCT01490632|9860719|FG018|Part B: Extension or Step-Up Period|Lost to Follow-up|0
6200953|NCT01490632|9860720|FG019|Part B: Extension or Step-Up Period|Lost to Follow-up|0
6200954|NCT01490632|9860701|FG000|Part B: Extension or Step-Up Period|Physician Decision|0
6200955|NCT01490632|9860702|FG001|Part B: Extension or Step-Up Period|Physician Decision|0
6200956|NCT01490632|9860703|FG002|Part B: Extension or Step-Up Period|Physician Decision|0
6200957|NCT01490632|9860704|FG003|Part B: Extension or Step-Up Period|Physician Decision|0
6200958|NCT01490632|9860705|FG004|Part B: Extension or Step-Up Period|Physician Decision|0
6200959|NCT01490632|9860706|FG005|Part B: Extension or Step-Up Period|Physician Decision|0
6200960|NCT01490632|9860707|FG006|Part B: Extension or Step-Up Period|Physician Decision|1
6200961|NCT01490632|9860708|FG007|Part B: Extension or Step-Up Period|Physician Decision|0
6200962|NCT01490632|9860709|FG008|Part B: Extension or Step-Up Period|Physician Decision|0
6200963|NCT01490632|9860710|FG009|Part B: Extension or Step-Up Period|Physician Decision|0
6200964|NCT01490632|9860711|FG010|Part B: Extension or Step-Up Period|Physician Decision|0
6200965|NCT01490632|9860712|FG011|Part B: Extension or Step-Up Period|Physician Decision|0
6200966|NCT01490632|9860713|FG012|Part B: Extension or Step-Up Period|Physician Decision|0
6200967|NCT01490632|9860714|FG013|Part B: Extension or Step-Up Period|Physician Decision|0
6200968|NCT01490632|9860715|FG014|Part B: Extension or Step-Up Period|Physician Decision|0
6200969|NCT01490632|9860716|FG015|Part B: Extension or Step-Up Period|Physician Decision|0
6200970|NCT01490632|9860717|FG016|Part B: Extension or Step-Up Period|Physician Decision|0
6200971|NCT01490632|9860718|FG017|Part B: Extension or Step-Up Period|Physician Decision|0
6200972|NCT01490632|9860719|FG018|Part B: Extension or Step-Up Period|Physician Decision|0
6200973|NCT01490632|9860720|FG019|Part B: Extension or Step-Up Period|Physician Decision|0
6200974|NCT01490632|9860701|FG000|Part B: Extension or Step-Up Period|Sponsor Decision|0
6200975|NCT01490632|9860702|FG001|Part B: Extension or Step-Up Period|Sponsor Decision|0
6200976|NCT01490632|9860703|FG002|Part B: Extension or Step-Up Period|Sponsor Decision|0
6200977|NCT01490632|9860704|FG003|Part B: Extension or Step-Up Period|Sponsor Decision|0
6200978|NCT01490632|9860705|FG004|Part B: Extension or Step-Up Period|Sponsor Decision|0
6200979|NCT01490632|9860706|FG005|Part B: Extension or Step-Up Period|Sponsor Decision|1
6200980|NCT01490632|9860707|FG006|Part B: Extension or Step-Up Period|Sponsor Decision|0
6200981|NCT01490632|9860708|FG007|Part B: Extension or Step-Up Period|Sponsor Decision|0
6200982|NCT01490632|9860709|FG008|Part B: Extension or Step-Up Period|Sponsor Decision|0
6200983|NCT01490632|9860710|FG009|Part B: Extension or Step-Up Period|Sponsor Decision|0
6200984|NCT01490632|9860711|FG010|Part B: Extension or Step-Up Period|Sponsor Decision|0
6200985|NCT01490632|9860712|FG011|Part B: Extension or Step-Up Period|Sponsor Decision|0
6200986|NCT01490632|9860713|FG012|Part B: Extension or Step-Up Period|Sponsor Decision|0
6200987|NCT01490632|9860714|FG013|Part B: Extension or Step-Up Period|Sponsor Decision|0
6200988|NCT01490632|9860715|FG014|Part B: Extension or Step-Up Period|Sponsor Decision|0
6200989|NCT01490632|9860716|FG015|Part B: Extension or Step-Up Period|Sponsor Decision|0
6277852|NCT02248480|9985113|FG001|Overall Study|Lack of Efficacy|6
6277853|NCT02248480|9985112|FG000|Overall Study|Adverse Event|11
6277854|NCT02248480|9985113|FG001|Overall Study|Adverse Event|2
6277855|NCT02248480|9985112|FG000|Overall Study|Withdrawal by Subject|2
6277856|NCT02248480|9985113|FG001|Overall Study|Withdrawal by Subject|4
6277857|NCT02248480|9985112|FG000|Overall Study|Entry Criteria Not Met|0
6277858|NCT02248480|9985113|FG001|Overall Study|Entry Criteria Not Met|1
6277859|NCT02248480|9985112|FG000|Overall Study|Other:Physician Decision|0
6277860|NCT02248480|9985113|FG001|Overall Study|Other:Physician Decision|1
6277861|NCT02248649|9985142|FG000|Overall Study|Death|7
5977499|NCT02659020|9564751|FG004|Overall Study|Withdrawal by Subject|3
5977500|NCT02659020|9564752|FG005|Overall Study|Withdrawal by Subject|6
5977501|NCT02659020|9564753|FG006|Overall Study|Withdrawal by Subject|3
5977502|NCT02659020|9564747|FG000|Overall Study|Progressive Disease|0
5977503|NCT02659020|9564748|FG001|Overall Study|Progressive Disease|0
5977504|NCT02659020|9564749|FG002|Overall Study|Progressive Disease|0
5977505|NCT02659020|9564750|FG003|Overall Study|Progressive Disease|4
5977506|NCT02659020|9564751|FG004|Overall Study|Progressive Disease|1
5977507|NCT02659020|9564752|FG005|Overall Study|Progressive Disease|0
5977508|NCT02659020|9564753|FG006|Overall Study|Progressive Disease|2
5977509|NCT02626949|9564778|FG000|Randomization, Pre-Enrollment|did not attend the baseline interview|15
5977510|NCT02626949|9564779|FG001|Randomization, Pre-Enrollment|did not attend the baseline interview|11
5977511|NCT02626949|9564778|FG000|Randomization, Pre-Enrollment|did not meet inclusion criteria post-randomization|1
5977512|NCT02626949|9564779|FG001|Randomization, Pre-Enrollment|did not meet inclusion criteria post-randomization|3
5977513|NCT02626949|9564778|FG000|Enrolled|Lost to Follow-up|7
5977514|NCT02626949|9564779|FG001|Enrolled|Lost to Follow-up|6
5977515|NCT02626949|9564778|FG000|Enrolled|Withdrawal by Subject|3
6200990|NCT01490632|9860717|FG016|Part B: Extension or Step-Up Period|Sponsor Decision|0
6200991|NCT01490632|9860718|FG017|Part B: Extension or Step-Up Period|Sponsor Decision|0
6200992|NCT01490632|9860719|FG018|Part B: Extension or Step-Up Period|Sponsor Decision|0
6200993|NCT01490632|9860720|FG019|Part B: Extension or Step-Up Period|Sponsor Decision|0
6200994|NCT01490632|9860701|FG000|Part B: Extension or Step-Up Period|Withdrawal by Subject|0
6200995|NCT01490632|9860702|FG001|Part B: Extension or Step-Up Period|Withdrawal by Subject|0
6200996|NCT01490632|9860703|FG002|Part B: Extension or Step-Up Period|Withdrawal by Subject|0
6200997|NCT01490632|9860704|FG003|Part B: Extension or Step-Up Period|Withdrawal by Subject|0
6200998|NCT01490632|9860705|FG004|Part B: Extension or Step-Up Period|Withdrawal by Subject|0
6200999|NCT01490632|9860706|FG005|Part B: Extension or Step-Up Period|Withdrawal by Subject|0
6201000|NCT01490632|9860707|FG006|Part B: Extension or Step-Up Period|Withdrawal by Subject|1
6201001|NCT01490632|9860708|FG007|Part B: Extension or Step-Up Period|Withdrawal by Subject|0
6201002|NCT01490632|9860709|FG008|Part B: Extension or Step-Up Period|Withdrawal by Subject|1
6201003|NCT01490632|9860710|FG009|Part B: Extension or Step-Up Period|Withdrawal by Subject|0
6201004|NCT01490632|9860711|FG010|Part B: Extension or Step-Up Period|Withdrawal by Subject|1
6201005|NCT01490632|9860712|FG011|Part B: Extension or Step-Up Period|Withdrawal by Subject|2
6201006|NCT01490632|9860713|FG012|Part B: Extension or Step-Up Period|Withdrawal by Subject|0
6201007|NCT01490632|9860714|FG013|Part B: Extension or Step-Up Period|Withdrawal by Subject|0
6201008|NCT01490632|9860715|FG014|Part B: Extension or Step-Up Period|Withdrawal by Subject|0
6201009|NCT01490632|9860716|FG015|Part B: Extension or Step-Up Period|Withdrawal by Subject|0
6201010|NCT01490632|9860717|FG016|Part B: Extension or Step-Up Period|Withdrawal by Subject|0
6201011|NCT01490632|9860718|FG017|Part B: Extension or Step-Up Period|Withdrawal by Subject|0
6201012|NCT01490632|9860719|FG018|Part B: Extension or Step-Up Period|Withdrawal by Subject|0
6201013|NCT01490632|9860720|FG019|Part B: Extension or Step-Up Period|Withdrawal by Subject|0
6201014|NCT01490632|9860701|FG000|Part B: Extension or Step-Up Period|Completed Part B and Not Moving to PartC|0
6201015|NCT01490632|9860702|FG001|Part B: Extension or Step-Up Period|Completed Part B and Not Moving to PartC|0
6201016|NCT01490632|9860703|FG002|Part B: Extension or Step-Up Period|Completed Part B and Not Moving to PartC|0
6201017|NCT01490632|9860704|FG003|Part B: Extension or Step-Up Period|Completed Part B and Not Moving to PartC|0
6201018|NCT01490632|9860705|FG004|Part B: Extension or Step-Up Period|Completed Part B and Not Moving to PartC|0
6201019|NCT01490632|9860706|FG005|Part B: Extension or Step-Up Period|Completed Part B and Not Moving to PartC|1
6201020|NCT01490632|9860707|FG006|Part B: Extension or Step-Up Period|Completed Part B and Not Moving to PartC|6
6201021|NCT01490632|9860708|FG007|Part B: Extension or Step-Up Period|Completed Part B and Not Moving to PartC|6
6201022|NCT01490632|9860709|FG008|Part B: Extension or Step-Up Period|Completed Part B and Not Moving to PartC|8
6201023|NCT01490632|9860710|FG009|Part B: Extension or Step-Up Period|Completed Part B and Not Moving to PartC|19
6277862|NCT02248649|9985143|FG001|Overall Study|Death|11
6277863|NCT02248649|9985142|FG000|Overall Study|Lost to Follow-up|14
6277864|NCT02248649|9985143|FG001|Overall Study|Lost to Follow-up|10
6277865|NCT02248675|9985164|FG000|Overall Study|Lost to Follow-up|3
6277866|NCT02248675|9985165|FG001|Overall Study|Lost to Follow-up|1
6277867|NCT02248818|9985203|FG000|Screening|Protocol Violation|0
6277868|NCT02248818|9985204|FG001|Screening|Protocol Violation|0
6277869|NCT02248818|9985205|FG002|Screening|Protocol Violation|0
6277870|NCT02248818|9985206|FG003|Screening|Protocol Violation|0
6277871|NCT02248818|9985207|FG004|Screening|Protocol Violation|0
6277872|NCT02248818|9985208|FG005|Screening|Protocol Violation|0
6277873|NCT02248818|9985209|FG006|Screening|Protocol Violation|0
6277874|NCT02248818|9985210|FG007|Screening|Protocol Violation|0
6277875|NCT02248818|9985211|FG008|Screening|Protocol Violation|7
6277876|NCT02248818|9985203|FG000|Screening|Study fully enrolled|0
6277877|NCT02248818|9985204|FG001|Screening|Study fully enrolled|0
6277878|NCT02248818|9985205|FG002|Screening|Study fully enrolled|0
6277879|NCT02248818|9985206|FG003|Screening|Study fully enrolled|0
6277880|NCT02248818|9985207|FG004|Screening|Study fully enrolled|0
6277881|NCT02248818|9985208|FG005|Screening|Study fully enrolled|0
6277882|NCT02248818|9985209|FG006|Screening|Study fully enrolled|0
6277883|NCT02248818|9985210|FG007|Screening|Study fully enrolled|0
6277884|NCT02248818|9985211|FG008|Screening|Study fully enrolled|14
6277885|NCT02248818|9985203|FG000|Screening|Physician Decision|0
6277886|NCT02248818|9985204|FG001|Screening|Physician Decision|0
6277887|NCT02248818|9985205|FG002|Screening|Physician Decision|0
6277888|NCT02248818|9985206|FG003|Screening|Physician Decision|0
6277889|NCT02248818|9985207|FG004|Screening|Physician Decision|0
6277890|NCT02248818|9985208|FG005|Screening|Physician Decision|0
6277891|NCT02248818|9985209|FG006|Screening|Physician Decision|0
6277892|NCT02248818|9985210|FG007|Screening|Physician Decision|0
6277893|NCT02248818|9985211|FG008|Screening|Physician Decision|73
6277894|NCT02248818|9985203|FG000|Screening|Withdrawal by Subject|0
6277895|NCT02248818|9985204|FG001|Screening|Withdrawal by Subject|0
6277896|NCT02248818|9985205|FG002|Screening|Withdrawal by Subject|0
6277897|NCT02248818|9985206|FG003|Screening|Withdrawal by Subject|0
6277898|NCT02248818|9985207|FG004|Screening|Withdrawal by Subject|0
6277899|NCT02248818|9985208|FG005|Screening|Withdrawal by Subject|0
5977516|NCT02626949|9564779|FG001|Enrolled|Withdrawal by Subject|2
5977517|NCT02565914|9564794|FG000|Overall Study|Adverse Event|17
6277900|NCT02248818|9985209|FG006|Screening|Withdrawal by Subject|0
6277901|NCT02248818|9985210|FG007|Screening|Withdrawal by Subject|0
6201024|NCT01490632|9860711|FG010|Part B: Extension or Step-Up Period|Completed Part B and Not Moving to PartC|16
6201025|NCT01490632|9860712|FG011|Part B: Extension or Step-Up Period|Completed Part B and Not Moving to PartC|5
6201026|NCT01490632|9860713|FG012|Part B: Extension or Step-Up Period|Completed Part B and Not Moving to PartC|0
6201027|NCT01490632|9860714|FG013|Part B: Extension or Step-Up Period|Completed Part B and Not Moving to PartC|0
6201028|NCT01490632|9860715|FG014|Part B: Extension or Step-Up Period|Completed Part B and Not Moving to PartC|0
6201029|NCT01490632|9860716|FG015|Part B: Extension or Step-Up Period|Completed Part B and Not Moving to PartC|0
6201030|NCT01490632|9860717|FG016|Part B: Extension or Step-Up Period|Completed Part B and Not Moving to PartC|0
6201031|NCT01490632|9860718|FG017|Part B: Extension or Step-Up Period|Completed Part B and Not Moving to PartC|0
6277902|NCT02248818|9985211|FG008|Screening|Withdrawal by Subject|6
6277903|NCT02248818|9985203|FG000|Screening|Lost to Follow-up|0
6277904|NCT02248818|9985204|FG001|Screening|Lost to Follow-up|0
6277905|NCT02248818|9985205|FG002|Screening|Lost to Follow-up|0
6277906|NCT02248818|9985206|FG003|Screening|Lost to Follow-up|0
6277907|NCT02248818|9985207|FG004|Screening|Lost to Follow-up|0
6277908|NCT02248818|9985208|FG005|Screening|Lost to Follow-up|0
6277909|NCT02248818|9985209|FG006|Screening|Lost to Follow-up|0
6277910|NCT02248818|9985210|FG007|Screening|Lost to Follow-up|0
6277911|NCT02248818|9985211|FG008|Screening|Lost to Follow-up|7
6277912|NCT02248818|9985203|FG000|Randomised Study|Administrative - randomization error|0
6277913|NCT02248818|9985204|FG001|Randomised Study|Administrative - randomization error|0
6277914|NCT02248818|9985205|FG002|Randomised Study|Administrative - randomization error|0
6277915|NCT02248818|9985206|FG003|Randomised Study|Administrative - randomization error|0
6277916|NCT02248818|9985207|FG004|Randomised Study|Administrative - randomization error|0
6277917|NCT02248818|9985208|FG005|Randomised Study|Administrative - randomization error|8
6277918|NCT02248818|9985209|FG006|Randomised Study|Administrative - randomization error|0
6277919|NCT02248818|9985210|FG007|Randomised Study|Administrative - randomization error|0
6277920|NCT02248818|9985211|FG008|Randomised Study|Administrative - randomization error|0
6277921|NCT02248857|9985232|FG000|3 Month|Withdrawal by Subject|9
6277922|NCT02248857|9985233|FG001|3 Month|Withdrawal by Subject|3
6277923|NCT02248857|9985234|FG002|3 Month|Withdrawal by Subject|4
6277924|NCT02248857|9985232|FG000|3 Month|Unable to reach for 3 month|35
6277925|NCT02248857|9985233|FG001|3 Month|Unable to reach for 3 month|29
6277926|NCT02248857|9985234|FG002|3 Month|Unable to reach for 3 month|26
6277927|NCT02248857|9985232|FG000|3 Month|Partially completed, unable to finish|2
6277928|NCT02248857|9985233|FG001|3 Month|Partially completed, unable to finish|2
6277929|NCT02248857|9985234|FG002|3 Month|Partially completed, unable to finish|1
6277930|NCT02248857|9985232|FG000|6 Month|Lost to Follow-up|27
6277931|NCT02248857|9985233|FG001|6 Month|Lost to Follow-up|26
6277932|NCT02248857|9985234|FG002|6 Month|Lost to Follow-up|15
6277933|NCT02248857|9985232|FG000|6 Month|Partially completed, unable to finish|0
6277934|NCT02248857|9985233|FG001|6 Month|Partially completed, unable to finish|1
6277935|NCT02248857|9985234|FG002|6 Month|Partially completed, unable to finish|0
6277936|NCT02248857|9985232|FG000|6 Month|Withdrawal by Subject|0
6277937|NCT02248857|9985233|FG001|6 Month|Withdrawal by Subject|2
6277938|NCT02248857|9985234|FG002|6 Month|Withdrawal by Subject|2
6277939|NCT02248857|9985232|FG000|6 Month|Death|1
6277940|NCT02248857|9985233|FG001|6 Month|Death|0
6277941|NCT02248857|9985234|FG002|6 Month|Death|0
6277942|NCT02248961|9985252|FG000|Overall Study|Adverse Event|1
6277943|NCT02248961|9985253|FG001|Overall Study|Adverse Event|0
6277944|NCT02248961|9985252|FG000|Overall Study|Withdrawal by Subject|1
6277945|NCT02248961|9985253|FG001|Overall Study|Withdrawal by Subject|2
6277946|NCT02248961|9985252|FG000|Overall Study|Unmet inclusion/exclusion criteria|1
6277947|NCT02248961|9985253|FG001|Overall Study|Unmet inclusion/exclusion criteria|0
6277948|NCT02248974|9985261|FG000|1-Day Follow-Up|Lost to Follow-up|4
6277949|NCT02248974|9985262|FG001|1-Day Follow-Up|Lost to Follow-up|0
6277950|NCT02248974|9985261|FG000|1-Day Follow-Up|Withdrawal by Subject|5
6277951|NCT02248974|9985262|FG001|1-Day Follow-Up|Withdrawal by Subject|0
6277952|NCT02248974|9985261|FG000|1-Day Follow-Up|Enrolled in another study|1
6277953|NCT02248974|9985262|FG001|1-Day Follow-Up|Enrolled in another study|0
6277954|NCT02248974|9985261|FG000|1-Week Follow-Up|Became ineligible for LVAD|4
6277955|NCT02248974|9985262|FG001|1-Week Follow-Up|Became ineligible for LVAD|1
6277956|NCT02248974|9985261|FG000|1-Week Follow-Up|Enrolled in another study|1
6277957|NCT02248974|9985262|FG001|1-Week Follow-Up|Enrolled in another study|1
6277958|NCT02248974|9985261|FG000|1-Week Follow-Up|Transferred to another facility|1
6277959|NCT02248974|9985262|FG001|1-Week Follow-Up|Transferred to another facility|0
6277960|NCT02248974|9985261|FG000|1-Week Follow-Up|Cognitive Difficulty|1
6277961|NCT02248974|9985262|FG001|1-Week Follow-Up|Cognitive Difficulty|0
5977518|NCT02565914|9564794|FG000|Overall Study|Withdrawal of consent (not due to AE)|25
5977519|NCT02565914|9564794|FG000|Overall Study|Lost to Follow-up|12
5977520|NCT02565914|9564794|FG000|Overall Study|Death (not treatment emergent)|1
5977521|NCT02565914|9564794|FG000|Overall Study|Other noncompliance|6
5977522|NCT02565914|9564794|FG000|Overall Study|Physician Decision|6
6201032|NCT01490632|9860719|FG018|Part B: Extension or Step-Up Period|Completed Part B and Not Moving to PartC|0
6277962|NCT02248974|9985261|FG000|1-Week Follow-Up|Death|1
6277963|NCT02248974|9985262|FG001|1-Week Follow-Up|Death|1
6277964|NCT02248974|9985261|FG000|1-Week Follow-Up|Excluded because of age|0
6277965|NCT02248974|9985262|FG001|1-Week Follow-Up|Excluded because of age|1
6201033|NCT01490632|9860720|FG019|Part B: Extension or Step-Up Period|Completed Part B and Not Moving to PartC|0
6201034|NCT01490632|9860701|FG000|Part C: Washout or Step-Down Period|Adverse Event|0
6201035|NCT01490632|9860702|FG001|Part C: Washout or Step-Down Period|Adverse Event|0
6201036|NCT01490632|9860703|FG002|Part C: Washout or Step-Down Period|Adverse Event|0
6201037|NCT01490632|9860704|FG003|Part C: Washout or Step-Down Period|Adverse Event|0
6201038|NCT01490632|9860705|FG004|Part C: Washout or Step-Down Period|Adverse Event|0
6201039|NCT01490632|9860706|FG005|Part C: Washout or Step-Down Period|Adverse Event|0
6201040|NCT01490632|9860707|FG006|Part C: Washout or Step-Down Period|Adverse Event|0
6201041|NCT01490632|9860708|FG007|Part C: Washout or Step-Down Period|Adverse Event|0
6201042|NCT01490632|9860709|FG008|Part C: Washout or Step-Down Period|Adverse Event|0
6201043|NCT01490632|9860710|FG009|Part C: Washout or Step-Down Period|Adverse Event|0
6201044|NCT01490632|9860711|FG010|Part C: Washout or Step-Down Period|Adverse Event|0
6201045|NCT01490632|9860712|FG011|Part C: Washout or Step-Down Period|Adverse Event|0
6201046|NCT01490632|9860713|FG012|Part C: Washout or Step-Down Period|Adverse Event|0
6201047|NCT01490632|9860714|FG013|Part C: Washout or Step-Down Period|Adverse Event|0
6201048|NCT01490632|9860715|FG014|Part C: Washout or Step-Down Period|Adverse Event|2
6201049|NCT01490632|9860716|FG015|Part C: Washout or Step-Down Period|Adverse Event|2
6201050|NCT01490632|9860717|FG016|Part C: Washout or Step-Down Period|Adverse Event|0
6201051|NCT01490632|9860718|FG017|Part C: Washout or Step-Down Period|Adverse Event|0
6201052|NCT01490632|9860719|FG018|Part C: Washout or Step-Down Period|Adverse Event|0
6201053|NCT01490632|9860720|FG019|Part C: Washout or Step-Down Period|Adverse Event|0
6201054|NCT01490632|9860701|FG000|Part C: Washout or Step-Down Period|Lost to Follow-up|0
6201055|NCT01490632|9860702|FG001|Part C: Washout or Step-Down Period|Lost to Follow-up|0
6201056|NCT01490632|9860703|FG002|Part C: Washout or Step-Down Period|Lost to Follow-up|0
6201057|NCT01490632|9860704|FG003|Part C: Washout or Step-Down Period|Lost to Follow-up|0
6201058|NCT01490632|9860705|FG004|Part C: Washout or Step-Down Period|Lost to Follow-up|0
6201059|NCT01490632|9860706|FG005|Part C: Washout or Step-Down Period|Lost to Follow-up|0
6201060|NCT01490632|9860707|FG006|Part C: Washout or Step-Down Period|Lost to Follow-up|0
6201061|NCT01490632|9860708|FG007|Part C: Washout or Step-Down Period|Lost to Follow-up|0
6201062|NCT01490632|9860709|FG008|Part C: Washout or Step-Down Period|Lost to Follow-up|0
6201063|NCT01490632|9860710|FG009|Part C: Washout or Step-Down Period|Lost to Follow-up|0
6201064|NCT01490632|9860711|FG010|Part C: Washout or Step-Down Period|Lost to Follow-up|0
6201065|NCT01490632|9860712|FG011|Part C: Washout or Step-Down Period|Lost to Follow-up|0
6201066|NCT01490632|9860713|FG012|Part C: Washout or Step-Down Period|Lost to Follow-up|0
6201067|NCT01490632|9860714|FG013|Part C: Washout or Step-Down Period|Lost to Follow-up|1
6201068|NCT01490632|9860715|FG014|Part C: Washout or Step-Down Period|Lost to Follow-up|0
6201069|NCT01490632|9860716|FG015|Part C: Washout or Step-Down Period|Lost to Follow-up|0
6201070|NCT01490632|9860717|FG016|Part C: Washout or Step-Down Period|Lost to Follow-up|0
6201071|NCT01490632|9860718|FG017|Part C: Washout or Step-Down Period|Lost to Follow-up|0
6201072|NCT01490632|9860719|FG018|Part C: Washout or Step-Down Period|Lost to Follow-up|0
6201073|NCT01490632|9860720|FG019|Part C: Washout or Step-Down Period|Lost to Follow-up|0
6201074|NCT01490632|9860701|FG000|Part C: Washout or Step-Down Period|Withdrawal by Subject|0
6201075|NCT01490632|9860702|FG001|Part C: Washout or Step-Down Period|Withdrawal by Subject|0
6201076|NCT01490632|9860703|FG002|Part C: Washout or Step-Down Period|Withdrawal by Subject|0
6201077|NCT01490632|9860704|FG003|Part C: Washout or Step-Down Period|Withdrawal by Subject|0
6277966|NCT02248974|9985261|FG000|1-Week Follow-Up|Noncompliant with terms of participation|0
6277967|NCT02248974|9985262|FG001|1-Week Follow-Up|Noncompliant with terms of participation|1
6277968|NCT02248974|9985261|FG000|1-Week Follow-Up|Timing: implanted before survey|0
6277969|NCT02248974|9985262|FG001|1-Week Follow-Up|Timing: implanted before survey|2
6277970|NCT02248974|9985261|FG000|1-Week Follow-Up|Withdrawal by Subject|0
6277971|NCT02248974|9985262|FG001|1-Week Follow-Up|Withdrawal by Subject|2
6277972|NCT02248974|9985261|FG000|1-Week Follow-Up|Lost to Follow-up|0
6277973|NCT02248974|9985262|FG001|1-Week Follow-Up|Lost to Follow-up|8
6277974|NCT02248974|9985261|FG000|1-Month Follow-Up|Lost to Follow-up|2
6277975|NCT02248974|9985262|FG001|1-Month Follow-Up|Lost to Follow-up|3
6277976|NCT02249091|9985282|FG000|Overall Study|Lack of Efficacy|8
6277977|NCT02249091|9985283|FG001|Overall Study|Lack of Efficacy|3
6277978|NCT02249091|9985282|FG000|Overall Study|Physician Decision|4
6277979|NCT02249091|9985283|FG001|Overall Study|Physician Decision|1
6277980|NCT02249091|9985282|FG000|Overall Study|Withdrawal by Subject|2
6277981|NCT02249091|9985283|FG001|Overall Study|Withdrawal by Subject|2
6277982|NCT02249091|9985282|FG000|Overall Study|Death|3
6277983|NCT02249091|9985283|FG001|Overall Study|Death|4
6277984|NCT02249091|9985282|FG000|Overall Study|Adverse Event|1
6277985|NCT02249091|9985283|FG001|Overall Study|Adverse Event|0
6277986|NCT02249091|9985282|FG000|Overall Study|Stable disease with following SCT|0
6277987|NCT02249091|9985283|FG001|Overall Study|Stable disease with following SCT|1
6277988|NCT02249091|9985282|FG000|Overall Study|Ongoing bone marrow aplasia, periph. pancytopenia|0
6277989|NCT02249091|9985283|FG001|Overall Study|Ongoing bone marrow aplasia, periph. pancytopenia|1
6277990|NCT02249091|9985282|FG000|Overall Study|CR with subsequent donor lymphocyte infusion|1
6201078|NCT01490632|9860705|FG004|Part C: Washout or Step-Down Period|Withdrawal by Subject|0
6201079|NCT01490632|9860706|FG005|Part C: Washout or Step-Down Period|Withdrawal by Subject|0
6201080|NCT01490632|9860707|FG006|Part C: Washout or Step-Down Period|Withdrawal by Subject|0
6277991|NCT02249091|9985283|FG001|Overall Study|CR with subsequent donor lymphocyte infusion|0
6201081|NCT01490632|9860708|FG007|Part C: Washout or Step-Down Period|Withdrawal by Subject|0
6201082|NCT01490632|9860709|FG008|Part C: Washout or Step-Down Period|Withdrawal by Subject|0
6201083|NCT01490632|9860710|FG009|Part C: Washout or Step-Down Period|Withdrawal by Subject|0
6201084|NCT01490632|9860711|FG010|Part C: Washout or Step-Down Period|Withdrawal by Subject|0
6201085|NCT01490632|9860712|FG011|Part C: Washout or Step-Down Period|Withdrawal by Subject|0
6201086|NCT01490632|9860713|FG012|Part C: Washout or Step-Down Period|Withdrawal by Subject|0
6201087|NCT01490632|9860714|FG013|Part C: Washout or Step-Down Period|Withdrawal by Subject|0
6201088|NCT01490632|9860715|FG014|Part C: Washout or Step-Down Period|Withdrawal by Subject|2
6201089|NCT01490632|9860716|FG015|Part C: Washout or Step-Down Period|Withdrawal by Subject|1
6201090|NCT01490632|9860717|FG016|Part C: Washout or Step-Down Period|Withdrawal by Subject|0
6201091|NCT01490632|9860718|FG017|Part C: Washout or Step-Down Period|Withdrawal by Subject|0
6201092|NCT01490632|9860719|FG018|Part C: Washout or Step-Down Period|Withdrawal by Subject|0
6201093|NCT01490632|9860720|FG019|Part C: Washout or Step-Down Period|Withdrawal by Subject|0
6201094|NCT01490632|9860701|FG000|Part C: Washout or Step-Down Period|Did Not Qualify for Part D Per Protocol|0
6201095|NCT01490632|9860702|FG001|Part C: Washout or Step-Down Period|Did Not Qualify for Part D Per Protocol|0
6201096|NCT01490632|9860703|FG002|Part C: Washout or Step-Down Period|Did Not Qualify for Part D Per Protocol|0
6201097|NCT01490632|9860704|FG003|Part C: Washout or Step-Down Period|Did Not Qualify for Part D Per Protocol|0
6201098|NCT01490632|9860705|FG004|Part C: Washout or Step-Down Period|Did Not Qualify for Part D Per Protocol|0
6201099|NCT01490632|9860706|FG005|Part C: Washout or Step-Down Period|Did Not Qualify for Part D Per Protocol|0
6201100|NCT01490632|9860707|FG006|Part C: Washout or Step-Down Period|Did Not Qualify for Part D Per Protocol|0
6201101|NCT01490632|9860708|FG007|Part C: Washout or Step-Down Period|Did Not Qualify for Part D Per Protocol|0
6277992|NCT02249091|9985282|FG000|Overall Study|Refractory AML|1
6277993|NCT02249091|9985283|FG001|Overall Study|Refractory AML|1
6277994|NCT02249182|9985307|FG000|Treatment Phase|Lost to Follow-up|4
6277995|NCT02249182|9985308|FG001|Treatment Phase|Lost to Follow-up|0
6277996|NCT02249182|9985309|FG002|Treatment Phase|Lost to Follow-up|0
6277997|NCT02249182|9985310|FG003|Treatment Phase|Lost to Follow-up|0
6277998|NCT02249182|9985311|FG004|Treatment Phase|Lost to Follow-up|0
6277999|NCT02249767|9985359|FG000|Overall Study|Did not use medication|8
6278000|NCT02249767|9985360|FG001|Overall Study|Did not use medication|9
6278001|NCT02249767|9985361|FG002|Overall Study|Did not use medication|8
6278002|NCT02249832|9985381|FG000|Overall Study|Withdrawal by Subject|3
6278003|NCT02249832|9985381|FG000|Overall Study|Lost to Follow-up|10
6278004|NCT02249949|9985390|FG000|Overall Study|Cancelled prior to treatment|2
6278005|NCT02250183|9985403|FG000|Overall Study|Withdrawal by Subject|2
6278006|NCT02250183|9985403|FG000|Overall Study|Adverse Event|5
6278007|NCT02250183|9985403|FG000|Overall Study|Lost to Follow-up|1
6278008|NCT02250274|9985412|FG000|Overall Study|Insufficient blood draw amount|7
6278009|NCT02250274|9985413|FG001|Overall Study|Insufficient blood draw amount|6
6278010|NCT02250443|9985435|FG000|Overall Study|Administrative problems|7
6278011|NCT02250443|9985435|FG000|Overall Study|Adverse Event|3
6278012|NCT02250651|9985474|FG000|Treatment Period 1 (Day 1 to Week 15)|Adverse Event|0
6278013|NCT02250651|9985475|FG001|Treatment Period 1 (Day 1 to Week 15)|Adverse Event|2
6278014|NCT02250651|9985476|FG002|Treatment Period 1 (Day 1 to Week 15)|Adverse Event|2
6278015|NCT02250651|9985474|FG000|Treatment Period 1 (Day 1 to Week 15)|Lost to Follow-up|1
6278016|NCT02250651|9985475|FG001|Treatment Period 1 (Day 1 to Week 15)|Lost to Follow-up|0
6278017|NCT02250651|9985476|FG002|Treatment Period 1 (Day 1 to Week 15)|Lost to Follow-up|0
6278018|NCT02250651|9985474|FG000|Treatment Period 1 (Day 1 to Week 15)|Personal Reasons|2
6278019|NCT02250651|9985475|FG001|Treatment Period 1 (Day 1 to Week 15)|Personal Reasons|3
6278020|NCT02250651|9985476|FG002|Treatment Period 1 (Day 1 to Week 15)|Personal Reasons|5
6278021|NCT02250651|9985474|FG000|Treatment Period 1 (Day 1 to Week 15)|Protocol Deviation|1
6278022|NCT02250651|9985475|FG001|Treatment Period 1 (Day 1 to Week 15)|Protocol Deviation|0
6278023|NCT02250651|9985476|FG002|Treatment Period 1 (Day 1 to Week 15)|Protocol Deviation|0
6278024|NCT02250651|9985474|FG000|Treatment Period 1 (Day 1 to Week 15)|Reason not Specified|0
6278025|NCT02250651|9985475|FG001|Treatment Period 1 (Day 1 to Week 15)|Reason not Specified|0
6278026|NCT02250651|9985476|FG002|Treatment Period 1 (Day 1 to Week 15)|Reason not Specified|1
6278027|NCT02250651|9985474|FG000|Treatment Period 1 (Day 1 to Week 15)|Randomized but not Treated|0
6278028|NCT02250651|9985475|FG001|Treatment Period 1 (Day 1 to Week 15)|Randomized but not Treated|1
6278029|NCT02250651|9985476|FG002|Treatment Period 1 (Day 1 to Week 15)|Randomized but not Treated|3
6278030|NCT02250651|9985474|FG000|Treatment Period 2 (Week 16 to Week 31)|Adverse Event|4
6278031|NCT02250651|9985475|FG001|Treatment Period 2 (Week 16 to Week 31)|Adverse Event|1
6278032|NCT02250651|9985476|FG002|Treatment Period 2 (Week 16 to Week 31)|Adverse Event|0
6278033|NCT02250651|9985474|FG000|Treatment Period 2 (Week 16 to Week 31)|Lost to Follow-up|0
5977523|NCT02565914|9564794|FG000|Overall Study|Parent study termination by sponsor|1
5977524|NCT02565914|9564794|FG000|Overall Study|Commercial drug available|5
5977525|NCT02565914|9564794|FG000|Overall Study|Other|18
5977526|NCT02565914|9564794|FG000|Overall Study|Enrolled, but did not receive study drug|2
5977527|NCT02550652|9564808|FG000|Overall Study|Death|1
5977528|NCT02550652|9564809|FG001|Overall Study|Death|4
5977529|NCT02550652|9564808|FG000|Overall Study|Lack of Efficacy|1
5977530|NCT02550652|9564809|FG001|Overall Study|Lack of Efficacy|0
5977531|NCT02550652|9564808|FG000|Overall Study|Withdrawal by Subject|3
6201102|NCT01490632|9860709|FG008|Part C: Washout or Step-Down Period|Did Not Qualify for Part D Per Protocol|0
6201103|NCT01490632|9860710|FG009|Part C: Washout or Step-Down Period|Did Not Qualify for Part D Per Protocol|0
6089030|NCT00680043|9700190|FG000|Overall Study|Patient Not Compliant With Study Reqs.|0
6089031|NCT00680043|9700191|FG001|Overall Study|Patient Not Compliant With Study Reqs.|1
6201104|NCT01490632|9860711|FG010|Part C: Washout or Step-Down Period|Did Not Qualify for Part D Per Protocol|0
6201105|NCT01490632|9860712|FG011|Part C: Washout or Step-Down Period|Did Not Qualify for Part D Per Protocol|0
6201106|NCT01490632|9860713|FG012|Part C: Washout or Step-Down Period|Did Not Qualify for Part D Per Protocol|5
6201107|NCT01490632|9860714|FG013|Part C: Washout or Step-Down Period|Did Not Qualify for Part D Per Protocol|9
6201108|NCT01490632|9860715|FG014|Part C: Washout or Step-Down Period|Did Not Qualify for Part D Per Protocol|14
6201109|NCT01490632|9860716|FG015|Part C: Washout or Step-Down Period|Did Not Qualify for Part D Per Protocol|34
6201110|NCT01490632|9860717|FG016|Part C: Washout or Step-Down Period|Did Not Qualify for Part D Per Protocol|0
6201111|NCT01490632|9860718|FG017|Part C: Washout or Step-Down Period|Did Not Qualify for Part D Per Protocol|0
6201112|NCT01490632|9860719|FG018|Part C: Washout or Step-Down Period|Did Not Qualify for Part D Per Protocol|0
6201113|NCT01490632|9860720|FG019|Part C: Washout or Step-Down Period|Did Not Qualify for Part D Per Protocol|0
6201114|NCT01490632|9860701|FG000|Part D: Re-Treatment Period|Adverse Event|0
6201115|NCT01490632|9860702|FG001|Part D: Re-Treatment Period|Adverse Event|0
6201116|NCT01490632|9860703|FG002|Part D: Re-Treatment Period|Adverse Event|0
6201117|NCT01490632|9860704|FG003|Part D: Re-Treatment Period|Adverse Event|0
6201118|NCT01490632|9860705|FG004|Part D: Re-Treatment Period|Adverse Event|0
6201119|NCT01490632|9860706|FG005|Part D: Re-Treatment Period|Adverse Event|0
6201120|NCT01490632|9860707|FG006|Part D: Re-Treatment Period|Adverse Event|0
6201121|NCT01490632|9860708|FG007|Part D: Re-Treatment Period|Adverse Event|0
6201122|NCT01490632|9860709|FG008|Part D: Re-Treatment Period|Adverse Event|0
6201123|NCT01490632|9860710|FG009|Part D: Re-Treatment Period|Adverse Event|0
6201124|NCT01490632|9860711|FG010|Part D: Re-Treatment Period|Adverse Event|0
6201125|NCT01490632|9860712|FG011|Part D: Re-Treatment Period|Adverse Event|0
6201126|NCT01490632|9860713|FG012|Part D: Re-Treatment Period|Adverse Event|0
6201127|NCT01490632|9860714|FG013|Part D: Re-Treatment Period|Adverse Event|0
6201128|NCT01490632|9860715|FG014|Part D: Re-Treatment Period|Adverse Event|0
6201129|NCT01490632|9860716|FG015|Part D: Re-Treatment Period|Adverse Event|0
6201130|NCT01490632|9860717|FG016|Part D: Re-Treatment Period|Adverse Event|0
6201131|NCT01490632|9860718|FG017|Part D: Re-Treatment Period|Adverse Event|1
6201132|NCT01490632|9860719|FG018|Part D: Re-Treatment Period|Adverse Event|1
6201133|NCT01490632|9860720|FG019|Part D: Re-Treatment Period|Adverse Event|3
6201134|NCT01490632|9860701|FG000|Part D: Re-Treatment Period|Death|0
6201135|NCT01490632|9860702|FG001|Part D: Re-Treatment Period|Death|0
6201136|NCT01490632|9860703|FG002|Part D: Re-Treatment Period|Death|0
6201137|NCT01490632|9860704|FG003|Part D: Re-Treatment Period|Death|0
6201138|NCT01490632|9860705|FG004|Part D: Re-Treatment Period|Death|0
6201139|NCT01490632|9860706|FG005|Part D: Re-Treatment Period|Death|0
6201140|NCT01490632|9860707|FG006|Part D: Re-Treatment Period|Death|0
6201141|NCT01490632|9860708|FG007|Part D: Re-Treatment Period|Death|0
6201142|NCT01490632|9860709|FG008|Part D: Re-Treatment Period|Death|0
6201143|NCT01490632|9860710|FG009|Part D: Re-Treatment Period|Death|0
6201144|NCT01490632|9860711|FG010|Part D: Re-Treatment Period|Death|0
6201145|NCT01490632|9860712|FG011|Part D: Re-Treatment Period|Death|0
6201146|NCT01490632|9860713|FG012|Part D: Re-Treatment Period|Death|0
6201147|NCT01490632|9860714|FG013|Part D: Re-Treatment Period|Death|0
6201148|NCT01490632|9860715|FG014|Part D: Re-Treatment Period|Death|0
6201149|NCT01490632|9860716|FG015|Part D: Re-Treatment Period|Death|0
6201150|NCT01490632|9860717|FG016|Part D: Re-Treatment Period|Death|0
6201151|NCT01490632|9860718|FG017|Part D: Re-Treatment Period|Death|0
6201152|NCT01490632|9860719|FG018|Part D: Re-Treatment Period|Death|1
6201153|NCT01490632|9860720|FG019|Part D: Re-Treatment Period|Death|0
6201154|NCT01490632|9860701|FG000|Part D: Re-Treatment Period|Lack of Efficacy|0
6201155|NCT01490632|9860702|FG001|Part D: Re-Treatment Period|Lack of Efficacy|0
6201156|NCT01490632|9860703|FG002|Part D: Re-Treatment Period|Lack of Efficacy|0
6201157|NCT01490632|9860704|FG003|Part D: Re-Treatment Period|Lack of Efficacy|0
6201158|NCT01490632|9860705|FG004|Part D: Re-Treatment Period|Lack of Efficacy|0
6201159|NCT01490632|9860706|FG005|Part D: Re-Treatment Period|Lack of Efficacy|0
6201160|NCT01490632|9860707|FG006|Part D: Re-Treatment Period|Lack of Efficacy|0
6201161|NCT01490632|9860708|FG007|Part D: Re-Treatment Period|Lack of Efficacy|0
6201162|NCT01490632|9860709|FG008|Part D: Re-Treatment Period|Lack of Efficacy|0
6201163|NCT01490632|9860710|FG009|Part D: Re-Treatment Period|Lack of Efficacy|0
6201164|NCT01490632|9860711|FG010|Part D: Re-Treatment Period|Lack of Efficacy|0
6201165|NCT01490632|9860712|FG011|Part D: Re-Treatment Period|Lack of Efficacy|0
6201166|NCT01490632|9860713|FG012|Part D: Re-Treatment Period|Lack of Efficacy|0
6201167|NCT01490632|9860714|FG013|Part D: Re-Treatment Period|Lack of Efficacy|0
6201168|NCT01490632|9860715|FG014|Part D: Re-Treatment Period|Lack of Efficacy|0
6201169|NCT01490632|9860716|FG015|Part D: Re-Treatment Period|Lack of Efficacy|0
6201170|NCT01490632|9860717|FG016|Part D: Re-Treatment Period|Lack of Efficacy|0
6201171|NCT01490632|9860718|FG017|Part D: Re-Treatment Period|Lack of Efficacy|3
6201172|NCT01490632|9860719|FG018|Part D: Re-Treatment Period|Lack of Efficacy|1
6201173|NCT01490632|9860720|FG019|Part D: Re-Treatment Period|Lack of Efficacy|2
6201174|NCT01490632|9860701|FG000|Part D: Re-Treatment Period|Lost to Follow-up|0
6201175|NCT01490632|9860702|FG001|Part D: Re-Treatment Period|Lost to Follow-up|0
6201176|NCT01490632|9860703|FG002|Part D: Re-Treatment Period|Lost to Follow-up|0
6201177|NCT01490632|9860704|FG003|Part D: Re-Treatment Period|Lost to Follow-up|0
6278034|NCT02250651|9985475|FG001|Treatment Period 2 (Week 16 to Week 31)|Lost to Follow-up|0
6278035|NCT02250651|9985476|FG002|Treatment Period 2 (Week 16 to Week 31)|Lost to Follow-up|3
6278036|NCT02250651|9985474|FG000|Treatment Period 2 (Week 16 to Week 31)|Personal Reasons|2
6278037|NCT02250651|9985475|FG001|Treatment Period 2 (Week 16 to Week 31)|Personal Reasons|3
6278038|NCT02250651|9985476|FG002|Treatment Period 2 (Week 16 to Week 31)|Personal Reasons|2
6278039|NCT02250651|9985474|FG000|Treatment Period 2 (Week 16 to Week 31)|Protocol Deviation|0
6278040|NCT02250651|9985475|FG001|Treatment Period 2 (Week 16 to Week 31)|Protocol Deviation|1
6278041|NCT02250651|9985476|FG002|Treatment Period 2 (Week 16 to Week 31)|Protocol Deviation|0
6278042|NCT02250651|9985474|FG000|Treatment Period 2 (Week 16 to Week 31)|Reason not Specified|0
6278043|NCT02250651|9985475|FG001|Treatment Period 2 (Week 16 to Week 31)|Reason not Specified|1
6278044|NCT02250651|9985476|FG002|Treatment Period 2 (Week 16 to Week 31)|Reason not Specified|0
6278045|NCT02250651|9985474|FG000|Treatment Period 3 (Week 32 to Week 52)|Adverse Event|4
6278046|NCT02250651|9985475|FG001|Treatment Period 3 (Week 32 to Week 52)|Adverse Event|1
6278047|NCT02250651|9985476|FG002|Treatment Period 3 (Week 32 to Week 52)|Adverse Event|1
6278048|NCT02250651|9985474|FG000|Treatment Period 3 (Week 32 to Week 52)|Lost to Follow-up|1
6278049|NCT02250651|9985475|FG001|Treatment Period 3 (Week 32 to Week 52)|Lost to Follow-up|2
6278050|NCT02250651|9985476|FG002|Treatment Period 3 (Week 32 to Week 52)|Lost to Follow-up|1
6278051|NCT02250651|9985474|FG000|Treatment Period 3 (Week 32 to Week 52)|Personal Reasons|2
6278052|NCT02250651|9985475|FG001|Treatment Period 3 (Week 32 to Week 52)|Personal Reasons|0
6278053|NCT02250651|9985476|FG002|Treatment Period 3 (Week 32 to Week 52)|Personal Reasons|2
6278054|NCT02250651|9985474|FG000|Treatment Period 3 (Week 32 to Week 52)|Reason not Specified|2
6278055|NCT02250651|9985475|FG001|Treatment Period 3 (Week 32 to Week 52)|Reason not Specified|1
6278056|NCT02250651|9985476|FG002|Treatment Period 3 (Week 32 to Week 52)|Reason not Specified|1
6278057|NCT02251275|9985515|FG000|Overall Study|Adverse Event|23
6278058|NCT02251275|9985516|FG001|Overall Study|Adverse Event|60
6278059|NCT02251275|9985517|FG002|Overall Study|Adverse Event|28
6278060|NCT02251275|9985518|FG003|Overall Study|Adverse Event|0
6278061|NCT02251275|9985519|FG004|Overall Study|Adverse Event|0
6278062|NCT02251275|9985515|FG000|Overall Study|Lost to Follow-up|5
6278063|NCT02251275|9985516|FG001|Overall Study|Lost to Follow-up|6
6278064|NCT02251275|9985517|FG002|Overall Study|Lost to Follow-up|4
6278065|NCT02251275|9985518|FG003|Overall Study|Lost to Follow-up|0
6278066|NCT02251275|9985519|FG004|Overall Study|Lost to Follow-up|0
6278067|NCT02251275|9985515|FG000|Overall Study|Physician Decision|19
6278068|NCT02251275|9985516|FG001|Overall Study|Physician Decision|30
6278069|NCT02251275|9985517|FG002|Overall Study|Physician Decision|26
6278070|NCT02251275|9985518|FG003|Overall Study|Physician Decision|0
6278071|NCT02251275|9985519|FG004|Overall Study|Physician Decision|1
6278072|NCT02251275|9985515|FG000|Overall Study|Protocol Deviation|0
6278073|NCT02251275|9985516|FG001|Overall Study|Protocol Deviation|0
6278074|NCT02251275|9985517|FG002|Overall Study|Protocol Deviation|1
6278075|NCT02251275|9985518|FG003|Overall Study|Protocol Deviation|0
6278076|NCT02251275|9985519|FG004|Overall Study|Protocol Deviation|0
6278077|NCT02251275|9985515|FG000|Overall Study|Withdrawal by Subject|25
6278078|NCT02251275|9985516|FG001|Overall Study|Withdrawal by Subject|51
6278079|NCT02251275|9985517|FG002|Overall Study|Withdrawal by Subject|35
6278080|NCT02251275|9985518|FG003|Overall Study|Withdrawal by Subject|1
6278081|NCT02251275|9985519|FG004|Overall Study|Withdrawal by Subject|0
6201178|NCT01490632|9860705|FG004|Part D: Re-Treatment Period|Lost to Follow-up|0
6201179|NCT01490632|9860706|FG005|Part D: Re-Treatment Period|Lost to Follow-up|0
6201180|NCT01490632|9860707|FG006|Part D: Re-Treatment Period|Lost to Follow-up|0
6201181|NCT01490632|9860708|FG007|Part D: Re-Treatment Period|Lost to Follow-up|0
6201182|NCT01490632|9860709|FG008|Part D: Re-Treatment Period|Lost to Follow-up|0
6201183|NCT01490632|9860710|FG009|Part D: Re-Treatment Period|Lost to Follow-up|0
6201184|NCT01490632|9860711|FG010|Part D: Re-Treatment Period|Lost to Follow-up|0
6201185|NCT01490632|9860712|FG011|Part D: Re-Treatment Period|Lost to Follow-up|0
6201186|NCT01490632|9860713|FG012|Part D: Re-Treatment Period|Lost to Follow-up|0
6201187|NCT01490632|9860714|FG013|Part D: Re-Treatment Period|Lost to Follow-up|0
6201188|NCT01490632|9860715|FG014|Part D: Re-Treatment Period|Lost to Follow-up|0
6201189|NCT01490632|9860716|FG015|Part D: Re-Treatment Period|Lost to Follow-up|0
6201190|NCT01490632|9860717|FG016|Part D: Re-Treatment Period|Lost to Follow-up|0
6201191|NCT01490632|9860718|FG017|Part D: Re-Treatment Period|Lost to Follow-up|0
6201192|NCT01490632|9860719|FG018|Part D: Re-Treatment Period|Lost to Follow-up|1
6201193|NCT01490632|9860720|FG019|Part D: Re-Treatment Period|Lost to Follow-up|0
6201194|NCT01490632|9860701|FG000|Part D: Re-Treatment Period|Physician Decision|0
6201195|NCT01490632|9860702|FG001|Part D: Re-Treatment Period|Physician Decision|0
6201196|NCT01490632|9860703|FG002|Part D: Re-Treatment Period|Physician Decision|0
6201197|NCT01490632|9860704|FG003|Part D: Re-Treatment Period|Physician Decision|0
6201198|NCT01490632|9860705|FG004|Part D: Re-Treatment Period|Physician Decision|0
6201199|NCT01490632|9860706|FG005|Part D: Re-Treatment Period|Physician Decision|0
6201200|NCT01490632|9860707|FG006|Part D: Re-Treatment Period|Physician Decision|0
6201201|NCT01490632|9860708|FG007|Part D: Re-Treatment Period|Physician Decision|0
6201202|NCT01490632|9860709|FG008|Part D: Re-Treatment Period|Physician Decision|0
6201203|NCT01490632|9860710|FG009|Part D: Re-Treatment Period|Physician Decision|0
6201204|NCT01490632|9860711|FG010|Part D: Re-Treatment Period|Physician Decision|0
6201205|NCT01490632|9860712|FG011|Part D: Re-Treatment Period|Physician Decision|0
6201206|NCT01490632|9860713|FG012|Part D: Re-Treatment Period|Physician Decision|0
6201207|NCT01490632|9860714|FG013|Part D: Re-Treatment Period|Physician Decision|0
6201208|NCT01490632|9860715|FG014|Part D: Re-Treatment Period|Physician Decision|0
6201209|NCT01490632|9860716|FG015|Part D: Re-Treatment Period|Physician Decision|0
6201210|NCT01490632|9860717|FG016|Part D: Re-Treatment Period|Physician Decision|0
6201211|NCT01490632|9860718|FG017|Part D: Re-Treatment Period|Physician Decision|0
6201212|NCT01490632|9860719|FG018|Part D: Re-Treatment Period|Physician Decision|1
6201213|NCT01490632|9860720|FG019|Part D: Re-Treatment Period|Physician Decision|1
6201214|NCT01490632|9860701|FG000|Part D: Re-Treatment Period|Protocol Violation|0
6201215|NCT01490632|9860702|FG001|Part D: Re-Treatment Period|Protocol Violation|0
6201216|NCT01490632|9860703|FG002|Part D: Re-Treatment Period|Protocol Violation|0
6201217|NCT01490632|9860704|FG003|Part D: Re-Treatment Period|Protocol Violation|0
6201218|NCT01490632|9860705|FG004|Part D: Re-Treatment Period|Protocol Violation|0
6201219|NCT01490632|9860706|FG005|Part D: Re-Treatment Period|Protocol Violation|0
6201220|NCT01490632|9860707|FG006|Part D: Re-Treatment Period|Protocol Violation|0
6201221|NCT01490632|9860708|FG007|Part D: Re-Treatment Period|Protocol Violation|0
6201222|NCT01490632|9860709|FG008|Part D: Re-Treatment Period|Protocol Violation|0
6201223|NCT01490632|9860710|FG009|Part D: Re-Treatment Period|Protocol Violation|0
6201224|NCT01490632|9860711|FG010|Part D: Re-Treatment Period|Protocol Violation|0
6201225|NCT01490632|9860712|FG011|Part D: Re-Treatment Period|Protocol Violation|0
6201226|NCT01490632|9860713|FG012|Part D: Re-Treatment Period|Protocol Violation|0
6201227|NCT01490632|9860714|FG013|Part D: Re-Treatment Period|Protocol Violation|0
6201228|NCT01490632|9860715|FG014|Part D: Re-Treatment Period|Protocol Violation|0
6201229|NCT01490632|9860716|FG015|Part D: Re-Treatment Period|Protocol Violation|0
6201230|NCT01490632|9860717|FG016|Part D: Re-Treatment Period|Protocol Violation|0
6201231|NCT01490632|9860718|FG017|Part D: Re-Treatment Period|Protocol Violation|0
6201232|NCT01490632|9860719|FG018|Part D: Re-Treatment Period|Protocol Violation|1
6201233|NCT01490632|9860720|FG019|Part D: Re-Treatment Period|Protocol Violation|0
6201234|NCT01490632|9860701|FG000|Part D: Re-Treatment Period|Withdrawal by Subject|0
6201235|NCT01490632|9860702|FG001|Part D: Re-Treatment Period|Withdrawal by Subject|0
6201236|NCT01490632|9860703|FG002|Part D: Re-Treatment Period|Withdrawal by Subject|0
6201237|NCT01490632|9860704|FG003|Part D: Re-Treatment Period|Withdrawal by Subject|0
6201238|NCT01490632|9860705|FG004|Part D: Re-Treatment Period|Withdrawal by Subject|0
6278082|NCT02251652|9985561|FG000|Overall Study|Withdrawal by Subject|1
6278083|NCT02251717|9985569|FG000|Overall Study|Adverse Event|0
6278084|NCT02251717|9985570|FG001|Overall Study|Adverse Event|1
6278085|NCT02251717|9985569|FG000|Overall Study|Withdrew Consent|1
6278086|NCT02251717|9985570|FG001|Overall Study|Withdrew Consent|0
6278087|NCT02251743|9985578|FG000|Overall Study|Withdrawal by Subject|1
6278088|NCT02251743|9985579|FG001|Overall Study|Withdrawal by Subject|1
6278089|NCT02251912|9985604|FG000|Overall Study|Withdrawal by Subject|2
6278090|NCT02251912|9985605|FG001|Overall Study|Withdrawal by Subject|3
6278091|NCT02251912|9985604|FG000|Overall Study|Adverse Event|0
6278092|NCT02251912|9985605|FG001|Overall Study|Adverse Event|2
6278093|NCT02251990|9985617|FG000|Period 1 (Double-blind [DB])|Adverse Event|1
6278094|NCT02251990|9985618|FG001|Period 1 (Double-blind [DB])|Adverse Event|1
6278095|NCT02251990|9985617|FG000|Period 1 (Double-blind [DB])|Lack of Efficacy|5
6278096|NCT02251990|9985618|FG001|Period 1 (Double-blind [DB])|Lack of Efficacy|0
6278097|NCT02251990|9985617|FG000|Period 1 (Double-blind [DB])|Withdrawal by Subject|1
6278098|NCT02251990|9985618|FG001|Period 1 (Double-blind [DB])|Withdrawal by Subject|0
6278099|NCT02251990|9985617|FG000|Period 1 (Double-blind [DB])|Not Treated|1
6278100|NCT02251990|9985618|FG001|Period 1 (Double-blind [DB])|Not Treated|0
6278101|NCT02251990|9985617|FG000|Period 2 (ITG Follow-up/DTG Open Label)|Lack of Efficacy|0
6278102|NCT02251990|9985618|FG001|Period 2 (ITG Follow-up/DTG Open Label)|Lack of Efficacy|1
6278103|NCT02251990|9985617|FG000|Period 2 (ITG Follow-up/DTG Open Label)|Adverse Event|0
6278104|NCT02251990|9985618|FG001|Period 2 (ITG Follow-up/DTG Open Label)|Adverse Event|2
6278105|NCT02252016|9985627|FG000|Overall Study|Lost to Follow-up|2
6278106|NCT02252016|9985628|FG001|Overall Study|Lost to Follow-up|1
6278107|NCT02252016|9985627|FG000|Overall Study|Physician Decision|1
6278108|NCT02252016|9985628|FG001|Overall Study|Physician Decision|0
6278109|NCT02252016|9985627|FG000|Overall Study|Withdrawal by Subject|0
6278110|NCT02252016|9985628|FG001|Overall Study|Withdrawal by Subject|2
6278111|NCT02252042|9985636|FG000|Overall Study|Death|170
6278112|NCT02252042|9985637|FG001|Overall Study|Death|192
6278113|NCT02252042|9985636|FG000|Overall Study|Physician Decision|0
6278114|NCT02252042|9985637|FG001|Overall Study|Physician Decision|1
5977532|NCT02550652|9564809|FG001|Overall Study|Withdrawal by Subject|7
6201239|NCT01490632|9860706|FG005|Part D: Re-Treatment Period|Withdrawal by Subject|0
6201240|NCT01490632|9860707|FG006|Part D: Re-Treatment Period|Withdrawal by Subject|0
6201241|NCT01490632|9860708|FG007|Part D: Re-Treatment Period|Withdrawal by Subject|0
6201242|NCT01490632|9860709|FG008|Part D: Re-Treatment Period|Withdrawal by Subject|0
6201243|NCT01490632|9860710|FG009|Part D: Re-Treatment Period|Withdrawal by Subject|0
6201244|NCT01490632|9860711|FG010|Part D: Re-Treatment Period|Withdrawal by Subject|0
6201245|NCT01490632|9860712|FG011|Part D: Re-Treatment Period|Withdrawal by Subject|0
6201246|NCT01490632|9860713|FG012|Part D: Re-Treatment Period|Withdrawal by Subject|0
6278115|NCT02252042|9985636|FG000|Overall Study|Withdrawal by Subject|13
6278116|NCT02252042|9985637|FG001|Overall Study|Withdrawal by Subject|20
6278117|NCT02252042|9985636|FG000|Overall Study|Ongoing in study|64
6278118|NCT02252042|9985637|FG001|Overall Study|Ongoing in study|35
6278119|NCT02252081|9985658|FG000|Overall Study|Withdrawal by Subject|2
6278120|NCT02252081|9985659|FG001|Overall Study|Withdrawal by Subject|1
6278121|NCT02252081|9985658|FG000|Overall Study|Adverse Event|4
6278122|NCT02252081|9985659|FG001|Overall Study|Adverse Event|1
5977533|NCT02550652|9564808|FG000|Overall Study|Post Trial Access|1
5977534|NCT02550652|9564809|FG001|Overall Study|Post Trial Access|0
5977535|NCT02550652|9564808|FG000|Overall Study|Lost to Follow-up|1
5977536|NCT02550652|9564809|FG001|Overall Study|Lost to Follow-up|3
5977537|NCT02550652|9564808|FG000|Overall Study|Physician Decision|0
5977538|NCT02550652|9564809|FG001|Overall Study|Physician Decision|2
5977539|NCT02550652|9564808|FG000|Overall Study|Ongoing in safety/B-cell follow-up period|14
5977540|NCT02550652|9564809|FG001|Overall Study|Ongoing in safety/B-cell follow-up period|5
5977541|NCT02385045|9564815|FG000|Overall Study|Endoscopy could not be completed|4
5977542|NCT02005471|9564830|FG000|Overall Study|Ongoing in Study|144
5977543|NCT02005471|9564831|FG001|Overall Study|Ongoing in Study|171
5977544|NCT02005471|9564830|FG000|Overall Study|Adverse Event|1
5977545|NCT02005471|9564831|FG001|Overall Study|Adverse Event|0
5977546|NCT02005471|9564830|FG000|Overall Study|Death|26
5977547|NCT02005471|9564831|FG001|Overall Study|Death|15
5977548|NCT02005471|9564830|FG000|Overall Study|Lost to Follow-up|1
5977549|NCT02005471|9564831|FG001|Overall Study|Lost to Follow-up|0
5977550|NCT02005471|9564830|FG000|Overall Study|Physician Decision|2
5977551|NCT02005471|9564831|FG001|Overall Study|Physician Decision|1
5977552|NCT02005471|9564830|FG000|Overall Study|Progressive Disease|3
5977553|NCT02005471|9564831|FG001|Overall Study|Progressive Disease|0
5977554|NCT02005471|9564830|FG000|Overall Study|Withdrawal by Subject|18
5977555|NCT02005471|9564831|FG001|Overall Study|Withdrawal by Subject|7
5977556|NCT01845649|9564842|FG000|Overall Study|Adverse Event|7
5977557|NCT01845649|9564843|FG001|Overall Study|Adverse Event|10
5977558|NCT01845649|9564842|FG000|Overall Study|Lack of Efficacy|1
5977559|NCT01845649|9564843|FG001|Overall Study|Lack of Efficacy|1
5977560|NCT01845649|9564842|FG000|Overall Study|Lost to Follow-up|2
5977561|NCT01845649|9564843|FG001|Overall Study|Lost to Follow-up|2
5977562|NCT01845649|9564842|FG000|Overall Study|Withdrew Consent|12
5977563|NCT01845649|9564843|FG001|Overall Study|Withdrew Consent|4
5977564|NCT01845649|9564842|FG000|Overall Study|Protocol Deviation|7
5977565|NCT01845649|9564843|FG001|Overall Study|Protocol Deviation|4
5977566|NCT01845649|9564842|FG000|Overall Study|Reason not Specified|2
5977567|NCT01845649|9564843|FG001|Overall Study|Reason not Specified|1
5977568|NCT01844986|9564851|FG000|Overall Study|Severe non-compliance to protocol|1
5977569|NCT01844986|9564852|FG001|Overall Study|Severe non-compliance to protocol|0
5977570|NCT01844986|9564851|FG000|Overall Study|Withdrawal by Subject|21
5977571|NCT01844986|9564852|FG001|Overall Study|Withdrawal by Subject|14
5977572|NCT01844986|9564851|FG000|Overall Study|Death|55
5977573|NCT01844986|9564852|FG001|Overall Study|Death|26
5977574|NCT01816139|9564860|FG000|Overall Study|Adverse Event|6
5977575|NCT01816139|9564861|FG001|Overall Study|Adverse Event|8
5977576|NCT01816139|9564860|FG000|Overall Study|Lack of Efficacy|1
5977577|NCT01816139|9564861|FG001|Overall Study|Lack of Efficacy|2
5977578|NCT01816139|9564860|FG000|Overall Study|Lost to Follow-up|5
5977579|NCT01816139|9564861|FG001|Overall Study|Lost to Follow-up|3
5977580|NCT01816139|9564860|FG000|Overall Study|Withdrew Consent|6
5977581|NCT01816139|9564861|FG001|Overall Study|Withdrew Consent|4
5977582|NCT01816139|9564860|FG000|Overall Study|Protocol Violation|6
5977583|NCT01816139|9564861|FG001|Overall Study|Protocol Violation|3
5977584|NCT01816139|9564860|FG000|Overall Study|Reason not Specified|4
5977585|NCT01816139|9564861|FG001|Overall Study|Reason not Specified|2
5977586|NCT01455597|9564867|FG000|Overall Study|Adverse Event|7
5977587|NCT01455597|9564868|FG001|Overall Study|Adverse Event|0
5977588|NCT01455597|9564869|FG002|Overall Study|Adverse Event|5
5977589|NCT01455597|9564870|FG003|Overall Study|Adverse Event|1
5977590|NCT01455597|9564867|FG000|Overall Study|Lack of Efficacy|0
5977591|NCT01455597|9564868|FG001|Overall Study|Lack of Efficacy|1
5977592|NCT01455597|9564869|FG002|Overall Study|Lack of Efficacy|2
6201247|NCT01490632|9860714|FG013|Part D: Re-Treatment Period|Withdrawal by Subject|0
5977593|NCT01455597|9564870|FG003|Overall Study|Lack of Efficacy|0
5977594|NCT01455597|9564867|FG000|Overall Study|Lost to Follow-up|3
5977595|NCT01455597|9564868|FG001|Overall Study|Lost to Follow-up|0
6201248|NCT01490632|9860715|FG014|Part D: Re-Treatment Period|Withdrawal by Subject|0
6201249|NCT01490632|9860716|FG015|Part D: Re-Treatment Period|Withdrawal by Subject|0
6201250|NCT01490632|9860717|FG016|Part D: Re-Treatment Period|Withdrawal by Subject|0
6201251|NCT01490632|9860718|FG017|Part D: Re-Treatment Period|Withdrawal by Subject|1
6201252|NCT01490632|9860719|FG018|Part D: Re-Treatment Period|Withdrawal by Subject|1
6201253|NCT01490632|9860720|FG019|Part D: Re-Treatment Period|Withdrawal by Subject|1
6201254|NCT01490697|9860769|FG000|Overall Study|Did Not Meet PTSD Diagnostic Criteria|1
6201255|NCT01490697|9860770|FG001|Overall Study|Did Not Meet PTSD Diagnostic Criteria|2
6201256|NCT01490814|9860795|FG000|Overall Study|Inclusion/Exclusion Criteria Violation|3
6201257|NCT01490814|9860796|FG001|Overall Study|Inclusion/Exclusion Criteria Violation|3
6201258|NCT01490814|9860795|FG000|Overall Study|Physician Decision|1
6201259|NCT01490814|9860796|FG001|Overall Study|Physician Decision|0
6201260|NCT01490814|9860795|FG000|Overall Study|Withdrawal by Subject|0
6201261|NCT01490814|9860796|FG001|Overall Study|Withdrawal by Subject|5
6201262|NCT01490840|9860804|FG000|Phase 1|Lost to Follow-up|1
6201263|NCT01490840|9860805|FG001|Phase 1|Lost to Follow-up|0
6201264|NCT01490840|9860804|FG000|Phase 1|Adverse Event|2
6201265|NCT01490840|9860805|FG001|Phase 1|Adverse Event|1
6201266|NCT01490840|9860804|FG000|Phase 1|Withdrawal by Subject|6
6201267|NCT01490840|9860805|FG001|Phase 1|Withdrawal by Subject|5
6201268|NCT01490840|9860804|FG000|Phase 1|Visit 6a omitted|1
6201269|NCT01490840|9860805|FG001|Phase 1|Visit 6a omitted|0
6201270|NCT01490840|9860804|FG000|Phase 2|Withdrawal by Subject|4
6201271|NCT01490840|9860805|FG001|Phase 2|Withdrawal by Subject|3
6201272|NCT01490840|9860804|FG000|Phase 2|Permanent interruption of fingolimod|0
6201273|NCT01490840|9860805|FG001|Phase 2|Permanent interruption of fingolimod|1
6201274|NCT01490840|9860804|FG000|Phase 2|Lost to Follow-up|1
6201275|NCT01490840|9860805|FG001|Phase 2|Lost to Follow-up|1
6201276|NCT01490840|9860804|FG000|Phase 2|Adverse Event|1
6201277|NCT01490840|9860805|FG001|Phase 2|Adverse Event|1
6201278|NCT01490866|9860811|FG000|FOLFOX/Bevacizumab Treatment|Disease Progression|6
6201279|NCT01490866|9860811|FG000|FOLFOX/Bevacizumab Treatment|Adverse Event|6
6201280|NCT01490866|9860811|FG000|FOLFOX/Bevacizumab Treatment|Withdrawal by Subject|5
6201281|NCT01490866|9860811|FG000|FOLFOX/Bevacizumab Treatment|Protocol Violation|1
6201282|NCT01490866|9860811|FG000|FOLFOX/Bevacizumab Treatment|Intercurrent illness|1
6201283|NCT01490866|9860811|FG000|FOLFOX/Bevacizumab Treatment|Physician Decision|2
6201284|NCT01490866|9860811|FG000|Axitinib Maintenance Therapy|Disease Progression|30
6201285|NCT01490866|9860811|FG000|Axitinib Maintenance Therapy|Adverse Event|12
6201286|NCT01490866|9860811|FG000|Axitinib Maintenance Therapy|Withdrawal by Subject|3
6201287|NCT01490866|9860811|FG000|Axitinib Maintenance Therapy|Protocol Violation|2
6201288|NCT01490866|9860811|FG000|Axitinib Maintenance Therapy|Intercurrent illness|2
6201289|NCT01490918|9860825|FG000|Overall Study|Lost to Follow-up|2
6201290|NCT01490918|9860826|FG001|Overall Study|Lost to Follow-up|1
6201291|NCT01490918|9860827|FG002|Overall Study|Lost to Follow-up|0
6201292|NCT01490918|9860825|FG000|Overall Study|Withdrawal by Subject|7
6201293|NCT01490918|9860826|FG001|Overall Study|Withdrawal by Subject|8
6201294|NCT01490918|9860827|FG002|Overall Study|Withdrawal by Subject|3
6201295|NCT01490918|9860825|FG000|Overall Study|Adverse Event|0
6201296|NCT01490918|9860826|FG001|Overall Study|Adverse Event|0
6201297|NCT01490918|9860827|FG002|Overall Study|Adverse Event|1
6278123|NCT02252081|9985658|FG000|Overall Study|non compliance & others|0
6278124|NCT02252081|9985659|FG001|Overall Study|non compliance & others|2
6278125|NCT02252146|9985677|FG000|Overall Study|Lack of Efficacy|4
6278126|NCT02252146|9985677|FG000|Overall Study|Entered hospice care|1
6201298|NCT01490918|9860825|FG000|Overall Study|other cause|4
6201299|NCT01490918|9860826|FG001|Overall Study|other cause|5
6201300|NCT01490918|9860827|FG002|Overall Study|other cause|8
6201301|NCT01491035|9860864|FG000|Overall Study|Lost to Follow-up|0
6201302|NCT01491035|9860865|FG001|Overall Study|Lost to Follow-up|0
6201303|NCT01491035|9860866|FG002|Overall Study|Lost to Follow-up|0
6201304|NCT01491035|9860867|FG003|Overall Study|Lost to Follow-up|0
6201305|NCT01491035|9860868|FG004|Overall Study|Lost to Follow-up|1
6201306|NCT01491035|9860869|FG005|Overall Study|Lost to Follow-up|0
6201307|NCT01491035|9860870|FG006|Overall Study|Lost to Follow-up|0
6201308|NCT01491035|9860871|FG007|Overall Study|Lost to Follow-up|0
6201309|NCT01491178|9860912|FG000|Overall Study|Adverse Event|1016
6201310|NCT01491178|9860912|FG000|Overall Study|Improvement of NVAF|210
6201311|NCT01491178|9860912|FG000|Overall Study|To conduct invasive treatment|59
6201312|NCT01491178|9860912|FG000|Overall Study|Lost to follow-up (unknown reason)|287
6201313|NCT01491178|9860912|FG000|Overall Study|Lost to follow-up (changing hospital)|545
6201314|NCT01491178|9860912|FG000|Overall Study|To take a contraindication|20
6201315|NCT01491178|9860912|FG000|Overall Study|Other than specified above|657
6201316|NCT01491607|9860929|FG000|Overall Study|Lost to Follow-up|7
6201317|NCT01491607|9860929|FG000|Overall Study|Withdrawal by Subject|3
6201318|NCT01491672|9861002|FG000|Overall Study|Lost to Follow-up|0
6201319|NCT01491672|9861003|FG001|Overall Study|Lost to Follow-up|4
6201320|NCT01491672|9861004|FG002|Overall Study|Lost to Follow-up|1
6201321|NCT01491672|9861002|FG000|Overall Study|Withdrawal by Subject|6
6201322|NCT01491672|9861003|FG001|Overall Study|Withdrawal by Subject|7
6201323|NCT01491672|9861004|FG002|Overall Study|Withdrawal by Subject|0
6201324|NCT01491672|9861002|FG000|Overall Study|Adverse Event|8
6201325|NCT01491672|9861003|FG001|Overall Study|Adverse Event|10
6201326|NCT01491672|9861004|FG002|Overall Study|Adverse Event|4
6201327|NCT01491672|9861002|FG000|Overall Study|Disease progression|42
6201328|NCT01491672|9861003|FG001|Overall Study|Disease progression|34
6201329|NCT01491672|9861004|FG002|Overall Study|Disease progression|6
6201330|NCT01491672|9861002|FG000|Overall Study|Protocol deviation|0
6201331|NCT01491672|9861003|FG001|Overall Study|Protocol deviation|1
6201332|NCT01491672|9861004|FG002|Overall Study|Protocol deviation|0
6201333|NCT01491672|9861002|FG000|Overall Study|Death|0
6201334|NCT01491672|9861003|FG001|Overall Study|Death|4
6201335|NCT01491672|9861004|FG002|Overall Study|Death|0
6201336|NCT01491737|9861016|FG000|Overall Study|Withdrawal by Subject|20
6201337|NCT01491737|9861017|FG001|Overall Study|Withdrawal by Subject|17
6201338|NCT01491737|9861016|FG000|Overall Study|Lost to Follow-up|2
6201339|NCT01491737|9861017|FG001|Overall Study|Lost to Follow-up|10
6201340|NCT01491737|9861016|FG000|Overall Study|Death|63
6201341|NCT01491737|9861017|FG001|Overall Study|Death|57
6201342|NCT01491737|9861016|FG000|Overall Study|Study Termination by Sponsor|36
6201343|NCT01491737|9861017|FG001|Overall Study|Study Termination by Sponsor|36
6201344|NCT01491737|9861016|FG000|Overall Study|Reason Not Specified|8
6201345|NCT01491737|9861017|FG001|Overall Study|Reason Not Specified|9
6201346|NCT01491802|9861023|FG000|Overall Study|Adverse Event|1
6201347|NCT01491802|9861024|FG001|Overall Study|Adverse Event|1
6201348|NCT01491802|9861023|FG000|Overall Study|Withdrawal by Subject|0
6201349|NCT01491802|9861024|FG001|Overall Study|Withdrawal by Subject|1
6201350|NCT01491841|9861031|FG000|Overall Study|Screen Failure|10
6201351|NCT01491841|9861031|FG000|Overall Study|Withdrawal by Subject|1
6201352|NCT01491854|9861043|FG000|Overall Study|mainly due to premature termination|93
6201353|NCT01491854|9861043|FG000|Overall Study|Death|1
6201354|NCT01491854|9861043|FG000|Overall Study|Withdrawal by Subject|3
6201355|NCT01491854|9861043|FG000|Overall Study|Lost to Follow-up|33
6201356|NCT01491919|9861050|FG000|Overall Study|Insufficient PK sampling|1
6201357|NCT01491919|9861051|FG001|Overall Study|Insufficient PK sampling|2
6201358|NCT01491919|9861052|FG002|Overall Study|Insufficient PK sampling|1
6201359|NCT01491945|9861062|FG000|Overall Study|Death|30
6201360|NCT01491945|9861062|FG000|Overall Study|Withdrwan/LTF|16
6201361|NCT01491945|9861062|FG000|Overall Study|Conversion|4
6201362|NCT01491945|9861062|FG000|Overall Study|Missed Visit|1
6201363|NCT01492088|9861087|FG000|Overall Study|Withdrawal by Patient|0
6201364|NCT01492088|9861088|FG001|Overall Study|Withdrawal by Patient|2
6201365|NCT01492088|9861089|FG002|Overall Study|Withdrawal by Patient|0
6201366|NCT01492088|9861087|FG000|Overall Study|Death|1
6201367|NCT01492088|9861088|FG001|Overall Study|Death|6
6201368|NCT01492088|9861089|FG002|Overall Study|Death|2
6201369|NCT01492088|9861087|FG000|Overall Study|Completed Post Treatment Followup (PTFU)|2
6201370|NCT01492088|9861088|FG001|Overall Study|Completed Post Treatment Followup (PTFU)|0
6201371|NCT01492088|9861089|FG002|Overall Study|Completed Post Treatment Followup (PTFU)|1
6201372|NCT01492088|9861087|FG000|Overall Study|Alive at Last Follow-up|0
6201373|NCT01492088|9861088|FG001|Overall Study|Alive at Last Follow-up|6
6201374|NCT01492088|9861089|FG002|Overall Study|Alive at Last Follow-up|11
6201375|NCT01492101|9861102|FG000|Overall Study|Death|323
6201376|NCT01492101|9861103|FG001|Overall Study|Death|322
6201377|NCT01492101|9861102|FG000|Overall Study|Withdrawal by Subject|14
6201378|NCT01492101|9861103|FG001|Overall Study|Withdrawal by Subject|18
6201379|NCT01492101|9861102|FG000|Overall Study|Lost to Follow-up|0
6201380|NCT01492101|9861103|FG001|Overall Study|Lost to Follow-up|2
6201381|NCT01492400|9861120|FG000|Overall Study|Miscellaneous Reasons|2
6201382|NCT01492400|9861121|FG001|Overall Study|Miscellaneous Reasons|3
6201383|NCT01492400|9861120|FG000|Overall Study|Personal Reasons|0
6201384|NCT01492400|9861121|FG001|Overall Study|Personal Reasons|5
6201385|NCT01492400|9861120|FG000|Overall Study|Lost to Follow-up|3
6201386|NCT01492400|9861121|FG001|Overall Study|Lost to Follow-up|1
6201387|NCT01492400|9861120|FG000|Overall Study|Pregnancy|0
6201388|NCT01492400|9861121|FG001|Overall Study|Pregnancy|1
6201389|NCT01492400|9861120|FG000|Overall Study|Lack of Efficacy|1
6201390|NCT01492400|9861121|FG001|Overall Study|Lack of Efficacy|1
6201391|NCT01492400|9861120|FG000|Overall Study|Adverse Event|10
6201392|NCT01492400|9861121|FG001|Overall Study|Adverse Event|5
6201393|NCT01492426|9861129|FG000|Treatment|Death|0
6201394|NCT01492426|9861130|FG001|Treatment|Death|1
6201395|NCT01492426|9861129|FG000|Treatment|Other|1
6201396|NCT01492426|9861130|FG001|Treatment|Other|0
6201397|NCT01492426|9861129|FG000|Treatment|Adverse Event|25
6201398|NCT01492426|9861130|FG001|Treatment|Adverse Event|25
6201399|NCT01492426|9861129|FG000|Treatment|Lack of Efficacy|38
6278127|NCT02252146|9985677|FG000|Overall Study|Inability to travel to study site|1
6278128|NCT02252211|9985683|FG000|Overall Study|Adverse Event|0
6278129|NCT02252211|9985684|FG001|Overall Study|Adverse Event|1
6278130|NCT02252211|9985685|FG002|Overall Study|Adverse Event|0
6278131|NCT02252211|9985683|FG000|Overall Study|Progressive disease|3
6278132|NCT02252211|9985684|FG001|Overall Study|Progressive disease|2
6278133|NCT02252211|9985685|FG002|Overall Study|Progressive disease|0
6278134|NCT02252211|9985683|FG000|Overall Study|Withdrawal by Subject|1
6278135|NCT02252211|9985684|FG001|Overall Study|Withdrawal by Subject|0
6278136|NCT02252211|9985685|FG002|Overall Study|Withdrawal by Subject|0
6278137|NCT02252211|9985683|FG000|Overall Study|Serious Adverse Event During Screening|1
6278138|NCT02252211|9985684|FG001|Overall Study|Serious Adverse Event During Screening|0
6278139|NCT02252211|9985685|FG002|Overall Study|Serious Adverse Event During Screening|1
6201400|NCT01492426|9861130|FG001|Treatment|Lack of Efficacy|5
6201401|NCT01492426|9861129|FG000|Treatment|Participant withdrew consent|1
6201402|NCT01492426|9861130|FG001|Treatment|Participant withdrew consent|2
6201403|NCT01492426|9861129|FG000|Treatment|Poor compliance/noncompliance|1
6278140|NCT02252406|9985703|FG000|Starting Dose Ranolazine 500 mg BID|Lost to Follow-up|2
6278141|NCT02252406|9985704|FG001|Starting Dose Ranolazine 500 mg BID|Lost to Follow-up|3
6278142|NCT02252406|9985703|FG000|Starting Dose Ranolazine 500 mg BID|Withdrawal by Subject|1
6278143|NCT02252406|9985704|FG001|Starting Dose Ranolazine 500 mg BID|Withdrawal by Subject|0
6278144|NCT02252406|9985703|FG000|Starting Dose Ranolazine 500 mg BID|Adverse Event|1
6278145|NCT02252406|9985704|FG001|Starting Dose Ranolazine 500 mg BID|Adverse Event|0
6278146|NCT02252406|9985703|FG000|Titrated to Ranolazine 1000mg BID|Lost to Follow-up|1
6278147|NCT02252406|9985704|FG001|Titrated to Ranolazine 1000mg BID|Lost to Follow-up|1
6278148|NCT02252406|9985703|FG000|Titrated to Ranolazine 1000mg BID|Adverse Event|2
6278149|NCT02252406|9985704|FG001|Titrated to Ranolazine 1000mg BID|Adverse Event|0
6278150|NCT02252536|9985721|FG000|Overall Study|Lost to Follow-up|5
6278151|NCT02252536|9985722|FG001|Overall Study|Lost to Follow-up|3
6278152|NCT02252588|9985740|FG000|Overall Study|Withdrawal by Subject|4
6278153|NCT02252588|9985741|FG001|Overall Study|Withdrawal by Subject|0
6278154|NCT02252939|9985759|FG000|Overall Study|Lost to Follow-up|3
6278155|NCT02252965|9985770|FG000|Overall Study|Adverse Event|9
6278156|NCT02252965|9985771|FG001|Overall Study|Adverse Event|14
6278157|NCT02252965|9985770|FG000|Overall Study|Lost to Follow-up|16
6278158|NCT02252965|9985771|FG001|Overall Study|Lost to Follow-up|8
6278159|NCT02252965|9985770|FG000|Overall Study|Protocol Violation|4
6278160|NCT02252965|9985771|FG001|Overall Study|Protocol Violation|5
6278161|NCT02252965|9985770|FG000|Overall Study|Lack of Efficacy|0
6278162|NCT02252965|9985771|FG001|Overall Study|Lack of Efficacy|2
6278163|NCT02252965|9985770|FG000|Overall Study|Withdrawal by Subject|7
6278164|NCT02252965|9985771|FG001|Overall Study|Withdrawal by Subject|9
6278165|NCT02252965|9985770|FG000|Overall Study|Other|4
6278166|NCT02252965|9985771|FG001|Overall Study|Other|5
6278167|NCT02253147|9985779|FG000|Overall Study|Protocol Violation|30
6278168|NCT02253147|9985779|FG000|Overall Study|Did not consent to study extension|9
6278169|NCT02253147|9985779|FG000|Overall Study|Conditional re-treatment at W52|5
6278170|NCT02253147|9985779|FG000|Overall Study|Lost to Follow-up|2
6278171|NCT02253147|9985779|FG000|Overall Study|Withdrawal by Subject|1
6278172|NCT02253433|9985823|FG000|Overall Study|Unable to Contact|9
6278173|NCT02253433|9985824|FG001|Overall Study|Unable to Contact|16
6278174|NCT02253433|9985823|FG000|Overall Study|Death|1
6278175|NCT02253433|9985824|FG001|Overall Study|Death|1
5977596|NCT01455597|9564869|FG002|Overall Study|Lost to Follow-up|2
5977597|NCT01455597|9564870|FG003|Overall Study|Lost to Follow-up|1
5977598|NCT01455597|9564867|FG000|Overall Study|Withdrew Consent|6
5977599|NCT01455597|9564868|FG001|Overall Study|Withdrew Consent|5
5977600|NCT01455597|9564869|FG002|Overall Study|Withdrew Consent|8
5977601|NCT01455597|9564870|FG003|Overall Study|Withdrew Consent|5
5977602|NCT01455597|9564867|FG000|Overall Study|Reason not Specified|1
5977603|NCT01455597|9564868|FG001|Overall Study|Reason not Specified|2
5977604|NCT01455597|9564869|FG002|Overall Study|Reason not Specified|3
5977605|NCT01455597|9564870|FG003|Overall Study|Reason not Specified|3
5977606|NCT01400776|9564886|FG000|Overall Study|Adverse Event|7
5977607|NCT01400776|9564887|FG001|Overall Study|Adverse Event|2
6050879|NCT00429793|9650145|FG000|Overall Study|Improper pre-protocol treatment|3
6050880|NCT00429793|9650145|FG000|Overall Study|Required test not done|1
6050881|NCT00429793|9650145|FG000|Overall Study|Never treated|1
6050882|NCT00429793|9650145|FG000|Overall Study|Non-measurable|1
6050883|NCT00430248|9650172|FG000|Overall Study|Adverse Event|49
6050884|NCT00430248|9650173|FG001|Overall Study|Adverse Event|61
6050885|NCT00430248|9650174|FG002|Overall Study|Adverse Event|64
6050886|NCT00430248|9650172|FG000|Overall Study|Protocol Violation|10
6050887|NCT00430248|9650173|FG001|Overall Study|Protocol Violation|2
6050888|NCT00430248|9650174|FG002|Overall Study|Protocol Violation|4
6050889|NCT00430248|9650172|FG000|Overall Study|Personal Reasons|12
6050890|NCT00430248|9650173|FG001|Overall Study|Personal Reasons|24
6050891|NCT00430248|9650174|FG002|Overall Study|Personal Reasons|9
6050892|NCT00430248|9650172|FG000|Overall Study|Lost to Follow-up|28
5977608|NCT01400776|9564888|FG002|Overall Study|Adverse Event|9
5977609|NCT01400776|9564889|FG003|Overall Study|Adverse Event|2
5977610|NCT01400776|9564886|FG000|Overall Study|Lost to Follow-up|1
5977611|NCT01400776|9564887|FG001|Overall Study|Lost to Follow-up|0
5977612|NCT01400776|9564888|FG002|Overall Study|Lost to Follow-up|4
5977613|NCT01400776|9564889|FG003|Overall Study|Lost to Follow-up|1
5977614|NCT01400776|9564886|FG000|Overall Study|Withdrew Consent|4
5977615|NCT01400776|9564887|FG001|Overall Study|Withdrew Consent|2
5977616|NCT01400776|9564888|FG002|Overall Study|Withdrew Consent|6
5977617|NCT01400776|9564889|FG003|Overall Study|Withdrew Consent|1
5977618|NCT01400776|9564886|FG000|Overall Study|Protocol Deviation|6
5977619|NCT01400776|9564887|FG001|Overall Study|Protocol Deviation|1
5977620|NCT01400776|9564888|FG002|Overall Study|Protocol Deviation|5
5977621|NCT01400776|9564889|FG003|Overall Study|Protocol Deviation|2
6050893|NCT00430248|9650173|FG001|Overall Study|Lost to Follow-up|33
6050894|NCT00430248|9650174|FG002|Overall Study|Lost to Follow-up|28
6278176|NCT02253433|9985823|FG000|Overall Study|No Longer Interested|3
6278177|NCT02253433|9985824|FG001|Overall Study|No Longer Interested|15
6278178|NCT02253433|9985823|FG000|Overall Study|Out of Study Area|2
5977622|NCT01400776|9564886|FG000|Overall Study|Reason not Specified|3
5977623|NCT01400776|9564887|FG001|Overall Study|Reason not Specified|0
5977624|NCT01400776|9564888|FG002|Overall Study|Reason not Specified|4
6201404|NCT01492426|9861130|FG001|Treatment|Poor compliance/noncompliance|0
6201405|NCT01492426|9861129|FG000|Treatment|Subject requested discontinue study drug|7
6201406|NCT01492426|9861130|FG001|Treatment|Subject requested discontinue study drug|3
6201407|NCT01492426|9861129|FG000|Treatment|Lost to Follow-up|9
6201408|NCT01492426|9861130|FG001|Treatment|Lost to Follow-up|4
6201409|NCT01492426|9861129|FG000|Treatment|Participant does not meet study criteria|1
6201410|NCT01492426|9861130|FG001|Treatment|Participant does not meet study criteria|0
6201411|NCT01492426|9861129|FG000|Follow-Up|Protocol Requires no Follow-Up|2
6201412|NCT01492426|9861130|FG001|Follow-Up|Protocol Requires no Follow-Up|1
6201413|NCT01492426|9861129|FG000|Follow-Up|Death|1
6201414|NCT01492426|9861130|FG001|Follow-Up|Death|0
6201415|NCT01492426|9861129|FG000|Follow-Up|Other|4
6201416|NCT01492426|9861130|FG001|Follow-Up|Other|2
6201417|NCT01492426|9861129|FG000|Follow-Up|Participant Withdrew Consent|6
6201418|NCT01492426|9861130|FG001|Follow-Up|Participant Withdrew Consent|1
6201419|NCT01492426|9861129|FG000|Follow-Up|Lost to Follow-up|12
6201420|NCT01492426|9861130|FG001|Follow-Up|Lost to Follow-up|6
6201421|NCT01492439|9861142|FG000|Overall Study|Withdrew from RTE|4
6201422|NCT01492439|9861143|FG001|Overall Study|Withdrew from RTE|9
6201423|NCT01492686|9861181|FG000|Double-blind Phase|Adverse Event|0
6201424|NCT01492686|9861182|FG001|Double-blind Phase|Adverse Event|2
6201425|NCT01492686|9861181|FG000|Double-blind Phase|Physician Decision|0
6201426|NCT01492686|9861182|FG001|Double-blind Phase|Physician Decision|1
6201427|NCT01492686|9861181|FG000|Double-blind Phase|Withdrawal by Subject|0
6201428|NCT01492686|9861182|FG001|Double-blind Phase|Withdrawal by Subject|2
6201429|NCT01492686|9861181|FG000|Double-blind Phase|Due to a discontinuation criterion|2
6201430|NCT01492686|9861182|FG001|Double-blind Phase|Due to a discontinuation criterion|3
6201431|NCT01492686|9861181|FG000|Open-label Phase|Adverse Event|1
6201432|NCT01492686|9861182|FG001|Open-label Phase|Adverse Event|2
6201433|NCT01492686|9861181|FG000|Open-label Phase|Physician Decision|1
6201434|NCT01492686|9861182|FG001|Open-label Phase|Physician Decision|0
6278179|NCT02253433|9985824|FG001|Overall Study|Out of Study Area|7
6278180|NCT02253433|9985823|FG000|Overall Study|Uncomfortable with home visitors|0
6278181|NCT02253433|9985824|FG001|Overall Study|Uncomfortable with home visitors|3
6278182|NCT02253433|9985823|FG000|Overall Study|Unstable Housing/Homeless|0
6278183|NCT02253433|9985824|FG001|Overall Study|Unstable Housing/Homeless|7
6278184|NCT02253433|9985823|FG000|Overall Study|Too Busy|0
6278185|NCT02253433|9985824|FG001|Overall Study|Too Busy|4
6278186|NCT02253433|9985823|FG000|Overall Study|Medical or Other Concerns|1
6278187|NCT02253433|9985824|FG001|Overall Study|Medical or Other Concerns|2
6278188|NCT02253654|9985837|FG000|Overall Study|Withdrawal by Subject|12
6278189|NCT02253654|9985838|FG001|Overall Study|Withdrawal by Subject|4
6278190|NCT02253654|9985837|FG000|Overall Study|Decision by Sponsor|1
6278191|NCT02253654|9985838|FG001|Overall Study|Decision by Sponsor|1
6278192|NCT02253654|9985837|FG000|Overall Study|Lost to Follow-up|2
6278193|NCT02253654|9985838|FG001|Overall Study|Lost to Follow-up|5
6278194|NCT02253654|9985837|FG000|Overall Study|Death|4
6278195|NCT02253654|9985838|FG001|Overall Study|Death|7
6278196|NCT02253654|9985837|FG000|Overall Study|Did Not Receive Study Treatment|4
6278197|NCT02253654|9985838|FG001|Overall Study|Did Not Receive Study Treatment|1
6278198|NCT02253992|9985847|FG000|Overall Study|Study drug toxicity|1
6278199|NCT02253992|9985848|FG001|Overall Study|Study drug toxicity|0
6278200|NCT02253992|9985849|FG002|Overall Study|Study drug toxicity|10
6278201|NCT02253992|9985847|FG000|Overall Study|Disease progression|4
6278202|NCT02253992|9985848|FG001|Overall Study|Disease progression|3
6278203|NCT02253992|9985849|FG002|Overall Study|Disease progression|98
6278204|NCT02253992|9985847|FG000|Overall Study|Withdrawal by Subject|0
6278205|NCT02253992|9985848|FG001|Overall Study|Withdrawal by Subject|0
6278206|NCT02253992|9985849|FG002|Overall Study|Withdrawal by Subject|3
6278207|NCT02253992|9985847|FG000|Overall Study|Adverse Event|0
6278208|NCT02253992|9985848|FG001|Overall Study|Adverse Event|0
6278209|NCT02253992|9985849|FG002|Overall Study|Adverse Event|8
6278210|NCT02253992|9985847|FG000|Overall Study|Death|0
6278211|NCT02253992|9985848|FG001|Overall Study|Death|0
6278212|NCT02253992|9985849|FG002|Overall Study|Death|1
6278213|NCT02253992|9985847|FG000|Overall Study|Subject discontinued study drug|1
6278214|NCT02253992|9985848|FG001|Overall Study|Subject discontinued study drug|0
6278215|NCT02253992|9985849|FG002|Overall Study|Subject discontinued study drug|1
6278216|NCT02253992|9985847|FG000|Overall Study|Completed treatment as per protocol|0
6278217|NCT02253992|9985848|FG001|Overall Study|Completed treatment as per protocol|1
6278218|NCT02253992|9985849|FG002|Overall Study|Completed treatment as per protocol|22
6278219|NCT02253992|9985847|FG000|Overall Study|Other|0
6278220|NCT02253992|9985848|FG001|Overall Study|Other|0
6278221|NCT02253992|9985849|FG002|Overall Study|Other|1
6278222|NCT02254291|9985896|FG000|Overall Study|Withdrawal by Subject|0
6201435|NCT01492686|9861181|FG000|Open-label Phase|Withdrawal by Subject|6
6201436|NCT01492686|9861182|FG001|Open-label Phase|Withdrawal by Subject|7
6201437|NCT01492686|9861181|FG000|Open-label Phase|Due to a discontinuation criterion|4
6201438|NCT01492686|9861182|FG001|Open-label Phase|Due to a discontinuation criterion|9
6278223|NCT02254291|9985897|FG001|Overall Study|Withdrawal by Subject|3
6201439|NCT01493089|9861210|FG000|Overall Study|Protocol Violation|2
6278224|NCT02254291|9985898|FG002|Overall Study|Withdrawal by Subject|1
6278225|NCT02254291|9985896|FG000|Overall Study|Missing follow-up information|0
6278226|NCT02254291|9985897|FG001|Overall Study|Missing follow-up information|0
6201440|NCT01493089|9861211|FG001|Overall Study|Protocol Violation|2
6201441|NCT01493089|9861210|FG000|Overall Study|Withdrawal by Subject|1
6201442|NCT01493089|9861211|FG001|Overall Study|Withdrawal by Subject|0
6201443|NCT01493089|9861210|FG000|Overall Study|Physician Decision|0
6201444|NCT01493089|9861211|FG001|Overall Study|Physician Decision|1
6201445|NCT01493284|9861232|FG000|Overall Study|Death|29
6201446|NCT01493284|9861232|FG000|Overall Study|Withdrawal by Subject|32
6201447|NCT01493414|9861236|FG000|Overall Study|Adverse Event|405
6201448|NCT01493414|9861236|FG000|Overall Study|Disease progression|204
6201449|NCT01493414|9861236|FG000|Overall Study|Death|101
6201450|NCT01493414|9861236|FG000|Overall Study|Physician Decision|93
6201451|NCT01493414|9861236|FG000|Overall Study|Withdrawal by Subject|79
6201452|NCT01493414|9861236|FG000|Overall Study|Protocol deviation|27
6201453|NCT01493414|9861236|FG000|Overall Study|Administrative problems|25
6201454|NCT01493414|9861236|FG000|Overall Study|Lost to Follow-up|16
6201455|NCT01493427|9861244|FG000|Overall Study|Adverse Event|10
6201456|NCT01493427|9861244|FG000|Overall Study|Personal Reasons|4
6201457|NCT01493427|9861244|FG000|Overall Study|Lost to Follow-up|2
6201458|NCT01493427|9861244|FG000|Overall Study|Inability to Follow Instructions|2
6201459|NCT01493427|9861244|FG000|Overall Study|Other|2
6201460|NCT01493531|9861251|FG000|Overall Study|Adverse Event|4
6201461|NCT01493531|9861252|FG001|Overall Study|Adverse Event|12
6201462|NCT01493531|9861253|FG002|Overall Study|Adverse Event|9
6201463|NCT01493531|9861251|FG000|Overall Study|Gout flare|3
6201464|NCT01493531|9861252|FG001|Overall Study|Gout flare|0
6201465|NCT01493531|9861253|FG002|Overall Study|Gout flare|2
6278227|NCT02254291|9985898|FG002|Overall Study|Missing follow-up information|1
6278228|NCT02254304|9985908|FG000|Overall Study|Adverse Event|2
6278229|NCT02254304|9985909|FG001|Overall Study|Adverse Event|1
6278230|NCT02254304|9985908|FG000|Overall Study|Lost to Follow-up|2
6278231|NCT02254304|9985909|FG001|Overall Study|Lost to Follow-up|2
6278232|NCT02254304|9985908|FG000|Overall Study|Protocol Violation|1
6278233|NCT02254304|9985909|FG001|Overall Study|Protocol Violation|0
6278234|NCT02254304|9985908|FG000|Overall Study|Withdrawal by Subject|3
6278235|NCT02254304|9985909|FG001|Overall Study|Withdrawal by Subject|0
6278236|NCT02254304|9985908|FG000|Overall Study|Injection site pain and Injection fear|1
6278237|NCT02254304|9985909|FG001|Overall Study|Injection site pain and Injection fear|0
6278238|NCT02254304|9985908|FG000|Overall Study|Personal causes|4
6278239|NCT02254304|9985909|FG001|Overall Study|Personal causes|1
6278240|NCT02254304|9985908|FG000|Overall Study|Personal decision|1
6278241|NCT02254304|9985909|FG001|Overall Study|Personal decision|0
6278242|NCT02254408|9985919|FG000|Overall Study|Randomized But Not Treated|1
6278243|NCT02254408|9985920|FG001|Overall Study|Randomized But Not Treated|3
6278244|NCT02254408|9985919|FG000|Overall Study|Adverse Event|1
6278245|NCT02254408|9985920|FG001|Overall Study|Adverse Event|0
6278246|NCT02254408|9985919|FG000|Overall Study|Death|2
6278247|NCT02254408|9985920|FG001|Overall Study|Death|3
6278248|NCT02254408|9985919|FG000|Overall Study|Investigator's Discretion|0
5977625|NCT01400776|9564889|FG003|Overall Study|Reason not Specified|3
5977626|NCT01194570|9564901|FG000|Overall Study|Death|1
5977627|NCT01194570|9564902|FG001|Overall Study|Death|3
5977628|NCT01194570|9564901|FG000|Overall Study|Ongoing at CCOD|162
5977629|NCT01194570|9564902|FG001|Overall Study|Ongoing at CCOD|387
5977630|NCT01194570|9564901|FG000|Overall Study|Physician Decision|2
5977631|NCT01194570|9564902|FG001|Overall Study|Physician Decision|6
5977632|NCT01194570|9564901|FG000|Overall Study|Reason not specified|13
5977633|NCT01194570|9564902|FG001|Overall Study|Reason not specified|20
5977634|NCT01194570|9564901|FG000|Overall Study|Protocol Violation|0
5977635|NCT01194570|9564902|FG001|Overall Study|Protocol Violation|2
5977636|NCT01194570|9564901|FG000|Overall Study|Non-compliance with study drug|2
5977637|NCT01194570|9564902|FG001|Overall Study|Non-compliance with study drug|2
5977638|NCT01194570|9564901|FG000|Overall Study|Adverse Event|12
5977639|NCT01194570|9564902|FG001|Overall Study|Adverse Event|18
5977640|NCT01194570|9564901|FG000|Overall Study|Non-compliance|2
5977641|NCT01194570|9564902|FG001|Overall Study|Non-compliance|2
5977642|NCT01194570|9564901|FG000|Overall Study|Lack of Efficacy|27
6278249|NCT02254408|9985920|FG001|Overall Study|Investigator's Discretion|1
6278250|NCT02254408|9985919|FG000|Overall Study|Withdrawal by Subject|3
6278251|NCT02254408|9985920|FG001|Overall Study|Withdrawal by Subject|3
6278252|NCT02254408|9985919|FG000|Overall Study|Lost to Follow-up|1
6278253|NCT02254408|9985920|FG001|Overall Study|Lost to Follow-up|0
6278254|NCT02254421|9985928|FG000|Overall Study|Randomized but Not Treated|1
6201466|NCT01493531|9861251|FG000|Overall Study|Protocol Violation|8
6201467|NCT01493531|9861252|FG001|Overall Study|Protocol Violation|15
6201468|NCT01493531|9861253|FG002|Overall Study|Protocol Violation|12
6201469|NCT01493531|9861251|FG000|Overall Study|Sponsor terminated study|5
6201470|NCT01493531|9861252|FG001|Overall Study|Sponsor terminated study|2
6201471|NCT01493531|9861253|FG002|Overall Study|Sponsor terminated study|3
6201472|NCT01493531|9861251|FG000|Overall Study|Lost to Follow-up|5
6201473|NCT01493531|9861252|FG001|Overall Study|Lost to Follow-up|7
6201474|NCT01493531|9861253|FG002|Overall Study|Lost to Follow-up|11
6201475|NCT01493531|9861251|FG000|Overall Study|Withdrawal by Subject|16
6201476|NCT01493531|9861252|FG001|Overall Study|Withdrawal by Subject|13
6201477|NCT01493531|9861253|FG002|Overall Study|Withdrawal by Subject|11
6201478|NCT01493531|9861251|FG000|Overall Study|Death|0
6201479|NCT01493531|9861252|FG001|Overall Study|Death|1
6201480|NCT01493531|9861253|FG002|Overall Study|Death|0
6201481|NCT01493557|9861264|FG000|Not Randomized to Management Strategies|Worsening of events associate with NVAF.|0
6201482|NCT01493557|9861265|FG001|Not Randomized to Management Strategies|Worsening of events associate with NVAF.|0
6201483|NCT01493557|9861266|FG002|Not Randomized to Management Strategies|Worsening of events associate with NVAF.|1
6201484|NCT01493557|9861264|FG000|Not Randomized to Management Strategies|Worsening of other pre-existing disease|0
6201485|NCT01493557|9861265|FG001|Not Randomized to Management Strategies|Worsening of other pre-existing disease|0
6201486|NCT01493557|9861266|FG002|Not Randomized to Management Strategies|Worsening of other pre-existing disease|9
6201487|NCT01493557|9861264|FG000|Not Randomized to Management Strategies|Other adverse event|0
6201488|NCT01493557|9861265|FG001|Not Randomized to Management Strategies|Other adverse event|0
6201489|NCT01493557|9861266|FG002|Not Randomized to Management Strategies|Other adverse event|54
6201490|NCT01493557|9861264|FG000|Not Randomized to Management Strategies|Protocol Violation|0
6201491|NCT01493557|9861265|FG001|Not Randomized to Management Strategies|Protocol Violation|0
6201492|NCT01493557|9861266|FG002|Not Randomized to Management Strategies|Protocol Violation|1
6201493|NCT01493557|9861264|FG000|Not Randomized to Management Strategies|Lost to Follow-up|0
6201494|NCT01493557|9861265|FG001|Not Randomized to Management Strategies|Lost to Follow-up|0
6201495|NCT01493557|9861266|FG002|Not Randomized to Management Strategies|Lost to Follow-up|4
6201496|NCT01493557|9861264|FG000|Not Randomized to Management Strategies|Withdrawal by Subject|0
6201497|NCT01493557|9861265|FG001|Not Randomized to Management Strategies|Withdrawal by Subject|0
6201498|NCT01493557|9861266|FG002|Not Randomized to Management Strategies|Withdrawal by Subject|10
6201499|NCT01493557|9861264|FG000|Not Randomized to Management Strategies|Early termination|0
6201500|NCT01493557|9861265|FG001|Not Randomized to Management Strategies|Early termination|0
6201501|NCT01493557|9861266|FG002|Not Randomized to Management Strategies|Early termination|34
6201502|NCT01493557|9861264|FG000|Not Randomized to Management Strategies|Other than stated above|0
6201503|NCT01493557|9861265|FG001|Not Randomized to Management Strategies|Other than stated above|0
6201504|NCT01493557|9861266|FG002|Not Randomized to Management Strategies|Other than stated above|21
6201505|NCT01493557|9861264|FG000|Randomized to Management Strategies|Worsening of events associate with GIS|3
6201506|NCT01493557|9861265|FG001|Randomized to Management Strategies|Worsening of events associate with GIS|2
6201507|NCT01493557|9861266|FG002|Randomized to Management Strategies|Worsening of events associate with GIS|0
6201508|NCT01493557|9861264|FG000|Randomized to Management Strategies|Other adverse event|8
6201509|NCT01493557|9861265|FG001|Randomized to Management Strategies|Other adverse event|5
6201510|NCT01493557|9861266|FG002|Randomized to Management Strategies|Other adverse event|0
6201511|NCT01493557|9861264|FG000|Randomized to Management Strategies|Protocol Violation|3
6201512|NCT01493557|9861265|FG001|Randomized to Management Strategies|Protocol Violation|0
6201513|NCT01493557|9861266|FG002|Randomized to Management Strategies|Protocol Violation|0
6201514|NCT01493557|9861264|FG000|Randomized to Management Strategies|Withdrawal by Subject|0
6201515|NCT01493557|9861265|FG001|Randomized to Management Strategies|Withdrawal by Subject|1
6201516|NCT01493557|9861266|FG002|Randomized to Management Strategies|Withdrawal by Subject|0
6201517|NCT01493557|9861264|FG000|Randomized to Management Strategies|Other than stated above|1
6201518|NCT01493557|9861265|FG001|Randomized to Management Strategies|Other than stated above|3
6201519|NCT01493557|9861266|FG002|Randomized to Management Strategies|Other than stated above|0
6201520|NCT01493557|9861264|FG000|Adding the Second Strategy|Worsening of events associate with GIS|1
6201521|NCT01493557|9861265|FG001|Adding the Second Strategy|Worsening of events associate with GIS|1
6201522|NCT01493557|9861266|FG002|Adding the Second Strategy|Worsening of events associate with GIS|0
6201523|NCT01493557|9861264|FG000|Adding the Second Strategy|Other adverse event|1
6201524|NCT01493557|9861265|FG001|Adding the Second Strategy|Other adverse event|2
6201525|NCT01493557|9861266|FG002|Adding the Second Strategy|Other adverse event|0
6201526|NCT01493557|9861264|FG000|Adding the Second Strategy|Withdrawal by Subject|0
6201527|NCT01493557|9861265|FG001|Adding the Second Strategy|Withdrawal by Subject|1
6201528|NCT01493557|9861266|FG002|Adding the Second Strategy|Withdrawal by Subject|0
6201529|NCT01493687|9861302|FG000|Part A Vehicle Control (12 Weeks)|Pregnancy|2
6201530|NCT01493687|9861303|FG001|Part A Vehicle Control (12 Weeks)|Pregnancy|0
6278255|NCT02254421|9985929|FG001|Overall Study|Randomized but Not Treated|0
6278256|NCT02254421|9985928|FG000|Overall Study|Death|0
6278257|NCT02254421|9985929|FG001|Overall Study|Death|2
6278258|NCT02254421|9985928|FG000|Overall Study|Withdrew Consent|1
6278259|NCT02254421|9985929|FG001|Overall Study|Withdrew Consent|1
6278260|NCT02254460|9985935|FG000|Overall Study|Adverse Event|1
6278261|NCT02254460|9985936|FG001|Overall Study|Adverse Event|0
6278262|NCT02254486|9985953|FG000|Overall Study|Adverse Event|1
6278263|NCT02254486|9985954|FG001|Overall Study|Adverse Event|1
6201531|NCT01493687|9861302|FG000|Part A Vehicle Control (12 Weeks)|Lack of Efficacy|0
6201532|NCT01493687|9861303|FG001|Part A Vehicle Control (12 Weeks)|Lack of Efficacy|1
6201533|NCT01493687|9861302|FG000|Part A Vehicle Control (12 Weeks)|Adverse Event|7
6201534|NCT01493687|9861303|FG001|Part A Vehicle Control (12 Weeks)|Adverse Event|4
6201535|NCT01493687|9861302|FG000|Part A Vehicle Control (12 Weeks)|Withdrawal by Subject|18
6201536|NCT01493687|9861303|FG001|Part A Vehicle Control (12 Weeks)|Withdrawal by Subject|7
6201537|NCT01493687|9861302|FG000|Part A Vehicle Control (12 Weeks)|Protocol Violation|2
6201538|NCT01493687|9861303|FG001|Part A Vehicle Control (12 Weeks)|Protocol Violation|1
6201539|NCT01493687|9861302|FG000|Part A Vehicle Control (12 Weeks)|Lost to Follow-up|7
6201540|NCT01493687|9861303|FG001|Part A Vehicle Control (12 Weeks)|Lost to Follow-up|8
6201541|NCT01493687|9861302|FG000|Part A Vehicle Control (12 Weeks)|Other (noted on CRF)|1
6201542|NCT01493687|9861303|FG001|Part A Vehicle Control (12 Weeks)|Other (noted on CRF)|1
6201543|NCT01493687|9861302|FG000|Part B Long Term Active Control 40 Weeks|Pregnancy|5
6201544|NCT01493687|9861303|FG001|Part B Long Term Active Control 40 Weeks|Pregnancy|1
6201545|NCT01493687|9861302|FG000|Part B Long Term Active Control 40 Weeks|Lack of Efficacy|2
6201546|NCT01493687|9861303|FG001|Part B Long Term Active Control 40 Weeks|Lack of Efficacy|3
6201547|NCT01493687|9861302|FG000|Part B Long Term Active Control 40 Weeks|Adverse Event|5
6201548|NCT01493687|9861303|FG001|Part B Long Term Active Control 40 Weeks|Adverse Event|4
6201549|NCT01493687|9861302|FG000|Part B Long Term Active Control 40 Weeks|Withdrawal by Subject|27
6201550|NCT01493687|9861303|FG001|Part B Long Term Active Control 40 Weeks|Withdrawal by Subject|16
6278264|NCT02254486|9985953|FG000|Overall Study|Lack of Efficacy|1
6278265|NCT02254486|9985954|FG001|Overall Study|Lack of Efficacy|0
6278266|NCT02254486|9985953|FG000|Overall Study|Lost to Follow-up|2
6278267|NCT02254486|9985954|FG001|Overall Study|Lost to Follow-up|4
6278268|NCT02254486|9985953|FG000|Overall Study|Protocol Violation|1
6278269|NCT02254486|9985954|FG001|Overall Study|Protocol Violation|2
6278270|NCT02254486|9985953|FG000|Overall Study|Withdrawal by Subject|17
6089032|NCT00680043|9700192|FG002|Overall Study|Patient Not Compliant With Study Reqs.|0
6089033|NCT00680043|9700190|FG000|Overall Study|Renal Transplant|1
6089034|NCT00680043|9700191|FG001|Overall Study|Renal Transplant|0
6201551|NCT01493687|9861302|FG000|Part B Long Term Active Control 40 Weeks|Protocol Violation|1
6201552|NCT01493687|9861303|FG001|Part B Long Term Active Control 40 Weeks|Protocol Violation|0
6201553|NCT01493687|9861302|FG000|Part B Long Term Active Control 40 Weeks|Lost to Follow-up|16
6201554|NCT01493687|9861303|FG001|Part B Long Term Active Control 40 Weeks|Lost to Follow-up|10
6201555|NCT01493687|9861302|FG000|Part B Long Term Active Control 40 Weeks|Other (noted on eCRF)|5
6201556|NCT01493687|9861303|FG001|Part B Long Term Active Control 40 Weeks|Other (noted on eCRF)|1
6201557|NCT01493687|9861302|FG000|Part C Safety Follow up (4 Weeks)|Adverse Event|0
6201558|NCT01493687|9861303|FG001|Part C Safety Follow up (4 Weeks)|Adverse Event|1
6201559|NCT01493778|9861315|FG000|Overall Study|Withdrawal by Subject|8
6201560|NCT01493960|9861342|FG000|Overall Study|Adverse Event|0
6201561|NCT01493960|9861343|FG001|Overall Study|Adverse Event|1
6201562|NCT01493960|9861342|FG000|Overall Study|Lack of Efficacy|15
6201563|NCT01493960|9861343|FG001|Overall Study|Lack of Efficacy|9
6201564|NCT01493960|9861342|FG000|Overall Study|Protocol Violation|3
6201565|NCT01493960|9861343|FG001|Overall Study|Protocol Violation|0
6201566|NCT01493960|9861342|FG000|Overall Study|Withdrawal by Subject|10
6201567|NCT01493960|9861343|FG001|Overall Study|Withdrawal by Subject|4
6201568|NCT01493960|9861342|FG000|Overall Study|Non-specified|4
6201569|NCT01493960|9861343|FG001|Overall Study|Non-specified|4
6201570|NCT01494038|9861351|FG000|Overall Study|Protocol Violation|1
6201571|NCT01494038|9861352|FG001|Overall Study|Protocol Violation|1
6201572|NCT01494038|9861351|FG000|Overall Study|Lost to Follow-up|18
6201573|NCT01494038|9861352|FG001|Overall Study|Lost to Follow-up|20
6201574|NCT01494038|9861351|FG000|Overall Study|Withdrawal by Subject|44
6201575|NCT01494038|9861352|FG001|Overall Study|Withdrawal by Subject|34
6201576|NCT01494038|9861351|FG000|Overall Study|Not able to get to clinic|21
6201577|NCT01494038|9861352|FG001|Overall Study|Not able to get to clinic|15
6201578|NCT01494038|9861351|FG000|Overall Study|Not willing to adhere to reqs|2
6201579|NCT01494038|9861352|FG001|Overall Study|Not willing to adhere to reqs|9
6201580|NCT01494038|9861351|FG000|Overall Study|Death|2
6201581|NCT01494038|9861352|FG001|Overall Study|Death|4
6201582|NCT01494298|9861384|FG000|Overall Study|Protocol Violation|2
6278271|NCT02254486|9985954|FG001|Overall Study|Withdrawal by Subject|15
6278272|NCT02254486|9985953|FG000|Overall Study|GFR<60mL/min|16
6278273|NCT02254486|9985954|FG001|Overall Study|GFR<60mL/min|21
6278274|NCT02254486|9985953|FG000|Overall Study|Various|12
6278275|NCT02254486|9985954|FG001|Overall Study|Various|12
6278276|NCT02254551|9985960|FG000|Dose Escalation|Physician Decision|1
6278277|NCT02254551|9985960|FG000|Dose Escalation|Dose-limiting toxicity|2
6278278|NCT02254681|9985967|FG000|Overall Study|Lack of Efficacy|6
6278279|NCT02254772|9985972|FG000|Overall Study|Ineligible|1
6278280|NCT02254772|9985972|FG000|Overall Study|Withdrawal by Subject|1
6278281|NCT02255097|9985985|FG000|Overall Study|Adverse Event|24
6278282|NCT02255097|9985985|FG000|Overall Study|Clinical Progression|23
6278283|NCT02255097|9985985|FG000|Overall Study|Complete Response|1
6278284|NCT02255097|9985985|FG000|Overall Study|Excluded Medication|1
6050895|NCT00430248|9650172|FG000|Overall Study|Therapeutic Failure|1
6050896|NCT00430248|9650173|FG001|Overall Study|Therapeutic Failure|1
6050897|NCT00430248|9650174|FG002|Overall Study|Therapeutic Failure|1
6050898|NCT00430248|9650172|FG000|Overall Study|Withdrawal by Subject|14
6050899|NCT00430248|9650173|FG001|Overall Study|Withdrawal by Subject|20
6050900|NCT00430248|9650174|FG002|Overall Study|Withdrawal by Subject|16
6050901|NCT00430248|9650172|FG000|Overall Study|Inclusion/Exclusion Criteria Not Met|0
6050902|NCT00430248|9650173|FG001|Overall Study|Inclusion/Exclusion Criteria Not Met|2
6201583|NCT01494298|9861385|FG001|Overall Study|Protocol Violation|8
6201584|NCT01494350|9861393|FG000|Overall Study|Worsening of lesion|1
6201585|NCT01494467|9861399|FG000|Part A Vehicle Control (12 Weeks)|Pregnancy|1
6201586|NCT01494467|9861400|FG001|Part A Vehicle Control (12 Weeks)|Pregnancy|0
6201587|NCT01494467|9861399|FG000|Part A Vehicle Control (12 Weeks)|Adverse Event|6
6201588|NCT01494467|9861400|FG001|Part A Vehicle Control (12 Weeks)|Adverse Event|4
6201589|NCT01494467|9861399|FG000|Part A Vehicle Control (12 Weeks)|Withdrawal by Subject|9
6201590|NCT01494467|9861400|FG001|Part A Vehicle Control (12 Weeks)|Withdrawal by Subject|8
6201591|NCT01494467|9861399|FG000|Part A Vehicle Control (12 Weeks)|Protocol Violation|4
6201592|NCT01494467|9861400|FG001|Part A Vehicle Control (12 Weeks)|Protocol Violation|0
6201593|NCT01494467|9861399|FG000|Part A Vehicle Control (12 Weeks)|Lost to Follow-up|8
6201594|NCT01494467|9861400|FG001|Part A Vehicle Control (12 Weeks)|Lost to Follow-up|8
6201595|NCT01494467|9861399|FG000|Part A Vehicle Control (12 Weeks)|Other|1
6201596|NCT01494467|9861400|FG001|Part A Vehicle Control (12 Weeks)|Other|1
6201597|NCT01494467|9861399|FG000|Part A Vehicle Control (12 Weeks)|Lack of Efficacy|1
6201598|NCT01494467|9861400|FG001|Part A Vehicle Control (12 Weeks)|Lack of Efficacy|0
6201599|NCT01494467|9861399|FG000|Part B Long Term Active Control 40 Weeks|Pregnancy|2
6201600|NCT01494467|9861400|FG001|Part B Long Term Active Control 40 Weeks|Pregnancy|0
6201601|NCT01494467|9861399|FG000|Part B Long Term Active Control 40 Weeks|Lack of Efficacy|1
6201602|NCT01494467|9861400|FG001|Part B Long Term Active Control 40 Weeks|Lack of Efficacy|3
6201603|NCT01494467|9861399|FG000|Part B Long Term Active Control 40 Weeks|Adverse Event|3
6201604|NCT01494467|9861400|FG001|Part B Long Term Active Control 40 Weeks|Adverse Event|5
6201605|NCT01494467|9861399|FG000|Part B Long Term Active Control 40 Weeks|Withdrawal by Subject|32
6201606|NCT01494467|9861400|FG001|Part B Long Term Active Control 40 Weeks|Withdrawal by Subject|24
6201607|NCT01494467|9861399|FG000|Part B Long Term Active Control 40 Weeks|Protocol Violation|3
6201608|NCT01494467|9861400|FG001|Part B Long Term Active Control 40 Weeks|Protocol Violation|5
6201609|NCT01494467|9861399|FG000|Part B Long Term Active Control 40 Weeks|Lost to Follow-up|26
6201610|NCT01494467|9861400|FG001|Part B Long Term Active Control 40 Weeks|Lost to Follow-up|10
6201611|NCT01494467|9861399|FG000|Part B Long Term Active Control 40 Weeks|Other (noted in eCRF)|8
6201612|NCT01494467|9861400|FG001|Part B Long Term Active Control 40 Weeks|Other (noted in eCRF)|2
6201613|NCT01494506|9861415|FG000|Overall Study|Lack of Efficacy|77
6201614|NCT01494506|9861416|FG001|Overall Study|Lack of Efficacy|83
6201615|NCT01494506|9861417|FG002|Overall Study|Lack of Efficacy|57
6201616|NCT01494506|9861415|FG000|Overall Study|Adverse Event|17
6201617|NCT01494506|9861416|FG001|Overall Study|Adverse Event|10
6201618|NCT01494506|9861417|FG002|Overall Study|Adverse Event|11
6201619|NCT01494506|9861415|FG000|Overall Study|Death|9
6201620|NCT01494506|9861416|FG001|Overall Study|Death|5
6201621|NCT01494506|9861417|FG002|Overall Study|Death|2
6201622|NCT01494506|9861415|FG000|Overall Study|Physician Decision|7
6201623|NCT01494506|9861416|FG001|Overall Study|Physician Decision|5
6278285|NCT02255097|9985985|FG000|Overall Study|Death|2
6278286|NCT02255097|9985985|FG000|Overall Study|Lost to Follow-up|1
6278287|NCT02255097|9985985|FG000|Overall Study|Physician Decision|1
6278288|NCT02255097|9985985|FG000|Overall Study|Progressive Disease|80
6278289|NCT02255097|9985985|FG000|Overall Study|Withdrawal by Subject|2
6278290|NCT02255097|9985985|FG000|Overall Study|Allocated but not treated|1
6278291|NCT02255097|9985985|FG000|Overall Study|Treatment Ongoing|36
6278292|NCT02255149|9985993|FG000|Overall Study|Lost to Follow-up|2
6278293|NCT02255149|9985993|FG000|Overall Study|Withdrawal by Subject|1
6278294|NCT02255149|9985993|FG000|Overall Study|Withdrawal by PI|1
6278295|NCT02255149|9985993|FG000|Overall Study|Implant Failure|1
6278296|NCT02255279|9986012|FG000|Overall Study|Lost to Follow-up|2
6278297|NCT02255279|9986013|FG001|Overall Study|Lost to Follow-up|2
6089035|NCT00680043|9700192|FG002|Overall Study|Renal Transplant|4
6089036|NCT00680056|9700202|FG000|First Intervention|Mainly Exacerbation of COPD|1
6089037|NCT00680056|9700203|FG001|First Intervention|Mainly Exacerbation of COPD|2
6089038|NCT00680056|9700202|FG000|Second Intervention|Protocol Violation|3
6089039|NCT00680056|9700203|FG001|Second Intervention|Protocol Violation|1
6201624|NCT01494506|9861417|FG002|Overall Study|Physician Decision|4
6201625|NCT01494506|9861415|FG000|Overall Study|Withdrawal by Subject|17
6201626|NCT01494506|9861416|FG001|Overall Study|Withdrawal by Subject|20
6201627|NCT01494506|9861417|FG002|Overall Study|Withdrawal by Subject|14
6201628|NCT01494506|9861415|FG000|Overall Study|Clinical Deterioration|21
6201629|NCT01494506|9861416|FG001|Overall Study|Clinical Deterioration|17
6201630|NCT01494506|9861417|FG002|Overall Study|Clinical Deterioration|13
6201631|NCT01494506|9861415|FG000|Overall Study|Sponsor Decision|0
6201632|NCT01494506|9861416|FG001|Overall Study|Sponsor Decision|0
6201633|NCT01494506|9861417|FG002|Overall Study|Sponsor Decision|1
6201634|NCT01494506|9861415|FG000|Overall Study|Other|0
6201635|NCT01494506|9861416|FG001|Overall Study|Other|3
6201636|NCT01494506|9861417|FG002|Overall Study|Other|1
6201637|NCT01494532|9861433|FG000|Overall Study|Adverse Event|4
6201638|NCT01494532|9861434|FG001|Overall Study|Adverse Event|1
6201639|NCT01494532|9861435|FG002|Overall Study|Adverse Event|8
6201640|NCT01494532|9861436|FG003|Overall Study|Adverse Event|6
6201641|NCT01494532|9861437|FG004|Overall Study|Adverse Event|5
6201642|NCT01494532|9861438|FG005|Overall Study|Adverse Event|0
6201643|NCT01494532|9861433|FG000|Overall Study|Lack of Efficacy|0
6278298|NCT02255279|9986012|FG000|Overall Study|Protocol Violation|0
6278299|NCT02255279|9986013|FG001|Overall Study|Protocol Violation|1
6201644|NCT01494532|9861434|FG001|Overall Study|Lack of Efficacy|0
6201645|NCT01494532|9861435|FG002|Overall Study|Lack of Efficacy|0
6201646|NCT01494532|9861436|FG003|Overall Study|Lack of Efficacy|0
6201647|NCT01494532|9861437|FG004|Overall Study|Lack of Efficacy|2
6201648|NCT01494532|9861438|FG005|Overall Study|Lack of Efficacy|0
6201649|NCT01494532|9861433|FG000|Overall Study|Protocol deviation|2
6201650|NCT01494532|9861434|FG001|Overall Study|Protocol deviation|1
6201651|NCT01494532|9861435|FG002|Overall Study|Protocol deviation|3
6201652|NCT01494532|9861436|FG003|Overall Study|Protocol deviation|2
6201653|NCT01494532|9861437|FG004|Overall Study|Protocol deviation|3
6201654|NCT01494532|9861438|FG005|Overall Study|Protocol deviation|0
6201655|NCT01494532|9861433|FG000|Overall Study|Protocol-defined stopping criteria|0
6201656|NCT01494532|9861434|FG001|Overall Study|Protocol-defined stopping criteria|0
6201657|NCT01494532|9861435|FG002|Overall Study|Protocol-defined stopping criteria|1
6201658|NCT01494532|9861436|FG003|Overall Study|Protocol-defined stopping criteria|0
6278300|NCT02255279|9986012|FG000|Overall Study|Withdrawal by Subject|3
6278301|NCT02255279|9986013|FG001|Overall Study|Withdrawal by Subject|6
6278302|NCT02255422|9986049|FG000|Overall Study|Withdrawal by Subject|0
6278303|NCT02255422|9986050|FG001|Overall Study|Withdrawal by Subject|0
6278304|NCT02255422|9986051|FG002|Overall Study|Withdrawal by Subject|0
6278305|NCT02255422|9986052|FG003|Overall Study|Withdrawal by Subject|0
6278306|NCT02255422|9986053|FG004|Overall Study|Withdrawal by Subject|0
6278307|NCT02255422|9986054|FG005|Overall Study|Withdrawal by Subject|0
6278308|NCT02255422|9986055|FG006|Overall Study|Withdrawal by Subject|2
6278309|NCT02255422|9986049|FG000|Overall Study|Lost to Follow-up|0
6278310|NCT02255422|9986050|FG001|Overall Study|Lost to Follow-up|0
6278311|NCT02255422|9986051|FG002|Overall Study|Lost to Follow-up|1
5977643|NCT01194570|9564902|FG001|Overall Study|Lack of Efficacy|21
5977644|NCT01194570|9564901|FG000|Overall Study|Withdrawal by Subject|21
5977645|NCT01194570|9564902|FG001|Overall Study|Withdrawal by Subject|22
5977646|NCT01194570|9564901|FG000|Overall Study|Pregnancy|1
5977647|NCT01194570|9564902|FG001|Overall Study|Pregnancy|1
5977648|NCT01194570|9564901|FG000|Overall Study|Lost to Follow-up|1
5977649|NCT01194570|9564902|FG001|Overall Study|Lost to Follow-up|4
5977650|NCT00511134|9564910|FG000|Overall Study|Withdrawal by Subject|0
5977651|NCT00511134|9564911|FG001|Overall Study|Withdrawal by Subject|2
5977652|NCT00180414|9564930|FG000|Overall Study|Study cancellation due to lack of overall enrollments|4
5977653|NCT00180414|9564931|FG001|Overall Study|Study cancellation due to lack of overall enrollments|4
5977654|NCT03894540|9564943|FG000|Overall Study|Adverse Event|0
5977655|NCT03894540|9564944|FG001|Overall Study|Adverse Event|0
5977656|NCT03894540|9564945|FG002|Overall Study|Adverse Event|0
5977657|NCT03894540|9564946|FG003|Overall Study|Adverse Event|0
5977658|NCT03894540|9564947|FG004|Overall Study|Adverse Event|1
5977659|NCT03894540|9564948|FG005|Overall Study|Adverse Event|0
5977660|NCT03894540|9564943|FG000|Overall Study|Withdrawal by Subject|0
5977661|NCT03894540|9564944|FG001|Overall Study|Withdrawal by Subject|0
5977662|NCT03894540|9564945|FG002|Overall Study|Withdrawal by Subject|0
5977663|NCT03894540|9564946|FG003|Overall Study|Withdrawal by Subject|0
5977664|NCT03894540|9564947|FG004|Overall Study|Withdrawal by Subject|1
5977665|NCT03894540|9564948|FG005|Overall Study|Withdrawal by Subject|0
5977666|NCT03894540|9564943|FG000|Overall Study|Progressive Disease Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1|0
5977667|NCT03894540|9564944|FG001|Overall Study|Progressive Disease Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1|0
5977668|NCT03894540|9564945|FG002|Overall Study|Progressive Disease Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1|1
5977669|NCT03894540|9564946|FG003|Overall Study|Progressive Disease Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1|3
5977670|NCT03894540|9564947|FG004|Overall Study|Progressive Disease Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1|2
5977671|NCT03894540|9564948|FG005|Overall Study|Progressive Disease Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1|3
5977672|NCT03894540|9564943|FG000|Overall Study|Progressive Disease Clinical|1
5977673|NCT03894540|9564944|FG001|Overall Study|Progressive Disease Clinical|1
5977674|NCT03894540|9564945|FG002|Overall Study|Progressive Disease Clinical|0
5977675|NCT03894540|9564946|FG003|Overall Study|Progressive Disease Clinical|1
5977676|NCT03894540|9564947|FG004|Overall Study|Progressive Disease Clinical|5
5977677|NCT03894540|9564948|FG005|Overall Study|Progressive Disease Clinical|1
5977678|NCT03894540|9564943|FG000|Overall Study|Study termination by sponsor|0
5977679|NCT03894540|9564944|FG001|Overall Study|Study termination by sponsor|0
5977680|NCT03894540|9564945|FG002|Overall Study|Study termination by sponsor|0
6201659|NCT01494532|9861437|FG004|Overall Study|Protocol-defined stopping criteria|0
6201660|NCT01494532|9861438|FG005|Overall Study|Protocol-defined stopping criteria|0
6201661|NCT01494532|9861433|FG000|Overall Study|Lost to Follow-up|1
6201662|NCT01494532|9861434|FG001|Overall Study|Lost to Follow-up|0
6201663|NCT01494532|9861435|FG002|Overall Study|Lost to Follow-up|0
6201664|NCT01494532|9861436|FG003|Overall Study|Lost to Follow-up|2
6201665|NCT01494532|9861437|FG004|Overall Study|Lost to Follow-up|0
6201666|NCT01494532|9861438|FG005|Overall Study|Lost to Follow-up|0
6201667|NCT01494532|9861433|FG000|Overall Study|Physician Decision|0
6201668|NCT01494532|9861434|FG001|Overall Study|Physician Decision|1
5977681|NCT03894540|9564946|FG003|Overall Study|Study termination by sponsor|0
5977682|NCT03894540|9564947|FG004|Overall Study|Study termination by sponsor|2
5977683|NCT03894540|9564948|FG005|Overall Study|Study termination by sponsor|0
6201669|NCT01494532|9861435|FG002|Overall Study|Physician Decision|1
6201670|NCT01494532|9861436|FG003|Overall Study|Physician Decision|2
6201671|NCT01494532|9861437|FG004|Overall Study|Physician Decision|0
6201672|NCT01494532|9861438|FG005|Overall Study|Physician Decision|0
6201673|NCT01494532|9861433|FG000|Overall Study|Withdrawal by Subject|3
6201674|NCT01494532|9861434|FG001|Overall Study|Withdrawal by Subject|1
6201675|NCT01494532|9861435|FG002|Overall Study|Withdrawal by Subject|4
6201676|NCT01494532|9861436|FG003|Overall Study|Withdrawal by Subject|3
6201677|NCT01494532|9861437|FG004|Overall Study|Withdrawal by Subject|2
6201678|NCT01494532|9861438|FG005|Overall Study|Withdrawal by Subject|0
6201679|NCT01494584|9861460|FG000|Overall Study|Study Closed/Terminated|1
6201680|NCT01494610|9861483|FG000|Period 1|Withdrawal by Subject|1
6201681|NCT01494610|9861484|FG001|Period 1|Withdrawal by Subject|1
6201682|NCT01494610|9861483|FG000|Period 3|Adverse Event|1
6201683|NCT01494610|9861484|FG001|Period 3|Adverse Event|0
6201684|NCT01494610|9861483|FG000|Period 3|Withdrawal by Subject|1
6201685|NCT01494610|9861484|FG001|Period 3|Withdrawal by Subject|0
6201686|NCT01494610|9861483|FG000|Period 4|Protocol Violation|1
6201687|NCT01494610|9861484|FG001|Period 4|Protocol Violation|0
6201688|NCT01494649|9861498|FG000|Overall Study|Lost to Follow-up|0
6201689|NCT01494649|9861499|FG001|Overall Study|Lost to Follow-up|1
6201690|NCT01494818|9861518|FG000|Overall Study|Relocation|1
6201691|NCT01494818|9861519|FG001|Overall Study|Relocation|2
6201692|NCT01494818|9861518|FG000|Overall Study|Lost to Follow-up|1
6201693|NCT01494818|9861519|FG001|Overall Study|Lost to Follow-up|0
6201694|NCT01494922|9861525|FG000|Overall Study|Adverse Event|1
6278312|NCT02255422|9986052|FG003|Overall Study|Lost to Follow-up|0
6278313|NCT02255422|9986053|FG004|Overall Study|Lost to Follow-up|0
6278314|NCT02255422|9986054|FG005|Overall Study|Lost to Follow-up|0
6278315|NCT02255422|9986055|FG006|Overall Study|Lost to Follow-up|0
6278316|NCT02255461|9986076|FG000|Overall Study|Adverse Event|0
6278317|NCT02255461|9986077|FG001|Overall Study|Adverse Event|1
6278318|NCT02255461|9986078|FG002|Overall Study|Adverse Event|0
6278319|NCT02255461|9986079|FG003|Overall Study|Adverse Event|0
6278320|NCT02255461|9986080|FG004|Overall Study|Adverse Event|1
6278321|NCT02255461|9986076|FG000|Overall Study|Withdrawal by Subject|0
6278322|NCT02255461|9986077|FG001|Overall Study|Withdrawal by Subject|0
6278323|NCT02255461|9986078|FG002|Overall Study|Withdrawal by Subject|1
6278324|NCT02255461|9986079|FG003|Overall Study|Withdrawal by Subject|0
6278325|NCT02255461|9986080|FG004|Overall Study|Withdrawal by Subject|1
6278326|NCT02255461|9986076|FG000|Overall Study|Not meet dose reduction BSA requirement|0
6278327|NCT02255461|9986077|FG001|Overall Study|Not meet dose reduction BSA requirement|1
6278328|NCT02255461|9986078|FG002|Overall Study|Not meet dose reduction BSA requirement|0
6278329|NCT02255461|9986079|FG003|Overall Study|Not meet dose reduction BSA requirement|0
6278330|NCT02255461|9986080|FG004|Overall Study|Not meet dose reduction BSA requirement|0
6278331|NCT02255474|9986100|FG000|Overall Study|Lost to Follow-up|1
6278332|NCT02255474|9986101|FG001|Overall Study|Lost to Follow-up|1
6278333|NCT02255474|9986102|FG002|Overall Study|Lost to Follow-up|3
6278334|NCT02255474|9986100|FG000|Overall Study|Withdrawal by Subject|1
6278335|NCT02255474|9986101|FG001|Overall Study|Withdrawal by Subject|1
6278336|NCT02255474|9986102|FG002|Overall Study|Withdrawal by Subject|0
6278337|NCT02255500|9986113|FG000|Overall Study|Withdrawal by Subject|1
6278338|NCT02255500|9986114|FG001|Overall Study|Withdrawal by Subject|0
6278339|NCT02255552|9986131|FG000|Overall Study|Participants enrolled into another study|0
6278340|NCT02255552|9986132|FG001|Overall Study|Participants enrolled into another study|11
6278341|NCT02255552|9986131|FG000|Overall Study|Withdrawal by Subject|1
6278342|NCT02255552|9986132|FG001|Overall Study|Withdrawal by Subject|4
6278343|NCT02255565|9986141|FG000|Overall Study|Withdrawal by Subject|0
6278344|NCT02255565|9986142|FG001|Overall Study|Withdrawal by Subject|1
6278345|NCT02255565|9986143|FG002|Overall Study|Withdrawal by Subject|0
6278346|NCT02255760|9986202|FG000|Overall Study|Lost to Follow-up|0
6278347|NCT02255760|9986203|FG001|Overall Study|Lost to Follow-up|1
6278348|NCT02255760|9986204|FG002|Overall Study|Lost to Follow-up|0
6278349|NCT02255760|9986205|FG003|Overall Study|Lost to Follow-up|0
6278350|NCT02255760|9986206|FG004|Overall Study|Lost to Follow-up|0
6278351|NCT02255981|9986222|FG000|Overall Study|Lost to Follow-up|3
6278352|NCT02255981|9986222|FG000|Overall Study|Withdrawal by Subject|1
6278353|NCT02256267|9986263|FG000|Period 1 (Day 1; Day 2 to Day 9 Washout)|Adverse Event|1
6278354|NCT02256267|9986263|FG000|Period 2 (Day 7 to Day 14)|Adverse Event|1
6278355|NCT02256384|9986288|FG000|Overall Study|Withdrawal by Subject|12
6278356|NCT02256384|9986288|FG000|Overall Study|Equipment not capturing data|2
6278357|NCT02256436|9986298|FG000|Overall Study|Adverse Event|9
6278358|NCT02256436|9986299|FG001|Overall Study|Adverse Event|14
6278359|NCT02256436|9986298|FG000|Overall Study|Death|216
6278360|NCT02256436|9986299|FG001|Overall Study|Death|208
6278361|NCT02256436|9986298|FG000|Overall Study|Lost to Follow-up|1
6278362|NCT02256436|9986299|FG001|Overall Study|Lost to Follow-up|2
6278363|NCT02256436|9986298|FG000|Overall Study|Physician Decision|1
6278364|NCT02256436|9986299|FG001|Overall Study|Physician Decision|0
6278365|NCT02256436|9986298|FG000|Overall Study|Protocol Violation|0
6278366|NCT02256436|9986299|FG001|Overall Study|Protocol Violation|1
6278367|NCT02256436|9986298|FG000|Overall Study|Withdrawal by Subject|26
6278368|NCT02256436|9986299|FG001|Overall Study|Withdrawal by Subject|10
6278369|NCT02256436|9986298|FG000|Overall Study|Transferred to Extension Study|11
6201695|NCT01494987|9861531|FG000|Overall Study|Adverse Event|6
6278370|NCT02256436|9986299|FG001|Overall Study|Transferred to Extension Study|23
6278371|NCT02256436|9986298|FG000|Overall Study|Did Not Continue on Extension Study|8
6278372|NCT02256436|9986299|FG001|Overall Study|Did Not Continue on Extension Study|12
6278373|NCT02256488|9986310|FG000|Overall Study|Lost to Follow-up|6
6278374|NCT02256488|9986311|FG001|Overall Study|Lost to Follow-up|6
5977684|NCT03725293|9564972|FG000|Overall Study|Physician Decision|9
5977685|NCT03725293|9564973|FG001|Overall Study|Physician Decision|6
5977686|NCT03725293|9564972|FG000|Overall Study|alternative vascular access needs|1
5977687|NCT03725293|9564973|FG001|Overall Study|alternative vascular access needs|2
5977688|NCT03725293|9564972|FG000|Overall Study|venous anatomy screen failures|2
5977689|NCT03725293|9564973|FG001|Overall Study|venous anatomy screen failures|1
5977690|NCT03702231|9564982|FG000|Overall Study|Withdrawal by Subject|1
5977691|NCT03702231|9564983|FG001|Overall Study|Withdrawal by Subject|0
5977692|NCT03702231|9564984|FG002|Overall Study|Withdrawal by Subject|0
5977693|NCT03702231|9564982|FG000|Overall Study|Protocol Violation|0
5977694|NCT03702231|9564983|FG001|Overall Study|Protocol Violation|0
5977695|NCT03702231|9564984|FG002|Overall Study|Protocol Violation|1
5977696|NCT03702231|9564982|FG000|Overall Study|COVID Pandemic|3
5977697|NCT03702231|9564983|FG001|Overall Study|COVID Pandemic|4
6201696|NCT01494987|9861532|FG001|Overall Study|Adverse Event|5
5977698|NCT03702231|9564984|FG002|Overall Study|COVID Pandemic|1
5977699|NCT03556358|9565015|FG000|Overall Study|Subjects Randomized that did not Treat|3
5977700|NCT03556358|9565016|FG001|Overall Study|Subjects Randomized that did not Treat|0
5977701|NCT03556358|9565015|FG000|Overall Study|Subjects who Randomized and Treated but Drop prior to Cycle 5|7
5977702|NCT03556358|9565016|FG001|Overall Study|Subjects who Randomized and Treated but Drop prior to Cycle 5|5
5977703|NCT03556358|9565015|FG000|Overall Study|Discontinued Treatment after Cycle 5 due to Adverse Event|0
5977704|NCT03556358|9565016|FG001|Overall Study|Discontinued Treatment after Cycle 5 due to Adverse Event|1
5977705|NCT03556358|9565015|FG000|Overall Study|Discontinued Treatment after Cycle 5 due to Death|0
5977706|NCT03556358|9565016|FG001|Overall Study|Discontinued Treatment after Cycle 5 due to Death|1
5977707|NCT03556358|9565015|FG000|Overall Study|Discontinued Treatment after Cycle 5 due to Consent Withdrawn|0
5977708|NCT03556358|9565016|FG001|Overall Study|Discontinued Treatment after Cycle 5 due to Consent Withdrawn|2
5977709|NCT03556358|9565015|FG000|Overall Study|Discontinued Treatment after Cycle 5 due to COVID-19|0
5977710|NCT03556358|9565016|FG001|Overall Study|Discontinued Treatment after Cycle 5 due to COVID-19|1
5977711|NCT03556358|9565015|FG000|Overall Study|Discontinued Treatment after Cycle 5 due to Other (Subject Decision)|1
5977712|NCT03556358|9565016|FG001|Overall Study|Discontinued Treatment after Cycle 5 due to Other (Subject Decision)|2
5977713|NCT03290781|9565029|FG000|Overall Study|Adverse Event|5
5977714|NCT03290781|9565030|FG001|Overall Study|Adverse Event|7
5977715|NCT03290781|9565031|FG002|Overall Study|Adverse Event|4
5977716|NCT03290781|9565032|FG003|Overall Study|Adverse Event|1
5977717|NCT03290781|9565033|FG004|Overall Study|Adverse Event|0
5977718|NCT03290781|9565034|FG005|Overall Study|Adverse Event|0
5977719|NCT03290781|9565035|FG006|Overall Study|Adverse Event|0
5977720|NCT03290781|9565029|FG000|Overall Study|Death|0
5977721|NCT03290781|9565030|FG001|Overall Study|Death|0
5977722|NCT03290781|9565031|FG002|Overall Study|Death|1
5977723|NCT03290781|9565032|FG003|Overall Study|Death|0
5977724|NCT03290781|9565033|FG004|Overall Study|Death|1
5977725|NCT03290781|9565034|FG005|Overall Study|Death|0
5977726|NCT03290781|9565035|FG006|Overall Study|Death|0
5977727|NCT03290781|9565029|FG000|Overall Study|Withdrawal by Subject|6
5977728|NCT03290781|9565030|FG001|Overall Study|Withdrawal by Subject|5
5977729|NCT03290781|9565031|FG002|Overall Study|Withdrawal by Subject|9
5977730|NCT03290781|9565032|FG003|Overall Study|Withdrawal by Subject|10
5977731|NCT03290781|9565033|FG004|Overall Study|Withdrawal by Subject|1
5977732|NCT03290781|9565034|FG005|Overall Study|Withdrawal by Subject|2
5977733|NCT03290781|9565035|FG006|Overall Study|Withdrawal by Subject|0
5977734|NCT03290781|9565029|FG000|Overall Study|Physician Decision|0
5977735|NCT03290781|9565030|FG001|Overall Study|Physician Decision|1
5977736|NCT03290781|9565031|FG002|Overall Study|Physician Decision|0
5977737|NCT03290781|9565032|FG003|Overall Study|Physician Decision|0
5977738|NCT03290781|9565033|FG004|Overall Study|Physician Decision|0
5977739|NCT03290781|9565034|FG005|Overall Study|Physician Decision|0
5977740|NCT03290781|9565035|FG006|Overall Study|Physician Decision|0
5977741|NCT03290781|9565029|FG000|Overall Study|Site Terminated by Sponsor|1
6201697|NCT01494987|9861531|FG000|Overall Study|Hyperglycemia|6
6201698|NCT01494987|9861532|FG001|Overall Study|Hyperglycemia|4
6201699|NCT01494987|9861531|FG000|Overall Study|Investigator's Discretion|1
6201700|NCT01494987|9861532|FG001|Overall Study|Investigator's Discretion|2
6201701|NCT01494987|9861531|FG000|Overall Study|Lost to Follow-up|1
6201702|NCT01494987|9861532|FG001|Overall Study|Lost to Follow-up|1
6201703|NCT01494987|9861531|FG000|Overall Study|Protocol Violation|3
6201704|NCT01494987|9861532|FG001|Overall Study|Protocol Violation|3
6201705|NCT01494987|9861531|FG000|Overall Study|Subject Non-Compliance|9
6201706|NCT01494987|9861532|FG001|Overall Study|Subject Non-Compliance|10
6201707|NCT01494987|9861531|FG000|Overall Study|Subject Withdrew Consent|2
6201708|NCT01494987|9861532|FG001|Overall Study|Subject Withdrew Consent|3
6201709|NCT01495000|9861540|FG000|Overall Study|Lost to Follow-up|2
6278375|NCT02256488|9986312|FG002|Overall Study|Lost to Follow-up|9
6201710|NCT01495000|9861541|FG001|Overall Study|Lost to Follow-up|2
6201711|NCT01495000|9861540|FG000|Overall Study|Protocol Violation|1
6201712|NCT01495000|9861541|FG001|Overall Study|Protocol Violation|0
6201713|NCT01495000|9861540|FG000|Overall Study|Withdrawal by Subject|10
6201714|NCT01495000|9861541|FG001|Overall Study|Withdrawal by Subject|10
6201715|NCT01495702|9861597|FG000|Randomized Phase|Randomized But Not Treated|1
6201716|NCT01495702|9861598|FG001|Randomized Phase|Randomized But Not Treated|4
6201717|NCT01495702|9861597|FG000|Randomized Phase|Adverse Event|2
6201718|NCT01495702|9861598|FG001|Randomized Phase|Adverse Event|2
6201719|NCT01495702|9861597|FG000|Randomized Phase|Death|1
6201720|NCT01495702|9861598|FG001|Randomized Phase|Death|0
6201721|NCT01495702|9861597|FG000|Randomized Phase|Lack of Efficacy|2
6201722|NCT01495702|9861598|FG001|Randomized Phase|Lack of Efficacy|0
6201723|NCT01495702|9861597|FG000|Randomized Phase|Investigators Discretion|2
6201724|NCT01495702|9861598|FG001|Randomized Phase|Investigators Discretion|0
6201725|NCT01495702|9861597|FG000|Randomized Phase|Withdrew Consent|10
6201726|NCT01495702|9861598|FG001|Randomized Phase|Withdrew Consent|18
6201727|NCT01495702|9861597|FG000|Randomized Phase|Lost to Follow-up|4
6201728|NCT01495702|9861598|FG001|Randomized Phase|Lost to Follow-up|3
6201729|NCT01495702|9861597|FG000|Randomized Phase|Participant Noncompliance|1
6201730|NCT01495702|9861598|FG001|Randomized Phase|Participant Noncompliance|0
6201731|NCT01495702|9861597|FG000|Randomized Phase|Protocol Violation|3
6201732|NCT01495702|9861598|FG001|Randomized Phase|Protocol Violation|1
6201733|NCT01495793|9861605|FG000|Overall Study|Lost to Follow-up|1
6201734|NCT01495793|9861605|FG000|Overall Study|Violation of inclusion criteria|1
6201735|NCT01495975|9861644|FG000|Overall Study|Lost to Follow-up|1
6201736|NCT01495975|9861645|FG001|Overall Study|Lost to Follow-up|0
6201737|NCT01496066|9861653|FG000|Overall Study|Lost to Follow-up|8
6201738|NCT01496066|9861654|FG001|Overall Study|Lost to Follow-up|5
6201739|NCT01496066|9861653|FG000|Overall Study|Explant|3
6201740|NCT01496066|9861654|FG001|Overall Study|Explant|0
6201741|NCT01496066|9861653|FG000|Overall Study|Death|1
6201742|NCT01496066|9861654|FG001|Overall Study|Death|4
6201743|NCT01496183|9861682|FG000|Overall Study|Physician Decision|3
6201744|NCT01496183|9861683|FG001|Overall Study|Physician Decision|1
6201745|NCT01496183|9861682|FG000|Overall Study|Withdrawal by Subject|0
6201746|NCT01496183|9861683|FG001|Overall Study|Withdrawal by Subject|1
6201747|NCT01496274|9861696|FG000|Overall Study|Protocol Violation|0
6201748|NCT01496274|9861697|FG001|Overall Study|Protocol Violation|1
6201749|NCT01496274|9861696|FG000|Overall Study|Adverse Event|1
6201750|NCT01496274|9861697|FG001|Overall Study|Adverse Event|1
6201751|NCT01496274|9861696|FG000|Overall Study|Withdrawal by Subject|2
6201752|NCT01496274|9861697|FG001|Overall Study|Withdrawal by Subject|0
6201753|NCT01496274|9861696|FG000|Overall Study|Lost to Follow-up|0
6201754|NCT01496274|9861697|FG001|Overall Study|Lost to Follow-up|3
6201755|NCT01496287|9861718|FG000|Overall Study|Lost to Follow-up|1
6201756|NCT01496287|9861718|FG000|Overall Study|Incomplete anesthesia|5
6201757|NCT01496365|9861757|FG000|Overall Study|Adverse Event|2
6201758|NCT01496365|9861758|FG001|Overall Study|Adverse Event|3
6201759|NCT01496365|9861759|FG002|Overall Study|Adverse Event|3
6201760|NCT01496365|9861760|FG003|Overall Study|Adverse Event|2
6201761|NCT01496365|9861761|FG004|Overall Study|Adverse Event|5
6201762|NCT01496365|9861762|FG005|Overall Study|Adverse Event|6
6201763|NCT01496365|9861763|FG006|Overall Study|Adverse Event|4
6201764|NCT01496365|9861757|FG000|Overall Study|Withdrawal by Subject|6
6201765|NCT01496365|9861758|FG001|Overall Study|Withdrawal by Subject|6
6201766|NCT01496365|9861759|FG002|Overall Study|Withdrawal by Subject|0
6201767|NCT01496365|9861760|FG003|Overall Study|Withdrawal by Subject|1
6201768|NCT01496365|9861761|FG004|Overall Study|Withdrawal by Subject|3
6201769|NCT01496365|9861762|FG005|Overall Study|Withdrawal by Subject|2
6201770|NCT01496365|9861763|FG006|Overall Study|Withdrawal by Subject|1
6201771|NCT01496365|9861757|FG000|Overall Study|Protocol Violation|2
6201772|NCT01496365|9861758|FG001|Overall Study|Protocol Violation|1
6201773|NCT01496365|9861759|FG002|Overall Study|Protocol Violation|1
6201774|NCT01496365|9861760|FG003|Overall Study|Protocol Violation|0
6201775|NCT01496365|9861761|FG004|Overall Study|Protocol Violation|0
6201776|NCT01496365|9861762|FG005|Overall Study|Protocol Violation|1
6201777|NCT01496365|9861763|FG006|Overall Study|Protocol Violation|0
6201778|NCT01496365|9861757|FG000|Overall Study|Lack of Efficacy|1
6201779|NCT01496365|9861758|FG001|Overall Study|Lack of Efficacy|0
6201780|NCT01496365|9861759|FG002|Overall Study|Lack of Efficacy|0
6201781|NCT01496365|9861760|FG003|Overall Study|Lack of Efficacy|0
6201782|NCT01496365|9861761|FG004|Overall Study|Lack of Efficacy|0
6201783|NCT01496365|9861762|FG005|Overall Study|Lack of Efficacy|1
6201784|NCT01496365|9861763|FG006|Overall Study|Lack of Efficacy|0
6201785|NCT01496365|9861757|FG000|Overall Study|Lost to Follow-up|0
6201786|NCT01496365|9861758|FG001|Overall Study|Lost to Follow-up|1
6201787|NCT01496365|9861759|FG002|Overall Study|Lost to Follow-up|0
6201788|NCT01496365|9861760|FG003|Overall Study|Lost to Follow-up|0
6201789|NCT01496365|9861761|FG004|Overall Study|Lost to Follow-up|2
6201790|NCT01496365|9861762|FG005|Overall Study|Lost to Follow-up|0
6201791|NCT01496365|9861763|FG006|Overall Study|Lost to Follow-up|0
6201792|NCT01496365|9861757|FG000|Overall Study|Other|4
6201793|NCT01496365|9861758|FG001|Overall Study|Other|4
6201794|NCT01496365|9861759|FG002|Overall Study|Other|2
6201795|NCT01496365|9861760|FG003|Overall Study|Other|1
6201796|NCT01496365|9861761|FG004|Overall Study|Other|3
6201797|NCT01496365|9861762|FG005|Overall Study|Other|0
6201798|NCT01496365|9861763|FG006|Overall Study|Other|1
6201799|NCT01496430|9861782|FG000|Overall Study|Adverse Event|0
6201800|NCT01496430|9861783|FG001|Overall Study|Adverse Event|0
6201801|NCT01496430|9861784|FG002|Overall Study|Adverse Event|1
6278376|NCT02256488|9986313|FG003|Overall Study|Lost to Follow-up|3
6278377|NCT02256488|9986310|FG000|Overall Study|OTHER|1
6278378|NCT02256488|9986311|FG001|Overall Study|OTHER|0
6278379|NCT02256488|9986312|FG002|Overall Study|OTHER|1
6278380|NCT02256488|9986313|FG003|Overall Study|OTHER|1
6278381|NCT02256488|9986310|FG000|Overall Study|Withdrawal by Subject|1
6278382|NCT02256488|9986311|FG001|Overall Study|Withdrawal by Subject|0
6278383|NCT02256488|9986312|FG002|Overall Study|Withdrawal by Subject|0
6278384|NCT02256488|9986313|FG003|Overall Study|Withdrawal by Subject|2
6278385|NCT02256540|9986324|FG000|Overall Study|Withdrawal by Subject|0
6278386|NCT02256540|9986325|FG001|Overall Study|Withdrawal by Subject|1
6278387|NCT02256540|9986326|FG002|Overall Study|Withdrawal by Subject|1
6278388|NCT02256540|9986324|FG000|Overall Study|Back pain preventing exercise|0
6278389|NCT02256540|9986325|FG001|Overall Study|Back pain preventing exercise|0
6278390|NCT02256540|9986326|FG002|Overall Study|Back pain preventing exercise|1
6278391|NCT02256553|9986334|FG000|Period I|Adverse Event|5
6278392|NCT02256553|9986334|FG000|Period I|Protocol Violation|1
6278393|NCT02256553|9986334|FG000|Period II|Adverse Event|1
6278394|NCT02256553|9986334|FG000|Period II|Subject Moved|1
6278395|NCT02256553|9986334|FG000|Period III|Adverse Event|3
6278396|NCT02256839|9986342|FG000|Overall Study|Did not meet Eligibility Criteria|2
6278397|NCT02256839|9986343|FG001|Overall Study|Did not meet Eligibility Criteria|3
6278398|NCT02256891|9986351|FG000|Overall Study|Death|0
6278399|NCT02256891|9986352|FG001|Overall Study|Death|2
6278400|NCT02256891|9986351|FG000|Overall Study|Lost to Follow-up|0
6278401|NCT02256891|9986352|FG001|Overall Study|Lost to Follow-up|3
6278402|NCT02256891|9986351|FG000|Overall Study|Physician Decision|7
6278403|NCT02256891|9986352|FG001|Overall Study|Physician Decision|3
6278404|NCT02256891|9986351|FG000|Overall Study|Screen Fail|5
6278405|NCT02256891|9986352|FG001|Overall Study|Screen Fail|4
6278406|NCT02256891|9986351|FG000|Overall Study|Equipment Malfunction|0
6278407|NCT02256891|9986352|FG001|Overall Study|Equipment Malfunction|1
6278408|NCT02256917|9986360|FG000|Prophylactic Treatment Phase I|Lost to Follow-up|1
6278409|NCT02256917|9986360|FG000|Prophylactic Treatment Phase II|Lost to Follow-up|1
6278410|NCT02256917|9986360|FG000|Prophylactic Treatment Phase II|Withdrawn Consent|1
6278411|NCT02256917|9986360|FG000|Prophylactic Treatment Phase II|Did not attend completion visit|1
6278412|NCT02256917|9986360|FG000|Prophylactic Treatment Phase II|Discontinued medication|1
6278413|NCT02256969|9986374|FG000|Overall Study|Screenfailed or withdrew|2
6278414|NCT02256969|9986375|FG001|Overall Study|Screenfailed or withdrew|1
6278415|NCT02256969|9986376|FG002|Overall Study|Screenfailed or withdrew|1
6278416|NCT02256982|9986386|FG000|Overall Study|Disease Progression|0
6278417|NCT02256982|9986387|FG001|Overall Study|Disease Progression|1
6278418|NCT02257372|9986446|FG000|Overall Study|Adverse Event|3
6278419|NCT02257372|9986447|FG001|Overall Study|Adverse Event|7
6278420|NCT02257372|9986446|FG000|Overall Study|Lack of Efficacy|2
6278421|NCT02257372|9986447|FG001|Overall Study|Lack of Efficacy|1
6278422|NCT02257372|9986446|FG000|Overall Study|Protocol Violation|1
6278423|NCT02257372|9986447|FG001|Overall Study|Protocol Violation|1
6278424|NCT02257372|9986446|FG000|Overall Study|Lost to Follow-up|0
6278425|NCT02257372|9986447|FG001|Overall Study|Lost to Follow-up|1
6278426|NCT02257372|9986446|FG000|Overall Study|Withdrew consent|1
6278427|NCT02257372|9986447|FG001|Overall Study|Withdrew consent|0
6278428|NCT02257385|9986455|FG000|Overall Study|Adverse Event|12
6278429|NCT02257385|9986456|FG001|Overall Study|Adverse Event|8
6201802|NCT01496430|9861782|FG000|Overall Study|Major Protocol Deviation|0
6201803|NCT01496430|9861783|FG001|Overall Study|Major Protocol Deviation|0
6201804|NCT01496430|9861784|FG002|Overall Study|Major Protocol Deviation|1
6201805|NCT01496430|9861782|FG000|Overall Study|Lost to Follow-up|2
6201806|NCT01496430|9861783|FG001|Overall Study|Lost to Follow-up|3
6201807|NCT01496430|9861784|FG002|Overall Study|Lost to Follow-up|1
6201808|NCT01496430|9861782|FG000|Overall Study|Voluntary Withdrawal|2
6201809|NCT01496430|9861783|FG001|Overall Study|Voluntary Withdrawal|1
6201810|NCT01496430|9861784|FG002|Overall Study|Voluntary Withdrawal|6
6201811|NCT01496430|9861782|FG000|Overall Study|Principal Investigator Discretion|0
6201812|NCT01496430|9861783|FG001|Overall Study|Principal Investigator Discretion|1
6278430|NCT02257385|9986455|FG000|Overall Study|Lack of Efficacy|1
6278431|NCT02257385|9986456|FG001|Overall Study|Lack of Efficacy|2
6278432|NCT02257385|9986455|FG000|Overall Study|Protocol Violation|5
6278433|NCT02257385|9986456|FG001|Overall Study|Protocol Violation|7
6278434|NCT02257385|9986455|FG000|Overall Study|Lost to Follow-up|0
6201813|NCT01496430|9861784|FG002|Overall Study|Principal Investigator Discretion|1
6278435|NCT02257385|9986456|FG001|Overall Study|Lost to Follow-up|1
6278436|NCT02257385|9986455|FG000|Overall Study|Withdrawal by Subject|4
6278437|NCT02257385|9986456|FG001|Overall Study|Withdrawal by Subject|4
6278438|NCT02257489|9986471|FG000|Overall Study|Withdrawal by Subject|0
6278439|NCT02257489|9986472|FG001|Overall Study|Withdrawal by Subject|0
6278440|NCT02257489|9986473|FG002|Overall Study|Withdrawal by Subject|0
6278441|NCT02257489|9986474|FG003|Overall Study|Withdrawal by Subject|1
6278442|NCT02257489|9986475|FG004|Overall Study|Withdrawal by Subject|0
6201814|NCT01496430|9861782|FG000|Overall Study|Other|2
6201815|NCT01496430|9861783|FG001|Overall Study|Other|0
6201816|NCT01496430|9861784|FG002|Overall Study|Other|0
6201817|NCT01496456|9861792|FG000|Overall Study|Protocol Violation|1
6201818|NCT01496456|9861792|FG000|Overall Study|Lost to Follow-up|7
6201819|NCT01496469|9861801|FG000|Overall Study|Adverse Event|1
6201820|NCT01496469|9861802|FG001|Overall Study|Adverse Event|0
6201821|NCT01496469|9861801|FG000|Overall Study|Protocol Violation|2
6201822|NCT01496469|9861802|FG001|Overall Study|Protocol Violation|0
6201823|NCT01496469|9861801|FG000|Overall Study|Lost to Follow-up|1
6201824|NCT01496469|9861802|FG001|Overall Study|Lost to Follow-up|1
6201825|NCT01496469|9861801|FG000|Overall Study|Withdrawal by Subject|4
6201826|NCT01496469|9861802|FG001|Overall Study|Withdrawal by Subject|4
6201827|NCT01496469|9861801|FG000|Overall Study|BP exceeds protocol limits|1
6201828|NCT01496469|9861802|FG001|Overall Study|BP exceeds protocol limits|2
6201829|NCT01496469|9861801|FG000|Overall Study|Other|1
6201830|NCT01496469|9861802|FG001|Overall Study|Other|1
6201831|NCT01496612|9861808|FG000|1st Intervention|Adverse Event|1
6201832|NCT01496612|9861809|FG001|1st Intervention|Adverse Event|0
6201833|NCT01496612|9861808|FG000|1st Intervention|Withdrawal by Subject|1
6201834|NCT01496612|9861809|FG001|1st Intervention|Withdrawal by Subject|0
6201835|NCT01496807|9861817|FG000|Overall Study|Progressive Disease|21
6201836|NCT01496807|9861817|FG000|Overall Study|Participant preference/toxicity|8
6201837|NCT01496807|9861817|FG000|Overall Study|Change in diagnosis|1
6201838|NCT01496846|9861827|FG000|IANB Articaine (All Participants)|"Inadequate lip numbness: missed block"|1
6201839|NCT01496846|9861828|FG001|IANB Articaine (All Participants)|"Inadequate lip numbness: missed block"|1
6201840|NCT01496846|9861829|FG002|IANB Articaine (All Participants)|"Inadequate lip numbness: missed block"|0
6201841|NCT01496846|9861830|FG003|IANB Articaine (All Participants)|"Inadequate lip numbness: missed block"|0
6201842|NCT01496846|9861831|FG004|IANB Articaine (All Participants)|"Inadequate lip numbness: missed block"|0
6201843|NCT01496846|9861832|FG005|IANB Articaine (All Participants)|"Inadequate lip numbness: missed block"|0
6201844|NCT01496885|9861843|FG000|Overall Study|Lost to Follow-up|13
6201845|NCT01496885|9861843|FG000|Overall Study|Withdrawal by Subject|7
6201846|NCT01496885|9861843|FG000|Overall Study|Clinically significant change in subject status that prevented compliance or impacted stroke outcome|2
6201847|NCT01496885|9861843|FG000|Overall Study|Death|1
6201848|NCT01497067|9861847|FG000|Overall Study|Lost to Follow-up|56
6201849|NCT01497067|9861847|FG000|Overall Study|Adverse Event|3
6201850|NCT01497067|9861847|FG000|Overall Study|Patient decision unrel to Adverse Event|10
6201851|NCT01497067|9861847|FG000|Overall Study|Other|13
6201852|NCT01497197|9861854|FG000|Overall Study|Lost to Follow-up|1
6201853|NCT01497197|9861855|FG001|Overall Study|Lost to Follow-up|0
6201854|NCT01497197|9861854|FG000|Overall Study|Protocol Violation|0
6201855|NCT01497197|9861855|FG001|Overall Study|Protocol Violation|2
6278443|NCT02257489|9986476|FG005|Overall Study|Withdrawal by Subject|0
6278444|NCT02257489|9986477|FG006|Overall Study|Withdrawal by Subject|0
6278445|NCT02257489|9986478|FG007|Overall Study|Withdrawal by Subject|0
6278446|NCT02257489|9986479|FG008|Overall Study|Withdrawal by Subject|0
6278447|NCT02257632|9986521|FG000|Overall Study|Withdrawal by Subject|0
6278448|NCT02257632|9986522|FG001|Overall Study|Withdrawal by Subject|1
6278449|NCT02257632|9986521|FG000|Overall Study|Adverse Event|1
6278450|NCT02257632|9986522|FG001|Overall Study|Adverse Event|2
6278451|NCT02257684|9986530|FG000|Overall Study|Adverse Event|2
6278452|NCT02257684|9986530|FG000|Overall Study|Lack of Efficacy|1
6278453|NCT02257684|9986530|FG000|Overall Study|Sponsor's Decision|1
6278454|NCT02258074|9986573|FG000|Overall Study|Withdrawal by Subject|1
6278455|NCT02258074|9986574|FG001|Overall Study|Withdrawal by Subject|0
6278456|NCT02258074|9986575|FG002|Overall Study|Withdrawal by Subject|0
6278457|NCT02258074|9986576|FG003|Overall Study|Withdrawal by Subject|0
6278458|NCT02258334|9986613|FG000|Overall Study|Adverse Event|1
6278459|NCT02258334|9986614|FG001|Overall Study|Adverse Event|0
6278460|NCT02258334|9986615|FG002|Overall Study|Adverse Event|0
6278461|NCT02258334|9986616|FG003|Overall Study|Adverse Event|0
6278462|NCT02258464|9986651|FG000|Overall Study|Progressive disease (PD)|9
6278463|NCT02258464|9986652|FG001|Overall Study|Progressive disease (PD)|17
6278464|NCT02258464|9986651|FG000|Overall Study|Study drug never administered|1
6278465|NCT02258464|9986652|FG001|Overall Study|Study drug never administered|1
6278466|NCT02258464|9986651|FG000|Overall Study|AE not related to clinical PD|1
6278467|NCT02258464|9986652|FG001|Overall Study|AE not related to clinical PD|3
6278468|NCT02258464|9986651|FG000|Overall Study|Withdrawal by Subject|5
6278469|NCT02258464|9986652|FG001|Overall Study|Withdrawal by Subject|4
6278470|NCT02258464|9986651|FG000|Overall Study|AE related to clinical PD|1
6278471|NCT02258464|9986652|FG001|Overall Study|AE related to clinical PD|0
6201856|NCT01497197|9861854|FG000|Overall Study|Withdrawal by Subject|2
6201857|NCT01497197|9861855|FG001|Overall Study|Withdrawal by Subject|1
6201858|NCT01497197|9861854|FG000|Overall Study|Excessive/lack of response to treatment|1
6201859|NCT01497197|9861855|FG001|Overall Study|Excessive/lack of response to treatment|0
6201860|NCT01497197|9861854|FG000|Overall Study|Risk of OHSS|1
6278472|NCT02258529|9986670|FG000|Overall Study|Study Terminated by Sponsor|9
6278473|NCT02258529|9986670|FG000|Overall Study|Adverse Event|1
6278474|NCT02259010|9986674|FG000|Overall Study|Didn't Completed Dosing; PK Assessment|5
6278475|NCT02259088|9986682|FG000|Overall Study|Adverse Event|6
6278476|NCT02259088|9986683|FG001|Overall Study|Adverse Event|4
6278477|NCT02259088|9986682|FG000|Overall Study|Lost to Follow-up|2
6278478|NCT02259088|9986683|FG001|Overall Study|Lost to Follow-up|0
6278479|NCT02259088|9986682|FG000|Overall Study|Death|2
6089040|NCT00680121|9700212|FG000|Overall Study|Lost to Follow-up|27
6278480|NCT02259088|9986683|FG001|Overall Study|Death|0
6278481|NCT02259088|9986682|FG000|Overall Study|Physician Decision|5
6278482|NCT02259088|9986683|FG001|Overall Study|Physician Decision|2
6278483|NCT02259088|9986682|FG000|Overall Study|Protocol deviation|5
6278484|NCT02259088|9986683|FG001|Overall Study|Protocol deviation|0
6278485|NCT02259088|9986682|FG000|Overall Study|Subject/guardian decision|8
6278486|NCT02259088|9986683|FG001|Overall Study|Subject/guardian decision|8
6278487|NCT02259114|9986694|FG000|Overall Study|Progressive Disease|14
6278488|NCT02259114|9986695|FG001|Overall Study|Progressive Disease|2
6278489|NCT02259114|9986696|FG002|Overall Study|Progressive Disease|10
6278490|NCT02259114|9986697|FG003|Overall Study|Progressive Disease|2
6278491|NCT02259114|9986698|FG004|Overall Study|Progressive Disease|5
6278492|NCT02259114|9986694|FG000|Overall Study|Adverse Event|2
6278493|NCT02259114|9986695|FG001|Overall Study|Adverse Event|1
6278494|NCT02259114|9986696|FG002|Overall Study|Adverse Event|0
6278495|NCT02259114|9986697|FG003|Overall Study|Adverse Event|0
6278496|NCT02259114|9986698|FG004|Overall Study|Adverse Event|1
6278497|NCT02259114|9986694|FG000|Overall Study|Death|3
6278498|NCT02259114|9986695|FG001|Overall Study|Death|0
6278499|NCT02259114|9986696|FG002|Overall Study|Death|1
6278500|NCT02259114|9986697|FG003|Overall Study|Death|0
6278501|NCT02259114|9986698|FG004|Overall Study|Death|0
6278502|NCT02259114|9986694|FG000|Overall Study|Treatment Delay >2 wks: Adverse Event|0
6278503|NCT02259114|9986695|FG001|Overall Study|Treatment Delay >2 wks: Adverse Event|0
6278504|NCT02259114|9986696|FG002|Overall Study|Treatment Delay >2 wks: Adverse Event|1
6278505|NCT02259114|9986697|FG003|Overall Study|Treatment Delay >2 wks: Adverse Event|0
6278506|NCT02259114|9986698|FG004|Overall Study|Treatment Delay >2 wks: Adverse Event|0
6278507|NCT02259114|9986694|FG000|Overall Study|Withdrawal by Subject|0
6278508|NCT02259114|9986695|FG001|Overall Study|Withdrawal by Subject|0
6278509|NCT02259114|9986696|FG002|Overall Study|Withdrawal by Subject|1
6278510|NCT02259114|9986697|FG003|Overall Study|Withdrawal by Subject|1
6278511|NCT02259114|9986698|FG004|Overall Study|Withdrawal by Subject|0
6278512|NCT02259114|9986694|FG000|Overall Study|Treatment Delay >2 wks: Toxicity|1
6278513|NCT02259114|9986695|FG001|Overall Study|Treatment Delay >2 wks: Toxicity|1
6278514|NCT02259114|9986696|FG002|Overall Study|Treatment Delay >2 wks: Toxicity|0
6278515|NCT02259114|9986697|FG003|Overall Study|Treatment Delay >2 wks: Toxicity|0
6278516|NCT02259114|9986698|FG004|Overall Study|Treatment Delay >2 wks: Toxicity|0
6278517|NCT02259114|9986694|FG000|Overall Study|Not Treated|1
6278518|NCT02259114|9986695|FG001|Overall Study|Not Treated|0
6278519|NCT02259114|9986696|FG002|Overall Study|Not Treated|0
6278520|NCT02259114|9986697|FG003|Overall Study|Not Treated|0
6278521|NCT02259114|9986698|FG004|Overall Study|Not Treated|0
6278522|NCT02259231|9986717|FG000|Overall Study|Adverse Event|1
6278523|NCT02259231|9986718|FG001|Overall Study|Adverse Event|1
6278524|NCT02259231|9986719|FG002|Overall Study|Adverse Event|2
6278525|NCT02259231|9986720|FG003|Overall Study|Adverse Event|0
6278526|NCT02259231|9986721|FG004|Overall Study|Adverse Event|0
6278527|NCT02259231|9986722|FG005|Overall Study|Adverse Event|0
6278528|NCT02259231|9986723|FG006|Overall Study|Adverse Event|0
6278529|NCT02259231|9986717|FG000|Overall Study|Progressive Disease|4
6278530|NCT02259231|9986718|FG001|Overall Study|Progressive Disease|5
6278531|NCT02259231|9986719|FG002|Overall Study|Progressive Disease|4
6278532|NCT02259231|9986720|FG003|Overall Study|Progressive Disease|5
6278533|NCT02259231|9986721|FG004|Overall Study|Progressive Disease|4
6278534|NCT02259231|9986722|FG005|Overall Study|Progressive Disease|5
6278535|NCT02259231|9986723|FG006|Overall Study|Progressive Disease|4
6278536|NCT02259231|9986717|FG000|Overall Study|Sponsor termination of study|1
6278537|NCT02259231|9986718|FG001|Overall Study|Sponsor termination of study|0
6278538|NCT02259231|9986719|FG002|Overall Study|Sponsor termination of study|0
6278539|NCT02259231|9986720|FG003|Overall Study|Sponsor termination of study|1
6089041|NCT00680121|9700213|FG001|Overall Study|Lost to Follow-up|23
6089042|NCT00680186|9700221|FG000|Overall Study|Adverse Event|47
6089043|NCT00680186|9700222|FG001|Overall Study|Adverse Event|44
6089044|NCT00680186|9700221|FG000|Overall Study|Protocol Violation|31
6089045|NCT00680186|9700222|FG001|Overall Study|Protocol Violation|26
6089046|NCT00680186|9700221|FG000|Overall Study|Lost to Follow-up|11
6089047|NCT00680186|9700222|FG001|Overall Study|Lost to Follow-up|6
6089048|NCT00680186|9700221|FG000|Overall Study|Withdrawal by Subject|32
6089049|NCT00680186|9700222|FG001|Overall Study|Withdrawal by Subject|39
6089050|NCT00680186|9700221|FG000|Overall Study|Other|4
6278540|NCT02259231|9986721|FG004|Overall Study|Sponsor termination of study|2
6278541|NCT02259231|9986722|FG005|Overall Study|Sponsor termination of study|1
6278542|NCT02259231|9986723|FG006|Overall Study|Sponsor termination of study|1
6278543|NCT02259348|9986739|FG000|Overall Study|Donors|6
6278544|NCT02259348|9986739|FG000|Overall Study|Death|4
6089051|NCT00680186|9700222|FG001|Overall Study|Other|1
6278545|NCT02259400|9986745|FG000|Overall Study|Death|0
6278546|NCT02259400|9986746|FG001|Overall Study|Death|2
6278547|NCT02259582|9986755|FG000|Overall Study|Physician Decision|0
6278548|NCT02259582|9986756|FG001|Overall Study|Physician Decision|1
6278549|NCT02259582|9986757|FG002|Overall Study|Physician Decision|0
6278550|NCT02259582|9986755|FG000|Overall Study|Death|0
6278551|NCT02259582|9986756|FG001|Overall Study|Death|0
6278552|NCT02259582|9986757|FG002|Overall Study|Death|1
6278553|NCT02259582|9986755|FG000|Overall Study|Adverse Event|1
6278554|NCT02259582|9986756|FG001|Overall Study|Adverse Event|0
6278555|NCT02259582|9986757|FG002|Overall Study|Adverse Event|1
6278556|NCT02259582|9986755|FG000|Overall Study|Withdrawal by Subject|0
6278557|NCT02259582|9986756|FG001|Overall Study|Withdrawal by Subject|0
6278558|NCT02259582|9986757|FG002|Overall Study|Withdrawal by Subject|1
6278559|NCT02259582|9986755|FG000|Overall Study|Disease progression|14
6278560|NCT02259582|9986756|FG001|Overall Study|Disease progression|15
6278561|NCT02259582|9986757|FG002|Overall Study|Disease progression|17
6278562|NCT02259582|9986755|FG000|Overall Study|Lack of Subject Adherence to Protocol|1
6278563|NCT02259582|9986756|FG001|Overall Study|Lack of Subject Adherence to Protocol|1
6278564|NCT02259582|9986757|FG002|Overall Study|Lack of Subject Adherence to Protocol|1
6278565|NCT02260154|9986778|FG000|Overall Study|Screening failure|2
6278566|NCT02260180|9986786|FG000|Overall Study|Adverse Event|2
6278567|NCT02260180|9986787|FG001|Overall Study|Adverse Event|0
6278568|NCT02260180|9986788|FG002|Overall Study|Adverse Event|1
6278569|NCT02260258|9986798|FG000|Overall Study|2 patients in NMB arm and 1 in control arm had clinical changes that precluded drug administration|2
6278570|NCT02260258|9986799|FG001|Overall Study|2 patients in NMB arm and 1 in control arm had clinical changes that precluded drug administration|1
6278571|NCT02260388|9986810|FG000|Overall Study|Lost to Follow-up|2
6278572|NCT02260388|9986811|FG001|Overall Study|Lost to Follow-up|8
6278573|NCT02260388|9986812|FG002|Overall Study|Lost to Follow-up|3
6278574|NCT02260388|9986813|FG003|Overall Study|Lost to Follow-up|4
6278575|NCT02260492|9986839|FG000|Overall Study|Adverse Event|6
6278576|NCT02260492|9986840|FG001|Overall Study|Adverse Event|1
6278577|NCT02260492|9986841|FG002|Overall Study|Adverse Event|2
6278578|NCT02260492|9986839|FG000|Overall Study|Death|0
6278579|NCT02260492|9986840|FG001|Overall Study|Death|1
6278580|NCT02260492|9986841|FG002|Overall Study|Death|0
6278581|NCT02260492|9986839|FG000|Overall Study|Lost to Follow-up|12
6278582|NCT02260492|9986840|FG001|Overall Study|Lost to Follow-up|9
6278583|NCT02260492|9986841|FG002|Overall Study|Lost to Follow-up|0
6278584|NCT02260492|9986839|FG000|Overall Study|Physician Decision|2
6278585|NCT02260492|9986840|FG001|Overall Study|Physician Decision|0
6278586|NCT02260492|9986841|FG002|Overall Study|Physician Decision|1
6278587|NCT02260492|9986839|FG000|Overall Study|Withdrawal by Subject|3
6278588|NCT02260492|9986840|FG001|Overall Study|Withdrawal by Subject|2
6278589|NCT02260492|9986841|FG002|Overall Study|Withdrawal by Subject|2
6278590|NCT02260635|9986880|FG000|Double-Blind Treatment Period|Failure to Meet Randomization Criteria|1
6278591|NCT02260635|9986881|FG001|Double-Blind Treatment Period|Failure to Meet Randomization Criteria|2
6278592|NCT02260635|9986880|FG000|Open-Label Extension|Study Termination|25
6278593|NCT02260635|9986881|FG001|Open-Label Extension|Study Termination|25
6278594|NCT02260635|9986880|FG000|Open-Label Extension|Withdrawal by Subject|1
6278595|NCT02260635|9986881|FG001|Open-Label Extension|Withdrawal by Subject|0
6278596|NCT02260648|9986892|FG000|Overall Study|Adverse Event|3
6278597|NCT02260648|9986893|FG001|Overall Study|Adverse Event|0
6278598|NCT02260648|9986894|FG002|Overall Study|Adverse Event|1
6278599|NCT02260648|9986892|FG000|Overall Study|Withdrawal by Subject|1
6278600|NCT02260648|9986893|FG001|Overall Study|Withdrawal by Subject|1
6278601|NCT02260648|9986894|FG002|Overall Study|Withdrawal by Subject|0
6278602|NCT02260648|9986892|FG000|Overall Study|Protocol Violation|1
6278603|NCT02260648|9986893|FG001|Overall Study|Protocol Violation|0
6278604|NCT02260648|9986894|FG002|Overall Study|Protocol Violation|0
6278605|NCT02260648|9986892|FG000|Overall Study|Discontinue Due to Study Termination|13
6278606|NCT02260648|9986893|FG001|Overall Study|Discontinue Due to Study Termination|12
6278607|NCT02260648|9986894|FG002|Overall Study|Discontinue Due to Study Termination|7
6278608|NCT02260791|9986904|FG000|Overall Study|Lost to Follow-up|4
6278609|NCT02260791|9986905|FG001|Overall Study|Lost to Follow-up|4
6278610|NCT02260791|9986904|FG000|Overall Study|Lack of Efficacy|2
6278611|NCT02260791|9986905|FG001|Overall Study|Lack of Efficacy|1
6278612|NCT02260791|9986904|FG000|Overall Study|Adverse Event|13
6278613|NCT02260791|9986905|FG001|Overall Study|Adverse Event|9
6278614|NCT02260791|9986904|FG000|Overall Study|Death|1
6278615|NCT02260791|9986905|FG001|Overall Study|Death|0
6278616|NCT02260791|9986904|FG000|Overall Study|Withdrawal by Subject|11
6278617|NCT02260791|9986905|FG001|Overall Study|Withdrawal by Subject|16
6278618|NCT02260791|9986904|FG000|Overall Study|Screen failure|0
6278619|NCT02260791|9986905|FG001|Overall Study|Screen failure|1
6278620|NCT02260791|9986904|FG000|Overall Study|Protocol deviation|2
6278621|NCT02260791|9986905|FG001|Overall Study|Protocol deviation|3
6278622|NCT02260804|9986913|FG000|Induction Study Period|Protocol Violation|2
6278623|NCT02260804|9986914|FG001|Induction Study Period|Protocol Violation|0
6278624|NCT02260804|9986913|FG000|1st Year of the Maintenance Period (MP1)|Lack of Efficacy|6
6278625|NCT02260804|9986914|FG001|1st Year of the Maintenance Period (MP1)|Lack of Efficacy|9
6278626|NCT02260804|9986913|FG000|1st Year of the Maintenance Period (MP1)|Adverse Event|3
6278627|NCT02260804|9986914|FG001|1st Year of the Maintenance Period (MP1)|Adverse Event|1
6278628|NCT02260804|9986913|FG000|1st Year of the Maintenance Period (MP1)|Physician Decision|1
6278629|NCT02260804|9986914|FG001|1st Year of the Maintenance Period (MP1)|Physician Decision|3
6278630|NCT02260804|9986913|FG000|1st Year of the Maintenance Period (MP1)|Protocol Violation|1
6278631|NCT02260804|9986914|FG001|1st Year of the Maintenance Period (MP1)|Protocol Violation|0
6278632|NCT02260804|9986913|FG000|1st Year of the Maintenance Period (MP1)|Withdrawal by Subject|1
6278633|NCT02260804|9986914|FG001|1st Year of the Maintenance Period (MP1)|Withdrawal by Subject|0
6278634|NCT02260804|9986913|FG000|1st Year of the Maintenance Period (MP1)|Death|0
6278635|NCT02260804|9986914|FG001|1st Year of the Maintenance Period (MP1)|Death|1
6278636|NCT02260804|9986913|FG000|1st Year of the Maintenance Period (MP1)|Lost to Follow-up|0
6278637|NCT02260804|9986914|FG001|1st Year of the Maintenance Period (MP1)|Lost to Follow-up|1
6278638|NCT02260804|9986913|FG000|2nd Year of the Maintenance Period (MP2)|Lack of Efficacy|6
6278639|NCT02260804|9986914|FG001|2nd Year of the Maintenance Period (MP2)|Lack of Efficacy|5
6278640|NCT02260804|9986913|FG000|2nd Year of the Maintenance Period (MP2)|Adverse Event|3
6278641|NCT02260804|9986914|FG001|2nd Year of the Maintenance Period (MP2)|Adverse Event|0
6278642|NCT02260804|9986913|FG000|2nd Year of the Maintenance Period (MP2)|Withdrawal by Subject|0
6278643|NCT02260804|9986914|FG001|2nd Year of the Maintenance Period (MP2)|Withdrawal by Subject|1
6278644|NCT02260817|9986922|FG000|Overall Study|Lost to Follow-up|0
6278645|NCT02260817|9986923|FG001|Overall Study|Lost to Follow-up|14
6278646|NCT02260817|9986922|FG000|Overall Study|Androgen deprivation therapy, no biopsy|0
6278647|NCT02260817|9986923|FG001|Overall Study|Androgen deprivation therapy, no biopsy|7
6278648|NCT02260817|9986922|FG000|Overall Study|Observation, no biopsy|0
6278649|NCT02260817|9986923|FG001|Overall Study|Observation, no biopsy|1
6278650|NCT02260817|9986922|FG000|Overall Study|Biopsy infeasible, ADT & rad. therapy|0
6278651|NCT02260817|9986923|FG001|Overall Study|Biopsy infeasible, ADT & rad. therapy|1
6278652|NCT02260817|9986922|FG000|Overall Study|Protocol Violation|0
6278653|NCT02260817|9986923|FG001|Overall Study|Protocol Violation|14
6278654|NCT02260882|9986931|FG000|Overall Study|Protocol Violation|0
6278655|NCT02260882|9986932|FG001|Overall Study|Protocol Violation|1
6278656|NCT02260921|9986941|FG000|Overall Study|Adverse Event|1
6278657|NCT02260921|9986942|FG001|Overall Study|Adverse Event|0
6278658|NCT02260921|9986941|FG000|Overall Study|Lost to Follow-up|4
6278659|NCT02260921|9986942|FG001|Overall Study|Lost to Follow-up|3
6278660|NCT02260921|9986941|FG000|Overall Study|Withdraw Consent|4
6278661|NCT02260921|9986942|FG001|Overall Study|Withdraw Consent|1
6278662|NCT02260921|9986941|FG000|Overall Study|Death|1
6278663|NCT02260921|9986942|FG001|Overall Study|Death|0
6278664|NCT02260921|9986941|FG000|Overall Study|Prohibited Treatment for Knee Pain|4
6278665|NCT02260921|9986942|FG001|Overall Study|Prohibited Treatment for Knee Pain|0
6278666|NCT02260934|9986950|FG000|Overall Study|Lost to Follow-up|2
6278667|NCT02260934|9986951|FG001|Overall Study|Lost to Follow-up|1
6278668|NCT02260934|9986950|FG000|Overall Study|Withdrawal by Subject|0
6278669|NCT02260934|9986951|FG001|Overall Study|Withdrawal by Subject|2
6278670|NCT02260934|9986950|FG000|Overall Study|Participant Relocated|1
6278671|NCT02260934|9986951|FG001|Overall Study|Participant Relocated|0
6278672|NCT02260934|9986950|FG000|Overall Study|Site error|0
6278673|NCT02260934|9986951|FG001|Overall Study|Site error|1
6278674|NCT02260986|9986967|FG000|Overall Study|Adverse Event|24
6278675|NCT02260986|9986968|FG001|Overall Study|Adverse Event|0
6278676|NCT02260986|9986969|FG002|Overall Study|Adverse Event|11
6278677|NCT02260986|9986967|FG000|Overall Study|Lack of Efficacy|27
6278678|NCT02260986|9986968|FG001|Overall Study|Lack of Efficacy|3
6278679|NCT02260986|9986969|FG002|Overall Study|Lack of Efficacy|0
6278680|NCT02260986|9986967|FG000|Overall Study|Protocol Violation|14
6278681|NCT02260986|9986968|FG001|Overall Study|Protocol Violation|5
6278682|NCT02260986|9986969|FG002|Overall Study|Protocol Violation|16
6278683|NCT02260986|9986967|FG000|Overall Study|Car accident|0
6278684|NCT02260986|9986968|FG001|Overall Study|Car accident|0
6278685|NCT02260986|9986969|FG002|Overall Study|Car accident|1
6278686|NCT02260986|9986967|FG000|Overall Study|Withdrawal by Subject|17
6278687|NCT02260986|9986968|FG001|Overall Study|Withdrawal by Subject|4
6278688|NCT02260986|9986969|FG002|Overall Study|Withdrawal by Subject|9
6278689|NCT02260986|9986967|FG000|Overall Study|Incorrect randomization|0
6278690|NCT02260986|9986968|FG001|Overall Study|Incorrect randomization|1
6278691|NCT02260986|9986969|FG002|Overall Study|Incorrect randomization|0
6278692|NCT02260986|9986967|FG000|Overall Study|Lack of investigation product supply|2
6278693|NCT02260986|9986968|FG001|Overall Study|Lack of investigation product supply|0
6278694|NCT02260986|9986969|FG002|Overall Study|Lack of investigation product supply|1
6278695|NCT02260986|9986967|FG000|Overall Study|Lost to Follow-up|4
6278696|NCT02260986|9986968|FG001|Overall Study|Lost to Follow-up|0
6278697|NCT02260986|9986969|FG002|Overall Study|Lost to Follow-up|3
6278698|NCT02260986|9986967|FG000|Overall Study|Pregnancy|2
6278699|NCT02260986|9986968|FG001|Overall Study|Pregnancy|0
6278700|NCT02260986|9986969|FG002|Overall Study|Pregnancy|0
6278701|NCT02261467|9987005|FG000|Overall Study|Enrolled in Error|1
5977742|NCT03290781|9565030|FG001|Overall Study|Site Terminated by Sponsor|0
6278702|NCT02261467|9987006|FG001|Overall Study|Enrolled in Error|0
6278703|NCT02261467|9987005|FG000|Overall Study|Protocol Violation|0
6278704|NCT02261467|9987006|FG001|Overall Study|Protocol Violation|1
6278705|NCT02261467|9987005|FG000|Overall Study|Personal Reasons|17
6050903|NCT00430248|9650174|FG002|Overall Study|Inclusion/Exclusion Criteria Not Met|0
6050904|NCT00430248|9650172|FG000|Overall Study|Gout Flare|3
6050905|NCT00430248|9650173|FG001|Overall Study|Gout Flare|7
6278706|NCT02261467|9987006|FG001|Overall Study|Personal Reasons|22
6278707|NCT02261467|9987005|FG000|Overall Study|Lost to Follow-up|2
6278708|NCT02261467|9987006|FG001|Overall Study|Lost to Follow-up|13
6278709|NCT02261467|9987005|FG000|Overall Study|Adverse Event|1
6278710|NCT02261467|9987006|FG001|Overall Study|Adverse Event|1
6278711|NCT02261493|9987015|FG000|Overall Study|Noncompliance|0
6278712|NCT02261493|9987016|FG001|Overall Study|Noncompliance|0
6278713|NCT02261493|9987017|FG002|Overall Study|Noncompliance|2
6278714|NCT02261493|9987015|FG000|Overall Study|Physician Decision|0
6278715|NCT02261493|9987016|FG001|Overall Study|Physician Decision|1
6278716|NCT02261493|9987017|FG002|Overall Study|Physician Decision|0
6278717|NCT02261493|9987015|FG000|Overall Study|Undisclosed alcohol abuse|0
6278718|NCT02261493|9987016|FG001|Overall Study|Undisclosed alcohol abuse|1
6278719|NCT02261493|9987017|FG002|Overall Study|Undisclosed alcohol abuse|0
6278720|NCT02261493|9987015|FG000|Overall Study|Protocol Violation|1
6278721|NCT02261493|9987016|FG001|Overall Study|Protocol Violation|0
5977743|NCT03290781|9565031|FG002|Overall Study|Site Terminated by Sponsor|2
5977744|NCT03290781|9565032|FG003|Overall Study|Site Terminated by Sponsor|1
5977745|NCT03290781|9565033|FG004|Overall Study|Site Terminated by Sponsor|0
5977746|NCT03290781|9565034|FG005|Overall Study|Site Terminated by Sponsor|0
5977747|NCT03290781|9565035|FG006|Overall Study|Site Terminated by Sponsor|0
5977748|NCT03290781|9565029|FG000|Overall Study|Lost to Follow-up|0
5977749|NCT03290781|9565030|FG001|Overall Study|Lost to Follow-up|0
5977750|NCT03290781|9565031|FG002|Overall Study|Lost to Follow-up|0
5977751|NCT03290781|9565032|FG003|Overall Study|Lost to Follow-up|1
5977752|NCT03290781|9565033|FG004|Overall Study|Lost to Follow-up|0
5977753|NCT03290781|9565034|FG005|Overall Study|Lost to Follow-up|0
5977754|NCT03290781|9565035|FG006|Overall Study|Lost to Follow-up|0
5977755|NCT03290781|9565029|FG000|Overall Study|Protocol Deviation|2
5977756|NCT03290781|9565030|FG001|Overall Study|Protocol Deviation|0
5977757|NCT03290781|9565031|FG002|Overall Study|Protocol Deviation|0
5977758|NCT03290781|9565032|FG003|Overall Study|Protocol Deviation|1
5977759|NCT03290781|9565033|FG004|Overall Study|Protocol Deviation|0
5977760|NCT03290781|9565034|FG005|Overall Study|Protocol Deviation|0
5977761|NCT03290781|9565035|FG006|Overall Study|Protocol Deviation|0
5977762|NCT03290781|9565029|FG000|Overall Study|Disease Relapse|32
5977763|NCT03290781|9565030|FG001|Overall Study|Disease Relapse|5
5977764|NCT03290781|9565031|FG002|Overall Study|Disease Relapse|38
5977765|NCT03290781|9565032|FG003|Overall Study|Disease Relapse|7
5977766|NCT03290781|9565033|FG004|Overall Study|Disease Relapse|3
5977767|NCT03290781|9565034|FG005|Overall Study|Disease Relapse|1
5977768|NCT03290781|9565035|FG006|Overall Study|Disease Relapse|4
5977769|NCT03290781|9565029|FG000|Overall Study|Other|3
5977770|NCT03290781|9565030|FG001|Overall Study|Other|0
5977771|NCT03290781|9565031|FG002|Overall Study|Other|2
5977772|NCT03290781|9565032|FG003|Overall Study|Other|2
5977773|NCT03290781|9565033|FG004|Overall Study|Other|0
5977774|NCT03290781|9565034|FG005|Overall Study|Other|0
5977775|NCT03290781|9565035|FG006|Overall Study|Other|0
5977776|NCT03228680|9565094|FG000|Overall Study|Adverse Event|13
5977777|NCT03228680|9565095|FG001|Overall Study|Adverse Event|18
5977778|NCT03228680|9565094|FG000|Overall Study|Randomization failure|0
5977779|NCT03228680|9565095|FG001|Overall Study|Randomization failure|1
5977780|NCT03228680|9565094|FG000|Overall Study|Withdrawal by Subject|1
5977781|NCT03228680|9565095|FG001|Overall Study|Withdrawal by Subject|0
5977782|NCT03228680|9565094|FG000|Overall Study|Other|9
5977783|NCT03228680|9565095|FG001|Overall Study|Other|16
5977784|NCT02679781|9565135|FG000|Overall Study|Lost to Follow-up|1
5977785|NCT02679781|9565136|FG001|Overall Study|Lost to Follow-up|2
5977786|NCT02679781|9565135|FG000|Overall Study|low cooperation, referral to treatment under general anesthesia|6
5977787|NCT02679781|9565136|FG001|Overall Study|low cooperation, referral to treatment under general anesthesia|1
5977788|NCT02624869|9565145|FG000|Overall Study|Lost to Follow-up|0
5977789|NCT02624869|9565146|FG001|Overall Study|Lost to Follow-up|0
5977790|NCT02624869|9565147|FG002|Overall Study|Lost to Follow-up|1
5977791|NCT02624869|9565145|FG000|Overall Study|Withdrawal by Subject|1
5977792|NCT02624869|9565146|FG001|Overall Study|Withdrawal by Subject|3
5977793|NCT02624869|9565147|FG002|Overall Study|Withdrawal by Subject|1
5977794|NCT02569242|9565171|FG000|Overall Study|Death|1
5977795|NCT02569242|9565172|FG001|Overall Study|Death|0
5977796|NCT02569242|9565171|FG000|Overall Study|Withdrawal by Subject|0
5977797|NCT02569242|9565172|FG001|Overall Study|Withdrawal by Subject|1
5977798|NCT02435433|9565195|FG000|Overall Study|On Treatment|11
5977799|NCT02435433|9565196|FG001|Overall Study|On Treatment|0
5977800|NCT02435433|9565197|FG002|Overall Study|On Treatment|0
5977801|NCT02435433|9565198|FG003|Overall Study|On Treatment|0
5977802|NCT02435433|9565199|FG004|Overall Study|On Treatment|0
5977803|NCT02435433|9565195|FG000|Overall Study|Withdrawal by Subject|2
6278722|NCT02261493|9987017|FG002|Overall Study|Protocol Violation|0
6278723|NCT02261493|9987015|FG000|Overall Study|Personal Reasons|14
5977804|NCT02435433|9565196|FG001|Overall Study|Withdrawal by Subject|3
5977805|NCT02435433|9565197|FG002|Overall Study|Withdrawal by Subject|0
5977806|NCT02435433|9565198|FG003|Overall Study|Withdrawal by Subject|0
5977807|NCT02435433|9565199|FG004|Overall Study|Withdrawal by Subject|0
6278724|NCT02261493|9987016|FG001|Overall Study|Personal Reasons|14
6278725|NCT02261493|9987017|FG002|Overall Study|Personal Reasons|16
6278726|NCT02261493|9987015|FG000|Overall Study|Lost to Follow-up|14
6278727|NCT02261493|9987016|FG001|Overall Study|Lost to Follow-up|27
6278728|NCT02261493|9987017|FG002|Overall Study|Lost to Follow-up|8
6278729|NCT02261493|9987015|FG000|Overall Study|Pregnancy|1
6278730|NCT02261493|9987016|FG001|Overall Study|Pregnancy|2
6278731|NCT02261493|9987017|FG002|Overall Study|Pregnancy|0
6278732|NCT02261493|9987015|FG000|Overall Study|Lack of Efficacy|0
6278733|NCT02261493|9987016|FG001|Overall Study|Lack of Efficacy|1
6278734|NCT02261493|9987017|FG002|Overall Study|Lack of Efficacy|0
6278735|NCT02261493|9987015|FG000|Overall Study|Adverse Event|0
6278736|NCT02261493|9987016|FG001|Overall Study|Adverse Event|1
6278737|NCT02261493|9987017|FG002|Overall Study|Adverse Event|0
6278738|NCT02261974|9987095|FG000|Overall Study|Withdrawal by Subject|3
6278739|NCT02261974|9987096|FG001|Overall Study|Withdrawal by Subject|2
6278740|NCT02261974|9987095|FG000|Overall Study|Pregnancy|0
6278741|NCT02261974|9987096|FG001|Overall Study|Pregnancy|1
6278742|NCT02261974|9987095|FG000|Overall Study|Missed treatment cut-off date|6
6278743|NCT02261974|9987096|FG001|Overall Study|Missed treatment cut-off date|3
6278744|NCT02261974|9987095|FG000|Overall Study|Received partial treatment; FU to 1 mo|3
6278745|NCT02261974|9987096|FG001|Overall Study|Received partial treatment; FU to 1 mo|1
6278746|NCT02261974|9987095|FG000|Overall Study|Lost to Follow-up|2
6278747|NCT02261974|9987096|FG001|Overall Study|Lost to Follow-up|0
6278748|NCT02261974|9987095|FG000|Overall Study|Adverse Event|1
6278749|NCT02261974|9987096|FG001|Overall Study|Adverse Event|0
6278750|NCT02262260|9987126|FG000|Overall Study|Adverse Event|4
6278751|NCT02262260|9987127|FG001|Overall Study|Adverse Event|1
6278752|NCT02262260|9987126|FG000|Overall Study|Withdrawal of consent|4
6278753|NCT02262260|9987127|FG001|Overall Study|Withdrawal of consent|2
6278754|NCT02262260|9987126|FG000|Overall Study|Lost to Follow-up|1
6278755|NCT02262260|9987127|FG001|Overall Study|Lost to Follow-up|2
6278756|NCT02262260|9987126|FG000|Overall Study|Protocol deviation|2
6278757|NCT02262260|9987127|FG001|Overall Study|Protocol deviation|5
6278758|NCT02262364|9987133|FG000|Blood Draw for Device Processing|Insufficient blood could be drawn|1
6278759|NCT02262377|9987139|FG000|Overall Study|Lost to Follow-up|5
6278760|NCT02262377|9987140|FG001|Overall Study|Lost to Follow-up|6
6278761|NCT02262377|9987139|FG000|Overall Study|Found ineligible after enrollment|3
6278762|NCT02262377|9987140|FG001|Overall Study|Found ineligible after enrollment|0
6278763|NCT02262377|9987139|FG000|Overall Study|Withdrawal by Subject|4
6278764|NCT02262377|9987140|FG001|Overall Study|Withdrawal by Subject|0
6278765|NCT02262728|9987154|FG000|Follow-up Phase (3 Years)|Death|0
6278766|NCT02262728|9987155|FG001|Follow-up Phase (3 Years)|Death|1
6278767|NCT02262728|9987154|FG000|Follow-up Phase (3 Years)|Lost to Follow-up|4
6278768|NCT02262728|9987155|FG001|Follow-up Phase (3 Years)|Lost to Follow-up|1
6278769|NCT02262728|9987154|FG000|Follow-up Phase (3 Years)|Withdrawal by Subject|0
6278770|NCT02262728|9987155|FG001|Follow-up Phase (3 Years)|Withdrawal by Subject|1
6278771|NCT02262754|9987164|FG000|Overall Study|Adverse Event|3
6278772|NCT02262754|9987165|FG001|Overall Study|Adverse Event|4
6278773|NCT02262754|9987166|FG002|Overall Study|Adverse Event|0
6278774|NCT02262754|9987164|FG000|Overall Study|Lack of Efficacy|2
6278775|NCT02262754|9987165|FG001|Overall Study|Lack of Efficacy|0
6278776|NCT02262754|9987166|FG002|Overall Study|Lack of Efficacy|1
6278777|NCT02262754|9987164|FG000|Overall Study|Lost to Follow-up|0
5977808|NCT02435433|9565195|FG000|Overall Study|Lost to Follow-up|2
5977809|NCT02435433|9565196|FG001|Overall Study|Lost to Follow-up|2
5977810|NCT02435433|9565197|FG002|Overall Study|Lost to Follow-up|0
5977811|NCT02435433|9565198|FG003|Overall Study|Lost to Follow-up|0
5977812|NCT02435433|9565199|FG004|Overall Study|Lost to Follow-up|0
5977813|NCT02426125|9565209|FG000|Overall Study|Lost to Follow-up|12
5977814|NCT02426125|9565210|FG001|Overall Study|Lost to Follow-up|10
5977815|NCT02426125|9565209|FG000|Overall Study|Protocol Violation|1
5977816|NCT02426125|9565210|FG001|Overall Study|Protocol Violation|0
5977817|NCT02426125|9565209|FG000|Overall Study|Withdrawal by Subject|16
5977818|NCT02426125|9565210|FG001|Overall Study|Withdrawal by Subject|16
5977819|NCT02368886|9565231|FG000|Overall Study|Cancel|1
5977820|NCT02368886|9565232|FG001|Overall Study|Cancel|1
5977821|NCT02368886|9565233|FG002|Overall Study|Cancel|1
5977822|NCT02368886|9565234|FG003|Overall Study|Cancel|3
5977823|NCT02368886|9565231|FG000|Overall Study|Ineligible|0
5977824|NCT02368886|9565232|FG001|Overall Study|Ineligible|0
5977825|NCT02368886|9565233|FG002|Overall Study|Ineligible|0
5977826|NCT02368886|9565234|FG003|Overall Study|Ineligible|1
6278778|NCT02262754|9987165|FG001|Overall Study|Lost to Follow-up|0
6278779|NCT02262754|9987166|FG002|Overall Study|Lost to Follow-up|1
6278780|NCT02262754|9987164|FG000|Overall Study|No longer meets eligibility criteria|0
6278781|NCT02262754|9987165|FG001|Overall Study|No longer meets eligibility criteria|1
6278782|NCT02262754|9987166|FG002|Overall Study|No longer meets eligibility criteria|0
6278783|NCT02262754|9987164|FG000|Overall Study|Study terminated by sponsor|5
6278784|NCT02262754|9987165|FG001|Overall Study|Study terminated by sponsor|4
5977827|NCT02354703|9565246|FG000|Overall Study|Withdrawal by Subject|1
5977828|NCT02354703|9565247|FG001|Overall Study|Withdrawal by Subject|1
5977829|NCT02354703|9565248|FG002|Overall Study|Withdrawal by Subject|1
5977830|NCT02354703|9565249|FG003|Overall Study|Withdrawal by Subject|1
5977831|NCT02354703|9565246|FG000|Overall Study|Lost to Follow-up|2
6278785|NCT02262754|9987166|FG002|Overall Study|Study terminated by sponsor|4
6278786|NCT02262754|9987164|FG000|Overall Study|Protocol Violation|1
6278787|NCT02262754|9987165|FG001|Overall Study|Protocol Violation|0
6278788|NCT02262754|9987166|FG002|Overall Study|Protocol Violation|0
6278789|NCT02262754|9987164|FG000|Overall Study|Withdrawal by Subject|1
6278790|NCT02262754|9987165|FG001|Overall Study|Withdrawal by Subject|0
6278791|NCT02262754|9987166|FG002|Overall Study|Withdrawal by Subject|1
6278792|NCT02262754|9987164|FG000|Overall Study|Other|4
6278793|NCT02262754|9987165|FG001|Overall Study|Other|0
6278794|NCT02262754|9987166|FG002|Overall Study|Other|2
6278795|NCT02263079|9987203|FG000|Overall Study|Physician Decision|1
6278796|NCT02263079|9987204|FG001|Overall Study|Physician Decision|0
6278797|NCT02263079|9987205|FG002|Overall Study|Physician Decision|0
6278798|NCT02263079|9987203|FG000|Overall Study|Withdrawal by Subject|2
6278799|NCT02263079|9987204|FG001|Overall Study|Withdrawal by Subject|8
6278800|NCT02263079|9987205|FG002|Overall Study|Withdrawal by Subject|0
6278801|NCT02263326|9987243|FG000|Overall Study|Lost to Follow-up|1
6278802|NCT02263326|9987244|FG001|Overall Study|Lost to Follow-up|1
6278803|NCT02263547|9987250|FG000|Overall Study|Adverse Event|1
6278804|NCT02263547|9987250|FG000|Overall Study|Lost to Follow-up|2
6278805|NCT02264574|9987297|FG000|Overall Study|Death|21
6278806|NCT02264574|9987298|FG001|Overall Study|Death|21
6278807|NCT02264574|9987297|FG000|Overall Study|Withdrawal by Subject|8
6278808|NCT02264574|9987298|FG001|Overall Study|Withdrawal by Subject|6
6278809|NCT02264574|9987297|FG000|Overall Study|Other, Not Specified|0
6278810|NCT02264574|9987298|FG001|Overall Study|Other, Not Specified|3
6278811|NCT02264639|9987309|FG000|Overall Study|Death (after completing single-dose phase)|1
6278812|NCT02264639|9987310|FG001|Overall Study|Death (after completing single-dose phase)|0
6278813|NCT02264639|9987311|FG002|Overall Study|Death (after completing single-dose phase)|0
6278814|NCT02264639|9987312|FG003|Overall Study|Death (after completing single-dose phase)|0
6278815|NCT02264639|9987313|FG004|Overall Study|Death (after completing single-dose phase)|0
6278816|NCT02264639|9987309|FG000|Overall Study|Withdrawal by subject (during multiple-dose phase)|1
6278817|NCT02264639|9987310|FG001|Overall Study|Withdrawal by subject (during multiple-dose phase)|0
6278818|NCT02264639|9987311|FG002|Overall Study|Withdrawal by subject (during multiple-dose phase)|0
6278819|NCT02264639|9987312|FG003|Overall Study|Withdrawal by subject (during multiple-dose phase)|0
6278820|NCT02264639|9987313|FG004|Overall Study|Withdrawal by subject (during multiple-dose phase)|0
6278821|NCT02264639|9987309|FG000|Overall Study|Pregnancy (during multiple-dose phase)|0
6278822|NCT02264639|9987310|FG001|Overall Study|Pregnancy (during multiple-dose phase)|0
6278823|NCT02264639|9987311|FG002|Overall Study|Pregnancy (during multiple-dose phase)|1
6278824|NCT02264639|9987312|FG003|Overall Study|Pregnancy (during multiple-dose phase)|0
6278825|NCT02264639|9987313|FG004|Overall Study|Pregnancy (during multiple-dose phase)|0
6278826|NCT02264639|9987309|FG000|Overall Study|Major Intercurrent Illness (during multiple-dose phase)|0
6278827|NCT02264639|9987310|FG001|Overall Study|Major Intercurrent Illness (during multiple-dose phase)|0
6278828|NCT02264639|9987311|FG002|Overall Study|Major Intercurrent Illness (during multiple-dose phase)|0
5977832|NCT02354703|9565247|FG001|Overall Study|Lost to Follow-up|7
5977833|NCT02354703|9565248|FG002|Overall Study|Lost to Follow-up|9
5977834|NCT02354703|9565249|FG003|Overall Study|Lost to Follow-up|2
5977835|NCT02354703|9565246|FG000|Overall Study|Adverse Event|0
5977836|NCT02354703|9565247|FG001|Overall Study|Adverse Event|0
5977837|NCT02354703|9565248|FG002|Overall Study|Adverse Event|1
5977838|NCT02354703|9565249|FG003|Overall Study|Adverse Event|0
6050906|NCT00430248|9650174|FG002|Overall Study|Gout Flare|2
6050907|NCT00430248|9650172|FG000|Overall Study|Reason Not Specified|8
6050908|NCT00430248|9650173|FG001|Overall Study|Reason Not Specified|8
6050909|NCT00430248|9650174|FG002|Overall Study|Reason Not Specified|11
6050910|NCT00430300|9650186|FG000|Overall Study|Adverse Event|0
6050911|NCT00430300|9650187|FG001|Overall Study|Adverse Event|2
6050912|NCT00430300|9650188|FG002|Overall Study|Adverse Event|1
6050913|NCT00430300|9650189|FG003|Overall Study|Adverse Event|1
6050914|NCT00430300|9650186|FG000|Overall Study|Withdrawal by Subject|1
6050915|NCT00430300|9650187|FG001|Overall Study|Withdrawal by Subject|0
6050916|NCT00430300|9650188|FG002|Overall Study|Withdrawal by Subject|5
6050917|NCT00430300|9650189|FG003|Overall Study|Withdrawal by Subject|0
6050918|NCT00430300|9650186|FG000|Overall Study|Laboratory abnormality|1
6050919|NCT00430300|9650187|FG001|Overall Study|Laboratory abnormality|0
6050920|NCT00430300|9650188|FG002|Overall Study|Laboratory abnormality|0
6050921|NCT00430300|9650189|FG003|Overall Study|Laboratory abnormality|0
6050922|NCT00430300|9650186|FG000|Overall Study|Other|0
6050923|NCT00430300|9650187|FG001|Overall Study|Other|0
6050924|NCT00430300|9650188|FG002|Overall Study|Other|0
6050925|NCT00430300|9650189|FG003|Overall Study|Other|1
6050926|NCT00430352|9650199|FG000|Overall Study|Disease progression|58
6050927|NCT00430352|9650199|FG000|Overall Study|Withdrawal by Subject|11
6050928|NCT00430352|9650199|FG000|Overall Study|Adverse Event|16
6050929|NCT00430352|9650199|FG000|Overall Study|Death|5
6050930|NCT00430352|9650199|FG000|Overall Study|Other|48
6050931|NCT00430482|9650205|FG000|Completed Treatment|Insufficient Treatment|7
6050932|NCT00430482|9650206|FG001|Completed Treatment|Insufficient Treatment|11
6050933|NCT00430495|9650216|FG000|Overall Study|Adverse Event|2
6050934|NCT00430495|9650217|FG001|Overall Study|Adverse Event|3
6050935|NCT00430495|9650218|FG002|Overall Study|Adverse Event|2
6278829|NCT02264639|9987312|FG003|Overall Study|Major Intercurrent Illness (during multiple-dose phase)|0
6278830|NCT02264639|9987313|FG004|Overall Study|Major Intercurrent Illness (during multiple-dose phase)|1
6278831|NCT02264821|9987331|FG000|Overall Study|Protocol Violation|1
6278832|NCT02264821|9987332|FG001|Overall Study|Protocol Violation|3
6278833|NCT02264821|9987333|FG002|Overall Study|Protocol Violation|6
6278834|NCT02264990|9987343|FG000|Overall Study|Death|255
6278835|NCT02264990|9987344|FG001|Overall Study|Death|250
6278836|NCT02264990|9987343|FG000|Overall Study|Withdrawal by Subject|4
6278837|NCT02264990|9987344|FG001|Overall Study|Withdrawal by Subject|5
6278838|NCT02264990|9987343|FG000|Overall Study|Lost to Follow-up|1
6278839|NCT02264990|9987344|FG001|Overall Study|Lost to Follow-up|3
6278840|NCT02264990|9987343|FG000|Overall Study|Other|0
6278841|NCT02264990|9987344|FG001|Overall Study|Other|1
6278842|NCT02265237|9987362|FG000|As Treated (Overall Study)|Adverse Event|1
6278843|NCT02265237|9987363|FG001|As Treated (Overall Study)|Adverse Event|1
6278844|NCT02265237|9987364|FG002|As Treated (Overall Study)|Adverse Event|0
6278845|NCT02265237|9987365|FG003|As Treated (Overall Study)|Adverse Event|0
6278846|NCT02265237|9987362|FG000|As Treated (Overall Study)|Withdrawal by Subject|1
6278847|NCT02265237|9987363|FG001|As Treated (Overall Study)|Withdrawal by Subject|0
6278848|NCT02265237|9987364|FG002|As Treated (Overall Study)|Withdrawal by Subject|1
6278849|NCT02265237|9987365|FG003|As Treated (Overall Study)|Withdrawal by Subject|0
6278850|NCT02265237|9987362|FG000|As Treated (Overall Study)|Lost to Follow-up|1
6278851|NCT02265237|9987363|FG001|As Treated (Overall Study)|Lost to Follow-up|2
6278852|NCT02265237|9987364|FG002|As Treated (Overall Study)|Lost to Follow-up|6
6278853|NCT02265237|9987365|FG003|As Treated (Overall Study)|Lost to Follow-up|0
5977839|NCT01981551|9565261|FG000|Overall Study|Refused further treatment|8
5977840|NCT01981551|9565261|FG000|Overall Study|Adverse Event|1
5977841|NCT00468130|9565271|FG000|Overall Study|Adverse Event|2
5977842|NCT00468130|9565272|FG001|Overall Study|Adverse Event|1
5977843|NCT00468130|9565271|FG000|Overall Study|Withdrawal by Subject|0
5977844|NCT00468130|9565272|FG001|Overall Study|Withdrawal by Subject|1
5977845|NCT00384111|9565280|FG000|Overall Study|Disease Progression|3
5977846|NCT00384111|9565280|FG000|Overall Study|Adverse Event|1
5977847|NCT00384111|9565280|FG000|Overall Study|Investigator Decision|3
5977848|NCT00384111|9565280|FG000|Overall Study|Study Terminated by the Sponsor|19
6050936|NCT00430495|9650219|FG003|Overall Study|Adverse Event|0
6050937|NCT00430495|9650216|FG000|Overall Study|Death|0
6050938|NCT00430495|9650217|FG001|Overall Study|Death|0
6050939|NCT00430495|9650218|FG002|Overall Study|Death|1
6050940|NCT00430495|9650219|FG003|Overall Study|Death|0
6050941|NCT00430495|9650216|FG000|Overall Study|Lost to Follow-up|0
6050942|NCT00430495|9650217|FG001|Overall Study|Lost to Follow-up|1
6050943|NCT00430495|9650218|FG002|Overall Study|Lost to Follow-up|4
6050944|NCT00430495|9650219|FG003|Overall Study|Lost to Follow-up|0
6050945|NCT00430495|9650216|FG000|Overall Study|Protocol Violation|1
6050946|NCT00430495|9650217|FG001|Overall Study|Protocol Violation|0
6050947|NCT00430495|9650218|FG002|Overall Study|Protocol Violation|1
6050948|NCT00430495|9650219|FG003|Overall Study|Protocol Violation|0
6050949|NCT00430495|9650216|FG000|Overall Study|Disease Progression|1
6050950|NCT00430495|9650217|FG001|Overall Study|Disease Progression|1
6050951|NCT00430495|9650218|FG002|Overall Study|Disease Progression|0
6050952|NCT00430495|9650219|FG003|Overall Study|Disease Progression|0
6050953|NCT00430495|9650216|FG000|Overall Study|Other|8
6050954|NCT00430495|9650217|FG001|Overall Study|Other|2
6050955|NCT00430495|9650218|FG002|Overall Study|Other|5
6050956|NCT00430495|9650219|FG003|Overall Study|Other|4
6050957|NCT00430495|9650216|FG000|Overall Study|Randomized but not Treated|2
6050958|NCT00430495|9650217|FG001|Overall Study|Randomized but not Treated|0
6050959|NCT00430495|9650218|FG002|Overall Study|Randomized but not Treated|0
6050960|NCT00430495|9650219|FG003|Overall Study|Randomized but not Treated|0
6050961|NCT00430521|9650237|FG000|Overall Study|Adverse Event|0
6050962|NCT00430521|9650238|FG001|Overall Study|Adverse Event|0
6050963|NCT00430521|9650239|FG002|Overall Study|Adverse Event|0
6050964|NCT00430521|9650240|FG003|Overall Study|Adverse Event|0
6050965|NCT00430521|9650241|FG004|Overall Study|Adverse Event|0
6050966|NCT00430521|9650242|FG005|Overall Study|Adverse Event|2
6050967|NCT00430521|9650243|FG006|Overall Study|Adverse Event|1
6050968|NCT00430521|9650244|FG007|Overall Study|Adverse Event|0
6050969|NCT00430521|9650237|FG000|Overall Study|Lost to Follow-up|7
6050970|NCT00430521|9650238|FG001|Overall Study|Lost to Follow-up|8
6050971|NCT00430521|9650239|FG002|Overall Study|Lost to Follow-up|3
6050972|NCT00430521|9650240|FG003|Overall Study|Lost to Follow-up|5
6050973|NCT00430521|9650241|FG004|Overall Study|Lost to Follow-up|5
6278854|NCT02265237|9987362|FG000|As Treated (Overall Study)|Other|2
6278855|NCT02265237|9987363|FG001|As Treated (Overall Study)|Other|0
6278856|NCT02265237|9987364|FG002|As Treated (Overall Study)|Other|3
6050974|NCT00430521|9650242|FG005|Overall Study|Lost to Follow-up|2
6050975|NCT00430521|9650243|FG006|Overall Study|Lost to Follow-up|8
6050976|NCT00430521|9650244|FG007|Overall Study|Lost to Follow-up|10
6050977|NCT00430521|9650237|FG000|Overall Study|Pregnancy|0
6050978|NCT00430521|9650238|FG001|Overall Study|Pregnancy|0
6050979|NCT00430521|9650239|FG002|Overall Study|Pregnancy|0
6050980|NCT00430521|9650240|FG003|Overall Study|Pregnancy|0
6050981|NCT00430521|9650241|FG004|Overall Study|Pregnancy|0
6050982|NCT00430521|9650242|FG005|Overall Study|Pregnancy|0
6278857|NCT02265237|9987365|FG003|As Treated (Overall Study)|Other|1
6278858|NCT02265510|9987394|FG000|Overall Study|Withdrawal by Subject|1
6278859|NCT02265510|9987395|FG001|Overall Study|Withdrawal by Subject|1
6278860|NCT02265510|9987396|FG002|Overall Study|Withdrawal by Subject|2
6278861|NCT02265510|9987397|FG003|Overall Study|Withdrawal by Subject|1
6278862|NCT02265510|9987398|FG004|Overall Study|Withdrawal by Subject|0
6278863|NCT02265510|9987399|FG005|Overall Study|Withdrawal by Subject|2
6278864|NCT02265510|9987400|FG006|Overall Study|Withdrawal by Subject|0
6278865|NCT02265510|9987401|FG007|Overall Study|Withdrawal by Subject|2
6278866|NCT02265510|9987402|FG008|Overall Study|Withdrawal by Subject|0
6278867|NCT02265510|9987403|FG009|Overall Study|Withdrawal by Subject|0
6278868|NCT02265510|9987404|FG010|Overall Study|Withdrawal by Subject|0
6278869|NCT02265510|9987405|FG011|Overall Study|Withdrawal by Subject|0
6278870|NCT02265510|9987406|FG012|Overall Study|Withdrawal by Subject|1
6278871|NCT02265510|9987407|FG013|Overall Study|Withdrawal by Subject|0
6278872|NCT02265510|9987394|FG000|Overall Study|Disease Progression|0
6278873|NCT02265510|9987395|FG001|Overall Study|Disease Progression|1
6278874|NCT02265510|9987396|FG002|Overall Study|Disease Progression|2
6278875|NCT02265510|9987397|FG003|Overall Study|Disease Progression|1
6278876|NCT02265510|9987398|FG004|Overall Study|Disease Progression|1
6278877|NCT02265510|9987399|FG005|Overall Study|Disease Progression|0
6278878|NCT02265510|9987400|FG006|Overall Study|Disease Progression|0
6278879|NCT02265510|9987401|FG007|Overall Study|Disease Progression|0
6278880|NCT02265510|9987402|FG008|Overall Study|Disease Progression|0
6278881|NCT02265510|9987403|FG009|Overall Study|Disease Progression|0
6278882|NCT02265510|9987404|FG010|Overall Study|Disease Progression|0
6278883|NCT02265510|9987405|FG011|Overall Study|Disease Progression|0
6278884|NCT02265510|9987406|FG012|Overall Study|Disease Progression|0
6278885|NCT02265510|9987407|FG013|Overall Study|Disease Progression|0
6278886|NCT02265510|9987394|FG000|Overall Study|Death|2
6278887|NCT02265510|9987395|FG001|Overall Study|Death|0
6278888|NCT02265510|9987396|FG002|Overall Study|Death|2
6278889|NCT02265510|9987397|FG003|Overall Study|Death|2
6278890|NCT02265510|9987398|FG004|Overall Study|Death|1
6278891|NCT02265510|9987399|FG005|Overall Study|Death|3
6278892|NCT02265510|9987400|FG006|Overall Study|Death|2
6278893|NCT02265510|9987401|FG007|Overall Study|Death|1
6278894|NCT02265510|9987402|FG008|Overall Study|Death|3
6278895|NCT02265510|9987403|FG009|Overall Study|Death|3
6278896|NCT02265510|9987404|FG010|Overall Study|Death|4
6278897|NCT02265510|9987405|FG011|Overall Study|Death|12
6278898|NCT02265510|9987406|FG012|Overall Study|Death|7
6278899|NCT02265510|9987407|FG013|Overall Study|Death|6
6278900|NCT02265510|9987394|FG000|Overall Study|Lost to Follow-up|0
6278901|NCT02265510|9987395|FG001|Overall Study|Lost to Follow-up|0
6278902|NCT02265510|9987396|FG002|Overall Study|Lost to Follow-up|0
6278903|NCT02265510|9987397|FG003|Overall Study|Lost to Follow-up|0
6278904|NCT02265510|9987398|FG004|Overall Study|Lost to Follow-up|1
6278905|NCT02265510|9987399|FG005|Overall Study|Lost to Follow-up|0
6278906|NCT02265510|9987400|FG006|Overall Study|Lost to Follow-up|0
6278907|NCT02265510|9987401|FG007|Overall Study|Lost to Follow-up|0
6278908|NCT02265510|9987402|FG008|Overall Study|Lost to Follow-up|0
6278909|NCT02265510|9987403|FG009|Overall Study|Lost to Follow-up|2
6278910|NCT02265510|9987404|FG010|Overall Study|Lost to Follow-up|0
6278911|NCT02265510|9987405|FG011|Overall Study|Lost to Follow-up|0
6278912|NCT02265510|9987406|FG012|Overall Study|Lost to Follow-up|0
6278913|NCT02265510|9987407|FG013|Overall Study|Lost to Follow-up|2
6278914|NCT02265510|9987394|FG000|Overall Study|Other|0
6278915|NCT02265510|9987395|FG001|Overall Study|Other|1
6278916|NCT02265510|9987396|FG002|Overall Study|Other|0
6278917|NCT02265510|9987397|FG003|Overall Study|Other|0
6278918|NCT02265510|9987398|FG004|Overall Study|Other|0
6278919|NCT02265510|9987399|FG005|Overall Study|Other|0
6278920|NCT02265510|9987400|FG006|Overall Study|Other|0
6278921|NCT02265510|9987401|FG007|Overall Study|Other|0
6278922|NCT02265510|9987402|FG008|Overall Study|Other|0
6278923|NCT02265510|9987403|FG009|Overall Study|Other|0
6278924|NCT02265510|9987404|FG010|Overall Study|Other|0
6278925|NCT02265510|9987405|FG011|Overall Study|Other|0
6278926|NCT02265510|9987406|FG012|Overall Study|Other|0
6278927|NCT02265510|9987407|FG013|Overall Study|Other|0
6278928|NCT02265510|9987394|FG000|Overall Study|Study Terminated by Sponsor|0
6278929|NCT02265510|9987395|FG001|Overall Study|Study Terminated by Sponsor|0
6278930|NCT02265510|9987396|FG002|Overall Study|Study Terminated by Sponsor|0
6278931|NCT02265510|9987397|FG003|Overall Study|Study Terminated by Sponsor|0
6278932|NCT02265510|9987398|FG004|Overall Study|Study Terminated by Sponsor|0
6278933|NCT02265510|9987399|FG005|Overall Study|Study Terminated by Sponsor|1
6278934|NCT02265510|9987400|FG006|Overall Study|Study Terminated by Sponsor|1
6278935|NCT02265510|9987401|FG007|Overall Study|Study Terminated by Sponsor|1
6278936|NCT02265510|9987402|FG008|Overall Study|Study Terminated by Sponsor|1
6278937|NCT02265510|9987403|FG009|Overall Study|Study Terminated by Sponsor|2
6278938|NCT02265510|9987404|FG010|Overall Study|Study Terminated by Sponsor|1
6278939|NCT02265510|9987405|FG011|Overall Study|Study Terminated by Sponsor|4
6278940|NCT02265510|9987406|FG012|Overall Study|Study Terminated by Sponsor|1
6278941|NCT02265510|9987407|FG013|Overall Study|Study Terminated by Sponsor|2
6278942|NCT02265705|9987465|FG000|Treatment Period Week 0-24|Adverse Event|3
6278943|NCT02265705|9987466|FG001|Treatment Period Week 0-24|Adverse Event|2
6278944|NCT02265705|9987467|FG002|Treatment Period Week 0-24|Adverse Event|0
6278945|NCT02265705|9987468|FG003|Treatment Period Week 0-24|Adverse Event|0
6278946|NCT02265705|9987469|FG004|Treatment Period Week 0-24|Adverse Event|0
6278947|NCT02265705|9987470|FG005|Treatment Period Week 0-24|Adverse Event|0
6278948|NCT02265705|9987471|FG006|Treatment Period Week 0-24|Adverse Event|0
6278949|NCT02265705|9987465|FG000|Treatment Period Week 0-24|Entry Criteria Not Met|1
6278950|NCT02265705|9987466|FG001|Treatment Period Week 0-24|Entry Criteria Not Met|1
6278951|NCT02265705|9987467|FG002|Treatment Period Week 0-24|Entry Criteria Not Met|0
6278952|NCT02265705|9987468|FG003|Treatment Period Week 0-24|Entry Criteria Not Met|0
6278953|NCT02265705|9987469|FG004|Treatment Period Week 0-24|Entry Criteria Not Met|0
6278954|NCT02265705|9987470|FG005|Treatment Period Week 0-24|Entry Criteria Not Met|0
6278955|NCT02265705|9987471|FG006|Treatment Period Week 0-24|Entry Criteria Not Met|0
6278956|NCT02265705|9987465|FG000|Treatment Period Week 0-24|Physician Decision|1
6278957|NCT02265705|9987466|FG001|Treatment Period Week 0-24|Physician Decision|0
6278958|NCT02265705|9987467|FG002|Treatment Period Week 0-24|Physician Decision|0
6278959|NCT02265705|9987468|FG003|Treatment Period Week 0-24|Physician Decision|0
6278960|NCT02265705|9987469|FG004|Treatment Period Week 0-24|Physician Decision|0
6278961|NCT02265705|9987470|FG005|Treatment Period Week 0-24|Physician Decision|0
6278962|NCT02265705|9987471|FG006|Treatment Period Week 0-24|Physician Decision|0
5977849|NCT04854642|9565284|FG000|Overall Study|Adverse Event|1
5977850|NCT04854642|9565285|FG001|Overall Study|Adverse Event|2
5977851|NCT04854642|9565284|FG000|Overall Study|Withdrawal by Subject|0
5977852|NCT04854642|9565285|FG001|Overall Study|Withdrawal by Subject|1
5977853|NCT04608344|9565295|FG000|Period 1 (AB: 3 Days, BA: 11 Days)|Adverse Event|0
5977854|NCT04608344|9565296|FG001|Period 1 (AB: 3 Days, BA: 11 Days)|Adverse Event|1
5977855|NCT04608344|9565295|FG000|Period 1 (AB: 3 Days, BA: 11 Days)|Investigator's Discretion|1
5977856|NCT04608344|9565296|FG001|Period 1 (AB: 3 Days, BA: 11 Days)|Investigator's Discretion|0
5977857|NCT04388787|9565323|FG000|Blinded Period|Patient could not follow instructions|1
5977858|NCT04388787|9565323|FG000|Unblinded Period|Patients became fatiged after a single round of testing with sham vs subthreshold|9
5977859|NCT04377620|9565347|FG000|Overall Study|Death|42
5977860|NCT04377620|9565348|FG001|Overall Study|Death|48
5977861|NCT04377620|9565349|FG002|Overall Study|Death|36
5977862|NCT04377620|9565347|FG000|Overall Study|Withdrawal by Subject|0
5977863|NCT04377620|9565348|FG001|Overall Study|Withdrawal by Subject|2
5977864|NCT04377620|9565349|FG002|Overall Study|Withdrawal by Subject|0
5977865|NCT04310566|9565380|FG000|Period 1|Study Termination due to COVID-19|15
5977866|NCT04310566|9565381|FG001|Period 1|Study Termination due to COVID-19|17
5977867|NCT04310566|9565380|FG000|Period 1|Protocol Violation|0
5977868|NCT04310566|9565381|FG001|Period 1|Protocol Violation|1
5977869|NCT04310566|9565380|FG000|Period 1|Subject no longer meets eligbility criteria|0
5977870|NCT04310566|9565381|FG001|Period 1|Subject no longer meets eligbility criteria|1
5977871|NCT04310566|9565380|FG000|Period 1|Lost to Follow-up|1
5977872|NCT04310566|9565381|FG001|Period 1|Lost to Follow-up|0
5977873|NCT04310566|9565380|FG000|Period 1|Withdrawal by Subject|0
5977874|NCT04310566|9565381|FG001|Period 1|Withdrawal by Subject|1
5977875|NCT04310566|9565380|FG000|Period 2|Study Termination|7
5977876|NCT04310566|9565381|FG001|Period 2|Study Termination|5
5977877|NCT04206020|9565389|FG000|Overall Study|Adverse Event|1
5977878|NCT04206020|9565390|FG001|Overall Study|Adverse Event|4
5977879|NCT04206020|9565389|FG000|Overall Study|Protocol Violation|2
5977880|NCT04206020|9565390|FG001|Overall Study|Protocol Violation|0
5977881|NCT04206020|9565389|FG000|Overall Study|Withdrawal by Subject|2
5977882|NCT04206020|9565390|FG001|Overall Study|Withdrawal by Subject|0
5977883|NCT04206020|9565389|FG000|Overall Study|Lost to Follow-up|2
5977884|NCT04206020|9565390|FG001|Overall Study|Lost to Follow-up|0
5977885|NCT04206020|9565389|FG000|Overall Study|Pregnancy|0
5977886|NCT04206020|9565390|FG001|Overall Study|Pregnancy|1
5977887|NCT04206020|9565389|FG000|Overall Study|Unable to attend visits|1
5977888|NCT04206020|9565390|FG001|Overall Study|Unable to attend visits|2
5977889|NCT04097301|9565396|FG000|Overall Study|Death|1
5977890|NCT04097301|9565396|FG000|Overall Study|Withdrawal by Subject|1
5977891|NCT04097301|9565396|FG000|Overall Study|Screening Failure|5
5977892|NCT03953079|9565409|FG000|Core Study|Withdrawal by Subject|1
5977893|NCT03953079|9565410|FG001|Core Study|Withdrawal by Subject|2
5977894|NCT03953079|9565411|FG002|Core Study|Withdrawal by Subject|1
5977895|NCT03953079|9565409|FG000|Core Study|COVID-19|0
5977896|NCT03953079|9565410|FG001|Core Study|COVID-19|1
5977897|NCT03953079|9565411|FG002|Core Study|COVID-19|0
5977898|NCT03953079|9565409|FG000|Core Study|Difficulties leaving the house|0
5977899|NCT03953079|9565410|FG001|Core Study|Difficulties leaving the house|1
5977900|NCT03953079|9565411|FG002|Core Study|Difficulties leaving the house|0
5977901|NCT03953079|9565409|FG000|Extension Study|Withdrawal by Subject|1
5977902|NCT03953079|9565410|FG001|Extension Study|Withdrawal by Subject|0
5977903|NCT03953079|9565411|FG002|Extension Study|Withdrawal by Subject|0
5977904|NCT03953079|9565409|FG000|Extension Study|Received Rescue Treatment|5
5977905|NCT03953079|9565410|FG001|Extension Study|Received Rescue Treatment|6
5977906|NCT03953079|9565411|FG002|Extension Study|Received Rescue Treatment|5
5977907|NCT03922750|9565423|FG000|Overall Study|Unclassified|0
5977908|NCT03922750|9565424|FG001|Overall Study|Unclassified|0
5977909|NCT03922750|9565425|FG002|Overall Study|Unclassified|1
5977910|NCT03922750|9565423|FG000|Overall Study|Adverse Event|0
6050983|NCT00430521|9650243|FG006|Overall Study|Pregnancy|1
6278963|NCT02265705|9987465|FG000|Treatment Period Week 0-24|Withdrawal by Subject|7
6278964|NCT02265705|9987466|FG001|Treatment Period Week 0-24|Withdrawal by Subject|5
6278965|NCT02265705|9987467|FG002|Treatment Period Week 0-24|Withdrawal by Subject|0
6278966|NCT02265705|9987468|FG003|Treatment Period Week 0-24|Withdrawal by Subject|0
6278967|NCT02265705|9987469|FG004|Treatment Period Week 0-24|Withdrawal by Subject|0
6278968|NCT02265705|9987470|FG005|Treatment Period Week 0-24|Withdrawal by Subject|0
6278969|NCT02265705|9987471|FG006|Treatment Period Week 0-24|Withdrawal by Subject|0
6278970|NCT02265705|9987465|FG000|Treatment Period Week 0-24|Lack of Efficacy|0
6278971|NCT02265705|9987466|FG001|Treatment Period Week 0-24|Lack of Efficacy|1
6278972|NCT02265705|9987467|FG002|Treatment Period Week 0-24|Lack of Efficacy|0
6278973|NCT02265705|9987468|FG003|Treatment Period Week 0-24|Lack of Efficacy|0
6278974|NCT02265705|9987469|FG004|Treatment Period Week 0-24|Lack of Efficacy|0
6278975|NCT02265705|9987470|FG005|Treatment Period Week 0-24|Lack of Efficacy|0
6278976|NCT02265705|9987471|FG006|Treatment Period Week 0-24|Lack of Efficacy|0
6278977|NCT02265705|9987465|FG000|Rescue Period|Withdrawal by Subject|0
6278978|NCT02265705|9987466|FG001|Rescue Period|Withdrawal by Subject|0
6278979|NCT02265705|9987467|FG002|Rescue Period|Withdrawal by Subject|1
6278980|NCT02265705|9987468|FG003|Rescue Period|Withdrawal by Subject|0
6278981|NCT02265705|9987469|FG004|Rescue Period|Withdrawal by Subject|0
6278982|NCT02265705|9987470|FG005|Rescue Period|Withdrawal by Subject|0
6278983|NCT02265705|9987471|FG006|Rescue Period|Withdrawal by Subject|0
6278984|NCT02265705|9987465|FG000|Rescue Period|Death|0
6278985|NCT02265705|9987466|FG001|Rescue Period|Death|0
6278986|NCT02265705|9987467|FG002|Rescue Period|Death|1
6278987|NCT02265705|9987468|FG003|Rescue Period|Death|0
6278988|NCT02265705|9987469|FG004|Rescue Period|Death|0
6278989|NCT02265705|9987470|FG005|Rescue Period|Death|0
6278990|NCT02265705|9987471|FG006|Rescue Period|Death|0
5977911|NCT03922750|9565424|FG001|Overall Study|Adverse Event|1
5977912|NCT03922750|9565425|FG002|Overall Study|Adverse Event|0
5977913|NCT03910673|9565438|FG000|Overall Study|Adverse Event|0
5977914|NCT03910673|9565439|FG001|Overall Study|Adverse Event|0
5977915|NCT03910673|9565440|FG002|Overall Study|Adverse Event|0
5977916|NCT03910673|9565441|FG003|Overall Study|Adverse Event|2
5977917|NCT03910673|9565442|FG004|Overall Study|Adverse Event|0
5977918|NCT03885999|9565446|FG000|Overall Study|Adverse Event|1
5977919|NCT03882970|9565454|FG000|Overall Study|Adverse Event|5
5977920|NCT03882970|9565455|FG001|Overall Study|Adverse Event|7
5977921|NCT03882970|9565456|FG002|Overall Study|Adverse Event|3
5977922|NCT03882970|9565457|FG003|Overall Study|Adverse Event|1
5977923|NCT03882970|9565454|FG000|Overall Study|Death|1
5977924|NCT03882970|9565455|FG001|Overall Study|Death|2
5977925|NCT03882970|9565456|FG002|Overall Study|Death|1
5977926|NCT03882970|9565457|FG003|Overall Study|Death|1
5977927|NCT03882970|9565454|FG000|Overall Study|Lost to Follow-up|8
5977928|NCT03882970|9565455|FG001|Overall Study|Lost to Follow-up|9
5977929|NCT03882970|9565456|FG002|Overall Study|Lost to Follow-up|5
5977930|NCT03882970|9565457|FG003|Overall Study|Lost to Follow-up|5
5977931|NCT03882970|9565454|FG000|Overall Study|Physician Decision|0
5977932|NCT03882970|9565455|FG001|Overall Study|Physician Decision|2
6278991|NCT02265705|9987465|FG000|Rescue Period|Lack of Efficacy|0
5977933|NCT03882970|9565456|FG002|Overall Study|Physician Decision|2
5977934|NCT03882970|9565457|FG003|Overall Study|Physician Decision|2
5977935|NCT03882970|9565454|FG000|Overall Study|Protocol Violation|2
5977936|NCT03882970|9565455|FG001|Overall Study|Protocol Violation|0
5977937|NCT03882970|9565456|FG002|Overall Study|Protocol Violation|0
5977938|NCT03882970|9565457|FG003|Overall Study|Protocol Violation|0
5977939|NCT03882970|9565454|FG000|Overall Study|Withdrawal by Subject|8
5977940|NCT03882970|9565455|FG001|Overall Study|Withdrawal by Subject|17
5977941|NCT03882970|9565456|FG002|Overall Study|Withdrawal by Subject|7
5977942|NCT03882970|9565457|FG003|Overall Study|Withdrawal by Subject|22
5977943|NCT03882970|9565454|FG000|Overall Study|Personal Reason|2
5977944|NCT03882970|9565455|FG001|Overall Study|Personal Reason|3
5977945|NCT03882970|9565456|FG002|Overall Study|Personal Reason|1
5977946|NCT03882970|9565457|FG003|Overall Study|Personal Reason|3
5977947|NCT03867734|9565481|FG000|Overall Study|Lost to Follow-up|2
5977948|NCT03781778|9565491|FG000|Overall Study|Withdrawal by Subject|2
5977949|NCT03781778|9565492|FG001|Overall Study|Withdrawal by Subject|2
6050984|NCT00430521|9650244|FG007|Overall Study|Pregnancy|0
6050985|NCT00430521|9650237|FG000|Overall Study|Vaccine Expired|0
6050986|NCT00430521|9650238|FG001|Overall Study|Vaccine Expired|0
6050987|NCT00430521|9650239|FG002|Overall Study|Vaccine Expired|0
6050988|NCT00430521|9650240|FG003|Overall Study|Vaccine Expired|0
6050989|NCT00430521|9650241|FG004|Overall Study|Vaccine Expired|0
6050990|NCT00430521|9650242|FG005|Overall Study|Vaccine Expired|1
6050991|NCT00430521|9650243|FG006|Overall Study|Vaccine Expired|0
6050992|NCT00430521|9650244|FG007|Overall Study|Vaccine Expired|0
6050993|NCT00430521|9650237|FG000|Overall Study|Protocol Violation|1
6050994|NCT00430521|9650238|FG001|Overall Study|Protocol Violation|0
6050995|NCT00430521|9650239|FG002|Overall Study|Protocol Violation|0
6050996|NCT00430521|9650240|FG003|Overall Study|Protocol Violation|0
6050997|NCT00430521|9650241|FG004|Overall Study|Protocol Violation|0
6050998|NCT00430521|9650242|FG005|Overall Study|Protocol Violation|0
6050999|NCT00430521|9650243|FG006|Overall Study|Protocol Violation|0
6051000|NCT00430521|9650244|FG007|Overall Study|Protocol Violation|0
6278992|NCT02265705|9987466|FG001|Rescue Period|Lack of Efficacy|0
6278993|NCT02265705|9987467|FG002|Rescue Period|Lack of Efficacy|1
6278994|NCT02265705|9987468|FG003|Rescue Period|Lack of Efficacy|0
6278995|NCT02265705|9987469|FG004|Rescue Period|Lack of Efficacy|0
6278996|NCT02265705|9987470|FG005|Rescue Period|Lack of Efficacy|0
6278997|NCT02265705|9987471|FG006|Rescue Period|Lack of Efficacy|0
6278998|NCT02265705|9987465|FG000|Open Label Period|Adverse Event|0
6278999|NCT02265705|9987466|FG001|Open Label Period|Adverse Event|0
6279000|NCT02265705|9987467|FG002|Open Label Period|Adverse Event|0
6279001|NCT02265705|9987468|FG003|Open Label Period|Adverse Event|2
6279002|NCT02265705|9987469|FG004|Open Label Period|Adverse Event|2
6279003|NCT02265705|9987470|FG005|Open Label Period|Adverse Event|0
6279004|NCT02265705|9987471|FG006|Open Label Period|Adverse Event|0
6279005|NCT02265705|9987465|FG000|Open Label Period|Physician Decision|0
6279006|NCT02265705|9987466|FG001|Open Label Period|Physician Decision|0
6279007|NCT02265705|9987467|FG002|Open Label Period|Physician Decision|0
6279008|NCT02265705|9987468|FG003|Open Label Period|Physician Decision|0
6279009|NCT02265705|9987469|FG004|Open Label Period|Physician Decision|1
6279010|NCT02265705|9987470|FG005|Open Label Period|Physician Decision|0
6279011|NCT02265705|9987471|FG006|Open Label Period|Physician Decision|0
6279012|NCT02265705|9987465|FG000|Open Label Period|Withdrawal by Subject|0
6279013|NCT02265705|9987466|FG001|Open Label Period|Withdrawal by Subject|0
6279014|NCT02265705|9987467|FG002|Open Label Period|Withdrawal by Subject|0
6279015|NCT02265705|9987468|FG003|Open Label Period|Withdrawal by Subject|0
6279016|NCT02265705|9987469|FG004|Open Label Period|Withdrawal by Subject|2
6279017|NCT02265705|9987470|FG005|Open Label Period|Withdrawal by Subject|0
6279018|NCT02265705|9987471|FG006|Open Label Period|Withdrawal by Subject|0
6279019|NCT02265705|9987465|FG000|Follow-up Period|Sponsor Decision|0
6279020|NCT02265705|9987466|FG001|Follow-up Period|Sponsor Decision|0
6279021|NCT02265705|9987467|FG002|Follow-up Period|Sponsor Decision|0
6279022|NCT02265705|9987468|FG003|Follow-up Period|Sponsor Decision|0
6279023|NCT02265705|9987469|FG004|Follow-up Period|Sponsor Decision|0
6279024|NCT02265705|9987470|FG005|Follow-up Period|Sponsor Decision|1
6279025|NCT02265705|9987471|FG006|Follow-up Period|Sponsor Decision|6
6279026|NCT02265705|9987465|FG000|Follow-up Period|Adverse Event|0
6279027|NCT02265705|9987466|FG001|Follow-up Period|Adverse Event|0
6279028|NCT02265705|9987467|FG002|Follow-up Period|Adverse Event|0
6279029|NCT02265705|9987468|FG003|Follow-up Period|Adverse Event|0
6279030|NCT02265705|9987469|FG004|Follow-up Period|Adverse Event|0
6279031|NCT02265705|9987470|FG005|Follow-up Period|Adverse Event|0
6279032|NCT02265705|9987471|FG006|Follow-up Period|Adverse Event|3
6279033|NCT02265705|9987465|FG000|Follow-up Period|Physician Decision|0
6279034|NCT02265705|9987466|FG001|Follow-up Period|Physician Decision|0
6279035|NCT02265705|9987467|FG002|Follow-up Period|Physician Decision|0
6279036|NCT02265705|9987468|FG003|Follow-up Period|Physician Decision|0
6279037|NCT02265705|9987469|FG004|Follow-up Period|Physician Decision|0
6279038|NCT02265705|9987470|FG005|Follow-up Period|Physician Decision|0
6279039|NCT02265705|9987471|FG006|Follow-up Period|Physician Decision|1
6279040|NCT02265705|9987465|FG000|Follow-up Period|Withdrawal by Subject|0
6279041|NCT02265705|9987466|FG001|Follow-up Period|Withdrawal by Subject|0
6279042|NCT02265705|9987467|FG002|Follow-up Period|Withdrawal by Subject|0
6279043|NCT02265705|9987468|FG003|Follow-up Period|Withdrawal by Subject|0
6279044|NCT02265705|9987469|FG004|Follow-up Period|Withdrawal by Subject|0
6279045|NCT02265705|9987470|FG005|Follow-up Period|Withdrawal by Subject|0
6279046|NCT02265705|9987471|FG006|Follow-up Period|Withdrawal by Subject|1
6279047|NCT02265744|9987487|FG000|Overall Study|Poor/Non-compliance|1
6279048|NCT02265744|9987488|FG001|Overall Study|Poor/Non-compliance|1
6279049|NCT02265744|9987489|FG002|Overall Study|Poor/Non-compliance|0
6279050|NCT02265744|9987490|FG003|Overall Study|Poor/Non-compliance|0
6279051|NCT02265744|9987491|FG004|Overall Study|Poor/Non-compliance|2
6279052|NCT02265744|9987487|FG000|Overall Study|Lost to Follow-up|0
6279053|NCT02265744|9987488|FG001|Overall Study|Lost to Follow-up|0
6279054|NCT02265744|9987489|FG002|Overall Study|Lost to Follow-up|0
6279055|NCT02265744|9987490|FG003|Overall Study|Lost to Follow-up|1
6279056|NCT02265744|9987491|FG004|Overall Study|Lost to Follow-up|0
6279057|NCT02265744|9987487|FG000|Overall Study|Death|0
6279058|NCT02265744|9987488|FG001|Overall Study|Death|0
6279059|NCT02265744|9987489|FG002|Overall Study|Death|0
6279060|NCT02265744|9987490|FG003|Overall Study|Death|2
6279061|NCT02265744|9987491|FG004|Overall Study|Death|0
6279062|NCT02265744|9987487|FG000|Overall Study|Withdrawal by Subject|2
6279063|NCT02265744|9987488|FG001|Overall Study|Withdrawal by Subject|0
6279064|NCT02265744|9987489|FG002|Overall Study|Withdrawal by Subject|0
6279065|NCT02265744|9987490|FG003|Overall Study|Withdrawal by Subject|2
6279066|NCT02265744|9987491|FG004|Overall Study|Withdrawal by Subject|0
6279067|NCT02265744|9987487|FG000|Overall Study|Participant request to discontinue|2
6279068|NCT02265744|9987488|FG001|Overall Study|Participant request to discontinue|2
6279069|NCT02265744|9987489|FG002|Overall Study|Participant request to discontinue|2
6279070|NCT02265744|9987490|FG003|Overall Study|Participant request to discontinue|0
6279071|NCT02265744|9987491|FG004|Overall Study|Participant request to discontinue|0
6279072|NCT02265744|9987487|FG000|Overall Study|Adverse Event|8
6279073|NCT02265744|9987488|FG001|Overall Study|Adverse Event|4
6279074|NCT02265744|9987489|FG002|Overall Study|Adverse Event|9
6279075|NCT02265744|9987490|FG003|Overall Study|Adverse Event|8
6279076|NCT02265744|9987491|FG004|Overall Study|Adverse Event|2
6279077|NCT02265744|9987487|FG000|Overall Study|Lack of Efficacy|2
6279078|NCT02265744|9987488|FG001|Overall Study|Lack of Efficacy|4
6279079|NCT02265744|9987489|FG002|Overall Study|Lack of Efficacy|3
6279080|NCT02265744|9987490|FG003|Overall Study|Lack of Efficacy|4
6279081|NCT02265744|9987491|FG004|Overall Study|Lack of Efficacy|5
6279082|NCT02265744|9987487|FG000|Overall Study|Reason not provided by Investigator|1
6279083|NCT02265744|9987488|FG001|Overall Study|Reason not provided by Investigator|0
6279084|NCT02265744|9987489|FG002|Overall Study|Reason not provided by Investigator|0
6279085|NCT02265744|9987490|FG003|Overall Study|Reason not provided by Investigator|2
6279086|NCT02265744|9987491|FG004|Overall Study|Reason not provided by Investigator|0
6279087|NCT02265744|9987487|FG000|Overall Study|Administrative reason by sponsor|3
6279088|NCT02265744|9987488|FG001|Overall Study|Administrative reason by sponsor|2
6279089|NCT02265744|9987489|FG002|Overall Study|Administrative reason by sponsor|2
6279090|NCT02265744|9987490|FG003|Overall Study|Administrative reason by sponsor|3
6279091|NCT02265744|9987491|FG004|Overall Study|Administrative reason by sponsor|3
6279092|NCT02265744|9987487|FG000|Overall Study|Subject no longer meets study criteria|0
6279093|NCT02265744|9987488|FG001|Overall Study|Subject no longer meets study criteria|0
6279094|NCT02265744|9987489|FG002|Overall Study|Subject no longer meets study criteria|0
6279095|NCT02265744|9987490|FG003|Overall Study|Subject no longer meets study criteria|0
6279096|NCT02265744|9987491|FG004|Overall Study|Subject no longer meets study criteria|1
6279097|NCT02265744|9987487|FG000|Overall Study|Pregnancy|1
6279098|NCT02265744|9987488|FG001|Overall Study|Pregnancy|2
6279099|NCT02265744|9987489|FG002|Overall Study|Pregnancy|1
6279100|NCT02265744|9987490|FG003|Overall Study|Pregnancy|1
6279101|NCT02265744|9987491|FG004|Overall Study|Pregnancy|0
6279102|NCT02265796|9987509|FG000|Overall Study|Death|1
6279103|NCT02265796|9987510|FG001|Overall Study|Death|0
6279104|NCT02265796|9987509|FG000|Overall Study|started on excluded medication|1
6279105|NCT02265796|9987510|FG001|Overall Study|started on excluded medication|0
6279106|NCT02265796|9987509|FG000|Overall Study|Withdrawal by Subject|1
6279107|NCT02265796|9987510|FG001|Overall Study|Withdrawal by Subject|1
6279108|NCT02265952|9987538|FG000|Open Label Extension (OLE) Period|Physician Decision|0
6279109|NCT02265952|9987539|FG001|Open Label Extension (OLE) Period|Physician Decision|7
6279110|NCT02265952|9987538|FG000|Open Label Extension (OLE) Period|Withdrawal by Subject|0
6279111|NCT02265952|9987539|FG001|Open Label Extension (OLE) Period|Withdrawal by Subject|1
6279112|NCT02266004|9987554|FG000|Overall Study|unrelated adverse event|1
6279113|NCT02266004|9987554|FG000|Overall Study|Physician Decision|1
6279114|NCT02266147|9987571|FG000|PART 1: Dose Escalation|Physician Decision|0
6279115|NCT02266147|9987572|FG001|PART 1: Dose Escalation|Physician Decision|0
6279116|NCT02266147|9987573|FG002|PART 1: Dose Escalation|Physician Decision|1
6279117|NCT02266147|9987574|FG003|PART 1: Dose Escalation|Physician Decision|0
6279118|NCT02266147|9987571|FG000|PART 1: Dose Escalation|Lack of Efficacy|0
6279119|NCT02266147|9987572|FG001|PART 1: Dose Escalation|Lack of Efficacy|2
6279120|NCT02266147|9987573|FG002|PART 1: Dose Escalation|Lack of Efficacy|1
6279121|NCT02266147|9987574|FG003|PART 1: Dose Escalation|Lack of Efficacy|1
6279122|NCT02266147|9987571|FG000|PART 1: Dose Escalation|Study Terminated by Sponsor|0
6279123|NCT02266147|9987572|FG001|PART 1: Dose Escalation|Study Terminated by Sponsor|0
6279124|NCT02266147|9987573|FG002|PART 1: Dose Escalation|Study Terminated by Sponsor|1
6279125|NCT02266147|9987574|FG003|PART 1: Dose Escalation|Study Terminated by Sponsor|3
6279126|NCT02266147|9987571|FG000|PART 1: Dose Escalation|Other|1
6279127|NCT02266147|9987572|FG001|PART 1: Dose Escalation|Other|1
6279128|NCT02266147|9987573|FG002|PART 1: Dose Escalation|Other|0
6279129|NCT02266147|9987574|FG003|PART 1: Dose Escalation|Other|0
6279130|NCT02266147|9987571|FG000|PART 2: Dose Expansion|Lack of Efficacy|1
6279131|NCT02266147|9987572|FG001|PART 2: Dose Expansion|Lack of Efficacy|0
6279132|NCT02266147|9987573|FG002|PART 2: Dose Expansion|Lack of Efficacy|0
6279133|NCT02266147|9987574|FG003|PART 2: Dose Expansion|Lack of Efficacy|1
6279134|NCT02266147|9987571|FG000|PART 2: Dose Expansion|Study Terminated by Sponsor|6
6279135|NCT02266147|9987572|FG001|PART 2: Dose Expansion|Study Terminated by Sponsor|0
6279136|NCT02266147|9987573|FG002|PART 2: Dose Expansion|Study Terminated by Sponsor|0
6279137|NCT02266147|9987574|FG003|PART 2: Dose Expansion|Study Terminated by Sponsor|8
6279138|NCT02266225|9987586|FG000|Overall Study|Lost to Follow-up|2
6279139|NCT02266225|9987586|FG000|Overall Study|Death|1
6279140|NCT02266225|9987586|FG000|Overall Study|Withdrawal by Subject|13
6279141|NCT02266381|9987621|FG000|Overall Study|Physician Decision|3
6279142|NCT02266381|9987622|FG001|Overall Study|Physician Decision|5
6279143|NCT02266381|9987623|FG002|Overall Study|Physician Decision|4
6279144|NCT02266433|9987635|FG000|Overall Study|Lost to Follow-up|54
6279145|NCT02266433|9987636|FG001|Overall Study|Lost to Follow-up|46
6279146|NCT02266433|9987635|FG000|Overall Study|Withdrawal by Subject|5
6279147|NCT02266433|9987636|FG001|Overall Study|Withdrawal by Subject|7
6279148|NCT02266706|9987670|FG000|Overall Study|Withdrawal by Subject|0
6279149|NCT02266706|9987671|FG001|Overall Study|Withdrawal by Subject|1
6279150|NCT02266706|9987672|FG002|Overall Study|Withdrawal by Subject|1
6279151|NCT02266706|9987673|FG003|Overall Study|Withdrawal by Subject|0
6279152|NCT02266706|9987674|FG004|Overall Study|Withdrawal by Subject|0
6279153|NCT02266706|9987675|FG005|Overall Study|Withdrawal by Subject|1
6279154|NCT02266706|9987676|FG006|Overall Study|Withdrawal by Subject|0
6279155|NCT02266706|9987677|FG007|Overall Study|Withdrawal by Subject|0
6279156|NCT02266706|9987678|FG008|Overall Study|Withdrawal by Subject|0
6279157|NCT02266706|9987670|FG000|Overall Study|Screen failure|0
6279158|NCT02266706|9987671|FG001|Overall Study|Screen failure|0
6279159|NCT02266706|9987672|FG002|Overall Study|Screen failure|0
6279160|NCT02266706|9987673|FG003|Overall Study|Screen failure|0
6279161|NCT02266706|9987674|FG004|Overall Study|Screen failure|0
6279162|NCT02266706|9987675|FG005|Overall Study|Screen failure|1
6279163|NCT02266706|9987676|FG006|Overall Study|Screen failure|1
6279164|NCT02266706|9987677|FG007|Overall Study|Screen failure|0
6279165|NCT02266706|9987678|FG008|Overall Study|Screen failure|0
6279166|NCT02266706|9987670|FG000|Overall Study|Enrollment in another study|0
6279167|NCT02266706|9987671|FG001|Overall Study|Enrollment in another study|0
6279168|NCT02266706|9987672|FG002|Overall Study|Enrollment in another study|0
6279169|NCT02266706|9987673|FG003|Overall Study|Enrollment in another study|1
6279170|NCT02266706|9987674|FG004|Overall Study|Enrollment in another study|0
6279171|NCT02266706|9987675|FG005|Overall Study|Enrollment in another study|0
6279172|NCT02266706|9987676|FG006|Overall Study|Enrollment in another study|0
6279173|NCT02266706|9987677|FG007|Overall Study|Enrollment in another study|0
6279174|NCT02266706|9987678|FG008|Overall Study|Enrollment in another study|0
5977950|NCT03730480|9565511|FG000|Overall Study|Meter displayed a HI result which is non evaluable.|1
5977951|NCT03713034|9565524|FG000|Overall Study|Withdrawn by staff for incomplete consent forms|5
5977952|NCT03713034|9565525|FG001|Overall Study|Withdrawn by staff for incomplete consent forms|4
5977953|NCT03654404|9565533|FG000|Overall Study|Death|1
5977954|NCT03654404|9565533|FG000|Overall Study|Lost to Follow-up|2
5977955|NCT03654404|9565533|FG000|Overall Study|Withdrawal by Subject|5
5977956|NCT03567057|9565540|FG000|Overall Study|Adverse Event|56
6279175|NCT02266875|9987718|FG000|Overall Study|Withdrawal by Subject|9
6279176|NCT02266875|9987719|FG001|Overall Study|Withdrawal by Subject|0
6279177|NCT02266875|9987718|FG000|Overall Study|Lost to Follow-up|2
6279178|NCT02266875|9987719|FG001|Overall Study|Lost to Follow-up|0
6279179|NCT02266888|9987727|FG000|Overall Study|Death|2
6279180|NCT02266888|9987728|FG001|Overall Study|Death|2
6279181|NCT02266888|9987729|FG002|Overall Study|Death|4
6279182|NCT02266888|9987730|FG003|Overall Study|Death|2
6279183|NCT02266888|9987727|FG000|Overall Study|Physician Decision|0
6279184|NCT02266888|9987728|FG001|Overall Study|Physician Decision|1
6279185|NCT02266888|9987729|FG002|Overall Study|Physician Decision|2
6279186|NCT02266888|9987730|FG003|Overall Study|Physician Decision|2
5977957|NCT03567057|9565541|FG001|Overall Study|Adverse Event|53
5977958|NCT03567057|9565542|FG002|Overall Study|Adverse Event|28
5977959|NCT03567057|9565540|FG000|Overall Study|Withdrawal by Subject|22
5977960|NCT03567057|9565541|FG001|Overall Study|Withdrawal by Subject|24
5977961|NCT03567057|9565542|FG002|Overall Study|Withdrawal by Subject|13
5977962|NCT03567057|9565540|FG000|Overall Study|Lost to Follow-up|3
5977963|NCT03567057|9565541|FG001|Overall Study|Lost to Follow-up|5
5977964|NCT03567057|9565542|FG002|Overall Study|Lost to Follow-up|2
5977965|NCT03567057|9565540|FG000|Overall Study|COVID-19 pandemic|4
5977966|NCT03567057|9565541|FG001|Overall Study|COVID-19 pandemic|3
5977967|NCT03567057|9565542|FG002|Overall Study|COVID-19 pandemic|0
5977968|NCT03567057|9565540|FG000|Overall Study|Non-compliance with study drug|4
5977969|NCT03567057|9565541|FG001|Overall Study|Non-compliance with study drug|2
5977970|NCT03567057|9565542|FG002|Overall Study|Non-compliance with study drug|0
5977971|NCT03567057|9565540|FG000|Overall Study|Lack of Efficacy|3
5977972|NCT03567057|9565541|FG001|Overall Study|Lack of Efficacy|0
5977973|NCT03567057|9565542|FG002|Overall Study|Lack of Efficacy|1
5977974|NCT03567057|9565540|FG000|Overall Study|Death|1
5977975|NCT03567057|9565541|FG001|Overall Study|Death|0
5977976|NCT03567057|9565542|FG002|Overall Study|Death|0
5977977|NCT03567057|9565540|FG000|Overall Study|Physician Decision|1
5977978|NCT03567057|9565541|FG001|Overall Study|Physician Decision|0
5977979|NCT03567057|9565542|FG002|Overall Study|Physician Decision|0
5977980|NCT03567057|9565540|FG000|Overall Study|Unstable medical condition|1
5977981|NCT03567057|9565541|FG001|Overall Study|Unstable medical condition|0
5977982|NCT03567057|9565542|FG002|Overall Study|Unstable medical condition|0
5977983|NCT03567057|9565540|FG000|Overall Study|Medical history event|0
5977984|NCT03567057|9565541|FG001|Overall Study|Medical history event|0
5977985|NCT03567057|9565542|FG002|Overall Study|Medical history event|1
5977986|NCT03567057|9565540|FG000|Overall Study|Other|0
5977987|NCT03567057|9565541|FG001|Overall Study|Other|0
5977988|NCT03567057|9565542|FG002|Overall Study|Other|1
5977989|NCT03548987|9565552|FG000|Run-in Period (Week 0 to Week 20)|Other|9
5977990|NCT03548987|9565553|FG001|Run-in Period (Week 0 to Week 20)|Other|0
5977991|NCT03548987|9565552|FG000|Run-in Period (Week 0 to Week 20)|Lost to Follow-up|8
5977992|NCT03548987|9565553|FG001|Run-in Period (Week 0 to Week 20)|Lost to Follow-up|0
5977993|NCT03548987|9565552|FG000|Run-in Period (Week 0 to Week 20)|Withdrawal by Subject|11
5977994|NCT03548987|9565553|FG001|Run-in Period (Week 0 to Week 20)|Withdrawal by Subject|0
5977995|NCT03548987|9565552|FG000|Run-in Period (Week 0 to Week 20)|Safety concern as judged by investigator|2
5977996|NCT03548987|9565553|FG001|Run-in Period (Week 0 to Week 20)|Safety concern as judged by investigator|0
5977997|NCT03548987|9565552|FG000|Run-in Period (Week 0 to Week 20)|Run-in failure|19
5977998|NCT03548987|9565553|FG001|Run-in Period (Week 0 to Week 20)|Run-in failure|0
5977999|NCT03548987|9565552|FG000|Run-in Period (Week 0 to Week 20)|Pregnancy|1
5978000|NCT03548987|9565553|FG001|Run-in Period (Week 0 to Week 20)|Pregnancy|0
5978001|NCT03548987|9565552|FG000|Run-in Period (Week 0 to Week 20)|Protocol Violation|1
5978002|NCT03548987|9565553|FG001|Run-in Period (Week 0 to Week 20)|Protocol Violation|0
5978003|NCT03548987|9565552|FG000|Run-in Period (Week 0 to Week 20)|Adverse Event|48
5978004|NCT03548987|9565553|FG001|Run-in Period (Week 0 to Week 20)|Adverse Event|0
5978005|NCT03548987|9565552|FG000|Maintenance Period (Week 20 to Week 68)|other|12
5978006|NCT03548987|9565553|FG001|Maintenance Period (Week 20 to Week 68)|other|23
5978007|NCT03548987|9565552|FG000|Maintenance Period (Week 20 to Week 68)|Lost to Follow-up|2
5978008|NCT03548987|9565553|FG001|Maintenance Period (Week 20 to Week 68)|Lost to Follow-up|1
5978009|NCT03548987|9565552|FG000|Maintenance Period (Week 20 to Week 68)|Withdrawal by Subject|1
5978010|NCT03548987|9565553|FG001|Maintenance Period (Week 20 to Week 68)|Withdrawal by Subject|1
5978011|NCT03548987|9565552|FG000|Maintenance Period (Week 20 to Week 68)|Pregnancy|2
5978012|NCT03548987|9565553|FG001|Maintenance Period (Week 20 to Week 68)|Pregnancy|0
5978013|NCT03548987|9565552|FG000|Maintenance Period (Week 20 to Week 68)|Protocol Violation|1
5978014|NCT03548987|9565553|FG001|Maintenance Period (Week 20 to Week 68)|Protocol Violation|0
5978015|NCT03548987|9565552|FG000|Maintenance Period (Week 20 to Week 68)|Adverse Event|13
5978016|NCT03548987|9565553|FG001|Maintenance Period (Week 20 to Week 68)|Adverse Event|6
5978017|NCT03548064|9565568|FG000|Overall Study|Withdrawal by Subject|0
5978018|NCT03548064|9565569|FG001|Overall Study|Withdrawal by Subject|0
5978019|NCT03548064|9565570|FG002|Overall Study|Withdrawal by Subject|0
6279187|NCT02266888|9987727|FG000|Overall Study|Study Terminated|5
6279188|NCT02266888|9987728|FG001|Overall Study|Study Terminated|1
6279189|NCT02266888|9987729|FG002|Overall Study|Study Terminated|0
6279190|NCT02266888|9987730|FG003|Overall Study|Study Terminated|0
6279191|NCT02266888|9987727|FG000|Overall Study|No Longer Eligible|0
6279192|NCT02266888|9987728|FG001|Overall Study|No Longer Eligible|0
6279193|NCT02266888|9987729|FG002|Overall Study|No Longer Eligible|0
6279194|NCT02266888|9987730|FG003|Overall Study|No Longer Eligible|2
6279195|NCT02266888|9987727|FG000|Overall Study|Randomization Closed|0
6279196|NCT02266888|9987728|FG001|Overall Study|Randomization Closed|0
6279197|NCT02266888|9987729|FG002|Overall Study|Randomization Closed|4
6279198|NCT02266888|9987730|FG003|Overall Study|Randomization Closed|0
6279199|NCT02266888|9987727|FG000|Overall Study|Personnel unavailable at transplant|0
6279200|NCT02266888|9987728|FG001|Overall Study|Personnel unavailable at transplant|0
6279201|NCT02266888|9987729|FG002|Overall Study|Personnel unavailable at transplant|0
6279202|NCT02266888|9987730|FG003|Overall Study|Personnel unavailable at transplant|1
6279203|NCT02266888|9987727|FG000|Overall Study|Transfer of care|0
6279204|NCT02266888|9987728|FG001|Overall Study|Transfer of care|0
6279205|NCT02266888|9987729|FG002|Overall Study|Transfer of care|1
6279206|NCT02266888|9987730|FG003|Overall Study|Transfer of care|0
6279207|NCT02267135|9987744|FG000|Period 1 (Randomized Set)|Withdrawal by Subject|1
6279208|NCT02267135|9987745|FG001|Period 1 (Randomized Set)|Withdrawal by Subject|3
6279209|NCT02267135|9987744|FG000|Period 1 (Randomized Set)|Lost to Follow-up|0
6279210|NCT02267135|9987745|FG001|Period 1 (Randomized Set)|Lost to Follow-up|1
6279211|NCT02267135|9987744|FG000|Period 2 (Randomized Set)|Lost to Follow-up|1
6279212|NCT02267135|9987745|FG001|Period 2 (Randomized Set)|Lost to Follow-up|1
6279213|NCT02267135|9987744|FG000|Period 2 (Randomized Set)|Adverse Event|2
6279214|NCT02267135|9987745|FG001|Period 2 (Randomized Set)|Adverse Event|0
5978020|NCT03548064|9565571|FG003|Overall Study|Withdrawal by Subject|1
5978021|NCT03548064|9565572|FG004|Overall Study|Withdrawal by Subject|0
5978022|NCT03548064|9565573|FG005|Overall Study|Withdrawal by Subject|0
5978023|NCT03548064|9565574|FG006|Overall Study|Withdrawal by Subject|0
5978024|NCT03548064|9565575|FG007|Overall Study|Withdrawal by Subject|0
5978025|NCT03548064|9565568|FG000|Overall Study|Lost to Follow-up|0
5978026|NCT03548064|9565569|FG001|Overall Study|Lost to Follow-up|0
5978027|NCT03548064|9565570|FG002|Overall Study|Lost to Follow-up|0
5978028|NCT03548064|9565571|FG003|Overall Study|Lost to Follow-up|0
5978029|NCT03548064|9565572|FG004|Overall Study|Lost to Follow-up|2
5978030|NCT03548064|9565573|FG005|Overall Study|Lost to Follow-up|0
5978031|NCT03548064|9565574|FG006|Overall Study|Lost to Follow-up|0
5978032|NCT03548064|9565575|FG007|Overall Study|Lost to Follow-up|0
5978033|NCT03548064|9565568|FG000|Overall Study|Covid-19 Pandemic|0
5978034|NCT03548064|9565569|FG001|Overall Study|Covid-19 Pandemic|0
5978035|NCT03548064|9565570|FG002|Overall Study|Covid-19 Pandemic|0
5978036|NCT03548064|9565571|FG003|Overall Study|Covid-19 Pandemic|0
5978037|NCT03548064|9565572|FG004|Overall Study|Covid-19 Pandemic|10
5978038|NCT03548064|9565573|FG005|Overall Study|Covid-19 Pandemic|3
5978039|NCT03548064|9565574|FG006|Overall Study|Covid-19 Pandemic|0
5978040|NCT03548064|9565575|FG007|Overall Study|Covid-19 Pandemic|0
5978041|NCT03446456|9565601|FG000|Overall Study|Participant was in a previous social learning study (exclusion criteria)|1
5978042|NCT03446456|9565602|FG001|Overall Study|Participant was in a previous social learning study (exclusion criteria)|1
5978043|NCT03446456|9565601|FG000|Overall Study|Lost to Follow-up|1
5978044|NCT03446456|9565602|FG001|Overall Study|Lost to Follow-up|3
5978045|NCT03446456|9565601|FG000|Overall Study|Participant failed the toxicology test|1
5978046|NCT03446456|9565602|FG001|Overall Study|Participant failed the toxicology test|0
5978047|NCT03446456|9565601|FG000|Overall Study|Break down of the experimental equipment|1
5978048|NCT03446456|9565602|FG001|Overall Study|Break down of the experimental equipment|0
5978049|NCT03382834|9565610|FG000|Overall Study|Lost to Follow-up|1
5978050|NCT03382834|9565611|FG001|Overall Study|Lost to Follow-up|0
5978051|NCT03382834|9565610|FG000|Overall Study|Withdrawal by Subject|0
5978052|NCT03382834|9565611|FG001|Overall Study|Withdrawal by Subject|1
5978053|NCT03371823|9565619|FG000|Overall Study|Screen fail (did not meet inclusion criteria)|1
5978054|NCT03371823|9565620|FG001|Overall Study|Screen fail (did not meet inclusion criteria)|0
5978055|NCT03353350|9565630|FG000|30-week Core Treatment Period|Protocol Violation|1
5978056|NCT03353350|9565631|FG001|30-week Core Treatment Period|Protocol Violation|1
5978057|NCT03353350|9565632|FG002|30-week Core Treatment Period|Protocol Violation|1
5978058|NCT03353350|9565633|FG003|30-week Core Treatment Period|Protocol Violation|0
5978059|NCT03353350|9565630|FG000|30-week Core Treatment Period|Other: Not related to COVID-19|2
5978060|NCT03353350|9565631|FG001|30-week Core Treatment Period|Other: Not related to COVID-19|2
5978061|NCT03353350|9565632|FG002|30-week Core Treatment Period|Other: Not related to COVID-19|2
5978062|NCT03353350|9565633|FG003|30-week Core Treatment Period|Other: Not related to COVID-19|0
5978063|NCT03353350|9565630|FG000|30-week Core Treatment Period|Adverse Event|0
5978064|NCT03353350|9565631|FG001|30-week Core Treatment Period|Adverse Event|4
5978065|NCT03353350|9565632|FG002|30-week Core Treatment Period|Adverse Event|2
5978066|NCT03353350|9565633|FG003|30-week Core Treatment Period|Adverse Event|3
5978067|NCT03353350|9565630|FG000|30-week Core Treatment Period|Withdrawal by Subject|19
5978068|NCT03353350|9565631|FG001|30-week Core Treatment Period|Withdrawal by Subject|12
5978069|NCT03353350|9565632|FG002|30-week Core Treatment Period|Withdrawal by Subject|19
5978070|NCT03353350|9565633|FG003|30-week Core Treatment Period|Withdrawal by Subject|19
5978071|NCT03353350|9565630|FG000|26-week Treatment Extension Period|Protocol Violation|2
5978072|NCT03353350|9565631|FG001|26-week Treatment Extension Period|Protocol Violation|0
6279215|NCT02267135|9987744|FG000|Period 2 (Randomized Set)|Withdrawal by Subject|1
6279216|NCT02267135|9987745|FG001|Period 2 (Randomized Set)|Withdrawal by Subject|0
6279217|NCT02267187|9987754|FG000|Overall Study|Physician Decision|2
6279218|NCT02267187|9987754|FG000|Overall Study|Screen fail|3
6279219|NCT02267278|9987777|FG000|Overall Study|Proceeded to transplantation (allo-HCT)|1
6279220|NCT02267278|9987777|FG000|Overall Study|transformation to acute leukemia (AML)|1
6279221|NCT02267278|9987777|FG000|Overall Study|Developed new cancer diagnoses|2
6279222|NCT02267278|9987777|FG000|Overall Study|prescribed prohibited medication|1
6279223|NCT02267317|9987784|FG000|Washout (3-4weeks Between Infusions)|Withdrawal by Subject|1
6279224|NCT02267317|9987785|FG001|Washout (3-4weeks Between Infusions)|Withdrawal by Subject|0
6279225|NCT02267317|9987786|FG002|Washout (3-4weeks Between Infusions)|Withdrawal by Subject|0
6279226|NCT02267317|9987787|FG003|Washout (3-4weeks Between Infusions)|Withdrawal by Subject|0
6279227|NCT02267317|9987788|FG004|Washout (3-4weeks Between Infusions)|Withdrawal by Subject|0
6279228|NCT02267317|9987789|FG005|Washout (3-4weeks Between Infusions)|Withdrawal by Subject|0
6279229|NCT02267317|9987784|FG000|Washout (3-4weeks Between Infusions)|Lost to Follow-up|1
6279230|NCT02267317|9987785|FG001|Washout (3-4weeks Between Infusions)|Lost to Follow-up|0
6279231|NCT02267317|9987786|FG002|Washout (3-4weeks Between Infusions)|Lost to Follow-up|0
6279232|NCT02267317|9987787|FG003|Washout (3-4weeks Between Infusions)|Lost to Follow-up|0
6279233|NCT02267317|9987788|FG004|Washout (3-4weeks Between Infusions)|Lost to Follow-up|0
6279234|NCT02267317|9987789|FG005|Washout (3-4weeks Between Infusions)|Lost to Follow-up|0
5978073|NCT03353350|9565632|FG002|26-week Treatment Extension Period|Protocol Violation|0
5978074|NCT03353350|9565633|FG003|26-week Treatment Extension Period|Protocol Violation|0
5978075|NCT03353350|9565630|FG000|26-week Treatment Extension Period|Other: Not related to COVID-19|0
5978076|NCT03353350|9565631|FG001|26-week Treatment Extension Period|Other: Not related to COVID-19|0
5978077|NCT03353350|9565632|FG002|26-week Treatment Extension Period|Other: Not related to COVID-19|1
5978078|NCT03353350|9565633|FG003|26-week Treatment Extension Period|Other: Not related to COVID-19|1
5978079|NCT03353350|9565630|FG000|26-week Treatment Extension Period|Adverse Event|1
5978080|NCT03353350|9565631|FG001|26-week Treatment Extension Period|Adverse Event|0
5978081|NCT03353350|9565632|FG002|26-week Treatment Extension Period|Adverse Event|0
5978082|NCT03353350|9565633|FG003|26-week Treatment Extension Period|Adverse Event|1
5978083|NCT03353350|9565630|FG000|26-week Treatment Extension Period|Withdrawal by Subject|2
5978084|NCT03353350|9565631|FG001|26-week Treatment Extension Period|Withdrawal by Subject|3
5978085|NCT03353350|9565632|FG002|26-week Treatment Extension Period|Withdrawal by Subject|3
5978086|NCT03353350|9565633|FG003|26-week Treatment Extension Period|Withdrawal by Subject|12
5978087|NCT03350503|9565643|FG000|Overall Study|Adverse Event|1
5978088|NCT03350503|9565643|FG000|Overall Study|Hospital Transfer or Removal|2
5978089|NCT03350503|9565643|FG000|Overall Study|Subject Wishes|2
5978090|NCT03326193|9565647|FG000|Overall Study|Treatment ongoing at the time of analysis|26
5978091|NCT03326193|9565647|FG000|Overall Study|Death|19
5978092|NCT03326193|9565647|FG000|Overall Study|Withdrawal by Subject|8
5978093|NCT03282565|9565663|FG000|Overall Study|COVID-19 Research Shutdown|0
5978094|NCT03282565|9565664|FG001|Overall Study|COVID-19 Research Shutdown|2
5978095|NCT03282565|9565665|FG002|Overall Study|COVID-19 Research Shutdown|2
5978096|NCT03276936|9565675|FG000|Overall Study|Adverse Event|4
5978097|NCT03276936|9565676|FG001|Overall Study|Adverse Event|2
5978098|NCT03276936|9565675|FG000|Overall Study|Lost to Follow-up|16
5978099|NCT03276936|9565676|FG001|Overall Study|Lost to Follow-up|13
5978100|NCT03276936|9565675|FG000|Overall Study|Withdrawal by Subject|30
5978101|NCT03276936|9565676|FG001|Overall Study|Withdrawal by Subject|20
5978102|NCT03276936|9565675|FG000|Overall Study|Not mentioned|6
5978103|NCT03276936|9565676|FG001|Overall Study|Not mentioned|3
6279235|NCT02267746|9987876|FG000|Overall Study|Adverse Event|0
6279236|NCT02267746|9987877|FG001|Overall Study|Adverse Event|2
6279237|NCT02267746|9987878|FG002|Overall Study|Adverse Event|1
6279238|NCT02267746|9987876|FG000|Overall Study|Protocol Violation|8
6279239|NCT02267746|9987877|FG001|Overall Study|Protocol Violation|7
6279240|NCT02267746|9987878|FG002|Overall Study|Protocol Violation|3
6279241|NCT02267746|9987876|FG000|Overall Study|Lack of Efficacy|11
6279242|NCT02267746|9987877|FG001|Overall Study|Lack of Efficacy|11
6279243|NCT02267746|9987878|FG002|Overall Study|Lack of Efficacy|15
6279244|NCT02267746|9987876|FG000|Overall Study|Protocol Violation|1
6279245|NCT02267746|9987877|FG001|Overall Study|Protocol Violation|2
6279246|NCT02267746|9987878|FG002|Overall Study|Protocol Violation|1
6279247|NCT02267746|9987876|FG000|Overall Study|Miscellaneous|1
6279248|NCT02267746|9987877|FG001|Overall Study|Miscellaneous|0
6279249|NCT02267746|9987878|FG002|Overall Study|Miscellaneous|1
6279250|NCT02267824|9987910|FG000|Overall Study|Pregnancy|1
6279251|NCT02267824|9987911|FG001|Overall Study|Pregnancy|1
6279252|NCT02267824|9987910|FG000|Overall Study|Lost to Follow-up|4
6279253|NCT02267824|9987911|FG001|Overall Study|Lost to Follow-up|0
6279254|NCT02267824|9987910|FG000|Overall Study|Protocol Violation|3
6279255|NCT02267824|9987911|FG001|Overall Study|Protocol Violation|0
6279256|NCT02267824|9987910|FG000|Overall Study|Did Not Meet Initial Dental Criteria|2
6279257|NCT02267824|9987911|FG001|Overall Study|Did Not Meet Initial Dental Criteria|0
6279258|NCT02268045|9987937|FG000|Overall Study|Death|4
6279259|NCT02268045|9987938|FG001|Overall Study|Death|4
6279260|NCT02268045|9987937|FG000|Overall Study|Disease Progression|2
6279261|NCT02268045|9987938|FG001|Overall Study|Disease Progression|1
6279262|NCT02268045|9987937|FG000|Overall Study|Adverse Event|7
6279263|NCT02268045|9987938|FG001|Overall Study|Adverse Event|7
6279264|NCT02268045|9987937|FG000|Overall Study|Withdrawal by Subject|2
6279265|NCT02268045|9987938|FG001|Overall Study|Withdrawal by Subject|6
6279266|NCT02268045|9987937|FG000|Overall Study|Physician Decision|0
6279267|NCT02268045|9987938|FG001|Overall Study|Physician Decision|1
6279268|NCT02268045|9987937|FG000|Overall Study|Protocol Violation|1
6279269|NCT02268045|9987938|FG001|Overall Study|Protocol Violation|1
6279270|NCT02268058|9987950|FG000|Overall Study|Protocol Violation|1
6279271|NCT02268058|9987951|FG001|Overall Study|Protocol Violation|0
6279272|NCT02268058|9987952|FG002|Overall Study|Protocol Violation|0
6279273|NCT02268058|9987953|FG003|Overall Study|Protocol Violation|0
6279274|NCT02268084|9987965|FG000|Overall Study|Three subjects in the sham had early blind code opening due to symptomatic worsening.|0
6279275|NCT02268084|9987966|FG001|Overall Study|Three subjects in the sham had early blind code opening due to symptomatic worsening.|3
6279276|NCT02268084|9987965|FG000|Overall Study|Combination of the following, exact numbers not available: Lost to follow-up, voluntary withdrawal|9
6279277|NCT02268084|9987966|FG001|Overall Study|Combination of the following, exact numbers not available: Lost to follow-up, voluntary withdrawal|4
6279278|NCT02268214|9987981|FG000|Overall Study|Subject no longer meets study criteria|0
6279279|NCT02268214|9987982|FG001|Overall Study|Subject no longer meets study criteria|2
6279280|NCT02268214|9987983|FG002|Overall Study|Subject no longer meets study criteria|0
6279281|NCT02268214|9987981|FG000|Overall Study|Pregnancy|2
6279282|NCT02268214|9987982|FG001|Overall Study|Pregnancy|2
6279283|NCT02268214|9987983|FG002|Overall Study|Pregnancy|1
6279284|NCT02268214|9987981|FG000|Overall Study|Lost to Follow-up|3
6279285|NCT02268214|9987982|FG001|Overall Study|Lost to Follow-up|3
6279286|NCT02268214|9987983|FG002|Overall Study|Lost to Follow-up|4
6279287|NCT02268214|9987981|FG000|Overall Study|Lack of Efficacy|1
6279288|NCT02268214|9987982|FG001|Overall Study|Lack of Efficacy|0
6279289|NCT02268214|9987983|FG002|Overall Study|Lack of Efficacy|2
6279290|NCT02268214|9987981|FG000|Overall Study|Adverse Event|11
6279291|NCT02268214|9987982|FG001|Overall Study|Adverse Event|14
6279292|NCT02268214|9987983|FG002|Overall Study|Adverse Event|9
6279293|NCT02268214|9987981|FG000|Overall Study|Withdrawal by Subject|4
6279294|NCT02268214|9987982|FG001|Overall Study|Withdrawal by Subject|5
6279295|NCT02268214|9987983|FG002|Overall Study|Withdrawal by Subject|10
6279296|NCT02268214|9987981|FG000|Overall Study|Subject request to discontinue treatment|10
6279297|NCT02268214|9987982|FG001|Overall Study|Subject request to discontinue treatment|8
6279298|NCT02268214|9987983|FG002|Overall Study|Subject request to discontinue treatment|6
5978104|NCT03271021|9565684|FG000|Overall Study|Adverse Event|3
5978105|NCT03271021|9565685|FG001|Overall Study|Adverse Event|2
5978106|NCT03271021|9565684|FG000|Overall Study|Withdrawal by Subject|36
5978107|NCT03271021|9565685|FG001|Overall Study|Withdrawal by Subject|53
5978108|NCT03271021|9565684|FG000|Overall Study|Lost to Follow-up|34
5978109|NCT03271021|9565685|FG001|Overall Study|Lost to Follow-up|39
5978110|NCT03271021|9565684|FG000|Overall Study|Protocol Violation|6
6279299|NCT02268214|9987981|FG000|Overall Study|Poor/non-compliance|2
6279300|NCT02268214|9987982|FG001|Overall Study|Poor/non-compliance|1
6279301|NCT02268214|9987983|FG002|Overall Study|Poor/non-compliance|2
6279302|NCT02268214|9987981|FG000|Overall Study|Other reasons|7
6279303|NCT02268214|9987982|FG001|Overall Study|Other reasons|3
6279304|NCT02268214|9987983|FG002|Overall Study|Other reasons|3
6279305|NCT02268214|9987981|FG000|Overall Study|Not entering long-term period|2
6279306|NCT02268214|9987982|FG001|Overall Study|Not entering long-term period|3
6279307|NCT02268214|9987983|FG002|Overall Study|Not entering long-term period|5
5978111|NCT03271021|9565685|FG001|Overall Study|Protocol Violation|4
5978112|NCT03271021|9565684|FG000|Overall Study|Abnormal Lab Results|1
6279308|NCT02268396|9987991|FG000|Overall Study|Adverse Event|3
6279309|NCT02268396|9987991|FG000|Overall Study|Administrative|2
6279310|NCT02268396|9987991|FG000|Overall Study|Withdrawal by Subject|1
6279311|NCT02268396|9987991|FG000|Overall Study|Lost to Follow-up|2
6279312|NCT02268396|9987991|FG000|Overall Study|Protocol-Specified Criteria|2
6279313|NCT02268396|9987991|FG000|Overall Study|2 Subjects no Day 29 Assessment|2
6279314|NCT02268526|9988007|FG000|Overall Study|Adverse Event|0
6279315|NCT02268526|9988008|FG001|Overall Study|Adverse Event|2
6279316|NCT02268526|9988009|FG002|Overall Study|Adverse Event|1
6279317|NCT02268526|9988007|FG000|Overall Study|Death|1
6279318|NCT02268526|9988008|FG001|Overall Study|Death|11
6279319|NCT02268526|9988009|FG002|Overall Study|Death|0
6279320|NCT02268526|9988007|FG000|Overall Study|protocol deviation|0
6279321|NCT02268526|9988008|FG001|Overall Study|protocol deviation|1
6279322|NCT02268526|9988009|FG002|Overall Study|protocol deviation|0
6279323|NCT02268526|9988007|FG000|Overall Study|Physician Decision|0
6279324|NCT02268526|9988008|FG001|Overall Study|Physician Decision|0
6279325|NCT02268526|9988009|FG002|Overall Study|Physician Decision|1
6279326|NCT02268526|9988007|FG000|Overall Study|Subject/guardian decision|0
6279327|NCT02268526|9988008|FG001|Overall Study|Subject/guardian decision|7
6279328|NCT02268526|9988009|FG002|Overall Study|Subject/guardian decision|3
6279329|NCT02268786|9988021|FG000|Overall Study|No Euploid Embryos available|42
6279330|NCT02268786|9988022|FG001|Overall Study|No Euploid Embryos available|0
6279331|NCT02268786|9988021|FG000|Overall Study|Withdrawal by Subject|7
6279332|NCT02268786|9988022|FG001|Overall Study|Withdrawal by Subject|14
6279333|NCT02268786|9988021|FG000|Overall Study|Thaw Failure|6
6279334|NCT02268786|9988022|FG001|Overall Study|Thaw Failure|4
6279335|NCT02268786|9988021|FG000|Overall Study|Protocol Violation|1
6279336|NCT02268786|9988022|FG001|Overall Study|Protocol Violation|0
6279337|NCT02268812|9988032|FG000|Overall Study|Adverse Event|8
6279338|NCT02268812|9988033|FG001|Overall Study|Adverse Event|26
6279339|NCT02268812|9988034|FG002|Overall Study|Adverse Event|7
6279340|NCT02268812|9988035|FG003|Overall Study|Adverse Event|10
6279341|NCT02268812|9988032|FG000|Overall Study|Protocol deviation|0
6279342|NCT02268812|9988033|FG001|Overall Study|Protocol deviation|0
6279343|NCT02268812|9988034|FG002|Overall Study|Protocol deviation|1
6279344|NCT02268812|9988035|FG003|Overall Study|Protocol deviation|0
6279345|NCT02268812|9988032|FG000|Overall Study|Withdrawal by Subject|0
6279346|NCT02268812|9988033|FG001|Overall Study|Withdrawal by Subject|1
6279347|NCT02268812|9988034|FG002|Overall Study|Withdrawal by Subject|0
6279348|NCT02268812|9988035|FG003|Overall Study|Withdrawal by Subject|0
6201861|NCT01497197|9861855|FG001|Overall Study|Risk of OHSS|0
6201862|NCT01497197|9861854|FG000|Overall Study|No oocytes retrieved|3
6201863|NCT01497197|9861855|FG001|Overall Study|No oocytes retrieved|2
6201864|NCT01497197|9861854|FG000|Overall Study|No fertilisation|6
6201865|NCT01497197|9861855|FG001|Overall Study|No fertilisation|5
6201866|NCT01497197|9861854|FG000|Overall Study|Intention to freeze all embryos|0
6201867|NCT01497197|9861855|FG001|Overall Study|Intention to freeze all embryos|1
6201868|NCT01497197|9861854|FG000|Overall Study|All embryos discarded|0
6201869|NCT01497197|9861855|FG001|Overall Study|All embryos discarded|3
6201870|NCT01497197|9861854|FG000|Overall Study|Other|3
6201871|NCT01497197|9861855|FG001|Overall Study|Other|1
6201872|NCT01497262|9861861|FG000|Overall Study|Abnormal Lab Values|4
6279349|NCT02268812|9988032|FG000|Overall Study|Physician Decision|3
6279350|NCT02268812|9988033|FG001|Overall Study|Physician Decision|1
6279351|NCT02268812|9988034|FG002|Overall Study|Physician Decision|0
6279352|NCT02268812|9988035|FG003|Overall Study|Physician Decision|1
6279353|NCT02268812|9988032|FG000|Overall Study|Other|5
6279354|NCT02268812|9988033|FG001|Overall Study|Other|4
6279355|NCT02268812|9988034|FG002|Overall Study|Other|1
6279356|NCT02268812|9988035|FG003|Overall Study|Other|3
6279357|NCT02268851|9988051|FG000|Overall Study|Death|0
6279358|NCT02268851|9988052|FG001|Overall Study|Death|0
6279359|NCT02268851|9988053|FG002|Overall Study|Death|0
6279360|NCT02268851|9988054|FG003|Overall Study|Death|1
6279361|NCT02268851|9988055|FG004|Overall Study|Death|2
6279362|NCT02268851|9988056|FG005|Overall Study|Death|1
6279363|NCT02268851|9988051|FG000|Overall Study|Adverse Event|0
6279364|NCT02268851|9988052|FG001|Overall Study|Adverse Event|0
6279365|NCT02268851|9988053|FG002|Overall Study|Adverse Event|0
6279366|NCT02268851|9988054|FG003|Overall Study|Adverse Event|0
6279367|NCT02268851|9988055|FG004|Overall Study|Adverse Event|2
6279368|NCT02268851|9988056|FG005|Overall Study|Adverse Event|2
6279369|NCT02268851|9988051|FG000|Overall Study|Withdrawal by Subject|0
6279370|NCT02268851|9988052|FG001|Overall Study|Withdrawal by Subject|0
6279371|NCT02268851|9988053|FG002|Overall Study|Withdrawal by Subject|0
6279372|NCT02268851|9988054|FG003|Overall Study|Withdrawal by Subject|2
6279373|NCT02268851|9988055|FG004|Overall Study|Withdrawal by Subject|0
6279374|NCT02268851|9988056|FG005|Overall Study|Withdrawal by Subject|1
6279375|NCT02268851|9988051|FG000|Overall Study|Progressive Disease|1
6279376|NCT02268851|9988052|FG001|Overall Study|Progressive Disease|3
6279377|NCT02268851|9988053|FG002|Overall Study|Progressive Disease|0
6279378|NCT02268851|9988054|FG003|Overall Study|Progressive Disease|0
6279379|NCT02268851|9988055|FG004|Overall Study|Progressive Disease|1
6279380|NCT02268851|9988056|FG005|Overall Study|Progressive Disease|4
6279381|NCT02268851|9988051|FG000|Overall Study|Physician Decision|0
6279382|NCT02268851|9988052|FG001|Overall Study|Physician Decision|0
6279383|NCT02268851|9988053|FG002|Overall Study|Physician Decision|1
6279384|NCT02268851|9988054|FG003|Overall Study|Physician Decision|0
6279385|NCT02268851|9988055|FG004|Overall Study|Physician Decision|0
6279386|NCT02268851|9988056|FG005|Overall Study|Physician Decision|1
6279387|NCT02268851|9988051|FG000|Overall Study|Patient Compliance|0
6279388|NCT02268851|9988052|FG001|Overall Study|Patient Compliance|0
6279389|NCT02268851|9988053|FG002|Overall Study|Patient Compliance|0
6279390|NCT02268851|9988054|FG003|Overall Study|Patient Compliance|0
6279391|NCT02268851|9988055|FG004|Overall Study|Patient Compliance|1
6279392|NCT02268851|9988056|FG005|Overall Study|Patient Compliance|1
6279393|NCT02268851|9988051|FG000|Overall Study|Co-Morbid Condition|0
6279394|NCT02268851|9988052|FG001|Overall Study|Co-Morbid Condition|0
6279395|NCT02268851|9988053|FG002|Overall Study|Co-Morbid Condition|0
6279396|NCT02268851|9988054|FG003|Overall Study|Co-Morbid Condition|0
6279397|NCT02268851|9988055|FG004|Overall Study|Co-Morbid Condition|1
6279398|NCT02268851|9988056|FG005|Overall Study|Co-Morbid Condition|1
6279399|NCT02268864|9988073|FG000|Overall Study|Withdrawal by Subject|2
6279400|NCT02268864|9988074|FG001|Overall Study|Withdrawal by Subject|0
6279401|NCT02268864|9988075|FG002|Overall Study|Withdrawal by Subject|0
6279402|NCT02268864|9988073|FG000|Overall Study|Death|0
6279403|NCT02268864|9988074|FG001|Overall Study|Death|1
6279404|NCT02268864|9988075|FG002|Overall Study|Death|0
6279405|NCT02269098|9988121|FG000|Overall Study|Lost to Follow-up|14
6279406|NCT02269098|9988122|FG001|Overall Study|Lost to Follow-up|9
6279407|NCT02269124|9988131|FG000|Overall Study|Lost to Follow-up|1
6279408|NCT02269124|9988132|FG001|Overall Study|Lost to Follow-up|0
6279409|NCT02269124|9988131|FG000|Overall Study|Withdrawal by Subject|0
6279410|NCT02269124|9988132|FG001|Overall Study|Withdrawal by Subject|2
6279411|NCT02269163|9988141|FG000|Overall Study|Lost to Follow-up|1
6279412|NCT02269163|9988142|FG001|Overall Study|Lost to Follow-up|0
6279413|NCT02269163|9988141|FG000|Overall Study|Major protocol violation|0
6279414|NCT02269163|9988142|FG001|Overall Study|Major protocol violation|1
6279415|NCT02269163|9988141|FG000|Overall Study|Other|2
6279416|NCT02269163|9988142|FG001|Overall Study|Other|2
6279417|NCT02269163|9988141|FG000|Overall Study|Withdrawal by Subject|0
6279418|NCT02269163|9988142|FG001|Overall Study|Withdrawal by Subject|3
6279419|NCT02269163|9988141|FG000|Overall Study|Physician Decision|0
5978113|NCT03271021|9565685|FG001|Overall Study|Abnormal Lab Results|0
5978114|NCT03271021|9565684|FG000|Overall Study|Miscellaneous|9
5978115|NCT03271021|9565685|FG001|Overall Study|Miscellaneous|8
5978116|NCT03255083|9565695|FG000|Overall Study|Clinical progression|1
5978117|NCT03255083|9565696|FG001|Overall Study|Clinical progression|0
5978118|NCT03255083|9565697|FG002|Overall Study|Clinical progression|0
6279420|NCT02269163|9988142|FG001|Overall Study|Physician Decision|1
6279421|NCT02269241|9988150|FG000|Overall Study|Lost to Follow-up|269
6279422|NCT02269241|9988150|FG000|Overall Study|Withdrawal by Subject|155
6279423|NCT02269241|9988150|FG000|Overall Study|Protocol Violation|1
6279424|NCT02269241|9988150|FG000|Overall Study|Physician Decision|7
6279425|NCT02269241|9988150|FG000|Overall Study|Pregnancy|15
5978119|NCT03255083|9565698|FG003|Overall Study|Clinical progression|0
6279426|NCT02269241|9988150|FG000|Overall Study|Wish for pregnancy|5
6279427|NCT02269241|9988150|FG000|Overall Study|Development of an exclusion criteria|16
6279428|NCT02269241|9988150|FG000|Overall Study|Adverse Event|113
6279429|NCT02269241|9988150|FG000|Overall Study|At the specific request of the sponsor|20
6279430|NCT02269241|9988150|FG000|Overall Study|Several reasons not classified|53
6279431|NCT02269241|9988150|FG000|Overall Study|Screening failures|546
6279432|NCT02269423|9988159|FG000|Overall Study|Discontinued due to change in residence|0
6279433|NCT02269423|9988160|FG001|Overall Study|Discontinued due to change in residence|1
6279434|NCT02269423|9988161|FG002|Overall Study|Discontinued due to change in residence|0
6279435|NCT02269423|9988162|FG003|Overall Study|Discontinued due to change in residence|1
6279436|NCT02269475|9988174|FG000|Overall Study|Meet Exclusion Criteria No. 17|3
6279437|NCT02269475|9988175|FG001|Overall Study|Meet Exclusion Criteria No. 17|0
6279438|NCT02269475|9988174|FG000|Overall Study|Withdrawal by Subject|0
6279439|NCT02269475|9988175|FG001|Overall Study|Withdrawal by Subject|1
6279440|NCT02269657|9988195|FG000|Overall Study|Protocol Violation|3
6279441|NCT02269709|9988201|FG000|Time of Enrollment|Withdrawal by Subject|3
6279442|NCT02269709|9988201|FG000|Follow-up #1 (24-72 Hours Post-surgery)|Lost to Follow-up|1
6279443|NCT02269709|9988201|FG000|Six Month Follow-up|Lost to Follow-up|12
6279444|NCT02269787|9988208|FG000|Overall Study|Lost to Follow-up|20
6279445|NCT02269787|9988209|FG001|Overall Study|Lost to Follow-up|6
6279446|NCT02269787|9988208|FG000|Overall Study|Death|2
6279447|NCT02269787|9988209|FG001|Overall Study|Death|3
6279448|NCT02269787|9988208|FG000|Overall Study|Incapacitated|0
6279449|NCT02269787|9988209|FG001|Overall Study|Incapacitated|1
6279450|NCT02269943|9988217|FG000|Treatment Period|Death|0
6279451|NCT02269943|9988218|FG001|Treatment Period|Death|1
6279452|NCT02269943|9988217|FG000|Treatment Period|Adverse Event|1
6279453|NCT02269943|9988218|FG001|Treatment Period|Adverse Event|10
6279454|NCT02269943|9988217|FG000|Treatment Period|Progressive Disease|5
5978120|NCT03255083|9565695|FG000|Overall Study|Adverse Event|0
5978121|NCT03255083|9565696|FG001|Overall Study|Adverse Event|1
5978122|NCT03255083|9565697|FG002|Overall Study|Adverse Event|0
5978123|NCT03255083|9565698|FG003|Overall Study|Adverse Event|0
5978124|NCT03255083|9565695|FG000|Overall Study|Progressive disease by RECIST version 1.1|4
5978125|NCT03255083|9565696|FG001|Overall Study|Progressive disease by RECIST version 1.1|1
5978126|NCT03255083|9565697|FG002|Overall Study|Progressive disease by RECIST version 1.1|2
5978127|NCT03255083|9565698|FG003|Overall Study|Progressive disease by RECIST version 1.1|1
5978128|NCT03255083|9565695|FG000|Overall Study|Withdrawal by Subject|1
5978129|NCT03255083|9565696|FG001|Overall Study|Withdrawal by Subject|1
5978130|NCT03255083|9565697|FG002|Overall Study|Withdrawal by Subject|1
5978131|NCT03255083|9565698|FG003|Overall Study|Withdrawal by Subject|0
5978132|NCT03227471|9565723|FG000|Overall Study|Withdrawal by Subject|0
5978133|NCT03227471|9565724|FG001|Overall Study|Withdrawal by Subject|0
5978134|NCT03227471|9565725|FG002|Overall Study|Withdrawal by Subject|0
5978135|NCT03227471|9565726|FG003|Overall Study|Withdrawal by Subject|0
5978136|NCT03227471|9565727|FG004|Overall Study|Withdrawal by Subject|1
5978137|NCT03227471|9565728|FG005|Overall Study|Withdrawal by Subject|0
5978138|NCT03227471|9565729|FG006|Overall Study|Withdrawal by Subject|0
5978139|NCT03227471|9565730|FG007|Overall Study|Withdrawal by Subject|0
5978140|NCT03227471|9565731|FG008|Overall Study|Withdrawal by Subject|0
5978141|NCT03227471|9565732|FG009|Overall Study|Withdrawal by Subject|0
5978142|NCT03227471|9565733|FG010|Overall Study|Withdrawal by Subject|0
5978143|NCT03227471|9565734|FG011|Overall Study|Withdrawal by Subject|0
5978144|NCT03227471|9565735|FG012|Overall Study|Withdrawal by Subject|1
5978145|NCT03227471|9565736|FG013|Overall Study|Withdrawal by Subject|0
5978146|NCT03227471|9565737|FG014|Overall Study|Withdrawal by Subject|0
5978147|NCT03227471|9565723|FG000|Overall Study|Randomized, Never Dosed|0
5978148|NCT03227471|9565724|FG001|Overall Study|Randomized, Never Dosed|0
5978149|NCT03227471|9565725|FG002|Overall Study|Randomized, Never Dosed|0
5978150|NCT03227471|9565726|FG003|Overall Study|Randomized, Never Dosed|0
5978151|NCT03227471|9565727|FG004|Overall Study|Randomized, Never Dosed|0
5978152|NCT03227471|9565728|FG005|Overall Study|Randomized, Never Dosed|0
5978153|NCT03227471|9565729|FG006|Overall Study|Randomized, Never Dosed|0
5978154|NCT03227471|9565730|FG007|Overall Study|Randomized, Never Dosed|0
5978155|NCT03227471|9565731|FG008|Overall Study|Randomized, Never Dosed|0
5978156|NCT03227471|9565732|FG009|Overall Study|Randomized, Never Dosed|0
5978157|NCT03227471|9565733|FG010|Overall Study|Randomized, Never Dosed|0
5978158|NCT03227471|9565734|FG011|Overall Study|Randomized, Never Dosed|0
5978159|NCT03227471|9565735|FG012|Overall Study|Randomized, Never Dosed|0
5978160|NCT03227471|9565736|FG013|Overall Study|Randomized, Never Dosed|0
5978161|NCT03227471|9565737|FG014|Overall Study|Randomized, Never Dosed|1
6051001|NCT00430521|9650237|FG000|Overall Study|Withdrawal by Subject|3
6051002|NCT00430521|9650238|FG001|Overall Study|Withdrawal by Subject|1
6051003|NCT00430521|9650239|FG002|Overall Study|Withdrawal by Subject|0
6051004|NCT00430521|9650240|FG003|Overall Study|Withdrawal by Subject|3
6051005|NCT00430521|9650241|FG004|Overall Study|Withdrawal by Subject|0
6051006|NCT00430521|9650242|FG005|Overall Study|Withdrawal by Subject|0
6051007|NCT00430521|9650243|FG006|Overall Study|Withdrawal by Subject|0
6051008|NCT00430521|9650244|FG007|Overall Study|Withdrawal by Subject|2
6051009|NCT00430573|9650275|FG000|Overall Study|Withdrawal by Subject|5
6051010|NCT00430638|9650292|FG000|Overall Study|Adverse Event|15
6051011|NCT00430638|9650293|FG001|Overall Study|Adverse Event|15
6051012|NCT00430638|9650292|FG000|Overall Study|Uncontrolled blood pressure|48
6051013|NCT00430638|9650293|FG001|Overall Study|Uncontrolled blood pressure|13
6279455|NCT02269943|9988218|FG001|Treatment Period|Progressive Disease|17
6279456|NCT02269943|9988217|FG000|Treatment Period|Symptomatic Deterioration|0
6279457|NCT02269943|9988218|FG001|Treatment Period|Symptomatic Deterioration|2
6279458|NCT02269943|9988217|FG000|Follow-Up Survival Period|Death|3
6279459|NCT02269943|9988218|FG001|Follow-Up Survival Period|Death|16
6279460|NCT02269943|9988217|FG000|Follow-Up Survival Period|Lost to Follow-up|0
6279461|NCT02269943|9988218|FG001|Follow-Up Survival Period|Lost to Follow-up|2
6279462|NCT02269943|9988217|FG000|Follow-Up Survival Period|Alive|2
6279463|NCT02269943|9988218|FG001|Follow-Up Survival Period|Alive|8
6279464|NCT02270242|9988239|FG000|Overall Study|Withdrawal by Subject|18
6279465|NCT02270242|9988240|FG001|Overall Study|Withdrawal by Subject|25
6279466|NCT02270242|9988239|FG000|Overall Study|Lost to Follow-up|41
6279467|NCT02270242|9988240|FG001|Overall Study|Lost to Follow-up|27
6279468|NCT02270242|9988239|FG000|Overall Study|Physician Decision|0
6279469|NCT02270242|9988240|FG001|Overall Study|Physician Decision|1
6279470|NCT02270515|9988255|FG000|Intervention Period 1: 0-6 Months|Withdrawal by Subject|1
6279471|NCT02270515|9988255|FG000|Intervention Period 1: 0-6 Months|No longer patient at study site|5
6279472|NCT02270515|9988255|FG000|Intervention Period 1: 0-6 Months|Received transplant|3
6279473|NCT02270515|9988255|FG000|Intervention Period 1: 0-6 Months|Death|7
6279474|NCT02270515|9988255|FG000|Intervention Period 2: 6-12 Months|Withdrawal by Subject|2
6279475|NCT02270515|9988255|FG000|Intervention Period 2: 6-12 Months|No longer patient at study site|7
6279476|NCT02270515|9988255|FG000|Intervention Period 2: 6-12 Months|Received transplant|1
6279477|NCT02270515|9988255|FG000|Intervention Period 2: 6-12 Months|Death|5
6279478|NCT02270515|9988255|FG000|Intervention Period 2: 6-12 Months|Intervention ended before follow-up|17
6279479|NCT02270515|9988255|FG000|Intervention Period 3: 12-18 Months|Withdrawal by Subject|1
6279480|NCT02270515|9988255|FG000|Intervention Period 3: 12-18 Months|No longer patient at study site|2
6279481|NCT02270515|9988255|FG000|Intervention Period 3: 12-18 Months|Received transplant|2
6279482|NCT02270515|9988255|FG000|Intervention Period 3: 12-18 Months|Death|3
6279483|NCT02270515|9988255|FG000|Intervention Period 3: 12-18 Months|Intervention ended before follow-up|16
6279484|NCT02270671|9988277|FG000|Overall Study|Withdrawal by Subject|1
6279485|NCT02270671|9988278|FG001|Overall Study|Withdrawal by Subject|1
6279486|NCT02270671|9988277|FG000|Overall Study|Protocol Violation|0
6279487|NCT02270671|9988278|FG001|Overall Study|Protocol Violation|1
6279488|NCT02270671|9988277|FG000|Overall Study|Missed Post-intervention Data Collection|2
6279489|NCT02270671|9988278|FG001|Overall Study|Missed Post-intervention Data Collection|2
6279490|NCT02270671|9988277|FG000|Overall Study|Lost to Follow-up|2
6279491|NCT02270671|9988278|FG001|Overall Study|Lost to Follow-up|1
6279492|NCT02270736|9988287|FG000|Main Period (MP) (up to 16 Weeks)|Adverse Event|0
6279493|NCT02270736|9988288|FG001|Main Period (MP) (up to 16 Weeks)|Adverse Event|1
6279494|NCT02270736|9988289|FG002|Main Period (MP) (up to 16 Weeks)|Adverse Event|0
6279495|NCT02270736|9988290|FG003|Main Period (MP) (up to 16 Weeks)|Adverse Event|0
6279496|NCT02270736|9988291|FG004|Main Period (MP) (up to 16 Weeks)|Adverse Event|0
6279497|NCT02270736|9988287|FG000|Main Period (MP) (up to 16 Weeks)|Withdrawal by Subject|2
6279498|NCT02270736|9988288|FG001|Main Period (MP) (up to 16 Weeks)|Withdrawal by Subject|0
6279499|NCT02270736|9988289|FG002|Main Period (MP) (up to 16 Weeks)|Withdrawal by Subject|1
6279500|NCT02270736|9988290|FG003|Main Period (MP) (up to 16 Weeks)|Withdrawal by Subject|0
6279501|NCT02270736|9988291|FG004|Main Period (MP) (up to 16 Weeks)|Withdrawal by Subject|0
6279502|NCT02270736|9988287|FG000|Main Period (MP) (up to 16 Weeks)|Lost to Follow-up|0
6279503|NCT02270736|9988288|FG001|Main Period (MP) (up to 16 Weeks)|Lost to Follow-up|1
6279504|NCT02270736|9988289|FG002|Main Period (MP) (up to 16 Weeks)|Lost to Follow-up|0
6279505|NCT02270736|9988290|FG003|Main Period (MP) (up to 16 Weeks)|Lost to Follow-up|0
6279506|NCT02270736|9988291|FG004|Main Period (MP) (up to 16 Weeks)|Lost to Follow-up|0
6279507|NCT02270736|9988287|FG000|Main Period (MP) (up to 16 Weeks)|Randomized, not Treated|0
6279508|NCT02270736|9988288|FG001|Main Period (MP) (up to 16 Weeks)|Randomized, not Treated|0
6279509|NCT02270736|9988289|FG002|Main Period (MP) (up to 16 Weeks)|Randomized, not Treated|1
6279510|NCT02270736|9988290|FG003|Main Period (MP) (up to 16 Weeks)|Randomized, not Treated|0
6279511|NCT02270736|9988291|FG004|Main Period (MP) (up to 16 Weeks)|Randomized, not Treated|0
6279512|NCT02270736|9988287|FG000|OLEX Period (up to 48 Weeks)|Physician Decision|0
6279513|NCT02270736|9988288|FG001|OLEX Period (up to 48 Weeks)|Physician Decision|0
6279514|NCT02270736|9988289|FG002|OLEX Period (up to 48 Weeks)|Physician Decision|0
6279515|NCT02270736|9988290|FG003|OLEX Period (up to 48 Weeks)|Physician Decision|1
6279516|NCT02270736|9988291|FG004|OLEX Period (up to 48 Weeks)|Physician Decision|0
6279517|NCT02270736|9988287|FG000|OLEX Period (up to 48 Weeks)|Lack of Efficacy|0
6279518|NCT02270736|9988288|FG001|OLEX Period (up to 48 Weeks)|Lack of Efficacy|0
6279519|NCT02270736|9988289|FG002|OLEX Period (up to 48 Weeks)|Lack of Efficacy|0
6279520|NCT02270736|9988290|FG003|OLEX Period (up to 48 Weeks)|Lack of Efficacy|2
6279521|NCT02270736|9988291|FG004|OLEX Period (up to 48 Weeks)|Lack of Efficacy|0
6279522|NCT02270736|9988287|FG000|OLEX Period (up to 48 Weeks)|Adverse Event|0
6279523|NCT02270736|9988288|FG001|OLEX Period (up to 48 Weeks)|Adverse Event|0
6279524|NCT02270736|9988289|FG002|OLEX Period (up to 48 Weeks)|Adverse Event|0
6279525|NCT02270736|9988290|FG003|OLEX Period (up to 48 Weeks)|Adverse Event|4
6279526|NCT02270736|9988291|FG004|OLEX Period (up to 48 Weeks)|Adverse Event|0
6279527|NCT02270736|9988287|FG000|OLEX Period (up to 48 Weeks)|Withdrawal by Subject|0
6279528|NCT02270736|9988288|FG001|OLEX Period (up to 48 Weeks)|Withdrawal by Subject|0
6279529|NCT02270736|9988289|FG002|OLEX Period (up to 48 Weeks)|Withdrawal by Subject|0
6279530|NCT02270736|9988290|FG003|OLEX Period (up to 48 Weeks)|Withdrawal by Subject|16
6279531|NCT02270736|9988291|FG004|OLEX Period (up to 48 Weeks)|Withdrawal by Subject|0
6279532|NCT02270736|9988287|FG000|OLEX Period (up to 48 Weeks)|Lost to Follow-up|0
6279533|NCT02270736|9988288|FG001|OLEX Period (up to 48 Weeks)|Lost to Follow-up|0
6279534|NCT02270736|9988289|FG002|OLEX Period (up to 48 Weeks)|Lost to Follow-up|0
6279535|NCT02270736|9988290|FG003|OLEX Period (up to 48 Weeks)|Lost to Follow-up|2
6279536|NCT02270736|9988291|FG004|OLEX Period (up to 48 Weeks)|Lost to Follow-up|0
6279537|NCT02270944|9988306|FG000|Overall Study|Lost to Follow-up|9
6279538|NCT02270944|9988307|FG001|Overall Study|Lost to Follow-up|4
6279539|NCT02270944|9988306|FG000|Overall Study|Withdrawal by Subject|2
6279540|NCT02270944|9988307|FG001|Overall Study|Withdrawal by Subject|1
6279541|NCT02270983|9988317|FG000|Overall Study|Adverse Event|3
6279542|NCT02270983|9988318|FG001|Overall Study|Adverse Event|2
6279543|NCT02270983|9988319|FG002|Overall Study|Adverse Event|6
5978162|NCT03221842|9565798|FG000|Period 1 (Open-label)|Adverse Event|4
5978163|NCT03221842|9565799|FG001|Period 1 (Open-label)|Adverse Event|0
5978164|NCT03221842|9565798|FG000|Period 1 (Open-label)|Physician Decision|2
5978165|NCT03221842|9565799|FG001|Period 1 (Open-label)|Physician Decision|0
5978166|NCT03221842|9565798|FG000|Period 1 (Open-label)|Lost to Follow-up|1
5978167|NCT03221842|9565799|FG001|Period 1 (Open-label)|Lost to Follow-up|0
5978168|NCT03221842|9565798|FG000|Period 1 (Open-label)|Terminated by sponsor|1
5978169|NCT03221842|9565799|FG001|Period 1 (Open-label)|Terminated by sponsor|0
5978170|NCT03221842|9565798|FG000|Period 1 (Open-label)|Other|2
5978171|NCT03221842|9565799|FG001|Period 1 (Open-label)|Other|0
5978172|NCT03221842|9565798|FG000|Period 2 (Randomized, Blinded)|Death|0
5978173|NCT03221842|9565799|FG001|Period 2 (Randomized, Blinded)|Death|1
5978174|NCT03221842|9565798|FG000|Period 2 (Randomized, Blinded)|Lack of Efficacy|1
5978175|NCT03221842|9565799|FG001|Period 2 (Randomized, Blinded)|Lack of Efficacy|0
5978176|NCT03194321|9565809|FG000|Overall Study|Withdrawal by Subject|1
5978177|NCT03194321|9565809|FG000|Overall Study|Lost to Follow-up|1
5978178|NCT03194321|9565809|FG000|Overall Study|Travel for Follow-up|1
5978179|NCT03085095|9565815|FG000|Overall Study|Adverse Event|23
5978180|NCT03085095|9565816|FG001|Overall Study|Adverse Event|8
5978181|NCT03085095|9565815|FG000|Overall Study|Protocol Violation|0
5978182|NCT03085095|9565816|FG001|Overall Study|Protocol Violation|1
5978183|NCT03085095|9565815|FG000|Overall Study|Lost to Follow-up|2
5978184|NCT03085095|9565816|FG001|Overall Study|Lost to Follow-up|1
5978185|NCT03085095|9565815|FG000|Overall Study|Withdrawal by Subject|17
5978186|NCT03085095|9565816|FG001|Overall Study|Withdrawal by Subject|6
5978187|NCT03085095|9565815|FG000|Overall Study|Physician Decision|9
5978188|NCT03085095|9565816|FG001|Overall Study|Physician Decision|3
5978189|NCT03085095|9565815|FG000|Overall Study|Testosterone Suppression Level Not Met|7
5978190|NCT03085095|9565816|FG001|Overall Study|Testosterone Suppression Level Not Met|13
5978191|NCT03085095|9565815|FG000|Overall Study|Did not Receive Study Drug|2
5978192|NCT03085095|9565816|FG001|Overall Study|Did not Receive Study Drug|2
5978193|NCT03085095|9565815|FG000|Overall Study|Dosing Interruption (Logistical Reason)|1
5978194|NCT03085095|9565816|FG001|Overall Study|Dosing Interruption (Logistical Reason)|0
5978195|NCT03048422|9565828|FG000|Overall Study|Death|1
5978196|NCT03048422|9565829|FG001|Overall Study|Death|0
5978197|NCT03048422|9565830|FG002|Overall Study|Death|0
5978198|NCT03048422|9565828|FG000|Overall Study|Lost to Follow-up|5
5978199|NCT03048422|9565829|FG001|Overall Study|Lost to Follow-up|0
5978200|NCT03048422|9565830|FG002|Overall Study|Lost to Follow-up|1
5978201|NCT03048422|9565828|FG000|Overall Study|Withdrawal by Subject|5
5978202|NCT03048422|9565829|FG001|Overall Study|Withdrawal by Subject|7
5978203|NCT03048422|9565830|FG002|Overall Study|Withdrawal by Subject|4
5978204|NCT03048422|9565828|FG000|Overall Study|Moved|3
5978205|NCT03048422|9565829|FG001|Overall Study|Moved|2
5978206|NCT03048422|9565830|FG002|Overall Study|Moved|2
5978207|NCT03048422|9565828|FG000|Overall Study|Noncompliant with Study Requirements|2
5978208|NCT03048422|9565829|FG001|Overall Study|Noncompliant with Study Requirements|1
5978209|NCT03048422|9565830|FG002|Overall Study|Noncompliant with Study Requirements|2
5978210|NCT03048422|9565828|FG000|Overall Study|Not Able to Get to Clinic|1
5978211|NCT03048422|9565829|FG001|Overall Study|Not Able to Get to Clinic|0
5978212|NCT03048422|9565830|FG002|Overall Study|Not Able to Get to Clinic|0
5978213|NCT03032068|9565848|FG000|Overall Study|Adverse Event|1
5978214|NCT02835690|9565868|FG000|Overall Study|Death|4
5978215|NCT02835690|9565869|FG001|Overall Study|Death|6
5978216|NCT02835690|9565870|FG002|Overall Study|Death|6
5978217|NCT02835690|9565868|FG000|Overall Study|Ongoing in Study (Follow-up)|10
5978218|NCT02835690|9565869|FG001|Overall Study|Ongoing in Study (Follow-up)|7
5978219|NCT02835690|9565870|FG002|Overall Study|Ongoing in Study (Follow-up)|9
5978220|NCT02835690|9565868|FG000|Overall Study|Not Treated|0
5978221|NCT02835690|9565869|FG001|Overall Study|Not Treated|2
5978222|NCT02835690|9565870|FG002|Overall Study|Not Treated|0
6279544|NCT02270983|9988317|FG000|Overall Study|Lack of Efficacy|2
6279545|NCT02270983|9988318|FG001|Overall Study|Lack of Efficacy|1
5978223|NCT02828982|9565878|FG000|First Intervention (3 Weeks)|Withdrawal by Subject|1
5978224|NCT02828982|9565879|FG001|First Intervention (3 Weeks)|Withdrawal by Subject|1
5978225|NCT02815280|9565893|FG000|Double-Blind Phase|Adverse Event|1
5978226|NCT02815280|9565894|FG001|Double-Blind Phase|Adverse Event|1
6279546|NCT02270983|9988319|FG002|Overall Study|Lack of Efficacy|1
6279547|NCT02270983|9988317|FG000|Overall Study|Withdrawal by Subject|1
6279548|NCT02270983|9988318|FG001|Overall Study|Withdrawal by Subject|0
6279549|NCT02270983|9988319|FG002|Overall Study|Withdrawal by Subject|2
6279550|NCT02270983|9988317|FG000|Overall Study|Lost to Follow-up|1
6279551|NCT02270983|9988318|FG001|Overall Study|Lost to Follow-up|1
6279552|NCT02270983|9988319|FG002|Overall Study|Lost to Follow-up|2
6279553|NCT02270983|9988317|FG000|Overall Study|Protocol Violation|1
6279554|NCT02270983|9988318|FG001|Overall Study|Protocol Violation|1
6279555|NCT02270983|9988319|FG002|Overall Study|Protocol Violation|1
6279556|NCT02270983|9988317|FG000|Overall Study|family emergency|0
6279557|NCT02270983|9988318|FG001|Overall Study|family emergency|1
6279558|NCT02270983|9988319|FG002|Overall Study|family emergency|0
6279559|NCT02270983|9988317|FG000|Overall Study|study procedure non-compliance|1
6279560|NCT02270983|9988318|FG001|Overall Study|study procedure non-compliance|0
6279561|NCT02270983|9988319|FG002|Overall Study|study procedure non-compliance|0
6279562|NCT02270983|9988317|FG000|Overall Study|moved away from study site|0
6279563|NCT02270983|9988318|FG001|Overall Study|moved away from study site|1
6279564|NCT02270983|9988319|FG002|Overall Study|moved away from study site|0
6279565|NCT02271529|9988385|FG000|Overall Study|Withdrawal by Subject|1
6279566|NCT02271854|9988406|FG000|Overall Study|Withdrawal by Subject|2
6279567|NCT02271854|9988406|FG000|Overall Study|Unable or unwilling to cooperate with st|1
6279568|NCT02271854|9988406|FG000|Overall Study|Lost to Follow-up|1
6279569|NCT02271880|9988413|FG000|Overall Study|Premature discontinuation of study|3
6279570|NCT02271880|9988414|FG001|Overall Study|Premature discontinuation of study|4
6279571|NCT02271945|9988428|FG000|Overall Study|Death|3
6279572|NCT02271945|9988429|FG001|Overall Study|Death|3
6279573|NCT02271945|9988428|FG000|Overall Study|Withdrawal by Subject|1
6279574|NCT02271945|9988429|FG001|Overall Study|Withdrawal by Subject|1
6279575|NCT02271945|9988428|FG000|Overall Study|Other|1
6279576|NCT02271945|9988429|FG001|Overall Study|Other|1
6279577|NCT02271984|9988435|FG000|Washout Period 4 (7 Days)|Withdrawal by Subject|0
6279578|NCT02271984|9988436|FG001|Washout Period 4 (7 Days)|Withdrawal by Subject|0
6279579|NCT02271984|9988437|FG002|Washout Period 4 (7 Days)|Withdrawal by Subject|0
6279580|NCT02271984|9988438|FG003|Washout Period 4 (7 Days)|Withdrawal by Subject|0
6279581|NCT02271984|9988439|FG004|Washout Period 4 (7 Days)|Withdrawal by Subject|0
6279582|NCT02271984|9988440|FG005|Washout Period 4 (7 Days)|Withdrawal by Subject|1
6279583|NCT02271984|9988441|FG006|Washout Period 4 (7 Days)|Withdrawal by Subject|0
6279584|NCT02271984|9988442|FG007|Washout Period 4 (7 Days)|Withdrawal by Subject|1
6279585|NCT02271984|9988443|FG008|Washout Period 4 (7 Days)|Withdrawal by Subject|0
6279586|NCT02271984|9988444|FG009|Washout Period 4 (7 Days)|Withdrawal by Subject|0
5978227|NCT02815280|9565893|FG000|Double-Blind Phase|Lost to Follow-up|10
5978228|NCT02815280|9565894|FG001|Double-Blind Phase|Lost to Follow-up|9
5978229|NCT02815280|9565893|FG000|Double-Blind Phase|Withdrawal by Subject|20
5978230|NCT02815280|9565894|FG001|Double-Blind Phase|Withdrawal by Subject|11
5978231|NCT02815280|9565893|FG000|Double-Blind Phase|Protocol Violation|2
5978232|NCT02815280|9565894|FG001|Double-Blind Phase|Protocol Violation|2
5978233|NCT02815280|9565893|FG000|Double-Blind Phase|Subject: withdrew consent; non-compliant with visits; moved;lack of efficacy;positive pregnancy test|3
5978234|NCT02815280|9565894|FG001|Double-Blind Phase|Subject: withdrew consent; non-compliant with visits; moved;lack of efficacy;positive pregnancy test|2
5978235|NCT02815280|9565893|FG000|Open-Label Phase|Adverse Event|2
5978236|NCT02815280|9565894|FG001|Open-Label Phase|Adverse Event|3
5978237|NCT02815280|9565893|FG000|Open-Label Phase|Lost to Follow-up|18
5978238|NCT02815280|9565894|FG001|Open-Label Phase|Lost to Follow-up|9
5978239|NCT02815280|9565893|FG000|Open-Label Phase|Withdrawal by Subject|33
5978240|NCT02815280|9565894|FG001|Open-Label Phase|Withdrawal by Subject|18
5978241|NCT02815280|9565893|FG000|Open-Label Phase|Protocol Violation|3
5978242|NCT02815280|9565894|FG001|Open-Label Phase|Protocol Violation|0
5978243|NCT02815280|9565893|FG000|Open-Label Phase|Administrative|26
5978244|NCT02815280|9565894|FG001|Open-Label Phase|Administrative|12
5978245|NCT02815280|9565893|FG000|Open-Label Phase|Positive pregnancy test; subject- noncompliance; withdrew consent; lack of efficacy etc.|5
5978246|NCT02815280|9565894|FG001|Open-Label Phase|Positive pregnancy test; subject- noncompliance; withdrew consent; lack of efficacy etc.|2
5978247|NCT02815267|9565906|FG000|Double-Blind Phase|Adverse Event|0
5978248|NCT02815267|9565907|FG001|Double-Blind Phase|Adverse Event|3
5978249|NCT02815267|9565906|FG000|Double-Blind Phase|Lost to Follow-up|17
5978250|NCT02815267|9565907|FG001|Double-Blind Phase|Lost to Follow-up|9
6051014|NCT00430638|9650292|FG000|Overall Study|Lost to Follow-up|1
6051015|NCT00430638|9650293|FG001|Overall Study|Lost to Follow-up|7
6279587|NCT02271984|9988445|FG010|Washout Period 4 (7 Days)|Withdrawal by Subject|0
6279588|NCT02271984|9988446|FG011|Washout Period 4 (7 Days)|Withdrawal by Subject|0
6279589|NCT02272413|9988472|FG000|Randomized Through Treatment Start|Not treated|3
6279590|NCT02272413|9988473|FG001|Randomized Through Treatment Start|Not treated|5
6279591|NCT02272413|9988472|FG000|Pre-switch Period|Adverse Event|38
6279592|NCT02272413|9988473|FG001|Pre-switch Period|Adverse Event|37
6279593|NCT02272413|9988472|FG000|Pre-switch Period|Death|26
6279594|NCT02272413|9988473|FG001|Pre-switch Period|Death|26
6279595|NCT02272413|9988472|FG000|Pre-switch Period|Withdrawal by Subject|27
6279596|NCT02272413|9988473|FG001|Pre-switch Period|Withdrawal by Subject|15
6279597|NCT02272413|9988472|FG000|Pre-switch Period|Physician Decision|6
6279598|NCT02272413|9988473|FG001|Pre-switch Period|Physician Decision|18
6279599|NCT02272413|9988472|FG000|Pre-switch Period|Progressive disease|185
6279600|NCT02272413|9988473|FG001|Pre-switch Period|Progressive disease|173
6279601|NCT02272413|9988472|FG000|Pre-switch Period|Lost to Follow-up|0
6279602|NCT02272413|9988473|FG001|Pre-switch Period|Lost to Follow-up|2
6279603|NCT02272413|9988472|FG000|Pre-switch Period|Protocol Violation|1
6279604|NCT02272413|9988473|FG001|Pre-switch Period|Protocol Violation|0
6279605|NCT02272413|9988472|FG000|Pre-switch Period|Other than listed|10
6279606|NCT02272413|9988473|FG001|Pre-switch Period|Other than listed|11
6279607|NCT02272413|9988472|FG000|Post-switch Period|Adverse Event|4
6279608|NCT02272413|9988473|FG001|Post-switch Period|Adverse Event|4
6279609|NCT02272413|9988472|FG000|Post-switch Period|Death|3
5978251|NCT02815267|9565906|FG000|Double-Blind Phase|Withdrawal by Subject|11
5978252|NCT02815267|9565907|FG001|Double-Blind Phase|Withdrawal by Subject|10
5978253|NCT02815267|9565906|FG000|Double-Blind Phase|Protocol Violation|3
5978254|NCT02815267|9565907|FG001|Double-Blind Phase|Protocol Violation|2
5978255|NCT02815267|9565906|FG000|Double-Blind Phase|Site withdrawal|1
5978256|NCT02815267|9565907|FG001|Double-Blind Phase|Site withdrawal|6
5978257|NCT02815267|9565906|FG000|Double-Blind Phase|Received a disallowed medication|1
5978258|NCT02815267|9565907|FG001|Double-Blind Phase|Received a disallowed medication|1
5978259|NCT02815267|9565906|FG000|Open-Label Phase|Adverse Event|1
5978260|NCT02815267|9565907|FG001|Open-Label Phase|Adverse Event|1
5978261|NCT02815267|9565906|FG000|Open-Label Phase|Lost to Follow-up|23
5978262|NCT02815267|9565907|FG001|Open-Label Phase|Lost to Follow-up|9
5978263|NCT02815267|9565906|FG000|Open-Label Phase|Withdrawal by Subject|24
5978264|NCT02815267|9565907|FG001|Open-Label Phase|Withdrawal by Subject|13
5978265|NCT02815267|9565906|FG000|Open-Label Phase|Protocol Violation|0
5978266|NCT02815267|9565907|FG001|Open-Label Phase|Protocol Violation|1
5978267|NCT02815267|9565906|FG000|Open-Label Phase|Administrative|21
5978268|NCT02815267|9565907|FG001|Open-Label Phase|Administrative|12
5978269|NCT02815267|9565906|FG000|Open-Label Phase|Other|2
5978270|NCT02815267|9565907|FG001|Open-Label Phase|Other|5
5978271|NCT02802228|9565919|FG000|Overall Study|Withdrawal by Subject|2
5978272|NCT02802228|9565920|FG001|Overall Study|Withdrawal by Subject|0
5978273|NCT02802228|9565919|FG000|Overall Study|Lost to Follow-up|1
5978274|NCT02802228|9565920|FG001|Overall Study|Lost to Follow-up|0
5978275|NCT02802228|9565919|FG000|Overall Study|Adverse Event|1
5978276|NCT02802228|9565920|FG001|Overall Study|Adverse Event|0
5978277|NCT02802228|9565919|FG000|Overall Study|Physician Decision|1
5978278|NCT02802228|9565920|FG001|Overall Study|Physician Decision|0
5978279|NCT02674516|9565951|FG000|Overall Study|Lost to Follow-up|3
5978280|NCT02674516|9565952|FG001|Overall Study|Lost to Follow-up|0
5978281|NCT02674516|9565951|FG000|Overall Study|Protocol Violation|0
5978282|NCT02674516|9565952|FG001|Overall Study|Protocol Violation|4
5978283|NCT02674516|9565951|FG000|Overall Study|Knowledge of study hypothesis|1
5978284|NCT02674516|9565952|FG001|Overall Study|Knowledge of study hypothesis|0
5978285|NCT02655016|9565960|FG000|Overall Study|Disease progression|6
5978286|NCT02655016|9565961|FG001|Overall Study|Disease progression|4
5978287|NCT02655016|9565960|FG000|Overall Study|Site closed|0
5978288|NCT02655016|9565961|FG001|Overall Study|Site closed|1
5978289|NCT02655016|9565960|FG000|Overall Study|Death|30
5978290|NCT02655016|9565961|FG001|Overall Study|Death|48
5978291|NCT02655016|9565960|FG000|Overall Study|Lost to Follow-up|1
5978292|NCT02655016|9565961|FG001|Overall Study|Lost to Follow-up|1
5978293|NCT02655016|9565960|FG000|Overall Study|Withdrawal by Subject|18
5978294|NCT02655016|9565961|FG001|Overall Study|Withdrawal by Subject|36
5978295|NCT02505425|9565981|FG000|Overall Study|Lost to Follow-up|41
5978296|NCT02505425|9565982|FG001|Overall Study|Lost to Follow-up|61
5978297|NCT02505425|9565983|FG002|Overall Study|Lost to Follow-up|31
5978298|NCT02505425|9565984|FG003|Overall Study|Lost to Follow-up|19
5978299|NCT02505425|9565981|FG000|Overall Study|Withdrawal by Subject|39
5978300|NCT02505425|9565982|FG001|Overall Study|Withdrawal by Subject|9
5978301|NCT02505425|9565983|FG002|Overall Study|Withdrawal by Subject|19
5978302|NCT02505425|9565984|FG003|Overall Study|Withdrawal by Subject|7
5978303|NCT02505425|9565981|FG000|Overall Study|Death|8
6051016|NCT00430638|9650292|FG000|Overall Study|Protocol Violation|6
6051017|NCT00430638|9650293|FG001|Overall Study|Protocol Violation|4
6201873|NCT01497262|9861861|FG000|Overall Study|Abnormal Test Procedure Result|1
6201874|NCT01497262|9861861|FG000|Overall Study|Physician Decision|1
6201875|NCT01497262|9861861|FG000|Overall Study|Withdrawal by Subject|2
6201876|NCT01497262|9861861|FG000|Overall Study|Adverse Event|2
6201877|NCT01497262|9861861|FG000|Overall Study|Protocol Violation|1
6201878|NCT01497275|9861865|FG000|Overall Study|Death|1
6201879|NCT01497275|9861865|FG000|Overall Study|Adverse Event|1
6201880|NCT01497366|9861871|FG000|Overall Study|Virologic failure|2
5978304|NCT02505425|9565982|FG001|Overall Study|Death|12
5978305|NCT02505425|9565983|FG002|Overall Study|Death|0
5978306|NCT02505425|9565984|FG003|Overall Study|Death|0
5978307|NCT02487979|9565994|FG000|Overall Study|Physician Decision|2
5978308|NCT02487979|9565994|FG000|Overall Study|Withdrawal by Subject|2
5978309|NCT02487979|9565994|FG000|Overall Study|Progressive Disease|17
5978310|NCT02463448|9565998|FG000|Enrollment Through 6 Months|Withdrawal by Subject|3
5978311|NCT02463448|9565998|FG000|6 Months Through 12 Months|Lost to Follow-up|1
5978312|NCT02463448|9565998|FG000|6 Months Through 12 Months|Withdrawal by Subject|1
6201881|NCT01497366|9861872|FG001|Overall Study|Virologic failure|50
6201882|NCT01497366|9861871|FG000|Overall Study|Lost to Follow-up|11
6279610|NCT02272413|9988473|FG001|Post-switch Period|Death|2
6279611|NCT02272413|9988472|FG000|Post-switch Period|Withdrawal by Subject|1
6279612|NCT02272413|9988473|FG001|Post-switch Period|Withdrawal by Subject|2
6279613|NCT02272413|9988472|FG000|Post-switch Period|Physician Decision|1
6279614|NCT02272413|9988473|FG001|Post-switch Period|Physician Decision|1
6279615|NCT02272413|9988472|FG000|Post-switch Period|Progressive disease|21
6279616|NCT02272413|9988473|FG001|Post-switch Period|Progressive disease|21
6279617|NCT02272413|9988472|FG000|Post-switch Period|Study terminated by sponsor|8
6279618|NCT02272413|9988473|FG001|Post-switch Period|Study terminated by sponsor|11
6279619|NCT02272413|9988472|FG000|Post-switch Period|Other than listed|4
6279620|NCT02272413|9988473|FG001|Post-switch Period|Other than listed|5
6089052|NCT00680368|9700232|FG000|Overall Study|not supervised, not eligible|15
6089053|NCT00680407|9700241|FG000|Overall Study|Lost to Follow-up|3
6089054|NCT00680407|9700242|FG001|Overall Study|Lost to Follow-up|3
6089055|NCT00680407|9700243|FG002|Overall Study|Lost to Follow-up|1
6089056|NCT00680407|9700241|FG000|Overall Study|Withdrawal by Subject|5
6089057|NCT00680407|9700242|FG001|Overall Study|Withdrawal by Subject|2
6089058|NCT00680407|9700243|FG002|Overall Study|Withdrawal by Subject|2
6089059|NCT00680745|9700286|FG000|Overall Study|Withdrawal by Subject|8
6089060|NCT00680745|9700287|FG001|Overall Study|Withdrawal by Subject|3
6089061|NCT00680745|9700288|FG002|Overall Study|Withdrawal by Subject|2
6089062|NCT00680745|9700289|FG003|Overall Study|Withdrawal by Subject|8
6089063|NCT00680745|9700286|FG000|Overall Study|Lost to Follow-up|0
6089064|NCT00680745|9700287|FG001|Overall Study|Lost to Follow-up|1
6089065|NCT00680745|9700288|FG002|Overall Study|Lost to Follow-up|1
6089066|NCT00680745|9700289|FG003|Overall Study|Lost to Follow-up|0
6089067|NCT00680745|9700286|FG000|Overall Study|Death|1
5978313|NCT02463448|9565998|FG000|12 Months Through End of Study|Lost to Follow-up|1
5978314|NCT02276547|9566011|FG000|Overall Study|Death|2
5978315|NCT02276547|9566011|FG000|Overall Study|Explant|2
5978316|NCT02263885|9566015|FG000|Overall Study|Withdrawal by Subject|7
6089068|NCT00680745|9700287|FG001|Overall Study|Death|0
6089069|NCT00680745|9700288|FG002|Overall Study|Death|1
6089070|NCT00680745|9700289|FG003|Overall Study|Death|0
6279621|NCT02272634|9988484|FG000|Overall Study|Adverse Event|1
6279622|NCT02272634|9988485|FG001|Overall Study|Adverse Event|0
5978317|NCT02263885|9566015|FG000|Overall Study|Alternative Treatment|3
5978318|NCT02213926|9566020|FG000|Overall Study|Death|59
5978319|NCT02213926|9566020|FG000|Overall Study|Withdrawal by Subject|10
5978320|NCT02213926|9566020|FG000|Overall Study|study terminated by sponsor|51
5978321|NCT02213926|9566020|FG000|Overall Study|Lost to Follow-up|3
5978322|NCT02213926|9566020|FG000|Overall Study|SITE CLOSURE - PI RETIREMENT|1
6051018|NCT00430638|9650292|FG000|Overall Study|Withdrawal by Subject|4
6051019|NCT00430638|9650293|FG001|Overall Study|Withdrawal by Subject|6
6051020|NCT00430638|9650292|FG000|Overall Study|Non-compliant|2
6051021|NCT00430638|9650293|FG001|Overall Study|Non-compliant|1
6051022|NCT00430638|9650292|FG000|Overall Study|Other|2
6051023|NCT00430638|9650293|FG001|Overall Study|Other|2
6051024|NCT00430677|9650306|FG000|Short-term Period|Death|1
6051025|NCT00430677|9650307|FG001|Short-term Period|Death|1
6051026|NCT00430677|9650308|FG002|Short-term Period|Death|5
6051027|NCT00430677|9650306|FG000|Short-term Period|Adverse Event|15
6051028|NCT00430677|9650307|FG001|Short-term Period|Adverse Event|13
6051029|NCT00430677|9650308|FG002|Short-term Period|Adverse Event|9
6051030|NCT00430677|9650306|FG000|Short-term Period|Lack of Efficacy|5
6051031|NCT00430677|9650307|FG001|Short-term Period|Lack of Efficacy|6
6051032|NCT00430677|9650308|FG002|Short-term Period|Lack of Efficacy|4
6051033|NCT00430677|9650306|FG000|Short-term Period|Withdrawal by Subject|1
6051034|NCT00430677|9650307|FG001|Short-term Period|Withdrawal by Subject|1
6051035|NCT00430677|9650308|FG002|Short-term Period|Withdrawal by Subject|2
6051036|NCT00430677|9650306|FG000|Short-term Period|Participant no longer met study criteria|1
6051037|NCT00430677|9650307|FG001|Short-term Period|Participant no longer met study criteria|1
6051038|NCT00430677|9650308|FG002|Short-term Period|Participant no longer met study criteria|2
6051039|NCT00430677|9650306|FG000|Short-term Period|Poor compliance/ noncompliance|0
6051040|NCT00430677|9650307|FG001|Short-term Period|Poor compliance/ noncompliance|1
6051041|NCT00430677|9650308|FG002|Short-term Period|Poor compliance/ noncompliance|0
6051042|NCT00430677|9650306|FG000|Short-term Period|Pregnancy|0
6051043|NCT00430677|9650307|FG001|Short-term Period|Pregnancy|2
6051044|NCT00430677|9650308|FG002|Short-term Period|Pregnancy|0
6051045|NCT00430677|9650306|FG000|Long-term Extension Period|Death|1
6051046|NCT00430677|9650307|FG001|Long-term Extension Period|Death|0
6051047|NCT00430677|9650308|FG002|Long-term Extension Period|Death|0
6051048|NCT00430677|9650306|FG000|Long-term Extension Period|Adverse Event|3
6051049|NCT00430677|9650307|FG001|Long-term Extension Period|Adverse Event|2
6051050|NCT00430677|9650308|FG002|Long-term Extension Period|Adverse Event|5
6051051|NCT00430677|9650306|FG000|Long-term Extension Period|Lack of Efficacy|5
6051052|NCT00430677|9650307|FG001|Long-term Extension Period|Lack of Efficacy|3
6089071|NCT00680745|9700286|FG000|Overall Study|Adverse Event|5
6089072|NCT00680745|9700287|FG001|Overall Study|Adverse Event|3
6089073|NCT00680745|9700288|FG002|Overall Study|Adverse Event|3
6089074|NCT00680745|9700289|FG003|Overall Study|Adverse Event|3
6089075|NCT00680745|9700286|FG000|Overall Study|Poor/Non-compliance|0
6279623|NCT02272634|9988486|FG002|Overall Study|Adverse Event|0
6279624|NCT02272634|9988484|FG000|Overall Study|Protocol Violation|0
6279625|NCT02272634|9988485|FG001|Overall Study|Protocol Violation|0
6279626|NCT02272634|9988486|FG002|Overall Study|Protocol Violation|1
6279627|NCT02272634|9988484|FG000|Overall Study|Withdrawal by Subject|0
6279628|NCT02272634|9988485|FG001|Overall Study|Withdrawal by Subject|1
6279629|NCT02272634|9988486|FG002|Overall Study|Withdrawal by Subject|0
6279630|NCT02272725|9988503|FG000|Overall Study|equipment malfunction|2
6279631|NCT02272725|9988504|FG001|Overall Study|equipment malfunction|0
6279632|NCT02272777|9988512|FG000|Overall Study|Adverse Event|0
6279633|NCT02272777|9988513|FG001|Overall Study|Adverse Event|1
6279634|NCT02272777|9988512|FG000|Overall Study|Withdrawal by Subject|0
6279635|NCT02272777|9988513|FG001|Overall Study|Withdrawal by Subject|3
6279636|NCT02272777|9988512|FG000|Overall Study|Lost to Follow-up|2
6279637|NCT02272777|9988513|FG001|Overall Study|Lost to Follow-up|0
6279638|NCT02272777|9988512|FG000|Overall Study|Other|2
6279639|NCT02272777|9988513|FG001|Overall Study|Other|0
6279640|NCT02272816|9988519|FG000|Overall Study|Adverse Event|1
6279641|NCT02272842|9988525|FG000|Overall Study|Lost to Follow-up|8
6279642|NCT02272842|9988526|FG001|Overall Study|Lost to Follow-up|8
6279643|NCT02272842|9988525|FG000|Overall Study|Withdrawal by Subject|8
6279644|NCT02272842|9988526|FG001|Overall Study|Withdrawal by Subject|2
6279645|NCT02272985|9988533|FG000|Overall Study|Withdrawal by Subject|1
6279646|NCT02272985|9988533|FG000|Overall Study|hip fracture|1
6279647|NCT02272985|9988533|FG000|Overall Study|kidney transplantation|1
6279648|NCT02273037|9988540|FG000|Overall Study|Lost to Follow-up|1
6279649|NCT02273037|9988541|FG001|Overall Study|Lost to Follow-up|0
6279650|NCT02273037|9988540|FG000|Overall Study|Delivered before monitoring initiated|1
6279651|NCT02273037|9988541|FG001|Overall Study|Delivered before monitoring initiated|3
6279652|NCT02273037|9988540|FG000|Overall Study|Breech delivery|2
6279653|NCT02273037|9988541|FG001|Overall Study|Breech delivery|3
6279654|NCT02273037|9988540|FG000|Overall Study|Multiple delivery|2
6279655|NCT02273037|9988541|FG001|Overall Study|Multiple delivery|2
6279656|NCT02273037|9988540|FG000|Overall Study|Other complication|2
6279657|NCT02273037|9988541|FG001|Overall Study|Other complication|0
6279658|NCT02273050|9988552|FG000|Overall Study|Adverse Event|4
6279659|NCT02273050|9988553|FG001|Overall Study|Adverse Event|3
5978323|NCT02008396|9566026|FG000|Overall Study|Protocol Violation|0
5978324|NCT02008396|9566027|FG001|Overall Study|Protocol Violation|1
5978325|NCT01995175|9566034|FG000|Overall Study|Withdrawal by Subject|35
5978326|NCT01995175|9566034|FG000|Overall Study|Lost to Follow-up|102
5978327|NCT01995175|9566034|FG000|Overall Study|Other|67
5978328|NCT01995175|9566034|FG000|Overall Study|Migrated / moved from the study area|49
5978329|NCT01804270|9566048|FG000|Overall Study|Withdrawal by Subject|1
5978330|NCT01804270|9566049|FG001|Overall Study|Withdrawal by Subject|1
6089076|NCT00680745|9700287|FG001|Overall Study|Poor/Non-compliance|3
6089077|NCT00680745|9700288|FG002|Overall Study|Poor/Non-compliance|0
6089078|NCT00680745|9700289|FG003|Overall Study|Poor/Non-compliance|0
6089079|NCT00680745|9700286|FG000|Overall Study|Subject No Longer Meets Study Criteria|0
6089080|NCT00680745|9700287|FG001|Overall Study|Subject No Longer Meets Study Criteria|2
6089081|NCT00680745|9700288|FG002|Overall Study|Subject No Longer Meets Study Criteria|0
6089082|NCT00680745|9700289|FG003|Overall Study|Subject No Longer Meets Study Criteria|2
6089083|NCT00680745|9700286|FG000|Overall Study|False Treatment|0
6089084|NCT00680745|9700287|FG001|Overall Study|False Treatment|1
6089085|NCT00680745|9700288|FG002|Overall Study|False Treatment|3
6089086|NCT00680745|9700289|FG003|Overall Study|False Treatment|0
6089087|NCT00680771|9700302|FG000|Overall Study|Withdrawal by Subject|1
6089088|NCT00680771|9700303|FG001|Overall Study|Withdrawal by Subject|0
6089089|NCT00680771|9700302|FG000|Overall Study|Sleep Apnea suspected after PSG|1
6279660|NCT02273050|9988554|FG002|Overall Study|Adverse Event|3
6279661|NCT02273050|9988552|FG000|Overall Study|Death|0
6279662|NCT02273050|9988553|FG001|Overall Study|Death|0
6279663|NCT02273050|9988554|FG002|Overall Study|Death|1
5978331|NCT01781390|9566058|FG000|Overall Study|Withdrawal of Consent|0
5978332|NCT01781390|9566059|FG001|Overall Study|Withdrawal of Consent|3
5978333|NCT01781390|9566060|FG002|Overall Study|Withdrawal of Consent|1
5978334|NCT01781390|9566058|FG000|Overall Study|Lost to Follow-up|1
5978335|NCT01781390|9566059|FG001|Overall Study|Lost to Follow-up|1
5978336|NCT01781390|9566060|FG002|Overall Study|Lost to Follow-up|1
5978337|NCT01781390|9566058|FG000|Overall Study|Adverse Event|1
5978338|NCT01781390|9566059|FG001|Overall Study|Adverse Event|2
5978339|NCT01781390|9566060|FG002|Overall Study|Adverse Event|1
6051053|NCT00430677|9650308|FG002|Long-term Extension Period|Lack of Efficacy|8
6051054|NCT00430677|9650306|FG000|Long-term Extension Period|Lost to Follow-up|1
6051055|NCT00430677|9650307|FG001|Long-term Extension Period|Lost to Follow-up|1
6051056|NCT00430677|9650308|FG002|Long-term Extension Period|Lost to Follow-up|1
6051057|NCT00430677|9650306|FG000|Long-term Extension Period|Withdrawal by Subject|5
6051058|NCT00430677|9650307|FG001|Long-term Extension Period|Withdrawal by Subject|1
6051059|NCT00430677|9650308|FG002|Long-term Extension Period|Withdrawal by Subject|2
6051060|NCT00430677|9650306|FG000|Long-term Extension Period|Pregnancy|1
6051061|NCT00430677|9650307|FG001|Long-term Extension Period|Pregnancy|1
6051062|NCT00430677|9650308|FG002|Long-term Extension Period|Pregnancy|0
6051063|NCT00430677|9650306|FG000|Long-term Extension Period|Administrative reason by sponsor|41
6089090|NCT00680771|9700303|FG001|Overall Study|Sleep Apnea suspected after PSG|0
6089091|NCT00680771|9700302|FG000|Overall Study|Prior Exposure to Hepatitus B Vaccine|4
6089092|NCT00680771|9700303|FG001|Overall Study|Prior Exposure to Hepatitus B Vaccine|2
6089093|NCT00680836|9700341|FG000|Overall Study|Withdrawal by Subject|3
6089094|NCT00680836|9700342|FG001|Overall Study|Withdrawal by Subject|0
6089095|NCT00680836|9700341|FG000|Overall Study|Lost to Follow-up|3
6089096|NCT00680836|9700342|FG001|Overall Study|Lost to Follow-up|1
6089097|NCT00680836|9700341|FG000|Overall Study|Physician Decision|2
6089098|NCT00680836|9700342|FG001|Overall Study|Physician Decision|1
6089099|NCT00680914|9700355|FG000|Overall Study|Consent withdrawal|6
6089100|NCT00680914|9700356|FG001|Overall Study|Consent withdrawal|3
6089101|NCT00680914|9700355|FG000|Overall Study|Lost to Follow-up|4
6089102|NCT00680914|9700356|FG001|Overall Study|Lost to Follow-up|0
6089103|NCT00680914|9700355|FG000|Overall Study|serious adverse event (SAE)|0
6089104|NCT00680914|9700356|FG001|Overall Study|serious adverse event (SAE)|1
6089105|NCT00680992|9700378|FG000|Overall Study|Complete Resection (as per protocol)|25
6089106|NCT00680992|9700379|FG001|Overall Study|Complete Resection (as per protocol)|121
6089107|NCT00680992|9700380|FG002|Overall Study|Complete Resection (as per protocol)|0
6089108|NCT00680992|9700378|FG000|Overall Study|Administrative Decision|83
6089109|NCT00680992|9700379|FG001|Overall Study|Administrative Decision|42
6089110|NCT00680992|9700380|FG002|Overall Study|Administrative Decision|5
6089111|NCT00680992|9700378|FG000|Overall Study|End of Trial|32
6089112|NCT00680992|9700379|FG001|Overall Study|End of Trial|12
6089113|NCT00680992|9700380|FG002|Overall Study|End of Trial|3
6089114|NCT00680992|9700378|FG000|Overall Study|Withdrawal by Subject|33
6089115|NCT00680992|9700379|FG001|Overall Study|Withdrawal by Subject|11
6089116|NCT00680992|9700380|FG002|Overall Study|Withdrawal by Subject|1
6089117|NCT00680992|9700378|FG000|Overall Study|Adverse Event|21
6279664|NCT02273050|9988552|FG000|Overall Study|Dev. of study spec. withdrawal criteria|0
6279665|NCT02273050|9988553|FG001|Overall Study|Dev. of study spec. withdrawal criteria|1
6279666|NCT02273050|9988554|FG002|Overall Study|Dev. of study spec. withdrawal criteria|1
6279667|NCT02273050|9988552|FG000|Overall Study|Lack of Efficacy|0
6279668|NCT02273050|9988553|FG001|Overall Study|Lack of Efficacy|1
6279669|NCT02273050|9988554|FG002|Overall Study|Lack of Efficacy|1
6279670|NCT02273050|9988552|FG000|Overall Study|Withdrawal by Subject|17
6279671|NCT02273050|9988553|FG001|Overall Study|Withdrawal by Subject|14
6279672|NCT02273050|9988554|FG002|Overall Study|Withdrawal by Subject|16
6279673|NCT02273050|9988552|FG000|Overall Study|Lost to Follow-up|0
6279674|NCT02273050|9988553|FG001|Overall Study|Lost to Follow-up|2
6279675|NCT02273050|9988554|FG002|Overall Study|Lost to Follow-up|3
6279676|NCT02273050|9988552|FG000|Overall Study|Protocol Violation|3
6279677|NCT02273050|9988553|FG001|Overall Study|Protocol Violation|1
6279678|NCT02273050|9988554|FG002|Overall Study|Protocol Violation|4
6279679|NCT02273141|9988586|FG000|Overall Study|Adverse Event|0
6279680|NCT02273141|9988587|FG001|Overall Study|Adverse Event|1
6279681|NCT02273141|9988586|FG000|Overall Study|Lost to Follow-up|1
6279682|NCT02273141|9988587|FG001|Overall Study|Lost to Follow-up|3
6279683|NCT02273141|9988586|FG000|Overall Study|Withdrawal by Subject|10
6279684|NCT02273141|9988587|FG001|Overall Study|Withdrawal by Subject|15
6279685|NCT02273141|9988586|FG000|Overall Study|Various|6
6279686|NCT02273141|9988587|FG001|Overall Study|Various|6
6279687|NCT02273167|9988596|FG000|Overall Study|Adverse Event|1
6279688|NCT02273167|9988597|FG001|Overall Study|Adverse Event|0
6279689|NCT02273167|9988598|FG002|Overall Study|Adverse Event|0
6279690|NCT02273167|9988596|FG000|Overall Study|Protocol Violation|3
5978340|NCT01781390|9566058|FG000|Overall Study|Participants who were Randomized and Not Treated|1
5978341|NCT01781390|9566059|FG001|Overall Study|Participants who were Randomized and Not Treated|1
5978342|NCT01781390|9566060|FG002|Overall Study|Participants who were Randomized and Not Treated|1
5978343|NCT01566695|9566070|FG000|Overall Study|Lack of Efficacy|18
5978344|NCT01566695|9566071|FG001|Overall Study|Lack of Efficacy|45
5978345|NCT01566695|9566070|FG000|Overall Study|Adverse Event|28
5978346|NCT01566695|9566071|FG001|Overall Study|Adverse Event|27
5978347|NCT01566695|9566070|FG000|Overall Study|Death|20
5978348|NCT01566695|9566071|FG001|Overall Study|Death|8
6051064|NCT00430677|9650307|FG001|Long-term Extension Period|Administrative reason by sponsor|49
6279691|NCT02273167|9988597|FG001|Overall Study|Protocol Violation|1
6279692|NCT02273167|9988598|FG002|Overall Study|Protocol Violation|1
6279693|NCT02273167|9988596|FG000|Overall Study|Lost to Follow-up|0
5978349|NCT01566695|9566070|FG000|Overall Study|Withdrawal by Subject|14
5978350|NCT01566695|9566071|FG001|Overall Study|Withdrawal by Subject|7
5978351|NCT01566695|9566070|FG000|Overall Study|Progressive Disease|11
6051065|NCT00430677|9650308|FG002|Long-term Extension Period|Administrative reason by sponsor|46
6051066|NCT00430677|9650306|FG000|Long-term Extension Period|Other|2
6051067|NCT00430677|9650307|FG001|Long-term Extension Period|Other|1
6051068|NCT00430677|9650308|FG002|Long-term Extension Period|Other|1
6051069|NCT00430677|9650306|FG000|Long-term Extension Period|Poor compliance/noncompliance|1
6051070|NCT00430677|9650307|FG001|Long-term Extension Period|Poor compliance/noncompliance|0
6051071|NCT00430677|9650308|FG002|Long-term Extension Period|Poor compliance/noncompliance|0
6051072|NCT00430716|9650337|FG000|Double Blind Phase|Death|1
6051073|NCT00430716|9650338|FG001|Double Blind Phase|Death|0
6089118|NCT00680992|9700379|FG001|Overall Study|Adverse Event|19
6089119|NCT00680992|9700380|FG002|Overall Study|Adverse Event|1
6089120|NCT00680992|9700378|FG000|Overall Study|Other|19
6279694|NCT02273167|9988597|FG001|Overall Study|Lost to Follow-up|1
6279695|NCT02273167|9988598|FG002|Overall Study|Lost to Follow-up|1
6279696|NCT02273167|9988596|FG000|Overall Study|Withdrawal by Subject|10
6279697|NCT02273167|9988597|FG001|Overall Study|Withdrawal by Subject|12
6279698|NCT02273167|9988598|FG002|Overall Study|Withdrawal by Subject|11
6279699|NCT02273167|9988596|FG000|Overall Study|Various|10
6279700|NCT02273167|9988597|FG001|Overall Study|Various|9
6279701|NCT02273167|9988598|FG002|Overall Study|Various|8
6279702|NCT02273180|9988609|FG000|Overall Study|Adverse Event|2
6279703|NCT02273180|9988610|FG001|Overall Study|Adverse Event|2
6279704|NCT02273180|9988609|FG000|Overall Study|Lack of Efficacy|1
6279705|NCT02273180|9988610|FG001|Overall Study|Lack of Efficacy|0
6279706|NCT02273180|9988609|FG000|Overall Study|Protocol Violation|1
6279707|NCT02273180|9988610|FG001|Overall Study|Protocol Violation|7
6279708|NCT02273180|9988609|FG000|Overall Study|Randomized but not treated|1
6279709|NCT02273180|9988610|FG001|Overall Study|Randomized but not treated|0
6279710|NCT02273180|9988609|FG000|Overall Study|Hypoglycemia(not reported as serious AE)|1
6279711|NCT02273180|9988610|FG001|Overall Study|Hypoglycemia(not reported as serious AE)|0
6279712|NCT02273180|9988609|FG000|Overall Study|Other than specified above|21
6279713|NCT02273180|9988610|FG001|Overall Study|Other than specified above|10
6279714|NCT02273596|9988642|FG000|24-Week Treatment Period|Adverse Event|3
6279715|NCT02273596|9988642|FG000|24-Week Treatment Period|Withdrawal by Participant Prior to First Dose|1
6279716|NCT02273596|9988642|FG000|24-Week Treatment Period|Participant was unable to Come|1
6279717|NCT02273596|9988642|FG000|24-Week Treatment Period|Physician Decision|1
6279718|NCT02273596|9988642|FG000|24-Week Treatment Period|Protocol Deviation|1
6279719|NCT02273596|9988642|FG000|Extension Period|Continued into Study WTX101-301 extension (NCT03403205).|19
6279720|NCT02273596|9988642|FG000|Extension Period|Participant Withdrew for Personal Reasons|1
6279721|NCT02273596|9988642|FG000|Extension Period|Lost to Follow-up|1
6279722|NCT02273596|9988642|FG000|Extension Period|Protocol Deviation|1
6279723|NCT02273726|9988654|FG000|Overall Study|Death|70
6279724|NCT02273726|9988655|FG001|Overall Study|Death|62
6279725|NCT02273726|9988654|FG000|Overall Study|Withdrawal by Subject|41
6279726|NCT02273726|9988655|FG001|Overall Study|Withdrawal by Subject|29
6279727|NCT02273726|9988654|FG000|Overall Study|Kidney transplant|31
6279728|NCT02273726|9988655|FG001|Overall Study|Kidney transplant|39
6279729|NCT02273726|9988654|FG000|Overall Study|Physician Decision|30
6279730|NCT02273726|9988655|FG001|Overall Study|Physician Decision|15
6279731|NCT02273726|9988654|FG000|Overall Study|Adverse Event|27
6279732|NCT02273726|9988655|FG001|Overall Study|Adverse Event|9
6279733|NCT02273726|9988654|FG000|Overall Study|Lost to Follow-up|6
6279734|NCT02273726|9988655|FG001|Overall Study|Lost to Follow-up|3
6279735|NCT02273726|9988654|FG000|Overall Study|Lack of Efficacy|6
6279736|NCT02273726|9988655|FG001|Overall Study|Lack of Efficacy|1
6279737|NCT02273726|9988654|FG000|Overall Study|Protocol Violation|4
6279738|NCT02273726|9988655|FG001|Overall Study|Protocol Violation|0
6279739|NCT02273726|9988654|FG000|Overall Study|Other than specified|28
6279740|NCT02273726|9988655|FG001|Overall Study|Other than specified|30
6279741|NCT02273739|9988665|FG000|Overall Study|Progression of Disease|3
6279742|NCT02273739|9988666|FG001|Overall Study|Progression of Disease|4
6279743|NCT02273739|9988667|FG002|Overall Study|Progression of Disease|5
6279744|NCT02273739|9988668|FG003|Overall Study|Progression of Disease|2
6279745|NCT02273739|9988665|FG000|Overall Study|Death|0
6279746|NCT02273739|9988666|FG001|Overall Study|Death|0
6279747|NCT02273739|9988667|FG002|Overall Study|Death|0
6279748|NCT02273739|9988668|FG003|Overall Study|Death|2
6279749|NCT02273739|9988665|FG000|Overall Study|Adverse Event|0
6279750|NCT02273739|9988666|FG001|Overall Study|Adverse Event|0
6279751|NCT02273739|9988667|FG002|Overall Study|Adverse Event|0
6279752|NCT02273739|9988668|FG003|Overall Study|Adverse Event|1
6279753|NCT02273739|9988665|FG000|Overall Study|Withdrawal by Subject|0
6279754|NCT02273739|9988666|FG001|Overall Study|Withdrawal by Subject|0
6279755|NCT02273739|9988667|FG002|Overall Study|Withdrawal by Subject|2
6279756|NCT02273739|9988668|FG003|Overall Study|Withdrawal by Subject|1
6279757|NCT02273739|9988665|FG000|Overall Study|Physician Decision|0
6279758|NCT02273739|9988666|FG001|Overall Study|Physician Decision|0
6279759|NCT02273739|9988667|FG002|Overall Study|Physician Decision|0
6279760|NCT02273739|9988668|FG003|Overall Study|Physician Decision|1
6279761|NCT02273908|9988685|FG000|Overall Study|Adverse Event|16
6279762|NCT02273908|9988686|FG001|Overall Study|Adverse Event|0
6279763|NCT02273908|9988685|FG000|Overall Study|Lost to Follow-up|10
6279764|NCT02273908|9988686|FG001|Overall Study|Lost to Follow-up|1
6279765|NCT02273908|9988685|FG000|Overall Study|Did not meet entrance criteria|3
6279766|NCT02273908|9988686|FG001|Overall Study|Did not meet entrance criteria|2
6279767|NCT02273908|9988685|FG000|Overall Study|Withdrawal by Subject|4
6279768|NCT02273908|9988686|FG001|Overall Study|Withdrawal by Subject|2
6279769|NCT02273960|9988700|FG000|Short Term Period|Lost to Follow-up|1
6279770|NCT02273960|9988701|FG001|Short Term Period|Lost to Follow-up|0
6279771|NCT02273960|9988702|FG002|Short Term Period|Lost to Follow-up|0
6279772|NCT02273960|9988703|FG003|Short Term Period|Lost to Follow-up|0
6279773|NCT02273960|9988700|FG000|Short Term Period|Lack of Efficacy|0
6279774|NCT02273960|9988701|FG001|Short Term Period|Lack of Efficacy|0
6279775|NCT02273960|9988702|FG002|Short Term Period|Lack of Efficacy|0
6279776|NCT02273960|9988703|FG003|Short Term Period|Lack of Efficacy|1
6279777|NCT02273960|9988700|FG000|Short Term Period|ST complete, not entering LTE|4
6279778|NCT02273960|9988701|FG001|Short Term Period|ST complete, not entering LTE|6
6279779|NCT02273960|9988702|FG002|Short Term Period|ST complete, not entering LTE|4
6279780|NCT02273960|9988703|FG003|Short Term Period|ST complete, not entering LTE|5
6279781|NCT02273960|9988700|FG000|Long Term Extension|Death|0
6279782|NCT02273960|9988701|FG001|Long Term Extension|Death|0
6279783|NCT02273960|9988702|FG002|Long Term Extension|Death|0
6279784|NCT02273960|9988703|FG003|Long Term Extension|Death|1
6279785|NCT02273973|9988715|FG000|Overall Study|Adverse Event|4
6279786|NCT02273973|9988716|FG001|Overall Study|Adverse Event|0
6279787|NCT02273973|9988715|FG000|Overall Study|Withdrawal by Subject|2
6279788|NCT02273973|9988716|FG001|Overall Study|Withdrawal by Subject|3
6279789|NCT02273973|9988715|FG000|Overall Study|Death|1
6279790|NCT02273973|9988716|FG001|Overall Study|Death|0
6279791|NCT02273973|9988715|FG000|Overall Study|Non-compliance|1
6279792|NCT02273973|9988716|FG001|Overall Study|Non-compliance|0
6279793|NCT02273973|9988715|FG000|Overall Study|Protocol Violation|1
6279794|NCT02273973|9988716|FG001|Overall Study|Protocol Violation|0
6279795|NCT02273973|9988715|FG000|Overall Study|Progression of disease|0
6279796|NCT02273973|9988716|FG001|Overall Study|Progression of disease|2
5978352|NCT01566695|9566071|FG001|Overall Study|Progressive Disease|6
5978353|NCT01566695|9566070|FG000|Overall Study|Miscellaneous|4
5978354|NCT01566695|9566071|FG001|Overall Study|Miscellaneous|6
5978355|NCT01338636|9566077|FG000|Overall Study|Withdrawn due to lack of improvement|8
5978356|NCT01208974|9566081|FG000|Post-Mastectomy Period (Weeks 1 to 4)|Physician Decision|1
5978357|NCT01208974|9566082|FG001|Post-Mastectomy Period (Weeks 1 to 4)|Physician Decision|0
5978358|NCT01208974|9566083|FG002|Post-Mastectomy Period (Weeks 1 to 4)|Physician Decision|0
5978359|NCT01208974|9566084|FG003|Post-Mastectomy Period (Weeks 1 to 4)|Physician Decision|0
5978360|NCT01208974|9566081|FG000|Post-Mastectomy Period (Weeks 1 to 4)|Withdrawal by Subject|1
5978361|NCT01208974|9566082|FG001|Post-Mastectomy Period (Weeks 1 to 4)|Withdrawal by Subject|0
5978362|NCT01208974|9566083|FG002|Post-Mastectomy Period (Weeks 1 to 4)|Withdrawal by Subject|0
5978363|NCT01208974|9566084|FG003|Post-Mastectomy Period (Weeks 1 to 4)|Withdrawal by Subject|0
5978364|NCT01208974|9566081|FG000|Post-Mastectomy Period (Weeks 1 to 4)|Adverse Event|1
5978365|NCT01208974|9566082|FG001|Post-Mastectomy Period (Weeks 1 to 4)|Adverse Event|0
5978366|NCT01208974|9566083|FG002|Post-Mastectomy Period (Weeks 1 to 4)|Adverse Event|0
5978367|NCT01208974|9566084|FG003|Post-Mastectomy Period (Weeks 1 to 4)|Adverse Event|0
5978368|NCT00938912|9566091|FG000|Overall Study|Withdrawal by Subject|28
5978369|NCT00938912|9566091|FG000|Overall Study|Lost to Follow-up|4
5978370|NCT00938912|9566091|FG000|Overall Study|Lack of Efficacy|43
5978371|NCT00938912|9566091|FG000|Overall Study|Adverse event, non-fatal|24
5978372|NCT00938912|9566091|FG000|Overall Study|Adverse event, fatal|1
5978373|NCT00938912|9566091|FG000|Overall Study|Participant self adjusted antiepileptic medication|1
5978374|NCT00938912|9566091|FG000|Overall Study|Participant had a creatinine clearance less than 30 mL/min|1
5978375|NCT00938912|9566091|FG000|Overall Study|Participant needed prohibit medication|1
5978376|NCT00938912|9566091|FG000|Overall Study|Participant was scheduled for lobal resection|1
5978377|NCT00938912|9566091|FG000|Overall Study|Did not meet Eligibility criteria|1
5978378|NCT00938912|9566091|FG000|Overall Study|Participant relocated not related to AE|1
5978379|NCT00938912|9566091|FG000|Overall Study|Participant moved to another city|1
5978380|NCT00938912|9566091|FG000|Overall Study|Participant experienced break through seizures|1
5978381|NCT00938912|9566091|FG000|Overall Study|No longer wished to participate in the study|1
5978382|NCT00938912|9566091|FG000|Overall Study|Protocol Deviation|2
5978383|NCT00676715|9566127|FG000|Overall Study|Withdrawal by Subject|7
5978384|NCT00676715|9566128|FG001|Overall Study|Withdrawal by Subject|9
5978385|NCT00676715|9566129|FG002|Overall Study|Withdrawal by Subject|10
5978386|NCT00676715|9566130|FG003|Overall Study|Withdrawal by Subject|10
5978387|NCT00676715|9566127|FG000|Overall Study|Other|2
5978388|NCT00676715|9566128|FG001|Overall Study|Other|6
5978389|NCT00676715|9566129|FG002|Overall Study|Other|4
5978390|NCT00676715|9566130|FG003|Overall Study|Other|3
5978391|NCT00676715|9566127|FG000|Overall Study|Lost to Follow-up|1
5978392|NCT00676715|9566128|FG001|Overall Study|Lost to Follow-up|1
5978393|NCT00676715|9566129|FG002|Overall Study|Lost to Follow-up|7
5978394|NCT00676715|9566130|FG003|Overall Study|Lost to Follow-up|3
5978395|NCT00676715|9566127|FG000|Overall Study|Death|1
5978396|NCT00676715|9566128|FG001|Overall Study|Death|1
5978397|NCT00676715|9566129|FG002|Overall Study|Death|1
5978398|NCT00676715|9566130|FG003|Overall Study|Death|0
5978399|NCT00676715|9566127|FG000|Overall Study|Adverse Event|0
5978400|NCT00676715|9566128|FG001|Overall Study|Adverse Event|1
5978401|NCT00676715|9566129|FG002|Overall Study|Adverse Event|2
5978402|NCT00676715|9566130|FG003|Overall Study|Adverse Event|0
5978403|NCT00676715|9566127|FG000|Overall Study|Participants Ongoing|29
5978404|NCT00676715|9566128|FG001|Overall Study|Participants Ongoing|29
5978405|NCT00676715|9566129|FG002|Overall Study|Participants Ongoing|17
5978406|NCT00676715|9566130|FG003|Overall Study|Participants Ongoing|24
5978407|NCT00579826|9566142|FG000|Overall Study|Withdrawal by Subject|5
5978408|NCT00579826|9566143|FG001|Overall Study|Withdrawal by Subject|3
5978409|NCT00322218|9566151|FG000|Overall Study|Death|3
5978410|NCT00322218|9566152|FG001|Overall Study|Death|6
6279797|NCT02273973|9988715|FG000|Overall Study|Lost to Follow-up|0
6279798|NCT02273973|9988716|FG001|Overall Study|Lost to Follow-up|1
6279799|NCT02273973|9988715|FG000|Overall Study|Physician Decision|0
6279800|NCT02273973|9988716|FG001|Overall Study|Physician Decision|1
6279801|NCT02273973|9988715|FG000|Overall Study|Reason not specified|0
6279802|NCT02273973|9988716|FG001|Overall Study|Reason not specified|1
6279803|NCT02274038|9988722|FG000|Overall Study|Death|1
6279804|NCT02274311|9988728|FG000|Three Months of Clomiphene Wash-out|Lost to Follow-up|1
5978411|NCT00186888|9566161|FG000|Overall Study|Toxicity|0
5978412|NCT00186888|9566162|FG001|Overall Study|Toxicity|1
5978413|NCT00186888|9566163|FG002|Overall Study|Toxicity|0
6279805|NCT02274493|9988734|FG000|Overall Study|Withdrawal by Subject|1
6279806|NCT02274558|9988741|FG000|Overall Study|Adverse Event|2
6279807|NCT02274558|9988742|FG001|Overall Study|Adverse Event|4
5978414|NCT00186888|9566161|FG000|Overall Study|Relapse or progression of disease|4
6051074|NCT00430716|9650339|FG002|Double Blind Phase|Death|0
6279808|NCT02274558|9988743|FG002|Overall Study|Adverse Event|2
6279809|NCT02274558|9988741|FG000|Overall Study|Non-compliance|2
6279810|NCT02274558|9988742|FG001|Overall Study|Non-compliance|1
6279811|NCT02274558|9988743|FG002|Overall Study|Non-compliance|0
6279812|NCT02274558|9988741|FG000|Overall Study|Withdrawal by Subject|1
6279813|NCT02274558|9988742|FG001|Overall Study|Withdrawal by Subject|5
6279814|NCT02274558|9988743|FG002|Overall Study|Withdrawal by Subject|4
6279815|NCT02274558|9988741|FG000|Overall Study|Death|0
6279816|NCT02274558|9988742|FG001|Overall Study|Death|0
6279817|NCT02274558|9988743|FG002|Overall Study|Death|1
6279818|NCT02274558|9988741|FG000|Overall Study|Lost to Follow-up|2
6279819|NCT02274558|9988742|FG001|Overall Study|Lost to Follow-up|1
5978415|NCT00186888|9566162|FG001|Overall Study|Relapse or progression of disease|2
5978416|NCT00186888|9566163|FG002|Overall Study|Relapse or progression of disease|0
6051075|NCT00430716|9650337|FG000|Double Blind Phase|No longer willing to participate|2
6051076|NCT00430716|9650338|FG001|Double Blind Phase|No longer willing to participate|1
6051077|NCT00430716|9650339|FG002|Double Blind Phase|No longer willing to participate|1
6051078|NCT00430716|9650337|FG000|Double Blind Phase|Other|0
6051079|NCT00430716|9650338|FG001|Double Blind Phase|Other|2
6051080|NCT00430716|9650339|FG002|Double Blind Phase|Other|0
6051081|NCT00430716|9650337|FG000|Double Blind Phase|Study terminated by sponsor|1
6051082|NCT00430716|9650338|FG001|Double Blind Phase|Study terminated by sponsor|1
6051083|NCT00430716|9650339|FG002|Double Blind Phase|Study terminated by sponsor|2
6051084|NCT00430716|9650337|FG000|Double Blind Phase|Adverse Event|1
6051085|NCT00430716|9650338|FG001|Double Blind Phase|Adverse Event|1
6051086|NCT00430716|9650339|FG002|Double Blind Phase|Adverse Event|3
6051087|NCT00430716|9650337|FG000|Double Blind Phase|Not treated|1
6051088|NCT00430716|9650338|FG001|Double Blind Phase|Not treated|0
6051089|NCT00430716|9650339|FG002|Double Blind Phase|Not treated|0
6051090|NCT00430716|9650337|FG000|Open Label Phase|Lost to Follow-up|1
6051091|NCT00430716|9650338|FG001|Open Label Phase|Lost to Follow-up|0
6051092|NCT00430716|9650339|FG002|Open Label Phase|Lost to Follow-up|1
6051093|NCT00430716|9650337|FG000|Open Label Phase|No longer willing to participate|0
6051094|NCT00430716|9650338|FG001|Open Label Phase|No longer willing to participate|1
6051095|NCT00430716|9650339|FG002|Open Label Phase|No longer willing to participate|1
6051096|NCT00430716|9650337|FG000|Open Label Phase|Other|3
6051097|NCT00430716|9650338|FG001|Open Label Phase|Other|1
6051098|NCT00430716|9650339|FG002|Open Label Phase|Other|1
6051099|NCT00430716|9650337|FG000|Open Label Phase|Protocol Violation|1
6089121|NCT00680992|9700379|FG001|Overall Study|Other|14
6279820|NCT02274558|9988743|FG002|Overall Study|Lost to Follow-up|1
6051100|NCT00430716|9650338|FG001|Open Label Phase|Protocol Violation|0
6051101|NCT00430716|9650339|FG002|Open Label Phase|Protocol Violation|0
6051102|NCT00430716|9650337|FG000|Open Label Phase|Study terminated by sponsor|4
6051103|NCT00430716|9650338|FG001|Open Label Phase|Study terminated by sponsor|5
6051104|NCT00430716|9650339|FG002|Open Label Phase|Study terminated by sponsor|4
6051105|NCT00430755|9650347|FG000|Overall Study|Withdrawal by Subject|53
6051106|NCT00430781|9650373|FG000|Interim Analysis; 11 February 2008|Adverse Event|10
6051107|NCT00430781|9650374|FG001|Interim Analysis; 11 February 2008|Adverse Event|3
6051108|NCT00430781|9650375|FG002|Interim Analysis; 11 February 2008|Adverse Event|7
6051109|NCT00430781|9650373|FG000|Interim Analysis; 11 February 2008|Lost to Follow-up|1
6051110|NCT00430781|9650374|FG001|Interim Analysis; 11 February 2008|Lost to Follow-up|0
6051111|NCT00430781|9650375|FG002|Interim Analysis; 11 February 2008|Lost to Follow-up|1
6051112|NCT00430781|9650373|FG000|Interim Analysis; 11 February 2008|Protocol Violation|0
6051113|NCT00430781|9650374|FG001|Interim Analysis; 11 February 2008|Protocol Violation|1
6051114|NCT00430781|9650375|FG002|Interim Analysis; 11 February 2008|Protocol Violation|0
6051115|NCT00430781|9650373|FG000|Interim Analysis; 11 February 2008|Withdrawal by Subject|4
6051116|NCT00430781|9650374|FG001|Interim Analysis; 11 February 2008|Withdrawal by Subject|0
6051117|NCT00430781|9650375|FG002|Interim Analysis; 11 February 2008|Withdrawal by Subject|2
6051118|NCT00430781|9650373|FG000|Interim Analysis; 11 February 2008|Sponsor Terminated Study|1
6051119|NCT00430781|9650374|FG001|Interim Analysis; 11 February 2008|Sponsor Terminated Study|0
6051120|NCT00430781|9650375|FG002|Interim Analysis; 11 February 2008|Sponsor Terminated Study|0
6051121|NCT00430781|9650373|FG000|Interim Analysis; 11 February 2008|Disease Progression|16
6051122|NCT00430781|9650374|FG001|Interim Analysis; 11 February 2008|Disease Progression|30
6051123|NCT00430781|9650375|FG002|Interim Analysis; 11 February 2008|Disease Progression|22
6051124|NCT00430781|9650373|FG000|Interim Analysis; 11 February 2008|Death|0
6051125|NCT00430781|9650374|FG001|Interim Analysis; 11 February 2008|Death|1
6051126|NCT00430781|9650375|FG002|Interim Analysis; 11 February 2008|Death|0
6051127|NCT00430781|9650373|FG000|Interim Analysis; 11 February 2008|Par. Withdrew; Followed for Survival|2
6051128|NCT00430781|9650374|FG001|Interim Analysis; 11 February 2008|Par. Withdrew; Followed for Survival|0
6051129|NCT00430781|9650375|FG002|Interim Analysis; 11 February 2008|Par. Withdrew; Followed for Survival|0
6051130|NCT00430781|9650373|FG000|Interim Analysis; 11 February 2008|Physician Decision|2
6051131|NCT00430781|9650374|FG001|Interim Analysis; 11 February 2008|Physician Decision|3
6051132|NCT00430781|9650375|FG002|Interim Analysis; 11 February 2008|Physician Decision|3
6051133|NCT00430781|9650373|FG000|Interim Analysis; 11 February 2008|Ongoing|23
6051134|NCT00430781|9650374|FG001|Interim Analysis; 11 February 2008|Ongoing|20
6279821|NCT02274558|9988741|FG000|Overall Study|Physician Decision|0
6279822|NCT02274558|9988742|FG001|Overall Study|Physician Decision|2
6279823|NCT02274558|9988743|FG002|Overall Study|Physician Decision|1
6279824|NCT02274766|9988778|FG000|Overall Study|Withdrawal by Subject|3
6279825|NCT02274766|9988779|FG001|Overall Study|Withdrawal by Subject|6
6279826|NCT02274766|9988778|FG000|Overall Study|Did Not Receive Study Drug|1
6279827|NCT02274766|9988779|FG001|Overall Study|Did Not Receive Study Drug|1
6279828|NCT02274766|9988778|FG000|Overall Study|Subject Unwilling to Proceed|0
6279829|NCT02274766|9988779|FG001|Overall Study|Subject Unwilling to Proceed|1
6279830|NCT02274766|9988778|FG000|Overall Study|Adverse Event|0
6279831|NCT02274766|9988779|FG001|Overall Study|Adverse Event|1
6279832|NCT02274792|9988785|FG000|Overall Study|Withdrawal by Subject|13
6279833|NCT02274792|9988785|FG000|Overall Study|Lost to Follow-up|8
6279834|NCT02274792|9988785|FG000|Overall Study|Protocol Specified Criteria|2
6279835|NCT02274792|9988785|FG000|Overall Study|Sponsor Decision|2
6279836|NCT02274857|9988800|FG000|Overall Study|Adverse Event|1
6279837|NCT02274857|9988801|FG001|Overall Study|Adverse Event|0
6279838|NCT02274857|9988800|FG000|Overall Study|Death|1
6279839|NCT02274857|9988801|FG001|Overall Study|Death|2
6279840|NCT02274857|9988800|FG000|Overall Study|Lost to Follow-up|3
6279841|NCT02274857|9988801|FG001|Overall Study|Lost to Follow-up|0
6279842|NCT02274857|9988800|FG000|Overall Study|Physician Decision|2
6279843|NCT02274857|9988801|FG001|Overall Study|Physician Decision|0
6279844|NCT02274857|9988800|FG000|Overall Study|Trial screen failure|0
5978417|NCT04311463|9566248|FG000|Period 1 (Up to Day 3)|Participant met Protocol defined withdrawal criteria|1
5978418|NCT04311463|9566249|FG001|Period 1 (Up to Day 3)|Participant met Protocol defined withdrawal criteria|0
5978419|NCT04311463|9566248|FG000|Washout Period (Up to Day 7)|Withdrawal by Subject|1
5978420|NCT04311463|9566249|FG001|Washout Period (Up to Day 7)|Withdrawal by Subject|1
5978421|NCT04311463|9566248|FG000|Period 2 (Up to Day 3)|Participant met Protocol defined withdrawal criteria|2
5978422|NCT04311463|9566249|FG001|Period 2 (Up to Day 3)|Participant met Protocol defined withdrawal criteria|1
5978423|NCT03930186|9566265|FG000|Weeks 0 to 16|Adverse Event|6
5978424|NCT03930186|9566265|FG000|Weeks 0 to 16|Withdrawal by Subject|6
5978425|NCT03930186|9566265|FG000|Weeks 16 to 32|Adverse Event|1
5978426|NCT03930186|9566265|FG000|Weeks 16 to 32|Withdrawal by Subject|3
5978427|NCT03740100|9566269|FG000|Overall Study|Adverse Event|1
5978428|NCT03740100|9566269|FG000|Overall Study|Death|1
5978429|NCT03597295|9566273|FG000|Overall Study|Death|37
5978430|NCT03597295|9566273|FG000|Overall Study|Lost to Follow-up|3
5978431|NCT03597295|9566273|FG000|Overall Study|Participants ongoing in the study|54
5978432|NCT03086369|9566283|FG000|Overall Study|Adverse Event|0
5978433|NCT03086369|9566284|FG001|Overall Study|Adverse Event|0
5978434|NCT03086369|9566285|FG002|Overall Study|Adverse Event|0
5978435|NCT03086369|9566286|FG003|Overall Study|Adverse Event|3
5978436|NCT03086369|9566287|FG004|Overall Study|Adverse Event|4
5978437|NCT03086369|9566283|FG000|Overall Study|Lost to Follow-up|1
5978438|NCT03086369|9566284|FG001|Overall Study|Lost to Follow-up|0
5978439|NCT03086369|9566285|FG002|Overall Study|Lost to Follow-up|0
5978440|NCT03086369|9566286|FG003|Overall Study|Lost to Follow-up|2
5978441|NCT03086369|9566287|FG004|Overall Study|Lost to Follow-up|1
5978442|NCT03086369|9566283|FG000|Overall Study|Physician Decision|0
5978443|NCT03086369|9566284|FG001|Overall Study|Physician Decision|0
5978444|NCT03086369|9566285|FG002|Overall Study|Physician Decision|0
5978445|NCT03086369|9566286|FG003|Overall Study|Physician Decision|2
5978446|NCT03086369|9566287|FG004|Overall Study|Physician Decision|5
5978447|NCT03086369|9566283|FG000|Overall Study|Withdrawal by Subject|0
5978448|NCT03086369|9566284|FG001|Overall Study|Withdrawal by Subject|0
5978449|NCT03086369|9566285|FG002|Overall Study|Withdrawal by Subject|0
5978450|NCT03086369|9566286|FG003|Overall Study|Withdrawal by Subject|5
5978451|NCT03086369|9566287|FG004|Overall Study|Withdrawal by Subject|5
5978452|NCT03086369|9566283|FG000|Overall Study|Progressive Disease|0
5978453|NCT03086369|9566284|FG001|Overall Study|Progressive Disease|0
5978454|NCT03086369|9566285|FG002|Overall Study|Progressive Disease|0
5978455|NCT03086369|9566286|FG003|Overall Study|Progressive Disease|14
5978456|NCT03086369|9566287|FG004|Overall Study|Progressive Disease|4
5978457|NCT03086369|9566283|FG000|Overall Study|On Treatment|0
5978458|NCT03086369|9566284|FG001|Overall Study|On Treatment|0
5978459|NCT03086369|9566285|FG002|Overall Study|On Treatment|0
5978460|NCT03086369|9566286|FG003|Overall Study|On Treatment|1
5978461|NCT03086369|9566287|FG004|Overall Study|On Treatment|2
5978462|NCT02849626|9566313|FG000|Core Phase (up to 23 Weeks)|Adverse Event|11
5978463|NCT02849626|9566314|FG001|Core Phase (up to 23 Weeks)|Adverse Event|3
5978464|NCT02849626|9566313|FG000|Core Phase (up to 23 Weeks)|Withdrawal by Subject|7
5978465|NCT02849626|9566314|FG001|Core Phase (up to 23 Weeks)|Withdrawal by Subject|2
5978466|NCT02849626|9566313|FG000|Core Phase (up to 23 Weeks)|Inadequate Therapeutic Effect|6
5978467|NCT02849626|9566314|FG001|Core Phase (up to 23 Weeks)|Inadequate Therapeutic Effect|2
5978468|NCT02849626|9566313|FG000|Core Phase (up to 23 Weeks)|Non-specified|3
5978469|NCT02849626|9566314|FG001|Core Phase (up to 23 Weeks)|Non-specified|0
5978470|NCT02849626|9566313|FG000|Extension Phase A (up to 29 Weeks)|Adverse Event|3
6279845|NCT02274857|9988801|FG001|Overall Study|Trial screen failure|2
6279846|NCT02274857|9988800|FG000|Overall Study|Withdrawal by Subject|11
6279847|NCT02274857|9988801|FG001|Overall Study|Withdrawal by Subject|2
6279848|NCT02274857|9988800|FG000|Overall Study|Other|2
5978471|NCT02849626|9566314|FG001|Extension Phase A (up to 29 Weeks)|Adverse Event|2
6279849|NCT02274857|9988801|FG001|Overall Study|Other|0
6279850|NCT02274948|9988822|FG000|Overall Study|Lost to Follow-up|28
6279851|NCT02274948|9988823|FG001|Overall Study|Lost to Follow-up|25
6279852|NCT02274948|9988822|FG000|Overall Study|Withdrawal by Subject|64
6279853|NCT02274948|9988823|FG001|Overall Study|Withdrawal by Subject|58
6279854|NCT02274948|9988822|FG000|Overall Study|Stopped on family Practitioner advice|2
6279855|NCT02274948|9988823|FG001|Overall Study|Stopped on family Practitioner advice|5
6279856|NCT02274948|9988822|FG000|Overall Study|Left the area|4
6279857|NCT02274948|9988823|FG001|Overall Study|Left the area|3
6279858|NCT02275026|9988830|FG000|Overall Study|Ineligible after cognitive baseline testing|11
6279859|NCT02275026|9988830|FG000|Overall Study|Withdrawal by Subject|4
6279860|NCT02275026|9988830|FG000|Overall Study|Ineligible due to medical history|13
6279861|NCT02275026|9988830|FG000|Overall Study|MRI malfunction precluded testing|1
6279862|NCT02275026|9988830|FG000|Overall Study|Ineligible after MRI findings|1
6279863|NCT02275026|9988830|FG000|Overall Study|Lost to Follow-up|2
6279864|NCT02275026|9988830|FG000|Overall Study|Scanner failure|1
6279865|NCT02275052|9988837|FG000|Period 1: Treatment Period 1 (12 Weeks)|Lost to Follow-up|0
6279866|NCT02275052|9988838|FG001|Period 1: Treatment Period 1 (12 Weeks)|Lost to Follow-up|1
6279867|NCT02275052|9988839|FG002|Period 1: Treatment Period 1 (12 Weeks)|Lost to Follow-up|0
6279868|NCT02275052|9988840|FG003|Period 1: Treatment Period 1 (12 Weeks)|Lost to Follow-up|0
6279869|NCT02275052|9988837|FG000|Period 1: Treatment Period 1 (12 Weeks)|Met protocol-defined stopping criteria|0
6279870|NCT02275052|9988838|FG001|Period 1: Treatment Period 1 (12 Weeks)|Met protocol-defined stopping criteria|1
6279871|NCT02275052|9988839|FG002|Period 1: Treatment Period 1 (12 Weeks)|Met protocol-defined stopping criteria|0
6279872|NCT02275052|9988840|FG003|Period 1: Treatment Period 1 (12 Weeks)|Met protocol-defined stopping criteria|0
6279873|NCT02275052|9988837|FG000|Period 1: Treatment Period 1 (12 Weeks)|Withdrawal by Subject|6
6279874|NCT02275052|9988838|FG001|Period 1: Treatment Period 1 (12 Weeks)|Withdrawal by Subject|4
6279875|NCT02275052|9988839|FG002|Period 1: Treatment Period 1 (12 Weeks)|Withdrawal by Subject|0
6279876|NCT02275052|9988840|FG003|Period 1: Treatment Period 1 (12 Weeks)|Withdrawal by Subject|0
6279877|NCT02275052|9988837|FG000|Period 1: Treatment Period 1 (12 Weeks)|Physician Decision|1
6279878|NCT02275052|9988838|FG001|Period 1: Treatment Period 1 (12 Weeks)|Physician Decision|0
6279879|NCT02275052|9988839|FG002|Period 1: Treatment Period 1 (12 Weeks)|Physician Decision|0
6279880|NCT02275052|9988840|FG003|Period 1: Treatment Period 1 (12 Weeks)|Physician Decision|0
6279881|NCT02275052|9988837|FG000|Period 1: Treatment Period 1 (12 Weeks)|Adverse Event|2
6279882|NCT02275052|9988838|FG001|Period 1: Treatment Period 1 (12 Weeks)|Adverse Event|0
6279883|NCT02275052|9988839|FG002|Period 1: Treatment Period 1 (12 Weeks)|Adverse Event|0
6279884|NCT02275052|9988840|FG003|Period 1: Treatment Period 1 (12 Weeks)|Adverse Event|0
6279885|NCT02275052|9988837|FG000|Washout Period (12-17 Days)|Withdrawal by Subject|3
6279886|NCT02275052|9988838|FG001|Washout Period (12-17 Days)|Withdrawal by Subject|0
6279887|NCT02275052|9988839|FG002|Washout Period (12-17 Days)|Withdrawal by Subject|0
6279888|NCT02275052|9988840|FG003|Washout Period (12-17 Days)|Withdrawal by Subject|0
6279889|NCT02275052|9988837|FG000|Washout Period (12-17 Days)|Lack of Efficacy|1
6279890|NCT02275052|9988838|FG001|Washout Period (12-17 Days)|Lack of Efficacy|0
5978472|NCT02849626|9566313|FG000|Extension Phase A (up to 29 Weeks)|Withdrawal by Subject|4
5978473|NCT02849626|9566314|FG001|Extension Phase A (up to 29 Weeks)|Withdrawal by Subject|0
5978474|NCT02849626|9566313|FG000|Extension Phase A (up to 29 Weeks)|Inadequate therapeutic effect|3
5978475|NCT02849626|9566314|FG001|Extension Phase A (up to 29 Weeks)|Inadequate therapeutic effect|1
5978476|NCT02849626|9566313|FG000|Extension Phase A (up to 29 Weeks)|Non-specified|1
5978477|NCT02849626|9566314|FG001|Extension Phase A (up to 29 Weeks)|Non-specified|0
5978478|NCT02779855|9566333|FG000|Overall Study|Withdrawal by patient prior to treatment|1
5978479|NCT02779855|9566334|FG001|Overall Study|Withdrawal by patient prior to treatment|0
5978480|NCT02779855|9566335|FG002|Overall Study|Withdrawal by patient prior to treatment|0
5978481|NCT02654132|9566346|FG000|Overall Study|Disease Progression|26
5978482|NCT02654132|9566347|FG001|Overall Study|Disease Progression|31
5978483|NCT02654132|9566346|FG000|Overall Study|Adverse Event Unrelated to Study Drug|5
5978484|NCT02654132|9566347|FG001|Overall Study|Adverse Event Unrelated to Study Drug|5
5978485|NCT02654132|9566346|FG000|Overall Study|Switched to another tx|0
5978486|NCT02654132|9566347|FG001|Overall Study|Switched to another tx|1
5978487|NCT02654132|9566346|FG000|Overall Study|Study Drug Toxicity|1
5978488|NCT02654132|9566347|FG001|Overall Study|Study Drug Toxicity|2
5978489|NCT02654132|9566346|FG000|Overall Study|Maximum Clinical Benefit|0
5978490|NCT02654132|9566347|FG001|Overall Study|Maximum Clinical Benefit|2
5978491|NCT02654132|9566346|FG000|Overall Study|Subj Request to Discontinue Treatment|1
5978492|NCT02654132|9566347|FG001|Overall Study|Subj Request to Discontinue Treatment|0
5978493|NCT02654132|9566346|FG000|Overall Study|Not Reported|0
5978494|NCT02654132|9566347|FG001|Overall Study|Not Reported|1
5978495|NCT02654132|9566346|FG000|Overall Study|Subject Withdrew Consent|2
5978496|NCT02654132|9566347|FG001|Overall Study|Subject Withdrew Consent|1
5978497|NCT02654132|9566346|FG000|Overall Study|Inadequate response to therapy|1
5978498|NCT02654132|9566347|FG001|Overall Study|Inadequate response to therapy|0
6089122|NCT00680992|9700380|FG002|Overall Study|Other|1
5978499|NCT02654132|9566346|FG000|Overall Study|Clinical Progression (not protocol)|0
5978500|NCT02654132|9566347|FG001|Overall Study|Clinical Progression (not protocol)|1
6089123|NCT00680992|9700378|FG000|Overall Study|Disease Progression|21
6279891|NCT02275052|9988839|FG002|Washout Period (12-17 Days)|Lack of Efficacy|0
6279892|NCT02275052|9988840|FG003|Washout Period (12-17 Days)|Lack of Efficacy|0
6279893|NCT02275052|9988837|FG000|Period 2: Treatment Period 2 (12 Weeks)|Adverse Event|0
6279894|NCT02275052|9988838|FG001|Period 2: Treatment Period 2 (12 Weeks)|Adverse Event|0
6279895|NCT02275052|9988839|FG002|Period 2: Treatment Period 2 (12 Weeks)|Adverse Event|3
6279896|NCT02275052|9988840|FG003|Period 2: Treatment Period 2 (12 Weeks)|Adverse Event|2
6279897|NCT02275052|9988837|FG000|Period 2: Treatment Period 2 (12 Weeks)|Withdrawal by Subject|0
6279898|NCT02275052|9988838|FG001|Period 2: Treatment Period 2 (12 Weeks)|Withdrawal by Subject|0
6279899|NCT02275052|9988839|FG002|Period 2: Treatment Period 2 (12 Weeks)|Withdrawal by Subject|1
6279900|NCT02275052|9988840|FG003|Period 2: Treatment Period 2 (12 Weeks)|Withdrawal by Subject|4
6279901|NCT02275052|9988837|FG000|Period 2: Treatment Period 2 (12 Weeks)|Lack of Efficacy|0
6279902|NCT02275052|9988838|FG001|Period 2: Treatment Period 2 (12 Weeks)|Lack of Efficacy|0
6279903|NCT02275052|9988839|FG002|Period 2: Treatment Period 2 (12 Weeks)|Lack of Efficacy|1
6279904|NCT02275052|9988840|FG003|Period 2: Treatment Period 2 (12 Weeks)|Lack of Efficacy|6
6279905|NCT02275052|9988837|FG000|Period 2: Treatment Period 2 (12 Weeks)|Met Protocol-defined Stopping Criteria|0
6279906|NCT02275052|9988838|FG001|Period 2: Treatment Period 2 (12 Weeks)|Met Protocol-defined Stopping Criteria|0
5978501|NCT02654132|9566346|FG000|Overall Study|Never treated|0
5978502|NCT02654132|9566347|FG001|Overall Study|Never treated|2
5978503|NCT02603432|9566356|FG000|Overall Study|Ongoing|184
5978504|NCT02603432|9566357|FG001|Overall Study|Ongoing|144
5978505|NCT02603432|9566356|FG000|Overall Study|Adverse Event|1
5978506|NCT02603432|9566357|FG001|Overall Study|Adverse Event|0
5978507|NCT02603432|9566356|FG000|Overall Study|Death|144
5978508|NCT02603432|9566357|FG001|Overall Study|Death|177
5978509|NCT02603432|9566356|FG000|Overall Study|Lost to Follow-up|4
5978510|NCT02603432|9566357|FG001|Overall Study|Lost to Follow-up|6
5978511|NCT02603432|9566356|FG000|Overall Study|Progressive Disease|5
5978512|NCT02603432|9566357|FG001|Overall Study|Progressive Disease|5
5978513|NCT02603432|9566356|FG000|Overall Study|Withdrawal by Subject|9
5978514|NCT02603432|9566357|FG001|Overall Study|Withdrawal by Subject|17
5978515|NCT02603432|9566356|FG000|Overall Study|No Longer Meets Eligibility Criteria|3
5978516|NCT02603432|9566357|FG001|Overall Study|No Longer Meets Eligibility Criteria|0
5978517|NCT02603432|9566356|FG000|Overall Study|Other|0
5978518|NCT02603432|9566357|FG001|Overall Study|Other|1
5978519|NCT02600923|9566363|FG000|Overall Study|Death|10
5978520|NCT02600923|9566363|FG000|Overall Study|Adverse Event|3
5978521|NCT02600923|9566363|FG000|Overall Study|Global deterioration of health status|2
5978522|NCT02600923|9566363|FG000|Overall Study|Insufficient clinical response|6
5978523|NCT02600923|9566363|FG000|Overall Study|Lost to Follow-up|1
5978524|NCT02600923|9566363|FG000|Overall Study|Withdrawal by Subject|5
5978525|NCT02600923|9566363|FG000|Overall Study|Objective progression or relapse|50
5978526|NCT02600923|9566363|FG000|Overall Study|Study terminated by Sponsor|53
5978527|NCT02600923|9566363|FG000|Overall Study|Not treated|1
5978528|NCT02412735|9566388|FG000|Overall Study|Adverse Event|0
5978529|NCT02412735|9566389|FG001|Overall Study|Adverse Event|1
5978530|NCT02412735|9566390|FG002|Overall Study|Adverse Event|2
5978531|NCT02412735|9566388|FG000|Overall Study|Withdrawal by Subject|23
5978532|NCT02412735|9566389|FG001|Overall Study|Withdrawal by Subject|27
5978533|NCT02412735|9566390|FG002|Overall Study|Withdrawal by Subject|22
5978534|NCT02412735|9566388|FG000|Overall Study|Investigator Decision|3
5978535|NCT02412735|9566389|FG001|Overall Study|Investigator Decision|3
5978536|NCT02412735|9566390|FG002|Overall Study|Investigator Decision|2
5978537|NCT02412735|9566388|FG000|Overall Study|Lost to Follow-up|17
5978538|NCT02412735|9566389|FG001|Overall Study|Lost to Follow-up|11
5978539|NCT02412735|9566390|FG002|Overall Study|Lost to Follow-up|18
5978540|NCT02412735|9566388|FG000|Overall Study|Reason not Specified|3
5978541|NCT02412735|9566389|FG001|Overall Study|Reason not Specified|2
5978542|NCT02412735|9566390|FG002|Overall Study|Reason not Specified|2
5978543|NCT02371889|9566400|FG000|Overall Study|Adverse medication effect|11
5978544|NCT02371889|9566401|FG001|Overall Study|Adverse medication effect|2
5978545|NCT02371889|9566400|FG000|Overall Study|Lost to Follow-up|6
5978546|NCT02371889|9566401|FG001|Overall Study|Lost to Follow-up|5
5978547|NCT02371889|9566400|FG000|Overall Study|Personal time constraints|2
5978548|NCT02371889|9566401|FG001|Overall Study|Personal time constraints|4
5978549|NCT02371889|9566400|FG000|Overall Study|Lack of Efficacy|0
5978550|NCT02371889|9566401|FG001|Overall Study|Lack of Efficacy|2
5978551|NCT02371889|9566400|FG000|Overall Study|Relapse|0
5978552|NCT02371889|9566401|FG001|Overall Study|Relapse|1
5978553|NCT02272803|9566413|FG000|Overall Study|Disease progression|4
5978554|NCT02272803|9566414|FG001|Overall Study|Disease progression|2
5978555|NCT02272803|9566413|FG000|Overall Study|Adverse Event unrelated to study drug|1
5978556|NCT02272803|9566414|FG001|Overall Study|Adverse Event unrelated to study drug|4
5978557|NCT02272803|9566413|FG000|Overall Study|Study drug toxicity|1
5978558|NCT02272803|9566414|FG001|Overall Study|Study drug toxicity|4
5978559|NCT02272803|9566413|FG000|Overall Study|Subj request to discontinue study trt|1
5978560|NCT02272803|9566414|FG001|Overall Study|Subj request to discontinue study trt|4
5978561|NCT02272803|9566413|FG000|Overall Study|Maximum clinical benefit|1
5978562|NCT02272803|9566414|FG001|Overall Study|Maximum clinical benefit|1
5978563|NCT02272803|9566413|FG000|Overall Study|Subject moved to care facility|0
6279907|NCT02275052|9988839|FG002|Period 2: Treatment Period 2 (12 Weeks)|Met Protocol-defined Stopping Criteria|0
6279908|NCT02275052|9988840|FG003|Period 2: Treatment Period 2 (12 Weeks)|Met Protocol-defined Stopping Criteria|2
6279909|NCT02275065|9988851|FG000|Overall Study|Randomized but not treated|1
6279910|NCT02275065|9988852|FG001|Overall Study|Randomized but not treated|0
6279911|NCT02275065|9988853|FG002|Overall Study|Randomized but not treated|1
6279912|NCT02275065|9988854|FG003|Overall Study|Randomized but not treated|1
6279913|NCT02275065|9988855|FG004|Overall Study|Randomized but not treated|0
6279914|NCT02275117|9988872|FG000|Overall Study|Adverse Event|0
6279915|NCT02275117|9988873|FG001|Overall Study|Adverse Event|0
6279916|NCT02275117|9988874|FG002|Overall Study|Adverse Event|0
6279917|NCT02275117|9988875|FG003|Overall Study|Adverse Event|0
6279918|NCT02275117|9988876|FG004|Overall Study|Adverse Event|1
6279919|NCT02275117|9988872|FG000|Overall Study|Lack of Efficacy|6
6279920|NCT02275117|9988873|FG001|Overall Study|Lack of Efficacy|7
6279921|NCT02275117|9988874|FG002|Overall Study|Lack of Efficacy|5
6279922|NCT02275117|9988875|FG003|Overall Study|Lack of Efficacy|2
6279923|NCT02275117|9988876|FG004|Overall Study|Lack of Efficacy|10
6279924|NCT02275117|9988872|FG000|Overall Study|Lost to Follow-up|11
6279925|NCT02275117|9988873|FG001|Overall Study|Lost to Follow-up|16
6279926|NCT02275117|9988874|FG002|Overall Study|Lost to Follow-up|15
6279927|NCT02275117|9988875|FG003|Overall Study|Lost to Follow-up|16
6279928|NCT02275117|9988876|FG004|Overall Study|Lost to Follow-up|8
6279929|NCT02275117|9988872|FG000|Overall Study|Physician Decision|0
6279930|NCT02275117|9988873|FG001|Overall Study|Physician Decision|1
6279931|NCT02275117|9988874|FG002|Overall Study|Physician Decision|1
6279932|NCT02275117|9988875|FG003|Overall Study|Physician Decision|0
6279933|NCT02275117|9988876|FG004|Overall Study|Physician Decision|1
6279934|NCT02275117|9988872|FG000|Overall Study|Protocol Violation|1
6279935|NCT02275117|9988873|FG001|Overall Study|Protocol Violation|0
6279936|NCT02275117|9988874|FG002|Overall Study|Protocol Violation|1
6279937|NCT02275117|9988875|FG003|Overall Study|Protocol Violation|1
6279938|NCT02275117|9988876|FG004|Overall Study|Protocol Violation|0
6279939|NCT02275117|9988872|FG000|Overall Study|Withdrawal by Subject|6
6279940|NCT02275117|9988873|FG001|Overall Study|Withdrawal by Subject|4
6279941|NCT02275117|9988874|FG002|Overall Study|Withdrawal by Subject|7
6279942|NCT02275117|9988875|FG003|Overall Study|Withdrawal by Subject|3
6279943|NCT02275117|9988876|FG004|Overall Study|Withdrawal by Subject|3
6279944|NCT02275117|9988872|FG000|Overall Study|Terminated by Sponsor|4
6279945|NCT02275117|9988873|FG001|Overall Study|Terminated by Sponsor|4
6279946|NCT02275117|9988874|FG002|Overall Study|Terminated by Sponsor|4
6279947|NCT02275117|9988875|FG003|Overall Study|Terminated by Sponsor|6
6279948|NCT02275117|9988876|FG004|Overall Study|Terminated by Sponsor|4
6279949|NCT02275117|9988872|FG000|Overall Study|Worsening of Study Indication|0
6279950|NCT02275117|9988873|FG001|Overall Study|Worsening of Study Indication|1
6279951|NCT02275117|9988874|FG002|Overall Study|Worsening of Study Indication|2
6279952|NCT02275117|9988875|FG003|Overall Study|Worsening of Study Indication|0
6279953|NCT02275117|9988876|FG004|Overall Study|Worsening of Study Indication|0
6279954|NCT02275117|9988872|FG000|Overall Study|Study Burden|5
6279955|NCT02275117|9988873|FG001|Overall Study|Study Burden|4
6279956|NCT02275117|9988874|FG002|Overall Study|Study Burden|7
6279957|NCT02275117|9988875|FG003|Overall Study|Study Burden|5
6279958|NCT02275117|9988876|FG004|Overall Study|Study Burden|7
6279959|NCT02275117|9988872|FG000|Overall Study|Other|1
6279960|NCT02275117|9988873|FG001|Overall Study|Other|0
6279961|NCT02275117|9988874|FG002|Overall Study|Other|0
5978564|NCT02272803|9566414|FG001|Overall Study|Subject moved to care facility|1
5978565|NCT02272803|9566413|FG000|Overall Study|Poor/non-compliance|0
5978566|NCT02272803|9566414|FG001|Overall Study|Poor/non-compliance|1
5978567|NCT02272803|9566413|FG000|Overall Study|Withdrawal by Subject|1
5978568|NCT02272803|9566414|FG001|Overall Study|Withdrawal by Subject|0
6051135|NCT00430781|9650375|FG002|Interim Analysis; 11 February 2008|Ongoing|25
6051136|NCT00430781|9650373|FG000|Final Analysis; 31 July 2008|Lost to Follow-up|0
6051137|NCT00430781|9650374|FG001|Final Analysis; 31 July 2008|Lost to Follow-up|0
6051138|NCT00430781|9650375|FG002|Final Analysis; 31 July 2008|Lost to Follow-up|3
6051139|NCT00430781|9650373|FG000|Final Analysis; 31 July 2008|Protocol Violation|0
6051140|NCT00430781|9650374|FG001|Final Analysis; 31 July 2008|Protocol Violation|1
6051141|NCT00430781|9650375|FG002|Final Analysis; 31 July 2008|Protocol Violation|0
6051142|NCT00430781|9650373|FG000|Final Analysis; 31 July 2008|Withdrawal by Subject|0
6051143|NCT00430781|9650374|FG001|Final Analysis; 31 July 2008|Withdrawal by Subject|2
6051144|NCT00430781|9650375|FG002|Final Analysis; 31 July 2008|Withdrawal by Subject|7
6051145|NCT00430781|9650373|FG000|Final Analysis; 31 July 2008|Physician Decision|0
6051146|NCT00430781|9650374|FG001|Final Analysis; 31 July 2008|Physician Decision|6
6279962|NCT02275117|9988875|FG003|Overall Study|Other|0
6279963|NCT02275117|9988876|FG004|Overall Study|Other|2
6279964|NCT02275338|9988902|FG000|Overall Study|Adverse Event|15
6279965|NCT02275338|9988902|FG000|Overall Study|Lack of Efficacy|3
6279966|NCT02275338|9988902|FG000|Overall Study|Withdrawal by Subject|4
6279967|NCT02275338|9988902|FG000|Overall Study|Disease progression (death)|1
6279968|NCT02275338|9988902|FG000|Overall Study|Ineligible to start Phase 2|4
6279969|NCT02275338|9988902|FG000|Overall Study|Reason not specified|5
6279970|NCT02275338|9988902|FG000|Overall Study|Does not meet entry criteria|1
6279971|NCT02275364|9988907|FG000|Period 1|Withdrawal by Subject|1
6279972|NCT02275364|9988908|FG001|Period 1|Withdrawal by Subject|0
6279973|NCT02275364|9988907|FG000|Period 1|Other reason|1
6279974|NCT02275364|9988908|FG001|Period 1|Other reason|0
5978569|NCT02186834|9566420|FG000|Dose Escalation|Death|0
5978570|NCT02186834|9566421|FG001|Dose Escalation|Death|0
5978571|NCT02186834|9566422|FG002|Dose Escalation|Death|0
5978572|NCT02186834|9566423|FG003|Dose Escalation|Death|1
5978573|NCT02186834|9566424|FG004|Dose Escalation|Death|0
5978574|NCT02186834|9566425|FG005|Dose Escalation|Death|0
5978575|NCT02186834|9566420|FG000|Treatment at RP2D|Died prior to treatment|0
5978576|NCT02186834|9566421|FG001|Treatment at RP2D|Died prior to treatment|0
5978577|NCT02186834|9566422|FG002|Treatment at RP2D|Died prior to treatment|0
5978578|NCT02186834|9566423|FG003|Treatment at RP2D|Died prior to treatment|0
5978579|NCT02186834|9566424|FG004|Treatment at RP2D|Died prior to treatment|0
5978580|NCT02186834|9566425|FG005|Treatment at RP2D|Died prior to treatment|1
5978581|NCT02100722|9566445|FG000|Overall Study|Withdrawal pre-procedure|4
5978582|NCT02100722|9566446|FG001|Overall Study|Withdrawal pre-procedure|9
5978583|NCT02100722|9566445|FG000|Overall Study|Withdrawal post-procedure|0
5978584|NCT02100722|9566446|FG001|Overall Study|Withdrawal post-procedure|3
5978585|NCT02100722|9566445|FG000|Overall Study|Lost to Follow-up|2
5978586|NCT02100722|9566446|FG001|Overall Study|Lost to Follow-up|2
5978587|NCT02100722|9566445|FG000|Overall Study|Continuing on study|751
5978588|NCT02100722|9566446|FG001|Overall Study|Continuing on study|729
5978589|NCT02046096|9566455|FG000|Overall Study|Death|28
5978590|NCT02046096|9566456|FG001|Overall Study|Death|45
5978591|NCT02046096|9566455|FG000|Overall Study|Lost to Follow-up|9
5978592|NCT02046096|9566456|FG001|Overall Study|Lost to Follow-up|20
5978593|NCT02046096|9566455|FG000|Overall Study|Withdrawal by Subject|5
5978594|NCT02046096|9566456|FG001|Overall Study|Withdrawal by Subject|17
5978595|NCT02046096|9566455|FG000|Overall Study|Other endpoint|2
5978596|NCT02046096|9566456|FG001|Overall Study|Other endpoint|19
5978597|NCT01945775|9566466|FG000|Overall Study|Death|214
5978598|NCT01945775|9566467|FG001|Overall Study|Death|98
5978599|NCT01945775|9566466|FG000|Overall Study|Lost to Follow-up|12
5978600|NCT01945775|9566467|FG001|Overall Study|Lost to Follow-up|7
5978601|NCT01945775|9566466|FG000|Overall Study|Withdrawal by Subject|11
5978602|NCT01945775|9566467|FG001|Overall Study|Withdrawal by Subject|21
5978603|NCT01945775|9566466|FG000|Overall Study|Other|50
5978604|NCT01945775|9566467|FG001|Overall Study|Other|18
5978605|NCT01781637|9566475|FG000|Overall Study|Adverse Event|1
5978606|NCT01781637|9566476|FG001|Overall Study|Adverse Event|0
5978607|NCT01781637|9566475|FG000|Overall Study|Lack of Efficacy|2
5978608|NCT01781637|9566476|FG001|Overall Study|Lack of Efficacy|6
5978609|NCT01781637|9566475|FG000|Overall Study|Withdrawal by Subject|1
5978610|NCT01781637|9566476|FG001|Overall Study|Withdrawal by Subject|0
5978611|NCT01711541|9566487|FG000|Overall Study|Cancel prior to treatment|0
5978612|NCT01711541|9566488|FG001|Overall Study|Cancel prior to treatment|0
5978613|NCT01711541|9566489|FG002|Overall Study|Cancel prior to treatment|0
5978614|NCT01711541|9566490|FG003|Overall Study|Cancel prior to treatment|1
5978615|NCT01711541|9566491|FG004|Overall Study|Cancel prior to treatment|0
5978616|NCT01711541|9566487|FG000|Overall Study|Ineligible|0
5978617|NCT01711541|9566488|FG001|Overall Study|Ineligible|1
5978618|NCT01711541|9566489|FG002|Overall Study|Ineligible|0
5978619|NCT01711541|9566490|FG003|Overall Study|Ineligible|0
5978620|NCT01711541|9566491|FG004|Overall Study|Ineligible|0
5978621|NCT01670539|9566508|FG000|Overall Study|Death|3
5978622|NCT01670539|9566509|FG001|Overall Study|Death|5
6051147|NCT00430781|9650375|FG002|Final Analysis; 31 July 2008|Physician Decision|6
5978623|NCT01670539|9566508|FG000|Overall Study|Withdrawal by Subject|3
5978624|NCT01670539|9566509|FG001|Overall Study|Withdrawal by Subject|0
5978625|NCT00407602|9566516|FG000|Overall Study|Death - unrelated to device|1
5978626|NCT00407602|9566516|FG000|Overall Study|Device explanted|5
5978627|NCT00407602|9566516|FG000|Overall Study|Withdrawal by Subject|1
6051148|NCT00430781|9650373|FG000|Final Analysis; 31 July 2008|Other|0
6051149|NCT00430781|9650374|FG001|Final Analysis; 31 July 2008|Other|1
6051150|NCT00430781|9650375|FG002|Final Analysis; 31 July 2008|Other|0
6051151|NCT00430781|9650373|FG000|Final Analysis; 31 July 2008|Ongoing|0
6051152|NCT00430781|9650374|FG001|Final Analysis; 31 July 2008|Ongoing|29
6279975|NCT02275611|9988929|FG000|Inpatient Withdrawal|Withdrawal by Subject|1
6279976|NCT02275611|9988930|FG001|Inpatient Withdrawal|Withdrawal by Subject|0
6279977|NCT02275611|9988931|FG002|Inpatient Withdrawal|Withdrawal by Subject|0
6279978|NCT02275611|9988932|FG003|Inpatient Withdrawal|Withdrawal by Subject|0
6279979|NCT02275780|9988959|FG000|Base Study: 96 Weeks|Adverse Event|6
6279980|NCT02275780|9988960|FG001|Base Study: 96 Weeks|Adverse Event|14
6279981|NCT02275780|9988959|FG000|Base Study: 96 Weeks|Death|3
6279982|NCT02275780|9988960|FG001|Base Study: 96 Weeks|Death|1
6279983|NCT02275780|9988959|FG000|Base Study: 96 Weeks|Lack of Efficacy|21
6279984|NCT02275780|9988960|FG001|Base Study: 96 Weeks|Lack of Efficacy|32
6279985|NCT02275780|9988959|FG000|Base Study: 96 Weeks|Lost to Follow-up|28
6279986|NCT02275780|9988960|FG001|Base Study: 96 Weeks|Lost to Follow-up|24
6279987|NCT02275780|9988959|FG000|Base Study: 96 Weeks|Protocol Violation|1
6279988|NCT02275780|9988960|FG001|Base Study: 96 Weeks|Protocol Violation|6
6279989|NCT02275780|9988959|FG000|Base Study: 96 Weeks|Withdrawal by Subject|19
6279990|NCT02275780|9988960|FG001|Base Study: 96 Weeks|Withdrawal by Subject|22
6279991|NCT02275780|9988959|FG000|Base Study: 96 Weeks|Noncompliance with drug|9
6279992|NCT02275780|9988960|FG001|Base Study: 96 Weeks|Noncompliance with drug|6
6279993|NCT02275780|9988959|FG000|Base Study: 96 Weeks|Physician Decision|2
6279994|NCT02275780|9988960|FG001|Base Study: 96 Weeks|Physician Decision|4
6279995|NCT02275780|9988959|FG000|Base Study: 96 Weeks|Pregnancy|2
6279996|NCT02275780|9988960|FG001|Base Study: 96 Weeks|Pregnancy|1
6279997|NCT02275780|9988959|FG000|Base Study: 96 Weeks|Randomized not treated|2
6279998|NCT02275780|9988960|FG001|Base Study: 96 Weeks|Randomized not treated|1
6279999|NCT02275780|9988959|FG000|Extension Study: up to 192 Weeks|Ongoing|260
6280000|NCT02275780|9988960|FG001|Extension Study: up to 192 Weeks|Ongoing|233
6280001|NCT02275819|9988968|FG000|Overall Study|Adverse Event|0
6280002|NCT02275819|9988969|FG001|Overall Study|Adverse Event|1
6280003|NCT02276027|9988983|FG000|Overall Study|Death|1
6280004|NCT02276027|9988984|FG001|Overall Study|Death|0
6280005|NCT02276027|9988985|FG002|Overall Study|Death|0
6280006|NCT02276027|9988986|FG003|Overall Study|Death|2
6280007|NCT02276027|9988983|FG000|Overall Study|Physician Decision|0
6280008|NCT02276027|9988984|FG001|Overall Study|Physician Decision|0
6280009|NCT02276027|9988985|FG002|Overall Study|Physician Decision|0
6280010|NCT02276027|9988986|FG003|Overall Study|Physician Decision|1
6280011|NCT02276027|9988983|FG000|Overall Study|Progressive disease|1
6280012|NCT02276027|9988984|FG001|Overall Study|Progressive disease|13
6280013|NCT02276027|9988985|FG002|Overall Study|Progressive disease|12
6280014|NCT02276027|9988986|FG003|Overall Study|Progressive disease|14
6280015|NCT02276027|9988983|FG000|Overall Study|Subject/guardian decision|0
6280016|NCT02276027|9988984|FG001|Overall Study|Subject/guardian decision|1
6280017|NCT02276027|9988985|FG002|Overall Study|Subject/guardian decision|0
6280018|NCT02276027|9988986|FG003|Overall Study|Subject/guardian decision|3
6280019|NCT02276027|9988983|FG000|Overall Study|Adverse Event|0
6280020|NCT02276027|9988984|FG001|Overall Study|Adverse Event|2
6280021|NCT02276027|9988985|FG002|Overall Study|Adverse Event|8
6280022|NCT02276027|9988986|FG003|Overall Study|Adverse Event|2
6280023|NCT02276040|9988996|FG000|Overall Study|Physician Decision|15
6280024|NCT02276053|9989000|FG000|Overall Study|Death|2
6280025|NCT02276053|9989000|FG000|Overall Study|Adverse Event|5
6280026|NCT02276053|9989000|FG000|Overall Study|Lack of Efficacy|2
6280027|NCT02276053|9989000|FG000|Overall Study|Withdrawal by Subject|1
6280028|NCT02276053|9989000|FG000|Overall Study|Patient does not meet selection criteria|3
6280029|NCT02276053|9989000|FG000|Overall Study|Patient needs to increase baseline AED|1
6280030|NCT02276222|9989007|FG000|Overall Study|Adverse Event|62
6280031|NCT02276222|9989008|FG001|Overall Study|Adverse Event|11
6280032|NCT02276222|9989007|FG000|Overall Study|Death|3
6280033|NCT02276222|9989008|FG001|Overall Study|Death|4
6280034|NCT02276222|9989007|FG000|Overall Study|Lack of Efficacy|13
6280035|NCT02276222|9989008|FG001|Overall Study|Lack of Efficacy|3
6280036|NCT02276222|9989007|FG000|Overall Study|Protocol Violation|3
6280037|NCT02276222|9989008|FG001|Overall Study|Protocol Violation|2
6280038|NCT02276222|9989007|FG000|Overall Study|Withdrawal by Subject|79
6280039|NCT02276222|9989008|FG001|Overall Study|Withdrawal by Subject|33
6280040|NCT02276222|9989007|FG000|Overall Study|non compliance with study medication|6
6280041|NCT02276222|9989008|FG001|Overall Study|non compliance with study medication|2
6280042|NCT02276222|9989007|FG000|Overall Study|sponsor decision|0
6280043|NCT02276222|9989008|FG001|Overall Study|sponsor decision|3
6280044|NCT02276222|9989007|FG000|Overall Study|Lost to Follow-up|15
6280045|NCT02276222|9989008|FG001|Overall Study|Lost to Follow-up|5
6280046|NCT02276222|9989007|FG000|Overall Study|Physician Decision|2
6280047|NCT02276222|9989008|FG001|Overall Study|Physician Decision|1
6280048|NCT02276222|9989007|FG000|Overall Study|sheduling conflict|1
6280049|NCT02276222|9989008|FG001|Overall Study|sheduling conflict|0
6280050|NCT02276222|9989007|FG000|Overall Study|subject withdrew after randomization|1
6280051|NCT02276222|9989008|FG001|Overall Study|subject withdrew after randomization|0
6280052|NCT02276482|9989025|FG000|Overall Study|Adverse Event|1
6280053|NCT02276482|9989026|FG001|Overall Study|Adverse Event|0
6280054|NCT02276482|9989025|FG000|Overall Study|Withdrawal by Subject|1
6280055|NCT02276482|9989026|FG001|Overall Study|Withdrawal by Subject|0
6280056|NCT02276482|9989025|FG000|Overall Study|Gram-negative infection|1
6280057|NCT02276482|9989026|FG001|Overall Study|Gram-negative infection|0
6280058|NCT02276482|9989025|FG000|Overall Study|Reason not specified|0
6280059|NCT02276482|9989026|FG001|Overall Study|Reason not specified|1
6280060|NCT02276612|9989034|FG000|Overall Study|Death|1
6280061|NCT02276612|9989035|FG001|Overall Study|Death|0
6280062|NCT02276612|9989034|FG000|Overall Study|Pregnancy|1
6280063|NCT02276612|9989035|FG001|Overall Study|Pregnancy|0
6280064|NCT02276612|9989034|FG000|Overall Study|Withdrew Consent|1
6280065|NCT02276612|9989035|FG001|Overall Study|Withdrew Consent|0
6280066|NCT02276612|9989034|FG000|Overall Study|Lost to Follow-up|1
6280067|NCT02276612|9989035|FG001|Overall Study|Lost to Follow-up|0
6280068|NCT02276807|9989056|FG000|Overall Study|Withdrawal by Subject|8
6280069|NCT02276807|9989057|FG001|Overall Study|Withdrawal by Subject|7
6280070|NCT02276807|9989056|FG000|Overall Study|Lost to Follow-up|10
6280071|NCT02276807|9989057|FG001|Overall Study|Lost to Follow-up|10
6280072|NCT02276872|9989066|FG000|Overall Study|Adverse Event|1
6280073|NCT02276872|9989067|FG001|Overall Study|Adverse Event|0
6280074|NCT02276872|9989068|FG002|Overall Study|Adverse Event|0
6280075|NCT02277691|9989144|FG000|Overall Study|Pretreatment Event/Adverse Event|33
6280076|NCT02277691|9989144|FG000|Overall Study|Voluntary Withdrawal|7
6280077|NCT02277691|9989144|FG000|Overall Study|Lack of Efficacy|5
6280078|NCT02277691|9989144|FG000|Overall Study|Used Other Antihypertensive Drug|1
6280079|NCT02277743|9989151|FG000|Overall Study|Protocol Violation|1
6280080|NCT02277743|9989152|FG001|Overall Study|Protocol Violation|1
5978628|NCT04567186|9566536|FG000|Period 1|COVID-19 related|1
5978629|NCT04567186|9566537|FG001|Period 1|COVID-19 related|0
5978630|NCT04567186|9566536|FG000|Period 1|Protocol Violation|0
5978631|NCT04567186|9566537|FG001|Period 1|Protocol Violation|1
5978632|NCT04567186|9566536|FG000|Period 1|Adverse Event|0
5978633|NCT04567186|9566537|FG001|Period 1|Adverse Event|2
5978634|NCT04567186|9566536|FG000|Period 2|COVID-19 Related|0
5978635|NCT04567186|9566537|FG001|Period 2|COVID-19 Related|1
5978636|NCT04567186|9566536|FG000|Period 2|Protocol Violation|0
5978637|NCT04567186|9566537|FG001|Period 2|Protocol Violation|1
5978638|NCT04567186|9566536|FG000|Period 2|Lost to Follow-up|0
5978639|NCT04567186|9566537|FG001|Period 2|Lost to Follow-up|1
5978640|NCT04567186|9566536|FG000|Period 3|Subject no longer meets eligibilty criteria|1
5978641|NCT04567186|9566537|FG001|Period 3|Subject no longer meets eligibilty criteria|0
5978642|NCT04065074|9566543|FG000|Overall Study|Adverse Event|1
5978643|NCT04065074|9566543|FG000|Overall Study|Protocol Non-Compliance after injection|1
5978644|NCT03980730|9566549|FG000|Overall Study|Study Terminated by Sponsor|0
5978645|NCT03980730|9566550|FG001|Overall Study|Study Terminated by Sponsor|3
5978646|NCT03980730|9566549|FG000|Overall Study|Adverse Event|2
5978647|NCT03980730|9566550|FG001|Overall Study|Adverse Event|0
5978648|NCT03980730|9566549|FG000|Overall Study|Sponsor Request|0
5978649|NCT03980730|9566550|FG001|Overall Study|Sponsor Request|1
6051153|NCT00430781|9650375|FG002|Final Analysis; 31 July 2008|Ongoing|32
6051154|NCT00430781|9650373|FG000|End-of-Study Analysis; 28 July 2011|Lost to Follow-up|5
6051155|NCT00430781|9650374|FG001|End-of-Study Analysis; 28 July 2011|Lost to Follow-up|3
6051156|NCT00430781|9650375|FG002|End-of-Study Analysis; 28 July 2011|Lost to Follow-up|3
6051157|NCT00430781|9650373|FG000|End-of-Study Analysis; 28 July 2011|Protocol Violation|0
6051158|NCT00430781|9650374|FG001|End-of-Study Analysis; 28 July 2011|Protocol Violation|1
6051159|NCT00430781|9650375|FG002|End-of-Study Analysis; 28 July 2011|Protocol Violation|0
6051160|NCT00430781|9650373|FG000|End-of-Study Analysis; 28 July 2011|Withdrawal by Subject|7
6051161|NCT00430781|9650374|FG001|End-of-Study Analysis; 28 July 2011|Withdrawal by Subject|2
6051162|NCT00430781|9650375|FG002|End-of-Study Analysis; 28 July 2011|Withdrawal by Subject|7
6051163|NCT00430781|9650373|FG000|End-of-Study Analysis; 28 July 2011|Sponsor Terminated Study|4
6051164|NCT00430781|9650374|FG001|End-of-Study Analysis; 28 July 2011|Sponsor Terminated Study|5
6051165|NCT00430781|9650375|FG002|End-of-Study Analysis; 28 July 2011|Sponsor Terminated Study|4
6051166|NCT00430781|9650373|FG000|End-of-Study Analysis; 28 July 2011|Physician Decision|4
6051167|NCT00430781|9650374|FG001|End-of-Study Analysis; 28 July 2011|Physician Decision|6
6051168|NCT00430781|9650375|FG002|End-of-Study Analysis; 28 July 2011|Physician Decision|6
6051169|NCT00430781|9650373|FG000|End-of-Study Analysis; 28 July 2011|Other|4
6051170|NCT00430781|9650374|FG001|End-of-Study Analysis; 28 July 2011|Other|1
6051171|NCT00430781|9650375|FG002|End-of-Study Analysis; 28 July 2011|Other|0
6051172|NCT00430937|9650388|FG000|Overall Study|Adverse Event|3
6051173|NCT00430937|9650389|FG001|Overall Study|Adverse Event|8
6051174|NCT00430937|9650388|FG000|Overall Study|Death|0
6051175|NCT00430937|9650389|FG001|Overall Study|Death|1
6051176|NCT00430937|9650388|FG000|Overall Study|Lost to Follow-up|6
6051177|NCT00430937|9650389|FG001|Overall Study|Lost to Follow-up|6
6280081|NCT02277743|9989153|FG002|Overall Study|Protocol Violation|1
6051178|NCT00430937|9650388|FG000|Overall Study|Withdrawal by Subject|5
6051179|NCT00430937|9650389|FG001|Overall Study|Withdrawal by Subject|2
6051180|NCT00430937|9650388|FG000|Overall Study|Protocol Violation|3
6280082|NCT02277743|9989151|FG000|Overall Study|Adverse Event|10
6280083|NCT02277743|9989152|FG001|Overall Study|Adverse Event|6
6280084|NCT02277743|9989153|FG002|Overall Study|Adverse Event|6
6280085|NCT02277743|9989151|FG000|Overall Study|Lack of Efficacy|11
6280086|NCT02277743|9989152|FG001|Overall Study|Lack of Efficacy|4
6280087|NCT02277743|9989153|FG002|Overall Study|Lack of Efficacy|3
6280088|NCT02277743|9989151|FG000|Overall Study|Other than specified above|18
6280089|NCT02277743|9989152|FG001|Overall Study|Other than specified above|5
6280090|NCT02277743|9989153|FG002|Overall Study|Other than specified above|16
6280091|NCT02277769|9989164|FG000|Overall Study|Protocol Violation|3
6280092|NCT02277769|9989165|FG001|Overall Study|Protocol Violation|3
6280093|NCT02277769|9989166|FG002|Overall Study|Protocol Violation|5
6280094|NCT02277769|9989164|FG000|Overall Study|Lack of Efficacy|17
6280095|NCT02277769|9989165|FG001|Overall Study|Lack of Efficacy|0
6280096|NCT02277769|9989166|FG002|Overall Study|Lack of Efficacy|4
6280097|NCT02277769|9989164|FG000|Overall Study|Adverse Event|14
6280098|NCT02277769|9989165|FG001|Overall Study|Adverse Event|2
6280099|NCT02277769|9989166|FG002|Overall Study|Adverse Event|4
6280100|NCT02277769|9989164|FG000|Overall Study|Other than specified above|12
6280101|NCT02277769|9989165|FG001|Overall Study|Other than specified above|8
6280102|NCT02277769|9989166|FG002|Overall Study|Other than specified above|5
6280103|NCT02277990|9989187|FG000|Overall Study|Death|170
6280104|NCT02277990|9989188|FG001|Overall Study|Death|188
6280105|NCT02277990|9989187|FG000|Overall Study|Withdrawal by Subject|64
6280106|NCT02277990|9989188|FG001|Overall Study|Withdrawal by Subject|53
6280107|NCT02277990|9989187|FG000|Overall Study|Physician Decision|40
6280108|NCT02277990|9989188|FG001|Overall Study|Physician Decision|34
6280109|NCT02277990|9989187|FG000|Overall Study|Lost to Follow-up|66
6280110|NCT02277990|9989188|FG001|Overall Study|Lost to Follow-up|69
6280111|NCT02277990|9989187|FG000|Overall Study|Had other reason|26
6280112|NCT02277990|9989188|FG001|Overall Study|Had other reason|32
6280113|NCT02278003|9989196|FG000|Overall Study|Withdrawal by Subject|11
6280114|NCT02278003|9989197|FG001|Overall Study|Withdrawal by Subject|0
6280115|NCT02278003|9989196|FG000|Overall Study|Not Treated|1
6280116|NCT02278003|9989197|FG001|Overall Study|Not Treated|0
6280117|NCT02278003|9989196|FG000|Overall Study|Recognition task improperly completed|7
6280118|NCT02278003|9989197|FG001|Overall Study|Recognition task improperly completed|0
6280119|NCT02278263|9989219|FG000|Overall Study|Protocol Violation|7
6280120|NCT02278263|9989220|FG001|Overall Study|Protocol Violation|0
6280121|NCT02278263|9989221|FG002|Overall Study|Protocol Violation|9
5978650|NCT03793010|9566558|FG000|Overall Study|Withdrawal by Subject|5
5978651|NCT03793010|9566559|FG001|Overall Study|Withdrawal by Subject|7
5978652|NCT03793010|9566558|FG000|Overall Study|Withdrawn by Investigator or Sponsor|19
5978653|NCT03793010|9566559|FG001|Overall Study|Withdrawn by Investigator or Sponsor|18
5978654|NCT03793010|9566558|FG000|Overall Study|Lost to Follow-up|1
5978655|NCT03793010|9566559|FG001|Overall Study|Lost to Follow-up|2
5978656|NCT03793010|9566558|FG000|Overall Study|Patient couldn't sit still for injection|1
5978657|NCT03793010|9566559|FG001|Overall Study|Patient couldn't sit still for injection|0
5978658|NCT03793010|9566558|FG000|Overall Study|Withdrew to pursue other treatment|1
5978659|NCT03793010|9566559|FG001|Overall Study|Withdrew to pursue other treatment|0
5978660|NCT03793010|9566558|FG000|Overall Study|Did not meet eligibility criteria|1
5978661|NCT03793010|9566559|FG001|Overall Study|Did not meet eligibility criteria|0
5978662|NCT03644017|9566565|FG000|Overall Study|Access Abandonment|5
5978663|NCT03644017|9566565|FG000|Overall Study|Kidney Transplant|2
5978664|NCT03592186|9566571|FG000|Overall Study|Withdrawal by Subject|1
5978665|NCT03592186|9566572|FG001|Overall Study|Withdrawal by Subject|0
5978666|NCT03592186|9566571|FG000|Overall Study|Lost to Follow-up|16
5978667|NCT03592186|9566572|FG001|Overall Study|Lost to Follow-up|11
5978668|NCT03529942|9566578|FG000|Overall Study|Withdrawal by Subject|13
5978669|NCT03529942|9566578|FG000|Overall Study|Physician Decision|1
5978670|NCT03529942|9566578|FG000|Overall Study|Lost to Follow-up|7
5978671|NCT03529942|9566578|FG000|Overall Study|Needle inserted but no drug administered|1
5978672|NCT03529942|9566578|FG000|Overall Study|Personal reasons|1
5978673|NCT03349775|9566587|FG000|Overall Study|Side Effects|1
5978674|NCT03349775|9566588|FG001|Overall Study|Side Effects|2
5978675|NCT03349775|9566587|FG000|Overall Study|Withdrawal by Subject|1
5978676|NCT03349775|9566588|FG001|Overall Study|Withdrawal by Subject|1
5978677|NCT03349775|9566587|FG000|Overall Study|No primary outcome measurements|0
5978678|NCT03349775|9566588|FG001|Overall Study|No primary outcome measurements|1
5978679|NCT03256344|9566605|FG000|Overall Study|Ongoing on study|3
5978680|NCT03256344|9566606|FG001|Overall Study|Ongoing on study|3
5978681|NCT03256344|9566605|FG000|Overall Study|Death|5
6280122|NCT02278328|9989241|FG000|Neuropsych Screening|found ineligible on neuropsych|1
6280123|NCT02278328|9989242|FG001|Neuropsych Screening|found ineligible on neuropsych|0
6280124|NCT02278328|9989243|FG002|Neuropsych Screening|found ineligible on neuropsych|0
6280125|NCT02278328|9989241|FG000|Neuropsych Screening|Withdrawal by Subject|0
6280126|NCT02278328|9989242|FG001|Neuropsych Screening|Withdrawal by Subject|1
6280127|NCT02278328|9989243|FG002|Neuropsych Screening|Withdrawal by Subject|0
6280128|NCT02278328|9989241|FG000|Neuropsych Screening|incomplete consent|0
6280129|NCT02278328|9989242|FG001|Neuropsych Screening|incomplete consent|0
5978682|NCT03256344|9566606|FG001|Overall Study|Death|19
5978683|NCT03256344|9566605|FG000|Overall Study|Withdrawal by Subject|3
6280130|NCT02278328|9989243|FG002|Neuropsych Screening|incomplete consent|2
6280131|NCT02278341|9989251|FG000|Overall Study|Randomized but never received study drug|1
6280132|NCT02278341|9989252|FG001|Overall Study|Randomized but never received study drug|1
6280133|NCT02278341|9989251|FG000|Overall Study|Adverse Event|3
6280134|NCT02278341|9989252|FG001|Overall Study|Adverse Event|0
6280135|NCT02278341|9989251|FG000|Overall Study|Death|68
6280136|NCT02278341|9989252|FG001|Overall Study|Death|56
6280137|NCT02278341|9989251|FG000|Overall Study|Withdrawal by Subject|30
6280138|NCT02278341|9989252|FG001|Overall Study|Withdrawal by Subject|19
6280139|NCT02278341|9989251|FG000|Overall Study|Lost to Follow-up|0
6280140|NCT02278341|9989252|FG001|Overall Study|Lost to Follow-up|1
6280141|NCT02278341|9989251|FG000|Overall Study|Physician Decision|1
6280142|NCT02278341|9989252|FG001|Overall Study|Physician Decision|1
6280143|NCT02278341|9989251|FG000|Overall Study|Miscellaneous|15
6280144|NCT02278341|9989252|FG001|Overall Study|Miscellaneous|14
6280145|NCT02278354|9989261|FG000|Overall Study|Lost to Follow-up|2
6280146|NCT02278354|9989262|FG001|Overall Study|Lost to Follow-up|2
6280147|NCT02278354|9989261|FG000|Overall Study|Withdrawal by Subject|0
6280148|NCT02278354|9989262|FG001|Overall Study|Withdrawal by Subject|1
6280149|NCT02278354|9989261|FG000|Overall Study|<10 professional fights|2
6280150|NCT02278354|9989262|FG001|Overall Study|<10 professional fights|0
6280151|NCT02278367|9989272|FG000|Overall Study|Physician Decision|5
6280152|NCT02278367|9989273|FG001|Overall Study|Physician Decision|0
6280153|NCT02278367|9989272|FG000|Overall Study|Withdrawal by Subject|5
6280154|NCT02278367|9989273|FG001|Overall Study|Withdrawal by Subject|0
6280155|NCT02278471|9989281|FG000|Overall Study|Lost to Follow-up|6
6280156|NCT02278471|9989282|FG001|Overall Study|Lost to Follow-up|15
6280157|NCT02278471|9989281|FG000|Overall Study|Death|2
6280158|NCT02278471|9989282|FG001|Overall Study|Death|2
6280159|NCT02278471|9989281|FG000|Overall Study|Withdrawal by Subject|0
6280160|NCT02278471|9989282|FG001|Overall Study|Withdrawal by Subject|3
6280161|NCT02278614|9989309|FG000|Overall Study|Withdrawal by Subject|3
6280162|NCT02278614|9989310|FG001|Overall Study|Withdrawal by Subject|5
6280163|NCT02278614|9989309|FG000|Overall Study|Adverse Event|1
6280164|NCT02278614|9989310|FG001|Overall Study|Adverse Event|0
6280165|NCT02278614|9989309|FG000|Overall Study|left eye was not eligible|1
6280166|NCT02278614|9989310|FG001|Overall Study|left eye was not eligible|0
6280167|NCT02278939|9989326|FG000|Overall Study|lack of time|1
6280168|NCT02278939|9989327|FG001|Overall Study|lack of time|0
6280169|NCT02278939|9989326|FG000|Overall Study|Lost to Follow-up|1
6280170|NCT02278939|9989327|FG001|Overall Study|Lost to Follow-up|1
6280171|NCT02278939|9989326|FG000|Overall Study|death in family|1
6280172|NCT02278939|9989327|FG001|Overall Study|death in family|0
6280173|NCT02278939|9989326|FG000|Overall Study|family emergency unable to commit|2
6280174|NCT02278939|9989327|FG001|Overall Study|family emergency unable to commit|0
6280175|NCT02278952|9989333|FG000|Overall Study|Insufficient Sample|6
6280176|NCT02279043|9989346|FG000|Overall Study|Post-rand. exclusion - not eligible|1
6280177|NCT02279043|9989347|FG001|Overall Study|Post-rand. exclusion - not eligible|1
6280178|NCT02279043|9989348|FG002|Overall Study|Post-rand. exclusion - not eligible|0
5978684|NCT03256344|9566606|FG001|Overall Study|Withdrawal by Subject|3
5978685|NCT03207815|9566614|FG000|Overall Study|Protocol Violation|3
5978686|NCT03207815|9566615|FG001|Overall Study|Protocol Violation|1
5978687|NCT03207815|9566614|FG000|Overall Study|Adverse Event|1
5978688|NCT03207815|9566615|FG001|Overall Study|Adverse Event|2
5978689|NCT03207815|9566614|FG000|Overall Study|Lost to Follow-up|1
5978690|NCT03207815|9566615|FG001|Overall Study|Lost to Follow-up|2
5978691|NCT03207815|9566614|FG000|Overall Study|Investigator's Discretion|1
5978692|NCT03207815|9566615|FG001|Overall Study|Investigator's Discretion|1
5978693|NCT03207815|9566614|FG000|Overall Study|Lack of Efficacy|0
5978694|NCT03207815|9566615|FG001|Overall Study|Lack of Efficacy|1
5978695|NCT03207815|9566614|FG000|Overall Study|Pregnancy/Partner Pregnancy|1
5978696|NCT03207815|9566615|FG001|Overall Study|Pregnancy/Partner Pregnancy|0
5978697|NCT03207815|9566614|FG000|Overall Study|Withdrew Consent|1
5978698|NCT03207815|9566615|FG001|Overall Study|Withdrew Consent|0
5978699|NCT02968563|9566641|FG000|Overall Study|Adverse Event|0
5978700|NCT02968563|9566642|FG001|Overall Study|Adverse Event|6
6201883|NCT01497366|9861872|FG001|Overall Study|Lost to Follow-up|10
6201884|NCT01497366|9861871|FG000|Overall Study|Withdrawal by Subject|6
6201885|NCT01497366|9861872|FG001|Overall Study|Withdrawal by Subject|6
6201886|NCT01497366|9861871|FG000|Overall Study|Initiated Non-protocol HCV Treatment|7
6201887|NCT01497366|9861872|FG001|Overall Study|Initiated Non-protocol HCV Treatment|0
6201888|NCT01497366|9861871|FG000|Overall Study|Other|5
6201889|NCT01497366|9861872|FG001|Overall Study|Other|0
6201890|NCT01497366|9861871|FG000|Overall Study|Death|1
6201891|NCT01497366|9861872|FG001|Overall Study|Death|1
6201892|NCT01497366|9861871|FG000|Overall Study|Randomized but not treated|7
6201893|NCT01497366|9861872|FG001|Overall Study|Randomized but not treated|21
6201894|NCT01497899|9861925|FG000|Double-Blind Phase|Randomized but not Treated|1
6201895|NCT01497899|9861926|FG001|Double-Blind Phase|Randomized but not Treated|0
6201896|NCT01497899|9861927|FG002|Double-Blind Phase|Randomized but not Treated|0
6201897|NCT01497899|9861928|FG003|Double-Blind Phase|Randomized but not Treated|0
6201898|NCT01497899|9861925|FG000|Double-Blind Phase|Adverse Event|1
6201899|NCT01497899|9861926|FG001|Double-Blind Phase|Adverse Event|0
6201900|NCT01497899|9861927|FG002|Double-Blind Phase|Adverse Event|0
6201901|NCT01497899|9861928|FG003|Double-Blind Phase|Adverse Event|0
6280179|NCT02279043|9989346|FG000|Overall Study|Lost to Follow-up|46
6280180|NCT02279043|9989347|FG001|Overall Study|Lost to Follow-up|88
6280181|NCT02279043|9989348|FG002|Overall Study|Lost to Follow-up|0
6280182|NCT02279173|9989376|FG000|Overall Study|Protocol-specified Criteria|67
6280183|NCT02279173|9989376|FG000|Overall Study|Withdrawal by Subject|20
6280184|NCT02279173|9989376|FG000|Overall Study|Decision by Sponsor|4
6280185|NCT02279173|9989376|FG000|Overall Study|Lost to Follow-up|3
6280186|NCT02279407|9989386|FG000|Overall Study|Couldn't swallow IP; noncompliance|0
6280187|NCT02279407|9989387|FG001|Overall Study|Couldn't swallow IP; noncompliance|0
6280188|NCT02279407|9989388|FG002|Overall Study|Couldn't swallow IP; noncompliance|2
6280189|NCT02279407|9989389|FG003|Overall Study|Couldn't swallow IP; noncompliance|0
6280190|NCT02279407|9989386|FG000|Overall Study|Withdrawal by Subject|1
6280191|NCT02279407|9989387|FG001|Overall Study|Withdrawal by Subject|0
6280192|NCT02279407|9989388|FG002|Overall Study|Withdrawal by Subject|1
6280193|NCT02279407|9989389|FG003|Overall Study|Withdrawal by Subject|1
6280194|NCT02279407|9989386|FG000|Overall Study|Adverse Event|1
6280195|NCT02279407|9989387|FG001|Overall Study|Adverse Event|1
6280196|NCT02279407|9989388|FG002|Overall Study|Adverse Event|2
6280197|NCT02279407|9989389|FG003|Overall Study|Adverse Event|0
5978701|NCT02968563|9566641|FG000|Overall Study|Death|1
5978702|NCT02968563|9566642|FG001|Overall Study|Death|1
5978703|NCT02968563|9566641|FG000|Overall Study|Lost to Follow-up|0
5978704|NCT02968563|9566642|FG001|Overall Study|Lost to Follow-up|1
5978705|NCT02915783|9566648|FG000|Overall Study|Ongoing: Receiving Treatment|6
5978706|NCT02915783|9566648|FG000|Overall Study|Ongoing: In Survival Follow Up|8
6051181|NCT00430937|9650389|FG001|Overall Study|Protocol Violation|2
6051182|NCT00430937|9650388|FG000|Overall Study|Lack of Efficacy|6
6051183|NCT00430937|9650389|FG001|Overall Study|Lack of Efficacy|5
6051184|NCT00430937|9650388|FG000|Overall Study|Inappropriate enrollment|2
6051185|NCT00430937|9650389|FG001|Overall Study|Inappropriate enrollment|1
6051186|NCT00430937|9650388|FG000|Overall Study|Administrative reasons|1
6051187|NCT00430937|9650389|FG001|Overall Study|Administrative reasons|0
6051188|NCT00430937|9650388|FG000|Overall Study|Protocol discontinuation criteria met|1
6051189|NCT00430937|9650389|FG001|Overall Study|Protocol discontinuation criteria met|2
6051190|NCT00430937|9650388|FG000|Overall Study|Unable to classify|0
6051191|NCT00430937|9650389|FG001|Overall Study|Unable to classify|1
6051192|NCT00430989|9650397|FG000|Overall Study|Lost to Follow-up|2
6051193|NCT00430989|9650398|FG001|Overall Study|Lost to Follow-up|3
6051194|NCT00430989|9650397|FG000|Overall Study|Withdrawal by Subject|15
6051195|NCT00430989|9650398|FG001|Overall Study|Withdrawal by Subject|14
6051196|NCT00430989|9650397|FG000|Overall Study|Protocol Violation|30
6051197|NCT00430989|9650398|FG001|Overall Study|Protocol Violation|37
6051198|NCT00430989|9650397|FG000|Overall Study|Not eligible|13
6051199|NCT00430989|9650398|FG001|Overall Study|Not eligible|6
6051200|NCT00431067|9650415|FG000|Overall Study|Other Adverse Event|9
6051201|NCT00431067|9650415|FG000|Overall Study|Progressive disease|30
6051202|NCT00431067|9650415|FG000|Overall Study|Non-compliance,lost to follow-up|2
6051203|NCT00431444|9650436|FG000|Overall Study|Protocol Violation|1
6051204|NCT00431444|9650437|FG001|Overall Study|Protocol Violation|4
6051205|NCT00431444|9650436|FG000|Overall Study|Adverse Event|2
6051206|NCT00431444|9650437|FG001|Overall Study|Adverse Event|1
6051207|NCT00431444|9650436|FG000|Overall Study|Withdrawal by Subject|1
6051208|NCT00431444|9650437|FG001|Overall Study|Withdrawal by Subject|1
6051209|NCT00431444|9650436|FG000|Overall Study|Lost to Follow-up|1
6051210|NCT00431444|9650437|FG001|Overall Study|Lost to Follow-up|0
6051211|NCT00431444|9650436|FG000|Overall Study|Administrative Problems|0
6051212|NCT00431444|9650437|FG001|Overall Study|Administrative Problems|1
6051213|NCT00431496|9650443|FG000|Overall Study|Adverse Event|3
6051214|NCT00431496|9650443|FG000|Overall Study|Lost to Follow-up|1
6051215|NCT00431496|9650443|FG000|Overall Study|Withdrawal by Subject|2
6051216|NCT00431496|9650443|FG000|Overall Study|Protocol-specified criteria|5
6051217|NCT00431834|9650456|FG000|Overall Study|Withdrawal by Subject|7
6051218|NCT00431834|9650456|FG000|Overall Study|Death|3
6051219|NCT00431834|9650456|FG000|Overall Study|Missed Endpoint Visit|2
6051220|NCT00431834|9650456|FG000|Overall Study|Lost to Follow-up|1
6051221|NCT00431847|9650467|FG000|Overall Study|completion of less than two study visits|6
6051222|NCT00431847|9650468|FG001|Overall Study|completion of less than two study visits|3
6051223|NCT00431847|9650469|FG002|Overall Study|completion of less than two study visits|4
6051224|NCT00431847|9650470|FG003|Overall Study|completion of less than two study visits|14
6051225|NCT00431847|9650471|FG004|Overall Study|completion of less than two study visits|0
6051226|NCT00431847|9650467|FG000|Overall Study|Protocol Violation|0
6051227|NCT00431847|9650468|FG001|Overall Study|Protocol Violation|0
6051228|NCT00431847|9650469|FG002|Overall Study|Protocol Violation|0
6051229|NCT00431847|9650470|FG003|Overall Study|Protocol Violation|0
6280198|NCT02279420|9989399|FG000|Overall Study|Lost to Follow-up|23
6280199|NCT02279498|9989405|FG000|Overall Study|Adverse Event|3
6280200|NCT02279498|9989406|FG001|Overall Study|Adverse Event|0
6280201|NCT02279498|9989405|FG000|Overall Study|Lack of Efficacy|4
6280202|NCT02279498|9989406|FG001|Overall Study|Lack of Efficacy|0
6280203|NCT02279498|9989405|FG000|Overall Study|Lost to Follow-up|0
6280204|NCT02279498|9989406|FG001|Overall Study|Lost to Follow-up|1
6280205|NCT02279498|9989405|FG000|Overall Study|Withdrawal by Subject|9
6280206|NCT02279498|9989406|FG001|Overall Study|Withdrawal by Subject|2
6280207|NCT02279498|9989405|FG000|Overall Study|Undefined|2
6280208|NCT02279498|9989406|FG001|Overall Study|Undefined|1
6280209|NCT02279524|9989416|FG000|Overall Study|Withdrawal by Subject|3
5978707|NCT02913482|9566655|FG000|Overall Study|Death|0
5978708|NCT02913482|9566656|FG001|Overall Study|Death|2
5978709|NCT02913482|9566657|FG002|Overall Study|Death|2
5978710|NCT02913482|9566655|FG000|Overall Study|Progressive Disease|1
5978711|NCT02913482|9566656|FG001|Overall Study|Progressive Disease|1
5978712|NCT02913482|9566657|FG002|Overall Study|Progressive Disease|1
5978713|NCT02787044|9566669|FG000|Overall Study|Lost to Follow-up|15
5978714|NCT02787044|9566670|FG001|Overall Study|Lost to Follow-up|19
5978715|NCT02698163|9566682|FG000|Overall Study|Lost to Follow-up|0
5978716|NCT02698163|9566683|FG001|Overall Study|Lost to Follow-up|1
5978717|NCT01816165|9566710|FG000|Overall Study|Adverse Event|1
5978718|NCT01816165|9566711|FG001|Overall Study|Adverse Event|0
6051230|NCT00431847|9650471|FG004|Overall Study|Protocol Violation|1
6051231|NCT00431951|9650485|FG000|Overall Study|Inability to follow study procedures|1
6051232|NCT00431951|9650486|FG001|Overall Study|Inability to follow study procedures|0
6051233|NCT00431951|9650487|FG002|Overall Study|Inability to follow study procedures|1
6051234|NCT00431951|9650488|FG003|Overall Study|Inability to follow study procedures|2
6201902|NCT01497899|9861925|FG000|Double-Blind Phase|Lack of Efficacy|0
6201903|NCT01497899|9861926|FG001|Double-Blind Phase|Lack of Efficacy|1
6280210|NCT02279524|9989417|FG001|Overall Study|Withdrawal by Subject|6
6280211|NCT02279524|9989418|FG002|Overall Study|Withdrawal by Subject|3
6280212|NCT02279524|9989416|FG000|Overall Study|Adverse Event|4
6280213|NCT02279524|9989417|FG001|Overall Study|Adverse Event|3
6280214|NCT02279524|9989418|FG002|Overall Study|Adverse Event|2
6280215|NCT02279524|9989416|FG000|Overall Study|Lost to Follow-up|1
6280216|NCT02279524|9989417|FG001|Overall Study|Lost to Follow-up|1
6280217|NCT02279524|9989418|FG002|Overall Study|Lost to Follow-up|0
6280218|NCT02279524|9989416|FG000|Overall Study|Disallowed medication|1
6280219|NCT02279524|9989417|FG001|Overall Study|Disallowed medication|1
6280220|NCT02279524|9989418|FG002|Overall Study|Disallowed medication|2
6280221|NCT02279524|9989416|FG000|Overall Study|Bariatric surgery|1
6280222|NCT02279524|9989417|FG001|Overall Study|Bariatric surgery|0
6280223|NCT02279524|9989418|FG002|Overall Study|Bariatric surgery|0
6280224|NCT02279732|9989461|FG000|Overall Study|Death|23
6280225|NCT02279732|9989462|FG001|Overall Study|Death|20
5978719|NCT01816165|9566712|FG002|Overall Study|Adverse Event|0
5978720|NCT01816165|9566713|FG003|Overall Study|Adverse Event|0
6051235|NCT00431951|9650485|FG000|Overall Study|Lost to Follow-up|0
6201904|NCT01497899|9861927|FG002|Double-Blind Phase|Lack of Efficacy|0
6201905|NCT01497899|9861928|FG003|Double-Blind Phase|Lack of Efficacy|0
6201906|NCT01497899|9861925|FG000|Double-Blind Phase|Investigator's Discretion|1
6201907|NCT01497899|9861926|FG001|Double-Blind Phase|Investigator's Discretion|0
6201908|NCT01497899|9861927|FG002|Double-Blind Phase|Investigator's Discretion|0
6201909|NCT01497899|9861928|FG003|Double-Blind Phase|Investigator's Discretion|0
6201910|NCT01497899|9861925|FG000|Double-Blind Phase|Withdrew Consent|0
6201911|NCT01497899|9861926|FG001|Double-Blind Phase|Withdrew Consent|1
6201912|NCT01497899|9861927|FG002|Double-Blind Phase|Withdrew Consent|0
6201913|NCT01497899|9861928|FG003|Double-Blind Phase|Withdrew Consent|0
6201914|NCT01497899|9861925|FG000|Double-Blind Phase|Lost to Follow-up|3
6201915|NCT01497899|9861926|FG001|Double-Blind Phase|Lost to Follow-up|2
6201916|NCT01497899|9861927|FG002|Double-Blind Phase|Lost to Follow-up|0
6201917|NCT01497899|9861928|FG003|Double-Blind Phase|Lost to Follow-up|0
6201918|NCT01497899|9861925|FG000|Double-Blind Phase|Subject Non-Compliance|0
6201919|NCT01497899|9861926|FG001|Double-Blind Phase|Subject Non-Compliance|1
6201920|NCT01497899|9861927|FG002|Double-Blind Phase|Subject Non-Compliance|0
6201921|NCT01497899|9861928|FG003|Double-Blind Phase|Subject Non-Compliance|0
6201922|NCT01497899|9861925|FG000|Open-Label Extension Phase|Adverse Event|1
6201923|NCT01497899|9861926|FG001|Open-Label Extension Phase|Adverse Event|0
6201924|NCT01497899|9861927|FG002|Open-Label Extension Phase|Adverse Event|0
6201925|NCT01497899|9861928|FG003|Open-Label Extension Phase|Adverse Event|0
6201926|NCT01497899|9861925|FG000|Open-Label Extension Phase|Death|1
6201927|NCT01497899|9861926|FG001|Open-Label Extension Phase|Death|0
6201928|NCT01497899|9861927|FG002|Open-Label Extension Phase|Death|0
6201929|NCT01497899|9861928|FG003|Open-Label Extension Phase|Death|0
6201930|NCT01497899|9861925|FG000|Open-Label Extension Phase|Withdrew Consent|8
6201931|NCT01497899|9861926|FG001|Open-Label Extension Phase|Withdrew Consent|3
6201932|NCT01497899|9861927|FG002|Open-Label Extension Phase|Withdrew Consent|2
6201933|NCT01497899|9861928|FG003|Open-Label Extension Phase|Withdrew Consent|0
6280226|NCT02279732|9989461|FG000|Overall Study|Disease Progression|13
6280227|NCT02279732|9989462|FG001|Overall Study|Disease Progression|3
6280228|NCT02279732|9989461|FG000|Overall Study|Withdrawal by Subject|2
6280229|NCT02279732|9989462|FG001|Overall Study|Withdrawal by Subject|7
6280230|NCT02279732|9989461|FG000|Overall Study|Adverse Event|1
6280231|NCT02279732|9989462|FG001|Overall Study|Adverse Event|2
6280232|NCT02279732|9989461|FG000|Overall Study|Administrative Reason By Sponsor|0
6280233|NCT02279732|9989462|FG001|Overall Study|Administrative Reason By Sponsor|2
6280234|NCT02279732|9989461|FG000|Overall Study|Study Drug Toxicity|2
6280235|NCT02279732|9989462|FG001|Overall Study|Study Drug Toxicity|0
6280236|NCT02279732|9989461|FG000|Overall Study|Lost to Follow-up|0
6280237|NCT02279732|9989462|FG001|Overall Study|Lost to Follow-up|1
6280238|NCT02279732|9989461|FG000|Overall Study|Maximum Clinical Benefit|1
6280239|NCT02279732|9989462|FG001|Overall Study|Maximum Clinical Benefit|0
6280240|NCT02279732|9989461|FG000|Overall Study|Subject Requested to Discontinue|0
6280241|NCT02279732|9989462|FG001|Overall Study|Subject Requested to Discontinue|1
6280242|NCT02279732|9989461|FG000|Overall Study|Other|53
6280243|NCT02279732|9989462|FG001|Overall Study|Other|67
6280244|NCT02279732|9989461|FG000|Overall Study|Other|3
6280245|NCT02279732|9989462|FG001|Overall Study|Other|3
6280246|NCT02279862|9989470|FG000|Overall Study|Study drug toxicity|3
6280247|NCT02279862|9989471|FG001|Overall Study|Study drug toxicity|6
6280248|NCT02279862|9989470|FG000|Overall Study|No longer meets criteria|0
6280249|NCT02279862|9989471|FG001|Overall Study|No longer meets criteria|1
6280250|NCT02279862|9989470|FG000|Overall Study|Administrative reason by sponsor|0
6280251|NCT02279862|9989471|FG001|Overall Study|Administrative reason by sponsor|1
6280252|NCT02279862|9989470|FG000|Overall Study|Disease progression|5
6280253|NCT02279862|9989471|FG001|Overall Study|Disease progression|2
6280254|NCT02279862|9989470|FG000|Overall Study|Study closed by sponsor|16
5978721|NCT01813929|9566735|FG000|Overall Study|Withdrawal by Subject|0
5978722|NCT01813929|9566736|FG001|Overall Study|Withdrawal by Subject|1
5978723|NCT00882050|9566757|FG000|Overall Study|Physician Decision|1
5978724|NCT00882050|9566758|FG001|Overall Study|Physician Decision|0
5978725|NCT00882050|9566759|FG002|Overall Study|Physician Decision|0
5978726|NCT00070564|9566773|FG000|Overall Study|Progression|2
5978727|NCT00070564|9566774|FG001|Overall Study|Progression|4
5978728|NCT00070564|9566775|FG002|Overall Study|Progression|7
5978729|NCT00070564|9566776|FG003|Overall Study|Progression|7
5978730|NCT00070564|9566777|FG004|Overall Study|Progression|1
5978731|NCT00070564|9566778|FG005|Overall Study|Progression|0
5978732|NCT00070564|9566773|FG000|Overall Study|Delinquent|1
5978733|NCT00070564|9566774|FG001|Overall Study|Delinquent|4
5978734|NCT00070564|9566775|FG002|Overall Study|Delinquent|2
5978735|NCT00070564|9566776|FG003|Overall Study|Delinquent|0
5978736|NCT00070564|9566777|FG004|Overall Study|Delinquent|0
5978737|NCT00070564|9566778|FG005|Overall Study|Delinquent|0
5978738|NCT00070564|9566773|FG000|Overall Study|Adverse Event|150
5978739|NCT00070564|9566774|FG001|Overall Study|Adverse Event|142
5978740|NCT00070564|9566775|FG002|Overall Study|Adverse Event|120
5978741|NCT00070564|9566776|FG003|Overall Study|Adverse Event|108
5978742|NCT00070564|9566777|FG004|Overall Study|Adverse Event|63
5978743|NCT00070564|9566778|FG005|Overall Study|Adverse Event|36
5978744|NCT00070564|9566773|FG000|Overall Study|Death|4
5978745|NCT00070564|9566774|FG001|Overall Study|Death|1
5978746|NCT00070564|9566775|FG002|Overall Study|Death|5
5978747|NCT00070564|9566776|FG003|Overall Study|Death|3
5978748|NCT00070564|9566777|FG004|Overall Study|Death|0
6280255|NCT02279862|9989471|FG001|Overall Study|Study closed by sponsor|13
6280256|NCT02279862|9989470|FG000|Overall Study|Other|1
6280257|NCT02279862|9989471|FG001|Overall Study|Other|2
5978749|NCT00070564|9566778|FG005|Overall Study|Death|1
5978750|NCT00070564|9566773|FG000|Overall Study|Other, not protocol specified|17
5978751|NCT00070564|9566774|FG001|Overall Study|Other, not protocol specified|15
5978752|NCT00070564|9566775|FG002|Overall Study|Other, not protocol specified|14
5978753|NCT00070564|9566776|FG003|Overall Study|Other, not protocol specified|19
5978754|NCT00070564|9566777|FG004|Overall Study|Other, not protocol specified|6
5978755|NCT00070564|9566778|FG005|Overall Study|Other, not protocol specified|7
5978756|NCT00070564|9566773|FG000|Overall Study|Withdrawal by Subject|26
5978757|NCT00070564|9566774|FG001|Overall Study|Withdrawal by Subject|37
5978758|NCT00070564|9566775|FG002|Overall Study|Withdrawal by Subject|23
5978759|NCT00070564|9566776|FG003|Overall Study|Withdrawal by Subject|30
5978760|NCT00070564|9566777|FG004|Overall Study|Withdrawal by Subject|8
5978761|NCT00070564|9566778|FG005|Overall Study|Withdrawal by Subject|8
5978762|NCT00070564|9566773|FG000|Overall Study|Not reported|0
5978763|NCT00070564|9566774|FG001|Overall Study|Not reported|0
5978764|NCT00070564|9566775|FG002|Overall Study|Not reported|0
5978765|NCT00070564|9566776|FG003|Overall Study|Not reported|0
5978766|NCT00070564|9566777|FG004|Overall Study|Not reported|1
5978767|NCT00070564|9566778|FG005|Overall Study|Not reported|0
6051236|NCT00431951|9650486|FG001|Overall Study|Lost to Follow-up|1
6051237|NCT00431951|9650487|FG002|Overall Study|Lost to Follow-up|0
6051238|NCT00431951|9650488|FG003|Overall Study|Lost to Follow-up|0
6280258|NCT02279862|9989470|FG000|Overall Study|Withdrawal by Subject|1
6051239|NCT00431951|9650485|FG000|Overall Study|Withdrawal by Subject|0
6051240|NCT00431951|9650486|FG001|Overall Study|Withdrawal by Subject|1
6051241|NCT00431951|9650487|FG002|Overall Study|Withdrawal by Subject|0
6280259|NCT02279862|9989471|FG001|Overall Study|Withdrawal by Subject|0
6280260|NCT02280044|9989479|FG000|Overall Study|Planned alternate|0
6051242|NCT00431951|9650488|FG003|Overall Study|Withdrawal by Subject|0
6051243|NCT00431951|9650485|FG000|Overall Study|Adverse Event|0
6280261|NCT02280044|9989480|FG001|Overall Study|Planned alternate|2
6280262|NCT02280096|9989488|FG000|Overall Study|Pregnancy|1
6280263|NCT02280096|9989489|FG001|Overall Study|Pregnancy|0
6280264|NCT02280096|9989488|FG000|Overall Study|Functional neurological disorder|1
6280265|NCT02280096|9989489|FG001|Overall Study|Functional neurological disorder|0
6280266|NCT02280096|9989488|FG000|Overall Study|Lack of attachment|0
6280267|NCT02280096|9989489|FG001|Overall Study|Lack of attachment|1
6280268|NCT02280187|9989514|FG000|Overall Study|Lost to Follow-up|218
6280269|NCT02280291|9989535|FG000|Overall Study|Lost to Follow-up|2
6089124|NCT00680992|9700379|FG001|Overall Study|Disease Progression|9
6089125|NCT00680992|9700380|FG002|Overall Study|Disease Progression|0
6089126|NCT00680992|9700378|FG000|Overall Study|Lost to Follow-up|12
6089127|NCT00680992|9700379|FG001|Overall Study|Lost to Follow-up|14
6280270|NCT02280291|9989536|FG001|Overall Study|Lost to Follow-up|1
6089128|NCT00680992|9700380|FG002|Overall Study|Lost to Follow-up|0
6280271|NCT02280291|9989537|FG002|Overall Study|Lost to Follow-up|3
6280272|NCT02280291|9989538|FG003|Overall Study|Lost to Follow-up|8
6280273|NCT02280291|9989535|FG000|Overall Study|Protocol Violation|1
6280274|NCT02280291|9989536|FG001|Overall Study|Protocol Violation|0
6280275|NCT02280291|9989537|FG002|Overall Study|Protocol Violation|0
6280276|NCT02280291|9989538|FG003|Overall Study|Protocol Violation|0
6280277|NCT02280291|9989535|FG000|Overall Study|Other|1
6280278|NCT02280291|9989536|FG001|Overall Study|Other|1
6280279|NCT02280291|9989537|FG002|Overall Study|Other|0
6280280|NCT02280291|9989538|FG003|Overall Study|Other|0
6280281|NCT02280304|9989552|FG000|Overall Study|Lost to Follow-up|7
6280282|NCT02280304|9989553|FG001|Overall Study|Lost to Follow-up|8
6280283|NCT02280408|9989602|FG000|Overall Study|Lost to Follow-up|0
6280284|NCT02280408|9989603|FG001|Overall Study|Lost to Follow-up|2
6280285|NCT02280408|9989604|FG002|Overall Study|Lost to Follow-up|0
6280286|NCT02280408|9989605|FG003|Overall Study|Lost to Follow-up|0
6280287|NCT02280421|9989617|FG000|Washout (2 Weeks)|Adverse Event|0
6280288|NCT02280421|9989618|FG001|Washout (2 Weeks)|Adverse Event|1
6280289|NCT02280421|9989617|FG000|Washout (2 Weeks)|Withdrawal by Subject|1
6280290|NCT02280421|9989618|FG001|Washout (2 Weeks)|Withdrawal by Subject|0
6280291|NCT02280473|9989638|FG000|Overall Study|Adverse Event|1
6280292|NCT02280473|9989639|FG001|Overall Study|Adverse Event|1
6280293|NCT02280473|9989638|FG000|Overall Study|Lack of Efficacy|0
6280294|NCT02280473|9989639|FG001|Overall Study|Lack of Efficacy|1
6280295|NCT02280473|9989638|FG000|Overall Study|Lost to Follow-up|0
6280296|NCT02280473|9989639|FG001|Overall Study|Lost to Follow-up|1
6280297|NCT02280499|9989645|FG000|Overall Study|Death|14
6280298|NCT02280499|9989645|FG000|Overall Study|Lost to Follow-up|42
6280299|NCT02280499|9989645|FG000|Overall Study|Adverse Event|5
6280300|NCT02280863|9989683|FG000|Integrated Platform|Met stopping criteria|0
6280301|NCT02280863|9989684|FG001|Integrated Platform|Met stopping criteria|1
6280302|NCT02281318|9989700|FG000|Overall Study|Adverse Event|2
6280303|NCT02281318|9989701|FG001|Overall Study|Adverse Event|2
6280304|NCT02281318|9989700|FG000|Overall Study|Lack of Efficacy|2
6280305|NCT02281318|9989701|FG001|Overall Study|Lack of Efficacy|0
6280306|NCT02281318|9989700|FG000|Overall Study|Lost to Follow-up|2
6280307|NCT02281318|9989701|FG001|Overall Study|Lost to Follow-up|1
6280308|NCT02281318|9989700|FG000|Overall Study|Physician Decision|2
6280309|NCT02281318|9989701|FG001|Overall Study|Physician Decision|0
6280310|NCT02281318|9989700|FG000|Overall Study|Withdrawal by Subject|6
6280311|NCT02281318|9989701|FG001|Overall Study|Withdrawal by Subject|2
6280312|NCT02281357|9989713|FG000|Overall Study|Adverse Event|2
6280313|NCT02281357|9989714|FG001|Overall Study|Adverse Event|1
6280314|NCT02281357|9989713|FG000|Overall Study|Lost to Follow-up|1
6280315|NCT02281357|9989714|FG001|Overall Study|Lost to Follow-up|0
6280316|NCT02281357|9989713|FG000|Overall Study|Withdrawal by Subject|4
6280317|NCT02281357|9989714|FG001|Overall Study|Withdrawal by Subject|3
6280318|NCT02281552|9989779|FG000|Overall Study|Medication error|1
6280319|NCT02281552|9989780|FG001|Overall Study|Medication error|0
6280320|NCT02281552|9989779|FG000|Overall Study|Insufficient clinical response|0
6280321|NCT02281552|9989780|FG001|Overall Study|Insufficient clinical response|1
5978768|NCT04425720|9566809|FG000|Overall Study|Withdrawal by Subject|0
5978769|NCT04425720|9566810|FG001|Overall Study|Withdrawal by Subject|20
5978770|NCT04409509|9566819|FG000|Overall Study|Failure to meet randomization requirement|1
5978771|NCT04409509|9566820|FG001|Overall Study|Failure to meet randomization requirement|0
5978772|NCT04409509|9566819|FG000|Overall Study|Adverse Event|0
5978773|NCT04409509|9566820|FG001|Overall Study|Adverse Event|1
5978774|NCT04409509|9566819|FG000|Overall Study|Death|11
5978775|NCT04409509|9566820|FG001|Overall Study|Death|10
5978776|NCT04409509|9566819|FG000|Overall Study|Non-compliance with study drug|0
5978777|NCT04409509|9566820|FG001|Overall Study|Non-compliance with study drug|1
5978778|NCT04409509|9566819|FG000|Overall Study|Lost to Follow-up|0
5978779|NCT04409509|9566820|FG001|Overall Study|Lost to Follow-up|3
5978780|NCT04409509|9566819|FG000|Overall Study|Withdrawal by Subject|0
5978781|NCT04409509|9566820|FG001|Overall Study|Withdrawal by Subject|3
5978782|NCT04409509|9566819|FG000|Overall Study|Randomized by mistake|0
5978783|NCT04409509|9566820|FG001|Overall Study|Randomized by mistake|1
5978784|NCT04409509|9566819|FG000|Overall Study|Other|1
5978785|NCT04409509|9566820|FG001|Overall Study|Other|1
5978786|NCT04380519|9566830|FG000|Overall Study|Withdrawal by Subject|4
5978787|NCT04380519|9566831|FG001|Overall Study|Withdrawal by Subject|0
5978788|NCT04380519|9566832|FG002|Overall Study|Withdrawal by Subject|1
5978789|NCT04380519|9566830|FG000|Overall Study|Death|14
5978790|NCT04380519|9566831|FG001|Overall Study|Death|9
6280322|NCT02281552|9989779|FG000|Overall Study|Adverse Event|3
5978791|NCT04380519|9566832|FG002|Overall Study|Death|6
5978792|NCT04380519|9566830|FG000|Overall Study|Adverse Event|0
5978793|NCT04380519|9566831|FG001|Overall Study|Adverse Event|1
5978794|NCT04380519|9566832|FG002|Overall Study|Adverse Event|0
5978795|NCT04380519|9566830|FG000|Overall Study|relatives' decision|0
6280323|NCT02281552|9989780|FG001|Overall Study|Adverse Event|9
6280324|NCT02281760|9989803|FG000|Overall Study|Withdrawal by Subject|1
6280325|NCT02281773|9989812|FG000|Overall Study|Adverse Event|6
6280326|NCT02281773|9989813|FG001|Overall Study|Adverse Event|1
6280327|NCT02281773|9989814|FG002|Overall Study|Adverse Event|4
6280328|NCT02281773|9989815|FG003|Overall Study|Adverse Event|8
6280329|NCT02281773|9989816|FG004|Overall Study|Adverse Event|9
6280330|NCT02281773|9989812|FG000|Overall Study|Protocol Violation|1
6280331|NCT02281773|9989813|FG001|Overall Study|Protocol Violation|0
6280332|NCT02281773|9989814|FG002|Overall Study|Protocol Violation|0
6280333|NCT02281773|9989815|FG003|Overall Study|Protocol Violation|2
6280334|NCT02281773|9989816|FG004|Overall Study|Protocol Violation|2
6280335|NCT02281773|9989812|FG000|Overall Study|Lost to Follow-up|2
6280336|NCT02281773|9989813|FG001|Overall Study|Lost to Follow-up|2
6280337|NCT02281773|9989814|FG002|Overall Study|Lost to Follow-up|6
6280338|NCT02281773|9989815|FG003|Overall Study|Lost to Follow-up|2
6280339|NCT02281773|9989816|FG004|Overall Study|Lost to Follow-up|10
6280340|NCT02281773|9989812|FG000|Overall Study|Withdrawal by Subject|2
6280341|NCT02281773|9989813|FG001|Overall Study|Withdrawal by Subject|8
6280342|NCT02281773|9989814|FG002|Overall Study|Withdrawal by Subject|6
6280343|NCT02281773|9989815|FG003|Overall Study|Withdrawal by Subject|6
6280344|NCT02281773|9989816|FG004|Overall Study|Withdrawal by Subject|8
6280345|NCT02281773|9989812|FG000|Overall Study|Other Reason|0
6280346|NCT02281773|9989813|FG001|Overall Study|Other Reason|4
6280347|NCT02281773|9989814|FG002|Overall Study|Other Reason|2
6280348|NCT02281773|9989815|FG003|Overall Study|Other Reason|3
6280349|NCT02281773|9989816|FG004|Overall Study|Other Reason|1
6280350|NCT02282163|9989846|FG000|Overall Study|Protocol Violation|1
6280351|NCT02282293|9989861|FG000|Overall Study|Lost to Follow-up|2
6280352|NCT02282293|9989862|FG001|Overall Study|Lost to Follow-up|2
6280353|NCT02282293|9989861|FG000|Overall Study|Unable to comply with study procedures|1
6280354|NCT02282293|9989862|FG001|Overall Study|Unable to comply with study procedures|0
6280355|NCT02282293|9989861|FG000|Overall Study|Moved out of study area|0
6280356|NCT02282293|9989862|FG001|Overall Study|Moved out of study area|1
6280357|NCT02282527|9989874|FG000|Overall Study|Lost to Follow-up|0
6280358|NCT02282527|9989875|FG001|Overall Study|Lost to Follow-up|1
6280359|NCT02282527|9989874|FG000|Overall Study|Lack of home health aid|1
6280360|NCT02282527|9989875|FG001|Overall Study|Lack of home health aid|0
6280361|NCT02282605|9989887|FG000|Overall Study|negative SA result on Day -1|3
6280362|NCT02282605|9989888|FG001|Overall Study|negative SA result on Day -1|0
6280363|NCT02282605|9989889|FG002|Overall Study|negative SA result on Day -1|0
6280364|NCT02282631|9989899|FG000|Overall Study|Lost to Follow-up|2
6280365|NCT02282631|9989900|FG001|Overall Study|Lost to Follow-up|0
6280366|NCT02282813|9989924|FG000|Overall Study|Withdrawal by Subject|4
6280367|NCT02282813|9989925|FG001|Overall Study|Withdrawal by Subject|5
6280368|NCT02282813|9989926|FG002|Overall Study|Withdrawal by Subject|0
6280369|NCT02282813|9989924|FG000|Overall Study|Adverse Event|3
6280370|NCT02282813|9989925|FG001|Overall Study|Adverse Event|10
6280371|NCT02282813|9989926|FG002|Overall Study|Adverse Event|1
6280372|NCT02282813|9989924|FG000|Overall Study|Subject non-compliance|1
6280373|NCT02282813|9989925|FG001|Overall Study|Subject non-compliance|4
6280374|NCT02282813|9989926|FG002|Overall Study|Subject non-compliance|0
6280375|NCT02282813|9989924|FG000|Overall Study|Physician Decision|0
6280376|NCT02282813|9989925|FG001|Overall Study|Physician Decision|3
6280377|NCT02282813|9989926|FG002|Overall Study|Physician Decision|1
6280378|NCT02282813|9989924|FG000|Overall Study|Lost to Follow-up|2
6280379|NCT02282813|9989925|FG001|Overall Study|Lost to Follow-up|0
6280380|NCT02282813|9989926|FG002|Overall Study|Lost to Follow-up|1
6280381|NCT02282813|9989924|FG000|Overall Study|Serum Ca >/=11.0mg/dL|1
6280382|NCT02282813|9989925|FG001|Overall Study|Serum Ca >/=11.0mg/dL|0
6280383|NCT02282813|9989926|FG002|Overall Study|Serum Ca >/=11.0mg/dL|0
6280384|NCT02282813|9989924|FG000|Overall Study|Lack of Efficacy|1
6280385|NCT02282813|9989925|FG001|Overall Study|Lack of Efficacy|0
5978796|NCT04380519|9566831|FG001|Overall Study|relatives' decision|1
5978797|NCT04380519|9566832|FG002|Overall Study|relatives' decision|0
5978798|NCT04362813|9566842|FG000|Overall Study|Death|12
5978799|NCT04362813|9566843|FG001|Overall Study|Death|16
5978800|NCT04362813|9566842|FG000|Overall Study|Withdrawal by Subject|3
5978801|NCT04362813|9566843|FG001|Overall Study|Withdrawal by Subject|1
5978802|NCT04362813|9566842|FG000|Overall Study|Protocol Violation|0
5978803|NCT04362813|9566843|FG001|Overall Study|Protocol Violation|3
5978804|NCT04362813|9566842|FG000|Overall Study|Lost to Follow-up|1
5978805|NCT04362813|9566843|FG001|Overall Study|Lost to Follow-up|1
5978806|NCT04362813|9566842|FG000|Overall Study|Enrolled but did not receive treatment|2
5978807|NCT04362813|9566843|FG001|Overall Study|Enrolled but did not receive treatment|4
6051244|NCT00431951|9650486|FG001|Overall Study|Adverse Event|0
6051245|NCT00431951|9650487|FG002|Overall Study|Adverse Event|1
6051246|NCT00431951|9650488|FG003|Overall Study|Adverse Event|0
6051247|NCT00431964|9650504|FG000|Overall Study|Adverse Event|1
6051248|NCT00431964|9650505|FG001|Overall Study|Adverse Event|0
6051249|NCT00431964|9650504|FG000|Overall Study|Lost to Follow-up|1
6280386|NCT02282813|9989926|FG002|Overall Study|Lack of Efficacy|0
6051250|NCT00431964|9650505|FG001|Overall Study|Lost to Follow-up|2
6051251|NCT00431964|9650504|FG000|Overall Study|Physician Decision|2
6051252|NCT00431964|9650505|FG001|Overall Study|Physician Decision|2
6051253|NCT00431964|9650504|FG000|Overall Study|Withdrawal by Subject|2
6051254|NCT00431964|9650505|FG001|Overall Study|Withdrawal by Subject|1
6280387|NCT02282813|9989924|FG000|Overall Study|Administrative reasons|0
6280388|NCT02282813|9989925|FG001|Overall Study|Administrative reasons|1
6280389|NCT02282813|9989926|FG002|Overall Study|Administrative reasons|0
6280390|NCT02282982|9989944|FG000|Overall Study|Lost to Follow-up|15
6280391|NCT02282982|9989944|FG000|Overall Study|Withdrew consent|2
6280392|NCT02282982|9989944|FG000|Overall Study|Death|4
6280393|NCT02282982|9989944|FG000|Overall Study|Lack of product|156
6280394|NCT02282982|9989944|FG000|Overall Study|Palivizumab is ended|11
6280395|NCT02282982|9989944|FG000|Overall Study|Other, not specified|18
6280396|NCT02283268|9989948|FG000|Overall Study|Withdrawal by Subject|1
5978808|NCT03922321|9566901|FG000|Overall Study|Participant Moved|1
5978809|NCT03922321|9566901|FG000|Overall Study|Unable to Come to Site Due to COVID 19|1
5978810|NCT03911713|9566910|FG000|Overall Study|Lost to Follow-up|0
5978811|NCT03911713|9566911|FG001|Overall Study|Lost to Follow-up|2
5978812|NCT03911713|9566912|FG002|Overall Study|Lost to Follow-up|0
5978813|NCT03911713|9566913|FG003|Overall Study|Lost to Follow-up|0
5978814|NCT03911713|9566914|FG004|Overall Study|Lost to Follow-up|0
5978815|NCT03911713|9566910|FG000|Overall Study|Other|0
5978816|NCT03911713|9566911|FG001|Overall Study|Other|0
5978817|NCT03911713|9566912|FG002|Overall Study|Other|0
5978818|NCT03911713|9566913|FG003|Overall Study|Other|1
5978819|NCT03911713|9566914|FG004|Overall Study|Other|0
5978820|NCT03911713|9566910|FG000|Overall Study|Randomized, Never Dosed|1
5978821|NCT03911713|9566911|FG001|Overall Study|Randomized, Never Dosed|0
5978822|NCT03911713|9566912|FG002|Overall Study|Randomized, Never Dosed|0
5978823|NCT03911713|9566913|FG003|Overall Study|Randomized, Never Dosed|1
5978824|NCT03911713|9566914|FG004|Overall Study|Randomized, Never Dosed|0
5978825|NCT03852459|9566939|FG000|Overall Study|Adverse Event|2
5978826|NCT03852459|9566940|FG001|Overall Study|Adverse Event|2
5978827|NCT03852459|9566939|FG000|Overall Study|Withdrawal by Subject|1
5978828|NCT03852459|9566940|FG001|Overall Study|Withdrawal by Subject|1
5978829|NCT03740919|9566949|FG000|Lead-in Period|Lost to Follow-up|1
5978830|NCT03740919|9566950|FG001|Lead-in Period|Lost to Follow-up|0
5978831|NCT03740919|9566951|FG002|Lead-in Period|Lost to Follow-up|0
5978832|NCT03740919|9566952|FG003|Lead-in Period|Lost to Follow-up|0
5978833|NCT03740919|9566949|FG000|Lead-in Period|Physician Decision|2
5978834|NCT03740919|9566950|FG001|Lead-in Period|Physician Decision|0
5978835|NCT03740919|9566951|FG002|Lead-in Period|Physician Decision|0
5978836|NCT03740919|9566952|FG003|Lead-in Period|Physician Decision|0
5978837|NCT03740919|9566949|FG000|Lead-in Period|Protocol Violation|1
5978838|NCT03740919|9566950|FG001|Lead-in Period|Protocol Violation|0
5978839|NCT03740919|9566951|FG002|Lead-in Period|Protocol Violation|0
5978840|NCT03740919|9566952|FG003|Lead-in Period|Protocol Violation|0
5978841|NCT03740919|9566949|FG000|Lead-in Period|Withdrawal by Subject|10
5978842|NCT03740919|9566950|FG001|Lead-in Period|Withdrawal by Subject|0
5978843|NCT03740919|9566951|FG002|Lead-in Period|Withdrawal by Subject|0
5978844|NCT03740919|9566952|FG003|Lead-in Period|Withdrawal by Subject|0
5978845|NCT03740919|9566949|FG000|Lead-in Period|Due to Coronavirus Disease 2019 (COVID-19)|18
5978846|NCT03740919|9566950|FG001|Lead-in Period|Due to Coronavirus Disease 2019 (COVID-19)|0
5978847|NCT03740919|9566951|FG002|Lead-in Period|Due to Coronavirus Disease 2019 (COVID-19)|0
5978848|NCT03740919|9566952|FG003|Lead-in Period|Due to Coronavirus Disease 2019 (COVID-19)|0
5978849|NCT03740919|9566949|FG000|Lead-in Period|Study Task Too Burdensome|1
5978850|NCT03740919|9566950|FG001|Lead-in Period|Study Task Too Burdensome|0
5978851|NCT03740919|9566951|FG002|Lead-in Period|Study Task Too Burdensome|0
5978852|NCT03740919|9566952|FG003|Lead-in Period|Study Task Too Burdensome|0
5978853|NCT03740919|9566949|FG000|Lead-in Period|Lab Results Did Not Match Inclusion Criteria|1
5978854|NCT03740919|9566950|FG001|Lead-in Period|Lab Results Did Not Match Inclusion Criteria|0
5978855|NCT03740919|9566951|FG002|Lead-in Period|Lab Results Did Not Match Inclusion Criteria|0
6280397|NCT02283294|9989962|FG000|Overall Study|Lost to Follow-up|1
6280398|NCT02283294|9989963|FG001|Overall Study|Lost to Follow-up|1
6280399|NCT02283294|9989962|FG000|Overall Study|Withdrawal by Subject|1
6280400|NCT02283294|9989963|FG001|Overall Study|Withdrawal by Subject|6
6280401|NCT02283294|9989962|FG000|Overall Study|Protocol Violation|1
6280402|NCT02283294|9989963|FG001|Overall Study|Protocol Violation|0
6280403|NCT02283294|9989962|FG000|Overall Study|Thrombus on transesophageal echocardiogram|0
6280404|NCT02283294|9989963|FG001|Overall Study|Thrombus on transesophageal echocardiogram|1
6280405|NCT02283411|9989979|FG000|Overall Study|Withdrawal by Subject|3
6280406|NCT02283411|9989979|FG000|Overall Study|Screen Failed|28
6280407|NCT02283658|9989992|FG000|Overall Study|Withdrawal by Subject|1
6280408|NCT02283762|9990002|FG000|Main Treatment Phase (MT)|Adverse Event|9
6280409|NCT02283762|9990003|FG001|Main Treatment Phase (MT)|Adverse Event|9
6280410|NCT02283762|9990002|FG000|Main Treatment Phase (MT)|Lack of Efficacy|1
6280411|NCT02283762|9990003|FG001|Main Treatment Phase (MT)|Lack of Efficacy|0
6280412|NCT02283762|9990002|FG000|Main Treatment Phase (MT)|Physician Decision|1
6280413|NCT02283762|9990003|FG001|Main Treatment Phase (MT)|Physician Decision|1
6280414|NCT02283762|9990002|FG000|Main Treatment Phase (MT)|Pregnancy|0
6280415|NCT02283762|9990003|FG001|Main Treatment Phase (MT)|Pregnancy|1
6280416|NCT02283762|9990002|FG000|Main Treatment Phase (MT)|Withdrawal by Subject|7
6280417|NCT02283762|9990003|FG001|Main Treatment Phase (MT)|Withdrawal by Subject|4
6280418|NCT02283762|9990002|FG000|Long-term Extension Phase (LTE)|Adverse Event|2
6280419|NCT02283762|9990003|FG001|Long-term Extension Phase (LTE)|Adverse Event|6
6280420|NCT02283762|9990002|FG000|Long-term Extension Phase (LTE)|Lack of Efficacy|1
6280421|NCT02283762|9990003|FG001|Long-term Extension Phase (LTE)|Lack of Efficacy|1
6280422|NCT02283762|9990002|FG000|Long-term Extension Phase (LTE)|Study terminated at site|1
6280423|NCT02283762|9990003|FG001|Long-term Extension Phase (LTE)|Study terminated at site|0
6280424|NCT02283762|9990002|FG000|Long-term Extension Phase (LTE)|Withdrawal by Subject|4
6280425|NCT02283762|9990003|FG001|Long-term Extension Phase (LTE)|Withdrawal by Subject|3
6280426|NCT02283762|9990002|FG000|Long-term Extension Phase (LTE)|Protocol Violation|1
6280427|NCT02283762|9990003|FG001|Long-term Extension Phase (LTE)|Protocol Violation|1
6280428|NCT02283762|9990002|FG000|Long-term Extension Phase (LTE)|Lost to Follow-up|0
6280429|NCT02283762|9990003|FG001|Long-term Extension Phase (LTE)|Lost to Follow-up|1
6280430|NCT02283762|9990002|FG000|Long-term Extension Phase (LTE)|Physician Decision|1
6280431|NCT02283762|9990003|FG001|Long-term Extension Phase (LTE)|Physician Decision|2
6280432|NCT02283788|9990015|FG000|Overall Study|Adverse Event|1
6280433|NCT02283788|9990016|FG001|Overall Study|Adverse Event|3
6280434|NCT02283788|9990017|FG002|Overall Study|Adverse Event|5
6280435|NCT02283788|9990018|FG003|Overall Study|Adverse Event|1
6280436|NCT02283788|9990015|FG000|Overall Study|Withdrawal by Subject|0
6280437|NCT02283788|9990016|FG001|Overall Study|Withdrawal by Subject|1
6280438|NCT02283788|9990017|FG002|Overall Study|Withdrawal by Subject|0
5978856|NCT03740919|9566952|FG003|Lead-in Period|Lab Results Did Not Match Inclusion Criteria|0
5978857|NCT03740919|9566949|FG000|Lead-in Period|Withdrew Consent Due to Required Procedures|1
5978858|NCT03740919|9566950|FG001|Lead-in Period|Withdrew Consent Due to Required Procedures|0
5978859|NCT03740919|9566951|FG002|Lead-in Period|Withdrew Consent Due to Required Procedures|0
5978860|NCT03740919|9566952|FG003|Lead-in Period|Withdrew Consent Due to Required Procedures|0
5978861|NCT03740919|9566949|FG000|Treatment Period|Adverse Event|0
5978862|NCT03740919|9566950|FG001|Treatment Period|Adverse Event|0
5978863|NCT03740919|9566951|FG002|Treatment Period|Adverse Event|2
5978864|NCT03740919|9566952|FG003|Treatment Period|Adverse Event|0
5978865|NCT03740919|9566949|FG000|Treatment Period|Protocol Violation|0
5978866|NCT03740919|9566950|FG001|Treatment Period|Protocol Violation|1
5978867|NCT03740919|9566951|FG002|Treatment Period|Protocol Violation|0
5978868|NCT03740919|9566952|FG003|Treatment Period|Protocol Violation|0
5978869|NCT03740919|9566949|FG000|Treatment Period|Withdrawal by Subject|0
5978870|NCT03740919|9566950|FG001|Treatment Period|Withdrawal by Subject|7
5978871|NCT03740919|9566951|FG002|Treatment Period|Withdrawal by Subject|6
5978872|NCT03740919|9566952|FG003|Treatment Period|Withdrawal by Subject|2
5978873|NCT03740919|9566949|FG000|Treatment Period|Terminated by Sponsor|0
5978874|NCT03740919|9566950|FG001|Treatment Period|Terminated by Sponsor|1
5978875|NCT03740919|9566951|FG002|Treatment Period|Terminated by Sponsor|0
5978876|NCT03740919|9566952|FG003|Treatment Period|Terminated by Sponsor|0
5978877|NCT03740919|9566949|FG000|Treatment Period|Issue with Insulin Pump|0
5978878|NCT03740919|9566950|FG001|Treatment Period|Issue with Insulin Pump|1
5978879|NCT03740919|9566951|FG002|Treatment Period|Issue with Insulin Pump|0
5978880|NCT03740919|9566952|FG003|Treatment Period|Issue with Insulin Pump|0
5978881|NCT03740919|9566949|FG000|Treatment Period|Due to COVID-19 Pandemic|0
5978882|NCT03740919|9566950|FG001|Treatment Period|Due to COVID-19 Pandemic|0
5978883|NCT03740919|9566951|FG002|Treatment Period|Due to COVID-19 Pandemic|3
5978884|NCT03740919|9566952|FG003|Treatment Period|Due to COVID-19 Pandemic|1
5978885|NCT03740919|9566949|FG000|Treatment Period|Failure of Inclusion Criteria|0
5978886|NCT03740919|9566950|FG001|Treatment Period|Failure of Inclusion Criteria|0
5978887|NCT03740919|9566951|FG002|Treatment Period|Failure of Inclusion Criteria|1
5978888|NCT03740919|9566952|FG003|Treatment Period|Failure of Inclusion Criteria|0
5978889|NCT03740919|9566949|FG000|Treatment Period|Not Completing Diary|0
5978890|NCT03740919|9566950|FG001|Treatment Period|Not Completing Diary|0
6280439|NCT02283788|9990018|FG003|Overall Study|Withdrawal by Subject|1
6280440|NCT02284009|9990070|FG000|Overall Study|Adverse Event|3
6280441|NCT02284009|9990071|FG001|Overall Study|Adverse Event|0
6280442|NCT02284009|9990070|FG000|Overall Study|Lost to Follow-up|1
6280443|NCT02284009|9990071|FG001|Overall Study|Lost to Follow-up|3
6280444|NCT02284009|9990070|FG000|Overall Study|Physician Decision|0
6280445|NCT02284009|9990071|FG001|Overall Study|Physician Decision|2
6280446|NCT02284009|9990070|FG000|Overall Study|Withdrawal by Subject|2
6280447|NCT02284009|9990071|FG001|Overall Study|Withdrawal by Subject|5
6280448|NCT02284178|9990101|FG000|Overall Study|Met exclusion criteria|49
5978891|NCT03740919|9566951|FG002|Treatment Period|Not Completing Diary|1
5978892|NCT03740919|9566952|FG003|Treatment Period|Not Completing Diary|0
5978893|NCT03740919|9566949|FG000|Treatment Period|Insulin Painful to Participant|0
5978894|NCT03740919|9566950|FG001|Treatment Period|Insulin Painful to Participant|0
5978895|NCT03740919|9566951|FG002|Treatment Period|Insulin Painful to Participant|1
5978896|NCT03740919|9566952|FG003|Treatment Period|Insulin Painful to Participant|0
5978897|NCT03647488|9566986|FG000|Overall Study|Progressive disease|10
5978898|NCT03647488|9566987|FG001|Overall Study|Progressive disease|0
5978899|NCT03647488|9566988|FG002|Overall Study|Progressive disease|0
5978900|NCT03647488|9566986|FG000|Overall Study|Adverse Event|5
5978901|NCT03647488|9566987|FG001|Overall Study|Adverse Event|0
5978902|NCT03647488|9566988|FG002|Overall Study|Adverse Event|0
5978903|NCT03647488|9566986|FG000|Overall Study|Clinical progression|2
5978904|NCT03647488|9566987|FG001|Overall Study|Clinical progression|0
6051255|NCT00431964|9650504|FG000|Overall Study|Parental Consent Withdrawn|0
6051256|NCT00431964|9650505|FG001|Overall Study|Parental Consent Withdrawn|2
6051257|NCT00431964|9650504|FG000|Overall Study|Due to Unstable Health|0
6051258|NCT00431964|9650505|FG001|Overall Study|Due to Unstable Health|1
6051259|NCT00432042|9650514|FG000|Overall Study|Protocol Violation|2
6051260|NCT00432042|9650515|FG001|Overall Study|Protocol Violation|0
6051261|NCT00432042|9650516|FG002|Overall Study|Protocol Violation|0
6051262|NCT00432042|9650514|FG000|Overall Study|Withdrawal by Subject|0
6051263|NCT00432042|9650515|FG001|Overall Study|Withdrawal by Subject|0
6051264|NCT00432042|9650516|FG002|Overall Study|Withdrawal by Subject|2
6051265|NCT00432042|9650514|FG000|Overall Study|Lost to Follow-up|5
6051266|NCT00432042|9650515|FG001|Overall Study|Lost to Follow-up|1
6051267|NCT00432042|9650516|FG002|Overall Study|Lost to Follow-up|0
6051268|NCT00432159|9650529|FG000|Overall Study|Death|0
6051269|NCT00432159|9650530|FG001|Overall Study|Death|1
6051270|NCT00432159|9650531|FG002|Overall Study|Death|0
6051271|NCT00432159|9650532|FG003|Overall Study|Death|0
6051272|NCT00432159|9650533|FG004|Overall Study|Death|0
6051273|NCT00432159|9650529|FG000|Overall Study|Failure|9
6051274|NCT00432159|9650530|FG001|Overall Study|Failure|5
6051275|NCT00432159|9650531|FG002|Overall Study|Failure|3
6051276|NCT00432159|9650532|FG003|Overall Study|Failure|2
6051277|NCT00432159|9650533|FG004|Overall Study|Failure|3
6051278|NCT00432159|9650529|FG000|Overall Study|Missing NDI and/or neuro. assessment|13
6051279|NCT00432159|9650530|FG001|Overall Study|Missing NDI and/or neuro. assessment|24
6051280|NCT00432159|9650531|FG002|Overall Study|Missing NDI and/or neuro. assessment|1
6051281|NCT00432159|9650532|FG003|Overall Study|Missing NDI and/or neuro. assessment|3
6051282|NCT00432159|9650533|FG004|Overall Study|Missing NDI and/or neuro. assessment|7
6051283|NCT00432172|9650549|FG000|Overall Study|Physician Decision|0
6051284|NCT00432172|9650550|FG001|Overall Study|Physician Decision|0
6051285|NCT00432172|9650551|FG002|Overall Study|Physician Decision|2
6051286|NCT00432172|9650552|FG003|Overall Study|Physician Decision|0
6051287|NCT00432172|9650549|FG000|Overall Study|Adverse Event|4
6051288|NCT00432172|9650550|FG001|Overall Study|Adverse Event|2
6051289|NCT00432172|9650551|FG002|Overall Study|Adverse Event|4
6051290|NCT00432172|9650552|FG003|Overall Study|Adverse Event|3
6051291|NCT00432172|9650549|FG000|Overall Study|Disease progression|0
6051292|NCT00432172|9650550|FG001|Overall Study|Disease progression|2
6051293|NCT00432172|9650551|FG002|Overall Study|Disease progression|5
6051294|NCT00432172|9650552|FG003|Overall Study|Disease progression|1
6051295|NCT00432172|9650549|FG000|Overall Study|Withdrawal by Subject|0
6051296|NCT00432172|9650550|FG001|Overall Study|Withdrawal by Subject|1
6051297|NCT00432172|9650551|FG002|Overall Study|Withdrawal by Subject|0
5978905|NCT03647488|9566988|FG002|Overall Study|Clinical progression|0
6051298|NCT00432172|9650552|FG003|Overall Study|Withdrawal by Subject|2
6051299|NCT00432172|9650549|FG000|Overall Study|No treatment received|2
6051300|NCT00432172|9650550|FG001|Overall Study|No treatment received|2
6051301|NCT00432172|9650551|FG002|Overall Study|No treatment received|0
6051302|NCT00432172|9650552|FG003|Overall Study|No treatment received|1
6051303|NCT00432237|9650568|FG000|Overall Study|Adverse Event|0
6051304|NCT00432237|9650569|FG001|Overall Study|Adverse Event|0
6051305|NCT00432237|9650570|FG002|Overall Study|Adverse Event|0
6051306|NCT00432237|9650571|FG003|Overall Study|Adverse Event|1
6051307|NCT00432237|9650568|FG000|Overall Study|Lack of Efficacy|0
6051308|NCT00432237|9650569|FG001|Overall Study|Lack of Efficacy|0
6051309|NCT00432237|9650570|FG002|Overall Study|Lack of Efficacy|0
6051310|NCT00432237|9650571|FG003|Overall Study|Lack of Efficacy|1
6051311|NCT00432237|9650568|FG000|Overall Study|Lost to Follow-up|10
6051312|NCT00432237|9650569|FG001|Overall Study|Lost to Follow-up|10
6051313|NCT00432237|9650570|FG002|Overall Study|Lost to Follow-up|18
6051314|NCT00432237|9650571|FG003|Overall Study|Lost to Follow-up|18
6280449|NCT02284178|9990102|FG001|Overall Study|Met exclusion criteria|54
6280450|NCT02284243|9990110|FG000|Overall Study|Lack of Efficacy|3
6280451|NCT02284243|9990111|FG001|Overall Study|Lack of Efficacy|3
6280452|NCT02284243|9990110|FG000|Overall Study|Adverse Event|1
6280453|NCT02284243|9990111|FG001|Overall Study|Adverse Event|0
6280454|NCT02284347|9990117|FG000|Overall Study|Lost to Follow-up|2
6280455|NCT02284347|9990117|FG000|Overall Study|Withdrawn prior to treatment|1
6280456|NCT02284893|9990207|FG000|26 Week (Short Term)|Adverse Event|1
6280457|NCT02284893|9990208|FG001|26 Week (Short Term)|Adverse Event|9
6280458|NCT02284893|9990207|FG000|26 Week (Short Term)|Discontinuation by the subject|2
6280459|NCT02284893|9990208|FG001|26 Week (Short Term)|Discontinuation by the subject|2
6280460|NCT02284893|9990207|FG000|26 Week (Short Term)|Withrawal of the consent by the subject|7
6280461|NCT02284893|9990208|FG001|26 Week (Short Term)|Withrawal of the consent by the subject|10
6280462|NCT02284893|9990207|FG000|26 Week (Short Term)|Lost to Follow-up|3
6280463|NCT02284893|9990208|FG001|26 Week (Short Term)|Lost to Follow-up|1
6280464|NCT02284893|9990207|FG000|26 Week (Short Term)|Subject no longer meets study criteria|5
6280465|NCT02284893|9990208|FG001|26 Week (Short Term)|Subject no longer meets study criteria|8
6280466|NCT02284893|9990207|FG000|26 Week (Short Term)|Other|1
6280467|NCT02284893|9990208|FG001|26 Week (Short Term)|Other|1
6280468|NCT02284893|9990207|FG000|52 Week (Long Term)|Adverse Event|3
6280469|NCT02284893|9990208|FG001|52 Week (Long Term)|Adverse Event|1
6280470|NCT02284893|9990207|FG000|52 Week (Long Term)|Subject no longer meets study criteria|0
6280471|NCT02284893|9990208|FG001|52 Week (Long Term)|Subject no longer meets study criteria|1
6280472|NCT02284893|9990207|FG000|52 Week (Long Term)|Withrawal of the consent by the subject|4
6280473|NCT02284893|9990208|FG001|52 Week (Long Term)|Withrawal of the consent by the subject|6
6280474|NCT02284893|9990207|FG000|52 Week (Long Term)|Lost to Follow-up|2
6280475|NCT02284893|9990208|FG001|52 Week (Long Term)|Lost to Follow-up|2
6280476|NCT02284893|9990207|FG000|52 Week (Long Term)|Non-Compliance|2
6280477|NCT02284893|9990208|FG001|52 Week (Long Term)|Non-Compliance|3
6280478|NCT02285010|9990216|FG000|Overall Study|not abdominal hysterectomy|2
6280479|NCT02285010|9990217|FG001|Overall Study|not abdominal hysterectomy|0
6280480|NCT02285010|9990216|FG000|Overall Study|Not spinal anesthesia|3
6280481|NCT02285010|9990217|FG001|Overall Study|Not spinal anesthesia|1
6280482|NCT02285153|9990235|FG000|Overall Study|Adverse Event|1
6280483|NCT02285153|9990236|FG001|Overall Study|Adverse Event|0
6280484|NCT02285361|9990251|FG000|Overall Study|Protocol Violation|43
6280485|NCT02285361|9990251|FG000|Overall Study|Lost to Follow-up|5
6280486|NCT02285361|9990251|FG000|Overall Study|Not taken GIOTRIF|2
6280487|NCT02285361|9990251|FG000|Overall Study|Consented prior to the contract date|1
6280488|NCT02285777|9990275|FG000|Overall Study|Withdrawal by Subject|1
6280489|NCT02285777|9990276|FG001|Overall Study|Withdrawal by Subject|1
6280490|NCT02285777|9990275|FG000|Overall Study|Lost to Follow-up|4
6280491|NCT02285777|9990276|FG001|Overall Study|Lost to Follow-up|2
6280492|NCT02285855|9990284|FG000|Overall Study|Withdrawal by Subject|2
6280493|NCT02285855|9990285|FG001|Overall Study|Withdrawal by Subject|1
6280494|NCT02285920|9990308|FG000|Overall Study|Kidney transplantation|2
6280495|NCT02285920|9990309|FG001|Overall Study|Kidney transplantation|2
5978906|NCT03647488|9566986|FG000|Overall Study|Participant refused to take investigational product|1
5978907|NCT03647488|9566987|FG001|Overall Study|Participant refused to take investigational product|0
5978908|NCT03647488|9566988|FG002|Overall Study|Participant refused to take investigational product|0
5978909|NCT03614923|9566997|FG000|Overall Study|Withdrawal by Subject|2
5978910|NCT03614923|9566998|FG001|Overall Study|Withdrawal by Subject|1
5978911|NCT03614923|9566999|FG002|Overall Study|Withdrawal by Subject|1
5978912|NCT03614923|9566997|FG000|Overall Study|Adverse Event|0
5978913|NCT03614923|9566998|FG001|Overall Study|Adverse Event|2
5978914|NCT03614923|9566999|FG002|Overall Study|Adverse Event|1
5978915|NCT03614923|9566997|FG000|Overall Study|Lost to Follow-up|1
5978916|NCT03614923|9566998|FG001|Overall Study|Lost to Follow-up|0
5978917|NCT03614923|9566999|FG002|Overall Study|Lost to Follow-up|1
5978918|NCT03614923|9566997|FG000|Overall Study|Lack of Efficacy|2
5978919|NCT03614923|9566998|FG001|Overall Study|Lack of Efficacy|0
5978920|NCT03614923|9566999|FG002|Overall Study|Lack of Efficacy|1
5978921|NCT03614923|9566997|FG000|Overall Study|Non-compliance|0
5978922|NCT03614923|9566998|FG001|Overall Study|Non-compliance|1
5978923|NCT03614923|9566999|FG002|Overall Study|Non-compliance|0
5978924|NCT03614923|9566997|FG000|Overall Study|Other|0
5978925|NCT03614923|9566998|FG001|Overall Study|Other|1
5978926|NCT03614923|9566999|FG002|Overall Study|Other|1
5978927|NCT03502187|9567010|FG000|Overall Study|Withdrawal by Subject|4
5978928|NCT03502187|9567011|FG001|Overall Study|Withdrawal by Subject|3
5978929|NCT03502187|9567012|FG002|Overall Study|Withdrawal by Subject|3
5978930|NCT03502187|9567010|FG000|Overall Study|Lost to Follow-up|5
5978931|NCT03502187|9567011|FG001|Overall Study|Lost to Follow-up|4
5978932|NCT03502187|9567012|FG002|Overall Study|Lost to Follow-up|5
5978933|NCT03447262|9567020|FG000|Overall Study|Adverse Event|7
5978934|NCT03447262|9567020|FG000|Overall Study|Withdrawal of Consent (not due to AE)|2
5978935|NCT03447262|9567020|FG000|Overall Study|Commercial Drug is Available for Participant|9
5978936|NCT03447262|9567020|FG000|Overall Study|Death|2
6280496|NCT02285920|9990310|FG002|Overall Study|Kidney transplantation|2
6280497|NCT02285920|9990311|FG003|Overall Study|Kidney transplantation|0
6280498|NCT02285920|9990308|FG000|Overall Study|Change to peritoneal dialysis|0
6280499|NCT02285920|9990309|FG001|Overall Study|Change to peritoneal dialysis|0
6280500|NCT02285920|9990310|FG002|Overall Study|Change to peritoneal dialysis|1
6280501|NCT02285920|9990311|FG003|Overall Study|Change to peritoneal dialysis|0
6280502|NCT02285920|9990308|FG000|Overall Study|Transfer to non-participating unit|0
6280503|NCT02285920|9990309|FG001|Overall Study|Transfer to non-participating unit|1
6280504|NCT02285920|9990310|FG002|Overall Study|Transfer to non-participating unit|0
6280505|NCT02285920|9990311|FG003|Overall Study|Transfer to non-participating unit|0
6280506|NCT02285920|9990308|FG000|Overall Study|Dialysis discontinuation|0
6280507|NCT02285920|9990309|FG001|Overall Study|Dialysis discontinuation|1
6280508|NCT02285920|9990310|FG002|Overall Study|Dialysis discontinuation|0
6280509|NCT02285920|9990311|FG003|Overall Study|Dialysis discontinuation|0
6280510|NCT02285920|9990308|FG000|Overall Study|Death|2
6280511|NCT02285920|9990309|FG001|Overall Study|Death|0
6280512|NCT02285920|9990310|FG002|Overall Study|Death|2
6280513|NCT02285920|9990311|FG003|Overall Study|Death|1
6280514|NCT02285998|9990323|FG000|Overall Study|Adverse Event|9
6280515|NCT02285998|9990324|FG001|Overall Study|Adverse Event|8
6280516|NCT02285998|9990323|FG000|Overall Study|Physician Decision|1
6280517|NCT02285998|9990324|FG001|Overall Study|Physician Decision|2
6280518|NCT02285998|9990323|FG000|Overall Study|Lost to Follow-up|176
6280519|NCT02285998|9990324|FG001|Overall Study|Lost to Follow-up|172
6280520|NCT02285998|9990323|FG000|Overall Study|Withdrawal by Subject|53
6280521|NCT02285998|9990324|FG001|Overall Study|Withdrawal by Subject|61
6280522|NCT02285998|9990323|FG000|Overall Study|Other Reasons|7
6280523|NCT02285998|9990324|FG001|Overall Study|Other Reasons|10
6280524|NCT02286102|9990332|FG000|Overall Study|Screen Failure|1
6280525|NCT02286102|9990333|FG001|Overall Study|Screen Failure|1
6280526|NCT02286193|9990339|FG000|Overall Study|Referred: CRS unable to make contact|62
6280527|NCT02286193|9990339|FG000|Overall Study|Referred: unable to reach/resource sent|104
6280528|NCT02286193|9990339|FG000|Overall Study|Referred: Declined service|38
6280529|NCT02286466|9990346|FG000|Overall Study|Death|1
6280530|NCT02286466|9990347|FG001|Overall Study|Death|3
6280531|NCT02286466|9990346|FG000|Overall Study|Withdrawal by Subject|5
6280532|NCT02286466|9990347|FG001|Overall Study|Withdrawal by Subject|2
6280533|NCT02286466|9990346|FG000|Overall Study|Lost to Follow-up|1
6280534|NCT02286466|9990347|FG001|Overall Study|Lost to Follow-up|4
6280535|NCT02286466|9990346|FG000|Overall Study|Declined Clinician Assessment|0
6280536|NCT02286466|9990347|FG001|Overall Study|Declined Clinician Assessment|1
6280537|NCT02286713|9990428|FG000|One Week Follow-Up|Death|1
6280538|NCT02286713|9990429|FG001|One Week Follow-Up|Death|0
6280539|NCT02286713|9990428|FG000|One Week Follow-Up|Lost to Follow-up|17
6280540|NCT02286713|9990429|FG001|One Week Follow-Up|Lost to Follow-up|21
6280541|NCT02286713|9990428|FG000|One Week Follow-Up|Withdrawal by Subject|6
6280542|NCT02286713|9990429|FG001|One Week Follow-Up|Withdrawal by Subject|3
5978937|NCT03447262|9567020|FG000|Overall Study|Study Termination by Sponsor|455
5978938|NCT03447262|9567020|FG000|Overall Study|Other|4
5978939|NCT03432819|9567029|FG000|Overall Study|Lost to Follow-up|2
5978940|NCT03432819|9567030|FG001|Overall Study|Lost to Follow-up|2
5978941|NCT03432819|9567029|FG000|Overall Study|Withdrawal by Subject|5
5978942|NCT03432819|9567030|FG001|Overall Study|Withdrawal by Subject|3
6051315|NCT00432237|9650568|FG000|Overall Study|Physician Decision|1
6051316|NCT00432237|9650569|FG001|Overall Study|Physician Decision|3
6051317|NCT00432237|9650570|FG002|Overall Study|Physician Decision|2
6051318|NCT00432237|9650571|FG003|Overall Study|Physician Decision|1
6051319|NCT00432237|9650568|FG000|Overall Study|Pregnancy|0
6051320|NCT00432237|9650569|FG001|Overall Study|Pregnancy|1
6051321|NCT00432237|9650570|FG002|Overall Study|Pregnancy|0
6051322|NCT00432237|9650571|FG003|Overall Study|Pregnancy|0
6051323|NCT00432237|9650568|FG000|Overall Study|Protocol Violation|13
6051324|NCT00432237|9650569|FG001|Overall Study|Protocol Violation|10
6051325|NCT00432237|9650570|FG002|Overall Study|Protocol Violation|11
6051326|NCT00432237|9650571|FG003|Overall Study|Protocol Violation|8
6051327|NCT00432237|9650568|FG000|Overall Study|Withdrawal by Subject|5
6051328|NCT00432237|9650569|FG001|Overall Study|Withdrawal by Subject|6
6051329|NCT00432237|9650570|FG002|Overall Study|Withdrawal by Subject|9
6280543|NCT02286713|9990428|FG000|Three Month Follow-Up|Death|1
6280544|NCT02286713|9990429|FG001|Three Month Follow-Up|Death|1
6280545|NCT02286713|9990428|FG000|Three Month Follow-Up|Lost to Follow-up|26
6280546|NCT02286713|9990429|FG001|Three Month Follow-Up|Lost to Follow-up|24
6280547|NCT02286713|9990428|FG000|Three Month Follow-Up|Withdrawal by Subject|1
6280548|NCT02286713|9990429|FG001|Three Month Follow-Up|Withdrawal by Subject|1
6280549|NCT02286713|9990428|FG000|Six Month Follow-Up|Death|2
6280550|NCT02286713|9990429|FG001|Six Month Follow-Up|Death|0
6280551|NCT02286713|9990428|FG000|Six Month Follow-Up|Lost to Follow-up|30
6280552|NCT02286713|9990429|FG001|Six Month Follow-Up|Lost to Follow-up|27
6280553|NCT02286843|9990448|FG000|Overall Study|Not Treated|4
6280554|NCT02286843|9990448|FG000|Overall Study|Protocol Violation|1
6280555|NCT02286843|9990448|FG000|Overall Study|Withdrawal by Subject|1
6280556|NCT02286895|9990454|FG000|Assessed for Measles Seroconversion|Protocol Violation|1
6280557|NCT02286895|9990455|FG001|Assessed for Measles Seroconversion|Protocol Violation|4
6280558|NCT02286895|9990454|FG000|Assessed for Measles Seroconversion|Missing measurement|6
6280559|NCT02286895|9990455|FG001|Assessed for Measles Seroconversion|Missing measurement|3
6280560|NCT02286895|9990454|FG000|Assessed for Measles Seroconversion|Baseline measure non-negative|41
6280561|NCT02286895|9990455|FG001|Assessed for Measles Seroconversion|Baseline measure non-negative|32
6280562|NCT02286947|9990470|FG000|Overall Study|Withdrawal by Subject|2
6280563|NCT02286960|9990478|FG000|Overall Study|Lost to Follow-up|3
6280564|NCT02286960|9990479|FG001|Overall Study|Lost to Follow-up|3
6280565|NCT02287038|9990487|FG000|Overall Study|Stopped attending appointments|3
6280566|NCT02287038|9990488|FG001|Overall Study|Stopped attending appointments|2
6280567|NCT02287038|9990487|FG000|Overall Study|Anxiety after starting medication|0
6280568|NCT02287038|9990488|FG001|Overall Study|Anxiety after starting medication|1
6280569|NCT02287038|9990487|FG000|Overall Study|Nausea after starting medication|1
6280570|NCT02287038|9990488|FG001|Overall Study|Nausea after starting medication|0
6280571|NCT02287038|9990487|FG000|Overall Study|Abnormal ECG after starting medication|1
6280572|NCT02287038|9990488|FG001|Overall Study|Abnormal ECG after starting medication|0
6280573|NCT02287402|9990504|FG000|Treatment Period|Adverse Event|17
6280574|NCT02287402|9990504|FG000|Treatment Period|Voluntary Withdrawal|10
6280575|NCT02287402|9990504|FG000|Follow-up|Lost to Follow-up|1
6201934|NCT01497899|9861925|FG000|Open-Label Extension Phase|Pregnancy|0
6201935|NCT01497899|9861926|FG001|Open-Label Extension Phase|Pregnancy|1
6201936|NCT01497899|9861927|FG002|Open-Label Extension Phase|Pregnancy|1
6201937|NCT01497899|9861928|FG003|Open-Label Extension Phase|Pregnancy|0
6201938|NCT01497899|9861925|FG000|Open-Label Extension Phase|Protocol Violation|0
6280576|NCT02287402|9990504|FG000|Follow-up|Voluntary Withdrawal|2
5978949|NCT03323749|9567043|FG000|Double-blind Period|Lost to Follow-up|4
5978950|NCT03323749|9567044|FG001|Double-blind Period|Lost to Follow-up|5
5978951|NCT03323749|9567043|FG000|Double-blind Period|Adverse Event|3
5978952|NCT03323749|9567044|FG001|Double-blind Period|Adverse Event|1
5978953|NCT03323749|9567043|FG000|Open-Label Period|Termination of the Clinical Development of Elamipretide in Subjects with PMM|83
5978954|NCT03323749|9567044|FG001|Open-Label Period|Termination of the Clinical Development of Elamipretide in Subjects with PMM|88
5978955|NCT03323749|9567043|FG000|Open-Label Period|Adverse Event|3
5978956|NCT03323749|9567044|FG001|Open-Label Period|Adverse Event|10
5978957|NCT03323749|9567043|FG000|Open-Label Period|Withdrawal by Subject|7
5978958|NCT03323749|9567044|FG001|Open-Label Period|Withdrawal by Subject|5
5978959|NCT03322566|9567057|FG000|Overall Study|Death|34
5978960|NCT03322566|9567058|FG001|Overall Study|Death|35
5978961|NCT03322566|9567059|FG002|Overall Study|Death|23
5978962|NCT03322566|9567057|FG000|Overall Study|Physician Decision|6
5978963|NCT03322566|9567058|FG001|Overall Study|Physician Decision|7
5978964|NCT03322566|9567059|FG002|Overall Study|Physician Decision|2
5978965|NCT03322566|9567057|FG000|Overall Study|Withdrawal by Subject|4
5978966|NCT03322566|9567058|FG001|Overall Study|Withdrawal by Subject|3
5978967|NCT03322566|9567059|FG002|Overall Study|Withdrawal by Subject|6
5978968|NCT03322566|9567057|FG000|Overall Study|Lost to Follow-up|0
5978969|NCT03322566|9567058|FG001|Overall Study|Lost to Follow-up|0
5978970|NCT03322566|9567059|FG002|Overall Study|Lost to Follow-up|1
5978971|NCT03322566|9567057|FG000|Overall Study|Study terminated by sponsor|1
5978972|NCT03322566|9567058|FG001|Overall Study|Study terminated by sponsor|0
5978973|NCT03322566|9567059|FG002|Overall Study|Study terminated by sponsor|1
5978974|NCT03322540|9567069|FG000|Overall Study|Death|21
5978975|NCT03322540|9567070|FG001|Overall Study|Death|28
5978976|NCT03322540|9567069|FG000|Overall Study|Lost to Follow-up|0
5978977|NCT03322540|9567070|FG001|Overall Study|Lost to Follow-up|1
5978978|NCT03322540|9567069|FG000|Overall Study|Physician Decision|7
5978979|NCT03322540|9567070|FG001|Overall Study|Physician Decision|6
5978980|NCT03322540|9567069|FG000|Overall Study|Withdrawal by Subject|3
5978981|NCT03322540|9567070|FG001|Overall Study|Withdrawal by Subject|1
6280577|NCT02287467|9990514|FG000|Overall Study|Protocol Violation|12
6280578|NCT02287467|9990515|FG001|Overall Study|Protocol Violation|9
5978982|NCT03322540|9567069|FG000|Overall Study|Study terminated by sponsor|0
5978983|NCT03322540|9567070|FG001|Overall Study|Study terminated by sponsor|1
5978984|NCT03189719|9567089|FG000|Overall Study|Death|260
5978985|NCT03189719|9567090|FG001|Overall Study|Death|308
5978986|NCT03189719|9567089|FG000|Overall Study|Withdrawal by Subject|5
5978987|NCT03189719|9567090|FG001|Overall Study|Withdrawal by Subject|3
5978988|NCT03189719|9567089|FG000|Overall Study|Ongoing in Study|108
5978989|NCT03189719|9567090|FG001|Overall Study|Ongoing in Study|65
5978990|NCT03155997|9567098|FG000|Overall Study|Withdrawal by Subject|119
5978991|NCT03155997|9567099|FG001|Overall Study|Withdrawal by Subject|134
6280579|NCT02287610|9990524|FG000|Overall Study|Lost to Follow-up|3
6280580|NCT02287610|9990524|FG000|Overall Study|Withdrawal by Subject|8
6280581|NCT02287610|9990524|FG000|Overall Study|Excluded-investigator non-responsiveness|5
6280582|NCT02287623|9990530|FG000|Overall Study|Protocol Violation|0
6280583|NCT02287623|9990531|FG001|Overall Study|Protocol Violation|1
6280584|NCT02287883|9990598|FG000|Overall Study|Death|8
6280585|NCT02287883|9990599|FG001|Overall Study|Death|7
6280586|NCT02287883|9990598|FG000|Overall Study|No longer eligible|222
6280587|NCT02287883|9990599|FG001|Overall Study|No longer eligible|182
6280588|NCT02287883|9990598|FG000|Overall Study|Non-response to survey|229
6280589|NCT02287883|9990599|FG001|Overall Study|Non-response to survey|237
6280590|NCT02287896|9990607|FG000|Second Injection Visit|Withdrawal by Subject|0
6280591|NCT02287896|9990608|FG001|Second Injection Visit|Withdrawal by Subject|1
6280592|NCT02287922|9990641|FG000|Overall Study|Adverse Event|1
6280593|NCT02287922|9990642|FG001|Overall Study|Adverse Event|1
6280594|NCT02287922|9990643|FG002|Overall Study|Adverse Event|3
6280595|NCT02287922|9990644|FG003|Overall Study|Adverse Event|4
6280596|NCT02287922|9990641|FG000|Overall Study|Withdrawal by Subject|1
6280597|NCT02287922|9990642|FG001|Overall Study|Withdrawal by Subject|1
6280598|NCT02287922|9990643|FG002|Overall Study|Withdrawal by Subject|1
6280599|NCT02287922|9990644|FG003|Overall Study|Withdrawal by Subject|2
6280600|NCT02287922|9990641|FG000|Overall Study|Lost to Follow-up|0
6280601|NCT02287922|9990642|FG001|Overall Study|Lost to Follow-up|0
6280602|NCT02287922|9990643|FG002|Overall Study|Lost to Follow-up|1
6280603|NCT02287922|9990644|FG003|Overall Study|Lost to Follow-up|0
6280604|NCT02287922|9990641|FG000|Overall Study|Sponsor's decision|0
6280605|NCT02287922|9990642|FG001|Overall Study|Sponsor's decision|0
6280606|NCT02287922|9990643|FG002|Overall Study|Sponsor's decision|0
6280607|NCT02287922|9990644|FG003|Overall Study|Sponsor's decision|1
6280608|NCT02287922|9990641|FG000|Overall Study|Other|1
6280609|NCT02287922|9990642|FG001|Overall Study|Other|0
6280610|NCT02287922|9990643|FG002|Overall Study|Other|2
6280611|NCT02287922|9990644|FG003|Overall Study|Other|0
6280612|NCT02288091|9990655|FG000|Overall Study|Lost to Follow-up|1
6280613|NCT02288091|9990655|FG000|Overall Study|Screen fail|7
6280614|NCT02288182|9990680|FG000|Overall Study|Adverse Event|0
6280615|NCT02288182|9990681|FG001|Overall Study|Adverse Event|1
6280616|NCT02288182|9990680|FG000|Overall Study|Lost to Follow-up|0
6280617|NCT02288182|9990681|FG001|Overall Study|Lost to Follow-up|1
6280618|NCT02288312|9990701|FG000|Overall Study|Pregnancy|1
5978992|NCT03155997|9567098|FG000|Overall Study|Lost to Follow-up|12
5978993|NCT03155997|9567099|FG001|Overall Study|Lost to Follow-up|13
5978994|NCT03155997|9567098|FG000|Overall Study|Missing disposition data|0
5978995|NCT03155997|9567099|FG001|Overall Study|Missing disposition data|1
5978996|NCT03155997|9567098|FG000|Overall Study|On study treatment|2027
5978997|NCT03155997|9567099|FG001|Overall Study|On study treatment|2074
5978998|NCT03104400|9567109|FG000|Overall Study|Adverse Event|5
5978999|NCT03104400|9567110|FG001|Overall Study|Adverse Event|7
5979000|NCT03104400|9567111|FG002|Overall Study|Adverse Event|11
5979001|NCT03104400|9567112|FG003|Overall Study|Adverse Event|9
5979002|NCT03104400|9567113|FG004|Overall Study|Adverse Event|21
5979003|NCT03104400|9567109|FG000|Overall Study|Withdrawal by Subject|17
5979004|NCT03104400|9567110|FG001|Overall Study|Withdrawal by Subject|19
5979005|NCT03104400|9567111|FG002|Overall Study|Withdrawal by Subject|29
5979006|NCT03104400|9567112|FG003|Overall Study|Withdrawal by Subject|25
5979007|NCT03104400|9567113|FG004|Overall Study|Withdrawal by Subject|24
5979008|NCT03104400|9567109|FG000|Overall Study|Lost to Follow-up|4
5979009|NCT03104400|9567110|FG001|Overall Study|Lost to Follow-up|1
5979010|NCT03104400|9567111|FG002|Overall Study|Lost to Follow-up|4
5979011|NCT03104400|9567112|FG003|Overall Study|Lost to Follow-up|8
5979012|NCT03104400|9567113|FG004|Overall Study|Lost to Follow-up|7
5979013|NCT03104400|9567109|FG000|Overall Study|Lack of Efficacy|6
5979014|NCT03104400|9567110|FG001|Overall Study|Lack of Efficacy|3
5979015|NCT03104400|9567111|FG002|Overall Study|Lack of Efficacy|8
6051330|NCT00432237|9650571|FG003|Overall Study|Withdrawal by Subject|11
5979016|NCT03104400|9567112|FG003|Overall Study|Lack of Efficacy|2
5979017|NCT03104400|9567113|FG004|Overall Study|Lack of Efficacy|1
5979018|NCT03104400|9567109|FG000|Overall Study|COVID Logistical Restrictions|0
5979019|NCT03104400|9567110|FG001|Overall Study|COVID Logistical Restrictions|0
5979020|NCT03104400|9567111|FG002|Overall Study|COVID Logistical Restrictions|0
5979021|NCT03104400|9567112|FG003|Overall Study|COVID Logistical Restrictions|1
5979022|NCT03104400|9567113|FG004|Overall Study|COVID Logistical Restrictions|0
5979023|NCT03104400|9567109|FG000|Overall Study|Other|2
5979024|NCT03104400|9567110|FG001|Overall Study|Other|3
5979025|NCT03104400|9567111|FG002|Overall Study|Other|7
6280619|NCT02288312|9990702|FG001|Overall Study|Pregnancy|0
5979026|NCT03104400|9567112|FG003|Overall Study|Other|6
6280620|NCT02288312|9990703|FG002|Overall Study|Pregnancy|0
6280621|NCT02288325|9990711|FG000|Run-in Period|Adverse Event|48
6280622|NCT02288325|9990712|FG001|Run-in Period|Adverse Event|0
6280623|NCT02288325|9990713|FG002|Run-in Period|Adverse Event|0
6280624|NCT02288325|9990711|FG000|Run-in Period|Lack of Efficacy|16
6280625|NCT02288325|9990712|FG001|Run-in Period|Lack of Efficacy|0
6280626|NCT02288325|9990713|FG002|Run-in Period|Lack of Efficacy|0
6280627|NCT02288325|9990711|FG000|Run-in Period|Withdrawal of Consent|28
6280628|NCT02288325|9990712|FG001|Run-in Period|Withdrawal of Consent|0
6280629|NCT02288325|9990713|FG002|Run-in Period|Withdrawal of Consent|0
6280630|NCT02288325|9990711|FG000|Run-in Period|Lost to Follow-up|25
6280631|NCT02288325|9990712|FG001|Run-in Period|Lost to Follow-up|0
6280632|NCT02288325|9990713|FG002|Run-in Period|Lost to Follow-up|0
6280633|NCT02288325|9990711|FG000|Run-in Period|Protocol Violation|17
6280634|NCT02288325|9990712|FG001|Run-in Period|Protocol Violation|0
6280635|NCT02288325|9990713|FG002|Run-in Period|Protocol Violation|0
6280636|NCT02288325|9990711|FG000|Run-in Period|Non-Compliance With Study Drug|3
6280637|NCT02288325|9990712|FG001|Run-in Period|Non-Compliance With Study Drug|0
6280638|NCT02288325|9990713|FG002|Run-in Period|Non-Compliance With Study Drug|0
6280639|NCT02288325|9990711|FG000|Run-in Period|Reason not Specified|8
6280640|NCT02288325|9990712|FG001|Run-in Period|Reason not Specified|0
6280641|NCT02288325|9990713|FG002|Run-in Period|Reason not Specified|0
6280642|NCT02288325|9990711|FG000|Stabilization Period|Adverse Event|13
6280643|NCT02288325|9990712|FG001|Stabilization Period|Adverse Event|0
6280644|NCT02288325|9990713|FG002|Stabilization Period|Adverse Event|0
6280645|NCT02288325|9990711|FG000|Stabilization Period|Lack of Efficacy|22
6280646|NCT02288325|9990712|FG001|Stabilization Period|Lack of Efficacy|0
6280647|NCT02288325|9990713|FG002|Stabilization Period|Lack of Efficacy|0
6280648|NCT02288325|9990711|FG000|Stabilization Period|Withdrawal of Consent|23
6280649|NCT02288325|9990712|FG001|Stabilization Period|Withdrawal of Consent|0
6280650|NCT02288325|9990713|FG002|Stabilization Period|Withdrawal of Consent|0
6280651|NCT02288325|9990711|FG000|Stabilization Period|Lost to Follow-up|12
6280652|NCT02288325|9990712|FG001|Stabilization Period|Lost to Follow-up|0
6280653|NCT02288325|9990713|FG002|Stabilization Period|Lost to Follow-up|0
6280654|NCT02288325|9990711|FG000|Stabilization Period|Protocol Violation|8
6280655|NCT02288325|9990712|FG001|Stabilization Period|Protocol Violation|0
6280656|NCT02288325|9990713|FG002|Stabilization Period|Protocol Violation|0
6280657|NCT02288325|9990711|FG000|Stabilization Period|Non-Compliance With Study Drug|5
6280658|NCT02288325|9990712|FG001|Stabilization Period|Non-Compliance With Study Drug|0
6280659|NCT02288325|9990713|FG002|Stabilization Period|Non-Compliance With Study Drug|0
6280660|NCT02288325|9990711|FG000|Stabilization Period|Reason not Specified|15
6280661|NCT02288325|9990712|FG001|Stabilization Period|Reason not Specified|0
6280662|NCT02288325|9990713|FG002|Stabilization Period|Reason not Specified|0
6280663|NCT02288325|9990711|FG000|Double-blind Treatment Period|Adverse Event|0
6280664|NCT02288325|9990712|FG001|Double-blind Treatment Period|Adverse Event|2
6280665|NCT02288325|9990713|FG002|Double-blind Treatment Period|Adverse Event|5
6280666|NCT02288325|9990711|FG000|Double-blind Treatment Period|Withdrawal of Consent|0
6280667|NCT02288325|9990712|FG001|Double-blind Treatment Period|Withdrawal of Consent|8
6280668|NCT02288325|9990713|FG002|Double-blind Treatment Period|Withdrawal of Consent|8
6280669|NCT02288325|9990711|FG000|Double-blind Treatment Period|Lost to Follow-up|0
6280670|NCT02288325|9990712|FG001|Double-blind Treatment Period|Lost to Follow-up|4
6280671|NCT02288325|9990713|FG002|Double-blind Treatment Period|Lost to Follow-up|5
6280672|NCT02288325|9990711|FG000|Double-blind Treatment Period|Protocol Violation|0
6280673|NCT02288325|9990712|FG001|Double-blind Treatment Period|Protocol Violation|1
6280674|NCT02288325|9990713|FG002|Double-blind Treatment Period|Protocol Violation|2
6280675|NCT02288325|9990711|FG000|Double-blind Treatment Period|Non-Compliance With Study Drug|0
6280676|NCT02288325|9990712|FG001|Double-blind Treatment Period|Non-Compliance With Study Drug|1
6280677|NCT02288325|9990713|FG002|Double-blind Treatment Period|Non-Compliance With Study Drug|4
6280678|NCT02288325|9990711|FG000|Double-blind Treatment Period|Multiple Reasons|0
6280679|NCT02288325|9990712|FG001|Double-blind Treatment Period|Multiple Reasons|8
6280680|NCT02288325|9990713|FG002|Double-blind Treatment Period|Multiple Reasons|2
6280681|NCT02288559|9990742|FG000|Overall Study|Adverse Event|1
6280682|NCT02288559|9990743|FG001|Overall Study|Adverse Event|1
6280683|NCT02288559|9990744|FG002|Overall Study|Adverse Event|5
6280684|NCT02288559|9990745|FG003|Overall Study|Adverse Event|0
6280685|NCT02288559|9990742|FG000|Overall Study|Death|0
6280686|NCT02288559|9990743|FG001|Overall Study|Death|0
6280687|NCT02288559|9990744|FG002|Overall Study|Death|1
6280688|NCT02288559|9990745|FG003|Overall Study|Death|0
6280689|NCT02288559|9990742|FG000|Overall Study|Lost to Follow-up|0
6280690|NCT02288559|9990743|FG001|Overall Study|Lost to Follow-up|0
6280691|NCT02288559|9990744|FG002|Overall Study|Lost to Follow-up|0
6280692|NCT02288559|9990745|FG003|Overall Study|Lost to Follow-up|1
6280693|NCT02288559|9990742|FG000|Overall Study|Withdrawal by Subject|0
6280694|NCT02288559|9990743|FG001|Overall Study|Withdrawal by Subject|0
6280695|NCT02288559|9990744|FG002|Overall Study|Withdrawal by Subject|2
5979027|NCT03104400|9567113|FG004|Overall Study|Other|4
5979028|NCT03104400|9567109|FG000|Overall Study|Other|0
5979029|NCT03104400|9567110|FG001|Overall Study|Other|1
6280696|NCT02288559|9990745|FG003|Overall Study|Withdrawal by Subject|1
6280697|NCT02288559|9990742|FG000|Overall Study|Reason Not Specified|0
6280698|NCT02288559|9990743|FG001|Overall Study|Reason Not Specified|0
6280699|NCT02288559|9990744|FG002|Overall Study|Reason Not Specified|3
5979030|NCT03104400|9567111|FG002|Overall Study|Other|0
6280700|NCT02288559|9990745|FG003|Overall Study|Reason Not Specified|0
6280701|NCT02289079|9990763|FG000|Overall Study|Physician Decision|2
6280702|NCT02289079|9990764|FG001|Overall Study|Physician Decision|0
6280703|NCT02289079|9990763|FG000|Overall Study|Lost to Follow-up|0
5979031|NCT03104400|9567112|FG003|Overall Study|Other|0
5979032|NCT03104400|9567113|FG004|Overall Study|Other|0
6280704|NCT02289079|9990764|FG001|Overall Study|Lost to Follow-up|1
6089129|NCT00680992|9700378|FG000|Overall Study|Noncompliance|4
6089130|NCT00680992|9700379|FG001|Overall Study|Noncompliance|6
6089131|NCT00680992|9700380|FG002|Overall Study|Noncompliance|0
6089132|NCT00680992|9700378|FG000|Overall Study|Requirement for Alternative Therapy|8
6201939|NCT01497899|9861926|FG001|Open-Label Extension Phase|Protocol Violation|0
6201940|NCT01497899|9861927|FG002|Open-Label Extension Phase|Protocol Violation|1
6201941|NCT01497899|9861928|FG003|Open-Label Extension Phase|Protocol Violation|0
6201942|NCT01497899|9861925|FG000|Open-Label Extension Phase|Lost to Follow-up|9
6201943|NCT01497899|9861926|FG001|Open-Label Extension Phase|Lost to Follow-up|3
6201944|NCT01497899|9861927|FG002|Open-Label Extension Phase|Lost to Follow-up|5
6201945|NCT01497899|9861928|FG003|Open-Label Extension Phase|Lost to Follow-up|5
6201946|NCT01497938|9861937|FG000|Overall Study|Adverse Event|0
6201947|NCT01497938|9861938|FG001|Overall Study|Adverse Event|1
6201948|NCT01497938|9861937|FG000|Overall Study|Physician Decision|0
6201949|NCT01497938|9861938|FG001|Overall Study|Physician Decision|1
6201950|NCT01497938|9861937|FG000|Overall Study|Withdrawal by Subject|4
6201951|NCT01497938|9861938|FG001|Overall Study|Withdrawal by Subject|0
6201952|NCT01497938|9861937|FG000|Overall Study|Device Violation|1
6201953|NCT01497938|9861938|FG001|Overall Study|Device Violation|0
6201954|NCT01498068|9861946|FG000|Overall Study|Withdrawal by Subject|1
6201955|NCT01498068|9861947|FG001|Overall Study|Withdrawal by Subject|1
6201956|NCT01498120|9861953|FG000|Overall Study|Lost to Follow-up|1
6201957|NCT01498120|9861953|FG000|Overall Study|Withdrawal by Subject|5
6201958|NCT01498120|9861953|FG000|Overall Study|AE, non-serious non-fatal|3
6201959|NCT01498120|9861953|FG000|Overall Study|Other|4
6201960|NCT01498185|9861962|FG000|Overall Study|Adverse Event|0
6201961|NCT01498185|9861963|FG001|Overall Study|Adverse Event|0
6201962|NCT01498185|9861964|FG002|Overall Study|Adverse Event|0
6201963|NCT01498185|9861965|FG003|Overall Study|Adverse Event|1
6201964|NCT01498185|9861966|FG004|Overall Study|Adverse Event|0
6201965|NCT01498185|9861962|FG000|Overall Study|Withdrawal by Subject|1
6201966|NCT01498185|9861963|FG001|Overall Study|Withdrawal by Subject|1
6201967|NCT01498185|9861964|FG002|Overall Study|Withdrawal by Subject|0
6201968|NCT01498185|9861965|FG003|Overall Study|Withdrawal by Subject|2
6201969|NCT01498185|9861966|FG004|Overall Study|Withdrawal by Subject|1
6201970|NCT01498185|9861962|FG000|Overall Study|No longer met criteria, etc|0
6201971|NCT01498185|9861963|FG001|Overall Study|No longer met criteria, etc|0
6201972|NCT01498185|9861964|FG002|Overall Study|No longer met criteria, etc|0
6201973|NCT01498185|9861965|FG003|Overall Study|No longer met criteria, etc|0
6280705|NCT02289352|9990795|FG000|Overall Study|Withdrawal by Subject|1
6280706|NCT02289352|9990796|FG001|Overall Study|Withdrawal by Subject|1
6280707|NCT02289352|9990797|FG002|Overall Study|Withdrawal by Subject|0
6280708|NCT02289417|9990809|FG000|Placebo-Controlled Phase Weeks 0-12|Adverse Event|3
6280709|NCT02289417|9990810|FG001|Placebo-Controlled Phase Weeks 0-12|Adverse Event|0
6280710|NCT02289417|9990811|FG002|Placebo-Controlled Phase Weeks 0-12|Adverse Event|1
6280711|NCT02289417|9990812|FG003|Placebo-Controlled Phase Weeks 0-12|Adverse Event|0
6280712|NCT02289417|9990813|FG004|Placebo-Controlled Phase Weeks 0-12|Adverse Event|0
6280713|NCT02289417|9990814|FG005|Placebo-Controlled Phase Weeks 0-12|Adverse Event|0
6280714|NCT02289417|9990815|FG006|Placebo-Controlled Phase Weeks 0-12|Adverse Event|0
6280715|NCT02289417|9990816|FG007|Placebo-Controlled Phase Weeks 0-12|Adverse Event|0
6280716|NCT02289417|9990817|FG008|Placebo-Controlled Phase Weeks 0-12|Adverse Event|0
6280717|NCT02289417|9990809|FG000|Placebo-Controlled Phase Weeks 0-12|Withdrawal by Subject|1
6280718|NCT02289417|9990810|FG001|Placebo-Controlled Phase Weeks 0-12|Withdrawal by Subject|3
6280719|NCT02289417|9990811|FG002|Placebo-Controlled Phase Weeks 0-12|Withdrawal by Subject|2
6280720|NCT02289417|9990812|FG003|Placebo-Controlled Phase Weeks 0-12|Withdrawal by Subject|0
6280721|NCT02289417|9990813|FG004|Placebo-Controlled Phase Weeks 0-12|Withdrawal by Subject|0
5979033|NCT03104374|9567130|FG000|Overall Study|Adverse Event|7
5979034|NCT03104374|9567131|FG001|Overall Study|Adverse Event|6
5979035|NCT03104374|9567132|FG002|Overall Study|Adverse Event|12
5979036|NCT03104374|9567133|FG003|Overall Study|Adverse Event|15
6201974|NCT01498185|9861966|FG004|Overall Study|No longer met criteria, etc|2
6201975|NCT01498289|9861984|FG000|Overall Study|Adverse Event|16
6201976|NCT01498289|9861985|FG001|Overall Study|Adverse Event|18
6201977|NCT01498289|9861984|FG000|Overall Study|Death|6
6201978|NCT01498289|9861985|FG001|Overall Study|Death|8
6201979|NCT01498289|9861984|FG000|Overall Study|Withdrawal unrelated to AE|16
6201980|NCT01498289|9861985|FG001|Overall Study|Withdrawal unrelated to AE|16
6280722|NCT02289417|9990814|FG005|Placebo-Controlled Phase Weeks 0-12|Withdrawal by Subject|0
5979037|NCT03104374|9567130|FG000|Overall Study|Withdrawal by Subject|18
6089133|NCT00680992|9700379|FG001|Overall Study|Requirement for Alternative Therapy|2
6201981|NCT01498289|9861984|FG000|Overall Study|Progression/relapse|53
6201982|NCT01498289|9861985|FG001|Overall Study|Progression/relapse|59
6201983|NCT01498289|9861984|FG000|Overall Study|Not protocol specified|7
6201984|NCT01498289|9861985|FG001|Overall Study|Not protocol specified|2
6201985|NCT01498289|9861984|FG000|Overall Study|Reason under review|0
6201986|NCT01498289|9861985|FG001|Overall Study|Reason under review|1
6201987|NCT01498445|9862018|FG000|Overall Study|Lack of Efficacy|0
6201988|NCT01498445|9862019|FG001|Overall Study|Lack of Efficacy|0
6201989|NCT01498445|9862020|FG002|Overall Study|Lack of Efficacy|1
6201990|NCT01498445|9862021|FG003|Overall Study|Lack of Efficacy|2
6280723|NCT02289417|9990815|FG006|Placebo-Controlled Phase Weeks 0-12|Withdrawal by Subject|0
6280724|NCT02289417|9990816|FG007|Placebo-Controlled Phase Weeks 0-12|Withdrawal by Subject|0
6280725|NCT02289417|9990817|FG008|Placebo-Controlled Phase Weeks 0-12|Withdrawal by Subject|0
6280726|NCT02289417|9990809|FG000|Placebo-Controlled Phase Weeks 0-12|Lost to Follow-up|0
6280727|NCT02289417|9990810|FG001|Placebo-Controlled Phase Weeks 0-12|Lost to Follow-up|1
6280728|NCT02289417|9990811|FG002|Placebo-Controlled Phase Weeks 0-12|Lost to Follow-up|0
6280729|NCT02289417|9990812|FG003|Placebo-Controlled Phase Weeks 0-12|Lost to Follow-up|0
5979038|NCT03104374|9567131|FG001|Overall Study|Withdrawal by Subject|10
5979039|NCT03104374|9567132|FG002|Overall Study|Withdrawal by Subject|10
5979040|NCT03104374|9567133|FG003|Overall Study|Withdrawal by Subject|17
5979041|NCT03104374|9567130|FG000|Overall Study|Lost to Follow-up|4
5979042|NCT03104374|9567131|FG001|Overall Study|Lost to Follow-up|4
5979043|NCT03104374|9567132|FG002|Overall Study|Lost to Follow-up|6
5979044|NCT03104374|9567133|FG003|Overall Study|Lost to Follow-up|8
5979045|NCT03104374|9567130|FG000|Overall Study|Lack of Efficacy|6
5979046|NCT03104374|9567131|FG001|Overall Study|Lack of Efficacy|7
5979047|NCT03104374|9567132|FG002|Overall Study|Lack of Efficacy|12
5979048|NCT03104374|9567133|FG003|Overall Study|Lack of Efficacy|6
5979049|NCT03104374|9567130|FG000|Overall Study|Other|2
5979050|NCT03104374|9567131|FG001|Overall Study|Other|2
5979051|NCT03104374|9567132|FG002|Overall Study|Other|4
5979052|NCT03104374|9567133|FG003|Overall Study|Other|7
5979053|NCT03072043|9567146|FG000|Overall Study|Death|0
5979054|NCT03072043|9567147|FG001|Overall Study|Death|0
5979055|NCT03072043|9567148|FG002|Overall Study|Death|3
5979056|NCT03072043|9567146|FG000|Overall Study|Adverse Event|0
5979057|NCT03072043|9567147|FG001|Overall Study|Adverse Event|0
5979058|NCT03072043|9567148|FG002|Overall Study|Adverse Event|2
5979059|NCT03072043|9567146|FG000|Overall Study|Withdrawal by Subject|0
5979060|NCT03072043|9567147|FG001|Overall Study|Withdrawal by Subject|0
5979061|NCT03072043|9567148|FG002|Overall Study|Withdrawal by Subject|4
5979062|NCT02905032|9567176|FG000|Overall Study|Withdrawal by Subject|2
5979063|NCT02905032|9567177|FG001|Overall Study|Withdrawal by Subject|0
5979064|NCT02905032|9567178|FG002|Overall Study|Withdrawal by Subject|0
5979065|NCT02905032|9567176|FG000|Overall Study|Protocol Violation|6
5979066|NCT02905032|9567177|FG001|Overall Study|Protocol Violation|12
5979067|NCT02905032|9567178|FG002|Overall Study|Protocol Violation|0
5979068|NCT02837029|9567188|FG000|Screening|Failed to meet screening requirements.|7
5979069|NCT02837029|9567189|FG001|Screening|Failed to meet screening requirements.|3
5979070|NCT02837029|9567190|FG002|Screening|Failed to meet screening requirements.|0
5979071|NCT02837029|9567188|FG000|Cycle 1 (DLT Monitoring Period)|Progressive Disease|2
6051331|NCT00432237|9650568|FG000|Overall Study|Lack of Qualifying Event|38
6051332|NCT00432237|9650569|FG001|Overall Study|Lack of Qualifying Event|71
6051333|NCT00432237|9650570|FG002|Overall Study|Lack of Qualifying Event|69
6051334|NCT00432237|9650571|FG003|Overall Study|Lack of Qualifying Event|84
6051335|NCT00432276|9650583|FG000|Overall Study|Hyperglycemic Rescue|44
6051336|NCT00432276|9650584|FG001|Overall Study|Hyperglycemic Rescue|87
6051337|NCT00432276|9650583|FG000|Overall Study|Adverse Event|13
6051338|NCT00432276|9650584|FG001|Overall Study|Adverse Event|16
6051339|NCT00432276|9650583|FG000|Overall Study|Protocol Violation|25
6051340|NCT00432276|9650584|FG001|Overall Study|Protocol Violation|20
6051341|NCT00432276|9650583|FG000|Overall Study|Lost to Follow-up|6
6051342|NCT00432276|9650584|FG001|Overall Study|Lost to Follow-up|2
6051343|NCT00432276|9650583|FG000|Overall Study|Withdrawal by Subject|25
6051344|NCT00432276|9650584|FG001|Overall Study|Withdrawal by Subject|20
6051345|NCT00432276|9650583|FG000|Overall Study|Physician Decision|6
6051346|NCT00432276|9650584|FG001|Overall Study|Physician Decision|8
6051347|NCT00432276|9650583|FG000|Overall Study|Other|2
6051348|NCT00432276|9650584|FG001|Overall Study|Other|3
6051349|NCT00432380|9650602|FG000|Overall Study|Migrated/moved from study area|3
6051350|NCT00432380|9650603|FG001|Overall Study|Migrated/moved from study area|4
6051351|NCT00432380|9650604|FG002|Overall Study|Migrated/moved from study area|1
6051352|NCT00432380|9650602|FG000|Overall Study|Adverse Event|1
6051353|NCT00432380|9650603|FG001|Overall Study|Adverse Event|0
6051354|NCT00432380|9650604|FG002|Overall Study|Adverse Event|0
6089134|NCT00680992|9700380|FG002|Overall Study|Requirement for Alternative Therapy|0
6089135|NCT00680992|9700378|FG000|Overall Study|Pregnancy|5
5979072|NCT02837029|9567189|FG001|Cycle 1 (DLT Monitoring Period)|Progressive Disease|0
5979073|NCT02837029|9567190|FG002|Cycle 1 (DLT Monitoring Period)|Progressive Disease|0
5979074|NCT02837029|9567188|FG000|Cycle 1 (DLT Monitoring Period)|Adverse Event|0
5979075|NCT02837029|9567189|FG001|Cycle 1 (DLT Monitoring Period)|Adverse Event|2
6089136|NCT00680992|9700379|FG001|Overall Study|Pregnancy|0
6089137|NCT00680992|9700380|FG002|Overall Study|Pregnancy|1
6089138|NCT00680992|9700378|FG000|Overall Study|Death|5
6089139|NCT00680992|9700379|FG001|Overall Study|Death|1
6089140|NCT00680992|9700380|FG002|Overall Study|Death|0
6089141|NCT00680992|9700378|FG000|Overall Study|Ineligibility Determined|0
6089142|NCT00680992|9700379|FG001|Overall Study|Ineligibility Determined|1
6089143|NCT00680992|9700380|FG002|Overall Study|Ineligibility Determined|0
6089144|NCT00681109|9700403|FG000|Overall Study|Lost to Follow-up|2
6089145|NCT00681109|9700404|FG001|Overall Study|Lost to Follow-up|6
6089146|NCT00681109|9700405|FG002|Overall Study|Lost to Follow-up|0
6089147|NCT00681187|9700418|FG000|Overall Study|Withdrawal by Subject|1
6280730|NCT02289417|9990813|FG004|Placebo-Controlled Phase Weeks 0-12|Lost to Follow-up|0
6280731|NCT02289417|9990814|FG005|Placebo-Controlled Phase Weeks 0-12|Lost to Follow-up|0
6280732|NCT02289417|9990815|FG006|Placebo-Controlled Phase Weeks 0-12|Lost to Follow-up|0
6280733|NCT02289417|9990816|FG007|Placebo-Controlled Phase Weeks 0-12|Lost to Follow-up|0
6280734|NCT02289417|9990817|FG008|Placebo-Controlled Phase Weeks 0-12|Lost to Follow-up|0
6280735|NCT02289417|9990809|FG000|Placebo-Controlled Phase Weeks 0-12|Lack of Efficacy|3
6280736|NCT02289417|9990810|FG001|Placebo-Controlled Phase Weeks 0-12|Lack of Efficacy|0
6280737|NCT02289417|9990811|FG002|Placebo-Controlled Phase Weeks 0-12|Lack of Efficacy|0
6280738|NCT02289417|9990812|FG003|Placebo-Controlled Phase Weeks 0-12|Lack of Efficacy|0
6280739|NCT02289417|9990813|FG004|Placebo-Controlled Phase Weeks 0-12|Lack of Efficacy|0
6280740|NCT02289417|9990814|FG005|Placebo-Controlled Phase Weeks 0-12|Lack of Efficacy|0
6280741|NCT02289417|9990815|FG006|Placebo-Controlled Phase Weeks 0-12|Lack of Efficacy|0
6280742|NCT02289417|9990816|FG007|Placebo-Controlled Phase Weeks 0-12|Lack of Efficacy|0
6280743|NCT02289417|9990817|FG008|Placebo-Controlled Phase Weeks 0-12|Lack of Efficacy|0
5979076|NCT02837029|9567190|FG002|Cycle 1 (DLT Monitoring Period)|Adverse Event|0
5979077|NCT02837029|9567188|FG000|Cycle 1 (DLT Monitoring Period)|Withdrawal by Subject|0
5979078|NCT02837029|9567189|FG001|Cycle 1 (DLT Monitoring Period)|Withdrawal by Subject|1
5979079|NCT02837029|9567190|FG002|Cycle 1 (DLT Monitoring Period)|Withdrawal by Subject|0
5979080|NCT02837029|9567188|FG000|Cycle 2 and Beyond|Adverse Event|1
5979081|NCT02837029|9567189|FG001|Cycle 2 and Beyond|Adverse Event|0
5979082|NCT02837029|9567190|FG002|Cycle 2 and Beyond|Adverse Event|0
5979083|NCT02837029|9567188|FG000|2 Year Follow-up|Death|6
5979084|NCT02837029|9567189|FG001|2 Year Follow-up|Death|7
5979085|NCT02837029|9567190|FG002|2 Year Follow-up|Death|0
5979086|NCT02737475|9567245|FG000|Overall Study|Other reasons|0
5979087|NCT02737475|9567246|FG001|Overall Study|Other reasons|0
5979088|NCT02737475|9567247|FG002|Overall Study|Other reasons|0
5979089|NCT02737475|9567248|FG003|Overall Study|Other reasons|0
5979090|NCT02737475|9567249|FG004|Overall Study|Other reasons|1
5979091|NCT02737475|9567250|FG005|Overall Study|Other reasons|1
5979092|NCT02737475|9567251|FG006|Overall Study|Other reasons|0
5979093|NCT02737475|9567252|FG007|Overall Study|Other reasons|0
5979094|NCT02737475|9567253|FG008|Overall Study|Other reasons|1
5979095|NCT02737475|9567254|FG009|Overall Study|Other reasons|0
5979096|NCT02737475|9567255|FG010|Overall Study|Other reasons|1
5979097|NCT02737475|9567256|FG011|Overall Study|Other reasons|0
5979098|NCT02737475|9567257|FG012|Overall Study|Other reasons|0
5979099|NCT02737475|9567258|FG013|Overall Study|Other reasons|0
5979100|NCT02737475|9567259|FG014|Overall Study|Other reasons|0
5979101|NCT02737475|9567260|FG015|Overall Study|Other reasons|0
5979102|NCT02737475|9567261|FG016|Overall Study|Other reasons|0
5979103|NCT02737475|9567262|FG017|Overall Study|Other reasons|0
5979104|NCT02737475|9567263|FG018|Overall Study|Other reasons|0
5979105|NCT02737475|9567264|FG019|Overall Study|Other reasons|0
5979106|NCT02737475|9567265|FG020|Overall Study|Other reasons|0
5979107|NCT02737475|9567266|FG021|Overall Study|Other reasons|1
5979108|NCT02737475|9567267|FG022|Overall Study|Other reasons|0
5979109|NCT02737475|9567268|FG023|Overall Study|Other reasons|1
5979110|NCT02737475|9567269|FG024|Overall Study|Other reasons|1
5979111|NCT02737475|9567270|FG025|Overall Study|Other reasons|1
5979112|NCT02737475|9567271|FG026|Overall Study|Other reasons|0
5979113|NCT02737475|9567245|FG000|Overall Study|Death|1
5979114|NCT02737475|9567246|FG001|Overall Study|Death|0
5979115|NCT02737475|9567247|FG002|Overall Study|Death|0
5979116|NCT02737475|9567248|FG003|Overall Study|Death|1
5979117|NCT02737475|9567249|FG004|Overall Study|Death|0
5979118|NCT02737475|9567250|FG005|Overall Study|Death|0
5979119|NCT02737475|9567251|FG006|Overall Study|Death|0
5979120|NCT02737475|9567252|FG007|Overall Study|Death|2
5979121|NCT02737475|9567253|FG008|Overall Study|Death|0
5979122|NCT02737475|9567254|FG009|Overall Study|Death|0
5979123|NCT02737475|9567255|FG010|Overall Study|Death|0
5979124|NCT02737475|9567256|FG011|Overall Study|Death|4
5979125|NCT02737475|9567257|FG012|Overall Study|Death|2
5979126|NCT02737475|9567258|FG013|Overall Study|Death|2
5979127|NCT02737475|9567259|FG014|Overall Study|Death|0
5979128|NCT02737475|9567260|FG015|Overall Study|Death|2
5979129|NCT02737475|9567261|FG016|Overall Study|Death|2
5979130|NCT02737475|9567262|FG017|Overall Study|Death|2
5979131|NCT02737475|9567263|FG018|Overall Study|Death|1
5979132|NCT02737475|9567264|FG019|Overall Study|Death|0
5979133|NCT02737475|9567265|FG020|Overall Study|Death|0
5979134|NCT02737475|9567266|FG021|Overall Study|Death|0
5979135|NCT02737475|9567267|FG022|Overall Study|Death|0
5979136|NCT02737475|9567268|FG023|Overall Study|Death|0
5979137|NCT02737475|9567269|FG024|Overall Study|Death|0
5979138|NCT02737475|9567270|FG025|Overall Study|Death|0
5979139|NCT02737475|9567271|FG026|Overall Study|Death|0
5979140|NCT02737475|9567245|FG000|Overall Study|Participant withdrew consent|0
5979141|NCT02737475|9567246|FG001|Overall Study|Participant withdrew consent|0
5979142|NCT02737475|9567247|FG002|Overall Study|Participant withdrew consent|0
5979143|NCT02737475|9567248|FG003|Overall Study|Participant withdrew consent|0
5979144|NCT02737475|9567249|FG004|Overall Study|Participant withdrew consent|0
5979145|NCT02737475|9567250|FG005|Overall Study|Participant withdrew consent|2
5979146|NCT02737475|9567251|FG006|Overall Study|Participant withdrew consent|0
6280744|NCT02289417|9990809|FG000|Active Treatment Phase Weeks 12-52|Adverse Event|0
6280745|NCT02289417|9990810|FG001|Active Treatment Phase Weeks 12-52|Adverse Event|1
6280746|NCT02289417|9990811|FG002|Active Treatment Phase Weeks 12-52|Adverse Event|4
6280747|NCT02289417|9990812|FG003|Active Treatment Phase Weeks 12-52|Adverse Event|2
6280748|NCT02289417|9990813|FG004|Active Treatment Phase Weeks 12-52|Adverse Event|2
6280749|NCT02289417|9990814|FG005|Active Treatment Phase Weeks 12-52|Adverse Event|1
6280750|NCT02289417|9990815|FG006|Active Treatment Phase Weeks 12-52|Adverse Event|0
6280751|NCT02289417|9990816|FG007|Active Treatment Phase Weeks 12-52|Adverse Event|0
6280752|NCT02289417|9990817|FG008|Active Treatment Phase Weeks 12-52|Adverse Event|0
6280753|NCT02289417|9990809|FG000|Active Treatment Phase Weeks 12-52|Pregnancy|0
6280754|NCT02289417|9990810|FG001|Active Treatment Phase Weeks 12-52|Pregnancy|0
6280755|NCT02289417|9990811|FG002|Active Treatment Phase Weeks 12-52|Pregnancy|1
6280756|NCT02289417|9990812|FG003|Active Treatment Phase Weeks 12-52|Pregnancy|0
6280757|NCT02289417|9990813|FG004|Active Treatment Phase Weeks 12-52|Pregnancy|0
6280758|NCT02289417|9990814|FG005|Active Treatment Phase Weeks 12-52|Pregnancy|0
6280759|NCT02289417|9990815|FG006|Active Treatment Phase Weeks 12-52|Pregnancy|0
6280760|NCT02289417|9990816|FG007|Active Treatment Phase Weeks 12-52|Pregnancy|0
6280761|NCT02289417|9990817|FG008|Active Treatment Phase Weeks 12-52|Pregnancy|0
6280762|NCT02289417|9990809|FG000|Active Treatment Phase Weeks 12-52|Lack of Efficacy|0
6280763|NCT02289417|9990810|FG001|Active Treatment Phase Weeks 12-52|Lack of Efficacy|1
6280764|NCT02289417|9990811|FG002|Active Treatment Phase Weeks 12-52|Lack of Efficacy|4
6280765|NCT02289417|9990812|FG003|Active Treatment Phase Weeks 12-52|Lack of Efficacy|6
6280766|NCT02289417|9990813|FG004|Active Treatment Phase Weeks 12-52|Lack of Efficacy|2
6280767|NCT02289417|9990814|FG005|Active Treatment Phase Weeks 12-52|Lack of Efficacy|3
6280768|NCT02289417|9990815|FG006|Active Treatment Phase Weeks 12-52|Lack of Efficacy|0
6280769|NCT02289417|9990816|FG007|Active Treatment Phase Weeks 12-52|Lack of Efficacy|0
6280770|NCT02289417|9990817|FG008|Active Treatment Phase Weeks 12-52|Lack of Efficacy|0
6280771|NCT02289417|9990809|FG000|Active Treatment Phase Weeks 12-52|Withdrawal by Subject|0
6280772|NCT02289417|9990810|FG001|Active Treatment Phase Weeks 12-52|Withdrawal by Subject|0
6280773|NCT02289417|9990811|FG002|Active Treatment Phase Weeks 12-52|Withdrawal by Subject|1
6280774|NCT02289417|9990812|FG003|Active Treatment Phase Weeks 12-52|Withdrawal by Subject|0
6280775|NCT02289417|9990813|FG004|Active Treatment Phase Weeks 12-52|Withdrawal by Subject|1
6280776|NCT02289417|9990814|FG005|Active Treatment Phase Weeks 12-52|Withdrawal by Subject|1
6280777|NCT02289417|9990815|FG006|Active Treatment Phase Weeks 12-52|Withdrawal by Subject|0
6280778|NCT02289417|9990816|FG007|Active Treatment Phase Weeks 12-52|Withdrawal by Subject|0
6280779|NCT02289417|9990817|FG008|Active Treatment Phase Weeks 12-52|Withdrawal by Subject|0
6280780|NCT02289417|9990809|FG000|Active Treatment Phase Weeks 12-52|Lost to Follow-up|0
6280781|NCT02289417|9990810|FG001|Active Treatment Phase Weeks 12-52|Lost to Follow-up|0
6280782|NCT02289417|9990811|FG002|Active Treatment Phase Weeks 12-52|Lost to Follow-up|0
6280783|NCT02289417|9990812|FG003|Active Treatment Phase Weeks 12-52|Lost to Follow-up|0
6280784|NCT02289417|9990813|FG004|Active Treatment Phase Weeks 12-52|Lost to Follow-up|0
6280785|NCT02289417|9990814|FG005|Active Treatment Phase Weeks 12-52|Lost to Follow-up|0
6280786|NCT02289417|9990815|FG006|Active Treatment Phase Weeks 12-52|Lost to Follow-up|1
6280787|NCT02289417|9990816|FG007|Active Treatment Phase Weeks 12-52|Lost to Follow-up|0
6280788|NCT02289417|9990817|FG008|Active Treatment Phase Weeks 12-52|Lost to Follow-up|0
6280789|NCT02289417|9990809|FG000|Active Treatment Phase Weeks 12-52|Miscellaneous|0
6280790|NCT02289417|9990810|FG001|Active Treatment Phase Weeks 12-52|Miscellaneous|0
6280791|NCT02289417|9990811|FG002|Active Treatment Phase Weeks 12-52|Miscellaneous|0
6280792|NCT02289417|9990812|FG003|Active Treatment Phase Weeks 12-52|Miscellaneous|1
6280793|NCT02289417|9990813|FG004|Active Treatment Phase Weeks 12-52|Miscellaneous|0
6280794|NCT02289417|9990814|FG005|Active Treatment Phase Weeks 12-52|Miscellaneous|0
6280795|NCT02289417|9990815|FG006|Active Treatment Phase Weeks 12-52|Miscellaneous|1
6280796|NCT02289417|9990816|FG007|Active Treatment Phase Weeks 12-52|Miscellaneous|0
6280797|NCT02289417|9990817|FG008|Active Treatment Phase Weeks 12-52|Miscellaneous|0
5979147|NCT02737475|9567252|FG007|Overall Study|Participant withdrew consent|0
5979148|NCT02737475|9567253|FG008|Overall Study|Participant withdrew consent|0
5979149|NCT02737475|9567254|FG009|Overall Study|Participant withdrew consent|0
5979150|NCT02737475|9567255|FG010|Overall Study|Participant withdrew consent|0
6089148|NCT00681187|9700419|FG001|Overall Study|Withdrawal by Subject|0
5979151|NCT02737475|9567256|FG011|Overall Study|Participant withdrew consent|0
5979152|NCT02737475|9567257|FG012|Overall Study|Participant withdrew consent|0
5979153|NCT02737475|9567258|FG013|Overall Study|Participant withdrew consent|0
5979154|NCT02737475|9567259|FG014|Overall Study|Participant withdrew consent|1
5979155|NCT02737475|9567260|FG015|Overall Study|Participant withdrew consent|0
5979156|NCT02737475|9567261|FG016|Overall Study|Participant withdrew consent|0
5979157|NCT02737475|9567262|FG017|Overall Study|Participant withdrew consent|2
5979158|NCT02737475|9567263|FG018|Overall Study|Participant withdrew consent|1
5979159|NCT02737475|9567264|FG019|Overall Study|Participant withdrew consent|0
5979160|NCT02737475|9567265|FG020|Overall Study|Participant withdrew consent|2
5979161|NCT02737475|9567266|FG021|Overall Study|Participant withdrew consent|0
5979162|NCT02737475|9567267|FG022|Overall Study|Participant withdrew consent|0
5979163|NCT02737475|9567268|FG023|Overall Study|Participant withdrew consent|0
6280798|NCT02289417|9990809|FG000|Extension Phase Weeks 52-104|Adverse Event|0
6280799|NCT02289417|9990810|FG001|Extension Phase Weeks 52-104|Adverse Event|0
6280800|NCT02289417|9990811|FG002|Extension Phase Weeks 52-104|Adverse Event|0
6280801|NCT02289417|9990812|FG003|Extension Phase Weeks 52-104|Adverse Event|0
6280802|NCT02289417|9990813|FG004|Extension Phase Weeks 52-104|Adverse Event|0
6280803|NCT02289417|9990814|FG005|Extension Phase Weeks 52-104|Adverse Event|0
6280804|NCT02289417|9990815|FG006|Extension Phase Weeks 52-104|Adverse Event|0
6280805|NCT02289417|9990816|FG007|Extension Phase Weeks 52-104|Adverse Event|2
6280806|NCT02289417|9990817|FG008|Extension Phase Weeks 52-104|Adverse Event|3
6280807|NCT02289417|9990809|FG000|Extension Phase Weeks 52-104|Lack of Efficacy|0
6280808|NCT02289417|9990810|FG001|Extension Phase Weeks 52-104|Lack of Efficacy|0
6280809|NCT02289417|9990811|FG002|Extension Phase Weeks 52-104|Lack of Efficacy|0
6280810|NCT02289417|9990812|FG003|Extension Phase Weeks 52-104|Lack of Efficacy|0
6280811|NCT02289417|9990813|FG004|Extension Phase Weeks 52-104|Lack of Efficacy|0
6280812|NCT02289417|9990814|FG005|Extension Phase Weeks 52-104|Lack of Efficacy|0
6280813|NCT02289417|9990815|FG006|Extension Phase Weeks 52-104|Lack of Efficacy|0
6280814|NCT02289417|9990816|FG007|Extension Phase Weeks 52-104|Lack of Efficacy|2
6280815|NCT02289417|9990817|FG008|Extension Phase Weeks 52-104|Lack of Efficacy|2
6280816|NCT02289417|9990809|FG000|Extension Phase Weeks 52-104|Withdrawal by Subject|0
6280817|NCT02289417|9990810|FG001|Extension Phase Weeks 52-104|Withdrawal by Subject|0
6280818|NCT02289417|9990811|FG002|Extension Phase Weeks 52-104|Withdrawal by Subject|0
6280819|NCT02289417|9990812|FG003|Extension Phase Weeks 52-104|Withdrawal by Subject|0
6280820|NCT02289417|9990813|FG004|Extension Phase Weeks 52-104|Withdrawal by Subject|0
6280821|NCT02289417|9990814|FG005|Extension Phase Weeks 52-104|Withdrawal by Subject|0
6280822|NCT02289417|9990815|FG006|Extension Phase Weeks 52-104|Withdrawal by Subject|0
6280823|NCT02289417|9990816|FG007|Extension Phase Weeks 52-104|Withdrawal by Subject|2
6280824|NCT02289417|9990817|FG008|Extension Phase Weeks 52-104|Withdrawal by Subject|1
6280825|NCT02289417|9990809|FG000|Extension Phase Weeks 52-104|Miscellaneous|0
6280826|NCT02289417|9990810|FG001|Extension Phase Weeks 52-104|Miscellaneous|0
6280827|NCT02289417|9990811|FG002|Extension Phase Weeks 52-104|Miscellaneous|0
6280828|NCT02289417|9990812|FG003|Extension Phase Weeks 52-104|Miscellaneous|0
6280829|NCT02289417|9990813|FG004|Extension Phase Weeks 52-104|Miscellaneous|0
6280830|NCT02289417|9990814|FG005|Extension Phase Weeks 52-104|Miscellaneous|0
6280831|NCT02289417|9990815|FG006|Extension Phase Weeks 52-104|Miscellaneous|0
6280832|NCT02289417|9990816|FG007|Extension Phase Weeks 52-104|Miscellaneous|1
6280833|NCT02289417|9990817|FG008|Extension Phase Weeks 52-104|Miscellaneous|0
6280834|NCT02289456|9990833|FG000|Induction Period|Death|2
6280835|NCT02289456|9990833|FG000|Induction Period|Adverse Event|11
6280836|NCT02289456|9990833|FG000|Induction Period|Progressive Disease (PD)|4
6280837|NCT02289456|9990833|FG000|Induction Period|Symptomatic Deterioration|4
6280838|NCT02289456|9990833|FG000|Induction Period|Withdrawal by Subject|2
6280839|NCT02289456|9990833|FG000|Induction Period|Miscellaneous|1
6280840|NCT02289456|9990833|FG000|Monotherapy Period|Death|1
6280841|NCT02289456|9990833|FG000|Monotherapy Period|Adverse Event|1
6280842|NCT02289456|9990833|FG000|Monotherapy Period|Progressive Disease (PD)|8
6280843|NCT02289456|9990833|FG000|Monotherapy Period|Symptomatic Deterioration|1
6280844|NCT02289456|9990833|FG000|Monotherapy Period|Withdrawal by Subject|2
6280845|NCT02289456|9990833|FG000|Monotherapy Period|Study Terminated by Sponsor|2
6280846|NCT02289456|9990833|FG000|Monotherapy Period|Miscellaneous|1
6280847|NCT02289469|9990844|FG000|Overall Study|Unable to match a control|6
6280848|NCT02289469|9990845|FG001|Overall Study|Unable to match a control|0
6280849|NCT02289690|9990861|FG000|Overall Study|Adverse Event Related to Progression|0
6280850|NCT02289690|9990862|FG001|Overall Study|Adverse Event Related to Progression|1
6280851|NCT02289690|9990863|FG002|Overall Study|Adverse Event Related to Progression|1
6280852|NCT02289690|9990864|FG003|Overall Study|Adverse Event Related to Progression|0
6280853|NCT02289690|9990865|FG004|Overall Study|Adverse Event Related to Progression|1
6280854|NCT02289690|9990866|FG005|Overall Study|Adverse Event Related to Progression|0
6280855|NCT02289690|9990867|FG006|Overall Study|Adverse Event Related to Progression|1
6280856|NCT02289690|9990868|FG007|Overall Study|Adverse Event Related to Progression|0
6280857|NCT02289690|9990869|FG008|Overall Study|Adverse Event Related to Progression|0
6280858|NCT02289690|9990870|FG009|Overall Study|Adverse Event Related to Progression|0
6280859|NCT02289690|9990861|FG000|Overall Study|Withdrawal by Subject|1
6280860|NCT02289690|9990862|FG001|Overall Study|Withdrawal by Subject|0
6280861|NCT02289690|9990863|FG002|Overall Study|Withdrawal by Subject|0
6280862|NCT02289690|9990864|FG003|Overall Study|Withdrawal by Subject|0
6280863|NCT02289690|9990865|FG004|Overall Study|Withdrawal by Subject|1
6280864|NCT02289690|9990866|FG005|Overall Study|Withdrawal by Subject|1
6280865|NCT02289690|9990867|FG006|Overall Study|Withdrawal by Subject|0
6280866|NCT02289690|9990868|FG007|Overall Study|Withdrawal by Subject|0
6280867|NCT02289690|9990869|FG008|Overall Study|Withdrawal by Subject|4
6280868|NCT02289690|9990870|FG009|Overall Study|Withdrawal by Subject|2
6280869|NCT02289690|9990861|FG000|Overall Study|Progressive Disease, Per Protocol|3
6280870|NCT02289690|9990862|FG001|Overall Study|Progressive Disease, Per Protocol|2
6280871|NCT02289690|9990863|FG002|Overall Study|Progressive Disease, Per Protocol|3
6280872|NCT02289690|9990864|FG003|Overall Study|Progressive Disease, Per Protocol|2
6280873|NCT02289690|9990865|FG004|Overall Study|Progressive Disease, Per Protocol|5
5979164|NCT02737475|9567269|FG024|Overall Study|Participant withdrew consent|0
5979165|NCT02737475|9567270|FG025|Overall Study|Participant withdrew consent|0
5979166|NCT02737475|9567271|FG026|Overall Study|Participant withdrew consent|0
5979167|NCT02737475|9567245|FG000|Overall Study|Lost to Follow-up|0
5979168|NCT02737475|9567246|FG001|Overall Study|Lost to Follow-up|0
5979169|NCT02737475|9567247|FG002|Overall Study|Lost to Follow-up|0
5979170|NCT02737475|9567248|FG003|Overall Study|Lost to Follow-up|0
5979171|NCT02737475|9567249|FG004|Overall Study|Lost to Follow-up|0
5979172|NCT02737475|9567250|FG005|Overall Study|Lost to Follow-up|0
5979173|NCT02737475|9567251|FG006|Overall Study|Lost to Follow-up|0
5979174|NCT02737475|9567252|FG007|Overall Study|Lost to Follow-up|0
5979175|NCT02737475|9567253|FG008|Overall Study|Lost to Follow-up|0
5979176|NCT02737475|9567254|FG009|Overall Study|Lost to Follow-up|0
5979177|NCT02737475|9567255|FG010|Overall Study|Lost to Follow-up|0
5979178|NCT02737475|9567256|FG011|Overall Study|Lost to Follow-up|0
5979179|NCT02737475|9567257|FG012|Overall Study|Lost to Follow-up|0
5979180|NCT02737475|9567258|FG013|Overall Study|Lost to Follow-up|0
5979181|NCT02737475|9567259|FG014|Overall Study|Lost to Follow-up|0
5979182|NCT02737475|9567260|FG015|Overall Study|Lost to Follow-up|1
5979183|NCT02737475|9567261|FG016|Overall Study|Lost to Follow-up|0
5979184|NCT02737475|9567262|FG017|Overall Study|Lost to Follow-up|0
5979185|NCT02737475|9567263|FG018|Overall Study|Lost to Follow-up|0
5979186|NCT02737475|9567264|FG019|Overall Study|Lost to Follow-up|0
5979187|NCT02737475|9567265|FG020|Overall Study|Lost to Follow-up|0
5979188|NCT02737475|9567266|FG021|Overall Study|Lost to Follow-up|0
5979189|NCT02737475|9567267|FG022|Overall Study|Lost to Follow-up|0
5979190|NCT02737475|9567268|FG023|Overall Study|Lost to Follow-up|0
5979191|NCT02737475|9567269|FG024|Overall Study|Lost to Follow-up|0
5979192|NCT02737475|9567270|FG025|Overall Study|Lost to Follow-up|0
5979193|NCT02737475|9567271|FG026|Overall Study|Lost to Follow-up|0
5979194|NCT02737475|9567245|FG000|Overall Study|Disease Progression|0
5979195|NCT02737475|9567246|FG001|Overall Study|Disease Progression|0
5979196|NCT02737475|9567247|FG002|Overall Study|Disease Progression|0
5979197|NCT02737475|9567248|FG003|Overall Study|Disease Progression|0
5979198|NCT02737475|9567249|FG004|Overall Study|Disease Progression|0
5979199|NCT02737475|9567250|FG005|Overall Study|Disease Progression|0
5979200|NCT02737475|9567251|FG006|Overall Study|Disease Progression|0
5979201|NCT02737475|9567252|FG007|Overall Study|Disease Progression|0
5979202|NCT02737475|9567253|FG008|Overall Study|Disease Progression|0
5979203|NCT02737475|9567254|FG009|Overall Study|Disease Progression|0
5979204|NCT02737475|9567255|FG010|Overall Study|Disease Progression|0
5979205|NCT02737475|9567256|FG011|Overall Study|Disease Progression|0
5979206|NCT02737475|9567257|FG012|Overall Study|Disease Progression|0
5979207|NCT02737475|9567258|FG013|Overall Study|Disease Progression|0
5979208|NCT02737475|9567259|FG014|Overall Study|Disease Progression|0
5979209|NCT02737475|9567260|FG015|Overall Study|Disease Progression|0
5979210|NCT02737475|9567261|FG016|Overall Study|Disease Progression|0
5979211|NCT02737475|9567262|FG017|Overall Study|Disease Progression|0
5979212|NCT02737475|9567263|FG018|Overall Study|Disease Progression|0
5979213|NCT02737475|9567264|FG019|Overall Study|Disease Progression|0
5979214|NCT02737475|9567265|FG020|Overall Study|Disease Progression|0
5979215|NCT02737475|9567266|FG021|Overall Study|Disease Progression|0
5979216|NCT02737475|9567267|FG022|Overall Study|Disease Progression|0
5979217|NCT02737475|9567268|FG023|Overall Study|Disease Progression|0
5979218|NCT02737475|9567269|FG024|Overall Study|Disease Progression|0
5979219|NCT02737475|9567270|FG025|Overall Study|Disease Progression|0
5979220|NCT02737475|9567271|FG026|Overall Study|Disease Progression|1
5979221|NCT02642965|9567363|FG000|Overall Study|Lack of Efficacy|4
5979222|NCT02642965|9567363|FG000|Overall Study|Physician Decision|9
6280874|NCT02289690|9990866|FG005|Overall Study|Progressive Disease, Per Protocol|13
6280875|NCT02289690|9990867|FG006|Overall Study|Progressive Disease, Per Protocol|2
6280876|NCT02289690|9990868|FG007|Overall Study|Progressive Disease, Per Protocol|0
6280877|NCT02289690|9990869|FG008|Overall Study|Progressive Disease, Per Protocol|0
6280878|NCT02289690|9990870|FG009|Overall Study|Progressive Disease, Per Protocol|0
6280879|NCT02289690|9990861|FG000|Overall Study|Lost to Follow-up|0
6051355|NCT00432562|9650624|FG000|Overall Study|Death|3
6051356|NCT00432562|9650625|FG001|Overall Study|Death|0
6051357|NCT00432666|9650642|FG000|Main Period|Adverse Event|1
6051358|NCT00432666|9650643|FG001|Main Period|Adverse Event|1
6051359|NCT00432666|9650642|FG000|Main Period|Consent Withdrawn|1
6051360|NCT00432666|9650643|FG001|Main Period|Consent Withdrawn|0
6051361|NCT00432666|9650642|FG000|Open-Label Extension Period|Withdrawal Criteria Occurred|1
6051362|NCT00432666|9650643|FG001|Open-Label Extension Period|Withdrawal Criteria Occurred|0
6051363|NCT00432666|9650642|FG000|Open-Label Extension Period|Lack of Efficacy|6
6051364|NCT00432666|9650643|FG001|Open-Label Extension Period|Lack of Efficacy|0
6051365|NCT00432666|9650642|FG000|Open-Label Extension Period|Adverse Event|5
6051366|NCT00432666|9650643|FG001|Open-Label Extension Period|Adverse Event|0
6051367|NCT00432666|9650642|FG000|Open-Label Extension Period|Consent withdrawn|10
6051368|NCT00432666|9650643|FG001|Open-Label Extension Period|Consent withdrawn|0
6051369|NCT00432666|9650642|FG000|Open-Label Extension Period|Physician Decision|3
6051370|NCT00432666|9650643|FG001|Open-Label Extension Period|Physician Decision|0
6051371|NCT00432679|9650651|FG000|Overall Study|Adverse Event|2
6280880|NCT02289690|9990862|FG001|Overall Study|Lost to Follow-up|0
6280881|NCT02289690|9990863|FG002|Overall Study|Lost to Follow-up|0
6280882|NCT02289690|9990864|FG003|Overall Study|Lost to Follow-up|0
6280883|NCT02289690|9990865|FG004|Overall Study|Lost to Follow-up|0
6280884|NCT02289690|9990866|FG005|Overall Study|Lost to Follow-up|0
6280885|NCT02289690|9990867|FG006|Overall Study|Lost to Follow-up|0
6280886|NCT02289690|9990868|FG007|Overall Study|Lost to Follow-up|1
6280887|NCT02289690|9990869|FG008|Overall Study|Lost to Follow-up|0
6280888|NCT02289690|9990870|FG009|Overall Study|Lost to Follow-up|2
6280889|NCT02289690|9990861|FG000|Overall Study|Death|0
6280890|NCT02289690|9990862|FG001|Overall Study|Death|0
6280891|NCT02289690|9990863|FG002|Overall Study|Death|0
6280892|NCT02289690|9990864|FG003|Overall Study|Death|0
6280893|NCT02289690|9990865|FG004|Overall Study|Death|0
6280894|NCT02289690|9990866|FG005|Overall Study|Death|0
6280895|NCT02289690|9990867|FG006|Overall Study|Death|0
6280896|NCT02289690|9990868|FG007|Overall Study|Death|49
6280897|NCT02289690|9990869|FG008|Overall Study|Death|45
6280898|NCT02289690|9990870|FG009|Overall Study|Death|41
6280899|NCT02289690|9990861|FG000|Overall Study|Sponsor Discontinued Study|0
6280900|NCT02289690|9990862|FG001|Overall Study|Sponsor Discontinued Study|0
6280901|NCT02289690|9990863|FG002|Overall Study|Sponsor Discontinued Study|0
6280902|NCT02289690|9990864|FG003|Overall Study|Sponsor Discontinued Study|0
6280903|NCT02289690|9990865|FG004|Overall Study|Sponsor Discontinued Study|0
6280904|NCT02289690|9990866|FG005|Overall Study|Sponsor Discontinued Study|0
6280905|NCT02289690|9990867|FG006|Overall Study|Sponsor Discontinued Study|0
6280906|NCT02289690|9990868|FG007|Overall Study|Sponsor Discontinued Study|9
6280907|NCT02289690|9990869|FG008|Overall Study|Sponsor Discontinued Study|7
6280908|NCT02289690|9990870|FG009|Overall Study|Sponsor Discontinued Study|15
6280909|NCT02289690|9990861|FG000|Overall Study|Other|0
6280910|NCT02289690|9990862|FG001|Overall Study|Other|0
6280911|NCT02289690|9990863|FG002|Overall Study|Other|0
6280912|NCT02289690|9990864|FG003|Overall Study|Other|1
6280913|NCT02289690|9990865|FG004|Overall Study|Other|1
6280914|NCT02289690|9990866|FG005|Overall Study|Other|0
6280915|NCT02289690|9990867|FG006|Overall Study|Other|1
6280916|NCT02289690|9990868|FG007|Overall Study|Other|2
6280917|NCT02289690|9990869|FG008|Overall Study|Other|3
6280918|NCT02289690|9990870|FG009|Overall Study|Other|1
6280919|NCT02289729|9990906|FG000|Overall Study|Lack of Efficacy|3
6280920|NCT02289729|9990906|FG000|Overall Study|Very Narrow Therapeutic Margin|1
6280921|NCT02289729|9990906|FG000|Overall Study|Withdrawal by Subject|1
6280922|NCT02289729|9990906|FG000|Overall Study|Death|1
6280923|NCT02289742|9990912|FG000|First Wear Period|Adverse event prior to treatment|0
6280924|NCT02289742|9990913|FG001|First Wear Period|Adverse event prior to treatment|1
6280925|NCT02289742|9990914|FG002|First Wear Period|Adverse event prior to treatment|0
6280926|NCT02289742|9990915|FG003|First Wear Period|Adverse event prior to treatment|0
6280927|NCT02289742|9990912|FG000|First Wear Period|Adverse Event|0
6280928|NCT02289742|9990913|FG001|First Wear Period|Adverse Event|0
6280929|NCT02289742|9990914|FG002|First Wear Period|Adverse Event|1
6280930|NCT02289742|9990915|FG003|First Wear Period|Adverse Event|0
6280931|NCT02289742|9990912|FG000|First Wear Period|Other prior to treatment|0
6280932|NCT02289742|9990913|FG001|First Wear Period|Other prior to treatment|0
6280933|NCT02289742|9990914|FG002|First Wear Period|Other prior to treatment|0
6280934|NCT02289742|9990915|FG003|First Wear Period|Other prior to treatment|1
6280935|NCT02289742|9990912|FG000|Third Wear Period|Adverse Event|0
6280936|NCT02289742|9990913|FG001|Third Wear Period|Adverse Event|1
6280937|NCT02289742|9990914|FG002|Third Wear Period|Adverse Event|0
6280938|NCT02289742|9990915|FG003|Third Wear Period|Adverse Event|0
6280939|NCT02289742|9990912|FG000|Third Wear Period|Reason not given|0
6280940|NCT02289742|9990913|FG001|Third Wear Period|Reason not given|0
6280941|NCT02289742|9990914|FG002|Third Wear Period|Reason not given|0
6280942|NCT02289742|9990915|FG003|Third Wear Period|Reason not given|1
6280943|NCT02289820|9990940|FG000|Overall Study|Withdrawal by Subject|2
6280944|NCT02289820|9990941|FG001|Overall Study|Withdrawal by Subject|1
6280945|NCT02289820|9990942|FG002|Overall Study|Withdrawal by Subject|2
6280946|NCT02289820|9990943|FG003|Overall Study|Withdrawal by Subject|1
6280947|NCT02289820|9990944|FG004|Overall Study|Withdrawal by Subject|0
6280948|NCT02289820|9990945|FG005|Overall Study|Withdrawal by Subject|0
6280949|NCT02289820|9990946|FG006|Overall Study|Withdrawal by Subject|1
6280950|NCT02289820|9990940|FG000|Overall Study|Death|0
6280951|NCT02289820|9990941|FG001|Overall Study|Death|0
6280952|NCT02289820|9990942|FG002|Overall Study|Death|1
6280953|NCT02289820|9990943|FG003|Overall Study|Death|0
6280954|NCT02289820|9990944|FG004|Overall Study|Death|0
6280955|NCT02289820|9990945|FG005|Overall Study|Death|0
6280956|NCT02289820|9990946|FG006|Overall Study|Death|0
6280957|NCT02289820|9990940|FG000|Overall Study|Lost to Follow-up|0
6280958|NCT02289820|9990941|FG001|Overall Study|Lost to Follow-up|0
6089149|NCT00681187|9700418|FG000|Overall Study|Death|0
6089150|NCT00681187|9700419|FG001|Overall Study|Death|1
6089151|NCT00681187|9700418|FG000|Overall Study|Adverse Event|0
6089152|NCT00681187|9700419|FG001|Overall Study|Adverse Event|1
6089153|NCT00681564|9700468|FG000|Overall Study|Lost to Follow-up|6
6089154|NCT00681564|9700469|FG001|Overall Study|Lost to Follow-up|6
6089155|NCT00681564|9700468|FG000|Overall Study|Withdrawal by Subject|0
6089156|NCT00681564|9700469|FG001|Overall Study|Withdrawal by Subject|1
6089157|NCT00681564|9700468|FG000|Overall Study|Death|0
6089158|NCT00681564|9700469|FG001|Overall Study|Death|1
6089159|NCT00681590|9700477|FG000|Overall Study|Withdrawal by Subject|2
6089160|NCT00681590|9700478|FG001|Overall Study|Withdrawal by Subject|12
6280959|NCT02289820|9990942|FG002|Overall Study|Lost to Follow-up|3
6280960|NCT02289820|9990943|FG003|Overall Study|Lost to Follow-up|1
6280961|NCT02289820|9990944|FG004|Overall Study|Lost to Follow-up|0
6280962|NCT02289820|9990945|FG005|Overall Study|Lost to Follow-up|1
6280963|NCT02289820|9990946|FG006|Overall Study|Lost to Follow-up|1
5979223|NCT02629159|9567370|FG000|Overall Study|Adverse Event|17
5979224|NCT02629159|9567371|FG001|Overall Study|Adverse Event|20
5979225|NCT02629159|9567372|FG002|Overall Study|Adverse Event|22
5979226|NCT02629159|9567370|FG000|Overall Study|Withdrawal by Subject|22
5979227|NCT02629159|9567371|FG001|Overall Study|Withdrawal by Subject|11
5979228|NCT02629159|9567372|FG002|Overall Study|Withdrawal by Subject|15
5979229|NCT02629159|9567370|FG000|Overall Study|Lost to Follow-up|7
5979230|NCT02629159|9567371|FG001|Overall Study|Lost to Follow-up|4
5979231|NCT02629159|9567372|FG002|Overall Study|Lost to Follow-up|5
5979232|NCT02629159|9567370|FG000|Overall Study|Lack of Efficacy|4
5979233|NCT02629159|9567371|FG001|Overall Study|Lack of Efficacy|0
5979234|NCT02629159|9567372|FG002|Overall Study|Lack of Efficacy|1
5979235|NCT02629159|9567370|FG000|Overall Study|Other|6
5979236|NCT02629159|9567371|FG001|Overall Study|Other|4
5979237|NCT02629159|9567372|FG002|Overall Study|Other|8
5979238|NCT02604433|9567385|FG000|Overall Study|Withdrawal by Subject|37
5979239|NCT02604433|9567386|FG001|Overall Study|Withdrawal by Subject|16
5979240|NCT02604433|9567385|FG000|Overall Study|Adverse Event|4
5979241|NCT02604433|9567386|FG001|Overall Study|Adverse Event|0
5979242|NCT02604433|9567385|FG000|Overall Study|Other reasons|3
5979243|NCT02604433|9567386|FG001|Overall Study|Other reasons|5
5979244|NCT02604433|9567385|FG000|Overall Study|Death|4
5979245|NCT02604433|9567386|FG001|Overall Study|Death|1
5979246|NCT02604433|9567385|FG000|Overall Study|Transition to Rollover Protocol|169
5979247|NCT02604433|9567386|FG001|Overall Study|Transition to Rollover Protocol|82
5979248|NCT02604433|9567385|FG000|Overall Study|Physician Decision|1
5979249|NCT02604433|9567386|FG001|Overall Study|Physician Decision|1
5979250|NCT02604433|9567385|FG000|Overall Study|Lack of Efficacy|0
5979251|NCT02604433|9567386|FG001|Overall Study|Lack of Efficacy|1
5979252|NCT02420821|9567411|FG000|Overall Study|Lost to Follow-up|2
5979253|NCT02420821|9567412|FG001|Overall Study|Lost to Follow-up|0
5979254|NCT02420821|9567411|FG000|Overall Study|Non-compliance|1
5979255|NCT02420821|9567412|FG001|Overall Study|Non-compliance|2
5979256|NCT02420821|9567411|FG000|Overall Study|Physician Decision|5
5979257|NCT02420821|9567412|FG001|Overall Study|Physician Decision|2
5979258|NCT02420821|9567411|FG000|Overall Study|Withdrawal by Subject|31
5979259|NCT02420821|9567412|FG001|Overall Study|Withdrawal by Subject|17
5979260|NCT02420821|9567411|FG000|Overall Study|Death|129
5979261|NCT02420821|9567412|FG001|Overall Study|Death|116
5979262|NCT02412670|9567421|FG000|Overall Study|Adverse Event|4
5979263|NCT02412670|9567422|FG001|Overall Study|Adverse Event|1
5979264|NCT02412670|9567421|FG000|Overall Study|Physician Decision|1
5979265|NCT02412670|9567422|FG001|Overall Study|Physician Decision|0
5979266|NCT02412670|9567421|FG000|Overall Study|Withdrawal by Subject|1
5979267|NCT02412670|9567422|FG001|Overall Study|Withdrawal by Subject|0
5979268|NCT02412670|9567421|FG000|Overall Study|Ineligible|1
5979269|NCT02412670|9567422|FG001|Overall Study|Ineligible|0
5979270|NCT02410343|9567430|FG000|Core Period (24 Weeks)|Adverse Event|1
5979271|NCT02410343|9567431|FG001|Core Period (24 Weeks)|Adverse Event|0
5979272|NCT02410343|9567430|FG000|Core Period (24 Weeks)|Early termination of study by sponsor|4
6089161|NCT00681668|9700484|FG000|Overall Study|Protocol Violation|1
6089162|NCT00681668|9700484|FG000|Overall Study|Withdrawal by Subject|1
6089163|NCT00681811|9700490|FG000|Overall Study|Adverse Event|1
6089164|NCT00681811|9700491|FG001|Overall Study|Adverse Event|1
6280964|NCT02289820|9990940|FG000|Overall Study|withdrawal of consent|0
6280965|NCT02289820|9990941|FG001|Overall Study|withdrawal of consent|1
6280966|NCT02289820|9990942|FG002|Overall Study|withdrawal of consent|0
6280967|NCT02289820|9990943|FG003|Overall Study|withdrawal of consent|0
6280968|NCT02289820|9990944|FG004|Overall Study|withdrawal of consent|0
6280969|NCT02289820|9990945|FG005|Overall Study|withdrawal of consent|0
6280970|NCT02289820|9990946|FG006|Overall Study|withdrawal of consent|0
6280971|NCT02289833|9990968|FG000|Overall Study|Study discontinuation|0
6280972|NCT02289833|9990969|FG001|Overall Study|Study discontinuation|1
6280973|NCT02289833|9990968|FG000|Overall Study|Lost to Follow-up|4
6280974|NCT02289833|9990969|FG001|Overall Study|Lost to Follow-up|0
6280975|NCT02289833|9990968|FG000|Overall Study|Death|23
6280976|NCT02289833|9990969|FG001|Overall Study|Death|16
6280977|NCT02289898|9990980|FG000|Overall Study|Death|5
6280978|NCT02289898|9990981|FG001|Overall Study|Death|4
6280979|NCT02289898|9990982|FG002|Overall Study|Death|3
6280980|NCT02289898|9990980|FG000|Overall Study|Physician Decision|2
6280981|NCT02289898|9990981|FG001|Overall Study|Physician Decision|5
6280982|NCT02289898|9990982|FG002|Overall Study|Physician Decision|2
6280983|NCT02289898|9990980|FG000|Overall Study|Withdrawal by Subject|0
6280984|NCT02289898|9990981|FG001|Overall Study|Withdrawal by Subject|4
6280985|NCT02289898|9990982|FG002|Overall Study|Withdrawal by Subject|1
6280986|NCT02289898|9990980|FG000|Overall Study|Adverse Event|3
6280987|NCT02289898|9990981|FG001|Overall Study|Adverse Event|5
6280988|NCT02289898|9990982|FG002|Overall Study|Adverse Event|5
6280989|NCT02289898|9990980|FG000|Overall Study|Disease progression|34
6280990|NCT02289898|9990981|FG001|Overall Study|Disease progression|28
6280991|NCT02289898|9990982|FG002|Overall Study|Disease progression|34
6280992|NCT02289898|9990980|FG000|Overall Study|Use of another anticancer therapy|0
6280993|NCT02289898|9990981|FG001|Overall Study|Use of another anticancer therapy|0
6280994|NCT02289898|9990982|FG002|Overall Study|Use of another anticancer therapy|1
6280995|NCT02289898|9990980|FG000|Overall Study|Other|8
6280996|NCT02289898|9990981|FG001|Overall Study|Other|7
6280997|NCT02289898|9990982|FG002|Overall Study|Other|10
6280998|NCT02289950|9990991|FG000|Overall Study|Progressive disease by RECIST 1.1|99
6280999|NCT02289950|9990992|FG001|Overall Study|Progressive disease by RECIST 1.1|52
6281000|NCT02289950|9990991|FG000|Overall Study|Progressive disease by Clinical Assessment|4
6281001|NCT02289950|9990992|FG001|Overall Study|Progressive disease by Clinical Assessment|4
6281002|NCT02289950|9990991|FG000|Overall Study|Lost to Follow-up|1
6281003|NCT02289950|9990992|FG001|Overall Study|Lost to Follow-up|0
6281004|NCT02289950|9990991|FG000|Overall Study|Physician Decision|9
6281005|NCT02289950|9990992|FG001|Overall Study|Physician Decision|3
6281006|NCT02289950|9990991|FG000|Overall Study|Subject chose to discontinue therapy but will continue to survival follow-up|9
6281007|NCT02289950|9990992|FG001|Overall Study|Subject chose to discontinue therapy but will continue to survival follow-up|2
6281008|NCT02289950|9990991|FG000|Overall Study|Withdrawal by Subject|1
6281009|NCT02289950|9990992|FG001|Overall Study|Withdrawal by Subject|3
6281010|NCT02289950|9990991|FG000|Overall Study|Test article held for greater than 28 days|0
5979273|NCT02410343|9567431|FG001|Core Period (24 Weeks)|Early termination of study by sponsor|7
5979274|NCT02410343|9567430|FG000|Extension Period (12 Months)|Adverse Event|1
5979275|NCT02410343|9567431|FG001|Extension Period (12 Months)|Adverse Event|0
6281011|NCT02289950|9990992|FG001|Overall Study|Test article held for greater than 28 days|1
6281012|NCT02289950|9990991|FG000|Overall Study|Adverse Event|11
6281013|NCT02289950|9990992|FG001|Overall Study|Adverse Event|3
6281014|NCT02289950|9990991|FG000|Overall Study|Death|1
6281015|NCT02289950|9990992|FG001|Overall Study|Death|1
6281016|NCT02289950|9990991|FG000|Overall Study|Other|5
6281017|NCT02289950|9990992|FG001|Overall Study|Other|2
6281018|NCT02289950|9990991|FG000|Overall Study|Not Treated|2
6281019|NCT02289950|9990992|FG001|Overall Study|Not Treated|1
6281020|NCT02289963|9991000|FG000|Overall Study|Adverse Event|1
6281021|NCT02289963|9991001|FG001|Overall Study|Adverse Event|2
6281022|NCT02289963|9991000|FG000|Overall Study|Poor compliance to protocol|1
6281023|NCT02289963|9991001|FG001|Overall Study|Poor compliance to protocol|0
6281024|NCT02289963|9991000|FG000|Overall Study|Withdrawal by Subject|1
6281025|NCT02289963|9991001|FG001|Overall Study|Withdrawal by Subject|0
6281026|NCT02289963|9991000|FG000|Overall Study|Last injection missed|2
6281027|NCT02289963|9991001|FG001|Overall Study|Last injection missed|2
6281028|NCT02289963|9991000|FG000|Overall Study|End treatment visit outside visit window|0
6281029|NCT02289963|9991001|FG001|Overall Study|End treatment visit outside visit window|4
6281030|NCT02289963|9991000|FG000|Overall Study|Other than specified above|0
6281031|NCT02289963|9991001|FG001|Overall Study|Other than specified above|2
6281032|NCT02290028|9991016|FG000|Overall Study|Death|217
6281033|NCT02290028|9991016|FG000|Overall Study|Sentus lead or required CRT-D was not implanted|186
6281034|NCT02290028|9991016|FG000|Overall Study|No longer under care of study physician|76
6281035|NCT02290028|9991016|FG000|Overall Study|Sentus lead or required CRT-D explanted|55
6281036|NCT02290028|9991016|FG000|Overall Study|Withdrawal by Subject|52
6281037|NCT02290028|9991016|FG000|Overall Study|Study site closure|44
6281038|NCT02290028|9991016|FG000|Overall Study|Lost to Follow-up|34
6281039|NCT02290028|9991016|FG000|Overall Study|Miscellaneous|10
6281040|NCT02290028|9991016|FG000|Overall Study|Transition to EP PASSION|1295
6281041|NCT02290028|9991016|FG000|Overall Study|Planned study completion at 12 months|257
6281042|NCT02290223|9991049|FG000|6 Months|Lost to Follow-up|9
6281043|NCT02290223|9991050|FG001|6 Months|Lost to Follow-up|6
6281044|NCT02290223|9991049|FG000|6 Months|Withdrawal by Subject|5
6281045|NCT02290223|9991050|FG001|6 Months|Withdrawal by Subject|0
6281046|NCT02290223|9991049|FG000|6 Months|deceased (not related to study)|2
6281047|NCT02290223|9991050|FG001|6 Months|deceased (not related to study)|0
6281048|NCT02290223|9991049|FG000|12 Months|Lost to Follow-up|16
6281049|NCT02290223|9991050|FG001|12 Months|Lost to Follow-up|10
6281050|NCT02290223|9991049|FG000|12 Months|Refusal|0
6281051|NCT02290223|9991050|FG001|12 Months|Refusal|1
6281052|NCT02290340|9991060|FG000|Overall Study|Lost to Follow-up|0
6281053|NCT02290340|9991061|FG001|Overall Study|Lost to Follow-up|0
6281054|NCT02290340|9991062|FG002|Overall Study|Lost to Follow-up|0
6281055|NCT02290340|9991063|FG003|Overall Study|Lost to Follow-up|1
6281056|NCT02290340|9991060|FG000|Overall Study|Withdrawal by Subject|1
6281057|NCT02290340|9991061|FG001|Overall Study|Withdrawal by Subject|0
6281058|NCT02290340|9991062|FG002|Overall Study|Withdrawal by Subject|0
6281059|NCT02290340|9991063|FG003|Overall Study|Withdrawal by Subject|0
6281060|NCT02290340|9991060|FG000|Overall Study|Other|1
6281061|NCT02290340|9991061|FG001|Overall Study|Other|0
6281062|NCT02290340|9991062|FG002|Overall Study|Other|0
6281063|NCT02290340|9991063|FG003|Overall Study|Other|1
6281064|NCT02290405|9991078|FG000|Overall Study|Withdrawal by Subject|1
6281065|NCT02290405|9991079|FG001|Overall Study|Withdrawal by Subject|0
5979276|NCT02410343|9567430|FG000|Extension Period (12 Months)|Early termination of study by sponsor|0
5979277|NCT02410343|9567431|FG001|Extension Period (12 Months)|Early termination of study by sponsor|1
5979278|NCT02339740|9567444|FG000|Overall Study|Death|1
6281066|NCT02290691|9991119|FG000|Overall Study|Noncompliance|0
6281067|NCT02290691|9991120|FG001|Overall Study|Noncompliance|1
6281068|NCT02290691|9991119|FG000|Overall Study|Withdrawal by Subject|1
6281069|NCT02290691|9991120|FG001|Overall Study|Withdrawal by Subject|1
6281070|NCT02290691|9991119|FG000|Overall Study|Lost to Follow-up|7
6281071|NCT02290691|9991120|FG001|Overall Study|Lost to Follow-up|7
6281072|NCT02290821|9991128|FG000|Overall Study|Withdrawal by Subject|1
6281073|NCT02290821|9991129|FG001|Overall Study|Withdrawal by Subject|1
6281074|NCT02290821|9991128|FG000|Overall Study|Unable or unwilling to cooperate with|2
6281075|NCT02290821|9991129|FG001|Overall Study|Unable or unwilling to cooperate with|0
6281076|NCT02290821|9991128|FG000|Overall Study|Lost to Follow-up|3
6281077|NCT02290821|9991129|FG001|Overall Study|Lost to Follow-up|2
6281078|NCT02290873|9991138|FG000|Overall Study|Withdrawal by Subject|0
6281079|NCT02290873|9991139|FG001|Overall Study|Withdrawal by Subject|1
6281080|NCT02290873|9991140|FG002|Overall Study|Withdrawal by Subject|1
6281081|NCT02290873|9991138|FG000|Overall Study|Nellcor device error|1
6281082|NCT02290873|9991139|FG001|Overall Study|Nellcor device error|0
6281083|NCT02290873|9991140|FG002|Overall Study|Nellcor device error|0
6281084|NCT02290873|9991138|FG000|Overall Study|Esophagogastroduodenoscopy was added|1
6281085|NCT02290873|9991139|FG001|Overall Study|Esophagogastroduodenoscopy was added|0
6281086|NCT02290873|9991140|FG002|Overall Study|Esophagogastroduodenoscopy was added|0
6281087|NCT02290873|9991138|FG000|Overall Study|Protocol Violation|0
6281088|NCT02290873|9991139|FG001|Overall Study|Protocol Violation|0
6281089|NCT02290873|9991140|FG002|Overall Study|Protocol Violation|1
6281090|NCT02290925|9991151|FG000|First Period of Three Months|Lost to Follow-up|2
6281091|NCT02290925|9991152|FG001|First Period of Three Months|Lost to Follow-up|1
5979279|NCT02339740|9567445|FG001|Overall Study|Death|0
5979280|NCT02339740|9567444|FG000|Overall Study|Physician Decision|0
5979281|NCT02339740|9567445|FG001|Overall Study|Physician Decision|2
5979282|NCT02339740|9567444|FG000|Overall Study|Withdrawal by Subject|5
5979283|NCT02339740|9567445|FG001|Overall Study|Withdrawal by Subject|1
5979284|NCT02339740|9567444|FG000|Overall Study|Inevaluable-RQPCR positive not confirmed|3
5979285|NCT02339740|9567445|FG001|Overall Study|Inevaluable-RQPCR positive not confirmed|1
5979286|NCT02045303|9567468|FG000|Overall Study|Protocol Violation|2
5979287|NCT02045303|9567469|FG001|Overall Study|Protocol Violation|1
5979288|NCT02045303|9567470|FG002|Overall Study|Protocol Violation|0
5979289|NCT02045303|9567468|FG000|Overall Study|Withdrawal by Subject|0
5979290|NCT02045303|9567469|FG001|Overall Study|Withdrawal by Subject|2
5979291|NCT02045303|9567470|FG002|Overall Study|Withdrawal by Subject|0
5979292|NCT02025556|9567482|FG000|Overall Study|Adverse Event|0
5979293|NCT02025556|9567483|FG001|Overall Study|Adverse Event|4
5979294|NCT02025556|9567484|FG002|Overall Study|Adverse Event|2
5979295|NCT02025556|9567482|FG000|Overall Study|Lack of Efficacy|2
5979296|NCT02025556|9567483|FG001|Overall Study|Lack of Efficacy|1
5979297|NCT02025556|9567484|FG002|Overall Study|Lack of Efficacy|0
5979298|NCT02025556|9567482|FG000|Overall Study|Protocol Violation|2
5979299|NCT02025556|9567483|FG001|Overall Study|Protocol Violation|1
5979300|NCT02025556|9567484|FG002|Overall Study|Protocol Violation|0
5979301|NCT02025556|9567482|FG000|Overall Study|Withdrawal by Subject|0
5979302|NCT02025556|9567483|FG001|Overall Study|Withdrawal by Subject|3
5979303|NCT02025556|9567484|FG002|Overall Study|Withdrawal by Subject|6
5979304|NCT02025556|9567482|FG000|Overall Study|Lost to Follow-up|2
5979305|NCT02025556|9567483|FG001|Overall Study|Lost to Follow-up|4
5979306|NCT02025556|9567484|FG002|Overall Study|Lost to Follow-up|0
5979307|NCT02025556|9567482|FG000|Overall Study|Reason not reported|0
5979308|NCT02025556|9567483|FG001|Overall Study|Reason not reported|0
5979309|NCT02025556|9567484|FG002|Overall Study|Reason not reported|1
5979310|NCT01986933|9567497|FG000|Placebo-controlled (Part A)|Adverse Event|1
5979311|NCT01986933|9567498|FG001|Placebo-controlled (Part A)|Adverse Event|5
5979312|NCT01986933|9567499|FG002|Placebo-controlled (Part A)|Adverse Event|2
5979313|NCT01986933|9567500|FG003|Placebo-controlled (Part A)|Adverse Event|2
5979314|NCT01986933|9567501|FG004|Placebo-controlled (Part A)|Adverse Event|4
5979315|NCT01986933|9567497|FG000|Placebo-controlled (Part A)|Lack of Efficacy|3
5979316|NCT01986933|9567498|FG001|Placebo-controlled (Part A)|Lack of Efficacy|1
5979317|NCT01986933|9567499|FG002|Placebo-controlled (Part A)|Lack of Efficacy|1
5979318|NCT01986933|9567500|FG003|Placebo-controlled (Part A)|Lack of Efficacy|2
5979319|NCT01986933|9567501|FG004|Placebo-controlled (Part A)|Lack of Efficacy|1
5979320|NCT01986933|9567497|FG000|Placebo-controlled (Part A)|Withdrawal by Subject|5
5979321|NCT01986933|9567498|FG001|Placebo-controlled (Part A)|Withdrawal by Subject|2
5979322|NCT01986933|9567499|FG002|Placebo-controlled (Part A)|Withdrawal by Subject|6
6051372|NCT00432679|9650652|FG001|Overall Study|Adverse Event|1
6281092|NCT02290925|9991151|FG000|First Period of Three Months|Death|1
6281093|NCT02290925|9991152|FG001|First Period of Three Months|Death|0
5979323|NCT01986933|9567500|FG003|Placebo-controlled (Part A)|Withdrawal by Subject|2
5979324|NCT01986933|9567501|FG004|Placebo-controlled (Part A)|Withdrawal by Subject|7
5979325|NCT01986933|9567497|FG000|Placebo-controlled (Part A)|Lost to Follow-up|0
5979326|NCT01986933|9567498|FG001|Placebo-controlled (Part A)|Lost to Follow-up|1
5979327|NCT01986933|9567499|FG002|Placebo-controlled (Part A)|Lost to Follow-up|0
5979328|NCT01986933|9567500|FG003|Placebo-controlled (Part A)|Lost to Follow-up|1
5979329|NCT01986933|9567501|FG004|Placebo-controlled (Part A)|Lost to Follow-up|0
6051373|NCT00432679|9650651|FG000|Overall Study|Withdrawal by Subject|3
6281094|NCT02290925|9991151|FG000|First Period of Three Months|Insulin Started|1
6281095|NCT02290925|9991152|FG001|First Period of Three Months|Insulin Started|1
6281096|NCT02290925|9991151|FG000|Second Period of 3 Months|Lost to Follow-up|1
6281097|NCT02290925|9991152|FG001|Second Period of 3 Months|Lost to Follow-up|3
6281098|NCT02290925|9991151|FG000|Second Period of 3 Months|insulin started|0
6281099|NCT02290925|9991152|FG001|Second Period of 3 Months|insulin started|1
6281100|NCT02291029|9991176|FG000|Overall Study|Withdrawal by Subject|0
6281101|NCT02291029|9991177|FG001|Overall Study|Withdrawal by Subject|0
6281102|NCT02291029|9991178|FG002|Overall Study|Withdrawal by Subject|1
6281103|NCT02291029|9991179|FG003|Overall Study|Withdrawal by Subject|0
6281104|NCT02291029|9991180|FG004|Overall Study|Withdrawal by Subject|0
6281105|NCT02291029|9991181|FG005|Overall Study|Withdrawal by Subject|0
6281106|NCT02291029|9991176|FG000|Overall Study|Adverse Event|0
6281107|NCT02291029|9991177|FG001|Overall Study|Adverse Event|1
6281108|NCT02291029|9991178|FG002|Overall Study|Adverse Event|0
6281109|NCT02291029|9991179|FG003|Overall Study|Adverse Event|0
6281110|NCT02291029|9991180|FG004|Overall Study|Adverse Event|0
6281111|NCT02291029|9991181|FG005|Overall Study|Adverse Event|0
6281112|NCT02291237|9991201|FG000|Overall Study|Study Terminated by Sponsor|72
6281113|NCT02291237|9991202|FG001|Overall Study|Study Terminated by Sponsor|67
6281114|NCT02291237|9991201|FG000|Overall Study|Adverse Event|1
6281115|NCT02291237|9991202|FG001|Overall Study|Adverse Event|3
6281116|NCT02291237|9991201|FG000|Overall Study|Investigator's Discretion|0
6281117|NCT02291237|9991202|FG001|Overall Study|Investigator's Discretion|3
6281118|NCT02291237|9991201|FG000|Overall Study|Withdrew Consent|11
6281119|NCT02291237|9991202|FG001|Overall Study|Withdrew Consent|11
6281120|NCT02291237|9991201|FG000|Overall Study|Lost to Follow-up|0
6281121|NCT02291237|9991202|FG001|Overall Study|Lost to Follow-up|2
6281122|NCT02291237|9991201|FG000|Overall Study|Subject Required Prohibited Medication|2
6281123|NCT02291237|9991202|FG001|Overall Study|Subject Required Prohibited Medication|0
6281124|NCT02291289|9991212|FG000|Induction Treatment|Not Dosed|2
6281125|NCT02291289|9991213|FG001|Induction Treatment|Not Dosed|0
6281126|NCT02291289|9991214|FG002|Induction Treatment|Not Dosed|0
6281127|NCT02291289|9991215|FG003|Induction Treatment|Not Dosed|9
6281128|NCT02291289|9991216|FG004|Induction Treatment|Not Dosed|0
6281129|NCT02291289|9991217|FG005|Induction Treatment|Not Dosed|0
6281130|NCT02291289|9991218|FG006|Induction Treatment|Not Dosed|0
6281131|NCT02291289|9991219|FG007|Induction Treatment|Not Dosed|0
6281132|NCT02291289|9991220|FG008|Induction Treatment|Not Dosed|0
6281133|NCT02291289|9991221|FG009|Induction Treatment|Not Dosed|1
6281134|NCT02291289|9991222|FG010|Induction Treatment|Not Dosed|0
6281135|NCT02291289|9991223|FG011|Induction Treatment|Not Dosed|0
6281136|NCT02291289|9991212|FG000|Maintenance Treatment Phase|Withdrawal by Subject|0
6281137|NCT02291289|9991213|FG001|Maintenance Treatment Phase|Withdrawal by Subject|0
6281138|NCT02291289|9991214|FG002|Maintenance Treatment Phase|Withdrawal by Subject|0
6281139|NCT02291289|9991215|FG003|Maintenance Treatment Phase|Withdrawal by Subject|0
6281140|NCT02291289|9991216|FG004|Maintenance Treatment Phase|Withdrawal by Subject|13
6281141|NCT02291289|9991217|FG005|Maintenance Treatment Phase|Withdrawal by Subject|11
6281142|NCT02291289|9991218|FG006|Maintenance Treatment Phase|Withdrawal by Subject|0
6281143|NCT02291289|9991219|FG007|Maintenance Treatment Phase|Withdrawal by Subject|0
6281144|NCT02291289|9991220|FG008|Maintenance Treatment Phase|Withdrawal by Subject|0
6281145|NCT02291289|9991221|FG009|Maintenance Treatment Phase|Withdrawal by Subject|0
6281146|NCT02291289|9991222|FG010|Maintenance Treatment Phase|Withdrawal by Subject|2
6281147|NCT02291289|9991223|FG011|Maintenance Treatment Phase|Withdrawal by Subject|3
6281148|NCT02291289|9991212|FG000|Maintenance Treatment Phase|Protocol Violation|0
6281149|NCT02291289|9991213|FG001|Maintenance Treatment Phase|Protocol Violation|1
6281150|NCT02291289|9991214|FG002|Maintenance Treatment Phase|Protocol Violation|0
6281151|NCT02291289|9991215|FG003|Maintenance Treatment Phase|Protocol Violation|0
6281152|NCT02291289|9991216|FG004|Maintenance Treatment Phase|Protocol Violation|2
6281153|NCT02291289|9991217|FG005|Maintenance Treatment Phase|Protocol Violation|1
6281154|NCT02291289|9991218|FG006|Maintenance Treatment Phase|Protocol Violation|0
5979330|NCT01986933|9567497|FG000|Placebo-controlled (Part A)|Others (not classified above reasons)|0
5979331|NCT01986933|9567498|FG001|Placebo-controlled (Part A)|Others (not classified above reasons)|0
5979332|NCT01986933|9567499|FG002|Placebo-controlled (Part A)|Others (not classified above reasons)|0
5979333|NCT01986933|9567500|FG003|Placebo-controlled (Part A)|Others (not classified above reasons)|0
5979334|NCT01986933|9567501|FG004|Placebo-controlled (Part A)|Others (not classified above reasons)|2
5979335|NCT01986933|9567497|FG000|Active-to-active (Part B)|Adverse Event|0
5979336|NCT01986933|9567498|FG001|Active-to-active (Part B)|Adverse Event|2
5979337|NCT01986933|9567499|FG002|Active-to-active (Part B)|Adverse Event|0
5979338|NCT01986933|9567500|FG003|Active-to-active (Part B)|Adverse Event|1
5979339|NCT01986933|9567501|FG004|Active-to-active (Part B)|Adverse Event|3
5979340|NCT01986933|9567497|FG000|Active-to-active (Part B)|Lack of Efficacy|0
5979341|NCT01986933|9567498|FG001|Active-to-active (Part B)|Lack of Efficacy|3
5979342|NCT01986933|9567499|FG002|Active-to-active (Part B)|Lack of Efficacy|2
5979343|NCT01986933|9567500|FG003|Active-to-active (Part B)|Lack of Efficacy|0
5979344|NCT01986933|9567501|FG004|Active-to-active (Part B)|Lack of Efficacy|4
5979345|NCT01986933|9567497|FG000|Active-to-active (Part B)|Pregnancy|0
6281155|NCT02291289|9991219|FG007|Maintenance Treatment Phase|Protocol Violation|0
6281156|NCT02291289|9991220|FG008|Maintenance Treatment Phase|Protocol Violation|0
6281157|NCT02291289|9991221|FG009|Maintenance Treatment Phase|Protocol Violation|0
6281158|NCT02291289|9991222|FG010|Maintenance Treatment Phase|Protocol Violation|0
6281159|NCT02291289|9991223|FG011|Maintenance Treatment Phase|Protocol Violation|0
6281160|NCT02291289|9991212|FG000|Maintenance Treatment Phase|Death|0
6281161|NCT02291289|9991213|FG001|Maintenance Treatment Phase|Death|23
6281162|NCT02291289|9991214|FG002|Maintenance Treatment Phase|Death|13
6281163|NCT02291289|9991215|FG003|Maintenance Treatment Phase|Death|0
6281164|NCT02291289|9991216|FG004|Maintenance Treatment Phase|Death|185
6281165|NCT02291289|9991217|FG005|Maintenance Treatment Phase|Death|100
5979346|NCT01986933|9567498|FG001|Active-to-active (Part B)|Pregnancy|0
5979347|NCT01986933|9567499|FG002|Active-to-active (Part B)|Pregnancy|0
5979348|NCT01986933|9567500|FG003|Active-to-active (Part B)|Pregnancy|0
5979349|NCT01986933|9567501|FG004|Active-to-active (Part B)|Pregnancy|1
5979350|NCT01986933|9567497|FG000|Active-to-active (Part B)|Physician Decision|0
5979351|NCT01986933|9567498|FG001|Active-to-active (Part B)|Physician Decision|0
5979352|NCT01986933|9567499|FG002|Active-to-active (Part B)|Physician Decision|1
5979353|NCT01986933|9567500|FG003|Active-to-active (Part B)|Physician Decision|1
5979354|NCT01986933|9567501|FG004|Active-to-active (Part B)|Physician Decision|0
5979355|NCT01986933|9567497|FG000|Active-to-active (Part B)|Withdrawal by Subject|0
5979356|NCT01986933|9567498|FG001|Active-to-active (Part B)|Withdrawal by Subject|4
5979357|NCT01986933|9567499|FG002|Active-to-active (Part B)|Withdrawal by Subject|7
5979358|NCT01986933|9567500|FG003|Active-to-active (Part B)|Withdrawal by Subject|6
5979359|NCT01986933|9567501|FG004|Active-to-active (Part B)|Withdrawal by Subject|6
5979360|NCT01986933|9567497|FG000|Active-to-active (Part B)|Lost to Follow-up|0
5979361|NCT01986933|9567498|FG001|Active-to-active (Part B)|Lost to Follow-up|0
5979362|NCT01986933|9567499|FG002|Active-to-active (Part B)|Lost to Follow-up|0
5979363|NCT01986933|9567500|FG003|Active-to-active (Part B)|Lost to Follow-up|0
5979364|NCT01986933|9567501|FG004|Active-to-active (Part B)|Lost to Follow-up|1
5979365|NCT01986933|9567497|FG000|Active-to-active (Part B)|Others (not classified above reasons)|0
5979366|NCT01986933|9567498|FG001|Active-to-active (Part B)|Others (not classified above reasons)|1
5979367|NCT01986933|9567499|FG002|Active-to-active (Part B)|Others (not classified above reasons)|0
5979368|NCT01986933|9567500|FG003|Active-to-active (Part B)|Others (not classified above reasons)|1
5979369|NCT01986933|9567501|FG004|Active-to-active (Part B)|Others (not classified above reasons)|1
5979370|NCT01986933|9567497|FG000|Placebo-to-active (Part B)|Adverse Event|0
5979371|NCT01986933|9567498|FG001|Placebo-to-active (Part B)|Adverse Event|1
5979372|NCT01986933|9567499|FG002|Placebo-to-active (Part B)|Adverse Event|0
5979373|NCT01986933|9567500|FG003|Placebo-to-active (Part B)|Adverse Event|1
5979374|NCT01986933|9567501|FG004|Placebo-to-active (Part B)|Adverse Event|0
5979375|NCT01986933|9567497|FG000|Placebo-to-active (Part B)|Lack of Efficacy|0
5979376|NCT01986933|9567498|FG001|Placebo-to-active (Part B)|Lack of Efficacy|0
5979377|NCT01986933|9567499|FG002|Placebo-to-active (Part B)|Lack of Efficacy|0
5979378|NCT01986933|9567500|FG003|Placebo-to-active (Part B)|Lack of Efficacy|1
5979379|NCT01986933|9567501|FG004|Placebo-to-active (Part B)|Lack of Efficacy|0
5979380|NCT01986933|9567497|FG000|Placebo-to-active (Part B)|Protocol Violation|0
5979381|NCT01986933|9567498|FG001|Placebo-to-active (Part B)|Protocol Violation|0
5979382|NCT01986933|9567499|FG002|Placebo-to-active (Part B)|Protocol Violation|1
5979383|NCT01986933|9567500|FG003|Placebo-to-active (Part B)|Protocol Violation|0
5979384|NCT01986933|9567501|FG004|Placebo-to-active (Part B)|Protocol Violation|0
5979385|NCT01986933|9567497|FG000|Placebo-to-active (Part B)|Withdrawal by Subject|0
5979386|NCT01986933|9567498|FG001|Placebo-to-active (Part B)|Withdrawal by Subject|3
6281166|NCT02291289|9991218|FG006|Maintenance Treatment Phase|Death|0
5979387|NCT01986933|9567499|FG002|Placebo-to-active (Part B)|Withdrawal by Subject|4
5979388|NCT01986933|9567500|FG003|Placebo-to-active (Part B)|Withdrawal by Subject|3
5979389|NCT01986933|9567501|FG004|Placebo-to-active (Part B)|Withdrawal by Subject|0
5979390|NCT01986933|9567497|FG000|Placebo-to-active (Part B)|Lost to Follow-up|0
5979391|NCT01986933|9567498|FG001|Placebo-to-active (Part B)|Lost to Follow-up|1
5979392|NCT01986933|9567499|FG002|Placebo-to-active (Part B)|Lost to Follow-up|0
5979393|NCT01986933|9567500|FG003|Placebo-to-active (Part B)|Lost to Follow-up|0
5979394|NCT01986933|9567501|FG004|Placebo-to-active (Part B)|Lost to Follow-up|0
5979395|NCT01701674|9567543|FG000|Overall Study|Unable to safely complete treatment|1
5979396|NCT01563107|9567551|FG000|Overall Study|Physician Decision|0
6051374|NCT00432679|9650652|FG001|Overall Study|Withdrawal by Subject|2
6051375|NCT00432744|9650660|FG000|Months 0-6|Withdrawal by Subject|4
6051376|NCT00432744|9650661|FG001|Months 0-6|Withdrawal by Subject|4
6051377|NCT00432744|9650660|FG000|Months 0-6|Too disabled to score|1
6281167|NCT02291289|9991219|FG007|Maintenance Treatment Phase|Death|1
6281168|NCT02291289|9991220|FG008|Maintenance Treatment Phase|Death|1
6281169|NCT02291289|9991221|FG009|Maintenance Treatment Phase|Death|0
6281170|NCT02291289|9991222|FG010|Maintenance Treatment Phase|Death|26
6281171|NCT02291289|9991223|FG011|Maintenance Treatment Phase|Death|11
6281172|NCT02291289|9991212|FG000|Maintenance Treatment Phase|Adverse Event|0
6281173|NCT02291289|9991213|FG001|Maintenance Treatment Phase|Adverse Event|0
6281174|NCT02291289|9991214|FG002|Maintenance Treatment Phase|Adverse Event|0
6281175|NCT02291289|9991215|FG003|Maintenance Treatment Phase|Adverse Event|0
6281176|NCT02291289|9991216|FG004|Maintenance Treatment Phase|Adverse Event|1
6281177|NCT02291289|9991217|FG005|Maintenance Treatment Phase|Adverse Event|0
6281178|NCT02291289|9991218|FG006|Maintenance Treatment Phase|Adverse Event|0
6281179|NCT02291289|9991219|FG007|Maintenance Treatment Phase|Adverse Event|0
6281180|NCT02291289|9991220|FG008|Maintenance Treatment Phase|Adverse Event|0
6281181|NCT02291289|9991221|FG009|Maintenance Treatment Phase|Adverse Event|0
6281182|NCT02291289|9991222|FG010|Maintenance Treatment Phase|Adverse Event|0
6281183|NCT02291289|9991223|FG011|Maintenance Treatment Phase|Adverse Event|0
6281184|NCT02291289|9991212|FG000|Maintenance Treatment Phase|Lost to Follow-up|0
6281185|NCT02291289|9991213|FG001|Maintenance Treatment Phase|Lost to Follow-up|0
6281186|NCT02291289|9991214|FG002|Maintenance Treatment Phase|Lost to Follow-up|0
6281187|NCT02291289|9991215|FG003|Maintenance Treatment Phase|Lost to Follow-up|0
6281188|NCT02291289|9991216|FG004|Maintenance Treatment Phase|Lost to Follow-up|12
6281189|NCT02291289|9991217|FG005|Maintenance Treatment Phase|Lost to Follow-up|3
6281190|NCT02291289|9991218|FG006|Maintenance Treatment Phase|Lost to Follow-up|0
6281191|NCT02291289|9991219|FG007|Maintenance Treatment Phase|Lost to Follow-up|1
6281192|NCT02291289|9991220|FG008|Maintenance Treatment Phase|Lost to Follow-up|0
6281193|NCT02291289|9991221|FG009|Maintenance Treatment Phase|Lost to Follow-up|0
6281194|NCT02291289|9991222|FG010|Maintenance Treatment Phase|Lost to Follow-up|2
6281195|NCT02291289|9991223|FG011|Maintenance Treatment Phase|Lost to Follow-up|1
6281196|NCT02291289|9991212|FG000|Maintenance Treatment Phase|Other|0
6281197|NCT02291289|9991213|FG001|Maintenance Treatment Phase|Other|0
6281198|NCT02291289|9991214|FG002|Maintenance Treatment Phase|Other|1
6281199|NCT02291289|9991215|FG003|Maintenance Treatment Phase|Other|0
6281200|NCT02291289|9991216|FG004|Maintenance Treatment Phase|Other|29
6281201|NCT02291289|9991217|FG005|Maintenance Treatment Phase|Other|8
6281202|NCT02291289|9991218|FG006|Maintenance Treatment Phase|Other|0
6281203|NCT02291289|9991219|FG007|Maintenance Treatment Phase|Other|0
6281204|NCT02291289|9991220|FG008|Maintenance Treatment Phase|Other|1
6281205|NCT02291289|9991221|FG009|Maintenance Treatment Phase|Other|0
6281206|NCT02291289|9991222|FG010|Maintenance Treatment Phase|Other|0
5979397|NCT01563107|9567552|FG001|Overall Study|Physician Decision|1
5979398|NCT01563107|9567553|FG002|Overall Study|Physician Decision|1
5979399|NCT01563107|9567554|FG003|Overall Study|Physician Decision|3
5979400|NCT01563107|9567551|FG000|Overall Study|Withdrawal by Subject|1
5979401|NCT01563107|9567552|FG001|Overall Study|Withdrawal by Subject|2
5979402|NCT01563107|9567553|FG002|Overall Study|Withdrawal by Subject|1
5979403|NCT01563107|9567554|FG003|Overall Study|Withdrawal by Subject|2
5979404|NCT01064479|9567626|FG000|Overall Study|Death|10
5979405|NCT01064479|9567627|FG001|Overall Study|Death|11
5979406|NCT01064479|9567626|FG000|Overall Study|Withdrawal by Subject|2
5979407|NCT01064479|9567627|FG001|Overall Study|Withdrawal by Subject|2
5979408|NCT01064479|9567626|FG000|Overall Study|Disease progression|1
5979409|NCT01064479|9567627|FG001|Overall Study|Disease progression|1
5979410|NCT01064479|9567626|FG000|Overall Study|Toxicity|1
5979411|NCT01064479|9567627|FG001|Overall Study|Toxicity|1
5979412|NCT01064479|9567626|FG000|Overall Study|Other|1
5979413|NCT01064479|9567627|FG001|Overall Study|Other|2
5979414|NCT01042522|9567635|FG000|Overall Study|Adverse Event|1
5979415|NCT01042522|9567636|FG001|Overall Study|Adverse Event|2
5979416|NCT01042522|9567635|FG000|Overall Study|Disease Progression|5
5979417|NCT01042522|9567636|FG001|Overall Study|Disease Progression|0
5979418|NCT01042522|9567635|FG000|Overall Study|Death|1
5979419|NCT01042522|9567636|FG001|Overall Study|Death|0
5979420|NCT01042522|9567635|FG000|Overall Study|Patient Refused|0
5979421|NCT01042522|9567636|FG001|Overall Study|Patient Refused|3
5979422|NCT01042522|9567635|FG000|Overall Study|Withdrawal by Subject|1
5979423|NCT01042522|9567636|FG001|Overall Study|Withdrawal by Subject|1
5979424|NCT00710970|9567675|FG000|Overall Study|Never took drug|3
5979425|NCT00685919|9567683|FG000|Overall Study|Withdrawal by Subject|0
5979426|NCT00685919|9567684|FG001|Overall Study|Withdrawal by Subject|0
5979427|NCT00685919|9567685|FG002|Overall Study|Withdrawal by Subject|1
6281207|NCT02291289|9991223|FG011|Maintenance Treatment Phase|Other|0
6281208|NCT02291289|9991212|FG000|Maintenance Treatment Phase|Physician Decision|0
6281209|NCT02291289|9991213|FG001|Maintenance Treatment Phase|Physician Decision|0
6281210|NCT02291289|9991214|FG002|Maintenance Treatment Phase|Physician Decision|0
6281211|NCT02291289|9991215|FG003|Maintenance Treatment Phase|Physician Decision|0
6281212|NCT02291289|9991216|FG004|Maintenance Treatment Phase|Physician Decision|2
6281213|NCT02291289|9991217|FG005|Maintenance Treatment Phase|Physician Decision|0
6281214|NCT02291289|9991218|FG006|Maintenance Treatment Phase|Physician Decision|0
6281215|NCT02291289|9991219|FG007|Maintenance Treatment Phase|Physician Decision|0
6281216|NCT02291289|9991220|FG008|Maintenance Treatment Phase|Physician Decision|0
6281217|NCT02291289|9991221|FG009|Maintenance Treatment Phase|Physician Decision|0
6281218|NCT02291289|9991222|FG010|Maintenance Treatment Phase|Physician Decision|0
6281219|NCT02291289|9991223|FG011|Maintenance Treatment Phase|Physician Decision|1
6281220|NCT02291289|9991212|FG000|Maintenance Treatment Phase|Multiple Reasons|0
6281221|NCT02291289|9991213|FG001|Maintenance Treatment Phase|Multiple Reasons|0
6089165|NCT00681811|9700490|FG000|Overall Study|Withdrawal by Subject|2
6089166|NCT00681811|9700491|FG001|Overall Study|Withdrawal by Subject|2
6089167|NCT00681811|9700490|FG000|Overall Study|Non-compliance|0
6089168|NCT00681811|9700491|FG001|Overall Study|Non-compliance|1
6089169|NCT00681824|9700511|FG000|Overall Study|withdrawn by investigator|0
6089170|NCT00681824|9700512|FG001|Overall Study|withdrawn by investigator|0
6089171|NCT00681824|9700513|FG002|Overall Study|withdrawn by investigator|1
6089172|NCT00681824|9700511|FG000|Overall Study|scheduling conflict|1
6089173|NCT00681824|9700512|FG001|Overall Study|scheduling conflict|0
6089174|NCT00681824|9700513|FG002|Overall Study|scheduling conflict|0
6089175|NCT00681824|9700511|FG000|Overall Study|Death|0
6089176|NCT00681824|9700512|FG001|Overall Study|Death|1
6089177|NCT00681824|9700513|FG002|Overall Study|Death|0
6089178|NCT00681863|9700521|FG000|Overall Study|Adverse Event|1
6089179|NCT00681863|9700521|FG000|Overall Study|Lost to Follow-up|2
6089180|NCT00681863|9700521|FG000|Overall Study|Lack of Efficacy|2
6089181|NCT00681863|9700521|FG000|Overall Study|Other|18
6089182|NCT00682435|9700542|FG000|Overall Study|Insufficient data|5
6089183|NCT00682435|9700542|FG000|Overall Study|Erroneously enrolled twice|2
6089184|NCT00682448|9700548|FG000|Overall Study|Adverse Event|1
6089185|NCT00682448|9700549|FG001|Overall Study|Adverse Event|2
6089186|NCT00682448|9700548|FG000|Overall Study|Lack of Efficacy|1
6089187|NCT00682448|9700549|FG001|Overall Study|Lack of Efficacy|0
6089188|NCT00682448|9700548|FG000|Overall Study|Lost to Follow-up|1
6281222|NCT02291289|9991214|FG002|Maintenance Treatment Phase|Multiple Reasons|0
6281223|NCT02291289|9991215|FG003|Maintenance Treatment Phase|Multiple Reasons|0
6281224|NCT02291289|9991216|FG004|Maintenance Treatment Phase|Multiple Reasons|4
6281225|NCT02291289|9991217|FG005|Maintenance Treatment Phase|Multiple Reasons|1
6281226|NCT02291289|9991218|FG006|Maintenance Treatment Phase|Multiple Reasons|0
6281227|NCT02291289|9991219|FG007|Maintenance Treatment Phase|Multiple Reasons|0
6281228|NCT02291289|9991220|FG008|Maintenance Treatment Phase|Multiple Reasons|0
6281229|NCT02291289|9991221|FG009|Maintenance Treatment Phase|Multiple Reasons|0
5979428|NCT00685919|9567686|FG003|Overall Study|Withdrawal by Subject|0
5979429|NCT00685919|9567683|FG000|Overall Study|Physician Decision|1
5979430|NCT00685919|9567684|FG001|Overall Study|Physician Decision|0
5979431|NCT00685919|9567685|FG002|Overall Study|Physician Decision|0
5979432|NCT00685919|9567686|FG003|Overall Study|Physician Decision|0
5979433|NCT00344487|9567696|FG000|Overall Study|immunologic failure|1
5979434|NCT00281658|9567704|FG000|Double-blind, Randomized Phase|Death|120
5979435|NCT00281658|9567705|FG001|Double-blind, Randomized Phase|Death|46
5979436|NCT00281658|9567706|FG002|Double-blind, Randomized Phase|Death|0
6089189|NCT00682448|9700549|FG001|Overall Study|Lost to Follow-up|3
6089190|NCT00682448|9700548|FG000|Overall Study|Pregnancy|0
5979437|NCT00281658|9567704|FG000|Double-blind, Randomized Phase|Lost to Follow-up|12
5979438|NCT00281658|9567705|FG001|Double-blind, Randomized Phase|Lost to Follow-up|5
5979439|NCT00281658|9567706|FG002|Double-blind, Randomized Phase|Lost to Follow-up|0
5979440|NCT00281658|9567704|FG000|Double-blind, Randomized Phase|Withdrawal by Subject|4
5979441|NCT00281658|9567705|FG001|Double-blind, Randomized Phase|Withdrawal by Subject|1
5979442|NCT00281658|9567706|FG002|Double-blind, Randomized Phase|Withdrawal by Subject|0
5979443|NCT00281658|9567704|FG000|Double-blind, Randomized Phase|Participant Entered New Protocol|1
5979444|NCT00281658|9567705|FG001|Double-blind, Randomized Phase|Participant Entered New Protocol|1
5979445|NCT00281658|9567706|FG002|Double-blind, Randomized Phase|Participant Entered New Protocol|0
5979446|NCT00281658|9567704|FG000|Double-blind, Randomized Phase|Screen Failure; Randomized in Error|0
6089191|NCT00682448|9700549|FG001|Overall Study|Pregnancy|1
6089192|NCT00682448|9700548|FG000|Overall Study|Withdrawal by Subject|2
6089193|NCT00682448|9700549|FG001|Overall Study|Withdrawal by Subject|0
6089194|NCT00682539|9700558|FG000|Bevacizumab vs Triamcinolone|Lost to Follow-up|3
6089195|NCT00682539|9700559|FG001|Bevacizumab vs Triamcinolone|Lost to Follow-up|1
6089196|NCT00682539|9700560|FG002|Bevacizumab vs Triamcinolone|Lost to Follow-up|0
6089197|NCT00682539|9700558|FG000|Ranibizumab vs Triamcinolone|Lost to Follow-up|0
6089198|NCT00682539|9700559|FG001|Ranibizumab vs Triamcinolone|Lost to Follow-up|3
6089199|NCT00682539|9700560|FG002|Ranibizumab vs Triamcinolone|Lost to Follow-up|8
6089200|NCT00682461|9700584|FG000|Overall Study|Adverse Event|5
6281230|NCT02291289|9991222|FG010|Maintenance Treatment Phase|Multiple Reasons|0
6089201|NCT00682461|9700585|FG001|Overall Study|Adverse Event|7
6089202|NCT00682461|9700584|FG000|Overall Study|Lost to Follow-up|8
6089203|NCT00682461|9700585|FG001|Overall Study|Lost to Follow-up|5
6089204|NCT00682461|9700584|FG000|Overall Study|Withdrawal by Subject|12
6089205|NCT00682461|9700585|FG001|Overall Study|Withdrawal by Subject|19
6089206|NCT00682643|9700603|FG000|Overall Study|Adverse Event|12
6281231|NCT02291289|9991223|FG011|Maintenance Treatment Phase|Multiple Reasons|0
6281232|NCT02291289|9991212|FG000|Maintenance Treatment Phase|No Treatment Received|0
6281233|NCT02291289|9991213|FG001|Maintenance Treatment Phase|No Treatment Received|0
6281234|NCT02291289|9991214|FG002|Maintenance Treatment Phase|No Treatment Received|2
6281235|NCT02291289|9991215|FG003|Maintenance Treatment Phase|No Treatment Received|0
6281236|NCT02291289|9991216|FG004|Maintenance Treatment Phase|No Treatment Received|4
6281237|NCT02291289|9991217|FG005|Maintenance Treatment Phase|No Treatment Received|5
6281238|NCT02291289|9991218|FG006|Maintenance Treatment Phase|No Treatment Received|0
6281239|NCT02291289|9991219|FG007|Maintenance Treatment Phase|No Treatment Received|0
6281240|NCT02291289|9991220|FG008|Maintenance Treatment Phase|No Treatment Received|0
6281241|NCT02291289|9991221|FG009|Maintenance Treatment Phase|No Treatment Received|0
6281242|NCT02291289|9991222|FG010|Maintenance Treatment Phase|No Treatment Received|1
6281243|NCT02291289|9991223|FG011|Maintenance Treatment Phase|No Treatment Received|0
6281244|NCT02291419|9991267|FG000|Overall Study|Early study termination|1
6281245|NCT02291419|9991268|FG001|Overall Study|Early study termination|5
6281246|NCT02291432|9991274|FG000|Overall Study|Withdrawal by Subject|2
6281247|NCT02291510|9991282|FG000|Overall Study|Adverse Event|0
6281248|NCT02291510|9991283|FG001|Overall Study|Adverse Event|0
6281249|NCT02291510|9991284|FG002|Overall Study|Adverse Event|0
5979447|NCT00281658|9567705|FG001|Double-blind, Randomized Phase|Screen Failure; Randomized in Error|1
5979448|NCT00281658|9567706|FG002|Double-blind, Randomized Phase|Screen Failure; Randomized in Error|0
5979449|NCT00281658|9567704|FG000|Open-label Monotherapy Extension Phase|Death|0
5979450|NCT00281658|9567705|FG001|Open-label Monotherapy Extension Phase|Death|0
5979451|NCT00281658|9567706|FG002|Open-label Monotherapy Extension Phase|Death|97
5979452|NCT00281658|9567704|FG000|Open-label Monotherapy Extension Phase|Lost to Follow-up|0
5979453|NCT00281658|9567705|FG001|Open-label Monotherapy Extension Phase|Lost to Follow-up|0
5979454|NCT00281658|9567706|FG002|Open-label Monotherapy Extension Phase|Lost to Follow-up|3
5979455|NCT00281658|9567704|FG000|Open-label Monotherapy Extension Phase|Withdrawal by Subject|0
5979456|NCT00281658|9567705|FG001|Open-label Monotherapy Extension Phase|Withdrawal by Subject|0
5979457|NCT00281658|9567706|FG002|Open-label Monotherapy Extension Phase|Withdrawal by Subject|1
6051378|NCT00432744|9650661|FG001|Months 0-6|Too disabled to score|0
6051379|NCT00432744|9650660|FG000|Months 7 - 12|Withdrawal by Subject|1
6051380|NCT00432744|9650661|FG001|Months 7 - 12|Withdrawal by Subject|0
6051381|NCT00432744|9650660|FG000|Months 7 - 12|Too disabled to score|0
6051382|NCT00432744|9650661|FG001|Months 7 - 12|Too disabled to score|1
6051383|NCT00432809|9650670|FG000|1 Year Follow-up|Misses 9 and 12 month visit|2
6051384|NCT00432809|9650671|FG001|1 Year Follow-up|Misses 9 and 12 month visit|0
6051385|NCT00432809|9650672|FG002|1 Year Follow-up|Misses 9 and 12 month visit|0
6051386|NCT00432809|9650670|FG000|1 Year Follow-up|Withdrawal by Subject|7
6051387|NCT00432809|9650671|FG001|1 Year Follow-up|Withdrawal by Subject|0
6051388|NCT00432809|9650672|FG002|1 Year Follow-up|Withdrawal by Subject|1
6051389|NCT00432835|9650682|FG000|Overall Study|Adverse event: lead dislodgement.|6
6051390|NCT00432835|9650683|FG001|Overall Study|Adverse event: lead dislodgement.|7
6051391|NCT00432965|9650691|FG000|Overall Study|Lost to Follow-up|22
6051392|NCT00432965|9650692|FG001|Overall Study|Lost to Follow-up|19
6051393|NCT00432965|9650691|FG000|Overall Study|Withdrawal by Subject|13
6051394|NCT00432965|9650692|FG001|Overall Study|Withdrawal by Subject|13
6051395|NCT00432965|9650691|FG000|Overall Study|Physician Decision|14
6051396|NCT00432965|9650692|FG001|Overall Study|Physician Decision|13
6051397|NCT00432965|9650691|FG000|Overall Study|Lack of Efficacy|8
6051398|NCT00432965|9650692|FG001|Overall Study|Lack of Efficacy|13
6051399|NCT00432965|9650691|FG000|Overall Study|Non-compliance|7
6051400|NCT00432965|9650692|FG001|Overall Study|Non-compliance|0
6051401|NCT00432965|9650691|FG000|Overall Study|Adverse Event|22
6051402|NCT00432965|9650692|FG001|Overall Study|Adverse Event|19
6051403|NCT00432965|9650691|FG000|Overall Study|Death|3
6051404|NCT00432965|9650692|FG001|Overall Study|Death|4
6051405|NCT00432965|9650691|FG000|Overall Study|Exclusionary Methods|1
6051406|NCT00432965|9650692|FG001|Overall Study|Exclusionary Methods|2
6051407|NCT00432965|9650691|FG000|Overall Study|Incomplete Data|4
6051408|NCT00432965|9650692|FG001|Overall Study|Incomplete Data|3
6051409|NCT00432991|9650700|FG000|Overall Study|Protocol Violation|7
6051410|NCT00432991|9650701|FG001|Overall Study|Protocol Violation|12
6051411|NCT00433004|9650709|FG000|Overall Study|Lost to Follow-up|5
6089207|NCT00682643|9700604|FG001|Overall Study|Adverse Event|23
6051412|NCT00433004|9650710|FG001|Overall Study|Lost to Follow-up|7
6051413|NCT00433017|9650718|FG000|Overall Study|Adverse Event|5
6051414|NCT00433017|9650719|FG001|Overall Study|Adverse Event|3
6051415|NCT00433017|9650718|FG000|Overall Study|Withdrawal by Subject|4
6051416|NCT00433017|9650719|FG001|Overall Study|Withdrawal by Subject|5
6051417|NCT00433017|9650718|FG000|Overall Study|Lost to Follow-up|3
6089208|NCT00682643|9700603|FG000|Overall Study|Lack of Efficacy|2
6281250|NCT02291510|9991285|FG003|Overall Study|Adverse Event|1
6281251|NCT02291549|9991297|FG000|Overall Study|Lost to Follow-up|1
6281252|NCT02291549|9991298|FG001|Overall Study|Lost to Follow-up|0
6281253|NCT02291549|9991297|FG000|Overall Study|Withdrawal by Subject|0
6281254|NCT02291549|9991298|FG001|Overall Study|Withdrawal by Subject|1
6281255|NCT02291601|9991306|FG000|Abdomen|Did not qualify|333
6281256|NCT02291601|9991307|FG001|Abdomen|Did not qualify|54
6281257|NCT02291601|9991308|FG002|Abdomen|Did not qualify|339
6281258|NCT02291601|9991306|FG000|Groin|Did not qualify|183
6281259|NCT02291601|9991307|FG001|Groin|Did not qualify|30
6281260|NCT02291601|9991308|FG002|Groin|Did not qualify|177
6281261|NCT02291614|9991330|FG000|Overall Study|Lost to Follow-up|0
6281262|NCT02291614|9991331|FG001|Overall Study|Lost to Follow-up|0
6281263|NCT02291614|9991332|FG002|Overall Study|Lost to Follow-up|0
6281264|NCT02291614|9991333|FG003|Overall Study|Lost to Follow-up|0
6281265|NCT02291614|9991334|FG004|Overall Study|Lost to Follow-up|0
6281266|NCT02291614|9991335|FG005|Overall Study|Lost to Follow-up|0
5979458|NCT04034355|9567737|FG000|Overall Study|Study terminated by Sponsor|10
5979459|NCT04034355|9567738|FG001|Overall Study|Study terminated by Sponsor|17
5979460|NCT04034355|9567737|FG000|Overall Study|Withdrawal by Subject|12
5979461|NCT04034355|9567738|FG001|Overall Study|Withdrawal by Subject|11
5979462|NCT04034355|9567737|FG000|Overall Study|Site terminated by Sponsor|4
5979463|NCT04034355|9567738|FG001|Overall Study|Site terminated by Sponsor|5
5979464|NCT04034355|9567737|FG000|Overall Study|Adverse Event|2
5979465|NCT04034355|9567738|FG001|Overall Study|Adverse Event|0
5979466|NCT04034355|9567737|FG000|Overall Study|Death|1
5979467|NCT04034355|9567738|FG001|Overall Study|Death|1
5979468|NCT04034355|9567737|FG000|Overall Study|Not reported|2
5979469|NCT04034355|9567738|FG001|Overall Study|Not reported|0
5979470|NCT04034355|9567737|FG000|Overall Study|Lost to Follow-up|1
5979471|NCT04034355|9567738|FG001|Overall Study|Lost to Follow-up|0
5979472|NCT04034355|9567737|FG000|Overall Study|Physician Decision|1
5979473|NCT04034355|9567738|FG001|Overall Study|Physician Decision|0
5979474|NCT04034355|9567737|FG000|Overall Study|Protocol Violation|0
5979475|NCT04034355|9567738|FG001|Overall Study|Protocol Violation|1
5979476|NCT04034355|9567737|FG000|Overall Study|Progressive disease|1
5979477|NCT04034355|9567738|FG001|Overall Study|Progressive disease|0
6051418|NCT00433017|9650719|FG001|Overall Study|Lost to Follow-up|4
6051419|NCT00433017|9650718|FG000|Overall Study|Administrative problems|80
6051420|NCT00433017|9650719|FG001|Overall Study|Administrative problems|86
6051421|NCT00433017|9650718|FG000|Overall Study|Protocol Violation|1
6051422|NCT00433017|9650719|FG001|Overall Study|Protocol Violation|0
6051423|NCT00433017|9650718|FG000|Overall Study|Death|2
6051424|NCT00433017|9650719|FG001|Overall Study|Death|2
6281267|NCT02291614|9991336|FG006|Overall Study|Lost to Follow-up|0
6281268|NCT02291614|9991337|FG007|Overall Study|Lost to Follow-up|1
6281269|NCT02291614|9991338|FG008|Overall Study|Lost to Follow-up|0
6281270|NCT02291614|9991339|FG009|Overall Study|Lost to Follow-up|0
6281271|NCT02291614|9991340|FG010|Overall Study|Lost to Follow-up|0
6281272|NCT02291614|9991330|FG000|Overall Study|Withdrawal by Subject|0
6281273|NCT02291614|9991331|FG001|Overall Study|Withdrawal by Subject|1
6281274|NCT02291614|9991332|FG002|Overall Study|Withdrawal by Subject|0
6281275|NCT02291614|9991333|FG003|Overall Study|Withdrawal by Subject|0
6051425|NCT00433017|9650718|FG000|Overall Study|Subject no longer requires study drug|1
6051426|NCT00433017|9650719|FG001|Overall Study|Subject no longer requires study drug|1
6051427|NCT00433147|9650729|FG000|Overall Study|Adverse Event|0
6051428|NCT00433147|9650730|FG001|Overall Study|Adverse Event|1
6051429|NCT00433147|9650731|FG002|Overall Study|Adverse Event|0
6051430|NCT00433147|9650732|FG003|Overall Study|Adverse Event|0
6051431|NCT00433160|9650744|FG000|52-Week Double-Blind (DB) Period|Adverse Event|6
6051432|NCT00433160|9650745|FG001|52-Week Double-Blind (DB) Period|Adverse Event|2
6051433|NCT00433160|9650744|FG000|52-Week Double-Blind (DB) Period|Death|0
6051434|NCT00433160|9650745|FG001|52-Week Double-Blind (DB) Period|Death|0
6051435|NCT00433160|9650744|FG000|52-Week Double-Blind (DB) Period|Lost to Follow-up|0
6051436|NCT00433160|9650745|FG001|52-Week Double-Blind (DB) Period|Lost to Follow-up|0
6051437|NCT00433160|9650744|FG000|52-Week Double-Blind (DB) Period|Entry Criteria Exclusion|0
6051438|NCT00433160|9650745|FG001|52-Week Double-Blind (DB) Period|Entry Criteria Exclusion|1
6051439|NCT00433160|9650744|FG000|52-Week Double-Blind (DB) Period|Protocol Violation|0
6051440|NCT00433160|9650745|FG001|52-Week Double-Blind (DB) Period|Protocol Violation|2
6051441|NCT00433160|9650744|FG000|52-Week Double-Blind (DB) Period|Withdrawal by Subject|6
6051442|NCT00433160|9650745|FG001|52-Week Double-Blind (DB) Period|Withdrawal by Subject|1
6051443|NCT00433160|9650744|FG000|52-Week Double-Blind (DB) Period|Physician Decision|4
6051444|NCT00433160|9650745|FG001|52-Week Double-Blind (DB) Period|Physician Decision|2
6051445|NCT00433160|9650744|FG000|52-Week Double-Blind (DB) Period|Sponsor Decision|0
6051446|NCT00433160|9650745|FG001|52-Week Double-Blind (DB) Period|Sponsor Decision|0
6051447|NCT00433160|9650744|FG000|52-Week Double-Blind (DB) Period|Lack of Efficacy|1
6051448|NCT00433160|9650745|FG001|52-Week Double-Blind (DB) Period|Lack of Efficacy|2
6051449|NCT00433160|9650744|FG000|76 Weeks, 24-Week Open Label (OL) Period|Adverse Event|3
6051450|NCT00433160|9650745|FG001|76 Weeks, 24-Week Open Label (OL) Period|Adverse Event|1
6281276|NCT02291614|9991334|FG004|Overall Study|Withdrawal by Subject|0
6281277|NCT02291614|9991335|FG005|Overall Study|Withdrawal by Subject|0
6281278|NCT02291614|9991336|FG006|Overall Study|Withdrawal by Subject|0
6281279|NCT02291614|9991337|FG007|Overall Study|Withdrawal by Subject|0
6281280|NCT02291614|9991338|FG008|Overall Study|Withdrawal by Subject|0
6281281|NCT02291614|9991339|FG009|Overall Study|Withdrawal by Subject|2
6281282|NCT02291614|9991340|FG010|Overall Study|Withdrawal by Subject|2
6281283|NCT02291614|9991330|FG000|Overall Study|Decision by sponsor|0
6281284|NCT02291614|9991331|FG001|Overall Study|Decision by sponsor|0
6281285|NCT02291614|9991332|FG002|Overall Study|Decision by sponsor|0
6281286|NCT02291614|9991333|FG003|Overall Study|Decision by sponsor|1
6281287|NCT02291614|9991334|FG004|Overall Study|Decision by sponsor|0
6281288|NCT02291614|9991335|FG005|Overall Study|Decision by sponsor|0
6281289|NCT02291614|9991336|FG006|Overall Study|Decision by sponsor|0
6281290|NCT02291614|9991337|FG007|Overall Study|Decision by sponsor|0
6281291|NCT02291614|9991338|FG008|Overall Study|Decision by sponsor|0
6281292|NCT02291614|9991339|FG009|Overall Study|Decision by sponsor|0
6281293|NCT02291614|9991340|FG010|Overall Study|Decision by sponsor|0
6281294|NCT02291614|9991330|FG000|Overall Study|Death|0
6281295|NCT02291614|9991331|FG001|Overall Study|Death|0
6281296|NCT02291614|9991332|FG002|Overall Study|Death|1
6281297|NCT02291614|9991333|FG003|Overall Study|Death|0
6281298|NCT02291614|9991334|FG004|Overall Study|Death|1
6281299|NCT02291614|9991335|FG005|Overall Study|Death|1
6281300|NCT02291614|9991336|FG006|Overall Study|Death|1
6281301|NCT02291614|9991337|FG007|Overall Study|Death|0
6281302|NCT02291614|9991338|FG008|Overall Study|Death|0
6281303|NCT02291614|9991339|FG009|Overall Study|Death|0
6281304|NCT02291614|9991340|FG010|Overall Study|Death|0
6281305|NCT02291679|9991373|FG000|Overall Study|Adverse Event|2
6281306|NCT02291679|9991374|FG001|Overall Study|Adverse Event|12
6281307|NCT02291679|9991375|FG002|Overall Study|Adverse Event|19
6281308|NCT02291679|9991373|FG000|Overall Study|Protocol Violation|5
6281309|NCT02291679|9991374|FG001|Overall Study|Protocol Violation|1
6281310|NCT02291679|9991375|FG002|Overall Study|Protocol Violation|7
6281311|NCT02291679|9991373|FG000|Overall Study|Withdrew Consent|18
6281312|NCT02291679|9991374|FG001|Overall Study|Withdrew Consent|10
6281313|NCT02291679|9991375|FG002|Overall Study|Withdrew Consent|15
6281314|NCT02291679|9991373|FG000|Overall Study|Lost to Follow-up|12
6281315|NCT02291679|9991374|FG001|Overall Study|Lost to Follow-up|10
6281316|NCT02291679|9991375|FG002|Overall Study|Lost to Follow-up|9
6281317|NCT02291679|9991373|FG000|Overall Study|Insufficient Therapeutic Response|5
6281318|NCT02291679|9991374|FG001|Overall Study|Insufficient Therapeutic Response|5
6281319|NCT02291679|9991375|FG002|Overall Study|Insufficient Therapeutic Response|7
6281320|NCT02291679|9991373|FG000|Overall Study|Other|2
6281321|NCT02291679|9991374|FG001|Overall Study|Other|4
6281322|NCT02291679|9991375|FG002|Overall Study|Other|2
5979478|NCT03721276|9567750|FG000|Overall Study|Lost to Follow-up|5
5979479|NCT03721276|9567751|FG001|Overall Study|Lost to Follow-up|3
5979480|NCT03721276|9567750|FG000|Overall Study|Adverse Event|0
5979481|NCT03721276|9567751|FG001|Overall Study|Adverse Event|1
5979482|NCT03637491|9567774|FG000|Overall Study|Death|9
5979483|NCT03637491|9567775|FG001|Overall Study|Death|9
5979484|NCT03637491|9567776|FG002|Overall Study|Death|5
5979485|NCT03637491|9567777|FG003|Overall Study|Death|3
5979486|NCT03637491|9567774|FG000|Overall Study|Lost to Follow-up|0
5979487|NCT03637491|9567775|FG001|Overall Study|Lost to Follow-up|1
5979488|NCT03637491|9567776|FG002|Overall Study|Lost to Follow-up|0
5979489|NCT03637491|9567777|FG003|Overall Study|Lost to Follow-up|1
5979490|NCT03637491|9567774|FG000|Overall Study|Study Terminated By Sponsor|0
5979491|NCT03637491|9567775|FG001|Overall Study|Study Terminated By Sponsor|2
5979492|NCT03637491|9567776|FG002|Overall Study|Study Terminated By Sponsor|1
5979493|NCT03637491|9567777|FG003|Overall Study|Study Terminated By Sponsor|0
5979494|NCT03637491|9567774|FG000|Overall Study|Withdrawal by Subject|1
5979495|NCT03637491|9567775|FG001|Overall Study|Withdrawal by Subject|0
5979496|NCT03637491|9567776|FG002|Overall Study|Withdrawal by Subject|1
5979497|NCT03637491|9567777|FG003|Overall Study|Withdrawal by Subject|2
5979498|NCT03334539|9567868|FG000|Overall Study|Adverse Event|3
5979499|NCT03334539|9567869|FG001|Overall Study|Adverse Event|5
5979500|NCT03334539|9567870|FG002|Overall Study|Adverse Event|0
5979501|NCT03334539|9567868|FG000|Overall Study|Withdrawal by Subject|0
5979502|NCT03334539|9567869|FG001|Overall Study|Withdrawal by Subject|1
5979503|NCT03334539|9567870|FG002|Overall Study|Withdrawal by Subject|1
5979504|NCT03334539|9567868|FG000|Overall Study|Administrative Reasons|1
5979505|NCT03334539|9567869|FG001|Overall Study|Administrative Reasons|0
5979506|NCT03334539|9567870|FG002|Overall Study|Administrative Reasons|0
5979507|NCT03334539|9567868|FG000|Overall Study|Hypertension Not Controlled|0
5979508|NCT03334539|9567869|FG001|Overall Study|Hypertension Not Controlled|1
6281323|NCT02291861|9991399|FG000|Overall Study|Adverse Event|2
6281324|NCT02291861|9991400|FG001|Overall Study|Adverse Event|4
6281325|NCT02291861|9991401|FG002|Overall Study|Adverse Event|1
6281326|NCT02291861|9991402|FG003|Overall Study|Adverse Event|2
6281327|NCT02291861|9991399|FG000|Overall Study|Death|0
6281328|NCT02291861|9991400|FG001|Overall Study|Death|0
6281329|NCT02291861|9991401|FG002|Overall Study|Death|1
6281330|NCT02291861|9991402|FG003|Overall Study|Death|1
6281331|NCT02291861|9991399|FG000|Overall Study|Protocol Violation|1
6281332|NCT02291861|9991400|FG001|Overall Study|Protocol Violation|0
6281333|NCT02291861|9991401|FG002|Overall Study|Protocol Violation|0
6281334|NCT02291861|9991402|FG003|Overall Study|Protocol Violation|1
6281335|NCT02291861|9991399|FG000|Overall Study|Withdrawal by Subject|1
6281336|NCT02291861|9991400|FG001|Overall Study|Withdrawal by Subject|2
6089209|NCT00682643|9700604|FG001|Overall Study|Lack of Efficacy|0
6089210|NCT00682643|9700603|FG000|Overall Study|Protocol Violation|38
6089211|NCT00682643|9700604|FG001|Overall Study|Protocol Violation|76
6089212|NCT00682643|9700603|FG000|Overall Study|Met Protocol-defined Stopping Criteria|3
6089213|NCT00682643|9700604|FG001|Overall Study|Met Protocol-defined Stopping Criteria|4
6089214|NCT00682643|9700603|FG000|Overall Study|Lost to Follow-up|1
6089215|NCT00682643|9700604|FG001|Overall Study|Lost to Follow-up|6
6089216|NCT00682643|9700603|FG000|Overall Study|Physician Decision|2
6089217|NCT00682643|9700604|FG001|Overall Study|Physician Decision|6
6089218|NCT00682643|9700603|FG000|Overall Study|Withdrawal by Subject|19
6089219|NCT00682643|9700604|FG001|Overall Study|Withdrawal by Subject|53
6089220|NCT00682643|9700603|FG000|Overall Study|Did Not Receive Study Drug|1
6089221|NCT00682643|9700604|FG001|Overall Study|Did Not Receive Study Drug|1
6089222|NCT00682786|9700626|FG000|Overall Study|Withdrawal by Subject|2
6089223|NCT00682786|9700627|FG001|Overall Study|Withdrawal by Subject|2
6089224|NCT00682786|9700626|FG000|Overall Study|Did not receive irinotecan|0
6089225|NCT00682786|9700627|FG001|Overall Study|Did not receive irinotecan|1
6089226|NCT00682890|9700667|FG000|Overall Study|Lost to Follow-up|1
6089227|NCT00682890|9700668|FG001|Overall Study|Lost to Follow-up|1
6089228|NCT00682890|9700667|FG000|Overall Study|subject moved away|0
6089229|NCT00682890|9700668|FG001|Overall Study|subject moved away|1
6089230|NCT00682890|9700667|FG000|Overall Study|heavy menstrual bleeding|1
6201991|NCT01498445|9862022|FG004|Overall Study|Lack of Efficacy|0
6201992|NCT01498445|9862023|FG005|Overall Study|Lack of Efficacy|0
6201993|NCT01498445|9862018|FG000|Overall Study|Screen Failure|0
6201994|NCT01498445|9862019|FG001|Overall Study|Screen Failure|0
6201995|NCT01498445|9862020|FG002|Overall Study|Screen Failure|0
6201996|NCT01498445|9862021|FG003|Overall Study|Screen Failure|0
6201997|NCT01498445|9862022|FG004|Overall Study|Screen Failure|1
6201998|NCT01498445|9862023|FG005|Overall Study|Screen Failure|1
6201999|NCT01498458|9862037|FG000|Overall Study|Adverse Event|4
6202000|NCT01498458|9862037|FG000|Overall Study|Physician Decision|3
6202001|NCT01498575|9862057|FG000|Overall Sample|Withdrawal by Subject|60
6202002|NCT01498575|9862058|FG001|Overall Sample|Withdrawal by Subject|14
6202003|NCT01498575|9862057|FG000|On the Road Driving Assessment (ODA)|Withdrawal by Subject|19
6202004|NCT01498575|9862058|FG001|On the Road Driving Assessment (ODA)|Withdrawal by Subject|6
6202005|NCT01498575|9862057|FG000|On the Road Driving Assessment (ODA)|Protocol Violation|23
6202006|NCT01498575|9862058|FG001|On the Road Driving Assessment (ODA)|Protocol Violation|18
6202007|NCT01498640|9862077|FG000|Overall Study|Lost to Follow-up|1
6202008|NCT01498640|9862077|FG000|Overall Study|Death|1
6202009|NCT01498640|9862077|FG000|Overall Study|Other|3
6202010|NCT01498653|9862087|FG000|Overall Study|Adverse Event|2
6202011|NCT01498653|9862088|FG001|Overall Study|Adverse Event|2
6202012|NCT01498653|9862087|FG000|Overall Study|Lack of Efficacy|12
6202013|NCT01498653|9862088|FG001|Overall Study|Lack of Efficacy|26
6202014|NCT01498653|9862087|FG000|Overall Study|Protocol Violation|0
6202015|NCT01498653|9862088|FG001|Overall Study|Protocol Violation|4
6202016|NCT01498653|9862087|FG000|Overall Study|Lost to Follow-up|1
6202017|NCT01498653|9862088|FG001|Overall Study|Lost to Follow-up|0
6202018|NCT01498653|9862087|FG000|Overall Study|Physician Decision|2
6202019|NCT01498653|9862088|FG001|Overall Study|Physician Decision|0
6202020|NCT01498653|9862087|FG000|Overall Study|Withdrawal by Subject|2
6202021|NCT01498653|9862088|FG001|Overall Study|Withdrawal by Subject|3
6202022|NCT01498679|9862096|FG000|Overall Study|Adverse Event|1
6202023|NCT01498679|9862097|FG001|Overall Study|Adverse Event|4
6202024|NCT01498679|9862096|FG000|Overall Study|Lack of Efficacy|72
6202025|NCT01498679|9862097|FG001|Overall Study|Lack of Efficacy|12
6202026|NCT01498679|9862096|FG000|Overall Study|Protocol Violation|4
6202027|NCT01498679|9862097|FG001|Overall Study|Protocol Violation|0
6202028|NCT01498679|9862096|FG000|Overall Study|Physician Decision|0
6202029|NCT01498679|9862097|FG001|Overall Study|Physician Decision|2
6202030|NCT01498679|9862096|FG000|Overall Study|Withdrawal by Subject|12
6202031|NCT01498679|9862097|FG001|Overall Study|Withdrawal by Subject|4
6202032|NCT01498692|9862103|FG000|Overall Study|Death|4
6202033|NCT01498692|9862103|FG000|Overall Study|Withdrawal by Subject|1
6202034|NCT01498692|9862103|FG000|Overall Study|Missed 12-month visit|3
6202035|NCT01498822|9862118|FG000|Overall Study|Protocol Violation|8
6089231|NCT00682890|9700668|FG001|Overall Study|heavy menstrual bleeding|0
6089232|NCT00682929|9700677|FG000|Overall Study|Adverse Event|4
6089233|NCT00682929|9700678|FG001|Overall Study|Adverse Event|1
6089234|NCT00682929|9700679|FG002|Overall Study|Adverse Event|1
6202036|NCT01498822|9862119|FG001|Overall Study|Protocol Violation|4
6202037|NCT01498822|9862118|FG000|Overall Study|Other Reason|5
6202038|NCT01498822|9862119|FG001|Overall Study|Other Reason|2
6202039|NCT01498822|9862118|FG000|Overall Study|Lack of Efficacy|7
6202040|NCT01498822|9862119|FG001|Overall Study|Lack of Efficacy|2
6202041|NCT01498822|9862118|FG000|Overall Study|AE, non-serious non-fatal|8
6202042|NCT01498822|9862119|FG001|Overall Study|AE, non-serious non-fatal|17
6202043|NCT01498822|9862118|FG000|Overall Study|SAE, non-fatal|2
6202044|NCT01498822|9862119|FG001|Overall Study|SAE, non-fatal|2
6202045|NCT01498822|9862118|FG000|Overall Study|Adverse Event, serious fatal|1
6202046|NCT01498822|9862119|FG001|Overall Study|Adverse Event, serious fatal|1
6202047|NCT01498822|9862118|FG000|Overall Study|Withdrawal by Subject|15
6202048|NCT01498822|9862119|FG001|Overall Study|Withdrawal by Subject|25
6281337|NCT02291861|9991401|FG002|Overall Study|Withdrawal by Subject|1
6281338|NCT02291861|9991402|FG003|Overall Study|Withdrawal by Subject|4
6281339|NCT02291861|9991399|FG000|Overall Study|Noncompliance|1
6281340|NCT02291861|9991400|FG001|Overall Study|Noncompliance|1
6281341|NCT02291861|9991401|FG002|Overall Study|Noncompliance|2
6281342|NCT02291861|9991402|FG003|Overall Study|Noncompliance|1
6281343|NCT02291861|9991399|FG000|Overall Study|Lost to Follow-up|2
6281344|NCT02291861|9991400|FG001|Overall Study|Lost to Follow-up|1
6281345|NCT02291861|9991401|FG002|Overall Study|Lost to Follow-up|4
6281346|NCT02291861|9991402|FG003|Overall Study|Lost to Follow-up|0
6281347|NCT02291861|9991399|FG000|Overall Study|Other|0
6281348|NCT02291861|9991400|FG001|Overall Study|Other|0
6281349|NCT02291861|9991401|FG002|Overall Study|Other|0
6281350|NCT02291861|9991402|FG003|Overall Study|Other|1
6281351|NCT02291913|9991412|FG000|Overall Study|Progressive Disease|32
6281352|NCT02291913|9991412|FG000|Overall Study|Adverse Event|11
6281353|NCT02291913|9991412|FG000|Overall Study|Death|2
6281354|NCT02291913|9991412|FG000|Overall Study|Physician Decision|1
6281355|NCT02291913|9991412|FG000|Overall Study|Withdrawal by Subject|1
6281356|NCT02291913|9991412|FG000|Overall Study|Protocol Violation|1
6281357|NCT02292212|9991429|FG000|ViE Phase|Withdrawal by Subject|1
6281358|NCT02292212|9991429|FG000|ViE Phase|Protocol Violation|2
6281359|NCT02292446|9991453|FG000|Overall Study|Adverse Event|12
6281360|NCT02292446|9991453|FG000|Overall Study|Death|1
6281361|NCT02292446|9991453|FG000|Overall Study|Disease progression|2
6281362|NCT02292446|9991453|FG000|Overall Study|Subject/guardian decision|2
6281363|NCT02292446|9991453|FG000|Overall Study|Withdrawal by Subject|3
6281364|NCT02292719|9991475|FG000|Overall Study|Withdrawal by Subject|0
6281365|NCT02292719|9991476|FG001|Overall Study|Withdrawal by Subject|0
6281366|NCT02292719|9991477|FG002|Overall Study|Withdrawal by Subject|0
6281367|NCT02292719|9991478|FG003|Overall Study|Withdrawal by Subject|1
6281368|NCT02292719|9991479|FG004|Overall Study|Withdrawal by Subject|1
6281369|NCT02292719|9991480|FG005|Overall Study|Withdrawal by Subject|0
6281370|NCT02292719|9991475|FG000|Overall Study|Subject enrolled in new study.|0
5979509|NCT03334539|9567870|FG002|Overall Study|Hypertension Not Controlled|0
5979510|NCT03269344|9567892|FG000|Overall Study|Protocol Violation|4
5979511|NCT03269344|9567893|FG001|Overall Study|Protocol Violation|3
5979512|NCT03076775|9567907|FG000|Overall Study|Lost to Follow-up|1
5979513|NCT03076775|9567908|FG001|Overall Study|Lost to Follow-up|0
6051451|NCT00433160|9650744|FG000|76 Weeks, 24-Week Open Label (OL) Period|Withdrawal by Subject|1
6051452|NCT00433160|9650745|FG001|76 Weeks, 24-Week Open Label (OL) Period|Withdrawal by Subject|2
6051453|NCT00433160|9650744|FG000|76 Weeks, 24-Week Open Label (OL) Period|Physician Decision|2
6051454|NCT00433160|9650745|FG001|76 Weeks, 24-Week Open Label (OL) Period|Physician Decision|0
6051455|NCT00433160|9650744|FG000|76 Weeks, 24-Week Open Label (OL) Period|Lack of Efficacy|0
6051456|NCT00433160|9650745|FG001|76 Weeks, 24-Week Open Label (OL) Period|Lack of Efficacy|1
6051457|NCT00433160|9650744|FG000|104 Weeks, 28-Week OL Period|Adverse Event|2
6051458|NCT00433160|9650745|FG001|104 Weeks, 28-Week OL Period|Adverse Event|0
6051459|NCT00433160|9650744|FG000|104 Weeks, 28-Week OL Period|Withdrawal by Subject|8
6051460|NCT00433160|9650745|FG001|104 Weeks, 28-Week OL Period|Withdrawal by Subject|2
6051461|NCT00433160|9650744|FG000|104 Weeks, 28-Week OL Period|Physician Decision|0
6051462|NCT00433160|9650745|FG001|104 Weeks, 28-Week OL Period|Physician Decision|1
6051463|NCT00433199|9650757|FG000|Double-Blind Period|Adverse Event|0
6051464|NCT00433199|9650758|FG001|Double-Blind Period|Adverse Event|25
6051465|NCT00433199|9650757|FG000|Double-Blind Period|Lack of Efficacy|0
6051466|NCT00433199|9650758|FG001|Double-Blind Period|Lack of Efficacy|2
6051467|NCT00433199|9650757|FG000|Double-Blind Period|Lost to Follow-up|2
6051468|NCT00433199|9650758|FG001|Double-Blind Period|Lost to Follow-up|5
6051469|NCT00433199|9650757|FG000|Double-Blind Period|Withdrawal by Subject|8
6051470|NCT00433199|9650758|FG001|Double-Blind Period|Withdrawal by Subject|19
6051471|NCT00433199|9650757|FG000|Double-Blind Period|Protocol Violation|1
6051472|NCT00433199|9650758|FG001|Double-Blind Period|Protocol Violation|10
6051473|NCT00433199|9650757|FG000|Double-Blind Period|Administrative|1
6051474|NCT00433199|9650758|FG001|Double-Blind Period|Administrative|5
6051475|NCT00433199|9650757|FG000|Open-Label Period|Adverse Event|0
6051476|NCT00433199|9650758|FG001|Open-Label Period|Adverse Event|19
6051477|NCT00433199|9650757|FG000|Open-Label Period|Lack of Efficacy|0
6051478|NCT00433199|9650758|FG001|Open-Label Period|Lack of Efficacy|2
6051479|NCT00433199|9650757|FG000|Open-Label Period|Lost to Follow-up|0
6051480|NCT00433199|9650758|FG001|Open-Label Period|Lost to Follow-up|3
6051481|NCT00433199|9650757|FG000|Open-Label Period|Withdrawal by Subject|0
6051482|NCT00433199|9650758|FG001|Open-Label Period|Withdrawal by Subject|7
6051483|NCT00433199|9650757|FG000|Open-Label Period|Protocol Violation|0
6051484|NCT00433199|9650758|FG001|Open-Label Period|Protocol Violation|2
6051485|NCT00433199|9650757|FG000|Open-Label Period|Administrative|0
6051486|NCT00433199|9650758|FG001|Open-Label Period|Administrative|1
6051487|NCT00433290|9650771|FG000|Overall Study|Adverse Event|24
6281371|NCT02292719|9991476|FG001|Overall Study|Subject enrolled in new study.|0
6281372|NCT02292719|9991477|FG002|Overall Study|Subject enrolled in new study.|1
6281373|NCT02292719|9991478|FG003|Overall Study|Subject enrolled in new study.|0
6281374|NCT02292719|9991479|FG004|Overall Study|Subject enrolled in new study.|0
6281375|NCT02292719|9991480|FG005|Overall Study|Subject enrolled in new study.|0
6281376|NCT02292771|9991496|FG000|Overall Study|Withdrawal by Subject|2
6281377|NCT02292771|9991497|FG001|Overall Study|Withdrawal by Subject|1
6281378|NCT02292771|9991496|FG000|Overall Study|Lost to Follow-up|2
6281379|NCT02292771|9991497|FG001|Overall Study|Lost to Follow-up|1
6281380|NCT02292784|9991510|FG000|Overall Study|Lost to Follow-up|1
6281381|NCT02292784|9991511|FG001|Overall Study|Lost to Follow-up|17
6281382|NCT02292784|9991512|FG002|Overall Study|Lost to Follow-up|18
6281383|NCT02292784|9991510|FG000|Overall Study|Withdrawal by Subject|0
6281384|NCT02292784|9991511|FG001|Overall Study|Withdrawal by Subject|3
6281385|NCT02292784|9991512|FG002|Overall Study|Withdrawal by Subject|3
6281386|NCT02292849|9991523|FG000|Overall Study|Lost to Follow-up|0
6281387|NCT02292849|9991524|FG001|Overall Study|Lost to Follow-up|2
6281388|NCT02292849|9991525|FG002|Overall Study|Lost to Follow-up|2
6281389|NCT02292849|9991523|FG000|Overall Study|Physician Decision|4
6281390|NCT02292849|9991524|FG001|Overall Study|Physician Decision|0
6281391|NCT02292849|9991525|FG002|Overall Study|Physician Decision|0
6281392|NCT02292927|9991535|FG000|Overall Study|Protocol Violation|13
6281393|NCT02292927|9991536|FG001|Overall Study|Protocol Violation|7
6281394|NCT02293395|9991565|FG000|Overall Study|Lost to Follow-up|1
6281395|NCT02293395|9991566|FG001|Overall Study|Lost to Follow-up|0
6281396|NCT02293395|9991565|FG000|Overall Study|Withdrawal by Subject|8
6281397|NCT02293395|9991566|FG001|Overall Study|Withdrawal by Subject|7
6281398|NCT02293460|9991572|FG000|Overall Study|Protocol Violation|1
6281399|NCT02293460|9991572|FG000|Overall Study|Lack of Efficacy|2
6281400|NCT02293460|9991572|FG000|Overall Study|Adverse Event|2
6281401|NCT02293460|9991572|FG000|Overall Study|Withdrawal by Subject|1
6281402|NCT02293499|9991579|FG000|Training - Peer Leaders Only|By design, two treatment groups did not participate; 10 peer leaders were Withdrawn by PI|0
6281403|NCT02293499|9991580|FG001|Training - Peer Leaders Only|By design, two treatment groups did not participate; 10 peer leaders were Withdrawn by PI|0
6281404|NCT02293499|9991581|FG002|Training - Peer Leaders Only|By design, two treatment groups did not participate; 10 peer leaders were Withdrawn by PI|10
6281405|NCT02293499|9991579|FG000|Intervention - Camp|Withdrawal by Subject|3
6281406|NCT02293499|9991580|FG001|Intervention - Camp|Withdrawal by Subject|6
6281407|NCT02293499|9991581|FG002|Intervention - Camp|Withdrawal by Subject|2
6281408|NCT02293499|9991579|FG000|Intervention - Camp|these are those not showing up at camp|24
6281409|NCT02293499|9991580|FG001|Intervention - Camp|these are those not showing up at camp|28
6281410|NCT02293499|9991581|FG002|Intervention - Camp|these are those not showing up at camp|4
6281411|NCT02293499|9991579|FG000|3 Month Follow Up|Withdrawal by Subject|1
6281412|NCT02293499|9991580|FG001|3 Month Follow Up|Withdrawal by Subject|0
6281413|NCT02293499|9991581|FG002|3 Month Follow Up|Withdrawal by Subject|4
6281414|NCT02293499|9991579|FG000|3 Month Follow Up|Lost to Follow-up|14
6281415|NCT02293499|9991580|FG001|3 Month Follow Up|Lost to Follow-up|15
6281416|NCT02293499|9991581|FG002|3 Month Follow Up|Lost to Follow-up|6
6281417|NCT02293499|9991579|FG000|6 Month Follow Up|Lost to Follow-up|17
6281418|NCT02293499|9991580|FG001|6 Month Follow Up|Lost to Follow-up|27
6281419|NCT02293499|9991581|FG002|6 Month Follow Up|Lost to Follow-up|6
6281420|NCT02293499|9991579|FG000|6 Month Follow Up|Withdrawal by Subject|0
5979514|NCT02660827|9567948|FG000|From Study to End of Continued Access|Withdrawal by Subject|21
5979515|NCT02660827|9567948|FG000|From Study to End of Continued Access|Withdrawal by Sponsor|2
5979516|NCT02660827|9567948|FG000|From Study to End of Continued Access|Adverse Event|3
5979517|NCT02660827|9567948|FG000|From Study to End of Continued Access|didn't participate continued access period|5
5979518|NCT02660827|9567948|FG000|Period 1: Study Period|Withdrawal by Subject|1
5979519|NCT02660827|9567948|FG000|Period 2: Continued Access Period|Withdrawal by Subject|20
5979520|NCT02660827|9567948|FG000|Period 2: Continued Access Period|Withdrawal by Sponsor|2
5979521|NCT02660827|9567948|FG000|Period 2: Continued Access Period|Adverse Event|3
5979522|NCT02425644|9567966|FG000|Overall Study|Lost to Follow-up|2
5979523|NCT02425644|9567967|FG001|Overall Study|Lost to Follow-up|3
5979524|NCT02425644|9567966|FG000|Overall Study|Withdrawal by Subject|41
5979525|NCT02425644|9567967|FG001|Overall Study|Withdrawal by Subject|36
5979526|NCT02425644|9567966|FG000|Overall Study|Lack of Efficacy|3
5979527|NCT02425644|9567967|FG001|Overall Study|Lack of Efficacy|10
5979528|NCT02425644|9567966|FG000|Overall Study|Adverse Event|13
5979529|NCT02425644|9567967|FG001|Overall Study|Adverse Event|3
5979530|NCT02425644|9567966|FG000|Overall Study|Death|0
5979531|NCT02425644|9567967|FG001|Overall Study|Death|2
5979532|NCT02425644|9567966|FG000|Overall Study|Other|18
5979533|NCT02425644|9567967|FG001|Overall Study|Other|17
5979534|NCT02340221|9567980|FG000|Overall Study|Death|58
5979535|NCT02340221|9567981|FG001|Overall Study|Death|101
5979536|NCT02340221|9567980|FG000|Overall Study|Withdrawal by Participant|14
5979537|NCT02340221|9567981|FG001|Overall Study|Withdrawal by Participant|22
5979538|NCT02340221|9567980|FG000|Overall Study|Lost to Follow-up|2
5979539|NCT02340221|9567981|FG001|Overall Study|Lost to Follow-up|3
5979540|NCT02340221|9567980|FG000|Overall Study|Reason Not Specified|0
5979541|NCT02340221|9567981|FG001|Overall Study|Reason Not Specified|1
5979542|NCT02340221|9567980|FG000|Overall Study|Continued on study|140
5979543|NCT02340221|9567981|FG001|Overall Study|Continued on study|290
5979544|NCT02270957|9567990|FG000|Overall Study|Lack of Efficacy|2
6281421|NCT02293499|9991580|FG001|6 Month Follow Up|Withdrawal by Subject|0
6281422|NCT02293499|9991581|FG002|6 Month Follow Up|Withdrawal by Subject|1
5979545|NCT02270957|9567991|FG001|Overall Study|Lack of Efficacy|4
5979546|NCT02270957|9567990|FG000|Overall Study|Adverse Event|2
6281423|NCT02293499|9991579|FG000|9 Month Follow Up|Withdrawal by Subject|2
6281424|NCT02293499|9991580|FG001|9 Month Follow Up|Withdrawal by Subject|0
6281425|NCT02293499|9991581|FG002|9 Month Follow Up|Withdrawal by Subject|0
6281426|NCT02293499|9991579|FG000|9 Month Follow Up|Lost to Follow-up|24
6281427|NCT02293499|9991580|FG001|9 Month Follow Up|Lost to Follow-up|28
6281428|NCT02293499|9991581|FG002|9 Month Follow Up|Lost to Follow-up|4
6281429|NCT02293499|9991579|FG000|12 Month Follow Up|Lost to Follow-up|26
6281430|NCT02293499|9991580|FG001|12 Month Follow Up|Lost to Follow-up|25
6281431|NCT02293499|9991581|FG002|12 Month Follow Up|Lost to Follow-up|6
6281432|NCT02293499|9991579|FG000|12 Month Follow Up|Withdrawal by Subject|0
6281433|NCT02293499|9991580|FG001|12 Month Follow Up|Withdrawal by Subject|1
6281434|NCT02293499|9991581|FG002|12 Month Follow Up|Withdrawal by Subject|0
6281435|NCT02293499|9991579|FG000|15 Month Follow Up|Lost to Follow-up|22
6281436|NCT02293499|9991580|FG001|15 Month Follow Up|Lost to Follow-up|22
6281437|NCT02293499|9991581|FG002|15 Month Follow Up|Lost to Follow-up|7
6281438|NCT02293538|9991609|FG000|Overall Study|Adverse Event|0
6281439|NCT02293538|9991610|FG001|Overall Study|Adverse Event|1
6281440|NCT02293538|9991609|FG000|Overall Study|Lost to Follow-up|1
6281441|NCT02293538|9991610|FG001|Overall Study|Lost to Follow-up|0
5979547|NCT02270957|9567991|FG001|Overall Study|Adverse Event|0
5979548|NCT02134925|9568000|FG000|Overall Study|Withdrawal by Subject|1
5979549|NCT02134925|9568001|FG001|Overall Study|Withdrawal by Subject|0
5979550|NCT02134925|9568000|FG000|Overall Study|Cancel|1
5979551|NCT02134925|9568001|FG001|Overall Study|Cancel|6
5979552|NCT02054104|9568009|FG000|Overall Study|Did not want to continue due to college classes|1
5979553|NCT02054104|9568010|FG001|Overall Study|Did not want to continue due to college classes|0
5979554|NCT02054104|9568009|FG000|Overall Study|Biopsy positive for malignancy, appears to be new primary|1
5979555|NCT02054104|9568010|FG001|Overall Study|Biopsy positive for malignancy, appears to be new primary|0
5979556|NCT02054104|9568009|FG000|Overall Study|No evidence of immunologic response|2
5979557|NCT02054104|9568010|FG001|Overall Study|No evidence of immunologic response|2
5979558|NCT02054104|9568009|FG000|Overall Study|Disease Progression On Study|4
5979559|NCT02054104|9568010|FG001|Overall Study|Disease Progression On Study|5
5979560|NCT02054104|9568009|FG000|Overall Study|Diagnosis of lymphoma|0
5979561|NCT02054104|9568010|FG001|Overall Study|Diagnosis of lymphoma|1
5979562|NCT02054104|9568009|FG000|Overall Study|Inconclusive response|0
5979563|NCT02054104|9568010|FG001|Overall Study|Inconclusive response|1
5979564|NCT01899144|9568016|FG000|Treatment Period 2|Other|1
5979565|NCT01899144|9568016|FG000|Treatment Period 3|Other|2
5979566|NCT01899144|9568016|FG000|Treatment Period 5|Other|1
5979567|NCT01793610|9568031|FG000|Overall Study|Withdrawal by Subject|1
5979568|NCT01793610|9568032|FG001|Overall Study|Withdrawal by Subject|0
5979569|NCT01793610|9568033|FG002|Overall Study|Withdrawal by Subject|1
5979570|NCT01757665|9568047|FG000|Overall Study|Still on Study - Visit Completed|240
5979571|NCT01757665|9568048|FG001|Overall Study|Still on Study - Visit Completed|30
5979572|NCT01757665|9568047|FG000|Overall Study|Still on Study - Visit Pending|398
5979573|NCT01757665|9568048|FG001|Overall Study|Still on Study - Visit Pending|40
5979574|NCT01757665|9568047|FG000|Overall Study|Still on Study - Missed Visit|14
5979575|NCT01757665|9568048|FG001|Overall Study|Still on Study - Missed Visit|1
5979576|NCT01757665|9568047|FG000|Overall Study|Death|25
5979577|NCT01757665|9568048|FG001|Overall Study|Death|8
5979578|NCT01757665|9568047|FG000|Overall Study|Explant|1
5979579|NCT01757665|9568048|FG001|Overall Study|Explant|2
5979580|NCT01757665|9568047|FG000|Overall Study|Withdrawal by Subject|10
5979581|NCT01757665|9568048|FG001|Overall Study|Withdrawal by Subject|0
5979582|NCT01757665|9568047|FG000|Overall Study|Lost to Follow-up|1
5979583|NCT01757665|9568048|FG001|Overall Study|Lost to Follow-up|1
5979584|NCT01757665|9568047|FG000|Overall Study|Not Implanted with Device|5
5979585|NCT01757665|9568048|FG001|Overall Study|Not Implanted with Device|1
5979586|NCT00822120|9568089|FG000|Initial Registration|Adverse Event|1
5979587|NCT00822120|9568090|FG001|Initial Registration|Adverse Event|0
5979588|NCT00822120|9568091|FG002|Initial Registration|Adverse Event|0
5979589|NCT00822120|9568092|FG003|Initial Registration|Adverse Event|0
5979590|NCT00822120|9568093|FG004|Initial Registration|Adverse Event|0
5979591|NCT00822120|9568094|FG005|Initial Registration|Adverse Event|0
5979592|NCT00822120|9568089|FG000|Initial Registration|Refusal Unrelated to Adverse Event|1
5979593|NCT00822120|9568090|FG001|Initial Registration|Refusal Unrelated to Adverse Event|0
5979594|NCT00822120|9568091|FG002|Initial Registration|Refusal Unrelated to Adverse Event|0
5979595|NCT00822120|9568092|FG003|Initial Registration|Refusal Unrelated to Adverse Event|0
5979596|NCT00822120|9568093|FG004|Initial Registration|Refusal Unrelated to Adverse Event|0
6281442|NCT02293538|9991609|FG000|Overall Study|Withdrawal by Subject|0
6281443|NCT02293538|9991610|FG001|Overall Study|Withdrawal by Subject|1
6281444|NCT02293837|9991625|FG000|Overall Study|Lost to Follow-up|0
6281445|NCT02293837|9991626|FG001|Overall Study|Lost to Follow-up|2
6281446|NCT02293837|9991627|FG002|Overall Study|Lost to Follow-up|1
6281447|NCT02293837|9991628|FG003|Overall Study|Lost to Follow-up|0
6281448|NCT02293837|9991625|FG000|Overall Study|Withdrawal by Subject|2
6281449|NCT02293837|9991626|FG001|Overall Study|Withdrawal by Subject|1
6281450|NCT02293837|9991627|FG002|Overall Study|Withdrawal by Subject|2
6281451|NCT02293837|9991628|FG003|Overall Study|Withdrawal by Subject|1
6281452|NCT02293837|9991625|FG000|Overall Study|COVID-19 Related|1
6281453|NCT02293837|9991626|FG001|Overall Study|COVID-19 Related|1
6281454|NCT02293837|9991627|FG002|Overall Study|COVID-19 Related|0
6281455|NCT02293837|9991628|FG003|Overall Study|COVID-19 Related|0
6281456|NCT02293837|9991625|FG000|Overall Study|Participant ill and could not be infused|0
6281457|NCT02293837|9991626|FG001|Overall Study|Participant ill and could not be infused|0
6281458|NCT02293837|9991627|FG002|Overall Study|Participant ill and could not be infused|1
6281459|NCT02293837|9991628|FG003|Overall Study|Participant ill and could not be infused|0
6281460|NCT02293863|9991645|FG000|Overall Study|Death|4
6281461|NCT02293863|9991646|FG001|Overall Study|Death|6
6281462|NCT02293863|9991647|FG002|Overall Study|Death|4
6281463|NCT02293863|9991645|FG000|Overall Study|Lost to Follow-up|2
6281464|NCT02293863|9991646|FG001|Overall Study|Lost to Follow-up|2
6281465|NCT02293863|9991647|FG002|Overall Study|Lost to Follow-up|2
6281466|NCT02293863|9991645|FG000|Overall Study|Withdrawal by Subject|3
6281467|NCT02293863|9991646|FG001|Overall Study|Withdrawal by Subject|3
6089235|NCT00682929|9700677|FG000|Overall Study|Withdrawal by Subject|1
6089236|NCT00682929|9700678|FG001|Overall Study|Withdrawal by Subject|2
6089237|NCT00682929|9700679|FG002|Overall Study|Withdrawal by Subject|1
6089238|NCT00682929|9700677|FG000|Overall Study|dosing compliance < 80%|0
6089239|NCT00682929|9700678|FG001|Overall Study|dosing compliance < 80%|2
6089240|NCT00682929|9700679|FG002|Overall Study|dosing compliance < 80%|0
6089241|NCT00682929|9700677|FG000|Overall Study|lag in DEA renewal|1
6089242|NCT00682929|9700678|FG001|Overall Study|lag in DEA renewal|0
6089243|NCT00682929|9700679|FG002|Overall Study|lag in DEA renewal|0
6089244|NCT00683293|9700715|FG000|Overall Study|Withdrawal by Subject|2
6089245|NCT00683293|9700716|FG001|Overall Study|Withdrawal by Subject|3
6089246|NCT00683384|9700726|FG000|Overall Study|Death|1
6089247|NCT00683384|9700726|FG000|Overall Study|Adverse Event|1
6089248|NCT00683449|9700739|FG000|Overall Study|Lost to Follow-up|0
6089249|NCT00683449|9700740|FG001|Overall Study|Lost to Follow-up|1
6089250|NCT00683449|9700741|FG002|Overall Study|Lost to Follow-up|0
6089251|NCT00683449|9700742|FG003|Overall Study|Lost to Follow-up|0
6089252|NCT00683449|9700743|FG004|Overall Study|Lost to Follow-up|0
6089253|NCT00683475|9700762|FG000|Overall Study|Withdrawal by Subject|1
6089254|NCT00683475|9700763|FG001|Overall Study|Withdrawal by Subject|0
6089255|NCT00683475|9700762|FG000|Overall Study|Never Treated: Adverse Event|2
6089256|NCT00683475|9700763|FG001|Overall Study|Never Treated: Adverse Event|3
6089257|NCT00683475|9700762|FG000|Overall Study|Never Treated: Progressive Disease|1
6089258|NCT00683475|9700763|FG001|Overall Study|Never Treated: Progressive Disease|0
6089259|NCT00683592|9700772|FG000|Overall Study|Adverse Event|12
6089260|NCT00683592|9700773|FG001|Overall Study|Adverse Event|4
6089261|NCT00683592|9700772|FG000|Overall Study|Withdrawal by Subject|11
6089262|NCT00683592|9700773|FG001|Overall Study|Withdrawal by Subject|11
6089263|NCT00683592|9700772|FG000|Overall Study|Lost to Follow-up|17
6089264|NCT00683592|9700773|FG001|Overall Study|Lost to Follow-up|17
6089265|NCT00683592|9700772|FG000|Overall Study|Lack of Efficacy|3
6089266|NCT00683592|9700773|FG001|Overall Study|Lack of Efficacy|7
6089267|NCT00683592|9700772|FG000|Overall Study|Physician Decision|0
6089268|NCT00683592|9700773|FG001|Overall Study|Physician Decision|1
6089269|NCT00683592|9700772|FG000|Overall Study|Non-compliance|3
6089270|NCT00683592|9700773|FG001|Overall Study|Non-compliance|5
6089271|NCT00683592|9700772|FG000|Overall Study|Other|1
6089272|NCT00683592|9700773|FG001|Overall Study|Other|1
6089273|NCT00683618|9700782|FG000|Randomised Treatment Period|Withdrawal by Subject|4
6089274|NCT00683618|9700783|FG001|Randomised Treatment Period|Withdrawal by Subject|1
6089275|NCT00683618|9700784|FG002|Randomised Treatment Period|Withdrawal by Subject|2
6089276|NCT00683618|9700782|FG000|Randomised Treatment Period|Protocol Violation|0
6089277|NCT00683618|9700783|FG001|Randomised Treatment Period|Protocol Violation|1
6089278|NCT00683618|9700784|FG002|Randomised Treatment Period|Protocol Violation|0
6089279|NCT00683618|9700782|FG000|Randomised Treatment Period|Adverse Event|2
6089280|NCT00683618|9700783|FG001|Randomised Treatment Period|Adverse Event|0
6281468|NCT02293863|9991647|FG002|Overall Study|Withdrawal by Subject|1
6281469|NCT02293863|9991645|FG000|Overall Study|Reason Not Specified|0
6281470|NCT02293863|9991646|FG001|Overall Study|Reason Not Specified|2
6281471|NCT02293863|9991647|FG002|Overall Study|Reason Not Specified|2
6281472|NCT02293902|9991660|FG000|Double-Blind Period (Up to Week 24)|Adverse Event|5
6281473|NCT02293902|9991661|FG001|Double-Blind Period (Up to Week 24)|Adverse Event|6
6281474|NCT02293902|9991662|FG002|Double-Blind Period (Up to Week 24)|Adverse Event|8
6281475|NCT02293902|9991663|FG003|Double-Blind Period (Up to Week 24)|Adverse Event|0
6281476|NCT02293902|9991664|FG004|Double-Blind Period (Up to Week 24)|Adverse Event|0
6089281|NCT00683618|9700784|FG002|Randomised Treatment Period|Adverse Event|2
6089282|NCT00683618|9700782|FG000|Randomised Treatment Period|Reason not provided|0
6281477|NCT02293902|9991660|FG000|Double-Blind Period (Up to Week 24)|Lack of Efficacy|5
6281478|NCT02293902|9991661|FG001|Double-Blind Period (Up to Week 24)|Lack of Efficacy|1
6051488|NCT00433290|9650772|FG001|Overall Study|Adverse Event|7
6089283|NCT00683618|9700783|FG001|Randomised Treatment Period|Reason not provided|0
6089284|NCT00683618|9700784|FG002|Randomised Treatment Period|Reason not provided|2
6089285|NCT00683618|9700782|FG000|Extension Treatment Period|Withdrawal by Subject|1
6089286|NCT00683618|9700783|FG001|Extension Treatment Period|Withdrawal by Subject|0
6089287|NCT00683618|9700784|FG002|Extension Treatment Period|Withdrawal by Subject|0
6089288|NCT00683618|9700782|FG000|Extension Treatment Period|Adverse Event|1
6089289|NCT00683618|9700783|FG001|Extension Treatment Period|Adverse Event|0
6281479|NCT02293902|9991662|FG002|Double-Blind Period (Up to Week 24)|Lack of Efficacy|2
6281480|NCT02293902|9991663|FG003|Double-Blind Period (Up to Week 24)|Lack of Efficacy|0
6281481|NCT02293902|9991664|FG004|Double-Blind Period (Up to Week 24)|Lack of Efficacy|0
6281482|NCT02293902|9991660|FG000|Double-Blind Period (Up to Week 24)|Randomized but not Treated|1
6281483|NCT02293902|9991661|FG001|Double-Blind Period (Up to Week 24)|Randomized but not Treated|0
6281484|NCT02293902|9991662|FG002|Double-Blind Period (Up to Week 24)|Randomized but not Treated|0
6281485|NCT02293902|9991663|FG003|Double-Blind Period (Up to Week 24)|Randomized but not Treated|0
6281486|NCT02293902|9991664|FG004|Double-Blind Period (Up to Week 24)|Randomized but not Treated|0
6281487|NCT02293902|9991660|FG000|Single-Blind Period (Week 25 to Week 52)|Adverse Event|0
6281488|NCT02293902|9991661|FG001|Single-Blind Period (Week 25 to Week 52)|Adverse Event|7
6281489|NCT02293902|9991662|FG002|Single-Blind Period (Week 25 to Week 52)|Adverse Event|1
6281490|NCT02293902|9991663|FG003|Single-Blind Period (Week 25 to Week 52)|Adverse Event|1
6281491|NCT02293902|9991664|FG004|Single-Blind Period (Week 25 to Week 52)|Adverse Event|6
6281492|NCT02293902|9991660|FG000|Single-Blind Period (Week 25 to Week 52)|Lack of Efficacy|0
6281493|NCT02293902|9991661|FG001|Single-Blind Period (Week 25 to Week 52)|Lack of Efficacy|1
6281494|NCT02293902|9991662|FG002|Single-Blind Period (Week 25 to Week 52)|Lack of Efficacy|1
6281495|NCT02293902|9991663|FG003|Single-Blind Period (Week 25 to Week 52)|Lack of Efficacy|0
6281496|NCT02293902|9991664|FG004|Single-Blind Period (Week 25 to Week 52)|Lack of Efficacy|0
5979597|NCT00822120|9568094|FG005|Initial Registration|Refusal Unrelated to Adverse Event|0
5979598|NCT00822120|9568089|FG000|Initial Registration|Reasons not Protocol Specified|2
5979599|NCT00822120|9568090|FG001|Initial Registration|Reasons not Protocol Specified|0
5979600|NCT00822120|9568091|FG002|Initial Registration|Reasons not Protocol Specified|0
5979601|NCT00822120|9568092|FG003|Initial Registration|Reasons not Protocol Specified|0
5979602|NCT00822120|9568093|FG004|Initial Registration|Reasons not Protocol Specified|0
5979603|NCT00822120|9568094|FG005|Initial Registration|Reasons not Protocol Specified|0
5979604|NCT00822120|9568089|FG000|Initial Registration|Ineligible|22
5979605|NCT00822120|9568090|FG001|Initial Registration|Ineligible|1
5979606|NCT00822120|9568091|FG002|Initial Registration|Ineligible|0
5979607|NCT00822120|9568092|FG003|Initial Registration|Ineligible|0
5979608|NCT00822120|9568093|FG004|Initial Registration|Ineligible|0
5979609|NCT00822120|9568094|FG005|Initial Registration|Ineligible|0
5979610|NCT00822120|9568089|FG000|PET-directed Therapy|Adverse Event|0
5979611|NCT00822120|9568090|FG001|PET-directed Therapy|Adverse Event|0
5979612|NCT00822120|9568091|FG002|PET-directed Therapy|Adverse Event|0
5979613|NCT00822120|9568092|FG003|PET-directed Therapy|Adverse Event|1
5979614|NCT00822120|9568093|FG004|PET-directed Therapy|Adverse Event|0
5979615|NCT00822120|9568094|FG005|PET-directed Therapy|Adverse Event|0
5979616|NCT00822120|9568089|FG000|PET-directed Therapy|Refusal Unrelated to Adverse Event|0
5979617|NCT00822120|9568090|FG001|PET-directed Therapy|Refusal Unrelated to Adverse Event|0
5979618|NCT00822120|9568091|FG002|PET-directed Therapy|Refusal Unrelated to Adverse Event|0
5979619|NCT00822120|9568092|FG003|PET-directed Therapy|Refusal Unrelated to Adverse Event|1
5979620|NCT00822120|9568093|FG004|PET-directed Therapy|Refusal Unrelated to Adverse Event|0
5979621|NCT00822120|9568094|FG005|PET-directed Therapy|Refusal Unrelated to Adverse Event|0
5979622|NCT00822120|9568089|FG000|PET-directed Therapy|Death|0
5979623|NCT00822120|9568090|FG001|PET-directed Therapy|Death|0
5979624|NCT00822120|9568091|FG002|PET-directed Therapy|Death|0
5979625|NCT00822120|9568092|FG003|PET-directed Therapy|Death|2
5979626|NCT00822120|9568093|FG004|PET-directed Therapy|Death|0
5979627|NCT00822120|9568094|FG005|PET-directed Therapy|Death|0
5979628|NCT00822120|9568089|FG000|PET-directed Therapy|Protocol Violation|0
5979629|NCT00822120|9568090|FG001|PET-directed Therapy|Protocol Violation|0
5979630|NCT00822120|9568091|FG002|PET-directed Therapy|Protocol Violation|0
5979631|NCT00822120|9568092|FG003|PET-directed Therapy|Protocol Violation|6
5979632|NCT00822120|9568093|FG004|PET-directed Therapy|Protocol Violation|0
5979633|NCT00822120|9568094|FG005|PET-directed Therapy|Protocol Violation|0
5979634|NCT00603954|9568117|FG000|Overall Study|Protocol Violation|1
5979635|NCT00603954|9568118|FG001|Overall Study|Protocol Violation|2
6051489|NCT00433290|9650771|FG000|Overall Study|Lack of Efficacy|1
6051490|NCT00433290|9650772|FG001|Overall Study|Lack of Efficacy|5
6051491|NCT00433290|9650771|FG000|Overall Study|Withdrawal by Subject|4
6051492|NCT00433290|9650772|FG001|Overall Study|Withdrawal by Subject|2
6051493|NCT00433290|9650771|FG000|Overall Study|Protocol Violation|3
6051494|NCT00433290|9650772|FG001|Overall Study|Protocol Violation|2
6051495|NCT00433290|9650771|FG000|Overall Study|Physician Decision|2
6051496|NCT00433290|9650772|FG001|Overall Study|Physician Decision|0
6051497|NCT00433290|9650771|FG000|Overall Study|Entry Criteria Not Met|0
6281497|NCT02293993|9991686|FG000|Course 1 (DLT Evaluation Period)|Clear progression of the primary disease including relapses|1
6281498|NCT02293993|9991687|FG001|Course 1 (DLT Evaluation Period)|Clear progression of the primary disease including relapses|0
6281499|NCT02293993|9991688|FG002|Course 1 (DLT Evaluation Period)|Clear progression of the primary disease including relapses|0
6281500|NCT02293993|9991689|FG003|Course 1 (DLT Evaluation Period)|Clear progression of the primary disease including relapses|1
6281501|NCT02293993|9991686|FG000|Course ≥2 (Extended Treatment Period)|Physician Decision|0
6281502|NCT02293993|9991687|FG001|Course ≥2 (Extended Treatment Period)|Physician Decision|2
6281503|NCT02293993|9991688|FG002|Course ≥2 (Extended Treatment Period)|Physician Decision|1
6281504|NCT02293993|9991689|FG003|Course ≥2 (Extended Treatment Period)|Physician Decision|0
6281505|NCT02293993|9991686|FG000|Course ≥2 (Extended Treatment Period)|Withdrawal by Subject|0
6281506|NCT02293993|9991687|FG001|Course ≥2 (Extended Treatment Period)|Withdrawal by Subject|0
6281507|NCT02293993|9991688|FG002|Course ≥2 (Extended Treatment Period)|Withdrawal by Subject|1
6281508|NCT02293993|9991689|FG003|Course ≥2 (Extended Treatment Period)|Withdrawal by Subject|0
6281509|NCT02293993|9991686|FG000|Course ≥2 (Extended Treatment Period)|Clear progression of the primary disease including relapses|2
6281510|NCT02293993|9991687|FG001|Course ≥2 (Extended Treatment Period)|Clear progression of the primary disease including relapses|2
6281511|NCT02293993|9991688|FG002|Course ≥2 (Extended Treatment Period)|Clear progression of the primary disease including relapses|3
6281512|NCT02293993|9991689|FG003|Course ≥2 (Extended Treatment Period)|Clear progression of the primary disease including relapses|1
6281513|NCT02293993|9991686|FG000|Course ≥2 (Extended Treatment Period)|Delay in commencement of the next course by more than 4 weeks|0
6281514|NCT02293993|9991687|FG001|Course ≥2 (Extended Treatment Period)|Delay in commencement of the next course by more than 4 weeks|1
6281515|NCT02293993|9991688|FG002|Course ≥2 (Extended Treatment Period)|Delay in commencement of the next course by more than 4 weeks|0
6281516|NCT02293993|9991689|FG003|Course ≥2 (Extended Treatment Period)|Delay in commencement of the next course by more than 4 weeks|0
6281517|NCT02294019|9991707|FG000|Overall Study|Adverse Event|2
6281518|NCT02294019|9991707|FG000|Overall Study|Protocol Violation|68
6281519|NCT02294019|9991707|FG000|Overall Study|Lost to Follow-up|31
6281520|NCT02294019|9991707|FG000|Overall Study|Other|1
6281521|NCT02294019|9991707|FG000|Overall Study|Withdrawal by Subject|1
6281522|NCT02294058|9991714|FG000|Overall Study|Adverse Event|16
6281523|NCT02294058|9991715|FG001|Overall Study|Adverse Event|7
6281524|NCT02294058|9991716|FG002|Overall Study|Adverse Event|13
6281525|NCT02294058|9991714|FG000|Overall Study|Lack of Efficacy|3
6281526|NCT02294058|9991715|FG001|Overall Study|Lack of Efficacy|3
6281527|NCT02294058|9991716|FG002|Overall Study|Lack of Efficacy|0
6281528|NCT02294058|9991714|FG000|Overall Study|Lost to Follow-up|1
6281529|NCT02294058|9991715|FG001|Overall Study|Lost to Follow-up|0
6281530|NCT02294058|9991716|FG002|Overall Study|Lost to Follow-up|2
6281531|NCT02294058|9991714|FG000|Overall Study|Withdrawal by Subject|10
6281532|NCT02294058|9991715|FG001|Overall Study|Withdrawal by Subject|14
6281533|NCT02294058|9991716|FG002|Overall Study|Withdrawal by Subject|13
6281534|NCT02294058|9991714|FG000|Overall Study|Physician Decision|2
6281535|NCT02294058|9991715|FG001|Overall Study|Physician Decision|1
6281536|NCT02294058|9991716|FG002|Overall Study|Physician Decision|0
6281537|NCT02294058|9991714|FG000|Overall Study|Miscellaneous|4
6281538|NCT02294058|9991715|FG001|Overall Study|Miscellaneous|1
6281539|NCT02294058|9991716|FG002|Overall Study|Miscellaneous|1
6281540|NCT02294175|9991727|FG000|Overall Study|Withdrawal by Subject|1
6281541|NCT02294175|9991728|FG001|Overall Study|Withdrawal by Subject|2
6281542|NCT02294175|9991727|FG000|Overall Study|pt taking excluded medication|3
6281543|NCT02294175|9991728|FG001|Overall Study|pt taking excluded medication|1
6281544|NCT02294175|9991727|FG000|Overall Study|Protocol Violation|1
6281545|NCT02294175|9991728|FG001|Overall Study|Protocol Violation|0
6281546|NCT02294175|9991727|FG000|Overall Study|Lost to Follow-up|0
6281547|NCT02294175|9991728|FG001|Overall Study|Lost to Follow-up|1
6281548|NCT02294175|9991727|FG000|Overall Study|wound healed|0
6281549|NCT02294175|9991728|FG001|Overall Study|wound healed|2
6281550|NCT02294227|9991737|FG000|Overall Study|Death|0
6281551|NCT02294227|9991738|FG001|Overall Study|Death|0
6281552|NCT02294227|9991739|FG002|Overall Study|Death|1
6281553|NCT02294227|9991737|FG000|Overall Study|Subject/Guardian Decision|6
6281554|NCT02294227|9991738|FG001|Overall Study|Subject/Guardian Decision|3
6281555|NCT02294227|9991739|FG002|Overall Study|Subject/Guardian Decision|7
6281556|NCT02294227|9991737|FG000|Overall Study|Physician Decision|1
6281557|NCT02294227|9991738|FG001|Overall Study|Physician Decision|2
6281558|NCT02294227|9991739|FG002|Overall Study|Physician Decision|1
6281559|NCT02294227|9991737|FG000|Overall Study|Lost to Follow-up|1
6281560|NCT02294227|9991738|FG001|Overall Study|Lost to Follow-up|0
6281561|NCT02294227|9991739|FG002|Overall Study|Lost to Follow-up|0
6281562|NCT02294227|9991737|FG000|Overall Study|Lack of Efficacy|11
6281563|NCT02294227|9991738|FG001|Overall Study|Lack of Efficacy|12
6281564|NCT02294227|9991739|FG002|Overall Study|Lack of Efficacy|8
6281565|NCT02294227|9991737|FG000|Overall Study|Adverse Event|6
6281566|NCT02294227|9991738|FG001|Overall Study|Adverse Event|8
6281567|NCT02294227|9991739|FG002|Overall Study|Adverse Event|2
6281568|NCT02294318|9991755|FG000|Overall Study|Worsening of drinking|3
6281569|NCT02294318|9991756|FG001|Overall Study|Worsening of drinking|0
6281570|NCT02294318|9991755|FG000|Overall Study|Not exposed to intervention|0
6281571|NCT02294318|9991756|FG001|Overall Study|Not exposed to intervention|2
6281572|NCT02294396|9991766|FG000|Overall Study|Adverse Event|26
6281573|NCT02294396|9991767|FG001|Overall Study|Adverse Event|25
6281574|NCT02294396|9991768|FG002|Overall Study|Adverse Event|21
6281575|NCT02294396|9991769|FG003|Overall Study|Adverse Event|24
6281576|NCT02294396|9991766|FG000|Overall Study|Electrocardiogram adviser's judgment|1
6281577|NCT02294396|9991767|FG001|Overall Study|Electrocardiogram adviser's judgment|0
6281578|NCT02294396|9991768|FG002|Overall Study|Electrocardiogram adviser's judgment|0
6281579|NCT02294396|9991769|FG003|Overall Study|Electrocardiogram adviser's judgment|1
6281580|NCT02294396|9991766|FG000|Overall Study|Withdrawal by Subject|8
6281581|NCT02294396|9991767|FG001|Overall Study|Withdrawal by Subject|6
6281582|NCT02294396|9991768|FG002|Overall Study|Withdrawal by Subject|6
6281583|NCT02294396|9991769|FG003|Overall Study|Withdrawal by Subject|8
5979636|NCT04532294|9568132|FG000|Overall Study|Withdrawal by Subject|0
5979637|NCT04532294|9568133|FG001|Overall Study|Withdrawal by Subject|0
5979638|NCT04532294|9568134|FG002|Overall Study|Withdrawal by Subject|1
6281584|NCT02294396|9991766|FG000|Overall Study|Lost to Follow-up|0
6281585|NCT02294396|9991767|FG001|Overall Study|Lost to Follow-up|0
6281586|NCT02294396|9991768|FG002|Overall Study|Lost to Follow-up|1
6281587|NCT02294396|9991769|FG003|Overall Study|Lost to Follow-up|1
6281588|NCT02294396|9991766|FG000|Overall Study|Protocol Deviation|3
6281589|NCT02294396|9991767|FG001|Overall Study|Protocol Deviation|2
6281590|NCT02294396|9991768|FG002|Overall Study|Protocol Deviation|2
6281591|NCT02294396|9991769|FG003|Overall Study|Protocol Deviation|1
6281592|NCT02294396|9991766|FG000|Overall Study|Miscellaneous|2
6281593|NCT02294396|9991767|FG001|Overall Study|Miscellaneous|0
6281594|NCT02294396|9991768|FG002|Overall Study|Miscellaneous|5
6281595|NCT02294396|9991769|FG003|Overall Study|Miscellaneous|2
6281596|NCT02294474|9991781|FG000|Overall Study|Adverse Event|7
6281597|NCT02294474|9991782|FG001|Overall Study|Adverse Event|7
6281598|NCT02294474|9991781|FG000|Overall Study|Lack of Efficacy|2
6281599|NCT02294474|9991782|FG001|Overall Study|Lack of Efficacy|1
6281600|NCT02294474|9991781|FG000|Overall Study|Protocol Violation|4
6281601|NCT02294474|9991782|FG001|Overall Study|Protocol Violation|2
6281602|NCT02294474|9991781|FG000|Overall Study|Other than specified above|12
6281603|NCT02294474|9991782|FG001|Overall Study|Other than specified above|12
6281604|NCT02294604|9991792|FG000|Overall Study|Did not provide samples for culture|0
6281605|NCT02294604|9991793|FG001|Overall Study|Did not provide samples for culture|1
6281606|NCT02294604|9991794|FG002|Overall Study|Did not provide samples for culture|0
6281607|NCT02294604|9991792|FG000|Overall Study|Culture contamination|1
6281608|NCT02294604|9991793|FG001|Overall Study|Culture contamination|2
6281609|NCT02294604|9991794|FG002|Overall Study|Culture contamination|0
6281610|NCT02294682|9991821|FG000|Overall Study|Could not swallow pills|1
6281611|NCT02294682|9991822|FG001|Overall Study|Could not swallow pills|0
6281612|NCT02294734|9991830|FG000|Overall Study|Adverse Event|5
6281613|NCT02294734|9991831|FG001|Overall Study|Adverse Event|5
6281614|NCT02294734|9991830|FG000|Overall Study|Met Protocol Defined Stopping Criteria|1
5979639|NCT04532294|9568132|FG000|Overall Study|Participants Not Dosed|0
5979640|NCT04532294|9568133|FG001|Overall Study|Participants Not Dosed|0
5979641|NCT04532294|9568134|FG002|Overall Study|Participants Not Dosed|2
6051498|NCT00433290|9650772|FG001|Overall Study|Entry Criteria Not Met|1
6051499|NCT00433290|9650771|FG000|Overall Study|Lost to Follow-up|1
6051500|NCT00433290|9650772|FG001|Overall Study|Lost to Follow-up|0
6051501|NCT00433329|9650778|FG000|Overall Study|Adverse Event|9
6051502|NCT00433329|9650778|FG000|Overall Study|Death|4
6051503|NCT00433329|9650778|FG000|Overall Study|Withdrew consent|3
6051504|NCT00433329|9650778|FG000|Overall Study|Discontinued sildenafil|2
6051505|NCT00433329|9650778|FG000|Overall Study|Moved out of state|1
6051506|NCT00433329|9650778|FG000|Overall Study|Lost to Follow-up|1
6051507|NCT00433329|9650778|FG000|Overall Study|Physician Decision|1
6051508|NCT00433381|9650784|FG000|Overall Study|Ineligible / no protocol treatment|3
6051509|NCT00433381|9650785|FG001|Overall Study|Ineligible / no protocol treatment|3
6051510|NCT00433446|9650799|FG000|Overall Study|Adverse Event|4
6051511|NCT00433446|9650799|FG000|Overall Study|Refusal Unrelated to Adverse Event|1
6051512|NCT00433446|9650799|FG000|Overall Study|Progression|44
6051513|NCT00433446|9650799|FG000|Overall Study|Other - Not Protocol specified|3
6051514|NCT00433446|9650799|FG000|Overall Study|Ineligible|9
6051515|NCT00433537|9650803|FG000|Step 1 - VcR-CVAD Induction|Path ineligible (not having MCL)|1
6051516|NCT00433537|9650804|FG001|Step 1 - VcR-CVAD Induction|Path ineligible (not having MCL)|0
6051517|NCT00433537|9650805|FG002|Step 1 - VcR-CVAD Induction|Path ineligible (not having MCL)|1
6051518|NCT00433537|9650803|FG000|Step 1 - VcR-CVAD Induction|Lack of Efficacy|0
6051519|NCT00433537|9650804|FG001|Step 1 - VcR-CVAD Induction|Lack of Efficacy|0
6051520|NCT00433537|9650805|FG002|Step 1 - VcR-CVAD Induction|Lack of Efficacy|2
6051521|NCT00433537|9650803|FG000|Step 1 - VcR-CVAD Induction|Adverse Event|0
6051522|NCT00433537|9650804|FG001|Step 1 - VcR-CVAD Induction|Adverse Event|0
6051523|NCT00433537|9650805|FG002|Step 1 - VcR-CVAD Induction|Adverse Event|4
6051524|NCT00433537|9650803|FG000|Step 1 - VcR-CVAD Induction|Withdrawal by Subject|0
6051525|NCT00433537|9650804|FG001|Step 1 - VcR-CVAD Induction|Withdrawal by Subject|0
6051526|NCT00433537|9650805|FG002|Step 1 - VcR-CVAD Induction|Withdrawal by Subject|2
6051527|NCT00433537|9650803|FG000|Step 2 - Maintenance Rituximab or ASCT|Path ineligible (not having MCL)|1
6051528|NCT00433537|9650804|FG001|Step 2 - Maintenance Rituximab or ASCT|Path ineligible (not having MCL)|0
6051529|NCT00433537|9650805|FG002|Step 2 - Maintenance Rituximab or ASCT|Path ineligible (not having MCL)|0
6051530|NCT00433537|9650803|FG000|Step 2 - Maintenance Rituximab or ASCT|Lack of Efficacy|8
6051531|NCT00433537|9650804|FG001|Step 2 - Maintenance Rituximab or ASCT|Lack of Efficacy|0
6051532|NCT00433537|9650805|FG002|Step 2 - Maintenance Rituximab or ASCT|Lack of Efficacy|0
6051533|NCT00433537|9650803|FG000|Step 2 - Maintenance Rituximab or ASCT|Adverse Event|2
6051534|NCT00433537|9650804|FG001|Step 2 - Maintenance Rituximab or ASCT|Adverse Event|0
6051535|NCT00433537|9650805|FG002|Step 2 - Maintenance Rituximab or ASCT|Adverse Event|0
6051536|NCT00433537|9650803|FG000|Step 2 - Maintenance Rituximab or ASCT|Alternative therapy|4
6051537|NCT00433537|9650804|FG001|Step 2 - Maintenance Rituximab or ASCT|Alternative therapy|0
6051538|NCT00433537|9650805|FG002|Step 2 - Maintenance Rituximab or ASCT|Alternative therapy|0
6051539|NCT00433537|9650803|FG000|Step 2 - Maintenance Rituximab or ASCT|Other|1
6051540|NCT00433537|9650804|FG001|Step 2 - Maintenance Rituximab or ASCT|Other|0
6281615|NCT02294734|9991831|FG001|Overall Study|Met Protocol Defined Stopping Criteria|0
6281616|NCT02294734|9991830|FG000|Overall Study|Lost to Follow-up|2
6281617|NCT02294734|9991831|FG001|Overall Study|Lost to Follow-up|0
6281618|NCT02294734|9991830|FG000|Overall Study|Physician Decision|2
6281619|NCT02294734|9991831|FG001|Overall Study|Physician Decision|1
6281620|NCT02294734|9991830|FG000|Overall Study|Withdrawal by Subject|4
6281621|NCT02294734|9991831|FG001|Overall Study|Withdrawal by Subject|2
6281622|NCT02294773|9991841|FG000|Overall Study|Withdrawal by Subject|0
6281623|NCT02294773|9991842|FG001|Overall Study|Withdrawal by Subject|2
6281624|NCT02294786|9991850|FG000|Overall Study|Withdrawal by Subject|0
6281625|NCT02294786|9991851|FG001|Overall Study|Withdrawal by Subject|1
6281626|NCT02294786|9991850|FG000|Overall Study|Physician Decision|6
6281627|NCT02294786|9991851|FG001|Overall Study|Physician Decision|7
6281628|NCT02294786|9991850|FG000|Overall Study|Lost to Follow-up|1
6281629|NCT02294786|9991851|FG001|Overall Study|Lost to Follow-up|2
6281630|NCT02294786|9991850|FG000|Overall Study|Protocol Violation|1
6281631|NCT02294786|9991851|FG001|Overall Study|Protocol Violation|0
6281632|NCT02294786|9991850|FG000|Overall Study|Adverse Event|1
6281633|NCT02294786|9991851|FG001|Overall Study|Adverse Event|1
6281634|NCT02294786|9991850|FG000|Overall Study|Death|2
6281635|NCT02294786|9991851|FG001|Overall Study|Death|3
6281636|NCT02295020|9991860|FG000|Overall Study|Adverse Event|0
6281637|NCT02295020|9991861|FG001|Overall Study|Adverse Event|1
6281638|NCT02295020|9991860|FG000|Overall Study|Withdrawal by Subject|3
6281639|NCT02295020|9991861|FG001|Overall Study|Withdrawal by Subject|2
6281640|NCT02295280|9991875|FG000|Overall Study|Adverse Event|0
6281641|NCT02295280|9991876|FG001|Overall Study|Adverse Event|1
6281642|NCT02295644|9991903|FG000|Overall Study|Did not meet inclusion criterion|0
6281643|NCT02295644|9991904|FG001|Overall Study|Did not meet inclusion criterion|0
6281644|NCT02295644|9991905|FG002|Overall Study|Did not meet inclusion criterion|1
6281645|NCT02295644|9991906|FG003|Overall Study|Did not meet inclusion criterion|2
5979642|NCT04250077|9568147|FG000|Overall Study|Withdrawal by Subject|0
5979643|NCT04250077|9568148|FG001|Overall Study|Withdrawal by Subject|1
5979644|NCT04250077|9568149|FG002|Overall Study|Withdrawal by Subject|0
5979645|NCT04250077|9568147|FG000|Overall Study|Lost to Follow-up|2
5979646|NCT04250077|9568148|FG001|Overall Study|Lost to Follow-up|3
5979647|NCT04250077|9568149|FG002|Overall Study|Lost to Follow-up|0
5979648|NCT03505710|9568203|FG000|Overall Study|Progressive Disease|22
5979649|NCT03505710|9568204|FG001|Overall Study|Progressive Disease|9
5979650|NCT03505710|9568205|FG002|Overall Study|Progressive Disease|34
5979651|NCT03505710|9568203|FG000|Overall Study|Clinical Progression|6
5979652|NCT03505710|9568204|FG001|Overall Study|Clinical Progression|6
5979653|NCT03505710|9568205|FG002|Overall Study|Clinical Progression|3
5979654|NCT03505710|9568203|FG000|Overall Study|Adverse Event|12
5979655|NCT03505710|9568204|FG001|Overall Study|Adverse Event|5
5979656|NCT03505710|9568205|FG002|Overall Study|Adverse Event|27
5979657|NCT03505710|9568203|FG000|Overall Study|Withdrawal by Subject|1
5979658|NCT03505710|9568204|FG001|Overall Study|Withdrawal by Subject|3
5979659|NCT03505710|9568205|FG002|Overall Study|Withdrawal by Subject|3
5979660|NCT03505710|9568203|FG000|Overall Study|Physician Decision|1
5979661|NCT03505710|9568204|FG001|Overall Study|Physician Decision|0
5979662|NCT03505710|9568205|FG002|Overall Study|Physician Decision|2
5979663|NCT03505710|9568203|FG000|Overall Study|Death|4
5979664|NCT03505710|9568204|FG001|Overall Study|Death|3
5979665|NCT03505710|9568205|FG002|Overall Study|Death|6
5979666|NCT03505710|9568203|FG000|Overall Study|Other Reasons|1
5979667|NCT03505710|9568204|FG001|Overall Study|Other Reasons|1
5979668|NCT03505710|9568205|FG002|Overall Study|Other Reasons|1
5979669|NCT03296553|9568215|FG000|Overall Study|Withdrawal by Subject|1
5979670|NCT03296553|9568216|FG001|Overall Study|Withdrawal by Subject|1
5979671|NCT03296553|9568215|FG000|Overall Study|Death|1
5979672|NCT03296553|9568216|FG001|Overall Study|Death|0
5979673|NCT03148795|9568222|FG000|Overall Study|Death|6
5979674|NCT03148795|9568222|FG000|Overall Study|Adverse Event|5
5979675|NCT03148795|9568222|FG000|Overall Study|Other|15
5979676|NCT03148795|9568222|FG000|Overall Study|No Longer Clinically Benefitting|2
5979677|NCT03148795|9568222|FG000|Overall Study|Global Deterioration Of Health Status|6
5979678|NCT03148795|9568222|FG000|Overall Study|Withdrawal by Subject|2
5979679|NCT03148795|9568222|FG000|Overall Study|Progressive Disease|62
5979680|NCT03148795|9568222|FG000|Overall Study|Ongoing|30
5979681|NCT03049449|9568234|FG000|Overall Study|Did not receive treatment.|0
5979682|NCT03049449|9568235|FG001|Overall Study|Did not receive treatment.|0
5979683|NCT03049449|9568236|FG002|Overall Study|Did not receive treatment.|0
5979684|NCT03049449|9568237|FG003|Overall Study|Did not receive treatment.|0
5979685|NCT03049449|9568238|FG004|Overall Study|Did not receive treatment.|0
5979686|NCT03049449|9568239|FG005|Overall Study|Did not receive treatment.|0
5979687|NCT03049449|9568240|FG006|Overall Study|Did not receive treatment.|0
5979688|NCT03049449|9568241|FG007|Overall Study|Did not receive treatment.|0
5979689|NCT03049449|9568242|FG008|Overall Study|Did not receive treatment.|1
5979690|NCT03049449|9568243|FG009|Overall Study|Did not receive treatment.|0
5979691|NCT03049449|9568234|FG000|Overall Study|Enrolled and removed from study with no treatment|0
5979692|NCT03049449|9568235|FG001|Overall Study|Enrolled and removed from study with no treatment|0
5979693|NCT03049449|9568236|FG002|Overall Study|Enrolled and removed from study with no treatment|1
5979694|NCT03049449|9568237|FG003|Overall Study|Enrolled and removed from study with no treatment|1
5979695|NCT03049449|9568238|FG004|Overall Study|Enrolled and removed from study with no treatment|0
5979696|NCT03049449|9568239|FG005|Overall Study|Enrolled and removed from study with no treatment|0
5979697|NCT03049449|9568240|FG006|Overall Study|Enrolled and removed from study with no treatment|0
6089290|NCT00683618|9700784|FG002|Extension Treatment Period|Adverse Event|0
6281646|NCT02295774|9991925|FG000|Overall Study|Physician Decision|1
6281647|NCT02295774|9991925|FG000|Overall Study|Withdrawal by Subject|2
6281648|NCT02295995|9991932|FG000|Overall Study|Lost to Follow-up|5
6281649|NCT02295995|9991933|FG001|Overall Study|Lost to Follow-up|1
6281650|NCT02296112|9991949|FG000|Overall Study|Disease progression|7
6281651|NCT02296112|9991949|FG000|Overall Study|Toxicity|1
6281652|NCT02296112|9991949|FG000|Overall Study|Began an alternate therapy|1
6281653|NCT02296138|9991960|FG000|Overall Study|Adverse Event|348
6281654|NCT02296138|9991961|FG001|Overall Study|Adverse Event|259
6281655|NCT02296138|9991960|FG000|Overall Study|Lack of Efficacy|59
6281656|NCT02296138|9991961|FG001|Overall Study|Lack of Efficacy|37
6281657|NCT02296138|9991960|FG000|Overall Study|Protocol Violation|35
6281658|NCT02296138|9991961|FG001|Overall Study|Protocol Violation|36
6281659|NCT02296138|9991960|FG000|Overall Study|Lost to Follow-up|9
6281660|NCT02296138|9991961|FG001|Overall Study|Lost to Follow-up|12
6281661|NCT02296138|9991960|FG000|Overall Study|Withdrawal by Subject|184
6281662|NCT02296138|9991961|FG001|Overall Study|Withdrawal by Subject|131
6281663|NCT02296138|9991960|FG000|Overall Study|Not Treated|1
6281664|NCT02296138|9991961|FG001|Overall Study|Not Treated|1
6281665|NCT02296138|9991960|FG000|Overall Study|Patients with data irregularities|10
6281666|NCT02296138|9991961|FG001|Overall Study|Patients with data irregularities|11
6281667|NCT02296138|9991960|FG000|Overall Study|Other than specified|15
6281668|NCT02296138|9991961|FG001|Overall Study|Other than specified|13
6281669|NCT02296190|9991977|FG000|Overall Study|Lost to Follow-up|0
6281670|NCT02296190|9991978|FG001|Overall Study|Lost to Follow-up|0
6281671|NCT02296190|9991979|FG002|Overall Study|Lost to Follow-up|0
6281672|NCT02296190|9991980|FG003|Overall Study|Lost to Follow-up|0
6281673|NCT02296190|9991981|FG004|Overall Study|Lost to Follow-up|1
6281674|NCT02296190|9991982|FG005|Overall Study|Lost to Follow-up|0
6281675|NCT02296190|9991977|FG000|Overall Study|Failure to induce PSVT|6
6281676|NCT02296190|9991978|FG001|Overall Study|Failure to induce PSVT|10
6281677|NCT02296190|9991979|FG002|Overall Study|Failure to induce PSVT|5
6281678|NCT02296190|9991980|FG003|Overall Study|Failure to induce PSVT|13
6281679|NCT02296190|9991981|FG004|Overall Study|Failure to induce PSVT|8
6281680|NCT02296190|9991982|FG005|Overall Study|Failure to induce PSVT|0
6281681|NCT02296190|9991977|FG000|Overall Study|Physician Decision|1
6281682|NCT02296190|9991978|FG001|Overall Study|Physician Decision|1
6281683|NCT02296190|9991979|FG002|Overall Study|Physician Decision|0
6281684|NCT02296190|9991980|FG003|Overall Study|Physician Decision|1
6281685|NCT02296190|9991981|FG004|Overall Study|Physician Decision|2
6281686|NCT02296190|9991982|FG005|Overall Study|Physician Decision|0
6281687|NCT02296190|9991977|FG000|Overall Study|Withdrawal by Subject|0
6281688|NCT02296190|9991978|FG001|Overall Study|Withdrawal by Subject|1
6281689|NCT02296190|9991979|FG002|Overall Study|Withdrawal by Subject|0
6281690|NCT02296190|9991980|FG003|Overall Study|Withdrawal by Subject|0
6281691|NCT02296190|9991981|FG004|Overall Study|Withdrawal by Subject|0
6281692|NCT02296190|9991982|FG005|Overall Study|Withdrawal by Subject|0
6281693|NCT02296190|9991977|FG000|Overall Study|PSVT < 5 minutes|5
6281694|NCT02296190|9991978|FG001|Overall Study|PSVT < 5 minutes|6
6281695|NCT02296190|9991979|FG002|Overall Study|PSVT < 5 minutes|6
6281696|NCT02296190|9991980|FG003|Overall Study|PSVT < 5 minutes|6
6281697|NCT02296190|9991981|FG004|Overall Study|PSVT < 5 minutes|5
6281698|NCT02296190|9991982|FG005|Overall Study|PSVT < 5 minutes|0
6281699|NCT02296190|9991977|FG000|Overall Study|Patient was given Propofol|0
6281700|NCT02296190|9991978|FG001|Overall Study|Patient was given Propofol|1
5979698|NCT03049449|9568241|FG007|Overall Study|Enrolled and removed from study with no treatment|0
5979699|NCT03049449|9568242|FG008|Overall Study|Enrolled and removed from study with no treatment|0
5979700|NCT03049449|9568243|FG009|Overall Study|Enrolled and removed from study with no treatment|0
5979701|NCT03049449|9568234|FG000|Overall Study|Chemotherapy was started and not finished & no Chimeric Antigen Receptor T-cells were administered.|0
5979702|NCT03049449|9568235|FG001|Overall Study|Chemotherapy was started and not finished & no Chimeric Antigen Receptor T-cells were administered.|0
6089291|NCT00683618|9700782|FG000|Extension Treatment Period|Protocol Violation|1
6089292|NCT00683618|9700783|FG001|Extension Treatment Period|Protocol Violation|0
6281701|NCT02296190|9991979|FG002|Overall Study|Patient was given Propofol|0
6281702|NCT02296190|9991980|FG003|Overall Study|Patient was given Propofol|1
6281703|NCT02296190|9991981|FG004|Overall Study|Patient was given Propofol|0
6281704|NCT02296190|9991982|FG005|Overall Study|Patient was given Propofol|0
6281705|NCT02296190|9991977|FG000|Overall Study|Patient with Atrial Tachycardia|0
6281706|NCT02296190|9991978|FG001|Overall Study|Patient with Atrial Tachycardia|0
6281707|NCT02296190|9991979|FG002|Overall Study|Patient with Atrial Tachycardia|0
6281708|NCT02296190|9991980|FG003|Overall Study|Patient with Atrial Tachycardia|1
6281709|NCT02296190|9991981|FG004|Overall Study|Patient with Atrial Tachycardia|0
6281710|NCT02296190|9991982|FG005|Overall Study|Patient with Atrial Tachycardia|0
6281711|NCT02296190|9991977|FG000|Overall Study|Blood pressure <100 after sedation|0
6281712|NCT02296190|9991978|FG001|Overall Study|Blood pressure <100 after sedation|0
6281713|NCT02296190|9991979|FG002|Overall Study|Blood pressure <100 after sedation|0
6281714|NCT02296190|9991980|FG003|Overall Study|Blood pressure <100 after sedation|1
6281715|NCT02296190|9991981|FG004|Overall Study|Blood pressure <100 after sedation|0
6281716|NCT02296190|9991982|FG005|Overall Study|Blood pressure <100 after sedation|0
6281717|NCT02296190|9991977|FG000|Overall Study|Atrial Tachycardia induced not PSVT|0
6281718|NCT02296190|9991978|FG001|Overall Study|Atrial Tachycardia induced not PSVT|1
6281719|NCT02296190|9991979|FG002|Overall Study|Atrial Tachycardia induced not PSVT|1
6281720|NCT02296190|9991980|FG003|Overall Study|Atrial Tachycardia induced not PSVT|0
6281721|NCT02296190|9991981|FG004|Overall Study|Atrial Tachycardia induced not PSVT|0
6281722|NCT02296190|9991982|FG005|Overall Study|Atrial Tachycardia induced not PSVT|0
6281723|NCT02296190|9991977|FG000|Overall Study|Patient on antiarrhythmic medication|1
6281724|NCT02296190|9991978|FG001|Overall Study|Patient on antiarrhythmic medication|0
6281725|NCT02296190|9991979|FG002|Overall Study|Patient on antiarrhythmic medication|0
6281726|NCT02296190|9991980|FG003|Overall Study|Patient on antiarrhythmic medication|0
6281727|NCT02296190|9991981|FG004|Overall Study|Patient on antiarrhythmic medication|0
6281728|NCT02296190|9991982|FG005|Overall Study|Patient on antiarrhythmic medication|0
6281729|NCT02296190|9991977|FG000|Overall Study|Failed PSVT with mechanism of AVNRT|0
6281730|NCT02296190|9991978|FG001|Overall Study|Failed PSVT with mechanism of AVNRT|1
6281731|NCT02296190|9991979|FG002|Overall Study|Failed PSVT with mechanism of AVNRT|0
6051541|NCT00433537|9650805|FG002|Step 2 - Maintenance Rituximab or ASCT|Other|0
6089293|NCT00683618|9700784|FG002|Extension Treatment Period|Protocol Violation|0
6089294|NCT00683644|9700796|FG000|Overall Study|Withdrawal by Subject|4
6089295|NCT00683644|9700797|FG001|Overall Study|Withdrawal by Subject|2
6089296|NCT00683644|9700796|FG000|Overall Study|Lost to Follow-up|1
6089297|NCT00683644|9700797|FG001|Overall Study|Lost to Follow-up|4
6089298|NCT00683644|9700796|FG000|Overall Study|Adverse Event|1
6089299|NCT00683644|9700797|FG001|Overall Study|Adverse Event|2
6089300|NCT00683644|9700796|FG000|Overall Study|Low copper, other health problems,|7
6089301|NCT00683644|9700797|FG001|Overall Study|Low copper, other health problems,|6
6089302|NCT00683657|9700809|FG000|Overall Study|Adverse Event|0
6089303|NCT00683657|9700810|FG001|Overall Study|Adverse Event|1
6089304|NCT00683657|9700809|FG000|Overall Study|Subject Withdrew Consent|1
6089305|NCT00683657|9700810|FG001|Overall Study|Subject Withdrew Consent|0
6089306|NCT00683696|9700818|FG000|Overall Study|Withdrawn due to study closure|337
6089307|NCT00683696|9700819|FG001|Overall Study|Withdrawn due to study closure|338
6089308|NCT00683696|9700818|FG000|Overall Study|Withdrawn prior to study closure|13
6089309|NCT00683696|9700819|FG001|Overall Study|Withdrawn prior to study closure|28
6089310|NCT00683696|9700818|FG000|Overall Study|Lost to Follow-up|5
6089311|NCT00683696|9700819|FG001|Overall Study|Lost to Follow-up|6
6089312|NCT00683696|9700818|FG000|Overall Study|Vital status follow-up only|3
6089313|NCT00683696|9700819|FG001|Overall Study|Vital status follow-up only|3
6089314|NCT00683696|9700818|FG000|Overall Study|Death|46
6089315|NCT00683696|9700819|FG001|Overall Study|Death|30
6089316|NCT00683774|9700828|FG000|Overall Study|Withdrawal by Subject|0
6089317|NCT00683774|9700829|FG001|Overall Study|Withdrawal by Subject|1
6089318|NCT00683774|9700828|FG000|Overall Study|Physician Decision|3
6089319|NCT00683774|9700829|FG001|Overall Study|Physician Decision|0
6089320|NCT00683800|9700837|FG000|Overall Study|Adverse Event|195
6089321|NCT00683800|9700838|FG001|Overall Study|Adverse Event|102
6089322|NCT00683800|9700837|FG000|Overall Study|Death|0
6089323|NCT00683800|9700838|FG001|Overall Study|Death|1
6089324|NCT00683800|9700837|FG000|Overall Study|Lost to Follow-up|57
6281732|NCT02296190|9991980|FG003|Overall Study|Failed PSVT with mechanism of AVNRT|0
6281733|NCT02296190|9991981|FG004|Overall Study|Failed PSVT with mechanism of AVNRT|0
6281734|NCT02296190|9991982|FG005|Overall Study|Failed PSVT with mechanism of AVNRT|0
6281735|NCT02296190|9991977|FG000|Overall Study|Lab result not available in time|1
6281736|NCT02296190|9991978|FG001|Overall Study|Lab result not available in time|0
6281737|NCT02296190|9991979|FG002|Overall Study|Lab result not available in time|0
6281738|NCT02296190|9991980|FG003|Overall Study|Lab result not available in time|0
5979703|NCT03049449|9568236|FG002|Overall Study|Chemotherapy was started and not finished & no Chimeric Antigen Receptor T-cells were administered.|0
5979704|NCT03049449|9568237|FG003|Overall Study|Chemotherapy was started and not finished & no Chimeric Antigen Receptor T-cells were administered.|0
5979705|NCT03049449|9568238|FG004|Overall Study|Chemotherapy was started and not finished & no Chimeric Antigen Receptor T-cells were administered.|0
5979706|NCT03049449|9568239|FG005|Overall Study|Chemotherapy was started and not finished & no Chimeric Antigen Receptor T-cells were administered.|0
5979707|NCT03049449|9568240|FG006|Overall Study|Chemotherapy was started and not finished & no Chimeric Antigen Receptor T-cells were administered.|0
5979708|NCT03049449|9568241|FG007|Overall Study|Chemotherapy was started and not finished & no Chimeric Antigen Receptor T-cells were administered.|1
5979709|NCT03049449|9568242|FG008|Overall Study|Chemotherapy was started and not finished & no Chimeric Antigen Receptor T-cells were administered.|0
5979710|NCT03049449|9568243|FG009|Overall Study|Chemotherapy was started and not finished & no Chimeric Antigen Receptor T-cells were administered.|1
5979711|NCT03000569|9568263|FG000|Overall Study|Withdrawal by Subject|1
5979712|NCT03000569|9568264|FG001|Overall Study|Withdrawal by Subject|0
5979713|NCT03000530|9568281|FG000|Overall Study|Adverse Event|0
5979714|NCT03000530|9568282|FG001|Overall Study|Adverse Event|0
5979715|NCT03000530|9568283|FG002|Overall Study|Adverse Event|2
5979716|NCT03000530|9568281|FG000|Overall Study|Lost to Follow-up|0
5979717|NCT03000530|9568282|FG001|Overall Study|Lost to Follow-up|3
5979718|NCT03000530|9568283|FG002|Overall Study|Lost to Follow-up|1
5979719|NCT03000530|9568281|FG000|Overall Study|Withdrawal by Subject|0
5979720|NCT03000530|9568282|FG001|Overall Study|Withdrawal by Subject|2
5979721|NCT03000530|9568283|FG002|Overall Study|Withdrawal by Subject|1
5979722|NCT02978781|9568297|FG000|Part A|Adverse Event|1
5979723|NCT02978781|9568298|FG001|Part A|Adverse Event|1
5979724|NCT02978781|9568299|FG002|Part A|Adverse Event|0
5979725|NCT02978781|9568300|FG003|Part A|Adverse Event|0
5979726|NCT02978781|9568301|FG004|Part A|Adverse Event|0
5979727|NCT02978781|9568297|FG000|Part A|Withdrawal by Subject|0
5979728|NCT02978781|9568298|FG001|Part A|Withdrawal by Subject|1
5979729|NCT02978781|9568299|FG002|Part A|Withdrawal by Subject|0
5979730|NCT02978781|9568300|FG003|Part A|Withdrawal by Subject|0
5979731|NCT02978781|9568301|FG004|Part A|Withdrawal by Subject|0
5979732|NCT02978781|9568297|FG000|Part B|Withdrawal by Subject|0
5979733|NCT02978781|9568298|FG001|Part B|Withdrawal by Subject|0
5979734|NCT02978781|9568299|FG002|Part B|Withdrawal by Subject|0
5979735|NCT02978781|9568300|FG003|Part B|Withdrawal by Subject|1
5979736|NCT02978781|9568301|FG004|Part B|Withdrawal by Subject|0
5979737|NCT02978781|9568297|FG000|Part C|Adverse Event|0
5979738|NCT02978781|9568298|FG001|Part C|Adverse Event|0
5979739|NCT02978781|9568299|FG002|Part C|Adverse Event|0
5979740|NCT02978781|9568300|FG003|Part C|Adverse Event|0
5979741|NCT02978781|9568301|FG004|Part C|Adverse Event|2
5979742|NCT02978781|9568297|FG000|Part C|Withdrawal by Subject|0
5979743|NCT02978781|9568298|FG001|Part C|Withdrawal by Subject|0
5979744|NCT02978781|9568299|FG002|Part C|Withdrawal by Subject|0
5979745|NCT02978781|9568300|FG003|Part C|Withdrawal by Subject|0
5979746|NCT02978781|9568301|FG004|Part C|Withdrawal by Subject|1
5979747|NCT02978781|9568297|FG000|Part C|Tremor not improved due to Topamax discontinuation|0
5979748|NCT02978781|9568298|FG001|Part C|Tremor not improved due to Topamax discontinuation|0
5979749|NCT02978781|9568299|FG002|Part C|Tremor not improved due to Topamax discontinuation|0
5979750|NCT02978781|9568300|FG003|Part C|Tremor not improved due to Topamax discontinuation|0
5979751|NCT02978781|9568301|FG004|Part C|Tremor not improved due to Topamax discontinuation|1
5979752|NCT02964507|9568335|FG000|Overall Study|Protocol specified Withdrawal criteria met|0
5979753|NCT02964507|9568336|FG001|Overall Study|Protocol specified Withdrawal criteria met|1
5979754|NCT02964507|9568337|FG002|Overall Study|Protocol specified Withdrawal criteria met|0
5979755|NCT02964507|9568338|FG003|Overall Study|Protocol specified Withdrawal criteria met|0
5979756|NCT02964507|9568339|FG004|Overall Study|Protocol specified Withdrawal criteria met|1
5979757|NCT02964507|9568340|FG005|Overall Study|Protocol specified Withdrawal criteria met|0
5979758|NCT02964507|9568341|FG006|Overall Study|Protocol specified Withdrawal criteria met|0
5979759|NCT02964507|9568342|FG007|Overall Study|Protocol specified Withdrawal criteria met|0
5979760|NCT02964507|9568335|FG000|Overall Study|Ongoing at the time of analysis|1
5979761|NCT02964507|9568336|FG001|Overall Study|Ongoing at the time of analysis|0
5979762|NCT02964507|9568337|FG002|Overall Study|Ongoing at the time of analysis|2
5979763|NCT02964507|9568338|FG003|Overall Study|Ongoing at the time of analysis|0
5979764|NCT02964507|9568339|FG004|Overall Study|Ongoing at the time of analysis|0
5979765|NCT02964507|9568340|FG005|Overall Study|Ongoing at the time of analysis|0
5979766|NCT02964507|9568341|FG006|Overall Study|Ongoing at the time of analysis|0
6281739|NCT02296190|9991981|FG004|Overall Study|Lab result not available in time|0
6281740|NCT02296190|9991982|FG005|Overall Study|Lab result not available in time|0
5979767|NCT02964507|9568342|FG007|Overall Study|Ongoing at the time of analysis|0
6281741|NCT02296242|9992000|FG000|Overall Study|Death|1
6281742|NCT02296242|9992001|FG001|Overall Study|Death|1
6089325|NCT00683800|9700838|FG001|Overall Study|Lost to Follow-up|44
6089326|NCT00683800|9700837|FG000|Overall Study|Other|5
6089327|NCT00683800|9700838|FG001|Overall Study|Other|2
6089328|NCT00683800|9700837|FG000|Overall Study|Protocol Violation|13
6089329|NCT00683800|9700838|FG001|Overall Study|Protocol Violation|16
6089330|NCT00683800|9700837|FG000|Overall Study|Withdrawal by Subject|66
6089331|NCT00683800|9700838|FG001|Overall Study|Withdrawal by Subject|64
6089332|NCT00683800|9700837|FG000|Overall Study|Lack of Efficacy|61
6089333|NCT00683800|9700838|FG001|Overall Study|Lack of Efficacy|104
6089334|NCT00683800|9700837|FG000|Overall Study|Randomized, not treated|35
6089335|NCT00683800|9700838|FG001|Overall Study|Randomized, not treated|33
6089336|NCT00683878|9700877|FG000|Overall Study|Lack of Efficacy|3
6089337|NCT00683878|9700878|FG001|Overall Study|Lack of Efficacy|0
6089338|NCT00683878|9700879|FG002|Overall Study|Lack of Efficacy|1
6089339|NCT00683878|9700877|FG000|Overall Study|Adverse Event|4
6281743|NCT02296242|9992002|FG002|Overall Study|Death|1
6281744|NCT02296242|9992003|FG003|Overall Study|Death|1
6281745|NCT02296242|9992004|FG004|Overall Study|Death|1
6281746|NCT02296242|9992000|FG000|Overall Study|Withdrawal by Subject|0
6281747|NCT02296242|9992001|FG001|Overall Study|Withdrawal by Subject|0
6281748|NCT02296242|9992002|FG002|Overall Study|Withdrawal by Subject|1
6281749|NCT02296242|9992003|FG003|Overall Study|Withdrawal by Subject|1
6281750|NCT02296242|9992004|FG004|Overall Study|Withdrawal by Subject|3
6281751|NCT02296242|9992000|FG000|Overall Study|Disease Progression|1
5979768|NCT02964507|9568335|FG000|Overall Study|Study terminated by Sponsor|9
5979769|NCT02964507|9568336|FG001|Overall Study|Study terminated by Sponsor|1
5979770|NCT02964507|9568337|FG002|Overall Study|Study terminated by Sponsor|9
5979771|NCT02964507|9568338|FG003|Overall Study|Study terminated by Sponsor|3
5979772|NCT02964507|9568339|FG004|Overall Study|Study terminated by Sponsor|3
5979773|NCT02964507|9568340|FG005|Overall Study|Study terminated by Sponsor|2
6281752|NCT02296242|9992001|FG001|Overall Study|Disease Progression|3
6281753|NCT02296242|9992002|FG002|Overall Study|Disease Progression|2
6281754|NCT02296242|9992003|FG003|Overall Study|Disease Progression|8
6281755|NCT02296242|9992004|FG004|Overall Study|Disease Progression|11
6281756|NCT02296242|9992000|FG000|Overall Study|Unacceptable Toxicity|0
6281757|NCT02296242|9992001|FG001|Overall Study|Unacceptable Toxicity|0
6281758|NCT02296242|9992002|FG002|Overall Study|Unacceptable Toxicity|0
6281759|NCT02296242|9992003|FG003|Overall Study|Unacceptable Toxicity|0
6281760|NCT02296242|9992004|FG004|Overall Study|Unacceptable Toxicity|1
6281761|NCT02296242|9992000|FG000|Overall Study|Patient Condition Changed|0
6281762|NCT02296242|9992001|FG001|Overall Study|Patient Condition Changed|0
6281763|NCT02296242|9992002|FG002|Overall Study|Patient Condition Changed|2
6281764|NCT02296242|9992003|FG003|Overall Study|Patient Condition Changed|0
6281765|NCT02296242|9992004|FG004|Overall Study|Patient Condition Changed|1
6281766|NCT02296242|9992000|FG000|Overall Study|At Least 3 Drug Interruptions|0
6281767|NCT02296242|9992001|FG001|Overall Study|At Least 3 Drug Interruptions|0
6281768|NCT02296242|9992002|FG002|Overall Study|At Least 3 Drug Interruptions|1
6281769|NCT02296242|9992003|FG003|Overall Study|At Least 3 Drug Interruptions|1
6281770|NCT02296242|9992004|FG004|Overall Study|At Least 3 Drug Interruptions|1
6281771|NCT02296242|9992000|FG000|Overall Study|Lost to Follow-up|1
6281772|NCT02296242|9992001|FG001|Overall Study|Lost to Follow-up|0
6281773|NCT02296242|9992002|FG002|Overall Study|Lost to Follow-up|0
6281774|NCT02296242|9992003|FG003|Overall Study|Lost to Follow-up|0
6281775|NCT02296242|9992004|FG004|Overall Study|Lost to Follow-up|0
6281776|NCT02296242|9992000|FG000|Overall Study|Need for Hydroxyurea|2
6281777|NCT02296242|9992001|FG001|Overall Study|Need for Hydroxyurea|0
6281778|NCT02296242|9992002|FG002|Overall Study|Need for Hydroxyurea|0
6281779|NCT02296242|9992003|FG003|Overall Study|Need for Hydroxyurea|0
6281780|NCT02296242|9992004|FG004|Overall Study|Need for Hydroxyurea|0
6281781|NCT02296242|9992000|FG000|Overall Study|Screened for Other Protocol|0
6281782|NCT02296242|9992001|FG001|Overall Study|Screened for Other Protocol|1
6281783|NCT02296242|9992002|FG002|Overall Study|Screened for Other Protocol|0
6281784|NCT02296242|9992003|FG003|Overall Study|Screened for Other Protocol|0
6281785|NCT02296242|9992004|FG004|Overall Study|Screened for Other Protocol|0
6281786|NCT02296242|9992000|FG000|Overall Study|Physician Decision|0
6281787|NCT02296242|9992001|FG001|Overall Study|Physician Decision|1
6281788|NCT02296242|9992002|FG002|Overall Study|Physician Decision|0
6281789|NCT02296242|9992003|FG003|Overall Study|Physician Decision|1
6281790|NCT02296242|9992004|FG004|Overall Study|Physician Decision|0
6281791|NCT02296242|9992000|FG000|Overall Study|Alternative Treatment|0
6281792|NCT02296242|9992001|FG001|Overall Study|Alternative Treatment|0
6281793|NCT02296242|9992002|FG002|Overall Study|Alternative Treatment|0
6281794|NCT02296242|9992003|FG003|Overall Study|Alternative Treatment|1
6281795|NCT02296242|9992004|FG004|Overall Study|Alternative Treatment|0
6281796|NCT02296242|9992000|FG000|Overall Study|Adverse Event|0
6281797|NCT02296242|9992001|FG001|Overall Study|Adverse Event|0
6281798|NCT02296242|9992002|FG002|Overall Study|Adverse Event|0
5979774|NCT02964507|9568341|FG006|Overall Study|Study terminated by Sponsor|0
6089340|NCT00683878|9700878|FG001|Overall Study|Adverse Event|3
6089341|NCT00683878|9700879|FG002|Overall Study|Adverse Event|3
6089342|NCT00683878|9700877|FG000|Overall Study|Withdrawal by Subject|9
6281799|NCT02296242|9992003|FG003|Overall Study|Adverse Event|1
6281800|NCT02296242|9992004|FG004|Overall Study|Adverse Event|0
6281801|NCT02296242|9992000|FG000|Overall Study|Lack of Efficacy|0
6281802|NCT02296242|9992001|FG001|Overall Study|Lack of Efficacy|0
6281803|NCT02296242|9992002|FG002|Overall Study|Lack of Efficacy|0
6281804|NCT02296242|9992003|FG003|Overall Study|Lack of Efficacy|0
6281805|NCT02296242|9992004|FG004|Overall Study|Lack of Efficacy|3
6281806|NCT02296320|9992027|FG000|Overall Study|Withdrawal by Subject|4
6281807|NCT02296320|9992028|FG001|Overall Study|Withdrawal by Subject|0
6281808|NCT02296320|9992029|FG002|Overall Study|Withdrawal by Subject|2
6281809|NCT02296320|9992027|FG000|Overall Study|Death|24
6281810|NCT02296320|9992028|FG001|Overall Study|Death|3
6281811|NCT02296320|9992029|FG002|Overall Study|Death|27
6281812|NCT02296320|9992027|FG000|Overall Study|Lost to Follow-up|5
6281813|NCT02296320|9992028|FG001|Overall Study|Lost to Follow-up|2
6281814|NCT02296320|9992029|FG002|Overall Study|Lost to Follow-up|7
6281815|NCT02296320|9992027|FG000|Overall Study|Not treated|2
6281816|NCT02296320|9992028|FG001|Overall Study|Not treated|0
6281817|NCT02296320|9992029|FG002|Overall Study|Not treated|0
6281818|NCT02296320|9992027|FG000|Overall Study|Not - specified|0
6281819|NCT02296320|9992028|FG001|Overall Study|Not - specified|0
6281820|NCT02296320|9992029|FG002|Overall Study|Not - specified|1
6281821|NCT02296424|9992052|FG000|Part 1|New therapy for study indication|0
6281822|NCT02296424|9992053|FG001|Part 1|New therapy for study indication|1
6281823|NCT02296424|9992054|FG002|Part 1|New therapy for study indication|0
6281824|NCT02296424|9992055|FG003|Part 1|New therapy for study indication|0
6281825|NCT02296424|9992052|FG000|Part 1|Protocol Violation|0
6281826|NCT02296424|9992053|FG001|Part 1|Protocol Violation|1
6281827|NCT02296424|9992054|FG002|Part 1|Protocol Violation|0
6281828|NCT02296424|9992055|FG003|Part 1|Protocol Violation|0
6281829|NCT02296424|9992052|FG000|Part 1|Withdrawal by Subject|0
6281830|NCT02296424|9992053|FG001|Part 1|Withdrawal by Subject|2
6281831|NCT02296424|9992054|FG002|Part 1|Withdrawal by Subject|0
6281832|NCT02296424|9992055|FG003|Part 1|Withdrawal by Subject|0
6281833|NCT02296424|9992052|FG000|Part 1|Study terminated by sponsor|0
6281834|NCT02296424|9992053|FG001|Part 1|Study terminated by sponsor|1
6281835|NCT02296424|9992054|FG002|Part 1|Study terminated by sponsor|0
6281836|NCT02296424|9992055|FG003|Part 1|Study terminated by sponsor|0
6281837|NCT02296424|9992052|FG000|Part 1|Adverse Event|2
6281838|NCT02296424|9992053|FG001|Part 1|Adverse Event|11
6281839|NCT02296424|9992054|FG002|Part 1|Adverse Event|0
6281840|NCT02296424|9992055|FG003|Part 1|Adverse Event|0
6281841|NCT02296424|9992052|FG000|Part 1|Lack of Efficacy|5
6281842|NCT02296424|9992053|FG001|Part 1|Lack of Efficacy|17
6281843|NCT02296424|9992054|FG002|Part 1|Lack of Efficacy|0
6281844|NCT02296424|9992055|FG003|Part 1|Lack of Efficacy|0
6281845|NCT02296424|9992052|FG000|Part 1|16 directly started part II|16
6281846|NCT02296424|9992053|FG001|Part 1|16 directly started part II|0
6281847|NCT02296424|9992054|FG002|Part 1|16 directly started part II|0
6281848|NCT02296424|9992055|FG003|Part 1|16 directly started part II|0
6281849|NCT02296424|9992052|FG000|Part 2|Lack of Efficacy|0
6281850|NCT02296424|9992053|FG001|Part 2|Lack of Efficacy|0
6281851|NCT02296424|9992054|FG002|Part 2|Lack of Efficacy|1
6281852|NCT02296424|9992055|FG003|Part 2|Lack of Efficacy|0
6281853|NCT02296424|9992052|FG000|Part 2|Adverse Event|0
6281854|NCT02296424|9992053|FG001|Part 2|Adverse Event|0
6281855|NCT02296424|9992054|FG002|Part 2|Adverse Event|1
6281856|NCT02296424|9992055|FG003|Part 2|Adverse Event|0
6281857|NCT02296424|9992052|FG000|Part 2|Lost to Follow-up|0
6281858|NCT02296424|9992053|FG001|Part 2|Lost to Follow-up|0
6281859|NCT02296424|9992054|FG002|Part 2|Lost to Follow-up|1
5979775|NCT02964507|9568342|FG007|Overall Study|Study terminated by Sponsor|0
5979776|NCT02964507|9568335|FG000|Overall Study|Other|3
5979777|NCT02964507|9568336|FG001|Overall Study|Other|0
5979778|NCT02964507|9568337|FG002|Overall Study|Other|0
5979779|NCT02964507|9568338|FG003|Overall Study|Other|0
5979780|NCT02964507|9568339|FG004|Overall Study|Other|1
5979781|NCT02964507|9568340|FG005|Overall Study|Other|0
5979782|NCT02964507|9568341|FG006|Overall Study|Other|0
5979783|NCT02964507|9568342|FG007|Overall Study|Other|0
5979784|NCT02964507|9568335|FG000|Overall Study|Death|11
6051542|NCT00433654|9650827|FG000|Overall Study|Death|4
6281860|NCT02296424|9992055|FG003|Part 2|Lost to Follow-up|0
6281861|NCT02296476|9992066|FG000|Overall Study|Disease Progression|6
6281862|NCT02296476|9992067|FG001|Overall Study|Disease Progression|4
6281863|NCT02296476|9992068|FG002|Overall Study|Disease Progression|2
6281864|NCT02296840|9992115|FG000|Overall Study|Adverse Event|1
6281865|NCT02296840|9992116|FG001|Overall Study|Adverse Event|1
6281866|NCT02296840|9992115|FG000|Overall Study|Protocol Violation|2
6281867|NCT02296840|9992116|FG001|Overall Study|Protocol Violation|1
6281868|NCT02296840|9992115|FG000|Overall Study|Lost to Follow-up|6
6281869|NCT02296840|9992116|FG001|Overall Study|Lost to Follow-up|17
5979785|NCT02964507|9568336|FG001|Overall Study|Death|9
5979786|NCT02964507|9568337|FG002|Overall Study|Death|12
6281870|NCT02296892|9992134|FG000|Overall Study|Exclusion Criteria at Day of Procedure|7
6281871|NCT02296892|9992135|FG001|Overall Study|Exclusion Criteria at Day of Procedure|4
6281872|NCT02296892|9992136|FG002|Overall Study|Exclusion Criteria at Day of Procedure|4
6281873|NCT02296892|9992134|FG000|Overall Study|Lost to Follow-up|5
6281874|NCT02296892|9992135|FG001|Overall Study|Lost to Follow-up|0
6281875|NCT02296892|9992136|FG002|Overall Study|Lost to Follow-up|1
6281876|NCT02296931|9992146|FG000|Overall Study|Protocol Violation|0
6281877|NCT02296931|9992147|FG001|Overall Study|Protocol Violation|2
6281878|NCT02297503|9992169|FG000|Overall Study|Withdrawal by Subject|1
6281879|NCT02297503|9992170|FG001|Overall Study|Withdrawal by Subject|1
6281880|NCT02297503|9992169|FG000|Overall Study|Protocol Violation|1
6281881|NCT02297503|9992170|FG001|Overall Study|Protocol Violation|0
6281882|NCT02297503|9992169|FG000|Overall Study|Pregnancy|0
6281883|NCT02297503|9992170|FG001|Overall Study|Pregnancy|1
6281884|NCT02297503|9992169|FG000|Overall Study|Lost to Follow-up|0
6281885|NCT02297503|9992170|FG001|Overall Study|Lost to Follow-up|1
6281886|NCT02297503|9992169|FG000|Overall Study|Medical reason|0
6281887|NCT02297503|9992170|FG001|Overall Study|Medical reason|1
6281888|NCT02297516|9992187|FG000|Single Treatment Phase (6 Months)|Medical reason|1
6281889|NCT02297516|9992188|FG001|Single Treatment Phase (6 Months)|Medical reason|0
6281890|NCT02297516|9992187|FG000|Single Treatment Phase (6 Months)|Protocol Violation|0
6281891|NCT02297516|9992188|FG001|Single Treatment Phase (6 Months)|Protocol Violation|2
6281892|NCT02297516|9992187|FG000|Combination Treatment Phase (up to 18 m)|Withdrawal by Subject|0
6281893|NCT02297516|9992188|FG001|Combination Treatment Phase (up to 18 m)|Withdrawal by Subject|1
6281894|NCT02297815|9992203|FG000|Overall Study|Lost to Follow-up|236
6281895|NCT02297815|9992204|FG001|Overall Study|Lost to Follow-up|140
6281896|NCT02297841|9992212|FG000|Overall Study|Withdrawal by Subject|1
6281897|NCT02297841|9992212|FG000|Overall Study|Protocol Violation|7
6281898|NCT02298023|9992219|FG000|Overall Study|Withdrawal by Subject|1
6281899|NCT02298023|9992220|FG001|Overall Study|Withdrawal by Subject|0
6281900|NCT02298023|9992221|FG002|Overall Study|Withdrawal by Subject|0
6281901|NCT02298179|9992244|FG000|Overall Study|Lost to Follow-up|0
6281902|NCT02298179|9992245|FG001|Overall Study|Lost to Follow-up|0
6281903|NCT02298179|9992246|FG002|Overall Study|Lost to Follow-up|1
6281904|NCT02298179|9992247|FG003|Overall Study|Lost to Follow-up|0
6281905|NCT02298179|9992248|FG004|Overall Study|Lost to Follow-up|0
6281906|NCT02298179|9992249|FG005|Overall Study|Lost to Follow-up|0
6281907|NCT02298179|9992250|FG006|Overall Study|Lost to Follow-up|0
6281908|NCT02298179|9992251|FG007|Overall Study|Lost to Follow-up|1
6281909|NCT02298179|9992252|FG008|Overall Study|Lost to Follow-up|0
6281910|NCT02298179|9992253|FG009|Overall Study|Lost to Follow-up|0
6281911|NCT02298179|9992254|FG010|Overall Study|Lost to Follow-up|0
6281912|NCT02298179|9992255|FG011|Overall Study|Lost to Follow-up|0
6281913|NCT02298192|9992283|FG000|Overall Study|Unclassified|3
6281914|NCT02298192|9992284|FG001|Overall Study|Unclassified|2
6281915|NCT02298192|9992283|FG000|Overall Study|Withdrawal criteria|2
6281916|NCT02298192|9992284|FG001|Overall Study|Withdrawal criteria|0
6281917|NCT02298192|9992283|FG000|Overall Study|Withdrawal by Subject|6
6281918|NCT02298192|9992284|FG001|Overall Study|Withdrawal by Subject|1
6281919|NCT02298192|9992283|FG000|Overall Study|Lost to Follow-up|2
6281920|NCT02298192|9992284|FG001|Overall Study|Lost to Follow-up|1
6281921|NCT02298192|9992283|FG000|Overall Study|Adverse Event|6
6281922|NCT02298192|9992284|FG001|Overall Study|Adverse Event|2
6281923|NCT02298868|9992336|FG000|Overall Study|Adverse Event|1
6281924|NCT02298868|9992336|FG000|Overall Study|Death|1
6281925|NCT02298868|9992336|FG000|Overall Study|Patient underwent transplant|1
6281926|NCT02298946|9992346|FG000|Overall Study|Did not receive treatment|2
6281927|NCT02298946|9992347|FG001|Overall Study|Did not receive treatment|0
6281928|NCT02298946|9992346|FG000|Overall Study|Unevaluable|2
6281929|NCT02298946|9992347|FG001|Overall Study|Unevaluable|1
6281930|NCT02299076|9992360|FG000|Overall Study|Fraudulent Entries|20
6281931|NCT02299076|9992361|FG001|Overall Study|Fraudulent Entries|14
6281932|NCT02299167|9992405|FG000|Overall Study|patients were excluded from the study|11
6281933|NCT02299336|9992422|FG000|Overall Study|Withdrawal by Subject|11
6281934|NCT02299336|9992422|FG000|Overall Study|Adverse Event|1
6281935|NCT02299336|9992422|FG000|Overall Study|Death|1
6281936|NCT02299336|9992422|FG000|Overall Study|Lost to Follow-up|1
6281937|NCT02299375|9992437|FG000|Overall Study|Adverse Event, serious fatal|1
6281938|NCT02299375|9992438|FG001|Overall Study|Adverse Event, serious fatal|3
6281939|NCT02299375|9992437|FG000|Overall Study|Adverse Event, non-fatal|8
6281940|NCT02299375|9992438|FG001|Overall Study|Adverse Event, non-fatal|9
6281941|NCT02299375|9992437|FG000|Overall Study|Lack of Efficacy|1
6281942|NCT02299375|9992438|FG001|Overall Study|Lack of Efficacy|3
6281943|NCT02299375|9992437|FG000|Overall Study|Protocol Violation|1
6281944|NCT02299375|9992438|FG001|Overall Study|Protocol Violation|3
6281945|NCT02299375|9992437|FG000|Overall Study|Other: Met stopping criteria|1
6281946|NCT02299375|9992438|FG001|Overall Study|Other: Met stopping criteria|0
6281947|NCT02299375|9992437|FG000|Overall Study|Other: Study closed/terminated|66
6281948|NCT02299375|9992438|FG001|Overall Study|Other: Study closed/terminated|55
6281949|NCT02299375|9992437|FG000|Overall Study|Lost to Follow-up|0
6281950|NCT02299375|9992438|FG001|Overall Study|Lost to Follow-up|2
6281951|NCT02299375|9992437|FG000|Overall Study|Physician Decision|1
6281952|NCT02299375|9992438|FG001|Overall Study|Physician Decision|1
6281953|NCT02299375|9992437|FG000|Overall Study|Withdrawal by Subject|1
6281954|NCT02299375|9992438|FG001|Overall Study|Withdrawal by Subject|4
6281955|NCT02299388|9992447|FG000|Overall Study|Withdrawal by Subject|0
6281956|NCT02299388|9992448|FG001|Overall Study|Withdrawal by Subject|1
6281957|NCT02299427|9992456|FG000|Overall Study|Withdrawal by Subject|1
6281958|NCT02299427|9992457|FG001|Overall Study|Withdrawal by Subject|0
6281959|NCT02299427|9992456|FG000|Overall Study|Lost to Follow-up|1
6281960|NCT02299427|9992457|FG001|Overall Study|Lost to Follow-up|3
6281961|NCT02299427|9992456|FG000|Overall Study|not adherent to dog website use|21
6281962|NCT02299427|9992457|FG001|Overall Study|not adherent to dog website use|0
6281963|NCT02299635|9992485|FG000|Overall Study|Adverse Event|2
6281964|NCT02299635|9992485|FG000|Overall Study|Death|1
6281965|NCT02299635|9992485|FG000|Overall Study|Global deterioration of health status|1
6281966|NCT02299635|9992485|FG000|Overall Study|Objective progression or relapse|10
6281967|NCT02299635|9992485|FG000|Overall Study|Withdrawal by Subject|2
6281968|NCT02299635|9992485|FG000|Overall Study|Other|3
6281969|NCT02300103|9992543|FG000|Overall Study|Lack of Efficacy|3
6281970|NCT02300103|9992543|FG000|Overall Study|Protocol Violation|1
6089343|NCT00683878|9700878|FG001|Overall Study|Withdrawal by Subject|8
6089344|NCT00683878|9700879|FG002|Overall Study|Withdrawal by Subject|6
6089345|NCT00683878|9700877|FG000|Overall Study|Death|0
6089346|NCT00683878|9700878|FG001|Overall Study|Death|1
6089347|NCT00683878|9700879|FG002|Overall Study|Death|0
6089348|NCT00683878|9700877|FG000|Overall Study|Lost to Follow-up|4
6089349|NCT00683878|9700878|FG001|Overall Study|Lost to Follow-up|2
6089350|NCT00683878|9700879|FG002|Overall Study|Lost to Follow-up|4
6089351|NCT00683878|9700877|FG000|Overall Study|Non-compliance, not met criteria etc.|3
6089352|NCT00683878|9700878|FG001|Overall Study|Non-compliance, not met criteria etc.|2
6089353|NCT00683878|9700879|FG002|Overall Study|Non-compliance, not met criteria etc.|0
6089354|NCT00683904|9700889|FG000|Dose Level 1|Disease progression|2
6089355|NCT00683904|9700890|FG001|Dose Level 1|Disease progression|0
6089356|NCT00683904|9700889|FG000|Dose Level 1|Adverse Event|1
6089357|NCT00683904|9700890|FG001|Dose Level 1|Adverse Event|0
6089358|NCT00683904|9700889|FG000|Dose Level 2|Adverse Event|0
6089359|NCT00683904|9700890|FG001|Dose Level 2|Adverse Event|2
6281971|NCT02300103|9992543|FG000|Overall Study|Withdrew Consent|2
6281972|NCT02300129|9992547|FG000|Period 1 Session 2 (Day 3)|Withdrawal by Subject|0
6281973|NCT02300129|9992548|FG001|Period 1 Session 2 (Day 3)|Withdrawal by Subject|1
6281974|NCT02300129|9992549|FG002|Period 1 Session 2 (Day 3)|Withdrawal by Subject|0
6281975|NCT02300129|9992550|FG003|Period 1 Session 2 (Day 3)|Withdrawal by Subject|0
6281976|NCT02300129|9992547|FG000|Period 2 Treatment 1 (2 Weeks)|Withdrawal by Subject|0
6281977|NCT02300129|9992548|FG001|Period 2 Treatment 1 (2 Weeks)|Withdrawal by Subject|0
6281978|NCT02300129|9992549|FG002|Period 2 Treatment 1 (2 Weeks)|Withdrawal by Subject|0
6281979|NCT02300129|9992550|FG003|Period 2 Treatment 1 (2 Weeks)|Withdrawal by Subject|1
6281980|NCT02300129|9992547|FG000|Period 2 Treatment 1 (2 Weeks)|Adverse Event|1
6281981|NCT02300129|9992548|FG001|Period 2 Treatment 1 (2 Weeks)|Adverse Event|0
6089360|NCT00684021|9700920|FG000|Overall Study|MRI Contraindicated|1
6089361|NCT00684021|9700921|FG001|Overall Study|MRI Contraindicated|1
6089362|NCT00684021|9700922|FG002|Overall Study|MRI Contraindicated|1
6089363|NCT00684021|9700923|FG003|Overall Study|MRI Contraindicated|0
6281982|NCT02300129|9992549|FG002|Period 2 Treatment 1 (2 Weeks)|Adverse Event|0
6281983|NCT02300129|9992550|FG003|Period 2 Treatment 1 (2 Weeks)|Adverse Event|0
6281984|NCT02300220|9992562|FG000|Overall Study|Lost to Follow-up|1
6281985|NCT02300220|9992563|FG001|Overall Study|Lost to Follow-up|2
6089364|NCT00684021|9700920|FG000|Overall Study|MRI not performed|0
6281986|NCT02300220|9992562|FG000|Overall Study|Death|1
6281987|NCT02300220|9992563|FG001|Overall Study|Death|1
6281988|NCT02300220|9992562|FG000|Overall Study|Adverse Event|1
6281989|NCT02300220|9992563|FG001|Overall Study|Adverse Event|1
6281990|NCT02300220|9992562|FG000|Overall Study|Protocol Violation|1
6281991|NCT02300220|9992563|FG001|Overall Study|Protocol Violation|0
6281992|NCT02300220|9992562|FG000|Overall Study|Withdrawal by Subject|0
6281993|NCT02300220|9992563|FG001|Overall Study|Withdrawal by Subject|2
6281994|NCT02300220|9992562|FG000|Overall Study|Did not tolerate IMP|0
6281995|NCT02300220|9992563|FG001|Overall Study|Did not tolerate IMP|1
6281996|NCT02300259|9992572|FG000|Period 1|Adverse Event|0
6281997|NCT02300259|9992573|FG001|Period 1|Adverse Event|0
6281998|NCT02300259|9992574|FG002|Period 1|Adverse Event|1
6281999|NCT02300259|9992572|FG000|Period 1|Withdrawal by Subject|0
6282000|NCT02300259|9992573|FG001|Period 1|Withdrawal by Subject|0
6282001|NCT02300259|9992574|FG002|Period 1|Withdrawal by Subject|1
6282002|NCT02300259|9992572|FG000|Period 2|Adverse Event|1
5979787|NCT02964507|9568338|FG003|Overall Study|Death|2
5979788|NCT02964507|9568339|FG004|Overall Study|Death|10
5979789|NCT02964507|9568340|FG005|Overall Study|Death|5
5979790|NCT02964507|9568341|FG006|Overall Study|Death|0
5979791|NCT02964507|9568342|FG007|Overall Study|Death|0
5979792|NCT02964507|9568335|FG000|Overall Study|Withdrawal by Subject|1
5979793|NCT02964507|9568336|FG001|Overall Study|Withdrawal by Subject|0
5979794|NCT02964507|9568337|FG002|Overall Study|Withdrawal by Subject|1
5979795|NCT02964507|9568338|FG003|Overall Study|Withdrawal by Subject|1
5979796|NCT02964507|9568339|FG004|Overall Study|Withdrawal by Subject|0
5979797|NCT02964507|9568340|FG005|Overall Study|Withdrawal by Subject|1
5979798|NCT02964507|9568341|FG006|Overall Study|Withdrawal by Subject|0
5979799|NCT02964507|9568342|FG007|Overall Study|Withdrawal by Subject|0
5979800|NCT02964507|9568335|FG000|Overall Study|Physician Decision|1
5979801|NCT02964507|9568336|FG001|Overall Study|Physician Decision|0
5979802|NCT02964507|9568337|FG002|Overall Study|Physician Decision|1
5979803|NCT02964507|9568338|FG003|Overall Study|Physician Decision|0
5979804|NCT02964507|9568339|FG004|Overall Study|Physician Decision|1
5979805|NCT02964507|9568340|FG005|Overall Study|Physician Decision|0
5979806|NCT02964507|9568341|FG006|Overall Study|Physician Decision|0
5979807|NCT02964507|9568342|FG007|Overall Study|Physician Decision|0
5979808|NCT02942277|9568372|FG000|Year 1|Withdrawal by Subject|0
5979809|NCT02942277|9568373|FG001|Year 1|Withdrawal by Subject|0
5979810|NCT02942277|9568374|FG002|Year 1|Withdrawal by Subject|0
5979811|NCT02942277|9568375|FG003|Year 1|Withdrawal by Subject|0
5979812|NCT02942277|9568376|FG004|Year 1|Withdrawal by Subject|1
5979813|NCT02942277|9568377|FG005|Year 1|Withdrawal by Subject|3
5979814|NCT02942277|9568378|FG006|Year 1|Withdrawal by Subject|0
5979815|NCT02942277|9568379|FG007|Year 1|Withdrawal by Subject|1
5979816|NCT02942277|9568380|FG008|Year 1|Withdrawal by Subject|0
5979817|NCT02942277|9568381|FG009|Year 1|Withdrawal by Subject|0
5979818|NCT02942277|9568382|FG010|Year 1|Withdrawal by Subject|3
5979819|NCT02942277|9568372|FG000|Year 1|Travel|0
5979820|NCT02942277|9568373|FG001|Year 1|Travel|1
5979821|NCT02942277|9568374|FG002|Year 1|Travel|0
5979822|NCT02942277|9568375|FG003|Year 1|Travel|0
5979823|NCT02942277|9568376|FG004|Year 1|Travel|4
5979824|NCT02942277|9568377|FG005|Year 1|Travel|5
5979825|NCT02942277|9568378|FG006|Year 1|Travel|0
5979826|NCT02942277|9568379|FG007|Year 1|Travel|0
5979827|NCT02942277|9568380|FG008|Year 1|Travel|0
5979828|NCT02942277|9568381|FG009|Year 1|Travel|0
5979829|NCT02942277|9568382|FG010|Year 1|Travel|8
5979830|NCT02942277|9568372|FG000|Year 1|Joined Army|0
5979831|NCT02942277|9568373|FG001|Year 1|Joined Army|1
5979832|NCT02942277|9568374|FG002|Year 1|Joined Army|0
5979833|NCT02942277|9568375|FG003|Year 1|Joined Army|0
5979834|NCT02942277|9568376|FG004|Year 1|Joined Army|0
5979835|NCT02942277|9568377|FG005|Year 1|Joined Army|0
5979836|NCT02942277|9568378|FG006|Year 1|Joined Army|0
5979837|NCT02942277|9568379|FG007|Year 1|Joined Army|0
5979838|NCT02942277|9568380|FG008|Year 1|Joined Army|0
5979839|NCT02942277|9568381|FG009|Year 1|Joined Army|0
5979840|NCT02942277|9568382|FG010|Year 1|Joined Army|0
5979841|NCT02942277|9568372|FG000|Year 1|Subject met withdrawal criteria|0
5979842|NCT02942277|9568373|FG001|Year 1|Subject met withdrawal criteria|0
5979843|NCT02942277|9568374|FG002|Year 1|Subject met withdrawal criteria|0
5979844|NCT02942277|9568375|FG003|Year 1|Subject met withdrawal criteria|1
5979845|NCT02942277|9568376|FG004|Year 1|Subject met withdrawal criteria|0
5979846|NCT02942277|9568377|FG005|Year 1|Subject met withdrawal criteria|0
5979847|NCT02942277|9568378|FG006|Year 1|Subject met withdrawal criteria|0
5979848|NCT02942277|9568379|FG007|Year 1|Subject met withdrawal criteria|0
5979849|NCT02942277|9568380|FG008|Year 1|Subject met withdrawal criteria|0
5979850|NCT02942277|9568381|FG009|Year 1|Subject met withdrawal criteria|0
5979851|NCT02942277|9568382|FG010|Year 1|Subject met withdrawal criteria|0
5979852|NCT02942277|9568372|FG000|Year 1|Lost to Follow-up|0
5979853|NCT02942277|9568373|FG001|Year 1|Lost to Follow-up|0
6282003|NCT02300259|9992573|FG001|Period 2|Adverse Event|0
6282004|NCT02300259|9992574|FG002|Period 2|Adverse Event|0
5979854|NCT02942277|9568374|FG002|Year 1|Lost to Follow-up|0
5979855|NCT02942277|9568375|FG003|Year 1|Lost to Follow-up|0
5979856|NCT02942277|9568376|FG004|Year 1|Lost to Follow-up|1
6282005|NCT02300259|9992572|FG000|Period 2|Withdrawal by Subject|0
6282006|NCT02300259|9992573|FG001|Period 2|Withdrawal by Subject|0
6282007|NCT02300259|9992574|FG002|Period 2|Withdrawal by Subject|1
6282008|NCT02300298|9992602|FG000|Disposition for Nintedanib|Progressive disease|10
6282009|NCT02300298|9992603|FG001|Disposition for Nintedanib|Progressive disease|0
6282010|NCT02300298|9992602|FG000|Disposition for Docetaxel|Progressive disease|0
6282011|NCT02300298|9992603|FG001|Disposition for Docetaxel|Progressive disease|6
6282012|NCT02300298|9992602|FG000|Disposition for Docetaxel|other adverse event|0
5979857|NCT02942277|9568377|FG005|Year 1|Lost to Follow-up|0
5979858|NCT02942277|9568378|FG006|Year 1|Lost to Follow-up|0
5979859|NCT02942277|9568379|FG007|Year 1|Lost to Follow-up|0
5979860|NCT02942277|9568380|FG008|Year 1|Lost to Follow-up|0
5979861|NCT02942277|9568381|FG009|Year 1|Lost to Follow-up|0
5979862|NCT02942277|9568382|FG010|Year 1|Lost to Follow-up|2
5979863|NCT02942277|9568372|FG000|Year 1|Protocol Violation|0
5979864|NCT02942277|9568373|FG001|Year 1|Protocol Violation|0
5979865|NCT02942277|9568374|FG002|Year 1|Protocol Violation|0
5979866|NCT02942277|9568375|FG003|Year 1|Protocol Violation|0
5979867|NCT02942277|9568376|FG004|Year 1|Protocol Violation|1
5979868|NCT02942277|9568377|FG005|Year 1|Protocol Violation|1
5979869|NCT02942277|9568378|FG006|Year 1|Protocol Violation|0
5979870|NCT02942277|9568379|FG007|Year 1|Protocol Violation|0
5979871|NCT02942277|9568380|FG008|Year 1|Protocol Violation|0
5979872|NCT02942277|9568381|FG009|Year 1|Protocol Violation|0
5979873|NCT02942277|9568382|FG010|Year 1|Protocol Violation|2
5979874|NCT02942277|9568372|FG000|Year 1|Pregnancy|0
5979875|NCT02942277|9568373|FG001|Year 1|Pregnancy|0
5979876|NCT02942277|9568374|FG002|Year 1|Pregnancy|0
5979877|NCT02942277|9568375|FG003|Year 1|Pregnancy|0
5979878|NCT02942277|9568376|FG004|Year 1|Pregnancy|0
5979879|NCT02942277|9568377|FG005|Year 1|Pregnancy|1
5979880|NCT02942277|9568378|FG006|Year 1|Pregnancy|0
5979881|NCT02942277|9568379|FG007|Year 1|Pregnancy|0
5979882|NCT02942277|9568380|FG008|Year 1|Pregnancy|0
5979883|NCT02942277|9568381|FG009|Year 1|Pregnancy|0
5979884|NCT02942277|9568382|FG010|Year 1|Pregnancy|0
5979885|NCT02942277|9568372|FG000|Year 2|Lost to Follow-up|0
5979886|NCT02942277|9568373|FG001|Year 2|Lost to Follow-up|0
5979887|NCT02942277|9568374|FG002|Year 2|Lost to Follow-up|0
5979888|NCT02942277|9568375|FG003|Year 2|Lost to Follow-up|0
5979889|NCT02942277|9568376|FG004|Year 2|Lost to Follow-up|2
5979890|NCT02942277|9568377|FG005|Year 2|Lost to Follow-up|1
5979891|NCT02942277|9568378|FG006|Year 2|Lost to Follow-up|0
5979892|NCT02942277|9568379|FG007|Year 2|Lost to Follow-up|0
5979893|NCT02942277|9568380|FG008|Year 2|Lost to Follow-up|0
5979894|NCT02942277|9568381|FG009|Year 2|Lost to Follow-up|0
5979895|NCT02942277|9568382|FG010|Year 2|Lost to Follow-up|0
5979896|NCT02942277|9568372|FG000|Year 2|Did not rescreen|0
5979897|NCT02942277|9568373|FG001|Year 2|Did not rescreen|0
5979898|NCT02942277|9568374|FG002|Year 2|Did not rescreen|1
5979899|NCT02942277|9568375|FG003|Year 2|Did not rescreen|1
5979900|NCT02942277|9568376|FG004|Year 2|Did not rescreen|9
5979901|NCT02942277|9568377|FG005|Year 2|Did not rescreen|6
5979902|NCT02942277|9568378|FG006|Year 2|Did not rescreen|0
5979903|NCT02942277|9568379|FG007|Year 2|Did not rescreen|1
5979904|NCT02942277|9568380|FG008|Year 2|Did not rescreen|0
5979905|NCT02942277|9568381|FG009|Year 2|Did not rescreen|0
5979906|NCT02942277|9568382|FG010|Year 2|Did not rescreen|21
5979907|NCT02942277|9568372|FG000|Year 2|Met withdrawal criteria|0
5979908|NCT02942277|9568373|FG001|Year 2|Met withdrawal criteria|0
5979909|NCT02942277|9568374|FG002|Year 2|Met withdrawal criteria|0
5979910|NCT02942277|9568375|FG003|Year 2|Met withdrawal criteria|0
5979911|NCT02942277|9568376|FG004|Year 2|Met withdrawal criteria|1
5979912|NCT02942277|9568377|FG005|Year 2|Met withdrawal criteria|2
5979913|NCT02942277|9568378|FG006|Year 2|Met withdrawal criteria|0
5979914|NCT02942277|9568379|FG007|Year 2|Met withdrawal criteria|0
5979915|NCT02942277|9568380|FG008|Year 2|Met withdrawal criteria|0
5979916|NCT02942277|9568381|FG009|Year 2|Met withdrawal criteria|0
5979917|NCT02942277|9568382|FG010|Year 2|Met withdrawal criteria|1
5979918|NCT02942277|9568372|FG000|Year 2|Travel|0
5979919|NCT02942277|9568373|FG001|Year 2|Travel|1
6282013|NCT02300298|9992603|FG001|Disposition for Docetaxel|other adverse event|4
6282014|NCT02300311|9992609|FG000|Overall Study|Other than the reason specified|1
6282015|NCT02300311|9992610|FG001|Overall Study|Other than the reason specified|0
6282016|NCT02300311|9992609|FG000|Overall Study|Refused to continue taking medication|18
6282017|NCT02300311|9992610|FG001|Overall Study|Refused to continue taking medication|0
6282018|NCT02300558|9992620|FG000|Single Blind Phase (24 Weeks)|Study Terminated by Sponsor|6
6282019|NCT02300558|9992620|FG000|Open-Label (OL) Extension Phase|Lack of Efficacy|2
6282020|NCT02300558|9992620|FG000|Open-Label (OL) Extension Phase|Withdrew Consent|1
5979920|NCT02942277|9568374|FG002|Year 2|Travel|0
5979921|NCT02942277|9568375|FG003|Year 2|Travel|0
5979922|NCT02942277|9568376|FG004|Year 2|Travel|0
5979923|NCT02942277|9568377|FG005|Year 2|Travel|1
5979924|NCT02942277|9568378|FG006|Year 2|Travel|0
5979925|NCT02942277|9568379|FG007|Year 2|Travel|0
5979926|NCT02942277|9568380|FG008|Year 2|Travel|0
5979927|NCT02942277|9568381|FG009|Year 2|Travel|1
5979928|NCT02942277|9568382|FG010|Year 2|Travel|3
5979929|NCT02942277|9568372|FG000|Year 2|Non-compliant|0
5979930|NCT02942277|9568373|FG001|Year 2|Non-compliant|0
5979931|NCT02942277|9568374|FG002|Year 2|Non-compliant|0
5979932|NCT02942277|9568375|FG003|Year 2|Non-compliant|0
5979933|NCT02942277|9568376|FG004|Year 2|Non-compliant|1
5979934|NCT02942277|9568377|FG005|Year 2|Non-compliant|1
5979935|NCT02942277|9568378|FG006|Year 2|Non-compliant|0
5979936|NCT02942277|9568379|FG007|Year 2|Non-compliant|0
6282021|NCT02300558|9992620|FG000|Open-Label (OL) Extension Phase|Study Terminated by Sponsor|29
6282022|NCT02300610|9992631|FG000|Overall Study|Withdrawal by Subject|1
6282023|NCT02300610|9992632|FG001|Overall Study|Withdrawal by Subject|0
6282024|NCT02300610|9992633|FG002|Overall Study|Withdrawal by Subject|1
6282025|NCT02300987|9992670|FG000|Primary Phase : Prior to Cross-over|Withdrawal by Subject|1
6282026|NCT02300987|9992671|FG001|Primary Phase : Prior to Cross-over|Withdrawal by Subject|0
6282027|NCT02300987|9992670|FG000|Primary Phase : Prior to Cross-over|Physician Decision|2
6282028|NCT02300987|9992671|FG001|Primary Phase : Prior to Cross-over|Physician Decision|0
6282029|NCT02300987|9992670|FG000|Primary Phase : Prior to Cross-over|progressive disease|3
6282030|NCT02300987|9992671|FG001|Primary Phase : Prior to Cross-over|progressive disease|2
6282031|NCT02300987|9992670|FG000|Secondary Phase : Cross-over to LEE011|Lack of Efficacy|1
6282032|NCT02300987|9992671|FG001|Secondary Phase : Cross-over to LEE011|Lack of Efficacy|0
6282033|NCT02300987|9992670|FG000|Secondary Phase : Cross-over to LEE011|Adverse Event|0
6282034|NCT02300987|9992671|FG001|Secondary Phase : Cross-over to LEE011|Adverse Event|1
6282035|NCT02301143|9992691|FG000|Induction Period|Enrolled But Not Treated|1
6282036|NCT02301143|9992692|FG001|Induction Period|Enrolled But Not Treated|0
6282037|NCT02301143|9992691|FG000|Induction Period|Death|1
6282038|NCT02301143|9992692|FG001|Induction Period|Death|0
6282039|NCT02301143|9992691|FG000|Induction Period|Adverse Event|22
6282040|NCT02301143|9992692|FG001|Induction Period|Adverse Event|0
6282041|NCT02301143|9992691|FG000|Induction Period|Progressive Disease|8
6282042|NCT02301143|9992692|FG001|Induction Period|Progressive Disease|0
6282043|NCT02301143|9992691|FG000|Induction Period|Withdrawal by Subject|3
6282044|NCT02301143|9992692|FG001|Induction Period|Withdrawal by Subject|0
6282045|NCT02301143|9992691|FG000|Induction Period|Noncompliance with Study Drug|1
6282046|NCT02301143|9992692|FG001|Induction Period|Noncompliance with Study Drug|0
6282047|NCT02301143|9992691|FG000|Induction Period|Physician Decision|4
6282048|NCT02301143|9992692|FG001|Induction Period|Physician Decision|0
6282049|NCT02301143|9992691|FG000|Induction Period|Symptomatic Deterioration|2
6282050|NCT02301143|9992692|FG001|Induction Period|Symptomatic Deterioration|0
6282051|NCT02301143|9992691|FG000|Induction Period|Protocol Violation|2
6282052|NCT02301143|9992692|FG001|Induction Period|Protocol Violation|0
6282053|NCT02301143|9992691|FG000|Induction Period|Other|1
6282054|NCT02301143|9992692|FG001|Induction Period|Other|0
6282055|NCT02301143|9992691|FG000|Investigator's Choice|Adverse Event|0
6282056|NCT02301143|9992692|FG001|Investigator's Choice|Adverse Event|3
6282057|NCT02301143|9992691|FG000|Investigator's Choice|Progressive Disease|0
6282058|NCT02301143|9992692|FG001|Investigator's Choice|Progressive Disease|3
5979937|NCT02942277|9568380|FG008|Year 2|Non-compliant|0
5979938|NCT02942277|9568381|FG009|Year 2|Non-compliant|0
5979939|NCT02942277|9568382|FG010|Year 2|Non-compliant|0
5979940|NCT02942277|9568372|FG000|Year 2|Withdrawal by Subject|0
5979941|NCT02942277|9568373|FG001|Year 2|Withdrawal by Subject|0
5979942|NCT02942277|9568374|FG002|Year 2|Withdrawal by Subject|0
5979943|NCT02942277|9568375|FG003|Year 2|Withdrawal by Subject|0
6051543|NCT00433654|9650828|FG001|Overall Study|Death|0
6051544|NCT00433654|9650827|FG000|Overall Study|Missed visit|6
6051545|NCT00433654|9650828|FG001|Overall Study|Missed visit|3
6282059|NCT02301143|9992691|FG000|Investigator's Choice|Noncompliance With Study Drug|0
6282060|NCT02301143|9992692|FG001|Investigator's Choice|Noncompliance With Study Drug|1
6282061|NCT02301143|9992691|FG000|Investigator's Choice|Symptomatic Deterioration|0
6282062|NCT02301143|9992692|FG001|Investigator's Choice|Symptomatic Deterioration|1
6282063|NCT02301143|9992691|FG000|Investigator's Choice|Other|0
6282064|NCT02301143|9992692|FG001|Investigator's Choice|Other|1
6282065|NCT02301143|9992691|FG000|Investigator's Choice|Unresectable Surgery|0
6282066|NCT02301143|9992692|FG001|Investigator's Choice|Unresectable Surgery|1
6282067|NCT02301169|9992705|FG000|Overall Study|Adverse Event|1
6282068|NCT02301169|9992706|FG001|Overall Study|Adverse Event|0
6282069|NCT02301390|9992734|FG000|Overall Study|Withdrawal by Subject|3
6282070|NCT02301390|9992735|FG001|Overall Study|Withdrawal by Subject|5
6282071|NCT02301390|9992734|FG000|Overall Study|Protocol Violation|1
6282072|NCT02301390|9992735|FG001|Overall Study|Protocol Violation|0
6282073|NCT02301390|9992734|FG000|Overall Study|Physician Decision|1
6282074|NCT02301390|9992735|FG001|Overall Study|Physician Decision|0
6282075|NCT02301390|9992734|FG000|Overall Study|Lost to Follow-up|0
6282076|NCT02301390|9992735|FG001|Overall Study|Lost to Follow-up|1
6282077|NCT02301390|9992734|FG000|Overall Study|Death|2
6282078|NCT02301390|9992735|FG001|Overall Study|Death|2
6282079|NCT02301390|9992734|FG000|Overall Study|Procedure not completed|0
6282080|NCT02301390|9992735|FG001|Overall Study|Procedure not completed|4
5979944|NCT02942277|9568376|FG004|Year 2|Withdrawal by Subject|0
5979945|NCT02942277|9568377|FG005|Year 2|Withdrawal by Subject|0
6051546|NCT00433654|9650827|FG000|Overall Study|Subject not yet due for visit|4
6282081|NCT02301390|9992734|FG000|Overall Study|Missed multiple visits|1
6282082|NCT02301390|9992735|FG001|Overall Study|Missed multiple visits|1
6282083|NCT02301390|9992734|FG000|Overall Study|study terminated|2
6282084|NCT02301390|9992735|FG001|Overall Study|study terminated|0
6282085|NCT02301403|9992743|FG000|Overall Study|Withdrawal by Subject|28
6282086|NCT02301403|9992744|FG001|Overall Study|Withdrawal by Subject|41
6282087|NCT02301429|9992759|FG000|Overall Study|not acceptable vascular anatomy|3
6282088|NCT02301546|9992765|FG000|Short-term Effectiveness (~13 Weeks)|Withdrawal by Subject|7
6282089|NCT02301546|9992766|FG001|Short-term Effectiveness (~13 Weeks)|Withdrawal by Subject|8
6282090|NCT02301546|9992765|FG000|Short-term Effectiveness (~13 Weeks)|non-compliant|10
6282091|NCT02301546|9992766|FG001|Short-term Effectiveness (~13 Weeks)|non-compliant|7
6282092|NCT02301546|9992765|FG000|Short-term Effectiveness (~13 Weeks)|screen fail|1
6282093|NCT02301546|9992766|FG001|Short-term Effectiveness (~13 Weeks)|screen fail|0
6282094|NCT02301546|9992765|FG000|Long Term Effectiveness (~1 Year)|Lost to Follow-up|3
6282095|NCT02301546|9992766|FG001|Long Term Effectiveness (~1 Year)|Lost to Follow-up|3
6282096|NCT02301546|9992765|FG000|Long Term Effectiveness (~1 Year)|Death|2
6282097|NCT02301546|9992766|FG001|Long Term Effectiveness (~1 Year)|Death|0
6282098|NCT02301546|9992765|FG000|Long Term Effectiveness (~1 Year)|Withdrawal by Subject|6
6282099|NCT02301546|9992766|FG001|Long Term Effectiveness (~1 Year)|Withdrawal by Subject|2
6282100|NCT02301546|9992765|FG000|Long Term Effectiveness (~1 Year)|moved away|1
6282101|NCT02301546|9992766|FG001|Long Term Effectiveness (~1 Year)|moved away|2
6282102|NCT02301624|9992774|FG000|Blind Induction Phase|Withdrawal by Subject|1
6282103|NCT02301624|9992775|FG001|Blind Induction Phase|Withdrawal by Subject|0
6282104|NCT02301624|9992774|FG000|Open-label Maintenance Phase|Withdrawal by Subject|4
6282105|NCT02301624|9992775|FG001|Open-label Maintenance Phase|Withdrawal by Subject|8
6282106|NCT02301624|9992774|FG000|Open-label Maintenance Phase|Adverse Event|2
6282107|NCT02301624|9992775|FG001|Open-label Maintenance Phase|Adverse Event|5
6282108|NCT02301624|9992774|FG000|Open-label Maintenance Phase|Physician Decision|3
6282109|NCT02301624|9992775|FG001|Open-label Maintenance Phase|Physician Decision|3
6282110|NCT02301624|9992774|FG000|Open-label Maintenance Phase|Death|2
6282111|NCT02301624|9992775|FG001|Open-label Maintenance Phase|Death|1
6282112|NCT02301624|9992774|FG000|Open-label Maintenance Phase|Participant felt no change in condition|1
6282113|NCT02301624|9992775|FG001|Open-label Maintenance Phase|Participant felt no change in condition|0
6282114|NCT02301897|9992794|FG000|Treatment Course 1|Non-Compliance|0
6282115|NCT02301897|9992795|FG001|Treatment Course 1|Non-Compliance|0
6282116|NCT02301897|9992796|FG002|Treatment Course 1|Non-Compliance|1
6282117|NCT02301897|9992794|FG000|Treatment Course 1|Adverse Event|1
6282118|NCT02301897|9992795|FG001|Treatment Course 1|Adverse Event|1
6282119|NCT02301897|9992796|FG002|Treatment Course 1|Adverse Event|0
6282120|NCT02301897|9992794|FG000|Treatment Course 1|Lost to Follow-up|1
6282121|NCT02301897|9992795|FG001|Treatment Course 1|Lost to Follow-up|2
6282122|NCT02301897|9992796|FG002|Treatment Course 1|Lost to Follow-up|1
6282123|NCT02301897|9992794|FG000|Treatment Course 1|Withdrawal by Sponsor|0
6282124|NCT02301897|9992795|FG001|Treatment Course 1|Withdrawal by Sponsor|0
6282125|NCT02301897|9992796|FG002|Treatment Course 1|Withdrawal by Sponsor|2
6282126|NCT02301897|9992794|FG000|Treatment Course 1|Withdrawal by Subject|0
6282127|NCT02301897|9992795|FG001|Treatment Course 1|Withdrawal by Subject|0
6282128|NCT02301897|9992796|FG002|Treatment Course 1|Withdrawal by Subject|2
6282129|NCT02301897|9992794|FG000|Treatment Course 1|Other Miscellaneous Reasons|1
6282130|NCT02301897|9992795|FG001|Treatment Course 1|Other Miscellaneous Reasons|0
6282131|NCT02301897|9992796|FG002|Treatment Course 1|Other Miscellaneous Reasons|0
6282132|NCT02301897|9992794|FG000|Treatment Course 2|Lost to Follow-up|0
6282133|NCT02301897|9992795|FG001|Treatment Course 2|Lost to Follow-up|2
6282134|NCT02301897|9992796|FG002|Treatment Course 2|Lost to Follow-up|0
6282135|NCT02301897|9992794|FG000|Treatment Course 2|Pregnancy|0
6282136|NCT02301897|9992795|FG001|Treatment Course 2|Pregnancy|1
6282137|NCT02301897|9992796|FG002|Treatment Course 2|Pregnancy|1
6282138|NCT02301897|9992794|FG000|Treatment Course 2|Withdrawal by Subject|0
6282139|NCT02301897|9992795|FG001|Treatment Course 2|Withdrawal by Subject|2
6282140|NCT02301897|9992796|FG002|Treatment Course 2|Withdrawal by Subject|0
6282141|NCT02301897|9992794|FG000|Treatment Course 2|Other Miscellaneous Reasons|1
6282142|NCT02301897|9992795|FG001|Treatment Course 2|Other Miscellaneous Reasons|0
6282143|NCT02301897|9992796|FG002|Treatment Course 2|Other Miscellaneous Reasons|0
6282144|NCT02301936|9992806|FG000|Overall Study|Lost to Follow-up|1
6282145|NCT02301936|9992807|FG001|Overall Study|Lost to Follow-up|0
6282146|NCT02301975|9992816|FG000|Overall Study|Adverse Event|8
6282147|NCT02301975|9992817|FG001|Overall Study|Adverse Event|3
6282148|NCT02301975|9992818|FG002|Overall Study|Adverse Event|2
6282149|NCT02301975|9992816|FG000|Overall Study|Lack of Efficacy|1
6282150|NCT02301975|9992817|FG001|Overall Study|Lack of Efficacy|1
6282151|NCT02301975|9992818|FG002|Overall Study|Lack of Efficacy|1
6282152|NCT02301975|9992816|FG000|Overall Study|Protocol Violation|3
6282153|NCT02301975|9992817|FG001|Overall Study|Protocol Violation|5
6282154|NCT02301975|9992818|FG002|Overall Study|Protocol Violation|3
6282155|NCT02301975|9992816|FG000|Overall Study|Lost to Follow-up|0
6282156|NCT02301975|9992817|FG001|Overall Study|Lost to Follow-up|2
6282157|NCT02301975|9992818|FG002|Overall Study|Lost to Follow-up|2
6282158|NCT02301975|9992816|FG000|Overall Study|Physician Decision|4
6282159|NCT02301975|9992817|FG001|Overall Study|Physician Decision|2
6282160|NCT02301975|9992818|FG002|Overall Study|Physician Decision|3
6282161|NCT02301975|9992816|FG000|Overall Study|Withdrawal by Subject|15
6282162|NCT02301975|9992817|FG001|Overall Study|Withdrawal by Subject|12
6282163|NCT02301975|9992818|FG002|Overall Study|Withdrawal by Subject|11
6282164|NCT02301988|9992828|FG000|Overall Study|Withdrawal by Subject|2
6282165|NCT02301988|9992829|FG001|Overall Study|Withdrawal by Subject|1
6282166|NCT02301988|9992828|FG000|Overall Study|Physician Decision|2
6282167|NCT02301988|9992829|FG001|Overall Study|Physician Decision|2
6282168|NCT02301988|9992828|FG000|Overall Study|Unknown Reason|1
6282169|NCT02301988|9992829|FG001|Overall Study|Unknown Reason|3
6282170|NCT02301988|9992828|FG000|Overall Study|Lack of Efficacy|3
6282171|NCT02301988|9992829|FG001|Overall Study|Lack of Efficacy|2
6282172|NCT02301988|9992828|FG000|Overall Study|Death|1
6282173|NCT02301988|9992829|FG001|Overall Study|Death|0
6282174|NCT02301988|9992828|FG000|Overall Study|Adverse Event|1
6282175|NCT02301988|9992829|FG001|Overall Study|Adverse Event|1
6282176|NCT02302066|9992839|FG000|Overall Study|Adverse Event|1
6282177|NCT02302066|9992840|FG001|Overall Study|Adverse Event|1
6282178|NCT02302066|9992841|FG002|Overall Study|Adverse Event|3
6282179|NCT02302066|9992842|FG003|Overall Study|Adverse Event|0
6282180|NCT02302066|9992839|FG000|Overall Study|Lost to Follow-up|4
6282181|NCT02302066|9992840|FG001|Overall Study|Lost to Follow-up|5
6282182|NCT02302066|9992841|FG002|Overall Study|Lost to Follow-up|24
6282183|NCT02302066|9992842|FG003|Overall Study|Lost to Follow-up|7
5979946|NCT02942277|9568378|FG006|Year 2|Withdrawal by Subject|1
5979947|NCT02942277|9568379|FG007|Year 2|Withdrawal by Subject|0
5979948|NCT02942277|9568380|FG008|Year 2|Withdrawal by Subject|0
5979949|NCT02942277|9568381|FG009|Year 2|Withdrawal by Subject|0
5979950|NCT02942277|9568382|FG010|Year 2|Withdrawal by Subject|0
5979951|NCT02942017|9568411|FG000|Overall Study|Adverse Event|0
5979952|NCT02942017|9568412|FG001|Overall Study|Adverse Event|1
5979953|NCT02942017|9568411|FG000|Overall Study|Withdrawal by Subject|0
5979954|NCT02942017|9568412|FG001|Overall Study|Withdrawal by Subject|1
5979955|NCT02942017|9568411|FG000|Overall Study|Lost to Follow-up|1
5979956|NCT02942017|9568412|FG001|Overall Study|Lost to Follow-up|1
5979957|NCT02942017|9568411|FG000|Overall Study|Randomized but not dosed|1
5979958|NCT02942017|9568412|FG001|Overall Study|Randomized but not dosed|3
5979959|NCT02942004|9568421|FG000|Overall Study|Withdrawal by Subject|0
5979960|NCT02942004|9568422|FG001|Overall Study|Withdrawal by Subject|2
5979961|NCT02942004|9568423|FG002|Overall Study|Withdrawal by Subject|3
5979962|NCT02942004|9568421|FG000|Overall Study|Lost to Follow-up|1
5979963|NCT02942004|9568422|FG001|Overall Study|Lost to Follow-up|1
5979964|NCT02942004|9568423|FG002|Overall Study|Lost to Follow-up|2
5979965|NCT02942004|9568421|FG000|Overall Study|Randomized but not dosed|3
5979966|NCT02942004|9568422|FG001|Overall Study|Randomized but not dosed|9
5979967|NCT02942004|9568423|FG002|Overall Study|Randomized but not dosed|4
5979968|NCT02861014|9568431|FG000|Primary Analysis|Adverse Event|7
5979969|NCT02861014|9568431|FG000|Primary Analysis|Death|1
5979970|NCT02861014|9568431|FG000|Primary Analysis|Lack of Efficacy|3
6051547|NCT00433654|9650828|FG001|Overall Study|Subject not yet due for visit|0
6051548|NCT00433654|9650827|FG000|Overall Study|Withdrawal by Subject|1
6051549|NCT00433654|9650828|FG001|Overall Study|Withdrawal by Subject|2
6051550|NCT00433771|9650845|FG000|Overall Study|screen fail|14
6089365|NCT00684021|9700921|FG001|Overall Study|MRI not performed|1
6089366|NCT00684021|9700922|FG002|Overall Study|MRI not performed|1
6089367|NCT00684021|9700923|FG003|Overall Study|MRI not performed|2
6089368|NCT00684021|9700920|FG000|Overall Study|Death|1
6089369|NCT00684021|9700921|FG001|Overall Study|Death|0
6282184|NCT02302066|9992839|FG000|Overall Study|Withdrawal by Subject|25
6282185|NCT02302066|9992840|FG001|Overall Study|Withdrawal by Subject|58
6282186|NCT02302066|9992841|FG002|Overall Study|Withdrawal by Subject|124
6282187|NCT02302066|9992842|FG003|Overall Study|Withdrawal by Subject|33
6282188|NCT02302066|9992839|FG000|Overall Study|Pregnancy|2
6282189|NCT02302066|9992840|FG001|Overall Study|Pregnancy|10
5979971|NCT02861014|9568431|FG000|Primary Analysis|Physician Decision|2
5979972|NCT02861014|9568431|FG000|Primary Analysis|Pregnancy|4
5979973|NCT02861014|9568431|FG000|Primary Analysis|Protocol Violation|2
5979974|NCT02861014|9568431|FG000|Primary Analysis|Study Terminated By Sponsor|3
6089370|NCT00684021|9700922|FG002|Overall Study|Death|0
6282190|NCT02302066|9992841|FG002|Overall Study|Pregnancy|12
6282191|NCT02302066|9992842|FG003|Overall Study|Pregnancy|0
6282192|NCT02302066|9992839|FG000|Overall Study|Reason Not Specified|1
6282193|NCT02302066|9992840|FG001|Overall Study|Reason Not Specified|1
6282194|NCT02302066|9992841|FG002|Overall Study|Reason Not Specified|9
6282195|NCT02302066|9992842|FG003|Overall Study|Reason Not Specified|1
6282196|NCT02302222|9992899|FG000|Overall Study|Physician Decision|0
6282197|NCT02302222|9992900|FG001|Overall Study|Physician Decision|4
6282198|NCT02302222|9992899|FG000|Overall Study|Lost to Follow-up|1
6282199|NCT02302222|9992900|FG001|Overall Study|Lost to Follow-up|0
6282200|NCT02302222|9992899|FG000|Overall Study|Treatment discontinued before day 5|0
6282201|NCT02302222|9992900|FG001|Overall Study|Treatment discontinued before day 5|1
6282202|NCT02302222|9992899|FG000|Overall Study|Withdrawn prior to any treatment|0
6282203|NCT02302222|9992900|FG001|Overall Study|Withdrawn prior to any treatment|1
6282204|NCT02302339|9992910|FG000|Overall Study|Lost to Follow-up|1
6282205|NCT02302339|9992911|FG001|Overall Study|Lost to Follow-up|0
6282206|NCT02302339|9992912|FG002|Overall Study|Lost to Follow-up|0
6282207|NCT02302339|9992913|FG003|Overall Study|Lost to Follow-up|0
6282208|NCT02302339|9992910|FG000|Overall Study|Withdrawal by Subject|0
6282209|NCT02302339|9992911|FG001|Overall Study|Withdrawal by Subject|2
6282210|NCT02302339|9992912|FG002|Overall Study|Withdrawal by Subject|1
6282211|NCT02302339|9992913|FG003|Overall Study|Withdrawal by Subject|0
6282212|NCT02302716|9992934|FG000|Overall Study|Adverse Event|1
6282213|NCT02302716|9992935|FG001|Overall Study|Adverse Event|1
6282214|NCT02302716|9992934|FG000|Overall Study|Death|0
6282215|NCT02302716|9992935|FG001|Overall Study|Death|1
6282216|NCT02302716|9992934|FG000|Overall Study|Lack of Efficacy|0
6282217|NCT02302716|9992935|FG001|Overall Study|Lack of Efficacy|1
6282218|NCT02302716|9992934|FG000|Overall Study|Lost to Follow-up|2
6282219|NCT02302716|9992935|FG001|Overall Study|Lost to Follow-up|4
6282220|NCT02302716|9992934|FG000|Overall Study|Physician Decision|3
6282221|NCT02302716|9992935|FG001|Overall Study|Physician Decision|4
6282222|NCT02302716|9992934|FG000|Overall Study|Withdrawal by Subject|13
6282223|NCT02302716|9992935|FG001|Overall Study|Withdrawal by Subject|7
6282224|NCT02302716|9992934|FG000|Overall Study|Protocol Violation|0
6282225|NCT02302716|9992935|FG001|Overall Study|Protocol Violation|1
6282226|NCT02302807|9992943|FG000|Overall Study|Withdrawal by Subject|28
6282227|NCT02302807|9992944|FG001|Overall Study|Withdrawal by Subject|11
6282228|NCT02302807|9992943|FG000|Overall Study|Lost to Follow-up|4
6282229|NCT02302807|9992944|FG001|Overall Study|Lost to Follow-up|6
6282230|NCT02302807|9992943|FG000|Overall Study|Death|397
6282231|NCT02302807|9992944|FG001|Overall Study|Death|385
6282232|NCT02302807|9992943|FG000|Overall Study|Study Terminated By Sponsor|35
6282233|NCT02302807|9992944|FG001|Overall Study|Study Terminated By Sponsor|64
6282234|NCT02302807|9992943|FG000|Overall Study|Physician Decision|0
6282235|NCT02302807|9992944|FG001|Overall Study|Physician Decision|1
6282236|NCT02302846|9992963|FG000|Overall Study|Withdrawal by Subject|1
6282237|NCT02303041|9992969|FG000|Overall Study|Adverse Event|1
6282238|NCT02303041|9992970|FG001|Overall Study|Adverse Event|2
6282239|NCT02303262|9993001|FG000|Overall Study|Withdrawal by Subject|2
6282240|NCT02303574|9993017|FG000|Part 1a (Fasted State)- SAD|Withdrawal by Subject|0
6282241|NCT02303574|9993018|FG001|Part 1a (Fasted State)- SAD|Withdrawal by Subject|0
6282242|NCT02303574|9993019|FG002|Part 1a (Fasted State)- SAD|Withdrawal by Subject|1
6282243|NCT02303574|9993020|FG003|Part 1a (Fasted State)- SAD|Withdrawal by Subject|0
6282244|NCT02303574|9993021|FG004|Part 1a (Fasted State)- SAD|Withdrawal by Subject|0
6282245|NCT02303574|9993022|FG005|Part 1a (Fasted State)- SAD|Withdrawal by Subject|0
6282246|NCT02303574|9993023|FG006|Part 1a (Fasted State)- SAD|Withdrawal by Subject|0
6282247|NCT02303574|9993024|FG007|Part 1a (Fasted State)- SAD|Withdrawal by Subject|0
6282248|NCT02303574|9993025|FG008|Part 1a (Fasted State)- SAD|Withdrawal by Subject|0
6282249|NCT02303574|9993026|FG009|Part 1a (Fasted State)- SAD|Withdrawal by Subject|0
6282250|NCT02303574|9993017|FG000|Part 2 - Multiple Ascending Dose (MAD)|Adverse Event|0
6282251|NCT02303574|9993018|FG001|Part 2 - Multiple Ascending Dose (MAD)|Adverse Event|0
6282252|NCT02303574|9993019|FG002|Part 2 - Multiple Ascending Dose (MAD)|Adverse Event|0
6282253|NCT02303574|9993020|FG003|Part 2 - Multiple Ascending Dose (MAD)|Adverse Event|0
6282254|NCT02303574|9993021|FG004|Part 2 - Multiple Ascending Dose (MAD)|Adverse Event|0
5979975|NCT02861014|9568431|FG000|Primary Analysis|Withdrawal by Subject|14
5979976|NCT02861014|9568431|FG000|Primary Analysis|Commercial ocrelizumab|3
5979977|NCT02861014|9568431|FG000|Safety Follow-up|Adverse Event|1
5979978|NCT02861014|9568431|FG000|Safety Follow-up|Pregnancy|1
5979979|NCT02861014|9568431|FG000|Safety Follow-up|Withdrawal by Subject|9
5979980|NCT02861014|9568431|FG000|Safety Follow-up|Study terminated by sponsor|1
5979981|NCT02861014|9568431|FG000|Safety Follow-up|Physician Decision|1
5979982|NCT02861014|9568431|FG000|Safety Follow-up|Roll-over to a long term extension study|1
6282255|NCT02303574|9993022|FG005|Part 2 - Multiple Ascending Dose (MAD)|Adverse Event|0
5979983|NCT02861014|9568431|FG000|Safety Follow-up|Commercial ocrelizumab|36
5979984|NCT02775435|9568439|FG000|Overall Study|Adverse Event|48
6282256|NCT02303574|9993023|FG006|Part 2 - Multiple Ascending Dose (MAD)|Adverse Event|0
6282257|NCT02303574|9993024|FG007|Part 2 - Multiple Ascending Dose (MAD)|Adverse Event|1
6282258|NCT02303574|9993025|FG008|Part 2 - Multiple Ascending Dose (MAD)|Adverse Event|0
6282259|NCT02303574|9993026|FG009|Part 2 - Multiple Ascending Dose (MAD)|Adverse Event|0
6282260|NCT02303704|9993061|FG000|Overall Study|Protocol Violation|5
6282261|NCT02303704|9993062|FG001|Overall Study|Protocol Violation|9
6282262|NCT02304380|9993101|FG000|Pediatric Adult Caregiver Survey (Aim 2)|Withdrawal by Subject|0
6282263|NCT02304380|9993102|FG001|Pediatric Adult Caregiver Survey (Aim 2)|Withdrawal by Subject|0
6282264|NCT02304380|9993103|FG002|Pediatric Adult Caregiver Survey (Aim 2)|Withdrawal by Subject|0
6282265|NCT02304380|9993104|FG003|Pediatric Adult Caregiver Survey (Aim 2)|Withdrawal by Subject|34
6282266|NCT02304380|9993105|FG004|Pediatric Adult Caregiver Survey (Aim 2)|Withdrawal by Subject|0
6282267|NCT02304380|9993106|FG005|Pediatric Adult Caregiver Survey (Aim 2)|Withdrawal by Subject|0
6282268|NCT02304484|9993142|FG000|Overall Study|Death|9
6282269|NCT02304484|9993142|FG000|Overall Study|Withdrawal by Subject|14
6282270|NCT02304484|9993142|FG000|Overall Study|Lost to Follow-up|2
6282271|NCT02304705|9993148|FG000|Overall Study|Withdrawal by Subject|2
6282272|NCT02304705|9993149|FG001|Overall Study|Withdrawal by Subject|0
6282273|NCT02304705|9993148|FG000|Overall Study|Physician Decision|2
6282274|NCT02304705|9993149|FG001|Overall Study|Physician Decision|4
6282275|NCT02304705|9993148|FG000|Overall Study|Death|0
6282276|NCT02304705|9993149|FG001|Overall Study|Death|1
6282277|NCT02304705|9993148|FG000|Overall Study|Lost to Follow-up|0
6282278|NCT02304705|9993149|FG001|Overall Study|Lost to Follow-up|2
6282279|NCT02304926|9993166|FG000|Overall Study|Lost to Follow-up|2
6282280|NCT02304926|9993167|FG001|Overall Study|Lost to Follow-up|1
6282281|NCT02305238|9993191|FG000|Overall Study|Death|2
6282282|NCT02305238|9993192|FG001|Overall Study|Death|1
6282283|NCT02305238|9993193|FG002|Overall Study|Death|0
6282284|NCT02305238|9993191|FG000|Overall Study|Progressive disease|4
6282285|NCT02305238|9993192|FG001|Overall Study|Progressive disease|4
6282286|NCT02305238|9993193|FG002|Overall Study|Progressive disease|0
6282287|NCT02305238|9993191|FG000|Overall Study|Logistical difficulties|1
6282288|NCT02305238|9993192|FG001|Overall Study|Logistical difficulties|3
6282289|NCT02305238|9993193|FG002|Overall Study|Logistical difficulties|0
6282290|NCT02305238|9993191|FG000|Overall Study|Protocol Violation|0
6282291|NCT02305238|9993192|FG001|Overall Study|Protocol Violation|3
6282292|NCT02305238|9993193|FG002|Overall Study|Protocol Violation|0
6282293|NCT02305238|9993191|FG000|Overall Study|Physician Decision|2
6282294|NCT02305238|9993192|FG001|Overall Study|Physician Decision|1
6282295|NCT02305238|9993193|FG002|Overall Study|Physician Decision|0
6282296|NCT02305238|9993191|FG000|Overall Study|Adverse Event|4
5979985|NCT02775435|9568440|FG001|Overall Study|Adverse Event|25
5979986|NCT02775435|9568439|FG000|Overall Study|Lost to Follow-up|0
5979987|NCT02775435|9568440|FG001|Overall Study|Lost to Follow-up|2
5979988|NCT02775435|9568439|FG000|Overall Study|Physician Decision|5
5979989|NCT02775435|9568440|FG001|Overall Study|Physician Decision|6
5979990|NCT02775435|9568439|FG000|Overall Study|Withdrawal by Subject|5
5979991|NCT02775435|9568440|FG001|Overall Study|Withdrawal by Subject|9
5979992|NCT02775435|9568439|FG000|Overall Study|Progressive Disease|86
5979993|NCT02775435|9568440|FG001|Overall Study|Progressive Disease|140
5979994|NCT02775435|9568439|FG000|Overall Study|Clinical Progression|13
5979995|NCT02775435|9568440|FG001|Overall Study|Clinical Progression|26
5979996|NCT02775435|9568439|FG000|Overall Study|Ongoing in Study|121
5979997|NCT02775435|9568440|FG001|Overall Study|Ongoing in Study|72
5979998|NCT02775435|9568439|FG000|Overall Study|Not Treated|0
5979999|NCT02775435|9568440|FG001|Overall Study|Not Treated|1
5980000|NCT02726880|9568455|FG000|Overall Study|Withdrawal by Subject|2
5980001|NCT02726880|9568456|FG001|Overall Study|Withdrawal by Subject|0
5980002|NCT02726880|9568455|FG000|Overall Study|Lost to Follow-up|1
5980003|NCT02726880|9568456|FG001|Overall Study|Lost to Follow-up|3
6051551|NCT00433771|9650845|FG000|Overall Study|Treated and later found to be ineligible|2
6051552|NCT00433771|9650845|FG000|Overall Study|Death|2
6051553|NCT00433771|9650845|FG000|Overall Study|Failure to deploy stent|1
6051554|NCT00433836|9650851|FG000|Overall Study|Adverse Event|7
6051555|NCT00433836|9650852|FG001|Overall Study|Adverse Event|0
6051556|NCT00433836|9650851|FG000|Overall Study|Lost to Follow-up|3
6051557|NCT00433836|9650852|FG001|Overall Study|Lost to Follow-up|0
6051558|NCT00433836|9650851|FG000|Overall Study|Withdrawal by Subject|2
6051559|NCT00433836|9650852|FG001|Overall Study|Withdrawal by Subject|1
6202049|NCT01498822|9862118|FG000|Overall Study|Lost to Follow-up|8
6202050|NCT01498822|9862119|FG001|Overall Study|Lost to Follow-up|3
6202051|NCT01498887|9862129|FG000|Overall Study|Administrative problems|1
6202052|NCT01498887|9862130|FG001|Overall Study|Administrative problems|0
6202053|NCT01498887|9862129|FG000|Overall Study|Lost to Follow-up|1
6202054|NCT01498887|9862130|FG001|Overall Study|Lost to Follow-up|1
6202055|NCT01498887|9862129|FG000|Overall Study|Withdrawal by Subject|1
6051560|NCT00433836|9650851|FG000|Overall Study|Unsatisfactory therapeutic effect|1
6051561|NCT00433836|9650852|FG001|Overall Study|Unsatisfactory therapeutic effect|1
6051562|NCT00433836|9650851|FG000|Overall Study|Protocol Violation|0
6051563|NCT00433836|9650852|FG001|Overall Study|Protocol Violation|2
6051564|NCT00433836|9650851|FG000|Overall Study|Condition no longer requires study drug|0
6051565|NCT00433836|9650852|FG001|Overall Study|Condition no longer requires study drug|1
6051566|NCT00433836|9650851|FG000|Overall Study|Abnormal laboratory values|0
6202056|NCT01498887|9862130|FG001|Overall Study|Withdrawal by Subject|0
6202057|NCT01498887|9862129|FG000|Overall Study|Protocol Violation|1
6282297|NCT02305238|9993192|FG001|Overall Study|Adverse Event|2
6282298|NCT02305238|9993193|FG002|Overall Study|Adverse Event|0
6282299|NCT02305238|9993191|FG000|Overall Study|Withdrawal by Subject|3
6282300|NCT02305238|9993192|FG001|Overall Study|Withdrawal by Subject|4
6282301|NCT02305238|9993193|FG002|Overall Study|Withdrawal by Subject|0
6282302|NCT02305238|9993191|FG000|Overall Study|Randomized failure|0
6282303|NCT02305238|9993192|FG001|Overall Study|Randomized failure|0
6282304|NCT02305238|9993193|FG002|Overall Study|Randomized failure|8
6282305|NCT02305238|9993191|FG000|Overall Study|Required procedure failed|0
6282306|NCT02305238|9993192|FG001|Overall Study|Required procedure failed|1
6282307|NCT02305238|9993193|FG002|Overall Study|Required procedure failed|0
6282308|NCT02305381|9993254|FG000|Overall Study|Unclassified|5
6282309|NCT02305381|9993255|FG001|Overall Study|Unclassified|5
6282310|NCT02305381|9993256|FG002|Overall Study|Unclassified|7
6282311|NCT02305446|9993264|FG000|Overall Study|Adverse Event|1
6282312|NCT02305563|9993273|FG000|Treatment Period|Disease progression|0
6282313|NCT02305563|9993274|FG001|Treatment Period|Disease progression|0
6282314|NCT02305563|9993275|FG002|Treatment Period|Disease progression|15
6282315|NCT02305563|9993276|FG003|Treatment Period|Disease progression|6
6282316|NCT02305563|9993277|FG004|Treatment Period|Disease progression|6
6282317|NCT02305563|9993273|FG000|Treatment Period|Study drug toxicity|0
6282318|NCT02305563|9993274|FG001|Treatment Period|Study drug toxicity|0
6282319|NCT02305563|9993275|FG002|Treatment Period|Study drug toxicity|0
5980004|NCT02592551|9568478|FG000|Overall Study|Not evaluable|1
5980005|NCT02592551|9568479|FG001|Overall Study|Not evaluable|3
5980006|NCT02592551|9568480|FG002|Overall Study|Not evaluable|0
5980007|NCT02583048|9568492|FG000|Overall Study|Withdrawal by Subject|0
5980008|NCT02583048|9568493|FG001|Overall Study|Withdrawal by Subject|1
5980009|NCT02583048|9568494|FG002|Overall Study|Withdrawal by Subject|0
5980010|NCT02583048|9568492|FG000|Overall Study|Failed to meet eligibility criterion|0
5980011|NCT02583048|9568493|FG001|Overall Study|Failed to meet eligibility criterion|0
5980012|NCT02583048|9568494|FG002|Overall Study|Failed to meet eligibility criterion|1
5980013|NCT02546986|9568507|FG000|Treatment Period|Progressive Disease|20
5980014|NCT02546986|9568508|FG001|Treatment Period|Progressive Disease|22
5980015|NCT02546986|9568507|FG000|Treatment Period|Adverse Event|14
5980016|NCT02546986|9568508|FG001|Treatment Period|Adverse Event|6
5980017|NCT02546986|9568507|FG000|Treatment Period|Symptomatic Deterioration|4
5980018|NCT02546986|9568508|FG001|Treatment Period|Symptomatic Deterioration|3
6051567|NCT00433836|9650852|FG001|Overall Study|Abnormal laboratory values|1
6051568|NCT00433914|9650860|FG000|Overall Study|Withdrawal by Subject|0
6051569|NCT00433914|9650861|FG001|Overall Study|Withdrawal by Subject|2
6051570|NCT00433914|9650860|FG000|Overall Study|Lost to Follow-up|0
6051571|NCT00433914|9650861|FG001|Overall Study|Lost to Follow-up|1
6051572|NCT00433966|9650869|FG000|Pharmacology Intervention/Randomization|Withdrawal by Subject|40
6051573|NCT00433966|9650870|FG001|Pharmacology Intervention/Randomization|Withdrawal by Subject|43
6051574|NCT00433966|9650871|FG002|Pharmacology Intervention/Randomization|Withdrawal by Subject|0
6051575|NCT00433966|9650872|FG003|Pharmacology Intervention/Randomization|Withdrawal by Subject|0
6051576|NCT00433966|9650869|FG000|Pharmacology Intervention/Randomization|Lost to Follow-up|97
6051577|NCT00433966|9650870|FG001|Pharmacology Intervention/Randomization|Lost to Follow-up|103
6051578|NCT00433966|9650871|FG002|Pharmacology Intervention/Randomization|Lost to Follow-up|0
6051579|NCT00433966|9650872|FG003|Pharmacology Intervention/Randomization|Lost to Follow-up|0
6051580|NCT00433966|9650869|FG000|Pharmacology Intervention/Randomization|Not true myocardial infarction|29
6089371|NCT00684021|9700923|FG003|Overall Study|Death|0
6089372|NCT00684060|9700948|FG000|Overall Study|Lost to Follow-up|1
6089373|NCT00684060|9700949|FG001|Overall Study|Lost to Follow-up|0
6089374|NCT00684060|9700948|FG000|Overall Study|New stenosis identified|1
6089375|NCT00684060|9700949|FG001|Overall Study|New stenosis identified|0
6089376|NCT00684060|9700948|FG000|Overall Study|Unable to collect MRI|1
6089377|NCT00684060|9700949|FG001|Overall Study|Unable to collect MRI|2
6089378|NCT00684060|9700948|FG000|Overall Study|Death|0
6089379|NCT00684060|9700949|FG001|Overall Study|Death|1
6089380|NCT00684073|9700955|FG000|Selection|Selection/non-selection criteria|3
6089381|NCT00684073|9700955|FG000|Selection|Death|1
6089382|NCT00684073|9700955|FG000|Selection|noncompliance|1
6089383|NCT00684073|9700955|FG000|Selection|Lost to Follow-up|1
6089384|NCT00684073|9700955|FG000|Selection|request of the sponsor|1
6089385|NCT00684073|9700955|FG000|Treatment (Days 1 Through 5)|non-respect of eligibility criteria|1
6089386|NCT00684177|9700976|FG000|Overall Study|Adverse Event|4
6089387|NCT00684177|9700977|FG001|Overall Study|Adverse Event|3
6089388|NCT00684177|9700976|FG000|Overall Study|Lack of Efficacy|10
6089389|NCT00684177|9700977|FG001|Overall Study|Lack of Efficacy|15
6282320|NCT02305563|9993276|FG003|Treatment Period|Study drug toxicity|1
6282321|NCT02305563|9993277|FG004|Treatment Period|Study drug toxicity|2
6282322|NCT02305563|9993273|FG000|Treatment Period|Death|0
6282323|NCT02305563|9993274|FG001|Treatment Period|Death|0
6282324|NCT02305563|9993275|FG002|Treatment Period|Death|1
6282325|NCT02305563|9993276|FG003|Treatment Period|Death|2
6282326|NCT02305563|9993277|FG004|Treatment Period|Death|1
6282327|NCT02305563|9993273|FG000|Treatment Period|Adverse Event (AE) unrelated to drug|0
6282328|NCT02305563|9993274|FG001|Treatment Period|Adverse Event (AE) unrelated to drug|0
5980019|NCT02546986|9568507|FG000|Treatment Period|Death|3
5980020|NCT02546986|9568508|FG001|Treatment Period|Death|4
5980021|NCT02546986|9568507|FG000|Treatment Period|Physician Decision|1
6282329|NCT02305563|9993275|FG002|Treatment Period|Adverse Event (AE) unrelated to drug|7
6282330|NCT02305563|9993276|FG003|Treatment Period|Adverse Event (AE) unrelated to drug|1
6282331|NCT02305563|9993277|FG004|Treatment Period|Adverse Event (AE) unrelated to drug|2
6282332|NCT02305563|9993273|FG000|Treatment Period|Participant request to stop therapy|0
6282333|NCT02305563|9993274|FG001|Treatment Period|Participant request to stop therapy|2
6282334|NCT02305563|9993275|FG002|Treatment Period|Participant request to stop therapy|0
6282335|NCT02305563|9993276|FG003|Treatment Period|Participant request to stop therapy|1
6282336|NCT02305563|9993277|FG004|Treatment Period|Participant request to stop therapy|0
6282337|NCT02305563|9993273|FG000|Treatment Period|Participant withdrew consent|0
6282338|NCT02305563|9993274|FG001|Treatment Period|Participant withdrew consent|0
6282339|NCT02305563|9993275|FG002|Treatment Period|Participant withdrew consent|1
6282340|NCT02305563|9993276|FG003|Treatment Period|Participant withdrew consent|1
6282341|NCT02305563|9993277|FG004|Treatment Period|Participant withdrew consent|1
6282342|NCT02305563|9993273|FG000|Treatment Period|Maximum clinical benefit|0
6282343|NCT02305563|9993274|FG001|Treatment Period|Maximum clinical benefit|0
6282344|NCT02305563|9993275|FG002|Treatment Period|Maximum clinical benefit|0
6282345|NCT02305563|9993276|FG003|Treatment Period|Maximum clinical benefit|0
6282346|NCT02305563|9993277|FG004|Treatment Period|Maximum clinical benefit|1
6282347|NCT02305563|9993273|FG000|Treatment Period|Poor/non-compliance|0
6282348|NCT02305563|9993274|FG001|Treatment Period|Poor/non-compliance|0
6282349|NCT02305563|9993275|FG002|Treatment Period|Poor/non-compliance|0
6282350|NCT02305563|9993276|FG003|Treatment Period|Poor/non-compliance|0
6282351|NCT02305563|9993277|FG004|Treatment Period|Poor/non-compliance|1
6282352|NCT02305563|9993273|FG000|Treatment Period|Administrative reason by Sponsor|0
6282353|NCT02305563|9993274|FG001|Treatment Period|Administrative reason by Sponsor|0
6282354|NCT02305563|9993275|FG002|Treatment Period|Administrative reason by Sponsor|0
6282355|NCT02305563|9993276|FG003|Treatment Period|Administrative reason by Sponsor|0
6282356|NCT02305563|9993277|FG004|Treatment Period|Administrative reason by Sponsor|1
6282357|NCT02305563|9993273|FG000|Treatment Period|other reason|2
6282358|NCT02305563|9993274|FG001|Treatment Period|other reason|0
6282359|NCT02305563|9993275|FG002|Treatment Period|other reason|2
6282360|NCT02305563|9993276|FG003|Treatment Period|other reason|2
6282361|NCT02305563|9993277|FG004|Treatment Period|other reason|1
6282362|NCT02305563|9993273|FG000|Treatment Period|Randomized but not treated|0
6282363|NCT02305563|9993274|FG001|Treatment Period|Randomized but not treated|0
6282364|NCT02305563|9993275|FG002|Treatment Period|Randomized but not treated|0
6282365|NCT02305563|9993276|FG003|Treatment Period|Randomized but not treated|0
6282366|NCT02305563|9993277|FG004|Treatment Period|Randomized but not treated|2
6282367|NCT02305563|9993273|FG000|Treatment Period|added ULO, then disease progression|0
6282368|NCT02305563|9993274|FG001|Treatment Period|added ULO, then disease progression|0
6282369|NCT02305563|9993275|FG002|Treatment Period|added ULO, then disease progression|0
6282370|NCT02305563|9993276|FG003|Treatment Period|added ULO, then disease progression|0
6282371|NCT02305563|9993277|FG004|Treatment Period|added ULO, then disease progression|4
6282372|NCT02305563|9993273|FG000|Treatment Period|added ULO; then other reason|0
6282373|NCT02305563|9993274|FG001|Treatment Period|added ULO; then other reason|0
6282374|NCT02305563|9993275|FG002|Treatment Period|added ULO; then other reason|0
6282375|NCT02305563|9993276|FG003|Treatment Period|added ULO; then other reason|0
6282376|NCT02305563|9993277|FG004|Treatment Period|added ULO; then other reason|1
6282377|NCT02305563|9993273|FG000|Treatment Period|added ULO, then request to stop|0
6282378|NCT02305563|9993274|FG001|Treatment Period|added ULO, then request to stop|0
6282379|NCT02305563|9993275|FG002|Treatment Period|added ULO, then request to stop|0
6282380|NCT02305563|9993276|FG003|Treatment Period|added ULO, then request to stop|0
6282381|NCT02305563|9993277|FG004|Treatment Period|added ULO, then request to stop|1
6282382|NCT02305563|9993273|FG000|Follow-up Period|Death|0
6282383|NCT02305563|9993274|FG001|Follow-up Period|Death|0
6282384|NCT02305563|9993275|FG002|Follow-up Period|Death|5
6282385|NCT02305563|9993276|FG003|Follow-up Period|Death|4
6282386|NCT02305563|9993277|FG004|Follow-up Period|Death|7
6282387|NCT02305563|9993273|FG000|Follow-up Period|Participant withdrew consent|0
6282388|NCT02305563|9993274|FG001|Follow-up Period|Participant withdrew consent|0
6282389|NCT02305563|9993275|FG002|Follow-up Period|Participant withdrew consent|2
6282390|NCT02305563|9993276|FG003|Follow-up Period|Participant withdrew consent|1
6282391|NCT02305563|9993277|FG004|Follow-up Period|Participant withdrew consent|0
6282392|NCT02305563|9993273|FG000|Follow-up Period|other reason|0
6282393|NCT02305563|9993274|FG001|Follow-up Period|other reason|0
6282394|NCT02305563|9993275|FG002|Follow-up Period|other reason|0
6282395|NCT02305563|9993276|FG003|Follow-up Period|other reason|0
6282396|NCT02305563|9993277|FG004|Follow-up Period|other reason|1
6282397|NCT02305563|9993273|FG000|Follow-up Period|Followup no longer required per protocol|3
6282398|NCT02305563|9993274|FG001|Follow-up Period|Followup no longer required per protocol|3
6282399|NCT02305563|9993275|FG002|Follow-up Period|Followup no longer required per protocol|4
6282400|NCT02305563|9993276|FG003|Follow-up Period|Followup no longer required per protocol|1
6282401|NCT02305563|9993277|FG004|Follow-up Period|Followup no longer required per protocol|4
6089390|NCT00684177|9700976|FG000|Overall Study|Protocol Violation|1
6089391|NCT00684177|9700977|FG001|Overall Study|Protocol Violation|0
6089392|NCT00684177|9700976|FG000|Overall Study|Lost to Follow-up|2
6089393|NCT00684177|9700977|FG001|Overall Study|Lost to Follow-up|1
6089394|NCT00684177|9700976|FG000|Overall Study|Physician Decision|2
6089395|NCT00684177|9700977|FG001|Overall Study|Physician Decision|0
6089396|NCT00684177|9700976|FG000|Overall Study|Withdrawal by Subject|1
6089397|NCT00684177|9700977|FG001|Overall Study|Withdrawal by Subject|2
6089398|NCT00684177|9700976|FG000|Overall Study|Other|1
6089399|NCT00684177|9700977|FG001|Overall Study|Other|2
6089400|NCT00684203|9700989|FG000|Overall Study|Adverse Event|6
6089401|NCT00684203|9700990|FG001|Overall Study|Adverse Event|4
6089402|NCT00684203|9700991|FG002|Overall Study|Adverse Event|8
6089403|NCT00684203|9700992|FG003|Overall Study|Adverse Event|0
6089404|NCT00684203|9700993|FG004|Overall Study|Adverse Event|0
6089405|NCT00684203|9700994|FG005|Overall Study|Adverse Event|0
6089406|NCT00684203|9700989|FG000|Overall Study|Protocol-defined clinical event|3
6089407|NCT00684203|9700990|FG001|Overall Study|Protocol-defined clinical event|1
6089408|NCT00684203|9700991|FG002|Overall Study|Protocol-defined clinical event|0
6089409|NCT00684203|9700992|FG003|Overall Study|Protocol-defined clinical event|0
6089410|NCT00684203|9700993|FG004|Overall Study|Protocol-defined clinical event|0
6089411|NCT00684203|9700994|FG005|Overall Study|Protocol-defined clinical event|0
6089412|NCT00684203|9700989|FG000|Overall Study|Withdrawal by Subject|0
6089413|NCT00684203|9700990|FG001|Overall Study|Withdrawal by Subject|2
6089414|NCT00684203|9700991|FG002|Overall Study|Withdrawal by Subject|1
6089415|NCT00684203|9700992|FG003|Overall Study|Withdrawal by Subject|0
6089416|NCT00684203|9700993|FG004|Overall Study|Withdrawal by Subject|0
6089417|NCT00684203|9700994|FG005|Overall Study|Withdrawal by Subject|0
6089418|NCT00684203|9700989|FG000|Overall Study|Did not meet protocol eligibility|0
6089419|NCT00684203|9700990|FG001|Overall Study|Did not meet protocol eligibility|1
6089420|NCT00684203|9700991|FG002|Overall Study|Did not meet protocol eligibility|0
6089421|NCT00684203|9700992|FG003|Overall Study|Did not meet protocol eligibility|0
6089422|NCT00684203|9700993|FG004|Overall Study|Did not meet protocol eligibility|0
6089423|NCT00684203|9700994|FG005|Overall Study|Did not meet protocol eligibility|0
6089424|NCT00684307|9701024|FG000|Overall Study|Adverse Event|11
6089425|NCT00684307|9701025|FG001|Overall Study|Adverse Event|6
6089426|NCT00684307|9701026|FG002|Overall Study|Adverse Event|15
6089427|NCT00684307|9701027|FG003|Overall Study|Adverse Event|16
6089428|NCT00684307|9701028|FG004|Overall Study|Adverse Event|8
6089429|NCT00684307|9701024|FG000|Overall Study|Development of increasing Liver Function|0
6089430|NCT00684307|9701025|FG001|Overall Study|Development of increasing Liver Function|2
6089431|NCT00684307|9701026|FG002|Overall Study|Development of increasing Liver Function|0
6089432|NCT00684307|9701027|FG003|Overall Study|Development of increasing Liver Function|1
6282402|NCT02305758|9993300|FG000|Overall Study|Death|27
6089433|NCT00684307|9701028|FG004|Overall Study|Development of increasing Liver Function|0
6089434|NCT00684307|9701024|FG000|Overall Study|Fullfillment of exclusion criteria|1
6282403|NCT02305758|9993301|FG001|Overall Study|Death|27
6282404|NCT02305758|9993300|FG000|Overall Study|Withdrew consent|9
6282405|NCT02305758|9993301|FG001|Overall Study|Withdrew consent|2
6282406|NCT02305758|9993300|FG000|Overall Study|Lost to Follow-up|6
6282407|NCT02305758|9993301|FG001|Overall Study|Lost to Follow-up|1
6282408|NCT02305758|9993300|FG000|Overall Study|Study Terminated by Sponsor|21
6282409|NCT02305758|9993301|FG001|Overall Study|Study Terminated by Sponsor|34
6282410|NCT02305758|9993300|FG000|Overall Study|Other, not specified|2
6282411|NCT02305758|9993301|FG001|Overall Study|Other, not specified|1
6282412|NCT02305797|9993309|FG000|Overall Study|Adverse Event|11
5980022|NCT02546986|9568508|FG001|Treatment Period|Physician Decision|2
5980023|NCT02546986|9568507|FG000|Treatment Period|Protocol Violation|1
5980024|NCT02546986|9568508|FG001|Treatment Period|Protocol Violation|0
5980025|NCT02546986|9568507|FG000|Treatment Period|Withdrawal by Subject|1
5980026|NCT02546986|9568508|FG001|Treatment Period|Withdrawal by Subject|1
5980027|NCT02546986|9568507|FG000|Treatment Period|Non-compliance with Study Drug|0
5980028|NCT02546986|9568508|FG001|Treatment Period|Non-compliance with Study Drug|1
5980029|NCT02546986|9568507|FG000|Treatment Period|Study Terminated by Sponsor|0
5980030|NCT02546986|9568508|FG001|Treatment Period|Study Terminated by Sponsor|1
5980031|NCT02546986|9568507|FG000|Treatment Period|Miscellaneous|7
5980032|NCT02546986|9568508|FG001|Treatment Period|Miscellaneous|9
5980033|NCT02546986|9568507|FG000|Survival Follow-Up Phase|Missing Status|3
5980034|NCT02546986|9568508|FG001|Survival Follow-Up Phase|Missing Status|5
5980035|NCT02546986|9568507|FG000|Survival Follow-Up Phase|Death|18
5980036|NCT02546986|9568508|FG001|Survival Follow-Up Phase|Death|12
5980037|NCT02546986|9568507|FG000|Survival Follow-Up Phase|Alive|13
5980038|NCT02546986|9568508|FG001|Survival Follow-Up Phase|Alive|16
5980039|NCT02546986|9568507|FG000|Survival Follow-Up Phase|Lost to Follow-up|2
5980040|NCT02546986|9568508|FG001|Survival Follow-Up Phase|Lost to Follow-up|2
5980041|NCT02539160|9568516|FG000|Phase 1 Pre-crossover|Adverse Event|3
5980042|NCT02539160|9568517|FG001|Phase 1 Pre-crossover|Adverse Event|3
5980043|NCT02539160|9568518|FG002|Phase 1 Pre-crossover|Adverse Event|2
5980044|NCT02539160|9568519|FG003|Phase 1 Pre-crossover|Adverse Event|1
5980045|NCT02539160|9568516|FG000|Phase 1 Pre-crossover|Withdrawal by Subject|2
5980046|NCT02539160|9568517|FG001|Phase 1 Pre-crossover|Withdrawal by Subject|1
5980047|NCT02539160|9568518|FG002|Phase 1 Pre-crossover|Withdrawal by Subject|1
5980048|NCT02539160|9568519|FG003|Phase 1 Pre-crossover|Withdrawal by Subject|0
5980049|NCT02539160|9568516|FG000|Phase 1 Pre-crossover|Protocol Violation|0
5980050|NCT02539160|9568517|FG001|Phase 1 Pre-crossover|Protocol Violation|0
5980051|NCT02539160|9568518|FG002|Phase 1 Pre-crossover|Protocol Violation|0
5980052|NCT02539160|9568519|FG003|Phase 1 Pre-crossover|Protocol Violation|2
5980053|NCT02507973|9568529|FG000|Overall Study|Adverse Event|1
5980054|NCT02477696|9568537|FG000|Overall Study|Adverse Event|40
5980055|NCT02477696|9568538|FG001|Overall Study|Adverse Event|59
5980056|NCT02477696|9568537|FG000|Overall Study|CLL Disease Progression|82
5980057|NCT02477696|9568538|FG001|Overall Study|CLL Disease Progression|68
5980058|NCT02477696|9568537|FG000|Overall Study|Includes Non-compliance, Relocation, Subject's Decision and Medical Monitor's Decision.|2
5980059|NCT02477696|9568538|FG001|Overall Study|Includes Non-compliance, Relocation, Subject's Decision and Medical Monitor's Decision.|10
5980060|NCT02477696|9568537|FG000|Overall Study|Death|5
5980061|NCT02477696|9568538|FG001|Overall Study|Death|6
5980062|NCT02477696|9568537|FG000|Overall Study|Withdrawal by Subject|7
5980063|NCT02477696|9568538|FG001|Overall Study|Withdrawal by Subject|7
5980064|NCT02477696|9568537|FG000|Overall Study|Physician Decision|5
5980065|NCT02477696|9568538|FG001|Overall Study|Physician Decision|5
5980066|NCT02477618|9568546|FG000|Overall Study|Completed Visits but Discontinued Drug|2
5980067|NCT02477618|9568547|FG001|Overall Study|Completed Visits but Discontinued Drug|1
5980068|NCT02477618|9568546|FG000|Overall Study|Died in Double-Blind Treatment Period|11
5980069|NCT02477618|9568547|FG001|Overall Study|Died in Double-Blind Treatment Period|11
5980070|NCT02477618|9568546|FG000|Overall Study|Adverse Event|1
5980071|NCT02477618|9568547|FG001|Overall Study|Adverse Event|1
6282413|NCT02305797|9993310|FG001|Overall Study|Adverse Event|2
6282414|NCT02305797|9993309|FG000|Overall Study|Withdrawal by Subject|9
6282415|NCT02305797|9993310|FG001|Overall Study|Withdrawal by Subject|10
6282416|NCT02305797|9993309|FG000|Overall Study|Lack of Efficacy|6
6282417|NCT02305797|9993310|FG001|Overall Study|Lack of Efficacy|0
6282418|NCT02305797|9993309|FG000|Overall Study|Lost to Follow-up|5
6282419|NCT02305797|9993310|FG001|Overall Study|Lost to Follow-up|11
6282420|NCT02305797|9993309|FG000|Overall Study|Pregnancy|0
6282421|NCT02305797|9993310|FG001|Overall Study|Pregnancy|2
6282422|NCT02305797|9993309|FG000|Overall Study|Noncompliance|14
6282423|NCT02305797|9993310|FG001|Overall Study|Noncompliance|12
6282424|NCT02305797|9993309|FG000|Overall Study|Reason not collected|0
6282425|NCT02305797|9993310|FG001|Overall Study|Reason not collected|1
6282426|NCT02305849|9993319|FG000|Overall Study|Adverse Event|10
6282427|NCT02305849|9993320|FG001|Overall Study|Adverse Event|12
6282428|NCT02305849|9993321|FG002|Overall Study|Adverse Event|7
6282429|NCT02305849|9993322|FG003|Overall Study|Adverse Event|3
6282430|NCT02305849|9993319|FG000|Overall Study|Lack of Efficacy|10
6282431|NCT02305849|9993320|FG001|Overall Study|Lack of Efficacy|6
6282432|NCT02305849|9993321|FG002|Overall Study|Lack of Efficacy|3
6282433|NCT02305849|9993322|FG003|Overall Study|Lack of Efficacy|9
5980072|NCT02477618|9568546|FG000|Overall Study|Transferred Away from Study Site|1
5980073|NCT02477618|9568547|FG001|Overall Study|Transferred Away from Study Site|0
6282434|NCT02305849|9993319|FG000|Overall Study|Withdrawal by Subject|2
6282435|NCT02305849|9993320|FG001|Overall Study|Withdrawal by Subject|2
6282436|NCT02305849|9993321|FG002|Overall Study|Withdrawal by Subject|1
6282437|NCT02305849|9993322|FG003|Overall Study|Withdrawal by Subject|4
6282438|NCT02305849|9993319|FG000|Overall Study|Lost to Follow-up|0
6282439|NCT02305849|9993320|FG001|Overall Study|Lost to Follow-up|2
6282440|NCT02305849|9993321|FG002|Overall Study|Lost to Follow-up|0
6282441|NCT02305849|9993322|FG003|Overall Study|Lost to Follow-up|0
6282442|NCT02305849|9993319|FG000|Overall Study|Protocol Violation|3
6282443|NCT02305849|9993320|FG001|Overall Study|Protocol Violation|2
6282444|NCT02305849|9993321|FG002|Overall Study|Protocol Violation|1
5980074|NCT02477618|9568546|FG000|Overall Study|Left Study Site for Rehabilitation|0
5980075|NCT02477618|9568547|FG001|Overall Study|Left Study Site for Rehabilitation|1
5980076|NCT02003924|9568579|FG000|Double-blind Phase|Lost to Follow-up|2
5980077|NCT02003924|9568580|FG001|Double-blind Phase|Lost to Follow-up|1
5980078|NCT02003924|9568581|FG002|Double-blind Phase|Lost to Follow-up|0
5980079|NCT02003924|9568579|FG000|Double-blind Phase|Protocol Violation|1
5980080|NCT02003924|9568580|FG001|Double-blind Phase|Protocol Violation|2
5980081|NCT02003924|9568581|FG002|Double-blind Phase|Protocol Violation|0
5980082|NCT02003924|9568579|FG000|Double-blind Phase|Withdrawal Consent to Continue Treatment|71
5980083|NCT02003924|9568580|FG001|Double-blind Phase|Withdrawal Consent to Continue Treatment|47
5980084|NCT02003924|9568581|FG002|Double-blind Phase|Withdrawal Consent to Continue Treatment|0
5980085|NCT02003924|9568579|FG000|Double-blind Phase|Disease Progression|229
5980086|NCT02003924|9568580|FG001|Double-blind Phase|Disease Progression|247
5980087|NCT02003924|9568581|FG002|Double-blind Phase|Disease Progression|0
5980088|NCT02003924|9568579|FG000|Double-blind Phase|Adverse Event|120
5980089|NCT02003924|9568580|FG001|Double-blind Phase|Adverse Event|31
5980090|NCT02003924|9568581|FG002|Double-blind Phase|Adverse Event|0
5980091|NCT02003924|9568579|FG000|Double-blind Phase|Randomized But not Treated|3
5980092|NCT02003924|9568580|FG001|Double-blind Phase|Randomized But not Treated|3
5980093|NCT02003924|9568581|FG002|Double-blind Phase|Randomized But not Treated|0
5980094|NCT02003924|9568579|FG000|Double-blind Phase|Other|29
5980095|NCT02003924|9568580|FG001|Double-blind Phase|Other|50
5980096|NCT02003924|9568581|FG002|Double-blind Phase|Other|0
5980097|NCT02003924|9568579|FG000|Open-label Phase|Lost to Follow-up|0
5980098|NCT02003924|9568580|FG001|Open-label Phase|Lost to Follow-up|0
5980099|NCT02003924|9568581|FG002|Open-label Phase|Lost to Follow-up|1
6051581|NCT00433966|9650870|FG001|Pharmacology Intervention/Randomization|Not true myocardial infarction|28
6051582|NCT00433966|9650871|FG002|Pharmacology Intervention/Randomization|Not true myocardial infarction|0
6202058|NCT01498887|9862130|FG001|Overall Study|Protocol Violation|3
6202059|NCT01498887|9862129|FG000|Overall Study|Lack of Efficacy|5
6202060|NCT01498887|9862130|FG001|Overall Study|Lack of Efficacy|3
6202061|NCT01498887|9862129|FG000|Overall Study|Abnormal result from test procedure|1
6202062|NCT01498887|9862130|FG001|Overall Study|Abnormal result from test procedure|1
6202063|NCT01498887|9862129|FG000|Overall Study|Abnormal laboratory value|2
6202064|NCT01498887|9862130|FG001|Overall Study|Abnormal laboratory value|2
6202065|NCT01498887|9862129|FG000|Overall Study|Adverse Event|4
6202066|NCT01498887|9862130|FG001|Overall Study|Adverse Event|1
6202067|NCT01498952|9862139|FG000|Overall Study|Death|2
6202068|NCT01498952|9862140|FG001|Overall Study|Death|2
6202069|NCT01498952|9862141|FG002|Overall Study|Death|0
6202070|NCT01498952|9862142|FG003|Overall Study|Death|0
6202071|NCT01498952|9862143|FG004|Overall Study|Death|0
6202072|NCT01499043|9862162|FG000|Overall Study|Progressive disease (radiographic)|2
6202073|NCT01499043|9862162|FG000|Overall Study|Progressive disease (clinical)|1
6202074|NCT01499043|9862162|FG000|Overall Study|Withdrawal by Subject|2
6202075|NCT01499043|9862162|FG000|Overall Study|Adverse Event|1
6202076|NCT01499134|9862173|FG000|Overall Study|Withdrawal by Subject|0
6202077|NCT01499134|9862174|FG001|Overall Study|Withdrawal by Subject|1
6202078|NCT01499199|9862198|FG000|Overall Study|Adverse Event|1
6282445|NCT02305849|9993322|FG003|Overall Study|Protocol Violation|1
6282446|NCT02305849|9993319|FG000|Overall Study|Lab data met discontinuation criteria|0
6282447|NCT02305849|9993320|FG001|Overall Study|Lab data met discontinuation criteria|1
6282448|NCT02305849|9993321|FG002|Overall Study|Lab data met discontinuation criteria|2
6282449|NCT02305849|9993322|FG003|Overall Study|Lab data met discontinuation criteria|1
6282450|NCT02305849|9993319|FG000|Overall Study|Miscellaneous|1
6282451|NCT02305849|9993320|FG001|Overall Study|Miscellaneous|2
6282452|NCT02305849|9993321|FG002|Overall Study|Miscellaneous|4
6282453|NCT02305849|9993322|FG003|Overall Study|Miscellaneous|1
6282454|NCT02305849|9993319|FG000|Overall Study|Not fulfill eligibility criteria|1
6282455|NCT02305849|9993320|FG001|Overall Study|Not fulfill eligibility criteria|1
6282456|NCT02305849|9993321|FG002|Overall Study|Not fulfill eligibility criteria|0
6282457|NCT02305849|9993322|FG003|Overall Study|Not fulfill eligibility criteria|0
6282458|NCT02305888|9993356|FG000|Overall Study|Lost to Follow-up|0
6282459|NCT02305888|9993357|FG001|Overall Study|Lost to Follow-up|0
6282460|NCT02305888|9993358|FG002|Overall Study|Lost to Follow-up|1
6282461|NCT02305888|9993356|FG000|Overall Study|Adverse Event|0
6282462|NCT02305888|9993357|FG001|Overall Study|Adverse Event|1
5980100|NCT02003924|9568579|FG000|Open-label Phase|Withdrawal Consent to Continue Treatment|9
5980101|NCT02003924|9568580|FG001|Open-label Phase|Withdrawal Consent to Continue Treatment|0
5980102|NCT02003924|9568581|FG002|Open-label Phase|Withdrawal Consent to Continue Treatment|1
5980103|NCT02003924|9568579|FG000|Open-label Phase|Disease Progression|59
6202079|NCT01499199|9862198|FG000|Overall Study|Lack of Efficacy|1
6202080|NCT01499277|9862204|FG000|Overall Study|Adverse Event|3
6202081|NCT01499277|9862205|FG001|Overall Study|Adverse Event|6
6282463|NCT02305888|9993358|FG002|Overall Study|Adverse Event|0
6282464|NCT02306265|9993366|FG000|Overall Study|Withdrawal by Subject|1
6282465|NCT02306694|9993371|FG000|Overall Study|Withdrawal by Subject|3
6282466|NCT02306694|9993371|FG000|Overall Study|Lost to Follow-up|1
6282467|NCT02306850|9993386|FG000|Overall Study|Lack of Efficacy|2
6282468|NCT02307266|9993402|FG000|Overall Study|Adverse Event|3
6282469|NCT02307266|9993403|FG001|Overall Study|Adverse Event|1
6282470|NCT02307266|9993404|FG002|Overall Study|Adverse Event|5
6282471|NCT02307266|9993402|FG000|Overall Study|Withdrawal by Subject|2
6282472|NCT02307266|9993403|FG001|Overall Study|Withdrawal by Subject|0
6282473|NCT02307266|9993404|FG002|Overall Study|Withdrawal by Subject|1
6282474|NCT02307266|9993402|FG000|Overall Study|Lost to Follow-up|3
6282475|NCT02307266|9993403|FG001|Overall Study|Lost to Follow-up|0
6282476|NCT02307266|9993404|FG002|Overall Study|Lost to Follow-up|0
6282477|NCT02307370|9993416|FG000|Overall Study|Death|5
6282478|NCT02307370|9993416|FG000|Overall Study|Lost to Follow-up|1
6282479|NCT02307370|9993416|FG000|Overall Study|Withdrawal by Subject|1
6282480|NCT02307370|9993416|FG000|Overall Study|Declined Addendum ICF|6
6282481|NCT02307370|9993416|FG000|Overall Study|No response during telephone contact|5
5980104|NCT02003924|9568580|FG001|Open-label Phase|Disease Progression|0
5980105|NCT02003924|9568581|FG002|Open-label Phase|Disease Progression|5
5980106|NCT02003924|9568579|FG000|Open-label Phase|Adverse Event|25
6202082|NCT01499277|9862204|FG000|Overall Study|Death|3
6202083|NCT01499277|9862205|FG001|Overall Study|Death|2
6202084|NCT01499277|9862204|FG000|Overall Study|Lost to Follow-up|15
6202085|NCT01499277|9862205|FG001|Overall Study|Lost to Follow-up|8
6202086|NCT01499277|9862204|FG000|Overall Study|Protocol Violation|2
6202087|NCT01499277|9862205|FG001|Overall Study|Protocol Violation|3
6202088|NCT01499277|9862204|FG000|Overall Study|Withdrawal by Subject|16
5980107|NCT02003924|9568580|FG001|Open-label Phase|Adverse Event|0
5980108|NCT02003924|9568581|FG002|Open-label Phase|Adverse Event|10
5980109|NCT02003924|9568579|FG000|Open-label Phase|Other|7
5980110|NCT02003924|9568580|FG001|Open-label Phase|Other|0
5980111|NCT02003924|9568581|FG002|Open-label Phase|Other|0
5980112|NCT02003924|9568579|FG000|Long-term Follow-up Phase|Death|288
5980113|NCT02003924|9568580|FG001|Long-term Follow-up Phase|Death|174
5980114|NCT02003924|9568581|FG002|Long-term Follow-up Phase|Death|4
5980115|NCT02003924|9568579|FG000|Long-term Follow-up Phase|Lost to Follow-up|8
5980116|NCT02003924|9568580|FG001|Long-term Follow-up Phase|Lost to Follow-up|6
5980117|NCT02003924|9568581|FG002|Long-term Follow-up Phase|Lost to Follow-up|1
5980118|NCT02003924|9568579|FG000|Long-term Follow-up Phase|Withdrew Consent to Be Followed|66
5980119|NCT02003924|9568580|FG001|Long-term Follow-up Phase|Withdrew Consent to Be Followed|55
5980120|NCT02003924|9568581|FG002|Long-term Follow-up Phase|Withdrew Consent to Be Followed|1
5980121|NCT02003924|9568579|FG000|Long-term Follow-up Phase|Other|5
5980122|NCT02003924|9568580|FG001|Long-term Follow-up Phase|Other|2
5980123|NCT02003924|9568581|FG002|Long-term Follow-up Phase|Other|1
5980124|NCT01971970|9568590|FG000|Baseline Until Week 6|Stopped anti-TNF use|1
5980125|NCT01971970|9568591|FG001|Baseline Until Week 6|Stopped anti-TNF use|0
6089435|NCT00684307|9701025|FG001|Overall Study|Fullfillment of exclusion criteria|0
6089436|NCT00684307|9701026|FG002|Overall Study|Fullfillment of exclusion criteria|0
6089437|NCT00684307|9701027|FG003|Overall Study|Fullfillment of exclusion criteria|3
6089438|NCT00684307|9701028|FG004|Overall Study|Fullfillment of exclusion criteria|1
6089439|NCT00684307|9701024|FG000|Overall Study|Incorrect enrolment or randomization|4
6089440|NCT00684307|9701025|FG001|Overall Study|Incorrect enrolment or randomization|0
6089441|NCT00684307|9701026|FG002|Overall Study|Incorrect enrolment or randomization|0
6089442|NCT00684307|9701027|FG003|Overall Study|Incorrect enrolment or randomization|0
6089443|NCT00684307|9701028|FG004|Overall Study|Incorrect enrolment or randomization|0
6089444|NCT00684307|9701024|FG000|Overall Study|Interupted IP for more than 7 days|0
6089445|NCT00684307|9701025|FG001|Overall Study|Interupted IP for more than 7 days|4
6089446|NCT00684307|9701026|FG002|Overall Study|Interupted IP for more than 7 days|1
6202089|NCT01499277|9862205|FG001|Overall Study|Withdrawal by Subject|6
6202090|NCT01499277|9862204|FG000|Overall Study|Lack of therapeutic response and other|8
6202091|NCT01499277|9862205|FG001|Overall Study|Lack of therapeutic response and other|7
6202092|NCT01499290|9862213|FG000|Overall Study|Withdrawal by Subject|22
5980126|NCT01971970|9568590|FG000|Week 6 Until Week 8|Stopped anti-TNF use|0
5980127|NCT01971970|9568591|FG001|Week 6 Until Week 8|Stopped anti-TNF use|1
5980128|NCT01971970|9568590|FG000|Week 14 Until Week 22|Lost to Follow-up|0
5980129|NCT01971970|9568591|FG001|Week 14 Until Week 22|Lost to Follow-up|1
5980130|NCT01971970|9568590|FG000|Week 22 Until Week 52|Stopped anti-TNF use|7
5980131|NCT01971970|9568591|FG001|Week 22 Until Week 52|Stopped anti-TNF use|3
5980132|NCT01971970|9568590|FG000|Week 22 Until Week 52|Stopped anti-TNF use without escalation because of antibody-to-infliximab (ATI) formation|1
5980133|NCT01971970|9568591|FG001|Week 22 Until Week 52|Stopped anti-TNF use without escalation because of antibody-to-infliximab (ATI) formation|0
5980134|NCT01971970|9568590|FG000|Week 22 Until Week 52|Stopped anti-TNF due to endoscopic improvement 1 year after start|0
5980135|NCT01971970|9568591|FG001|Week 22 Until Week 52|Stopped anti-TNF due to endoscopic improvement 1 year after start|1
5980136|NCT01971970|9568590|FG000|Week 52 Until Week 78|Stopped anti-TNF use|1
6282482|NCT02307370|9993416|FG000|Overall Study|Protocol Violation|1
6282483|NCT02307513|9993424|FG000|Placebo Controlled Phase (Weeks 0-12)|Adverse Event|4
6282484|NCT02307513|9993425|FG001|Placebo Controlled Phase (Weeks 0-12)|Adverse Event|3
6282485|NCT02307513|9993424|FG000|Placebo Controlled Phase (Weeks 0-12)|Lack of Efficacy|8
6282486|NCT02307513|9993425|FG001|Placebo Controlled Phase (Weeks 0-12)|Lack of Efficacy|0
6282487|NCT02307513|9993424|FG000|Placebo Controlled Phase (Weeks 0-12)|Non-Compliance with Study Drug|1
6282488|NCT02307513|9993425|FG001|Placebo Controlled Phase (Weeks 0-12)|Non-Compliance with Study Drug|0
5980137|NCT01971970|9568591|FG001|Week 52 Until Week 78|Stopped anti-TNF use|3
5980138|NCT01969409|9568604|FG000|Overall Study|Death|2
5980139|NCT01969409|9568605|FG001|Overall Study|Death|2
6282489|NCT02307513|9993424|FG000|Placebo Controlled Phase (Weeks 0-12)|Withdrawal by Subject|5
6282490|NCT02307513|9993425|FG001|Placebo Controlled Phase (Weeks 0-12)|Withdrawal by Subject|4
5980140|NCT01969409|9568604|FG000|Overall Study|Transplant|1
5980141|NCT01969409|9568605|FG001|Overall Study|Transplant|1
5980142|NCT01969409|9568604|FG000|Overall Study|Withdrawal by Subject|0
5980143|NCT01969409|9568605|FG001|Overall Study|Withdrawal by Subject|1
5980144|NCT01459497|9568613|FG000|Overall Study|Inability to meet trial constraints.|1
5980145|NCT01459497|9568614|FG001|Overall Study|Inability to meet trial constraints.|0
5980146|NCT01459497|9568613|FG000|Overall Study|Physician Decision|1
5980147|NCT01459497|9568614|FG001|Overall Study|Physician Decision|1
5980148|NCT01459497|9568613|FG000|Overall Study|Hospitalization.|0
5980149|NCT01459497|9568614|FG001|Overall Study|Hospitalization.|3
5980150|NCT01459497|9568613|FG000|Overall Study|Disease progression.|0
5980151|NCT01459497|9568614|FG001|Overall Study|Disease progression.|1
5980152|NCT01307787|9568622|FG000|Overall Study|Withdrawal by Subject|2
5980153|NCT01307787|9568623|FG001|Overall Study|Withdrawal by Subject|0
5980154|NCT01250912|9568634|FG000|Overall Study|Lost to Follow-up|1
5980155|NCT01141712|9568650|FG000|Overall Study|Disease progression|3
5980156|NCT00659646|9568667|FG000|Overall Study|Protocol Violation|12
5980157|NCT00659646|9568668|FG001|Overall Study|Protocol Violation|8
5980158|NCT00659646|9568667|FG000|Overall Study|Adverse Event|1
5980159|NCT00659646|9568668|FG001|Overall Study|Adverse Event|0
5980160|NCT00659646|9568667|FG000|Overall Study|Lost to Follow-up|1
5980161|NCT00659646|9568668|FG001|Overall Study|Lost to Follow-up|0
5980162|NCT00659646|9568667|FG000|Overall Study|protocol noncompliance after randomized|1
5980163|NCT00659646|9568668|FG001|Overall Study|protocol noncompliance after randomized|0
5980164|NCT00567580|9568679|FG000|Overall Study|Protocol Violation|28
5980165|NCT00567580|9568680|FG001|Overall Study|Protocol Violation|24
5980166|NCT00567580|9568681|FG002|Overall Study|Protocol Violation|24
6051583|NCT00433966|9650872|FG003|Pharmacology Intervention/Randomization|Not true myocardial infarction|0
6051584|NCT00433966|9650869|FG000|Stent Intervention/Randomization|Withdrawal by Subject|0
6051585|NCT00433966|9650870|FG001|Stent Intervention/Randomization|Withdrawal by Subject|0
6051586|NCT00433966|9650871|FG002|Stent Intervention/Randomization|Withdrawal by Subject|41
6051587|NCT00433966|9650872|FG003|Stent Intervention/Randomization|Withdrawal by Subject|15
6051588|NCT00433966|9650869|FG000|Stent Intervention/Randomization|Lost to Follow-up|0
6051589|NCT00433966|9650870|FG001|Stent Intervention/Randomization|Lost to Follow-up|0
6051590|NCT00433966|9650871|FG002|Stent Intervention/Randomization|Lost to Follow-up|113
6051591|NCT00433966|9650872|FG003|Stent Intervention/Randomization|Lost to Follow-up|47
6051592|NCT00434057|9650905|FG000|Overall Study|Withdrawal by Subject|1
6051593|NCT00434109|9650909|FG000|Overall Study|Physician Decision|9
6051594|NCT00434109|9650909|FG000|Overall Study|Adverse Event|5
6051595|NCT00434109|9650909|FG000|Overall Study|Protocol Violation|1
6051596|NCT00434109|9650909|FG000|Overall Study|had embolism, did not receive sunitinib|3
6051597|NCT00434122|9650915|FG000|Overall Study|Non-compliance with protocol|0
6051598|NCT00434122|9650916|FG001|Overall Study|Non-compliance with protocol|1
6051599|NCT00434122|9650915|FG000|Overall Study|loss of subject contact|1
6051600|NCT00434122|9650916|FG001|Overall Study|loss of subject contact|1
6051601|NCT00434122|9650915|FG000|Overall Study|Personal reasons|1
6051602|NCT00434122|9650916|FG001|Overall Study|Personal reasons|1
6051603|NCT00434122|9650915|FG000|Overall Study|Large follicle size|2
6051604|NCT00434122|9650916|FG001|Overall Study|Large follicle size|2
6051605|NCT00434122|9650915|FG000|Overall Study|Low follicular response.|1
6051606|NCT00434122|9650916|FG001|Overall Study|Low follicular response.|2
6051607|NCT00434122|9650915|FG000|Overall Study|Travelling of subject.|1
6051608|NCT00434122|9650916|FG001|Overall Study|Travelling of subject.|0
6051609|NCT00434148|9650926|FG000|Overall Study|Adverse Event|18
6051610|NCT00434148|9650927|FG001|Overall Study|Adverse Event|18
6051611|NCT00434148|9650926|FG000|Overall Study|Lack of Efficacy|25
6051612|NCT00434148|9650927|FG001|Overall Study|Lack of Efficacy|28
6051613|NCT00434148|9650926|FG000|Overall Study|Withdrawal by Subject|15
6051614|NCT00434148|9650927|FG001|Overall Study|Withdrawal by Subject|15
6282491|NCT02307513|9993424|FG000|Placebo Controlled Phase (Weeks 0-12)|Lost to Follow-up|1
6282492|NCT02307513|9993425|FG001|Placebo Controlled Phase (Weeks 0-12)|Lost to Follow-up|0
6282493|NCT02307513|9993424|FG000|Placebo Controlled Phase (Weeks 0-12)|Protocol Violation|1
6282494|NCT02307513|9993425|FG001|Placebo Controlled Phase (Weeks 0-12)|Protocol Violation|1
6282495|NCT02307513|9993424|FG000|Active Treatment Phase (Weeks 13-64)|Miscellaneous|0
6282496|NCT02307513|9993425|FG001|Active Treatment Phase (Weeks 13-64)|Miscellaneous|1
6282497|NCT02307513|9993424|FG000|Active Treatment Phase (Weeks 13-64)|Adverse Event|4
6051615|NCT00434148|9650926|FG000|Overall Study|Protocol Violation|4
6051616|NCT00434148|9650927|FG001|Overall Study|Protocol Violation|0
6051617|NCT00434148|9650926|FG000|Overall Study|Administrative problems|6
6051618|NCT00434148|9650927|FG001|Overall Study|Administrative problems|10
6282498|NCT02307513|9993425|FG001|Active Treatment Phase (Weeks 13-64)|Adverse Event|9
6282499|NCT02307513|9993424|FG000|Active Treatment Phase (Weeks 13-64)|Lack of Efficacy|2
6282500|NCT02307513|9993425|FG001|Active Treatment Phase (Weeks 13-64)|Lack of Efficacy|2
6282501|NCT02307513|9993424|FG000|Active Treatment Phase (Weeks 13-64)|Withdrawal by Subject|7
6282502|NCT02307513|9993425|FG001|Active Treatment Phase (Weeks 13-64)|Withdrawal by Subject|7
6282503|NCT02307513|9993424|FG000|Active Treatment Phase (Weeks 13-64)|Lost to Follow-up|1
6282504|NCT02307513|9993425|FG001|Active Treatment Phase (Weeks 13-64)|Lost to Follow-up|1
6282505|NCT02307513|9993424|FG000|Active Treatment Phase (Weeks 13-64)|Pregnancy|1
5980167|NCT00477412|9568696|FG000|Overall Study|Death|0
5980168|NCT00477412|9568697|FG001|Overall Study|Death|0
5980169|NCT00477412|9568698|FG002|Overall Study|Death|0
5980170|NCT00477412|9568699|FG003|Overall Study|Death|4
5980171|NCT00477412|9568696|FG000|Overall Study|Lost to Follow-up|0
5980172|NCT00477412|9568697|FG001|Overall Study|Lost to Follow-up|0
5980173|NCT00477412|9568698|FG002|Overall Study|Lost to Follow-up|0
5980174|NCT00477412|9568699|FG003|Overall Study|Lost to Follow-up|1
5980175|NCT00477412|9568696|FG000|Overall Study|Withdrawal by Subject|0
5980176|NCT00477412|9568697|FG001|Overall Study|Withdrawal by Subject|0
5980177|NCT00477412|9568698|FG002|Overall Study|Withdrawal by Subject|0
5980178|NCT00477412|9568699|FG003|Overall Study|Withdrawal by Subject|2
5980179|NCT00477412|9568696|FG000|Overall Study|Second Malignancy|0
5980180|NCT00477412|9568697|FG001|Overall Study|Second Malignancy|0
5980181|NCT00477412|9568698|FG002|Overall Study|Second Malignancy|0
5980182|NCT00477412|9568699|FG003|Overall Study|Second Malignancy|1
5980183|NCT00477412|9568696|FG000|Overall Study|Adverse Event|1
5980184|NCT00477412|9568697|FG001|Overall Study|Adverse Event|0
5980185|NCT00477412|9568698|FG002|Overall Study|Adverse Event|1
5980186|NCT00477412|9568699|FG003|Overall Study|Adverse Event|0
6051619|NCT00434148|9650926|FG000|Overall Study|Lost to Follow-up|0
6051620|NCT00434148|9650927|FG001|Overall Study|Lost to Follow-up|1
6051621|NCT00434148|9650926|FG000|Overall Study|Condition no longer requires study drug|1
6089447|NCT00684307|9701027|FG003|Overall Study|Interupted IP for more than 7 days|3
6089448|NCT00684307|9701028|FG004|Overall Study|Interupted IP for more than 7 days|3
6089449|NCT00684307|9701024|FG000|Overall Study|Severe non compliance to protocol|1
6089450|NCT00684307|9701025|FG001|Overall Study|Severe non compliance to protocol|0
6089451|NCT00684307|9701026|FG002|Overall Study|Severe non compliance to protocol|0
6089452|NCT00684307|9701027|FG003|Overall Study|Severe non compliance to protocol|1
6089453|NCT00684307|9701028|FG004|Overall Study|Severe non compliance to protocol|2
6089454|NCT00684307|9701024|FG000|Overall Study|Participant not willing to continue|7
6089455|NCT00684307|9701025|FG001|Overall Study|Participant not willing to continue|10
6089456|NCT00684307|9701026|FG002|Overall Study|Participant not willing to continue|11
6089457|NCT00684307|9701027|FG003|Overall Study|Participant not willing to continue|5
6089458|NCT00684307|9701028|FG004|Overall Study|Participant not willing to continue|8
6089459|NCT00684307|9701024|FG000|Overall Study|Criteria from the CSR|0
6089460|NCT00684307|9701025|FG001|Overall Study|Criteria from the CSR|0
6089461|NCT00684307|9701026|FG002|Overall Study|Criteria from the CSR|1
6089462|NCT00684307|9701027|FG003|Overall Study|Criteria from the CSR|3
6089463|NCT00684307|9701028|FG004|Overall Study|Criteria from the CSR|3
6089464|NCT00684411|9701049|FG000|Overall Study|New Primary Cancer|1
6089465|NCT00684411|9701049|FG000|Overall Study|Disease Progression|10
6089466|NCT00684411|9701049|FG000|Overall Study|Adverse Event|1
6089467|NCT00684424|9701053|FG000|Overall Study|Adverse Event|1
6089468|NCT00684424|9701053|FG000|Overall Study|Lost to Follow-up|2
6089469|NCT00684424|9701053|FG000|Overall Study|Other|2
6089470|NCT00684515|9701061|FG000|Overall Study|Adverse Event|3
6089471|NCT00684515|9701062|FG001|Overall Study|Adverse Event|3
6089472|NCT00684515|9701063|FG002|Overall Study|Adverse Event|1
6089473|NCT00684515|9701061|FG000|Overall Study|Protocol-Defined Clinical Event|1
6089474|NCT00684515|9701062|FG001|Overall Study|Protocol-Defined Clinical Event|0
6089475|NCT00684515|9701063|FG002|Overall Study|Protocol-Defined Clinical Event|0
6089476|NCT00684567|9701090|FG000|Concomitant Radiotherapy Period|Adverse Event|2
6089477|NCT00684567|9701090|FG000|Monotherapy Period|Adverse Event|2
6089478|NCT00684567|9701090|FG000|Monotherapy Period|Death|1
6089479|NCT00684567|9701090|FG000|Monotherapy Period|Progression of primary disease|11
6089480|NCT00684593|9701096|FG000|Overall Study|Adverse Event|0
6089481|NCT00684593|9701097|FG001|Overall Study|Adverse Event|2
6089482|NCT00684645|9701103|FG000|Overall Study|Death|2
6089483|NCT00684645|9701103|FG000|Overall Study|Progressive disease|67
6089484|NCT00684645|9701103|FG000|Overall Study|Adverse Event|27
6282506|NCT02307513|9993425|FG001|Active Treatment Phase (Weeks 13-64)|Pregnancy|0
6282507|NCT02307513|9993424|FG000|Long-term Extension|Physician Decision|1
6282508|NCT02307513|9993425|FG001|Long-term Extension|Physician Decision|0
6051622|NCT00434148|9650927|FG001|Overall Study|Condition no longer requires study drug|0
6051623|NCT00434148|9650926|FG000|Overall Study|Abnormal test procedure result|0
6051624|NCT00434148|9650927|FG001|Overall Study|Abnormal test procedure result|1
6051625|NCT00434161|9650936|FG000|Overall Study|Adverse Event|5
6051626|NCT00434161|9650937|FG001|Overall Study|Adverse Event|1
6051627|NCT00434161|9650938|FG002|Overall Study|Adverse Event|4
6282509|NCT02307682|9993448|FG000|Overall Study|Adverse Event|9
6282510|NCT02307682|9993449|FG001|Overall Study|Adverse Event|8
6282511|NCT02307682|9993450|FG002|Overall Study|Adverse Event|12
6282512|NCT02307682|9993448|FG000|Overall Study|Lack of Efficacy|1
6282513|NCT02307682|9993449|FG001|Overall Study|Lack of Efficacy|0
6282514|NCT02307682|9993450|FG002|Overall Study|Lack of Efficacy|1
6282515|NCT02307682|9993448|FG000|Overall Study|Physician Decision|2
6282516|NCT02307682|9993449|FG001|Overall Study|Physician Decision|2
6282517|NCT02307682|9993450|FG002|Overall Study|Physician Decision|8
6282518|NCT02307682|9993448|FG000|Overall Study|Progressive Disease|1
6282519|NCT02307682|9993449|FG001|Overall Study|Progressive Disease|0
6282520|NCT02307682|9993450|FG002|Overall Study|Progressive Disease|0
6282521|NCT02307682|9993448|FG000|Overall Study|Withdrawal by Subject|26
6282522|NCT02307682|9993449|FG001|Overall Study|Withdrawal by Subject|34
6282523|NCT02307682|9993450|FG002|Overall Study|Withdrawal by Subject|23
6282524|NCT02307682|9993448|FG000|Overall Study|Death|9
6282525|NCT02307682|9993449|FG001|Overall Study|Death|7
6282526|NCT02307682|9993450|FG002|Overall Study|Death|12
6282527|NCT02307682|9993448|FG000|Overall Study|Lost to Follow-up|1
6089485|NCT00684645|9701103|FG000|Overall Study|Lost to Follow-up|3
6089486|NCT00684645|9701103|FG000|Overall Study|Other|15
6089487|NCT00684671|9701110|FG000|Overall Study|Adverse Event|1
6089488|NCT00684671|9701111|FG001|Overall Study|Adverse Event|0
6089489|NCT00684671|9701112|FG002|Overall Study|Adverse Event|0
6282528|NCT02307682|9993449|FG001|Overall Study|Lost to Follow-up|5
6282529|NCT02307682|9993450|FG002|Overall Study|Lost to Follow-up|6
6282530|NCT02307682|9993448|FG000|Overall Study|Protocol Deviation|0
6282531|NCT02307682|9993449|FG001|Overall Study|Protocol Deviation|0
6282532|NCT02307682|9993450|FG002|Overall Study|Protocol Deviation|2
6282533|NCT02307682|9993448|FG000|Overall Study|Other|1
6282534|NCT02307682|9993449|FG001|Overall Study|Other|1
6282535|NCT02307682|9993450|FG002|Overall Study|Other|0
6282536|NCT02308007|9993484|FG000|Overall Study|Normal Gram stain or neg yeast culture|66
6282537|NCT02308007|9993485|FG001|Overall Study|Normal Gram stain or neg yeast culture|64
6282538|NCT02308007|9993486|FG002|Overall Study|Normal Gram stain or neg yeast culture|67
6282539|NCT02308007|9993484|FG000|Overall Study|Positive for STD at Baseline|7
6282540|NCT02308007|9993485|FG001|Overall Study|Positive for STD at Baseline|11
6282541|NCT02308007|9993486|FG002|Overall Study|Positive for STD at Baseline|7
6282542|NCT02308007|9993484|FG000|Overall Study|Lost to Follow-up|3
6282543|NCT02308007|9993485|FG001|Overall Study|Lost to Follow-up|0
6282544|NCT02308007|9993486|FG002|Overall Study|Lost to Follow-up|1
6282545|NCT02308020|9993500|FG000|Overall Study|Lost to Follow-up|1
6282546|NCT02308020|9993501|FG001|Overall Study|Lost to Follow-up|7
6282547|NCT02308020|9993502|FG002|Overall Study|Lost to Follow-up|0
6282548|NCT02308020|9993503|FG003|Overall Study|Lost to Follow-up|0
6282549|NCT02308020|9993504|FG004|Overall Study|Lost to Follow-up|1
6282550|NCT02308020|9993505|FG005|Overall Study|Lost to Follow-up|2
6282551|NCT02308020|9993500|FG000|Overall Study|Sponsor Decision|0
6282552|NCT02308020|9993501|FG001|Overall Study|Sponsor Decision|8
6282553|NCT02308020|9993502|FG002|Overall Study|Sponsor Decision|0
6282554|NCT02308020|9993503|FG003|Overall Study|Sponsor Decision|2
6282555|NCT02308020|9993504|FG004|Overall Study|Sponsor Decision|2
6282556|NCT02308020|9993505|FG005|Overall Study|Sponsor Decision|1
6282557|NCT02308020|9993500|FG000|Overall Study|Withdrawal by Subject|3
6282558|NCT02308020|9993501|FG001|Overall Study|Withdrawal by Subject|5
6282559|NCT02308020|9993502|FG002|Overall Study|Withdrawal by Subject|3
6282560|NCT02308020|9993503|FG003|Overall Study|Withdrawal by Subject|2
6282561|NCT02308020|9993504|FG004|Overall Study|Withdrawal by Subject|1
5980187|NCT00369317|9568707|FG000|Overall Study|Adverse Event|3
5980188|NCT00369317|9568707|FG000|Overall Study|Death|1
5980189|NCT00369317|9568707|FG000|Overall Study|Lack of Efficacy|5
6051628|NCT00434161|9650936|FG000|Overall Study|Lost to Follow-up|0
6051629|NCT00434161|9650937|FG001|Overall Study|Lost to Follow-up|1
6051630|NCT00434161|9650938|FG002|Overall Study|Lost to Follow-up|0
6051631|NCT00434161|9650936|FG000|Overall Study|Death|1
6051632|NCT00434161|9650937|FG001|Overall Study|Death|0
6089490|NCT00684671|9701110|FG000|Overall Study|Lost to Follow-up|1
6282562|NCT02308020|9993505|FG005|Overall Study|Withdrawal by Subject|2
6282563|NCT02308033|9993527|FG000|Overall Study|Normal Gram stain at Baseline|13
6282564|NCT02308033|9993528|FG001|Overall Study|Normal Gram stain at Baseline|10
6282565|NCT02308033|9993527|FG000|Overall Study|Positive for STD at Baseline|7
6282566|NCT02308033|9993528|FG001|Overall Study|Positive for STD at Baseline|4
6282567|NCT02308033|9993527|FG000|Overall Study|Lost to Follow-up|6
6282568|NCT02308033|9993528|FG001|Overall Study|Lost to Follow-up|5
5980190|NCT00369317|9568707|FG000|Overall Study|Physician Decision|2
5980191|NCT00369317|9568707|FG000|Overall Study|Withdrawal by Subject|8
5980192|NCT00369317|9568707|FG000|Overall Study|Ineligible|1
5980193|NCT00261807|9568712|FG000|Overall Study|Lost to Follow-up|2
5980194|NCT00261807|9568712|FG000|Overall Study|Adverse Event|2
5980195|NCT00261807|9568712|FG000|Overall Study|Death|1
5980196|NCT00261807|9568712|FG000|Overall Study|Protocol Violation|2
6282569|NCT02308046|9993536|FG000|Overall Study|Negative yeast culture at Baseline|32
6282570|NCT02308046|9993537|FG001|Overall Study|Negative yeast culture at Baseline|33
6282571|NCT02308046|9993536|FG000|Overall Study|Positive for STD at Baseline|1
6282572|NCT02308046|9993537|FG001|Overall Study|Positive for STD at Baseline|2
6282573|NCT02308046|9993536|FG000|Overall Study|Lost to Follow-up|1
6282574|NCT02308046|9993537|FG001|Overall Study|Lost to Follow-up|3
6282575|NCT02308124|9993546|FG000|Overall Study|Lost to Follow-up|6
6282576|NCT02308124|9993547|FG001|Overall Study|Lost to Follow-up|6
6282577|NCT02308124|9993548|FG002|Overall Study|Lost to Follow-up|6
6282578|NCT02308124|9993546|FG000|Overall Study|Adverse Event|0
6282579|NCT02308124|9993547|FG001|Overall Study|Adverse Event|2
6282580|NCT02308124|9993548|FG002|Overall Study|Adverse Event|2
6282581|NCT02308163|9993560|FG000|Overall Study|Not fulfill eligible criteria|1
6282582|NCT02308163|9993561|FG001|Overall Study|Not fulfill eligible criteria|2
6282583|NCT02308163|9993562|FG002|Overall Study|Not fulfill eligible criteria|0
6282584|NCT02308163|9993563|FG003|Overall Study|Not fulfill eligible criteria|1
6282585|NCT02308163|9993564|FG004|Overall Study|Not fulfill eligible criteria|1
6282586|NCT02308163|9993560|FG000|Overall Study|Adverse Event|9
6282587|NCT02308163|9993561|FG001|Overall Study|Adverse Event|5
6282588|NCT02308163|9993562|FG002|Overall Study|Adverse Event|2
6282589|NCT02308163|9993563|FG003|Overall Study|Adverse Event|2
6282590|NCT02308163|9993564|FG004|Overall Study|Adverse Event|11
6282591|NCT02308163|9993560|FG000|Overall Study|Lack of Efficacy|11
6282592|NCT02308163|9993561|FG001|Overall Study|Lack of Efficacy|3
6282593|NCT02308163|9993562|FG002|Overall Study|Lack of Efficacy|8
6282594|NCT02308163|9993563|FG003|Overall Study|Lack of Efficacy|4
6282595|NCT02308163|9993564|FG004|Overall Study|Lack of Efficacy|6
6282596|NCT02308163|9993560|FG000|Overall Study|Withdrawal of consent|2
6282597|NCT02308163|9993561|FG001|Overall Study|Withdrawal of consent|3
6282598|NCT02308163|9993562|FG002|Overall Study|Withdrawal of consent|0
6282599|NCT02308163|9993563|FG003|Overall Study|Withdrawal of consent|2
6282600|NCT02308163|9993564|FG004|Overall Study|Withdrawal of consent|6
6282601|NCT02308163|9993560|FG000|Overall Study|Protocol Violation|3
6282602|NCT02308163|9993561|FG001|Overall Study|Protocol Violation|3
6282603|NCT02308163|9993562|FG002|Overall Study|Protocol Violation|3
6282604|NCT02308163|9993563|FG003|Overall Study|Protocol Violation|2
6282605|NCT02308163|9993564|FG004|Overall Study|Protocol Violation|5
6282606|NCT02308163|9993560|FG000|Overall Study|Lab data met discontinuation criteria|3
6282607|NCT02308163|9993561|FG001|Overall Study|Lab data met discontinuation criteria|0
6282608|NCT02308163|9993562|FG002|Overall Study|Lab data met discontinuation criteria|0
6282609|NCT02308163|9993563|FG003|Overall Study|Lab data met discontinuation criteria|2
6282610|NCT02308163|9993564|FG004|Overall Study|Lab data met discontinuation criteria|0
6282611|NCT02308163|9993560|FG000|Overall Study|Miscellaneous|2
6282612|NCT02308163|9993561|FG001|Overall Study|Miscellaneous|2
6282613|NCT02308163|9993562|FG002|Overall Study|Miscellaneous|1
6282614|NCT02308163|9993563|FG003|Overall Study|Miscellaneous|0
6282615|NCT02308163|9993564|FG004|Overall Study|Miscellaneous|5
6282616|NCT02308228|9993602|FG000|Overall Study|Adverse Event|3
6282617|NCT02308228|9993603|FG001|Overall Study|Adverse Event|4
6282618|NCT02308228|9993602|FG000|Overall Study|Withdrawal by Subject|5
6282619|NCT02308228|9993603|FG001|Overall Study|Withdrawal by Subject|3
6282620|NCT02308540|9993641|FG000|Overall Study|Lost to Follow-up|0
6282621|NCT02308540|9993642|FG001|Overall Study|Lost to Follow-up|0
6051633|NCT00434161|9650938|FG002|Overall Study|Death|1
6051634|NCT00434161|9650936|FG000|Overall Study|Non-Compliance|1
6051635|NCT00434161|9650937|FG001|Overall Study|Non-Compliance|1
6051636|NCT00434161|9650938|FG002|Overall Study|Non-Compliance|0
6051637|NCT00434161|9650936|FG000|Overall Study|Withdrawal by Subject|2
6051638|NCT00434161|9650937|FG001|Overall Study|Withdrawal by Subject|0
6051639|NCT00434161|9650938|FG002|Overall Study|Withdrawal by Subject|3
6051640|NCT00434161|9650936|FG000|Overall Study|Logistical error study assessments|1
6051641|NCT00434161|9650937|FG001|Overall Study|Logistical error study assessments|0
6051642|NCT00434161|9650938|FG002|Overall Study|Logistical error study assessments|3
6051643|NCT00434213|9650953|FG000|Overall Study|Adverse Event|12
6051644|NCT00434213|9650953|FG000|Overall Study|Lack of Efficacy|9
6051645|NCT00434213|9650953|FG000|Overall Study|Lost to Follow-up|14
6051646|NCT00434213|9650953|FG000|Overall Study|Withdrawal by Subject|7
6051647|NCT00434213|9650953|FG000|Overall Study|Protocol Violation|3
6051648|NCT00434213|9650953|FG000|Overall Study|Unable to comply with study visit window|2
6051649|NCT00434213|9650953|FG000|Overall Study|Application site reaction|1
6051650|NCT00434213|9650953|FG000|Overall Study|Non-compliant to study schedule|1
6051651|NCT00434252|9650959|FG000|Overall Study|Lack of Efficacy|50
6051652|NCT00434252|9650960|FG001|Overall Study|Lack of Efficacy|100
6282622|NCT02308540|9993643|FG002|Overall Study|Lost to Follow-up|0
6282623|NCT02308540|9993644|FG003|Overall Study|Lost to Follow-up|0
6282624|NCT02308540|9993645|FG004|Overall Study|Lost to Follow-up|0
6282625|NCT02308540|9993646|FG005|Overall Study|Lost to Follow-up|1
6051653|NCT00434252|9650959|FG000|Overall Study|Adverse Event|6
6051654|NCT00434252|9650960|FG001|Overall Study|Adverse Event|13
6051655|NCT00434252|9650959|FG000|Overall Study|Death|1
6051656|NCT00434252|9650960|FG001|Overall Study|Death|2
6282626|NCT02308696|9993697|FG000|Overall Study|Lost to Follow-up|28
6282627|NCT02308696|9993698|FG001|Overall Study|Lost to Follow-up|21
6282628|NCT02308696|9993697|FG000|Overall Study|Death|8
6282629|NCT02308696|9993698|FG001|Overall Study|Death|4
6282630|NCT02308696|9993697|FG000|Overall Study|Moved to a Higher Level of Care|17
6282631|NCT02308696|9993698|FG001|Overall Study|Moved to a Higher Level of Care|6
6282632|NCT02308748|9993704|FG000|Period 1|Withdrawal by Subject|0
6282633|NCT02308748|9993705|FG001|Period 1|Withdrawal by Subject|0
6282634|NCT02308748|9993706|FG002|Period 1|Withdrawal by Subject|1
6282635|NCT02308748|9993707|FG003|Period 1|Withdrawal by Subject|0
6282636|NCT02308748|9993708|FG004|Period 1|Withdrawal by Subject|0
6282637|NCT02308748|9993709|FG005|Period 1|Withdrawal by Subject|0
6282638|NCT02308748|9993710|FG006|Period 1|Withdrawal by Subject|0
6282639|NCT02308748|9993711|FG007|Period 1|Withdrawal by Subject|0
6282640|NCT02308748|9993712|FG008|Period 1|Withdrawal by Subject|0
6282641|NCT02308748|9993713|FG009|Period 1|Withdrawal by Subject|0
6282642|NCT02308748|9993704|FG000|Period 2|Adverse Event|0
6282643|NCT02308748|9993705|FG001|Period 2|Adverse Event|0
6282644|NCT02308748|9993706|FG002|Period 2|Adverse Event|0
6282645|NCT02308748|9993707|FG003|Period 2|Adverse Event|0
6282646|NCT02308748|9993708|FG004|Period 2|Adverse Event|0
6282647|NCT02308748|9993709|FG005|Period 2|Adverse Event|0
6282648|NCT02308748|9993710|FG006|Period 2|Adverse Event|0
6282649|NCT02308748|9993711|FG007|Period 2|Adverse Event|1
6282650|NCT02308748|9993712|FG008|Period 2|Adverse Event|0
6282651|NCT02308748|9993713|FG009|Period 2|Adverse Event|0
6282652|NCT02308748|9993704|FG000|Period 3|Protocol Violation|0
6282653|NCT02308748|9993705|FG001|Period 3|Protocol Violation|0
6282654|NCT02308748|9993706|FG002|Period 3|Protocol Violation|0
6282655|NCT02308748|9993707|FG003|Period 3|Protocol Violation|0
6282656|NCT02308748|9993708|FG004|Period 3|Protocol Violation|0
6282657|NCT02308748|9993709|FG005|Period 3|Protocol Violation|0
6282658|NCT02308748|9993710|FG006|Period 3|Protocol Violation|0
6282659|NCT02308748|9993711|FG007|Period 3|Protocol Violation|0
6282660|NCT02308748|9993712|FG008|Period 3|Protocol Violation|0
6282661|NCT02308748|9993713|FG009|Period 3|Protocol Violation|1
6282662|NCT02308748|9993704|FG000|Period 5|Adverse Event|1
6282663|NCT02308748|9993705|FG001|Period 5|Adverse Event|0
6282664|NCT02308748|9993706|FG002|Period 5|Adverse Event|0
6282665|NCT02308748|9993707|FG003|Period 5|Adverse Event|0
6282666|NCT02308748|9993708|FG004|Period 5|Adverse Event|0
6282667|NCT02308748|9993709|FG005|Period 5|Adverse Event|0
6282668|NCT02308748|9993710|FG006|Period 5|Adverse Event|0
6282669|NCT02308748|9993711|FG007|Period 5|Adverse Event|0
6282670|NCT02308748|9993712|FG008|Period 5|Adverse Event|1
6282671|NCT02308748|9993713|FG009|Period 5|Adverse Event|0
6282672|NCT02309099|9993735|FG000|Overall Study|Adverse Event|2
6282673|NCT02309099|9993736|FG001|Overall Study|Adverse Event|0
6282674|NCT02309112|9993745|FG000|Overall Study|Withdrawal by Subject|1
6282675|NCT02309112|9993746|FG001|Overall Study|Withdrawal by Subject|0
6282676|NCT02309112|9993747|FG002|Overall Study|Withdrawal by Subject|1
6282677|NCT02309112|9993745|FG000|Overall Study|Lost to Follow-up|0
6282678|NCT02309112|9993746|FG001|Overall Study|Lost to Follow-up|1
6282679|NCT02309112|9993747|FG002|Overall Study|Lost to Follow-up|0
6282680|NCT02309138|9993759|FG000|Overall Study|Withdrawal by Subject|44
6282681|NCT02309138|9993760|FG001|Overall Study|Withdrawal by Subject|15
6282682|NCT02309138|9993759|FG000|Overall Study|Protocol Violation|4
6282683|NCT02309138|9993760|FG001|Overall Study|Protocol Violation|2
6282684|NCT02309138|9993759|FG000|Overall Study|delivered before visit 2|0
6282685|NCT02309138|9993760|FG001|Overall Study|delivered before visit 2|1
6282686|NCT02309294|9993776|FG000|Overall Study|Withdrawal by Subject|2
6282687|NCT02309359|9993785|FG000|Overall Study|Adverse Event|4
6282688|NCT02309359|9993786|FG001|Overall Study|Adverse Event|5
6282689|NCT02309359|9993787|FG002|Overall Study|Adverse Event|5
6282690|NCT02309359|9993788|FG003|Overall Study|Adverse Event|4
6282691|NCT02309359|9993789|FG004|Overall Study|Adverse Event|4
6282692|NCT02309359|9993785|FG000|Overall Study|Death|1
6282693|NCT02309359|9993786|FG001|Overall Study|Death|0
6282694|NCT02309359|9993787|FG002|Overall Study|Death|0
6282695|NCT02309359|9993788|FG003|Overall Study|Death|0
6282696|NCT02309359|9993789|FG004|Overall Study|Death|0
6282697|NCT02309359|9993785|FG000|Overall Study|Withdrawal by Subject|2
6282698|NCT02309359|9993786|FG001|Overall Study|Withdrawal by Subject|2
6282699|NCT02309359|9993787|FG002|Overall Study|Withdrawal by Subject|4
6282700|NCT02309359|9993788|FG003|Overall Study|Withdrawal by Subject|4
6282701|NCT02309359|9993789|FG004|Overall Study|Withdrawal by Subject|0
6282702|NCT02309359|9993785|FG000|Overall Study|Lack of Efficacy|3
6282703|NCT02309359|9993786|FG001|Overall Study|Lack of Efficacy|1
6282704|NCT02309359|9993787|FG002|Overall Study|Lack of Efficacy|0
6282705|NCT02309359|9993788|FG003|Overall Study|Lack of Efficacy|0
6282706|NCT02309359|9993789|FG004|Overall Study|Lack of Efficacy|3
6282707|NCT02309359|9993785|FG000|Overall Study|Lost to Follow-up|0
6282708|NCT02309359|9993786|FG001|Overall Study|Lost to Follow-up|0
6282709|NCT02309359|9993787|FG002|Overall Study|Lost to Follow-up|0
6282710|NCT02309359|9993788|FG003|Overall Study|Lost to Follow-up|1
6282711|NCT02309359|9993789|FG004|Overall Study|Lost to Follow-up|0
6282712|NCT02309359|9993785|FG000|Overall Study|Other|2
6282713|NCT02309359|9993786|FG001|Overall Study|Other|0
6282714|NCT02309359|9993787|FG002|Overall Study|Other|2
6282715|NCT02309359|9993788|FG003|Overall Study|Other|3
6282716|NCT02309359|9993789|FG004|Overall Study|Other|2
6282717|NCT02309372|9993804|FG000|Overall Study|Lost to Follow-up|3
6282718|NCT02309372|9993805|FG001|Overall Study|Lost to Follow-up|2
6282719|NCT02309411|9993814|FG000|Overall Study|Physician Decision|1
6282720|NCT02309411|9993815|FG001|Overall Study|Physician Decision|0
6051657|NCT00434252|9650959|FG000|Overall Study|Lost to Follow-up|0
6051658|NCT00434252|9650960|FG001|Overall Study|Lost to Follow-up|1
6051659|NCT00434252|9650959|FG000|Overall Study|Physician Decision|4
6051660|NCT00434252|9650960|FG001|Overall Study|Physician Decision|8
6051661|NCT00434252|9650959|FG000|Overall Study|Withdrawal by Subject|3
6051662|NCT00434252|9650960|FG001|Overall Study|Withdrawal by Subject|7
6051663|NCT00434304|9650975|FG000|Overall Study|Adverse Event|14
6051664|NCT00434304|9650975|FG000|Overall Study|Lack of Efficacy|2
6051665|NCT00434304|9650975|FG000|Overall Study|Withdrawal by Subject|4
6051666|NCT00434330|9650986|FG000|Overall Study|Adverse Event|0
6051667|NCT00434330|9650987|FG001|Overall Study|Adverse Event|0
6051668|NCT00434330|9650988|FG002|Overall Study|Adverse Event|1
6051669|NCT00434330|9650989|FG003|Overall Study|Adverse Event|0
6051670|NCT00434330|9650990|FG004|Overall Study|Adverse Event|0
6051671|NCT00434330|9650991|FG005|Overall Study|Adverse Event|0
6051672|NCT00434330|9650986|FG000|Overall Study|Death|1
6051673|NCT00434330|9650987|FG001|Overall Study|Death|0
6051674|NCT00434330|9650988|FG002|Overall Study|Death|0
6051675|NCT00434330|9650989|FG003|Overall Study|Death|0
6051676|NCT00434330|9650990|FG004|Overall Study|Death|1
6051677|NCT00434330|9650991|FG005|Overall Study|Death|1
6051678|NCT00434330|9650986|FG000|Overall Study|Withdrawal by Subject|0
6051679|NCT00434330|9650987|FG001|Overall Study|Withdrawal by Subject|0
6051680|NCT00434330|9650988|FG002|Overall Study|Withdrawal by Subject|1
6051681|NCT00434330|9650989|FG003|Overall Study|Withdrawal by Subject|1
6051682|NCT00434330|9650990|FG004|Overall Study|Withdrawal by Subject|0
6051683|NCT00434330|9650991|FG005|Overall Study|Withdrawal by Subject|0
6051684|NCT00434330|9650986|FG000|Overall Study|Renal transplant|0
6051685|NCT00434330|9650987|FG001|Overall Study|Renal transplant|0
6051686|NCT00434330|9650988|FG002|Overall Study|Renal transplant|0
6051687|NCT00434330|9650989|FG003|Overall Study|Renal transplant|1
6051688|NCT00434330|9650990|FG004|Overall Study|Renal transplant|0
6051689|NCT00434330|9650991|FG005|Overall Study|Renal transplant|0
6051690|NCT00434330|9650986|FG000|Overall Study|Subject Not Compliant With Study|0
6051691|NCT00434330|9650987|FG001|Overall Study|Subject Not Compliant With Study|0
6051692|NCT00434330|9650988|FG002|Overall Study|Subject Not Compliant With Study|1
6051693|NCT00434330|9650989|FG003|Overall Study|Subject Not Compliant With Study|0
6051694|NCT00434330|9650990|FG004|Overall Study|Subject Not Compliant With Study|0
6089491|NCT00684671|9701111|FG001|Overall Study|Lost to Follow-up|0
6089492|NCT00684671|9701112|FG002|Overall Study|Lost to Follow-up|0
6089493|NCT00684671|9701110|FG000|Overall Study|Alcoholic dependance|1
6089494|NCT00684671|9701111|FG001|Overall Study|Alcoholic dependance|0
6089495|NCT00684671|9701112|FG002|Overall Study|Alcoholic dependance|0
6089496|NCT00684762|9701131|FG000|Washout Period of 7 Days|Withdrawal by Subject|2
6089497|NCT00684762|9701132|FG001|Washout Period of 7 Days|Withdrawal by Subject|2
6089498|NCT00684814|9701170|FG000|Washout Period of 7 Days|Adverse Event|1
6089499|NCT00684814|9701171|FG001|Washout Period of 7 Days|Adverse Event|2
6089500|NCT00684814|9701170|FG000|Washout Period of 7 Days|Withdrawal by Subject|1
6089501|NCT00684814|9701171|FG001|Washout Period of 7 Days|Withdrawal by Subject|2
6089502|NCT00684814|9701170|FG000|Second Intervention|Adverse Event|1
6089503|NCT00684814|9701171|FG001|Second Intervention|Adverse Event|0
6089504|NCT00684996|9701188|FG000|Overall Study|Adverse Event|1
6089505|NCT00684996|9701188|FG000|Overall Study|Refusal unrelated to adverse event|1
6089506|NCT00684996|9701188|FG000|Overall Study|Progression/relapse|2
6089507|NCT00684996|9701188|FG000|Overall Study|Other reasons not protocol specified|1
6089508|NCT00685035|9701195|FG000|Period 1: First Intervention: 30 Minutes|Pulmonary lab plethysmography malfunctio|1
6089509|NCT00685035|9701196|FG001|Period 1: First Intervention: 30 Minutes|Pulmonary lab plethysmography malfunctio|0
6089510|NCT00685165|9701227|FG000|Washout Period of 14 Days|Adverse Event|1
6089511|NCT00685165|9701228|FG001|Washout Period of 14 Days|Adverse Event|0
6089512|NCT00685178|9701238|FG000|Overall Study|Adverse Event|1
6089513|NCT00685178|9701239|FG001|Overall Study|Adverse Event|5
6089514|NCT00685178|9701240|FG002|Overall Study|Adverse Event|2
6282721|NCT02309411|9993816|FG002|Overall Study|Physician Decision|0
6282722|NCT02309411|9993814|FG000|Overall Study|Withdrawal by Subject|1
6089515|NCT00685178|9701241|FG003|Overall Study|Adverse Event|4
6089516|NCT00685178|9701238|FG000|Overall Study|missed 3 consecutive methadone clin days|7
6089517|NCT00685178|9701239|FG001|Overall Study|missed 3 consecutive methadone clin days|5
6089518|NCT00685178|9701240|FG002|Overall Study|missed 3 consecutive methadone clin days|2
6089519|NCT00685178|9701241|FG003|Overall Study|missed 3 consecutive methadone clin days|6
6089520|NCT00685178|9701238|FG000|Overall Study|voluntary study discharge|4
6089521|NCT00685178|9701239|FG001|Overall Study|voluntary study discharge|5
6089522|NCT00685178|9701240|FG002|Overall Study|voluntary study discharge|1
6089523|NCT00685178|9701241|FG003|Overall Study|voluntary study discharge|1
6089524|NCT00685178|9701238|FG000|Overall Study|incarcerated|1
6089525|NCT00685178|9701239|FG001|Overall Study|incarcerated|3
6089526|NCT00685178|9701240|FG002|Overall Study|incarcerated|7
6089527|NCT00685178|9701241|FG003|Overall Study|incarcerated|0
6089528|NCT00685178|9701238|FG000|Overall Study|administrative (disciplinary) discharge|0
6089529|NCT00685178|9701239|FG001|Overall Study|administrative (disciplinary) discharge|1
6089530|NCT00685178|9701240|FG002|Overall Study|administrative (disciplinary) discharge|0
6282723|NCT02309411|9993815|FG001|Overall Study|Withdrawal by Subject|1
6282724|NCT02309411|9993816|FG002|Overall Study|Withdrawal by Subject|0
6282725|NCT02309515|9993834|FG000|Overall Study|Withdrawal by Subject|0
6282726|NCT02309515|9993835|FG001|Overall Study|Withdrawal by Subject|1
6282727|NCT02309723|9993844|FG000|Overall Study|Withdrawal by Subject|24
6282728|NCT02309723|9993845|FG001|Overall Study|Withdrawal by Subject|23
6282729|NCT02309723|9993846|FG002|Overall Study|Withdrawal by Subject|24
6282730|NCT02310100|9993863|FG000|Overall Study|Physician Decision|3
6282731|NCT02310100|9993863|FG000|Overall Study|Withdrawal by Subject|10
6282732|NCT02310100|9993863|FG000|Overall Study|Enrollment closure|1
6282733|NCT02310100|9993863|FG000|Overall Study|Unapproved ablation operator|1
6282734|NCT02310100|9993863|FG000|Overall Study|Visit compliance|1
6282735|NCT02310100|9993863|FG000|Overall Study|Lost to Follow-up|2
6282736|NCT02310126|9993870|FG000|Period 1 (15 Minutes)|Lost to Follow-up|0
6282737|NCT02310126|9993871|FG001|Period 1 (15 Minutes)|Lost to Follow-up|1
6282738|NCT02310126|9993870|FG000|Period 1 (15 Minutes)|Protocol Violation|0
6282739|NCT02310126|9993871|FG001|Period 1 (15 Minutes)|Protocol Violation|1
6282740|NCT02310568|9993882|FG000|Stage 1 ( 4 Weeks)|Lack of Efficacy|0
6282741|NCT02310568|9993883|FG001|Stage 1 ( 4 Weeks)|Lack of Efficacy|0
6282742|NCT02310568|9993884|FG002|Stage 1 ( 4 Weeks)|Lack of Efficacy|0
6282743|NCT02310568|9993885|FG003|Stage 1 ( 4 Weeks)|Lack of Efficacy|0
6282744|NCT02310568|9993886|FG004|Stage 1 ( 4 Weeks)|Lack of Efficacy|1
6282745|NCT02310568|9993882|FG000|Stage 1 ( 4 Weeks)|Withdrawal by Participants|1
6282746|NCT02310568|9993883|FG001|Stage 1 ( 4 Weeks)|Withdrawal by Participants|0
6282747|NCT02310568|9993884|FG002|Stage 1 ( 4 Weeks)|Withdrawal by Participants|0
6282748|NCT02310568|9993885|FG003|Stage 1 ( 4 Weeks)|Withdrawal by Participants|0
6282749|NCT02310568|9993886|FG004|Stage 1 ( 4 Weeks)|Withdrawal by Participants|0
6282750|NCT02310568|9993882|FG000|Stage 1 ( 4 Weeks)|Other|1
6282751|NCT02310568|9993883|FG001|Stage 1 ( 4 Weeks)|Other|1
6282752|NCT02310568|9993884|FG002|Stage 1 ( 4 Weeks)|Other|0
6282753|NCT02310568|9993885|FG003|Stage 1 ( 4 Weeks)|Other|0
6282754|NCT02310568|9993886|FG004|Stage 1 ( 4 Weeks)|Other|0
6282755|NCT02310568|9993882|FG000|Stage 1 ( 4 Weeks)|Adverse Event|1
6282756|NCT02310568|9993883|FG001|Stage 1 ( 4 Weeks)|Adverse Event|1
6282757|NCT02310568|9993884|FG002|Stage 1 ( 4 Weeks)|Adverse Event|1
6282758|NCT02310568|9993885|FG003|Stage 1 ( 4 Weeks)|Adverse Event|0
6282759|NCT02310568|9993886|FG004|Stage 1 ( 4 Weeks)|Adverse Event|0
5980197|NCT04620798|9568735|FG000|Overall Study|Lost to Follow-up|126
5980198|NCT04620798|9568736|FG001|Overall Study|Lost to Follow-up|138
5980199|NCT04256629|9568761|FG000|Overall Study|Adverse Event|0
5980200|NCT04256629|9568762|FG001|Overall Study|Adverse Event|0
5980201|NCT04256629|9568763|FG002|Overall Study|Adverse Event|0
5980202|NCT04256629|9568764|FG003|Overall Study|Adverse Event|0
5980203|NCT04256629|9568765|FG004|Overall Study|Adverse Event|0
5980204|NCT04256629|9568766|FG005|Overall Study|Adverse Event|1
5980205|NCT04256629|9568761|FG000|Overall Study|Protocol Violation|0
5980206|NCT04256629|9568762|FG001|Overall Study|Protocol Violation|1
5980207|NCT04256629|9568763|FG002|Overall Study|Protocol Violation|0
5980208|NCT04256629|9568764|FG003|Overall Study|Protocol Violation|0
6051695|NCT00434330|9650991|FG005|Overall Study|Subject Not Compliant With Study|0
6051696|NCT00434421|9651014|FG000|Overall Study|Withdrawal by Subject|1
6051697|NCT00434421|9651014|FG000|Overall Study|Non-compliance with study treatment|1
6051698|NCT00434512|9651037|FG000|Overall Study|Migrated/moved from study area|0
6051699|NCT00434512|9651038|FG001|Overall Study|Migrated/moved from study area|0
6051700|NCT00434512|9651039|FG002|Overall Study|Migrated/moved from study area|0
6051701|NCT00434512|9651040|FG003|Overall Study|Migrated/moved from study area|1
6051702|NCT00434512|9651041|FG004|Overall Study|Migrated/moved from study area|1
6051703|NCT00434512|9651042|FG005|Overall Study|Migrated/moved from study area|1
6051704|NCT00434512|9651037|FG000|Overall Study|Other|0
6051705|NCT00434512|9651038|FG001|Overall Study|Other|1
6051706|NCT00434512|9651039|FG002|Overall Study|Other|0
6051707|NCT00434512|9651040|FG003|Overall Study|Other|0
6051708|NCT00434512|9651041|FG004|Overall Study|Other|0
6051709|NCT00434512|9651042|FG005|Overall Study|Other|0
6051710|NCT00434577|9651065|FG000|Months 0-3|Serious Adverse Event|0
6051711|NCT00434577|9651066|FG001|Months 0-3|Serious Adverse Event|0
6051712|NCT00434577|9651067|FG002|Months 0-3|Serious Adverse Event|1
6051713|NCT00434577|9651068|FG003|Months 0-3|Serious Adverse Event|0
6051714|NCT00434577|9651069|FG004|Months 0-3|Serious Adverse Event|0
6051715|NCT00434577|9651065|FG000|Months 0-3|Adverse Event|0
6051716|NCT00434577|9651066|FG001|Months 0-3|Adverse Event|1
6051717|NCT00434577|9651067|FG002|Months 0-3|Adverse Event|1
6051718|NCT00434577|9651068|FG003|Months 0-3|Adverse Event|0
6051719|NCT00434577|9651069|FG004|Months 0-3|Adverse Event|0
6051720|NCT00434577|9651065|FG000|Months 0-3|Lost to Follow-up|0
6051721|NCT00434577|9651066|FG001|Months 0-3|Lost to Follow-up|0
6051722|NCT00434577|9651067|FG002|Months 0-3|Lost to Follow-up|0
5980209|NCT04256629|9568765|FG004|Overall Study|Protocol Violation|0
5980210|NCT04256629|9568766|FG005|Overall Study|Protocol Violation|0
5980211|NCT04014075|9568778|FG000|Overall Study|Progressive Disease|39
5980212|NCT04014075|9568778|FG000|Overall Study|Adverse Event|9
6051723|NCT00434577|9651068|FG003|Months 0-3|Lost to Follow-up|0
6051724|NCT00434577|9651069|FG004|Months 0-3|Lost to Follow-up|2
6051725|NCT00434577|9651065|FG000|Months 0-3|Protocol Violation|1
6051726|NCT00434577|9651066|FG001|Months 0-3|Protocol Violation|0
6282760|NCT02310568|9993882|FG000|Stage 1 ( 4 Weeks)|No Longer Meets Eligibility Criteria|0
6282761|NCT02310568|9993883|FG001|Stage 1 ( 4 Weeks)|No Longer Meets Eligibility Criteria|0
6282762|NCT02310568|9993884|FG002|Stage 1 ( 4 Weeks)|No Longer Meets Eligibility Criteria|0
6282763|NCT02310568|9993885|FG003|Stage 1 ( 4 Weeks)|No Longer Meets Eligibility Criteria|1
6282764|NCT02310568|9993886|FG004|Stage 1 ( 4 Weeks)|No Longer Meets Eligibility Criteria|0
6282765|NCT02310568|9993882|FG000|Stage 1 ( 4 Weeks)|Lost to Follow-up|0
6282766|NCT02310568|9993883|FG001|Stage 1 ( 4 Weeks)|Lost to Follow-up|0
6282767|NCT02310568|9993884|FG002|Stage 1 ( 4 Weeks)|Lost to Follow-up|0
6282768|NCT02310568|9993885|FG003|Stage 1 ( 4 Weeks)|Lost to Follow-up|1
6282769|NCT02310568|9993886|FG004|Stage 1 ( 4 Weeks)|Lost to Follow-up|0
6282770|NCT02310568|9993882|FG000|Stage 2 (4 Weeks)|Withdrawal by Participants|1
6282771|NCT02310568|9993883|FG001|Stage 2 (4 Weeks)|Withdrawal by Participants|0
6282772|NCT02310568|9993884|FG002|Stage 2 (4 Weeks)|Withdrawal by Participants|0
6282773|NCT02310568|9993885|FG003|Stage 2 (4 Weeks)|Withdrawal by Participants|1
6282774|NCT02310568|9993886|FG004|Stage 2 (4 Weeks)|Withdrawal by Participants|0
6282775|NCT02310568|9993882|FG000|Stage 2 (4 Weeks)|Other|0
6282776|NCT02310568|9993883|FG001|Stage 2 (4 Weeks)|Other|1
6282777|NCT02310568|9993884|FG002|Stage 2 (4 Weeks)|Other|1
6282778|NCT02310568|9993885|FG003|Stage 2 (4 Weeks)|Other|0
6282779|NCT02310568|9993886|FG004|Stage 2 (4 Weeks)|Other|0
6282780|NCT02310568|9993882|FG000|Stage 2 (4 Weeks)|Adverse Event|0
6282781|NCT02310568|9993883|FG001|Stage 2 (4 Weeks)|Adverse Event|0
6282782|NCT02310568|9993884|FG002|Stage 2 (4 Weeks)|Adverse Event|0
6282783|NCT02310568|9993885|FG003|Stage 2 (4 Weeks)|Adverse Event|1
6282784|NCT02310568|9993886|FG004|Stage 2 (4 Weeks)|Adverse Event|1
6282785|NCT02310568|9993882|FG000|Stage 2 (4 Weeks)|Protocol Violation|0
6282786|NCT02310568|9993883|FG001|Stage 2 (4 Weeks)|Protocol Violation|0
6282787|NCT02310568|9993884|FG002|Stage 2 (4 Weeks)|Protocol Violation|0
6282788|NCT02310568|9993885|FG003|Stage 2 (4 Weeks)|Protocol Violation|1
6282789|NCT02310568|9993886|FG004|Stage 2 (4 Weeks)|Protocol Violation|0
6282790|NCT02310568|9993882|FG000|Stage 2 (4 Weeks)|Lost to Follow-up|0
6282791|NCT02310568|9993883|FG001|Stage 2 (4 Weeks)|Lost to Follow-up|0
6282792|NCT02310568|9993884|FG002|Stage 2 (4 Weeks)|Lost to Follow-up|0
6282793|NCT02310568|9993885|FG003|Stage 2 (4 Weeks)|Lost to Follow-up|2
6282794|NCT02310568|9993886|FG004|Stage 2 (4 Weeks)|Lost to Follow-up|0
6282795|NCT02310581|9993908|FG000|Overall Study|Adverse Event|1
6282796|NCT02310581|9993909|FG001|Overall Study|Adverse Event|1
6282797|NCT02310581|9993910|FG002|Overall Study|Adverse Event|1
6282798|NCT02310581|9993911|FG003|Overall Study|Adverse Event|0
6282799|NCT02310581|9993908|FG000|Overall Study|Withdrawal by Subject|2
6282800|NCT02310581|9993909|FG001|Overall Study|Withdrawal by Subject|1
6051727|NCT00434577|9651067|FG002|Months 0-3|Protocol Violation|1
6051728|NCT00434577|9651068|FG003|Months 0-3|Protocol Violation|0
6051729|NCT00434577|9651069|FG004|Months 0-3|Protocol Violation|0
6051730|NCT00434577|9651065|FG000|Months 0-3|Withdrawal by Subject|2
6051731|NCT00434577|9651066|FG001|Months 0-3|Withdrawal by Subject|1
6051732|NCT00434577|9651067|FG002|Months 0-3|Withdrawal by Subject|1
6051733|NCT00434577|9651068|FG003|Months 0-3|Withdrawal by Subject|1
6051734|NCT00434577|9651069|FG004|Months 0-3|Withdrawal by Subject|1
6051735|NCT00434642|9651083|FG000|Blinded Treatment Phase|Adverse Event|12
6051736|NCT00434642|9651084|FG001|Blinded Treatment Phase|Adverse Event|58
6051737|NCT00434642|9651083|FG000|Blinded Treatment Phase|Clinical Disease Progression|4
6051738|NCT00434642|9651084|FG001|Blinded Treatment Phase|Clinical Disease Progression|5
6051739|NCT00434642|9651083|FG000|Blinded Treatment Phase|Disease Progression Per RECIST|168
6051740|NCT00434642|9651084|FG001|Blinded Treatment Phase|Disease Progression Per RECIST|109
6051741|NCT00434642|9651083|FG000|Blinded Treatment Phase|Physician Decision|19
6051742|NCT00434642|9651084|FG001|Blinded Treatment Phase|Physician Decision|27
6051743|NCT00434642|9651083|FG000|Blinded Treatment Phase|Sponsor's Decision To Terminate Study|3
6051744|NCT00434642|9651084|FG001|Blinded Treatment Phase|Sponsor's Decision To Terminate Study|0
6051745|NCT00434642|9651083|FG000|Blinded Treatment Phase|Subject's Decision-Discontinue Treatment|32
6051746|NCT00434642|9651084|FG001|Blinded Treatment Phase|Subject's Decision-Discontinue Treatment|29
6051747|NCT00434642|9651083|FG000|Blinded Treatment Phase|Did not Receive Treatment|4
6051748|NCT00434642|9651084|FG001|Blinded Treatment Phase|Did not Receive Treatment|1
6051749|NCT00434642|9651083|FG000|Open-label Treatment Phase|Adverse Event|0
6051750|NCT00434642|9651084|FG001|Open-label Treatment Phase|Adverse Event|5
6051751|NCT00434642|9651083|FG000|Open-label Treatment Phase|Disease Progression Per RECIST|0
6051752|NCT00434642|9651084|FG001|Open-label Treatment Phase|Disease Progression Per RECIST|6
6051753|NCT00434759|9651092|FG000|Overall Study|Lack of Efficacy|5
6051754|NCT00434759|9651093|FG001|Overall Study|Lack of Efficacy|4
6051755|NCT00434759|9651092|FG000|Overall Study|Withdrawal by Subject|17
6051756|NCT00434759|9651093|FG001|Overall Study|Withdrawal by Subject|1
6051757|NCT00434759|9651092|FG000|Overall Study|family affairs|2
6051758|NCT00434759|9651093|FG001|Overall Study|family affairs|0
6051759|NCT00434876|9651103|FG000|Overall Study|Lost to Follow-up|1
6051760|NCT00434876|9651104|FG001|Overall Study|Lost to Follow-up|1
6051761|NCT00434954|9651112|FG000|Overall Study|Adverse Event|17
6051762|NCT00434954|9651113|FG001|Overall Study|Adverse Event|2
6051763|NCT00434954|9651112|FG000|Overall Study|Entry criteria not met|14
6051764|NCT00434954|9651113|FG001|Overall Study|Entry criteria not met|16
6282801|NCT02310581|9993910|FG002|Overall Study|Withdrawal by Subject|0
6282802|NCT02310581|9993911|FG003|Overall Study|Withdrawal by Subject|1
6282803|NCT02310646|9993923|FG000|First Intervention (Day 1 - Day 7)|Withdrawal by Subject|1
6282804|NCT02310646|9993924|FG001|First Intervention (Day 1 - Day 7)|Withdrawal by Subject|0
6282805|NCT02310646|9993923|FG000|First Intervention (Day 1 - Day 7)|Lost to Follow-up|1
6282806|NCT02310646|9993924|FG001|First Intervention (Day 1 - Day 7)|Lost to Follow-up|0
6282807|NCT02310672|9993946|FG000|Overall Study|Death|1
6282808|NCT02310672|9993946|FG000|Overall Study|Lost to Follow-up|1
6282809|NCT02310672|9993946|FG000|Overall Study|Withdrawal by Subject|1
6282810|NCT02310672|9993946|FG000|Overall Study|Sponsor's decision|12
6282811|NCT02310750|9993961|FG000|HP Period 1|Lost to Follow-up|0
6282812|NCT02310750|9993962|FG001|HP Period 1|Lost to Follow-up|0
6282813|NCT02310750|9993963|FG002|HP Period 1|Lost to Follow-up|0
6282814|NCT02310750|9993964|FG003|HP Period 1|Lost to Follow-up|0
6282815|NCT02310750|9993965|FG004|HP Period 1|Lost to Follow-up|0
6282816|NCT02310750|9993966|FG005|HP Period 1|Lost to Follow-up|0
6282817|NCT02310750|9993967|FG006|HP Period 1|Lost to Follow-up|1
6282818|NCT02310750|9993968|FG007|HP Period 1|Lost to Follow-up|0
6282819|NCT02310750|9993969|FG008|HP Period 1|Lost to Follow-up|0
6282820|NCT02310750|9993970|FG009|HP Period 1|Lost to Follow-up|0
6282821|NCT02310750|9993971|FG010|HP Period 1|Lost to Follow-up|0
6282822|NCT02310750|9993972|FG011|HP Period 1|Lost to Follow-up|0
5980213|NCT04014075|9568778|FG000|Overall Study|Clinical Progression|2
5980214|NCT04014075|9568778|FG000|Overall Study|Death|2
5980215|NCT04014075|9568778|FG000|Overall Study|Withdrawal by Subject|2
5980216|NCT04014075|9568778|FG000|Overall Study|Miscellaneous|1
5980217|NCT04014075|9568778|FG000|Overall Study|Physician Decision|1
6051765|NCT00434954|9651112|FG000|Overall Study|Lost to Follow-up|0
6051766|NCT00434954|9651113|FG001|Overall Study|Lost to Follow-up|1
6051767|NCT00434954|9651112|FG000|Overall Study|Physician Decision|6
6051768|NCT00434954|9651113|FG001|Overall Study|Physician Decision|3
6051769|NCT00434954|9651112|FG000|Overall Study|Protocol Violation|36
6051770|NCT00434954|9651113|FG001|Overall Study|Protocol Violation|27
6051771|NCT00434954|9651112|FG000|Overall Study|Sponsor decision|1
6051772|NCT00434954|9651113|FG001|Overall Study|Sponsor decision|0
6051773|NCT00434954|9651112|FG000|Overall Study|Subject decision|8
6051774|NCT00434954|9651113|FG001|Overall Study|Subject decision|22
6051775|NCT00434967|9651123|FG000|Overall Study|Adverse Event|2
6051776|NCT00434967|9651124|FG001|Overall Study|Adverse Event|4
6051777|NCT00434967|9651125|FG002|Overall Study|Adverse Event|3
6051778|NCT00434967|9651126|FG003|Overall Study|Adverse Event|3
6051779|NCT00434967|9651123|FG000|Overall Study|Lost to Follow-up|0
6051780|NCT00434967|9651124|FG001|Overall Study|Lost to Follow-up|0
6051781|NCT00434967|9651125|FG002|Overall Study|Lost to Follow-up|1
6051782|NCT00434967|9651126|FG003|Overall Study|Lost to Follow-up|0
6051783|NCT00434967|9651123|FG000|Overall Study|Withdrawal by Subject|2
6051784|NCT00434967|9651124|FG001|Overall Study|Withdrawal by Subject|2
6051785|NCT00434967|9651125|FG002|Overall Study|Withdrawal by Subject|4
6051786|NCT00434967|9651126|FG003|Overall Study|Withdrawal by Subject|6
6051787|NCT00434967|9651123|FG000|Overall Study|Randomized in error|0
6051788|NCT00434967|9651124|FG001|Overall Study|Randomized in error|0
6051789|NCT00434967|9651125|FG002|Overall Study|Randomized in error|0
6051790|NCT00434967|9651126|FG003|Overall Study|Randomized in error|1
6051791|NCT00434967|9651123|FG000|Overall Study|Protocol Violation|0
6051792|NCT00434967|9651124|FG001|Overall Study|Protocol Violation|1
6051793|NCT00434967|9651125|FG002|Overall Study|Protocol Violation|0
6051794|NCT00434967|9651126|FG003|Overall Study|Protocol Violation|1
6051795|NCT00434967|9651123|FG000|Overall Study|Physician Decision|1
6051796|NCT00434967|9651124|FG001|Overall Study|Physician Decision|1
6051797|NCT00434967|9651125|FG002|Overall Study|Physician Decision|1
6051798|NCT00434967|9651126|FG003|Overall Study|Physician Decision|0
6051799|NCT00434967|9651123|FG000|Overall Study|Patient Disposition Challenges|2
6051800|NCT00434967|9651124|FG001|Overall Study|Patient Disposition Challenges|0
6051801|NCT00434967|9651125|FG002|Overall Study|Patient Disposition Challenges|0
6051802|NCT00434967|9651126|FG003|Overall Study|Patient Disposition Challenges|3
6051803|NCT00435019|9651147|FG000|Overall Study|Adverse Event|1
6051804|NCT00435019|9651148|FG001|Overall Study|Adverse Event|0
6051805|NCT00435019|9651147|FG000|Overall Study|Lack of Efficacy|1
6051806|NCT00435019|9651148|FG001|Overall Study|Lack of Efficacy|2
6051807|NCT00435019|9651147|FG000|Overall Study|Protocol Violation|3
6051808|NCT00435019|9651148|FG001|Overall Study|Protocol Violation|1
6051809|NCT00435019|9651147|FG000|Overall Study|Personal reasons for withdrawal|8
6051810|NCT00435019|9651148|FG001|Overall Study|Personal reasons for withdrawal|7
6051811|NCT00435045|9651156|FG000|Weeks 1-8 / 10 mg Dose Level|Adverse Event|1
6051812|NCT00435045|9651157|FG001|Weeks 1-8 / 10 mg Dose Level|Adverse Event|1
6051813|NCT00435045|9651156|FG000|Weeks 1-8 / 10 mg Dose Level|Lost to Follow-up|1
6051814|NCT00435045|9651157|FG001|Weeks 1-8 / 10 mg Dose Level|Lost to Follow-up|1
6051815|NCT00435045|9651156|FG000|Weeks 1-8 / 10 mg Dose Level|Withdrawal by Subject|2
6051816|NCT00435045|9651157|FG001|Weeks 1-8 / 10 mg Dose Level|Withdrawal by Subject|1
6282823|NCT02310750|9993973|FG012|HP Period 1|Lost to Follow-up|0
6282824|NCT02310750|9993974|FG013|HP Period 1|Lost to Follow-up|0
6282825|NCT02310750|9993975|FG014|HP Period 1|Lost to Follow-up|0
6282826|NCT02310750|9993976|FG015|HP Period 1|Lost to Follow-up|0
6282827|NCT02310750|9993961|FG000|HP Period 1|Withdrawal by Subject|1
6282828|NCT02310750|9993962|FG001|HP Period 1|Withdrawal by Subject|0
6282829|NCT02310750|9993963|FG002|HP Period 1|Withdrawal by Subject|0
6282830|NCT02310750|9993964|FG003|HP Period 1|Withdrawal by Subject|1
6282831|NCT02310750|9993965|FG004|HP Period 1|Withdrawal by Subject|0
6282832|NCT02310750|9993966|FG005|HP Period 1|Withdrawal by Subject|0
6282833|NCT02310750|9993967|FG006|HP Period 1|Withdrawal by Subject|0
6282834|NCT02310750|9993968|FG007|HP Period 1|Withdrawal by Subject|0
6282835|NCT02310750|9993969|FG008|HP Period 1|Withdrawal by Subject|0
6282836|NCT02310750|9993970|FG009|HP Period 1|Withdrawal by Subject|0
6282837|NCT02310750|9993971|FG010|HP Period 1|Withdrawal by Subject|0
6282838|NCT02310750|9993972|FG011|HP Period 1|Withdrawal by Subject|0
6282839|NCT02310750|9993973|FG012|HP Period 1|Withdrawal by Subject|0
6282840|NCT02310750|9993974|FG013|HP Period 1|Withdrawal by Subject|0
6282841|NCT02310750|9993975|FG014|HP Period 1|Withdrawal by Subject|0
6282842|NCT02310750|9993976|FG015|HP Period 1|Withdrawal by Subject|0
6282843|NCT02310750|9993961|FG000|HP Washout 1|Lost to Follow-up|0
6282844|NCT02310750|9993962|FG001|HP Washout 1|Lost to Follow-up|0
6282845|NCT02310750|9993963|FG002|HP Washout 1|Lost to Follow-up|1
6282846|NCT02310750|9993964|FG003|HP Washout 1|Lost to Follow-up|1
6282847|NCT02310750|9993965|FG004|HP Washout 1|Lost to Follow-up|2
6282848|NCT02310750|9993966|FG005|HP Washout 1|Lost to Follow-up|2
6282849|NCT02310750|9993967|FG006|HP Washout 1|Lost to Follow-up|3
6282850|NCT02310750|9993968|FG007|HP Washout 1|Lost to Follow-up|0
6282851|NCT02310750|9993969|FG008|HP Washout 1|Lost to Follow-up|0
6282852|NCT02310750|9993970|FG009|HP Washout 1|Lost to Follow-up|0
6282853|NCT02310750|9993971|FG010|HP Washout 1|Lost to Follow-up|0
6282854|NCT02310750|9993972|FG011|HP Washout 1|Lost to Follow-up|0
6282855|NCT02310750|9993973|FG012|HP Washout 1|Lost to Follow-up|0
6051817|NCT00435045|9651156|FG000|Weeks 1-8 / 10 mg Dose Level|Family Crisis - could not participate|1
6051818|NCT00435045|9651157|FG001|Weeks 1-8 / 10 mg Dose Level|Family Crisis - could not participate|0
6051819|NCT00435045|9651156|FG000|Weeks 1-8 / 10 mg Dose Level|Requirement for Excluded Medications|0
6051820|NCT00435045|9651157|FG001|Weeks 1-8 / 10 mg Dose Level|Requirement for Excluded Medications|1
6051821|NCT00435045|9651156|FG000|Weeks 9-12 / 20mg Dose Level|Adverse Event|4
6051822|NCT00435045|9651157|FG001|Weeks 9-12 / 20mg Dose Level|Adverse Event|3
6051823|NCT00435045|9651156|FG000|Weeks 9-12 / 20mg Dose Level|Lost to Follow-up|1
6051824|NCT00435045|9651157|FG001|Weeks 9-12 / 20mg Dose Level|Lost to Follow-up|1
6051825|NCT00435045|9651156|FG000|Weeks 9-12 / 20mg Dose Level|Withdrawal by Subject|0
6051826|NCT00435045|9651157|FG001|Weeks 9-12 / 20mg Dose Level|Withdrawal by Subject|1
6051827|NCT00435045|9651156|FG000|Weeks 13-16 / 40mg Dose Level|Adverse Event|3
6051828|NCT00435045|9651157|FG001|Weeks 13-16 / 40mg Dose Level|Adverse Event|2
6051829|NCT00435045|9651156|FG000|Weeks 13-16 / 40mg Dose Level|Withdrawal by Subject|1
6051830|NCT00435045|9651157|FG001|Weeks 13-16 / 40mg Dose Level|Withdrawal by Subject|0
6051831|NCT00435045|9651156|FG000|Weeks 13-16 / 40mg Dose Level|Per Sponsors Request|1
6051832|NCT00435045|9651157|FG001|Weeks 13-16 / 40mg Dose Level|Per Sponsors Request|0
6051833|NCT00435162|9651166|FG000|Period 2 (2 Weeks)|Adverse Event|0
6051834|NCT00435162|9651167|FG001|Period 2 (2 Weeks)|Adverse Event|1
6051835|NCT00435162|9651168|FG002|Period 2 (2 Weeks)|Adverse Event|0
6051836|NCT00435162|9651169|FG003|Period 2 (2 Weeks)|Adverse Event|0
6051837|NCT00435162|9651170|FG004|Period 2 (2 Weeks)|Adverse Event|0
6051838|NCT00435162|9651171|FG005|Period 2 (2 Weeks)|Adverse Event|0
6051839|NCT00435188|9651186|FG000|Overall Study|Death|1
6051840|NCT00435188|9651187|FG001|Overall Study|Death|6
6051841|NCT00435188|9651186|FG000|Overall Study|Withdrawal by Subject|16
6051842|NCT00435188|9651187|FG001|Overall Study|Withdrawal by Subject|11
6051843|NCT00435188|9651186|FG000|Overall Study|Lost to Follow-up|5
6051844|NCT00435188|9651187|FG001|Overall Study|Lost to Follow-up|6
6051845|NCT00435370|9651197|FG000|Overall Study|Adverse Event|8
6051846|NCT00435370|9651198|FG001|Overall Study|Adverse Event|8
6051847|NCT00435370|9651197|FG000|Overall Study|Withdrawal by Subject|10
6051848|NCT00435370|9651198|FG001|Overall Study|Withdrawal by Subject|10
6051849|NCT00435370|9651197|FG000|Overall Study|Antipsychotic medication changed|4
6051850|NCT00435370|9651198|FG001|Overall Study|Antipsychotic medication changed|2
6051851|NCT00435409|9651206|FG000|Overall Study|Protocol Violation|1
6051852|NCT00435409|9651207|FG001|Overall Study|Protocol Violation|2
6051853|NCT00435409|9651208|FG002|Overall Study|Protocol Violation|0
6051854|NCT00435409|9651206|FG000|Overall Study|Lost to Follow-up|1
6089531|NCT00685178|9701241|FG003|Overall Study|administrative (disciplinary) discharge|2
6282856|NCT02310750|9993974|FG013|HP Washout 1|Lost to Follow-up|0
6051855|NCT00435409|9651207|FG001|Overall Study|Lost to Follow-up|2
6051856|NCT00435409|9651208|FG002|Overall Study|Lost to Follow-up|0
6051857|NCT00435409|9651206|FG000|Overall Study|Death|8
6051858|NCT00435409|9651207|FG001|Overall Study|Death|6
6051859|NCT00435409|9651208|FG002|Overall Study|Death|6
6051860|NCT00435409|9651206|FG000|Overall Study|Objective progression or relapse|158
6051861|NCT00435409|9651207|FG001|Overall Study|Objective progression or relapse|93
6051862|NCT00435409|9651208|FG002|Overall Study|Objective progression or relapse|58
6282857|NCT02310750|9993975|FG014|HP Washout 1|Lost to Follow-up|0
6282858|NCT02310750|9993976|FG015|HP Washout 1|Lost to Follow-up|0
6282859|NCT02310750|9993961|FG000|HP MAD, Psoriasis MD, HP Fasted/Fed|Adverse Event|0
6282860|NCT02310750|9993962|FG001|HP MAD, Psoriasis MD, HP Fasted/Fed|Adverse Event|0
6282861|NCT02310750|9993963|FG002|HP MAD, Psoriasis MD, HP Fasted/Fed|Adverse Event|0
6282862|NCT02310750|9993964|FG003|HP MAD, Psoriasis MD, HP Fasted/Fed|Adverse Event|1
6282863|NCT02310750|9993965|FG004|HP MAD, Psoriasis MD, HP Fasted/Fed|Adverse Event|0
6282864|NCT02310750|9993966|FG005|HP MAD, Psoriasis MD, HP Fasted/Fed|Adverse Event|2
6282865|NCT02310750|9993967|FG006|HP MAD, Psoriasis MD, HP Fasted/Fed|Adverse Event|0
6282866|NCT02310750|9993968|FG007|HP MAD, Psoriasis MD, HP Fasted/Fed|Adverse Event|0
6282867|NCT02310750|9993969|FG008|HP MAD, Psoriasis MD, HP Fasted/Fed|Adverse Event|6
6282868|NCT02310750|9993970|FG009|HP MAD, Psoriasis MD, HP Fasted/Fed|Adverse Event|1
6282869|NCT02310750|9993971|FG010|HP MAD, Psoriasis MD, HP Fasted/Fed|Adverse Event|0
6282870|NCT02310750|9993972|FG011|HP MAD, Psoriasis MD, HP Fasted/Fed|Adverse Event|0
6282871|NCT02310750|9993973|FG012|HP MAD, Psoriasis MD, HP Fasted/Fed|Adverse Event|0
6282872|NCT02310750|9993974|FG013|HP MAD, Psoriasis MD, HP Fasted/Fed|Adverse Event|0
6282873|NCT02310750|9993975|FG014|HP MAD, Psoriasis MD, HP Fasted/Fed|Adverse Event|0
6282874|NCT02310750|9993976|FG015|HP MAD, Psoriasis MD, HP Fasted/Fed|Adverse Event|0
6282875|NCT02310750|9993961|FG000|HP MAD, Psoriasis MD, HP Fasted/Fed|Non-Compliance|0
6282876|NCT02310750|9993962|FG001|HP MAD, Psoriasis MD, HP Fasted/Fed|Non-Compliance|0
6282877|NCT02310750|9993963|FG002|HP MAD, Psoriasis MD, HP Fasted/Fed|Non-Compliance|0
6282878|NCT02310750|9993964|FG003|HP MAD, Psoriasis MD, HP Fasted/Fed|Non-Compliance|0
6282879|NCT02310750|9993965|FG004|HP MAD, Psoriasis MD, HP Fasted/Fed|Non-Compliance|0
6282880|NCT02310750|9993966|FG005|HP MAD, Psoriasis MD, HP Fasted/Fed|Non-Compliance|0
6282881|NCT02310750|9993967|FG006|HP MAD, Psoriasis MD, HP Fasted/Fed|Non-Compliance|0
6282882|NCT02310750|9993968|FG007|HP MAD, Psoriasis MD, HP Fasted/Fed|Non-Compliance|0
6282883|NCT02310750|9993969|FG008|HP MAD, Psoriasis MD, HP Fasted/Fed|Non-Compliance|0
6282884|NCT02310750|9993970|FG009|HP MAD, Psoriasis MD, HP Fasted/Fed|Non-Compliance|1
6282885|NCT02310750|9993971|FG010|HP MAD, Psoriasis MD, HP Fasted/Fed|Non-Compliance|0
6282886|NCT02310750|9993972|FG011|HP MAD, Psoriasis MD, HP Fasted/Fed|Non-Compliance|0
6282887|NCT02310750|9993973|FG012|HP MAD, Psoriasis MD, HP Fasted/Fed|Non-Compliance|0
6282888|NCT02310750|9993974|FG013|HP MAD, Psoriasis MD, HP Fasted/Fed|Non-Compliance|0
6282889|NCT02310750|9993975|FG014|HP MAD, Psoriasis MD, HP Fasted/Fed|Non-Compliance|0
6282890|NCT02310750|9993976|FG015|HP MAD, Psoriasis MD, HP Fasted/Fed|Non-Compliance|0
6282891|NCT02310750|9993961|FG000|HP MAD, Psoriasis MD, HP Fasted/Fed|Withdrawal by Subject|0
6282892|NCT02310750|9993962|FG001|HP MAD, Psoriasis MD, HP Fasted/Fed|Withdrawal by Subject|0
6282893|NCT02310750|9993963|FG002|HP MAD, Psoriasis MD, HP Fasted/Fed|Withdrawal by Subject|0
6282894|NCT02310750|9993964|FG003|HP MAD, Psoriasis MD, HP Fasted/Fed|Withdrawal by Subject|0
6282895|NCT02310750|9993965|FG004|HP MAD, Psoriasis MD, HP Fasted/Fed|Withdrawal by Subject|0
6282896|NCT02310750|9993966|FG005|HP MAD, Psoriasis MD, HP Fasted/Fed|Withdrawal by Subject|0
6051863|NCT00435409|9651206|FG000|Overall Study|Global deterioration of health status|0
6051864|NCT00435409|9651207|FG001|Overall Study|Global deterioration of health status|0
6051865|NCT00435409|9651208|FG002|Overall Study|Global deterioration of health status|4
6051866|NCT00435409|9651206|FG000|Overall Study|Withdrawal by Subject|8
6051867|NCT00435409|9651207|FG001|Overall Study|Withdrawal by Subject|7
6051868|NCT00435409|9651208|FG002|Overall Study|Withdrawal by Subject|1
6051869|NCT00435409|9651206|FG000|Overall Study|Other|45
6051870|NCT00435409|9651207|FG001|Overall Study|Other|30
6051871|NCT00435409|9651208|FG002|Overall Study|Other|1
6051872|NCT00435409|9651206|FG000|Overall Study|Adverse Event|0
6051873|NCT00435409|9651207|FG001|Overall Study|Adverse Event|0
6051874|NCT00435409|9651208|FG002|Overall Study|Adverse Event|8
6051875|NCT00435409|9651206|FG000|Overall Study|Sponsor decision|0
6051876|NCT00435409|9651207|FG001|Overall Study|Sponsor decision|3
6051877|NCT00435409|9651208|FG002|Overall Study|Sponsor decision|0
6051878|NCT00435461|9651217|FG000|Overall Study|Visit changed to EarlyWithdrawn Visit|1
6051879|NCT00435461|9651218|FG001|Overall Study|Visit changed to EarlyWithdrawn Visit|0
6051880|NCT00435461|9651219|FG002|Overall Study|Visit changed to EarlyWithdrawn Visit|0
6051881|NCT00435461|9651217|FG000|Overall Study|Protocol Violation|6
6051882|NCT00435461|9651218|FG001|Overall Study|Protocol Violation|9
6051883|NCT00435461|9651219|FG002|Overall Study|Protocol Violation|10
6051884|NCT00435461|9651217|FG000|Overall Study|Participant randomized(inadequate score)|1
6051885|NCT00435461|9651218|FG001|Overall Study|Participant randomized(inadequate score)|0
6051886|NCT00435461|9651219|FG002|Overall Study|Participant randomized(inadequate score)|0
6282897|NCT02310750|9993967|FG006|HP MAD, Psoriasis MD, HP Fasted/Fed|Withdrawal by Subject|0
6282898|NCT02310750|9993968|FG007|HP MAD, Psoriasis MD, HP Fasted/Fed|Withdrawal by Subject|1
6282899|NCT02310750|9993969|FG008|HP MAD, Psoriasis MD, HP Fasted/Fed|Withdrawal by Subject|1
6282900|NCT02310750|9993970|FG009|HP MAD, Psoriasis MD, HP Fasted/Fed|Withdrawal by Subject|1
6282901|NCT02310750|9993971|FG010|HP MAD, Psoriasis MD, HP Fasted/Fed|Withdrawal by Subject|0
6282902|NCT02310750|9993972|FG011|HP MAD, Psoriasis MD, HP Fasted/Fed|Withdrawal by Subject|0
6282903|NCT02310750|9993973|FG012|HP MAD, Psoriasis MD, HP Fasted/Fed|Withdrawal by Subject|0
6282904|NCT02310750|9993974|FG013|HP MAD, Psoriasis MD, HP Fasted/Fed|Withdrawal by Subject|0
6282905|NCT02310750|9993975|FG014|HP MAD, Psoriasis MD, HP Fasted/Fed|Withdrawal by Subject|0
6282906|NCT02310750|9993976|FG015|HP MAD, Psoriasis MD, HP Fasted/Fed|Withdrawal by Subject|0
6282907|NCT02310750|9993961|FG000|HP MAD, Psoriasis MD, HP Fasted/Fed|Lost to Follow-up|0
6282908|NCT02310750|9993962|FG001|HP MAD, Psoriasis MD, HP Fasted/Fed|Lost to Follow-up|0
6051887|NCT00435461|9651217|FG000|Overall Study|Compliance less than 80 percent|1
6051888|NCT00435461|9651218|FG001|Overall Study|Compliance less than 80 percent|0
6051889|NCT00435461|9651219|FG002|Overall Study|Compliance less than 80 percent|0
6051890|NCT00435461|9651217|FG000|Overall Study|In error, two study medications switched|1
6282909|NCT02310750|9993963|FG002|HP MAD, Psoriasis MD, HP Fasted/Fed|Lost to Follow-up|0
6282910|NCT02310750|9993964|FG003|HP MAD, Psoriasis MD, HP Fasted/Fed|Lost to Follow-up|0
6282911|NCT02310750|9993965|FG004|HP MAD, Psoriasis MD, HP Fasted/Fed|Lost to Follow-up|0
6282912|NCT02310750|9993966|FG005|HP MAD, Psoriasis MD, HP Fasted/Fed|Lost to Follow-up|0
6282913|NCT02310750|9993967|FG006|HP MAD, Psoriasis MD, HP Fasted/Fed|Lost to Follow-up|0
6282914|NCT02310750|9993968|FG007|HP MAD, Psoriasis MD, HP Fasted/Fed|Lost to Follow-up|1
6282915|NCT02310750|9993969|FG008|HP MAD, Psoriasis MD, HP Fasted/Fed|Lost to Follow-up|1
6282916|NCT02310750|9993970|FG009|HP MAD, Psoriasis MD, HP Fasted/Fed|Lost to Follow-up|0
6282917|NCT02310750|9993971|FG010|HP MAD, Psoriasis MD, HP Fasted/Fed|Lost to Follow-up|0
6282918|NCT02310750|9993972|FG011|HP MAD, Psoriasis MD, HP Fasted/Fed|Lost to Follow-up|0
6282919|NCT02310750|9993973|FG012|HP MAD, Psoriasis MD, HP Fasted/Fed|Lost to Follow-up|0
6282920|NCT02310750|9993974|FG013|HP MAD, Psoriasis MD, HP Fasted/Fed|Lost to Follow-up|0
6282921|NCT02310750|9993975|FG014|HP MAD, Psoriasis MD, HP Fasted/Fed|Lost to Follow-up|0
6282922|NCT02310750|9993976|FG015|HP MAD, Psoriasis MD, HP Fasted/Fed|Lost to Follow-up|0
6282923|NCT02310750|9993961|FG000|HP Washout 2|Lost to Follow-up|0
6282924|NCT02310750|9993962|FG001|HP Washout 2|Lost to Follow-up|0
6282925|NCT02310750|9993963|FG002|HP Washout 2|Lost to Follow-up|0
6282926|NCT02310750|9993964|FG003|HP Washout 2|Lost to Follow-up|0
6282927|NCT02310750|9993965|FG004|HP Washout 2|Lost to Follow-up|1
6282928|NCT02310750|9993966|FG005|HP Washout 2|Lost to Follow-up|0
6282929|NCT02310750|9993967|FG006|HP Washout 2|Lost to Follow-up|7
6282930|NCT02310750|9993968|FG007|HP Washout 2|Lost to Follow-up|0
6282931|NCT02310750|9993969|FG008|HP Washout 2|Lost to Follow-up|0
6282932|NCT02310750|9993970|FG009|HP Washout 2|Lost to Follow-up|0
6282933|NCT02310750|9993971|FG010|HP Washout 2|Lost to Follow-up|0
6282934|NCT02310750|9993972|FG011|HP Washout 2|Lost to Follow-up|0
6282935|NCT02310750|9993973|FG012|HP Washout 2|Lost to Follow-up|0
6282936|NCT02310750|9993974|FG013|HP Washout 2|Lost to Follow-up|0
6282937|NCT02310750|9993975|FG014|HP Washout 2|Lost to Follow-up|0
6282938|NCT02310750|9993976|FG015|HP Washout 2|Lost to Follow-up|0
6282939|NCT02310763|9994060|FG000|Period 1 (Weeks 1 to 48)|Withdrawal by Subject|1
6282940|NCT02310763|9994061|FG001|Period 1 (Weeks 1 to 48)|Withdrawal by Subject|1
6051891|NCT00435461|9651218|FG001|Overall Study|In error, two study medications switched|0
6051892|NCT00435461|9651219|FG002|Overall Study|In error, two study medications switched|0
6051893|NCT00435461|9651217|FG000|Overall Study|Lack of Efficacy|2
6051894|NCT00435461|9651218|FG001|Overall Study|Lack of Efficacy|1
6051895|NCT00435461|9651219|FG002|Overall Study|Lack of Efficacy|0
6051896|NCT00435461|9651217|FG000|Overall Study|Withdrawal by Subject|1
6051897|NCT00435461|9651218|FG001|Overall Study|Withdrawal by Subject|0
6051898|NCT00435461|9651219|FG002|Overall Study|Withdrawal by Subject|2
6051899|NCT00435461|9651217|FG000|Overall Study|Randomized in error|1
6051900|NCT00435461|9651218|FG001|Overall Study|Randomized in error|0
6051901|NCT00435461|9651219|FG002|Overall Study|Randomized in error|0
6051902|NCT00435461|9651217|FG000|Overall Study|Participant could not tolerate symptoms|0
6051903|NCT00435461|9651218|FG001|Overall Study|Participant could not tolerate symptoms|0
6051904|NCT00435461|9651219|FG002|Overall Study|Participant could not tolerate symptoms|1
6051905|NCT00435461|9651217|FG000|Overall Study|Participant could not swallow capsule|0
6051906|NCT00435461|9651218|FG001|Overall Study|Participant could not swallow capsule|0
6051907|NCT00435461|9651219|FG002|Overall Study|Participant could not swallow capsule|1
6051908|NCT00435461|9651217|FG000|Overall Study|Pregnancy|2
6051909|NCT00435461|9651218|FG001|Overall Study|Pregnancy|0
6051910|NCT00435461|9651219|FG002|Overall Study|Pregnancy|0
6051911|NCT00435461|9651217|FG000|Overall Study|Participant moved eDiary,studymedication|1
6051912|NCT00435461|9651218|FG001|Overall Study|Participant moved eDiary,studymedication|0
6051913|NCT00435461|9651219|FG002|Overall Study|Participant moved eDiary,studymedication|0
6051914|NCT00435461|9651217|FG000|Overall Study|Participant ended study one day early|1
6051915|NCT00435461|9651218|FG001|Overall Study|Participant ended study one day early|0
6282941|NCT02310763|9994062|FG002|Period 1 (Weeks 1 to 48)|Withdrawal by Subject|1
6282942|NCT02310763|9994060|FG000|Period 1 (Weeks 1 to 48)|Unable to comply with study procedures|0
6282943|NCT02310763|9994061|FG001|Period 1 (Weeks 1 to 48)|Unable to comply with study procedures|1
6282944|NCT02310763|9994062|FG002|Period 1 (Weeks 1 to 48)|Unable to comply with study procedures|1
6282945|NCT02310763|9994060|FG000|Period 1 (Weeks 1 to 48)|Lost to Follow-up|1
6282946|NCT02310763|9994061|FG001|Period 1 (Weeks 1 to 48)|Lost to Follow-up|0
6282947|NCT02310763|9994062|FG002|Period 1 (Weeks 1 to 48)|Lost to Follow-up|0
6282948|NCT02310763|9994060|FG000|Period 1 (Weeks 1 to 48)|Adverse Event|1
6051916|NCT00435461|9651219|FG002|Overall Study|Participant ended study one day early|0
6051917|NCT00435461|9651217|FG000|Overall Study|Noncompliance with study requirements|1
6051918|NCT00435461|9651218|FG001|Overall Study|Noncompliance with study requirements|1
6051919|NCT00435461|9651219|FG002|Overall Study|Noncompliance with study requirements|1
6051920|NCT00435461|9651217|FG000|Overall Study|Adverse Event|1
6282949|NCT02310763|9994061|FG001|Period 1 (Weeks 1 to 48)|Adverse Event|0
6282950|NCT02310763|9994062|FG002|Period 1 (Weeks 1 to 48)|Adverse Event|0
6282951|NCT02310763|9994060|FG000|Period 2 (Weeks 49 to 96)|Study terminated by sponsor|16
6282952|NCT02310763|9994061|FG001|Period 2 (Weeks 49 to 96)|Study terminated by sponsor|16
6282953|NCT02310763|9994062|FG002|Period 2 (Weeks 49 to 96)|Study terminated by sponsor|16
6282954|NCT02310789|9994092|FG000|Overall Study|Adverse Event|1
5980218|NCT03284853|9568792|FG000|Overall Study|Adverse Event|40
6051921|NCT00435461|9651218|FG001|Overall Study|Adverse Event|2
6051922|NCT00435461|9651219|FG002|Overall Study|Adverse Event|6
6051923|NCT00435461|9651217|FG000|Overall Study|Non-Compliance of diary|2
6051924|NCT00435461|9651218|FG001|Overall Study|Non-Compliance of diary|0
6051925|NCT00435461|9651219|FG002|Overall Study|Non-Compliance of diary|1
6051926|NCT00435461|9651217|FG000|Overall Study|Lost to Follow-up|1
6051927|NCT00435461|9651218|FG001|Overall Study|Lost to Follow-up|1
6051928|NCT00435461|9651219|FG002|Overall Study|Lost to Follow-up|2
6051929|NCT00435487|9651229|FG000|Overall Study|Death|3
6089532|NCT00685178|9701238|FG000|Overall Study|Pregnancy|0
6089533|NCT00685178|9701239|FG001|Overall Study|Pregnancy|0
6089534|NCT00685178|9701240|FG002|Overall Study|Pregnancy|0
6089535|NCT00685178|9701241|FG003|Overall Study|Pregnancy|1
6202093|NCT01499290|9862214|FG001|Overall Study|Withdrawal by Subject|15
6202094|NCT01499290|9862213|FG000|Overall Study|Not specified in study report|11
6202095|NCT01499290|9862214|FG001|Overall Study|Not specified in study report|5
6202096|NCT01499290|9862213|FG000|Overall Study|Condition improved/subject recovered|1
6202097|NCT01499290|9862214|FG001|Overall Study|Condition improved/subject recovered|0
6202098|NCT01499290|9862213|FG000|Overall Study|Lack of Efficacy|7
6202099|NCT01499290|9862214|FG001|Overall Study|Lack of Efficacy|8
6202100|NCT01499290|9862213|FG000|Overall Study|Adverse Event|14
6202101|NCT01499290|9862214|FG001|Overall Study|Adverse Event|7
6202102|NCT01499303|9862241|FG000|Overall Study|Ongoing|2
6202103|NCT01499303|9862242|FG001|Overall Study|Ongoing|1
6202104|NCT01499303|9862241|FG000|Overall Study|Withdrawal by Subject|0
6202105|NCT01499303|9862242|FG001|Overall Study|Withdrawal by Subject|1
6202106|NCT01499303|9862241|FG000|Overall Study|Adverse Event|1
6202107|NCT01499303|9862242|FG001|Overall Study|Adverse Event|4
6202108|NCT01499303|9862241|FG000|Overall Study|Other|0
6202109|NCT01499303|9862242|FG001|Overall Study|Other|1
6202110|NCT01499355|9862248|FG000|Run-In Period|Study Termination|15
6202111|NCT01499355|9862249|FG001|Run-In Period|Study Termination|0
6202112|NCT01499355|9862250|FG002|Run-In Period|Study Termination|0
6202113|NCT01499355|9862251|FG003|Run-In Period|Study Termination|0
6202114|NCT01499355|9862248|FG000|Run-In Period|Other|3
6202115|NCT01499355|9862249|FG001|Run-In Period|Other|0
6202116|NCT01499355|9862250|FG002|Run-In Period|Other|0
6202117|NCT01499355|9862251|FG003|Run-In Period|Other|0
6202118|NCT01499355|9862248|FG000|Run-In Period|Death|2
6202119|NCT01499355|9862249|FG001|Run-In Period|Death|0
6202120|NCT01499355|9862250|FG002|Run-In Period|Death|0
6202121|NCT01499355|9862251|FG003|Run-In Period|Death|0
6202122|NCT01499355|9862248|FG000|Run-In Period|Investigator Decision|2
6202123|NCT01499355|9862249|FG001|Run-In Period|Investigator Decision|0
6202124|NCT01499355|9862250|FG002|Run-In Period|Investigator Decision|0
6202125|NCT01499355|9862251|FG003|Run-In Period|Investigator Decision|0
6202126|NCT01499355|9862248|FG000|Run-In Period|Consent Withdrawn|1
6202127|NCT01499355|9862249|FG001|Run-In Period|Consent Withdrawn|0
6202128|NCT01499355|9862250|FG002|Run-In Period|Consent Withdrawn|0
6202129|NCT01499355|9862251|FG003|Run-In Period|Consent Withdrawn|0
6202130|NCT01499355|9862248|FG000|Run-In Period|Adverse Event|8
6202131|NCT01499355|9862249|FG001|Run-In Period|Adverse Event|0
6202132|NCT01499355|9862250|FG002|Run-In Period|Adverse Event|0
6202133|NCT01499355|9862251|FG003|Run-In Period|Adverse Event|0
6202134|NCT01499355|9862248|FG000|Double-Blind Period|Adverse Event|0
6202135|NCT01499355|9862249|FG001|Double-Blind Period|Adverse Event|2
6202136|NCT01499355|9862250|FG002|Double-Blind Period|Adverse Event|3
6202137|NCT01499355|9862251|FG003|Double-Blind Period|Adverse Event|2
6202138|NCT01499355|9862248|FG000|Double-Blind Period|Study Termination|0
6202139|NCT01499355|9862249|FG001|Double-Blind Period|Study Termination|18
6202140|NCT01499355|9862250|FG002|Double-Blind Period|Study Termination|16
6202141|NCT01499355|9862251|FG003|Double-Blind Period|Study Termination|14
6202142|NCT01499355|9862248|FG000|Double-Blind Period|Other|0
6202143|NCT01499355|9862249|FG001|Double-Blind Period|Other|1
6202144|NCT01499355|9862250|FG002|Double-Blind Period|Other|2
6202145|NCT01499355|9862251|FG003|Double-Blind Period|Other|2
6202146|NCT01499355|9862248|FG000|Double-Blind Period|Death|0
6202147|NCT01499355|9862249|FG001|Double-Blind Period|Death|1
6202148|NCT01499355|9862250|FG002|Double-Blind Period|Death|0
6202149|NCT01499355|9862251|FG003|Double-Blind Period|Death|0
6202150|NCT01499355|9862248|FG000|Double-Blind Period|Investigator Decision|0
6202151|NCT01499355|9862249|FG001|Double-Blind Period|Investigator Decision|0
6202152|NCT01499355|9862250|FG002|Double-Blind Period|Investigator Decision|3
5980219|NCT03284853|9568793|FG001|Overall Study|Adverse Event|4
5980220|NCT03284853|9568792|FG000|Overall Study|Withdrawal by Subject|5
5980221|NCT03284853|9568793|FG001|Overall Study|Withdrawal by Subject|1
5980222|NCT03284853|9568792|FG000|Overall Study|Lost to Follow-up|1
5980223|NCT03284853|9568793|FG001|Overall Study|Lost to Follow-up|0
5980224|NCT03284853|9568792|FG000|Overall Study|Lack of Efficacy|1
5980225|NCT03284853|9568793|FG001|Overall Study|Lack of Efficacy|0
5980226|NCT03284853|9568792|FG000|Overall Study|Disallowed Concurrent Medication|1
5980227|NCT03284853|9568793|FG001|Overall Study|Disallowed Concurrent Medication|1
5980228|NCT03284853|9568792|FG000|Overall Study|Protocol Violation|3
5980229|NCT03284853|9568793|FG001|Overall Study|Protocol Violation|3
5980230|NCT03284853|9568792|FG000|Overall Study|Death|0
6051930|NCT00435487|9651230|FG001|Overall Study|Death|4
6051931|NCT00435487|9651229|FG000|Overall Study|Adverse Event|0
6051932|NCT00435487|9651230|FG001|Overall Study|Adverse Event|3
6051933|NCT00435487|9651229|FG000|Overall Study|Lost to Follow-up|2
6051934|NCT00435487|9651230|FG001|Overall Study|Lost to Follow-up|2
6051935|NCT00435487|9651229|FG000|Overall Study|Other|5
6051936|NCT00435487|9651230|FG001|Overall Study|Other|2
6051937|NCT00435487|9651229|FG000|Overall Study|Withdrawal by Subject|2
6051938|NCT00435487|9651230|FG001|Overall Study|Withdrawal by Subject|1
6051939|NCT00435487|9651229|FG000|Overall Study|Withdrawal by Subject Prior to Treatment|0
6051940|NCT00435487|9651230|FG001|Overall Study|Withdrawal by Subject Prior to Treatment|2
6051941|NCT00435487|9651229|FG000|Overall Study|Received Drug in Other Treatment Group|0
6051942|NCT00435487|9651230|FG001|Overall Study|Received Drug in Other Treatment Group|1
6051943|NCT00435825|9651289|FG000|Overall Study|Abnormality of Laboratory Test|0
6051944|NCT00435825|9651290|FG001|Overall Study|Abnormality of Laboratory Test|1
6051945|NCT00435825|9651291|FG002|Overall Study|Abnormality of Laboratory Test|0
6051946|NCT00435825|9651292|FG003|Overall Study|Abnormality of Laboratory Test|0
6051947|NCT00435825|9651289|FG000|Overall Study|Insufficient Therapeutic Response|3
6051948|NCT00435825|9651290|FG001|Overall Study|Insufficient Therapeutic Response|1
6051949|NCT00435825|9651291|FG002|Overall Study|Insufficient Therapeutic Response|0
6051950|NCT00435825|9651292|FG003|Overall Study|Insufficient Therapeutic Response|3
6051951|NCT00435825|9651289|FG000|Overall Study|Other Protocol Violation|1
6051952|NCT00435825|9651290|FG001|Overall Study|Other Protocol Violation|0
6051953|NCT00435825|9651291|FG002|Overall Study|Other Protocol Violation|0
6051954|NCT00435825|9651292|FG003|Overall Study|Other Protocol Violation|0
6051955|NCT00435825|9651289|FG000|Overall Study|Refused treatment|2
6051956|NCT00435825|9651290|FG001|Overall Study|Refused treatment|0
6051957|NCT00435825|9651291|FG002|Overall Study|Refused treatment|0
6051958|NCT00435825|9651292|FG003|Overall Study|Refused treatment|5
6051959|NCT00435825|9651289|FG000|Overall Study|Failure to return|5
6051960|NCT00435825|9651290|FG001|Overall Study|Failure to return|0
6051961|NCT00435825|9651291|FG002|Overall Study|Failure to return|4
6051962|NCT00435825|9651292|FG003|Overall Study|Failure to return|0
6051963|NCT00435825|9651289|FG000|Overall Study|Did not receive study drug|1
6051964|NCT00435825|9651290|FG001|Overall Study|Did not receive study drug|0
6051965|NCT00435825|9651291|FG002|Overall Study|Did not receive study drug|2
6051966|NCT00435825|9651292|FG003|Overall Study|Did not receive study drug|0
6051967|NCT00435825|9651289|FG000|Overall Study|Did not enter follow-up|0
6051968|NCT00435825|9651290|FG001|Overall Study|Did not enter follow-up|4
6051969|NCT00435825|9651291|FG002|Overall Study|Did not enter follow-up|1
6051970|NCT00435825|9651292|FG003|Overall Study|Did not enter follow-up|3
6051971|NCT00435825|9651289|FG000|Overall Study|Did not complete full follow-up period|6
6051972|NCT00435825|9651290|FG001|Overall Study|Did not complete full follow-up period|6
6089536|NCT00685334|9701264|FG000|Overall Study|Withdrawal by Subject|5
6089537|NCT00685334|9701265|FG001|Overall Study|Withdrawal by Subject|6
6051973|NCT00435825|9651291|FG002|Overall Study|Did not complete full follow-up period|4
6051974|NCT00435825|9651292|FG003|Overall Study|Did not complete full follow-up period|5
6051975|NCT00435942|9651313|FG000|Overall Study|Death|17
6051976|NCT00435942|9651314|FG001|Overall Study|Death|10
6089538|NCT00685334|9701264|FG000|Overall Study|Lost to Follow-up|4
6089539|NCT00685334|9701265|FG001|Overall Study|Lost to Follow-up|0
6089540|NCT00685334|9701264|FG000|Overall Study|Chose to enter hospital|1
6089541|NCT00685334|9701265|FG001|Overall Study|Chose to enter hospital|1
6089542|NCT00685373|9701271|FG000|Overall Study|Adverse Event|3
6089543|NCT00685373|9701271|FG000|Overall Study|Withdrawal by Subject|5
6089544|NCT00685373|9701271|FG000|Overall Study|Lack of Efficacy|3
6089545|NCT00685373|9701271|FG000|Overall Study|Condition no longer requires study drug|1
6089546|NCT00685373|9701271|FG000|Overall Study|Lost to Follow-up|2
6089547|NCT00685373|9701271|FG000|Overall Study|Protocol Violation|1
6089548|NCT00685399|9701282|FG000|Treatment Period 1|Withdrawal by Subject|2
6089549|NCT00685399|9701283|FG001|Treatment Period 1|Withdrawal by Subject|0
6089550|NCT00685399|9701284|FG002|Treatment Period 1|Withdrawal by Subject|0
6089551|NCT00685399|9701285|FG003|Treatment Period 1|Withdrawal by Subject|0
6089552|NCT00685399|9701286|FG004|Treatment Period 1|Withdrawal by Subject|0
6089553|NCT00685399|9701287|FG005|Treatment Period 1|Withdrawal by Subject|0
6089554|NCT00685399|9701288|FG006|Treatment Period 1|Withdrawal by Subject|0
6089555|NCT00685399|9701289|FG007|Treatment Period 1|Withdrawal by Subject|0
6089556|NCT00685399|9701282|FG000|Treatment Period 1|Protocol Violation|1
6089557|NCT00685399|9701283|FG001|Treatment Period 1|Protocol Violation|0
6089558|NCT00685399|9701284|FG002|Treatment Period 1|Protocol Violation|0
6089559|NCT00685399|9701285|FG003|Treatment Period 1|Protocol Violation|0
6089560|NCT00685399|9701286|FG004|Treatment Period 1|Protocol Violation|0
6089561|NCT00685399|9701287|FG005|Treatment Period 1|Protocol Violation|0
6089562|NCT00685399|9701288|FG006|Treatment Period 1|Protocol Violation|0
6089563|NCT00685399|9701289|FG007|Treatment Period 1|Protocol Violation|0
6089564|NCT00685399|9701282|FG000|Treatment Period 1|Administrative|2
6089565|NCT00685399|9701283|FG001|Treatment Period 1|Administrative|0
6089566|NCT00685399|9701284|FG002|Treatment Period 1|Administrative|0
6089567|NCT00685399|9701285|FG003|Treatment Period 1|Administrative|0
6089568|NCT00685399|9701286|FG004|Treatment Period 1|Administrative|0
6089569|NCT00685399|9701287|FG005|Treatment Period 1|Administrative|0
6089570|NCT00685399|9701288|FG006|Treatment Period 1|Administrative|0
6089571|NCT00685399|9701289|FG007|Treatment Period 1|Administrative|0
6089572|NCT00685399|9701282|FG000|Treatment Period 1|Lack of Efficacy|1
6051977|NCT00435942|9651313|FG000|Overall Study|Withdrawal by Subject|2
6051978|NCT00435942|9651314|FG001|Overall Study|Withdrawal by Subject|0
6089573|NCT00685399|9701283|FG001|Treatment Period 1|Lack of Efficacy|0
6089574|NCT00685399|9701284|FG002|Treatment Period 1|Lack of Efficacy|0
6089575|NCT00685399|9701285|FG003|Treatment Period 1|Lack of Efficacy|0
6089576|NCT00685399|9701286|FG004|Treatment Period 1|Lack of Efficacy|0
6089577|NCT00685399|9701287|FG005|Treatment Period 1|Lack of Efficacy|0
6282955|NCT02310906|9994100|FG000|Part 2: Open Label Phase (168 Weeks)|Enrollment in other therapeutic study|0
6282956|NCT02310906|9994101|FG001|Part 2: Open Label Phase (168 Weeks)|Enrollment in other therapeutic study|0
6282957|NCT02310906|9994102|FG002|Part 2: Open Label Phase (168 Weeks)|Enrollment in other therapeutic study|0
6282958|NCT02310906|9994103|FG003|Part 2: Open Label Phase (168 Weeks)|Enrollment in other therapeutic study|2
6282959|NCT02310906|9994100|FG000|Part 2: Open Label Phase (168 Weeks)|Withdrawal by Subject|0
6282960|NCT02310906|9994101|FG001|Part 2: Open Label Phase (168 Weeks)|Withdrawal by Subject|0
6282961|NCT02310906|9994102|FG002|Part 2: Open Label Phase (168 Weeks)|Withdrawal by Subject|2
6282962|NCT02310906|9994103|FG003|Part 2: Open Label Phase (168 Weeks)|Withdrawal by Subject|4
6282963|NCT02310906|9994100|FG000|Part 2: Open Label Phase (168 Weeks)|Personal reasons|0
6282964|NCT02310906|9994101|FG001|Part 2: Open Label Phase (168 Weeks)|Personal reasons|0
6282965|NCT02310906|9994102|FG002|Part 2: Open Label Phase (168 Weeks)|Personal reasons|0
6282966|NCT02310906|9994103|FG003|Part 2: Open Label Phase (168 Weeks)|Personal reasons|1
6282967|NCT02310906|9994100|FG000|Part 2: Open Label Phase (168 Weeks)|Lost to Follow-up|0
6282968|NCT02310906|9994101|FG001|Part 2: Open Label Phase (168 Weeks)|Lost to Follow-up|0
6282969|NCT02310906|9994102|FG002|Part 2: Open Label Phase (168 Weeks)|Lost to Follow-up|0
6282970|NCT02310906|9994103|FG003|Part 2: Open Label Phase (168 Weeks)|Lost to Follow-up|1
6282971|NCT02311153|9994126|FG000|Overall Study|Lost to Follow-up|5
6282972|NCT02311153|9994127|FG001|Overall Study|Lost to Follow-up|7
6282973|NCT02311361|9994150|FG000|Overall Study|Did not receive treatment|0
6282974|NCT02311361|9994151|FG001|Overall Study|Did not receive treatment|1
6282975|NCT02311361|9994152|FG002|Overall Study|Did not receive treatment|0
6282976|NCT02311361|9994153|FG003|Overall Study|Did not receive treatment|1
6282977|NCT02311478|9994167|FG000|Overall Study|Withdrawal by Subject|1
6282978|NCT02311478|9994167|FG000|Overall Study|Lost to Follow-up|5
6282979|NCT02311478|9994167|FG000|Overall Study|Failed IUD Insertion|1
6282980|NCT02311881|9994174|FG000|Overall Study|Did not meet the study criteria|2
6282981|NCT02311881|9994175|FG001|Overall Study|Did not meet the study criteria|2
6282982|NCT02311881|9994176|FG002|Overall Study|Did not meet the study criteria|0
6282983|NCT02311881|9994174|FG000|Overall Study|Adverse Event|7
6282984|NCT02311881|9994175|FG001|Overall Study|Adverse Event|15
6282985|NCT02311881|9994176|FG002|Overall Study|Adverse Event|8
6282986|NCT02311881|9994174|FG000|Overall Study|Lost to Follow-up|3
6282987|NCT02311881|9994175|FG001|Overall Study|Lost to Follow-up|3
6282988|NCT02311881|9994176|FG002|Overall Study|Lost to Follow-up|2
6282989|NCT02311881|9994174|FG000|Overall Study|Protocol Violation|1
6282990|NCT02311881|9994175|FG001|Overall Study|Protocol Violation|2
6282991|NCT02311881|9994176|FG002|Overall Study|Protocol Violation|3
6282992|NCT02311881|9994174|FG000|Overall Study|Withdrawal of consent|14
6282993|NCT02311881|9994175|FG001|Overall Study|Withdrawal of consent|16
6089578|NCT00685399|9701288|FG006|Treatment Period 1|Lack of Efficacy|0
6089579|NCT00685399|9701289|FG007|Treatment Period 1|Lack of Efficacy|0
6089580|NCT00685399|9701282|FG000|Treatment Period 2|Administrative Problems|0
6089581|NCT00685399|9701283|FG001|Treatment Period 2|Administrative Problems|2
6089582|NCT00685399|9701284|FG002|Treatment Period 2|Administrative Problems|1
6089583|NCT00685399|9701285|FG003|Treatment Period 2|Administrative Problems|0
6089584|NCT00685399|9701286|FG004|Treatment Period 2|Administrative Problems|0
6089585|NCT00685399|9701287|FG005|Treatment Period 2|Administrative Problems|0
6089586|NCT00685399|9701288|FG006|Treatment Period 2|Administrative Problems|0
6089587|NCT00685399|9701289|FG007|Treatment Period 2|Administrative Problems|0
6089588|NCT00685399|9701282|FG000|Treatment Period 2|Withdrawal by Subject|0
6089589|NCT00685399|9701283|FG001|Treatment Period 2|Withdrawal by Subject|0
6089590|NCT00685399|9701284|FG002|Treatment Period 2|Withdrawal by Subject|0
6089591|NCT00685399|9701285|FG003|Treatment Period 2|Withdrawal by Subject|0
6089592|NCT00685399|9701286|FG004|Treatment Period 2|Withdrawal by Subject|0
6089593|NCT00685399|9701287|FG005|Treatment Period 2|Withdrawal by Subject|0
6089594|NCT00685399|9701288|FG006|Treatment Period 2|Withdrawal by Subject|0
6089595|NCT00685399|9701289|FG007|Treatment Period 2|Withdrawal by Subject|2
6089596|NCT00685399|9701282|FG000|Treatment Period 2|Adverse Event|0
6089597|NCT00685399|9701283|FG001|Treatment Period 2|Adverse Event|0
6089598|NCT00685399|9701284|FG002|Treatment Period 2|Adverse Event|0
6089599|NCT00685399|9701285|FG003|Treatment Period 2|Adverse Event|0
6089600|NCT00685399|9701286|FG004|Treatment Period 2|Adverse Event|0
6282994|NCT02311881|9994176|FG002|Overall Study|Withdrawal of consent|17
6282995|NCT02311881|9994174|FG000|Overall Study|Other|0
6282996|NCT02311881|9994175|FG001|Overall Study|Other|0
6282997|NCT02311881|9994176|FG002|Overall Study|Other|1
6282998|NCT02311881|9994174|FG000|Overall Study|Lack of Efficacy|1
6282999|NCT02311881|9994175|FG001|Overall Study|Lack of Efficacy|2
6283000|NCT02311881|9994176|FG002|Overall Study|Lack of Efficacy|0
6283001|NCT02311881|9994174|FG000|Overall Study|Subject has border line pregnancy test|1
6283002|NCT02311881|9994175|FG001|Overall Study|Subject has border line pregnancy test|0
6283003|NCT02311881|9994176|FG002|Overall Study|Subject has border line pregnancy test|0
6283004|NCT02311881|9994174|FG000|Overall Study|Withdrawal by Subject|3
6283005|NCT02311881|9994175|FG001|Overall Study|Withdrawal by Subject|1
6283006|NCT02311881|9994176|FG002|Overall Study|Withdrawal by Subject|4
6283007|NCT02311881|9994174|FG000|Overall Study|Sponsor Decision|1
6283008|NCT02311881|9994175|FG001|Overall Study|Sponsor Decision|1
6283009|NCT02311881|9994176|FG002|Overall Study|Sponsor Decision|1
6283010|NCT02311881|9994174|FG000|Overall Study|Protocol Deviation|1
6283011|NCT02311881|9994175|FG001|Overall Study|Protocol Deviation|0
6283012|NCT02311881|9994176|FG002|Overall Study|Protocol Deviation|0
6283013|NCT02311881|9994174|FG000|Overall Study|Non-Compliance|1
6283014|NCT02311881|9994175|FG001|Overall Study|Non-Compliance|0
6283015|NCT02311881|9994176|FG002|Overall Study|Non-Compliance|2
6283016|NCT02311881|9994174|FG000|Overall Study|Physician Decision|0
6283017|NCT02311881|9994175|FG001|Overall Study|Physician Decision|0
6283018|NCT02311881|9994176|FG002|Overall Study|Physician Decision|1
6283019|NCT02311881|9994174|FG000|Overall Study|Medical Monitor Discretion|0
6283020|NCT02311881|9994175|FG001|Overall Study|Medical Monitor Discretion|0
6283021|NCT02311881|9994176|FG002|Overall Study|Medical Monitor Discretion|1
6283022|NCT02311881|9994174|FG000|Overall Study|Participant taking another medication|0
6283023|NCT02311881|9994175|FG001|Overall Study|Participant taking another medication|0
6283024|NCT02311881|9994176|FG002|Overall Study|Participant taking another medication|1
6283025|NCT02311881|9994174|FG000|Overall Study|Serious Adverse Event|0
6283026|NCT02311881|9994175|FG001|Overall Study|Serious Adverse Event|1
6283027|NCT02311881|9994176|FG002|Overall Study|Serious Adverse Event|0
6283028|NCT02311894|9994187|FG000|Overall Study|Discontinued in error|1
6283029|NCT02311894|9994187|FG000|Overall Study|Lost to Follow-up|1
6283030|NCT02311894|9994187|FG000|Overall Study|Adverse Event|1
6283031|NCT02311894|9994187|FG000|Overall Study|Withdrawal by Subject|1
6283032|NCT02312063|9994221|FG000|Overall Study|Withdrawal by Subject|0
6051979|NCT00435942|9651313|FG000|Overall Study|Lost to Follow-up|0
6051980|NCT00435942|9651314|FG001|Overall Study|Lost to Follow-up|16
6051981|NCT00435942|9651313|FG000|Overall Study|Conversion to Open Repair|1
6051982|NCT00435942|9651314|FG001|Overall Study|Conversion to Open Repair|0
6051983|NCT00435942|9651313|FG000|Overall Study|Technical Failure|3
6051984|NCT00435942|9651314|FG001|Overall Study|Technical Failure|0
6051985|NCT00435942|9651313|FG000|Overall Study|Other|0
6051986|NCT00435942|9651314|FG001|Overall Study|Other|1
6051987|NCT00435994|9651323|FG000|Overall Study|Lost to Follow-up|7
6051988|NCT00435994|9651324|FG001|Overall Study|Lost to Follow-up|0
6051989|NCT00435994|9651325|FG002|Overall Study|Lost to Follow-up|0
6051990|NCT00436007|9651337|FG000|Overall Study|Withdrawal by Subject|5
6051991|NCT00436007|9651338|FG001|Overall Study|Withdrawal by Subject|3
6051992|NCT00436007|9651339|FG002|Overall Study|Withdrawal by Subject|4
6051993|NCT00436007|9651337|FG000|Overall Study|Lost to Follow-up|14
6051994|NCT00436007|9651338|FG001|Overall Study|Lost to Follow-up|10
6051995|NCT00436007|9651339|FG002|Overall Study|Lost to Follow-up|13
6051996|NCT00436007|9651337|FG000|Overall Study|Physician Decision|0
6051997|NCT00436007|9651338|FG001|Overall Study|Physician Decision|0
6089601|NCT00685399|9701287|FG005|Treatment Period 2|Adverse Event|1
6089602|NCT00685399|9701288|FG006|Treatment Period 2|Adverse Event|0
6089603|NCT00685399|9701289|FG007|Treatment Period 2|Adverse Event|0
6089604|NCT00685399|9701282|FG000|Treatment Period 2|Lack of Efficacy|0
6089605|NCT00685399|9701283|FG001|Treatment Period 2|Lack of Efficacy|10
6089606|NCT00685399|9701284|FG002|Treatment Period 2|Lack of Efficacy|2
6089607|NCT00685399|9701285|FG003|Treatment Period 2|Lack of Efficacy|0
6089608|NCT00685399|9701286|FG004|Treatment Period 2|Lack of Efficacy|0
6089609|NCT00685399|9701287|FG005|Treatment Period 2|Lack of Efficacy|1
6089610|NCT00685399|9701288|FG006|Treatment Period 2|Lack of Efficacy|0
6089611|NCT00685399|9701289|FG007|Treatment Period 2|Lack of Efficacy|0
6089612|NCT00685399|9701282|FG000|Extension|Administrative Issues|0
6089613|NCT00685399|9701283|FG001|Extension|Administrative Issues|0
6089614|NCT00685399|9701284|FG002|Extension|Administrative Issues|0
6089615|NCT00685399|9701285|FG003|Extension|Administrative Issues|1
6089616|NCT00685399|9701286|FG004|Extension|Administrative Issues|0
6089617|NCT00685399|9701287|FG005|Extension|Administrative Issues|0
6089618|NCT00685399|9701288|FG006|Extension|Administrative Issues|0
6089619|NCT00685399|9701289|FG007|Extension|Administrative Issues|0
6089620|NCT00685399|9701282|FG000|Extension|Withdrawal by Subject|0
6089621|NCT00685399|9701283|FG001|Extension|Withdrawal by Subject|0
6089622|NCT00685399|9701284|FG002|Extension|Withdrawal by Subject|0
6283033|NCT02312063|9994222|FG001|Overall Study|Withdrawal by Subject|1
6089623|NCT00685399|9701285|FG003|Extension|Withdrawal by Subject|1
6089624|NCT00685399|9701286|FG004|Extension|Withdrawal by Subject|0
6089625|NCT00685399|9701287|FG005|Extension|Withdrawal by Subject|0
6283034|NCT02312206|9994236|FG000|Overall Study|Adverse Event|3
6283035|NCT02312206|9994237|FG001|Overall Study|Adverse Event|6
6283036|NCT02312206|9994236|FG000|Overall Study|Withdrawal by Subject|7
6283037|NCT02312206|9994237|FG001|Overall Study|Withdrawal by Subject|6
6051998|NCT00436007|9651339|FG002|Overall Study|Physician Decision|2
6051999|NCT00436007|9651337|FG000|Overall Study|Death|0
6089626|NCT00685399|9701288|FG006|Extension|Withdrawal by Subject|0
6283038|NCT02312206|9994236|FG000|Overall Study|Physician Decision|7
6283039|NCT02312206|9994237|FG001|Overall Study|Physician Decision|6
6283040|NCT02312206|9994236|FG000|Overall Study|Death|30
6283041|NCT02312206|9994237|FG001|Overall Study|Death|36
6283042|NCT02312206|9994236|FG000|Overall Study|Study Terminated by Sponsor|81
6283043|NCT02312206|9994237|FG001|Overall Study|Study Terminated by Sponsor|74
6283044|NCT02312206|9994236|FG000|Overall Study|Disease Progression|1
6283045|NCT02312206|9994237|FG001|Overall Study|Disease Progression|0
6283046|NCT02312206|9994236|FG000|Overall Study|Patient progression and new therapy|1
6283047|NCT02312206|9994237|FG001|Overall Study|Patient progression and new therapy|0
6283048|NCT02312206|9994236|FG000|Overall Study|Patient transferred to hospice|0
6283049|NCT02312206|9994237|FG001|Overall Study|Patient transferred to hospice|1
6283050|NCT02312206|9994236|FG000|Overall Study|Subject missed 3 consecutive tx visits|0
6283051|NCT02312206|9994237|FG001|Overall Study|Subject missed 3 consecutive tx visits|1
6283052|NCT02312219|9994245|FG000|Overall Study|Withdrawal by Subject|1
6283053|NCT02312219|9994246|FG001|Overall Study|Withdrawal by Subject|2
6283054|NCT02312219|9994245|FG000|Overall Study|could not schedule imaging in time|0
6283055|NCT02312219|9994246|FG001|Overall Study|could not schedule imaging in time|2
6283056|NCT02312219|9994245|FG000|Overall Study|Other|0
6283057|NCT02312219|9994246|FG001|Overall Study|Other|1
6283058|NCT02312219|9994245|FG000|Overall Study|Not randomized. Ineligible|0
6283059|NCT02312219|9994246|FG001|Overall Study|Not randomized. Ineligible|1
6283060|NCT02312687|9994289|FG000|Overall Study|Other, Not Specified|1
6283061|NCT02312856|9994333|FG000|Overall Study|Death|1
6283062|NCT02312856|9994333|FG000|Overall Study|Lost to Follow-up|3
6283063|NCT02312934|9994343|FG000|Overall Study|Lost to Follow-up|1
6283064|NCT02312934|9994344|FG001|Overall Study|Lost to Follow-up|0
6283065|NCT02312934|9994343|FG000|Overall Study|Physician Decision|1
6283066|NCT02312934|9994344|FG001|Overall Study|Physician Decision|0
6283067|NCT02313155|9994357|FG000|Overall Study|Lost to Follow-up|0
6283068|NCT02313155|9994358|FG001|Overall Study|Lost to Follow-up|1
6283069|NCT02313233|9994366|FG000|Overall Study|Withdrawal by Subject|1
6283070|NCT02313233|9994367|FG001|Overall Study|Withdrawal by Subject|2
6283071|NCT02313233|9994366|FG000|Overall Study|Administrative reason|1
6283072|NCT02313233|9994367|FG001|Overall Study|Administrative reason|1
6283073|NCT02313558|9994394|FG000|Overall Study|Withdrawal by Subject|2
6283074|NCT02313558|9994395|FG001|Overall Study|Withdrawal by Subject|0
6283075|NCT02313558|9994394|FG000|Overall Study|Lost to Follow-up|4
6283076|NCT02313558|9994395|FG001|Overall Study|Lost to Follow-up|4
6283077|NCT02313766|9994430|FG000|Overall Study|surgery cancelled|1
6283078|NCT02313766|9994431|FG001|Overall Study|surgery cancelled|0
6283079|NCT02313766|9994432|FG002|Overall Study|surgery cancelled|0
6283080|NCT02313766|9994430|FG000|Overall Study|Lost to Follow-up|0
6283081|NCT02313766|9994431|FG001|Overall Study|Lost to Follow-up|2
6283082|NCT02313766|9994432|FG002|Overall Study|Lost to Follow-up|0
6283083|NCT02313766|9994430|FG000|Overall Study|Adverse Event|0
6283084|NCT02313766|9994431|FG001|Overall Study|Adverse Event|1
6283085|NCT02313766|9994432|FG002|Overall Study|Adverse Event|0
6283086|NCT02313909|9994442|FG000|Overall Study|Consent withdrawn by participant|33
6283087|NCT02313909|9994443|FG001|Overall Study|Consent withdrawn by participant|33
6283088|NCT02313909|9994442|FG000|Overall Study|Lost to Follow-up|24
6283089|NCT02313909|9994443|FG001|Overall Study|Lost to Follow-up|17
6283090|NCT02314026|9994459|FG000|Overall Study|Protocol Violation|28
6283091|NCT02314052|9994463|FG000|Cycle One|Adverse Event|0
6283092|NCT02314052|9994464|FG001|Cycle One|Adverse Event|0
6283093|NCT02314052|9994465|FG002|Cycle One|Adverse Event|0
6283094|NCT02314052|9994466|FG003|Cycle One|Adverse Event|1
6283095|NCT02314052|9994467|FG004|Cycle One|Adverse Event|0
6283096|NCT02314052|9994468|FG005|Cycle One|Adverse Event|0
6283097|NCT02314117|9994497|FG000|Overall Study|Lost to Follow-up|9
6283098|NCT02314117|9994498|FG001|Overall Study|Lost to Follow-up|14
6283099|NCT02314117|9994497|FG000|Overall Study|Withdrawal by Subject|3
6283100|NCT02314117|9994498|FG001|Overall Study|Withdrawal by Subject|2
6283101|NCT02314143|9994508|FG000|Overall Study|Adverse Event|0
6283102|NCT02314143|9994509|FG001|Overall Study|Adverse Event|6
6283103|NCT02314143|9994510|FG002|Overall Study|Adverse Event|4
6283104|NCT02314143|9994508|FG000|Overall Study|Other (Study Closed/Terminated)|5
6283105|NCT02314143|9994509|FG001|Overall Study|Other (Study Closed/Terminated)|3
6283106|NCT02314143|9994510|FG002|Overall Study|Other (Study Closed/Terminated)|4
6283107|NCT02314143|9994508|FG000|Overall Study|Physician Decision|2
6283108|NCT02314143|9994509|FG001|Overall Study|Physician Decision|1
6283109|NCT02314143|9994510|FG002|Overall Study|Physician Decision|0
6283110|NCT02314143|9994508|FG000|Overall Study|Withdrawal by Subject|1
6283111|NCT02314143|9994509|FG001|Overall Study|Withdrawal by Subject|0
6283112|NCT02314143|9994510|FG002|Overall Study|Withdrawal by Subject|1
6283113|NCT02314247|9994521|FG000|Overall Study|Adverse Event|2
6283114|NCT02314247|9994522|FG001|Overall Study|Adverse Event|1
6283115|NCT02314247|9994523|FG002|Overall Study|Adverse Event|0
6283116|NCT02314247|9994521|FG000|Overall Study|Withdrawal by Subject|1
6283117|NCT02314247|9994522|FG001|Overall Study|Withdrawal by Subject|3
6283118|NCT02314247|9994523|FG002|Overall Study|Withdrawal by Subject|1
6283119|NCT02314247|9994521|FG000|Overall Study|Progression of Disease|6
6283120|NCT02314247|9994522|FG001|Overall Study|Progression of Disease|2
6283121|NCT02314247|9994523|FG002|Overall Study|Progression of Disease|0
6089627|NCT00685399|9701289|FG007|Extension|Withdrawal by Subject|0
6089628|NCT00685399|9701282|FG000|Extension|Protocol Violation|0
6089629|NCT00685399|9701283|FG001|Extension|Protocol Violation|0
6089630|NCT00685399|9701284|FG002|Extension|Protocol Violation|0
6089631|NCT00685399|9701285|FG003|Extension|Protocol Violation|1
6089632|NCT00685399|9701286|FG004|Extension|Protocol Violation|0
6089633|NCT00685399|9701287|FG005|Extension|Protocol Violation|0
6089634|NCT00685399|9701288|FG006|Extension|Protocol Violation|0
6089635|NCT00685399|9701289|FG007|Extension|Protocol Violation|0
6283122|NCT02314637|9994570|FG000|Overall Study|Adverse Event|4
6283123|NCT02314637|9994571|FG001|Overall Study|Adverse Event|8
6283124|NCT02314637|9994570|FG000|Overall Study|Lack of Efficacy|1
6283125|NCT02314637|9994571|FG001|Overall Study|Lack of Efficacy|0
6283126|NCT02314637|9994570|FG000|Overall Study|Physician Decision|5
6283127|NCT02314637|9994571|FG001|Overall Study|Physician Decision|2
6283128|NCT02314637|9994570|FG000|Overall Study|Withdrawal by Subject|5
6283129|NCT02314637|9994571|FG001|Overall Study|Withdrawal by Subject|4
6283130|NCT02314637|9994570|FG000|Overall Study|Other Reason|1
6283131|NCT02314637|9994571|FG001|Overall Study|Other Reason|0
6283132|NCT02314728|9994583|FG000|Overall Study|Protocol Violation|1
6283133|NCT02314728|9994584|FG001|Overall Study|Protocol Violation|0
6283134|NCT02314728|9994583|FG000|Overall Study|Lost to Follow-up|0
6283135|NCT02314728|9994584|FG001|Overall Study|Lost to Follow-up|1
6052000|NCT00436007|9651338|FG001|Overall Study|Death|1
6052001|NCT00436007|9651339|FG002|Overall Study|Death|3
6052002|NCT00436007|9651337|FG000|Overall Study|Other|0
6052003|NCT00436007|9651338|FG001|Overall Study|Other|0
6052004|NCT00436007|9651339|FG002|Overall Study|Other|1
6052005|NCT00436163|9651365|FG000|Overall Study|Lost to Follow-up|2
6052006|NCT00436163|9651365|FG000|Overall Study|Adverse Event|1
6052007|NCT00436215|9651370|FG000|Overall Study|Refused further treatment|3
6052008|NCT00436215|9651370|FG000|Overall Study|Small bowel obstruction|1
6052009|NCT00436280|9651374|FG000|Period 1: Induction|Adverse Event|8
6052010|NCT00436280|9651374|FG000|Period 1: Induction|Progressive Disease|12
6052011|NCT00436280|9651374|FG000|Period 1: Induction|Stable Disease|6
6052012|NCT00436280|9651374|FG000|Period 1: Induction|Withdrawal by Subject|1
6052013|NCT00436280|9651374|FG000|Period 1: Induction|Death|1
6052014|NCT00436280|9651374|FG000|Period 2: Consolidation|Adverse Event|1
6052015|NCT00436280|9651374|FG000|Period 2: Consolidation|Progressive Disease|10
6052016|NCT00436280|9651374|FG000|Period 2: Consolidation|Stable Disease|1
6052017|NCT00436280|9651374|FG000|Period 2: Consolidation|Physician Decision|2
6052018|NCT00436280|9651374|FG000|Period 2: Consolidation|Withdrawal by Subject|2
6052019|NCT00436280|9651374|FG000|Period 2: Consolidation|Death|1
6052020|NCT00436280|9651374|FG000|Period 3: Maintenance|Adverse Event|6
6052021|NCT00436280|9651374|FG000|Period 3: Maintenance|Progressive Disease|12
6052022|NCT00436332|9651378|FG000|Overall Study|Adverse Event|9
6052023|NCT00436332|9651378|FG000|Overall Study|Withdrawal by Subject|2
6052024|NCT00436332|9651378|FG000|Overall Study|Progression|59
6052025|NCT00436332|9651378|FG000|Overall Study|Death|2
6052026|NCT00436332|9651378|FG000|Overall Study|Not Protocol Specified|6
6052027|NCT00436332|9651378|FG000|Overall Study|Ineligible|2
6052028|NCT00436332|9651378|FG000|Overall Study|Never Received Treatment|3
6052029|NCT00436345|9651384|FG000|Overall Study|ICU resident beyond follow-up period|3
6052030|NCT00436345|9651385|FG001|Overall Study|ICU resident beyond follow-up period|0
6052031|NCT00436436|9651392|FG000|Overall Study|Progression|4
6052032|NCT00436436|9651392|FG000|Overall Study|Adverse Event|2
6052033|NCT00436436|9651392|FG000|Overall Study|Death|6
6052034|NCT00436501|9651415|FG000|Phase 2: MTD VEGF Trap + Docetaxel|Withdrawal by Subject|0
6052035|NCT00436501|9651416|FG001|Phase 2: MTD VEGF Trap + Docetaxel|Withdrawal by Subject|2
6052036|NCT00436501|9651415|FG000|Phase 2: MTD VEGF Trap + Docetaxel|Incomplete Assessment|0
6052037|NCT00436501|9651416|FG001|Phase 2: MTD VEGF Trap + Docetaxel|Incomplete Assessment|1
6052038|NCT00436553|9651426|FG000|Overall Study|Adverse Event|4
6052039|NCT00436553|9651427|FG001|Overall Study|Adverse Event|3
6052040|NCT00436553|9651428|FG002|Overall Study|Adverse Event|4
6052041|NCT00436553|9651426|FG000|Overall Study|Death|3
6052042|NCT00436553|9651427|FG001|Overall Study|Death|1
6052043|NCT00436553|9651428|FG002|Overall Study|Death|3
6089636|NCT00685399|9701282|FG000|Extension|Lack of Efficacy|0
6089637|NCT00685399|9701283|FG001|Extension|Lack of Efficacy|0
6283136|NCT02314780|9994595|FG000|Overall Study|organizational reasons|0
6052044|NCT00436553|9651426|FG000|Overall Study|Lost to Follow-up|0
6052045|NCT00436553|9651427|FG001|Overall Study|Lost to Follow-up|2
6052046|NCT00436553|9651428|FG002|Overall Study|Lost to Follow-up|0
6052047|NCT00436553|9651426|FG000|Overall Study|Protocol Violation|1
6052048|NCT00436553|9651427|FG001|Overall Study|Protocol Violation|0
6052049|NCT00436553|9651428|FG002|Overall Study|Protocol Violation|0
6052050|NCT00436553|9651426|FG000|Overall Study|Withdrawal by Subject|5
6052051|NCT00436553|9651427|FG001|Overall Study|Withdrawal by Subject|6
6052052|NCT00436553|9651428|FG002|Overall Study|Withdrawal by Subject|3
6052053|NCT00436566|9651436|FG000|Overall Study|Withdrawal by Subject|2
6052054|NCT00436566|9651436|FG000|Overall Study|Protocol Violation|1
6052055|NCT00436605|9651440|FG000|Overall Study|Protocol Violation|3
6283137|NCT02314780|9994596|FG001|Overall Study|organizational reasons|2
6283138|NCT02314780|9994597|FG002|Overall Study|organizational reasons|0
6283139|NCT02314780|9994595|FG000|Overall Study|Adverse Event|0
6283140|NCT02314780|9994596|FG001|Overall Study|Adverse Event|1
6283141|NCT02314780|9994597|FG002|Overall Study|Adverse Event|0
6283142|NCT02315560|9994658|FG000|Overall Study|noncompliance by subjects|3
6052056|NCT00436618|9651447|FG000|Overall Study|Withdrawal by Subject|5
6052057|NCT00436618|9651448|FG001|Overall Study|Withdrawal by Subject|8
6052058|NCT00436618|9651449|FG002|Overall Study|Withdrawal by Subject|11
6052059|NCT00436618|9651447|FG000|Overall Study|Adverse Event|8
6052060|NCT00436618|9651448|FG001|Overall Study|Adverse Event|8
6052061|NCT00436618|9651449|FG002|Overall Study|Adverse Event|9
6052062|NCT00436618|9651447|FG000|Overall Study|Alternate Treatment|3
6052063|NCT00436618|9651448|FG001|Overall Study|Alternate Treatment|4
6052064|NCT00436618|9651449|FG002|Overall Study|Alternate Treatment|12
6052065|NCT00436618|9651447|FG000|Overall Study|Other Medical Problems|3
6052066|NCT00436618|9651448|FG001|Overall Study|Other Medical Problems|1
6052067|NCT00436618|9651449|FG002|Overall Study|Other Medical Problems|7
6052068|NCT00436618|9651447|FG000|Overall Study|Death|4
6052069|NCT00436618|9651448|FG001|Overall Study|Death|2
6052070|NCT00436618|9651449|FG002|Overall Study|Death|3
6052071|NCT00436618|9651447|FG000|Overall Study|New Primary or Other Reasons|6
6052072|NCT00436618|9651448|FG001|Overall Study|New Primary or Other Reasons|2
6052073|NCT00436618|9651449|FG002|Overall Study|New Primary or Other Reasons|12
6052074|NCT00436618|9651447|FG000|Overall Study|Still on treatment|1
6052075|NCT00436618|9651448|FG001|Overall Study|Still on treatment|2
6052076|NCT00436618|9651449|FG002|Overall Study|Still on treatment|7
6052077|NCT00436644|9651457|FG000|Overall Study|Adverse Event|2
6052078|NCT00436644|9651457|FG000|Overall Study|Death|1
6052079|NCT00436748|9651463|FG000|Overall Study|Ineligibility Determined|1
6052080|NCT00436748|9651464|FG001|Overall Study|Ineligibility Determined|1
6052081|NCT00436748|9651463|FG000|Overall Study|Adverse Event|0
6052082|NCT00436748|9651464|FG001|Overall Study|Adverse Event|2
6052083|NCT00436748|9651463|FG000|Overall Study|Consent Withdrawn|1
6052084|NCT00436748|9651464|FG001|Overall Study|Consent Withdrawn|4
6052085|NCT00436748|9651463|FG000|Overall Study|Administrative Decision|1
6052086|NCT00436748|9651464|FG001|Overall Study|Administrative Decision|0
6052087|NCT00436748|9651463|FG000|Overall Study|Lost to Follow-up|0
6052088|NCT00436748|9651464|FG001|Overall Study|Lost to Follow-up|1
6052089|NCT00436748|9651463|FG000|Overall Study|Protocol-specified Criteria|5
6052090|NCT00436748|9651464|FG001|Overall Study|Protocol-specified Criteria|4
6052091|NCT00436748|9651463|FG000|Overall Study|Other|3
6052092|NCT00436748|9651464|FG001|Overall Study|Other|0
6052093|NCT00436852|9651472|FG000|Overall Study|Death|23
6052094|NCT00436852|9651473|FG001|Overall Study|Death|34
6052095|NCT00436852|9651472|FG000|Overall Study|Lack of Efficacy|9
6052096|NCT00436852|9651473|FG001|Overall Study|Lack of Efficacy|7
6052097|NCT00436852|9651472|FG000|Overall Study|Withdrawal by Subject|2
6052098|NCT00436852|9651473|FG001|Overall Study|Withdrawal by Subject|4
6052099|NCT00436852|9651472|FG000|Overall Study|Ineligible|1
6052100|NCT00436852|9651473|FG001|Overall Study|Ineligible|0
6052101|NCT00436917|9651486|FG000|Overall Study|Withdrawal by Subject|13
6052102|NCT00436917|9651486|FG000|Overall Study|Adverse Event|2
6052103|NCT00436917|9651486|FG000|Overall Study|Physician Decision|1
6052104|NCT00436917|9651486|FG000|Overall Study|Death|1
6052105|NCT00436917|9651486|FG000|Overall Study|Lost to Follow-up|1
6052106|NCT00436917|9651486|FG000|Overall Study|Treatment for polymyalgia rheumatic|1
6052107|NCT00436917|9651486|FG000|Overall Study|Increased creatinine|1
6052108|NCT00436917|9651486|FG000|Overall Study|Personal conflicts of patient|1
6052109|NCT00436956|9651490|FG000|Overall Study|Not evaluable|1
6052110|NCT00436956|9651491|FG001|Overall Study|Not evaluable|0
6052111|NCT00436982|9651509|FG000|Overall Study|Withdrawal by Subject|3
6052112|NCT00436982|9651510|FG001|Overall Study|Withdrawal by Subject|1
6052113|NCT00436982|9651509|FG000|Overall Study|Did not receive allocated intervention|0
6052114|NCT00436982|9651510|FG001|Overall Study|Did not receive allocated intervention|1
6052115|NCT00436982|9651509|FG000|Overall Study|no RSA data|1
6052116|NCT00436982|9651510|FG001|Overall Study|no RSA data|2
6052117|NCT00437034|9651520|FG000|Overall Study|Adverse Event|1
6052118|NCT00437034|9651520|FG000|Overall Study|Disease progression during treatment|5
6052119|NCT00437073|9651526|FG000|Overall Study|Sponsor Terminated Study|1
6052120|NCT00437073|9651527|FG001|Overall Study|Sponsor Terminated Study|0
6052121|NCT00437073|9651526|FG000|Overall Study|Physician Decision|0
6052122|NCT00437073|9651527|FG001|Overall Study|Physician Decision|1
6052123|NCT00437125|9651533|FG000|Overall Study|Adverse Event|12
6052124|NCT00437125|9651533|FG000|Overall Study|Death|1
6202153|NCT01499355|9862251|FG003|Double-Blind Period|Investigator Decision|3
6202154|NCT01499355|9862248|FG000|Double-Blind Period|Consent Withdrawn|0
6202155|NCT01499355|9862249|FG001|Double-Blind Period|Consent Withdrawn|0
6202156|NCT01499355|9862250|FG002|Double-Blind Period|Consent Withdrawn|1
6202157|NCT01499355|9862251|FG003|Double-Blind Period|Consent Withdrawn|2
6202158|NCT01499355|9862248|FG000|Double-Blind Period|Lost to Follow-up|0
6283143|NCT02315625|9994664|FG000|First Intervention|Disease Progression|1
6052125|NCT00437125|9651533|FG000|Overall Study|Clinical Relapse|1
6052126|NCT00437125|9651533|FG000|Overall Study|Lack of Efficacy|1
6052127|NCT00437125|9651533|FG000|Overall Study|Lost to Follow-up|1
6052128|NCT00437125|9651533|FG000|Overall Study|Withdrawal by Subject|13
6202159|NCT01499355|9862249|FG001|Double-Blind Period|Lost to Follow-up|1
6202160|NCT01499355|9862250|FG002|Double-Blind Period|Lost to Follow-up|0
6283144|NCT02315625|9994665|FG001|First Intervention|Disease Progression|0
6283145|NCT02315625|9994664|FG000|Second Intervention|Physician Decision|2
6283146|NCT02315625|9994665|FG001|Second Intervention|Physician Decision|1
6283147|NCT02315625|9994664|FG000|Second Intervention|Study closure|1
6283148|NCT02315625|9994665|FG001|Second Intervention|Study closure|0
6283149|NCT02315625|9994664|FG000|Second Intervention|Disease Progression|1
6283150|NCT02315625|9994665|FG001|Second Intervention|Disease Progression|0
6283151|NCT02315664|9994675|FG000|Overall Study|Lost to Follow-up|1
6283152|NCT02315664|9994676|FG001|Overall Study|Lost to Follow-up|1
6283153|NCT02315664|9994675|FG000|Overall Study|Withdrawal by Subject|0
6283154|NCT02315664|9994676|FG001|Overall Study|Withdrawal by Subject|3
6089638|NCT00685399|9701284|FG002|Extension|Lack of Efficacy|0
6089639|NCT00685399|9701285|FG003|Extension|Lack of Efficacy|2
6089640|NCT00685399|9701286|FG004|Extension|Lack of Efficacy|0
6089641|NCT00685399|9701287|FG005|Extension|Lack of Efficacy|0
6089642|NCT00685399|9701288|FG006|Extension|Lack of Efficacy|0
6089643|NCT00685399|9701289|FG007|Extension|Lack of Efficacy|0
6052129|NCT00437125|9651533|FG000|Overall Study|Withdrawal by Caregiver|2
6052130|NCT00437125|9651533|FG000|Overall Study|Physician Decision|1
6052131|NCT00437203|9651547|FG000|Overall Study|Death|0
6052132|NCT00437203|9651548|FG001|Overall Study|Death|0
6052133|NCT00437203|9651549|FG002|Overall Study|Death|1
6052134|NCT00437203|9651550|FG003|Overall Study|Death|0
6052135|NCT00437203|9651551|FG004|Overall Study|Death|0
6052136|NCT00437203|9651552|FG005|Overall Study|Death|0
6052137|NCT00437203|9651553|FG006|Overall Study|Death|0
6052138|NCT00437203|9651554|FG007|Overall Study|Death|1
6052139|NCT00437203|9651555|FG008|Overall Study|Death|0
6052140|NCT00437203|9651556|FG009|Overall Study|Death|1
6052141|NCT00437203|9651547|FG000|Overall Study|Adverse Event|1
6052142|NCT00437203|9651548|FG001|Overall Study|Adverse Event|1
6052143|NCT00437203|9651549|FG002|Overall Study|Adverse Event|0
6052144|NCT00437203|9651550|FG003|Overall Study|Adverse Event|0
6052145|NCT00437203|9651551|FG004|Overall Study|Adverse Event|0
6052146|NCT00437203|9651552|FG005|Overall Study|Adverse Event|0
6052147|NCT00437203|9651553|FG006|Overall Study|Adverse Event|0
6052148|NCT00437203|9651554|FG007|Overall Study|Adverse Event|1
6052149|NCT00437203|9651555|FG008|Overall Study|Adverse Event|0
6052150|NCT00437203|9651556|FG009|Overall Study|Adverse Event|1
6052151|NCT00437203|9651547|FG000|Overall Study|Study terminated by sponsor|0
6052152|NCT00437203|9651548|FG001|Overall Study|Study terminated by sponsor|0
6283155|NCT02316171|9994705|FG000|Overall Study|difficulties with urinary catheter|1
6283156|NCT02316171|9994706|FG001|Overall Study|difficulties with urinary catheter|0
6283157|NCT02316171|9994707|FG002|Overall Study|difficulties with urinary catheter|0
6283158|NCT02316171|9994708|FG003|Overall Study|difficulties with urinary catheter|0
6283159|NCT02316223|9994717|FG000|Overall Study|Lack of Efficacy|0
6283160|NCT02316223|9994718|FG001|Overall Study|Lack of Efficacy|1
6283161|NCT02316223|9994719|FG002|Overall Study|Lack of Efficacy|1
6283162|NCT02316223|9994717|FG000|Overall Study|Lost to Follow-up|27
6283163|NCT02316223|9994718|FG001|Overall Study|Lost to Follow-up|34
6283164|NCT02316223|9994719|FG002|Overall Study|Lost to Follow-up|36
6283165|NCT02316223|9994717|FG000|Overall Study|COPD Diagnosis|3
6283166|NCT02316223|9994718|FG001|Overall Study|COPD Diagnosis|2
5980231|NCT03284853|9568793|FG001|Overall Study|Death|1
5980232|NCT03284853|9568792|FG000|Overall Study|Other - Reason not reported in CSR|4
5980233|NCT03284853|9568793|FG001|Overall Study|Other - Reason not reported in CSR|3
5980234|NCT02774889|9568816|FG000|Overall Study|Lost to Follow-up|2
5980235|NCT02774889|9568817|FG001|Overall Study|Lost to Follow-up|1
5980236|NCT02297438|9568837|FG000|Overall Study|Death|79
5980237|NCT02297438|9568838|FG001|Overall Study|Death|86
5980238|NCT02297438|9568837|FG000|Overall Study|Lost to Follow-up|9
5980239|NCT02297438|9568838|FG001|Overall Study|Lost to Follow-up|7
5980240|NCT02297438|9568837|FG000|Overall Study|Withdrawal by Subject|7
5980241|NCT02297438|9568838|FG001|Overall Study|Withdrawal by Subject|0
5980242|NCT02297438|9568837|FG000|Overall Study|Other|9
5980243|NCT02297438|9568838|FG001|Overall Study|Other|5
5980244|NCT02297438|9568837|FG000|Overall Study|Ongoing|65
5980245|NCT02297438|9568838|FG001|Overall Study|Ongoing|73
5980246|NCT02297412|9568846|FG000|Overall Study|Canceled|1
5980247|NCT02297412|9568847|FG001|Overall Study|Canceled|1
5980248|NCT02250326|9568865|FG000|Treatment Period|Death|1
5980249|NCT02250326|9568866|FG001|Treatment Period|Death|12
5980250|NCT02250326|9568867|FG002|Treatment Period|Death|2
5980251|NCT02250326|9568865|FG000|Treatment Period|Adverse Event|8
5980252|NCT02250326|9568866|FG001|Treatment Period|Adverse Event|4
5980253|NCT02250326|9568867|FG002|Treatment Period|Adverse Event|8
5980254|NCT02250326|9568865|FG000|Treatment Period|Progressive Disease|42
5980255|NCT02250326|9568866|FG001|Treatment Period|Progressive Disease|36
5980256|NCT02250326|9568867|FG002|Treatment Period|Progressive Disease|45
5980257|NCT02250326|9568865|FG000|Treatment Period|Symptomatic Deterioration|9
5980258|NCT02250326|9568866|FG001|Treatment Period|Symptomatic Deterioration|4
5980259|NCT02250326|9568867|FG002|Treatment Period|Symptomatic Deterioration|10
5980260|NCT02250326|9568865|FG000|Treatment Period|Withdrawal by Subject|11
5980261|NCT02250326|9568866|FG001|Treatment Period|Withdrawal by Subject|5
5980262|NCT02250326|9568867|FG002|Treatment Period|Withdrawal by Subject|4
6089644|NCT00685399|9701282|FG000|Extension|Adverse Event|0
6089645|NCT00685399|9701283|FG001|Extension|Adverse Event|0
5980263|NCT02250326|9568865|FG000|Treatment Period|Miscellaneous|8
5980264|NCT02250326|9568866|FG001|Treatment Period|Miscellaneous|2
5980265|NCT02250326|9568867|FG002|Treatment Period|Miscellaneous|7
5980266|NCT02250326|9568865|FG000|Treatment Period|Randomized or assigned; not treated|2
5980267|NCT02250326|9568866|FG001|Treatment Period|Randomized or assigned; not treated|1
5980268|NCT02250326|9568867|FG002|Treatment Period|Randomized or assigned; not treated|1
5980269|NCT02250326|9568865|FG000|Follow-Up Period|Death|46
5980270|NCT02250326|9568866|FG001|Follow-Up Period|Death|26
5980271|NCT02250326|9568867|FG002|Follow-Up Period|Death|32
5980272|NCT02250326|9568865|FG000|Follow-Up Period|Unknown or Missing|2
5980273|NCT02250326|9568866|FG001|Follow-Up Period|Unknown or Missing|3
5980274|NCT02250326|9568867|FG002|Follow-Up Period|Unknown or Missing|3
5980275|NCT02250326|9568865|FG000|Follow-Up Period|Lost to Follow-up|1
5980276|NCT02250326|9568866|FG001|Follow-Up Period|Lost to Follow-up|1
5980277|NCT02250326|9568867|FG002|Follow-Up Period|Lost to Follow-up|3
5980278|NCT01503515|9568889|FG000|Overall Study|Adverse Event|4
5980279|NCT01503515|9568890|FG001|Overall Study|Adverse Event|5
5980280|NCT01503515|9568889|FG000|Overall Study|Death|0
5980281|NCT01503515|9568890|FG001|Overall Study|Death|1
5980282|NCT01503515|9568889|FG000|Overall Study|Physician Decision|14
5980283|NCT01503515|9568890|FG001|Overall Study|Physician Decision|23
5980284|NCT01503515|9568889|FG000|Overall Study|Withdrawal by Subject|0
5980285|NCT01503515|9568890|FG001|Overall Study|Withdrawal by Subject|1
5980286|NCT01503515|9568889|FG000|Overall Study|Institutional dx of proven/probable IFI|2
6089646|NCT00685399|9701284|FG002|Extension|Adverse Event|0
6089647|NCT00685399|9701285|FG003|Extension|Adverse Event|2
5980287|NCT01503515|9568890|FG001|Overall Study|Institutional dx of proven/probable IFI|4
5980288|NCT01503515|9568889|FG000|Overall Study|Ineligible|1
5980289|NCT01503515|9568890|FG001|Overall Study|Ineligible|1
5980290|NCT00245960|9568923|FG000|Period 1 (Double Blind): 1-12 Weeks|Adverse Event|6
5980291|NCT00245960|9568924|FG001|Period 1 (Double Blind): 1-12 Weeks|Adverse Event|7
5980292|NCT00245960|9568923|FG000|Period 1 (Double Blind): 1-12 Weeks|Pregnancy|0
5980293|NCT00245960|9568924|FG001|Period 1 (Double Blind): 1-12 Weeks|Pregnancy|1
5980294|NCT00245960|9568923|FG000|Period 1 (Double Blind): 1-12 Weeks|Withdrawal of consent|2
5980295|NCT00245960|9568924|FG001|Period 1 (Double Blind): 1-12 Weeks|Withdrawal of consent|0
5980296|NCT00245960|9568923|FG000|Period 1 (Double Blind): 1-12 Weeks|Unsatisfactory Response|2
5980297|NCT00245960|9568924|FG001|Period 1 (Double Blind): 1-12 Weeks|Unsatisfactory Response|1
5980298|NCT00245960|9568923|FG000|Period 1 (Double Blind): 1-12 Weeks|Protocol Violation|3
6283167|NCT02316223|9994719|FG002|Overall Study|COPD Diagnosis|3
6283168|NCT02316223|9994717|FG000|Overall Study|Reside outside study area|1
6283169|NCT02316223|9994718|FG001|Overall Study|Reside outside study area|1
6283170|NCT02316223|9994719|FG002|Overall Study|Reside outside study area|1
6283171|NCT02316223|9994717|FG000|Overall Study|No asthma|2
6283172|NCT02316223|9994718|FG001|Overall Study|No asthma|0
6283173|NCT02316223|9994719|FG002|Overall Study|No asthma|0
6283174|NCT02316223|9994717|FG000|Overall Study|Discontinued by PI|11
6283175|NCT02316223|9994718|FG001|Overall Study|Discontinued by PI|19
6283176|NCT02316223|9994719|FG002|Overall Study|Discontinued by PI|3
6283177|NCT02316353|9994729|FG000|Overall Study|Pregnancy|1
6283178|NCT02316353|9994730|FG001|Overall Study|Pregnancy|3
6283179|NCT02316353|9994729|FG000|Overall Study|Adverse Event|1
6283180|NCT02316353|9994730|FG001|Overall Study|Adverse Event|3
6283181|NCT02316353|9994729|FG000|Overall Study|Withdrawal by Subject|6
6283182|NCT02316353|9994730|FG001|Overall Study|Withdrawal by Subject|2
6283183|NCT02316548|9994767|FG000|Overall Study|Protocol Violation|0
6283184|NCT02316548|9994768|FG001|Overall Study|Protocol Violation|1
6283185|NCT02316613|9994774|FG000|Overall Study|Death|63
6283186|NCT02316613|9994774|FG000|Overall Study|Lost to Follow-up|9
6283187|NCT02316613|9994774|FG000|Overall Study|Lymphoma transformation|2
6283188|NCT02316613|9994774|FG000|Overall Study|Participant moved/changed medical team|11
6283189|NCT02316613|9994774|FG000|Overall Study|No data and duplicate cases|5
6283190|NCT02316613|9994774|FG000|Overall Study|Did not met selection criteria|14
6283191|NCT02316717|9994801|FG000|Overall Study|Adverse Event|2
6283192|NCT02316717|9994802|FG001|Overall Study|Adverse Event|2
6283193|NCT02316717|9994803|FG002|Overall Study|Adverse Event|0
6283194|NCT02316717|9994801|FG000|Overall Study|Lost to Follow-up|1
6283195|NCT02316717|9994802|FG001|Overall Study|Lost to Follow-up|2
6283196|NCT02316717|9994803|FG002|Overall Study|Lost to Follow-up|1
6283197|NCT02316717|9994801|FG000|Overall Study|Non compliance|3
6283198|NCT02316717|9994802|FG001|Overall Study|Non compliance|1
6283199|NCT02316717|9994803|FG002|Overall Study|Non compliance|0
6283200|NCT02316717|9994801|FG000|Overall Study|Protocol Violation|2
6283201|NCT02316717|9994802|FG001|Overall Study|Protocol Violation|0
6283202|NCT02316717|9994803|FG002|Overall Study|Protocol Violation|0
6283203|NCT02316717|9994801|FG000|Overall Study|Withdrawal by Subject|2
6283204|NCT02316717|9994802|FG001|Overall Study|Withdrawal by Subject|1
6283205|NCT02316717|9994803|FG002|Overall Study|Withdrawal by Subject|1
6283206|NCT02316717|9994801|FG000|Overall Study|Death|0
6283207|NCT02316717|9994802|FG001|Overall Study|Death|0
6283208|NCT02316717|9994803|FG002|Overall Study|Death|1
6283209|NCT02316717|9994801|FG000|Overall Study|Physician Decision|0
6283210|NCT02316717|9994802|FG001|Overall Study|Physician Decision|1
6283211|NCT02316717|9994803|FG002|Overall Study|Physician Decision|0
6283212|NCT02316717|9994801|FG000|Overall Study|TBC|1
6283213|NCT02316717|9994802|FG001|Overall Study|TBC|0
6052153|NCT00437203|9651549|FG002|Overall Study|Study terminated by sponsor|0
6052154|NCT00437203|9651550|FG003|Overall Study|Study terminated by sponsor|0
6052155|NCT00437203|9651551|FG004|Overall Study|Study terminated by sponsor|0
6052156|NCT00437203|9651552|FG005|Overall Study|Study terminated by sponsor|0
6052157|NCT00437203|9651553|FG006|Overall Study|Study terminated by sponsor|0
6052158|NCT00437203|9651554|FG007|Overall Study|Study terminated by sponsor|0
6052159|NCT00437203|9651555|FG008|Overall Study|Study terminated by sponsor|1
6052160|NCT00437203|9651556|FG009|Overall Study|Study terminated by sponsor|0
6052161|NCT00437203|9651547|FG000|Overall Study|Objective progression or relapse|5
6052162|NCT00437203|9651548|FG001|Overall Study|Objective progression or relapse|6
6052163|NCT00437203|9651549|FG002|Overall Study|Objective progression or relapse|2
6052164|NCT00437203|9651550|FG003|Overall Study|Objective progression or relapse|3
6052165|NCT00437203|9651551|FG004|Overall Study|Objective progression or relapse|3
6052166|NCT00437203|9651552|FG005|Overall Study|Objective progression or relapse|3
6052167|NCT00437203|9651553|FG006|Overall Study|Objective progression or relapse|6
6052168|NCT00437203|9651554|FG007|Overall Study|Objective progression or relapse|1
6052169|NCT00437203|9651555|FG008|Overall Study|Objective progression or relapse|2
6052170|NCT00437203|9651556|FG009|Overall Study|Objective progression or relapse|2
6052171|NCT00437203|9651547|FG000|Overall Study|Other|0
6052172|NCT00437203|9651548|FG001|Overall Study|Other|1
6052173|NCT00437203|9651549|FG002|Overall Study|Other|0
6052174|NCT00437203|9651550|FG003|Overall Study|Other|0
6052175|NCT00437203|9651551|FG004|Overall Study|Other|0
6052176|NCT00437203|9651552|FG005|Overall Study|Other|0
6052177|NCT00437203|9651553|FG006|Overall Study|Other|1
6052178|NCT00437203|9651554|FG007|Overall Study|Other|0
6283214|NCT02316717|9994803|FG002|Overall Study|TBC|0
6052179|NCT00437203|9651555|FG008|Overall Study|Other|0
6052180|NCT00437203|9651556|FG009|Overall Study|Other|0
6283215|NCT02316769|9994816|FG000|Overall Study|Physician Decision|1
6283216|NCT02316769|9994817|FG001|Overall Study|Physician Decision|0
6283217|NCT02316769|9994816|FG000|Overall Study|Withdrawal by Subject|1
6283218|NCT02316769|9994817|FG001|Overall Study|Withdrawal by Subject|0
6283219|NCT02316847|9994825|FG000|Overall Study|Adverse Event|0
6283220|NCT02316847|9994826|FG001|Overall Study|Adverse Event|3
6283221|NCT02316847|9994825|FG000|Overall Study|Lost to Follow-up|0
6283222|NCT02316847|9994826|FG001|Overall Study|Lost to Follow-up|2
6283223|NCT02316847|9994825|FG000|Overall Study|Physician Decision|0
6283224|NCT02316847|9994826|FG001|Overall Study|Physician Decision|1
6283225|NCT02316847|9994825|FG000|Overall Study|Pregnancy|0
6283226|NCT02316847|9994826|FG001|Overall Study|Pregnancy|1
6283227|NCT02316847|9994825|FG000|Overall Study|Withdrawal by Subject|2
6283228|NCT02316847|9994826|FG001|Overall Study|Withdrawal by Subject|9
6283229|NCT02316847|9994825|FG000|Overall Study|Noncompliance with study drug|0
6283230|NCT02316847|9994826|FG001|Overall Study|Noncompliance with study drug|3
6283231|NCT02316847|9994825|FG000|Overall Study|Withdrawn due to termination by Sponsor|7
6283232|NCT02316847|9994826|FG001|Overall Study|Withdrawn due to termination by Sponsor|67
6283233|NCT02317016|9994834|FG000|Part A: Day 4-31 (AZD9291 Alone)|Adverse Event|1
6283234|NCT02317016|9994834|FG000|Part A: Day 32-34 (Rosuvastatin+AZD9291)|Condition under investigation worsened|1
6283235|NCT02317016|9994834|FG000|Part A: Day 32-34 (Rosuvastatin+AZD9291)|Death|1
6283236|NCT02317016|9994834|FG000|Part B: Day 35 to End Part B (AZD9291)|Condition under investigation worsened|23
6283237|NCT02317016|9994834|FG000|Part B: Day 35 to End Part B (AZD9291)|Adverse Event|1
6283238|NCT02317016|9994834|FG000|Part B: Day 35 to End Part B (AZD9291)|Withdrawal by Subject|2
6283239|NCT02317016|9994834|FG000|Part B: Day 35 to End Part B (AZD9291)|Death|5
6283240|NCT02317432|9994853|FG000|Overall Study|Death|4
6283241|NCT02317432|9994854|FG001|Overall Study|Death|1
6283242|NCT02317432|9994853|FG000|Overall Study|Lost to Follow-up|0
6283243|NCT02317432|9994854|FG001|Overall Study|Lost to Follow-up|5
6283244|NCT02317432|9994853|FG000|Overall Study|Did not complete any CBT/InVEST sessions or the recommended number of sessions|27
6283245|NCT02317432|9994854|FG001|Overall Study|Did not complete any CBT/InVEST sessions or the recommended number of sessions|0
6283246|NCT02317510|9994862|FG000|Overall Study|Adverse Event|0
6283247|NCT02317510|9994863|FG001|Overall Study|Adverse Event|1
6283248|NCT02317562|9994881|FG000|Overall Study|Physician Decision|1
6283249|NCT02317562|9994881|FG000|Overall Study|early termination of the study|8
6283250|NCT02317562|9994881|FG000|Overall Study|Lack of Efficacy|4
6283251|NCT02317562|9994881|FG000|Overall Study|Withdrawal by Subject|1
6283252|NCT02317575|9994885|FG000|Period 1|Difficulty with venous cannulation|0
6283253|NCT02317575|9994886|FG001|Period 1|Difficulty with venous cannulation|1
6283254|NCT02317575|9994887|FG002|Period 1|Difficulty with venous cannulation|0
6283255|NCT02317575|9994888|FG003|Period 1|Difficulty with venous cannulation|0
6283256|NCT02317575|9994889|FG004|Period 1|Difficulty with venous cannulation|0
6283257|NCT02317575|9994885|FG000|Period 1|Withdrawal by Subject|1
6283258|NCT02317575|9994886|FG001|Period 1|Withdrawal by Subject|0
6283259|NCT02317575|9994887|FG002|Period 1|Withdrawal by Subject|0
6283260|NCT02317575|9994888|FG003|Period 1|Withdrawal by Subject|0
6283261|NCT02317575|9994889|FG004|Period 1|Withdrawal by Subject|0
6283262|NCT02317614|9994909|FG000|Overall Study|Lost to Follow-up|1
6283263|NCT02317614|9994910|FG001|Overall Study|Lost to Follow-up|1
6283264|NCT02317614|9994909|FG000|Overall Study|Withdrawal by Subject|1
6283265|NCT02317614|9994910|FG001|Overall Study|Withdrawal by Subject|0
6283266|NCT02317614|9994909|FG000|Overall Study|Death|1
6283267|NCT02317614|9994910|FG001|Overall Study|Death|1
6283268|NCT02317809|9994934|FG000|First Intervention Period (8 Days)|Protocol Non-Compliance|2
6283269|NCT02317809|9994935|FG001|First Intervention Period (8 Days)|Protocol Non-Compliance|0
6052181|NCT00437268|9651589|FG000|Overall Study|Adverse Event|1
6052182|NCT00437268|9651590|FG001|Overall Study|Adverse Event|1
6052183|NCT00437268|9651589|FG000|Overall Study|Withdrawal by Subject|2
6052184|NCT00437268|9651590|FG001|Overall Study|Withdrawal by Subject|2
6052185|NCT00437268|9651589|FG000|Overall Study|Progressive disease|9
6052186|NCT00437268|9651590|FG001|Overall Study|Progressive disease|9
6052187|NCT00437268|9651589|FG000|Overall Study|Physician Decision|1
6052188|NCT00437268|9651590|FG001|Overall Study|Physician Decision|0
6052189|NCT00437268|9651589|FG000|Overall Study|Death|0
6052190|NCT00437268|9651590|FG001|Overall Study|Death|1
6052191|NCT00437281|9651618|FG000|Overall Study|Adverse Event|0
6052192|NCT00437281|9651619|FG001|Overall Study|Adverse Event|0
6052193|NCT00437281|9651620|FG002|Overall Study|Adverse Event|0
6052194|NCT00437281|9651621|FG003|Overall Study|Adverse Event|1
6052195|NCT00437281|9651622|FG004|Overall Study|Adverse Event|0
6052196|NCT00437281|9651623|FG005|Overall Study|Adverse Event|1
6052197|NCT00437281|9651624|FG006|Overall Study|Adverse Event|0
6052198|NCT00437281|9651625|FG007|Overall Study|Adverse Event|0
6052199|NCT00437281|9651626|FG008|Overall Study|Adverse Event|0
6052200|NCT00437281|9651627|FG009|Overall Study|Adverse Event|1
6052201|NCT00437281|9651628|FG010|Overall Study|Adverse Event|0
6052202|NCT00437281|9651629|FG011|Overall Study|Adverse Event|0
6052203|NCT00437281|9651630|FG012|Overall Study|Adverse Event|0
6052204|NCT00437281|9651631|FG013|Overall Study|Adverse Event|1
6052205|NCT00437281|9651632|FG014|Overall Study|Adverse Event|1
6052206|NCT00437281|9651633|FG015|Overall Study|Adverse Event|0
6052207|NCT00437281|9651634|FG016|Overall Study|Adverse Event|0
6089648|NCT00685399|9701286|FG004|Extension|Adverse Event|0
6283270|NCT02317809|9994934|FG000|First Intervention Period (8 Days)|Withdrawn Due To Multiple Follicles|1
6283271|NCT02317809|9994935|FG001|First Intervention Period (8 Days)|Withdrawn Due To Multiple Follicles|0
6283272|NCT02318134|9994946|FG000|Overall Study|Withdrawal by Subject|2
6283273|NCT02318134|9994947|FG001|Overall Study|Withdrawal by Subject|1
6283274|NCT02318368|9994986|FG000|Overall Study|Withdrawal by Subject|2
6283275|NCT02318368|9994987|FG001|Overall Study|Withdrawal by Subject|0
6052208|NCT00437281|9651635|FG017|Overall Study|Adverse Event|0
6052209|NCT00437281|9651636|FG018|Overall Study|Adverse Event|1
6052210|NCT00437281|9651637|FG019|Overall Study|Adverse Event|0
6283276|NCT02318368|9994986|FG000|Overall Study|Study terminated by the sponsor|5
6283277|NCT02318368|9994987|FG001|Overall Study|Study terminated by the sponsor|2
6283278|NCT02318368|9994986|FG000|Overall Study|Death|0
6283279|NCT02318368|9994987|FG001|Overall Study|Death|1
6283280|NCT02318602|9995000|FG000|Overall Study|Adverse Event|0
6283281|NCT02318602|9995001|FG001|Overall Study|Adverse Event|1
6283282|NCT02318602|9995002|FG002|Overall Study|Adverse Event|1
6283283|NCT02318602|9995000|FG000|Overall Study|Withdrawal by Subject|0
6283284|NCT02318602|9995001|FG001|Overall Study|Withdrawal by Subject|3
6283285|NCT02318602|9995002|FG002|Overall Study|Withdrawal by Subject|0
6283286|NCT02318602|9995000|FG000|Overall Study|Death|1
6283287|NCT02318602|9995001|FG001|Overall Study|Death|0
6283288|NCT02318602|9995002|FG002|Overall Study|Death|0
6283289|NCT02318602|9995000|FG000|Overall Study|Guardian decision to withdraw|0
6283290|NCT02318602|9995001|FG001|Overall Study|Guardian decision to withdraw|0
6283291|NCT02318602|9995002|FG002|Overall Study|Guardian decision to withdraw|1
6283292|NCT02318667|9995016|FG000|Overall Study|Adverse Event|1
6283293|NCT02318667|9995016|FG000|Overall Study|Lack of Efficacy|6
6283294|NCT02318667|9995016|FG000|Overall Study|Protocol Violation|2
6283295|NCT02318693|9995026|FG000|Overall Study|Protocol Violation|0
6283296|NCT02318693|9995027|FG001|Overall Study|Protocol Violation|1
6283297|NCT02318706|9995037|FG000|Double-blind Phase|Adverse Event|7
6283298|NCT02318706|9995038|FG001|Double-blind Phase|Adverse Event|4
6283299|NCT02318706|9995039|FG002|Double-blind Phase|Adverse Event|3
6283300|NCT02318706|9995040|FG003|Double-blind Phase|Adverse Event|10
6283301|NCT02318706|9995041|FG004|Double-blind Phase|Adverse Event|0
6283302|NCT02318706|9995037|FG000|Double-blind Phase|Lost to Follow-up|1
6283303|NCT02318706|9995038|FG001|Double-blind Phase|Lost to Follow-up|0
6052211|NCT00437281|9651618|FG000|Overall Study|Lost to Follow-up|0
6052212|NCT00437281|9651619|FG001|Overall Study|Lost to Follow-up|0
6052213|NCT00437281|9651620|FG002|Overall Study|Lost to Follow-up|0
6052214|NCT00437281|9651621|FG003|Overall Study|Lost to Follow-up|0
6052215|NCT00437281|9651622|FG004|Overall Study|Lost to Follow-up|0
6052216|NCT00437281|9651623|FG005|Overall Study|Lost to Follow-up|0
6052217|NCT00437281|9651624|FG006|Overall Study|Lost to Follow-up|0
6052218|NCT00437281|9651625|FG007|Overall Study|Lost to Follow-up|0
6052219|NCT00437281|9651626|FG008|Overall Study|Lost to Follow-up|0
6052220|NCT00437281|9651627|FG009|Overall Study|Lost to Follow-up|0
6052221|NCT00437281|9651628|FG010|Overall Study|Lost to Follow-up|0
6052222|NCT00437281|9651629|FG011|Overall Study|Lost to Follow-up|0
6052223|NCT00437281|9651630|FG012|Overall Study|Lost to Follow-up|0
6052224|NCT00437281|9651631|FG013|Overall Study|Lost to Follow-up|0
6052225|NCT00437281|9651632|FG014|Overall Study|Lost to Follow-up|0
6052226|NCT00437281|9651633|FG015|Overall Study|Lost to Follow-up|0
6052227|NCT00437281|9651634|FG016|Overall Study|Lost to Follow-up|0
6052228|NCT00437281|9651635|FG017|Overall Study|Lost to Follow-up|0
6052229|NCT00437281|9651636|FG018|Overall Study|Lost to Follow-up|0
6052230|NCT00437281|9651637|FG019|Overall Study|Lost to Follow-up|1
6052231|NCT00437294|9651711|FG000|Overall Study|Adverse Event|5
6052232|NCT00437294|9651712|FG001|Overall Study|Adverse Event|4
6052233|NCT00437294|9651711|FG000|Overall Study|Death|5
6052234|NCT00437294|9651712|FG001|Overall Study|Death|2
6052235|NCT00437294|9651711|FG000|Overall Study|Physician Decision|0
6052236|NCT00437294|9651712|FG001|Overall Study|Physician Decision|3
6052237|NCT00437294|9651711|FG000|Overall Study|Withdrawal by Subject|5
6052238|NCT00437294|9651712|FG001|Overall Study|Withdrawal by Subject|0
6052239|NCT00437294|9651711|FG000|Overall Study|Progressive Disease|19
6052240|NCT00437294|9651712|FG001|Overall Study|Progressive Disease|23
6052241|NCT00437294|9651711|FG000|Overall Study|Sponsor Decision|8
6052242|NCT00437294|9651712|FG001|Overall Study|Sponsor Decision|9
6052243|NCT00437294|9651711|FG000|Overall Study|Protocol Violation|0
6052244|NCT00437294|9651712|FG001|Overall Study|Protocol Violation|1
6052245|NCT00437294|9651711|FG000|Overall Study|Entry criteria not met|1
6052246|NCT00437294|9651712|FG001|Overall Study|Entry criteria not met|1
6052247|NCT00437489|9651726|FG000|Overall Study|Study terminated by sponsor|23
6052248|NCT00437489|9651727|FG001|Overall Study|Study terminated by sponsor|21
6052249|NCT00437489|9651726|FG000|Overall Study|Lost to Follow-up|0
6052250|NCT00437489|9651727|FG001|Overall Study|Lost to Follow-up|1
6052251|NCT00437645|9651735|FG000|Overall Study|Adverse Event|15
6052252|NCT00437645|9651736|FG001|Overall Study|Adverse Event|84
6283304|NCT02318706|9995039|FG002|Double-blind Phase|Lost to Follow-up|0
6283305|NCT02318706|9995040|FG003|Double-blind Phase|Lost to Follow-up|0
6283306|NCT02318706|9995041|FG004|Double-blind Phase|Lost to Follow-up|0
6283307|NCT02318706|9995037|FG000|Double-blind Phase|Protocol Violation|4
6283308|NCT02318706|9995038|FG001|Double-blind Phase|Protocol Violation|2
6283309|NCT02318706|9995039|FG002|Double-blind Phase|Protocol Violation|4
6283310|NCT02318706|9995040|FG003|Double-blind Phase|Protocol Violation|3
6283311|NCT02318706|9995041|FG004|Double-blind Phase|Protocol Violation|0
6283312|NCT02318706|9995037|FG000|Double-blind Phase|Withdrawal by Subject|9
6283313|NCT02318706|9995038|FG001|Double-blind Phase|Withdrawal by Subject|5
6283314|NCT02318706|9995039|FG002|Double-blind Phase|Withdrawal by Subject|7
6052253|NCT00437645|9651735|FG000|Overall Study|Withdrawal by Subject|10
6052254|NCT00437645|9651736|FG001|Overall Study|Withdrawal by Subject|22
6052255|NCT00437645|9651735|FG000|Overall Study|Protocol Violation|3
6052256|NCT00437645|9651736|FG001|Overall Study|Protocol Violation|3
6052257|NCT00437645|9651735|FG000|Overall Study|Lost to Follow-up|2
6283315|NCT02318706|9995040|FG003|Double-blind Phase|Withdrawal by Subject|10
6283316|NCT02318706|9995041|FG004|Double-blind Phase|Withdrawal by Subject|0
6283317|NCT02318706|9995037|FG000|Double-blind Phase|Other|4
6283318|NCT02318706|9995038|FG001|Double-blind Phase|Other|1
6283319|NCT02318706|9995039|FG002|Double-blind Phase|Other|2
6283320|NCT02318706|9995040|FG003|Double-blind Phase|Other|1
6283321|NCT02318706|9995041|FG004|Double-blind Phase|Other|0
6283322|NCT02318706|9995037|FG000|Double-blind Phase|Death|0
6283323|NCT02318706|9995038|FG001|Double-blind Phase|Death|0
6283324|NCT02318706|9995039|FG002|Double-blind Phase|Death|2
6283325|NCT02318706|9995040|FG003|Double-blind Phase|Death|0
6283326|NCT02318706|9995041|FG004|Double-blind Phase|Death|0
6283327|NCT02318706|9995037|FG000|Open-label Extension Phase|Adverse Event|0
6283328|NCT02318706|9995038|FG001|Open-label Extension Phase|Adverse Event|0
6283329|NCT02318706|9995039|FG002|Open-label Extension Phase|Adverse Event|0
6283330|NCT02318706|9995040|FG003|Open-label Extension Phase|Adverse Event|0
6283331|NCT02318706|9995041|FG004|Open-label Extension Phase|Adverse Event|21
6283332|NCT02318706|9995037|FG000|Open-label Extension Phase|Lack of Efficacy|0
6283333|NCT02318706|9995038|FG001|Open-label Extension Phase|Lack of Efficacy|0
6283334|NCT02318706|9995039|FG002|Open-label Extension Phase|Lack of Efficacy|0
6283335|NCT02318706|9995040|FG003|Open-label Extension Phase|Lack of Efficacy|0
6283336|NCT02318706|9995041|FG004|Open-label Extension Phase|Lack of Efficacy|1
6283337|NCT02318706|9995037|FG000|Open-label Extension Phase|Death|0
6283338|NCT02318706|9995038|FG001|Open-label Extension Phase|Death|0
6283339|NCT02318706|9995039|FG002|Open-label Extension Phase|Death|0
6052258|NCT00437645|9651736|FG001|Overall Study|Lost to Follow-up|3
6052259|NCT00437645|9651735|FG000|Overall Study|Administrative problems|2
6052260|NCT00437645|9651736|FG001|Overall Study|Administrative problems|1
6052261|NCT00437645|9651735|FG000|Overall Study|Lack of Efficacy|2
6052262|NCT00437645|9651736|FG001|Overall Study|Lack of Efficacy|1
6052263|NCT00437645|9651735|FG000|Overall Study|Condition no longer requires study drug|1
6052264|NCT00437645|9651736|FG001|Overall Study|Condition no longer requires study drug|1
6052265|NCT00437658|9651745|FG000|Treatment Period (24 Weeks)|Adverse Event|4
6052266|NCT00437658|9651746|FG001|Treatment Period (24 Weeks)|Adverse Event|7
6052267|NCT00437658|9651747|FG002|Treatment Period (24 Weeks)|Adverse Event|14
6052268|NCT00437658|9651745|FG000|Treatment Period (24 Weeks)|Non-compliance|1
6052269|NCT00437658|9651746|FG001|Treatment Period (24 Weeks)|Non-compliance|1
6052270|NCT00437658|9651747|FG002|Treatment Period (24 Weeks)|Non-compliance|4
6052271|NCT00437658|9651745|FG000|Treatment Period (24 Weeks)|Withdrawal by Subject|9
6052272|NCT00437658|9651746|FG001|Treatment Period (24 Weeks)|Withdrawal by Subject|7
6052273|NCT00437658|9651747|FG002|Treatment Period (24 Weeks)|Withdrawal by Subject|7
6052274|NCT00437658|9651745|FG000|Treatment Period (24 Weeks)|Lack of Efficacy|4
6052275|NCT00437658|9651746|FG001|Treatment Period (24 Weeks)|Lack of Efficacy|2
6052276|NCT00437658|9651747|FG002|Treatment Period (24 Weeks)|Lack of Efficacy|3
6052277|NCT00437658|9651745|FG000|Treatment Period (24 Weeks)|Lost to Follow-up|5
6052278|NCT00437658|9651746|FG001|Treatment Period (24 Weeks)|Lost to Follow-up|4
6052279|NCT00437658|9651747|FG002|Treatment Period (24 Weeks)|Lost to Follow-up|5
6052280|NCT00437658|9651745|FG000|Treatment Period (24 Weeks)|Sponsor/Investigator Decision|5
6052281|NCT00437658|9651746|FG001|Treatment Period (24 Weeks)|Sponsor/Investigator Decision|1
6052282|NCT00437658|9651747|FG002|Treatment Period (24 Weeks)|Sponsor/Investigator Decision|0
6052283|NCT00437658|9651745|FG000|Post-treatment Period (24 Weeks)|Adverse Event|1
6052284|NCT00437658|9651746|FG001|Post-treatment Period (24 Weeks)|Adverse Event|0
6052285|NCT00437658|9651747|FG002|Post-treatment Period (24 Weeks)|Adverse Event|1
6052286|NCT00437658|9651745|FG000|Post-treatment Period (24 Weeks)|Non-compliance|3
6052287|NCT00437658|9651746|FG001|Post-treatment Period (24 Weeks)|Non-compliance|0
6052288|NCT00437658|9651747|FG002|Post-treatment Period (24 Weeks)|Non-compliance|1
6052289|NCT00437658|9651745|FG000|Post-treatment Period (24 Weeks)|Withdrawal by Subject|12
6052290|NCT00437658|9651746|FG001|Post-treatment Period (24 Weeks)|Withdrawal by Subject|6
6052291|NCT00437658|9651747|FG002|Post-treatment Period (24 Weeks)|Withdrawal by Subject|8
6052292|NCT00437658|9651745|FG000|Post-treatment Period (24 Weeks)|Lack of Efficacy|0
6052293|NCT00437658|9651746|FG001|Post-treatment Period (24 Weeks)|Lack of Efficacy|2
6052294|NCT00437658|9651747|FG002|Post-treatment Period (24 Weeks)|Lack of Efficacy|2
6052295|NCT00437658|9651745|FG000|Post-treatment Period (24 Weeks)|Lost to Follow-up|5
6052296|NCT00437658|9651746|FG001|Post-treatment Period (24 Weeks)|Lost to Follow-up|0
6052297|NCT00437658|9651747|FG002|Post-treatment Period (24 Weeks)|Lost to Follow-up|1
6052298|NCT00437658|9651745|FG000|Post-treatment Period (24 Weeks)|Sponsor/Investigator Decision|3
6052299|NCT00437658|9651746|FG001|Post-treatment Period (24 Weeks)|Sponsor/Investigator Decision|0
6052300|NCT00437658|9651747|FG002|Post-treatment Period (24 Weeks)|Sponsor/Investigator Decision|1
6052301|NCT00437983|9651757|FG000|Overall Study|Adverse Event|6
6052302|NCT00437983|9651758|FG001|Overall Study|Adverse Event|6
6283340|NCT02318706|9995040|FG003|Open-label Extension Phase|Death|0
6283341|NCT02318706|9995041|FG004|Open-label Extension Phase|Death|1
6283342|NCT02318706|9995037|FG000|Open-label Extension Phase|Withdrawal by Subject|0
6283343|NCT02318706|9995038|FG001|Open-label Extension Phase|Withdrawal by Subject|0
6283344|NCT02318706|9995039|FG002|Open-label Extension Phase|Withdrawal by Subject|0
6283345|NCT02318706|9995040|FG003|Open-label Extension Phase|Withdrawal by Subject|0
6283346|NCT02318706|9995041|FG004|Open-label Extension Phase|Withdrawal by Subject|19
6283347|NCT02318719|9995057|FG000|Double-blind Phase|Adverse Event|7
6283348|NCT02318719|9995058|FG001|Double-blind Phase|Adverse Event|6
6283349|NCT02318719|9995059|FG002|Double-blind Phase|Adverse Event|12
6283350|NCT02318719|9995060|FG003|Double-blind Phase|Adverse Event|4
6283351|NCT02318719|9995061|FG004|Double-blind Phase|Adverse Event|0
6283352|NCT02318719|9995057|FG000|Double-blind Phase|Lack of Efficacy|5
6283353|NCT02318719|9995058|FG001|Double-blind Phase|Lack of Efficacy|0
6283354|NCT02318719|9995059|FG002|Double-blind Phase|Lack of Efficacy|1
6283355|NCT02318719|9995060|FG003|Double-blind Phase|Lack of Efficacy|1
6283356|NCT02318719|9995061|FG004|Double-blind Phase|Lack of Efficacy|0
6283357|NCT02318719|9995057|FG000|Double-blind Phase|Protocol Violation|0
6283358|NCT02318719|9995058|FG001|Double-blind Phase|Protocol Violation|1
6283359|NCT02318719|9995059|FG002|Double-blind Phase|Protocol Violation|3
6283360|NCT02318719|9995060|FG003|Double-blind Phase|Protocol Violation|0
6283361|NCT02318719|9995061|FG004|Double-blind Phase|Protocol Violation|0
6283362|NCT02318719|9995057|FG000|Double-blind Phase|Withdrawal by Subject|25
6283363|NCT02318719|9995058|FG001|Double-blind Phase|Withdrawal by Subject|7
6052303|NCT00437983|9651757|FG000|Overall Study|Protocol Violation|2
6052304|NCT00437983|9651758|FG001|Overall Study|Protocol Violation|1
6052305|NCT00437983|9651757|FG000|Overall Study|Withdrawal by Subject|5
6052306|NCT00437983|9651758|FG001|Overall Study|Withdrawal by Subject|6
6089649|NCT00685399|9701287|FG005|Extension|Adverse Event|0
6089650|NCT00685399|9701288|FG006|Extension|Adverse Event|0
6089651|NCT00685399|9701289|FG007|Extension|Adverse Event|0
6089652|NCT00685685|9701359|FG000|Washout Period of 7 Days|Adverse Event|2
6089653|NCT00685685|9701360|FG001|Washout Period of 7 Days|Adverse Event|0
6089654|NCT00685685|9701359|FG000|Washout Period of 7 Days|Withdrawal by Subject|0
6089655|NCT00685685|9701360|FG001|Washout Period of 7 Days|Withdrawal by Subject|1
6089656|NCT00685698|9701366|FG000|Overall Study|Withdrawal by Subject|1
6089657|NCT00685698|9701366|FG000|Overall Study|Protocol Violation|6
6089658|NCT00685698|9701366|FG000|Overall Study|Adverse Event|3
6089659|NCT00685698|9701366|FG000|Overall Study|CULTURE GRAM NEG SPECIES|1
6089660|NCT00685698|9701366|FG000|Overall Study|CULTURE RESULTS: GRAM-VE|1
6089661|NCT00685698|9701366|FG000|Overall Study|NO GRAM POSITIVE CULTURE GROWN|1
6089662|NCT00685750|9701389|FG000|Overall Study|Tumor sampling failure|0
6089663|NCT00685750|9701390|FG001|Overall Study|Tumor sampling failure|0
6089664|NCT00685750|9701391|FG002|Overall Study|Tumor sampling failure|1
6089665|NCT00685750|9701392|FG003|Overall Study|Tumor sampling failure|0
6089666|NCT00685750|9701393|FG004|Overall Study|Tumor sampling failure|0
6089667|NCT00685750|9701394|FG005|Overall Study|Tumor sampling failure|0
6089668|NCT00685750|9701395|FG006|Overall Study|Tumor sampling failure|0
6089669|NCT00685750|9701389|FG000|Overall Study|Patient didn't receive the treatment|0
6089670|NCT00685750|9701390|FG001|Overall Study|Patient didn't receive the treatment|0
6089671|NCT00685750|9701391|FG002|Overall Study|Patient didn't receive the treatment|0
6089672|NCT00685750|9701392|FG003|Overall Study|Patient didn't receive the treatment|0
6089673|NCT00685750|9701393|FG004|Overall Study|Patient didn't receive the treatment|0
6089674|NCT00685750|9701394|FG005|Overall Study|Patient didn't receive the treatment|0
6089675|NCT00685750|9701395|FG006|Overall Study|Patient didn't receive the treatment|1
6089676|NCT00685750|9701389|FG000|Overall Study|Eligibility criteria not fulfilled|0
6089677|NCT00685750|9701390|FG001|Overall Study|Eligibility criteria not fulfilled|0
6089678|NCT00685750|9701391|FG002|Overall Study|Eligibility criteria not fulfilled|1
6089679|NCT00685750|9701392|FG003|Overall Study|Eligibility criteria not fulfilled|0
6089680|NCT00685750|9701393|FG004|Overall Study|Eligibility criteria not fulfilled|0
6089681|NCT00685750|9701394|FG005|Overall Study|Eligibility criteria not fulfilled|0
6089682|NCT00685750|9701395|FG006|Overall Study|Eligibility criteria not fulfilled|0
6089683|NCT00685763|9701415|FG000|Overall Study|Intercurrent death-incomplete treatment|1
6089684|NCT00685763|9701415|FG000|Overall Study|Protocol Violation|1
6089685|NCT00685802|9701419|FG000|Washout Period of 7 Days|Protocol Violation|2
6089686|NCT00685802|9701420|FG001|Washout Period of 7 Days|Protocol Violation|0
6089687|NCT00685802|9701419|FG000|Washout Period of 7 Days|Withdrawal by Subject|0
6089688|NCT00685802|9701420|FG001|Washout Period of 7 Days|Withdrawal by Subject|1
6089689|NCT00685945|9701435|FG000|L-NMMA + Bradykinin|Physician Decision|1
6089690|NCT00686075|9701455|FG000|Overall Study|Withdrawal by Subject|4
6089691|NCT00686075|9701456|FG001|Overall Study|Withdrawal by Subject|3
6089692|NCT00686075|9701457|FG002|Overall Study|Withdrawal by Subject|3
6089693|NCT00686075|9701458|FG003|Overall Study|Withdrawal by Subject|7
6089694|NCT00686075|9701459|FG004|Overall Study|Withdrawal by Subject|1
6089695|NCT00686075|9701460|FG005|Overall Study|Withdrawal by Subject|0
6089696|NCT00686075|9701461|FG006|Overall Study|Withdrawal by Subject|0
6089697|NCT00686075|9701462|FG007|Overall Study|Withdrawal by Subject|2
6089698|NCT00686075|9701463|FG008|Overall Study|Withdrawal by Subject|4
6089699|NCT00686075|9701464|FG009|Overall Study|Withdrawal by Subject|6
6089700|NCT00686075|9701455|FG000|Overall Study|Lost to Follow-up|3
6089701|NCT00686075|9701456|FG001|Overall Study|Lost to Follow-up|6
6089702|NCT00686075|9701457|FG002|Overall Study|Lost to Follow-up|3
6283364|NCT02318719|9995059|FG002|Double-blind Phase|Withdrawal by Subject|9
6089703|NCT00686075|9701458|FG003|Overall Study|Lost to Follow-up|2
6089704|NCT00686075|9701459|FG004|Overall Study|Lost to Follow-up|3
6089705|NCT00686075|9701460|FG005|Overall Study|Lost to Follow-up|3
6089706|NCT00686075|9701461|FG006|Overall Study|Lost to Follow-up|0
6283365|NCT02318719|9995060|FG003|Double-blind Phase|Withdrawal by Subject|10
6283366|NCT02318719|9995061|FG004|Double-blind Phase|Withdrawal by Subject|0
6283367|NCT02318719|9995057|FG000|Double-blind Phase|Other|1
6283368|NCT02318719|9995058|FG001|Double-blind Phase|Other|2
6283369|NCT02318719|9995059|FG002|Double-blind Phase|Other|0
6283370|NCT02318719|9995060|FG003|Double-blind Phase|Other|0
6283371|NCT02318719|9995061|FG004|Double-blind Phase|Other|0
6283372|NCT02318719|9995057|FG000|Open-label Extension Phase|Adverse Event|0
6283373|NCT02318719|9995058|FG001|Open-label Extension Phase|Adverse Event|0
6283374|NCT02318719|9995059|FG002|Open-label Extension Phase|Adverse Event|0
6283375|NCT02318719|9995060|FG003|Open-label Extension Phase|Adverse Event|0
6283376|NCT02318719|9995061|FG004|Open-label Extension Phase|Adverse Event|15
6283377|NCT02318719|9995057|FG000|Open-label Extension Phase|Death|0
6283378|NCT02318719|9995058|FG001|Open-label Extension Phase|Death|0
6283379|NCT02318719|9995059|FG002|Open-label Extension Phase|Death|0
6283380|NCT02318719|9995060|FG003|Open-label Extension Phase|Death|0
6283381|NCT02318719|9995061|FG004|Open-label Extension Phase|Death|1
6283382|NCT02318719|9995057|FG000|Open-label Extension Phase|Lack of Efficacy|0
6283383|NCT02318719|9995058|FG001|Open-label Extension Phase|Lack of Efficacy|0
6283384|NCT02318719|9995059|FG002|Open-label Extension Phase|Lack of Efficacy|0
6283385|NCT02318719|9995060|FG003|Open-label Extension Phase|Lack of Efficacy|0
6283386|NCT02318719|9995061|FG004|Open-label Extension Phase|Lack of Efficacy|1
6283387|NCT02318719|9995057|FG000|Open-label Extension Phase|Withdrawal by Subject|0
6283388|NCT02318719|9995058|FG001|Open-label Extension Phase|Withdrawal by Subject|0
6283389|NCT02318719|9995059|FG002|Open-label Extension Phase|Withdrawal by Subject|0
6283390|NCT02318719|9995060|FG003|Open-label Extension Phase|Withdrawal by Subject|0
6283391|NCT02318719|9995061|FG004|Open-label Extension Phase|Withdrawal by Subject|31
6283392|NCT02318719|9995057|FG000|Open-label Extension Phase|Other|0
6283393|NCT02318719|9995058|FG001|Open-label Extension Phase|Other|0
6283394|NCT02318719|9995059|FG002|Open-label Extension Phase|Other|0
6283395|NCT02318719|9995060|FG003|Open-label Extension Phase|Other|0
6283396|NCT02318719|9995061|FG004|Open-label Extension Phase|Other|7
6283397|NCT02318797|9995075|FG000|Overall Study|Death|3
6283398|NCT02318797|9995076|FG001|Overall Study|Death|6
6283399|NCT02318797|9995075|FG000|Overall Study|Lost to Follow-up|85
6283400|NCT02318797|9995076|FG001|Overall Study|Lost to Follow-up|96
6283401|NCT02318940|9995084|FG000|Overall Study|lost the record|1
6283402|NCT02318940|9995085|FG001|Overall Study|lost the record|0
6283403|NCT02319031|9995119|FG000|Treatment Period|Death|1
6283404|NCT02319031|9995120|FG001|Treatment Period|Death|0
6283405|NCT02319044|9995129|FG000|Overall Study|Death, PI/sponsor decision, med history|0
6283406|NCT02319044|9995130|FG001|Overall Study|Death, PI/sponsor decision, med history|1
6283407|NCT02319044|9995131|FG002|Overall Study|Death, PI/sponsor decision, med history|4
6283408|NCT02319044|9995129|FG000|Overall Study|Withdrawal by Subject|3
6283409|NCT02319044|9995130|FG001|Overall Study|Withdrawal by Subject|3
6283410|NCT02319044|9995131|FG002|Overall Study|Withdrawal by Subject|6
6283411|NCT02319044|9995129|FG000|Overall Study|Condition under investigation worsened|100
6283412|NCT02319044|9995130|FG001|Overall Study|Condition under investigation worsened|50
6283413|NCT02319044|9995131|FG002|Overall Study|Condition under investigation worsened|46
6283414|NCT02319044|9995129|FG000|Overall Study|Adverse Event|17
6283415|NCT02319044|9995130|FG001|Overall Study|Adverse Event|2
6283416|NCT02319044|9995131|FG002|Overall Study|Adverse Event|8
6283417|NCT02319044|9995129|FG000|Overall Study|Study specific discontinuation criteria|2
6283418|NCT02319044|9995130|FG001|Overall Study|Study specific discontinuation criteria|2
6283419|NCT02319044|9995131|FG002|Overall Study|Study specific discontinuation criteria|1
6283420|NCT02319044|9995129|FG000|Overall Study|Not treated|0
6283421|NCT02319044|9995130|FG001|Overall Study|Not treated|2
6283422|NCT02319044|9995131|FG002|Overall Study|Not treated|2
6283423|NCT02319148|9995143|FG000|Second Intervention Period|Adverse event (AE) related to study drug|0
6283424|NCT02319148|9995144|FG001|Second Intervention Period|Adverse event (AE) related to study drug|0
6283425|NCT02319148|9995145|FG002|Second Intervention Period|Adverse event (AE) related to study drug|1
6283426|NCT02319148|9995146|FG003|Second Intervention Period|Adverse event (AE) related to study drug|1
6283427|NCT02319148|9995143|FG000|Second Intervention Period|No longer willing to participate|0
6283428|NCT02319148|9995144|FG001|Second Intervention Period|No longer willing to participate|1
6283429|NCT02319148|9995145|FG002|Second Intervention Period|No longer willing to participate|0
6283430|NCT02319148|9995146|FG003|Second Intervention Period|No longer willing to participate|0
6283431|NCT02319148|9995143|FG000|Second Intervention Period|Other|0
6283432|NCT02319148|9995144|FG001|Second Intervention Period|Other|0
6283433|NCT02319148|9995145|FG002|Second Intervention Period|Other|0
6283434|NCT02319148|9995146|FG003|Second Intervention Period|Other|1
6283435|NCT02319525|9995254|FG000|Overall Study|Withdrawal by Subject|2
6283436|NCT02319525|9995255|FG001|Overall Study|Withdrawal by Subject|1
6283437|NCT02319642|9995263|FG000|Overall Study|Adverse Event|2
6283438|NCT02319642|9995264|FG001|Overall Study|Adverse Event|4
6283439|NCT02319642|9995263|FG000|Overall Study|Lack of Efficacy|1
6283440|NCT02319642|9995264|FG001|Overall Study|Lack of Efficacy|1
6283441|NCT02319642|9995263|FG000|Overall Study|Withdrawal by Subject|1
6283442|NCT02319642|9995264|FG001|Overall Study|Withdrawal by Subject|1
6283443|NCT02319668|9995274|FG000|Overall Study|Other (Not specified)|0
6283444|NCT02319668|9995275|FG001|Overall Study|Other (Not specified)|2
6283445|NCT02319759|9995286|FG000|Week 0 - 16|Lack of Efficacy|1
6283446|NCT02319759|9995287|FG001|Week 0 - 16|Lack of Efficacy|0
6283447|NCT02319759|9995288|FG002|Week 0 - 16|Lack of Efficacy|0
6283448|NCT02319759|9995289|FG003|Week 0 - 16|Lack of Efficacy|0
6283449|NCT02319759|9995290|FG004|Week 0 - 16|Lack of Efficacy|0
6283450|NCT02319759|9995286|FG000|Week 0 - 16|Not met all Inclusion Criteria|0
6283451|NCT02319759|9995287|FG001|Week 0 - 16|Not met all Inclusion Criteria|0
6283452|NCT02319759|9995288|FG002|Week 0 - 16|Not met all Inclusion Criteria|1
6283453|NCT02319759|9995289|FG003|Week 0 - 16|Not met all Inclusion Criteria|0
6283454|NCT02319759|9995290|FG004|Week 0 - 16|Not met all Inclusion Criteria|0
6283455|NCT02319759|9995286|FG000|Week 16 - 24|Lack of Efficacy|1
6283456|NCT02319759|9995287|FG001|Week 16 - 24|Lack of Efficacy|0
6283457|NCT02319759|9995288|FG002|Week 16 - 24|Lack of Efficacy|1
6283458|NCT02319759|9995289|FG003|Week 16 - 24|Lack of Efficacy|0
6283459|NCT02319759|9995290|FG004|Week 16 - 24|Lack of Efficacy|0
6283460|NCT02319759|9995286|FG000|Week 16 - 24|Lost to Follow-up|1
6283461|NCT02319759|9995287|FG001|Week 16 - 24|Lost to Follow-up|0
6283462|NCT02319759|9995288|FG002|Week 16 - 24|Lost to Follow-up|0
6283463|NCT02319759|9995289|FG003|Week 16 - 24|Lost to Follow-up|0
6283464|NCT02319759|9995290|FG004|Week 16 - 24|Lost to Follow-up|0
6283465|NCT02319759|9995286|FG000|Week 16 - 24|Withdrawal by Subject|0
6283466|NCT02319759|9995287|FG001|Week 16 - 24|Withdrawal by Subject|0
6283467|NCT02319759|9995288|FG002|Week 16 - 24|Withdrawal by Subject|2
6283468|NCT02319759|9995289|FG003|Week 16 - 24|Withdrawal by Subject|0
6283469|NCT02319759|9995290|FG004|Week 16 - 24|Withdrawal by Subject|0
6283470|NCT02319759|9995286|FG000|Week 24 - 56|Adverse Event|0
6283471|NCT02319759|9995287|FG001|Week 24 - 56|Adverse Event|0
6283472|NCT02319759|9995288|FG002|Week 24 - 56|Adverse Event|2
6283473|NCT02319759|9995289|FG003|Week 24 - 56|Adverse Event|0
6283474|NCT02319759|9995290|FG004|Week 24 - 56|Adverse Event|0
6283475|NCT02319759|9995286|FG000|Week 24 - 56|Lack of Efficacy|0
6283476|NCT02319759|9995287|FG001|Week 24 - 56|Lack of Efficacy|0
6283477|NCT02319759|9995288|FG002|Week 24 - 56|Lack of Efficacy|0
6283478|NCT02319759|9995289|FG003|Week 24 - 56|Lack of Efficacy|2
6283479|NCT02319759|9995290|FG004|Week 24 - 56|Lack of Efficacy|1
6283480|NCT02319759|9995286|FG000|Week 24 - 56|Withdrawal by Subject|0
6283481|NCT02319759|9995287|FG001|Week 24 - 56|Withdrawal by Subject|1
6283482|NCT02319759|9995288|FG002|Week 24 - 56|Withdrawal by Subject|0
6283483|NCT02319759|9995289|FG003|Week 24 - 56|Withdrawal by Subject|0
6283484|NCT02319759|9995290|FG004|Week 24 - 56|Withdrawal by Subject|0
6283485|NCT02319759|9995286|FG000|Week 24 - 56|Lost to Follow-up|0
6283486|NCT02319759|9995287|FG001|Week 24 - 56|Lost to Follow-up|0
6283487|NCT02319759|9995288|FG002|Week 24 - 56|Lost to Follow-up|0
6283488|NCT02319759|9995289|FG003|Week 24 - 56|Lost to Follow-up|0
6283489|NCT02319759|9995290|FG004|Week 24 - 56|Lost to Follow-up|1
6283490|NCT02320058|9995323|FG000|Overall Study|Death|25
6283491|NCT02320058|9995324|FG001|Overall Study|Death|10
6283492|NCT02320058|9995323|FG000|Overall Study|Lost to Follow-up|4
6283493|NCT02320058|9995324|FG001|Overall Study|Lost to Follow-up|0
6283494|NCT02320058|9995323|FG000|Overall Study|Other reasons|4
6283495|NCT02320058|9995324|FG001|Overall Study|Other reasons|1
6283496|NCT02320058|9995323|FG000|Overall Study|Withdrawal by Subject|8
6283497|NCT02320058|9995324|FG001|Overall Study|Withdrawal by Subject|2
6283498|NCT02320058|9995323|FG000|Overall Study|Not reported|1
6283499|NCT02320058|9995324|FG001|Overall Study|Not reported|0
6283500|NCT02320123|9995332|FG000|Overall Study|Lost to Follow-up|4
6283501|NCT02320123|9995333|FG001|Overall Study|Lost to Follow-up|6
6283502|NCT02320123|9995332|FG000|Overall Study|Death|6
6283503|NCT02320123|9995333|FG001|Overall Study|Death|5
6283504|NCT02320149|9995345|FG000|Overall Study|Adverse Event|3
6283505|NCT02320149|9995346|FG001|Overall Study|Adverse Event|7
6283506|NCT02320149|9995345|FG000|Overall Study|Withdrawal of Consent|28
6283507|NCT02320149|9995346|FG001|Overall Study|Withdrawal of Consent|32
6283508|NCT02320149|9995345|FG000|Overall Study|Lost to Follow-up|21
6283509|NCT02320149|9995346|FG001|Overall Study|Lost to Follow-up|34
6283510|NCT02320149|9995345|FG000|Overall Study|Protocol Violation|2
6283511|NCT02320149|9995346|FG001|Overall Study|Protocol Violation|1
6283512|NCT02320149|9995345|FG000|Overall Study|Noncompliance with Study Treatment|7
6283513|NCT02320149|9995346|FG001|Overall Study|Noncompliance with Study Treatment|2
6283514|NCT02320149|9995345|FG000|Overall Study|Lack of Efficacy|0
6283515|NCT02320149|9995346|FG001|Overall Study|Lack of Efficacy|1
6283516|NCT02320149|9995345|FG000|Overall Study|Other Miscellaneous Reasons|2
6283517|NCT02320149|9995346|FG001|Overall Study|Other Miscellaneous Reasons|3
6283518|NCT02320253|9995376|FG000|Overall Study|Withdrawal by Subject|3
6052307|NCT00438256|9651787|FG000|Overall Study|Ineligible for Resection|2
6283519|NCT02320253|9995377|FG001|Overall Study|Withdrawal by Subject|0
6283520|NCT02320253|9995378|FG002|Overall Study|Withdrawal by Subject|0
6283521|NCT02320253|9995376|FG000|Overall Study|Lost to Follow-up|2
6052308|NCT00438256|9651788|FG001|Overall Study|Ineligible for Resection|1
6052309|NCT00438256|9651789|FG002|Overall Study|Ineligible for Resection|1
6283522|NCT02320253|9995377|FG001|Overall Study|Lost to Follow-up|2
6283523|NCT02320253|9995378|FG002|Overall Study|Lost to Follow-up|1
6283524|NCT02320253|9995376|FG000|Overall Study|Death|1
6283525|NCT02320253|9995377|FG001|Overall Study|Death|0
6283526|NCT02320253|9995378|FG002|Overall Study|Death|1
6283527|NCT02320487|9995386|FG000|Overall Study|Reason not Specified|1
6283528|NCT02320487|9995386|FG000|Overall Study|Physician Decision|5
6283529|NCT02320487|9995386|FG000|Overall Study|Withdrawal by Subject|1
6283530|NCT02320487|9995386|FG000|Overall Study|Death|3
6283531|NCT02320487|9995386|FG000|Overall Study|Adverse Event|11
6283532|NCT02320721|9995401|FG000|Overall Study|Adverse Event|6
6283533|NCT02320721|9995402|FG001|Overall Study|Adverse Event|6
6283534|NCT02320721|9995401|FG000|Overall Study|Lack of Efficacy|2
6283535|NCT02320721|9995402|FG001|Overall Study|Lack of Efficacy|0
6283536|NCT02320721|9995401|FG000|Overall Study|Poor compliance to protocol|3
6283537|NCT02320721|9995402|FG001|Overall Study|Poor compliance to protocol|7
6283538|NCT02320721|9995401|FG000|Overall Study|Randomized but not treated|0
6283539|NCT02320721|9995402|FG001|Overall Study|Randomized but not treated|1
6283540|NCT02320721|9995401|FG000|Overall Study|Hypoglycemia|1
6283541|NCT02320721|9995402|FG001|Overall Study|Hypoglycemia|0
6283542|NCT02320721|9995401|FG000|Overall Study|Other than specified above|15
6283543|NCT02320721|9995402|FG001|Overall Study|Other than specified above|20
6283544|NCT02320903|9995431|FG000|Overall Study|Withdrawal by Subject|0
6283545|NCT02320903|9995432|FG001|Overall Study|Withdrawal by Subject|9
6283546|NCT02320903|9995433|FG002|Overall Study|Withdrawal by Subject|9
6283547|NCT02320903|9995431|FG000|Overall Study|Exited therapy; no longer eligible|8
6283548|NCT02320903|9995432|FG001|Overall Study|Exited therapy; no longer eligible|2
6283549|NCT02320903|9995433|FG002|Overall Study|Exited therapy; no longer eligible|2
6283550|NCT02320903|9995431|FG000|Overall Study|Lost to Follow-up|0
6283551|NCT02320903|9995432|FG001|Overall Study|Lost to Follow-up|5
6283552|NCT02320903|9995433|FG002|Overall Study|Lost to Follow-up|5
6283553|NCT02321098|9995445|FG000|12 Weeks Treament|Lost to Follow-up|1
6283554|NCT02321098|9995446|FG001|12 Weeks Treament|Lost to Follow-up|1
6283555|NCT02321098|9995447|FG002|12 Weeks Treament|Lost to Follow-up|0
6283556|NCT02321098|9995445|FG000|Additional 15 Months Treatment|Lack of Efficacy|0
6283557|NCT02321098|9995446|FG001|Additional 15 Months Treatment|Lack of Efficacy|0
6283558|NCT02321098|9995447|FG002|Additional 15 Months Treatment|Lack of Efficacy|6
6283559|NCT02321098|9995445|FG000|Additional 15 Months Treatment|Lost to Follow-up|0
6283560|NCT02321098|9995446|FG001|Additional 15 Months Treatment|Lost to Follow-up|0
6283561|NCT02321098|9995447|FG002|Additional 15 Months Treatment|Lost to Follow-up|1
6283562|NCT02321098|9995445|FG000|Additional 15 Months Treatment|Withdrawal by Subject|0
6283563|NCT02321098|9995446|FG001|Additional 15 Months Treatment|Withdrawal by Subject|0
6283564|NCT02321098|9995447|FG002|Additional 15 Months Treatment|Withdrawal by Subject|1
6283565|NCT02321319|9995469|FG000|Overall Study|Product discontinued|5
6283566|NCT02321436|9995475|FG000|Overall Study|Withdrawal by Subject|1
6283567|NCT02321436|9995476|FG001|Overall Study|Withdrawal by Subject|0
6283568|NCT02321436|9995475|FG000|Overall Study|Lost to Follow-up|0
6283569|NCT02321436|9995476|FG001|Overall Study|Lost to Follow-up|1
6283570|NCT02321462|9995485|FG000|Overall Study|Withdrawal by Subject|5
6283571|NCT02321462|9995486|FG001|Overall Study|Withdrawal by Subject|2
6283572|NCT02321462|9995485|FG000|Overall Study|Subject withdrawn before any treatment|1
6283573|NCT02321462|9995486|FG001|Overall Study|Subject withdrawn before any treatment|1
6283574|NCT02321800|9995511|FG000|Overall Study|Withdrawal by Subject|3
6283575|NCT02321800|9995512|FG001|Overall Study|Withdrawal by Subject|3
6283576|NCT02321800|9995511|FG000|Overall Study|Death|1
6283577|NCT02321800|9995512|FG001|Overall Study|Death|0
6283578|NCT02321800|9995511|FG000|Overall Study|Protocol Violation|1
6283579|NCT02321800|9995512|FG001|Overall Study|Protocol Violation|0
6283580|NCT02321800|9995511|FG000|Overall Study|Lost to Follow-up|10
6283581|NCT02321800|9995512|FG001|Overall Study|Lost to Follow-up|4
6283582|NCT02321800|9995511|FG000|Overall Study|Adverse Event|2
6283583|NCT02321800|9995512|FG001|Overall Study|Adverse Event|3
6283584|NCT02321800|9995511|FG000|Overall Study|Other, Miscellaneous|3
6283585|NCT02321800|9995512|FG001|Overall Study|Other, Miscellaneous|1
6283586|NCT02321930|9995518|FG000|Overall Study|Lost to Follow-up|1
6283587|NCT02322021|9995526|FG000|Core Phase|Adverse Event|1
6283588|NCT02322021|9995527|FG001|Core Phase|Adverse Event|3
6283589|NCT02322021|9995528|FG002|Core Phase|Adverse Event|4
6283590|NCT02322021|9995529|FG003|Core Phase|Adverse Event|2
6283591|NCT02322021|9995530|FG004|Core Phase|Adverse Event|0
6283592|NCT02322021|9995526|FG000|Core Phase|Participant Choice|4
6283593|NCT02322021|9995527|FG001|Core Phase|Participant Choice|5
6283594|NCT02322021|9995528|FG002|Core Phase|Participant Choice|4
6283595|NCT02322021|9995529|FG003|Core Phase|Participant Choice|2
6283596|NCT02322021|9995530|FG004|Core Phase|Participant Choice|0
6283597|NCT02322021|9995526|FG000|Core Phase|Lost to Follow-up|0
6283598|NCT02322021|9995527|FG001|Core Phase|Lost to Follow-up|0
6283599|NCT02322021|9995528|FG002|Core Phase|Lost to Follow-up|0
6283600|NCT02322021|9995529|FG003|Core Phase|Lost to Follow-up|1
6283601|NCT02322021|9995530|FG004|Core Phase|Lost to Follow-up|0
6283602|NCT02322021|9995526|FG000|Core Phase|Other|0
6283603|NCT02322021|9995527|FG001|Core Phase|Other|0
6283604|NCT02322021|9995528|FG002|Core Phase|Other|1
6283605|NCT02322021|9995529|FG003|Core Phase|Other|0
6283606|NCT02322021|9995530|FG004|Core Phase|Other|0
6283607|NCT02322021|9995526|FG000|Extension Phase|Adverse Event|0
6283608|NCT02322021|9995527|FG001|Extension Phase|Adverse Event|0
6283609|NCT02322021|9995528|FG002|Extension Phase|Adverse Event|0
6283610|NCT02322021|9995529|FG003|Extension Phase|Adverse Event|0
6283611|NCT02322021|9995530|FG004|Extension Phase|Adverse Event|3
6283612|NCT02322021|9995526|FG000|Extension Phase|Participant Choice|0
6283613|NCT02322021|9995527|FG001|Extension Phase|Participant Choice|0
6283614|NCT02322021|9995528|FG002|Extension Phase|Participant Choice|0
6283615|NCT02322021|9995529|FG003|Extension Phase|Participant Choice|0
6283616|NCT02322021|9995530|FG004|Extension Phase|Participant Choice|6
6283617|NCT02322021|9995526|FG000|Extension Phase|Other|0
6283618|NCT02322021|9995527|FG001|Extension Phase|Other|0
6283619|NCT02322021|9995528|FG002|Extension Phase|Other|0
6283620|NCT02322021|9995529|FG003|Extension Phase|Other|0
6283621|NCT02322021|9995530|FG004|Extension Phase|Other|3
6283622|NCT02322021|9995526|FG000|Extension Phase|Lost to Follow-up|0
6283623|NCT02322021|9995527|FG001|Extension Phase|Lost to Follow-up|0
6283624|NCT02322021|9995528|FG002|Extension Phase|Lost to Follow-up|0
6283625|NCT02322021|9995529|FG003|Extension Phase|Lost to Follow-up|0
6283626|NCT02322021|9995530|FG004|Extension Phase|Lost to Follow-up|1
6283627|NCT02322021|9995526|FG000|Extension Phase|Study terminated by sponsor|0
6283628|NCT02322021|9995527|FG001|Extension Phase|Study terminated by sponsor|0
6283629|NCT02322021|9995528|FG002|Extension Phase|Study terminated by sponsor|0
6283630|NCT02322021|9995529|FG003|Extension Phase|Study terminated by sponsor|0
6283631|NCT02322021|9995530|FG004|Extension Phase|Study terminated by sponsor|28
6283632|NCT02322047|9995549|FG000|Overall Study|Physician Decision|1
6283633|NCT02322047|9995550|FG001|Overall Study|Physician Decision|0
6283634|NCT02322047|9995551|FG002|Overall Study|Physician Decision|0
6283635|NCT02322047|9995552|FG003|Overall Study|Physician Decision|0
6283636|NCT02322047|9995549|FG000|Overall Study|Withdrawal by Subject|1
6283637|NCT02322047|9995550|FG001|Overall Study|Withdrawal by Subject|0
6283638|NCT02322047|9995551|FG002|Overall Study|Withdrawal by Subject|0
6052310|NCT00438256|9651790|FG003|Overall Study|Ineligible for Resection|7
6052311|NCT00438256|9651787|FG000|Overall Study|Excluded final Diagnosis|0
6052312|NCT00438256|9651788|FG001|Overall Study|Excluded final Diagnosis|0
6052313|NCT00438256|9651789|FG002|Overall Study|Excluded final Diagnosis|0
6052314|NCT00438256|9651790|FG003|Overall Study|Excluded final Diagnosis|2
6052315|NCT00438360|9651805|FG000|Overall Study|Adverse Event|6
6052316|NCT00438360|9651806|FG001|Overall Study|Adverse Event|1
6052317|NCT00438360|9651805|FG000|Overall Study|Lack of Efficacy|42
6052318|NCT00438360|9651806|FG001|Overall Study|Lack of Efficacy|27
6052319|NCT00438360|9651805|FG000|Overall Study|Other|24
6052320|NCT00438360|9651806|FG001|Overall Study|Other|15
6052321|NCT00438399|9651815|FG000|Overall Study|Lost to Follow-up|2
6052322|NCT00438399|9651816|FG001|Overall Study|Lost to Follow-up|2
6052323|NCT00438399|9651817|FG002|Overall Study|Lost to Follow-up|1
6052324|NCT00438399|9651818|FG003|Overall Study|Lost to Follow-up|1
6052325|NCT00438399|9651819|FG004|Overall Study|Lost to Follow-up|1
6052326|NCT00438399|9651820|FG005|Overall Study|Lost to Follow-up|1
6052327|NCT00438399|9651815|FG000|Overall Study|Adverse Event|0
6052328|NCT00438399|9651816|FG001|Overall Study|Adverse Event|0
6052329|NCT00438399|9651817|FG002|Overall Study|Adverse Event|1
6052330|NCT00438399|9651818|FG003|Overall Study|Adverse Event|1
6052331|NCT00438399|9651819|FG004|Overall Study|Adverse Event|0
6052332|NCT00438399|9651820|FG005|Overall Study|Adverse Event|1
6052333|NCT00438399|9651815|FG000|Overall Study|Withdrawal by Subject|5
6089707|NCT00686075|9701462|FG007|Overall Study|Lost to Follow-up|0
6089708|NCT00686075|9701463|FG008|Overall Study|Lost to Follow-up|2
6089709|NCT00686075|9701464|FG009|Overall Study|Lost to Follow-up|3
6089710|NCT00686075|9701455|FG000|Overall Study|Other|1
6089711|NCT00686075|9701456|FG001|Overall Study|Other|1
6089712|NCT00686075|9701457|FG002|Overall Study|Other|0
6089713|NCT00686075|9701458|FG003|Overall Study|Other|0
6089714|NCT00686075|9701459|FG004|Overall Study|Other|0
6089715|NCT00686075|9701460|FG005|Overall Study|Other|0
6089716|NCT00686075|9701461|FG006|Overall Study|Other|0
6089717|NCT00686075|9701462|FG007|Overall Study|Other|0
6089718|NCT00686075|9701463|FG008|Overall Study|Other|0
6089719|NCT00686075|9701464|FG009|Overall Study|Other|1
6089720|NCT00686127|9701488|FG000|Overall Study|Withdrawal by Subject|14
6089721|NCT00686127|9701489|FG001|Overall Study|Withdrawal by Subject|6
6089722|NCT00686166|9701495|FG000|Overall Study|Adverse Event|7
6089723|NCT00686166|9701495|FG000|Overall Study|Withdrawal by Subject|1
6283639|NCT02322047|9995552|FG003|Overall Study|Withdrawal by Subject|1
6283640|NCT02322047|9995549|FG000|Overall Study|Adverse Event|0
6283641|NCT02322047|9995550|FG001|Overall Study|Adverse Event|1
6052334|NCT00438399|9651816|FG001|Overall Study|Withdrawal by Subject|6
6089724|NCT00686166|9701495|FG000|Overall Study|Progression/Relapse|1
6089725|NCT00686166|9701495|FG000|Overall Study|Death|1
6089726|NCT00686166|9701495|FG000|Overall Study|Not Protocol Specified|1
6089727|NCT00686166|9701495|FG000|Overall Study|Ineligible|5
6089728|NCT00686166|9701495|FG000|Overall Study|Did not begin protocol therapy|4
6089729|NCT00686205|9701506|FG000|Overall Study|Protocol Violation|127
6089730|NCT00686205|9701507|FG001|Overall Study|Protocol Violation|0
6089731|NCT00686205|9701506|FG000|Overall Study|Withdrawal by Subject|2
6089732|NCT00686205|9701507|FG001|Overall Study|Withdrawal by Subject|0
6089733|NCT00686205|9701506|FG000|Overall Study|Specimen handling procedure altered|5878
6089734|NCT00686205|9701507|FG001|Overall Study|Specimen handling procedure altered|0
6089735|NCT00686205|9701506|FG000|Overall Study|Specimens not confirmed HIV positive|0
6089736|NCT00686205|9701507|FG001|Overall Study|Specimens not confirmed HIV positive|981
6089737|NCT00686335|9701537|FG000|Run-in Period|Adverse Event|1
6283642|NCT02322047|9995551|FG002|Overall Study|Adverse Event|0
6283643|NCT02322047|9995552|FG003|Overall Study|Adverse Event|0
6283644|NCT02322047|9995549|FG000|Overall Study|Lost to Follow-up|0
6283645|NCT02322047|9995550|FG001|Overall Study|Lost to Follow-up|0
6283646|NCT02322047|9995551|FG002|Overall Study|Lost to Follow-up|1
6283647|NCT02322047|9995552|FG003|Overall Study|Lost to Follow-up|1
6283648|NCT02322125|9995562|FG000|Overall Study|Withdrawal by Subject|2
6283649|NCT02322190|9995566|FG000|Overall Study|Death on study|1
6283650|NCT02322190|9995567|FG001|Overall Study|Death on study|0
6283651|NCT02322216|9995574|FG000|Overall Study|Adverse Event|1
6283652|NCT02322216|9995575|FG001|Overall Study|Adverse Event|0
6283653|NCT02322216|9995574|FG000|Overall Study|Withdrawal by Subject|1
6283654|NCT02322216|9995575|FG001|Overall Study|Withdrawal by Subject|4
6283655|NCT02322229|9995582|FG000|Overall Study|Physician Decision|2
6283656|NCT02322281|9995599|FG000|Overall Study|Progressive Disease|42
6283657|NCT02322281|9995600|FG001|Overall Study|Progressive Disease|14
6283658|NCT02322281|9995601|FG002|Overall Study|Progressive Disease|49
6283659|NCT02322281|9995599|FG000|Overall Study|Adverse Event|3
6283660|NCT02322281|9995600|FG001|Overall Study|Adverse Event|4
6283661|NCT02322281|9995601|FG002|Overall Study|Adverse Event|6
6283662|NCT02322281|9995599|FG000|Overall Study|Death|3
6283663|NCT02322281|9995600|FG001|Overall Study|Death|3
6283664|NCT02322281|9995601|FG002|Overall Study|Death|3
6283665|NCT02322281|9995599|FG000|Overall Study|Withdrawal by Subject|1
6283666|NCT02322281|9995600|FG001|Overall Study|Withdrawal by Subject|1
6283667|NCT02322281|9995601|FG002|Overall Study|Withdrawal by Subject|6
6283668|NCT02322281|9995599|FG000|Overall Study|Physician Decision|2
6283669|NCT02322281|9995600|FG001|Overall Study|Physician Decision|0
6283670|NCT02322281|9995601|FG002|Overall Study|Physician Decision|5
6283671|NCT02322281|9995599|FG000|Overall Study|Study Terminated by Sponsor|2
6283672|NCT02322281|9995600|FG001|Overall Study|Study Terminated by Sponsor|0
6283673|NCT02322281|9995601|FG002|Overall Study|Study Terminated by Sponsor|0
6283674|NCT02322281|9995599|FG000|Overall Study|Missing|0
6283675|NCT02322281|9995600|FG001|Overall Study|Missing|0
6283676|NCT02322281|9995601|FG002|Overall Study|Missing|1
6283677|NCT02322281|9995599|FG000|Overall Study|Miscellaneous|0
6283678|NCT02322281|9995600|FG001|Overall Study|Miscellaneous|0
6283679|NCT02322281|9995601|FG002|Overall Study|Miscellaneous|4
6283680|NCT02322411|9995635|FG000|Overall Study|Lost to Follow-up|4
6283681|NCT02322411|9995636|FG001|Overall Study|Lost to Follow-up|7
6283682|NCT02322411|9995635|FG000|Overall Study|Withdrawal by Subject|1
6283683|NCT02322411|9995636|FG001|Overall Study|Withdrawal by Subject|0
6283684|NCT02322749|9995646|FG000|Period 2|Adverse Event|0
6283685|NCT02322749|9995647|FG001|Period 2|Adverse Event|0
6283686|NCT02322749|9995648|FG002|Period 2|Adverse Event|0
6283687|NCT02322749|9995649|FG003|Period 2|Adverse Event|1
6283688|NCT02322749|9995650|FG004|Period 2|Adverse Event|0
6283689|NCT02322749|9995651|FG005|Period 2|Adverse Event|0
6283690|NCT02322749|9995646|FG000|Period 2|Withdrawal by Subject|0
6283691|NCT02322749|9995647|FG001|Period 2|Withdrawal by Subject|0
6283692|NCT02322749|9995648|FG002|Period 2|Withdrawal by Subject|0
5980299|NCT00245960|9568924|FG001|Period 1 (Double Blind): 1-12 Weeks|Protocol Violation|0
5980300|NCT00245960|9568923|FG000|Period 1 (Double Blind): 1-12 Weeks|Withdrawal by Subject|2
5980301|NCT00245960|9568924|FG001|Period 1 (Double Blind): 1-12 Weeks|Withdrawal by Subject|2
5980302|NCT00245960|9568923|FG000|Period 2 (Open Label): 13-24 Weeks|Adverse Event|8
5980303|NCT00245960|9568924|FG001|Period 2 (Open Label): 13-24 Weeks|Adverse Event|4
5980304|NCT00245960|9568923|FG000|Period 2 (Open Label): 13-24 Weeks|Lost to Follow-up|2
5980305|NCT00245960|9568924|FG001|Period 2 (Open Label): 13-24 Weeks|Lost to Follow-up|2
5980306|NCT00245960|9568923|FG000|Period 2 (Open Label): 13-24 Weeks|Unsatisfactory Response|2
5980307|NCT00245960|9568924|FG001|Period 2 (Open Label): 13-24 Weeks|Unsatisfactory Response|5
5980308|NCT00245960|9568923|FG000|Period 2 (Open Label): 13-24 Weeks|Withdrawal by Subject|1
5980309|NCT00245960|9568924|FG001|Period 2 (Open Label): 13-24 Weeks|Withdrawal by Subject|3
5980310|NCT00245960|9568923|FG000|Period 2 (Open Label): 13-24 Weeks|Protocol Violation|1
5980311|NCT00245960|9568924|FG001|Period 2 (Open Label): 13-24 Weeks|Protocol Violation|3
5980312|NCT00245960|9568923|FG000|Period 2 (Open Label): 13-24 Weeks|Withdrawal of consent|0
5980313|NCT00245960|9568924|FG001|Period 2 (Open Label): 13-24 Weeks|Withdrawal of consent|1
6052335|NCT00438399|9651817|FG002|Overall Study|Withdrawal by Subject|3
6052336|NCT00438399|9651818|FG003|Overall Study|Withdrawal by Subject|2
6052337|NCT00438399|9651819|FG004|Overall Study|Withdrawal by Subject|2
6052338|NCT00438399|9651820|FG005|Overall Study|Withdrawal by Subject|2
6052339|NCT00438399|9651815|FG000|Overall Study|Protocol Violation|0
6052340|NCT00438399|9651816|FG001|Overall Study|Protocol Violation|0
6052341|NCT00438399|9651817|FG002|Overall Study|Protocol Violation|1
6052342|NCT00438399|9651818|FG003|Overall Study|Protocol Violation|0
6052343|NCT00438399|9651819|FG004|Overall Study|Protocol Violation|0
6052344|NCT00438399|9651820|FG005|Overall Study|Protocol Violation|1
6052345|NCT00438399|9651815|FG000|Overall Study|Subje stopped study|0
6052346|NCT00438399|9651816|FG001|Overall Study|Subje stopped study|0
6052347|NCT00438399|9651817|FG002|Overall Study|Subje stopped study|1
6283693|NCT02322749|9995649|FG003|Period 2|Withdrawal by Subject|1
6283694|NCT02322749|9995650|FG004|Period 2|Withdrawal by Subject|0
6283695|NCT02322749|9995651|FG005|Period 2|Withdrawal by Subject|0
6283696|NCT02322749|9995646|FG000|Period 3|Withdrawal by Subject|0
6283697|NCT02322749|9995647|FG001|Period 3|Withdrawal by Subject|0
6283698|NCT02322749|9995648|FG002|Period 3|Withdrawal by Subject|1
6283699|NCT02322749|9995649|FG003|Period 3|Withdrawal by Subject|0
6283700|NCT02322749|9995650|FG004|Period 3|Withdrawal by Subject|0
6283701|NCT02322749|9995651|FG005|Period 3|Withdrawal by Subject|0
6283702|NCT02322775|9995662|FG000|Overall Study|Adverse Event|1
6283703|NCT02322775|9995663|FG001|Overall Study|Adverse Event|0
6283704|NCT02322775|9995662|FG000|Overall Study|Lost to Follow-up|0
6283705|NCT02322775|9995663|FG001|Overall Study|Lost to Follow-up|1
6283706|NCT02322775|9995662|FG000|Overall Study|Protocol Violation|1
6283707|NCT02322775|9995663|FG001|Overall Study|Protocol Violation|0
6283708|NCT02322775|9995662|FG000|Overall Study|Withdrawal by Subject|3
6283709|NCT02322775|9995663|FG001|Overall Study|Withdrawal by Subject|4
6283710|NCT02322775|9995662|FG000|Overall Study|Not willing to perform all FU visits|0
6283711|NCT02322775|9995663|FG001|Overall Study|Not willing to perform all FU visits|1
6283712|NCT02322814|9995687|FG000|Overall Study|Ongoing Study|0
6283713|NCT02322814|9995688|FG001|Overall Study|Ongoing Study|13
6283714|NCT02322814|9995689|FG002|Overall Study|Ongoing Study|14
6283715|NCT02322814|9995690|FG003|Overall Study|Ongoing Study|20
6283716|NCT02322814|9995691|FG004|Overall Study|Ongoing Study|22
6283717|NCT02322814|9995687|FG000|Overall Study|Progressive Disease|0
6283718|NCT02322814|9995688|FG001|Overall Study|Progressive Disease|2
6283719|NCT02322814|9995689|FG002|Overall Study|Progressive Disease|0
6283720|NCT02322814|9995690|FG003|Overall Study|Progressive Disease|1
6283721|NCT02322814|9995691|FG004|Overall Study|Progressive Disease|0
6283722|NCT02322814|9995687|FG000|Overall Study|Lost to Follow-up|1
6283723|NCT02322814|9995688|FG001|Overall Study|Lost to Follow-up|2
6283724|NCT02322814|9995689|FG002|Overall Study|Lost to Follow-up|1
6283725|NCT02322814|9995690|FG003|Overall Study|Lost to Follow-up|0
6283726|NCT02322814|9995691|FG004|Overall Study|Lost to Follow-up|0
6283727|NCT02322814|9995687|FG000|Overall Study|Other|2
6283728|NCT02322814|9995688|FG001|Overall Study|Other|0
6283729|NCT02322814|9995689|FG002|Overall Study|Other|0
6283730|NCT02322814|9995690|FG003|Overall Study|Other|0
6283731|NCT02322814|9995691|FG004|Overall Study|Other|0
6283732|NCT02322814|9995687|FG000|Overall Study|Protocol Violation|1
6283733|NCT02322814|9995688|FG001|Overall Study|Protocol Violation|0
6283734|NCT02322814|9995689|FG002|Overall Study|Protocol Violation|0
6283735|NCT02322814|9995690|FG003|Overall Study|Protocol Violation|0
6283736|NCT02322814|9995691|FG004|Overall Study|Protocol Violation|0
6283737|NCT02322814|9995687|FG000|Overall Study|Death|7
6283738|NCT02322814|9995688|FG001|Overall Study|Death|22
6283739|NCT02322814|9995689|FG002|Overall Study|Death|30
6283740|NCT02322814|9995690|FG003|Overall Study|Death|10
6283741|NCT02322814|9995691|FG004|Overall Study|Death|6
6283742|NCT02322814|9995687|FG000|Overall Study|Withdrawal by Subject|5
6283743|NCT02322814|9995688|FG001|Overall Study|Withdrawal by Subject|4
6283744|NCT02322814|9995689|FG002|Overall Study|Withdrawal by Subject|2
6283745|NCT02322814|9995690|FG003|Overall Study|Withdrawal by Subject|1
6283746|NCT02322814|9995691|FG004|Overall Study|Withdrawal by Subject|3
6283747|NCT02322866|9995704|FG000|Overall Study|Adverse Event|6
6283748|NCT02322866|9995705|FG001|Overall Study|Adverse Event|11
6283749|NCT02322866|9995704|FG000|Overall Study|Withdrawal of Consent|16
6283750|NCT02322866|9995705|FG001|Overall Study|Withdrawal of Consent|25
6283751|NCT02322866|9995704|FG000|Overall Study|Lost to Follow-up|36
6283752|NCT02322866|9995705|FG001|Overall Study|Lost to Follow-up|39
6283753|NCT02322866|9995704|FG000|Overall Study|Protocol Violation|1
6283754|NCT02322866|9995705|FG001|Overall Study|Protocol Violation|0
6283755|NCT02322866|9995704|FG000|Overall Study|Noncompliance with Treatment|3
6283756|NCT02322866|9995705|FG001|Overall Study|Noncompliance with Treatment|4
6283757|NCT02322866|9995704|FG000|Overall Study|Lack of Efficacy|3
6283758|NCT02322866|9995705|FG001|Overall Study|Lack of Efficacy|1
6283759|NCT02322866|9995704|FG000|Overall Study|Other Miscellaneous Reasons|6
6283760|NCT02322866|9995705|FG001|Overall Study|Other Miscellaneous Reasons|6
6283761|NCT02322879|9995713|FG000|First Intervention|Physician Decision|1
6283762|NCT02322879|9995714|FG001|First Intervention|Physician Decision|0
6052348|NCT00438399|9651818|FG003|Overall Study|Subje stopped study|0
6052349|NCT00438399|9651819|FG004|Overall Study|Subje stopped study|0
6052350|NCT00438399|9651820|FG005|Overall Study|Subje stopped study|0
6052351|NCT00438399|9651815|FG000|Overall Study|Pregnancy|0
6052352|NCT00438399|9651816|FG001|Overall Study|Pregnancy|0
6052353|NCT00438399|9651817|FG002|Overall Study|Pregnancy|0
6052354|NCT00438399|9651818|FG003|Overall Study|Pregnancy|0
6052355|NCT00438399|9651819|FG004|Overall Study|Pregnancy|0
6052356|NCT00438399|9651820|FG005|Overall Study|Pregnancy|1
6283763|NCT02322892|9995722|FG000|Overall Study|Surgery cancelled|1
6283764|NCT02322892|9995723|FG001|Overall Study|Surgery cancelled|2
6283765|NCT02322892|9995722|FG000|Overall Study|Met exclusion criteria|0
6052357|NCT00438399|9651815|FG000|Overall Study|Patien stopped study at visit 4 by error|1
6052358|NCT00438399|9651816|FG001|Overall Study|Patien stopped study at visit 4 by error|0
6283766|NCT02322892|9995723|FG001|Overall Study|Met exclusion criteria|1
6283767|NCT02322892|9995722|FG000|Overall Study|Protocol Violation|1
6283768|NCT02322892|9995723|FG001|Overall Study|Protocol Violation|0
6283769|NCT02323113|9995757|FG000|Overall Study|Adverse Event|3
6283770|NCT02323113|9995758|FG001|Overall Study|Adverse Event|3
6283771|NCT02323113|9995759|FG002|Overall Study|Adverse Event|2
6283772|NCT02323113|9995760|FG003|Overall Study|Adverse Event|5
6283773|NCT02323113|9995761|FG004|Overall Study|Adverse Event|8
6283774|NCT02323113|9995762|FG005|Overall Study|Adverse Event|3
6283775|NCT02323113|9995763|FG006|Overall Study|Adverse Event|6
6283776|NCT02323113|9995764|FG007|Overall Study|Adverse Event|0
6283777|NCT02323113|9995757|FG000|Overall Study|Progressive Disease|0
6283778|NCT02323113|9995758|FG001|Overall Study|Progressive Disease|1
6283779|NCT02323113|9995759|FG002|Overall Study|Progressive Disease|1
6283780|NCT02323113|9995760|FG003|Overall Study|Progressive Disease|0
6283781|NCT02323113|9995761|FG004|Overall Study|Progressive Disease|0
6283782|NCT02323113|9995762|FG005|Overall Study|Progressive Disease|3
6283783|NCT02323113|9995763|FG006|Overall Study|Progressive Disease|0
6283784|NCT02323113|9995764|FG007|Overall Study|Progressive Disease|0
6283785|NCT02323113|9995757|FG000|Overall Study|Symptomatic Deterioration|0
6283786|NCT02323113|9995758|FG001|Overall Study|Symptomatic Deterioration|0
6283787|NCT02323113|9995759|FG002|Overall Study|Symptomatic Deterioration|1
6283788|NCT02323113|9995760|FG003|Overall Study|Symptomatic Deterioration|0
6283789|NCT02323113|9995761|FG004|Overall Study|Symptomatic Deterioration|1
6283790|NCT02323113|9995762|FG005|Overall Study|Symptomatic Deterioration|0
6283791|NCT02323113|9995763|FG006|Overall Study|Symptomatic Deterioration|0
6052359|NCT00438399|9651817|FG002|Overall Study|Patien stopped study at visit 4 by error|0
6052360|NCT00438399|9651818|FG003|Overall Study|Patien stopped study at visit 4 by error|0
6052361|NCT00438399|9651819|FG004|Overall Study|Patien stopped study at visit 4 by error|0
6052362|NCT00438399|9651820|FG005|Overall Study|Patien stopped study at visit 4 by error|0
6052363|NCT00438464|9651844|FG000|Overall Study|Terminated Early|14
6052364|NCT00438464|9651845|FG001|Overall Study|Terminated Early|5
6052365|NCT00438464|9651844|FG000|Overall Study|Incomplete data submission|0
6052366|NCT00438464|9651845|FG001|Overall Study|Incomplete data submission|2
6052367|NCT00438633|9651878|FG000|Overall Study|Withdrawal by Subject|1
6052368|NCT00438633|9651879|FG001|Overall Study|Withdrawal by Subject|0
6052369|NCT00438633|9651878|FG000|Overall Study|Lost to Follow-up|15
6052370|NCT00438633|9651879|FG001|Overall Study|Lost to Follow-up|17
6052371|NCT00438659|9651887|FG000|Overall Study|Discontinued Mometasone/Placebo|1
6052372|NCT00438659|9651888|FG001|Overall Study|Discontinued Mometasone/Placebo|2
6052373|NCT00438659|9651887|FG000|Overall Study|Cancel|5
6052374|NCT00438659|9651888|FG001|Overall Study|Cancel|2
6052375|NCT00438672|9651897|FG000|Overall Study|Lost to Follow-up|7
6052376|NCT00438672|9651898|FG001|Overall Study|Lost to Follow-up|9
6052377|NCT00438815|9651928|FG000|Overall Study|Transferred to LEVP2006-4 (NCT00462709)|30
6052378|NCT00438815|9651928|FG000|Overall Study|3-month follow-up no longer required|12
6052379|NCT00438815|9651928|FG000|Overall Study|Noncompliance with protocol requirements|9
6052380|NCT00438815|9651928|FG000|Overall Study|Transitioned to commercial C1INH-nf|6
6052381|NCT00438815|9651928|FG000|Overall Study|Lost to Follow-up|6
6052382|NCT00438815|9651928|FG000|Overall Study|Withdrawal by Subject|6
6052383|NCT00438815|9651928|FG000|Overall Study|Death|1
6052384|NCT00439140|9651970|FG000|Treatment Cycle 1|Lost to Follow-up|1
6052385|NCT00439140|9651971|FG001|Treatment Cycle 1|Lost to Follow-up|1
6052386|NCT00439140|9651972|FG002|Treatment Cycle 1|Lost to Follow-up|1
6052387|NCT00439140|9651970|FG000|Treatment Cycle 1|Personal reasons|0
6052388|NCT00439140|9651971|FG001|Treatment Cycle 1|Personal reasons|2
6052389|NCT00439140|9651972|FG002|Treatment Cycle 1|Personal reasons|0
6052390|NCT00439140|9651970|FG000|Treatment Cycle 1|Withdrawal by Subject|0
6052391|NCT00439140|9651971|FG001|Treatment Cycle 1|Withdrawal by Subject|1
6052392|NCT00439140|9651972|FG002|Treatment Cycle 1|Withdrawal by Subject|0
6052393|NCT00439140|9651970|FG000|Treatment Cycle 2|Withdrawal by Subject|1
6052394|NCT00439140|9651971|FG001|Treatment Cycle 2|Withdrawal by Subject|0
6052395|NCT00439140|9651972|FG002|Treatment Cycle 2|Withdrawal by Subject|0
6052396|NCT00439140|9651970|FG000|Treatment Cycle 2|Lost to Follow-up|1
6052397|NCT00439140|9651971|FG001|Treatment Cycle 2|Lost to Follow-up|1
6052398|NCT00439140|9651972|FG002|Treatment Cycle 2|Lost to Follow-up|0
6052399|NCT00439179|9651984|FG000|Overall Study|* 1 pt inelig, 1 pt numb not used|0
6052400|NCT00439179|9651985|FG001|Overall Study|* 1 pt inelig, 1 pt numb not used|2
6052401|NCT00439179|9651986|FG002|Overall Study|* 1 pt inelig, 1 pt numb not used|0
6052402|NCT00439179|9651987|FG003|Overall Study|* 1 pt inelig, 1 pt numb not used|0
6052403|NCT00439218|9652000|FG000|Cohort 1 (500 mg/kg/Day)|Less than 80% study drug compliance|1
6052404|NCT00439231|9652004|FG000|Overall Study|Lack of Efficacy|28
6052405|NCT00439244|9652011|FG000|Overall Study|Adverse Event|5
6052406|NCT00439244|9652012|FG001|Overall Study|Adverse Event|2
6052407|NCT00439244|9652013|FG002|Overall Study|Adverse Event|3
6052408|NCT00439244|9652011|FG000|Overall Study|Withdrawal by Subject|3
6052409|NCT00439244|9652012|FG001|Overall Study|Withdrawal by Subject|1
6052410|NCT00439244|9652013|FG002|Overall Study|Withdrawal by Subject|2
6052411|NCT00439244|9652011|FG000|Overall Study|Lost to Follow-up|2
6052412|NCT00439244|9652012|FG001|Overall Study|Lost to Follow-up|1
6052413|NCT00439244|9652013|FG002|Overall Study|Lost to Follow-up|2
6052414|NCT00439244|9652011|FG000|Overall Study|Death|0
6052415|NCT00439244|9652012|FG001|Overall Study|Death|1
6052416|NCT00439244|9652013|FG002|Overall Study|Death|0
6052417|NCT00439244|9652011|FG000|Overall Study|Protocol Violation|0
6052418|NCT00439244|9652012|FG001|Overall Study|Protocol Violation|1
6283792|NCT02323113|9995764|FG007|Overall Study|Symptomatic Deterioration|0
6283793|NCT02323113|9995757|FG000|Overall Study|Unsatisfactory Therapeutic Response|1
6283794|NCT02323113|9995758|FG001|Overall Study|Unsatisfactory Therapeutic Response|2
6283795|NCT02323113|9995759|FG002|Overall Study|Unsatisfactory Therapeutic Response|0
6283796|NCT02323113|9995760|FG003|Overall Study|Unsatisfactory Therapeutic Response|0
6283797|NCT02323113|9995761|FG004|Overall Study|Unsatisfactory Therapeutic Response|0
6283798|NCT02323113|9995762|FG005|Overall Study|Unsatisfactory Therapeutic Response|2
6283799|NCT02323113|9995763|FG006|Overall Study|Unsatisfactory Therapeutic Response|0
6283800|NCT02323113|9995764|FG007|Overall Study|Unsatisfactory Therapeutic Response|0
6283801|NCT02323113|9995757|FG000|Overall Study|Study Drug was Held due to AE for >21 Days, Therefore Participant was Discontinued Per Protocol|0
6052419|NCT00439244|9652013|FG002|Overall Study|Protocol Violation|0
6052420|NCT00439244|9652011|FG000|Overall Study|Administrative problems|1
6052421|NCT00439244|9652012|FG001|Overall Study|Administrative problems|0
6052422|NCT00439244|9652013|FG002|Overall Study|Administrative problems|0
6052423|NCT00439270|9652026|FG000|Phase 1 (18.1 Months)|Disease progression|3
6052424|NCT00439270|9652027|FG001|Phase 1 (18.1 Months)|Disease progression|2
6052425|NCT00439270|9652028|FG002|Phase 1 (18.1 Months)|Disease progression|3
6052426|NCT00439270|9652029|FG003|Phase 1 (18.1 Months)|Disease progression|0
6052427|NCT00439270|9652030|FG004|Phase 1 (18.1 Months)|Disease progression|3
6052428|NCT00439270|9652026|FG000|Phase 1 (18.1 Months)|Study drug toxicity|0
6052429|NCT00439270|9652027|FG001|Phase 1 (18.1 Months)|Study drug toxicity|1
6052430|NCT00439270|9652028|FG002|Phase 1 (18.1 Months)|Study drug toxicity|0
6052431|NCT00439270|9652029|FG003|Phase 1 (18.1 Months)|Study drug toxicity|0
6052432|NCT00439270|9652030|FG004|Phase 1 (18.1 Months)|Study drug toxicity|0
6052433|NCT00439270|9652026|FG000|Phase 2 (51.6 Months)|Disease progression|0
6052434|NCT00439270|9652027|FG001|Phase 2 (51.6 Months)|Disease progression|0
6052435|NCT00439270|9652028|FG002|Phase 2 (51.6 Months)|Disease progression|0
6052436|NCT00439270|9652029|FG003|Phase 2 (51.6 Months)|Disease progression|18
6052437|NCT00439270|9652030|FG004|Phase 2 (51.6 Months)|Disease progression|0
6052438|NCT00439270|9652026|FG000|Phase 2 (51.6 Months)|Poor compliance/noncompliance|0
6052439|NCT00439270|9652027|FG001|Phase 2 (51.6 Months)|Poor compliance/noncompliance|0
6052440|NCT00439270|9652028|FG002|Phase 2 (51.6 Months)|Poor compliance/noncompliance|0
6283802|NCT02323113|9995758|FG001|Overall Study|Study Drug was Held due to AE for >21 Days, Therefore Participant was Discontinued Per Protocol|1
6283803|NCT02323113|9995759|FG002|Overall Study|Study Drug was Held due to AE for >21 Days, Therefore Participant was Discontinued Per Protocol|0
6283804|NCT02323113|9995760|FG003|Overall Study|Study Drug was Held due to AE for >21 Days, Therefore Participant was Discontinued Per Protocol|0
6283805|NCT02323113|9995761|FG004|Overall Study|Study Drug was Held due to AE for >21 Days, Therefore Participant was Discontinued Per Protocol|0
6283806|NCT02323113|9995762|FG005|Overall Study|Study Drug was Held due to AE for >21 Days, Therefore Participant was Discontinued Per Protocol|0
6283807|NCT02323113|9995763|FG006|Overall Study|Study Drug was Held due to AE for >21 Days, Therefore Participant was Discontinued Per Protocol|0
6052441|NCT00439270|9652029|FG003|Phase 2 (51.6 Months)|Poor compliance/noncompliance|1
6052442|NCT00439270|9652030|FG004|Phase 2 (51.6 Months)|Poor compliance/noncompliance|0
6052443|NCT00439270|9652026|FG000|Phase 2 (51.6 Months)|Study drug toxicity|0
6052444|NCT00439270|9652027|FG001|Phase 2 (51.6 Months)|Study drug toxicity|0
6052445|NCT00439270|9652028|FG002|Phase 2 (51.6 Months)|Study drug toxicity|0
6052446|NCT00439270|9652029|FG003|Phase 2 (51.6 Months)|Study drug toxicity|6
6089738|NCT00686335|9701537|FG000|Run-in Period|asthma exacerbation|1
6089739|NCT00686335|9701537|FG000|Run-in Period|violation of inclusion/exclusion criteri|3
6089740|NCT00686517|9701546|FG000|Treatment|Serious Adverse Event|1
6089741|NCT00686517|9701547|FG001|Treatment|Serious Adverse Event|2
6089742|NCT00686517|9701548|FG002|Treatment|Serious Adverse Event|1
6089743|NCT00686517|9701546|FG000|Treatment|Adverse Event|2
6089744|NCT00686517|9701547|FG001|Treatment|Adverse Event|0
6089745|NCT00686517|9701548|FG002|Treatment|Adverse Event|0
6089746|NCT00686517|9701546|FG000|Treatment|Poor Protocol Compliance|1
6089747|NCT00686517|9701547|FG001|Treatment|Poor Protocol Compliance|0
6089748|NCT00686517|9701548|FG002|Treatment|Poor Protocol Compliance|0
6089749|NCT00686517|9701546|FG000|Treatment|Protocol Violation|2
6089750|NCT00686517|9701547|FG001|Treatment|Protocol Violation|1
6089751|NCT00686517|9701548|FG002|Treatment|Protocol Violation|0
6089752|NCT00686543|9701560|FG000|Overall Study|Adverse Event|9
6089753|NCT00686543|9701561|FG001|Overall Study|Adverse Event|1
6089754|NCT00686543|9701562|FG002|Overall Study|Adverse Event|3
6089755|NCT00686543|9701563|FG003|Overall Study|Adverse Event|2
6089756|NCT00686543|9701560|FG000|Overall Study|Withdrawal by Subject|2
6089757|NCT00686543|9701561|FG001|Overall Study|Withdrawal by Subject|0
6089758|NCT00686543|9701562|FG002|Overall Study|Withdrawal by Subject|0
6089759|NCT00686543|9701563|FG003|Overall Study|Withdrawal by Subject|0
6089760|NCT00686543|9701560|FG000|Overall Study|Protocol Violation|3
6089761|NCT00686543|9701561|FG001|Overall Study|Protocol Violation|0
6089762|NCT00686543|9701562|FG002|Overall Study|Protocol Violation|2
6089763|NCT00686543|9701563|FG003|Overall Study|Protocol Violation|1
6089764|NCT00686595|9701584|FG000|Overall Study|Adverse Event|3
6089765|NCT00686595|9701584|FG000|Overall Study|Protocol Violation|1
6089766|NCT00686595|9701584|FG000|Overall Study|Lost to Follow-up|1
6089767|NCT00686595|9701584|FG000|Overall Study|Lack of Efficacy|1
6089768|NCT00686595|9701584|FG000|Overall Study|Poor Compliance|1
6089769|NCT00686634|9701588|FG000|Overall Study|Protocol Violation|6
6089770|NCT00686647|9701593|FG000|Overall Study|Lost to Follow-up|1
6089771|NCT00686647|9701593|FG000|Overall Study|Death|1
6089772|NCT00686686|9701598|FG000|Overall Study|Non-compliance|1
6089773|NCT00686686|9701598|FG000|Overall Study|Adverse Event|2
6283808|NCT02323113|9995764|FG007|Overall Study|Study Drug was Held due to AE for >21 Days, Therefore Participant was Discontinued Per Protocol|0
6283809|NCT02323204|9995787|FG000|Baseline Survey Completion|Withdrawal by Subject|10
6283810|NCT02323204|9995788|FG001|Baseline Survey Completion|Withdrawal by Subject|9
6283811|NCT02323204|9995789|FG002|Baseline Survey Completion|Withdrawal by Subject|5
6283812|NCT02323204|9995790|FG003|Baseline Survey Completion|Withdrawal by Subject|3
6283813|NCT02323204|9995787|FG000|6-week Follow-up Survey Completion|Lost to Follow-up|29
6283814|NCT02323204|9995788|FG001|6-week Follow-up Survey Completion|Lost to Follow-up|28
6283815|NCT02323204|9995789|FG002|6-week Follow-up Survey Completion|Lost to Follow-up|39
6283816|NCT02323204|9995790|FG003|6-week Follow-up Survey Completion|Lost to Follow-up|35
6283817|NCT02323204|9995787|FG000|6-week Follow-up Survey Completion|Withdrawal by Subject|12
6283818|NCT02323204|9995788|FG001|6-week Follow-up Survey Completion|Withdrawal by Subject|8
6283819|NCT02323204|9995789|FG002|6-week Follow-up Survey Completion|Withdrawal by Subject|3
6283820|NCT02323204|9995790|FG003|6-week Follow-up Survey Completion|Withdrawal by Subject|2
6283821|NCT02323204|9995787|FG000|6-week Follow-up Intervention Booster|Lost to Follow-up|0
6283822|NCT02323204|9995788|FG001|6-week Follow-up Intervention Booster|Lost to Follow-up|35
6283823|NCT02323204|9995789|FG002|6-week Follow-up Intervention Booster|Lost to Follow-up|0
6283824|NCT02323204|9995790|FG003|6-week Follow-up Intervention Booster|Lost to Follow-up|34
6283825|NCT02323204|9995787|FG000|6-week Follow-up Intervention Booster|Withdrawal by Subject|0
6283826|NCT02323204|9995788|FG001|6-week Follow-up Intervention Booster|Withdrawal by Subject|8
6283827|NCT02323204|9995789|FG002|6-week Follow-up Intervention Booster|Withdrawal by Subject|0
6283828|NCT02323204|9995790|FG003|6-week Follow-up Intervention Booster|Withdrawal by Subject|2
6283829|NCT02323204|9995787|FG000|3-month Follow-up Survey Completion|Lost to Follow-up|54
6283830|NCT02323204|9995788|FG001|3-month Follow-up Survey Completion|Lost to Follow-up|45
6283831|NCT02323204|9995789|FG002|3-month Follow-up Survey Completion|Lost to Follow-up|41
6283832|NCT02323204|9995790|FG003|3-month Follow-up Survey Completion|Lost to Follow-up|42
6283833|NCT02323204|9995787|FG000|3-month Follow-up Survey Completion|Withdrawal by Subject|0
6283834|NCT02323204|9995788|FG001|3-month Follow-up Survey Completion|Withdrawal by Subject|2
6283835|NCT02323204|9995789|FG002|3-month Follow-up Survey Completion|Withdrawal by Subject|0
6283836|NCT02323204|9995790|FG003|3-month Follow-up Survey Completion|Withdrawal by Subject|2
6283837|NCT02323204|9995787|FG000|6-month Follow-up Survey Completion|Lost to Follow-up|49
6283838|NCT02323204|9995788|FG001|6-month Follow-up Survey Completion|Lost to Follow-up|50
6283839|NCT02323204|9995789|FG002|6-month Follow-up Survey Completion|Lost to Follow-up|38
6283840|NCT02323204|9995790|FG003|6-month Follow-up Survey Completion|Lost to Follow-up|43
6283841|NCT02323204|9995787|FG000|6-month Follow-up Survey Completion|Withdrawal by Subject|0
6283842|NCT02323204|9995788|FG001|6-month Follow-up Survey Completion|Withdrawal by Subject|0
6283843|NCT02323204|9995789|FG002|6-month Follow-up Survey Completion|Withdrawal by Subject|3
6283844|NCT02323204|9995790|FG003|6-month Follow-up Survey Completion|Withdrawal by Subject|1
6283845|NCT02323334|9995814|FG000|Period 3|Lost to Follow-up|0
6283846|NCT02323334|9995815|FG001|Period 3|Lost to Follow-up|0
6283847|NCT02323334|9995816|FG002|Period 3|Lost to Follow-up|1
6283848|NCT02323334|9995817|FG003|Period 3|Lost to Follow-up|0
6283849|NCT02323334|9995818|FG004|Period 3|Lost to Follow-up|0
6283850|NCT02323334|9995819|FG005|Period 3|Lost to Follow-up|0
6283851|NCT02323334|9995820|FG006|Period 3|Lost to Follow-up|0
6283852|NCT02323334|9995821|FG007|Period 3|Lost to Follow-up|0
6283853|NCT02323334|9995822|FG008|Period 3|Lost to Follow-up|0
6283854|NCT02323334|9995823|FG009|Period 3|Lost to Follow-up|0
6283855|NCT02323334|9995824|FG010|Period 3|Lost to Follow-up|0
5980314|NCT04015336|9569011|FG000|Overall Study|Participant signed consent and was later deemed a screen failure. Participant was not treated|1
5980315|NCT03920280|9569090|FG000|Overall Study|Adverse Event|2
5980316|NCT03920280|9569091|FG001|Overall Study|Adverse Event|3
5980317|NCT03920280|9569090|FG000|Overall Study|Lost to Follow-up|0
5980318|NCT03920280|9569091|FG001|Overall Study|Lost to Follow-up|1
5980319|NCT03920280|9569090|FG000|Overall Study|Withdrawal by Subject|1
5980320|NCT03920280|9569091|FG001|Overall Study|Withdrawal by Subject|1
5980321|NCT03920280|9569090|FG000|Overall Study|Corneal cylinder greater than 1.00 diopter|0
5980322|NCT03920280|9569091|FG001|Overall Study|Corneal cylinder greater than 1.00 diopter|1
5980323|NCT03913091|9569102|FG000|Overall Study|Lost to Follow-up|18
5980324|NCT03913091|9569103|FG001|Overall Study|Lost to Follow-up|11
6052447|NCT00439270|9652030|FG004|Phase 2 (51.6 Months)|Study drug toxicity|0
6052448|NCT00439270|9652026|FG000|Phase 2 (51.6 Months)|Maximum clinical benefit|0
6052449|NCT00439270|9652027|FG001|Phase 2 (51.6 Months)|Maximum clinical benefit|0
6052450|NCT00439270|9652028|FG002|Phase 2 (51.6 Months)|Maximum clinical benefit|0
6052451|NCT00439270|9652029|FG003|Phase 2 (51.6 Months)|Maximum clinical benefit|3
6052452|NCT00439270|9652030|FG004|Phase 2 (51.6 Months)|Maximum clinical benefit|0
5980325|NCT03913091|9569102|FG000|Overall Study|Required additional meds/surgery|1
5980326|NCT03913091|9569103|FG001|Overall Study|Required additional meds/surgery|2
5980327|NCT03913091|9569102|FG000|Overall Study|Chronic pain/history of substance abuse|1
5980328|NCT03913091|9569103|FG001|Overall Study|Chronic pain/history of substance abuse|1
5980329|NCT03802565|9569114|FG000|Overall Study|Adverse Event|0
5980330|NCT03802565|9569115|FG001|Overall Study|Adverse Event|1
5980331|NCT03802565|9569116|FG002|Overall Study|Adverse Event|2
5980332|NCT03802565|9569117|FG003|Overall Study|Adverse Event|1
5980333|NCT03802565|9569118|FG004|Overall Study|Adverse Event|1
6283856|NCT02323334|9995825|FG011|Period 3|Lost to Follow-up|0
6283857|NCT02323334|9995826|FG012|Period 3|Lost to Follow-up|0
6283858|NCT02323334|9995827|FG013|Period 3|Lost to Follow-up|0
6283859|NCT02323334|9995828|FG014|Period 3|Lost to Follow-up|0
6283860|NCT02323334|9995829|FG015|Period 3|Lost to Follow-up|0
6283861|NCT02323334|9995830|FG016|Period 3|Lost to Follow-up|0
6283862|NCT02323334|9995814|FG000|Period 3|Withdrawal by Subject|1
6283863|NCT02323334|9995815|FG001|Period 3|Withdrawal by Subject|0
6283864|NCT02323334|9995816|FG002|Period 3|Withdrawal by Subject|0
6283865|NCT02323334|9995817|FG003|Period 3|Withdrawal by Subject|0
6283866|NCT02323334|9995818|FG004|Period 3|Withdrawal by Subject|0
6283867|NCT02323334|9995819|FG005|Period 3|Withdrawal by Subject|0
6283868|NCT02323334|9995820|FG006|Period 3|Withdrawal by Subject|0
6283869|NCT02323334|9995821|FG007|Period 3|Withdrawal by Subject|0
6283870|NCT02323334|9995822|FG008|Period 3|Withdrawal by Subject|0
6283871|NCT02323334|9995823|FG009|Period 3|Withdrawal by Subject|0
6283872|NCT02323334|9995824|FG010|Period 3|Withdrawal by Subject|0
6283873|NCT02323334|9995825|FG011|Period 3|Withdrawal by Subject|0
6052453|NCT00439270|9652026|FG000|Phase 2 (51.6 Months)|No longer meets study criteria|0
6052454|NCT00439270|9652027|FG001|Phase 2 (51.6 Months)|No longer meets study criteria|0
6052455|NCT00439270|9652028|FG002|Phase 2 (51.6 Months)|No longer meets study criteria|0
6052456|NCT00439270|9652029|FG003|Phase 2 (51.6 Months)|No longer meets study criteria|1
6052457|NCT00439270|9652030|FG004|Phase 2 (51.6 Months)|No longer meets study criteria|0
6052458|NCT00439270|9652026|FG000|Phase 2 (51.6 Months)|Withdrawal by Subject|0
6052459|NCT00439270|9652027|FG001|Phase 2 (51.6 Months)|Withdrawal by Subject|0
6052460|NCT00439270|9652028|FG002|Phase 2 (51.6 Months)|Withdrawal by Subject|0
6052461|NCT00439270|9652029|FG003|Phase 2 (51.6 Months)|Withdrawal by Subject|2
6052462|NCT00439270|9652030|FG004|Phase 2 (51.6 Months)|Withdrawal by Subject|0
6052463|NCT00439270|9652026|FG000|Phase 2 (51.6 Months)|Adverse event unrelated to study drug|0
6052464|NCT00439270|9652027|FG001|Phase 2 (51.6 Months)|Adverse event unrelated to study drug|0
6052465|NCT00439270|9652028|FG002|Phase 2 (51.6 Months)|Adverse event unrelated to study drug|0
6052466|NCT00439270|9652029|FG003|Phase 2 (51.6 Months)|Adverse event unrelated to study drug|2
6052467|NCT00439270|9652030|FG004|Phase 2 (51.6 Months)|Adverse event unrelated to study drug|0
6052468|NCT00439270|9652026|FG000|Phase 2 (51.6 Months)|Insurance no longer covered patient care|0
6052469|NCT00439270|9652027|FG001|Phase 2 (51.6 Months)|Insurance no longer covered patient care|0
6052470|NCT00439270|9652028|FG002|Phase 2 (51.6 Months)|Insurance no longer covered patient care|0
6052471|NCT00439270|9652029|FG003|Phase 2 (51.6 Months)|Insurance no longer covered patient care|1
6052472|NCT00439270|9652030|FG004|Phase 2 (51.6 Months)|Insurance no longer covered patient care|0
6052473|NCT00439309|9652060|FG000|Follow-Up|Death|1
6052474|NCT00439309|9652061|FG001|Follow-Up|Death|0
6052475|NCT00439309|9652060|FG000|Follow-Up|Lost to Follow-up|2
6052476|NCT00439309|9652061|FG001|Follow-Up|Lost to Follow-up|0
6052477|NCT00439309|9652060|FG000|Follow-Up|Withdrawal by Subject|0
6052478|NCT00439309|9652061|FG001|Follow-Up|Withdrawal by Subject|1
6052479|NCT00439309|9652060|FG000|Follow-Up|Late response by subject|0
6052480|NCT00439309|9652061|FG001|Follow-Up|Late response by subject|1
6052481|NCT00439517|9652105|FG000|Overall Study|Subject on treatment|1
6052482|NCT00439517|9652106|FG001|Overall Study|Subject on treatment|0
6052483|NCT00439517|9652105|FG000|Overall Study|Subject in survival follow-up|1
6052484|NCT00439517|9652106|FG001|Overall Study|Subject in survival follow-up|0
6089774|NCT00686686|9701598|FG000|Overall Study|Lost to Follow-up|3
6089775|NCT00686699|9701604|FG000|Treatment Period 1|Adverse Event|0
6089776|NCT00686699|9701605|FG001|Treatment Period 1|Adverse Event|2
6089777|NCT00686712|9701614|FG000|Overall Study|Protocol Violation|8
6089778|NCT00686712|9701615|FG001|Overall Study|Protocol Violation|8
6089779|NCT00686712|9701616|FG002|Overall Study|Protocol Violation|10
6089780|NCT00686712|9701614|FG000|Overall Study|Lost to Follow-up|1
6089781|NCT00686712|9701615|FG001|Overall Study|Lost to Follow-up|2
6089782|NCT00686712|9701616|FG002|Overall Study|Lost to Follow-up|3
6089783|NCT00686712|9701614|FG000|Overall Study|Adverse Event|1
6089784|NCT00686712|9701615|FG001|Overall Study|Adverse Event|1
6089785|NCT00686712|9701616|FG002|Overall Study|Adverse Event|0
6089786|NCT00686725|9701629|FG000|Overall Study|Adverse Event|1
6089787|NCT00686725|9701630|FG001|Overall Study|Adverse Event|1
6089788|NCT00686725|9701629|FG000|Overall Study|Progressive Disease|17
6089789|NCT00686725|9701630|FG001|Overall Study|Progressive Disease|23
6089790|NCT00686725|9701629|FG000|Overall Study|Lost to Follow-up|7
6089791|NCT00686725|9701630|FG001|Overall Study|Lost to Follow-up|5
6089792|NCT00686725|9701629|FG000|Overall Study|Death|6
6089793|NCT00686725|9701630|FG001|Overall Study|Death|3
6089794|NCT00686725|9701629|FG000|Overall Study|Withdrawal by Subject|13
6089795|NCT00686725|9701630|FG001|Overall Study|Withdrawal by Subject|4
6089796|NCT00686725|9701629|FG000|Overall Study|Protocol Violation|1
6089797|NCT00686725|9701630|FG001|Overall Study|Protocol Violation|3
6089798|NCT00686725|9701629|FG000|Overall Study|Other|1
6283874|NCT02323334|9995826|FG012|Period 3|Withdrawal by Subject|0
6283875|NCT02323334|9995827|FG013|Period 3|Withdrawal by Subject|0
6283876|NCT02323334|9995828|FG014|Period 3|Withdrawal by Subject|0
6283877|NCT02323334|9995829|FG015|Period 3|Withdrawal by Subject|0
6089799|NCT00686725|9701630|FG001|Overall Study|Other|3
6089800|NCT00686777|9701636|FG000|Overall Study|Adverse Event|2
6283878|NCT02323334|9995830|FG016|Period 3|Withdrawal by Subject|0
6283879|NCT02323646|9995895|FG000|Treatment Course 1|Adverse Event|1
6283880|NCT02323646|9995896|FG001|Treatment Course 1|Adverse Event|0
6283881|NCT02323646|9995897|FG002|Treatment Course 1|Adverse Event|1
6283882|NCT02323646|9995895|FG000|Treatment Course 1|Heavy Bleeding|1
6283883|NCT02323646|9995896|FG001|Treatment Course 1|Heavy Bleeding|1
6283884|NCT02323646|9995897|FG002|Treatment Course 1|Heavy Bleeding|0
6283885|NCT02323646|9995895|FG000|Treatment Course 1|Lost to Follow-up|1
6283886|NCT02323646|9995896|FG001|Treatment Course 1|Lost to Follow-up|0
6283887|NCT02323646|9995897|FG002|Treatment Course 1|Lost to Follow-up|2
6283888|NCT02323646|9995895|FG000|Treatment Course 1|Withdrawal by Subject|0
6283889|NCT02323646|9995896|FG001|Treatment Course 1|Withdrawal by Subject|2
6283890|NCT02323646|9995897|FG002|Treatment Course 1|Withdrawal by Subject|0
6283891|NCT02323646|9995895|FG000|Treatment Course 2|Adverse Event|1
6283892|NCT02323646|9995896|FG001|Treatment Course 2|Adverse Event|0
6283893|NCT02323646|9995897|FG002|Treatment Course 2|Adverse Event|1
6283894|NCT02323646|9995895|FG000|Treatment Course 2|Lost to Follow-up|0
6283895|NCT02323646|9995896|FG001|Treatment Course 2|Lost to Follow-up|0
6283896|NCT02323646|9995897|FG002|Treatment Course 2|Lost to Follow-up|1
6283897|NCT02323646|9995895|FG000|Treatment Course 2|Non-compliance|0
6283898|NCT02323646|9995896|FG001|Treatment Course 2|Non-compliance|1
6283899|NCT02323646|9995897|FG002|Treatment Course 2|Non-compliance|1
6283900|NCT02324049|9995909|FG000|Part C|Study terminated|11
6052485|NCT00439556|9652115|FG000|Overall Study|Patient was taken off study for non-comp|0
6052486|NCT00439556|9652116|FG001|Overall Study|Patient was taken off study for non-comp|1
6052487|NCT00439556|9652117|FG002|Overall Study|Patient was taken off study for non-comp|0
6052488|NCT00439647|9652132|FG000|Overall Study|Withdrawal by Subject|25
6052489|NCT00439647|9652133|FG001|Overall Study|Withdrawal by Subject|22
6052490|NCT00439647|9652132|FG000|Overall Study|Death|15
6052491|NCT00439647|9652133|FG001|Overall Study|Death|18
6052492|NCT00439647|9652132|FG000|Overall Study|Adverse Event|11
6052493|NCT00439647|9652133|FG001|Overall Study|Adverse Event|11
6052494|NCT00439647|9652132|FG000|Overall Study|Lost to Follow-up|4
6052495|NCT00439647|9652133|FG001|Overall Study|Lost to Follow-up|12
6052496|NCT00439647|9652132|FG000|Overall Study|Protocol Violation|3
6052497|NCT00439647|9652133|FG001|Overall Study|Protocol Violation|4
6052498|NCT00439647|9652132|FG000|Overall Study|Lack of Efficacy|0
6052499|NCT00439647|9652133|FG001|Overall Study|Lack of Efficacy|4
6052500|NCT00439725|9652145|FG000|Treatment Period|Withdrawal by Subject|22
6052501|NCT00439725|9652146|FG001|Treatment Period|Withdrawal by Subject|19
6052502|NCT00439725|9652145|FG000|Treatment Period|Study terminated by sponsor|156
6052503|NCT00439725|9652146|FG001|Treatment Period|Study terminated by sponsor|148
6052504|NCT00439725|9652145|FG000|Treatment Period|Site closed by investigator|1
6052505|NCT00439725|9652146|FG001|Treatment Period|Site closed by investigator|2
6052506|NCT00439725|9652145|FG000|Treatment Period|Adverse Event|39
6052507|NCT00439725|9652146|FG001|Treatment Period|Adverse Event|18
6052508|NCT00439725|9652145|FG000|Treatment Period|Physician Decision|1
6052509|NCT00439725|9652146|FG001|Treatment Period|Physician Decision|1
6052510|NCT00439725|9652145|FG000|Treatment Period|Protocol Violation|2
6052511|NCT00439725|9652146|FG001|Treatment Period|Protocol Violation|1
6052512|NCT00439725|9652145|FG000|Treatment Period|Clinical endpoint reached|6
6052513|NCT00439725|9652146|FG001|Treatment Period|Clinical endpoint reached|50
6052514|NCT00439725|9652145|FG000|Treatment Period|Technical problems|1
6052515|NCT00439725|9652146|FG001|Treatment Period|Technical problems|0
6052516|NCT00439725|9652145|FG000|Treatment Period|Lost to Follow-up|1
6089801|NCT00686777|9701636|FG000|Overall Study|Pregnancy|1
6089802|NCT00686777|9701636|FG000|Overall Study|Withdrawal by Subject|2
6089803|NCT00686777|9701636|FG000|Overall Study|Discontinuance Criteria (specified AEs)|4
6089804|NCT00686777|9701636|FG000|Overall Study|No Visit|1
6089805|NCT00686790|9701640|FG000|Overall Study|Adverse Event|2
6089806|NCT00686790|9701640|FG000|Overall Study|Withdrawal by Subject|1
6089807|NCT00686790|9701640|FG000|Overall Study|Death|1
6089808|NCT00686790|9701640|FG000|Overall Study|Lost to Follow-up|12
6089809|NCT00686829|9701657|FG000|Overall Study|Adverse Event|5
6089810|NCT00686829|9701657|FG000|Overall Study|Lack of Efficacy|6
6089811|NCT00686829|9701657|FG000|Overall Study|Lost to Follow-up|4
6089812|NCT00686829|9701657|FG000|Overall Study|Withdrawal by Subject|14
6089813|NCT00686829|9701657|FG000|Overall Study|Protocol Violation|3
6089814|NCT00686829|9701657|FG000|Overall Study|Sponsor discontinued VCV|47
6052517|NCT00439725|9652146|FG001|Treatment Period|Lost to Follow-up|1
6052518|NCT00439725|9652145|FG000|Treatment Period|Participant convenience|1
6052519|NCT00439725|9652146|FG001|Treatment Period|Participant convenience|0
6052520|NCT00439725|9652145|FG000|Treatment Period|Protocol driven decision point|1
6052521|NCT00439725|9652146|FG001|Treatment Period|Protocol driven decision point|1
6052522|NCT00439725|9652145|FG000|Treatment Period|Death|1
6089815|NCT00686855|9701667|FG000|Overall Study|Lost to Follow-up|1
6089816|NCT00686855|9701668|FG001|Overall Study|Lost to Follow-up|0
6052523|NCT00439725|9652146|FG001|Treatment Period|Death|1
6089817|NCT00686855|9701667|FG000|Overall Study|Progressive GVHD|0
6283901|NCT02324153|9995925|FG000|Overall Study|Withdrawal by Subject|4
6283902|NCT02324153|9995926|FG001|Overall Study|Withdrawal by Subject|1
6283903|NCT02324153|9995925|FG000|Overall Study|Surgery postponed after randomization|3
6283904|NCT02324153|9995926|FG001|Overall Study|Surgery postponed after randomization|0
6283905|NCT02324153|9995925|FG000|Overall Study|Developed delirium preoperatively|1
6283906|NCT02324153|9995926|FG001|Overall Study|Developed delirium preoperatively|0
6283907|NCT02324205|9995932|FG000|Overall Study|Withdrawal by Subject|37
6283908|NCT02324270|9995939|FG000|Overall Study|Withdrawal by Subject|0
6283909|NCT02324270|9995940|FG001|Overall Study|Withdrawal by Subject|1
6283910|NCT02324270|9995941|FG002|Overall Study|Withdrawal by Subject|0
6283911|NCT02324270|9995939|FG000|Overall Study|Lost to Follow-up|4
6283912|NCT02324270|9995940|FG001|Overall Study|Lost to Follow-up|3
6283913|NCT02324270|9995941|FG002|Overall Study|Lost to Follow-up|4
6283914|NCT02324270|9995939|FG000|Overall Study|Protocol Violation|0
6283915|NCT02324270|9995940|FG001|Overall Study|Protocol Violation|1
6283916|NCT02324270|9995941|FG002|Overall Study|Protocol Violation|1
6052524|NCT00439725|9652145|FG000|Treatment Period|Participant did not receive treatment|4
6052525|NCT00439725|9652146|FG001|Treatment Period|Participant did not receive treatment|4
6052526|NCT00439725|9652145|FG000|Observational Period|Withdrawal by Subject|2
6052527|NCT00439725|9652146|FG001|Observational Period|Withdrawal by Subject|2
6052528|NCT00439725|9652145|FG000|Observational Period|Lost to Follow-up|0
6052529|NCT00439725|9652146|FG001|Observational Period|Lost to Follow-up|1
6052530|NCT00439725|9652145|FG000|Observational Period|Death|0
6052531|NCT00439725|9652146|FG001|Observational Period|Death|2
6052532|NCT00439725|9652145|FG000|Observational Period|Study termination by sponsor|1
6052533|NCT00439725|9652146|FG001|Observational Period|Study termination by sponsor|1
6052534|NCT00439725|9652145|FG000|Observational Period|Clinical endpoint reached|3
6052535|NCT00439725|9652146|FG001|Observational Period|Clinical endpoint reached|1
6052536|NCT00439725|9652145|FG000|Observational Period|Technical problems|1
6052537|NCT00439725|9652146|FG001|Observational Period|Technical problems|0
6052538|NCT00439725|9652145|FG000|Observational Period|Participant convenience|1
6052539|NCT00439725|9652146|FG001|Observational Period|Participant convenience|0
6052540|NCT00439777|9652154|FG000|Treatment Period|Death|29
6052541|NCT00439777|9652155|FG001|Treatment Period|Death|21
6052542|NCT00439777|9652154|FG000|Treatment Period|Study terminated by sponsor|125
6052543|NCT00439777|9652155|FG001|Treatment Period|Study terminated by sponsor|132
6052544|NCT00439777|9652154|FG000|Treatment Period|Site closed by investigator|0
6052545|NCT00439777|9652155|FG001|Treatment Period|Site closed by investigator|1
6052546|NCT00439777|9652154|FG000|Treatment Period|Did not take study treatment|7
6052547|NCT00439777|9652155|FG001|Treatment Period|Did not take study treatment|8
6052548|NCT00439777|9652154|FG000|Treatment Period|Adverse Event|111
6052549|NCT00439777|9652155|FG001|Treatment Period|Adverse Event|92
6052550|NCT00439777|9652154|FG000|Treatment Period|Protocol Violation|23
6052551|NCT00439777|9652155|FG001|Treatment Period|Protocol Violation|30
6052552|NCT00439777|9652154|FG000|Treatment Period|Withdrawal by Subject|66
6052553|NCT00439777|9652155|FG001|Treatment Period|Withdrawal by Subject|118
6052554|NCT00439777|9652154|FG000|Treatment Period|Lack of Efficacy|1
6052555|NCT00439777|9652155|FG001|Treatment Period|Lack of Efficacy|4
6052556|NCT00439777|9652154|FG000|Treatment Period|Lost to Follow-up|8
6052557|NCT00439777|9652155|FG001|Treatment Period|Lost to Follow-up|10
6052558|NCT00439777|9652154|FG000|Treatment Period|Protocol driven decision point|1
6052559|NCT00439777|9652155|FG001|Treatment Period|Protocol driven decision point|3
6052560|NCT00439777|9652154|FG000|Treatment Period|Physician Decision|7
6052561|NCT00439777|9652155|FG001|Treatment Period|Physician Decision|18
6052562|NCT00439777|9652154|FG000|Treatment Period|Clinical endpoint reached|26
6052563|NCT00439777|9652155|FG001|Treatment Period|Clinical endpoint reached|13
6052564|NCT00439777|9652154|FG000|Treatment Period|Technical problems|3
6052565|NCT00439777|9652155|FG001|Treatment Period|Technical problems|1
6052566|NCT00439777|9652154|FG000|Treatment Period|Participant convenience|12
6052567|NCT00439777|9652155|FG001|Treatment Period|Participant convenience|8
6052568|NCT00439777|9652154|FG000|Observational Period|Protocol Violation|0
6052569|NCT00439777|9652155|FG001|Observational Period|Protocol Violation|2
6052570|NCT00439777|9652154|FG000|Observational Period|Withdrawal by Subject|9
6052571|NCT00439777|9652155|FG001|Observational Period|Withdrawal by Subject|5
6052572|NCT00439777|9652154|FG000|Observational Period|Lost to Follow-up|1
6052573|NCT00439777|9652155|FG001|Observational Period|Lost to Follow-up|11
6052574|NCT00439777|9652154|FG000|Observational Period|Death|27
6052575|NCT00439777|9652155|FG001|Observational Period|Death|20
6089818|NCT00686855|9701668|FG001|Overall Study|Progressive GVHD|1
6052576|NCT00439777|9652154|FG000|Observational Period|Study terminated by sponsor|3
6052577|NCT00439777|9652155|FG001|Observational Period|Study terminated by sponsor|1
6052578|NCT00439777|9652154|FG000|Observational Period|Protocol driven decision point|0
6052579|NCT00439777|9652155|FG001|Observational Period|Protocol driven decision point|1
6052580|NCT00439777|9652154|FG000|Observational Period|Lack of Efficacy|1
6052581|NCT00439777|9652155|FG001|Observational Period|Lack of Efficacy|0
6052582|NCT00439777|9652154|FG000|Observational Period|Technical problems|0
6052583|NCT00439777|9652155|FG001|Observational Period|Technical problems|1
6283917|NCT02324270|9995939|FG000|Overall Study|Non Compliance with Study Drug|1
6283918|NCT02324270|9995940|FG001|Overall Study|Non Compliance with Study Drug|2
6283919|NCT02324270|9995941|FG002|Overall Study|Non Compliance with Study Drug|0
6283920|NCT02324361|9995960|FG000|Overall Study|Lost to Follow-up|5
6283921|NCT02324361|9995961|FG001|Overall Study|Lost to Follow-up|2
6283922|NCT02324465|9995969|FG000|Overall Study|device failure|0
6283923|NCT02324465|9995970|FG001|Overall Study|device failure|1
6283924|NCT02324569|9996006|FG000|Overall Study|Pretreatment Event/Adverse Event|9
6283925|NCT02324569|9996007|FG001|Overall Study|Pretreatment Event/Adverse Event|10
6283926|NCT02324569|9996006|FG000|Overall Study|Voluntary Withdrawal|3
6283927|NCT02324569|9996007|FG001|Overall Study|Voluntary Withdrawal|6
6283928|NCT02324569|9996006|FG000|Overall Study|Lack of Efficacy|2
6283929|NCT02324569|9996007|FG001|Overall Study|Lack of Efficacy|3
6283930|NCT02324569|9996006|FG000|Overall Study|Change Insulin Dosage Exceeding Criteria|0
6283931|NCT02324569|9996007|FG001|Overall Study|Change Insulin Dosage Exceeding Criteria|2
6283932|NCT02324569|9996006|FG000|Overall Study|Inconvenient Schedule|2
6283933|NCT02324569|9996007|FG001|Overall Study|Inconvenient Schedule|0
6283934|NCT02324699|9996031|FG000|Overall Study|study terminated|1
6283935|NCT02324842|9996038|FG000|Overall Study|Lost to Follow-up|1
6283936|NCT02324842|9996039|FG001|Overall Study|Lost to Follow-up|1
6283937|NCT02324842|9996040|FG002|Overall Study|Lost to Follow-up|2
6283938|NCT02325219|9996069|FG000|Controlled Period (Week 0 - 16)|Adverse Event|6
6283939|NCT02325219|9996070|FG001|Controlled Period (Week 0 - 16)|Adverse Event|1
6283940|NCT02325219|9996071|FG002|Controlled Period (Week 0 - 16)|Adverse Event|0
6283941|NCT02325219|9996072|FG003|Controlled Period (Week 0 - 16)|Adverse Event|0
6283942|NCT02325219|9996073|FG004|Controlled Period (Week 0 - 16)|Adverse Event|0
6283943|NCT02325219|9996069|FG000|Controlled Period (Week 0 - 16)|Withdrawal by Subject|6
6283944|NCT02325219|9996070|FG001|Controlled Period (Week 0 - 16)|Withdrawal by Subject|1
6283945|NCT02325219|9996071|FG002|Controlled Period (Week 0 - 16)|Withdrawal by Subject|0
6283946|NCT02325219|9996072|FG003|Controlled Period (Week 0 - 16)|Withdrawal by Subject|0
6283947|NCT02325219|9996073|FG004|Controlled Period (Week 0 - 16)|Withdrawal by Subject|0
6283948|NCT02325219|9996069|FG000|Controlled Period (Week 0 - 16)|Other|0
6283949|NCT02325219|9996070|FG001|Controlled Period (Week 0 - 16)|Other|0
6283950|NCT02325219|9996071|FG002|Controlled Period (Week 0 - 16)|Other|1
6283951|NCT02325219|9996072|FG003|Controlled Period (Week 0 - 16)|Other|0
6283952|NCT02325219|9996073|FG004|Controlled Period (Week 0 - 16)|Other|0
6283953|NCT02325219|9996069|FG000|After Controlled Period (Week 16 - 52)|Adverse Event|0
6283954|NCT02325219|9996070|FG001|After Controlled Period (Week 16 - 52)|Adverse Event|0
6283955|NCT02325219|9996071|FG002|After Controlled Period (Week 16 - 52)|Adverse Event|0
6283956|NCT02325219|9996072|FG003|After Controlled Period (Week 16 - 52)|Adverse Event|0
6283957|NCT02325219|9996073|FG004|After Controlled Period (Week 16 - 52)|Adverse Event|1
6283958|NCT02325219|9996069|FG000|After Controlled Period (Week 16 - 52)|Withdrawal by Subject|0
6283959|NCT02325219|9996070|FG001|After Controlled Period (Week 16 - 52)|Withdrawal by Subject|2
6283960|NCT02325219|9996071|FG002|After Controlled Period (Week 16 - 52)|Withdrawal by Subject|0
6283961|NCT02325219|9996072|FG003|After Controlled Period (Week 16 - 52)|Withdrawal by Subject|0
6283962|NCT02325219|9996073|FG004|After Controlled Period (Week 16 - 52)|Withdrawal by Subject|0
6283963|NCT02325219|9996069|FG000|After Controlled Period (Week 16 - 52)|Pregnancy|0
6283964|NCT02325219|9996070|FG001|After Controlled Period (Week 16 - 52)|Pregnancy|1
6283965|NCT02325219|9996071|FG002|After Controlled Period (Week 16 - 52)|Pregnancy|0
6283966|NCT02325219|9996072|FG003|After Controlled Period (Week 16 - 52)|Pregnancy|0
6283967|NCT02325219|9996073|FG004|After Controlled Period (Week 16 - 52)|Pregnancy|0
6283968|NCT02325401|9996089|FG000|Overall Study|Withdrawal by Subject|0
6283969|NCT02325401|9996090|FG001|Overall Study|Withdrawal by Subject|1
6283970|NCT02325401|9996091|FG002|Overall Study|Withdrawal by Subject|1
6283971|NCT02325414|9996107|FG000|Overall Study|Withdrawal by Subject|3
6283972|NCT02325414|9996108|FG001|Overall Study|Withdrawal by Subject|1
6052584|NCT00440011|9652167|FG000|Overall Study|Adverse Event|2
6052585|NCT00440011|9652168|FG001|Overall Study|Adverse Event|0
6052586|NCT00440011|9652167|FG000|Overall Study|Lost to Follow-up|0
6052587|NCT00440011|9652168|FG001|Overall Study|Lost to Follow-up|2
6052588|NCT00440011|9652167|FG000|Overall Study|Protocol Violation|1
6052589|NCT00440011|9652168|FG001|Overall Study|Protocol Violation|1
6052590|NCT00440011|9652167|FG000|Overall Study|Withdrawal by Subject|1
6052591|NCT00440011|9652168|FG001|Overall Study|Withdrawal by Subject|0
6052592|NCT00440037|9652174|FG000|Overall Study|Withdrawal by Subject|6
6052593|NCT00440037|9652174|FG000|Overall Study|Administrative decision|3
6052594|NCT00440115|9652190|FG000|Overall Study|Death|7
6052595|NCT00440115|9652191|FG001|Overall Study|Death|9
6052596|NCT00440115|9652192|FG002|Overall Study|Death|5
6052597|NCT00440115|9652190|FG000|Overall Study|Incarceration|0
6052598|NCT00440115|9652191|FG001|Overall Study|Incarceration|2
6052599|NCT00440115|9652192|FG002|Overall Study|Incarceration|1
6052600|NCT00440193|9652211|FG000|Treatment Period|Adverse Event|74
6089819|NCT00686881|9701676|FG000|Overall Study|Withdrawal by Subject|11
6052601|NCT00440193|9652212|FG001|Treatment Period|Adverse Event|67
6052602|NCT00440193|9652211|FG000|Treatment Period|Death|19
6052603|NCT00440193|9652212|FG001|Treatment Period|Death|22
6052604|NCT00440193|9652211|FG000|Treatment Period|Lack of Efficacy|0
6052605|NCT00440193|9652212|FG001|Treatment Period|Lack of Efficacy|1
6052606|NCT00440193|9652211|FG000|Treatment Period|Lost to Follow-up|12
6052607|NCT00440193|9652212|FG001|Treatment Period|Lost to Follow-up|18
6283973|NCT02325414|9996107|FG000|Overall Study|Lost to Follow-up|5
6283974|NCT02325414|9996108|FG001|Overall Study|Lost to Follow-up|5
6052608|NCT00440193|9652211|FG000|Treatment Period|Physician Decision|3
6052609|NCT00440193|9652212|FG001|Treatment Period|Physician Decision|6
6052610|NCT00440193|9652211|FG000|Treatment Period|Protocol Violation|16
6052611|NCT00440193|9652212|FG001|Treatment Period|Protocol Violation|19
6052612|NCT00440193|9652211|FG000|Treatment Period|Withdrawal by Subject|36
6052613|NCT00440193|9652212|FG001|Treatment Period|Withdrawal by Subject|77
6052614|NCT00440193|9652211|FG000|Treatment Period|Clinical endpoint reached|28
6052615|NCT00440193|9652212|FG001|Treatment Period|Clinical endpoint reached|25
6052616|NCT00440193|9652211|FG000|Treatment Period|Study terminated by sponsor|102
6052617|NCT00440193|9652212|FG001|Treatment Period|Study terminated by sponsor|94
6052618|NCT00440193|9652211|FG000|Treatment Period|Protocol driven decision point|2
6052619|NCT00440193|9652212|FG001|Treatment Period|Protocol driven decision point|2
6052620|NCT00440193|9652211|FG000|Treatment Period|Switch to commercial drug|0
6052621|NCT00440193|9652212|FG001|Treatment Period|Switch to commercial drug|2
6052622|NCT00440193|9652211|FG000|Treatment Period|Technical problems|1
6052623|NCT00440193|9652212|FG001|Treatment Period|Technical problems|1
6052624|NCT00440193|9652211|FG000|Treatment Period|Participant convenience|5
6052625|NCT00440193|9652212|FG001|Treatment Period|Participant convenience|2
6052626|NCT00440193|9652211|FG000|Treatment Period|Participant did not receive treatment|7
6089820|NCT00686881|9701677|FG001|Overall Study|Withdrawal by Subject|18
6089821|NCT00686881|9701676|FG000|Overall Study|Lost to Follow-up|0
6089822|NCT00686881|9701677|FG001|Overall Study|Lost to Follow-up|1
6089823|NCT00686881|9701676|FG000|Overall Study|Treatment-related adverse event|10
6089824|NCT00686881|9701677|FG001|Overall Study|Treatment-related adverse event|9
6089825|NCT00686881|9701676|FG000|Overall Study|Met discontinuation criteria|5
6089826|NCT00686881|9701677|FG001|Overall Study|Met discontinuation criteria|0
6089827|NCT00686881|9701676|FG000|Overall Study|Onset of malignant tumor|11
6089828|NCT00686881|9701677|FG001|Overall Study|Onset of malignant tumor|11
6089829|NCT00686881|9701676|FG000|Overall Study|Lack of Efficacy|4
6089830|NCT00686881|9701677|FG001|Overall Study|Lack of Efficacy|3
6089831|NCT00686881|9701676|FG000|Overall Study|Physician Decision|1
6089832|NCT00686881|9701677|FG001|Overall Study|Physician Decision|0
6089833|NCT00686881|9701676|FG000|Overall Study|Circumstances of site|1
6089834|NCT00686881|9701677|FG001|Overall Study|Circumstances of site|1
6089835|NCT00686881|9701676|FG000|Overall Study|Did not meet protocol eligibility|1
6089836|NCT00686881|9701677|FG001|Overall Study|Did not meet protocol eligibility|0
6089837|NCT00686881|9701676|FG000|Overall Study|Irregular visits|1
6089838|NCT00686881|9701677|FG001|Overall Study|Irregular visits|0
6089839|NCT00686881|9701676|FG000|Overall Study|Study discontinuation|35
6089840|NCT00686881|9701677|FG001|Overall Study|Study discontinuation|32
6089841|NCT00686881|9701676|FG000|Overall Study|Never received study drug|2
6089842|NCT00686881|9701677|FG001|Overall Study|Never received study drug|6
6089843|NCT00686894|9701685|FG000|Overall Study|Relapse|2
6089844|NCT00686894|9701685|FG000|Overall Study|Protocol Violation|4
6089845|NCT00686920|9701691|FG000|Overall Study|Death|45
6089846|NCT00686920|9701692|FG001|Overall Study|Death|14
6089847|NCT00686920|9701691|FG000|Overall Study|Liver Transplant|23
6089848|NCT00686920|9701692|FG001|Overall Study|Liver Transplant|8
6089849|NCT00686920|9701691|FG000|Overall Study|Recurrent Hepatic Encephalopathy Episode|1
6089850|NCT00686920|9701692|FG001|Overall Study|Recurrent Hepatic Encephalopathy Episode|2
6089851|NCT00686920|9701691|FG000|Overall Study|Withdrawal by Subject|23
6283975|NCT02325518|9996118|FG000|Overall Study|Adverse Event|4
6283976|NCT02325518|9996119|FG001|Overall Study|Adverse Event|1
6283977|NCT02325518|9996118|FG000|Overall Study|Physician Decision|0
6283978|NCT02325518|9996119|FG001|Overall Study|Physician Decision|1
6283979|NCT02325518|9996118|FG000|Overall Study|Withdrawal by Subject|0
6283980|NCT02325518|9996119|FG001|Overall Study|Withdrawal by Subject|1
6283981|NCT02325713|9996155|FG000|Intervention Period 1 (2 Days)|Protocol Non-Compliance|0
6283982|NCT02325713|9996156|FG001|Intervention Period 1 (2 Days)|Protocol Non-Compliance|0
6283983|NCT02325713|9996157|FG002|Intervention Period 1 (2 Days)|Protocol Non-Compliance|0
6283984|NCT02325713|9996158|FG003|Intervention Period 1 (2 Days)|Protocol Non-Compliance|0
6283985|NCT02325713|9996159|FG004|Intervention Period 1 (2 Days)|Protocol Non-Compliance|0
6283986|NCT02325713|9996160|FG005|Intervention Period 1 (2 Days)|Protocol Non-Compliance|0
6052627|NCT00440193|9652212|FG001|Treatment Period|Participant did not receive treatment|13
6052628|NCT00440193|9652211|FG000|Treatment Period|Site closed by investigator|0
6052629|NCT00440193|9652212|FG001|Treatment Period|Site closed by investigator|2
6052630|NCT00440193|9652211|FG000|Observational Period|Adverse Event|2
6052631|NCT00440193|9652212|FG001|Observational Period|Adverse Event|2
6052632|NCT00440193|9652211|FG000|Observational Period|Death|15
6052633|NCT00440193|9652212|FG001|Observational Period|Death|20
6052634|NCT00440193|9652211|FG000|Observational Period|Lost to Follow-up|12
6089852|NCT00686920|9701692|FG001|Overall Study|Withdrawal by Subject|5
6089853|NCT00686920|9701691|FG000|Overall Study|Protocol Violation|2
6052635|NCT00440193|9652212|FG001|Observational Period|Lost to Follow-up|8
6052636|NCT00440193|9652211|FG000|Observational Period|Protocol Violation|1
6052637|NCT00440193|9652212|FG001|Observational Period|Protocol Violation|0
6089854|NCT00686920|9701692|FG001|Overall Study|Protocol Violation|1
6052638|NCT00440193|9652211|FG000|Observational Period|Withdrawal by Subject|11
6089855|NCT00686920|9701691|FG000|Overall Study|Adverse Event|10
6089856|NCT00686920|9701692|FG001|Overall Study|Adverse Event|2
6089857|NCT00686920|9701691|FG000|Overall Study|Personal Reason|0
6089858|NCT00686920|9701692|FG001|Overall Study|Personal Reason|1
6089859|NCT00686920|9701691|FG000|Overall Study|Lost to Follow-up|15
6089860|NCT00686920|9701692|FG001|Overall Study|Lost to Follow-up|3
6089861|NCT00686920|9701691|FG000|Overall Study|Moved to Another State|1
6089862|NCT00686920|9701692|FG001|Overall Study|Moved to Another State|0
6089863|NCT00686920|9701691|FG000|Overall Study|Transferred to Nursing Home|1
6089864|NCT00686920|9701692|FG001|Overall Study|Transferred to Nursing Home|0
6089865|NCT00686920|9701691|FG000|Overall Study|Noncompliance|9
6089866|NCT00686920|9701692|FG001|Overall Study|Noncompliance|0
6089867|NCT00686920|9701691|FG000|Overall Study|Principal Investigator Decision|2
6089868|NCT00686920|9701692|FG001|Overall Study|Principal Investigator Decision|0
6089869|NCT00686959|9701700|FG000|Overall Study|Participants censored (no death events)|124
6089870|NCT00686959|9701701|FG001|Overall Study|Participants censored (no death events)|117
6089871|NCT00686998|9701710|FG000|Overall Study|Adverse Event|3
6283987|NCT02325713|9996161|FG006|Intervention Period 1 (2 Days)|Protocol Non-Compliance|0
6283988|NCT02325713|9996162|FG007|Intervention Period 1 (2 Days)|Protocol Non-Compliance|0
6283989|NCT02325713|9996163|FG008|Intervention Period 1 (2 Days)|Protocol Non-Compliance|0
6283990|NCT02325713|9996164|FG009|Intervention Period 1 (2 Days)|Protocol Non-Compliance|0
6283991|NCT02325713|9996165|FG010|Intervention Period 1 (2 Days)|Protocol Non-Compliance|1
6283992|NCT02325713|9996166|FG011|Intervention Period 1 (2 Days)|Protocol Non-Compliance|0
6283993|NCT02325713|9996167|FG012|Intervention Period 1 (2 Days)|Protocol Non-Compliance|0
6283994|NCT02325713|9996168|FG013|Intervention Period 1 (2 Days)|Protocol Non-Compliance|0
6283995|NCT02325713|9996169|FG014|Intervention Period 1 (2 Days)|Protocol Non-Compliance|0
6283996|NCT02325713|9996170|FG015|Intervention Period 1 (2 Days)|Protocol Non-Compliance|0
6283997|NCT02325713|9996155|FG000|Intervention Period 2 (2 Days)|Protocol Non-Compliance|1
6283998|NCT02325713|9996156|FG001|Intervention Period 2 (2 Days)|Protocol Non-Compliance|0
6283999|NCT02325713|9996157|FG002|Intervention Period 2 (2 Days)|Protocol Non-Compliance|0
6284000|NCT02325713|9996158|FG003|Intervention Period 2 (2 Days)|Protocol Non-Compliance|0
6284001|NCT02325713|9996159|FG004|Intervention Period 2 (2 Days)|Protocol Non-Compliance|0
6284002|NCT02325713|9996160|FG005|Intervention Period 2 (2 Days)|Protocol Non-Compliance|0
6284003|NCT02325713|9996161|FG006|Intervention Period 2 (2 Days)|Protocol Non-Compliance|0
6284004|NCT02325713|9996162|FG007|Intervention Period 2 (2 Days)|Protocol Non-Compliance|0
6284005|NCT02325713|9996163|FG008|Intervention Period 2 (2 Days)|Protocol Non-Compliance|0
6284006|NCT02325713|9996164|FG009|Intervention Period 2 (2 Days)|Protocol Non-Compliance|0
6284007|NCT02325713|9996165|FG010|Intervention Period 2 (2 Days)|Protocol Non-Compliance|0
6284008|NCT02325713|9996166|FG011|Intervention Period 2 (2 Days)|Protocol Non-Compliance|0
6284009|NCT02325713|9996167|FG012|Intervention Period 2 (2 Days)|Protocol Non-Compliance|0
6284010|NCT02325713|9996168|FG013|Intervention Period 2 (2 Days)|Protocol Non-Compliance|0
6284011|NCT02325713|9996169|FG014|Intervention Period 2 (2 Days)|Protocol Non-Compliance|0
6284012|NCT02325713|9996170|FG015|Intervention Period 2 (2 Days)|Protocol Non-Compliance|0
6284013|NCT02325713|9996155|FG000|Intervention Period 3 (2 Days)|Withdrawal by Subject|0
6284014|NCT02325713|9996156|FG001|Intervention Period 3 (2 Days)|Withdrawal by Subject|0
6284015|NCT02325713|9996157|FG002|Intervention Period 3 (2 Days)|Withdrawal by Subject|0
5980334|NCT03802565|9569114|FG000|Overall Study|Withdrawal by Subject|2
5980335|NCT03802565|9569115|FG001|Overall Study|Withdrawal by Subject|2
5980336|NCT03802565|9569116|FG002|Overall Study|Withdrawal by Subject|2
5980337|NCT03802565|9569117|FG003|Overall Study|Withdrawal by Subject|0
5980338|NCT03802565|9569118|FG004|Overall Study|Withdrawal by Subject|1
5980339|NCT03802565|9569114|FG000|Overall Study|Protocol Violation|2
5980340|NCT03802565|9569115|FG001|Overall Study|Protocol Violation|1
6052639|NCT00440193|9652212|FG001|Observational Period|Withdrawal by Subject|8
6052640|NCT00440193|9652211|FG000|Observational Period|Physician Decision|1
6052641|NCT00440193|9652212|FG001|Observational Period|Physician Decision|0
6052642|NCT00440193|9652211|FG000|Observational Period|Clinical endpoint reached|1
6052643|NCT00440193|9652212|FG001|Observational Period|Clinical endpoint reached|0
6052644|NCT00440193|9652211|FG000|Observational Period|Participant convenience|2
6052645|NCT00440193|9652212|FG001|Observational Period|Participant convenience|0
6052646|NCT00440232|9652220|FG000|Overall Study|Lost to Follow-up|1
6052647|NCT00440232|9652221|FG001|Overall Study|Lost to Follow-up|1
6052648|NCT00440232|9652220|FG000|Overall Study|Unable to treat within allowed time|0
6052649|NCT00440232|9652221|FG001|Overall Study|Unable to treat within allowed time|1
6052650|NCT00440232|9652220|FG000|Overall Study|Onset of headache within 4 hours of fast|2
6089872|NCT00686998|9701711|FG001|Overall Study|Adverse Event|2
6089873|NCT00686998|9701712|FG002|Overall Study|Adverse Event|1
5980341|NCT03802565|9569116|FG002|Overall Study|Protocol Violation|4
6052651|NCT00440232|9652221|FG001|Overall Study|Onset of headache within 4 hours of fast|2
6052652|NCT00440297|9652229|FG000|Overall Study|Adverse Event|8
6052653|NCT00440297|9652230|FG001|Overall Study|Adverse Event|5
6052654|NCT00440297|9652229|FG000|Overall Study|Lost to Follow-up|1
6089874|NCT00686998|9701710|FG000|Overall Study|Withdrawal by Subject|2
6089875|NCT00686998|9701711|FG001|Overall Study|Withdrawal by Subject|1
5980342|NCT03802565|9569117|FG003|Overall Study|Protocol Violation|5
5980343|NCT03802565|9569118|FG004|Overall Study|Protocol Violation|1
6284016|NCT02325713|9996158|FG003|Intervention Period 3 (2 Days)|Withdrawal by Subject|0
6284017|NCT02325713|9996159|FG004|Intervention Period 3 (2 Days)|Withdrawal by Subject|0
6284018|NCT02325713|9996160|FG005|Intervention Period 3 (2 Days)|Withdrawal by Subject|0
6284019|NCT02325713|9996161|FG006|Intervention Period 3 (2 Days)|Withdrawal by Subject|0
6284020|NCT02325713|9996162|FG007|Intervention Period 3 (2 Days)|Withdrawal by Subject|0
6284021|NCT02325713|9996163|FG008|Intervention Period 3 (2 Days)|Withdrawal by Subject|0
6284022|NCT02325713|9996164|FG009|Intervention Period 3 (2 Days)|Withdrawal by Subject|1
6284023|NCT02325713|9996165|FG010|Intervention Period 3 (2 Days)|Withdrawal by Subject|0
6284024|NCT02325713|9996166|FG011|Intervention Period 3 (2 Days)|Withdrawal by Subject|0
6284025|NCT02325713|9996167|FG012|Intervention Period 3 (2 Days)|Withdrawal by Subject|0
6284026|NCT02325713|9996168|FG013|Intervention Period 3 (2 Days)|Withdrawal by Subject|0
6284027|NCT02325713|9996169|FG014|Intervention Period 3 (2 Days)|Withdrawal by Subject|0
6284028|NCT02325713|9996170|FG015|Intervention Period 3 (2 Days)|Withdrawal by Subject|0
6284029|NCT02325739|9996196|FG000|Phase I Part|Adverse Event|1
6284030|NCT02325739|9996197|FG001|Phase I Part|Adverse Event|0
6284031|NCT02325739|9996198|FG002|Phase I Part|Adverse Event|1
6284032|NCT02325739|9996199|FG003|Phase I Part|Adverse Event|2
6284033|NCT02325739|9996200|FG004|Phase I Part|Adverse Event|3
6284034|NCT02325739|9996201|FG005|Phase I Part|Adverse Event|1
6284035|NCT02325739|9996202|FG006|Phase I Part|Adverse Event|0
6284036|NCT02325739|9996203|FG007|Phase I Part|Adverse Event|2
6284037|NCT02325739|9996204|FG008|Phase I Part|Adverse Event|0
6284038|NCT02325739|9996205|FG009|Phase I Part|Adverse Event|0
6089876|NCT00686998|9701712|FG002|Overall Study|Withdrawal by Subject|2
6089877|NCT00686998|9701710|FG000|Overall Study|Lack of Efficacy|7
6089878|NCT00686998|9701711|FG001|Overall Study|Lack of Efficacy|5
6089879|NCT00686998|9701712|FG002|Overall Study|Lack of Efficacy|0
6089880|NCT00686998|9701710|FG000|Overall Study|Other|0
6089881|NCT00686998|9701711|FG001|Overall Study|Other|0
6089882|NCT00686998|9701712|FG002|Overall Study|Other|1
6089883|NCT00686998|9701710|FG000|Overall Study|Safety Reasons|1
6089884|NCT00686998|9701711|FG001|Overall Study|Safety Reasons|0
6089885|NCT00686998|9701712|FG002|Overall Study|Safety Reasons|0
6089886|NCT00687193|9701751|FG000|Overall Study|Adverse Event|0
6089887|NCT00687193|9701752|FG001|Overall Study|Adverse Event|1
6284039|NCT02325739|9996206|FG010|Phase I Part|Adverse Event|0
6284040|NCT02325739|9996196|FG000|Phase I Part|Progressive disease|9
6284041|NCT02325739|9996197|FG001|Phase I Part|Progressive disease|6
6284042|NCT02325739|9996198|FG002|Phase I Part|Progressive disease|3
6284043|NCT02325739|9996199|FG003|Phase I Part|Progressive disease|23
6284044|NCT02325739|9996200|FG004|Phase I Part|Progressive disease|14
6284045|NCT02325739|9996201|FG005|Phase I Part|Progressive disease|6
6284046|NCT02325739|9996202|FG006|Phase I Part|Progressive disease|6
6284047|NCT02325739|9996203|FG007|Phase I Part|Progressive disease|3
6284048|NCT02325739|9996204|FG008|Phase I Part|Progressive disease|0
6284049|NCT02325739|9996205|FG009|Phase I Part|Progressive disease|0
6284050|NCT02325739|9996206|FG010|Phase I Part|Progressive disease|0
6284051|NCT02325739|9996196|FG000|Phase I Part|Subject/guardian decision|1
6284052|NCT02325739|9996197|FG001|Phase I Part|Subject/guardian decision|0
6284053|NCT02325739|9996198|FG002|Phase I Part|Subject/guardian decision|1
6284054|NCT02325739|9996199|FG003|Phase I Part|Subject/guardian decision|1
6284055|NCT02325739|9996200|FG004|Phase I Part|Subject/guardian decision|0
6284056|NCT02325739|9996201|FG005|Phase I Part|Subject/guardian decision|0
6284057|NCT02325739|9996202|FG006|Phase I Part|Subject/guardian decision|0
6284058|NCT02325739|9996203|FG007|Phase I Part|Subject/guardian decision|1
6284059|NCT02325739|9996204|FG008|Phase I Part|Subject/guardian decision|0
6284060|NCT02325739|9996205|FG009|Phase I Part|Subject/guardian decision|0
6284061|NCT02325739|9996206|FG010|Phase I Part|Subject/guardian decision|0
6284062|NCT02325739|9996196|FG000|Phase I Part|Death|0
6284063|NCT02325739|9996197|FG001|Phase I Part|Death|0
6284064|NCT02325739|9996198|FG002|Phase I Part|Death|0
6284065|NCT02325739|9996199|FG003|Phase I Part|Death|0
6284066|NCT02325739|9996200|FG004|Phase I Part|Death|2
6284067|NCT02325739|9996201|FG005|Phase I Part|Death|0
6284068|NCT02325739|9996202|FG006|Phase I Part|Death|0
6284069|NCT02325739|9996203|FG007|Phase I Part|Death|0
6284070|NCT02325739|9996204|FG008|Phase I Part|Death|0
6284071|NCT02325739|9996205|FG009|Phase I Part|Death|0
6284072|NCT02325739|9996206|FG010|Phase I Part|Death|0
6284073|NCT02325739|9996196|FG000|Phase II Part|Adverse Event|0
6284074|NCT02325739|9996197|FG001|Phase II Part|Adverse Event|0
6284075|NCT02325739|9996198|FG002|Phase II Part|Adverse Event|0
6284076|NCT02325739|9996199|FG003|Phase II Part|Adverse Event|0
6284077|NCT02325739|9996200|FG004|Phase II Part|Adverse Event|0
6284078|NCT02325739|9996201|FG005|Phase II Part|Adverse Event|0
6284079|NCT02325739|9996202|FG006|Phase II Part|Adverse Event|0
6284080|NCT02325739|9996203|FG007|Phase II Part|Adverse Event|0
6089888|NCT00687193|9701753|FG002|Overall Study|Adverse Event|2
6089889|NCT00687193|9701754|FG003|Overall Study|Adverse Event|3
6089890|NCT00687193|9701755|FG004|Overall Study|Adverse Event|0
6089891|NCT00687193|9701756|FG005|Overall Study|Adverse Event|2
6089892|NCT00687193|9701751|FG000|Overall Study|Lack of Efficacy|1
6284081|NCT02325739|9996204|FG008|Phase II Part|Adverse Event|4
6284082|NCT02325739|9996205|FG009|Phase II Part|Adverse Event|5
6284083|NCT02325739|9996206|FG010|Phase II Part|Adverse Event|1
6284084|NCT02325739|9996196|FG000|Phase II Part|Physician Decision|0
6284085|NCT02325739|9996197|FG001|Phase II Part|Physician Decision|0
6284086|NCT02325739|9996198|FG002|Phase II Part|Physician Decision|0
6284087|NCT02325739|9996199|FG003|Phase II Part|Physician Decision|0
6284088|NCT02325739|9996200|FG004|Phase II Part|Physician Decision|0
6284089|NCT02325739|9996201|FG005|Phase II Part|Physician Decision|0
6284090|NCT02325739|9996202|FG006|Phase II Part|Physician Decision|0
6284091|NCT02325739|9996203|FG007|Phase II Part|Physician Decision|0
6284092|NCT02325739|9996204|FG008|Phase II Part|Physician Decision|0
6284093|NCT02325739|9996205|FG009|Phase II Part|Physician Decision|1
6284094|NCT02325739|9996206|FG010|Phase II Part|Physician Decision|0
6284095|NCT02325739|9996196|FG000|Phase II Part|Progressive disease|0
6284096|NCT02325739|9996197|FG001|Phase II Part|Progressive disease|0
6284097|NCT02325739|9996198|FG002|Phase II Part|Progressive disease|0
6284098|NCT02325739|9996199|FG003|Phase II Part|Progressive disease|0
6284099|NCT02325739|9996200|FG004|Phase II Part|Progressive disease|0
6284100|NCT02325739|9996201|FG005|Phase II Part|Progressive disease|0
6284101|NCT02325739|9996202|FG006|Phase II Part|Progressive disease|0
6284102|NCT02325739|9996203|FG007|Phase II Part|Progressive disease|0
6284103|NCT02325739|9996204|FG008|Phase II Part|Progressive disease|22
6284104|NCT02325739|9996205|FG009|Phase II Part|Progressive disease|29
6052655|NCT00440297|9652230|FG001|Overall Study|Lost to Follow-up|0
6052656|NCT00440297|9652229|FG000|Overall Study|Physician Decision|1
6052657|NCT00440297|9652230|FG001|Overall Study|Physician Decision|0
6052658|NCT00440297|9652229|FG000|Overall Study|Protocol Violation|11
6052659|NCT00440297|9652230|FG001|Overall Study|Protocol Violation|7
6052660|NCT00440297|9652229|FG000|Overall Study|Withdrawal by Subject|1
6052661|NCT00440297|9652230|FG001|Overall Study|Withdrawal by Subject|6
6052662|NCT00440297|9652229|FG000|Overall Study|Randomized by mistake|1
6052663|NCT00440297|9652230|FG001|Overall Study|Randomized by mistake|0
6052664|NCT00440310|9652238|FG000|Overall Study|Lost to Follow-up|4
6052665|NCT00440310|9652239|FG001|Overall Study|Lost to Follow-up|5
6052666|NCT00440310|9652238|FG000|Overall Study|Protocol Violation|0
6052667|NCT00440310|9652239|FG001|Overall Study|Protocol Violation|1
6052668|NCT00440310|9652238|FG000|Overall Study|Withdrawal by Subject|15
6052669|NCT00440310|9652239|FG001|Overall Study|Withdrawal by Subject|14
6052670|NCT00440310|9652238|FG000|Overall Study|No Reply at EOS|7
6052671|NCT00440310|9652239|FG001|Overall Study|No Reply at EOS|7
6052672|NCT00440310|9652238|FG000|Overall Study|Other|1
6052673|NCT00440310|9652239|FG001|Overall Study|Other|0
6052674|NCT00440310|9652238|FG000|Overall Study|Status Unknown|1
6052675|NCT00440310|9652239|FG001|Overall Study|Status Unknown|3
6052676|NCT00440401|9652247|FG000|Overall Study|Adverse Event|2
6052677|NCT00440401|9652248|FG001|Overall Study|Adverse Event|1
6052678|NCT00440401|9652247|FG000|Overall Study|Other|2
6052679|NCT00440401|9652248|FG001|Overall Study|Other|5
6052680|NCT00440466|9652257|FG000|Overall Study|Death|3
6052681|NCT00440466|9652258|FG001|Overall Study|Death|2
6052682|NCT00440466|9652259|FG002|Overall Study|Death|9
6052683|NCT00440466|9652257|FG000|Overall Study|Adverse Event|3
6052684|NCT00440466|9652258|FG001|Overall Study|Adverse Event|4
6052685|NCT00440466|9652259|FG002|Overall Study|Adverse Event|11
6052686|NCT00440466|9652257|FG000|Overall Study|Lost to Follow-up|1
6052687|NCT00440466|9652258|FG001|Overall Study|Lost to Follow-up|0
6052688|NCT00440466|9652259|FG002|Overall Study|Lost to Follow-up|2
6052689|NCT00440466|9652257|FG000|Overall Study|Physician Decision|2
6052690|NCT00440466|9652258|FG001|Overall Study|Physician Decision|0
6052691|NCT00440466|9652259|FG002|Overall Study|Physician Decision|1
6052692|NCT00440466|9652257|FG000|Overall Study|Protocol Violation|2
6052693|NCT00440466|9652258|FG001|Overall Study|Protocol Violation|0
6052694|NCT00440466|9652259|FG002|Overall Study|Protocol Violation|4
6052695|NCT00440466|9652257|FG000|Overall Study|Withdrawal by Subject|2
6052696|NCT00440466|9652258|FG001|Overall Study|Withdrawal by Subject|5
6052697|NCT00440466|9652259|FG002|Overall Study|Withdrawal by Subject|9
6052698|NCT00440466|9652257|FG000|Overall Study|Began Dialysis|0
6052699|NCT00440466|9652258|FG001|Overall Study|Began Dialysis|0
6052700|NCT00440466|9652259|FG002|Overall Study|Began Dialysis|1
6052701|NCT00440466|9652257|FG000|Overall Study|Met Hemoglobin Withdrawal Criteria|0
6052702|NCT00440466|9652258|FG001|Overall Study|Met Hemoglobin Withdrawal Criteria|4
6052703|NCT00440466|9652259|FG002|Overall Study|Met Hemoglobin Withdrawal Criteria|4
6284105|NCT02325739|9996206|FG010|Phase II Part|Progressive disease|18
6284106|NCT02325739|9996196|FG000|Phase II Part|Subject/guardian decision|0
6284107|NCT02325739|9996197|FG001|Phase II Part|Subject/guardian decision|0
6052704|NCT00440518|9652283|FG000|Randomized /Titration Period|Lack of Efficacy|1
6052705|NCT00440518|9652284|FG001|Randomized /Titration Period|Lack of Efficacy|0
6052706|NCT00440518|9652285|FG002|Randomized /Titration Period|Lack of Efficacy|1
6052707|NCT00440518|9652283|FG000|Randomized /Titration Period|Subject Withdrew Consent|4
6052708|NCT00440518|9652284|FG001|Randomized /Titration Period|Subject Withdrew Consent|1
6052709|NCT00440518|9652285|FG002|Randomized /Titration Period|Subject Withdrew Consent|0
6052710|NCT00440518|9652283|FG000|Randomized /Titration Period|Protocol Deviation|1
6052711|NCT00440518|9652284|FG001|Randomized /Titration Period|Protocol Deviation|0
6284108|NCT02325739|9996198|FG002|Phase II Part|Subject/guardian decision|0
6284109|NCT02325739|9996199|FG003|Phase II Part|Subject/guardian decision|0
6052712|NCT00440518|9652285|FG002|Randomized /Titration Period|Protocol Deviation|0
6284110|NCT02325739|9996200|FG004|Phase II Part|Subject/guardian decision|0
6284111|NCT02325739|9996201|FG005|Phase II Part|Subject/guardian decision|0
6284112|NCT02325739|9996202|FG006|Phase II Part|Subject/guardian decision|0
6284113|NCT02325739|9996203|FG007|Phase II Part|Subject/guardian decision|0
6284114|NCT02325739|9996204|FG008|Phase II Part|Subject/guardian decision|4
6284115|NCT02325739|9996205|FG009|Phase II Part|Subject/guardian decision|1
6284116|NCT02325739|9996206|FG010|Phase II Part|Subject/guardian decision|1
6284117|NCT02325791|9996255|FG000|Overall Study|Adverse Event|0
6284118|NCT02325791|9996256|FG001|Overall Study|Adverse Event|1
6284119|NCT02325791|9996257|FG002|Overall Study|Adverse Event|1
6284120|NCT02325791|9996258|FG003|Overall Study|Adverse Event|0
6284121|NCT02325791|9996255|FG000|Overall Study|Death|0
6284122|NCT02325791|9996256|FG001|Overall Study|Death|3
6284123|NCT02325791|9996257|FG002|Overall Study|Death|0
6284124|NCT02325791|9996258|FG003|Overall Study|Death|1
6284125|NCT02325791|9996255|FG000|Overall Study|Lost to Follow-up|0
6284126|NCT02325791|9996256|FG001|Overall Study|Lost to Follow-up|15
6284127|NCT02325791|9996257|FG002|Overall Study|Lost to Follow-up|14
6284128|NCT02325791|9996258|FG003|Overall Study|Lost to Follow-up|9
6284129|NCT02325791|9996255|FG000|Overall Study|Physician Decision|0
6284130|NCT02325791|9996256|FG001|Overall Study|Physician Decision|1
6284131|NCT02325791|9996257|FG002|Overall Study|Physician Decision|1
6284132|NCT02325791|9996258|FG003|Overall Study|Physician Decision|0
6284133|NCT02325791|9996255|FG000|Overall Study|Protocol Violation|0
6284134|NCT02325791|9996256|FG001|Overall Study|Protocol Violation|0
6284135|NCT02325791|9996257|FG002|Overall Study|Protocol Violation|1
6284136|NCT02325791|9996258|FG003|Overall Study|Protocol Violation|0
6284137|NCT02325791|9996255|FG000|Overall Study|Withdrawal by Subject|0
6284138|NCT02325791|9996256|FG001|Overall Study|Withdrawal by Subject|5
6284139|NCT02325791|9996257|FG002|Overall Study|Withdrawal by Subject|8
6284140|NCT02325791|9996258|FG003|Overall Study|Withdrawal by Subject|16
6284141|NCT02326025|9996282|FG000|Overall Study|Adverse Event|3
6284142|NCT02326025|9996283|FG001|Overall Study|Adverse Event|0
6284143|NCT02326025|9996282|FG000|Overall Study|Physician Decision|1
6284144|NCT02326025|9996283|FG001|Overall Study|Physician Decision|2
6284145|NCT02326025|9996282|FG000|Overall Study|Physician and Participant Decision|1
6284146|NCT02326025|9996283|FG001|Overall Study|Physician and Participant Decision|0
6284147|NCT02326025|9996282|FG000|Overall Study|Withdrawal by Subject|0
6284148|NCT02326025|9996283|FG001|Overall Study|Withdrawal by Subject|2
6284149|NCT02326025|9996282|FG000|Overall Study|Protocol Violation|0
6284150|NCT02326025|9996283|FG001|Overall Study|Protocol Violation|1
6284151|NCT02326220|9996304|FG000|Double-blind Treatment Period|Adverse Event|1
6284152|NCT02326220|9996305|FG001|Double-blind Treatment Period|Adverse Event|2
6052713|NCT00440518|9652283|FG000|Randomized /Titration Period|Unsatisfactory Compliance|2
6052714|NCT00440518|9652284|FG001|Randomized /Titration Period|Unsatisfactory Compliance|3
6052715|NCT00440518|9652285|FG002|Randomized /Titration Period|Unsatisfactory Compliance|2
6052716|NCT00440518|9652283|FG000|Randomized /Titration Period|Other|1
6052717|NCT00440518|9652284|FG001|Randomized /Titration Period|Other|0
6052718|NCT00440518|9652285|FG002|Randomized /Titration Period|Other|0
6052719|NCT00440518|9652283|FG000|Randomized /Titration Period|Lost to Follow-up|2
6052720|NCT00440518|9652284|FG001|Randomized /Titration Period|Lost to Follow-up|2
6052721|NCT00440518|9652285|FG002|Randomized /Titration Period|Lost to Follow-up|1
6052722|NCT00440518|9652283|FG000|Randomized /Titration Period|Adverse Event|2
6052723|NCT00440518|9652284|FG001|Randomized /Titration Period|Adverse Event|3
6052724|NCT00440518|9652285|FG002|Randomized /Titration Period|Adverse Event|0
6052725|NCT00440518|9652283|FG000|Maintenance and Safety Follow-up Periods|Adverse Event|3
6052726|NCT00440518|9652284|FG001|Maintenance and Safety Follow-up Periods|Adverse Event|4
6052727|NCT00440518|9652285|FG002|Maintenance and Safety Follow-up Periods|Adverse Event|2
6052728|NCT00440518|9652283|FG000|Maintenance and Safety Follow-up Periods|Lack of Efficacy|0
6052729|NCT00440518|9652284|FG001|Maintenance and Safety Follow-up Periods|Lack of Efficacy|1
6052730|NCT00440518|9652285|FG002|Maintenance and Safety Follow-up Periods|Lack of Efficacy|1
6052731|NCT00440518|9652283|FG000|Maintenance and Safety Follow-up Periods|Subject Withdrew Consent|3
6052732|NCT00440518|9652284|FG001|Maintenance and Safety Follow-up Periods|Subject Withdrew Consent|2
6089893|NCT00687193|9701752|FG001|Overall Study|Lack of Efficacy|1
6089894|NCT00687193|9701753|FG002|Overall Study|Lack of Efficacy|0
6089895|NCT00687193|9701754|FG003|Overall Study|Lack of Efficacy|0
6089896|NCT00687193|9701755|FG004|Overall Study|Lack of Efficacy|0
6089897|NCT00687193|9701756|FG005|Overall Study|Lack of Efficacy|2
6089898|NCT00687193|9701751|FG000|Overall Study|Protocol Violation|1
6089899|NCT00687193|9701752|FG001|Overall Study|Protocol Violation|2
6089900|NCT00687193|9701753|FG002|Overall Study|Protocol Violation|0
6089901|NCT00687193|9701754|FG003|Overall Study|Protocol Violation|1
6089902|NCT00687193|9701755|FG004|Overall Study|Protocol Violation|2
6089903|NCT00687193|9701756|FG005|Overall Study|Protocol Violation|0
6089904|NCT00687219|9701773|FG000|Overall Study|Adverse Event|8
6089905|NCT00687219|9701773|FG000|Overall Study|Discontinuance criteria met|7
6089906|NCT00687219|9701773|FG000|Overall Study|HCV-RNA positive conversion|34
6284153|NCT02326220|9996306|FG002|Double-blind Treatment Period|Adverse Event|0
6284154|NCT02326220|9996304|FG000|Double-blind Treatment Period|Protocol Violation|0
6284155|NCT02326220|9996305|FG001|Double-blind Treatment Period|Protocol Violation|1
6284156|NCT02326220|9996306|FG002|Double-blind Treatment Period|Protocol Violation|0
6284157|NCT02326220|9996304|FG000|Double-blind Treatment Period|Withdrawal by Subject|0
6284158|NCT02326220|9996305|FG001|Double-blind Treatment Period|Withdrawal by Subject|1
6284159|NCT02326220|9996306|FG002|Double-blind Treatment Period|Withdrawal by Subject|0
6284160|NCT02326220|9996304|FG000|Open-label Treatment Period|Withdrawal by Subject|0
6284161|NCT02326220|9996305|FG001|Open-label Treatment Period|Withdrawal by Subject|0
6284162|NCT02326220|9996306|FG002|Open-label Treatment Period|Withdrawal by Subject|1
6284163|NCT02326220|9996304|FG000|Open-label Treatment Period|Lost to Follow-up|0
6284164|NCT02326220|9996305|FG001|Open-label Treatment Period|Lost to Follow-up|0
6284165|NCT02326220|9996306|FG002|Open-label Treatment Period|Lost to Follow-up|1
6284166|NCT02326272|9996328|FG000|Initial Period (Week 0 to Week 16)|Adverse Event|0
6284167|NCT02326272|9996329|FG001|Initial Period (Week 0 to Week 16)|Adverse Event|3
6052733|NCT00440518|9652285|FG002|Maintenance and Safety Follow-up Periods|Subject Withdrew Consent|4
6052734|NCT00440518|9652283|FG000|Maintenance and Safety Follow-up Periods|Unsatisfactory Compliance|0
6052735|NCT00440518|9652284|FG001|Maintenance and Safety Follow-up Periods|Unsatisfactory Compliance|3
6052736|NCT00440518|9652285|FG002|Maintenance and Safety Follow-up Periods|Unsatisfactory Compliance|6
6052737|NCT00440518|9652283|FG000|Maintenance and Safety Follow-up Periods|Other|0
6052738|NCT00440518|9652284|FG001|Maintenance and Safety Follow-up Periods|Other|0
6089907|NCT00687219|9701773|FG000|Overall Study|Withdrawal by Subject|1
6089908|NCT00687219|9701773|FG000|Overall Study|Lack of Efficacy|1
6089909|NCT00687271|9701781|FG000|Overall Study|Adverse Event|1
6089910|NCT00687271|9701782|FG001|Overall Study|Adverse Event|3
6089911|NCT00687271|9701783|FG002|Overall Study|Adverse Event|1
6089912|NCT00687271|9701784|FG003|Overall Study|Adverse Event|0
6089913|NCT00687271|9701781|FG000|Overall Study|Lost to Follow-up|0
6089914|NCT00687271|9701782|FG001|Overall Study|Lost to Follow-up|1
6089915|NCT00687271|9701783|FG002|Overall Study|Lost to Follow-up|0
6089916|NCT00687271|9701784|FG003|Overall Study|Lost to Follow-up|0
6089917|NCT00687271|9701781|FG000|Overall Study|Protocol Violation|2
6089918|NCT00687271|9701782|FG001|Overall Study|Protocol Violation|1
6089919|NCT00687271|9701783|FG002|Overall Study|Protocol Violation|1
6089920|NCT00687271|9701784|FG003|Overall Study|Protocol Violation|0
6089921|NCT00687271|9701781|FG000|Overall Study|Withdrawal by Subject|0
6089922|NCT00687271|9701782|FG001|Overall Study|Withdrawal by Subject|1
6089923|NCT00687271|9701783|FG002|Overall Study|Withdrawal by Subject|3
6089924|NCT00687271|9701784|FG003|Overall Study|Withdrawal by Subject|0
6089925|NCT00687297|9701796|FG000|Randomization|Withdrawal by Subject|2
6089926|NCT00687297|9701797|FG001|Randomization|Withdrawal by Subject|0
6089927|NCT00687297|9701796|FG000|Randomization|Withdrew before treatment, ineligible|1
6089928|NCT00687297|9701797|FG001|Randomization|Withdrew before treatment, ineligible|1
6089929|NCT00687297|9701796|FG000|Induction|Withdrawal by Subject|4
6089930|NCT00687297|9701797|FG001|Induction|Withdrawal by Subject|4
6089931|NCT00687297|9701796|FG000|Induction|Adverse Event|16
6089932|NCT00687297|9701797|FG001|Induction|Adverse Event|15
6089933|NCT00687297|9701796|FG000|Induction|Death|7
6089934|NCT00687297|9701797|FG001|Induction|Death|11
6089935|NCT00687297|9701796|FG000|Induction|Lack of Efficacy|17
6089936|NCT00687297|9701797|FG001|Induction|Lack of Efficacy|21
6089937|NCT00687297|9701796|FG000|Induction|Ineligible|0
6052739|NCT00440518|9652285|FG002|Maintenance and Safety Follow-up Periods|Other|2
6052740|NCT00440518|9652283|FG000|Maintenance and Safety Follow-up Periods|Lost to Follow-up|1
6052741|NCT00440518|9652284|FG001|Maintenance and Safety Follow-up Periods|Lost to Follow-up|2
6052742|NCT00440518|9652285|FG002|Maintenance and Safety Follow-up Periods|Lost to Follow-up|0
6052743|NCT00440557|9652296|FG000|Overall Study|Withdrawal by Subject|10
6052744|NCT00440557|9652297|FG001|Overall Study|Withdrawal by Subject|5
6052745|NCT00440557|9652298|FG002|Overall Study|Withdrawal by Subject|11
6052746|NCT00440557|9652296|FG000|Overall Study|Lost to Follow-up|1
6052747|NCT00440557|9652297|FG001|Overall Study|Lost to Follow-up|2
6052748|NCT00440557|9652298|FG002|Overall Study|Lost to Follow-up|6
6052749|NCT00440557|9652296|FG000|Overall Study|Adverse Event|3
6052750|NCT00440557|9652297|FG001|Overall Study|Adverse Event|3
6052751|NCT00440557|9652298|FG002|Overall Study|Adverse Event|5
6052752|NCT00440557|9652296|FG000|Overall Study|Death|2
6052753|NCT00440557|9652297|FG001|Overall Study|Death|6
6052754|NCT00440557|9652298|FG002|Overall Study|Death|3
6052755|NCT00440557|9652296|FG000|Overall Study|Began Dialysis|4
6052756|NCT00440557|9652297|FG001|Overall Study|Began Dialysis|1
6052757|NCT00440557|9652298|FG002|Overall Study|Began Dialysis|4
6052758|NCT00440557|9652296|FG000|Overall Study|Principal Investigator decision|0
6052759|NCT00440557|9652297|FG001|Overall Study|Principal Investigator decision|3
6052760|NCT00440557|9652298|FG002|Overall Study|Principal Investigator decision|1
6052761|NCT00440557|9652296|FG000|Overall Study|Patient moved|1
6052762|NCT00440557|9652297|FG001|Overall Study|Patient moved|2
6052763|NCT00440557|9652298|FG002|Overall Study|Patient moved|1
6052764|NCT00440557|9652296|FG000|Overall Study|Principal Investigator's office closed|3
6052765|NCT00440557|9652297|FG001|Overall Study|Principal Investigator's office closed|6
6052766|NCT00440557|9652298|FG002|Overall Study|Principal Investigator's office closed|4
6052767|NCT00440557|9652296|FG000|Overall Study|Patient transferred to nursing home|0
6052768|NCT00440557|9652297|FG001|Overall Study|Patient transferred to nursing home|1
6052769|NCT00440557|9652298|FG002|Overall Study|Patient transferred to nursing home|0
6052770|NCT00440557|9652296|FG000|Overall Study|Patient had surgery|1
6284168|NCT02326272|9996330|FG002|Initial Period (Week 0 to Week 16)|Adverse Event|1
6284169|NCT02326272|9996331|FG003|Initial Period (Week 0 to Week 16)|Adverse Event|0
6284170|NCT02326272|9996332|FG004|Initial Period (Week 0 to Week 16)|Adverse Event|0
6284171|NCT02326272|9996333|FG005|Initial Period (Week 0 to Week 16)|Adverse Event|0
6284172|NCT02326272|9996334|FG006|Initial Period (Week 0 to Week 16)|Adverse Event|0
6284173|NCT02326272|9996335|FG007|Initial Period (Week 0 to Week 16)|Adverse Event|0
6284174|NCT02326272|9996336|FG008|Initial Period (Week 0 to Week 16)|Adverse Event|0
6284175|NCT02326272|9996337|FG009|Initial Period (Week 0 to Week 16)|Adverse Event|0
6284176|NCT02326272|9996338|FG010|Initial Period (Week 0 to Week 16)|Adverse Event|0
6284177|NCT02326272|9996339|FG011|Initial Period (Week 0 to Week 16)|Adverse Event|0
6284178|NCT02326272|9996340|FG012|Initial Period (Week 0 to Week 16)|Adverse Event|0
6284179|NCT02326272|9996341|FG013|Initial Period (Week 0 to Week 16)|Adverse Event|0
6284180|NCT02326272|9996342|FG014|Initial Period (Week 0 to Week 16)|Adverse Event|0
6284181|NCT02326272|9996328|FG000|Initial Period (Week 0 to Week 16)|Lost to Follow-up|1
6284182|NCT02326272|9996329|FG001|Initial Period (Week 0 to Week 16)|Lost to Follow-up|2
6284183|NCT02326272|9996330|FG002|Initial Period (Week 0 to Week 16)|Lost to Follow-up|0
6284184|NCT02326272|9996331|FG003|Initial Period (Week 0 to Week 16)|Lost to Follow-up|0
6284185|NCT02326272|9996332|FG004|Initial Period (Week 0 to Week 16)|Lost to Follow-up|0
6284186|NCT02326272|9996333|FG005|Initial Period (Week 0 to Week 16)|Lost to Follow-up|0
6284187|NCT02326272|9996334|FG006|Initial Period (Week 0 to Week 16)|Lost to Follow-up|0
6284188|NCT02326272|9996335|FG007|Initial Period (Week 0 to Week 16)|Lost to Follow-up|0
6284189|NCT02326272|9996336|FG008|Initial Period (Week 0 to Week 16)|Lost to Follow-up|0
6284190|NCT02326272|9996337|FG009|Initial Period (Week 0 to Week 16)|Lost to Follow-up|0
6284191|NCT02326272|9996338|FG010|Initial Period (Week 0 to Week 16)|Lost to Follow-up|0
6284192|NCT02326272|9996339|FG011|Initial Period (Week 0 to Week 16)|Lost to Follow-up|0
6284193|NCT02326272|9996340|FG012|Initial Period (Week 0 to Week 16)|Lost to Follow-up|0
6284194|NCT02326272|9996341|FG013|Initial Period (Week 0 to Week 16)|Lost to Follow-up|0
6284195|NCT02326272|9996342|FG014|Initial Period (Week 0 to Week 16)|Lost to Follow-up|0
6284196|NCT02326272|9996328|FG000|Initial Period (Week 0 to Week 16)|Withdrawal by Subject|3
6284197|NCT02326272|9996329|FG001|Initial Period (Week 0 to Week 16)|Withdrawal by Subject|2
6284198|NCT02326272|9996330|FG002|Initial Period (Week 0 to Week 16)|Withdrawal by Subject|1
6284199|NCT02326272|9996331|FG003|Initial Period (Week 0 to Week 16)|Withdrawal by Subject|0
6284200|NCT02326272|9996332|FG004|Initial Period (Week 0 to Week 16)|Withdrawal by Subject|0
6284201|NCT02326272|9996333|FG005|Initial Period (Week 0 to Week 16)|Withdrawal by Subject|0
6284202|NCT02326272|9996334|FG006|Initial Period (Week 0 to Week 16)|Withdrawal by Subject|0
6284203|NCT02326272|9996335|FG007|Initial Period (Week 0 to Week 16)|Withdrawal by Subject|0
6284204|NCT02326272|9996336|FG008|Initial Period (Week 0 to Week 16)|Withdrawal by Subject|0
6052771|NCT00440557|9652297|FG001|Overall Study|Patient had surgery|0
6052772|NCT00440557|9652298|FG002|Overall Study|Patient had surgery|0
6052773|NCT00440700|9652320|FG000|Overall Study|Withdrawal by Subject|8
6052774|NCT00440700|9652321|FG001|Overall Study|Withdrawal by Subject|8
6052775|NCT00440700|9652322|FG002|Overall Study|Withdrawal by Subject|4
6052776|NCT00440726|9652333|FG000|Phase 1|Dose-Limiting Toxicity|0
6052777|NCT00440726|9652334|FG001|Phase 1|Dose-Limiting Toxicity|1
6052778|NCT00440726|9652335|FG002|Phase 1|Dose-Limiting Toxicity|0
6052779|NCT00440726|9652333|FG000|Phase 1|Physician Decision|1
6052780|NCT00440726|9652334|FG001|Phase 1|Physician Decision|0
6052781|NCT00440726|9652335|FG002|Phase 1|Physician Decision|0
6052782|NCT00440726|9652333|FG000|Phase 2|Death|0
6052783|NCT00440726|9652334|FG001|Phase 2|Death|0
6052784|NCT00440726|9652335|FG002|Phase 2|Death|1
6052785|NCT00440726|9652333|FG000|Phase 2|Adverse Event|0
6052786|NCT00440726|9652334|FG001|Phase 2|Adverse Event|0
6052787|NCT00440726|9652335|FG002|Phase 2|Adverse Event|1
6052788|NCT00440947|9652367|FG000|36-Week Induction Phase|Adverse Event|16
6052789|NCT00440947|9652368|FG001|36-Week Induction Phase|Adverse Event|0
6052790|NCT00440947|9652369|FG002|36-Week Induction Phase|Adverse Event|0
6052791|NCT00440947|9652370|FG003|36-Week Induction Phase|Adverse Event|0
6052792|NCT00440947|9652371|FG004|36-Week Induction Phase|Adverse Event|0
6052793|NCT00440947|9652367|FG000|36-Week Induction Phase|Insufficient Viral Load Response|11
6052794|NCT00440947|9652368|FG001|36-Week Induction Phase|Insufficient Viral Load Response|0
6052795|NCT00440947|9652369|FG002|36-Week Induction Phase|Insufficient Viral Load Response|0
6052796|NCT00440947|9652370|FG003|36-Week Induction Phase|Insufficient Viral Load Response|0
6052797|NCT00440947|9652371|FG004|36-Week Induction Phase|Insufficient Viral Load Response|0
6052798|NCT00440947|9652367|FG000|36-Week Induction Phase|Protocol-defined Virologic Failure|5
6052799|NCT00440947|9652368|FG001|36-Week Induction Phase|Protocol-defined Virologic Failure|0
6052800|NCT00440947|9652369|FG002|36-Week Induction Phase|Protocol-defined Virologic Failure|0
6089938|NCT00687297|9701797|FG001|Induction|Ineligible|1
6089939|NCT00687297|9701796|FG000|Induction|Patient Noncompliance|1
6089940|NCT00687297|9701797|FG001|Induction|Patient Noncompliance|0
6089941|NCT00687297|9701796|FG000|Induction|Physician Decision|0
6052801|NCT00440947|9652370|FG003|36-Week Induction Phase|Protocol-defined Virologic Failure|0
6052802|NCT00440947|9652371|FG004|36-Week Induction Phase|Protocol-defined Virologic Failure|0
6052803|NCT00440947|9652367|FG000|36-Week Induction Phase|Non-compliance|10
6089942|NCT00687297|9701797|FG001|Induction|Physician Decision|2
6089943|NCT00687297|9701796|FG000|Induction|Other|0
6052804|NCT00440947|9652368|FG001|36-Week Induction Phase|Non-compliance|0
6052805|NCT00440947|9652369|FG002|36-Week Induction Phase|Non-compliance|0
6052806|NCT00440947|9652370|FG003|36-Week Induction Phase|Non-compliance|0
6052807|NCT00440947|9652371|FG004|36-Week Induction Phase|Non-compliance|0
6052808|NCT00440947|9652367|FG000|36-Week Induction Phase|Lost to Follow-up|16
6052809|NCT00440947|9652368|FG001|36-Week Induction Phase|Lost to Follow-up|0
6052810|NCT00440947|9652369|FG002|36-Week Induction Phase|Lost to Follow-up|0
6052811|NCT00440947|9652370|FG003|36-Week Induction Phase|Lost to Follow-up|0
6052812|NCT00440947|9652371|FG004|36-Week Induction Phase|Lost to Follow-up|0
6052813|NCT00440947|9652367|FG000|36-Week Induction Phase|Withdrawal by Subject|7
6052814|NCT00440947|9652368|FG001|36-Week Induction Phase|Withdrawal by Subject|0
6052815|NCT00440947|9652369|FG002|36-Week Induction Phase|Withdrawal by Subject|0
6052816|NCT00440947|9652370|FG003|36-Week Induction Phase|Withdrawal by Subject|0
6052817|NCT00440947|9652371|FG004|36-Week Induction Phase|Withdrawal by Subject|0
6052818|NCT00440947|9652367|FG000|36-Week Induction Phase|Kaposi Lesions Requiring Chemotherapy|1
6052819|NCT00440947|9652368|FG001|36-Week Induction Phase|Kaposi Lesions Requiring Chemotherapy|0
6052820|NCT00440947|9652369|FG002|36-Week Induction Phase|Kaposi Lesions Requiring Chemotherapy|0
6052821|NCT00440947|9652370|FG003|36-Week Induction Phase|Kaposi Lesions Requiring Chemotherapy|0
6052822|NCT00440947|9652371|FG004|36-Week Induction Phase|Kaposi Lesions Requiring Chemotherapy|0
6052823|NCT00440947|9652367|FG000|36-Week Induction Phase|Took Exclusionary Medications|1
6052824|NCT00440947|9652368|FG001|36-Week Induction Phase|Took Exclusionary Medications|0
6052825|NCT00440947|9652369|FG002|36-Week Induction Phase|Took Exclusionary Medications|0
6052826|NCT00440947|9652370|FG003|36-Week Induction Phase|Took Exclusionary Medications|0
6052827|NCT00440947|9652371|FG004|36-Week Induction Phase|Took Exclusionary Medications|0
6052828|NCT00440947|9652367|FG000|36-Week Induction Phase|Genotype Had Exclusionary Mutations|1
6052829|NCT00440947|9652368|FG001|36-Week Induction Phase|Genotype Had Exclusionary Mutations|0
6052830|NCT00440947|9652369|FG002|36-Week Induction Phase|Genotype Had Exclusionary Mutations|0
6052831|NCT00440947|9652370|FG003|36-Week Induction Phase|Genotype Had Exclusionary Mutations|0
6052832|NCT00440947|9652371|FG004|36-Week Induction Phase|Genotype Had Exclusionary Mutations|0
6052833|NCT00440947|9652367|FG000|36-Week Induction Phase|Fleeing Police; Outstanding Warrants|1
6052834|NCT00440947|9652368|FG001|36-Week Induction Phase|Fleeing Police; Outstanding Warrants|0
6052835|NCT00440947|9652369|FG002|36-Week Induction Phase|Fleeing Police; Outstanding Warrants|0
6052836|NCT00440947|9652370|FG003|36-Week Induction Phase|Fleeing Police; Outstanding Warrants|0
6052837|NCT00440947|9652371|FG004|36-Week Induction Phase|Fleeing Police; Outstanding Warrants|0
6052838|NCT00440947|9652367|FG000|36-Week Induction Phase|Incarceration|3
6052839|NCT00440947|9652368|FG001|36-Week Induction Phase|Incarceration|0
6052840|NCT00440947|9652369|FG002|36-Week Induction Phase|Incarceration|0
6052841|NCT00440947|9652370|FG003|36-Week Induction Phase|Incarceration|0
6052842|NCT00440947|9652371|FG004|36-Week Induction Phase|Incarceration|0
6052843|NCT00440947|9652367|FG000|36-Week Induction Phase|Pregnancy|1
6052844|NCT00440947|9652368|FG001|36-Week Induction Phase|Pregnancy|0
6052845|NCT00440947|9652369|FG002|36-Week Induction Phase|Pregnancy|0
6052846|NCT00440947|9652370|FG003|36-Week Induction Phase|Pregnancy|0
6052847|NCT00440947|9652371|FG004|36-Week Induction Phase|Pregnancy|0
6052848|NCT00440947|9652367|FG000|48-Week Randomization Phase|Adverse Event|0
6052849|NCT00440947|9652368|FG001|48-Week Randomization Phase|Adverse Event|2
6052850|NCT00440947|9652369|FG002|48-Week Randomization Phase|Adverse Event|5
6052851|NCT00440947|9652370|FG003|48-Week Randomization Phase|Adverse Event|0
6052852|NCT00440947|9652371|FG004|48-Week Randomization Phase|Adverse Event|0
6052853|NCT00440947|9652367|FG000|48-Week Randomization Phase|Protocol-defined Virologic Failure|0
6052854|NCT00440947|9652368|FG001|48-Week Randomization Phase|Protocol-defined Virologic Failure|1
6052855|NCT00440947|9652369|FG002|48-Week Randomization Phase|Protocol-defined Virologic Failure|1
6052856|NCT00440947|9652370|FG003|48-Week Randomization Phase|Protocol-defined Virologic Failure|0
6052857|NCT00440947|9652371|FG004|48-Week Randomization Phase|Protocol-defined Virologic Failure|0
6052858|NCT00440947|9652367|FG000|48-Week Randomization Phase|Non-compliance|0
6052859|NCT00440947|9652368|FG001|48-Week Randomization Phase|Non-compliance|3
6052860|NCT00440947|9652369|FG002|48-Week Randomization Phase|Non-compliance|4
6052861|NCT00440947|9652370|FG003|48-Week Randomization Phase|Non-compliance|0
6052862|NCT00440947|9652371|FG004|48-Week Randomization Phase|Non-compliance|0
6052863|NCT00440947|9652367|FG000|48-Week Randomization Phase|Lost to Follow-up|0
6052864|NCT00440947|9652368|FG001|48-Week Randomization Phase|Lost to Follow-up|2
6052865|NCT00440947|9652369|FG002|48-Week Randomization Phase|Lost to Follow-up|8
6052866|NCT00440947|9652370|FG003|48-Week Randomization Phase|Lost to Follow-up|0
6052867|NCT00440947|9652371|FG004|48-Week Randomization Phase|Lost to Follow-up|0
6052868|NCT00440947|9652367|FG000|48-Week Randomization Phase|Protocol Violation|0
6052869|NCT00440947|9652368|FG001|48-Week Randomization Phase|Protocol Violation|0
6052870|NCT00440947|9652369|FG002|48-Week Randomization Phase|Protocol Violation|1
6202161|NCT01499355|9862251|FG003|Double-Blind Period|Lost to Follow-up|0
6052871|NCT00440947|9652370|FG003|48-Week Randomization Phase|Protocol Violation|0
6052872|NCT00440947|9652371|FG004|48-Week Randomization Phase|Protocol Violation|0
6202162|NCT01499368|9862264|FG000|Overall Study|Did not meet I/E criteria|8
6052873|NCT00440947|9652367|FG000|48-Week Randomization Phase|Withdrawal by Subject|0
6052874|NCT00440947|9652368|FG001|48-Week Randomization Phase|Withdrawal by Subject|2
6202163|NCT01499368|9862265|FG001|Overall Study|Did not meet I/E criteria|4
6052875|NCT00440947|9652369|FG002|48-Week Randomization Phase|Withdrawal by Subject|4
6052876|NCT00440947|9652370|FG003|48-Week Randomization Phase|Withdrawal by Subject|0
6052877|NCT00440947|9652371|FG004|48-Week Randomization Phase|Withdrawal by Subject|0
6052878|NCT00440947|9652367|FG000|48-Week Randomization Phase|Pregnancy|0
6052879|NCT00440947|9652368|FG001|48-Week Randomization Phase|Pregnancy|0
6052880|NCT00440947|9652369|FG002|48-Week Randomization Phase|Pregnancy|1
6052881|NCT00440947|9652370|FG003|48-Week Randomization Phase|Pregnancy|0
6052882|NCT00440947|9652371|FG004|48-Week Randomization Phase|Pregnancy|0
6052883|NCT00440947|9652367|FG000|48-Week Randomization Phase|Incarceration|0
6052884|NCT00440947|9652368|FG001|48-Week Randomization Phase|Incarceration|3
6052885|NCT00440947|9652369|FG002|48-Week Randomization Phase|Incarceration|0
6052886|NCT00440947|9652370|FG003|48-Week Randomization Phase|Incarceration|0
6052887|NCT00440947|9652371|FG004|48-Week Randomization Phase|Incarceration|0
6052888|NCT00440947|9652367|FG000|48-Week Randomization Phase|Trying to Get Pregnant|0
6052889|NCT00440947|9652368|FG001|48-Week Randomization Phase|Trying to Get Pregnant|1
6052890|NCT00440947|9652369|FG002|48-Week Randomization Phase|Trying to Get Pregnant|0
6052891|NCT00440947|9652370|FG003|48-Week Randomization Phase|Trying to Get Pregnant|0
6052892|NCT00440947|9652371|FG004|48-Week Randomization Phase|Trying to Get Pregnant|0
6052893|NCT00440947|9652367|FG000|48-Week Randomization Phase|Physician Decision|0
6052894|NCT00440947|9652368|FG001|48-Week Randomization Phase|Physician Decision|2
6052895|NCT00440947|9652369|FG002|48-Week Randomization Phase|Physician Decision|0
6052896|NCT00440947|9652370|FG003|48-Week Randomization Phase|Physician Decision|0
6052897|NCT00440947|9652371|FG004|48-Week Randomization Phase|Physician Decision|0
6052898|NCT00440947|9652367|FG000|Optional 60-Week Extension Phase|Adverse Event|0
6052899|NCT00440947|9652368|FG001|Optional 60-Week Extension Phase|Adverse Event|0
6052900|NCT00440947|9652369|FG002|Optional 60-Week Extension Phase|Adverse Event|0
6052901|NCT00440947|9652370|FG003|Optional 60-Week Extension Phase|Adverse Event|1
6052902|NCT00440947|9652371|FG004|Optional 60-Week Extension Phase|Adverse Event|3
6052903|NCT00440947|9652367|FG000|Optional 60-Week Extension Phase|Insufficient Viral Load Response|0
6052904|NCT00440947|9652368|FG001|Optional 60-Week Extension Phase|Insufficient Viral Load Response|0
6052905|NCT00440947|9652369|FG002|Optional 60-Week Extension Phase|Insufficient Viral Load Response|0
6052906|NCT00440947|9652370|FG003|Optional 60-Week Extension Phase|Insufficient Viral Load Response|1
6052907|NCT00440947|9652371|FG004|Optional 60-Week Extension Phase|Insufficient Viral Load Response|1
6052908|NCT00440947|9652367|FG000|Optional 60-Week Extension Phase|Protocol-defined Virologic Failure|0
6052909|NCT00440947|9652368|FG001|Optional 60-Week Extension Phase|Protocol-defined Virologic Failure|0
6052910|NCT00440947|9652369|FG002|Optional 60-Week Extension Phase|Protocol-defined Virologic Failure|0
6052911|NCT00440947|9652370|FG003|Optional 60-Week Extension Phase|Protocol-defined Virologic Failure|3
6052912|NCT00440947|9652371|FG004|Optional 60-Week Extension Phase|Protocol-defined Virologic Failure|2
6052913|NCT00440947|9652367|FG000|Optional 60-Week Extension Phase|Non-compliance|0
6052914|NCT00440947|9652368|FG001|Optional 60-Week Extension Phase|Non-compliance|0
6052915|NCT00440947|9652369|FG002|Optional 60-Week Extension Phase|Non-compliance|0
6052916|NCT00440947|9652370|FG003|Optional 60-Week Extension Phase|Non-compliance|1
6052917|NCT00440947|9652371|FG004|Optional 60-Week Extension Phase|Non-compliance|1
6052918|NCT00440947|9652367|FG000|Optional 60-Week Extension Phase|Lost to Follow-up|0
6089944|NCT00687297|9701797|FG001|Induction|Other|1
6089945|NCT00687323|9701805|FG000|Overall Study|Death|25
6089946|NCT00687323|9701805|FG000|Overall Study|Withdrawal by Subject|1
6089947|NCT00687323|9701805|FG000|Overall Study|Excluded from efficacy evaluations|6
6089948|NCT00687323|9701805|FG000|Overall Study|Screen failure|148
6089949|NCT00687362|9701809|FG000|Overall Study|Protocol Violation|2
6089950|NCT00687362|9701809|FG000|Overall Study|Withdrawal by Subject|1
6089951|NCT00687401|9701813|FG000|Overall Study|Protocol Violation|7
6089952|NCT00687401|9701813|FG000|Overall Study|Adverse Event|6
6089953|NCT00687401|9701813|FG000|Overall Study|Lack of Efficacy|6
6089954|NCT00687401|9701813|FG000|Overall Study|Withdrawal by Subject|4
6089955|NCT00687401|9701813|FG000|Overall Study|Did not return for visit|3
6089956|NCT00687401|9701813|FG000|Overall Study|For reasons different from those above|4
6089957|NCT00687440|9701818|FG000|Overall Study|Adverse Event|3
6089958|NCT00687440|9701818|FG000|Overall Study|Lost to Follow-up|3
6089959|NCT00687440|9701818|FG000|Overall Study|Lack of Efficacy|2
6089960|NCT00687440|9701818|FG000|Overall Study|Death|2
6089961|NCT00687440|9701818|FG000|Overall Study|Other|1
6089962|NCT00687440|9701818|FG000|Overall Study|Missing|1
6089963|NCT00687609|9701835|FG000|Overall Study|Physician Decision|1
6089964|NCT00687609|9701835|FG000|Overall Study|Withdrawal by Subject|2
6089965|NCT00687739|9701858|FG000|Overall Study|Lost to Follow-up|2
6089966|NCT00687739|9701859|FG001|Overall Study|Lost to Follow-up|2
6089967|NCT00687739|9701860|FG002|Overall Study|Lost to Follow-up|1
6089968|NCT00687739|9701861|FG003|Overall Study|Lost to Follow-up|2
6089969|NCT00687739|9701858|FG000|Overall Study|Adverse Event|0
6089970|NCT00687739|9701859|FG001|Overall Study|Adverse Event|1
6089971|NCT00687739|9701860|FG002|Overall Study|Adverse Event|1
6089972|NCT00687739|9701861|FG003|Overall Study|Adverse Event|0
6089973|NCT00687804|9701876|FG000|Core Study|Adverse Event|5
6089974|NCT00687804|9701877|FG001|Core Study|Adverse Event|3
6089975|NCT00687804|9701878|FG002|Core Study|Adverse Event|3
6089976|NCT00687804|9701876|FG000|Core Study|Abnormal laboratory value(s)|1
6089977|NCT00687804|9701877|FG001|Core Study|Abnormal laboratory value(s)|0
6052919|NCT00440947|9652368|FG001|Optional 60-Week Extension Phase|Lost to Follow-up|0
6052920|NCT00440947|9652369|FG002|Optional 60-Week Extension Phase|Lost to Follow-up|0
6052921|NCT00440947|9652370|FG003|Optional 60-Week Extension Phase|Lost to Follow-up|9
6052922|NCT00440947|9652371|FG004|Optional 60-Week Extension Phase|Lost to Follow-up|9
6052923|NCT00440947|9652367|FG000|Optional 60-Week Extension Phase|Protocol Violation|0
6052924|NCT00440947|9652368|FG001|Optional 60-Week Extension Phase|Protocol Violation|0
6052925|NCT00440947|9652369|FG002|Optional 60-Week Extension Phase|Protocol Violation|0
6052926|NCT00440947|9652370|FG003|Optional 60-Week Extension Phase|Protocol Violation|1
6052927|NCT00440947|9652371|FG004|Optional 60-Week Extension Phase|Protocol Violation|0
6052928|NCT00440947|9652367|FG000|Optional 60-Week Extension Phase|Withdrawal by Subject|0
6052929|NCT00440947|9652368|FG001|Optional 60-Week Extension Phase|Withdrawal by Subject|0
6052930|NCT00440947|9652369|FG002|Optional 60-Week Extension Phase|Withdrawal by Subject|0
6052931|NCT00440947|9652370|FG003|Optional 60-Week Extension Phase|Withdrawal by Subject|4
6052932|NCT00440947|9652371|FG004|Optional 60-Week Extension Phase|Withdrawal by Subject|3
6052933|NCT00440947|9652367|FG000|Optional 60-Week Extension Phase|Pregnancy|0
6052934|NCT00440947|9652368|FG001|Optional 60-Week Extension Phase|Pregnancy|0
6052935|NCT00440947|9652369|FG002|Optional 60-Week Extension Phase|Pregnancy|0
6052936|NCT00440947|9652370|FG003|Optional 60-Week Extension Phase|Pregnancy|3
6052937|NCT00440947|9652371|FG004|Optional 60-Week Extension Phase|Pregnancy|0
6052938|NCT00440947|9652367|FG000|Optional 60-Week Extension Phase|Participant Moved|0
6052939|NCT00440947|9652368|FG001|Optional 60-Week Extension Phase|Participant Moved|0
6052940|NCT00440947|9652369|FG002|Optional 60-Week Extension Phase|Participant Moved|0
6052941|NCT00440947|9652370|FG003|Optional 60-Week Extension Phase|Participant Moved|1
6052942|NCT00440947|9652371|FG004|Optional 60-Week Extension Phase|Participant Moved|1
6052943|NCT00440947|9652367|FG000|Optional 60-Week Extension Phase|Sponsor Request|0
6052944|NCT00440947|9652368|FG001|Optional 60-Week Extension Phase|Sponsor Request|0
6052945|NCT00440947|9652369|FG002|Optional 60-Week Extension Phase|Sponsor Request|0
6052946|NCT00440947|9652370|FG003|Optional 60-Week Extension Phase|Sponsor Request|1
6052947|NCT00440947|9652371|FG004|Optional 60-Week Extension Phase|Sponsor Request|1
6052948|NCT00440947|9652367|FG000|Optional 60-Week Extension Phase|Sponsor Terminated Site|0
6052949|NCT00440947|9652368|FG001|Optional 60-Week Extension Phase|Sponsor Terminated Site|0
6052950|NCT00440947|9652369|FG002|Optional 60-Week Extension Phase|Sponsor Terminated Site|0
6052951|NCT00440947|9652370|FG003|Optional 60-Week Extension Phase|Sponsor Terminated Site|3
6052952|NCT00440947|9652371|FG004|Optional 60-Week Extension Phase|Sponsor Terminated Site|3
6052953|NCT00440947|9652367|FG000|Optional 60-Week Extension Phase|Other|0
6052954|NCT00440947|9652368|FG001|Optional 60-Week Extension Phase|Other|0
6052955|NCT00440947|9652369|FG002|Optional 60-Week Extension Phase|Other|0
6052956|NCT00440947|9652370|FG003|Optional 60-Week Extension Phase|Other|1
6052957|NCT00440947|9652371|FG004|Optional 60-Week Extension Phase|Other|0
6052958|NCT00440947|9652367|FG000|Optional 60-Week Extension Phase|Physician Decision|0
6052959|NCT00440947|9652368|FG001|Optional 60-Week Extension Phase|Physician Decision|0
6052960|NCT00440947|9652369|FG002|Optional 60-Week Extension Phase|Physician Decision|0
6052961|NCT00440947|9652370|FG003|Optional 60-Week Extension Phase|Physician Decision|0
6052962|NCT00440947|9652371|FG004|Optional 60-Week Extension Phase|Physician Decision|1
6052963|NCT00440947|9652367|FG000|Optional 60-Week Extension Phase|Participant Remained in Cuba|0
6052964|NCT00440947|9652368|FG001|Optional 60-Week Extension Phase|Participant Remained in Cuba|0
6052965|NCT00440947|9652369|FG002|Optional 60-Week Extension Phase|Participant Remained in Cuba|0
6089978|NCT00687804|9701878|FG002|Core Study|Abnormal laboratory value(s)|0
6089979|NCT00687804|9701876|FG000|Core Study|Lack of Efficacy|1
6089980|NCT00687804|9701877|FG001|Core Study|Lack of Efficacy|1
6089981|NCT00687804|9701878|FG002|Core Study|Lack of Efficacy|1
6089982|NCT00687804|9701876|FG000|Core Study|Withdrawal by Subject|4
6089983|NCT00687804|9701877|FG001|Core Study|Withdrawal by Subject|7
6089984|NCT00687804|9701878|FG002|Core Study|Withdrawal by Subject|7
6089985|NCT00687804|9701876|FG000|Core Study|Lost to Follow-up|0
6089986|NCT00687804|9701877|FG001|Core Study|Lost to Follow-up|1
6089987|NCT00687804|9701878|FG002|Core Study|Lost to Follow-up|0
6089988|NCT00687804|9701876|FG000|Core Study|Death|2
6089989|NCT00687804|9701877|FG001|Core Study|Death|2
6089990|NCT00687804|9701878|FG002|Core Study|Death|2
6089991|NCT00687804|9701876|FG000|Core Study|Protocol Violation|1
6089992|NCT00687804|9701877|FG001|Core Study|Protocol Violation|1
6089993|NCT00687804|9701878|FG002|Core Study|Protocol Violation|0
6089994|NCT00687804|9701876|FG000|Open-Label Extension Study|Adverse Event|2
6089995|NCT00687804|9701877|FG001|Open-Label Extension Study|Adverse Event|2
6089996|NCT00687804|9701878|FG002|Open-Label Extension Study|Adverse Event|2
6089997|NCT00687804|9701876|FG000|Open-Label Extension Study|Subject withdrew consent|3
6089998|NCT00687804|9701877|FG001|Open-Label Extension Study|Subject withdrew consent|4
6089999|NCT00687804|9701878|FG002|Open-Label Extension Study|Subject withdrew consent|4
6090000|NCT00687804|9701876|FG000|Open-Label Extension Study|Lost to Follow-up|2
6090001|NCT00687804|9701877|FG001|Open-Label Extension Study|Lost to Follow-up|1
6090002|NCT00687804|9701878|FG002|Open-Label Extension Study|Lost to Follow-up|2
6090003|NCT00687804|9701876|FG000|Open-Label Extension Study|Administrative problems|1
6090004|NCT00687804|9701877|FG001|Open-Label Extension Study|Administrative problems|1
6090005|NCT00687804|9701878|FG002|Open-Label Extension Study|Administrative problems|0
6052966|NCT00440947|9652370|FG003|Optional 60-Week Extension Phase|Participant Remained in Cuba|0
6052967|NCT00440947|9652371|FG004|Optional 60-Week Extension Phase|Participant Remained in Cuba|1
6052968|NCT00440999|9652385|FG000|Overall Study|Adverse Event|0
6052969|NCT00440999|9652386|FG001|Overall Study|Adverse Event|2
6052970|NCT00440999|9652385|FG000|Overall Study|Lack of Efficacy|6
6052971|NCT00440999|9652386|FG001|Overall Study|Lack of Efficacy|7
6052972|NCT00440999|9652385|FG000|Overall Study|Lost to Follow-up|19
6052973|NCT00440999|9652386|FG001|Overall Study|Lost to Follow-up|12
6052974|NCT00440999|9652385|FG000|Overall Study|Protocol Violation|1
6052975|NCT00440999|9652386|FG001|Overall Study|Protocol Violation|0
6052976|NCT00440999|9652385|FG000|Overall Study|Withdrawal by Subject|2
6052977|NCT00440999|9652386|FG001|Overall Study|Withdrawal by Subject|5
6052978|NCT00440999|9652385|FG000|Overall Study|Subjets missed the visit|1
6052979|NCT00440999|9652386|FG001|Overall Study|Subjets missed the visit|0
6052980|NCT00440999|9652385|FG000|Overall Study|Mixed infection at entry|1
6052981|NCT00440999|9652386|FG001|Overall Study|Mixed infection at entry|0
6052982|NCT00440999|9652385|FG000|Overall Study|P. falciparum malaria|5
6052983|NCT00440999|9652386|FG001|Overall Study|P. falciparum malaria|14
6052984|NCT00440999|9652385|FG000|Overall Study|Subj left hosp without inform staff|0
6052985|NCT00440999|9652386|FG001|Overall Study|Subj left hosp without inform staff|1
6052986|NCT00441012|9652396|FG000|Overall Study|Adverse Event|0
6052987|NCT00441012|9652397|FG001|Overall Study|Adverse Event|1
6052988|NCT00441012|9652396|FG000|Overall Study|Lost to Follow-up|3
6052989|NCT00441012|9652397|FG001|Overall Study|Lost to Follow-up|3
6052990|NCT00441012|9652396|FG000|Overall Study|Protocol Violation|10
6052991|NCT00441012|9652397|FG001|Overall Study|Protocol Violation|9
6052992|NCT00441012|9652396|FG000|Overall Study|Withdrawal by Subject|4
6052993|NCT00441012|9652397|FG001|Overall Study|Withdrawal by Subject|0
6052994|NCT00441012|9652396|FG000|Overall Study|Subject Randomized but Not Vaccinated|1
6052995|NCT00441012|9652397|FG001|Overall Study|Subject Randomized but Not Vaccinated|0
6052996|NCT00441064|9652405|FG000|Overall Study|Adverse Event|1
6052997|NCT00441064|9652406|FG001|Overall Study|Adverse Event|0
6052998|NCT00441064|9652405|FG000|Overall Study|Abnormal laboratory values|0
6052999|NCT00441064|9652406|FG001|Overall Study|Abnormal laboratory values|2
6053000|NCT00441064|9652405|FG000|Overall Study|Abnormal test procedure results|0
6053001|NCT00441064|9652406|FG001|Overall Study|Abnormal test procedure results|1
6053002|NCT00441064|9652405|FG000|Overall Study|Unsatisfactory therapeutic effect|1
6053003|NCT00441064|9652406|FG001|Overall Study|Unsatisfactory therapeutic effect|0
6053004|NCT00441064|9652405|FG000|Overall Study|Protocol Deviation|3
6053005|NCT00441064|9652406|FG001|Overall Study|Protocol Deviation|2
6053006|NCT00441064|9652405|FG000|Overall Study|Patient withdrew consent|5
6053007|NCT00441064|9652406|FG001|Overall Study|Patient withdrew consent|2
6053008|NCT00441090|9652417|FG000|Overall Study|Adverse Event|0
6053009|NCT00441090|9652418|FG001|Overall Study|Adverse Event|1
6053010|NCT00441090|9652419|FG002|Overall Study|Adverse Event|1
6053011|NCT00441090|9652420|FG003|Overall Study|Adverse Event|0
6053012|NCT00441090|9652421|FG004|Overall Study|Adverse Event|0
6053013|NCT00441090|9652417|FG000|Overall Study|Platelet increase;more than 500,000 mm^3|0
6053014|NCT00441090|9652418|FG001|Overall Study|Platelet increase;more than 500,000 mm^3|0
6053015|NCT00441090|9652419|FG002|Overall Study|Platelet increase;more than 500,000 mm^3|0
6053016|NCT00441090|9652420|FG003|Overall Study|Platelet increase;more than 500,000 mm^3|2
6053017|NCT00441090|9652421|FG004|Overall Study|Platelet increase;more than 500,000 mm^3|0
6053018|NCT00441090|9652417|FG000|Overall Study|Withdrawal by Subject|1
6053019|NCT00441090|9652418|FG001|Overall Study|Withdrawal by Subject|0
6053020|NCT00441090|9652419|FG002|Overall Study|Withdrawal by Subject|1
6053021|NCT00441090|9652420|FG003|Overall Study|Withdrawal by Subject|0
6053022|NCT00441090|9652421|FG004|Overall Study|Withdrawal by Subject|0
6053023|NCT00441090|9652417|FG000|Overall Study|Lack of Efficacy|1
6053024|NCT00441090|9652418|FG001|Overall Study|Lack of Efficacy|0
6053025|NCT00441090|9652419|FG002|Overall Study|Lack of Efficacy|0
6053026|NCT00441090|9652420|FG003|Overall Study|Lack of Efficacy|0
6053027|NCT00441090|9652421|FG004|Overall Study|Lack of Efficacy|0
6053028|NCT00441103|9652435|FG000|Overall Study|Adverse Event|2
6053029|NCT00441103|9652436|FG001|Overall Study|Adverse Event|1
6053030|NCT00441103|9652435|FG000|Overall Study|Death|1
6053031|NCT00441103|9652436|FG001|Overall Study|Death|0
6053032|NCT00441103|9652435|FG000|Overall Study|Disease Progression|2
6053033|NCT00441103|9652436|FG001|Overall Study|Disease Progression|0
6053034|NCT00441103|9652435|FG000|Overall Study|Lost to Follow-up|1
6053035|NCT00441103|9652436|FG001|Overall Study|Lost to Follow-up|0
6053036|NCT00441103|9652435|FG000|Overall Study|Protocol Violation|1
6053037|NCT00441103|9652436|FG001|Overall Study|Protocol Violation|0
6053038|NCT00441103|9652435|FG000|Overall Study|Participant unable to use Rebiject II|1
6053039|NCT00441103|9652436|FG001|Overall Study|Participant unable to use Rebiject II|0
6053040|NCT00441103|9652435|FG000|Overall Study|Participant refused MRI|1
6053041|NCT00441103|9652436|FG001|Overall Study|Participant refused MRI|0
6053042|NCT00441103|9652435|FG000|Overall Study|Inclusion criteria absent|1
6053043|NCT00441103|9652436|FG001|Overall Study|Inclusion criteria absent|0
6053044|NCT00441103|9652435|FG000|Overall Study|Non-compliant|0
6053045|NCT00441103|9652436|FG001|Overall Study|Non-compliant|1
6053046|NCT00441103|9652435|FG000|Overall Study|Participant decided to withdraw|1
6053047|NCT00441103|9652436|FG001|Overall Study|Participant decided to withdraw|0
6053048|NCT00441103|9652435|FG000|Overall Study|Participant's reason|0
6053049|NCT00441103|9652436|FG001|Overall Study|Participant's reason|1
6053050|NCT00441103|9652435|FG000|Overall Study|Participant decided to stop|0
6053051|NCT00441103|9652436|FG001|Overall Study|Participant decided to stop|1
6053052|NCT00441116|9652445|FG000|Overall Study|Adverse Event|1
6053053|NCT00441116|9652446|FG001|Overall Study|Adverse Event|1
6053054|NCT00441116|9652445|FG000|Overall Study|Withdrawal by Subject|1
6053055|NCT00441116|9652446|FG001|Overall Study|Withdrawal by Subject|0
6053056|NCT00441116|9652445|FG000|Overall Study|Did not meet Eligibility Criteria|1
6053057|NCT00441116|9652446|FG001|Overall Study|Did not meet Eligibility Criteria|1
6053058|NCT00441129|9652454|FG000|Overall Study|Withdrawal by Subject|6
6053059|NCT00441129|9652455|FG001|Overall Study|Withdrawal by Subject|14
6053060|NCT00441142|9652465|FG000|Overall Study|Adverse Event|2
6053061|NCT00441142|9652466|FG001|Overall Study|Adverse Event|3
6053062|NCT00441142|9652467|FG002|Overall Study|Adverse Event|3
6053063|NCT00441142|9652468|FG003|Overall Study|Adverse Event|22
6053064|NCT00441142|9652465|FG000|Overall Study|Lack of Efficacy|3
6053065|NCT00441142|9652466|FG001|Overall Study|Lack of Efficacy|3
6053066|NCT00441142|9652467|FG002|Overall Study|Lack of Efficacy|17
6053067|NCT00441142|9652468|FG003|Overall Study|Lack of Efficacy|32
6053068|NCT00441142|9652465|FG000|Overall Study|Withdrawal by Subject|0
6053069|NCT00441142|9652466|FG001|Overall Study|Withdrawal by Subject|0
6053070|NCT00441142|9652467|FG002|Overall Study|Withdrawal by Subject|2
6053071|NCT00441142|9652468|FG003|Overall Study|Withdrawal by Subject|10
6053072|NCT00441142|9652465|FG000|Overall Study|Patient still receiving active study tx|1
6053073|NCT00441142|9652466|FG001|Overall Study|Patient still receiving active study tx|0
6053074|NCT00441142|9652467|FG002|Overall Study|Patient still receiving active study tx|0
6053075|NCT00441142|9652468|FG003|Overall Study|Patient still receiving active study tx|2
6053076|NCT00441142|9652465|FG000|Overall Study|Physician Decision|0
6053077|NCT00441142|9652466|FG001|Overall Study|Physician Decision|1
6053078|NCT00441142|9652467|FG002|Overall Study|Physician Decision|0
6053079|NCT00441142|9652468|FG003|Overall Study|Physician Decision|1
6053080|NCT00441142|9652465|FG000|Overall Study|Death|0
6053081|NCT00441142|9652466|FG001|Overall Study|Death|0
6053082|NCT00441142|9652467|FG002|Overall Study|Death|0
6053083|NCT00441142|9652468|FG003|Overall Study|Death|1
6053084|NCT00441168|9652482|FG000|Treatment Period|Death|3
6053085|NCT00441168|9652483|FG001|Treatment Period|Death|0
6053086|NCT00441168|9652482|FG000|Treatment Period|Adverse Event|1
6053087|NCT00441168|9652483|FG001|Treatment Period|Adverse Event|2
6053088|NCT00441168|9652482|FG000|Treatment Period|Progressive Disease|0
6053089|NCT00441168|9652483|FG001|Treatment Period|Progressive Disease|2
6053090|NCT00441168|9652482|FG000|Treatment Period|Protocol Violation|0
6053091|NCT00441168|9652483|FG001|Treatment Period|Protocol Violation|1
6053092|NCT00441168|9652482|FG000|Treatment Period|Lost to Follow-up|0
6053093|NCT00441168|9652483|FG001|Treatment Period|Lost to Follow-up|1
6053094|NCT00441168|9652482|FG000|Treatment Period|Withdrawal by Subject|3
6053095|NCT00441168|9652483|FG001|Treatment Period|Withdrawal by Subject|0
6053096|NCT00441168|9652482|FG000|Treatment Period|qualified for stem-cell transplantation|3
6053097|NCT00441168|9652483|FG001|Treatment Period|qualified for stem-cell transplantation|0
6053098|NCT00441168|9652482|FG000|Treatment Period|refractory disease|1
6053099|NCT00441168|9652483|FG001|Treatment Period|refractory disease|0
6053100|NCT00441168|9652482|FG000|Follow-up Period|Death|3
6053101|NCT00441168|9652483|FG001|Follow-up Period|Death|0
6053102|NCT00441168|9652482|FG000|Follow-up Period|Lost to Follow-up|5
6053103|NCT00441168|9652483|FG001|Follow-up Period|Lost to Follow-up|6
6053104|NCT00441168|9652482|FG000|Follow-up Period|Withdrawal by Subject|3
6053105|NCT00441168|9652483|FG001|Follow-up Period|Withdrawal by Subject|0
6053106|NCT00441168|9652482|FG000|Follow-up Period|Other|1
6053107|NCT00441168|9652483|FG001|Follow-up Period|Other|3
6053108|NCT00441337|9652523|FG000|Overall Study|Disease Progression|6
6053109|NCT00441337|9652524|FG001|Overall Study|Disease Progression|6
6053110|NCT00441337|9652525|FG002|Overall Study|Disease Progression|4
6053111|NCT00441337|9652526|FG003|Overall Study|Disease Progression|18
6053112|NCT00441337|9652523|FG000|Overall Study|Lost to Follow-up|0
6053113|NCT00441337|9652524|FG001|Overall Study|Lost to Follow-up|0
6053114|NCT00441337|9652525|FG002|Overall Study|Lost to Follow-up|0
6053115|NCT00441337|9652526|FG003|Overall Study|Lost to Follow-up|1
6053116|NCT00441337|9652523|FG000|Overall Study|Sponsor Decision|0
6053117|NCT00441337|9652524|FG001|Overall Study|Sponsor Decision|0
6053118|NCT00441337|9652525|FG002|Overall Study|Sponsor Decision|1
6053119|NCT00441337|9652526|FG003|Overall Study|Sponsor Decision|2
6053120|NCT00441337|9652523|FG000|Overall Study|Did not meet inclusion criteria|0
6053121|NCT00441337|9652524|FG001|Overall Study|Did not meet inclusion criteria|0
6053122|NCT00441337|9652525|FG002|Overall Study|Did not meet inclusion criteria|1
6053123|NCT00441337|9652526|FG003|Overall Study|Did not meet inclusion criteria|0
6053124|NCT00441363|9652567|FG000|Overall Study|Adverse Event|4
6053125|NCT00441363|9652568|FG001|Overall Study|Adverse Event|2
6053126|NCT00441363|9652567|FG000|Overall Study|Withdrawal by Subject|3
6053127|NCT00441363|9652568|FG001|Overall Study|Withdrawal by Subject|4
6053128|NCT00441363|9652567|FG000|Overall Study|Physician Decision|6
6053129|NCT00441363|9652568|FG001|Overall Study|Physician Decision|7
6053130|NCT00441363|9652567|FG000|Overall Study|Lost to Follow-up|2
6053131|NCT00441363|9652568|FG001|Overall Study|Lost to Follow-up|2
6053132|NCT00441363|9652567|FG000|Overall Study|Other|2
6053133|NCT00441363|9652568|FG001|Overall Study|Other|0
6053134|NCT00441441|9652576|FG000|Overall Study|Adverse Event|2
6053135|NCT00441441|9652577|FG001|Overall Study|Adverse Event|1
6053136|NCT00441441|9652576|FG000|Overall Study|Protocol Violation|4
6053137|NCT00441441|9652577|FG001|Overall Study|Protocol Violation|6
6053138|NCT00441441|9652576|FG000|Overall Study|Exacerbation of asthma|1
6090006|NCT00687804|9701876|FG000|Open-Label Extension Study|Death|2
6090007|NCT00687804|9701877|FG001|Open-Label Extension Study|Death|3
6090008|NCT00687804|9701878|FG002|Open-Label Extension Study|Death|3
6090009|NCT00687973|9701916|FG000|Overall Study|Adverse Event|18
6090010|NCT00687973|9701917|FG001|Overall Study|Adverse Event|28
6090011|NCT00687973|9701916|FG000|Overall Study|Lack of Efficacy|2
6090012|NCT00687973|9701917|FG001|Overall Study|Lack of Efficacy|3
6090013|NCT00687973|9701916|FG000|Overall Study|Protocol Violation|1
6090014|NCT00687973|9701917|FG001|Overall Study|Protocol Violation|2
6090015|NCT00687973|9701916|FG000|Overall Study|Administrative Reasons|0
6090016|NCT00687973|9701917|FG001|Overall Study|Administrative Reasons|2
6090017|NCT00687973|9701916|FG000|Overall Study|Withdrawal by Subject|3
6090018|NCT00687973|9701917|FG001|Overall Study|Withdrawal by Subject|3
6090019|NCT00688064|9701926|FG000|Overall Study|Protocol Violation|0
6090020|NCT00688064|9701927|FG001|Overall Study|Protocol Violation|1
6090021|NCT00688064|9701926|FG000|Overall Study|Adverse Event|2
6090022|NCT00688064|9701927|FG001|Overall Study|Adverse Event|4
6090023|NCT00688064|9701926|FG000|Overall Study|Withdrawal by Subject|7
6090024|NCT00688064|9701927|FG001|Overall Study|Withdrawal by Subject|7
6090025|NCT00688064|9701926|FG000|Overall Study|Lost to Follow-up|10
6090026|NCT00688064|9701927|FG001|Overall Study|Lost to Follow-up|10
6090027|NCT00688064|9701926|FG000|Overall Study|Lack of Efficacy|0
6090028|NCT00688064|9701927|FG001|Overall Study|Lack of Efficacy|1
6090029|NCT00688064|9701926|FG000|Overall Study|Pregnancy|1
6090030|NCT00688064|9701927|FG001|Overall Study|Pregnancy|0
6090031|NCT00688064|9701926|FG000|Overall Study|Any other reasons|1
6090032|NCT00688064|9701927|FG001|Overall Study|Any other reasons|3
6090033|NCT00688103|9701935|FG000|Overall Study|Adverse Event|4
6090034|NCT00688103|9701936|FG001|Overall Study|Adverse Event|1
6090035|NCT00688103|9701935|FG000|Overall Study|Lack of Efficacy|11
6090036|NCT00688103|9701936|FG001|Overall Study|Lack of Efficacy|1
6090037|NCT00688103|9701935|FG000|Overall Study|Withdrawal by Subject|4
6090038|NCT00688103|9701936|FG001|Overall Study|Withdrawal by Subject|2
6090039|NCT00688103|9701935|FG000|Overall Study|complex reasons|11
6090040|NCT00688103|9701936|FG001|Overall Study|complex reasons|9
6090041|NCT00688155|9701948|FG000|Overall Study|Withdrawal by Subject|2
6090042|NCT00688155|9701949|FG001|Overall Study|Withdrawal by Subject|2
6090043|NCT00688155|9701950|FG002|Overall Study|Withdrawal by Subject|1
6090044|NCT00688155|9701951|FG003|Overall Study|Withdrawal by Subject|1
6090045|NCT00688181|9701961|FG000|Overall Study|Lost to Follow-up|17
6090046|NCT00688181|9701961|FG000|Overall Study|Unknown Reason|4
6090047|NCT00688181|9701961|FG000|Overall Study|Non-clinical Reason|2
6090048|NCT00688259|9701969|FG000|Overall Study|Lost to Follow-up|2
6090049|NCT00688259|9701970|FG001|Overall Study|Lost to Follow-up|4
6090050|NCT00688259|9701969|FG000|Overall Study|Physician Decision|1
6090051|NCT00688259|9701970|FG001|Overall Study|Physician Decision|0
6090052|NCT00688259|9701969|FG000|Overall Study|Withdrawal by Subject|2
6090053|NCT00688259|9701970|FG001|Overall Study|Withdrawal by Subject|0
6090054|NCT00688259|9701969|FG000|Overall Study|Declined Interview|2
6090055|NCT00688259|9701970|FG001|Overall Study|Declined Interview|3
6090056|NCT00688259|9701969|FG000|Overall Study|Hospitalized at Follow-up|0
6090057|NCT00688259|9701970|FG001|Overall Study|Hospitalized at Follow-up|1
6090058|NCT00688324|9701976|FG000|Overall Study|Withdrawal by Subject|2
6090059|NCT00688324|9701976|FG000|Overall Study|Physician Decision|5
6090060|NCT00688324|9701976|FG000|Overall Study|Lost to Follow-up|1
6090061|NCT00688467|9701983|FG000|Treatment Period 1|Adverse Event|2
6090062|NCT00688467|9701984|FG001|Treatment Period 1|Adverse Event|1
6090063|NCT00688467|9701983|FG000|Treatment Period 1|Did not meet protocol eligibility|0
6090064|NCT00688467|9701984|FG001|Treatment Period 1|Did not meet protocol eligibility|1
6090065|NCT00688467|9701983|FG000|Treatment Period 2|Protocol Violation|0
6090066|NCT00688467|9701984|FG001|Treatment Period 2|Protocol Violation|1
6090067|NCT00688467|9701983|FG000|Treatment Period 2|Adverse Event|0
6090068|NCT00688467|9701984|FG001|Treatment Period 2|Adverse Event|1
6090069|NCT00688519|9701992|FG000|Overall Study|Adverse Event|2
6090070|NCT00688519|9701993|FG001|Overall Study|Adverse Event|3
6090071|NCT00688519|9701992|FG000|Overall Study|Lost to Follow-up|3
6090072|NCT00688519|9701993|FG001|Overall Study|Lost to Follow-up|3
6090073|NCT00688519|9701992|FG000|Overall Study|Lack of Efficacy|3
6090074|NCT00688519|9701993|FG001|Overall Study|Lack of Efficacy|1
6090075|NCT00688519|9701992|FG000|Overall Study|Withdrawal by Subject|7
6053139|NCT00441441|9652577|FG001|Overall Study|Exacerbation of asthma|2
6053140|NCT00441441|9652576|FG000|Overall Study|Withdrawal by Subject|1
6090076|NCT00688519|9701993|FG001|Overall Study|Withdrawal by Subject|6
6090077|NCT00688519|9701992|FG000|Overall Study|Prohibited medication|1
6090078|NCT00688519|9701993|FG001|Overall Study|Prohibited medication|0
6090079|NCT00688519|9701992|FG000|Overall Study|Non-compliance|0
6053141|NCT00441441|9652577|FG001|Overall Study|Withdrawal by Subject|2
6053142|NCT00441441|9652576|FG000|Overall Study|Other|3
6053143|NCT00441441|9652577|FG001|Overall Study|Other|3
6053144|NCT00441467|9652597|FG000|Overall Study|Adverse Event|6
6053145|NCT00441467|9652597|FG000|Overall Study|Withdrawal by Subject|3
6053146|NCT00441467|9652597|FG000|Overall Study|Progressive disease|9
6053147|NCT00441480|9652603|FG000|Overall Study|Protocol Violation|1
6053148|NCT00441480|9652604|FG001|Overall Study|Protocol Violation|1
6053149|NCT00441480|9652603|FG000|Overall Study|Withdrawal by Subject|2
6053150|NCT00441480|9652604|FG001|Overall Study|Withdrawal by Subject|3
6053151|NCT00441545|9652610|FG000|First Intervention|Adverse Event|6
6053152|NCT00441545|9652611|FG001|First Intervention|Adverse Event|5
6053153|NCT00441545|9652610|FG000|First Intervention|Protocol Violation|2
6053154|NCT00441545|9652611|FG001|First Intervention|Protocol Violation|2
6053155|NCT00441545|9652610|FG000|First Intervention|Withdrawal by Subject|3
6053156|NCT00441545|9652611|FG001|First Intervention|Withdrawal by Subject|3
6053157|NCT00441545|9652610|FG000|First Intervention|Kidney transplant|1
6053158|NCT00441545|9652611|FG001|First Intervention|Kidney transplant|1
6053159|NCT00441545|9652610|FG000|First Intervention|Lack of Efficacy|2
6053160|NCT00441545|9652611|FG001|First Intervention|Lack of Efficacy|0
6053161|NCT00441545|9652610|FG000|First Intervention|Subject exceeded safety criteria|0
6053162|NCT00441545|9652611|FG001|First Intervention|Subject exceeded safety criteria|1
6053163|NCT00441545|9652610|FG000|First Intervention|Subject met an exclusionary criteria|1
6053164|NCT00441545|9652611|FG001|First Intervention|Subject met an exclusionary criteria|0
6053165|NCT00441545|9652610|FG000|First Intervention|Extended hospitalization|1
6053166|NCT00441545|9652611|FG001|First Intervention|Extended hospitalization|0
6053167|NCT00441545|9652610|FG000|First Intervention|Site error|1
6053168|NCT00441545|9652611|FG001|First Intervention|Site error|0
6053169|NCT00441545|9652610|FG000|First Intervention|Sponsor's request|1
6053170|NCT00441545|9652611|FG001|First Intervention|Sponsor's request|0
6053171|NCT00441545|9652610|FG000|Second Intervention|Adverse Event|5
6053172|NCT00441545|9652611|FG001|Second Intervention|Adverse Event|2
6053173|NCT00441545|9652610|FG000|Second Intervention|Protocol Violation|4
6053174|NCT00441545|9652611|FG001|Second Intervention|Protocol Violation|1
6053175|NCT00441545|9652610|FG000|Second Intervention|Withdrawal by Subject|1
6053176|NCT00441545|9652611|FG001|Second Intervention|Withdrawal by Subject|1
6053177|NCT00441545|9652610|FG000|Second Intervention|Kidney Transplant|1
6053178|NCT00441545|9652611|FG001|Second Intervention|Kidney Transplant|1
6053179|NCT00441545|9652610|FG000|Second Intervention|Lack of Efficacy|0
6053180|NCT00441545|9652611|FG001|Second Intervention|Lack of Efficacy|1
6053181|NCT00441545|9652610|FG000|Second Intervention|Subject exceeded safety criteria|1
6053182|NCT00441545|9652611|FG001|Second Intervention|Subject exceeded safety criteria|0
6053183|NCT00441545|9652610|FG000|Second Intervention|Subject moved|0
6053184|NCT00441545|9652611|FG001|Second Intervention|Subject moved|1
6053185|NCT00441584|9652621|FG000|Overall Study|Lack of Efficacy|79
6053186|NCT00441584|9652621|FG000|Overall Study|Withdrawal by Subject|8
6053187|NCT00441584|9652621|FG000|Overall Study|Adverse Event|6
6053188|NCT00441584|9652621|FG000|Overall Study|Protocol Violation|5
6053189|NCT00441584|9652621|FG000|Overall Study|Lost to Follow-up|4
6053190|NCT00441584|9652621|FG000|Overall Study|Failure to meet eligibility criteria|3
6053191|NCT00441701|9652635|FG000|Overall Study|Adverse Event|3
6053192|NCT00441701|9652636|FG001|Overall Study|Adverse Event|2
6053193|NCT00441701|9652637|FG002|Overall Study|Adverse Event|1
6053194|NCT00441701|9652638|FG003|Overall Study|Adverse Event|0
6053195|NCT00441701|9652639|FG004|Overall Study|Adverse Event|2
6053196|NCT00441701|9652640|FG005|Overall Study|Adverse Event|2
6053197|NCT00441701|9652641|FG006|Overall Study|Adverse Event|0
6053198|NCT00441701|9652642|FG007|Overall Study|Adverse Event|0
6053199|NCT00441701|9652643|FG008|Overall Study|Adverse Event|0
6053200|NCT00441701|9652644|FG009|Overall Study|Adverse Event|0
6053201|NCT00441701|9652635|FG000|Overall Study|Lack of Efficacy|2
6053202|NCT00441701|9652636|FG001|Overall Study|Lack of Efficacy|0
6053203|NCT00441701|9652637|FG002|Overall Study|Lack of Efficacy|2
6053204|NCT00441701|9652638|FG003|Overall Study|Lack of Efficacy|2
6053205|NCT00441701|9652639|FG004|Overall Study|Lack of Efficacy|0
6053206|NCT00441701|9652640|FG005|Overall Study|Lack of Efficacy|1
6053207|NCT00441701|9652641|FG006|Overall Study|Lack of Efficacy|0
6053208|NCT00441701|9652642|FG007|Overall Study|Lack of Efficacy|0
6053209|NCT00441701|9652643|FG008|Overall Study|Lack of Efficacy|0
6053210|NCT00441701|9652644|FG009|Overall Study|Lack of Efficacy|0
6053211|NCT00441701|9652635|FG000|Overall Study|Withdrawal by Subject|0
6053212|NCT00441701|9652636|FG001|Overall Study|Withdrawal by Subject|2
6053213|NCT00441701|9652637|FG002|Overall Study|Withdrawal by Subject|1
6053214|NCT00441701|9652638|FG003|Overall Study|Withdrawal by Subject|1
6053215|NCT00441701|9652639|FG004|Overall Study|Withdrawal by Subject|0
6053216|NCT00441701|9652640|FG005|Overall Study|Withdrawal by Subject|0
6053217|NCT00441701|9652641|FG006|Overall Study|Withdrawal by Subject|0
6053218|NCT00441701|9652642|FG007|Overall Study|Withdrawal by Subject|0
6053219|NCT00441701|9652643|FG008|Overall Study|Withdrawal by Subject|0
6053220|NCT00441701|9652644|FG009|Overall Study|Withdrawal by Subject|0
6053221|NCT00441727|9652665|FG000|Overall Study|Protocol Violation|19
6053222|NCT00441727|9652666|FG001|Overall Study|Protocol Violation|28
6053223|NCT00441727|9652667|FG002|Overall Study|Protocol Violation|32
6053224|NCT00441727|9652665|FG000|Overall Study|Adverse Event|26
6053225|NCT00441727|9652666|FG001|Overall Study|Adverse Event|33
6053226|NCT00441727|9652667|FG002|Overall Study|Adverse Event|28
6053227|NCT00441727|9652665|FG000|Overall Study|Lack of Efficacy|7
6053228|NCT00441727|9652666|FG001|Overall Study|Lack of Efficacy|8
6053229|NCT00441727|9652667|FG002|Overall Study|Lack of Efficacy|48
6053230|NCT00441727|9652665|FG000|Overall Study|Withdrawal by Subject|40
6053231|NCT00441727|9652666|FG001|Overall Study|Withdrawal by Subject|34
6053232|NCT00441727|9652667|FG002|Overall Study|Withdrawal by Subject|47
6053233|NCT00441727|9652665|FG000|Overall Study|Lost to Follow-up|5
6053234|NCT00441727|9652666|FG001|Overall Study|Lost to Follow-up|6
6053235|NCT00441727|9652667|FG002|Overall Study|Lost to Follow-up|5
6053236|NCT00441727|9652665|FG000|Overall Study|Safety Reasons|3
6053237|NCT00441727|9652666|FG001|Overall Study|Safety Reasons|1
6053238|NCT00441727|9652667|FG002|Overall Study|Safety Reasons|3
6053239|NCT00441727|9652665|FG000|Overall Study|Various reason specified|6
6053240|NCT00441727|9652666|FG001|Overall Study|Various reason specified|8
6053241|NCT00441727|9652667|FG002|Overall Study|Various reason specified|5
6053242|NCT00441792|9652699|FG000|Overall Study|Lost to Follow-up|0
6053243|NCT00441792|9652700|FG001|Overall Study|Lost to Follow-up|2
6053244|NCT00441974|9652727|FG000|Overall Study|Adverse Event|6
6053245|NCT00441974|9652727|FG000|Overall Study|Consent Withdrawn|35
6053246|NCT00441974|9652727|FG000|Overall Study|Lost to Follow-up|80
6053247|NCT00441974|9652727|FG000|Overall Study|Protocol Violation|7
6053248|NCT00442286|9652772|FG000|Overall Study|Death|2
6053249|NCT00442286|9652773|FG001|Overall Study|Death|2
6053250|NCT00442286|9652772|FG000|Overall Study|Lost to Follow-up|1
6053251|NCT00442286|9652773|FG001|Overall Study|Lost to Follow-up|0
6053252|NCT00442286|9652772|FG000|Overall Study|Withdrawal by Subject|2
6053253|NCT00442286|9652773|FG001|Overall Study|Withdrawal by Subject|0
6053254|NCT00442286|9652772|FG000|Overall Study|System explanted|1
6053255|NCT00442286|9652773|FG001|Overall Study|System explanted|0
6090080|NCT00688519|9701993|FG001|Overall Study|Non-compliance|1
6090081|NCT00688519|9701992|FG000|Overall Study|Subject moved out of state|1
6090082|NCT00688519|9701993|FG001|Overall Study|Subject moved out of state|0
6090083|NCT00688519|9701992|FG000|Overall Study|Investigator decision|1
6090084|NCT00688519|9701993|FG001|Overall Study|Investigator decision|0
6090085|NCT00688519|9701992|FG000|Overall Study|Subject moved out of area|1
6090086|NCT00688519|9701993|FG001|Overall Study|Subject moved out of area|0
6090087|NCT00688519|9701992|FG000|Overall Study|Pregnancy|0
6090088|NCT00688519|9701993|FG001|Overall Study|Pregnancy|1
6090089|NCT00688545|9702001|FG000|Overall Study|Lost to Follow-up|1
6090090|NCT00688545|9702002|FG001|Overall Study|Lost to Follow-up|4
6090091|NCT00688545|9702001|FG000|Overall Study|Insurance/cost of drug|0
6090092|NCT00688545|9702002|FG001|Overall Study|Insurance/cost of drug|1
6090093|NCT00688545|9702001|FG000|Overall Study|Withdrawal by Subject|2
6090094|NCT00688545|9702002|FG001|Overall Study|Withdrawal by Subject|3
6090095|NCT00688545|9702001|FG000|Overall Study|Unspecified, unrelated to AE/Toxicity|2
6090096|NCT00688545|9702002|FG001|Overall Study|Unspecified, unrelated to AE/Toxicity|7
6090097|NCT00688597|9702013|FG000|Overall Study|Adverse Event|2
6090098|NCT00688597|9702014|FG001|Overall Study|Adverse Event|0
6090099|NCT00688597|9702015|FG002|Overall Study|Adverse Event|0
6090100|NCT00688597|9702013|FG000|Overall Study|Physician Decision|1
6090101|NCT00688597|9702014|FG001|Overall Study|Physician Decision|0
6090102|NCT00688597|9702015|FG002|Overall Study|Physician Decision|0
6090103|NCT00688623|9702023|FG000|Overall Study|Adverse Event|22
6090104|NCT00688623|9702023|FG000|Overall Study|abnormal lab value|1
6090105|NCT00688623|9702023|FG000|Overall Study|Withdrawal by Subject|4
6090106|NCT00688623|9702023|FG000|Overall Study|Death|3
6090107|NCT00688623|9702023|FG000|Overall Study|disease progression|23
6090108|NCT00688623|9702023|FG000|Overall Study|Protocol Violation|2
6090109|NCT00688636|9702029|FG000|Overall Study|Adverse Event|2
6090110|NCT00688636|9702030|FG001|Overall Study|Adverse Event|1
6090111|NCT00688688|9702049|FG000|Overall Study|Eligibility criterion not met|7
6090112|NCT00688688|9702050|FG001|Overall Study|Eligibility criterion not met|7
6090113|NCT00688688|9702051|FG002|Overall Study|Eligibility criterion not met|10
6090114|NCT00688688|9702049|FG000|Overall Study|Adverse Event|52
6090115|NCT00688688|9702050|FG001|Overall Study|Adverse Event|51
6090116|NCT00688688|9702051|FG002|Overall Study|Adverse Event|50
6090117|NCT00688688|9702049|FG000|Overall Study|Lack of Efficacy|34
6090118|NCT00688688|9702050|FG001|Overall Study|Lack of Efficacy|25
6090119|NCT00688688|9702051|FG002|Overall Study|Lack of Efficacy|45
6090120|NCT00688688|9702049|FG000|Overall Study|Withdrawal by Subject|66
6090121|NCT00688688|9702050|FG001|Overall Study|Withdrawal by Subject|75
6053256|NCT00442286|9652772|FG000|Overall Study|Patient Injury|1
6053257|NCT00442286|9652773|FG001|Overall Study|Patient Injury|0
6053258|NCT00442416|9652787|FG000|Overall Study|Adverse Event|4
6090122|NCT00688688|9702051|FG002|Overall Study|Withdrawal by Subject|65
6090123|NCT00688688|9702049|FG000|Overall Study|Lost to Follow-up|14
6090124|NCT00688688|9702050|FG001|Overall Study|Lost to Follow-up|7
6053259|NCT00442416|9652788|FG001|Overall Study|Adverse Event|1
6053260|NCT00442416|9652787|FG000|Overall Study|Death|1
6053261|NCT00442416|9652788|FG001|Overall Study|Death|0
6053262|NCT00442416|9652787|FG000|Overall Study|Lack of Efficacy|2
6053263|NCT00442416|9652788|FG001|Overall Study|Lack of Efficacy|0
6053264|NCT00442416|9652787|FG000|Overall Study|Protocol Violation|2
6053265|NCT00442416|9652788|FG001|Overall Study|Protocol Violation|3
6053266|NCT00442416|9652787|FG000|Overall Study|Withdrew consent|1
6053267|NCT00442416|9652788|FG001|Overall Study|Withdrew consent|2
6053268|NCT00442416|9652787|FG000|Overall Study|Administrative/Other|27
6053269|NCT00442416|9652788|FG001|Overall Study|Administrative/Other|33
6053270|NCT00442468|9652794|FG000|Overall Study|Adverse Event|4
6053271|NCT00442468|9652794|FG000|Overall Study|Withdrawal by Subject|91
6053272|NCT00442468|9652794|FG000|Overall Study|Did not complete all study procedures|88
6053273|NCT00442572|9652804|FG000|Overall Study|Relapse|8
6053274|NCT00442572|9652805|FG001|Overall Study|Relapse|1
6053275|NCT00442572|9652804|FG000|Overall Study|Lost to Follow-up|0
6053276|NCT00442572|9652805|FG001|Overall Study|Lost to Follow-up|1
6053277|NCT00442572|9652804|FG000|Overall Study|Withdrawal by Subject|0
6053278|NCT00442572|9652805|FG001|Overall Study|Withdrawal by Subject|1
6053279|NCT00442598|9652815|FG000|Overall Study|Adverse Event|1
6053280|NCT00442598|9652816|FG001|Overall Study|Adverse Event|0
6053281|NCT00442598|9652817|FG002|Overall Study|Adverse Event|0
6053282|NCT00442598|9652815|FG000|Overall Study|Tumor progression|3
6053283|NCT00442598|9652816|FG001|Overall Study|Tumor progression|4
6053284|NCT00442598|9652817|FG002|Overall Study|Tumor progression|0
6053285|NCT00442598|9652815|FG000|Overall Study|Clinical deterioration|1
6053286|NCT00442598|9652816|FG001|Overall Study|Clinical deterioration|2
6053287|NCT00442598|9652817|FG002|Overall Study|Clinical deterioration|0
6053288|NCT00442598|9652815|FG000|Overall Study|CA125 progression|0
6053289|NCT00442598|9652816|FG001|Overall Study|CA125 progression|1
6053290|NCT00442598|9652817|FG002|Overall Study|CA125 progression|0
6053291|NCT00442598|9652815|FG000|Overall Study|Reduced creatinine clearance|1
6053292|NCT00442598|9652816|FG001|Overall Study|Reduced creatinine clearance|0
6053293|NCT00442598|9652817|FG002|Overall Study|Reduced creatinine clearance|0
6053294|NCT00442598|9652815|FG000|Overall Study|Death|0
6053295|NCT00442598|9652816|FG001|Overall Study|Death|1
6053296|NCT00442598|9652817|FG002|Overall Study|Death|0
6053297|NCT00442702|9652848|FG000|Titration Period|Adverse Event|2
6053298|NCT00442702|9652849|FG001|Titration Period|Adverse Event|0
6053299|NCT00442702|9652848|FG000|Titration Period|Death|3
6053300|NCT00442702|9652849|FG001|Titration Period|Death|2
6053301|NCT00442702|9652848|FG000|Titration Period|Insufficient Therapeutic Response|1
6053302|NCT00442702|9652849|FG001|Titration Period|Insufficient Therapeutic Response|0
6053303|NCT00442702|9652848|FG000|Titration Period|Refused Treatment|4
6053304|NCT00442702|9652849|FG001|Titration Period|Refused Treatment|1
6053305|NCT00442702|9652848|FG000|Titration Period|Failure to return|1
6053306|NCT00442702|9652849|FG001|Titration Period|Failure to return|0
6053307|NCT00442702|9652848|FG000|Titration Period|Hospitalized in another hospital|1
6053308|NCT00442702|9652849|FG001|Titration Period|Hospitalized in another hospital|0
6053309|NCT00442702|9652848|FG000|Evaluation Period|Adverse Event|1
6053310|NCT00442702|9652849|FG001|Evaluation Period|Adverse Event|0
6053311|NCT00442702|9652848|FG000|Evaluation Period|Death|1
6053312|NCT00442702|9652849|FG001|Evaluation Period|Death|1
6053313|NCT00442702|9652848|FG000|Evaluation Period|Insufficient Therapeutic Response|1
6053314|NCT00442702|9652849|FG001|Evaluation Period|Insufficient Therapeutic Response|0
6053315|NCT00442702|9652848|FG000|Evaluation Period|Refused treatment|1
6053316|NCT00442702|9652849|FG001|Evaluation Period|Refused treatment|1
6053317|NCT00442702|9652848|FG000|Evaluation Period|Renal transplant|0
6053318|NCT00442702|9652849|FG001|Evaluation Period|Renal transplant|1
6053319|NCT00442702|9652848|FG000|Evaluation Period|Failure to return|1
6053320|NCT00442702|9652849|FG001|Evaluation Period|Failure to return|0
6053321|NCT00442702|9652848|FG000|Evaluation Period|Site closure|0
6053322|NCT00442702|9652849|FG001|Evaluation Period|Site closure|1
6053323|NCT00442936|9652865|FG000|Overall Study|Protocol Violation|1
6053324|NCT00442936|9652866|FG001|Overall Study|Protocol Violation|0
6053325|NCT00442936|9652867|FG002|Overall Study|Protocol Violation|1
6053326|NCT00442936|9652868|FG003|Overall Study|Protocol Violation|1
6053327|NCT00442962|9652878|FG000|Overall Study|Pregnancy|1
6053328|NCT00442962|9652878|FG000|Overall Study|Lost to Follow-up|7
6053329|NCT00443053|9652884|FG000|Overall Study|Adverse Event|2
6053330|NCT00443053|9652885|FG001|Overall Study|Adverse Event|1
6090125|NCT00688688|9702051|FG002|Overall Study|Lost to Follow-up|7
6090126|NCT00688688|9702049|FG000|Overall Study|Protocol Violation|6
6090127|NCT00688688|9702050|FG001|Overall Study|Protocol Violation|9
6090128|NCT00688688|9702051|FG002|Overall Study|Protocol Violation|11
6090129|NCT00688688|9702049|FG000|Overall Study|Randomized but never received study drug|1
6090130|NCT00688688|9702050|FG001|Overall Study|Randomized but never received study drug|0
6090131|NCT00688688|9702051|FG002|Overall Study|Randomized but never received study drug|0
6090132|NCT00688688|9702049|FG000|Overall Study|Non-compliance with study procedures|5
6202164|NCT01499368|9862266|FG002|Overall Study|Did not meet I/E criteria|4
6202165|NCT01499368|9862264|FG000|Overall Study|Prohibited Concomitant medication|1
6202166|NCT01499368|9862265|FG001|Overall Study|Prohibited Concomitant medication|1
6202167|NCT01499368|9862266|FG002|Overall Study|Prohibited Concomitant medication|0
6202168|NCT01499368|9862264|FG000|Overall Study|Withdrawal by Subject|11
6202169|NCT01499368|9862265|FG001|Overall Study|Withdrawal by Subject|10
6202170|NCT01499368|9862266|FG002|Overall Study|Withdrawal by Subject|8
6202171|NCT01499368|9862264|FG000|Overall Study|Lost to Follow-up|3
6284205|NCT02326272|9996337|FG009|Initial Period (Week 0 to Week 16)|Withdrawal by Subject|0
6053331|NCT00443053|9652884|FG000|Overall Study|Withdrawal by Subject|9
6053332|NCT00443053|9652885|FG001|Overall Study|Withdrawal by Subject|18
6053333|NCT00443053|9652884|FG000|Overall Study|Lost to Follow-up|4
6053334|NCT00443053|9652885|FG001|Overall Study|Lost to Follow-up|5
6053335|NCT00443053|9652884|FG000|Overall Study|Did Not Meet Eligibility Criteria|1
6053336|NCT00443053|9652885|FG001|Overall Study|Did Not Meet Eligibility Criteria|0
6053337|NCT00443053|9652884|FG000|Overall Study|Noncompliance|2
6053338|NCT00443053|9652885|FG001|Overall Study|Noncompliance|1
6053339|NCT00443053|9652884|FG000|Overall Study|Other|3
6053340|NCT00443053|9652885|FG001|Overall Study|Other|4
6053341|NCT00443053|9652884|FG000|Overall Study|Physician Decision|0
6053342|NCT00443053|9652885|FG001|Overall Study|Physician Decision|4
6053343|NCT00443079|9652893|FG000|Overall Study|Lost to Follow-up|0
6053344|NCT00443079|9652894|FG001|Overall Study|Lost to Follow-up|1
6053345|NCT00443118|9652905|FG000|Overall Study|unknown primary outcome|3
6053346|NCT00443118|9652906|FG001|Overall Study|unknown primary outcome|1
6053347|NCT00443118|9652907|FG002|Overall Study|unknown primary outcome|0
6053348|NCT00443118|9652905|FG000|Overall Study|Withdrawal by Subject|1
6053349|NCT00443118|9652906|FG001|Overall Study|Withdrawal by Subject|0
6053350|NCT00443118|9652907|FG002|Overall Study|Withdrawal by Subject|0
6090133|NCT00688688|9702050|FG001|Overall Study|Non-compliance with study procedures|3
6090134|NCT00688688|9702051|FG002|Overall Study|Non-compliance with study procedures|4
6090135|NCT00688688|9702049|FG000|Overall Study|Taking exclusionary medications|1
6090136|NCT00688688|9702050|FG001|Overall Study|Taking exclusionary medications|0
6090137|NCT00688688|9702051|FG002|Overall Study|Taking exclusionary medications|0
6090138|NCT00688688|9702049|FG000|Overall Study|Site closure|0
6090139|NCT00688688|9702050|FG001|Overall Study|Site closure|1
6090140|NCT00688688|9702051|FG002|Overall Study|Site closure|0
6090141|NCT00688688|9702049|FG000|Overall Study|Violation of exclusion criterion|0
6090142|NCT00688688|9702050|FG001|Overall Study|Violation of exclusion criterion|1
6090143|NCT00688688|9702051|FG002|Overall Study|Violation of exclusion criterion|0
6090144|NCT00688701|9702062|FG000|Overall Study|Adverse Event|1
6090145|NCT00688701|9702063|FG001|Overall Study|Adverse Event|0
6090146|NCT00688701|9702064|FG002|Overall Study|Adverse Event|5
6090147|NCT00688701|9702065|FG003|Overall Study|Adverse Event|3
6090148|NCT00688701|9702062|FG000|Overall Study|Lack of Efficacy|0
6284206|NCT02326272|9996338|FG010|Initial Period (Week 0 to Week 16)|Withdrawal by Subject|0
6284207|NCT02326272|9996339|FG011|Initial Period (Week 0 to Week 16)|Withdrawal by Subject|0
6284208|NCT02326272|9996340|FG012|Initial Period (Week 0 to Week 16)|Withdrawal by Subject|0
6284209|NCT02326272|9996341|FG013|Initial Period (Week 0 to Week 16)|Withdrawal by Subject|0
6284210|NCT02326272|9996342|FG014|Initial Period (Week 0 to Week 16)|Withdrawal by Subject|0
6284211|NCT02326272|9996328|FG000|Initial Period (Week 0 to Week 16)|Moved from the study area|0
6090149|NCT00688701|9702063|FG001|Overall Study|Lack of Efficacy|1
6090150|NCT00688701|9702064|FG002|Overall Study|Lack of Efficacy|0
6090151|NCT00688701|9702065|FG003|Overall Study|Lack of Efficacy|0
6284212|NCT02326272|9996329|FG001|Initial Period (Week 0 to Week 16)|Moved from the study area|0
6284213|NCT02326272|9996330|FG002|Initial Period (Week 0 to Week 16)|Moved from the study area|1
6284214|NCT02326272|9996331|FG003|Initial Period (Week 0 to Week 16)|Moved from the study area|0
6090152|NCT00688701|9702062|FG000|Overall Study|Withdrawal by Subject|3
6090153|NCT00688701|9702063|FG001|Overall Study|Withdrawal by Subject|3
6090154|NCT00688701|9702064|FG002|Overall Study|Withdrawal by Subject|4
6090155|NCT00688701|9702065|FG003|Overall Study|Withdrawal by Subject|8
6090156|NCT00688701|9702062|FG000|Overall Study|Poor compliance to protocol|0
6090157|NCT00688701|9702063|FG001|Overall Study|Poor compliance to protocol|1
6090158|NCT00688701|9702064|FG002|Overall Study|Poor compliance to protocol|1
6090159|NCT00688701|9702065|FG003|Overall Study|Poor compliance to protocol|0
6090160|NCT00688740|9702078|FG000|Overall Study|Adverse Event|45
6090161|NCT00688740|9702079|FG001|Overall Study|Adverse Event|8
6090162|NCT00688740|9702078|FG000|Overall Study|Death|2
6090163|NCT00688740|9702079|FG001|Overall Study|Death|2
6090164|NCT00688740|9702078|FG000|Overall Study|Lost to Follow-up|0
6090165|NCT00688740|9702079|FG001|Overall Study|Lost to Follow-up|1
6090166|NCT00688740|9702078|FG000|Overall Study|Consent Withdrawn|17
6090167|NCT00688740|9702079|FG001|Overall Study|Consent Withdrawn|17
6090168|NCT00688740|9702078|FG000|Overall Study|Breast Cancer Relapse|1
6090169|NCT00688740|9702079|FG001|Overall Study|Breast Cancer Relapse|4
6090170|NCT00688740|9702078|FG000|Overall Study|Violation of Inclusion Criteria|1
6090171|NCT00688740|9702079|FG001|Overall Study|Violation of Inclusion Criteria|3
6090172|NCT00688753|9702085|FG000|Overall Study|Disease progression|55
6090173|NCT00688753|9702085|FG000|Overall Study|Missing|1
6090174|NCT00688753|9702085|FG000|Overall Study|Death|9
6090175|NCT00688753|9702085|FG000|Overall Study|Withdrawal by Subject|3
6090176|NCT00688753|9702085|FG000|Overall Study|Adverse Event|20
6090177|NCT00688753|9702085|FG000|Overall Study|Protocol Violation|1
6090178|NCT00688753|9702085|FG000|Overall Study|Lost to Follow-up|3
6090179|NCT00688844|9702089|FG000|Overall Study|Lost to Follow-up|10
6090180|NCT00688870|9702095|FG000|Infant Series|Parent or legal guardian request|4
6090181|NCT00688870|9702096|FG001|Infant Series|Parent or legal guardian request|0
6090182|NCT00688909|9702106|FG000|Overall Study|Adverse Event|28
6090183|NCT00688909|9702106|FG000|Overall Study|Patient withdrew consent|2
6053351|NCT00443209|9652935|FG000|Months 1 to 12 Treatment Period|Adverse Event|22
6053352|NCT00443209|9652936|FG001|Months 1 to 12 Treatment Period|Adverse Event|11
6053353|NCT00443209|9652935|FG000|Months 1 to 12 Treatment Period|Protocol Violation|14
6053354|NCT00443209|9652936|FG001|Months 1 to 12 Treatment Period|Protocol Violation|7
6053355|NCT00443209|9652935|FG000|Months 1 to 12 Treatment Period|Lack of Efficacy|50
6053356|NCT00443209|9652936|FG001|Months 1 to 12 Treatment Period|Lack of Efficacy|11
6053357|NCT00443209|9652935|FG000|Months 1 to 12 Treatment Period|Lack of Qualifying Event|1
6053358|NCT00443209|9652936|FG001|Months 1 to 12 Treatment Period|Lack of Qualifying Event|1
6053359|NCT00443209|9652935|FG000|Months 1 to 12 Treatment Period|Lost to Follow-up|36
6053360|NCT00443209|9652936|FG001|Months 1 to 12 Treatment Period|Lost to Follow-up|15
6053361|NCT00443209|9652935|FG000|Months 1 to 12 Treatment Period|Physician Decision|8
6053362|NCT00443209|9652936|FG001|Months 1 to 12 Treatment Period|Physician Decision|4
6053363|NCT00443209|9652935|FG000|Months 1 to 12 Treatment Period|Pregnancy|3
6053364|NCT00443209|9652936|FG001|Months 1 to 12 Treatment Period|Pregnancy|4
6053365|NCT00443209|9652935|FG000|Months 1 to 12 Treatment Period|Trial Terminated|43
6053366|NCT00443209|9652936|FG001|Months 1 to 12 Treatment Period|Trial Terminated|23
6053367|NCT00443209|9652935|FG000|Months 1 to 12 Treatment Period|Withdrawal by Subject|95
6053368|NCT00443209|9652936|FG001|Months 1 to 12 Treatment Period|Withdrawal by Subject|34
6053369|NCT00443209|9652935|FG000|Months 1 to 12 Treatment Period|Missing|2
6053370|NCT00443209|9652936|FG001|Months 1 to 12 Treatment Period|Missing|1
6053371|NCT00443209|9652935|FG000|Months 1 to 12 Treatment Period|Not Treated|71
6053372|NCT00443209|9652936|FG001|Months 1 to 12 Treatment Period|Not Treated|43
6053373|NCT00443209|9652935|FG000|Months 13 to 18 Treatment Period|Adverse Event|1
6053374|NCT00443209|9652936|FG001|Months 13 to 18 Treatment Period|Adverse Event|0
6053375|NCT00443209|9652935|FG000|Months 13 to 18 Treatment Period|Protocol Violation|1
6053376|NCT00443209|9652936|FG001|Months 13 to 18 Treatment Period|Protocol Violation|0
6053377|NCT00443209|9652935|FG000|Months 13 to 18 Treatment Period|Lack of Efficacy|1
6053378|NCT00443209|9652936|FG001|Months 13 to 18 Treatment Period|Lack of Efficacy|0
6053379|NCT00443209|9652935|FG000|Months 13 to 18 Treatment Period|Lost to Follow-up|2
6053380|NCT00443209|9652936|FG001|Months 13 to 18 Treatment Period|Lost to Follow-up|2
6053381|NCT00443209|9652935|FG000|Months 13 to 18 Treatment Period|Trial Terminated|87
6053382|NCT00443209|9652936|FG001|Months 13 to 18 Treatment Period|Trial Terminated|43
6053383|NCT00443209|9652935|FG000|Months 13 to 18 Treatment Period|Withdrawal by Subject|7
6053384|NCT00443209|9652936|FG001|Months 13 to 18 Treatment Period|Withdrawal by Subject|2
6053385|NCT00443261|9652942|FG000|Overall Study|Death|1
6053386|NCT00443430|9652952|FG000|Overall Study|Lack of Efficacy|3
6053387|NCT00443430|9652953|FG001|Overall Study|Lack of Efficacy|3
6053388|NCT00443430|9652952|FG000|Overall Study|Adverse Event|1
6053389|NCT00443430|9652953|FG001|Overall Study|Adverse Event|1
6053390|NCT00443456|9652959|FG000|Overall Study|Adverse Event|16
6053391|NCT00443456|9652959|FG000|Overall Study|Move|1
6053392|NCT00443456|9652959|FG000|Overall Study|Withdrawal by Subject|1
6053393|NCT00443534|9652967|FG000|Overall Study|Lack of Efficacy|67
6053394|NCT00443534|9652967|FG000|Overall Study|Adverse Event|16
6053395|NCT00443534|9652967|FG000|Overall Study|Death|9
6053396|NCT00443534|9652967|FG000|Overall Study|Withdrawal by Subject|8
6053397|NCT00443534|9652967|FG000|Overall Study|Study Terminated by Sponsor|12
6053398|NCT00443534|9652967|FG000|Overall Study|Other|10
6053399|NCT00443534|9652967|FG000|Overall Study|Enrolled, Not Treated|1
6053400|NCT00443560|9652990|FG000|Overall Study|No intrathecal dose|58
6053401|NCT00443560|9652991|FG001|Overall Study|No intrathecal dose|26
6053402|NCT00443560|9652990|FG000|Overall Study|Multiple pregnancies or fetal demise|2
6053403|NCT00443560|9652991|FG001|Overall Study|Multiple pregnancies or fetal demise|4
6053404|NCT00443599|9652999|FG000|Overall Study|Physician Decision|2
6053405|NCT00443599|9653000|FG001|Overall Study|Physician Decision|1
6053406|NCT00443599|9652999|FG000|Overall Study|Death|1
6053407|NCT00443599|9653000|FG001|Overall Study|Death|1
6053408|NCT00443599|9652999|FG000|Overall Study|Cardiopulmonary bypass canceled|3
6053409|NCT00443599|9653000|FG001|Overall Study|Cardiopulmonary bypass canceled|1
6053410|NCT00443651|9653008|FG000|Overall Study|Death|1
6053411|NCT00443651|9653009|FG001|Overall Study|Death|5
6053412|NCT00443651|9653008|FG000|Overall Study|Adverse Event|5
6053413|NCT00443651|9653009|FG001|Overall Study|Adverse Event|6
6053414|NCT00443651|9653008|FG000|Overall Study|Lost to Follow-up|18
6053415|NCT00443651|9653009|FG001|Overall Study|Lost to Follow-up|12
6053416|NCT00443651|9653008|FG000|Overall Study|Patient's/Guardian's Decision|58
6053417|NCT00443651|9653009|FG001|Overall Study|Patient's/Guardian's Decision|30
6053418|NCT00443651|9653008|FG000|Overall Study|Physician Decision|13
6053419|NCT00443651|9653009|FG001|Overall Study|Physician Decision|4
6053420|NCT00443651|9653008|FG000|Overall Study|Pregnancy|0
6053421|NCT00443651|9653009|FG001|Overall Study|Pregnancy|1
6053422|NCT00443703|9653017|FG000|Overall Study|Never Treated|3
6053423|NCT00443703|9653018|FG001|Overall Study|Never Treated|1
6053424|NCT00443703|9653017|FG000|Overall Study|Adverse Event|7
6053425|NCT00443703|9653018|FG001|Overall Study|Adverse Event|3
6053426|NCT00443703|9653017|FG000|Overall Study|Lack of Efficacy|3
6053427|NCT00443703|9653018|FG001|Overall Study|Lack of Efficacy|1
6053428|NCT00443703|9653017|FG000|Overall Study|Lost to Follow-up|0
6053429|NCT00443703|9653018|FG001|Overall Study|Lost to Follow-up|4
6053430|NCT00443703|9653017|FG000|Overall Study|Physician Decision|4
6053431|NCT00443703|9653018|FG001|Overall Study|Physician Decision|2
6053432|NCT00443703|9653017|FG000|Overall Study|Protocol Violation|1
6053433|NCT00443703|9653018|FG001|Overall Study|Protocol Violation|1
6053434|NCT00443703|9653017|FG000|Overall Study|Withdrawal by Subject|9
6053435|NCT00443703|9653018|FG001|Overall Study|Withdrawal by Subject|6
6053436|NCT00443703|9653017|FG000|Overall Study|Progressive Disease|1
6053437|NCT00443703|9653018|FG001|Overall Study|Progressive Disease|0
6053438|NCT00443729|9653026|FG000|Overall Study|Never Treated|0
6053439|NCT00443729|9653027|FG001|Overall Study|Never Treated|1
6053440|NCT00443729|9653026|FG000|Overall Study|Lack of Efficacy|4
6053441|NCT00443729|9653027|FG001|Overall Study|Lack of Efficacy|2
6053442|NCT00443729|9653026|FG000|Overall Study|Lost to Follow-up|0
6053443|NCT00443729|9653027|FG001|Overall Study|Lost to Follow-up|1
6053444|NCT00443729|9653026|FG000|Overall Study|Physician Decision|2
6053445|NCT00443729|9653027|FG001|Overall Study|Physician Decision|1
6053446|NCT00443729|9653026|FG000|Overall Study|Protocol Violation|1
6053447|NCT00443729|9653027|FG001|Overall Study|Protocol Violation|1
6053448|NCT00443729|9653026|FG000|Overall Study|Withdrawal by Subject|3
6053449|NCT00443729|9653027|FG001|Overall Study|Withdrawal by Subject|1
6053450|NCT00443755|9653035|FG000|Overall Study|Withdrawal by Subject|2
6053451|NCT00443755|9653036|FG001|Overall Study|Withdrawal by Subject|1
6053452|NCT00443781|9653042|FG000|Overall Study|Lost to Follow-up|10
6053453|NCT00443781|9653042|FG000|Overall Study|Physician Decision|2
6053454|NCT00443781|9653042|FG000|Overall Study|Protocol Violation|1
6053455|NCT00443781|9653042|FG000|Overall Study|Withdrawal by Subject|6
6053456|NCT00443781|9653042|FG000|Overall Study|Unable to comply with study follow up|2
6053457|NCT00443781|9653042|FG000|Overall Study|Investigator terminated participation|1
6202172|NCT01499368|9862265|FG001|Overall Study|Lost to Follow-up|2
6202173|NCT01499368|9862266|FG002|Overall Study|Lost to Follow-up|5
6202174|NCT01499368|9862264|FG000|Overall Study|Adverse Event|4
6202175|NCT01499368|9862265|FG001|Overall Study|Adverse Event|0
6202176|NCT01499368|9862266|FG002|Overall Study|Adverse Event|2
6202177|NCT01499368|9862264|FG000|Overall Study|Physician Decision|0
6202178|NCT01499368|9862265|FG001|Overall Study|Physician Decision|1
6202179|NCT01499368|9862266|FG002|Overall Study|Physician Decision|0
6202180|NCT01499368|9862264|FG000|Overall Study|Deviation from visit window|0
6202181|NCT01499368|9862265|FG001|Overall Study|Deviation from visit window|0
6202182|NCT01499368|9862266|FG002|Overall Study|Deviation from visit window|1
6053458|NCT00443781|9653042|FG000|Overall Study|Insurance not covered|2
6090184|NCT00688909|9702106|FG000|Overall Study|Administrative problems|1
6090185|NCT00688909|9702106|FG000|Overall Study|Protocol Violation|2
6090186|NCT00689026|9702113|FG000|Overall Study|Withdrawal by Subject|13
6090187|NCT00689026|9702114|FG001|Overall Study|Withdrawal by Subject|6
6090188|NCT00689104|9702154|FG000|Overall Study|Eligibility criterion not met|5
6090189|NCT00689104|9702155|FG001|Overall Study|Eligibility criterion not met|8
6090190|NCT00689104|9702156|FG002|Overall Study|Eligibility criterion not met|0
6090191|NCT00689104|9702157|FG003|Overall Study|Eligibility criterion not met|4
6090192|NCT00689104|9702154|FG000|Overall Study|Adverse Event|13
6090193|NCT00689104|9702155|FG001|Overall Study|Adverse Event|25
6090194|NCT00689104|9702156|FG002|Overall Study|Adverse Event|16
6090195|NCT00689104|9702157|FG003|Overall Study|Adverse Event|24
6090196|NCT00689104|9702154|FG000|Overall Study|Lack of Efficacy|5
6090197|NCT00689104|9702155|FG001|Overall Study|Lack of Efficacy|6
6090198|NCT00689104|9702156|FG002|Overall Study|Lack of Efficacy|2
6090199|NCT00689104|9702157|FG003|Overall Study|Lack of Efficacy|3
6090200|NCT00689104|9702154|FG000|Overall Study|Withdrawal by Subject|12
6090201|NCT00689104|9702155|FG001|Overall Study|Withdrawal by Subject|11
6090202|NCT00689104|9702156|FG002|Overall Study|Withdrawal by Subject|18
6090203|NCT00689104|9702157|FG003|Overall Study|Withdrawal by Subject|11
6090204|NCT00689104|9702154|FG000|Overall Study|Lost to Follow-up|4
6090205|NCT00689104|9702155|FG001|Overall Study|Lost to Follow-up|3
6090206|NCT00689104|9702156|FG002|Overall Study|Lost to Follow-up|2
6090207|NCT00689104|9702157|FG003|Overall Study|Lost to Follow-up|5
6090208|NCT00689104|9702154|FG000|Overall Study|Protocol Violation|2
6090209|NCT00689104|9702155|FG001|Overall Study|Protocol Violation|3
6090210|NCT00689104|9702156|FG002|Overall Study|Protocol Violation|5
6090211|NCT00689104|9702157|FG003|Overall Study|Protocol Violation|3
6090212|NCT00689104|9702154|FG000|Overall Study|Randomized but never received study drug|2
6090213|NCT00689104|9702155|FG001|Overall Study|Randomized but never received study drug|1
6053459|NCT00443781|9653042|FG000|Overall Study|PD/FAD not done|1
6053460|NCT00443820|9653050|FG000|Overall Study|Adverse Event|1
6090214|NCT00689104|9702156|FG002|Overall Study|Randomized but never received study drug|1
6090215|NCT00689104|9702157|FG003|Overall Study|Randomized but never received study drug|0
6090216|NCT00689104|9702154|FG000|Overall Study|Physician Decision|1
6090217|NCT00689104|9702155|FG001|Overall Study|Physician Decision|0
6090218|NCT00689104|9702156|FG002|Overall Study|Physician Decision|0
6090219|NCT00689104|9702157|FG003|Overall Study|Physician Decision|0
6090220|NCT00689104|9702154|FG000|Overall Study|Non-compliance with study procedures|0
6090221|NCT00689104|9702155|FG001|Overall Study|Non-compliance with study procedures|0
6202183|NCT01499368|9862264|FG000|Overall Study|Error of Prescriptions|0
6202184|NCT01499368|9862265|FG001|Overall Study|Error of Prescriptions|0
6053461|NCT00443820|9653051|FG001|Overall Study|Adverse Event|1
6053462|NCT00443820|9653052|FG002|Overall Study|Adverse Event|0
6202185|NCT01499368|9862266|FG002|Overall Study|Error of Prescriptions|1
6202186|NCT01499511|9862283|FG000|Overall Study|Death|1
6202187|NCT01499511|9862284|FG001|Overall Study|Death|0
6202188|NCT01499576|9862291|FG000|Overall Study|Physician Decision|12
6202189|NCT01499576|9862291|FG000|Overall Study|Withdrawal by Subject|9
6202190|NCT01499667|9862309|FG000|Overall Study|administrative problems|4
6202191|NCT01499667|9862310|FG001|Overall Study|administrative problems|5
6202192|NCT01499667|9862311|FG002|Overall Study|administrative problems|5
6202193|NCT01499667|9862309|FG000|Overall Study|Protocol Violation|1
6202194|NCT01499667|9862310|FG001|Overall Study|Protocol Violation|3
6202195|NCT01499667|9862311|FG002|Overall Study|Protocol Violation|2
6202196|NCT01499667|9862309|FG000|Overall Study|Adverse Event|0
6202197|NCT01499667|9862310|FG001|Overall Study|Adverse Event|2
6202198|NCT01499667|9862311|FG002|Overall Study|Adverse Event|2
6202199|NCT01499667|9862309|FG000|Overall Study|Withdrawal by Subject|2
6202200|NCT01499667|9862310|FG001|Overall Study|Withdrawal by Subject|1
6202201|NCT01499667|9862311|FG002|Overall Study|Withdrawal by Subject|1
6202202|NCT01499667|9862309|FG000|Overall Study|Lack of Efficacy|2
6202203|NCT01499667|9862310|FG001|Overall Study|Lack of Efficacy|0
6202204|NCT01499667|9862311|FG002|Overall Study|Lack of Efficacy|0
6202205|NCT01499810|9862319|FG000|Overall Study|Lost to Follow-up|10
6202206|NCT01499810|9862319|FG000|Overall Study|Protocol Violation|1
6202207|NCT01499810|9862319|FG000|Overall Study|Withdrawal by Subject|1
6202208|NCT01499849|9862326|FG000|Overall Study|Adverse Event|28
6202209|NCT01499849|9862327|FG001|Overall Study|Adverse Event|32
6202210|NCT01499849|9862326|FG000|Overall Study|Chemo completed or Change in Therapy|70
6202211|NCT01499849|9862327|FG001|Overall Study|Chemo completed or Change in Therapy|67
6202212|NCT01499849|9862326|FG000|Overall Study|Withdrawal by Subject|43
6053463|NCT00443820|9653053|FG003|Overall Study|Adverse Event|0
6053464|NCT00443820|9653050|FG000|Overall Study|Lack of Efficacy|3
6053465|NCT00443820|9653051|FG001|Overall Study|Lack of Efficacy|2
6053466|NCT00443820|9653052|FG002|Overall Study|Lack of Efficacy|1
6053467|NCT00443820|9653053|FG003|Overall Study|Lack of Efficacy|1
6053468|NCT00443820|9653050|FG000|Overall Study|Protocol Violation|2
6053469|NCT00443820|9653051|FG001|Overall Study|Protocol Violation|1
6053470|NCT00443820|9653052|FG002|Overall Study|Protocol Violation|2
6053471|NCT00443820|9653053|FG003|Overall Study|Protocol Violation|1
6053472|NCT00443820|9653050|FG000|Overall Study|Withdrawal by Subject|6
6053473|NCT00443820|9653051|FG001|Overall Study|Withdrawal by Subject|7
6053474|NCT00443820|9653052|FG002|Overall Study|Withdrawal by Subject|8
6053475|NCT00443820|9653053|FG003|Overall Study|Withdrawal by Subject|9
6053476|NCT00443820|9653050|FG000|Overall Study|Lost to Follow-up|9
6053477|NCT00443820|9653051|FG001|Overall Study|Lost to Follow-up|8
6053478|NCT00443820|9653052|FG002|Overall Study|Lost to Follow-up|6
6053479|NCT00443820|9653053|FG003|Overall Study|Lost to Follow-up|5
6053480|NCT00443820|9653050|FG000|Overall Study|Administrative problems|0
6053481|NCT00443820|9653051|FG001|Overall Study|Administrative problems|0
6053482|NCT00443820|9653052|FG002|Overall Study|Administrative problems|0
6053483|NCT00443820|9653053|FG003|Overall Study|Administrative problems|1
6053484|NCT00443820|9653050|FG000|Overall Study|Death|0
6053485|NCT00443820|9653051|FG001|Overall Study|Death|0
6053486|NCT00443820|9653052|FG002|Overall Study|Death|1
6053487|NCT00443820|9653053|FG003|Overall Study|Death|0
6053488|NCT00443846|9653065|FG000|Overall Study|Withdrawn due to intercurrent disease|1
6053489|NCT00443846|9653066|FG001|Overall Study|Withdrawn due to intercurrent disease|0
6053490|NCT00443846|9653065|FG000|Overall Study|Not vaccinated, no blood sample drawn|1
6053491|NCT00443846|9653066|FG001|Overall Study|Not vaccinated, no blood sample drawn|0
6053492|NCT00443846|9653065|FG000|Overall Study|Adverse Event|0
6053493|NCT00443846|9653066|FG001|Overall Study|Adverse Event|1
6053494|NCT00443846|9653065|FG000|Overall Study|Personal reason|8
6053495|NCT00443846|9653066|FG001|Overall Study|Personal reason|3
6053496|NCT00443846|9653065|FG000|Overall Study|Lost to Follow-up|1
6053497|NCT00443846|9653066|FG001|Overall Study|Lost to Follow-up|2
6053498|NCT00443872|9653072|FG000|Overall Study|Protocol Violation|7
6053499|NCT00443872|9653072|FG000|Overall Study|Lost to Follow-up|2
6053500|NCT00443872|9653072|FG000|Overall Study|Adverse Event|8
6053501|NCT00443898|9653089|FG000|Overall Study|Adverse Event|0
6053502|NCT00443898|9653090|FG001|Overall Study|Adverse Event|0
6053503|NCT00443898|9653091|FG002|Overall Study|Adverse Event|1
6053504|NCT00443898|9653092|FG003|Overall Study|Adverse Event|1
6053505|NCT00443898|9653089|FG000|Overall Study|Lack of Efficacy|2
6053506|NCT00443898|9653090|FG001|Overall Study|Lack of Efficacy|3
6053507|NCT00443898|9653091|FG002|Overall Study|Lack of Efficacy|3
6053508|NCT00443898|9653092|FG003|Overall Study|Lack of Efficacy|1
6053509|NCT00443898|9653089|FG000|Overall Study|Protocol Violation|1
6202213|NCT01499849|9862327|FG001|Overall Study|Withdrawal by Subject|43
6202214|NCT01499849|9862326|FG000|Overall Study|Death|5
6202215|NCT01499849|9862327|FG001|Overall Study|Death|7
6202216|NCT01499849|9862326|FG000|Overall Study|Disease Progression|11
6202217|NCT01499849|9862327|FG001|Overall Study|Disease Progression|10
6202218|NCT01499849|9862326|FG000|Overall Study|Protocol Violation|11
6202219|NCT01499849|9862327|FG001|Overall Study|Protocol Violation|11
6202220|NCT01499849|9862326|FG000|Overall Study|Physician Decision|20
6202221|NCT01499849|9862327|FG001|Overall Study|Physician Decision|19
6202222|NCT01499849|9862326|FG000|Overall Study|Lack of Efficacy|3
6053510|NCT00443898|9653090|FG001|Overall Study|Protocol Violation|1
6053511|NCT00443898|9653091|FG002|Overall Study|Protocol Violation|1
6053512|NCT00443898|9653092|FG003|Overall Study|Protocol Violation|0
6053513|NCT00443898|9653089|FG000|Overall Study|Withdrawal by Subject|11
6053514|NCT00443898|9653090|FG001|Overall Study|Withdrawal by Subject|10
6053515|NCT00443898|9653091|FG002|Overall Study|Withdrawal by Subject|10
6053516|NCT00443898|9653092|FG003|Overall Study|Withdrawal by Subject|6
6053517|NCT00443898|9653089|FG000|Overall Study|Lost to Follow-up|10
6053518|NCT00443898|9653090|FG001|Overall Study|Lost to Follow-up|10
6053519|NCT00443898|9653091|FG002|Overall Study|Lost to Follow-up|14
6053520|NCT00443898|9653092|FG003|Overall Study|Lost to Follow-up|10
6053521|NCT00443898|9653089|FG000|Overall Study|Death|0
6053522|NCT00443898|9653090|FG001|Overall Study|Death|1
6053523|NCT00443898|9653091|FG002|Overall Study|Death|0
6053524|NCT00443898|9653092|FG003|Overall Study|Death|0
6053525|NCT00444067|9653128|FG000|Overall Study|Lost to Follow-up|0
6053526|NCT00444067|9653129|FG001|Overall Study|Lost to Follow-up|1
6053527|NCT00444106|9653150|FG000|Overall Study|Lost to Follow-up|2
6053528|NCT00444106|9653151|FG001|Overall Study|Lost to Follow-up|1
6053529|NCT00444106|9653152|FG002|Overall Study|Lost to Follow-up|0
6053530|NCT00444106|9653150|FG000|Overall Study|Abnormal Test Procedure Results|0
6053531|NCT00444106|9653151|FG001|Overall Study|Abnormal Test Procedure Results|0
6053532|NCT00444106|9653152|FG002|Overall Study|Abnormal Test Procedure Results|1
6053533|NCT00444145|9653163|FG000|Overall Study|Withdrawal by Subject|2
6053534|NCT00444145|9653163|FG000|Overall Study|Lost to Follow-up|1
6053535|NCT00444145|9653163|FG000|Overall Study|non-compliant|11
6053536|NCT00444145|9653163|FG000|Overall Study|Screen Failures|5
6053537|NCT00444275|9653170|FG000|Maintenance Treatment Phase|Didn'r receive the treatment|0
6053538|NCT00444275|9653171|FG001|Maintenance Treatment Phase|Didn'r receive the treatment|0
6053539|NCT00444275|9653172|FG002|Maintenance Treatment Phase|Didn'r receive the treatment|22
6053540|NCT00444275|9653173|FG003|Maintenance Treatment Phase|Didn'r receive the treatment|17
6053541|NCT00444275|9653174|FG004|Maintenance Treatment Phase|Didn'r receive the treatment|29
6053542|NCT00444275|9653170|FG000|Maintenance Treatment Phase|Lost to Follow-up|0
6053543|NCT00444275|9653171|FG001|Maintenance Treatment Phase|Lost to Follow-up|0
6053544|NCT00444275|9653172|FG002|Maintenance Treatment Phase|Lost to Follow-up|8
6053545|NCT00444275|9653173|FG003|Maintenance Treatment Phase|Lost to Follow-up|14
6053546|NCT00444275|9653174|FG004|Maintenance Treatment Phase|Lost to Follow-up|10
6053547|NCT00444275|9653170|FG000|Maintenance Treatment Phase|Adverse Event|0
6053548|NCT00444275|9653171|FG001|Maintenance Treatment Phase|Adverse Event|0
6053549|NCT00444275|9653172|FG002|Maintenance Treatment Phase|Adverse Event|3
6053550|NCT00444275|9653173|FG003|Maintenance Treatment Phase|Adverse Event|2
6053551|NCT00444275|9653174|FG004|Maintenance Treatment Phase|Adverse Event|13
6053552|NCT00444275|9653170|FG000|Maintenance Treatment Phase|Protocol specific criteria's development|0
6053553|NCT00444275|9653171|FG001|Maintenance Treatment Phase|Protocol specific criteria's development|0
6053554|NCT00444275|9653172|FG002|Maintenance Treatment Phase|Protocol specific criteria's development|1
6053555|NCT00444275|9653173|FG003|Maintenance Treatment Phase|Protocol specific criteria's development|0
6053556|NCT00444275|9653174|FG004|Maintenance Treatment Phase|Protocol specific criteria's development|6
6053557|NCT00444275|9653170|FG000|Maintenance Treatment Phase|Patient's wish|0
6053558|NCT00444275|9653171|FG001|Maintenance Treatment Phase|Patient's wish|0
6053559|NCT00444275|9653172|FG002|Maintenance Treatment Phase|Patient's wish|19
6053560|NCT00444275|9653173|FG003|Maintenance Treatment Phase|Patient's wish|9
6053561|NCT00444275|9653174|FG004|Maintenance Treatment Phase|Patient's wish|20
6053562|NCT00444275|9653170|FG000|Maintenance Treatment Phase|Protocol Violation|0
6053563|NCT00444275|9653171|FG001|Maintenance Treatment Phase|Protocol Violation|0
6053564|NCT00444275|9653172|FG002|Maintenance Treatment Phase|Protocol Violation|103
6053565|NCT00444275|9653173|FG003|Maintenance Treatment Phase|Protocol Violation|88
6053566|NCT00444275|9653174|FG004|Maintenance Treatment Phase|Protocol Violation|87
6053567|NCT00444275|9653170|FG000|Maintenance Treatment Phase|Ineffectiveness|0
6053568|NCT00444275|9653171|FG001|Maintenance Treatment Phase|Ineffectiveness|0
6053569|NCT00444275|9653172|FG002|Maintenance Treatment Phase|Ineffectiveness|5
6053570|NCT00444275|9653173|FG003|Maintenance Treatment Phase|Ineffectiveness|3
6053571|NCT00444275|9653174|FG004|Maintenance Treatment Phase|Ineffectiveness|14
6053572|NCT00444457|9653193|FG000|Infant Series|Other|0
6053573|NCT00444457|9653194|FG001|Infant Series|Other|1
6053574|NCT00444457|9653195|FG002|Infant Series|Other|0
6053575|NCT00444457|9653196|FG003|Infant Series|Other|0
6053576|NCT00444457|9653193|FG000|Infant Series|Parent or legal guardian request|18
6053577|NCT00444457|9653194|FG001|Infant Series|Parent or legal guardian request|29
6053578|NCT00444457|9653195|FG002|Infant Series|Parent or legal guardian request|34
6053579|NCT00444457|9653196|FG003|Infant Series|Parent or legal guardian request|14
6053580|NCT00444457|9653193|FG000|Infant Series|Lost to Follow-up|10
6053581|NCT00444457|9653194|FG001|Infant Series|Lost to Follow-up|11
6053582|NCT00444457|9653195|FG002|Infant Series|Lost to Follow-up|7
6053583|NCT00444457|9653196|FG003|Infant Series|Lost to Follow-up|6
6053584|NCT00444457|9653193|FG000|Infant Series|Protocol Violation|16
6053585|NCT00444457|9653194|FG001|Infant Series|Protocol Violation|8
6053586|NCT00444457|9653195|FG002|Infant Series|Protocol Violation|6
6053587|NCT00444457|9653196|FG003|Infant Series|Protocol Violation|3
6053588|NCT00444457|9653193|FG000|Infant Series|Failed to return|5
6053589|NCT00444457|9653194|FG001|Infant Series|Failed to return|4
6053590|NCT00444457|9653195|FG002|Infant Series|Failed to return|4
6053591|NCT00444457|9653196|FG003|Infant Series|Failed to return|2
6053592|NCT00444457|9653193|FG000|Infant Series|Investigator request|4
6053593|NCT00444457|9653194|FG001|Infant Series|Investigator request|3
6053594|NCT00444457|9653195|FG002|Infant Series|Investigator request|3
6053595|NCT00444457|9653196|FG003|Infant Series|Investigator request|2
6053596|NCT00444457|9653193|FG000|Infant Series|Other|0
6053597|NCT00444457|9653194|FG001|Infant Series|Other|2
6053598|NCT00444457|9653195|FG002|Infant Series|Other|4
6053599|NCT00444457|9653196|FG003|Infant Series|Other|0
6053600|NCT00444457|9653193|FG000|Infant Series|Adverse Event|1
6053601|NCT00444457|9653194|FG001|Infant Series|Adverse Event|2
6053602|NCT00444457|9653195|FG002|Infant Series|Adverse Event|2
6053603|NCT00444457|9653196|FG003|Infant Series|Adverse Event|0
6053604|NCT00444457|9653193|FG000|Infant Series|Death|0
6053605|NCT00444457|9653194|FG001|Infant Series|Death|1
6053606|NCT00444457|9653195|FG002|Infant Series|Death|1
6053607|NCT00444457|9653196|FG003|Infant Series|Death|1
6053608|NCT00444457|9653193|FG000|After Infant Series|Other|0
6053609|NCT00444457|9653194|FG001|After Infant Series|Other|1
6053610|NCT00444457|9653195|FG002|After Infant Series|Other|1
6053611|NCT00444457|9653196|FG003|After Infant Series|Other|1
6053612|NCT00444457|9653193|FG000|After Infant Series|Parent or legal guardian request|4
6053613|NCT00444457|9653194|FG001|After Infant Series|Parent or legal guardian request|11
6053614|NCT00444457|9653195|FG002|After Infant Series|Parent or legal guardian request|6
6053615|NCT00444457|9653196|FG003|After Infant Series|Parent or legal guardian request|3
6053616|NCT00444457|9653193|FG000|After Infant Series|Failed to return|7
6053617|NCT00444457|9653194|FG001|After Infant Series|Failed to return|6
6053618|NCT00444457|9653195|FG002|After Infant Series|Failed to return|5
6053619|NCT00444457|9653196|FG003|After Infant Series|Failed to return|1
6053620|NCT00444457|9653193|FG000|After Infant Series|Lost to Follow-up|5
6053621|NCT00444457|9653194|FG001|After Infant Series|Lost to Follow-up|5
6053622|NCT00444457|9653195|FG002|After Infant Series|Lost to Follow-up|5
6053623|NCT00444457|9653196|FG003|After Infant Series|Lost to Follow-up|2
6053624|NCT00444457|9653193|FG000|After Infant Series|Protocol Violation|2
6053625|NCT00444457|9653194|FG001|After Infant Series|Protocol Violation|4
6053626|NCT00444457|9653195|FG002|After Infant Series|Protocol Violation|2
6053627|NCT00444457|9653196|FG003|After Infant Series|Protocol Violation|2
6053628|NCT00444457|9653193|FG000|After Infant Series|Adverse Event|2
6053629|NCT00444457|9653194|FG001|After Infant Series|Adverse Event|2
6053630|NCT00444457|9653195|FG002|After Infant Series|Adverse Event|0
6053631|NCT00444457|9653196|FG003|After Infant Series|Adverse Event|0
6053632|NCT00444457|9653193|FG000|After Infant Series|Investigator request|0
6053633|NCT00444457|9653194|FG001|After Infant Series|Investigator request|0
6053634|NCT00444457|9653195|FG002|After Infant Series|Investigator request|0
6053635|NCT00444457|9653196|FG003|After Infant Series|Investigator request|1
6053636|NCT00444457|9653193|FG000|After Infant Series|Other|0
6053637|NCT00444457|9653194|FG001|After Infant Series|Other|1
6053638|NCT00444457|9653195|FG002|After Infant Series|Other|0
6053639|NCT00444457|9653196|FG003|After Infant Series|Other|0
6090222|NCT00689104|9702156|FG002|Overall Study|Non-compliance with study procedures|1
6090223|NCT00689104|9702157|FG003|Overall Study|Non-compliance with study procedures|0
6090224|NCT00689117|9702171|FG000|Overall Study|Adverse Event|6
6090225|NCT00689117|9702172|FG001|Overall Study|Adverse Event|0
6090226|NCT00689117|9702173|FG002|Overall Study|Adverse Event|5
6090227|NCT00689117|9702174|FG003|Overall Study|Adverse Event|0
6090228|NCT00689117|9702171|FG000|Overall Study|Lost to Follow-up|26
6090229|NCT00689117|9702172|FG001|Overall Study|Lost to Follow-up|19
6090230|NCT00689117|9702173|FG002|Overall Study|Lost to Follow-up|17
6090231|NCT00689117|9702174|FG003|Overall Study|Lost to Follow-up|11
6090232|NCT00689117|9702171|FG000|Overall Study|Lack of Efficacy|1
6090233|NCT00689117|9702172|FG001|Overall Study|Lack of Efficacy|2
6090234|NCT00689117|9702173|FG002|Overall Study|Lack of Efficacy|2
6090235|NCT00689117|9702174|FG003|Overall Study|Lack of Efficacy|2
6090236|NCT00689117|9702171|FG000|Overall Study|Non-Compliance with Study Treatment|3
6090237|NCT00689117|9702172|FG001|Overall Study|Non-Compliance with Study Treatment|3
6090238|NCT00689117|9702173|FG002|Overall Study|Non-Compliance with Study Treatment|3
6090239|NCT00689117|9702174|FG003|Overall Study|Non-Compliance with Study Treatment|1
6090240|NCT00689117|9702171|FG000|Overall Study|Withdrawal by Subject|19
6090241|NCT00689117|9702172|FG001|Overall Study|Withdrawal by Subject|18
6090242|NCT00689117|9702173|FG002|Overall Study|Withdrawal by Subject|26
6090243|NCT00689117|9702174|FG003|Overall Study|Withdrawal by Subject|13
6090244|NCT00689117|9702171|FG000|Overall Study|Unable to Comply with Visit Schedule|0
6090245|NCT00689117|9702172|FG001|Overall Study|Unable to Comply with Visit Schedule|0
6053640|NCT00444457|9653193|FG000|Toddler Dose|Lost to Follow-up|4
6053641|NCT00444457|9653194|FG001|Toddler Dose|Lost to Follow-up|1
6053642|NCT00444457|9653195|FG002|Toddler Dose|Lost to Follow-up|1
6053643|NCT00444457|9653196|FG003|Toddler Dose|Lost to Follow-up|3
6053644|NCT00444457|9653193|FG000|Toddler Dose|Failed to return|2
6053645|NCT00444457|9653194|FG001|Toddler Dose|Failed to return|2
6053646|NCT00444457|9653195|FG002|Toddler Dose|Failed to return|1
6053647|NCT00444457|9653196|FG003|Toddler Dose|Failed to return|3
6053648|NCT00444457|9653193|FG000|Toddler Dose|Parent or legal guardian request|0
6053649|NCT00444457|9653194|FG001|Toddler Dose|Parent or legal guardian request|3
6053650|NCT00444457|9653195|FG002|Toddler Dose|Parent or legal guardian request|2
6053651|NCT00444457|9653196|FG003|Toddler Dose|Parent or legal guardian request|1
6053652|NCT00444457|9653193|FG000|Toddler Dose|Protocol Violation|1
6053653|NCT00444457|9653194|FG001|Toddler Dose|Protocol Violation|0
6053654|NCT00444457|9653195|FG002|Toddler Dose|Protocol Violation|0
6053655|NCT00444457|9653196|FG003|Toddler Dose|Protocol Violation|1
6053656|NCT00444535|9653217|FG000|Overall Study|Withdrawal by Subject|5
6053657|NCT00444535|9653217|FG000|Overall Study|Physician Decision|5
6053658|NCT00444535|9653217|FG000|Overall Study|progressive disease|1
6053659|NCT00444535|9653217|FG000|Overall Study|Adverse Event|2
6053660|NCT00444587|9653223|FG000|Overall Study|Death|2
6053661|NCT00444587|9653224|FG001|Overall Study|Death|1
6053662|NCT00444587|9653223|FG000|Overall Study|Progression of the disease|73
6053663|NCT00444587|9653224|FG001|Overall Study|Progression of the disease|8
6053664|NCT00444587|9653223|FG000|Overall Study|Refused treatment/did not cooperate|4
6053665|NCT00444587|9653224|FG001|Overall Study|Refused treatment/did not cooperate|1
6053666|NCT00444587|9653223|FG000|Overall Study|Investigator decision|3
6053667|NCT00444587|9653224|FG001|Overall Study|Investigator decision|0
6053668|NCT00444587|9653223|FG000|Overall Study|Protocol Violation|1
6053669|NCT00444587|9653224|FG001|Overall Study|Protocol Violation|0
6053670|NCT00444587|9653223|FG000|Overall Study|Missing|0
6053671|NCT00444587|9653224|FG001|Overall Study|Missing|5
6053672|NCT00444600|9653236|FG000|Overall Study|Death|7
6053673|NCT00444600|9653237|FG001|Overall Study|Death|5
6053674|NCT00444600|9653238|FG002|Overall Study|Death|3
6053675|NCT00444600|9653239|FG003|Overall Study|Death|2
6053676|NCT00444600|9653236|FG000|Overall Study|Dropped|11
6053677|NCT00444600|9653237|FG001|Overall Study|Dropped|11
6053678|NCT00444600|9653238|FG002|Overall Study|Dropped|7
6053679|NCT00444600|9653239|FG003|Overall Study|Dropped|7
6053680|NCT00444600|9653236|FG000|Overall Study|Missed visit|1
6053681|NCT00444600|9653237|FG001|Overall Study|Missed visit|0
6053682|NCT00444600|9653238|FG002|Overall Study|Missed visit|0
6053683|NCT00444600|9653239|FG003|Overall Study|Missed visit|1
6053684|NCT00444626|9653255|FG000|Initial Treatment Period|Withdrawal by Subject|2
6053685|NCT00444626|9653255|FG000|Initial Treatment Period|Adverse Event|1
6053686|NCT00444626|9653255|FG000|Initial Treatment Period|Lost to Follow-up|9
6053687|NCT00444678|9653268|FG000|Overall Study|Toxicity|11
6053688|NCT00444678|9653268|FG000|Overall Study|Disease Progression|12
6053689|NCT00444678|9653268|FG000|Overall Study|Death|3
6053690|NCT00444678|9653268|FG000|Overall Study|Physician Decision|3
6053691|NCT00444678|9653268|FG000|Overall Study|Withdrawal by Subject|2
6053692|NCT00444795|9653272|FG000|Overall Study|Not Treated|1
6053693|NCT00444795|9653272|FG000|Overall Study|Treated Prior to the Contract Date|2
6053694|NCT00444912|9653287|FG000|Overall Study|Death|1
6053695|NCT00444912|9653288|FG001|Overall Study|Death|2
6053696|NCT00444912|9653287|FG000|Overall Study|Lost to Follow-up|1
6053697|NCT00444912|9653288|FG001|Overall Study|Lost to Follow-up|0
6053698|NCT00444912|9653287|FG000|Overall Study|Participant Failed Mobilization|1
6053699|NCT00444912|9653288|FG001|Overall Study|Participant Failed Mobilization|0
6053700|NCT00444925|9653297|FG000|Randomized to Double-blind Treatment|Never returned after randomization|3
6053701|NCT00444925|9653298|FG001|Randomized to Double-blind Treatment|Never returned after randomization|6
6053702|NCT00444925|9653299|FG002|Randomized to Double-blind Treatment|Never returned after randomization|6
6053703|NCT00444925|9653297|FG000|Double-blind Treatment Period|Death|2
6053704|NCT00444925|9653298|FG001|Double-blind Treatment Period|Death|0
6053705|NCT00444925|9653299|FG002|Double-blind Treatment Period|Death|0
6053706|NCT00444925|9653297|FG000|Double-blind Treatment Period|Adverse Event|6
6053707|NCT00444925|9653298|FG001|Double-blind Treatment Period|Adverse Event|28
6053708|NCT00444925|9653299|FG002|Double-blind Treatment Period|Adverse Event|44
6053709|NCT00444925|9653297|FG000|Double-blind Treatment Period|Lack of Efficacy|5
6053710|NCT00444925|9653298|FG001|Double-blind Treatment Period|Lack of Efficacy|5
6053711|NCT00444925|9653299|FG002|Double-blind Treatment Period|Lack of Efficacy|13
6053712|NCT00444925|9653297|FG000|Double-blind Treatment Period|Lost to Follow-up|4
6053713|NCT00444925|9653298|FG001|Double-blind Treatment Period|Lost to Follow-up|8
6053714|NCT00444925|9653299|FG002|Double-blind Treatment Period|Lost to Follow-up|5
6053715|NCT00444925|9653297|FG000|Double-blind Treatment Period|Withdrawal by Subject|6
6053716|NCT00444925|9653298|FG001|Double-blind Treatment Period|Withdrawal by Subject|8
6053717|NCT00444925|9653299|FG002|Double-blind Treatment Period|Withdrawal by Subject|7
6053718|NCT00444925|9653297|FG000|Double-blind Treatment Period|Other|7
6053719|NCT00444925|9653298|FG001|Double-blind Treatment Period|Other|7
6053720|NCT00444925|9653299|FG002|Double-blind Treatment Period|Other|12
6053721|NCT00444951|9653310|FG000|Overall Study|Lost to Follow-up|1
6053722|NCT00444951|9653311|FG001|Overall Study|Lost to Follow-up|1
6053723|NCT00444951|9653312|FG002|Overall Study|Lost to Follow-up|0
6053724|NCT00444951|9653310|FG000|Overall Study|Withdrawal by Subject|4
6053725|NCT00444951|9653311|FG001|Overall Study|Withdrawal by Subject|5
6053726|NCT00444951|9653312|FG002|Overall Study|Withdrawal by Subject|3
6053727|NCT00445003|9653327|FG000|Overall Study|Death|1
6053728|NCT00445003|9653328|FG001|Overall Study|Death|2
6053729|NCT00445003|9653329|FG002|Overall Study|Death|1
6053730|NCT00445003|9653327|FG000|Overall Study|Missed Visit|3
6053731|NCT00445003|9653328|FG001|Overall Study|Missed Visit|5
6053732|NCT00445003|9653329|FG002|Overall Study|Missed Visit|1
6053733|NCT00445003|9653327|FG000|Overall Study|Dropped|1
6053734|NCT00445003|9653328|FG001|Overall Study|Dropped|3
6053735|NCT00445003|9653329|FG002|Overall Study|Dropped|2
6053736|NCT00445068|9653337|FG000|Overall Study|Disease progression|26
6053737|NCT00445068|9653337|FG000|Overall Study|Adverse Event|5
6053738|NCT00445068|9653337|FG000|Overall Study|Abnormal laboratory value|2
6053739|NCT00445068|9653337|FG000|Overall Study|Withdrawal by Subject|2
6053740|NCT00445068|9653337|FG000|Overall Study|Death|1
6053741|NCT00445146|9653341|FG000|Overall Study|Withdrew Consent|29
6053742|NCT00445146|9653341|FG000|Overall Study|Lack of Efficacy|28
6053743|NCT00445146|9653341|FG000|Overall Study|Investigator's Discretion|22
6053744|NCT00445146|9653341|FG000|Overall Study|Adverse Event|13
6053745|NCT00445146|9653341|FG000|Overall Study|Lost to Follow-up|13
6053746|NCT00445146|9653341|FG000|Overall Study|Death|9
6053747|NCT00445146|9653341|FG000|Overall Study|Protocol Violation|4
6053748|NCT00445146|9653341|FG000|Overall Study|Pregnancy|1
6053749|NCT00445224|9653356|FG000|Specific Exercises|Withdrawal by Subject|3
6053750|NCT00445224|9653357|FG001|Specific Exercises|Withdrawal by Subject|3
6053751|NCT00445224|9653356|FG000|Specific Exercises|Withdrawal by Subject|1
6053752|NCT00445224|9653357|FG001|Specific Exercises|Withdrawal by Subject|0
6053753|NCT00445328|9653413|FG000|Overall Study|Death|0
6053754|NCT00445328|9653414|FG001|Overall Study|Death|1
6053755|NCT00445328|9653413|FG000|Overall Study|Adverse Event|0
6053756|NCT00445328|9653414|FG001|Overall Study|Adverse Event|3
6053757|NCT00445328|9653413|FG000|Overall Study|Other|0
6053758|NCT00445328|9653414|FG001|Overall Study|Other|2
6053759|NCT00445328|9653413|FG000|Overall Study|Withdrawal by Subject|2
6053760|NCT00445328|9653414|FG001|Overall Study|Withdrawal by Subject|0
6053761|NCT00445328|9653413|FG000|Overall Study|Protocol Violation|1
6053762|NCT00445328|9653414|FG001|Overall Study|Protocol Violation|0
6053763|NCT00445341|9653420|FG000|Overall Study|refused further treatment|1
6053764|NCT00445341|9653420|FG000|Overall Study|taken off treatment too early|1
6053765|NCT00445432|9653427|FG000|Through Week 52 of NCT00445432 (M06-837)|Adverse Event|1
6053766|NCT00445432|9653428|FG001|Through Week 52 of NCT00445432 (M06-837)|Adverse Event|2
6053767|NCT00445432|9653429|FG002|Through Week 52 of NCT00445432 (M06-837)|Adverse Event|7
6053768|NCT00445432|9653430|FG003|Through Week 52 of NCT00445432 (M06-837)|Adverse Event|0
6053769|NCT00445432|9653427|FG000|Through Week 52 of NCT00445432 (M06-837)|Withdrawal by Subject|0
6053770|NCT00445432|9653428|FG001|Through Week 52 of NCT00445432 (M06-837)|Withdrawal by Subject|0
6053771|NCT00445432|9653429|FG002|Through Week 52 of NCT00445432 (M06-837)|Withdrawal by Subject|2
6053772|NCT00445432|9653430|FG003|Through Week 52 of NCT00445432 (M06-837)|Withdrawal by Subject|0
6053773|NCT00445432|9653427|FG000|Through Week 52 of NCT00445432 (M06-837)|Moved to open-label|14
6053774|NCT00445432|9653428|FG001|Through Week 52 of NCT00445432 (M06-837)|Moved to open-label|20
6053775|NCT00445432|9653429|FG002|Through Week 52 of NCT00445432 (M06-837)|Moved to open-label|0
6053776|NCT00445432|9653430|FG003|Through Week 52 of NCT00445432 (M06-837)|Moved to open-label|0
6053777|NCT00445432|9653427|FG000|Through Week 52 of NCT00445432 (M06-837)|Other|0
6053778|NCT00445432|9653428|FG001|Through Week 52 of NCT00445432 (M06-837)|Other|1
6053779|NCT00445432|9653429|FG002|Through Week 52 of NCT00445432 (M06-837)|Other|2
6053780|NCT00445432|9653430|FG003|Through Week 52 of NCT00445432 (M06-837)|Other|0
6053781|NCT00445432|9653427|FG000|148 Weeks of Adalimumab Treatment|Adverse Event|0
6053782|NCT00445432|9653428|FG001|148 Weeks of Adalimumab Treatment|Adverse Event|0
6053783|NCT00445432|9653429|FG002|148 Weeks of Adalimumab Treatment|Adverse Event|0
6053784|NCT00445432|9653430|FG003|148 Weeks of Adalimumab Treatment|Adverse Event|32
6053785|NCT00445432|9653427|FG000|148 Weeks of Adalimumab Treatment|Withdrawal by Subject|0
6053786|NCT00445432|9653428|FG001|148 Weeks of Adalimumab Treatment|Withdrawal by Subject|0
6053787|NCT00445432|9653429|FG002|148 Weeks of Adalimumab Treatment|Withdrawal by Subject|0
6053788|NCT00445432|9653430|FG003|148 Weeks of Adalimumab Treatment|Withdrawal by Subject|3
6053789|NCT00445432|9653427|FG000|148 Weeks of Adalimumab Treatment|Other|0
6053790|NCT00445432|9653428|FG001|148 Weeks of Adalimumab Treatment|Other|0
6053791|NCT00445432|9653429|FG002|148 Weeks of Adalimumab Treatment|Other|0
6053792|NCT00445432|9653430|FG003|148 Weeks of Adalimumab Treatment|Other|9
6053793|NCT00445458|9653445|FG000|Overall Study|Disease Progression|3
6053794|NCT00445458|9653446|FG001|Overall Study|Disease Progression|4
6053795|NCT00445458|9653447|FG002|Overall Study|Disease Progression|54
6053796|NCT00445458|9653448|FG003|Overall Study|Disease Progression|27
6053797|NCT00445458|9653445|FG000|Overall Study|Withdrawal by Subject|0
6053798|NCT00445458|9653446|FG001|Overall Study|Withdrawal by Subject|0
6053799|NCT00445458|9653447|FG002|Overall Study|Withdrawal by Subject|7
6053800|NCT00445458|9653448|FG003|Overall Study|Withdrawal by Subject|0
6053801|NCT00445458|9653445|FG000|Overall Study|Adverse Event|0
6053802|NCT00445458|9653446|FG001|Overall Study|Adverse Event|0
6053803|NCT00445458|9653447|FG002|Overall Study|Adverse Event|3
6284215|NCT02326272|9996332|FG004|Initial Period (Week 0 to Week 16)|Moved from the study area|0
6284216|NCT02326272|9996333|FG005|Initial Period (Week 0 to Week 16)|Moved from the study area|0
6284217|NCT02326272|9996334|FG006|Initial Period (Week 0 to Week 16)|Moved from the study area|0
6284218|NCT02326272|9996335|FG007|Initial Period (Week 0 to Week 16)|Moved from the study area|0
6284219|NCT02326272|9996336|FG008|Initial Period (Week 0 to Week 16)|Moved from the study area|0
6284220|NCT02326272|9996337|FG009|Initial Period (Week 0 to Week 16)|Moved from the study area|0
6053804|NCT00445458|9653448|FG003|Overall Study|Adverse Event|0
6053805|NCT00445458|9653445|FG000|Overall Study|Death|0
6053806|NCT00445458|9653446|FG001|Overall Study|Death|1
6053807|NCT00445458|9653447|FG002|Overall Study|Death|2
6053808|NCT00445458|9653448|FG003|Overall Study|Death|0
6053809|NCT00445458|9653445|FG000|Overall Study|Physician Decision|0
6053810|NCT00445458|9653446|FG001|Overall Study|Physician Decision|0
6053811|NCT00445458|9653447|FG002|Overall Study|Physician Decision|1
6053812|NCT00445458|9653448|FG003|Overall Study|Physician Decision|1
6053813|NCT00445458|9653445|FG000|Overall Study|Surgery|0
6053814|NCT00445458|9653446|FG001|Overall Study|Surgery|0
6053815|NCT00445458|9653447|FG002|Overall Study|Surgery|1
6053816|NCT00445458|9653448|FG003|Overall Study|Surgery|0
6090246|NCT00689117|9702173|FG002|Overall Study|Unable to Comply with Visit Schedule|1
6090247|NCT00689117|9702174|FG003|Overall Study|Unable to Comply with Visit Schedule|1
6090248|NCT00689117|9702171|FG000|Overall Study|Inclusion/Exclusion Criteria Not Met|1
6090249|NCT00689117|9702172|FG001|Overall Study|Inclusion/Exclusion Criteria Not Met|2
6090250|NCT00689117|9702173|FG002|Overall Study|Inclusion/Exclusion Criteria Not Met|0
6090251|NCT00689117|9702174|FG003|Overall Study|Inclusion/Exclusion Criteria Not Met|0
6090252|NCT00689117|9702171|FG000|Overall Study|Non-compliance with Treatment Regimen|0
6090253|NCT00689117|9702172|FG001|Overall Study|Non-compliance with Treatment Regimen|1
6090254|NCT00689117|9702173|FG002|Overall Study|Non-compliance with Treatment Regimen|0
6090255|NCT00689117|9702174|FG003|Overall Study|Non-compliance with Treatment Regimen|0
6090256|NCT00689117|9702171|FG000|Overall Study|Change/Discontinuation of Birth Control|1
6090257|NCT00689117|9702172|FG001|Overall Study|Change/Discontinuation of Birth Control|1
6090258|NCT00689117|9702173|FG002|Overall Study|Change/Discontinuation of Birth Control|1
6090259|NCT00689117|9702174|FG003|Overall Study|Change/Discontinuation of Birth Control|0
6090260|NCT00689117|9702171|FG000|Overall Study|Use of Prohibitive Medication|2
6090261|NCT00689117|9702172|FG001|Overall Study|Use of Prohibitive Medication|1
6090262|NCT00689117|9702173|FG002|Overall Study|Use of Prohibitive Medication|3
6090263|NCT00689117|9702174|FG003|Overall Study|Use of Prohibitive Medication|0
6090264|NCT00689117|9702171|FG000|Overall Study|Pregnancy|0
6090265|NCT00689117|9702172|FG001|Overall Study|Pregnancy|2
6090266|NCT00689117|9702173|FG002|Overall Study|Pregnancy|0
6090267|NCT00689117|9702174|FG003|Overall Study|Pregnancy|2
6090268|NCT00689117|9702171|FG000|Overall Study|Incarceration|2
6090269|NCT00689117|9702172|FG001|Overall Study|Incarceration|0
6090270|NCT00689117|9702173|FG002|Overall Study|Incarceration|0
6090271|NCT00689117|9702174|FG003|Overall Study|Incarceration|0
6090272|NCT00689117|9702171|FG000|Overall Study|Fear of Birth Defects|0
6090273|NCT00689117|9702172|FG001|Overall Study|Fear of Birth Defects|0
6090274|NCT00689117|9702173|FG002|Overall Study|Fear of Birth Defects|1
6090275|NCT00689117|9702174|FG003|Overall Study|Fear of Birth Defects|0
6090276|NCT00689117|9702171|FG000|Overall Study|Transportation|1
6090277|NCT00689117|9702172|FG001|Overall Study|Transportation|0
6090278|NCT00689117|9702173|FG002|Overall Study|Transportation|0
6090279|NCT00689117|9702174|FG003|Overall Study|Transportation|0
6090280|NCT00689117|9702171|FG000|Overall Study|Patient Withdrew from Study|0
6090281|NCT00689117|9702172|FG001|Overall Study|Patient Withdrew from Study|0
6090282|NCT00689117|9702173|FG002|Overall Study|Patient Withdrew from Study|0
6090283|NCT00689117|9702174|FG003|Overall Study|Patient Withdrew from Study|1
6090284|NCT00689117|9702171|FG000|Overall Study|Personal Reason|0
6090285|NCT00689117|9702172|FG001|Overall Study|Personal Reason|1
6090286|NCT00689117|9702173|FG002|Overall Study|Personal Reason|0
6090287|NCT00689117|9702174|FG003|Overall Study|Personal Reason|0
6090288|NCT00689117|9702171|FG000|Overall Study|Dispensing Error|0
6090289|NCT00689117|9702172|FG001|Overall Study|Dispensing Error|1
6090290|NCT00689117|9702173|FG002|Overall Study|Dispensing Error|0
6090291|NCT00689117|9702174|FG003|Overall Study|Dispensing Error|0
6090292|NCT00689221|9702186|FG000|Overall Study|Ongoing at cut-off date|39
6090293|NCT00689221|9702187|FG001|Overall Study|Ongoing at cut-off date|36
6090294|NCT00689273|9702207|FG000|Overall Study|Adverse Event|3
6090295|NCT00689273|9702208|FG001|Overall Study|Adverse Event|1
6090296|NCT00689273|9702207|FG000|Overall Study|Lack of Efficacy|3
6090297|NCT00689273|9702208|FG001|Overall Study|Lack of Efficacy|0
6090298|NCT00689273|9702207|FG000|Overall Study|Lost to Follow-up|0
6090299|NCT00689273|9702208|FG001|Overall Study|Lost to Follow-up|2
6090300|NCT00689273|9702207|FG000|Overall Study|Other|6
6090301|NCT00689273|9702208|FG001|Overall Study|Other|2
6090302|NCT00689273|9702207|FG000|Overall Study|Randomized but not Treated|1
6053817|NCT00445549|9653470|FG000|Overall Study|progressive disease|12
6053818|NCT00445601|9653481|FG000|Overall Study|Withdrawal by Subject|11
6053819|NCT00445601|9653482|FG001|Overall Study|Withdrawal by Subject|11
6053820|NCT00445601|9653481|FG000|Overall Study|TURBT Complication|12
6090303|NCT00689273|9702208|FG001|Overall Study|Randomized but not Treated|0
6090304|NCT00689299|9702217|FG000|Overall Study|Adverse Event|2
6090305|NCT00689299|9702218|FG001|Overall Study|Adverse Event|1
6090306|NCT00689299|9702219|FG002|Overall Study|Adverse Event|1
6090307|NCT00689299|9702217|FG000|Overall Study|Lost to Follow-up|0
6090308|NCT00689299|9702218|FG001|Overall Study|Lost to Follow-up|1
6090309|NCT00689299|9702219|FG002|Overall Study|Lost to Follow-up|1
6090310|NCT00689299|9702217|FG000|Overall Study|Withdrawal by Subject|4
6090311|NCT00689299|9702218|FG001|Overall Study|Withdrawal by Subject|1
6090312|NCT00689299|9702219|FG002|Overall Study|Withdrawal by Subject|3
6053821|NCT00445601|9653482|FG001|Overall Study|TURBT Complication|8
6053822|NCT00445601|9653481|FG000|Overall Study|Incorrect Disease Status|6
6053823|NCT00445601|9653482|FG001|Overall Study|Incorrect Disease Status|6
6053824|NCT00445601|9653481|FG000|Overall Study|Drug Delivery Issue|2
6053825|NCT00445601|9653482|FG001|Overall Study|Drug Delivery Issue|2
6053826|NCT00445601|9653481|FG000|Overall Study|Adverse Event|2
6053827|NCT00445601|9653482|FG001|Overall Study|Adverse Event|0
6053828|NCT00445601|9653481|FG000|Overall Study|Death prior to TURBT|0
6053829|NCT00445601|9653482|FG001|Overall Study|Death prior to TURBT|1
6053830|NCT00445679|9653496|FG000|Overall Study|Adverse Event|22
6053831|NCT00445679|9653497|FG001|Overall Study|Adverse Event|12
6053832|NCT00445679|9653498|FG002|Overall Study|Adverse Event|30
6053833|NCT00445679|9653499|FG003|Overall Study|Adverse Event|19
6053834|NCT00445679|9653496|FG000|Overall Study|Failed to return|1
6053835|NCT00445679|9653497|FG001|Overall Study|Failed to return|3
6053836|NCT00445679|9653498|FG002|Overall Study|Failed to return|2
6053837|NCT00445679|9653499|FG003|Overall Study|Failed to return|2
6053838|NCT00445679|9653496|FG000|Overall Study|Physician Decision|0
6053839|NCT00445679|9653497|FG001|Overall Study|Physician Decision|0
6053840|NCT00445679|9653498|FG002|Overall Study|Physician Decision|1
6053841|NCT00445679|9653499|FG003|Overall Study|Physician Decision|0
6053842|NCT00445679|9653496|FG000|Overall Study|Lost to Follow-up|10
6053843|NCT00445679|9653497|FG001|Overall Study|Lost to Follow-up|6
6053844|NCT00445679|9653498|FG002|Overall Study|Lost to Follow-up|6
6053845|NCT00445679|9653499|FG003|Overall Study|Lost to Follow-up|5
6053846|NCT00445679|9653496|FG000|Overall Study|Compliance|3
6053847|NCT00445679|9653497|FG001|Overall Study|Compliance|2
6053848|NCT00445679|9653498|FG002|Overall Study|Compliance|1
6053849|NCT00445679|9653499|FG003|Overall Study|Compliance|2
6053850|NCT00445679|9653496|FG000|Overall Study|Withdrawal of Informed Consent|0
6053851|NCT00445679|9653497|FG001|Overall Study|Withdrawal of Informed Consent|0
6053852|NCT00445679|9653498|FG002|Overall Study|Withdrawal of Informed Consent|1
6053853|NCT00445679|9653499|FG003|Overall Study|Withdrawal of Informed Consent|0
6053854|NCT00445679|9653496|FG000|Overall Study|Protocol Violation|2
6053855|NCT00445679|9653497|FG001|Overall Study|Protocol Violation|3
6053856|NCT00445679|9653498|FG002|Overall Study|Protocol Violation|3
6053857|NCT00445679|9653499|FG003|Overall Study|Protocol Violation|1
6053858|NCT00445679|9653496|FG000|Overall Study|Withdrawal by Subject|8
6053859|NCT00445679|9653497|FG001|Overall Study|Withdrawal by Subject|14
6053860|NCT00445679|9653498|FG002|Overall Study|Withdrawal by Subject|20
6053861|NCT00445679|9653499|FG003|Overall Study|Withdrawal by Subject|18
6053862|NCT00445679|9653496|FG000|Overall Study|Lack of Efficacy|2
6053863|NCT00445679|9653497|FG001|Overall Study|Lack of Efficacy|6
6053864|NCT00445679|9653498|FG002|Overall Study|Lack of Efficacy|2
6053865|NCT00445679|9653499|FG003|Overall Study|Lack of Efficacy|0
6053866|NCT00445692|9653509|FG000|Overall Study|Adverse Event|11
6053867|NCT00445692|9653509|FG000|Overall Study|Lack of Efficacy|5
6053868|NCT00445770|9653539|FG000|Overall Study|Adverse Event|9
6053869|NCT00445770|9653540|FG001|Overall Study|Adverse Event|15
6053870|NCT00445770|9653541|FG002|Overall Study|Adverse Event|19
6053871|NCT00445770|9653539|FG000|Overall Study|Lack of Efficacy|38
6053872|NCT00445770|9653540|FG001|Overall Study|Lack of Efficacy|13
6053873|NCT00445770|9653541|FG002|Overall Study|Lack of Efficacy|6
6053874|NCT00445770|9653539|FG000|Overall Study|Lost to Follow-up|0
6053875|NCT00445770|9653540|FG001|Overall Study|Lost to Follow-up|2
6053876|NCT00445770|9653541|FG002|Overall Study|Lost to Follow-up|0
6053877|NCT00445770|9653539|FG000|Overall Study|Other|6
6053878|NCT00445770|9653540|FG001|Overall Study|Other|5
6053879|NCT00445770|9653541|FG002|Overall Study|Other|6
6053880|NCT00445848|9653551|FG000|Overall Study|Adverse Event|14
6053881|NCT00445848|9653551|FG000|Overall Study|Withdrawal by Subject|4
6053882|NCT00445848|9653551|FG000|Overall Study|Progression|62
6053883|NCT00445848|9653551|FG000|Overall Study|Other-Not protocol specified|5
6053884|NCT00445939|9653577|FG000|Period A - Week 0 - Week 4|Adverse Event|1
6053885|NCT00445939|9653578|FG001|Period A - Week 0 - Week 4|Adverse Event|2
6053886|NCT00445939|9653579|FG002|Period A - Week 0 - Week 4|Adverse Event|0
6053887|NCT00445939|9653580|FG003|Period A - Week 0 - Week 4|Adverse Event|0
6053888|NCT00445939|9653577|FG000|Period B - Week 4 - Week 8|Adverse Event|2
6053889|NCT00445939|9653578|FG001|Period B - Week 4 - Week 8|Adverse Event|0
6053890|NCT00445939|9653579|FG002|Period B - Week 4 - Week 8|Adverse Event|0
6053891|NCT00445939|9653580|FG003|Period B - Week 4 - Week 8|Adverse Event|1
6053892|NCT00445978|9653600|FG000|Week 0 - Week 4 (2.5 mg/kg/Day)|Adverse Event|1
6053893|NCT00445978|9653600|FG000|Week 0 - Week 4 (2.5 mg/kg/Day)|Physician Decision|1
6053894|NCT00445978|9653600|FG000|Week 0 - Week 4 (2.5 mg/kg/Day)|Study Compliance|1
6053895|NCT00445978|9653600|FG000|Week 4 - Week 8 (5 mg/kg/Day)|Adverse Event|1
6053896|NCT00445978|9653600|FG000|Week 4 - Week 8 (5 mg/kg/Day)|Physician Decision|1
6053897|NCT00445978|9653600|FG000|Week 4 - Week 8 (5 mg/kg/Day)|Lost to Follow-up|1
6053898|NCT00445978|9653600|FG000|Week 4 - Week 8 (5 mg/kg/Day)|Withdrew Consent|1
6053899|NCT00445978|9653600|FG000|Week 8 - Week 12 (10 mg/kg/Day)|Pregnancy|1
6053900|NCT00445978|9653600|FG000|Week 12 - Week 16 (20 mg/kg/Day)|Lost to Follow-up|1
6053901|NCT00446030|9653613|FG000|TREATMENT (up to 52 Weeks)|Adverse Event|29
6053902|NCT00446030|9653614|FG001|TREATMENT (up to 52 Weeks)|Adverse Event|8
6053903|NCT00446030|9653613|FG000|TREATMENT (up to 52 Weeks)|Subject Request|9
6053904|NCT00446030|9653614|FG001|TREATMENT (up to 52 Weeks)|Subject Request|1
6053905|NCT00446030|9653613|FG000|TREATMENT (up to 52 Weeks)|Poor compliance|1
6053906|NCT00446030|9653614|FG001|TREATMENT (up to 52 Weeks)|Poor compliance|0
6053907|NCT00446030|9653613|FG000|TREATMENT (up to 52 Weeks)|Suspicious meningioma|1
6053908|NCT00446030|9653614|FG001|TREATMENT (up to 52 Weeks)|Suspicious meningioma|0
6053909|NCT00446030|9653613|FG000|TREATMENT (up to 52 Weeks)|Protocol Violation|1
6053910|NCT00446030|9653614|FG001|TREATMENT (up to 52 Weeks)|Protocol Violation|0
6053911|NCT00446030|9653613|FG000|TREATMENT (up to 52 Weeks)|Physician Decision|1
6053912|NCT00446030|9653614|FG001|TREATMENT (up to 52 Weeks)|Physician Decision|0
6053913|NCT00446030|9653613|FG000|TREATMENT (up to 52 Weeks)|Patient concern|1
6053914|NCT00446030|9653614|FG001|TREATMENT (up to 52 Weeks)|Patient concern|0
6053915|NCT00446030|9653613|FG000|TREATMENT (up to 52 Weeks)|No treatment, but went to follow-up|1
6053916|NCT00446030|9653614|FG001|TREATMENT (up to 52 Weeks)|No treatment, but went to follow-up|0
6053917|NCT00446030|9653613|FG000|FOLLOW-UP (up to 2-years)|Subject's request|9
6053918|NCT00446030|9653614|FG001|FOLLOW-UP (up to 2-years)|Subject's request|4
6053919|NCT00446030|9653613|FG000|FOLLOW-UP (up to 2-years)|Poor compliance to protocol|5
6053920|NCT00446030|9653614|FG001|FOLLOW-UP (up to 2-years)|Poor compliance to protocol|0
6053921|NCT00446030|9653613|FG000|FOLLOW-UP (up to 2-years)|Lost to Follow-up|4
6053922|NCT00446030|9653614|FG001|FOLLOW-UP (up to 2-years)|Lost to Follow-up|0
6053923|NCT00446030|9653613|FG000|FOLLOW-UP (up to 2-years)|Death|2
6053924|NCT00446030|9653614|FG001|FOLLOW-UP (up to 2-years)|Death|2
6053925|NCT00446030|9653613|FG000|FOLLOW-UP (up to 2-years)|Disease/Breast cancer recurrence/relapse|3
6053926|NCT00446030|9653614|FG001|FOLLOW-UP (up to 2-years)|Disease/Breast cancer recurrence/relapse|2
6053927|NCT00446030|9653613|FG000|FOLLOW-UP (up to 2-years)|Investigator decision to close the study|2
6053928|NCT00446030|9653614|FG001|FOLLOW-UP (up to 2-years)|Investigator decision to close the study|0
6053929|NCT00446030|9653613|FG000|FOLLOW-UP (up to 2-years)|Per physician discretion|2
6053930|NCT00446030|9653614|FG001|FOLLOW-UP (up to 2-years)|Per physician discretion|0
6053931|NCT00446030|9653613|FG000|FOLLOW-UP (up to 2-years)|Protocol Violation|1
6053932|NCT00446030|9653614|FG001|FOLLOW-UP (up to 2-years)|Protocol Violation|0
6053933|NCT00446030|9653613|FG000|FOLLOW-UP (up to 2-years)|Patient concern|1
6053934|NCT00446030|9653614|FG001|FOLLOW-UP (up to 2-years)|Patient concern|0
6053935|NCT00446030|9653613|FG000|FOLLOW-UP (up to 2-years)|Right axilla wound|1
6053936|NCT00446030|9653614|FG001|FOLLOW-UP (up to 2-years)|Right axilla wound|0
6053937|NCT00446030|9653613|FG000|FOLLOW-UP (up to 2-years)|Missed last visit due to hysterectomy|0
6053938|NCT00446030|9653614|FG001|FOLLOW-UP (up to 2-years)|Missed last visit due to hysterectomy|1
6053939|NCT00446095|9653625|FG000|Phase II (8 Weeks)|Lost to Follow-up|1
6053940|NCT00446095|9653626|FG001|Phase II (8 Weeks)|Lost to Follow-up|0
6053941|NCT00446095|9653627|FG002|Phase II (8 Weeks)|Lost to Follow-up|0
6053942|NCT00446095|9653628|FG003|Phase II (8 Weeks)|Lost to Follow-up|0
6053943|NCT00446095|9653629|FG004|Phase II (8 Weeks)|Lost to Follow-up|0
6053944|NCT00446095|9653625|FG000|Phase II (8 Weeks)|Adverse Event|0
6053945|NCT00446095|9653626|FG001|Phase II (8 Weeks)|Adverse Event|1
6053946|NCT00446095|9653627|FG002|Phase II (8 Weeks)|Adverse Event|1
6053947|NCT00446095|9653628|FG003|Phase II (8 Weeks)|Adverse Event|0
6053948|NCT00446095|9653629|FG004|Phase II (8 Weeks)|Adverse Event|0
6053949|NCT00446095|9653625|FG000|Phase II (8 Weeks)|Withdrawal by Subject|1
6053950|NCT00446095|9653626|FG001|Phase II (8 Weeks)|Withdrawal by Subject|0
6053951|NCT00446095|9653627|FG002|Phase II (8 Weeks)|Withdrawal by Subject|0
6053952|NCT00446095|9653628|FG003|Phase II (8 Weeks)|Withdrawal by Subject|0
6053953|NCT00446095|9653629|FG004|Phase II (8 Weeks)|Withdrawal by Subject|0
6053954|NCT00446095|9653625|FG000|Phase II (8 Weeks)|Physician Decision|1
6053955|NCT00446095|9653626|FG001|Phase II (8 Weeks)|Physician Decision|0
6053956|NCT00446095|9653627|FG002|Phase II (8 Weeks)|Physician Decision|0
6053957|NCT00446095|9653628|FG003|Phase II (8 Weeks)|Physician Decision|0
6053958|NCT00446095|9653629|FG004|Phase II (8 Weeks)|Physician Decision|0
6053959|NCT00446095|9653625|FG000|Phase II (8 Weeks)|Lack of Efficacy|9
6053960|NCT00446095|9653626|FG001|Phase II (8 Weeks)|Lack of Efficacy|2
6053961|NCT00446095|9653627|FG002|Phase II (8 Weeks)|Lack of Efficacy|1
6053962|NCT00446095|9653628|FG003|Phase II (8 Weeks)|Lack of Efficacy|0
6053963|NCT00446095|9653629|FG004|Phase II (8 Weeks)|Lack of Efficacy|0
6053964|NCT00446095|9653625|FG000|Phase II (8 Weeks)|Ongoing|0
6053965|NCT00446095|9653626|FG001|Phase II (8 Weeks)|Ongoing|0
6053966|NCT00446095|9653627|FG002|Phase II (8 Weeks)|Ongoing|1
6053967|NCT00446095|9653628|FG003|Phase II (8 Weeks)|Ongoing|0
6053968|NCT00446095|9653629|FG004|Phase II (8 Weeks)|Ongoing|0
6053969|NCT00446095|9653625|FG000|Phase I (28 Days)|Adverse Event|0
6202223|NCT01499849|9862327|FG001|Overall Study|Lack of Efficacy|4
6202224|NCT01499849|9862326|FG000|Overall Study|Lost to Follow-up|6
6202225|NCT01499849|9862327|FG001|Overall Study|Lost to Follow-up|3
6053970|NCT00446095|9653626|FG001|Phase I (28 Days)|Adverse Event|0
6053971|NCT00446095|9653627|FG002|Phase I (28 Days)|Adverse Event|0
6090313|NCT00689299|9702217|FG000|Overall Study|Protocol Violation|1
6053972|NCT00446095|9653628|FG003|Phase I (28 Days)|Adverse Event|1
6053973|NCT00446095|9653629|FG004|Phase I (28 Days)|Adverse Event|0
6053974|NCT00446095|9653625|FG000|Phase I (28 Days)|Lack of Efficacy|0
6053975|NCT00446095|9653626|FG001|Phase I (28 Days)|Lack of Efficacy|0
6053976|NCT00446095|9653627|FG002|Phase I (28 Days)|Lack of Efficacy|0
6053977|NCT00446095|9653628|FG003|Phase I (28 Days)|Lack of Efficacy|0
6202226|NCT01499849|9862326|FG000|Overall Study|Other Reasons|27
6053978|NCT00446095|9653629|FG004|Phase I (28 Days)|Lack of Efficacy|3
6053979|NCT00446134|9653644|FG000|Overall Study|Adverse Event|7
6053980|NCT00446134|9653645|FG001|Overall Study|Adverse Event|17
6053981|NCT00446134|9653646|FG002|Overall Study|Adverse Event|13
6053982|NCT00446134|9653647|FG003|Overall Study|Adverse Event|18
6053983|NCT00446134|9653644|FG000|Overall Study|Lack of Efficacy|19
6053984|NCT00446134|9653645|FG001|Overall Study|Lack of Efficacy|19
6053985|NCT00446134|9653646|FG002|Overall Study|Lack of Efficacy|24
6053986|NCT00446134|9653647|FG003|Overall Study|Lack of Efficacy|19
6053987|NCT00446134|9653644|FG000|Overall Study|Protocol Violation|0
6053988|NCT00446134|9653645|FG001|Overall Study|Protocol Violation|2
6053989|NCT00446134|9653646|FG002|Overall Study|Protocol Violation|1
6053990|NCT00446134|9653647|FG003|Overall Study|Protocol Violation|0
6053991|NCT00446134|9653644|FG000|Overall Study|Lost to Follow-up|1
6053992|NCT00446134|9653645|FG001|Overall Study|Lost to Follow-up|3
6053993|NCT00446134|9653646|FG002|Overall Study|Lost to Follow-up|1
6053994|NCT00446134|9653647|FG003|Overall Study|Lost to Follow-up|1
6053995|NCT00446134|9653644|FG000|Overall Study|Withdrawal by Subject|3
6053996|NCT00446134|9653645|FG001|Overall Study|Withdrawal by Subject|3
6053997|NCT00446134|9653646|FG002|Overall Study|Withdrawal by Subject|1
6053998|NCT00446134|9653647|FG003|Overall Study|Withdrawal by Subject|3
6053999|NCT00446134|9653644|FG000|Overall Study|Physician Decision|0
6054000|NCT00446134|9653645|FG001|Overall Study|Physician Decision|0
6054001|NCT00446134|9653646|FG002|Overall Study|Physician Decision|0
6054002|NCT00446134|9653647|FG003|Overall Study|Physician Decision|2
6054003|NCT00446134|9653644|FG000|Overall Study|Adverse Event-Diarrhea|1
6054004|NCT00446134|9653645|FG001|Overall Study|Adverse Event-Diarrhea|1
6054005|NCT00446134|9653646|FG002|Overall Study|Adverse Event-Diarrhea|2
6054006|NCT00446134|9653647|FG003|Overall Study|Adverse Event-Diarrhea|0
6054007|NCT00446134|9653644|FG000|Overall Study|Reason Not Completed|3
6054008|NCT00446134|9653645|FG001|Overall Study|Reason Not Completed|0
6054009|NCT00446134|9653646|FG002|Overall Study|Reason Not Completed|1
6054010|NCT00446134|9653647|FG003|Overall Study|Reason Not Completed|2
6054011|NCT00446199|9653670|FG000|Overall Study|Adverse Event|7
6090314|NCT00689299|9702218|FG001|Overall Study|Protocol Violation|0
6090315|NCT00689299|9702219|FG002|Overall Study|Protocol Violation|0
6090316|NCT00689338|9702227|FG000|Overall Study|Death|65
6090317|NCT00689338|9702227|FG000|Overall Study|Adverse Event|13
6054012|NCT00446199|9653671|FG001|Overall Study|Adverse Event|4
6054013|NCT00446199|9653672|FG002|Overall Study|Adverse Event|6
6054014|NCT00446199|9653673|FG003|Overall Study|Adverse Event|4
6054015|NCT00446199|9653670|FG000|Overall Study|Lost to Follow-up|4
6054016|NCT00446199|9653671|FG001|Overall Study|Lost to Follow-up|5
6054017|NCT00446199|9653672|FG002|Overall Study|Lost to Follow-up|2
6054018|NCT00446199|9653673|FG003|Overall Study|Lost to Follow-up|6
6054019|NCT00446199|9653670|FG000|Overall Study|Protocol Violation|1
6054020|NCT00446199|9653671|FG001|Overall Study|Protocol Violation|2
6054021|NCT00446199|9653672|FG002|Overall Study|Protocol Violation|1
6054022|NCT00446199|9653673|FG003|Overall Study|Protocol Violation|3
6054023|NCT00446199|9653670|FG000|Overall Study|Withdrawal by Subject|2
6054024|NCT00446199|9653671|FG001|Overall Study|Withdrawal by Subject|5
6054025|NCT00446199|9653672|FG002|Overall Study|Withdrawal by Subject|9
6054026|NCT00446199|9653673|FG003|Overall Study|Withdrawal by Subject|10
6054027|NCT00446199|9653670|FG000|Overall Study|Site termination|2
6054028|NCT00446199|9653671|FG001|Overall Study|Site termination|0
6054029|NCT00446199|9653672|FG002|Overall Study|Site termination|0
6054030|NCT00446199|9653673|FG003|Overall Study|Site termination|1
6054031|NCT00446199|9653670|FG000|Overall Study|Randomization in Error|2
6054032|NCT00446199|9653671|FG001|Overall Study|Randomization in Error|0
6054033|NCT00446199|9653672|FG002|Overall Study|Randomization in Error|1
6054034|NCT00446199|9653673|FG003|Overall Study|Randomization in Error|1
6054035|NCT00446199|9653670|FG000|Overall Study|Lack of Efficacy|1
6054036|NCT00446199|9653671|FG001|Overall Study|Lack of Efficacy|0
6054037|NCT00446199|9653672|FG002|Overall Study|Lack of Efficacy|0
6054038|NCT00446199|9653673|FG003|Overall Study|Lack of Efficacy|1
6054039|NCT00446199|9653670|FG000|Overall Study|Non-compliant with study drug|1
6054040|NCT00446199|9653671|FG001|Overall Study|Non-compliant with study drug|0
6090318|NCT00689338|9702227|FG000|Overall Study|Insufficient Clinical Response|1
6090319|NCT00689338|9702227|FG000|Overall Study|Lack of Efficacy|6
6054041|NCT00446199|9653672|FG002|Overall Study|Non-compliant with study drug|5
6054042|NCT00446199|9653673|FG003|Overall Study|Non-compliant with study drug|0
6054043|NCT00446199|9653670|FG000|Overall Study|Non-compliant with visit schedule|1
6054044|NCT00446199|9653671|FG001|Overall Study|Non-compliant with visit schedule|1
6054045|NCT00446199|9653672|FG002|Overall Study|Non-compliant with visit schedule|1
6054046|NCT00446199|9653673|FG003|Overall Study|Non-compliant with visit schedule|2
6054047|NCT00446199|9653670|FG000|Overall Study|Hormone fear|0
6054048|NCT00446199|9653671|FG001|Overall Study|Hormone fear|0
6054049|NCT00446199|9653672|FG002|Overall Study|Hormone fear|0
6054050|NCT00446199|9653673|FG003|Overall Study|Hormone fear|1
6054051|NCT00446199|9653670|FG000|Overall Study|Lost interest in study participation|0
6054052|NCT00446199|9653671|FG001|Overall Study|Lost interest in study participation|1
6054053|NCT00446199|9653672|FG002|Overall Study|Lost interest in study participation|0
6054054|NCT00446199|9653673|FG003|Overall Study|Lost interest in study participation|0
6054055|NCT00446199|9653670|FG000|Overall Study|In-/Exclusion criterion violated|2
6054056|NCT00446199|9653671|FG001|Overall Study|In-/Exclusion criterion violated|1
6054057|NCT00446199|9653672|FG002|Overall Study|In-/Exclusion criterion violated|2
6054058|NCT00446199|9653673|FG003|Overall Study|In-/Exclusion criterion violated|1
6054059|NCT00446199|9653670|FG000|Overall Study|Move|0
6054060|NCT00446199|9653671|FG001|Overall Study|Move|1
6054061|NCT00446199|9653672|FG002|Overall Study|Move|0
6054062|NCT00446199|9653673|FG003|Overall Study|Move|0
6054063|NCT00446251|9653683|FG000|Overall Study|On-study Transplants|2
6054064|NCT00446251|9653683|FG000|Overall Study|Rituximab Infusion Reaction|2
6054065|NCT00446251|9653683|FG000|Overall Study|Lost to Follow-up|1
6054066|NCT00446446|9653695|FG000|Overall Study|Death|10
6054067|NCT00446446|9653695|FG000|Overall Study|Withdrawal by Subject|6
6090320|NCT00689338|9702227|FG000|Overall Study|Other|8
6090321|NCT00689338|9702227|FG000|Overall Study|Did not Meet Entrance Criteria|27
6090322|NCT00689338|9702227|FG000|Overall Study|Lost to Follow-up|5
6090323|NCT00689338|9702227|FG000|Overall Study|Withdrawal by Subject|3
6090324|NCT00689338|9702227|FG000|Overall Study|Protocol Violation|15
6090325|NCT00689351|9702233|FG000|Infant Series of Dosing|Parent/legal guardian request|5
6090326|NCT00689351|9702234|FG001|Infant Series of Dosing|Parent/legal guardian request|0
6090327|NCT00689351|9702233|FG000|Infant Series of Dosing|Adverse Event|1
6090328|NCT00689351|9702234|FG001|Infant Series of Dosing|Adverse Event|0
6090329|NCT00689351|9702233|FG000|Infant Series of Dosing|Lost to Follow-up|0
6054068|NCT00446446|9653695|FG000|Overall Study|Other|4
6054069|NCT00446446|9653695|FG000|Overall Study|Disease Progession|2
6054070|NCT00446446|9653695|FG000|Overall Study|Adverse Event|1
6054071|NCT00446446|9653695|FG000|Overall Study|On Treatment at Time of Data Cut-off|1
6054072|NCT00446459|9653699|FG000|8 Months|Protocol Violation|12
6054073|NCT00446459|9653699|FG000|12 Months|Protocol Violation|4
6054074|NCT00446459|9653699|FG000|12 Months|14 subjects to MMF + Rituximab Study|14
6054075|NCT00446511|9653707|FG000|Overall Study|Adverse Event|7
6054076|NCT00446511|9653708|FG001|Overall Study|Adverse Event|2
6054077|NCT00446511|9653709|FG002|Overall Study|Adverse Event|3
6054078|NCT00446511|9653710|FG003|Overall Study|Adverse Event|1
6054079|NCT00446511|9653707|FG000|Overall Study|Protocol Violation|0
6054080|NCT00446511|9653708|FG001|Overall Study|Protocol Violation|0
6054081|NCT00446511|9653709|FG002|Overall Study|Protocol Violation|0
6054082|NCT00446511|9653710|FG003|Overall Study|Protocol Violation|1
6054083|NCT00446511|9653707|FG000|Overall Study|Withdrawal by Subject|0
6054084|NCT00446511|9653708|FG001|Overall Study|Withdrawal by Subject|0
6054085|NCT00446511|9653709|FG002|Overall Study|Withdrawal by Subject|0
6054086|NCT00446511|9653710|FG003|Overall Study|Withdrawal by Subject|3
6054087|NCT00446511|9653707|FG000|Overall Study|Administrative Problems|3
6054088|NCT00446511|9653708|FG001|Overall Study|Administrative Problems|0
6054089|NCT00446511|9653709|FG002|Overall Study|Administrative Problems|4
6054090|NCT00446511|9653710|FG003|Overall Study|Administrative Problems|1
6054091|NCT00446550|9653724|FG000|Overall Study|Adverse Event|1
6054092|NCT00446550|9653725|FG001|Overall Study|Adverse Event|0
6054093|NCT00446563|9653734|FG000|Overall Study|Adverse Event|4
6054094|NCT00446563|9653735|FG001|Overall Study|Adverse Event|3
6054095|NCT00446563|9653734|FG000|Overall Study|Abnormal laboratory value(s)|0
6054096|NCT00446563|9653735|FG001|Overall Study|Abnormal laboratory value(s)|1
6054097|NCT00446563|9653734|FG000|Overall Study|Abnormal test procedure result(s)|1
6054098|NCT00446563|9653735|FG001|Overall Study|Abnormal test procedure result(s)|0
6054099|NCT00446563|9653734|FG000|Overall Study|Unsatisfactory therapeutic effect|0
6054100|NCT00446563|9653735|FG001|Overall Study|Unsatisfactory therapeutic effect|3
6054101|NCT00446563|9653734|FG000|Overall Study|Withdrawal by Subject|2
6054102|NCT00446563|9653735|FG001|Overall Study|Withdrawal by Subject|1
6054103|NCT00446563|9653734|FG000|Overall Study|Administrative problems|0
6054104|NCT00446563|9653735|FG001|Overall Study|Administrative problems|1
6054105|NCT00446641|9653743|FG000|Overall Study|Withdrawal by Subject|8
6054106|NCT00446641|9653744|FG001|Overall Study|Withdrawal by Subject|3
6054107|NCT00446641|9653743|FG000|Overall Study|poor compliance|8
6054108|NCT00446641|9653744|FG001|Overall Study|poor compliance|6
6054109|NCT00446641|9653743|FG000|Overall Study|Lost to Follow-up|1
6054110|NCT00446641|9653744|FG001|Overall Study|Lost to Follow-up|1
6054111|NCT00446654|9653752|FG000|Overall Study|Withdrawal by Subject|1
6054112|NCT00446654|9653753|FG001|Overall Study|Withdrawal by Subject|0
6054113|NCT00446654|9653752|FG000|Overall Study|Adverse Event|1
6054114|NCT00446654|9653753|FG001|Overall Study|Adverse Event|0
6054115|NCT00446797|9653761|FG000|Overall Study|Lack of Efficacy|0
6054116|NCT00446797|9653762|FG001|Overall Study|Lack of Efficacy|2
6054117|NCT00446797|9653761|FG000|Overall Study|Lost to Follow-up|5
6054118|NCT00446797|9653762|FG001|Overall Study|Lost to Follow-up|3
6054119|NCT00446797|9653761|FG000|Overall Study|Withdrawal by Subject|2
6054120|NCT00446797|9653762|FG001|Overall Study|Withdrawal by Subject|2
6054121|NCT00446797|9653761|FG000|Overall Study|Protocol Violation|1
6054122|NCT00446797|9653762|FG001|Overall Study|Protocol Violation|3
6054123|NCT00446797|9653761|FG000|Overall Study|subject entered at another site|0
6054124|NCT00446797|9653762|FG001|Overall Study|subject entered at another site|1
6054125|NCT00446797|9653761|FG000|Overall Study|did not meet entrance criteria|0
6054126|NCT00446797|9653762|FG001|Overall Study|did not meet entrance criteria|1
6054127|NCT00446849|9653768|FG000|Acute Phase|Lack of Efficacy|64
6054128|NCT00446849|9653768|FG000|Acute Phase|Protocol Violation|10
6054129|NCT00446849|9653768|FG000|Acute Phase|Consent withdrawn|4
6054130|NCT00446849|9653768|FG000|Acute Phase|Lost to Follow-up|2
6054131|NCT00446849|9653768|FG000|Acute Phase|Physician Decision|1
6054132|NCT00446849|9653768|FG000|Acute Phase|noncompliance|1
6054133|NCT00446849|9653768|FG000|Maintenance Phase|Lack of Efficacy|40
6054134|NCT00446849|9653768|FG000|Maintenance Phase|Protocol Violation|7
6054135|NCT00446849|9653768|FG000|Maintenance Phase|Adverse Event|6
6054136|NCT00446849|9653768|FG000|Maintenance Phase|Consent withdrawn|5
6054137|NCT00446849|9653768|FG000|Maintenance Phase|Lost to Follow-up|3
6054138|NCT00446849|9653768|FG000|Maintenance Phase|Pregnancy|1
6054139|NCT00446849|9653768|FG000|Maintenance Phase|noncompliance|2
6054140|NCT00446849|9653768|FG000|Maintenance Phase|prohibited medication use|2
6054141|NCT00446849|9653768|FG000|Maintenance Phase|antibiotic use|1
6054142|NCT00446849|9653768|FG000|Maintenance Phase|study closure|1
6054143|NCT00446849|9653768|FG000|Maintenance Phase|hydrocodone use|1
6054144|NCT00446849|9653768|FG000|Maintenance Phase|concomitant medication use|1
6054145|NCT00446966|9653775|FG000|Overall Study|Lost to Follow-up|10
6054146|NCT00446966|9653776|FG001|Overall Study|Lost to Follow-up|7
6054147|NCT00446992|9653782|FG000|Overall Study|Adverse Event|11
6054148|NCT00446992|9653782|FG000|Overall Study|Lost to Follow-up|5
6054149|NCT00447005|9653786|FG000|Overall Study|Adverse Event|1
6054150|NCT00447005|9653786|FG000|Overall Study|Lack of Efficacy|11
6054151|NCT00447057|9653794|FG000|Overall Study|Adverse Event|4
6054152|NCT00447057|9653795|FG001|Overall Study|Adverse Event|10
6054153|NCT00447057|9653796|FG002|Overall Study|Adverse Event|0
6054154|NCT00447057|9653797|FG003|Overall Study|Adverse Event|3
6054155|NCT00447057|9653794|FG000|Overall Study|Death due to study disease|6
6054156|NCT00447057|9653795|FG001|Overall Study|Death due to study disease|4
6054157|NCT00447057|9653796|FG002|Overall Study|Death due to study disease|1
6054158|NCT00447057|9653797|FG003|Overall Study|Death due to study disease|1
6054159|NCT00447057|9653794|FG000|Overall Study|Lost to Follow-up|0
6054160|NCT00447057|9653795|FG001|Overall Study|Lost to Follow-up|1
6054161|NCT00447057|9653796|FG002|Overall Study|Lost to Follow-up|0
6054162|NCT00447057|9653797|FG003|Overall Study|Lost to Follow-up|0
6054163|NCT00447057|9653794|FG000|Overall Study|Entry criteria not met|1
6054164|NCT00447057|9653795|FG001|Overall Study|Entry criteria not met|1
6054165|NCT00447057|9653796|FG002|Overall Study|Entry criteria not met|0
6054166|NCT00447057|9653797|FG003|Overall Study|Entry criteria not met|0
6054167|NCT00447057|9653794|FG000|Overall Study|Protocol Violation|0
6054168|NCT00447057|9653795|FG001|Overall Study|Protocol Violation|1
6054169|NCT00447057|9653796|FG002|Overall Study|Protocol Violation|0
6054170|NCT00447057|9653797|FG003|Overall Study|Protocol Violation|0
6054171|NCT00447057|9653794|FG000|Overall Study|Withdrawal by Subject|4
6054172|NCT00447057|9653795|FG001|Overall Study|Withdrawal by Subject|5
6054173|NCT00447057|9653796|FG002|Overall Study|Withdrawal by Subject|1
6054174|NCT00447057|9653797|FG003|Overall Study|Withdrawal by Subject|1
6054175|NCT00447057|9653794|FG000|Overall Study|Physician Decision|9
6054176|NCT00447057|9653795|FG001|Overall Study|Physician Decision|6
6054177|NCT00447057|9653796|FG002|Overall Study|Physician Decision|3
6054178|NCT00447057|9653797|FG003|Overall Study|Physician Decision|1
6054179|NCT00447057|9653794|FG000|Overall Study|Sponsor decision|1
6054180|NCT00447057|9653795|FG001|Overall Study|Sponsor decision|1
6054181|NCT00447057|9653796|FG002|Overall Study|Sponsor decision|0
6054182|NCT00447057|9653797|FG003|Overall Study|Sponsor decision|0
6054183|NCT00447057|9653794|FG000|Overall Study|Progressive disease|58
6054184|NCT00447057|9653795|FG001|Overall Study|Progressive disease|43
6054185|NCT00447057|9653796|FG002|Overall Study|Progressive disease|13
6054186|NCT00447057|9653797|FG003|Overall Study|Progressive disease|18
6054187|NCT00447057|9653794|FG000|Overall Study|Death due to adverse event|0
6054188|NCT00447057|9653795|FG001|Overall Study|Death due to adverse event|0
6054189|NCT00447057|9653796|FG002|Overall Study|Death due to adverse event|1
6054190|NCT00447057|9653797|FG003|Overall Study|Death due to adverse event|2
6054191|NCT00447057|9653794|FG000|Overall Study|Death, study drug related|0
6054192|NCT00447057|9653795|FG001|Overall Study|Death, study drug related|1
6054193|NCT00447057|9653796|FG002|Overall Study|Death, study drug related|0
6054194|NCT00447057|9653797|FG003|Overall Study|Death, study drug related|0
6054195|NCT00447226|9653818|FG000|12-Week Open-label Phase|Adverse Event|0
6054196|NCT00447226|9653819|FG001|12-Week Open-label Phase|Adverse Event|3
6054197|NCT00447226|9653818|FG000|12-Week Open-label Phase|Protocol Violation|0
6054198|NCT00447226|9653819|FG001|12-Week Open-label Phase|Protocol Violation|1
6054199|NCT00447226|9653818|FG000|12-Week Open-label Phase|Disease Progression|0
6054200|NCT00447226|9653819|FG001|12-Week Open-label Phase|Disease Progression|20
6054201|NCT00447226|9653818|FG000|12-Week Open-label Phase|Physician Decision|0
6054202|NCT00447226|9653819|FG001|12-Week Open-label Phase|Physician Decision|1
6054203|NCT00447226|9653818|FG000|Double-blind Phase|Disease Progression|4
6054204|NCT00447226|9653819|FG001|Double-blind Phase|Disease Progression|3
6054205|NCT00447265|9653834|FG000|Overall Study|Physician Decision|1
6054206|NCT00447265|9653835|FG001|Overall Study|Physician Decision|0
6054207|NCT00447278|9653841|FG000|Period II (6 Month Open-Label)|Adverse Event|7
6054208|NCT00447278|9653842|FG001|Period II (6 Month Open-Label)|Adverse Event|3
6054209|NCT00447278|9653841|FG000|Period II (6 Month Open-Label)|Lost to Follow-up|0
6054210|NCT00447278|9653842|FG001|Period II (6 Month Open-Label)|Lost to Follow-up|4
6054211|NCT00447278|9653841|FG000|Period II (6 Month Open-Label)|Protocol Violation|10
6054212|NCT00447278|9653842|FG001|Period II (6 Month Open-Label)|Protocol Violation|7
6054213|NCT00447278|9653841|FG000|Period II (6 Month Open-Label)|Withdrawal by Subject|1
6054214|NCT00447278|9653842|FG001|Period II (6 Month Open-Label)|Withdrawal by Subject|3
6054215|NCT00447278|9653841|FG000|Period II (6 Month Open-Label)|Physician Decision|4
6054216|NCT00447278|9653842|FG001|Period II (6 Month Open-Label)|Physician Decision|1
6054217|NCT00447278|9653841|FG000|Period II (6 Month Open-Label)|Lack of Efficacy|11
6054218|NCT00447278|9653842|FG001|Period II (6 Month Open-Label)|Lack of Efficacy|1
6054219|NCT00447278|9653841|FG000|Period II (6 Month Open-Label)|Parent/Guardian Decision|9
6054220|NCT00447278|9653842|FG001|Period II (6 Month Open-Label)|Parent/Guardian Decision|10
6054221|NCT00447278|9653841|FG000|Period III (Optional 6 Month Extension)|Adverse Event|2
6054222|NCT00447278|9653842|FG001|Period III (Optional 6 Month Extension)|Adverse Event|2
6054223|NCT00447278|9653841|FG000|Period III (Optional 6 Month Extension)|Lost to Follow-up|2
6054224|NCT00447278|9653842|FG001|Period III (Optional 6 Month Extension)|Lost to Follow-up|2
6054225|NCT00447278|9653841|FG000|Period III (Optional 6 Month Extension)|Protocol Violation|6
6054226|NCT00447278|9653842|FG001|Period III (Optional 6 Month Extension)|Protocol Violation|1
6054227|NCT00447278|9653841|FG000|Period III (Optional 6 Month Extension)|Withdrawal by Subject|4
6054228|NCT00447278|9653842|FG001|Period III (Optional 6 Month Extension)|Withdrawal by Subject|1
6054229|NCT00447278|9653841|FG000|Period III (Optional 6 Month Extension)|Physician Decision|1
6054230|NCT00447278|9653842|FG001|Period III (Optional 6 Month Extension)|Physician Decision|1
6054231|NCT00447278|9653841|FG000|Period III (Optional 6 Month Extension)|Lack of Efficacy|4
6054232|NCT00447278|9653842|FG001|Period III (Optional 6 Month Extension)|Lack of Efficacy|0
6054233|NCT00447278|9653841|FG000|Period III (Optional 6 Month Extension)|Parent/Guardian Decision|11
6054234|NCT00447278|9653842|FG001|Period III (Optional 6 Month Extension)|Parent/Guardian Decision|8
6054235|NCT00447382|9653856|FG000|Overall Study|Adverse Event|1
6054236|NCT00447382|9653857|FG001|Overall Study|Adverse Event|1
6054237|NCT00447382|9653856|FG000|Overall Study|Lack of Efficacy|1
6054238|NCT00447382|9653857|FG001|Overall Study|Lack of Efficacy|0
6054239|NCT00447382|9653856|FG000|Overall Study|Protocol Violation|2
6054240|NCT00447382|9653857|FG001|Overall Study|Protocol Violation|0
6054241|NCT00447382|9653856|FG000|Overall Study|Unclassified|2
6054242|NCT00447382|9653857|FG001|Overall Study|Unclassified|5
6054243|NCT00447499|9653863|FG000|Overall Study|Adverse Event|1
6054244|NCT00447499|9653863|FG000|Overall Study|Patient Decision|4
6054245|NCT00447499|9653863|FG000|Overall Study|Sponsor Decision|1
6054246|NCT00447499|9653863|FG000|Overall Study|Physician Decision|1
6054247|NCT00447590|9653869|FG000|Overall Study|Withdrawal by Subject|26
6054248|NCT00447590|9653869|FG000|Overall Study|Lost to Follow-up|24
6054249|NCT00447590|9653869|FG000|Overall Study|Band Removed/Eroded/Other Follow-Up Loss|10
6054250|NCT00447694|9653873|FG000|Overall Study|Adverse Event|2
6054251|NCT00447694|9653873|FG000|Overall Study|Abnormal laboratory value|1
6054252|NCT00447694|9653873|FG000|Overall Study|Abnormal test procedure result|1
6054253|NCT00447694|9653873|FG000|Overall Study|Withdrawal by Subject|2
6054254|NCT00447772|9653877|FG000|Overall Study|Lack of Efficacy|3
6054255|NCT00447772|9653877|FG000|Overall Study|Insufficient compliance|6
6054256|NCT00447772|9653877|FG000|Overall Study|Discontinuation of drug therapy|1
6054257|NCT00447772|9653877|FG000|Overall Study|Lost to Follow-up|9
6054258|NCT00447772|9653877|FG000|Overall Study|Withdrawal by Subject|1
6054259|NCT00447772|9653877|FG000|Overall Study|Unable to attend all study visits|2
6054260|NCT00447772|9653877|FG000|Overall Study|Adverse Event|1
6054261|NCT00447772|9653877|FG000|Overall Study|Patient relocated|1
6054262|NCT00447772|9653877|FG000|Overall Study|Incomplete documentation at visit 1|1
6054263|NCT00447772|9653877|FG000|Overall Study|Chemotherapy for lung cancer|1
6054264|NCT00447772|9653877|FG000|Overall Study|Premature re-injection required|1
6054265|NCT00447876|9653886|FG000|Overall Study|Withdrawal by Subject|1
6054266|NCT00447876|9653887|FG001|Overall Study|Withdrawal by Subject|4
6054267|NCT00447876|9653886|FG000|Overall Study|Lost to Follow-up|1
6054268|NCT00447876|9653887|FG001|Overall Study|Lost to Follow-up|0
6054269|NCT00447876|9653886|FG000|Overall Study|Deterioration of symptomology|1
6054270|NCT00447876|9653887|FG001|Overall Study|Deterioration of symptomology|0
6054271|NCT00447902|9653895|FG000|Overall Study|Adverse Event|0
6054272|NCT00447902|9653896|FG001|Overall Study|Adverse Event|3
6054273|NCT00447902|9653895|FG000|Overall Study|Protocol Violation|1
6054274|NCT00447902|9653896|FG001|Overall Study|Protocol Violation|0
6054275|NCT00447902|9653895|FG000|Overall Study|Withdrawal by Subject|0
6054276|NCT00447902|9653896|FG001|Overall Study|Withdrawal by Subject|1
6054277|NCT00447902|9653895|FG000|Overall Study|included patients who discontinued|1
6054278|NCT00447902|9653896|FG001|Overall Study|included patients who discontinued|1
6054279|NCT00447902|9653895|FG000|Overall Study|Lack of Efficacy|2
6054280|NCT00447902|9653896|FG001|Overall Study|Lack of Efficacy|1
6054281|NCT00448019|9653902|FG000|Overall Study|Withdrawal by Subject|3
6054282|NCT00448019|9653902|FG000|Overall Study|Disease progression|1
6054283|NCT00448019|9653902|FG000|Overall Study|Death|2
6054284|NCT00448019|9653902|FG000|Overall Study|Insurance Issues|1
6054285|NCT00448123|9653908|FG000|Overall Study|Lost to Follow-up|9
6054286|NCT00448123|9653909|FG001|Overall Study|Lost to Follow-up|6
6054287|NCT00448123|9653908|FG000|Overall Study|Physician Decision|6
6054288|NCT00448123|9653909|FG001|Overall Study|Physician Decision|6
6090330|NCT00689351|9702234|FG001|Infant Series of Dosing|Lost to Follow-up|1
6054289|NCT00448136|9653920|FG000|Overall Study|Death|3
6054290|NCT00448136|9653921|FG001|Overall Study|Death|8
6054291|NCT00448136|9653920|FG000|Overall Study|Investigator's decision (progression)|1
6054292|NCT00448136|9653921|FG001|Overall Study|Investigator's decision (progression)|0
6090331|NCT00689351|9702233|FG000|After Infant Series|Parent/legal guardian request|1
6090332|NCT00689351|9702234|FG001|After Infant Series|Parent/legal guardian request|0
6090333|NCT00689390|9702246|FG000|Overall Study|Adverse Event|19
6090334|NCT00689390|9702247|FG001|Overall Study|Adverse Event|0
6090335|NCT00689390|9702246|FG000|Overall Study|Lost to Follow-up|179
6090336|NCT00689390|9702247|FG001|Overall Study|Lost to Follow-up|7
6090337|NCT00689390|9702246|FG000|Overall Study|Withdrawal by Subject|117
6090338|NCT00689390|9702247|FG001|Overall Study|Withdrawal by Subject|3
6090339|NCT00689390|9702246|FG000|Overall Study|Withdrew Consent-Retreatment Opportunity|52
6090340|NCT00689390|9702247|FG001|Overall Study|Withdrew Consent-Retreatment Opportunity|0
6090341|NCT00689390|9702246|FG000|Overall Study|Non-Compliance With Protocol|21
6090342|NCT00689390|9702247|FG001|Overall Study|Non-Compliance With Protocol|0
6090343|NCT00689390|9702246|FG000|Overall Study|Did Not Meet Protocol Eligibility|1
6090344|NCT00689390|9702247|FG001|Overall Study|Did Not Meet Protocol Eligibility|0
6090345|NCT00689390|9702246|FG000|Overall Study|Administrative|37
6090346|NCT00689390|9702247|FG001|Overall Study|Administrative|0
6090347|NCT00689481|9702260|FG000|Overall Study|Adverse Event|7
6090348|NCT00689481|9702261|FG001|Overall Study|Adverse Event|1
6090349|NCT00689481|9702260|FG000|Overall Study|Lost to Follow-up|4
6090350|NCT00689481|9702261|FG001|Overall Study|Lost to Follow-up|3
6090351|NCT00689481|9702260|FG000|Overall Study|Lack of Efficacy|4
6090352|NCT00689481|9702261|FG001|Overall Study|Lack of Efficacy|3
6090353|NCT00689481|9702260|FG000|Overall Study|Non-compliance with study treatment|1
6090354|NCT00689481|9702261|FG001|Overall Study|Non-compliance with study treatment|1
6090355|NCT00689481|9702260|FG000|Overall Study|Withdrawal by Subject|8
6090356|NCT00689481|9702261|FG001|Overall Study|Withdrawal by Subject|4
6090357|NCT00689481|9702260|FG000|Overall Study|Excluded medication started during study|0
6090358|NCT00689481|9702261|FG001|Overall Study|Excluded medication started during study|1
6090359|NCT00689481|9702260|FG000|Overall Study|Subject early term, left on vacation|0
6090360|NCT00689481|9702261|FG001|Overall Study|Subject early term, left on vacation|1
6090361|NCT00689611|9702278|FG000|Overall Study|Death|6
6090362|NCT00689611|9702279|FG001|Overall Study|Death|9
6090363|NCT00689611|9702278|FG000|Overall Study|Withdrawal by Subject|8
6090364|NCT00689611|9702279|FG001|Overall Study|Withdrawal by Subject|9
6090365|NCT00689611|9702278|FG000|Overall Study|Lost to Follow-up|27
6090366|NCT00689611|9702279|FG001|Overall Study|Lost to Follow-up|28
6090367|NCT00689728|9702288|FG000|Double-Blind Treatment|Adverse Event|1
6090368|NCT00689728|9702289|FG001|Double-Blind Treatment|Adverse Event|0
6090369|NCT00689728|9702290|FG002|Double-Blind Treatment|Adverse Event|0
6090370|NCT00689728|9702288|FG000|Double-Blind Treatment|Protocol Violation|0
6090371|NCT00689728|9702289|FG001|Double-Blind Treatment|Protocol Violation|0
6090372|NCT00689728|9702290|FG002|Double-Blind Treatment|Protocol Violation|1
6090373|NCT00689728|9702288|FG000|Double-Blind Treatment|Withdrawal by Subject|3
6090374|NCT00689728|9702289|FG001|Double-Blind Treatment|Withdrawal by Subject|3
6090375|NCT00689728|9702290|FG002|Double-Blind Treatment|Withdrawal by Subject|2
6090376|NCT00689728|9702288|FG000|Double-Blind Treatment|Lack of Efficacy|0
6090377|NCT00689728|9702289|FG001|Double-Blind Treatment|Lack of Efficacy|1
6090378|NCT00689728|9702290|FG002|Double-Blind Treatment|Lack of Efficacy|2
6090379|NCT00689728|9702288|FG000|Rescue|Adverse Event|0
6090380|NCT00689728|9702289|FG001|Rescue|Adverse Event|1
6090381|NCT00689728|9702290|FG002|Rescue|Adverse Event|0
6090382|NCT00689728|9702288|FG000|Rescue|Withdrawal by Subject|1
6090383|NCT00689728|9702289|FG001|Rescue|Withdrawal by Subject|1
6090384|NCT00689728|9702290|FG002|Rescue|Withdrawal by Subject|1
6090385|NCT00689728|9702288|FG000|Optional Follow-Up|Adverse Event|1
6090386|NCT00689728|9702289|FG001|Optional Follow-Up|Adverse Event|0
6090387|NCT00689728|9702290|FG002|Optional Follow-Up|Adverse Event|0
6090388|NCT00689728|9702288|FG000|Optional Follow-Up|Lack of Efficacy|0
6090389|NCT00689728|9702289|FG001|Optional Follow-Up|Lack of Efficacy|1
6090390|NCT00689728|9702290|FG002|Optional Follow-Up|Lack of Efficacy|1
6090391|NCT00689728|9702288|FG000|Optional Follow-Up|Lost to Follow-up|0
6090392|NCT00689728|9702289|FG001|Optional Follow-Up|Lost to Follow-up|1
6090393|NCT00689728|9702290|FG002|Optional Follow-Up|Lost to Follow-up|1
6090394|NCT00689728|9702288|FG000|Optional Follow-Up|Protocol Violation|0
6090395|NCT00689728|9702289|FG001|Optional Follow-Up|Protocol Violation|0
6090396|NCT00689728|9702290|FG002|Optional Follow-Up|Protocol Violation|1
6090397|NCT00689728|9702288|FG000|Optional Follow-Up|Withdrawal by Subject|2
6090398|NCT00689728|9702289|FG001|Optional Follow-Up|Withdrawal by Subject|4
6090399|NCT00689728|9702290|FG002|Optional Follow-Up|Withdrawal by Subject|3
6202227|NCT01499849|9862327|FG001|Overall Study|Other Reasons|30
6202228|NCT01499940|9862351|FG000|Overall Study|Study was withdrawn before completion.|9
6202229|NCT01500031|9862355|FG000|Overall Study|Death|1
6202230|NCT01500031|9862355|FG000|Overall Study|Withdrawal by Subject|4
6202231|NCT01500057|9862361|FG000|Overall Study|Lost to Follow-up|6
6202232|NCT01500057|9862362|FG001|Overall Study|Lost to Follow-up|4
6202233|NCT01500083|9862370|FG000|Overall Study|Adverse Event|4
6202234|NCT01500083|9862371|FG001|Overall Study|Adverse Event|17
6202235|NCT01500083|9862370|FG000|Overall Study|Death|0
6054293|NCT00448279|9653951|FG000|Overall Study|Lost to Follow-up|2
6054294|NCT00448279|9653952|FG001|Overall Study|Lost to Follow-up|2
6054295|NCT00448279|9653951|FG000|Overall Study|Adverse Event|1
6054296|NCT00448279|9653952|FG001|Overall Study|Adverse Event|1
6054297|NCT00448279|9653951|FG000|Overall Study|Disease progression|16
6054298|NCT00448279|9653952|FG001|Overall Study|Disease progression|18
6054299|NCT00448279|9653951|FG000|Overall Study|Withdrawal by Subject|4
6054300|NCT00448279|9653952|FG001|Overall Study|Withdrawal by Subject|3
6054301|NCT00448279|9653951|FG000|Overall Study|Other|6
6054302|NCT00448279|9653952|FG001|Overall Study|Other|4
6054303|NCT00448279|9653951|FG000|Overall Study|Protocol Violation|0
6054304|NCT00448279|9653952|FG001|Overall Study|Protocol Violation|1
6054305|NCT00448344|9653960|FG000|Overall Study|Lost to Follow-up|20
6054306|NCT00448344|9653961|FG001|Overall Study|Lost to Follow-up|22
6054307|NCT00448344|9653960|FG000|Overall Study|Withdrawal by Subject|6
6054308|NCT00448344|9653961|FG001|Overall Study|Withdrawal by Subject|8
6054309|NCT00448344|9653960|FG000|Overall Study|Death|3
6054310|NCT00448344|9653961|FG001|Overall Study|Death|4
6054311|NCT00448344|9653960|FG000|Overall Study|Physician Decision|1
6054312|NCT00448344|9653961|FG001|Overall Study|Physician Decision|2
6054313|NCT00448435|9653983|FG000|Washout Period - 2 Weeks|Withdrawal by Subject|1
6054314|NCT00448435|9653984|FG001|Washout Period - 2 Weeks|Withdrawal by Subject|0
6054315|NCT00448448|9653995|FG000|Overall Study|Withdrawal by Subject|13
6054316|NCT00448448|9653996|FG001|Overall Study|Withdrawal by Subject|2
6054317|NCT00448448|9653995|FG000|Overall Study|On protocol when study ended|83
6054318|NCT00448448|9653996|FG001|Overall Study|On protocol when study ended|36
6054319|NCT00448448|9653995|FG000|Overall Study|Lost to Follow-up|2
6054320|NCT00448448|9653996|FG001|Overall Study|Lost to Follow-up|1
6054321|NCT00448448|9653995|FG000|Overall Study|Wrong diagnosis (n=3) or other|2
6054322|NCT00448448|9653996|FG001|Overall Study|Wrong diagnosis (n=3) or other|1
6054323|NCT00448448|9653995|FG000|Overall Study|Signed consent lost|0
6054324|NCT00448448|9653996|FG001|Overall Study|Signed consent lost|1
6054325|NCT00448539|9654004|FG000|Overall Study|Medication non-compliance|4
6054326|NCT00448539|9654005|FG001|Overall Study|Medication non-compliance|1
6054327|NCT00448539|9654004|FG000|Overall Study|Protocol Violation|1
6054328|NCT00448539|9654005|FG001|Overall Study|Protocol Violation|0
6054329|NCT00448539|9654004|FG000|Overall Study|Request of the investigator or sponsor|67
6054330|NCT00448539|9654005|FG001|Overall Study|Request of the investigator or sponsor|54
6054331|NCT00448539|9654004|FG000|Overall Study|Withdrawal by Subject|20
6054332|NCT00448539|9654005|FG001|Overall Study|Withdrawal by Subject|24
6054333|NCT00448539|9654004|FG000|Overall Study|Diary non-compliance|1
6054334|NCT00448539|9654005|FG001|Overall Study|Diary non-compliance|0
6054335|NCT00448539|9654004|FG000|Overall Study|Adverse Event|9
6054336|NCT00448539|9654005|FG001|Overall Study|Adverse Event|26
6054337|NCT00448539|9654004|FG000|Overall Study|Lack of Efficacy|27
6054338|NCT00448539|9654005|FG001|Overall Study|Lack of Efficacy|40
6054339|NCT00448539|9654004|FG000|Overall Study|Miscellaneous|2
6054340|NCT00448539|9654005|FG001|Overall Study|Miscellaneous|1
6054341|NCT00448539|9654004|FG000|Overall Study|Change of meds|2
6054342|NCT00448539|9654005|FG001|Overall Study|Change of meds|3
6054343|NCT00448539|9654004|FG000|Overall Study|Lost to Follow-up|1
6054344|NCT00448539|9654005|FG001|Overall Study|Lost to Follow-up|3
6054345|NCT00448591|9654011|FG000|Overall Study|Withdrawal by Subject|178
6054346|NCT00448591|9654011|FG000|Overall Study|Progressive Disease|1382
6054347|NCT00448591|9654011|FG000|Overall Study|Adverse Event|382
6054348|NCT00448591|9654011|FG000|Overall Study|Protocol Violation|41
6054349|NCT00448591|9654011|FG000|Overall Study|Lost to Follow-up|19
6054350|NCT00448591|9654011|FG000|Overall Study|Treatment Regimen Completed|70
6054351|NCT00448591|9654011|FG000|Overall Study|Other|154
6054352|NCT00448591|9654011|FG000|Overall Study|Termination of Study|70
6054353|NCT00448669|9654019|FG000|Overall Study|Lost to Follow-up|52
6054354|NCT00448669|9654020|FG001|Overall Study|Lost to Follow-up|63
6054355|NCT00448669|9654019|FG000|Overall Study|Withdrawal by Subject|90
6054356|NCT00448669|9654020|FG001|Overall Study|Withdrawal by Subject|74
6054357|NCT00448669|9654019|FG000|Overall Study|Relocated|49
6054358|NCT00448669|9654020|FG001|Overall Study|Relocated|36
6054359|NCT00448669|9654019|FG000|Overall Study|Were withdrawn by investigator|10
6054360|NCT00448669|9654020|FG001|Overall Study|Were withdrawn by investigator|6
6054361|NCT00448669|9654019|FG000|Overall Study|Death|2
6054362|NCT00448669|9654020|FG001|Overall Study|Death|4
6054363|NCT00448669|9654019|FG000|Overall Study|Had other reasons|5
6054364|NCT00448669|9654020|FG001|Overall Study|Had other reasons|6
6054365|NCT00448669|9654019|FG000|Overall Study|HIV-infected at enrollment|1
6054366|NCT00448669|9654020|FG001|Overall Study|HIV-infected at enrollment|2
6054367|NCT00448669|9654019|FG000|Overall Study|Never started drug|9
6054368|NCT00448669|9654020|FG001|Overall Study|Never started drug|7
6054369|NCT00448708|9654030|FG000|Overall Study|Death|21
6054370|NCT00448708|9654031|FG001|Overall Study|Death|17
6054371|NCT00448708|9654030|FG000|Overall Study|Withdrawal by Subject|8
6284221|NCT02326272|9996338|FG010|Initial Period (Week 0 to Week 16)|Moved from the study area|0
6054372|NCT00448708|9654031|FG001|Overall Study|Withdrawal by Subject|4
6054373|NCT00448708|9654030|FG000|Overall Study|Lost to Follow-up|6
6054374|NCT00448708|9654031|FG001|Overall Study|Lost to Follow-up|8
6054375|NCT00448708|9654030|FG000|Overall Study|not listed|0
6054376|NCT00448708|9654031|FG001|Overall Study|not listed|2
6054377|NCT00448747|9654039|FG000|Overall Study|collapsed veins|1
6090400|NCT00689793|9702321|FG000|Overall Study|Lost to Follow-up|4
6090401|NCT00689793|9702322|FG001|Overall Study|Lost to Follow-up|5
6090402|NCT00689871|9702343|FG000|Overall Study|Lost to Follow-up|123
6090403|NCT00689871|9702344|FG001|Overall Study|Lost to Follow-up|13
6090404|NCT00689871|9702345|FG002|Overall Study|Lost to Follow-up|37
6090405|NCT00689871|9702346|FG003|Overall Study|Lost to Follow-up|1
6090406|NCT00689871|9702343|FG000|Overall Study|Explanted of All Study Devices|36
6090407|NCT00689871|9702344|FG001|Overall Study|Explanted of All Study Devices|25
6090408|NCT00689871|9702345|FG002|Overall Study|Explanted of All Study Devices|29
6090409|NCT00689871|9702346|FG003|Overall Study|Explanted of All Study Devices|3
6090410|NCT00689871|9702343|FG000|Overall Study|Withdrawal by Subject|13
6090411|NCT00689871|9702344|FG001|Overall Study|Withdrawal by Subject|3
6090412|NCT00689871|9702345|FG002|Overall Study|Withdrawal by Subject|4
6090413|NCT00689871|9702346|FG003|Overall Study|Withdrawal by Subject|1
6090414|NCT00689871|9702343|FG000|Overall Study|Death|1
6090415|NCT00689871|9702344|FG001|Overall Study|Death|10
6090416|NCT00689871|9702345|FG002|Overall Study|Death|2
6090417|NCT00689871|9702346|FG003|Overall Study|Death|2
6090418|NCT00689871|9702343|FG000|Overall Study|Physician Decision|2
6090419|NCT00689871|9702344|FG001|Overall Study|Physician Decision|1
6090420|NCT00689871|9702345|FG002|Overall Study|Physician Decision|1
6090421|NCT00689871|9702346|FG003|Overall Study|Physician Decision|0
6090422|NCT00689936|9702359|FG000|Active Treatment Phase|Adverse Event|68
6090423|NCT00689936|9702360|FG001|Active Treatment Phase|Adverse Event|71
6090424|NCT00689936|9702361|FG002|Active Treatment Phase|Adverse Event|76
6090425|NCT00689936|9702359|FG000|Active Treatment Phase|Disease Progression|273
6090426|NCT00689936|9702360|FG001|Active Treatment Phase|Disease Progression|362
6090427|NCT00689936|9702361|FG002|Active Treatment Phase|Disease Progression|339
6090428|NCT00689936|9702359|FG000|Active Treatment Phase|Withdrawal by Subject|16
6090429|NCT00689936|9702360|FG001|Active Treatment Phase|Withdrawal by Subject|16
6090430|NCT00689936|9702361|FG002|Active Treatment Phase|Withdrawal by Subject|21
6090431|NCT00689936|9702359|FG000|Active Treatment Phase|Death|60
6090432|NCT00689936|9702360|FG001|Active Treatment Phase|Death|28
6090433|NCT00689936|9702361|FG002|Active Treatment Phase|Death|37
6090434|NCT00689936|9702359|FG000|Active Treatment Phase|Lost to Follow-up|0
6090435|NCT00689936|9702360|FG001|Active Treatment Phase|Lost to Follow-up|2
6090436|NCT00689936|9702361|FG002|Active Treatment Phase|Lost to Follow-up|2
6090437|NCT00689936|9702359|FG000|Active Treatment Phase|Protocol Violation|2
6090438|NCT00689936|9702360|FG001|Active Treatment Phase|Protocol Violation|2
6090439|NCT00689936|9702361|FG002|Active Treatment Phase|Protocol Violation|4
6090440|NCT00689936|9702359|FG000|Active Treatment Phase|Study Close Out|64
6090441|NCT00689936|9702360|FG001|Active Treatment Phase|Study Close Out|26
6090442|NCT00689936|9702361|FG002|Active Treatment Phase|Study Close Out|21
6090443|NCT00689936|9702359|FG000|Active Treatment Phase|Miscellaneous|52
6090444|NCT00689936|9702360|FG001|Active Treatment Phase|Miscellaneous|34
6090445|NCT00689936|9702361|FG002|Active Treatment Phase|Miscellaneous|47
6090446|NCT00689936|9702359|FG000|Long-Term Follow Up Phase|Continue in Long Term Follow Up|127
6090447|NCT00689936|9702360|FG001|Long-Term Follow Up Phase|Continue in Long Term Follow Up|188
6090448|NCT00689936|9702361|FG002|Long-Term Follow Up Phase|Continue in Long Term Follow Up|144
6090449|NCT00690378|9702415|FG000|Overall Study|Adverse Event|1
6090450|NCT00690378|9702416|FG001|Overall Study|Adverse Event|0
6090451|NCT00690378|9702415|FG000|Overall Study|Withdrawal by Subject|2
6090452|NCT00690378|9702416|FG001|Overall Study|Withdrawal by Subject|0
6090453|NCT00690378|9702415|FG000|Overall Study|Protocol Violation|1
6090454|NCT00690378|9702416|FG001|Overall Study|Protocol Violation|0
6090455|NCT00690378|9702415|FG000|Overall Study|Lost to Follow-up|2
6090456|NCT00690378|9702416|FG001|Overall Study|Lost to Follow-up|3
6090457|NCT00690378|9702415|FG000|Overall Study|Did not meet inc/exc criteria|13
6090458|NCT00690378|9702416|FG001|Overall Study|Did not meet inc/exc criteria|11
6090459|NCT00690378|9702415|FG000|Overall Study|Social problem|1
6090460|NCT00690378|9702416|FG001|Overall Study|Social problem|0
6090461|NCT00690430|9702424|FG000|Core Phase|Abnormal Laboratory value|0
6090462|NCT00690430|9702425|FG001|Core Phase|Abnormal Laboratory value|1
6090463|NCT00690430|9702426|FG002|Core Phase|Abnormal Laboratory value|0
6090464|NCT00690430|9702424|FG000|Core Phase|Adverse Event|5
6090465|NCT00690430|9702425|FG001|Core Phase|Adverse Event|1
6090466|NCT00690430|9702426|FG002|Core Phase|Adverse Event|0
6090467|NCT00690430|9702424|FG000|Core Phase|Death|0
6090468|NCT00690430|9702425|FG001|Core Phase|Death|2
6090469|NCT00690430|9702426|FG002|Core Phase|Death|0
6090470|NCT00690430|9702424|FG000|Core Phase|Protocol Violation|1
6090471|NCT00690430|9702425|FG001|Core Phase|Protocol Violation|0
6090472|NCT00690430|9702426|FG002|Core Phase|Protocol Violation|0
6090473|NCT00690430|9702424|FG000|Core Phase|Withdrawal by Subject|3
6054378|NCT00448747|9654040|FG001|Overall Study|collapsed veins|0
6090474|NCT00690430|9702425|FG001|Core Phase|Withdrawal by Subject|3
6090475|NCT00690430|9702426|FG002|Core Phase|Withdrawal by Subject|0
6090476|NCT00690430|9702424|FG000|Core Phase|Subject no longer requires study drug|1
6090477|NCT00690430|9702425|FG001|Core Phase|Subject no longer requires study drug|0
6090478|NCT00690430|9702426|FG002|Core Phase|Subject no longer requires study drug|0
6090479|NCT00690430|9702424|FG000|Core Phase|Lack of Efficacy|8
6054379|NCT00448760|9654056|FG000|Overall Study|Death|3
6054380|NCT00448812|9654062|FG000|Year 2|Missed visit but remained in study|4
6054381|NCT00448812|9654063|FG001|Year 2|Missed visit but remained in study|1
6054382|NCT00448812|9654062|FG000|Year 3|Withdrawal by Subject|1
6054383|NCT00448812|9654063|FG001|Year 3|Withdrawal by Subject|3
6054384|NCT00448812|9654062|FG000|Year 3|Lost to Follow-up|1
6054385|NCT00448812|9654063|FG001|Year 3|Lost to Follow-up|0
6054386|NCT00448812|9654062|FG000|Year 3|Missed visit but remained in study|2
6054387|NCT00448812|9654063|FG001|Year 3|Missed visit but remained in study|0
6054388|NCT00448812|9654062|FG000|Year 5|Missed visit but remained in study|1
6054389|NCT00448812|9654063|FG001|Year 5|Missed visit but remained in study|0
6054390|NCT00448864|9654084|FG000|Overall Study|Death|1
6054391|NCT00448864|9654085|FG001|Overall Study|Death|0
6054392|NCT00448864|9654086|FG002|Overall Study|Death|0
6054393|NCT00448864|9654084|FG000|Overall Study|Lost to Follow-up|3
6054394|NCT00448864|9654085|FG001|Overall Study|Lost to Follow-up|1
6054395|NCT00448864|9654086|FG002|Overall Study|Lost to Follow-up|0
6054396|NCT00448864|9654084|FG000|Overall Study|Physician Decision|1
6054397|NCT00448864|9654085|FG001|Overall Study|Physician Decision|0
6054398|NCT00448864|9654086|FG002|Overall Study|Physician Decision|1
6054399|NCT00448864|9654084|FG000|Overall Study|Withdrawal by Subject|0
6054400|NCT00448864|9654085|FG001|Overall Study|Withdrawal by Subject|2
6054401|NCT00448864|9654086|FG002|Overall Study|Withdrawal by Subject|0
6054402|NCT00448864|9654084|FG000|Overall Study|Protocol Violation|0
6054403|NCT00448864|9654085|FG001|Overall Study|Protocol Violation|2
6054404|NCT00448864|9654086|FG002|Overall Study|Protocol Violation|0
6054405|NCT00448916|9654100|FG000|Overall Study|Adverse Event|2
6054406|NCT00448916|9654101|FG001|Overall Study|Adverse Event|2
6054407|NCT00448916|9654102|FG002|Overall Study|Adverse Event|3
6054408|NCT00448916|9654103|FG003|Overall Study|Adverse Event|2
6054409|NCT00448916|9654100|FG000|Overall Study|Lack of Efficacy|1
6054410|NCT00448916|9654101|FG001|Overall Study|Lack of Efficacy|0
6054411|NCT00448916|9654102|FG002|Overall Study|Lack of Efficacy|2
6054412|NCT00448916|9654103|FG003|Overall Study|Lack of Efficacy|1
6054413|NCT00448916|9654100|FG000|Overall Study|Withdrawal by Subject|3
6054414|NCT00448916|9654101|FG001|Overall Study|Withdrawal by Subject|3
6054415|NCT00448916|9654102|FG002|Overall Study|Withdrawal by Subject|1
6054416|NCT00448916|9654103|FG003|Overall Study|Withdrawal by Subject|1
6054417|NCT00448916|9654100|FG000|Overall Study|Other|1
6054418|NCT00448916|9654101|FG001|Overall Study|Other|0
6054419|NCT00448916|9654102|FG002|Overall Study|Other|0
6054420|NCT00448916|9654103|FG003|Overall Study|Other|0
6054421|NCT00448916|9654100|FG000|Overall Study|Lost to Follow-up|0
6054422|NCT00448916|9654101|FG001|Overall Study|Lost to Follow-up|1
6054423|NCT00448916|9654102|FG002|Overall Study|Lost to Follow-up|0
6054424|NCT00448916|9654103|FG003|Overall Study|Lost to Follow-up|1
6054425|NCT00448916|9654100|FG000|Overall Study|Protocol Violation|0
6054426|NCT00448916|9654101|FG001|Overall Study|Protocol Violation|0
6054427|NCT00448916|9654102|FG002|Overall Study|Protocol Violation|0
6054428|NCT00448916|9654103|FG003|Overall Study|Protocol Violation|1
6054429|NCT00449033|9654128|FG000|Treatment Period|Adverse Event|117
6054430|NCT00449033|9654129|FG001|Treatment Period|Adverse Event|83
6054431|NCT00449033|9654128|FG000|Treatment Period|Death|21
6054432|NCT00449033|9654129|FG001|Treatment Period|Death|12
6054433|NCT00449033|9654128|FG000|Treatment Period|Lost to Follow-up|0
6054434|NCT00449033|9654129|FG001|Treatment Period|Lost to Follow-up|2
6054435|NCT00449033|9654128|FG000|Treatment Period|Physician Decision|4
6054436|NCT00449033|9654129|FG001|Treatment Period|Physician Decision|5
6054437|NCT00449033|9654128|FG000|Treatment Period|Protocol Violation|8
6054438|NCT00449033|9654129|FG001|Treatment Period|Protocol Violation|7
6054439|NCT00449033|9654128|FG000|Treatment Period|Disease Progression|231
6054440|NCT00449033|9654129|FG001|Treatment Period|Disease Progression|288
6054441|NCT00449033|9654128|FG000|Treatment Period|Consent Withdrawn|36
6054442|NCT00449033|9654129|FG001|Treatment Period|Consent Withdrawn|20
6054443|NCT00449033|9654128|FG000|Treatment Period|Amended Protocol Criteria|22
6054444|NCT00449033|9654129|FG001|Treatment Period|Amended Protocol Criteria|18
6054445|NCT00449033|9654128|FG000|Treatment Period|Non-compliance|7
6054446|NCT00449033|9654129|FG001|Treatment Period|Non-compliance|8
6054447|NCT00449033|9654128|FG000|Treatment Period|Second Malignancy|0
6054448|NCT00449033|9654129|FG001|Treatment Period|Second Malignancy|1
6054449|NCT00449033|9654128|FG000|Treatment Period|Reason Missing|0
6054450|NCT00449033|9654129|FG001|Treatment Period|Reason Missing|4
6054451|NCT00449033|9654128|FG000|Treatment Period|Treatment Ongoing|6
6054452|NCT00449033|9654129|FG001|Treatment Period|Treatment Ongoing|4
6054453|NCT00449033|9654128|FG000|Follow-up Period|Death|299
6054454|NCT00449033|9654129|FG001|Follow-up Period|Death|311
6054455|NCT00449033|9654128|FG000|Follow-up Period|Lost to Follow-up|6
6054456|NCT00449033|9654129|FG001|Follow-up Period|Lost to Follow-up|10
6054457|NCT00449033|9654128|FG000|Follow-up Period|Reason Missing|120
6054458|NCT00449033|9654129|FG001|Follow-up Period|Reason Missing|113
6054459|NCT00449072|9654141|FG000|Overall Study|Adverse Event|3
6054460|NCT00449072|9654142|FG001|Overall Study|Adverse Event|1
6054461|NCT00449072|9654141|FG000|Overall Study|Protocol Violation|14
6054462|NCT00449072|9654142|FG001|Overall Study|Protocol Violation|12
6054463|NCT00449072|9654141|FG000|Overall Study|Lost to Follow-up|5
6054464|NCT00449072|9654142|FG001|Overall Study|Lost to Follow-up|7
6054465|NCT00449072|9654141|FG000|Overall Study|Withdrawal by Subject|11
6090480|NCT00690430|9702425|FG001|Core Phase|Lack of Efficacy|10
6090481|NCT00690430|9702426|FG002|Core Phase|Lack of Efficacy|0
6090482|NCT00690430|9702424|FG000|Core Phase|Administrative Problems|0
6090483|NCT00690430|9702425|FG001|Core Phase|Administrative Problems|1
6090484|NCT00690430|9702426|FG002|Core Phase|Administrative Problems|0
6090485|NCT00690430|9702424|FG000|Core Phase|Early Termination|0
6090486|NCT00690430|9702425|FG001|Core Phase|Early Termination|5
6090487|NCT00690430|9702426|FG002|Core Phase|Early Termination|0
6090488|NCT00690430|9702424|FG000|Extension Phase|Lack of Efficacy|3
6090489|NCT00690430|9702425|FG001|Extension Phase|Lack of Efficacy|1
6090490|NCT00690430|9702426|FG002|Extension Phase|Lack of Efficacy|4
6090491|NCT00690430|9702424|FG000|Extension Phase|Abnormal Lab Values|1
6090492|NCT00690430|9702425|FG001|Extension Phase|Abnormal Lab Values|0
6090493|NCT00690430|9702426|FG002|Extension Phase|Abnormal Lab Values|0
6090494|NCT00690430|9702424|FG000|Extension Phase|Abnormal test procedure results|1
6090495|NCT00690430|9702425|FG001|Extension Phase|Abnormal test procedure results|0
6090496|NCT00690430|9702426|FG002|Extension Phase|Abnormal test procedure results|0
6090497|NCT00690430|9702424|FG000|Extension Phase|Administrative Problems|0
6090498|NCT00690430|9702425|FG001|Extension Phase|Administrative Problems|1
6090499|NCT00690430|9702426|FG002|Extension Phase|Administrative Problems|1
6090500|NCT00690430|9702424|FG000|Extension Phase|Adverse Event|2
6090501|NCT00690430|9702425|FG001|Extension Phase|Adverse Event|1
6090502|NCT00690430|9702426|FG002|Extension Phase|Adverse Event|2
6090503|NCT00690430|9702424|FG000|Extension Phase|Death|1
6090504|NCT00690430|9702425|FG001|Extension Phase|Death|1
6090505|NCT00690430|9702426|FG002|Extension Phase|Death|1
6090506|NCT00690430|9702424|FG000|Extension Phase|Withdrawal by Subject|0
6090507|NCT00690430|9702425|FG001|Extension Phase|Withdrawal by Subject|0
6090508|NCT00690430|9702426|FG002|Extension Phase|Withdrawal by Subject|2
6090509|NCT00690430|9702424|FG000|Extension Phase|Early Termination|10
6090510|NCT00690430|9702425|FG001|Extension Phase|Early Termination|1
6090511|NCT00690430|9702426|FG002|Extension Phase|Early Termination|3
6090512|NCT00690443|9702437|FG000|Overall Study|Adverse Event|1
6090513|NCT00690443|9702438|FG001|Overall Study|Adverse Event|2
6090514|NCT00690482|9702446|FG000|Overall Study|Adverse Event|2
6090515|NCT00690482|9702447|FG001|Overall Study|Adverse Event|1
6090516|NCT00690482|9702446|FG000|Overall Study|Incorrect enrolment|0
6090517|NCT00690482|9702447|FG001|Overall Study|Incorrect enrolment|1
6090518|NCT00690482|9702446|FG000|Overall Study|Study-specific discontinuation criteria|1
6090519|NCT00690482|9702447|FG001|Overall Study|Study-specific discontinuation criteria|0
6090520|NCT00690482|9702446|FG000|Overall Study|Intake of prohibited medicine|1
6090521|NCT00690482|9702447|FG001|Overall Study|Intake of prohibited medicine|0
6090522|NCT00690482|9702446|FG000|Overall Study|withdrew consent at rand.day|0
6090523|NCT00690482|9702447|FG001|Overall Study|withdrew consent at rand.day|1
6202236|NCT01500083|9862371|FG001|Overall Study|Death|2
6202237|NCT01500083|9862370|FG000|Overall Study|Lost to Follow-up|1
6202238|NCT01500083|9862371|FG001|Overall Study|Lost to Follow-up|0
6202239|NCT01500083|9862370|FG000|Overall Study|Withdrawal of Consent|0
6202240|NCT01500083|9862371|FG001|Overall Study|Withdrawal of Consent|1
6202241|NCT01500083|9862370|FG000|Overall Study|Disease Progression|2
6202242|NCT01500083|9862371|FG001|Overall Study|Disease Progression|10
6202243|NCT01500083|9862370|FG000|Overall Study|Investigator Discretion|3
6202244|NCT01500083|9862371|FG001|Overall Study|Investigator Discretion|8
6202245|NCT01500083|9862370|FG000|Overall Study|Other Reasons|2
6202246|NCT01500083|9862371|FG001|Overall Study|Other Reasons|5
6202247|NCT01500096|9862381|FG000|Overall Study|Lost to Follow-up|1
6202248|NCT01500096|9862382|FG001|Overall Study|Lost to Follow-up|0
6202249|NCT01500096|9862383|FG002|Overall Study|Lost to Follow-up|0
6202250|NCT01500096|9862384|FG003|Overall Study|Lost to Follow-up|2
6202251|NCT01500135|9862396|FG000|Overall Study|Withdrawal of Consent|4
6202252|NCT01500135|9862397|FG001|Overall Study|Withdrawal of Consent|0
6202253|NCT01500135|9862396|FG000|Overall Study|Lost to Follow-up|6
6202254|NCT01500135|9862397|FG001|Overall Study|Lost to Follow-up|4
6202255|NCT01500135|9862396|FG000|Overall Study|Fatal Adverse Event (AE)|5
6202256|NCT01500135|9862397|FG001|Overall Study|Fatal Adverse Event (AE)|5
6202257|NCT01500135|9862396|FG000|Overall Study|Principal Investigator (PI) Discretion|1
6054466|NCT00449072|9654142|FG001|Overall Study|Withdrawal by Subject|8
6054467|NCT00449072|9654141|FG000|Overall Study|Lack of Efficacy|1
6054468|NCT00449072|9654142|FG001|Overall Study|Lack of Efficacy|1
6054469|NCT00449072|9654141|FG000|Overall Study|Physician Decision|1
6054470|NCT00449072|9654142|FG001|Overall Study|Physician Decision|0
6054471|NCT00449072|9654141|FG000|Overall Study|Not treated|0
6054472|NCT00449072|9654142|FG001|Overall Study|Not treated|1
6054473|NCT00449072|9654141|FG000|Overall Study|Excluded medication|0
6054474|NCT00449072|9654142|FG001|Overall Study|Excluded medication|2
6054475|NCT00449072|9654141|FG000|Overall Study|Non-compliance|2
6054476|NCT00449072|9654142|FG001|Overall Study|Non-compliance|5
6054477|NCT00449072|9654141|FG000|Overall Study|Sponsor decision|1
6054478|NCT00449072|9654142|FG001|Overall Study|Sponsor decision|3
6054479|NCT00449072|9654141|FG000|Overall Study|Relocation|3
6054480|NCT00449072|9654142|FG001|Overall Study|Relocation|2
6054481|NCT00449150|9654151|FG000|Overall Study|Adverse Event|11
6054482|NCT00449150|9654152|FG001|Overall Study|Adverse Event|18
6054483|NCT00449150|9654153|FG002|Overall Study|Adverse Event|9
6054484|NCT00449150|9654151|FG000|Overall Study|Lack of Efficacy|1
6054485|NCT00449150|9654152|FG001|Overall Study|Lack of Efficacy|2
6054486|NCT00449150|9654153|FG002|Overall Study|Lack of Efficacy|2
6054487|NCT00449150|9654151|FG000|Overall Study|Other|16
6054488|NCT00449150|9654152|FG001|Overall Study|Other|13
6054489|NCT00449150|9654153|FG002|Overall Study|Other|14
6054490|NCT00449150|9654151|FG000|Overall Study|Withdrawal by Subject|17
6054491|NCT00449150|9654152|FG001|Overall Study|Withdrawal by Subject|18
6054492|NCT00449150|9654153|FG002|Overall Study|Withdrawal by Subject|21
6054493|NCT00449150|9654151|FG000|Overall Study|Protocol Violation|1
6054494|NCT00449150|9654152|FG001|Overall Study|Protocol Violation|2
6054495|NCT00449150|9654153|FG002|Overall Study|Protocol Violation|1
6054496|NCT00449163|9654164|FG000|Overall Study|Physician Decision|3
6054497|NCT00449176|9654171|FG000|Overall Study|Withdrawal by Subject|39
6054498|NCT00449176|9654172|FG001|Overall Study|Withdrawal by Subject|43
6054499|NCT00449176|9654173|FG002|Overall Study|Withdrawal by Subject|59
6054500|NCT00449176|9654171|FG000|Overall Study|Lost to Follow-up|13
6054501|NCT00449176|9654172|FG001|Overall Study|Lost to Follow-up|8
6054502|NCT00449176|9654173|FG002|Overall Study|Lost to Follow-up|12
6054503|NCT00449176|9654171|FG000|Overall Study|Adverse Event|51
6054504|NCT00449176|9654172|FG001|Overall Study|Adverse Event|107
6054505|NCT00449176|9654173|FG002|Overall Study|Adverse Event|15
6054506|NCT00449176|9654171|FG000|Overall Study|Lack of Efficacy|13
6054507|NCT00449176|9654172|FG001|Overall Study|Lack of Efficacy|7
6054508|NCT00449176|9654173|FG002|Overall Study|Lack of Efficacy|50
6054509|NCT00449176|9654171|FG000|Overall Study|Study drug non-compliant|14
6054510|NCT00449176|9654172|FG001|Overall Study|Study drug non-compliant|11
6054511|NCT00449176|9654173|FG002|Overall Study|Study drug non-compliant|11
6054512|NCT00449176|9654171|FG000|Overall Study|all other|22
6054513|NCT00449176|9654172|FG001|Overall Study|all other|19
6054514|NCT00449176|9654173|FG002|Overall Study|all other|20
6054515|NCT00449540|9654183|FG000|Pretreatment Phase|No migraine experienced|66
6054516|NCT00449540|9654184|FG001|Pretreatment Phase|No migraine experienced|0
6054517|NCT00449540|9654185|FG002|Pretreatment Phase|No migraine experienced|0
6054518|NCT00449540|9654183|FG000|Treatment Phase|did not experience or treat migraine|0
6054519|NCT00449540|9654184|FG001|Treatment Phase|did not experience or treat migraine|20
6054520|NCT00449540|9654185|FG002|Treatment Phase|did not experience or treat migraine|17
6054521|NCT00449644|9654197|FG000|Overall Study|Adverse Event|0
6054522|NCT00449644|9654198|FG001|Overall Study|Adverse Event|0
6054523|NCT00449644|9654199|FG002|Overall Study|Adverse Event|3
6054524|NCT00449644|9654200|FG003|Overall Study|Adverse Event|5
6054525|NCT00449644|9654197|FG000|Overall Study|Death|1
6054526|NCT00449644|9654198|FG001|Overall Study|Death|0
6054527|NCT00449644|9654199|FG002|Overall Study|Death|6
6054528|NCT00449644|9654200|FG003|Overall Study|Death|1
6054529|NCT00449644|9654197|FG000|Overall Study|Lost to Follow-up|1
6054530|NCT00449644|9654198|FG001|Overall Study|Lost to Follow-up|1
6054531|NCT00449644|9654199|FG002|Overall Study|Lost to Follow-up|5
6054532|NCT00449644|9654200|FG003|Overall Study|Lost to Follow-up|3
6054533|NCT00449644|9654197|FG000|Overall Study|Pregnancy|0
6054534|NCT00449644|9654198|FG001|Overall Study|Pregnancy|0
6054535|NCT00449644|9654199|FG002|Overall Study|Pregnancy|3
6054536|NCT00449644|9654200|FG003|Overall Study|Pregnancy|2
6054537|NCT00449644|9654197|FG000|Overall Study|Protocol Violation|4
6054538|NCT00449644|9654198|FG001|Overall Study|Protocol Violation|4
6054539|NCT00449644|9654199|FG002|Overall Study|Protocol Violation|3
6054540|NCT00449644|9654200|FG003|Overall Study|Protocol Violation|7
6054541|NCT00449644|9654197|FG000|Overall Study|Withdrawal by Subject|3
6054542|NCT00449644|9654198|FG001|Overall Study|Withdrawal by Subject|4
6054543|NCT00449644|9654199|FG002|Overall Study|Withdrawal by Subject|6
6054544|NCT00449644|9654200|FG003|Overall Study|Withdrawal by Subject|7
6054545|NCT00449644|9654197|FG000|Overall Study|Inclusion/exclusion criteria not met|0
6054546|NCT00449644|9654198|FG001|Overall Study|Inclusion/exclusion criteria not met|0
6054547|NCT00449644|9654199|FG002|Overall Study|Inclusion/exclusion criteria not met|2
6054548|NCT00449644|9654200|FG003|Overall Study|Inclusion/exclusion criteria not met|6
6054549|NCT00449644|9654197|FG000|Overall Study|Other|1
6054550|NCT00449644|9654198|FG001|Overall Study|Other|4
6054551|NCT00449644|9654199|FG002|Overall Study|Other|1
6054552|NCT00449644|9654200|FG003|Overall Study|Other|0
6054553|NCT00449644|9654197|FG000|Overall Study|Rolled-over to treatment with TMC207|0
6054554|NCT00449644|9654198|FG001|Overall Study|Rolled-over to treatment with TMC207|0
6054555|NCT00449644|9654199|FG002|Overall Study|Rolled-over to treatment with TMC207|0
6054556|NCT00449644|9654200|FG003|Overall Study|Rolled-over to treatment with TMC207|1
6054557|NCT00449670|9654215|FG000|Primary Phase (Study no.109630)|Serious Adverse Event|1
6054558|NCT00449670|9654216|FG001|Primary Phase (Study no.109630)|Serious Adverse Event|0
6054559|NCT00449670|9654215|FG000|Primary Phase (Study no.109630)|Non-serious adverse event|4
6090524|NCT00690573|9702462|FG000|Overall Study|Lack of Efficacy|8
6054560|NCT00449670|9654216|FG001|Primary Phase (Study no.109630)|Non-serious adverse event|0
6054561|NCT00449670|9654215|FG000|Primary Phase (Study no.109630)|Withdrawal by Subject|4
6054562|NCT00449670|9654216|FG001|Primary Phase (Study no.109630)|Withdrawal by Subject|1
6054563|NCT00449670|9654215|FG000|Primary Phase (Study no.109630)|Lost to Follow-up|5
6054564|NCT00449670|9654216|FG001|Primary Phase (Study no.109630)|Lost to Follow-up|1
6054565|NCT00449670|9654215|FG000|Booster Phase (Study no.109873)|Migrated/moved from study area|0
6054566|NCT00449670|9654216|FG001|Booster Phase (Study no.109873)|Migrated/moved from study area|1
6054567|NCT00449670|9654215|FG000|Booster Phase (Study no.109873)|Other|0
6054568|NCT00449670|9654216|FG001|Booster Phase (Study no.109873)|Other|2
6054569|NCT00449696|9654231|FG000|Overall Study|Other Treatment Required|6
6054570|NCT00449696|9654232|FG001|Overall Study|Other Treatment Required|1
6054571|NCT00449696|9654231|FG000|Overall Study|Withdrawal by Subject|5
6054572|NCT00449696|9654232|FG001|Overall Study|Withdrawal by Subject|5
6054573|NCT00449696|9654231|FG000|Overall Study|Lost to Follow-up|2
6054574|NCT00449696|9654232|FG001|Overall Study|Lost to Follow-up|3
6054575|NCT00449696|9654231|FG000|Overall Study|Others|7
6054576|NCT00449696|9654232|FG001|Overall Study|Others|0
6054577|NCT00449761|9654242|FG000|Overall Study|Disease progression|12
6054578|NCT00449761|9654242|FG000|Overall Study|Death|5
6054579|NCT00449761|9654242|FG000|Overall Study|New cancer therapy|1
6054580|NCT00449787|9654249|FG000|Overall Study|Lost to Follow-up|10
6054581|NCT00449787|9654250|FG001|Overall Study|Lost to Follow-up|8
6054582|NCT00449787|9654249|FG000|Overall Study|Did not require medication|95
6054583|NCT00449787|9654250|FG001|Overall Study|Did not require medication|92
6054584|NCT00449865|9654260|FG000|Overall Study|Withdrawal by Subject|110
6054585|NCT00449865|9654261|FG001|Overall Study|Withdrawal by Subject|110
6090525|NCT00690573|9702462|FG000|Overall Study|Withdrawal by Subject|1
6090526|NCT00690612|9702466|FG000|Overall Study|Adverse Event|1
6090527|NCT00690612|9702466|FG000|Overall Study|Withdrawal by Subject|2
6090528|NCT00690755|9702477|FG000|Overall Study|Physician Decision|2
6090529|NCT00690755|9702478|FG001|Overall Study|Physician Decision|0
6090530|NCT00690755|9702479|FG002|Overall Study|Physician Decision|46
6090531|NCT00690755|9702480|FG003|Overall Study|Physician Decision|5
6090532|NCT00690755|9702481|FG004|Overall Study|Physician Decision|0
6090533|NCT00690755|9702482|FG005|Overall Study|Physician Decision|4
6090534|NCT00690755|9702483|FG006|Overall Study|Physician Decision|0
6090535|NCT00690794|9702501|FG000|Overall Study|Adverse Event|12
6090536|NCT00690794|9702502|FG001|Overall Study|Adverse Event|10
6090537|NCT00690794|9702501|FG000|Overall Study|Lost to Follow-up|1
6090538|NCT00690794|9702502|FG001|Overall Study|Lost to Follow-up|4
6090539|NCT00690794|9702501|FG000|Overall Study|Withdrawal by Subject|0
6090540|NCT00690794|9702502|FG001|Overall Study|Withdrawal by Subject|9
6090541|NCT00690794|9702501|FG000|Overall Study|Protocol Violation|6
6090542|NCT00690794|9702502|FG001|Overall Study|Protocol Violation|7
6090543|NCT00690794|9702501|FG000|Overall Study|Noncompliance|1
6090544|NCT00690794|9702502|FG001|Overall Study|Noncompliance|2
6090545|NCT00690794|9702501|FG000|Overall Study|Other not specified|1
6090546|NCT00690794|9702502|FG001|Overall Study|Other not specified|3
6090547|NCT00690820|9702510|FG000|Period 1|Withdrawal by Subject|0
6090548|NCT00690820|9702511|FG001|Period 1|Withdrawal by Subject|1
6090549|NCT00690898|9702521|FG000|SCREENING|Screen failure|18
6090550|NCT00690898|9702521|FG000|TREATMENT|Adverse Event|3
6090551|NCT00690898|9702521|FG000|TREATMENT|Lack of Efficacy|18
6090552|NCT00690898|9702521|FG000|TREATMENT|Withdrawal by Subject|4
6090553|NCT00690898|9702521|FG000|TREATMENT|Other (not otherwise specified)|1
6090554|NCT00691015|9702548|FG000|Overall Study|Refused further treatment|1
6090555|NCT00691028|9702555|FG000|Open-label Period|Adverse Event|0
6090556|NCT00691028|9702556|FG001|Open-label Period|Adverse Event|0
6090557|NCT00691028|9702557|FG002|Open-label Period|Adverse Event|0
6090558|NCT00691028|9702558|FG003|Open-label Period|Adverse Event|16
6090559|NCT00691028|9702555|FG000|Open-label Period|Withdrawal by Subject|0
6090560|NCT00691028|9702556|FG001|Open-label Period|Withdrawal by Subject|0
6090561|NCT00691028|9702557|FG002|Open-label Period|Withdrawal by Subject|0
6090562|NCT00691028|9702558|FG003|Open-label Period|Withdrawal by Subject|3
6090563|NCT00691028|9702555|FG000|Open-label Period|not come to a hospital|0
6090564|NCT00691028|9702556|FG001|Open-label Period|not come to a hospital|0
6090565|NCT00691028|9702557|FG002|Open-label Period|not come to a hospital|0
6090566|NCT00691028|9702558|FG003|Open-label Period|not come to a hospital|1
6090567|NCT00691028|9702555|FG000|Double-blind Period|Adverse Event|8
6090568|NCT00691028|9702556|FG001|Double-blind Period|Adverse Event|9
6090569|NCT00691028|9702557|FG002|Double-blind Period|Adverse Event|6
6090570|NCT00691028|9702558|FG003|Double-blind Period|Adverse Event|0
6090571|NCT00691028|9702555|FG000|Double-blind Period|Lack of Efficacy|4
6090572|NCT00691028|9702556|FG001|Double-blind Period|Lack of Efficacy|3
6090573|NCT00691028|9702557|FG002|Double-blind Period|Lack of Efficacy|2
6090574|NCT00691028|9702558|FG003|Double-blind Period|Lack of Efficacy|0
6090575|NCT00691028|9702555|FG000|Double-blind Period|Withdrawal by Subject|1
6090576|NCT00691028|9702556|FG001|Double-blind Period|Withdrawal by Subject|0
6090577|NCT00691028|9702557|FG002|Double-blind Period|Withdrawal by Subject|1
6090578|NCT00691028|9702558|FG003|Double-blind Period|Withdrawal by Subject|0
6090579|NCT00691028|9702555|FG000|Double-blind Period|not come to a hospital.|0
6090580|NCT00691028|9702556|FG001|Double-blind Period|not come to a hospital.|1
6090581|NCT00691028|9702557|FG002|Double-blind Period|not come to a hospital.|0
6090582|NCT00691028|9702558|FG003|Double-blind Period|not come to a hospital.|0
6090583|NCT00691054|9702570|FG000|Overall Study|Withdrawal by Subject|1
6090584|NCT00691093|9702576|FG000|Overall Study|Adverse Event|1
6090585|NCT00691093|9702576|FG000|Overall Study|Lost to Follow-up|1
6090586|NCT00691093|9702576|FG000|Overall Study|Lack of Efficacy|1
6054586|NCT00449865|9654260|FG000|Overall Study|Lost to Follow-up|36
6054587|NCT00449865|9654261|FG001|Overall Study|Lost to Follow-up|37
6054588|NCT00449865|9654260|FG000|Overall Study|Physician Decision|13
6054589|NCT00449865|9654261|FG001|Overall Study|Physician Decision|12
6054590|NCT00449865|9654260|FG000|Overall Study|Death|31
6054591|NCT00449865|9654261|FG001|Overall Study|Death|40
6054592|NCT00449865|9654260|FG000|Overall Study|Protocol Violation|8
6054593|NCT00449865|9654261|FG001|Overall Study|Protocol Violation|7
6054594|NCT00449865|9654260|FG000|Overall Study|Study was stopped|324
6054595|NCT00449865|9654261|FG001|Overall Study|Study was stopped|328
6054596|NCT00449930|9654269|FG000|Overall Study|Adverse Event|9
6054597|NCT00449930|9654270|FG001|Overall Study|Adverse Event|19
6054598|NCT00449930|9654269|FG000|Overall Study|Trial Terminated ( Site Closed)|1
6054599|NCT00449930|9654270|FG001|Overall Study|Trial Terminated ( Site Closed)|0
6054600|NCT00449930|9654269|FG000|Overall Study|Lack of Efficacy|10
6054601|NCT00449930|9654270|FG001|Overall Study|Lack of Efficacy|1
6054602|NCT00449930|9654269|FG000|Overall Study|Lost to Follow-up|9
6054603|NCT00449930|9654270|FG001|Overall Study|Lost to Follow-up|14
6054604|NCT00449930|9654269|FG000|Overall Study|Physician Decision|1
6054605|NCT00449930|9654270|FG001|Overall Study|Physician Decision|2
6054606|NCT00449930|9654269|FG000|Overall Study|Protocol Violation|14
6054607|NCT00449930|9654270|FG001|Overall Study|Protocol Violation|15
6054608|NCT00449930|9654269|FG000|Overall Study|Withdrawal by Subject|16
6054609|NCT00449930|9654270|FG001|Overall Study|Withdrawal by Subject|23
6054610|NCT00449930|9654269|FG000|Overall Study|Glycemic discontinuation criteria|1
6054611|NCT00449930|9654270|FG001|Overall Study|Glycemic discontinuation criteria|1
6054612|NCT00449956|9654279|FG000|Overall Study|Adverse Event|7
6054613|NCT00449956|9654280|FG001|Overall Study|Adverse Event|1
6054614|NCT00449956|9654281|FG002|Overall Study|Adverse Event|6
6054615|NCT00449956|9654279|FG000|Overall Study|Lack of Efficacy|0
6054616|NCT00449956|9654280|FG001|Overall Study|Lack of Efficacy|0
6054617|NCT00449956|9654281|FG002|Overall Study|Lack of Efficacy|1
6054618|NCT00449956|9654279|FG000|Overall Study|Protocol Violation|1
6054619|NCT00449956|9654280|FG001|Overall Study|Protocol Violation|1
6054620|NCT00449956|9654281|FG002|Overall Study|Protocol Violation|1
6054621|NCT00449956|9654279|FG000|Overall Study|Withdrawal by Subject|0
6054622|NCT00449956|9654280|FG001|Overall Study|Withdrawal by Subject|1
6054623|NCT00449956|9654281|FG002|Overall Study|Withdrawal by Subject|0
6054624|NCT00449956|9654279|FG000|Overall Study|Physician Decision|2
6054625|NCT00449956|9654280|FG001|Overall Study|Physician Decision|1
6054626|NCT00449956|9654281|FG002|Overall Study|Physician Decision|1
6054627|NCT00450112|9654304|FG000|Overall Study|Other Treatment Required|5
6054628|NCT00450112|9654305|FG001|Overall Study|Other Treatment Required|1
6054629|NCT00450112|9654304|FG000|Overall Study|Withdrawal by Subject|4
6054630|NCT00450112|9654305|FG001|Overall Study|Withdrawal by Subject|1
6054631|NCT00450112|9654304|FG000|Overall Study|Lost to Follow-up|2
6054632|NCT00450112|9654305|FG001|Overall Study|Lost to Follow-up|1
6054633|NCT00450112|9654304|FG000|Overall Study|Others|2
6054634|NCT00450112|9654305|FG001|Overall Study|Others|3
6054635|NCT00450177|9654313|FG000|Overall Study|Adverse Event|7
6054636|NCT00450177|9654314|FG001|Overall Study|Adverse Event|4
6054637|NCT00450177|9654313|FG000|Overall Study|Withdrawal by Subject|1
6054638|NCT00450177|9654314|FG001|Overall Study|Withdrawal by Subject|6
6054639|NCT00450177|9654313|FG000|Overall Study|Withdrawal by Primary Team|1
6054640|NCT00450177|9654314|FG001|Overall Study|Withdrawal by Primary Team|1
6054641|NCT00450190|9654320|FG000|Overall Study|Withdrawal by Subject|2
6054642|NCT00450216|9654326|FG000|Overall Study|Adverse Event|38
6090587|NCT00691093|9702576|FG000|Overall Study|Ongoing at Date of Cut-Off|4
6090588|NCT00691132|9702587|FG000|Overall Study|Adverse Event|2
6090589|NCT00691132|9702588|FG001|Overall Study|Adverse Event|3
6090590|NCT00691132|9702587|FG000|Overall Study|Withdrawal by Subject|10
6090591|NCT00691132|9702588|FG001|Overall Study|Withdrawal by Subject|10
6090592|NCT00691210|9702621|FG000|Overall Study|Progression of Disease|0
6090593|NCT00691210|9702622|FG001|Overall Study|Progression of Disease|0
6090594|NCT00691210|9702623|FG002|Overall Study|Progression of Disease|0
6090595|NCT00691210|9702624|FG003|Overall Study|Progression of Disease|2
6090596|NCT00691210|9702625|FG004|Overall Study|Progression of Disease|0
6090597|NCT00691210|9702626|FG005|Overall Study|Progression of Disease|0
6090598|NCT00691210|9702627|FG006|Overall Study|Progression of Disease|0
6090599|NCT00691210|9702628|FG007|Overall Study|Progression of Disease|0
6090600|NCT00691210|9702621|FG000|Overall Study|Lack of Efficacy|0
6090601|NCT00691210|9702622|FG001|Overall Study|Lack of Efficacy|0
6090602|NCT00691210|9702623|FG002|Overall Study|Lack of Efficacy|0
6202258|NCT01500135|9862397|FG001|Overall Study|Principal Investigator (PI) Discretion|0
6090603|NCT00691210|9702624|FG003|Overall Study|Lack of Efficacy|1
6090604|NCT00691210|9702625|FG004|Overall Study|Lack of Efficacy|0
6054643|NCT00450216|9654327|FG001|Overall Study|Adverse Event|23
6054644|NCT00450216|9654326|FG000|Overall Study|Withdrawal by Subject|48
6054645|NCT00450216|9654327|FG001|Overall Study|Withdrawal by Subject|26
6054646|NCT00450216|9654326|FG000|Overall Study|Lost to Follow-up|16
6054647|NCT00450216|9654327|FG001|Overall Study|Lost to Follow-up|9
6054648|NCT00450216|9654326|FG000|Overall Study|upper gastrointestinal (UGI) ulcer|51
6054649|NCT00450216|9654327|FG001|Overall Study|upper gastrointestinal (UGI) ulcer|51
6054650|NCT00450216|9654326|FG000|Overall Study|misc|21
6054651|NCT00450216|9654327|FG001|Overall Study|misc|20
6090605|NCT00691210|9702626|FG005|Overall Study|Lack of Efficacy|1
6054652|NCT00450255|9654344|FG000|Overall Study|Prior RFA ablation of liver|1
6054653|NCT00450372|9654354|FG000|Overall Study|Physician Decision|1
6054654|NCT00450385|9654361|FG000|Overall Study|Death|3
6054655|NCT00450385|9654361|FG000|Overall Study|Protocol Violation|1
6054656|NCT00450385|9654361|FG000|Overall Study|Withdrawal by Subject|2
6054657|NCT00450385|9654361|FG000|Overall Study|Lack of Efficacy|2
6054658|NCT00450385|9654361|FG000|Overall Study|Adverse Event|1
6054659|NCT00450385|9654361|FG000|Overall Study|Physician Decision|1
6054660|NCT00450385|9654361|FG000|Overall Study|Other|3
6054661|NCT00450411|9654366|FG000|Overall Study|Protocol Violation|6
6054662|NCT00450411|9654366|FG000|Overall Study|No protocol treatment|2
6054663|NCT00450437|9654381|FG000|Overall Study|Withdrawal by Subject|10
6054664|NCT00450437|9654382|FG001|Overall Study|Withdrawal by Subject|2
6054665|NCT00450437|9654383|FG002|Overall Study|Withdrawal by Subject|0
6054666|NCT00450437|9654384|FG003|Overall Study|Withdrawal by Subject|1
6054667|NCT00450437|9654381|FG000|Overall Study|Lost to Follow-up|31
6054668|NCT00450437|9654382|FG001|Overall Study|Lost to Follow-up|12
6054669|NCT00450437|9654383|FG002|Overall Study|Lost to Follow-up|19
6054670|NCT00450437|9654384|FG003|Overall Study|Lost to Follow-up|9
6054671|NCT00450437|9654381|FG000|Overall Study|Protocol Violation|0
6054672|NCT00450437|9654382|FG001|Overall Study|Protocol Violation|1
6054673|NCT00450437|9654383|FG002|Overall Study|Protocol Violation|0
6054674|NCT00450437|9654384|FG003|Overall Study|Protocol Violation|1
6054675|NCT00450437|9654381|FG000|Overall Study|Inappropriate enrollment|4
6054676|NCT00450437|9654382|FG001|Overall Study|Inappropriate enrollment|1
6054677|NCT00450437|9654383|FG002|Overall Study|Inappropriate enrollment|3
6054678|NCT00450437|9654384|FG003|Overall Study|Inappropriate enrollment|0
6054679|NCT00450437|9654381|FG000|Overall Study|Administrative reason|0
6054680|NCT00450437|9654382|FG001|Overall Study|Administrative reason|0
6054681|NCT00450437|9654383|FG002|Overall Study|Administrative reason|1
6054682|NCT00450437|9654384|FG003|Overall Study|Administrative reason|0
6054683|NCT00450437|9654381|FG000|Overall Study|Unable to Classify|1
6054684|NCT00450437|9654382|FG001|Overall Study|Unable to Classify|0
6054685|NCT00450437|9654383|FG002|Overall Study|Unable to Classify|1
6054686|NCT00450437|9654384|FG003|Overall Study|Unable to Classify|0
6054687|NCT00450580|9654412|FG000|Overall Study|Adverse Event|5
6054688|NCT00450580|9654413|FG001|Overall Study|Adverse Event|7
6054689|NCT00450580|9654412|FG000|Overall Study|Lost to Follow-up|4
6054690|NCT00450580|9654413|FG001|Overall Study|Lost to Follow-up|5
6054691|NCT00450580|9654412|FG000|Overall Study|Withdrawal by Subject|2
6054692|NCT00450580|9654413|FG001|Overall Study|Withdrawal by Subject|2
6054693|NCT00450580|9654412|FG000|Overall Study|Protocol Violation|1
6054694|NCT00450580|9654413|FG001|Overall Study|Protocol Violation|1
6202259|NCT01500135|9862396|FG000|Overall Study|Patient Missed Scheduled Appointments|0
6202260|NCT01500135|9862397|FG001|Overall Study|Patient Missed Scheduled Appointments|1
6202261|NCT01500135|9862396|FG000|Overall Study|Participant was a Safety Concern|1
6202262|NCT01500135|9862397|FG001|Overall Study|Participant was a Safety Concern|0
6284222|NCT02326272|9996339|FG011|Initial Period (Week 0 to Week 16)|Moved from the study area|0
6284223|NCT02326272|9996340|FG012|Initial Period (Week 0 to Week 16)|Moved from the study area|0
6284224|NCT02326272|9996341|FG013|Initial Period (Week 0 to Week 16)|Moved from the study area|0
6284225|NCT02326272|9996342|FG014|Initial Period (Week 0 to Week 16)|Moved from the study area|0
6284226|NCT02326272|9996328|FG000|Initial Period (Week 0 to Week 16)|Missed two doses|0
6054695|NCT00450580|9654412|FG000|Overall Study|Protocol-defined virologic failure|1
6054696|NCT00450580|9654413|FG001|Overall Study|Protocol-defined virologic failure|0
6054697|NCT00450580|9654412|FG000|Overall Study|Could not comply with scheduled visits|1
6054698|NCT00450580|9654413|FG001|Overall Study|Could not comply with scheduled visits|0
6054699|NCT00450580|9654412|FG000|Overall Study|Patient went to Brazil|1
6054700|NCT00450580|9654413|FG001|Overall Study|Patient went to Brazil|0
6054701|NCT00450580|9654412|FG000|Overall Study|Patient could not swallow Norvir|1
6054702|NCT00450580|9654413|FG001|Overall Study|Patient could not swallow Norvir|0
6054703|NCT00450580|9654412|FG000|Overall Study|Withdrawal due to pregnancy|0
6054704|NCT00450580|9654413|FG001|Overall Study|Withdrawal due to pregnancy|1
6054705|NCT00450619|9654421|FG000|Overall Study|refused treatment after randomization|2
6054706|NCT00450619|9654422|FG001|Overall Study|refused treatment after randomization|0
6054707|NCT00450619|9654421|FG000|Overall Study|did not progress; refused further trmt|1
6054708|NCT00450619|9654422|FG001|Overall Study|did not progress; refused further trmt|1
6054709|NCT00450619|9654421|FG000|Overall Study|Adverse Event|1
6054710|NCT00450619|9654422|FG001|Overall Study|Adverse Event|0
6054711|NCT00450658|9654431|FG000|Overall Study|Adverse Event|24
6054712|NCT00450658|9654432|FG001|Overall Study|Adverse Event|15
6054713|NCT00450658|9654431|FG000|Overall Study|Withdrawal by Subject|43
6054714|NCT00450658|9654432|FG001|Overall Study|Withdrawal by Subject|26
6054715|NCT00450658|9654431|FG000|Overall Study|Lost to Follow-up|22
6054716|NCT00450658|9654432|FG001|Overall Study|Lost to Follow-up|5
6054717|NCT00450658|9654431|FG000|Overall Study|UGI ulcer|33
6054718|NCT00450658|9654432|FG001|Overall Study|UGI ulcer|34
6054719|NCT00450658|9654431|FG000|Overall Study|misc|21
6054720|NCT00450658|9654432|FG001|Overall Study|misc|10
6054721|NCT00450723|9654438|FG000|Overall Study|Physician Decision|5
6054722|NCT00450749|9654446|FG000|Overall Study|Withdrawal by Subject|0
6054723|NCT00450749|9654447|FG001|Overall Study|Withdrawal by Subject|0
6054724|NCT00450749|9654448|FG002|Overall Study|Withdrawal by Subject|2
6090606|NCT00691210|9702627|FG006|Overall Study|Lack of Efficacy|0
6090607|NCT00691210|9702628|FG007|Overall Study|Lack of Efficacy|0
6090608|NCT00691301|9702646|FG000|Overall Study|Adverse Event|10
6090609|NCT00691301|9702646|FG000|Overall Study|Death|2
6090610|NCT00691301|9702646|FG000|Overall Study|Lack of Efficacy|32
6090611|NCT00691301|9702646|FG000|Overall Study|Withdrawal by Subject|4
6090612|NCT00691301|9702646|FG000|Overall Study|Concurrent illness|2
6090613|NCT00691301|9702646|FG000|Overall Study|other reason|3
6090614|NCT00691301|9702646|FG000|Overall Study|Did not initiate study treatment|1
6090615|NCT00691483|9702667|FG000|Overall Study|Adverse Event|14
6090616|NCT00691483|9702668|FG001|Overall Study|Adverse Event|6
6090617|NCT00691483|9702667|FG000|Overall Study|Lost to Follow-up|17
6090618|NCT00691483|9702668|FG001|Overall Study|Lost to Follow-up|10
6090619|NCT00691483|9702667|FG000|Overall Study|Withdrawal by Subject|24
6090620|NCT00691483|9702668|FG001|Overall Study|Withdrawal by Subject|7
6090621|NCT00691483|9702667|FG000|Overall Study|Other known cause|6
6090622|NCT00691483|9702668|FG001|Overall Study|Other known cause|1
6090623|NCT00691483|9702667|FG000|Overall Study|Randomized by not treated|7
6090624|NCT00691483|9702668|FG001|Overall Study|Randomized by not treated|1
6090625|NCT00691704|9702692|FG000|Induction Therapy|Disease Progression|1
6090626|NCT00691704|9702692|FG000|Induction Therapy|Active Hepatitis|1
6090627|NCT00691704|9702692|FG000|Two Years of Maintenance Therapy|Disease Progression|8
6090628|NCT00691704|9702692|FG000|Two Years of Maintenance Therapy|Physician Decision|4
6090629|NCT00691704|9702692|FG000|Two Years of Maintenance Therapy|Withdrawal by Subject|1
6090630|NCT00691938|9702716|FG000|Overall Study|QTc prolongation|1
6090631|NCT00691938|9702717|FG001|Overall Study|QTc prolongation|0
6090632|NCT00691938|9702718|FG002|Overall Study|QTc prolongation|0
6090633|NCT00691938|9702719|FG003|Overall Study|QTc prolongation|0
6090634|NCT00691938|9702720|FG004|Overall Study|QTc prolongation|0
6090635|NCT00691938|9702721|FG005|Overall Study|QTc prolongation|0
6090636|NCT00691938|9702722|FG006|Overall Study|QTc prolongation|0
6090637|NCT00692237|9702765|FG000|Overall Study|Withdrawal by Subject|1
6090638|NCT00692237|9702766|FG001|Overall Study|Withdrawal by Subject|3
6090639|NCT00692237|9702765|FG000|Overall Study|Adverse Event|0
6090640|NCT00692237|9702766|FG001|Overall Study|Adverse Event|1
6090641|NCT00692406|9702794|FG000|Overall Study|PI dropped, bad data|57
6090642|NCT00692770|9702820|FG000|Overall Study|Protocol Violation|2
6090643|NCT00692770|9702821|FG001|Overall Study|Protocol Violation|7
6090644|NCT00692770|9702820|FG000|Overall Study|Withdrawal by Subject|97
6090645|NCT00692770|9702821|FG001|Overall Study|Withdrawal by Subject|36
6090646|NCT00692770|9702820|FG000|Overall Study|Adverse Event|136
6090647|NCT00692770|9702821|FG001|Overall Study|Adverse Event|41
6090648|NCT00692770|9702820|FG000|Overall Study|Death|10
6090649|NCT00692770|9702821|FG001|Overall Study|Death|5
6090650|NCT00692770|9702820|FG000|Overall Study|Lost to Follow-up|7
6090651|NCT00692770|9702821|FG001|Overall Study|Lost to Follow-up|3
6090652|NCT00692770|9702820|FG000|Overall Study|Non-compliant with study medication|11
6090653|NCT00692770|9702821|FG001|Overall Study|Non-compliant with study medication|5
6090654|NCT00692770|9702820|FG000|Overall Study|Progression by clinical judgment|2
6090655|NCT00692770|9702821|FG001|Overall Study|Progression by clinical judgment|3
6090656|NCT00692770|9702820|FG000|Overall Study|Physician decision not protocol driven|10
6090657|NCT00692770|9702821|FG001|Overall Study|Physician decision not protocol driven|14
6090658|NCT00692770|9702820|FG000|Overall Study|Disease progression, recurrence/relapse|170
6090659|NCT00692770|9702821|FG001|Overall Study|Disease progression, recurrence/relapse|279
6090660|NCT00692770|9702820|FG000|Overall Study|Protocol driven decision point|3
6090661|NCT00692770|9702821|FG001|Overall Study|Protocol driven decision point|7
6090662|NCT00692770|9702820|FG000|Overall Study|Completed all planned assessments|79
6090663|NCT00692770|9702821|FG001|Overall Study|Completed all planned assessments|101
6090664|NCT00692770|9702820|FG000|Overall Study|Radiological and clinical progression|8
6090665|NCT00692770|9702821|FG001|Overall Study|Radiological and clinical progression|8
6090666|NCT00692770|9702820|FG000|Overall Study|Clinical endpoint reached|16
6090667|NCT00692770|9702821|FG001|Overall Study|Clinical endpoint reached|43
6090668|NCT00692770|9702820|FG000|Overall Study|Study terminated by sponsor|2
6090669|NCT00692770|9702821|FG001|Overall Study|Study terminated by sponsor|2
6090670|NCT00692770|9702820|FG000|Overall Study|Randomized but not treated|3
6090671|NCT00692770|9702821|FG001|Overall Study|Randomized but not treated|4
6090672|NCT00693225|9702865|FG000|Overall Study|Lost to Follow-up|1
5980344|NCT03802565|9569114|FG000|Overall Study|Lost to Follow-up|0
5980345|NCT03802565|9569115|FG001|Overall Study|Lost to Follow-up|0
5980346|NCT03802565|9569116|FG002|Overall Study|Lost to Follow-up|1
5980347|NCT03802565|9569117|FG003|Overall Study|Lost to Follow-up|0
5980348|NCT03802565|9569118|FG004|Overall Study|Lost to Follow-up|0
5980349|NCT03802565|9569114|FG000|Overall Study|Subjects Related to Each Other|1
5980350|NCT03802565|9569115|FG001|Overall Study|Subjects Related to Each Other|0
5980351|NCT03802565|9569116|FG002|Overall Study|Subjects Related to Each Other|0
5980352|NCT03802565|9569117|FG003|Overall Study|Subjects Related to Each Other|2
5980353|NCT03802565|9569118|FG004|Overall Study|Subjects Related to Each Other|1
5980354|NCT03802565|9569114|FG000|Overall Study|Elevated Enzymes|0
5980355|NCT03802565|9569115|FG001|Overall Study|Elevated Enzymes|0
5980356|NCT03802565|9569116|FG002|Overall Study|Elevated Enzymes|0
5980357|NCT03802565|9569117|FG003|Overall Study|Elevated Enzymes|0
5980358|NCT03802565|9569118|FG004|Overall Study|Elevated Enzymes|2
6054725|NCT00450749|9654446|FG000|Overall Study|Noncompliant|0
6054726|NCT00450749|9654447|FG001|Overall Study|Noncompliant|1
6054727|NCT00450749|9654448|FG002|Overall Study|Noncompliant|0
6054728|NCT00450801|9654456|FG000|Overall Study|Death|1
6054729|NCT00450814|9654475|FG000|Overall Study|Failed to complete the initial therapy|0
6054730|NCT00450814|9654476|FG001|Overall Study|Failed to complete the initial therapy|0
6054731|NCT00450814|9654477|FG002|Overall Study|Failed to complete the initial therapy|0
6054732|NCT00450814|9654478|FG003|Overall Study|Failed to complete the initial therapy|1
6054733|NCT00450814|9654479|FG004|Overall Study|Failed to complete the initial therapy|1
6054734|NCT00450814|9654480|FG005|Overall Study|Failed to complete the initial therapy|1
6054735|NCT00450814|9654481|FG006|Overall Study|Failed to complete the initial therapy|0
6054736|NCT00450814|9654482|FG007|Overall Study|Failed to complete the initial therapy|0
6054737|NCT00450814|9654483|FG008|Overall Study|Failed to complete the initial therapy|0
6054738|NCT00450814|9654484|FG009|Overall Study|Failed to complete the initial therapy|0
6054739|NCT00450814|9654485|FG010|Overall Study|Failed to complete the initial therapy|0
6054740|NCT00450814|9654475|FG000|Overall Study|Patient withdrawal prior to treatment|0
6054741|NCT00450814|9654476|FG001|Overall Study|Patient withdrawal prior to treatment|0
6054742|NCT00450814|9654477|FG002|Overall Study|Patient withdrawal prior to treatment|0
6054743|NCT00450814|9654478|FG003|Overall Study|Patient withdrawal prior to treatment|0
6054744|NCT00450814|9654479|FG004|Overall Study|Patient withdrawal prior to treatment|0
6054745|NCT00450814|9654480|FG005|Overall Study|Patient withdrawal prior to treatment|0
6054746|NCT00450814|9654481|FG006|Overall Study|Patient withdrawal prior to treatment|0
6054747|NCT00450814|9654482|FG007|Overall Study|Patient withdrawal prior to treatment|0
6054748|NCT00450814|9654483|FG008|Overall Study|Patient withdrawal prior to treatment|0
6054749|NCT00450814|9654484|FG009|Overall Study|Patient withdrawal prior to treatment|1
6054750|NCT00450814|9654485|FG010|Overall Study|Patient withdrawal prior to treatment|0
6054751|NCT00450866|9654510|FG000|Overall Study|Adverse Event|0
6054752|NCT00450866|9654511|FG001|Overall Study|Adverse Event|1
6054753|NCT00450866|9654510|FG000|Overall Study|Withdrawal by Subject|5
6054754|NCT00450866|9654511|FG001|Overall Study|Withdrawal by Subject|2
6054755|NCT00450866|9654510|FG000|Overall Study|Death|1
6054756|NCT00450866|9654511|FG001|Overall Study|Death|0
6054757|NCT00450866|9654510|FG000|Overall Study|Physician Decision|1
6090673|NCT00693225|9702866|FG001|Overall Study|Lost to Follow-up|2
6090674|NCT00693225|9702865|FG000|Overall Study|Adverse Event|1
6090675|NCT00693225|9702866|FG001|Overall Study|Adverse Event|3
6090676|NCT00693420|9702878|FG000|Overall Study|Adverse Event|4
6090677|NCT00693420|9702879|FG001|Overall Study|Adverse Event|4
6090678|NCT00693420|9702878|FG000|Overall Study|Lost to Follow-up|0
6090679|NCT00693420|9702879|FG001|Overall Study|Lost to Follow-up|3
6090680|NCT00693420|9702878|FG000|Overall Study|Withdrawal by Subject|1
6090681|NCT00693420|9702879|FG001|Overall Study|Withdrawal by Subject|0
6090682|NCT00693420|9702878|FG000|Overall Study|Protocol Violation|0
6090683|NCT00693420|9702879|FG001|Overall Study|Protocol Violation|2
6090684|NCT00693420|9702878|FG000|Overall Study|Sponsor Request - Conflict of Interest|0
6090685|NCT00693420|9702879|FG001|Overall Study|Sponsor Request - Conflict of Interest|2
6090686|NCT00693420|9702878|FG000|Overall Study|Personal Reasons|1
6090687|NCT00693420|9702879|FG001|Overall Study|Personal Reasons|4
6090688|NCT00693472|9702889|FG000|Part 1|Adverse Event|1
6090689|NCT00693472|9702890|FG001|Part 1|Adverse Event|1
6090690|NCT00693472|9702891|FG002|Part 1|Adverse Event|0
6090691|NCT00693472|9702892|FG003|Part 1|Adverse Event|0
6090692|NCT00693472|9702889|FG000|Part 1|Lost to Follow-up|0
6090693|NCT00693472|9702890|FG001|Part 1|Lost to Follow-up|1
6090694|NCT00693472|9702891|FG002|Part 1|Lost to Follow-up|0
6090695|NCT00693472|9702892|FG003|Part 1|Lost to Follow-up|0
6090696|NCT00693472|9702889|FG000|Part 1|Withdrew - reason unrelated to treatment|5
6090697|NCT00693472|9702890|FG001|Part 1|Withdrew - reason unrelated to treatment|2
6090698|NCT00693472|9702891|FG002|Part 1|Withdrew - reason unrelated to treatment|0
6090699|NCT00693472|9702892|FG003|Part 1|Withdrew - reason unrelated to treatment|0
6090700|NCT00693472|9702889|FG000|Part 2|Adverse Event|0
6090701|NCT00693472|9702890|FG001|Part 2|Adverse Event|0
6090702|NCT00693472|9702891|FG002|Part 2|Adverse Event|1
6090703|NCT00693472|9702892|FG003|Part 2|Adverse Event|0
6090704|NCT00693472|9702889|FG000|Part 2|Withdrew - reason unrelated to treatment|0
6090705|NCT00693472|9702890|FG001|Part 2|Withdrew - reason unrelated to treatment|0
6090706|NCT00693472|9702891|FG002|Part 2|Withdrew - reason unrelated to treatment|1
6090707|NCT00693472|9702892|FG003|Part 2|Withdrew - reason unrelated to treatment|2
6090708|NCT00693693|9702937|FG000|Overall Study|Lost to Follow-up|1
6090709|NCT00693693|9702938|FG001|Overall Study|Lost to Follow-up|1
6090710|NCT00693693|9702939|FG002|Overall Study|Lost to Follow-up|2
6090711|NCT00693706|9702949|FG000|Overall Study|Protocol Violation|0
6090712|NCT00693706|9702950|FG001|Overall Study|Protocol Violation|1
6090713|NCT00693784|9702960|FG000|Overall Study|Lost to Follow-up|2
6090714|NCT00693784|9702960|FG000|Overall Study|Withdrawal by Subject|2
6090715|NCT00694096|9702986|FG000|Overall Study|Withdrawal by Subject|5
6090716|NCT00694109|9702990|FG000|Overall Study|Physician Decision|3
6090717|NCT00694109|9702990|FG000|Overall Study|Adverse Event|74
6090718|NCT00694109|9702990|FG000|Overall Study|Not consent of more 2 years of treatment|18
6090719|NCT00694109|9702990|FG000|Overall Study|Lack of Efficacy|2
6090720|NCT00694109|9702990|FG000|Overall Study|Withdrawal by Subject|13
6054758|NCT00450866|9654511|FG001|Overall Study|Physician Decision|0
6054759|NCT00451035|9654521|FG000|Overall Study|Disease progression|11
6054760|NCT00451035|9654521|FG000|Overall Study|Death|3
6054761|NCT00451035|9654521|FG000|Overall Study|New anti-neoplastic therapy|3
6054762|NCT00451178|9654532|FG000|Chemotherapy (Up To Six 21-Day Cycles)|Adverse Event|6
6054763|NCT00451178|9654533|FG001|Chemotherapy (Up To Six 21-Day Cycles)|Adverse Event|6
6054764|NCT00451178|9654532|FG000|Chemotherapy (Up To Six 21-Day Cycles)|Withdrawal by Subject|4
6054765|NCT00451178|9654533|FG001|Chemotherapy (Up To Six 21-Day Cycles)|Withdrawal by Subject|3
6054766|NCT00451178|9654532|FG000|Chemotherapy (Up To Six 21-Day Cycles)|Protocol Violation|2
6054767|NCT00451178|9654533|FG001|Chemotherapy (Up To Six 21-Day Cycles)|Protocol Violation|1
6054768|NCT00451178|9654532|FG000|Chemotherapy (Up To Six 21-Day Cycles)|Physician Decision|1
6054769|NCT00451178|9654533|FG001|Chemotherapy (Up To Six 21-Day Cycles)|Physician Decision|2
6054770|NCT00451178|9654532|FG000|Chemotherapy (Up To Six 21-Day Cycles)|Death|4
6054771|NCT00451178|9654533|FG001|Chemotherapy (Up To Six 21-Day Cycles)|Death|3
6054772|NCT00451178|9654532|FG000|Chemotherapy (Up To Six 21-Day Cycles)|Progressive Disease (PD)|1
6054773|NCT00451178|9654533|FG001|Chemotherapy (Up To Six 21-Day Cycles)|Progressive Disease (PD)|2
6054774|NCT00451178|9654532|FG000|Prior to Maintenance Therapy|Physician Decision|2
6054775|NCT00451178|9654533|FG001|Prior to Maintenance Therapy|Physician Decision|0
6054776|NCT00451178|9654532|FG000|Prior to Maintenance Therapy|PD|2
6054777|NCT00451178|9654533|FG001|Prior to Maintenance Therapy|PD|0
6054778|NCT00451178|9654532|FG000|Maintenance Therapy (up to 3 Years)|Adverse Event|4
6054779|NCT00451178|9654533|FG001|Maintenance Therapy (up to 3 Years)|Adverse Event|0
6054780|NCT00451178|9654532|FG000|Maintenance Therapy (up to 3 Years)|Withdrawal by Subject|5
6054781|NCT00451178|9654533|FG001|Maintenance Therapy (up to 3 Years)|Withdrawal by Subject|0
6054782|NCT00451178|9654532|FG000|Maintenance Therapy (up to 3 Years)|Physician Decision|1
6054783|NCT00451178|9654533|FG001|Maintenance Therapy (up to 3 Years)|Physician Decision|0
6054784|NCT00451178|9654532|FG000|Maintenance Therapy (up to 3 Years)|Death|1
6054785|NCT00451178|9654533|FG001|Maintenance Therapy (up to 3 Years)|Death|0
6054786|NCT00451178|9654532|FG000|Maintenance Therapy (up to 3 Years)|PD|10
6054787|NCT00451178|9654533|FG001|Maintenance Therapy (up to 3 Years)|PD|0
6054788|NCT00451178|9654532|FG000|Maintenance Therapy (up to 3 Years)|Continuing Maintenance|9
6054789|NCT00451178|9654533|FG001|Maintenance Therapy (up to 3 Years)|Continuing Maintenance|0
6054790|NCT00451178|9654532|FG000|Long-Term Follow-Up (Up to 2 Years)|Continuing Follow-Up|6
6054791|NCT00451178|9654533|FG001|Long-Term Follow-Up (Up to 2 Years)|Continuing Follow-Up|26
6054792|NCT00451191|9654545|FG000|Overall Study|withdrawal or received alternate tx|15
6054793|NCT00451191|9654546|FG001|Overall Study|withdrawal or received alternate tx|11
6054794|NCT00451204|9654554|FG000|Overall Study|Adverse Event|4
6054795|NCT00451204|9654555|FG001|Overall Study|Adverse Event|6
6054796|NCT00451204|9654554|FG000|Overall Study|Lack of Efficacy|4
6054797|NCT00451204|9654555|FG001|Overall Study|Lack of Efficacy|4
6054798|NCT00451204|9654554|FG000|Overall Study|Lost to Follow-up|4
6054799|NCT00451204|9654555|FG001|Overall Study|Lost to Follow-up|4
6054800|NCT00451204|9654554|FG000|Overall Study|Protocol Violation|1
6054801|NCT00451204|9654555|FG001|Overall Study|Protocol Violation|0
6054802|NCT00451204|9654554|FG000|Overall Study|Patient refusal|8
6054803|NCT00451204|9654555|FG001|Overall Study|Patient refusal|4
6054804|NCT00451204|9654554|FG000|Overall Study|Other|1
6054805|NCT00451204|9654555|FG001|Overall Study|Other|2
6054806|NCT00451217|9654568|FG000|Overall Study|Lost to Follow-up|0
6054807|NCT00451217|9654569|FG001|Overall Study|Lost to Follow-up|1
6054808|NCT00451217|9654570|FG002|Overall Study|Lost to Follow-up|1
6054809|NCT00451217|9654571|FG003|Overall Study|Lost to Follow-up|1
6054810|NCT00451217|9654568|FG000|Overall Study|Withdrawal by Subject|1
6054811|NCT00451217|9654569|FG001|Overall Study|Withdrawal by Subject|0
6054812|NCT00451217|9654570|FG002|Overall Study|Withdrawal by Subject|0
6054813|NCT00451217|9654571|FG003|Overall Study|Withdrawal by Subject|0
6054814|NCT00451217|9654568|FG000|Overall Study|Not Treated|1
6054815|NCT00451217|9654569|FG001|Overall Study|Not Treated|1
6054816|NCT00451217|9654570|FG002|Overall Study|Not Treated|3
6054817|NCT00451217|9654571|FG003|Overall Study|Not Treated|4
6054818|NCT00451282|9654583|FG000|Overall Study|Lost to Follow-up|6
6054819|NCT00451282|9654584|FG001|Overall Study|Lost to Follow-up|5
6054820|NCT00451321|9654598|FG000|Overall Study|Lost to Follow-up|3
6054821|NCT00451321|9654599|FG001|Overall Study|Lost to Follow-up|3
6054822|NCT00451321|9654600|FG002|Overall Study|Lost to Follow-up|1
6054823|NCT00451321|9654601|FG003|Overall Study|Lost to Follow-up|3
6054824|NCT00451321|9654602|FG004|Overall Study|Lost to Follow-up|0
6054825|NCT00451321|9654603|FG005|Overall Study|Lost to Follow-up|1
6054826|NCT00451321|9654604|FG006|Overall Study|Lost to Follow-up|0
6054827|NCT00451321|9654605|FG007|Overall Study|Lost to Follow-up|0
6054828|NCT00451321|9654598|FG000|Overall Study|Withdrawal by Subject|3
6054829|NCT00451321|9654599|FG001|Overall Study|Withdrawal by Subject|1
6054830|NCT00451321|9654600|FG002|Overall Study|Withdrawal by Subject|0
6054831|NCT00451321|9654601|FG003|Overall Study|Withdrawal by Subject|4
6054832|NCT00451321|9654602|FG004|Overall Study|Withdrawal by Subject|0
6054833|NCT00451321|9654603|FG005|Overall Study|Withdrawal by Subject|0
6054834|NCT00451321|9654604|FG006|Overall Study|Withdrawal by Subject|0
6054835|NCT00451321|9654605|FG007|Overall Study|Withdrawal by Subject|0
6054836|NCT00451321|9654598|FG000|Overall Study|Study closed/terminated|1
6054837|NCT00451321|9654599|FG001|Overall Study|Study closed/terminated|1
6054838|NCT00451321|9654600|FG002|Overall Study|Study closed/terminated|17
6054839|NCT00451321|9654601|FG003|Overall Study|Study closed/terminated|5
6054840|NCT00451321|9654602|FG004|Overall Study|Study closed/terminated|7
6054841|NCT00451321|9654603|FG005|Overall Study|Study closed/terminated|7
6054842|NCT00451321|9654604|FG006|Overall Study|Study closed/terminated|5
6054843|NCT00451321|9654605|FG007|Overall Study|Study closed/terminated|3
6054844|NCT00451321|9654598|FG000|Overall Study|Sponsor decision to amend protocol|0
6054845|NCT00451321|9654599|FG001|Overall Study|Sponsor decision to amend protocol|0
6054846|NCT00451321|9654600|FG002|Overall Study|Sponsor decision to amend protocol|0
6054847|NCT00451321|9654601|FG003|Overall Study|Sponsor decision to amend protocol|0
6054848|NCT00451321|9654602|FG004|Overall Study|Sponsor decision to amend protocol|0
6054849|NCT00451321|9654603|FG005|Overall Study|Sponsor decision to amend protocol|1
6054850|NCT00451321|9654604|FG006|Overall Study|Sponsor decision to amend protocol|1
6054851|NCT00451321|9654605|FG007|Overall Study|Sponsor decision to amend protocol|3
6054852|NCT00451451|9654627|FG000|Overall Study|Adverse Event|11
6054853|NCT00451451|9654628|FG001|Overall Study|Adverse Event|21
6054854|NCT00451451|9654629|FG002|Overall Study|Adverse Event|26
6054855|NCT00451451|9654630|FG003|Overall Study|Adverse Event|10
6054856|NCT00451451|9654627|FG000|Overall Study|Lost to Follow-up|11
6054857|NCT00451451|9654628|FG001|Overall Study|Lost to Follow-up|9
6054858|NCT00451451|9654629|FG002|Overall Study|Lost to Follow-up|8
6054859|NCT00451451|9654630|FG003|Overall Study|Lost to Follow-up|11
6054860|NCT00451451|9654627|FG000|Overall Study|Consent Withdrawn|14
6090721|NCT00694109|9702990|FG000|Overall Study|Pregnancy|1
6090722|NCT00694109|9702990|FG000|Overall Study|Enrolled but not treated|1
6090723|NCT00694109|9702990|FG000|Overall Study|Other|2
6090724|NCT00694109|9702990|FG000|Overall Study|Consented but no additional treatment|3
6090725|NCT00694122|9702995|FG000|First Intervention (3-4 Weeks)|Withdrawal by Subject|7
6090726|NCT00694122|9702996|FG001|First Intervention (3-4 Weeks)|Withdrawal by Subject|0
6090727|NCT00694122|9702995|FG000|First Intervention (3-4 Weeks)|Lost to Follow-up|1
6090728|NCT00694122|9702996|FG001|First Intervention (3-4 Weeks)|Lost to Follow-up|1
6054861|NCT00451451|9654628|FG001|Overall Study|Consent Withdrawn|9
6054862|NCT00451451|9654629|FG002|Overall Study|Consent Withdrawn|17
6054863|NCT00451451|9654630|FG003|Overall Study|Consent Withdrawn|17
6054864|NCT00451451|9654627|FG000|Overall Study|Investigator Decision|6
6054865|NCT00451451|9654628|FG001|Overall Study|Investigator Decision|2
6054866|NCT00451451|9654629|FG002|Overall Study|Investigator Decision|1
6054867|NCT00451451|9654630|FG003|Overall Study|Investigator Decision|2
6054868|NCT00451451|9654627|FG000|Overall Study|Subject Non-Compliance|8
6054869|NCT00451451|9654628|FG001|Overall Study|Subject Non-Compliance|4
6054870|NCT00451451|9654629|FG002|Overall Study|Subject Non-Compliance|3
6054871|NCT00451451|9654630|FG003|Overall Study|Subject Non-Compliance|3
6054872|NCT00451451|9654627|FG000|Overall Study|Death|1
6054873|NCT00451451|9654628|FG001|Overall Study|Death|0
6054874|NCT00451451|9654629|FG002|Overall Study|Death|0
6054875|NCT00451451|9654630|FG003|Overall Study|Death|1
6054876|NCT00451451|9654627|FG000|Overall Study|Other Reasons for Not Completing Study|34
6054877|NCT00451451|9654628|FG001|Overall Study|Other Reasons for Not Completing Study|30
6054878|NCT00451451|9654629|FG002|Overall Study|Other Reasons for Not Completing Study|17
6054879|NCT00451451|9654630|FG003|Overall Study|Other Reasons for Not Completing Study|14
6054880|NCT00451555|9654645|FG000|Overall Study|Protocol Violation|2
6054881|NCT00451555|9654646|FG001|Overall Study|Protocol Violation|2
6054882|NCT00451555|9654645|FG000|Overall Study|Adverse Event|3
6054883|NCT00451555|9654646|FG001|Overall Study|Adverse Event|1
6054884|NCT00451555|9654645|FG000|Overall Study|Withdrawal by Subject|6
6054885|NCT00451555|9654646|FG001|Overall Study|Withdrawal by Subject|0
6054886|NCT00451555|9654645|FG000|Overall Study|Physician Decision|2
6054887|NCT00451555|9654646|FG001|Overall Study|Physician Decision|1
6054888|NCT00451906|9654672|FG000|Overall Study|Adverse Event|515
6054889|NCT00451906|9654672|FG000|Overall Study|Lost to Follow-up|31
6054890|NCT00451906|9654672|FG000|Overall Study|Withdrawal by Subject|111
6054891|NCT00451906|9654672|FG000|Overall Study|Protocol Violation|21
6054892|NCT00451906|9654672|FG000|Overall Study|Progressive disease|1328
6054893|NCT00451906|9654672|FG000|Overall Study|Termination of the study|108
6054894|NCT00451906|9654672|FG000|Overall Study|Other Reasons|121
6054895|NCT00451906|9654672|FG000|Overall Study|Did not complete final visit|4
6054896|NCT00451958|9654680|FG000|CS21A (NCT00451958)|Adverse Event|21
6090729|NCT00694122|9702995|FG000|First Intervention (3-4 Weeks)|Did not meet entrance criteria|2
6090730|NCT00694122|9702996|FG001|First Intervention (3-4 Weeks)|Did not meet entrance criteria|1
6054897|NCT00451958|9654681|FG001|CS21A (NCT00451958)|Adverse Event|34
6054898|NCT00451958|9654682|FG002|CS21A (NCT00451958)|Adverse Event|14
6054899|NCT00451958|9654683|FG003|CS21A (NCT00451958)|Adverse Event|17
6054900|NCT00451958|9654684|FG004|CS21A (NCT00451958)|Adverse Event|0
6054901|NCT00451958|9654680|FG000|CS21A (NCT00451958)|Lost to Follow-up|6
6054902|NCT00451958|9654681|FG001|CS21A (NCT00451958)|Lost to Follow-up|5
6054903|NCT00451958|9654682|FG002|CS21A (NCT00451958)|Lost to Follow-up|1
6054904|NCT00451958|9654683|FG003|CS21A (NCT00451958)|Lost to Follow-up|1
6054905|NCT00451958|9654684|FG004|CS21A (NCT00451958)|Lost to Follow-up|0
6054906|NCT00451958|9654680|FG000|CS21A (NCT00451958)|Protocol Violation|1
6054907|NCT00451958|9654681|FG001|CS21A (NCT00451958)|Protocol Violation|3
6054908|NCT00451958|9654682|FG002|CS21A (NCT00451958)|Protocol Violation|2
6054909|NCT00451958|9654683|FG003|CS21A (NCT00451958)|Protocol Violation|0
6054910|NCT00451958|9654684|FG004|CS21A (NCT00451958)|Protocol Violation|0
6054911|NCT00451958|9654680|FG000|CS21A (NCT00451958)|Physician Decision|2
6054912|NCT00451958|9654681|FG001|CS21A (NCT00451958)|Physician Decision|4
6054913|NCT00451958|9654682|FG002|CS21A (NCT00451958)|Physician Decision|4
6054914|NCT00451958|9654683|FG003|CS21A (NCT00451958)|Physician Decision|4
6054915|NCT00451958|9654684|FG004|CS21A (NCT00451958)|Physician Decision|0
6054916|NCT00451958|9654680|FG000|CS21A (NCT00451958)|Withdrawal by Subject|7
6054917|NCT00451958|9654681|FG001|CS21A (NCT00451958)|Withdrawal by Subject|4
6054918|NCT00451958|9654682|FG002|CS21A (NCT00451958)|Withdrawal by Subject|4
6054919|NCT00451958|9654683|FG003|CS21A (NCT00451958)|Withdrawal by Subject|3
6054920|NCT00451958|9654684|FG004|CS21A (NCT00451958)|Withdrawal by Subject|0
6054921|NCT00451958|9654680|FG000|CS21A (NCT00451958)|Miscellaneous reasons|28
6054922|NCT00451958|9654681|FG001|CS21A (NCT00451958)|Miscellaneous reasons|27
6054923|NCT00451958|9654682|FG002|CS21A (NCT00451958)|Miscellaneous reasons|17
6054924|NCT00451958|9654683|FG003|CS21A (NCT00451958)|Miscellaneous reasons|14
6054925|NCT00451958|9654684|FG004|CS21A (NCT00451958)|Miscellaneous reasons|0
6054926|NCT00452114|9654700|FG000|Overall Study|Physician Decision|3
6054927|NCT00452114|9654701|FG001|Overall Study|Physician Decision|3
6054928|NCT00452348|9654725|FG000|Overall Study|Adverse Event|6
6054929|NCT00452348|9654726|FG001|Overall Study|Adverse Event|9
6054930|NCT00452348|9654725|FG000|Overall Study|Lack of Efficacy|10
6054931|NCT00452348|9654726|FG001|Overall Study|Lack of Efficacy|9
6054932|NCT00452348|9654725|FG000|Overall Study|Lost to Follow-up|14
6054933|NCT00452348|9654726|FG001|Overall Study|Lost to Follow-up|8
6054934|NCT00452348|9654725|FG000|Overall Study|Protocol Violation|22
6054935|NCT00452348|9654726|FG001|Overall Study|Protocol Violation|28
6054936|NCT00452348|9654725|FG000|Overall Study|Withdrawal by Subject|18
6054937|NCT00452348|9654726|FG001|Overall Study|Withdrawal by Subject|21
6054938|NCT00452348|9654725|FG000|Overall Study|Other|9
6054939|NCT00452348|9654726|FG001|Overall Study|Other|9
6054940|NCT00452400|9654747|FG000|Overall Study|Adverse Event|1
6054941|NCT00452400|9654748|FG001|Overall Study|Adverse Event|1
6054942|NCT00452400|9654749|FG002|Overall Study|Adverse Event|5
6054943|NCT00452400|9654750|FG003|Overall Study|Adverse Event|0
6054944|NCT00452400|9654751|FG004|Overall Study|Adverse Event|2
6054945|NCT00452400|9654747|FG000|Overall Study|Protocol Violation|0
6054946|NCT00452400|9654748|FG001|Overall Study|Protocol Violation|0
6054947|NCT00452400|9654749|FG002|Overall Study|Protocol Violation|1
6054948|NCT00452400|9654750|FG003|Overall Study|Protocol Violation|0
6054949|NCT00452400|9654751|FG004|Overall Study|Protocol Violation|0
6054950|NCT00452400|9654747|FG000|Overall Study|Lost to Follow-up|1
6054951|NCT00452400|9654748|FG001|Overall Study|Lost to Follow-up|0
6054952|NCT00452400|9654749|FG002|Overall Study|Lost to Follow-up|0
6054953|NCT00452400|9654750|FG003|Overall Study|Lost to Follow-up|0
6054954|NCT00452400|9654751|FG004|Overall Study|Lost to Follow-up|0
6054955|NCT00452400|9654747|FG000|Overall Study|Withdrawal by Subject|1
6054956|NCT00452400|9654748|FG001|Overall Study|Withdrawal by Subject|0
6054957|NCT00452400|9654749|FG002|Overall Study|Withdrawal by Subject|1
6054958|NCT00452400|9654750|FG003|Overall Study|Withdrawal by Subject|0
6054959|NCT00452400|9654751|FG004|Overall Study|Withdrawal by Subject|0
6054960|NCT00452400|9654747|FG000|Overall Study|Lack of Efficacy|2
6054961|NCT00452400|9654748|FG001|Overall Study|Lack of Efficacy|0
6054962|NCT00452400|9654749|FG002|Overall Study|Lack of Efficacy|0
6054963|NCT00452400|9654750|FG003|Overall Study|Lack of Efficacy|0
6054964|NCT00452400|9654751|FG004|Overall Study|Lack of Efficacy|0
6054965|NCT00452400|9654747|FG000|Overall Study|Other reasons not listed above|0
6054966|NCT00452400|9654748|FG001|Overall Study|Other reasons not listed above|0
6054967|NCT00452400|9654749|FG002|Overall Study|Other reasons not listed above|0
6054968|NCT00452400|9654750|FG003|Overall Study|Other reasons not listed above|1
6054969|NCT00452400|9654751|FG004|Overall Study|Other reasons not listed above|1
6054970|NCT00452413|9654766|FG000|Overall Study|Progressive Disease|4
6054971|NCT00452413|9654767|FG001|Overall Study|Progressive Disease|11
6054972|NCT00452413|9654768|FG002|Overall Study|Progressive Disease|30
6054973|NCT00452413|9654766|FG000|Overall Study|Withdrawal by Subject|0
6054974|NCT00452413|9654767|FG001|Overall Study|Withdrawal by Subject|1
6054975|NCT00452413|9654768|FG002|Overall Study|Withdrawal by Subject|4
6054976|NCT00452413|9654766|FG000|Overall Study|Adverse Event|0
6054977|NCT00452413|9654767|FG001|Overall Study|Adverse Event|0
6054978|NCT00452413|9654768|FG002|Overall Study|Adverse Event|5
6054979|NCT00452413|9654766|FG000|Overall Study|Physician Decision|0
6054980|NCT00452413|9654767|FG001|Overall Study|Physician Decision|0
6054981|NCT00452413|9654768|FG002|Overall Study|Physician Decision|4
6054982|NCT00452413|9654766|FG000|Overall Study|Death due to study disease|0
6054983|NCT00452413|9654767|FG001|Overall Study|Death due to study disease|0
6054984|NCT00452413|9654768|FG002|Overall Study|Death due to study disease|2
6054985|NCT00452413|9654766|FG000|Overall Study|Death due to adverse event (AE)|0
6054986|NCT00452413|9654767|FG001|Overall Study|Death due to adverse event (AE)|0
6054987|NCT00452413|9654768|FG002|Overall Study|Death due to adverse event (AE)|1
6054988|NCT00452413|9654766|FG000|Overall Study|On treatment|0
6054989|NCT00452413|9654767|FG001|Overall Study|On treatment|0
6054990|NCT00452413|9654768|FG002|Overall Study|On treatment|3
6054991|NCT00452439|9654788|FG000|Overall Study|Lost to Follow-up|1
6054992|NCT00452439|9654789|FG001|Overall Study|Lost to Follow-up|1
6054993|NCT00452439|9654788|FG000|Overall Study|Refused Treatment|4
6054994|NCT00452439|9654789|FG001|Overall Study|Refused Treatment|3
6054995|NCT00452439|9654788|FG000|Overall Study|Death|3
6054996|NCT00452439|9654789|FG001|Overall Study|Death|1
6054997|NCT00452439|9654788|FG000|Overall Study|Bone Marrow Transplant|0
6054998|NCT00452439|9654789|FG001|Overall Study|Bone Marrow Transplant|1
6054999|NCT00452439|9654788|FG000|Overall Study|Too Ill to Continue|0
6055000|NCT00452439|9654789|FG001|Overall Study|Too Ill to Continue|1
6055001|NCT00452439|9654788|FG000|Overall Study|Failed to achieve complete response|2
6055002|NCT00452439|9654789|FG001|Overall Study|Failed to achieve complete response|0
6055003|NCT00452439|9654788|FG000|Overall Study|Relapse|3
6055004|NCT00452439|9654789|FG001|Overall Study|Relapse|0
6055005|NCT00452439|9654788|FG000|Overall Study|Fracture|1
6055006|NCT00452439|9654789|FG001|Overall Study|Fracture|0
6055007|NCT00452452|9654798|FG000|Overall Study|Protocol Violation|0
6055008|NCT00452452|9654799|FG001|Overall Study|Protocol Violation|0
6055009|NCT00452452|9654800|FG002|Overall Study|Protocol Violation|1
6055010|NCT00452452|9654798|FG000|Overall Study|Withdrawal by Subject|1
6055011|NCT00452452|9654799|FG001|Overall Study|Withdrawal by Subject|0
6055012|NCT00452452|9654800|FG002|Overall Study|Withdrawal by Subject|0
6055013|NCT00452452|9654798|FG000|Overall Study|Lost to Follow-up|1
6055014|NCT00452452|9654799|FG001|Overall Study|Lost to Follow-up|0
6055015|NCT00452452|9654800|FG002|Overall Study|Lost to Follow-up|0
6055016|NCT00452530|9654816|FG000|Overall Study|Death|1
6055017|NCT00452530|9654817|FG001|Overall Study|Death|0
6055018|NCT00452530|9654816|FG000|Overall Study|Adverse Event|40
6055019|NCT00452530|9654817|FG001|Overall Study|Adverse Event|44
6055020|NCT00452530|9654816|FG000|Overall Study|Withdrawal by Subject|68
6055021|NCT00452530|9654817|FG001|Overall Study|Withdrawal by Subject|57
6055022|NCT00452530|9654816|FG000|Overall Study|Lost to Follow-up|1
6055023|NCT00452530|9654817|FG001|Overall Study|Lost to Follow-up|0
6055024|NCT00452530|9654816|FG000|Overall Study|Poor compliance/noncompliance|1
6055025|NCT00452530|9654817|FG001|Overall Study|Poor compliance/noncompliance|2
6055026|NCT00452530|9654816|FG000|Overall Study|No longer met study criteria|18
6055027|NCT00452530|9654817|FG001|Overall Study|No longer met study criteria|22
6055028|NCT00452530|9654816|FG000|Overall Study|Other|7
6055029|NCT00452530|9654817|FG001|Overall Study|Other|11
6055030|NCT00452673|9654840|FG000|Dose Escalation Period|Disease Progression|6
6055031|NCT00452673|9654841|FG001|Dose Escalation Period|Disease Progression|6
6055032|NCT00452673|9654842|FG002|Dose Escalation Period|Disease Progression|2
6055033|NCT00452673|9654843|FG003|Dose Escalation Period|Disease Progression|6
6055034|NCT00452673|9654844|FG004|Dose Escalation Period|Disease Progression|0
6055035|NCT00452673|9654840|FG000|Dose Escalation Period|study drug toxicity|1
6055036|NCT00452673|9654841|FG001|Dose Escalation Period|study drug toxicity|3
6055037|NCT00452673|9654842|FG002|Dose Escalation Period|study drug toxicity|3
6055038|NCT00452673|9654843|FG003|Dose Escalation Period|study drug toxicity|1
6055039|NCT00452673|9654844|FG004|Dose Escalation Period|study drug toxicity|0
6202263|NCT01500135|9862396|FG000|Overall Study|Patient Unable to Make Follow-up Visit|0
6202264|NCT01500135|9862397|FG001|Overall Study|Patient Unable to Make Follow-up Visit|1
6202265|NCT01500187|9862405|FG000|Overall Study|Lost to Follow-up|6
6202266|NCT01500187|9862406|FG001|Overall Study|Lost to Follow-up|0
6202267|NCT01500200|9862415|FG000|Stage 1|Adverse Event|1
6202268|NCT01500200|9862416|FG001|Stage 1|Adverse Event|4
6202269|NCT01500200|9862417|FG002|Stage 1|Adverse Event|5
6202270|NCT01500200|9862418|FG003|Stage 1|Adverse Event|0
6202271|NCT01500200|9862419|FG004|Stage 1|Adverse Event|0
6202272|NCT01500200|9862420|FG005|Stage 1|Adverse Event|0
6202273|NCT01500200|9862415|FG000|Stage 1|Lost to Follow-up|2
6202274|NCT01500200|9862416|FG001|Stage 1|Lost to Follow-up|2
6055040|NCT00452673|9654840|FG000|Dose Escalation Period|Other|0
6055041|NCT00452673|9654841|FG001|Dose Escalation Period|Other|0
6055042|NCT00452673|9654842|FG002|Dose Escalation Period|Other|1
6055043|NCT00452673|9654843|FG003|Dose Escalation Period|Other|0
6055044|NCT00452673|9654844|FG004|Dose Escalation Period|Other|0
6055045|NCT00452673|9654840|FG000|Dose Escalation Period|Adverse Event|0
6055046|NCT00452673|9654841|FG001|Dose Escalation Period|Adverse Event|0
6055047|NCT00452673|9654842|FG002|Dose Escalation Period|Adverse Event|0
6055048|NCT00452673|9654843|FG003|Dose Escalation Period|Adverse Event|1
6055049|NCT00452673|9654844|FG004|Dose Escalation Period|Adverse Event|0
6055050|NCT00452673|9654840|FG000|Dose Escalation Period|Withdrawal by Subject|0
6055051|NCT00452673|9654841|FG001|Dose Escalation Period|Withdrawal by Subject|0
6055052|NCT00452673|9654842|FG002|Dose Escalation Period|Withdrawal by Subject|0
6055053|NCT00452673|9654843|FG003|Dose Escalation Period|Withdrawal by Subject|1
6055054|NCT00452673|9654844|FG004|Dose Escalation Period|Withdrawal by Subject|0
6055055|NCT00452673|9654840|FG000|Dose Expansion Period|Disease Progression|0
6055056|NCT00452673|9654841|FG001|Dose Expansion Period|Disease Progression|0
6055057|NCT00452673|9654842|FG002|Dose Expansion Period|Disease Progression|0
6055058|NCT00452673|9654843|FG003|Dose Expansion Period|Disease Progression|0
6055059|NCT00452673|9654844|FG004|Dose Expansion Period|Disease Progression|19
6055060|NCT00452673|9654840|FG000|Dose Expansion Period|Other|0
6055061|NCT00452673|9654841|FG001|Dose Expansion Period|Other|0
6202275|NCT01500200|9862417|FG002|Stage 1|Lost to Follow-up|1
6202276|NCT01500200|9862418|FG003|Stage 1|Lost to Follow-up|0
6202277|NCT01500200|9862419|FG004|Stage 1|Lost to Follow-up|0
6202278|NCT01500200|9862420|FG005|Stage 1|Lost to Follow-up|0
6055062|NCT00452673|9654842|FG002|Dose Expansion Period|Other|0
6090731|NCT00694161|9703007|FG000|Part 2 (After Week 6 up to Month 12)|Adverse Event|1
6090732|NCT00694161|9703007|FG000|Part 2 (After Week 6 up to Month 12)|Physician Decision|1
6090733|NCT00694161|9703007|FG000|Part 2 (After Week 6 up to Month 12)|Death|1
6090734|NCT00694304|9703011|FG000|Overall Study|Adverse Event|42
6090735|NCT00694304|9703011|FG000|Overall Study|Lack of Efficacy|35
6090736|NCT00694304|9703011|FG000|Overall Study|Non-compliance With Study Product|16
6090737|NCT00694304|9703011|FG000|Overall Study|Protocol Violation|6
6090738|NCT00694304|9703011|FG000|Overall Study|Withdrawal of Consent|61
6090739|NCT00694304|9703011|FG000|Overall Study|Lost to Follow-up|15
6055063|NCT00452673|9654843|FG003|Dose Expansion Period|Other|0
6055064|NCT00452673|9654844|FG004|Dose Expansion Period|Other|2
6055065|NCT00452699|9654857|FG000|Overall Study|Adverse Event|10
6055066|NCT00452699|9654858|FG001|Overall Study|Adverse Event|3
6055067|NCT00452699|9654857|FG000|Overall Study|Lack of Efficacy|6
6055068|NCT00452699|9654858|FG001|Overall Study|Lack of Efficacy|4
6055069|NCT00452699|9654857|FG000|Overall Study|Lost to Follow-up|6
6055070|NCT00452699|9654858|FG001|Overall Study|Lost to Follow-up|9
6055071|NCT00452699|9654857|FG000|Overall Study|Protocol Violation|21
6055072|NCT00452699|9654858|FG001|Overall Study|Protocol Violation|25
6055073|NCT00452699|9654857|FG000|Overall Study|Withdrawal by Subject|26
6055074|NCT00452699|9654858|FG001|Overall Study|Withdrawal by Subject|25
6055075|NCT00452699|9654857|FG000|Overall Study|Other|12
6055076|NCT00452699|9654858|FG001|Overall Study|Other|7
6055077|NCT00452790|9654866|FG000|Infant Series|Clinical hold - consent withdrawn|118
6055078|NCT00452790|9654867|FG001|Infant Series|Clinical hold - consent withdrawn|123
6055079|NCT00452790|9654866|FG000|Infant Series|Parent/legal guardian request|8
6055080|NCT00452790|9654867|FG001|Infant Series|Parent/legal guardian request|6
6055081|NCT00452790|9654866|FG000|Infant Series|Failed to return|4
6055082|NCT00452790|9654867|FG001|Infant Series|Failed to return|1
6055083|NCT00452790|9654866|FG000|Infant Series|Protocol Violation|1
6055084|NCT00452790|9654867|FG001|Infant Series|Protocol Violation|3
6055085|NCT00452790|9654866|FG000|Infant Series|Lost to Follow-up|2
6055086|NCT00452790|9654867|FG001|Infant Series|Lost to Follow-up|2
6055087|NCT00452790|9654866|FG000|Infant Series|Adverse Event|1
6055088|NCT00452790|9654867|FG001|Infant Series|Adverse Event|2
6055089|NCT00452790|9654866|FG000|Infant Series|Other reasons|1
6055090|NCT00452790|9654867|FG001|Infant Series|Other reasons|2
6055091|NCT00452790|9654866|FG000|Infant Series|Investigator request|0
6055092|NCT00452790|9654867|FG001|Infant Series|Investigator request|1
6055093|NCT00452790|9654866|FG000|Infant Series|Death|0
6055094|NCT00452790|9654867|FG001|Infant Series|Death|1
6055095|NCT00452790|9654866|FG000|After Infant Series|Investigator request|10
6055096|NCT00452790|9654867|FG001|After Infant Series|Investigator request|10
6055097|NCT00452790|9654866|FG000|After Infant Series|Adverse Event|4
6055098|NCT00452790|9654867|FG001|After Infant Series|Adverse Event|1
6055099|NCT00452790|9654866|FG000|After Infant Series|Parent/legal guardian request|1
6055100|NCT00452790|9654867|FG001|After Infant Series|Parent/legal guardian request|3
6055101|NCT00452790|9654866|FG000|After Infant Series|Lost to Follow-up|4
6055102|NCT00452790|9654867|FG001|After Infant Series|Lost to Follow-up|0
6055103|NCT00452790|9654866|FG000|After Infant Series|Failed to return|1
6055104|NCT00452790|9654867|FG001|After Infant Series|Failed to return|0
6055105|NCT00452790|9654866|FG000|After Infant Series|Other reasons|1
6055106|NCT00452790|9654867|FG001|After Infant Series|Other reasons|0
6055107|NCT00452790|9654866|FG000|Toddler Dose|Failed to return|0
6055108|NCT00452790|9654867|FG001|Toddler Dose|Failed to return|1
6055109|NCT00452790|9654866|FG000|Toddler Dose|Parent/legal guardian request|0
6055110|NCT00452790|9654867|FG001|Toddler Dose|Parent/legal guardian request|1
6055111|NCT00453102|9654881|FG000|Overall Study|Withdrawal by Subject|2
6055112|NCT00453154|9654888|FG000|Double BIind Maintenance|Adverse Event|0
6055113|NCT00453154|9654889|FG001|Double BIind Maintenance|Adverse Event|0
6055114|NCT00453154|9654890|FG002|Double BIind Maintenance|Adverse Event|3
6055115|NCT00453154|9654891|FG003|Double BIind Maintenance|Adverse Event|12
6055116|NCT00453154|9654888|FG000|Double BIind Maintenance|Death|0
6055117|NCT00453154|9654889|FG001|Double BIind Maintenance|Death|0
6055118|NCT00453154|9654890|FG002|Double BIind Maintenance|Death|2
6055119|NCT00453154|9654891|FG003|Double BIind Maintenance|Death|1
6055120|NCT00453154|9654888|FG000|Double BIind Maintenance|Withdrawal by Subject|0
6055121|NCT00453154|9654889|FG001|Double BIind Maintenance|Withdrawal by Subject|0
6055122|NCT00453154|9654890|FG002|Double BIind Maintenance|Withdrawal by Subject|4
6055123|NCT00453154|9654891|FG003|Double BIind Maintenance|Withdrawal by Subject|4
6055124|NCT00453154|9654888|FG000|Double BIind Maintenance|Progression|0
6055125|NCT00453154|9654889|FG001|Double BIind Maintenance|Progression|0
6055126|NCT00453154|9654890|FG002|Double BIind Maintenance|Progression|29
6055127|NCT00453154|9654891|FG003|Double BIind Maintenance|Progression|26
6055128|NCT00453154|9654888|FG000|Double BIind Maintenance|Medical Issues|0
6055129|NCT00453154|9654889|FG001|Double BIind Maintenance|Medical Issues|0
6055130|NCT00453154|9654890|FG002|Double BIind Maintenance|Medical Issues|3
6055131|NCT00453154|9654891|FG003|Double BIind Maintenance|Medical Issues|1
6055132|NCT00453154|9654888|FG000|Double BIind Maintenance|Randomized, did not receive therapy|0
6055133|NCT00453154|9654889|FG001|Double BIind Maintenance|Randomized, did not receive therapy|0
6055134|NCT00453154|9654890|FG002|Double BIind Maintenance|Randomized, did not receive therapy|5
6055135|NCT00453154|9654891|FG003|Double BIind Maintenance|Randomized, did not receive therapy|5
6055136|NCT00453180|9654902|FG000|Overall Study|Lost to Follow-up|2
6055137|NCT00453180|9654903|FG001|Overall Study|Lost to Follow-up|1
6055138|NCT00453180|9654902|FG000|Overall Study|Adverse Event|1
6055139|NCT00453180|9654903|FG001|Overall Study|Adverse Event|2
6055140|NCT00453206|9654913|FG000|Overall Study|Death|1
6055141|NCT00453310|9654917|FG000|Overall Study|Progression of Disease|10
6055142|NCT00453349|9654927|FG000|Randomized|Adverse Event|12
6055143|NCT00453349|9654928|FG001|Randomized|Adverse Event|11
6055144|NCT00453349|9654927|FG000|Randomized|Lack of Efficacy|2
6055145|NCT00453349|9654928|FG001|Randomized|Lack of Efficacy|1
6055146|NCT00453349|9654927|FG000|Randomized|Lost to Follow-up|7
6055147|NCT00453349|9654928|FG001|Randomized|Lost to Follow-up|5
6055148|NCT00453349|9654927|FG000|Randomized|Protocol Violation|1
6055149|NCT00453349|9654928|FG001|Randomized|Protocol Violation|1
6055150|NCT00453349|9654927|FG000|Randomized|Withdrawal by Subject|3
6055151|NCT00453349|9654928|FG001|Randomized|Withdrawal by Subject|5
6055152|NCT00453349|9654927|FG000|Reaching of Primary Endpoint (TOC)|Missing information|10
6055153|NCT00453349|9654928|FG001|Reaching of Primary Endpoint (TOC)|Missing information|11
6055154|NCT00453349|9654927|FG000|Completed Study|Adverse Event|12
6055155|NCT00453349|9654928|FG001|Completed Study|Adverse Event|11
6055156|NCT00453349|9654927|FG000|Completed Study|Lack of Efficacy|2
6055157|NCT00453349|9654928|FG001|Completed Study|Lack of Efficacy|1
6055158|NCT00453349|9654927|FG000|Completed Study|Lost to Follow-up|7
6055159|NCT00453349|9654928|FG001|Completed Study|Lost to Follow-up|5
6055160|NCT00453349|9654927|FG000|Completed Study|Protocol Violation|1
6055161|NCT00453349|9654928|FG001|Completed Study|Protocol Violation|1
6055162|NCT00453349|9654927|FG000|Completed Study|Withdrawal by Subject|3
6055163|NCT00453349|9654928|FG001|Completed Study|Withdrawal by Subject|5
6055164|NCT00453349|9654927|FG000|Completed Study|Lost to follow up after study treatment|2
6055165|NCT00453349|9654928|FG001|Completed Study|Lost to follow up after study treatment|11
6055166|NCT00453362|9654934|FG000|Overall Study|Adverse Event|5
6055167|NCT00453362|9654934|FG000|Overall Study|Death|7
6055168|NCT00453362|9654934|FG000|Overall Study|Physician Decision|2
6055169|NCT00453362|9654934|FG000|Overall Study|Withdrawal by Subject|3
6055170|NCT00453362|9654934|FG000|Overall Study|Progression of disease|56
6055171|NCT00453362|9654934|FG000|Overall Study|Screening Failure|14
6055172|NCT00453921|9654990|FG000|Overall Study|Withdrawal by Subject|1
6055173|NCT00453921|9654991|FG001|Overall Study|Withdrawal by Subject|1
6055174|NCT00453921|9654992|FG002|Overall Study|Withdrawal by Subject|1
6055175|NCT00453921|9654993|FG003|Overall Study|Withdrawal by Subject|1
6055176|NCT00453921|9654990|FG000|Overall Study|Lost to Follow-up|0
6055177|NCT00453921|9654991|FG001|Overall Study|Lost to Follow-up|0
6055178|NCT00453921|9654992|FG002|Overall Study|Lost to Follow-up|1
6055179|NCT00453921|9654993|FG003|Overall Study|Lost to Follow-up|0
6055180|NCT00453973|9655009|FG000|Overall Study|Adverse Event|4
6055181|NCT00453973|9655010|FG001|Overall Study|Adverse Event|9
6055182|NCT00453973|9655009|FG000|Overall Study|Withdrawal by Subject|7
6055183|NCT00453973|9655010|FG001|Overall Study|Withdrawal by Subject|6
6055184|NCT00453973|9655009|FG000|Overall Study|PI Decision|0
6055185|NCT00453973|9655010|FG001|Overall Study|PI Decision|2
6055186|NCT00453973|9655009|FG000|Overall Study|Relocation|1
6055187|NCT00453973|9655010|FG001|Overall Study|Relocation|0
6055188|NCT00453973|9655009|FG000|Overall Study|Renal transplant|1
6055189|NCT00453973|9655010|FG001|Overall Study|Renal transplant|1
6055190|NCT00453973|9655009|FG000|Overall Study|Site closed by sponsor|3
6055191|NCT00453973|9655010|FG001|Overall Study|Site closed by sponsor|0
6055192|NCT00453973|9655009|FG000|Overall Study|Sponsor Decision to Terminate Study|35
6055193|NCT00453973|9655010|FG001|Overall Study|Sponsor Decision to Terminate Study|30
6055194|NCT00453986|9655021|FG000|Overall Study|Lost to Follow-up|6
6055195|NCT00453986|9655022|FG001|Overall Study|Lost to Follow-up|5
6055196|NCT00453986|9655023|FG002|Overall Study|Lost to Follow-up|6
6055197|NCT00453986|9655024|FG003|Overall Study|Lost to Follow-up|2
6055198|NCT00453986|9655025|FG004|Overall Study|Lost to Follow-up|0
6202279|NCT01500200|9862415|FG000|Stage 1|Withdrawal by Subject|3
6055199|NCT00453999|9655044|FG000|Overall Study|Adverse Event|1
6055200|NCT00453999|9655045|FG001|Overall Study|Adverse Event|2
6055201|NCT00453999|9655046|FG002|Overall Study|Adverse Event|1
6055202|NCT00453999|9655044|FG000|Overall Study|Lost to Follow-up|0
6055203|NCT00453999|9655045|FG001|Overall Study|Lost to Follow-up|1
6055204|NCT00453999|9655046|FG002|Overall Study|Lost to Follow-up|1
6055205|NCT00453999|9655044|FG000|Overall Study|Withdrawal by Subject|2
6055206|NCT00453999|9655045|FG001|Overall Study|Withdrawal by Subject|1
6055207|NCT00453999|9655046|FG002|Overall Study|Withdrawal by Subject|1
6055208|NCT00453999|9655044|FG000|Overall Study|Subject Request|2
6055209|NCT00453999|9655045|FG001|Overall Study|Subject Request|1
6055210|NCT00453999|9655046|FG002|Overall Study|Subject Request|0
6055211|NCT00454051|9655057|FG000|Overall Study|Adverse Event|1
6055212|NCT00454051|9655058|FG001|Overall Study|Adverse Event|2
6055213|NCT00454051|9655057|FG000|Overall Study|Withdrawal by Subject|1
6055214|NCT00454051|9655058|FG001|Overall Study|Withdrawal by Subject|0
6055215|NCT00454051|9655057|FG000|Overall Study|Protocol Violation|1
6055216|NCT00454051|9655058|FG001|Overall Study|Protocol Violation|1
6055217|NCT00454116|9655067|FG000|Overall Study|Adverse Event|5
6055218|NCT00454116|9655068|FG001|Overall Study|Adverse Event|11
6055219|NCT00454116|9655069|FG002|Overall Study|Adverse Event|9
6055220|NCT00454116|9655067|FG000|Overall Study|Condition under investigation worsened|17
6055221|NCT00454116|9655068|FG001|Overall Study|Condition under investigation worsened|13
6055222|NCT00454116|9655069|FG002|Overall Study|Condition under investigation worsened|18
6055223|NCT00454116|9655067|FG000|Overall Study|Withdrawal by Subject|3
6055224|NCT00454116|9655068|FG001|Overall Study|Withdrawal by Subject|3
6055225|NCT00454116|9655069|FG002|Overall Study|Withdrawal by Subject|1
6055226|NCT00454116|9655067|FG000|Overall Study|Other|2
6055227|NCT00454116|9655068|FG001|Overall Study|Other|2
6055228|NCT00454116|9655069|FG002|Overall Study|Other|0
6055229|NCT00454142|9655077|FG000|Overall Study|Withdrawal by Subject|1
6055230|NCT00454181|9655085|FG000|Overall Study|Adverse Event|1
6055231|NCT00454181|9655086|FG001|Overall Study|Adverse Event|1
6055232|NCT00454181|9655085|FG000|Overall Study|Lost to Follow-up|11
6055233|NCT00454181|9655086|FG001|Overall Study|Lost to Follow-up|1
6055234|NCT00454181|9655085|FG000|Overall Study|Protocol Violation|1
6055235|NCT00454181|9655086|FG001|Overall Study|Protocol Violation|1
6055236|NCT00454181|9655085|FG000|Overall Study|Withdrawal by Subject|2
6055237|NCT00454181|9655086|FG001|Overall Study|Withdrawal by Subject|0
6055238|NCT00454194|9655094|FG000|Overall Study|Adverse Event|7
6055239|NCT00454194|9655095|FG001|Overall Study|Adverse Event|2
6055240|NCT00454194|9655094|FG000|Overall Study|Withdrawal by Subject|12
6055241|NCT00454194|9655095|FG001|Overall Study|Withdrawal by Subject|8
6055242|NCT00454194|9655094|FG000|Overall Study|Other Medical Problems|1
6055243|NCT00454194|9655095|FG001|Overall Study|Other Medical Problems|2
6055244|NCT00454194|9655094|FG000|Overall Study|Other Unspecified Reason|2
6055245|NCT00454194|9655095|FG001|Overall Study|Other Unspecified Reason|2
6055246|NCT00454207|9655103|FG000|Overall Study|Adverse Event|3
6055247|NCT00454207|9655104|FG001|Overall Study|Adverse Event|1
6055248|NCT00454207|9655103|FG000|Overall Study|Lack of Efficacy|1
6055249|NCT00454207|9655104|FG001|Overall Study|Lack of Efficacy|0
6055250|NCT00454207|9655103|FG000|Overall Study|Protocol Violation|0
6055251|NCT00454207|9655104|FG001|Overall Study|Protocol Violation|1
6055252|NCT00454246|9655125|FG000|Overall Study|Adverse Event|2
6055253|NCT00454246|9655126|FG001|Overall Study|Adverse Event|2
6055254|NCT00454246|9655127|FG002|Overall Study|Adverse Event|0
6055255|NCT00454246|9655125|FG000|Overall Study|Violation of selection criteria at entry|6
6055256|NCT00454246|9655126|FG001|Overall Study|Violation of selection criteria at entry|0
6055257|NCT00454246|9655127|FG002|Overall Study|Violation of selection criteria at entry|0
6055258|NCT00454246|9655125|FG000|Overall Study|Protocol Violation|1
6055259|NCT00454246|9655126|FG001|Overall Study|Protocol Violation|0
6055260|NCT00454246|9655127|FG002|Overall Study|Protocol Violation|0
6055261|NCT00454246|9655125|FG000|Overall Study|Refused Treatment|1
6055262|NCT00454246|9655126|FG001|Overall Study|Refused Treatment|1
6055263|NCT00454246|9655127|FG002|Overall Study|Refused Treatment|0
6090740|NCT00694304|9703011|FG000|Overall Study|Administrative or Other Reasons|32
6090741|NCT00694356|9703018|FG000|Overall Study|Adverse Event|1
6090742|NCT00694356|9703019|FG001|Overall Study|Adverse Event|0
6090743|NCT00694356|9703020|FG002|Overall Study|Adverse Event|0
6090744|NCT00694356|9703018|FG000|Overall Study|Progressive Disease|2
6090745|NCT00694356|9703019|FG001|Overall Study|Progressive Disease|6
6090746|NCT00694356|9703020|FG002|Overall Study|Progressive Disease|6
6090747|NCT00694551|9703035|FG000|Overall Study|Disease Progression|1
6090748|NCT00694551|9703036|FG001|Overall Study|Disease Progression|0
6090749|NCT00694551|9703037|FG002|Overall Study|Disease Progression|1
6090750|NCT00694707|9703059|FG000|Overall Study|Did Not Receive Treatment|0
6090751|NCT00694707|9703060|FG001|Overall Study|Did Not Receive Treatment|0
6090752|NCT00694707|9703061|FG002|Overall Study|Did Not Receive Treatment|1
6090753|NCT00694707|9703062|FG003|Overall Study|Did Not Receive Treatment|1
6090754|NCT00694707|9703063|FG004|Overall Study|Did Not Receive Treatment|1
6090755|NCT00694707|9703059|FG000|Overall Study|Adverse Event|22
6090756|NCT00694707|9703060|FG001|Overall Study|Adverse Event|14
6090757|NCT00694707|9703061|FG002|Overall Study|Adverse Event|8
6090758|NCT00694707|9703062|FG003|Overall Study|Adverse Event|12
6090759|NCT00694707|9703063|FG004|Overall Study|Adverse Event|13
6090760|NCT00694707|9703059|FG000|Overall Study|Insufficient Therapeutic Response|33
6090761|NCT00694707|9703060|FG001|Overall Study|Insufficient Therapeutic Response|18
6090762|NCT00694707|9703061|FG002|Overall Study|Insufficient Therapeutic Response|17
6090763|NCT00694707|9703062|FG003|Overall Study|Insufficient Therapeutic Response|15
6090764|NCT00694707|9703063|FG004|Overall Study|Insufficient Therapeutic Response|10
6090765|NCT00694707|9703059|FG000|Overall Study|Protocol Violation|1
6090766|NCT00694707|9703060|FG001|Overall Study|Protocol Violation|2
6090767|NCT00694707|9703061|FG002|Overall Study|Protocol Violation|1
6090768|NCT00694707|9703062|FG003|Overall Study|Protocol Violation|3
6090769|NCT00694707|9703063|FG004|Overall Study|Protocol Violation|1
6090770|NCT00694707|9703059|FG000|Overall Study|Withdrawal of Consent|14
6090771|NCT00694707|9703060|FG001|Overall Study|Withdrawal of Consent|18
6090772|NCT00694707|9703061|FG002|Overall Study|Withdrawal of Consent|22
6090773|NCT00694707|9703062|FG003|Overall Study|Withdrawal of Consent|16
6090774|NCT00694707|9703063|FG004|Overall Study|Withdrawal of Consent|15
6090775|NCT00694707|9703059|FG000|Overall Study|Lost to Follow-up|0
6090776|NCT00694707|9703060|FG001|Overall Study|Lost to Follow-up|1
6055264|NCT00454246|9655125|FG000|Overall Study|Failure to return|1
6055265|NCT00454246|9655126|FG001|Overall Study|Failure to return|0
6055266|NCT00454246|9655127|FG002|Overall Study|Failure to return|0
6055267|NCT00454246|9655125|FG000|Overall Study|Early termination of study|62
6055268|NCT00454246|9655126|FG001|Overall Study|Early termination of study|26
6055269|NCT00454246|9655127|FG002|Overall Study|Early termination of study|9
6055270|NCT00454363|9655146|FG000|Overall Study|Adverse Event|1
6055271|NCT00454363|9655147|FG001|Overall Study|Adverse Event|2
6055272|NCT00454363|9655146|FG000|Overall Study|Withdrawal prior to 12 weeks treatment|4
6055273|NCT00454363|9655147|FG001|Overall Study|Withdrawal prior to 12 weeks treatment|0
6055274|NCT00454584|9655172|FG000|Controlled Period|Adverse Event|5
6055275|NCT00454584|9655173|FG001|Controlled Period|Adverse Event|2
6055276|NCT00454584|9655174|FG002|Controlled Period|Adverse Event|1
6055277|NCT00454584|9655175|FG003|Controlled Period|Adverse Event|0
6055278|NCT00454584|9655176|FG004|Controlled Period|Adverse Event|0
6055279|NCT00454584|9655177|FG005|Controlled Period|Adverse Event|0
6055280|NCT00454584|9655172|FG000|Controlled Period|Lost to Follow-up|1
6055281|NCT00454584|9655173|FG001|Controlled Period|Lost to Follow-up|2
6055282|NCT00454584|9655174|FG002|Controlled Period|Lost to Follow-up|2
6055283|NCT00454584|9655175|FG003|Controlled Period|Lost to Follow-up|0
6055284|NCT00454584|9655176|FG004|Controlled Period|Lost to Follow-up|0
6055285|NCT00454584|9655177|FG005|Controlled Period|Lost to Follow-up|0
6055286|NCT00454584|9655172|FG000|Controlled Period|Other|5
6055287|NCT00454584|9655173|FG001|Controlled Period|Other|4
6055288|NCT00454584|9655174|FG002|Controlled Period|Other|2
6055289|NCT00454584|9655175|FG003|Controlled Period|Other|0
6055290|NCT00454584|9655176|FG004|Controlled Period|Other|0
6055291|NCT00454584|9655177|FG005|Controlled Period|Other|0
6055292|NCT00454584|9655172|FG000|After Controlled Period|Adverse Event|0
6055293|NCT00454584|9655173|FG001|After Controlled Period|Adverse Event|0
6055294|NCT00454584|9655174|FG002|After Controlled Period|Adverse Event|0
6055295|NCT00454584|9655175|FG003|After Controlled Period|Adverse Event|9
6055296|NCT00454584|9655176|FG004|After Controlled Period|Adverse Event|3
6055297|NCT00454584|9655177|FG005|After Controlled Period|Adverse Event|9
6055298|NCT00454584|9655172|FG000|After Controlled Period|Lack of Efficacy|0
6055299|NCT00454584|9655173|FG001|After Controlled Period|Lack of Efficacy|0
6055300|NCT00454584|9655174|FG002|After Controlled Period|Lack of Efficacy|0
6055301|NCT00454584|9655175|FG003|After Controlled Period|Lack of Efficacy|1
6055302|NCT00454584|9655176|FG004|After Controlled Period|Lack of Efficacy|0
6055303|NCT00454584|9655177|FG005|After Controlled Period|Lack of Efficacy|0
6055304|NCT00454584|9655172|FG000|After Controlled Period|Lost to Follow-up|0
6055305|NCT00454584|9655173|FG001|After Controlled Period|Lost to Follow-up|0
6055306|NCT00454584|9655174|FG002|After Controlled Period|Lost to Follow-up|0
6055307|NCT00454584|9655175|FG003|After Controlled Period|Lost to Follow-up|2
6055308|NCT00454584|9655176|FG004|After Controlled Period|Lost to Follow-up|4
6055309|NCT00454584|9655177|FG005|After Controlled Period|Lost to Follow-up|6
6055310|NCT00454584|9655172|FG000|After Controlled Period|Other|0
6055311|NCT00454584|9655173|FG001|After Controlled Period|Other|0
6055312|NCT00454584|9655174|FG002|After Controlled Period|Other|0
6055313|NCT00454584|9655175|FG003|After Controlled Period|Other|1
6055314|NCT00454584|9655176|FG004|After Controlled Period|Other|0
6055315|NCT00454584|9655177|FG005|After Controlled Period|Other|0
6055316|NCT00454584|9655172|FG000|After Controlled Period|Other|0
6055317|NCT00454584|9655173|FG001|After Controlled Period|Other|0
6055318|NCT00454584|9655174|FG002|After Controlled Period|Other|0
6055319|NCT00454584|9655175|FG003|After Controlled Period|Other|13
6055320|NCT00454584|9655176|FG004|After Controlled Period|Other|5
6055321|NCT00454584|9655177|FG005|After Controlled Period|Other|17
6055322|NCT00454636|9655195|FG000|Overall Study|Adverse Event|10
6055323|NCT00454636|9655196|FG001|Overall Study|Adverse Event|6
6055324|NCT00454636|9655197|FG002|Overall Study|Adverse Event|9
6055325|NCT00454636|9655198|FG003|Overall Study|Adverse Event|15
6055326|NCT00454636|9655195|FG000|Overall Study|Disease Progression|11
6055327|NCT00454636|9655196|FG001|Overall Study|Disease Progression|12
6055328|NCT00454636|9655197|FG002|Overall Study|Disease Progression|4
6055329|NCT00454636|9655198|FG003|Overall Study|Disease Progression|11
6055330|NCT00454636|9655195|FG000|Overall Study|Protocol Violation|3
6055331|NCT00454636|9655196|FG001|Overall Study|Protocol Violation|2
6055332|NCT00454636|9655197|FG002|Overall Study|Protocol Violation|3
6055333|NCT00454636|9655198|FG003|Overall Study|Protocol Violation|3
6055334|NCT00454636|9655195|FG000|Overall Study|Death|6
6055335|NCT00454636|9655196|FG001|Overall Study|Death|1
6055336|NCT00454636|9655197|FG002|Overall Study|Death|1
6055337|NCT00454636|9655198|FG003|Overall Study|Death|1
6055338|NCT00454636|9655195|FG000|Overall Study|Patient refusal|1
6055339|NCT00454636|9655196|FG001|Overall Study|Patient refusal|1
6055340|NCT00454636|9655197|FG002|Overall Study|Patient refusal|3
6055341|NCT00454636|9655198|FG003|Overall Study|Patient refusal|2
6055342|NCT00454636|9655195|FG000|Overall Study|Lost to Follow-up|0
6055343|NCT00454636|9655196|FG001|Overall Study|Lost to Follow-up|1
6055344|NCT00454636|9655197|FG002|Overall Study|Lost to Follow-up|0
6055345|NCT00454636|9655198|FG003|Overall Study|Lost to Follow-up|0
6055346|NCT00454649|9655218|FG000|Overall Study|Lack of Efficacy|2
6090777|NCT00694707|9703061|FG002|Overall Study|Lost to Follow-up|2
6090778|NCT00694707|9703062|FG003|Overall Study|Lost to Follow-up|0
6090779|NCT00694707|9703063|FG004|Overall Study|Lost to Follow-up|0
6055347|NCT00454649|9655219|FG001|Overall Study|Lack of Efficacy|2
6055348|NCT00454649|9655220|FG002|Overall Study|Lack of Efficacy|10
6055349|NCT00454649|9655221|FG003|Overall Study|Lack of Efficacy|3
6055350|NCT00454649|9655222|FG004|Overall Study|Lack of Efficacy|0
6055351|NCT00454649|9655223|FG005|Overall Study|Lack of Efficacy|4
6055352|NCT00454649|9655224|FG006|Overall Study|Lack of Efficacy|5
6055353|NCT00454649|9655225|FG007|Overall Study|Lack of Efficacy|13
6055354|NCT00454649|9655226|FG008|Overall Study|Lack of Efficacy|10
6055355|NCT00454649|9655227|FG009|Overall Study|Lack of Efficacy|2
6055356|NCT00454649|9655218|FG000|Overall Study|Adverse Event|0
6055357|NCT00454649|9655219|FG001|Overall Study|Adverse Event|1
6055358|NCT00454649|9655220|FG002|Overall Study|Adverse Event|3
6055359|NCT00454649|9655221|FG003|Overall Study|Adverse Event|0
6055360|NCT00454649|9655222|FG004|Overall Study|Adverse Event|1
6055361|NCT00454649|9655223|FG005|Overall Study|Adverse Event|2
6055362|NCT00454649|9655224|FG006|Overall Study|Adverse Event|3
6055363|NCT00454649|9655225|FG007|Overall Study|Adverse Event|4
6055364|NCT00454649|9655226|FG008|Overall Study|Adverse Event|6
6055365|NCT00454649|9655227|FG009|Overall Study|Adverse Event|2
6055366|NCT00454649|9655218|FG000|Overall Study|Lost to Follow-up|0
6055367|NCT00454649|9655219|FG001|Overall Study|Lost to Follow-up|0
6055368|NCT00454649|9655220|FG002|Overall Study|Lost to Follow-up|1
6055369|NCT00454649|9655221|FG003|Overall Study|Lost to Follow-up|0
6055370|NCT00454649|9655222|FG004|Overall Study|Lost to Follow-up|0
6055371|NCT00454649|9655223|FG005|Overall Study|Lost to Follow-up|0
6055372|NCT00454649|9655224|FG006|Overall Study|Lost to Follow-up|1
6055373|NCT00454649|9655225|FG007|Overall Study|Lost to Follow-up|0
6055374|NCT00454649|9655226|FG008|Overall Study|Lost to Follow-up|0
6055375|NCT00454649|9655227|FG009|Overall Study|Lost to Follow-up|0
6055376|NCT00454649|9655218|FG000|Overall Study|Other|1
6055377|NCT00454649|9655219|FG001|Overall Study|Other|1
6055378|NCT00454649|9655220|FG002|Overall Study|Other|5
6055379|NCT00454649|9655221|FG003|Overall Study|Other|3
6055380|NCT00454649|9655222|FG004|Overall Study|Other|0
6055381|NCT00454649|9655223|FG005|Overall Study|Other|0
6055382|NCT00454649|9655224|FG006|Overall Study|Other|0
6055383|NCT00454649|9655225|FG007|Overall Study|Other|0
6055384|NCT00454649|9655226|FG008|Overall Study|Other|3
6090780|NCT00694707|9703059|FG000|Overall Study|Jeopardizing Parole Status|1
6090781|NCT00694707|9703060|FG001|Overall Study|Jeopardizing Parole Status|0
6090782|NCT00694707|9703061|FG002|Overall Study|Jeopardizing Parole Status|0
6090783|NCT00694707|9703062|FG003|Overall Study|Jeopardizing Parole Status|0
6090784|NCT00694707|9703063|FG004|Overall Study|Jeopardizing Parole Status|0
6090785|NCT00694707|9703059|FG000|Overall Study|Death in the Family|1
6090786|NCT00694707|9703060|FG001|Overall Study|Death in the Family|0
6090787|NCT00694707|9703061|FG002|Overall Study|Death in the Family|0
6090788|NCT00694707|9703062|FG003|Overall Study|Death in the Family|0
6090789|NCT00694707|9703063|FG004|Overall Study|Death in the Family|0
6090790|NCT00694707|9703059|FG000|Overall Study|Arrest by Police|0
6090791|NCT00694707|9703060|FG001|Overall Study|Arrest by Police|1
6090792|NCT00694707|9703061|FG002|Overall Study|Arrest by Police|0
6090793|NCT00694707|9703062|FG003|Overall Study|Arrest by Police|0
6090794|NCT00694707|9703063|FG004|Overall Study|Arrest by Police|0
6090795|NCT00694707|9703059|FG000|Overall Study|Administrative Reasons|0
6090796|NCT00694707|9703060|FG001|Overall Study|Administrative Reasons|1
6090797|NCT00694707|9703061|FG002|Overall Study|Administrative Reasons|0
6202280|NCT01500200|9862416|FG001|Stage 1|Withdrawal by Subject|0
6202281|NCT01500200|9862417|FG002|Stage 1|Withdrawal by Subject|0
6202282|NCT01500200|9862418|FG003|Stage 1|Withdrawal by Subject|0
6202283|NCT01500200|9862419|FG004|Stage 1|Withdrawal by Subject|0
6202284|NCT01500200|9862420|FG005|Stage 1|Withdrawal by Subject|0
6202285|NCT01500200|9862415|FG000|Stage 1|Noncompliance with Study Drug|1
6202286|NCT01500200|9862416|FG001|Stage 1|Noncompliance with Study Drug|0
6202287|NCT01500200|9862417|FG002|Stage 1|Noncompliance with Study Drug|0
6202288|NCT01500200|9862418|FG003|Stage 1|Noncompliance with Study Drug|0
6202289|NCT01500200|9862419|FG004|Stage 1|Noncompliance with Study Drug|0
6202290|NCT01500200|9862420|FG005|Stage 1|Noncompliance with Study Drug|0
6055385|NCT00454649|9655227|FG009|Overall Study|Other|1
6055386|NCT00454649|9655218|FG000|Overall Study|Withdrawal by Subject|0
6055387|NCT00454649|9655219|FG001|Overall Study|Withdrawal by Subject|0
6055388|NCT00454649|9655220|FG002|Overall Study|Withdrawal by Subject|0
6055389|NCT00454649|9655221|FG003|Overall Study|Withdrawal by Subject|0
6055390|NCT00454649|9655222|FG004|Overall Study|Withdrawal by Subject|0
6055391|NCT00454649|9655223|FG005|Overall Study|Withdrawal by Subject|1
6055392|NCT00454649|9655224|FG006|Overall Study|Withdrawal by Subject|0
6055393|NCT00454649|9655225|FG007|Overall Study|Withdrawal by Subject|2
6055394|NCT00454649|9655226|FG008|Overall Study|Withdrawal by Subject|1
6090798|NCT00694707|9703062|FG003|Overall Study|Administrative Reasons|2
6090799|NCT00694707|9703063|FG004|Overall Study|Administrative Reasons|0
6090800|NCT00694707|9703059|FG000|Overall Study|Notification of Past Head Injury|0
6202291|NCT01500200|9862415|FG000|Stage 1|Physician Decision|1
6202292|NCT01500200|9862416|FG001|Stage 1|Physician Decision|0
6202293|NCT01500200|9862417|FG002|Stage 1|Physician Decision|0
6202294|NCT01500200|9862418|FG003|Stage 1|Physician Decision|0
6055395|NCT00454649|9655227|FG009|Overall Study|Withdrawal by Subject|0
6055396|NCT00454779|9655270|FG000|First-line Treatment Phase|Lack of Efficacy|0
6055397|NCT00454779|9655271|FG001|First-line Treatment Phase|Lack of Efficacy|2
6055398|NCT00454779|9655270|FG000|First-line Treatment Phase|Withdrawal by Subject|2
6055399|NCT00454779|9655271|FG001|First-line Treatment Phase|Withdrawal by Subject|4
6055400|NCT00454779|9655270|FG000|First-line Treatment Phase|Lost to Follow-up|1
6055401|NCT00454779|9655271|FG001|First-line Treatment Phase|Lost to Follow-up|0
6055402|NCT00454779|9655270|FG000|First-line Treatment Phase|Protocol Violation|0
6055403|NCT00454779|9655271|FG001|First-line Treatment Phase|Protocol Violation|1
6055404|NCT00454779|9655270|FG000|First-line Treatment Phase|Ended follow-up prior to analysis|1
6055405|NCT00454779|9655271|FG001|First-line Treatment Phase|Ended follow-up prior to analysis|1
6055406|NCT00454779|9655270|FG000|First-line Treatment Phase|Ongoing|1
6055407|NCT00454779|9655271|FG001|First-line Treatment Phase|Ongoing|0
6055408|NCT00454779|9655270|FG000|Second-line Treatment Phase|Withdrawal by Subject|0
6055409|NCT00454779|9655271|FG001|Second-line Treatment Phase|Withdrawal by Subject|1
6055410|NCT00454779|9655270|FG000|Second-line Treatment Phase|Ended follow-up prior to analysis|0
6055411|NCT00454779|9655271|FG001|Second-line Treatment Phase|Ended follow-up prior to analysis|1
6055412|NCT00454779|9655270|FG000|Second-line Treatment Phase|Ongoing|0
6055413|NCT00454779|9655271|FG001|Second-line Treatment Phase|Ongoing|1
6055414|NCT00454805|9655279|FG000|Overall Study|Withdrawal by Subject|9
6055415|NCT00454805|9655280|FG001|Overall Study|Withdrawal by Subject|2
6055416|NCT00454805|9655279|FG000|Overall Study|Death|0
6055417|NCT00454805|9655280|FG001|Overall Study|Death|2
6055418|NCT00454805|9655279|FG000|Overall Study|Disease progression|16
6055419|NCT00454805|9655280|FG001|Overall Study|Disease progression|19
6055420|NCT00454805|9655279|FG000|Overall Study|In order to begin radiotherapy|1
6055421|NCT00454805|9655280|FG001|Overall Study|In order to begin radiotherapy|0
6055422|NCT00454818|9655294|FG000|Phase I: Open-label Dose-escalation|Received heart transplant|1
6055423|NCT00454818|9655295|FG001|Phase I: Open-label Dose-escalation|Received heart transplant|0
6055424|NCT00454818|9655296|FG002|Phase I: Open-label Dose-escalation|Received heart transplant|0
6055425|NCT00454818|9655297|FG003|Phase I: Open-label Dose-escalation|Received heart transplant|0
6055426|NCT00454818|9655298|FG004|Phase I: Open-label Dose-escalation|Received heart transplant|0
6055427|NCT00454818|9655294|FG000|Phase I: Open-label Dose-escalation|Death|0
6055428|NCT00454818|9655295|FG001|Phase I: Open-label Dose-escalation|Death|1
6055429|NCT00454818|9655296|FG002|Phase I: Open-label Dose-escalation|Death|0
6055430|NCT00454818|9655297|FG003|Phase I: Open-label Dose-escalation|Death|0
6055431|NCT00454818|9655298|FG004|Phase I: Open-label Dose-escalation|Death|0
6055432|NCT00454818|9655294|FG000|Phase I: Open-label Dose-escalation|Received left ventricular assist device|0
6055433|NCT00454818|9655295|FG001|Phase I: Open-label Dose-escalation|Received left ventricular assist device|0
6055434|NCT00454818|9655296|FG002|Phase I: Open-label Dose-escalation|Received left ventricular assist device|1
6055435|NCT00454818|9655297|FG003|Phase I: Open-label Dose-escalation|Received left ventricular assist device|1
6055436|NCT00454818|9655298|FG004|Phase I: Open-label Dose-escalation|Received left ventricular assist device|0
6055437|NCT00454818|9655294|FG000|Phase 2: Randomized Double-blind|Received milrinone or dobutamine|0
6055438|NCT00454818|9655295|FG001|Phase 2: Randomized Double-blind|Received milrinone or dobutamine|1
6055439|NCT00454818|9655296|FG002|Phase 2: Randomized Double-blind|Received milrinone or dobutamine|0
6055440|NCT00454818|9655297|FG003|Phase 2: Randomized Double-blind|Received milrinone or dobutamine|1
6055441|NCT00454818|9655298|FG004|Phase 2: Randomized Double-blind|Received milrinone or dobutamine|0
6055442|NCT00454818|9655294|FG000|Phase 2: Randomized Double-blind|Death|0
6055443|NCT00454818|9655295|FG001|Phase 2: Randomized Double-blind|Death|1
6055444|NCT00454818|9655296|FG002|Phase 2: Randomized Double-blind|Death|0
6055445|NCT00454818|9655297|FG003|Phase 2: Randomized Double-blind|Death|0
6055446|NCT00454818|9655298|FG004|Phase 2: Randomized Double-blind|Death|1
6055447|NCT00454818|9655294|FG000|Phase 2: Randomized Double-blind|Received a heart transplant|0
6055448|NCT00454818|9655295|FG001|Phase 2: Randomized Double-blind|Received a heart transplant|0
6055449|NCT00454818|9655296|FG002|Phase 2: Randomized Double-blind|Received a heart transplant|2
6055450|NCT00454818|9655297|FG003|Phase 2: Randomized Double-blind|Received a heart transplant|0
6055451|NCT00454818|9655298|FG004|Phase 2: Randomized Double-blind|Received a heart transplant|1
6055452|NCT00454818|9655294|FG000|Phase 2: Randomized Double-blind|Received left ventricular assist device|0
6055453|NCT00454818|9655295|FG001|Phase 2: Randomized Double-blind|Received left ventricular assist device|0
6055454|NCT00454818|9655296|FG002|Phase 2: Randomized Double-blind|Received left ventricular assist device|1
6055455|NCT00454818|9655297|FG003|Phase 2: Randomized Double-blind|Received left ventricular assist device|0
6055456|NCT00454818|9655298|FG004|Phase 2: Randomized Double-blind|Received left ventricular assist device|2
6055457|NCT00454857|9655315|FG000|Overall Study|Withdrawal by Subject|15
6055458|NCT00454857|9655315|FG000|Overall Study|Lost to Follow-up|16
6055459|NCT00454857|9655315|FG000|Overall Study|Noncompliance|6
6055460|NCT00454857|9655315|FG000|Overall Study|Death|5
6055461|NCT00454857|9655315|FG000|Overall Study|Other|11
6055462|NCT00454857|9655315|FG000|Overall Study|Reason unknown|1
6055463|NCT00454909|9655322|FG000|Overall Study|Withdrawal by Subject|1
6055464|NCT00454909|9655323|FG001|Overall Study|Withdrawal by Subject|0
6055465|NCT00454909|9655324|FG002|Overall Study|Withdrawal by Subject|0
6055466|NCT00454909|9655322|FG000|Overall Study|Migrated/moved from study area|0
6055467|NCT00454909|9655323|FG001|Overall Study|Migrated/moved from study area|0
6055468|NCT00454909|9655324|FG002|Overall Study|Migrated/moved from study area|1
6055469|NCT00454909|9655322|FG000|Overall Study|Lost to follow-up (complete vaccination)|5
6055470|NCT00454909|9655323|FG001|Overall Study|Lost to follow-up (complete vaccination)|3
6055471|NCT00454909|9655324|FG002|Overall Study|Lost to follow-up (complete vaccination)|1
6055472|NCT00454909|9655322|FG000|Overall Study|Others|1
6055473|NCT00454909|9655323|FG001|Overall Study|Others|0
6055474|NCT00454909|9655324|FG002|Overall Study|Others|0
6055475|NCT00454987|9655336|FG000|Booster Period (NCT00258700)|Adverse Event|1
6055476|NCT00454987|9655337|FG001|Booster Period (NCT00258700)|Adverse Event|0
6055477|NCT00454987|9655338|FG002|Booster Period (NCT00258700)|Adverse Event|0
6055478|NCT00454987|9655336|FG000|Booster Period (NCT00258700)|Withdrawal by Subject|0
6055479|NCT00454987|9655337|FG001|Booster Period (NCT00258700)|Withdrawal by Subject|1
6055480|NCT00454987|9655338|FG002|Booster Period (NCT00258700)|Withdrawal by Subject|0
6055481|NCT00454987|9655336|FG000|Booster Period (NCT00258700)|Lost to Follow-up|1
6055482|NCT00454987|9655337|FG001|Booster Period (NCT00258700)|Lost to Follow-up|0
6055483|NCT00454987|9655338|FG002|Booster Period (NCT00258700)|Lost to Follow-up|0
6055484|NCT00455013|9655350|FG000|Short Term Period|Adverse Event|2
6055485|NCT00455013|9655351|FG001|Short Term Period|Adverse Event|5
6055486|NCT00455013|9655352|FG002|Short Term Period|Adverse Event|0
6055487|NCT00455013|9655350|FG000|Short Term Period|Withdrawal by Subject|0
6055488|NCT00455013|9655351|FG001|Short Term Period|Withdrawal by Subject|0
6055489|NCT00455013|9655352|FG002|Short Term Period|Withdrawal by Subject|1
6055490|NCT00455013|9655350|FG000|Short Term Period|Lack of Efficacy|4
6055491|NCT00455013|9655351|FG001|Short Term Period|Lack of Efficacy|0
6055492|NCT00455013|9655352|FG002|Short Term Period|Lack of Efficacy|0
6055493|NCT00455013|9655350|FG000|Short Term Period|Other|0
6055494|NCT00455013|9655351|FG001|Short Term Period|Other|0
6055495|NCT00455013|9655352|FG002|Short Term Period|Other|1
6055496|NCT00455013|9655350|FG000|Long Term Extension (LTE)|Adverse Event|0
6055497|NCT00455013|9655351|FG001|Long Term Extension (LTE)|Adverse Event|1
6055498|NCT00455013|9655352|FG002|Long Term Extension (LTE)|Adverse Event|1
6055499|NCT00455013|9655350|FG000|Long Term Extension (LTE)|Withdrawal by Subject|1
6055500|NCT00455013|9655351|FG001|Long Term Extension (LTE)|Withdrawal by Subject|0
6055501|NCT00455013|9655352|FG002|Long Term Extension (LTE)|Withdrawal by Subject|1
6055502|NCT00455013|9655350|FG000|Long Term Extension (LTE)|Death|1
6055503|NCT00455013|9655351|FG001|Long Term Extension (LTE)|Death|1
6055504|NCT00455013|9655352|FG002|Long Term Extension (LTE)|Death|0
6055505|NCT00455013|9655350|FG000|Long Term Extension (LTE)|No longer met criteria|0
6055506|NCT00455013|9655351|FG001|Long Term Extension (LTE)|No longer met criteria|0
6055507|NCT00455013|9655352|FG002|Long Term Extension (LTE)|No longer met criteria|1
6055508|NCT00455013|9655350|FG000|Long Term Extension (LTE)|Subject Request or refused|0
6055509|NCT00455013|9655351|FG001|Long Term Extension (LTE)|Subject Request or refused|0
6055510|NCT00455013|9655352|FG002|Long Term Extension (LTE)|Subject Request or refused|3
6055511|NCT00455013|9655350|FG000|Long Term Extension (LTE)|Poor non-compliance|0
6055512|NCT00455013|9655351|FG001|Long Term Extension (LTE)|Poor non-compliance|1
6055513|NCT00455013|9655352|FG002|Long Term Extension (LTE)|Poor non-compliance|0
6055514|NCT00455013|9655350|FG000|Long Term Extension (LTE)|non-specified|0
6055515|NCT00455013|9655351|FG001|Long Term Extension (LTE)|non-specified|0
6055516|NCT00455013|9655352|FG002|Long Term Extension (LTE)|non-specified|1
6055517|NCT00455195|9655362|FG000|Double-blind Study AGLU02704|Adverse Event|2
6055518|NCT00455195|9655363|FG001|Double-blind Study AGLU02704|Adverse Event|1
6055519|NCT00455195|9655362|FG000|Double-blind Study AGLU02704|Death|1
6055520|NCT00455195|9655363|FG001|Double-blind Study AGLU02704|Death|0
6055521|NCT00455195|9655362|FG000|Double-blind Study AGLU02704|Withdrawal by Subject|2
6055522|NCT00455195|9655363|FG001|Double-blind Study AGLU02704|Withdrawal by Subject|2
6055523|NCT00455195|9655362|FG000|Double-blind Study AGLU02704|Unable to commit time to study|0
6055524|NCT00455195|9655363|FG001|Double-blind Study AGLU02704|Unable to commit time to study|1
6055525|NCT00455312|9655371|FG000|Overall Study|Death|0
6055526|NCT00455312|9655372|FG001|Overall Study|Death|1
6055527|NCT00455429|9655382|FG000|Overall Study|Study Terminated by Sponsor|0
6055528|NCT00455429|9655383|FG001|Overall Study|Study Terminated by Sponsor|0
6055529|NCT00455429|9655384|FG002|Overall Study|Study Terminated by Sponsor|0
6055530|NCT00455429|9655385|FG003|Overall Study|Study Terminated by Sponsor|3
6055531|NCT00455429|9655382|FG000|Overall Study|Lost to Follow-up|1
6055532|NCT00455429|9655383|FG001|Overall Study|Lost to Follow-up|0
6055533|NCT00455429|9655384|FG002|Overall Study|Lost to Follow-up|0
6055534|NCT00455429|9655385|FG003|Overall Study|Lost to Follow-up|3
6055535|NCT00455429|9655382|FG000|Overall Study|Withdrawal by Subject|0
6055536|NCT00455429|9655383|FG001|Overall Study|Withdrawal by Subject|1
6055537|NCT00455429|9655384|FG002|Overall Study|Withdrawal by Subject|1
6055538|NCT00455429|9655385|FG003|Overall Study|Withdrawal by Subject|0
6055539|NCT00455429|9655382|FG000|Overall Study|Lack of Efficacy|0
6055540|NCT00455429|9655383|FG001|Overall Study|Lack of Efficacy|1
6055541|NCT00455429|9655384|FG002|Overall Study|Lack of Efficacy|0
6055542|NCT00455429|9655385|FG003|Overall Study|Lack of Efficacy|1
6055543|NCT00455429|9655382|FG000|Overall Study|Adverse Event|0
6055544|NCT00455429|9655383|FG001|Overall Study|Adverse Event|1
6055545|NCT00455429|9655384|FG002|Overall Study|Adverse Event|0
6055546|NCT00455429|9655385|FG003|Overall Study|Adverse Event|3
6055547|NCT00455429|9655382|FG000|Overall Study|Randomly assigned but not treated|0
6055548|NCT00455429|9655383|FG001|Overall Study|Randomly assigned but not treated|0
6055549|NCT00455429|9655384|FG002|Overall Study|Randomly assigned but not treated|0
6055550|NCT00455429|9655385|FG003|Overall Study|Randomly assigned but not treated|2
6055551|NCT00455429|9655382|FG000|Overall Study|Personal Reason|1
6055552|NCT00455429|9655383|FG001|Overall Study|Personal Reason|0
6055553|NCT00455429|9655384|FG002|Overall Study|Personal Reason|0
6055554|NCT00455429|9655385|FG003|Overall Study|Personal Reason|0
6055555|NCT00455429|9655382|FG000|Overall Study|Non-compliance|0
6055556|NCT00455429|9655383|FG001|Overall Study|Non-compliance|0
6055557|NCT00455429|9655384|FG002|Overall Study|Non-compliance|0
6055558|NCT00455429|9655385|FG003|Overall Study|Non-compliance|1
6055559|NCT00455429|9655382|FG000|Overall Study|Other|0
6055560|NCT00455429|9655383|FG001|Overall Study|Other|2
6055561|NCT00455429|9655384|FG002|Overall Study|Other|0
6055562|NCT00455429|9655385|FG003|Overall Study|Other|1
6055563|NCT00455455|9655398|FG000|Washout|Withdrawal by Subject|0
6055564|NCT00455455|9655399|FG001|Washout|Withdrawal by Subject|1
6055565|NCT00455455|9655398|FG000|Washout|Withdrawal by Subject|1
6055566|NCT00455455|9655399|FG001|Washout|Withdrawal by Subject|0
6055567|NCT00455520|9655410|FG000|Open Label Tapentadol Extended Release|Withdrawal by Subject|24
6055568|NCT00455520|9655411|FG001|Open Label Tapentadol Extended Release|Withdrawal by Subject|0
6055569|NCT00455520|9655410|FG000|Open Label Tapentadol Extended Release|Lost to Follow-up|3
6055570|NCT00455520|9655411|FG001|Open Label Tapentadol Extended Release|Lost to Follow-up|0
6055571|NCT00455520|9655410|FG000|Open Label Tapentadol Extended Release|Adverse Event|100
6055572|NCT00455520|9655411|FG001|Open Label Tapentadol Extended Release|Adverse Event|0
6055573|NCT00455520|9655410|FG000|Open Label Tapentadol Extended Release|Lack of Efficacy|23
6055574|NCT00455520|9655411|FG001|Open Label Tapentadol Extended Release|Lack of Efficacy|0
6055575|NCT00455520|9655410|FG000|Open Label Tapentadol Extended Release|Study drug non-compliant|13
6055576|NCT00455520|9655411|FG001|Open Label Tapentadol Extended Release|Study drug non-compliant|0
6055577|NCT00455520|9655410|FG000|Open Label Tapentadol Extended Release|All other|33
6055578|NCT00455520|9655411|FG001|Open Label Tapentadol Extended Release|All other|0
6055579|NCT00455520|9655410|FG000|Double Blind Tapentadol ER vs Placebo|Adverse Event|29
6055580|NCT00455520|9655411|FG001|Double Blind Tapentadol ER vs Placebo|Adverse Event|15
6055581|NCT00455520|9655410|FG000|Double Blind Tapentadol ER vs Placebo|Lack of Efficacy|8
6055582|NCT00455520|9655411|FG001|Double Blind Tapentadol ER vs Placebo|Lack of Efficacy|29
6055583|NCT00455520|9655410|FG000|Double Blind Tapentadol ER vs Placebo|Withdrawal by Subject|15
6055584|NCT00455520|9655411|FG001|Double Blind Tapentadol ER vs Placebo|Withdrawal by Subject|7
6055585|NCT00455520|9655410|FG000|Double Blind Tapentadol ER vs Placebo|Lost to Follow-up|3
6055586|NCT00455520|9655411|FG001|Double Blind Tapentadol ER vs Placebo|Lost to Follow-up|3
6055587|NCT00455520|9655410|FG000|Double Blind Tapentadol ER vs Placebo|Study drug non compliant|4
6055588|NCT00455520|9655411|FG001|Double Blind Tapentadol ER vs Placebo|Study drug non compliant|2
6055589|NCT00455520|9655410|FG000|Double Blind Tapentadol ER vs Placebo|All other|4
6055590|NCT00455520|9655411|FG001|Double Blind Tapentadol ER vs Placebo|All other|6
6055591|NCT00455533|9655419|FG000|Period One: Initial Chemotherapy|Adverse Event Not Related to Study Drug|1
6055592|NCT00455533|9655420|FG001|Period One: Initial Chemotherapy|Adverse Event Not Related to Study Drug|0
6055593|NCT00455533|9655421|FG002|Period One: Initial Chemotherapy|Adverse Event Not Related to Study Drug|0
6055594|NCT00455533|9655419|FG000|Period One: Initial Chemotherapy|Disease Progression|5
6055595|NCT00455533|9655420|FG001|Period One: Initial Chemotherapy|Disease Progression|0
6055596|NCT00455533|9655421|FG002|Period One: Initial Chemotherapy|Disease Progression|0
6055597|NCT00455533|9655419|FG000|Period One: Initial Chemotherapy|Lost to Follow-up|2
6055598|NCT00455533|9655420|FG001|Period One: Initial Chemotherapy|Lost to Follow-up|0
6055599|NCT00455533|9655421|FG002|Period One: Initial Chemotherapy|Lost to Follow-up|0
6055600|NCT00455533|9655419|FG000|Period One: Initial Chemotherapy|Not Reported|1
6055601|NCT00455533|9655420|FG001|Period One: Initial Chemotherapy|Not Reported|0
6055602|NCT00455533|9655421|FG002|Period One: Initial Chemotherapy|Not Reported|0
6055603|NCT00455533|9655419|FG000|Period One: Initial Chemotherapy|Other--Need Reasons|2
6090801|NCT00694707|9703060|FG001|Overall Study|Notification of Past Head Injury|0
6090802|NCT00694707|9703061|FG002|Overall Study|Notification of Past Head Injury|0
6090803|NCT00694707|9703062|FG003|Overall Study|Notification of Past Head Injury|1
6090804|NCT00694707|9703063|FG004|Overall Study|Notification of Past Head Injury|0
6090805|NCT00695019|9703078|FG000|Overall Study|Withdrawal by Subject|8
6090806|NCT00695019|9703079|FG001|Overall Study|Withdrawal by Subject|6
6090807|NCT00695019|9703080|FG002|Overall Study|Withdrawal by Subject|4
6090808|NCT00695019|9703078|FG000|Overall Study|Protocol Violation|1
6090809|NCT00695019|9703079|FG001|Overall Study|Protocol Violation|3
6090810|NCT00695019|9703080|FG002|Overall Study|Protocol Violation|1
6090811|NCT00695019|9703078|FG000|Overall Study|Lack of Efficacy|0
6090812|NCT00695019|9703079|FG001|Overall Study|Lack of Efficacy|0
6090813|NCT00695019|9703080|FG002|Overall Study|Lack of Efficacy|1
6090814|NCT00695019|9703078|FG000|Overall Study|Various|4
6090815|NCT00695019|9703079|FG001|Overall Study|Various|5
6090816|NCT00695019|9703080|FG002|Overall Study|Various|4
6090817|NCT00695110|9703097|FG000|Treatment Period 1|Adverse Event|1
6090818|NCT00695110|9703097|FG000|Treatment Period 1|Withdrawal by Subject|2
6090819|NCT00695110|9703097|FG000|Treatment Period 3|Withdrawal by Subject|1
6055604|NCT00455533|9655420|FG001|Period One: Initial Chemotherapy|Other--Need Reasons|0
6055605|NCT00455533|9655421|FG002|Period One: Initial Chemotherapy|Other--Need Reasons|0
6090820|NCT00695110|9703097|FG000|Treatment Period 4|Adverse Event|1
6090821|NCT00695136|9703104|FG000|Overall Study|Withdrawal by Subject|1
6090822|NCT00695136|9703104|FG000|Overall Study|unrelated adverse event|1
6090823|NCT00695318|9703128|FG000|Overall Study|Lost to Follow-up|1
6090824|NCT00695318|9703129|FG001|Overall Study|Lost to Follow-up|0
6090825|NCT00695318|9703128|FG000|Overall Study|Withdrawal by Subject|2
6090826|NCT00695318|9703129|FG001|Overall Study|Withdrawal by Subject|0
6090827|NCT00695318|9703128|FG000|Overall Study|Death|1
6090828|NCT00695318|9703129|FG001|Overall Study|Death|1
6090829|NCT00695318|9703128|FG000|Overall Study|Study Terminated|1
6090830|NCT00695318|9703129|FG001|Overall Study|Study Terminated|0
6090831|NCT00695396|9703143|FG000|Overall Study|Study Closed Prematurely|5
6090832|NCT00695396|9703144|FG001|Overall Study|Study Closed Prematurely|6
6090833|NCT00695396|9703145|FG002|Overall Study|Study Closed Prematurely|8
6090834|NCT00695396|9703143|FG000|Overall Study|Withdrawal by Subject|2
6090835|NCT00695396|9703144|FG001|Overall Study|Withdrawal by Subject|2
6090836|NCT00695396|9703145|FG002|Overall Study|Withdrawal by Subject|0
6090837|NCT00695565|9703179|FG000|Overall Study|Lost to Follow-up|4
6090838|NCT00695565|9703180|FG001|Overall Study|Lost to Follow-up|4
6090839|NCT00695565|9703179|FG000|Overall Study|Adverse Event|3
6090840|NCT00695565|9703180|FG001|Overall Study|Adverse Event|1
6090841|NCT00695565|9703179|FG000|Overall Study|Protocol Violation|3
6090842|NCT00695565|9703180|FG001|Overall Study|Protocol Violation|1
6090843|NCT00695565|9703179|FG000|Overall Study|Withdrawal by Subject|1
6090844|NCT00695565|9703180|FG001|Overall Study|Withdrawal by Subject|1
6090845|NCT00695565|9703179|FG000|Overall Study|Lack of Efficacy|1
6090846|NCT00695565|9703180|FG001|Overall Study|Lack of Efficacy|1
6090847|NCT00695565|9703179|FG000|Overall Study|Subject did not follow instructions|1
6090848|NCT00695565|9703180|FG001|Overall Study|Subject did not follow instructions|1
6090849|NCT00695669|9703199|FG000|Overall Study|Adverse Event|0
6090850|NCT00695669|9703200|FG001|Overall Study|Adverse Event|0
6090851|NCT00695669|9703201|FG002|Overall Study|Adverse Event|2
6090852|NCT00695669|9703202|FG003|Overall Study|Adverse Event|0
6090853|NCT00695669|9703199|FG000|Overall Study|Lost to Follow-up|4
6090854|NCT00695669|9703200|FG001|Overall Study|Lost to Follow-up|4
6090855|NCT00695669|9703201|FG002|Overall Study|Lost to Follow-up|1
6090856|NCT00695669|9703202|FG003|Overall Study|Lost to Follow-up|4
6090857|NCT00695786|9703219|FG000|Overall Study|Adverse Event|0
6090858|NCT00695786|9703220|FG001|Overall Study|Adverse Event|3
6090859|NCT00695786|9703221|FG002|Overall Study|Adverse Event|4
6090860|NCT00695786|9703222|FG003|Overall Study|Adverse Event|2
6090861|NCT00695786|9703219|FG000|Overall Study|Lost to Follow-up|0
6090862|NCT00695786|9703220|FG001|Overall Study|Lost to Follow-up|5
6090863|NCT00695786|9703221|FG002|Overall Study|Lost to Follow-up|1
6090864|NCT00695786|9703222|FG003|Overall Study|Lost to Follow-up|1
6090865|NCT00695786|9703219|FG000|Overall Study|Withdrawal by Subject|0
6090866|NCT00695786|9703220|FG001|Overall Study|Withdrawal by Subject|4
6090867|NCT00695786|9703221|FG002|Overall Study|Withdrawal by Subject|3
6090868|NCT00695786|9703222|FG003|Overall Study|Withdrawal by Subject|1
6090869|NCT00695786|9703219|FG000|Overall Study|Deemed Ineligible|1
6090870|NCT00695786|9703220|FG001|Overall Study|Deemed Ineligible|0
6090871|NCT00695786|9703221|FG002|Overall Study|Deemed Ineligible|0
6090872|NCT00695786|9703222|FG003|Overall Study|Deemed Ineligible|0
6090873|NCT00695786|9703219|FG000|Overall Study|Lack of Efficacy|0
6090874|NCT00695786|9703220|FG001|Overall Study|Lack of Efficacy|0
6090875|NCT00695786|9703221|FG002|Overall Study|Lack of Efficacy|0
6090876|NCT00695786|9703222|FG003|Overall Study|Lack of Efficacy|4
6090877|NCT00695864|9703232|FG000|Placebo|Withdrawal by Subject|1
6090878|NCT00695864|9703232|FG000|Placebo|Physician Decision|4
6090879|NCT00695903|9703240|FG000|Had End of Therapy (EOT) Assessment|Randomized not treated|0
6090880|NCT00695903|9703241|FG001|Had End of Therapy (EOT) Assessment|Randomized not treated|2
6090881|NCT00695903|9703240|FG000|Had End of Therapy (EOT) Assessment|No confirmed MRSA|9
6090882|NCT00695903|9703241|FG001|Had End of Therapy (EOT) Assessment|No confirmed MRSA|9
6090883|NCT00695903|9703240|FG000|Had End of Therapy (EOT) Assessment|Adverse Event|1
6090884|NCT00695903|9703241|FG001|Had End of Therapy (EOT) Assessment|Adverse Event|0
6090885|NCT00695903|9703240|FG000|Had End of Therapy (EOT) Assessment|Withdrawal by Subject|1
6090886|NCT00695903|9703241|FG001|Had End of Therapy (EOT) Assessment|Withdrawal by Subject|1
6090887|NCT00695903|9703240|FG000|Had End of Therapy (EOT) Assessment|Physician Decision|0
6090888|NCT00695903|9703241|FG001|Had End of Therapy (EOT) Assessment|Physician Decision|1
6090889|NCT00695903|9703240|FG000|Had End of Therapy (EOT) Assessment|Protocol Violation|1
6090890|NCT00695903|9703241|FG001|Had End of Therapy (EOT) Assessment|Protocol Violation|2
6090891|NCT00695903|9703240|FG000|Had Test of Cure (TOC) Assessment|Lack of Efficacy|1
6090892|NCT00695903|9703241|FG001|Had Test of Cure (TOC) Assessment|Lack of Efficacy|0
6090893|NCT00695903|9703240|FG000|Had Test of Cure (TOC) Assessment|Lost to Follow-up|1
6090894|NCT00695903|9703241|FG001|Had Test of Cure (TOC) Assessment|Lost to Follow-up|0
6090895|NCT00695903|9703240|FG000|Had Test of Cure (TOC) Assessment|Adverse Event|0
6090896|NCT00695903|9703241|FG001|Had Test of Cure (TOC) Assessment|Adverse Event|1
6090897|NCT00695955|9703247|FG000|Cohort 1|Adverse Event|26
6090898|NCT00695955|9703247|FG000|Cohort 1|Protocol Violation|2
6090899|NCT00695955|9703247|FG000|Cohort 1|Lost to Follow-up|30
6055606|NCT00455533|9655419|FG000|Period One: Initial Chemotherapy|Study Drug Toxicity|2
6055607|NCT00455533|9655420|FG001|Period One: Initial Chemotherapy|Study Drug Toxicity|0
6055608|NCT00455533|9655421|FG002|Period One: Initial Chemotherapy|Study Drug Toxicity|0
6055609|NCT00455533|9655419|FG000|Period One: Initial Chemotherapy|Subject Request to Discontinue Study|1
6055610|NCT00455533|9655420|FG001|Period One: Initial Chemotherapy|Subject Request to Discontinue Study|0
6055611|NCT00455533|9655421|FG002|Period One: Initial Chemotherapy|Subject Request to Discontinue Study|0
6055612|NCT00455533|9655419|FG000|Period One: Initial Chemotherapy|Subject No Longer Meets Study Criteria|2
6055613|NCT00455533|9655420|FG001|Period One: Initial Chemotherapy|Subject No Longer Meets Study Criteria|0
6055614|NCT00455533|9655421|FG002|Period One: Initial Chemotherapy|Subject No Longer Meets Study Criteria|0
6055615|NCT00455533|9655419|FG000|Period One: Initial Chemotherapy|Subject Withdrew Consent|2
6055616|NCT00455533|9655420|FG001|Period One: Initial Chemotherapy|Subject Withdrew Consent|0
6055617|NCT00455533|9655421|FG002|Period One: Initial Chemotherapy|Subject Withdrew Consent|0
6055618|NCT00455533|9655419|FG000|Period Two: Randomized Period|Death|0
6055619|NCT00455533|9655420|FG001|Period Two: Randomized Period|Death|0
6055620|NCT00455533|9655421|FG002|Period Two: Randomized Period|Death|3
6055621|NCT00455533|9655419|FG000|Period Two: Randomized Period|Disease Progression|0
6055622|NCT00455533|9655420|FG001|Period Two: Randomized Period|Disease Progression|1
6055623|NCT00455533|9655421|FG002|Period Two: Randomized Period|Disease Progression|1
6055624|NCT00455533|9655419|FG000|Period Two: Randomized Period|Lost to Follow-up|0
6055625|NCT00455533|9655420|FG001|Period Two: Randomized Period|Lost to Follow-up|0
6055626|NCT00455533|9655421|FG002|Period Two: Randomized Period|Lost to Follow-up|1
6055627|NCT00455533|9655419|FG000|Period Two: Randomized Period|Other - need reasons|0
6090900|NCT00695955|9703247|FG000|Cohort 1|Withdrawal by Subject|25
6090901|NCT00695955|9703247|FG000|Cohort 1|Lack of Efficacy|3
6090902|NCT00695955|9703247|FG000|Cohort 1|Other|16
6090903|NCT00695955|9703247|FG000|Cohort 2|Adverse Event|24
6090904|NCT00695955|9703247|FG000|Cohort 2|Protocol Violation|5
6090905|NCT00695955|9703247|FG000|Cohort 2|Lost to Follow-up|38
6090906|NCT00695955|9703247|FG000|Cohort 2|Withdrawal by Subject|28
6090907|NCT00695955|9703247|FG000|Cohort 2|Lack of Efficacy|4
6090908|NCT00695955|9703247|FG000|Cohort 2|Other|5
6090909|NCT00696020|9703257|FG000|Overall Study|Adverse Event|3
6090910|NCT00696020|9703258|FG001|Overall Study|Adverse Event|1
6090911|NCT00696020|9703259|FG002|Overall Study|Adverse Event|2
6090912|NCT00696020|9703260|FG003|Overall Study|Adverse Event|1
6090913|NCT00696020|9703257|FG000|Overall Study|Lack of Efficacy|1
6090914|NCT00696020|9703258|FG001|Overall Study|Lack of Efficacy|0
6090915|NCT00696020|9703259|FG002|Overall Study|Lack of Efficacy|0
6090916|NCT00696020|9703260|FG003|Overall Study|Lack of Efficacy|0
6090917|NCT00696020|9703257|FG000|Overall Study|Protocol Violation|0
6090918|NCT00696020|9703258|FG001|Overall Study|Protocol Violation|0
6090919|NCT00696020|9703259|FG002|Overall Study|Protocol Violation|0
6090920|NCT00696020|9703260|FG003|Overall Study|Protocol Violation|1
6090921|NCT00696020|9703257|FG000|Overall Study|Withdrawal by Subject|0
6090922|NCT00696020|9703258|FG001|Overall Study|Withdrawal by Subject|1
6090923|NCT00696020|9703259|FG002|Overall Study|Withdrawal by Subject|0
6090924|NCT00696020|9703260|FG003|Overall Study|Withdrawal by Subject|1
6090925|NCT00696020|9703257|FG000|Overall Study|Other not stated above|0
6090926|NCT00696020|9703258|FG001|Overall Study|Other not stated above|0
6090927|NCT00696020|9703259|FG002|Overall Study|Other not stated above|1
6090928|NCT00696020|9703260|FG003|Overall Study|Other not stated above|1
6090929|NCT00696072|9703274|FG000|Overall Study|continuing active treatment|10
6090930|NCT00696072|9703275|FG001|Overall Study|continuing active treatment|13
6090931|NCT00696072|9703274|FG000|Overall Study|Adverse Event|10
6090932|NCT00696072|9703275|FG001|Overall Study|Adverse Event|6
6090933|NCT00696072|9703274|FG000|Overall Study|Patient Request|3
6090934|NCT00696072|9703275|FG001|Overall Study|Patient Request|7
6090935|NCT00696072|9703274|FG000|Overall Study|Investigator Request|1
6090936|NCT00696072|9703275|FG001|Overall Study|Investigator Request|4
6090937|NCT00696072|9703274|FG000|Overall Study|Sponsor Request|0
6090938|NCT00696072|9703275|FG001|Overall Study|Sponsor Request|1
6090939|NCT00696072|9703274|FG000|Overall Study|Disease Progression|32
6090940|NCT00696072|9703275|FG001|Overall Study|Disease Progression|30
6090941|NCT00696072|9703274|FG000|Overall Study|Non-specified|1
6090942|NCT00696072|9703275|FG001|Overall Study|Non-specified|2
6090943|NCT00696137|9703282|FG000|Overall Study|Withdrawal by Subject|2
6090944|NCT00696241|9703291|FG000|Overall Study|Adverse Event|11
6090945|NCT00696241|9703292|FG001|Overall Study|Adverse Event|3
6090946|NCT00696241|9703293|FG002|Overall Study|Adverse Event|6
6090947|NCT00696241|9703294|FG003|Overall Study|Adverse Event|4
6090948|NCT00696241|9703295|FG004|Overall Study|Adverse Event|5
6090949|NCT00696241|9703291|FG000|Overall Study|Protocol Violation|1
6090950|NCT00696241|9703292|FG001|Overall Study|Protocol Violation|1
6090951|NCT00696241|9703293|FG002|Overall Study|Protocol Violation|2
6090952|NCT00696241|9703294|FG003|Overall Study|Protocol Violation|0
6055628|NCT00455533|9655420|FG001|Period Two: Randomized Period|Other - need reasons|1
6090953|NCT00696241|9703295|FG004|Overall Study|Protocol Violation|3
6090954|NCT00696241|9703291|FG000|Overall Study|Lost to Follow-up|1
6090955|NCT00696241|9703292|FG001|Overall Study|Lost to Follow-up|4
6090956|NCT00696241|9703293|FG002|Overall Study|Lost to Follow-up|1
6090957|NCT00696241|9703294|FG003|Overall Study|Lost to Follow-up|2
6055629|NCT00455533|9655421|FG002|Period Two: Randomized Period|Other - need reasons|0
6055630|NCT00455533|9655419|FG000|Period Two: Randomized Period|Study Drug Toxicity|0
6055631|NCT00455533|9655420|FG001|Period Two: Randomized Period|Study Drug Toxicity|2
6055632|NCT00455533|9655421|FG002|Period Two: Randomized Period|Study Drug Toxicity|0
6055633|NCT00455533|9655419|FG000|Period Two: Randomized Period|Subject Withdrew Consent|0
6055634|NCT00455533|9655420|FG001|Period Two: Randomized Period|Subject Withdrew Consent|2
6055635|NCT00455533|9655421|FG002|Period Two: Randomized Period|Subject Withdrew Consent|1
6055636|NCT00455741|9655484|FG000|Overall Study|Physician Decision|0
6055637|NCT00455741|9655485|FG001|Overall Study|Physician Decision|1
6055638|NCT00455858|9655501|FG000|Overall Study|Lost to Follow-up|2
6055639|NCT00455858|9655501|FG000|Overall Study|Protocol Violation|1
6055640|NCT00455858|9655501|FG000|Overall Study|Lack of Efficacy|1
6055641|NCT00455858|9655501|FG000|Overall Study|Well controlled FPG without insulin|1
6055642|NCT00455858|9655501|FG000|Overall Study|Withdrawal|1
6055643|NCT00455923|9655507|FG000|Overall Study|Pregnancy|0
6055644|NCT00455923|9655508|FG001|Overall Study|Pregnancy|2
6055645|NCT00455923|9655507|FG000|Overall Study|Other|3
6055646|NCT00455923|9655508|FG001|Overall Study|Other|1
6055647|NCT00456092|9655541|FG000|Extension Phase|Grade 2 or Greater AE|2
6055648|NCT00456092|9655542|FG001|Extension Phase|Grade 2 or Greater AE|2
6055649|NCT00456092|9655543|FG002|Extension Phase|Grade 2 or Greater AE|0
6055650|NCT00456092|9655544|FG003|Extension Phase|Grade 2 or Greater AE|0
6055651|NCT00456092|9655545|FG004|Extension Phase|Grade 2 or Greater AE|2
6055652|NCT00456092|9655541|FG000|Extension Phase|Flare of Psoriatic Arthritis|1
6055653|NCT00456092|9655542|FG001|Extension Phase|Flare of Psoriatic Arthritis|0
6055654|NCT00456092|9655543|FG002|Extension Phase|Flare of Psoriatic Arthritis|0
6055655|NCT00456092|9655544|FG003|Extension Phase|Flare of Psoriatic Arthritis|0
6055656|NCT00456092|9655545|FG004|Extension Phase|Flare of Psoriatic Arthritis|1
6055657|NCT00456092|9655541|FG000|Extension Phase|Worsening / Not Responding to Study Drug|3
6055658|NCT00456092|9655542|FG001|Extension Phase|Worsening / Not Responding to Study Drug|1
6055659|NCT00456092|9655543|FG002|Extension Phase|Worsening / Not Responding to Study Drug|0
6055660|NCT00456092|9655544|FG003|Extension Phase|Worsening / Not Responding to Study Drug|0
6055661|NCT00456092|9655545|FG004|Extension Phase|Worsening / Not Responding to Study Drug|2
6055662|NCT00456092|9655541|FG000|Extension Phase|Withdrew Consent|2
6055663|NCT00456092|9655542|FG001|Extension Phase|Withdrew Consent|0
6055664|NCT00456092|9655543|FG002|Extension Phase|Withdrew Consent|0
6055665|NCT00456092|9655544|FG003|Extension Phase|Withdrew Consent|0
6055666|NCT00456092|9655545|FG004|Extension Phase|Withdrew Consent|0
6055667|NCT00456092|9655541|FG000|Extension Phase|Lost to Follow-up|1
6055668|NCT00456092|9655542|FG001|Extension Phase|Lost to Follow-up|1
6055669|NCT00456092|9655543|FG002|Extension Phase|Lost to Follow-up|0
6055670|NCT00456092|9655544|FG003|Extension Phase|Lost to Follow-up|0
6055671|NCT00456092|9655545|FG004|Extension Phase|Lost to Follow-up|1
6055672|NCT00456092|9655541|FG000|Extension Phase|Other|2
6055673|NCT00456092|9655542|FG001|Extension Phase|Other|0
6055674|NCT00456092|9655543|FG002|Extension Phase|Other|0
6055675|NCT00456092|9655544|FG003|Extension Phase|Other|1
6055676|NCT00456092|9655545|FG004|Extension Phase|Other|1
6055677|NCT00456092|9655541|FG000|Treatment Phase (12 Weeks)|Grade 2 or Greater Adverse Event (AE)|3
6055678|NCT00456092|9655542|FG001|Treatment Phase (12 Weeks)|Grade 2 or Greater Adverse Event (AE)|4
6055679|NCT00456092|9655543|FG002|Treatment Phase (12 Weeks)|Grade 2 or Greater Adverse Event (AE)|2
6055680|NCT00456092|9655544|FG003|Treatment Phase (12 Weeks)|Grade 2 or Greater Adverse Event (AE)|0
6055681|NCT00456092|9655545|FG004|Treatment Phase (12 Weeks)|Grade 2 or Greater Adverse Event (AE)|0
6055682|NCT00456092|9655541|FG000|Treatment Phase (12 Weeks)|AEs not Included in NCI Terminology|1
6055683|NCT00456092|9655542|FG001|Treatment Phase (12 Weeks)|AEs not Included in NCI Terminology|2
6055684|NCT00456092|9655543|FG002|Treatment Phase (12 Weeks)|AEs not Included in NCI Terminology|0
6055685|NCT00456092|9655544|FG003|Treatment Phase (12 Weeks)|AEs not Included in NCI Terminology|0
6055686|NCT00456092|9655545|FG004|Treatment Phase (12 Weeks)|AEs not Included in NCI Terminology|0
6055687|NCT00456092|9655541|FG000|Treatment Phase (12 Weeks)|Intolerability of the Study Drug|2
6055688|NCT00456092|9655542|FG001|Treatment Phase (12 Weeks)|Intolerability of the Study Drug|0
6055689|NCT00456092|9655543|FG002|Treatment Phase (12 Weeks)|Intolerability of the Study Drug|0
6055690|NCT00456092|9655544|FG003|Treatment Phase (12 Weeks)|Intolerability of the Study Drug|0
6055691|NCT00456092|9655545|FG004|Treatment Phase (12 Weeks)|Intolerability of the Study Drug|0
6055692|NCT00456092|9655541|FG000|Treatment Phase (12 Weeks)|Flare of Psoriasis|0
6055693|NCT00456092|9655542|FG001|Treatment Phase (12 Weeks)|Flare of Psoriasis|1
6055694|NCT00456092|9655543|FG002|Treatment Phase (12 Weeks)|Flare of Psoriasis|2
6055695|NCT00456092|9655544|FG003|Treatment Phase (12 Weeks)|Flare of Psoriasis|0
6055696|NCT00456092|9655545|FG004|Treatment Phase (12 Weeks)|Flare of Psoriasis|0
6055697|NCT00456092|9655541|FG000|Treatment Phase (12 Weeks)|Flare of Psoriatic Arthritis|0
6055698|NCT00456092|9655542|FG001|Treatment Phase (12 Weeks)|Flare of Psoriatic Arthritis|3
6055699|NCT00456092|9655543|FG002|Treatment Phase (12 Weeks)|Flare of Psoriatic Arthritis|3
6055700|NCT00456092|9655544|FG003|Treatment Phase (12 Weeks)|Flare of Psoriatic Arthritis|0
6055701|NCT00456092|9655545|FG004|Treatment Phase (12 Weeks)|Flare of Psoriatic Arthritis|0
6055702|NCT00456092|9655541|FG000|Treatment Phase (12 Weeks)|Worsening / Not Responding to Study Drug|0
6055703|NCT00456092|9655542|FG001|Treatment Phase (12 Weeks)|Worsening / Not Responding to Study Drug|2
6055704|NCT00456092|9655543|FG002|Treatment Phase (12 Weeks)|Worsening / Not Responding to Study Drug|7
6055705|NCT00456092|9655544|FG003|Treatment Phase (12 Weeks)|Worsening / Not Responding to Study Drug|0
6055706|NCT00456092|9655545|FG004|Treatment Phase (12 Weeks)|Worsening / Not Responding to Study Drug|0
6055707|NCT00456092|9655541|FG000|Treatment Phase (12 Weeks)|Withdrew Consent|0
6055708|NCT00456092|9655542|FG001|Treatment Phase (12 Weeks)|Withdrew Consent|1
6055709|NCT00456092|9655543|FG002|Treatment Phase (12 Weeks)|Withdrew Consent|2
6055710|NCT00456092|9655544|FG003|Treatment Phase (12 Weeks)|Withdrew Consent|0
6055711|NCT00456092|9655545|FG004|Treatment Phase (12 Weeks)|Withdrew Consent|0
6055712|NCT00456092|9655541|FG000|Treatment Phase (12 Weeks)|Lost to Follow-up|0
6055713|NCT00456092|9655542|FG001|Treatment Phase (12 Weeks)|Lost to Follow-up|1
6055714|NCT00456092|9655543|FG002|Treatment Phase (12 Weeks)|Lost to Follow-up|1
6055715|NCT00456092|9655544|FG003|Treatment Phase (12 Weeks)|Lost to Follow-up|0
6055716|NCT00456092|9655545|FG004|Treatment Phase (12 Weeks)|Lost to Follow-up|0
6055717|NCT00456092|9655541|FG000|Treatment Phase (12 Weeks)|Other|1
6055718|NCT00456092|9655542|FG001|Treatment Phase (12 Weeks)|Other|0
6055719|NCT00456092|9655543|FG002|Treatment Phase (12 Weeks)|Other|1
6055720|NCT00456092|9655544|FG003|Treatment Phase (12 Weeks)|Other|0
6055721|NCT00456092|9655545|FG004|Treatment Phase (12 Weeks)|Other|0
6055722|NCT00456300|9655559|FG000|Overall Study|Adverse Event|1
6055723|NCT00456300|9655560|FG001|Overall Study|Adverse Event|0
6055724|NCT00456365|9655570|FG000|Overall Study|Lost to Follow-up|1
6055725|NCT00456365|9655571|FG001|Overall Study|Lost to Follow-up|3
6055726|NCT00456365|9655570|FG000|Overall Study|Withdrawal by Subject|4
6055727|NCT00456365|9655571|FG001|Overall Study|Withdrawal by Subject|7
6055728|NCT00456365|9655570|FG000|Overall Study|Pregnancy|1
6055729|NCT00456365|9655571|FG001|Overall Study|Pregnancy|1
6055730|NCT00456365|9655570|FG000|Overall Study|oncologic diagnosis|1
6055731|NCT00456365|9655571|FG001|Overall Study|oncologic diagnosis|1
6055732|NCT00456495|9655579|FG000|Overall Study|Physician Decision|2
6055733|NCT00456521|9655590|FG000|Overall Study|Adverse Event|150
6055734|NCT00456521|9655591|FG001|Overall Study|Adverse Event|25
6055735|NCT00456521|9655590|FG000|Overall Study|Withdrawal by Subject|43
6055736|NCT00456521|9655591|FG001|Overall Study|Withdrawal by Subject|24
6055737|NCT00456521|9655590|FG000|Overall Study|Lost to Follow-up|22
6055738|NCT00456521|9655591|FG001|Overall Study|Lost to Follow-up|17
6055739|NCT00456521|9655590|FG000|Overall Study|Lack of Efficacy|3
6055740|NCT00456521|9655591|FG001|Overall Study|Lack of Efficacy|6
6055741|NCT00456521|9655590|FG000|Overall Study|Protocol Violation|4
6055742|NCT00456521|9655591|FG001|Overall Study|Protocol Violation|0
6055743|NCT00456521|9655590|FG000|Overall Study|Pregnancy|1
6055744|NCT00456521|9655591|FG001|Overall Study|Pregnancy|1
6055745|NCT00456521|9655590|FG000|Overall Study|Drug non-compliance, moved, other|26
6055746|NCT00456521|9655591|FG001|Overall Study|Drug non-compliance, moved, other|11
6055747|NCT00456599|9655607|FG000|Overall Study|Non-compliance|1
6055748|NCT00456599|9655607|FG000|Overall Study|Withdrawal by Subject|2
6055749|NCT00456755|9655617|FG000|Overall Study|Lost to Follow-up|2
6055750|NCT00456755|9655618|FG001|Overall Study|Lost to Follow-up|1
6055751|NCT00456846|9655635|FG000|Overall Study|Adverse Event|2
6055752|NCT00456846|9655636|FG001|Overall Study|Adverse Event|15
6055753|NCT00456846|9655635|FG000|Overall Study|Physician Decision|11
6055754|NCT00456846|9655636|FG001|Overall Study|Physician Decision|6
6055755|NCT00456846|9655635|FG000|Overall Study|Protocol Deviation|2
6055756|NCT00456846|9655636|FG001|Overall Study|Protocol Deviation|0
6055757|NCT00456846|9655635|FG000|Overall Study|Participant Discretion|1
6055758|NCT00456846|9655636|FG001|Overall Study|Participant Discretion|5
6055759|NCT00456846|9655635|FG000|Overall Study|Other|0
6055760|NCT00456846|9655636|FG001|Overall Study|Other|2
6055761|NCT00457002|9655650|FG000|Overall Study|Death|40
6055762|NCT00457002|9655651|FG001|Overall Study|Death|47
6055763|NCT00457002|9655650|FG000|Overall Study|Adverse Event|284
6055764|NCT00457002|9655651|FG001|Overall Study|Adverse Event|260
6055765|NCT00457002|9655650|FG000|Overall Study|Withdrawal by Subject|299
6055766|NCT00457002|9655651|FG001|Overall Study|Withdrawal by Subject|271
6055767|NCT00457002|9655650|FG000|Overall Study|Lost to Follow-up|72
6055768|NCT00457002|9655651|FG001|Overall Study|Lost to Follow-up|71
6055769|NCT00457002|9655650|FG000|Overall Study|Poor/Non-compliance|46
6055770|NCT00457002|9655651|FG001|Overall Study|Poor/Non-compliance|33
6055771|NCT00457002|9655650|FG000|Overall Study|No longer met criteria|41
6055772|NCT00457002|9655651|FG001|Overall Study|No longer met criteria|37
6055773|NCT00457002|9655650|FG000|Overall Study|Administrative reason by Sponsor|1
6055774|NCT00457002|9655651|FG001|Overall Study|Administrative reason by Sponsor|0
6055775|NCT00457002|9655650|FG000|Overall Study|non-specified|29
6055776|NCT00457002|9655651|FG001|Overall Study|non-specified|38
6055777|NCT00457002|9655650|FG000|Overall Study|treated for 1 day; missing status/reason|1
6055778|NCT00457002|9655651|FG001|Overall Study|treated for 1 day; missing status/reason|0
6055779|NCT00457015|9655659|FG000|Overall Study|Left study site against medical advice|0
6055780|NCT00457015|9655660|FG001|Overall Study|Left study site against medical advice|1
6055781|NCT00457249|9655677|FG000|Overall Study|Lost to Follow-up|3
6055782|NCT00457249|9655678|FG001|Overall Study|Lost to Follow-up|0
6055783|NCT00457249|9655677|FG000|Overall Study|Protocol Violation|4
6055784|NCT00457249|9655678|FG001|Overall Study|Protocol Violation|1
6055785|NCT00457249|9655677|FG000|Overall Study|Withdrawal by Subject|3
6055786|NCT00457249|9655678|FG001|Overall Study|Withdrawal by Subject|1
6055787|NCT00457249|9655677|FG000|Overall Study|Serious Adverse Events|2
6055788|NCT00457249|9655678|FG001|Overall Study|Serious Adverse Events|0
6055789|NCT00457301|9655688|FG000|Overall Study|Withdrawal by Subject|3
6055790|NCT00457301|9655689|FG001|Overall Study|Withdrawal by Subject|3
6055791|NCT00457301|9655688|FG000|Overall Study|Censored out of the study|15
6055792|NCT00457301|9655689|FG001|Overall Study|Censored out of the study|14
6055793|NCT00457301|9655688|FG000|Overall Study|Death|5
6055794|NCT00457301|9655689|FG001|Overall Study|Death|7
6055795|NCT00457392|9655706|FG000|Overall Study|Objective Progression or Relapse|229
6055796|NCT00457392|9655707|FG001|Overall Study|Objective Progression or Relapse|296
6055797|NCT00457392|9655706|FG000|Overall Study|Death|106
6055798|NCT00457392|9655707|FG001|Overall Study|Death|106
6055799|NCT00457392|9655706|FG000|Overall Study|Adverse Event|84
6055800|NCT00457392|9655707|FG001|Overall Study|Adverse Event|41
6055801|NCT00457392|9655706|FG000|Overall Study|Global Deterioration of Health Status|22
6055802|NCT00457392|9655707|FG001|Overall Study|Global Deterioration of Health Status|8
6055803|NCT00457392|9655706|FG000|Overall Study|Withdrawal by Subject|14
6055804|NCT00457392|9655707|FG001|Overall Study|Withdrawal by Subject|8
6055805|NCT00457392|9655706|FG000|Overall Study|Lost to Follow-up|6
6055806|NCT00457392|9655707|FG001|Overall Study|Lost to Follow-up|7
6055807|NCT00457392|9655706|FG000|Overall Study|Protocol Violation|4
6055808|NCT00457392|9655707|FG001|Overall Study|Protocol Violation|3
6055809|NCT00457392|9655706|FG000|Overall Study|Other|7
6055810|NCT00457392|9655707|FG001|Overall Study|Other|4
6090958|NCT00696241|9703295|FG004|Overall Study|Lost to Follow-up|0
6090959|NCT00696241|9703291|FG000|Overall Study|Withdrawal by Subject|4
6090960|NCT00696241|9703292|FG001|Overall Study|Withdrawal by Subject|8
6090961|NCT00696241|9703293|FG002|Overall Study|Withdrawal by Subject|6
6090962|NCT00696241|9703294|FG003|Overall Study|Withdrawal by Subject|1
6090963|NCT00696241|9703295|FG004|Overall Study|Withdrawal by Subject|0
6090964|NCT00696241|9703291|FG000|Overall Study|Lack of Efficacy|1
6090965|NCT00696241|9703292|FG001|Overall Study|Lack of Efficacy|5
6090966|NCT00696241|9703293|FG002|Overall Study|Lack of Efficacy|4
6090967|NCT00696241|9703294|FG003|Overall Study|Lack of Efficacy|5
6090968|NCT00696241|9703295|FG004|Overall Study|Lack of Efficacy|3
6090969|NCT00696241|9703291|FG000|Overall Study|Other|6
6090970|NCT00696241|9703292|FG001|Overall Study|Other|1
6090971|NCT00696241|9703293|FG002|Overall Study|Other|5
6090972|NCT00696241|9703294|FG003|Overall Study|Other|2
6090973|NCT00696241|9703295|FG004|Overall Study|Other|1
6090974|NCT00696384|9703312|FG000|Open Label Phase|Adverse Event|27
6090975|NCT00696384|9703313|FG001|Open Label Phase|Adverse Event|0
6090976|NCT00696384|9703314|FG002|Open Label Phase|Adverse Event|0
6090977|NCT00696384|9703312|FG000|Open Label Phase|Protocol Violation|18
6090978|NCT00696384|9703313|FG001|Open Label Phase|Protocol Violation|0
6090979|NCT00696384|9703314|FG002|Open Label Phase|Protocol Violation|0
6090980|NCT00696384|9703312|FG000|Open Label Phase|Lost to Follow-up|24
6090981|NCT00696384|9703313|FG001|Open Label Phase|Lost to Follow-up|0
6090982|NCT00696384|9703314|FG002|Open Label Phase|Lost to Follow-up|0
6090983|NCT00696384|9703312|FG000|Open Label Phase|Withdrawal by Subject|37
6090984|NCT00696384|9703313|FG001|Open Label Phase|Withdrawal by Subject|0
6090985|NCT00696384|9703314|FG002|Open Label Phase|Withdrawal by Subject|0
6090986|NCT00696384|9703312|FG000|Open Label Phase|Other|6
6090987|NCT00696384|9703313|FG001|Open Label Phase|Other|0
6090988|NCT00696384|9703314|FG002|Open Label Phase|Other|0
6090989|NCT00696384|9703312|FG000|Open Label Phase|Lack of Efficacy|3
6090990|NCT00696384|9703313|FG001|Open Label Phase|Lack of Efficacy|0
6090991|NCT00696384|9703314|FG002|Open Label Phase|Lack of Efficacy|0
6090992|NCT00696384|9703312|FG000|Open Label Phase|Physician Decision|4
6090993|NCT00696384|9703313|FG001|Open Label Phase|Physician Decision|0
6090994|NCT00696384|9703314|FG002|Open Label Phase|Physician Decision|0
6090995|NCT00696384|9703312|FG000|Double Blind Phase|Adverse Event|0
6090996|NCT00696384|9703313|FG001|Double Blind Phase|Adverse Event|2
6090997|NCT00696384|9703314|FG002|Double Blind Phase|Adverse Event|2
6090998|NCT00696384|9703312|FG000|Double Blind Phase|Lost to Follow-up|0
6090999|NCT00696384|9703313|FG001|Double Blind Phase|Lost to Follow-up|2
6091000|NCT00696384|9703314|FG002|Double Blind Phase|Lost to Follow-up|1
6091001|NCT00696384|9703312|FG000|Double Blind Phase|Withdrawal by Subject|0
6091002|NCT00696384|9703313|FG001|Double Blind Phase|Withdrawal by Subject|4
6091003|NCT00696384|9703314|FG002|Double Blind Phase|Withdrawal by Subject|3
6091004|NCT00696384|9703312|FG000|Double Blind Phase|Lack of Efficacy|0
6091005|NCT00696384|9703313|FG001|Double Blind Phase|Lack of Efficacy|1
6055811|NCT00457392|9655706|FG000|Overall Study|Study Terminated by Sponsor|1
6055812|NCT00457392|9655707|FG001|Overall Study|Study Terminated by Sponsor|4
6055813|NCT00457392|9655706|FG000|Overall Study|Randomized, Not Treated|7
6055814|NCT00457392|9655707|FG001|Overall Study|Randomized, Not Treated|3
6055815|NCT00457418|9655713|FG000|Pharmacokinetic (PK) Sampling Phase|Adverse Event|2
6091006|NCT00696384|9703314|FG002|Double Blind Phase|Lack of Efficacy|0
6091007|NCT00696384|9703312|FG000|Double Blind Phase|Physician Decision|0
6091008|NCT00696384|9703313|FG001|Double Blind Phase|Physician Decision|2
6091009|NCT00696384|9703314|FG002|Double Blind Phase|Physician Decision|0
6091010|NCT00696410|9703325|FG000|Overall Study|Lost to Follow-up|2
6091011|NCT00696410|9703326|FG001|Overall Study|Lost to Follow-up|0
6091012|NCT00696410|9703325|FG000|Overall Study|Withdrawal by Subject|8
6091013|NCT00696410|9703326|FG001|Overall Study|Withdrawal by Subject|0
6091014|NCT00696410|9703325|FG000|Overall Study|Physician Decision|3
6055816|NCT00457418|9655713|FG000|Pharmacokinetic (PK) Sampling Phase|Progression of Disease|1
6055817|NCT00457418|9655713|FG000|Pharmacokinetic (PK) Sampling Phase|Non-compliance with protocol|2
6055818|NCT00457418|9655713|FG000|Post PK Maintenance|Adverse Event|10
6055819|NCT00457418|9655713|FG000|Post PK Maintenance|Progression of Disease|6
6055820|NCT00457418|9655713|FG000|Post PK Maintenance|Withdrawal by Subject|11
6055821|NCT00457418|9655713|FG000|Post PK Maintenance|Lost to Follow-up|1
6055822|NCT00457626|9655717|FG000|Overall Study|Adverse Event|3
6055823|NCT00457626|9655717|FG000|Overall Study|Administrative Problems|2
6055824|NCT00457626|9655717|FG000|Overall Study|Participant's Condition No Longer Requires Study Drug|1
6055825|NCT00457639|9655721|FG000|Intervention 1 (6 Months)|Lost to Follow-up|3
6055826|NCT00457639|9655722|FG001|Intervention 1 (6 Months)|Lost to Follow-up|0
6055827|NCT00457639|9655721|FG000|Intervention 1 (6 Months)|unrelated illness|0
6055828|NCT00457639|9655722|FG001|Intervention 1 (6 Months)|unrelated illness|2
6055829|NCT00457639|9655721|FG000|Intervention 2 (6 Months)|Unrelated illness ineligible for MRS|0
6055830|NCT00457639|9655722|FG001|Intervention 2 (6 Months)|Unrelated illness ineligible for MRS|1
6055831|NCT00457665|9655730|FG000|12 Months|Drug allergy|1
6055832|NCT00457665|9655731|FG001|12 Months|Drug allergy|1
6055833|NCT00457665|9655730|FG000|12 Months|High HIV viral load|5
6055834|NCT00457665|9655731|FG001|12 Months|High HIV viral load|1
6055835|NCT00457665|9655730|FG000|12 Months|Lipodystrophy|2
6055836|NCT00457665|9655731|FG001|12 Months|Lipodystrophy|0
6055837|NCT00457665|9655730|FG000|12 Months|Withdrawal by Subject|0
6055838|NCT00457665|9655731|FG001|12 Months|Withdrawal by Subject|2
6055839|NCT00457665|9655730|FG000|12 Months|Abnormal Liver function tests|0
6055840|NCT00457665|9655731|FG001|12 Months|Abnormal Liver function tests|5
6055841|NCT00457665|9655730|FG000|24 Months|Withdrawal by Subject|3
6055842|NCT00457665|9655731|FG001|24 Months|Withdrawal by Subject|2
6055843|NCT00457665|9655730|FG000|24 Months|Lipodystrophy|1
6055844|NCT00457665|9655731|FG001|24 Months|Lipodystrophy|1
6055845|NCT00457665|9655730|FG000|24 Months|Abnormal liver function tests|1
6055846|NCT00457665|9655731|FG001|24 Months|Abnormal liver function tests|5
6055847|NCT00457691|9655739|FG000|Overall Study|Adverse Event|4
6055848|NCT00457691|9655740|FG001|Overall Study|Adverse Event|1
6055849|NCT00457691|9655739|FG000|Overall Study|Death|163
6055850|NCT00457691|9655740|FG001|Overall Study|Death|148
6055851|NCT00457691|9655739|FG000|Overall Study|Protocol Violation|1
6055852|NCT00457691|9655740|FG001|Overall Study|Protocol Violation|3
6055853|NCT00457691|9655739|FG000|Overall Study|Lost to Follow-up|23
6055854|NCT00457691|9655740|FG001|Overall Study|Lost to Follow-up|14
6055855|NCT00457691|9655739|FG000|Overall Study|Study terminated by Sponsor|1
6055856|NCT00457691|9655740|FG001|Overall Study|Study terminated by Sponsor|1
6055857|NCT00457691|9655739|FG000|Overall Study|Subject refused (reason other than AE)|14
6055858|NCT00457691|9655740|FG001|Overall Study|Subject refused (reason other than AE)|19
6055859|NCT00457691|9655739|FG000|Overall Study|Disease progression, study terminated|180
6055860|NCT00457691|9655740|FG001|Overall Study|Disease progression, study terminated|196
6055861|NCT00457743|9655762|FG000|Overall Study|Adverse Event|0
6055862|NCT00457743|9655763|FG001|Overall Study|Adverse Event|4
6055863|NCT00457743|9655764|FG002|Overall Study|Adverse Event|0
6055864|NCT00457743|9655762|FG000|Overall Study|Lack of Efficacy|3
6055865|NCT00457743|9655763|FG001|Overall Study|Lack of Efficacy|23
6055866|NCT00457743|9655764|FG002|Overall Study|Lack of Efficacy|3
6055867|NCT00457821|9655785|FG000|Part 2|Withdrawal by Subject|0
6055868|NCT00457821|9655786|FG001|Part 2|Withdrawal by Subject|0
6055869|NCT00457821|9655787|FG002|Part 2|Withdrawal by Subject|0
6055870|NCT00457821|9655788|FG003|Part 2|Withdrawal by Subject|0
6055871|NCT00457821|9655789|FG004|Part 2|Withdrawal by Subject|0
6055872|NCT00457821|9655790|FG005|Part 2|Withdrawal by Subject|0
6055873|NCT00457821|9655791|FG006|Part 2|Withdrawal by Subject|0
6055874|NCT00457821|9655792|FG007|Part 2|Withdrawal by Subject|1
6055875|NCT00458211|9655818|FG000|Overall Study|Lack of Efficacy|12
6055876|NCT00458211|9655818|FG000|Overall Study|Withdrawal by Subject|2
6055877|NCT00458211|9655818|FG000|Overall Study|Protocol Violation|2
6055878|NCT00458302|9655842|FG000|Overall Study|Adverse Event|4
6055879|NCT00458302|9655843|FG001|Overall Study|Adverse Event|14
6055880|NCT00458302|9655842|FG000|Overall Study|Pregnancy|2
6055881|NCT00458302|9655843|FG001|Overall Study|Pregnancy|1
6055882|NCT00458302|9655842|FG000|Overall Study|Protocol Violation|0
6055883|NCT00458302|9655843|FG001|Overall Study|Protocol Violation|2
6055884|NCT00458302|9655842|FG000|Overall Study|Withdrawal by Subject|6
6055885|NCT00458302|9655843|FG001|Overall Study|Withdrawal by Subject|4
6055886|NCT00458302|9655842|FG000|Overall Study|Inc/Exc Criteria Not Met|1
6055887|NCT00458302|9655843|FG001|Overall Study|Inc/Exc Criteria Not Met|1
6055888|NCT00458302|9655842|FG000|Overall Study|Study Termination By Sponsor|1
6055889|NCT00458302|9655843|FG001|Overall Study|Study Termination By Sponsor|0
6055890|NCT00458302|9655842|FG000|Overall Study|Lost to Follow-up|2
6055891|NCT00458302|9655843|FG001|Overall Study|Lost to Follow-up|0
6055892|NCT00458302|9655842|FG000|Overall Study|Other|4
6055893|NCT00458302|9655843|FG001|Overall Study|Other|2
6055894|NCT00458341|9655852|FG000|Cycle 1|Adverse Event|1
6055895|NCT00458341|9655853|FG001|Cycle 1|Adverse Event|0
6055896|NCT00458393|9655861|FG000|Overall Study|Withdrawal by Subject|67
6055897|NCT00458393|9655862|FG001|Overall Study|Withdrawal by Subject|80
6055898|NCT00458393|9655861|FG000|Overall Study|Physician Decision|31
6055899|NCT00458393|9655862|FG001|Overall Study|Physician Decision|22
6055900|NCT00458393|9655861|FG000|Overall Study|Relocated|77
6055901|NCT00458393|9655862|FG001|Overall Study|Relocated|81
6055902|NCT00458393|9655861|FG000|Overall Study|Lost to Follow-up|115
6055903|NCT00458393|9655862|FG001|Overall Study|Lost to Follow-up|92
6055904|NCT00458393|9655861|FG000|Overall Study|Sites marked other on the form.|19
6055905|NCT00458393|9655862|FG001|Overall Study|Sites marked other on the form.|20
6055906|NCT00458484|9655893|FG000|Overall Study|Not eligible b/c prior radiation history|0
6055907|NCT00458484|9655894|FG001|Overall Study|Not eligible b/c prior radiation history|0
6055908|NCT00458484|9655895|FG002|Overall Study|Not eligible b/c prior radiation history|0
6055909|NCT00458484|9655896|FG003|Overall Study|Not eligible b/c prior radiation history|0
6055910|NCT00458484|9655897|FG004|Overall Study|Not eligible b/c prior radiation history|0
6202295|NCT01500200|9862419|FG004|Stage 1|Physician Decision|0
6202296|NCT01500200|9862420|FG005|Stage 1|Physician Decision|0
6202297|NCT01500200|9862415|FG000|Stage 2|Adverse Event|0
6284227|NCT02326272|9996329|FG001|Initial Period (Week 0 to Week 16)|Missed two doses|0
6055911|NCT00458484|9655898|FG005|Overall Study|Not eligible b/c prior radiation history|1
6055912|NCT00458484|9655899|FG006|Overall Study|Not eligible b/c prior radiation history|0
6202298|NCT01500200|9862416|FG001|Stage 2|Adverse Event|0
6055913|NCT00458705|9655924|FG000|Overall Study|Adverse Event|4
6055914|NCT00458705|9655924|FG000|Overall Study|Not Treated|1
6055915|NCT00458783|9655930|FG000|Overall Study|Protocol Violation|1228
6055916|NCT00458783|9655931|FG001|Overall Study|Protocol Violation|1220
6055917|NCT00459043|9655954|FG000|Overall Study|Withdrawal by Subject|1
6055918|NCT00459043|9655955|FG001|Overall Study|Withdrawal by Subject|0
6055919|NCT00459056|9655963|FG000|First Intervention (First Three Months)|Lost to Follow-up|1
6055920|NCT00459056|9655964|FG001|First Intervention (First Three Months)|Lost to Follow-up|1
6055921|NCT00459108|9655970|FG000|Overall Study|Withdrawal by Subject|5
6055922|NCT00459108|9655970|FG000|Overall Study|Adverse Event|3
6055923|NCT00459108|9655970|FG000|Overall Study|Death|2
6055924|NCT00459108|9655970|FG000|Overall Study|Progression|1
6055925|NCT00459134|9655977|FG000|Overall Study|Physician Decision|1
6055926|NCT00459134|9655978|FG001|Overall Study|Physician Decision|1
6055927|NCT00459134|9655977|FG000|Overall Study|Withdrawal by Subject|8
6055928|NCT00459134|9655978|FG001|Overall Study|Withdrawal by Subject|7
6055929|NCT00459134|9655977|FG000|Overall Study|Lost to Follow-up|6
6055930|NCT00459134|9655978|FG001|Overall Study|Lost to Follow-up|7
6055931|NCT00459134|9655977|FG000|Overall Study|Surgery|1
6055932|NCT00459134|9655978|FG001|Overall Study|Surgery|2
6055933|NCT00459134|9655977|FG000|Overall Study|Toxicity|4
6055934|NCT00459134|9655978|FG001|Overall Study|Toxicity|5
6055935|NCT00459134|9655977|FG000|Overall Study|Progression|1
6055936|NCT00459134|9655978|FG001|Overall Study|Progression|0
6055937|NCT00459134|9655977|FG000|Overall Study|Multiple Reasons|2
6055938|NCT00459134|9655978|FG001|Overall Study|Multiple Reasons|3
6055939|NCT00459186|9655984|FG000|Single Agent RAD001|Withdrawal by Subject|1
6055940|NCT00459186|9655984|FG000|PET Imaging and Assessment|Adverse Event|3
6055941|NCT00459290|9655988|FG000|Overall Study|Adverse Event|3
6055942|NCT00459290|9655988|FG000|Overall Study|Ineligible|2
6055943|NCT00459316|9656011|FG000|Steps 1 & 2|Other eligibility failure|1
6091015|NCT00696410|9703326|FG001|Overall Study|Physician Decision|0
6202299|NCT01500200|9862417|FG002|Stage 2|Adverse Event|0
6202300|NCT01500200|9862418|FG003|Stage 2|Adverse Event|0
6202301|NCT01500200|9862419|FG004|Stage 2|Adverse Event|5
6202302|NCT01500200|9862420|FG005|Stage 2|Adverse Event|4
6202303|NCT01500213|9862436|FG000|Overall Study|Adverse Event|35
6202304|NCT01500213|9862437|FG001|Overall Study|Adverse Event|35
6202305|NCT01500213|9862436|FG000|Overall Study|Chemo Completed or Change in Therapy|84
6202306|NCT01500213|9862437|FG001|Overall Study|Chemo Completed or Change in Therapy|81
6202307|NCT01500213|9862436|FG000|Overall Study|Withdrawal by Subject|28
6202308|NCT01500213|9862437|FG001|Overall Study|Withdrawal by Subject|37
6202309|NCT01500213|9862436|FG000|Overall Study|Death|7
6202310|NCT01500213|9862437|FG001|Overall Study|Death|3
6202311|NCT01500213|9862436|FG000|Overall Study|Disease Progression|13
6202312|NCT01500213|9862437|FG001|Overall Study|Disease Progression|21
6202313|NCT01500213|9862436|FG000|Overall Study|Protocol Violation|19
6202314|NCT01500213|9862437|FG001|Overall Study|Protocol Violation|19
6202315|NCT01500213|9862436|FG000|Overall Study|Physician Decision|12
6202316|NCT01500213|9862437|FG001|Overall Study|Physician Decision|10
6202317|NCT01500213|9862436|FG000|Overall Study|Lack of Efficacy|9
6202318|NCT01500213|9862437|FG001|Overall Study|Lack of Efficacy|7
6202319|NCT01500213|9862436|FG000|Overall Study|Lost to Follow-up|3
6202320|NCT01500213|9862437|FG001|Overall Study|Lost to Follow-up|6
6202321|NCT01500213|9862436|FG000|Overall Study|Other Reasons|7
6202322|NCT01500213|9862437|FG001|Overall Study|Other Reasons|5
6202323|NCT01500226|9862445|FG000|Overall Study|Adverse Event|31
6202324|NCT01500226|9862446|FG001|Overall Study|Adverse Event|38
6202325|NCT01500226|9862445|FG000|Overall Study|Chemo Completed or Change in Therapy|235
6202326|NCT01500226|9862446|FG001|Overall Study|Chemo Completed or Change in Therapy|237
6202327|NCT01500226|9862445|FG000|Overall Study|Withdrawal by Subject|93
6202328|NCT01500226|9862446|FG001|Overall Study|Withdrawal by Subject|96
6202329|NCT01500226|9862445|FG000|Overall Study|Death|12
6202330|NCT01500226|9862446|FG001|Overall Study|Death|4
6202331|NCT01500226|9862445|FG000|Overall Study|Disease Progression|16
6202332|NCT01500226|9862446|FG001|Overall Study|Disease Progression|14
6202333|NCT01500226|9862445|FG000|Overall Study|Protocol Violation|53
6055944|NCT00459316|9656012|FG001|Steps 1 & 2|Other eligibility failure|1
6055945|NCT00459316|9656013|FG002|Steps 1 & 2|Other eligibility failure|0
6055946|NCT00459316|9656011|FG000|Steps 1 & 2|Death|1
6055947|NCT00459316|9656012|FG001|Steps 1 & 2|Death|1
6055948|NCT00459316|9656013|FG002|Steps 1 & 2|Death|0
6055949|NCT00459316|9656011|FG000|Steps 1 & 2|Not able to get to clinic|7
6055950|NCT00459316|9656012|FG001|Steps 1 & 2|Not able to get to clinic|4
6055951|NCT00459316|9656013|FG002|Steps 1 & 2|Not able to get to clinic|0
6055952|NCT00459316|9656011|FG000|Steps 1 & 2|Withdrawal by Subject|6
6055953|NCT00459316|9656012|FG001|Steps 1 & 2|Withdrawal by Subject|1
6055954|NCT00459316|9656013|FG002|Steps 1 & 2|Withdrawal by Subject|0
6055955|NCT00459316|9656011|FG000|Steps 1 & 2|Not willing to adhere to regulations|1
6055956|NCT00459316|9656012|FG001|Steps 1 & 2|Not willing to adhere to regulations|0
6055957|NCT00459316|9656013|FG002|Steps 1 & 2|Not willing to adhere to regulations|0
6055958|NCT00459316|9656011|FG000|Steps 1 & 2|Lost to Follow-up|5
6055959|NCT00459316|9656012|FG001|Steps 1 & 2|Lost to Follow-up|0
6055960|NCT00459316|9656013|FG002|Steps 1 & 2|Lost to Follow-up|2
6055961|NCT00459316|9656011|FG000|Step 3|Withdrawal by Subject|3
6055962|NCT00459316|9656012|FG001|Step 3|Withdrawal by Subject|0
6055963|NCT00459316|9656013|FG002|Step 3|Withdrawal by Subject|1
6055964|NCT00459342|9656036|FG000|Overall Study|Not eligible|1
6055965|NCT00459355|9656042|FG000|Overall Study|Subject no longer met inc criteria|20
6055966|NCT00459355|9656043|FG001|Overall Study|Subject no longer met inc criteria|18
6055967|NCT00459537|9656068|FG000|Overall Study|Adverse Event|1
6055968|NCT00459537|9656069|FG001|Overall Study|Adverse Event|6
6055969|NCT00459537|9656068|FG000|Overall Study|Lack of Efficacy|10
6055970|NCT00459537|9656069|FG001|Overall Study|Lack of Efficacy|11
6055971|NCT00459537|9656068|FG000|Overall Study|Withdrawal by Subject|20
6055972|NCT00459537|9656069|FG001|Overall Study|Withdrawal by Subject|26
6055973|NCT00459537|9656068|FG000|Overall Study|Lost to Follow-up|27
6055974|NCT00459537|9656069|FG001|Overall Study|Lost to Follow-up|30
6055975|NCT00459537|9656068|FG000|Overall Study|Administrative problems|3
6055976|NCT00459537|9656069|FG001|Overall Study|Administrative problems|0
6055977|NCT00459537|9656068|FG000|Overall Study|Protocol Violation|4
6055978|NCT00459537|9656069|FG001|Overall Study|Protocol Violation|3
6055979|NCT00459537|9656068|FG000|Overall Study|Missing|1
6055980|NCT00459537|9656069|FG001|Overall Study|Missing|0
6055981|NCT00459667|9656078|FG000|Overall Study|Adverse Event|9
6055982|NCT00459667|9656079|FG001|Overall Study|Adverse Event|12
6055983|NCT00459667|9656080|FG002|Overall Study|Adverse Event|8
6055984|NCT00459667|9656078|FG000|Overall Study|Lost to Follow-up|5
6055985|NCT00459667|9656079|FG001|Overall Study|Lost to Follow-up|9
6055986|NCT00459667|9656080|FG002|Overall Study|Lost to Follow-up|3
6055987|NCT00459667|9656078|FG000|Overall Study|Pregnancy|1
6055988|NCT00459667|9656079|FG001|Overall Study|Pregnancy|1
6055989|NCT00459667|9656080|FG002|Overall Study|Pregnancy|1
6055990|NCT00459667|9656078|FG000|Overall Study|Protocol Violation|1
6055991|NCT00459667|9656079|FG001|Overall Study|Protocol Violation|0
6055992|NCT00459667|9656080|FG002|Overall Study|Protocol Violation|0
6055993|NCT00459667|9656078|FG000|Overall Study|Withdrawal by Subject|3
6055994|NCT00459667|9656079|FG001|Overall Study|Withdrawal by Subject|5
6055995|NCT00459667|9656080|FG002|Overall Study|Withdrawal by Subject|5
6055996|NCT00459667|9656078|FG000|Overall Study|Other disease modifying treatment|1
6055997|NCT00459667|9656079|FG001|Overall Study|Other disease modifying treatment|2
6055998|NCT00459667|9656080|FG002|Overall Study|Other disease modifying treatment|1
6055999|NCT00459667|9656078|FG000|Overall Study|Other reason (incl. 2 missing subjects)|12
6056000|NCT00459667|9656079|FG001|Overall Study|Other reason (incl. 2 missing subjects)|15
6056001|NCT00459667|9656080|FG002|Overall Study|Other reason (incl. 2 missing subjects)|1
6056002|NCT00459667|9656078|FG000|Overall Study|No treatment administered|6
6056003|NCT00459667|9656079|FG001|Overall Study|No treatment administered|3
6056004|NCT00459667|9656080|FG002|Overall Study|No treatment administered|1
6056005|NCT00459706|9656090|FG000|Overall Study|Adverse Event|19
6056006|NCT00459706|9656091|FG001|Overall Study|Adverse Event|13
6056007|NCT00459706|9656090|FG000|Overall Study|Withdrawal by Subject|1
6091016|NCT00696423|9703339|FG000|Overall Study|Lost to Follow-up|0
6091017|NCT00696423|9703340|FG001|Overall Study|Lost to Follow-up|5
6091018|NCT00696436|9703351|FG000|Overall Study|Adverse Event|7
6056008|NCT00459706|9656091|FG001|Overall Study|Withdrawal by Subject|6
6056009|NCT00459706|9656090|FG000|Overall Study|Physician Decision|2
6056010|NCT00459706|9656091|FG001|Overall Study|Physician Decision|0
6056011|NCT00459706|9656090|FG000|Overall Study|Discontinuation of Study by Sponsor|1
6056012|NCT00459706|9656091|FG001|Overall Study|Discontinuation of Study by Sponsor|0
6056013|NCT00459706|9656090|FG000|Overall Study|Protocol Violation|2
6056014|NCT00459706|9656091|FG001|Overall Study|Protocol Violation|1
6056015|NCT00459706|9656090|FG000|Overall Study|Failed to Return|1
6056016|NCT00459706|9656091|FG001|Overall Study|Failed to Return|0
6056017|NCT00459706|9656090|FG000|Overall Study|Other|0
6056018|NCT00459706|9656091|FG001|Overall Study|Other|1
6056019|NCT00459875|9656114|FG000|Overall Study|Ineligible participant|1
6056020|NCT00459875|9656114|FG000|Overall Study|Adverse Event|2
6056021|NCT00459953|9656120|FG000|Overall Study|not analyzed-household member in study|1
6056022|NCT00459953|9656121|FG001|Overall Study|not analyzed-household member in study|1
6056023|NCT00459979|9656127|FG000|Overall Study|Withdrawal by Subject|1
6056024|NCT00459979|9656127|FG000|Overall Study|Protocol Violation|1
6091019|NCT00696436|9703352|FG001|Overall Study|Adverse Event|9
6056025|NCT00460031|9656131|FG000|Overall Study|Adverse Event|5
6056026|NCT00460031|9656131|FG000|Overall Study|Withdrawal by Subject|5
6056027|NCT00460031|9656131|FG000|Overall Study|Death|1
6056028|NCT00460109|9656135|FG000|Overall Study|Death|1
6091020|NCT00696436|9703353|FG002|Overall Study|Adverse Event|8
6091021|NCT00696436|9703354|FG003|Overall Study|Adverse Event|6
6091022|NCT00696436|9703355|FG004|Overall Study|Adverse Event|4
6091023|NCT00696436|9703351|FG000|Overall Study|Protocol Violation|3
6091024|NCT00696436|9703352|FG001|Overall Study|Protocol Violation|2
6091025|NCT00696436|9703353|FG002|Overall Study|Protocol Violation|2
6091026|NCT00696436|9703354|FG003|Overall Study|Protocol Violation|0
6091027|NCT00696436|9703355|FG004|Overall Study|Protocol Violation|1
6091028|NCT00696436|9703351|FG000|Overall Study|Lost to Follow-up|1
6091029|NCT00696436|9703352|FG001|Overall Study|Lost to Follow-up|6
6091030|NCT00696436|9703353|FG002|Overall Study|Lost to Follow-up|2
6091031|NCT00696436|9703354|FG003|Overall Study|Lost to Follow-up|4
6091032|NCT00696436|9703355|FG004|Overall Study|Lost to Follow-up|3
6091033|NCT00696436|9703351|FG000|Overall Study|Withdrawal by Subject|4
6091034|NCT00696436|9703352|FG001|Overall Study|Withdrawal by Subject|11
6091035|NCT00696436|9703353|FG002|Overall Study|Withdrawal by Subject|5
6091036|NCT00696436|9703354|FG003|Overall Study|Withdrawal by Subject|7
6091037|NCT00696436|9703355|FG004|Overall Study|Withdrawal by Subject|1
6091038|NCT00696436|9703351|FG000|Overall Study|Lack of Efficacy|3
6091039|NCT00696436|9703352|FG001|Overall Study|Lack of Efficacy|1
6091040|NCT00696436|9703353|FG002|Overall Study|Lack of Efficacy|5
6091041|NCT00696436|9703354|FG003|Overall Study|Lack of Efficacy|2
6091042|NCT00696436|9703355|FG004|Overall Study|Lack of Efficacy|4
6091043|NCT00696436|9703351|FG000|Overall Study|Participant Unavailability|2
6091044|NCT00696436|9703352|FG001|Overall Study|Participant Unavailability|0
6091045|NCT00696436|9703353|FG002|Overall Study|Participant Unavailability|2
6091046|NCT00696436|9703354|FG003|Overall Study|Participant Unavailability|1
6091047|NCT00696436|9703355|FG004|Overall Study|Participant Unavailability|0
6091048|NCT00696436|9703351|FG000|Overall Study|Administrative Error|2
6091049|NCT00696436|9703352|FG001|Overall Study|Administrative Error|0
6091050|NCT00696436|9703353|FG002|Overall Study|Administrative Error|2
6091051|NCT00696436|9703354|FG003|Overall Study|Administrative Error|0
6091052|NCT00696436|9703355|FG004|Overall Study|Administrative Error|0
6091053|NCT00696436|9703351|FG000|Overall Study|Participant Non-compliance|0
6091054|NCT00696436|9703352|FG001|Overall Study|Participant Non-compliance|0
6091055|NCT00696436|9703353|FG002|Overall Study|Participant Non-compliance|1
6091056|NCT00696436|9703354|FG003|Overall Study|Participant Non-compliance|2
6091057|NCT00696436|9703355|FG004|Overall Study|Participant Non-compliance|0
6091058|NCT00696436|9703351|FG000|Overall Study|Administrative Decision|1
6091059|NCT00696436|9703352|FG001|Overall Study|Administrative Decision|0
6091060|NCT00696436|9703353|FG002|Overall Study|Administrative Decision|0
6091061|NCT00696436|9703354|FG003|Overall Study|Administrative Decision|0
6091062|NCT00696436|9703355|FG004|Overall Study|Administrative Decision|0
6091063|NCT00696436|9703351|FG000|Overall Study|Missing|0
6091064|NCT00696436|9703352|FG001|Overall Study|Missing|1
6091065|NCT00696436|9703353|FG002|Overall Study|Missing|1
6091066|NCT00696436|9703354|FG003|Overall Study|Missing|0
6091067|NCT00696436|9703355|FG004|Overall Study|Missing|0
6091068|NCT00696657|9703410|FG000|Overall Study|Protocol Violation|0
6091069|NCT00696657|9703411|FG001|Overall Study|Protocol Violation|0
6091070|NCT00696657|9703412|FG002|Overall Study|Protocol Violation|0
6091071|NCT00696657|9703413|FG003|Overall Study|Protocol Violation|0
6091072|NCT00696657|9703414|FG004|Overall Study|Protocol Violation|0
6091073|NCT00696657|9703415|FG005|Overall Study|Protocol Violation|1
6091074|NCT00696657|9703416|FG006|Overall Study|Protocol Violation|0
6091075|NCT00696657|9703417|FG007|Overall Study|Protocol Violation|0
6091076|NCT00696657|9703418|FG008|Overall Study|Protocol Violation|1
6091077|NCT00696657|9703410|FG000|Overall Study|Lack of Efficacy|0
6091078|NCT00696657|9703411|FG001|Overall Study|Lack of Efficacy|1
6091079|NCT00696657|9703412|FG002|Overall Study|Lack of Efficacy|0
6091080|NCT00696657|9703413|FG003|Overall Study|Lack of Efficacy|0
6091081|NCT00696657|9703414|FG004|Overall Study|Lack of Efficacy|0
6091082|NCT00696657|9703415|FG005|Overall Study|Lack of Efficacy|0
6091083|NCT00696657|9703416|FG006|Overall Study|Lack of Efficacy|0
6091084|NCT00696657|9703417|FG007|Overall Study|Lack of Efficacy|0
6091085|NCT00696657|9703418|FG008|Overall Study|Lack of Efficacy|0
6091086|NCT00696657|9703410|FG000|Overall Study|Withdrawal criteria|1
6091087|NCT00696657|9703411|FG001|Overall Study|Withdrawal criteria|3
6091088|NCT00696657|9703412|FG002|Overall Study|Withdrawal criteria|2
6091089|NCT00696657|9703413|FG003|Overall Study|Withdrawal criteria|2
6091090|NCT00696657|9703414|FG004|Overall Study|Withdrawal criteria|0
6091091|NCT00696657|9703415|FG005|Overall Study|Withdrawal criteria|0
6091092|NCT00696657|9703416|FG006|Overall Study|Withdrawal criteria|1
6091093|NCT00696657|9703417|FG007|Overall Study|Withdrawal criteria|1
6091094|NCT00696657|9703418|FG008|Overall Study|Withdrawal criteria|2
6091095|NCT00696657|9703410|FG000|Overall Study|Unclassified|0
6091096|NCT00696657|9703411|FG001|Overall Study|Unclassified|1
6091097|NCT00696657|9703412|FG002|Overall Study|Unclassified|3
6091098|NCT00696657|9703413|FG003|Overall Study|Unclassified|2
6091099|NCT00696657|9703414|FG004|Overall Study|Unclassified|4
6091100|NCT00696657|9703415|FG005|Overall Study|Unclassified|2
6091101|NCT00696657|9703416|FG006|Overall Study|Unclassified|0
6091102|NCT00696657|9703417|FG007|Overall Study|Unclassified|0
6056029|NCT00460239|9656139|FG000|Overall Study|Physician Decision|0
6056030|NCT00460239|9656140|FG001|Overall Study|Physician Decision|1
6056031|NCT00460239|9656141|FG002|Overall Study|Physician Decision|0
6056032|NCT00460239|9656142|FG003|Overall Study|Physician Decision|0
6056033|NCT00460239|9656143|FG004|Overall Study|Physician Decision|0
6056034|NCT00460239|9656144|FG005|Overall Study|Physician Decision|2
6056035|NCT00460239|9656145|FG006|Overall Study|Physician Decision|0
6056036|NCT00460239|9656146|FG007|Overall Study|Physician Decision|0
6056037|NCT00460239|9656147|FG008|Overall Study|Physician Decision|0
6056038|NCT00460239|9656139|FG000|Overall Study|Withdrawal by Subject|0
6056039|NCT00460239|9656140|FG001|Overall Study|Withdrawal by Subject|0
6056040|NCT00460239|9656141|FG002|Overall Study|Withdrawal by Subject|0
6056041|NCT00460239|9656142|FG003|Overall Study|Withdrawal by Subject|0
6056042|NCT00460239|9656143|FG004|Overall Study|Withdrawal by Subject|0
6056043|NCT00460239|9656144|FG005|Overall Study|Withdrawal by Subject|1
6056044|NCT00460239|9656145|FG006|Overall Study|Withdrawal by Subject|0
6056045|NCT00460239|9656146|FG007|Overall Study|Withdrawal by Subject|0
6056046|NCT00460239|9656147|FG008|Overall Study|Withdrawal by Subject|0
6056047|NCT00460265|9656162|FG000|Overall Study|Lost to Follow-up|14
6056048|NCT00460265|9656163|FG001|Overall Study|Lost to Follow-up|15
6056049|NCT00460265|9656162|FG000|Overall Study|Physician Decision|1
6056050|NCT00460265|9656163|FG001|Overall Study|Physician Decision|2
6056051|NCT00460265|9656162|FG000|Overall Study|Withdrawal by Subject|10
6056052|NCT00460265|9656163|FG001|Overall Study|Withdrawal by Subject|25
6056053|NCT00460265|9656162|FG000|Overall Study|Ongoing|60
6056054|NCT00460265|9656163|FG001|Overall Study|Ongoing|47
6056055|NCT00460408|9656173|FG000|Overall Study|Adverse Event|1
6056056|NCT00460408|9656174|FG001|Overall Study|Adverse Event|0
6056057|NCT00460408|9656175|FG002|Overall Study|Adverse Event|0
6056058|NCT00460408|9656176|FG003|Overall Study|Adverse Event|0
6056059|NCT00460408|9656173|FG000|Overall Study|Death|7
6056060|NCT00460408|9656174|FG001|Overall Study|Death|0
6056061|NCT00460408|9656175|FG002|Overall Study|Death|0
6056062|NCT00460408|9656176|FG003|Overall Study|Death|0
6056063|NCT00460408|9656173|FG000|Overall Study|Lost to Follow-up|11
6056064|NCT00460408|9656174|FG001|Overall Study|Lost to Follow-up|0
6056065|NCT00460408|9656175|FG002|Overall Study|Lost to Follow-up|1
6056066|NCT00460408|9656176|FG003|Overall Study|Lost to Follow-up|0
6056067|NCT00460408|9656173|FG000|Overall Study|Withdrawal by Subject|31
6056068|NCT00460408|9656174|FG001|Overall Study|Withdrawal by Subject|0
6056069|NCT00460408|9656175|FG002|Overall Study|Withdrawal by Subject|0
6056070|NCT00460408|9656176|FG003|Overall Study|Withdrawal by Subject|0
6056071|NCT00460408|9656173|FG000|Overall Study|Insufficient clinical response|5
6056072|NCT00460408|9656174|FG001|Overall Study|Insufficient clinical response|1
6056073|NCT00460408|9656175|FG002|Overall Study|Insufficient clinical response|5
6056074|NCT00460408|9656176|FG003|Overall Study|Insufficient clinical response|0
6056075|NCT00460408|9656173|FG000|Overall Study|Other|12
6056076|NCT00460408|9656174|FG001|Overall Study|Other|2
6056077|NCT00460408|9656175|FG002|Overall Study|Other|0
6056078|NCT00460408|9656176|FG003|Overall Study|Other|0
6056079|NCT00460434|9656200|FG000|Overall Study|Lost to Follow-up|3
6056080|NCT00460434|9656201|FG001|Overall Study|Lost to Follow-up|7
6056081|NCT00460564|9656224|FG000|Double-Blind Phase (12 Weeks)|Adverse Event|3
6056082|NCT00460564|9656225|FG001|Double-Blind Phase (12 Weeks)|Adverse Event|1
6056083|NCT00460564|9656226|FG002|Double-Blind Phase (12 Weeks)|Adverse Event|0
6056084|NCT00460564|9656227|FG003|Double-Blind Phase (12 Weeks)|Adverse Event|0
6056085|NCT00460564|9656228|FG004|Double-Blind Phase (12 Weeks)|Adverse Event|0
6056086|NCT00460564|9656229|FG005|Double-Blind Phase (12 Weeks)|Adverse Event|0
6056087|NCT00460564|9656230|FG006|Double-Blind Phase (12 Weeks)|Adverse Event|0
6056088|NCT00460564|9656231|FG007|Double-Blind Phase (12 Weeks)|Adverse Event|0
6056089|NCT00460564|9656224|FG000|Double-Blind Phase (12 Weeks)|Withdrawal by Subject|1
6056090|NCT00460564|9656225|FG001|Double-Blind Phase (12 Weeks)|Withdrawal by Subject|0
6056091|NCT00460564|9656226|FG002|Double-Blind Phase (12 Weeks)|Withdrawal by Subject|0
6056092|NCT00460564|9656227|FG003|Double-Blind Phase (12 Weeks)|Withdrawal by Subject|0
6056093|NCT00460564|9656228|FG004|Double-Blind Phase (12 Weeks)|Withdrawal by Subject|0
6056094|NCT00460564|9656229|FG005|Double-Blind Phase (12 Weeks)|Withdrawal by Subject|0
6056095|NCT00460564|9656230|FG006|Double-Blind Phase (12 Weeks)|Withdrawal by Subject|0
6056096|NCT00460564|9656231|FG007|Double-Blind Phase (12 Weeks)|Withdrawal by Subject|0
6056097|NCT00460564|9656224|FG000|Open-Label Phase (36 Weeks)|Adverse Event|0
6056098|NCT00460564|9656225|FG001|Open-Label Phase (36 Weeks)|Adverse Event|0
6056099|NCT00460564|9656226|FG002|Open-Label Phase (36 Weeks)|Adverse Event|0
6056100|NCT00460564|9656227|FG003|Open-Label Phase (36 Weeks)|Adverse Event|0
6056101|NCT00460564|9656228|FG004|Open-Label Phase (36 Weeks)|Adverse Event|3
6056102|NCT00460564|9656229|FG005|Open-Label Phase (36 Weeks)|Adverse Event|5
6056103|NCT00460564|9656230|FG006|Open-Label Phase (36 Weeks)|Adverse Event|2
6056104|NCT00460564|9656231|FG007|Open-Label Phase (36 Weeks)|Adverse Event|0
6056105|NCT00460564|9656224|FG000|Open-Label Phase (36 Weeks)|Withdrawal by Subject|0
6056106|NCT00460564|9656225|FG001|Open-Label Phase (36 Weeks)|Withdrawal by Subject|0
6056107|NCT00460564|9656226|FG002|Open-Label Phase (36 Weeks)|Withdrawal by Subject|0
6056108|NCT00460564|9656227|FG003|Open-Label Phase (36 Weeks)|Withdrawal by Subject|0
6056109|NCT00460564|9656228|FG004|Open-Label Phase (36 Weeks)|Withdrawal by Subject|5
6056110|NCT00460564|9656229|FG005|Open-Label Phase (36 Weeks)|Withdrawal by Subject|1
6056111|NCT00460564|9656230|FG006|Open-Label Phase (36 Weeks)|Withdrawal by Subject|0
6056112|NCT00460564|9656231|FG007|Open-Label Phase (36 Weeks)|Withdrawal by Subject|0
6056113|NCT00460564|9656224|FG000|Open-Label Phase (36 Weeks)|Concentrate on Treatment of Diabetes|0
6056114|NCT00460564|9656225|FG001|Open-Label Phase (36 Weeks)|Concentrate on Treatment of Diabetes|0
6056115|NCT00460564|9656226|FG002|Open-Label Phase (36 Weeks)|Concentrate on Treatment of Diabetes|0
6056116|NCT00460564|9656227|FG003|Open-Label Phase (36 Weeks)|Concentrate on Treatment of Diabetes|0
6056117|NCT00460564|9656228|FG004|Open-Label Phase (36 Weeks)|Concentrate on Treatment of Diabetes|1
6091103|NCT00696657|9703418|FG008|Overall Study|Unclassified|1
6091104|NCT00696657|9703410|FG000|Overall Study|Adverse Event|0
6091105|NCT00696657|9703411|FG001|Overall Study|Adverse Event|0
6091106|NCT00696657|9703412|FG002|Overall Study|Adverse Event|3
6091107|NCT00696657|9703413|FG003|Overall Study|Adverse Event|7
6091108|NCT00696657|9703414|FG004|Overall Study|Adverse Event|6
6091109|NCT00696657|9703415|FG005|Overall Study|Adverse Event|9
6091110|NCT00696657|9703416|FG006|Overall Study|Adverse Event|14
6091111|NCT00696657|9703417|FG007|Overall Study|Adverse Event|2
6091112|NCT00696657|9703418|FG008|Overall Study|Adverse Event|5
6091113|NCT00696696|9703438|FG000|Overall Study|Adverse Event|5
6091114|NCT00696696|9703438|FG000|Overall Study|Withdrawal by Subject|8
6091115|NCT00696696|9703438|FG000|Overall Study|Physician Decision|2
6091116|NCT00696696|9703438|FG000|Overall Study|Death|3
6091117|NCT00696709|9703447|FG000|Overall Study|Withdrawal by Subject|1
6091118|NCT00696709|9703448|FG001|Overall Study|Withdrawal by Subject|2
6091119|NCT00696709|9703449|FG002|Overall Study|Withdrawal by Subject|1
6091120|NCT00696709|9703450|FG003|Overall Study|Withdrawal by Subject|4
6091121|NCT00696709|9703451|FG004|Overall Study|Withdrawal by Subject|3
6091122|NCT00696709|9703447|FG000|Overall Study|Protocol Violation|1
6091123|NCT00696709|9703448|FG001|Overall Study|Protocol Violation|0
6091124|NCT00696709|9703449|FG002|Overall Study|Protocol Violation|0
6091125|NCT00696709|9703450|FG003|Overall Study|Protocol Violation|0
6091126|NCT00696709|9703451|FG004|Overall Study|Protocol Violation|0
6091127|NCT00696709|9703447|FG000|Overall Study|Lost to Follow-up|1
6091128|NCT00696709|9703448|FG001|Overall Study|Lost to Follow-up|1
6091129|NCT00696709|9703449|FG002|Overall Study|Lost to Follow-up|0
6091130|NCT00696709|9703450|FG003|Overall Study|Lost to Follow-up|0
6091131|NCT00696709|9703451|FG004|Overall Study|Lost to Follow-up|0
6091132|NCT00696709|9703447|FG000|Overall Study|Adverse Event|0
6091133|NCT00696709|9703448|FG001|Overall Study|Adverse Event|0
6091134|NCT00696709|9703449|FG002|Overall Study|Adverse Event|0
6091135|NCT00696709|9703450|FG003|Overall Study|Adverse Event|1
6091136|NCT00696709|9703451|FG004|Overall Study|Adverse Event|0
6091137|NCT00696774|9703495|FG000|Period II|Adverse Event|0
6091138|NCT00696774|9703496|FG001|Period II|Adverse Event|0
6091139|NCT00696774|9703497|FG002|Period II|Adverse Event|15
6091140|NCT00696774|9703495|FG000|Period II|Lost to Follow-up|0
6091141|NCT00696774|9703496|FG001|Period II|Lost to Follow-up|0
6091142|NCT00696774|9703497|FG002|Period II|Lost to Follow-up|4
6091143|NCT00696774|9703495|FG000|Period II|Protocol Violation|0
6091144|NCT00696774|9703496|FG001|Period II|Protocol Violation|0
6091145|NCT00696774|9703497|FG002|Period II|Protocol Violation|11
6091146|NCT00696774|9703495|FG000|Period II|Withdrawal by Subject|0
6091147|NCT00696774|9703496|FG001|Period II|Withdrawal by Subject|0
6091148|NCT00696774|9703497|FG002|Period II|Withdrawal by Subject|4
6091149|NCT00696774|9703495|FG000|Period II|Sponsor Decision|0
6091150|NCT00696774|9703496|FG001|Period II|Sponsor Decision|0
6091151|NCT00696774|9703497|FG002|Period II|Sponsor Decision|0
6091152|NCT00696774|9703495|FG000|Period II|Lack of Efficacy|0
6091153|NCT00696774|9703496|FG001|Period II|Lack of Efficacy|0
6091154|NCT00696774|9703497|FG002|Period II|Lack of Efficacy|2
6091155|NCT00696774|9703495|FG000|Period III|Adverse Event|1
6091156|NCT00696774|9703496|FG001|Period III|Adverse Event|1
6091157|NCT00696774|9703497|FG002|Period III|Adverse Event|0
6091158|NCT00696774|9703495|FG000|Period III|Lost to Follow-up|2
6091159|NCT00696774|9703496|FG001|Period III|Lost to Follow-up|1
6091160|NCT00696774|9703497|FG002|Period III|Lost to Follow-up|0
6091161|NCT00696774|9703495|FG000|Period III|Protocol Violation|1
6091162|NCT00696774|9703496|FG001|Period III|Protocol Violation|1
6091163|NCT00696774|9703497|FG002|Period III|Protocol Violation|0
6091164|NCT00696774|9703495|FG000|Period III|Withdrawal by Subject|1
6091165|NCT00696774|9703496|FG001|Period III|Withdrawal by Subject|2
6091166|NCT00696774|9703497|FG002|Period III|Withdrawal by Subject|0
6091167|NCT00696774|9703495|FG000|Period III|Sponsor Decision|2
6091168|NCT00696774|9703496|FG001|Period III|Sponsor Decision|0
6091169|NCT00696774|9703497|FG002|Period III|Sponsor Decision|0
6091170|NCT00696774|9703495|FG000|Period III|Lack of Efficacy|0
6091171|NCT00696774|9703496|FG001|Period III|Lack of Efficacy|2
6091172|NCT00696774|9703497|FG002|Period III|Lack of Efficacy|0
6091173|NCT00696787|9703508|FG000|Overall Study|Adverse Event|1
6091174|NCT00696787|9703509|FG001|Overall Study|Adverse Event|0
6091175|NCT00696787|9703510|FG002|Overall Study|Adverse Event|6
6091176|NCT00696787|9703508|FG000|Overall Study|Discontinuation by Sponsor|9
6091177|NCT00696787|9703509|FG001|Overall Study|Discontinuation by Sponsor|13
6091178|NCT00696787|9703510|FG002|Overall Study|Discontinuation by Sponsor|14
6091179|NCT00696787|9703508|FG000|Overall Study|Lack of Efficacy|0
6091180|NCT00696787|9703509|FG001|Overall Study|Lack of Efficacy|1
6091181|NCT00696787|9703510|FG002|Overall Study|Lack of Efficacy|0
6056118|NCT00460564|9656229|FG005|Open-Label Phase (36 Weeks)|Concentrate on Treatment of Diabetes|0
6056119|NCT00460564|9656230|FG006|Open-Label Phase (36 Weeks)|Concentrate on Treatment of Diabetes|0
6056120|NCT00460564|9656231|FG007|Open-Label Phase (36 Weeks)|Concentrate on Treatment of Diabetes|0
6056121|NCT00460577|9656253|FG000|Overall Study|Protocol Violation|2
6056122|NCT00460577|9656254|FG001|Overall Study|Protocol Violation|6
6056123|NCT00460603|9656272|FG000|Phase 1|Death|1
6056124|NCT00460603|9656273|FG001|Phase 1|Death|0
6091182|NCT00696787|9703508|FG000|Overall Study|Lost to Follow-up|4
6091183|NCT00696787|9703509|FG001|Overall Study|Lost to Follow-up|0
6091184|NCT00696787|9703510|FG002|Overall Study|Lost to Follow-up|3
6091185|NCT00696787|9703508|FG000|Overall Study|Withdrawal by Subject|0
6091186|NCT00696787|9703509|FG001|Overall Study|Withdrawal by Subject|3
6091187|NCT00696787|9703510|FG002|Overall Study|Withdrawal by Subject|2
6091188|NCT00696787|9703508|FG000|Overall Study|Failed to return|1
6091189|NCT00696787|9703509|FG001|Overall Study|Failed to return|3
6091190|NCT00696787|9703510|FG002|Overall Study|Failed to return|1
6091191|NCT00697073|9703518|FG000|Overall Study|Withdrawal by Subject|2
6091192|NCT00697073|9703518|FG000|Overall Study|Pregnancy|1
6091193|NCT00697073|9703518|FG000|Overall Study|non compliance and other|6
6202334|NCT01500226|9862446|FG001|Overall Study|Protocol Violation|39
6202335|NCT01500226|9862445|FG000|Overall Study|Physician Decision|17
6202336|NCT01500226|9862446|FG001|Overall Study|Physician Decision|15
6202337|NCT01500226|9862445|FG000|Overall Study|Lack of Efficacy|14
6202338|NCT01500226|9862446|FG001|Overall Study|Lack of Efficacy|30
6202339|NCT01500226|9862445|FG000|Overall Study|Lost to Follow-up|9
6202340|NCT01500226|9862446|FG001|Overall Study|Lost to Follow-up|5
6202341|NCT01500226|9862445|FG000|Overall Study|Other Reasons|19
6202342|NCT01500226|9862446|FG001|Overall Study|Other Reasons|16
6202343|NCT01500252|9862454|FG000|Overall Study|Death|4
6202344|NCT01500252|9862455|FG001|Overall Study|Death|2
6202345|NCT01500252|9862454|FG000|Overall Study|Lost to Follow-up|5
6202346|NCT01500252|9862455|FG001|Overall Study|Lost to Follow-up|4
6202347|NCT01500278|9862464|FG000|Week 0 - Week 12|Lack of Efficacy|0
6202348|NCT01500278|9862465|FG001|Week 0 - Week 12|Lack of Efficacy|1
6202349|NCT01500278|9862464|FG000|Week 0 - Week 12|Protocol Violation|10
6202350|NCT01500278|9862465|FG001|Week 0 - Week 12|Protocol Violation|16
6202351|NCT01500278|9862464|FG000|Week 0 - Week 12|Lost to Follow-up|1
6202352|NCT01500278|9862465|FG001|Week 0 - Week 12|Lost to Follow-up|1
6202353|NCT01500278|9862464|FG000|Week 0 - Week 12|Withdrawal by Subject|7
6202354|NCT01500278|9862465|FG001|Week 0 - Week 12|Withdrawal by Subject|2
6202355|NCT01500278|9862464|FG000|Week 0 - Week 12|Protocol violation on screening X-ray|1
6202356|NCT01500278|9862465|FG001|Week 0 - Week 12|Protocol violation on screening X-ray|0
6202357|NCT01500278|9862464|FG000|Week 0 - Week 12|Patient decision|1
6202358|NCT01500278|9862465|FG001|Week 0 - Week 12|Patient decision|0
6202359|NCT01500278|9862464|FG000|Week 0 - Week 12|Exclusion criteria not met|1
6202360|NCT01500278|9862465|FG001|Week 0 - Week 12|Exclusion criteria not met|0
6202361|NCT01500278|9862464|FG000|Week 0 - Week 12|Investigator decision|1
6202362|NCT01500278|9862465|FG001|Week 0 - Week 12|Investigator decision|0
6202363|NCT01500278|9862464|FG000|Week 0 - Week 12|Prior history of serious disease|1
6202364|NCT01500278|9862465|FG001|Week 0 - Week 12|Prior history of serious disease|0
6202365|NCT01500278|9862464|FG000|Week 0 - Week 12|Sponsor decision|1
6202366|NCT01500278|9862465|FG001|Week 0 - Week 12|Sponsor decision|0
6202367|NCT01500278|9862464|FG000|Week 0 - Week 12|Personal reason|0
6202368|NCT01500278|9862465|FG001|Week 0 - Week 12|Personal reason|1
6202369|NCT01500278|9862464|FG000|Week 0 - Week 12|Other serious disease|0
6202370|NCT01500278|9862465|FG001|Week 0 - Week 12|Other serious disease|1
6202371|NCT01500278|9862464|FG000|Week 0 - Week 12|Adverse event (AE), not fatal|7
6202372|NCT01500278|9862465|FG001|Week 0 - Week 12|Adverse event (AE), not fatal|8
6202373|NCT01500278|9862464|FG000|Week 13 - Week 104|Lack of Efficacy|11
6202374|NCT01500278|9862465|FG001|Week 13 - Week 104|Lack of Efficacy|12
6202375|NCT01500278|9862464|FG000|Week 13 - Week 104|Protocol Violation|6
6202376|NCT01500278|9862465|FG001|Week 13 - Week 104|Protocol Violation|6
6202377|NCT01500278|9862464|FG000|Week 13 - Week 104|Lost to Follow-up|6
6056125|NCT00460603|9656274|FG002|Phase 1|Death|0
6056126|NCT00460603|9656275|FG003|Phase 1|Death|2
6056127|NCT00460603|9656276|FG004|Phase 1|Death|0
6056128|NCT00460603|9656277|FG005|Phase 1|Death|0
6056129|NCT00460603|9656278|FG006|Phase 1|Death|0
6056130|NCT00460603|9656279|FG007|Phase 1|Death|0
6056131|NCT00460603|9656280|FG008|Phase 1|Death|1
6056132|NCT00460603|9656281|FG009|Phase 1|Death|0
6056133|NCT00460603|9656282|FG010|Phase 1|Death|0
6056134|NCT00460603|9656283|FG011|Phase 1|Death|0
6056135|NCT00460603|9656272|FG000|Phase 1|Adverse Event|3
6056136|NCT00460603|9656273|FG001|Phase 1|Adverse Event|1
6056137|NCT00460603|9656274|FG002|Phase 1|Adverse Event|1
6056138|NCT00460603|9656275|FG003|Phase 1|Adverse Event|2
6056139|NCT00460603|9656276|FG004|Phase 1|Adverse Event|0
6056140|NCT00460603|9656277|FG005|Phase 1|Adverse Event|0
6202378|NCT01500278|9862465|FG001|Week 13 - Week 104|Lost to Follow-up|5
6202379|NCT01500278|9862464|FG000|Week 13 - Week 104|Withdrawal by Subject|22
6202380|NCT01500278|9862465|FG001|Week 13 - Week 104|Withdrawal by Subject|13
6202381|NCT01500278|9862464|FG000|Week 13 - Week 104|Week 24 Non-Responder|20
6202382|NCT01500278|9862465|FG001|Week 13 - Week 104|Week 24 Non-Responder|16
6202383|NCT01500278|9862464|FG000|Week 13 - Week 104|Non/bad compliance|7
6202384|NCT01500278|9862465|FG001|Week 13 - Week 104|Non/bad compliance|5
6056141|NCT00460603|9656278|FG006|Phase 1|Adverse Event|3
6056142|NCT00460603|9656279|FG007|Phase 1|Adverse Event|0
6056143|NCT00460603|9656280|FG008|Phase 1|Adverse Event|4
6056144|NCT00460603|9656281|FG009|Phase 1|Adverse Event|0
6056145|NCT00460603|9656282|FG010|Phase 1|Adverse Event|0
6056146|NCT00460603|9656283|FG011|Phase 1|Adverse Event|0
6056147|NCT00460603|9656272|FG000|Phase 1|Lack of Efficacy|1
6056148|NCT00460603|9656273|FG001|Phase 1|Lack of Efficacy|0
6056149|NCT00460603|9656274|FG002|Phase 1|Lack of Efficacy|1
6056150|NCT00460603|9656275|FG003|Phase 1|Lack of Efficacy|2
6056151|NCT00460603|9656276|FG004|Phase 1|Lack of Efficacy|2
6056152|NCT00460603|9656277|FG005|Phase 1|Lack of Efficacy|2
6056153|NCT00460603|9656278|FG006|Phase 1|Lack of Efficacy|2
6056154|NCT00460603|9656279|FG007|Phase 1|Lack of Efficacy|2
6056155|NCT00460603|9656280|FG008|Phase 1|Lack of Efficacy|11
6056156|NCT00460603|9656281|FG009|Phase 1|Lack of Efficacy|0
6056157|NCT00460603|9656282|FG010|Phase 1|Lack of Efficacy|0
6056158|NCT00460603|9656283|FG011|Phase 1|Lack of Efficacy|0
6056159|NCT00460603|9656272|FG000|Phase 1|Withdrawal by Subject|1
6056160|NCT00460603|9656273|FG001|Phase 1|Withdrawal by Subject|2
6056161|NCT00460603|9656274|FG002|Phase 1|Withdrawal by Subject|1
6056162|NCT00460603|9656275|FG003|Phase 1|Withdrawal by Subject|1
6056163|NCT00460603|9656276|FG004|Phase 1|Withdrawal by Subject|3
6056164|NCT00460603|9656277|FG005|Phase 1|Withdrawal by Subject|0
6056165|NCT00460603|9656278|FG006|Phase 1|Withdrawal by Subject|1
6056166|NCT00460603|9656279|FG007|Phase 1|Withdrawal by Subject|0
6056167|NCT00460603|9656280|FG008|Phase 1|Withdrawal by Subject|2
6056168|NCT00460603|9656281|FG009|Phase 1|Withdrawal by Subject|0
6056169|NCT00460603|9656282|FG010|Phase 1|Withdrawal by Subject|0
6056170|NCT00460603|9656283|FG011|Phase 1|Withdrawal by Subject|0
6056171|NCT00460603|9656272|FG000|Phase 1|Other|0
6056172|NCT00460603|9656273|FG001|Phase 1|Other|3
6056173|NCT00460603|9656274|FG002|Phase 1|Other|1
6056174|NCT00460603|9656275|FG003|Phase 1|Other|1
6056175|NCT00460603|9656276|FG004|Phase 1|Other|1
6056176|NCT00460603|9656277|FG005|Phase 1|Other|2
6056177|NCT00460603|9656278|FG006|Phase 1|Other|0
6056178|NCT00460603|9656279|FG007|Phase 1|Other|1
6056179|NCT00460603|9656280|FG008|Phase 1|Other|0
6056180|NCT00460603|9656281|FG009|Phase 1|Other|0
6056181|NCT00460603|9656282|FG010|Phase 1|Other|0
6056182|NCT00460603|9656283|FG011|Phase 1|Other|0
6056183|NCT00460603|9656272|FG000|Phase 2|Ongoing in study A4061008 (NCT00828919)|0
6056184|NCT00460603|9656273|FG001|Phase 2|Ongoing in study A4061008 (NCT00828919)|0
6056185|NCT00460603|9656274|FG002|Phase 2|Ongoing in study A4061008 (NCT00828919)|0
6056186|NCT00460603|9656275|FG003|Phase 2|Ongoing in study A4061008 (NCT00828919)|0
6056187|NCT00460603|9656276|FG004|Phase 2|Ongoing in study A4061008 (NCT00828919)|0
6056188|NCT00460603|9656277|FG005|Phase 2|Ongoing in study A4061008 (NCT00828919)|0
6056189|NCT00460603|9656278|FG006|Phase 2|Ongoing in study A4061008 (NCT00828919)|0
6056190|NCT00460603|9656279|FG007|Phase 2|Ongoing in study A4061008 (NCT00828919)|0
6056191|NCT00460603|9656280|FG008|Phase 2|Ongoing in study A4061008 (NCT00828919)|0
6056192|NCT00460603|9656281|FG009|Phase 2|Ongoing in study A4061008 (NCT00828919)|1
6056193|NCT00460603|9656282|FG010|Phase 2|Ongoing in study A4061008 (NCT00828919)|0
6056194|NCT00460603|9656283|FG011|Phase 2|Ongoing in study A4061008 (NCT00828919)|0
6056195|NCT00460603|9656272|FG000|Phase 2|Adverse Event|0
6056196|NCT00460603|9656273|FG001|Phase 2|Adverse Event|0
6056197|NCT00460603|9656274|FG002|Phase 2|Adverse Event|0
6056198|NCT00460603|9656275|FG003|Phase 2|Adverse Event|0
6056199|NCT00460603|9656276|FG004|Phase 2|Adverse Event|0
6056200|NCT00460603|9656277|FG005|Phase 2|Adverse Event|0
6091194|NCT00697112|9703522|FG000|Overall Study|Adverse Event|8
6091195|NCT00697112|9703522|FG000|Overall Study|Lost to Follow-up|1
6091196|NCT00697112|9703522|FG000|Overall Study|Did not meet inclusion criteria|1
6091197|NCT00697346|9703557|FG000|Overall Study|Adverse Event|4
6091198|NCT00697346|9703558|FG001|Overall Study|Adverse Event|5
6091199|NCT00697346|9703559|FG002|Overall Study|Adverse Event|0
6091200|NCT00697346|9703557|FG000|Overall Study|Progressive Disease|19
6091201|NCT00697346|9703558|FG001|Overall Study|Progressive Disease|18
6091202|NCT00697346|9703559|FG002|Overall Study|Progressive Disease|0
6202385|NCT01500278|9862464|FG000|Week 13 - Week 104|Recurrent infections|1
6091203|NCT00697346|9703557|FG000|Overall Study|Symptomatic Deterioration|0
6091204|NCT00697346|9703558|FG001|Overall Study|Symptomatic Deterioration|1
6091205|NCT00697346|9703559|FG002|Overall Study|Symptomatic Deterioration|0
6091206|NCT00697346|9703557|FG000|Overall Study|Withdrawal by Subject|2
6091207|NCT00697346|9703558|FG001|Overall Study|Withdrawal by Subject|2
6091208|NCT00697346|9703559|FG002|Overall Study|Withdrawal by Subject|0
6091209|NCT00697346|9703557|FG000|Overall Study|Reason not Specified|3
6091210|NCT00697346|9703558|FG001|Overall Study|Reason not Specified|0
6091211|NCT00697346|9703559|FG002|Overall Study|Reason not Specified|1
6091212|NCT00697463|9703586|FG000|Overall Study|Withdrawal by Subject|1
6091213|NCT00697515|9703590|FG000|Dose Optimization Period|Adverse Event|4
6056201|NCT00460603|9656278|FG006|Phase 2|Adverse Event|0
6056202|NCT00460603|9656279|FG007|Phase 2|Adverse Event|0
6056203|NCT00460603|9656280|FG008|Phase 2|Adverse Event|0
6056204|NCT00460603|9656281|FG009|Phase 2|Adverse Event|12
6056205|NCT00460603|9656282|FG010|Phase 2|Adverse Event|9
6056206|NCT00460603|9656283|FG011|Phase 2|Adverse Event|10
6056207|NCT00460603|9656272|FG000|Phase 2|Death|0
6091214|NCT00697515|9703591|FG001|Dose Optimization Period|Adverse Event|0
6202386|NCT01500278|9862465|FG001|Week 13 - Week 104|Recurrent infections|0
6091215|NCT00697515|9703590|FG000|Dose Optimization Period|Withdrawal by Subject|5
6091216|NCT00697515|9703591|FG001|Dose Optimization Period|Withdrawal by Subject|0
6091217|NCT00697515|9703590|FG000|Dose Optimization Period|Lost to Follow-up|2
6091218|NCT00697515|9703591|FG001|Dose Optimization Period|Lost to Follow-up|0
6091219|NCT00697515|9703590|FG000|Dose Optimization Period|sponsor request|2
6091220|NCT00697515|9703591|FG001|Dose Optimization Period|sponsor request|0
6091221|NCT00697515|9703590|FG000|Dose Optimization Period|called to active duty|1
6091222|NCT00697515|9703591|FG001|Dose Optimization Period|called to active duty|0
6091223|NCT00697515|9703590|FG000|Dose Optimization Period|elevated QTc|1
6091224|NCT00697515|9703591|FG001|Dose Optimization Period|elevated QTc|0
6091225|NCT00697515|9703590|FG000|First Intervention (Crossover Period)|Natural disaster|8
6056208|NCT00460603|9656273|FG001|Phase 2|Death|0
6056209|NCT00460603|9656274|FG002|Phase 2|Death|0
6056210|NCT00460603|9656275|FG003|Phase 2|Death|0
6056211|NCT00460603|9656276|FG004|Phase 2|Death|0
6056212|NCT00460603|9656277|FG005|Phase 2|Death|0
6056213|NCT00460603|9656278|FG006|Phase 2|Death|0
6056214|NCT00460603|9656279|FG007|Phase 2|Death|0
6056215|NCT00460603|9656280|FG008|Phase 2|Death|0
6056216|NCT00460603|9656281|FG009|Phase 2|Death|4
6056217|NCT00460603|9656282|FG010|Phase 2|Death|2
6056218|NCT00460603|9656283|FG011|Phase 2|Death|2
6056219|NCT00460603|9656272|FG000|Phase 2|Protocol Violation|0
6056220|NCT00460603|9656273|FG001|Phase 2|Protocol Violation|0
6056221|NCT00460603|9656274|FG002|Phase 2|Protocol Violation|0
6056222|NCT00460603|9656275|FG003|Phase 2|Protocol Violation|0
6056223|NCT00460603|9656276|FG004|Phase 2|Protocol Violation|0
6056224|NCT00460603|9656277|FG005|Phase 2|Protocol Violation|0
6056225|NCT00460603|9656278|FG006|Phase 2|Protocol Violation|0
6056226|NCT00460603|9656279|FG007|Phase 2|Protocol Violation|0
6056227|NCT00460603|9656280|FG008|Phase 2|Protocol Violation|0
6056228|NCT00460603|9656281|FG009|Phase 2|Protocol Violation|1
6056229|NCT00460603|9656282|FG010|Phase 2|Protocol Violation|1
6056230|NCT00460603|9656283|FG011|Phase 2|Protocol Violation|0
6056231|NCT00460603|9656272|FG000|Phase 2|Lost to Follow-up|0
6056232|NCT00460603|9656273|FG001|Phase 2|Lost to Follow-up|0
6056233|NCT00460603|9656274|FG002|Phase 2|Lost to Follow-up|0
6056234|NCT00460603|9656275|FG003|Phase 2|Lost to Follow-up|0
6056235|NCT00460603|9656276|FG004|Phase 2|Lost to Follow-up|0
6056236|NCT00460603|9656277|FG005|Phase 2|Lost to Follow-up|0
6056237|NCT00460603|9656278|FG006|Phase 2|Lost to Follow-up|0
6056238|NCT00460603|9656279|FG007|Phase 2|Lost to Follow-up|0
6056239|NCT00460603|9656280|FG008|Phase 2|Lost to Follow-up|0
6056240|NCT00460603|9656281|FG009|Phase 2|Lost to Follow-up|1
6056241|NCT00460603|9656282|FG010|Phase 2|Lost to Follow-up|0
6056242|NCT00460603|9656283|FG011|Phase 2|Lost to Follow-up|0
6056243|NCT00460603|9656272|FG000|Phase 2|Other|0
6056244|NCT00460603|9656273|FG001|Phase 2|Other|0
6056245|NCT00460603|9656274|FG002|Phase 2|Other|0
6056246|NCT00460603|9656275|FG003|Phase 2|Other|0
6056247|NCT00460603|9656276|FG004|Phase 2|Other|0
6056248|NCT00460603|9656277|FG005|Phase 2|Other|0
6056249|NCT00460603|9656278|FG006|Phase 2|Other|0
6056250|NCT00460603|9656279|FG007|Phase 2|Other|0
6056251|NCT00460603|9656280|FG008|Phase 2|Other|0
6056252|NCT00460603|9656281|FG009|Phase 2|Other|6
6056253|NCT00460603|9656282|FG010|Phase 2|Other|16
6056254|NCT00460603|9656283|FG011|Phase 2|Other|7
6056255|NCT00460603|9656272|FG000|Phase 2|Objective Progression or Relapse|0
6056256|NCT00460603|9656273|FG001|Phase 2|Objective Progression or Relapse|0
6056257|NCT00460603|9656274|FG002|Phase 2|Objective Progression or Relapse|0
6056258|NCT00460603|9656275|FG003|Phase 2|Objective Progression or Relapse|0
6056259|NCT00460603|9656276|FG004|Phase 2|Objective Progression or Relapse|0
6056260|NCT00460603|9656277|FG005|Phase 2|Objective Progression or Relapse|0
6056261|NCT00460603|9656278|FG006|Phase 2|Objective Progression or Relapse|0
6056262|NCT00460603|9656279|FG007|Phase 2|Objective Progression or Relapse|0
6056263|NCT00460603|9656280|FG008|Phase 2|Objective Progression or Relapse|0
6056264|NCT00460603|9656281|FG009|Phase 2|Objective Progression or Relapse|9
6056265|NCT00460603|9656282|FG010|Phase 2|Objective Progression or Relapse|10
6056266|NCT00460603|9656283|FG011|Phase 2|Objective Progression or Relapse|17
6056267|NCT00460603|9656272|FG000|Phase 2|Global Deterioration of Health Status|0
6056268|NCT00460603|9656273|FG001|Phase 2|Global Deterioration of Health Status|0
6056269|NCT00460603|9656274|FG002|Phase 2|Global Deterioration of Health Status|0
6056270|NCT00460603|9656275|FG003|Phase 2|Global Deterioration of Health Status|0
6091226|NCT00697515|9703591|FG001|First Intervention (Crossover Period)|Natural disaster|9
6056271|NCT00460603|9656276|FG004|Phase 2|Global Deterioration of Health Status|0
6056272|NCT00460603|9656277|FG005|Phase 2|Global Deterioration of Health Status|0
6056273|NCT00460603|9656278|FG006|Phase 2|Global Deterioration of Health Status|0
6056274|NCT00460603|9656279|FG007|Phase 2|Global Deterioration of Health Status|0
6056275|NCT00460603|9656280|FG008|Phase 2|Global Deterioration of Health Status|0
6056276|NCT00460603|9656281|FG009|Phase 2|Global Deterioration of Health Status|0
6056277|NCT00460603|9656282|FG010|Phase 2|Global Deterioration of Health Status|1
6056278|NCT00460603|9656283|FG011|Phase 2|Global Deterioration of Health Status|0
6056279|NCT00460603|9656272|FG000|Phase 2|Withdrawal by Subject|0
6056280|NCT00460603|9656273|FG001|Phase 2|Withdrawal by Subject|0
6056281|NCT00460603|9656274|FG002|Phase 2|Withdrawal by Subject|0
6056282|NCT00460603|9656275|FG003|Phase 2|Withdrawal by Subject|0
6056283|NCT00460603|9656276|FG004|Phase 2|Withdrawal by Subject|0
6056284|NCT00460603|9656277|FG005|Phase 2|Withdrawal by Subject|0
6056285|NCT00460603|9656278|FG006|Phase 2|Withdrawal by Subject|0
6056286|NCT00460603|9656279|FG007|Phase 2|Withdrawal by Subject|0
6056287|NCT00460603|9656280|FG008|Phase 2|Withdrawal by Subject|0
6056288|NCT00460603|9656281|FG009|Phase 2|Withdrawal by Subject|5
6056289|NCT00460603|9656282|FG010|Phase 2|Withdrawal by Subject|4
6056290|NCT00460603|9656283|FG011|Phase 2|Withdrawal by Subject|5
6056291|NCT00460603|9656272|FG000|Phase 2|Randomized, but not treated|0
6056292|NCT00460603|9656273|FG001|Phase 2|Randomized, but not treated|0
6056293|NCT00460603|9656274|FG002|Phase 2|Randomized, but not treated|0
6056294|NCT00460603|9656275|FG003|Phase 2|Randomized, but not treated|0
6056295|NCT00460603|9656276|FG004|Phase 2|Randomized, but not treated|0
6056296|NCT00460603|9656277|FG005|Phase 2|Randomized, but not treated|0
6056297|NCT00460603|9656278|FG006|Phase 2|Randomized, but not treated|0
6056298|NCT00460603|9656279|FG007|Phase 2|Randomized, but not treated|0
6056299|NCT00460603|9656280|FG008|Phase 2|Randomized, but not treated|0
6056300|NCT00460603|9656281|FG009|Phase 2|Randomized, but not treated|3
6056301|NCT00460603|9656282|FG010|Phase 2|Randomized, but not treated|0
6056302|NCT00460603|9656283|FG011|Phase 2|Randomized, but not treated|0
6056303|NCT00460655|9656311|FG000|Double-Blind Phase (12 Weeks)|Adverse Event|3
6056304|NCT00460655|9656312|FG001|Double-Blind Phase (12 Weeks)|Adverse Event|0
6056305|NCT00460655|9656313|FG002|Double-Blind Phase (12 Weeks)|Adverse Event|0
6056306|NCT00460655|9656314|FG003|Double-Blind Phase (12 Weeks)|Adverse Event|0
6056307|NCT00460655|9656311|FG000|Double-Blind Phase (12 Weeks)|Withdrawal by Subject|3
6056308|NCT00460655|9656312|FG001|Double-Blind Phase (12 Weeks)|Withdrawal by Subject|0
6056309|NCT00460655|9656313|FG002|Double-Blind Phase (12 Weeks)|Withdrawal by Subject|0
6056310|NCT00460655|9656314|FG003|Double-Blind Phase (12 Weeks)|Withdrawal by Subject|0
6056311|NCT00460655|9656311|FG000|Double-Blind Phase (12 Weeks)|Protocol Violation|0
6091227|NCT00697515|9703590|FG000|First Intervention (Crossover Period)|Adverse Event|0
6091228|NCT00697515|9703591|FG001|First Intervention (Crossover Period)|Adverse Event|2
6056312|NCT00460655|9656312|FG001|Double-Blind Phase (12 Weeks)|Protocol Violation|1
6056313|NCT00460655|9656313|FG002|Double-Blind Phase (12 Weeks)|Protocol Violation|0
6056314|NCT00460655|9656314|FG003|Double-Blind Phase (12 Weeks)|Protocol Violation|0
6056315|NCT00460655|9656311|FG000|Open-Label Phase (36 Weeks)|Adverse Event|0
6056316|NCT00460655|9656312|FG001|Open-Label Phase (36 Weeks)|Adverse Event|0
6056317|NCT00460655|9656313|FG002|Open-Label Phase (36 Weeks)|Adverse Event|1
6056318|NCT00460655|9656314|FG003|Open-Label Phase (36 Weeks)|Adverse Event|6
6056319|NCT00460655|9656311|FG000|Open-Label Phase (36 Weeks)|Withdrawal by Subject|0
6056320|NCT00460655|9656312|FG001|Open-Label Phase (36 Weeks)|Withdrawal by Subject|0
6056321|NCT00460655|9656313|FG002|Open-Label Phase (36 Weeks)|Withdrawal by Subject|6
6056322|NCT00460655|9656314|FG003|Open-Label Phase (36 Weeks)|Withdrawal by Subject|2
6056323|NCT00460655|9656311|FG000|Open-Label Phase (36 Weeks)|Meeting the Exclusion Criteria|0
6056324|NCT00460655|9656312|FG001|Open-Label Phase (36 Weeks)|Meeting the Exclusion Criteria|0
6056325|NCT00460655|9656313|FG002|Open-Label Phase (36 Weeks)|Meeting the Exclusion Criteria|0
6056326|NCT00460655|9656314|FG003|Open-Label Phase (36 Weeks)|Meeting the Exclusion Criteria|1
6056327|NCT00460746|9656324|FG000|Overall Study|Adverse Event|1
6056328|NCT00460746|9656324|FG000|Overall Study|Lost to Follow-up|1
6056329|NCT00460798|9656328|FG000|Overall Study|Death|59
6056330|NCT00460798|9656328|FG000|Overall Study|Adverse Event|27
6056331|NCT00460798|9656328|FG000|Overall Study|Lost to Follow-up|19
6056332|NCT00460798|9656328|FG000|Overall Study|Progressive Disease|99
6056333|NCT00460798|9656328|FG000|Overall Study|Other|27
6056334|NCT00460798|9656328|FG000|Overall Study|Ongoing at Date of Cut-Off|82
6056335|NCT00460798|9656328|FG000|Overall Study|Missing/Incomplete Dosing Information|27
6056336|NCT00460811|9656337|FG000|Overall Study|Adverse Event|4
6056337|NCT00460811|9656338|FG001|Overall Study|Adverse Event|6
6056338|NCT00460811|9656339|FG002|Overall Study|Adverse Event|3
6056339|NCT00460811|9656340|FG003|Overall Study|Adverse Event|10
6056340|NCT00460811|9656341|FG004|Overall Study|Adverse Event|2
6056341|NCT00460811|9656337|FG000|Overall Study|Noncompliance|1
6056342|NCT00460811|9656338|FG001|Overall Study|Noncompliance|0
6056343|NCT00460811|9656339|FG002|Overall Study|Noncompliance|0
6056344|NCT00460811|9656340|FG003|Overall Study|Noncompliance|2
6056345|NCT00460811|9656341|FG004|Overall Study|Noncompliance|1
6056346|NCT00460811|9656337|FG000|Overall Study|Withdrawal by Subject|7
6056347|NCT00460811|9656338|FG001|Overall Study|Withdrawal by Subject|7
6056348|NCT00460811|9656339|FG002|Overall Study|Withdrawal by Subject|6
6056349|NCT00460811|9656340|FG003|Overall Study|Withdrawal by Subject|3
6056350|NCT00460811|9656341|FG004|Overall Study|Withdrawal by Subject|11
6056351|NCT00460811|9656337|FG000|Overall Study|Physician Decision|1
6056352|NCT00460811|9656338|FG001|Overall Study|Physician Decision|0
6056353|NCT00460811|9656339|FG002|Overall Study|Physician Decision|0
6056354|NCT00460811|9656340|FG003|Overall Study|Physician Decision|0
6056355|NCT00460811|9656341|FG004|Overall Study|Physician Decision|0
6056356|NCT00460811|9656337|FG000|Overall Study|Lost to Follow-up|3
6056357|NCT00460811|9656338|FG001|Overall Study|Lost to Follow-up|2
6056358|NCT00460811|9656339|FG002|Overall Study|Lost to Follow-up|5
6056359|NCT00460811|9656340|FG003|Overall Study|Lost to Follow-up|3
6202387|NCT01500278|9862464|FG000|Week 13 - Week 104|False positive test|1
6056360|NCT00460811|9656341|FG004|Overall Study|Lost to Follow-up|6
6056361|NCT00461123|9656383|FG000|Overall Study|Adverse Event|1
6056362|NCT00461123|9656384|FG001|Overall Study|Adverse Event|0
6056363|NCT00461123|9656383|FG000|Overall Study|Lost to Follow-up|1
6056364|NCT00461123|9656384|FG001|Overall Study|Lost to Follow-up|1
6056365|NCT00461123|9656383|FG000|Overall Study|Protocol Violation|3
6056366|NCT00461123|9656384|FG001|Overall Study|Protocol Violation|2
6056367|NCT00461123|9656383|FG000|Overall Study|Withdrawal by Subject|1
6056368|NCT00461123|9656384|FG001|Overall Study|Withdrawal by Subject|3
6056369|NCT00461175|9656392|FG000|Overall Study|Protocol Violation|522
6056370|NCT00461175|9656393|FG001|Overall Study|Protocol Violation|365
6056371|NCT00461253|9656401|FG000|Overall Study|Death|985
6056372|NCT00461253|9656402|FG001|Overall Study|Death|0
6056373|NCT00461253|9656401|FG000|Overall Study|Protocol Violation|613
6091229|NCT00697515|9703590|FG000|First Intervention (Crossover Period)|Withdrawal by Subject|2
6091230|NCT00697515|9703591|FG001|First Intervention (Crossover Period)|Withdrawal by Subject|1
6091231|NCT00697515|9703590|FG000|Second Intervention (Crossover Period)|Withdrawal by Subject|1
6091232|NCT00697515|9703591|FG001|Second Intervention (Crossover Period)|Withdrawal by Subject|1
6091233|NCT00697593|9703607|FG000|Overall Study|Adverse Event|3
6091234|NCT00697593|9703607|FG000|Overall Study|Protocol Violation|1
6091235|NCT00697593|9703607|FG000|Overall Study|Lack of Efficacy|3
6091236|NCT00697593|9703607|FG000|Overall Study|Suspension of the study by sponsor|12
6091237|NCT00697619|9703613|FG000|Overall Study|Lack of Efficacy|2
6091238|NCT00697619|9703614|FG001|Overall Study|Lack of Efficacy|2
6091239|NCT00697619|9703613|FG000|Overall Study|Adverse Event|4
6091240|NCT00697619|9703614|FG001|Overall Study|Adverse Event|6
6091241|NCT00697788|9703629|FG000|Dexmedetomidine 0.7 mcg/kg/hr Infusion|Physician Decision|0
6091242|NCT00697788|9703630|FG001|Dexmedetomidine 0.7 mcg/kg/hr Infusion|Physician Decision|2
6091243|NCT00697788|9703631|FG002|Dexmedetomidine 0.7 mcg/kg/hr Infusion|Physician Decision|0
6091244|NCT00697788|9703632|FG003|Dexmedetomidine 0.7 mcg/kg/hr Infusion|Physician Decision|0
6091245|NCT00697788|9703633|FG004|Dexmedetomidine 0.7 mcg/kg/hr Infusion|Physician Decision|0
6091246|NCT00697788|9703634|FG005|Dexmedetomidine 0.7 mcg/kg/hr Infusion|Physician Decision|0
6091247|NCT00697788|9703635|FG006|Dexmedetomidine 0.7 mcg/kg/hr Infusion|Physician Decision|0
6091248|NCT00697788|9703636|FG007|Dexmedetomidine 0.7 mcg/kg/hr Infusion|Physician Decision|0
6091249|NCT00697788|9703629|FG000|Dexmedetomidine 1.6 mcg.kg.hr Infusion|Physician Decision|0
6091250|NCT00697788|9703630|FG001|Dexmedetomidine 1.6 mcg.kg.hr Infusion|Physician Decision|0
6091251|NCT00697788|9703631|FG002|Dexmedetomidine 1.6 mcg.kg.hr Infusion|Physician Decision|0
6091252|NCT00697788|9703632|FG003|Dexmedetomidine 1.6 mcg.kg.hr Infusion|Physician Decision|0
6091253|NCT00697788|9703633|FG004|Dexmedetomidine 1.6 mcg.kg.hr Infusion|Physician Decision|1
6091254|NCT00697788|9703634|FG005|Dexmedetomidine 1.6 mcg.kg.hr Infusion|Physician Decision|0
6091255|NCT00697788|9703635|FG006|Dexmedetomidine 1.6 mcg.kg.hr Infusion|Physician Decision|0
6091256|NCT00697788|9703636|FG007|Dexmedetomidine 1.6 mcg.kg.hr Infusion|Physician Decision|0
6091257|NCT00697827|9703678|FG000|Overall Study|enrolled but not treated|2
6091258|NCT00697827|9703679|FG001|Overall Study|enrolled but not treated|1
6091259|NCT00698204|9703712|FG000|Overall Study|Withdrawal by Subject|1
6091260|NCT00698204|9703713|FG001|Overall Study|Withdrawal by Subject|0
6091261|NCT00698451|9703721|FG000|Overall Study|Adverse Event|22
6091262|NCT00698451|9703721|FG000|Overall Study|Physician Decision|2
6091263|NCT00698451|9703721|FG000|Overall Study|Protocol Violation|6
6091264|NCT00698451|9703721|FG000|Overall Study|Withdrawal by Subject|6
6091265|NCT00698451|9703721|FG000|Overall Study|Disease progression|3
6091266|NCT00698516|9703725|FG000|Overall Study|Study Termination|2
6091267|NCT00698516|9703725|FG000|Overall Study|Withdrawal by Subject|3
6091268|NCT00698581|9703735|FG000|Overall Study|Lack of Efficacy|23
6091269|NCT00698581|9703736|FG001|Overall Study|Lack of Efficacy|11
6091270|NCT00698581|9703735|FG000|Overall Study|Withdrawal by Subject|6
6091271|NCT00698581|9703736|FG001|Overall Study|Withdrawal by Subject|0
6091272|NCT00698581|9703735|FG000|Overall Study|Other reason|9
6091273|NCT00698581|9703736|FG001|Overall Study|Other reason|1
6091274|NCT00698581|9703735|FG000|Overall Study|SAE, non-fatal|1
6091275|NCT00698581|9703736|FG001|Overall Study|SAE, non-fatal|0
6091276|NCT00698581|9703735|FG000|Overall Study|AE, non-serious non-fatal|4
6091277|NCT00698581|9703736|FG001|Overall Study|AE, non-serious non-fatal|0
6091278|NCT00698581|9703735|FG000|Overall Study|SAE, non-fatal+AE, non-serious non-fatal|1
6091279|NCT00698581|9703736|FG001|Overall Study|SAE, non-fatal+AE, non-serious non-fatal|0
5980359|NCT03769194|9569134|FG000|Overall Study|Withdrawal by Subject|0
5980360|NCT03769194|9569135|FG001|Overall Study|Withdrawal by Subject|7
5980361|NCT03769194|9569136|FG002|Overall Study|Withdrawal by Subject|4
5980362|NCT03769194|9569137|FG003|Overall Study|Withdrawal by Subject|1
5980363|NCT03769194|9569134|FG000|Overall Study|moved from study area|0
5980364|NCT03769194|9569135|FG001|Overall Study|moved from study area|2
5980365|NCT03769194|9569136|FG002|Overall Study|moved from study area|1
5980366|NCT03769194|9569137|FG003|Overall Study|moved from study area|1
5980367|NCT03769194|9569134|FG000|Overall Study|Lost to Follow-up|3
5980368|NCT03769194|9569135|FG001|Overall Study|Lost to Follow-up|6
5980369|NCT03769194|9569136|FG002|Overall Study|Lost to Follow-up|3
5980370|NCT03769194|9569137|FG003|Overall Study|Lost to Follow-up|6
5980371|NCT03769194|9569134|FG000|Overall Study|other|1
5980372|NCT03769194|9569135|FG001|Overall Study|other|3
5980373|NCT03769194|9569136|FG002|Overall Study|other|0
5980374|NCT03769194|9569137|FG003|Overall Study|other|1
5980375|NCT03738332|9569147|FG000|Overall Study|Withdrawal by Subject|1
6056374|NCT00461253|9656402|FG001|Overall Study|Protocol Violation|236
6056375|NCT00461253|9656401|FG000|Overall Study|no response|2609
6056376|NCT00461253|9656402|FG001|Overall Study|no response|11789
6056377|NCT00461253|9656401|FG000|Overall Study|administrative|773
6056378|NCT00461253|9656402|FG001|Overall Study|administrative|7773
6056379|NCT00461305|9656423|FG000|Treatment|Adverse Event|26
6056380|NCT00461305|9656424|FG001|Treatment|Adverse Event|3
6056381|NCT00461305|9656423|FG000|Treatment|Lost to Follow-up|4
6056382|NCT00461305|9656424|FG001|Treatment|Lost to Follow-up|2
6056383|NCT00461305|9656423|FG000|Treatment|Protocol Violation|13
6056384|NCT00461305|9656424|FG001|Treatment|Protocol Violation|2
6056385|NCT00461305|9656423|FG000|Treatment|Withdrawal by Subject|48
6056386|NCT00461305|9656424|FG001|Treatment|Withdrawal by Subject|2
6056387|NCT00461305|9656423|FG000|Treatment|Never dispensed|5
6056388|NCT00461305|9656424|FG001|Treatment|Never dispensed|0
6056389|NCT00461305|9656423|FG000|Treatment|Study drug not taken|1
6056390|NCT00461305|9656424|FG001|Treatment|Study drug not taken|0
6056391|NCT00461305|9656423|FG000|Treatment|Partially missing diary|2
6056392|NCT00461305|9656424|FG001|Treatment|Partially missing diary|0
6056393|NCT00461305|9656423|FG000|Treatment|Other (missing drug etc)|2
6056394|NCT00461305|9656424|FG001|Treatment|Other (missing drug etc)|0
6056395|NCT00461305|9656423|FG000|Continued Treatment|Adverse Event|26
6056396|NCT00461305|9656424|FG001|Continued Treatment|Adverse Event|0
6056397|NCT00461305|9656423|FG000|Continued Treatment|Lost to Follow-up|4
6056398|NCT00461305|9656424|FG001|Continued Treatment|Lost to Follow-up|0
6056399|NCT00461305|9656423|FG000|Continued Treatment|Protocol Violation|13
6056400|NCT00461305|9656424|FG001|Continued Treatment|Protocol Violation|0
6056401|NCT00461305|9656423|FG000|Continued Treatment|Withdrawal by Subject|48
6056402|NCT00461305|9656424|FG001|Continued Treatment|Withdrawal by Subject|0
6056403|NCT00461305|9656423|FG000|Continued Treatment|Partially missing diary|2
6056404|NCT00461305|9656424|FG001|Continued Treatment|Partially missing diary|0
6056405|NCT00461305|9656423|FG000|Continued Treatment|Other (missing drug etc)|2
6056406|NCT00461305|9656424|FG001|Continued Treatment|Other (missing drug etc)|0
6056407|NCT00461500|9656441|FG000|Overall Study|Adverse Event|1
6056408|NCT00461500|9656442|FG001|Overall Study|Adverse Event|0
6056409|NCT00461500|9656441|FG000|Overall Study|Lack of Efficacy|0
6056410|NCT00461500|9656442|FG001|Overall Study|Lack of Efficacy|1
6056411|NCT00461500|9656441|FG000|Overall Study|Expired Drug Treatment|1
6056412|NCT00461500|9656442|FG001|Overall Study|Expired Drug Treatment|1
6056413|NCT00461500|9656441|FG000|Overall Study|Study Stopped|1
6056414|NCT00461500|9656442|FG001|Overall Study|Study Stopped|2
6056415|NCT00461500|9656441|FG000|Overall Study|Drug Treatment Misuse|1
6056416|NCT00461500|9656442|FG001|Overall Study|Drug Treatment Misuse|0
6056417|NCT00461500|9656441|FG000|Overall Study|No Longer Willing to Take Part in Study|1
6056418|NCT00461500|9656442|FG001|Overall Study|No Longer Willing to Take Part in Study|0
6056419|NCT00461500|9656441|FG000|Overall Study|Lost to Follow-up|2
6056420|NCT00461500|9656442|FG001|Overall Study|Lost to Follow-up|2
6056421|NCT00461552|9656463|FG000|Overall Study|Drug Dispensing error|0
6056422|NCT00461552|9656464|FG001|Overall Study|Drug Dispensing error|2
6056423|NCT00461630|9656481|FG000|Overall Study|Death|798
6056424|NCT00461630|9656482|FG001|Overall Study|Death|732
6056425|NCT00461630|9656481|FG000|Overall Study|Lost to Follow-up|108
6056426|NCT00461630|9656482|FG001|Overall Study|Lost to Follow-up|95
6091280|NCT00698581|9703735|FG000|Overall Study|AE of unknown type|1
6091281|NCT00698581|9703736|FG001|Overall Study|AE of unknown type|0
6091282|NCT00698646|9703746|FG000|Overall Study|Adverse Event|8
6091283|NCT00698646|9703747|FG001|Overall Study|Adverse Event|7
6091284|NCT00698646|9703748|FG002|Overall Study|Adverse Event|8
6091285|NCT00698646|9703746|FG000|Overall Study|Unsatisfactory Therapeutic Effect|11
6091286|NCT00698646|9703747|FG001|Overall Study|Unsatisfactory Therapeutic Effect|11
6091287|NCT00698646|9703748|FG002|Overall Study|Unsatisfactory Therapeutic Effect|7
6091288|NCT00698646|9703746|FG000|Overall Study|Protocol Deviation|6
6091289|NCT00698646|9703747|FG001|Overall Study|Protocol Deviation|2
6091290|NCT00698646|9703748|FG002|Overall Study|Protocol Deviation|3
6091291|NCT00698646|9703746|FG000|Overall Study|Withdrawal by Subject|10
6091292|NCT00698646|9703747|FG001|Overall Study|Withdrawal by Subject|11
6091293|NCT00698646|9703748|FG002|Overall Study|Withdrawal by Subject|8
6091294|NCT00698646|9703746|FG000|Overall Study|Lost to Follow-up|0
6091295|NCT00698646|9703747|FG001|Overall Study|Lost to Follow-up|0
6091296|NCT00698646|9703748|FG002|Overall Study|Lost to Follow-up|2
6091297|NCT00698646|9703746|FG000|Overall Study|Administrative problems|1
6091298|NCT00698646|9703747|FG001|Overall Study|Administrative problems|0
6091299|NCT00698646|9703748|FG002|Overall Study|Administrative problems|1
6091300|NCT00698685|9703756|FG000|Overall Study|Sister withdrew as donor|1
6091301|NCT00698685|9703756|FG000|Overall Study|Off study pre transplant by clinic MD|1
6091302|NCT00698841|9703760|FG000|Overall Study|Withdrawal by Subject|2
6091303|NCT00698841|9703760|FG000|Overall Study|Adverse Event|3
6091304|NCT00698841|9703760|FG000|Overall Study|Disease progression|7
6091305|NCT00698841|9703760|FG000|Overall Study|Failure to meet eligibility criteria|2
6091306|NCT00698841|9703760|FG000|Overall Study|Study drug toxicity|2
6091307|NCT00698841|9703760|FG000|Overall Study|Other|2
6091308|NCT00698932|9703770|FG000|Overall Study|Adverse Event|0
6091309|NCT00698932|9703771|FG001|Overall Study|Adverse Event|2
6091310|NCT00698932|9703770|FG000|Overall Study|Incorrect enrollment|0
6091311|NCT00698932|9703771|FG001|Overall Study|Incorrect enrollment|2
6056427|NCT00461708|9656490|FG000|Overall Study|Adverse Event|17
6056428|NCT00461708|9656491|FG001|Overall Study|Adverse Event|7
6056429|NCT00461708|9656490|FG000|Overall Study|Lack of Efficacy|68
6056430|NCT00461708|9656491|FG001|Overall Study|Lack of Efficacy|20
6056431|NCT00461708|9656490|FG000|Overall Study|Physician Decision|10
6056432|NCT00461708|9656491|FG001|Overall Study|Physician Decision|4
6056433|NCT00461708|9656490|FG000|Overall Study|Withdrawal by Subject|8
6056434|NCT00461708|9656491|FG001|Overall Study|Withdrawal by Subject|2
6056435|NCT00461708|9656490|FG000|Overall Study|Other|4
6056436|NCT00461708|9656491|FG001|Overall Study|Other|4
6056437|NCT00461708|9656490|FG000|Overall Study|Death|8
6056438|NCT00461708|9656491|FG001|Overall Study|Death|1
6056439|NCT00461786|9656523|FG000|Overall Study|Entry Criteria Not Met|2
6056440|NCT00461786|9656523|FG000|Overall Study|Inevaluable (Never Treated)|1
6056441|NCT00461981|9656533|FG000|Overall Study|Lost to Follow-up|9
6056442|NCT00461981|9656534|FG001|Overall Study|Lost to Follow-up|6
6056443|NCT00461981|9656533|FG000|Overall Study|Withdrawal by Subject|2
6056444|NCT00461981|9656534|FG001|Overall Study|Withdrawal by Subject|3
6056445|NCT00462306|9656599|FG000|Overall Study|insufficient data|0
6056446|NCT00462306|9656600|FG001|Overall Study|insufficient data|13
6056447|NCT00462345|9656619|FG000|Overall Study|Withdrawal by Subject|2
6056448|NCT00462345|9656619|FG000|Overall Study|Did not complete second course|1
6056449|NCT00462384|9656623|FG000|Overall Study|Adverse Event|2
6056450|NCT00462384|9656623|FG000|Overall Study|Death|2
6056451|NCT00462384|9656623|FG000|Overall Study|Withdrawal by Subject|1
6056452|NCT00462384|9656623|FG000|Overall Study|Other|4
6056453|NCT00462462|9656643|FG000|Overall Study|Physician Decision|0
6056454|NCT00462462|9656644|FG001|Overall Study|Physician Decision|1
6056455|NCT00462488|9656654|FG000|Overall Study|Protocol Violation|1
6056456|NCT00462488|9656655|FG001|Overall Study|Protocol Violation|0
6056457|NCT00462488|9656654|FG000|Overall Study|Lack of Efficacy|19
6056458|NCT00462488|9656655|FG001|Overall Study|Lack of Efficacy|17
6056459|NCT00462501|9656661|FG000|Overall Study|Not treated|3
6056460|NCT00462501|9656661|FG000|Overall Study|Adverse Event|2
6056461|NCT00462670|9656680|FG000|Overall Study|Adverse Event|3
6056462|NCT00462670|9656681|FG001|Overall Study|Adverse Event|5
6056463|NCT00462670|9656680|FG000|Overall Study|Lack of Efficacy|1
6056464|NCT00462670|9656681|FG001|Overall Study|Lack of Efficacy|0
6056465|NCT00462670|9656680|FG000|Overall Study|Protocol Violation|1
6056466|NCT00462670|9656681|FG001|Overall Study|Protocol Violation|0
6056467|NCT00462670|9656680|FG000|Overall Study|Resolution of signs and symptoms|0
6056468|NCT00462670|9656681|FG001|Overall Study|Resolution of signs and symptoms|2
6056469|NCT00462709|9656687|FG000|Overall Study|Transitioned to commercial C1INH-nf|40
6056470|NCT00462709|9656687|FG000|Overall Study|Lost to Follow-up|10
6056471|NCT00462709|9656687|FG000|Overall Study|Withdrawal by Subject|8
6056472|NCT00462709|9656687|FG000|Overall Study|Transferred to LEVP2006-1 (NCT00438815)|3
6056473|NCT00462709|9656687|FG000|Overall Study|Death|2
6056474|NCT00462709|9656687|FG000|Overall Study|Logistical reasons|2
6056475|NCT00462709|9656687|FG000|Overall Study|Physician Decision|1
6056476|NCT00462709|9656687|FG000|Overall Study|Withdrew to start treatment with Cetor|1
6056477|NCT00462761|9656709|FG000|Overall Study|Adverse Event|6
6056478|NCT00462761|9656709|FG000|Overall Study|Withdrawal by Subject|9
6056479|NCT00462761|9656709|FG000|Overall Study|Physician Decision|5
6056480|NCT00462761|9656709|FG000|Overall Study|Disease progression|43
6056481|NCT00462761|9656709|FG000|Overall Study|Death|12
6056482|NCT00462761|9656709|FG000|Overall Study|Other|1
6056483|NCT00462826|9656741|FG000|Overall Study|Ineligible - second primary|1
6056484|NCT00462826|9656741|FG000|Overall Study|Ineligible - wrong cell type|1
6056485|NCT00462826|9656741|FG000|Overall Study|Ineligible - wrong primary|2
6056486|NCT00462826|9656741|FG000|Overall Study|Never treated|1
6056487|NCT00462865|9656760|FG000|Overall Study|Adverse Event|1
6056488|NCT00462982|9656781|FG000|Overall Study|Adverse Event|1
6056489|NCT00462982|9656781|FG000|Overall Study|Patient Not Treated|2
6056490|NCT00463047|9656785|FG000|Titration Period 1|Adverse Event|10
6056491|NCT00463047|9656786|FG001|Titration Period 1|Adverse Event|8
6056492|NCT00463047|9656785|FG000|Titration Period 1|Lack of Efficacy|10
6056493|NCT00463047|9656786|FG001|Titration Period 1|Lack of Efficacy|4
6056494|NCT00463047|9656785|FG000|Titration Period 1|Lost to Follow-up|2
6056495|NCT00463047|9656786|FG001|Titration Period 1|Lost to Follow-up|0
6056496|NCT00463047|9656785|FG000|Titration Period 1|Non-compliance with study medication|3
6056497|NCT00463047|9656786|FG001|Titration Period 1|Non-compliance with study medication|5
6056498|NCT00463047|9656785|FG000|Titration Period 1|Protocol Violation|5
6056499|NCT00463047|9656786|FG001|Titration Period 1|Protocol Violation|5
6056500|NCT00463047|9656785|FG000|Titration Period 1|Withdrawal by Subject|3
6056501|NCT00463047|9656786|FG001|Titration Period 1|Withdrawal by Subject|5
6056502|NCT00463047|9656785|FG000|Titration Period 1|Non-compliance procedures|4
6056503|NCT00463047|9656786|FG001|Titration Period 1|Non-compliance procedures|10
6056504|NCT00463047|9656785|FG000|Titration Period 1|Other|0
6056505|NCT00463047|9656786|FG001|Titration Period 1|Other|2
6056506|NCT00463047|9656785|FG000|Titration Period 2|Adverse Event|9
6056507|NCT00463047|9656786|FG001|Titration Period 2|Adverse Event|9
6056508|NCT00463047|9656785|FG000|Titration Period 2|Lack of Efficacy|6
6056509|NCT00463047|9656786|FG001|Titration Period 2|Lack of Efficacy|4
6056510|NCT00463047|9656785|FG000|Titration Period 2|Withdrawal by Subject|1
6056511|NCT00463047|9656786|FG001|Titration Period 2|Withdrawal by Subject|0
6056512|NCT00463047|9656785|FG000|Titration Period 2|Protocol Violation|2
6056513|NCT00463047|9656786|FG001|Titration Period 2|Protocol Violation|3
6091312|NCT00698932|9703770|FG000|Overall Study|Study specific discontinuation criteria|3
6091313|NCT00698932|9703771|FG001|Overall Study|Study specific discontinuation criteria|4
6091314|NCT00698932|9703770|FG000|Overall Study|Withdrawal by Subject|11
6091315|NCT00698932|9703771|FG001|Overall Study|Withdrawal by Subject|23
6091316|NCT00698932|9703770|FG000|Overall Study|Lost to Follow-up|6
6091317|NCT00698932|9703771|FG001|Overall Study|Lost to Follow-up|1
6091318|NCT00698932|9703770|FG000|Overall Study|Severe non-compliance to protocol|1
6091319|NCT00698932|9703771|FG001|Overall Study|Severe non-compliance to protocol|2
6091320|NCT00698932|9703770|FG000|Overall Study|Safety reasons|0
6091321|NCT00698932|9703771|FG001|Overall Study|Safety reasons|2
6091322|NCT00698932|9703770|FG000|Overall Study|Death|1
6091323|NCT00698932|9703771|FG001|Overall Study|Death|0
6091324|NCT00698997|9703779|FG000|Overall Study|Lost to Follow-up|3
6091325|NCT00698997|9703780|FG001|Overall Study|Lost to Follow-up|0
6091326|NCT00698997|9703779|FG000|Overall Study|Withdrawal by Subject|7
6091327|NCT00698997|9703780|FG001|Overall Study|Withdrawal by Subject|27
6091328|NCT00699153|9703806|FG000|Overall Study|Lost to Follow-up|1
6091329|NCT00699153|9703807|FG001|Overall Study|Lost to Follow-up|0
6091330|NCT00699153|9703806|FG000|Overall Study|Adverse Event|0
6091331|NCT00699153|9703807|FG001|Overall Study|Adverse Event|2
6091332|NCT00699153|9703806|FG000|Overall Study|Protocol Violation|1
6091333|NCT00699153|9703807|FG001|Overall Study|Protocol Violation|0
6091334|NCT00699153|9703806|FG000|Overall Study|Travel Problem|1
6091335|NCT00699153|9703807|FG001|Overall Study|Travel Problem|0
6091336|NCT00699192|9703816|FG000|Overall Study|Missing|1
6091337|NCT00699192|9703817|FG001|Overall Study|Missing|1
6091338|NCT00699192|9703818|FG002|Overall Study|Missing|1
6091339|NCT00699192|9703816|FG000|Overall Study|Adverse Event|9
6091340|NCT00699192|9703817|FG001|Overall Study|Adverse Event|4
6091341|NCT00699192|9703818|FG002|Overall Study|Adverse Event|3
6091342|NCT00699192|9703816|FG000|Overall Study|Abnormal test procedure result(s)|0
6091343|NCT00699192|9703817|FG001|Overall Study|Abnormal test procedure result(s)|0
6091344|NCT00699192|9703818|FG002|Overall Study|Abnormal test procedure result(s)|1
6091345|NCT00699192|9703816|FG000|Overall Study|Lack of Efficacy|0
6091346|NCT00699192|9703817|FG001|Overall Study|Lack of Efficacy|0
6091347|NCT00699192|9703818|FG002|Overall Study|Lack of Efficacy|1
6091348|NCT00699192|9703816|FG000|Overall Study|Withdrawal by Subject|3
6091349|NCT00699192|9703817|FG001|Overall Study|Withdrawal by Subject|2
6091350|NCT00699192|9703818|FG002|Overall Study|Withdrawal by Subject|4
6091351|NCT00699192|9703816|FG000|Overall Study|Administrative problems|1
6091352|NCT00699192|9703817|FG001|Overall Study|Administrative problems|3
6091353|NCT00699192|9703818|FG002|Overall Study|Administrative problems|1
6091354|NCT00699192|9703816|FG000|Overall Study|Protocol Violation|2
6091355|NCT00699192|9703817|FG001|Overall Study|Protocol Violation|2
6091356|NCT00699192|9703818|FG002|Overall Study|Protocol Violation|0
6091357|NCT00699283|9703832|FG000|Overall Study|Lack of Efficacy|15
6091358|NCT00699283|9703833|FG001|Overall Study|Lack of Efficacy|5
6091359|NCT00699283|9703832|FG000|Overall Study|Lost to Follow-up|2
6091360|NCT00699283|9703833|FG001|Overall Study|Lost to Follow-up|0
6091361|NCT00699283|9703832|FG000|Overall Study|Withdrawal by Subject|1
6091362|NCT00699283|9703833|FG001|Overall Study|Withdrawal by Subject|0
6091363|NCT00699283|9703832|FG000|Overall Study|Other Reason|5
6091364|NCT00699283|9703833|FG001|Overall Study|Other Reason|1
6091365|NCT00699283|9703832|FG000|Overall Study|SAE, non-fatal|1
6091366|NCT00699283|9703833|FG001|Overall Study|SAE, non-fatal|1
6091367|NCT00699283|9703832|FG000|Overall Study|AE, non-serious non-fatal|8
6091368|NCT00699283|9703833|FG001|Overall Study|AE, non-serious non-fatal|1
6091369|NCT00699283|9703832|FG000|Overall Study|AE of unknown type|1
6091370|NCT00699283|9703833|FG001|Overall Study|AE of unknown type|0
6091371|NCT00699335|9703838|FG000|Overall Study|Combination of multiple reasons|176
6091372|NCT00699335|9703838|FG000|Overall Study|Missing data|52
6091373|NCT00699348|9703845|FG000|Overall Study|Death|6
6091374|NCT00699348|9703845|FG000|Overall Study|Adverse Event|15
6091375|NCT00699348|9703845|FG000|Overall Study|Withdrawal by Subject|11
6091376|NCT00699348|9703845|FG000|Overall Study|Protocol Violation|10
6091377|NCT00699348|9703845|FG000|Overall Study|Lack of Efficacy|8
6091378|NCT00699348|9703845|FG000|Overall Study|Failure to return|1
6091379|NCT00699348|9703845|FG000|Overall Study|Blood transfusion|24
6091380|NCT00699348|9703845|FG000|Overall Study|Renal transplantation|10
6091381|NCT00699348|9703845|FG000|Overall Study|Other|5
6091382|NCT00699374|9703851|FG000|Overall Study|Death|93
6091383|NCT00699374|9703852|FG001|Overall Study|Death|83
6091384|NCT00699374|9703851|FG000|Overall Study|Adverse Event|70
6091385|NCT00699374|9703852|FG001|Overall Study|Adverse Event|67
6202388|NCT01500278|9862465|FG001|Week 13 - Week 104|False positive test|2
6056514|NCT00463047|9656785|FG000|Titration Period 2|Lost to Follow-up|1
6056515|NCT00463047|9656786|FG001|Titration Period 2|Lost to Follow-up|2
6056516|NCT00463047|9656785|FG000|Titration Period 2|Non-compliance study medication|4
6056517|NCT00463047|9656786|FG001|Titration Period 2|Non-compliance study medication|2
6056518|NCT00463047|9656785|FG000|Titration Period 2|Non-compliance procedures|4
6056519|NCT00463047|9656786|FG001|Titration Period 2|Non-compliance procedures|1
6056520|NCT00463047|9656785|FG000|Titration Period 2|Other|3
6056521|NCT00463047|9656786|FG001|Titration Period 2|Other|2
6056522|NCT00463047|9656785|FG000|Double-Blind Treatment Period 1|Adverse Event|0
6056523|NCT00463047|9656786|FG001|Double-Blind Treatment Period 1|Adverse Event|2
6056524|NCT00463047|9656785|FG000|Double-Blind Treatment Period 1|Protocol Violation|1
6056525|NCT00463047|9656786|FG001|Double-Blind Treatment Period 1|Protocol Violation|2
6056526|NCT00463047|9656785|FG000|Double-Blind Treatment Period 1|Non-compliance with procedures|1
6056527|NCT00463047|9656786|FG001|Double-Blind Treatment Period 1|Non-compliance with procedures|0
6056528|NCT00463047|9656785|FG000|Double-Blind Treatment Period 1|Other|1
6056529|NCT00463047|9656786|FG001|Double-Blind Treatment Period 1|Other|0
6056530|NCT00463047|9656785|FG000|Double-Blind Treatment Period 2|Adverse Event|0
6056531|NCT00463047|9656786|FG001|Double-Blind Treatment Period 2|Adverse Event|1
6056532|NCT00463047|9656785|FG000|Double-Blind Treatment Period 2|Withdrawal by Subject|0
6056533|NCT00463047|9656786|FG001|Double-Blind Treatment Period 2|Withdrawal by Subject|1
6056534|NCT00463047|9656785|FG000|Double-Blind Treatment Period 2|Non-compliance with procedures|1
6056535|NCT00463047|9656786|FG001|Double-Blind Treatment Period 2|Non-compliance with procedures|0
6056536|NCT00463060|9656795|FG000|Phase 1-Radiation 50Gy +Sunitinib 50mg|acute toxicity|5
6056537|NCT00463060|9656795|FG000|Phase 2-Radiation 50Gy +Sunitinib 37.5mg|Withdrawal by Subject|1
6056538|NCT00463151|9656808|FG000|Overall Study|Adverse Event|0
6056539|NCT00463151|9656809|FG001|Overall Study|Adverse Event|0
6056540|NCT00463151|9656810|FG002|Overall Study|Adverse Event|1
6056541|NCT00463151|9656811|FG003|Overall Study|Adverse Event|0
6056542|NCT00463151|9656808|FG000|Overall Study|Lack of Efficacy|2
6056543|NCT00463151|9656809|FG001|Overall Study|Lack of Efficacy|5
6056544|NCT00463151|9656810|FG002|Overall Study|Lack of Efficacy|2
6056545|NCT00463151|9656811|FG003|Overall Study|Lack of Efficacy|5
6056546|NCT00463151|9656808|FG000|Overall Study|Protocol Violation|0
6056547|NCT00463151|9656809|FG001|Overall Study|Protocol Violation|0
6056548|NCT00463151|9656810|FG002|Overall Study|Protocol Violation|0
6056549|NCT00463151|9656811|FG003|Overall Study|Protocol Violation|1
6056550|NCT00463151|9656808|FG000|Overall Study|Withdrawal by Subject|0
6056551|NCT00463151|9656809|FG001|Overall Study|Withdrawal by Subject|0
6056552|NCT00463151|9656810|FG002|Overall Study|Withdrawal by Subject|0
6056553|NCT00463151|9656811|FG003|Overall Study|Withdrawal by Subject|1
6056554|NCT00463229|9656823|FG000|Overall Study|Lost to Follow-up|5
6056555|NCT00463229|9656824|FG001|Overall Study|Lost to Follow-up|7
6056556|NCT00463229|9656823|FG000|Overall Study|Death|4
6056557|NCT00463229|9656824|FG001|Overall Study|Death|3
6056558|NCT00463346|9656833|FG000|Overall Study|Withdrawal by Subject|3
6056559|NCT00463346|9656834|FG001|Overall Study|Withdrawal by Subject|3
6056560|NCT00463385|9656846|FG000|Overall Study|Other|4
6056561|NCT00463385|9656847|FG001|Overall Study|Other|3
6056562|NCT00463385|9656848|FG002|Overall Study|Other|6
6056563|NCT00463385|9656849|FG003|Overall Study|Other|4
6056564|NCT00463385|9656846|FG000|Overall Study|Adverse Event|5
6056565|NCT00463385|9656847|FG001|Overall Study|Adverse Event|8
6056566|NCT00463385|9656848|FG002|Overall Study|Adverse Event|4
6056567|NCT00463385|9656849|FG003|Overall Study|Adverse Event|2
6056568|NCT00463385|9656846|FG000|Overall Study|Lack of Efficacy|6
6056569|NCT00463385|9656847|FG001|Overall Study|Lack of Efficacy|6
6056570|NCT00463385|9656848|FG002|Overall Study|Lack of Efficacy|7
6056571|NCT00463385|9656849|FG003|Overall Study|Lack of Efficacy|9
6056572|NCT00463385|9656846|FG000|Overall Study|Withdrawal by Subject|3
6056573|NCT00463385|9656847|FG001|Overall Study|Withdrawal by Subject|3
6056574|NCT00463385|9656848|FG002|Overall Study|Withdrawal by Subject|3
6056575|NCT00463385|9656849|FG003|Overall Study|Withdrawal by Subject|4
6056576|NCT00463385|9656846|FG000|Overall Study|Lost to Follow-up|0
6056577|NCT00463385|9656847|FG001|Overall Study|Lost to Follow-up|0
6056578|NCT00463385|9656848|FG002|Overall Study|Lost to Follow-up|0
6056579|NCT00463385|9656849|FG003|Overall Study|Lost to Follow-up|1
6056580|NCT00463385|9656846|FG000|Overall Study|Death|2
6056581|NCT00463385|9656847|FG001|Overall Study|Death|1
6056582|NCT00463385|9656848|FG002|Overall Study|Death|2
6056583|NCT00463385|9656849|FG003|Overall Study|Death|0
6056584|NCT00463385|9656846|FG000|Overall Study|Missing|2
6056585|NCT00463385|9656847|FG001|Overall Study|Missing|0
6056586|NCT00463385|9656848|FG002|Overall Study|Missing|0
6056587|NCT00463385|9656849|FG003|Overall Study|Missing|2
6056588|NCT00463385|9656846|FG000|Overall Study|1 participant received commercial drug|0
6056589|NCT00463385|9656847|FG001|Overall Study|1 participant received commercial drug|1
6056590|NCT00463385|9656848|FG002|Overall Study|1 participant received commercial drug|0
6056591|NCT00463385|9656849|FG003|Overall Study|1 participant received commercial drug|0
6056592|NCT00463476|9656886|FG000|Overall Study|Withdrawal by Subject|1
6056593|NCT00463476|9656887|FG001|Overall Study|Withdrawal by Subject|2
6056594|NCT00463476|9656886|FG000|Overall Study|Lost to Follow-up|1
6056595|NCT00463476|9656887|FG001|Overall Study|Lost to Follow-up|1
6056596|NCT00463567|9656900|FG000|Overall Study|Adverse Event|29
6056597|NCT00463567|9656901|FG001|Overall Study|Adverse Event|26
6056598|NCT00463567|9656902|FG002|Overall Study|Adverse Event|17
6056599|NCT00463567|9656903|FG003|Overall Study|Adverse Event|46
6056600|NCT00463567|9656904|FG004|Overall Study|Adverse Event|10
6056601|NCT00463567|9656905|FG005|Overall Study|Adverse Event|10
6056602|NCT00463567|9656906|FG006|Overall Study|Adverse Event|4
6056603|NCT00463567|9656900|FG000|Overall Study|Withdrawal by Subject|29
6056604|NCT00463567|9656901|FG001|Overall Study|Withdrawal by Subject|22
6091386|NCT00699374|9703851|FG000|Overall Study|Global deterioration of health status|7
6091387|NCT00699374|9703852|FG001|Overall Study|Global deterioration of health status|8
6056605|NCT00463567|9656902|FG002|Overall Study|Withdrawal by Subject|20
6056606|NCT00463567|9656903|FG003|Overall Study|Withdrawal by Subject|37
6056607|NCT00463567|9656904|FG004|Overall Study|Withdrawal by Subject|6
6056608|NCT00463567|9656905|FG005|Overall Study|Withdrawal by Subject|5
6056609|NCT00463567|9656906|FG006|Overall Study|Withdrawal by Subject|1
6056610|NCT00463567|9656900|FG000|Overall Study|Protocol Deviation|13
6056611|NCT00463567|9656901|FG001|Overall Study|Protocol Deviation|9
6056612|NCT00463567|9656902|FG002|Overall Study|Protocol Deviation|14
6056613|NCT00463567|9656903|FG003|Overall Study|Protocol Deviation|11
6056614|NCT00463567|9656904|FG004|Overall Study|Protocol Deviation|1
6056615|NCT00463567|9656905|FG005|Overall Study|Protocol Deviation|1
6056616|NCT00463567|9656906|FG006|Overall Study|Protocol Deviation|2
6056617|NCT00463567|9656900|FG000|Overall Study|Lost to Follow-up|12
6056618|NCT00463567|9656901|FG001|Overall Study|Lost to Follow-up|6
6056619|NCT00463567|9656902|FG002|Overall Study|Lost to Follow-up|13
6056620|NCT00463567|9656903|FG003|Overall Study|Lost to Follow-up|8
6056621|NCT00463567|9656904|FG004|Overall Study|Lost to Follow-up|1
6056622|NCT00463567|9656905|FG005|Overall Study|Lost to Follow-up|1
6056623|NCT00463567|9656906|FG006|Overall Study|Lost to Follow-up|1
6056624|NCT00463567|9656900|FG000|Overall Study|Administrative problems|5
6056625|NCT00463567|9656901|FG001|Overall Study|Administrative problems|3
6056626|NCT00463567|9656902|FG002|Overall Study|Administrative problems|6
6056627|NCT00463567|9656903|FG003|Overall Study|Administrative problems|9
6056628|NCT00463567|9656904|FG004|Overall Study|Administrative problems|3
6056629|NCT00463567|9656905|FG005|Overall Study|Administrative problems|2
6056630|NCT00463567|9656906|FG006|Overall Study|Administrative problems|2
6056631|NCT00463567|9656900|FG000|Overall Study|Lack of Efficacy|4
6056632|NCT00463567|9656901|FG001|Overall Study|Lack of Efficacy|9
6056633|NCT00463567|9656902|FG002|Overall Study|Lack of Efficacy|9
6056634|NCT00463567|9656903|FG003|Overall Study|Lack of Efficacy|17
6056635|NCT00463567|9656904|FG004|Overall Study|Lack of Efficacy|1
6056636|NCT00463567|9656905|FG005|Overall Study|Lack of Efficacy|0
6056637|NCT00463567|9656906|FG006|Overall Study|Lack of Efficacy|1
6056638|NCT00463567|9656900|FG000|Overall Study|Abnormal lab value(s)|1
6056639|NCT00463567|9656901|FG001|Overall Study|Abnormal lab value(s)|1
6056640|NCT00463567|9656902|FG002|Overall Study|Abnormal lab value(s)|2
6056641|NCT00463567|9656903|FG003|Overall Study|Abnormal lab value(s)|1
6056642|NCT00463567|9656904|FG004|Overall Study|Abnormal lab value(s)|1
6056643|NCT00463567|9656905|FG005|Overall Study|Abnormal lab value(s)|0
6056644|NCT00463567|9656906|FG006|Overall Study|Abnormal lab value(s)|0
6056645|NCT00463567|9656900|FG000|Overall Study|Abnormal test procedure result(s)|1
6056646|NCT00463567|9656901|FG001|Overall Study|Abnormal test procedure result(s)|1
6056647|NCT00463567|9656902|FG002|Overall Study|Abnormal test procedure result(s)|6
6056648|NCT00463567|9656903|FG003|Overall Study|Abnormal test procedure result(s)|2
6056649|NCT00463567|9656904|FG004|Overall Study|Abnormal test procedure result(s)|0
6056650|NCT00463567|9656905|FG005|Overall Study|Abnormal test procedure result(s)|2
6056651|NCT00463567|9656906|FG006|Overall Study|Abnormal test procedure result(s)|0
6056652|NCT00463567|9656900|FG000|Overall Study|Death|1
6056653|NCT00463567|9656901|FG001|Overall Study|Death|0
6056654|NCT00463567|9656902|FG002|Overall Study|Death|2
6056655|NCT00463567|9656903|FG003|Overall Study|Death|0
6056656|NCT00463567|9656904|FG004|Overall Study|Death|0
6056657|NCT00463567|9656905|FG005|Overall Study|Death|0
6056658|NCT00463567|9656906|FG006|Overall Study|Death|0
6056659|NCT00463580|9656930|FG000|Overall Study|Lost to Follow-up|1
6056660|NCT00463580|9656931|FG001|Overall Study|Lost to Follow-up|0
6056661|NCT00463580|9656930|FG000|Overall Study|Schedule conflict|2
6056662|NCT00463580|9656931|FG001|Overall Study|Schedule conflict|0
6056663|NCT00463580|9656930|FG000|Overall Study|Medical/psychiatric complications|0
6056664|NCT00463580|9656931|FG001|Overall Study|Medical/psychiatric complications|2
6056665|NCT00463606|9656946|FG000|Overall Study|Adverse Event|21
6056666|NCT00463606|9656947|FG001|Overall Study|Adverse Event|18
6056667|NCT00463606|9656948|FG002|Overall Study|Adverse Event|11
6056668|NCT00463606|9656946|FG000|Overall Study|Withdrawal by Subject|11
6056669|NCT00463606|9656947|FG001|Overall Study|Withdrawal by Subject|11
6056670|NCT00463606|9656948|FG002|Overall Study|Withdrawal by Subject|5
6056671|NCT00463606|9656946|FG000|Overall Study|Lost to Follow-up|2
6056672|NCT00463606|9656947|FG001|Overall Study|Lost to Follow-up|2
6056673|NCT00463606|9656948|FG002|Overall Study|Lost to Follow-up|3
6056674|NCT00463606|9656946|FG000|Overall Study|Subject noncompliance|1
6056675|NCT00463606|9656947|FG001|Overall Study|Subject noncompliance|1
6056676|NCT00463606|9656948|FG002|Overall Study|Subject noncompliance|0
6056677|NCT00463606|9656946|FG000|Overall Study|Subject moved out of town|1
6056678|NCT00463606|9656947|FG001|Overall Study|Subject moved out of town|0
6056679|NCT00463606|9656948|FG002|Overall Study|Subject moved out of town|0
6056680|NCT00463606|9656946|FG000|Overall Study|Physician Decision|0
6056681|NCT00463606|9656947|FG001|Overall Study|Physician Decision|1
6056682|NCT00463606|9656948|FG002|Overall Study|Physician Decision|0
6056683|NCT00463606|9656946|FG000|Overall Study|Sponsor request|0
6056684|NCT00463606|9656947|FG001|Overall Study|Sponsor request|1
6056685|NCT00463606|9656948|FG002|Overall Study|Sponsor request|0
6056686|NCT00463606|9656946|FG000|Overall Study|Exclusion criteria violation|2
6056687|NCT00463606|9656947|FG001|Overall Study|Exclusion criteria violation|0
6056688|NCT00463606|9656948|FG002|Overall Study|Exclusion criteria violation|0
6056689|NCT00463606|9656946|FG000|Overall Study|Coordinator error|1
6056690|NCT00463606|9656947|FG001|Overall Study|Coordinator error|0
6091388|NCT00699374|9703851|FG000|Overall Study|Lost to Follow-up|3
6091389|NCT00699374|9703852|FG001|Overall Study|Lost to Follow-up|5
6056691|NCT00463606|9656948|FG002|Overall Study|Coordinator error|0
6056692|NCT00463606|9656946|FG000|Overall Study|Patient randomized in error|1
6056693|NCT00463606|9656947|FG001|Overall Study|Patient randomized in error|0
6056694|NCT00463606|9656948|FG002|Overall Study|Patient randomized in error|0
6056695|NCT00463606|9656946|FG000|Overall Study|Participation in another ABT-335 trial|1
6056696|NCT00463606|9656947|FG001|Overall Study|Participation in another ABT-335 trial|0
6056697|NCT00463606|9656948|FG002|Overall Study|Participation in another ABT-335 trial|0
6056698|NCT00463606|9656946|FG000|Overall Study|Protocol Violation|0
6056699|NCT00463606|9656947|FG001|Overall Study|Protocol Violation|0
6056700|NCT00463606|9656948|FG002|Overall Study|Protocol Violation|1
6056701|NCT00463684|9656956|FG000|Overall Study|Withdrawal by Subject|1
6056702|NCT00463684|9656956|FG000|Overall Study|Lost to Follow-up|3
6056703|NCT00463788|9656962|FG000|Overall Study|Progressive Disease|86
6056704|NCT00463788|9656963|FG001|Overall Study|Progressive Disease|42
6056705|NCT00463788|9656962|FG000|Overall Study|Adverse Event|6
6091390|NCT00699374|9703851|FG000|Overall Study|Withdrawal by Subject|34
6091391|NCT00699374|9703852|FG001|Overall Study|Withdrawal by Subject|44
6091392|NCT00699374|9703851|FG000|Overall Study|Objective progression or relapse|281
6091393|NCT00699374|9703852|FG001|Overall Study|Objective progression or relapse|277
6091394|NCT00699374|9703851|FG000|Overall Study|Other|18
6091395|NCT00699374|9703852|FG001|Overall Study|Other|15
6091396|NCT00699374|9703851|FG000|Overall Study|Protocol Violation|2
6091397|NCT00699374|9703852|FG001|Overall Study|Protocol Violation|6
6091398|NCT00699374|9703851|FG000|Overall Study|Study terminated by sponsor|13
6091399|NCT00699374|9703852|FG001|Overall Study|Study terminated by sponsor|28
6091400|NCT00699374|9703851|FG000|Overall Study|Randomized but not treated|4
6056706|NCT00463788|9656963|FG001|Overall Study|Adverse Event|2
6056707|NCT00463788|9656962|FG000|Overall Study|Withdrawal by Subject|6
6056708|NCT00463788|9656963|FG001|Overall Study|Withdrawal by Subject|2
6056709|NCT00463788|9656962|FG000|Overall Study|Death|4
6056710|NCT00463788|9656963|FG001|Overall Study|Death|3
6056711|NCT00463788|9656962|FG000|Overall Study|Symptomatic Deterioration|2
6056712|NCT00463788|9656963|FG001|Overall Study|Symptomatic Deterioration|3
6056713|NCT00463788|9656962|FG000|Overall Study|Lost to Follow-up|1
6056714|NCT00463788|9656963|FG001|Overall Study|Lost to Follow-up|0
6056715|NCT00463788|9656962|FG000|Overall Study|Protocol Violation|0
6056716|NCT00463788|9656963|FG001|Overall Study|Protocol Violation|1
6056717|NCT00463788|9656962|FG000|Overall Study|Other|3
6056718|NCT00463788|9656963|FG001|Overall Study|Other|0
6056719|NCT00463788|9656962|FG000|Overall Study|Randomized but not treated|1
6056720|NCT00463788|9656963|FG001|Overall Study|Randomized but not treated|1
6056721|NCT00463801|9656970|FG000|Overall Study|Protocol Violation|1
6056722|NCT00463801|9656970|FG000|Overall Study|Lack of Efficacy|2
6056723|NCT00463801|9656970|FG000|Overall Study|Adverse Event|4
6056724|NCT00463801|9656970|FG000|Overall Study|Lost to Follow-up|5
6056725|NCT00463801|9656970|FG000|Overall Study|No longer require therapy|1
6056726|NCT00463840|9656974|FG000|Overall Study|Disease progression|7
6056727|NCT00463840|9656974|FG000|Overall Study|Withdrawal by Subject|2
6056728|NCT00463840|9656974|FG000|Overall Study|Adverse Event|3
6056729|NCT00463866|9656980|FG000|Overall Study|Adverse Event|70
6056730|NCT00463866|9656981|FG001|Overall Study|Adverse Event|93
6056731|NCT00463866|9656980|FG000|Overall Study|Withdrawal by Subject|81
6056732|NCT00463866|9656981|FG001|Overall Study|Withdrawal by Subject|79
6056733|NCT00463866|9656980|FG000|Overall Study|Lost to Follow-up|46
6056734|NCT00463866|9656981|FG001|Overall Study|Lost to Follow-up|55
6056735|NCT00463866|9656980|FG000|Overall Study|Incorrect Enrolment|64
6056736|NCT00463866|9656981|FG001|Overall Study|Incorrect Enrolment|66
6056737|NCT00463866|9656980|FG000|Overall Study|Severe Non-Compliance to Protocol|25
6056738|NCT00463866|9656981|FG001|Overall Study|Severe Non-Compliance to Protocol|21
6091401|NCT00699374|9703852|FG001|Overall Study|Randomized but not treated|2
6091402|NCT00699374|9703851|FG000|Overall Study|Died 28 days after last dose|5
6091403|NCT00699374|9703852|FG001|Overall Study|Died 28 days after last dose|9
6091404|NCT00699582|9703910|FG000|Overall Study|Adverse Event|4
6091405|NCT00699582|9703911|FG001|Overall Study|Adverse Event|11
6056739|NCT00463866|9656980|FG000|Overall Study|Safety Reason|1
6056740|NCT00463866|9656981|FG001|Overall Study|Safety Reason|3
6056741|NCT00463866|9656980|FG000|Overall Study|Mis-Randomization of subject|0
6056742|NCT00463866|9656981|FG001|Overall Study|Mis-Randomization of subject|1
6091406|NCT00699582|9703912|FG002|Overall Study|Adverse Event|23
6091407|NCT00699582|9703910|FG000|Overall Study|Withdrawal by Subject|6
6056743|NCT00463866|9656980|FG000|Overall Study|Other|22
6056744|NCT00463866|9656981|FG001|Overall Study|Other|22
6056745|NCT00464087|9656990|FG000|Overall Study|No PCI per inclusion criteria|0
6056746|NCT00464087|9656991|FG001|Overall Study|No PCI per inclusion criteria|0
6056747|NCT00464087|9656992|FG002|Overall Study|No PCI per inclusion criteria|29
6091408|NCT00699582|9703911|FG001|Overall Study|Withdrawal by Subject|7
6091409|NCT00699582|9703912|FG002|Overall Study|Withdrawal by Subject|4
6091410|NCT00699582|9703910|FG000|Overall Study|Lack of Efficacy|1
6091411|NCT00699582|9703911|FG001|Overall Study|Lack of Efficacy|0
6091412|NCT00699582|9703912|FG002|Overall Study|Lack of Efficacy|1
6091413|NCT00699582|9703910|FG000|Overall Study|Progressive Disease|1
6056748|NCT00464269|9657015|FG000|Overall Study|Lack of Efficacy|1
6056749|NCT00464269|9657016|FG001|Overall Study|Lack of Efficacy|0
6056750|NCT00464269|9657017|FG002|Overall Study|Lack of Efficacy|0
6056751|NCT00464269|9657018|FG003|Overall Study|Lack of Efficacy|0
6056752|NCT00464269|9657015|FG000|Overall Study|Lost to Follow-up|0
6056753|NCT00464269|9657016|FG001|Overall Study|Lost to Follow-up|4
6056754|NCT00464269|9657017|FG002|Overall Study|Lost to Follow-up|0
6056755|NCT00464269|9657018|FG003|Overall Study|Lost to Follow-up|1
6056756|NCT00464269|9657015|FG000|Overall Study|Withdrawal by Subject|0
6056757|NCT00464269|9657016|FG001|Overall Study|Withdrawal by Subject|2
6056758|NCT00464269|9657017|FG002|Overall Study|Withdrawal by Subject|1
6056759|NCT00464269|9657018|FG003|Overall Study|Withdrawal by Subject|1
6056760|NCT00464269|9657015|FG000|Overall Study|Other reason|3
6056761|NCT00464269|9657016|FG001|Overall Study|Other reason|3
6056762|NCT00464269|9657017|FG002|Overall Study|Other reason|1
6056763|NCT00464269|9657018|FG003|Overall Study|Other reason|1
6056764|NCT00464269|9657015|FG000|Overall Study|AE, serious fatal|0
6056765|NCT00464269|9657016|FG001|Overall Study|AE, serious fatal|0
6056766|NCT00464269|9657017|FG002|Overall Study|AE, serious fatal|1
6056767|NCT00464269|9657018|FG003|Overall Study|AE, serious fatal|1
6056768|NCT00464269|9657015|FG000|Overall Study|SAE, non-fatal|0
6056769|NCT00464269|9657016|FG001|Overall Study|SAE, non-fatal|0
6056770|NCT00464269|9657017|FG002|Overall Study|SAE, non-fatal|0
6056771|NCT00464269|9657018|FG003|Overall Study|SAE, non-fatal|1
6056772|NCT00464269|9657015|FG000|Overall Study|AE, non-serious non-fatal|2
6056773|NCT00464269|9657016|FG001|Overall Study|AE, non-serious non-fatal|8
6056774|NCT00464269|9657017|FG002|Overall Study|AE, non-serious non-fatal|3
6056775|NCT00464269|9657018|FG003|Overall Study|AE, non-serious non-fatal|4
6056776|NCT00464269|9657015|FG000|Overall Study|SAE,non-fatal+AE,non-serious non-fatal|0
6056777|NCT00464269|9657016|FG001|Overall Study|SAE,non-fatal+AE,non-serious non-fatal|0
6056778|NCT00464269|9657017|FG002|Overall Study|SAE,non-fatal+AE,non-serious non-fatal|1
6056779|NCT00464269|9657018|FG003|Overall Study|SAE,non-fatal+AE,non-serious non-fatal|0
6056780|NCT00464308|9657033|FG000|Overall Study|Adverse Event|22
6056781|NCT00464308|9657034|FG001|Overall Study|Adverse Event|27
6056782|NCT00464308|9657035|FG002|Overall Study|Adverse Event|16
6056783|NCT00464308|9657033|FG000|Overall Study|Lost to Follow-up|29
6056784|NCT00464308|9657034|FG001|Overall Study|Lost to Follow-up|19
6056785|NCT00464308|9657035|FG002|Overall Study|Lost to Follow-up|20
6091414|NCT00699582|9703911|FG001|Overall Study|Progressive Disease|0
6091415|NCT00699582|9703912|FG002|Overall Study|Progressive Disease|0
6091416|NCT00699582|9703910|FG000|Overall Study|Administrative/Other|4
6091417|NCT00699582|9703911|FG001|Overall Study|Administrative/Other|3
6091418|NCT00699582|9703912|FG002|Overall Study|Administrative/Other|0
6091419|NCT00699582|9703910|FG000|Overall Study|Randomized, Not Treated|2
6091420|NCT00699582|9703911|FG001|Overall Study|Randomized, Not Treated|1
6091421|NCT00699582|9703912|FG002|Overall Study|Randomized, Not Treated|0
6091422|NCT00699608|9703920|FG000|First Intervention|Withdrawal by Subject|0
6091423|NCT00699608|9703921|FG001|First Intervention|Withdrawal by Subject|0
6091424|NCT00699608|9703922|FG002|First Intervention|Withdrawal by Subject|1
6091425|NCT00699608|9703923|FG003|First Intervention|Withdrawal by Subject|0
6091426|NCT00699608|9703924|FG004|First Intervention|Withdrawal by Subject|0
6091427|NCT00699608|9703925|FG005|First Intervention|Withdrawal by Subject|0
6091428|NCT00699608|9703920|FG000|First Intervention|Protocol Violation|0
6091429|NCT00699608|9703921|FG001|First Intervention|Protocol Violation|0
6091430|NCT00699608|9703922|FG002|First Intervention|Protocol Violation|0
6091431|NCT00699608|9703923|FG003|First Intervention|Protocol Violation|0
6091432|NCT00699608|9703924|FG004|First Intervention|Protocol Violation|1
6091433|NCT00699608|9703925|FG005|First Intervention|Protocol Violation|0
6091434|NCT00699608|9703920|FG000|Second Intervention|Adverse Event|0
6091435|NCT00699608|9703921|FG001|Second Intervention|Adverse Event|0
6091436|NCT00699608|9703922|FG002|Second Intervention|Adverse Event|1
6091437|NCT00699608|9703923|FG003|Second Intervention|Adverse Event|0
6091438|NCT00699608|9703924|FG004|Second Intervention|Adverse Event|0
6091439|NCT00699608|9703925|FG005|Second Intervention|Adverse Event|0
6202389|NCT01500278|9862464|FG000|Week 13 - Week 104|Sponsor request|4
6056786|NCT00464308|9657033|FG000|Overall Study|Patient discontinued and other reasons|17
6056787|NCT00464308|9657034|FG001|Overall Study|Patient discontinued and other reasons|17
6056788|NCT00464308|9657035|FG002|Overall Study|Patient discontinued and other reasons|23
6056789|NCT00464308|9657033|FG000|Overall Study|Physician Decision|1
6056790|NCT00464308|9657034|FG001|Overall Study|Physician Decision|0
6056791|NCT00464308|9657035|FG002|Overall Study|Physician Decision|0
6056792|NCT00464334|9657054|FG000|Overall Study|Adverse Event|0
6056793|NCT00464334|9657055|FG001|Overall Study|Adverse Event|0
6091440|NCT00699608|9703920|FG000|Second Intervention|Withdrawal by Subject|0
6091441|NCT00699608|9703921|FG001|Second Intervention|Withdrawal by Subject|0
6091442|NCT00699608|9703922|FG002|Second Intervention|Withdrawal by Subject|0
6091443|NCT00699608|9703923|FG003|Second Intervention|Withdrawal by Subject|1
6091444|NCT00699608|9703924|FG004|Second Intervention|Withdrawal by Subject|0
6091445|NCT00699608|9703925|FG005|Second Intervention|Withdrawal by Subject|0
6091446|NCT00699660|9703935|FG000|Overall Study|Lost to Follow-up|4
6056794|NCT00464334|9657056|FG002|Overall Study|Adverse Event|0
6056795|NCT00464334|9657057|FG003|Overall Study|Adverse Event|1
6056796|NCT00464334|9657058|FG004|Overall Study|Adverse Event|1
6056797|NCT00464334|9657059|FG005|Overall Study|Adverse Event|1
6056798|NCT00464334|9657060|FG006|Overall Study|Adverse Event|0
6056799|NCT00464334|9657061|FG007|Overall Study|Adverse Event|0
6056800|NCT00464334|9657062|FG008|Overall Study|Adverse Event|2
6056801|NCT00464334|9657063|FG009|Overall Study|Adverse Event|1
6056802|NCT00464334|9657064|FG010|Overall Study|Adverse Event|2
6056803|NCT00464334|9657054|FG000|Overall Study|Lack of Efficacy|0
6056804|NCT00464334|9657055|FG001|Overall Study|Lack of Efficacy|1
6056805|NCT00464334|9657056|FG002|Overall Study|Lack of Efficacy|0
6056806|NCT00464334|9657057|FG003|Overall Study|Lack of Efficacy|0
6056807|NCT00464334|9657058|FG004|Overall Study|Lack of Efficacy|0
6056808|NCT00464334|9657059|FG005|Overall Study|Lack of Efficacy|0
6056809|NCT00464334|9657060|FG006|Overall Study|Lack of Efficacy|0
6056810|NCT00464334|9657061|FG007|Overall Study|Lack of Efficacy|0
6056811|NCT00464334|9657062|FG008|Overall Study|Lack of Efficacy|0
6056812|NCT00464334|9657063|FG009|Overall Study|Lack of Efficacy|0
6056813|NCT00464334|9657064|FG010|Overall Study|Lack of Efficacy|0
6056814|NCT00464334|9657054|FG000|Overall Study|Lost to Follow-up|0
6056815|NCT00464334|9657055|FG001|Overall Study|Lost to Follow-up|0
6056816|NCT00464334|9657056|FG002|Overall Study|Lost to Follow-up|1
6056817|NCT00464334|9657057|FG003|Overall Study|Lost to Follow-up|0
6056818|NCT00464334|9657058|FG004|Overall Study|Lost to Follow-up|1
6056819|NCT00464334|9657059|FG005|Overall Study|Lost to Follow-up|0
6056820|NCT00464334|9657060|FG006|Overall Study|Lost to Follow-up|1
6056821|NCT00464334|9657061|FG007|Overall Study|Lost to Follow-up|0
6056822|NCT00464334|9657062|FG008|Overall Study|Lost to Follow-up|0
6056823|NCT00464334|9657063|FG009|Overall Study|Lost to Follow-up|0
6056824|NCT00464334|9657064|FG010|Overall Study|Lost to Follow-up|2
6056825|NCT00464334|9657054|FG000|Overall Study|Progressive Disease|0
6056826|NCT00464334|9657055|FG001|Overall Study|Progressive Disease|0
6056827|NCT00464334|9657056|FG002|Overall Study|Progressive Disease|0
6056828|NCT00464334|9657057|FG003|Overall Study|Progressive Disease|0
6056829|NCT00464334|9657058|FG004|Overall Study|Progressive Disease|0
6056830|NCT00464334|9657059|FG005|Overall Study|Progressive Disease|1
6056831|NCT00464334|9657060|FG006|Overall Study|Progressive Disease|0
6056832|NCT00464334|9657061|FG007|Overall Study|Progressive Disease|0
6056833|NCT00464334|9657062|FG008|Overall Study|Progressive Disease|1
6091447|NCT00699660|9703936|FG001|Overall Study|Lost to Follow-up|2
6091448|NCT00699660|9703935|FG000|Overall Study|missing reports and recording failures|10
6091449|NCT00699660|9703936|FG001|Overall Study|missing reports and recording failures|6
6091450|NCT00699699|9703942|FG000|Overall Study|Adverse Event|36
6091451|NCT00699699|9703942|FG000|Overall Study|Individual different reasons|21
6091452|NCT00699751|9703948|FG000|Period 1: Without/Before Drug Switch|Investigator Request|27
6091453|NCT00699751|9703949|FG001|Period 1: Without/Before Drug Switch|Investigator Request|27
6091454|NCT00699751|9703948|FG000|Period 1: Without/Before Drug Switch|Death|28
6091455|NCT00699751|9703949|FG001|Period 1: Without/Before Drug Switch|Death|29
6091456|NCT00699751|9703948|FG000|Period 1: Without/Before Drug Switch|Subject Request|43
6091457|NCT00699751|9703949|FG001|Period 1: Without/Before Drug Switch|Subject Request|23
6091458|NCT00699751|9703948|FG000|Period 1: Without/Before Drug Switch|Other|30
6091459|NCT00699751|9703949|FG001|Period 1: Without/Before Drug Switch|Other|20
6091460|NCT00699751|9703948|FG000|Period 1: Without/Before Drug Switch|Adverse Event|97
6091461|NCT00699751|9703949|FG001|Period 1: Without/Before Drug Switch|Adverse Event|63
6091462|NCT00699751|9703948|FG000|Period 2:Switched From Placebo to Xofigo|Adverse Event|0
6091463|NCT00699751|9703949|FG001|Period 2:Switched From Placebo to Xofigo|Adverse Event|4
6091464|NCT00699751|9703948|FG000|Period 2:Switched From Placebo to Xofigo|Investigator Request|0
6091465|NCT00699751|9703949|FG001|Period 2:Switched From Placebo to Xofigo|Investigator Request|1
6091466|NCT00699751|9703948|FG000|Period 2:Switched From Placebo to Xofigo|Completion page not expected|0
6091467|NCT00699751|9703949|FG001|Period 2:Switched From Placebo to Xofigo|Completion page not expected|4
6091468|NCT00699816|9703967|FG000|Overall Study|Protocol Violation|1
6091469|NCT00699816|9703968|FG001|Overall Study|Protocol Violation|3
6091470|NCT00699907|9703977|FG000|Overall Study|Withdrawal by Subject|2
6091471|NCT00699907|9703978|FG001|Overall Study|Withdrawal by Subject|1
6091472|NCT00699907|9703979|FG002|Overall Study|Withdrawal by Subject|0
6091473|NCT00699907|9703977|FG000|Overall Study|No usable sample|0
6091474|NCT00699907|9703978|FG001|Overall Study|No usable sample|9
6091475|NCT00699907|9703979|FG002|Overall Study|No usable sample|8
6091476|NCT00699972|9703990|FG000|Overall Study|Adverse Event|7
6091477|NCT00699972|9703991|FG001|Overall Study|Adverse Event|9
6091478|NCT00699972|9703992|FG002|Overall Study|Adverse Event|24
6056834|NCT00464334|9657063|FG009|Overall Study|Progressive Disease|0
6056835|NCT00464334|9657064|FG010|Overall Study|Progressive Disease|0
6056836|NCT00464334|9657054|FG000|Overall Study|Study Terminated by Sponsor|0
6056837|NCT00464334|9657055|FG001|Overall Study|Study Terminated by Sponsor|0
6056838|NCT00464334|9657056|FG002|Overall Study|Study Terminated by Sponsor|0
6056839|NCT00464334|9657057|FG003|Overall Study|Study Terminated by Sponsor|1
6056840|NCT00464334|9657058|FG004|Overall Study|Study Terminated by Sponsor|0
6056841|NCT00464334|9657059|FG005|Overall Study|Study Terminated by Sponsor|0
6056842|NCT00464334|9657060|FG006|Overall Study|Study Terminated by Sponsor|0
6056843|NCT00464334|9657061|FG007|Overall Study|Study Terminated by Sponsor|0
6056844|NCT00464334|9657062|FG008|Overall Study|Study Terminated by Sponsor|0
6056845|NCT00464334|9657063|FG009|Overall Study|Study Terminated by Sponsor|0
6056846|NCT00464334|9657064|FG010|Overall Study|Study Terminated by Sponsor|0
6056847|NCT00464334|9657054|FG000|Overall Study|Withdrawal by Subject|1
6056848|NCT00464334|9657055|FG001|Overall Study|Withdrawal by Subject|7
6056849|NCT00464334|9657056|FG002|Overall Study|Withdrawal by Subject|4
6056850|NCT00464334|9657057|FG003|Overall Study|Withdrawal by Subject|2
6056851|NCT00464334|9657058|FG004|Overall Study|Withdrawal by Subject|2
6056852|NCT00464334|9657059|FG005|Overall Study|Withdrawal by Subject|2
6056853|NCT00464334|9657060|FG006|Overall Study|Withdrawal by Subject|2
6056854|NCT00464334|9657061|FG007|Overall Study|Withdrawal by Subject|1
6056855|NCT00464334|9657062|FG008|Overall Study|Withdrawal by Subject|3
6056856|NCT00464334|9657063|FG009|Overall Study|Withdrawal by Subject|0
6056857|NCT00464334|9657064|FG010|Overall Study|Withdrawal by Subject|0
6056858|NCT00464490|9657119|FG000|Overall Study|Physician Decision|11
6056859|NCT00464490|9657120|FG001|Overall Study|Physician Decision|11
6056860|NCT00464542|9657126|FG000|Pre-treatment|Withdrawal by Subject|2
6056861|NCT00464568|9657130|FG000|Overall Study|Adverse Event|2
6056862|NCT00464620|9657147|FG000|Overall Study|Physician Decision|1
6056863|NCT00464620|9657148|FG001|Overall Study|Physician Decision|0
6056864|NCT00464620|9657149|FG002|Overall Study|Physician Decision|0
6056865|NCT00464620|9657147|FG000|Overall Study|Withdrawal by Subject|1
6056866|NCT00464620|9657148|FG001|Overall Study|Withdrawal by Subject|0
6056867|NCT00464620|9657149|FG002|Overall Study|Withdrawal by Subject|3
6056868|NCT00464620|9657147|FG000|Overall Study|Ineligible sarcoma subtype|0
6091479|NCT00699972|9703990|FG000|Overall Study|Lost to Follow-up|0
6091480|NCT00699972|9703991|FG001|Overall Study|Lost to Follow-up|2
6091481|NCT00699972|9703992|FG002|Overall Study|Lost to Follow-up|0
6091482|NCT00699972|9703990|FG000|Overall Study|Withdrawal by Subject|3
6091483|NCT00699972|9703991|FG001|Overall Study|Withdrawal by Subject|7
6091484|NCT00699972|9703992|FG002|Overall Study|Withdrawal by Subject|4
6091485|NCT00699972|9703990|FG000|Overall Study|Lack of Efficacy|2
6091486|NCT00699972|9703991|FG001|Overall Study|Lack of Efficacy|0
6091487|NCT00699972|9703992|FG002|Overall Study|Lack of Efficacy|2
6091488|NCT00699972|9703990|FG000|Overall Study|Administrative/Other|3
6091489|NCT00699972|9703991|FG001|Overall Study|Administrative/Other|1
6056869|NCT00464620|9657148|FG001|Overall Study|Ineligible sarcoma subtype|2
6056870|NCT00464620|9657149|FG002|Overall Study|Ineligible sarcoma subtype|2
6056871|NCT00464620|9657147|FG000|Overall Study|Use of prohibited concomitant medication|0
6056872|NCT00464620|9657148|FG001|Overall Study|Use of prohibited concomitant medication|0
6056873|NCT00464620|9657149|FG002|Overall Study|Use of prohibited concomitant medication|2
6056874|NCT00464672|9657174|FG000|Overall Study|withdrawal of consent|0
6056875|NCT00464672|9657175|FG001|Overall Study|withdrawal of consent|0
6056876|NCT00464672|9657176|FG002|Overall Study|withdrawal of consent|0
6056877|NCT00464672|9657177|FG003|Overall Study|withdrawal of consent|1
6056878|NCT00464672|9657178|FG004|Overall Study|withdrawal of consent|9
6056879|NCT00464672|9657179|FG005|Overall Study|withdrawal of consent|4
6056880|NCT00464672|9657174|FG000|Overall Study|Lost to Follow-up|25
6056881|NCT00464672|9657175|FG001|Overall Study|Lost to Follow-up|10
6056882|NCT00464672|9657176|FG002|Overall Study|Lost to Follow-up|0
6056883|NCT00464672|9657177|FG003|Overall Study|Lost to Follow-up|0
6056884|NCT00464672|9657178|FG004|Overall Study|Lost to Follow-up|1
6056885|NCT00464672|9657179|FG005|Overall Study|Lost to Follow-up|0
6056886|NCT00464737|9657229|FG000|Overall Study|Adverse Event|12
6056887|NCT00464737|9657230|FG001|Overall Study|Adverse Event|17
6056888|NCT00464737|9657231|FG002|Overall Study|Adverse Event|33
6056889|NCT00464737|9657229|FG000|Overall Study|Lack of Efficacy|7
6056890|NCT00464737|9657230|FG001|Overall Study|Lack of Efficacy|7
6091490|NCT00699972|9703992|FG002|Overall Study|Administrative/Other|4
6091491|NCT00699972|9703990|FG000|Overall Study|Randomized, Not Treated|1
6091492|NCT00699972|9703991|FG001|Overall Study|Randomized, Not Treated|0
6091493|NCT00699972|9703992|FG002|Overall Study|Randomized, Not Treated|1
6091494|NCT00699998|9704004|FG000|Overall Study|Withdrawal by Subject|194
6091495|NCT00699998|9704005|FG001|Overall Study|Withdrawal by Subject|83
6091496|NCT00699998|9704006|FG002|Overall Study|Withdrawal by Subject|202
6091497|NCT00699998|9704007|FG003|Overall Study|Withdrawal by Subject|80
6091498|NCT00699998|9704004|FG000|Overall Study|Physician Decision|3
6091499|NCT00699998|9704005|FG001|Overall Study|Physician Decision|2
6202390|NCT01500278|9862465|FG001|Week 13 - Week 104|Sponsor request|0
6202391|NCT01500278|9862464|FG000|Week 13 - Week 104|Withdrawn in error|1
6202392|NCT01500278|9862465|FG001|Week 13 - Week 104|Withdrawn in error|0
6202393|NCT01500278|9862464|FG000|Week 13 - Week 104|Exclusion criteria not met|1
6202394|NCT01500278|9862465|FG001|Week 13 - Week 104|Exclusion criteria not met|0
6202395|NCT01500278|9862464|FG000|Week 13 - Week 104|Protocol deviation|1
6202396|NCT01500278|9862465|FG001|Week 13 - Week 104|Protocol deviation|0
6202397|NCT01500278|9862464|FG000|Week 13 - Week 104|Principal investigator retiring|1
6202398|NCT01500278|9862465|FG001|Week 13 - Week 104|Principal investigator retiring|0
6202399|NCT01500278|9862464|FG000|Week 13 - Week 104|Patient declined Safety Follow Up Visit|1
6202400|NCT01500278|9862465|FG001|Week 13 - Week 104|Patient declined Safety Follow Up Visit|0
6056891|NCT00464737|9657231|FG002|Overall Study|Lack of Efficacy|4
6056892|NCT00464737|9657229|FG000|Overall Study|Withdrawal by Subject|5
6056893|NCT00464737|9657230|FG001|Overall Study|Withdrawal by Subject|3
6056894|NCT00464737|9657231|FG002|Overall Study|Withdrawal by Subject|5
6056895|NCT00464737|9657229|FG000|Overall Study|Protocol Violation|1
6202401|NCT01500278|9862464|FG000|Week 13 - Week 104|Abnormal questionable chest X-ray|0
6056896|NCT00464737|9657230|FG001|Overall Study|Protocol Violation|1
6056897|NCT00464737|9657231|FG002|Overall Study|Protocol Violation|5
6056898|NCT00464737|9657229|FG000|Overall Study|Non-compliance|0
6056899|NCT00464737|9657230|FG001|Overall Study|Non-compliance|1
6056900|NCT00464737|9657231|FG002|Overall Study|Non-compliance|1
6056901|NCT00464737|9657229|FG000|Overall Study|Lost to Follow-up|5
6056902|NCT00464737|9657230|FG001|Overall Study|Lost to Follow-up|2
6056903|NCT00464737|9657231|FG002|Overall Study|Lost to Follow-up|5
6056904|NCT00464737|9657229|FG000|Overall Study|Other: Subject's schedule doesn't permit|1
6056905|NCT00464737|9657230|FG001|Overall Study|Other: Subject's schedule doesn't permit|0
6056906|NCT00464737|9657231|FG002|Overall Study|Other: Subject's schedule doesn't permit|0
6056907|NCT00464737|9657229|FG000|Overall Study|Other: Subject left town; family illness|1
6056908|NCT00464737|9657230|FG001|Overall Study|Other: Subject left town; family illness|0
6056909|NCT00464737|9657231|FG002|Overall Study|Other: Subject left town; family illness|0
6056910|NCT00464737|9657229|FG000|Overall Study|Other: Study demands too great|0
6056911|NCT00464737|9657230|FG001|Overall Study|Other: Study demands too great|1
6056912|NCT00464737|9657231|FG002|Overall Study|Other: Study demands too great|0
6056913|NCT00464737|9657229|FG000|Overall Study|Other: Personal family reasons|0
6056914|NCT00464737|9657230|FG001|Overall Study|Other: Personal family reasons|0
6056915|NCT00464737|9657231|FG002|Overall Study|Other: Personal family reasons|1
6056916|NCT00464737|9657229|FG000|Overall Study|Other: Subject's disability per sponsor|0
6056917|NCT00464737|9657230|FG001|Overall Study|Other: Subject's disability per sponsor|0
6056918|NCT00464737|9657231|FG002|Overall Study|Other: Subject's disability per sponsor|1
6056919|NCT00464815|9657241|FG000|Overall Study|Withdrawal by Subject|6
6056920|NCT00464815|9657242|FG001|Overall Study|Withdrawal by Subject|3
6056921|NCT00464945|9657250|FG000|Infant Series|Withdrawal by parent/guardian request|2
6056922|NCT00464945|9657251|FG001|Infant Series|Withdrawal by parent/guardian request|1
6056923|NCT00464945|9657250|FG000|Infant Series|Protocol Violation|1
6056924|NCT00464945|9657251|FG001|Infant Series|Protocol Violation|0
6056925|NCT00464945|9657250|FG000|Infant Series|Lost to Follow-up|1
6056926|NCT00464945|9657251|FG001|Infant Series|Lost to Follow-up|0
6056927|NCT00464945|9657250|FG000|After Infant Series|Withdrawal by Subject|0
6056928|NCT00464945|9657251|FG001|After Infant Series|Withdrawal by Subject|2
6056929|NCT00464945|9657250|FG000|Toddler Dose|Lost to Follow-up|0
6056930|NCT00464945|9657251|FG001|Toddler Dose|Lost to Follow-up|1
6056931|NCT00465101|9657282|FG000|Overall Study|Aborted Proc./Treatment Not Attempted|3
6056932|NCT00465101|9657282|FG000|Overall Study|Change in health precluded follow up|4
6056933|NCT00465101|9657282|FG000|Overall Study|Did not meet study criteria|4
6056934|NCT00465101|9657282|FG000|Overall Study|Lost to Follow-up|5
6056935|NCT00465101|9657282|FG000|Overall Study|Other|6
6056936|NCT00465101|9657282|FG000|Overall Study|Pt. Insurance not accepted at center|2
6056937|NCT00465101|9657282|FG000|Overall Study|Patient postponed procedure|1
6056938|NCT00465101|9657282|FG000|Overall Study|Site closed due to IRB expiration|1
6056939|NCT00465101|9657282|FG000|Overall Study|Unable to obtain IRB approval|1
6056940|NCT00465101|9657282|FG000|Overall Study|Death|3
6056941|NCT00465101|9657282|FG000|Overall Study|Withdrawal by Subject|25
6056942|NCT00465101|9657282|FG000|Overall Study|Physician Decision|1
6056943|NCT00465101|9657282|FG000|Overall Study|Withdrew consent prior to procedure|3
6056944|NCT00465179|9657308|FG000|Overall Study|Adverse Event|4
6056945|NCT00465179|9657308|FG000|Overall Study|Withdrawal by Subject|2
6056946|NCT00465179|9657308|FG000|Overall Study|Progression of Disease|47
6056947|NCT00465270|9657314|FG000|Overall Study|Death|7
6056948|NCT00465270|9657315|FG001|Overall Study|Death|11
6056949|NCT00465270|9657314|FG000|Overall Study|Withdrawal by Subject|34
6056950|NCT00465270|9657315|FG001|Overall Study|Withdrawal by Subject|78
6056951|NCT00465270|9657314|FG000|Overall Study|Lost to Follow-up|60
6056952|NCT00465270|9657315|FG001|Overall Study|Lost to Follow-up|67
6056953|NCT00465270|9657314|FG000|Overall Study|Investigator request|3
6056954|NCT00465270|9657315|FG001|Overall Study|Investigator request|4
6056955|NCT00465361|9657321|FG000|Baseline Assessment|Personal Issues/Scheduling|4
6091500|NCT00699998|9704006|FG002|Overall Study|Physician Decision|1
6091501|NCT00699998|9704007|FG003|Overall Study|Physician Decision|1
6091502|NCT00699998|9704004|FG000|Overall Study|Lost to Follow-up|2
6091503|NCT00699998|9704005|FG001|Overall Study|Lost to Follow-up|1
6091504|NCT00699998|9704006|FG002|Overall Study|Lost to Follow-up|3
6091505|NCT00699998|9704007|FG003|Overall Study|Lost to Follow-up|1
6091506|NCT00700011|9704024|FG000|Overall Study|Death|0
6091507|NCT00700011|9704025|FG001|Overall Study|Death|1
6091508|NCT00700102|9704066|FG000|Overall Study|Died|394
6091509|NCT00700102|9704067|FG001|Overall Study|Died|385
6091510|NCT00700102|9704066|FG000|Overall Study|Lost to Follow-up|8
6091511|NCT00700102|9704067|FG001|Overall Study|Lost to Follow-up|10
6091512|NCT00700115|9704075|FG000|Overall Study|Withdrawal by Subject|1
6091513|NCT00700115|9704076|FG001|Overall Study|Withdrawal by Subject|0
6091514|NCT00700115|9704075|FG000|Overall Study|Lost to Follow-up|0
6202402|NCT01500278|9862465|FG001|Week 13 - Week 104|Abnormal questionable chest X-ray|2
6202403|NCT01500278|9862464|FG000|Week 13 - Week 104|Relocation|0
6202404|NCT01500278|9862465|FG001|Week 13 - Week 104|Relocation|1
6056956|NCT00465569|9657336|FG000|Overall Study|persistent eczema during dose escalation|1
6056957|NCT00465569|9657337|FG001|Overall Study|persistent eczema during dose escalation|0
6056958|NCT00465647|9657362|FG000|Overall Study|Administrative|2
6056959|NCT00465647|9657363|FG001|Overall Study|Administrative|2
6056960|NCT00465647|9657364|FG002|Overall Study|Administrative|3
6056961|NCT00465647|9657365|FG003|Overall Study|Administrative|2
6056962|NCT00465647|9657362|FG000|Overall Study|Adverse Event|2
6056963|NCT00465647|9657363|FG001|Overall Study|Adverse Event|0
6056964|NCT00465647|9657364|FG002|Overall Study|Adverse Event|3
6056965|NCT00465647|9657365|FG003|Overall Study|Adverse Event|2
6056966|NCT00465647|9657362|FG000|Overall Study|Withdrawal by Subject|1
6056967|NCT00465647|9657363|FG001|Overall Study|Withdrawal by Subject|2
6056968|NCT00465647|9657364|FG002|Overall Study|Withdrawal by Subject|2
6056969|NCT00465647|9657365|FG003|Overall Study|Withdrawal by Subject|7
6056970|NCT00465647|9657362|FG000|Overall Study|"The other reasons included loss of IV"|8
6056971|NCT00465647|9657363|FG001|Overall Study|"The other reasons included loss of IV"|4
6056972|NCT00465647|9657364|FG002|Overall Study|"The other reasons included loss of IV"|3
6056973|NCT00465647|9657365|FG003|Overall Study|"The other reasons included loss of IV"|2
6056974|NCT00465738|9657387|FG000|Overall Study|Lost to Follow-up|2
6056975|NCT00465738|9657388|FG001|Overall Study|Lost to Follow-up|0
6056976|NCT00465738|9657387|FG000|Overall Study|Adverse Event|0
6056977|NCT00465738|9657388|FG001|Overall Study|Adverse Event|1
6056978|NCT00465738|9657387|FG000|Overall Study|Withdrawal by Subject|2
6056979|NCT00465738|9657388|FG001|Overall Study|Withdrawal by Subject|0
6056980|NCT00465738|9657387|FG000|Overall Study|Other|2
6056981|NCT00465738|9657388|FG001|Overall Study|Other|5
6056982|NCT00465816|9657397|FG000|Overall Study|Lost to Follow-up|0
6056983|NCT00465816|9657398|FG001|Overall Study|Lost to Follow-up|0
6056984|NCT00465816|9657399|FG002|Overall Study|Lost to Follow-up|2
6056985|NCT00465894|9657410|FG000|Treatment For 12 Weeks|Lost to Follow-up|4
6056986|NCT00465894|9657411|FG001|Treatment For 12 Weeks|Lost to Follow-up|1
6056987|NCT00465894|9657410|FG000|Treatment For 12 Weeks|Family Issues|1
6056988|NCT00465894|9657411|FG001|Treatment For 12 Weeks|Family Issues|1
6056989|NCT00465894|9657410|FG000|Treatment For 12 Weeks|Withdrawal by Subject|0
6056990|NCT00465894|9657411|FG001|Treatment For 12 Weeks|Withdrawal by Subject|1
6056991|NCT00465972|9657435|FG000|Overall Study|Withdrawal by Subject|2
6056992|NCT00465972|9657436|FG001|Overall Study|Withdrawal by Subject|1
6056993|NCT00465985|9657444|FG000|Part I - Open-label Treatment Period|Unsatisfactory therapeutic effect|4
6056994|NCT00465985|9657445|FG001|Part I - Open-label Treatment Period|Unsatisfactory therapeutic effect|0
6056995|NCT00465985|9657444|FG000|Part II - 1:1 ACZ885:Placebo|Unsatisfactory therapeutic effect|0
6056996|NCT00465985|9657445|FG001|Part II - 1:1 ACZ885:Placebo|Unsatisfactory therapeutic effect|12
6056997|NCT00465985|9657444|FG000|Part III - Open-label Treatment Period|Unsatisfactory therapeutic effect|1
6056998|NCT00465985|9657445|FG001|Part III - Open-label Treatment Period|Unsatisfactory therapeutic effect|0
6056999|NCT00465985|9657444|FG000|Part III - Open-label Treatment Period|Adverse Event|1
6057000|NCT00465985|9657445|FG001|Part III - Open-label Treatment Period|Adverse Event|0
6057001|NCT00466167|9657462|FG000|Overall Study|Adverse Event|8
6057002|NCT00466167|9657463|FG001|Overall Study|Adverse Event|8
6057003|NCT00466167|9657464|FG002|Overall Study|Adverse Event|7
6057004|NCT00466167|9657462|FG000|Overall Study|Lack of Efficacy|2
6057005|NCT00466167|9657463|FG001|Overall Study|Lack of Efficacy|0
6057006|NCT00466167|9657464|FG002|Overall Study|Lack of Efficacy|3
6057007|NCT00466167|9657462|FG000|Overall Study|Protocol Violation|1
6057008|NCT00466167|9657463|FG001|Overall Study|Protocol Violation|1
6057009|NCT00466167|9657464|FG002|Overall Study|Protocol Violation|2
6057010|NCT00466167|9657462|FG000|Overall Study|Lost to Follow-up|3
6057011|NCT00466167|9657463|FG001|Overall Study|Lost to Follow-up|2
6057012|NCT00466167|9657464|FG002|Overall Study|Lost to Follow-up|2
6057013|NCT00466167|9657462|FG000|Overall Study|Withdrawal by Subject|4
6057014|NCT00466167|9657463|FG001|Overall Study|Withdrawal by Subject|1
6057015|NCT00466167|9657464|FG002|Overall Study|Withdrawal by Subject|6
6057016|NCT00466167|9657462|FG000|Overall Study|patient did not meet inclusion criteria|1
6057017|NCT00466167|9657463|FG001|Overall Study|patient did not meet inclusion criteria|0
6057018|NCT00466167|9657464|FG002|Overall Study|patient did not meet inclusion criteria|1
6057019|NCT00466167|9657462|FG000|Overall Study|Not treated|1
6057020|NCT00466167|9657463|FG001|Overall Study|Not treated|0
6057021|NCT00466167|9657464|FG002|Overall Study|Not treated|0
6057022|NCT00466193|9657474|FG000|Overall Study|Adverse Event|0
6057023|NCT00466193|9657475|FG001|Overall Study|Adverse Event|1
6057024|NCT00466193|9657474|FG000|Overall Study|Lost to Follow-up|2
6057025|NCT00466193|9657475|FG001|Overall Study|Lost to Follow-up|4
6057026|NCT00466193|9657474|FG000|Overall Study|Physician Decision|1
6057027|NCT00466193|9657475|FG001|Overall Study|Physician Decision|0
6057028|NCT00466193|9657474|FG000|Overall Study|Protocol Violation|1
6057029|NCT00466193|9657475|FG001|Overall Study|Protocol Violation|1
6057030|NCT00466193|9657474|FG000|Overall Study|Withdrawal by Subject|7
6057031|NCT00466193|9657475|FG001|Overall Study|Withdrawal by Subject|2
6057032|NCT00466193|9657474|FG000|Overall Study|Patient refused Visit 4 procedures|1
6057033|NCT00466193|9657475|FG001|Overall Study|Patient refused Visit 4 procedures|0
6057034|NCT00466440|9657513|FG000|Overall Study|Adverse Event|0
6057035|NCT00466440|9657514|FG001|Overall Study|Adverse Event|3
6057036|NCT00466440|9657515|FG002|Overall Study|Adverse Event|1
6057037|NCT00466440|9657513|FG000|Overall Study|Death|1
6057038|NCT00466440|9657514|FG001|Overall Study|Death|1
6057039|NCT00466440|9657515|FG002|Overall Study|Death|0
6057040|NCT00466440|9657513|FG000|Overall Study|Progressive disease|13
6057041|NCT00466440|9657514|FG001|Overall Study|Progressive disease|5
6057042|NCT00466440|9657515|FG002|Overall Study|Progressive disease|4
6057043|NCT00466440|9657513|FG000|Overall Study|Lost to Follow-up|0
6057044|NCT00466440|9657514|FG001|Overall Study|Lost to Follow-up|1
6057045|NCT00466440|9657515|FG002|Overall Study|Lost to Follow-up|0
6057046|NCT00466440|9657513|FG000|Overall Study|Physician Decision|0
6091515|NCT00700115|9704076|FG001|Overall Study|Lost to Follow-up|1
6057047|NCT00466440|9657514|FG001|Overall Study|Physician Decision|1
6057048|NCT00466440|9657515|FG002|Overall Study|Physician Decision|2
6057049|NCT00466440|9657513|FG000|Overall Study|Protocol entry criteria not met|0
6057050|NCT00466440|9657514|FG001|Overall Study|Protocol entry criteria not met|0
6057051|NCT00466440|9657515|FG002|Overall Study|Protocol entry criteria not met|4
6057052|NCT00466440|9657513|FG000|Overall Study|Withdrawal by Subject|0
6057053|NCT00466440|9657514|FG001|Overall Study|Withdrawal by Subject|1
6057054|NCT00466440|9657515|FG002|Overall Study|Withdrawal by Subject|0
6057055|NCT00466440|9657513|FG000|Overall Study|Sponsor decision|0
6057056|NCT00466440|9657514|FG001|Overall Study|Sponsor decision|0
6057057|NCT00466440|9657515|FG002|Overall Study|Sponsor decision|1
6057058|NCT00466505|9657532|FG000|Overall Study|disease progression|13
6057059|NCT00466505|9657532|FG000|Overall Study|Adverse Event|4
6057060|NCT00466687|9657545|FG000|Overall Study|Adverse Event|1
6057061|NCT00466687|9657545|FG000|Overall Study|Other complicating illness|3
6057062|NCT00466687|9657545|FG000|Overall Study|Withdrawal by Subject|1
6057063|NCT00466687|9657545|FG000|Overall Study|Disease progression|29
6057064|NCT00466726|9657551|FG000|Overall Study|Not evaluable for response|14
6091516|NCT00700180|9704088|FG000|Overall Study|Death|99
6091517|NCT00700180|9704089|FG001|Overall Study|Death|114
6091518|NCT00700180|9704088|FG000|Overall Study|Alive on treatment|5
6091519|NCT00700180|9704089|FG001|Overall Study|Alive on treatment|3
6091520|NCT00700180|9704088|FG000|Overall Study|Alive in follow-up|46
6091521|NCT00700180|9704089|FG001|Overall Study|Alive in follow-up|27
6091522|NCT00700180|9704088|FG000|Overall Study|Lost to Follow-up|4
6091523|NCT00700180|9704089|FG001|Overall Study|Lost to Follow-up|5
6091524|NCT00700271|9704097|FG000|Overall Study|Adverse Event|4
6091525|NCT00700271|9704098|FG001|Overall Study|Adverse Event|6
6091526|NCT00700271|9704097|FG000|Overall Study|Protocol Violation|1
6091527|NCT00700271|9704098|FG001|Overall Study|Protocol Violation|0
6091528|NCT00700271|9704097|FG000|Overall Study|Administrative Reasons|1
6091529|NCT00700271|9704098|FG001|Overall Study|Administrative Reasons|0
6091530|NCT00700271|9704097|FG000|Overall Study|Withdrawal by Subject|6
6091531|NCT00700271|9704098|FG001|Overall Study|Withdrawal by Subject|4
6091532|NCT00700271|9704097|FG000|Overall Study|Lost to Follow-up|2
6091533|NCT00700271|9704098|FG001|Overall Study|Lost to Follow-up|2
6091534|NCT00700310|9704108|FG000|Overall Study|Adverse Event|6
6091535|NCT00700310|9704109|FG001|Overall Study|Adverse Event|10
6091536|NCT00700310|9704110|FG002|Overall Study|Adverse Event|5
6091537|NCT00700310|9704111|FG003|Overall Study|Adverse Event|11
6091538|NCT00700310|9704108|FG000|Overall Study|Lost to Follow-up|4
6091539|NCT00700310|9704109|FG001|Overall Study|Lost to Follow-up|1
6091540|NCT00700310|9704110|FG002|Overall Study|Lost to Follow-up|0
6091541|NCT00700310|9704111|FG003|Overall Study|Lost to Follow-up|1
6091542|NCT00700310|9704108|FG000|Overall Study|Withdrawal by Subject|8
6091543|NCT00700310|9704109|FG001|Overall Study|Withdrawal by Subject|9
6091544|NCT00700310|9704110|FG002|Overall Study|Withdrawal by Subject|8
6091545|NCT00700310|9704111|FG003|Overall Study|Withdrawal by Subject|8
6091546|NCT00700310|9704108|FG000|Overall Study|Lack of Efficacy|0
6091547|NCT00700310|9704109|FG001|Overall Study|Lack of Efficacy|3
6091548|NCT00700310|9704110|FG002|Overall Study|Lack of Efficacy|0
6091549|NCT00700310|9704111|FG003|Overall Study|Lack of Efficacy|1
6091550|NCT00700310|9704108|FG000|Overall Study|Administrative/Other|1
6091551|NCT00700310|9704109|FG001|Overall Study|Administrative/Other|3
6091552|NCT00700310|9704110|FG002|Overall Study|Administrative/Other|1
6091553|NCT00700310|9704111|FG003|Overall Study|Administrative/Other|3
6091554|NCT00700310|9704108|FG000|Overall Study|Randomized, Not Treated|2
6091555|NCT00700310|9704109|FG001|Overall Study|Randomized, Not Treated|0
6091556|NCT00700310|9704110|FG002|Overall Study|Randomized, Not Treated|2
6091557|NCT00700310|9704111|FG003|Overall Study|Randomized, Not Treated|2
6091558|NCT00700401|9704142|FG000|Overall Study|Detectable HCV RNA after Week 4|82
6091559|NCT00700401|9704142|FG000|Overall Study|Adverse Event|5
6091560|NCT00700401|9704142|FG000|Overall Study|Refused Treatment|2
6091561|NCT00700401|9704142|FG000|Overall Study|Lost to Follow-up|1
6091562|NCT00700401|9704142|FG000|Overall Study|Treatment never started|1
6091563|NCT00700401|9704142|FG000|Overall Study|HCV RNA not detected at baseline and SAE|1
6091564|NCT00700401|9704142|FG000|Overall Study|Withdrawal by Subject|2
6091565|NCT00700427|9704146|FG000|Study Period 2 (Open-Label Acute Trx)|Adverse Event|298
6202405|NCT01500278|9862464|FG000|Week 13 - Week 104|Sponsor decision|0
6202406|NCT01500278|9862465|FG001|Week 13 - Week 104|Sponsor decision|2
6202407|NCT01500278|9862464|FG000|Week 13 - Week 104|Medical monitor decision|0
6202408|NCT01500278|9862465|FG001|Week 13 - Week 104|Medical monitor decision|2
6202409|NCT01500278|9862464|FG000|Week 13 - Week 104|Personal reason|0
6057065|NCT00466921|9657582|FG000|First 3 Cycles of Treatment|Adverse Event|2
6057066|NCT00466921|9657582|FG000|First 3 Cycles of Treatment|Withdrawal by Subject|5
6057067|NCT00466921|9657582|FG000|Completed 4 Cycles/Reached 1st Response|Withdrawal by Subject|2
6057068|NCT00466921|9657582|FG000|Completed 4 Cycles/Reached 1st Response|Progressive Disease|2
6057069|NCT00466921|9657582|FG000|Completed 4 Cycles/Reached 1st Response|Other|1
6057070|NCT00466921|9657582|FG000|Follow up for a Minimum of 1 Year|Death|6
6057071|NCT00466947|9657588|FG000|Primary Outcome Analysis Period|Other: study still ongoing|11875
6057072|NCT00466947|9657589|FG001|Primary Outcome Analysis Period|Other: study still ongoing|11863
6057073|NCT00466947|9657588|FG000|Study End Analysis Period|Adverse Event|35
6057074|NCT00466947|9657589|FG001|Study End Analysis Period|Adverse Event|43
6057075|NCT00466947|9657588|FG000|Study End Analysis Period|Lost to Follow-up|1137
6057076|NCT00466947|9657589|FG001|Study End Analysis Period|Lost to Follow-up|1167
6057077|NCT00466947|9657588|FG000|Study End Analysis Period|Physician Decision|29
6057078|NCT00466947|9657589|FG001|Study End Analysis Period|Physician Decision|29
6057079|NCT00466947|9657588|FG000|Study End Analysis Period|Protocol Violation|9
6057080|NCT00466947|9657589|FG001|Study End Analysis Period|Protocol Violation|17
6057081|NCT00466947|9657588|FG000|Study End Analysis Period|Withdrawal by Subject|1264
6057082|NCT00466947|9657589|FG001|Study End Analysis Period|Withdrawal by Subject|1267
6057083|NCT00466947|9657588|FG000|Study End Analysis Period|Other - Forbidden vaccination|21
6057084|NCT00466947|9657589|FG001|Study End Analysis Period|Other - Forbidden vaccination|10
6057085|NCT00466947|9657588|FG000|Study End Analysis Period|Other - Subject without a legal guardian|1
6057086|NCT00466947|9657589|FG001|Study End Analysis Period|Other - Subject without a legal guardian|0
6057087|NCT00466947|9657588|FG000|Study End Analysis Period|Other - Unconformity in team's treatment|0
6057088|NCT00466947|9657589|FG001|Study End Analysis Period|Other - Unconformity in team's treatment|1
6057089|NCT00467051|9657610|FG000|Overall Study|Adverse Event|2
6057090|NCT00467259|9657621|FG000|Overall Study|Adverse Event|24
6057091|NCT00467259|9657622|FG001|Overall Study|Adverse Event|90
6057092|NCT00467259|9657621|FG000|Overall Study|Protocol Violation|1
6057093|NCT00467259|9657622|FG001|Overall Study|Protocol Violation|7
6057094|NCT00467259|9657621|FG000|Overall Study|Withdrawal by Subject|34
6057095|NCT00467259|9657622|FG001|Overall Study|Withdrawal by Subject|108
6057096|NCT00467259|9657621|FG000|Overall Study|Physician Decision|0
6057097|NCT00467259|9657622|FG001|Overall Study|Physician Decision|2
6057098|NCT00467259|9657621|FG000|Overall Study|Lost to Follow-up|14
6057099|NCT00467259|9657622|FG001|Overall Study|Lost to Follow-up|34
6057100|NCT00467259|9657621|FG000|Overall Study|Site Closed|2
6057101|NCT00467259|9657622|FG001|Overall Study|Site Closed|1
6057102|NCT00467272|9657628|FG000|Overall Study|Pneumonia|2
6057103|NCT00467272|9657628|FG000|Overall Study|Thrombophlebitis|1
6057104|NCT00467285|9657634|FG000|Overall Study|Lost to Follow-up|4
6057105|NCT00467285|9657635|FG001|Overall Study|Lost to Follow-up|4
6057106|NCT00467363|9657663|FG000|Overall Study|Lost to Follow-up|80
6057107|NCT00467363|9657664|FG001|Overall Study|Lost to Follow-up|70
6057108|NCT00467519|9657679|FG000|Overall Study|Protocol Violation|8
6057109|NCT00467519|9657680|FG001|Overall Study|Protocol Violation|4
6057110|NCT00467519|9657679|FG000|Overall Study|Lost to Follow-up|2
6057111|NCT00467519|9657680|FG001|Overall Study|Lost to Follow-up|9
6057112|NCT00467519|9657679|FG000|Overall Study|Withdrawal by Subject|4
6057113|NCT00467519|9657680|FG001|Overall Study|Withdrawal by Subject|10
6057114|NCT00467558|9657688|FG000|Overall Study|Lost to Follow-up|2
6057115|NCT00467558|9657689|FG001|Overall Study|Lost to Follow-up|0
6057116|NCT00467584|9657698|FG000|Overall Study|Withdrawal by Subject|4
6057117|NCT00467584|9657699|FG001|Overall Study|Withdrawal by Subject|5
6057118|NCT00467584|9657700|FG002|Overall Study|Withdrawal by Subject|1
6057119|NCT00467597|9657712|FG000|Overall Study|Withdrawal by Subject|2
6057120|NCT00467597|9657713|FG001|Overall Study|Withdrawal by Subject|0
6057121|NCT00467610|9657723|FG000|Overall Study|Withdrawal by Subject|1
6057122|NCT00467649|9657729|FG000|Phase 1 (Randomized Population)|Adverse Event|2
6057123|NCT00467649|9657730|FG001|Phase 1 (Randomized Population)|Adverse Event|0
6057124|NCT00467649|9657731|FG002|Phase 1 (Randomized Population)|Adverse Event|0
6057125|NCT00467649|9657732|FG003|Phase 1 (Randomized Population)|Adverse Event|0
6091566|NCT00700427|9704147|FG001|Study Period 2 (Open-Label Acute Trx)|Adverse Event|0
6091567|NCT00700427|9704148|FG002|Study Period 2 (Open-Label Acute Trx)|Adverse Event|0
6091568|NCT00700427|9704149|FG003|Study Period 2 (Open-Label Acute Trx)|Adverse Event|0
6091569|NCT00700427|9704150|FG004|Study Period 2 (Open-Label Acute Trx)|Adverse Event|0
6091570|NCT00700427|9704146|FG000|Study Period 2 (Open-Label Acute Trx)|Protocol Violation|173
6091571|NCT00700427|9704147|FG001|Study Period 2 (Open-Label Acute Trx)|Protocol Violation|0
6091572|NCT00700427|9704148|FG002|Study Period 2 (Open-Label Acute Trx)|Protocol Violation|0
6091573|NCT00700427|9704149|FG003|Study Period 2 (Open-Label Acute Trx)|Protocol Violation|0
6091574|NCT00700427|9704150|FG004|Study Period 2 (Open-Label Acute Trx)|Protocol Violation|0
6091575|NCT00700427|9704146|FG000|Study Period 2 (Open-Label Acute Trx)|Withdrawal by Subject|164
6091576|NCT00700427|9704147|FG001|Study Period 2 (Open-Label Acute Trx)|Withdrawal by Subject|0
6091577|NCT00700427|9704148|FG002|Study Period 2 (Open-Label Acute Trx)|Withdrawal by Subject|0
6057126|NCT00467649|9657733|FG004|Phase 1 (Randomized Population)|Adverse Event|0
6057127|NCT00467649|9657734|FG005|Phase 1 (Randomized Population)|Adverse Event|0
6057128|NCT00467649|9657729|FG000|Phase 1 (Randomized Population)|Investigator Decision|1
6057129|NCT00467649|9657730|FG001|Phase 1 (Randomized Population)|Investigator Decision|0
6091578|NCT00700427|9704149|FG003|Study Period 2 (Open-Label Acute Trx)|Withdrawal by Subject|0
6091579|NCT00700427|9704150|FG004|Study Period 2 (Open-Label Acute Trx)|Withdrawal by Subject|0
6091580|NCT00700427|9704146|FG000|Study Period 2 (Open-Label Acute Trx)|Protocol Interim Criteria Not Met|161
6091581|NCT00700427|9704147|FG001|Study Period 2 (Open-Label Acute Trx)|Protocol Interim Criteria Not Met|0
6091582|NCT00700427|9704148|FG002|Study Period 2 (Open-Label Acute Trx)|Protocol Interim Criteria Not Met|0
6091583|NCT00700427|9704149|FG003|Study Period 2 (Open-Label Acute Trx)|Protocol Interim Criteria Not Met|0
6091584|NCT00700427|9704150|FG004|Study Period 2 (Open-Label Acute Trx)|Protocol Interim Criteria Not Met|0
6091585|NCT00700427|9704146|FG000|Study Period 2 (Open-Label Acute Trx)|Lost to Follow-up|108
6091586|NCT00700427|9704147|FG001|Study Period 2 (Open-Label Acute Trx)|Lost to Follow-up|0
6091587|NCT00700427|9704148|FG002|Study Period 2 (Open-Label Acute Trx)|Lost to Follow-up|0
6091588|NCT00700427|9704149|FG003|Study Period 2 (Open-Label Acute Trx)|Lost to Follow-up|0
6091589|NCT00700427|9704150|FG004|Study Period 2 (Open-Label Acute Trx)|Lost to Follow-up|0
6091590|NCT00700427|9704146|FG000|Study Period 2 (Open-Label Acute Trx)|Lack of Efficacy|90
6202410|NCT01500278|9862465|FG001|Week 13 - Week 104|Personal reason|1
6202411|NCT01500278|9862464|FG000|Week 13 - Week 104|Not completed|0
6284228|NCT02326272|9996330|FG002|Initial Period (Week 0 to Week 16)|Missed two doses|1
6284229|NCT02326272|9996331|FG003|Initial Period (Week 0 to Week 16)|Missed two doses|0
6284230|NCT02326272|9996332|FG004|Initial Period (Week 0 to Week 16)|Missed two doses|0
6284231|NCT02326272|9996333|FG005|Initial Period (Week 0 to Week 16)|Missed two doses|0
6284232|NCT02326272|9996334|FG006|Initial Period (Week 0 to Week 16)|Missed two doses|0
6284233|NCT02326272|9996335|FG007|Initial Period (Week 0 to Week 16)|Missed two doses|0
6284234|NCT02326272|9996336|FG008|Initial Period (Week 0 to Week 16)|Missed two doses|0
6057130|NCT00467649|9657731|FG002|Phase 1 (Randomized Population)|Investigator Decision|0
6057131|NCT00467649|9657732|FG003|Phase 1 (Randomized Population)|Investigator Decision|0
6057132|NCT00467649|9657733|FG004|Phase 1 (Randomized Population)|Investigator Decision|0
6057133|NCT00467649|9657734|FG005|Phase 1 (Randomized Population)|Investigator Decision|0
6057134|NCT00467649|9657729|FG000|Phase 1 (Randomized Population)|Lost to Follow-up|2
6057135|NCT00467649|9657730|FG001|Phase 1 (Randomized Population)|Lost to Follow-up|4
6057136|NCT00467649|9657731|FG002|Phase 1 (Randomized Population)|Lost to Follow-up|0
6057137|NCT00467649|9657732|FG003|Phase 1 (Randomized Population)|Lost to Follow-up|0
6057138|NCT00467649|9657733|FG004|Phase 1 (Randomized Population)|Lost to Follow-up|0
6057139|NCT00467649|9657734|FG005|Phase 1 (Randomized Population)|Lost to Follow-up|0
6057140|NCT00467649|9657729|FG000|Phase 1 (Randomized Population)|Withdrawal of Consent|4
6057141|NCT00467649|9657730|FG001|Phase 1 (Randomized Population)|Withdrawal of Consent|2
6057142|NCT00467649|9657731|FG002|Phase 1 (Randomized Population)|Withdrawal of Consent|0
6057143|NCT00467649|9657732|FG003|Phase 1 (Randomized Population)|Withdrawal of Consent|0
6057144|NCT00467649|9657733|FG004|Phase 1 (Randomized Population)|Withdrawal of Consent|0
6057145|NCT00467649|9657734|FG005|Phase 1 (Randomized Population)|Withdrawal of Consent|0
6057146|NCT00467649|9657729|FG000|Phase 2 (Intent-to-Treat Population)|Lost to Follow-up|0
6057147|NCT00467649|9657730|FG001|Phase 2 (Intent-to-Treat Population)|Lost to Follow-up|0
6057148|NCT00467649|9657731|FG002|Phase 2 (Intent-to-Treat Population)|Lost to Follow-up|0
6057149|NCT00467649|9657732|FG003|Phase 2 (Intent-to-Treat Population)|Lost to Follow-up|1
6057150|NCT00467649|9657733|FG004|Phase 2 (Intent-to-Treat Population)|Lost to Follow-up|0
6057151|NCT00467649|9657734|FG005|Phase 2 (Intent-to-Treat Population)|Lost to Follow-up|0
6091591|NCT00700427|9704147|FG001|Study Period 2 (Open-Label Acute Trx)|Lack of Efficacy|0
6091592|NCT00700427|9704148|FG002|Study Period 2 (Open-Label Acute Trx)|Lack of Efficacy|0
6091593|NCT00700427|9704149|FG003|Study Period 2 (Open-Label Acute Trx)|Lack of Efficacy|0
6091594|NCT00700427|9704150|FG004|Study Period 2 (Open-Label Acute Trx)|Lack of Efficacy|0
6091595|NCT00700427|9704146|FG000|Study Period 2 (Open-Label Acute Trx)|Physician Decision|8
6091596|NCT00700427|9704147|FG001|Study Period 2 (Open-Label Acute Trx)|Physician Decision|0
6091597|NCT00700427|9704148|FG002|Study Period 2 (Open-Label Acute Trx)|Physician Decision|0
6091598|NCT00700427|9704149|FG003|Study Period 2 (Open-Label Acute Trx)|Physician Decision|0
6091599|NCT00700427|9704150|FG004|Study Period 2 (Open-Label Acute Trx)|Physician Decision|0
6091600|NCT00700427|9704146|FG000|Study Period 2 (Open-Label Acute Trx)|Clinical Relapse|7
6091601|NCT00700427|9704147|FG001|Study Period 2 (Open-Label Acute Trx)|Clinical Relapse|0
6091602|NCT00700427|9704148|FG002|Study Period 2 (Open-Label Acute Trx)|Clinical Relapse|0
6091603|NCT00700427|9704149|FG003|Study Period 2 (Open-Label Acute Trx)|Clinical Relapse|0
6091604|NCT00700427|9704150|FG004|Study Period 2 (Open-Label Acute Trx)|Clinical Relapse|0
6091605|NCT00700427|9704146|FG000|Study Period 2 (Open-Label Acute Trx)|Entry Criteria Not Met|2
6091606|NCT00700427|9704147|FG001|Study Period 2 (Open-Label Acute Trx)|Entry Criteria Not Met|0
6091607|NCT00700427|9704148|FG002|Study Period 2 (Open-Label Acute Trx)|Entry Criteria Not Met|0
6091608|NCT00700427|9704149|FG003|Study Period 2 (Open-Label Acute Trx)|Entry Criteria Not Met|0
6091609|NCT00700427|9704150|FG004|Study Period 2 (Open-Label Acute Trx)|Entry Criteria Not Met|0
6202412|NCT01500278|9862465|FG001|Week 13 - Week 104|Not completed|1
6202413|NCT01500278|9862464|FG000|Week 13 - Week 104|Death|2
6202414|NCT01500278|9862465|FG001|Week 13 - Week 104|Death|4
6202415|NCT01500278|9862464|FG000|Week 13 - Week 104|Adverse Event|54
6202416|NCT01500278|9862465|FG001|Week 13 - Week 104|Adverse Event|54
6202417|NCT01500317|9862476|FG000|Overall Study|Withdrawal by Subject|3
6202418|NCT01500317|9862477|FG001|Overall Study|Withdrawal by Subject|2
6057152|NCT00467649|9657729|FG000|Phase 2 (Intent-to-Treat Population)|Protocol Violation|0
6057153|NCT00467649|9657730|FG001|Phase 2 (Intent-to-Treat Population)|Protocol Violation|0
6057154|NCT00467649|9657731|FG002|Phase 2 (Intent-to-Treat Population)|Protocol Violation|0
6057155|NCT00467649|9657732|FG003|Phase 2 (Intent-to-Treat Population)|Protocol Violation|1
6057156|NCT00467649|9657733|FG004|Phase 2 (Intent-to-Treat Population)|Protocol Violation|0
6057157|NCT00467649|9657734|FG005|Phase 2 (Intent-to-Treat Population)|Protocol Violation|0
6057158|NCT00467649|9657729|FG000|Phase 2 (Intent-to-Treat Population)|Withdrawal of Consent|0
6057159|NCT00467649|9657730|FG001|Phase 2 (Intent-to-Treat Population)|Withdrawal of Consent|0
6057160|NCT00467649|9657731|FG002|Phase 2 (Intent-to-Treat Population)|Withdrawal of Consent|0
6057161|NCT00467649|9657732|FG003|Phase 2 (Intent-to-Treat Population)|Withdrawal of Consent|0
6057162|NCT00467649|9657733|FG004|Phase 2 (Intent-to-Treat Population)|Withdrawal of Consent|0
6057163|NCT00467649|9657734|FG005|Phase 2 (Intent-to-Treat Population)|Withdrawal of Consent|1
6057164|NCT00467740|9657757|FG000|Overall Study|Adverse Event|0
6057165|NCT00467740|9657758|FG001|Overall Study|Adverse Event|0
6057166|NCT00467740|9657759|FG002|Overall Study|Adverse Event|1
6057167|NCT00467740|9657760|FG003|Overall Study|Adverse Event|0
6057168|NCT00467740|9657761|FG004|Overall Study|Adverse Event|0
6057169|NCT00467740|9657757|FG000|Overall Study|Protocol Violation|0
6057170|NCT00467740|9657758|FG001|Overall Study|Protocol Violation|0
6057171|NCT00467740|9657759|FG002|Overall Study|Protocol Violation|1
6057172|NCT00467740|9657760|FG003|Overall Study|Protocol Violation|0
6057173|NCT00467740|9657761|FG004|Overall Study|Protocol Violation|0
6057174|NCT00467740|9657757|FG000|Overall Study|Lost to Follow-up|0
6057175|NCT00467740|9657758|FG001|Overall Study|Lost to Follow-up|1
6057176|NCT00467740|9657759|FG002|Overall Study|Lost to Follow-up|0
6057177|NCT00467740|9657760|FG003|Overall Study|Lost to Follow-up|0
6057178|NCT00467740|9657761|FG004|Overall Study|Lost to Follow-up|0
6057179|NCT00467740|9657757|FG000|Overall Study|Withdrawal by Subject|1
6057180|NCT00467740|9657758|FG001|Overall Study|Withdrawal by Subject|1
6057181|NCT00467740|9657759|FG002|Overall Study|Withdrawal by Subject|0
6057182|NCT00467740|9657760|FG003|Overall Study|Withdrawal by Subject|1
6057183|NCT00467740|9657761|FG004|Overall Study|Withdrawal by Subject|0
6057184|NCT00467740|9657757|FG000|Overall Study|Lack of Efficacy|0
6057185|NCT00467740|9657758|FG001|Overall Study|Lack of Efficacy|1
6057186|NCT00467740|9657759|FG002|Overall Study|Lack of Efficacy|0
6057187|NCT00467740|9657760|FG003|Overall Study|Lack of Efficacy|0
6057188|NCT00467740|9657761|FG004|Overall Study|Lack of Efficacy|0
6057189|NCT00467779|9657788|FG000|Stage 1|Adverse Event|1
6057190|NCT00467779|9657789|FG001|Stage 1|Adverse Event|0
6057191|NCT00467779|9657790|FG002|Stage 1|Adverse Event|0
6057192|NCT00467779|9657791|FG003|Stage 1|Adverse Event|0
6057193|NCT00467779|9657792|FG004|Stage 1|Adverse Event|0
6057194|NCT00467779|9657793|FG005|Stage 1|Adverse Event|1
6057195|NCT00467779|9657794|FG006|Stage 1|Adverse Event|2
6057196|NCT00467779|9657795|FG007|Stage 1|Adverse Event|1
6057197|NCT00467779|9657796|FG008|Stage 1|Adverse Event|0
6057198|NCT00467779|9657797|FG009|Stage 1|Adverse Event|0
6057199|NCT00467779|9657798|FG010|Stage 1|Adverse Event|0
6057200|NCT00467779|9657799|FG011|Stage 1|Adverse Event|0
6057201|NCT00467779|9657800|FG012|Stage 1|Adverse Event|0
6057202|NCT00467779|9657801|FG013|Stage 1|Adverse Event|0
6057203|NCT00467779|9657802|FG014|Stage 1|Adverse Event|0
6057204|NCT00467779|9657788|FG000|Stage 1|Disease Progression|2
6057205|NCT00467779|9657789|FG001|Stage 1|Disease Progression|2
6057206|NCT00467779|9657790|FG002|Stage 1|Disease Progression|2
6057207|NCT00467779|9657791|FG003|Stage 1|Disease Progression|3
6057208|NCT00467779|9657792|FG004|Stage 1|Disease Progression|2
6057209|NCT00467779|9657793|FG005|Stage 1|Disease Progression|2
6057210|NCT00467779|9657794|FG006|Stage 1|Disease Progression|4
6057211|NCT00467779|9657795|FG007|Stage 1|Disease Progression|5
6057212|NCT00467779|9657796|FG008|Stage 1|Disease Progression|0
6057213|NCT00467779|9657797|FG009|Stage 1|Disease Progression|0
6057214|NCT00467779|9657798|FG010|Stage 1|Disease Progression|0
6057215|NCT00467779|9657799|FG011|Stage 1|Disease Progression|0
6057216|NCT00467779|9657800|FG012|Stage 1|Disease Progression|0
6057217|NCT00467779|9657801|FG013|Stage 1|Disease Progression|0
6057218|NCT00467779|9657802|FG014|Stage 1|Disease Progression|0
6057219|NCT00467779|9657788|FG000|Stage 1|Unspecified Reason|1
6057220|NCT00467779|9657789|FG001|Stage 1|Unspecified Reason|0
6057221|NCT00467779|9657790|FG002|Stage 1|Unspecified Reason|1
6057222|NCT00467779|9657791|FG003|Stage 1|Unspecified Reason|0
6057223|NCT00467779|9657792|FG004|Stage 1|Unspecified Reason|1
6057224|NCT00467779|9657793|FG005|Stage 1|Unspecified Reason|2
6057225|NCT00467779|9657794|FG006|Stage 1|Unspecified Reason|0
6057226|NCT00467779|9657795|FG007|Stage 1|Unspecified Reason|0
6057227|NCT00467779|9657796|FG008|Stage 1|Unspecified Reason|0
6057228|NCT00467779|9657797|FG009|Stage 1|Unspecified Reason|0
6057229|NCT00467779|9657798|FG010|Stage 1|Unspecified Reason|0
6057230|NCT00467779|9657799|FG011|Stage 1|Unspecified Reason|0
6057231|NCT00467779|9657800|FG012|Stage 1|Unspecified Reason|0
6057232|NCT00467779|9657801|FG013|Stage 1|Unspecified Reason|0
6057233|NCT00467779|9657802|FG014|Stage 1|Unspecified Reason|0
6057234|NCT00467779|9657788|FG000|Stage 1|Physician Decision|0
6057235|NCT00467779|9657789|FG001|Stage 1|Physician Decision|1
6057236|NCT00467779|9657790|FG002|Stage 1|Physician Decision|0
6057237|NCT00467779|9657791|FG003|Stage 1|Physician Decision|0
6057238|NCT00467779|9657792|FG004|Stage 1|Physician Decision|0
6057239|NCT00467779|9657793|FG005|Stage 1|Physician Decision|0
6057240|NCT00467779|9657794|FG006|Stage 1|Physician Decision|0
6057241|NCT00467779|9657795|FG007|Stage 1|Physician Decision|0
6057242|NCT00467779|9657796|FG008|Stage 1|Physician Decision|0
6057243|NCT00467779|9657797|FG009|Stage 1|Physician Decision|0
6057244|NCT00467779|9657798|FG010|Stage 1|Physician Decision|0
6057245|NCT00467779|9657799|FG011|Stage 1|Physician Decision|0
6057246|NCT00467779|9657800|FG012|Stage 1|Physician Decision|0
6057247|NCT00467779|9657801|FG013|Stage 1|Physician Decision|0
6057248|NCT00467779|9657802|FG014|Stage 1|Physician Decision|0
6057249|NCT00467779|9657788|FG000|Stage 1|Withdrawal by Subject|0
6057250|NCT00467779|9657789|FG001|Stage 1|Withdrawal by Subject|0
6057251|NCT00467779|9657790|FG002|Stage 1|Withdrawal by Subject|0
6057252|NCT00467779|9657791|FG003|Stage 1|Withdrawal by Subject|0
6057253|NCT00467779|9657792|FG004|Stage 1|Withdrawal by Subject|0
6057254|NCT00467779|9657793|FG005|Stage 1|Withdrawal by Subject|0
6057255|NCT00467779|9657794|FG006|Stage 1|Withdrawal by Subject|1
6057256|NCT00467779|9657795|FG007|Stage 1|Withdrawal by Subject|1
6057257|NCT00467779|9657796|FG008|Stage 1|Withdrawal by Subject|0
6057258|NCT00467779|9657797|FG009|Stage 1|Withdrawal by Subject|0
6057259|NCT00467779|9657798|FG010|Stage 1|Withdrawal by Subject|0
6057260|NCT00467779|9657799|FG011|Stage 1|Withdrawal by Subject|0
6057261|NCT00467779|9657800|FG012|Stage 1|Withdrawal by Subject|0
6057262|NCT00467779|9657801|FG013|Stage 1|Withdrawal by Subject|0
6057263|NCT00467779|9657802|FG014|Stage 1|Withdrawal by Subject|0
6202419|NCT01500317|9862478|FG002|Overall Study|Withdrawal by Subject|0
6202420|NCT01500382|9862490|FG000|Washout Period|Study site went out of business|0
6202421|NCT01500382|9862491|FG001|Washout Period|Study site went out of business|0
6057264|NCT00467779|9657788|FG000|Stage 1A|Adverse Event|0
6057265|NCT00467779|9657789|FG001|Stage 1A|Adverse Event|0
6057266|NCT00467779|9657790|FG002|Stage 1A|Adverse Event|0
6057267|NCT00467779|9657791|FG003|Stage 1A|Adverse Event|0
6057268|NCT00467779|9657792|FG004|Stage 1A|Adverse Event|0
6057269|NCT00467779|9657793|FG005|Stage 1A|Adverse Event|0
6057270|NCT00467779|9657794|FG006|Stage 1A|Adverse Event|0
6057271|NCT00467779|9657795|FG007|Stage 1A|Adverse Event|0
6057272|NCT00467779|9657796|FG008|Stage 1A|Adverse Event|0
6057273|NCT00467779|9657797|FG009|Stage 1A|Adverse Event|0
6057274|NCT00467779|9657798|FG010|Stage 1A|Adverse Event|0
6057275|NCT00467779|9657799|FG011|Stage 1A|Adverse Event|0
6057276|NCT00467779|9657800|FG012|Stage 1A|Adverse Event|1
6057277|NCT00467779|9657801|FG013|Stage 1A|Adverse Event|0
6057278|NCT00467779|9657802|FG014|Stage 1A|Adverse Event|0
6057279|NCT00467779|9657788|FG000|Stage 1A|Death|0
6057280|NCT00467779|9657789|FG001|Stage 1A|Death|0
6057281|NCT00467779|9657790|FG002|Stage 1A|Death|0
6057282|NCT00467779|9657791|FG003|Stage 1A|Death|0
6057283|NCT00467779|9657792|FG004|Stage 1A|Death|0
6057284|NCT00467779|9657793|FG005|Stage 1A|Death|0
6057285|NCT00467779|9657794|FG006|Stage 1A|Death|0
6057286|NCT00467779|9657795|FG007|Stage 1A|Death|0
6057287|NCT00467779|9657796|FG008|Stage 1A|Death|0
6057288|NCT00467779|9657797|FG009|Stage 1A|Death|0
6057289|NCT00467779|9657798|FG010|Stage 1A|Death|0
6057290|NCT00467779|9657799|FG011|Stage 1A|Death|1
6057291|NCT00467779|9657800|FG012|Stage 1A|Death|1
6057292|NCT00467779|9657801|FG013|Stage 1A|Death|0
6057293|NCT00467779|9657802|FG014|Stage 1A|Death|0
6057294|NCT00467779|9657788|FG000|Stage 1A|Disease Progression|0
6091610|NCT00700427|9704146|FG000|Study Period 3A (Blinded Maintenance)|Adverse Event|0
6091611|NCT00700427|9704147|FG001|Study Period 3A (Blinded Maintenance)|Adverse Event|50
6091612|NCT00700427|9704148|FG002|Study Period 3A (Blinded Maintenance)|Adverse Event|0
6091613|NCT00700427|9704149|FG003|Study Period 3A (Blinded Maintenance)|Adverse Event|0
6091614|NCT00700427|9704150|FG004|Study Period 3A (Blinded Maintenance)|Adverse Event|0
6091615|NCT00700427|9704146|FG000|Study Period 3A (Blinded Maintenance)|Protocol Interim Criteria Not Met|0
6091616|NCT00700427|9704147|FG001|Study Period 3A (Blinded Maintenance)|Protocol Interim Criteria Not Met|162
6091617|NCT00700427|9704148|FG002|Study Period 3A (Blinded Maintenance)|Protocol Interim Criteria Not Met|0
6091618|NCT00700427|9704149|FG003|Study Period 3A (Blinded Maintenance)|Protocol Interim Criteria Not Met|0
6091619|NCT00700427|9704150|FG004|Study Period 3A (Blinded Maintenance)|Protocol Interim Criteria Not Met|0
6091620|NCT00700427|9704146|FG000|Study Period 3A (Blinded Maintenance)|Withdrawal by Subject|0
6091621|NCT00700427|9704147|FG001|Study Period 3A (Blinded Maintenance)|Withdrawal by Subject|81
6091622|NCT00700427|9704148|FG002|Study Period 3A (Blinded Maintenance)|Withdrawal by Subject|0
6091623|NCT00700427|9704149|FG003|Study Period 3A (Blinded Maintenance)|Withdrawal by Subject|0
6091624|NCT00700427|9704150|FG004|Study Period 3A (Blinded Maintenance)|Withdrawal by Subject|0
6091625|NCT00700427|9704146|FG000|Study Period 3A (Blinded Maintenance)|Protocol Violation|0
6202422|NCT01500382|9862492|FG002|Washout Period|Study site went out of business|1
6057295|NCT00467779|9657789|FG001|Stage 1A|Disease Progression|0
6057296|NCT00467779|9657790|FG002|Stage 1A|Disease Progression|0
6057297|NCT00467779|9657791|FG003|Stage 1A|Disease Progression|0
6057298|NCT00467779|9657792|FG004|Stage 1A|Disease Progression|0
6057299|NCT00467779|9657793|FG005|Stage 1A|Disease Progression|0
6057300|NCT00467779|9657794|FG006|Stage 1A|Disease Progression|0
6057301|NCT00467779|9657795|FG007|Stage 1A|Disease Progression|0
6057302|NCT00467779|9657796|FG008|Stage 1A|Disease Progression|0
6057303|NCT00467779|9657797|FG009|Stage 1A|Disease Progression|2
6202423|NCT01500382|9862493|FG003|Washout Period|Study site went out of business|0
6202424|NCT01500434|9862503|FG000|Overall Study|Death|1
6202425|NCT01500434|9862503|FG000|Overall Study|Withdrawal by Subject|1
6202426|NCT01500434|9862503|FG000|Overall Study|Missed 12-month follow-up|5
6202427|NCT01500629|9862518|FG000|Washout Period of 14 to 30 Days|Pregnancy|1
6202428|NCT01500629|9862519|FG001|Washout Period of 14 to 30 Days|Pregnancy|0
6202429|NCT01500694|9862534|FG000|Overall Study|Adverse Event|4
6057304|NCT00467779|9657798|FG010|Stage 1A|Disease Progression|2
6057305|NCT00467779|9657799|FG011|Stage 1A|Disease Progression|5
6057306|NCT00467779|9657800|FG012|Stage 1A|Disease Progression|2
6057307|NCT00467779|9657801|FG013|Stage 1A|Disease Progression|0
6057308|NCT00467779|9657802|FG014|Stage 1A|Disease Progression|0
6057309|NCT00467779|9657788|FG000|Stage 1A|Physician Decision|0
6057310|NCT00467779|9657789|FG001|Stage 1A|Physician Decision|0
6057311|NCT00467779|9657790|FG002|Stage 1A|Physician Decision|0
6057312|NCT00467779|9657791|FG003|Stage 1A|Physician Decision|0
6057313|NCT00467779|9657792|FG004|Stage 1A|Physician Decision|0
6057314|NCT00467779|9657793|FG005|Stage 1A|Physician Decision|0
6057315|NCT00467779|9657794|FG006|Stage 1A|Physician Decision|0
6057316|NCT00467779|9657795|FG007|Stage 1A|Physician Decision|0
6057317|NCT00467779|9657796|FG008|Stage 1A|Physician Decision|0
6057318|NCT00467779|9657797|FG009|Stage 1A|Physician Decision|1
6057319|NCT00467779|9657798|FG010|Stage 1A|Physician Decision|0
6057320|NCT00467779|9657799|FG011|Stage 1A|Physician Decision|0
6057321|NCT00467779|9657800|FG012|Stage 1A|Physician Decision|0
6091626|NCT00700427|9704147|FG001|Study Period 3A (Blinded Maintenance)|Protocol Violation|56
6091627|NCT00700427|9704148|FG002|Study Period 3A (Blinded Maintenance)|Protocol Violation|0
6091628|NCT00700427|9704149|FG003|Study Period 3A (Blinded Maintenance)|Protocol Violation|0
6091629|NCT00700427|9704150|FG004|Study Period 3A (Blinded Maintenance)|Protocol Violation|0
6091630|NCT00700427|9704146|FG000|Study Period 3A (Blinded Maintenance)|Clinical Relapse|0
6091631|NCT00700427|9704147|FG001|Study Period 3A (Blinded Maintenance)|Clinical Relapse|49
6091632|NCT00700427|9704148|FG002|Study Period 3A (Blinded Maintenance)|Clinical Relapse|0
6091633|NCT00700427|9704149|FG003|Study Period 3A (Blinded Maintenance)|Clinical Relapse|0
6091634|NCT00700427|9704150|FG004|Study Period 3A (Blinded Maintenance)|Clinical Relapse|0
6091635|NCT00700427|9704146|FG000|Study Period 3A (Blinded Maintenance)|Lost to Follow-up|0
6091636|NCT00700427|9704147|FG001|Study Period 3A (Blinded Maintenance)|Lost to Follow-up|41
6091637|NCT00700427|9704148|FG002|Study Period 3A (Blinded Maintenance)|Lost to Follow-up|0
6091638|NCT00700427|9704149|FG003|Study Period 3A (Blinded Maintenance)|Lost to Follow-up|0
6091639|NCT00700427|9704150|FG004|Study Period 3A (Blinded Maintenance)|Lost to Follow-up|0
6091640|NCT00700427|9704146|FG000|Study Period 3A (Blinded Maintenance)|Lack of Efficacy|0
6091641|NCT00700427|9704147|FG001|Study Period 3A (Blinded Maintenance)|Lack of Efficacy|32
6091642|NCT00700427|9704148|FG002|Study Period 3A (Blinded Maintenance)|Lack of Efficacy|0
6091643|NCT00700427|9704149|FG003|Study Period 3A (Blinded Maintenance)|Lack of Efficacy|0
6091644|NCT00700427|9704150|FG004|Study Period 3A (Blinded Maintenance)|Lack of Efficacy|0
6091645|NCT00700427|9704146|FG000|Study Period 3A (Blinded Maintenance)|Sponsor Decision|0
6091646|NCT00700427|9704147|FG001|Study Period 3A (Blinded Maintenance)|Sponsor Decision|3
6091647|NCT00700427|9704148|FG002|Study Period 3A (Blinded Maintenance)|Sponsor Decision|0
6091648|NCT00700427|9704149|FG003|Study Period 3A (Blinded Maintenance)|Sponsor Decision|0
6091649|NCT00700427|9704150|FG004|Study Period 3A (Blinded Maintenance)|Sponsor Decision|0
6091650|NCT00700427|9704146|FG000|Study Period 3A (Blinded Maintenance)|Physician Decision|0
6091651|NCT00700427|9704147|FG001|Study Period 3A (Blinded Maintenance)|Physician Decision|2
6091652|NCT00700427|9704148|FG002|Study Period 3A (Blinded Maintenance)|Physician Decision|0
6091653|NCT00700427|9704149|FG003|Study Period 3A (Blinded Maintenance)|Physician Decision|0
6091654|NCT00700427|9704150|FG004|Study Period 3A (Blinded Maintenance)|Physician Decision|0
6091655|NCT00700427|9704146|FG000|Study Period 3A (Blinded Maintenance)|Missing - Not Otherwise Defined|0
6091656|NCT00700427|9704147|FG001|Study Period 3A (Blinded Maintenance)|Missing - Not Otherwise Defined|5
6091657|NCT00700427|9704148|FG002|Study Period 3A (Blinded Maintenance)|Missing - Not Otherwise Defined|0
6091658|NCT00700427|9704149|FG003|Study Period 3A (Blinded Maintenance)|Missing - Not Otherwise Defined|0
6091659|NCT00700427|9704150|FG004|Study Period 3A (Blinded Maintenance)|Missing - Not Otherwise Defined|0
6091660|NCT00700427|9704146|FG000|Study Period 3B (Randomized Withdrawal)|Adverse Event|0
6091661|NCT00700427|9704147|FG001|Study Period 3B (Randomized Withdrawal)|Adverse Event|0
6091662|NCT00700427|9704148|FG002|Study Period 3B (Randomized Withdrawal)|Adverse Event|8
6091663|NCT00700427|9704149|FG003|Study Period 3B (Randomized Withdrawal)|Adverse Event|5
6091664|NCT00700427|9704150|FG004|Study Period 3B (Randomized Withdrawal)|Adverse Event|0
6091665|NCT00700427|9704146|FG000|Study Period 3B (Randomized Withdrawal)|Withdrawal by Subject|0
6091666|NCT00700427|9704147|FG001|Study Period 3B (Randomized Withdrawal)|Withdrawal by Subject|0
6091667|NCT00700427|9704148|FG002|Study Period 3B (Randomized Withdrawal)|Withdrawal by Subject|25
6091668|NCT00700427|9704149|FG003|Study Period 3B (Randomized Withdrawal)|Withdrawal by Subject|34
6091669|NCT00700427|9704150|FG004|Study Period 3B (Randomized Withdrawal)|Withdrawal by Subject|0
6091670|NCT00700427|9704146|FG000|Study Period 3B (Randomized Withdrawal)|Protocol Violation|0
6202430|NCT01500694|9862535|FG001|Overall Study|Adverse Event|3
6057322|NCT00467779|9657801|FG013|Stage 1A|Physician Decision|0
6057323|NCT00467779|9657802|FG014|Stage 1A|Physician Decision|0
6057324|NCT00467779|9657788|FG000|Stage 1A|Withdrawal by Subject|0
6057325|NCT00467779|9657789|FG001|Stage 1A|Withdrawal by Subject|0
6057326|NCT00467779|9657790|FG002|Stage 1A|Withdrawal by Subject|0
6057327|NCT00467779|9657791|FG003|Stage 1A|Withdrawal by Subject|0
6057328|NCT00467779|9657792|FG004|Stage 1A|Withdrawal by Subject|0
6057329|NCT00467779|9657793|FG005|Stage 1A|Withdrawal by Subject|0
6057330|NCT00467779|9657794|FG006|Stage 1A|Withdrawal by Subject|0
6057331|NCT00467779|9657795|FG007|Stage 1A|Withdrawal by Subject|0
6057332|NCT00467779|9657796|FG008|Stage 1A|Withdrawal by Subject|0
6057333|NCT00467779|9657797|FG009|Stage 1A|Withdrawal by Subject|0
6057334|NCT00467779|9657798|FG010|Stage 1A|Withdrawal by Subject|1
6057335|NCT00467779|9657799|FG011|Stage 1A|Withdrawal by Subject|1
6057336|NCT00467779|9657800|FG012|Stage 1A|Withdrawal by Subject|1
6057337|NCT00467779|9657801|FG013|Stage 1A|Withdrawal by Subject|0
6057338|NCT00467779|9657802|FG014|Stage 1A|Withdrawal by Subject|0
6057339|NCT00467779|9657788|FG000|Stage 1A|Unspecified Reason|0
6057340|NCT00467779|9657789|FG001|Stage 1A|Unspecified Reason|0
6057341|NCT00467779|9657790|FG002|Stage 1A|Unspecified Reason|0
6057342|NCT00467779|9657791|FG003|Stage 1A|Unspecified Reason|0
6057343|NCT00467779|9657792|FG004|Stage 1A|Unspecified Reason|0
6057344|NCT00467779|9657793|FG005|Stage 1A|Unspecified Reason|0
6057345|NCT00467779|9657794|FG006|Stage 1A|Unspecified Reason|0
6057346|NCT00467779|9657795|FG007|Stage 1A|Unspecified Reason|0
6057347|NCT00467779|9657796|FG008|Stage 1A|Unspecified Reason|0
6057348|NCT00467779|9657797|FG009|Stage 1A|Unspecified Reason|0
6057349|NCT00467779|9657798|FG010|Stage 1A|Unspecified Reason|0
6057350|NCT00467779|9657799|FG011|Stage 1A|Unspecified Reason|1
6057351|NCT00467779|9657800|FG012|Stage 1A|Unspecified Reason|1
6057352|NCT00467779|9657801|FG013|Stage 1A|Unspecified Reason|0
6057353|NCT00467779|9657802|FG014|Stage 1A|Unspecified Reason|0
6057354|NCT00467779|9657788|FG000|Stage 2|Adverse Event|0
6057355|NCT00467779|9657789|FG001|Stage 2|Adverse Event|0
6057356|NCT00467779|9657790|FG002|Stage 2|Adverse Event|0
6057357|NCT00467779|9657791|FG003|Stage 2|Adverse Event|0
6057358|NCT00467779|9657792|FG004|Stage 2|Adverse Event|0
6057359|NCT00467779|9657793|FG005|Stage 2|Adverse Event|0
6057360|NCT00467779|9657794|FG006|Stage 2|Adverse Event|0
6057361|NCT00467779|9657795|FG007|Stage 2|Adverse Event|0
6057362|NCT00467779|9657796|FG008|Stage 2|Adverse Event|1
6057363|NCT00467779|9657797|FG009|Stage 2|Adverse Event|0
6057364|NCT00467779|9657798|FG010|Stage 2|Adverse Event|0
6057365|NCT00467779|9657799|FG011|Stage 2|Adverse Event|0
6057366|NCT00467779|9657800|FG012|Stage 2|Adverse Event|0
6057367|NCT00467779|9657801|FG013|Stage 2|Adverse Event|0
6057368|NCT00467779|9657802|FG014|Stage 2|Adverse Event|0
6057369|NCT00467779|9657788|FG000|Stage 2|Death|0
6057370|NCT00467779|9657789|FG001|Stage 2|Death|0
6057371|NCT00467779|9657790|FG002|Stage 2|Death|0
6057372|NCT00467779|9657791|FG003|Stage 2|Death|0
6057373|NCT00467779|9657792|FG004|Stage 2|Death|0
6057374|NCT00467779|9657793|FG005|Stage 2|Death|0
6057375|NCT00467779|9657794|FG006|Stage 2|Death|0
6057376|NCT00467779|9657795|FG007|Stage 2|Death|0
6057377|NCT00467779|9657796|FG008|Stage 2|Death|1
6057378|NCT00467779|9657797|FG009|Stage 2|Death|0
6057379|NCT00467779|9657798|FG010|Stage 2|Death|0
6057380|NCT00467779|9657799|FG011|Stage 2|Death|0
6057381|NCT00467779|9657800|FG012|Stage 2|Death|0
6057382|NCT00467779|9657801|FG013|Stage 2|Death|0
6057383|NCT00467779|9657802|FG014|Stage 2|Death|0
6057384|NCT00467779|9657788|FG000|Stage 2|Disease Progression|0
6057385|NCT00467779|9657789|FG001|Stage 2|Disease Progression|0
6057386|NCT00467779|9657790|FG002|Stage 2|Disease Progression|0
6057387|NCT00467779|9657791|FG003|Stage 2|Disease Progression|0
6057388|NCT00467779|9657792|FG004|Stage 2|Disease Progression|0
6057389|NCT00467779|9657793|FG005|Stage 2|Disease Progression|0
6057390|NCT00467779|9657794|FG006|Stage 2|Disease Progression|0
6057391|NCT00467779|9657795|FG007|Stage 2|Disease Progression|0
6057392|NCT00467779|9657796|FG008|Stage 2|Disease Progression|16
6057393|NCT00467779|9657797|FG009|Stage 2|Disease Progression|0
6057394|NCT00467779|9657798|FG010|Stage 2|Disease Progression|0
6057395|NCT00467779|9657799|FG011|Stage 2|Disease Progression|0
6057396|NCT00467779|9657800|FG012|Stage 2|Disease Progression|0
6057397|NCT00467779|9657801|FG013|Stage 2|Disease Progression|0
6057398|NCT00467779|9657802|FG014|Stage 2|Disease Progression|0
6057399|NCT00467779|9657788|FG000|Stage 2|Unspecified Reason|0
6057400|NCT00467779|9657789|FG001|Stage 2|Unspecified Reason|0
6057401|NCT00467779|9657790|FG002|Stage 2|Unspecified Reason|0
6057402|NCT00467779|9657791|FG003|Stage 2|Unspecified Reason|0
6057403|NCT00467779|9657792|FG004|Stage 2|Unspecified Reason|0
6057404|NCT00467779|9657793|FG005|Stage 2|Unspecified Reason|0
6057405|NCT00467779|9657794|FG006|Stage 2|Unspecified Reason|0
6057406|NCT00467779|9657795|FG007|Stage 2|Unspecified Reason|0
6057407|NCT00467779|9657796|FG008|Stage 2|Unspecified Reason|3
6057408|NCT00467779|9657797|FG009|Stage 2|Unspecified Reason|0
6057409|NCT00467779|9657798|FG010|Stage 2|Unspecified Reason|0
6057410|NCT00467779|9657799|FG011|Stage 2|Unspecified Reason|0
6057411|NCT00467779|9657800|FG012|Stage 2|Unspecified Reason|0
6057412|NCT00467779|9657801|FG013|Stage 2|Unspecified Reason|0
6057413|NCT00467779|9657802|FG014|Stage 2|Unspecified Reason|0
6057414|NCT00467779|9657788|FG000|Stage 2A|Adverse Event|0
6057415|NCT00467779|9657789|FG001|Stage 2A|Adverse Event|0
6057416|NCT00467779|9657790|FG002|Stage 2A|Adverse Event|0
6057417|NCT00467779|9657791|FG003|Stage 2A|Adverse Event|0
6057418|NCT00467779|9657792|FG004|Stage 2A|Adverse Event|0
6091671|NCT00700427|9704147|FG001|Study Period 3B (Randomized Withdrawal)|Protocol Violation|0
6091672|NCT00700427|9704148|FG002|Study Period 3B (Randomized Withdrawal)|Protocol Violation|23
6091673|NCT00700427|9704149|FG003|Study Period 3B (Randomized Withdrawal)|Protocol Violation|25
6091674|NCT00700427|9704150|FG004|Study Period 3B (Randomized Withdrawal)|Protocol Violation|0
6091675|NCT00700427|9704146|FG000|Study Period 3B (Randomized Withdrawal)|Lost to Follow-up|0
6091676|NCT00700427|9704147|FG001|Study Period 3B (Randomized Withdrawal)|Lost to Follow-up|0
6091677|NCT00700427|9704148|FG002|Study Period 3B (Randomized Withdrawal)|Lost to Follow-up|19
6091678|NCT00700427|9704149|FG003|Study Period 3B (Randomized Withdrawal)|Lost to Follow-up|9
6091679|NCT00700427|9704150|FG004|Study Period 3B (Randomized Withdrawal)|Lost to Follow-up|0
6091680|NCT00700427|9704146|FG000|Study Period 3B (Randomized Withdrawal)|Lack of Efficacy|0
6091681|NCT00700427|9704147|FG001|Study Period 3B (Randomized Withdrawal)|Lack of Efficacy|0
6091682|NCT00700427|9704148|FG002|Study Period 3B (Randomized Withdrawal)|Lack of Efficacy|3
6091683|NCT00700427|9704149|FG003|Study Period 3B (Randomized Withdrawal)|Lack of Efficacy|11
6091684|NCT00700427|9704150|FG004|Study Period 3B (Randomized Withdrawal)|Lack of Efficacy|0
6091685|NCT00700427|9704146|FG000|Study Period 3B (Randomized Withdrawal)|Protocol Interim Criteria Not Met|0
6091686|NCT00700427|9704147|FG001|Study Period 3B (Randomized Withdrawal)|Protocol Interim Criteria Not Met|0
6091687|NCT00700427|9704148|FG002|Study Period 3B (Randomized Withdrawal)|Protocol Interim Criteria Not Met|0
6091688|NCT00700427|9704149|FG003|Study Period 3B (Randomized Withdrawal)|Protocol Interim Criteria Not Met|5
6091689|NCT00700427|9704150|FG004|Study Period 3B (Randomized Withdrawal)|Protocol Interim Criteria Not Met|0
6091690|NCT00700427|9704146|FG000|Study Period 3B (Randomized Withdrawal)|Clinical Relapse|0
6091691|NCT00700427|9704147|FG001|Study Period 3B (Randomized Withdrawal)|Clinical Relapse|0
6091692|NCT00700427|9704148|FG002|Study Period 3B (Randomized Withdrawal)|Clinical Relapse|0
6091693|NCT00700427|9704149|FG003|Study Period 3B (Randomized Withdrawal)|Clinical Relapse|3
6091694|NCT00700427|9704150|FG004|Study Period 3B (Randomized Withdrawal)|Clinical Relapse|0
6091695|NCT00700427|9704146|FG000|Study Period 3B (Randomized Withdrawal)|Missing|0
6091696|NCT00700427|9704147|FG001|Study Period 3B (Randomized Withdrawal)|Missing|0
6091697|NCT00700427|9704148|FG002|Study Period 3B (Randomized Withdrawal)|Missing|1
6091698|NCT00700427|9704149|FG003|Study Period 3B (Randomized Withdrawal)|Missing|1
6091699|NCT00700427|9704150|FG004|Study Period 3B (Randomized Withdrawal)|Missing|0
6091700|NCT00700427|9704146|FG000|Study Period 3B (Randomized Withdrawal)|Physician Decision|0
6091701|NCT00700427|9704147|FG001|Study Period 3B (Randomized Withdrawal)|Physician Decision|0
6091702|NCT00700427|9704148|FG002|Study Period 3B (Randomized Withdrawal)|Physician Decision|2
6091703|NCT00700427|9704149|FG003|Study Period 3B (Randomized Withdrawal)|Physician Decision|0
6091704|NCT00700427|9704150|FG004|Study Period 3B (Randomized Withdrawal)|Physician Decision|0
6057419|NCT00467779|9657793|FG005|Stage 2A|Adverse Event|0
6057420|NCT00467779|9657794|FG006|Stage 2A|Adverse Event|0
6057421|NCT00467779|9657795|FG007|Stage 2A|Adverse Event|0
6057422|NCT00467779|9657796|FG008|Stage 2A|Adverse Event|0
6057423|NCT00467779|9657797|FG009|Stage 2A|Adverse Event|0
6057424|NCT00467779|9657798|FG010|Stage 2A|Adverse Event|0
6057425|NCT00467779|9657799|FG011|Stage 2A|Adverse Event|0
6057426|NCT00467779|9657800|FG012|Stage 2A|Adverse Event|0
6057427|NCT00467779|9657801|FG013|Stage 2A|Adverse Event|2
6057428|NCT00467779|9657802|FG014|Stage 2A|Adverse Event|0
6057429|NCT00467779|9657788|FG000|Stage 2A|Death|0
6057430|NCT00467779|9657789|FG001|Stage 2A|Death|0
6057431|NCT00467779|9657790|FG002|Stage 2A|Death|0
6057432|NCT00467779|9657791|FG003|Stage 2A|Death|0
6057433|NCT00467779|9657792|FG004|Stage 2A|Death|0
6057434|NCT00467779|9657793|FG005|Stage 2A|Death|0
6057435|NCT00467779|9657794|FG006|Stage 2A|Death|0
6057436|NCT00467779|9657795|FG007|Stage 2A|Death|0
6057437|NCT00467779|9657796|FG008|Stage 2A|Death|0
6057438|NCT00467779|9657797|FG009|Stage 2A|Death|0
6057439|NCT00467779|9657798|FG010|Stage 2A|Death|0
6057440|NCT00467779|9657799|FG011|Stage 2A|Death|0
6057441|NCT00467779|9657800|FG012|Stage 2A|Death|0
6057442|NCT00467779|9657801|FG013|Stage 2A|Death|1
6057443|NCT00467779|9657802|FG014|Stage 2A|Death|0
6057444|NCT00467779|9657788|FG000|Stage 2A|Disease Progression|0
6057445|NCT00467779|9657789|FG001|Stage 2A|Disease Progression|0
6057446|NCT00467779|9657790|FG002|Stage 2A|Disease Progression|0
6057447|NCT00467779|9657791|FG003|Stage 2A|Disease Progression|0
6057448|NCT00467779|9657792|FG004|Stage 2A|Disease Progression|0
6057449|NCT00467779|9657793|FG005|Stage 2A|Disease Progression|0
6057450|NCT00467779|9657794|FG006|Stage 2A|Disease Progression|0
6057451|NCT00467779|9657795|FG007|Stage 2A|Disease Progression|0
6057452|NCT00467779|9657796|FG008|Stage 2A|Disease Progression|0
6057453|NCT00467779|9657797|FG009|Stage 2A|Disease Progression|0
6057454|NCT00467779|9657798|FG010|Stage 2A|Disease Progression|0
6057455|NCT00467779|9657799|FG011|Stage 2A|Disease Progression|0
6057456|NCT00467779|9657800|FG012|Stage 2A|Disease Progression|0
6057457|NCT00467779|9657801|FG013|Stage 2A|Disease Progression|10
6057458|NCT00467779|9657802|FG014|Stage 2A|Disease Progression|0
6057459|NCT00467779|9657788|FG000|Stage 2A|Unspecified Reason|0
6057460|NCT00467779|9657789|FG001|Stage 2A|Unspecified Reason|0
6057461|NCT00467779|9657790|FG002|Stage 2A|Unspecified Reason|0
6057462|NCT00467779|9657791|FG003|Stage 2A|Unspecified Reason|0
6057463|NCT00467779|9657792|FG004|Stage 2A|Unspecified Reason|0
6057464|NCT00467779|9657793|FG005|Stage 2A|Unspecified Reason|0
6057465|NCT00467779|9657794|FG006|Stage 2A|Unspecified Reason|0
6057466|NCT00467779|9657795|FG007|Stage 2A|Unspecified Reason|0
6057467|NCT00467779|9657796|FG008|Stage 2A|Unspecified Reason|0
6057468|NCT00467779|9657797|FG009|Stage 2A|Unspecified Reason|0
6057469|NCT00467779|9657798|FG010|Stage 2A|Unspecified Reason|0
6057470|NCT00467779|9657799|FG011|Stage 2A|Unspecified Reason|0
6057471|NCT00467779|9657800|FG012|Stage 2A|Unspecified Reason|0
6057472|NCT00467779|9657801|FG013|Stage 2A|Unspecified Reason|7
6057473|NCT00467779|9657802|FG014|Stage 2A|Unspecified Reason|0
6057474|NCT00467779|9657788|FG000|Stage 2A|Withdrawal by Subject|0
6057475|NCT00467779|9657789|FG001|Stage 2A|Withdrawal by Subject|0
6057476|NCT00467779|9657790|FG002|Stage 2A|Withdrawal by Subject|0
6057477|NCT00467779|9657791|FG003|Stage 2A|Withdrawal by Subject|0
6057478|NCT00467779|9657792|FG004|Stage 2A|Withdrawal by Subject|0
6057479|NCT00467779|9657793|FG005|Stage 2A|Withdrawal by Subject|0
6057480|NCT00467779|9657794|FG006|Stage 2A|Withdrawal by Subject|0
6057481|NCT00467779|9657795|FG007|Stage 2A|Withdrawal by Subject|0
6057482|NCT00467779|9657796|FG008|Stage 2A|Withdrawal by Subject|0
6057483|NCT00467779|9657797|FG009|Stage 2A|Withdrawal by Subject|0
6057484|NCT00467779|9657798|FG010|Stage 2A|Withdrawal by Subject|0
6057485|NCT00467779|9657799|FG011|Stage 2A|Withdrawal by Subject|0
6057486|NCT00467779|9657800|FG012|Stage 2A|Withdrawal by Subject|0
6057487|NCT00467779|9657801|FG013|Stage 2A|Withdrawal by Subject|1
6057488|NCT00467779|9657802|FG014|Stage 2A|Withdrawal by Subject|0
6057489|NCT00467779|9657788|FG000|Stage 3|Adverse Event|0
6057490|NCT00467779|9657789|FG001|Stage 3|Adverse Event|0
6057491|NCT00467779|9657790|FG002|Stage 3|Adverse Event|0
6057492|NCT00467779|9657791|FG003|Stage 3|Adverse Event|0
6057493|NCT00467779|9657792|FG004|Stage 3|Adverse Event|0
6057494|NCT00467779|9657793|FG005|Stage 3|Adverse Event|0
6057495|NCT00467779|9657794|FG006|Stage 3|Adverse Event|0
6057496|NCT00467779|9657795|FG007|Stage 3|Adverse Event|0
6057497|NCT00467779|9657796|FG008|Stage 3|Adverse Event|0
6057498|NCT00467779|9657797|FG009|Stage 3|Adverse Event|0
6057499|NCT00467779|9657798|FG010|Stage 3|Adverse Event|0
6057500|NCT00467779|9657799|FG011|Stage 3|Adverse Event|0
6057501|NCT00467779|9657800|FG012|Stage 3|Adverse Event|0
6057502|NCT00467779|9657801|FG013|Stage 3|Adverse Event|0
6057503|NCT00467779|9657802|FG014|Stage 3|Adverse Event|2
6057504|NCT00467779|9657788|FG000|Stage 3|Death|0
6057505|NCT00467779|9657789|FG001|Stage 3|Death|0
6057506|NCT00467779|9657790|FG002|Stage 3|Death|0
6057507|NCT00467779|9657791|FG003|Stage 3|Death|0
6057508|NCT00467779|9657792|FG004|Stage 3|Death|0
6057509|NCT00467779|9657793|FG005|Stage 3|Death|0
6057510|NCT00467779|9657794|FG006|Stage 3|Death|0
6057511|NCT00467779|9657795|FG007|Stage 3|Death|0
6057512|NCT00467779|9657796|FG008|Stage 3|Death|0
6057513|NCT00467779|9657797|FG009|Stage 3|Death|0
6057514|NCT00467779|9657798|FG010|Stage 3|Death|0
6057515|NCT00467779|9657799|FG011|Stage 3|Death|0
6057516|NCT00467779|9657800|FG012|Stage 3|Death|0
6057517|NCT00467779|9657801|FG013|Stage 3|Death|0
6057518|NCT00467779|9657802|FG014|Stage 3|Death|1
6057519|NCT00467779|9657788|FG000|Stage 3|Disease Progression|0
6057520|NCT00467779|9657789|FG001|Stage 3|Disease Progression|0
6057521|NCT00467779|9657790|FG002|Stage 3|Disease Progression|0
6057522|NCT00467779|9657791|FG003|Stage 3|Disease Progression|0
6057523|NCT00467779|9657792|FG004|Stage 3|Disease Progression|0
6057524|NCT00467779|9657793|FG005|Stage 3|Disease Progression|0
6057525|NCT00467779|9657794|FG006|Stage 3|Disease Progression|0
6057526|NCT00467779|9657795|FG007|Stage 3|Disease Progression|0
6057527|NCT00467779|9657796|FG008|Stage 3|Disease Progression|0
6057528|NCT00467779|9657797|FG009|Stage 3|Disease Progression|0
6057529|NCT00467779|9657798|FG010|Stage 3|Disease Progression|0
6057530|NCT00467779|9657799|FG011|Stage 3|Disease Progression|0
6057531|NCT00467779|9657800|FG012|Stage 3|Disease Progression|0
6057532|NCT00467779|9657801|FG013|Stage 3|Disease Progression|0
6057533|NCT00467779|9657802|FG014|Stage 3|Disease Progression|9
6057534|NCT00467779|9657788|FG000|Stage 3|Unspecified Reason|0
6057535|NCT00467779|9657789|FG001|Stage 3|Unspecified Reason|0
6057536|NCT00467779|9657790|FG002|Stage 3|Unspecified Reason|0
6057537|NCT00467779|9657791|FG003|Stage 3|Unspecified Reason|0
6057538|NCT00467779|9657792|FG004|Stage 3|Unspecified Reason|0
6057539|NCT00467779|9657793|FG005|Stage 3|Unspecified Reason|0
6057540|NCT00467779|9657794|FG006|Stage 3|Unspecified Reason|0
6057541|NCT00467779|9657795|FG007|Stage 3|Unspecified Reason|0
6057542|NCT00467779|9657796|FG008|Stage 3|Unspecified Reason|0
6057543|NCT00467779|9657797|FG009|Stage 3|Unspecified Reason|0
6057544|NCT00467779|9657798|FG010|Stage 3|Unspecified Reason|0
6057545|NCT00467779|9657799|FG011|Stage 3|Unspecified Reason|0
6057546|NCT00467779|9657800|FG012|Stage 3|Unspecified Reason|0
6057547|NCT00467779|9657801|FG013|Stage 3|Unspecified Reason|0
6057548|NCT00467779|9657802|FG014|Stage 3|Unspecified Reason|5
6057549|NCT00467818|9657842|FG000|Overall Study|Adverse Event|1
6057550|NCT00467818|9657843|FG001|Overall Study|Adverse Event|0
6057551|NCT00467818|9657842|FG000|Overall Study|Lost to Follow-up|2
6057552|NCT00467818|9657843|FG001|Overall Study|Lost to Follow-up|2
6057553|NCT00467831|9657851|FG000|Overall Study|Death|2
6057554|NCT00467831|9657851|FG000|Overall Study|Withdrawal by Subject|1
6057555|NCT00467857|9657873|FG000|Overall Study|Adverse Event|1
6057556|NCT00467857|9657874|FG001|Overall Study|Adverse Event|0
6057557|NCT00467857|9657873|FG000|Overall Study|Withdrew consent|2
6057558|NCT00467857|9657874|FG001|Overall Study|Withdrew consent|0
6057559|NCT00467857|9657873|FG000|Overall Study|Death|0
6057560|NCT00467857|9657874|FG001|Overall Study|Death|1
6057561|NCT00467857|9657873|FG000|Overall Study|Discharged from court service|0
6057562|NCT00467857|9657874|FG001|Overall Study|Discharged from court service|1
6057563|NCT00467857|9657873|FG000|Overall Study|Emergency care required|0
6057564|NCT00467857|9657874|FG001|Overall Study|Emergency care required|1
6057565|NCT00467857|9657873|FG000|Overall Study|Did not meet inclusion/exclusion criteri|0
6057566|NCT00467857|9657874|FG001|Overall Study|Did not meet inclusion/exclusion criteri|2
6057567|NCT00467857|9657873|FG000|Overall Study|Discontinuation reason missing|0
6057568|NCT00467857|9657874|FG001|Overall Study|Discontinuation reason missing|3
6057569|NCT00467870|9657886|FG000|Overall Study|Adverse Event|13
6057570|NCT00467870|9657887|FG001|Overall Study|Adverse Event|9
6057571|NCT00467870|9657888|FG002|Overall Study|Adverse Event|1
6057572|NCT00467870|9657889|FG003|Overall Study|Adverse Event|15
6057573|NCT00467870|9657890|FG004|Overall Study|Adverse Event|15
6057574|NCT00467870|9657891|FG005|Overall Study|Adverse Event|1
6057575|NCT00467870|9657886|FG000|Overall Study|Protocol Violation|2
6057576|NCT00467870|9657887|FG001|Overall Study|Protocol Violation|1
6057577|NCT00467870|9657888|FG002|Overall Study|Protocol Violation|1
6057578|NCT00467870|9657889|FG003|Overall Study|Protocol Violation|2
6057579|NCT00467870|9657890|FG004|Overall Study|Protocol Violation|0
6057580|NCT00467870|9657891|FG005|Overall Study|Protocol Violation|0
6057581|NCT00467870|9657886|FG000|Overall Study|Withdrawal by Subject|14
6057582|NCT00467870|9657887|FG001|Overall Study|Withdrawal by Subject|21
6057583|NCT00467870|9657888|FG002|Overall Study|Withdrawal by Subject|0
6057584|NCT00467870|9657889|FG003|Overall Study|Withdrawal by Subject|9
6057585|NCT00467870|9657890|FG004|Overall Study|Withdrawal by Subject|10
6057586|NCT00467870|9657891|FG005|Overall Study|Withdrawal by Subject|1
6057587|NCT00467870|9657886|FG000|Overall Study|Lost to Follow-up|5
6057588|NCT00467870|9657887|FG001|Overall Study|Lost to Follow-up|3
6057589|NCT00467870|9657888|FG002|Overall Study|Lost to Follow-up|1
6057590|NCT00467870|9657889|FG003|Overall Study|Lost to Follow-up|1
6057591|NCT00467870|9657890|FG004|Overall Study|Lost to Follow-up|3
6057592|NCT00467870|9657891|FG005|Overall Study|Lost to Follow-up|0
6057593|NCT00467870|9657886|FG000|Overall Study|Subject Non-compliance|3
6057594|NCT00467870|9657887|FG001|Overall Study|Subject Non-compliance|4
6057595|NCT00467870|9657888|FG002|Overall Study|Subject Non-compliance|0
6057596|NCT00467870|9657889|FG003|Overall Study|Subject Non-compliance|1
6057597|NCT00467870|9657890|FG004|Overall Study|Subject Non-compliance|5
6057598|NCT00467870|9657891|FG005|Overall Study|Subject Non-compliance|0
6057599|NCT00467870|9657886|FG000|Overall Study|Other/Unknown|8
6057600|NCT00467870|9657887|FG001|Overall Study|Other/Unknown|5
6057601|NCT00467870|9657888|FG002|Overall Study|Other/Unknown|1
6057602|NCT00467870|9657889|FG003|Overall Study|Other/Unknown|5
6091705|NCT00700427|9704146|FG000|Study Period 3B (Randomized Withdrawal)|Death|0
6091706|NCT00700427|9704147|FG001|Study Period 3B (Randomized Withdrawal)|Death|0
6091707|NCT00700427|9704148|FG002|Study Period 3B (Randomized Withdrawal)|Death|1
6091708|NCT00700427|9704149|FG003|Study Period 3B (Randomized Withdrawal)|Death|0
6091709|NCT00700427|9704150|FG004|Study Period 3B (Randomized Withdrawal)|Death|0
6091710|NCT00700427|9704146|FG000|Study Period 4 (Open-Label Extension)|Adverse Event|0
6091711|NCT00700427|9704147|FG001|Study Period 4 (Open-Label Extension)|Adverse Event|0
6091712|NCT00700427|9704148|FG002|Study Period 4 (Open-Label Extension)|Adverse Event|0
6091713|NCT00700427|9704149|FG003|Study Period 4 (Open-Label Extension)|Adverse Event|0
6091714|NCT00700427|9704150|FG004|Study Period 4 (Open-Label Extension)|Adverse Event|16
6091715|NCT00700427|9704146|FG000|Study Period 4 (Open-Label Extension)|Death|0
6091716|NCT00700427|9704147|FG001|Study Period 4 (Open-Label Extension)|Death|0
6091717|NCT00700427|9704148|FG002|Study Period 4 (Open-Label Extension)|Death|0
6091718|NCT00700427|9704149|FG003|Study Period 4 (Open-Label Extension)|Death|0
6091719|NCT00700427|9704150|FG004|Study Period 4 (Open-Label Extension)|Death|1
6091720|NCT00700427|9704146|FG000|Study Period 4 (Open-Label Extension)|Protocol Violation|0
6091721|NCT00700427|9704147|FG001|Study Period 4 (Open-Label Extension)|Protocol Violation|0
6091722|NCT00700427|9704148|FG002|Study Period 4 (Open-Label Extension)|Protocol Violation|0
6091723|NCT00700427|9704149|FG003|Study Period 4 (Open-Label Extension)|Protocol Violation|0
6091724|NCT00700427|9704150|FG004|Study Period 4 (Open-Label Extension)|Protocol Violation|12
6091725|NCT00700427|9704146|FG000|Study Period 4 (Open-Label Extension)|Withdrawal by Subject|0
6091726|NCT00700427|9704147|FG001|Study Period 4 (Open-Label Extension)|Withdrawal by Subject|0
6091727|NCT00700427|9704148|FG002|Study Period 4 (Open-Label Extension)|Withdrawal by Subject|0
6091728|NCT00700427|9704149|FG003|Study Period 4 (Open-Label Extension)|Withdrawal by Subject|0
6091729|NCT00700427|9704150|FG004|Study Period 4 (Open-Label Extension)|Withdrawal by Subject|38
6202431|NCT01500694|9862534|FG000|Overall Study|Protocol Violation|0
6057603|NCT00467870|9657890|FG004|Overall Study|Other/Unknown|4
6057604|NCT00467870|9657891|FG005|Overall Study|Other/Unknown|0
6057605|NCT00467896|9657901|FG000|Overall Study|Consent Withdrawal|18
6057606|NCT00467896|9657901|FG000|Overall Study|Adverse Event|7
6057607|NCT00467896|9657901|FG000|Overall Study|Serious Adverse Event|13
6057608|NCT00467896|9657901|FG000|Overall Study|Non-compliance|3
6057609|NCT00467896|9657901|FG000|Overall Study|Changed therapy|2
6057610|NCT00467896|9657901|FG000|Overall Study|Patient received transplant|2
6057611|NCT00467896|9657901|FG000|Overall Study|Patient had atrial septostomy|1
6057612|NCT00467896|9657901|FG000|Overall Study|Patient weaned off iloprost|1
6057613|NCT00467896|9657901|FG000|Overall Study|Mainly used Prodose not I-neb® device|1
6057614|NCT00467896|9657901|FG000|Overall Study|Started intravenous prostacyclin|1
6057615|NCT00467896|9657901|FG000|Overall Study|Started inhaled Remodulin|1
6057616|NCT00467896|9657901|FG000|Overall Study|Patient had no improvement|1
6057617|NCT00467961|9657907|FG000|Overall Study|Technical Failures|5
6057618|NCT00467961|9657907|FG000|Overall Study|Disease Progression|2
6057619|NCT00468052|9657913|FG000|Overall Study|Protocol Violation|7
6057620|NCT00468052|9657914|FG001|Overall Study|Protocol Violation|8
6057621|NCT00468104|9657922|FG000|First Intervention|Protocol Violation|2
6057622|NCT00468104|9657923|FG001|First Intervention|Protocol Violation|1
6057623|NCT00468104|9657922|FG000|First Intervention|bleeding at chest tube site--first dose|1
6057624|NCT00468104|9657923|FG001|First Intervention|bleeding at chest tube site--first dose|0
6057625|NCT00468104|9657922|FG000|First Intervention|died within 3 weeks|1
6057626|NCT00468104|9657923|FG001|First Intervention|died within 3 weeks|0
6057627|NCT00468104|9657922|FG000|First Intervention|malposition/blocked chest tube tube|2
6057628|NCT00468104|9657923|FG001|First Intervention|malposition/blocked chest tube tube|0
6057629|NCT00468104|9657922|FG000|First Intervention|large lung mass with minimal effusion|1
6057630|NCT00468104|9657923|FG001|First Intervention|large lung mass with minimal effusion|0
6057631|NCT00468104|9657922|FG000|First Intervention|associated prolonged pneumothorax|1
6057632|NCT00468104|9657923|FG001|First Intervention|associated prolonged pneumothorax|0
6057633|NCT00468104|9657922|FG000|First Intervention|trapped lung|1
6057634|NCT00468104|9657923|FG001|First Intervention|trapped lung|0
6057635|NCT00468104|9657922|FG000|Second Intervention|Withdrawal by Subject|5
6057636|NCT00468104|9657923|FG001|Second Intervention|Withdrawal by Subject|2
6057637|NCT00468104|9657922|FG000|Second Intervention|discarded for malposition of chest tube|0
6057638|NCT00468104|9657923|FG001|Second Intervention|discarded for malposition of chest tube|2
6057639|NCT00468143|9657932|FG000|First Intervention (3 Weeks)|Withdrawal by Subject|3
6057640|NCT00468143|9657933|FG001|First Intervention (3 Weeks)|Withdrawal by Subject|4
6057641|NCT00468143|9657932|FG000|Second Intervention (3 Weeks)|Withdrawal by Subject|3
6057642|NCT00468143|9657933|FG001|Second Intervention (3 Weeks)|Withdrawal by Subject|3
6057643|NCT00468169|9657941|FG000|Overall Study|Withdrawal by Subject|1
6057644|NCT00468169|9657942|FG001|Overall Study|Withdrawal by Subject|0
6057645|NCT00468286|9657956|FG000|Overall Study|Adverse Event|1
6057646|NCT00468286|9657957|FG001|Overall Study|Adverse Event|6
6057647|NCT00468286|9657956|FG000|Overall Study|Protocol Violation|2
6057648|NCT00468286|9657957|FG001|Overall Study|Protocol Violation|2
6057649|NCT00468286|9657956|FG000|Overall Study|Withdrawal by Subject|4
6057650|NCT00468286|9657957|FG001|Overall Study|Withdrawal by Subject|3
6057651|NCT00468286|9657956|FG000|Overall Study|Physician Decision|0
6057652|NCT00468286|9657957|FG001|Overall Study|Physician Decision|1
6057653|NCT00468299|9657965|FG000|Overall Study|Withdrawal by Subject|0
6091730|NCT00700427|9704146|FG000|Study Period 4 (Open-Label Extension)|Physician Decision|0
6091731|NCT00700427|9704147|FG001|Study Period 4 (Open-Label Extension)|Physician Decision|0
6091732|NCT00700427|9704148|FG002|Study Period 4 (Open-Label Extension)|Physician Decision|0
6057654|NCT00468299|9657966|FG001|Overall Study|Withdrawal by Subject|1
6057655|NCT00468481|9657976|FG000|Overall Study|Adverse Event|13
6057656|NCT00468481|9657977|FG001|Overall Study|Adverse Event|3
6057657|NCT00468481|9657976|FG000|Overall Study|Lost to Follow-up|25
6057658|NCT00468481|9657977|FG001|Overall Study|Lost to Follow-up|8
6057659|NCT00468481|9657976|FG000|Overall Study|Pregnancy|2
6057660|NCT00468481|9657977|FG001|Overall Study|Pregnancy|0
6057661|NCT00468481|9657976|FG000|Overall Study|Protocol Violation|18
6057662|NCT00468481|9657977|FG001|Overall Study|Protocol Violation|8
6057663|NCT00468481|9657976|FG000|Overall Study|Withdrawal by Subject|12
6057664|NCT00468481|9657977|FG001|Overall Study|Withdrawal by Subject|3
6057665|NCT00468481|9657976|FG000|Overall Study|susp/diag malignant/premalignant disease|1
6057666|NCT00468481|9657977|FG001|Overall Study|susp/diag malignant/premalignant disease|0
6057667|NCT00468481|9657976|FG000|Overall Study|Prohibited Medication|1
6057668|NCT00468481|9657977|FG001|Overall Study|Prohibited Medication|1
6057669|NCT00468481|9657976|FG000|Overall Study|Egg Donor|1
6057670|NCT00468481|9657977|FG001|Overall Study|Egg Donor|0
6057671|NCT00468481|9657976|FG000|Overall Study|Moved out of area|4
6057672|NCT00468481|9657977|FG001|Overall Study|Moved out of area|1
6057673|NCT00468481|9657976|FG000|Overall Study|Non-Compliance|5
6057674|NCT00468481|9657977|FG001|Overall Study|Non-Compliance|0
6057675|NCT00468481|9657976|FG000|Overall Study|Other|6
6057676|NCT00468481|9657977|FG001|Overall Study|Other|0
6057677|NCT00468546|9657985|FG000|Week 24 Analysis|Lack of Efficacy|83
6057678|NCT00468546|9657986|FG001|Week 24 Analysis|Lack of Efficacy|37
6057679|NCT00468546|9657985|FG000|Week 24 Analysis|Refused treatment|5
6057680|NCT00468546|9657986|FG001|Week 24 Analysis|Refused treatment|5
6057681|NCT00468546|9657985|FG000|Week 24 Analysis|Adverse Event|1
6202432|NCT01500694|9862535|FG001|Overall Study|Protocol Violation|1
6057682|NCT00468546|9657986|FG001|Week 24 Analysis|Adverse Event|8
6057683|NCT00468546|9657985|FG000|Week 24 Analysis|Failure to return|3
6057684|NCT00468546|9657986|FG001|Week 24 Analysis|Failure to return|4
6057685|NCT00468546|9657985|FG000|Week 24 Analysis|Rescue therapy|2
6057686|NCT00468546|9657986|FG001|Week 24 Analysis|Rescue therapy|0
6057687|NCT00468546|9657985|FG000|Week 24 Analysis|Incorrect diagnosis and treatment|0
6057688|NCT00468546|9657986|FG001|Week 24 Analysis|Incorrect diagnosis and treatment|1
6057689|NCT00468546|9657985|FG000|Week 24 Analysis|Due to clinical hold|1
6057690|NCT00468546|9657986|FG001|Week 24 Analysis|Due to clinical hold|0
6057691|NCT00468546|9657985|FG000|Week 24 Analysis|Went onto rescue therapy|1
6057692|NCT00468546|9657986|FG001|Week 24 Analysis|Went onto rescue therapy|0
6057693|NCT00468546|9657985|FG000|Week 24 Analysis|Participant unblinded (clinical hold)|1
6057694|NCT00468546|9657986|FG001|Week 24 Analysis|Participant unblinded (clinical hold)|0
6057695|NCT00468546|9657985|FG000|Week 24 to Week 104 Analysis|Adverse Event|2
6057696|NCT00468546|9657986|FG001|Week 24 to Week 104 Analysis|Adverse Event|5
6057697|NCT00468546|9657985|FG000|Week 24 to Week 104 Analysis|Death|1
6057698|NCT00468546|9657986|FG001|Week 24 to Week 104 Analysis|Death|0
6057699|NCT00468546|9657985|FG000|Week 24 to Week 104 Analysis|Lack of Efficacy|3
6057700|NCT00468546|9657986|FG001|Week 24 to Week 104 Analysis|Lack of Efficacy|12
6057701|NCT00468546|9657985|FG000|Week 24 to Week 104 Analysis|Protocol Violation|0
6057702|NCT00468546|9657986|FG001|Week 24 to Week 104 Analysis|Protocol Violation|2
6057703|NCT00468546|9657985|FG000|Week 24 to Week 104 Analysis|Refused treatment|4
6057704|NCT00468546|9657986|FG001|Week 24 to Week 104 Analysis|Refused treatment|7
6057705|NCT00468546|9657985|FG000|Week 24 to Week 104 Analysis|Failure to return|1
6057706|NCT00468546|9657986|FG001|Week 24 to Week 104 Analysis|Failure to return|2
6057707|NCT00468546|9657985|FG000|Week 24 to Week 104 Analysis|Movement into re-treatment study|77
6091733|NCT00700427|9704149|FG003|Study Period 4 (Open-Label Extension)|Physician Decision|0
6091734|NCT00700427|9704150|FG004|Study Period 4 (Open-Label Extension)|Physician Decision|2
6091735|NCT00700427|9704146|FG000|Study Period 4 (Open-Label Extension)|Sponsor Decision|0
6091736|NCT00700427|9704147|FG001|Study Period 4 (Open-Label Extension)|Sponsor Decision|0
6091737|NCT00700427|9704148|FG002|Study Period 4 (Open-Label Extension)|Sponsor Decision|0
6091738|NCT00700427|9704149|FG003|Study Period 4 (Open-Label Extension)|Sponsor Decision|0
6091739|NCT00700427|9704150|FG004|Study Period 4 (Open-Label Extension)|Sponsor Decision|2
6091740|NCT00700427|9704146|FG000|Study Period 4 (Open-Label Extension)|Lack of Efficacy|0
6091741|NCT00700427|9704147|FG001|Study Period 4 (Open-Label Extension)|Lack of Efficacy|0
6091742|NCT00700427|9704148|FG002|Study Period 4 (Open-Label Extension)|Lack of Efficacy|0
6091743|NCT00700427|9704149|FG003|Study Period 4 (Open-Label Extension)|Lack of Efficacy|0
6057708|NCT00468546|9657986|FG001|Week 24 to Week 104 Analysis|Movement into re-treatment study|183
6057709|NCT00468546|9657985|FG000|Week 24 to Week 104 Analysis|Other|17
6057710|NCT00468546|9657986|FG001|Week 24 to Week 104 Analysis|Other|14
6057711|NCT00468559|9657994|FG000|Open-label Treatment Phase|Adverse Event|5
6057712|NCT00468559|9657995|FG001|Open-label Treatment Phase|Adverse Event|0
6057713|NCT00468559|9657996|FG002|Open-label Treatment Phase|Adverse Event|0
6057714|NCT00468559|9657994|FG000|Open-label Treatment Phase|Lack of Efficacy|9
6057715|NCT00468559|9657995|FG001|Open-label Treatment Phase|Lack of Efficacy|0
6057716|NCT00468559|9657996|FG002|Open-label Treatment Phase|Lack of Efficacy|0
6057717|NCT00468559|9657994|FG000|Open-label Treatment Phase|Withdrawal by Subject|4
6057718|NCT00468559|9657995|FG001|Open-label Treatment Phase|Withdrawal by Subject|0
6057719|NCT00468559|9657996|FG002|Open-label Treatment Phase|Withdrawal by Subject|0
6057720|NCT00468559|9657994|FG000|Double-blind, Treatment-withdrawal Phase|Lack of Efficacy|0
6057721|NCT00468559|9657995|FG001|Double-blind, Treatment-withdrawal Phase|Lack of Efficacy|8
6057722|NCT00468559|9657996|FG002|Double-blind, Treatment-withdrawal Phase|Lack of Efficacy|17
6057723|NCT00468559|9657994|FG000|Double-blind, Treatment-withdrawal Phase|Adverse Event|0
6057724|NCT00468559|9657995|FG001|Double-blind, Treatment-withdrawal Phase|Adverse Event|2
6057725|NCT00468559|9657996|FG002|Double-blind, Treatment-withdrawal Phase|Adverse Event|0
6057726|NCT00468585|9658008|FG000|Overall Study|Patient not treated|1
6057727|NCT00468585|9658009|FG001|Overall Study|Patient not treated|0
6057728|NCT00468585|9658010|FG002|Overall Study|Patient not treated|1
6057729|NCT00468585|9658011|FG003|Overall Study|Patient not treated|0
6057730|NCT00468585|9658008|FG000|Overall Study|Patient found to be ineligible|0
6057731|NCT00468585|9658009|FG001|Overall Study|Patient found to be ineligible|0
6057732|NCT00468585|9658010|FG002|Overall Study|Patient found to be ineligible|1
6057733|NCT00468585|9658011|FG003|Overall Study|Patient found to be ineligible|0
6057734|NCT00468585|9658008|FG000|Overall Study|Adverse Event|0
6057735|NCT00468585|9658009|FG001|Overall Study|Adverse Event|0
6057736|NCT00468585|9658010|FG002|Overall Study|Adverse Event|1
6057737|NCT00468585|9658011|FG003|Overall Study|Adverse Event|0
6057738|NCT00468585|9658008|FG000|Overall Study|Withdrawal by Subject|0
6057739|NCT00468585|9658009|FG001|Overall Study|Withdrawal by Subject|0
6057740|NCT00468585|9658010|FG002|Overall Study|Withdrawal by Subject|2
6057741|NCT00468585|9658011|FG003|Overall Study|Withdrawal by Subject|1
6057742|NCT00468650|9658021|FG000|Overall Study|Lost to Follow-up|4
6057743|NCT00468650|9658021|FG000|Overall Study|Withdrawal by Subject|2
6057744|NCT00468650|9658021|FG000|Overall Study|Protocol Violation|1
6057745|NCT00468676|9658028|FG000|Overall Study|Lost to Follow-up|14
6057746|NCT00468676|9658029|FG001|Overall Study|Lost to Follow-up|11
6057747|NCT00468676|9658028|FG000|Overall Study|Death|2
6057748|NCT00468676|9658029|FG001|Overall Study|Death|1
6057749|NCT00468728|9658039|FG000|Treatment|criteria for mITT population|4
6057750|NCT00468728|9658040|FG001|Treatment|criteria for mITT population|11
6057751|NCT00468728|9658039|FG000|Follow-up|mITT failure|34
6057752|NCT00468728|9658040|FG001|Follow-up|mITT failure|31
6057753|NCT00468819|9658051|FG000|Overall Study|Withdrawal by Subject|4
6057754|NCT00468819|9658052|FG001|Overall Study|Withdrawal by Subject|0
6057755|NCT00468819|9658053|FG002|Overall Study|Withdrawal by Subject|1
6057756|NCT00468819|9658051|FG000|Overall Study|Lost to Follow-up|0
6057757|NCT00468819|9658052|FG001|Overall Study|Lost to Follow-up|0
6057758|NCT00468819|9658053|FG002|Overall Study|Lost to Follow-up|1
6057759|NCT00468819|9658051|FG000|Overall Study|Drop-outs (Treatment never received)|2
6057760|NCT00468819|9658052|FG001|Overall Study|Drop-outs (Treatment never received)|0
6057761|NCT00468819|9658053|FG002|Overall Study|Drop-outs (Treatment never received)|0
6057762|NCT00468845|9658066|FG000|Overall Study|Adverse Event|9
6057763|NCT00468845|9658067|FG001|Overall Study|Adverse Event|14
6057764|NCT00468845|9658068|FG002|Overall Study|Adverse Event|11
6057765|NCT00468845|9658066|FG000|Overall Study|Lost to Follow-up|2
6057766|NCT00468845|9658067|FG001|Overall Study|Lost to Follow-up|1
6057767|NCT00468845|9658068|FG002|Overall Study|Lost to Follow-up|2
6057768|NCT00468845|9658066|FG000|Overall Study|Other|4
6057769|NCT00468845|9658067|FG001|Overall Study|Other|9
6057770|NCT00468845|9658068|FG002|Overall Study|Other|5
6057771|NCT00468845|9658066|FG000|Overall Study|No longer willing to participate|5
6057772|NCT00468845|9658067|FG001|Overall Study|No longer willing to participate|6
6057773|NCT00468845|9658068|FG002|Overall Study|No longer willing to participate|10
6057774|NCT00468845|9658066|FG000|Overall Study|Randomized, not treated|1
6057775|NCT00468845|9658067|FG001|Overall Study|Randomized, not treated|4
6057776|NCT00468845|9658068|FG002|Overall Study|Randomized, not treated|2
6057777|NCT00468858|9658079|FG000|Overall Study|Adverse Event|0
6057778|NCT00468858|9658080|FG001|Overall Study|Adverse Event|1
6057779|NCT00468858|9658081|FG002|Overall Study|Adverse Event|0
6057780|NCT00468858|9658079|FG000|Overall Study|Withdrawal by Subject|7
6057781|NCT00468858|9658080|FG001|Overall Study|Withdrawal by Subject|4
6057782|NCT00468858|9658081|FG002|Overall Study|Withdrawal by Subject|5
6057783|NCT00468858|9658079|FG000|Overall Study|Relocation|1
6057784|NCT00468858|9658080|FG001|Overall Study|Relocation|3
6057785|NCT00468858|9658081|FG002|Overall Study|Relocation|3
6057786|NCT00468858|9658079|FG000|Overall Study|Lost to Follow-up|1
6057787|NCT00468858|9658080|FG001|Overall Study|Lost to Follow-up|2
6057788|NCT00468858|9658081|FG002|Overall Study|Lost to Follow-up|5
6057789|NCT00468858|9658079|FG000|Overall Study|Other|0
6057790|NCT00468858|9658080|FG001|Overall Study|Other|0
6057791|NCT00468858|9658081|FG002|Overall Study|Other|1
6091744|NCT00700427|9704150|FG004|Study Period 4 (Open-Label Extension)|Lack of Efficacy|1
6091745|NCT00700427|9704146|FG000|Study Period 4 (Open-Label Extension)|Lost to Follow-up|0
6091746|NCT00700427|9704147|FG001|Study Period 4 (Open-Label Extension)|Lost to Follow-up|0
6091747|NCT00700427|9704148|FG002|Study Period 4 (Open-Label Extension)|Lost to Follow-up|0
6091748|NCT00700427|9704149|FG003|Study Period 4 (Open-Label Extension)|Lost to Follow-up|0
6091749|NCT00700427|9704150|FG004|Study Period 4 (Open-Label Extension)|Lost to Follow-up|11
6091750|NCT00700427|9704146|FG000|Study Period 4 (Open-Label Extension)|Clinical Relapse|0
6091751|NCT00700427|9704147|FG001|Study Period 4 (Open-Label Extension)|Clinical Relapse|0
6091752|NCT00700427|9704148|FG002|Study Period 4 (Open-Label Extension)|Clinical Relapse|0
6091753|NCT00700427|9704149|FG003|Study Period 4 (Open-Label Extension)|Clinical Relapse|0
6091754|NCT00700427|9704150|FG004|Study Period 4 (Open-Label Extension)|Clinical Relapse|1
6091755|NCT00700570|9704164|FG000|Overall Study|Adverse Event|2
6091756|NCT00700570|9704165|FG001|Overall Study|Adverse Event|6
6091757|NCT00700570|9704164|FG000|Overall Study|Discretion of Investigator or Sponsor|0
6091758|NCT00700570|9704165|FG001|Overall Study|Discretion of Investigator or Sponsor|3
6091759|NCT00700570|9704164|FG000|Overall Study|Disease Progression|8
6091760|NCT00700570|9704165|FG001|Overall Study|Disease Progression|11
6091761|NCT00700570|9704164|FG000|Overall Study|Withdrawal by Subject|1
6091762|NCT00700570|9704165|FG001|Overall Study|Withdrawal by Subject|6
6091763|NCT00700622|9704173|FG000|Overall Study|Adverse Event|4
6091764|NCT00700622|9704174|FG001|Overall Study|Adverse Event|0
6091765|NCT00700622|9704173|FG000|Overall Study|Lost to Follow-up|0
6091766|NCT00700622|9704174|FG001|Overall Study|Lost to Follow-up|1
6091767|NCT00700622|9704173|FG000|Overall Study|Physician Decision|2
6091768|NCT00700622|9704174|FG001|Overall Study|Physician Decision|1
6091769|NCT00700622|9704173|FG000|Overall Study|Protocol Violation|0
6091770|NCT00700622|9704174|FG001|Overall Study|Protocol Violation|1
6091771|NCT00700622|9704173|FG000|Overall Study|Withdrawal by Subject|4
6091772|NCT00700622|9704174|FG001|Overall Study|Withdrawal by Subject|1
6091773|NCT00700622|9704173|FG000|Overall Study|Other|3
6091774|NCT00700622|9704174|FG001|Overall Study|Other|1
6091775|NCT00700635|9704183|FG000|Overall Study|Adverse Event|1
6091776|NCT00700635|9704184|FG001|Overall Study|Adverse Event|0
6091777|NCT00700635|9704185|FG002|Overall Study|Adverse Event|0
6091778|NCT00700635|9704183|FG000|Overall Study|Lost to Follow-up|1
6091779|NCT00700635|9704184|FG001|Overall Study|Lost to Follow-up|3
6057792|NCT00468910|9658145|FG000|Overall Study|Lost to Follow-up|2
6057793|NCT00468910|9658146|FG001|Overall Study|Lost to Follow-up|1
6057794|NCT00468910|9658145|FG000|Overall Study|Withdrawal by Subject|2
6057795|NCT00468910|9658146|FG001|Overall Study|Withdrawal by Subject|1
6057796|NCT00468910|9658145|FG000|Overall Study|Medical Contraindication|0
6057797|NCT00468910|9658146|FG001|Overall Study|Medical Contraindication|1
6057798|NCT00469014|9658157|FG000|Initial Phase Randomization|Disease Progression|0
6057799|NCT00469014|9658158|FG001|Initial Phase Randomization|Disease Progression|1
6057800|NCT00469014|9658159|FG002|Initial Phase Randomization|Disease Progression|1
6057801|NCT00469014|9658160|FG003|Initial Phase Randomization|Disease Progression|0
6057802|NCT00469014|9658157|FG000|Initial Phase Randomization|No Response|1
6057803|NCT00469014|9658158|FG001|Initial Phase Randomization|No Response|0
6091780|NCT00700635|9704185|FG002|Overall Study|Lost to Follow-up|0
6091781|NCT00700635|9704183|FG000|Overall Study|Protocol Violation|2
6091782|NCT00700635|9704184|FG001|Overall Study|Protocol Violation|2
6091783|NCT00700635|9704185|FG002|Overall Study|Protocol Violation|0
6091784|NCT00700635|9704183|FG000|Overall Study|Withdrawal by Subject|7
6057804|NCT00469014|9658159|FG002|Initial Phase Randomization|No Response|0
6057805|NCT00469014|9658160|FG003|Initial Phase Randomization|No Response|1
6057806|NCT00469014|9658157|FG000|Adaptive Randomization|Not Evaluable|1
6057807|NCT00469014|9658158|FG001|Adaptive Randomization|Not Evaluable|0
6057808|NCT00469014|9658159|FG002|Adaptive Randomization|Not Evaluable|0
6057809|NCT00469014|9658160|FG003|Adaptive Randomization|Not Evaluable|1
6057810|NCT00469014|9658157|FG000|Adaptive Randomization|No Response|0
6057811|NCT00469014|9658158|FG001|Adaptive Randomization|No Response|1
6057812|NCT00469014|9658159|FG002|Adaptive Randomization|No Response|0
6057813|NCT00469014|9658160|FG003|Adaptive Randomization|No Response|0
6057814|NCT00469014|9658157|FG000|Adaptive Randomization|Death|0
6057815|NCT00469014|9658158|FG001|Adaptive Randomization|Death|0
6057816|NCT00469014|9658159|FG002|Adaptive Randomization|Death|1
6057817|NCT00469014|9658160|FG003|Adaptive Randomization|Death|0
6057818|NCT00469079|9658173|FG000|Overall Study|Lack of Efficacy|3
6057819|NCT00469079|9658174|FG001|Overall Study|Lack of Efficacy|8
6057820|NCT00469079|9658175|FG002|Overall Study|Lack of Efficacy|5
6057821|NCT00469079|9658173|FG000|Overall Study|Adverse Event|1
6057822|NCT00469079|9658174|FG001|Overall Study|Adverse Event|3
6057823|NCT00469079|9658175|FG002|Overall Study|Adverse Event|2
6057824|NCT00469079|9658173|FG000|Overall Study|Lost to Follow-up|4
6057825|NCT00469079|9658174|FG001|Overall Study|Lost to Follow-up|8
6057826|NCT00469079|9658175|FG002|Overall Study|Lost to Follow-up|10
6057827|NCT00469079|9658173|FG000|Overall Study|Withdrawal by Subject|1
6057828|NCT00469079|9658174|FG001|Overall Study|Withdrawal by Subject|2
6057829|NCT00469079|9658175|FG002|Overall Study|Withdrawal by Subject|2
6057830|NCT00469079|9658173|FG000|Overall Study|Ineligible|0
6057831|NCT00469079|9658174|FG001|Overall Study|Ineligible|1
6057832|NCT00469079|9658175|FG002|Overall Study|Ineligible|0
6057833|NCT00469092|9658191|FG000|Overall Study|Adverse Event|5
6057834|NCT00469092|9658192|FG001|Overall Study|Adverse Event|4
6057835|NCT00469092|9658191|FG000|Overall Study|Lack of Efficacy|1
6057836|NCT00469092|9658192|FG001|Overall Study|Lack of Efficacy|0
6057837|NCT00469092|9658191|FG000|Overall Study|Lost to Follow-up|1
6057838|NCT00469092|9658192|FG001|Overall Study|Lost to Follow-up|2
6057839|NCT00469092|9658191|FG000|Overall Study|Protocol Violation|3
6057840|NCT00469092|9658192|FG001|Overall Study|Protocol Violation|3
6057841|NCT00469092|9658191|FG000|Overall Study|Withdrawal by Subject|4
6057842|NCT00469092|9658192|FG001|Overall Study|Withdrawal by Subject|4
6057843|NCT00469092|9658191|FG000|Overall Study|Withdrawal Criteria|3
6057844|NCT00469092|9658192|FG001|Overall Study|Withdrawal Criteria|4
6057845|NCT00469092|9658191|FG000|Overall Study|Incorrectly Randomised|4
6057846|NCT00469092|9658192|FG001|Overall Study|Incorrectly Randomised|3
6057847|NCT00469092|9658191|FG000|Overall Study|Contraindication metformin/glimepiride|1
6057848|NCT00469092|9658192|FG001|Overall Study|Contraindication metformin/glimepiride|0
6057849|NCT00469092|9658191|FG000|Overall Study|Use of lipid lowering drug|1
6057850|NCT00469092|9658192|FG001|Overall Study|Use of lipid lowering drug|0
6057851|NCT00469092|9658191|FG000|Overall Study|Hypoglycaemic Episodes|1
6057852|NCT00469092|9658192|FG001|Overall Study|Hypoglycaemic Episodes|1
6057853|NCT00469092|9658191|FG000|Overall Study|Abnormal lab value|1
6057854|NCT00469092|9658192|FG001|Overall Study|Abnormal lab value|0
6057855|NCT00469092|9658191|FG000|Overall Study|Use of Corticosteroid|1
6057856|NCT00469092|9658192|FG001|Overall Study|Use of Corticosteroid|0
6057857|NCT00469144|9658200|FG000|Overall Study|Death|0
6057858|NCT00469144|9658201|FG001|Overall Study|Death|1
6057859|NCT00469144|9658200|FG000|Overall Study|No Response|5
6057860|NCT00469144|9658201|FG001|Overall Study|No Response|5
6057861|NCT00469144|9658200|FG000|Overall Study|Progressive Disease|1
6057862|NCT00469144|9658201|FG001|Overall Study|Progressive Disease|0
6057863|NCT00469209|9658214|FG000|Overall Study|Adverse Event|1
6057864|NCT00469209|9658215|FG001|Overall Study|Adverse Event|0
6057865|NCT00469209|9658216|FG002|Overall Study|Adverse Event|1
6057866|NCT00469456|9658244|FG000|Overall Study|Adverse Event|4
6057867|NCT00469456|9658245|FG001|Overall Study|Adverse Event|3
6057868|NCT00469456|9658244|FG000|Overall Study|Protocol Violation|1
6057869|NCT00469456|9658245|FG001|Overall Study|Protocol Violation|0
6057870|NCT00469456|9658244|FG000|Overall Study|Withdrawal by Subject|4
6091785|NCT00700635|9704184|FG001|Overall Study|Withdrawal by Subject|3
6091786|NCT00700635|9704185|FG002|Overall Study|Withdrawal by Subject|1
6057871|NCT00469456|9658245|FG001|Overall Study|Withdrawal by Subject|1
6057872|NCT00469833|9658260|FG000|Overall Study|No IV access|2
6057873|NCT00469859|9658272|FG000|Overall Study|Inevaluable|0
6057874|NCT00469859|9658273|FG001|Overall Study|Inevaluable|2
6057875|NCT00469898|9658279|FG000|Overall Study|Adverse Event|7
6057876|NCT00469898|9658279|FG000|Overall Study|Withdrawal by Subject|4
6057877|NCT00469898|9658279|FG000|Overall Study|Death|4
6057878|NCT00469898|9658279|FG000|Overall Study|Disease progression|9
6057879|NCT00469898|9658279|FG000|Overall Study|Decreased performance status|1
6057880|NCT00470054|9658291|FG000|Overall Study|Ineligible|1
6091787|NCT00700713|9704196|FG000|Overall Study|Protocol Violation|1
6091788|NCT00700713|9704197|FG001|Overall Study|Protocol Violation|0
6091789|NCT00700713|9704198|FG002|Overall Study|Protocol Violation|1
6091790|NCT00700713|9704196|FG000|Overall Study|Withdrawal by Subject|0
6091791|NCT00700713|9704197|FG001|Overall Study|Withdrawal by Subject|0
6091792|NCT00700713|9704198|FG002|Overall Study|Withdrawal by Subject|1
6091793|NCT00700739|9704208|FG000|Overall Study|Lost to Follow-up|4
6091794|NCT00700739|9704209|FG001|Overall Study|Lost to Follow-up|4
6091795|NCT00700752|9704216|FG000|First Intervention|Withdrawal by Subject|0
6091796|NCT00700752|9704217|FG001|First Intervention|Withdrawal by Subject|2
6091797|NCT00700804|9704225|FG000|Overall Study|Withdrawal by Subject|1
6091798|NCT00700804|9704226|FG001|Overall Study|Withdrawal by Subject|2
6091799|NCT00700804|9704225|FG000|Overall Study|Protocol Violation|1
6091800|NCT00700804|9704226|FG001|Overall Study|Protocol Violation|1
6091801|NCT00700804|9704225|FG000|Overall Study|Loose Stools|1
6091802|NCT00700804|9704226|FG001|Overall Study|Loose Stools|1
6091803|NCT00700817|9704237|FG000|Week 0-26 (Main Period)|Adverse Event|14
6091804|NCT00700817|9704238|FG001|Week 0-26 (Main Period)|Adverse Event|15
6091805|NCT00700817|9704239|FG002|Week 0-26 (Main Period)|Adverse Event|4
6091806|NCT00700817|9704240|FG003|Week 0-26 (Main Period)|Adverse Event|0
6091807|NCT00700817|9704241|FG004|Week 0-26 (Main Period)|Adverse Event|0
6091808|NCT00700817|9704237|FG000|Week 0-26 (Main Period)|Lack of Efficacy|4
6091809|NCT00700817|9704238|FG001|Week 0-26 (Main Period)|Lack of Efficacy|0
6091810|NCT00700817|9704239|FG002|Week 0-26 (Main Period)|Lack of Efficacy|4
6091811|NCT00700817|9704240|FG003|Week 0-26 (Main Period)|Lack of Efficacy|0
6091812|NCT00700817|9704241|FG004|Week 0-26 (Main Period)|Lack of Efficacy|0
6091813|NCT00700817|9704237|FG000|Week 0-26 (Main Period)|Protocol Violation|14
6091814|NCT00700817|9704238|FG001|Week 0-26 (Main Period)|Protocol Violation|4
6091815|NCT00700817|9704239|FG002|Week 0-26 (Main Period)|Protocol Violation|4
6091816|NCT00700817|9704240|FG003|Week 0-26 (Main Period)|Protocol Violation|0
6091817|NCT00700817|9704241|FG004|Week 0-26 (Main Period)|Protocol Violation|0
6091818|NCT00700817|9704237|FG000|Week 0-26 (Main Period)|Withdrawal criteria|10
6091819|NCT00700817|9704238|FG001|Week 0-26 (Main Period)|Withdrawal criteria|7
6091820|NCT00700817|9704239|FG002|Week 0-26 (Main Period)|Withdrawal criteria|5
6091821|NCT00700817|9704240|FG003|Week 0-26 (Main Period)|Withdrawal criteria|0
6091822|NCT00700817|9704241|FG004|Week 0-26 (Main Period)|Withdrawal criteria|0
6091823|NCT00700817|9704237|FG000|Week 0-26 (Main Period)|Unclassified|14
6091824|NCT00700817|9704238|FG001|Week 0-26 (Main Period)|Unclassified|4
6091825|NCT00700817|9704239|FG002|Week 0-26 (Main Period)|Unclassified|8
6091826|NCT00700817|9704240|FG003|Week 0-26 (Main Period)|Unclassified|0
6091827|NCT00700817|9704241|FG004|Week 0-26 (Main Period)|Unclassified|0
6091828|NCT00700817|9704237|FG000|Week 26-52 (Extension Period 1)|Adverse Event|5
6091829|NCT00700817|9704238|FG001|Week 26-52 (Extension Period 1)|Adverse Event|10
6091830|NCT00700817|9704239|FG002|Week 26-52 (Extension Period 1)|Adverse Event|3
6091831|NCT00700817|9704240|FG003|Week 26-52 (Extension Period 1)|Adverse Event|0
6091832|NCT00700817|9704241|FG004|Week 26-52 (Extension Period 1)|Adverse Event|0
6091833|NCT00700817|9704237|FG000|Week 26-52 (Extension Period 1)|Protocol Violation|3
6091834|NCT00700817|9704238|FG001|Week 26-52 (Extension Period 1)|Protocol Violation|2
6091835|NCT00700817|9704239|FG002|Week 26-52 (Extension Period 1)|Protocol Violation|2
6091836|NCT00700817|9704240|FG003|Week 26-52 (Extension Period 1)|Protocol Violation|0
6091837|NCT00700817|9704241|FG004|Week 26-52 (Extension Period 1)|Protocol Violation|0
6091838|NCT00700817|9704237|FG000|Week 26-52 (Extension Period 1)|Lack of Efficacy|2
6091839|NCT00700817|9704238|FG001|Week 26-52 (Extension Period 1)|Lack of Efficacy|3
6091840|NCT00700817|9704239|FG002|Week 26-52 (Extension Period 1)|Lack of Efficacy|7
6091841|NCT00700817|9704240|FG003|Week 26-52 (Extension Period 1)|Lack of Efficacy|0
6091842|NCT00700817|9704241|FG004|Week 26-52 (Extension Period 1)|Lack of Efficacy|0
6091843|NCT00700817|9704237|FG000|Week 26-52 (Extension Period 1)|Withdrawal criteria|6
6091844|NCT00700817|9704238|FG001|Week 26-52 (Extension Period 1)|Withdrawal criteria|8
6091845|NCT00700817|9704239|FG002|Week 26-52 (Extension Period 1)|Withdrawal criteria|2
6091846|NCT00700817|9704240|FG003|Week 26-52 (Extension Period 1)|Withdrawal criteria|0
6091847|NCT00700817|9704241|FG004|Week 26-52 (Extension Period 1)|Withdrawal criteria|0
6091848|NCT00700817|9704237|FG000|Week 26-52 (Extension Period 1)|Unclassified|4
6091849|NCT00700817|9704238|FG001|Week 26-52 (Extension Period 1)|Unclassified|3
6091850|NCT00700817|9704239|FG002|Week 26-52 (Extension Period 1)|Unclassified|1
6091851|NCT00700817|9704240|FG003|Week 26-52 (Extension Period 1)|Unclassified|0
6091852|NCT00700817|9704241|FG004|Week 26-52 (Extension Period 1)|Unclassified|0
6091853|NCT00700817|9704237|FG000|Week 52-78 (Extension Period 2)|Adverse Event|0
6091854|NCT00700817|9704238|FG001|Week 52-78 (Extension Period 2)|Adverse Event|3
6057881|NCT00470093|9658295|FG000|Overall Study|Adverse Event|2
6057882|NCT00470158|9658325|FG000|Overall Study|Death|0
6057883|NCT00470158|9658326|FG001|Overall Study|Death|0
6057884|NCT00470158|9658327|FG002|Overall Study|Death|0
6057885|NCT00470158|9658328|FG003|Overall Study|Death|0
6057886|NCT00470158|9658329|FG004|Overall Study|Death|2
6057887|NCT00470158|9658325|FG000|Overall Study|Lost to Follow-up|7
6057888|NCT00470158|9658326|FG001|Overall Study|Lost to Follow-up|8
6057889|NCT00470158|9658327|FG002|Overall Study|Lost to Follow-up|8
6057890|NCT00470158|9658328|FG003|Overall Study|Lost to Follow-up|5
6057891|NCT00470158|9658329|FG004|Overall Study|Lost to Follow-up|4
6057892|NCT00470158|9658325|FG000|Overall Study|Protocol Violation|1
6057893|NCT00470158|9658326|FG001|Overall Study|Protocol Violation|0
6057894|NCT00470158|9658327|FG002|Overall Study|Protocol Violation|0
6057895|NCT00470158|9658328|FG003|Overall Study|Protocol Violation|0
6057896|NCT00470158|9658329|FG004|Overall Study|Protocol Violation|0
6057897|NCT00470184|9658341|FG000|Overall Study|Not Treated(became ineligible)|4
6057898|NCT00470184|9658341|FG000|Overall Study|Not treated (other)|1
6057899|NCT00470184|9658341|FG000|Overall Study|disease Progression|4
6057900|NCT00470184|9658341|FG000|Overall Study|Adverse Event|3
6057901|NCT00470184|9658341|FG000|Overall Study|Withdrawal by Subject|4
6057902|NCT00470184|9658341|FG000|Overall Study|other|5
6057903|NCT00470184|9658341|FG000|Overall Study|recurrence|1
6057904|NCT00470262|9658348|FG000|Overall Study|Withdrawal by Subject|2
6057905|NCT00470262|9658349|FG001|Overall Study|Withdrawal by Subject|0
6057906|NCT00470275|9658356|FG000|Overall Study|Death|1
6057907|NCT00470275|9658356|FG000|Overall Study|Lack of Efficacy|7
6057908|NCT00470275|9658356|FG000|Overall Study|Withdrawal by Subject|2
6057909|NCT00470366|9658365|FG000|Overall Study|Adverse Event|3
6057910|NCT00470366|9658365|FG000|Overall Study|Poor compliance|1
6057911|NCT00470418|9658381|FG000|Overall Study|Withdrawal by Subject|1
6057912|NCT00470418|9658382|FG001|Overall Study|Withdrawal by Subject|0
6057913|NCT00470470|9658388|FG000|Overall Study|Adverse Event|2
6057914|NCT00470470|9658388|FG000|Overall Study|Death|2
6057915|NCT00470470|9658388|FG000|Overall Study|Not treated|1
6057916|NCT00470535|9658392|FG000|Overall Study|Disease Progression|13
6057917|NCT00470535|9658392|FG000|Overall Study|Withdrawal by Subject|1
6057918|NCT00470535|9658392|FG000|Overall Study|Adverse Event|1
6057919|NCT00470535|9658392|FG000|Overall Study|Death|1
6057920|NCT00470535|9658392|FG000|Overall Study|Other|2
6057921|NCT00470626|9658420|FG000|Overall Study|Lost to Follow-up|10
6057922|NCT00470626|9658420|FG000|Overall Study|Withdrawal by Subject|7
6057923|NCT00470834|9658430|FG000|Treatment Period (18 Months)|Protocol-defined Stopping Criteria|16
6057924|NCT00470834|9658431|FG001|Treatment Period (18 Months)|Protocol-defined Stopping Criteria|14
6057925|NCT00470834|9658430|FG000|Treatment Period (18 Months)|Adverse Event|7
6057926|NCT00470834|9658431|FG001|Treatment Period (18 Months)|Adverse Event|6
6057927|NCT00470834|9658430|FG000|Treatment Period (18 Months)|Withdrawal by Subject|4
6057928|NCT00470834|9658431|FG001|Treatment Period (18 Months)|Withdrawal by Subject|5
6057929|NCT00470834|9658430|FG000|Treatment Period (18 Months)|Physician Decision|4
6057930|NCT00470834|9658431|FG001|Treatment Period (18 Months)|Physician Decision|4
6202433|NCT01500694|9862534|FG000|Overall Study|Withdrawal by Subject|23
6202434|NCT01500694|9862535|FG001|Overall Study|Withdrawal by Subject|14
6202435|NCT01500694|9862534|FG000|Overall Study|Lost to Follow-up|2
6202436|NCT01500694|9862535|FG001|Overall Study|Lost to Follow-up|3
6202437|NCT01500694|9862534|FG000|Overall Study|Lack of Efficacy|14
6202438|NCT01500694|9862535|FG001|Overall Study|Lack of Efficacy|5
6202439|NCT01500694|9862534|FG000|Overall Study|Other|9
6202440|NCT01500694|9862535|FG001|Overall Study|Other|3
6284235|NCT02326272|9996337|FG009|Initial Period (Week 0 to Week 16)|Missed two doses|0
6284236|NCT02326272|9996338|FG010|Initial Period (Week 0 to Week 16)|Missed two doses|0
6284237|NCT02326272|9996339|FG011|Initial Period (Week 0 to Week 16)|Missed two doses|0
6284238|NCT02326272|9996340|FG012|Initial Period (Week 0 to Week 16)|Missed two doses|0
6057931|NCT00470834|9658430|FG000|Treatment Period (18 Months)|Protocol Violation|3
6057932|NCT00470834|9658431|FG001|Treatment Period (18 Months)|Protocol Violation|1
6057933|NCT00470834|9658430|FG000|Treatment Period (18 Months)|Sponsor Terminated Study|1
6057934|NCT00470834|9658431|FG001|Treatment Period (18 Months)|Sponsor Terminated Study|1
6057935|NCT00470834|9658430|FG000|Treatment Period (18 Months)|Lost to Follow-up|1
6057936|NCT00470834|9658431|FG001|Treatment Period (18 Months)|Lost to Follow-up|0
6057937|NCT00470834|9658430|FG000|Treatment Period (18 Months)|Non-compliance|1
6057938|NCT00470834|9658431|FG001|Treatment Period (18 Months)|Non-compliance|0
6057939|NCT00470834|9658430|FG000|Treatment Period (18 Months)|Lack of Efficacy|1
6057940|NCT00470834|9658431|FG001|Treatment Period (18 Months)|Lack of Efficacy|0
6057941|NCT00470834|9658430|FG000|Extension Period (24 Months)|Protocol-defined Stopping Criteria|6
6057942|NCT00470834|9658431|FG001|Extension Period (24 Months)|Protocol-defined Stopping Criteria|7
6057943|NCT00470834|9658430|FG000|Extension Period (24 Months)|Adverse Event|3
6057944|NCT00470834|9658431|FG001|Extension Period (24 Months)|Adverse Event|4
6057945|NCT00470834|9658430|FG000|Extension Period (24 Months)|Withdrawal by Subject|2
6057946|NCT00470834|9658431|FG001|Extension Period (24 Months)|Withdrawal by Subject|5
6057947|NCT00470834|9658430|FG000|Extension Period (24 Months)|Physician Decision|4
6057948|NCT00470834|9658431|FG001|Extension Period (24 Months)|Physician Decision|3
6057949|NCT00470834|9658430|FG000|Extension Period (24 Months)|Sponsor Terminated Study|0
6284239|NCT02326272|9996341|FG013|Initial Period (Week 0 to Week 16)|Missed two doses|0
6284240|NCT02326272|9996342|FG014|Initial Period (Week 0 to Week 16)|Missed two doses|0
6057950|NCT00470834|9658431|FG001|Extension Period (24 Months)|Sponsor Terminated Study|1
6057951|NCT00470834|9658430|FG000|Extension Period (24 Months)|Lost to Follow-up|0
6057952|NCT00470834|9658431|FG001|Extension Period (24 Months)|Lost to Follow-up|1
6057953|NCT00470834|9658430|FG000|Extension Period (24 Months)|Non-compliance|0
6057954|NCT00470834|9658431|FG001|Extension Period (24 Months)|Non-compliance|1
6057955|NCT00470834|9658430|FG000|Extension Period (24 Months)|Disease Progression|0
6057956|NCT00470834|9658431|FG001|Extension Period (24 Months)|Disease Progression|1
6057957|NCT00470847|9658437|FG000|Overall Study|Pt still receiving treatment|1
6091855|NCT00700817|9704239|FG002|Week 52-78 (Extension Period 2)|Adverse Event|0
6091856|NCT00700817|9704240|FG003|Week 52-78 (Extension Period 2)|Adverse Event|6
6091857|NCT00700817|9704241|FG004|Week 52-78 (Extension Period 2)|Adverse Event|0
6091858|NCT00700817|9704237|FG000|Week 52-78 (Extension Period 2)|Protocol Violation|1
6091859|NCT00700817|9704238|FG001|Week 52-78 (Extension Period 2)|Protocol Violation|2
6091860|NCT00700817|9704239|FG002|Week 52-78 (Extension Period 2)|Protocol Violation|0
6091861|NCT00700817|9704240|FG003|Week 52-78 (Extension Period 2)|Protocol Violation|1
6091862|NCT00700817|9704241|FG004|Week 52-78 (Extension Period 2)|Protocol Violation|1
6091863|NCT00700817|9704237|FG000|Week 52-78 (Extension Period 2)|Lack of Efficacy|3
6091864|NCT00700817|9704238|FG001|Week 52-78 (Extension Period 2)|Lack of Efficacy|3
6091865|NCT00700817|9704239|FG002|Week 52-78 (Extension Period 2)|Lack of Efficacy|0
6091866|NCT00700817|9704240|FG003|Week 52-78 (Extension Period 2)|Lack of Efficacy|0
6091867|NCT00700817|9704241|FG004|Week 52-78 (Extension Period 2)|Lack of Efficacy|0
6091868|NCT00700817|9704237|FG000|Week 52-78 (Extension Period 2)|Withdrawal criteria|4
6091869|NCT00700817|9704238|FG001|Week 52-78 (Extension Period 2)|Withdrawal criteria|3
6091870|NCT00700817|9704239|FG002|Week 52-78 (Extension Period 2)|Withdrawal criteria|0
6091871|NCT00700817|9704240|FG003|Week 52-78 (Extension Period 2)|Withdrawal criteria|1
6091872|NCT00700817|9704241|FG004|Week 52-78 (Extension Period 2)|Withdrawal criteria|3
6091873|NCT00700817|9704237|FG000|Week 52-78 (Extension Period 2)|Unclassified|2
6091874|NCT00700817|9704238|FG001|Week 52-78 (Extension Period 2)|Unclassified|4
6091875|NCT00700817|9704239|FG002|Week 52-78 (Extension Period 2)|Unclassified|0
6091876|NCT00700817|9704240|FG003|Week 52-78 (Extension Period 2)|Unclassified|0
6091877|NCT00700817|9704241|FG004|Week 52-78 (Extension Period 2)|Unclassified|1
6091878|NCT00700882|9704251|FG000|Overall Study|Never received treatment|6
6091879|NCT00700882|9704251|FG000|Overall Study|Ineligible|2
6091880|NCT00700882|9704251|FG000|Overall Study|No KIT mutation|51
6091881|NCT00700999|9704266|FG000|Overall Study|Lost to Follow-up|7
6091882|NCT00700999|9704267|FG001|Overall Study|Lost to Follow-up|7
6091883|NCT00700999|9704266|FG000|Overall Study|Excluded - did not meet study criteria|0
6091884|NCT00700999|9704267|FG001|Overall Study|Excluded - did not meet study criteria|1
6091885|NCT00700999|9704266|FG000|Overall Study|Withdrawal by Subject|8
6091886|NCT00700999|9704267|FG001|Overall Study|Withdrawal by Subject|1
6091887|NCT00701038|9704275|FG000|Overall Study|study amended pilot group of patients|4
6091888|NCT00701038|9704276|FG001|Overall Study|study amended pilot group of patients|4
6091889|NCT00701051|9704284|FG000|Screening|Failed Screening|40
6091890|NCT00701051|9704285|FG001|Screening|Failed Screening|0
6091891|NCT00701051|9704286|FG002|Screening|Failed Screening|0
6091892|NCT00701051|9704284|FG000|Screening|Time conflicts|19
6091893|NCT00701051|9704285|FG001|Screening|Time conflicts|0
6091894|NCT00701051|9704286|FG002|Screening|Time conflicts|0
6091895|NCT00701051|9704284|FG000|Exercise Intervention|time conflict; non-study related illness|0
6091896|NCT00701051|9704285|FG001|Exercise Intervention|time conflict; non-study related illness|5
6091897|NCT00701051|9704286|FG002|Exercise Intervention|time conflict; non-study related illness|3
6091898|NCT00701064|9704294|FG000|Overall Study|Protocol Violation|1
6091899|NCT00701064|9704295|FG001|Overall Study|Protocol Violation|1
6091900|NCT00701064|9704294|FG000|Overall Study|Withdrawal by Subject|1
6091901|NCT00701064|9704295|FG001|Overall Study|Withdrawal by Subject|1
6091902|NCT00701064|9704294|FG000|Overall Study|initiated other PTSD treatment|2
6091903|NCT00701064|9704295|FG001|Overall Study|initiated other PTSD treatment|2
6091904|NCT00701090|9704303|FG000|Overall Study|Adverse Event|11
6091905|NCT00701090|9704304|FG001|Overall Study|Adverse Event|2
6091906|NCT00701090|9704303|FG000|Overall Study|Death|0
6091907|NCT00701090|9704304|FG001|Overall Study|Death|1
6091908|NCT00701090|9704303|FG000|Overall Study|Lack of Efficacy|5
6091909|NCT00701090|9704304|FG001|Overall Study|Lack of Efficacy|4
6091910|NCT00701090|9704303|FG000|Overall Study|Lost to Follow-up|9
6091911|NCT00701090|9704304|FG001|Overall Study|Lost to Follow-up|9
6091912|NCT00701090|9704303|FG000|Overall Study|Physician Decision|3
6091913|NCT00701090|9704304|FG001|Overall Study|Physician Decision|4
6091914|NCT00701090|9704303|FG000|Overall Study|Protocol Violation|2
6091915|NCT00701090|9704304|FG001|Overall Study|Protocol Violation|3
6091916|NCT00701090|9704303|FG000|Overall Study|Withdrawal by Subject|11
6091917|NCT00701090|9704304|FG001|Overall Study|Withdrawal by Subject|16
6091918|NCT00701090|9704303|FG000|Overall Study|Other|7
6091919|NCT00701090|9704304|FG001|Overall Study|Other|12
6091920|NCT00701103|9704321|FG000|Overall Study|Adverse Event|0
6091921|NCT00701103|9704322|FG001|Overall Study|Adverse Event|0
6091922|NCT00701103|9704323|FG002|Overall Study|Adverse Event|1
6091923|NCT00701103|9704324|FG003|Overall Study|Adverse Event|1
6091924|NCT00701103|9704325|FG004|Overall Study|Adverse Event|0
6091925|NCT00701103|9704326|FG005|Overall Study|Adverse Event|1
6057958|NCT00471081|9658454|FG000|Active Phase|Protocol Violation|1
6057959|NCT00471081|9658455|FG001|Active Phase|Protocol Violation|1
6057960|NCT00471081|9658454|FG000|Active Phase|Withdrawal by Subject|0
6057961|NCT00471081|9658455|FG001|Active Phase|Withdrawal by Subject|3
6057962|NCT00471081|9658454|FG000|Active Phase|Lost to Follow-up|0
6057963|NCT00471081|9658455|FG001|Active Phase|Lost to Follow-up|1
6057964|NCT00471081|9658454|FG000|Active Phase|Lost health plan/insurance|1
6057965|NCT00471081|9658455|FG001|Active Phase|Lost health plan/insurance|8
6057966|NCT00471081|9658454|FG000|Extended Safety Follow-Up|Withdrawal by Subject|1
6057967|NCT00471081|9658455|FG001|Extended Safety Follow-Up|Withdrawal by Subject|4
6057968|NCT00471081|9658454|FG000|Extended Safety Follow-Up|Lost to Follow-up|1
6057969|NCT00471081|9658455|FG001|Extended Safety Follow-Up|Lost to Follow-up|8
6057970|NCT00471081|9658454|FG000|Extended Safety Follow-Up|Missing confirmed|0
6057971|NCT00471081|9658455|FG001|Extended Safety Follow-Up|Missing confirmed|1
6057972|NCT00471107|9658465|FG000|Overall Study|Technical problems/data loss|3
6057973|NCT00471107|9658466|FG001|Overall Study|Technical problems/data loss|1
6057974|NCT00471107|9658467|FG002|Overall Study|Technical problems/data loss|3
6057975|NCT00471146|9658477|FG000|Overall Study|Adverse Event|32
6057976|NCT00471146|9658478|FG001|Overall Study|Adverse Event|33
6091926|NCT00701103|9704327|FG006|Overall Study|Adverse Event|1
6091927|NCT00701103|9704328|FG007|Overall Study|Adverse Event|0
6091928|NCT00701103|9704329|FG008|Overall Study|Adverse Event|0
6091929|NCT00701103|9704330|FG009|Overall Study|Adverse Event|2
6091930|NCT00701103|9704331|FG010|Overall Study|Adverse Event|0
6091931|NCT00701103|9704321|FG000|Overall Study|Progressive Disease|5
6091932|NCT00701103|9704322|FG001|Overall Study|Progressive Disease|2
6091933|NCT00701103|9704323|FG002|Overall Study|Progressive Disease|6
6091934|NCT00701103|9704324|FG003|Overall Study|Progressive Disease|5
6091935|NCT00701103|9704325|FG004|Overall Study|Progressive Disease|6
6091936|NCT00701103|9704326|FG005|Overall Study|Progressive Disease|5
6091937|NCT00701103|9704327|FG006|Overall Study|Progressive Disease|7
6091938|NCT00701103|9704328|FG007|Overall Study|Progressive Disease|7
6091939|NCT00701103|9704329|FG008|Overall Study|Progressive Disease|8
6091940|NCT00701103|9704330|FG009|Overall Study|Progressive Disease|8
6091941|NCT00701103|9704331|FG010|Overall Study|Progressive Disease|11
6091942|NCT00701103|9704321|FG000|Overall Study|Withdrawal by Subject|0
6091943|NCT00701103|9704322|FG001|Overall Study|Withdrawal by Subject|1
6091944|NCT00701103|9704323|FG002|Overall Study|Withdrawal by Subject|1
6091945|NCT00701103|9704324|FG003|Overall Study|Withdrawal by Subject|0
6091946|NCT00701103|9704325|FG004|Overall Study|Withdrawal by Subject|0
6091947|NCT00701103|9704326|FG005|Overall Study|Withdrawal by Subject|0
6091948|NCT00701103|9704327|FG006|Overall Study|Withdrawal by Subject|0
6091949|NCT00701103|9704328|FG007|Overall Study|Withdrawal by Subject|0
6091950|NCT00701103|9704329|FG008|Overall Study|Withdrawal by Subject|0
6091951|NCT00701103|9704330|FG009|Overall Study|Withdrawal by Subject|0
6091952|NCT00701103|9704331|FG010|Overall Study|Withdrawal by Subject|0
6091953|NCT00701103|9704321|FG000|Overall Study|Other|0
6091954|NCT00701103|9704322|FG001|Overall Study|Other|0
6202441|NCT01500720|9862543|FG000|Overall Study|Randomized But Not Treated|1
6202442|NCT01500720|9862544|FG001|Overall Study|Randomized But Not Treated|1
6202443|NCT01500720|9862543|FG000|Overall Study|Other|4
6202444|NCT01500720|9862544|FG001|Overall Study|Other|8
6202445|NCT01501110|9862579|FG000|Overall Study|Death|0
6202446|NCT01501110|9862580|FG001|Overall Study|Death|1
6202447|NCT01502033|9862602|FG000|Overall Study|1 participant had scalp discomfort|1
6202448|NCT01502033|9862602|FG000|Overall Study|1 participant had worsening depression|1
6202449|NCT01502033|9862602|FG000|Overall Study|1 participant went back to school|1
6202450|NCT01502072|9862611|FG000|Overall Study|Withdrawal by Subject|1
6202451|NCT01502072|9862612|FG001|Overall Study|Withdrawal by Subject|0
6202452|NCT01502072|9862613|FG002|Overall Study|Withdrawal by Subject|0
6202453|NCT01502072|9862611|FG000|Overall Study|Death|0
6202454|NCT01502072|9862612|FG001|Overall Study|Death|1
6202455|NCT01502072|9862613|FG002|Overall Study|Death|0
6202456|NCT01502228|9862621|FG000|Overall Study|Death|1
6202457|NCT01502293|9862628|FG000|Overall Study|Progressive Disease|20
6202458|NCT01502293|9862629|FG001|Overall Study|Progressive Disease|12
6202459|NCT01502293|9862630|FG002|Overall Study|Progressive Disease|2
6202460|NCT01502293|9862628|FG000|Overall Study|Withdrawal by Subject|3
6202461|NCT01502293|9862629|FG001|Overall Study|Withdrawal by Subject|3
6202462|NCT01502293|9862630|FG002|Overall Study|Withdrawal by Subject|1
6202463|NCT01502293|9862628|FG000|Overall Study|Adverse Event|0
6202464|NCT01502293|9862629|FG001|Overall Study|Adverse Event|2
6091955|NCT00701103|9704323|FG002|Overall Study|Other|0
6091956|NCT00701103|9704324|FG003|Overall Study|Other|0
6091957|NCT00701103|9704325|FG004|Overall Study|Other|0
6091958|NCT00701103|9704326|FG005|Overall Study|Other|0
6091959|NCT00701103|9704327|FG006|Overall Study|Other|0
6091960|NCT00701103|9704328|FG007|Overall Study|Other|0
6091961|NCT00701103|9704329|FG008|Overall Study|Other|1
6202465|NCT01502293|9862630|FG002|Overall Study|Adverse Event|0
6202466|NCT01502293|9862628|FG000|Overall Study|Reason Not Specified|2
6202467|NCT01502293|9862629|FG001|Overall Study|Reason Not Specified|0
6202468|NCT01502293|9862630|FG002|Overall Study|Reason Not Specified|0
6202469|NCT01502293|9862628|FG000|Overall Study|Physician Decision|0
6202470|NCT01502293|9862629|FG001|Overall Study|Physician Decision|0
6057977|NCT00471146|9658477|FG000|Overall Study|Withdrawal by Subject|14
6057978|NCT00471146|9658478|FG001|Overall Study|Withdrawal by Subject|11
6057979|NCT00471146|9658477|FG000|Overall Study|Death|11
6057980|NCT00471146|9658478|FG001|Overall Study|Death|12
6057981|NCT00471146|9658477|FG000|Overall Study|Lost to Follow-up|4
6057982|NCT00471146|9658478|FG001|Overall Study|Lost to Follow-up|2
6057983|NCT00471146|9658477|FG000|Overall Study|Protocol Violation|2
6057984|NCT00471146|9658478|FG001|Overall Study|Protocol Violation|2
6057985|NCT00471146|9658477|FG000|Overall Study|Objective progression or relapse|84
6057986|NCT00471146|9658478|FG001|Overall Study|Objective progression or relapse|87
6057987|NCT00471146|9658477|FG000|Overall Study|Global deterioration of health status|12
6057988|NCT00471146|9658478|FG001|Overall Study|Global deterioration of health status|14
6057989|NCT00471146|9658477|FG000|Overall Study|Randomized but not treated|9
6057990|NCT00471146|9658478|FG001|Overall Study|Randomized but not treated|8
6057991|NCT00471146|9658477|FG000|Overall Study|Other|4
6057992|NCT00471146|9658478|FG001|Overall Study|Other|5
6057993|NCT00471237|9658491|FG000|Overall Study|Adverse Event|6
6057994|NCT00471237|9658492|FG001|Overall Study|Adverse Event|5
6057995|NCT00471237|9658493|FG002|Overall Study|Adverse Event|4
6057996|NCT00471237|9658494|FG003|Overall Study|Adverse Event|8
6057997|NCT00471237|9658495|FG004|Overall Study|Adverse Event|7
6057998|NCT00471237|9658496|FG005|Overall Study|Adverse Event|5
6057999|NCT00471237|9658497|FG006|Overall Study|Adverse Event|0
6058000|NCT00471237|9658491|FG000|Overall Study|Lost to Follow-up|1
6058001|NCT00471237|9658492|FG001|Overall Study|Lost to Follow-up|1
6058002|NCT00471237|9658493|FG002|Overall Study|Lost to Follow-up|0
6058003|NCT00471237|9658494|FG003|Overall Study|Lost to Follow-up|2
6058004|NCT00471237|9658495|FG004|Overall Study|Lost to Follow-up|3
6058005|NCT00471237|9658496|FG005|Overall Study|Lost to Follow-up|0
6058006|NCT00471237|9658497|FG006|Overall Study|Lost to Follow-up|0
6058007|NCT00471237|9658491|FG000|Overall Study|Protocol Violation|3
6058008|NCT00471237|9658492|FG001|Overall Study|Protocol Violation|6
6058009|NCT00471237|9658493|FG002|Overall Study|Protocol Violation|3
6058010|NCT00471237|9658494|FG003|Overall Study|Protocol Violation|2
6091962|NCT00701103|9704330|FG009|Overall Study|Other|1
6091963|NCT00701103|9704331|FG010|Overall Study|Other|0
6091964|NCT00701129|9704359|FG000|Overall Study|Death|2
6091965|NCT00701311|9704363|FG000|Overall Study|Lack of Efficacy|3
6091966|NCT00701311|9704363|FG000|Overall Study|Adverse Event|3
6091967|NCT00701311|9704363|FG000|Overall Study|Withdrawal by Subject|2
6091968|NCT00701363|9704371|FG000|Screening (Pre-assignment) Phase|Does not meet entry Criteria|4
6091969|NCT00701363|9704372|FG001|Screening (Pre-assignment) Phase|Does not meet entry Criteria|0
6091970|NCT00701363|9704373|FG002|Screening (Pre-assignment) Phase|Does not meet entry Criteria|0
6091971|NCT00701363|9704374|FG003|Screening (Pre-assignment) Phase|Does not meet entry Criteria|0
6091972|NCT00701363|9704371|FG000|Treatment Phase 1|Does not meet entry Criteria|1
6091973|NCT00701363|9704372|FG001|Treatment Phase 1|Does not meet entry Criteria|0
6091974|NCT00701363|9704373|FG002|Treatment Phase 1|Does not meet entry Criteria|0
6091975|NCT00701363|9704374|FG003|Treatment Phase 1|Does not meet entry Criteria|0
6091976|NCT00701363|9704371|FG000|Treatment Phase 1|Adverse Event|7
6091977|NCT00701363|9704372|FG001|Treatment Phase 1|Adverse Event|0
6091978|NCT00701363|9704373|FG002|Treatment Phase 1|Adverse Event|0
6091979|NCT00701363|9704374|FG003|Treatment Phase 1|Adverse Event|0
6091980|NCT00701363|9704371|FG000|Treatment Phase 1|Protocol Violation|1
6091981|NCT00701363|9704372|FG001|Treatment Phase 1|Protocol Violation|0
6091982|NCT00701363|9704373|FG002|Treatment Phase 1|Protocol Violation|0
6091983|NCT00701363|9704374|FG003|Treatment Phase 1|Protocol Violation|0
6091984|NCT00701363|9704371|FG000|Treatment Phase 1|Withdrawal by Subject|5
6091985|NCT00701363|9704372|FG001|Treatment Phase 1|Withdrawal by Subject|0
6091986|NCT00701363|9704373|FG002|Treatment Phase 1|Withdrawal by Subject|0
6091987|NCT00701363|9704374|FG003|Treatment Phase 1|Withdrawal by Subject|0
6091988|NCT00701363|9704371|FG000|Treatment Phase 1|Lack of Efficacy|1
6091989|NCT00701363|9704372|FG001|Treatment Phase 1|Lack of Efficacy|0
6091990|NCT00701363|9704373|FG002|Treatment Phase 1|Lack of Efficacy|0
6091991|NCT00701363|9704374|FG003|Treatment Phase 1|Lack of Efficacy|0
6091992|NCT00701363|9704371|FG000|Treatment Phase 2|Adverse Event|0
6091993|NCT00701363|9704372|FG001|Treatment Phase 2|Adverse Event|0
6091994|NCT00701363|9704373|FG002|Treatment Phase 2|Adverse Event|1
6091995|NCT00701363|9704374|FG003|Treatment Phase 2|Adverse Event|0
6091996|NCT00701363|9704371|FG000|Treatment Phase 2|Withdrawal by Subject|0
6091997|NCT00701363|9704372|FG001|Treatment Phase 2|Withdrawal by Subject|0
6091998|NCT00701363|9704373|FG002|Treatment Phase 2|Withdrawal by Subject|1
6091999|NCT00701363|9704374|FG003|Treatment Phase 2|Withdrawal by Subject|0
6092000|NCT00701415|9704418|FG000|Overall Study|Adverse Event|0
6092001|NCT00701415|9704419|FG001|Overall Study|Adverse Event|1
6092002|NCT00701415|9704418|FG000|Overall Study|Social/family issues and needle phobia|1
6092003|NCT00701415|9704419|FG001|Overall Study|Social/family issues and needle phobia|0
6092004|NCT00701441|9704427|FG000|Overall Study|failure in cpap compliance|0
6092005|NCT00701441|9704428|FG001|Overall Study|failure in cpap compliance|4
6092006|NCT00701558|9704438|FG000|Overall Study|Death|7
6092007|NCT00701558|9704438|FG000|Overall Study|Lost to Follow-up|8
6092008|NCT00701662|9704450|FG000|Overall Study|Lack of Efficacy|1
6058011|NCT00471237|9658495|FG004|Overall Study|Protocol Violation|2
6058012|NCT00471237|9658496|FG005|Overall Study|Protocol Violation|4
6058013|NCT00471237|9658497|FG006|Overall Study|Protocol Violation|1
6058014|NCT00471237|9658491|FG000|Overall Study|Withdrawal by Subject|8
6058015|NCT00471237|9658492|FG001|Overall Study|Withdrawal by Subject|6
6058016|NCT00471237|9658493|FG002|Overall Study|Withdrawal by Subject|5
6058017|NCT00471237|9658494|FG003|Overall Study|Withdrawal by Subject|8
6058018|NCT00471237|9658495|FG004|Overall Study|Withdrawal by Subject|7
6058019|NCT00471237|9658496|FG005|Overall Study|Withdrawal by Subject|4
6058020|NCT00471237|9658497|FG006|Overall Study|Withdrawal by Subject|2
6058021|NCT00471237|9658491|FG000|Overall Study|Sponsor terminated study|20
6058022|NCT00471237|9658492|FG001|Overall Study|Sponsor terminated study|23
6058023|NCT00471237|9658493|FG002|Overall Study|Sponsor terminated study|19
6058024|NCT00471237|9658494|FG003|Overall Study|Sponsor terminated study|22
6058025|NCT00471237|9658495|FG004|Overall Study|Sponsor terminated study|18
6058026|NCT00471237|9658496|FG005|Overall Study|Sponsor terminated study|24
6058027|NCT00471237|9658497|FG006|Overall Study|Sponsor terminated study|0
6058028|NCT00471237|9658491|FG000|Overall Study|Non-compliance|0
6058029|NCT00471237|9658492|FG001|Overall Study|Non-compliance|1
6058030|NCT00471237|9658493|FG002|Overall Study|Non-compliance|0
6058031|NCT00471237|9658494|FG003|Overall Study|Non-compliance|1
6058032|NCT00471237|9658495|FG004|Overall Study|Non-compliance|0
6058033|NCT00471237|9658496|FG005|Overall Study|Non-compliance|0
6058034|NCT00471237|9658497|FG006|Overall Study|Non-compliance|0
6058035|NCT00471237|9658491|FG000|Overall Study|Met serum creatinine withdrawal criteria|1
6058036|NCT00471237|9658492|FG001|Overall Study|Met serum creatinine withdrawal criteria|0
6058037|NCT00471237|9658493|FG002|Overall Study|Met serum creatinine withdrawal criteria|2
6058038|NCT00471237|9658494|FG003|Overall Study|Met serum creatinine withdrawal criteria|2
6058039|NCT00471237|9658495|FG004|Overall Study|Met serum creatinine withdrawal criteria|0
6058040|NCT00471237|9658496|FG005|Overall Study|Met serum creatinine withdrawal criteria|0
6058041|NCT00471237|9658497|FG006|Overall Study|Met serum creatinine withdrawal criteria|0
6058042|NCT00471237|9658491|FG000|Overall Study|Early stopping due to non-efficacy|1
6058043|NCT00471237|9658492|FG001|Overall Study|Early stopping due to non-efficacy|0
6058044|NCT00471237|9658493|FG002|Overall Study|Early stopping due to non-efficacy|0
6058045|NCT00471237|9658494|FG003|Overall Study|Early stopping due to non-efficacy|0
6058046|NCT00471237|9658495|FG004|Overall Study|Early stopping due to non-efficacy|1
6058047|NCT00471237|9658496|FG005|Overall Study|Early stopping due to non-efficacy|0
6058048|NCT00471237|9658497|FG006|Overall Study|Early stopping due to non-efficacy|0
6058049|NCT00471237|9658491|FG000|Overall Study|Participant planned to travel to abraod|1
6058050|NCT00471237|9658492|FG001|Overall Study|Participant planned to travel to abraod|0
6058051|NCT00471237|9658493|FG002|Overall Study|Participant planned to travel to abraod|0
6058052|NCT00471237|9658494|FG003|Overall Study|Participant planned to travel to abraod|0
6058053|NCT00471237|9658495|FG004|Overall Study|Participant planned to travel to abraod|0
6058054|NCT00471237|9658496|FG005|Overall Study|Participant planned to travel to abraod|1
6058055|NCT00471237|9658497|FG006|Overall Study|Participant planned to travel to abraod|0
6058056|NCT00471237|9658491|FG000|Overall Study|High parathyroid hormone|0
6058057|NCT00471237|9658492|FG001|Overall Study|High parathyroid hormone|0
6058058|NCT00471237|9658493|FG002|Overall Study|High parathyroid hormone|1
6058059|NCT00471237|9658494|FG003|Overall Study|High parathyroid hormone|0
6058060|NCT00471237|9658495|FG004|Overall Study|High parathyroid hormone|0
6058061|NCT00471237|9658496|FG005|Overall Study|High parathyroid hormone|0
6058062|NCT00471237|9658497|FG006|Overall Study|High parathyroid hormone|0
6058063|NCT00471237|9658491|FG000|Overall Study|Participant lost medication|0
6058064|NCT00471237|9658492|FG001|Overall Study|Participant lost medication|0
6058065|NCT00471237|9658493|FG002|Overall Study|Participant lost medication|0
6058066|NCT00471237|9658494|FG003|Overall Study|Participant lost medication|0
6058067|NCT00471237|9658495|FG004|Overall Study|Participant lost medication|1
6058068|NCT00471237|9658496|FG005|Overall Study|Participant lost medication|0
6058069|NCT00471237|9658497|FG006|Overall Study|Participant lost medication|0
6058070|NCT00471237|9658491|FG000|Overall Study|Administration of prohibited medicine|0
6058071|NCT00471237|9658492|FG001|Overall Study|Administration of prohibited medicine|0
6058072|NCT00471237|9658493|FG002|Overall Study|Administration of prohibited medicine|0
6058073|NCT00471237|9658494|FG003|Overall Study|Administration of prohibited medicine|0
6058074|NCT00471237|9658495|FG004|Overall Study|Administration of prohibited medicine|1
6058075|NCT00471237|9658496|FG005|Overall Study|Administration of prohibited medicine|0
6058076|NCT00471237|9658497|FG006|Overall Study|Administration of prohibited medicine|0
6058077|NCT00471237|9658491|FG000|Overall Study|Participant shifted residence|0
6058078|NCT00471237|9658492|FG001|Overall Study|Participant shifted residence|0
6058079|NCT00471237|9658493|FG002|Overall Study|Participant shifted residence|0
6058080|NCT00471237|9658494|FG003|Overall Study|Participant shifted residence|0
6058081|NCT00471237|9658495|FG004|Overall Study|Participant shifted residence|1
6058082|NCT00471237|9658496|FG005|Overall Study|Participant shifted residence|0
6058083|NCT00471237|9658497|FG006|Overall Study|Participant shifted residence|0
6058084|NCT00471237|9658491|FG000|Overall Study|Participant's decision|0
6058085|NCT00471237|9658492|FG001|Overall Study|Participant's decision|0
6058086|NCT00471237|9658493|FG002|Overall Study|Participant's decision|0
6058087|NCT00471237|9658494|FG003|Overall Study|Participant's decision|0
6058088|NCT00471237|9658495|FG004|Overall Study|Participant's decision|0
6058089|NCT00471237|9658496|FG005|Overall Study|Participant's decision|1
6058090|NCT00471237|9658497|FG006|Overall Study|Participant's decision|0
6092009|NCT00701701|9704469|FG000|Overall Study|Withdrawal by Subject|0
6092010|NCT00701701|9704470|FG001|Overall Study|Withdrawal by Subject|1
6092011|NCT00701701|9704469|FG000|Overall Study|Adverse Event|0
6092012|NCT00701701|9704470|FG001|Overall Study|Adverse Event|1
6202471|NCT01502293|9862630|FG002|Overall Study|Physician Decision|1
6202472|NCT01502410|9862667|FG000|Overall Study|Adverse Event|1
6202473|NCT01502410|9862668|FG001|Overall Study|Adverse Event|2
6202474|NCT01502410|9862669|FG002|Overall Study|Adverse Event|0
6202475|NCT01502410|9862670|FG003|Overall Study|Adverse Event|0
6202476|NCT01502410|9862667|FG000|Overall Study|Lack of Efficacy|7
6202477|NCT01502410|9862668|FG001|Overall Study|Lack of Efficacy|7
6202478|NCT01502410|9862669|FG002|Overall Study|Lack of Efficacy|0
6202479|NCT01502410|9862670|FG003|Overall Study|Lack of Efficacy|0
6202480|NCT01502410|9862667|FG000|Overall Study|Physician Decision|0
6202481|NCT01502410|9862668|FG001|Overall Study|Physician Decision|1
6202482|NCT01502410|9862669|FG002|Overall Study|Physician Decision|0
6202483|NCT01502410|9862670|FG003|Overall Study|Physician Decision|0
6202484|NCT01502410|9862667|FG000|Overall Study|Withdrawal by Subject|2
6202485|NCT01502410|9862668|FG001|Overall Study|Withdrawal by Subject|0
6202486|NCT01502410|9862669|FG002|Overall Study|Withdrawal by Subject|0
6202487|NCT01502410|9862670|FG003|Overall Study|Withdrawal by Subject|0
6202488|NCT01502423|9862681|FG000|Overall Study|Withdrawal by Subject|0
6202489|NCT01502423|9862682|FG001|Overall Study|Withdrawal by Subject|1
6202490|NCT01502631|9862690|FG000|Overall Study|Adverse Event|5
6202491|NCT01502631|9862691|FG001|Overall Study|Adverse Event|8
6202492|NCT01502631|9862690|FG000|Overall Study|Lost to Follow-up|2
6202493|NCT01502631|9862691|FG001|Overall Study|Lost to Follow-up|2
6202494|NCT01502631|9862690|FG000|Overall Study|Participant withdrew consent|2
6202495|NCT01502631|9862691|FG001|Overall Study|Participant withdrew consent|4
6202496|NCT01502631|9862690|FG000|Overall Study|Participant non-compliant|1
6202497|NCT01502631|9862691|FG001|Overall Study|Participant non-compliant|0
6202498|NCT01502631|9862690|FG000|Overall Study|Investigator's decision|0
6202499|NCT01502631|9862691|FG001|Overall Study|Investigator's decision|1
6202500|NCT01502631|9862690|FG000|Overall Study|Other|10
6202501|NCT01502631|9862691|FG001|Overall Study|Other|5
6202502|NCT01502644|9862700|FG000|Enrolled at Visit 1 After Pre-screening|Illegal Drugs in Urine Drug Test|1
6202503|NCT01502644|9862701|FG001|Enrolled at Visit 1 After Pre-screening|Illegal Drugs in Urine Drug Test|0
6202504|NCT01502644|9862702|FG002|Enrolled at Visit 1 After Pre-screening|Illegal Drugs in Urine Drug Test|0
6202505|NCT01502644|9862703|FG003|Enrolled at Visit 1 After Pre-screening|Illegal Drugs in Urine Drug Test|0
6202506|NCT01502644|9862700|FG000|Enrolled at Visit 1 After Pre-screening|History of Opioid Substance Use Disorder|2
6202507|NCT01502644|9862701|FG001|Enrolled at Visit 1 After Pre-screening|History of Opioid Substance Use Disorder|0
6202508|NCT01502644|9862702|FG002|Enrolled at Visit 1 After Pre-screening|History of Opioid Substance Use Disorder|0
6202509|NCT01502644|9862703|FG003|Enrolled at Visit 1 After Pre-screening|History of Opioid Substance Use Disorder|0
6202510|NCT01502644|9862700|FG000|Enrolled at Visit 1 After Pre-screening|Declined to Participate further|6
6202511|NCT01502644|9862701|FG001|Enrolled at Visit 1 After Pre-screening|Declined to Participate further|0
6202512|NCT01502644|9862702|FG002|Enrolled at Visit 1 After Pre-screening|Declined to Participate further|0
6202513|NCT01502644|9862703|FG003|Enrolled at Visit 1 After Pre-screening|Declined to Participate further|0
6202514|NCT01502644|9862700|FG000|Assigned to NA Groups|Drop Out due to Side Effects|0
6202515|NCT01502644|9862701|FG001|Assigned to NA Groups|Drop Out due to Side Effects|6
6202516|NCT01502644|9862702|FG002|Assigned to NA Groups|Drop Out due to Side Effects|2
6202517|NCT01502644|9862703|FG003|Assigned to NA Groups|Drop Out due to Side Effects|7
6202518|NCT01502644|9862700|FG000|Assigned to NA Groups|Illegal Drugs in Urine Drug Test|0
6202519|NCT01502644|9862701|FG001|Assigned to NA Groups|Illegal Drugs in Urine Drug Test|0
6202520|NCT01502644|9862702|FG002|Assigned to NA Groups|Illegal Drugs in Urine Drug Test|1
6202521|NCT01502644|9862703|FG003|Assigned to NA Groups|Illegal Drugs in Urine Drug Test|1
6202522|NCT01502709|9862713|FG000|Overall Study|Lost to Follow-up|4
6202523|NCT01502709|9862714|FG001|Overall Study|Lost to Follow-up|0
6202524|NCT01502956|9862755|FG000|Overall Study|Death|0
6202525|NCT01502956|9862756|FG001|Overall Study|Death|2
6202526|NCT01502956|9862755|FG000|Overall Study|Lost to Follow-up|14
6202527|NCT01502956|9862756|FG001|Overall Study|Lost to Follow-up|11
6202528|NCT01502956|9862755|FG000|Overall Study|Physician Decision|2
6202529|NCT01502956|9862756|FG001|Overall Study|Physician Decision|3
6058091|NCT00471276|9658517|FG000|Overall Study|Death|2
6058092|NCT00471276|9658517|FG000|Overall Study|Adverse Event|16
6058093|NCT00471276|9658517|FG000|Overall Study|Protocol Violation|1
6058094|NCT00471276|9658517|FG000|Overall Study|Objective progression or relapse|54
6058095|NCT00471276|9658517|FG000|Overall Study|Global deterioration of health status|1
6058096|NCT00471276|9658517|FG000|Overall Study|Other|3
6058097|NCT00471276|9658517|FG000|Overall Study|Refused treatment|6
6058098|NCT00471315|9658521|FG000|Overall Study|Adverse Event|7
6058099|NCT00471315|9658521|FG000|Overall Study|Withdrawal by Subject|1
6058100|NCT00471328|9658527|FG000|Core Phase|Adverse Event|18
6058101|NCT00471328|9658528|FG001|Core Phase|Adverse Event|6
6058102|NCT00471328|9658527|FG000|Core Phase|Death|8
6058103|NCT00471328|9658528|FG001|Core Phase|Death|4
6058104|NCT00471328|9658527|FG000|Core Phase|Withdrawal by Subject|2
6058105|NCT00471328|9658528|FG001|Core Phase|Withdrawal by Subject|2
6058106|NCT00471328|9658527|FG000|Core Phase|Abnormal laboratory value|1
6058107|NCT00471328|9658528|FG001|Core Phase|Abnormal laboratory value|0
6058108|NCT00471328|9658527|FG000|Core Phase|Disease Progression|78
6058109|NCT00471328|9658528|FG001|Core Phase|Disease Progression|53
6058110|NCT00471328|9658527|FG000|Core Phase|Administrative Problem|0
6058111|NCT00471328|9658528|FG001|Core Phase|Administrative Problem|1
6058112|NCT00471328|9658527|FG000|Core Phase|Protocol Deviation|0
6058113|NCT00471328|9658528|FG001|Core Phase|Protocol Deviation|1
6058114|NCT00471328|9658527|FG000|Extension Phase|Adverse Event|3
6058115|NCT00471328|9658528|FG001|Extension Phase|Adverse Event|12
6058116|NCT00471328|9658527|FG000|Extension Phase|Withdrawal by Subject|0
6058117|NCT00471328|9658528|FG001|Extension Phase|Withdrawal by Subject|2
6058118|NCT00471328|9658527|FG000|Extension Phase|Death|1
6058119|NCT00471328|9658528|FG001|Extension Phase|Death|7
6058120|NCT00471328|9658527|FG000|Extension Phase|Protocol Deviation|3
6058121|NCT00471328|9658528|FG001|Extension Phase|Protocol Deviation|1
6058122|NCT00471328|9658527|FG000|Extension Phase|Treatment duration as per protocol|0
6058123|NCT00471328|9658528|FG001|Extension Phase|Treatment duration as per protocol|1
6058124|NCT00471328|9658527|FG000|Extension Phase|Disease Progression|32
6058125|NCT00471328|9658528|FG001|Extension Phase|Disease Progression|44
6058126|NCT00471328|9658527|FG000|Extension Phase|New cancer Therapy|1
6058127|NCT00471328|9658528|FG001|Extension Phase|New cancer Therapy|0
6058128|NCT00471328|9658527|FG000|Extension Phase|Administrative Problem|1
6058129|NCT00471328|9658528|FG001|Extension Phase|Administrative Problem|0
6058130|NCT00471354|9658536|FG000|Overall Study|Protocol Entry Criteria Not Met|1
6058131|NCT00471354|9658536|FG000|Overall Study|Adverse Event|13
6058132|NCT00471354|9658536|FG000|Overall Study|Protocol Violation|12
6058133|NCT00471354|9658536|FG000|Overall Study|Withdrawal by Subject|1
6058134|NCT00471354|9658536|FG000|Overall Study|Physician Decision|4
6058135|NCT00471354|9658536|FG000|Overall Study|Sponsor Decision|1
6058136|NCT00471354|9658536|FG000|Overall Study|Lost to Follow-up|3
6058137|NCT00471354|9658536|FG000|Overall Study|Lack of Efficacy|5
6058138|NCT00471354|9658536|FG000|Overall Study|Patient/Caregiver Decision|12
6058139|NCT00471445|9658549|FG000|Overall Study|Withdrawal by Subject|1
6058140|NCT00471445|9658550|FG001|Overall Study|Withdrawal by Subject|1
6058141|NCT00471445|9658549|FG000|Overall Study|Ineligible|1
6058142|NCT00471445|9658550|FG001|Overall Study|Ineligible|0
6058143|NCT00471445|9658549|FG000|Overall Study|Protocol Violation|0
6058144|NCT00471445|9658550|FG001|Overall Study|Protocol Violation|1
6058145|NCT00471497|9658559|FG000|Core Treatment Phase|Abnormal Laboratory Values|3
6058146|NCT00471497|9658560|FG001|Core Treatment Phase|Abnormal Laboratory Values|9
6058147|NCT00471497|9658561|FG002|Core Treatment Phase|Abnormal Laboratory Values|9
6058148|NCT00471497|9658559|FG000|Core Treatment Phase|Abnormal Test Procedures|1
6058149|NCT00471497|9658560|FG001|Core Treatment Phase|Abnormal Test Procedures|0
6058150|NCT00471497|9658561|FG002|Core Treatment Phase|Abnormal Test Procedures|1
6058151|NCT00471497|9658559|FG000|Core Treatment Phase|Condition no longer requires study drug|0
6058152|NCT00471497|9658560|FG001|Core Treatment Phase|Condition no longer requires study drug|1
6058153|NCT00471497|9658561|FG002|Core Treatment Phase|Condition no longer requires study drug|0
6058154|NCT00471497|9658559|FG000|Core Treatment Phase|Withdrawal by Subject|31
6058155|NCT00471497|9658560|FG001|Core Treatment Phase|Withdrawal by Subject|29
6058156|NCT00471497|9658561|FG002|Core Treatment Phase|Withdrawal by Subject|34
6058157|NCT00471497|9658559|FG000|Core Treatment Phase|Lost to Follow-up|6
6058158|NCT00471497|9658560|FG001|Core Treatment Phase|Lost to Follow-up|6
6058159|NCT00471497|9658561|FG002|Core Treatment Phase|Lost to Follow-up|3
6058160|NCT00471497|9658559|FG000|Core Treatment Phase|Death|3
6058161|NCT00471497|9658560|FG001|Core Treatment Phase|Death|9
6058162|NCT00471497|9658561|FG002|Core Treatment Phase|Death|3
6058163|NCT00471497|9658559|FG000|Core Treatment Phase|Disease Progression|10
6058164|NCT00471497|9658560|FG001|Core Treatment Phase|Disease Progression|2
6058165|NCT00471497|9658561|FG002|Core Treatment Phase|Disease Progression|4
6058166|NCT00471497|9658559|FG000|Core Treatment Phase|Protocol Violation|6
6058167|NCT00471497|9658560|FG001|Core Treatment Phase|Protocol Violation|15
6058168|NCT00471497|9658561|FG002|Core Treatment Phase|Protocol Violation|11
6058169|NCT00471497|9658559|FG000|Core Treatment Phase|Sub optimal response or treat. failure|19
6058170|NCT00471497|9658560|FG001|Core Treatment Phase|Sub optimal response or treat. failure|11
6058171|NCT00471497|9658561|FG002|Core Treatment Phase|Sub optimal response or treat. failure|13
6058172|NCT00471497|9658559|FG000|Core Treatment Phase|Administrative problems|14
6058173|NCT00471497|9658560|FG001|Core Treatment Phase|Administrative problems|14
6058174|NCT00471497|9658561|FG002|Core Treatment Phase|Administrative problems|12
6058175|NCT00471497|9658559|FG000|Core Treatment Phase|Adverse Event|43
6202530|NCT01502956|9862755|FG000|Overall Study|Withdrawal by Subject|8
6058176|NCT00471497|9658560|FG001|Core Treatment Phase|Adverse Event|53
6058177|NCT00471497|9658561|FG002|Core Treatment Phase|Adverse Event|89
6058178|NCT00471497|9658559|FG000|Core Treatment Phase|Disc. Core/Entered Ext. - DP progression|2
6058179|NCT00471497|9658560|FG001|Core Treatment Phase|Disc. Core/Entered Ext. - DP progression|0
6058180|NCT00471497|9658561|FG002|Core Treatment Phase|Disc. Core/Entered Ext. - DP progression|0
6058181|NCT00471497|9658559|FG000|Core Treatment Phase|Disc. Core/Entered Ext.- SOR/TF|46
6058182|NCT00471497|9658560|FG001|Core Treatment Phase|Disc. Core/Entered Ext.- SOR/TF|26
6058183|NCT00471497|9658561|FG002|Core Treatment Phase|Disc. Core/Entered Ext.- SOR/TF|3
6058184|NCT00471497|9658559|FG000|Extension Phase|Adverse Event|9
6058185|NCT00471497|9658560|FG001|Extension Phase|Adverse Event|5
6058186|NCT00471497|9658561|FG002|Extension Phase|Adverse Event|1
6058187|NCT00471497|9658559|FG000|Extension Phase|Unsatisfactory therapeutic effect|8
6058188|NCT00471497|9658560|FG001|Extension Phase|Unsatisfactory therapeutic effect|6
6058189|NCT00471497|9658561|FG002|Extension Phase|Unsatisfactory therapeutic effect|0
6058190|NCT00471497|9658559|FG000|Extension Phase|Withdrawal by Subject|3
6058191|NCT00471497|9658560|FG001|Extension Phase|Withdrawal by Subject|1
6058192|NCT00471497|9658561|FG002|Extension Phase|Withdrawal by Subject|0
6058193|NCT00471497|9658559|FG000|Extension Phase|Lost to Follow-up|2
6058194|NCT00471497|9658560|FG001|Extension Phase|Lost to Follow-up|0
6092013|NCT00701727|9704490|FG000|First Treatment Period|Adverse Event|0
6092014|NCT00701727|9704491|FG001|First Treatment Period|Adverse Event|0
6058195|NCT00471497|9658561|FG002|Extension Phase|Lost to Follow-up|0
6058196|NCT00471497|9658559|FG000|Extension Phase|Death|1
6058197|NCT00471497|9658560|FG001|Extension Phase|Death|0
6058198|NCT00471497|9658561|FG002|Extension Phase|Death|0
6058199|NCT00471497|9658559|FG000|Extension Phase|Disease progression|2
6058200|NCT00471497|9658560|FG001|Extension Phase|Disease progression|0
6058201|NCT00471497|9658561|FG002|Extension Phase|Disease progression|0
6058202|NCT00471497|9658559|FG000|Extension Phase|Protocol Violation|2
6058203|NCT00471497|9658560|FG001|Extension Phase|Protocol Violation|2
6058204|NCT00471497|9658561|FG002|Extension Phase|Protocol Violation|0
6058205|NCT00471536|9658572|FG000|Overall Study|Withdrawal by Subject|1
6058206|NCT00471718|9658589|FG000|Overall Study|Adverse Event|3
6058207|NCT00471718|9658589|FG000|Overall Study|other complicating disease|1
6058208|NCT00471718|9658589|FG000|Overall Study|disease progression|22
6058209|NCT00471718|9658589|FG000|Overall Study|Withdrawal by Subject|1
6058210|NCT00471822|9658597|FG000|Overall Study|Protocol Violation|2
6058211|NCT00471887|9658605|FG000|Overall Study|Adverse Event|9
6092015|NCT00701727|9704490|FG000|First Treatment Period|Withdrawal by Subject|1
6092016|NCT00701727|9704491|FG001|First Treatment Period|Withdrawal by Subject|0
6092017|NCT00701727|9704490|FG000|First Treatment Period|sponsor decision|0
6092018|NCT00701727|9704491|FG001|First Treatment Period|sponsor decision|1
6092019|NCT00701727|9704490|FG000|First Treatment Period|Lost to Follow-up|0
6092020|NCT00701727|9704491|FG001|First Treatment Period|Lost to Follow-up|1
6092021|NCT00701727|9704490|FG000|Second Treatment Period|Withdrawal by Subject|2
6092022|NCT00701727|9704491|FG001|Second Treatment Period|Withdrawal by Subject|0
6092023|NCT00701779|9704497|FG000|Overall Study|Adverse Event|6
6092024|NCT00701779|9704497|FG000|Overall Study|Lost to Follow-up|1
6092025|NCT00701779|9704497|FG000|Overall Study|Withdrawal by Subject|2
6092026|NCT00701805|9704505|FG000|Overall Study|Withdrawal by Subject|3
6092027|NCT00701805|9704506|FG001|Overall Study|Withdrawal by Subject|1
6092028|NCT00701805|9704507|FG002|Overall Study|Withdrawal by Subject|4
6092029|NCT00701805|9704508|FG003|Overall Study|Withdrawal by Subject|3
6092030|NCT00701805|9704505|FG000|Overall Study|Adverse Event|0
6092031|NCT00701805|9704506|FG001|Overall Study|Adverse Event|1
6092032|NCT00701805|9704507|FG002|Overall Study|Adverse Event|1
6092033|NCT00701805|9704508|FG003|Overall Study|Adverse Event|0
6092034|NCT00701805|9704505|FG000|Overall Study|Missed 7 consecutive doses|0
6092035|NCT00701805|9704506|FG001|Overall Study|Missed 7 consecutive doses|1
6092036|NCT00701805|9704507|FG002|Overall Study|Missed 7 consecutive doses|0
6092037|NCT00701805|9704508|FG003|Overall Study|Missed 7 consecutive doses|0
6092038|NCT00701805|9704505|FG000|Overall Study|Admitted to hospital for 2 weeks|0
6092039|NCT00701805|9704506|FG001|Overall Study|Admitted to hospital for 2 weeks|0
6092040|NCT00701805|9704507|FG002|Overall Study|Admitted to hospital for 2 weeks|1
6092041|NCT00701805|9704508|FG003|Overall Study|Admitted to hospital for 2 weeks|0
6092042|NCT00701805|9704505|FG000|Overall Study|Physician decision, change of therapy|0
6092043|NCT00701805|9704506|FG001|Overall Study|Physician decision, change of therapy|0
6092044|NCT00701805|9704507|FG002|Overall Study|Physician decision, change of therapy|0
6092045|NCT00701805|9704508|FG003|Overall Study|Physician decision, change of therapy|1
6092046|NCT00701805|9704505|FG000|Overall Study|Difficult to travel to dialysis site|0
6092047|NCT00701805|9704506|FG001|Overall Study|Difficult to travel to dialysis site|0
6092048|NCT00701805|9704507|FG002|Overall Study|Difficult to travel to dialysis site|1
6092049|NCT00701805|9704508|FG003|Overall Study|Difficult to travel to dialysis site|0
6092050|NCT00701805|9704505|FG000|Overall Study|Resumption criteria were not met|0
6092051|NCT00701805|9704506|FG001|Overall Study|Resumption criteria were not met|1
6092052|NCT00701805|9704507|FG002|Overall Study|Resumption criteria were not met|0
6092053|NCT00701805|9704508|FG003|Overall Study|Resumption criteria were not met|0
6092054|NCT00702052|9704536|FG000|Overall Study|Adverse Event|23
6092055|NCT00702052|9704536|FG000|Overall Study|Disease Progression|30
6092056|NCT00702052|9704536|FG000|Overall Study|Withdrawal by Subject|5
6092057|NCT00702143|9704543|FG000|Overall Study|Lost to Follow-up|0
6092058|NCT00702143|9704544|FG001|Overall Study|Lost to Follow-up|0
6058212|NCT00472030|9658611|FG000|Overall Study|Physician Decision|1
6058213|NCT00472030|9658612|FG001|Overall Study|Physician Decision|0
6058214|NCT00472199|9658639|FG000|Overall Study|Adverse Event|19
6058215|NCT00472199|9658640|FG001|Overall Study|Adverse Event|23
6058216|NCT00472199|9658639|FG000|Overall Study|Lack of Efficacy|4
6058217|NCT00472199|9658640|FG001|Overall Study|Lack of Efficacy|25
6058218|NCT00472199|9658639|FG000|Overall Study|Lost to Follow-up|2
6058219|NCT00472199|9658640|FG001|Overall Study|Lost to Follow-up|4
6058220|NCT00472199|9658639|FG000|Overall Study|Protocol Violation|3
6058221|NCT00472199|9658640|FG001|Overall Study|Protocol Violation|2
6058222|NCT00472199|9658639|FG000|Overall Study|Withdrawal by Subject|6
6058223|NCT00472199|9658640|FG001|Overall Study|Withdrawal by Subject|5
6058224|NCT00472199|9658639|FG000|Overall Study|personal reason|0
6058225|NCT00472199|9658640|FG001|Overall Study|personal reason|1
6058226|NCT00472199|9658639|FG000|Overall Study|patient was asymptomatic|1
6058227|NCT00472199|9658640|FG001|Overall Study|patient was asymptomatic|0
6058228|NCT00472290|9658646|FG000|Overall Study|Progression of Therapy-Related MDS|1
6058229|NCT00472290|9658646|FG000|Overall Study|Protocol Specified Criteria|7
6058230|NCT00472290|9658646|FG000|Overall Study|Administrative Decision|37
6058231|NCT00472290|9658646|FG000|Overall Study|Death|3
6058232|NCT00472290|9658646|FG000|Overall Study|Lost to Follow-up|1
6058233|NCT00472290|9658646|FG000|Overall Study|Lack of Efficacy|1
6058234|NCT00472290|9658646|FG000|Overall Study|Disease Progression|4
6058235|NCT00472290|9658646|FG000|Overall Study|Withdrawal by Subject|5
6058236|NCT00472290|9658646|FG000|Overall Study|Adverse Event|6
6058237|NCT00472290|9658646|FG000|Overall Study|Requirement for alternative therapy|7
6058238|NCT00472303|9658652|FG000|Titration Phase|Adverse Event|22
6092059|NCT00702143|9704545|FG002|Overall Study|Lost to Follow-up|1
6092060|NCT00702208|9704551|FG000|Overall Study|Lost to Follow-up|28
6092061|NCT00702208|9704551|FG000|Overall Study|Did not self-lavage|1
6092062|NCT00702208|9704551|FG000|Overall Study|Unsatisfactory colposcopy|2
6092063|NCT00702221|9704558|FG000|Overall Study|Adverse Event|4
6092064|NCT00702221|9704559|FG001|Overall Study|Adverse Event|3
6092065|NCT00702325|9704574|FG000|Overall Study|Adverse Event|1
6092066|NCT00702325|9704575|FG001|Overall Study|Adverse Event|0
6092067|NCT00702325|9704574|FG000|Overall Study|Withdrawal by Subject|7
6092068|NCT00702325|9704575|FG001|Overall Study|Withdrawal by Subject|7
6092069|NCT00702325|9704574|FG000|Overall Study|Lost to Follow-up|3
6092070|NCT00702325|9704575|FG001|Overall Study|Lost to Follow-up|4
6092071|NCT00702325|9704574|FG000|Overall Study|Incorrect enrollment|5
6092072|NCT00702325|9704575|FG001|Overall Study|Incorrect enrollment|7
6092073|NCT00702325|9704574|FG000|Overall Study|Developed study discontinuation criteria|18
6092074|NCT00702325|9704575|FG001|Overall Study|Developed study discontinuation criteria|28
6058239|NCT00472303|9658653|FG001|Titration Phase|Adverse Event|12
6058240|NCT00472303|9658654|FG002|Titration Phase|Adverse Event|0
6058241|NCT00472303|9658652|FG000|Titration Phase|Death|4
6058242|NCT00472303|9658653|FG001|Titration Phase|Death|2
6058243|NCT00472303|9658654|FG002|Titration Phase|Death|0
6058244|NCT00472303|9658652|FG000|Titration Phase|Lack of Efficacy|10
6058245|NCT00472303|9658653|FG001|Titration Phase|Lack of Efficacy|0
6058246|NCT00472303|9658654|FG002|Titration Phase|Lack of Efficacy|0
6058247|NCT00472303|9658652|FG000|Titration Phase|Withdrawal by Subject|16
6058248|NCT00472303|9658653|FG001|Titration Phase|Withdrawal by Subject|13
6058249|NCT00472303|9658654|FG002|Titration Phase|Withdrawal by Subject|0
6058250|NCT00472303|9658652|FG000|Titration Phase|Trial Medication non-compliant|4
6058251|NCT00472303|9658653|FG001|Titration Phase|Trial Medication non-compliant|1
6058252|NCT00472303|9658654|FG002|Titration Phase|Trial Medication non-compliant|0
6058253|NCT00472303|9658652|FG000|Titration Phase|Other|3
6058254|NCT00472303|9658653|FG001|Titration Phase|Other|1
6058255|NCT00472303|9658654|FG002|Titration Phase|Other|0
6058256|NCT00472303|9658652|FG000|Discontinuations After Titration Phase|Adverse Event|6
6058257|NCT00472303|9658653|FG001|Discontinuations After Titration Phase|Adverse Event|0
6058258|NCT00472303|9658654|FG002|Discontinuations After Titration Phase|Adverse Event|0
6058259|NCT00472303|9658652|FG000|Discontinuations After Titration Phase|Lack of Efficacy|48
6058260|NCT00472303|9658653|FG001|Discontinuations After Titration Phase|Lack of Efficacy|17
6058261|NCT00472303|9658654|FG002|Discontinuations After Titration Phase|Lack of Efficacy|0
6058262|NCT00472303|9658652|FG000|Discontinuations After Titration Phase|Withdrawal by Subject|2
6092075|NCT00702325|9704574|FG000|Overall Study|Severe noncompliance to protocol|3
6092076|NCT00702325|9704575|FG001|Overall Study|Severe noncompliance to protocol|3
6092077|NCT00702325|9704574|FG000|Overall Study|Termination due to lab results|1
6092078|NCT00702325|9704575|FG001|Overall Study|Termination due to lab results|0
6092079|NCT00702325|9704574|FG000|Overall Study|Didn't follow study medication dosage|0
6092080|NCT00702325|9704575|FG001|Overall Study|Didn't follow study medication dosage|2
6092081|NCT00702325|9704574|FG000|Overall Study|Withdrew consent|0
6092082|NCT00702325|9704575|FG001|Overall Study|Withdrew consent|1
6092083|NCT00702325|9704574|FG000|Overall Study|Incorrectly Discontinued|0
6092084|NCT00702325|9704575|FG001|Overall Study|Incorrectly Discontinued|1
6092085|NCT00702403|9704599|FG000|From Consent to Engraftment|Progressive leukemia|6
6092086|NCT00702403|9704599|FG000|From Consent to Engraftment|Critically ill|2
6092087|NCT00702403|9704599|FG000|From Consent to Engraftment|Corrected QT interval (QTc) >450 msec|2
6092088|NCT00702403|9704599|FG000|From Consent to Engraftment|Myocardial infarction|1
6058263|NCT00472303|9658653|FG001|Discontinuations After Titration Phase|Withdrawal by Subject|2
6058264|NCT00472303|9658654|FG002|Discontinuations After Titration Phase|Withdrawal by Subject|0
6058265|NCT00472303|9658652|FG000|Discontinuations After Titration Phase|Trial Medication non-compliant|0
6058266|NCT00472303|9658653|FG001|Discontinuations After Titration Phase|Trial Medication non-compliant|1
6092089|NCT00702403|9704599|FG000|From Consent to Engraftment|ANC<1500, plts<20K or hyperbilirubinemia|4
6058267|NCT00472303|9658654|FG002|Discontinuations After Titration Phase|Trial Medication non-compliant|0
6058268|NCT00472303|9658652|FG000|Discontinuations After Titration Phase|Other|5
6058269|NCT00472303|9658653|FG001|Discontinuations After Titration Phase|Other|0
6058270|NCT00472303|9658654|FG002|Discontinuations After Titration Phase|Other|0
6058271|NCT00472303|9658652|FG000|Maintenance Phase|Adverse Event|5
6058272|NCT00472303|9658653|FG001|Maintenance Phase|Adverse Event|6
6058273|NCT00472303|9658654|FG002|Maintenance Phase|Adverse Event|6
6058274|NCT00472303|9658652|FG000|Maintenance Phase|Death|3
6058275|NCT00472303|9658653|FG001|Maintenance Phase|Death|0
6058276|NCT00472303|9658654|FG002|Maintenance Phase|Death|2
6058277|NCT00472303|9658652|FG000|Maintenance Phase|Lack of Efficacy|2
6058278|NCT00472303|9658653|FG001|Maintenance Phase|Lack of Efficacy|2
6058279|NCT00472303|9658654|FG002|Maintenance Phase|Lack of Efficacy|4
6058280|NCT00472303|9658652|FG000|Maintenance Phase|Withdrawal by Subject|6
6058281|NCT00472303|9658653|FG001|Maintenance Phase|Withdrawal by Subject|7
6058282|NCT00472303|9658654|FG002|Maintenance Phase|Withdrawal by Subject|3
6058283|NCT00472303|9658652|FG000|Maintenance Phase|Trial medication non-compliant|0
6058284|NCT00472303|9658653|FG001|Maintenance Phase|Trial medication non-compliant|0
6058285|NCT00472303|9658654|FG002|Maintenance Phase|Trial medication non-compliant|1
6058286|NCT00472303|9658652|FG000|Maintenance Phase|Resolution of pain|0
6058287|NCT00472303|9658653|FG001|Maintenance Phase|Resolution of pain|0
6058288|NCT00472303|9658654|FG002|Maintenance Phase|Resolution of pain|1
6058289|NCT00472303|9658652|FG000|Maintenance Phase|Other|1
6092090|NCT00702403|9704599|FG000|From Consent to Engraftment|Miscellaneous (unanticipated) other|2
6092091|NCT00702403|9704599|FG000|From Engraftment to Study Completion|Failed pre-1st dose criteria|11
6092092|NCT00702403|9704599|FG000|From Engraftment to Study Completion|Relapse (1 Central Nervous System, 3 BM)|4
6092093|NCT00702403|9704599|FG000|From Engraftment to Study Completion|Non-compliance|2
6092094|NCT00702403|9704599|FG000|From Engraftment to Study Completion|Adenocarcinoma|1
6092095|NCT00702403|9704599|FG000|From Engraftment to Study Completion|Liver GVHD|1
6092096|NCT00702403|9704599|FG000|From Engraftment to Study Completion|Suicide|1
6092097|NCT00702403|9704599|FG000|From Engraftment to Study Completion|Acute respiratory distress syndrome|1
6092098|NCT00702403|9704599|FG000|From Engraftment to Study Completion|Dyspnea (unrelated to nilotinib)|1
6092099|NCT00702403|9704599|FG000|From Engraftment to Study Completion|Toxicity attributed to Nilotinib|5
6092100|NCT00702507|9704615|FG000|Initial Treatment Phase|Adverse Event|2
6092101|NCT00702507|9704615|FG000|Initial Treatment Phase|Participant's Caretaker Withdrew Consent|3
6092102|NCT00702507|9704615|FG000|Initial Treatment Phase|Lost to Follow-up|2
6092103|NCT00702507|9704615|FG000|Initial Treatment Phase|Negative Candida Culture|34
6092104|NCT00702507|9704615|FG000|Follow-up Phase|Participant's Caretaker Withdrew Consent|1
6092105|NCT00702507|9704615|FG000|Follow-up Phase|Protocol Violation|2
6092106|NCT00702507|9704615|FG000|Follow-up Phase|Lost to Follow-up|23
6092107|NCT00702507|9704615|FG000|Follow-up Phase|Late Enrollment|1
6092108|NCT00702650|9704620|FG000|Overall Study|Withdrawal by Subject|9
6092109|NCT00702650|9704620|FG000|Overall Study|Non-Compliance of Study Drug|3
6092110|NCT00702650|9704620|FG000|Overall Study|Lost to Follow-up|2
6092111|NCT00702650|9704620|FG000|Overall Study|Non-Compliance with Site Directives|1
6092112|NCT00702650|9704620|FG000|Overall Study|Sponsor Request|1
6092113|NCT00702650|9704620|FG000|Overall Study|Screening Testosterone Levels >300 ng/dL|1
6092114|NCT00702650|9704620|FG000|Overall Study|Adverse Event|3
6092115|NCT00702689|9704624|FG000|Overall Study|Withdrawal by Subject|4
6092116|NCT00702689|9704624|FG000|Overall Study|Recurrent malignancy|1
6092117|NCT00702689|9704624|FG000|Overall Study|Adverse Event|1
6092118|NCT00702715|9704630|FG000|Overall Study|Lost to Follow-up|1
6092119|NCT00702715|9704631|FG001|Overall Study|Lost to Follow-up|0
6092120|NCT00702923|9704657|FG000|Overall Study|Adverse Event|1
6092121|NCT00702949|9704665|FG000|Overall Study|Refusal|3
6092122|NCT00702949|9704666|FG001|Overall Study|Refusal|2
6092123|NCT00702949|9704667|FG002|Overall Study|Refusal|2
6092124|NCT00702949|9704665|FG000|Overall Study|Adverse Event|1
6092125|NCT00702949|9704666|FG001|Overall Study|Adverse Event|6
6092126|NCT00702949|9704667|FG002|Overall Study|Adverse Event|3
6092127|NCT00702949|9704665|FG000|Overall Study|Other Medical Reason/unknown|1
6092128|NCT00702949|9704666|FG001|Overall Study|Other Medical Reason/unknown|1
6092129|NCT00702949|9704667|FG002|Overall Study|Other Medical Reason/unknown|3
6092130|NCT00703118|9704719|FG000|Overall Study|Adverse Event|1
6092131|NCT00703118|9704720|FG001|Overall Study|Adverse Event|2
6092132|NCT00703118|9704721|FG002|Overall Study|Adverse Event|2
6092133|NCT00703118|9704719|FG000|Overall Study|Subject Ineligible To Continue The Trial|6
6092134|NCT00703118|9704720|FG001|Overall Study|Subject Ineligible To Continue The Trial|3
6092135|NCT00703118|9704721|FG002|Overall Study|Subject Ineligible To Continue The Trial|2
6092136|NCT00703118|9704719|FG000|Overall Study|Lost to Follow-up|6
6092137|NCT00703118|9704720|FG001|Overall Study|Lost to Follow-up|4
6092138|NCT00703118|9704721|FG002|Overall Study|Lost to Follow-up|4
6092139|NCT00703118|9704719|FG000|Overall Study|Withdrawal by Subject|8
6092140|NCT00703118|9704720|FG001|Overall Study|Withdrawal by Subject|7
6092141|NCT00703118|9704721|FG002|Overall Study|Withdrawal by Subject|13
6092142|NCT00703118|9704719|FG000|Overall Study|Other|0
6092143|NCT00703118|9704720|FG001|Overall Study|Other|0
6092144|NCT00703118|9704721|FG002|Overall Study|Other|1
6092145|NCT00703157|9704734|FG000|Overall Study|Lost to Follow-up|0
6092146|NCT00703157|9704735|FG001|Overall Study|Lost to Follow-up|1
6058290|NCT00472303|9658653|FG001|Maintenance Phase|Other|1
6058291|NCT00472303|9658654|FG002|Maintenance Phase|Other|0
6058292|NCT00472420|9658682|FG000|Induction Treatment Period|Physician Decision|9
6058293|NCT00472420|9658682|FG000|Induction Treatment Period|Adverse Event|3
6058294|NCT00472420|9658682|FG000|Induction Treatment Period|Non-compliance|1
6058295|NCT00472420|9658682|FG000|Induction Treatment Period|Death|3
6058296|NCT00472420|9658682|FG000|Follow-up Period|Death|5
6058297|NCT00472420|9658682|FG000|Follow-up Period|Physician Decision|9
6058298|NCT00472420|9658682|FG000|Follow-up Period|Lost to Follow-up|2
6092147|NCT00703157|9704734|FG000|Overall Study|source data permanently lost/ other|4
6092148|NCT00703157|9704735|FG001|Overall Study|source data permanently lost/ other|1
6092149|NCT00703677|9704781|FG000|Overall Study|Dropout-withdrawal not related to drug|3
6092150|NCT00703781|9704796|FG000|Overall Study|Withdrawal by Subject|1
6092151|NCT00703781|9704797|FG001|Overall Study|Withdrawal by Subject|2
6202531|NCT01502956|9862756|FG001|Overall Study|Withdrawal by Subject|10
6202532|NCT01503021|9862764|FG000|Overall Study|Adverse Event|7
6202533|NCT01503021|9862765|FG001|Overall Study|Adverse Event|6
5980376|NCT03416179|9569160|FG000|Overall Study|Death|67
6092152|NCT00703781|9704796|FG000|Overall Study|Cancelled surgery|1
6092153|NCT00703781|9704797|FG001|Overall Study|Cancelled surgery|0
6092154|NCT00703820|9704805|FG000|Overall Study|Adverse Event|12
6092155|NCT00703820|9704806|FG001|Overall Study|Adverse Event|17
6092156|NCT00703820|9704805|FG000|Overall Study|Death|5
6092157|NCT00703820|9704806|FG001|Overall Study|Death|0
6092158|NCT00703820|9704805|FG000|Overall Study|Lack of Efficacy|11
6092159|NCT00703820|9704806|FG001|Overall Study|Lack of Efficacy|11
6092160|NCT00703820|9704805|FG000|Overall Study|Received non-protocol therapy|1
6092161|NCT00703820|9704806|FG001|Overall Study|Received non-protocol therapy|0
6092162|NCT00703820|9704805|FG000|Overall Study|Physician Decision|4
6092163|NCT00703820|9704806|FG001|Overall Study|Physician Decision|5
6092164|NCT00703820|9704805|FG000|Overall Study|Withdrawal by Subject|2
6092165|NCT00703820|9704806|FG001|Overall Study|Withdrawal by Subject|1
6092166|NCT00703846|9704814|FG000|Overall Study|Adverse Event|8
6092167|NCT00703846|9704814|FG000|Overall Study|Lost to Follow-up|55
6092168|NCT00703846|9704814|FG000|Overall Study|Lack of Efficacy|15
6092169|NCT00703846|9704814|FG000|Overall Study|Noncompliance with Study Treatment|2
6092170|NCT00703846|9704814|FG000|Overall Study|Withdrawal by Subject|40
6092171|NCT00703846|9704814|FG000|Overall Study|Death|1
6092172|NCT00703846|9704814|FG000|Overall Study|Other|14
6092173|NCT00703846|9704814|FG000|Overall Study|Did Not Receive Study Drug|2
6092174|NCT00703911|9704818|FG000|Overall Study|Death|1
6092175|NCT00703911|9704818|FG000|Overall Study|Physician Decision|6
6092176|NCT00703911|9704818|FG000|Overall Study|Lost to Follow-up|1
6092177|NCT00703911|9704818|FG000|Overall Study|Withdrawal by Subject|2
6092178|NCT00703924|9704824|FG000|Overall Study|Withdrawal by Subject|1
6092179|NCT00703924|9704825|FG001|Overall Study|Withdrawal by Subject|1
6092180|NCT00703963|9704846|FG000|Overall Study|Withdrawal by Subject|7
6092181|NCT00703963|9704847|FG001|Overall Study|Withdrawal by Subject|13
6092182|NCT00703963|9704846|FG000|Overall Study|Physician Decision|0
6092183|NCT00703963|9704847|FG001|Overall Study|Physician Decision|1
6092184|NCT00704132|9704875|FG000|Overall Study|Clinical Adverse Experience|1
6092185|NCT00704132|9704876|FG001|Overall Study|Clinical Adverse Experience|0
6092186|NCT00704132|9704875|FG000|Overall Study|Lack of Efficacy|0
6092187|NCT00704132|9704876|FG001|Overall Study|Lack of Efficacy|1
6092188|NCT00704132|9704875|FG000|Overall Study|Withdrawal by Subject|0
6092189|NCT00704132|9704876|FG001|Overall Study|Withdrawal by Subject|1
6092190|NCT00704171|9704884|FG000|Overall Study|Withdrawal by Subject|1
6092191|NCT00704171|9704885|FG001|Overall Study|Withdrawal by Subject|0
6092192|NCT00704184|9704896|FG000|Double-Blind Treatment|Withdrawal by Subject|1
6092193|NCT00704184|9704897|FG001|Double-Blind Treatment|Withdrawal by Subject|0
6092194|NCT00704184|9704898|FG002|Double-Blind Treatment|Withdrawal by Subject|0
6092195|NCT00704184|9704899|FG003|Double-Blind Treatment|Withdrawal by Subject|0
6092196|NCT00704184|9704900|FG004|Double-Blind Treatment|Withdrawal by Subject|0
6092197|NCT00704184|9704896|FG000|Open-Label Treatment|Adverse Event|0
6092198|NCT00704184|9704897|FG001|Open-Label Treatment|Adverse Event|0
6092199|NCT00704184|9704898|FG002|Open-Label Treatment|Adverse Event|2
6092200|NCT00704184|9704899|FG003|Open-Label Treatment|Adverse Event|0
6092201|NCT00704184|9704900|FG004|Open-Label Treatment|Adverse Event|1
6092202|NCT00704184|9704896|FG000|Open-Label Treatment|Lack of Efficacy|0
6092203|NCT00704184|9704897|FG001|Open-Label Treatment|Lack of Efficacy|2
5980377|NCT03416179|9569161|FG001|Overall Study|Death|60
5980378|NCT03416179|9569162|FG002|Overall Study|Death|96
5980379|NCT03416179|9569163|FG003|Overall Study|Death|88
5980380|NCT03416179|9569160|FG000|Overall Study|Withdrawal by Subject|13
5980381|NCT03416179|9569161|FG001|Overall Study|Withdrawal by Subject|19
5980382|NCT03416179|9569162|FG002|Overall Study|Withdrawal by Subject|5
5980383|NCT03416179|9569163|FG003|Overall Study|Withdrawal by Subject|6
5980384|NCT03416179|9569160|FG000|Overall Study|Ongoing|121
5980385|NCT03416179|9569161|FG001|Overall Study|Ongoing|123
5980386|NCT03416179|9569162|FG002|Overall Study|Ongoing|62
5980387|NCT03416179|9569163|FG003|Overall Study|Ongoing|66
5980388|NCT03416179|9569160|FG000|Overall Study|Lost to Follow-up|0
5980389|NCT03416179|9569161|FG001|Overall Study|Lost to Follow-up|0
5980390|NCT03416179|9569162|FG002|Overall Study|Lost to Follow-up|0
6058299|NCT00472420|9658682|FG000|Follow-up Period|Protocol Violation|1
6058300|NCT00472446|9658690|FG000|Overall Study|Protocol Violation|0
6058301|NCT00472446|9658691|FG001|Overall Study|Protocol Violation|0
6058302|NCT00472446|9658692|FG002|Overall Study|Protocol Violation|0
6058303|NCT00472446|9658693|FG003|Overall Study|Protocol Violation|1
6058304|NCT00472446|9658690|FG000|Overall Study|Reintervention|0
6058305|NCT00472446|9658691|FG001|Overall Study|Reintervention|0
6058306|NCT00472446|9658692|FG002|Overall Study|Reintervention|1
6058307|NCT00472446|9658693|FG003|Overall Study|Reintervention|1
6058308|NCT00472446|9658690|FG000|Overall Study|Questionnaires not returned|5
6058309|NCT00472446|9658691|FG001|Overall Study|Questionnaires not returned|6
6058310|NCT00472446|9658692|FG002|Overall Study|Questionnaires not returned|6
6058311|NCT00472446|9658693|FG003|Overall Study|Questionnaires not returned|4
6058312|NCT00472641|9658712|FG000|Overall Study|Lack of Efficacy|3
6058313|NCT00472641|9658712|FG000|Overall Study|Adverse Event|3
6058314|NCT00472641|9658712|FG000|Overall Study|Lost to Follow-up|1
6058315|NCT00473083|9658749|FG000|Overall Study|Adverse Event|1
6058316|NCT00473083|9658750|FG001|Overall Study|Adverse Event|0
6058317|NCT00473083|9658751|FG002|Overall Study|Adverse Event|0
6058318|NCT00473265|9658762|FG000|Overall Study|Unrelated adverse event|5
6058319|NCT00473265|9658762|FG000|Overall Study|Off treatment early|15
6058320|NCT00473330|9658769|FG000|Core Study|Adverse Event|4
6058321|NCT00473330|9658770|FG001|Core Study|Adverse Event|4
6058322|NCT00473330|9658771|FG002|Core Study|Adverse Event|1
6058323|NCT00473330|9658769|FG000|Core Study|Death|6
6058324|NCT00473330|9658770|FG001|Core Study|Death|4
6058325|NCT00473330|9658771|FG002|Core Study|Death|4
6058326|NCT00473330|9658769|FG000|Core Study|Lost to Follow-up|5
6058327|NCT00473330|9658770|FG001|Core Study|Lost to Follow-up|5
6058328|NCT00473330|9658771|FG002|Core Study|Lost to Follow-up|10
6058329|NCT00473330|9658769|FG000|Core Study|Physician Decision|2
6058330|NCT00473330|9658770|FG001|Core Study|Physician Decision|1
6058331|NCT00473330|9658771|FG002|Core Study|Physician Decision|3
6058332|NCT00473330|9658769|FG000|Core Study|Subject Non-compliance|1
6058333|NCT00473330|9658770|FG001|Core Study|Subject Non-compliance|2
6058334|NCT00473330|9658771|FG002|Core Study|Subject Non-compliance|1
6058335|NCT00473330|9658769|FG000|Core Study|Subject Required Other Therapy|0
6058336|NCT00473330|9658770|FG001|Core Study|Subject Required Other Therapy|1
6058337|NCT00473330|9658771|FG002|Core Study|Subject Required Other Therapy|3
6058338|NCT00473330|9658769|FG000|Core Study|Subject's Decision|9
6058339|NCT00473330|9658770|FG001|Core Study|Subject's Decision|8
6058340|NCT00473330|9658771|FG002|Core Study|Subject's Decision|19
6058341|NCT00473330|9658769|FG000|Open-label Extension Through Month 48|Adverse Event|0
6058342|NCT00473330|9658770|FG001|Open-label Extension Through Month 48|Adverse Event|0
6058343|NCT00473330|9658771|FG002|Open-label Extension Through Month 48|Adverse Event|2
6058344|NCT00473330|9658769|FG000|Open-label Extension Through Month 48|Death|2
6058345|NCT00473330|9658770|FG001|Open-label Extension Through Month 48|Death|0
6058346|NCT00473330|9658771|FG002|Open-label Extension Through Month 48|Death|0
6058347|NCT00473330|9658769|FG000|Open-label Extension Through Month 48|Lost to Follow-up|1
6058348|NCT00473330|9658770|FG001|Open-label Extension Through Month 48|Lost to Follow-up|0
6058349|NCT00473330|9658771|FG002|Open-label Extension Through Month 48|Lost to Follow-up|2
6058350|NCT00473330|9658769|FG000|Open-label Extension Through Month 48|Physician's Decision|2
6058351|NCT00473330|9658770|FG001|Open-label Extension Through Month 48|Physician's Decision|1
6058352|NCT00473330|9658771|FG002|Open-label Extension Through Month 48|Physician's Decision|3
6058353|NCT00473330|9658769|FG000|Open-label Extension Through Month 48|Subject's Decision|1
6058354|NCT00473330|9658770|FG001|Open-label Extension Through Month 48|Subject's Decision|3
6058355|NCT00473330|9658771|FG002|Open-label Extension Through Month 48|Subject's Decision|3
6058356|NCT00473330|9658769|FG000|Open-label Extension Through Month 48|Sponsor's Decision to Terminate Study|18
6058357|NCT00473330|9658770|FG001|Open-label Extension Through Month 48|Sponsor's Decision to Terminate Study|15
6058358|NCT00473330|9658771|FG002|Open-label Extension Through Month 48|Sponsor's Decision to Terminate Study|16
6058359|NCT00473330|9658769|FG000|Open-label Extension Through Month 48|Subject Non-compliance|2
6058360|NCT00473330|9658770|FG001|Open-label Extension Through Month 48|Subject Non-compliance|1
6058361|NCT00473330|9658771|FG002|Open-label Extension Through Month 48|Subject Non-compliance|0
6058362|NCT00473330|9658769|FG000|Open-label Extension Through Month 48|Subject Required Other Therapy|0
6058363|NCT00473330|9658770|FG001|Open-label Extension Through Month 48|Subject Required Other Therapy|0
6058364|NCT00473330|9658771|FG002|Open-label Extension Through Month 48|Subject Required Other Therapy|1
6058365|NCT00473330|9658769|FG000|Open-label Extension Through Month 60|Adverse Event|0
6058366|NCT00473330|9658770|FG001|Open-label Extension Through Month 60|Adverse Event|0
6058367|NCT00473330|9658771|FG002|Open-label Extension Through Month 60|Adverse Event|2
6058368|NCT00473330|9658769|FG000|Open-label Extension Through Month 60|Death|2
6058369|NCT00473330|9658770|FG001|Open-label Extension Through Month 60|Death|2
6058370|NCT00473330|9658771|FG002|Open-label Extension Through Month 60|Death|1
6058371|NCT00473330|9658769|FG000|Open-label Extension Through Month 60|Lost to Follow-up|3
6058372|NCT00473330|9658770|FG001|Open-label Extension Through Month 60|Lost to Follow-up|0
6058373|NCT00473330|9658771|FG002|Open-label Extension Through Month 60|Lost to Follow-up|4
6058374|NCT00473330|9658769|FG000|Open-label Extension Through Month 60|Physician's Decision|2
6058375|NCT00473330|9658770|FG001|Open-label Extension Through Month 60|Physician's Decision|1
6058376|NCT00473330|9658771|FG002|Open-label Extension Through Month 60|Physician's Decision|3
6058377|NCT00473330|9658769|FG000|Open-label Extension Through Month 60|Subject's Decision|1
6058378|NCT00473330|9658770|FG001|Open-label Extension Through Month 60|Subject's Decision|3
6058379|NCT00473330|9658771|FG002|Open-label Extension Through Month 60|Subject's Decision|4
6058380|NCT00473330|9658769|FG000|Open-label Extension Through Month 60|Sponsor's Decision to Terminate Study|77
6058381|NCT00473330|9658770|FG001|Open-label Extension Through Month 60|Sponsor's Decision to Terminate Study|71
6058382|NCT00473330|9658771|FG002|Open-label Extension Through Month 60|Sponsor's Decision to Terminate Study|62
6058383|NCT00473330|9658769|FG000|Open-label Extension Through Month 60|Subject Non-compliance|2
6058384|NCT00473330|9658770|FG001|Open-label Extension Through Month 60|Subject Non-compliance|1
6058385|NCT00473330|9658771|FG002|Open-label Extension Through Month 60|Subject Non-compliance|0
6058386|NCT00473330|9658769|FG000|Open-label Extension Through Month 60|Subject Required Other Therapy|1
6058387|NCT00473330|9658770|FG001|Open-label Extension Through Month 60|Subject Required Other Therapy|0
6058388|NCT00473330|9658771|FG002|Open-label Extension Through Month 60|Subject Required Other Therapy|1
6058389|NCT00473382|9658802|FG000|Core Study|Adverse Event|3
6058390|NCT00473382|9658803|FG001|Core Study|Adverse Event|1
6058391|NCT00473382|9658804|FG002|Core Study|Adverse Event|1
6058392|NCT00473382|9658802|FG000|Core Study|Death|3
6058393|NCT00473382|9658803|FG001|Core Study|Death|5
6058394|NCT00473382|9658804|FG002|Core Study|Death|10
6058395|NCT00473382|9658802|FG000|Core Study|Lost to Follow-up|3
6058396|NCT00473382|9658803|FG001|Core Study|Lost to Follow-up|3
6058397|NCT00473382|9658804|FG002|Core Study|Lost to Follow-up|3
6058398|NCT00473382|9658802|FG000|Core Study|Physician Decision|1
6058399|NCT00473382|9658803|FG001|Core Study|Physician Decision|2
6058400|NCT00473382|9658804|FG002|Core Study|Physician Decision|2
6058401|NCT00473382|9658802|FG000|Core Study|Subject non-compliance|5
6058402|NCT00473382|9658803|FG001|Core Study|Subject non-compliance|2
6058403|NCT00473382|9658804|FG002|Core Study|Subject non-compliance|1
6058404|NCT00473382|9658802|FG000|Core Study|Subject needed other treatment|1
6058405|NCT00473382|9658803|FG001|Core Study|Subject needed other treatment|3
6058406|NCT00473382|9658804|FG002|Core Study|Subject needed other treatment|2
6058407|NCT00473382|9658802|FG000|Core Study|Subject's decision|12
6058408|NCT00473382|9658803|FG001|Core Study|Subject's decision|11
6058409|NCT00473382|9658804|FG002|Core Study|Subject's decision|10
6058410|NCT00473382|9658802|FG000|Open-label Extension Through Month 48|Adverse Event|0
6058411|NCT00473382|9658803|FG001|Open-label Extension Through Month 48|Adverse Event|0
6058412|NCT00473382|9658804|FG002|Open-label Extension Through Month 48|Adverse Event|1
6058413|NCT00473382|9658802|FG000|Open-label Extension Through Month 48|Death|1
6058414|NCT00473382|9658803|FG001|Open-label Extension Through Month 48|Death|3
6058415|NCT00473382|9658804|FG002|Open-label Extension Through Month 48|Death|3
6058416|NCT00473382|9658802|FG000|Open-label Extension Through Month 48|Lost to Follow-up|1
6058417|NCT00473382|9658803|FG001|Open-label Extension Through Month 48|Lost to Follow-up|2
6058418|NCT00473382|9658804|FG002|Open-label Extension Through Month 48|Lost to Follow-up|1
6058419|NCT00473382|9658802|FG000|Open-label Extension Through Month 48|Subject's Decision|5
6058420|NCT00473382|9658803|FG001|Open-label Extension Through Month 48|Subject's Decision|1
6058421|NCT00473382|9658804|FG002|Open-label Extension Through Month 48|Subject's Decision|6
6058422|NCT00473382|9658802|FG000|Open-label Extension Through Month 48|Sponsor's Decision to Terminate Study|41
6058423|NCT00473382|9658803|FG001|Open-label Extension Through Month 48|Sponsor's Decision to Terminate Study|34
6058424|NCT00473382|9658804|FG002|Open-label Extension Through Month 48|Sponsor's Decision to Terminate Study|36
6058425|NCT00473382|9658802|FG000|Open-label Extension Through Month 48|Subject Required Other Intervention|2
6058426|NCT00473382|9658803|FG001|Open-label Extension Through Month 48|Subject Required Other Intervention|1
6058427|NCT00473382|9658804|FG002|Open-label Extension Through Month 48|Subject Required Other Intervention|0
6058428|NCT00473382|9658802|FG000|Open-label Extension Through Month 60|Adverse Event|0
6058429|NCT00473382|9658803|FG001|Open-label Extension Through Month 60|Adverse Event|0
6058430|NCT00473382|9658804|FG002|Open-label Extension Through Month 60|Adverse Event|2
6058431|NCT00473382|9658802|FG000|Open-label Extension Through Month 60|Death|1
6058432|NCT00473382|9658803|FG001|Open-label Extension Through Month 60|Death|7
6058433|NCT00473382|9658804|FG002|Open-label Extension Through Month 60|Death|4
6058434|NCT00473382|9658802|FG000|Open-label Extension Through Month 60|Lost to Follow-up|1
6058435|NCT00473382|9658803|FG001|Open-label Extension Through Month 60|Lost to Follow-up|3
6058436|NCT00473382|9658804|FG002|Open-label Extension Through Month 60|Lost to Follow-up|1
6202534|NCT01503021|9862764|FG000|Overall Study|Death|0
6202535|NCT01503021|9862765|FG001|Overall Study|Death|2
6202536|NCT01503021|9862764|FG000|Overall Study|Lost to Follow-up|2
6058437|NCT00473382|9658802|FG000|Open-label Extension Through Month 60|Subject's Decision|7
6058438|NCT00473382|9658803|FG001|Open-label Extension Through Month 60|Subject's Decision|1
6058439|NCT00473382|9658804|FG002|Open-label Extension Through Month 60|Subject's Decision|6
6058440|NCT00473382|9658802|FG000|Open-label Extension Through Month 60|Sponsor's Decision to Terminate Study|75
6058441|NCT00473382|9658803|FG001|Open-label Extension Through Month 60|Sponsor's Decision to Terminate Study|70
6058442|NCT00473382|9658804|FG002|Open-label Extension Through Month 60|Sponsor's Decision to Terminate Study|69
6058443|NCT00473382|9658802|FG000|Open-label Extension Through Month 60|Subject Required Other Intervention|2
6092204|NCT00704184|9704898|FG002|Open-Label Treatment|Lack of Efficacy|2
6202537|NCT01503021|9862765|FG001|Overall Study|Lost to Follow-up|0
6058444|NCT00473382|9658803|FG001|Open-label Extension Through Month 60|Subject Required Other Intervention|1
6058445|NCT00473382|9658804|FG002|Open-label Extension Through Month 60|Subject Required Other Intervention|0
6058446|NCT00473434|9658830|FG000|Overall Study|Physician Decision|3
6058447|NCT00473434|9658830|FG000|Overall Study|Withdrawal by Subject|9
6058448|NCT00473434|9658830|FG000|Overall Study|Compliance|3
6058449|NCT00473434|9658830|FG000|Overall Study|Lack of Efficacy|3
6058450|NCT00473434|9658830|FG000|Overall Study|Adverse Event|3
6058451|NCT00473434|9658830|FG000|Overall Study|Patient was selling medication to others|1
6058452|NCT00473434|9658830|FG000|Overall Study|Safety evaluation|1
6058453|NCT00473434|9658830|FG000|Overall Study|Reason not specified|6
6058454|NCT00473434|9658830|FG000|Overall Study|Ceased in favor of Paliperidone|1
6058455|NCT00473434|9658830|FG000|Overall Study|Switching to trial medication|1
6058456|NCT00473434|9658830|FG000|Overall Study|No longer required|1
6058457|NCT00473512|9658852|FG000|Period 1 (Phase 1)|Adverse Event|0
6058458|NCT00473512|9658853|FG001|Period 1 (Phase 1)|Adverse Event|0
6058459|NCT00473512|9658854|FG002|Period 1 (Phase 1)|Adverse Event|0
6058460|NCT00473512|9658855|FG003|Period 1 (Phase 1)|Adverse Event|5
6058461|NCT00473512|9658856|FG004|Period 1 (Phase 1)|Adverse Event|0
6058462|NCT00473512|9658852|FG000|Period 1 (Phase 1)|Death|0
6058463|NCT00473512|9658853|FG001|Period 1 (Phase 1)|Death|0
6058464|NCT00473512|9658854|FG002|Period 1 (Phase 1)|Death|0
6058465|NCT00473512|9658855|FG003|Period 1 (Phase 1)|Death|1
6058466|NCT00473512|9658856|FG004|Period 1 (Phase 1)|Death|0
6058467|NCT00473512|9658852|FG000|Period 1 (Phase 1)|Disease Progression|1
6058468|NCT00473512|9658853|FG001|Period 1 (Phase 1)|Disease Progression|1
6058469|NCT00473512|9658854|FG002|Period 1 (Phase 1)|Disease Progression|0
6058470|NCT00473512|9658855|FG003|Period 1 (Phase 1)|Disease Progression|10
6202538|NCT01503021|9862764|FG000|Overall Study|Physician Decision|3
6202539|NCT01503021|9862765|FG001|Overall Study|Physician Decision|0
6202540|NCT01503021|9862764|FG000|Overall Study|Protocol Violation|1
6202541|NCT01503021|9862765|FG001|Overall Study|Protocol Violation|3
6202542|NCT01503021|9862764|FG000|Overall Study|Withdrawal by Subject|9
6202543|NCT01503021|9862765|FG001|Overall Study|Withdrawal by Subject|8
6202544|NCT01503021|9862764|FG000|Overall Study|Moved, received transplant, etc.|5
6202545|NCT01503021|9862765|FG001|Overall Study|Moved, received transplant, etc.|7
6202546|NCT01503164|9862778|FG000|Overall Study|Withdrawal by Subject|2
6202547|NCT01503164|9862779|FG001|Overall Study|Withdrawal by Subject|1
6202548|NCT01503229|9862785|FG000|Overall Study|Withdrew consent|1
6202549|NCT01504204|9862821|FG000|Overall Study|Lost to Follow-up|1
6202550|NCT01504204|9862822|FG001|Overall Study|Lost to Follow-up|1
6202551|NCT01504412|9862833|FG000|Overall Study|Adverse Event|1
6202552|NCT01504412|9862834|FG001|Overall Study|Adverse Event|8
6202553|NCT01504412|9862835|FG002|Overall Study|Adverse Event|1
6202554|NCT01504412|9862836|FG003|Overall Study|Adverse Event|7
6202555|NCT01504412|9862837|FG004|Overall Study|Adverse Event|10
6202556|NCT01504412|9862833|FG000|Overall Study|Withdrawal by Subject|2
6202557|NCT01504412|9862834|FG001|Overall Study|Withdrawal by Subject|1
6202558|NCT01504412|9862835|FG002|Overall Study|Withdrawal by Subject|1
6202559|NCT01504412|9862836|FG003|Overall Study|Withdrawal by Subject|5
6202560|NCT01504412|9862837|FG004|Overall Study|Withdrawal by Subject|1
6202561|NCT01504412|9862833|FG000|Overall Study|Other|2
6202562|NCT01504412|9862834|FG001|Overall Study|Other|1
6202563|NCT01504412|9862835|FG002|Overall Study|Other|1
6202564|NCT01504412|9862836|FG003|Overall Study|Other|6
6202565|NCT01504412|9862837|FG004|Overall Study|Other|1
6202566|NCT01504412|9862833|FG000|Overall Study|Lost to Follow-up|0
6202567|NCT01504412|9862834|FG001|Overall Study|Lost to Follow-up|2
6202568|NCT01504412|9862835|FG002|Overall Study|Lost to Follow-up|0
6202569|NCT01504412|9862836|FG003|Overall Study|Lost to Follow-up|0
6202570|NCT01504412|9862837|FG004|Overall Study|Lost to Follow-up|0
6202571|NCT01504412|9862833|FG000|Overall Study|Lack of Efficacy|0
6202572|NCT01504412|9862834|FG001|Overall Study|Lack of Efficacy|0
6202573|NCT01504412|9862835|FG002|Overall Study|Lack of Efficacy|1
5980391|NCT03416179|9569163|FG003|Overall Study|Lost to Follow-up|2
5980392|NCT03416179|9569160|FG000|Overall Study|Other|0
5980393|NCT03416179|9569161|FG001|Overall Study|Other|1
6202574|NCT01504412|9862836|FG003|Overall Study|Lack of Efficacy|0
6202575|NCT01504412|9862837|FG004|Overall Study|Lack of Efficacy|1
5980394|NCT03416179|9569162|FG002|Overall Study|Other|0
5980395|NCT03416179|9569163|FG003|Overall Study|Other|0
5980396|NCT03353922|9569173|FG000|Overall Study|Withdrawal by Subject|1
5980397|NCT03353922|9569174|FG001|Overall Study|Withdrawal by Subject|0
5980398|NCT03353922|9569175|FG002|Overall Study|Withdrawal by Subject|1
5980399|NCT03353922|9569176|FG003|Overall Study|Withdrawal by Subject|1
5980400|NCT03353922|9569177|FG004|Overall Study|Withdrawal by Subject|0
5980401|NCT03353922|9569178|FG005|Overall Study|Withdrawal by Subject|0
5980402|NCT03353922|9569173|FG000|Overall Study|Adverse Event|0
5980403|NCT03353922|9569174|FG001|Overall Study|Adverse Event|1
5980404|NCT03353922|9569175|FG002|Overall Study|Adverse Event|0
5980405|NCT03353922|9569176|FG003|Overall Study|Adverse Event|0
5980406|NCT03353922|9569177|FG004|Overall Study|Adverse Event|0
5980407|NCT03353922|9569178|FG005|Overall Study|Adverse Event|0
5980408|NCT03173456|9569213|FG000|Baseline|Medication dispensing system malfunction'|0
5980409|NCT03173456|9569214|FG001|Baseline|Medication dispensing system malfunction'|1
5980410|NCT03173456|9569215|FG002|Baseline|Medication dispensing system malfunction'|0
6058471|NCT00473512|9658856|FG004|Period 1 (Phase 1)|Disease Progression|1
6058472|NCT00473512|9658852|FG000|Period 1 (Phase 1)|Other|0
6058473|NCT00473512|9658853|FG001|Period 1 (Phase 1)|Other|0
6058474|NCT00473512|9658854|FG002|Period 1 (Phase 1)|Other|0
6058475|NCT00473512|9658855|FG003|Period 1 (Phase 1)|Other|1
6058476|NCT00473512|9658856|FG004|Period 1 (Phase 1)|Other|0
6058477|NCT00473512|9658852|FG000|Period 2 (Phase 2)|Adverse Event|0
6058478|NCT00473512|9658853|FG001|Period 2 (Phase 2)|Adverse Event|0
6058479|NCT00473512|9658854|FG002|Period 2 (Phase 2)|Adverse Event|0
6058480|NCT00473512|9658855|FG003|Period 2 (Phase 2)|Adverse Event|1
6058481|NCT00473512|9658856|FG004|Period 2 (Phase 2)|Adverse Event|0
6058482|NCT00473512|9658852|FG000|Period 2 (Phase 2)|Death|0
6058483|NCT00473512|9658853|FG001|Period 2 (Phase 2)|Death|0
6058484|NCT00473512|9658854|FG002|Period 2 (Phase 2)|Death|0
6058485|NCT00473512|9658855|FG003|Period 2 (Phase 2)|Death|1
6058486|NCT00473512|9658856|FG004|Period 2 (Phase 2)|Death|1
6058487|NCT00473512|9658852|FG000|Period 2 (Phase 2)|Disease Progression|0
6058488|NCT00473512|9658853|FG001|Period 2 (Phase 2)|Disease Progression|2
6058489|NCT00473512|9658854|FG002|Period 2 (Phase 2)|Disease Progression|2
6058490|NCT00473512|9658855|FG003|Period 2 (Phase 2)|Disease Progression|17
6058491|NCT00473512|9658856|FG004|Period 2 (Phase 2)|Disease Progression|1
6058492|NCT00473512|9658852|FG000|Period 2 (Phase 2)|Symptomatic Deterioration|0
6058493|NCT00473512|9658853|FG001|Period 2 (Phase 2)|Symptomatic Deterioration|0
6058494|NCT00473512|9658854|FG002|Period 2 (Phase 2)|Symptomatic Deterioration|0
6058495|NCT00473512|9658855|FG003|Period 2 (Phase 2)|Symptomatic Deterioration|1
6058496|NCT00473512|9658856|FG004|Period 2 (Phase 2)|Symptomatic Deterioration|0
6058497|NCT00473512|9658852|FG000|Period 2 (Phase 2)|Other|1
6058498|NCT00473512|9658853|FG001|Period 2 (Phase 2)|Other|0
6058499|NCT00473512|9658854|FG002|Period 2 (Phase 2)|Other|0
6058500|NCT00473512|9658855|FG003|Period 2 (Phase 2)|Other|3
6058501|NCT00473512|9658856|FG004|Period 2 (Phase 2)|Other|0
6058502|NCT00473564|9658876|FG000|Overall Study|robot surgery aborted in OR|23
6058503|NCT00473590|9658882|FG000|Overall Study|Adverse Event|3
6058504|NCT00473590|9658883|FG001|Overall Study|Adverse Event|3
6058505|NCT00473590|9658882|FG000|Overall Study|Death|4
6058506|NCT00473590|9658883|FG001|Overall Study|Death|2
6058507|NCT00473590|9658882|FG000|Overall Study|Progression not resulting in death|24
6058508|NCT00473590|9658883|FG001|Overall Study|Progression not resulting in death|20
6058509|NCT00473590|9658882|FG000|Overall Study|Non-protocol-specified therapy|7
6058510|NCT00473590|9658883|FG001|Overall Study|Non-protocol-specified therapy|5
6058511|NCT00473590|9658882|FG000|Overall Study|Physician Decision|2
6058512|NCT00473590|9658883|FG001|Overall Study|Physician Decision|4
6058513|NCT00473590|9658882|FG000|Overall Study|Withdrawal by Subject|5
6058514|NCT00473590|9658883|FG001|Overall Study|Withdrawal by Subject|3
6058515|NCT00473590|9658882|FG000|Overall Study|Other|0
6058516|NCT00473590|9658883|FG001|Overall Study|Other|1
6058517|NCT00473655|9658908|FG000|Overall Study|Lost to Follow-up|9
6058518|NCT00473655|9658909|FG001|Overall Study|Lost to Follow-up|5
6058519|NCT00473655|9658910|FG002|Overall Study|Lost to Follow-up|8
6058520|NCT00473668|9658921|FG000|Overall Study|Withdrawal by Subject|0
6058521|NCT00473668|9658922|FG001|Overall Study|Withdrawal by Subject|2
6058522|NCT00473668|9658923|FG002|Overall Study|Withdrawal by Subject|0
6058523|NCT00473668|9658921|FG000|Overall Study|Migrated/moved from study area|3
6058524|NCT00473668|9658922|FG001|Overall Study|Migrated/moved from study area|2
6058525|NCT00473668|9658923|FG002|Overall Study|Migrated/moved from study area|0
6058526|NCT00473668|9658921|FG000|Overall Study|Lost to Follow-up|0
6092205|NCT00704184|9704899|FG003|Open-Label Treatment|Lack of Efficacy|2
6092206|NCT00704184|9704900|FG004|Open-Label Treatment|Lack of Efficacy|1
6092207|NCT00704184|9704896|FG000|Open-Label Treatment|Physician Decision|0
6092208|NCT00704184|9704897|FG001|Open-Label Treatment|Physician Decision|0
6092209|NCT00704184|9704898|FG002|Open-Label Treatment|Physician Decision|0
6092210|NCT00704184|9704899|FG003|Open-Label Treatment|Physician Decision|0
6092211|NCT00704184|9704900|FG004|Open-Label Treatment|Physician Decision|1
6092212|NCT00704184|9704896|FG000|Open-Label Treatment|Withdrawal by Subject|1
6092213|NCT00704184|9704897|FG001|Open-Label Treatment|Withdrawal by Subject|0
6092214|NCT00704184|9704898|FG002|Open-Label Treatment|Withdrawal by Subject|0
6092215|NCT00704184|9704899|FG003|Open-Label Treatment|Withdrawal by Subject|3
6092216|NCT00704184|9704900|FG004|Open-Label Treatment|Withdrawal by Subject|0
6092217|NCT00704340|9704918|FG000|Overall Study|Lost to Follow-up|2
6092218|NCT00704340|9704919|FG001|Overall Study|Lost to Follow-up|1
6092219|NCT00704340|9704918|FG000|Overall Study|Death|0
6092220|NCT00704340|9704919|FG001|Overall Study|Death|1
6092221|NCT00704405|9704950|FG000|Overall Study (NC Population)|Adverse Event|1
6092222|NCT00704405|9704951|FG001|Overall Study (NC Population)|Adverse Event|0
6092223|NCT00704405|9704952|FG002|Overall Study (NC Population)|Adverse Event|0
6058527|NCT00473668|9658922|FG001|Overall Study|Lost to Follow-up|4
6058528|NCT00473668|9658923|FG002|Overall Study|Lost to Follow-up|6
6058529|NCT00473668|9658921|FG000|Overall Study|Other|2
6058530|NCT00473668|9658922|FG001|Overall Study|Other|3
6092224|NCT00704405|9704953|FG003|Overall Study (NC Population)|Adverse Event|0
6092225|NCT00704405|9704954|FG004|Overall Study (NC Population)|Adverse Event|0
6092226|NCT00704405|9704950|FG000|Overall Study (NC Population)|Lost to Follow-up|2
6092227|NCT00704405|9704951|FG001|Overall Study (NC Population)|Lost to Follow-up|1
6092228|NCT00704405|9704952|FG002|Overall Study (NC Population)|Lost to Follow-up|1
6058531|NCT00473668|9658923|FG002|Overall Study|Other|4
6058532|NCT00473694|9658935|FG000|Overall Study|Adverse Event|0
6058533|NCT00473694|9658936|FG001|Overall Study|Adverse Event|1
6058534|NCT00473694|9658937|FG002|Overall Study|Adverse Event|0
6058535|NCT00473694|9658938|FG003|Overall Study|Adverse Event|0
6058536|NCT00473694|9658935|FG000|Overall Study|Participants did not receive treatment|11
6058537|NCT00473694|9658936|FG001|Overall Study|Participants did not receive treatment|3
6058538|NCT00473694|9658937|FG002|Overall Study|Participants did not receive treatment|5
6058539|NCT00473694|9658938|FG003|Overall Study|Participants did not receive treatment|6
6058540|NCT00473694|9658935|FG000|Overall Study|Lost to Follow-up|0
6058541|NCT00473694|9658936|FG001|Overall Study|Lost to Follow-up|0
6058542|NCT00473694|9658937|FG002|Overall Study|Lost to Follow-up|0
6058543|NCT00473694|9658938|FG003|Overall Study|Lost to Follow-up|1
6058544|NCT00473746|9658956|FG000|Period 1 (Phase 1)|Adverse Event|1
6058545|NCT00473746|9658957|FG001|Period 1 (Phase 1)|Adverse Event|0
6058546|NCT00473746|9658958|FG002|Period 1 (Phase 1)|Adverse Event|0
6058547|NCT00473746|9658959|FG003|Period 1 (Phase 1)|Adverse Event|0
6058548|NCT00473746|9658960|FG004|Period 1 (Phase 1)|Adverse Event|0
6058549|NCT00473746|9658956|FG000|Period 1 (Phase 1)|Withdrawal by Subject|0
6058550|NCT00473746|9658957|FG001|Period 1 (Phase 1)|Withdrawal by Subject|1
6058551|NCT00473746|9658958|FG002|Period 1 (Phase 1)|Withdrawal by Subject|0
6058552|NCT00473746|9658959|FG003|Period 1 (Phase 1)|Withdrawal by Subject|0
6058553|NCT00473746|9658960|FG004|Period 1 (Phase 1)|Withdrawal by Subject|0
6058554|NCT00473746|9658956|FG000|Period 1 (Phase 1)|Progressive Disease|5
6058555|NCT00473746|9658957|FG001|Period 1 (Phase 1)|Progressive Disease|6
6058556|NCT00473746|9658958|FG002|Period 1 (Phase 1)|Progressive Disease|6
6058557|NCT00473746|9658959|FG003|Period 1 (Phase 1)|Progressive Disease|10
6058558|NCT00473746|9658960|FG004|Period 1 (Phase 1)|Progressive Disease|0
6058559|NCT00473746|9658956|FG000|Period 1 (Phase 1)|Symptomatic Deterioration|0
6058560|NCT00473746|9658957|FG001|Period 1 (Phase 1)|Symptomatic Deterioration|1
6058561|NCT00473746|9658958|FG002|Period 1 (Phase 1)|Symptomatic Deterioration|0
6058562|NCT00473746|9658959|FG003|Period 1 (Phase 1)|Symptomatic Deterioration|0
6058563|NCT00473746|9658960|FG004|Period 1 (Phase 1)|Symptomatic Deterioration|0
6058564|NCT00473746|9658956|FG000|Period 1 (Phase 1)|Reason not specified|0
6058565|NCT00473746|9658957|FG001|Period 1 (Phase 1)|Reason not specified|1
6058566|NCT00473746|9658958|FG002|Period 1 (Phase 1)|Reason not specified|0
6058567|NCT00473746|9658959|FG003|Period 1 (Phase 1)|Reason not specified|0
6058568|NCT00473746|9658960|FG004|Period 1 (Phase 1)|Reason not specified|0
6092229|NCT00704405|9704953|FG003|Overall Study (NC Population)|Lost to Follow-up|2
6092230|NCT00704405|9704954|FG004|Overall Study (NC Population)|Lost to Follow-up|2
6092231|NCT00704405|9704950|FG000|Overall Study (NC Population)|Withdrawal by Subject|2
6092232|NCT00704405|9704951|FG001|Overall Study (NC Population)|Withdrawal by Subject|3
6092233|NCT00704405|9704952|FG002|Overall Study (NC Population)|Withdrawal by Subject|2
6092234|NCT00704405|9704953|FG003|Overall Study (NC Population)|Withdrawal by Subject|2
6092235|NCT00704405|9704954|FG004|Overall Study (NC Population)|Withdrawal by Subject|2
6092236|NCT00704405|9704950|FG000|Overall Study (NC Population)|Other|0
6092237|NCT00704405|9704951|FG001|Overall Study (NC Population)|Other|0
6092238|NCT00704405|9704952|FG002|Overall Study (NC Population)|Other|0
6092239|NCT00704405|9704953|FG003|Overall Study (NC Population)|Other|0
6092240|NCT00704405|9704954|FG004|Overall Study (NC Population)|Other|1
6092241|NCT00704405|9704950|FG000|Overall Study (C Population)|Withdrawal by Subject|1
6092242|NCT00704405|9704951|FG001|Overall Study (C Population)|Withdrawal by Subject|1
6092243|NCT00704405|9704952|FG002|Overall Study (C Population)|Withdrawal by Subject|1
6092244|NCT00704405|9704953|FG003|Overall Study (C Population)|Withdrawal by Subject|1
6092245|NCT00704405|9704954|FG004|Overall Study (C Population)|Withdrawal by Subject|0
6092246|NCT00704405|9704950|FG000|Overall Study (C Population)|Lost to Follow-up|0
6092247|NCT00704405|9704951|FG001|Overall Study (C Population)|Lost to Follow-up|2
6092248|NCT00704405|9704952|FG002|Overall Study (C Population)|Lost to Follow-up|0
6092249|NCT00704405|9704953|FG003|Overall Study (C Population)|Lost to Follow-up|0
6092250|NCT00704405|9704954|FG004|Overall Study (C Population)|Lost to Follow-up|0
6092251|NCT00704418|9704974|FG000|Overall Study|Withdrawal by Subject|2
6092252|NCT00704418|9704975|FG001|Overall Study|Withdrawal by Subject|0
6092253|NCT00704418|9704974|FG000|Overall Study|Over-enrolled/surgery postponed|3
6092254|NCT00704418|9704975|FG001|Overall Study|Over-enrolled/surgery postponed|6
6092255|NCT00704522|9704983|FG000|Overall Study|Lack of Efficacy|65
6092256|NCT00704522|9704984|FG001|Overall Study|Lack of Efficacy|17
6092257|NCT00704522|9704983|FG000|Overall Study|Failure to appear again at hospital|56
6092258|NCT00704522|9704984|FG001|Overall Study|Failure to appear again at hospital|10
6058569|NCT00473746|9658956|FG000|Period 2 (Phase 2)|Adverse Event|0
6058570|NCT00473746|9658957|FG001|Period 2 (Phase 2)|Adverse Event|0
6058571|NCT00473746|9658958|FG002|Period 2 (Phase 2)|Adverse Event|0
6058572|NCT00473746|9658959|FG003|Period 2 (Phase 2)|Adverse Event|0
6058573|NCT00473746|9658960|FG004|Period 2 (Phase 2)|Adverse Event|3
6058574|NCT00473746|9658956|FG000|Period 2 (Phase 2)|Death|0
6092259|NCT00704522|9704983|FG000|Overall Study|Withdrawal by Subject|17
6092260|NCT00704522|9704984|FG001|Overall Study|Withdrawal by Subject|8
6092261|NCT00704522|9704983|FG000|Overall Study|Adverse Event|9
6092262|NCT00704522|9704984|FG001|Overall Study|Adverse Event|1
6092263|NCT00704522|9704983|FG000|Overall Study|Undefined causes|9
6092264|NCT00704522|9704984|FG001|Overall Study|Undefined causes|7
6092265|NCT00704522|9704983|FG000|Overall Study|No information on therapy end|27
6092266|NCT00704522|9704984|FG001|Overall Study|No information on therapy end|2
6092267|NCT00704730|9704995|FG000|Overall Study|Adverse Event|35
6092268|NCT00704730|9704996|FG001|Overall Study|Adverse Event|9
6092269|NCT00704730|9704995|FG000|Overall Study|Death|11
6092270|NCT00704730|9704996|FG001|Overall Study|Death|5
6092271|NCT00704730|9704995|FG000|Overall Study|Physician Decision|2
6092272|NCT00704730|9704996|FG001|Overall Study|Physician Decision|0
6202576|NCT01504412|9862833|FG000|Overall Study|Death|0
6058575|NCT00473746|9658957|FG001|Period 2 (Phase 2)|Death|0
6058576|NCT00473746|9658958|FG002|Period 2 (Phase 2)|Death|0
6058577|NCT00473746|9658959|FG003|Period 2 (Phase 2)|Death|0
6058578|NCT00473746|9658960|FG004|Period 2 (Phase 2)|Death|1
6058579|NCT00473746|9658956|FG000|Period 2 (Phase 2)|Progressive Disease|0
6058580|NCT00473746|9658957|FG001|Period 2 (Phase 2)|Progressive Disease|0
6058581|NCT00473746|9658958|FG002|Period 2 (Phase 2)|Progressive Disease|0
6058582|NCT00473746|9658959|FG003|Period 2 (Phase 2)|Progressive Disease|0
6058583|NCT00473746|9658960|FG004|Period 2 (Phase 2)|Progressive Disease|20
6058584|NCT00473746|9658956|FG000|Period 2 (Phase 2)|Reason not specified|0
6058585|NCT00473746|9658957|FG001|Period 2 (Phase 2)|Reason not specified|0
6058586|NCT00473746|9658958|FG002|Period 2 (Phase 2)|Reason not specified|0
6058587|NCT00473746|9658959|FG003|Period 2 (Phase 2)|Reason not specified|0
6058588|NCT00473746|9658960|FG004|Period 2 (Phase 2)|Reason not specified|3
6058589|NCT00473824|9658976|FG000|Overall Study|Virologic Breakthrough|1
6058590|NCT00473824|9658977|FG001|Overall Study|Virologic Breakthrough|0
6058591|NCT00473824|9658976|FG000|Overall Study|Adverse Event|1
6058592|NCT00473824|9658977|FG001|Overall Study|Adverse Event|0
6058593|NCT00473824|9658976|FG000|Overall Study|Death|1
6058594|NCT00473824|9658977|FG001|Overall Study|Death|0
6058595|NCT00473824|9658976|FG000|Overall Study|Lost to Follow-up|1
6058596|NCT00473824|9658977|FG001|Overall Study|Lost to Follow-up|0
6058597|NCT00473824|9658976|FG000|Overall Study|Withdrawal by physician|1
6058598|NCT00473824|9658977|FG001|Overall Study|Withdrawal by physician|0
6058599|NCT00473876|9658994|FG000|Overall Study|Lost to Follow-up|3
6058600|NCT00473876|9658995|FG001|Overall Study|Lost to Follow-up|1
6058601|NCT00473889|9659005|FG000|Overall Study|Did not receive study medication|1
6058602|NCT00473889|9659006|FG001|Overall Study|Did not receive study medication|4
6058603|NCT00473889|9659005|FG000|Overall Study|Adverse Event|30
6058604|NCT00473889|9659006|FG001|Overall Study|Adverse Event|17
6058605|NCT00473889|9659005|FG000|Overall Study|Protocol Violation|4
6058606|NCT00473889|9659006|FG001|Overall Study|Protocol Violation|2
6058607|NCT00473889|9659005|FG000|Overall Study|Lack of Efficacy|28
6058608|NCT00473889|9659006|FG001|Overall Study|Lack of Efficacy|29
6058609|NCT00473889|9659005|FG000|Overall Study|Lost to Follow-up|2
6058610|NCT00473889|9659006|FG001|Overall Study|Lost to Follow-up|1
6058611|NCT00473889|9659005|FG000|Overall Study|Physician Decision|10
6058612|NCT00473889|9659006|FG001|Overall Study|Physician Decision|5
6058613|NCT00473889|9659005|FG000|Overall Study|Trial Terminated|3
6058614|NCT00473889|9659006|FG001|Overall Study|Trial Terminated|6
6058615|NCT00473889|9659005|FG000|Overall Study|Withdrawal by Subject|5
6058616|NCT00473889|9659006|FG001|Overall Study|Withdrawal by Subject|0
6058617|NCT00474045|9659014|FG000|Overall Study|Adverse Event|18
6058618|NCT00474045|9659015|FG001|Overall Study|Adverse Event|8
6058619|NCT00474045|9659014|FG000|Overall Study|Unclassified|1
6058620|NCT00474045|9659015|FG001|Overall Study|Unclassified|3
6058621|NCT00474045|9659014|FG000|Overall Study|Lack of Efficacy|0
6058622|NCT00474045|9659015|FG001|Overall Study|Lack of Efficacy|9
6058623|NCT00474045|9659014|FG000|Overall Study|Lost to Follow-up|1
6058624|NCT00474045|9659015|FG001|Overall Study|Lost to Follow-up|1
6058625|NCT00474045|9659014|FG000|Overall Study|Protocol Violation|10
6058626|NCT00474045|9659015|FG001|Overall Study|Protocol Violation|12
6058627|NCT00474045|9659014|FG000|Overall Study|Withdrawal by Subject|16
6058628|NCT00474045|9659015|FG001|Overall Study|Withdrawal by Subject|18
6058629|NCT00474045|9659014|FG000|Overall Study|Withdrawal criteria|60
6058630|NCT00474045|9659015|FG001|Overall Study|Withdrawal criteria|50
6058631|NCT00474058|9659023|FG000|Overall Study|Adverse Event|11
6058632|NCT00474058|9659024|FG001|Overall Study|Adverse Event|6
6058633|NCT00474058|9659023|FG000|Overall Study|Lack of Efficacy|0
6058634|NCT00474058|9659024|FG001|Overall Study|Lack of Efficacy|4
6058635|NCT00474058|9659023|FG000|Overall Study|Withdrawal by Subject|11
6058636|NCT00474058|9659024|FG001|Overall Study|Withdrawal by Subject|7
6058637|NCT00474058|9659023|FG000|Overall Study|Other|2
6058638|NCT00474058|9659024|FG001|Overall Study|Other|0
6058639|NCT00474175|9659042|FG000|Overall Study|Lack of Efficacy|0
6058640|NCT00474175|9659043|FG001|Overall Study|Lack of Efficacy|0
6058641|NCT00474175|9659044|FG002|Overall Study|Lack of Efficacy|1
6058642|NCT00474175|9659042|FG000|Overall Study|Withdrawal by Subject|0
6058643|NCT00474175|9659043|FG001|Overall Study|Withdrawal by Subject|1
6058644|NCT00474175|9659044|FG002|Overall Study|Withdrawal by Subject|1
6058645|NCT00474175|9659042|FG000|Overall Study|Ineligible|1
6058646|NCT00474175|9659043|FG001|Overall Study|Ineligible|3
6058647|NCT00474175|9659044|FG002|Overall Study|Ineligible|1
6058648|NCT00474175|9659042|FG000|Overall Study|Protocol Violation|0
6092273|NCT00704730|9704995|FG000|Overall Study|Did not receive drug|5
6092274|NCT00704730|9704996|FG001|Overall Study|Did not receive drug|2
6092275|NCT00704730|9704995|FG000|Overall Study|Disease progression per PI|58
6058649|NCT00474175|9659043|FG001|Overall Study|Protocol Violation|2
6058650|NCT00474175|9659044|FG002|Overall Study|Protocol Violation|1
6058651|NCT00474175|9659042|FG000|Overall Study|Administrative|0
6058652|NCT00474175|9659043|FG001|Overall Study|Administrative|1
6058653|NCT00474175|9659044|FG002|Overall Study|Administrative|0
6058654|NCT00474240|9659063|FG000|Overall Study|Withdrawal by Subject|1
6058655|NCT00474240|9659064|FG001|Overall Study|Withdrawal by Subject|1
6058656|NCT00474240|9659065|FG002|Overall Study|Withdrawal by Subject|0
6058657|NCT00474240|9659066|FG003|Overall Study|Withdrawal by Subject|2
6058658|NCT00474240|9659067|FG004|Overall Study|Withdrawal by Subject|3
6058659|NCT00474240|9659068|FG005|Overall Study|Withdrawal by Subject|1
6058660|NCT00474240|9659063|FG000|Overall Study|Adverse Event|0
6058661|NCT00474240|9659064|FG001|Overall Study|Adverse Event|0
6058662|NCT00474240|9659065|FG002|Overall Study|Adverse Event|9
6058663|NCT00474240|9659066|FG003|Overall Study|Adverse Event|14
6058664|NCT00474240|9659067|FG004|Overall Study|Adverse Event|5
6058665|NCT00474240|9659068|FG005|Overall Study|Adverse Event|16
6058666|NCT00474240|9659063|FG000|Overall Study|Removed due to lab value|0
6058667|NCT00474240|9659064|FG001|Overall Study|Removed due to lab value|0
6058668|NCT00474240|9659065|FG002|Overall Study|Removed due to lab value|0
6058669|NCT00474240|9659066|FG003|Overall Study|Removed due to lab value|0
6058670|NCT00474240|9659067|FG004|Overall Study|Removed due to lab value|0
6058671|NCT00474240|9659068|FG005|Overall Study|Removed due to lab value|1
6058672|NCT00474253|9659084|FG000|Overall Study|Withdrew consent|2
6058673|NCT00474253|9659085|FG001|Overall Study|Withdrew consent|0
6058674|NCT00474253|9659084|FG000|Overall Study|Withdrew due to surgery-related issues|0
6092276|NCT00704730|9704996|FG001|Overall Study|Disease progression per PI|67
6092277|NCT00704730|9704995|FG000|Overall Study|data unavailable|1
6092278|NCT00704730|9704996|FG001|Overall Study|data unavailable|0
6092279|NCT00704730|9704995|FG000|Overall Study|Withdrawal by Subject|9
6092280|NCT00704730|9704996|FG001|Overall Study|Withdrawal by Subject|13
6092281|NCT00704808|9705003|FG000|Overall Study|Discontinued prior to starting treatment|14
6092282|NCT00704808|9705003|FG000|Overall Study|Death|7
6092283|NCT00704808|9705003|FG000|Overall Study|Tumor progression|80
6092284|NCT00704808|9705003|FG000|Overall Study|Patient's decision|11
6092285|NCT00704808|9705003|FG000|Overall Study|Early therapy discontinuation|16
6092286|NCT00704808|9705003|FG000|Overall Study|Adverse Event|1
6092287|NCT00704808|9705003|FG000|Overall Study|Lost to Follow-up|1
6092288|NCT00704808|9705003|FG000|Overall Study|Treatment change|1
6092289|NCT00704964|9705038|FG000|Overall Study|Not completed on time|328
6092290|NCT00705016|9705059|FG000|Overall Study|Adverse Event|6
6092291|NCT00705016|9705060|FG001|Overall Study|Adverse Event|11
6092292|NCT00705016|9705061|FG002|Overall Study|Adverse Event|10
6092293|NCT00705016|9705059|FG000|Overall Study|Death|5
6092294|NCT00705016|9705060|FG001|Overall Study|Death|7
6092295|NCT00705016|9705061|FG002|Overall Study|Death|5
6092296|NCT00705016|9705059|FG000|Overall Study|Protocol Violation|0
6092297|NCT00705016|9705060|FG001|Overall Study|Protocol Violation|1
6092298|NCT00705016|9705061|FG002|Overall Study|Protocol Violation|1
6092299|NCT00705016|9705059|FG000|Overall Study|Withdrawal by Subject|4
6092300|NCT00705016|9705060|FG001|Overall Study|Withdrawal by Subject|3
6092301|NCT00705016|9705061|FG002|Overall Study|Withdrawal by Subject|2
6092302|NCT00705016|9705059|FG000|Overall Study|Progressive Disease|33
6092303|NCT00705016|9705060|FG001|Overall Study|Progressive Disease|29
6092304|NCT00705016|9705061|FG002|Overall Study|Progressive Disease|33
6092305|NCT00705016|9705059|FG000|Overall Study|Symptomatic Deterioration|3
6092306|NCT00705016|9705060|FG001|Overall Study|Symptomatic Deterioration|1
6092307|NCT00705016|9705061|FG002|Overall Study|Symptomatic Deterioration|1
6092308|NCT00705016|9705059|FG000|Overall Study|Other|9
6092309|NCT00705016|9705060|FG001|Overall Study|Other|6
6092310|NCT00705016|9705061|FG002|Overall Study|Other|6
6092311|NCT00705146|9705079|FG000|Overall Study|Lost to Follow-up|1
6092312|NCT00705146|9705080|FG001|Overall Study|Lost to Follow-up|1
6092313|NCT00705159|9705090|FG000|Overall Study|Withdrawal by Subject|0
6092314|NCT00705159|9705091|FG001|Overall Study|Withdrawal by Subject|1
6092315|NCT00705159|9705092|FG002|Overall Study|Withdrawal by Subject|1
6092316|NCT00705159|9705093|FG003|Overall Study|Withdrawal by Subject|1
6092317|NCT00705159|9705090|FG000|Overall Study|Protocol Violation|0
6092318|NCT00705159|9705091|FG001|Overall Study|Protocol Violation|1
6092319|NCT00705159|9705092|FG002|Overall Study|Protocol Violation|0
6092320|NCT00705159|9705093|FG003|Overall Study|Protocol Violation|0
6092321|NCT00705159|9705090|FG000|Overall Study|Adverse Event|0
6092322|NCT00705159|9705091|FG001|Overall Study|Adverse Event|0
6092323|NCT00705159|9705092|FG002|Overall Study|Adverse Event|1
6092324|NCT00705159|9705093|FG003|Overall Study|Adverse Event|0
6092325|NCT00705159|9705090|FG000|Overall Study|Lost to Follow-up|0
6092326|NCT00705159|9705091|FG001|Overall Study|Lost to Follow-up|0
6092327|NCT00705159|9705092|FG002|Overall Study|Lost to Follow-up|3
6092328|NCT00705159|9705093|FG003|Overall Study|Lost to Follow-up|2
6092329|NCT00705159|9705090|FG000|Overall Study|Screen Failure|0
6092330|NCT00705159|9705091|FG001|Overall Study|Screen Failure|0
6092331|NCT00705159|9705092|FG002|Overall Study|Screen Failure|0
6092332|NCT00705159|9705093|FG003|Overall Study|Screen Failure|1
6092333|NCT00705224|9705103|FG000|Overall Study|Adverse Event|1
6092334|NCT00705224|9705103|FG000|Overall Study|Lack of Efficacy|2
6092335|NCT00705224|9705103|FG000|Overall Study|Withdrawal by Subject|3
6058675|NCT00474253|9659085|FG001|Overall Study|Withdrew due to surgery-related issues|3
6058676|NCT00474253|9659084|FG000|Overall Study|Lost to Follow-up|1
6058677|NCT00474253|9659085|FG001|Overall Study|Lost to Follow-up|0
6058678|NCT00474253|9659084|FG000|Overall Study|Discharged prior to study completion|0
6058679|NCT00474253|9659085|FG001|Overall Study|Discharged prior to study completion|1
6058680|NCT00474266|9659095|FG000|Overall Study|Withdrawal by Subject|7
6058681|NCT00474266|9659096|FG001|Overall Study|Withdrawal by Subject|20
6058682|NCT00474266|9659097|FG002|Overall Study|Withdrawal by Subject|4
6058683|NCT00474266|9659098|FG003|Overall Study|Withdrawal by Subject|7
6058684|NCT00474383|9659111|FG000|Main Study|Adverse Event|11
6058685|NCT00474383|9659112|FG001|Main Study|Adverse Event|0
6058686|NCT00474383|9659111|FG000|Main Study|Symptomatic Deterioration|1
6058687|NCT00474383|9659112|FG001|Main Study|Symptomatic Deterioration|0
6058688|NCT00474383|9659111|FG000|Main Study|Progressive Disease|23
6058689|NCT00474383|9659112|FG001|Main Study|Progressive Disease|0
6058690|NCT00474383|9659111|FG000|Main Study|Other|1
6058691|NCT00474383|9659112|FG001|Main Study|Other|0
6058692|NCT00474383|9659111|FG000|Between Main Study and Extension|Did Not Enter Extension Phase|6
6058693|NCT00474383|9659112|FG001|Between Main Study and Extension|Did Not Enter Extension Phase|0
6058694|NCT00474383|9659111|FG000|Extension|Progressive Disease|0
6058695|NCT00474383|9659112|FG001|Extension|Progressive Disease|5
6058696|NCT00474487|9659120|FG000|Overall Study|Withdrawal by Subject|6
6058697|NCT00474487|9659121|FG001|Overall Study|Withdrawal by Subject|0
6058698|NCT00474487|9659122|FG002|Overall Study|Withdrawal by Subject|0
6058699|NCT00474487|9659123|FG003|Overall Study|Withdrawal by Subject|0
6058700|NCT00474487|9659120|FG000|Overall Study|Lost to Follow-up|20
6058701|NCT00474487|9659121|FG001|Overall Study|Lost to Follow-up|1
6058702|NCT00474487|9659122|FG002|Overall Study|Lost to Follow-up|7
6058703|NCT00474487|9659123|FG003|Overall Study|Lost to Follow-up|0
6058704|NCT00474487|9659120|FG000|Overall Study|Inappropriate enrollment|4
6058705|NCT00474487|9659121|FG001|Overall Study|Inappropriate enrollment|0
6058706|NCT00474487|9659122|FG002|Overall Study|Inappropriate enrollment|7
6058707|NCT00474487|9659123|FG003|Overall Study|Inappropriate enrollment|0
6058708|NCT00474487|9659120|FG000|Overall Study|Death|0
6058709|NCT00474487|9659121|FG001|Overall Study|Death|1
6058710|NCT00474487|9659122|FG002|Overall Study|Death|0
6058711|NCT00474487|9659123|FG003|Overall Study|Death|0
6058712|NCT00474526|9659150|FG000|Overall Study|ADMINISTRATIVE REASON|11
6058713|NCT00474526|9659151|FG001|Overall Study|ADMINISTRATIVE REASON|9
6058714|NCT00474526|9659152|FG002|Overall Study|ADMINISTRATIVE REASON|9
6058715|NCT00474526|9659153|FG003|Overall Study|ADMINISTRATIVE REASON|20
6058716|NCT00474526|9659154|FG004|Overall Study|ADMINISTRATIVE REASON|9
6092336|NCT00705224|9705103|FG000|Overall Study|Lost to Follow-up|5
6092337|NCT00705250|9705110|FG000|Overall Study|Withdrawal by Subject|1
6092338|NCT00705250|9705110|FG000|Overall Study|Patient died in car accident|1
6092339|NCT00705263|9705114|FG000|Overall Study|Withdrawal by Subject|2
6092340|NCT00705289|9705118|FG000|Overall Study|Subject or treating physician's choice|131
6092341|NCT00705341|9705141|FG000|Phase 2: Trial|Withdrawal by Subject|0
6092342|NCT00705341|9705142|FG001|Phase 2: Trial|Withdrawal by Subject|0
6092343|NCT00705341|9705143|FG002|Phase 2: Trial|Withdrawal by Subject|6
6092344|NCT00705341|9705144|FG003|Phase 2: Trial|Withdrawal by Subject|4
6092345|NCT00705341|9705141|FG000|Phase 2: Trial|Did not meet post-diluent threshold|0
6092346|NCT00705341|9705142|FG001|Phase 2: Trial|Did not meet post-diluent threshold|0
6092347|NCT00705341|9705143|FG002|Phase 2: Trial|Did not meet post-diluent threshold|1
6092348|NCT00705341|9705144|FG003|Phase 2: Trial|Did not meet post-diluent threshold|0
6092349|NCT00705367|9705154|FG000|Long-term Extension Period|Adverse Event|2
6092350|NCT00705367|9705155|FG001|Long-term Extension Period|Adverse Event|0
6092351|NCT00705367|9705154|FG000|Long-term Extension Period|Withdrawal by Subject|2
6092352|NCT00705367|9705155|FG001|Long-term Extension Period|Withdrawal by Subject|0
6092353|NCT00705367|9705154|FG000|Long-term Extension Period|Lack of Efficacy|1
6092354|NCT00705367|9705155|FG001|Long-term Extension Period|Lack of Efficacy|0
6092355|NCT00705367|9705154|FG000|Long-term Extension Period|No longer met study criteria|1
6092356|NCT00705367|9705155|FG001|Long-term Extension Period|No longer met study criteria|0
6092357|NCT00705367|9705154|FG000|Long-term Extension Period|Administrative reason by sponsor|3
6092358|NCT00705367|9705155|FG001|Long-term Extension Period|Administrative reason by sponsor|0
6092359|NCT00705406|9705165|FG000|Overall Study|Lost to Follow-up|3
6092360|NCT00705406|9705166|FG001|Overall Study|Lost to Follow-up|3
6092361|NCT00705406|9705165|FG000|Overall Study|Did not receive study drug|1
6092362|NCT00705406|9705166|FG001|Overall Study|Did not receive study drug|2
6092363|NCT00705432|9705179|FG000|Treatment Period|Adverse Event|45
6092364|NCT00705432|9705180|FG001|Treatment Period|Adverse Event|37
6092365|NCT00705432|9705181|FG002|Treatment Period|Adverse Event|51
6092366|NCT00705432|9705182|FG003|Treatment Period|Adverse Event|12
6092367|NCT00705432|9705183|FG004|Treatment Period|Adverse Event|8
6092368|NCT00705432|9705184|FG005|Treatment Period|Adverse Event|9
6092369|NCT00705432|9705179|FG000|Treatment Period|Treatment failure|92
6092370|NCT00705432|9705180|FG001|Treatment Period|Treatment failure|42
6092371|NCT00705432|9705181|FG002|Treatment Period|Treatment failure|33
6092372|NCT00705432|9705182|FG003|Treatment Period|Treatment failure|25
6058717|NCT00474526|9659155|FG005|Overall Study|ADMINISTRATIVE REASON|1
6058718|NCT00474526|9659156|FG006|Overall Study|ADMINISTRATIVE REASON|1
6058719|NCT00474526|9659157|FG007|Overall Study|ADMINISTRATIVE REASON|0
6058720|NCT00474526|9659158|FG008|Overall Study|ADMINISTRATIVE REASON|2
6058721|NCT00474526|9659159|FG009|Overall Study|ADMINISTRATIVE REASON|1
6058722|NCT00474526|9659160|FG010|Overall Study|ADMINISTRATIVE REASON|1
6058723|NCT00474526|9659161|FG011|Overall Study|ADMINISTRATIVE REASON|1
6058724|NCT00474526|9659162|FG012|Overall Study|ADMINISTRATIVE REASON|1
6058725|NCT00474526|9659163|FG013|Overall Study|ADMINISTRATIVE REASON|1
6058726|NCT00474526|9659164|FG014|Overall Study|ADMINISTRATIVE REASON|2
6058727|NCT00474526|9659165|FG015|Overall Study|ADMINISTRATIVE REASON|0
6058728|NCT00474526|9659166|FG016|Overall Study|ADMINISTRATIVE REASON|0
6058729|NCT00474526|9659150|FG000|Overall Study|Adverse Event|2
6058730|NCT00474526|9659151|FG001|Overall Study|Adverse Event|0
6058731|NCT00474526|9659152|FG002|Overall Study|Adverse Event|2
6058732|NCT00474526|9659153|FG003|Overall Study|Adverse Event|4
6058733|NCT00474526|9659154|FG004|Overall Study|Adverse Event|2
6058734|NCT00474526|9659155|FG005|Overall Study|Adverse Event|1
6058735|NCT00474526|9659156|FG006|Overall Study|Adverse Event|1
6058736|NCT00474526|9659157|FG007|Overall Study|Adverse Event|0
6058737|NCT00474526|9659158|FG008|Overall Study|Adverse Event|0
6058738|NCT00474526|9659159|FG009|Overall Study|Adverse Event|0
6058739|NCT00474526|9659160|FG010|Overall Study|Adverse Event|0
6058740|NCT00474526|9659161|FG011|Overall Study|Adverse Event|0
6058741|NCT00474526|9659162|FG012|Overall Study|Adverse Event|0
6058742|NCT00474526|9659163|FG013|Overall Study|Adverse Event|0
6058743|NCT00474526|9659164|FG014|Overall Study|Adverse Event|1
6058744|NCT00474526|9659165|FG015|Overall Study|Adverse Event|1
6058745|NCT00474526|9659166|FG016|Overall Study|Adverse Event|0
6058746|NCT00474526|9659150|FG000|Overall Study|Death|0
6058747|NCT00474526|9659151|FG001|Overall Study|Death|0
6058748|NCT00474526|9659152|FG002|Overall Study|Death|0
6058749|NCT00474526|9659153|FG003|Overall Study|Death|0
6058750|NCT00474526|9659154|FG004|Overall Study|Death|0
6058751|NCT00474526|9659155|FG005|Overall Study|Death|0
6058752|NCT00474526|9659156|FG006|Overall Study|Death|0
6058753|NCT00474526|9659157|FG007|Overall Study|Death|0
6058754|NCT00474526|9659158|FG008|Overall Study|Death|0
6058755|NCT00474526|9659159|FG009|Overall Study|Death|0
6058756|NCT00474526|9659160|FG010|Overall Study|Death|0
6058757|NCT00474526|9659161|FG011|Overall Study|Death|0
6058758|NCT00474526|9659162|FG012|Overall Study|Death|0
6058759|NCT00474526|9659163|FG013|Overall Study|Death|3
6058760|NCT00474526|9659164|FG014|Overall Study|Death|0
6058761|NCT00474526|9659165|FG015|Overall Study|Death|0
6058762|NCT00474526|9659166|FG016|Overall Study|Death|0
6058763|NCT00474526|9659150|FG000|Overall Study|INAPPROPRIATE ENROLLMENT|0
6058764|NCT00474526|9659151|FG001|Overall Study|INAPPROPRIATE ENROLLMENT|1
6058765|NCT00474526|9659152|FG002|Overall Study|INAPPROPRIATE ENROLLMENT|0
6058766|NCT00474526|9659153|FG003|Overall Study|INAPPROPRIATE ENROLLMENT|1
6058767|NCT00474526|9659154|FG004|Overall Study|INAPPROPRIATE ENROLLMENT|2
6058768|NCT00474526|9659155|FG005|Overall Study|INAPPROPRIATE ENROLLMENT|0
6058769|NCT00474526|9659156|FG006|Overall Study|INAPPROPRIATE ENROLLMENT|0
6058770|NCT00474526|9659157|FG007|Overall Study|INAPPROPRIATE ENROLLMENT|0
6058771|NCT00474526|9659158|FG008|Overall Study|INAPPROPRIATE ENROLLMENT|0
6058772|NCT00474526|9659159|FG009|Overall Study|INAPPROPRIATE ENROLLMENT|0
6058773|NCT00474526|9659160|FG010|Overall Study|INAPPROPRIATE ENROLLMENT|0
6058774|NCT00474526|9659161|FG011|Overall Study|INAPPROPRIATE ENROLLMENT|0
6058775|NCT00474526|9659162|FG012|Overall Study|INAPPROPRIATE ENROLLMENT|0
6058776|NCT00474526|9659163|FG013|Overall Study|INAPPROPRIATE ENROLLMENT|2
6058777|NCT00474526|9659164|FG014|Overall Study|INAPPROPRIATE ENROLLMENT|2
6058778|NCT00474526|9659165|FG015|Overall Study|INAPPROPRIATE ENROLLMENT|0
6058779|NCT00474526|9659166|FG016|Overall Study|INAPPROPRIATE ENROLLMENT|0
6058780|NCT00474526|9659150|FG000|Overall Study|Lost to Follow-up|8
6058781|NCT00474526|9659151|FG001|Overall Study|Lost to Follow-up|6
6058782|NCT00474526|9659152|FG002|Overall Study|Lost to Follow-up|13
6058783|NCT00474526|9659153|FG003|Overall Study|Lost to Follow-up|29
6058784|NCT00474526|9659154|FG004|Overall Study|Lost to Follow-up|11
6092373|NCT00705432|9705183|FG004|Treatment Period|Treatment failure|13
6092374|NCT00705432|9705184|FG005|Treatment Period|Treatment failure|14
6092375|NCT00705432|9705179|FG000|Treatment Period|Non medical reason|26
6092376|NCT00705432|9705180|FG001|Treatment Period|Non medical reason|32
6058785|NCT00474526|9659155|FG005|Overall Study|Lost to Follow-up|5
6058786|NCT00474526|9659156|FG006|Overall Study|Lost to Follow-up|8
6058787|NCT00474526|9659157|FG007|Overall Study|Lost to Follow-up|1
6058788|NCT00474526|9659158|FG008|Overall Study|Lost to Follow-up|0
6058789|NCT00474526|9659159|FG009|Overall Study|Lost to Follow-up|6
6092377|NCT00705432|9705181|FG002|Treatment Period|Non medical reason|37
6058790|NCT00474526|9659160|FG010|Overall Study|Lost to Follow-up|2
6058791|NCT00474526|9659161|FG011|Overall Study|Lost to Follow-up|4
6058792|NCT00474526|9659162|FG012|Overall Study|Lost to Follow-up|6
6058793|NCT00474526|9659163|FG013|Overall Study|Lost to Follow-up|74
6058794|NCT00474526|9659164|FG014|Overall Study|Lost to Follow-up|29
6058795|NCT00474526|9659165|FG015|Overall Study|Lost to Follow-up|4
6058796|NCT00474526|9659166|FG016|Overall Study|Lost to Follow-up|5
6058797|NCT00474526|9659150|FG000|Overall Study|Protocol Violation|2
6058798|NCT00474526|9659151|FG001|Overall Study|Protocol Violation|6
6058799|NCT00474526|9659152|FG002|Overall Study|Protocol Violation|4
6058800|NCT00474526|9659153|FG003|Overall Study|Protocol Violation|12
6058801|NCT00474526|9659154|FG004|Overall Study|Protocol Violation|3
6058802|NCT00474526|9659155|FG005|Overall Study|Protocol Violation|1
6058803|NCT00474526|9659156|FG006|Overall Study|Protocol Violation|3
6058804|NCT00474526|9659157|FG007|Overall Study|Protocol Violation|0
6058805|NCT00474526|9659158|FG008|Overall Study|Protocol Violation|0
6058806|NCT00474526|9659159|FG009|Overall Study|Protocol Violation|4
6058807|NCT00474526|9659160|FG010|Overall Study|Protocol Violation|2
6058808|NCT00474526|9659161|FG011|Overall Study|Protocol Violation|2
6058809|NCT00474526|9659162|FG012|Overall Study|Protocol Violation|4
6058810|NCT00474526|9659163|FG013|Overall Study|Protocol Violation|19
6058811|NCT00474526|9659164|FG014|Overall Study|Protocol Violation|9
6058812|NCT00474526|9659165|FG015|Overall Study|Protocol Violation|6
6058813|NCT00474526|9659166|FG016|Overall Study|Protocol Violation|2
6058814|NCT00474526|9659150|FG000|Overall Study|UNABLE TO CLASSIFY|1
6058815|NCT00474526|9659151|FG001|Overall Study|UNABLE TO CLASSIFY|0
6058816|NCT00474526|9659152|FG002|Overall Study|UNABLE TO CLASSIFY|0
6058817|NCT00474526|9659153|FG003|Overall Study|UNABLE TO CLASSIFY|1
6058818|NCT00474526|9659154|FG004|Overall Study|UNABLE TO CLASSIFY|3
6058819|NCT00474526|9659155|FG005|Overall Study|UNABLE TO CLASSIFY|2
6058820|NCT00474526|9659156|FG006|Overall Study|UNABLE TO CLASSIFY|0
6058821|NCT00474526|9659157|FG007|Overall Study|UNABLE TO CLASSIFY|1
6058822|NCT00474526|9659158|FG008|Overall Study|UNABLE TO CLASSIFY|0
6058823|NCT00474526|9659159|FG009|Overall Study|UNABLE TO CLASSIFY|3
6058824|NCT00474526|9659160|FG010|Overall Study|UNABLE TO CLASSIFY|0
6058825|NCT00474526|9659161|FG011|Overall Study|UNABLE TO CLASSIFY|0
6058826|NCT00474526|9659162|FG012|Overall Study|UNABLE TO CLASSIFY|0
6058827|NCT00474526|9659163|FG013|Overall Study|UNABLE TO CLASSIFY|20
6058828|NCT00474526|9659164|FG014|Overall Study|UNABLE TO CLASSIFY|12
6058829|NCT00474526|9659165|FG015|Overall Study|UNABLE TO CLASSIFY|6
6058830|NCT00474526|9659166|FG016|Overall Study|UNABLE TO CLASSIFY|1
6058831|NCT00474526|9659150|FG000|Overall Study|Withdrawal by Subject|9
6058832|NCT00474526|9659151|FG001|Overall Study|Withdrawal by Subject|24
6058833|NCT00474526|9659152|FG002|Overall Study|Withdrawal by Subject|21
6058834|NCT00474526|9659153|FG003|Overall Study|Withdrawal by Subject|52
6058835|NCT00474526|9659154|FG004|Overall Study|Withdrawal by Subject|38
6058836|NCT00474526|9659155|FG005|Overall Study|Withdrawal by Subject|6
6058837|NCT00474526|9659156|FG006|Overall Study|Withdrawal by Subject|12
6058838|NCT00474526|9659157|FG007|Overall Study|Withdrawal by Subject|4
6058839|NCT00474526|9659158|FG008|Overall Study|Withdrawal by Subject|4
6058840|NCT00474526|9659159|FG009|Overall Study|Withdrawal by Subject|13
6058841|NCT00474526|9659160|FG010|Overall Study|Withdrawal by Subject|5
6058842|NCT00474526|9659161|FG011|Overall Study|Withdrawal by Subject|4
6058843|NCT00474526|9659162|FG012|Overall Study|Withdrawal by Subject|4
6058844|NCT00474526|9659163|FG013|Overall Study|Withdrawal by Subject|37
6058845|NCT00474526|9659164|FG014|Overall Study|Withdrawal by Subject|22
6058846|NCT00474526|9659165|FG015|Overall Study|Withdrawal by Subject|1
6058847|NCT00474526|9659166|FG016|Overall Study|Withdrawal by Subject|1
6058848|NCT00474539|9659254|FG000|Infant Series|Withdrawal by Subject|3
6058849|NCT00474539|9659255|FG001|Infant Series|Withdrawal by Subject|4
6058850|NCT00474539|9659254|FG000|Infant Series|Randomization error|5
6058851|NCT00474539|9659255|FG001|Infant Series|Randomization error|0
6058852|NCT00474539|9659254|FG000|Infant Series|Lost to Follow-up|2
6058853|NCT00474539|9659255|FG001|Infant Series|Lost to Follow-up|1
6058854|NCT00474539|9659254|FG000|Infant Series|Protocol Violation|0
6058855|NCT00474539|9659255|FG001|Infant Series|Protocol Violation|1
6058856|NCT00474539|9659254|FG000|After Infant Series|Lost to Follow-up|3
6058857|NCT00474539|9659255|FG001|After Infant Series|Lost to Follow-up|0
6058858|NCT00474539|9659254|FG000|After Infant Series|Withdrawal by Subject|1
6058859|NCT00474539|9659255|FG001|After Infant Series|Withdrawal by Subject|0
6058860|NCT00474539|9659254|FG000|Toddler Dose|Protocol Violation|1
6058861|NCT00474539|9659255|FG001|Toddler Dose|Protocol Violation|0
6058862|NCT00474630|9659301|FG000|Overall Study|Adverse Event|98
6058863|NCT00474630|9659302|FG001|Overall Study|Adverse Event|26
6058864|NCT00474630|9659301|FG000|Overall Study|Lost to Follow-up|22
6058865|NCT00474630|9659302|FG001|Overall Study|Lost to Follow-up|15
6058866|NCT00474630|9659301|FG000|Overall Study|Withdrawal by Subject|21
6058867|NCT00474630|9659302|FG001|Overall Study|Withdrawal by Subject|15
6058868|NCT00474630|9659301|FG000|Overall Study|Protocol Violation|3
6058869|NCT00474630|9659302|FG001|Overall Study|Protocol Violation|4
6058870|NCT00474630|9659301|FG000|Overall Study|Lack of Efficacy|5
6058871|NCT00474630|9659302|FG001|Overall Study|Lack of Efficacy|6
6058872|NCT00474630|9659301|FG000|Overall Study|Drug noncompliance, other|11
6058873|NCT00474630|9659302|FG001|Overall Study|Drug noncompliance, other|4
6092378|NCT00705432|9705182|FG003|Treatment Period|Non medical reason|4
6092379|NCT00705432|9705183|FG004|Treatment Period|Non medical reason|7
6058874|NCT00474708|9659311|FG000|Overall Study|Lack of Efficacy|11
6058875|NCT00474708|9659312|FG001|Overall Study|Lack of Efficacy|5
6058876|NCT00474708|9659311|FG000|Overall Study|Suicide ideation/behavior|0
6058877|NCT00474708|9659312|FG001|Overall Study|Suicide ideation/behavior|1
6058878|NCT00474708|9659311|FG000|Overall Study|Withdrawal by Subject|7
6058879|NCT00474708|9659312|FG001|Overall Study|Withdrawal by Subject|0
6058880|NCT00474708|9659311|FG000|Overall Study|Lack of compliance|12
6058881|NCT00474708|9659312|FG001|Overall Study|Lack of compliance|4
6058882|NCT00474708|9659311|FG000|Overall Study|Lost to Follow-up|18
6058883|NCT00474708|9659312|FG001|Overall Study|Lost to Follow-up|9
6058884|NCT00474708|9659311|FG000|Overall Study|Physician Decision|9
6058885|NCT00474708|9659312|FG001|Overall Study|Physician Decision|6
6058886|NCT00474760|9659325|FG000|Overall Study|Death|0
6058887|NCT00474760|9659326|FG001|Overall Study|Death|0
6058888|NCT00474760|9659327|FG002|Overall Study|Death|0
6092380|NCT00705432|9705184|FG005|Treatment Period|Non medical reason|7
6092381|NCT00705432|9705179|FG000|Follow-up Period (Upto Week 72)|Adverse Event|2
6092382|NCT00705432|9705180|FG001|Follow-up Period (Upto Week 72)|Adverse Event|1
6092383|NCT00705432|9705181|FG002|Follow-up Period (Upto Week 72)|Adverse Event|1
6092384|NCT00705432|9705182|FG003|Follow-up Period (Upto Week 72)|Adverse Event|0
6092385|NCT00705432|9705183|FG004|Follow-up Period (Upto Week 72)|Adverse Event|0
6092386|NCT00705432|9705184|FG005|Follow-up Period (Upto Week 72)|Adverse Event|0
6092387|NCT00705432|9705179|FG000|Follow-up Period (Upto Week 72)|Non medical reason|69
6092388|NCT00705432|9705180|FG001|Follow-up Period (Upto Week 72)|Non medical reason|42
6092389|NCT00705432|9705181|FG002|Follow-up Period (Upto Week 72)|Non medical reason|24
6092390|NCT00705432|9705182|FG003|Follow-up Period (Upto Week 72)|Non medical reason|14
6092391|NCT00705432|9705183|FG004|Follow-up Period (Upto Week 72)|Non medical reason|6
6092392|NCT00705432|9705184|FG005|Follow-up Period (Upto Week 72)|Non medical reason|7
6092393|NCT00705484|9705197|FG000|Overall Study|Adverse Event|28
6092394|NCT00705484|9705198|FG001|Overall Study|Adverse Event|27
6092395|NCT00705484|9705197|FG000|Overall Study|Lost to Follow-up|169
6092396|NCT00705484|9705198|FG001|Overall Study|Lost to Follow-up|250
6092397|NCT00705484|9705197|FG000|Overall Study|Withdrawal by Subject|96
6092398|NCT00705484|9705198|FG001|Overall Study|Withdrawal by Subject|72
6092399|NCT00705484|9705197|FG000|Overall Study|Administrative|89
6092400|NCT00705484|9705198|FG001|Overall Study|Administrative|59
6092401|NCT00705523|9705208|FG000|Overall Study|Lost to Follow-up|2
6092402|NCT00705523|9705209|FG001|Overall Study|Lost to Follow-up|3
6092403|NCT00705536|9705217|FG000|Start Period 1|Withdrawal by Subject|0
6092404|NCT00705536|9705218|FG001|Start Period 1|Withdrawal by Subject|0
6092405|NCT00705536|9705219|FG002|Start Period 1|Withdrawal by Subject|0
6092406|NCT00705536|9705220|FG003|Start Period 1|Withdrawal by Subject|1
6092407|NCT00705575|9705241|FG000|Overall Study|Abnormal laboratory value(s)|0
6092408|NCT00705575|9705242|FG001|Overall Study|Abnormal laboratory value(s)|3
6092409|NCT00705575|9705241|FG000|Overall Study|Abnormal test procedure result(s)|2
6092410|NCT00705575|9705242|FG001|Overall Study|Abnormal test procedure result(s)|12
6092411|NCT00705575|9705241|FG000|Overall Study|Adverse Event|11
6092412|NCT00705575|9705242|FG001|Overall Study|Adverse Event|15
6092413|NCT00705575|9705241|FG000|Overall Study|Lost to Follow-up|3
6092414|NCT00705575|9705242|FG001|Overall Study|Lost to Follow-up|4
6092415|NCT00705575|9705241|FG000|Overall Study|Protocol Violation|2
6092416|NCT00705575|9705242|FG001|Overall Study|Protocol Violation|2
6092417|NCT00705575|9705241|FG000|Overall Study|Withdrawal by Subject|5
6092418|NCT00705575|9705242|FG001|Overall Study|Withdrawal by Subject|10
6092419|NCT00705614|9705250|FG000|Initial Intervention|Adverse Event|40
6092420|NCT00705614|9705251|FG001|Initial Intervention|Adverse Event|21
6092421|NCT00705614|9705250|FG000|Initial Intervention|Lost to Follow-up|310
6092422|NCT00705614|9705251|FG001|Initial Intervention|Lost to Follow-up|191
6092423|NCT00705614|9705250|FG000|Initial Intervention|Withdrawal by Subject|114
6092424|NCT00705614|9705251|FG001|Initial Intervention|Withdrawal by Subject|71
6092425|NCT00705614|9705250|FG000|Initial Intervention|Administrative Reason|51
6092426|NCT00705614|9705251|FG001|Initial Intervention|Administrative Reason|38
6092427|NCT00705614|9705250|FG000|Initial Intervention|Status completion unknown|3
6092428|NCT00705614|9705251|FG001|Initial Intervention|Status completion unknown|0
6092429|NCT00705614|9705250|FG000|Switch to Remicade|Adverse Event|0
6092430|NCT00705614|9705251|FG001|Switch to Remicade|Adverse Event|5
6092431|NCT00705614|9705250|FG000|Switch to Remicade|Lost to Follow-up|0
6092432|NCT00705614|9705251|FG001|Switch to Remicade|Lost to Follow-up|23
6092433|NCT00705614|9705250|FG000|Switch to Remicade|Withdrawal by Subject|0
6202577|NCT01504412|9862834|FG001|Overall Study|Death|0
6202578|NCT01504412|9862835|FG002|Overall Study|Death|0
6202579|NCT01504412|9862836|FG003|Overall Study|Death|1
6202580|NCT01504412|9862837|FG004|Overall Study|Death|0
6202581|NCT01504841|9862871|FG000|Overall Study|Withdrawal by Subject|1
6202582|NCT01504841|9862872|FG001|Overall Study|Withdrawal by Subject|1
6202583|NCT01504841|9862873|FG002|Overall Study|Withdrawal by Subject|0
6058889|NCT00474760|9659328|FG003|Overall Study|Death|0
6058890|NCT00474760|9659329|FG004|Overall Study|Death|2
6058891|NCT00474760|9659330|FG005|Overall Study|Death|0
6058892|NCT00474760|9659331|FG006|Overall Study|Death|0
6058893|NCT00474760|9659325|FG000|Overall Study|Adverse Event|0
6058894|NCT00474760|9659326|FG001|Overall Study|Adverse Event|0
6058895|NCT00474760|9659327|FG002|Overall Study|Adverse Event|0
6058896|NCT00474760|9659328|FG003|Overall Study|Adverse Event|0
6058897|NCT00474760|9659329|FG004|Overall Study|Adverse Event|1
6058898|NCT00474760|9659330|FG005|Overall Study|Adverse Event|7
6058899|NCT00474760|9659331|FG006|Overall Study|Adverse Event|0
6058900|NCT00474760|9659325|FG000|Overall Study|Laboratory abnormality|0
6058901|NCT00474760|9659326|FG001|Overall Study|Laboratory abnormality|0
6058902|NCT00474760|9659327|FG002|Overall Study|Laboratory abnormality|0
6058903|NCT00474760|9659328|FG003|Overall Study|Laboratory abnormality|0
6058904|NCT00474760|9659329|FG004|Overall Study|Laboratory abnormality|0
6092434|NCT00705614|9705251|FG001|Switch to Remicade|Withdrawal by Subject|12
6092435|NCT00705614|9705250|FG000|Switch to Remicade|Administrative Reason|0
6092436|NCT00705614|9705251|FG001|Switch to Remicade|Administrative Reason|9
6092437|NCT00705666|9705263|FG000|Overall Study|No post-treatment questionnaire|279
6092438|NCT00705666|9705263|FG000|Overall Study|Withdrawal by Subject|21
6092439|NCT00705666|9705263|FG000|Overall Study|Physician Decision|7
6092440|NCT00705666|9705263|FG000|Overall Study|Lost to Follow-up|5
6092441|NCT00705666|9705263|FG000|Overall Study|Death|1
6092442|NCT00705666|9705263|FG000|Overall Study|Adverse Event|4
6092443|NCT00705666|9705263|FG000|Overall Study|Other|12
6092444|NCT00705666|9705263|FG000|Overall Study|Other|2
6092445|NCT00705666|9705263|FG000|Overall Study|Lack of data|3
6092446|NCT00705666|9705263|FG000|Overall Study|Untreated|5
6202584|NCT01504867|9862891|FG000|Overall Study|Inclusion criteria not met|2
6202585|NCT01504867|9862892|FG001|Overall Study|Inclusion criteria not met|2
6202586|NCT01504867|9862891|FG000|Overall Study|Consent revoked|5
6202587|NCT01504867|9862892|FG001|Overall Study|Consent revoked|1
6202588|NCT01504971|9862911|FG000|Overall Study|Physician Decision|13
6202589|NCT01505010|9862925|FG000|Overall Study|Protocol Violation|0
6202590|NCT01505010|9862926|FG001|Overall Study|Protocol Violation|1
6058905|NCT00474760|9659330|FG005|Overall Study|Laboratory abnormality|1
6058906|NCT00474760|9659331|FG006|Overall Study|Laboratory abnormality|0
6058907|NCT00474760|9659325|FG000|Overall Study|Withdrawal by Subject|0
6058908|NCT00474760|9659326|FG001|Overall Study|Withdrawal by Subject|0
6058909|NCT00474760|9659327|FG002|Overall Study|Withdrawal by Subject|0
6058910|NCT00474760|9659328|FG003|Overall Study|Withdrawal by Subject|1
6058911|NCT00474760|9659329|FG004|Overall Study|Withdrawal by Subject|0
6058912|NCT00474760|9659330|FG005|Overall Study|Withdrawal by Subject|1
6058913|NCT00474760|9659331|FG006|Overall Study|Withdrawal by Subject|1
6058914|NCT00474760|9659325|FG000|Overall Study|Other|0
6058915|NCT00474760|9659326|FG001|Overall Study|Other|1
6058916|NCT00474760|9659327|FG002|Overall Study|Other|0
6058917|NCT00474760|9659328|FG003|Overall Study|Other|0
6058918|NCT00474760|9659329|FG004|Overall Study|Other|1
6058919|NCT00474760|9659330|FG005|Overall Study|Other|0
6058920|NCT00474760|9659331|FG006|Overall Study|Other|0
6058921|NCT00474760|9659325|FG000|Overall Study|Progressive disease|3
6058922|NCT00474760|9659326|FG001|Overall Study|Progressive disease|2
6058923|NCT00474760|9659327|FG002|Overall Study|Progressive disease|3
6092447|NCT00705679|9705272|FG000|Overall Study|Adverse Event|1
6092448|NCT00705679|9705273|FG001|Overall Study|Adverse Event|1
6092449|NCT00705679|9705274|FG002|Overall Study|Adverse Event|0
6092450|NCT00705679|9705275|FG003|Overall Study|Adverse Event|0
6092451|NCT00705679|9705276|FG004|Overall Study|Adverse Event|0
6092452|NCT00705679|9705272|FG000|Overall Study|Death|0
6092453|NCT00705679|9705273|FG001|Overall Study|Death|0
6092454|NCT00705679|9705274|FG002|Overall Study|Death|3
6092455|NCT00705679|9705275|FG003|Overall Study|Death|2
6092456|NCT00705679|9705276|FG004|Overall Study|Death|1
6092457|NCT00705679|9705272|FG000|Overall Study|Lost to Follow-up|32
6092458|NCT00705679|9705273|FG001|Overall Study|Lost to Follow-up|60
6092459|NCT00705679|9705274|FG002|Overall Study|Lost to Follow-up|44
6092460|NCT00705679|9705275|FG003|Overall Study|Lost to Follow-up|30
6092461|NCT00705679|9705276|FG004|Overall Study|Lost to Follow-up|35
6092462|NCT00705679|9705272|FG000|Overall Study|Physician Decision|0
6092463|NCT00705679|9705273|FG001|Overall Study|Physician Decision|1
6092464|NCT00705679|9705274|FG002|Overall Study|Physician Decision|0
6092465|NCT00705679|9705275|FG003|Overall Study|Physician Decision|1
6092466|NCT00705679|9705276|FG004|Overall Study|Physician Decision|0
6092467|NCT00705679|9705272|FG000|Overall Study|Withdrawal by Subject|32
6092468|NCT00705679|9705273|FG001|Overall Study|Withdrawal by Subject|77
6092469|NCT00705679|9705274|FG002|Overall Study|Withdrawal by Subject|68
6092470|NCT00705679|9705275|FG003|Overall Study|Withdrawal by Subject|47
6092471|NCT00705679|9705276|FG004|Overall Study|Withdrawal by Subject|33
6092472|NCT00705718|9705295|FG000|Overall Study|Death|6
6092473|NCT00705718|9705296|FG001|Overall Study|Death|6
6092474|NCT00705718|9705295|FG000|Overall Study|Not due for Visit|0
6092475|NCT00705718|9705296|FG001|Overall Study|Not due for Visit|12
6092476|NCT00705718|9705295|FG000|Overall Study|Follow up not done|1
6092477|NCT00705718|9705296|FG001|Overall Study|Follow up not done|4
6092478|NCT00705757|9705305|FG000|Overall Study|Lack of Efficacy|5
6092479|NCT00705757|9705306|FG001|Overall Study|Lack of Efficacy|1
6092480|NCT00705757|9705307|FG002|Overall Study|Lack of Efficacy|3
6092481|NCT00705757|9705305|FG000|Overall Study|Lost to Follow-up|7
6092482|NCT00705757|9705306|FG001|Overall Study|Lost to Follow-up|6
6092483|NCT00705757|9705307|FG002|Overall Study|Lost to Follow-up|6
6092484|NCT00705757|9705305|FG000|Overall Study|Withdrawal by Subject|1
6092485|NCT00705757|9705306|FG001|Overall Study|Withdrawal by Subject|1
6058924|NCT00474760|9659328|FG003|Overall Study|Progressive disease|2
6092486|NCT00705757|9705307|FG002|Overall Study|Withdrawal by Subject|2
6092487|NCT00705783|9705317|FG000|Conversion Phase|Sponsor Discontinued Study|54
6092488|NCT00705783|9705318|FG001|Conversion Phase|Sponsor Discontinued Study|0
6092489|NCT00705783|9705319|FG002|Conversion Phase|Sponsor Discontinued Study|0
6092490|NCT00705783|9705317|FG000|Conversion Phase|Lost to Follow-up|13
6092491|NCT00705783|9705318|FG001|Conversion Phase|Lost to Follow-up|0
6202591|NCT01505010|9862925|FG000|Overall Study|Lost to Follow-up|0
6202592|NCT01505010|9862926|FG001|Overall Study|Lost to Follow-up|1
6058925|NCT00474760|9659329|FG004|Overall Study|Progressive disease|8
6092492|NCT00705783|9705319|FG002|Conversion Phase|Lost to Follow-up|0
6092493|NCT00705783|9705317|FG000|Conversion Phase|Met Withdrawal Criteria|4
6092494|NCT00705783|9705318|FG001|Conversion Phase|Met Withdrawal Criteria|0
6092495|NCT00705783|9705319|FG002|Conversion Phase|Met Withdrawal Criteria|0
6092496|NCT00705783|9705317|FG000|Conversion Phase|Withdrawn by Investigator|4
6092497|NCT00705783|9705318|FG001|Conversion Phase|Withdrawn by Investigator|0
6092498|NCT00705783|9705319|FG002|Conversion Phase|Withdrawn by Investigator|0
6092499|NCT00705783|9705317|FG000|Conversion Phase|Withdrew Consent|24
6092500|NCT00705783|9705318|FG001|Conversion Phase|Withdrew Consent|0
6092501|NCT00705783|9705319|FG002|Conversion Phase|Withdrew Consent|0
6092502|NCT00705783|9705317|FG000|Conversion Phase|Protocol Deviation|2
6092503|NCT00705783|9705318|FG001|Conversion Phase|Protocol Deviation|0
6092504|NCT00705783|9705319|FG002|Conversion Phase|Protocol Deviation|0
6092505|NCT00705783|9705317|FG000|Conversion Phase|Adverse Event|11
6092506|NCT00705783|9705318|FG001|Conversion Phase|Adverse Event|0
6092507|NCT00705783|9705319|FG002|Conversion Phase|Adverse Event|0
6092508|NCT00705783|9705317|FG000|Conversion Phase|Lack of Efficacy with Adverse Event|13
6092509|NCT00705783|9705318|FG001|Conversion Phase|Lack of Efficacy with Adverse Event|0
6092510|NCT00705783|9705319|FG002|Conversion Phase|Lack of Efficacy with Adverse Event|0
6092511|NCT00705783|9705317|FG000|Conversion Phase|Lack of Efficacy without Adverse Event|8
6092512|NCT00705783|9705318|FG001|Conversion Phase|Lack of Efficacy without Adverse Event|0
6092513|NCT00705783|9705319|FG002|Conversion Phase|Lack of Efficacy without Adverse Event|0
6092514|NCT00705783|9705317|FG000|Oral Stabilization Phase|Sponsor Discontinue Study|42
6092515|NCT00705783|9705318|FG001|Oral Stabilization Phase|Sponsor Discontinue Study|0
6092516|NCT00705783|9705319|FG002|Oral Stabilization Phase|Sponsor Discontinue Study|0
6092517|NCT00705783|9705317|FG000|Oral Stabilization Phase|Lost to Follow-up|7
6092518|NCT00705783|9705318|FG001|Oral Stabilization Phase|Lost to Follow-up|0
6092519|NCT00705783|9705319|FG002|Oral Stabilization Phase|Lost to Follow-up|0
6092520|NCT00705783|9705317|FG000|Oral Stabilization Phase|Met Withdrawal Criteria|19
6092521|NCT00705783|9705318|FG001|Oral Stabilization Phase|Met Withdrawal Criteria|0
6092522|NCT00705783|9705319|FG002|Oral Stabilization Phase|Met Withdrawal Criteria|0
6092523|NCT00705783|9705317|FG000|Oral Stabilization Phase|Withdrawn by Investigator|12
6092524|NCT00705783|9705318|FG001|Oral Stabilization Phase|Withdrawn by Investigator|0
6092525|NCT00705783|9705319|FG002|Oral Stabilization Phase|Withdrawn by Investigator|0
6092526|NCT00705783|9705317|FG000|Oral Stabilization Phase|Withdrew Consent|29
6092527|NCT00705783|9705318|FG001|Oral Stabilization Phase|Withdrew Consent|0
6092528|NCT00705783|9705319|FG002|Oral Stabilization Phase|Withdrew Consent|0
6092529|NCT00705783|9705317|FG000|Oral Stabilization Phase|Adverse Event|14
6092530|NCT00705783|9705318|FG001|Oral Stabilization Phase|Adverse Event|0
6092531|NCT00705783|9705319|FG002|Oral Stabilization Phase|Adverse Event|0
6092532|NCT00705783|9705317|FG000|Oral Stabilization Phase|Lack of Efficacy with Adverse Event|7
6092533|NCT00705783|9705318|FG001|Oral Stabilization Phase|Lack of Efficacy with Adverse Event|0
6092534|NCT00705783|9705319|FG002|Oral Stabilization Phase|Lack of Efficacy with Adverse Event|0
6092535|NCT00705783|9705317|FG000|Oral Stabilization Phase|Lack of Efficacy without Adverse Event|4
6092536|NCT00705783|9705318|FG001|Oral Stabilization Phase|Lack of Efficacy without Adverse Event|0
6092537|NCT00705783|9705319|FG002|Oral Stabilization Phase|Lack of Efficacy without Adverse Event|0
6092538|NCT00705783|9705317|FG000|Depot Stabilization Phase|Sponsor Discontinued Study|86
6092539|NCT00705783|9705318|FG001|Depot Stabilization Phase|Sponsor Discontinued Study|0
6092540|NCT00705783|9705319|FG002|Depot Stabilization Phase|Sponsor Discontinued Study|0
6092541|NCT00705783|9705317|FG000|Depot Stabilization Phase|Lost to Follow-up|11
6202593|NCT01505114|9862936|FG000|Overall Study|Withdrawal by Subject|5
6202594|NCT01505114|9862937|FG001|Overall Study|Withdrawal by Subject|4
6202595|NCT01505114|9862938|FG002|Overall Study|Withdrawal by Subject|4
6202596|NCT01505114|9862939|FG003|Overall Study|Withdrawal by Subject|7
6202597|NCT01505114|9862936|FG000|Overall Study|Death|1
6202598|NCT01505114|9862937|FG001|Overall Study|Death|0
6202599|NCT01505114|9862938|FG002|Overall Study|Death|0
6202600|NCT01505114|9862939|FG003|Overall Study|Death|1
6202601|NCT01505114|9862936|FG000|Overall Study|unable to adhere to visit schedule|3
6202602|NCT01505114|9862937|FG001|Overall Study|unable to adhere to visit schedule|2
6058926|NCT00474760|9659330|FG005|Overall Study|Progressive disease|20
6058927|NCT00474760|9659331|FG006|Overall Study|Progressive disease|7
6058928|NCT00474760|9659325|FG000|Overall Study|Terminated by sponsor|0
6058929|NCT00474760|9659326|FG001|Overall Study|Terminated by sponsor|0
6058930|NCT00474760|9659327|FG002|Overall Study|Terminated by sponsor|0
6058931|NCT00474760|9659328|FG003|Overall Study|Terminated by sponsor|0
6058932|NCT00474760|9659329|FG004|Overall Study|Terminated by sponsor|0
6202603|NCT01505114|9862938|FG002|Overall Study|unable to adhere to visit schedule|3
6202604|NCT01505114|9862939|FG003|Overall Study|unable to adhere to visit schedule|3
6202605|NCT01505114|9862936|FG000|Overall Study|Lost to Follow-up|11
6202606|NCT01505114|9862937|FG001|Overall Study|Lost to Follow-up|5
6202607|NCT01505114|9862938|FG002|Overall Study|Lost to Follow-up|8
6202608|NCT01505114|9862939|FG003|Overall Study|Lost to Follow-up|7
6202609|NCT01505114|9862936|FG000|Overall Study|relocated|4
6202610|NCT01505114|9862937|FG001|Overall Study|relocated|2
6202611|NCT01505114|9862938|FG002|Overall Study|relocated|2
6202612|NCT01505114|9862939|FG003|Overall Study|relocated|3
6202613|NCT01505114|9862936|FG000|Overall Study|inadvertent enrollment due to peanut all|0
6202614|NCT01505114|9862937|FG001|Overall Study|inadvertent enrollment due to peanut all|0
6202615|NCT01505114|9862938|FG002|Overall Study|inadvertent enrollment due to peanut all|0
6202616|NCT01505114|9862939|FG003|Overall Study|inadvertent enrollment due to peanut all|1
6202617|NCT01505114|9862936|FG000|Overall Study|staff safety concerns|0
6202618|NCT01505114|9862937|FG001|Overall Study|staff safety concerns|0
6202619|NCT01505114|9862938|FG002|Overall Study|staff safety concerns|0
6202620|NCT01505114|9862939|FG003|Overall Study|staff safety concerns|1
6202621|NCT01505114|9862936|FG000|Overall Study|investigator decision|1
6202622|NCT01505114|9862937|FG001|Overall Study|investigator decision|0
6202623|NCT01505114|9862938|FG002|Overall Study|investigator decision|1
6202624|NCT01505114|9862939|FG003|Overall Study|investigator decision|0
6202625|NCT01505374|9862973|FG000|Overall Study|Lost to Follow-up|1
6202626|NCT01505374|9862974|FG001|Overall Study|Lost to Follow-up|0
6202627|NCT01505387|9862983|FG000|Overall Study|Protocol Violation|1
6202628|NCT01505387|9862984|FG001|Overall Study|Protocol Violation|0
6202629|NCT01505387|9862983|FG000|Overall Study|Withdrawal by Subject|1
6202630|NCT01505387|9862984|FG001|Overall Study|Withdrawal by Subject|1
6202631|NCT01505491|9862993|FG000|Overall Study|Other reason not listed|1
6202632|NCT01505491|9862994|FG001|Overall Study|Other reason not listed|0
6202633|NCT01505491|9862995|FG002|Overall Study|Other reason not listed|0
6202634|NCT01505491|9862993|FG000|Overall Study|Withdrawal by Subject|1
6202635|NCT01505491|9862994|FG001|Overall Study|Withdrawal by Subject|1
6202636|NCT01505491|9862995|FG002|Overall Study|Withdrawal by Subject|4
6202637|NCT01505491|9862993|FG000|Overall Study|Lost to Follow-up|0
6202638|NCT01505491|9862994|FG001|Overall Study|Lost to Follow-up|0
6058933|NCT00474760|9659330|FG005|Overall Study|Terminated by sponsor|0
6058934|NCT00474760|9659331|FG006|Overall Study|Terminated by sponsor|2
6058935|NCT00474786|9659356|FG000|Overall Study|Not Meeting Study Criteria|0
6058936|NCT00474786|9659357|FG001|Overall Study|Not Meeting Study Criteria|1
6058937|NCT00474786|9659356|FG000|Overall Study|Investigator Request|2
6058938|NCT00474786|9659357|FG001|Overall Study|Investigator Request|1
6058939|NCT00474786|9659356|FG000|Overall Study|Death|189
6058940|NCT00474786|9659357|FG001|Overall Study|Death|170
6058941|NCT00474786|9659356|FG000|Overall Study|Discontinuation of Study by Sponsor|42
6058942|NCT00474786|9659357|FG001|Overall Study|Discontinuation of Study by Sponsor|59
6058943|NCT00474786|9659356|FG000|Overall Study|Lost to Follow-up|4
6058944|NCT00474786|9659357|FG001|Overall Study|Lost to Follow-up|7
6058945|NCT00474786|9659356|FG000|Overall Study|Protocol Violation|2
6058946|NCT00474786|9659357|FG001|Overall Study|Protocol Violation|0
6058947|NCT00474786|9659356|FG000|Overall Study|Withdrawal by Subject|15
6058948|NCT00474786|9659357|FG001|Overall Study|Withdrawal by Subject|15
6058949|NCT00474786|9659356|FG000|Overall Study|Other|5
6058950|NCT00474786|9659357|FG001|Overall Study|Other|0
6058951|NCT00474812|9659363|FG000|Overall Study|Withdrawal by Subject|5
6058952|NCT00474812|9659363|FG000|Overall Study|No Initiation of treatment|2
6058953|NCT00474903|9659380|FG000|Overall Study|Protocol Violation|1
6058954|NCT00474903|9659381|FG001|Overall Study|Protocol Violation|5
6058955|NCT00474903|9659382|FG002|Overall Study|Protocol Violation|2
6058956|NCT00474929|9659395|FG000|Overall Study|Withdrawal by Subject|0
6058957|NCT00474929|9659396|FG001|Overall Study|Withdrawal by Subject|1
6058958|NCT00474929|9659397|FG002|Overall Study|Withdrawal by Subject|0
6058959|NCT00474929|9659398|FG003|Overall Study|Withdrawal by Subject|0
6058960|NCT00474929|9659399|FG004|Overall Study|Withdrawal by Subject|0
6058961|NCT00474929|9659395|FG000|Overall Study|Unrelated medical condition|0
6058962|NCT00474929|9659396|FG001|Overall Study|Unrelated medical condition|0
6058963|NCT00474929|9659397|FG002|Overall Study|Unrelated medical condition|1
6058964|NCT00474929|9659398|FG003|Overall Study|Unrelated medical condition|0
6058965|NCT00474929|9659399|FG004|Overall Study|Unrelated medical condition|0
6058966|NCT00474929|9659395|FG000|Overall Study|Physician Decision|0
6058967|NCT00474929|9659396|FG001|Overall Study|Physician Decision|0
6058968|NCT00474929|9659397|FG002|Overall Study|Physician Decision|1
6058969|NCT00474929|9659398|FG003|Overall Study|Physician Decision|2
6058970|NCT00474929|9659399|FG004|Overall Study|Physician Decision|0
6058971|NCT00474955|9659412|FG000|Overall Study|Adverse Event|2
6058972|NCT00474955|9659412|FG000|Overall Study|Drug unavailability|1
6058973|NCT00474955|9659412|FG000|Overall Study|Personal reasons|5
6058974|NCT00474968|9659418|FG000|Overall Study|Withdrawal by Subject|8
6058975|NCT00474968|9659419|FG001|Overall Study|Withdrawal by Subject|7
6058976|NCT00474968|9659418|FG000|Overall Study|Protocol Violation|9
6058977|NCT00474968|9659419|FG001|Overall Study|Protocol Violation|8
6058978|NCT00474968|9659418|FG000|Overall Study|Sample not collected|1
6058979|NCT00474968|9659419|FG001|Overall Study|Sample not collected|1
6058980|NCT00474994|9659425|FG000|Overall Study|Patient Not treated|1
6058981|NCT00474994|9659425|FG000|Overall Study|Patient evaluable for toxicity only|3
6058982|NCT00474994|9659425|FG000|Overall Study|Patient found to be ineligible|1
6058983|NCT00475020|9659429|FG000|Overall Study|Physician Decision|3
6058984|NCT00475020|9659429|FG000|Overall Study|Insurance Denial|1
6058985|NCT00475020|9659429|FG000|Overall Study|Donor not able to donate the last minute|1
6202639|NCT01505491|9862995|FG002|Overall Study|Lost to Follow-up|1
6202640|NCT01505530|9863006|FG000|Overall Study|Progressive Disease|19
6202641|NCT01505530|9863007|FG001|Overall Study|Progressive Disease|17
6202642|NCT01505530|9863008|FG002|Overall Study|Progressive Disease|18
6058986|NCT00475033|9659435|FG000|Infant Series|Failed to return|3
6058987|NCT00475033|9659436|FG001|Infant Series|Failed to return|4
6058988|NCT00475033|9659435|FG000|Infant Series|Parent or legal guardian request|1
6058989|NCT00475033|9659436|FG001|Infant Series|Parent or legal guardian request|5
6058990|NCT00475033|9659435|FG000|Infant Series|Protocol Violation|1
6058991|NCT00475033|9659436|FG001|Infant Series|Protocol Violation|2
6058992|NCT00475033|9659435|FG000|Infant Series|Lost to Follow-up|2
6058993|NCT00475033|9659436|FG001|Infant Series|Lost to Follow-up|0
6058994|NCT00475033|9659435|FG000|Infant Series|Adverse Event|0
6058995|NCT00475033|9659436|FG001|Infant Series|Adverse Event|2
6058996|NCT00475033|9659435|FG000|After the Infant Series|Adverse Event|0
6058997|NCT00475033|9659436|FG001|After the Infant Series|Adverse Event|4
6058998|NCT00475033|9659435|FG000|After the Infant Series|Parent or legal guardian request|2
6058999|NCT00475033|9659436|FG001|After the Infant Series|Parent or legal guardian request|2
6059000|NCT00475033|9659435|FG000|After the Infant Series|Failed to return|2
6059001|NCT00475033|9659436|FG001|After the Infant Series|Failed to return|1
6059002|NCT00475033|9659435|FG000|After the Infant Series|Protocol Violation|1
6059003|NCT00475033|9659436|FG001|After the Infant Series|Protocol Violation|0
6059004|NCT00475033|9659435|FG000|After the Infant Series|Lost to Follow-up|1
6059005|NCT00475033|9659436|FG001|After the Infant Series|Lost to Follow-up|0
6059006|NCT00475033|9659435|FG000|After the Infant Series|Other|0
6059007|NCT00475033|9659436|FG001|After the Infant Series|Other|1
6059008|NCT00475033|9659435|FG000|Toddler Dose|Parent or legal guardian request|2
6059009|NCT00475033|9659436|FG001|Toddler Dose|Parent or legal guardian request|0
6059010|NCT00475033|9659435|FG000|Toddler Dose|Failed to return|1
6059011|NCT00475033|9659436|FG001|Toddler Dose|Failed to return|0
6059012|NCT00475033|9659435|FG000|Toddler Dose|Lost to Follow-up|1
6059013|NCT00475033|9659436|FG001|Toddler Dose|Lost to Follow-up|0
6059014|NCT00475176|9659474|FG000|Overall Study|Adverse Event|2
6059015|NCT00475176|9659474|FG000|Overall Study|Withdrawal by Subject|1
6059016|NCT00475176|9659474|FG000|Overall Study|Protocol Violation|1
6059017|NCT00475228|9659489|FG000|Overall Study|Lost to Follow-up|17
6059018|NCT00475228|9659490|FG001|Overall Study|Lost to Follow-up|17
6059019|NCT00475306|9659514|FG000|Overall Study|Protocol Violation|1
6059020|NCT00475306|9659515|FG001|Overall Study|Protocol Violation|1
6059021|NCT00475306|9659516|FG002|Overall Study|Protocol Violation|0
6059022|NCT00475306|9659517|FG003|Overall Study|Protocol Violation|1
6059023|NCT00475423|9659543|FG000|Overall Study|Protocol Violation|5
6059024|NCT00475423|9659543|FG000|Overall Study|Adverse Event|4
6059025|NCT00475423|9659543|FG000|Overall Study|Withdrawal by Subject|6
6059026|NCT00475423|9659543|FG000|Overall Study|Lack of Efficacy|8
6059027|NCT00475423|9659543|FG000|Overall Study|Death|1
6059028|NCT00475423|9659543|FG000|Overall Study|Reason not specified|1
6059029|NCT00475423|9659543|FG000|Overall Study|Lost to Follow-up|7
6059030|NCT00475644|9659596|FG000|Overall Study|Protocol Violation|13
6059031|NCT00475670|9659602|FG000|Overall Study|Death|0
6059032|NCT00475670|9659603|FG001|Overall Study|Death|1
6059033|NCT00475670|9659602|FG000|Overall Study|Lack of Efficacy|3
6059034|NCT00475670|9659603|FG001|Overall Study|Lack of Efficacy|34
6059035|NCT00475670|9659602|FG000|Overall Study|Refused treatment|0
6059036|NCT00475670|9659603|FG001|Overall Study|Refused treatment|2
6059037|NCT00475670|9659602|FG000|Overall Study|Failure to Return|0
6059038|NCT00475670|9659603|FG001|Overall Study|Failure to Return|1
6059039|NCT00475670|9659602|FG000|Overall Study|Other|0
6059040|NCT00475670|9659603|FG001|Overall Study|Other|3
6059041|NCT00475709|9659609|FG000|Overall Study|Did not meet eligibility criteria|8
6059042|NCT00475709|9659609|FG000|Overall Study|Death|41
6059043|NCT00475709|9659609|FG000|Overall Study|Device Explant|6
6059044|NCT00475709|9659609|FG000|Overall Study|Lost to Follow-up|21
6059045|NCT00475722|9659615|FG000|Overall Study|Withdrawal by Subject|12
6059046|NCT00475722|9659616|FG001|Overall Study|Withdrawal by Subject|12
6059047|NCT00475722|9659615|FG000|Overall Study|Protocol Violation|3
6059048|NCT00475722|9659616|FG001|Overall Study|Protocol Violation|0
6059049|NCT00475735|9659628|FG000|Treatment Period 1|Adverse Event|2
6059050|NCT00475735|9659629|FG001|Treatment Period 1|Adverse Event|0
6059051|NCT00475735|9659630|FG002|Treatment Period 1|Adverse Event|0
6059052|NCT00475735|9659631|FG003|Treatment Period 1|Adverse Event|0
6059053|NCT00475735|9659632|FG004|Treatment Period 1|Adverse Event|0
6059054|NCT00475735|9659633|FG005|Treatment Period 1|Adverse Event|0
6059055|NCT00475735|9659628|FG000|Treatment Period 1|Lack of Efficacy|1
6059056|NCT00475735|9659629|FG001|Treatment Period 1|Lack of Efficacy|0
6059057|NCT00475735|9659630|FG002|Treatment Period 1|Lack of Efficacy|0
6059058|NCT00475735|9659631|FG003|Treatment Period 1|Lack of Efficacy|0
6059059|NCT00475735|9659632|FG004|Treatment Period 1|Lack of Efficacy|0
6059060|NCT00475735|9659633|FG005|Treatment Period 1|Lack of Efficacy|0
6059061|NCT00475735|9659628|FG000|Treatment Period 1|Lost to Follow-up|0
6059062|NCT00475735|9659629|FG001|Treatment Period 1|Lost to Follow-up|0
6059063|NCT00475735|9659630|FG002|Treatment Period 1|Lost to Follow-up|0
6059064|NCT00475735|9659631|FG003|Treatment Period 1|Lost to Follow-up|0
6059065|NCT00475735|9659632|FG004|Treatment Period 1|Lost to Follow-up|0
6059066|NCT00475735|9659633|FG005|Treatment Period 1|Lost to Follow-up|1
6059067|NCT00475735|9659628|FG000|Treatment Period 1|Protocol Violation|0
6059068|NCT00475735|9659629|FG001|Treatment Period 1|Protocol Violation|0
6059069|NCT00475735|9659630|FG002|Treatment Period 1|Protocol Violation|0
6059070|NCT00475735|9659631|FG003|Treatment Period 1|Protocol Violation|1
6059071|NCT00475735|9659632|FG004|Treatment Period 1|Protocol Violation|0
6059072|NCT00475735|9659633|FG005|Treatment Period 1|Protocol Violation|0
6059073|NCT00475735|9659628|FG000|Treatment Period 1|Withdrawal by Subject|1
6059074|NCT00475735|9659629|FG001|Treatment Period 1|Withdrawal by Subject|1
6059075|NCT00475735|9659630|FG002|Treatment Period 1|Withdrawal by Subject|0
6059076|NCT00475735|9659631|FG003|Treatment Period 1|Withdrawal by Subject|0
6059077|NCT00475735|9659632|FG004|Treatment Period 1|Withdrawal by Subject|0
6059078|NCT00475735|9659633|FG005|Treatment Period 1|Withdrawal by Subject|0
6059079|NCT00475735|9659628|FG000|Treatment Period 1|DC due to AE but continuing|0
6059080|NCT00475735|9659629|FG001|Treatment Period 1|DC due to AE but continuing|0
6059081|NCT00475735|9659630|FG002|Treatment Period 1|DC due to AE but continuing|0
6059082|NCT00475735|9659631|FG003|Treatment Period 1|DC due to AE but continuing|1
6059083|NCT00475735|9659632|FG004|Treatment Period 1|DC due to AE but continuing|2
6059084|NCT00475735|9659633|FG005|Treatment Period 1|DC due to AE but continuing|2
6059085|NCT00475735|9659628|FG000|Treatment Period 1|DC due to no efficacy but Continuing|0
6059086|NCT00475735|9659629|FG001|Treatment Period 1|DC due to no efficacy but Continuing|1
6059087|NCT00475735|9659630|FG002|Treatment Period 1|DC due to no efficacy but Continuing|0
6059088|NCT00475735|9659631|FG003|Treatment Period 1|DC due to no efficacy but Continuing|0
6059089|NCT00475735|9659632|FG004|Treatment Period 1|DC due to no efficacy but Continuing|0
6059090|NCT00475735|9659633|FG005|Treatment Period 1|DC due to no efficacy but Continuing|0
6059091|NCT00475735|9659628|FG000|Treatment Washout|Lost to Follow-up|0
6059092|NCT00475735|9659629|FG001|Treatment Washout|Lost to Follow-up|1
6059093|NCT00475735|9659630|FG002|Treatment Washout|Lost to Follow-up|0
6059094|NCT00475735|9659631|FG003|Treatment Washout|Lost to Follow-up|0
6059095|NCT00475735|9659632|FG004|Treatment Washout|Lost to Follow-up|0
6059096|NCT00475735|9659633|FG005|Treatment Washout|Lost to Follow-up|0
6059097|NCT00475735|9659628|FG000|Treatment Washout|Protocol Violation|0
6059098|NCT00475735|9659629|FG001|Treatment Washout|Protocol Violation|1
6059099|NCT00475735|9659630|FG002|Treatment Washout|Protocol Violation|0
6059100|NCT00475735|9659631|FG003|Treatment Washout|Protocol Violation|0
6059101|NCT00475735|9659632|FG004|Treatment Washout|Protocol Violation|0
6059102|NCT00475735|9659633|FG005|Treatment Washout|Protocol Violation|0
6059103|NCT00475735|9659628|FG000|Treatment Period 2|Adverse Event|0
6059104|NCT00475735|9659629|FG001|Treatment Period 2|Adverse Event|1
6059105|NCT00475735|9659630|FG002|Treatment Period 2|Adverse Event|0
6059106|NCT00475735|9659631|FG003|Treatment Period 2|Adverse Event|2
6059107|NCT00475735|9659632|FG004|Treatment Period 2|Adverse Event|0
6059108|NCT00475735|9659633|FG005|Treatment Period 2|Adverse Event|0
6059109|NCT00475735|9659628|FG000|Treatment Period 2|Lack of Efficacy|0
6059110|NCT00475735|9659629|FG001|Treatment Period 2|Lack of Efficacy|0
6059111|NCT00475735|9659630|FG002|Treatment Period 2|Lack of Efficacy|0
6059112|NCT00475735|9659631|FG003|Treatment Period 2|Lack of Efficacy|0
6059113|NCT00475735|9659632|FG004|Treatment Period 2|Lack of Efficacy|0
6059114|NCT00475735|9659633|FG005|Treatment Period 2|Lack of Efficacy|1
6059115|NCT00475735|9659628|FG000|Treatment Period 2|Withdrawal by Subject|0
6059116|NCT00475735|9659629|FG001|Treatment Period 2|Withdrawal by Subject|0
6059117|NCT00475735|9659630|FG002|Treatment Period 2|Withdrawal by Subject|0
6059118|NCT00475735|9659631|FG003|Treatment Period 2|Withdrawal by Subject|0
6059119|NCT00475735|9659632|FG004|Treatment Period 2|Withdrawal by Subject|1
6059120|NCT00475735|9659633|FG005|Treatment Period 2|Withdrawal by Subject|0
6059121|NCT00475852|9659654|FG000|Overall Study|Death|444
6059122|NCT00475852|9659655|FG001|Overall Study|Death|456
6059123|NCT00475852|9659654|FG000|Overall Study|Withdrawal by Subject|19
6059124|NCT00475852|9659655|FG001|Overall Study|Withdrawal by Subject|24
6059125|NCT00475852|9659654|FG000|Overall Study|Lost to Follow-up|54
6059126|NCT00475852|9659655|FG001|Overall Study|Lost to Follow-up|68
6059127|NCT00475865|9659664|FG000|Overall Study|Adverse Event|0
6059128|NCT00475865|9659665|FG001|Overall Study|Adverse Event|3
6059129|NCT00475865|9659666|FG002|Overall Study|Adverse Event|4
6059130|NCT00475865|9659664|FG000|Overall Study|Lack of Efficacy|1
6059131|NCT00475865|9659665|FG001|Overall Study|Lack of Efficacy|0
6059132|NCT00475865|9659666|FG002|Overall Study|Lack of Efficacy|0
6059133|NCT00475865|9659664|FG000|Overall Study|Progressive disease|0
6059134|NCT00475865|9659665|FG001|Overall Study|Progressive disease|1
6059135|NCT00475865|9659666|FG002|Overall Study|Progressive disease|2
6059136|NCT00475865|9659664|FG000|Overall Study|Participant did not wish to continue|1
6059137|NCT00475865|9659665|FG001|Overall Study|Participant did not wish to continue|0
6059138|NCT00475865|9659666|FG002|Overall Study|Participant did not wish to continue|0
6059139|NCT00475865|9659664|FG000|Overall Study|Other than above|0
6059140|NCT00475865|9659665|FG001|Overall Study|Other than above|1
6059141|NCT00475865|9659666|FG002|Overall Study|Other than above|0
6059142|NCT00475982|9659702|FG000|Overall Study|surgery rescheduled|7
6059143|NCT00475982|9659703|FG001|Overall Study|surgery rescheduled|3
6059144|NCT00476008|9659711|FG000|Overall Study|Adverse Event|4
6059145|NCT00476008|9659712|FG001|Overall Study|Adverse Event|4
6059146|NCT00476008|9659711|FG000|Overall Study|Placebo concerns|2
6059147|NCT00476008|9659712|FG001|Overall Study|Placebo concerns|2
6059148|NCT00476008|9659711|FG000|Overall Study|Physician Decision: Medication Noncompli|2
6059149|NCT00476008|9659712|FG001|Overall Study|Physician Decision: Medication Noncompli|1
6059150|NCT00476008|9659711|FG000|Overall Study|Withdrawal by Subject|0
6059151|NCT00476008|9659712|FG001|Overall Study|Withdrawal by Subject|1
6059152|NCT00476008|9659711|FG000|Overall Study|Death|1
6059153|NCT00476008|9659712|FG001|Overall Study|Death|0
6059154|NCT00476047|9659737|FG000|Overall Study|Lost to Follow-up|1
6059155|NCT00476086|9659743|FG000|Overall Study|Alternative therapy|1
6059156|NCT00476086|9659743|FG000|Overall Study|Progressive Disease|4
6059157|NCT00476151|9659751|FG000|Overall Study|Adverse Event|0
6059158|NCT00476151|9659752|FG001|Overall Study|Adverse Event|2
6059159|NCT00476151|9659751|FG000|Overall Study|Protocol Violation|1
6059160|NCT00476151|9659752|FG001|Overall Study|Protocol Violation|3
6059161|NCT00476151|9659751|FG000|Overall Study|Withdrawal by Subject|2
6059162|NCT00476151|9659752|FG001|Overall Study|Withdrawal by Subject|0
6059163|NCT00476151|9659751|FG000|Overall Study|Physician Decision|0
6059164|NCT00476151|9659752|FG001|Overall Study|Physician Decision|2
6059165|NCT00476229|9659758|FG000|Overall Study|Progressive shortness of breath|1
6092542|NCT00705783|9705318|FG001|Depot Stabilization Phase|Lost to Follow-up|0
6092543|NCT00705783|9705319|FG002|Depot Stabilization Phase|Lost to Follow-up|0
6092544|NCT00705783|9705317|FG000|Depot Stabilization Phase|Met Withdrawal Criteria|8
6092545|NCT00705783|9705318|FG001|Depot Stabilization Phase|Met Withdrawal Criteria|0
6092546|NCT00705783|9705319|FG002|Depot Stabilization Phase|Met Withdrawal Criteria|0
6092547|NCT00705783|9705317|FG000|Depot Stabilization Phase|Withdrawn by Investigator|9
6092548|NCT00705783|9705318|FG001|Depot Stabilization Phase|Withdrawn by Investigator|0
6092549|NCT00705783|9705319|FG002|Depot Stabilization Phase|Withdrawn by Investigator|0
6092550|NCT00705783|9705317|FG000|Depot Stabilization Phase|Withdrew Consent|29
6092551|NCT00705783|9705318|FG001|Depot Stabilization Phase|Withdrew Consent|0
6092552|NCT00705783|9705319|FG002|Depot Stabilization Phase|Withdrew Consent|0
6092553|NCT00705783|9705317|FG000|Depot Stabilization Phase|Adverse Event|17
6092554|NCT00705783|9705318|FG001|Depot Stabilization Phase|Adverse Event|0
6092555|NCT00705783|9705319|FG002|Depot Stabilization Phase|Adverse Event|0
6092556|NCT00705783|9705317|FG000|Depot Stabilization Phase|Lack of Efficacy with Adverse Event|12
6092557|NCT00705783|9705318|FG001|Depot Stabilization Phase|Lack of Efficacy with Adverse Event|0
6092558|NCT00705783|9705319|FG002|Depot Stabilization Phase|Lack of Efficacy with Adverse Event|0
6092559|NCT00705783|9705317|FG000|Depot Stabilization Phase|Lack of Efficacy without Adverse Event|1
6092560|NCT00705783|9705318|FG001|Depot Stabilization Phase|Lack of Efficacy without Adverse Event|0
6092561|NCT00705783|9705319|FG002|Depot Stabilization Phase|Lack of Efficacy without Adverse Event|0
6092562|NCT00705783|9705317|FG000|Depot Maintenance Phase|Sponsor Discontinued Study|0
6092563|NCT00705783|9705318|FG001|Depot Maintenance Phase|Sponsor Discontinued Study|179
6092564|NCT00705783|9705319|FG002|Depot Maintenance Phase|Sponsor Discontinued Study|58
6092565|NCT00705783|9705317|FG000|Depot Maintenance Phase|Lost to Follow-up|0
6092566|NCT00705783|9705318|FG001|Depot Maintenance Phase|Lost to Follow-up|5
6092567|NCT00705783|9705319|FG002|Depot Maintenance Phase|Lost to Follow-up|3
6092568|NCT00705783|9705317|FG000|Depot Maintenance Phase|Met Withdrawal Criteria|0
6092569|NCT00705783|9705318|FG001|Depot Maintenance Phase|Met Withdrawal Criteria|2
6092570|NCT00705783|9705319|FG002|Depot Maintenance Phase|Met Withdrawal Criteria|2
6092571|NCT00705783|9705317|FG000|Depot Maintenance Phase|Withdrawn by Investigator|0
6092572|NCT00705783|9705318|FG001|Depot Maintenance Phase|Withdrawn by Investigator|8
6092573|NCT00705783|9705319|FG002|Depot Maintenance Phase|Withdrawn by Investigator|6
6092574|NCT00705783|9705317|FG000|Depot Maintenance Phase|Withdrew Consent|0
6092575|NCT00705783|9705318|FG001|Depot Maintenance Phase|Withdrew Consent|14
6092576|NCT00705783|9705319|FG002|Depot Maintenance Phase|Withdrew Consent|4
6092577|NCT00705783|9705317|FG000|Depot Maintenance Phase|Protocol Deviation|0
6092578|NCT00705783|9705318|FG001|Depot Maintenance Phase|Protocol Deviation|2
6092579|NCT00705783|9705319|FG002|Depot Maintenance Phase|Protocol Deviation|0
6092580|NCT00705783|9705317|FG000|Depot Maintenance Phase|Adverse Event without Impending Relapse|0
6092581|NCT00705783|9705318|FG001|Depot Maintenance Phase|Adverse Event without Impending Relapse|9
6092582|NCT00705783|9705319|FG002|Depot Maintenance Phase|Adverse Event without Impending Relapse|5
6092583|NCT00705783|9705317|FG000|Depot Maintenance Phase|Impending Relapse with Adverse Event|0
6092584|NCT00705783|9705318|FG001|Depot Maintenance Phase|Impending Relapse with Adverse Event|11
6092585|NCT00705783|9705319|FG002|Depot Maintenance Phase|Impending Relapse with Adverse Event|13
6092586|NCT00705783|9705317|FG000|Depot Maintenance Phase|Impending Relapse without Adverse Event|0
6092587|NCT00705783|9705318|FG001|Depot Maintenance Phase|Impending Relapse without Adverse Event|16
6092588|NCT00705783|9705319|FG002|Depot Maintenance Phase|Impending Relapse without Adverse Event|40
6092589|NCT00705939|9705360|FG000|Overall Study|Protocol Violation|0
6092590|NCT00705939|9705361|FG001|Overall Study|Protocol Violation|0
6092591|NCT00705939|9705362|FG002|Overall Study|Protocol Violation|1
6092592|NCT00705939|9705360|FG000|Overall Study|Withdrawal by Subject|0
6092593|NCT00705939|9705361|FG001|Overall Study|Withdrawal by Subject|1
6092594|NCT00705939|9705362|FG002|Overall Study|Withdrawal by Subject|3
6092595|NCT00705939|9705360|FG000|Overall Study|Physician Decision|0
6092596|NCT00705939|9705361|FG001|Overall Study|Physician Decision|1
6092597|NCT00705939|9705362|FG002|Overall Study|Physician Decision|0
6092598|NCT00706004|9705371|FG000|Overall Study|Did not meet eligibility criteria|2
6092599|NCT00706030|9705380|FG000|Overall Study|Disease Progression|4
6092600|NCT00706030|9705381|FG001|Overall Study|Disease Progression|6
6092601|NCT00706030|9705382|FG002|Overall Study|Disease Progression|46
6092602|NCT00706030|9705383|FG003|Overall Study|Disease Progression|12
6092603|NCT00706030|9705380|FG000|Overall Study|Adverse Event|1
6059166|NCT00476476|9659775|FG000|Overall Study|Adverse Event|2
6059167|NCT00476476|9659776|FG001|Overall Study|Adverse Event|7
6059168|NCT00476476|9659775|FG000|Overall Study|Progressive Disease|0
6059169|NCT00476476|9659776|FG001|Overall Study|Progressive Disease|17
6059170|NCT00476593|9659785|FG000|Overall Study|Lost to Follow-up|10
6059171|NCT00476593|9659786|FG001|Overall Study|Lost to Follow-up|2
6059172|NCT00476593|9659787|FG002|Overall Study|Lost to Follow-up|8
6092604|NCT00706030|9705381|FG001|Overall Study|Adverse Event|0
6092605|NCT00706030|9705382|FG002|Overall Study|Adverse Event|4
6092606|NCT00706030|9705383|FG003|Overall Study|Adverse Event|2
6092607|NCT00706030|9705380|FG000|Overall Study|Withdrawal by Subject|1
6092608|NCT00706030|9705381|FG001|Overall Study|Withdrawal by Subject|0
6092609|NCT00706030|9705382|FG002|Overall Study|Withdrawal by Subject|2
6092610|NCT00706030|9705383|FG003|Overall Study|Withdrawal by Subject|0
6092611|NCT00706030|9705380|FG000|Overall Study|Physician Decision|0
6092612|NCT00706030|9705381|FG001|Overall Study|Physician Decision|0
6092613|NCT00706030|9705382|FG002|Overall Study|Physician Decision|2
6092614|NCT00706030|9705383|FG003|Overall Study|Physician Decision|0
6092615|NCT00706030|9705380|FG000|Overall Study|Not recorded|0
6092616|NCT00706030|9705381|FG001|Overall Study|Not recorded|0
6092617|NCT00706030|9705382|FG002|Overall Study|Not recorded|2
6092618|NCT00706030|9705383|FG003|Overall Study|Not recorded|0
6092619|NCT00706030|9705380|FG000|Overall Study|Protocol Violation|0
6092620|NCT00706030|9705381|FG001|Overall Study|Protocol Violation|0
6092621|NCT00706030|9705382|FG002|Overall Study|Protocol Violation|1
6092622|NCT00706030|9705383|FG003|Overall Study|Protocol Violation|1
6092623|NCT00706030|9705380|FG000|Overall Study|Failed to return|0
6092624|NCT00706030|9705381|FG001|Overall Study|Failed to return|0
6092625|NCT00706030|9705382|FG002|Overall Study|Failed to return|1
6092626|NCT00706030|9705383|FG003|Overall Study|Failed to return|0
6092627|NCT00706030|9705380|FG000|Overall Study|Symptomatic Deterioration|0
6092628|NCT00706030|9705381|FG001|Overall Study|Symptomatic Deterioration|0
6092629|NCT00706030|9705382|FG002|Overall Study|Symptomatic Deterioration|1
6092630|NCT00706030|9705383|FG003|Overall Study|Symptomatic Deterioration|0
6092631|NCT00706030|9705380|FG000|Overall Study|No treatment received|0
6092632|NCT00706030|9705381|FG001|Overall Study|No treatment received|0
6092633|NCT00706030|9705382|FG002|Overall Study|No treatment received|0
6092634|NCT00706030|9705383|FG003|Overall Study|No treatment received|1
6092635|NCT00706030|9705380|FG000|Overall Study|Death|0
6092636|NCT00706030|9705381|FG001|Overall Study|Death|0
6092637|NCT00706030|9705382|FG002|Overall Study|Death|1
6092638|NCT00706030|9705383|FG003|Overall Study|Death|0
6092639|NCT00706095|9705397|FG000|Overall Study|Progressive Disease|4
6092640|NCT00706095|9705398|FG001|Overall Study|Progressive Disease|5
6092641|NCT00706095|9705399|FG002|Overall Study|Progressive Disease|3
6092642|NCT00706095|9705397|FG000|Overall Study|Clinical Progression|1
6092643|NCT00706095|9705398|FG001|Overall Study|Clinical Progression|2
6092644|NCT00706095|9705399|FG002|Overall Study|Clinical Progression|2
6092645|NCT00706095|9705397|FG000|Overall Study|Withdrawal by Subject|1
6092646|NCT00706095|9705398|FG001|Overall Study|Withdrawal by Subject|0
6092647|NCT00706095|9705399|FG002|Overall Study|Withdrawal by Subject|0
6092648|NCT00706134|9705436|FG000|Overall Study|Adverse Event|8
6092649|NCT00706134|9705437|FG001|Overall Study|Adverse Event|7
6092650|NCT00706134|9705438|FG002|Overall Study|Adverse Event|2
6092651|NCT00706134|9705439|FG003|Overall Study|Adverse Event|3
6092652|NCT00706134|9705436|FG000|Overall Study|Lost to Follow-up|0
6092653|NCT00706134|9705437|FG001|Overall Study|Lost to Follow-up|1
6092654|NCT00706134|9705438|FG002|Overall Study|Lost to Follow-up|0
6092655|NCT00706134|9705439|FG003|Overall Study|Lost to Follow-up|0
6092656|NCT00706134|9705436|FG000|Overall Study|Protocol Violation|0
6092657|NCT00706134|9705437|FG001|Overall Study|Protocol Violation|6
6092658|NCT00706134|9705438|FG002|Overall Study|Protocol Violation|0
6092659|NCT00706134|9705439|FG003|Overall Study|Protocol Violation|3
6092660|NCT00706134|9705436|FG000|Overall Study|Withdrawal by Subject|1
6092661|NCT00706134|9705437|FG001|Overall Study|Withdrawal by Subject|2
6092662|NCT00706134|9705438|FG002|Overall Study|Withdrawal by Subject|1
6092663|NCT00706134|9705439|FG003|Overall Study|Withdrawal by Subject|0
6092664|NCT00706134|9705436|FG000|Overall Study|Unsatisfactory therapeutic effect|9
6092665|NCT00706134|9705437|FG001|Overall Study|Unsatisfactory therapeutic effect|3
6092666|NCT00706134|9705438|FG002|Overall Study|Unsatisfactory therapeutic effect|3
6092667|NCT00706134|9705439|FG003|Overall Study|Unsatisfactory therapeutic effect|5
6059173|NCT00476593|9659788|FG003|Overall Study|Lost to Follow-up|22
6059174|NCT00476957|9659808|FG000|Overall Study|Lost to Follow-up|176
6059175|NCT00476957|9659809|FG001|Overall Study|Lost to Follow-up|193
6059176|NCT00476996|9659818|FG000|Blinded Treatment Phase (up to Week 48)|Withdrawal by Subject|12
6092668|NCT00706134|9705436|FG000|Overall Study|Did not meet study criteria|2
6092669|NCT00706134|9705437|FG001|Overall Study|Did not meet study criteria|0
6092670|NCT00706134|9705438|FG002|Overall Study|Did not meet study criteria|0
6092671|NCT00706134|9705439|FG003|Overall Study|Did not meet study criteria|0
6092672|NCT00706238|9705449|FG000|Overall Study|Disease progression|4
6092673|NCT00706238|9705449|FG000|Overall Study|Other|1
6092674|NCT00706342|9705464|FG000|Overall Study|Adverse Event|3
6092675|NCT00706342|9705464|FG000|Overall Study|Not responding to treatment|2
6092676|NCT00706342|9705464|FG000|Overall Study|Withdrawn due to failure to respond|1
6092677|NCT00706342|9705464|FG000|Overall Study|Death|1
6059177|NCT00476996|9659819|FG001|Blinded Treatment Phase (up to Week 48)|Withdrawal by Subject|7
6092678|NCT00706342|9705464|FG000|Overall Study|Withdrew from the study on his own.|1
6092679|NCT00706342|9705464|FG000|Overall Study|Investigator discretion|2
6092680|NCT00706342|9705464|FG000|Overall Study|Non-responder Week 12|1
6092681|NCT00706342|9705464|FG000|Overall Study|Ongoing|6
6092682|NCT00706342|9705464|FG000|Overall Study|WIthdrawal of consent|1
6092683|NCT00706355|9705472|FG000|Period 1: PF-04217903 50 mg|Withdrawal by Subject|1
6092684|NCT00706355|9705473|FG001|Period 1: PF-04217903 50 mg|Withdrawal by Subject|0
6092685|NCT00706355|9705474|FG002|Period 1: PF-04217903 50 mg|Withdrawal by Subject|0
6092686|NCT00706355|9705475|FG003|Period 1: PF-04217903 50 mg|Withdrawal by Subject|0
6092687|NCT00706355|9705472|FG000|Period 1: PF-04217903 50 mg|Objective progression or relapse|2
6092688|NCT00706355|9705473|FG001|Period 1: PF-04217903 50 mg|Objective progression or relapse|0
6092689|NCT00706355|9705474|FG002|Period 1: PF-04217903 50 mg|Objective progression or relapse|0
6092690|NCT00706355|9705475|FG003|Period 1: PF-04217903 50 mg|Objective progression or relapse|0
6092691|NCT00706355|9705472|FG000|Period 2: PF-04217903 100 mg|Withdrawal by Subject|0
6092692|NCT00706355|9705473|FG001|Period 2: PF-04217903 100 mg|Withdrawal by Subject|1
6092693|NCT00706355|9705474|FG002|Period 2: PF-04217903 100 mg|Withdrawal by Subject|0
6092694|NCT00706355|9705475|FG003|Period 2: PF-04217903 100 mg|Withdrawal by Subject|0
6092695|NCT00706355|9705472|FG000|Period 2: PF-04217903 100 mg|Global deterioration of health status|0
6092696|NCT00706355|9705473|FG001|Period 2: PF-04217903 100 mg|Global deterioration of health status|1
6092697|NCT00706355|9705474|FG002|Period 2: PF-04217903 100 mg|Global deterioration of health status|0
6092698|NCT00706355|9705475|FG003|Period 2: PF-04217903 100 mg|Global deterioration of health status|0
6092699|NCT00706355|9705472|FG000|Period 2: PF-04217903 100 mg|Objective progression or relapse|0
6092700|NCT00706355|9705473|FG001|Period 2: PF-04217903 100 mg|Objective progression or relapse|5
6092701|NCT00706355|9705474|FG002|Period 2: PF-04217903 100 mg|Objective progression or relapse|0
6092702|NCT00706355|9705475|FG003|Period 2: PF-04217903 100 mg|Objective progression or relapse|0
6092703|NCT00706355|9705472|FG000|Period 3: PF-04217903 200 mg|Adverse Event|0
6092704|NCT00706355|9705473|FG001|Period 3: PF-04217903 200 mg|Adverse Event|0
6092705|NCT00706355|9705474|FG002|Period 3: PF-04217903 200 mg|Adverse Event|1
6092706|NCT00706355|9705475|FG003|Period 3: PF-04217903 200 mg|Adverse Event|0
6092707|NCT00706355|9705472|FG000|Period 3: PF-04217903 200 mg|Withdrawal by Subject|0
6092708|NCT00706355|9705473|FG001|Period 3: PF-04217903 200 mg|Withdrawal by Subject|0
6092709|NCT00706355|9705474|FG002|Period 3: PF-04217903 200 mg|Withdrawal by Subject|1
6092710|NCT00706355|9705475|FG003|Period 3: PF-04217903 200 mg|Withdrawal by Subject|0
6092711|NCT00706355|9705472|FG000|Period 4: PF-04217903 150 mg|Adverse Event|0
6092712|NCT00706355|9705473|FG001|Period 4: PF-04217903 150 mg|Adverse Event|0
6092713|NCT00706355|9705474|FG002|Period 4: PF-04217903 150 mg|Adverse Event|0
6092714|NCT00706355|9705475|FG003|Period 4: PF-04217903 150 mg|Adverse Event|2
6092715|NCT00706355|9705472|FG000|Period 4: PF-04217903 150 mg|Objective progression or relapse|0
6092716|NCT00706355|9705473|FG001|Period 4: PF-04217903 150 mg|Objective progression or relapse|0
6092717|NCT00706355|9705474|FG002|Period 4: PF-04217903 150 mg|Objective progression or relapse|0
6092718|NCT00706355|9705475|FG003|Period 4: PF-04217903 150 mg|Objective progression or relapse|2
6092719|NCT00706381|9705491|FG000|Overall Study|Lost to Follow-up|0
6092720|NCT00706381|9705492|FG001|Overall Study|Lost to Follow-up|1
6092721|NCT00706381|9705493|FG002|Overall Study|Lost to Follow-up|1
6092722|NCT00706381|9705494|FG003|Overall Study|Lost to Follow-up|0
6092723|NCT00706433|9705524|FG000|Overall Study|Lost to Follow-up|3
6092724|NCT00706433|9705525|FG001|Overall Study|Lost to Follow-up|1
6092725|NCT00706433|9705526|FG002|Overall Study|Lost to Follow-up|6
6092726|NCT00706433|9705527|FG003|Overall Study|Lost to Follow-up|0
6092727|NCT00706433|9705524|FG000|Overall Study|Withdrawal by Subject|1
6092728|NCT00706433|9705525|FG001|Overall Study|Withdrawal by Subject|2
6092729|NCT00706433|9705526|FG002|Overall Study|Withdrawal by Subject|3
6092730|NCT00706433|9705527|FG003|Overall Study|Withdrawal by Subject|1
6092731|NCT00706433|9705524|FG000|Overall Study|Adverse Event|0
6059178|NCT00476996|9659820|FG002|Blinded Treatment Phase (up to Week 48)|Withdrawal by Subject|7
6059179|NCT00476996|9659821|FG003|Blinded Treatment Phase (up to Week 48)|Withdrawal by Subject|0
6059180|NCT00476996|9659818|FG000|Blinded Treatment Phase (up to Week 48)|Protocol Violation|1
6059181|NCT00476996|9659819|FG001|Blinded Treatment Phase (up to Week 48)|Protocol Violation|3
6059182|NCT00476996|9659820|FG002|Blinded Treatment Phase (up to Week 48)|Protocol Violation|0
6059183|NCT00476996|9659821|FG003|Blinded Treatment Phase (up to Week 48)|Protocol Violation|0
6059184|NCT00476996|9659818|FG000|Blinded Treatment Phase (up to Week 48)|Early termination of the study|24
6059185|NCT00476996|9659819|FG001|Blinded Treatment Phase (up to Week 48)|Early termination of the study|20
6059186|NCT00476996|9659820|FG002|Blinded Treatment Phase (up to Week 48)|Early termination of the study|21
6092732|NCT00706433|9705525|FG001|Overall Study|Adverse Event|0
6092733|NCT00706433|9705526|FG002|Overall Study|Adverse Event|1
6092734|NCT00706433|9705527|FG003|Overall Study|Adverse Event|0
6092735|NCT00706433|9705524|FG000|Overall Study|Protocol Violation|1
6092736|NCT00706433|9705525|FG001|Overall Study|Protocol Violation|0
6092737|NCT00706433|9705526|FG002|Overall Study|Protocol Violation|0
6092738|NCT00706433|9705527|FG003|Overall Study|Protocol Violation|0
6092739|NCT00706433|9705524|FG000|Overall Study|new job|0
6092740|NCT00706433|9705525|FG001|Overall Study|new job|0
6059187|NCT00476996|9659821|FG003|Blinded Treatment Phase (up to Week 48)|Early termination of the study|0
6059188|NCT00476996|9659818|FG000|Blinded Treatment Phase (up to Week 48)|Non-Compliance with Study Drug|0
6059189|NCT00476996|9659819|FG001|Blinded Treatment Phase (up to Week 48)|Non-Compliance with Study Drug|2
6059190|NCT00476996|9659820|FG002|Blinded Treatment Phase (up to Week 48)|Non-Compliance with Study Drug|0
6059191|NCT00476996|9659821|FG003|Blinded Treatment Phase (up to Week 48)|Non-Compliance with Study Drug|0
6059192|NCT00476996|9659818|FG000|Blinded Treatment Phase (up to Week 48)|Lost to Follow-up|0
6059193|NCT00476996|9659819|FG001|Blinded Treatment Phase (up to Week 48)|Lost to Follow-up|4
6059194|NCT00476996|9659820|FG002|Blinded Treatment Phase (up to Week 48)|Lost to Follow-up|3
6059195|NCT00476996|9659821|FG003|Blinded Treatment Phase (up to Week 48)|Lost to Follow-up|0
6059196|NCT00476996|9659818|FG000|Blinded Treatment Phase (up to Week 48)|Lack of Efficacy|22
6059197|NCT00476996|9659819|FG001|Blinded Treatment Phase (up to Week 48)|Lack of Efficacy|5
6059198|NCT00476996|9659820|FG002|Blinded Treatment Phase (up to Week 48)|Lack of Efficacy|6
6059199|NCT00476996|9659821|FG003|Blinded Treatment Phase (up to Week 48)|Lack of Efficacy|0
6059200|NCT00476996|9659818|FG000|Blinded Treatment Phase (up to Week 48)|Death|2
6059201|NCT00476996|9659819|FG001|Blinded Treatment Phase (up to Week 48)|Death|1
6059202|NCT00476996|9659820|FG002|Blinded Treatment Phase (up to Week 48)|Death|1
6059203|NCT00476996|9659821|FG003|Blinded Treatment Phase (up to Week 48)|Death|0
6059204|NCT00476996|9659818|FG000|Blinded Treatment Phase (up to Week 48)|Adverse Event|11
6059205|NCT00476996|9659819|FG001|Blinded Treatment Phase (up to Week 48)|Adverse Event|13
6059206|NCT00476996|9659820|FG002|Blinded Treatment Phase (up to Week 48)|Adverse Event|7
6059207|NCT00476996|9659821|FG003|Blinded Treatment Phase (up to Week 48)|Adverse Event|0
6059208|NCT00476996|9659818|FG000|OLE Phase (From Week 48)|Withdrawal by Subject|0
6059209|NCT00476996|9659819|FG001|OLE Phase (From Week 48)|Withdrawal by Subject|0
6059210|NCT00476996|9659820|FG002|OLE Phase (From Week 48)|Withdrawal by Subject|0
6059211|NCT00476996|9659821|FG003|OLE Phase (From Week 48)|Withdrawal by Subject|50
6059212|NCT00476996|9659818|FG000|OLE Phase (From Week 48)|Adverse Event|0
6059213|NCT00476996|9659819|FG001|OLE Phase (From Week 48)|Adverse Event|0
6059214|NCT00476996|9659820|FG002|OLE Phase (From Week 48)|Adverse Event|0
6059215|NCT00476996|9659821|FG003|OLE Phase (From Week 48)|Adverse Event|8
6059216|NCT00476996|9659818|FG000|OLE Phase (From Week 48)|Death|0
6059217|NCT00476996|9659819|FG001|OLE Phase (From Week 48)|Death|0
6059218|NCT00476996|9659820|FG002|OLE Phase (From Week 48)|Death|0
6059219|NCT00476996|9659821|FG003|OLE Phase (From Week 48)|Death|7
6092741|NCT00706433|9705526|FG002|Overall Study|new job|0
6092742|NCT00706433|9705527|FG003|Overall Study|new job|1
6202643|NCT01505530|9863006|FG000|Overall Study|Adverse Event|1
6202644|NCT01505530|9863007|FG001|Overall Study|Adverse Event|1
6202645|NCT01505530|9863008|FG002|Overall Study|Adverse Event|0
6202646|NCT01505530|9863006|FG000|Overall Study|Withdrawal by Subject|7
6202647|NCT01505530|9863007|FG001|Overall Study|Withdrawal by Subject|8
6202648|NCT01505530|9863008|FG002|Overall Study|Withdrawal by Subject|6
6202649|NCT01505530|9863006|FG000|Overall Study|Physician Decision|6
6202650|NCT01505530|9863007|FG001|Overall Study|Physician Decision|2
6202651|NCT01505530|9863008|FG002|Overall Study|Physician Decision|5
6202652|NCT01505530|9863006|FG000|Overall Study|Sponsor Decision|1
6202653|NCT01505530|9863007|FG001|Overall Study|Sponsor Decision|8
6202654|NCT01505530|9863008|FG002|Overall Study|Sponsor Decision|7
6202655|NCT01505530|9863006|FG000|Overall Study|Death|7
6202656|NCT01505530|9863007|FG001|Overall Study|Death|6
6202657|NCT01505530|9863008|FG002|Overall Study|Death|5
6202658|NCT01505530|9863006|FG000|Overall Study|entry criteria not met|0
6202659|NCT01505530|9863007|FG001|Overall Study|entry criteria not met|1
6202660|NCT01505530|9863008|FG002|Overall Study|entry criteria not met|0
6202661|NCT01505634|9863019|FG000|Overall Study|Withdrawal by Subject|2
6202662|NCT01505634|9863020|FG001|Overall Study|Withdrawal by Subject|5
6202663|NCT01505634|9863021|FG002|Overall Study|Withdrawal by Subject|1
6202664|NCT01505634|9863019|FG000|Overall Study|Physician Decision|1
6202665|NCT01505634|9863020|FG001|Overall Study|Physician Decision|1
6202666|NCT01505634|9863021|FG002|Overall Study|Physician Decision|0
6202667|NCT01505634|9863019|FG000|Overall Study|Adverse Event|1
6202668|NCT01505634|9863020|FG001|Overall Study|Adverse Event|0
6202669|NCT01505634|9863021|FG002|Overall Study|Adverse Event|0
6202670|NCT01505634|9863019|FG000|Overall Study|Insufficient supply of drug at site|1
6202671|NCT01505634|9863020|FG001|Overall Study|Insufficient supply of drug at site|0
6202672|NCT01505634|9863021|FG002|Overall Study|Insufficient supply of drug at site|0
6202673|NCT01505634|9863019|FG000|Overall Study|Protocol Violation|2
6202674|NCT01505634|9863020|FG001|Overall Study|Protocol Violation|0
6202675|NCT01505634|9863021|FG002|Overall Study|Protocol Violation|0
6202676|NCT01505634|9863019|FG000|Overall Study|Lost to Follow-up|1
6202677|NCT01505634|9863020|FG001|Overall Study|Lost to Follow-up|4
6202678|NCT01505634|9863021|FG002|Overall Study|Lost to Follow-up|4
6202679|NCT01505634|9863019|FG000|Overall Study|Death|1
6202680|NCT01505634|9863020|FG001|Overall Study|Death|0
6202681|NCT01505634|9863021|FG002|Overall Study|Death|0
6202682|NCT01505634|9863019|FG000|Overall Study|In a conflict zone|0
6202683|NCT01505634|9863020|FG001|Overall Study|In a conflict zone|0
6202684|NCT01505634|9863021|FG002|Overall Study|In a conflict zone|1
6202685|NCT01505647|9863031|FG000|Day 1 Through Day 42 Follow-up|Lost to Follow-up|1
6202686|NCT01505647|9863032|FG001|Day 1 Through Day 42 Follow-up|Lost to Follow-up|0
6202687|NCT01505647|9863031|FG000|Day 1 Through Day 42 Follow-up|Physician Decision|1
6059220|NCT00476996|9659818|FG000|OLE Phase (From Week 48)|Lack of Efficacy|0
6059221|NCT00476996|9659819|FG001|OLE Phase (From Week 48)|Lack of Efficacy|0
6059222|NCT00476996|9659820|FG002|OLE Phase (From Week 48)|Lack of Efficacy|0
6059223|NCT00476996|9659821|FG003|OLE Phase (From Week 48)|Lack of Efficacy|13
6059224|NCT00476996|9659818|FG000|OLE Phase (From Week 48)|Lost to Follow-up|0
6059225|NCT00476996|9659819|FG001|OLE Phase (From Week 48)|Lost to Follow-up|0
6059226|NCT00476996|9659820|FG002|OLE Phase (From Week 48)|Lost to Follow-up|0
6059227|NCT00476996|9659821|FG003|OLE Phase (From Week 48)|Lost to Follow-up|4
6059228|NCT00476996|9659818|FG000|OLE Phase (From Week 48)|Non-Compliance with Study Drug|0
6059229|NCT00476996|9659819|FG001|OLE Phase (From Week 48)|Non-Compliance with Study Drug|0
6059230|NCT00476996|9659820|FG002|OLE Phase (From Week 48)|Non-Compliance with Study Drug|0
6059231|NCT00476996|9659821|FG003|OLE Phase (From Week 48)|Non-Compliance with Study Drug|4
6059232|NCT00476996|9659818|FG000|OLE Phase (From Week 48)|Early termination of the study|0
6059233|NCT00476996|9659819|FG001|OLE Phase (From Week 48)|Early termination of the study|0
6059234|NCT00476996|9659820|FG002|OLE Phase (From Week 48)|Early termination of the study|0
6059235|NCT00476996|9659821|FG003|OLE Phase (From Week 48)|Early termination of the study|578
6059236|NCT00477152|9659834|FG000|Overall Study|Parent withdrew consent|2
6059237|NCT00477152|9659834|FG000|Overall Study|Adverse Event|1
6059238|NCT00477165|9659840|FG000|Overall Study|Adverse Event|7
6059239|NCT00477165|9659841|FG001|Overall Study|Adverse Event|2
6059240|NCT00477269|9659862|FG000|Core Study|Adverse Event|6
6059241|NCT00477269|9659863|FG001|Core Study|Adverse Event|4
6059242|NCT00477269|9659864|FG002|Core Study|Adverse Event|0
6059243|NCT00477269|9659862|FG000|Core Study|Death|3
6059244|NCT00477269|9659863|FG001|Core Study|Death|3
6059245|NCT00477269|9659864|FG002|Core Study|Death|0
6059246|NCT00477269|9659862|FG000|Core Study|Withdrawn Consent|0
6059247|NCT00477269|9659863|FG001|Core Study|Withdrawn Consent|1
6059248|NCT00477269|9659864|FG002|Core Study|Withdrawn Consent|0
6059249|NCT00477269|9659862|FG000|Open Label Extension|Adverse Event|0
6059250|NCT00477269|9659863|FG001|Open Label Extension|Adverse Event|0
6059251|NCT00477269|9659864|FG002|Open Label Extension|Adverse Event|4
6059252|NCT00477269|9659862|FG000|Open Label Extension|Abnormal laboratory values|0
6059253|NCT00477269|9659863|FG001|Open Label Extension|Abnormal laboratory values|0
6059254|NCT00477269|9659864|FG002|Open Label Extension|Abnormal laboratory values|1
6059255|NCT00477269|9659862|FG000|Open Label Extension|unsatisfactory therapeutic effects|0
6059256|NCT00477269|9659863|FG001|Open Label Extension|unsatisfactory therapeutic effects|0
6059257|NCT00477269|9659864|FG002|Open Label Extension|unsatisfactory therapeutic effects|2
6059258|NCT00477269|9659862|FG000|Open Label Extension|Adminiatrative problems|0
6059259|NCT00477269|9659863|FG001|Open Label Extension|Adminiatrative problems|0
6059260|NCT00477269|9659864|FG002|Open Label Extension|Adminiatrative problems|2
6059261|NCT00477269|9659862|FG000|Open Label Extension|Death|0
6059262|NCT00477269|9659863|FG001|Open Label Extension|Death|0
6059263|NCT00477269|9659864|FG002|Open Label Extension|Death|4
6059264|NCT00477295|9659874|FG000|Overall Study|Adverse Event|31
6059265|NCT00477295|9659875|FG001|Overall Study|Adverse Event|35
6059266|NCT00477295|9659874|FG000|Overall Study|Withdrawal by Subject|35
6059267|NCT00477295|9659875|FG001|Overall Study|Withdrawal by Subject|24
6059268|NCT00477295|9659874|FG000|Overall Study|Lack of Efficacy|23
6059269|NCT00477295|9659875|FG001|Overall Study|Lack of Efficacy|23
6059270|NCT00477295|9659874|FG000|Overall Study|Protocol Violation|3
6059271|NCT00477295|9659875|FG001|Overall Study|Protocol Violation|8
6059272|NCT00477295|9659874|FG000|Overall Study|Physician Decision|4
6059273|NCT00477295|9659875|FG001|Overall Study|Physician Decision|5
6059274|NCT00477295|9659874|FG000|Overall Study|Lost to Follow-up|21
6059275|NCT00477295|9659875|FG001|Overall Study|Lost to Follow-up|11
6059276|NCT00477295|9659874|FG000|Overall Study|Other|4
6059277|NCT00477295|9659875|FG001|Overall Study|Other|3
6059278|NCT00477334|9659885|FG000|Overall Study|Discontinued prior to taking study drug|106
6059279|NCT00477334|9659886|FG001|Overall Study|Discontinued prior to taking study drug|53
6059280|NCT00477334|9659885|FG000|Overall Study|Adverse Event|1
6059281|NCT00477334|9659886|FG001|Overall Study|Adverse Event|2
6059282|NCT00477334|9659885|FG000|Overall Study|Withdrawal by Subject|2
6059283|NCT00477334|9659886|FG001|Overall Study|Withdrawal by Subject|1
6059284|NCT00477334|9659885|FG000|Overall Study|Lost to Follow-up|15
6059285|NCT00477334|9659886|FG001|Overall Study|Lost to Follow-up|4
6059286|NCT00477334|9659885|FG000|Overall Study|Administrative Problems|39
6059287|NCT00477334|9659886|FG001|Overall Study|Administrative Problems|15
6059288|NCT00477334|9659885|FG000|Overall Study|Protocol Violation|7
6059289|NCT00477334|9659886|FG001|Overall Study|Protocol Violation|1
6059290|NCT00477386|9659898|FG000|Overall Study|Adverse Event|4
6059291|NCT00477386|9659899|FG001|Overall Study|Adverse Event|8
6059292|NCT00477386|9659898|FG000|Overall Study|Disease progression, relapse|3
6059293|NCT00477386|9659899|FG001|Overall Study|Disease progression, relapse|4
6059294|NCT00477386|9659898|FG000|Overall Study|Disease progression, refractory|1
6059295|NCT00477386|9659899|FG001|Overall Study|Disease progression, refractory|3
6059296|NCT00477386|9659898|FG000|Overall Study|Other|1
6059297|NCT00477386|9659899|FG001|Overall Study|Other|2
6059298|NCT00477386|9659898|FG000|Overall Study|Physician Decision|1
6059299|NCT00477386|9659899|FG001|Overall Study|Physician Decision|0
6059300|NCT00477386|9659898|FG000|Overall Study|Withdrawal by Subject|1
6059301|NCT00477386|9659899|FG001|Overall Study|Withdrawal by Subject|0
6059302|NCT00477464|9659920|FG000|Overall Study|Lost to Follow-up|1
6059303|NCT00477464|9659920|FG000|Overall Study|Death|36
6059304|NCT00477464|9659920|FG000|Overall Study|Completion of protocol-defined follow-up|14
6059305|NCT00477490|9659931|FG000|Part I: 4 Week Efficacy|Adverse Event|1
6059306|NCT00477490|9659932|FG001|Part I: 4 Week Efficacy|Adverse Event|4
6059307|NCT00477490|9659933|FG002|Part I: 4 Week Efficacy|Adverse Event|0
6092743|NCT00706511|9705570|FG000|Overall Study|Withdrawal by Subject|1
6092744|NCT00706511|9705571|FG001|Overall Study|Withdrawal by Subject|0
6092745|NCT00706511|9705572|FG002|Overall Study|Withdrawal by Subject|0
6092746|NCT00706511|9705573|FG003|Overall Study|Withdrawal by Subject|0
6092747|NCT00706628|9705613|FG000|Overall Study|Other Adverse Event|16
6092748|NCT00706628|9705614|FG001|Overall Study|Other Adverse Event|5
6092749|NCT00706628|9705615|FG002|Overall Study|Other Adverse Event|5
6092750|NCT00706628|9705616|FG003|Overall Study|Other Adverse Event|2
6092751|NCT00706628|9705613|FG000|Overall Study|Non compliant with protocol|0
6092752|NCT00706628|9705614|FG001|Overall Study|Non compliant with protocol|1
6092753|NCT00706628|9705615|FG002|Overall Study|Non compliant with protocol|0
6092754|NCT00706628|9705616|FG003|Overall Study|Non compliant with protocol|0
6092755|NCT00706628|9705613|FG000|Overall Study|Consent withdrawn|6
6092756|NCT00706628|9705614|FG001|Overall Study|Consent withdrawn|1
6092757|NCT00706628|9705615|FG002|Overall Study|Consent withdrawn|3
6092758|NCT00706628|9705616|FG003|Overall Study|Consent withdrawn|0
6092759|NCT00706628|9705613|FG000|Overall Study|Progressive disease|20
6092760|NCT00706628|9705614|FG001|Overall Study|Progressive disease|13
6092761|NCT00706628|9705615|FG002|Overall Study|Progressive disease|8
6092762|NCT00706628|9705616|FG003|Overall Study|Progressive disease|1
6092763|NCT00706628|9705613|FG000|Overall Study|Other than those stated above|4
6092764|NCT00706628|9705614|FG001|Overall Study|Other than those stated above|0
6092765|NCT00706628|9705615|FG002|Overall Study|Other than those stated above|0
6092766|NCT00706628|9705616|FG003|Overall Study|Other than those stated above|0
6092767|NCT00706628|9705613|FG000|Overall Study|Not treated|1
6092768|NCT00706628|9705614|FG001|Overall Study|Not treated|1
6092769|NCT00706628|9705615|FG002|Overall Study|Not treated|0
6092770|NCT00706628|9705616|FG003|Overall Study|Not treated|0
6092771|NCT00706641|9705629|FG000|Dasatinib Administration|Withdrawal by Subject|1
6092772|NCT00706641|9705629|FG000|Dasatinib Administration|Ineligible after start of therapy|1
6092773|NCT00706641|9705629|FG000|Radical Cystectomy|Deemed unresectable upon exploration|1
6092774|NCT00706654|9705636|FG000|Conversion Phase|Lost to Follow-up|4
6092775|NCT00706654|9705637|FG001|Conversion Phase|Lost to Follow-up|0
6092776|NCT00706654|9705638|FG002|Conversion Phase|Lost to Follow-up|0
6092777|NCT00706654|9705639|FG003|Conversion Phase|Lost to Follow-up|0
6092778|NCT00706654|9705636|FG000|Conversion Phase|Sponsor Discontinued Trial|8
6092779|NCT00706654|9705637|FG001|Conversion Phase|Sponsor Discontinued Trial|0
6092780|NCT00706654|9705638|FG002|Conversion Phase|Sponsor Discontinued Trial|0
6092781|NCT00706654|9705639|FG003|Conversion Phase|Sponsor Discontinued Trial|0
6092782|NCT00706654|9705636|FG000|Conversion Phase|Met Withdrawal Criteria|2
6092783|NCT00706654|9705637|FG001|Conversion Phase|Met Withdrawal Criteria|0
6092784|NCT00706654|9705638|FG002|Conversion Phase|Met Withdrawal Criteria|0
6092785|NCT00706654|9705639|FG003|Conversion Phase|Met Withdrawal Criteria|0
6092786|NCT00706654|9705636|FG000|Conversion Phase|Withdrawn by Investigator|14
6092787|NCT00706654|9705637|FG001|Conversion Phase|Withdrawn by Investigator|0
6092788|NCT00706654|9705638|FG002|Conversion Phase|Withdrawn by Investigator|0
6092789|NCT00706654|9705639|FG003|Conversion Phase|Withdrawn by Investigator|0
6092790|NCT00706654|9705636|FG000|Conversion Phase|Withdrew Consent|38
6092791|NCT00706654|9705637|FG001|Conversion Phase|Withdrew Consent|0
6092792|NCT00706654|9705638|FG002|Conversion Phase|Withdrew Consent|0
6092793|NCT00706654|9705639|FG003|Conversion Phase|Withdrew Consent|0
6092794|NCT00706654|9705636|FG000|Conversion Phase|Adverse Event|18
6092795|NCT00706654|9705637|FG001|Conversion Phase|Adverse Event|0
6092796|NCT00706654|9705638|FG002|Conversion Phase|Adverse Event|0
6092797|NCT00706654|9705639|FG003|Conversion Phase|Adverse Event|0
6092798|NCT00706654|9705636|FG000|Conversion Phase|Lack of Efficacy with Adverse Event|9
6092799|NCT00706654|9705637|FG001|Conversion Phase|Lack of Efficacy with Adverse Event|0
6059308|NCT00477490|9659934|FG003|Part I: 4 Week Efficacy|Adverse Event|5
6059309|NCT00477490|9659935|FG004|Part I: 4 Week Efficacy|Adverse Event|6
6059310|NCT00477490|9659936|FG005|Part I: 4 Week Efficacy|Adverse Event|0
6059311|NCT00477490|9659937|FG006|Part I: 4 Week Efficacy|Adverse Event|0
6059312|NCT00477490|9659938|FG007|Part I: 4 Week Efficacy|Adverse Event|0
6059313|NCT00477490|9659939|FG008|Part I: 4 Week Efficacy|Adverse Event|0
6059314|NCT00477490|9659931|FG000|Part I: 4 Week Efficacy|Serum Sodium <= 125mmol/L|1
6059315|NCT00477490|9659932|FG001|Part I: 4 Week Efficacy|Serum Sodium <= 125mmol/L|0
6059316|NCT00477490|9659933|FG002|Part I: 4 Week Efficacy|Serum Sodium <= 125mmol/L|0
6059317|NCT00477490|9659934|FG003|Part I: 4 Week Efficacy|Serum Sodium <= 125mmol/L|5
6059318|NCT00477490|9659935|FG004|Part I: 4 Week Efficacy|Serum Sodium <= 125mmol/L|4
6059319|NCT00477490|9659936|FG005|Part I: 4 Week Efficacy|Serum Sodium <= 125mmol/L|0
6059320|NCT00477490|9659937|FG006|Part I: 4 Week Efficacy|Serum Sodium <= 125mmol/L|0
6092800|NCT00706654|9705638|FG002|Conversion Phase|Lack of Efficacy with Adverse Event|0
6092801|NCT00706654|9705639|FG003|Conversion Phase|Lack of Efficacy with Adverse Event|0
6092802|NCT00706654|9705636|FG000|Conversion Phase|Lack of Efficacy without Adverse Event|2
6092803|NCT00706654|9705637|FG001|Conversion Phase|Lack of Efficacy without Adverse Event|0
6059321|NCT00477490|9659938|FG007|Part I: 4 Week Efficacy|Serum Sodium <= 125mmol/L|0
6059322|NCT00477490|9659939|FG008|Part I: 4 Week Efficacy|Serum Sodium <= 125mmol/L|0
6059323|NCT00477490|9659931|FG000|Part I: 4 Week Efficacy|Protocol Violation|2
6059324|NCT00477490|9659932|FG001|Part I: 4 Week Efficacy|Protocol Violation|0
6059325|NCT00477490|9659933|FG002|Part I: 4 Week Efficacy|Protocol Violation|0
6059326|NCT00477490|9659934|FG003|Part I: 4 Week Efficacy|Protocol Violation|0
6059327|NCT00477490|9659935|FG004|Part I: 4 Week Efficacy|Protocol Violation|1
6092804|NCT00706654|9705638|FG002|Conversion Phase|Lack of Efficacy without Adverse Event|0
6092805|NCT00706654|9705639|FG003|Conversion Phase|Lack of Efficacy without Adverse Event|0
6092806|NCT00706654|9705636|FG000|Oral Stabilization Phase|Lost to Follow-up|17
6092807|NCT00706654|9705637|FG001|Oral Stabilization Phase|Lost to Follow-up|0
6059328|NCT00477490|9659936|FG005|Part I: 4 Week Efficacy|Protocol Violation|0
6059329|NCT00477490|9659937|FG006|Part I: 4 Week Efficacy|Protocol Violation|0
6059330|NCT00477490|9659938|FG007|Part I: 4 Week Efficacy|Protocol Violation|0
6059331|NCT00477490|9659939|FG008|Part I: 4 Week Efficacy|Protocol Violation|0
6059332|NCT00477490|9659931|FG000|Part I: 4 Week Efficacy|Withdrawal by Subject|6
6059333|NCT00477490|9659932|FG001|Part I: 4 Week Efficacy|Withdrawal by Subject|5
6059334|NCT00477490|9659933|FG002|Part I: 4 Week Efficacy|Withdrawal by Subject|6
6059335|NCT00477490|9659934|FG003|Part I: 4 Week Efficacy|Withdrawal by Subject|4
6059336|NCT00477490|9659935|FG004|Part I: 4 Week Efficacy|Withdrawal by Subject|9
6059337|NCT00477490|9659936|FG005|Part I: 4 Week Efficacy|Withdrawal by Subject|0
6059338|NCT00477490|9659937|FG006|Part I: 4 Week Efficacy|Withdrawal by Subject|0
6059339|NCT00477490|9659938|FG007|Part I: 4 Week Efficacy|Withdrawal by Subject|0
6059340|NCT00477490|9659939|FG008|Part I: 4 Week Efficacy|Withdrawal by Subject|0
6059341|NCT00477490|9659931|FG000|Part I: 4 Week Efficacy|Lost to Follow-up|2
6059342|NCT00477490|9659932|FG001|Part I: 4 Week Efficacy|Lost to Follow-up|4
6059343|NCT00477490|9659933|FG002|Part I: 4 Week Efficacy|Lost to Follow-up|1
6059344|NCT00477490|9659934|FG003|Part I: 4 Week Efficacy|Lost to Follow-up|5
6059345|NCT00477490|9659935|FG004|Part I: 4 Week Efficacy|Lost to Follow-up|3
6059346|NCT00477490|9659936|FG005|Part I: 4 Week Efficacy|Lost to Follow-up|0
6059347|NCT00477490|9659937|FG006|Part I: 4 Week Efficacy|Lost to Follow-up|0
6092808|NCT00706654|9705638|FG002|Oral Stabilization Phase|Lost to Follow-up|0
6092809|NCT00706654|9705639|FG003|Oral Stabilization Phase|Lost to Follow-up|0
6092810|NCT00706654|9705636|FG000|Oral Stabilization Phase|Sponsor Discontinue Trial|19
6092811|NCT00706654|9705637|FG001|Oral Stabilization Phase|Sponsor Discontinue Trial|0
6092812|NCT00706654|9705638|FG002|Oral Stabilization Phase|Sponsor Discontinue Trial|0
6092813|NCT00706654|9705639|FG003|Oral Stabilization Phase|Sponsor Discontinue Trial|0
6092814|NCT00706654|9705636|FG000|Oral Stabilization Phase|Met Withdrawal Criteria|15
6092815|NCT00706654|9705637|FG001|Oral Stabilization Phase|Met Withdrawal Criteria|0
6092816|NCT00706654|9705638|FG002|Oral Stabilization Phase|Met Withdrawal Criteria|0
6092817|NCT00706654|9705639|FG003|Oral Stabilization Phase|Met Withdrawal Criteria|0
6092818|NCT00706654|9705636|FG000|Oral Stabilization Phase|Withdrawn by Investigator|21
6092819|NCT00706654|9705637|FG001|Oral Stabilization Phase|Withdrawn by Investigator|0
6059348|NCT00477490|9659938|FG007|Part I: 4 Week Efficacy|Lost to Follow-up|0
6059349|NCT00477490|9659939|FG008|Part I: 4 Week Efficacy|Lost to Follow-up|0
6059350|NCT00477490|9659931|FG000|Part I: 4 Week Efficacy|Other, not specified|2
6059351|NCT00477490|9659932|FG001|Part I: 4 Week Efficacy|Other, not specified|4
6059352|NCT00477490|9659933|FG002|Part I: 4 Week Efficacy|Other, not specified|0
6059353|NCT00477490|9659934|FG003|Part I: 4 Week Efficacy|Other, not specified|1
6059354|NCT00477490|9659935|FG004|Part I: 4 Week Efficacy|Other, not specified|1
6059355|NCT00477490|9659936|FG005|Part I: 4 Week Efficacy|Other, not specified|0
6059356|NCT00477490|9659937|FG006|Part I: 4 Week Efficacy|Other, not specified|0
6059357|NCT00477490|9659938|FG007|Part I: 4 Week Efficacy|Other, not specified|0
6059358|NCT00477490|9659939|FG008|Part I: 4 Week Efficacy|Other, not specified|0
6059359|NCT00477490|9659931|FG000|Part I: 4 Week Efficacy|Not Reported|1
6059360|NCT00477490|9659932|FG001|Part I: 4 Week Efficacy|Not Reported|2
6059361|NCT00477490|9659933|FG002|Part I: 4 Week Efficacy|Not Reported|3
6059362|NCT00477490|9659934|FG003|Part I: 4 Week Efficacy|Not Reported|0
6059363|NCT00477490|9659935|FG004|Part I: 4 Week Efficacy|Not Reported|1
6059364|NCT00477490|9659936|FG005|Part I: 4 Week Efficacy|Not Reported|0
6059365|NCT00477490|9659937|FG006|Part I: 4 Week Efficacy|Not Reported|0
6059366|NCT00477490|9659938|FG007|Part I: 4 Week Efficacy|Not Reported|0
6059367|NCT00477490|9659939|FG008|Part I: 4 Week Efficacy|Not Reported|0
6059368|NCT00477490|9659931|FG000|Part II: Extension Week 5 up to Day 169|Withdrawal by Subject|0
6059369|NCT00477490|9659932|FG001|Part II: Extension Week 5 up to Day 169|Withdrawal by Subject|15
6059370|NCT00477490|9659933|FG002|Part II: Extension Week 5 up to Day 169|Withdrawal by Subject|7
6059371|NCT00477490|9659934|FG003|Part II: Extension Week 5 up to Day 169|Withdrawal by Subject|7
6059372|NCT00477490|9659935|FG004|Part II: Extension Week 5 up to Day 169|Withdrawal by Subject|10
6059373|NCT00477490|9659936|FG005|Part II: Extension Week 5 up to Day 169|Withdrawal by Subject|4
6059374|NCT00477490|9659937|FG006|Part II: Extension Week 5 up to Day 169|Withdrawal by Subject|2
6059375|NCT00477490|9659938|FG007|Part II: Extension Week 5 up to Day 169|Withdrawal by Subject|3
6059376|NCT00477490|9659939|FG008|Part II: Extension Week 5 up to Day 169|Withdrawal by Subject|2
6059377|NCT00477490|9659931|FG000|Part II: Extension Week 5 up to Day 169|Adverse Event|0
6059378|NCT00477490|9659932|FG001|Part II: Extension Week 5 up to Day 169|Adverse Event|2
6059379|NCT00477490|9659933|FG002|Part II: Extension Week 5 up to Day 169|Adverse Event|3
6059380|NCT00477490|9659934|FG003|Part II: Extension Week 5 up to Day 169|Adverse Event|1
6059381|NCT00477490|9659935|FG004|Part II: Extension Week 5 up to Day 169|Adverse Event|1
6059382|NCT00477490|9659936|FG005|Part II: Extension Week 5 up to Day 169|Adverse Event|1
6059383|NCT00477490|9659937|FG006|Part II: Extension Week 5 up to Day 169|Adverse Event|1
6059384|NCT00477490|9659938|FG007|Part II: Extension Week 5 up to Day 169|Adverse Event|1
6059385|NCT00477490|9659939|FG008|Part II: Extension Week 5 up to Day 169|Adverse Event|4
6059386|NCT00477490|9659931|FG000|Part II: Extension Week 5 up to Day 169|Lost to Follow-up|0
6059387|NCT00477490|9659932|FG001|Part II: Extension Week 5 up to Day 169|Lost to Follow-up|3
6059388|NCT00477490|9659933|FG002|Part II: Extension Week 5 up to Day 169|Lost to Follow-up|2
6059389|NCT00477490|9659934|FG003|Part II: Extension Week 5 up to Day 169|Lost to Follow-up|0
6059390|NCT00477490|9659935|FG004|Part II: Extension Week 5 up to Day 169|Lost to Follow-up|5
6059391|NCT00477490|9659936|FG005|Part II: Extension Week 5 up to Day 169|Lost to Follow-up|0
6059392|NCT00477490|9659937|FG006|Part II: Extension Week 5 up to Day 169|Lost to Follow-up|1
6059393|NCT00477490|9659938|FG007|Part II: Extension Week 5 up to Day 169|Lost to Follow-up|0
6059394|NCT00477490|9659939|FG008|Part II: Extension Week 5 up to Day 169|Lost to Follow-up|0
6092820|NCT00706654|9705638|FG002|Oral Stabilization Phase|Withdrawn by Investigator|0
6092821|NCT00706654|9705639|FG003|Oral Stabilization Phase|Withdrawn by Investigator|0
6092822|NCT00706654|9705636|FG000|Oral Stabilization Phase|Withdrew consent|55
6092823|NCT00706654|9705637|FG001|Oral Stabilization Phase|Withdrew consent|0
6092824|NCT00706654|9705638|FG002|Oral Stabilization Phase|Withdrew consent|0
6092825|NCT00706654|9705639|FG003|Oral Stabilization Phase|Withdrew consent|0
6092826|NCT00706654|9705636|FG000|Oral Stabilization Phase|Protocol Deviation|2
6092827|NCT00706654|9705637|FG001|Oral Stabilization Phase|Protocol Deviation|0
6092828|NCT00706654|9705638|FG002|Oral Stabilization Phase|Protocol Deviation|0
6092829|NCT00706654|9705639|FG003|Oral Stabilization Phase|Protocol Deviation|0
6092830|NCT00706654|9705636|FG000|Oral Stabilization Phase|Adverse Event|21
6092831|NCT00706654|9705637|FG001|Oral Stabilization Phase|Adverse Event|0
6092832|NCT00706654|9705638|FG002|Oral Stabilization Phase|Adverse Event|0
6092833|NCT00706654|9705639|FG003|Oral Stabilization Phase|Adverse Event|0
6092834|NCT00706654|9705636|FG000|Oral Stabilization Phase|Lack of Efficacy with Adverse Event|20
6092835|NCT00706654|9705637|FG001|Oral Stabilization Phase|Lack of Efficacy with Adverse Event|0
6092836|NCT00706654|9705638|FG002|Oral Stabilization Phase|Lack of Efficacy with Adverse Event|0
6092837|NCT00706654|9705639|FG003|Oral Stabilization Phase|Lack of Efficacy with Adverse Event|0
6092838|NCT00706654|9705636|FG000|Oral Stabilization Phase|Lack of Efficacy without Adverse Event|10
6092839|NCT00706654|9705637|FG001|Oral Stabilization Phase|Lack of Efficacy without Adverse Event|0
6092840|NCT00706654|9705638|FG002|Oral Stabilization Phase|Lack of Efficacy without Adverse Event|0
6092841|NCT00706654|9705639|FG003|Oral Stabilization Phase|Lack of Efficacy without Adverse Event|0
6092842|NCT00706654|9705636|FG000|Depot Maintenance Phase|Lost to Follow-up|0
6092843|NCT00706654|9705637|FG001|Depot Maintenance Phase|Lost to Follow-up|4
6092844|NCT00706654|9705638|FG002|Depot Maintenance Phase|Lost to Follow-up|10
6092845|NCT00706654|9705639|FG003|Depot Maintenance Phase|Lost to Follow-up|6
6092846|NCT00706654|9705636|FG000|Depot Maintenance Phase|Met Withdrawal Criteria|0
6092847|NCT00706654|9705637|FG001|Depot Maintenance Phase|Met Withdrawal Criteria|4
6092848|NCT00706654|9705638|FG002|Depot Maintenance Phase|Met Withdrawal Criteria|6
6092849|NCT00706654|9705639|FG003|Depot Maintenance Phase|Met Withdrawal Criteria|5
6092850|NCT00706654|9705636|FG000|Depot Maintenance Phase|Withdrawn by Investigator|0
6092851|NCT00706654|9705637|FG001|Depot Maintenance Phase|Withdrawn by Investigator|8
6092852|NCT00706654|9705638|FG002|Depot Maintenance Phase|Withdrawn by Investigator|12
6092853|NCT00706654|9705639|FG003|Depot Maintenance Phase|Withdrawn by Investigator|8
6092854|NCT00706654|9705636|FG000|Depot Maintenance Phase|Withdrew Consent|0
6092855|NCT00706654|9705637|FG001|Depot Maintenance Phase|Withdrew Consent|21
6092856|NCT00706654|9705638|FG002|Depot Maintenance Phase|Withdrew Consent|29
6092857|NCT00706654|9705639|FG003|Depot Maintenance Phase|Withdrew Consent|14
6092858|NCT00706654|9705636|FG000|Depot Maintenance Phase|Protocol Deviation|0
6092859|NCT00706654|9705637|FG001|Depot Maintenance Phase|Protocol Deviation|2
6092860|NCT00706654|9705638|FG002|Depot Maintenance Phase|Protocol Deviation|3
6092861|NCT00706654|9705639|FG003|Depot Maintenance Phase|Protocol Deviation|1
6092862|NCT00706654|9705636|FG000|Depot Maintenance Phase|Adverse Event without Impending Relapse|0
6092863|NCT00706654|9705637|FG001|Depot Maintenance Phase|Adverse Event without Impending Relapse|8
6092864|NCT00706654|9705638|FG002|Depot Maintenance Phase|Adverse Event without Impending Relapse|7
6092865|NCT00706654|9705639|FG003|Depot Maintenance Phase|Adverse Event without Impending Relapse|7
6092866|NCT00706654|9705636|FG000|Depot Maintenance Phase|Impending Relapse with Adverse Event|0
6092867|NCT00706654|9705637|FG001|Depot Maintenance Phase|Impending Relapse with Adverse Event|13
6092868|NCT00706654|9705638|FG002|Depot Maintenance Phase|Impending Relapse with Adverse Event|12
6092869|NCT00706654|9705639|FG003|Depot Maintenance Phase|Impending Relapse with Adverse Event|17
6092870|NCT00706654|9705636|FG000|Depot Maintenance Phase|Impending Relapse without Adverse Event|0
6092871|NCT00706654|9705637|FG001|Depot Maintenance Phase|Impending Relapse without Adverse Event|9
6092872|NCT00706654|9705638|FG002|Depot Maintenance Phase|Impending Relapse without Adverse Event|9
6092873|NCT00706654|9705639|FG003|Depot Maintenance Phase|Impending Relapse without Adverse Event|12
6092874|NCT00706706|9705649|FG000|Overall Study|Death|53
6092875|NCT00706706|9705649|FG000|Overall Study|Lost to Follow-up|7
6059395|NCT00477490|9659931|FG000|Part II: Extension Week 5 up to Day 169|Decreased sodium|0
6059396|NCT00477490|9659932|FG001|Part II: Extension Week 5 up to Day 169|Decreased sodium|0
6059397|NCT00477490|9659933|FG002|Part II: Extension Week 5 up to Day 169|Decreased sodium|0
6059398|NCT00477490|9659934|FG003|Part II: Extension Week 5 up to Day 169|Decreased sodium|0
6059399|NCT00477490|9659935|FG004|Part II: Extension Week 5 up to Day 169|Decreased sodium|1
6059400|NCT00477490|9659936|FG005|Part II: Extension Week 5 up to Day 169|Decreased sodium|0
6059401|NCT00477490|9659937|FG006|Part II: Extension Week 5 up to Day 169|Decreased sodium|0
6059402|NCT00477490|9659938|FG007|Part II: Extension Week 5 up to Day 169|Decreased sodium|1
6059403|NCT00477490|9659939|FG008|Part II: Extension Week 5 up to Day 169|Decreased sodium|1
6059404|NCT00477490|9659931|FG000|Part II: Extension Week 5 up to Day 169|Excluded medication|0
6059405|NCT00477490|9659932|FG001|Part II: Extension Week 5 up to Day 169|Excluded medication|1
6059406|NCT00477490|9659933|FG002|Part II: Extension Week 5 up to Day 169|Excluded medication|0
6059407|NCT00477490|9659934|FG003|Part II: Extension Week 5 up to Day 169|Excluded medication|0
6059408|NCT00477490|9659935|FG004|Part II: Extension Week 5 up to Day 169|Excluded medication|0
6059409|NCT00477490|9659936|FG005|Part II: Extension Week 5 up to Day 169|Excluded medication|0
6059410|NCT00477490|9659937|FG006|Part II: Extension Week 5 up to Day 169|Excluded medication|0
6059411|NCT00477490|9659938|FG007|Part II: Extension Week 5 up to Day 169|Excluded medication|0
6059412|NCT00477490|9659939|FG008|Part II: Extension Week 5 up to Day 169|Excluded medication|0
6059413|NCT00477490|9659931|FG000|Part II: Extension Week 5 up to Day 169|Other, not specified|0
6059414|NCT00477490|9659932|FG001|Part II: Extension Week 5 up to Day 169|Other, not specified|4
6059415|NCT00477490|9659933|FG002|Part II: Extension Week 5 up to Day 169|Other, not specified|2
6059416|NCT00477490|9659934|FG003|Part II: Extension Week 5 up to Day 169|Other, not specified|4
6059417|NCT00477490|9659935|FG004|Part II: Extension Week 5 up to Day 169|Other, not specified|2
6059418|NCT00477490|9659936|FG005|Part II: Extension Week 5 up to Day 169|Other, not specified|1
6059419|NCT00477490|9659937|FG006|Part II: Extension Week 5 up to Day 169|Other, not specified|1
6059420|NCT00477490|9659938|FG007|Part II: Extension Week 5 up to Day 169|Other, not specified|0
6059421|NCT00477490|9659939|FG008|Part II: Extension Week 5 up to Day 169|Other, not specified|1
6059422|NCT00477490|9659931|FG000|Part II: Extension Week 5 up to Day 169|Not reported|0
6059423|NCT00477490|9659932|FG001|Part II: Extension Week 5 up to Day 169|Not reported|3
6059424|NCT00477490|9659933|FG002|Part II: Extension Week 5 up to Day 169|Not reported|1
6059425|NCT00477490|9659934|FG003|Part II: Extension Week 5 up to Day 169|Not reported|0
6059426|NCT00477490|9659935|FG004|Part II: Extension Week 5 up to Day 169|Not reported|1
6059427|NCT00477490|9659936|FG005|Part II: Extension Week 5 up to Day 169|Not reported|0
6059428|NCT00477490|9659937|FG006|Part II: Extension Week 5 up to Day 169|Not reported|0
6059429|NCT00477490|9659938|FG007|Part II: Extension Week 5 up to Day 169|Not reported|0
6059430|NCT00477490|9659939|FG008|Part II: Extension Week 5 up to Day 169|Not reported|0
6059431|NCT00477594|9659969|FG000|Year 1 and Year 2|Adverse Event|4
6059432|NCT00477594|9659970|FG001|Year 1 and Year 2|Adverse Event|2
6059433|NCT00477594|9659969|FG000|Year 1 and Year 2|Physician Decision|2
6059434|NCT00477594|9659970|FG001|Year 1 and Year 2|Physician Decision|1
6092876|NCT00706706|9705649|FG000|Overall Study|Study endpoint had reached|45
6092877|NCT00706849|9705698|FG000|Treatment Period|Adverse Event|0
6092878|NCT00706849|9705699|FG001|Treatment Period|Adverse Event|9
6092879|NCT00706849|9705698|FG000|Treatment Period|Other|0
6092880|NCT00706849|9705699|FG001|Treatment Period|Other|1
6092881|NCT00706849|9705698|FG000|Follow-up Period|Withdrawal by Subject|0
6092882|NCT00706849|9705699|FG001|Follow-up Period|Withdrawal by Subject|2
6092883|NCT00706849|9705698|FG000|Follow-up Period|Protocol non-compliance|0
6092884|NCT00706849|9705699|FG001|Follow-up Period|Protocol non-compliance|1
6092885|NCT00706901|9705708|FG000|Overall Study|Lost to Follow-up|2
6092886|NCT00706901|9705709|FG001|Overall Study|Lost to Follow-up|3
6092887|NCT00706901|9705710|FG002|Overall Study|Lost to Follow-up|2
6092888|NCT00706901|9705708|FG000|Overall Study|Withdrawal by Subject|4
6092889|NCT00706901|9705709|FG001|Overall Study|Withdrawal by Subject|2
6092890|NCT00706901|9705710|FG002|Overall Study|Withdrawal by Subject|5
6092891|NCT00706901|9705708|FG000|Overall Study|In Jail|1
6092892|NCT00706901|9705709|FG001|Overall Study|In Jail|0
6092893|NCT00706901|9705710|FG002|Overall Study|In Jail|1
6092894|NCT00706901|9705708|FG000|Overall Study|Death|1
6092895|NCT00706901|9705709|FG001|Overall Study|Death|0
6092896|NCT00706901|9705710|FG002|Overall Study|Death|0
6092897|NCT00706914|9705722|FG000|Overall Study|Lack of Efficacy|0
6092898|NCT00706914|9705723|FG001|Overall Study|Lack of Efficacy|1
6092899|NCT00706914|9705724|FG002|Overall Study|Lack of Efficacy|0
6092900|NCT00706914|9705722|FG000|Overall Study|Lost to Follow-up|1
6092901|NCT00706914|9705723|FG001|Overall Study|Lost to Follow-up|0
6092902|NCT00706914|9705724|FG002|Overall Study|Lost to Follow-up|0
6092903|NCT00706914|9705722|FG000|Overall Study|Adverse Event|2
6092904|NCT00706914|9705723|FG001|Overall Study|Adverse Event|2
6092905|NCT00706914|9705724|FG002|Overall Study|Adverse Event|0
6092906|NCT00706914|9705722|FG000|Overall Study|Protocol Violation|3
6092907|NCT00706914|9705723|FG001|Overall Study|Protocol Violation|1
6092908|NCT00706914|9705724|FG002|Overall Study|Protocol Violation|1
6092909|NCT00706966|9705732|FG000|Overall Study|Adverse Event|1
6092910|NCT00706992|9705780|FG000|Overall Study|Study termination|5
6092911|NCT00706992|9705781|FG001|Overall Study|Study termination|5
6092912|NCT00706992|9705782|FG002|Overall Study|Study termination|6
6059435|NCT00477594|9659969|FG000|Year 1 and Year 2|Withdrawal by Subject|2
6059436|NCT00477594|9659970|FG001|Year 1 and Year 2|Withdrawal by Subject|1
6059437|NCT00477594|9659969|FG000|Year 1 and Year 2|Other|1
6059438|NCT00477594|9659970|FG001|Year 1 and Year 2|Other|0
6059439|NCT00477594|9659969|FG000|Year 3|Adverse Event|1
6059440|NCT00477594|9659970|FG001|Year 3|Adverse Event|0
6059441|NCT00477594|9659969|FG000|Year 3|Withdrawal by Subject|1
6059442|NCT00477594|9659970|FG001|Year 3|Withdrawal by Subject|0
6059443|NCT00477594|9659969|FG000|Follow-up Period|Withdrawal by Subject|2
6059444|NCT00477594|9659970|FG001|Follow-up Period|Withdrawal by Subject|1
6059445|NCT00477594|9659969|FG000|Follow-up Period|Other|1
6059446|NCT00477594|9659970|FG001|Follow-up Period|Other|0
6059447|NCT00477607|9659978|FG000|Overall Study|Lost to Follow-up|7
6059448|NCT00477607|9659979|FG001|Overall Study|Lost to Follow-up|7
6059449|NCT00477633|9659985|FG000|Overall Study|Did not receive treatment|23
6059450|NCT00477633|9659985|FG000|Overall Study|Adverse Event|143
6059451|NCT00477633|9659985|FG000|Overall Study|Pregnancy|23
6059452|NCT00477633|9659985|FG000|Overall Study|Lost to Follow-up|271
6059453|NCT00477633|9659985|FG000|Overall Study|Withdrawal by Subject|149
6059454|NCT00477633|9659985|FG000|Overall Study|Protocol Violation|25
6059455|NCT00477633|9659985|FG000|Overall Study|Various (Moving, Enrollment closed)|75
6059456|NCT00477672|9659996|FG000|Overall Study|Adverse Event|3
6059457|NCT00477672|9659997|FG001|Overall Study|Adverse Event|5
6059458|NCT00477672|9659998|FG002|Overall Study|Adverse Event|6
6059459|NCT00477672|9659996|FG000|Overall Study|Death|0
6059460|NCT00477672|9659997|FG001|Overall Study|Death|1
6059461|NCT00477672|9659998|FG002|Overall Study|Death|0
6059462|NCT00477672|9659996|FG000|Overall Study|Disease progression|0
6059463|NCT00477672|9659997|FG001|Overall Study|Disease progression|1
6059464|NCT00477672|9659998|FG002|Overall Study|Disease progression|0
6059465|NCT00477672|9659996|FG000|Overall Study|Physician Decision|1
6059466|NCT00477672|9659997|FG001|Overall Study|Physician Decision|0
6059467|NCT00477672|9659998|FG002|Overall Study|Physician Decision|0
6059468|NCT00477672|9659996|FG000|Overall Study|Protocol noncompliance|0
6059469|NCT00477672|9659997|FG001|Overall Study|Protocol noncompliance|2
6059470|NCT00477672|9659998|FG002|Overall Study|Protocol noncompliance|0
6059471|NCT00477672|9659996|FG000|Overall Study|Consent withdrawn|2
6059472|NCT00477672|9659997|FG001|Overall Study|Consent withdrawn|5
6059473|NCT00477672|9659998|FG002|Overall Study|Consent withdrawn|10
6059474|NCT00477672|9659996|FG000|Overall Study|Discretion of Sponsor|1
6059475|NCT00477672|9659997|FG001|Overall Study|Discretion of Sponsor|2
6059476|NCT00477672|9659998|FG002|Overall Study|Discretion of Sponsor|0
6059477|NCT00477750|9660010|FG000|Overall Study|Currently Receiving Treatment|11
6059478|NCT00477971|9660018|FG000|Overall Study|Disease progression|6
6059479|NCT00477971|9660019|FG001|Overall Study|Disease progression|0
6059480|NCT00477971|9660018|FG000|Overall Study|Withdrawal by Subject|3
6059481|NCT00477971|9660019|FG001|Overall Study|Withdrawal by Subject|1
6059482|NCT00477971|9660018|FG000|Overall Study|Adverse Event|3
6059483|NCT00477971|9660019|FG001|Overall Study|Adverse Event|0
6059484|NCT00477971|9660018|FG000|Overall Study|Death|2
6059485|NCT00477971|9660019|FG001|Overall Study|Death|4
6059486|NCT00477971|9660018|FG000|Overall Study|Alternative treatment|3
6059487|NCT00477971|9660019|FG001|Overall Study|Alternative treatment|1
6059488|NCT00478023|9660030|FG000|Overall Study|Adverse Event|11
6059489|NCT00478023|9660031|FG001|Overall Study|Adverse Event|7
6059490|NCT00478023|9660032|FG002|Overall Study|Adverse Event|8
6059491|NCT00478023|9660033|FG003|Overall Study|Adverse Event|14
6059492|NCT00478023|9660034|FG004|Overall Study|Adverse Event|6
6059493|NCT00478023|9660030|FG000|Overall Study|Death|1
6059494|NCT00478023|9660031|FG001|Overall Study|Death|0
6059495|NCT00478023|9660032|FG002|Overall Study|Death|0
6059496|NCT00478023|9660033|FG003|Overall Study|Death|0
6059497|NCT00478023|9660034|FG004|Overall Study|Death|0
6059498|NCT00478023|9660030|FG000|Overall Study|Lack of Efficacy|11
6059499|NCT00478023|9660031|FG001|Overall Study|Lack of Efficacy|10
6059500|NCT00478023|9660032|FG002|Overall Study|Lack of Efficacy|4
6059501|NCT00478023|9660033|FG003|Overall Study|Lack of Efficacy|5
6059502|NCT00478023|9660034|FG004|Overall Study|Lack of Efficacy|41
6059503|NCT00478023|9660030|FG000|Overall Study|Lost to Follow-up|3
6059504|NCT00478023|9660031|FG001|Overall Study|Lost to Follow-up|1
6059505|NCT00478023|9660032|FG002|Overall Study|Lost to Follow-up|1
6059506|NCT00478023|9660033|FG003|Overall Study|Lost to Follow-up|1
6059507|NCT00478023|9660034|FG004|Overall Study|Lost to Follow-up|0
6059508|NCT00478023|9660030|FG000|Overall Study|Withdrawal by Subject|2
6059509|NCT00478023|9660031|FG001|Overall Study|Withdrawal by Subject|3
6059510|NCT00478023|9660032|FG002|Overall Study|Withdrawal by Subject|2
6059511|NCT00478023|9660033|FG003|Overall Study|Withdrawal by Subject|4
6059512|NCT00478023|9660034|FG004|Overall Study|Withdrawal by Subject|5
6059513|NCT00478023|9660030|FG000|Overall Study|Lack of pain, Technical difficulties|7
6059514|NCT00478023|9660031|FG001|Overall Study|Lack of pain, Technical difficulties|3
6059515|NCT00478023|9660032|FG002|Overall Study|Lack of pain, Technical difficulties|5
6059516|NCT00478023|9660033|FG003|Overall Study|Lack of pain, Technical difficulties|6
6059517|NCT00478023|9660034|FG004|Overall Study|Lack of pain, Technical difficulties|3
6059518|NCT00478140|9660059|FG000|Overall Study|Clinical Disease Progression|1
6059519|NCT00478205|9660079|FG000|Overall Study|Adverse Event|182
6059520|NCT00478205|9660080|FG001|Overall Study|Adverse Event|39
6059521|NCT00478205|9660079|FG000|Overall Study|Medication Non-compliance|9
6059522|NCT00478205|9660080|FG001|Overall Study|Medication Non-compliance|4
6059523|NCT00478205|9660079|FG000|Overall Study|Protocol Violation|15
6059524|NCT00478205|9660080|FG001|Overall Study|Protocol Violation|5
6059525|NCT00478205|9660079|FG000|Overall Study|Request of Investigator or Sponsor|4
6059526|NCT00478205|9660080|FG001|Overall Study|Request of Investigator or Sponsor|5
6059527|NCT00478205|9660079|FG000|Overall Study|Withdrawal by Subject|61
6092913|NCT00706992|9705783|FG003|Overall Study|Study termination|2
6092914|NCT00706992|9705784|FG004|Overall Study|Study termination|3
6092915|NCT00706992|9705785|FG005|Overall Study|Study termination|2
6092916|NCT00706992|9705786|FG006|Overall Study|Study termination|3
6092917|NCT00706992|9705780|FG000|Overall Study|Disease progression before treatment|0
6092918|NCT00706992|9705781|FG001|Overall Study|Disease progression before treatment|0
6092919|NCT00706992|9705782|FG002|Overall Study|Disease progression before treatment|0
6092920|NCT00706992|9705783|FG003|Overall Study|Disease progression before treatment|0
6092921|NCT00706992|9705784|FG004|Overall Study|Disease progression before treatment|1
6092922|NCT00706992|9705785|FG005|Overall Study|Disease progression before treatment|0
6092923|NCT00706992|9705786|FG006|Overall Study|Disease progression before treatment|0
6092924|NCT00707031|9705805|FG000|Overall Study|Adverse Event|45
6092925|NCT00707031|9705806|FG001|Overall Study|Adverse Event|45
6092926|NCT00707031|9705805|FG000|Overall Study|Lack of Efficacy|19
6092927|NCT00707031|9705806|FG001|Overall Study|Lack of Efficacy|6
6092928|NCT00707031|9705805|FG000|Overall Study|Lost to Follow-up|2
6092929|NCT00707031|9705806|FG001|Overall Study|Lost to Follow-up|1
6092930|NCT00707031|9705805|FG000|Overall Study|Protocol Violation|1
6092931|NCT00707031|9705806|FG001|Overall Study|Protocol Violation|0
6092932|NCT00707031|9705805|FG000|Overall Study|Withdrawal by Subject|7
6092933|NCT00707031|9705806|FG001|Overall Study|Withdrawal by Subject|8
6092934|NCT00707031|9705805|FG000|Overall Study|Poor Compliance to Protocol|7
6092935|NCT00707031|9705806|FG001|Overall Study|Poor Compliance to Protocol|13
6092936|NCT00707031|9705805|FG000|Overall Study|Familial or Personal Reasons|12
6092937|NCT00707031|9705806|FG001|Overall Study|Familial or Personal Reasons|15
6092938|NCT00707031|9705805|FG000|Overall Study|Serious Noncompliance|2
6092939|NCT00707031|9705806|FG001|Overall Study|Serious Noncompliance|3
6092940|NCT00707031|9705805|FG000|Overall Study|Sponsor Decision|9
6092941|NCT00707031|9705806|FG001|Overall Study|Sponsor Decision|8
6092942|NCT00707057|9705815|FG000|Overall Study|Withdrawal by Subject|8
6092943|NCT00707057|9705816|FG001|Overall Study|Withdrawal by Subject|3
6092944|NCT00707057|9705815|FG000|Overall Study|Dosed incorrectly|0
6092945|NCT00707057|9705816|FG001|Overall Study|Dosed incorrectly|1
6092946|NCT00707174|9705824|FG000|Overall Study|Adverse Event|1
6092947|NCT00707174|9705825|FG001|Overall Study|Adverse Event|6
6092948|NCT00707174|9705824|FG000|Overall Study|Withdrawal by Subject|4
6092949|NCT00707174|9705825|FG001|Overall Study|Withdrawal by Subject|1
6092950|NCT00707239|9705834|FG000|Overall Study|Adverse Event|5
6092951|NCT00707239|9705835|FG001|Overall Study|Adverse Event|3
6092952|NCT00707239|9705836|FG002|Overall Study|Adverse Event|2
6092953|NCT00707239|9705834|FG000|Overall Study|Death|3
6092954|NCT00707239|9705835|FG001|Overall Study|Death|1
6092955|NCT00707239|9705836|FG002|Overall Study|Death|3
6092956|NCT00707239|9705834|FG000|Overall Study|Physician Decision|1
6092957|NCT00707239|9705835|FG001|Overall Study|Physician Decision|1
6092958|NCT00707239|9705836|FG002|Overall Study|Physician Decision|2
6092959|NCT00707239|9705834|FG000|Overall Study|Protocol Violation|0
6092960|NCT00707239|9705835|FG001|Overall Study|Protocol Violation|0
6092961|NCT00707239|9705836|FG002|Overall Study|Protocol Violation|1
6092962|NCT00707239|9705834|FG000|Overall Study|Lack of Efficacy|1
6092963|NCT00707239|9705835|FG001|Overall Study|Lack of Efficacy|2
6092964|NCT00707239|9705836|FG002|Overall Study|Lack of Efficacy|0
6092965|NCT00707239|9705834|FG000|Overall Study|Randomized, but not treated|1
6092966|NCT00707239|9705835|FG001|Overall Study|Randomized, but not treated|1
6092967|NCT00707239|9705836|FG002|Overall Study|Randomized, but not treated|1
6092968|NCT00707239|9705834|FG000|Overall Study|Other|8
6092969|NCT00707239|9705835|FG001|Overall Study|Other|3
6092970|NCT00707239|9705836|FG002|Overall Study|Other|5
6092971|NCT00707486|9705860|FG000|Overall Study|Withdrawal by Subject|1
6092972|NCT00707577|9705868|FG000|Overall Study|Withdrawal by Subject|3
6092973|NCT00707577|9705869|FG001|Overall Study|Withdrawal by Subject|2
6092974|NCT00707577|9705868|FG000|Overall Study|Lost to Follow-up|34
6092975|NCT00707577|9705869|FG001|Overall Study|Lost to Follow-up|25
6092976|NCT00707577|9705868|FG000|Overall Study|Left employment|13
6092977|NCT00707577|9705869|FG001|Overall Study|Left employment|10
6092978|NCT00707577|9705868|FG000|Overall Study|Pregnancy|4
6092979|NCT00707577|9705869|FG001|Overall Study|Pregnancy|1
6092980|NCT00707746|9705888|FG000|Treatment Period|Adverse Event|2
6092981|NCT00707746|9705889|FG001|Treatment Period|Adverse Event|4
6092982|NCT00707746|9705888|FG000|Treatment Period|Ineligibility|0
6059528|NCT00478205|9660080|FG001|Overall Study|Withdrawal by Subject|22
6092983|NCT00707746|9705889|FG001|Treatment Period|Ineligibility|1
6092984|NCT00707954|9705922|FG000|Overall Study|Physician Decision|0
6092985|NCT00707954|9705923|FG001|Overall Study|Physician Decision|0
6092986|NCT00707954|9705924|FG002|Overall Study|Physician Decision|0
6092987|NCT00707954|9705925|FG003|Overall Study|Physician Decision|0
6092988|NCT00707954|9705926|FG004|Overall Study|Physician Decision|1
6092989|NCT00707980|9705951|FG000|Overall Study|Adverse Event|49
6059529|NCT00478205|9660079|FG000|Overall Study|Lack of Efficacy|1
6059530|NCT00478205|9660080|FG001|Overall Study|Lack of Efficacy|0
6092990|NCT00707980|9705951|FG000|Overall Study|Lack of Efficacy|35
6092991|NCT00707980|9705951|FG000|Overall Study|Non-Compliance with Study Drug|28
6092992|NCT00707980|9705951|FG000|Overall Study|Protocol Deviations|19
6092993|NCT00707980|9705951|FG000|Overall Study|Withdrawal of Consent|81
6092994|NCT00707980|9705951|FG000|Overall Study|Lost to Follow-up|59
6092995|NCT00707980|9705951|FG000|Overall Study|Other|39
6092996|NCT00707993|9705957|FG000|Overall Study|Adverse Event|16
6092997|NCT00707993|9705958|FG001|Overall Study|Adverse Event|20
6092998|NCT00707993|9705957|FG000|Overall Study|Protocol Violation|4
6092999|NCT00707993|9705958|FG001|Overall Study|Protocol Violation|7
6093000|NCT00707993|9705957|FG000|Overall Study|Lost to Follow-up|0
6093001|NCT00707993|9705958|FG001|Overall Study|Lost to Follow-up|4
6093002|NCT00707993|9705957|FG000|Overall Study|Withdrawal by Subject|12
6093003|NCT00707993|9705958|FG001|Overall Study|Withdrawal by Subject|16
6093004|NCT00707993|9705957|FG000|Overall Study|Hyperglycemic Rescue|55
6093005|NCT00707993|9705958|FG001|Overall Study|Hyperglycemic Rescue|47
6093006|NCT00707993|9705957|FG000|Overall Study|Other|2
6093007|NCT00707993|9705958|FG001|Overall Study|Other|0
6093008|NCT00708032|9705975|FG000|Overall Study|Adverse Event|0
6093009|NCT00708032|9705976|FG001|Overall Study|Adverse Event|2
6093010|NCT00708032|9705975|FG000|Overall Study|Lost to Follow-up|1
6093011|NCT00708032|9705976|FG001|Overall Study|Lost to Follow-up|2
6093012|NCT00708032|9705975|FG000|Overall Study|Pregnancy|0
6093013|NCT00708032|9705976|FG001|Overall Study|Pregnancy|1
6093014|NCT00708032|9705975|FG000|Overall Study|Poor vision|0
6093015|NCT00708032|9705976|FG001|Overall Study|Poor vision|6
6093016|NCT00708032|9705975|FG000|Overall Study|Visit out of range at month 12|4
6093017|NCT00708032|9705976|FG001|Overall Study|Visit out of range at month 12|1
6093018|NCT00708032|9705975|FG000|Overall Study|Did not meet protocol criteria|1
6093019|NCT00708032|9705976|FG001|Overall Study|Did not meet protocol criteria|2
6093020|NCT00708032|9705975|FG000|Overall Study|Protocol Violation|4
6093021|NCT00708032|9705976|FG001|Overall Study|Protocol Violation|1
6093022|NCT00708032|9705975|FG000|Overall Study|Withdrawal by Subject|0
6093023|NCT00708032|9705976|FG001|Overall Study|Withdrawal by Subject|1
6093024|NCT00708097|9706016|FG000|Period 1|Protocol Violation|0
6093025|NCT00708097|9706017|FG001|Period 1|Protocol Violation|1
6093026|NCT00708097|9706018|FG002|Period 1|Protocol Violation|0
6093027|NCT00708097|9706019|FG003|Period 1|Protocol Violation|2
6093028|NCT00708097|9706020|FG004|Period 1|Protocol Violation|0
6093029|NCT00708097|9706016|FG000|Period 1|Other Reason|0
6093030|NCT00708097|9706017|FG001|Period 1|Other Reason|0
6093031|NCT00708097|9706018|FG002|Period 1|Other Reason|0
6093032|NCT00708097|9706019|FG003|Period 1|Other Reason|0
6093033|NCT00708097|9706020|FG004|Period 1|Other Reason|1
6093034|NCT00708097|9706016|FG000|Period 2|Protocol Violation|0
6093035|NCT00708097|9706017|FG001|Period 2|Protocol Violation|1
6093036|NCT00708097|9706018|FG002|Period 2|Protocol Violation|1
6093037|NCT00708097|9706019|FG003|Period 2|Protocol Violation|1
6093038|NCT00708097|9706020|FG004|Period 2|Protocol Violation|0
6093039|NCT00708123|9706054|FG000|Period 1|Protocol Violation|0
6093040|NCT00708123|9706055|FG001|Period 1|Protocol Violation|1
6093041|NCT00708123|9706056|FG002|Period 1|Protocol Violation|0
6093042|NCT00708123|9706057|FG003|Period 1|Protocol Violation|1
6093043|NCT00708123|9706058|FG004|Period 1|Protocol Violation|0
6093044|NCT00708123|9706054|FG000|Period 1|Adverse Event|0
6093045|NCT00708123|9706055|FG001|Period 1|Adverse Event|0
6093046|NCT00708123|9706056|FG002|Period 1|Adverse Event|1
6093047|NCT00708123|9706057|FG003|Period 1|Adverse Event|0
6059531|NCT00478205|9660079|FG000|Overall Study|Other|24
6059532|NCT00478205|9660080|FG001|Overall Study|Other|12
6059533|NCT00478231|9660095|FG000|Overall Study|Death|7
6059534|NCT00478231|9660095|FG000|Overall Study|Lack of Efficacy|47
6059535|NCT00478231|9660095|FG000|Overall Study|Lost to Follow-up|7
6059536|NCT00478231|9660095|FG000|Overall Study|Withdrawal by Subject|6
6059537|NCT00478231|9660095|FG000|Overall Study|Other|9
6059538|NCT00478231|9660095|FG000|Overall Study|Adverse Event|5
6059539|NCT00478231|9660095|FG000|Overall Study|Randomized, not treated|3
6059540|NCT00478244|9660099|FG000|Overall Study|Did not receive transplant|1
6059541|NCT00478257|9660105|FG000|Overall Study|Withdrawal by Subject|8
6059542|NCT00478257|9660106|FG001|Overall Study|Withdrawal by Subject|3
6059543|NCT00478426|9660125|FG000|Overall Study|Withdrawal by Subject|1
6059544|NCT00478608|9660150|FG000|Overall Study|Adverse Event|1
6059545|NCT00478608|9660150|FG000|Overall Study|Serious Adverse Event|14
6059546|NCT00478608|9660150|FG000|Overall Study|Withdrawal by Subject|2
6093048|NCT00708123|9706058|FG004|Period 1|Adverse Event|0
6093049|NCT00708123|9706054|FG000|Period 2|Protocol Violation|0
6093050|NCT00708123|9706055|FG001|Period 2|Protocol Violation|0
6093051|NCT00708123|9706056|FG002|Period 2|Protocol Violation|0
6093052|NCT00708123|9706057|FG003|Period 2|Protocol Violation|1
6093053|NCT00708123|9706058|FG004|Period 2|Protocol Violation|0
6093054|NCT00708123|9706054|FG000|Period 2|Other Reason|1
6093055|NCT00708123|9706055|FG001|Period 2|Other Reason|0
6093056|NCT00708123|9706056|FG002|Period 2|Other Reason|0
6093057|NCT00708123|9706057|FG003|Period 2|Other Reason|0
6093058|NCT00708123|9706058|FG004|Period 2|Other Reason|0
6059547|NCT00478608|9660150|FG000|Overall Study|Protocol Violation|3
6059548|NCT00478647|9660154|FG000|Overall Study|Adverse Event|1
6059549|NCT00478647|9660154|FG000|Overall Study|Withdrawal by Subject|1
6059550|NCT00478673|9660158|FG000|30-Days Post-Procedure|Death|2
6059551|NCT00478673|9660158|FG000|30-Days Post-Procedure|Withdrawal by Subject|1
6059552|NCT00478673|9660158|FG000|30-Days Post-Procedure|Missed Visit|7
6059553|NCT00478673|9660158|FG000|12-Months Post-Procedure|Death|23
6059554|NCT00478673|9660158|FG000|12-Months Post-Procedure|Lost to Follow-up|4
6059555|NCT00478673|9660158|FG000|12-Months Post-Procedure|Withdrawal by Subject|6
6059556|NCT00478673|9660158|FG000|12-Months Post-Procedure|Missed Visit|25
6059557|NCT00478673|9660158|FG000|12-Months Post-Procedure|Visit Not Required by Protocol|6
6059558|NCT00478777|9660162|FG000|Overall Study|Adverse Event|29
6059559|NCT00478777|9660162|FG000|Overall Study|Lack of Efficacy|23
6059560|NCT00478777|9660162|FG000|Overall Study|Withdrawal by Subject|4
6093059|NCT00708123|9706054|FG000|Period 3|Lost to Follow-up|0
6093060|NCT00708123|9706055|FG001|Period 3|Lost to Follow-up|0
6093061|NCT00708123|9706056|FG002|Period 3|Lost to Follow-up|1
6093062|NCT00708123|9706057|FG003|Period 3|Lost to Follow-up|1
6093063|NCT00708123|9706058|FG004|Period 3|Lost to Follow-up|0
6093064|NCT00708123|9706054|FG000|Period 4|Protocol Violation|0
6093065|NCT00708123|9706055|FG001|Period 4|Protocol Violation|1
6093066|NCT00708123|9706056|FG002|Period 4|Protocol Violation|0
6093067|NCT00708123|9706057|FG003|Period 4|Protocol Violation|0
6093068|NCT00708123|9706058|FG004|Period 4|Protocol Violation|0
6093069|NCT00708162|9706076|FG000|Randomized Phase|Randomized but Not Treated|7
6093070|NCT00708162|9706077|FG001|Randomized Phase|Randomized but Not Treated|5
6093071|NCT00708162|9706076|FG000|Randomized Phase|Participant Noncompliance|40
6093072|NCT00708162|9706077|FG001|Randomized Phase|Participant Noncompliance|32
6093073|NCT00708162|9706076|FG000|Randomized Phase|Lost to Follow-up|34
6093074|NCT00708162|9706077|FG001|Randomized Phase|Lost to Follow-up|34
6093075|NCT00708162|9706076|FG000|Randomized Phase|Withdrew Consent|31
6093076|NCT00708162|9706077|FG001|Randomized Phase|Withdrew Consent|22
6093077|NCT00708162|9706076|FG000|Randomized Phase|Lack of Efficacy|14
6093078|NCT00708162|9706077|FG001|Randomized Phase|Lack of Efficacy|19
6093079|NCT00708162|9706076|FG000|Randomized Phase|Protocol Violation|10
6093080|NCT00708162|9706077|FG001|Randomized Phase|Protocol Violation|11
6093081|NCT00708162|9706076|FG000|Randomized Phase|Adverse Event|8
6093082|NCT00708162|9706077|FG001|Randomized Phase|Adverse Event|12
6093083|NCT00708162|9706076|FG000|Randomized Phase|Investigator's Discretion|7
6093084|NCT00708162|9706077|FG001|Randomized Phase|Investigator's Discretion|10
6093085|NCT00708162|9706076|FG000|Randomized Phase|Death|2
6093086|NCT00708162|9706077|FG001|Randomized Phase|Death|9
6093087|NCT00708162|9706076|FG000|Randomized Phase|Pregnancy|3
6093088|NCT00708162|9706077|FG001|Randomized Phase|Pregnancy|0
6093089|NCT00708162|9706076|FG000|Open-Label Phase|Lost to Follow-up|10
6093090|NCT00708162|9706077|FG001|Open-Label Phase|Lost to Follow-up|8
6093091|NCT00708162|9706076|FG000|Open-Label Phase|Withdrew Consent|12
6093092|NCT00708162|9706077|FG001|Open-Label Phase|Withdrew Consent|6
6093093|NCT00708162|9706076|FG000|Open-Label Phase|Participant Noncompliance|7
6093094|NCT00708162|9706077|FG001|Open-Label Phase|Participant Noncompliance|7
6093095|NCT00708162|9706076|FG000|Open-Label Phase|Lack of Efficacy|7
6093096|NCT00708162|9706077|FG001|Open-Label Phase|Lack of Efficacy|4
6093097|NCT00708162|9706076|FG000|Open-Label Phase|Investigator's Discretion|3
6093098|NCT00708162|9706077|FG001|Open-Label Phase|Investigator's Discretion|2
6093099|NCT00708162|9706076|FG000|Open-Label Phase|Death|3
6093100|NCT00708162|9706077|FG001|Open-Label Phase|Death|1
6093101|NCT00708162|9706076|FG000|Open-Label Phase|Adverse Event|1
6093102|NCT00708162|9706077|FG001|Open-Label Phase|Adverse Event|2
6093103|NCT00708162|9706076|FG000|Open-Label Phase|Other|1
6093104|NCT00708162|9706077|FG001|Open-Label Phase|Other|0
6093105|NCT00708175|9706086|FG000|Overall Study|Adverse Event|4
6093106|NCT00708175|9706087|FG001|Overall Study|Adverse Event|5
6093107|NCT00708175|9706086|FG000|Overall Study|Protocol Violation|2
6202688|NCT01505647|9863032|FG001|Day 1 Through Day 42 Follow-up|Physician Decision|0
6202689|NCT01505647|9863031|FG000|Day 1 Through Day 42 Follow-up|Withdrawal by Subject|1
6202690|NCT01505647|9863032|FG001|Day 1 Through Day 42 Follow-up|Withdrawal by Subject|0
6202691|NCT01505647|9863031|FG000|Day 43 Through Day 182 Follow-up|Death|0
6202692|NCT01505647|9863032|FG001|Day 43 Through Day 182 Follow-up|Death|1
6202693|NCT01505647|9863031|FG000|Day 43 Through Day 182 Follow-up|Lost to Follow-up|1
6059561|NCT00478777|9660162|FG000|Overall Study|Death|3
6059562|NCT00478777|9660162|FG000|Overall Study|Protocol Violation|3
6093108|NCT00708175|9706087|FG001|Overall Study|Protocol Violation|3
6093109|NCT00708175|9706086|FG000|Overall Study|Lost to Follow-up|5
6093110|NCT00708175|9706087|FG001|Overall Study|Lost to Follow-up|3
6093111|NCT00708175|9706086|FG000|Overall Study|Withdrawal by Subject|5
6093112|NCT00708175|9706087|FG001|Overall Study|Withdrawal by Subject|7
6093113|NCT00708175|9706086|FG000|Overall Study|BMD loss >7%|2
6093114|NCT00708175|9706087|FG001|Overall Study|BMD loss >7%|3
6093115|NCT00708201|9706095|FG000|Overall Study|Adverse Event|4
6093116|NCT00708201|9706096|FG001|Overall Study|Adverse Event|4
6093117|NCT00708201|9706095|FG000|Overall Study|Withdrawal by Subject|1
6093118|NCT00708201|9706096|FG001|Overall Study|Withdrawal by Subject|1
6093119|NCT00708201|9706095|FG000|Overall Study|Lost to Follow-up|2
6059563|NCT00478777|9660162|FG000|Overall Study|Lost to Follow-up|3
6059564|NCT00478777|9660162|FG000|Overall Study|Physician Decision|1
6059565|NCT00478777|9660162|FG000|Overall Study|Intolerance of therapy|1
6059566|NCT00478777|9660162|FG000|Overall Study|Lack of compliance|1
6093120|NCT00708201|9706096|FG001|Overall Study|Lost to Follow-up|0
6093121|NCT00708201|9706095|FG000|Overall Study|Protocol Violation|0
6093122|NCT00708201|9706096|FG001|Overall Study|Protocol Violation|1
6093123|NCT00708214|9706105|FG000|Overall Study|Other Adverse Event|3
6093124|NCT00708214|9706106|FG001|Overall Study|Other Adverse Event|6
6093125|NCT00708214|9706107|FG002|Overall Study|Other Adverse Event|2
6093126|NCT00708214|9706105|FG000|Overall Study|Other|0
6093127|NCT00708214|9706106|FG001|Overall Study|Other|1
6093128|NCT00708214|9706107|FG002|Overall Study|Other|1
6093129|NCT00708214|9706105|FG000|Overall Study|Progressive Disease|4
6093130|NCT00708214|9706106|FG001|Overall Study|Progressive Disease|6
6093131|NCT00708214|9706107|FG002|Overall Study|Progressive Disease|5
6093132|NCT00708227|9706124|FG000|Overall Study|Physician Decision|0
6093133|NCT00708227|9706125|FG001|Overall Study|Physician Decision|3
6093134|NCT00708227|9706126|FG002|Overall Study|Physician Decision|1
6093135|NCT00708227|9706127|FG003|Overall Study|Physician Decision|2
6093136|NCT00708227|9706124|FG000|Overall Study|Withdrawal by Subject|1
6093137|NCT00708227|9706125|FG001|Overall Study|Withdrawal by Subject|2
6093138|NCT00708227|9706126|FG002|Overall Study|Withdrawal by Subject|0
6093139|NCT00708227|9706127|FG003|Overall Study|Withdrawal by Subject|1
6093140|NCT00708305|9706157|FG000|Period 1|Protocol Violation|1
6093141|NCT00708305|9706158|FG001|Period 1|Protocol Violation|0
6093142|NCT00708305|9706159|FG002|Period 1|Protocol Violation|1
6093143|NCT00708305|9706160|FG003|Period 1|Protocol Violation|0
6093144|NCT00708305|9706157|FG000|Period 1|Other Reason|0
6093145|NCT00708305|9706158|FG001|Period 1|Other Reason|0
6093146|NCT00708305|9706159|FG002|Period 1|Other Reason|0
6093147|NCT00708305|9706160|FG003|Period 1|Other Reason|2
6093148|NCT00708305|9706157|FG000|Period 2|Lost to Follow-up|0
6093149|NCT00708305|9706158|FG001|Period 2|Lost to Follow-up|1
6093150|NCT00708305|9706159|FG002|Period 2|Lost to Follow-up|0
6093151|NCT00708305|9706160|FG003|Period 2|Lost to Follow-up|0
6093152|NCT00708305|9706157|FG000|Period 2|Protocol Violation|0
6093153|NCT00708305|9706158|FG001|Period 2|Protocol Violation|1
6093154|NCT00708305|9706159|FG002|Period 2|Protocol Violation|0
6093155|NCT00708305|9706160|FG003|Period 2|Protocol Violation|0
6093156|NCT00708305|9706157|FG000|Period 2|Other Reason|1
6093157|NCT00708305|9706158|FG001|Period 2|Other Reason|0
6093158|NCT00708305|9706159|FG002|Period 2|Other Reason|0
6093159|NCT00708305|9706160|FG003|Period 2|Other Reason|1
6093160|NCT00708305|9706157|FG000|Period 3|Protocol Violation|0
6093161|NCT00708305|9706158|FG001|Period 3|Protocol Violation|2
6093162|NCT00708305|9706159|FG002|Period 3|Protocol Violation|0
6093163|NCT00708305|9706160|FG003|Period 3|Protocol Violation|0
6093164|NCT00708305|9706157|FG000|Period 3|Other Reason|1
6093165|NCT00708305|9706158|FG001|Period 3|Other Reason|0
6093166|NCT00708305|9706159|FG002|Period 3|Other Reason|0
6093167|NCT00708305|9706160|FG003|Period 3|Other Reason|0
6093168|NCT00708422|9706175|FG000|Overall Study|Adverse Event|3
6093169|NCT00708422|9706176|FG001|Overall Study|Adverse Event|1
6093170|NCT00708422|9706175|FG000|Overall Study|Withdrawal by Subject|1
6093171|NCT00708422|9706176|FG001|Overall Study|Withdrawal by Subject|0
6093172|NCT00708435|9706184|FG000|Overall Study|Death / Serious Adverse Event|10
6093173|NCT00708435|9706185|FG001|Overall Study|Death / Serious Adverse Event|5
6093174|NCT00708435|9706184|FG000|Overall Study|Lost to Follow-up|9
6093175|NCT00708435|9706185|FG001|Overall Study|Lost to Follow-up|4
6093176|NCT00708435|9706184|FG000|Overall Study|Withdrawal by Subject|3
6093177|NCT00708435|9706185|FG001|Overall Study|Withdrawal by Subject|7
6093178|NCT00708435|9706184|FG000|Overall Study|Adverse Event|1
6093179|NCT00708435|9706185|FG001|Overall Study|Adverse Event|0
6093180|NCT00708435|9706184|FG000|Overall Study|Protocol Violation|0
6093181|NCT00708435|9706185|FG001|Overall Study|Protocol Violation|1
6093182|NCT00708435|9706184|FG000|Overall Study|Intervention by primary care physician|1
6093183|NCT00708435|9706185|FG001|Overall Study|Intervention by primary care physician|0
6093184|NCT00708435|9706184|FG000|Overall Study|Refused hospitalization|1
6093185|NCT00708435|9706185|FG001|Overall Study|Refused hospitalization|0
6093186|NCT00708461|9706195|FG000|Overall Study|Lost to Follow-up|18
6093187|NCT00708461|9706196|FG001|Overall Study|Lost to Follow-up|11
6093188|NCT00708461|9706195|FG000|Overall Study|Withdrawal by Subject|8
6093189|NCT00708461|9706196|FG001|Overall Study|Withdrawal by Subject|9
6093190|NCT00708461|9706195|FG000|Overall Study|left workforce|115
6093191|NCT00708461|9706196|FG001|Overall Study|left workforce|180
6093192|NCT00708500|9706205|FG000|Treatment (Tx): 4 WEEK LEAD-IN PERIOD|Adverse Event|1
6093193|NCT00708500|9706206|FG001|Treatment (Tx): 4 WEEK LEAD-IN PERIOD|Adverse Event|3
6093194|NCT00708500|9706207|FG002|Treatment (Tx): 4 WEEK LEAD-IN PERIOD|Adverse Event|1
6093195|NCT00708500|9706205|FG000|Treatment (Tx): 4 WEEK LEAD-IN PERIOD|Subject withdrawal unrelated to Tx|1
6093196|NCT00708500|9706206|FG001|Treatment (Tx): 4 WEEK LEAD-IN PERIOD|Subject withdrawal unrelated to Tx|0
6093197|NCT00708500|9706207|FG002|Treatment (Tx): 4 WEEK LEAD-IN PERIOD|Subject withdrawal unrelated to Tx|0
6093198|NCT00708500|9706205|FG000|Treatment (Tx): 4 WEEK LEAD-IN PERIOD|Subject withdrawal related to Tx|0
6093199|NCT00708500|9706206|FG001|Treatment (Tx): 4 WEEK LEAD-IN PERIOD|Subject withdrawal related to Tx|1
6059567|NCT00478777|9660162|FG000|Overall Study|Lymphocytes infusion|1
6059568|NCT00478777|9660162|FG000|Overall Study|End of therapy|2
6059569|NCT00478777|9660162|FG000|Overall Study|Not treated with lenalidomide|6
6059570|NCT00478881|9660168|FG000|Overall Study|Adverse Event|31
6059571|NCT00478881|9660169|FG001|Overall Study|Adverse Event|12
6059572|NCT00478881|9660168|FG000|Overall Study|Lack of Efficacy|0
6059573|NCT00478881|9660169|FG001|Overall Study|Lack of Efficacy|3
6059574|NCT00478881|9660168|FG000|Overall Study|Lost to Follow-up|0
6059575|NCT00478881|9660169|FG001|Overall Study|Lost to Follow-up|1
6059576|NCT00478881|9660168|FG000|Overall Study|Protocol Violation|2
6059577|NCT00478881|9660169|FG001|Overall Study|Protocol Violation|2
6059578|NCT00478881|9660168|FG000|Overall Study|Withdrawal by Subject|6
6059579|NCT00478881|9660169|FG001|Overall Study|Withdrawal by Subject|2
6093200|NCT00708500|9706207|FG002|Treatment (Tx): 4 WEEK LEAD-IN PERIOD|Subject withdrawal related to Tx|0
6093201|NCT00708500|9706205|FG000|Treatment (Tx): 4 WEEK LEAD-IN PERIOD|Subject withdrew consent|0
6093202|NCT00708500|9706206|FG001|Treatment (Tx): 4 WEEK LEAD-IN PERIOD|Subject withdrew consent|2
6093203|NCT00708500|9706207|FG002|Treatment (Tx): 4 WEEK LEAD-IN PERIOD|Subject withdrew consent|0
6093204|NCT00708500|9706205|FG000|Treatment (Tx): 4 WEEK LEAD-IN PERIOD|Randomized but not treated|0
6093205|NCT00708500|9706206|FG001|Treatment (Tx): 4 WEEK LEAD-IN PERIOD|Randomized but not treated|0
6093206|NCT00708500|9706207|FG002|Treatment (Tx): 4 WEEK LEAD-IN PERIOD|Randomized but not treated|1
6093207|NCT00708500|9706205|FG000|Tx: RECEIVING BOCEPREVIR/PLACEBO|Adverse Event|1
6093208|NCT00708500|9706206|FG001|Tx: RECEIVING BOCEPREVIR/PLACEBO|Adverse Event|10
6093209|NCT00708500|9706207|FG002|Tx: RECEIVING BOCEPREVIR/PLACEBO|Adverse Event|19
6093210|NCT00708500|9706205|FG000|Tx: RECEIVING BOCEPREVIR/PLACEBO|Treatment Failure|49
6093211|NCT00708500|9706206|FG001|Tx: RECEIVING BOCEPREVIR/PLACEBO|Treatment Failure|36
6093212|NCT00708500|9706207|FG002|Tx: RECEIVING BOCEPREVIR/PLACEBO|Treatment Failure|29
6093213|NCT00708500|9706205|FG000|Tx: RECEIVING BOCEPREVIR/PLACEBO|Lost to Follow-up|0
6093214|NCT00708500|9706206|FG001|Tx: RECEIVING BOCEPREVIR/PLACEBO|Lost to Follow-up|1
6093215|NCT00708500|9706207|FG002|Tx: RECEIVING BOCEPREVIR/PLACEBO|Lost to Follow-up|0
6093216|NCT00708500|9706205|FG000|Tx: RECEIVING BOCEPREVIR/PLACEBO|Subject withdrawal unrelated to Tx|3
6093217|NCT00708500|9706206|FG001|Tx: RECEIVING BOCEPREVIR/PLACEBO|Subject withdrawal unrelated to Tx|1
6093218|NCT00708500|9706207|FG002|Tx: RECEIVING BOCEPREVIR/PLACEBO|Subject withdrawal unrelated to Tx|4
6202694|NCT01505647|9863032|FG001|Day 43 Through Day 182 Follow-up|Lost to Follow-up|2
6202695|NCT01505868|9863062|FG000|Overall Study|Withdrawal by Subject|1
6202696|NCT01505868|9863063|FG001|Overall Study|Withdrawal by Subject|0
6202697|NCT01505868|9863064|FG002|Overall Study|Withdrawal by Subject|0
6202698|NCT01505868|9863065|FG003|Overall Study|Withdrawal by Subject|0
6202699|NCT01505868|9863066|FG004|Overall Study|Withdrawal by Subject|0
6202700|NCT01505881|9863080|FG000|Overall Study|Adverse Event|0
6202701|NCT01505881|9863081|FG001|Overall Study|Adverse Event|1
6202702|NCT01505881|9863080|FG000|Overall Study|Lost to Follow-up|2
6202703|NCT01505881|9863081|FG001|Overall Study|Lost to Follow-up|0
6202704|NCT01505881|9863080|FG000|Overall Study|Withdrawal by Subject|2
6202705|NCT01505881|9863081|FG001|Overall Study|Withdrawal by Subject|0
6202706|NCT01506193|9863100|FG000|Overall Study|Protocol Violation|1
6202707|NCT01506193|9863101|FG001|Overall Study|Protocol Violation|0
6202708|NCT01506193|9863102|FG002|Overall Study|Protocol Violation|1
6202709|NCT01506193|9863100|FG000|Overall Study|Migrated/moved from study area|0
6202710|NCT01506193|9863101|FG001|Overall Study|Migrated/moved from study area|0
6202711|NCT01506193|9863102|FG002|Overall Study|Migrated/moved from study area|1
6202712|NCT01506193|9863100|FG000|Overall Study|Adverse event, non-fatal|0
6202713|NCT01506193|9863101|FG001|Overall Study|Adverse event, non-fatal|0
6202714|NCT01506193|9863102|FG002|Overall Study|Adverse event, non-fatal|1
6202715|NCT01506193|9863100|FG000|Overall Study|Withdrawal by Subject|5
6202716|NCT01506193|9863101|FG001|Overall Study|Withdrawal by Subject|1
6202717|NCT01506193|9863102|FG002|Overall Study|Withdrawal by Subject|8
6202718|NCT01506193|9863100|FG000|Overall Study|Lost to Follow-up|8
6202719|NCT01506193|9863101|FG001|Overall Study|Lost to Follow-up|3
6202720|NCT01506193|9863102|FG002|Overall Study|Lost to Follow-up|3
6202721|NCT01506271|9863114|FG000|Overall Study|Progressive disease|0
6202722|NCT01506271|9863115|FG001|Overall Study|Progressive disease|1
6202723|NCT01506271|9863116|FG002|Overall Study|Progressive disease|0
6202724|NCT01506271|9863114|FG000|Overall Study|Protocol Violation|3
6202725|NCT01506271|9863115|FG001|Overall Study|Protocol Violation|1
6202726|NCT01506271|9863116|FG002|Overall Study|Protocol Violation|0
6202727|NCT01506271|9863114|FG000|Overall Study|Death|0
6202728|NCT01506271|9863115|FG001|Overall Study|Death|1
6059580|NCT00478881|9660168|FG000|Overall Study|Non-Compliance with Study Medication|0
6059581|NCT00478881|9660169|FG001|Overall Study|Non-Compliance with Study Medication|2
6059582|NCT00478933|9660175|FG000|Overall Study|Protocol Violation|22
6059583|NCT00478933|9660175|FG000|Overall Study|Informed consent not verified|3
6202729|NCT01506271|9863116|FG002|Overall Study|Death|0
6202730|NCT01506271|9863114|FG000|Overall Study|Adverse Event|0
6202731|NCT01506271|9863115|FG001|Overall Study|Adverse Event|2
6202732|NCT01506271|9863116|FG002|Overall Study|Adverse Event|0
6202733|NCT01506271|9863114|FG000|Overall Study|Insufficient supply of study drug|1
6202734|NCT01506271|9863115|FG001|Overall Study|Insufficient supply of study drug|0
6202735|NCT01506271|9863116|FG002|Overall Study|Insufficient supply of study drug|0
6202736|NCT01506271|9863114|FG000|Overall Study|Withdrawal by Subject|0
6059584|NCT00478933|9660175|FG000|Overall Study|Inadequate data available|53
6059585|NCT00479232|9660232|FG000|Overall Study|Adverse Event|0
6059586|NCT00479232|9660233|FG001|Overall Study|Adverse Event|0
6059587|NCT00479232|9660234|FG002|Overall Study|Adverse Event|5
6059588|NCT00479232|9660235|FG003|Overall Study|Adverse Event|0
6059589|NCT00479232|9660236|FG004|Overall Study|Adverse Event|0
6059590|NCT00479232|9660237|FG005|Overall Study|Adverse Event|10
6059591|NCT00479232|9660232|FG000|Overall Study|Deviation from Protocol|0
6059592|NCT00479232|9660233|FG001|Overall Study|Deviation from Protocol|0
6059593|NCT00479232|9660234|FG002|Overall Study|Deviation from Protocol|1
6059594|NCT00479232|9660235|FG003|Overall Study|Deviation from Protocol|0
6059595|NCT00479232|9660236|FG004|Overall Study|Deviation from Protocol|0
6059596|NCT00479232|9660237|FG005|Overall Study|Deviation from Protocol|0
6059597|NCT00479232|9660232|FG000|Overall Study|Lack of Efficacy|0
6059598|NCT00479232|9660233|FG001|Overall Study|Lack of Efficacy|0
6059599|NCT00479232|9660234|FG002|Overall Study|Lack of Efficacy|2
6059600|NCT00479232|9660235|FG003|Overall Study|Lack of Efficacy|0
6059601|NCT00479232|9660236|FG004|Overall Study|Lack of Efficacy|0
6059602|NCT00479232|9660237|FG005|Overall Study|Lack of Efficacy|4
6059603|NCT00479232|9660232|FG000|Overall Study|Physician Decision|0
6059604|NCT00479232|9660233|FG001|Overall Study|Physician Decision|0
6093219|NCT00708500|9706205|FG000|Tx: RECEIVING BOCEPREVIR/PLACEBO|Subject withdrawal related to Tx|2
6093220|NCT00708500|9706206|FG001|Tx: RECEIVING BOCEPREVIR/PLACEBO|Subject withdrawal related to Tx|0
6059605|NCT00479232|9660234|FG002|Overall Study|Physician Decision|2
6059606|NCT00479232|9660235|FG003|Overall Study|Physician Decision|0
6059607|NCT00479232|9660236|FG004|Overall Study|Physician Decision|0
6059608|NCT00479232|9660237|FG005|Overall Study|Physician Decision|1
6059609|NCT00479232|9660232|FG000|Overall Study|Progressive Disease|3
6059610|NCT00479232|9660233|FG001|Overall Study|Progressive Disease|1
6059611|NCT00479232|9660234|FG002|Overall Study|Progressive Disease|12
6059612|NCT00479232|9660235|FG003|Overall Study|Progressive Disease|3
6059613|NCT00479232|9660236|FG004|Overall Study|Progressive Disease|3
6059614|NCT00479232|9660237|FG005|Overall Study|Progressive Disease|12
6059615|NCT00479232|9660232|FG000|Overall Study|Withdrew Consent|0
6059616|NCT00479232|9660233|FG001|Overall Study|Withdrew Consent|2
6059617|NCT00479232|9660234|FG002|Overall Study|Withdrew Consent|6
6059618|NCT00479232|9660235|FG003|Overall Study|Withdrew Consent|0
6059619|NCT00479232|9660236|FG004|Overall Study|Withdrew Consent|1
6059620|NCT00479232|9660237|FG005|Overall Study|Withdrew Consent|3
6059621|NCT00479336|9660259|FG000|Overall Study|Adverse Event|1
6059622|NCT00479336|9660260|FG001|Overall Study|Adverse Event|1
6059623|NCT00479336|9660261|FG002|Overall Study|Adverse Event|1
6059624|NCT00479336|9660262|FG003|Overall Study|Adverse Event|3
6059625|NCT00479336|9660259|FG000|Overall Study|Lack of Efficacy|1
6059626|NCT00479336|9660260|FG001|Overall Study|Lack of Efficacy|0
6059627|NCT00479336|9660261|FG002|Overall Study|Lack of Efficacy|0
6059628|NCT00479336|9660262|FG003|Overall Study|Lack of Efficacy|0
6059629|NCT00479336|9660259|FG000|Overall Study|Protocol Violation|0
6059630|NCT00479336|9660260|FG001|Overall Study|Protocol Violation|1
6093221|NCT00708500|9706207|FG002|Tx: RECEIVING BOCEPREVIR/PLACEBO|Subject withdrawal related to Tx|1
6093222|NCT00708500|9706205|FG000|Tx: RECEIVING BOCEPREVIR/PLACEBO|Subject withdrew consent|0
6093223|NCT00708500|9706206|FG001|Tx: RECEIVING BOCEPREVIR/PLACEBO|Subject withdrew consent|2
6093224|NCT00708500|9706207|FG002|Tx: RECEIVING BOCEPREVIR/PLACEBO|Subject withdrew consent|1
6093225|NCT00708500|9706205|FG000|Tx: RECEIVING BOCEPREVIR/PLACEBO|Non-compliance with protocol|0
6093226|NCT00708500|9706206|FG001|Tx: RECEIVING BOCEPREVIR/PLACEBO|Non-compliance with protocol|1
6093227|NCT00708500|9706207|FG002|Tx: RECEIVING BOCEPREVIR/PLACEBO|Non-compliance with protocol|1
6093228|NCT00708500|9706205|FG000|Tx: RECEIVING BOCEPREVIR/PLACEBO|Administrative|0
6093229|NCT00708500|9706206|FG001|Tx: RECEIVING BOCEPREVIR/PLACEBO|Administrative|1
6093230|NCT00708500|9706207|FG002|Tx: RECEIVING BOCEPREVIR/PLACEBO|Administrative|0
6093231|NCT00708500|9706205|FG000|FOLLOWUP|Adverse Event|0
6093232|NCT00708500|9706206|FG001|FOLLOWUP|Adverse Event|1
6093233|NCT00708500|9706207|FG002|FOLLOWUP|Adverse Event|0
6093234|NCT00708500|9706205|FG000|FOLLOWUP|Lost to Follow-up|1
6093235|NCT00708500|9706206|FG001|FOLLOWUP|Lost to Follow-up|6
6093236|NCT00708500|9706207|FG002|FOLLOWUP|Lost to Follow-up|4
6093237|NCT00708500|9706205|FG000|FOLLOWUP|Subject withdrawal unrelated to Tx|3
6093238|NCT00708500|9706206|FG001|FOLLOWUP|Subject withdrawal unrelated to Tx|4
6093239|NCT00708500|9706207|FG002|FOLLOWUP|Subject withdrawal unrelated to Tx|5
6059631|NCT00479336|9660261|FG002|Overall Study|Protocol Violation|0
6059632|NCT00479336|9660262|FG003|Overall Study|Protocol Violation|0
6059633|NCT00479336|9660259|FG000|Overall Study|Withdrawal by Subject|1
6059634|NCT00479336|9660260|FG001|Overall Study|Withdrawal by Subject|2
6059635|NCT00479336|9660261|FG002|Overall Study|Withdrawal by Subject|0
6059636|NCT00479336|9660262|FG003|Overall Study|Withdrawal by Subject|0
6059637|NCT00479336|9660259|FG000|Overall Study|Physician Decision|0
6059638|NCT00479336|9660260|FG001|Overall Study|Physician Decision|1
6059639|NCT00479336|9660261|FG002|Overall Study|Physician Decision|0
6059640|NCT00479336|9660262|FG003|Overall Study|Physician Decision|2
6059641|NCT00479336|9660259|FG000|Overall Study|Resolution of all hepatic edema findings|1
6059642|NCT00479336|9660260|FG001|Overall Study|Resolution of all hepatic edema findings|1
6059643|NCT00479336|9660261|FG002|Overall Study|Resolution of all hepatic edema findings|0
6093240|NCT00708500|9706205|FG000|FOLLOWUP|Subject withdrew consent|31
6093241|NCT00708500|9706206|FG001|FOLLOWUP|Subject withdrew consent|4
6059644|NCT00479336|9660262|FG003|Overall Study|Resolution of all hepatic edema findings|0
6059645|NCT00479388|9660274|FG000|Overall Study|Adverse Event|90
6059646|NCT00479388|9660275|FG001|Overall Study|Adverse Event|45
6059647|NCT00479388|9660274|FG000|Overall Study|Lost to Follow-up|0
6059648|NCT00479388|9660275|FG001|Overall Study|Lost to Follow-up|2
6059649|NCT00479388|9660274|FG000|Overall Study|Protocol Violation|10
6059650|NCT00479388|9660275|FG001|Overall Study|Protocol Violation|9
6059651|NCT00479388|9660274|FG000|Overall Study|Withdrawal by Subject|32
6059652|NCT00479388|9660275|FG001|Overall Study|Withdrawal by Subject|17
6059653|NCT00479401|9660284|FG000|Overall Study|Adverse Event|24
6059654|NCT00479401|9660285|FG001|Overall Study|Adverse Event|20
6059655|NCT00479401|9660286|FG002|Overall Study|Adverse Event|4
6059656|NCT00479401|9660284|FG000|Overall Study|Lack of Efficacy|2
6059657|NCT00479401|9660285|FG001|Overall Study|Lack of Efficacy|2
6059658|NCT00479401|9660286|FG002|Overall Study|Lack of Efficacy|4
6059659|NCT00479401|9660284|FG000|Overall Study|Protocol Violation|2
6059660|NCT00479401|9660285|FG001|Overall Study|Protocol Violation|1
6059661|NCT00479401|9660286|FG002|Overall Study|Protocol Violation|1
6059662|NCT00479401|9660284|FG000|Overall Study|Lost to Follow-up|1
6059663|NCT00479401|9660285|FG001|Overall Study|Lost to Follow-up|1
6059664|NCT00479401|9660286|FG002|Overall Study|Lost to Follow-up|1
6059665|NCT00479401|9660284|FG000|Overall Study|Withdrawal by Subject|16
6059666|NCT00479401|9660285|FG001|Overall Study|Withdrawal by Subject|10
6059667|NCT00479401|9660286|FG002|Overall Study|Withdrawal by Subject|2
6059668|NCT00479401|9660284|FG000|Overall Study|Exclusion criteria, relocation|4
6059669|NCT00479401|9660285|FG001|Overall Study|Exclusion criteria, relocation|3
6059670|NCT00479401|9660286|FG002|Overall Study|Exclusion criteria, relocation|0
6059671|NCT00479466|9660300|FG000|Overall Study|Adverse Event|5
6059672|NCT00479466|9660301|FG001|Overall Study|Adverse Event|1
6059673|NCT00479466|9660302|FG002|Overall Study|Adverse Event|0
6059674|NCT00479466|9660303|FG003|Overall Study|Adverse Event|1
6059675|NCT00479466|9660304|FG004|Overall Study|Adverse Event|2
6059676|NCT00479466|9660305|FG005|Overall Study|Adverse Event|0
6059677|NCT00479466|9660300|FG000|Overall Study|Hyperglycemia|0
6059678|NCT00479466|9660301|FG001|Overall Study|Hyperglycemia|0
6059679|NCT00479466|9660302|FG002|Overall Study|Hyperglycemia|0
6059680|NCT00479466|9660303|FG003|Overall Study|Hyperglycemia|0
6059681|NCT00479466|9660304|FG004|Overall Study|Hyperglycemia|0
6059682|NCT00479466|9660305|FG005|Overall Study|Hyperglycemia|1
6059683|NCT00479466|9660300|FG000|Overall Study|Lack of Efficacy|2
6059684|NCT00479466|9660301|FG001|Overall Study|Lack of Efficacy|0
6059685|NCT00479466|9660302|FG002|Overall Study|Lack of Efficacy|1
6059686|NCT00479466|9660303|FG003|Overall Study|Lack of Efficacy|0
6059687|NCT00479466|9660304|FG004|Overall Study|Lack of Efficacy|0
6059688|NCT00479466|9660305|FG005|Overall Study|Lack of Efficacy|0
6059689|NCT00479466|9660300|FG000|Overall Study|Lost to Follow-up|0
6059690|NCT00479466|9660301|FG001|Overall Study|Lost to Follow-up|1
6059691|NCT00479466|9660302|FG002|Overall Study|Lost to Follow-up|1
6059692|NCT00479466|9660303|FG003|Overall Study|Lost to Follow-up|0
6059693|NCT00479466|9660304|FG004|Overall Study|Lost to Follow-up|2
6059694|NCT00479466|9660305|FG005|Overall Study|Lost to Follow-up|2
6059695|NCT00479466|9660300|FG000|Overall Study|Physician Decision|2
6059696|NCT00479466|9660301|FG001|Overall Study|Physician Decision|1
6059697|NCT00479466|9660302|FG002|Overall Study|Physician Decision|1
6059698|NCT00479466|9660303|FG003|Overall Study|Physician Decision|0
6059699|NCT00479466|9660304|FG004|Overall Study|Physician Decision|0
6059700|NCT00479466|9660305|FG005|Overall Study|Physician Decision|0
6059701|NCT00479466|9660300|FG000|Overall Study|Pregnancy|0
6059702|NCT00479466|9660301|FG001|Overall Study|Pregnancy|0
6059703|NCT00479466|9660302|FG002|Overall Study|Pregnancy|0
6059704|NCT00479466|9660303|FG003|Overall Study|Pregnancy|0
6059705|NCT00479466|9660304|FG004|Overall Study|Pregnancy|1
6059706|NCT00479466|9660305|FG005|Overall Study|Pregnancy|0
6093242|NCT00708500|9706207|FG002|FOLLOWUP|Subject withdrew consent|5
6093243|NCT00708500|9706205|FG000|FOLLOWUP|Non-compliance with protocol|5
6059707|NCT00479466|9660300|FG000|Overall Study|Protocol Violation|1
6059708|NCT00479466|9660301|FG001|Overall Study|Protocol Violation|0
6059709|NCT00479466|9660302|FG002|Overall Study|Protocol Violation|0
6059710|NCT00479466|9660303|FG003|Overall Study|Protocol Violation|0
6059711|NCT00479466|9660304|FG004|Overall Study|Protocol Violation|0
6059712|NCT00479466|9660305|FG005|Overall Study|Protocol Violation|0
6059713|NCT00479466|9660300|FG000|Overall Study|Withdrawal by Subject|3
6059714|NCT00479466|9660301|FG001|Overall Study|Withdrawal by Subject|5
6059715|NCT00479466|9660302|FG002|Overall Study|Withdrawal by Subject|0
6059716|NCT00479466|9660303|FG003|Overall Study|Withdrawal by Subject|2
6059717|NCT00479466|9660304|FG004|Overall Study|Withdrawal by Subject|3
6059718|NCT00479466|9660305|FG005|Overall Study|Withdrawal by Subject|1
6059719|NCT00479557|9660326|FG000|Overall Study|Death|0
6059720|NCT00479557|9660327|FG001|Overall Study|Death|0
6059721|NCT00479557|9660328|FG002|Overall Study|Death|0
6059722|NCT00479557|9660329|FG003|Overall Study|Death|0
6059723|NCT00479557|9660330|FG004|Overall Study|Death|0
6059724|NCT00479557|9660331|FG005|Overall Study|Death|1
6059725|NCT00479557|9660332|FG006|Overall Study|Death|0
6059726|NCT00479557|9660326|FG000|Overall Study|Lack of Efficacy|1
6059727|NCT00479557|9660327|FG001|Overall Study|Lack of Efficacy|0
6059728|NCT00479557|9660328|FG002|Overall Study|Lack of Efficacy|0
6059729|NCT00479557|9660329|FG003|Overall Study|Lack of Efficacy|0
6059730|NCT00479557|9660330|FG004|Overall Study|Lack of Efficacy|0
6059731|NCT00479557|9660331|FG005|Overall Study|Lack of Efficacy|0
6059732|NCT00479557|9660332|FG006|Overall Study|Lack of Efficacy|0
6059733|NCT00479557|9660326|FG000|Overall Study|Lost to Follow-up|0
6059734|NCT00479557|9660327|FG001|Overall Study|Lost to Follow-up|2
6059735|NCT00479557|9660328|FG002|Overall Study|Lost to Follow-up|0
6059736|NCT00479557|9660329|FG003|Overall Study|Lost to Follow-up|2
6059737|NCT00479557|9660330|FG004|Overall Study|Lost to Follow-up|0
6059738|NCT00479557|9660331|FG005|Overall Study|Lost to Follow-up|0
6059739|NCT00479557|9660332|FG006|Overall Study|Lost to Follow-up|0
6059740|NCT00479557|9660326|FG000|Overall Study|Adverse Event (AE) related to Study Drug|1
6059741|NCT00479557|9660327|FG001|Overall Study|Adverse Event (AE) related to Study Drug|0
6059742|NCT00479557|9660328|FG002|Overall Study|Adverse Event (AE) related to Study Drug|3
6059743|NCT00479557|9660329|FG003|Overall Study|Adverse Event (AE) related to Study Drug|2
6059744|NCT00479557|9660330|FG004|Overall Study|Adverse Event (AE) related to Study Drug|0
6059745|NCT00479557|9660331|FG005|Overall Study|Adverse Event (AE) related to Study Drug|1
6059746|NCT00479557|9660332|FG006|Overall Study|Adverse Event (AE) related to Study Drug|0
6059747|NCT00479557|9660326|FG000|Overall Study|AE not related to Study Drug|1
6059748|NCT00479557|9660327|FG001|Overall Study|AE not related to Study Drug|3
6059749|NCT00479557|9660328|FG002|Overall Study|AE not related to Study Drug|0
6059750|NCT00479557|9660329|FG003|Overall Study|AE not related to Study Drug|0
6059751|NCT00479557|9660330|FG004|Overall Study|AE not related to Study Drug|2
6059752|NCT00479557|9660331|FG005|Overall Study|AE not related to Study Drug|2
6059753|NCT00479557|9660332|FG006|Overall Study|AE not related to Study Drug|1
6059754|NCT00479557|9660326|FG000|Overall Study|Caregiver Request|2
6059755|NCT00479557|9660327|FG001|Overall Study|Caregiver Request|2
6059756|NCT00479557|9660328|FG002|Overall Study|Caregiver Request|2
6059757|NCT00479557|9660329|FG003|Overall Study|Caregiver Request|0
6059758|NCT00479557|9660330|FG004|Overall Study|Caregiver Request|1
6059759|NCT00479557|9660331|FG005|Overall Study|Caregiver Request|2
6059760|NCT00479557|9660332|FG006|Overall Study|Caregiver Request|0
6059761|NCT00479557|9660326|FG000|Overall Study|Investigator Request|0
6059762|NCT00479557|9660327|FG001|Overall Study|Investigator Request|0
6059763|NCT00479557|9660328|FG002|Overall Study|Investigator Request|1
6059764|NCT00479557|9660329|FG003|Overall Study|Investigator Request|0
6059765|NCT00479557|9660330|FG004|Overall Study|Investigator Request|0
6059766|NCT00479557|9660331|FG005|Overall Study|Investigator Request|0
6059767|NCT00479557|9660332|FG006|Overall Study|Investigator Request|0
6059768|NCT00479557|9660326|FG000|Overall Study|Subject Request|3
6059769|NCT00479557|9660327|FG001|Overall Study|Subject Request|0
6059770|NCT00479557|9660328|FG002|Overall Study|Subject Request|1
6059771|NCT00479557|9660329|FG003|Overall Study|Subject Request|1
6059772|NCT00479557|9660330|FG004|Overall Study|Subject Request|1
6059773|NCT00479557|9660331|FG005|Overall Study|Subject Request|4
6059774|NCT00479557|9660332|FG006|Overall Study|Subject Request|1
6059775|NCT00479557|9660326|FG000|Overall Study|Other|2
6059776|NCT00479557|9660327|FG001|Overall Study|Other|3
6059777|NCT00479557|9660328|FG002|Overall Study|Other|1
6059778|NCT00479557|9660329|FG003|Overall Study|Other|0
6059779|NCT00479557|9660330|FG004|Overall Study|Other|0
6059780|NCT00479557|9660331|FG005|Overall Study|Other|3
6059781|NCT00479557|9660332|FG006|Overall Study|Other|0
6059782|NCT00479674|9660354|FG000|Overall Study|Adverse Event|18
6059783|NCT00479674|9660354|FG000|Overall Study|Withdrawal by Subject|6
6059784|NCT00479674|9660354|FG000|Overall Study|Physician Decision|14
6059785|NCT00479674|9660354|FG000|Overall Study|none provided|3
6059786|NCT00479687|9660360|FG000|Ph 1: Blinded, Randomized, Controlled|Adverse Event|0
6059787|NCT00479687|9660361|FG001|Ph 1: Blinded, Randomized, Controlled|Adverse Event|2
6059788|NCT00479687|9660362|FG002|Ph 1: Blinded, Randomized, Controlled|Adverse Event|0
6059789|NCT00479687|9660360|FG000|Ph 1: Blinded, Randomized, Controlled|Death|0
6059790|NCT00479687|9660361|FG001|Ph 1: Blinded, Randomized, Controlled|Death|1
6059791|NCT00479687|9660362|FG002|Ph 1: Blinded, Randomized, Controlled|Death|0
6059792|NCT00479687|9660360|FG000|Ph 1: Blinded, Randomized, Controlled|Lost to Follow-up|4
6059793|NCT00479687|9660361|FG001|Ph 1: Blinded, Randomized, Controlled|Lost to Follow-up|5
6059794|NCT00479687|9660362|FG002|Ph 1: Blinded, Randomized, Controlled|Lost to Follow-up|0
6059795|NCT00479687|9660360|FG000|Ph 1: Blinded, Randomized, Controlled|Physician Decision|2
6059796|NCT00479687|9660361|FG001|Ph 1: Blinded, Randomized, Controlled|Physician Decision|0
6059797|NCT00479687|9660362|FG002|Ph 1: Blinded, Randomized, Controlled|Physician Decision|0
6059798|NCT00479687|9660360|FG000|Ph 1: Blinded, Randomized, Controlled|Withdrawal by Subject|19
6059799|NCT00479687|9660361|FG001|Ph 1: Blinded, Randomized, Controlled|Withdrawal by Subject|11
6059800|NCT00479687|9660362|FG002|Ph 1: Blinded, Randomized, Controlled|Withdrawal by Subject|0
6059801|NCT00479687|9660360|FG000|Ph 2: Open Label, Single (Supartz) Arm|Adverse Event|0
6059802|NCT00479687|9660361|FG001|Ph 2: Open Label, Single (Supartz) Arm|Adverse Event|0
6059803|NCT00479687|9660362|FG002|Ph 2: Open Label, Single (Supartz) Arm|Adverse Event|4
6059804|NCT00479687|9660360|FG000|Ph 2: Open Label, Single (Supartz) Arm|Withdrawal by Subject|0
6059805|NCT00479687|9660361|FG001|Ph 2: Open Label, Single (Supartz) Arm|Withdrawal by Subject|0
6059806|NCT00479687|9660362|FG002|Ph 2: Open Label, Single (Supartz) Arm|Withdrawal by Subject|3
6059807|NCT00479687|9660360|FG000|Ph 2: Open Label, Single (Supartz) Arm|Lost to Follow-up|0
6059808|NCT00479687|9660361|FG001|Ph 2: Open Label, Single (Supartz) Arm|Lost to Follow-up|0
6093244|NCT00708500|9706206|FG001|FOLLOWUP|Non-compliance with protocol|0
6093245|NCT00708500|9706207|FG002|FOLLOWUP|Non-compliance with protocol|1
6093246|NCT00708552|9706228|FG000|Overall Study|Adverse Event|10
6093247|NCT00708552|9706229|FG001|Overall Study|Adverse Event|3
6093248|NCT00708552|9706230|FG002|Overall Study|Adverse Event|4
6093249|NCT00708552|9706231|FG003|Overall Study|Adverse Event|6
6093250|NCT00708552|9706228|FG000|Overall Study|Lack of Efficacy|0
6093251|NCT00708552|9706229|FG001|Overall Study|Lack of Efficacy|4
6093252|NCT00708552|9706230|FG002|Overall Study|Lack of Efficacy|1
6093253|NCT00708552|9706231|FG003|Overall Study|Lack of Efficacy|0
6093254|NCT00708552|9706228|FG000|Overall Study|Protocol Violation|0
6093255|NCT00708552|9706229|FG001|Overall Study|Protocol Violation|0
6093256|NCT00708552|9706230|FG002|Overall Study|Protocol Violation|2
6093257|NCT00708552|9706231|FG003|Overall Study|Protocol Violation|4
6093258|NCT00708552|9706228|FG000|Overall Study|Lost to Follow-up|4
6093259|NCT00708552|9706229|FG001|Overall Study|Lost to Follow-up|2
6093260|NCT00708552|9706230|FG002|Overall Study|Lost to Follow-up|0
6093261|NCT00708552|9706231|FG003|Overall Study|Lost to Follow-up|1
6093262|NCT00708552|9706228|FG000|Overall Study|Physician Decision|1
6093263|NCT00708552|9706229|FG001|Overall Study|Physician Decision|2
6093264|NCT00708552|9706230|FG002|Overall Study|Physician Decision|0
6093265|NCT00708552|9706231|FG003|Overall Study|Physician Decision|0
6093266|NCT00708552|9706228|FG000|Overall Study|Withdrawal by Subject|12
6093267|NCT00708552|9706229|FG001|Overall Study|Withdrawal by Subject|7
6093268|NCT00708552|9706230|FG002|Overall Study|Withdrawal by Subject|8
6093269|NCT00708552|9706231|FG003|Overall Study|Withdrawal by Subject|10
6093270|NCT00708643|9706247|FG000|Overall Study|Adverse Event|0
6093271|NCT00708643|9706248|FG001|Overall Study|Adverse Event|1
6093272|NCT00708682|9706254|FG000|Infant Series|Adverse Event|1
6093273|NCT00708682|9706254|FG000|Infant Series|Lost to Follow-up|4
6093274|NCT00708682|9706254|FG000|Infant Series|Protocol Violation|1
6093275|NCT00708682|9706254|FG000|Infant Series|Parent/legal guardian request|6
6093276|NCT00708682|9706254|FG000|Infant Series|Failed to return|2
6093277|NCT00708682|9706254|FG000|Infant Series|Other|19
6093278|NCT00708682|9706254|FG000|After Infant Series|Parent/Legal Guardian Request|1
6093279|NCT00708682|9706254|FG000|Toddler Dose|Parent/Legal Guardian Request|1
6093280|NCT00708682|9706254|FG000|Toddler Dose|Lost to Follow-up|3
6093281|NCT00708682|9706254|FG000|Toddler Dose|Failed to Return|4
6093282|NCT00708708|9706260|FG000|Overall Study|Another therapy instead of Enbrel|141
6093283|NCT00708708|9706260|FG000|Overall Study|Lost to Follow-up|52
6093284|NCT00708708|9706260|FG000|Overall Study|Withdrawal by Subject|51
6093285|NCT00708708|9706260|FG000|Overall Study|Intolerance|42
6093286|NCT00708708|9706260|FG000|Overall Study|Another therapy along with Enbrel|15
6093287|NCT00708708|9706260|FG000|Overall Study|Other unspecified|11
6093288|NCT00708708|9706260|FG000|Overall Study|Good effectiveness|9
6093289|NCT00708708|9706260|FG000|Overall Study|Ineffectiveness (no systemic therapy)|9
6093290|NCT00708708|9706260|FG000|Overall Study|Administrative reasons|7
6093291|NCT00708708|9706260|FG000|Overall Study|Lack of effectiveness|4
6093292|NCT00708708|9706260|FG000|Overall Study|Lack of compliance|3
6093293|NCT00708708|9706260|FG000|Overall Study|Pregnancy|3
6093294|NCT00708708|9706260|FG000|Overall Study|Adverse Event|3
6093295|NCT00708708|9706260|FG000|Overall Study|Missing values|392
6093296|NCT00709059|9706312|FG000|Overall Study|Lost to Follow-up|34
6093297|NCT00709059|9706312|FG000|Overall Study|Withdrawal by Subject|19
6093298|NCT00709059|9706312|FG000|Overall Study|Physician Decision|7
6093299|NCT00709059|9706312|FG000|Overall Study|Disease complication|3
6093300|NCT00709059|9706312|FG000|Overall Study|Side effects|20
6093301|NCT00709059|9706312|FG000|Overall Study|Serious side effects|11
6059809|NCT00479687|9660362|FG002|Ph 2: Open Label, Single (Supartz) Arm|Lost to Follow-up|1
6059810|NCT00479687|9660360|FG000|Ph 2: Open Label, Single (Supartz) Arm|Death|0
6059811|NCT00479687|9660361|FG001|Ph 2: Open Label, Single (Supartz) Arm|Death|0
6059812|NCT00479687|9660362|FG002|Ph 2: Open Label, Single (Supartz) Arm|Death|1
6059813|NCT00479856|9660369|FG000|Overall Study|Adverse Event|1
6059814|NCT00479856|9660369|FG000|Overall Study|Withdrawal by Subject|1
6059815|NCT00479856|9660369|FG000|Overall Study|Physician Decision|1
6059816|NCT00479882|9660377|FG000|Precrossover: Periods I/II (Weeks 1-12)|Clinical Adverse Event|96
6059817|NCT00479882|9660378|FG001|Precrossover: Periods I/II (Weeks 1-12)|Clinical Adverse Event|99
6059818|NCT00479882|9660379|FG002|Precrossover: Periods I/II (Weeks 1-12)|Clinical Adverse Event|98
6059819|NCT00479882|9660380|FG003|Precrossover: Periods I/II (Weeks 1-12)|Clinical Adverse Event|87
6059820|NCT00479882|9660377|FG000|Precrossover: Periods I/II (Weeks 1-12)|Laboratory Adverse Event|0
6059821|NCT00479882|9660378|FG001|Precrossover: Periods I/II (Weeks 1-12)|Laboratory Adverse Event|4
6059822|NCT00479882|9660379|FG002|Precrossover: Periods I/II (Weeks 1-12)|Laboratory Adverse Event|4
6059823|NCT00479882|9660380|FG003|Precrossover: Periods I/II (Weeks 1-12)|Laboratory Adverse Event|4
6059824|NCT00479882|9660377|FG000|Precrossover: Periods I/II (Weeks 1-12)|Lost to Follow-up|12
6093302|NCT00709098|9706319|FG000|Double-blind Period|Withdrawal of consent|3
6093303|NCT00709098|9706320|FG001|Double-blind Period|Withdrawal of consent|3
6093304|NCT00709098|9706321|FG002|Double-blind Period|Withdrawal of consent|0
6093305|NCT00709098|9706319|FG000|Double-blind Period|Administrative reason|1
6093306|NCT00709098|9706320|FG001|Double-blind Period|Administrative reason|3
6059825|NCT00479882|9660378|FG001|Precrossover: Periods I/II (Weeks 1-12)|Lost to Follow-up|9
6059826|NCT00479882|9660379|FG002|Precrossover: Periods I/II (Weeks 1-12)|Lost to Follow-up|9
6059827|NCT00479882|9660380|FG003|Precrossover: Periods I/II (Weeks 1-12)|Lost to Follow-up|11
6059828|NCT00479882|9660377|FG000|Precrossover: Periods I/II (Weeks 1-12)|Other|4
6059829|NCT00479882|9660378|FG001|Precrossover: Periods I/II (Weeks 1-12)|Other|6
6059830|NCT00479882|9660379|FG002|Precrossover: Periods I/II (Weeks 1-12)|Other|9
6059831|NCT00479882|9660380|FG003|Precrossover: Periods I/II (Weeks 1-12)|Other|5
6059832|NCT00479882|9660377|FG000|Precrossover: Periods I/II (Weeks 1-12)|Participant moved|0
6059833|NCT00479882|9660378|FG001|Precrossover: Periods I/II (Weeks 1-12)|Participant moved|4
6093307|NCT00709098|9706321|FG002|Double-blind Period|Administrative reason|0
6093308|NCT00709098|9706319|FG000|Double-blind Period|Death|1
6093309|NCT00709098|9706320|FG001|Double-blind Period|Death|1
6093310|NCT00709098|9706321|FG002|Double-blind Period|Death|0
6202737|NCT01506271|9863115|FG001|Overall Study|Withdrawal by Subject|1
6202738|NCT01506271|9863116|FG002|Overall Study|Withdrawal by Subject|1
6202739|NCT01506271|9863114|FG000|Overall Study|Lost to Follow-up|0
6202740|NCT01506271|9863115|FG001|Overall Study|Lost to Follow-up|1
6202741|NCT01506271|9863116|FG002|Overall Study|Lost to Follow-up|2
6202742|NCT01506323|9863126|FG000|Overall Study|Lost to Follow-up|5
6202743|NCT01506323|9863127|FG001|Overall Study|Lost to Follow-up|4
6202744|NCT01506323|9863126|FG000|Overall Study|Withdrawal by Subject|4
6202745|NCT01506323|9863127|FG001|Overall Study|Withdrawal by Subject|4
6202746|NCT01506323|9863126|FG000|Overall Study|Lack of Efficacy|1
6202747|NCT01506323|9863127|FG001|Overall Study|Lack of Efficacy|3
6202748|NCT01506323|9863126|FG000|Overall Study|Moved out of area|5
6202749|NCT01506323|9863127|FG001|Overall Study|Moved out of area|2
6202750|NCT01506323|9863126|FG000|Overall Study|Schedule or Transportation conflict|8
6202751|NCT01506323|9863127|FG001|Overall Study|Schedule or Transportation conflict|0
6202752|NCT01506323|9863126|FG000|Overall Study|Started another treatment|1
6202753|NCT01506323|9863127|FG001|Overall Study|Started another treatment|0
6202754|NCT01506453|9863144|FG000|Overall Study|Withdrawal prior to treatment|0
6202755|NCT01506453|9863145|FG001|Overall Study|Withdrawal prior to treatment|2
6202756|NCT01506479|9863154|FG000|Overall Study|Lost to Follow-up|1
6202757|NCT01506479|9863155|FG001|Overall Study|Lost to Follow-up|2
6202758|NCT01506479|9863156|FG002|Overall Study|Lost to Follow-up|2
6202759|NCT01506479|9863154|FG000|Overall Study|Withdrawal by Subject|1
6202760|NCT01506479|9863155|FG001|Overall Study|Withdrawal by Subject|2
6202761|NCT01506479|9863156|FG002|Overall Study|Withdrawal by Subject|1
6202762|NCT01506479|9863154|FG000|Overall Study|Missing assessment|1
6202763|NCT01506479|9863155|FG001|Overall Study|Missing assessment|0
6202764|NCT01506479|9863156|FG002|Overall Study|Missing assessment|0
6202765|NCT01506479|9863154|FG000|Overall Study|Adverse Event|0
6202766|NCT01506479|9863155|FG001|Overall Study|Adverse Event|1
6202767|NCT01506479|9863156|FG002|Overall Study|Adverse Event|0
6202768|NCT01506596|9863166|FG000|Overall Study|ineligible pathology|1
6202769|NCT01506609|9863176|FG000|Overall Study|Adverse Event Related to Progression|0
6202770|NCT01506609|9863177|FG001|Overall Study|Adverse Event Related to Progression|0
6202771|NCT01506609|9863178|FG002|Overall Study|Adverse Event Related to Progression|0
6202772|NCT01506609|9863179|FG003|Overall Study|Adverse Event Related to Progression|3
6202773|NCT01506609|9863180|FG004|Overall Study|Adverse Event Related to Progression|7
6202774|NCT01506609|9863181|FG005|Overall Study|Adverse Event Related to Progression|3
6202775|NCT01506609|9863176|FG000|Overall Study|Adverse Event Not Related to Progression|0
6202776|NCT01506609|9863177|FG001|Overall Study|Adverse Event Not Related to Progression|1
6202777|NCT01506609|9863178|FG002|Overall Study|Adverse Event Not Related to Progression|0
6202778|NCT01506609|9863179|FG003|Overall Study|Adverse Event Not Related to Progression|6
6202779|NCT01506609|9863180|FG004|Overall Study|Adverse Event Not Related to Progression|10
6202780|NCT01506609|9863181|FG005|Overall Study|Adverse Event Not Related to Progression|5
6202781|NCT01506609|9863176|FG000|Overall Study|Withdrawal by Subject|0
6202782|NCT01506609|9863177|FG001|Overall Study|Withdrawal by Subject|0
6202783|NCT01506609|9863178|FG002|Overall Study|Withdrawal by Subject|0
6202784|NCT01506609|9863179|FG003|Overall Study|Withdrawal by Subject|9
6202785|NCT01506609|9863180|FG004|Overall Study|Withdrawal by Subject|7
6202786|NCT01506609|9863181|FG005|Overall Study|Withdrawal by Subject|7
6202787|NCT01506609|9863176|FG000|Overall Study|Lost to Follow-up|0
6202788|NCT01506609|9863177|FG001|Overall Study|Lost to Follow-up|0
6202789|NCT01506609|9863178|FG002|Overall Study|Lost to Follow-up|0
6202790|NCT01506609|9863179|FG003|Overall Study|Lost to Follow-up|1
6202791|NCT01506609|9863180|FG004|Overall Study|Lost to Follow-up|2
6202792|NCT01506609|9863181|FG005|Overall Study|Lost to Follow-up|0
6202793|NCT01506609|9863176|FG000|Overall Study|Sponsor Discontinued Study|0
6202794|NCT01506609|9863177|FG001|Overall Study|Sponsor Discontinued Study|0
6202795|NCT01506609|9863178|FG002|Overall Study|Sponsor Discontinued Study|0
6202796|NCT01506609|9863179|FG003|Overall Study|Sponsor Discontinued Study|2
6093311|NCT00709098|9706319|FG000|Double-blind Period|Lost to Follow-up|1
6202797|NCT01506609|9863180|FG004|Overall Study|Sponsor Discontinued Study|2
6202798|NCT01506609|9863181|FG005|Overall Study|Sponsor Discontinued Study|0
6202799|NCT01506609|9863176|FG000|Overall Study|Progressive Disease per Protocol|1
6202800|NCT01506609|9863177|FG001|Overall Study|Progressive Disease per Protocol|0
6202801|NCT01506609|9863178|FG002|Overall Study|Progressive Disease per Protocol|0
6202802|NCT01506609|9863179|FG003|Overall Study|Progressive Disease per Protocol|64
6059834|NCT00479882|9660379|FG002|Precrossover: Periods I/II (Weeks 1-12)|Participant moved|2
6059835|NCT00479882|9660380|FG003|Precrossover: Periods I/II (Weeks 1-12)|Participant moved|1
6059836|NCT00479882|9660377|FG000|Precrossover: Periods I/II (Weeks 1-12)|Withdrawal by Subject|24
6059837|NCT00479882|9660378|FG001|Precrossover: Periods I/II (Weeks 1-12)|Withdrawal by Subject|33
6059838|NCT00479882|9660379|FG002|Precrossover: Periods I/II (Weeks 1-12)|Withdrawal by Subject|30
6059839|NCT00479882|9660380|FG003|Precrossover: Periods I/II (Weeks 1-12)|Withdrawal by Subject|25
6059840|NCT00479882|9660377|FG000|Precrossover: Periods I/II (Weeks 1-12)|Protocol Violation|2
6059841|NCT00479882|9660378|FG001|Precrossover: Periods I/II (Weeks 1-12)|Protocol Violation|7
6059842|NCT00479882|9660379|FG002|Precrossover: Periods I/II (Weeks 1-12)|Protocol Violation|5
6059843|NCT00479882|9660380|FG003|Precrossover: Periods I/II (Weeks 1-12)|Protocol Violation|7
6059844|NCT00479882|9660377|FG000|Crossover: Period III (Weeks 13-20)|Clinical Adverse Event|12
6059845|NCT00479882|9660378|FG001|Crossover: Period III (Weeks 13-20)|Clinical Adverse Event|13
6059846|NCT00479882|9660379|FG002|Crossover: Period III (Weeks 13-20)|Clinical Adverse Event|12
6059847|NCT00479882|9660380|FG003|Crossover: Period III (Weeks 13-20)|Clinical Adverse Event|10
6059848|NCT00479882|9660377|FG000|Crossover: Period III (Weeks 13-20)|Laboratory Adverse Event|3
6093312|NCT00709098|9706320|FG001|Double-blind Period|Lost to Follow-up|1
6093313|NCT00709098|9706321|FG002|Double-blind Period|Lost to Follow-up|0
6093314|NCT00709098|9706319|FG000|Open-label Period|Withdrawal of consent|0
6093315|NCT00709098|9706320|FG001|Open-label Period|Withdrawal of consent|0
6093316|NCT00709098|9706321|FG002|Open-label Period|Withdrawal of consent|7
6093317|NCT00709098|9706319|FG000|Open-label Period|Administrative reason|0
6093318|NCT00709098|9706320|FG001|Open-label Period|Administrative reason|0
6093319|NCT00709098|9706321|FG002|Open-label Period|Administrative reason|5
6093320|NCT00709098|9706319|FG000|Open-label Period|Death|0
6093321|NCT00709098|9706320|FG001|Open-label Period|Death|0
6093322|NCT00709098|9706321|FG002|Open-label Period|Death|1
6093323|NCT00709098|9706319|FG000|Open-label Period|Lost to Follow-up|0
6093324|NCT00709098|9706320|FG001|Open-label Period|Lost to Follow-up|0
6093325|NCT00709098|9706321|FG002|Open-label Period|Lost to Follow-up|1
6093326|NCT00709111|9706330|FG000|Overall Study|Withdrawal by Subject|1
6093327|NCT00709111|9706330|FG000|Overall Study|Unable to attend clinic visits|1
6093328|NCT00709124|9706336|FG000|Overall Study|Death|3
6093329|NCT00709124|9706337|FG001|Overall Study|Death|1
6093330|NCT00709124|9706336|FG000|Overall Study|encephalopathy; can't do assessment|1
6093331|NCT00709124|9706337|FG001|Overall Study|encephalopathy; can't do assessment|0
6093332|NCT00709202|9706349|FG000|Overall Study|Withdrawal by Subject|6
6093333|NCT00709202|9706350|FG001|Overall Study|Withdrawal by Subject|6
6093334|NCT00709228|9706357|FG000|Overall Study|Not treated|14
6093335|NCT00709228|9706357|FG000|Overall Study|Eligibility criteria not met|281
6093336|NCT00709228|9706357|FG000|Overall Study|Adverse events|2
6093337|NCT00709228|9706357|FG000|Overall Study|Discontinued treatment|14
6093338|NCT00709228|9706357|FG000|Overall Study|Did not enter follow-up|4
6093339|NCT00709228|9706357|FG000|Overall Study|Discontinued follow-up|5
6093340|NCT00709228|9706357|FG000|Overall Study|Disease progression|1
6093341|NCT00709228|9706357|FG000|Overall Study|Lost to Follow-up|6
6093342|NCT00709228|9706357|FG000|Overall Study|Non-compliance|5
6093343|NCT00709319|9706378|FG000|Overall Study|Death|4
6093344|NCT00709319|9706378|FG000|Overall Study|Withdrawal by Subject|2
6093345|NCT00709592|9706384|FG000|Overall Study|Unable to proceed to transplant|0
6093346|NCT00709592|9706385|FG001|Overall Study|Unable to proceed to transplant|1
6093347|NCT00709618|9706391|FG000|Overall Study|Withdrawal by Subject|4
6093348|NCT00709618|9706391|FG000|Overall Study|Lost to Follow-up|1
6093349|NCT00709618|9706391|FG000|Overall Study|Study Closed/Terminated|25
6093350|NCT00709722|9706404|FG000|Overall Study|Adverse Event|1
6093351|NCT00709735|9706410|FG000|Overall Study|Lost to Follow-up|1
6093352|NCT00709735|9706411|FG001|Overall Study|Lost to Follow-up|1
6093353|NCT00709735|9706410|FG000|Overall Study|Relapse into Opioid Abuse|0
6093354|NCT00709735|9706411|FG001|Overall Study|Relapse into Opioid Abuse|1
6093355|NCT00709735|9706410|FG000|Overall Study|Did not meet PTSD Diagnostic Criteria|2
6093356|NCT00709735|9706411|FG001|Overall Study|Did not meet PTSD Diagnostic Criteria|0
6093357|NCT00709761|9706417|FG000|Overall Study|Withdrawal by Subject|8
6093358|NCT00709761|9706417|FG000|Overall Study|study closed/terminated|17
6093359|NCT00709761|9706417|FG000|Overall Study|Lost to Follow-up|2
6093360|NCT00709852|9706430|FG000|Period 1|Adverse Event|2
6093361|NCT00709852|9706431|FG001|Period 1|Adverse Event|0
6093362|NCT00709852|9706430|FG000|Period 1|Withdrawal by Subject|4
6093363|NCT00709852|9706431|FG001|Period 1|Withdrawal by Subject|2
6093364|NCT00709852|9706430|FG000|Period 1|Protocol Violation|1
6093365|NCT00709852|9706431|FG001|Period 1|Protocol Violation|0
6093366|NCT00709852|9706430|FG000|Period 1|Defective scanner|0
6093367|NCT00709852|9706431|FG001|Period 1|Defective scanner|1
6093368|NCT00709852|9706430|FG000|Period 1|Lost to Follow-up|1
6093369|NCT00709852|9706431|FG001|Period 1|Lost to Follow-up|0
6093370|NCT00709852|9706430|FG000|Period 2|Protocol Violation|4
6093371|NCT00709852|9706431|FG001|Period 2|Protocol Violation|1
6093372|NCT00709852|9706430|FG000|Period 2|Adverse Event|1
6093373|NCT00709852|9706431|FG001|Period 2|Adverse Event|1
6093374|NCT00709852|9706430|FG000|Period 2|Lost to Follow-up|1
6093375|NCT00709852|9706431|FG001|Period 2|Lost to Follow-up|0
6093376|NCT00709852|9706430|FG000|Period 2|No 72-hour follow-up|3
6059849|NCT00479882|9660378|FG001|Crossover: Period III (Weeks 13-20)|Laboratory Adverse Event|1
6059850|NCT00479882|9660379|FG002|Crossover: Period III (Weeks 13-20)|Laboratory Adverse Event|2
6059851|NCT00479882|9660380|FG003|Crossover: Period III (Weeks 13-20)|Laboratory Adverse Event|2
6059852|NCT00479882|9660377|FG000|Crossover: Period III (Weeks 13-20)|Lost to Follow-up|1
6059853|NCT00479882|9660378|FG001|Crossover: Period III (Weeks 13-20)|Lost to Follow-up|2
6059854|NCT00479882|9660379|FG002|Crossover: Period III (Weeks 13-20)|Lost to Follow-up|1
6059855|NCT00479882|9660380|FG003|Crossover: Period III (Weeks 13-20)|Lost to Follow-up|1
6059856|NCT00479882|9660377|FG000|Crossover: Period III (Weeks 13-20)|Other|5
6059857|NCT00479882|9660378|FG001|Crossover: Period III (Weeks 13-20)|Other|0
6059858|NCT00479882|9660379|FG002|Crossover: Period III (Weeks 13-20)|Other|2
6059859|NCT00479882|9660380|FG003|Crossover: Period III (Weeks 13-20)|Other|2
6059860|NCT00479882|9660377|FG000|Crossover: Period III (Weeks 13-20)|Participant moved|1
6059861|NCT00479882|9660378|FG001|Crossover: Period III (Weeks 13-20)|Participant moved|2
6059862|NCT00479882|9660379|FG002|Crossover: Period III (Weeks 13-20)|Participant moved|1
6059863|NCT00479882|9660380|FG003|Crossover: Period III (Weeks 13-20)|Participant moved|0
6059864|NCT00479882|9660377|FG000|Crossover: Period III (Weeks 13-20)|Withdrawal by Subject|3
6059865|NCT00479882|9660378|FG001|Crossover: Period III (Weeks 13-20)|Withdrawal by Subject|3
6059866|NCT00479882|9660379|FG002|Crossover: Period III (Weeks 13-20)|Withdrawal by Subject|1
6059867|NCT00479882|9660380|FG003|Crossover: Period III (Weeks 13-20)|Withdrawal by Subject|3
6059868|NCT00479882|9660377|FG000|Crossover: Period III (Weeks 13-20)|Protocol Violation|0
6059869|NCT00479882|9660378|FG001|Crossover: Period III (Weeks 13-20)|Protocol Violation|0
6059870|NCT00479882|9660379|FG002|Crossover: Period III (Weeks 13-20)|Protocol Violation|1
6059871|NCT00479882|9660380|FG003|Crossover: Period III (Weeks 13-20)|Protocol Violation|0
6059872|NCT00480025|9660408|FG000|Overall Study|Protocol Violation|12
6059873|NCT00480025|9660409|FG001|Overall Study|Protocol Violation|7
6059874|NCT00480025|9660408|FG000|Overall Study|Patients remaining ongoing at Data Lock|101
6059875|NCT00480025|9660409|FG001|Overall Study|Patients remaining ongoing at Data Lock|55
6059876|NCT00480025|9660408|FG000|Overall Study|Disease Progression / Recurrence|449
6059877|NCT00480025|9660409|FG001|Overall Study|Disease Progression / Recurrence|224
6059878|NCT00480025|9660408|FG000|Overall Study|Adverse Event|44
6059879|NCT00480025|9660409|FG001|Overall Study|Adverse Event|12
6059880|NCT00480025|9660408|FG000|Overall Study|Other|70
6059881|NCT00480025|9660409|FG001|Overall Study|Other|29
6059882|NCT00480025|9660408|FG000|Overall Study|SAE including intercurrent illness|76
6059883|NCT00480025|9660409|FG001|Overall Study|SAE including intercurrent illness|42
6059884|NCT00480077|9660423|FG000|Overall Study|Death|19
6059885|NCT00480077|9660424|FG001|Overall Study|Death|15
6059886|NCT00480077|9660423|FG000|Overall Study|early exit|12
6059887|NCT00480077|9660424|FG001|Overall Study|early exit|11
6059888|NCT00480324|9660432|FG000|Overall Study|Adverse Event|1
6059889|NCT00480324|9660433|FG001|Overall Study|Adverse Event|1
6059890|NCT00480324|9660432|FG000|Overall Study|Protocol Violation|0
6059891|NCT00480324|9660433|FG001|Overall Study|Protocol Violation|1
6059892|NCT00480324|9660432|FG000|Overall Study|Withdrawal by Subject|14
6059893|NCT00480324|9660433|FG001|Overall Study|Withdrawal by Subject|5
6059894|NCT00480324|9660432|FG000|Overall Study|Lost to Follow-up|17
6059895|NCT00480324|9660433|FG001|Overall Study|Lost to Follow-up|8
6059896|NCT00480324|9660432|FG000|Overall Study|Subject's mother pregnant|0
6093377|NCT00709852|9706431|FG001|Period 2|No 72-hour follow-up|0
6093378|NCT00709956|9706469|FG000|Overall Study|Withdrawal by Subject|1
6093379|NCT00709956|9706470|FG001|Overall Study|Withdrawal by Subject|1
6093380|NCT00709956|9706469|FG000|Overall Study|Inclusion/exclusion criteria violation|2
6093381|NCT00709956|9706470|FG001|Overall Study|Inclusion/exclusion criteria violation|3
6093382|NCT00709995|9706480|FG000|Overall Study|Adverse Event|4
6093383|NCT00709995|9706481|FG001|Overall Study|Adverse Event|2
6093384|NCT00709995|9706480|FG000|Overall Study|Withdrawal by Subject|1
6093385|NCT00709995|9706481|FG001|Overall Study|Withdrawal by Subject|3
6093386|NCT00710021|9706493|FG000|Overall Study|Lost to Follow-up|1
6093387|NCT00710021|9706494|FG001|Overall Study|Lost to Follow-up|0
6093388|NCT00710021|9706495|FG002|Overall Study|Lost to Follow-up|0
6093389|NCT00710021|9706493|FG000|Overall Study|Subject's Decision|0
6093390|NCT00710021|9706494|FG001|Overall Study|Subject's Decision|1
6093391|NCT00710021|9706495|FG002|Overall Study|Subject's Decision|0
6093392|NCT00710021|9706493|FG000|Overall Study|Subject misrandomized|0
6093393|NCT00710021|9706494|FG001|Overall Study|Subject misrandomized|1
6093394|NCT00710021|9706495|FG002|Overall Study|Subject misrandomized|1
6093395|NCT00710021|9706493|FG000|Overall Study|Physician Decision|0
6059897|NCT00480324|9660433|FG001|Overall Study|Subject's mother pregnant|1
6059898|NCT00480441|9660441|FG000|Screening|Not Eligible|37
6059899|NCT00480441|9660442|FG001|Screening|Not Eligible|0
6059900|NCT00480441|9660443|FG002|Screening|Not Eligible|0
6059901|NCT00480441|9660441|FG000|Baseline Functional MRI|Functional MRI data not usable|4
6059902|NCT00480441|9660442|FG001|Baseline Functional MRI|Functional MRI data not usable|0
6059903|NCT00480441|9660443|FG002|Baseline Functional MRI|Functional MRI data not usable|0
6059904|NCT00480441|9660441|FG000|Baseline Functional MRI|Lost to Follow-up|4
6093396|NCT00710021|9706494|FG001|Overall Study|Physician Decision|1
6093397|NCT00710021|9706495|FG002|Overall Study|Physician Decision|0
6093398|NCT00710034|9706506|FG000|Completed 6 Weeks of Treatment|Adverse Event|5
6093399|NCT00710034|9706507|FG001|Completed 6 Weeks of Treatment|Adverse Event|12
6059905|NCT00480441|9660442|FG001|Baseline Functional MRI|Lost to Follow-up|0
6059906|NCT00480441|9660443|FG002|Baseline Functional MRI|Lost to Follow-up|0
6059907|NCT00480441|9660441|FG000|Baseline Functional MRI|physical contraindication|4
6059908|NCT00480441|9660442|FG001|Baseline Functional MRI|physical contraindication|0
6059909|NCT00480441|9660443|FG002|Baseline Functional MRI|physical contraindication|0
6059910|NCT00480441|9660441|FG000|Randomization|Lost to Follow-up|0
6059911|NCT00480441|9660442|FG001|Randomization|Lost to Follow-up|7
6059912|NCT00480441|9660443|FG002|Randomization|Lost to Follow-up|2
6059913|NCT00480493|9660452|FG000|Overall Study|moved|2
6059914|NCT00480493|9660453|FG001|Overall Study|moved|7
6059915|NCT00480532|9660465|FG000|Overall Study|Withdrawal by Subject|2
6059916|NCT00480532|9660466|FG001|Overall Study|Withdrawal by Subject|4
6059917|NCT00480532|9660467|FG002|Overall Study|Withdrawal by Subject|3
6059918|NCT00480532|9660468|FG003|Overall Study|Withdrawal by Subject|1
6059919|NCT00480532|9660465|FG000|Overall Study|Protocol Violation|0
6059920|NCT00480532|9660466|FG001|Overall Study|Protocol Violation|0
6059921|NCT00480532|9660467|FG002|Overall Study|Protocol Violation|1
6059922|NCT00480532|9660468|FG003|Overall Study|Protocol Violation|0
6059923|NCT00480636|9660478|FG000|Overall Study|Death|12
6059924|NCT00480636|9660478|FG000|Overall Study|Lost to Follow-up|4
6059925|NCT00480636|9660478|FG000|Overall Study|Other|2
6059926|NCT00480636|9660478|FG000|Overall Study|Lost to follow-up; subsequently died|1
6059927|NCT00480779|9660497|FG000|Overall Study|Other|2
6059928|NCT00480779|9660498|FG001|Overall Study|Other|0
6059929|NCT00480779|9660497|FG000|Overall Study|Job and Health-related|0
6059930|NCT00480779|9660498|FG001|Overall Study|Job and Health-related|3
6059931|NCT00480857|9660504|FG000|Overall Study|Lack of Efficacy|2
6059932|NCT00481065|9660520|FG000|Overall Study|Adverse event or death|1
6059933|NCT00481065|9660521|FG001|Overall Study|Adverse event or death|1
6059934|NCT00481065|9660522|FG002|Overall Study|Adverse event or death|3
6059935|NCT00481065|9660523|FG003|Overall Study|Adverse event or death|0
6059936|NCT00481065|9660524|FG004|Overall Study|Adverse event or death|2
6059937|NCT00481065|9660525|FG005|Overall Study|Adverse event or death|0
6059938|NCT00481065|9660526|FG006|Overall Study|Adverse event or death|1
6059939|NCT00481065|9660527|FG007|Overall Study|Adverse event or death|1
6059940|NCT00481065|9660520|FG000|Overall Study|Withdrawal by Subject|11
6059941|NCT00481065|9660521|FG001|Overall Study|Withdrawal by Subject|12
6059942|NCT00481065|9660522|FG002|Overall Study|Withdrawal by Subject|7
6059943|NCT00481065|9660523|FG003|Overall Study|Withdrawal by Subject|11
6059944|NCT00481065|9660524|FG004|Overall Study|Withdrawal by Subject|13
6059945|NCT00481065|9660525|FG005|Overall Study|Withdrawal by Subject|12
6059946|NCT00481065|9660526|FG006|Overall Study|Withdrawal by Subject|9
6059947|NCT00481065|9660527|FG007|Overall Study|Withdrawal by Subject|10
6059948|NCT00481065|9660520|FG000|Overall Study|Lost to Follow-up|4
6059949|NCT00481065|9660521|FG001|Overall Study|Lost to Follow-up|2
6059950|NCT00481065|9660522|FG002|Overall Study|Lost to Follow-up|4
6059951|NCT00481065|9660523|FG003|Overall Study|Lost to Follow-up|3
6059952|NCT00481065|9660524|FG004|Overall Study|Lost to Follow-up|3
6059953|NCT00481065|9660525|FG005|Overall Study|Lost to Follow-up|3
6059954|NCT00481065|9660526|FG006|Overall Study|Lost to Follow-up|2
6059955|NCT00481065|9660527|FG007|Overall Study|Lost to Follow-up|5
6059956|NCT00481065|9660520|FG000|Overall Study|Inappropriate enrollment|4
6093400|NCT00710034|9706506|FG000|Completed 6 Weeks of Treatment|Lack of Efficacy|12
6093401|NCT00710034|9706507|FG001|Completed 6 Weeks of Treatment|Lack of Efficacy|8
6093402|NCT00710034|9706506|FG000|Completed 6 Weeks of Treatment|Lost to Follow-up|15
6093403|NCT00710034|9706507|FG001|Completed 6 Weeks of Treatment|Lost to Follow-up|17
6093404|NCT00710034|9706506|FG000|Completed 6 Weeks of Treatment|Product dissatisfaction|2
6093405|NCT00710034|9706507|FG001|Completed 6 Weeks of Treatment|Product dissatisfaction|6
6093406|NCT00710034|9706506|FG000|Completed 6 Weeks of Treatment|Withdrawal by Subject|6
6093407|NCT00710034|9706507|FG001|Completed 6 Weeks of Treatment|Withdrawal by Subject|4
6093408|NCT00710034|9706506|FG000|Completed 6 Weeks of Treatment|Physician Decision|1
6093409|NCT00710034|9706507|FG001|Completed 6 Weeks of Treatment|Physician Decision|0
6093410|NCT00710034|9706506|FG000|Completed 12 Weeks of Treatment|Adverse Event|0
6093411|NCT00710034|9706507|FG001|Completed 12 Weeks of Treatment|Adverse Event|1
6093412|NCT00710034|9706506|FG000|Completed 12 Weeks of Treatment|Lack of Efficacy|0
6093413|NCT00710034|9706507|FG001|Completed 12 Weeks of Treatment|Lack of Efficacy|2
6093414|NCT00710034|9706506|FG000|Completed 12 Weeks of Treatment|Lost to Follow-up|5
6093415|NCT00710034|9706507|FG001|Completed 12 Weeks of Treatment|Lost to Follow-up|5
6059957|NCT00481065|9660521|FG001|Overall Study|Inappropriate enrollment|0
6059958|NCT00481065|9660522|FG002|Overall Study|Inappropriate enrollment|2
6059959|NCT00481065|9660523|FG003|Overall Study|Inappropriate enrollment|0
6059960|NCT00481065|9660524|FG004|Overall Study|Inappropriate enrollment|2
6059961|NCT00481065|9660525|FG005|Overall Study|Inappropriate enrollment|1
6059962|NCT00481065|9660526|FG006|Overall Study|Inappropriate enrollment|0
6059963|NCT00481065|9660527|FG007|Overall Study|Inappropriate enrollment|1
6059964|NCT00481065|9660520|FG000|Overall Study|Administrative reason|0
6059965|NCT00481065|9660521|FG001|Overall Study|Administrative reason|0
6059966|NCT00481065|9660522|FG002|Overall Study|Administrative reason|0
6059967|NCT00481065|9660523|FG003|Overall Study|Administrative reason|0
6059968|NCT00481065|9660524|FG004|Overall Study|Administrative reason|0
6093416|NCT00710034|9706506|FG000|Completed 12 Weeks of Treatment|Product Dissatisfaction|0
6059969|NCT00481065|9660525|FG005|Overall Study|Administrative reason|2
6059970|NCT00481065|9660526|FG006|Overall Study|Administrative reason|1
6059971|NCT00481065|9660527|FG007|Overall Study|Administrative reason|0
6059972|NCT00481065|9660520|FG000|Overall Study|Protocol Violation|2
6059973|NCT00481065|9660521|FG001|Overall Study|Protocol Violation|1
6059974|NCT00481065|9660522|FG002|Overall Study|Protocol Violation|1
6059975|NCT00481065|9660523|FG003|Overall Study|Protocol Violation|1
6059976|NCT00481065|9660524|FG004|Overall Study|Protocol Violation|2
6059977|NCT00481065|9660525|FG005|Overall Study|Protocol Violation|6
6059978|NCT00481065|9660526|FG006|Overall Study|Protocol Violation|3
6059979|NCT00481065|9660527|FG007|Overall Study|Protocol Violation|2
6059980|NCT00481065|9660520|FG000|Overall Study|Unable to classify|0
6059981|NCT00481065|9660521|FG001|Overall Study|Unable to classify|1
6059982|NCT00481065|9660522|FG002|Overall Study|Unable to classify|2
6059983|NCT00481065|9660523|FG003|Overall Study|Unable to classify|0
6059984|NCT00481065|9660524|FG004|Overall Study|Unable to classify|1
6059985|NCT00481065|9660525|FG005|Overall Study|Unable to classify|0
6059986|NCT00481065|9660526|FG006|Overall Study|Unable to classify|0
6059987|NCT00481065|9660527|FG007|Overall Study|Unable to classify|0
6059988|NCT00481078|9660549|FG000|Overall Study|Progression of disease|11
6059989|NCT00481078|9660550|FG001|Overall Study|Progression of disease|11
6059990|NCT00481078|9660549|FG000|Overall Study|Adverse Event|15
6059991|NCT00481078|9660550|FG001|Overall Study|Adverse Event|3
6059992|NCT00481078|9660549|FG000|Overall Study|Death|5
6059993|NCT00481078|9660550|FG001|Overall Study|Death|3
6059994|NCT00481078|9660549|FG000|Overall Study|Intercurrent illness|1
6059995|NCT00481078|9660550|FG001|Overall Study|Intercurrent illness|0
6059996|NCT00481078|9660549|FG000|Overall Study|Withdrawal by Subject|7
6059997|NCT00481078|9660550|FG001|Overall Study|Withdrawal by Subject|1
6059998|NCT00481078|9660549|FG000|Overall Study|Information not available|1
6059999|NCT00481078|9660550|FG001|Overall Study|Information not available|0
6060000|NCT00481078|9660549|FG000|Overall Study|Received other treatment|2
6060001|NCT00481078|9660550|FG001|Overall Study|Received other treatment|1
6060002|NCT00481078|9660549|FG000|Overall Study|Brain metastasis|0
6060003|NCT00481078|9660550|FG001|Overall Study|Brain metastasis|1
6060004|NCT00481195|9660558|FG000|Overall Study|Adverse Event|16
6060005|NCT00481195|9660559|FG001|Overall Study|Adverse Event|11
6060006|NCT00481195|9660558|FG000|Overall Study|Lack of Efficacy|1
6060007|NCT00481195|9660559|FG001|Overall Study|Lack of Efficacy|3
6060008|NCT00481195|9660558|FG000|Overall Study|Lost to Follow-up|4
6060009|NCT00481195|9660559|FG001|Overall Study|Lost to Follow-up|6
6060010|NCT00481195|9660558|FG000|Overall Study|Physician Decision|3
6060011|NCT00481195|9660559|FG001|Overall Study|Physician Decision|1
6060012|NCT00481195|9660558|FG000|Overall Study|Protocol Violation|10
6060013|NCT00481195|9660559|FG001|Overall Study|Protocol Violation|7
6060014|NCT00481195|9660558|FG000|Overall Study|Withdrawal by Subject|3
6060015|NCT00481195|9660559|FG001|Overall Study|Withdrawal by Subject|9
6060016|NCT00481195|9660558|FG000|Overall Study|Miscellaneous|2
6060017|NCT00481195|9660559|FG001|Overall Study|Miscellaneous|2
6060018|NCT00481247|9660567|FG000|Overall Study|Death|0
6060019|NCT00481247|9660568|FG001|Overall Study|Death|1
6060020|NCT00481247|9660567|FG000|Overall Study|Disease progression|18
6060021|NCT00481247|9660568|FG001|Overall Study|Disease progression|22
6060022|NCT00481247|9660567|FG000|Overall Study|Intolerance|42
6060023|NCT00481247|9660568|FG001|Overall Study|Intolerance|17
6060024|NCT00481247|9660567|FG000|Overall Study|Treatment failure|10
6060025|NCT00481247|9660568|FG001|Overall Study|Treatment failure|14
6060026|NCT00481247|9660567|FG000|Overall Study|AE unrelated to study drug|13
6060027|NCT00481247|9660568|FG001|Overall Study|AE unrelated to study drug|4
6060028|NCT00481247|9660567|FG000|Overall Study|Withdrawal by Subject|8
6060029|NCT00481247|9660568|FG001|Overall Study|Withdrawal by Subject|13
6060030|NCT00481247|9660567|FG000|Overall Study|Pregnancy|2
6060031|NCT00481247|9660568|FG001|Overall Study|Pregnancy|1
6060032|NCT00481247|9660567|FG000|Overall Study|Lost to Follow-up|1
6060033|NCT00481247|9660568|FG001|Overall Study|Lost to Follow-up|2
6060034|NCT00481247|9660567|FG000|Overall Study|Poor compliance/noncompliance|1
6060035|NCT00481247|9660568|FG001|Overall Study|Poor compliance/noncompliance|7
6060036|NCT00481247|9660567|FG000|Overall Study|Administrative reason by sponsor|157
6060037|NCT00481247|9660568|FG001|Overall Study|Administrative reason by sponsor|162
6060038|NCT00481247|9660567|FG000|Overall Study|Varied|6
6060039|NCT00481247|9660568|FG001|Overall Study|Varied|15
6060040|NCT00481247|9660567|FG000|Overall Study|Did not receive treatment|1
6060041|NCT00481247|9660568|FG001|Overall Study|Did not receive treatment|2
6060042|NCT00481676|9660594|FG000|Overall Study|Adverse Event|0
6060043|NCT00481676|9660595|FG001|Overall Study|Adverse Event|1
6060044|NCT00481676|9660594|FG000|Overall Study|Unsatisfactory therapeutic effect|1
6060045|NCT00481676|9660595|FG001|Overall Study|Unsatisfactory therapeutic effect|4
6060046|NCT00481676|9660594|FG000|Overall Study|Administrative problem|1
6060047|NCT00481676|9660595|FG001|Overall Study|Administrative problem|0
6060048|NCT00481767|9660603|FG000|Overall Study|Withdrawal by Subject|16
6060049|NCT00481767|9660604|FG001|Overall Study|Withdrawal by Subject|11
6060050|NCT00481767|9660603|FG000|Overall Study|Lost to Follow-up|16
6060051|NCT00481767|9660604|FG001|Overall Study|Lost to Follow-up|10
6060052|NCT00481832|9660610|FG000|Enrollment|Physician Decision|8
6060053|NCT00481832|9660610|FG000|Enrollment|Unable to collect enough stem cells|2
6060054|NCT00481832|9660610|FG000|Inter-transplant Period|Adverse Event|4
6060055|NCT00481832|9660610|FG000|Inter-transplant Period|Death|3
6093417|NCT00710034|9706507|FG001|Completed 12 Weeks of Treatment|Product Dissatisfaction|1
6093418|NCT00710034|9706506|FG000|Completed 12 Weeks of Treatment|Withdrawal by Subject|8
6093419|NCT00710034|9706507|FG001|Completed 12 Weeks of Treatment|Withdrawal by Subject|2
6093420|NCT00710385|9706523|FG000|Overall Study|Did not qualify|1
6093421|NCT00710385|9706523|FG000|Overall Study|Withdrawal by Subject|1
6093422|NCT00710385|9706523|FG000|Overall Study|Undisclosed back pain|1
6093423|NCT00710385|9706523|FG000|Overall Study|Physician Decision|1
6093424|NCT00710385|9706523|FG000|Overall Study|Undisclosed excessive methadone use|1
6060056|NCT00481832|9660610|FG000|Inter-transplant Period|Physician Decision|4
6060057|NCT00481832|9660610|FG000|Inter-transplant Period|Disease relapse|11
6060058|NCT00481832|9660610|FG000|Inter-transplant Period|Lack of allogeneic donor|5
6060059|NCT00481871|9660628|FG000|Overall Study|Progressive Disease - pt withdrew|0
6060060|NCT00481871|9660629|FG001|Overall Study|Progressive Disease - pt withdrew|0
6060061|NCT00481871|9660630|FG002|Overall Study|Progressive Disease - pt withdrew|1
6060062|NCT00481871|9660631|FG003|Overall Study|Progressive Disease - pt withdrew|0
6060063|NCT00481871|9660632|FG004|Overall Study|Progressive Disease - pt withdrew|0
6060064|NCT00481988|9660642|FG000|Overall Study|Withdrawal by Subject|1
6060065|NCT00481988|9660643|FG001|Overall Study|Withdrawal by Subject|1
6060066|NCT00482001|9660651|FG000|Overall Study|Protocol Violation|1
6060067|NCT00482001|9660652|FG001|Overall Study|Protocol Violation|1
6060068|NCT00482014|9660664|FG000|Overall Study|Withdrawal by Subject|1
6060069|NCT00482014|9660665|FG001|Overall Study|Withdrawal by Subject|2
6060070|NCT00482014|9660666|FG002|Overall Study|Withdrawal by Subject|3
6060071|NCT00482014|9660667|FG003|Overall Study|Withdrawal by Subject|4
6060072|NCT00482014|9660664|FG000|Overall Study|Adverse Event|3
6060073|NCT00482014|9660665|FG001|Overall Study|Adverse Event|0
6093425|NCT00710424|9706535|FG000|Overall Study|Adverse Event|30
6093426|NCT00710424|9706536|FG001|Overall Study|Adverse Event|12
6093427|NCT00710424|9706535|FG000|Overall Study|Lack of Efficacy|4
6093428|NCT00710424|9706536|FG001|Overall Study|Lack of Efficacy|5
6093429|NCT00710424|9706535|FG000|Overall Study|Withdrawal by Subject|5
6093430|NCT00710424|9706536|FG001|Overall Study|Withdrawal by Subject|3
6093431|NCT00710424|9706535|FG000|Overall Study|Lost to Follow-up|0
6093432|NCT00710424|9706536|FG001|Overall Study|Lost to Follow-up|1
6093433|NCT00710424|9706535|FG000|Overall Study|Refused medication, no side effects|1
6093434|NCT00710424|9706536|FG001|Overall Study|Refused medication, no side effects|0
6093435|NCT00710424|9706535|FG000|Overall Study|Non-compliance with stable analgesia|1
6093436|NCT00710424|9706536|FG001|Overall Study|Non-compliance with stable analgesia|0
6093437|NCT00710424|9706535|FG000|Overall Study|Did not meet entry criteria at visit 1|1
6093438|NCT00710424|9706536|FG001|Overall Study|Did not meet entry criteria at visit 1|0
6093439|NCT00710424|9706535|FG000|Overall Study|Subject thought medication changed|1
6093440|NCT00710424|9706536|FG001|Overall Study|Subject thought medication changed|0
6093441|NCT00710424|9706535|FG000|Overall Study|Ceased treatment due to travel|1
6093442|NCT00710424|9706536|FG001|Overall Study|Ceased treatment due to travel|0
6093443|NCT00710424|9706535|FG000|Overall Study|Subject preferred paracetamol|0
6093444|NCT00710424|9706536|FG001|Overall Study|Subject preferred paracetamol|1
6093445|NCT00710424|9706535|FG000|Overall Study|Felt good so stopped treatment|0
6093446|NCT00710424|9706536|FG001|Overall Study|Felt good so stopped treatment|1
6093447|NCT00710554|9706544|FG000|Overall Study|Adverse Event|24
6093448|NCT00710554|9706545|FG001|Overall Study|Adverse Event|7
6093449|NCT00710554|9706544|FG000|Overall Study|Withdrawal by Subject|7
6093450|NCT00710554|9706545|FG001|Overall Study|Withdrawal by Subject|3
6093451|NCT00710554|9706544|FG000|Overall Study|Lost to Follow-up|7
6093452|NCT00710554|9706545|FG001|Overall Study|Lost to Follow-up|1
6093453|NCT00710554|9706544|FG000|Overall Study|Lack of Efficacy|11
6093454|NCT00710554|9706545|FG001|Overall Study|Lack of Efficacy|12
6093455|NCT00710554|9706544|FG000|Overall Study|Receiving radiotherapy - prostate cancer|0
6093456|NCT00710554|9706545|FG001|Overall Study|Receiving radiotherapy - prostate cancer|1
6093457|NCT00710593|9706553|FG000|Overall Study|Incarceration|1
6093458|NCT00710593|9706554|FG001|Overall Study|Incarceration|0
6093459|NCT00710593|9706553|FG000|Overall Study|Unable to complete Wk 48 within window|2
6093460|NCT00710593|9706554|FG001|Overall Study|Unable to complete Wk 48 within window|0
6093461|NCT00710593|9706553|FG000|Overall Study|Lost to Follow-up|3
6093462|NCT00710593|9706554|FG001|Overall Study|Lost to Follow-up|1
6093463|NCT00710593|9706553|FG000|Overall Study|Moved out of area|1
6093464|NCT00710593|9706554|FG001|Overall Study|Moved out of area|0
6093465|NCT00710593|9706553|FG000|Overall Study|Failure to adhere or complete study eval|1
6093466|NCT00710593|9706554|FG001|Overall Study|Failure to adhere or complete study eval|1
6093467|NCT00710593|9706553|FG000|Overall Study|Protocol Violation|1
6093468|NCT00710593|9706554|FG001|Overall Study|Protocol Violation|1
6093469|NCT00710593|9706553|FG000|Overall Study|Prem disc vaccine, completed all visits|6
6093470|NCT00710593|9706554|FG001|Overall Study|Prem disc vaccine, completed all visits|2
6093471|NCT00710606|9706578|FG000|Overall Study|Adverse Event|0
6093472|NCT00710606|9706579|FG001|Overall Study|Adverse Event|2
6093473|NCT00710684|9706590|FG000|Overall Study|Adverse Event|11
6060074|NCT00482014|9660666|FG002|Overall Study|Adverse Event|2
6060075|NCT00482014|9660667|FG003|Overall Study|Adverse Event|8
6060076|NCT00482014|9660664|FG000|Overall Study|Death|1
6060077|NCT00482014|9660665|FG001|Overall Study|Death|2
6060078|NCT00482014|9660666|FG002|Overall Study|Death|1
6060079|NCT00482014|9660667|FG003|Overall Study|Death|4
6060080|NCT00482014|9660664|FG000|Overall Study|Lack of Efficacy|1
6060081|NCT00482014|9660665|FG001|Overall Study|Lack of Efficacy|0
6060082|NCT00482014|9660666|FG002|Overall Study|Lack of Efficacy|4
6060083|NCT00482014|9660667|FG003|Overall Study|Lack of Efficacy|6
6060084|NCT00482014|9660664|FG000|Overall Study|Sponsor Decision|1
6060085|NCT00482014|9660665|FG001|Overall Study|Sponsor Decision|2
6060086|NCT00482014|9660666|FG002|Overall Study|Sponsor Decision|1
6060087|NCT00482014|9660667|FG003|Overall Study|Sponsor Decision|1
6060088|NCT00482053|9660679|FG000|Inter-treatment Period|Disease progression|1
6060089|NCT00482170|9660685|FG000|Overall Study|Adverse Event|5
6060090|NCT00482170|9660686|FG001|Overall Study|Adverse Event|14
6060091|NCT00482170|9660685|FG000|Overall Study|Withdrawal by Subject|6
6060092|NCT00482170|9660686|FG001|Overall Study|Withdrawal by Subject|1
6060093|NCT00482170|9660685|FG000|Overall Study|Protocol Violation|2
6060094|NCT00482170|9660686|FG001|Overall Study|Protocol Violation|3
6060095|NCT00482170|9660685|FG000|Overall Study|Lost to Follow-up|2
6060096|NCT00482170|9660686|FG001|Overall Study|Lost to Follow-up|0
6060097|NCT00482170|9660685|FG000|Overall Study|Unspecified reason|0
6060098|NCT00482170|9660686|FG001|Overall Study|Unspecified reason|2
6060099|NCT00482274|9660692|FG000|Overall Study|Adverse Event|1
6060100|NCT00482391|9660696|FG000|Overall Study|Withdrawal by Subject|1
6060101|NCT00482391|9660696|FG000|Overall Study|Adverse Event|1
6060102|NCT00482391|9660696|FG000|Overall Study|Death|1
6060103|NCT00482612|9660714|FG000|In-treatment Period|No study medication administered|0
6060104|NCT00482612|9660715|FG001|In-treatment Period|No study medication administered|0
6060105|NCT00482612|9660716|FG002|In-treatment Period|No study medication administered|1
6060106|NCT00482612|9660717|FG003|In-treatment Period|No study medication administered|0
6060107|NCT00482612|9660714|FG000|Follow-up Period|Other|4
6060108|NCT00482612|9660715|FG001|Follow-up Period|Other|2
6060109|NCT00482612|9660716|FG002|Follow-up Period|Other|1
6060110|NCT00482612|9660717|FG003|Follow-up Period|Other|2
6060111|NCT00482612|9660714|FG000|Follow-up Period|Lack of compliance|0
6060112|NCT00482612|9660715|FG001|Follow-up Period|Lack of compliance|0
6060113|NCT00482612|9660716|FG002|Follow-up Period|Lack of compliance|1
6060114|NCT00482612|9660717|FG003|Follow-up Period|Lack of compliance|0
6060115|NCT00482612|9660714|FG000|Follow-up Period|Lost to Follow-up|0
6060116|NCT00482612|9660715|FG001|Follow-up Period|Lost to Follow-up|4
6060117|NCT00482612|9660716|FG002|Follow-up Period|Lost to Follow-up|2
6060118|NCT00482612|9660717|FG003|Follow-up Period|Lost to Follow-up|1
6060119|NCT00482612|9660714|FG000|Follow-up Period|Adverse Event|4
6060120|NCT00482612|9660715|FG001|Follow-up Period|Adverse Event|7
6060121|NCT00482612|9660716|FG002|Follow-up Period|Adverse Event|9
6060122|NCT00482612|9660717|FG003|Follow-up Period|Adverse Event|0
6060123|NCT00482612|9660714|FG000|Follow-up Period|Lack of Efficacy|2
6060124|NCT00482612|9660715|FG001|Follow-up Period|Lack of Efficacy|0
6060125|NCT00482612|9660716|FG002|Follow-up Period|Lack of Efficacy|1
6060126|NCT00482612|9660717|FG003|Follow-up Period|Lack of Efficacy|0
6060127|NCT00482612|9660714|FG000|Follow-up Period|Withdrawal by Subject|3
6060128|NCT00482612|9660715|FG001|Follow-up Period|Withdrawal by Subject|5
6060129|NCT00482612|9660716|FG002|Follow-up Period|Withdrawal by Subject|7
6060130|NCT00482612|9660717|FG003|Follow-up Period|Withdrawal by Subject|2
6060131|NCT00482612|9660714|FG000|Follow-up Period|Reasons not related to trial|1
6060132|NCT00482612|9660715|FG001|Follow-up Period|Reasons not related to trial|0
6060133|NCT00482612|9660716|FG002|Follow-up Period|Reasons not related to trial|1
6060134|NCT00482612|9660717|FG003|Follow-up Period|Reasons not related to trial|3
6060135|NCT00482703|9660746|FG000|Overall Study|Poor compliance|1
6060136|NCT00482703|9660747|FG001|Overall Study|Poor compliance|0
6060137|NCT00482729|9660762|FG000|Overall Study|Adverse Event|29
6060138|NCT00482729|9660763|FG001|Overall Study|Adverse Event|33
6060139|NCT00482729|9660762|FG000|Overall Study|Creatinine/Creatinine Clearance Criteria|0
6060140|NCT00482729|9660763|FG001|Overall Study|Creatinine/Creatinine Clearance Criteria|2
6093474|NCT00710684|9706591|FG001|Overall Study|Adverse Event|19
6093475|NCT00710684|9706592|FG002|Overall Study|Adverse Event|16
6093476|NCT00710684|9706590|FG000|Overall Study|Lack of Efficacy|4
6060141|NCT00482729|9660762|FG000|Overall Study|Hyperglycemia Criteria|7
6093477|NCT00710684|9706591|FG001|Overall Study|Lack of Efficacy|3
6093478|NCT00710684|9706592|FG002|Overall Study|Lack of Efficacy|5
6093479|NCT00710684|9706590|FG000|Overall Study|Protocol Violation|5
6093480|NCT00710684|9706591|FG001|Overall Study|Protocol Violation|5
6093481|NCT00710684|9706592|FG002|Overall Study|Protocol Violation|5
6093482|NCT00710684|9706590|FG000|Overall Study|Lost to Follow-up|4
6093483|NCT00710684|9706591|FG001|Overall Study|Lost to Follow-up|6
6093484|NCT00710684|9706592|FG002|Overall Study|Lost to Follow-up|7
6093485|NCT00710684|9706590|FG000|Overall Study|Physician Decision|0
6060142|NCT00482729|9660763|FG001|Overall Study|Hyperglycemia Criteria|5
6060143|NCT00482729|9660762|FG000|Overall Study|Lack of Efficacy|4
6060144|NCT00482729|9660763|FG001|Overall Study|Lack of Efficacy|16
6060145|NCT00482729|9660762|FG000|Overall Study|Lost to Follow-up|86
6093486|NCT00710684|9706591|FG001|Overall Study|Physician Decision|2
6060146|NCT00482729|9660763|FG001|Overall Study|Lost to Follow-up|66
6060147|NCT00482729|9660762|FG000|Overall Study|Physician Decision|10
6060148|NCT00482729|9660763|FG001|Overall Study|Physician Decision|7
6060149|NCT00482729|9660762|FG000|Overall Study|Pregnancy|4
6060150|NCT00482729|9660763|FG001|Overall Study|Pregnancy|2
6060151|NCT00482729|9660762|FG000|Overall Study|Protocol Violation|10
6060152|NCT00482729|9660763|FG001|Overall Study|Protocol Violation|18
6060153|NCT00482729|9660762|FG000|Overall Study|Withdrawal by Subject|67
6060154|NCT00482729|9660763|FG001|Overall Study|Withdrawal by Subject|69
6060155|NCT00483002|9660778|FG000|Overall Study|Adverse Event|68
6093487|NCT00710684|9706592|FG002|Overall Study|Physician Decision|4
6093488|NCT00710684|9706590|FG000|Overall Study|Withdrawal by Subject|24
6093489|NCT00710684|9706591|FG001|Overall Study|Withdrawal by Subject|18
6093490|NCT00710684|9706592|FG002|Overall Study|Withdrawal by Subject|11
6093491|NCT00710684|9706590|FG000|Overall Study|Missing|1
6093492|NCT00710684|9706591|FG001|Overall Study|Missing|0
6093493|NCT00710684|9706592|FG002|Overall Study|Missing|0
6093494|NCT00710684|9706590|FG000|Overall Study|Did not continue after week 24|25
6093495|NCT00710684|9706591|FG001|Overall Study|Did not continue after week 24|21
6093496|NCT00710684|9706592|FG002|Overall Study|Did not continue after week 24|16
6093497|NCT00710749|9706606|FG000|First Intervention|Withdrawal by Subject|1
6093498|NCT00710749|9706607|FG001|First Intervention|Withdrawal by Subject|0
6093499|NCT00710762|9706617|FG000|Overall Study|Progressive disease|27
6093500|NCT00710762|9706618|FG001|Overall Study|Progressive disease|30
6093501|NCT00710762|9706617|FG000|Overall Study|Adverse Event other disease worsening|2
6093502|NCT00710762|9706618|FG001|Overall Study|Adverse Event other disease worsening|1
6093503|NCT00710762|9706617|FG000|Overall Study|Other Adverse Event|7
6093504|NCT00710762|9706618|FG001|Overall Study|Other Adverse Event|7
6093505|NCT00710762|9706617|FG000|Overall Study|Lost to Follow-up|1
6093506|NCT00710762|9706618|FG001|Overall Study|Lost to Follow-up|0
6093507|NCT00710762|9706617|FG000|Overall Study|Reason other than listed above|2
6093508|NCT00710762|9706618|FG001|Overall Study|Reason other than listed above|2
6093509|NCT00710866|9706644|FG000|Overall Study|Protocol Violation|5
6093510|NCT00710866|9706645|FG001|Overall Study|Protocol Violation|4
6093511|NCT00710866|9706644|FG000|Overall Study|Withdrawal by Subject|2
6093512|NCT00710866|9706645|FG001|Overall Study|Withdrawal by Subject|1
6093513|NCT00710866|9706644|FG000|Overall Study|Lost to Follow-up|1
6093514|NCT00710866|9706645|FG001|Overall Study|Lost to Follow-up|0
6093515|NCT00710866|9706644|FG000|Overall Study|Failed to meet eligibility|1
6093516|NCT00710866|9706645|FG001|Overall Study|Failed to meet eligibility|1
6093517|NCT00710879|9706653|FG000|Overall Study|Lost to Follow-up|2
6093518|NCT00710879|9706654|FG001|Overall Study|Lost to Follow-up|1
6093519|NCT00710879|9706653|FG000|Overall Study|Protocol Violation|0
6093520|NCT00710879|9706654|FG001|Overall Study|Protocol Violation|3
6202803|NCT01506609|9863180|FG004|Overall Study|Progressive Disease per Protocol|57
6202804|NCT01506609|9863181|FG005|Overall Study|Progressive Disease per Protocol|74
6202805|NCT01506609|9863176|FG000|Overall Study|Other, Not Specified|0
6202806|NCT01506609|9863177|FG001|Overall Study|Other, Not Specified|0
6202807|NCT01506609|9863178|FG002|Overall Study|Other, Not Specified|0
6202808|NCT01506609|9863179|FG003|Overall Study|Other, Not Specified|10
6202809|NCT01506609|9863180|FG004|Overall Study|Other, Not Specified|7
6202810|NCT01506609|9863181|FG005|Overall Study|Other, Not Specified|3
6202811|NCT01506609|9863176|FG000|Overall Study|Missing / Unknown Reason|1
6202812|NCT01506609|9863177|FG001|Overall Study|Missing / Unknown Reason|0
6202813|NCT01506609|9863178|FG002|Overall Study|Missing / Unknown Reason|1
6202814|NCT01506609|9863179|FG003|Overall Study|Missing / Unknown Reason|4
6202815|NCT01506609|9863180|FG004|Overall Study|Missing / Unknown Reason|4
6202816|NCT01506609|9863181|FG005|Overall Study|Missing / Unknown Reason|2
6202817|NCT01506726|9863194|FG000|Overall Study|Adverse Event|1
6202818|NCT01506726|9863195|FG001|Overall Study|Adverse Event|2
6202819|NCT01506882|9863203|FG000|Overall Study|Lack of Efficacy|4
6202820|NCT01506882|9863204|FG001|Overall Study|Lack of Efficacy|3
6202821|NCT01506882|9863203|FG000|Overall Study|Lost to Follow-up|1
6202822|NCT01506882|9863204|FG001|Overall Study|Lost to Follow-up|0
6202823|NCT01506882|9863203|FG000|Overall Study|Withdrawal by Subject|9
6202824|NCT01506882|9863204|FG001|Overall Study|Withdrawal by Subject|3
6202825|NCT01506882|9863203|FG000|Overall Study|SAE, non-fatal|2
6202826|NCT01506882|9863204|FG001|Overall Study|SAE, non-fatal|0
6202827|NCT01506882|9863203|FG000|Overall Study|AE, non-serious non-fatal|3
6202828|NCT01506882|9863204|FG001|Overall Study|AE, non-serious non-fatal|1
6202829|NCT01506882|9863203|FG000|Overall Study|SAE,non-fatal+AE,non-serious non-fatal|1
6202830|NCT01506882|9863204|FG001|Overall Study|SAE,non-fatal+AE,non-serious non-fatal|0
6202831|NCT01506882|9863203|FG000|Overall Study|Other Reason|2
6202832|NCT01506882|9863204|FG001|Overall Study|Other Reason|0
6060156|NCT00483002|9660778|FG000|Overall Study|Lack of Efficacy|555
6060157|NCT00483002|9660778|FG000|Overall Study|Lost to Follow-up|962
6060158|NCT00483002|9660778|FG000|Overall Study|Other|2
6060159|NCT00483002|9660778|FG000|Overall Study|Other|967
6202833|NCT01506908|9863214|FG000|Overall Study|Adverse Event|1
6202834|NCT01506908|9863215|FG001|Overall Study|Adverse Event|0
6202835|NCT01506947|9863223|FG000|Overall Study|Lost to Follow-up|7
6202836|NCT01506947|9863223|FG000|Overall Study|Adverse Event|5
6202837|NCT01506947|9863223|FG000|Overall Study|Death|1
6202838|NCT01506947|9863223|FG000|Overall Study|Did Not Meet Eligibility Criteria|3
6060160|NCT00483041|9660784|FG000|Overall Study|ABNORMAL LAB DATA AT SCREENING|0
6060161|NCT00483041|9660785|FG001|Overall Study|ABNORMAL LAB DATA AT SCREENING|1
6060162|NCT00483184|9660794|FG000|Overall Study|Withdrawal by Subject|2
6060163|NCT00483184|9660795|FG001|Overall Study|Withdrawal by Subject|2
6060164|NCT00483184|9660796|FG002|Overall Study|Withdrawal by Subject|0
6060165|NCT00483184|9660794|FG000|Overall Study|Lost to Follow-up|1
6060166|NCT00483184|9660795|FG001|Overall Study|Lost to Follow-up|0
6060167|NCT00483184|9660796|FG002|Overall Study|Lost to Follow-up|0
6060168|NCT00483184|9660794|FG000|Overall Study|Adverse Event|1
6060169|NCT00483184|9660795|FG001|Overall Study|Adverse Event|2
6060170|NCT00483184|9660796|FG002|Overall Study|Adverse Event|2
6060171|NCT00483184|9660794|FG000|Overall Study|Protocol Violation|1
6060172|NCT00483184|9660795|FG001|Overall Study|Protocol Violation|0
6060173|NCT00483184|9660796|FG002|Overall Study|Protocol Violation|1
6093521|NCT00711009|9706696|FG000|Overall Study|Adverse Event/HIV-Related Event|4
6093522|NCT00711009|9706697|FG001|Overall Study|Adverse Event/HIV-Related Event|5
6093523|NCT00711009|9706696|FG000|Overall Study|Withdrawal by Subject|4
6093524|NCT00711009|9706697|FG001|Overall Study|Withdrawal by Subject|2
6093525|NCT00711009|9706696|FG000|Overall Study|Lost to Follow-up|3
6093526|NCT00711009|9706697|FG001|Overall Study|Lost to Follow-up|9
6093527|NCT00711009|9706696|FG000|Overall Study|Participant Noncompliant|0
6093528|NCT00711009|9706697|FG001|Overall Study|Participant Noncompliant|1
6093529|NCT00711009|9706696|FG000|Overall Study|Virologic Failure|2
6093530|NCT00711009|9706697|FG001|Overall Study|Virologic Failure|1
6093531|NCT00711009|9706696|FG000|Overall Study|Pregnancy|1
6093532|NCT00711009|9706697|FG001|Overall Study|Pregnancy|0
6093533|NCT00711009|9706696|FG000|Overall Study|Site closing|0
6093534|NCT00711009|9706697|FG001|Overall Study|Site closing|1
6093535|NCT00711009|9706696|FG000|Overall Study|Dose adjustment|1
6093536|NCT00711009|9706697|FG001|Overall Study|Dose adjustment|0
6093537|NCT00711100|9706707|FG000|Overall Study|Lack of Efficacy|5
6093538|NCT00711100|9706707|FG000|Overall Study|Withdrawal by Subject|8
6093539|NCT00711113|9706723|FG000|Overall Study|Lost to Follow-up|9
6093540|NCT00711113|9706723|FG000|Overall Study|Implant lost|2
6093541|NCT00711191|9706730|FG000|Overall Study|Adverse Event|1
6093542|NCT00711191|9706731|FG001|Overall Study|Adverse Event|1
6093543|NCT00711191|9706732|FG002|Overall Study|Adverse Event|2
6093544|NCT00711191|9706730|FG000|Overall Study|Objective progression or relapse|2
6093545|NCT00711191|9706731|FG001|Overall Study|Objective progression or relapse|3
6093546|NCT00711191|9706732|FG002|Overall Study|Objective progression or relapse|7
6093547|NCT00711191|9706730|FG000|Overall Study|Withdrawal by Subject|0
6093548|NCT00711191|9706731|FG001|Overall Study|Withdrawal by Subject|1
6093549|NCT00711191|9706732|FG002|Overall Study|Withdrawal by Subject|3
6093550|NCT00711243|9706749|FG000|Registed and Started Treatment|Withdrawal by Subject|0
6093551|NCT00711243|9706750|FG001|Registed and Started Treatment|Withdrawal by Subject|0
6093552|NCT00711243|9706751|FG002|Registed and Started Treatment|Withdrawal by Subject|0
6093553|NCT00711243|9706752|FG003|Registed and Started Treatment|Withdrawal by Subject|0
6093554|NCT00711243|9706753|FG004|Registed and Started Treatment|Withdrawal by Subject|0
6093555|NCT00711243|9706754|FG005|Registed and Started Treatment|Withdrawal by Subject|1
6093556|NCT00711243|9706749|FG000|Reached First Response/4 Cycles|Death|0
6093557|NCT00711243|9706750|FG001|Reached First Response/4 Cycles|Death|0
6093558|NCT00711243|9706751|FG002|Reached First Response/4 Cycles|Death|0
6093559|NCT00711243|9706752|FG003|Reached First Response/4 Cycles|Death|0
6093560|NCT00711243|9706753|FG004|Reached First Response/4 Cycles|Death|0
6093561|NCT00711243|9706754|FG005|Reached First Response/4 Cycles|Death|2
6093562|NCT00711243|9706749|FG000|Reached First Response/4 Cycles|Progressive disease|0
6093563|NCT00711243|9706750|FG001|Reached First Response/4 Cycles|Progressive disease|0
6093564|NCT00711243|9706751|FG002|Reached First Response/4 Cycles|Progressive disease|0
6093565|NCT00711243|9706752|FG003|Reached First Response/4 Cycles|Progressive disease|1
6093566|NCT00711243|9706753|FG004|Reached First Response/4 Cycles|Progressive disease|0
6093567|NCT00711243|9706754|FG005|Reached First Response/4 Cycles|Progressive disease|0
6093568|NCT00711243|9706749|FG000|Treated Cycle 5 After First Response|Progressive disease|1
6093569|NCT00711243|9706750|FG001|Treated Cycle 5 After First Response|Progressive disease|2
6093570|NCT00711243|9706751|FG002|Treated Cycle 5 After First Response|Progressive disease|0
6093571|NCT00711243|9706752|FG003|Treated Cycle 5 After First Response|Progressive disease|0
6093572|NCT00711243|9706753|FG004|Treated Cycle 5 After First Response|Progressive disease|1
6093573|NCT00711243|9706754|FG005|Treated Cycle 5 After First Response|Progressive disease|1
6093574|NCT00711243|9706749|FG000|Treated Cycle 5 After First Response|Death|0
6093575|NCT00711243|9706750|FG001|Treated Cycle 5 After First Response|Death|0
6093576|NCT00711243|9706751|FG002|Treated Cycle 5 After First Response|Death|0
6093577|NCT00711243|9706752|FG003|Treated Cycle 5 After First Response|Death|0
6093578|NCT00711243|9706753|FG004|Treated Cycle 5 After First Response|Death|0
6093579|NCT00711243|9706754|FG005|Treated Cycle 5 After First Response|Death|2
6093580|NCT00711243|9706749|FG000|Treated Cycle 5 After First Response|Decline in performance status|0
6093581|NCT00711243|9706750|FG001|Treated Cycle 5 After First Response|Decline in performance status|0
6093582|NCT00711243|9706751|FG002|Treated Cycle 5 After First Response|Decline in performance status|0
6093583|NCT00711243|9706752|FG003|Treated Cycle 5 After First Response|Decline in performance status|0
6060174|NCT00483327|9660821|FG000|Overall Study|Adverse Event|1
6060175|NCT00483327|9660821|FG000|Overall Study|Withdrawal by Subject|3
6060176|NCT00483327|9660821|FG000|Overall Study|Lost to Follow-up|4
6060177|NCT00483327|9660821|FG000|Overall Study|Patient Non Compliance|2
6060178|NCT00483379|9660829|FG000|Treatment Period|Adverse Event|1
6060179|NCT00483379|9660830|FG001|Treatment Period|Adverse Event|0
6060180|NCT00483379|9660829|FG000|Treatment Period|Withdrawal by Subject|1
6060181|NCT00483379|9660830|FG001|Treatment Period|Withdrawal by Subject|0
6060182|NCT00483405|9660838|FG000|Overall Study|Adverse Event|8
6060183|NCT00483405|9660838|FG000|Overall Study|Lack of Efficacy|14
6060184|NCT00483405|9660838|FG000|Overall Study|Death|3
6060185|NCT00483405|9660838|FG000|Overall Study|Withdrawal by Subject|2
6060186|NCT00483405|9660838|FG000|Overall Study|Other complicating disease|1
6060187|NCT00483548|9660860|FG000|Overall Study|Randomized; not treated with study drug|1
6060188|NCT00483548|9660861|FG001|Overall Study|Randomized; not treated with study drug|3
6060189|NCT00483548|9660860|FG000|Overall Study|Adverse Event|25
6060190|NCT00483548|9660861|FG001|Overall Study|Adverse Event|14
6060191|NCT00483548|9660860|FG000|Overall Study|Laboratory abnormality|1
6060192|NCT00483548|9660861|FG001|Overall Study|Laboratory abnormality|2
6060193|NCT00483548|9660860|FG000|Overall Study|Lack of Efficacy|4
6060194|NCT00483548|9660861|FG001|Overall Study|Lack of Efficacy|8
6060195|NCT00483548|9660860|FG000|Overall Study|Protocol Violation|11
6060196|NCT00483548|9660861|FG001|Overall Study|Protocol Violation|7
6060197|NCT00483548|9660860|FG000|Overall Study|Pregnancy|1
6060198|NCT00483548|9660861|FG001|Overall Study|Pregnancy|0
6060199|NCT00483548|9660860|FG000|Overall Study|Protocol required discontinuation|6
6060200|NCT00483548|9660861|FG001|Overall Study|Protocol required discontinuation|6
6060201|NCT00483548|9660860|FG000|Overall Study|Unable to comply with protocol schedule|1
6060202|NCT00483548|9660861|FG001|Overall Study|Unable to comply with protocol schedule|0
6060203|NCT00483548|9660860|FG000|Overall Study|Non-compliance with medication|2
6060204|NCT00483548|9660861|FG001|Overall Study|Non-compliance with medication|0
6060205|NCT00483548|9660860|FG000|Overall Study|Lost to Follow-up|3
6060206|NCT00483548|9660861|FG001|Overall Study|Lost to Follow-up|4
6060207|NCT00483548|9660860|FG000|Overall Study|Withdrawal by Subject|5
6060208|NCT00483548|9660861|FG001|Overall Study|Withdrawal by Subject|2
6060209|NCT00483574|9660873|FG000|Overall Study|Adverse Event|6
6060210|NCT00483574|9660874|FG001|Overall Study|Adverse Event|0
6060211|NCT00483574|9660873|FG000|Overall Study|Protocol Violation|28
6060212|NCT00483574|9660874|FG001|Overall Study|Protocol Violation|9
6060213|NCT00483574|9660873|FG000|Overall Study|Lost to Follow-up|16
6060214|NCT00483574|9660874|FG001|Overall Study|Lost to Follow-up|4
6060215|NCT00483574|9660873|FG000|Overall Study|Withdrawal by Subject|52
6060216|NCT00483574|9660874|FG001|Overall Study|Withdrawal by Subject|0
6060217|NCT00483652|9660884|FG000|Double-blind Treatment Period|Protocol Violation|2
6060218|NCT00483652|9660885|FG001|Double-blind Treatment Period|Protocol Violation|1
6060219|NCT00483652|9660884|FG000|Double-blind Treatment Period|Adverse Event|3
6060220|NCT00483652|9660885|FG001|Double-blind Treatment Period|Adverse Event|4
6060221|NCT00483652|9660884|FG000|Double-blind Treatment Period|Protocol inclusion deviation|1
6060222|NCT00483652|9660885|FG001|Double-blind Treatment Period|Protocol inclusion deviation|0
6060223|NCT00483652|9660884|FG000|Double-blind Treatment Period|Withdrawal due to AE before study began|1
6060224|NCT00483652|9660885|FG001|Double-blind Treatment Period|Withdrawal due to AE before study began|0
6060225|NCT00483704|9660894|FG000|Randomization|Withdrawal by Subject|19
6060226|NCT00483704|9660895|FG001|Randomization|Withdrawal by Subject|28
6060227|NCT00483704|9660896|FG002|Randomization|Withdrawal by Subject|18
6060228|NCT00483704|9660894|FG000|Randomization|Protocol Violation|14
6060229|NCT00483704|9660895|FG001|Randomization|Protocol Violation|25
6060230|NCT00483704|9660896|FG002|Randomization|Protocol Violation|22
6060231|NCT00483704|9660894|FG000|Randomization|Lost to Follow-up|14
6060232|NCT00483704|9660895|FG001|Randomization|Lost to Follow-up|14
6060233|NCT00483704|9660896|FG002|Randomization|Lost to Follow-up|19
6060234|NCT00483704|9660894|FG000|Randomization|Pregnancy|1
6060235|NCT00483704|9660895|FG001|Randomization|Pregnancy|0
6060236|NCT00483704|9660896|FG002|Randomization|Pregnancy|0
6060237|NCT00483704|9660894|FG000|Randomization|Physician Decision|2
6093584|NCT00711243|9706753|FG004|Treated Cycle 5 After First Response|Decline in performance status|0
6093585|NCT00711243|9706754|FG005|Treated Cycle 5 After First Response|Decline in performance status|1
6093586|NCT00711243|9706749|FG000|Follow up Every 3 Months Until Death|Lost to Follow-up|0
6060238|NCT00483704|9660895|FG001|Randomization|Physician Decision|4
6060239|NCT00483704|9660896|FG002|Randomization|Physician Decision|0
6060240|NCT00483704|9660894|FG000|Randomization|Progressive disease|0
6060241|NCT00483704|9660895|FG001|Randomization|Progressive disease|0
6060242|NCT00483704|9660896|FG002|Randomization|Progressive disease|1
6060243|NCT00483704|9660894|FG000|Randomization|Lack of qualifying migraines|21
6060244|NCT00483704|9660895|FG001|Randomization|Lack of qualifying migraines|25
6060245|NCT00483704|9660896|FG002|Randomization|Lack of qualifying migraines|31
6060246|NCT00483704|9660894|FG000|Treatment|Lack of qualifying migraines|101
6060247|NCT00483704|9660895|FG001|Treatment|Lack of qualifying migraines|99
6060248|NCT00483704|9660896|FG002|Treatment|Lack of qualifying migraines|116
6060249|NCT00483704|9660894|FG000|Treatment|Adverse Event|3
6060250|NCT00483704|9660895|FG001|Treatment|Adverse Event|5
6060251|NCT00483704|9660896|FG002|Treatment|Adverse Event|4
6060252|NCT00483704|9660894|FG000|Treatment|Withdrawal by Subject|16
6060253|NCT00483704|9660895|FG001|Treatment|Withdrawal by Subject|12
6060254|NCT00483704|9660896|FG002|Treatment|Withdrawal by Subject|21
6060255|NCT00483704|9660894|FG000|Treatment|Protocol Violation|6
6060256|NCT00483704|9660895|FG001|Treatment|Protocol Violation|3
6060257|NCT00483704|9660896|FG002|Treatment|Protocol Violation|5
6060258|NCT00483704|9660894|FG000|Treatment|Lost to Follow-up|2
6060259|NCT00483704|9660895|FG001|Treatment|Lost to Follow-up|7
6060260|NCT00483704|9660896|FG002|Treatment|Lost to Follow-up|5
6060261|NCT00483704|9660894|FG000|Treatment|Lack of Efficacy|1
6060262|NCT00483704|9660895|FG001|Treatment|Lack of Efficacy|1
6060263|NCT00483704|9660896|FG002|Treatment|Lack of Efficacy|1
6060264|NCT00483704|9660894|FG000|Treatment|Pregnancy|0
6060265|NCT00483704|9660895|FG001|Treatment|Pregnancy|1
6060266|NCT00483704|9660896|FG002|Treatment|Pregnancy|0
6060267|NCT00483704|9660894|FG000|Treatment|Physician Decision|0
6060268|NCT00483704|9660895|FG001|Treatment|Physician Decision|1
6060269|NCT00483704|9660896|FG002|Treatment|Physician Decision|4
6060270|NCT00483717|9660909|FG000|Overall Study|Protocol Violation|5
6060271|NCT00483717|9660910|FG001|Overall Study|Protocol Violation|7
6060272|NCT00483717|9660909|FG000|Overall Study|Time of dosing missing|1
6060273|NCT00483717|9660910|FG001|Overall Study|Time of dosing missing|1
6060274|NCT00483717|9660909|FG000|Overall Study|No treatment for migraine|16
6060275|NCT00483717|9660910|FG001|Overall Study|No treatment for migraine|13
6060276|NCT00483717|9660909|FG000|Overall Study|Lost to Follow-up|1
6060277|NCT00483717|9660910|FG001|Overall Study|Lost to Follow-up|0
6060278|NCT00483717|9660909|FG000|Overall Study|Withdrawal by Subject|1
6060279|NCT00483717|9660910|FG001|Overall Study|Withdrawal by Subject|0
6060280|NCT00483756|9660919|FG000|Overall Study|Death|2
6060281|NCT00483756|9660920|FG001|Overall Study|Death|0
6060282|NCT00483756|9660921|FG002|Overall Study|Death|1
6060283|NCT00483756|9660919|FG000|Overall Study|Adverse Event|19
6060284|NCT00483756|9660920|FG001|Overall Study|Adverse Event|38
6060285|NCT00483756|9660921|FG002|Overall Study|Adverse Event|40
6093587|NCT00711243|9706750|FG001|Follow up Every 3 Months Until Death|Lost to Follow-up|0
6093588|NCT00711243|9706751|FG002|Follow up Every 3 Months Until Death|Lost to Follow-up|0
6093589|NCT00711243|9706752|FG003|Follow up Every 3 Months Until Death|Lost to Follow-up|0
6093590|NCT00711243|9706753|FG004|Follow up Every 3 Months Until Death|Lost to Follow-up|0
6093591|NCT00711243|9706754|FG005|Follow up Every 3 Months Until Death|Lost to Follow-up|2
6093592|NCT00711412|9706779|FG000|Induction Treatment|Death|2
6093593|NCT00711412|9706779|FG000|Induction Treatment|Adverse Event|1
6093594|NCT00711412|9706779|FG000|Induction Treatment|Other|1
6093595|NCT00711412|9706779|FG000|Evaluated for Combination Treatment|Adverse Event|2
6093596|NCT00711412|9706779|FG000|Evaluated for Combination Treatment|Death|1
6093597|NCT00711412|9706779|FG000|Evaluated for Combination Treatment|Withdrawal by Subject|1
6093598|NCT00711412|9706779|FG000|Evaluated for Combination Treatment|Progressive disease|2
6093599|NCT00711412|9706779|FG000|Combination Treatment|Progressive Disease|1
6093600|NCT00711412|9706779|FG000|Evaluation for Response and Surgery|Progressive Disease|2
6093601|NCT00711412|9706779|FG000|Evaluation for Response and Surgery|Too high risk for surgery|2
6093602|NCT00711412|9706779|FG000|Evaluation for Response and Surgery|Withdrawal by Subject|1
6093603|NCT00711412|9706779|FG000|Evaluation for Response and Surgery|Death|1
6093604|NCT00711412|9706779|FG000|Survival Follow up Until Death|Other|12
6093605|NCT00711425|9706784|FG000|Overall Study|Protocol Violation|1
6093606|NCT00711425|9706784|FG000|Overall Study|Death|2
6093607|NCT00711425|9706784|FG000|Overall Study|Lost to Follow-up|1
6093608|NCT00711477|9706800|FG000|Overall Study|Adverse Event|3
6093609|NCT00711477|9706801|FG001|Overall Study|Adverse Event|1
6093610|NCT00711477|9706800|FG000|Overall Study|Lost to Follow-up|0
6093611|NCT00711477|9706801|FG001|Overall Study|Lost to Follow-up|1
6093612|NCT00711477|9706800|FG000|Overall Study|Noncompliance|0
6093613|NCT00711477|9706801|FG001|Overall Study|Noncompliance|1
6093614|NCT00711516|9706816|FG000|Overall Study|Adverse Event|1
6093615|NCT00711516|9706817|FG001|Overall Study|Adverse Event|1
6093616|NCT00711516|9706816|FG000|Overall Study|Withdrawal by Subject|0
6093617|NCT00711516|9706817|FG001|Overall Study|Withdrawal by Subject|1
6093618|NCT00711516|9706816|FG000|Overall Study|Protocol Violation|0
6093619|NCT00711516|9706817|FG001|Overall Study|Protocol Violation|1
6093620|NCT00711529|9706825|FG000|Overall Study|Protocol Violation|2
6093621|NCT00711529|9706826|FG001|Overall Study|Protocol Violation|0
6093622|NCT00711529|9706825|FG000|Overall Study|Withdrawal by Subject|2
6093623|NCT00711529|9706826|FG001|Overall Study|Withdrawal by Subject|6
6093624|NCT00711594|9706836|FG000|Overall Study|Progressive disease|2
6093625|NCT00711594|9706837|FG001|Overall Study|Progressive disease|2
6093626|NCT00711594|9706838|FG002|Overall Study|Progressive disease|6
6093627|NCT00711594|9706839|FG003|Overall Study|Progressive disease|44
6093628|NCT00711594|9706836|FG000|Overall Study|Other Adverse Event|1
6093629|NCT00711594|9706837|FG001|Overall Study|Other Adverse Event|0
6093630|NCT00711594|9706838|FG002|Overall Study|Other Adverse Event|0
6093631|NCT00711594|9706839|FG003|Overall Study|Other Adverse Event|16
6093632|NCT00711594|9706836|FG000|Overall Study|Withdrawal by Subject|0
6093633|NCT00711594|9706837|FG001|Overall Study|Withdrawal by Subject|1
6093634|NCT00711594|9706838|FG002|Overall Study|Withdrawal by Subject|0
6093635|NCT00711594|9706839|FG003|Overall Study|Withdrawal by Subject|2
6060286|NCT00483756|9660919|FG000|Overall Study|Lack of Efficacy|1
6060287|NCT00483756|9660920|FG001|Overall Study|Lack of Efficacy|0
6060288|NCT00483756|9660921|FG002|Overall Study|Lack of Efficacy|0
6060289|NCT00483756|9660919|FG000|Overall Study|Lost to Follow-up|3
6060290|NCT00483756|9660920|FG001|Overall Study|Lost to Follow-up|1
6060291|NCT00483756|9660921|FG002|Overall Study|Lost to Follow-up|0
6060292|NCT00483756|9660919|FG000|Overall Study|Withdrawal by Subject|5
6060293|NCT00483756|9660920|FG001|Overall Study|Withdrawal by Subject|3
6060294|NCT00483756|9660921|FG002|Overall Study|Withdrawal by Subject|4
6060295|NCT00483756|9660919|FG000|Overall Study|Other|2
6060296|NCT00483756|9660920|FG001|Overall Study|Other|4
6060297|NCT00483756|9660921|FG002|Overall Study|Other|3
6060298|NCT00483756|9660919|FG000|Overall Study|Randomized, Not Treated|1
6060299|NCT00483756|9660920|FG001|Overall Study|Randomized, Not Treated|4
6060300|NCT00483756|9660921|FG002|Overall Study|Randomized, Not Treated|4
6060301|NCT00483938|9660936|FG000|Overall Study|Protocol Violation|0
6060302|NCT00483938|9660937|FG001|Overall Study|Protocol Violation|0
6060303|NCT00483938|9660938|FG002|Overall Study|Protocol Violation|0
6060304|NCT00483938|9660939|FG003|Overall Study|Protocol Violation|0
6060305|NCT00483938|9660940|FG004|Overall Study|Protocol Violation|0
6060306|NCT00483938|9660941|FG005|Overall Study|Protocol Violation|0
6060307|NCT00483938|9660942|FG006|Overall Study|Protocol Violation|3
6060308|NCT00483938|9660936|FG000|Overall Study|Withdrawal by Subject|1
6060309|NCT00483938|9660937|FG001|Overall Study|Withdrawal by Subject|6
6093636|NCT00711646|9706853|FG000|Overall Study|Adverse Event|6
6093637|NCT00711646|9706854|FG001|Overall Study|Adverse Event|1
6093638|NCT00711646|9706853|FG000|Overall Study|Withdrawal by Subject|4
6093639|NCT00711646|9706854|FG001|Overall Study|Withdrawal by Subject|0
6093640|NCT00711646|9706853|FG000|Overall Study|Protocol Violation|0
6093641|NCT00711646|9706854|FG001|Overall Study|Protocol Violation|1
6093642|NCT00711646|9706853|FG000|Overall Study|Lost to Follow-up|1
6093643|NCT00711646|9706854|FG001|Overall Study|Lost to Follow-up|0
6093644|NCT00711646|9706853|FG000|Overall Study|administrative decision|0
6093645|NCT00711646|9706854|FG001|Overall Study|administrative decision|1
6093646|NCT00711646|9706853|FG000|Overall Study|patient non-compliance|1
6093647|NCT00711646|9706854|FG001|Overall Study|patient non-compliance|0
6093648|NCT00711802|9706879|FG000|Overall Study|Not treated (no further detail)|2
6093649|NCT00711802|9706880|FG001|Overall Study|Not treated (no further detail)|1
6093650|NCT00711802|9706881|FG002|Overall Study|Not treated (no further detail)|2
6093651|NCT00711802|9706882|FG003|Overall Study|Not treated (no further detail)|0
6093652|NCT00711802|9706883|FG004|Overall Study|Not treated (no further detail)|2
6093653|NCT00711802|9706884|FG005|Overall Study|Not treated (no further detail)|0
6202839|NCT01506960|9863229|FG000|Overall Study|Did not meet angiographic criteria|47
6202840|NCT01507051|9863239|FG000|Overall Study|Withdrawal by Subject|1
6202841|NCT01507051|9863240|FG001|Overall Study|Withdrawal by Subject|3
6202842|NCT01507051|9863241|FG002|Overall Study|Withdrawal by Subject|1
6202843|NCT01507051|9863242|FG003|Overall Study|Withdrawal by Subject|6
6202844|NCT01507051|9863239|FG000|Overall Study|Physician Decision|0
6202845|NCT01507051|9863240|FG001|Overall Study|Physician Decision|0
6202846|NCT01507051|9863241|FG002|Overall Study|Physician Decision|0
6202847|NCT01507051|9863242|FG003|Overall Study|Physician Decision|1
6202848|NCT01507051|9863239|FG000|Overall Study|Adverse Event|1
6202849|NCT01507051|9863240|FG001|Overall Study|Adverse Event|0
6202850|NCT01507051|9863241|FG002|Overall Study|Adverse Event|0
6202851|NCT01507051|9863242|FG003|Overall Study|Adverse Event|0
6202852|NCT01507090|9863252|FG000|Overall Study|incomplete dataset|18
6202853|NCT01507246|9863300|FG000|Overall Study|Required different surgical procedures|2
6202854|NCT01507246|9863301|FG001|Overall Study|Required different surgical procedures|1
6202855|NCT01507298|9863312|FG000|Overall Study|Protocol Violation|0
6202856|NCT01507298|9863313|FG001|Overall Study|Protocol Violation|6
6202857|NCT01507662|9863335|FG000|Overall Study|Death|26
6202858|NCT01507662|9863336|FG001|Overall Study|Death|18
6202859|NCT01507662|9863335|FG000|Overall Study|Withdrawal by Subject|290
6202860|NCT01507662|9863336|FG001|Overall Study|Withdrawal by Subject|287
6202861|NCT01507662|9863335|FG000|Overall Study|Lost to Follow-up|498
6202862|NCT01507662|9863336|FG001|Overall Study|Lost to Follow-up|523
6202863|NCT01507662|9863335|FG000|Overall Study|Proxy interview done|2
6202864|NCT01507662|9863336|FG001|Overall Study|Proxy interview done|3
6202865|NCT01507831|9863364|FG000|Overall Study|Randomized but not treated|0
6202866|NCT01507831|9863365|FG001|Overall Study|Randomized but not treated|3
6202867|NCT01507831|9863364|FG000|Overall Study|Adverse Event|48
6202868|NCT01507831|9863365|FG001|Overall Study|Adverse Event|113
6202869|NCT01507831|9863364|FG000|Overall Study|Death|6
6202870|NCT01507831|9863365|FG001|Overall Study|Death|2
6202871|NCT01507831|9863364|FG000|Overall Study|Poor compliance to protocol|38
6202872|NCT01507831|9863365|FG001|Overall Study|Poor compliance to protocol|60
6202873|NCT01507831|9863364|FG000|Overall Study|Physician Decision|0
6202874|NCT01507831|9863365|FG001|Overall Study|Physician Decision|4
6060310|NCT00483938|9660938|FG002|Overall Study|Withdrawal by Subject|0
6060311|NCT00483938|9660939|FG003|Overall Study|Withdrawal by Subject|0
6060312|NCT00483938|9660940|FG004|Overall Study|Withdrawal by Subject|1
6060313|NCT00483938|9660941|FG005|Overall Study|Withdrawal by Subject|3
6060314|NCT00483938|9660942|FG006|Overall Study|Withdrawal by Subject|2
6202875|NCT01507831|9863364|FG000|Overall Study|Participant moved|5
6202876|NCT01507831|9863365|FG001|Overall Study|Participant moved|19
6060315|NCT00483938|9660936|FG000|Overall Study|Lost to Follow-up|1
6060316|NCT00483938|9660937|FG001|Overall Study|Lost to Follow-up|2
6060317|NCT00483938|9660938|FG002|Overall Study|Lost to Follow-up|0
6060318|NCT00483938|9660939|FG003|Overall Study|Lost to Follow-up|2
6060319|NCT00483938|9660940|FG004|Overall Study|Lost to Follow-up|1
6060320|NCT00483938|9660941|FG005|Overall Study|Lost to Follow-up|1
6060321|NCT00483938|9660942|FG006|Overall Study|Lost to Follow-up|3
6060322|NCT00483938|9660936|FG000|Overall Study|Death|0
6060323|NCT00483938|9660937|FG001|Overall Study|Death|2
6060324|NCT00483938|9660938|FG002|Overall Study|Death|0
6060325|NCT00483938|9660939|FG003|Overall Study|Death|0
6060326|NCT00483938|9660940|FG004|Overall Study|Death|0
6060327|NCT00483938|9660941|FG005|Overall Study|Death|0
6060328|NCT00483938|9660942|FG006|Overall Study|Death|0
6060329|NCT00483938|9660936|FG000|Overall Study|Other|3
6060330|NCT00483938|9660937|FG001|Overall Study|Other|9
6060331|NCT00483938|9660938|FG002|Overall Study|Other|0
6060332|NCT00483938|9660939|FG003|Overall Study|Other|4
6060333|NCT00483938|9660940|FG004|Overall Study|Other|0
6060334|NCT00483938|9660941|FG005|Overall Study|Other|4
6060335|NCT00483938|9660942|FG006|Overall Study|Other|32
6060336|NCT00484094|9660961|FG000|Overall Study|Discontinued|39
6060337|NCT00484094|9660961|FG000|Overall Study|Other|3
6060338|NCT00484159|9660968|FG000|Overall Study|Lost to Follow-up|1
6060339|NCT00484159|9660969|FG001|Overall Study|Lost to Follow-up|1
6060340|NCT00484159|9660970|FG002|Overall Study|Lost to Follow-up|0
6060341|NCT00484185|9660978|FG000|Overall Study|Lost to Follow-up|44
6060342|NCT00484185|9660978|FG000|Overall Study|Other|20
6060343|NCT00484185|9660978|FG000|Overall Study|Randomized but not treated|5
6060344|NCT00484185|9660978|FG000|Overall Study|Death|2
6060345|NCT00484198|9660986|FG000|Overall Study|Participant Withdrew Consent|12
6060346|NCT00484198|9660987|FG001|Overall Study|Participant Withdrew Consent|21
6060347|NCT00484198|9660988|FG002|Overall Study|Participant Withdrew Consent|47
6093654|NCT00711802|9706885|FG006|Overall Study|Not treated (no further detail)|0
6093655|NCT00711802|9706886|FG007|Overall Study|Not treated (no further detail)|0
6093656|NCT00711802|9706879|FG000|Overall Study|Adverse Event|0
6093657|NCT00711802|9706880|FG001|Overall Study|Adverse Event|0
6093658|NCT00711802|9706881|FG002|Overall Study|Adverse Event|0
6093659|NCT00711802|9706882|FG003|Overall Study|Adverse Event|0
6093660|NCT00711802|9706883|FG004|Overall Study|Adverse Event|1
6093661|NCT00711802|9706884|FG005|Overall Study|Adverse Event|1
6093662|NCT00711802|9706885|FG006|Overall Study|Adverse Event|0
6093663|NCT00711802|9706886|FG007|Overall Study|Adverse Event|0
6093664|NCT00711802|9706879|FG000|Overall Study|Microbiological failure|0
6093665|NCT00711802|9706880|FG001|Overall Study|Microbiological failure|1
6093666|NCT00711802|9706881|FG002|Overall Study|Microbiological failure|0
6093667|NCT00711802|9706882|FG003|Overall Study|Microbiological failure|0
6093668|NCT00711802|9706883|FG004|Overall Study|Microbiological failure|0
6093669|NCT00711802|9706884|FG005|Overall Study|Microbiological failure|1
6093670|NCT00711802|9706885|FG006|Overall Study|Microbiological failure|0
6093671|NCT00711802|9706886|FG007|Overall Study|Microbiological failure|0
6093672|NCT00711802|9706879|FG000|Overall Study|Protocol Violation|0
6093673|NCT00711802|9706880|FG001|Overall Study|Protocol Violation|0
6093674|NCT00711802|9706881|FG002|Overall Study|Protocol Violation|0
6093675|NCT00711802|9706882|FG003|Overall Study|Protocol Violation|1
6093676|NCT00711802|9706883|FG004|Overall Study|Protocol Violation|0
6093677|NCT00711802|9706884|FG005|Overall Study|Protocol Violation|0
6093678|NCT00711802|9706885|FG006|Overall Study|Protocol Violation|0
6093679|NCT00711802|9706886|FG007|Overall Study|Protocol Violation|0
6093680|NCT00711802|9706879|FG000|Overall Study|Physician Decision|0
6093681|NCT00711802|9706880|FG001|Overall Study|Physician Decision|2
6093682|NCT00711802|9706881|FG002|Overall Study|Physician Decision|0
6093683|NCT00711802|9706882|FG003|Overall Study|Physician Decision|0
6093684|NCT00711802|9706883|FG004|Overall Study|Physician Decision|0
6093685|NCT00711802|9706884|FG005|Overall Study|Physician Decision|0
6093686|NCT00711802|9706885|FG006|Overall Study|Physician Decision|0
6093687|NCT00711802|9706886|FG007|Overall Study|Physician Decision|0
6093688|NCT00711802|9706879|FG000|Overall Study|Withdrawal by Subject|0
6093689|NCT00711802|9706880|FG001|Overall Study|Withdrawal by Subject|1
6093690|NCT00711802|9706881|FG002|Overall Study|Withdrawal by Subject|0
6093691|NCT00711802|9706882|FG003|Overall Study|Withdrawal by Subject|1
6093692|NCT00711802|9706883|FG004|Overall Study|Withdrawal by Subject|0
6093693|NCT00711802|9706884|FG005|Overall Study|Withdrawal by Subject|0
6093694|NCT00711802|9706885|FG006|Overall Study|Withdrawal by Subject|0
6093695|NCT00711802|9706886|FG007|Overall Study|Withdrawal by Subject|0
6093696|NCT00711802|9706879|FG000|Overall Study|Lost to Follow-up|0
6093697|NCT00711802|9706880|FG001|Overall Study|Lost to Follow-up|0
6093698|NCT00711802|9706881|FG002|Overall Study|Lost to Follow-up|3
6093699|NCT00711802|9706882|FG003|Overall Study|Lost to Follow-up|1
6093700|NCT00711802|9706883|FG004|Overall Study|Lost to Follow-up|10
6093701|NCT00711802|9706884|FG005|Overall Study|Lost to Follow-up|6
6093702|NCT00711802|9706885|FG006|Overall Study|Lost to Follow-up|4
6060348|NCT00484198|9660989|FG003|Overall Study|Participant Withdrew Consent|59
6093703|NCT00711802|9706886|FG007|Overall Study|Lost to Follow-up|2
6093704|NCT00711802|9706879|FG000|Overall Study|Reason not reported|0
6093705|NCT00711802|9706880|FG001|Overall Study|Reason not reported|1
6093706|NCT00711802|9706881|FG002|Overall Study|Reason not reported|1
6060349|NCT00484198|9660986|FG000|Overall Study|Hyperglycemia Meeting Discontinuation Criteria|16
6060350|NCT00484198|9660987|FG001|Overall Study|Hyperglycemia Meeting Discontinuation Criteria|17
6060351|NCT00484198|9660988|FG002|Overall Study|Hyperglycemia Meeting Discontinuation Criteria|29
6060352|NCT00484198|9660989|FG003|Overall Study|Hyperglycemia Meeting Discontinuation Criteria|38
6060353|NCT00484198|9660986|FG000|Overall Study|Therapeutic failure/ lack of efficacy|3
6060354|NCT00484198|9660987|FG001|Overall Study|Therapeutic failure/ lack of efficacy|2
6060355|NCT00484198|9660988|FG002|Overall Study|Therapeutic failure/ lack of efficacy|6
6060356|NCT00484198|9660989|FG003|Overall Study|Therapeutic failure/ lack of efficacy|8
6060357|NCT00484198|9660986|FG000|Overall Study|Adverse Event|3
6060358|NCT00484198|9660987|FG001|Overall Study|Adverse Event|11
6093707|NCT00711802|9706882|FG003|Overall Study|Reason not reported|0
6093708|NCT00711802|9706883|FG004|Overall Study|Reason not reported|1
6093709|NCT00711802|9706884|FG005|Overall Study|Reason not reported|0
6060359|NCT00484198|9660988|FG002|Overall Study|Adverse Event|32
6060360|NCT00484198|9660989|FG003|Overall Study|Adverse Event|31
6060361|NCT00484198|9660986|FG000|Overall Study|Protocol Violation|0
6060362|NCT00484198|9660987|FG001|Overall Study|Protocol Violation|5
6060363|NCT00484198|9660988|FG002|Overall Study|Protocol Violation|6
6060364|NCT00484198|9660989|FG003|Overall Study|Protocol Violation|8
6060365|NCT00484198|9660986|FG000|Overall Study|Other|7
6060366|NCT00484198|9660987|FG001|Overall Study|Other|10
6060367|NCT00484198|9660988|FG002|Overall Study|Other|31
6060368|NCT00484198|9660989|FG003|Overall Study|Other|28
6060369|NCT00484289|9661007|FG000|Long Term Phase|Adverse Event|1
6060370|NCT00484289|9661008|FG001|Long Term Phase|Adverse Event|17
6060371|NCT00484289|9661009|FG002|Long Term Phase|Adverse Event|5
6060372|NCT00484289|9661007|FG000|Long Term Phase|Withdrawal by Subject|0
6060373|NCT00484289|9661008|FG001|Long Term Phase|Withdrawal by Subject|7
6060374|NCT00484289|9661009|FG002|Long Term Phase|Withdrawal by Subject|6
6060375|NCT00484289|9661007|FG000|Long Term Phase|Inadequate response|2
6060376|NCT00484289|9661008|FG001|Long Term Phase|Inadequate response|7
6093710|NCT00711802|9706885|FG006|Overall Study|Reason not reported|1
6093711|NCT00711802|9706886|FG007|Overall Study|Reason not reported|0
6093712|NCT00711880|9706922|FG000|Overall Study|Adverse Event|11
6093713|NCT00711880|9706923|FG001|Overall Study|Adverse Event|2
6093714|NCT00711880|9706922|FG000|Overall Study|Patient non-compliance|1
6093715|NCT00711880|9706923|FG001|Overall Study|Patient non-compliance|0
6093716|NCT00711880|9706922|FG000|Overall Study|Lack of Efficacy|1
6093717|NCT00711880|9706923|FG001|Overall Study|Lack of Efficacy|5
6093718|NCT00711958|9706931|FG000|Overall Study|Withdrawal by Subject|6
6093719|NCT00711958|9706932|FG001|Overall Study|Withdrawal by Subject|8
6093720|NCT00711958|9706931|FG000|Overall Study|Lack of Efficacy|3
6093721|NCT00711958|9706932|FG001|Overall Study|Lack of Efficacy|1
6093722|NCT00711958|9706931|FG000|Overall Study|Clinical deterioration|1
6093723|NCT00711958|9706932|FG001|Overall Study|Clinical deterioration|0
6093724|NCT00711958|9706931|FG000|Overall Study|Adverse Event|9
6093725|NCT00711958|9706932|FG001|Overall Study|Adverse Event|7
6093726|NCT00711958|9706931|FG000|Overall Study|Protocol Violation|1
6093727|NCT00711958|9706932|FG001|Overall Study|Protocol Violation|0
6093728|NCT00711958|9706931|FG000|Overall Study|Lost to Follow-up|2
6093729|NCT00711958|9706932|FG001|Overall Study|Lost to Follow-up|2
6093730|NCT00711958|9706931|FG000|Overall Study|Death|10
6093731|NCT00711958|9706932|FG001|Overall Study|Death|5
6093732|NCT00711958|9706931|FG000|Overall Study|Progression of disease|1
6093733|NCT00711958|9706932|FG001|Overall Study|Progression of disease|0
6093734|NCT00711971|9706941|FG000|Overall Study|Lost to Follow-up|3
6093735|NCT00711971|9706942|FG001|Overall Study|Lost to Follow-up|4
6093736|NCT00711971|9706943|FG002|Overall Study|Lost to Follow-up|1
6093737|NCT00712010|9706966|FG000|Washout (7 Days)|Withdrawal by Subject|1
6093738|NCT00712166|9706997|FG000|Overall Study|Noncompliance|0
6093739|NCT00712166|9706998|FG001|Overall Study|Noncompliance|1
6093740|NCT00712270|9707030|FG000|Overall Study|Withdrawal by Subject|11
6093741|NCT00712270|9707030|FG000|Overall Study|Screen Failure|3
6093742|NCT00712335|9707084|FG000|Overall Study|Withdrawal by Subject|0
6093743|NCT00712335|9707085|FG001|Overall Study|Withdrawal by Subject|7
6093744|NCT00712335|9707086|FG002|Overall Study|Withdrawal by Subject|2
6093745|NCT00712335|9707087|FG003|Overall Study|Withdrawal by Subject|3
6093746|NCT00712335|9707088|FG004|Overall Study|Withdrawal by Subject|0
6093747|NCT00712335|9707084|FG000|Overall Study|Lost to Follow-up|2
6093748|NCT00712335|9707085|FG001|Overall Study|Lost to Follow-up|5
6093749|NCT00712335|9707086|FG002|Overall Study|Lost to Follow-up|0
6093750|NCT00712335|9707087|FG003|Overall Study|Lost to Follow-up|1
6093751|NCT00712335|9707088|FG004|Overall Study|Lost to Follow-up|0
6060377|NCT00484289|9661009|FG002|Long Term Phase|Inadequate response|4
6060378|NCT00484289|9661007|FG000|Long Term Phase|Other Reason|0
6060379|NCT00484289|9661008|FG001|Long Term Phase|Other Reason|5
6060380|NCT00484289|9661009|FG002|Long Term Phase|Other Reason|1
6093752|NCT00712335|9707084|FG000|Overall Study|Protocol Violation|1
6093753|NCT00712335|9707085|FG001|Overall Study|Protocol Violation|2
6093754|NCT00712335|9707086|FG002|Overall Study|Protocol Violation|1
6093755|NCT00712335|9707087|FG003|Overall Study|Protocol Violation|0
6093756|NCT00712335|9707088|FG004|Overall Study|Protocol Violation|0
6093757|NCT00712335|9707084|FG000|Overall Study|Lack of Efficacy|0
6093758|NCT00712335|9707085|FG001|Overall Study|Lack of Efficacy|0
6060381|NCT00484289|9661007|FG000|Post Marketing Phase|Adverse Event|0
6060382|NCT00484289|9661008|FG001|Post Marketing Phase|Adverse Event|1
6060383|NCT00484289|9661009|FG002|Post Marketing Phase|Adverse Event|0
6060384|NCT00484315|9661020|FG000|12-Month Clinical Follow-up|Death|6
6060385|NCT00484315|9661021|FG001|12-Month Clinical Follow-up|Death|2
6060386|NCT00484315|9661020|FG000|12-Month Clinical Follow-up|Withdrawal by Subject|4
6060387|NCT00484315|9661021|FG001|12-Month Clinical Follow-up|Withdrawal by Subject|0
6060388|NCT00484315|9661020|FG000|12-Month Clinical Follow-up|Lost to Follow-up|2
6060389|NCT00484315|9661021|FG001|12-Month Clinical Follow-up|Lost to Follow-up|1
6060390|NCT00484315|9661020|FG000|12-Month Clinical Follow-up|Missed 12-Month Visit|13
6060391|NCT00484315|9661021|FG001|12-Month Clinical Follow-up|Missed 12-Month Visit|4
6060392|NCT00484315|9661020|FG000|12-Month Clinical Follow-up|Withdrawn at Investigator's discretion|3
6060393|NCT00484315|9661021|FG001|12-Month Clinical Follow-up|Withdrawn at Investigator's discretion|2
6060394|NCT00484315|9661020|FG000|9-Month Angiographic Follow-up|No 9-Month Angiography Performed|25
6060395|NCT00484315|9661021|FG001|9-Month Angiographic Follow-up|No 9-Month Angiography Performed|11
6060396|NCT00484315|9661020|FG000|9-Month Angiographic Follow-up|Not Evaluable for Angiography Analysis|3
6093759|NCT00712335|9707086|FG002|Overall Study|Lack of Efficacy|1
6093760|NCT00712335|9707087|FG003|Overall Study|Lack of Efficacy|1
6093761|NCT00712335|9707088|FG004|Overall Study|Lack of Efficacy|0
6093762|NCT00712335|9707084|FG000|Overall Study|Other Reason|0
6093763|NCT00712335|9707085|FG001|Overall Study|Other Reason|3
6093764|NCT00712335|9707086|FG002|Overall Study|Other Reason|1
6093765|NCT00712335|9707087|FG003|Overall Study|Other Reason|0
6093766|NCT00712335|9707088|FG004|Overall Study|Other Reason|0
6093767|NCT00712348|9707100|FG000|Overall Study|Withdrawal by Subject|1
6093768|NCT00712543|9707119|FG000|Day 8-14|Lost to Follow-up|0
6093769|NCT00712543|9707120|FG001|Day 8-14|Lost to Follow-up|2
6093770|NCT00712673|9707129|FG000|Overall Study|Adverse Event|3
6093771|NCT00712673|9707130|FG001|Overall Study|Adverse Event|3
6093772|NCT00712673|9707131|FG002|Overall Study|Adverse Event|21
6093773|NCT00712673|9707132|FG003|Overall Study|Adverse Event|26
6093774|NCT00712673|9707129|FG000|Overall Study|Lack of Efficacy|2
6093775|NCT00712673|9707130|FG001|Overall Study|Lack of Efficacy|8
6093776|NCT00712673|9707131|FG002|Overall Study|Lack of Efficacy|8
6093777|NCT00712673|9707132|FG003|Overall Study|Lack of Efficacy|6
6093778|NCT00712673|9707129|FG000|Overall Study|Poor Compliance to Protocol|3
6093779|NCT00712673|9707130|FG001|Overall Study|Poor Compliance to Protocol|3
6093780|NCT00712673|9707131|FG002|Overall Study|Poor Compliance to Protocol|4
6093781|NCT00712673|9707132|FG003|Overall Study|Poor Compliance to Protocol|16
6093782|NCT00712673|9707129|FG000|Overall Study|Lost to Follow-up|1
6093783|NCT00712673|9707130|FG001|Overall Study|Lost to Follow-up|0
6093784|NCT00712673|9707131|FG002|Overall Study|Lost to Follow-up|2
6093785|NCT00712673|9707132|FG003|Overall Study|Lost to Follow-up|0
6093786|NCT00712673|9707129|FG000|Overall Study|Withdrawal by Subject|6
6093787|NCT00712673|9707130|FG001|Overall Study|Withdrawal by Subject|7
6093788|NCT00712673|9707131|FG002|Overall Study|Withdrawal by Subject|15
6093789|NCT00712673|9707132|FG003|Overall Study|Withdrawal by Subject|20
6093790|NCT00712673|9707129|FG000|Overall Study|Familial and Personal Reasons|5
6093791|NCT00712673|9707130|FG001|Overall Study|Familial and Personal Reasons|0
6093792|NCT00712673|9707131|FG002|Overall Study|Familial and Personal Reasons|5
6093793|NCT00712673|9707132|FG003|Overall Study|Familial and Personal Reasons|2
6093794|NCT00712673|9707129|FG000|Overall Study|Investigator's Decision|1
6093795|NCT00712673|9707130|FG001|Overall Study|Investigator's Decision|0
6093796|NCT00712673|9707131|FG002|Overall Study|Investigator's Decision|0
6093797|NCT00712673|9707132|FG003|Overall Study|Investigator's Decision|0
6093798|NCT00712673|9707129|FG000|Overall Study|Protocol Violation|0
6093799|NCT00712673|9707130|FG001|Overall Study|Protocol Violation|0
6093800|NCT00712673|9707131|FG002|Overall Study|Protocol Violation|2
6093801|NCT00712673|9707132|FG003|Overall Study|Protocol Violation|0
6093802|NCT00712712|9707151|FG000|Overall Study|Protocol Violation|11
6093803|NCT00712712|9707151|FG000|Overall Study|Radiofrequency not done|3
6093804|NCT00712712|9707151|FG000|Overall Study|Death|8
6093805|NCT00712712|9707151|FG000|Overall Study|Withdrawal by Subject|1
6093806|NCT00712725|9707163|FG000|Overall Study|Adverse Event|1
6093807|NCT00712725|9707164|FG001|Overall Study|Adverse Event|0
6093808|NCT00712725|9707165|FG002|Overall Study|Adverse Event|0
6093809|NCT00712725|9707166|FG003|Overall Study|Adverse Event|1
6093810|NCT00712725|9707167|FG004|Overall Study|Adverse Event|0
6093811|NCT00712725|9707168|FG005|Overall Study|Adverse Event|0
6093812|NCT00712725|9707169|FG006|Overall Study|Adverse Event|0
6093813|NCT00712725|9707170|FG007|Overall Study|Adverse Event|0
6093814|NCT00712725|9707163|FG000|Overall Study|Lost to Follow-up|3
6093815|NCT00712725|9707164|FG001|Overall Study|Lost to Follow-up|2
6093816|NCT00712725|9707165|FG002|Overall Study|Lost to Follow-up|1
6093817|NCT00712725|9707166|FG003|Overall Study|Lost to Follow-up|1
6093818|NCT00712725|9707167|FG004|Overall Study|Lost to Follow-up|2
6093819|NCT00712725|9707168|FG005|Overall Study|Lost to Follow-up|2
6093820|NCT00712725|9707169|FG006|Overall Study|Lost to Follow-up|3
6093821|NCT00712725|9707170|FG007|Overall Study|Lost to Follow-up|1
6093822|NCT00712725|9707163|FG000|Overall Study|Physician Decision|2
6093823|NCT00712725|9707164|FG001|Overall Study|Physician Decision|0
6093824|NCT00712725|9707165|FG002|Overall Study|Physician Decision|0
6093825|NCT00712725|9707166|FG003|Overall Study|Physician Decision|0
6060397|NCT00484315|9661021|FG001|9-Month Angiographic Follow-up|Not Evaluable for Angiography Analysis|2
6060398|NCT00484679|9661045|FG000|Overall Study|Withdrawal by Subject|3
6060399|NCT00484939|9661058|FG000|Overall Study|Death|9
6060400|NCT00484939|9661059|FG001|Overall Study|Death|13
6060401|NCT00484939|9661058|FG000|Overall Study|Adverse Event|22
6060402|NCT00484939|9661059|FG001|Overall Study|Adverse Event|12
6060403|NCT00484939|9661058|FG000|Overall Study|Patient Withdrew Consent|19
6060404|NCT00484939|9661059|FG001|Overall Study|Patient Withdrew Consent|10
6060405|NCT00484939|9661058|FG000|Overall Study|Protocol Violation|3
6060406|NCT00484939|9661059|FG001|Overall Study|Protocol Violation|3
6060407|NCT00484939|9661058|FG000|Overall Study|Lost to Follow-up|0
6060408|NCT00484939|9661059|FG001|Overall Study|Lost to Follow-up|3
6060409|NCT00484939|9661058|FG000|Overall Study|Discretion of Investigator or Sponsor|7
6060410|NCT00484939|9661059|FG001|Overall Study|Discretion of Investigator or Sponsor|3
6060411|NCT00484939|9661058|FG000|Overall Study|Disease progression|67
6060412|NCT00484939|9661059|FG001|Overall Study|Disease progression|88
6060413|NCT00484939|9661058|FG000|Overall Study|Screen Failure|2
6093826|NCT00712725|9707167|FG004|Overall Study|Physician Decision|1
6093827|NCT00712725|9707168|FG005|Overall Study|Physician Decision|0
6093828|NCT00712725|9707169|FG006|Overall Study|Physician Decision|2
6093829|NCT00712725|9707170|FG007|Overall Study|Physician Decision|0
6093830|NCT00712725|9707163|FG000|Overall Study|Pregnancy|0
6093831|NCT00712725|9707164|FG001|Overall Study|Pregnancy|1
6093832|NCT00712725|9707165|FG002|Overall Study|Pregnancy|0
6093833|NCT00712725|9707166|FG003|Overall Study|Pregnancy|0
6093834|NCT00712725|9707167|FG004|Overall Study|Pregnancy|1
6093835|NCT00712725|9707168|FG005|Overall Study|Pregnancy|0
6093836|NCT00712725|9707169|FG006|Overall Study|Pregnancy|2
6093837|NCT00712725|9707170|FG007|Overall Study|Pregnancy|0
6093838|NCT00712725|9707163|FG000|Overall Study|Protocol Violation|2
6093839|NCT00712725|9707164|FG001|Overall Study|Protocol Violation|0
6093840|NCT00712725|9707165|FG002|Overall Study|Protocol Violation|1
6093841|NCT00712725|9707166|FG003|Overall Study|Protocol Violation|3
6093842|NCT00712725|9707167|FG004|Overall Study|Protocol Violation|2
6093843|NCT00712725|9707168|FG005|Overall Study|Protocol Violation|0
6093844|NCT00712725|9707169|FG006|Overall Study|Protocol Violation|1
6093845|NCT00712725|9707170|FG007|Overall Study|Protocol Violation|1
6093846|NCT00712725|9707163|FG000|Overall Study|Withdrawal by Subject|2
6093847|NCT00712725|9707164|FG001|Overall Study|Withdrawal by Subject|1
6093848|NCT00712725|9707165|FG002|Overall Study|Withdrawal by Subject|1
6093849|NCT00712725|9707166|FG003|Overall Study|Withdrawal by Subject|2
6093850|NCT00712725|9707167|FG004|Overall Study|Withdrawal by Subject|1
6093851|NCT00712725|9707168|FG005|Overall Study|Withdrawal by Subject|1
6093852|NCT00712725|9707169|FG006|Overall Study|Withdrawal by Subject|1
6093853|NCT00712725|9707170|FG007|Overall Study|Withdrawal by Subject|2
6093854|NCT00712725|9707163|FG000|Overall Study|Lack of Qualifying Event|16
6093855|NCT00712725|9707164|FG001|Overall Study|Lack of Qualifying Event|2
6093856|NCT00712725|9707165|FG002|Overall Study|Lack of Qualifying Event|6
6093857|NCT00712725|9707166|FG003|Overall Study|Lack of Qualifying Event|8
6093858|NCT00712725|9707167|FG004|Overall Study|Lack of Qualifying Event|11
6093859|NCT00712725|9707168|FG005|Overall Study|Lack of Qualifying Event|13
6093860|NCT00712725|9707169|FG006|Overall Study|Lack of Qualifying Event|11
6093861|NCT00712725|9707170|FG007|Overall Study|Lack of Qualifying Event|6
6093862|NCT00712725|9707163|FG000|Overall Study|Protocol Specified Criteria|3
6093863|NCT00712725|9707164|FG001|Overall Study|Protocol Specified Criteria|0
6093864|NCT00712725|9707165|FG002|Overall Study|Protocol Specified Criteria|1
6093865|NCT00712725|9707166|FG003|Overall Study|Protocol Specified Criteria|2
6093866|NCT00712725|9707167|FG004|Overall Study|Protocol Specified Criteria|1
6093867|NCT00712725|9707168|FG005|Overall Study|Protocol Specified Criteria|0
6093868|NCT00712725|9707169|FG006|Overall Study|Protocol Specified Criteria|2
6093869|NCT00712725|9707170|FG007|Overall Study|Protocol Specified Criteria|1
6093870|NCT00712920|9707191|FG000|Overall Study|Adverse Event|3
6093871|NCT00712920|9707192|FG001|Overall Study|Adverse Event|4
6093872|NCT00712920|9707193|FG002|Overall Study|Adverse Event|7
6093873|NCT00712920|9707191|FG000|Overall Study|Withdrawal by Subject|4
6093874|NCT00712920|9707192|FG001|Overall Study|Withdrawal by Subject|2
6093875|NCT00712920|9707193|FG002|Overall Study|Withdrawal by Subject|1
6093876|NCT00712920|9707191|FG000|Overall Study|Lost to Follow-up|1
6093877|NCT00712920|9707192|FG001|Overall Study|Lost to Follow-up|4
6060414|NCT00484939|9661059|FG001|Overall Study|Screen Failure|2
6060415|NCT00484939|9661058|FG000|Overall Study|Reason Not Specified|11
6060416|NCT00484939|9661059|FG001|Overall Study|Reason Not Specified|6
6060417|NCT00485069|9661067|FG000|Overall Study|Adverse Event|10
6060418|NCT00485069|9661068|FG001|Overall Study|Adverse Event|4
6060419|NCT00485069|9661067|FG000|Overall Study|Lack of Efficacy|2
6093878|NCT00712920|9707193|FG002|Overall Study|Lost to Follow-up|0
6093879|NCT00712920|9707191|FG000|Overall Study|Lack of Efficacy|1
6093880|NCT00712920|9707192|FG001|Overall Study|Lack of Efficacy|0
6093881|NCT00712920|9707193|FG002|Overall Study|Lack of Efficacy|1
6093882|NCT00712920|9707191|FG000|Overall Study|Other|5
6093883|NCT00712920|9707192|FG001|Overall Study|Other|7
6093884|NCT00712920|9707193|FG002|Overall Study|Other|3
6093885|NCT00712920|9707191|FG000|Overall Study|Non-compliance|3
6093886|NCT00712920|9707192|FG001|Overall Study|Non-compliance|0
6093887|NCT00712920|9707193|FG002|Overall Study|Non-compliance|0
6060420|NCT00485069|9661068|FG001|Overall Study|Lack of Efficacy|1
6060421|NCT00485069|9661067|FG000|Overall Study|Protocol Violation|0
6060422|NCT00485069|9661068|FG001|Overall Study|Protocol Violation|1
6060423|NCT00485069|9661067|FG000|Overall Study|Withdrawal by Subject|6
6060424|NCT00485069|9661068|FG001|Overall Study|Withdrawal by Subject|6
6060425|NCT00485134|9661089|FG000|Overall Study|Lost to Follow-up|1
6060426|NCT00485134|9661090|FG001|Overall Study|Lost to Follow-up|0
6060427|NCT00485134|9661091|FG002|Overall Study|Lost to Follow-up|0
6060428|NCT00485134|9661092|FG003|Overall Study|Lost to Follow-up|0
6060429|NCT00485134|9661093|FG004|Overall Study|Lost to Follow-up|0
6060430|NCT00485134|9661094|FG005|Overall Study|Lost to Follow-up|0
6060431|NCT00485134|9661095|FG006|Overall Study|Lost to Follow-up|0
6060432|NCT00485134|9661096|FG007|Overall Study|Lost to Follow-up|0
6060433|NCT00485134|9661089|FG000|Overall Study|Withdrawal by Subject|0
6060434|NCT00485134|9661090|FG001|Overall Study|Withdrawal by Subject|1
6060435|NCT00485134|9661091|FG002|Overall Study|Withdrawal by Subject|0
6060436|NCT00485134|9661092|FG003|Overall Study|Withdrawal by Subject|0
6060437|NCT00485134|9661093|FG004|Overall Study|Withdrawal by Subject|0
6060438|NCT00485134|9661094|FG005|Overall Study|Withdrawal by Subject|0
6060439|NCT00485134|9661095|FG006|Overall Study|Withdrawal by Subject|0
6060440|NCT00485134|9661096|FG007|Overall Study|Withdrawal by Subject|0
6060441|NCT00485134|9661089|FG000|Overall Study|Change in health status|0
6060442|NCT00485134|9661090|FG001|Overall Study|Change in health status|1
6060443|NCT00485134|9661091|FG002|Overall Study|Change in health status|2
6060444|NCT00485134|9661092|FG003|Overall Study|Change in health status|1
6060445|NCT00485134|9661093|FG004|Overall Study|Change in health status|0
6060446|NCT00485134|9661094|FG005|Overall Study|Change in health status|1
6060447|NCT00485134|9661095|FG006|Overall Study|Change in health status|0
6060448|NCT00485134|9661096|FG007|Overall Study|Change in health status|0
6060449|NCT00485134|9661089|FG000|Overall Study|Withdrew for adverse event|0
6060450|NCT00485134|9661090|FG001|Overall Study|Withdrew for adverse event|0
6060451|NCT00485134|9661091|FG002|Overall Study|Withdrew for adverse event|1
6060452|NCT00485134|9661092|FG003|Overall Study|Withdrew for adverse event|0
6093888|NCT00712959|9707203|FG000|Overall Study|Protocol Violation|3
6093889|NCT00712959|9707204|FG001|Overall Study|Protocol Violation|1
6093890|NCT00712959|9707203|FG000|Overall Study|Lost to Follow-up|13
6093891|NCT00712959|9707204|FG001|Overall Study|Lost to Follow-up|2
6093892|NCT00712959|9707203|FG000|Overall Study|Withdrawal by Subject|3
6093893|NCT00712959|9707204|FG001|Overall Study|Withdrawal by Subject|0
6093894|NCT00712985|9707210|FG000|Overall Study|1 withdrew prior to start of drug|1
6093895|NCT00712985|9707210|FG000|Overall Study|1 patient moved out of state|1
6093896|NCT00712985|9707210|FG000|Overall Study|Lack of Efficacy|3
6093897|NCT00713219|9707214|FG000|Overall Study|Death|1
6093898|NCT00713219|9707214|FG000|Overall Study|Protocol Violation|1
6093899|NCT00713310|9707224|FG000|Overall Study|Adverse Event|5
6093900|NCT00713310|9707225|FG001|Overall Study|Adverse Event|2
6093901|NCT00713310|9707224|FG000|Overall Study|Lack of Efficacy|0
6093902|NCT00713310|9707225|FG001|Overall Study|Lack of Efficacy|2
6093903|NCT00713310|9707224|FG000|Overall Study|Withdrawal by Subject|0
6093904|NCT00713310|9707225|FG001|Overall Study|Withdrawal by Subject|2
6093905|NCT00713323|9707231|FG000|Overall Study|Adverse Event|75
6093906|NCT00713323|9707231|FG000|Overall Study|Withdrawal by Subject|15
6093907|NCT00713323|9707231|FG000|Overall Study|Lost to Follow-up|11
6093908|NCT00713323|9707231|FG000|Overall Study|Lack of Efficacy|36
6093909|NCT00713323|9707231|FG000|Overall Study|Low creatine clearance at screening|1
6093910|NCT00713323|9707231|FG000|Overall Study|Withdrawn due to exclusion criteria 11|1
6093911|NCT00713323|9707231|FG000|Overall Study|Surgery cured allodynic pain|1
6093912|NCT00713323|9707231|FG000|Overall Study|Pain free|1
6093913|NCT00713323|9707231|FG000|Overall Study|Non-compliance|1
6093914|NCT00713323|9707231|FG000|Overall Study|Pain resolved|1
6093915|NCT00713323|9707231|FG000|Overall Study|Subject travelling to USA|1
6093916|NCT00713323|9707231|FG000|Overall Study|Subject travelling to Dominica Republic|1
6093917|NCT00713323|9707231|FG000|Overall Study|Treatment that may interact with Sativex|1
6093918|NCT00713349|9707235|FG000|Overall Study|Protocol Violation|1
6093919|NCT00713544|9707260|FG000|Overall Study|Adverse Event|5
6093920|NCT00713544|9707261|FG001|Overall Study|Adverse Event|3
6093921|NCT00713544|9707262|FG002|Overall Study|Adverse Event|7
6093922|NCT00713544|9707263|FG003|Overall Study|Adverse Event|7
6093923|NCT00713544|9707264|FG004|Overall Study|Adverse Event|3
6093924|NCT00713544|9707265|FG005|Overall Study|Adverse Event|5
6093925|NCT00713544|9707260|FG000|Overall Study|Withdrawal by Subject|2
6093926|NCT00713544|9707261|FG001|Overall Study|Withdrawal by Subject|0
6093927|NCT00713544|9707262|FG002|Overall Study|Withdrawal by Subject|3
6093928|NCT00713544|9707263|FG003|Overall Study|Withdrawal by Subject|2
6093929|NCT00713544|9707264|FG004|Overall Study|Withdrawal by Subject|3
6093930|NCT00713544|9707265|FG005|Overall Study|Withdrawal by Subject|1
6093931|NCT00713544|9707260|FG000|Overall Study|Protocol Violation|0
6093932|NCT00713544|9707261|FG001|Overall Study|Protocol Violation|0
6093933|NCT00713544|9707262|FG002|Overall Study|Protocol Violation|0
6093934|NCT00713544|9707263|FG003|Overall Study|Protocol Violation|0
6093935|NCT00713544|9707264|FG004|Overall Study|Protocol Violation|0
6093936|NCT00713544|9707265|FG005|Overall Study|Protocol Violation|1
6093937|NCT00713544|9707260|FG000|Overall Study|Physician Decision|0
6093938|NCT00713544|9707261|FG001|Overall Study|Physician Decision|0
6060453|NCT00485134|9661093|FG004|Overall Study|Withdrew for adverse event|0
6060454|NCT00485134|9661094|FG005|Overall Study|Withdrew for adverse event|0
6060455|NCT00485134|9661095|FG006|Overall Study|Withdrew for adverse event|0
6060456|NCT00485134|9661096|FG007|Overall Study|Withdrew for adverse event|0
6060457|NCT00485134|9661089|FG000|Overall Study|Positive drug test|0
6060458|NCT00485134|9661090|FG001|Overall Study|Positive drug test|0
6060459|NCT00485134|9661091|FG002|Overall Study|Positive drug test|0
6060460|NCT00485134|9661092|FG003|Overall Study|Positive drug test|0
6060461|NCT00485134|9661093|FG004|Overall Study|Positive drug test|2
6060462|NCT00485134|9661094|FG005|Overall Study|Positive drug test|1
6093939|NCT00713544|9707262|FG002|Overall Study|Physician Decision|0
6093940|NCT00713544|9707263|FG003|Overall Study|Physician Decision|0
6093941|NCT00713544|9707264|FG004|Overall Study|Physician Decision|0
6093942|NCT00713544|9707265|FG005|Overall Study|Physician Decision|2
6093943|NCT00713544|9707260|FG000|Overall Study|Lack of Efficacy|0
6093944|NCT00713544|9707261|FG001|Overall Study|Lack of Efficacy|1
6093945|NCT00713544|9707262|FG002|Overall Study|Lack of Efficacy|0
6093946|NCT00713544|9707263|FG003|Overall Study|Lack of Efficacy|1
6093947|NCT00713544|9707264|FG004|Overall Study|Lack of Efficacy|1
6093948|NCT00713544|9707265|FG005|Overall Study|Lack of Efficacy|0
6093949|NCT00713544|9707260|FG000|Overall Study|Lost to Follow-up|0
6093950|NCT00713544|9707261|FG001|Overall Study|Lost to Follow-up|0
6093951|NCT00713544|9707262|FG002|Overall Study|Lost to Follow-up|1
6093952|NCT00713544|9707263|FG003|Overall Study|Lost to Follow-up|0
6093953|NCT00713544|9707264|FG004|Overall Study|Lost to Follow-up|0
6093954|NCT00713544|9707265|FG005|Overall Study|Lost to Follow-up|0
6093955|NCT00713544|9707260|FG000|Overall Study|AZ decision - Hepatitis C ab reactive|0
6093956|NCT00713544|9707261|FG001|Overall Study|AZ decision - Hepatitis C ab reactive|1
6093957|NCT00713544|9707262|FG002|Overall Study|AZ decision - Hepatitis C ab reactive|0
6093958|NCT00713544|9707263|FG003|Overall Study|AZ decision - Hepatitis C ab reactive|0
6093959|NCT00713544|9707264|FG004|Overall Study|AZ decision - Hepatitis C ab reactive|0
6093960|NCT00713544|9707265|FG005|Overall Study|AZ decision - Hepatitis C ab reactive|0
6093961|NCT00713544|9707260|FG000|Overall Study|Incorrect enrollment|0
6093962|NCT00713544|9707261|FG001|Overall Study|Incorrect enrollment|1
6093963|NCT00713544|9707262|FG002|Overall Study|Incorrect enrollment|0
6093964|NCT00713544|9707263|FG003|Overall Study|Incorrect enrollment|0
6093965|NCT00713544|9707264|FG004|Overall Study|Incorrect enrollment|0
6093966|NCT00713544|9707265|FG005|Overall Study|Incorrect enrollment|0
6093967|NCT00713544|9707260|FG000|Overall Study|Hepatotoxicity - not an AE|0
6093968|NCT00713544|9707261|FG001|Overall Study|Hepatotoxicity - not an AE|0
6093969|NCT00713544|9707262|FG002|Overall Study|Hepatotoxicity - not an AE|0
6093970|NCT00713544|9707263|FG003|Overall Study|Hepatotoxicity - not an AE|0
6202877|NCT01507831|9863364|FG000|Overall Study|Consent withdrawn by participant|34
6202878|NCT01507831|9863365|FG001|Overall Study|Consent withdrawn by participant|72
6202879|NCT01507831|9863364|FG000|Overall Study|Related to study drug administration|5
6202880|NCT01507831|9863365|FG001|Overall Study|Related to study drug administration|14
6202881|NCT01507831|9863364|FG000|Overall Study|Last visit outside protocol visit window|51
6202882|NCT01507831|9863365|FG001|Overall Study|Last visit outside protocol visit window|143
6202883|NCT01507831|9863364|FG000|Overall Study|Selection criteria finally not met|0
6202884|NCT01507831|9863365|FG001|Overall Study|Selection criteria finally not met|1
6202885|NCT01507831|9863364|FG000|Overall Study|Site closure|0
6202886|NCT01507831|9863365|FG001|Overall Study|Site closure|3
6202887|NCT01507831|9863364|FG000|Overall Study|Potential lost to follow-up|3
6202888|NCT01507831|9863365|FG001|Overall Study|Potential lost to follow-up|0
6202889|NCT01507831|9863364|FG000|Overall Study|Other|3
6202890|NCT01507831|9863365|FG001|Overall Study|Other|6
6202891|NCT01507896|9863371|FG000|Overall Study|Withdrawal by Subject|1
6202892|NCT01507896|9863371|FG000|Overall Study|The surgery was denied by the sponsor.|1
6202893|NCT01508130|9863438|FG000|Overall Study|Adverse Event|81
6202894|NCT01508130|9863439|FG001|Overall Study|Adverse Event|28
6202895|NCT01508130|9863438|FG000|Overall Study|Death|3
6202896|NCT01508130|9863439|FG001|Overall Study|Death|1
6202897|NCT01508130|9863438|FG000|Overall Study|Protocol Violation|2
6202898|NCT01508130|9863439|FG001|Overall Study|Protocol Violation|0
6202899|NCT01508130|9863438|FG000|Overall Study|Lost to Follow-up|25
6202900|NCT01508130|9863439|FG001|Overall Study|Lost to Follow-up|2
6202901|NCT01508130|9863438|FG000|Overall Study|Withdrawal by Subject|3
6202902|NCT01508130|9863439|FG001|Overall Study|Withdrawal by Subject|3
6202903|NCT01508130|9863438|FG000|Overall Study|Subject's substantial non-compliance|25
6202904|NCT01508130|9863439|FG001|Overall Study|Subject's substantial non-compliance|9
6202905|NCT01508130|9863438|FG000|Overall Study|Insufficient therapeutic response|74
6060463|NCT00485134|9661095|FG006|Overall Study|Positive drug test|0
6060464|NCT00485134|9661096|FG007|Overall Study|Positive drug test|0
6060465|NCT00485134|9661089|FG000|Overall Study|Non-compliance|0
6060466|NCT00485134|9661090|FG001|Overall Study|Non-compliance|0
6093971|NCT00713544|9707264|FG004|Overall Study|Hepatotoxicity - not an AE|1
6093972|NCT00713544|9707265|FG005|Overall Study|Hepatotoxicity - not an AE|0
6093973|NCT00713609|9707294|FG000|Overall Study|Adverse Event|2
6093974|NCT00713609|9707295|FG001|Overall Study|Adverse Event|0
6093975|NCT00713609|9707296|FG002|Overall Study|Adverse Event|2
6093976|NCT00713609|9707297|FG003|Overall Study|Adverse Event|2
6093977|NCT00713609|9707298|FG004|Overall Study|Adverse Event|3
6060467|NCT00485134|9661091|FG002|Overall Study|Non-compliance|0
6060468|NCT00485134|9661092|FG003|Overall Study|Non-compliance|0
6060469|NCT00485134|9661093|FG004|Overall Study|Non-compliance|1
6060470|NCT00485134|9661094|FG005|Overall Study|Non-compliance|2
6060471|NCT00485134|9661095|FG006|Overall Study|Non-compliance|2
6060472|NCT00485134|9661096|FG007|Overall Study|Non-compliance|0
6060473|NCT00485134|9661089|FG000|Overall Study|Unable to comply with study schedule|0
6060474|NCT00485134|9661090|FG001|Overall Study|Unable to comply with study schedule|0
6060475|NCT00485134|9661091|FG002|Overall Study|Unable to comply with study schedule|0
6060476|NCT00485134|9661092|FG003|Overall Study|Unable to comply with study schedule|0
6060477|NCT00485134|9661093|FG004|Overall Study|Unable to comply with study schedule|0
6060478|NCT00485134|9661094|FG005|Overall Study|Unable to comply with study schedule|0
6060479|NCT00485134|9661095|FG006|Overall Study|Unable to comply with study schedule|0
6060480|NCT00485134|9661096|FG007|Overall Study|Unable to comply with study schedule|1
6060481|NCT00485134|9661089|FG000|Overall Study|Pregnancy|0
6060482|NCT00485134|9661090|FG001|Overall Study|Pregnancy|0
6060483|NCT00485134|9661091|FG002|Overall Study|Pregnancy|0
6060484|NCT00485134|9661092|FG003|Overall Study|Pregnancy|0
6060485|NCT00485134|9661093|FG004|Overall Study|Pregnancy|0
6060486|NCT00485134|9661094|FG005|Overall Study|Pregnancy|0
6060487|NCT00485134|9661095|FG006|Overall Study|Pregnancy|1
6060488|NCT00485134|9661096|FG007|Overall Study|Pregnancy|0
6060489|NCT00485173|9661110|FG000|Overall Study|Death|4
6060490|NCT00485173|9661111|FG001|Overall Study|Death|3
6060491|NCT00485173|9661110|FG000|Overall Study|Lost to Follow-up|32
6060492|NCT00485173|9661111|FG001|Overall Study|Lost to Follow-up|61
6060493|NCT00485264|9661123|FG000|Overall Study|Enrolled But Not Given Treatment|0
6060494|NCT00485264|9661124|FG001|Overall Study|Enrolled But Not Given Treatment|0
6060495|NCT00485264|9661125|FG002|Overall Study|Enrolled But Not Given Treatment|0
6060496|NCT00485264|9661126|FG003|Overall Study|Enrolled But Not Given Treatment|0
6060497|NCT00485264|9661127|FG004|Overall Study|Enrolled But Not Given Treatment|1
6060498|NCT00485264|9661128|FG005|Overall Study|Enrolled But Not Given Treatment|0
6060499|NCT00485264|9661123|FG000|Overall Study|Death|1
6060500|NCT00485264|9661124|FG001|Overall Study|Death|0
6060501|NCT00485264|9661125|FG002|Overall Study|Death|0
6060502|NCT00485264|9661126|FG003|Overall Study|Death|0
6060503|NCT00485264|9661127|FG004|Overall Study|Death|1
6060504|NCT00485264|9661128|FG005|Overall Study|Death|0
6060505|NCT00485264|9661123|FG000|Overall Study|Adverse Event|1
6060506|NCT00485264|9661124|FG001|Overall Study|Adverse Event|0
6060507|NCT00485264|9661125|FG002|Overall Study|Adverse Event|2
6060508|NCT00485264|9661126|FG003|Overall Study|Adverse Event|3
6060509|NCT00485264|9661127|FG004|Overall Study|Adverse Event|1
6093978|NCT00713609|9707299|FG005|Overall Study|Adverse Event|1
6093979|NCT00713609|9707294|FG000|Overall Study|Lost to Follow-up|5
6093980|NCT00713609|9707295|FG001|Overall Study|Lost to Follow-up|7
6093981|NCT00713609|9707296|FG002|Overall Study|Lost to Follow-up|5
6093982|NCT00713609|9707297|FG003|Overall Study|Lost to Follow-up|5
6093983|NCT00713609|9707298|FG004|Overall Study|Lost to Follow-up|7
6093984|NCT00713609|9707299|FG005|Overall Study|Lost to Follow-up|0
6093985|NCT00713609|9707294|FG000|Overall Study|Lack of Efficacy|1
6093986|NCT00713609|9707295|FG001|Overall Study|Lack of Efficacy|3
6093987|NCT00713609|9707296|FG002|Overall Study|Lack of Efficacy|0
6093988|NCT00713609|9707297|FG003|Overall Study|Lack of Efficacy|0
6093989|NCT00713609|9707298|FG004|Overall Study|Lack of Efficacy|1
6093990|NCT00713609|9707299|FG005|Overall Study|Lack of Efficacy|0
6093991|NCT00713609|9707294|FG000|Overall Study|Non-Compliance with Study Treatment|1
6093992|NCT00713609|9707295|FG001|Overall Study|Non-Compliance with Study Treatment|1
6093993|NCT00713609|9707296|FG002|Overall Study|Non-Compliance with Study Treatment|2
6093994|NCT00713609|9707297|FG003|Overall Study|Non-Compliance with Study Treatment|0
6060510|NCT00485264|9661128|FG005|Overall Study|Adverse Event|3
6060511|NCT00485264|9661123|FG000|Overall Study|Pregnancy|4
6060512|NCT00485264|9661124|FG001|Overall Study|Pregnancy|0
6060513|NCT00485264|9661125|FG002|Overall Study|Pregnancy|0
6060514|NCT00485264|9661126|FG003|Overall Study|Pregnancy|0
6060515|NCT00485264|9661127|FG004|Overall Study|Pregnancy|0
6060516|NCT00485264|9661128|FG005|Overall Study|Pregnancy|0
6060517|NCT00485264|9661123|FG000|Overall Study|Disallowed Medication|0
6060518|NCT00485264|9661124|FG001|Overall Study|Disallowed Medication|0
6060519|NCT00485264|9661125|FG002|Overall Study|Disallowed Medication|0
6060520|NCT00485264|9661126|FG003|Overall Study|Disallowed Medication|0
6060521|NCT00485264|9661127|FG004|Overall Study|Disallowed Medication|0
6060522|NCT00485264|9661128|FG005|Overall Study|Disallowed Medication|1
6060523|NCT00485264|9661123|FG000|Overall Study|Number/Volume/Timing of Study Meds|2
6060524|NCT00485264|9661124|FG001|Overall Study|Number/Volume/Timing of Study Meds|1
6060525|NCT00485264|9661125|FG002|Overall Study|Number/Volume/Timing of Study Meds|1
6060526|NCT00485264|9661126|FG003|Overall Study|Number/Volume/Timing of Study Meds|0
6060527|NCT00485264|9661127|FG004|Overall Study|Number/Volume/Timing of Study Meds|0
6060528|NCT00485264|9661128|FG005|Overall Study|Number/Volume/Timing of Study Meds|0
6093995|NCT00713609|9707298|FG004|Overall Study|Non-Compliance with Study Treatment|1
6093996|NCT00713609|9707299|FG005|Overall Study|Non-Compliance with Study Treatment|0
6093997|NCT00713609|9707294|FG000|Overall Study|Withdrawal by Subject|6
6093998|NCT00713609|9707295|FG001|Overall Study|Withdrawal by Subject|1
6093999|NCT00713609|9707296|FG002|Overall Study|Withdrawal by Subject|5
6060529|NCT00485264|9661123|FG000|Overall Study|Lack of Efficacy|0
6060530|NCT00485264|9661124|FG001|Overall Study|Lack of Efficacy|1
6060531|NCT00485264|9661125|FG002|Overall Study|Lack of Efficacy|0
6060532|NCT00485264|9661126|FG003|Overall Study|Lack of Efficacy|0
6060533|NCT00485264|9661127|FG004|Overall Study|Lack of Efficacy|0
6060534|NCT00485264|9661128|FG005|Overall Study|Lack of Efficacy|0
6060535|NCT00485264|9661123|FG000|Overall Study|Guardian Consent Withdrawn|1
6060536|NCT00485264|9661124|FG001|Overall Study|Guardian Consent Withdrawn|0
6060537|NCT00485264|9661125|FG002|Overall Study|Guardian Consent Withdrawn|0
6060538|NCT00485264|9661126|FG003|Overall Study|Guardian Consent Withdrawn|0
6060539|NCT00485264|9661127|FG004|Overall Study|Guardian Consent Withdrawn|1
6060540|NCT00485264|9661128|FG005|Overall Study|Guardian Consent Withdrawn|0
6060541|NCT00485264|9661123|FG000|Overall Study|Physician Decision|0
6060542|NCT00485264|9661124|FG001|Overall Study|Physician Decision|2
6060543|NCT00485264|9661125|FG002|Overall Study|Physician Decision|0
6060544|NCT00485264|9661126|FG003|Overall Study|Physician Decision|0
6094000|NCT00713609|9707297|FG003|Overall Study|Withdrawal by Subject|1
6094001|NCT00713609|9707298|FG004|Overall Study|Withdrawal by Subject|5
6094002|NCT00713609|9707299|FG005|Overall Study|Withdrawal by Subject|7
6094003|NCT00713609|9707294|FG000|Overall Study|Protocol Violation|6
6094004|NCT00713609|9707295|FG001|Overall Study|Protocol Violation|3
6094005|NCT00713609|9707296|FG002|Overall Study|Protocol Violation|1
6094006|NCT00713609|9707297|FG003|Overall Study|Protocol Violation|1
6094007|NCT00713609|9707298|FG004|Overall Study|Protocol Violation|2
6094008|NCT00713609|9707299|FG005|Overall Study|Protocol Violation|0
6094009|NCT00713648|9707313|FG000|Overall Study|Adverse Event|1
6094010|NCT00713648|9707313|FG000|Overall Study|Unclassified|2
6094011|NCT00713648|9707313|FG000|Overall Study|According to Protocol|2
6094012|NCT00713648|9707313|FG000|Overall Study|Development of antibodies|3
6094013|NCT00713700|9707334|FG000|Overall Study|Lost to Follow-up|3
6094014|NCT00713700|9707334|FG000|Overall Study|Withdrawal by Subject|1
6094015|NCT00713830|9707349|FG000|Overall Study|Adverse Event|23
6094016|NCT00713830|9707350|FG001|Overall Study|Adverse Event|71
6094017|NCT00713830|9707349|FG000|Overall Study|Lack of Efficacy|24
6094018|NCT00713830|9707350|FG001|Overall Study|Lack of Efficacy|16
6094019|NCT00713830|9707349|FG000|Overall Study|Lost to Follow-up|2
6094020|NCT00713830|9707350|FG001|Overall Study|Lost to Follow-up|9
6094021|NCT00713830|9707349|FG000|Overall Study|Withdrawal by Subject|13
6094022|NCT00713830|9707350|FG001|Overall Study|Withdrawal by Subject|23
6094023|NCT00713830|9707349|FG000|Overall Study|Poor Compliance to Protocol|7
6094024|NCT00713830|9707350|FG001|Overall Study|Poor Compliance to Protocol|14
6094025|NCT00713830|9707349|FG000|Overall Study|Familial and Personal Reasons|9
6094026|NCT00713830|9707350|FG001|Overall Study|Familial and Personal Reasons|34
6094027|NCT00713830|9707349|FG000|Overall Study|Sponsor Decision|4
6094028|NCT00713830|9707350|FG001|Overall Study|Sponsor Decision|10
6094029|NCT00714051|9707358|FG000|Overall Study|Withdrawal by Subject|1
6094030|NCT00714051|9707359|FG001|Overall Study|Withdrawal by Subject|0
6094031|NCT00714051|9707358|FG000|Overall Study|Death|0
6094032|NCT00714051|9707359|FG001|Overall Study|Death|1
6094033|NCT00714168|9707367|FG000|Overall Study|Pregnancy|5
6094034|NCT00714168|9707368|FG001|Overall Study|Pregnancy|4
6094035|NCT00714168|9707367|FG000|Overall Study|Lost to Follow-up|32
6094036|NCT00714168|9707368|FG001|Overall Study|Lost to Follow-up|50
6094037|NCT00714168|9707367|FG000|Overall Study|Relocation|4
6094038|NCT00714168|9707368|FG001|Overall Study|Relocation|3
6094039|NCT00714168|9707367|FG000|Overall Study|Non-study medical condition|3
6094040|NCT00714168|9707368|FG001|Overall Study|Non-study medical condition|2
6094041|NCT00714259|9707396|FG000|Overall Study|Death|2
6094042|NCT00714285|9707413|FG000|Overall Study|Lost to Follow-up|0
6094043|NCT00714285|9707414|FG001|Overall Study|Lost to Follow-up|2
6094044|NCT00714285|9707415|FG002|Overall Study|Lost to Follow-up|0
6094045|NCT00714285|9707416|FG003|Overall Study|Lost to Follow-up|1
6094046|NCT00714285|9707413|FG000|Overall Study|Migrated/moved from study area|0
6094047|NCT00714285|9707414|FG001|Overall Study|Migrated/moved from study area|1
6094048|NCT00714285|9707415|FG002|Overall Study|Migrated/moved from study area|0
6094049|NCT00714285|9707416|FG003|Overall Study|Migrated/moved from study area|0
6094050|NCT00714415|9707443|FG000|Overall Study|Lack of Efficacy|1
6094051|NCT00714415|9707444|FG001|Overall Study|Lack of Efficacy|0
6094052|NCT00714415|9707443|FG000|Overall Study|Death|1
6094053|NCT00714415|9707444|FG001|Overall Study|Death|0
6060545|NCT00485264|9661127|FG004|Overall Study|Physician Decision|0
6060546|NCT00485264|9661128|FG005|Overall Study|Physician Decision|0
6060547|NCT00485264|9661123|FG000|Overall Study|Intolerance/Unable to Tolerate Dose|0
6060548|NCT00485264|9661124|FG001|Overall Study|Intolerance/Unable to Tolerate Dose|0
6060549|NCT00485264|9661125|FG002|Overall Study|Intolerance/Unable to Tolerate Dose|1
6094054|NCT00714493|9707450|FG000|Overall Study|Adverse Event|11
6094055|NCT00714493|9707450|FG000|Overall Study|Death|3
6094056|NCT00714493|9707450|FG000|Overall Study|Lack of Efficacy|10
6094057|NCT00714493|9707450|FG000|Overall Study|Lost to Follow-up|3
6094058|NCT00714493|9707450|FG000|Overall Study|Protocol Violation|12
6094059|NCT00714493|9707450|FG000|Overall Study|SUBJECT CHOICE (SUBJECT WITHDREW CONSENT|8
6094060|NCT00714493|9707450|FG000|Overall Study|OTHER|2
6094061|NCT00714688|9707482|FG000|Overall Study|Lack of Efficacy|14
6094062|NCT00714688|9707483|FG001|Overall Study|Lack of Efficacy|1
6094063|NCT00714688|9707484|FG002|Overall Study|Lack of Efficacy|4
6060550|NCT00485264|9661126|FG003|Overall Study|Intolerance/Unable to Tolerate Dose|0
6060551|NCT00485264|9661127|FG004|Overall Study|Intolerance/Unable to Tolerate Dose|0
6060552|NCT00485264|9661128|FG005|Overall Study|Intolerance/Unable to Tolerate Dose|0
6060553|NCT00485264|9661123|FG000|Overall Study|Not Able to Attend Clinic|5
6060554|NCT00485264|9661124|FG001|Overall Study|Not Able to Attend Clinic|0
6060555|NCT00485264|9661125|FG002|Overall Study|Not Able to Attend Clinic|0
6060556|NCT00485264|9661126|FG003|Overall Study|Not Able to Attend Clinic|1
6094064|NCT00714688|9707482|FG000|Overall Study|Withdrawal by Subject|4
6094065|NCT00714688|9707483|FG001|Overall Study|Withdrawal by Subject|3
6094066|NCT00714688|9707484|FG002|Overall Study|Withdrawal by Subject|3
6094067|NCT00714688|9707482|FG000|Overall Study|Lost to Follow-up|5
6094068|NCT00714688|9707483|FG001|Overall Study|Lost to Follow-up|2
6094069|NCT00714688|9707484|FG002|Overall Study|Lost to Follow-up|0
6094070|NCT00714688|9707482|FG000|Overall Study|Adverse Event|2
6094071|NCT00714688|9707483|FG001|Overall Study|Adverse Event|15
6094072|NCT00714688|9707484|FG002|Overall Study|Adverse Event|19
6094073|NCT00714688|9707482|FG000|Overall Study|Subject Non-compliant|3
6094074|NCT00714688|9707483|FG001|Overall Study|Subject Non-compliant|5
6094075|NCT00714688|9707484|FG002|Overall Study|Subject Non-compliant|5
6094076|NCT00714688|9707482|FG000|Overall Study|Ineligible to Continue the Study|0
6094077|NCT00714688|9707483|FG001|Overall Study|Ineligible to Continue the Study|1
6094078|NCT00714688|9707484|FG002|Overall Study|Ineligible to Continue the Study|1
6094079|NCT00714688|9707482|FG000|Overall Study|Sponsor's Decision|0
6094080|NCT00714688|9707483|FG001|Overall Study|Sponsor's Decision|2
6094081|NCT00714688|9707484|FG002|Overall Study|Sponsor's Decision|0
6094082|NCT00714688|9707482|FG000|Overall Study|Other|1
6094083|NCT00714688|9707483|FG001|Overall Study|Other|6
6094084|NCT00714688|9707484|FG002|Overall Study|Other|5
6094085|NCT00714714|9707492|FG000|Overall Study|Adverse Event|1
6094086|NCT00714870|9707513|FG000|Overall Study|Lost to Follow-up|22
6094087|NCT00714870|9707514|FG001|Overall Study|Lost to Follow-up|5
6094088|NCT00714870|9707513|FG000|Overall Study|patient unable to come b/c back pain|1
6094089|NCT00714870|9707514|FG001|Overall Study|patient unable to come b/c back pain|0
6094090|NCT00714870|9707513|FG000|Overall Study|did not attend minimum of 4 sessions|4
6094091|NCT00714870|9707514|FG001|Overall Study|did not attend minimum of 4 sessions|0
6094092|NCT00715026|9707520|FG000|Overall Study|Withdrawal by Subject|5
6094093|NCT00715026|9707520|FG000|Overall Study|Lost to Follow-up|3
6094094|NCT00715026|9707520|FG000|Overall Study|Protocol Violation|1
6202906|NCT01508130|9863439|FG001|Overall Study|Insufficient therapeutic response|23
6202907|NCT01508130|9863438|FG000|Overall Study|Administrative|14
6202908|NCT01508130|9863439|FG001|Overall Study|Administrative|3
6202909|NCT01508169|9863449|FG000|Overall Study|Adverse Event|1
6202910|NCT01508169|9863450|FG001|Overall Study|Adverse Event|0
6202911|NCT01508169|9863449|FG000|Overall Study|Withdrawal by Subject|1
6202912|NCT01508169|9863450|FG001|Overall Study|Withdrawal by Subject|0
6202913|NCT01508169|9863449|FG000|Overall Study|Lost to Follow-up|1
6202914|NCT01508169|9863450|FG001|Overall Study|Lost to Follow-up|2
6202915|NCT01508325|9863464|FG000|Overall Study|Withdrawal by Subject|8
6202916|NCT01508325|9863465|FG001|Overall Study|Withdrawal by Subject|9
6202917|NCT01508325|9863464|FG000|Overall Study|Protocol Violation|0
6202918|NCT01508325|9863465|FG001|Overall Study|Protocol Violation|3
6202919|NCT01508325|9863464|FG000|Overall Study|Physician Decision|2
6202920|NCT01508325|9863465|FG001|Overall Study|Physician Decision|1
6202921|NCT01508325|9863464|FG000|Overall Study|Adverse Event|1
6202922|NCT01508325|9863465|FG001|Overall Study|Adverse Event|0
6202923|NCT01508325|9863464|FG000|Overall Study|Lost to Follow-up|5
6202924|NCT01508325|9863465|FG001|Overall Study|Lost to Follow-up|6
6202925|NCT01508325|9863464|FG000|Overall Study|Other|2
6202926|NCT01508325|9863465|FG001|Overall Study|Other|2
6202927|NCT01508650|9863477|FG000|Overall Study|Lost to Follow-up|0
6202928|NCT01508650|9863478|FG001|Overall Study|Lost to Follow-up|3
6202929|NCT01508676|9863486|FG000|Phase I (2 Weeks)|Medication Exclusion|1
6202930|NCT01508676|9863487|FG001|Phase I (2 Weeks)|Medication Exclusion|1
6202931|NCT01508676|9863486|FG000|Phase I (2 Weeks)|Wrong Pain Type|1
6202932|NCT01508676|9863487|FG001|Phase I (2 Weeks)|Wrong Pain Type|0
6202933|NCT01508676|9863486|FG000|Phase I (2 Weeks)|Positive Drug Screen|0
6202934|NCT01508676|9863487|FG001|Phase I (2 Weeks)|Positive Drug Screen|2
6202935|NCT01508676|9863486|FG000|Phase II (2 Weeks)|Skin Sensitivity|0
6284241|NCT02326272|9996328|FG000|Initial Period (Week 0 to Week 16)|Lost to follow-up after completing wk16|0
6284242|NCT02326272|9996329|FG001|Initial Period (Week 0 to Week 16)|Lost to follow-up after completing wk16|0
6284243|NCT02326272|9996330|FG002|Initial Period (Week 0 to Week 16)|Lost to follow-up after completing wk16|1
6284244|NCT02326272|9996331|FG003|Initial Period (Week 0 to Week 16)|Lost to follow-up after completing wk16|0
6284245|NCT02326272|9996332|FG004|Initial Period (Week 0 to Week 16)|Lost to follow-up after completing wk16|0
6094095|NCT00715026|9707520|FG000|Overall Study|Surgery done on non-study consented hip|1
6202936|NCT01508676|9863487|FG001|Phase II (2 Weeks)|Skin Sensitivity|1
6202937|NCT01508676|9863486|FG000|Phase II (2 Weeks)|Medication Exclusion|1
6202938|NCT01508676|9863487|FG001|Phase II (2 Weeks)|Medication Exclusion|0
6202939|NCT01508702|9863496|FG000|Overall Study|Adverse Event|7
6202940|NCT01508702|9863497|FG001|Overall Study|Adverse Event|3
6202941|NCT01508702|9863496|FG000|Overall Study|Gout flare|2
6202942|NCT01508702|9863497|FG001|Overall Study|Gout flare|0
6060557|NCT00485264|9661127|FG004|Overall Study|Not Able to Attend Clinic|1
6060558|NCT00485264|9661128|FG005|Overall Study|Not Able to Attend Clinic|2
6060559|NCT00485264|9661123|FG000|Overall Study|Non-Compliant|17
6060560|NCT00485264|9661124|FG001|Overall Study|Non-Compliant|2
6060561|NCT00485264|9661125|FG002|Overall Study|Non-Compliant|1
6060562|NCT00485264|9661126|FG003|Overall Study|Non-Compliant|0
6060563|NCT00485264|9661127|FG004|Overall Study|Non-Compliant|1
6060564|NCT00485264|9661128|FG005|Overall Study|Non-Compliant|0
6060565|NCT00485264|9661123|FG000|Overall Study|Lost to Follow-up|2
6060566|NCT00485264|9661124|FG001|Overall Study|Lost to Follow-up|1
6094096|NCT00715078|9707527|FG000|Overall Study|Death|29
6094097|NCT00715078|9707528|FG001|Overall Study|Death|36
6094098|NCT00715078|9707529|FG002|Overall Study|Death|36
6094099|NCT00715078|9707527|FG000|Overall Study|Withdrawal by Subject|1
6094100|NCT00715078|9707528|FG001|Overall Study|Withdrawal by Subject|0
6094101|NCT00715078|9707529|FG002|Overall Study|Withdrawal by Subject|1
6094102|NCT00715078|9707527|FG000|Overall Study|Unable to start due to disease prog.|0
6094103|NCT00715078|9707528|FG001|Overall Study|Unable to start due to disease prog.|0
6094104|NCT00715078|9707529|FG002|Overall Study|Unable to start due to disease prog.|1
6094105|NCT00715117|9707586|FG000|Overall Study|Crohn's flare and rescue with steroids|0
6094106|NCT00715117|9707587|FG001|Overall Study|Crohn's flare and rescue with steroids|1
6094107|NCT00715208|9707600|FG000|Overall Study|Withdrawal by Subject|1
6094108|NCT00715208|9707601|FG001|Overall Study|Withdrawal by Subject|1
6094109|NCT00715208|9707600|FG000|Overall Study|Adverse Event|0
6094110|NCT00715208|9707601|FG001|Overall Study|Adverse Event|6
6094111|NCT00715208|9707600|FG000|Overall Study|Lack of Efficacy|0
6094112|NCT00715208|9707601|FG001|Overall Study|Lack of Efficacy|2
6094113|NCT00715299|9707607|FG000|Overall Study|Withdrawal by Subject|1
6094114|NCT00715299|9707607|FG000|Overall Study|Adverse Event|3
6094115|NCT00715299|9707607|FG000|Overall Study|failed the pre-screen exercise test|2
6094116|NCT00715403|9707622|FG000|Overall Study|Progressive disease|0
6094117|NCT00715403|9707623|FG001|Overall Study|Progressive disease|1
6094118|NCT00715403|9707624|FG002|Overall Study|Progressive disease|3
6094119|NCT00715403|9707625|FG003|Overall Study|Progressive disease|9
6094120|NCT00715403|9707626|FG004|Overall Study|Progressive disease|5
6094121|NCT00715403|9707627|FG005|Overall Study|Progressive disease|14
6094122|NCT00715403|9707628|FG006|Overall Study|Progressive disease|1
6094123|NCT00715403|9707622|FG000|Overall Study|Dose limiting Toxicity (DLT)|0
6094124|NCT00715403|9707623|FG001|Overall Study|Dose limiting Toxicity (DLT)|0
6094125|NCT00715403|9707624|FG002|Overall Study|Dose limiting Toxicity (DLT)|0
6094126|NCT00715403|9707625|FG003|Overall Study|Dose limiting Toxicity (DLT)|0
6094127|NCT00715403|9707626|FG004|Overall Study|Dose limiting Toxicity (DLT)|0
6094128|NCT00715403|9707627|FG005|Overall Study|Dose limiting Toxicity (DLT)|1
6094129|NCT00715403|9707628|FG006|Overall Study|Dose limiting Toxicity (DLT)|0
6094130|NCT00715403|9707622|FG000|Overall Study|Other Adverse Event than DLT|1
6094131|NCT00715403|9707623|FG001|Overall Study|Other Adverse Event than DLT|0
6094132|NCT00715403|9707624|FG002|Overall Study|Other Adverse Event than DLT|0
6284246|NCT02326272|9996333|FG005|Initial Period (Week 0 to Week 16)|Lost to follow-up after completing wk16|0
6284247|NCT02326272|9996334|FG006|Initial Period (Week 0 to Week 16)|Lost to follow-up after completing wk16|0
6284248|NCT02326272|9996335|FG007|Initial Period (Week 0 to Week 16)|Lost to follow-up after completing wk16|0
6284249|NCT02326272|9996336|FG008|Initial Period (Week 0 to Week 16)|Lost to follow-up after completing wk16|0
6284250|NCT02326272|9996337|FG009|Initial Period (Week 0 to Week 16)|Lost to follow-up after completing wk16|0
6284251|NCT02326272|9996338|FG010|Initial Period (Week 0 to Week 16)|Lost to follow-up after completing wk16|0
6284252|NCT02326272|9996339|FG011|Initial Period (Week 0 to Week 16)|Lost to follow-up after completing wk16|0
6284253|NCT02326272|9996340|FG012|Initial Period (Week 0 to Week 16)|Lost to follow-up after completing wk16|0
6284254|NCT02326272|9996341|FG013|Initial Period (Week 0 to Week 16)|Lost to follow-up after completing wk16|0
6284255|NCT02326272|9996342|FG014|Initial Period (Week 0 to Week 16)|Lost to follow-up after completing wk16|0
6284256|NCT02326272|9996328|FG000|Initial Period (Week 0 to Week 16)|Consent withdrawn after completing wk16|0
6284257|NCT02326272|9996329|FG001|Initial Period (Week 0 to Week 16)|Consent withdrawn after completing wk16|0
6284258|NCT02326272|9996330|FG002|Initial Period (Week 0 to Week 16)|Consent withdrawn after completing wk16|1
6284259|NCT02326272|9996331|FG003|Initial Period (Week 0 to Week 16)|Consent withdrawn after completing wk16|0
6284260|NCT02326272|9996332|FG004|Initial Period (Week 0 to Week 16)|Consent withdrawn after completing wk16|0
6284261|NCT02326272|9996333|FG005|Initial Period (Week 0 to Week 16)|Consent withdrawn after completing wk16|0
6284262|NCT02326272|9996334|FG006|Initial Period (Week 0 to Week 16)|Consent withdrawn after completing wk16|0
6284263|NCT02326272|9996335|FG007|Initial Period (Week 0 to Week 16)|Consent withdrawn after completing wk16|0
6284264|NCT02326272|9996336|FG008|Initial Period (Week 0 to Week 16)|Consent withdrawn after completing wk16|0
6284265|NCT02326272|9996337|FG009|Initial Period (Week 0 to Week 16)|Consent withdrawn after completing wk16|0
6060567|NCT00485264|9661125|FG002|Overall Study|Lost to Follow-up|1
6060568|NCT00485264|9661126|FG003|Overall Study|Lost to Follow-up|0
6060569|NCT00485264|9661127|FG004|Overall Study|Lost to Follow-up|0
6060570|NCT00485264|9661128|FG005|Overall Study|Lost to Follow-up|1
6060571|NCT00485264|9661123|FG000|Overall Study|Other Reason|3
6060572|NCT00485264|9661124|FG001|Overall Study|Other Reason|0
6060573|NCT00485264|9661125|FG002|Overall Study|Other Reason|0
6060574|NCT00485264|9661126|FG003|Overall Study|Other Reason|0
6060575|NCT00485264|9661127|FG004|Overall Study|Other Reason|0
6060576|NCT00485264|9661128|FG005|Overall Study|Other Reason|0
6060577|NCT00485303|9661147|FG000|Overall Study|Adverse Event|5
6060578|NCT00485303|9661147|FG000|Overall Study|Progressive Disease|44
6060579|NCT00485303|9661147|FG000|Overall Study|Other|3
6060580|NCT00485303|9661147|FG000|Overall Study|Initiation of new anti-cancer treatment|2
6060581|NCT00485303|9661147|FG000|Overall Study|Treatment ongoing at cutoff date|2
6060582|NCT00485472|9661168|FG000|Overall Study|Adverse Event|8
6060583|NCT00485472|9661169|FG001|Overall Study|Adverse Event|5
6060584|NCT00485472|9661168|FG000|Overall Study|Lack of Efficacy|5
6060585|NCT00485472|9661169|FG001|Overall Study|Lack of Efficacy|4
6060586|NCT00485472|9661168|FG000|Overall Study|Withdrawal by Subject|1
6060587|NCT00485472|9661169|FG001|Overall Study|Withdrawal by Subject|0
6060588|NCT00485472|9661168|FG000|Overall Study|Protocol Violation|0
6060589|NCT00485472|9661169|FG001|Overall Study|Protocol Violation|1
6060590|NCT00485472|9661168|FG000|Overall Study|Other|2
6060591|NCT00485472|9661169|FG001|Overall Study|Other|1
6060592|NCT00485472|9661168|FG000|Overall Study|Lost to Follow-up|0
6060593|NCT00485472|9661169|FG001|Overall Study|Lost to Follow-up|1
6060594|NCT00485589|9661182|FG000|Overall Study|Death|2
6060595|NCT00485589|9661183|FG001|Overall Study|Death|2
6060596|NCT00485589|9661184|FG002|Overall Study|Death|0
6060597|NCT00485589|9661182|FG000|Overall Study|Failure to return|6
6060598|NCT00485589|9661183|FG001|Overall Study|Failure to return|5
6060599|NCT00485589|9661184|FG002|Overall Study|Failure to return|1
6060600|NCT00485589|9661182|FG000|Overall Study|Protocol Violation|1
6060601|NCT00485589|9661183|FG001|Overall Study|Protocol Violation|0
6060602|NCT00485589|9661184|FG002|Overall Study|Protocol Violation|0
6060603|NCT00485589|9661182|FG000|Overall Study|Violation of selection criteria at entry|0
6060604|NCT00485589|9661183|FG001|Overall Study|Violation of selection criteria at entry|3
6060605|NCT00485589|9661184|FG002|Overall Study|Violation of selection criteria at entry|1
6060606|NCT00485589|9661182|FG000|Overall Study|Administrative/Other|1
6060607|NCT00485589|9661183|FG001|Overall Study|Administrative/Other|2
6060608|NCT00485589|9661184|FG002|Overall Study|Administrative/Other|1
6060609|NCT00485589|9661182|FG000|Overall Study|Insufficient therapeutic response|10
6060610|NCT00485589|9661183|FG001|Overall Study|Insufficient therapeutic response|3
6060611|NCT00485589|9661184|FG002|Overall Study|Insufficient therapeutic response|1
6060612|NCT00485589|9661182|FG000|Overall Study|Refused treatment/did not cooperate|1
6284266|NCT02326272|9996338|FG010|Initial Period (Week 0 to Week 16)|Consent withdrawn after completing wk16|0
6284267|NCT02326272|9996339|FG011|Initial Period (Week 0 to Week 16)|Consent withdrawn after completing wk16|0
6284268|NCT02326272|9996340|FG012|Initial Period (Week 0 to Week 16)|Consent withdrawn after completing wk16|0
6284269|NCT02326272|9996341|FG013|Initial Period (Week 0 to Week 16)|Consent withdrawn after completing wk16|0
6284270|NCT02326272|9996342|FG014|Initial Period (Week 0 to Week 16)|Consent withdrawn after completing wk16|0
6284271|NCT02326272|9996328|FG000|Maintenance Period (Week 16 to Week 48)|Adverse Event|0
6284272|NCT02326272|9996329|FG001|Maintenance Period (Week 16 to Week 48)|Adverse Event|0
6284273|NCT02326272|9996330|FG002|Maintenance Period (Week 16 to Week 48)|Adverse Event|0
6284274|NCT02326272|9996331|FG003|Maintenance Period (Week 16 to Week 48)|Adverse Event|0
6284275|NCT02326272|9996332|FG004|Maintenance Period (Week 16 to Week 48)|Adverse Event|2
6284276|NCT02326272|9996333|FG005|Maintenance Period (Week 16 to Week 48)|Adverse Event|3
6284277|NCT02326272|9996334|FG006|Maintenance Period (Week 16 to Week 48)|Adverse Event|4
6284278|NCT02326272|9996335|FG007|Maintenance Period (Week 16 to Week 48)|Adverse Event|2
6284279|NCT02326272|9996336|FG008|Maintenance Period (Week 16 to Week 48)|Adverse Event|1
5980411|NCT03173456|9569216|FG003|Baseline|Medication dispensing system malfunction'|0
5980412|NCT03173456|9569217|FG004|Baseline|Medication dispensing system malfunction'|2
5980413|NCT03173456|9569213|FG000|2 Hour Follow-up|Withdrawal by Subject|0
5980414|NCT03173456|9569214|FG001|2 Hour Follow-up|Withdrawal by Subject|1
5980415|NCT03173456|9569215|FG002|2 Hour Follow-up|Withdrawal by Subject|1
6060613|NCT00485589|9661183|FG001|Overall Study|Refused treatment/did not cooperate|0
6060614|NCT00485589|9661184|FG002|Overall Study|Refused treatment/did not cooperate|2
6060615|NCT00485589|9661182|FG000|Overall Study|Withdrawal by Subject|3
6060616|NCT00485589|9661183|FG001|Overall Study|Withdrawal by Subject|2
6060617|NCT00485589|9661184|FG002|Overall Study|Withdrawal by Subject|2
6060618|NCT00485589|9661182|FG000|Overall Study|Adverse Event|3
6060619|NCT00485589|9661183|FG001|Overall Study|Adverse Event|3
6060620|NCT00485589|9661184|FG002|Overall Study|Adverse Event|10
6060621|NCT00485732|9661203|FG000|Overall Study|Protocol Violation|1
6060622|NCT00485732|9661204|FG001|Overall Study|Protocol Violation|3
6060623|NCT00485732|9661203|FG000|Overall Study|Withdrawal by Subject|5
6060624|NCT00485732|9661204|FG001|Overall Study|Withdrawal by Subject|4
6094133|NCT00715403|9707625|FG003|Overall Study|Other Adverse Event than DLT|0
6094134|NCT00715403|9707626|FG004|Overall Study|Other Adverse Event than DLT|0
6094135|NCT00715403|9707627|FG005|Overall Study|Other Adverse Event than DLT|2
5980416|NCT03173456|9569216|FG003|2 Hour Follow-up|Withdrawal by Subject|1
5980417|NCT03173456|9569217|FG004|2 Hour Follow-up|Withdrawal by Subject|2
5980418|NCT03003520|9569240|FG000|Induction|Ongoing|1
5980419|NCT03003520|9569241|FG001|Induction|Ongoing|0
5980420|NCT03003520|9569240|FG000|Induction|Adverse Event|4
6060625|NCT00485732|9661203|FG000|Overall Study|Lost to Follow-up|2
6060626|NCT00485732|9661204|FG001|Overall Study|Lost to Follow-up|2
6060627|NCT00485758|9661212|FG000|Overall Study|Adverse Event|102
6060628|NCT00485758|9661213|FG001|Overall Study|Adverse Event|31
6060629|NCT00485758|9661212|FG000|Overall Study|Death|0
6060630|NCT00485758|9661213|FG001|Overall Study|Death|1
6060631|NCT00485758|9661212|FG000|Overall Study|Lost to Follow-up|5
6060632|NCT00485758|9661213|FG001|Overall Study|Lost to Follow-up|1
6060633|NCT00485758|9661212|FG000|Overall Study|Physician Decision|3
6060634|NCT00485758|9661213|FG001|Overall Study|Physician Decision|3
6060635|NCT00485758|9661212|FG000|Overall Study|Protocol Violation|11
6060636|NCT00485758|9661213|FG001|Overall Study|Protocol Violation|2
6060637|NCT00485758|9661212|FG000|Overall Study|Withdrawal by Subject|32
6060638|NCT00485758|9661213|FG001|Overall Study|Withdrawal by Subject|27
6060639|NCT00485758|9661212|FG000|Overall Study|Study Terminated by Sponsor|3
6060640|NCT00485758|9661213|FG001|Overall Study|Study Terminated by Sponsor|0
6060641|NCT00486044|9661263|FG000|Overall Study|Withdrawal by Subject|2
6060642|NCT00486044|9661264|FG001|Overall Study|Withdrawal by Subject|1
6060643|NCT00486044|9661263|FG000|Overall Study|Adverse Event|0
6060644|NCT00486044|9661264|FG001|Overall Study|Adverse Event|1
6060645|NCT00486044|9661263|FG000|Overall Study|Lost to Follow-up|0
6060646|NCT00486044|9661264|FG001|Overall Study|Lost to Follow-up|1
6060647|NCT00486226|9661270|FG000|Overall Study|Death|3
6060648|NCT00486226|9661270|FG000|Overall Study|Adverse Event|1
6060649|NCT00486226|9661270|FG000|Overall Study|Withdrawal by Subject|1
6060650|NCT00486226|9661270|FG000|Overall Study|Lost to Follow-up|8
6060651|NCT00486252|9661277|FG000|Overall Study|Adverse Event|7
6060652|NCT00486252|9661277|FG000|Overall Study|Lack of Efficacy|9
6060653|NCT00486252|9661277|FG000|Overall Study|Lost to Follow-up|24
6060654|NCT00486252|9661277|FG000|Overall Study|Other|18
6060655|NCT00486265|9661283|FG000|Overall Study|Adverse Event|1
6060656|NCT00486265|9661283|FG000|Overall Study|Lack of Efficacy|8
6060657|NCT00486278|9661287|FG000|Overall Study|Adverse Event|5
6060658|NCT00486278|9661287|FG000|Overall Study|Withdrawal by Subject|2
6060659|NCT00486278|9661287|FG000|Overall Study|Physician Decision|2
6060660|NCT00486291|9661303|FG000|Overall Study|Adverse Event|3
6060661|NCT00486291|9661304|FG001|Overall Study|Adverse Event|4
6060662|NCT00486291|9661303|FG000|Overall Study|Lost to Follow-up|3
6060663|NCT00486291|9661304|FG001|Overall Study|Lost to Follow-up|7
6060664|NCT00486291|9661303|FG000|Overall Study|protocol non-compliance|10
6060665|NCT00486291|9661304|FG001|Overall Study|protocol non-compliance|15
6060666|NCT00486291|9661303|FG000|Overall Study|requirement for restricted medication|0
6060667|NCT00486291|9661304|FG001|Overall Study|requirement for restricted medication|3
6060668|NCT00486330|9661310|FG000|Overall Study|Adverse Event|2
6060669|NCT00486434|9661316|FG000|Overall Study|Withdrawal by Subject|34
6060670|NCT00486434|9661317|FG001|Overall Study|Withdrawal by Subject|39
6060671|NCT00486434|9661316|FG000|Overall Study|Adverse Event|118
6060672|NCT00486434|9661317|FG001|Overall Study|Adverse Event|44
6060673|NCT00486434|9661316|FG000|Overall Study|Protocol Violation|22
6060674|NCT00486434|9661317|FG001|Overall Study|Protocol Violation|21
6060675|NCT00486434|9661316|FG000|Overall Study|Lack of Efficacy|12
6060676|NCT00486434|9661317|FG001|Overall Study|Lack of Efficacy|19
6060677|NCT00486434|9661316|FG000|Overall Study|Lost to Follow-up|2
6060678|NCT00486434|9661317|FG001|Overall Study|Lost to Follow-up|3
6060679|NCT00486434|9661316|FG000|Overall Study|Death|1
6060680|NCT00486434|9661317|FG001|Overall Study|Death|2
6284280|NCT02326272|9996337|FG009|Maintenance Period (Week 16 to Week 48)|Adverse Event|0
6284281|NCT02326272|9996338|FG010|Maintenance Period (Week 16 to Week 48)|Adverse Event|0
6284282|NCT02326272|9996339|FG011|Maintenance Period (Week 16 to Week 48)|Adverse Event|0
6284283|NCT02326272|9996340|FG012|Maintenance Period (Week 16 to Week 48)|Adverse Event|0
6284284|NCT02326272|9996341|FG013|Maintenance Period (Week 16 to Week 48)|Adverse Event|0
6284285|NCT02326272|9996342|FG014|Maintenance Period (Week 16 to Week 48)|Adverse Event|0
6284286|NCT02326272|9996328|FG000|Maintenance Period (Week 16 to Week 48)|Lack of Efficacy|0
6284287|NCT02326272|9996329|FG001|Maintenance Period (Week 16 to Week 48)|Lack of Efficacy|0
6284288|NCT02326272|9996330|FG002|Maintenance Period (Week 16 to Week 48)|Lack of Efficacy|0
6284289|NCT02326272|9996331|FG003|Maintenance Period (Week 16 to Week 48)|Lack of Efficacy|0
6284290|NCT02326272|9996332|FG004|Maintenance Period (Week 16 to Week 48)|Lack of Efficacy|0
6284291|NCT02326272|9996333|FG005|Maintenance Period (Week 16 to Week 48)|Lack of Efficacy|2
6284292|NCT02326272|9996334|FG006|Maintenance Period (Week 16 to Week 48)|Lack of Efficacy|1
6284293|NCT02326272|9996335|FG007|Maintenance Period (Week 16 to Week 48)|Lack of Efficacy|0
6284294|NCT02326272|9996336|FG008|Maintenance Period (Week 16 to Week 48)|Lack of Efficacy|1
6284295|NCT02326272|9996337|FG009|Maintenance Period (Week 16 to Week 48)|Lack of Efficacy|1
6202943|NCT01508702|9863496|FG000|Overall Study|Protocol Violation|2
6202944|NCT01508702|9863497|FG001|Overall Study|Protocol Violation|1
6060681|NCT00486434|9661316|FG000|Overall Study|Personal reasons|5
6060682|NCT00486434|9661317|FG001|Overall Study|Personal reasons|6
6060683|NCT00486603|9661340|FG000|Overall Study|Withdrawal by Subject|1
6060684|NCT00486603|9661341|FG001|Overall Study|Withdrawal by Subject|0
6060685|NCT00486603|9661342|FG002|Overall Study|Withdrawal by Subject|0
6060686|NCT00486603|9661343|FG003|Overall Study|Withdrawal by Subject|0
6060687|NCT00486603|9661344|FG004|Overall Study|Withdrawal by Subject|0
6060688|NCT00486603|9661340|FG000|Overall Study|Physician Decision|0
6060689|NCT00486603|9661341|FG001|Overall Study|Physician Decision|1
6060690|NCT00486603|9661342|FG002|Overall Study|Physician Decision|0
6060691|NCT00486603|9661343|FG003|Overall Study|Physician Decision|0
6060692|NCT00486603|9661344|FG004|Overall Study|Physician Decision|0
6060693|NCT00486720|9661372|FG000|Overall Study|Adverse Event|1
6060694|NCT00486720|9661373|FG001|Overall Study|Adverse Event|2
6060695|NCT00486720|9661372|FG000|Overall Study|Lack of Efficacy|4
6060696|NCT00486720|9661373|FG001|Overall Study|Lack of Efficacy|6
6094136|NCT00715403|9707628|FG006|Overall Study|Other Adverse Event than DLT|0
6094137|NCT00715403|9707622|FG000|Overall Study|Protocol Violation|0
6094138|NCT00715403|9707623|FG001|Overall Study|Protocol Violation|0
6284296|NCT02326272|9996338|FG010|Maintenance Period (Week 16 to Week 48)|Lack of Efficacy|0
6284297|NCT02326272|9996339|FG011|Maintenance Period (Week 16 to Week 48)|Lack of Efficacy|0
6284298|NCT02326272|9996340|FG012|Maintenance Period (Week 16 to Week 48)|Lack of Efficacy|0
6094139|NCT00715403|9707624|FG002|Overall Study|Protocol Violation|0
6094140|NCT00715403|9707625|FG003|Overall Study|Protocol Violation|0
6094141|NCT00715403|9707626|FG004|Overall Study|Protocol Violation|0
6094142|NCT00715403|9707627|FG005|Overall Study|Protocol Violation|1
6094143|NCT00715403|9707628|FG006|Overall Study|Protocol Violation|0
6094144|NCT00715403|9707622|FG000|Overall Study|Other reason not defined above|0
6094145|NCT00715403|9707623|FG001|Overall Study|Other reason not defined above|0
6094146|NCT00715403|9707624|FG002|Overall Study|Other reason not defined above|1
6094147|NCT00715403|9707625|FG003|Overall Study|Other reason not defined above|0
6094148|NCT00715403|9707626|FG004|Overall Study|Other reason not defined above|1
6094149|NCT00715403|9707627|FG005|Overall Study|Other reason not defined above|1
6094150|NCT00715403|9707628|FG006|Overall Study|Other reason not defined above|0
6094151|NCT00715429|9707646|FG000|Overall Study|Did not complete the study diary|0
6094152|NCT00715429|9707647|FG001|Overall Study|Did not complete the study diary|1
6094153|NCT00715520|9707656|FG000|Overall Study|Screen failure|8
6094154|NCT00715520|9707657|FG001|Overall Study|Screen failure|1
6094155|NCT00715520|9707658|FG002|Overall Study|Screen failure|1
6094156|NCT00715520|9707656|FG000|Overall Study|Withdrawal by Subject|2
6094157|NCT00715520|9707657|FG001|Overall Study|Withdrawal by Subject|0
6094158|NCT00715520|9707658|FG002|Overall Study|Withdrawal by Subject|1
6094159|NCT00715559|9707666|FG000|Overall Study|medication not tolerated - nausea|1
6094160|NCT00715624|9707672|FG000|Overall Study|Adverse Event|12
6094161|NCT00715624|9707673|FG001|Overall Study|Adverse Event|37
6094162|NCT00715624|9707672|FG000|Overall Study|Lack of Efficacy|11
6094163|NCT00715624|9707673|FG001|Overall Study|Lack of Efficacy|11
6094164|NCT00715624|9707672|FG000|Overall Study|Lost to Follow-up|1
6094165|NCT00715624|9707673|FG001|Overall Study|Lost to Follow-up|2
6094166|NCT00715624|9707672|FG000|Overall Study|Protocol Violation|1
6094167|NCT00715624|9707673|FG001|Overall Study|Protocol Violation|0
6094168|NCT00715624|9707672|FG000|Overall Study|Withdrawal by Subject|11
6094169|NCT00715624|9707673|FG001|Overall Study|Withdrawal by Subject|25
6094170|NCT00715624|9707672|FG000|Overall Study|Familial and personal reasons|10
6094171|NCT00715624|9707673|FG001|Overall Study|Familial and personal reasons|22
6094172|NCT00715624|9707672|FG000|Overall Study|Poor compliance|6
6094173|NCT00715624|9707673|FG001|Overall Study|Poor compliance|13
6094174|NCT00715624|9707672|FG000|Overall Study|Sponsor decision|0
6094175|NCT00715624|9707673|FG001|Overall Study|Sponsor decision|4
6094176|NCT00715624|9707672|FG000|Overall Study|Incorrect randomization (not treated)|0
6094177|NCT00715624|9707673|FG001|Overall Study|Incorrect randomization (not treated)|1
6094178|NCT00715624|9707672|FG000|Overall Study|Other|0
6094179|NCT00715624|9707673|FG001|Overall Study|Other|1
6094180|NCT00715676|9707691|FG000|Overall Study|Adverse Event|3
6094181|NCT00715676|9707692|FG001|Overall Study|Adverse Event|5
6094182|NCT00715676|9707693|FG002|Overall Study|Adverse Event|21
6094183|NCT00715676|9707691|FG000|Overall Study|Withdrawal by Subject|1
6094184|NCT00715676|9707692|FG001|Overall Study|Withdrawal by Subject|3
6094185|NCT00715676|9707693|FG002|Overall Study|Withdrawal by Subject|8
6094186|NCT00715676|9707691|FG000|Overall Study|Lost to Follow-up|1
6094187|NCT00715676|9707692|FG001|Overall Study|Lost to Follow-up|2
6094188|NCT00715676|9707693|FG002|Overall Study|Lost to Follow-up|1
6094189|NCT00715676|9707691|FG000|Overall Study|Terminated by Sponsor|1
6094190|NCT00715676|9707692|FG001|Overall Study|Terminated by Sponsor|0
6094191|NCT00715676|9707693|FG002|Overall Study|Terminated by Sponsor|0
6094192|NCT00715676|9707691|FG000|Overall Study|Did Not Meet Entry Criteria|0
6094193|NCT00715676|9707692|FG001|Overall Study|Did Not Meet Entry Criteria|0
6094194|NCT00715676|9707693|FG002|Overall Study|Did Not Meet Entry Criteria|1
6094195|NCT00715676|9707691|FG000|Overall Study|Use of Exclusionary Medication|0
6094196|NCT00715676|9707692|FG001|Overall Study|Use of Exclusionary Medication|0
6094197|NCT00715676|9707693|FG002|Overall Study|Use of Exclusionary Medication|1
6094198|NCT00715676|9707691|FG000|Overall Study|Elevated Blood Glucose|0
6094199|NCT00715676|9707692|FG001|Overall Study|Elevated Blood Glucose|1
6094200|NCT00715676|9707693|FG002|Overall Study|Elevated Blood Glucose|0
6094201|NCT00715793|9707733|FG000|Phase 1 RP2D DAC + TMZ|secondary disease in Cycle 1|1
6060697|NCT00486720|9661372|FG000|Overall Study|Physician Decision|1
6060698|NCT00486720|9661373|FG001|Overall Study|Physician Decision|2
6060699|NCT00486720|9661372|FG000|Overall Study|Protocol Violation|1
6094202|NCT00715793|9707734|FG001|Phase 1 RP2D DAC + TMZ|secondary disease in Cycle 1|0
6094203|NCT00715793|9707733|FG000|Phase 2 DAC (0.15 mg/kg) + TMZ|not assessable for tumor response|0
6060700|NCT00486720|9661373|FG001|Overall Study|Protocol Violation|0
6060701|NCT00486720|9661372|FG000|Overall Study|Withdrawal by Subject|3
6060702|NCT00486720|9661373|FG001|Overall Study|Withdrawal by Subject|1
6060703|NCT00486720|9661372|FG000|Overall Study|Progressive Disease|0
6060704|NCT00486720|9661373|FG001|Overall Study|Progressive Disease|1
6060705|NCT00486759|9661381|FG000|Treatment|Adverse event/intercurrent illness|86
6060706|NCT00486759|9661382|FG001|Treatment|Adverse event/intercurrent illness|39
6060707|NCT00486759|9661381|FG000|Treatment|Insufficient therapeutic response|37
6060708|NCT00486759|9661382|FG001|Treatment|Insufficient therapeutic response|39
6060709|NCT00486759|9661381|FG000|Treatment|Death|17
6060710|NCT00486759|9661382|FG001|Treatment|Death|10
6060711|NCT00486759|9661381|FG000|Treatment|Withdrew consent|15
6060712|NCT00486759|9661382|FG001|Treatment|Withdrew consent|12
6060713|NCT00486759|9661381|FG000|Treatment|Administrative/reason not specified|17
6060714|NCT00486759|9661382|FG001|Treatment|Administrative/reason not specified|21
6060715|NCT00486759|9661381|FG000|Treatment|Refused treatment|10
6060716|NCT00486759|9661382|FG001|Treatment|Refused treatment|7
6060717|NCT00486759|9661381|FG000|Treatment|Violation of selection criteria at entry|3
6060718|NCT00486759|9661382|FG001|Treatment|Violation of selection criteria at entry|3
6060719|NCT00486759|9661381|FG000|Treatment|Other protocol violation|1
6060720|NCT00486759|9661382|FG001|Treatment|Other protocol violation|5
6060721|NCT00486759|9661381|FG000|Treatment|Failure to return|1
6060722|NCT00486759|9661382|FG001|Treatment|Failure to return|1
6060723|NCT00486759|9661381|FG000|Safety Follow-up|Insufficient therapeutic response|40
6060724|NCT00486759|9661382|FG001|Safety Follow-up|Insufficient therapeutic response|50
6060725|NCT00486759|9661381|FG000|Safety Follow-up|Death|40
6060726|NCT00486759|9661382|FG001|Safety Follow-up|Death|29
6060727|NCT00486759|9661381|FG000|Safety Follow-up|Withdrew consent|32
6060728|NCT00486759|9661382|FG001|Safety Follow-up|Withdrew consent|23
6060729|NCT00486759|9661381|FG000|Safety Follow-up|Failure to return|9
6060730|NCT00486759|9661382|FG001|Safety Follow-up|Failure to return|6
6060731|NCT00486759|9661381|FG000|Safety Follow-up|Administrative/not specified|8
6060732|NCT00486759|9661382|FG001|Safety Follow-up|Administrative/not specified|6
6060733|NCT00486759|9661381|FG000|Safety Follow-up|Refused treatment/did not cooperate|6
6060734|NCT00486759|9661382|FG001|Safety Follow-up|Refused treatment/did not cooperate|4
6060735|NCT00486759|9661381|FG000|Safety Follow-up|Adverse event/intercurrent illness|4
6060736|NCT00486759|9661382|FG001|Safety Follow-up|Adverse event/intercurrent illness|0
6060737|NCT00486811|9661391|FG000|Overall Study|Adverse Event|28
6060738|NCT00486811|9661392|FG001|Overall Study|Adverse Event|60
6060739|NCT00486811|9661393|FG002|Overall Study|Adverse Event|135
6060740|NCT00486811|9661391|FG000|Overall Study|Lack of Efficacy|34
6060741|NCT00486811|9661392|FG001|Overall Study|Lack of Efficacy|14
6060742|NCT00486811|9661393|FG002|Overall Study|Lack of Efficacy|7
6060743|NCT00486811|9661391|FG000|Overall Study|Lost to Follow-up|4
6060744|NCT00486811|9661392|FG001|Overall Study|Lost to Follow-up|6
6060745|NCT00486811|9661393|FG002|Overall Study|Lost to Follow-up|4
6060746|NCT00486811|9661391|FG000|Overall Study|Withdrawal by Subject|33
6060747|NCT00486811|9661392|FG001|Overall Study|Withdrawal by Subject|44
6060748|NCT00486811|9661393|FG002|Overall Study|Withdrawal by Subject|58
6060749|NCT00486811|9661391|FG000|Overall Study|Study drug non-compliant|5
6060750|NCT00486811|9661392|FG001|Overall Study|Study drug non-compliant|6
6060751|NCT00486811|9661393|FG002|Overall Study|Study drug non-compliant|3
6060752|NCT00486811|9661391|FG000|Overall Study|All other|18
6060753|NCT00486811|9661392|FG001|Overall Study|All other|11
6060754|NCT00486811|9661393|FG002|Overall Study|All other|7
6060755|NCT00486837|9661412|FG000|Overall Study|Withdrawal by Subject|1
6060756|NCT00486837|9661413|FG001|Overall Study|Withdrawal by Subject|0
6060757|NCT00486837|9661412|FG000|Overall Study|Adverse Event|1
6060758|NCT00486837|9661413|FG001|Overall Study|Adverse Event|1
6060759|NCT00486837|9661412|FG000|Overall Study|Protocol Violation|4
6060760|NCT00486837|9661413|FG001|Overall Study|Protocol Violation|2
6060761|NCT00486837|9661412|FG000|Overall Study|No sputum, devise issues, exacerbation|3
6060762|NCT00486837|9661413|FG001|Overall Study|No sputum, devise issues, exacerbation|4
6060763|NCT00486902|9661433|FG000|Overall Study|Withdrawal by Subject|1
6060764|NCT00486902|9661434|FG001|Overall Study|Withdrawal by Subject|2
6060765|NCT00486902|9661433|FG000|Overall Study|decision for postpartum tubal ligation|3
6060766|NCT00486902|9661434|FG001|Overall Study|decision for postpartum tubal ligation|1
6060767|NCT00486902|9661433|FG000|Overall Study|spinal anesthetic protocal violation|1
6060768|NCT00486902|9661434|FG001|Overall Study|spinal anesthetic protocal violation|1
6060769|NCT00486902|9661433|FG000|Overall Study|Did not meet inclusion criteria|1
6060770|NCT00486902|9661434|FG001|Overall Study|Did not meet inclusion criteria|0
6060771|NCT00486902|9661433|FG000|Overall Study|No toradol due to hemmorhage or allergy|3
6060772|NCT00486902|9661434|FG001|Overall Study|No toradol due to hemmorhage or allergy|1
6060773|NCT00486954|9661444|FG000|Pilot Part|Adverse Event|4
6060774|NCT00486954|9661445|FG001|Pilot Part|Adverse Event|0
6060775|NCT00486954|9661446|FG002|Pilot Part|Adverse Event|5
6060776|NCT00486954|9661447|FG003|Pilot Part|Adverse Event|0
6060777|NCT00486954|9661448|FG004|Pilot Part|Adverse Event|0
6060778|NCT00486954|9661444|FG000|Pilot Part|Disease Progression|2
6060779|NCT00486954|9661445|FG001|Pilot Part|Disease Progression|0
6060780|NCT00486954|9661446|FG002|Pilot Part|Disease Progression|1
6060781|NCT00486954|9661447|FG003|Pilot Part|Disease Progression|0
6060782|NCT00486954|9661448|FG004|Pilot Part|Disease Progression|0
6060783|NCT00486954|9661444|FG000|Randomized Part|Lost to Follow-up|0
6060784|NCT00486954|9661445|FG001|Randomized Part|Lost to Follow-up|0
6060785|NCT00486954|9661446|FG002|Randomized Part|Lost to Follow-up|0
6060786|NCT00486954|9661447|FG003|Randomized Part|Lost to Follow-up|0
6060787|NCT00486954|9661448|FG004|Randomized Part|Lost to Follow-up|1
6060788|NCT00486954|9661444|FG000|Randomized Part|Withdrawal by Subject|0
6060789|NCT00486954|9661445|FG001|Randomized Part|Withdrawal by Subject|0
6060790|NCT00486954|9661446|FG002|Randomized Part|Withdrawal by Subject|0
6060791|NCT00486954|9661447|FG003|Randomized Part|Withdrawal by Subject|1
6094204|NCT00715793|9707734|FG001|Phase 2 DAC (0.15 mg/kg) + TMZ|not assessable for tumor response|2
6094205|NCT00715910|9707754|FG000|Booster and ESFU Phase|Lost to Follow-up|0
6094206|NCT00715910|9707755|FG001|Booster and ESFU Phase|Lost to Follow-up|0
6094207|NCT00715910|9707756|FG002|Booster and ESFU Phase|Lost to Follow-up|0
6094208|NCT00715910|9707757|FG003|Booster and ESFU Phase|Lost to Follow-up|6
6284299|NCT02326272|9996341|FG013|Maintenance Period (Week 16 to Week 48)|Lack of Efficacy|0
6284300|NCT02326272|9996342|FG014|Maintenance Period (Week 16 to Week 48)|Lack of Efficacy|0
6284301|NCT02326272|9996328|FG000|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|0
6284302|NCT02326272|9996329|FG001|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|0
6284303|NCT02326272|9996330|FG002|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|0
6284304|NCT02326272|9996331|FG003|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|0
6284305|NCT02326272|9996332|FG004|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|0
6284306|NCT02326272|9996333|FG005|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|2
6284307|NCT02326272|9996334|FG006|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|0
6284308|NCT02326272|9996335|FG007|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|2
6284309|NCT02326272|9996336|FG008|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|0
6284310|NCT02326272|9996337|FG009|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|0
6284311|NCT02326272|9996338|FG010|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|0
6284312|NCT02326272|9996339|FG011|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|0
6284313|NCT02326272|9996340|FG012|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|0
6284314|NCT02326272|9996341|FG013|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|0
6060792|NCT00486954|9661448|FG004|Randomized Part|Withdrawal by Subject|0
6094209|NCT00715910|9707758|FG004|Booster and ESFU Phase|Lost to Follow-up|1
6094210|NCT00715910|9707759|FG005|Booster and ESFU Phase|Lost to Follow-up|13
6094211|NCT00715910|9707754|FG000|Booster and ESFU Phase|Other|0
6094212|NCT00715910|9707755|FG001|Booster and ESFU Phase|Other|0
6094213|NCT00715910|9707756|FG002|Booster and ESFU Phase|Other|0
6094214|NCT00715910|9707757|FG003|Booster and ESFU Phase|Other|5
6094215|NCT00715910|9707758|FG004|Booster and ESFU Phase|Other|1
6094216|NCT00715910|9707759|FG005|Booster and ESFU Phase|Other|0
6094217|NCT00715949|9707775|FG000|Overall Study|could not finish first test|4
6094218|NCT00716092|9707801|FG000|Overall Study|Other incl. Lack of Efficacy|2
6094219|NCT00716092|9707802|FG001|Overall Study|Other incl. Lack of Efficacy|1
6094220|NCT00716092|9707803|FG002|Overall Study|Other incl. Lack of Efficacy|0
6094221|NCT00716144|9707815|FG000|Overall Study|Withdrawal by Subject|4
6094222|NCT00716144|9707816|FG001|Overall Study|Withdrawal by Subject|2
6094223|NCT00716144|9707817|FG002|Overall Study|Withdrawal by Subject|6
6094224|NCT00716144|9707818|FG003|Overall Study|Withdrawal by Subject|6
6094225|NCT00716144|9707815|FG000|Overall Study|Lost to Follow-up|2
6094226|NCT00716144|9707816|FG001|Overall Study|Lost to Follow-up|2
6094227|NCT00716144|9707817|FG002|Overall Study|Lost to Follow-up|1
6094228|NCT00716144|9707818|FG003|Overall Study|Lost to Follow-up|2
6094229|NCT00716144|9707815|FG000|Overall Study|Adverse Event|0
6094230|NCT00716144|9707816|FG001|Overall Study|Adverse Event|0
6094231|NCT00716144|9707817|FG002|Overall Study|Adverse Event|0
6094232|NCT00716144|9707818|FG003|Overall Study|Adverse Event|2
6094233|NCT00716144|9707815|FG000|Overall Study|Non-compliance|1
6094234|NCT00716144|9707816|FG001|Overall Study|Non-compliance|0
6094235|NCT00716144|9707817|FG002|Overall Study|Non-compliance|0
6094236|NCT00716144|9707818|FG003|Overall Study|Non-compliance|0
6202945|NCT01508702|9863496|FG000|Overall Study|Lost to Follow-up|1
6202946|NCT01508702|9863497|FG001|Overall Study|Lost to Follow-up|2
6202947|NCT01508702|9863496|FG000|Overall Study|Withdrawal by Subject|11
6202948|NCT01508702|9863497|FG001|Overall Study|Withdrawal by Subject|7
6202949|NCT01508910|9863515|FG000|Treatment|Death|2
6202950|NCT01508910|9863516|FG001|Treatment|Death|3
6202951|NCT01508910|9863517|FG002|Treatment|Death|2
6202952|NCT01508910|9863518|FG003|Treatment|Death|0
6202953|NCT01508910|9863515|FG000|Treatment|Lost to Follow-up|0
6202954|NCT01508910|9863516|FG001|Treatment|Lost to Follow-up|0
6060793|NCT00486954|9661444|FG000|Randomized Part|Sponsor Terminated Study|0
6060794|NCT00486954|9661445|FG001|Randomized Part|Sponsor Terminated Study|0
6060795|NCT00486954|9661446|FG002|Randomized Part|Sponsor Terminated Study|0
6094237|NCT00716144|9707815|FG000|Overall Study|Protocol Violation|2
6094238|NCT00716144|9707816|FG001|Overall Study|Protocol Violation|0
6094239|NCT00716144|9707817|FG002|Overall Study|Protocol Violation|1
6094240|NCT00716144|9707818|FG003|Overall Study|Protocol Violation|0
6094241|NCT00716144|9707815|FG000|Overall Study|Physician Decision|0
6094242|NCT00716144|9707816|FG001|Overall Study|Physician Decision|1
6094243|NCT00716144|9707817|FG002|Overall Study|Physician Decision|2
6094244|NCT00716144|9707818|FG003|Overall Study|Physician Decision|2
6202955|NCT01508910|9863517|FG002|Treatment|Lost to Follow-up|2
6060796|NCT00486954|9661447|FG003|Randomized Part|Sponsor Terminated Study|19
6060797|NCT00486954|9661448|FG004|Randomized Part|Sponsor Terminated Study|13
6060798|NCT00487084|9661461|FG000|Overall Study|Did not receive intervention|4
6060799|NCT00487084|9661462|FG001|Overall Study|Did not receive intervention|3
6060800|NCT00487084|9661463|FG002|Overall Study|Did not receive intervention|5
6060801|NCT00487188|9661473|FG000|Induction Phase|Abnormality of Laboratory Test|0
6060802|NCT00487188|9661474|FG001|Induction Phase|Abnormality of Laboratory Test|1
6060803|NCT00487188|9661475|FG002|Induction Phase|Abnormality of Laboratory Test|0
6060804|NCT00487188|9661473|FG000|Induction Phase|Adverse Event|5
6060805|NCT00487188|9661474|FG001|Induction Phase|Adverse Event|0
6060806|NCT00487188|9661475|FG002|Induction Phase|Adverse Event|0
6060807|NCT00487188|9661473|FG000|Induction Phase|Lack of Efficacy|0
6060808|NCT00487188|9661474|FG001|Induction Phase|Lack of Efficacy|1
6060809|NCT00487188|9661475|FG002|Induction Phase|Lack of Efficacy|0
6060810|NCT00487188|9661473|FG000|Induction Phase|Protocol Violation|1
6060811|NCT00487188|9661474|FG001|Induction Phase|Protocol Violation|0
6060812|NCT00487188|9661475|FG002|Induction Phase|Protocol Violation|0
6060813|NCT00487188|9661473|FG000|Induction Phase|Refused Treatment|1
6060814|NCT00487188|9661474|FG001|Induction Phase|Refused Treatment|2
6060815|NCT00487188|9661475|FG002|Induction Phase|Refused Treatment|0
6060816|NCT00487188|9661473|FG000|Induction Phase|Lost to Follow-up|2
6060817|NCT00487188|9661474|FG001|Induction Phase|Lost to Follow-up|2
6060818|NCT00487188|9661475|FG002|Induction Phase|Lost to Follow-up|0
6060819|NCT00487188|9661473|FG000|Induction Phase|Administrative|0
6060820|NCT00487188|9661474|FG001|Induction Phase|Administrative|1
6060821|NCT00487188|9661475|FG002|Induction Phase|Administrative|0
6060822|NCT00487188|9661473|FG000|Maintenance Phase|Adverse Event|1
6060823|NCT00487188|9661474|FG001|Maintenance Phase|Adverse Event|0
6060824|NCT00487188|9661475|FG002|Maintenance Phase|Adverse Event|0
6094245|NCT00716144|9707815|FG000|Overall Study|Intercurrent illness|0
6094246|NCT00716144|9707816|FG001|Overall Study|Intercurrent illness|0
6094247|NCT00716144|9707817|FG002|Overall Study|Intercurrent illness|1
6094248|NCT00716144|9707818|FG003|Overall Study|Intercurrent illness|0
6094249|NCT00716144|9707815|FG000|Overall Study|Withdrew consent, allowed use of data|0
6094250|NCT00716144|9707816|FG001|Overall Study|Withdrew consent, allowed use of data|0
6094251|NCT00716144|9707817|FG002|Overall Study|Withdrew consent, allowed use of data|1
6094252|NCT00716144|9707818|FG003|Overall Study|Withdrew consent, allowed use of data|0
6094253|NCT00716144|9707815|FG000|Overall Study|Adverse event: left foot pain|0
6094254|NCT00716144|9707816|FG001|Overall Study|Adverse event: left foot pain|1
6202956|NCT01508910|9863518|FG003|Treatment|Lost to Follow-up|1
6202957|NCT01508910|9863515|FG000|Treatment|Withdrawal by Subject|0
6202958|NCT01508910|9863516|FG001|Treatment|Withdrawal by Subject|1
6202959|NCT01508910|9863517|FG002|Treatment|Withdrawal by Subject|6
6202960|NCT01508910|9863518|FG003|Treatment|Withdrawal by Subject|1
6202961|NCT01508910|9863515|FG000|Treatment|Sponsor Decision|0
6202962|NCT01508910|9863516|FG001|Treatment|Sponsor Decision|0
6202963|NCT01508910|9863517|FG002|Treatment|Sponsor Decision|0
6202964|NCT01508910|9863518|FG003|Treatment|Sponsor Decision|1
6284315|NCT02326272|9996342|FG014|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|0
6284316|NCT02326272|9996328|FG000|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|0
6284317|NCT02326272|9996329|FG001|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|0
6284318|NCT02326272|9996330|FG002|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|0
6284319|NCT02326272|9996331|FG003|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|1
6284320|NCT02326272|9996332|FG004|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|0
6284321|NCT02326272|9996333|FG005|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|3
6284322|NCT02326272|9996334|FG006|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|1
6284323|NCT02326272|9996335|FG007|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|1
6284324|NCT02326272|9996336|FG008|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|0
6284325|NCT02326272|9996337|FG009|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|1
6284326|NCT02326272|9996338|FG010|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|0
6284327|NCT02326272|9996339|FG011|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|0
6284328|NCT02326272|9996340|FG012|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|0
6284329|NCT02326272|9996341|FG013|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|0
6284330|NCT02326272|9996342|FG014|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|0
6060825|NCT00487188|9661473|FG000|Maintenance Phase|Death|1
6060826|NCT00487188|9661474|FG001|Maintenance Phase|Death|0
6060827|NCT00487188|9661475|FG002|Maintenance Phase|Death|0
6060828|NCT00487188|9661473|FG000|Maintenance Phase|Lost to Follow-up|1
6060829|NCT00487188|9661474|FG001|Maintenance Phase|Lost to Follow-up|0
6060830|NCT00487188|9661475|FG002|Maintenance Phase|Lost to Follow-up|0
6060831|NCT00487188|9661473|FG000|Maintenance Phase|Administrative|0
6060832|NCT00487188|9661474|FG001|Maintenance Phase|Administrative|0
6060833|NCT00487188|9661475|FG002|Maintenance Phase|Administrative|1
6060834|NCT00487240|9661493|FG000|Overall Study|Withdrawal by Subject|12
6060835|NCT00487240|9661494|FG001|Overall Study|Withdrawal by Subject|6
6094255|NCT00716144|9707817|FG002|Overall Study|Adverse event: left foot pain|0
6202965|NCT01508936|9863532|FG000|Overall Study|Adverse Event|11
6202966|NCT01508936|9863533|FG001|Overall Study|Adverse Event|32
6060836|NCT00487240|9661493|FG000|Overall Study|Lost to Follow-up|7
6060837|NCT00487240|9661494|FG001|Overall Study|Lost to Follow-up|6
6060838|NCT00487240|9661493|FG000|Overall Study|Adverse Event|0
6060839|NCT00487240|9661494|FG001|Overall Study|Adverse Event|4
6060840|NCT00487240|9661493|FG000|Overall Study|Protocol Violation|5
6060841|NCT00487240|9661494|FG001|Overall Study|Protocol Violation|5
6060842|NCT00487240|9661493|FG000|Overall Study|Entry Criteria Not Met|3
6060843|NCT00487240|9661494|FG001|Overall Study|Entry Criteria Not Met|4
6060844|NCT00487240|9661493|FG000|Overall Study|Sponsor Decision|2
6060845|NCT00487240|9661494|FG001|Overall Study|Sponsor Decision|1
6060846|NCT00487240|9661493|FG000|Overall Study|Physician Decision|2
6060847|NCT00487240|9661494|FG001|Overall Study|Physician Decision|0
6060848|NCT00487279|9661502|FG000|Overall Study|Death|1
6060849|NCT00487279|9661503|FG001|Overall Study|Death|0
6060850|NCT00487279|9661502|FG000|Overall Study|Withdrawal by Subject|0
6060851|NCT00487279|9661503|FG001|Overall Study|Withdrawal by Subject|2
6060852|NCT00487435|9661518|FG000|Overall Study|Adverse Event|146
6060853|NCT00487435|9661518|FG000|Overall Study|Death|2
6060854|NCT00487435|9661518|FG000|Overall Study|Lack of Efficacy|33
6060855|NCT00487435|9661518|FG000|Overall Study|Lost to Follow-up|54
6060856|NCT00487435|9661518|FG000|Overall Study|Pregnancy|2
6060857|NCT00487435|9661518|FG000|Overall Study|Withdrawal by Subject|132
6060858|NCT00487435|9661518|FG000|Overall Study|Resolution Of Pain|1
6060859|NCT00487435|9661518|FG000|Overall Study|Study Medication Non-Compliant|32
6060860|NCT00487435|9661518|FG000|Overall Study|Other|83
6060861|NCT00487539|9661526|FG000|Overall Study|Adverse Event|3
6060862|NCT00487539|9661527|FG001|Overall Study|Adverse Event|2
6060863|NCT00487539|9661528|FG002|Overall Study|Adverse Event|1
6060864|NCT00487539|9661529|FG003|Overall Study|Adverse Event|1
6060865|NCT00487539|9661526|FG000|Overall Study|Unsatisfactory therapeutic effect|1
6060866|NCT00487539|9661527|FG001|Overall Study|Unsatisfactory therapeutic effect|0
6060867|NCT00487539|9661528|FG002|Overall Study|Unsatisfactory therapeutic effect|0
6060868|NCT00487539|9661529|FG003|Overall Study|Unsatisfactory therapeutic effect|1
6060869|NCT00487539|9661526|FG000|Overall Study|Other|3
6060870|NCT00487539|9661527|FG001|Overall Study|Other|1
6060871|NCT00487539|9661528|FG002|Overall Study|Other|2
6060872|NCT00487539|9661529|FG003|Overall Study|Other|2
6060873|NCT00487552|9661538|FG000|Overall Study|Unsuccessful magnet placements|3
6060874|NCT00487552|9661538|FG000|Overall Study|Death due to progressive malignancy|2
6060875|NCT00487552|9661538|FG000|Overall Study|Stent not placed|1
6060876|NCT00487695|9661553|FG000|First Procedure|invasive cancer on EGD (excl criteria)|1
6060877|NCT00487695|9661554|FG001|First Procedure|invasive cancer on EGD (excl criteria)|0
6060878|NCT00487695|9661553|FG000|First Procedure|active wheezing (did not have procedure)|1
6060879|NCT00487695|9661554|FG001|First Procedure|active wheezing (did not have procedure)|0
6060880|NCT00487695|9661553|FG000|First Procedure|esophageal stricture found (excl crit)|1
6060881|NCT00487695|9661554|FG001|First Procedure|esophageal stricture found (excl crit)|0
6060882|NCT00487695|9661553|FG000|Second Procedure|active wheezing|0
6060883|NCT00487695|9661554|FG001|Second Procedure|active wheezing|1
6060884|NCT00487695|9661553|FG000|Second Procedure|Withdrawal by Subject|1
6060885|NCT00487695|9661554|FG001|Second Procedure|Withdrawal by Subject|2
6060886|NCT00487747|9661568|FG000|Overall Study|Adverse Event|1
6060887|NCT00487747|9661568|FG000|Overall Study|Lost to Follow-up|9
6060888|NCT00487747|9661568|FG000|Overall Study|Lack of Efficacy|1
6060889|NCT00487825|9661574|FG000|Overall Study|Adverse Event|2
6060890|NCT00487825|9661575|FG001|Overall Study|Adverse Event|2
6060891|NCT00487825|9661574|FG000|Overall Study|Lack of Efficacy|1
6060892|NCT00487825|9661575|FG001|Overall Study|Lack of Efficacy|1
6060893|NCT00487825|9661574|FG000|Overall Study|Other|3
6060894|NCT00487825|9661575|FG001|Overall Study|Other|2
6060895|NCT00487942|9661585|FG000|Overall Study|Adverse Event|1
6060896|NCT00487942|9661586|FG001|Overall Study|Adverse Event|1
6060897|NCT00487942|9661587|FG002|Overall Study|Adverse Event|1
6060898|NCT00487942|9661588|FG003|Overall Study|Adverse Event|1
6060899|NCT00487942|9661585|FG000|Overall Study|Lost to Follow-up|1
6060900|NCT00487942|9661586|FG001|Overall Study|Lost to Follow-up|0
6060901|NCT00487942|9661587|FG002|Overall Study|Lost to Follow-up|0
6060902|NCT00487942|9661588|FG003|Overall Study|Lost to Follow-up|1
6060903|NCT00487942|9661585|FG000|Overall Study|Protocol Violation|1
6060904|NCT00487942|9661586|FG001|Overall Study|Protocol Violation|1
6060905|NCT00487942|9661587|FG002|Overall Study|Protocol Violation|0
6060906|NCT00487942|9661588|FG003|Overall Study|Protocol Violation|0
6060907|NCT00487942|9661585|FG000|Overall Study|Withdrawal by Subject|0
6060908|NCT00487942|9661586|FG001|Overall Study|Withdrawal by Subject|1
6060909|NCT00487942|9661587|FG002|Overall Study|Withdrawal by Subject|2
6060910|NCT00487942|9661588|FG003|Overall Study|Withdrawal by Subject|0
6060911|NCT00488033|9661600|FG000|Overall Study|Withdrawal by Subject|1
6060912|NCT00488033|9661601|FG001|Overall Study|Withdrawal by Subject|0
6060913|NCT00488293|9661624|FG000|Overall Study|Lost to Follow-up|28
6060914|NCT00488293|9661625|FG001|Overall Study|Lost to Follow-up|25
6060915|NCT00488293|9661624|FG000|Overall Study|Withdrawal by Subject|5
6060916|NCT00488293|9661625|FG001|Overall Study|Withdrawal by Subject|3
6060917|NCT00488293|9661624|FG000|Overall Study|Death|2
6060918|NCT00488293|9661625|FG001|Overall Study|Death|1
6060919|NCT00488293|9661624|FG000|Overall Study|Misrandomization/Other Unspecified|1
6060920|NCT00488293|9661625|FG001|Overall Study|Misrandomization/Other Unspecified|1
6060921|NCT00488319|9661634|FG000|Overall Study|Adverse Event|1
6060922|NCT00488319|9661635|FG001|Overall Study|Adverse Event|2
6060923|NCT00488319|9661636|FG002|Overall Study|Adverse Event|23
6060924|NCT00488319|9661634|FG000|Overall Study|Lack of Efficacy|6
6060925|NCT00488319|9661635|FG001|Overall Study|Lack of Efficacy|12
6060926|NCT00488319|9661636|FG002|Overall Study|Lack of Efficacy|27
6094256|NCT00716144|9707818|FG003|Overall Study|Adverse event: left foot pain|0
6094257|NCT00716144|9707815|FG000|Overall Study|Clinical Depression|0
6094258|NCT00716144|9707816|FG001|Overall Study|Clinical Depression|1
6094259|NCT00716144|9707817|FG002|Overall Study|Clinical Depression|0
6202967|NCT01508936|9863532|FG000|Overall Study|Lack of Efficacy|0
6202968|NCT01508936|9863533|FG001|Overall Study|Lack of Efficacy|1
6202969|NCT01508936|9863532|FG000|Overall Study|Withdrawal by Subject|4
6202970|NCT01508936|9863533|FG001|Overall Study|Withdrawal by Subject|18
6202971|NCT01508936|9863532|FG000|Overall Study|Protocol Violation|2
6202972|NCT01508936|9863533|FG001|Overall Study|Protocol Violation|3
6202973|NCT01508936|9863532|FG000|Overall Study|Lost to Follow-up|2
6202974|NCT01508936|9863533|FG001|Overall Study|Lost to Follow-up|9
6202975|NCT01508936|9863532|FG000|Overall Study|Other|0
6202976|NCT01508936|9863533|FG001|Overall Study|Other|5
6202977|NCT01508936|9863532|FG000|Overall Study|Data from 2 sites deemed invalid|4
6202978|NCT01508936|9863533|FG001|Overall Study|Data from 2 sites deemed invalid|11
6202979|NCT01509079|9863561|FG000|Overall Study|Lack of Efficacy|0
6202980|NCT01509079|9863562|FG001|Overall Study|Lack of Efficacy|2
6202981|NCT01509079|9863561|FG000|Overall Study|started an excluded medication|0
6202982|NCT01509079|9863562|FG001|Overall Study|started an excluded medication|1
6202983|NCT01509547|9863594|FG000|Overall Study|Lost to Follow-up|24
6202984|NCT01509547|9863595|FG001|Overall Study|Lost to Follow-up|14
6202985|NCT01509547|9863594|FG000|Overall Study|Withdrawal by Subject|11
6202986|NCT01509547|9863595|FG001|Overall Study|Withdrawal by Subject|24
6202987|NCT01509547|9863594|FG000|Overall Study|Physician Decision|0
6202988|NCT01509547|9863595|FG001|Overall Study|Physician Decision|1
6284331|NCT02326272|9996328|FG000|Maintenance Period (Week 16 to Week 48)|Subject moved out of state|0
6284332|NCT02326272|9996329|FG001|Maintenance Period (Week 16 to Week 48)|Subject moved out of state|0
6284333|NCT02326272|9996330|FG002|Maintenance Period (Week 16 to Week 48)|Subject moved out of state|0
6284334|NCT02326272|9996331|FG003|Maintenance Period (Week 16 to Week 48)|Subject moved out of state|0
6284335|NCT02326272|9996332|FG004|Maintenance Period (Week 16 to Week 48)|Subject moved out of state|0
6284336|NCT02326272|9996333|FG005|Maintenance Period (Week 16 to Week 48)|Subject moved out of state|0
6284337|NCT02326272|9996334|FG006|Maintenance Period (Week 16 to Week 48)|Subject moved out of state|0
6284338|NCT02326272|9996335|FG007|Maintenance Period (Week 16 to Week 48)|Subject moved out of state|1
6284339|NCT02326272|9996336|FG008|Maintenance Period (Week 16 to Week 48)|Subject moved out of state|0
6284340|NCT02326272|9996337|FG009|Maintenance Period (Week 16 to Week 48)|Subject moved out of state|0
6284341|NCT02326272|9996338|FG010|Maintenance Period (Week 16 to Week 48)|Subject moved out of state|0
6284342|NCT02326272|9996339|FG011|Maintenance Period (Week 16 to Week 48)|Subject moved out of state|0
6284343|NCT02326272|9996340|FG012|Maintenance Period (Week 16 to Week 48)|Subject moved out of state|0
6284344|NCT02326272|9996341|FG013|Maintenance Period (Week 16 to Week 48)|Subject moved out of state|0
6284345|NCT02326272|9996342|FG014|Maintenance Period (Week 16 to Week 48)|Subject moved out of state|0
6284346|NCT02326272|9996328|FG000|Maintenance Period (Week 16 to Week 48)|Pregnancy|0
6284347|NCT02326272|9996329|FG001|Maintenance Period (Week 16 to Week 48)|Pregnancy|0
6284348|NCT02326272|9996330|FG002|Maintenance Period (Week 16 to Week 48)|Pregnancy|0
6284349|NCT02326272|9996331|FG003|Maintenance Period (Week 16 to Week 48)|Pregnancy|0
6284350|NCT02326272|9996332|FG004|Maintenance Period (Week 16 to Week 48)|Pregnancy|0
6284351|NCT02326272|9996333|FG005|Maintenance Period (Week 16 to Week 48)|Pregnancy|0
6284352|NCT02326272|9996334|FG006|Maintenance Period (Week 16 to Week 48)|Pregnancy|1
6284353|NCT02326272|9996335|FG007|Maintenance Period (Week 16 to Week 48)|Pregnancy|0
6284354|NCT02326272|9996336|FG008|Maintenance Period (Week 16 to Week 48)|Pregnancy|0
6060927|NCT00488319|9661634|FG000|Overall Study|Lost to Follow-up|3
6060928|NCT00488319|9661635|FG001|Overall Study|Lost to Follow-up|5
6060929|NCT00488319|9661636|FG002|Overall Study|Lost to Follow-up|16
6060930|NCT00488319|9661634|FG000|Overall Study|Withdrawal by Subject|5
6060931|NCT00488319|9661635|FG001|Overall Study|Withdrawal by Subject|20
6060932|NCT00488319|9661636|FG002|Overall Study|Withdrawal by Subject|44
6060933|NCT00488319|9661634|FG000|Overall Study|Other reasons for withdrawal|0
6060934|NCT00488319|9661635|FG001|Overall Study|Other reasons for withdrawal|4
6060935|NCT00488319|9661636|FG002|Overall Study|Other reasons for withdrawal|12
6060936|NCT00488345|9661648|FG000|Overall Study|Adverse Event|0
6060937|NCT00488345|9661649|FG001|Overall Study|Adverse Event|1
6060938|NCT00488345|9661650|FG002|Overall Study|Adverse Event|1
6060939|NCT00488345|9661648|FG000|Overall Study|Unable to administer antibiotics at home|0
6060940|NCT00488345|9661649|FG001|Overall Study|Unable to administer antibiotics at home|1
6060941|NCT00488345|9661650|FG002|Overall Study|Unable to administer antibiotics at home|0
6060942|NCT00488345|9661648|FG000|Overall Study|Institutional Review Board review|0
6060943|NCT00488345|9661649|FG001|Overall Study|Institutional Review Board review|0
6060944|NCT00488345|9661650|FG002|Overall Study|Institutional Review Board review|1
6060945|NCT00488345|9661648|FG000|Overall Study|Surgical team recommendation|0
6094260|NCT00716144|9707818|FG003|Overall Study|Clinical Depression|0
6060946|NCT00488345|9661649|FG001|Overall Study|Surgical team recommendation|1
6060947|NCT00488345|9661650|FG002|Overall Study|Surgical team recommendation|0
6060948|NCT00488345|9661648|FG000|Overall Study|Parent/legal guardian request|0
6060949|NCT00488345|9661649|FG001|Overall Study|Parent/legal guardian request|1
6060950|NCT00488345|9661650|FG002|Overall Study|Parent/legal guardian request|1
6060951|NCT00488475|9661659|FG000|Overall Study|Other|1754
6060952|NCT00488514|9661667|FG000|Overall Study|Adverse Event|41
6060953|NCT00488514|9661667|FG000|Overall Study|Lost to Follow-up|44
6060954|NCT00488514|9661667|FG000|Overall Study|Protocol Violation|32
6060955|NCT00488514|9661667|FG000|Overall Study|Withdrawal by Subject|106
6060956|NCT00488514|9661667|FG000|Overall Study|Lack of Efficacy|28
6060957|NCT00488514|9661667|FG000|Overall Study|Did not meet criteria for treatment|30
6060958|NCT00488514|9661667|FG000|Overall Study|Postive drug screen|1
6060959|NCT00488514|9661667|FG000|Overall Study|Withdrawn per medical monitor decision|2
6060960|NCT00488514|9661667|FG000|Overall Study|Investigator decision|1
6060961|NCT00488514|9661667|FG000|Overall Study|Participant had too few migraines|5
6060962|NCT00488514|9661667|FG000|Overall Study|Increase in number of migraines|2
6060963|NCT00488514|9661667|FG000|Overall Study|Increased use of concomitant medication|1
6060964|NCT00488592|9661688|FG000|Overall Study|Withdrawal by Subject|1
6060965|NCT00488592|9661688|FG000|Overall Study|Disease progression|1
6060966|NCT00488592|9661688|FG000|Overall Study|Enrolled but not treated|1
6060967|NCT00488618|9661694|FG000|Overall Study|Adverse Event|13
6060968|NCT00488618|9661695|FG001|Overall Study|Adverse Event|17
6060969|NCT00488618|9661694|FG000|Overall Study|Insufficient Therapeutic Response|18
6060970|NCT00488618|9661695|FG001|Overall Study|Insufficient Therapeutic Response|11
6060971|NCT00488618|9661694|FG000|Overall Study|Protocol Violation|0
6060972|NCT00488618|9661695|FG001|Overall Study|Protocol Violation|2
6060973|NCT00488618|9661694|FG000|Overall Study|Withdrawal of Consent|15
6060974|NCT00488618|9661695|FG001|Overall Study|Withdrawal of Consent|13
6060975|NCT00488618|9661694|FG000|Overall Study|Lost to Follow-up|1
6060976|NCT00488618|9661695|FG001|Overall Study|Lost to Follow-up|0
6060977|NCT00488631|9661707|FG000|Double Blind Period (Week 0-54)|Adverse Event|17
6060978|NCT00488631|9661708|FG001|Double Blind Period (Week 0-54)|Adverse Event|12
6060979|NCT00488631|9661709|FG002|Double Blind Period (Week 0-54)|Adverse Event|12
6060980|NCT00488631|9661710|FG003|Double Blind Period (Week 0-54)|Adverse Event|12
6060981|NCT00488631|9661711|FG004|Double Blind Period (Week 0-54)|Adverse Event|30
6060982|NCT00488631|9661712|FG005|Double Blind Period (Week 0-54)|Adverse Event|50
6060983|NCT00488631|9661713|FG006|Double Blind Period (Week 0-54)|Adverse Event|0
6060984|NCT00488631|9661714|FG007|Double Blind Period (Week 0-54)|Adverse Event|0
6060985|NCT00488631|9661715|FG008|Double Blind Period (Week 0-54)|Adverse Event|0
6060986|NCT00488631|9661716|FG009|Double Blind Period (Week 0-54)|Adverse Event|0
6060987|NCT00488631|9661707|FG000|Double Blind Period (Week 0-54)|Death|0
6060988|NCT00488631|9661708|FG001|Double Blind Period (Week 0-54)|Death|0
6060989|NCT00488631|9661709|FG002|Double Blind Period (Week 0-54)|Death|0
6060990|NCT00488631|9661710|FG003|Double Blind Period (Week 0-54)|Death|0
6060991|NCT00488631|9661711|FG004|Double Blind Period (Week 0-54)|Death|0
6060992|NCT00488631|9661712|FG005|Double Blind Period (Week 0-54)|Death|1
6094261|NCT00716274|9707831|FG000|Study Period II (16-Weeks)|Entry Criteria Not Met|2
6094262|NCT00716274|9707832|FG001|Study Period II (16-Weeks)|Entry Criteria Not Met|0
6094263|NCT00716274|9707833|FG002|Study Period II (16-Weeks)|Entry Criteria Not Met|0
6094264|NCT00716274|9707834|FG003|Study Period II (16-Weeks)|Entry Criteria Not Met|0
6094265|NCT00716274|9707835|FG004|Study Period II (16-Weeks)|Entry Criteria Not Met|0
6094266|NCT00716274|9707836|FG005|Study Period II (16-Weeks)|Entry Criteria Not Met|0
6094267|NCT00716274|9707831|FG000|Study Period II (16-Weeks)|Protocol Violation|0
6094268|NCT00716274|9707832|FG001|Study Period II (16-Weeks)|Protocol Violation|3
6094269|NCT00716274|9707833|FG002|Study Period II (16-Weeks)|Protocol Violation|0
6094270|NCT00716274|9707834|FG003|Study Period II (16-Weeks)|Protocol Violation|0
6094271|NCT00716274|9707835|FG004|Study Period II (16-Weeks)|Protocol Violation|0
6094272|NCT00716274|9707836|FG005|Study Period II (16-Weeks)|Protocol Violation|1
6094273|NCT00716274|9707831|FG000|Study Period II (16-Weeks)|Withdrawal by Subject|1
6094274|NCT00716274|9707832|FG001|Study Period II (16-Weeks)|Withdrawal by Subject|0
6094275|NCT00716274|9707833|FG002|Study Period II (16-Weeks)|Withdrawal by Subject|0
6094276|NCT00716274|9707834|FG003|Study Period II (16-Weeks)|Withdrawal by Subject|0
6094277|NCT00716274|9707835|FG004|Study Period II (16-Weeks)|Withdrawal by Subject|0
6094278|NCT00716274|9707836|FG005|Study Period II (16-Weeks)|Withdrawal by Subject|0
6094279|NCT00716274|9707831|FG000|Study Period II (16-Weeks)|Physician Decision|3
6094280|NCT00716274|9707832|FG001|Study Period II (16-Weeks)|Physician Decision|1
6094281|NCT00716274|9707833|FG002|Study Period II (16-Weeks)|Physician Decision|0
6094282|NCT00716274|9707834|FG003|Study Period II (16-Weeks)|Physician Decision|0
6202989|NCT01509664|9863650|FG000|Overall Study|Lost to Follow-up|15
6094283|NCT00716274|9707835|FG004|Study Period II (16-Weeks)|Physician Decision|0
6094284|NCT00716274|9707836|FG005|Study Period II (16-Weeks)|Physician Decision|1
6202990|NCT01509664|9863651|FG001|Overall Study|Lost to Follow-up|21
6060993|NCT00488631|9661713|FG006|Double Blind Period (Week 0-54)|Death|0
6060994|NCT00488631|9661714|FG007|Double Blind Period (Week 0-54)|Death|0
6094285|NCT00716274|9707831|FG000|Study Period II (16-Weeks)|Parent/Caregiver Decision|3
6094286|NCT00716274|9707832|FG001|Study Period II (16-Weeks)|Parent/Caregiver Decision|3
6094287|NCT00716274|9707833|FG002|Study Period II (16-Weeks)|Parent/Caregiver Decision|0
6060995|NCT00488631|9661715|FG008|Double Blind Period (Week 0-54)|Death|0
6060996|NCT00488631|9661716|FG009|Double Blind Period (Week 0-54)|Death|0
6060997|NCT00488631|9661707|FG000|Double Blind Period (Week 0-54)|Unsatisfactory therapeutic effect|19
6060998|NCT00488631|9661708|FG001|Double Blind Period (Week 0-54)|Unsatisfactory therapeutic effect|17
6060999|NCT00488631|9661709|FG002|Double Blind Period (Week 0-54)|Unsatisfactory therapeutic effect|22
6061000|NCT00488631|9661710|FG003|Double Blind Period (Week 0-54)|Unsatisfactory therapeutic effect|18
6061001|NCT00488631|9661711|FG004|Double Blind Period (Week 0-54)|Unsatisfactory therapeutic effect|56
6061002|NCT00488631|9661712|FG005|Double Blind Period (Week 0-54)|Unsatisfactory therapeutic effect|124
6061003|NCT00488631|9661713|FG006|Double Blind Period (Week 0-54)|Unsatisfactory therapeutic effect|0
6061004|NCT00488631|9661714|FG007|Double Blind Period (Week 0-54)|Unsatisfactory therapeutic effect|0
6061005|NCT00488631|9661715|FG008|Double Blind Period (Week 0-54)|Unsatisfactory therapeutic effect|0
6061006|NCT00488631|9661716|FG009|Double Blind Period (Week 0-54)|Unsatisfactory therapeutic effect|0
6061007|NCT00488631|9661707|FG000|Double Blind Period (Week 0-54)|Lost to Follow-up|1
6061008|NCT00488631|9661708|FG001|Double Blind Period (Week 0-54)|Lost to Follow-up|2
6061009|NCT00488631|9661709|FG002|Double Blind Period (Week 0-54)|Lost to Follow-up|1
6061010|NCT00488631|9661710|FG003|Double Blind Period (Week 0-54)|Lost to Follow-up|0
6061011|NCT00488631|9661711|FG004|Double Blind Period (Week 0-54)|Lost to Follow-up|3
6061012|NCT00488631|9661712|FG005|Double Blind Period (Week 0-54)|Lost to Follow-up|7
6061013|NCT00488631|9661713|FG006|Double Blind Period (Week 0-54)|Lost to Follow-up|0
6061014|NCT00488631|9661714|FG007|Double Blind Period (Week 0-54)|Lost to Follow-up|0
6061015|NCT00488631|9661715|FG008|Double Blind Period (Week 0-54)|Lost to Follow-up|0
6061016|NCT00488631|9661716|FG009|Double Blind Period (Week 0-54)|Lost to Follow-up|0
6061017|NCT00488631|9661707|FG000|Double Blind Period (Week 0-54)|Other|6
6061018|NCT00488631|9661708|FG001|Double Blind Period (Week 0-54)|Other|12
6061019|NCT00488631|9661709|FG002|Double Blind Period (Week 0-54)|Other|10
6061020|NCT00488631|9661710|FG003|Double Blind Period (Week 0-54)|Other|11
6061021|NCT00488631|9661711|FG004|Double Blind Period (Week 0-54)|Other|14
6061022|NCT00488631|9661712|FG005|Double Blind Period (Week 0-54)|Other|34
6061023|NCT00488631|9661713|FG006|Double Blind Period (Week 0-54)|Other|0
6061024|NCT00488631|9661714|FG007|Double Blind Period (Week 0-54)|Other|0
6061025|NCT00488631|9661715|FG008|Double Blind Period (Week 0-54)|Other|0
6061026|NCT00488631|9661716|FG009|Double Blind Period (Week 0-54)|Other|0
6061027|NCT00488631|9661707|FG000|Open Label Study Extension (Week 54-228)|Adverse Event|0
6061028|NCT00488631|9661708|FG001|Open Label Study Extension (Week 54-228)|Adverse Event|0
6061029|NCT00488631|9661709|FG002|Open Label Study Extension (Week 54-228)|Adverse Event|0
6061030|NCT00488631|9661710|FG003|Open Label Study Extension (Week 54-228)|Adverse Event|0
6061031|NCT00488631|9661711|FG004|Open Label Study Extension (Week 54-228)|Adverse Event|0
6061032|NCT00488631|9661712|FG005|Open Label Study Extension (Week 54-228)|Adverse Event|0
6061033|NCT00488631|9661713|FG006|Open Label Study Extension (Week 54-228)|Adverse Event|10
6061034|NCT00488631|9661714|FG007|Open Label Study Extension (Week 54-228)|Adverse Event|8
6061035|NCT00488631|9661715|FG008|Open Label Study Extension (Week 54-228)|Adverse Event|54
6061036|NCT00488631|9661716|FG009|Open Label Study Extension (Week 54-228)|Adverse Event|0
6061037|NCT00488631|9661707|FG000|Open Label Study Extension (Week 54-228)|Death|0
6061038|NCT00488631|9661708|FG001|Open Label Study Extension (Week 54-228)|Death|0
6061039|NCT00488631|9661709|FG002|Open Label Study Extension (Week 54-228)|Death|0
6061040|NCT00488631|9661710|FG003|Open Label Study Extension (Week 54-228)|Death|0
6061041|NCT00488631|9661711|FG004|Open Label Study Extension (Week 54-228)|Death|0
6061042|NCT00488631|9661712|FG005|Open Label Study Extension (Week 54-228)|Death|0
6061043|NCT00488631|9661713|FG006|Open Label Study Extension (Week 54-228)|Death|0
6061044|NCT00488631|9661714|FG007|Open Label Study Extension (Week 54-228)|Death|0
6061045|NCT00488631|9661715|FG008|Open Label Study Extension (Week 54-228)|Death|1
6061046|NCT00488631|9661716|FG009|Open Label Study Extension (Week 54-228)|Death|0
6061047|NCT00488631|9661707|FG000|Open Label Study Extension (Week 54-228)|Unsatisfactory therapeutic effect|0
6061048|NCT00488631|9661708|FG001|Open Label Study Extension (Week 54-228)|Unsatisfactory therapeutic effect|0
6061049|NCT00488631|9661709|FG002|Open Label Study Extension (Week 54-228)|Unsatisfactory therapeutic effect|0
6061050|NCT00488631|9661710|FG003|Open Label Study Extension (Week 54-228)|Unsatisfactory therapeutic effect|0
6061051|NCT00488631|9661711|FG004|Open Label Study Extension (Week 54-228)|Unsatisfactory therapeutic effect|0
6061052|NCT00488631|9661712|FG005|Open Label Study Extension (Week 54-228)|Unsatisfactory therapeutic effect|0
6061053|NCT00488631|9661713|FG006|Open Label Study Extension (Week 54-228)|Unsatisfactory therapeutic effect|5
6061054|NCT00488631|9661714|FG007|Open Label Study Extension (Week 54-228)|Unsatisfactory therapeutic effect|5
6061055|NCT00488631|9661715|FG008|Open Label Study Extension (Week 54-228)|Unsatisfactory therapeutic effect|34
6061056|NCT00488631|9661716|FG009|Open Label Study Extension (Week 54-228)|Unsatisfactory therapeutic effect|3
6061057|NCT00488631|9661707|FG000|Open Label Study Extension (Week 54-228)|Lost to Follow-up|0
6061058|NCT00488631|9661708|FG001|Open Label Study Extension (Week 54-228)|Lost to Follow-up|0
6061059|NCT00488631|9661709|FG002|Open Label Study Extension (Week 54-228)|Lost to Follow-up|0
6061060|NCT00488631|9661710|FG003|Open Label Study Extension (Week 54-228)|Lost to Follow-up|0
6061061|NCT00488631|9661711|FG004|Open Label Study Extension (Week 54-228)|Lost to Follow-up|0
6061062|NCT00488631|9661712|FG005|Open Label Study Extension (Week 54-228)|Lost to Follow-up|0
6061063|NCT00488631|9661713|FG006|Open Label Study Extension (Week 54-228)|Lost to Follow-up|2
6061064|NCT00488631|9661714|FG007|Open Label Study Extension (Week 54-228)|Lost to Follow-up|0
6061065|NCT00488631|9661715|FG008|Open Label Study Extension (Week 54-228)|Lost to Follow-up|6
6061066|NCT00488631|9661716|FG009|Open Label Study Extension (Week 54-228)|Lost to Follow-up|0
6061067|NCT00488631|9661707|FG000|Open Label Study Extension (Week 54-228)|Unspecified reasons|0
6061068|NCT00488631|9661708|FG001|Open Label Study Extension (Week 54-228)|Unspecified reasons|0
6061069|NCT00488631|9661709|FG002|Open Label Study Extension (Week 54-228)|Unspecified reasons|0
6061070|NCT00488631|9661710|FG003|Open Label Study Extension (Week 54-228)|Unspecified reasons|0
6061071|NCT00488631|9661711|FG004|Open Label Study Extension (Week 54-228)|Unspecified reasons|0
6061072|NCT00488631|9661712|FG005|Open Label Study Extension (Week 54-228)|Unspecified reasons|0
6061073|NCT00488631|9661713|FG006|Open Label Study Extension (Week 54-228)|Unspecified reasons|63
6061074|NCT00488631|9661714|FG007|Open Label Study Extension (Week 54-228)|Unspecified reasons|14
6061075|NCT00488631|9661715|FG008|Open Label Study Extension (Week 54-228)|Unspecified reasons|87
6061076|NCT00488631|9661716|FG009|Open Label Study Extension (Week 54-228)|Unspecified reasons|0
6061077|NCT00488644|9661739|FG000|Overall Study|Not Eligible|1
6061078|NCT00488644|9661739|FG000|Overall Study|Not Evaluable|1
6061079|NCT00488683|9661746|FG000|Overall Study|Withdrawal by Subject|1
6061080|NCT00488683|9661747|FG001|Overall Study|Withdrawal by Subject|2
6061081|NCT00488683|9661748|FG002|Overall Study|Withdrawal by Subject|2
6061082|NCT00488683|9661746|FG000|Overall Study|Lost to Follow-up|5
6061083|NCT00488683|9661747|FG001|Overall Study|Lost to Follow-up|3
6061084|NCT00488683|9661748|FG002|Overall Study|Lost to Follow-up|0
6061085|NCT00488683|9661746|FG000|Overall Study|Protocol Violation|5
6061086|NCT00488683|9661747|FG001|Overall Study|Protocol Violation|1
6061087|NCT00488683|9661748|FG002|Overall Study|Protocol Violation|0
6061088|NCT00488683|9661746|FG000|Overall Study|Unable to Classify|1
6061089|NCT00488683|9661747|FG001|Overall Study|Unable to Classify|0
6061090|NCT00488683|9661748|FG002|Overall Study|Unable to Classify|0
6061091|NCT00488774|9661764|FG000|Overall Study|Withdrawal of consent|2
6061092|NCT00488774|9661765|FG001|Overall Study|Withdrawal of consent|2
6061093|NCT00488774|9661766|FG002|Overall Study|Withdrawal of consent|2
6061094|NCT00488774|9661767|FG003|Overall Study|Withdrawal of consent|0
6061095|NCT00488774|9661764|FG000|Overall Study|Other|6
6061096|NCT00488774|9661765|FG001|Overall Study|Other|3
6061097|NCT00488774|9661766|FG002|Overall Study|Other|2
6094288|NCT00716274|9707834|FG003|Study Period II (16-Weeks)|Parent/Caregiver Decision|0
6094289|NCT00716274|9707835|FG004|Study Period II (16-Weeks)|Parent/Caregiver Decision|0
6094290|NCT00716274|9707836|FG005|Study Period II (16-Weeks)|Parent/Caregiver Decision|0
6094291|NCT00716274|9707831|FG000|Study Period II (16-Weeks)|Lost to Follow-up|0
6094292|NCT00716274|9707832|FG001|Study Period II (16-Weeks)|Lost to Follow-up|2
6094293|NCT00716274|9707833|FG002|Study Period II (16-Weeks)|Lost to Follow-up|0
6094294|NCT00716274|9707834|FG003|Study Period II (16-Weeks)|Lost to Follow-up|0
6094295|NCT00716274|9707835|FG004|Study Period II (16-Weeks)|Lost to Follow-up|0
6094296|NCT00716274|9707836|FG005|Study Period II (16-Weeks)|Lost to Follow-up|0
6094297|NCT00716274|9707831|FG000|Study Period III (16-Weeks)|Withdrawal by Subject|0
6094298|NCT00716274|9707832|FG001|Study Period III (16-Weeks)|Withdrawal by Subject|0
6094299|NCT00716274|9707833|FG002|Study Period III (16-Weeks)|Withdrawal by Subject|2
6094300|NCT00716274|9707834|FG003|Study Period III (16-Weeks)|Withdrawal by Subject|0
6094301|NCT00716274|9707835|FG004|Study Period III (16-Weeks)|Withdrawal by Subject|0
6094302|NCT00716274|9707836|FG005|Study Period III (16-Weeks)|Withdrawal by Subject|0
6094303|NCT00716274|9707831|FG000|Study Period III (16-Weeks)|Physician Decision|0
6094304|NCT00716274|9707832|FG001|Study Period III (16-Weeks)|Physician Decision|0
6094305|NCT00716274|9707833|FG002|Study Period III (16-Weeks)|Physician Decision|0
6094306|NCT00716274|9707834|FG003|Study Period III (16-Weeks)|Physician Decision|0
6094307|NCT00716274|9707835|FG004|Study Period III (16-Weeks)|Physician Decision|1
6094308|NCT00716274|9707836|FG005|Study Period III (16-Weeks)|Physician Decision|0
6094309|NCT00716274|9707831|FG000|Study Period III (16-Weeks)|Parent Caregiver Decision|0
6094310|NCT00716274|9707832|FG001|Study Period III (16-Weeks)|Parent Caregiver Decision|0
6094311|NCT00716274|9707833|FG002|Study Period III (16-Weeks)|Parent Caregiver Decision|0
6094312|NCT00716274|9707834|FG003|Study Period III (16-Weeks)|Parent Caregiver Decision|1
6094313|NCT00716274|9707835|FG004|Study Period III (16-Weeks)|Parent Caregiver Decision|1
6094314|NCT00716274|9707836|FG005|Study Period III (16-Weeks)|Parent Caregiver Decision|0
6094315|NCT00716274|9707831|FG000|Study Period III (16-Weeks)|Adverse Event|0
6094316|NCT00716274|9707832|FG001|Study Period III (16-Weeks)|Adverse Event|0
6094317|NCT00716274|9707833|FG002|Study Period III (16-Weeks)|Adverse Event|0
6094318|NCT00716274|9707834|FG003|Study Period III (16-Weeks)|Adverse Event|0
6094319|NCT00716274|9707835|FG004|Study Period III (16-Weeks)|Adverse Event|1
6094320|NCT00716274|9707836|FG005|Study Period III (16-Weeks)|Adverse Event|0
6202991|NCT01509846|9863680|FG000|Received Vaccination 2|Withdrawal by Subject|0
6202992|NCT01509846|9863681|FG001|Received Vaccination 2|Withdrawal by Subject|0
6202993|NCT01509846|9863682|FG002|Received Vaccination 2|Withdrawal by Subject|1
6202994|NCT01509846|9863683|FG003|Received Vaccination 2|Withdrawal by Subject|0
6202995|NCT01509846|9863684|FG004|Received Vaccination 2|Withdrawal by Subject|0
6202996|NCT01509846|9863680|FG000|Received Vaccination 2|Illness|0
6202997|NCT01509846|9863681|FG001|Received Vaccination 2|Illness|0
6202998|NCT01509846|9863682|FG002|Received Vaccination 2|Illness|0
6202999|NCT01509846|9863683|FG003|Received Vaccination 2|Illness|0
6061098|NCT00488774|9661767|FG003|Overall Study|Other|2
6061099|NCT00488774|9661764|FG000|Overall Study|Lost to Follow-up|0
6061100|NCT00488774|9661765|FG001|Overall Study|Lost to Follow-up|0
6061101|NCT00488774|9661766|FG002|Overall Study|Lost to Follow-up|1
6094321|NCT00716417|9707863|FG000|Overall Study|Adverse Event|0
6094322|NCT00716417|9707864|FG001|Overall Study|Adverse Event|0
6094323|NCT00716417|9707865|FG002|Overall Study|Adverse Event|2
6094324|NCT00716417|9707866|FG003|Overall Study|Adverse Event|1
6094325|NCT00716417|9707867|FG004|Overall Study|Adverse Event|0
6094326|NCT00716417|9707868|FG005|Overall Study|Adverse Event|0
6094327|NCT00716417|9707869|FG006|Overall Study|Adverse Event|3
6094328|NCT00716417|9707870|FG007|Overall Study|Adverse Event|1
6094329|NCT00716417|9707871|FG008|Overall Study|Adverse Event|0
6094330|NCT00716417|9707872|FG009|Overall Study|Adverse Event|3
6094331|NCT00716417|9707863|FG000|Overall Study|Withdrawal by Subject|0
6094332|NCT00716417|9707864|FG001|Overall Study|Withdrawal by Subject|1
6094333|NCT00716417|9707865|FG002|Overall Study|Withdrawal by Subject|0
6094334|NCT00716417|9707866|FG003|Overall Study|Withdrawal by Subject|2
6094335|NCT00716417|9707867|FG004|Overall Study|Withdrawal by Subject|0
6094336|NCT00716417|9707868|FG005|Overall Study|Withdrawal by Subject|0
6094337|NCT00716417|9707869|FG006|Overall Study|Withdrawal by Subject|1
6094338|NCT00716417|9707870|FG007|Overall Study|Withdrawal by Subject|0
6094339|NCT00716417|9707871|FG008|Overall Study|Withdrawal by Subject|0
6094340|NCT00716417|9707872|FG009|Overall Study|Withdrawal by Subject|0
6094341|NCT00716417|9707863|FG000|Overall Study|Progressive disease|3
6094342|NCT00716417|9707864|FG001|Overall Study|Progressive disease|5
6094343|NCT00716417|9707865|FG002|Overall Study|Progressive disease|3
6094344|NCT00716417|9707866|FG003|Overall Study|Progressive disease|8
6094345|NCT00716417|9707867|FG004|Overall Study|Progressive disease|0
6094346|NCT00716417|9707868|FG005|Overall Study|Progressive disease|3
6094347|NCT00716417|9707869|FG006|Overall Study|Progressive disease|3
6094348|NCT00716417|9707870|FG007|Overall Study|Progressive disease|1
6094349|NCT00716417|9707871|FG008|Overall Study|Progressive disease|5
6094350|NCT00716417|9707872|FG009|Overall Study|Progressive disease|0
6094351|NCT00716417|9707863|FG000|Overall Study|Dose limiting toxicity (DLT)|0
6094352|NCT00716417|9707864|FG001|Overall Study|Dose limiting toxicity (DLT)|0
6094353|NCT00716417|9707865|FG002|Overall Study|Dose limiting toxicity (DLT)|0
6094354|NCT00716417|9707866|FG003|Overall Study|Dose limiting toxicity (DLT)|0
6094355|NCT00716417|9707867|FG004|Overall Study|Dose limiting toxicity (DLT)|1
6094356|NCT00716417|9707868|FG005|Overall Study|Dose limiting toxicity (DLT)|0
6094357|NCT00716417|9707869|FG006|Overall Study|Dose limiting toxicity (DLT)|0
6094358|NCT00716417|9707870|FG007|Overall Study|Dose limiting toxicity (DLT)|0
6094359|NCT00716417|9707871|FG008|Overall Study|Dose limiting toxicity (DLT)|0
6094360|NCT00716417|9707872|FG009|Overall Study|Dose limiting toxicity (DLT)|0
6094361|NCT00716417|9707863|FG000|Overall Study|On patient request due to toxicities|0
6094362|NCT00716417|9707864|FG001|Overall Study|On patient request due to toxicities|0
6094363|NCT00716417|9707865|FG002|Overall Study|On patient request due to toxicities|0
6094364|NCT00716417|9707866|FG003|Overall Study|On patient request due to toxicities|0
6094365|NCT00716417|9707867|FG004|Overall Study|On patient request due to toxicities|0
6094366|NCT00716417|9707868|FG005|Overall Study|On patient request due to toxicities|0
6094367|NCT00716417|9707869|FG006|Overall Study|On patient request due to toxicities|0
6094368|NCT00716417|9707870|FG007|Overall Study|On patient request due to toxicities|1
6094369|NCT00716417|9707871|FG008|Overall Study|On patient request due to toxicities|0
6094370|NCT00716417|9707872|FG009|Overall Study|On patient request due to toxicities|0
6094371|NCT00716456|9707904|FG000|Overall Study|Adverse Event|0
6094372|NCT00716456|9707905|FG001|Overall Study|Adverse Event|2
6094373|NCT00716456|9707906|FG002|Overall Study|Adverse Event|0
6094374|NCT00716482|9707914|FG000|Overall Study|Lost to Follow-up|6
6094375|NCT00716482|9707914|FG000|Overall Study|Inadequate acquisition or analysis|50
6094376|NCT00716482|9707914|FG000|Overall Study|no pathology obtained|10
6094377|NCT00716482|9707914|FG000|Overall Study|technical/machine error|28
6094378|NCT00716482|9707914|FG000|Overall Study|inclusion/exclusion criteria not met|25
6094379|NCT00716625|9707929|FG000|Overall Study|Safety was not Assessable|1
6094380|NCT00716859|9707987|FG000|Overall Study|Adverse Event|4
6094381|NCT00716859|9707988|FG001|Overall Study|Adverse Event|1
6094382|NCT00716859|9707987|FG000|Overall Study|Lack of Efficacy|3
6094383|NCT00716859|9707988|FG001|Overall Study|Lack of Efficacy|0
6203000|NCT01509846|9863684|FG004|Received Vaccination 2|Illness|1
6203001|NCT01509846|9863680|FG000|Received Vaccination 2|Not vaccinated per protocol|5
6061102|NCT00488774|9661767|FG003|Overall Study|Lost to Follow-up|1
6061103|NCT00488826|9661781|FG000|Overall Study|Withdrawal by Subject|40
6061104|NCT00488826|9661782|FG001|Overall Study|Withdrawal by Subject|35
6061105|NCT00488826|9661783|FG002|Overall Study|Withdrawal by Subject|19
6094384|NCT00716859|9707987|FG000|Overall Study|Withdrawal by Subject|1
6094385|NCT00716859|9707988|FG001|Overall Study|Withdrawal by Subject|3
6094386|NCT00716859|9707987|FG000|Overall Study|Not treated|1
6094387|NCT00716859|9707988|FG001|Overall Study|Not treated|1
6094388|NCT00716976|9708009|FG000|Overall Study|Adverse Event|2
6094389|NCT00716976|9708010|FG001|Overall Study|Adverse Event|0
6094390|NCT00716976|9708009|FG000|Overall Study|Death|1
6094391|NCT00716976|9708010|FG001|Overall Study|Death|0
6094392|NCT00716976|9708009|FG000|Overall Study|Physician Decision|2
6061106|NCT00488826|9661781|FG000|Overall Study|Protocol Violation|0
6061107|NCT00488826|9661782|FG001|Overall Study|Protocol Violation|0
6061108|NCT00488826|9661783|FG002|Overall Study|Protocol Violation|2
6061109|NCT00488826|9661781|FG000|Overall Study|Adverse Event|9
6061110|NCT00488826|9661782|FG001|Overall Study|Adverse Event|15
6061111|NCT00488826|9661783|FG002|Overall Study|Adverse Event|4
6061112|NCT00488826|9661781|FG000|Overall Study|Lost to Follow-up|5
6061113|NCT00488826|9661782|FG001|Overall Study|Lost to Follow-up|1
6061114|NCT00488826|9661783|FG002|Overall Study|Lost to Follow-up|0
6061115|NCT00488826|9661781|FG000|Overall Study|Protocol Deviations|2
6061116|NCT00488826|9661782|FG001|Overall Study|Protocol Deviations|1
6061117|NCT00488826|9661783|FG002|Overall Study|Protocol Deviations|1
6061118|NCT00488982|9661795|FG000|Course 1|Physician Decision|0
6061119|NCT00488982|9661796|FG001|Course 1|Physician Decision|2
6061120|NCT00488982|9661797|FG002|Course 1|Physician Decision|4
6061121|NCT00488982|9661795|FG000|Course 1|Withdrawal by Subject|0
6094393|NCT00716976|9708010|FG001|Overall Study|Physician Decision|2
6094394|NCT00716976|9708009|FG000|Overall Study|Withdrawal by Subject|5
6094395|NCT00716976|9708010|FG001|Overall Study|Withdrawal by Subject|1
6094396|NCT00716976|9708009|FG000|Overall Study|Premature discontinuation cisplatin|5
6094397|NCT00716976|9708010|FG001|Overall Study|Premature discontinuation cisplatin|4
6094398|NCT00716976|9708009|FG000|Overall Study|Radiation during protocol|1
6094399|NCT00716976|9708010|FG001|Overall Study|Radiation during protocol|0
6094400|NCT00716976|9708009|FG000|Overall Study|Ineligibles|4
6094401|NCT00716976|9708010|FG001|Overall Study|Ineligibles|2
6094402|NCT00717067|9708039|FG000|Part 1a: Normal/Mild/Moderate Group|Adverse Event|0
6094403|NCT00717067|9708040|FG001|Part 1a: Normal/Mild/Moderate Group|Adverse Event|0
6094404|NCT00717067|9708041|FG002|Part 1a: Normal/Mild/Moderate Group|Adverse Event|1
6094405|NCT00717067|9708042|FG003|Part 1a: Normal/Mild/Moderate Group|Adverse Event|0
6094406|NCT00717067|9708043|FG004|Part 1a: Normal/Mild/Moderate Group|Adverse Event|0
6094407|NCT00717093|9708067|FG000|Overall Study|Adverse Event|19
6094408|NCT00717093|9708068|FG001|Overall Study|Adverse Event|9
6094409|NCT00717093|9708067|FG000|Overall Study|Lack of Efficacy|3
6094410|NCT00717093|9708068|FG001|Overall Study|Lack of Efficacy|13
6094411|NCT00717093|9708067|FG000|Overall Study|Lost to Follow-up|9
6094412|NCT00717093|9708068|FG001|Overall Study|Lost to Follow-up|6
6094413|NCT00717093|9708067|FG000|Overall Study|Withdrawal by Subject|12
6094414|NCT00717093|9708068|FG001|Overall Study|Withdrawal by Subject|19
6094415|NCT00717093|9708067|FG000|Overall Study|Other|0
6094416|NCT00717093|9708068|FG001|Overall Study|Other|1
6094417|NCT00717093|9708067|FG000|Overall Study|Randomized but not treated|1
6094418|NCT00717093|9708068|FG001|Overall Study|Randomized but not treated|0
6094419|NCT00717197|9708074|FG000|Overall Study|Unable to purchase study drug|5
6094420|NCT00717197|9708074|FG000|Overall Study|Tumor Progression|1
6094421|NCT00717197|9708074|FG000|Overall Study|Physician Decision|1
6094422|NCT00717236|9708080|FG000|Double-Blind Period|Adverse Event|33
6094423|NCT00717236|9708081|FG001|Double-Blind Period|Adverse Event|6
6094424|NCT00717236|9708080|FG000|Double-Blind Period|Lack of Efficacy|6
6094425|NCT00717236|9708081|FG001|Double-Blind Period|Lack of Efficacy|6
6094426|NCT00717236|9708080|FG000|Double-Blind Period|Lost to Follow-up|3
6203002|NCT01509846|9863681|FG001|Received Vaccination 2|Not vaccinated per protocol|0
6203003|NCT01509846|9863682|FG002|Received Vaccination 2|Not vaccinated per protocol|0
6203004|NCT01509846|9863683|FG003|Received Vaccination 2|Not vaccinated per protocol|0
6203005|NCT01509846|9863684|FG004|Received Vaccination 2|Not vaccinated per protocol|2
6203006|NCT01509846|9863680|FG000|Received Vaccination 3|Withdrawal by Subject|0
6203007|NCT01509846|9863681|FG001|Received Vaccination 3|Withdrawal by Subject|1
6203008|NCT01509846|9863682|FG002|Received Vaccination 3|Withdrawal by Subject|0
6203009|NCT01509846|9863683|FG003|Received Vaccination 3|Withdrawal by Subject|0
6203010|NCT01509846|9863684|FG004|Received Vaccination 3|Withdrawal by Subject|0
6203011|NCT01509846|9863680|FG000|Received Vaccination 3|Pregnancy|0
6203012|NCT01509846|9863681|FG001|Received Vaccination 3|Pregnancy|0
6203013|NCT01509846|9863682|FG002|Received Vaccination 3|Pregnancy|0
6203014|NCT01509846|9863683|FG003|Received Vaccination 3|Pregnancy|1
6203015|NCT01509846|9863684|FG004|Received Vaccination 3|Pregnancy|0
6203016|NCT01509846|9863680|FG000|Received Vaccination 3|Lost to Follow-up|0
6203017|NCT01509846|9863681|FG001|Received Vaccination 3|Lost to Follow-up|0
6203018|NCT01509846|9863682|FG002|Received Vaccination 3|Lost to Follow-up|1
6203019|NCT01509846|9863683|FG003|Received Vaccination 3|Lost to Follow-up|0
6203020|NCT01509846|9863684|FG004|Received Vaccination 3|Lost to Follow-up|0
6203021|NCT01510028|9863728|FG000|Overall Study|Lack of Efficacy|1
6203022|NCT01510028|9863729|FG001|Overall Study|Lack of Efficacy|0
6203023|NCT01510028|9863730|FG002|Overall Study|Lack of Efficacy|0
6203024|NCT01510028|9863731|FG003|Overall Study|Lack of Efficacy|0
6061122|NCT00488982|9661796|FG001|Course 1|Withdrawal by Subject|8
6203025|NCT01510145|9863743|FG000|Overall Study|Adverse Event|6
6203026|NCT01510145|9863743|FG000|Overall Study|Lost to Follow-up|5
6203027|NCT01510145|9863743|FG000|Overall Study|Withdrawal by Subject|6
6203028|NCT01510145|9863743|FG000|Overall Study|Relative reported subject withdrew|1
6203029|NCT01510158|9863750|FG000|Overall Study|Adverse Event|7
6203030|NCT01510158|9863751|FG001|Overall Study|Adverse Event|8
6061123|NCT00488982|9661797|FG002|Course 1|Withdrawal by Subject|2
6061124|NCT00488982|9661795|FG000|Course 1|nonprotocol therapy|0
6061125|NCT00488982|9661796|FG001|Course 1|nonprotocol therapy|2
6061126|NCT00488982|9661797|FG002|Course 1|nonprotocol therapy|2
6061127|NCT00488982|9661795|FG000|Course 1|Adverse Event|0
6061128|NCT00488982|9661796|FG001|Course 1|Adverse Event|0
6061129|NCT00488982|9661797|FG002|Course 1|Adverse Event|6
6061130|NCT00489216|9661815|FG000|Overall Study|Adverse Event|1
6061131|NCT00489255|9661821|FG000|Screening and Initial Randomization|Discontinued prior to taking study drug|9
6061132|NCT00489255|9661822|FG001|Screening and Initial Randomization|Discontinued prior to taking study drug|3
6061133|NCT00489255|9661821|FG000|Period 1: Days 1 to 28|Adverse Event|21
6061134|NCT00489255|9661822|FG001|Period 1: Days 1 to 28|Adverse Event|8
6061135|NCT00489255|9661821|FG000|Period 1: Days 1 to 28|Withdrawal by Subject|5
6061136|NCT00489255|9661822|FG001|Period 1: Days 1 to 28|Withdrawal by Subject|0
6061137|NCT00489255|9661821|FG000|Period 1: Days 1 to 28|Physician Decision|1
6061138|NCT00489255|9661822|FG001|Period 1: Days 1 to 28|Physician Decision|4
6061139|NCT00489255|9661821|FG000|Period 1: Days 1 to 28|Noncompliance|2
6061140|NCT00489255|9661822|FG001|Period 1: Days 1 to 28|Noncompliance|0
6061141|NCT00489255|9661821|FG000|Period 2: Days 29 to 56|Adverse Event|3
6094427|NCT00717236|9708081|FG001|Double-Blind Period|Lost to Follow-up|5
6094428|NCT00717236|9708080|FG000|Double-Blind Period|Withdrawal by Subject|10
6094429|NCT00717236|9708081|FG001|Double-Blind Period|Withdrawal by Subject|2
6094430|NCT00717236|9708080|FG000|Double-Blind Period|Loss of efficacy|3
6094431|NCT00717236|9708081|FG001|Double-Blind Period|Loss of efficacy|0
6094432|NCT00717236|9708080|FG000|Double-Blind Period|Other: Death|1
6094433|NCT00717236|9708081|FG001|Double-Blind Period|Other: Death|0
6094434|NCT00717236|9708080|FG000|Double-Blind Period|Other: Pregnancy|1
6094435|NCT00717236|9708081|FG001|Double-Blind Period|Other: Pregnancy|0
6094436|NCT00717236|9708080|FG000|Double-Blind Period|Other: Protocol Violation|2
6094437|NCT00717236|9708081|FG001|Double-Blind Period|Other: Protocol Violation|0
6094438|NCT00717236|9708080|FG000|Double-Blind Period|Other: Inclusion/Exclusion criteria|6
6094439|NCT00717236|9708081|FG001|Double-Blind Period|Other: Inclusion/Exclusion criteria|2
6094440|NCT00717236|9708080|FG000|Double-Blind Period|Other: Site withdrew|2
6094441|NCT00717236|9708081|FG001|Double-Blind Period|Other: Site withdrew|0
6094442|NCT00717236|9708080|FG000|Double-Blind Period|Other: Screening failure|1
6094443|NCT00717236|9708081|FG001|Double-Blind Period|Other: Screening failure|0
6094444|NCT00717236|9708080|FG000|Double-Blind Period|Other: subject withdrew consent|1
6094445|NCT00717236|9708081|FG001|Double-Blind Period|Other: subject withdrew consent|1
6094446|NCT00717236|9708080|FG000|Double-Blind Period|Other: Abnormal chest X-ray|2
6094447|NCT00717236|9708081|FG001|Double-Blind Period|Other: Abnormal chest X-ray|1
6094448|NCT00717236|9708080|FG000|Double-Blind Period|Other: History of adenoid grown|1
6094449|NCT00717236|9708081|FG001|Double-Blind Period|Other: History of adenoid grown|0
6094450|NCT00717236|9708080|FG000|Double-Blind Period|Other: History of cancer|1
6094451|NCT00717236|9708081|FG001|Double-Blind Period|Other: History of cancer|0
6094452|NCT00717236|9708080|FG000|Double-Blind Period|Other: Sponsor request|1
6094453|NCT00717236|9708081|FG001|Double-Blind Period|Other: Sponsor request|0
6094454|NCT00717236|9708080|FG000|Double-Blind Period|Other: Inappropriate randomization|1
6094455|NCT00717236|9708081|FG001|Double-Blind Period|Other: Inappropriate randomization|0
6094456|NCT00717236|9708080|FG000|Double-Blind Period|Other: Detection of Hepatitis C Virus|1
6094457|NCT00717236|9708081|FG001|Double-Blind Period|Other: Detection of Hepatitis C Virus|0
6094458|NCT00717236|9708080|FG000|Double-Blind Period|Other: Subject moved|1
6094459|NCT00717236|9708081|FG001|Double-Blind Period|Other: Subject moved|1
6094460|NCT00717236|9708080|FG000|Double-Blind Period|Other: Stopped taking DMARD|1
6094461|NCT00717236|9708081|FG001|Double-Blind Period|Other: Stopped taking DMARD|0
6094462|NCT00717236|9708080|FG000|Double-Blind Period|Other: Prohibited medication taken|2
6094463|NCT00717236|9708081|FG001|Double-Blind Period|Other: Prohibited medication taken|2
6094464|NCT00717236|9708080|FG000|Double-Blind Period|Other: Transportation problems|0
6094465|NCT00717236|9708081|FG001|Double-Blind Period|Other: Transportation problems|1
6094466|NCT00717236|9708080|FG000|Double-Blind Period|Other: Investigator Decision|0
6094467|NCT00717236|9708081|FG001|Double-Blind Period|Other: Investigator Decision|1
6094468|NCT00717236|9708080|FG000|Open-Label Period|Adverse Event|29
6094469|NCT00717236|9708081|FG001|Open-Label Period|Adverse Event|4
6094470|NCT00717236|9708080|FG000|Open-Label Period|Lack of Efficacy|30
6094471|NCT00717236|9708081|FG001|Open-Label Period|Lack of Efficacy|8
6094472|NCT00717236|9708080|FG000|Open-Label Period|Lost to Follow-up|28
6094473|NCT00717236|9708081|FG001|Open-Label Period|Lost to Follow-up|4
6094474|NCT00717236|9708080|FG000|Open-Label Period|Withdrawal by Subject|20
6094475|NCT00717236|9708081|FG001|Open-Label Period|Withdrawal by Subject|2
6094476|NCT00717236|9708080|FG000|Open-Label Period|Loss of Efficacy|6
6094477|NCT00717236|9708081|FG001|Open-Label Period|Loss of Efficacy|1
6094478|NCT00717236|9708080|FG000|Open-Label Period|Other: Peripheral Neuropathy|0
6094479|NCT00717236|9708081|FG001|Open-Label Period|Other: Peripheral Neuropathy|1
6094480|NCT00717236|9708080|FG000|Open-Label Period|Other: Lack of Compliance|1
6094481|NCT00717236|9708081|FG001|Open-Label Period|Other: Lack of Compliance|1
6094482|NCT00717236|9708080|FG000|Open-Label Period|Other: History of Basal Cell Carcinoma|1
6094483|NCT00717236|9708081|FG001|Open-Label Period|Other: History of Basal Cell Carcinoma|0
6094484|NCT00717236|9708080|FG000|Open-Label Period|Other: Moved|1
6094485|NCT00717236|9708081|FG001|Open-Label Period|Other: Moved|0
6094486|NCT00717236|9708080|FG000|Open-Label Period|Other: Investigator Decision|1
6094487|NCT00717236|9708081|FG001|Open-Label Period|Other: Investigator Decision|0
6061142|NCT00489255|9661822|FG001|Period 2: Days 29 to 56|Adverse Event|1
6061143|NCT00489255|9661821|FG000|Period 2: Days 29 to 56|Withdrawal by Subject|0
6061144|NCT00489255|9661822|FG001|Period 2: Days 29 to 56|Withdrawal by Subject|3
6061145|NCT00489255|9661821|FG000|Period 3: Days 57 to 84|Adverse Event|3
6061146|NCT00489255|9661822|FG001|Period 3: Days 57 to 84|Adverse Event|3
6061147|NCT00489255|9661821|FG000|Period 3: Days 57 to 84|Withdrawal by Subject|1
6061148|NCT00489255|9661822|FG001|Period 3: Days 57 to 84|Withdrawal by Subject|0
6061149|NCT00489255|9661821|FG000|Period 3: Days 57 to 84|Lost to Follow-up|0
6061150|NCT00489255|9661822|FG001|Period 3: Days 57 to 84|Lost to Follow-up|1
6061151|NCT00489359|9661860|FG000|Overall Study|Death|0
6061152|NCT00489359|9661861|FG001|Overall Study|Death|2
6061153|NCT00489359|9661860|FG000|Overall Study|Progressive Disease|5
6061154|NCT00489359|9661861|FG001|Overall Study|Progressive Disease|6
6061155|NCT00489359|9661860|FG000|Overall Study|Lost to Follow-up|1
6061156|NCT00489359|9661861|FG001|Overall Study|Lost to Follow-up|0
6061157|NCT00489359|9661860|FG000|Overall Study|Withdrawal by Subject|1
6061158|NCT00489359|9661861|FG001|Overall Study|Withdrawal by Subject|5
6094488|NCT00717236|9708080|FG000|Open-Label Period|Other: Loss of Staff (unblinded)|1
6094489|NCT00717236|9708081|FG001|Open-Label Period|Other: Loss of Staff (unblinded)|0
6094490|NCT00717236|9708080|FG000|Open-Label Period|Other: Sponsor Request|3
6094491|NCT00717236|9708081|FG001|Open-Label Period|Other: Sponsor Request|0
6094492|NCT00717236|9708080|FG000|Open-Label Period|Other: Cataract Surgery|1
6094493|NCT00717236|9708081|FG001|Open-Label Period|Other: Cataract Surgery|0
6094494|NCT00717236|9708080|FG000|Open-Label Period|Other: Administration of Golimumab|1
6094495|NCT00717236|9708081|FG001|Open-Label Period|Other: Administration of Golimumab|0
6094496|NCT00717236|9708080|FG000|Open-Label Period|Other: Completion Accidently Performed|1
6094497|NCT00717236|9708081|FG001|Open-Label Period|Other: Completion Accidently Performed|0
6094498|NCT00717236|9708080|FG000|Open-Label Period|Other: Medical Monitor Recommendation|1
6094499|NCT00717236|9708081|FG001|Open-Label Period|Other: Medical Monitor Recommendation|0
6094500|NCT00717249|9708091|FG000|Overall Study|Lens Discomfort|4
6094501|NCT00717249|9708092|FG001|Overall Study|Lens Discomfort|1
6094502|NCT00717249|9708091|FG000|Overall Study|Unsatisfactory visual Response|0
6094503|NCT00717249|9708092|FG001|Overall Study|Unsatisfactory visual Response|2
6094504|NCT00717249|9708091|FG000|Overall Study|Adverse Event|4
6094505|NCT00717249|9708092|FG001|Overall Study|Adverse Event|2
6094506|NCT00717249|9708091|FG000|Overall Study|Lost to Follow-up|2
6094507|NCT00717249|9708092|FG001|Overall Study|Lost to Follow-up|0
6094508|NCT00717249|9708091|FG000|Overall Study|Withdrawal by Subject|1
6094509|NCT00717249|9708092|FG001|Overall Study|Withdrawal by Subject|2
6094510|NCT00717249|9708091|FG000|Overall Study|Pregnancy|6
6094511|NCT00717249|9708092|FG001|Overall Study|Pregnancy|3
6094512|NCT00717249|9708091|FG000|Overall Study|Protocol Violation|0
6094513|NCT00717249|9708092|FG001|Overall Study|Protocol Violation|2
6094514|NCT00717249|9708091|FG000|Overall Study|Subject became Ineligible|1
6094515|NCT00717249|9708092|FG001|Overall Study|Subject became Ineligible|1
6094516|NCT00717249|9708091|FG000|Overall Study|Unsatisfactory Physiological Response|0
6094517|NCT00717249|9708092|FG001|Overall Study|Unsatisfactory Physiological Response|1
6094518|NCT00717249|9708091|FG000|Overall Study|Gastric Surgery|0
6094519|NCT00717249|9708092|FG001|Overall Study|Gastric Surgery|1
6094520|NCT00717249|9708091|FG000|Overall Study|Diagnosed with Diabetes|1
6094521|NCT00717249|9708092|FG001|Overall Study|Diagnosed with Diabetes|0
6094522|NCT00717249|9708091|FG000|Overall Study|Diagnosed with Multiple Scletosis|1
6094523|NCT00717249|9708092|FG001|Overall Study|Diagnosed with Multiple Scletosis|0
6094524|NCT00717249|9708091|FG000|Overall Study|Subject relocated|1
6094525|NCT00717249|9708092|FG001|Overall Study|Subject relocated|0
6094526|NCT00717249|9708091|FG000|Overall Study|Headaches|1
6094527|NCT00717249|9708092|FG001|Overall Study|Headaches|0
6094528|NCT00717314|9708119|FG000|Overall Study|Adverse Event|3
6094529|NCT00717314|9708120|FG001|Overall Study|Adverse Event|2
6094530|NCT00717314|9708119|FG000|Overall Study|Protocol Violation|1
6094531|NCT00717314|9708120|FG001|Overall Study|Protocol Violation|0
6094532|NCT00717314|9708119|FG000|Overall Study|Lost to Follow-up|1
6094533|NCT00717314|9708120|FG001|Overall Study|Lost to Follow-up|5
6094534|NCT00717314|9708119|FG000|Overall Study|Withdrawal by Subject|1
6094535|NCT00717314|9708120|FG001|Overall Study|Withdrawal by Subject|3
6094536|NCT00717366|9708128|FG000|Core Study Period (20 Weeks)|Renal transplant|4
6094537|NCT00717366|9708129|FG001|Core Study Period (20 Weeks)|Renal transplant|9
6094538|NCT00717366|9708128|FG000|Core Study Period (20 Weeks)|Admin/Other than specified|0
6094539|NCT00717366|9708129|FG001|Core Study Period (20 Weeks)|Admin/Other than specified|2
6094540|NCT00717366|9708128|FG000|Core Study Period (20 Weeks)|Death|0
6094541|NCT00717366|9708129|FG001|Core Study Period (20 Weeks)|Death|1
6094542|NCT00717366|9708128|FG000|Core Study Period (20 Weeks)|Refused treatment/Did not cooperate|0
6094543|NCT00717366|9708129|FG001|Core Study Period (20 Weeks)|Refused treatment/Did not cooperate|1
6094544|NCT00717366|9708128|FG000|Extension Period (52 Weeks)|Renal transplant|3
6094545|NCT00717366|9708129|FG001|Extension Period (52 Weeks)|Renal transplant|13
6094546|NCT00717366|9708128|FG000|Extension Period (52 Weeks)|Admin/Other than specified|0
6061159|NCT00489359|9661860|FG000|Overall Study|Adverse Event|0
6061160|NCT00489359|9661861|FG001|Overall Study|Adverse Event|16
6094547|NCT00717366|9708129|FG001|Extension Period (52 Weeks)|Admin/Other than specified|2
6061161|NCT00489411|9661874|FG000|Initial Treatment Period (Weeks 1-5)|Withdrew consent prior to intervention|6
6061162|NCT00489411|9661875|FG001|Initial Treatment Period (Weeks 1-5)|Withdrew consent prior to intervention|5
6061163|NCT00489411|9661874|FG000|Initial Treatment Period (Weeks 1-5)|Discontinued study drug early|21
6061164|NCT00489411|9661875|FG001|Initial Treatment Period (Weeks 1-5)|Discontinued study drug early|12
6061165|NCT00489411|9661874|FG000|Initial Treatment Period (Weeks 1-5)|Incomplete data|1
6061166|NCT00489411|9661875|FG001|Initial Treatment Period (Weeks 1-5)|Incomplete data|5
6061167|NCT00489411|9661874|FG000|Crossover Treatment Period (Weeks 8-12)|Discontinued intervention early|11
6061168|NCT00489411|9661875|FG001|Crossover Treatment Period (Weeks 8-12)|Discontinued intervention early|12
6061169|NCT00489411|9661874|FG000|Crossover Treatment Period (Weeks 8-12)|Incomplete data|7
6061170|NCT00489411|9661875|FG001|Crossover Treatment Period (Weeks 8-12)|Incomplete data|7
6094548|NCT00717366|9708128|FG000|Extension Period (52 Weeks)|Withdrew consent|1
6094549|NCT00717366|9708129|FG001|Extension Period (52 Weeks)|Withdrew consent|1
6094550|NCT00717522|9708150|FG000|Overall Study|Disease Progression|5
6094551|NCT00717522|9708150|FG000|Overall Study|Adverse Event|1
6094552|NCT00717522|9708150|FG000|Overall Study|Death|1
6094553|NCT00717756|9708167|FG000|Overall Study|Withdrawal by Subject|1
6094554|NCT00717769|9708174|FG000|Overall Study|Adverse Event|9
6094555|NCT00717769|9708175|FG001|Overall Study|Adverse Event|6
6094556|NCT00717769|9708176|FG002|Overall Study|Adverse Event|1
6094557|NCT00717769|9708174|FG000|Overall Study|Lack of compliance|0
6094558|NCT00717769|9708175|FG001|Overall Study|Lack of compliance|2
6094559|NCT00717769|9708176|FG002|Overall Study|Lack of compliance|0
6094560|NCT00717769|9708174|FG000|Overall Study|Lost to Follow-up|3
6094561|NCT00717769|9708175|FG001|Overall Study|Lost to Follow-up|4
6094562|NCT00717769|9708176|FG002|Overall Study|Lost to Follow-up|0
6094563|NCT00717769|9708174|FG000|Overall Study|Lack of Efficacy|1
6094564|NCT00717769|9708175|FG001|Overall Study|Lack of Efficacy|2
6094565|NCT00717769|9708176|FG002|Overall Study|Lack of Efficacy|0
6094566|NCT00717769|9708174|FG000|Overall Study|Protocol Violation|0
6094567|NCT00717769|9708175|FG001|Overall Study|Protocol Violation|2
6094568|NCT00717769|9708176|FG002|Overall Study|Protocol Violation|0
6094569|NCT00717769|9708174|FG000|Overall Study|Sponsor decision|1
6094570|NCT00717769|9708175|FG001|Overall Study|Sponsor decision|0
6094571|NCT00717769|9708176|FG002|Overall Study|Sponsor decision|10
6094572|NCT00717769|9708174|FG000|Overall Study|Withdrew consent|2
6094573|NCT00717769|9708175|FG001|Overall Study|Withdrew consent|2
6094574|NCT00717769|9708176|FG002|Overall Study|Withdrew consent|0
6094575|NCT00717860|9708188|FG000|Overall Study|Clinical adverse experience|5
6094576|NCT00717860|9708189|FG001|Overall Study|Clinical adverse experience|9
6094577|NCT00717860|9708188|FG000|Overall Study|Laboratory adverse experience|2
6094578|NCT00717860|9708189|FG001|Overall Study|Laboratory adverse experience|2
6094579|NCT00717860|9708188|FG000|Overall Study|Lack of Efficacy|7
6094580|NCT00717860|9708189|FG001|Overall Study|Lack of Efficacy|13
6094581|NCT00717860|9708188|FG000|Overall Study|Discontinued for other reason|6
6094582|NCT00717860|9708189|FG001|Overall Study|Discontinued for other reason|1
6094583|NCT00717860|9708188|FG000|Overall Study|Withdrew consent|7
6094584|NCT00717860|9708189|FG001|Overall Study|Withdrew consent|3
6094585|NCT00717886|9708204|FG000|Overall Study|Withdrawal by Subject|3
6094586|NCT00717886|9708204|FG000|Overall Study|Treatment Failure|1
6094587|NCT00718042|9708232|FG000|ABBOTT PRISM Chagas Testing|Withdrawal by Subject|0
6094588|NCT00718042|9708233|FG001|ABBOTT PRISM Chagas Testing|Withdrawal by Subject|0
6094589|NCT00718042|9708234|FG002|ABBOTT PRISM Chagas Testing|Withdrawal by Subject|0
6094590|NCT00718042|9708235|FG003|ABBOTT PRISM Chagas Testing|Withdrawal by Subject|0
6094591|NCT00718042|9708236|FG004|ABBOTT PRISM Chagas Testing|Withdrawal by Subject|2
6094592|NCT00718042|9708237|FG005|ABBOTT PRISM Chagas Testing|Withdrawal by Subject|0
6094593|NCT00718042|9708232|FG000|ABBOTT PRISM Chagas Testing|Protocol Violation|64
6094594|NCT00718042|9708233|FG001|ABBOTT PRISM Chagas Testing|Protocol Violation|0
6094595|NCT00718042|9708234|FG002|ABBOTT PRISM Chagas Testing|Protocol Violation|0
6094596|NCT00718042|9708235|FG003|ABBOTT PRISM Chagas Testing|Protocol Violation|0
6094597|NCT00718042|9708236|FG004|ABBOTT PRISM Chagas Testing|Protocol Violation|36
6094598|NCT00718042|9708237|FG005|ABBOTT PRISM Chagas Testing|Protocol Violation|0
6094599|NCT00718042|9708232|FG000|ABBOTT PRISM Chagas Testing|Insufficient sample|0
6094600|NCT00718042|9708233|FG001|ABBOTT PRISM Chagas Testing|Insufficient sample|1
6094601|NCT00718042|9708234|FG002|ABBOTT PRISM Chagas Testing|Insufficient sample|1
6094602|NCT00718042|9708235|FG003|ABBOTT PRISM Chagas Testing|Insufficient sample|0
6094603|NCT00718042|9708236|FG004|ABBOTT PRISM Chagas Testing|Insufficient sample|0
6094604|NCT00718042|9708237|FG005|ABBOTT PRISM Chagas Testing|Insufficient sample|0
6203031|NCT01510158|9863752|FG002|Overall Study|Adverse Event|5
6203032|NCT01510158|9863750|FG000|Overall Study|Gout flare|1
6203033|NCT01510158|9863751|FG001|Overall Study|Gout flare|0
6203034|NCT01510158|9863752|FG002|Overall Study|Gout flare|0
6203035|NCT01510158|9863750|FG000|Overall Study|Protocol Violation|17
6203036|NCT01510158|9863751|FG001|Overall Study|Protocol Violation|16
6203037|NCT01510158|9863752|FG002|Overall Study|Protocol Violation|24
6203038|NCT01510158|9863750|FG000|Overall Study|Sponsor terminated study.|2
6203039|NCT01510158|9863751|FG001|Overall Study|Sponsor terminated study.|0
6203040|NCT01510158|9863752|FG002|Overall Study|Sponsor terminated study.|2
6203041|NCT01510158|9863750|FG000|Overall Study|Lost to Follow-up|13
6094605|NCT00718042|9708232|FG000|ABBOTT PRISM Chagas Testing|No result on comparator assay|0
6203042|NCT01510158|9863751|FG001|Overall Study|Lost to Follow-up|16
6203043|NCT01510158|9863752|FG002|Overall Study|Lost to Follow-up|9
6061171|NCT00489424|9661884|FG000|Overall Study|Adverse Event|3
6061172|NCT00489424|9661885|FG001|Overall Study|Adverse Event|3
6061173|NCT00489424|9661886|FG002|Overall Study|Adverse Event|4
6061174|NCT00489424|9661884|FG000|Overall Study|Lack of Efficacy|1
6061175|NCT00489424|9661885|FG001|Overall Study|Lack of Efficacy|0
6061176|NCT00489424|9661886|FG002|Overall Study|Lack of Efficacy|0
6061177|NCT00489424|9661884|FG000|Overall Study|Administrative problems|0
6061178|NCT00489424|9661885|FG001|Overall Study|Administrative problems|2
6061179|NCT00489424|9661886|FG002|Overall Study|Administrative problems|1
6061180|NCT00489476|9661898|FG000|Overall Study|Lost to Follow-up|0
6061181|NCT00489476|9661899|FG001|Overall Study|Lost to Follow-up|1
6061182|NCT00489476|9661900|FG002|Overall Study|Lost to Follow-up|0
6061183|NCT00489476|9661901|FG003|Overall Study|Lost to Follow-up|0
6061184|NCT00489489|9661914|FG000|Overall Study|Not treated due to protocol violation|0
6061185|NCT00489489|9661915|FG001|Overall Study|Not treated due to protocol violation|1
6061186|NCT00489489|9661916|FG002|Overall Study|Not treated due to protocol violation|1
6061187|NCT00489489|9661914|FG000|Overall Study|Adverse Event|1
6061188|NCT00489489|9661915|FG001|Overall Study|Adverse Event|1
6061189|NCT00489489|9661916|FG002|Overall Study|Adverse Event|1
6061190|NCT00489489|9661914|FG000|Overall Study|Protocol Violation|1
6061191|NCT00489489|9661915|FG001|Overall Study|Protocol Violation|0
6061192|NCT00489489|9661916|FG002|Overall Study|Protocol Violation|1
6061193|NCT00489489|9661914|FG000|Overall Study|Progressive disease|0
6061194|NCT00489489|9661915|FG001|Overall Study|Progressive disease|1
6061195|NCT00489489|9661916|FG002|Overall Study|Progressive disease|0
6061196|NCT00489489|9661914|FG000|Overall Study|Participant did not wish to continue|1
6061197|NCT00489489|9661915|FG001|Overall Study|Participant did not wish to continue|1
6061198|NCT00489489|9661916|FG002|Overall Study|Participant did not wish to continue|0
6061199|NCT00489489|9661914|FG000|Overall Study|Other than above|0
6061200|NCT00489489|9661915|FG001|Overall Study|Other than above|1
6061201|NCT00489489|9661916|FG002|Overall Study|Other than above|0
6061202|NCT00489541|9661928|FG000|12-Month Clinical Follow-up|Withdrawal by Subject|2
6061203|NCT00489541|9661929|FG001|12-Month Clinical Follow-up|Withdrawal by Subject|3
6061204|NCT00489541|9661928|FG000|12-Month Clinical Follow-up|Lost to Follow-up|2
6061205|NCT00489541|9661929|FG001|12-Month Clinical Follow-up|Lost to Follow-up|0
6061206|NCT00489541|9661928|FG000|12-Month Clinical Follow-up|Missed 12-Month Visit|2
6061207|NCT00489541|9661929|FG001|12-Month Clinical Follow-up|Missed 12-Month Visit|0
6061208|NCT00489541|9661928|FG000|12-Month Clinical Follow-up|Death|3
6061209|NCT00489541|9661929|FG001|12-Month Clinical Follow-up|Death|2
6061210|NCT00489541|9661928|FG000|9-Month Angiographic Follow-up|No 9-Month Angiography Performed|23
6061211|NCT00489541|9661929|FG001|9-Month Angiographic Follow-up|No 9-Month Angiography Performed|12
6061212|NCT00489541|9661928|FG000|9-Month Angiographic Follow-up|Not Evaluable for 9-Month Angiography|4
6061213|NCT00489541|9661929|FG001|9-Month Angiographic Follow-up|Not Evaluable for 9-Month Angiography|5
6061214|NCT00489554|9661935|FG000|Overall Study|Adverse Event|2
6061215|NCT00489554|9661935|FG000|Overall Study|Withdrawal by Subject|1
6061216|NCT00489554|9661935|FG000|Overall Study|Lost to Follow-up|1
6061217|NCT00489736|9661941|FG000|Overall Study|Lack of Efficacy|53
6061218|NCT00489736|9661942|FG001|Overall Study|Lack of Efficacy|14
6061219|NCT00489736|9661941|FG000|Overall Study|Adverse Event|32
6061220|NCT00489736|9661942|FG001|Overall Study|Adverse Event|45
6061221|NCT00489736|9661941|FG000|Overall Study|Poor compliance|6
6094606|NCT00718042|9708233|FG001|ABBOTT PRISM Chagas Testing|No result on comparator assay|1
6094607|NCT00718042|9708234|FG002|ABBOTT PRISM Chagas Testing|No result on comparator assay|0
6094608|NCT00718042|9708235|FG003|ABBOTT PRISM Chagas Testing|No result on comparator assay|0
6094609|NCT00718042|9708236|FG004|ABBOTT PRISM Chagas Testing|No result on comparator assay|0
6094610|NCT00718042|9708237|FG005|ABBOTT PRISM Chagas Testing|No result on comparator assay|0
6094611|NCT00718042|9708232|FG000|Donor Follow-up|Lost to Follow-up|13
6094612|NCT00718042|9708233|FG001|Donor Follow-up|Lost to Follow-up|0
6094613|NCT00718042|9708234|FG002|Donor Follow-up|Lost to Follow-up|0
6094614|NCT00718042|9708235|FG003|Donor Follow-up|Lost to Follow-up|0
6094615|NCT00718042|9708236|FG004|Donor Follow-up|Lost to Follow-up|19
6094616|NCT00718042|9708237|FG005|Donor Follow-up|Lost to Follow-up|0
6094617|NCT00718081|9708252|FG000|Overall Study|Adverse Event|0
6094618|NCT00718081|9708253|FG001|Overall Study|Adverse Event|1
6094619|NCT00718081|9708254|FG002|Overall Study|Adverse Event|0
6094620|NCT00718081|9708252|FG000|Overall Study|Lack of Efficacy|7
6094621|NCT00718081|9708253|FG001|Overall Study|Lack of Efficacy|3
6094622|NCT00718081|9708254|FG002|Overall Study|Lack of Efficacy|21
6094623|NCT00718159|9708287|FG000|Overall Study|Progressive Disease|3
6094624|NCT00718159|9708288|FG001|Overall Study|Progressive Disease|3
6094625|NCT00718159|9708289|FG002|Overall Study|Progressive Disease|2
6203044|NCT01510158|9863750|FG000|Overall Study|Withdrawal by Subject|10
6061222|NCT00489736|9661942|FG001|Overall Study|Poor compliance|2
6061223|NCT00489736|9661941|FG000|Overall Study|Not coded/ Not pre-specified|5
6061224|NCT00489736|9661942|FG001|Overall Study|Not coded/ Not pre-specified|8
6061225|NCT00489827|9661950|FG000|Overall Study|Intraoperative exclusion criteria|1
6061226|NCT00489827|9661951|FG001|Overall Study|Intraoperative exclusion criteria|1
6094626|NCT00718159|9708290|FG003|Overall Study|Progressive Disease|0
6094627|NCT00718159|9708291|FG004|Overall Study|Progressive Disease|6
6094628|NCT00718159|9708292|FG005|Overall Study|Progressive Disease|0
6094629|NCT00718159|9708293|FG006|Overall Study|Progressive Disease|0
6061227|NCT00489827|9661950|FG000|Overall Study|Intraoperative exclusion criteria|1
6061228|NCT00489827|9661951|FG001|Overall Study|Intraoperative exclusion criteria|1
6061229|NCT00489853|9661957|FG000|Wash-out Period 1|Withdrawal by Subject|1
6094630|NCT00718159|9708287|FG000|Overall Study|Death due to Adverse Event|0
6094631|NCT00718159|9708288|FG001|Overall Study|Death due to Adverse Event|0
6094632|NCT00718159|9708289|FG002|Overall Study|Death due to Adverse Event|0
6094633|NCT00718159|9708290|FG003|Overall Study|Death due to Adverse Event|2
6094634|NCT00718159|9708291|FG004|Overall Study|Death due to Adverse Event|2
6094635|NCT00718159|9708292|FG005|Overall Study|Death due to Adverse Event|0
6094636|NCT00718159|9708293|FG006|Overall Study|Death due to Adverse Event|0
6094637|NCT00718159|9708287|FG000|Overall Study|Death due to Study Drug Toxicity|0
6094638|NCT00718159|9708288|FG001|Overall Study|Death due to Study Drug Toxicity|0
6094639|NCT00718159|9708289|FG002|Overall Study|Death due to Study Drug Toxicity|1
6094640|NCT00718159|9708290|FG003|Overall Study|Death due to Study Drug Toxicity|2
6094641|NCT00718159|9708291|FG004|Overall Study|Death due to Study Drug Toxicity|0
6094642|NCT00718159|9708292|FG005|Overall Study|Death due to Study Drug Toxicity|0
6094643|NCT00718159|9708293|FG006|Overall Study|Death due to Study Drug Toxicity|0
6094644|NCT00718159|9708287|FG000|Overall Study|Investigator Decision|0
6094645|NCT00718159|9708288|FG001|Overall Study|Investigator Decision|0
6094646|NCT00718159|9708289|FG002|Overall Study|Investigator Decision|0
6094647|NCT00718159|9708290|FG003|Overall Study|Investigator Decision|0
6094648|NCT00718159|9708291|FG004|Overall Study|Investigator Decision|0
6094649|NCT00718159|9708292|FG005|Overall Study|Investigator Decision|1
6061230|NCT00489853|9661958|FG001|Wash-out Period 1|Withdrawal by Subject|0
6061231|NCT00489853|9661959|FG002|Wash-out Period 1|Withdrawal by Subject|0
6061232|NCT00489853|9661957|FG000|Wash-out Period 1|Adverse Event|0
6061233|NCT00489853|9661958|FG001|Wash-out Period 1|Adverse Event|1
6061234|NCT00489853|9661959|FG002|Wash-out Period 1|Adverse Event|1
6061235|NCT00489853|9661957|FG000|Wash-out Period 1|Protocol Violation|0
6061236|NCT00489853|9661958|FG001|Wash-out Period 1|Protocol Violation|1
6061237|NCT00489853|9661959|FG002|Wash-out Period 1|Protocol Violation|1
6061238|NCT00489853|9661957|FG000|Wash-out Period 1|Study-specific discontinuation criteria|0
6061239|NCT00489853|9661958|FG001|Wash-out Period 1|Study-specific discontinuation criteria|1
6061240|NCT00489853|9661959|FG002|Wash-out Period 1|Study-specific discontinuation criteria|4
6061241|NCT00489853|9661957|FG000|Wash-out Period 2|Adverse Event|1
6061242|NCT00489853|9661958|FG001|Wash-out Period 2|Adverse Event|1
6061243|NCT00489853|9661959|FG002|Wash-out Period 2|Adverse Event|0
6061244|NCT00489853|9661957|FG000|Wash-out Period 2|Study specific discontinuation criteria|3
6061245|NCT00489853|9661958|FG001|Wash-out Period 2|Study specific discontinuation criteria|2
6061246|NCT00489853|9661959|FG002|Wash-out Period 2|Study specific discontinuation criteria|2
6061247|NCT00489853|9661957|FG000|Treatment Period 3|Study specific discontinuation criteria|0
6061248|NCT00489853|9661958|FG001|Treatment Period 3|Study specific discontinuation criteria|1
6061249|NCT00489853|9661959|FG002|Treatment Period 3|Study specific discontinuation criteria|0
6061250|NCT00489918|9661989|FG000|Overall Study|Withdrawal by Subject|2
6061251|NCT00489918|9661990|FG001|Overall Study|Withdrawal by Subject|1
6061252|NCT00489918|9661991|FG002|Overall Study|Withdrawal by Subject|1
6061253|NCT00489918|9661992|FG003|Overall Study|Withdrawal by Subject|0
6061254|NCT00489918|9661993|FG004|Overall Study|Withdrawal by Subject|1
6061255|NCT00489918|9661989|FG000|Overall Study|Adverse Event|0
6061256|NCT00489918|9661990|FG001|Overall Study|Adverse Event|1
6061257|NCT00489918|9661991|FG002|Overall Study|Adverse Event|1
6061258|NCT00489918|9661992|FG003|Overall Study|Adverse Event|0
6061259|NCT00489918|9661993|FG004|Overall Study|Adverse Event|0
6061260|NCT00489918|9661989|FG000|Overall Study|Lost to Follow-up|0
6061261|NCT00489918|9661990|FG001|Overall Study|Lost to Follow-up|0
6061262|NCT00489918|9661991|FG002|Overall Study|Lost to Follow-up|1
6061263|NCT00489918|9661992|FG003|Overall Study|Lost to Follow-up|1
6061264|NCT00489918|9661993|FG004|Overall Study|Lost to Follow-up|0
6061265|NCT00489918|9661989|FG000|Overall Study|Physician Decision|0
6061266|NCT00489918|9661990|FG001|Overall Study|Physician Decision|0
6061267|NCT00489918|9661991|FG002|Overall Study|Physician Decision|1
6061268|NCT00489918|9661992|FG003|Overall Study|Physician Decision|0
6061269|NCT00489918|9661993|FG004|Overall Study|Physician Decision|0
6061270|NCT00489970|9662008|FG000|Persistence Year 9|Lost to Follow-up|2
6061271|NCT00489970|9662009|FG001|Persistence Year 9|Lost to Follow-up|2
6061272|NCT00489970|9662010|FG002|Persistence Year 9|Lost to Follow-up|3
6061273|NCT00489970|9662008|FG000|Persistence Year 9|Other|1
6061274|NCT00489970|9662009|FG001|Persistence Year 9|Other|0
6061275|NCT00489970|9662010|FG002|Persistence Year 9|Other|2
6061276|NCT00490022|9662028|FG000|Overall Study|Adverse Event|0
6061277|NCT00490022|9662029|FG001|Overall Study|Adverse Event|2
6061278|NCT00490022|9662028|FG000|Overall Study|Withdrawal by Subject|1
6061279|NCT00490022|9662029|FG001|Overall Study|Withdrawal by Subject|0
6061280|NCT00490022|9662028|FG000|Overall Study|Subject failed to disclose concommitant|0
6061281|NCT00490022|9662029|FG001|Overall Study|Subject failed to disclose concommitant|1
6094650|NCT00718159|9708293|FG006|Overall Study|Investigator Decision|1
6094651|NCT00718237|9708311|FG000|Overall Study|Adverse Event|1
6094652|NCT00718237|9708312|FG001|Overall Study|Adverse Event|3
6094653|NCT00718237|9708311|FG000|Overall Study|Lost to Follow-up|2
6061282|NCT00490035|9662039|FG000|Overall Study|AE, non-serious non-fatal|3
6061283|NCT00490035|9662040|FG001|Overall Study|AE, non-serious non-fatal|4
6061284|NCT00490035|9662041|FG002|Overall Study|AE, non-serious non-fatal|4
6061285|NCT00490035|9662042|FG003|Overall Study|AE, non-serious non-fatal|5
6061286|NCT00490035|9662039|FG000|Overall Study|Lost to Follow-up|2
6061287|NCT00490035|9662040|FG001|Overall Study|Lost to Follow-up|0
6061288|NCT00490035|9662041|FG002|Overall Study|Lost to Follow-up|1
6061289|NCT00490035|9662042|FG003|Overall Study|Lost to Follow-up|0
6061290|NCT00490035|9662039|FG000|Overall Study|Withdrawal by Subject|2
6061291|NCT00490035|9662040|FG001|Overall Study|Withdrawal by Subject|1
6061292|NCT00490035|9662041|FG002|Overall Study|Withdrawal by Subject|1
6061293|NCT00490035|9662042|FG003|Overall Study|Withdrawal by Subject|0
6061294|NCT00490035|9662039|FG000|Overall Study|Other reason|0
6061295|NCT00490035|9662040|FG001|Overall Study|Other reason|1
6061296|NCT00490035|9662041|FG002|Overall Study|Other reason|3
6061297|NCT00490035|9662042|FG003|Overall Study|Other reason|1
6061298|NCT00490035|9662039|FG000|Overall Study|AE, serious fatal|1
6061299|NCT00490035|9662040|FG001|Overall Study|AE, serious fatal|0
6061300|NCT00490035|9662041|FG002|Overall Study|AE, serious fatal|0
6061301|NCT00490035|9662042|FG003|Overall Study|AE, serious fatal|0
6061302|NCT00490035|9662039|FG000|Overall Study|Serious adverse event (SAE), non-fatal|0
6061303|NCT00490035|9662040|FG001|Overall Study|Serious adverse event (SAE), non-fatal|0
6061304|NCT00490035|9662041|FG002|Overall Study|Serious adverse event (SAE), non-fatal|1
6061305|NCT00490035|9662042|FG003|Overall Study|Serious adverse event (SAE), non-fatal|0
6061306|NCT00490035|9662039|FG000|Overall Study|AE of unknown type|0
6061307|NCT00490035|9662040|FG001|Overall Study|AE of unknown type|0
6061308|NCT00490035|9662041|FG002|Overall Study|AE of unknown type|2
6061309|NCT00490035|9662042|FG003|Overall Study|AE of unknown type|0
6061310|NCT00490061|9662052|FG000|Overall Study|Physician Decision|1
6061311|NCT00490139|9662065|FG000|Overall Study|Death|106
6061312|NCT00490139|9662066|FG001|Overall Study|Death|119
6061313|NCT00490139|9662067|FG002|Overall Study|Death|168
6061314|NCT00490139|9662068|FG003|Overall Study|Death|135
6061315|NCT00490139|9662065|FG000|Overall Study|Lost to Follow-up|56
6061316|NCT00490139|9662066|FG001|Overall Study|Lost to Follow-up|46
6061317|NCT00490139|9662067|FG002|Overall Study|Lost to Follow-up|58
6061318|NCT00490139|9662068|FG003|Overall Study|Lost to Follow-up|56
6061319|NCT00490139|9662065|FG000|Overall Study|Participant Withdrew Consent|146
6061320|NCT00490139|9662066|FG001|Overall Study|Participant Withdrew Consent|110
6061321|NCT00490139|9662067|FG002|Overall Study|Participant Withdrew Consent|208
6061322|NCT00490139|9662068|FG003|Overall Study|Participant Withdrew Consent|116
6061323|NCT00490282|9662098|FG000|Overall Study|Withdrawal by Subject|3
6061324|NCT00490451|9662105|FG000|Overall Study|Adverse Event|3
6061325|NCT00490451|9662106|FG001|Overall Study|Adverse Event|3
6061326|NCT00490451|9662105|FG000|Overall Study|Death|3
6061327|NCT00490451|9662106|FG001|Overall Study|Death|1
6061328|NCT00490451|9662105|FG000|Overall Study|Withdrawal by Subject|2
6061329|NCT00490451|9662106|FG001|Overall Study|Withdrawal by Subject|0
6061330|NCT00490451|9662105|FG000|Overall Study|Investigator Decision|1
6061331|NCT00490451|9662106|FG001|Overall Study|Investigator Decision|0
6061332|NCT00490451|9662105|FG000|Overall Study|Protocol Violation|1
6061333|NCT00490451|9662106|FG001|Overall Study|Protocol Violation|0
6061334|NCT00490451|9662105|FG000|Overall Study|Progressive Disease|53
6061335|NCT00490451|9662106|FG001|Overall Study|Progressive Disease|34
6061336|NCT00490490|9662121|FG000|Completed Assessment for TTP|Withdrawal by Subject|1
6061337|NCT00490490|9662121|FG000|Completed Assessment for TTP|Lost to Follow-up|2
6061338|NCT00490529|9662125|FG000|Completed Pre-CpG-MCL Vaccine Procedures|Death|4
6061339|NCT00490529|9662125|FG000|Completed Pre-CpG-MCL Vaccine Procedures|Withdrawal by Subject|4
6061340|NCT00490529|9662125|FG000|Completed Pre-CpG-MCL Vaccine Procedures|Withdrawn, AHCT not suitable treatment|1
6061341|NCT00490529|9662125|FG000|Completed Pre-CpG-MCL Vaccine Procedures|Withdrawn, chemo not suitable treatment|1
6061342|NCT00490529|9662125|FG000|Completed Pre-CpG-MCL Vaccine Procedures|Withdrawal due to insurance refusal|1
6061343|NCT00490529|9662125|FG000|Treatment With CpG-MCL Vaccine|Received vaccine, did not receive AHCT|1
6061344|NCT00490542|9662131|FG000|Overall Study|Lost to Follow-up|3
6061345|NCT00490542|9662132|FG001|Overall Study|Lost to Follow-up|0
6061346|NCT00490542|9662131|FG000|Overall Study|Adverse Event|3
6061347|NCT00490542|9662132|FG001|Overall Study|Adverse Event|3
6061348|NCT00490542|9662131|FG000|Overall Study|Lack of Efficacy|1
6061349|NCT00490542|9662132|FG001|Overall Study|Lack of Efficacy|1
6061350|NCT00490555|9662142|FG000|Overall Study|noncompliant with drug administration|0
6061351|NCT00490555|9662143|FG001|Overall Study|noncompliant with drug administration|0
6061352|NCT00490555|9662144|FG002|Overall Study|noncompliant with drug administration|2
6061353|NCT00490555|9662145|FG003|Overall Study|noncompliant with drug administration|0
6284355|NCT02326272|9996337|FG009|Maintenance Period (Week 16 to Week 48)|Pregnancy|0
6061354|NCT00490568|9662155|FG000|Overall Study|Adverse Event|116
6061355|NCT00490568|9662155|FG000|Overall Study|Lost to Follow-up|13
6061356|NCT00490568|9662155|FG000|Overall Study|Protocol Violation|45
6061357|NCT00490568|9662155|FG000|Overall Study|Withdrawal by Subject|135
6061358|NCT00490568|9662155|FG000|Overall Study|Still in the study at termination|974
6061359|NCT00490568|9662155|FG000|Overall Study|Other|1
6061360|NCT00490568|9662155|FG000|Overall Study|Exclusion criteria met|1
6061361|NCT00490568|9662155|FG000|Overall Study|Caregiver related|20
6061362|NCT00490568|9662155|FG000|Overall Study|Abnormal ECG|25
6061363|NCT00490568|9662155|FG000|Overall Study|Participant refused follow-up|9
6061364|NCT00490568|9662155|FG000|Overall Study|Legal representative withdrew consent|1
6061365|NCT00490568|9662155|FG000|Overall Study|Disease progression|4
6061366|NCT00490568|9662155|FG000|Overall Study|Unmet inclusion-exclusion criteria|5
6061367|NCT00490568|9662155|FG000|Overall Study|Investigator decision|3
6094654|NCT00718237|9708312|FG001|Overall Study|Lost to Follow-up|2
6094655|NCT00718237|9708311|FG000|Overall Study|Physician Decision|1
6094656|NCT00718237|9708312|FG001|Overall Study|Physician Decision|0
6094657|NCT00718237|9708311|FG000|Overall Study|Withdrawal by Subject|9
6094658|NCT00718237|9708312|FG001|Overall Study|Withdrawal by Subject|10
6094659|NCT00718315|9708334|FG000|Overall Study|Adverse Event|1
6094660|NCT00718315|9708335|FG001|Overall Study|Adverse Event|2
6094661|NCT00718315|9708336|FG002|Overall Study|Adverse Event|3
6094662|NCT00718315|9708334|FG000|Overall Study|Death|6
6094663|NCT00718315|9708335|FG001|Overall Study|Death|6
6094664|NCT00718315|9708336|FG002|Overall Study|Death|5
6094665|NCT00718315|9708334|FG000|Overall Study|Lost to Follow-up|2
6094666|NCT00718315|9708335|FG001|Overall Study|Lost to Follow-up|3
6094667|NCT00718315|9708336|FG002|Overall Study|Lost to Follow-up|4
6094668|NCT00718315|9708334|FG000|Overall Study|Protocol Violation|5
6094669|NCT00718315|9708335|FG001|Overall Study|Protocol Violation|5
6094670|NCT00718315|9708336|FG002|Overall Study|Protocol Violation|3
6094671|NCT00718315|9708334|FG000|Overall Study|Erlotinib dose decreased|4
6094672|NCT00718315|9708335|FG001|Overall Study|Erlotinib dose decreased|3
6094673|NCT00718315|9708336|FG002|Overall Study|Erlotinib dose decreased|1
6094674|NCT00718315|9708334|FG000|Overall Study|Use of Minocyclin|1
6094675|NCT00718315|9708335|FG001|Overall Study|Use of Minocyclin|1
6094676|NCT00718315|9708336|FG002|Overall Study|Use of Minocyclin|1
6094677|NCT00718315|9708334|FG000|Overall Study|Disease progression|0
6094678|NCT00718315|9708335|FG001|Overall Study|Disease progression|1
6094679|NCT00718315|9708336|FG002|Overall Study|Disease progression|1
6094680|NCT00718315|9708334|FG000|Overall Study|Other|0
6094681|NCT00718315|9708335|FG001|Overall Study|Other|0
6094682|NCT00718315|9708336|FG002|Overall Study|Other|1
6094683|NCT00718315|9708334|FG000|Overall Study|Use of ATB and Corticoids|0
6094684|NCT00718315|9708335|FG001|Overall Study|Use of ATB and Corticoids|1
6094685|NCT00718315|9708336|FG002|Overall Study|Use of ATB and Corticoids|2
6094686|NCT00718328|9708346|FG000|Overall Study|Lost to Follow-up|1
6094687|NCT00718328|9708347|FG001|Overall Study|Lost to Follow-up|0
6094688|NCT00718419|9708355|FG000|Overall Study|Adverse Event|2
6094689|NCT00718419|9708356|FG001|Overall Study|Adverse Event|1
6094690|NCT00718419|9708355|FG000|Overall Study|Physician Decision|1
6094691|NCT00718419|9708356|FG001|Overall Study|Physician Decision|6
6094692|NCT00718419|9708355|FG000|Overall Study|Sponsor decision|0
6094693|NCT00718419|9708356|FG001|Overall Study|Sponsor decision|1
6094694|NCT00718419|9708355|FG000|Overall Study|Withdrawal by Subject|0
6094695|NCT00718419|9708356|FG001|Overall Study|Withdrawal by Subject|5
6094696|NCT00718419|9708355|FG000|Overall Study|Progressive Disease|7
6094697|NCT00718419|9708356|FG001|Overall Study|Progressive Disease|25
6094698|NCT00718419|9708355|FG000|Overall Study|Death Due to Progressive Disease|2
6094699|NCT00718419|9708356|FG001|Overall Study|Death Due to Progressive Disease|0
6094700|NCT00718419|9708355|FG000|Overall Study|Death Due to Study Drug Related|0
6094701|NCT00718419|9708356|FG001|Overall Study|Death Due to Study Drug Related|1
6094702|NCT00718419|9708355|FG000|Overall Study|Death Due to Adverse Events|1
6094703|NCT00718419|9708356|FG001|Overall Study|Death Due to Adverse Events|0
6094704|NCT00718510|9708364|FG000|First Intervention (3 Weeks)|Withdrawal by Subject|0
6094705|NCT00718510|9708365|FG001|First Intervention (3 Weeks)|Withdrawal by Subject|1
6094706|NCT00718510|9708364|FG000|Second Intervention (3 Weeks)|Withdrawal by Subject|1
6094707|NCT00718510|9708365|FG001|Second Intervention (3 Weeks)|Withdrawal by Subject|0
6094708|NCT00718523|9708373|FG000|Overall Study|Withdrawal by Subject|5
6094709|NCT00718523|9708374|FG001|Overall Study|Withdrawal by Subject|7
6094710|NCT00718523|9708373|FG000|Overall Study|Death|13
6094711|NCT00718523|9708374|FG001|Overall Study|Death|17
6094712|NCT00718549|9708380|FG000|Induction Phase|Disease Progression|1
6094713|NCT00718549|9708381|FG001|Induction Phase|Disease Progression|0
6094714|NCT00718549|9708382|FG002|Induction Phase|Disease Progression|0
6094715|NCT00718549|9708380|FG000|Induction Phase|Eligibility Criteria Violation|2
6094716|NCT00718549|9708381|FG001|Induction Phase|Eligibility Criteria Violation|0
6094717|NCT00718549|9708382|FG002|Induction Phase|Eligibility Criteria Violation|0
6094718|NCT00718549|9708380|FG000|Induction Phase|Early Termination - No Additional Info|59
6094719|NCT00718549|9708381|FG001|Induction Phase|Early Termination - No Additional Info|0
6094720|NCT00718549|9708382|FG002|Induction Phase|Early Termination - No Additional Info|0
6094721|NCT00718549|9708380|FG000|Maintenance/ Observation Phase|Early Termination - No Additional Info|0
6094722|NCT00718549|9708381|FG001|Maintenance/ Observation Phase|Early Termination - No Additional Info|15
6094723|NCT00718549|9708382|FG002|Maintenance/ Observation Phase|Early Termination - No Additional Info|8
6094724|NCT00718549|9708380|FG000|Maintenance/ Observation Phase|Death|0
6094725|NCT00718549|9708381|FG001|Maintenance/ Observation Phase|Death|1
6094726|NCT00718549|9708382|FG002|Maintenance/ Observation Phase|Death|2
6094727|NCT00718549|9708380|FG000|Maintenance/ Observation Phase|Lost to Follow-up|0
6094728|NCT00718549|9708381|FG001|Maintenance/ Observation Phase|Lost to Follow-up|4
6061368|NCT00490568|9662155|FG000|Overall Study|Non-Compliance|7
6061369|NCT00490568|9662155|FG000|Overall Study|Efficacy related|3
6061370|NCT00490568|9662155|FG000|Overall Study|Participant died|1
6061371|NCT00490568|9662155|FG000|Overall Study|Participant withdrawal due to surgery|1
6061372|NCT00490646|9662162|FG000|Overall Study|Still on trastuzumab monotherapy|1
6061373|NCT00490646|9662163|FG001|Overall Study|Still on trastuzumab monotherapy|1
6061374|NCT00490646|9662162|FG000|Overall Study|Never Treated (had an adverse event)|1
6061375|NCT00490646|9662163|FG001|Overall Study|Never Treated (had an adverse event)|0
6061376|NCT00490646|9662162|FG000|Overall Study|Never Treated (withdrew consent)|0
6061377|NCT00490646|9662163|FG001|Overall Study|Never Treated (withdrew consent)|1
6061378|NCT00490698|9662169|FG000|Overall Study|Withdrawal by Subject|1
6061379|NCT00490698|9662169|FG000|Overall Study|Disease Progression|7
6061380|NCT00490698|9662169|FG000|Overall Study|Physician Decision|2
6061381|NCT00490724|9662176|FG000|Period I|Physician Decision|0
6061382|NCT00490724|9662177|FG001|Period I|Physician Decision|0
6061383|NCT00490724|9662178|FG002|Period I|Physician Decision|1
6061384|NCT00490724|9662176|FG000|Period II|Treatment Discontinuation|3
6061385|NCT00490724|9662177|FG001|Period II|Treatment Discontinuation|1
6061386|NCT00490724|9662178|FG002|Period II|Treatment Discontinuation|3
6061387|NCT00490815|9662198|FG000|Overall Study|Adverse Event|2
6061388|NCT00490815|9662199|FG001|Overall Study|Adverse Event|3
6061389|NCT00490815|9662198|FG000|Overall Study|Withdrawal by Subject|4
6061390|NCT00490815|9662199|FG001|Overall Study|Withdrawal by Subject|0
6061391|NCT00490815|9662198|FG000|Overall Study|Lost to Follow-up|1
6061392|NCT00490815|9662199|FG001|Overall Study|Lost to Follow-up|3
6061393|NCT00490815|9662198|FG000|Overall Study|Death|1
6061394|NCT00490815|9662199|FG001|Overall Study|Death|3
6061395|NCT00490841|9662205|FG000|Overall Study|Death|5
6061396|NCT00490841|9662205|FG000|Overall Study|Withdrawal by Subject|4
6061397|NCT00490841|9662205|FG000|Overall Study|Lost to Follow-up|1
6061398|NCT00490841|9662205|FG000|Overall Study|30 day f/u, only non-study stent used|3
6061399|NCT00490919|9662212|FG000|Open-label Run-in Period|Adverse Event|239
6061400|NCT00490919|9662213|FG001|Open-label Run-in Period|Adverse Event|0
6061401|NCT00490919|9662214|FG002|Open-label Run-in Period|Adverse Event|0
6061402|NCT00490919|9662212|FG000|Open-label Run-in Period|Withdrawal by Subject|37
6061403|NCT00490919|9662213|FG001|Open-label Run-in Period|Withdrawal by Subject|0
6061404|NCT00490919|9662214|FG002|Open-label Run-in Period|Withdrawal by Subject|0
6061405|NCT00490919|9662212|FG000|Open-label Run-in Period|Lost to Follow-up|21
6061406|NCT00490919|9662213|FG001|Open-label Run-in Period|Lost to Follow-up|0
6061407|NCT00490919|9662214|FG002|Open-label Run-in Period|Lost to Follow-up|0
6061408|NCT00490919|9662212|FG000|Open-label Run-in Period|Lack of Efficacy|143
6061409|NCT00490919|9662213|FG001|Open-label Run-in Period|Lack of Efficacy|0
6061410|NCT00490919|9662214|FG002|Open-label Run-in Period|Lack of Efficacy|0
6061411|NCT00490919|9662212|FG000|Open-label Run-in Period|Administrative|40
6061412|NCT00490919|9662213|FG001|Open-label Run-in Period|Administrative|0
6061413|NCT00490919|9662214|FG002|Open-label Run-in Period|Administrative|0
6061414|NCT00490919|9662212|FG000|Open-label Run-in Period|Confirmed or suspected diversion|3
6061415|NCT00490919|9662213|FG001|Open-label Run-in Period|Confirmed or suspected diversion|0
6061416|NCT00490919|9662214|FG002|Open-label Run-in Period|Confirmed or suspected diversion|0
6061417|NCT00490919|9662212|FG000|Double-blind Phase|Adverse Event|0
6061418|NCT00490919|9662213|FG001|Double-blind Phase|Adverse Event|40
6061419|NCT00490919|9662214|FG002|Double-blind Phase|Adverse Event|20
6061420|NCT00490919|9662212|FG000|Double-blind Phase|Withdrawal by Subject|0
6061421|NCT00490919|9662213|FG001|Double-blind Phase|Withdrawal by Subject|10
6061422|NCT00490919|9662214|FG002|Double-blind Phase|Withdrawal by Subject|11
6061423|NCT00490919|9662212|FG000|Double-blind Phase|Lost to Follow-up|0
6061424|NCT00490919|9662213|FG001|Double-blind Phase|Lost to Follow-up|8
6061425|NCT00490919|9662214|FG002|Double-blind Phase|Lost to Follow-up|11
6061426|NCT00490919|9662212|FG000|Double-blind Phase|Lack of Efficacy|0
6061427|NCT00490919|9662213|FG001|Double-blind Phase|Lack of Efficacy|22
6061428|NCT00490919|9662214|FG002|Double-blind Phase|Lack of Efficacy|36
6061429|NCT00490919|9662212|FG000|Double-blind Phase|Administrative|0
6061430|NCT00490919|9662213|FG001|Double-blind Phase|Administrative|6
6061431|NCT00490919|9662214|FG002|Double-blind Phase|Administrative|6
6061432|NCT00490945|9662226|FG000|Overall Study|Adverse Event|0
6061433|NCT00490945|9662227|FG001|Overall Study|Adverse Event|1
6061434|NCT00490945|9662228|FG002|Overall Study|Adverse Event|0
6061435|NCT00490945|9662229|FG003|Overall Study|Adverse Event|0
6061436|NCT00490945|9662230|FG004|Overall Study|Adverse Event|0
6061437|NCT00490971|9662250|FG000|Acute/Continuation|Adverse Event|62
6061438|NCT00490971|9662251|FG001|Acute/Continuation|Adverse Event|13
6061439|NCT00490971|9662252|FG002|Acute/Continuation|Adverse Event|0
6061440|NCT00490971|9662253|FG003|Acute/Continuation|Adverse Event|0
6061441|NCT00490971|9662254|FG004|Acute/Continuation|Adverse Event|0
6061442|NCT00490971|9662250|FG000|Acute/Continuation|Death|2
6061443|NCT00490971|9662251|FG001|Acute/Continuation|Death|0
6061444|NCT00490971|9662252|FG002|Acute/Continuation|Death|0
6061445|NCT00490971|9662253|FG003|Acute/Continuation|Death|0
6061446|NCT00490971|9662254|FG004|Acute/Continuation|Death|0
6061447|NCT00490971|9662250|FG000|Acute/Continuation|Lack of Efficacy|106
6061448|NCT00490971|9662251|FG001|Acute/Continuation|Lack of Efficacy|12
6061449|NCT00490971|9662252|FG002|Acute/Continuation|Lack of Efficacy|0
6061450|NCT00490971|9662253|FG003|Acute/Continuation|Lack of Efficacy|0
6061451|NCT00490971|9662254|FG004|Acute/Continuation|Lack of Efficacy|0
6061452|NCT00490971|9662250|FG000|Acute/Continuation|Lost to Follow-up|23
6061453|NCT00490971|9662251|FG001|Acute/Continuation|Lost to Follow-up|7
6061454|NCT00490971|9662252|FG002|Acute/Continuation|Lost to Follow-up|0
6061455|NCT00490971|9662253|FG003|Acute/Continuation|Lost to Follow-up|0
6061456|NCT00490971|9662254|FG004|Acute/Continuation|Lost to Follow-up|0
6061457|NCT00490971|9662250|FG000|Acute/Continuation|Protocol Violation|10
6061458|NCT00490971|9662251|FG001|Acute/Continuation|Protocol Violation|2
6061459|NCT00490971|9662252|FG002|Acute/Continuation|Protocol Violation|0
6061460|NCT00490971|9662253|FG003|Acute/Continuation|Protocol Violation|0
6061461|NCT00490971|9662254|FG004|Acute/Continuation|Protocol Violation|0
6061462|NCT00490971|9662250|FG000|Acute/Continuation|Withdrawal by Subject|92
6061463|NCT00490971|9662251|FG001|Acute/Continuation|Withdrawal by Subject|24
6061464|NCT00490971|9662252|FG002|Acute/Continuation|Withdrawal by Subject|0
6061465|NCT00490971|9662253|FG003|Acute/Continuation|Withdrawal by Subject|0
6061466|NCT00490971|9662254|FG004|Acute/Continuation|Withdrawal by Subject|0
6061467|NCT00490971|9662250|FG000|Acute/Continuation|Other|11
6061468|NCT00490971|9662251|FG001|Acute/Continuation|Other|4
6061469|NCT00490971|9662252|FG002|Acute/Continuation|Other|0
6061470|NCT00490971|9662253|FG003|Acute/Continuation|Other|0
6061471|NCT00490971|9662254|FG004|Acute/Continuation|Other|0
6061472|NCT00490971|9662250|FG000|Maintenance|Adverse Event|0
6061473|NCT00490971|9662251|FG001|Maintenance|Adverse Event|0
6061474|NCT00490971|9662252|FG002|Maintenance|Adverse Event|4
6061475|NCT00490971|9662253|FG003|Maintenance|Adverse Event|5
6061476|NCT00490971|9662254|FG004|Maintenance|Adverse Event|7
6061477|NCT00490971|9662250|FG000|Maintenance|Death|0
6061478|NCT00490971|9662251|FG001|Maintenance|Death|0
6061479|NCT00490971|9662252|FG002|Maintenance|Death|0
6061480|NCT00490971|9662253|FG003|Maintenance|Death|2
6061481|NCT00490971|9662254|FG004|Maintenance|Death|0
6061482|NCT00490971|9662250|FG000|Maintenance|Lost to Follow-up|0
6061483|NCT00490971|9662251|FG001|Maintenance|Lost to Follow-up|0
6061484|NCT00490971|9662252|FG002|Maintenance|Lost to Follow-up|5
6061485|NCT00490971|9662253|FG003|Maintenance|Lost to Follow-up|8
6061486|NCT00490971|9662254|FG004|Maintenance|Lost to Follow-up|10
6061487|NCT00490971|9662250|FG000|Maintenance|Pregnancy|0
6061488|NCT00490971|9662251|FG001|Maintenance|Pregnancy|0
6061489|NCT00490971|9662252|FG002|Maintenance|Pregnancy|1
6061490|NCT00490971|9662253|FG003|Maintenance|Pregnancy|0
6061491|NCT00490971|9662254|FG004|Maintenance|Pregnancy|0
6061492|NCT00490971|9662250|FG000|Maintenance|Protocol Violation|0
6061493|NCT00490971|9662251|FG001|Maintenance|Protocol Violation|0
6061494|NCT00490971|9662252|FG002|Maintenance|Protocol Violation|4
6061495|NCT00490971|9662253|FG003|Maintenance|Protocol Violation|1
6061496|NCT00490971|9662254|FG004|Maintenance|Protocol Violation|1
6061497|NCT00490971|9662250|FG000|Maintenance|Withdrawal by Subject|0
6061498|NCT00490971|9662251|FG001|Maintenance|Withdrawal by Subject|0
6061499|NCT00490971|9662252|FG002|Maintenance|Withdrawal by Subject|26
6061500|NCT00490971|9662253|FG003|Maintenance|Withdrawal by Subject|28
6061501|NCT00490971|9662254|FG004|Maintenance|Withdrawal by Subject|18
6061502|NCT00490971|9662250|FG000|Maintenance|Other|0
6061503|NCT00490971|9662251|FG001|Maintenance|Other|0
6061504|NCT00490971|9662252|FG002|Maintenance|Other|11
6061505|NCT00490971|9662253|FG003|Maintenance|Other|9
6061506|NCT00490971|9662254|FG004|Maintenance|Other|3
6061507|NCT00491075|9662266|FG000|Overall Study|Withdrawal by Subject|1
6061508|NCT00491075|9662266|FG000|Overall Study|Physician Decision|1
6061509|NCT00491179|9662272|FG000|Overall Study|Adverse Event|5
6061510|NCT00491179|9662273|FG001|Overall Study|Adverse Event|1
6061511|NCT00491179|9662272|FG000|Overall Study|Withdrawal by Subject|2
6061512|NCT00491179|9662273|FG001|Overall Study|Withdrawal by Subject|1
6061513|NCT00491322|9662290|FG000|Overall Study|Protocol Violation|1
6061514|NCT00491322|9662291|FG001|Overall Study|Protocol Violation|0
6061515|NCT00491322|9662290|FG000|Overall Study|Pregnancy|0
6061516|NCT00491322|9662291|FG001|Overall Study|Pregnancy|1
6061517|NCT00491530|9662318|FG000|Overall Study|Adverse Event|6
6061518|NCT00491530|9662319|FG001|Overall Study|Adverse Event|1
6061519|NCT00491530|9662320|FG002|Overall Study|Adverse Event|2
6061520|NCT00491530|9662318|FG000|Overall Study|Withdrawal by Subject|3
6061521|NCT00491530|9662319|FG001|Overall Study|Withdrawal by Subject|0
6061522|NCT00491530|9662320|FG002|Overall Study|Withdrawal by Subject|0
6061523|NCT00491530|9662318|FG000|Overall Study|Lost to Follow-up|3
6061524|NCT00491530|9662319|FG001|Overall Study|Lost to Follow-up|2
6061525|NCT00491530|9662320|FG002|Overall Study|Lost to Follow-up|2
6061526|NCT00491530|9662318|FG000|Overall Study|Lack of Efficacy|0
6061527|NCT00491530|9662319|FG001|Overall Study|Lack of Efficacy|1
6061528|NCT00491530|9662320|FG002|Overall Study|Lack of Efficacy|0
6061529|NCT00491530|9662318|FG000|Overall Study|Investigator Discretion|0
6061530|NCT00491530|9662319|FG001|Overall Study|Investigator Discretion|1
6061531|NCT00491530|9662320|FG002|Overall Study|Investigator Discretion|0
6061532|NCT00491530|9662318|FG000|Overall Study|Patient Request|0
6061533|NCT00491530|9662319|FG001|Overall Study|Patient Request|1
6061534|NCT00491530|9662320|FG002|Overall Study|Patient Request|0
6061535|NCT00491530|9662318|FG000|Overall Study|Use of Prohibited Medication|0
6061536|NCT00491530|9662319|FG001|Overall Study|Use of Prohibited Medication|0
6061537|NCT00491530|9662320|FG002|Overall Study|Use of Prohibited Medication|1
6061538|NCT00491556|9662330|FG000|Entry-Week (WK) 48: EXP/Standard Care|Lost to Follow-up|1
6061539|NCT00491556|9662331|FG001|Entry-Week (WK) 48: EXP/Standard Care|Lost to Follow-up|0
6061540|NCT00491556|9662330|FG000|Entry-Week (WK) 48: EXP/Standard Care|Physician Decision|1
6094729|NCT00718549|9708382|FG002|Maintenance/ Observation Phase|Lost to Follow-up|4
6094730|NCT00718549|9708380|FG000|Maintenance/ Observation Phase|Progression|0
6094731|NCT00718549|9708381|FG001|Maintenance/ Observation Phase|Progression|5
6094732|NCT00718549|9708382|FG002|Maintenance/ Observation Phase|Progression|14
6094733|NCT00718549|9708380|FG000|Maintenance/ Observation Phase|Relapse|0
6094734|NCT00718549|9708381|FG001|Maintenance/ Observation Phase|Relapse|3
6094735|NCT00718549|9708382|FG002|Maintenance/ Observation Phase|Relapse|2
6094736|NCT00718666|9708398|FG000|Booster Phase Year 5|No active participation request|0
6094737|NCT00718666|9708399|FG001|Booster Phase Year 5|No active participation request|0
6094738|NCT00718666|9708400|FG002|Booster Phase Year 5|No active participation request|1
6094739|NCT00718666|9708398|FG000|Booster Phase Year 5|Declined v-4 serology|1
6094740|NCT00718666|9708399|FG001|Booster Phase Year 5|Declined v-4 serology|0
6094741|NCT00718666|9708400|FG002|Booster Phase Year 5|Declined v-4 serology|0
6094742|NCT00718666|9708398|FG000|Booster Phase Year 5|Withdrawal by Subject|0
6094743|NCT00718666|9708399|FG001|Booster Phase Year 5|Withdrawal by Subject|0
6094744|NCT00718666|9708400|FG002|Booster Phase Year 5|Withdrawal by Subject|1
6094745|NCT00718666|9708398|FG000|Booster Phase Year 5|Lost to Follow-up|1
6094746|NCT00718666|9708399|FG001|Booster Phase Year 5|Lost to Follow-up|0
6094747|NCT00718666|9708400|FG002|Booster Phase Year 5|Lost to Follow-up|4
6094748|NCT00718718|9708425|FG000|Prior to Week 12|Adverse Event|0
6094749|NCT00718718|9708426|FG001|Prior to Week 12|Adverse Event|0
6094750|NCT00718718|9708427|FG002|Prior to Week 12|Adverse Event|0
6094751|NCT00718718|9708428|FG003|Prior to Week 12|Adverse Event|0
6094752|NCT00718718|9708429|FG004|Prior to Week 12|Adverse Event|0
6094753|NCT00718718|9708430|FG005|Prior to Week 12|Adverse Event|0
6094754|NCT00718718|9708431|FG006|Prior to Week 12|Adverse Event|0
6094755|NCT00718718|9708432|FG007|Prior to Week 12|Adverse Event|1
6094756|NCT00718718|9708433|FG008|Prior to Week 12|Adverse Event|1
6094757|NCT00718718|9708434|FG009|Prior to Week 12|Adverse Event|0
6094758|NCT00718718|9708425|FG000|Prior to Week 12|Withdrawal by Subject|0
6094759|NCT00718718|9708426|FG001|Prior to Week 12|Withdrawal by Subject|0
6094760|NCT00718718|9708427|FG002|Prior to Week 12|Withdrawal by Subject|0
6094761|NCT00718718|9708428|FG003|Prior to Week 12|Withdrawal by Subject|0
6094762|NCT00718718|9708429|FG004|Prior to Week 12|Withdrawal by Subject|3
6094763|NCT00718718|9708430|FG005|Prior to Week 12|Withdrawal by Subject|0
6094764|NCT00718718|9708431|FG006|Prior to Week 12|Withdrawal by Subject|1
6094765|NCT00718718|9708432|FG007|Prior to Week 12|Withdrawal by Subject|1
6094766|NCT00718718|9708433|FG008|Prior to Week 12|Withdrawal by Subject|1
6094767|NCT00718718|9708434|FG009|Prior to Week 12|Withdrawal by Subject|0
6094768|NCT00718718|9708425|FG000|Prior to Week 12|Other|1
6094769|NCT00718718|9708426|FG001|Prior to Week 12|Other|0
6094770|NCT00718718|9708427|FG002|Prior to Week 12|Other|1
6094771|NCT00718718|9708428|FG003|Prior to Week 12|Other|0
6094772|NCT00718718|9708429|FG004|Prior to Week 12|Other|0
6094773|NCT00718718|9708430|FG005|Prior to Week 12|Other|0
6094774|NCT00718718|9708431|FG006|Prior to Week 12|Other|0
6094775|NCT00718718|9708432|FG007|Prior to Week 12|Other|0
6094776|NCT00718718|9708433|FG008|Prior to Week 12|Other|0
6094777|NCT00718718|9708434|FG009|Prior to Week 12|Other|0
6094778|NCT00718718|9708425|FG000|Week 12 to End of Study|Adverse Event|0
6094779|NCT00718718|9708426|FG001|Week 12 to End of Study|Adverse Event|0
6094780|NCT00718718|9708427|FG002|Week 12 to End of Study|Adverse Event|0
6094781|NCT00718718|9708428|FG003|Week 12 to End of Study|Adverse Event|0
6094782|NCT00718718|9708429|FG004|Week 12 to End of Study|Adverse Event|0
6094783|NCT00718718|9708430|FG005|Week 12 to End of Study|Adverse Event|0
6094784|NCT00718718|9708431|FG006|Week 12 to End of Study|Adverse Event|0
6094785|NCT00718718|9708432|FG007|Week 12 to End of Study|Adverse Event|1
6094786|NCT00718718|9708433|FG008|Week 12 to End of Study|Adverse Event|0
6094787|NCT00718718|9708434|FG009|Week 12 to End of Study|Adverse Event|0
6094788|NCT00718718|9708425|FG000|Week 12 to End of Study|Death|0
6094789|NCT00718718|9708426|FG001|Week 12 to End of Study|Death|0
6061541|NCT00491556|9662331|FG001|Entry-Week (WK) 48: EXP/Standard Care|Physician Decision|0
6061542|NCT00491556|9662330|FG000|Entry-Week (WK) 48: EXP/Standard Care|Withdrawal by Subject|1
6061543|NCT00491556|9662331|FG001|Entry-Week (WK) 48: EXP/Standard Care|Withdrawal by Subject|0
6061544|NCT00491556|9662330|FG000|Entry-Week (WK) 48: EXP/Standard Care|Moved Out of Area|2
6061545|NCT00491556|9662331|FG001|Entry-Week (WK) 48: EXP/Standard Care|Moved Out of Area|0
6061546|NCT00491556|9662330|FG000|Entry-Week (WK) 48: EXP/Standard Care|Failure to Suppress VL at Week 24|11
6061547|NCT00491556|9662331|FG001|Entry-Week (WK) 48: EXP/Standard Care|Failure to Suppress VL at Week 24|0
6061548|NCT00491556|9662330|FG000|Entry-Week (WK) 48: EXP/Standard Care|VL Failure at Week 24|2
6061549|NCT00491556|9662331|FG001|Entry-Week (WK) 48: EXP/Standard Care|VL Failure at Week 24|0
6061550|NCT00491556|9662330|FG000|Entry-Week (WK) 48: EXP/Standard Care|Adherence Issues|2
6061551|NCT00491556|9662331|FG001|Entry-Week (WK) 48: EXP/Standard Care|Adherence Issues|0
6094790|NCT00718718|9708427|FG002|Week 12 to End of Study|Death|0
6094791|NCT00718718|9708428|FG003|Week 12 to End of Study|Death|0
6094792|NCT00718718|9708429|FG004|Week 12 to End of Study|Death|0
6094793|NCT00718718|9708430|FG005|Week 12 to End of Study|Death|1
6094794|NCT00718718|9708431|FG006|Week 12 to End of Study|Death|0
6094795|NCT00718718|9708432|FG007|Week 12 to End of Study|Death|0
6061552|NCT00491556|9662330|FG000|Entry-Week (WK) 48: EXP/Standard Care|Toxicity|3
6061553|NCT00491556|9662331|FG001|Entry-Week (WK) 48: EXP/Standard Care|Toxicity|0
6061554|NCT00491556|9662330|FG000|Entry-Week (WK) 48: EXP/Standard Care|Other|3
6061555|NCT00491556|9662331|FG001|Entry-Week (WK) 48: EXP/Standard Care|Other|0
6061556|NCT00491556|9662330|FG000|Wk 48-152: EXP (On De-Int)/Standard Care|Lost to Follow-up|2
6061557|NCT00491556|9662331|FG001|Wk 48-152: EXP (On De-Int)/Standard Care|Lost to Follow-up|2
6061558|NCT00491556|9662330|FG000|Wk 48-152: EXP (On De-Int)/Standard Care|Pregnancy|2
6061559|NCT00491556|9662331|FG001|Wk 48-152: EXP (On De-Int)/Standard Care|Pregnancy|0
6061560|NCT00491556|9662330|FG000|Wk 48-152: EXP (On De-Int)/Standard Care|Moved Out of Area|2
6061561|NCT00491556|9662331|FG001|Wk 48-152: EXP (On De-Int)/Standard Care|Moved Out of Area|1
6061562|NCT00491556|9662330|FG000|Wk 48-152: EXP (On De-Int)/Standard Care|VL Failure After Week 48|5
6061563|NCT00491556|9662331|FG001|Wk 48-152: EXP (On De-Int)/Standard Care|VL Failure After Week 48|0
6061564|NCT00491556|9662330|FG000|Wk 48-152: EXP (On De-Int)/Standard Care|CD4 Failure|2
6061565|NCT00491556|9662331|FG001|Wk 48-152: EXP (On De-Int)/Standard Care|CD4 Failure|0
6061566|NCT00491556|9662330|FG000|Wk 48-152: EXP (On De-Int)/Standard Care|Adherence Issues|5
6061567|NCT00491556|9662331|FG001|Wk 48-152: EXP (On De-Int)/Standard Care|Adherence Issues|0
6061568|NCT00491556|9662330|FG000|Wk 48-152: EXP (On De-Int)/Standard Care|Toxicity|2
6061569|NCT00491556|9662331|FG001|Wk 48-152: EXP (On De-Int)/Standard Care|Toxicity|0
6061570|NCT00491556|9662330|FG000|Wk 48-152: EXP (On De-Int)/Standard Care|End of Funding|2
6061571|NCT00491556|9662331|FG001|Wk 48-152: EXP (On De-Int)/Standard Care|End of Funding|0
6061572|NCT00491556|9662330|FG000|Wk 48-152: EXP (On De-Int)/Standard Care|Other|2
6061573|NCT00491556|9662331|FG001|Wk 48-152: EXP (On De-Int)/Standard Care|Other|0
6061574|NCT00491556|9662330|FG000|Wk 48-152: EXP (On De-Int)/Standard Care|Incarceration|0
6061575|NCT00491556|9662331|FG001|Wk 48-152: EXP (On De-Int)/Standard Care|Incarceration|1
6061576|NCT00491556|9662330|FG000|Wk 48-152: EXP (On De-Int)/Standard Care|Death of Participant|0
6061577|NCT00491556|9662331|FG001|Wk 48-152: EXP (On De-Int)/Standard Care|Death of Participant|1
6061578|NCT00491608|9662337|FG000|Overall Study|Death|2
6061579|NCT00491608|9662337|FG000|Overall Study|Withdrawal by Subject|1
6061580|NCT00491764|9662362|FG000|Overall Study|Adverse Event|1
6061581|NCT00491764|9662363|FG001|Overall Study|Adverse Event|2
6061582|NCT00491764|9662364|FG002|Overall Study|Adverse Event|4
6061583|NCT00491764|9662365|FG003|Overall Study|Adverse Event|4
6061584|NCT00491764|9662366|FG004|Overall Study|Adverse Event|0
6061585|NCT00491764|9662367|FG005|Overall Study|Adverse Event|1
6061586|NCT00491764|9662362|FG000|Overall Study|Lost to Follow-up|0
6061587|NCT00491764|9662363|FG001|Overall Study|Lost to Follow-up|1
6061588|NCT00491764|9662364|FG002|Overall Study|Lost to Follow-up|0
6061589|NCT00491764|9662365|FG003|Overall Study|Lost to Follow-up|1
6061590|NCT00491764|9662366|FG004|Overall Study|Lost to Follow-up|0
6061591|NCT00491764|9662367|FG005|Overall Study|Lost to Follow-up|3
6061592|NCT00491764|9662362|FG000|Overall Study|Withdrawal by Subject|2
6061593|NCT00491764|9662363|FG001|Overall Study|Withdrawal by Subject|3
6061594|NCT00491764|9662364|FG002|Overall Study|Withdrawal by Subject|1
6061595|NCT00491764|9662365|FG003|Overall Study|Withdrawal by Subject|2
6061596|NCT00491764|9662366|FG004|Overall Study|Withdrawal by Subject|2
6061597|NCT00491764|9662367|FG005|Overall Study|Withdrawal by Subject|4
6061598|NCT00491764|9662362|FG000|Overall Study|Non Compliance with the Protocol|1
6061599|NCT00491764|9662363|FG001|Overall Study|Non Compliance with the Protocol|0
6061600|NCT00491764|9662364|FG002|Overall Study|Non Compliance with the Protocol|0
6061601|NCT00491764|9662365|FG003|Overall Study|Non Compliance with the Protocol|0
6061602|NCT00491764|9662366|FG004|Overall Study|Non Compliance with the Protocol|0
6061603|NCT00491764|9662367|FG005|Overall Study|Non Compliance with the Protocol|0
6061604|NCT00491764|9662362|FG000|Overall Study|Did not Meet Protocol Eligibility|0
6061605|NCT00491764|9662363|FG001|Overall Study|Did not Meet Protocol Eligibility|1
6061606|NCT00491764|9662364|FG002|Overall Study|Did not Meet Protocol Eligibility|1
6061607|NCT00491764|9662365|FG003|Overall Study|Did not Meet Protocol Eligibility|0
6061608|NCT00491764|9662366|FG004|Overall Study|Did not Meet Protocol Eligibility|1
6061609|NCT00491764|9662367|FG005|Overall Study|Did not Meet Protocol Eligibility|1
6094796|NCT00718718|9708433|FG008|Week 12 to End of Study|Death|0
6094797|NCT00718718|9708434|FG009|Week 12 to End of Study|Death|0
6094798|NCT00718718|9708425|FG000|Week 12 to End of Study|Withdrawal by Subject|0
6094799|NCT00718718|9708426|FG001|Week 12 to End of Study|Withdrawal by Subject|0
6094800|NCT00718718|9708427|FG002|Week 12 to End of Study|Withdrawal by Subject|0
6094801|NCT00718718|9708428|FG003|Week 12 to End of Study|Withdrawal by Subject|0
6094802|NCT00718718|9708429|FG004|Week 12 to End of Study|Withdrawal by Subject|0
6094803|NCT00718718|9708430|FG005|Week 12 to End of Study|Withdrawal by Subject|2
6094804|NCT00718718|9708431|FG006|Week 12 to End of Study|Withdrawal by Subject|1
6094805|NCT00718718|9708432|FG007|Week 12 to End of Study|Withdrawal by Subject|0
6094806|NCT00718718|9708433|FG008|Week 12 to End of Study|Withdrawal by Subject|0
6094807|NCT00718718|9708434|FG009|Week 12 to End of Study|Withdrawal by Subject|0
6094808|NCT00718718|9708425|FG000|Week 12 to End of Study|Lost to Follow-up|0
6094809|NCT00718718|9708426|FG001|Week 12 to End of Study|Lost to Follow-up|0
6094810|NCT00718718|9708427|FG002|Week 12 to End of Study|Lost to Follow-up|0
6094811|NCT00718718|9708428|FG003|Week 12 to End of Study|Lost to Follow-up|0
6061610|NCT00491764|9662362|FG000|Overall Study|Administrative|1
6094812|NCT00718718|9708429|FG004|Week 12 to End of Study|Lost to Follow-up|0
6061611|NCT00491764|9662363|FG001|Overall Study|Administrative|0
6061612|NCT00491764|9662364|FG002|Overall Study|Administrative|2
6061613|NCT00491764|9662365|FG003|Overall Study|Administrative|1
6061614|NCT00491764|9662366|FG004|Overall Study|Administrative|0
6061615|NCT00491764|9662367|FG005|Overall Study|Administrative|0
6061616|NCT00491894|9662394|FG000|Overall Study|Adverse Event|14
6061617|NCT00491894|9662394|FG000|Overall Study|Withdrawal by Subject|5
6061618|NCT00491894|9662394|FG000|Overall Study|Death|3
6061619|NCT00491894|9662394|FG000|Overall Study|Lost to Follow-up|3
6061620|NCT00491894|9662394|FG000|Overall Study|Lack of Efficacy|2
6061621|NCT00491894|9662394|FG000|Overall Study|Other-Failed to meet any criteria|2
6061622|NCT00491894|9662394|FG000|Overall Study|Physician Decision|2
6061623|NCT00491894|9662394|FG000|Overall Study|Protocol Violation|2
6061624|NCT00491894|9662394|FG000|Overall Study|Other-Intake of prohibited medication|1
6061625|NCT00492024|9662400|FG000|Treatment|Adverse Event|3
6061626|NCT00492024|9662401|FG001|Treatment|Adverse Event|1
6061627|NCT00492024|9662400|FG000|Treatment|Lack of Efficacy|21
6061628|NCT00492024|9662401|FG001|Treatment|Lack of Efficacy|20
6061629|NCT00492024|9662400|FG000|Treatment|Lost to Follow-up|3
6061630|NCT00492024|9662401|FG001|Treatment|Lost to Follow-up|1
6061631|NCT00492024|9662400|FG000|Treatment|Withdrawal by Subject|2
6061632|NCT00492024|9662401|FG001|Treatment|Withdrawal by Subject|0
6061633|NCT00492024|9662400|FG000|Follow up|Lack of Efficacy|0
6061634|NCT00492024|9662401|FG001|Follow up|Lack of Efficacy|1
6061635|NCT00492024|9662400|FG000|Follow up|Lost to Follow-up|1
6061636|NCT00492024|9662401|FG001|Follow up|Lost to Follow-up|1
6061637|NCT00492063|9662411|FG000|Overall Study|Death|0
6061638|NCT00492063|9662412|FG001|Overall Study|Death|0
6061639|NCT00492063|9662413|FG002|Overall Study|Death|1
6061640|NCT00492063|9662414|FG003|Overall Study|Death|2
6061641|NCT00492063|9662411|FG000|Overall Study|Withdrawal by Subject|4
6061642|NCT00492063|9662412|FG001|Overall Study|Withdrawal by Subject|3
6094813|NCT00718718|9708430|FG005|Week 12 to End of Study|Lost to Follow-up|0
6094814|NCT00718718|9708431|FG006|Week 12 to End of Study|Lost to Follow-up|0
6094815|NCT00718718|9708432|FG007|Week 12 to End of Study|Lost to Follow-up|0
6094816|NCT00718718|9708433|FG008|Week 12 to End of Study|Lost to Follow-up|1
6094817|NCT00718718|9708434|FG009|Week 12 to End of Study|Lost to Follow-up|0
6094818|NCT00718718|9708425|FG000|Week 12 to End of Study|Other|0
6094819|NCT00718718|9708426|FG001|Week 12 to End of Study|Other|1
6094820|NCT00718718|9708427|FG002|Week 12 to End of Study|Other|0
6094821|NCT00718718|9708428|FG003|Week 12 to End of Study|Other|1
6094822|NCT00718718|9708429|FG004|Week 12 to End of Study|Other|0
6094823|NCT00718718|9708430|FG005|Week 12 to End of Study|Other|0
6094824|NCT00718718|9708431|FG006|Week 12 to End of Study|Other|1
6094825|NCT00718718|9708432|FG007|Week 12 to End of Study|Other|0
6094826|NCT00718718|9708433|FG008|Week 12 to End of Study|Other|0
6094827|NCT00718718|9708434|FG009|Week 12 to End of Study|Other|0
6094828|NCT00718770|9708460|FG000|Overall Study|Adverse Event|1
6094829|NCT00718770|9708460|FG000|Overall Study|Lack of Efficacy|1
6094830|NCT00718770|9708460|FG000|Overall Study|Lack of Efficacy|1
6094831|NCT00718770|9708460|FG000|Overall Study|Adverse Event|1
6094832|NCT00718770|9708460|FG000|Overall Study|Lack of Efficacy|1
6094833|NCT00718770|9708460|FG000|Overall Study|Adverse Event|1
6094834|NCT00718770|9708460|FG000|Overall Study|Lack of Efficacy|1
6094835|NCT00718770|9708460|FG000|Overall Study|Adverse Event|1
6094836|NCT00718809|9708466|FG000|Overall Study|Disease progression|9
6094837|NCT00718809|9708467|FG001|Overall Study|Disease progression|7
6094838|NCT00718809|9708466|FG000|Overall Study|Adverse Event|1
6094839|NCT00718809|9708467|FG001|Overall Study|Adverse Event|1
6094840|NCT00718809|9708466|FG000|Overall Study|Withdrawal by Subject|0
6094841|NCT00718809|9708467|FG001|Overall Study|Withdrawal by Subject|1
6094842|NCT00718809|9708466|FG000|Overall Study|Lost to Follow-up|1
6094843|NCT00718809|9708467|FG001|Overall Study|Lost to Follow-up|0
6094844|NCT00718809|9708466|FG000|Overall Study|Noncompliance|1
6094845|NCT00718809|9708467|FG001|Overall Study|Noncompliance|0
6094846|NCT00718861|9708475|FG000|Overall Study|Withdrawal by Subject|15
6094847|NCT00718861|9708476|FG001|Overall Study|Withdrawal by Subject|10
6094848|NCT00718861|9708475|FG000|Overall Study|Adverse Event|2
6094849|NCT00718861|9708476|FG001|Overall Study|Adverse Event|1
6094850|NCT00718861|9708475|FG000|Overall Study|Lost to Follow-up|2
6094851|NCT00718861|9708476|FG001|Overall Study|Lost to Follow-up|1
6094852|NCT00718861|9708475|FG000|Overall Study|Administrative Problems|1
6094853|NCT00718861|9708476|FG001|Overall Study|Administrative Problems|1
6094854|NCT00718861|9708475|FG000|Overall Study|Death|1
6094855|NCT00718861|9708476|FG001|Overall Study|Death|5
6094856|NCT00718887|9708484|FG000|Overall Study|Withdrawal by Subject|3
6094857|NCT00718887|9708485|FG001|Overall Study|Withdrawal by Subject|2
6094858|NCT00718887|9708484|FG000|Overall Study|Not identified|2
6094859|NCT00718887|9708485|FG001|Overall Study|Not identified|7
6094860|NCT00719043|9708504|FG000|Overall Study|Adverse Event|5
6094861|NCT00719043|9708505|FG001|Overall Study|Adverse Event|1
6094862|NCT00719043|9708506|FG002|Overall Study|Adverse Event|2
6061643|NCT00492063|9662413|FG002|Overall Study|Withdrawal by Subject|5
6094863|NCT00719043|9708507|FG003|Overall Study|Adverse Event|2
6094864|NCT00719043|9708508|FG004|Overall Study|Adverse Event|1
6094865|NCT00719043|9708509|FG005|Overall Study|Adverse Event|4
6061644|NCT00492063|9662414|FG003|Overall Study|Withdrawal by Subject|4
6061645|NCT00492063|9662411|FG000|Overall Study|Lost to Follow-up|6
6061646|NCT00492063|9662412|FG001|Overall Study|Lost to Follow-up|11
6061647|NCT00492063|9662413|FG002|Overall Study|Lost to Follow-up|5
6061648|NCT00492063|9662414|FG003|Overall Study|Lost to Follow-up|3
6061649|NCT00492063|9662411|FG000|Overall Study|Protocol Violation|0
6061650|NCT00492063|9662412|FG001|Overall Study|Protocol Violation|0
6061651|NCT00492063|9662413|FG002|Overall Study|Protocol Violation|0
6061652|NCT00492063|9662414|FG003|Overall Study|Protocol Violation|1
6061653|NCT00492115|9662435|FG000|Overall Study|Withdrawal by Subject|3
6061654|NCT00492115|9662436|FG001|Overall Study|Withdrawal by Subject|4
6094866|NCT00719043|9708510|FG006|Overall Study|Adverse Event|4
6094867|NCT00719043|9708504|FG000|Overall Study|Lost to Follow-up|14
6094868|NCT00719043|9708505|FG001|Overall Study|Lost to Follow-up|10
6094869|NCT00719043|9708506|FG002|Overall Study|Lost to Follow-up|8
6094870|NCT00719043|9708507|FG003|Overall Study|Lost to Follow-up|9
6094871|NCT00719043|9708508|FG004|Overall Study|Lost to Follow-up|10
6094872|NCT00719043|9708509|FG005|Overall Study|Lost to Follow-up|9
6094873|NCT00719043|9708510|FG006|Overall Study|Lost to Follow-up|9
6094874|NCT00719043|9708504|FG000|Overall Study|Protocol Violation|0
6094875|NCT00719043|9708505|FG001|Overall Study|Protocol Violation|0
6094876|NCT00719043|9708506|FG002|Overall Study|Protocol Violation|0
6094877|NCT00719043|9708507|FG003|Overall Study|Protocol Violation|0
6094878|NCT00719043|9708508|FG004|Overall Study|Protocol Violation|0
6094879|NCT00719043|9708509|FG005|Overall Study|Protocol Violation|1
6094880|NCT00719043|9708510|FG006|Overall Study|Protocol Violation|0
6094881|NCT00719043|9708504|FG000|Overall Study|Other|1
6094882|NCT00719043|9708505|FG001|Overall Study|Other|0
6094883|NCT00719043|9708506|FG002|Overall Study|Other|1
6094884|NCT00719043|9708507|FG003|Overall Study|Other|2
6094885|NCT00719043|9708508|FG004|Overall Study|Other|0
6094886|NCT00719043|9708509|FG005|Overall Study|Other|2
6094887|NCT00719043|9708510|FG006|Overall Study|Other|1
6094888|NCT00719043|9708504|FG000|Overall Study|Withdrawal by Subject|12
6094889|NCT00719043|9708505|FG001|Overall Study|Withdrawal by Subject|14
6094890|NCT00719043|9708506|FG002|Overall Study|Withdrawal by Subject|9
6094891|NCT00719043|9708507|FG003|Overall Study|Withdrawal by Subject|10
6094892|NCT00719043|9708508|FG004|Overall Study|Withdrawal by Subject|16
6094893|NCT00719043|9708509|FG005|Overall Study|Withdrawal by Subject|18
6094894|NCT00719043|9708510|FG006|Overall Study|Withdrawal by Subject|14
6094895|NCT00719212|9708560|FG000|Overall Study|Death|41
6094896|NCT00719212|9708560|FG000|Overall Study|Lost to Follow-up|2
6094897|NCT00719212|9708560|FG000|Overall Study|Withdrawal by Subject|1
6094898|NCT00719264|9708566|FG000|Overall Study|Adverse Event|41
6094899|NCT00719264|9708567|FG001|Overall Study|Adverse Event|49
6094900|NCT00719264|9708566|FG000|Overall Study|Death|13
6094901|NCT00719264|9708567|FG001|Overall Study|Death|10
6094902|NCT00719264|9708566|FG000|Overall Study|Administrative Problems|6
6094903|NCT00719264|9708567|FG001|Overall Study|Administrative Problems|4
6094904|NCT00719264|9708566|FG000|Overall Study|Lost to Follow-up|1
6094905|NCT00719264|9708567|FG001|Overall Study|Lost to Follow-up|1
6094906|NCT00719264|9708566|FG000|Overall Study|Withdrawal by Subject|12
6094907|NCT00719264|9708567|FG001|Overall Study|Withdrawal by Subject|7
6094908|NCT00719264|9708566|FG000|Overall Study|Protocol Deviation|1
6094909|NCT00719264|9708567|FG001|Overall Study|Protocol Deviation|3
6094910|NCT00719264|9708566|FG000|Overall Study|New Cancer Therapy|4
6094911|NCT00719264|9708567|FG001|Overall Study|New Cancer Therapy|2
6094912|NCT00719264|9708566|FG000|Overall Study|Disease Progression|104
6094913|NCT00719264|9708567|FG001|Overall Study|Disease Progression|107
6094914|NCT00719355|9708591|FG000|Overall Study|Death|0
6094915|NCT00719355|9708592|FG001|Overall Study|Death|1
6094916|NCT00719355|9708591|FG000|Overall Study|Medical|14
6094917|NCT00719355|9708592|FG001|Overall Study|Medical|5
6094918|NCT00719355|9708591|FG000|Overall Study|Compliance|4
6094919|NCT00719355|9708592|FG001|Overall Study|Compliance|6
6094920|NCT00719355|9708591|FG000|Overall Study|Moved|0
6094921|NCT00719355|9708592|FG001|Overall Study|Moved|1
6094922|NCT00719472|9708598|FG000|Enrolled in Study|Physician decision to withdraw patient|1
6094923|NCT00719472|9708598|FG000|Enrolled in Study|Subject decision to withdraw|8
6061655|NCT00492232|9662450|FG000|Placebo Run-in|Adverse Event|0
6061656|NCT00492232|9662451|FG001|Placebo Run-in|Adverse Event|2
6061657|NCT00492232|9662450|FG000|Placebo Run-in|Protocol Violation|0
6094924|NCT00719472|9708598|FG000|Enrolled in Study|Various Reasons|17
6094925|NCT00719472|9708598|FG000|Received Cycle 1 Treatment|Adverse Event|8
6094926|NCT00719472|9708598|FG000|Received Cycle 1 Treatment|Death|5
6094927|NCT00719472|9708598|FG000|Received Cycle 1 Treatment|Eligibility criteria for Cycle 2 not met|11
6094928|NCT00719472|9708598|FG000|Received Cycle 1 Treatment|Physician decision to withdraw patient|7
6094929|NCT00719472|9708598|FG000|Received Cycle 1 Treatment|Subject decision to withdraw|9
6094930|NCT00719472|9708598|FG000|Received Cycle 1 Treatment|Various Reasons|13
6061658|NCT00492232|9662451|FG001|Placebo Run-in|Protocol Violation|3
6094931|NCT00719472|9708598|FG000|Received Cycle 2 Treatment|Adverse Event|12
6094932|NCT00719472|9708598|FG000|Received Cycle 2 Treatment|Death|6
6094933|NCT00719472|9708598|FG000|Received Cycle 2 Treatment|Disease progression|3
6094934|NCT00719472|9708598|FG000|Received Cycle 2 Treatment|Lost to Follow-up|3
6094935|NCT00719472|9708598|FG000|Received Cycle 2 Treatment|Physician decision to withdraw patient|13
6094936|NCT00719472|9708598|FG000|Received Cycle 2 Treatment|Subject decision to withdraw|6
6061659|NCT00492232|9662450|FG000|Placebo Run-in|Lost to Follow-up|0
6061660|NCT00492232|9662451|FG001|Placebo Run-in|Lost to Follow-up|3
6061661|NCT00492232|9662450|FG000|Placebo Run-in|Withdrawal by Subject|0
6061662|NCT00492232|9662451|FG001|Placebo Run-in|Withdrawal by Subject|8
6061663|NCT00492232|9662450|FG000|Placebo Run-in|Pregnancy|0
6061664|NCT00492232|9662451|FG001|Placebo Run-in|Pregnancy|1
6061665|NCT00492232|9662450|FG000|Placebo Run-in|Entrance criteria not met|0
6061666|NCT00492232|9662451|FG001|Placebo Run-in|Entrance criteria not met|45
6061667|NCT00492232|9662450|FG000|Placebo Run-in|Other|0
6094937|NCT00719472|9708598|FG000|Received Cycle 2 Treatment|Various Reasons|25
6094938|NCT00719537|9708604|FG000|Overall Study|Withdrawal by Subject|1
6094939|NCT00719537|9708605|FG001|Overall Study|Withdrawal by Subject|0
6094940|NCT00719537|9708604|FG000|Overall Study|Lost to Follow-up|0
6094941|NCT00719537|9708605|FG001|Overall Study|Lost to Follow-up|1
6094942|NCT00719563|9708613|FG000|Overall Study|Adverse Event|16
6094943|NCT00719563|9708614|FG001|Overall Study|Adverse Event|13
6094944|NCT00719563|9708613|FG000|Overall Study|Medical condition changed|3
6094945|NCT00719563|9708614|FG001|Overall Study|Medical condition changed|5
6094946|NCT00719563|9708613|FG000|Overall Study|Lack of Efficacy|3
6094947|NCT00719563|9708614|FG001|Overall Study|Lack of Efficacy|7
6094948|NCT00719563|9708613|FG000|Overall Study|Personal reasons|6
6094949|NCT00719563|9708614|FG001|Overall Study|Personal reasons|7
6094950|NCT00719563|9708613|FG000|Overall Study|Unknown reasons|4
6094951|NCT00719563|9708614|FG001|Overall Study|Unknown reasons|6
6094952|NCT00719563|9708613|FG000|Overall Study|Noncompliant|1
6094953|NCT00719563|9708614|FG001|Overall Study|Noncompliant|1
6094954|NCT00719563|9708613|FG000|Overall Study|Lost to Follow-up|5
6094955|NCT00719563|9708614|FG001|Overall Study|Lost to Follow-up|3
6094956|NCT00719680|9708645|FG000|Overall Study|Adverse Event|1
6094957|NCT00719680|9708645|FG000|Overall Study|Lost to Follow-up|1
6094958|NCT00719680|9708645|FG000|Overall Study|Withdrawal by Subject|3
6094959|NCT00719706|9708651|FG000|Overall Study|Adverse Event|5
6094960|NCT00719706|9708652|FG001|Overall Study|Adverse Event|4
6094961|NCT00719706|9708651|FG000|Overall Study|Withdrawal by Subject|1
6094962|NCT00719706|9708652|FG001|Overall Study|Withdrawal by Subject|2
6094963|NCT00719706|9708651|FG000|Overall Study|Protocol Violation|3
6094964|NCT00719706|9708652|FG001|Overall Study|Protocol Violation|0
6094965|NCT00719732|9708658|FG000|Overall Study|Lost to Follow-up|20
6094966|NCT00719732|9708658|FG000|Overall Study|Unilateral (not bilateral) implantation|1
6061668|NCT00492232|9662451|FG001|Placebo Run-in|Other|6
6094967|NCT00719732|9708658|FG000|Overall Study|Illness not associated with device|1
6094968|NCT00719810|9708665|FG000|Overall Study|Adverse Event|0
6094969|NCT00719810|9708666|FG001|Overall Study|Adverse Event|2
6094970|NCT00719810|9708667|FG002|Overall Study|Adverse Event|3
6094971|NCT00719810|9708665|FG000|Overall Study|Lost to Follow-up|2
6094972|NCT00719810|9708666|FG001|Overall Study|Lost to Follow-up|0
6094973|NCT00719810|9708667|FG002|Overall Study|Lost to Follow-up|3
6094974|NCT00719810|9708665|FG000|Overall Study|Physician Decision|0
6094975|NCT00719810|9708666|FG001|Overall Study|Physician Decision|1
6094976|NCT00719810|9708667|FG002|Overall Study|Physician Decision|0
6094977|NCT00719810|9708665|FG000|Overall Study|Withdrawal by Subject|1
6094978|NCT00719810|9708666|FG001|Overall Study|Withdrawal by Subject|1
6094979|NCT00719810|9708667|FG002|Overall Study|Withdrawal by Subject|2
6094980|NCT00719849|9708677|FG000|Overall Study|Death|0
6094981|NCT00719849|9708678|FG001|Overall Study|Death|1
6094982|NCT00719862|9708686|FG000|Overall Study|Adverse Event|1
6094983|NCT00719862|9708687|FG001|Overall Study|Adverse Event|2
6094984|NCT00719862|9708686|FG000|Overall Study|Lack of Efficacy|3
6094985|NCT00719862|9708687|FG001|Overall Study|Lack of Efficacy|0
6094986|NCT00719862|9708686|FG000|Overall Study|Non-Compliance|1
6094987|NCT00719862|9708687|FG001|Overall Study|Non-Compliance|0
6094988|NCT00719862|9708686|FG000|Overall Study|Withdrawal by Subject|1
6094989|NCT00719862|9708687|FG001|Overall Study|Withdrawal by Subject|0
6094990|NCT00719862|9708686|FG000|Overall Study|Lost to Follow-up|0
6094991|NCT00719862|9708687|FG001|Overall Study|Lost to Follow-up|1
6094992|NCT00719862|9708686|FG000|Overall Study|Other|2
6094993|NCT00719862|9708687|FG001|Overall Study|Other|3
6094994|NCT00719901|9708693|FG000|Overall Study|Adverse Event|5
6094995|NCT00719901|9708693|FG000|Overall Study|Withdrawal by Subject|1
6094996|NCT00719901|9708693|FG000|Overall Study|Alternate Treatment|1
6094997|NCT00719901|9708693|FG000|Overall Study|Disease Progression|3
6094998|NCT00719901|9708693|FG000|Overall Study|Availability of Study Drug|1
6094999|NCT00719953|9708697|FG000|Overall Study|Adverse Event|4
6095000|NCT00720057|9708703|FG000|Overall Study|Lost to Follow-up|0
6095001|NCT00720057|9708704|FG001|Overall Study|Lost to Follow-up|2
6061669|NCT00492232|9662450|FG000|Placebo Run-in|Missing|0
6061670|NCT00492232|9662451|FG001|Placebo Run-in|Missing|2
6061671|NCT00492232|9662450|FG000|Double-Blind Treatment|Adverse Event|1
6061672|NCT00492232|9662451|FG001|Double-Blind Treatment|Adverse Event|2
6095002|NCT00720057|9708703|FG000|Overall Study|Protocol Violation|1
6095003|NCT00720057|9708704|FG001|Overall Study|Protocol Violation|0
6095004|NCT00720057|9708703|FG000|Overall Study|Withdrawal by Subject|0
6095005|NCT00720057|9708704|FG001|Overall Study|Withdrawal by Subject|1
6095006|NCT00720096|9708712|FG000|Overall Study|Withdrawal by Subject|0
6095007|NCT00720096|9708713|FG001|Overall Study|Withdrawal by Subject|2
6061673|NCT00492232|9662450|FG000|Double-Blind Treatment|Protocol Violation|3
6061674|NCT00492232|9662451|FG001|Double-Blind Treatment|Protocol Violation|7
6061675|NCT00492232|9662450|FG000|Double-Blind Treatment|Lost to Follow-up|2
6061676|NCT00492232|9662451|FG001|Double-Blind Treatment|Lost to Follow-up|3
6061677|NCT00492232|9662450|FG000|Double-Blind Treatment|Withdrawal by Subject|4
6061678|NCT00492232|9662451|FG001|Double-Blind Treatment|Withdrawal by Subject|8
6061679|NCT00492232|9662450|FG000|Double-Blind Treatment|Lack of Efficacy|1
6061680|NCT00492232|9662451|FG001|Double-Blind Treatment|Lack of Efficacy|0
6061681|NCT00492232|9662450|FG000|Double-Blind Treatment|Other|6
6061682|NCT00492232|9662451|FG001|Double-Blind Treatment|Other|5
6061683|NCT00492232|9662450|FG000|Double-Blind Treatment|Randomized not treated|1
6061684|NCT00492232|9662451|FG001|Double-Blind Treatment|Randomized not treated|0
6061685|NCT00492232|9662450|FG000|Open-Label Treatment|Withdrawal by Subject|1
6061686|NCT00492232|9662451|FG001|Open-Label Treatment|Withdrawal by Subject|0
6061687|NCT00492284|9662461|FG000|Overall Study|Adverse Event|0
6061688|NCT00492284|9662462|FG001|Overall Study|Adverse Event|1
6061689|NCT00492284|9662463|FG002|Overall Study|Adverse Event|1
6061690|NCT00492284|9662464|FG003|Overall Study|Adverse Event|2
6061691|NCT00492284|9662461|FG000|Overall Study|Lost to Follow-up|0
6061692|NCT00492284|9662462|FG001|Overall Study|Lost to Follow-up|0
6061693|NCT00492284|9662463|FG002|Overall Study|Lost to Follow-up|3
6061694|NCT00492284|9662464|FG003|Overall Study|Lost to Follow-up|1
6061695|NCT00492284|9662461|FG000|Overall Study|Death|0
6061696|NCT00492284|9662462|FG001|Overall Study|Death|3
6061697|NCT00492284|9662463|FG002|Overall Study|Death|2
6061698|NCT00492284|9662464|FG003|Overall Study|Death|5
6061699|NCT00492284|9662461|FG000|Overall Study|Withdrawal by Subject|1
6061700|NCT00492284|9662462|FG001|Overall Study|Withdrawal by Subject|0
6061701|NCT00492284|9662463|FG002|Overall Study|Withdrawal by Subject|0
6061702|NCT00492284|9662464|FG003|Overall Study|Withdrawal by Subject|2
6061703|NCT00492297|9662474|FG000|Treatment|Death|2
6061704|NCT00492297|9662474|FG000|Treatment|Study terminated by sponsor|3
6061705|NCT00492297|9662474|FG000|Active Follow-up 30(+4) Days Duration|Death|17
6061706|NCT00492297|9662474|FG000|Active Follow-up 30(+4) Days Duration|Study terminated by sponsor|2
6061707|NCT00492297|9662474|FG000|Survival Only Follow-up|Death|46
6061708|NCT00492297|9662474|FG000|Survival Only Follow-up|Lack of Efficacy|1
6061709|NCT00492297|9662474|FG000|Survival Only Follow-up|Study terminated by sponsor|12
6061710|NCT00492531|9662495|FG000|Overall Study|Withdrawn(More than one reason selected)|22
6061711|NCT00492531|9662496|FG001|Overall Study|Withdrawn(More than one reason selected)|23
6061712|NCT00492557|9662508|FG000|Overall Study|Subject request|12
6061713|NCT00492557|9662509|FG001|Overall Study|Subject request|11
6061714|NCT00492557|9662508|FG000|Overall Study|Protocol Violation|7
6061715|NCT00492557|9662509|FG001|Overall Study|Protocol Violation|8
6061716|NCT00492557|9662508|FG000|Overall Study|Other|2
6061717|NCT00492557|9662509|FG001|Overall Study|Other|2
6095008|NCT00720109|9708719|FG000|Induction Period|Did not meet eligibility criteria|3
6095009|NCT00720109|9708720|FG001|Induction Period|Did not meet eligibility criteria|0
6095010|NCT00720109|9708721|FG002|Induction Period|Did not meet eligibility criteria|0
6095011|NCT00720109|9708719|FG000|Induction Period|Bone Marrow Transplant|2
6095012|NCT00720109|9708720|FG001|Induction Period|Bone Marrow Transplant|0
6095013|NCT00720109|9708721|FG002|Induction Period|Bone Marrow Transplant|0
6095014|NCT00720109|9708719|FG000|Induction Period|Physician Decision|1
6095015|NCT00720109|9708720|FG001|Induction Period|Physician Decision|0
6095016|NCT00720109|9708721|FG002|Induction Period|Physician Decision|0
6095017|NCT00720109|9708719|FG000|Risk Stratification Period|Adverse Event|0
6095018|NCT00720109|9708720|FG001|Risk Stratification Period|Adverse Event|1
6095019|NCT00720109|9708721|FG002|Risk Stratification Period|Adverse Event|0
6095020|NCT00720109|9708719|FG000|Risk Stratification Period|Physician Decision|0
6095021|NCT00720109|9708720|FG001|Risk Stratification Period|Physician Decision|2
6095022|NCT00720109|9708721|FG002|Risk Stratification Period|Physician Decision|1
6095023|NCT00720109|9708719|FG000|Risk Stratification Period|Bone marrow transplant|0
6095024|NCT00720109|9708720|FG001|Risk Stratification Period|Bone marrow transplant|9
6095025|NCT00720109|9708721|FG002|Risk Stratification Period|Bone marrow transplant|7
6095026|NCT00720109|9708719|FG000|Risk Stratification Period|Disease progression or relapse|0
6095027|NCT00720109|9708720|FG001|Risk Stratification Period|Disease progression or relapse|2
6095028|NCT00720109|9708721|FG002|Risk Stratification Period|Disease progression or relapse|0
6095029|NCT00720109|9708719|FG000|Risk Stratification Period|Development of second malignant neoplasm|0
6095030|NCT00720109|9708720|FG001|Risk Stratification Period|Development of second malignant neoplasm|1
6095031|NCT00720109|9708721|FG002|Risk Stratification Period|Development of second malignant neoplasm|0
6095032|NCT00720122|9708730|FG000|Overall Study|Lost to Follow-up|1
6095033|NCT00720122|9708730|FG000|Overall Study|Physician Decision|1
6061718|NCT00492557|9662508|FG000|Overall Study|Death|1
6095034|NCT00720122|9708730|FG000|Overall Study|Withdrawal by Subject|7
6095035|NCT00720213|9708734|FG000|Screening Phase With Diagnostic PSG|Screen Failure|7
6061719|NCT00492557|9662509|FG001|Overall Study|Death|1
6061720|NCT00492557|9662508|FG000|Overall Study|Adverse Event|1
6061721|NCT00492557|9662509|FG001|Overall Study|Adverse Event|0
6061722|NCT00492557|9662508|FG000|Overall Study|Failed to return|1
6061723|NCT00492557|9662509|FG001|Overall Study|Failed to return|0
6061724|NCT00492557|9662508|FG000|Overall Study|Lost to Follow-up|0
6061725|NCT00492557|9662509|FG001|Overall Study|Lost to Follow-up|1
6061726|NCT00492648|9662537|FG000|Month 30 (109671 Study)|Protocol Violation|0
6061727|NCT00492648|9662538|FG001|Month 30 (109671 Study)|Protocol Violation|1
6061728|NCT00492726|9662546|FG000|Overall Study|Adverse Event|10
6061729|NCT00492726|9662547|FG001|Overall Study|Adverse Event|6
6061730|NCT00492726|9662546|FG000|Overall Study|Death|7
6061731|NCT00492726|9662547|FG001|Overall Study|Death|2
6061732|NCT00492726|9662546|FG000|Overall Study|Lack of Efficacy|0
6061733|NCT00492726|9662547|FG001|Overall Study|Lack of Efficacy|2
6061734|NCT00492726|9662546|FG000|Overall Study|Lost to Follow-up|27
6061735|NCT00492726|9662547|FG001|Overall Study|Lost to Follow-up|19
6061736|NCT00492726|9662546|FG000|Overall Study|Physician Decision|0
6061737|NCT00492726|9662547|FG001|Overall Study|Physician Decision|1
6061738|NCT00492726|9662546|FG000|Overall Study|Withdrawal by Subject|6
6061739|NCT00492726|9662547|FG001|Overall Study|Withdrawal by Subject|3
6061740|NCT00492726|9662546|FG000|Overall Study|Non compliant with study medication|0
6061741|NCT00492726|9662547|FG001|Overall Study|Non compliant with study medication|3
6061742|NCT00492752|9662555|FG000|Double Blind Treatment|Death|13
6061743|NCT00492752|9662556|FG001|Double Blind Treatment|Death|0
6061744|NCT00492752|9662557|FG002|Double Blind Treatment|Death|2
6061745|NCT00492752|9662558|FG003|Double Blind Treatment|Death|0
6061746|NCT00492752|9662555|FG000|Double Blind Treatment|Adverse Event|1
6061747|NCT00492752|9662556|FG001|Double Blind Treatment|Adverse Event|0
6061748|NCT00492752|9662557|FG002|Double Blind Treatment|Adverse Event|0
6061749|NCT00492752|9662558|FG003|Double Blind Treatment|Adverse Event|0
6061750|NCT00492752|9662555|FG000|Double Blind Treatment|Protocol Violation|0
6061751|NCT00492752|9662556|FG001|Double Blind Treatment|Protocol Violation|0
6061752|NCT00492752|9662557|FG002|Double Blind Treatment|Protocol Violation|1
6061753|NCT00492752|9662558|FG003|Double Blind Treatment|Protocol Violation|0
6061754|NCT00492752|9662555|FG000|Follow-up and/or Open Label Sorafenib|Adverse Event|0
6061755|NCT00492752|9662556|FG001|Follow-up and/or Open Label Sorafenib|Adverse Event|2
6061756|NCT00492752|9662557|FG002|Follow-up and/or Open Label Sorafenib|Adverse Event|0
6061757|NCT00492752|9662558|FG003|Follow-up and/or Open Label Sorafenib|Adverse Event|2
6061758|NCT00492752|9662555|FG000|Follow-up and/or Open Label Sorafenib|Death|75
6061759|NCT00492752|9662556|FG001|Follow-up and/or Open Label Sorafenib|Death|5
6061760|NCT00492752|9662557|FG002|Follow-up and/or Open Label Sorafenib|Death|45
6061761|NCT00492752|9662558|FG003|Follow-up and/or Open Label Sorafenib|Death|1
6061762|NCT00492752|9662555|FG000|Follow-up and/or Open Label Sorafenib|Lost to Follow-up|8
6061763|NCT00492752|9662556|FG001|Follow-up and/or Open Label Sorafenib|Lost to Follow-up|1
6061764|NCT00492752|9662557|FG002|Follow-up and/or Open Label Sorafenib|Lost to Follow-up|2
6061765|NCT00492752|9662558|FG003|Follow-up and/or Open Label Sorafenib|Lost to Follow-up|0
6061766|NCT00492752|9662555|FG000|Follow-up and/or Open Label Sorafenib|Withdrawal by Subject|2
6061767|NCT00492752|9662556|FG001|Follow-up and/or Open Label Sorafenib|Withdrawal by Subject|1
6061768|NCT00492752|9662557|FG002|Follow-up and/or Open Label Sorafenib|Withdrawal by Subject|0
6061769|NCT00492752|9662558|FG003|Follow-up and/or Open Label Sorafenib|Withdrawal by Subject|0
6061770|NCT00492752|9662555|FG000|Follow-up and/or Open Label Sorafenib|Progression by clinical judgement|0
6061771|NCT00492752|9662556|FG001|Follow-up and/or Open Label Sorafenib|Progression by clinical judgement|1
6061772|NCT00492752|9662557|FG002|Follow-up and/or Open Label Sorafenib|Progression by clinical judgement|0
6095036|NCT00720213|9708735|FG001|Screening Phase With Diagnostic PSG|Screen Failure|0
6095037|NCT00720213|9708736|FG002|Screening Phase With Diagnostic PSG|Screen Failure|0
6095038|NCT00720226|9708746|FG000|Overall Study|Withdrawal by Subject|7
6095039|NCT00720226|9708747|FG001|Overall Study|Withdrawal by Subject|4
6095040|NCT00720278|9708756|FG000|Overall Study|Adverse Event|5
6095041|NCT00720278|9708757|FG001|Overall Study|Adverse Event|3
6095042|NCT00720278|9708758|FG002|Overall Study|Adverse Event|4
6095043|NCT00720278|9708756|FG000|Overall Study|Withdrawal by Subject|0
6095044|NCT00720278|9708757|FG001|Overall Study|Withdrawal by Subject|1
6095045|NCT00720278|9708758|FG002|Overall Study|Withdrawal by Subject|0
6095046|NCT00720278|9708756|FG000|Overall Study|Lost to Follow-up|0
6095047|NCT00720278|9708757|FG001|Overall Study|Lost to Follow-up|0
6095048|NCT00720278|9708758|FG002|Overall Study|Lost to Follow-up|1
6095049|NCT00720278|9708756|FG000|Overall Study|Non-compliance|1
6095050|NCT00720278|9708757|FG001|Overall Study|Non-compliance|0
6095051|NCT00720278|9708758|FG002|Overall Study|Non-compliance|0
6095052|NCT00720278|9708756|FG000|Overall Study|eligibility criteria violation|1
6095053|NCT00720278|9708757|FG001|Overall Study|eligibility criteria violation|0
6095054|NCT00720278|9708758|FG002|Overall Study|eligibility criteria violation|1
6095055|NCT00720356|9708779|FG000|Registration to Study|Determined to have methylated MGMT|67
6203045|NCT01510158|9863751|FG001|Overall Study|Withdrawal by Subject|13
6203046|NCT01510158|9863752|FG002|Overall Study|Withdrawal by Subject|10
6203047|NCT01510158|9863750|FG000|Overall Study|Death|1
6203048|NCT01510158|9863751|FG001|Overall Study|Death|0
6203049|NCT01510158|9863752|FG002|Overall Study|Death|0
6203050|NCT01510717|9863818|FG000|Overall Study|Adverse Event|1
6095056|NCT00720356|9708779|FG000|Reached 1st Response/2 Cycles|Progressive Disease|1
6095057|NCT00720356|9708779|FG000|Reached 1st Response/2 Cycles|Withdrawal by Subject|1
6095058|NCT00720356|9708779|FG000|Went on to be Treated Cycle 3|Adverse Event|1
6095059|NCT00720356|9708779|FG000|Went on to be Treated Cycle 3|Physician Decision|1
6061773|NCT00492752|9662558|FG003|Follow-up and/or Open Label Sorafenib|Progression by clinical judgement|2
6061774|NCT00492752|9662555|FG000|Follow-up and/or Open Label Sorafenib|Radiological and clinical progression|0
6061775|NCT00492752|9662556|FG001|Follow-up and/or Open Label Sorafenib|Radiological and clinical progression|0
6061776|NCT00492752|9662557|FG002|Follow-up and/or Open Label Sorafenib|Radiological and clinical progression|0
6061777|NCT00492752|9662558|FG003|Follow-up and/or Open Label Sorafenib|Radiological and clinical progression|1
6061778|NCT00492752|9662555|FG000|Follow-up and/or Open Label Sorafenib|Switch to commercial drug|0
6061779|NCT00492752|9662556|FG001|Follow-up and/or Open Label Sorafenib|Switch to commercial drug|6
6061780|NCT00492752|9662557|FG002|Follow-up and/or Open Label Sorafenib|Switch to commercial drug|0
6061781|NCT00492752|9662558|FG003|Follow-up and/or Open Label Sorafenib|Switch to commercial drug|0
6061782|NCT00492752|9662555|FG000|Follow-up and/or Open Label Sorafenib|Progression measurement proven|1
6061783|NCT00492752|9662556|FG001|Follow-up and/or Open Label Sorafenib|Progression measurement proven|0
6061784|NCT00492752|9662557|FG002|Follow-up and/or Open Label Sorafenib|Progression measurement proven|0
6095060|NCT00720356|9708779|FG000|Follow up Until Death|Withdrawal by Subject|1
6095061|NCT00720356|9708779|FG000|Follow up Until Death|Alive at last data collection|4
6095062|NCT00720382|9708796|FG000|Overall Study|Adverse Event|54
6095063|NCT00720382|9708797|FG001|Overall Study|Adverse Event|17
6095064|NCT00720382|9708796|FG000|Overall Study|Lack of Efficacy|18
6095065|NCT00720382|9708797|FG001|Overall Study|Lack of Efficacy|7
6095066|NCT00720382|9708796|FG000|Overall Study|Non-Compliance|15
6095067|NCT00720382|9708797|FG001|Overall Study|Non-Compliance|5
6095068|NCT00720382|9708796|FG000|Overall Study|Withdrawal by Subject|47
6095069|NCT00720382|9708797|FG001|Overall Study|Withdrawal by Subject|11
6095070|NCT00720382|9708796|FG000|Overall Study|Lost to Follow-up|28
6095071|NCT00720382|9708797|FG001|Overall Study|Lost to Follow-up|14
6095072|NCT00720382|9708796|FG000|Overall Study|administrative|14
6095073|NCT00720382|9708797|FG001|Overall Study|administrative|5
6095074|NCT00720434|9708807|FG000|Double-Blind Period (Week 1-4)|Withdrawal by Subject|0
6095075|NCT00720434|9708808|FG001|Double-Blind Period (Week 1-4)|Withdrawal by Subject|1
6095076|NCT00720434|9708809|FG002|Double-Blind Period (Week 1-4)|Withdrawal by Subject|0
6095077|NCT00720434|9708810|FG003|Double-Blind Period (Week 1-4)|Withdrawal by Subject|0
6095078|NCT00720434|9708807|FG000|Open-Label Period (Week 5-72)|Adverse Event|0
6095079|NCT00720434|9708808|FG001|Open-Label Period (Week 5-72)|Adverse Event|0
6095080|NCT00720434|9708809|FG002|Open-Label Period (Week 5-72)|Adverse Event|0
6095081|NCT00720434|9708810|FG003|Open-Label Period (Week 5-72)|Adverse Event|2
6095082|NCT00720434|9708807|FG000|Open-Label Period (Week 5-72)|Lost to Follow-up|1
6095083|NCT00720434|9708808|FG001|Open-Label Period (Week 5-72)|Lost to Follow-up|0
6095084|NCT00720434|9708809|FG002|Open-Label Period (Week 5-72)|Lost to Follow-up|0
6095085|NCT00720434|9708810|FG003|Open-Label Period (Week 5-72)|Lost to Follow-up|0
6095086|NCT00720434|9708807|FG000|Open-Label Period (Week 5-72)|Withdrawal by Subject|1
6095087|NCT00720434|9708808|FG001|Open-Label Period (Week 5-72)|Withdrawal by Subject|0
6095088|NCT00720434|9708809|FG002|Open-Label Period (Week 5-72)|Withdrawal by Subject|1
6095089|NCT00720434|9708810|FG003|Open-Label Period (Week 5-72)|Withdrawal by Subject|0
6095090|NCT00720434|9708807|FG000|Open-Label Period (Week 5-72)|Other|4
6095091|NCT00720434|9708808|FG001|Open-Label Period (Week 5-72)|Other|3
6095092|NCT00720434|9708809|FG002|Open-Label Period (Week 5-72)|Other|3
6095093|NCT00720434|9708810|FG003|Open-Label Period (Week 5-72)|Other|2
6095094|NCT00720499|9708830|FG000|Treatment Period 1 (4 Weeks)|Adverse Event|2
6095095|NCT00720499|9708831|FG001|Treatment Period 1 (4 Weeks)|Adverse Event|0
6095096|NCT00720499|9708830|FG000|Treatment Period 1 (4 Weeks)|Protocol Violation|1
6095097|NCT00720499|9708831|FG001|Treatment Period 1 (4 Weeks)|Protocol Violation|2
6095098|NCT00720499|9708830|FG000|Treatment Period 2 (4 Weeks)|Adverse Event|2
6095099|NCT00720499|9708831|FG001|Treatment Period 2 (4 Weeks)|Adverse Event|3
6095100|NCT00720759|9708848|FG000|Overall Study|Lost to Follow-up|0
6095101|NCT00720759|9708849|FG001|Overall Study|Lost to Follow-up|1
6095102|NCT00720759|9708850|FG002|Overall Study|Lost to Follow-up|1
6095103|NCT00720759|9708851|FG003|Overall Study|Lost to Follow-up|0
6095104|NCT00720798|9708861|FG000|Overall Study|Adverse Event|304
6095105|NCT00720798|9708861|FG000|Overall Study|Death|39
6095106|NCT00720798|9708861|FG000|Overall Study|Insufficient Therapeutic Response|129
6095107|NCT00720798|9708861|FG000|Overall Study|Protocol Violation|4
6095108|NCT00720798|9708861|FG000|Overall Study|Refused Treatment|151
6095109|NCT00720798|9708861|FG000|Overall Study|Failure to Return|46
6095110|NCT00720798|9708861|FG000|Overall Study|Reason not Specified|83
6095111|NCT00720876|9708865|FG000|Overall Study|found to be ineligible after starting tx|2
6095112|NCT00720941|9708871|FG000|Overall Study|Death|334
6095113|NCT00720941|9708872|FG001|Overall Study|Death|335
6095114|NCT00720941|9708871|FG000|Overall Study|Protocol Violation|0
6095115|NCT00720941|9708872|FG001|Overall Study|Protocol Violation|2
6095116|NCT00720941|9708871|FG000|Overall Study|Lost to Follow-up|17
6095117|NCT00720941|9708872|FG001|Overall Study|Lost to Follow-up|15
6095118|NCT00720941|9708871|FG000|Overall Study|Physician Decision|1
6095119|NCT00720941|9708872|FG001|Overall Study|Physician Decision|5
6095120|NCT00720941|9708871|FG000|Overall Study|Withdrawal by Subject|27
6095121|NCT00720941|9708872|FG001|Overall Study|Withdrawal by Subject|35
6095122|NCT00720941|9708871|FG000|Overall Study|Ongoing|34
6095123|NCT00720941|9708872|FG001|Overall Study|Ongoing|23
6095124|NCT00721110|9708882|FG000|Overall Study|Ultram use|1
6061785|NCT00492752|9662558|FG003|Follow-up and/or Open Label Sorafenib|Progression measurement proven|0
6061786|NCT00492856|9662565|FG000|Induction|Adverse Event|2
6061787|NCT00492856|9662566|FG001|Induction|Adverse Event|0
6095125|NCT00721110|9708883|FG001|Overall Study|Ultram use|0
6095126|NCT00721110|9708884|FG002|Overall Study|Ultram use|0
6095127|NCT00721110|9708885|FG003|Overall Study|Ultram use|0
6095128|NCT00721110|9708882|FG000|Overall Study|vertical incision|0
6095129|NCT00721110|9708883|FG001|Overall Study|vertical incision|0
6095130|NCT00721110|9708884|FG002|Overall Study|vertical incision|1
6095131|NCT00721110|9708885|FG003|Overall Study|vertical incision|0
6095132|NCT00721123|9708895|FG000|Overall Study|Adverse Event|96
6095133|NCT00721123|9708895|FG000|Overall Study|Death|10
6095134|NCT00721123|9708895|FG000|Overall Study|Insufficient Therapeutic Response|21
6095135|NCT00721123|9708895|FG000|Overall Study|Protocol Violation|1
6095136|NCT00721123|9708895|FG000|Overall Study|Refused Treatment|41
6095137|NCT00721123|9708895|FG000|Overall Study|Failure to Return|9
6095138|NCT00721123|9708895|FG000|Overall Study|Withdrawal by Subject|5
6095139|NCT00721149|9708936|FG000|Overall Study|Physician Decision|1
6095140|NCT00721214|9708957|FG000|Overall Study|Chose another center for transplant|1
6095141|NCT00721214|9708957|FG000|Overall Study|Death|3
6203051|NCT01510717|9863819|FG001|Overall Study|Adverse Event|2
6203052|NCT01510717|9863818|FG000|Overall Study|Death|1
6203053|NCT01510717|9863819|FG001|Overall Study|Death|0
6203054|NCT01510717|9863818|FG000|Overall Study|Lost to Follow-up|0
6203055|NCT01510717|9863819|FG001|Overall Study|Lost to Follow-up|1
6203056|NCT01510717|9863818|FG000|Overall Study|Withdrawal by Subject|0
6203057|NCT01510717|9863819|FG001|Overall Study|Withdrawal by Subject|2
6203058|NCT01510769|9863829|FG000|Overall Study|Adverse Event|7
6203059|NCT01510769|9863830|FG001|Overall Study|Adverse Event|6
6203060|NCT01510769|9863831|FG002|Overall Study|Adverse Event|4
6203061|NCT01510769|9863829|FG000|Overall Study|Gout Flare|0
6203062|NCT01510769|9863830|FG001|Overall Study|Gout Flare|3
6203063|NCT01510769|9863831|FG002|Overall Study|Gout Flare|1
6203064|NCT01510769|9863829|FG000|Overall Study|Protocol Violation|11
6203065|NCT01510769|9863830|FG001|Overall Study|Protocol Violation|10
6203066|NCT01510769|9863831|FG002|Overall Study|Protocol Violation|9
6203067|NCT01510769|9863829|FG000|Overall Study|Lost to Follow-up|5
6203068|NCT01510769|9863830|FG001|Overall Study|Lost to Follow-up|1
6203069|NCT01510769|9863831|FG002|Overall Study|Lost to Follow-up|5
6203070|NCT01510769|9863829|FG000|Overall Study|Withdrawal by Subject|3
6203071|NCT01510769|9863830|FG001|Overall Study|Withdrawal by Subject|4
6203072|NCT01510769|9863831|FG002|Overall Study|Withdrawal by Subject|3
6203073|NCT01510769|9863829|FG000|Overall Study|Death|1
6203074|NCT01510769|9863830|FG001|Overall Study|Death|1
6203075|NCT01510769|9863831|FG002|Overall Study|Death|0
6203076|NCT01510912|9863846|FG000|Overall Study|Adverse Event|99
6203077|NCT01510912|9863846|FG000|Overall Study|Lack of Efficacy|12
6203078|NCT01510912|9863846|FG000|Overall Study|Non-compliance with trial drug|23
6203079|NCT01510912|9863846|FG000|Overall Study|Withdrawal by Subject|49
6203080|NCT01510912|9863846|FG000|Overall Study|Physician Decision|1
6203081|NCT01510912|9863846|FG000|Overall Study|Protocol Violation|27
6203082|NCT01510912|9863846|FG000|Overall Study|Lost to Follow-up|26
6061788|NCT00492856|9662567|FG002|Induction|Adverse Event|0
6061789|NCT00492856|9662568|FG003|Induction|Adverse Event|0
6061790|NCT00492856|9662565|FG000|Induction|Withdrawal by Subject|1
6061791|NCT00492856|9662566|FG001|Induction|Withdrawal by Subject|0
6061792|NCT00492856|9662567|FG002|Induction|Withdrawal by Subject|0
6061793|NCT00492856|9662568|FG003|Induction|Withdrawal by Subject|0
6061794|NCT00492856|9662565|FG000|Induction|Death|3
6061795|NCT00492856|9662566|FG001|Induction|Death|0
6061796|NCT00492856|9662567|FG002|Induction|Death|0
6061797|NCT00492856|9662568|FG003|Induction|Death|0
6203083|NCT01510912|9863846|FG000|Overall Study|Other, including joint replacement|5
6203084|NCT01511055|9863860|FG000|Overall Study|Withdrawal by Subject|6
6203085|NCT01511107|9863870|FG000|Overall Study|Ineligible|3
6203086|NCT01511107|9863871|FG001|Overall Study|Ineligible|2
6203087|NCT01511107|9863870|FG000|Overall Study|Lost to Follow-up|10
6203088|NCT01511107|9863871|FG001|Overall Study|Lost to Follow-up|19
6203089|NCT01511107|9863870|FG000|Overall Study|Withdrawal by Subject|9
6203090|NCT01511107|9863871|FG001|Overall Study|Withdrawal by Subject|20
6203091|NCT01511250|9863887|FG000|Overall Study|Withdrawal of Consent|1
6203092|NCT01511250|9863888|FG001|Overall Study|Withdrawal of Consent|0
6203093|NCT01511250|9863889|FG002|Overall Study|Withdrawal of Consent|0
6203094|NCT01511250|9863890|FG003|Overall Study|Withdrawal of Consent|0
6203095|NCT01511250|9863891|FG004|Overall Study|Withdrawal of Consent|0
6203096|NCT01511250|9863892|FG005|Overall Study|Withdrawal of Consent|0
6203097|NCT01511250|9863893|FG006|Overall Study|Withdrawal of Consent|0
6203098|NCT01511250|9863894|FG007|Overall Study|Withdrawal of Consent|1
6203099|NCT01511250|9863895|FG008|Overall Study|Withdrawal of Consent|1
6284356|NCT02326272|9996338|FG010|Maintenance Period (Week 16 to Week 48)|Pregnancy|0
6284357|NCT02326272|9996339|FG011|Maintenance Period (Week 16 to Week 48)|Pregnancy|0
6284358|NCT02326272|9996340|FG012|Maintenance Period (Week 16 to Week 48)|Pregnancy|0
6284359|NCT02326272|9996341|FG013|Maintenance Period (Week 16 to Week 48)|Pregnancy|0
6284360|NCT02326272|9996342|FG014|Maintenance Period (Week 16 to Week 48)|Pregnancy|0
6203100|NCT01511250|9863896|FG009|Overall Study|Withdrawal of Consent|0
6061798|NCT00492856|9662565|FG000|Consolidation|Adverse Event|6
6061799|NCT00492856|9662566|FG001|Consolidation|Adverse Event|0
6061800|NCT00492856|9662567|FG002|Consolidation|Adverse Event|0
6061801|NCT00492856|9662568|FG003|Consolidation|Adverse Event|0
6061802|NCT00492856|9662565|FG000|Consolidation|Not protocol specified|2
6061803|NCT00492856|9662566|FG001|Consolidation|Not protocol specified|0
6061804|NCT00492856|9662567|FG002|Consolidation|Not protocol specified|0
6061805|NCT00492856|9662568|FG003|Consolidation|Not protocol specified|0
6061806|NCT00492856|9662565|FG000|Consolidation|Lost to Follow-up|1
6061807|NCT00492856|9662566|FG001|Consolidation|Lost to Follow-up|0
6061808|NCT00492856|9662567|FG002|Consolidation|Lost to Follow-up|0
6061809|NCT00492856|9662568|FG003|Consolidation|Lost to Follow-up|0
6061810|NCT00492856|9662565|FG000|Post-consolidation|Adverse Event|0
6061811|NCT00492856|9662566|FG001|Post-consolidation|Adverse Event|4
6061812|NCT00492856|9662567|FG002|Post-consolidation|Adverse Event|0
6061813|NCT00492856|9662568|FG003|Post-consolidation|Adverse Event|1
6061814|NCT00492856|9662565|FG000|Post-consolidation|Withdrawal by Subject|0
6061815|NCT00492856|9662566|FG001|Post-consolidation|Withdrawal by Subject|4
6061816|NCT00492856|9662567|FG002|Post-consolidation|Withdrawal by Subject|0
6061817|NCT00492856|9662568|FG003|Post-consolidation|Withdrawal by Subject|0
6061818|NCT00492856|9662565|FG000|Post-consolidation|Death|0
6061819|NCT00492856|9662566|FG001|Post-consolidation|Death|1
6061820|NCT00492856|9662567|FG002|Post-consolidation|Death|0
6061821|NCT00492856|9662568|FG003|Post-consolidation|Death|0
6061822|NCT00492856|9662565|FG000|Post-consolidation|Not protocol specified|0
6061823|NCT00492856|9662566|FG001|Post-consolidation|Not protocol specified|1
6061824|NCT00492856|9662567|FG002|Post-consolidation|Not protocol specified|0
6061825|NCT00492856|9662568|FG003|Post-consolidation|Not protocol specified|0
6061826|NCT00492856|9662565|FG000|Post-consolidation|Lost to Follow-up|0
6061827|NCT00492856|9662566|FG001|Post-consolidation|Lost to Follow-up|2
6061828|NCT00492856|9662567|FG002|Post-consolidation|Lost to Follow-up|0
6061829|NCT00492856|9662568|FG003|Post-consolidation|Lost to Follow-up|0
6061830|NCT00492856|9662565|FG000|Post-consolidation|Observation Arm|0
6095142|NCT00721227|9708963|FG000|Overall Study|Lost to Follow-up|3
6095143|NCT00721227|9708964|FG001|Overall Study|Lost to Follow-up|0
6095144|NCT00721227|9708963|FG000|Overall Study|Noncompliance with scheduled visits.|1
6095145|NCT00721227|9708964|FG001|Overall Study|Noncompliance with scheduled visits.|0
6095146|NCT00721279|9708982|FG000|Overall Study|Lack of Efficacy|6
6095147|NCT00721279|9708983|FG001|Overall Study|Lack of Efficacy|3
6095148|NCT00721279|9708982|FG000|Overall Study|Tolerability insufficient|5
6095149|NCT00721279|9708983|FG001|Overall Study|Tolerability insufficient|2
6095150|NCT00721279|9708982|FG000|Overall Study|Withdrawal by Subject|13
6095151|NCT00721279|9708983|FG001|Overall Study|Withdrawal by Subject|3
6095152|NCT00721279|9708982|FG000|Overall Study|Other|12
6095153|NCT00721279|9708983|FG001|Overall Study|Other|16
6095154|NCT00721396|9709005|FG000|Overall Study|Adverse Event|4
6095155|NCT00721396|9709006|FG001|Overall Study|Adverse Event|7
6095156|NCT00721396|9709007|FG002|Overall Study|Adverse Event|2
6095157|NCT00721396|9709008|FG003|Overall Study|Adverse Event|0
6095158|NCT00721396|9709005|FG000|Overall Study|Withdrawal by Subject|12
6095159|NCT00721396|9709006|FG001|Overall Study|Withdrawal by Subject|15
6095160|NCT00721396|9709007|FG002|Overall Study|Withdrawal by Subject|3
6095161|NCT00721396|9709008|FG003|Overall Study|Withdrawal by Subject|7
6095162|NCT00721396|9709005|FG000|Overall Study|Lost to Follow-up|7
6095163|NCT00721396|9709006|FG001|Overall Study|Lost to Follow-up|9
6095164|NCT00721396|9709007|FG002|Overall Study|Lost to Follow-up|3
6095165|NCT00721396|9709008|FG003|Overall Study|Lost to Follow-up|3
6095166|NCT00721396|9709005|FG000|Overall Study|Protocol Violation|4
6095167|NCT00721396|9709006|FG001|Overall Study|Protocol Violation|3
6095168|NCT00721396|9709007|FG002|Overall Study|Protocol Violation|1
6095169|NCT00721396|9709008|FG003|Overall Study|Protocol Violation|0
6095170|NCT00721396|9709005|FG000|Overall Study|Inappropriate enrollment|0
6095171|NCT00721396|9709006|FG001|Overall Study|Inappropriate enrollment|2
6095172|NCT00721396|9709007|FG002|Overall Study|Inappropriate enrollment|0
6095173|NCT00721396|9709008|FG003|Overall Study|Inappropriate enrollment|0
6095174|NCT00721396|9709005|FG000|Overall Study|Administrative reason|3
6095175|NCT00721396|9709006|FG001|Overall Study|Administrative reason|0
6095176|NCT00721396|9709007|FG002|Overall Study|Administrative reason|1
6095177|NCT00721396|9709008|FG003|Overall Study|Administrative reason|0
6095178|NCT00721409|9709026|FG000|Overall Study|Global deterioration of health status|2
6095179|NCT00721409|9709027|FG001|Overall Study|Global deterioration of health status|6
6095180|NCT00721409|9709028|FG002|Overall Study|Global deterioration of health status|3
6061831|NCT00492856|9662566|FG001|Post-consolidation|Observation Arm|0
6061832|NCT00492856|9662567|FG002|Post-consolidation|Observation Arm|27
6061833|NCT00492856|9662568|FG003|Post-consolidation|Observation Arm|0
6061834|NCT00492921|9662580|FG000|Overall Study|Death|1
6061835|NCT00492921|9662581|FG001|Overall Study|Death|0
6061836|NCT00492921|9662582|FG002|Overall Study|Death|1
6061837|NCT00493012|9662601|FG000|Overall Study|Lost to Follow-up|18
6061838|NCT00493012|9662602|FG001|Overall Study|Lost to Follow-up|17
6061839|NCT00493038|9662610|FG000|Treatment|Adverse Event|8
6095181|NCT00721409|9709026|FG000|Overall Study|Death|0
6095182|NCT00721409|9709027|FG001|Overall Study|Death|1
6095183|NCT00721409|9709028|FG002|Overall Study|Death|0
6095184|NCT00721409|9709026|FG000|Overall Study|Randomized not Treated|0
6095185|NCT00721409|9709027|FG001|Overall Study|Randomized not Treated|1
6061840|NCT00493038|9662611|FG001|Treatment|Adverse Event|4
6061841|NCT00493038|9662610|FG000|Treatment|Lost to Follow-up|5
6061842|NCT00493038|9662611|FG001|Treatment|Lost to Follow-up|3
6061843|NCT00493038|9662610|FG000|Treatment|Withdrawal by Subject|11
6061844|NCT00493038|9662611|FG001|Treatment|Withdrawal by Subject|12
6061845|NCT00493038|9662610|FG000|Treatment|Other|0
6061846|NCT00493038|9662611|FG001|Treatment|Other|1
6061847|NCT00493038|9662610|FG000|Follow-up|Lost to Follow-up|1
6061848|NCT00493038|9662611|FG001|Follow-up|Lost to Follow-up|0
6061849|NCT00493220|9662631|FG000|Third Intervention|Withdrawal by Subject|1
6061850|NCT00493220|9662632|FG001|Third Intervention|Withdrawal by Subject|0
6061851|NCT00493220|9662633|FG002|Third Intervention|Withdrawal by Subject|0
6061852|NCT00493220|9662634|FG003|Third Intervention|Withdrawal by Subject|0
6061853|NCT00493220|9662635|FG004|Third Intervention|Withdrawal by Subject|0
6061854|NCT00493220|9662636|FG005|Third Intervention|Withdrawal by Subject|0
6061855|NCT00493246|9662654|FG000|Overall Study|Withdrawal by Subject|0
6061856|NCT00493246|9662655|FG001|Overall Study|Withdrawal by Subject|0
6061857|NCT00493246|9662656|FG002|Overall Study|Withdrawal by Subject|0
6061858|NCT00493246|9662657|FG003|Overall Study|Withdrawal by Subject|0
6061859|NCT00493246|9662658|FG004|Overall Study|Withdrawal by Subject|1
6061860|NCT00493246|9662659|FG005|Overall Study|Withdrawal by Subject|0
6061861|NCT00493246|9662660|FG006|Overall Study|Withdrawal by Subject|0
6061862|NCT00493246|9662661|FG007|Overall Study|Withdrawal by Subject|0
6061863|NCT00493246|9662654|FG000|Overall Study|No access to draw blood|0
6061864|NCT00493246|9662655|FG001|Overall Study|No access to draw blood|0
6061865|NCT00493246|9662656|FG002|Overall Study|No access to draw blood|0
6061866|NCT00493246|9662657|FG003|Overall Study|No access to draw blood|0
6061867|NCT00493246|9662658|FG004|Overall Study|No access to draw blood|0
6061868|NCT00493246|9662659|FG005|Overall Study|No access to draw blood|1
6061869|NCT00493246|9662660|FG006|Overall Study|No access to draw blood|0
6061870|NCT00493246|9662661|FG007|Overall Study|No access to draw blood|0
6061871|NCT00493246|9662654|FG000|Overall Study|Lost to Follow-up|0
6061872|NCT00493246|9662655|FG001|Overall Study|Lost to Follow-up|0
6061873|NCT00493246|9662656|FG002|Overall Study|Lost to Follow-up|0
6061874|NCT00493246|9662657|FG003|Overall Study|Lost to Follow-up|0
6061875|NCT00493246|9662658|FG004|Overall Study|Lost to Follow-up|0
6061876|NCT00493246|9662659|FG005|Overall Study|Lost to Follow-up|0
6061877|NCT00493246|9662660|FG006|Overall Study|Lost to Follow-up|1
6061878|NCT00493246|9662661|FG007|Overall Study|Lost to Follow-up|0
6061879|NCT00493285|9662685|FG000|Overall Study|Lost to Follow-up|0
6061880|NCT00493285|9662686|FG001|Overall Study|Lost to Follow-up|0
6061881|NCT00493285|9662687|FG002|Overall Study|Lost to Follow-up|0
6061882|NCT00493285|9662688|FG003|Overall Study|Lost to Follow-up|0
6061883|NCT00493285|9662689|FG004|Overall Study|Lost to Follow-up|1
6061884|NCT00493285|9662690|FG005|Overall Study|Lost to Follow-up|0
6061885|NCT00493311|9662706|FG000|Overall Study|Need for rescue medication|2
6061886|NCT00493311|9662707|FG001|Overall Study|Need for rescue medication|2
6061887|NCT00493454|9662713|FG000|Overall Study|Withdrawal by Subject|1
6061888|NCT00493467|9662717|FG000|Overall Study|Death|1
6061889|NCT00493636|9662723|FG000|Overall Study|Withdrawal by Subject|1
6061890|NCT00493636|9662724|FG001|Overall Study|Withdrawal by Subject|0
6061891|NCT00493636|9662723|FG000|Overall Study|Disease progression/recurrence/relapse|0
6061892|NCT00493636|9662724|FG001|Overall Study|Disease progression/recurrence/relapse|1
6061893|NCT00493636|9662723|FG000|Overall Study|Mis-randomization|1
6061894|NCT00493636|9662724|FG001|Overall Study|Mis-randomization|1
6061895|NCT00493649|9662730|FG000|Overall Study|Adverse Event|44
6061896|NCT00493649|9662730|FG000|Overall Study|Patient Request|21
6061897|NCT00493649|9662730|FG000|Overall Study|Investigator Request|2
6061898|NCT00493649|9662730|FG000|Overall Study|Disease Progression|1
6061899|NCT00493649|9662730|FG000|Overall Study|Lost to Follow-up|1
6061900|NCT00493649|9662730|FG000|Overall Study|Other|13
6061901|NCT00493779|9662737|FG000|Overall Study|Logistical issue at site|1
6061902|NCT00493974|9662751|FG000|Overall Study|Death|1
6061903|NCT00493974|9662752|FG001|Overall Study|Death|2
6061904|NCT00493974|9662751|FG000|Overall Study|Withdrawal by Subject|8
6061905|NCT00493974|9662752|FG001|Overall Study|Withdrawal by Subject|6
6061906|NCT00493974|9662751|FG000|Overall Study|Lost to Follow-up|4
6061907|NCT00493974|9662752|FG001|Overall Study|Lost to Follow-up|6
6061908|NCT00494013|9662760|FG000|Overall Study|Adverse Event|0
6061909|NCT00494013|9662761|FG001|Overall Study|Adverse Event|1
6061910|NCT00494013|9662760|FG000|Overall Study|Entry Criteria Not Met|1
6095186|NCT00721409|9709028|FG002|Overall Study|Randomized not Treated|4
6095187|NCT00721409|9709026|FG000|Overall Study|Reason not specified|1
6095188|NCT00721409|9709027|FG001|Overall Study|Reason not specified|0
6095189|NCT00721409|9709028|FG002|Overall Study|Reason not specified|2
6061911|NCT00494013|9662761|FG001|Overall Study|Entry Criteria Not Met|4
6061912|NCT00494013|9662760|FG000|Overall Study|Lost to Follow-up|5
6061913|NCT00494013|9662761|FG001|Overall Study|Lost to Follow-up|6
6061914|NCT00494013|9662760|FG000|Overall Study|Physician Decision|3
6061915|NCT00494013|9662761|FG001|Overall Study|Physician Decision|5
6061916|NCT00494013|9662760|FG000|Overall Study|Protocol Violation|8
6061917|NCT00494013|9662761|FG001|Overall Study|Protocol Violation|5
6061918|NCT00494013|9662760|FG000|Overall Study|Withdrawal by Subject|13
6061919|NCT00494013|9662761|FG001|Overall Study|Withdrawal by Subject|14
6061920|NCT00494013|9662760|FG000|Overall Study|Sponsor Decision|0
6061921|NCT00494013|9662761|FG001|Overall Study|Sponsor Decision|1
6061922|NCT00494026|9662767|FG000|Overall Study|Sponsor Decision|4
6061923|NCT00494091|9662773|FG000|Overall Study|Death|5
6061924|NCT00494091|9662774|FG001|Overall Study|Death|54
6061925|NCT00494091|9662773|FG000|Overall Study|Lost to Follow-up|0
6061926|NCT00494091|9662774|FG001|Overall Study|Lost to Follow-up|4
6061927|NCT00494091|9662773|FG000|Overall Study|Other|1
6061928|NCT00494091|9662774|FG001|Overall Study|Other|11
6061929|NCT00494091|9662773|FG000|Overall Study|Withdrawal by Subject|0
6061930|NCT00494091|9662774|FG001|Overall Study|Withdrawal by Subject|7
6061931|NCT00494221|9662801|FG000|Overall Study|Death|15
6061932|NCT00494221|9662802|FG001|Overall Study|Death|9
6061933|NCT00494221|9662803|FG002|Overall Study|Death|14
6061934|NCT00494221|9662801|FG000|Overall Study|Withdrawal by Subject|1
6061935|NCT00494221|9662802|FG001|Overall Study|Withdrawal by Subject|2
6061936|NCT00494221|9662803|FG002|Overall Study|Withdrawal by Subject|0
6061937|NCT00494299|9662813|FG000|Overall Study|Adverse Event|93
6061938|NCT00494299|9662814|FG001|Overall Study|Adverse Event|13
6061939|NCT00494299|9662813|FG000|Overall Study|Lost to Follow-up|1
6095190|NCT00721409|9709026|FG000|Overall Study|Adverse Event|0
6095191|NCT00721409|9709027|FG001|Overall Study|Adverse Event|13
6095192|NCT00721409|9709028|FG002|Overall Study|Adverse Event|2
6095193|NCT00721409|9709026|FG000|Overall Study|Lost to Follow-up|0
6095194|NCT00721409|9709027|FG001|Overall Study|Lost to Follow-up|0
6095195|NCT00721409|9709028|FG002|Overall Study|Lost to Follow-up|1
6095196|NCT00721409|9709026|FG000|Overall Study|Withdrawal by Subject|1
6095197|NCT00721409|9709027|FG001|Overall Study|Withdrawal by Subject|6
6095198|NCT00721409|9709028|FG002|Overall Study|Withdrawal by Subject|5
6095199|NCT00721409|9709026|FG000|Overall Study|Objective progression or relapse|8
6203101|NCT01511250|9863887|FG000|Overall Study|Sponsor/Investigator Decision|1
6203102|NCT01511250|9863888|FG001|Overall Study|Sponsor/Investigator Decision|0
6203103|NCT01511250|9863889|FG002|Overall Study|Sponsor/Investigator Decision|0
6203104|NCT01511250|9863890|FG003|Overall Study|Sponsor/Investigator Decision|0
6203105|NCT01511250|9863891|FG004|Overall Study|Sponsor/Investigator Decision|0
6203106|NCT01511250|9863892|FG005|Overall Study|Sponsor/Investigator Decision|0
6203107|NCT01511250|9863893|FG006|Overall Study|Sponsor/Investigator Decision|0
6203108|NCT01511250|9863894|FG007|Overall Study|Sponsor/Investigator Decision|0
6203109|NCT01511250|9863895|FG008|Overall Study|Sponsor/Investigator Decision|0
6203110|NCT01511250|9863896|FG009|Overall Study|Sponsor/Investigator Decision|0
6203111|NCT01511250|9863887|FG000|Overall Study|Lost to Follow-up|7
6203112|NCT01511250|9863888|FG001|Overall Study|Lost to Follow-up|3
6203113|NCT01511250|9863889|FG002|Overall Study|Lost to Follow-up|3
6203114|NCT01511250|9863890|FG003|Overall Study|Lost to Follow-up|3
6203115|NCT01511250|9863891|FG004|Overall Study|Lost to Follow-up|0
6203116|NCT01511250|9863892|FG005|Overall Study|Lost to Follow-up|0
6203117|NCT01511250|9863893|FG006|Overall Study|Lost to Follow-up|2
6203118|NCT01511250|9863894|FG007|Overall Study|Lost to Follow-up|3
6203119|NCT01511250|9863895|FG008|Overall Study|Lost to Follow-up|13
6203120|NCT01511250|9863896|FG009|Overall Study|Lost to Follow-up|5
6203121|NCT01511250|9863887|FG000|Overall Study|Protocol Violation|0
6203122|NCT01511250|9863888|FG001|Overall Study|Protocol Violation|2
6203123|NCT01511250|9863889|FG002|Overall Study|Protocol Violation|1
6203124|NCT01511250|9863890|FG003|Overall Study|Protocol Violation|0
6203125|NCT01511250|9863891|FG004|Overall Study|Protocol Violation|0
6203126|NCT01511250|9863892|FG005|Overall Study|Protocol Violation|0
6203127|NCT01511250|9863893|FG006|Overall Study|Protocol Violation|0
6203128|NCT01511250|9863894|FG007|Overall Study|Protocol Violation|0
6203129|NCT01511250|9863895|FG008|Overall Study|Protocol Violation|0
6203130|NCT01511250|9863896|FG009|Overall Study|Protocol Violation|0
6203131|NCT01511419|9863924|FG000|Dose 2|Physician Decision|1
6203132|NCT01511419|9863925|FG001|Dose 2|Physician Decision|0
6203133|NCT01511445|9863957|FG000|Overall Study|Lost to Follow-up|3
6203134|NCT01511445|9863958|FG001|Overall Study|Lost to Follow-up|1
6203135|NCT01511445|9863957|FG000|Overall Study|Protocol Violation|1
6203136|NCT01511445|9863958|FG001|Overall Study|Protocol Violation|3
6203137|NCT01511445|9863957|FG000|Overall Study|Protocol Violation|1
6203138|NCT01511445|9863958|FG001|Overall Study|Protocol Violation|0
6203139|NCT01511536|9863967|FG000|Phase 1|Other|0
6203140|NCT01511536|9863968|FG001|Phase 1|Other|1
6203141|NCT01511536|9863969|FG002|Phase 1|Other|0
6203142|NCT01511536|9863967|FG000|Phase 2|Other|0
6203143|NCT01511536|9863968|FG001|Phase 2|Other|0
6203144|NCT01511536|9863969|FG002|Phase 2|Other|9
6203145|NCT01511939|9864006|FG000|Overall Study|Withdrawal by Subject|2
6203146|NCT01511939|9864007|FG001|Overall Study|Withdrawal by Subject|1
6203147|NCT01511939|9864008|FG002|Overall Study|Withdrawal by Subject|0
6203148|NCT01512108|9864029|FG000|Overall Study|Adverse Event|9
6203149|NCT01512108|9864030|FG001|Overall Study|Adverse Event|4
6061940|NCT00494299|9662814|FG001|Overall Study|Lost to Follow-up|0
6203150|NCT01512108|9864029|FG000|Overall Study|Protocol Violation|1
6203151|NCT01512108|9864030|FG001|Overall Study|Protocol Violation|2
6203152|NCT01512108|9864029|FG000|Overall Study|Withdrawal Criteria|1
6203153|NCT01512108|9864030|FG001|Overall Study|Withdrawal Criteria|0
6203154|NCT01512108|9864029|FG000|Overall Study|Unclassified|11
6203155|NCT01512108|9864030|FG001|Overall Study|Unclassified|3
6203156|NCT01512160|9864040|FG000|Overall Study|Lost to Follow-up|1
6203157|NCT01512160|9864041|FG001|Overall Study|Lost to Follow-up|0
6061941|NCT00494299|9662813|FG000|Overall Study|Physician Decision|0
6061942|NCT00494299|9662814|FG001|Overall Study|Physician Decision|2
6061943|NCT00494299|9662813|FG000|Overall Study|Protocol Violation|1
6061944|NCT00494299|9662814|FG001|Overall Study|Protocol Violation|2
6061945|NCT00494299|9662813|FG000|Overall Study|Withdrawal by Subject|8
6061946|NCT00494299|9662814|FG001|Overall Study|Withdrawal by Subject|3
6061947|NCT00494299|9662813|FG000|Overall Study|Disease Progression, Recurrence/Relapse|109
6061948|NCT00494299|9662814|FG001|Overall Study|Disease Progression, Recurrence/Relapse|185
6061949|NCT00494299|9662813|FG000|Overall Study|Participant Did Not Take Study Drug|0
6061950|NCT00494299|9662814|FG001|Overall Study|Participant Did Not Take Study Drug|2
6061951|NCT00494299|9662813|FG000|Overall Study|Site Closed by Sponsor|6
6061952|NCT00494299|9662814|FG001|Overall Study|Site Closed by Sponsor|0
6061953|NCT00494299|9662813|FG000|Overall Study|Protocol Driven Decision Point|11
6061954|NCT00494299|9662814|FG001|Overall Study|Protocol Driven Decision Point|22
6061955|NCT00494442|9662822|FG000|Overall Study|Death|1
6061956|NCT00494442|9662823|FG001|Overall Study|Death|1
6061957|NCT00494442|9662822|FG000|Overall Study|Lack of Efficacy|16
6095200|NCT00721409|9709027|FG001|Overall Study|Objective progression or relapse|55
6095201|NCT00721409|9709028|FG002|Overall Study|Objective progression or relapse|62
6095202|NCT00721578|9709075|FG000|Overall Study|Death|1
6095203|NCT00721578|9709076|FG001|Overall Study|Death|1
6095204|NCT00721578|9709075|FG000|Overall Study|Withdrawal by Subject|1
6095205|NCT00721578|9709076|FG001|Overall Study|Withdrawal by Subject|1
6095206|NCT00721630|9709087|FG000|Overall Study|Participant found to be ineligible|1
6095207|NCT00721734|9709096|FG000|Overall Study|Progressive Disease|3
6095208|NCT00721734|9709097|FG001|Overall Study|Progressive Disease|10
6095209|NCT00721734|9709098|FG002|Overall Study|Progressive Disease|4
6095210|NCT00721734|9709099|FG003|Overall Study|Progressive Disease|5
6095211|NCT00721734|9709100|FG004|Overall Study|Progressive Disease|2
6095212|NCT00721734|9709096|FG000|Overall Study|Adverse Event|3
6095213|NCT00721734|9709097|FG001|Overall Study|Adverse Event|1
6095214|NCT00721734|9709098|FG002|Overall Study|Adverse Event|4
6095215|NCT00721734|9709099|FG003|Overall Study|Adverse Event|0
6095216|NCT00721734|9709100|FG004|Overall Study|Adverse Event|3
6095217|NCT00721734|9709096|FG000|Overall Study|Withdrawal by Subject|2
6095218|NCT00721734|9709097|FG001|Overall Study|Withdrawal by Subject|1
6095219|NCT00721734|9709098|FG002|Overall Study|Withdrawal by Subject|0
6095220|NCT00721734|9709099|FG003|Overall Study|Withdrawal by Subject|0
6095221|NCT00721734|9709100|FG004|Overall Study|Withdrawal by Subject|1
6095222|NCT00721734|9709096|FG000|Overall Study|Other|0
6095223|NCT00721734|9709097|FG001|Overall Study|Other|0
6095224|NCT00721734|9709098|FG002|Overall Study|Other|0
6095225|NCT00721734|9709099|FG003|Overall Study|Other|1
6095226|NCT00721734|9709100|FG004|Overall Study|Other|0
6095227|NCT00721799|9709112|FG000|Overall Study|Withdrawal by Subject|7
6095228|NCT00721799|9709112|FG000|Overall Study|withdraw by subject after scan 1|1
6095229|NCT00721955|9709119|FG000|Overall Study|Adverse Event|0
6095230|NCT00721955|9709120|FG001|Overall Study|Adverse Event|0
6095231|NCT00721955|9709121|FG002|Overall Study|Adverse Event|2
6095232|NCT00721968|9709131|FG000|Overall Study|Lost to Follow-up|2
6095233|NCT00721968|9709132|FG001|Overall Study|Lost to Follow-up|0
6095234|NCT00722137|9709182|FG000|Overall Study|Overt Disease Progression|5
6095235|NCT00722137|9709183|FG001|Overall Study|Overt Disease Progression|4
6095236|NCT00722137|9709182|FG000|Overall Study|Adverse Event|17
6095237|NCT00722137|9709183|FG001|Overall Study|Adverse Event|21
6095238|NCT00722137|9709182|FG000|Overall Study|Death|12
6095239|NCT00722137|9709183|FG001|Overall Study|Death|7
6095240|NCT00722137|9709182|FG000|Overall Study|Withdrawal by Subject|6
6095241|NCT00722137|9709183|FG001|Overall Study|Withdrawal by Subject|9
6095242|NCT00722137|9709182|FG000|Overall Study|Other Reason Unknown|3
6095243|NCT00722137|9709183|FG001|Overall Study|Other Reason Unknown|4
6284361|NCT02326272|9996328|FG000|Maintenance Period (Week 16 to Week 48)|Non-compliance|0
6284362|NCT02326272|9996329|FG001|Maintenance Period (Week 16 to Week 48)|Non-compliance|0
6284363|NCT02326272|9996330|FG002|Maintenance Period (Week 16 to Week 48)|Non-compliance|0
6284364|NCT02326272|9996331|FG003|Maintenance Period (Week 16 to Week 48)|Non-compliance|0
6284365|NCT02326272|9996332|FG004|Maintenance Period (Week 16 to Week 48)|Non-compliance|0
6284366|NCT02326272|9996333|FG005|Maintenance Period (Week 16 to Week 48)|Non-compliance|0
6284367|NCT02326272|9996334|FG006|Maintenance Period (Week 16 to Week 48)|Non-compliance|0
6284368|NCT02326272|9996335|FG007|Maintenance Period (Week 16 to Week 48)|Non-compliance|0
6284369|NCT02326272|9996336|FG008|Maintenance Period (Week 16 to Week 48)|Non-compliance|1
6284370|NCT02326272|9996337|FG009|Maintenance Period (Week 16 to Week 48)|Non-compliance|0
6284371|NCT02326272|9996338|FG010|Maintenance Period (Week 16 to Week 48)|Non-compliance|0
6284372|NCT02326272|9996339|FG011|Maintenance Period (Week 16 to Week 48)|Non-compliance|0
6095244|NCT00722137|9709182|FG000|Overall Study|Randomized But Not Treated|2
6095245|NCT00722137|9709183|FG001|Overall Study|Randomized But Not Treated|3
6095246|NCT00722371|9709196|FG000|Overall Study|Adverse Event|6
6095247|NCT00722371|9709197|FG001|Overall Study|Adverse Event|13
6061958|NCT00494442|9662823|FG001|Overall Study|Lack of Efficacy|10
6061959|NCT00494442|9662822|FG000|Overall Study|Adverse Event|0
6095248|NCT00722371|9709198|FG002|Overall Study|Adverse Event|9
6095249|NCT00722371|9709199|FG003|Overall Study|Adverse Event|10
6095250|NCT00722371|9709200|FG004|Overall Study|Adverse Event|6
6061960|NCT00494442|9662823|FG001|Overall Study|Adverse Event|2
6061961|NCT00494442|9662822|FG000|Overall Study|Physician Decision|0
6095251|NCT00722371|9709201|FG005|Overall Study|Adverse Event|8
6095252|NCT00722371|9709202|FG006|Overall Study|Adverse Event|4
6095253|NCT00722371|9709196|FG000|Overall Study|Contraindication|0
6095254|NCT00722371|9709197|FG001|Overall Study|Contraindication|0
6095255|NCT00722371|9709198|FG002|Overall Study|Contraindication|1
6095256|NCT00722371|9709199|FG003|Overall Study|Contraindication|0
6095257|NCT00722371|9709200|FG004|Overall Study|Contraindication|0
6095258|NCT00722371|9709201|FG005|Overall Study|Contraindication|0
6095259|NCT00722371|9709202|FG006|Overall Study|Contraindication|0
6061962|NCT00494442|9662823|FG001|Overall Study|Physician Decision|1
6061963|NCT00494442|9662822|FG000|Overall Study|Non-compliance|0
6061964|NCT00494442|9662823|FG001|Overall Study|Non-compliance|1
6061965|NCT00494442|9662822|FG000|Overall Study|Intercurrent illness|0
6061966|NCT00494442|9662823|FG001|Overall Study|Intercurrent illness|1
6061967|NCT00494481|9662831|FG000|Overall Study|Condition under investigation worsened|11
6061968|NCT00494481|9662832|FG001|Overall Study|Condition under investigation worsened|13
6061969|NCT00494481|9662831|FG000|Overall Study|Adverse Event|15
6061970|NCT00494481|9662832|FG001|Overall Study|Adverse Event|11
6061971|NCT00494481|9662831|FG000|Overall Study|Other|1
6061972|NCT00494481|9662832|FG001|Overall Study|Other|0
6061973|NCT00494481|9662831|FG000|Overall Study|Never received IP|2
6061974|NCT00494481|9662832|FG001|Overall Study|Never received IP|0
6061975|NCT00494507|9662851|FG000|Double-Blind Phase|Adverse Event|2
6061976|NCT00494507|9662852|FG001|Double-Blind Phase|Adverse Event|0
6061977|NCT00494507|9662853|FG002|Double-Blind Phase|Adverse Event|1
6061978|NCT00494507|9662854|FG003|Double-Blind Phase|Adverse Event|0
6061979|NCT00494507|9662851|FG000|Double-Blind Phase|Withdrawal by Subject|1
6061980|NCT00494507|9662852|FG001|Double-Blind Phase|Withdrawal by Subject|0
6061981|NCT00494507|9662853|FG002|Double-Blind Phase|Withdrawal by Subject|0
6061982|NCT00494507|9662854|FG003|Double-Blind Phase|Withdrawal by Subject|0
6061983|NCT00494507|9662851|FG000|Double-Blind Phase|Subject Non-compliance|0
6061984|NCT00494507|9662852|FG001|Double-Blind Phase|Subject Non-compliance|0
6095260|NCT00722371|9709196|FG000|Overall Study|Creatinine / Creatinine clearance|2
6095261|NCT00722371|9709197|FG001|Overall Study|Creatinine / Creatinine clearance|1
6095262|NCT00722371|9709198|FG002|Overall Study|Creatinine / Creatinine clearance|2
6095263|NCT00722371|9709199|FG003|Overall Study|Creatinine / Creatinine clearance|3
6095264|NCT00722371|9709200|FG004|Overall Study|Creatinine / Creatinine clearance|2
6095265|NCT00722371|9709201|FG005|Overall Study|Creatinine / Creatinine clearance|1
6095266|NCT00722371|9709202|FG006|Overall Study|Creatinine / Creatinine clearance|1
6095267|NCT00722371|9709196|FG000|Overall Study|Excluded medication|0
6095268|NCT00722371|9709197|FG001|Overall Study|Excluded medication|1
6095269|NCT00722371|9709198|FG002|Overall Study|Excluded medication|1
6095270|NCT00722371|9709199|FG003|Overall Study|Excluded medication|0
6095271|NCT00722371|9709200|FG004|Overall Study|Excluded medication|0
6095272|NCT00722371|9709201|FG005|Overall Study|Excluded medication|0
6095273|NCT00722371|9709202|FG006|Overall Study|Excluded medication|1
6095274|NCT00722371|9709196|FG000|Overall Study|Hyperglycemia|2
6095275|NCT00722371|9709197|FG001|Overall Study|Hyperglycemia|6
6095276|NCT00722371|9709198|FG002|Overall Study|Hyperglycemia|4
6095277|NCT00722371|9709199|FG003|Overall Study|Hyperglycemia|2
6095278|NCT00722371|9709200|FG004|Overall Study|Hyperglycemia|5
6095279|NCT00722371|9709201|FG005|Overall Study|Hyperglycemia|1
6095280|NCT00722371|9709202|FG006|Overall Study|Hyperglycemia|1
6095281|NCT00722371|9709196|FG000|Overall Study|Hypoglycemia|1
6095282|NCT00722371|9709197|FG001|Overall Study|Hypoglycemia|0
6095283|NCT00722371|9709198|FG002|Overall Study|Hypoglycemia|0
6095284|NCT00722371|9709199|FG003|Overall Study|Hypoglycemia|0
6095285|NCT00722371|9709200|FG004|Overall Study|Hypoglycemia|0
6095286|NCT00722371|9709201|FG005|Overall Study|Hypoglycemia|0
6095287|NCT00722371|9709202|FG006|Overall Study|Hypoglycemia|0
6095288|NCT00722371|9709196|FG000|Overall Study|Lack of Efficacy|4
6095289|NCT00722371|9709197|FG001|Overall Study|Lack of Efficacy|6
6095290|NCT00722371|9709198|FG002|Overall Study|Lack of Efficacy|6
6095291|NCT00722371|9709199|FG003|Overall Study|Lack of Efficacy|6
6095292|NCT00722371|9709200|FG004|Overall Study|Lack of Efficacy|2
6095293|NCT00722371|9709201|FG005|Overall Study|Lack of Efficacy|3
6095294|NCT00722371|9709202|FG006|Overall Study|Lack of Efficacy|0
6095295|NCT00722371|9709196|FG000|Overall Study|Lost to Follow-up|11
5980421|NCT03003520|9569241|FG001|Induction|Adverse Event|0
5980422|NCT03003520|9569240|FG000|Induction|Death|1
5980423|NCT03003520|9569241|FG001|Induction|Death|0
5980424|NCT03003520|9569240|FG000|Induction|Palliative care|1
5980425|NCT03003520|9569241|FG001|Induction|Palliative care|0
5980426|NCT03003520|9569240|FG000|Induction|Physician Decision|2
5980427|NCT03003520|9569241|FG001|Induction|Physician Decision|0
5980428|NCT03003520|9569240|FG000|Induction|Withdrawal by Subject|3
5980429|NCT03003520|9569241|FG001|Induction|Withdrawal by Subject|0
5980430|NCT03003520|9569240|FG000|Induction|Progressive disease|1
5980431|NCT03003520|9569241|FG001|Induction|Progressive disease|0
5980432|NCT03003520|9569240|FG000|Consolidation|Ongoing|18
6095296|NCT00722371|9709197|FG001|Overall Study|Lost to Follow-up|14
6095297|NCT00722371|9709198|FG002|Overall Study|Lost to Follow-up|21
5980433|NCT03003520|9569241|FG001|Consolidation|Ongoing|0
5980434|NCT03003520|9569240|FG000|Consolidation|Adverse Event|2
6061985|NCT00494507|9662853|FG002|Double-Blind Phase|Subject Non-compliance|1
6061986|NCT00494507|9662854|FG003|Double-Blind Phase|Subject Non-compliance|0
6061987|NCT00494507|9662851|FG000|Double-Blind Phase|Negative DNA test|0
6061988|NCT00494507|9662852|FG001|Double-Blind Phase|Negative DNA test|0
6061989|NCT00494507|9662853|FG002|Double-Blind Phase|Negative DNA test|0
6061990|NCT00494507|9662854|FG003|Double-Blind Phase|Negative DNA test|1
6061991|NCT00494507|9662851|FG000|Open-Label Phase|Adverse Event|0
6061992|NCT00494507|9662852|FG001|Open-Label Phase|Adverse Event|1
6061993|NCT00494507|9662853|FG002|Open-Label Phase|Adverse Event|5
6061994|NCT00494507|9662854|FG003|Open-Label Phase|Adverse Event|3
6061995|NCT00494507|9662851|FG000|Open-Label Phase|Worsening Disease|0
6095298|NCT00722371|9709199|FG003|Overall Study|Lost to Follow-up|13
6095299|NCT00722371|9709200|FG004|Overall Study|Lost to Follow-up|8
6095300|NCT00722371|9709201|FG005|Overall Study|Lost to Follow-up|16
6095301|NCT00722371|9709202|FG006|Overall Study|Lost to Follow-up|13
6095302|NCT00722371|9709196|FG000|Overall Study|Physician Decision|5
6095303|NCT00722371|9709197|FG001|Overall Study|Physician Decision|2
6095304|NCT00722371|9709198|FG002|Overall Study|Physician Decision|2
6095305|NCT00722371|9709199|FG003|Overall Study|Physician Decision|5
6095306|NCT00722371|9709200|FG004|Overall Study|Physician Decision|2
6095307|NCT00722371|9709201|FG005|Overall Study|Physician Decision|3
6095308|NCT00722371|9709202|FG006|Overall Study|Physician Decision|4
6095309|NCT00722371|9709196|FG000|Overall Study|Pregnancy|1
6095310|NCT00722371|9709197|FG001|Overall Study|Pregnancy|1
6095311|NCT00722371|9709198|FG002|Overall Study|Pregnancy|0
6095312|NCT00722371|9709199|FG003|Overall Study|Pregnancy|0
6095313|NCT00722371|9709200|FG004|Overall Study|Pregnancy|0
6095314|NCT00722371|9709201|FG005|Overall Study|Pregnancy|1
6095315|NCT00722371|9709202|FG006|Overall Study|Pregnancy|0
6095316|NCT00722371|9709196|FG000|Overall Study|Protocol Violation|6
6095317|NCT00722371|9709197|FG001|Overall Study|Protocol Violation|1
6095318|NCT00722371|9709198|FG002|Overall Study|Protocol Violation|0
6095319|NCT00722371|9709199|FG003|Overall Study|Protocol Violation|1
6095320|NCT00722371|9709200|FG004|Overall Study|Protocol Violation|4
6095321|NCT00722371|9709201|FG005|Overall Study|Protocol Violation|2
6095322|NCT00722371|9709202|FG006|Overall Study|Protocol Violation|1
6095323|NCT00722371|9709196|FG000|Overall Study|Withdrawal by Subject|18
6095324|NCT00722371|9709197|FG001|Overall Study|Withdrawal by Subject|27
6095325|NCT00722371|9709198|FG002|Overall Study|Withdrawal by Subject|19
6095326|NCT00722371|9709199|FG003|Overall Study|Withdrawal by Subject|23
6095327|NCT00722371|9709200|FG004|Overall Study|Withdrawal by Subject|19
6095328|NCT00722371|9709201|FG005|Overall Study|Withdrawal by Subject|18
6095329|NCT00722371|9709202|FG006|Overall Study|Withdrawal by Subject|26
6095330|NCT00722423|9709220|FG000|Overall Study|Protocol Violation|0
6095331|NCT00722423|9709221|FG001|Overall Study|Protocol Violation|1
6095332|NCT00722761|9709270|FG000|Overall Study|Lost to Follow-up|1
6095333|NCT00722761|9709271|FG001|Overall Study|Lost to Follow-up|4
6095334|NCT00722761|9709270|FG000|Overall Study|Withdrawal by Subject|5
6095335|NCT00722761|9709271|FG001|Overall Study|Withdrawal by Subject|2
6095336|NCT00722800|9709279|FG000|Overall Study|Withdrawal by Subject|1
6095337|NCT00722800|9709280|FG001|Overall Study|Withdrawal by Subject|0
6095338|NCT00722800|9709279|FG000|Overall Study|Physician Decision|1
6095339|NCT00722800|9709280|FG001|Overall Study|Physician Decision|0
6095340|NCT00723008|9709292|FG000|Enrollment|Lost to Follow-up|1
6095341|NCT00723008|9709293|FG001|Enrollment|Lost to Follow-up|0
6095342|NCT00723008|9709292|FG000|4-Week Double Blinded|Lack of Efficacy|0
6095343|NCT00723008|9709293|FG001|4-Week Double Blinded|Lack of Efficacy|1
6095344|NCT00723008|9709292|FG000|4-Week Double Blinded|Withdrawal by Subject|1
6095345|NCT00723008|9709293|FG001|4-Week Double Blinded|Withdrawal by Subject|1
6095346|NCT00723008|9709292|FG000|4-Week Double Blinded|Lost to Follow-up|4
6095347|NCT00723008|9709293|FG001|4-Week Double Blinded|Lost to Follow-up|3
6203158|NCT01512160|9864042|FG002|Overall Study|Lost to Follow-up|0
6203159|NCT01512160|9864043|FG003|Overall Study|Lost to Follow-up|0
6203160|NCT01512160|9864040|FG000|Overall Study|Withdrawal by Subject|1
6203161|NCT01512160|9864041|FG001|Overall Study|Withdrawal by Subject|0
6203162|NCT01512160|9864042|FG002|Overall Study|Withdrawal by Subject|0
5980435|NCT03003520|9569241|FG001|Consolidation|Adverse Event|0
5980436|NCT03003520|9569240|FG000|Consolidation|Progressive disease|3
5980437|NCT03003520|9569241|FG001|Consolidation|Progressive disease|1
5980438|NCT03003520|9569240|FG000|Consolidation|Withdrawal by Subject|1
5980439|NCT03003520|9569241|FG001|Consolidation|Withdrawal by Subject|0
5980440|NCT03003520|9569240|FG000|Follow-up|Death|1
5980441|NCT03003520|9569241|FG001|Follow-up|Death|1
5980442|NCT03003520|9569240|FG000|Follow-up|Ongoing|12
5980443|NCT03003520|9569241|FG001|Follow-up|Ongoing|2
5980444|NCT03003520|9569240|FG000|Follow-up|Withdrawal by Subject|1
5980445|NCT03003520|9569241|FG001|Follow-up|Withdrawal by Subject|0
5980446|NCT02862457|9569262|FG000|Overall Study|Death|1
5980447|NCT02862457|9569263|FG001|Overall Study|Death|3
5980448|NCT02862457|9569264|FG002|Overall Study|Death|2
5980449|NCT02862457|9569265|FG003|Overall Study|Death|3
6061996|NCT00494507|9662852|FG001|Open-Label Phase|Worsening Disease|0
6061997|NCT00494507|9662853|FG002|Open-Label Phase|Worsening Disease|0
6095348|NCT00723008|9709292|FG000|4-Week Unblinded Treatment|Adverse Event|1
6095349|NCT00723008|9709293|FG001|4-Week Unblinded Treatment|Adverse Event|0
6203163|NCT01512160|9864043|FG003|Overall Study|Withdrawal by Subject|1
6061998|NCT00494507|9662854|FG003|Open-Label Phase|Worsening Disease|2
6061999|NCT00494676|9662878|FG000|Allocation|Withdrawal by Subject|2
6062000|NCT00494676|9662879|FG001|Allocation|Withdrawal by Subject|4
6062001|NCT00494676|9662878|FG000|First Intervention|Withdrawal by Subject|1
6062002|NCT00494676|9662879|FG001|First Intervention|Withdrawal by Subject|3
6062003|NCT00494676|9662878|FG000|Second Intervention|Withdrawal by Subject|1
6062004|NCT00494676|9662879|FG001|Second Intervention|Withdrawal by Subject|1
6062005|NCT00494780|9662887|FG000|Overall Study|Adverse Event|1
6062006|NCT00494780|9662888|FG001|Overall Study|Adverse Event|0
6062007|NCT00494780|9662887|FG000|Overall Study|Withdrew before Dosed|0
6062008|NCT00494780|9662888|FG001|Overall Study|Withdrew before Dosed|1
6062009|NCT00494780|9662887|FG000|Overall Study|Progression of Study Disease|7
6062010|NCT00494780|9662888|FG001|Overall Study|Progression of Study Disease|8
6062011|NCT00494780|9662887|FG000|Overall Study|New Treatment|2
6062012|NCT00494780|9662888|FG001|Overall Study|New Treatment|2
6062013|NCT00494780|9662887|FG000|Overall Study|Non-compliance|1
6062014|NCT00494780|9662888|FG001|Overall Study|Non-compliance|0
6062015|NCT00494780|9662887|FG000|Overall Study|Residual Tumour Mass|0
6062016|NCT00494780|9662888|FG001|Overall Study|Residual Tumour Mass|1
6062017|NCT00494780|9662887|FG000|Overall Study|Insurance Issues|0
6062018|NCT00494780|9662888|FG001|Overall Study|Insurance Issues|1
6062019|NCT00494871|9662907|FG000|Double-blind (DB) Treatment Period|Adverse Event|73
6062020|NCT00494871|9662908|FG001|Double-blind (DB) Treatment Period|Adverse Event|70
6062021|NCT00494871|9662907|FG000|Double-blind (DB) Treatment Period|Withdrawal by Subject|26
6062022|NCT00494871|9662908|FG001|Double-blind (DB) Treatment Period|Withdrawal by Subject|35
6062023|NCT00494871|9662907|FG000|Double-blind (DB) Treatment Period|Death|8
6062024|NCT00494871|9662908|FG001|Double-blind (DB) Treatment Period|Death|3
6062025|NCT00494871|9662907|FG000|Double-blind (DB) Treatment Period|Physician Decision|4
6062026|NCT00494871|9662908|FG001|Double-blind (DB) Treatment Period|Physician Decision|13
6062027|NCT00494871|9662907|FG000|Double-blind (DB) Treatment Period|Lost to Follow-up|4
6062028|NCT00494871|9662908|FG001|Double-blind (DB) Treatment Period|Lost to Follow-up|1
6062029|NCT00494871|9662907|FG000|Double-blind (DB) Treatment Period|Protocol Violation|9
6062030|NCT00494871|9662908|FG001|Double-blind (DB) Treatment Period|Protocol Violation|9
6062031|NCT00494871|9662907|FG000|Double-blind (DB) Treatment Period|Clinical Endpoint Reached|18
6062032|NCT00494871|9662908|FG001|Double-blind (DB) Treatment Period|Clinical Endpoint Reached|28
6062033|NCT00494871|9662907|FG000|Double-blind (DB) Treatment Period|Non-compliant with Study Medication|3
6062034|NCT00494871|9662908|FG001|Double-blind (DB) Treatment Period|Non-compliant with Study Medication|1
6062035|NCT00494871|9662907|FG000|Double-blind (DB) Treatment Period|Protocol Driven Decision Point|12
6062036|NCT00494871|9662908|FG001|Double-blind (DB) Treatment Period|Protocol Driven Decision Point|8
6062037|NCT00494871|9662907|FG000|Double-blind (DB) Treatment Period|Site Closed by Investigator|1
6062038|NCT00494871|9662908|FG001|Double-blind (DB) Treatment Period|Site Closed by Investigator|2
6062039|NCT00494871|9662907|FG000|Double-blind (DB) Treatment Period|Site Closed by Sponsor|1
6062040|NCT00494871|9662908|FG001|Double-blind (DB) Treatment Period|Site Closed by Sponsor|1
6062041|NCT00494871|9662907|FG000|Double-blind (DB) Treatment Period|Drop out before Treatment Start|1
6062042|NCT00494871|9662908|FG001|Double-blind (DB) Treatment Period|Drop out before Treatment Start|1
6062043|NCT00494871|9662907|FG000|Follow-up (FU) Period|Adverse Event|1
6062044|NCT00494871|9662908|FG001|Follow-up (FU) Period|Adverse Event|1
6062045|NCT00494871|9662907|FG000|Follow-up (FU) Period|Death|13
6062046|NCT00494871|9662908|FG001|Follow-up (FU) Period|Death|12
6062047|NCT00494871|9662907|FG000|Follow-up (FU) Period|Lost to Follow-up|6
6062048|NCT00494871|9662908|FG001|Follow-up (FU) Period|Lost to Follow-up|2
6062049|NCT00494871|9662907|FG000|Follow-up (FU) Period|Physician Decision|0
6062050|NCT00494871|9662908|FG001|Follow-up (FU) Period|Physician Decision|1
6062051|NCT00494871|9662907|FG000|Follow-up (FU) Period|Protocol Violation|1
6062052|NCT00494871|9662908|FG001|Follow-up (FU) Period|Protocol Violation|0
6062053|NCT00494871|9662907|FG000|Follow-up (FU) Period|Withdrawal by Subject|5
6062054|NCT00494871|9662908|FG001|Follow-up (FU) Period|Withdrawal by Subject|5
6062055|NCT00494871|9662907|FG000|Follow-up (FU) Period|Clinical Endpoint Reached|3
6062056|NCT00494871|9662908|FG001|Follow-up (FU) Period|Clinical Endpoint Reached|2
6095350|NCT00723008|9709292|FG000|4-Week Unblinded Treatment|Lost to Follow-up|0
6095351|NCT00723008|9709293|FG001|4-Week Unblinded Treatment|Lost to Follow-up|1
6095352|NCT00723021|9709307|FG000|Intervention Period 4|Adverse Event|0
6095353|NCT00723021|9709308|FG001|Intervention Period 4|Adverse Event|0
6095354|NCT00723021|9709309|FG002|Intervention Period 4|Adverse Event|0
6095355|NCT00723021|9709310|FG003|Intervention Period 4|Adverse Event|0
6095356|NCT00723021|9709311|FG004|Intervention Period 4|Adverse Event|1
6095357|NCT00723125|9709346|FG000|Overall Study|Met Dx|1
6095358|NCT00723125|9709347|FG001|Overall Study|Met Dx|0
6095359|NCT00723125|9709346|FG000|Overall Study|Withdrawal by Subject|15
6095360|NCT00723125|9709347|FG001|Overall Study|Withdrawal by Subject|6
6095361|NCT00723125|9709346|FG000|Overall Study|Adverse Event|2
6095362|NCT00723125|9709347|FG001|Overall Study|Adverse Event|0
6095363|NCT00723190|9709372|FG000|Overall Study|Withdrawal by Subject|45
6095364|NCT00723190|9709372|FG000|Overall Study|Lost to Follow-up|37
6095365|NCT00723190|9709372|FG000|Overall Study|Adverse Event|18
6095366|NCT00723190|9709372|FG000|Overall Study|Lack of Efficacy|16
6095367|NCT00723190|9709372|FG000|Overall Study|Protocol Violation|15
6062057|NCT00495040|9662925|FG000|Overall Study|Withdrawal by Subject|3
6062058|NCT00495170|9662949|FG000|Overall Study|Lost to Follow-up|9
6062059|NCT00495170|9662949|FG000|Overall Study|Withdrawal by Subject|3
6062060|NCT00495170|9662949|FG000|Overall Study|Inappropriate staging|8
6062061|NCT00495391|9662955|FG000|Overall Study|Lack of Efficacy|34
6062062|NCT00495391|9662956|FG001|Overall Study|Lack of Efficacy|18
6062063|NCT00495391|9662955|FG000|Overall Study|Withdrawal by Subject|2
6062064|NCT00495391|9662956|FG001|Overall Study|Withdrawal by Subject|3
6062065|NCT00495469|9662969|FG000|Overall Study|Adverse Event|0
6062066|NCT00495469|9662970|FG001|Overall Study|Adverse Event|1
6062067|NCT00495469|9662971|FG002|Overall Study|Adverse Event|3
6095368|NCT00723190|9709372|FG000|Overall Study|Other-Premature Discontinuation|9
6095369|NCT00723190|9709372|FG000|Overall Study|Other-Not included in safety population|2
6095370|NCT00723203|9709376|FG000|Overall Study|Withdrawal by Subject|3
6095371|NCT00723229|9709382|FG000|First Intervention|Lost to Follow-up|7
6095372|NCT00723229|9709383|FG001|First Intervention|Lost to Follow-up|3
6095373|NCT00723255|9709389|FG000|Overall Study|Ineligible: Inadequate pathology|1
6095374|NCT00723255|9709389|FG000|Overall Study|Ineligible: Second primary|1
6095375|NCT00723255|9709389|FG000|Overall Study|Ineligible: Wrong Primary|2
6095376|NCT00723294|9709405|FG000|Overall Study|Lobular histology|2
6095377|NCT00723294|9709405|FG000|Overall Study|>25% intraductal component|1
6095378|NCT00723294|9709405|FG000|Overall Study|No MRI tumor enhancement|1
6095379|NCT00723294|9709405|FG000|Overall Study|1.0-Tesla MRI|1
6095380|NCT00723294|9709405|FG000|Overall Study|No cryoabalation|2
6095381|NCT00723294|9709405|FG000|Overall Study|Did not undergo surgery|1
6095382|NCT00723294|9709405|FG000|Overall Study|Treated prior to registration|1
6095383|NCT00723294|9709405|FG000|Overall Study|Treated by non-credentialed surgeon|1
6095384|NCT00723294|9709405|FG000|Overall Study|Benign lesion|1
6095385|NCT00723294|9709405|FG000|Overall Study|Withdrawal by Subject|1
6095386|NCT00723294|9709405|FG000|Overall Study|No treatment due to probe failure|1
6095387|NCT00723398|9709414|FG000|Overall Study|Withdrawal by Subject|2
6095388|NCT00723398|9709415|FG001|Overall Study|Withdrawal by Subject|6
6095389|NCT00723398|9709416|FG002|Overall Study|Withdrawal by Subject|4
6095390|NCT00723398|9709417|FG003|Overall Study|Withdrawal by Subject|4
6095391|NCT00723398|9709418|FG004|Overall Study|Withdrawal by Subject|4
6095392|NCT00723398|9709414|FG000|Overall Study|Protocol Violation|2
6095393|NCT00723398|9709415|FG001|Overall Study|Protocol Violation|1
6095394|NCT00723398|9709416|FG002|Overall Study|Protocol Violation|5
6095395|NCT00723398|9709417|FG003|Overall Study|Protocol Violation|0
6095396|NCT00723398|9709418|FG004|Overall Study|Protocol Violation|0
6095397|NCT00723398|9709414|FG000|Overall Study|Physician Decision|2
6095398|NCT00723398|9709415|FG001|Overall Study|Physician Decision|2
6095399|NCT00723398|9709416|FG002|Overall Study|Physician Decision|5
6095400|NCT00723398|9709417|FG003|Overall Study|Physician Decision|0
6095401|NCT00723398|9709418|FG004|Overall Study|Physician Decision|1
6095402|NCT00723398|9709414|FG000|Overall Study|Adverse Event|0
6095403|NCT00723398|9709415|FG001|Overall Study|Adverse Event|5
6095404|NCT00723398|9709416|FG002|Overall Study|Adverse Event|3
6095405|NCT00723398|9709417|FG003|Overall Study|Adverse Event|1
6095406|NCT00723398|9709418|FG004|Overall Study|Adverse Event|4
6095407|NCT00723398|9709414|FG000|Overall Study|Lost to Follow-up|0
6095408|NCT00723398|9709415|FG001|Overall Study|Lost to Follow-up|1
6095409|NCT00723398|9709416|FG002|Overall Study|Lost to Follow-up|0
6095410|NCT00723398|9709417|FG003|Overall Study|Lost to Follow-up|0
6095411|NCT00723398|9709418|FG004|Overall Study|Lost to Follow-up|0
6095412|NCT00723450|9709432|FG000|Open-Label Phase|Adverse Event|26
6095413|NCT00723450|9709433|FG001|Open-Label Phase|Adverse Event|0
6095414|NCT00723450|9709434|FG002|Open-Label Phase|Adverse Event|0
6095415|NCT00723450|9709432|FG000|Open-Label Phase|Lack of Efficacy|18
6095416|NCT00723450|9709433|FG001|Open-Label Phase|Lack of Efficacy|0
6095417|NCT00723450|9709434|FG002|Open-Label Phase|Lack of Efficacy|0
6095418|NCT00723450|9709432|FG000|Open-Label Phase|Protocol Violation|35
6095419|NCT00723450|9709433|FG001|Open-Label Phase|Protocol Violation|0
6095420|NCT00723450|9709434|FG002|Open-Label Phase|Protocol Violation|0
6095421|NCT00723450|9709432|FG000|Open-Label Phase|Lost to Follow-up|7
6095422|NCT00723450|9709433|FG001|Open-Label Phase|Lost to Follow-up|0
6095423|NCT00723450|9709434|FG002|Open-Label Phase|Lost to Follow-up|0
6095424|NCT00723450|9709432|FG000|Open-Label Phase|Physician Decision|2
6095425|NCT00723450|9709433|FG001|Open-Label Phase|Physician Decision|0
6095426|NCT00723450|9709434|FG002|Open-Label Phase|Physician Decision|0
6095427|NCT00723450|9709432|FG000|Open-Label Phase|Withdrawal by Subject|37
6095428|NCT00723450|9709433|FG001|Open-Label Phase|Withdrawal by Subject|0
6095429|NCT00723450|9709434|FG002|Open-Label Phase|Withdrawal by Subject|0
6095430|NCT00723450|9709432|FG000|Randomized Phase|Adverse Event|0
6095431|NCT00723450|9709433|FG001|Randomized Phase|Adverse Event|26
6095432|NCT00723450|9709434|FG002|Randomized Phase|Adverse Event|17
6095433|NCT00723450|9709432|FG000|Randomized Phase|Lack of Efficacy|0
6095434|NCT00723450|9709433|FG001|Randomized Phase|Lack of Efficacy|11
6095435|NCT00723450|9709434|FG002|Randomized Phase|Lack of Efficacy|11
6095436|NCT00723450|9709432|FG000|Randomized Phase|Protocol Violation|0
6095437|NCT00723450|9709433|FG001|Randomized Phase|Protocol Violation|9
6062068|NCT00495469|9662972|FG003|Overall Study|Adverse Event|0
6062069|NCT00495469|9662973|FG004|Overall Study|Adverse Event|1
6062070|NCT00495469|9662974|FG005|Overall Study|Adverse Event|1
6062071|NCT00495469|9662975|FG006|Overall Study|Adverse Event|1
6062072|NCT00495469|9662969|FG000|Overall Study|Lost to Follow-up|1
6062073|NCT00495469|9662970|FG001|Overall Study|Lost to Follow-up|1
6062074|NCT00495469|9662971|FG002|Overall Study|Lost to Follow-up|3
6062075|NCT00495469|9662972|FG003|Overall Study|Lost to Follow-up|1
6062076|NCT00495469|9662973|FG004|Overall Study|Lost to Follow-up|0
6062077|NCT00495469|9662974|FG005|Overall Study|Lost to Follow-up|0
6062078|NCT00495469|9662975|FG006|Overall Study|Lost to Follow-up|0
6062079|NCT00495469|9662969|FG000|Overall Study|Protocol Violation|0
6062080|NCT00495469|9662970|FG001|Overall Study|Protocol Violation|0
6062081|NCT00495469|9662971|FG002|Overall Study|Protocol Violation|0
6062082|NCT00495469|9662972|FG003|Overall Study|Protocol Violation|0
6062083|NCT00495469|9662973|FG004|Overall Study|Protocol Violation|1
6062084|NCT00495469|9662974|FG005|Overall Study|Protocol Violation|2
6095438|NCT00723450|9709434|FG002|Randomized Phase|Protocol Violation|13
6095439|NCT00723450|9709432|FG000|Randomized Phase|Lost to Follow-up|0
6095440|NCT00723450|9709433|FG001|Randomized Phase|Lost to Follow-up|2
6095441|NCT00723450|9709434|FG002|Randomized Phase|Lost to Follow-up|3
6095442|NCT00723450|9709432|FG000|Randomized Phase|Physician Decision|0
6095443|NCT00723450|9709433|FG001|Randomized Phase|Physician Decision|3
6095444|NCT00723450|9709434|FG002|Randomized Phase|Physician Decision|1
6095445|NCT00723450|9709432|FG000|Randomized Phase|Withdrawal by Subject|0
6095446|NCT00723450|9709433|FG001|Randomized Phase|Withdrawal by Subject|14
6095447|NCT00723450|9709434|FG002|Randomized Phase|Withdrawal by Subject|22
6095448|NCT00723489|9709447|FG000|Overall Study|Physician Decision|0
6095449|NCT00723489|9709448|FG001|Overall Study|Physician Decision|1
6095450|NCT00723489|9709449|FG002|Overall Study|Physician Decision|0
6095451|NCT00723489|9709450|FG003|Overall Study|Physician Decision|0
6095452|NCT00723489|9709447|FG000|Overall Study|Pregnancy|0
6095453|NCT00723489|9709448|FG001|Overall Study|Pregnancy|0
6095454|NCT00723489|9709449|FG002|Overall Study|Pregnancy|0
6095455|NCT00723489|9709450|FG003|Overall Study|Pregnancy|1
6095456|NCT00723489|9709447|FG000|Overall Study|Withdrawal by Subject|0
6095457|NCT00723489|9709448|FG001|Overall Study|Withdrawal by Subject|0
6095458|NCT00723489|9709449|FG002|Overall Study|Withdrawal by Subject|0
6095459|NCT00723489|9709450|FG003|Overall Study|Withdrawal by Subject|1
6095460|NCT00723489|9709447|FG000|Overall Study|Seropositive at baseline|1
6095461|NCT00723489|9709448|FG001|Overall Study|Seropositive at baseline|0
6095462|NCT00723489|9709449|FG002|Overall Study|Seropositive at baseline|0
6095463|NCT00723489|9709450|FG003|Overall Study|Seropositive at baseline|0
6095464|NCT00723489|9709447|FG000|Overall Study|Prohibited Medication|0
6095465|NCT00723489|9709448|FG001|Overall Study|Prohibited Medication|0
6095466|NCT00723489|9709449|FG002|Overall Study|Prohibited Medication|0
6095467|NCT00723489|9709450|FG003|Overall Study|Prohibited Medication|1
6095468|NCT00723489|9709447|FG000|Overall Study|Samples Collected Out of Window|0
6095469|NCT00723489|9709448|FG001|Overall Study|Samples Collected Out of Window|3
6095470|NCT00723489|9709449|FG002|Overall Study|Samples Collected Out of Window|0
6095471|NCT00723489|9709450|FG003|Overall Study|Samples Collected Out of Window|0
6095472|NCT00723528|9709463|FG000|Period 1: Controlled Period (CP)|Adverse Event|0
6095473|NCT00723528|9709464|FG001|Period 1: Controlled Period (CP)|Adverse Event|0
6095474|NCT00723528|9709465|FG002|Period 1: Controlled Period (CP)|Adverse Event|1
6095475|NCT00723528|9709466|FG003|Period 1: Controlled Period (CP)|Adverse Event|0
6095476|NCT00723528|9709467|FG004|Period 1: Controlled Period (CP)|Adverse Event|0
6095477|NCT00723528|9709468|FG005|Period 1: Controlled Period (CP)|Adverse Event|0
6095478|NCT00723528|9709469|FG006|Period 1: Controlled Period (CP)|Adverse Event|0
6095479|NCT00723528|9709463|FG000|Period 1: Controlled Period (CP)|Withdrawal by Subject|2
6095480|NCT00723528|9709464|FG001|Period 1: Controlled Period (CP)|Withdrawal by Subject|0
6095481|NCT00723528|9709465|FG002|Period 1: Controlled Period (CP)|Withdrawal by Subject|0
6095482|NCT00723528|9709466|FG003|Period 1: Controlled Period (CP)|Withdrawal by Subject|0
6095483|NCT00723528|9709467|FG004|Period 1: Controlled Period (CP)|Withdrawal by Subject|0
6095484|NCT00723528|9709468|FG005|Period 1: Controlled Period (CP)|Withdrawal by Subject|0
6095485|NCT00723528|9709469|FG006|Period 1: Controlled Period (CP)|Withdrawal by Subject|0
6095486|NCT00723528|9709463|FG000|Period 1: Controlled Period (CP)|Physician Decision|0
6095487|NCT00723528|9709464|FG001|Period 1: Controlled Period (CP)|Physician Decision|0
6095488|NCT00723528|9709465|FG002|Period 1: Controlled Period (CP)|Physician Decision|1
6095489|NCT00723528|9709466|FG003|Period 1: Controlled Period (CP)|Physician Decision|0
6095490|NCT00723528|9709467|FG004|Period 1: Controlled Period (CP)|Physician Decision|0
6095491|NCT00723528|9709468|FG005|Period 1: Controlled Period (CP)|Physician Decision|0
6095492|NCT00723528|9709469|FG006|Period 1: Controlled Period (CP)|Physician Decision|0
6095493|NCT00723528|9709463|FG000|Period 1: Controlled Period (CP)|Onset of Tuberculosis Infection|0
6095494|NCT00723528|9709464|FG001|Period 1: Controlled Period (CP)|Onset of Tuberculosis Infection|0
6095495|NCT00723528|9709465|FG002|Period 1: Controlled Period (CP)|Onset of Tuberculosis Infection|1
6095496|NCT00723528|9709466|FG003|Period 1: Controlled Period (CP)|Onset of Tuberculosis Infection|0
6095497|NCT00723528|9709467|FG004|Period 1: Controlled Period (CP)|Onset of Tuberculosis Infection|0
6095498|NCT00723528|9709468|FG005|Period 1: Controlled Period (CP)|Onset of Tuberculosis Infection|0
6203164|NCT01512264|9864079|FG000|Overall Study|Lost to Follow-up|0
6062085|NCT00495469|9662975|FG006|Overall Study|Protocol Violation|0
6062086|NCT00495469|9662969|FG000|Overall Study|Withdrawal by Subject|5
6062087|NCT00495469|9662970|FG001|Overall Study|Withdrawal by Subject|3
6062088|NCT00495469|9662971|FG002|Overall Study|Withdrawal by Subject|1
6062089|NCT00495469|9662972|FG003|Overall Study|Withdrawal by Subject|3
6062090|NCT00495469|9662973|FG004|Overall Study|Withdrawal by Subject|3
6095499|NCT00723528|9709469|FG006|Period 1: Controlled Period (CP)|Onset of Tuberculosis Infection|0
6095500|NCT00723528|9709463|FG000|Period 1: Controlled Period (CP)|Withdrawal due to worsened symptoms|2
6095501|NCT00723528|9709464|FG001|Period 1: Controlled Period (CP)|Withdrawal due to worsened symptoms|0
6095502|NCT00723528|9709465|FG002|Period 1: Controlled Period (CP)|Withdrawal due to worsened symptoms|1
6095503|NCT00723528|9709466|FG003|Period 1: Controlled Period (CP)|Withdrawal due to worsened symptoms|0
6095504|NCT00723528|9709467|FG004|Period 1: Controlled Period (CP)|Withdrawal due to worsened symptoms|0
6095505|NCT00723528|9709468|FG005|Period 1: Controlled Period (CP)|Withdrawal due to worsened symptoms|0
6095506|NCT00723528|9709469|FG006|Period 1: Controlled Period (CP)|Withdrawal due to worsened symptoms|0
6095507|NCT00723528|9709463|FG000|Period 2: After Controlled Period|Withdrawal by Subject|0
6095508|NCT00723528|9709464|FG001|Period 2: After Controlled Period|Withdrawal by Subject|0
6095509|NCT00723528|9709465|FG002|Period 2: After Controlled Period|Withdrawal by Subject|0
6095510|NCT00723528|9709466|FG003|Period 2: After Controlled Period|Withdrawal by Subject|1
6095511|NCT00723528|9709467|FG004|Period 2: After Controlled Period|Withdrawal by Subject|0
6095512|NCT00723528|9709468|FG005|Period 2: After Controlled Period|Withdrawal by Subject|1
6095513|NCT00723528|9709469|FG006|Period 2: After Controlled Period|Withdrawal by Subject|1
6095514|NCT00723528|9709463|FG000|Period 2: After Controlled Period|Onset of tuberculosis infection|0
6095515|NCT00723528|9709464|FG001|Period 2: After Controlled Period|Onset of tuberculosis infection|0
6095516|NCT00723528|9709465|FG002|Period 2: After Controlled Period|Onset of tuberculosis infection|0
6095517|NCT00723528|9709466|FG003|Period 2: After Controlled Period|Onset of tuberculosis infection|0
6095518|NCT00723528|9709467|FG004|Period 2: After Controlled Period|Onset of tuberculosis infection|0
6095519|NCT00723528|9709468|FG005|Period 2: After Controlled Period|Onset of tuberculosis infection|1
6095520|NCT00723528|9709469|FG006|Period 2: After Controlled Period|Onset of tuberculosis infection|0
6095521|NCT00723528|9709463|FG000|Period 2: After Controlled Period|Other|0
6095522|NCT00723528|9709464|FG001|Period 2: After Controlled Period|Other|0
6095523|NCT00723528|9709465|FG002|Period 2: After Controlled Period|Other|0
6095524|NCT00723528|9709466|FG003|Period 2: After Controlled Period|Other|0
6095525|NCT00723528|9709467|FG004|Period 2: After Controlled Period|Other|1
6095526|NCT00723528|9709468|FG005|Period 2: After Controlled Period|Other|4
6095527|NCT00723528|9709469|FG006|Period 2: After Controlled Period|Other|0
6095528|NCT00723528|9709463|FG000|Period 2: After Controlled Period|Adverse Event|0
6095529|NCT00723528|9709464|FG001|Period 2: After Controlled Period|Adverse Event|0
6095530|NCT00723528|9709465|FG002|Period 2: After Controlled Period|Adverse Event|0
6095531|NCT00723528|9709466|FG003|Period 2: After Controlled Period|Adverse Event|0
6095532|NCT00723528|9709467|FG004|Period 2: After Controlled Period|Adverse Event|1
6095533|NCT00723528|9709468|FG005|Period 2: After Controlled Period|Adverse Event|0
6095534|NCT00723528|9709469|FG006|Period 2: After Controlled Period|Adverse Event|1
6095535|NCT00723528|9709463|FG000|Period 2: After Controlled Period|Use of prohibited concomitant medication|0
5980450|NCT02862457|9569266|FG004|Overall Study|Death|0
5980451|NCT02862457|9569267|FG005|Overall Study|Death|2
5980452|NCT02862457|9569268|FG006|Overall Study|Death|1
5980453|NCT02862457|9569262|FG000|Overall Study|Lost to Follow-up|1
5980454|NCT02862457|9569263|FG001|Overall Study|Lost to Follow-up|0
5980455|NCT02862457|9569264|FG002|Overall Study|Lost to Follow-up|0
5980456|NCT02862457|9569265|FG003|Overall Study|Lost to Follow-up|1
5980457|NCT02862457|9569266|FG004|Overall Study|Lost to Follow-up|0
6062091|NCT00495469|9662974|FG005|Overall Study|Withdrawal by Subject|2
6062092|NCT00495469|9662975|FG006|Overall Study|Withdrawal by Subject|3
6062093|NCT00495469|9662969|FG000|Overall Study|Lack of Efficacy|0
6062094|NCT00495469|9662970|FG001|Overall Study|Lack of Efficacy|0
6062095|NCT00495469|9662971|FG002|Overall Study|Lack of Efficacy|0
6062096|NCT00495469|9662972|FG003|Overall Study|Lack of Efficacy|0
6062097|NCT00495469|9662973|FG004|Overall Study|Lack of Efficacy|0
6062098|NCT00495469|9662974|FG005|Overall Study|Lack of Efficacy|0
6062099|NCT00495469|9662975|FG006|Overall Study|Lack of Efficacy|1
5980458|NCT02862457|9569267|FG005|Overall Study|Lost to Follow-up|0
5980459|NCT02862457|9569268|FG006|Overall Study|Lost to Follow-up|0
5980460|NCT02862457|9569262|FG000|Overall Study|Withdrawal by Subject|0
5980461|NCT02862457|9569263|FG001|Overall Study|Withdrawal by Subject|0
5980462|NCT02862457|9569264|FG002|Overall Study|Withdrawal by Subject|1
5980463|NCT02862457|9569265|FG003|Overall Study|Withdrawal by Subject|0
5980464|NCT02862457|9569266|FG004|Overall Study|Withdrawal by Subject|0
5980465|NCT02862457|9569267|FG005|Overall Study|Withdrawal by Subject|1
5980466|NCT02862457|9569268|FG006|Overall Study|Withdrawal by Subject|0
5980467|NCT02820753|9569294|FG000|2 Month|Withdrawal by Subject|3
5980468|NCT02820753|9569295|FG001|2 Month|Withdrawal by Subject|3
5980469|NCT02820753|9569294|FG000|2 Month|Lost to Follow-up|24
5980470|NCT02820753|9569295|FG001|2 Month|Lost to Follow-up|26
5980471|NCT02820753|9569294|FG000|2 Month|Stopped per NIH Hold|51
5980472|NCT02820753|9569295|FG001|2 Month|Stopped per NIH Hold|13
5980473|NCT02820753|9569294|FG000|6 Month|Withdrawal by Subject|2
5980474|NCT02820753|9569295|FG001|6 Month|Withdrawal by Subject|2
5980475|NCT02820753|9569294|FG000|6 Month|Lost to Follow-up|20
6062100|NCT00495469|9662969|FG000|Overall Study|Liver function test abnormality|0
6062101|NCT00495469|9662970|FG001|Overall Study|Liver function test abnormality|1
6062102|NCT00495469|9662971|FG002|Overall Study|Liver function test abnormality|0
6062103|NCT00495469|9662972|FG003|Overall Study|Liver function test abnormality|0
6062104|NCT00495469|9662973|FG004|Overall Study|Liver function test abnormality|0
6062105|NCT00495469|9662974|FG005|Overall Study|Liver function test abnormality|0
6062106|NCT00495469|9662975|FG006|Overall Study|Liver function test abnormality|0
6095536|NCT00723528|9709464|FG001|Period 2: After Controlled Period|Use of prohibited concomitant medication|0
6095537|NCT00723528|9709465|FG002|Period 2: After Controlled Period|Use of prohibited concomitant medication|0
6095538|NCT00723528|9709466|FG003|Period 2: After Controlled Period|Use of prohibited concomitant medication|0
6095539|NCT00723528|9709467|FG004|Period 2: After Controlled Period|Use of prohibited concomitant medication|0
6095540|NCT00723528|9709468|FG005|Period 2: After Controlled Period|Use of prohibited concomitant medication|0
6095541|NCT00723528|9709469|FG006|Period 2: After Controlled Period|Use of prohibited concomitant medication|1
6095542|NCT00723528|9709463|FG000|Period 2: After Controlled Period|Withdrawal due to worsened symptoms|0
6095543|NCT00723528|9709464|FG001|Period 2: After Controlled Period|Withdrawal due to worsened symptoms|0
6095544|NCT00723528|9709465|FG002|Period 2: After Controlled Period|Withdrawal due to worsened symptoms|0
6095545|NCT00723528|9709466|FG003|Period 2: After Controlled Period|Withdrawal due to worsened symptoms|0
6095546|NCT00723528|9709467|FG004|Period 2: After Controlled Period|Withdrawal due to worsened symptoms|0
6095547|NCT00723528|9709468|FG005|Period 2: After Controlled Period|Withdrawal due to worsened symptoms|0
6095548|NCT00723528|9709469|FG006|Period 2: After Controlled Period|Withdrawal due to worsened symptoms|1
6095549|NCT00723554|9709485|FG000|Overall Study|Adverse Event|12
6095550|NCT00723554|9709485|FG000|Overall Study|Investigator's judgement|5
6095551|NCT00723554|9709485|FG000|Overall Study|Inhaled medication other than iloprost|4
6095552|NCT00723554|9709485|FG000|Overall Study|Withdrawal of consent|3
6095553|NCT00723554|9709485|FG000|Overall Study|Other|3
6095554|NCT00723554|9709485|FG000|Overall Study|Lost to Follow-up|1
6095555|NCT00723554|9709485|FG000|Overall Study|Non-compliance|1
6095556|NCT00723606|9709497|FG000|Overall Study|Adverse Event|2
6095557|NCT00723606|9709498|FG001|Overall Study|Adverse Event|5
6095558|NCT00723606|9709497|FG000|Overall Study|Other|2
6095559|NCT00723606|9709498|FG001|Overall Study|Other|0
6095560|NCT00723606|9709497|FG000|Overall Study|Withdrawal by Subject|0
6095561|NCT00723606|9709498|FG001|Overall Study|Withdrawal by Subject|2
6095562|NCT00723697|9709512|FG000|Overall Study|Physician questionnaires not received|2
6095563|NCT00723697|9709512|FG000|Overall Study|Missing Informed Consent Form|10
6095564|NCT00723697|9709512|FG000|Overall Study|Other exclusion criteria applied|6
6095565|NCT00723710|9709519|FG000|Overall Study|Disease progression|48
6095566|NCT00723710|9709519|FG000|Overall Study|Adverse Event|88
6095567|NCT00723710|9709519|FG000|Overall Study|Withdrawal by Subject|36
6095568|NCT00723710|9709519|FG000|Overall Study|Physician Decision|2
6095569|NCT00723801|9709535|FG000|Overall Study|Lost to Follow-up|1
6095570|NCT00723801|9709536|FG001|Overall Study|Lost to Follow-up|2
6095571|NCT00723801|9709535|FG000|Overall Study|Protocol Violation|2
6095572|NCT00723801|9709536|FG001|Overall Study|Protocol Violation|1
6095573|NCT00723840|9709546|FG000|Overall Study|Lost to Follow-up|2
6095574|NCT00723840|9709546|FG000|Overall Study|Failure to return|18
6095575|NCT00723840|9709546|FG000|Overall Study|Withdrawal by Subject|55
6095576|NCT00723840|9709546|FG000|Overall Study|Serious Adverse Events|3
6095577|NCT00723840|9709546|FG000|Overall Study|Other Medical Event|2
6095578|NCT00723840|9709546|FG000|Overall Study|Unspecified reason|2
6095579|NCT00723892|9709559|FG000|Overall Study|Participant not tracked|33
6095580|NCT00723892|9709560|FG001|Overall Study|Participant not tracked|35
6095581|NCT00723892|9709559|FG000|Overall Study|Virological criterion|24
6095582|NCT00723892|9709560|FG001|Overall Study|Virological criterion|9
6095583|NCT00723892|9709559|FG000|Overall Study|Withdrawal by Subject|6
6095584|NCT00723892|9709560|FG001|Overall Study|Withdrawal by Subject|9
6095585|NCT00723892|9709559|FG000|Overall Study|End planned|11
6095586|NCT00723892|9709560|FG001|Overall Study|End planned|7
6095587|NCT00723892|9709559|FG000|Overall Study|Bad tolerance|5
6095588|NCT00723892|9709560|FG001|Overall Study|Bad tolerance|5
6095589|NCT00723892|9709559|FG000|Overall Study|Multiple reasons|17
6095590|NCT00723892|9709560|FG001|Overall Study|Multiple reasons|12
6095591|NCT00723892|9709559|FG000|Overall Study|Other|6
6095592|NCT00723892|9709560|FG001|Overall Study|Other|3
6095593|NCT00723892|9709559|FG000|Overall Study|Study end|1
6095594|NCT00723892|9709560|FG001|Overall Study|Study end|3
6095595|NCT00723892|9709559|FG000|Overall Study|Weight loss|1
6095596|NCT00723892|9709560|FG001|Overall Study|Weight loss|3
6095597|NCT00723892|9709559|FG000|Overall Study|Alcohol abuse|0
6062107|NCT00495469|9662969|FG000|Overall Study|ST depression at randomisation in ECG|0
6095598|NCT00723892|9709560|FG001|Overall Study|Alcohol abuse|1
6095599|NCT00723892|9709559|FG000|Overall Study|Intercurrent infection|2
6095600|NCT00723892|9709560|FG001|Overall Study|Intercurrent infection|0
6095601|NCT00723892|9709559|FG000|Overall Study|Drug addiction|1
6095602|NCT00723892|9709560|FG001|Overall Study|Drug addiction|0
6095603|NCT00723957|9709572|FG000|Overall Study|Adverse event unrelated to study drug|1
6095604|NCT00723957|9709573|FG001|Overall Study|Adverse event unrelated to study drug|4
6095605|NCT00723957|9709572|FG000|Overall Study|Death|3
6095606|NCT00723957|9709573|FG001|Overall Study|Death|4
6062108|NCT00495469|9662970|FG001|Overall Study|ST depression at randomisation in ECG|1
6062109|NCT00495469|9662971|FG002|Overall Study|ST depression at randomisation in ECG|0
6062110|NCT00495469|9662972|FG003|Overall Study|ST depression at randomisation in ECG|0
6062111|NCT00495469|9662973|FG004|Overall Study|ST depression at randomisation in ECG|0
6062112|NCT00495469|9662974|FG005|Overall Study|ST depression at randomisation in ECG|0
6062113|NCT00495469|9662975|FG006|Overall Study|ST depression at randomisation in ECG|0
6062114|NCT00495495|9662998|FG000|Overall Study|Protocol Violation|99
6062115|NCT00495521|9663005|FG000|Overall Study|Physician Decision|0
6062116|NCT00495521|9663006|FG001|Overall Study|Physician Decision|1
6062117|NCT00495586|9663014|FG000|Overall Study|Withdrawal by Subject|4
6095607|NCT00723957|9709572|FG000|Overall Study|Disease progression|27
6095608|NCT00723957|9709573|FG001|Overall Study|Disease progression|25
6095609|NCT00723957|9709572|FG000|Overall Study|Maximum clinical benefit|4
6095610|NCT00723957|9709573|FG001|Overall Study|Maximum clinical benefit|5
6095611|NCT00723957|9709572|FG000|Overall Study|Investigator decision|1
6095612|NCT00723957|9709573|FG001|Overall Study|Investigator decision|1
6095613|NCT00723957|9709572|FG000|Overall Study|Study drug toxicity|4
6095614|NCT00723957|9709573|FG001|Overall Study|Study drug toxicity|6
6095615|NCT00723957|9709572|FG000|Overall Study|Withdrawal by Subject|7
6095616|NCT00723957|9709573|FG001|Overall Study|Withdrawal by Subject|5
6095617|NCT00723957|9709572|FG000|Overall Study|Reason not analyzed|1
6095618|NCT00723957|9709573|FG001|Overall Study|Reason not analyzed|0
6095619|NCT00723957|9709572|FG000|Overall Study|Never received treatment|3
6203165|NCT01512264|9864080|FG001|Overall Study|Lost to Follow-up|0
6203166|NCT01512264|9864081|FG002|Overall Study|Lost to Follow-up|0
6203167|NCT01512264|9864082|FG003|Overall Study|Lost to Follow-up|1
6203168|NCT01512368|9864092|FG000|Overall Study|Protocol Violation|3
6203169|NCT01512693|9864116|FG000|Overall Study|Withdrawal by Subject|0
6203170|NCT01512693|9864117|FG001|Overall Study|Withdrawal by Subject|1
6203171|NCT01512745|9864125|FG000|Overall Study|Adverse Event|22
6203172|NCT01512745|9864126|FG001|Overall Study|Adverse Event|3
6203173|NCT01512745|9864125|FG000|Overall Study|Death|9
6203174|NCT01512745|9864126|FG001|Overall Study|Death|13
6203175|NCT01512745|9864125|FG000|Overall Study|Withdrawal by Subject|2
6203176|NCT01512745|9864126|FG001|Overall Study|Withdrawal by Subject|2
6203177|NCT01512745|9864125|FG000|Overall Study|Lost to Follow-up|4
6203178|NCT01512745|9864126|FG001|Overall Study|Lost to Follow-up|0
6203179|NCT01512745|9864125|FG000|Overall Study|Lack of Efficacy|2
6203180|NCT01512745|9864126|FG001|Overall Study|Lack of Efficacy|2
6203181|NCT01512745|9864125|FG000|Overall Study|Protocol Violation|1
6203182|NCT01512745|9864126|FG001|Overall Study|Protocol Violation|0
6203183|NCT01512979|9864168|FG000|Overall Study|Adverse Event|2
6203184|NCT01512979|9864169|FG001|Overall Study|Adverse Event|2
6203185|NCT01512979|9864168|FG000|Overall Study|Protocol Violation|1
6203186|NCT01512979|9864169|FG001|Overall Study|Protocol Violation|4
6203187|NCT01512979|9864168|FG000|Overall Study|Lost to Follow-up|2
6203188|NCT01512979|9864169|FG001|Overall Study|Lost to Follow-up|5
6203189|NCT01512979|9864168|FG000|Overall Study|Withdrawal by Subject|1
6203190|NCT01512979|9864169|FG001|Overall Study|Withdrawal by Subject|2
6203191|NCT01512979|9864168|FG000|Overall Study|Reason other than stated above|13
6203192|NCT01512979|9864169|FG001|Overall Study|Reason other than stated above|9
6284373|NCT02326272|9996340|FG012|Maintenance Period (Week 16 to Week 48)|Non-compliance|0
6284374|NCT02326272|9996341|FG013|Maintenance Period (Week 16 to Week 48)|Non-compliance|0
6284375|NCT02326272|9996342|FG014|Maintenance Period (Week 16 to Week 48)|Non-compliance|0
6284376|NCT02326272|9996328|FG000|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50|0
6284377|NCT02326272|9996329|FG001|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50|0
6284378|NCT02326272|9996330|FG002|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50|0
6284379|NCT02326272|9996331|FG003|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50|0
6284380|NCT02326272|9996332|FG004|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50|0
6284381|NCT02326272|9996333|FG005|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50|2
6284382|NCT02326272|9996334|FG006|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50|1
5980476|NCT02820753|9569295|FG001|6 Month|Lost to Follow-up|27
5980477|NCT02820753|9569294|FG000|6 Month|Stopped per NIH Hold|81
5980478|NCT02820753|9569295|FG001|6 Month|Stopped per NIH Hold|81
5980479|NCT02820753|9569294|FG000|6 Month|Death|0
5980480|NCT02820753|9569295|FG001|6 Month|Death|1
5980481|NCT02733042|9569320|FG000|Treatment Period|Adverse Event|1
5980482|NCT02733042|9569321|FG001|Treatment Period|Adverse Event|0
5980483|NCT02733042|9569322|FG002|Treatment Period|Adverse Event|1
5980484|NCT02733042|9569323|FG003|Treatment Period|Adverse Event|1
5980485|NCT02733042|9569324|FG004|Treatment Period|Adverse Event|0
5980486|NCT02733042|9569325|FG005|Treatment Period|Adverse Event|0
5980487|NCT02733042|9569326|FG006|Treatment Period|Adverse Event|0
5980488|NCT02733042|9569327|FG007|Treatment Period|Adverse Event|0
5980489|NCT02733042|9569328|FG008|Treatment Period|Adverse Event|0
6062118|NCT00495586|9663015|FG001|Overall Study|Withdrawal by Subject|4
6062119|NCT00495612|9663025|FG000|Overall Study|Lost to Follow-up|1
6062120|NCT00495612|9663026|FG001|Overall Study|Lost to Follow-up|0
6062121|NCT00495612|9663025|FG000|Overall Study|Subject's Decision to Withdraw|3
6062122|NCT00495612|9663026|FG001|Overall Study|Subject's Decision to Withdraw|0
6062123|NCT00495625|9663032|FG000|Overall Study|Did not complete at least 1 42 day cycle|10
6062124|NCT00495677|9663043|FG000|Stage 1 (25 Days)|Adverse Event|0
6062125|NCT00495677|9663044|FG001|Stage 1 (25 Days)|Adverse Event|0
6062126|NCT00495677|9663045|FG002|Stage 1 (25 Days)|Adverse Event|1
6062127|NCT00495677|9663046|FG003|Stage 1 (25 Days)|Adverse Event|0
6062128|NCT00495677|9663047|FG004|Stage 1 (25 Days)|Adverse Event|0
6062129|NCT00495677|9663048|FG005|Stage 1 (25 Days)|Adverse Event|0
6062130|NCT00495677|9663049|FG006|Stage 1 (25 Days)|Adverse Event|0
6062131|NCT00495755|9663065|FG000|Overall Study|Adverse Event|3
6062132|NCT00495794|9663072|FG000|Overall Study|Pharmacist did not activate patient|522
6062133|NCT00495794|9663073|FG001|Overall Study|Pharmacist did not activate patient|0
6062134|NCT00495820|9663081|FG000|Overall Study|Adverse Event|1
6095620|NCT00723957|9709573|FG001|Overall Study|Never received treatment|3
6095621|NCT00724061|9709583|FG000|Dose Escalation Phase|Adverse Event|2
6095622|NCT00724061|9709583|FG000|Dose Escalation Phase|Disease Progression|3
6095623|NCT00724126|9709589|FG000|Overall Study|Adverse Event|2
6095624|NCT00724126|9709590|FG001|Overall Study|Adverse Event|0
6095625|NCT00724126|9709589|FG000|Overall Study|Withdrawal by Subject|8
6095626|NCT00724126|9709590|FG001|Overall Study|Withdrawal by Subject|6
6095627|NCT00724126|9709589|FG000|Overall Study|Lost to Follow-up|6
6095628|NCT00724126|9709590|FG001|Overall Study|Lost to Follow-up|6
6095629|NCT00724126|9709589|FG000|Overall Study|Noncompliance|2
6095630|NCT00724126|9709590|FG001|Overall Study|Noncompliance|1
6095631|NCT00724126|9709589|FG000|Overall Study|Subject randomized although ineligible|1
6095632|NCT00724126|9709590|FG001|Overall Study|Subject randomized although ineligible|1
6095633|NCT00724126|9709589|FG000|Overall Study|Subject had to leave vicinity of site|0
6095634|NCT00724126|9709590|FG001|Overall Study|Subject had to leave vicinity of site|1
6095635|NCT00724152|9709601|FG000|Two-arm Study Period|Withdrawal by Subject|3
6095636|NCT00724152|9709602|FG001|Two-arm Study Period|Withdrawal by Subject|2
6095637|NCT00724152|9709603|FG002|Two-arm Study Period|Withdrawal by Subject|0
6095638|NCT00724152|9709601|FG000|Three-arm Study Period (+Standard Care)|Withdrawal by Subject|1
6095639|NCT00724152|9709602|FG001|Three-arm Study Period (+Standard Care)|Withdrawal by Subject|2
6095640|NCT00724152|9709603|FG002|Three-arm Study Period (+Standard Care)|Withdrawal by Subject|1
6095641|NCT00724243|9709613|FG000|Overall Study|Lack of Efficacy|10
6095642|NCT00724243|9709613|FG000|Overall Study|Adverse Event|5
6095643|NCT00724373|9709630|FG000|Overall Study|Adverse Event|41
6095644|NCT00724373|9709630|FG000|Overall Study|Lack of Efficacy|82
6095645|NCT00724373|9709630|FG000|Overall Study|Lost to Follow-up|7
6095646|NCT00724373|9709630|FG000|Overall Study|Non-compliance|2
6095647|NCT00724373|9709630|FG000|Overall Study|HCV RNA negative after 4 weeks|9
6095648|NCT00724373|9709630|FG000|Overall Study|Participant moved away|1
6095649|NCT00724373|9709630|FG000|Overall Study|Responder at 12 weeks, PCR + at 24 weeks|2
6095650|NCT00724373|9709630|FG000|Overall Study|Only to have 24 week regimen|1
6095651|NCT00724373|9709630|FG000|Overall Study|Viral Relapse|1
6095652|NCT00724373|9709630|FG000|Overall Study|Acute HCV infection|1
6095653|NCT00724373|9709630|FG000|Overall Study|Drug Relapse|1
6095654|NCT00724373|9709630|FG000|Overall Study|Tolerability|23
6095655|NCT00724451|9709634|FG000|Overall Study|Excluded - Prior Use of Peginterferon|7
6095656|NCT00724451|9709634|FG000|Overall Study|Excluded - Hepatitis C Virus Negative|3
6095657|NCT00724451|9709634|FG000|Overall Study|Not Eligible for Treatment|431
6095658|NCT00724451|9709634|FG000|Overall Study|Participant Refused Treatment|89
6095659|NCT00724451|9709634|FG000|Overall Study|Never Started Treatment|89
6095660|NCT00724451|9709634|FG000|Overall Study|Unknown; No Data Sources Available|9
6095661|NCT00724451|9709634|FG000|Overall Study|Physician Decision|116
6095662|NCT00724451|9709634|FG000|Overall Study|Withdrawal by Subject|45
6095663|NCT00724451|9709634|FG000|Overall Study|Investigator + Participant Decision|13
6095664|NCT00724503|9709645|FG000|Overall Study|Lost to Follow-up|4
6095665|NCT00724503|9709646|FG001|Overall Study|Lost to Follow-up|8
6095666|NCT00724503|9709645|FG000|Overall Study|Withdrawal by Subject|11
6095667|NCT00724503|9709646|FG001|Overall Study|Withdrawal by Subject|23
6095668|NCT00724503|9709645|FG000|Overall Study|Death|190
6095669|NCT00724503|9709646|FG001|Overall Study|Death|182
6095670|NCT00724503|9709645|FG000|Overall Study|Adverse Event|1
6095671|NCT00724503|9709646|FG001|Overall Study|Adverse Event|0
6095672|NCT00724503|9709645|FG000|Overall Study|Not otherwise specified|4
6095673|NCT00724503|9709646|FG001|Overall Study|Not otherwise specified|7
6095674|NCT00724711|9709693|FG000|Overall Study|Adverse Event|7
6095675|NCT00724711|9709694|FG001|Overall Study|Adverse Event|3
6095676|NCT00724711|9709693|FG000|Overall Study|Pregnancy|0
6095677|NCT00724711|9709694|FG001|Overall Study|Pregnancy|1
6095678|NCT00724711|9709693|FG000|Overall Study|Lack of Efficacy|0
6095679|NCT00724711|9709694|FG001|Overall Study|Lack of Efficacy|1
6095680|NCT00724711|9709693|FG000|Overall Study|Physician Decision|0
6095681|NCT00724711|9709694|FG001|Overall Study|Physician Decision|3
6095682|NCT00724711|9709693|FG000|Overall Study|Withdrawal by Subject|5
6095683|NCT00724711|9709694|FG001|Overall Study|Withdrawal by Subject|4
6062135|NCT00495820|9663082|FG001|Overall Study|Adverse Event|1
6095684|NCT00724711|9709693|FG000|Overall Study|Lost to Follow-up|4
6095685|NCT00724711|9709694|FG001|Overall Study|Lost to Follow-up|5
6095686|NCT00724711|9709693|FG000|Overall Study|Protocol Violation|1
6095687|NCT00724711|9709694|FG001|Overall Study|Protocol Violation|0
6062136|NCT00496015|9663093|FG000|Overall Study|Other|1
6062137|NCT00496015|9663094|FG001|Overall Study|Other|0
6062138|NCT00496015|9663095|FG002|Overall Study|Other|0
6062139|NCT00496015|9663096|FG003|Overall Study|Other|1
6062140|NCT00496015|9663097|FG004|Overall Study|Other|0
6062141|NCT00496054|9663117|FG000|Overall Study|Adverse Event|1
6062142|NCT00496054|9663117|FG000|Overall Study|Lost to Follow-up|7
6062143|NCT00496080|9663121|FG000|Overall Study|Lost to Follow-up|9
6062144|NCT00496080|9663121|FG000|Overall Study|Surgical re-intervention|7
6062145|NCT00496080|9663121|FG000|Overall Study|Withdrawal by Subject|5
6062146|NCT00496080|9663121|FG000|Overall Study|Physician Decision|6
6062147|NCT00496197|9663126|FG000|Overall Study|Discontinued study due to death|43
6062148|NCT00496197|9663126|FG000|Overall Study|Adverse Event|13
6062149|NCT00496197|9663126|FG000|Overall Study|Does not meet entrance criteria|5
6062150|NCT00496197|9663126|FG000|Overall Study|Insufficient clinical response|3
6062151|NCT00496197|9663126|FG000|Overall Study|Insufficient bacteriological response|10
6062152|NCT00496197|9663126|FG000|Overall Study|Lost to Follow-up|11
6062153|NCT00496197|9663126|FG000|Overall Study|Withdrawal by Subject|11
6062154|NCT00496197|9663126|FG000|Overall Study|Pathogen not isolated baseline specimen|4
6062155|NCT00496197|9663126|FG000|Overall Study|Other|14
6062156|NCT00496197|9663126|FG000|Overall Study|Protocol Violation|8
6062157|NCT00496366|9663140|FG000|Overall Study|Death|1
6062158|NCT00496470|9663150|FG000|Overall Study|Adverse Event|8
6062159|NCT00496470|9663151|FG001|Overall Study|Adverse Event|10
6062160|NCT00496470|9663150|FG000|Overall Study|Withdrawal by Subject|5
6062161|NCT00496470|9663151|FG001|Overall Study|Withdrawal by Subject|12
6062162|NCT00496470|9663150|FG000|Overall Study|Incorrectly enrolled|13
6062163|NCT00496470|9663151|FG001|Overall Study|Incorrectly enrolled|5
6062164|NCT00496470|9663150|FG000|Overall Study|Other reason|0
6062165|NCT00496470|9663151|FG001|Overall Study|Other reason|2
6062166|NCT00496483|9663157|FG000|Overall Study|Not dosed|9
6062167|NCT00496483|9663157|FG000|Overall Study|Adverse Event|2
6062168|NCT00496483|9663157|FG000|Overall Study|Lack of Efficacy|1
6062169|NCT00496587|9663164|FG000|Overall Study|Adverse Event|2
6062170|NCT00496587|9663164|FG000|Overall Study|Progressive Disease|24
6062171|NCT00496587|9663164|FG000|Overall Study|Withdrawal by Subject|2
6062172|NCT00496587|9663164|FG000|Overall Study|Death|1
6062173|NCT00496587|9663164|FG000|Overall Study|Complications unrelated|2
6095688|NCT00724815|9709711|FG000|Overall Study|Randomized, not treated|31
6095689|NCT00724815|9709712|FG001|Overall Study|Randomized, not treated|30
6095690|NCT00724815|9709711|FG000|Overall Study|Adverse Event|5
6095691|NCT00724815|9709712|FG001|Overall Study|Adverse Event|3
6095692|NCT00724815|9709711|FG000|Overall Study|Lost to Follow-up|4
6095693|NCT00724815|9709712|FG001|Overall Study|Lost to Follow-up|1
6095694|NCT00724815|9709711|FG000|Overall Study|Other Various|3
6095695|NCT00724815|9709712|FG001|Overall Study|Other Various|5
6095696|NCT00724854|9709720|FG000|Overall Study|Lack of Efficacy|187
6095697|NCT00724854|9709721|FG001|Overall Study|Lack of Efficacy|13
6095698|NCT00724854|9709720|FG000|Overall Study|Lost to Follow-up|87
6095699|NCT00724854|9709721|FG001|Overall Study|Lost to Follow-up|10
6095700|NCT00724854|9709720|FG000|Overall Study|Adverse Event|62
6095701|NCT00724854|9709721|FG001|Overall Study|Adverse Event|4
6095702|NCT00724854|9709720|FG000|Overall Study|Other|42
6095703|NCT00724854|9709721|FG001|Overall Study|Other|3
6095704|NCT00724854|9709720|FG000|Overall Study|Death|11
6095705|NCT00724854|9709721|FG001|Overall Study|Death|0
6095706|NCT00724854|9709720|FG000|Overall Study|Change of treatment|7
6095707|NCT00724854|9709721|FG001|Overall Study|Change of treatment|0
6095708|NCT00724854|9709720|FG000|Overall Study|Withdrawal by Subject|5
6095709|NCT00724854|9709721|FG001|Overall Study|Withdrawal by Subject|0
6095710|NCT00724854|9709720|FG000|Overall Study|Adverse event + lack of efficacy|2
6095711|NCT00724854|9709721|FG001|Overall Study|Adverse event + lack of efficacy|1
6095712|NCT00724867|9709728|FG000|Overall Study|Adverse Event|25
6095713|NCT00724867|9709728|FG000|Overall Study|Lack of Efficacy|14
6095714|NCT00724867|9709728|FG000|Overall Study|Lost to Follow-up|12
6095715|NCT00724867|9709728|FG000|Overall Study|Non-compliance with study drug|6
6095716|NCT00724867|9709728|FG000|Overall Study|Physician Decision|17
6095717|NCT00724867|9709728|FG000|Overall Study|Protocol Violation|1
6095718|NCT00724867|9709728|FG000|Overall Study|Withdrawal by Subject|31
6095719|NCT00724867|9709728|FG000|Overall Study|Sponsor decision to end study|14
6095720|NCT00724867|9709728|FG000|Overall Study|Subject incarcerated|1
6095721|NCT00724867|9709728|FG000|Overall Study|Developed withdrawal criteria- pregnancy|4
6062174|NCT00496626|9663170|FG000|Overall Study|Lost to Follow-up|0
6062175|NCT00496626|9663171|FG001|Overall Study|Lost to Follow-up|1
6062176|NCT00496626|9663170|FG000|Overall Study|Protocol Violation|1
6062177|NCT00496626|9663171|FG001|Overall Study|Protocol Violation|0
6095722|NCT00724867|9709728|FG000|Overall Study|Subject moved out of state|1
6095723|NCT00724867|9709728|FG000|Overall Study|Elected to exit due to site closure|2
6095724|NCT00724893|9709737|FG000|Overall Study|Adverse Event|76
6095725|NCT00724893|9709738|FG001|Overall Study|Adverse Event|142
6095726|NCT00724893|9709737|FG000|Overall Study|Withdrawal by Subject|0
6095727|NCT00724893|9709738|FG001|Overall Study|Withdrawal by Subject|1
6062178|NCT00496626|9663170|FG000|Overall Study|Withdrawal by Subject|5
6062179|NCT00496626|9663171|FG001|Overall Study|Withdrawal by Subject|4
6095728|NCT00724893|9709737|FG000|Overall Study|Lack of virologic response|94
6062180|NCT00496626|9663170|FG000|Overall Study|Relocated|0
6062181|NCT00496626|9663171|FG001|Overall Study|Relocated|1
6062182|NCT00496769|9663183|FG000|Double Blind|>=1 reason assigned per patient|558
6062183|NCT00496769|9663184|FG001|Double Blind|>=1 reason assigned per patient|649
6062184|NCT00496769|9663185|FG002|Double Blind|>=1 reason assigned per patient|0
6062185|NCT00496769|9663183|FG000|Open Label|>=1 reason assigned per patient|0
6062186|NCT00496769|9663184|FG001|Open Label|>=1 reason assigned per patient|0
6062187|NCT00496769|9663185|FG002|Open Label|>=1 reason assigned per patient|1011
6062188|NCT00496873|9663211|FG000|Overall Study|Ineligible|2
6062189|NCT00496873|9663211|FG000|Overall Study|Death|2
6062190|NCT00496873|9663211|FG000|Overall Study|Withdrawal by Subject|3
6062191|NCT00496964|9663217|FG000|Overall Study|Withdrawal by Subject|0
6062192|NCT00496964|9663218|FG001|Overall Study|Withdrawal by Subject|1
6062193|NCT00497146|9663246|FG000|Treatment Period|Adverse Event|6
6062194|NCT00497146|9663247|FG001|Treatment Period|Adverse Event|2
6062195|NCT00497146|9663246|FG000|Treatment Period|Withdrawal by Subject|5
6062196|NCT00497146|9663247|FG001|Treatment Period|Withdrawal by Subject|9
6062197|NCT00497146|9663246|FG000|Treatment Period|Lost to Follow-up|1
6062198|NCT00497146|9663247|FG001|Treatment Period|Lost to Follow-up|3
6062199|NCT00497146|9663246|FG000|Treatment Period|Required dialysis|4
6062200|NCT00497146|9663247|FG001|Treatment Period|Required dialysis|1
6062201|NCT00497146|9663246|FG000|Treatment Period|Change in RAAS inhibitor therapy|5
6062202|NCT00497146|9663247|FG001|Treatment Period|Change in RAAS inhibitor therapy|2
6095729|NCT00724893|9709738|FG001|Overall Study|Lack of virologic response|202
6095730|NCT00724893|9709737|FG000|Overall Study|Reason not specified|193
6095731|NCT00724893|9709738|FG001|Overall Study|Reason not specified|7
6095732|NCT00724893|9709737|FG000|Overall Study|Patient choice|0
6095733|NCT00724893|9709738|FG001|Overall Study|Patient choice|26
6095734|NCT00724893|9709737|FG000|Overall Study|Geographic reasons|0
6095735|NCT00724893|9709738|FG001|Overall Study|Geographic reasons|11
6095736|NCT00724893|9709737|FG000|Overall Study|Incarceration|0
6095737|NCT00724893|9709738|FG001|Overall Study|Incarceration|9
6095738|NCT00724893|9709737|FG000|Overall Study|Substance abuse|0
6095739|NCT00724893|9709738|FG001|Overall Study|Substance abuse|3
6095740|NCT00724893|9709737|FG000|Overall Study|Financial reasons|0
6095741|NCT00724893|9709738|FG001|Overall Study|Financial reasons|2
6203193|NCT01513148|9864186|FG000|Overall Study|Protocol Violation|2
6284383|NCT02326272|9996335|FG007|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50|1
6284384|NCT02326272|9996336|FG008|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50|2
6284385|NCT02326272|9996337|FG009|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50|0
6284386|NCT02326272|9996338|FG010|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50|0
6284387|NCT02326272|9996339|FG011|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50|0
6284388|NCT02326272|9996340|FG012|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50|0
6284389|NCT02326272|9996341|FG013|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50|0
6284390|NCT02326272|9996342|FG014|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50|0
6284391|NCT02326272|9996328|FG000|Maintenance Period (Week 16 to Week 48)|Adverse event after completing wk48|0
6284392|NCT02326272|9996329|FG001|Maintenance Period (Week 16 to Week 48)|Adverse event after completing wk48|0
6284393|NCT02326272|9996330|FG002|Maintenance Period (Week 16 to Week 48)|Adverse event after completing wk48|0
6284394|NCT02326272|9996331|FG003|Maintenance Period (Week 16 to Week 48)|Adverse event after completing wk48|0
6284395|NCT02326272|9996332|FG004|Maintenance Period (Week 16 to Week 48)|Adverse event after completing wk48|0
6284396|NCT02326272|9996333|FG005|Maintenance Period (Week 16 to Week 48)|Adverse event after completing wk48|1
6284397|NCT02326272|9996334|FG006|Maintenance Period (Week 16 to Week 48)|Adverse event after completing wk48|0
6284398|NCT02326272|9996335|FG007|Maintenance Period (Week 16 to Week 48)|Adverse event after completing wk48|0
6284399|NCT02326272|9996336|FG008|Maintenance Period (Week 16 to Week 48)|Adverse event after completing wk48|0
6284400|NCT02326272|9996337|FG009|Maintenance Period (Week 16 to Week 48)|Adverse event after completing wk48|0
6284401|NCT02326272|9996338|FG010|Maintenance Period (Week 16 to Week 48)|Adverse event after completing wk48|0
6284402|NCT02326272|9996339|FG011|Maintenance Period (Week 16 to Week 48)|Adverse event after completing wk48|0
6284403|NCT02326272|9996340|FG012|Maintenance Period (Week 16 to Week 48)|Adverse event after completing wk48|0
6284404|NCT02326272|9996341|FG013|Maintenance Period (Week 16 to Week 48)|Adverse event after completing wk48|0
6284405|NCT02326272|9996342|FG014|Maintenance Period (Week 16 to Week 48)|Adverse event after completing wk48|0
6284406|NCT02326272|9996328|FG000|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50 after wk48|0
6284407|NCT02326272|9996329|FG001|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50 after wk48|0
6284408|NCT02326272|9996330|FG002|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50 after wk48|0
6284409|NCT02326272|9996331|FG003|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50 after wk48|0
6284410|NCT02326272|9996332|FG004|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50 after wk48|0
6284411|NCT02326272|9996333|FG005|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50 after wk48|0
6284412|NCT02326272|9996334|FG006|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50 after wk48|1
6062203|NCT00497146|9663246|FG000|Treatment Period|Unable to dose reduce per protocol|4
6062204|NCT00497146|9663247|FG001|Treatment Period|Unable to dose reduce per protocol|1
6062205|NCT00497146|9663246|FG000|Treatment Period|Other Reason|2
6062206|NCT00497146|9663247|FG001|Treatment Period|Other Reason|3
6062207|NCT00497146|9663246|FG000|Long-term Follow-up Period|Adverse Event|2
6095742|NCT00724893|9709737|FG000|Overall Study|Assigned shorter treatment|0
6062208|NCT00497146|9663247|FG001|Long-term Follow-up Period|Adverse Event|2
6062209|NCT00497146|9663246|FG000|Long-term Follow-up Period|Withdrawal by Subject|8
6062210|NCT00497146|9663247|FG001|Long-term Follow-up Period|Withdrawal by Subject|2
6062211|NCT00497146|9663246|FG000|Long-term Follow-up Period|Lost to Follow-up|5
6062212|NCT00497146|9663247|FG001|Long-term Follow-up Period|Lost to Follow-up|1
6062213|NCT00497146|9663246|FG000|Long-term Follow-up Period|Other|0
6062214|NCT00497146|9663247|FG001|Long-term Follow-up Period|Other|1
6062215|NCT00497198|9663257|FG000|Overall Study|Adverse Event|4
6062216|NCT00497198|9663258|FG001|Overall Study|Adverse Event|2
6062217|NCT00497198|9663257|FG000|Overall Study|Physician Decision|1
6062218|NCT00497198|9663258|FG001|Overall Study|Physician Decision|2
6062219|NCT00497198|9663257|FG000|Overall Study|Withdrawal by Subject|0
6062220|NCT00497198|9663258|FG001|Overall Study|Withdrawal by Subject|1
6062221|NCT00497796|9663295|FG000|Overall Study|Adverse event (not related)|9
6062222|NCT00497796|9663296|FG001|Overall Study|Adverse event (not related)|9
6062223|NCT00497796|9663295|FG000|Overall Study|Adverse event (related)|5
6062224|NCT00497796|9663296|FG001|Overall Study|Adverse event (related)|4
6062225|NCT00497796|9663295|FG000|Overall Study|CMV infection or disease treatment|30
6062226|NCT00497796|9663296|FG001|Overall Study|CMV infection or disease treatment|4
6062227|NCT00497796|9663295|FG000|Overall Study|Consent withdrawn|10
6062228|NCT00497796|9663296|FG001|Overall Study|Consent withdrawn|3
6062229|NCT00497796|9663295|FG000|Overall Study|Investigator/sponsor discretion|31
6062230|NCT00497796|9663296|FG001|Overall Study|Investigator/sponsor discretion|34
6062231|NCT00497796|9663295|FG000|Overall Study|Lost to Follow-up|0
6062232|NCT00497796|9663296|FG001|Overall Study|Lost to Follow-up|1
6062233|NCT00497796|9663295|FG000|Overall Study|Not applicable (randomized not treated)|0
6062234|NCT00497796|9663296|FG001|Overall Study|Not applicable (randomized not treated)|4
6062235|NCT00497874|9663304|FG000|Overall Study|Withdrawal by Subject|48
6062236|NCT00497874|9663305|FG001|Overall Study|Withdrawal by Subject|17
6062237|NCT00497874|9663304|FG000|Overall Study|Illness|8
6062238|NCT00497874|9663305|FG001|Overall Study|Illness|4
6062239|NCT00497874|9663304|FG000|Overall Study|Death|2
6062240|NCT00497874|9663305|FG001|Overall Study|Death|4
6062241|NCT00497874|9663304|FG000|Overall Study|Unable to contact|52
6062242|NCT00497874|9663305|FG001|Overall Study|Unable to contact|67
6062243|NCT00497874|9663304|FG000|Overall Study|Unable to schedule|37
6062244|NCT00497874|9663305|FG001|Overall Study|Unable to schedule|24
6062245|NCT00498173|9663315|FG000|Phase 1-Blinded Randomization (8 Weeks)|no post-baseline ratings|2
6062246|NCT00498173|9663316|FG001|Phase 1-Blinded Randomization (8 Weeks)|no post-baseline ratings|1
6062247|NCT00498173|9663317|FG002|Phase 1-Blinded Randomization (8 Weeks)|no post-baseline ratings|0
6062248|NCT00498186|9663325|FG000|Overall Study|Protocol Violation|10
6062249|NCT00498186|9663325|FG000|Overall Study|Lack of Efficacy|31
6062250|NCT00498186|9663325|FG000|Overall Study|Adverse Event|89
6062251|NCT00498186|9663325|FG000|Overall Study|Unsatisfactory compliance of subject|12
6062252|NCT00498186|9663325|FG000|Overall Study|Withdrawal by Subject|18
6062253|NCT00498186|9663325|FG000|Overall Study|Lost to Follow-up|3
6062254|NCT00498186|9663325|FG000|Overall Study|Other|10
6062255|NCT00498355|9663329|FG000|Overall Study|Lost to Follow-up|1
6062256|NCT00498368|9663336|FG000|Overall Study|Withdrawal by Subject|3
6095743|NCT00724893|9709738|FG001|Overall Study|Assigned shorter treatment|2
6095744|NCT00724893|9709737|FG000|Overall Study|Lost to Follow-up|0
6062257|NCT00498368|9663337|FG001|Overall Study|Withdrawal by Subject|2
6062258|NCT00498433|9663346|FG000|Part 2: Placebo Run-in (2 Weeks)|Adverse Event|2
6062259|NCT00498433|9663347|FG001|Part 2: Placebo Run-in (2 Weeks)|Adverse Event|0
6095745|NCT00724893|9709738|FG001|Overall Study|Lost to Follow-up|52
6095746|NCT00724893|9709737|FG000|Overall Study|Unknown, missing data|1
6095747|NCT00724893|9709738|FG001|Overall Study|Unknown, missing data|1
6095748|NCT00724932|9709761|FG000|Overall Study|Lost to Follow-up|1
6095749|NCT00724932|9709762|FG001|Overall Study|Lost to Follow-up|0
6095750|NCT00724932|9709761|FG000|Overall Study|Not treated|4
6095751|NCT00724932|9709762|FG001|Overall Study|Not treated|3
6095752|NCT00724945|9709770|FG000|Period 1|non-compliance|1
6095753|NCT00724945|9709771|FG001|Period 1|non-compliance|0
6095754|NCT00724945|9709770|FG000|Period 1|Adverse Event|1
6095755|NCT00724945|9709771|FG001|Period 1|Adverse Event|1
6095756|NCT00724945|9709770|FG000|Period 1|Lost to Follow-up|1
6095757|NCT00724945|9709771|FG001|Period 1|Lost to Follow-up|0
6203194|NCT01513148|9864187|FG001|Overall Study|Protocol Violation|2
6062260|NCT00498433|9663348|FG002|Part 2: Placebo Run-in (2 Weeks)|Adverse Event|0
6062261|NCT00498433|9663346|FG000|Part 2: Placebo Run-in (2 Weeks)|Abnormal laboratory value|2
6062262|NCT00498433|9663347|FG001|Part 2: Placebo Run-in (2 Weeks)|Abnormal laboratory value|0
6062263|NCT00498433|9663348|FG002|Part 2: Placebo Run-in (2 Weeks)|Abnormal laboratory value|0
6062264|NCT00498433|9663346|FG000|Part 2: Placebo Run-in (2 Weeks)|Abnormal test procedure|15
6062265|NCT00498433|9663347|FG001|Part 2: Placebo Run-in (2 Weeks)|Abnormal test procedure|0
6095758|NCT00724945|9709770|FG000|Period 2|lens comfort issue|3
6095759|NCT00724945|9709771|FG001|Period 2|lens comfort issue|0
6095760|NCT00724945|9709770|FG000|Period 2|lens physiology issue|1
6095761|NCT00724945|9709771|FG001|Period 2|lens physiology issue|0
6095762|NCT00724958|9709777|FG000|Overall Study|Adverse Event|28
6095763|NCT00724958|9709777|FG000|Overall Study|Loss of Response|40
6095764|NCT00724958|9709777|FG000|Overall Study|No Response|18
6095765|NCT00724958|9709777|FG000|Overall Study|Remission|7
6284413|NCT02326272|9996335|FG007|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50 after wk48|0
6284414|NCT02326272|9996336|FG008|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50 after wk48|0
6284415|NCT02326272|9996337|FG009|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50 after wk48|0
6284416|NCT02326272|9996338|FG010|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50 after wk48|0
6284417|NCT02326272|9996339|FG011|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50 after wk48|0
6284418|NCT02326272|9996340|FG012|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50 after wk48|0
6284419|NCT02326272|9996341|FG013|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50 after wk48|0
6284420|NCT02326272|9996342|FG014|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50 after wk48|0
6284421|NCT02326272|9996328|FG000|Open-label Period (Week 48 to Week 144)|Death|0
6284422|NCT02326272|9996329|FG001|Open-label Period (Week 48 to Week 144)|Death|0
6284423|NCT02326272|9996330|FG002|Open-label Period (Week 48 to Week 144)|Death|0
6284424|NCT02326272|9996331|FG003|Open-label Period (Week 48 to Week 144)|Death|0
6284425|NCT02326272|9996332|FG004|Open-label Period (Week 48 to Week 144)|Death|0
6284426|NCT02326272|9996333|FG005|Open-label Period (Week 48 to Week 144)|Death|0
6284427|NCT02326272|9996334|FG006|Open-label Period (Week 48 to Week 144)|Death|0
6284428|NCT02326272|9996335|FG007|Open-label Period (Week 48 to Week 144)|Death|0
6284429|NCT02326272|9996336|FG008|Open-label Period (Week 48 to Week 144)|Death|0
6284430|NCT02326272|9996337|FG009|Open-label Period (Week 48 to Week 144)|Death|0
6284431|NCT02326272|9996338|FG010|Open-label Period (Week 48 to Week 144)|Death|0
6284432|NCT02326272|9996339|FG011|Open-label Period (Week 48 to Week 144)|Death|0
6284433|NCT02326272|9996340|FG012|Open-label Period (Week 48 to Week 144)|Death|1
6284434|NCT02326272|9996341|FG013|Open-label Period (Week 48 to Week 144)|Death|0
6284435|NCT02326272|9996342|FG014|Open-label Period (Week 48 to Week 144)|Death|0
6284436|NCT02326272|9996328|FG000|Open-label Period (Week 48 to Week 144)|Adverse Event|0
6284437|NCT02326272|9996329|FG001|Open-label Period (Week 48 to Week 144)|Adverse Event|0
6284438|NCT02326272|9996330|FG002|Open-label Period (Week 48 to Week 144)|Adverse Event|0
6284439|NCT02326272|9996331|FG003|Open-label Period (Week 48 to Week 144)|Adverse Event|0
6284440|NCT02326272|9996332|FG004|Open-label Period (Week 48 to Week 144)|Adverse Event|0
6284441|NCT02326272|9996333|FG005|Open-label Period (Week 48 to Week 144)|Adverse Event|0
6284442|NCT02326272|9996334|FG006|Open-label Period (Week 48 to Week 144)|Adverse Event|0
6284443|NCT02326272|9996335|FG007|Open-label Period (Week 48 to Week 144)|Adverse Event|0
6284444|NCT02326272|9996336|FG008|Open-label Period (Week 48 to Week 144)|Adverse Event|0
6284445|NCT02326272|9996337|FG009|Open-label Period (Week 48 to Week 144)|Adverse Event|0
6284446|NCT02326272|9996338|FG010|Open-label Period (Week 48 to Week 144)|Adverse Event|1
6284447|NCT02326272|9996339|FG011|Open-label Period (Week 48 to Week 144)|Adverse Event|8
6284448|NCT02326272|9996340|FG012|Open-label Period (Week 48 to Week 144)|Adverse Event|3
6284449|NCT02326272|9996341|FG013|Open-label Period (Week 48 to Week 144)|Adverse Event|0
6284450|NCT02326272|9996342|FG014|Open-label Period (Week 48 to Week 144)|Adverse Event|1
6095766|NCT00724958|9709777|FG000|Overall Study|Other Reason|76
6095767|NCT00724958|9709777|FG000|Overall Study|No documentation for end of therapy|13
6095768|NCT00724971|9709781|FG000|Overall Study|Adverse Event|5
6095769|NCT00724971|9709781|FG000|Overall Study|Withdrawal by Subject|1
6095770|NCT00725010|9709810|FG000|Overall Study|Toxicity|9
6095771|NCT00725010|9709810|FG000|Overall Study|Tumor Progression|7
6095772|NCT00725010|9709810|FG000|Overall Study|Withdrawal by Subject|2
6095773|NCT00725010|9709810|FG000|Overall Study|Death|1
6095774|NCT00725010|9709810|FG000|Overall Study|Lost to Follow-up|1
6095775|NCT00725010|9709810|FG000|Overall Study|Hepatopathy probably not Temodal-related|1
6095776|NCT00725010|9709810|FG000|Overall Study|Suspect lymph nodes neck thorax abdomen|1
6095777|NCT00725010|9709810|FG000|Overall Study|No further documentation|1
6095778|NCT00725010|9709810|FG000|Overall Study|Intensified treatment scheme: 3 on 1 off|2
6095779|NCT00725075|9709819|FG000|Overall Study|Use of Excluded Medication|0
6095780|NCT00725075|9709820|FG001|Overall Study|Use of Excluded Medication|1
6095781|NCT00725075|9709821|FG002|Overall Study|Use of Excluded Medication|0
6095782|NCT00725075|9709819|FG000|Overall Study|Protocol Violation|0
6095783|NCT00725075|9709820|FG001|Overall Study|Protocol Violation|0
6095784|NCT00725075|9709821|FG002|Overall Study|Protocol Violation|1
6095785|NCT00725075|9709819|FG000|Overall Study|Lost to Follow-up|1
6095786|NCT00725075|9709820|FG001|Overall Study|Lost to Follow-up|0
6095787|NCT00725075|9709821|FG002|Overall Study|Lost to Follow-up|0
6095788|NCT00725075|9709819|FG000|Overall Study|Withdrawal by Subject|4
6095789|NCT00725075|9709820|FG001|Overall Study|Withdrawal by Subject|5
6095790|NCT00725075|9709821|FG002|Overall Study|Withdrawal by Subject|4
6095791|NCT00725075|9709819|FG000|Overall Study|Adverse Event|2
6095792|NCT00725075|9709820|FG001|Overall Study|Adverse Event|1
6095793|NCT00725075|9709821|FG002|Overall Study|Adverse Event|1
6095794|NCT00725075|9709819|FG000|Overall Study|Worsening of Disease|2
6095795|NCT00725075|9709820|FG001|Overall Study|Worsening of Disease|1
6095796|NCT00725075|9709821|FG002|Overall Study|Worsening of Disease|2
6095797|NCT00725075|9709819|FG000|Overall Study|Inclusion/Exclusion Criteria|1
6095798|NCT00725075|9709820|FG001|Overall Study|Inclusion/Exclusion Criteria|0
6095799|NCT00725075|9709821|FG002|Overall Study|Inclusion/Exclusion Criteria|1
6095800|NCT00725075|9709819|FG000|Overall Study|Other|1
6095801|NCT00725075|9709820|FG001|Overall Study|Other|0
6095802|NCT00725075|9709821|FG002|Overall Study|Other|0
6095803|NCT00725101|9709829|FG000|Overall Study|Death|3
6284451|NCT02326272|9996328|FG000|Open-label Period (Week 48 to Week 144)|Lack of Efficacy|0
6284452|NCT02326272|9996329|FG001|Open-label Period (Week 48 to Week 144)|Lack of Efficacy|0
6284453|NCT02326272|9996330|FG002|Open-label Period (Week 48 to Week 144)|Lack of Efficacy|0
6284454|NCT02326272|9996331|FG003|Open-label Period (Week 48 to Week 144)|Lack of Efficacy|0
6284455|NCT02326272|9996332|FG004|Open-label Period (Week 48 to Week 144)|Lack of Efficacy|0
6284456|NCT02326272|9996333|FG005|Open-label Period (Week 48 to Week 144)|Lack of Efficacy|0
6284457|NCT02326272|9996334|FG006|Open-label Period (Week 48 to Week 144)|Lack of Efficacy|0
6284458|NCT02326272|9996335|FG007|Open-label Period (Week 48 to Week 144)|Lack of Efficacy|0
6284459|NCT02326272|9996336|FG008|Open-label Period (Week 48 to Week 144)|Lack of Efficacy|0
6284460|NCT02326272|9996337|FG009|Open-label Period (Week 48 to Week 144)|Lack of Efficacy|0
6284461|NCT02326272|9996338|FG010|Open-label Period (Week 48 to Week 144)|Lack of Efficacy|1
6284462|NCT02326272|9996339|FG011|Open-label Period (Week 48 to Week 144)|Lack of Efficacy|0
6284463|NCT02326272|9996340|FG012|Open-label Period (Week 48 to Week 144)|Lack of Efficacy|1
6284464|NCT02326272|9996341|FG013|Open-label Period (Week 48 to Week 144)|Lack of Efficacy|0
6284465|NCT02326272|9996342|FG014|Open-label Period (Week 48 to Week 144)|Lack of Efficacy|0
6284466|NCT02326272|9996328|FG000|Open-label Period (Week 48 to Week 144)|Protocol Violation|0
6284467|NCT02326272|9996329|FG001|Open-label Period (Week 48 to Week 144)|Protocol Violation|0
6284468|NCT02326272|9996330|FG002|Open-label Period (Week 48 to Week 144)|Protocol Violation|0
6284469|NCT02326272|9996331|FG003|Open-label Period (Week 48 to Week 144)|Protocol Violation|0
6284470|NCT02326272|9996332|FG004|Open-label Period (Week 48 to Week 144)|Protocol Violation|0
6284471|NCT02326272|9996333|FG005|Open-label Period (Week 48 to Week 144)|Protocol Violation|0
6284472|NCT02326272|9996334|FG006|Open-label Period (Week 48 to Week 144)|Protocol Violation|0
6284473|NCT02326272|9996335|FG007|Open-label Period (Week 48 to Week 144)|Protocol Violation|0
6203195|NCT01513239|9864236|FG000|Period 1: Main Phase|Adverse Event|1
6203196|NCT01513239|9864237|FG001|Period 1: Main Phase|Adverse Event|1
6203197|NCT01513239|9864238|FG002|Period 1: Main Phase|Adverse Event|2
6203198|NCT01513239|9864239|FG003|Period 1: Main Phase|Adverse Event|0
6284474|NCT02326272|9996336|FG008|Open-label Period (Week 48 to Week 144)|Protocol Violation|0
6284475|NCT02326272|9996337|FG009|Open-label Period (Week 48 to Week 144)|Protocol Violation|0
6284476|NCT02326272|9996338|FG010|Open-label Period (Week 48 to Week 144)|Protocol Violation|0
6284477|NCT02326272|9996339|FG011|Open-label Period (Week 48 to Week 144)|Protocol Violation|1
6284478|NCT02326272|9996340|FG012|Open-label Period (Week 48 to Week 144)|Protocol Violation|0
6284479|NCT02326272|9996341|FG013|Open-label Period (Week 48 to Week 144)|Protocol Violation|0
6284480|NCT02326272|9996342|FG014|Open-label Period (Week 48 to Week 144)|Protocol Violation|0
6284481|NCT02326272|9996328|FG000|Open-label Period (Week 48 to Week 144)|Lost to Follow-up|0
6284482|NCT02326272|9996329|FG001|Open-label Period (Week 48 to Week 144)|Lost to Follow-up|0
6284483|NCT02326272|9996330|FG002|Open-label Period (Week 48 to Week 144)|Lost to Follow-up|0
6284484|NCT02326272|9996331|FG003|Open-label Period (Week 48 to Week 144)|Lost to Follow-up|0
6284485|NCT02326272|9996332|FG004|Open-label Period (Week 48 to Week 144)|Lost to Follow-up|0
6284486|NCT02326272|9996333|FG005|Open-label Period (Week 48 to Week 144)|Lost to Follow-up|0
6284487|NCT02326272|9996334|FG006|Open-label Period (Week 48 to Week 144)|Lost to Follow-up|0
6284488|NCT02326272|9996335|FG007|Open-label Period (Week 48 to Week 144)|Lost to Follow-up|0
6284489|NCT02326272|9996336|FG008|Open-label Period (Week 48 to Week 144)|Lost to Follow-up|0
6284490|NCT02326272|9996337|FG009|Open-label Period (Week 48 to Week 144)|Lost to Follow-up|0
6284491|NCT02326272|9996338|FG010|Open-label Period (Week 48 to Week 144)|Lost to Follow-up|1
6284492|NCT02326272|9996339|FG011|Open-label Period (Week 48 to Week 144)|Lost to Follow-up|0
6284493|NCT02326272|9996340|FG012|Open-label Period (Week 48 to Week 144)|Lost to Follow-up|2
6284494|NCT02326272|9996341|FG013|Open-label Period (Week 48 to Week 144)|Lost to Follow-up|0
6284495|NCT02326272|9996342|FG014|Open-label Period (Week 48 to Week 144)|Lost to Follow-up|3
6284496|NCT02326272|9996328|FG000|Open-label Period (Week 48 to Week 144)|Withdrawal by Subject|0
6284497|NCT02326272|9996329|FG001|Open-label Period (Week 48 to Week 144)|Withdrawal by Subject|0
6284498|NCT02326272|9996330|FG002|Open-label Period (Week 48 to Week 144)|Withdrawal by Subject|0
6284499|NCT02326272|9996331|FG003|Open-label Period (Week 48 to Week 144)|Withdrawal by Subject|0
6284500|NCT02326272|9996332|FG004|Open-label Period (Week 48 to Week 144)|Withdrawal by Subject|0
6062266|NCT00498433|9663348|FG002|Part 2: Placebo Run-in (2 Weeks)|Abnormal test procedure|0
6062267|NCT00498433|9663346|FG000|Part 2: Placebo Run-in (2 Weeks)|Administrative problems|1
6062268|NCT00498433|9663347|FG001|Part 2: Placebo Run-in (2 Weeks)|Administrative problems|0
6062269|NCT00498433|9663348|FG002|Part 2: Placebo Run-in (2 Weeks)|Administrative problems|0
6062270|NCT00498485|9663367|FG000|Overall Study|Adverse Event|1
6062271|NCT00498485|9663368|FG001|Overall Study|Adverse Event|5
6062272|NCT00498602|9663392|FG000|Overall Study|Death|0
6062273|NCT00498602|9663393|FG001|Overall Study|Death|0
6062274|NCT00498602|9663394|FG002|Overall Study|Death|0
6062275|NCT00498602|9663395|FG003|Overall Study|Death|0
6062276|NCT00498602|9663396|FG004|Overall Study|Death|0
6062277|NCT00498602|9663397|FG005|Overall Study|Death|1
6062278|NCT00498602|9663398|FG006|Overall Study|Death|0
6062279|NCT00498602|9663392|FG000|Overall Study|Lack of Efficacy|1
6062280|NCT00498602|9663393|FG001|Overall Study|Lack of Efficacy|0
6062281|NCT00498602|9663394|FG002|Overall Study|Lack of Efficacy|0
6062282|NCT00498602|9663395|FG003|Overall Study|Lack of Efficacy|0
6062283|NCT00498602|9663396|FG004|Overall Study|Lack of Efficacy|0
6062284|NCT00498602|9663397|FG005|Overall Study|Lack of Efficacy|0
6062285|NCT00498602|9663398|FG006|Overall Study|Lack of Efficacy|0
6062286|NCT00498602|9663392|FG000|Overall Study|Lost to Follow-up|0
6095804|NCT00725101|9709829|FG000|Overall Study|Lost to Follow-up|353
6095805|NCT00725101|9709829|FG000|Overall Study|Protocol Violation|1
6095806|NCT00725101|9709829|FG000|Overall Study|Withdrawal by Subject|127
6095807|NCT00725101|9709829|FG000|Overall Study|not specified/no reason given|11
6095808|NCT00725205|9709840|FG000|Overall Study|Adverse Event|22
6095809|NCT00725205|9709840|FG000|Overall Study|Investigator Discontinued|1
6095810|NCT00725205|9709840|FG000|Overall Study|Non-compliance With Protocol|14
6095811|NCT00725205|9709840|FG000|Overall Study|Other|8
6095812|NCT00725205|9709840|FG000|Overall Study|Protocol Defined Clinical Event|1
6095813|NCT00725205|9709840|FG000|Overall Study|Treatment Failure|41
6095814|NCT00725283|9709853|FG000|Overall Study|Missing Code|3
6095815|NCT00725283|9709853|FG000|Overall Study|Death|5
6095816|NCT00725283|9709853|FG000|Overall Study|Other|6
6095817|NCT00725283|9709853|FG000|Overall Study|Withdrawal by Subject|10
6095818|NCT00725296|9709857|FG000|Overall Study|Adverse Event|11
6095819|NCT00725296|9709857|FG000|Overall Study|Lack of Efficacy|7
6095820|NCT00725296|9709857|FG000|Overall Study|Withdrawal by Subject|3
6095821|NCT00725296|9709857|FG000|Overall Study|Non-Compliance|2
6095822|NCT00725296|9709857|FG000|Overall Study|Lost to Follow-up|1
6095823|NCT00725296|9709857|FG000|Overall Study|Other|38
6095824|NCT00725322|9709864|FG000|Washout (28 Days)|Withdrawal by Subject|2
6095825|NCT00725322|9709865|FG001|Washout (28 Days)|Withdrawal by Subject|0
6095826|NCT00725322|9709864|FG000|Washout (28 Days)|Protocol Violation|0
6095827|NCT00725322|9709865|FG001|Washout (28 Days)|Protocol Violation|1
6095828|NCT00725452|9709875|FG000|Overall Study|Adverse Event|3
6095829|NCT00725452|9709875|FG000|Overall Study|Lack of Efficacy|2
6095830|NCT00725452|9709875|FG000|Overall Study|Reason not specified|1
6095831|NCT00725452|9709875|FG000|Overall Study|Physician Decision|1
6095832|NCT00725452|9709875|FG000|Overall Study|Withdrawal by Subject|3
6095833|NCT00725452|9709875|FG000|Overall Study|Lost to Follow-up|1
6095834|NCT00725543|9709893|FG000|Overall Study|Adverse Event|10
6095835|NCT00725543|9709893|FG000|Overall Study|Lack of Efficacy|3
6095836|NCT00725543|9709893|FG000|Overall Study|Withdrawal by Subject|10
6095837|NCT00725543|9709893|FG000|Overall Study|Physician Decision|5
6095838|NCT00725543|9709893|FG000|Overall Study|Lost to Follow-up|4
6095839|NCT00725543|9709893|FG000|Overall Study|Non-compliance|2
6095840|NCT00725543|9709893|FG000|Overall Study|Other|119
6095841|NCT00725608|9709897|FG000|Overall Study|Lost to Follow-up|60
6062287|NCT00498602|9663393|FG001|Overall Study|Lost to Follow-up|2
6062288|NCT00498602|9663394|FG002|Overall Study|Lost to Follow-up|0
6062289|NCT00498602|9663395|FG003|Overall Study|Lost to Follow-up|2
6062290|NCT00498602|9663396|FG004|Overall Study|Lost to Follow-up|0
6062291|NCT00498602|9663397|FG005|Overall Study|Lost to Follow-up|0
6062292|NCT00498602|9663398|FG006|Overall Study|Lost to Follow-up|0
6062293|NCT00498602|9663392|FG000|Overall Study|Adverse Event (AE) related to Study Drug|1
6062294|NCT00498602|9663393|FG001|Overall Study|Adverse Event (AE) related to Study Drug|0
6062295|NCT00498602|9663394|FG002|Overall Study|Adverse Event (AE) related to Study Drug|3
6062296|NCT00498602|9663395|FG003|Overall Study|Adverse Event (AE) related to Study Drug|2
6062297|NCT00498602|9663396|FG004|Overall Study|Adverse Event (AE) related to Study Drug|0
6062298|NCT00498602|9663397|FG005|Overall Study|Adverse Event (AE) related to Study Drug|1
6062299|NCT00498602|9663398|FG006|Overall Study|Adverse Event (AE) related to Study Drug|0
6062300|NCT00498602|9663392|FG000|Overall Study|AE not related to Study Drug|1
6062301|NCT00498602|9663393|FG001|Overall Study|AE not related to Study Drug|3
6062302|NCT00498602|9663394|FG002|Overall Study|AE not related to Study Drug|0
6062303|NCT00498602|9663395|FG003|Overall Study|AE not related to Study Drug|0
6062304|NCT00498602|9663396|FG004|Overall Study|AE not related to Study Drug|2
6062305|NCT00498602|9663397|FG005|Overall Study|AE not related to Study Drug|2
6062306|NCT00498602|9663398|FG006|Overall Study|AE not related to Study Drug|1
6062307|NCT00498602|9663392|FG000|Overall Study|Caregiver Request|2
6062308|NCT00498602|9663393|FG001|Overall Study|Caregiver Request|2
6062309|NCT00498602|9663394|FG002|Overall Study|Caregiver Request|2
6062310|NCT00498602|9663395|FG003|Overall Study|Caregiver Request|0
6062311|NCT00498602|9663396|FG004|Overall Study|Caregiver Request|1
6062312|NCT00498602|9663397|FG005|Overall Study|Caregiver Request|2
6062313|NCT00498602|9663398|FG006|Overall Study|Caregiver Request|0
6062314|NCT00498602|9663392|FG000|Overall Study|Investigator Request|0
6062315|NCT00498602|9663393|FG001|Overall Study|Investigator Request|0
6062316|NCT00498602|9663394|FG002|Overall Study|Investigator Request|1
6062317|NCT00498602|9663395|FG003|Overall Study|Investigator Request|0
6062318|NCT00498602|9663396|FG004|Overall Study|Investigator Request|0
6062319|NCT00498602|9663397|FG005|Overall Study|Investigator Request|0
6062320|NCT00498602|9663398|FG006|Overall Study|Investigator Request|0
6062321|NCT00498602|9663392|FG000|Overall Study|Subject Request|3
6062322|NCT00498602|9663393|FG001|Overall Study|Subject Request|0
6062323|NCT00498602|9663394|FG002|Overall Study|Subject Request|1
6062324|NCT00498602|9663395|FG003|Overall Study|Subject Request|1
6062325|NCT00498602|9663396|FG004|Overall Study|Subject Request|1
6062326|NCT00498602|9663397|FG005|Overall Study|Subject Request|4
6062327|NCT00498602|9663398|FG006|Overall Study|Subject Request|1
6062328|NCT00498602|9663392|FG000|Overall Study|Other|2
6062329|NCT00498602|9663393|FG001|Overall Study|Other|3
6062330|NCT00498602|9663394|FG002|Overall Study|Other|1
6062331|NCT00498602|9663395|FG003|Overall Study|Other|0
6062332|NCT00498602|9663396|FG004|Overall Study|Other|0
6062333|NCT00498602|9663397|FG005|Overall Study|Other|3
6062334|NCT00498602|9663398|FG006|Overall Study|Other|0
6062335|NCT00498797|9663457|FG000|Overall Study|Withdrawal by Subject|4
6062336|NCT00498797|9663458|FG001|Overall Study|Withdrawal by Subject|2
6062337|NCT00498797|9663457|FG000|Overall Study|Adverse Event|12
6062338|NCT00498797|9663458|FG001|Overall Study|Adverse Event|5
6062339|NCT00498797|9663457|FG000|Overall Study|Condition under investigation worsened|19
6062340|NCT00498797|9663458|FG001|Overall Study|Condition under investigation worsened|21
6062341|NCT00498797|9663457|FG000|Overall Study|Other|3
6062342|NCT00498797|9663458|FG001|Overall Study|Other|1
6062343|NCT00499031|9663477|FG000|Overall Study|Improper pre-protocol treatment|1
6062344|NCT00499031|9663477|FG000|Overall Study|Required test not done|1
6062345|NCT00499031|9663477|FG000|Overall Study|Never treated|1
6062346|NCT00499083|9663481|FG000|Overall Study|Not evaluable|3
6062347|NCT00499122|9663508|FG000|Overall Study|Withdrawal by Subject|2
6062348|NCT00499174|9663515|FG000|Overall Study|Physician Decision|78
6062349|NCT00499174|9663516|FG001|Overall Study|Physician Decision|9
6062350|NCT00499252|9663524|FG000|Overall Study|Adverse Event|3
6062351|NCT00499252|9663524|FG000|Overall Study|Refused further treatment|2
6062352|NCT00499252|9663524|FG000|Overall Study|Ineligible|4
6062353|NCT00499252|9663524|FG000|Overall Study|<no further label>|3
6062354|NCT00499369|9663546|FG000|Overall Study|Adverse Event|2
6062355|NCT00499369|9663547|FG001|Overall Study|Adverse Event|2
6062356|NCT00499369|9663548|FG002|Overall Study|Adverse Event|3
6062357|NCT00499369|9663549|FG003|Overall Study|Adverse Event|1
6062358|NCT00499369|9663550|FG004|Overall Study|Adverse Event|2
6062359|NCT00499369|9663546|FG000|Overall Study|Withdrawal by Subject|0
6062360|NCT00499369|9663547|FG001|Overall Study|Withdrawal by Subject|1
6062361|NCT00499369|9663548|FG002|Overall Study|Withdrawal by Subject|1
6062362|NCT00499369|9663549|FG003|Overall Study|Withdrawal by Subject|0
6062363|NCT00499369|9663550|FG004|Overall Study|Withdrawal by Subject|0
6062364|NCT00499369|9663546|FG000|Overall Study|Progression|10
6062365|NCT00499369|9663547|FG001|Overall Study|Progression|12
6062366|NCT00499369|9663548|FG002|Overall Study|Progression|9
6062367|NCT00499369|9663549|FG003|Overall Study|Progression|6
6062368|NCT00499369|9663550|FG004|Overall Study|Progression|10
6062369|NCT00499369|9663546|FG000|Overall Study|Death|0
6062370|NCT00499369|9663547|FG001|Overall Study|Death|1
6062371|NCT00499369|9663548|FG002|Overall Study|Death|0
6062372|NCT00499369|9663549|FG003|Overall Study|Death|0
6062373|NCT00499369|9663550|FG004|Overall Study|Death|0
6062374|NCT00499369|9663546|FG000|Overall Study|Not protocol specified|2
6062375|NCT00499369|9663547|FG001|Overall Study|Not protocol specified|0
6062376|NCT00499369|9663548|FG002|Overall Study|Not protocol specified|3
6062377|NCT00499369|9663549|FG003|Overall Study|Not protocol specified|1
6062378|NCT00499369|9663550|FG004|Overall Study|Not protocol specified|0
6062379|NCT00499369|9663546|FG000|Overall Study|Ineligible|2
6062380|NCT00499369|9663547|FG001|Overall Study|Ineligible|2
6062381|NCT00499369|9663548|FG002|Overall Study|Ineligible|1
6062382|NCT00499369|9663549|FG003|Overall Study|Ineligible|1
6062383|NCT00499369|9663550|FG004|Overall Study|Ineligible|0
6062384|NCT00499460|9663572|FG000|Intervention 1 (30 Days)|Withdrawal by Subject|1
6062385|NCT00499460|9663573|FG001|Intervention 1 (30 Days)|Withdrawal by Subject|0
6062386|NCT00499460|9663572|FG000|Intervention 1 (30 Days)|Fainting upon Blood Draw|1
6062387|NCT00499460|9663573|FG001|Intervention 1 (30 Days)|Fainting upon Blood Draw|0
6062388|NCT00499460|9663572|FG000|Intervention 2 (30 Days)|Withdrawal by Subject|0
6062389|NCT00499460|9663573|FG001|Intervention 2 (30 Days)|Withdrawal by Subject|1
6062390|NCT00499486|9663598|FG000|Overall Study|Withdrawal by Subject|16
6062391|NCT00499603|9663604|FG000|Overall Study|Adverse Event|0
6062392|NCT00499603|9663605|FG001|Overall Study|Adverse Event|1
6062393|NCT00499616|9663617|FG000|Overall Study|Death|1
6062394|NCT00499616|9663618|FG001|Overall Study|Death|5
6062395|NCT00499616|9663619|FG002|Overall Study|Death|3
6062396|NCT00499616|9663620|FG003|Overall Study|Death|1
6062397|NCT00499616|9663617|FG000|Overall Study|Lack of Efficacy|5
6062398|NCT00499616|9663618|FG001|Overall Study|Lack of Efficacy|0
6062399|NCT00499616|9663619|FG002|Overall Study|Lack of Efficacy|19
6062400|NCT00499616|9663620|FG003|Overall Study|Lack of Efficacy|0
6062401|NCT00499616|9663617|FG000|Overall Study|Lost to Follow-up|0
6062402|NCT00499616|9663618|FG001|Overall Study|Lost to Follow-up|0
6062403|NCT00499616|9663619|FG002|Overall Study|Lost to Follow-up|1
6062404|NCT00499616|9663620|FG003|Overall Study|Lost to Follow-up|0
6095842|NCT00725608|9709897|FG000|Overall Study|Adverse Event|14
6095843|NCT00725608|9709897|FG000|Overall Study|Individual reasons|86
6095844|NCT00725608|9709897|FG000|Overall Study|Other|7
6203199|NCT01513239|9864240|FG004|Period 1: Main Phase|Adverse Event|0
6062405|NCT00499616|9663617|FG000|Overall Study|Physician Decision|6
6062406|NCT00499616|9663618|FG001|Overall Study|Physician Decision|16
6062407|NCT00499616|9663619|FG002|Overall Study|Physician Decision|9
6062408|NCT00499616|9663620|FG003|Overall Study|Physician Decision|0
6062409|NCT00499616|9663617|FG000|Overall Study|Withdrawal by Subject|1
6062410|NCT00499616|9663618|FG001|Overall Study|Withdrawal by Subject|0
6062411|NCT00499616|9663619|FG002|Overall Study|Withdrawal by Subject|1
6062412|NCT00499616|9663620|FG003|Overall Study|Withdrawal by Subject|0
6062413|NCT00499616|9663617|FG000|Overall Study|Ineligible|1
6062414|NCT00499616|9663618|FG001|Overall Study|Ineligible|2
6062415|NCT00499616|9663619|FG002|Overall Study|Ineligible|0
6062416|NCT00499616|9663620|FG003|Overall Study|Ineligible|15
6062417|NCT00499616|9663617|FG000|Overall Study|Not evaluable|0
6062418|NCT00499616|9663618|FG001|Overall Study|Not evaluable|0
6062419|NCT00499616|9663619|FG002|Overall Study|Not evaluable|0
6062420|NCT00499616|9663620|FG003|Overall Study|Not evaluable|41
6062421|NCT00499616|9663617|FG000|Overall Study|Patient/Parent Refusal|1
6062422|NCT00499616|9663618|FG001|Overall Study|Patient/Parent Refusal|5
6062423|NCT00499616|9663619|FG002|Overall Study|Patient/Parent Refusal|3
6062424|NCT00499616|9663620|FG003|Overall Study|Patient/Parent Refusal|0
6062425|NCT00499681|9663645|FG000|Overall Study|toxicity|0
6062426|NCT00499681|9663646|FG001|Overall Study|toxicity|1
6062427|NCT00499681|9663645|FG000|Overall Study|disease progression|0
6062428|NCT00499681|9663646|FG001|Overall Study|disease progression|1
6062429|NCT00499694|9663652|FG000|Overall Study|Patient never received treatment.|1
6062430|NCT00499746|9663657|FG000|Phase 1(6-9 One Day Sessions)|Failed to perform study task|7
6062431|NCT00499746|9663657|FG000|Phase 1(6-9 One Day Sessions)|Withdrawal by Subject|3
6062432|NCT00499746|9663657|FG000|Phase 1(6-9 One Day Sessions)|Investigator decision|1
6062433|NCT00499746|9663657|FG000|Phase 1(6-9 One Day Sessions)|Unable to determine|1
6062434|NCT00499863|9663673|FG000|Overall Study|Lack of Efficacy|21
6062435|NCT00499863|9663674|FG001|Overall Study|Lack of Efficacy|27
6062436|NCT00499863|9663673|FG000|Overall Study|Protocol Violation|12
6062437|NCT00499863|9663674|FG001|Overall Study|Protocol Violation|7
6062438|NCT00499863|9663673|FG000|Overall Study|Withdrawal by Subject|6
6062439|NCT00499863|9663674|FG001|Overall Study|Withdrawal by Subject|4
6062440|NCT00499863|9663673|FG000|Overall Study|Adverse Event|8
6062441|NCT00499863|9663674|FG001|Overall Study|Adverse Event|2
6062442|NCT00499863|9663673|FG000|Overall Study|Sponsor decision|2
6062443|NCT00499863|9663674|FG001|Overall Study|Sponsor decision|2
6062444|NCT00499863|9663673|FG000|Overall Study|Lost to Follow-up|1
6062445|NCT00499863|9663674|FG001|Overall Study|Lost to Follow-up|1
6062446|NCT00499889|9663680|FG000|Overall Study|Infection prior to treatment|1
6062447|NCT00500110|9663693|FG000|Overall Study|Withdrawal by Subject|3
6062448|NCT00500149|9663697|FG000|Enrolled (Dose-optimization Phase)|Withdrawal by Subject|3
6062449|NCT00500149|9663698|FG001|Enrolled (Dose-optimization Phase)|Withdrawal by Subject|0
6062450|NCT00500149|9663697|FG000|Enrolled (Dose-optimization Phase)|Adverse Event|8
6062451|NCT00500149|9663698|FG001|Enrolled (Dose-optimization Phase)|Adverse Event|0
6062452|NCT00500149|9663697|FG000|Enrolled (Dose-optimization Phase)|Protocol Violation|1
6062453|NCT00500149|9663698|FG001|Enrolled (Dose-optimization Phase)|Protocol Violation|0
6062454|NCT00500149|9663697|FG000|First Intervention (Cross-over Phase)|Adverse Event|0
6062455|NCT00500149|9663698|FG001|First Intervention (Cross-over Phase)|Adverse Event|1
6095845|NCT00725621|9709901|FG000|Overall Study|Adverse Event|25
6095846|NCT00725621|9709901|FG000|Overall Study|Lack of Efficacy|46
6095847|NCT00725621|9709901|FG000|Overall Study|Withdrawal by Subject|57
6095848|NCT00725621|9709901|FG000|Overall Study|Physician Decision|19
6095849|NCT00725621|9709901|FG000|Overall Study|Lost to Follow-up|52
6095850|NCT00725621|9709901|FG000|Overall Study|Non-compliance|8
6095851|NCT00725621|9709901|FG000|Overall Study|Continued treatment by other physician|6
6095852|NCT00725621|9709901|FG000|Overall Study|Switched to other study|1
6095853|NCT00725621|9709901|FG000|Overall Study|Switched to other drug|1
6095854|NCT00725621|9709901|FG000|Overall Study|Prepared for elective surgery|1
6095855|NCT00725621|9709901|FG000|Overall Study|Reason not specified|55
6095856|NCT00725712|9709911|FG000|Overall Study|Withdrawal by Subject|2
6095857|NCT00725712|9709912|FG001|Overall Study|Withdrawal by Subject|1
6095858|NCT00725712|9709911|FG000|Overall Study|Protocol Violation|1
6095859|NCT00725712|9709912|FG001|Overall Study|Protocol Violation|0
6095860|NCT00725712|9709911|FG000|Overall Study|Progressive disease|37
6095861|NCT00725712|9709912|FG001|Overall Study|Progressive disease|16
6095862|NCT00725712|9709911|FG000|Overall Study|Clinical progression not based on RECIST|0
6095863|NCT00725712|9709912|FG001|Overall Study|Clinical progression not based on RECIST|3
6095864|NCT00725712|9709911|FG000|Overall Study|Adverse Event|5
6095865|NCT00725712|9709912|FG001|Overall Study|Adverse Event|5
6095866|NCT00725712|9709911|FG000|Overall Study|Death|2
6095867|NCT00725712|9709912|FG001|Overall Study|Death|0
6095868|NCT00725712|9709911|FG000|Overall Study|Other: Death|1
6095869|NCT00725712|9709912|FG001|Overall Study|Other: Death|0
6095870|NCT00725712|9709911|FG000|Overall Study|Hospitalized, unable to continue|0
6095871|NCT00725712|9709912|FG001|Overall Study|Hospitalized, unable to continue|1
6095872|NCT00725725|9709925|FG000|Overall Study|Adverse Event|1
6095873|NCT00725725|9709926|FG001|Overall Study|Adverse Event|3
6095874|NCT00725725|9709927|FG002|Overall Study|Adverse Event|2
6095875|NCT00725725|9709925|FG000|Overall Study|Lost to Follow-up|2
6095876|NCT00725725|9709926|FG001|Overall Study|Lost to Follow-up|0
6095877|NCT00725725|9709927|FG002|Overall Study|Lost to Follow-up|2
6203200|NCT01513239|9864241|FG005|Period 1: Main Phase|Adverse Event|0
6095878|NCT00725725|9709925|FG000|Overall Study|Withdrawal by Subject|1
6095879|NCT00725725|9709926|FG001|Overall Study|Withdrawal by Subject|0
6095880|NCT00725725|9709927|FG002|Overall Study|Withdrawal by Subject|1
6203201|NCT01513239|9864236|FG000|Period 1: Main Phase|Death|29
6062456|NCT00500149|9663697|FG000|First Intervention (Cross-over Phase)|Withdrawal by Subject|1
6062457|NCT00500149|9663698|FG001|First Intervention (Cross-over Phase)|Withdrawal by Subject|1
6062458|NCT00500149|9663697|FG000|First Intervention (Cross-over Phase)|Protocol Violation|1
6062459|NCT00500149|9663698|FG001|First Intervention (Cross-over Phase)|Protocol Violation|0
6062460|NCT00500149|9663697|FG000|Second Intervention (Cross-over Phase)|Lost to Follow-up|2
6062461|NCT00500149|9663698|FG001|Second Intervention (Cross-over Phase)|Lost to Follow-up|0
6062462|NCT00500266|9663715|FG000|Overall Study|Death|3
6062463|NCT00500266|9663715|FG000|Overall Study|Lost to Follow-up|3
6062464|NCT00500266|9663715|FG000|Overall Study|Withdrawal by Subject|3
6062465|NCT00500266|9663715|FG000|Overall Study|Assigned, not treated|4
6062466|NCT00500292|9663723|FG000|Overall Study|Adverse Event|3
6062467|NCT00500292|9663724|FG001|Overall Study|Adverse Event|6
6062468|NCT00500292|9663725|FG002|Overall Study|Adverse Event|4
6062469|NCT00500292|9663723|FG000|Overall Study|Condition under investigation worsened|21
6062470|NCT00500292|9663724|FG001|Overall Study|Condition under investigation worsened|23
6062471|NCT00500292|9663725|FG002|Overall Study|Condition under investigation worsened|19
6062472|NCT00500292|9663723|FG000|Overall Study|Withdrawal by Subject|0
6062473|NCT00500292|9663724|FG001|Overall Study|Withdrawal by Subject|1
6062474|NCT00500292|9663725|FG002|Overall Study|Withdrawal by Subject|0
6062475|NCT00500292|9663723|FG000|Overall Study|Other|1
6062476|NCT00500292|9663724|FG001|Overall Study|Other|1
6062477|NCT00500292|9663725|FG002|Overall Study|Other|4
6062478|NCT00500318|9663735|FG000|Overall Study|Adverse Event|3
6062479|NCT00500318|9663736|FG001|Overall Study|Adverse Event|8
6062480|NCT00500318|9663735|FG000|Overall Study|Protocol Violation|1
6062481|NCT00500318|9663736|FG001|Overall Study|Protocol Violation|3
6062482|NCT00500318|9663735|FG000|Overall Study|Withdrawal by Subject|1
6062483|NCT00500318|9663736|FG001|Overall Study|Withdrawal by Subject|2
6062484|NCT00500318|9663735|FG000|Overall Study|Lack of Efficacy|0
6062485|NCT00500318|9663736|FG001|Overall Study|Lack of Efficacy|3
6062486|NCT00500318|9663735|FG000|Overall Study|Other Reason|0
6062487|NCT00500318|9663736|FG001|Overall Study|Other Reason|1
6062488|NCT00500331|9663749|FG000|Overall Study|Adverse Event|0
6062489|NCT00500331|9663750|FG001|Overall Study|Adverse Event|2
6062490|NCT00500331|9663751|FG002|Overall Study|Adverse Event|0
6062491|NCT00500331|9663752|FG003|Overall Study|Adverse Event|1
6062492|NCT00500331|9663753|FG004|Overall Study|Adverse Event|2
6062493|NCT00500331|9663754|FG005|Overall Study|Adverse Event|2
6062494|NCT00500331|9663755|FG006|Overall Study|Adverse Event|0
6062495|NCT00500331|9663749|FG000|Overall Study|Lost to Follow-up|1
6062496|NCT00500331|9663750|FG001|Overall Study|Lost to Follow-up|1
6062497|NCT00500331|9663751|FG002|Overall Study|Lost to Follow-up|1
6062498|NCT00500331|9663752|FG003|Overall Study|Lost to Follow-up|2
6095881|NCT00725725|9709925|FG000|Overall Study|Protocol Violation|0
6095882|NCT00725725|9709926|FG001|Overall Study|Protocol Violation|1
6095883|NCT00725725|9709927|FG002|Overall Study|Protocol Violation|0
6095884|NCT00725764|9709945|FG000|Overall Study|Withdrawal by Subject|2
6095885|NCT00725764|9709945|FG000|Overall Study|Physician Decision|1
6095886|NCT00725764|9709945|FG000|Overall Study|Progressive Disease|7
6095887|NCT00725764|9709945|FG000|Overall Study|Lost to Follow-up|1
6095888|NCT00725764|9709945|FG000|Overall Study|Death|1
6095889|NCT00725764|9709945|FG000|Overall Study|Participant non compliant with protocol|1
6095890|NCT00725764|9709945|FG000|Overall Study|Decline in performance status|1
6095891|NCT00725842|9709950|FG000|Overall Study|Lost to Follow-up|19
6095892|NCT00725842|9709950|FG000|Overall Study|Death|1
6095893|NCT00725842|9709950|FG000|Overall Study|Positive HCV-RNA at Visit 2|13
6095894|NCT00725842|9709950|FG000|Overall Study|Consent date prior to study start date|5
6095895|NCT00725842|9709950|FG000|Overall Study|Inclusion criterion not met|1
6095896|NCT00725842|9709950|FG000|Overall Study|No Visit 1 data|1
6095897|NCT00725920|9709956|FG000|Overall Study|Lack of Efficacy|3
6095898|NCT00725920|9709957|FG001|Overall Study|Lack of Efficacy|6
6095899|NCT00726232|9709978|FG000|Initial Phase (Dose-finding)|Death|0
6095900|NCT00726232|9709979|FG001|Initial Phase (Dose-finding)|Death|0
6095901|NCT00726232|9709980|FG002|Initial Phase (Dose-finding)|Death|0
6095902|NCT00726232|9709981|FG003|Initial Phase (Dose-finding)|Death|0
6095903|NCT00726232|9709982|FG004|Initial Phase (Dose-finding)|Death|1
6095904|NCT00726232|9709983|FG005|Initial Phase (Dose-finding)|Death|0
6095905|NCT00726232|9709984|FG006|Initial Phase (Dose-finding)|Death|0
6095906|NCT00726232|9709985|FG007|Initial Phase (Dose-finding)|Death|0
6095907|NCT00726232|9709978|FG000|Initial Phase (Dose-finding)|Adverse Event|2
6095908|NCT00726232|9709979|FG001|Initial Phase (Dose-finding)|Adverse Event|2
6095909|NCT00726232|9709980|FG002|Initial Phase (Dose-finding)|Adverse Event|2
6095910|NCT00726232|9709981|FG003|Initial Phase (Dose-finding)|Adverse Event|1
6095911|NCT00726232|9709982|FG004|Initial Phase (Dose-finding)|Adverse Event|7
6062499|NCT00500331|9663753|FG004|Overall Study|Lost to Follow-up|1
6062500|NCT00500331|9663754|FG005|Overall Study|Lost to Follow-up|0
6095912|NCT00726232|9709983|FG005|Initial Phase (Dose-finding)|Adverse Event|3
6095913|NCT00726232|9709984|FG006|Initial Phase (Dose-finding)|Adverse Event|0
6095914|NCT00726232|9709985|FG007|Initial Phase (Dose-finding)|Adverse Event|0
6095915|NCT00726232|9709978|FG000|Initial Phase (Dose-finding)|Withdrawal by Subject|2
6095916|NCT00726232|9709979|FG001|Initial Phase (Dose-finding)|Withdrawal by Subject|0
6095917|NCT00726232|9709980|FG002|Initial Phase (Dose-finding)|Withdrawal by Subject|0
6062501|NCT00500331|9663755|FG006|Overall Study|Lost to Follow-up|0
6062502|NCT00500331|9663749|FG000|Overall Study|Protocol Violation|3
6062503|NCT00500331|9663750|FG001|Overall Study|Protocol Violation|1
6062504|NCT00500331|9663751|FG002|Overall Study|Protocol Violation|1
6062505|NCT00500331|9663752|FG003|Overall Study|Protocol Violation|0
6062506|NCT00500331|9663753|FG004|Overall Study|Protocol Violation|1
6062507|NCT00500331|9663754|FG005|Overall Study|Protocol Violation|1
6062508|NCT00500331|9663755|FG006|Overall Study|Protocol Violation|1
6062509|NCT00500331|9663749|FG000|Overall Study|Withdrawal by Subject|4
6062510|NCT00500331|9663750|FG001|Overall Study|Withdrawal by Subject|0
6062511|NCT00500331|9663751|FG002|Overall Study|Withdrawal by Subject|1
6062512|NCT00500331|9663752|FG003|Overall Study|Withdrawal by Subject|5
6062513|NCT00500331|9663753|FG004|Overall Study|Withdrawal by Subject|0
6062514|NCT00500331|9663754|FG005|Overall Study|Withdrawal by Subject|1
6062515|NCT00500331|9663755|FG006|Overall Study|Withdrawal by Subject|1
6062516|NCT00500331|9663749|FG000|Overall Study|Lack of Efficacy|3
6062517|NCT00500331|9663750|FG001|Overall Study|Lack of Efficacy|1
6062518|NCT00500331|9663751|FG002|Overall Study|Lack of Efficacy|0
6062519|NCT00500331|9663752|FG003|Overall Study|Lack of Efficacy|0
6062520|NCT00500331|9663753|FG004|Overall Study|Lack of Efficacy|0
6062521|NCT00500331|9663754|FG005|Overall Study|Lack of Efficacy|0
6062522|NCT00500331|9663755|FG006|Overall Study|Lack of Efficacy|0
6062523|NCT00500331|9663749|FG000|Overall Study|Liver function test abnormality|0
6062524|NCT00500331|9663750|FG001|Overall Study|Liver function test abnormality|0
6095918|NCT00726232|9709981|FG003|Initial Phase (Dose-finding)|Withdrawal by Subject|1
6062525|NCT00500331|9663751|FG002|Overall Study|Liver function test abnormality|1
6062526|NCT00500331|9663752|FG003|Overall Study|Liver function test abnormality|0
6062527|NCT00500331|9663753|FG004|Overall Study|Liver function test abnormality|0
6062528|NCT00500331|9663754|FG005|Overall Study|Liver function test abnormality|0
6062529|NCT00500331|9663755|FG006|Overall Study|Liver function test abnormality|0
6062530|NCT00500331|9663749|FG000|Overall Study|Increased serum creatinine from Baseline|0
6062531|NCT00500331|9663750|FG001|Overall Study|Increased serum creatinine from Baseline|0
6062532|NCT00500331|9663751|FG002|Overall Study|Increased serum creatinine from Baseline|0
6062533|NCT00500331|9663752|FG003|Overall Study|Increased serum creatinine from Baseline|0
6062534|NCT00500331|9663753|FG004|Overall Study|Increased serum creatinine from Baseline|0
6062535|NCT00500331|9663754|FG005|Overall Study|Increased serum creatinine from Baseline|1
6062536|NCT00500331|9663755|FG006|Overall Study|Increased serum creatinine from Baseline|0
6062537|NCT00500331|9663749|FG000|Overall Study|Didn't return for continuation of study|1
6062538|NCT00500331|9663750|FG001|Overall Study|Didn't return for continuation of study|0
6062539|NCT00500331|9663751|FG002|Overall Study|Didn't return for continuation of study|0
6062540|NCT00500331|9663752|FG003|Overall Study|Didn't return for continuation of study|0
6062541|NCT00500331|9663753|FG004|Overall Study|Didn't return for continuation of study|0
6062542|NCT00500331|9663754|FG005|Overall Study|Didn't return for continuation of study|0
6062543|NCT00500331|9663755|FG006|Overall Study|Didn't return for continuation of study|0
6062544|NCT00500331|9663749|FG000|Overall Study|Exclusion citeria not met on Visit 4|1
6095919|NCT00726232|9709982|FG004|Initial Phase (Dose-finding)|Withdrawal by Subject|0
6095920|NCT00726232|9709983|FG005|Initial Phase (Dose-finding)|Withdrawal by Subject|2
6095921|NCT00726232|9709984|FG006|Initial Phase (Dose-finding)|Withdrawal by Subject|0
6095922|NCT00726232|9709985|FG007|Initial Phase (Dose-finding)|Withdrawal by Subject|0
6095923|NCT00726232|9709978|FG000|Initial Phase (Dose-finding)|Disease progression|3
6095924|NCT00726232|9709979|FG001|Initial Phase (Dose-finding)|Disease progression|1
6095925|NCT00726232|9709980|FG002|Initial Phase (Dose-finding)|Disease progression|0
6284501|NCT02326272|9996333|FG005|Open-label Period (Week 48 to Week 144)|Withdrawal by Subject|0
6284502|NCT02326272|9996334|FG006|Open-label Period (Week 48 to Week 144)|Withdrawal by Subject|0
6095926|NCT00726232|9709981|FG003|Initial Phase (Dose-finding)|Disease progression|0
6095927|NCT00726232|9709982|FG004|Initial Phase (Dose-finding)|Disease progression|0
6095928|NCT00726232|9709983|FG005|Initial Phase (Dose-finding)|Disease progression|0
6095929|NCT00726232|9709984|FG006|Initial Phase (Dose-finding)|Disease progression|0
6095930|NCT00726232|9709985|FG007|Initial Phase (Dose-finding)|Disease progression|0
6095931|NCT00726232|9709978|FG000|Initial Phase (Dose-finding)|Termination of the trial by sponsor|4
6095932|NCT00726232|9709979|FG001|Initial Phase (Dose-finding)|Termination of the trial by sponsor|3
6095933|NCT00726232|9709980|FG002|Initial Phase (Dose-finding)|Termination of the trial by sponsor|3
6095934|NCT00726232|9709981|FG003|Initial Phase (Dose-finding)|Termination of the trial by sponsor|4
6095935|NCT00726232|9709982|FG004|Initial Phase (Dose-finding)|Termination of the trial by sponsor|9
6095936|NCT00726232|9709983|FG005|Initial Phase (Dose-finding)|Termination of the trial by sponsor|3
6095937|NCT00726232|9709984|FG006|Initial Phase (Dose-finding)|Termination of the trial by sponsor|0
6095938|NCT00726232|9709985|FG007|Initial Phase (Dose-finding)|Termination of the trial by sponsor|0
6095939|NCT00726232|9709978|FG000|Initial Phase (Dose-finding)|Per Investigator: lack of response|1
6095940|NCT00726232|9709979|FG001|Initial Phase (Dose-finding)|Per Investigator: lack of response|0
6095941|NCT00726232|9709980|FG002|Initial Phase (Dose-finding)|Per Investigator: lack of response|0
6095942|NCT00726232|9709981|FG003|Initial Phase (Dose-finding)|Per Investigator: lack of response|2
6062545|NCT00500331|9663750|FG001|Overall Study|Exclusion citeria not met on Visit 4|0
6062546|NCT00500331|9663751|FG002|Overall Study|Exclusion citeria not met on Visit 4|0
6284503|NCT02326272|9996335|FG007|Open-label Period (Week 48 to Week 144)|Withdrawal by Subject|0
6284504|NCT02326272|9996336|FG008|Open-label Period (Week 48 to Week 144)|Withdrawal by Subject|0
6284505|NCT02326272|9996337|FG009|Open-label Period (Week 48 to Week 144)|Withdrawal by Subject|0
6284506|NCT02326272|9996338|FG010|Open-label Period (Week 48 to Week 144)|Withdrawal by Subject|0
6284507|NCT02326272|9996339|FG011|Open-label Period (Week 48 to Week 144)|Withdrawal by Subject|4
6284508|NCT02326272|9996340|FG012|Open-label Period (Week 48 to Week 144)|Withdrawal by Subject|0
5980490|NCT02733042|9569329|FG009|Treatment Period|Adverse Event|0
6062547|NCT00500331|9663752|FG003|Overall Study|Exclusion citeria not met on Visit 4|0
6062548|NCT00500331|9663753|FG004|Overall Study|Exclusion citeria not met on Visit 4|0
6062549|NCT00500331|9663754|FG005|Overall Study|Exclusion citeria not met on Visit 4|0
6062550|NCT00500331|9663755|FG006|Overall Study|Exclusion citeria not met on Visit 4|0
6062551|NCT00500331|9663749|FG000|Overall Study|Sponsor decided to withdraw participant|1
6062552|NCT00500331|9663750|FG001|Overall Study|Sponsor decided to withdraw participant|0
6062553|NCT00500331|9663751|FG002|Overall Study|Sponsor decided to withdraw participant|0
6062554|NCT00500331|9663752|FG003|Overall Study|Sponsor decided to withdraw participant|0
6203202|NCT01513239|9864237|FG001|Period 1: Main Phase|Death|22
6203203|NCT01513239|9864238|FG002|Period 1: Main Phase|Death|32
6203204|NCT01513239|9864239|FG003|Period 1: Main Phase|Death|0
6062555|NCT00500331|9663753|FG004|Overall Study|Sponsor decided to withdraw participant|0
6062556|NCT00500331|9663754|FG005|Overall Study|Sponsor decided to withdraw participant|0
6062557|NCT00500331|9663755|FG006|Overall Study|Sponsor decided to withdraw participant|0
6062558|NCT00500331|9663749|FG000|Overall Study|Participant was randomized by mistake|1
6062559|NCT00500331|9663750|FG001|Overall Study|Participant was randomized by mistake|0
6062560|NCT00500331|9663751|FG002|Overall Study|Participant was randomized by mistake|0
6062561|NCT00500331|9663752|FG003|Overall Study|Participant was randomized by mistake|0
6062562|NCT00500331|9663753|FG004|Overall Study|Participant was randomized by mistake|0
6062563|NCT00500331|9663754|FG005|Overall Study|Participant was randomized by mistake|0
6062564|NCT00500331|9663755|FG006|Overall Study|Participant was randomized by mistake|0
6062565|NCT00500331|9663749|FG000|Overall Study|Diabetologist nurse in the study|0
6062566|NCT00500331|9663750|FG001|Overall Study|Diabetologist nurse in the study|0
6062567|NCT00500331|9663751|FG002|Overall Study|Diabetologist nurse in the study|1
6062568|NCT00500331|9663752|FG003|Overall Study|Diabetologist nurse in the study|0
6062569|NCT00500331|9663753|FG004|Overall Study|Diabetologist nurse in the study|0
6062570|NCT00500331|9663754|FG005|Overall Study|Diabetologist nurse in the study|0
6062571|NCT00500331|9663755|FG006|Overall Study|Diabetologist nurse in the study|0
6062572|NCT00500331|9663749|FG000|Overall Study|State ban of biological samples export|0
6062573|NCT00500331|9663750|FG001|Overall Study|State ban of biological samples export|0
6062574|NCT00500331|9663751|FG002|Overall Study|State ban of biological samples export|0
6062575|NCT00500331|9663752|FG003|Overall Study|State ban of biological samples export|1
6062576|NCT00500331|9663753|FG004|Overall Study|State ban of biological samples export|0
6062577|NCT00500331|9663754|FG005|Overall Study|State ban of biological samples export|0
6062578|NCT00500331|9663755|FG006|Overall Study|State ban of biological samples export|0
6062579|NCT00500331|9663749|FG000|Overall Study|Protocol violated|0
6062580|NCT00500331|9663750|FG001|Overall Study|Protocol violated|0
6062581|NCT00500331|9663751|FG002|Overall Study|Protocol violated|0
6095943|NCT00726232|9709982|FG004|Initial Phase (Dose-finding)|Per Investigator: lack of response|4
6095944|NCT00726232|9709983|FG005|Initial Phase (Dose-finding)|Per Investigator: lack of response|1
6095945|NCT00726232|9709984|FG006|Initial Phase (Dose-finding)|Per Investigator: lack of response|0
6095946|NCT00726232|9709985|FG007|Initial Phase (Dose-finding)|Per Investigator: lack of response|0
6095947|NCT00726232|9709978|FG000|Initial Phase (Dose-finding)|Unspecified reason|1
6095948|NCT00726232|9709979|FG001|Initial Phase (Dose-finding)|Unspecified reason|0
6095949|NCT00726232|9709980|FG002|Initial Phase (Dose-finding)|Unspecified reason|0
6095950|NCT00726232|9709981|FG003|Initial Phase (Dose-finding)|Unspecified reason|0
6095951|NCT00726232|9709982|FG004|Initial Phase (Dose-finding)|Unspecified reason|0
6095952|NCT00726232|9709983|FG005|Initial Phase (Dose-finding)|Unspecified reason|0
6095953|NCT00726232|9709984|FG006|Initial Phase (Dose-finding)|Unspecified reason|0
6095954|NCT00726232|9709985|FG007|Initial Phase (Dose-finding)|Unspecified reason|0
6095955|NCT00726232|9709978|FG000|Expansion Phase|Death|0
6095956|NCT00726232|9709979|FG001|Expansion Phase|Death|0
6095957|NCT00726232|9709980|FG002|Expansion Phase|Death|0
6095958|NCT00726232|9709981|FG003|Expansion Phase|Death|0
6095959|NCT00726232|9709982|FG004|Expansion Phase|Death|0
6095960|NCT00726232|9709983|FG005|Expansion Phase|Death|0
6203205|NCT01513239|9864240|FG004|Period 1: Main Phase|Death|0
5980491|NCT02733042|9569330|FG010|Treatment Period|Adverse Event|2
5980492|NCT02733042|9569331|FG011|Treatment Period|Adverse Event|2
5980493|NCT02733042|9569332|FG012|Treatment Period|Adverse Event|0
5980494|NCT02733042|9569333|FG013|Treatment Period|Adverse Event|2
5980495|NCT02733042|9569334|FG014|Treatment Period|Adverse Event|0
5980496|NCT02733042|9569335|FG015|Treatment Period|Adverse Event|0
5980497|NCT02733042|9569336|FG016|Treatment Period|Adverse Event|0
5980498|NCT02733042|9569337|FG017|Treatment Period|Adverse Event|1
5980499|NCT02733042|9569338|FG018|Treatment Period|Adverse Event|0
5980500|NCT02733042|9569320|FG000|Treatment Period|Progressive Disease|2
5980501|NCT02733042|9569321|FG001|Treatment Period|Progressive Disease|1
6062582|NCT00500331|9663752|FG003|Overall Study|Protocol violated|1
6062583|NCT00500331|9663753|FG004|Overall Study|Protocol violated|0
6062584|NCT00500331|9663754|FG005|Overall Study|Protocol violated|0
6062585|NCT00500331|9663755|FG006|Overall Study|Protocol violated|0
6062586|NCT00500357|9663772|FG000|Overall Study|Death|1
6062587|NCT00500370|9663789|FG000|Overall Study|Adverse Event|9
6062588|NCT00500370|9663790|FG001|Overall Study|Adverse Event|3
6062589|NCT00500370|9663789|FG000|Overall Study|Lost to Follow-up|10
6062590|NCT00500370|9663790|FG001|Overall Study|Lost to Follow-up|10
6062591|NCT00500370|9663789|FG000|Overall Study|Protocol Violation|2
6062592|NCT00500370|9663790|FG001|Overall Study|Protocol Violation|4
6062593|NCT00500370|9663789|FG000|Overall Study|Sponsor Decision|2
6062594|NCT00500370|9663790|FG001|Overall Study|Sponsor Decision|0
6062595|NCT00500370|9663789|FG000|Overall Study|Subject Decision|10
6062596|NCT00500370|9663790|FG001|Overall Study|Subject Decision|17
6062597|NCT00500539|9663805|FG000|Treatment Period (24 Weeks)|Adverse Event|4
6062598|NCT00500539|9663805|FG000|Treatment Period (24 Weeks)|Unsatisfactory therapeutic effect|1
6062599|NCT00500539|9663805|FG000|Treatment Period (24 Weeks)|Subject withdrew consent|1
6062600|NCT00500539|9663805|FG000|Treatment Period (24 Weeks)|Lost to Follow-up|2
6062601|NCT00500539|9663805|FG000|Treatment Period (24 Weeks)|Administrative problems|2
6062602|NCT00500539|9663805|FG000|Treatment Period (24 Weeks)|Protocol Deviation|5
6062603|NCT00500539|9663805|FG000|Follow-up Period (16 Weeks)|Adverse Event|1
6062604|NCT00500539|9663805|FG000|Follow-up Period (16 Weeks)|Subject withdrew consent|2
6062605|NCT00500539|9663805|FG000|Follow-up Period (16 Weeks)|Lost to Follow-up|3
6062606|NCT00500539|9663805|FG000|Follow-up Period (16 Weeks)|Administrative problems|1
6062607|NCT00500539|9663805|FG000|Follow-up Period (16 Weeks)|Death|1
6062608|NCT00500539|9663805|FG000|Follow-up Period (16 Weeks)|Protocol Deviation|1
6062609|NCT00500539|9663805|FG000|Follow-up Period (16 Weeks)|Missing|3
6062610|NCT00500682|9663840|FG000|Overall Study|Adverse Event|37
6062611|NCT00500682|9663841|FG001|Overall Study|Adverse Event|29
6062612|NCT00500682|9663840|FG000|Overall Study|Death|25
6062613|NCT00500682|9663841|FG001|Overall Study|Death|16
6062614|NCT00500682|9663840|FG000|Overall Study|Lost to Follow-up|11
6062615|NCT00500682|9663841|FG001|Overall Study|Lost to Follow-up|11
6062616|NCT00500682|9663840|FG000|Overall Study|Physician Decision|6
6062617|NCT00500682|9663841|FG001|Overall Study|Physician Decision|10
6062618|NCT00500682|9663840|FG000|Overall Study|Pregnancy|2
6062619|NCT00500682|9663841|FG001|Overall Study|Pregnancy|0
6062620|NCT00500682|9663840|FG000|Overall Study|Protocol Violation|1
6062621|NCT00500682|9663841|FG001|Overall Study|Protocol Violation|3
6062622|NCT00500682|9663840|FG000|Overall Study|Withdrawal by Subject|80
6062623|NCT00500682|9663841|FG001|Overall Study|Withdrawal by Subject|74
6095961|NCT00726232|9709984|FG006|Expansion Phase|Death|0
6095962|NCT00726232|9709985|FG007|Expansion Phase|Death|1
6095963|NCT00726232|9709978|FG000|Expansion Phase|Adverse Event|0
6095964|NCT00726232|9709979|FG001|Expansion Phase|Adverse Event|0
6095965|NCT00726232|9709980|FG002|Expansion Phase|Adverse Event|0
6095966|NCT00726232|9709981|FG003|Expansion Phase|Adverse Event|0
6095967|NCT00726232|9709982|FG004|Expansion Phase|Adverse Event|0
6095968|NCT00726232|9709983|FG005|Expansion Phase|Adverse Event|0
6095969|NCT00726232|9709984|FG006|Expansion Phase|Adverse Event|6
6095970|NCT00726232|9709985|FG007|Expansion Phase|Adverse Event|11
6095971|NCT00726232|9709978|FG000|Expansion Phase|Withdrawal by Subject|0
6095972|NCT00726232|9709979|FG001|Expansion Phase|Withdrawal by Subject|0
6095973|NCT00726232|9709980|FG002|Expansion Phase|Withdrawal by Subject|0
6095974|NCT00726232|9709981|FG003|Expansion Phase|Withdrawal by Subject|0
6095975|NCT00726232|9709982|FG004|Expansion Phase|Withdrawal by Subject|0
6095976|NCT00726232|9709983|FG005|Expansion Phase|Withdrawal by Subject|0
6095977|NCT00726232|9709984|FG006|Expansion Phase|Withdrawal by Subject|2
6095978|NCT00726232|9709985|FG007|Expansion Phase|Withdrawal by Subject|3
6095979|NCT00726232|9709978|FG000|Expansion Phase|Disease progression|0
6095980|NCT00726232|9709979|FG001|Expansion Phase|Disease progression|0
6095981|NCT00726232|9709980|FG002|Expansion Phase|Disease progression|0
6095982|NCT00726232|9709981|FG003|Expansion Phase|Disease progression|0
6095983|NCT00726232|9709982|FG004|Expansion Phase|Disease progression|0
6095984|NCT00726232|9709983|FG005|Expansion Phase|Disease progression|0
6095985|NCT00726232|9709984|FG006|Expansion Phase|Disease progression|4
6095986|NCT00726232|9709985|FG007|Expansion Phase|Disease progression|0
6062624|NCT00500682|9663840|FG000|Overall Study|Reaching endpoints, Noncompliance, etc|144
6062625|NCT00500682|9663841|FG001|Overall Study|Reaching endpoints, Noncompliance, etc|144
6062626|NCT00500760|9663849|FG000|Overall Study|Death|32
6062627|NCT00500760|9663850|FG001|Overall Study|Death|15
6062628|NCT00500760|9663849|FG000|Overall Study|Withdrawal by Subject|5
6062629|NCT00500760|9663850|FG001|Overall Study|Withdrawal by Subject|7
6062630|NCT00500760|9663849|FG000|Overall Study|Administrative decision|2
6062631|NCT00500760|9663850|FG001|Overall Study|Administrative decision|0
6095987|NCT00726232|9709978|FG000|Expansion Phase|Termination of the trial by sponsor|0
6095988|NCT00726232|9709979|FG001|Expansion Phase|Termination of the trial by sponsor|0
6095989|NCT00726232|9709980|FG002|Expansion Phase|Termination of the trial by sponsor|0
6095990|NCT00726232|9709981|FG003|Expansion Phase|Termination of the trial by sponsor|0
6095991|NCT00726232|9709982|FG004|Expansion Phase|Termination of the trial by sponsor|0
6203206|NCT01513239|9864241|FG005|Period 1: Main Phase|Death|0
6062632|NCT00500760|9663849|FG000|Overall Study|Lost to Follow-up|3
6062633|NCT00500760|9663850|FG001|Overall Study|Lost to Follow-up|0
6062634|NCT00500760|9663849|FG000|Overall Study|Other|1
6062635|NCT00500760|9663850|FG001|Overall Study|Other|2
6062636|NCT00500903|9663859|FG000|Overall Study|Occurrence of Adverse Event(s)|10
6062637|NCT00500903|9663860|FG001|Overall Study|Occurrence of Adverse Event(s)|0
6062638|NCT00500903|9663861|FG002|Overall Study|Occurrence of Adverse Event(s)|0
6062639|NCT00500903|9663859|FG000|Overall Study|Unsatisfactory Therapeutic Response|2
6062640|NCT00500903|9663860|FG001|Overall Study|Unsatisfactory Therapeutic Response|0
6062641|NCT00500903|9663861|FG002|Overall Study|Unsatisfactory Therapeutic Response|0
6095992|NCT00726232|9709983|FG005|Expansion Phase|Termination of the trial by sponsor|0
6095993|NCT00726232|9709984|FG006|Expansion Phase|Termination of the trial by sponsor|10
6095994|NCT00726232|9709985|FG007|Expansion Phase|Termination of the trial by sponsor|16
6095995|NCT00726232|9709978|FG000|Expansion Phase|Per Investigator: lack of response|0
6095996|NCT00726232|9709979|FG001|Expansion Phase|Per Investigator: lack of response|0
6095997|NCT00726232|9709980|FG002|Expansion Phase|Per Investigator: lack of response|0
6095998|NCT00726232|9709981|FG003|Expansion Phase|Per Investigator: lack of response|0
6095999|NCT00726232|9709982|FG004|Expansion Phase|Per Investigator: lack of response|0
6096000|NCT00726232|9709983|FG005|Expansion Phase|Per Investigator: lack of response|0
6096001|NCT00726232|9709984|FG006|Expansion Phase|Per Investigator: lack of response|1
6096002|NCT00726232|9709985|FG007|Expansion Phase|Per Investigator: lack of response|7
6096003|NCT00726232|9709978|FG000|Expansion Phase|Unspecified reason|0
6096004|NCT00726232|9709979|FG001|Expansion Phase|Unspecified reason|0
6096005|NCT00726232|9709980|FG002|Expansion Phase|Unspecified reason|0
6096006|NCT00726232|9709981|FG003|Expansion Phase|Unspecified reason|0
6096007|NCT00726232|9709982|FG004|Expansion Phase|Unspecified reason|0
6096008|NCT00726232|9709983|FG005|Expansion Phase|Unspecified reason|0
6096009|NCT00726232|9709984|FG006|Expansion Phase|Unspecified reason|1
6096010|NCT00726232|9709985|FG007|Expansion Phase|Unspecified reason|0
6096011|NCT00726323|9710006|FG000|Overall Study|Withdrawal by Subject|3
6096012|NCT00726323|9710007|FG001|Overall Study|Withdrawal by Subject|1
6096013|NCT00726323|9710006|FG000|Overall Study|Physician Decision|1
6096014|NCT00726323|9710007|FG001|Overall Study|Physician Decision|0
6096015|NCT00726323|9710006|FG000|Overall Study|Progressive disease|23
6096016|NCT00726323|9710007|FG001|Overall Study|Progressive disease|16
6096017|NCT00726323|9710006|FG000|Overall Study|Clinical progression|0
6096018|NCT00726323|9710007|FG001|Overall Study|Clinical progression|3
6096019|NCT00726323|9710006|FG000|Overall Study|Adverse Event|9
6096020|NCT00726323|9710007|FG001|Overall Study|Adverse Event|9
6096021|NCT00726323|9710006|FG000|Overall Study|Death|1
6096022|NCT00726323|9710007|FG001|Overall Study|Death|0
6096023|NCT00726323|9710006|FG000|Overall Study|Participant wished to discontinue|0
6096024|NCT00726323|9710007|FG001|Overall Study|Participant wished to discontinue|1
6096025|NCT00726323|9710006|FG000|Overall Study|Metastatic lesions inferred cyst|0
6096026|NCT00726323|9710007|FG001|Overall Study|Metastatic lesions inferred cyst|1
6096027|NCT00726388|9710017|FG000|Overall Study|Withdrawal by Subject|5
6096028|NCT00726388|9710017|FG000|Overall Study|Adverse Event|3
6096029|NCT00726388|9710017|FG000|Overall Study|Lost to Follow-up|10
6096030|NCT00726388|9710017|FG000|Overall Study|Participants Non-compliant With Study Procedures|5
6096031|NCT00726388|9710017|FG000|Overall Study|Other|5
6096032|NCT00726388|9710017|FG000|Overall Study|Enrolled, Not Treated|79
6096033|NCT00726453|9710030|FG000|Primary Enrollment Group|Death|18
6096034|NCT00726453|9710031|FG001|Primary Enrollment Group|Death|0
6096035|NCT00726453|9710030|FG000|Primary Enrollment Group|Withdrawal by Subject|13
6096036|NCT00726453|9710031|FG001|Primary Enrollment Group|Withdrawal by Subject|0
6096037|NCT00726453|9710030|FG000|38 mm Length Group|Death|0
6096038|NCT00726453|9710031|FG001|38 mm Length Group|Death|3
6096039|NCT00726557|9710036|FG000|Overall Study|Screening failure|4
6096040|NCT00726557|9710036|FG000|Overall Study|No end of treatment documentation|37
6096041|NCT00726557|9710036|FG000|Overall Study|No follow-up documentation available|55
6096042|NCT00726557|9710036|FG000|Overall Study|Treatment less than 3 months|17
6096043|NCT00726557|9710036|FG000|Overall Study|Inclusion criteria not met|15
6096044|NCT00726609|9710041|FG000|Overall Study|Adverse Event|10
6096045|NCT00726609|9710041|FG000|Overall Study|Withdrawal by Subject|2
6096046|NCT00726609|9710041|FG000|Overall Study|Lack of Efficacy|25
6096047|NCT00726609|9710041|FG000|Overall Study|Other|16
6096048|NCT00726609|9710041|FG000|Overall Study|Missing|42
6096049|NCT00726609|9710041|FG000|Overall Study|Other|3
6096050|NCT00726622|9710047|FG000|Overall Study|Withdrawal by Subject|16
6096051|NCT00726622|9710048|FG001|Overall Study|Withdrawal by Subject|2
6096052|NCT00726622|9710047|FG000|Overall Study|Physician Decision|0
6096053|NCT00726622|9710048|FG001|Overall Study|Physician Decision|1
6096054|NCT00726622|9710047|FG000|Overall Study|Metastasis|2
6096055|NCT00726622|9710048|FG001|Overall Study|Metastasis|0
6062642|NCT00500903|9663859|FG000|Overall Study|Progressive Disease|41
6062643|NCT00500903|9663860|FG001|Overall Study|Progressive Disease|2
6062644|NCT00500903|9663861|FG002|Overall Study|Progressive Disease|15
6096056|NCT00726661|9710056|FG000|Overall Study|Lost to Follow-up|36
6096057|NCT00726661|9710057|FG001|Overall Study|Lost to Follow-up|11
6096058|NCT00726661|9710056|FG000|Overall Study|Withdrawal by Subject|17
6096059|NCT00726661|9710057|FG001|Overall Study|Withdrawal by Subject|13
6062645|NCT00500903|9663859|FG000|Overall Study|Patient Declined Further Treatment|0
6062646|NCT00500903|9663860|FG001|Overall Study|Patient Declined Further Treatment|0
6062647|NCT00500903|9663861|FG002|Overall Study|Patient Declined Further Treatment|3
6062648|NCT00500903|9663859|FG000|Overall Study|Symptomatic Deterioration|2
6062649|NCT00500903|9663860|FG001|Overall Study|Symptomatic Deterioration|0
6062650|NCT00500903|9663861|FG002|Overall Study|Symptomatic Deterioration|0
6062651|NCT00500903|9663859|FG000|Overall Study|Reason Not Specified|10
6062652|NCT00500903|9663860|FG001|Overall Study|Reason Not Specified|0
6062653|NCT00500903|9663861|FG002|Overall Study|Reason Not Specified|2
6062654|NCT00501007|9663899|FG000|Overall Study|Inclusion criteria not met.|29
6062655|NCT00501007|9663900|FG001|Overall Study|Inclusion criteria not met.|25
6062656|NCT00501046|9663908|FG000|Overall Study|Adverse Event|21
6062657|NCT00501046|9663909|FG001|Overall Study|Adverse Event|25
6096060|NCT00726661|9710056|FG000|Overall Study|Trial terminated by sponsor|214
6096061|NCT00726661|9710057|FG001|Overall Study|Trial terminated by sponsor|187
6096062|NCT00726661|9710056|FG000|Overall Study|Death|475
6096063|NCT00726661|9710057|FG001|Overall Study|Death|159
6096064|NCT00726661|9710056|FG000|Overall Study|Physician Decision|25
6096065|NCT00726661|9710057|FG001|Overall Study|Physician Decision|13
6096066|NCT00726661|9710056|FG000|Overall Study|Other|47
6096067|NCT00726661|9710057|FG001|Overall Study|Other|35
6096068|NCT00726752|9710084|FG000|Overall Study|Lack of Efficacy|6
6096069|NCT00726882|9710088|FG000|Overall Study|Withdrawal by Subject|5
6096070|NCT00726882|9710088|FG000|Overall Study|Lost to Follow-up|7
6096071|NCT00726882|9710088|FG000|Overall Study|Other|10
6096072|NCT00726895|9710094|FG000|Washout Period of 7 Days|Withdrawal by Subject|0
6096073|NCT00726895|9710095|FG001|Washout Period of 7 Days|Withdrawal by Subject|1
6096074|NCT00726986|9710102|FG000|Induction Phase|Adverse Event|4
6096075|NCT00726986|9710102|FG000|Induction Phase|Withdrawal by Subject|2
6096076|NCT00726986|9710102|FG000|Induction Phase|Death|2
6096077|NCT00726986|9710102|FG000|Induction Phase|Lack of Efficacy|5
6096078|NCT00726986|9710102|FG000|Induction Phase|Secondary Disease|2
6096079|NCT00726986|9710102|FG000|Maintenance Phase|Adverse Event|1
6096080|NCT00726986|9710102|FG000|Maintenance Phase|Lack of Efficacy|2
6096081|NCT00726999|9710108|FG000|Overall Study|Physician Decision|0
6096082|NCT00726999|9710109|FG001|Overall Study|Physician Decision|1
6096083|NCT00726999|9710108|FG000|Overall Study|Withdrawal by Subject|2
6096084|NCT00726999|9710109|FG001|Overall Study|Withdrawal by Subject|0
6096085|NCT00726999|9710108|FG000|Overall Study|Protocol Violation|1
6096086|NCT00726999|9710109|FG001|Overall Study|Protocol Violation|0
6203207|NCT01513239|9864236|FG000|Period 1: Main Phase|Lost to Follow-up|11
6203208|NCT01513239|9864237|FG001|Period 1: Main Phase|Lost to Follow-up|10
6203209|NCT01513239|9864238|FG002|Period 1: Main Phase|Lost to Follow-up|6
6203210|NCT01513239|9864239|FG003|Period 1: Main Phase|Lost to Follow-up|0
6203211|NCT01513239|9864240|FG004|Period 1: Main Phase|Lost to Follow-up|0
6203212|NCT01513239|9864241|FG005|Period 1: Main Phase|Lost to Follow-up|0
6203213|NCT01513239|9864236|FG000|Period 1: Main Phase|Physician Decision|4
6203214|NCT01513239|9864237|FG001|Period 1: Main Phase|Physician Decision|4
6203215|NCT01513239|9864238|FG002|Period 1: Main Phase|Physician Decision|4
6203216|NCT01513239|9864239|FG003|Period 1: Main Phase|Physician Decision|0
6203217|NCT01513239|9864240|FG004|Period 1: Main Phase|Physician Decision|0
6203218|NCT01513239|9864241|FG005|Period 1: Main Phase|Physician Decision|0
6203219|NCT01513239|9864236|FG000|Period 1: Main Phase|Protocol Violation|2
6203220|NCT01513239|9864237|FG001|Period 1: Main Phase|Protocol Violation|2
6203221|NCT01513239|9864238|FG002|Period 1: Main Phase|Protocol Violation|2
6203222|NCT01513239|9864239|FG003|Period 1: Main Phase|Protocol Violation|0
6203223|NCT01513239|9864240|FG004|Period 1: Main Phase|Protocol Violation|0
6203224|NCT01513239|9864241|FG005|Period 1: Main Phase|Protocol Violation|0
6203225|NCT01513239|9864236|FG000|Period 1: Main Phase|Technical Problems|1
6203226|NCT01513239|9864237|FG001|Period 1: Main Phase|Technical Problems|2
6203227|NCT01513239|9864238|FG002|Period 1: Main Phase|Technical Problems|0
6203228|NCT01513239|9864239|FG003|Period 1: Main Phase|Technical Problems|0
6203229|NCT01513239|9864240|FG004|Period 1: Main Phase|Technical Problems|0
6203230|NCT01513239|9864241|FG005|Period 1: Main Phase|Technical Problems|0
6203231|NCT01513239|9864236|FG000|Period 1: Main Phase|Withdrawal by Subject|27
6203232|NCT01513239|9864237|FG001|Period 1: Main Phase|Withdrawal by Subject|29
6203233|NCT01513239|9864238|FG002|Period 1: Main Phase|Withdrawal by Subject|42
6203234|NCT01513239|9864239|FG003|Period 1: Main Phase|Withdrawal by Subject|0
6203235|NCT01513239|9864240|FG004|Period 1: Main Phase|Withdrawal by Subject|0
6203236|NCT01513239|9864241|FG005|Period 1: Main Phase|Withdrawal by Subject|0
6203237|NCT01513239|9864236|FG000|Period 2: 9 Month Extension Phase|Withdrawal by Subject|0
6203238|NCT01513239|9864237|FG001|Period 2: 9 Month Extension Phase|Withdrawal by Subject|0
6203239|NCT01513239|9864238|FG002|Period 2: 9 Month Extension Phase|Withdrawal by Subject|0
6203240|NCT01513239|9864239|FG003|Period 2: 9 Month Extension Phase|Withdrawal by Subject|5
6203241|NCT01513239|9864240|FG004|Period 2: 9 Month Extension Phase|Withdrawal by Subject|3
6203242|NCT01513239|9864241|FG005|Period 2: 9 Month Extension Phase|Withdrawal by Subject|2
6203243|NCT01513239|9864236|FG000|Period 2: 9 Month Extension Phase|Death|0
6203244|NCT01513239|9864237|FG001|Period 2: 9 Month Extension Phase|Death|0
6203245|NCT01513239|9864238|FG002|Period 2: 9 Month Extension Phase|Death|0
6203246|NCT01513239|9864239|FG003|Period 2: 9 Month Extension Phase|Death|2
6203247|NCT01513239|9864240|FG004|Period 2: 9 Month Extension Phase|Death|5
6062658|NCT00501046|9663908|FG000|Overall Study|Death|23
6062659|NCT00501046|9663909|FG001|Overall Study|Death|30
6062660|NCT00501046|9663908|FG000|Overall Study|Lost to Follow-up|14
6062661|NCT00501046|9663909|FG001|Overall Study|Lost to Follow-up|13
6062662|NCT00501046|9663908|FG000|Overall Study|Physician Decision|7
6062663|NCT00501046|9663909|FG001|Overall Study|Physician Decision|2
6062664|NCT00501046|9663908|FG000|Overall Study|Pregnancy|0
6062665|NCT00501046|9663909|FG001|Overall Study|Pregnancy|3
6062666|NCT00501046|9663908|FG000|Overall Study|Protocol Violation|2
6062667|NCT00501046|9663909|FG001|Overall Study|Protocol Violation|1
6062668|NCT00501046|9663908|FG000|Overall Study|Withdrawal by Subject|84
6062669|NCT00501046|9663909|FG001|Overall Study|Withdrawal by Subject|83
6062670|NCT00501046|9663908|FG000|Overall Study|Reaching endpoints,Noncompliance,etc|119
6062671|NCT00501046|9663909|FG001|Overall Study|Reaching endpoints,Noncompliance,etc|137
6062672|NCT00501059|9663917|FG000|Overall Study|Protocol Violation|80
6062673|NCT00501059|9663918|FG001|Overall Study|Protocol Violation|69
6062674|NCT00501059|9663917|FG000|Overall Study|Death|140
6062675|NCT00501059|9663918|FG001|Overall Study|Death|137
6062676|NCT00501059|9663917|FG000|Overall Study|Other|236
6062677|NCT00501059|9663918|FG001|Overall Study|Other|239
6062678|NCT00501059|9663917|FG000|Overall Study|Missing end-of-study page|91
6062679|NCT00501059|9663918|FG001|Overall Study|Missing end-of-study page|92
6062680|NCT00501059|9663917|FG000|Overall Study|Clinical endpoint reached|110
6062681|NCT00501059|9663918|FG001|Overall Study|Clinical endpoint reached|123
6062682|NCT00501059|9663917|FG000|Overall Study|Insufficient therapeutic effect|4
6062683|NCT00501059|9663918|FG001|Overall Study|Insufficient therapeutic effect|5
6062684|NCT00501059|9663917|FG000|Overall Study|Consent withdrawn by subject|817
6062685|NCT00501059|9663918|FG001|Overall Study|Consent withdrawn by subject|873
6062686|NCT00501059|9663917|FG000|Overall Study|Non-compliant with study treatment|23
6062687|NCT00501059|9663918|FG001|Overall Study|Non-compliant with study treatment|16
6062688|NCT00501059|9663917|FG000|Overall Study|Reason not given|3
6062689|NCT00501059|9663918|FG001|Overall Study|Reason not given|1
6062690|NCT00501059|9663917|FG000|Overall Study|Adverse Event|129
6062691|NCT00501059|9663918|FG001|Overall Study|Adverse Event|122
6062692|NCT00501059|9663917|FG000|Overall Study|Lost to Follow-up|210
6062693|NCT00501059|9663918|FG001|Overall Study|Lost to Follow-up|198
6062694|NCT00501059|9663917|FG000|Overall Study|Not treated|25
6062695|NCT00501059|9663918|FG001|Overall Study|Not treated|17
6062696|NCT00501085|9663926|FG000|Overall Study|Lost to Follow-up|195
6062697|NCT00501085|9663926|FG000|Overall Study|Withdrawal by Subject|34
6062698|NCT00501085|9663926|FG000|Overall Study|Subject Decision|1
6062699|NCT00501085|9663926|FG000|Overall Study|Revision Surgery|7
6062700|NCT00501085|9663926|FG000|Overall Study|Explantation Surgery|26
6062701|NCT00501085|9663926|FG000|Overall Study|Adverse Event|4
6062702|NCT00501085|9663926|FG000|Overall Study|Non-Compliance|24
6203248|NCT01513239|9864241|FG005|Period 2: 9 Month Extension Phase|Death|2
6203249|NCT01513239|9864236|FG000|Period 2: 9 Month Extension Phase|Lost to Follow-up|0
6096087|NCT00727025|9710117|FG000|Overall Study|Physician Decision|23
6096088|NCT00727194|9710134|FG000|Screening Period|Low QMG scores|0
6096089|NCT00727194|9710135|FG001|Screening Period|Low QMG scores|0
6096090|NCT00727194|9710136|FG002|Screening Period|Low QMG scores|6
6096091|NCT00727194|9710134|FG000|Screening Period|Lacked AChR antibodies|0
6096092|NCT00727194|9710135|FG001|Screening Period|Lacked AChR antibodies|0
6096093|NCT00727194|9710136|FG002|Screening Period|Lacked AChR antibodies|5
6096094|NCT00727194|9710134|FG000|Screening Period|Not stable on concomitant MG therapy|0
6096095|NCT00727194|9710135|FG001|Screening Period|Not stable on concomitant MG therapy|0
6203250|NCT01513239|9864237|FG001|Period 2: 9 Month Extension Phase|Lost to Follow-up|0
6203251|NCT01513239|9864238|FG002|Period 2: 9 Month Extension Phase|Lost to Follow-up|0
6203252|NCT01513239|9864239|FG003|Period 2: 9 Month Extension Phase|Lost to Follow-up|2
6203253|NCT01513239|9864240|FG004|Period 2: 9 Month Extension Phase|Lost to Follow-up|1
6203254|NCT01513239|9864241|FG005|Period 2: 9 Month Extension Phase|Lost to Follow-up|0
6203255|NCT01513239|9864236|FG000|Period 2: 9 Month Extension Phase|Physician Decision|0
6203256|NCT01513239|9864237|FG001|Period 2: 9 Month Extension Phase|Physician Decision|0
6203257|NCT01513239|9864238|FG002|Period 2: 9 Month Extension Phase|Physician Decision|0
6203258|NCT01513239|9864239|FG003|Period 2: 9 Month Extension Phase|Physician Decision|1
6203259|NCT01513239|9864240|FG004|Period 2: 9 Month Extension Phase|Physician Decision|0
6203260|NCT01513239|9864241|FG005|Period 2: 9 Month Extension Phase|Physician Decision|0
6203261|NCT01513239|9864236|FG000|Period 2: 9 Month Extension Phase|Technical Problems|0
6203262|NCT01513239|9864237|FG001|Period 2: 9 Month Extension Phase|Technical Problems|0
6203263|NCT01513239|9864238|FG002|Period 2: 9 Month Extension Phase|Technical Problems|0
6203264|NCT01513239|9864239|FG003|Period 2: 9 Month Extension Phase|Technical Problems|0
6062703|NCT00501085|9663926|FG000|Overall Study|Study closed by sponsor|109
6062704|NCT00501085|9663926|FG000|Overall Study|Other loss to follow-up|32
6096096|NCT00727194|9710136|FG002|Screening Period|Not stable on concomitant MG therapy|2
6096097|NCT00727194|9710134|FG000|Screening Period|Severe infections|0
6062705|NCT00501293|9663932|FG000|Optimization Period|Enrolled in error|1
6062706|NCT00501293|9663933|FG001|Optimization Period|Enrolled in error|0
6062707|NCT00501293|9663932|FG000|Maintenance Period|Withdrawal by Subject|14
6096098|NCT00727194|9710135|FG001|Screening Period|Severe infections|0
6096099|NCT00727194|9710136|FG002|Screening Period|Severe infections|2
6062708|NCT00501293|9663933|FG001|Maintenance Period|Withdrawal by Subject|13
6062709|NCT00501293|9663932|FG000|Maintenance Period|Lost to Follow-up|12
6062710|NCT00501293|9663933|FG001|Maintenance Period|Lost to Follow-up|7
6062711|NCT00501293|9663932|FG000|Maintenance Period|Adverse Event|6
6062712|NCT00501293|9663933|FG001|Maintenance Period|Adverse Event|6
6062713|NCT00501293|9663932|FG000|Maintenance Period|Protocol Violation|2
6062714|NCT00501293|9663933|FG001|Maintenance Period|Protocol Violation|1
6062715|NCT00501293|9663932|FG000|Maintenance Period|Lack of Efficacy|4
6062716|NCT00501293|9663933|FG001|Maintenance Period|Lack of Efficacy|1
6062717|NCT00501293|9663932|FG000|Maintenance Period|Noncompliant with study medication|5
6062718|NCT00501293|9663933|FG001|Maintenance Period|Noncompliant with study medication|0
6062719|NCT00501293|9663932|FG000|Maintenance Period|Went into rehabilitation|1
6062720|NCT00501293|9663933|FG001|Maintenance Period|Went into rehabilitation|0
6062721|NCT00501293|9663932|FG000|Maintenance Period|Would not wear patch|1
6062722|NCT00501293|9663933|FG001|Maintenance Period|Would not wear patch|0
6062723|NCT00501293|9663932|FG000|Maintenance Period|Application site reaction|1
6062724|NCT00501293|9663933|FG001|Maintenance Period|Application site reaction|0
6062725|NCT00501540|9663940|FG000|Overall Study|Death|5
6096100|NCT00727194|9710134|FG000|Screening Period|History of thymoma|0
6096101|NCT00727194|9710135|FG001|Screening Period|History of thymoma|0
6096102|NCT00727194|9710136|FG002|Screening Period|History of thymoma|1
6096103|NCT00727194|9710134|FG000|Treatment Period 2|Lack of Efficacy|0
6096104|NCT00727194|9710135|FG001|Treatment Period 2|Lack of Efficacy|1
6096105|NCT00727194|9710136|FG002|Treatment Period 2|Lack of Efficacy|0
6096106|NCT00727246|9710163|FG000|Overall Study|could not complete MRI|0
6096107|NCT00727246|9710164|FG001|Overall Study|could not complete MRI|1
6096108|NCT00727246|9710165|FG002|Overall Study|could not complete MRI|0
6096109|NCT00727246|9710166|FG003|Overall Study|could not complete MRI|1
6096110|NCT00727246|9710163|FG000|Overall Study|incidental finding|0
6096111|NCT00727246|9710164|FG001|Overall Study|incidental finding|0
6096112|NCT00727246|9710165|FG002|Overall Study|incidental finding|0
6096113|NCT00727246|9710166|FG003|Overall Study|incidental finding|1
6096114|NCT00727246|9710163|FG000|Overall Study|withdrawn|0
6096115|NCT00727246|9710164|FG001|Overall Study|withdrawn|0
6096116|NCT00727246|9710165|FG002|Overall Study|withdrawn|1
6096117|NCT00727246|9710166|FG003|Overall Study|withdrawn|0
6096118|NCT00727259|9710176|FG000|Overall Study|Not all questionnaires completed|1055
6096119|NCT00727272|9710181|FG000|Washout Period A|Adverse Event|0
6096120|NCT00727272|9710182|FG001|Washout Period A|Adverse Event|0
6096121|NCT00727272|9710183|FG002|Washout Period A|Adverse Event|1
6096122|NCT00727272|9710181|FG000|Washout Period B|Withdrawal by Subject|0
6096123|NCT00727272|9710182|FG001|Washout Period B|Withdrawal by Subject|0
6096124|NCT00727272|9710183|FG002|Washout Period B|Withdrawal by Subject|1
6096125|NCT00727311|9710197|FG000|Overall Study|Did not receive drug|316
6096126|NCT00727311|9710197|FG000|Overall Study|Missing end of therapy data|205
6096127|NCT00727311|9710197|FG000|Overall Study|Adverse Event|58
6096128|NCT00727311|9710197|FG000|Overall Study|Lack of Efficacy|242
6096129|NCT00727311|9710197|FG000|Overall Study|Lost to Follow-up|73
6096130|NCT00727311|9710197|FG000|Overall Study|Withdrawal by Subject|77
6096131|NCT00727311|9710197|FG000|Overall Study|Other|97
6096132|NCT00727311|9710197|FG000|Overall Study|Multiple reasons|39
6096133|NCT00727402|9710223|FG000|Overall Study|Physician Decision|116
6096134|NCT00727415|9710227|FG000|Phase I|Dose Limiting Toxicity|2
6096135|NCT00727441|9710234|FG000|Overall Study|Disease Progression|11
6096136|NCT00727441|9710235|FG001|Overall Study|Disease Progression|14
6096137|NCT00727441|9710236|FG002|Overall Study|Disease Progression|17
6096138|NCT00727441|9710234|FG000|Overall Study|Eligibility|7
6096139|NCT00727441|9710235|FG001|Overall Study|Eligibility|5
6096140|NCT00727441|9710236|FG002|Overall Study|Eligibility|7
6096141|NCT00727441|9710234|FG000|Overall Study|Death|0
6096142|NCT00727441|9710235|FG001|Overall Study|Death|1
6096143|NCT00727441|9710236|FG002|Overall Study|Death|1
6096144|NCT00727441|9710234|FG000|Overall Study|Physician Decision|0
6096145|NCT00727441|9710235|FG001|Overall Study|Physician Decision|1
6096146|NCT00727441|9710236|FG002|Overall Study|Physician Decision|0
6096147|NCT00727441|9710234|FG000|Overall Study|Withdrawal by Subject|0
6096148|NCT00727441|9710235|FG001|Overall Study|Withdrawal by Subject|1
6096149|NCT00727441|9710236|FG002|Overall Study|Withdrawal by Subject|0
6096150|NCT00727506|9710253|FG000|Overall Study|Adverse Event|0
6096151|NCT00727506|9710254|FG001|Overall Study|Adverse Event|0
6096152|NCT00727506|9710255|FG002|Overall Study|Adverse Event|4
6096153|NCT00727506|9710256|FG003|Overall Study|Adverse Event|4
6096154|NCT00727506|9710257|FG004|Overall Study|Adverse Event|1
6096155|NCT00727506|9710258|FG005|Overall Study|Adverse Event|8
6096156|NCT00727506|9710253|FG000|Overall Study|Dose Limiting Toxicity (DLT)|2
6096157|NCT00727506|9710254|FG001|Overall Study|Dose Limiting Toxicity (DLT)|0
6096158|NCT00727506|9710255|FG002|Overall Study|Dose Limiting Toxicity (DLT)|2
6096159|NCT00727506|9710256|FG003|Overall Study|Dose Limiting Toxicity (DLT)|0
6096160|NCT00727506|9710257|FG004|Overall Study|Dose Limiting Toxicity (DLT)|0
6096161|NCT00727506|9710258|FG005|Overall Study|Dose Limiting Toxicity (DLT)|0
6096162|NCT00727506|9710253|FG000|Overall Study|Progressive disease|4
6096163|NCT00727506|9710254|FG001|Overall Study|Progressive disease|7
6096164|NCT00727506|9710255|FG002|Overall Study|Progressive disease|9
6096165|NCT00727506|9710256|FG003|Overall Study|Progressive disease|28
6062726|NCT00501644|9663966|FG000|Overall Study|Adverse Event|4
6062727|NCT00501644|9663966|FG000|Overall Study|Withdrawal by Subject|1
6062728|NCT00501852|9663970|FG000|Overall Study|Adverse Event|3
6062729|NCT00501852|9663970|FG000|Overall Study|Withdrawal by Subject|2
6062730|NCT00501969|9664000|FG000|Overall Study|Major Protocol Violation|4
6062731|NCT00501969|9664000|FG000|Overall Study|Lack of Efficacy|29
6062732|NCT00501969|9664000|FG000|Overall Study|Adverse Event|76
6062733|NCT00501969|9664000|FG000|Overall Study|Unsatisfactory compliance of subject|7
6062734|NCT00501969|9664000|FG000|Overall Study|Subject withdrew consent|51
6096166|NCT00727506|9710257|FG004|Overall Study|Progressive disease|38
6096167|NCT00727506|9710258|FG005|Overall Study|Progressive disease|28
6096168|NCT00727506|9710253|FG000|Overall Study|Refused to continue medication|0
6096169|NCT00727506|9710254|FG001|Overall Study|Refused to continue medication|1
6096170|NCT00727506|9710255|FG002|Overall Study|Refused to continue medication|2
6096171|NCT00727506|9710256|FG003|Overall Study|Refused to continue medication|3
6096172|NCT00727506|9710257|FG004|Overall Study|Refused to continue medication|1
6096173|NCT00727506|9710258|FG005|Overall Study|Refused to continue medication|2
6096174|NCT00727506|9710253|FG000|Overall Study|Other reason not described above|0
6096175|NCT00727506|9710254|FG001|Overall Study|Other reason not described above|0
6096176|NCT00727506|9710255|FG002|Overall Study|Other reason not described above|1
6096177|NCT00727506|9710256|FG003|Overall Study|Other reason not described above|4
6096178|NCT00727506|9710257|FG004|Overall Study|Other reason not described above|1
6096179|NCT00727506|9710258|FG005|Overall Study|Other reason not described above|1
6096180|NCT00727532|9710278|FG000|Overall Study|Adverse Event|1
6096181|NCT00727532|9710278|FG000|Overall Study|Withdrawal by Subject|1
6096182|NCT00727558|9710284|FG000|Overall Study|Lens issue|0
6096183|NCT00727558|9710285|FG001|Overall Study|Lens issue|1
6096184|NCT00727558|9710284|FG000|Overall Study|Adverse Event|0
6096185|NCT00727558|9710285|FG001|Overall Study|Adverse Event|1
6096186|NCT00727558|9710284|FG000|Overall Study|Subject unable to return for follow-up|1
6096187|NCT00727558|9710285|FG001|Overall Study|Subject unable to return for follow-up|1
6096188|NCT00727558|9710284|FG000|Overall Study|Lost to Follow-up|1
6096189|NCT00727558|9710285|FG001|Overall Study|Lost to Follow-up|0
6096190|NCT00727571|9710295|FG000|Overall Study|Ineligibility determined|1
6096191|NCT00727571|9710296|FG001|Overall Study|Ineligibility determined|1
6096192|NCT00727571|9710297|FG002|Overall Study|Ineligibility determined|1
6096193|NCT00727571|9710298|FG003|Overall Study|Ineligibility determined|0
6096194|NCT00727571|9710295|FG000|Overall Study|Death|0
6096195|NCT00727571|9710296|FG001|Overall Study|Death|19
6096196|NCT00727571|9710297|FG002|Overall Study|Death|5
6096197|NCT00727571|9710298|FG003|Overall Study|Death|1
6096198|NCT00727571|9710295|FG000|Overall Study|Physician Decision|0
6096199|NCT00727571|9710296|FG001|Overall Study|Physician Decision|5
6096200|NCT00727571|9710297|FG002|Overall Study|Physician Decision|0
6096201|NCT00727571|9710298|FG003|Overall Study|Physician Decision|0
6096202|NCT00727571|9710295|FG000|Overall Study|Withdrawal by Subject|0
6096203|NCT00727571|9710296|FG001|Overall Study|Withdrawal by Subject|10
6096204|NCT00727571|9710297|FG002|Overall Study|Withdrawal by Subject|11
6096205|NCT00727571|9710298|FG003|Overall Study|Withdrawal by Subject|0
6096206|NCT00727571|9710295|FG000|Overall Study|Subject Non Compliance|0
6096207|NCT00727571|9710296|FG001|Overall Study|Subject Non Compliance|6
6096208|NCT00727571|9710297|FG002|Overall Study|Subject Non Compliance|0
6096209|NCT00727571|9710298|FG003|Overall Study|Subject Non Compliance|4
6096210|NCT00727571|9710295|FG000|Overall Study|Dismissed from nursing home|0
6096211|NCT00727571|9710296|FG001|Overall Study|Dismissed from nursing home|9
6096212|NCT00727571|9710297|FG002|Overall Study|Dismissed from nursing home|5
6096213|NCT00727571|9710298|FG003|Overall Study|Dismissed from nursing home|0
6096214|NCT00727571|9710295|FG000|Overall Study|Hospitalization|0
6096215|NCT00727571|9710296|FG001|Overall Study|Hospitalization|1
6096216|NCT00727571|9710297|FG002|Overall Study|Hospitalization|0
6096217|NCT00727571|9710298|FG003|Overall Study|Hospitalization|1
6096218|NCT00727571|9710295|FG000|Overall Study|AE not leading to hospitalization|0
6096219|NCT00727571|9710296|FG001|Overall Study|AE not leading to hospitalization|0
6096220|NCT00727571|9710297|FG002|Overall Study|AE not leading to hospitalization|2
6096221|NCT00727571|9710298|FG003|Overall Study|AE not leading to hospitalization|0
6096222|NCT00727571|9710295|FG000|Overall Study|Other|0
6096223|NCT00727571|9710296|FG001|Overall Study|Other|4
6096224|NCT00727571|9710297|FG002|Overall Study|Other|6
6096225|NCT00727571|9710298|FG003|Overall Study|Other|0
6096226|NCT00727649|9710328|FG000|First Intervention (4-weeks)|Lost to Follow-up|1
6096227|NCT00727649|9710329|FG001|First Intervention (4-weeks)|Lost to Follow-up|2
6096228|NCT00727649|9710328|FG000|First Intervention (4-weeks)|Withdrawal by Subject|2
6096229|NCT00727649|9710329|FG001|First Intervention (4-weeks)|Withdrawal by Subject|1
6062735|NCT00501969|9664000|FG000|Overall Study|Lost to Follow-up|4
6096230|NCT00727649|9710328|FG000|Wash-out (2-weeks)|Lost to Follow-up|3
6096231|NCT00727649|9710329|FG001|Wash-out (2-weeks)|Lost to Follow-up|1
6096232|NCT00727649|9710328|FG000|Wash-out (2-weeks)|Withdrawal by Subject|1
6096233|NCT00727649|9710329|FG001|Wash-out (2-weeks)|Withdrawal by Subject|2
6096234|NCT00727649|9710328|FG000|Second Intervention (4-weeks)|Death|1
6096235|NCT00727649|9710329|FG001|Second Intervention (4-weeks)|Death|0
6096236|NCT00727649|9710328|FG000|Second Intervention (4-weeks)|Lost to Follow-up|0
6062736|NCT00501969|9664000|FG000|Overall Study|Other: Tired Of Clinical Trial Process|1
6062737|NCT00501969|9664000|FG000|Overall Study|Other: Sponsors Request|10
6062738|NCT00501969|9664000|FG000|Overall Study|Other: Sponsor Termination at Site|1
6062739|NCT00501969|9664000|FG000|Overall Study|Other: Sponsor Stopped Study|12
6062740|NCT00501969|9664000|FG000|Overall Study|Other: Severe Dementia Unable Sign PIC|1
6062741|NCT00501969|9664000|FG000|Overall Study|Other: Patients + Investigator Agreement|1
6062742|NCT00501969|9664000|FG000|Overall Study|Other: Patient is Going to Have DBS|1
6062743|NCT00501969|9664000|FG000|Overall Study|Other: Pat Pending Surgery for PD|1
6062744|NCT00501969|9664000|FG000|Overall Study|Other: DX Changed - Parkinsons to PSNP|1
6062745|NCT00501969|9664000|FG000|Overall Study|Other: As Required by Local EC|2
6062746|NCT00501969|9664000|FG000|Overall Study|Other: Admin Request from the Sponsor|3
6062747|NCT00501969|9664000|FG000|Overall Study|Other: Sponsor Termination/Commercial RX|1
6062748|NCT00502203|9664008|FG000|Overall Study|Inevaluable|1
6062749|NCT00502242|9664023|FG000|Overall Study|Lack of Efficacy|1
6062750|NCT00502242|9664024|FG001|Overall Study|Lack of Efficacy|11
6062751|NCT00502242|9664023|FG000|Overall Study|Adverse Event|31
6062752|NCT00502242|9664024|FG001|Overall Study|Adverse Event|20
6062753|NCT00502242|9664023|FG000|Overall Study|Physician Decision|2
6062754|NCT00502242|9664024|FG001|Overall Study|Physician Decision|3
6062755|NCT00502242|9664023|FG000|Overall Study|Other - Unspecified|8
6062756|NCT00502242|9664024|FG001|Overall Study|Other - Unspecified|14
6062757|NCT00502242|9664023|FG000|Overall Study|Protocol Violation|3
6062758|NCT00502242|9664024|FG001|Overall Study|Protocol Violation|1
6062759|NCT00502242|9664023|FG000|Overall Study|Withdrawal by Subject|6
6062760|NCT00502242|9664024|FG001|Overall Study|Withdrawal by Subject|7
6096237|NCT00727649|9710329|FG001|Second Intervention (4-weeks)|Lost to Follow-up|1
6096238|NCT00727649|9710328|FG000|Second Intervention (4-weeks)|Withdrawal by Subject|0
6096239|NCT00727649|9710329|FG001|Second Intervention (4-weeks)|Withdrawal by Subject|2
6096240|NCT00727714|9710337|FG000|Overall Study|Lost to Follow-up|2
6096241|NCT00727844|9710352|FG000|Initial Randomization|Physician Decision|2
6096242|NCT00727844|9710353|FG001|Initial Randomization|Physician Decision|0
6096243|NCT00727844|9710354|FG002|Initial Randomization|Physician Decision|0
6096244|NCT00727844|9710355|FG003|Initial Randomization|Physician Decision|0
6096245|NCT00727909|9710374|FG000|Overall Study|Withdrawal by Subject|5
6096246|NCT00727909|9710375|FG001|Overall Study|Withdrawal by Subject|11
6096247|NCT00727909|9710376|FG002|Overall Study|Withdrawal by Subject|8
6096248|NCT00727909|9710377|FG003|Overall Study|Withdrawal by Subject|5
6096249|NCT00727909|9710374|FG000|Overall Study|Death|0
6096250|NCT00727909|9710375|FG001|Overall Study|Death|0
6096251|NCT00727909|9710376|FG002|Overall Study|Death|1
6096252|NCT00727909|9710377|FG003|Overall Study|Death|0
6096253|NCT00727961|9710381|FG000|Overall Study|Lost to Follow-up|1
6096254|NCT00727961|9710381|FG000|Overall Study|Adverse Event|4
6096255|NCT00727961|9710381|FG000|Overall Study|Patient's refusal|2
6096256|NCT00727961|9710381|FG000|Overall Study|Progression|30
6096257|NCT00728130|9710385|FG000|Overall Study|Withdrawal by Subject|1
6096258|NCT00728130|9710385|FG000|Overall Study|Paperwork not completed in time|1
6096259|NCT00728130|9710385|FG000|Overall Study|Physician Decision|1
6096260|NCT00728182|9710391|FG000|Overall Study|Adverse Event|1
6096261|NCT00728182|9710392|FG001|Overall Study|Adverse Event|0
6096262|NCT00728182|9710391|FG000|Overall Study|Lost to Follow-up|2
6096263|NCT00728182|9710392|FG001|Overall Study|Lost to Follow-up|0
6096264|NCT00728182|9710391|FG000|Overall Study|Death|0
6096265|NCT00728182|9710392|FG001|Overall Study|Death|2
6096266|NCT00728182|9710391|FG000|Overall Study|Protocol Noncompliance|0
6096267|NCT00728182|9710392|FG001|Overall Study|Protocol Noncompliance|1
6096268|NCT00728468|9710404|FG000|Overall Study|Enrolled but not treated|1
6096269|NCT00728468|9710404|FG000|Overall Study|Death|1
6096270|NCT00728468|9710404|FG000|Overall Study|Protocol Violation|4
6096271|NCT00728468|9710404|FG000|Overall Study|Objective progression or relapse|9
6096272|NCT00728468|9710404|FG000|Overall Study|Study terminated by sponsor|1
6096273|NCT00728481|9710410|FG000|Overall Study|Withdrawal by Subject|0
6096274|NCT00728481|9710411|FG001|Overall Study|Withdrawal by Subject|1
6096275|NCT00728481|9710410|FG000|Overall Study|Adverse Event|0
6096276|NCT00728481|9710411|FG001|Overall Study|Adverse Event|1
6096277|NCT00728481|9710410|FG000|Overall Study|Study medication non-compliance|0
6096278|NCT00728481|9710411|FG001|Overall Study|Study medication non-compliance|2
6096279|NCT00728481|9710410|FG000|Overall Study|Incorrectly assigned to opposite arm|1
6096280|NCT00728481|9710411|FG001|Overall Study|Incorrectly assigned to opposite arm|0
6096281|NCT00728494|9710419|FG000|Overall Study|Adverse Event|7
6096282|NCT00728494|9710420|FG001|Overall Study|Adverse Event|0
6096283|NCT00728494|9710419|FG000|Overall Study|Withdrawal by Subject|0
6284509|NCT02326272|9996341|FG013|Open-label Period (Week 48 to Week 144)|Withdrawal by Subject|0
6096284|NCT00728494|9710420|FG001|Overall Study|Withdrawal by Subject|2
6096285|NCT00728494|9710419|FG000|Overall Study|Lack of Efficacy|2
6096286|NCT00728494|9710420|FG001|Overall Study|Lack of Efficacy|4
6096287|NCT00728494|9710419|FG000|Overall Study|No data available|0
6096288|NCT00728494|9710420|FG001|Overall Study|No data available|1
6096289|NCT00728689|9710437|FG000|Washout Period (Days 4 - 10)|Death in family|1
6096290|NCT00728689|9710438|FG001|Washout Period (Days 4 - 10)|Death in family|0
6096291|NCT00728936|9710485|FG000|Overall Study|Withdrawal by Subject|0
6096292|NCT00728936|9710486|FG001|Overall Study|Withdrawal by Subject|0
6062761|NCT00502307|9664030|FG000|Open Label Period (16 Weeks)|Progressive disease|50
6062762|NCT00502307|9664031|FG001|Open Label Period (16 Weeks)|Progressive disease|0
6062763|NCT00502307|9664032|FG002|Open Label Period (16 Weeks)|Progressive disease|0
6062764|NCT00502307|9664030|FG000|Open Label Period (16 Weeks)|Discontinued due to other reasons|26
6062765|NCT00502307|9664031|FG001|Open Label Period (16 Weeks)|Discontinued due to other reasons|0
6062766|NCT00502307|9664032|FG002|Open Label Period (16 Weeks)|Discontinued due to other reasons|0
6096293|NCT00728936|9710487|FG002|Overall Study|Withdrawal by Subject|0
6096294|NCT00728936|9710488|FG003|Overall Study|Withdrawal by Subject|0
6096295|NCT00728936|9710489|FG004|Overall Study|Withdrawal by Subject|0
6096296|NCT00728936|9710490|FG005|Overall Study|Withdrawal by Subject|1
6096297|NCT00728936|9710491|FG006|Overall Study|Withdrawal by Subject|0
6096298|NCT00728949|9710509|FG000|Overall Study|Adverse Event|8
6096299|NCT00728949|9710510|FG001|Overall Study|Adverse Event|0
6096300|NCT00728949|9710509|FG000|Overall Study|Withdrawal by Subject|2
6096301|NCT00728949|9710510|FG001|Overall Study|Withdrawal by Subject|2
6096302|NCT00728949|9710509|FG000|Overall Study|Abnormal Lab Results|0
6096303|NCT00728949|9710510|FG001|Overall Study|Abnormal Lab Results|2
6096304|NCT00728949|9710509|FG000|Overall Study|On treatment at cutoff date|1
6096305|NCT00728949|9710510|FG001|Overall Study|On treatment at cutoff date|0
6096306|NCT00728988|9710518|FG000|Overall Study|Not Treated|2
6096307|NCT00728988|9710519|FG001|Overall Study|Not Treated|2
6096308|NCT00728988|9710518|FG000|Overall Study|Death|1
6096309|NCT00728988|9710519|FG001|Overall Study|Death|1
6096310|NCT00728988|9710518|FG000|Overall Study|Adverse Event|3
6096311|NCT00728988|9710519|FG001|Overall Study|Adverse Event|2
6096312|NCT00728988|9710518|FG000|Overall Study|Other|85
6096313|NCT00728988|9710519|FG001|Overall Study|Other|77
6096314|NCT00728988|9710518|FG000|Overall Study|Withdrawal by Subject|2
6096315|NCT00728988|9710519|FG001|Overall Study|Withdrawal by Subject|6
6096316|NCT00729157|9710543|FG000|Overall Study|Withdrawal by Subject|1
6096317|NCT00729183|9710549|FG000|Overall Study|Adverse Event|11
6096318|NCT00729183|9710550|FG001|Overall Study|Adverse Event|5
6096319|NCT00729183|9710549|FG000|Overall Study|Lack of Efficacy|0
6096320|NCT00729183|9710550|FG001|Overall Study|Lack of Efficacy|1
6096321|NCT00729183|9710549|FG000|Overall Study|Lost to Follow-up|3
6096322|NCT00729183|9710550|FG001|Overall Study|Lost to Follow-up|1
6096323|NCT00729183|9710549|FG000|Overall Study|Physician Decision|1
6096324|NCT00729183|9710550|FG001|Overall Study|Physician Decision|1
6096325|NCT00729183|9710549|FG000|Overall Study|Protocol Violation|1
6096326|NCT00729183|9710550|FG001|Overall Study|Protocol Violation|0
6096327|NCT00729183|9710549|FG000|Overall Study|Withdrawal by Subject|9
6096328|NCT00729183|9710550|FG001|Overall Study|Withdrawal by Subject|7
6096329|NCT00729248|9710556|FG000|Overall Study|Physician Decision|2
6096330|NCT00729326|9710563|FG000|Overall Study|Lost to Follow-up|2
6096331|NCT00729326|9710564|FG001|Overall Study|Lost to Follow-up|0
6096332|NCT00729326|9710563|FG000|Overall Study|Physician Decision|0
6096333|NCT00729326|9710564|FG001|Overall Study|Physician Decision|1
6096334|NCT00729326|9710563|FG000|Overall Study|Protocol Violation|3
6096335|NCT00729326|9710564|FG001|Overall Study|Protocol Violation|2
6096336|NCT00729326|9710563|FG000|Overall Study|Subject Decision|4
6096337|NCT00729326|9710564|FG001|Overall Study|Subject Decision|4
6096338|NCT00729326|9710563|FG000|Overall Study|Sponsor Decision|1
6096339|NCT00729326|9710564|FG001|Overall Study|Sponsor Decision|2
6096340|NCT00729378|9710572|FG000|Baseline|Did not complete study measurements|72
6096341|NCT00729378|9710573|FG001|Baseline|Did not complete study measurements|33
6203265|NCT01513239|9864240|FG004|Period 2: 9 Month Extension Phase|Technical Problems|1
6203266|NCT01513239|9864241|FG005|Period 2: 9 Month Extension Phase|Technical Problems|1
6203267|NCT01513291|9864255|FG000|Treatment Period|Adverse Event|8
6203268|NCT01513291|9864256|FG001|Treatment Period|Adverse Event|4
6203269|NCT01513291|9864257|FG002|Treatment Period|Adverse Event|0
6203270|NCT01513291|9864258|FG003|Treatment Period|Adverse Event|0
6203271|NCT01513291|9864259|FG004|Treatment Period|Adverse Event|0
6062767|NCT00502307|9664030|FG000|Double-Blind Period (12 Weeks)|Progressive disease|0
6096342|NCT00729378|9710572|FG000|Baseline|Withdrawal by Subject|66
6096343|NCT00729378|9710573|FG001|Baseline|Withdrawal by Subject|59
6096344|NCT00729378|9710572|FG000|12-months|Lost to Follow-up|100
6096345|NCT00729378|9710573|FG001|12-months|Lost to Follow-up|65
6096346|NCT00729378|9710572|FG000|24-months|Lost to Follow-up|72
6096347|NCT00729378|9710573|FG001|24-months|Lost to Follow-up|51
6203272|NCT01513291|9864255|FG000|Treatment Period|Lack of Efficacy|3
6203273|NCT01513291|9864256|FG001|Treatment Period|Lack of Efficacy|0
6062768|NCT00502307|9664031|FG001|Double-Blind Period (12 Weeks)|Progressive disease|23
6062769|NCT00502307|9664032|FG002|Double-Blind Period (12 Weeks)|Progressive disease|2
6062770|NCT00502307|9664030|FG000|Double-Blind Period (12 Weeks)|Discontinued due to other reasons|0
6062771|NCT00502307|9664031|FG001|Double-Blind Period (12 Weeks)|Discontinued due to other reasons|3
6062772|NCT00502307|9664032|FG002|Double-Blind Period (12 Weeks)|Discontinued due to other reasons|7
6062773|NCT00502307|9664030|FG000|Maintenance Period|Progressive disease|80
6062774|NCT00502307|9664031|FG001|Maintenance Period|Progressive disease|0
6062775|NCT00502307|9664032|FG002|Maintenance Period|Progressive disease|0
6062776|NCT00502307|9664030|FG000|Maintenance Period|Discontinued due to other reasons|68
6062777|NCT00502307|9664031|FG001|Maintenance Period|Discontinued due to other reasons|0
6062778|NCT00502307|9664032|FG002|Maintenance Period|Discontinued due to other reasons|0
6062779|NCT00502320|9664051|FG000|Overall Study|Lost to Follow-up|1
6062780|NCT00502320|9664052|FG001|Overall Study|Lost to Follow-up|1
6062781|NCT00502320|9664051|FG000|Overall Study|Withdrew Consent|1
6062782|NCT00502320|9664052|FG001|Overall Study|Withdrew Consent|0
6062783|NCT00502320|9664051|FG000|Overall Study|No longer met criteria|1
6062784|NCT00502320|9664052|FG001|Overall Study|No longer met criteria|0
6062785|NCT00502320|9664051|FG000|Overall Study|Screen Failure|0
6062786|NCT00502320|9664052|FG001|Overall Study|Screen Failure|1
6062787|NCT00502320|9664051|FG000|Overall Study|Adverse Event|3
6062788|NCT00502320|9664052|FG001|Overall Study|Adverse Event|5
6062789|NCT00502593|9664070|FG000|Overall Study|Withdrawn unspecified reason|1
6062790|NCT00502593|9664071|FG001|Overall Study|Withdrawn unspecified reason|1
6062791|NCT00502593|9664072|FG002|Overall Study|Withdrawn unspecified reason|3
6062792|NCT00502593|9664073|FG003|Overall Study|Withdrawn unspecified reason|1
6062793|NCT00502593|9664074|FG004|Overall Study|Withdrawn unspecified reason|2
6062794|NCT00502593|9664075|FG005|Overall Study|Withdrawn unspecified reason|0
6062795|NCT00502593|9664076|FG006|Overall Study|Withdrawn unspecified reason|2
6062796|NCT00502593|9664077|FG007|Overall Study|Withdrawn unspecified reason|0
6062797|NCT00502593|9664078|FG008|Overall Study|Withdrawn unspecified reason|0
6062798|NCT00502593|9664079|FG009|Overall Study|Withdrawn unspecified reason|0
6062799|NCT00502593|9664080|FG010|Overall Study|Withdrawn unspecified reason|0
6062800|NCT00502593|9664081|FG011|Overall Study|Withdrawn unspecified reason|0
6062801|NCT00502593|9664070|FG000|Overall Study|Withdrawal by Subject|0
6062802|NCT00502593|9664071|FG001|Overall Study|Withdrawal by Subject|0
6062803|NCT00502593|9664072|FG002|Overall Study|Withdrawal by Subject|6
6062804|NCT00502593|9664073|FG003|Overall Study|Withdrawal by Subject|2
6062805|NCT00502593|9664074|FG004|Overall Study|Withdrawal by Subject|2
6062806|NCT00502593|9664075|FG005|Overall Study|Withdrawal by Subject|0
6062807|NCT00502593|9664076|FG006|Overall Study|Withdrawal by Subject|3
6062808|NCT00502593|9664077|FG007|Overall Study|Withdrawal by Subject|0
6062809|NCT00502593|9664078|FG008|Overall Study|Withdrawal by Subject|3
6062810|NCT00502593|9664079|FG009|Overall Study|Withdrawal by Subject|0
6062811|NCT00502593|9664080|FG010|Overall Study|Withdrawal by Subject|1
6062812|NCT00502593|9664081|FG011|Overall Study|Withdrawal by Subject|0
6062813|NCT00502593|9664070|FG000|Overall Study|Lost to Follow-up|2
6062814|NCT00502593|9664071|FG001|Overall Study|Lost to Follow-up|1
6062815|NCT00502593|9664072|FG002|Overall Study|Lost to Follow-up|1
6062816|NCT00502593|9664073|FG003|Overall Study|Lost to Follow-up|1
6062817|NCT00502593|9664074|FG004|Overall Study|Lost to Follow-up|0
6062818|NCT00502593|9664075|FG005|Overall Study|Lost to Follow-up|0
6062819|NCT00502593|9664076|FG006|Overall Study|Lost to Follow-up|0
6062820|NCT00502593|9664077|FG007|Overall Study|Lost to Follow-up|0
6062821|NCT00502593|9664078|FG008|Overall Study|Lost to Follow-up|3
6062822|NCT00502593|9664079|FG009|Overall Study|Lost to Follow-up|0
6062823|NCT00502593|9664080|FG010|Overall Study|Lost to Follow-up|1
6062824|NCT00502593|9664081|FG011|Overall Study|Lost to Follow-up|0
6062825|NCT00502671|9664130|FG000|Overall Study|Disease Progression|13
6062826|NCT00502671|9664130|FG000|Overall Study|Personal Reasons|22
6062827|NCT00502671|9664130|FG000|Overall Study|Lost to Follow-up|7
6062828|NCT00502671|9664130|FG000|Overall Study|Protocol Violation|16
6062829|NCT00502671|9664130|FG000|Overall Study|Adverse Event|19
6062830|NCT00502697|9664136|FG000|Overall Study|Withdrawal by Subject|3
6062831|NCT00502697|9664137|FG001|Overall Study|Withdrawal by Subject|1
6062832|NCT00502697|9664136|FG000|Overall Study|disenrolled due to pregnancy loss|3
6062833|NCT00502697|9664137|FG001|Overall Study|disenrolled due to pregnancy loss|5
6062834|NCT00502697|9664136|FG000|Overall Study|found not to meet eligibility criteria|3
6062835|NCT00502697|9664137|FG001|Overall Study|found not to meet eligibility criteria|4
6062836|NCT00502697|9664136|FG000|Overall Study|did not meet assignment criteria|4
6062837|NCT00502697|9664137|FG001|Overall Study|did not meet assignment criteria|2
6062838|NCT00502775|9664146|FG000|Overall Study|Adverse Event|1
6062839|NCT00502775|9664147|FG001|Overall Study|Adverse Event|2
6062840|NCT00502775|9664148|FG002|Overall Study|Adverse Event|1
6062841|NCT00502775|9664146|FG000|Overall Study|Protocol Violation|1
6062842|NCT00502775|9664147|FG001|Overall Study|Protocol Violation|5
6062843|NCT00502775|9664148|FG002|Overall Study|Protocol Violation|2
6062844|NCT00502775|9664146|FG000|Overall Study|Withdrawal by Subject|1
6062845|NCT00502775|9664147|FG001|Overall Study|Withdrawal by Subject|1
6062846|NCT00502775|9664148|FG002|Overall Study|Withdrawal by Subject|2
6062847|NCT00502775|9664146|FG000|Overall Study|Sponsor Terminated Study|1
6062848|NCT00502775|9664147|FG001|Overall Study|Sponsor Terminated Study|0
6062849|NCT00502775|9664148|FG002|Overall Study|Sponsor Terminated Study|1
6062850|NCT00502775|9664146|FG000|Overall Study|Non-compliance with eDiary|4
6062851|NCT00502775|9664147|FG001|Overall Study|Non-compliance with eDiary|1
6062852|NCT00502775|9664148|FG002|Overall Study|Non-compliance with eDiary|1
6062853|NCT00502775|9664146|FG000|Overall Study|Subject unable to swallow capsule|1
6062854|NCT00502775|9664147|FG001|Overall Study|Subject unable to swallow capsule|0
6062855|NCT00502775|9664148|FG002|Overall Study|Subject unable to swallow capsule|1
6062856|NCT00502775|9664146|FG000|Overall Study|Logpad compliance <80%|1
6062857|NCT00502775|9664147|FG001|Overall Study|Logpad compliance <80%|0
6062858|NCT00502775|9664148|FG002|Overall Study|Logpad compliance <80%|0
6062859|NCT00502775|9664146|FG000|Overall Study|Randomized in error|0
6062860|NCT00502775|9664147|FG001|Overall Study|Randomized in error|1
6062861|NCT00502775|9664148|FG002|Overall Study|Randomized in error|1
6062862|NCT00502775|9664146|FG000|Overall Study|Non-compliance|0
6062863|NCT00502775|9664147|FG001|Overall Study|Non-compliance|2
6062864|NCT00502775|9664148|FG002|Overall Study|Non-compliance|2
6062865|NCT00502775|9664146|FG000|Overall Study|Outside pollen area more than 48 hours|0
6062866|NCT00502775|9664147|FG001|Overall Study|Outside pollen area more than 48 hours|1
6062867|NCT00502775|9664148|FG002|Overall Study|Outside pollen area more than 48 hours|0
6062868|NCT00502775|9664146|FG000|Overall Study|Declining pollen counts|0
6062869|NCT00502775|9664147|FG001|Overall Study|Declining pollen counts|1
6062870|NCT00502775|9664148|FG002|Overall Study|Declining pollen counts|1
6062871|NCT00502775|9664146|FG000|Overall Study|Subject in jail|0
6062872|NCT00502775|9664147|FG001|Overall Study|Subject in jail|1
6062873|NCT00502775|9664148|FG002|Overall Study|Subject in jail|0
6062874|NCT00502775|9664146|FG000|Overall Study|Subject took disallowed drug|0
6062875|NCT00502775|9664147|FG001|Overall Study|Subject took disallowed drug|0
6062876|NCT00502775|9664148|FG002|Overall Study|Subject took disallowed drug|1
6062877|NCT00502801|9664156|FG000|Treatment Period|Withdrawal by Subject|3
6062878|NCT00502801|9664156|FG000|Treatment Period|Adverse Event|7
6062879|NCT00502801|9664156|FG000|Treatment Period|Death|14
6062880|NCT00502801|9664156|FG000|Treatment Period|OTHER|30
6062881|NCT00502801|9664156|FG000|End of Therapy to Test of Cure|Withdrawal by Subject|1
6062882|NCT00502801|9664156|FG000|End of Therapy to Test of Cure|Lost to Follow-up|2
6062883|NCT00502801|9664156|FG000|End of Therapy to Test of Cure|Death|3
6062884|NCT00502801|9664156|FG000|End of Therapy to Test of Cure|OTHER|2
6062885|NCT00502840|9664160|FG000|Overall Study|Adverse Event|5
6062886|NCT00502840|9664160|FG000|Overall Study|Additional or changed therapy|48
6062887|NCT00502840|9664160|FG000|Overall Study|Lack of Efficacy|11
6062888|NCT00502840|9664160|FG000|Overall Study|Protocol Violation|4
6062889|NCT00502840|9664160|FG000|Overall Study|Withdrawal by Subject|5
6062890|NCT00502840|9664160|FG000|Overall Study|Lost to Follow-up|6
6062891|NCT00502840|9664160|FG000|Overall Study|Administrative problems|1
6062892|NCT00502840|9664160|FG000|Overall Study|Other|20
6062893|NCT00502996|9664183|FG000|Overall Study|Lost to Follow-up|9
6062894|NCT00502996|9664183|FG000|Overall Study|Protocol Violation|2
6062895|NCT00502996|9664183|FG000|Overall Study|Treatment failure|25
6062896|NCT00502996|9664183|FG000|Overall Study|Withdrawal Informed Consent|6
6062897|NCT00502996|9664183|FG000|Overall Study|Adverse Event|2
6062898|NCT00503139|9664200|FG000|Overall Study|Case Report Forms were not collected|4
6062899|NCT00503139|9664200|FG000|Overall Study|Protocol Violation|4
6062900|NCT00503308|9664206|FG000|Overall Study|Protocol Violation|2
6062901|NCT00503308|9664207|FG001|Overall Study|Protocol Violation|1
6062902|NCT00503399|9664215|FG000|Overall Study|Death|2
6062903|NCT00503399|9664216|FG001|Overall Study|Death|1
6096348|NCT00729378|9710572|FG000|36-months|Lost to Follow-up|15
6096349|NCT00729378|9710573|FG001|36-months|Lost to Follow-up|6
6096350|NCT00729469|9710594|FG000|Overall Study|Adverse Event|14
6096351|NCT00729469|9710595|FG001|Overall Study|Adverse Event|25
6096352|NCT00729469|9710594|FG000|Overall Study|Lost to Follow-up|9
6096353|NCT00729469|9710595|FG001|Overall Study|Lost to Follow-up|9
6096354|NCT00729469|9710594|FG000|Overall Study|Protocol Violation|2
6096355|NCT00729469|9710595|FG001|Overall Study|Protocol Violation|1
6096356|NCT00729469|9710594|FG000|Overall Study|Withdrawal by Subject|19
6096357|NCT00729469|9710595|FG001|Overall Study|Withdrawal by Subject|8
6096358|NCT00729469|9710594|FG000|Overall Study|Other-Not mentioned|9
6096359|NCT00729469|9710595|FG001|Overall Study|Other-Not mentioned|4
6096360|NCT00729586|9710620|FG000|Overall Study|Ineligible|0
6096361|NCT00729586|9710621|FG001|Overall Study|Ineligible|1
6096362|NCT00729586|9710620|FG000|Overall Study|never treated|1
6096363|NCT00729586|9710621|FG001|Overall Study|never treated|0
6096364|NCT00729612|9710628|FG000|Overall Study|Non evaluable for response|10
6096365|NCT00729690|9710646|FG000|Overall Study|IT Catheter Malfunction|0
6096366|NCT00729690|9710647|FG001|Overall Study|IT Catheter Malfunction|2
6096367|NCT00729690|9710648|FG002|Overall Study|IT Catheter Malfunction|2
6096368|NCT00729833|9710664|FG000|Overall Study|Death|5
6096369|NCT00729833|9710665|FG001|Overall Study|Death|1
6096370|NCT00729833|9710666|FG002|Overall Study|Death|3
6096371|NCT00729833|9710667|FG003|Overall Study|Death|5
6096372|NCT00729833|9710664|FG000|Overall Study|Study Terminated by Sponsor|0
6096373|NCT00729833|9710665|FG001|Overall Study|Study Terminated by Sponsor|0
6096374|NCT00729833|9710666|FG002|Overall Study|Study Terminated by Sponsor|1
6096375|NCT00729833|9710667|FG003|Overall Study|Study Terminated by Sponsor|0
6096376|NCT00729833|9710664|FG000|Overall Study|Lost to Follow-up|1
6096377|NCT00729833|9710665|FG001|Overall Study|Lost to Follow-up|0
6096378|NCT00729833|9710666|FG002|Overall Study|Lost to Follow-up|0
6062904|NCT00503399|9664215|FG000|Overall Study|Protocol Violation|1
6062905|NCT00503399|9664216|FG001|Overall Study|Protocol Violation|0
6062906|NCT00503399|9664215|FG000|Overall Study|Withdrawal by Subject|4
6062907|NCT00503399|9664216|FG001|Overall Study|Withdrawal by Subject|2
6096379|NCT00729833|9710667|FG003|Overall Study|Lost to Follow-up|0
6096380|NCT00729833|9710664|FG000|Overall Study|Withdrawal by Subject|3
6096381|NCT00729833|9710665|FG001|Overall Study|Withdrawal by Subject|1
6096382|NCT00729833|9710666|FG002|Overall Study|Withdrawal by Subject|3
6096383|NCT00729833|9710667|FG003|Overall Study|Withdrawal by Subject|0
6062908|NCT00503399|9664215|FG000|Overall Study|Adverse Event|0
6062909|NCT00503399|9664216|FG001|Overall Study|Adverse Event|3
6062910|NCT00503399|9664215|FG000|Overall Study|Lost to Follow-up|0
6062911|NCT00503399|9664216|FG001|Overall Study|Lost to Follow-up|2
6062912|NCT00503425|9664222|FG000|Overall Study|Participant files lost|6
6062913|NCT00503425|9664222|FG000|Overall Study|Adverse Event|5
6062914|NCT00503425|9664222|FG000|Overall Study|Lack of Efficacy|25
6062915|NCT00503425|9664222|FG000|Overall Study|Withdrawal by Subject|8
6062916|NCT00503425|9664222|FG000|Overall Study|Lost to Follow-up|3
6062917|NCT00503425|9664222|FG000|Overall Study|Death|3
6062918|NCT00503425|9664222|FG000|Overall Study|Missing Data/Unknown|4
6062919|NCT00503685|9664230|FG000|Overall Study|Adverse Event|0
6062920|NCT00503685|9664231|FG001|Overall Study|Adverse Event|0
6062921|NCT00503685|9664232|FG002|Overall Study|Adverse Event|2
6062922|NCT00503685|9664230|FG000|Overall Study|Withdrawal by Subject|0
6062923|NCT00503685|9664231|FG001|Overall Study|Withdrawal by Subject|1
6062924|NCT00503685|9664232|FG002|Overall Study|Withdrawal by Subject|0
6062925|NCT00503685|9664230|FG000|Overall Study|Protocol Violation|0
6062926|NCT00503685|9664231|FG001|Overall Study|Protocol Violation|1
6062927|NCT00503685|9664232|FG002|Overall Study|Protocol Violation|0
6062928|NCT00503685|9664230|FG000|Overall Study|Eligibility Criteria Not Met|0
6062929|NCT00503685|9664231|FG001|Overall Study|Eligibility Criteria Not Met|1
6062930|NCT00503685|9664232|FG002|Overall Study|Eligibility Criteria Not Met|0
6062931|NCT00503698|9664243|FG000|Overall Study|Protocol Violation|5
6062932|NCT00503698|9664244|FG001|Overall Study|Protocol Violation|6
6062933|NCT00503698|9664243|FG000|Overall Study|Adverse Event|52
6062934|NCT00503698|9664244|FG001|Overall Study|Adverse Event|41
6062935|NCT00503698|9664243|FG000|Overall Study|Death|1
6062936|NCT00503698|9664244|FG001|Overall Study|Death|0
6062937|NCT00503698|9664243|FG000|Overall Study|Lack of Efficacy|3
6062938|NCT00503698|9664244|FG001|Overall Study|Lack of Efficacy|4
6062939|NCT00503698|9664243|FG000|Overall Study|Trial terminated|216
6062940|NCT00503698|9664244|FG001|Overall Study|Trial terminated|253
6062941|NCT00503698|9664243|FG000|Overall Study|End hemodialysis due to renal transplant|10
6062942|NCT00503698|9664244|FG001|Overall Study|End hemodialysis due to renal transplant|4
6062943|NCT00503698|9664243|FG000|Overall Study|Pregnancy/intention to become pregnant|1
6062944|NCT00503698|9664244|FG001|Overall Study|Pregnancy/intention to become pregnant|0
6062945|NCT00503698|9664243|FG000|Overall Study|Any condition in exclusion criteria|4
6062946|NCT00503698|9664244|FG001|Overall Study|Any condition in exclusion criteria|6
6062947|NCT00503698|9664243|FG000|Overall Study|Switch to peritoneal or home dialysis|2
6062948|NCT00503698|9664244|FG001|Overall Study|Switch to peritoneal or home dialysis|2
6062949|NCT00503698|9664243|FG000|Overall Study|Move to nonparticipating dialysis center|2
6062950|NCT00503698|9664244|FG001|Overall Study|Move to nonparticipating dialysis center|1
6062951|NCT00503698|9664243|FG000|Overall Study|Critically ill|2
6062952|NCT00503698|9664244|FG001|Overall Study|Critically ill|0
6062953|NCT00503698|9664243|FG000|Overall Study|Unclassified|48
6062954|NCT00503698|9664244|FG001|Overall Study|Unclassified|32
6062955|NCT00503698|9664243|FG000|Overall Study|Not exposed to trial drug|11
6062956|NCT00503698|9664244|FG001|Overall Study|Not exposed to trial drug|6
6062957|NCT00503776|9664258|FG000|Overall Study|Withdrawal by Subject|1
6062958|NCT00503776|9664259|FG001|Overall Study|Withdrawal by Subject|0
6062959|NCT00503776|9664260|FG002|Overall Study|Withdrawal by Subject|1
6062960|NCT00503776|9664261|FG003|Overall Study|Withdrawal by Subject|1
6062961|NCT00503776|9664258|FG000|Overall Study|Physician Decision|0
6062962|NCT00503776|9664259|FG001|Overall Study|Physician Decision|0
6062963|NCT00503776|9664260|FG002|Overall Study|Physician Decision|1
6062964|NCT00503776|9664261|FG003|Overall Study|Physician Decision|1
6062965|NCT00503867|9664276|FG000|Overall Study|Lost to Follow-up|1
6062966|NCT00503867|9664276|FG000|Overall Study|Adverse Event|1
6062967|NCT00503906|9664280|FG000|Overall Study|Withdrawal by Subject|1
6062968|NCT00503984|9664287|FG000|Overall Study|Protocol Violation|0
6062969|NCT00503984|9664288|FG001|Overall Study|Protocol Violation|1
6062970|NCT00503984|9664289|FG002|Overall Study|Protocol Violation|0
6062971|NCT00503984|9664290|FG003|Overall Study|Protocol Violation|0
6062972|NCT00503984|9664291|FG004|Overall Study|Protocol Violation|0
6062973|NCT00503984|9664292|FG005|Overall Study|Protocol Violation|0
6062974|NCT00503984|9664287|FG000|Overall Study|Adverse Event|0
6062975|NCT00503984|9664288|FG001|Overall Study|Adverse Event|1
6062976|NCT00503984|9664289|FG002|Overall Study|Adverse Event|0
6062977|NCT00503984|9664290|FG003|Overall Study|Adverse Event|0
6062978|NCT00503984|9664291|FG004|Overall Study|Adverse Event|0
6062979|NCT00503984|9664292|FG005|Overall Study|Adverse Event|0
6062980|NCT00503984|9664287|FG000|Overall Study|Death|0
6062981|NCT00503984|9664288|FG001|Overall Study|Death|0
6062982|NCT00503984|9664289|FG002|Overall Study|Death|0
6062983|NCT00503984|9664290|FG003|Overall Study|Death|0
6062984|NCT00503984|9664291|FG004|Overall Study|Death|1
6062985|NCT00503984|9664292|FG005|Overall Study|Death|0
6062986|NCT00503997|9664316|FG000|Overall Study|disease progression|1
6062987|NCT00503997|9664316|FG000|Overall Study|Adverse Event|5
6062988|NCT00503997|9664316|FG000|Overall Study|Death|1
6062989|NCT00503997|9664316|FG000|Overall Study|Withdrawal by Subject|1
6062990|NCT00504075|9664324|FG000|Overall Study|Adverse Event|1
6062991|NCT00504075|9664324|FG000|Overall Study|Lost to Follow-up|5
6062992|NCT00504075|9664324|FG000|Overall Study|Withdrawal by Subject|1
6062993|NCT00504075|9664324|FG000|Overall Study|Required other therapeutic intervention|1
6062994|NCT00504153|9664329|FG000|Overall Study|Withdrawal by Subject|1
6062995|NCT00504153|9664329|FG000|Overall Study|Adverse Event|4
6062996|NCT00504153|9664329|FG000|Overall Study|Death|1
6062997|NCT00504166|9664335|FG000|Overall Study|Adverse Event|1
6062998|NCT00504166|9664336|FG001|Overall Study|Adverse Event|4
6062999|NCT00504166|9664335|FG000|Overall Study|Withdrawal by Subject|3
6063000|NCT00504166|9664336|FG001|Overall Study|Withdrawal by Subject|6
6063001|NCT00504166|9664335|FG000|Overall Study|Physician Decision|1
6096384|NCT00729833|9710664|FG000|Overall Study|Unspecified Reasons|11
6096385|NCT00729833|9710665|FG001|Overall Study|Unspecified Reasons|5
6096386|NCT00729833|9710666|FG002|Overall Study|Unspecified Reasons|5
6096387|NCT00729833|9710667|FG003|Overall Study|Unspecified Reasons|1
6096388|NCT00729859|9710690|FG000|Overall Study|Adverse Event|0
6096389|NCT00729859|9710691|FG001|Overall Study|Adverse Event|1
6096390|NCT00729859|9710692|FG002|Overall Study|Adverse Event|0
6096391|NCT00729859|9710690|FG000|Overall Study|Withdrawal by Subject|0
6096392|NCT00729859|9710691|FG001|Overall Study|Withdrawal by Subject|1
6096393|NCT00729859|9710692|FG002|Overall Study|Withdrawal by Subject|0
6096394|NCT00729937|9710721|FG000|Overall Study|Lost to Follow-up|49
6096395|NCT00729937|9710722|FG001|Overall Study|Lost to Follow-up|58
6096396|NCT00729937|9710723|FG002|Overall Study|Lost to Follow-up|18
6096397|NCT00729937|9710724|FG003|Overall Study|Lost to Follow-up|33
6096398|NCT00729937|9710725|FG004|Overall Study|Lost to Follow-up|18
6096399|NCT00729937|9710726|FG005|Overall Study|Lost to Follow-up|23
6096400|NCT00729937|9710721|FG000|Overall Study|Physician Decision|7
6096401|NCT00729937|9710722|FG001|Overall Study|Physician Decision|16
6096402|NCT00729937|9710723|FG002|Overall Study|Physician Decision|2
6096403|NCT00729937|9710724|FG003|Overall Study|Physician Decision|0
6096404|NCT00729937|9710725|FG004|Overall Study|Physician Decision|5
6096405|NCT00729937|9710726|FG005|Overall Study|Physician Decision|8
6096406|NCT00729937|9710721|FG000|Overall Study|Death|1
6096407|NCT00729937|9710722|FG001|Overall Study|Death|0
6096408|NCT00729937|9710723|FG002|Overall Study|Death|1
6096409|NCT00729937|9710724|FG003|Overall Study|Death|0
6096410|NCT00729937|9710725|FG004|Overall Study|Death|0
6096411|NCT00729937|9710726|FG005|Overall Study|Death|1
6096412|NCT00729937|9710721|FG000|Overall Study|Withdrawal by Subject|3
6096413|NCT00729937|9710722|FG001|Overall Study|Withdrawal by Subject|5
6096414|NCT00729937|9710723|FG002|Overall Study|Withdrawal by Subject|6
6096415|NCT00729937|9710724|FG003|Overall Study|Withdrawal by Subject|0
6096416|NCT00729937|9710725|FG004|Overall Study|Withdrawal by Subject|4
6096417|NCT00729937|9710726|FG005|Overall Study|Withdrawal by Subject|2
6096418|NCT00729937|9710721|FG000|Overall Study|Randomized but not treated|12
6096419|NCT00729937|9710722|FG001|Overall Study|Randomized but not treated|6
6096420|NCT00729937|9710723|FG002|Overall Study|Randomized but not treated|1
6096421|NCT00729937|9710724|FG003|Overall Study|Randomized but not treated|0
6096422|NCT00729937|9710725|FG004|Overall Study|Randomized but not treated|1
6096423|NCT00729937|9710726|FG005|Overall Study|Randomized but not treated|3
6096424|NCT00729937|9710721|FG000|Overall Study|Did not meet eligibility criteria|2
6096425|NCT00729937|9710722|FG001|Overall Study|Did not meet eligibility criteria|1
6096426|NCT00729937|9710723|FG002|Overall Study|Did not meet eligibility criteria|0
6096427|NCT00729937|9710724|FG003|Overall Study|Did not meet eligibility criteria|0
6096428|NCT00729937|9710725|FG004|Overall Study|Did not meet eligibility criteria|0
6096429|NCT00729937|9710726|FG005|Overall Study|Did not meet eligibility criteria|0
6096430|NCT00729937|9710721|FG000|Overall Study|Incarcerated|0
6096431|NCT00729937|9710722|FG001|Overall Study|Incarcerated|2
6096432|NCT00729937|9710723|FG002|Overall Study|Incarcerated|1
6096433|NCT00729937|9710724|FG003|Overall Study|Incarcerated|1
6096434|NCT00729937|9710725|FG004|Overall Study|Incarcerated|0
6096435|NCT00729937|9710726|FG005|Overall Study|Incarcerated|0
6096436|NCT00730015|9710743|FG000|Overall Study|Adverse Event|11
6096437|NCT00730015|9710744|FG001|Overall Study|Adverse Event|10
6096438|NCT00730015|9710745|FG002|Overall Study|Adverse Event|8
6096439|NCT00730015|9710743|FG000|Overall Study|Protocol Violation|2
6096440|NCT00730015|9710744|FG001|Overall Study|Protocol Violation|6
6096441|NCT00730015|9710745|FG002|Overall Study|Protocol Violation|4
6096442|NCT00730015|9710743|FG000|Overall Study|Withdrawal by Subject|12
6096443|NCT00730015|9710744|FG001|Overall Study|Withdrawal by Subject|12
6096444|NCT00730015|9710745|FG002|Overall Study|Withdrawal by Subject|8
6096445|NCT00730015|9710743|FG000|Overall Study|Lost to Follow-up|4
6096446|NCT00730015|9710744|FG001|Overall Study|Lost to Follow-up|10
6096447|NCT00730015|9710745|FG002|Overall Study|Lost to Follow-up|3
6096448|NCT00730015|9710743|FG000|Overall Study|Lack of Efficacy|1
6096449|NCT00730015|9710744|FG001|Overall Study|Lack of Efficacy|2
6096450|NCT00730015|9710745|FG002|Overall Study|Lack of Efficacy|8
6096451|NCT00730015|9710743|FG000|Overall Study|Other Reason|1
6096452|NCT00730015|9710744|FG001|Overall Study|Other Reason|0
6096453|NCT00730015|9710745|FG002|Overall Study|Other Reason|1
6096454|NCT00730028|9710763|FG000|Overall Study|Adverse Event|23
6096455|NCT00730028|9710764|FG001|Overall Study|Adverse Event|26
6096456|NCT00730028|9710765|FG002|Overall Study|Adverse Event|16
6096457|NCT00730028|9710766|FG003|Overall Study|Adverse Event|20
6096458|NCT00730028|9710767|FG004|Overall Study|Adverse Event|43
6096459|NCT00730028|9710763|FG000|Overall Study|Lost to Follow-up|13
6096460|NCT00730028|9710764|FG001|Overall Study|Lost to Follow-up|26
6063002|NCT00504166|9664336|FG001|Overall Study|Physician Decision|1
6063003|NCT00504166|9664335|FG000|Overall Study|Lost to Follow-up|1
6063004|NCT00504166|9664336|FG001|Overall Study|Lost to Follow-up|3
6063005|NCT00504231|9664346|FG000|Overall Study|Discrepant chart documentation re route|0
6063006|NCT00504231|9664347|FG001|Overall Study|Discrepant chart documentation re route|0
6063007|NCT00504231|9664348|FG002|Overall Study|Discrepant chart documentation re route|1
6063008|NCT00504231|9664349|FG003|Overall Study|Discrepant chart documentation re route|0
6063009|NCT00504257|9664363|FG000|Overall Study|Withdrawal by Subject|2
6063010|NCT00504257|9664363|FG000|Overall Study|ineligible histology|2
6063011|NCT00504309|9664373|FG000|Overall Study|Death|0
6063012|NCT00504309|9664374|FG001|Overall Study|Death|0
6063013|NCT00504309|9664375|FG002|Overall Study|Death|0
6063014|NCT00504309|9664376|FG003|Overall Study|Death|0
6063015|NCT00504309|9664377|FG004|Overall Study|Death|1
6063016|NCT00504309|9664378|FG005|Overall Study|Death|0
6063017|NCT00504309|9664373|FG000|Overall Study|Withdrawal by Subject|0
6063018|NCT00504309|9664374|FG001|Overall Study|Withdrawal by Subject|0
6063019|NCT00504309|9664375|FG002|Overall Study|Withdrawal by Subject|1
6063020|NCT00504309|9664376|FG003|Overall Study|Withdrawal by Subject|0
6063021|NCT00504309|9664377|FG004|Overall Study|Withdrawal by Subject|0
6063022|NCT00504309|9664378|FG005|Overall Study|Withdrawal by Subject|0
6063023|NCT00504348|9664390|FG000|Overall Study|Adverse Event|3
6063024|NCT00504348|9664390|FG000|Overall Study|Lack of Efficacy|4
6063025|NCT00504348|9664390|FG000|Overall Study|Physician Decision|1
6063026|NCT00504426|9664398|FG000|Overall Study|Adverse Event|0
6063027|NCT00504426|9664399|FG001|Overall Study|Adverse Event|0
6063028|NCT00504426|9664400|FG002|Overall Study|Adverse Event|2
6063029|NCT00504426|9664401|FG003|Overall Study|Adverse Event|0
6063030|NCT00504426|9664398|FG000|Overall Study|Protocol Violation|1
6063031|NCT00504426|9664399|FG001|Overall Study|Protocol Violation|1
6063032|NCT00504426|9664400|FG002|Overall Study|Protocol Violation|2
6063033|NCT00504426|9664401|FG003|Overall Study|Protocol Violation|0
6063034|NCT00504426|9664398|FG000|Overall Study|Withdrawal by Subject|2
6063035|NCT00504426|9664399|FG001|Overall Study|Withdrawal by Subject|0
6063036|NCT00504426|9664400|FG002|Overall Study|Withdrawal by Subject|0
6063037|NCT00504426|9664401|FG003|Overall Study|Withdrawal by Subject|0
6063038|NCT00504556|9664423|FG000|Overall Study|Adverse Event|11
6063039|NCT00504556|9664424|FG001|Overall Study|Adverse Event|11
6063040|NCT00504556|9664425|FG002|Overall Study|Adverse Event|14
6063041|NCT00504556|9664426|FG003|Overall Study|Adverse Event|13
6063042|NCT00504556|9664427|FG004|Overall Study|Adverse Event|5
6063043|NCT00504556|9664423|FG000|Overall Study|Death|3
6063044|NCT00504556|9664424|FG001|Overall Study|Death|3
6063045|NCT00504556|9664425|FG002|Overall Study|Death|1
6063046|NCT00504556|9664426|FG003|Overall Study|Death|0
6063047|NCT00504556|9664427|FG004|Overall Study|Death|2
6063048|NCT00504556|9664423|FG000|Overall Study|Protocol Violation|1
6063049|NCT00504556|9664424|FG001|Overall Study|Protocol Violation|3
6063050|NCT00504556|9664425|FG002|Overall Study|Protocol Violation|2
6063051|NCT00504556|9664426|FG003|Overall Study|Protocol Violation|1
6063052|NCT00504556|9664427|FG004|Overall Study|Protocol Violation|2
6063053|NCT00504556|9664423|FG000|Overall Study|Lost to Follow-up|0
6063054|NCT00504556|9664424|FG001|Overall Study|Lost to Follow-up|0
6063055|NCT00504556|9664425|FG002|Overall Study|Lost to Follow-up|1
6063056|NCT00504556|9664426|FG003|Overall Study|Lost to Follow-up|1
6063057|NCT00504556|9664427|FG004|Overall Study|Lost to Follow-up|1
6063058|NCT00504556|9664423|FG000|Overall Study|Withdrawal by Subject|16
6063059|NCT00504556|9664424|FG001|Overall Study|Withdrawal by Subject|16
6063060|NCT00504556|9664425|FG002|Overall Study|Withdrawal by Subject|7
6063061|NCT00504556|9664426|FG003|Overall Study|Withdrawal by Subject|8
6063062|NCT00504556|9664427|FG004|Overall Study|Withdrawal by Subject|12
6063063|NCT00504556|9664423|FG000|Overall Study|administrative reasons|0
6063064|NCT00504556|9664424|FG001|Overall Study|administrative reasons|2
6063065|NCT00504556|9664425|FG002|Overall Study|administrative reasons|2
6063066|NCT00504556|9664426|FG003|Overall Study|administrative reasons|1
6063067|NCT00504556|9664427|FG004|Overall Study|administrative reasons|2
6063068|NCT00504556|9664423|FG000|Overall Study|did not meet entry criteria|2
6063069|NCT00504556|9664424|FG001|Overall Study|did not meet entry criteria|0
6063070|NCT00504556|9664425|FG002|Overall Study|did not meet entry criteria|1
6063071|NCT00504556|9664426|FG003|Overall Study|did not meet entry criteria|1
6063072|NCT00504556|9664427|FG004|Overall Study|did not meet entry criteria|0
6063073|NCT00504556|9664423|FG000|Overall Study|data monitor committee decision|0
6063074|NCT00504556|9664424|FG001|Overall Study|data monitor committee decision|0
6063075|NCT00504556|9664425|FG002|Overall Study|data monitor committee decision|0
6063076|NCT00504556|9664426|FG003|Overall Study|data monitor committee decision|100
6063077|NCT00504556|9664427|FG004|Overall Study|data monitor committee decision|0
6063078|NCT00504556|9664423|FG000|Overall Study|Other|2
6063079|NCT00504556|9664424|FG001|Overall Study|Other|2
6063080|NCT00504556|9664425|FG002|Overall Study|Other|2
6063081|NCT00504556|9664426|FG003|Overall Study|Other|3
6063082|NCT00504556|9664427|FG004|Overall Study|Other|0
6063083|NCT00504556|9664423|FG000|Overall Study|not in safety analysis set|0
6063084|NCT00504556|9664424|FG001|Overall Study|not in safety analysis set|1
6063085|NCT00504556|9664425|FG002|Overall Study|not in safety analysis set|1
6063086|NCT00504556|9664426|FG003|Overall Study|not in safety analysis set|0
6063087|NCT00504556|9664427|FG004|Overall Study|not in safety analysis set|1
6063088|NCT00504595|9664443|FG000|Overall Study|Lack of Efficacy|1
6063089|NCT00504595|9664444|FG001|Overall Study|Lack of Efficacy|0
6063090|NCT00504595|9664445|FG002|Overall Study|Lack of Efficacy|0
6063091|NCT00504595|9664446|FG003|Overall Study|Lack of Efficacy|0
6063092|NCT00504595|9664443|FG000|Overall Study|Other|0
6063093|NCT00504595|9664444|FG001|Overall Study|Other|0
6063094|NCT00504595|9664445|FG002|Overall Study|Other|2
6063095|NCT00504595|9664446|FG003|Overall Study|Other|0
6063096|NCT00504725|9664467|FG000|Overall Study|Protocol Violation|1
6063097|NCT00504725|9664468|FG001|Overall Study|Protocol Violation|0
6063098|NCT00504777|9664478|FG000|Overall Study|Adverse Event|1
6063099|NCT00504829|9664485|FG000|Overall Study|Protocol Violation|6
6063100|NCT00504829|9664486|FG001|Overall Study|Protocol Violation|4
6063101|NCT00504829|9664487|FG002|Overall Study|Protocol Violation|10
6063102|NCT00504881|9664497|FG000|Overall Study|Lack of Efficacy|1
6063103|NCT00504881|9664498|FG001|Overall Study|Lack of Efficacy|5
6063104|NCT00504881|9664497|FG000|Overall Study|Lost to Follow-up|0
6063105|NCT00504881|9664498|FG001|Overall Study|Lost to Follow-up|2
6063106|NCT00504881|9664497|FG000|Overall Study|Withdrawal by Subject|1
6063107|NCT00504881|9664498|FG001|Overall Study|Withdrawal by Subject|4
6063108|NCT00504881|9664497|FG000|Overall Study|Non-Compliance|1
6063109|NCT00504881|9664498|FG001|Overall Study|Non-Compliance|0
6063110|NCT00504881|9664497|FG000|Overall Study|No Birth Control|0
6063111|NCT00504881|9664498|FG001|Overall Study|No Birth Control|1
6063112|NCT00504881|9664497|FG000|Overall Study|Safety Visit not performed|0
6063113|NCT00504881|9664498|FG001|Overall Study|Safety Visit not performed|1
6063114|NCT00504881|9664497|FG000|Overall Study|AE, serious fatal|0
6063115|NCT00504881|9664498|FG001|Overall Study|AE, serious fatal|1
6063116|NCT00504881|9664497|FG000|Overall Study|SAE, non-fatal|2
6063117|NCT00504881|9664498|FG001|Overall Study|SAE, non-fatal|6
6063118|NCT00504881|9664497|FG000|Overall Study|AE, non-serious non-fatal|4
6063119|NCT00504881|9664498|FG001|Overall Study|AE, non-serious non-fatal|14
6063120|NCT00504881|9664497|FG000|Overall Study|SAE,non-fatal+AE,non-serious non-fatal|0
6063121|NCT00504881|9664498|FG001|Overall Study|SAE,non-fatal+AE,non-serious non-fatal|2
6063122|NCT00504881|9664497|FG000|Overall Study|AE of unknown type|1
6063123|NCT00504881|9664498|FG001|Overall Study|AE of unknown type|0
6063124|NCT00504894|9664509|FG000|Overall Study|fMRI technical problems|1
6063125|NCT00504894|9664510|FG001|Overall Study|fMRI technical problems|1
6063126|NCT00504894|9664511|FG002|Overall Study|fMRI technical problems|0
6063127|NCT00504894|9664509|FG000|Overall Study|Withdrawal by Subject|0
6063128|NCT00504894|9664510|FG001|Overall Study|Withdrawal by Subject|1
6063129|NCT00504894|9664511|FG002|Overall Study|Withdrawal by Subject|0
6063130|NCT00504894|9664509|FG000|Overall Study|Infusion technical problems|0
6063131|NCT00504894|9664510|FG001|Overall Study|Infusion technical problems|1
6063132|NCT00504894|9664511|FG002|Overall Study|Infusion technical problems|0
6063133|NCT00504894|9664509|FG000|Overall Study|poor subject data|2
6063134|NCT00504894|9664510|FG001|Overall Study|poor subject data|0
6063135|NCT00504894|9664511|FG002|Overall Study|poor subject data|0
6063136|NCT00505076|9664522|FG000|Overall Study|Adverse Event|1
6063137|NCT00505076|9664523|FG001|Overall Study|Adverse Event|0
6063138|NCT00505076|9664524|FG002|Overall Study|Adverse Event|1
6063139|NCT00505076|9664522|FG000|Overall Study|Protocol Violation|2
6063140|NCT00505076|9664523|FG001|Overall Study|Protocol Violation|1
6063141|NCT00505076|9664524|FG002|Overall Study|Protocol Violation|2
6063142|NCT00505076|9664522|FG000|Overall Study|Withdrawal by Subject|0
6063143|NCT00505076|9664523|FG001|Overall Study|Withdrawal by Subject|1
6063144|NCT00505076|9664524|FG002|Overall Study|Withdrawal by Subject|2
6063145|NCT00505284|9664537|FG000|Overall Study|Adverse Event|3
6063146|NCT00505284|9664538|FG001|Overall Study|Adverse Event|7
6063147|NCT00505284|9664539|FG002|Overall Study|Adverse Event|9
6063148|NCT00505284|9664540|FG003|Overall Study|Adverse Event|14
6063149|NCT00505284|9664541|FG004|Overall Study|Adverse Event|22
6063150|NCT00505284|9664537|FG000|Overall Study|Protocol Violation|0
6063151|NCT00505284|9664538|FG001|Overall Study|Protocol Violation|1
6063152|NCT00505284|9664539|FG002|Overall Study|Protocol Violation|1
6063153|NCT00505284|9664540|FG003|Overall Study|Protocol Violation|0
6063154|NCT00505284|9664541|FG004|Overall Study|Protocol Violation|0
6063155|NCT00505284|9664537|FG000|Overall Study|Withdrawal by Subject|2
6063156|NCT00505284|9664538|FG001|Overall Study|Withdrawal by Subject|6
6063157|NCT00505284|9664539|FG002|Overall Study|Withdrawal by Subject|1
6063158|NCT00505284|9664540|FG003|Overall Study|Withdrawal by Subject|0
6063159|NCT00505284|9664541|FG004|Overall Study|Withdrawal by Subject|6
6063160|NCT00505284|9664537|FG000|Overall Study|Lack of Efficacy|0
6063161|NCT00505284|9664538|FG001|Overall Study|Lack of Efficacy|1
6063162|NCT00505284|9664539|FG002|Overall Study|Lack of Efficacy|1
6063163|NCT00505284|9664540|FG003|Overall Study|Lack of Efficacy|1
6063164|NCT00505284|9664541|FG004|Overall Study|Lack of Efficacy|1
6203274|NCT01513291|9864257|FG002|Treatment Period|Lack of Efficacy|0
6063165|NCT00505284|9664537|FG000|Overall Study|Physician Decision|0
6063166|NCT00505284|9664538|FG001|Overall Study|Physician Decision|1
6063167|NCT00505284|9664539|FG002|Overall Study|Physician Decision|0
6063168|NCT00505284|9664540|FG003|Overall Study|Physician Decision|0
6063169|NCT00505284|9664541|FG004|Overall Study|Physician Decision|0
6063170|NCT00505284|9664537|FG000|Overall Study|Other|5
6063171|NCT00505284|9664538|FG001|Overall Study|Other|0
6063172|NCT00505284|9664539|FG002|Overall Study|Other|0
6063173|NCT00505284|9664540|FG003|Overall Study|Other|4
6063174|NCT00505284|9664541|FG004|Overall Study|Other|4
6063175|NCT00505375|9664564|FG000|Overall Study|Death|1
6063176|NCT00505375|9664565|FG001|Overall Study|Death|0
6063177|NCT00505375|9664564|FG000|Overall Study|Withdrawal by Subject|2
6063178|NCT00505375|9664565|FG001|Overall Study|Withdrawal by Subject|2
6063179|NCT00505375|9664564|FG000|Overall Study|Lost to Follow-up|0
6063180|NCT00505375|9664565|FG001|Overall Study|Lost to Follow-up|2
6063181|NCT00505375|9664564|FG000|Overall Study|Pregnancy|1
6063182|NCT00505375|9664565|FG001|Overall Study|Pregnancy|0
6063183|NCT00505375|9664564|FG000|Overall Study|Travel issues|0
6063184|NCT00505375|9664565|FG001|Overall Study|Travel issues|1
6063185|NCT00505414|9664573|FG000|Titration Phase|Adverse Event|0
6063186|NCT00505414|9664574|FG001|Titration Phase|Adverse Event|0
6096461|NCT00730028|9710765|FG002|Overall Study|Lost to Follow-up|22
6096462|NCT00730028|9710766|FG003|Overall Study|Lost to Follow-up|26
6096463|NCT00730028|9710767|FG004|Overall Study|Lost to Follow-up|25
6096464|NCT00730028|9710763|FG000|Overall Study|Protocol Violation|6
6096465|NCT00730028|9710764|FG001|Overall Study|Protocol Violation|1
6096466|NCT00730028|9710765|FG002|Overall Study|Protocol Violation|1
6096467|NCT00730028|9710766|FG003|Overall Study|Protocol Violation|2
6096468|NCT00730028|9710767|FG004|Overall Study|Protocol Violation|0
6096469|NCT00730028|9710763|FG000|Overall Study|Withdrawal by Subject|9
6096470|NCT00730028|9710764|FG001|Overall Study|Withdrawal by Subject|5
6096471|NCT00730028|9710765|FG002|Overall Study|Withdrawal by Subject|4
6096472|NCT00730028|9710766|FG003|Overall Study|Withdrawal by Subject|5
6096473|NCT00730028|9710767|FG004|Overall Study|Withdrawal by Subject|9
6096474|NCT00730028|9710763|FG000|Overall Study|Physician Decision|3
6096475|NCT00730028|9710764|FG001|Overall Study|Physician Decision|3
6096476|NCT00730028|9710765|FG002|Overall Study|Physician Decision|2
6096477|NCT00730028|9710766|FG003|Overall Study|Physician Decision|3
6096478|NCT00730028|9710767|FG004|Overall Study|Physician Decision|2
6096479|NCT00730028|9710763|FG000|Overall Study|Treatment Failure|5
6096480|NCT00730028|9710764|FG001|Overall Study|Treatment Failure|5
6096481|NCT00730028|9710765|FG002|Overall Study|Treatment Failure|0
6096482|NCT00730028|9710766|FG003|Overall Study|Treatment Failure|0
6096483|NCT00730028|9710767|FG004|Overall Study|Treatment Failure|1
6096484|NCT00730028|9710763|FG000|Overall Study|Randomization Error|1
6096485|NCT00730028|9710764|FG001|Overall Study|Randomization Error|0
6096486|NCT00730028|9710765|FG002|Overall Study|Randomization Error|0
6096487|NCT00730028|9710766|FG003|Overall Study|Randomization Error|0
6096488|NCT00730028|9710767|FG004|Overall Study|Randomization Error|2
6096489|NCT00730041|9710781|FG000|Overall Study|Lost to Follow-up|0
6096490|NCT00730041|9710782|FG001|Overall Study|Lost to Follow-up|2
6096491|NCT00730158|9710790|FG000|Overall Study|Withdrawal by Subject|1
6096492|NCT00730158|9710791|FG001|Overall Study|Withdrawal by Subject|1
6096493|NCT00730171|9710801|FG000|Overall Study|Didn't Meet Inclusion/Exclusion Criteria|5
6096494|NCT00730171|9710801|FG000|Overall Study|Adverse Event|193
6096495|NCT00730171|9710801|FG000|Overall Study|Protocol Violation|48
6096496|NCT00730171|9710801|FG000|Overall Study|Withdrawal by Subject|202
6096497|NCT00730171|9710801|FG000|Overall Study|Lost to Follow-up|121
6096498|NCT00730171|9710801|FG000|Overall Study|Insufficient Therapeutic Response|141
6096499|NCT00730171|9710801|FG000|Overall Study|Other|61
6096500|NCT00730236|9710809|FG000|Overall Study|Adverse Event|4
6096501|NCT00730236|9710809|FG000|Overall Study|Withdrawal by Subject|1
6096502|NCT00730236|9710809|FG000|Overall Study|Non-compliance|1
6096503|NCT00730275|9710817|FG000|Overall Study|Withdrawal by Subject|0
6096504|NCT00730275|9710818|FG001|Overall Study|Withdrawal by Subject|0
6096505|NCT00730275|9710819|FG002|Overall Study|Withdrawal by Subject|0
6096506|NCT00730275|9710820|FG003|Overall Study|Withdrawal by Subject|1
6096507|NCT00730327|9710833|FG000|Overall Study|Lost to Follow-up|14
6096508|NCT00730327|9710834|FG001|Overall Study|Lost to Follow-up|16
6096509|NCT00730327|9710833|FG000|Overall Study|Adverse Event|8
6096510|NCT00730327|9710834|FG001|Overall Study|Adverse Event|1
6096511|NCT00730327|9710833|FG000|Overall Study|Withdrawal by Subject|3
6096512|NCT00730327|9710834|FG001|Overall Study|Withdrawal by Subject|13
6096513|NCT00730327|9710833|FG000|Overall Study|Subject withdrew (reason not specified)|2
6096514|NCT00730327|9710834|FG001|Overall Study|Subject withdrew (reason not specified)|7
6096515|NCT00730405|9710849|FG000|Overall Study-Treatment Phase|Adverse Event|5
6096516|NCT00730405|9710850|FG001|Overall Study-Treatment Phase|Adverse Event|10
6096517|NCT00730405|9710851|FG002|Overall Study-Treatment Phase|Adverse Event|4
6096518|NCT00730405|9710852|FG003|Overall Study-Treatment Phase|Adverse Event|8
6096519|NCT00730405|9710853|FG004|Overall Study-Treatment Phase|Adverse Event|4
6096520|NCT00730405|9710849|FG000|Overall Study-Treatment Phase|Lost to Follow-up|4
6063187|NCT00505414|9664575|FG002|Titration Phase|Adverse Event|0
6063188|NCT00505414|9664576|FG003|Titration Phase|Adverse Event|8
6096521|NCT00730405|9710850|FG001|Overall Study-Treatment Phase|Lost to Follow-up|5
6096522|NCT00730405|9710851|FG002|Overall Study-Treatment Phase|Lost to Follow-up|6
6096523|NCT00730405|9710852|FG003|Overall Study-Treatment Phase|Lost to Follow-up|4
6096524|NCT00730405|9710853|FG004|Overall Study-Treatment Phase|Lost to Follow-up|4
6096525|NCT00730405|9710849|FG000|Overall Study-Treatment Phase|Non-compliance with Study Treatment|1
6063189|NCT00505414|9664577|FG004|Titration Phase|Adverse Event|3
6063190|NCT00505414|9664573|FG000|Titration Phase|Death|0
6096526|NCT00730405|9710850|FG001|Overall Study-Treatment Phase|Non-compliance with Study Treatment|0
6096527|NCT00730405|9710851|FG002|Overall Study-Treatment Phase|Non-compliance with Study Treatment|5
6096528|NCT00730405|9710852|FG003|Overall Study-Treatment Phase|Non-compliance with Study Treatment|0
6096529|NCT00730405|9710853|FG004|Overall Study-Treatment Phase|Non-compliance with Study Treatment|1
6096530|NCT00730405|9710849|FG000|Overall Study-Treatment Phase|Withdrawal by Subject|7
6096531|NCT00730405|9710850|FG001|Overall Study-Treatment Phase|Withdrawal by Subject|1
6096532|NCT00730405|9710851|FG002|Overall Study-Treatment Phase|Withdrawal by Subject|2
6096533|NCT00730405|9710852|FG003|Overall Study-Treatment Phase|Withdrawal by Subject|5
6096534|NCT00730405|9710853|FG004|Overall Study-Treatment Phase|Withdrawal by Subject|8
6096535|NCT00730405|9710849|FG000|Overall Study-Treatment Phase|Did not met eligibility|0
6096536|NCT00730405|9710850|FG001|Overall Study-Treatment Phase|Did not met eligibility|0
6096537|NCT00730405|9710851|FG002|Overall Study-Treatment Phase|Did not met eligibility|1
6096538|NCT00730405|9710852|FG003|Overall Study-Treatment Phase|Did not met eligibility|0
6096539|NCT00730405|9710853|FG004|Overall Study-Treatment Phase|Did not met eligibility|0
6096540|NCT00730405|9710849|FG000|Overall Study-Treatment Phase|Participant meets exclusion|0
6096541|NCT00730405|9710850|FG001|Overall Study-Treatment Phase|Participant meets exclusion|0
6096542|NCT00730405|9710851|FG002|Overall Study-Treatment Phase|Participant meets exclusion|1
6096543|NCT00730405|9710852|FG003|Overall Study-Treatment Phase|Participant meets exclusion|0
6096544|NCT00730405|9710853|FG004|Overall Study-Treatment Phase|Participant meets exclusion|0
6096545|NCT00730405|9710849|FG000|Overall Study-Treatment Phase|Prohibited concomitant medication|1
6096546|NCT00730405|9710850|FG001|Overall Study-Treatment Phase|Prohibited concomitant medication|0
6096547|NCT00730405|9710851|FG002|Overall Study-Treatment Phase|Prohibited concomitant medication|0
6096548|NCT00730405|9710852|FG003|Overall Study-Treatment Phase|Prohibited concomitant medication|0
6096549|NCT00730405|9710853|FG004|Overall Study-Treatment Phase|Prohibited concomitant medication|0
6096550|NCT00730405|9710849|FG000|Overall Study-Treatment Phase|Withdrew from study treatment|0
6096551|NCT00730405|9710850|FG001|Overall Study-Treatment Phase|Withdrew from study treatment|1
6096552|NCT00730405|9710851|FG002|Overall Study-Treatment Phase|Withdrew from study treatment|0
6096553|NCT00730405|9710852|FG003|Overall Study-Treatment Phase|Withdrew from study treatment|0
6096554|NCT00730405|9710853|FG004|Overall Study-Treatment Phase|Withdrew from study treatment|0
6096555|NCT00730405|9710849|FG000|Overall Study-Treatment Phase|Use of prohibited medication|0
6096556|NCT00730405|9710850|FG001|Overall Study-Treatment Phase|Use of prohibited medication|1
6096557|NCT00730405|9710851|FG002|Overall Study-Treatment Phase|Use of prohibited medication|0
6096558|NCT00730405|9710852|FG003|Overall Study-Treatment Phase|Use of prohibited medication|0
6096559|NCT00730405|9710853|FG004|Overall Study-Treatment Phase|Use of prohibited medication|2
6096560|NCT00730405|9710849|FG000|Overall Study-Treatment Phase|Human immunodeficiency virus positive|0
6096561|NCT00730405|9710850|FG001|Overall Study-Treatment Phase|Human immunodeficiency virus positive|0
6096562|NCT00730405|9710851|FG002|Overall Study-Treatment Phase|Human immunodeficiency virus positive|1
6096563|NCT00730405|9710852|FG003|Overall Study-Treatment Phase|Human immunodeficiency virus positive|0
6096564|NCT00730405|9710853|FG004|Overall Study-Treatment Phase|Human immunodeficiency virus positive|0
6096565|NCT00730405|9710849|FG000|Overall Study-Treatment Phase|Misrandomized|0
6096566|NCT00730405|9710850|FG001|Overall Study-Treatment Phase|Misrandomized|1
6096567|NCT00730405|9710851|FG002|Overall Study-Treatment Phase|Misrandomized|0
6096568|NCT00730405|9710852|FG003|Overall Study-Treatment Phase|Misrandomized|0
6096569|NCT00730405|9710853|FG004|Overall Study-Treatment Phase|Misrandomized|0
6096570|NCT00730405|9710849|FG000|Overall Study-Treatment Phase|Study drug interrupted|0
6096571|NCT00730405|9710850|FG001|Overall Study-Treatment Phase|Study drug interrupted|1
6096572|NCT00730405|9710851|FG002|Overall Study-Treatment Phase|Study drug interrupted|0
6096573|NCT00730405|9710852|FG003|Overall Study-Treatment Phase|Study drug interrupted|0
6096574|NCT00730405|9710853|FG004|Overall Study-Treatment Phase|Study drug interrupted|0
6096575|NCT00730405|9710849|FG000|Overall Study-Treatment Phase|Due to in-vitro fertilization|0
6096576|NCT00730405|9710850|FG001|Overall Study-Treatment Phase|Due to in-vitro fertilization|0
6096577|NCT00730405|9710851|FG002|Overall Study-Treatment Phase|Due to in-vitro fertilization|0
6096578|NCT00730405|9710852|FG003|Overall Study-Treatment Phase|Due to in-vitro fertilization|1
6203275|NCT01513291|9864258|FG003|Treatment Period|Lack of Efficacy|0
6203276|NCT01513291|9864259|FG004|Treatment Period|Lack of Efficacy|0
6203277|NCT01513291|9864255|FG000|Treatment Period|Lost to Follow-up|2
6203278|NCT01513291|9864256|FG001|Treatment Period|Lost to Follow-up|3
6203279|NCT01513291|9864257|FG002|Treatment Period|Lost to Follow-up|0
6203280|NCT01513291|9864258|FG003|Treatment Period|Lost to Follow-up|0
6203281|NCT01513291|9864259|FG004|Treatment Period|Lost to Follow-up|0
6203282|NCT01513291|9864255|FG000|Treatment Period|Physician Decision|1
6203283|NCT01513291|9864256|FG001|Treatment Period|Physician Decision|0
6203284|NCT01513291|9864257|FG002|Treatment Period|Physician Decision|0
6203285|NCT01513291|9864258|FG003|Treatment Period|Physician Decision|0
6203286|NCT01513291|9864259|FG004|Treatment Period|Physician Decision|0
6203287|NCT01513291|9864255|FG000|Treatment Period|Protocol Violation|1
6203288|NCT01513291|9864256|FG001|Treatment Period|Protocol Violation|2
6203289|NCT01513291|9864257|FG002|Treatment Period|Protocol Violation|0
6096579|NCT00730405|9710853|FG004|Overall Study-Treatment Phase|Due to in-vitro fertilization|0
6096580|NCT00730405|9710849|FG000|Overall Study-Treatment Phase|Protocol violation due to eligibility|0
6096581|NCT00730405|9710850|FG001|Overall Study-Treatment Phase|Protocol violation due to eligibility|0
6096582|NCT00730405|9710851|FG002|Overall Study-Treatment Phase|Protocol violation due to eligibility|1
6096583|NCT00730405|9710852|FG003|Overall Study-Treatment Phase|Protocol violation due to eligibility|0
6096584|NCT00730405|9710853|FG004|Overall Study-Treatment Phase|Protocol violation due to eligibility|0
6096585|NCT00730405|9710849|FG000|Overall Study-Treatment Phase|Change of location|0
6096586|NCT00730405|9710850|FG001|Overall Study-Treatment Phase|Change of location|0
6096587|NCT00730405|9710851|FG002|Overall Study-Treatment Phase|Change of location|0
6096588|NCT00730405|9710852|FG003|Overall Study-Treatment Phase|Change of location|1
6096589|NCT00730405|9710853|FG004|Overall Study-Treatment Phase|Change of location|0
6096590|NCT00730405|9710849|FG000|Overall Study-Treatment Phase|Pregnancy|0
6096591|NCT00730405|9710850|FG001|Overall Study-Treatment Phase|Pregnancy|1
6096592|NCT00730405|9710851|FG002|Overall Study-Treatment Phase|Pregnancy|0
6096593|NCT00730405|9710852|FG003|Overall Study-Treatment Phase|Pregnancy|0
6096594|NCT00730405|9710853|FG004|Overall Study-Treatment Phase|Pregnancy|0
6096595|NCT00730405|9710849|FG000|Overall Study-Treatment Phase|QTCF: 454 millisecond, withdrew consent|0
6096596|NCT00730405|9710850|FG001|Overall Study-Treatment Phase|QTCF: 454 millisecond, withdrew consent|0
6096597|NCT00730405|9710851|FG002|Overall Study-Treatment Phase|QTCF: 454 millisecond, withdrew consent|0
6096598|NCT00730405|9710852|FG003|Overall Study-Treatment Phase|QTCF: 454 millisecond, withdrew consent|0
6096599|NCT00730405|9710853|FG004|Overall Study-Treatment Phase|QTCF: 454 millisecond, withdrew consent|1
6096600|NCT00730405|9710849|FG000|Overall Study-Treatment Phase|Atrial fibrillation history|1
6096601|NCT00730405|9710850|FG001|Overall Study-Treatment Phase|Atrial fibrillation history|0
6096602|NCT00730405|9710851|FG002|Overall Study-Treatment Phase|Atrial fibrillation history|0
6096603|NCT00730405|9710852|FG003|Overall Study-Treatment Phase|Atrial fibrillation history|0
6096604|NCT00730405|9710853|FG004|Overall Study-Treatment Phase|Atrial fibrillation history|0
6096605|NCT00730405|9710849|FG000|Overall Study-follow-up Phase|Adverse Event|2
6096606|NCT00730405|9710850|FG001|Overall Study-follow-up Phase|Adverse Event|6
6096607|NCT00730405|9710851|FG002|Overall Study-follow-up Phase|Adverse Event|2
6096608|NCT00730405|9710852|FG003|Overall Study-follow-up Phase|Adverse Event|3
6096609|NCT00730405|9710853|FG004|Overall Study-follow-up Phase|Adverse Event|4
6096610|NCT00730405|9710849|FG000|Overall Study-follow-up Phase|Lost to Follow-up|7
6096611|NCT00730405|9710850|FG001|Overall Study-follow-up Phase|Lost to Follow-up|6
6096612|NCT00730405|9710851|FG002|Overall Study-follow-up Phase|Lost to Follow-up|8
6096613|NCT00730405|9710852|FG003|Overall Study-follow-up Phase|Lost to Follow-up|4
6096614|NCT00730405|9710853|FG004|Overall Study-follow-up Phase|Lost to Follow-up|6
6096615|NCT00730405|9710849|FG000|Overall Study-follow-up Phase|Withdrawal by Subject|7
6096616|NCT00730405|9710850|FG001|Overall Study-follow-up Phase|Withdrawal by Subject|3
6096617|NCT00730405|9710851|FG002|Overall Study-follow-up Phase|Withdrawal by Subject|3
6096618|NCT00730405|9710852|FG003|Overall Study-follow-up Phase|Withdrawal by Subject|6
6096619|NCT00730405|9710853|FG004|Overall Study-follow-up Phase|Withdrawal by Subject|10
6096620|NCT00730405|9710849|FG000|Overall Study-follow-up Phase|Death|0
6096621|NCT00730405|9710850|FG001|Overall Study-follow-up Phase|Death|1
6096622|NCT00730405|9710851|FG002|Overall Study-follow-up Phase|Death|0
6096623|NCT00730405|9710852|FG003|Overall Study-follow-up Phase|Death|1
6096624|NCT00730405|9710853|FG004|Overall Study-follow-up Phase|Death|0
6096625|NCT00730405|9710849|FG000|Overall Study-follow-up Phase|Change of location|1
6096626|NCT00730405|9710850|FG001|Overall Study-follow-up Phase|Change of location|1
6096627|NCT00730405|9710851|FG002|Overall Study-follow-up Phase|Change of location|0
6096628|NCT00730405|9710852|FG003|Overall Study-follow-up Phase|Change of location|1
6096629|NCT00730405|9710853|FG004|Overall Study-follow-up Phase|Change of location|0
6096630|NCT00730405|9710849|FG000|Overall Study-follow-up Phase|Did not met eligibility|0
6096631|NCT00730405|9710850|FG001|Overall Study-follow-up Phase|Did not met eligibility|0
6096632|NCT00730405|9710851|FG002|Overall Study-follow-up Phase|Did not met eligibility|1
6096633|NCT00730405|9710852|FG003|Overall Study-follow-up Phase|Did not met eligibility|0
6096634|NCT00730405|9710853|FG004|Overall Study-follow-up Phase|Did not met eligibility|0
6096635|NCT00730405|9710849|FG000|Overall Study-follow-up Phase|Non-compliance with study treatment|0
6203290|NCT01513291|9864258|FG003|Treatment Period|Protocol Violation|0
6203291|NCT01513291|9864259|FG004|Treatment Period|Protocol Violation|0
6203292|NCT01513291|9864255|FG000|Treatment Period|Withdrawal by Subject|8
6203293|NCT01513291|9864256|FG001|Treatment Period|Withdrawal by Subject|5
6203294|NCT01513291|9864257|FG002|Treatment Period|Withdrawal by Subject|0
6203295|NCT01513291|9864258|FG003|Treatment Period|Withdrawal by Subject|0
6203296|NCT01513291|9864259|FG004|Treatment Period|Withdrawal by Subject|0
6203297|NCT01513291|9864255|FG000|Treatment Period|Randomized not treated|0
6203298|NCT01513291|9864256|FG001|Treatment Period|Randomized not treated|2
6203299|NCT01513291|9864257|FG002|Treatment Period|Randomized not treated|0
6203300|NCT01513291|9864258|FG003|Treatment Period|Randomized not treated|0
6203301|NCT01513291|9864259|FG004|Treatment Period|Randomized not treated|0
6203302|NCT01513291|9864255|FG000|Run-out Period|Lost to Follow-up|0
6203303|NCT01513291|9864256|FG001|Run-out Period|Lost to Follow-up|0
6203304|NCT01513291|9864257|FG002|Run-out Period|Lost to Follow-up|0
6203305|NCT01513291|9864258|FG003|Run-out Period|Lost to Follow-up|1
6096636|NCT00730405|9710850|FG001|Overall Study-follow-up Phase|Non-compliance with study treatment|0
6096637|NCT00730405|9710851|FG002|Overall Study-follow-up Phase|Non-compliance with study treatment|1
6096638|NCT00730405|9710852|FG003|Overall Study-follow-up Phase|Non-compliance with study treatment|0
6096639|NCT00730405|9710853|FG004|Overall Study-follow-up Phase|Non-compliance with study treatment|0
6096640|NCT00730405|9710849|FG000|Overall Study-follow-up Phase|Participant meets exclusion criteria|0
6096641|NCT00730405|9710850|FG001|Overall Study-follow-up Phase|Participant meets exclusion criteria|0
6096642|NCT00730405|9710851|FG002|Overall Study-follow-up Phase|Participant meets exclusion criteria|1
6096643|NCT00730405|9710852|FG003|Overall Study-follow-up Phase|Participant meets exclusion criteria|0
6096644|NCT00730405|9710853|FG004|Overall Study-follow-up Phase|Participant meets exclusion criteria|0
6096645|NCT00730405|9710849|FG000|Overall Study-follow-up Phase|Terminated due to adverse event (AE)|0
6096646|NCT00730405|9710850|FG001|Overall Study-follow-up Phase|Terminated due to adverse event (AE)|0
6096647|NCT00730405|9710851|FG002|Overall Study-follow-up Phase|Terminated due to adverse event (AE)|0
6096648|NCT00730405|9710852|FG003|Overall Study-follow-up Phase|Terminated due to adverse event (AE)|0
6096649|NCT00730405|9710853|FG004|Overall Study-follow-up Phase|Terminated due to adverse event (AE)|1
6096650|NCT00730405|9710849|FG000|Overall Study-follow-up Phase|Prohibited concomitant medication|1
6096651|NCT00730405|9710850|FG001|Overall Study-follow-up Phase|Prohibited concomitant medication|0
6096652|NCT00730405|9710851|FG002|Overall Study-follow-up Phase|Prohibited concomitant medication|0
6096653|NCT00730405|9710852|FG003|Overall Study-follow-up Phase|Prohibited concomitant medication|0
6096654|NCT00730405|9710853|FG004|Overall Study-follow-up Phase|Prohibited concomitant medication|0
6096655|NCT00730405|9710849|FG000|Overall Study-follow-up Phase|Refused follow-up due to AE|0
6096656|NCT00730405|9710850|FG001|Overall Study-follow-up Phase|Refused follow-up due to AE|0
6096657|NCT00730405|9710851|FG002|Overall Study-follow-up Phase|Refused follow-up due to AE|0
6096658|NCT00730405|9710852|FG003|Overall Study-follow-up Phase|Refused follow-up due to AE|1
6096659|NCT00730405|9710853|FG004|Overall Study-follow-up Phase|Refused follow-up due to AE|0
6096660|NCT00730405|9710849|FG000|Overall Study-follow-up Phase|Requested to withdraw from follow-up|0
6096661|NCT00730405|9710850|FG001|Overall Study-follow-up Phase|Requested to withdraw from follow-up|1
6096662|NCT00730405|9710851|FG002|Overall Study-follow-up Phase|Requested to withdraw from follow-up|1
6096663|NCT00730405|9710852|FG003|Overall Study-follow-up Phase|Requested to withdraw from follow-up|0
6096664|NCT00730405|9710853|FG004|Overall Study-follow-up Phase|Requested to withdraw from follow-up|0
6096665|NCT00730405|9710849|FG000|Overall Study-follow-up Phase|Declined to continue with follow-up|1
6096666|NCT00730405|9710850|FG001|Overall Study-follow-up Phase|Declined to continue with follow-up|1
6096667|NCT00730405|9710851|FG002|Overall Study-follow-up Phase|Declined to continue with follow-up|0
6096668|NCT00730405|9710852|FG003|Overall Study-follow-up Phase|Declined to continue with follow-up|0
6096669|NCT00730405|9710853|FG004|Overall Study-follow-up Phase|Declined to continue with follow-up|0
6096670|NCT00730405|9710849|FG000|Overall Study-follow-up Phase|Use of restricted medication|0
6096671|NCT00730405|9710850|FG001|Overall Study-follow-up Phase|Use of restricted medication|1
6096672|NCT00730405|9710851|FG002|Overall Study-follow-up Phase|Use of restricted medication|0
6096673|NCT00730405|9710852|FG003|Overall Study-follow-up Phase|Use of restricted medication|0
6096674|NCT00730405|9710853|FG004|Overall Study-follow-up Phase|Use of restricted medication|0
6096675|NCT00730405|9710849|FG000|Overall Study-follow-up Phase|Non-compliance|1
6096676|NCT00730405|9710850|FG001|Overall Study-follow-up Phase|Non-compliance|0
6096677|NCT00730405|9710851|FG002|Overall Study-follow-up Phase|Non-compliance|2
6096678|NCT00730405|9710852|FG003|Overall Study-follow-up Phase|Non-compliance|0
6096679|NCT00730405|9710853|FG004|Overall Study-follow-up Phase|Non-compliance|0
6096680|NCT00730405|9710849|FG000|Overall Study-follow-up Phase|Missing|0
6096681|NCT00730405|9710850|FG001|Overall Study-follow-up Phase|Missing|0
6096682|NCT00730405|9710851|FG002|Overall Study-follow-up Phase|Missing|2
6096683|NCT00730405|9710852|FG003|Overall Study-follow-up Phase|Missing|0
6096684|NCT00730405|9710853|FG004|Overall Study-follow-up Phase|Missing|0
6096685|NCT00730405|9710849|FG000|Overall Study-follow-up Phase|Use an exclusionary medication|0
6096686|NCT00730405|9710850|FG001|Overall Study-follow-up Phase|Use an exclusionary medication|0
6096687|NCT00730405|9710851|FG002|Overall Study-follow-up Phase|Use an exclusionary medication|0
6096688|NCT00730405|9710852|FG003|Overall Study-follow-up Phase|Use an exclusionary medication|0
6096689|NCT00730405|9710853|FG004|Overall Study-follow-up Phase|Use an exclusionary medication|1
6096690|NCT00730405|9710849|FG000|Overall Study-follow-up Phase|Human immunodeficiency virus positive|0
6096691|NCT00730405|9710850|FG001|Overall Study-follow-up Phase|Human immunodeficiency virus positive|0
6096692|NCT00730405|9710851|FG002|Overall Study-follow-up Phase|Human immunodeficiency virus positive|1
6096693|NCT00730405|9710852|FG003|Overall Study-follow-up Phase|Human immunodeficiency virus positive|0
6096694|NCT00730405|9710853|FG004|Overall Study-follow-up Phase|Human immunodeficiency virus positive|0
6096695|NCT00730405|9710849|FG000|Overall Study-follow-up Phase|Mis-randomized|0
6096696|NCT00730405|9710850|FG001|Overall Study-follow-up Phase|Mis-randomized|1
6096697|NCT00730405|9710851|FG002|Overall Study-follow-up Phase|Mis-randomized|0
6096698|NCT00730405|9710852|FG003|Overall Study-follow-up Phase|Mis-randomized|0
6096699|NCT00730405|9710853|FG004|Overall Study-follow-up Phase|Mis-randomized|0
6096700|NCT00730405|9710849|FG000|Overall Study-follow-up Phase|Other Protocol violation|0
6096701|NCT00730405|9710850|FG001|Overall Study-follow-up Phase|Other Protocol violation|0
6096702|NCT00730405|9710851|FG002|Overall Study-follow-up Phase|Other Protocol violation|1
6096703|NCT00730405|9710852|FG003|Overall Study-follow-up Phase|Other Protocol violation|0
6096704|NCT00730405|9710853|FG004|Overall Study-follow-up Phase|Other Protocol violation|0
6096705|NCT00730405|9710849|FG000|Overall Study-follow-up Phase|discontinued AE, investigator discretion|0
6096706|NCT00730405|9710850|FG001|Overall Study-follow-up Phase|discontinued AE, investigator discretion|0
6096707|NCT00730405|9710851|FG002|Overall Study-follow-up Phase|discontinued AE, investigator discretion|0
6096708|NCT00730405|9710852|FG003|Overall Study-follow-up Phase|discontinued AE, investigator discretion|1
6096709|NCT00730405|9710853|FG004|Overall Study-follow-up Phase|discontinued AE, investigator discretion|0
6096710|NCT00730405|9710849|FG000|Overall Study-follow-up Phase|Atrial fibrillation history|1
6096711|NCT00730405|9710850|FG001|Overall Study-follow-up Phase|Atrial fibrillation history|0
6096712|NCT00730405|9710851|FG002|Overall Study-follow-up Phase|Atrial fibrillation history|0
6096713|NCT00730405|9710852|FG003|Overall Study-follow-up Phase|Atrial fibrillation history|0
6096714|NCT00730405|9710853|FG004|Overall Study-follow-up Phase|Atrial fibrillation history|0
6096715|NCT00730691|9710888|FG000|Overall Study|Adverse Event|4
6096716|NCT00730691|9710889|FG001|Overall Study|Adverse Event|8
6096717|NCT00730691|9710890|FG002|Overall Study|Adverse Event|11
6096718|NCT00730691|9710891|FG003|Overall Study|Adverse Event|11
6096719|NCT00730691|9710892|FG004|Overall Study|Adverse Event|23
6096720|NCT00730691|9710888|FG000|Overall Study|Lack of Efficacy|4
6096721|NCT00730691|9710889|FG001|Overall Study|Lack of Efficacy|4
6096722|NCT00730691|9710890|FG002|Overall Study|Lack of Efficacy|2
6096723|NCT00730691|9710891|FG003|Overall Study|Lack of Efficacy|1
6096724|NCT00730691|9710892|FG004|Overall Study|Lack of Efficacy|1
6096725|NCT00730691|9710888|FG000|Overall Study|Non-compliance with Study Drug|6
6096726|NCT00730691|9710889|FG001|Overall Study|Non-compliance with Study Drug|1
6096727|NCT00730691|9710890|FG002|Overall Study|Non-compliance with Study Drug|6
6096728|NCT00730691|9710891|FG003|Overall Study|Non-compliance with Study Drug|3
6096729|NCT00730691|9710892|FG004|Overall Study|Non-compliance with Study Drug|3
6096730|NCT00730691|9710888|FG000|Overall Study|Protocol Deviations|3
6096731|NCT00730691|9710889|FG001|Overall Study|Protocol Deviations|5
6096732|NCT00730691|9710890|FG002|Overall Study|Protocol Deviations|3
6096733|NCT00730691|9710891|FG003|Overall Study|Protocol Deviations|7
6096734|NCT00730691|9710892|FG004|Overall Study|Protocol Deviations|5
6096735|NCT00730691|9710888|FG000|Overall Study|Withdrawal of Consent|7
6096736|NCT00730691|9710889|FG001|Overall Study|Withdrawal of Consent|9
6096737|NCT00730691|9710890|FG002|Overall Study|Withdrawal of Consent|3
6096738|NCT00730691|9710891|FG003|Overall Study|Withdrawal of Consent|6
6096739|NCT00730691|9710892|FG004|Overall Study|Withdrawal of Consent|3
6096740|NCT00730691|9710888|FG000|Overall Study|Lost to Follow-up|11
6096741|NCT00730691|9710889|FG001|Overall Study|Lost to Follow-up|8
6096742|NCT00730691|9710890|FG002|Overall Study|Lost to Follow-up|13
6096743|NCT00730691|9710891|FG003|Overall Study|Lost to Follow-up|15
6096744|NCT00730691|9710892|FG004|Overall Study|Lost to Follow-up|13
6096745|NCT00730691|9710888|FG000|Overall Study|Other|1
6096746|NCT00730691|9710889|FG001|Overall Study|Other|1
6096747|NCT00730691|9710890|FG002|Overall Study|Other|1
6096748|NCT00730691|9710891|FG003|Overall Study|Other|2
6096749|NCT00730691|9710892|FG004|Overall Study|Other|2
6203306|NCT01513291|9864259|FG004|Run-out Period|Lost to Follow-up|0
6203307|NCT01513291|9864255|FG000|Run-out Period|Withdrawal by Subject|0
6203308|NCT01513291|9864256|FG001|Run-out Period|Withdrawal by Subject|0
6203309|NCT01513291|9864257|FG002|Run-out Period|Withdrawal by Subject|0
6203310|NCT01513291|9864258|FG003|Run-out Period|Withdrawal by Subject|1
6203311|NCT01513291|9864259|FG004|Run-out Period|Withdrawal by Subject|0
6203312|NCT01513317|9864273|FG000|Overall Study|Withdrawal by Subject|15
6203313|NCT01513317|9864274|FG001|Overall Study|Withdrawal by Subject|4
6203314|NCT01513317|9864273|FG000|Overall Study|Death|1
6203315|NCT01513317|9864274|FG001|Overall Study|Death|1
6203316|NCT01513317|9864273|FG000|Overall Study|Study terminated by sponsor|18
6203317|NCT01513317|9864274|FG001|Overall Study|Study terminated by sponsor|18
6203318|NCT01513317|9864273|FG000|Overall Study|Other|0
6203319|NCT01513317|9864274|FG001|Overall Study|Other|1
6203320|NCT01513330|9864280|FG000|SenSura Mio First,|Adverse Event|2
6203321|NCT01513330|9864281|FG001|SenSura Mio First,|Adverse Event|0
6203322|NCT01513330|9864280|FG000|SenSura Mio First,|Lack of Efficacy|0
6203323|NCT01513330|9864281|FG001|SenSura Mio First,|Lack of Efficacy|1
6203324|NCT01513330|9864280|FG000|SenSura Mio First,|Withdrawal by Subject|1
6203325|NCT01513330|9864281|FG001|SenSura Mio First,|Withdrawal by Subject|1
6203326|NCT01513330|9864280|FG000|SenSura Mio First,|Other|1
6203327|NCT01513330|9864281|FG001|SenSura Mio First,|Other|0
6203328|NCT01513330|9864280|FG000|Standard Care First,|Lack of Efficacy|2
6203329|NCT01513330|9864281|FG001|Standard Care First,|Lack of Efficacy|2
6203330|NCT01513330|9864280|FG000|Standard Care First,|Withdrawal by Subject|1
6203331|NCT01513330|9864281|FG001|Standard Care First,|Withdrawal by Subject|2
6203332|NCT01513330|9864280|FG000|Standard Care First,|Other|1
6203333|NCT01513330|9864281|FG001|Standard Care First,|Other|0
6203334|NCT01513460|9864299|FG000|Overall Study|Death|0
6203335|NCT01513460|9864300|FG001|Overall Study|Death|0
6203336|NCT01513460|9864301|FG002|Overall Study|Death|1
6203337|NCT01513460|9864299|FG000|Overall Study|Lost to Follow-up|0
6203338|NCT01513460|9864300|FG001|Overall Study|Lost to Follow-up|0
6203339|NCT01513460|9864301|FG002|Overall Study|Lost to Follow-up|2
6096750|NCT00730756|9710910|FG000|Overall Study|Adverse Event|2
6096751|NCT00730756|9710911|FG001|Overall Study|Adverse Event|0
6096752|NCT00730756|9710910|FG000|Overall Study|Lack of Efficacy|1
6096753|NCT00730756|9710911|FG001|Overall Study|Lack of Efficacy|1
6096754|NCT00730756|9710910|FG000|Overall Study|Protocol Deviation|1
6096755|NCT00730756|9710911|FG001|Overall Study|Protocol Deviation|2
6096756|NCT00730756|9710910|FG000|Overall Study|Lost to Follow-up|0
6096757|NCT00730756|9710911|FG001|Overall Study|Lost to Follow-up|1
6096758|NCT00730756|9710910|FG000|Overall Study|Withdrew Consent|0
6096759|NCT00730756|9710911|FG001|Overall Study|Withdrew Consent|1
6096760|NCT00730847|9710917|FG000|Overall Study|Adverse Event|1
6096761|NCT00730847|9710917|FG000|Overall Study|Protocol Violation|2
6096762|NCT00730847|9710917|FG000|Overall Study|Withdrawal by Subject|16
6096763|NCT00730847|9710917|FG000|Overall Study|Lost to Follow-up|67
6096764|NCT00730847|9710917|FG000|Overall Study|Unknown completion status|21
6096765|NCT00730847|9710917|FG000|Overall Study|Other|24
6096766|NCT00730912|9710924|FG000|Overall Study|Discontinued|0
6096767|NCT00730912|9710925|FG001|Overall Study|Discontinued|0
6096768|NCT00730912|9710926|FG002|Overall Study|Discontinued|1
6096769|NCT00730925|9710934|FG000|Overall Study|Progressive Disease|21
6096770|NCT00730925|9710934|FG000|Overall Study|Dose reducing Event|2
6096771|NCT00730925|9710934|FG000|Overall Study|Other Averse Event|7
6096772|NCT00730925|9710934|FG000|Overall Study|Protocol Violation|1
6096773|NCT00730925|9710934|FG000|Overall Study|Withdrawal by Subject|1
6096774|NCT00730925|9710934|FG000|Overall Study|Switch to combination therapy|8
6096775|NCT00730925|9710934|FG000|Overall Study|Other|1
6096776|NCT00731042|9710945|FG000|Second Intervention|Did not meet inclusion criteria|0
6096777|NCT00731042|9710946|FG001|Second Intervention|Did not meet inclusion criteria|2
6096778|NCT00731120|9710971|FG000|Overall Study|Adverse Event|7
6096779|NCT00731120|9710972|FG001|Overall Study|Adverse Event|6
6096780|NCT00731120|9710973|FG002|Overall Study|Adverse Event|8
6203340|NCT01513460|9864299|FG000|Overall Study|Abnormal laboratory value|1
6203341|NCT01513460|9864300|FG001|Overall Study|Abnormal laboratory value|0
6203342|NCT01513460|9864301|FG002|Overall Study|Abnormal laboratory value|1
6203343|NCT01513460|9864299|FG000|Overall Study|Lack of Efficacy|1
6203344|NCT01513460|9864300|FG001|Overall Study|Lack of Efficacy|2
6203345|NCT01513460|9864301|FG002|Overall Study|Lack of Efficacy|5
6203346|NCT01513460|9864299|FG000|Overall Study|Protocol deviations|3
6203347|NCT01513460|9864300|FG001|Overall Study|Protocol deviations|4
6203348|NCT01513460|9864301|FG002|Overall Study|Protocol deviations|3
6203349|NCT01513460|9864299|FG000|Overall Study|Withdrawal by Subject|7
6203350|NCT01513460|9864300|FG001|Overall Study|Withdrawal by Subject|8
6203351|NCT01513460|9864301|FG002|Overall Study|Withdrawal by Subject|21
6203352|NCT01513460|9864299|FG000|Overall Study|Adverse Event|16
6203353|NCT01513460|9864300|FG001|Overall Study|Adverse Event|18
6203354|NCT01513460|9864301|FG002|Overall Study|Adverse Event|23
6203355|NCT01513460|9864299|FG000|Overall Study|Abnormal test procedure|1
6203356|NCT01513460|9864300|FG001|Overall Study|Abnormal test procedure|0
6203357|NCT01513460|9864301|FG002|Overall Study|Abnormal test procedure|0
6203358|NCT01513473|9864313|FG000|Main Trial (26 Weeks)|Adverse Event|0
6203359|NCT01513473|9864314|FG001|Main Trial (26 Weeks)|Adverse Event|2
6203360|NCT01513473|9864313|FG000|Main Trial (26 Weeks)|Withdrawal by Subject|4
6203361|NCT01513473|9864314|FG001|Main Trial (26 Weeks)|Withdrawal by Subject|7
6203362|NCT01513473|9864313|FG000|Main Trial (26 Weeks)|Unclassified|0
6203363|NCT01513473|9864314|FG001|Main Trial (26 Weeks)|Unclassified|2
6203364|NCT01513473|9864313|FG000|Extension Trial (26 Weeks)|Adverse Event|0
6203365|NCT01513473|9864314|FG001|Extension Trial (26 Weeks)|Adverse Event|1
6203366|NCT01513473|9864313|FG000|Extension Trial (26 Weeks)|Withdrawal by Subject|1
6203367|NCT01513473|9864314|FG001|Extension Trial (26 Weeks)|Withdrawal by Subject|5
6203368|NCT01513551|9864327|FG000|Overall Study|Death|0
6203369|NCT01513551|9864328|FG001|Overall Study|Death|1
6203370|NCT01513551|9864329|FG002|Overall Study|Death|0
6203371|NCT01513551|9864327|FG000|Overall Study|Lost to Follow-up|3
6203372|NCT01513551|9864328|FG001|Overall Study|Lost to Follow-up|5
6203373|NCT01513551|9864329|FG002|Overall Study|Lost to Follow-up|2
6203374|NCT01513551|9864327|FG000|Overall Study|Withdrawal by Subject|1
6203375|NCT01513551|9864328|FG001|Overall Study|Withdrawal by Subject|0
6203376|NCT01513551|9864329|FG002|Overall Study|Withdrawal by Subject|2
6203377|NCT01513551|9864327|FG000|Overall Study|Randomized but not vaccinated|0
6203378|NCT01513551|9864328|FG001|Overall Study|Randomized but not vaccinated|0
6203379|NCT01513551|9864329|FG002|Overall Study|Randomized but not vaccinated|1
6203380|NCT01513590|9864339|FG000|Overall Study|Adverse Event|2
6203381|NCT01513590|9864340|FG001|Overall Study|Adverse Event|3
6203382|NCT01513590|9864339|FG000|Overall Study|Withdrawal Criteria|3
6203383|NCT01513590|9864340|FG001|Overall Study|Withdrawal Criteria|0
6203384|NCT01513590|9864339|FG000|Overall Study|Unclassified|5
6203385|NCT01513590|9864340|FG001|Overall Study|Unclassified|10
6203386|NCT01513759|9864346|FG000|Overall Study|Protocol Violation|4
6096781|NCT00731120|9710971|FG000|Overall Study|Lack of Efficacy|4
6096782|NCT00731120|9710972|FG001|Overall Study|Lack of Efficacy|5
6203387|NCT01513759|9864346|FG000|Overall Study|Death during catheter placement|1
6203388|NCT01513967|9864371|FG000|Overall Study|Pregnancy|0
6203389|NCT01513967|9864372|FG001|Overall Study|Pregnancy|0
6203390|NCT01513967|9864373|FG002|Overall Study|Pregnancy|0
6203391|NCT01513967|9864374|FG003|Overall Study|Pregnancy|0
6096783|NCT00731120|9710973|FG002|Overall Study|Lack of Efficacy|4
6096784|NCT00731120|9710971|FG000|Overall Study|Noncompliance with Study Drug|3
6096785|NCT00731120|9710972|FG001|Overall Study|Noncompliance with Study Drug|3
6096786|NCT00731120|9710973|FG002|Overall Study|Noncompliance with Study Drug|1
6096787|NCT00731120|9710971|FG000|Overall Study|Protocol Deviations|1
6096788|NCT00731120|9710972|FG001|Overall Study|Protocol Deviations|6
6096789|NCT00731120|9710973|FG002|Overall Study|Protocol Deviations|1
6096790|NCT00731120|9710971|FG000|Overall Study|Withdrawal of Consent|13
6096791|NCT00731120|9710972|FG001|Overall Study|Withdrawal of Consent|8
6096792|NCT00731120|9710973|FG002|Overall Study|Withdrawal of Consent|4
6096793|NCT00731120|9710971|FG000|Overall Study|Lost to Follow-up|10
6096794|NCT00731120|9710972|FG001|Overall Study|Lost to Follow-up|15
6096795|NCT00731120|9710973|FG002|Overall Study|Lost to Follow-up|17
6096796|NCT00731120|9710971|FG000|Overall Study|Other|4
5980502|NCT02733042|9569322|FG002|Treatment Period|Progressive Disease|3
6096797|NCT00731120|9710972|FG001|Overall Study|Other|0
6096798|NCT00731120|9710973|FG002|Overall Study|Other|1
6096799|NCT00731133|9710981|FG000|Overall Study|Withdrawal by Subject|10
6096800|NCT00731549|9711006|FG000|Overall Study|Lost to Follow-up|19
6203392|NCT01513967|9864375|FG004|Overall Study|Pregnancy|0
6203393|NCT01513967|9864376|FG005|Overall Study|Pregnancy|0
6203394|NCT01513967|9864377|FG006|Overall Study|Pregnancy|1
6203395|NCT01513967|9864378|FG007|Overall Study|Pregnancy|0
6203396|NCT01513967|9864371|FG000|Overall Study|missed a study visit|0
6203397|NCT01513967|9864372|FG001|Overall Study|missed a study visit|0
6203398|NCT01513967|9864373|FG002|Overall Study|missed a study visit|0
6203399|NCT01513967|9864374|FG003|Overall Study|missed a study visit|0
6203400|NCT01513967|9864375|FG004|Overall Study|missed a study visit|0
6203401|NCT01513967|9864376|FG005|Overall Study|missed a study visit|0
6203402|NCT01513967|9864377|FG006|Overall Study|missed a study visit|1
6203403|NCT01513967|9864378|FG007|Overall Study|missed a study visit|0
6203404|NCT01513967|9864371|FG000|Overall Study|excluded due to positive drug screen|0
6203405|NCT01513967|9864372|FG001|Overall Study|excluded due to positive drug screen|0
6203406|NCT01513967|9864373|FG002|Overall Study|excluded due to positive drug screen|0
6203407|NCT01513967|9864374|FG003|Overall Study|excluded due to positive drug screen|0
6203408|NCT01513967|9864375|FG004|Overall Study|excluded due to positive drug screen|0
6203409|NCT01513967|9864376|FG005|Overall Study|excluded due to positive drug screen|0
6203410|NCT01513967|9864377|FG006|Overall Study|excluded due to positive drug screen|0
6203411|NCT01513967|9864378|FG007|Overall Study|excluded due to positive drug screen|2
6203412|NCT01513967|9864371|FG000|Overall Study|Physician Decision|0
6203413|NCT01513967|9864372|FG001|Overall Study|Physician Decision|0
6203414|NCT01513967|9864373|FG002|Overall Study|Physician Decision|0
6203415|NCT01513967|9864374|FG003|Overall Study|Physician Decision|0
6203416|NCT01513967|9864375|FG004|Overall Study|Physician Decision|0
6203417|NCT01513967|9864376|FG005|Overall Study|Physician Decision|1
6203418|NCT01513967|9864377|FG006|Overall Study|Physician Decision|0
6203419|NCT01513967|9864378|FG007|Overall Study|Physician Decision|0
6203420|NCT01514136|9864398|FG000|Test Period 1; Test A|Protocol Violation|1
6203421|NCT01514136|9864399|FG001|Test Period 1; Test A|Protocol Violation|0
6203422|NCT01514136|9864400|FG002|Test Period 1; Test A|Protocol Violation|0
6203423|NCT01514136|9864401|FG003|Test Period 1; Test A|Protocol Violation|0
6203424|NCT01514136|9864402|FG004|Test Period 1; Test A|Protocol Violation|0
6203425|NCT01514136|9864403|FG005|Test Period 1; Test A|Protocol Violation|0
6203426|NCT01514136|9864404|FG006|Test Period 1; Test A|Protocol Violation|0
6203427|NCT01514136|9864405|FG007|Test Period 1; Test A|Protocol Violation|0
6203428|NCT01514136|9864398|FG000|Test Period 1; Test A|Break from study holiday|2
6203429|NCT01514136|9864399|FG001|Test Period 1; Test A|Break from study holiday|0
6203430|NCT01514136|9864400|FG002|Test Period 1; Test A|Break from study holiday|0
6203431|NCT01514136|9864401|FG003|Test Period 1; Test A|Break from study holiday|0
6203432|NCT01514136|9864402|FG004|Test Period 1; Test A|Break from study holiday|0
6203433|NCT01514136|9864403|FG005|Test Period 1; Test A|Break from study holiday|0
6203434|NCT01514136|9864404|FG006|Test Period 1; Test A|Break from study holiday|0
6203435|NCT01514136|9864405|FG007|Test Period 1; Test A|Break from study holiday|0
6203436|NCT01514136|9864398|FG000|Test Period 1; Test B|Withdrawal by Subject|0
6203437|NCT01514136|9864399|FG001|Test Period 1; Test B|Withdrawal by Subject|1
6203438|NCT01514136|9864400|FG002|Test Period 1; Test B|Withdrawal by Subject|0
6203439|NCT01514136|9864401|FG003|Test Period 1; Test B|Withdrawal by Subject|0
6203440|NCT01514136|9864402|FG004|Test Period 1; Test B|Withdrawal by Subject|0
6203441|NCT01514136|9864403|FG005|Test Period 1; Test B|Withdrawal by Subject|0
6203442|NCT01514136|9864404|FG006|Test Period 1; Test B|Withdrawal by Subject|0
6203443|NCT01514136|9864405|FG007|Test Period 1; Test B|Withdrawal by Subject|0
6203444|NCT01514136|9864398|FG000|Test Period 1; Test D|Subject took a break due to holiday|0
6203445|NCT01514136|9864399|FG001|Test Period 1; Test D|Subject took a break due to holiday|0
6203446|NCT01514136|9864400|FG002|Test Period 1; Test D|Subject took a break due to holiday|0
6203447|NCT01514136|9864401|FG003|Test Period 1; Test D|Subject took a break due to holiday|2
6203448|NCT01514136|9864402|FG004|Test Period 1; Test D|Subject took a break due to holiday|0
6203449|NCT01514136|9864403|FG005|Test Period 1; Test D|Subject took a break due to holiday|0
6203450|NCT01514136|9864404|FG006|Test Period 1; Test D|Subject took a break due to holiday|0
6203451|NCT01514136|9864405|FG007|Test Period 1; Test D|Subject took a break due to holiday|0
6096801|NCT00731549|9711006|FG000|Overall Study|Met withdrawal criteria|24
6096802|NCT00731549|9711006|FG000|Overall Study|Physician Decision|16
6096803|NCT00731549|9711006|FG000|Overall Study|Withdrawal by Subject|89
6096804|NCT00731549|9711006|FG000|Overall Study|Protocol deviation|1
6096805|NCT00731549|9711006|FG000|Overall Study|Adverse Event|31
6096806|NCT00731549|9711006|FG000|Overall Study|Lack of efficacy with AE|37
6096807|NCT00731549|9711006|FG000|Overall Study|Lack of efficacy without AE|6
6096808|NCT00731666|9711042|FG000|Overall Study|Adverse Event|2
6096809|NCT00731666|9711042|FG000|Overall Study|Lost to Follow-up|8
6096810|NCT00731666|9711042|FG000|Overall Study|Withdrawal by Subject|2
6096811|NCT00731679|9711048|FG000|Overall Study|Adverse Event|7
6096812|NCT00731679|9711049|FG001|Overall Study|Adverse Event|8
6096813|NCT00731679|9711048|FG000|Overall Study|Withdrawal by Subject|8
6096814|NCT00731679|9711049|FG001|Overall Study|Withdrawal by Subject|8
6096815|NCT00731679|9711048|FG000|Overall Study|Lost to Follow-up|7
6096816|NCT00731679|9711049|FG001|Overall Study|Lost to Follow-up|8
6096817|NCT00731679|9711048|FG000|Overall Study|Noncompliance|0
6096818|NCT00731679|9711049|FG001|Overall Study|Noncompliance|1
6096819|NCT00731679|9711048|FG000|Overall Study|Pregnancy|0
6096820|NCT00731679|9711049|FG001|Overall Study|Pregnancy|1
6096821|NCT00731692|9711058|FG000|Core Study (36 Months)|Lack of Efficacy|11
6096822|NCT00731692|9711059|FG001|Core Study (36 Months)|Lack of Efficacy|23
6096823|NCT00731692|9711060|FG002|Core Study (36 Months)|Lack of Efficacy|64
6096824|NCT00731692|9711058|FG000|Core Study (36 Months)|Physician Decision|1
6096825|NCT00731692|9711059|FG001|Core Study (36 Months)|Physician Decision|0
6096826|NCT00731692|9711060|FG002|Core Study (36 Months)|Physician Decision|2
6096827|NCT00731692|9711058|FG000|Core Study (36 Months)|Death|2
6096828|NCT00731692|9711059|FG001|Core Study (36 Months)|Death|1
6096829|NCT00731692|9711060|FG002|Core Study (36 Months)|Death|2
6096830|NCT00731692|9711058|FG000|Core Study (36 Months)|Lost to Follow-up|1
6096831|NCT00731692|9711059|FG001|Core Study (36 Months)|Lost to Follow-up|3
6096832|NCT00731692|9711060|FG002|Core Study (36 Months)|Lost to Follow-up|3
6096833|NCT00731692|9711058|FG000|Core Study (36 Months)|Administrative|2
6096834|NCT00731692|9711059|FG001|Core Study (36 Months)|Administrative|2
6096835|NCT00731692|9711060|FG002|Core Study (36 Months)|Administrative|6
6096836|NCT00731692|9711058|FG000|Core Study (36 Months)|Abnormal Test Procedure Result|4
6096837|NCT00731692|9711059|FG001|Core Study (36 Months)|Abnormal Test Procedure Result|3
6096838|NCT00731692|9711060|FG002|Core Study (36 Months)|Abnormal Test Procedure Result|5
6096839|NCT00731692|9711058|FG000|Core Study (36 Months)|Protocol Violation|4
6096840|NCT00731692|9711059|FG001|Core Study (36 Months)|Protocol Violation|5
6096841|NCT00731692|9711060|FG002|Core Study (36 Months)|Protocol Violation|8
6096842|NCT00731692|9711058|FG000|Core Study (36 Months)|Abnormal Lab values|6
6096843|NCT00731692|9711059|FG001|Core Study (36 Months)|Abnormal Lab values|19
6096844|NCT00731692|9711060|FG002|Core Study (36 Months)|Abnormal Lab values|5
6096845|NCT00731692|9711058|FG000|Core Study (36 Months)|Adverse Event|25
6096846|NCT00731692|9711059|FG001|Core Study (36 Months)|Adverse Event|28
6096847|NCT00731692|9711060|FG002|Core Study (36 Months)|Adverse Event|29
6096848|NCT00731692|9711058|FG000|Core Study (36 Months)|Withdrawal by Subject|12
6096849|NCT00731692|9711059|FG001|Core Study (36 Months)|Withdrawal by Subject|32
6096850|NCT00731692|9711060|FG002|Core Study (36 Months)|Withdrawal by Subject|46
6096851|NCT00731692|9711058|FG000|Extension Phase|Admin Problems: Terminated # patients|69
6096852|NCT00731692|9711059|FG001|Extension Phase|Admin Problems: Terminated # patients|189
6096853|NCT00731692|9711060|FG002|Extension Phase|Admin Problems: Terminated # patients|277
6096854|NCT00731692|9711058|FG000|Extension Phase|Abnormal test procedure|0
6096855|NCT00731692|9711059|FG001|Extension Phase|Abnormal test procedure|0
6096856|NCT00731692|9711060|FG002|Extension Phase|Abnormal test procedure|1
6096857|NCT00731692|9711058|FG000|Extension Phase|Abnormal lab values|0
6096858|NCT00731692|9711059|FG001|Extension Phase|Abnormal lab values|0
6096859|NCT00731692|9711060|FG002|Extension Phase|Abnormal lab values|1
6096860|NCT00731692|9711058|FG000|Extension Phase|Lost to Follow-up|0
6096861|NCT00731692|9711059|FG001|Extension Phase|Lost to Follow-up|1
6096862|NCT00731692|9711060|FG002|Extension Phase|Lost to Follow-up|4
6096863|NCT00731692|9711058|FG000|Extension Phase|Withdrawal by Subject|4
6096864|NCT00731692|9711059|FG001|Extension Phase|Withdrawal by Subject|5
6096865|NCT00731692|9711060|FG002|Extension Phase|Withdrawal by Subject|3
6096866|NCT00731692|9711058|FG000|Extension Phase|Adverse Event|1
6096867|NCT00731692|9711059|FG001|Extension Phase|Adverse Event|1
6096868|NCT00731692|9711060|FG002|Extension Phase|Adverse Event|15
6096869|NCT00731783|9711078|FG000|One Month Follow-Up Visit|Lost to Follow-up|14
6096870|NCT00731783|9711079|FG001|One Month Follow-Up Visit|Lost to Follow-up|22
6096871|NCT00731783|9711078|FG000|Three Month Follow-Up Visit|Lost to Follow-up|7
6096872|NCT00731783|9711079|FG001|Three Month Follow-Up Visit|Lost to Follow-up|16
6096873|NCT00731783|9711078|FG000|Six Month Follow-Up Visit|Lost to Follow-up|6
6096874|NCT00731783|9711079|FG001|Six Month Follow-Up Visit|Lost to Follow-up|3
6096875|NCT00731783|9711078|FG000|12 Month Follow-Up Visit|Lost to Follow-up|6
6096876|NCT00731783|9711079|FG001|12 Month Follow-Up Visit|Lost to Follow-up|7
6096877|NCT00731822|9711087|FG000|Overall Study|Adverse Event|2
6096878|NCT00731822|9711088|FG001|Overall Study|Adverse Event|1
6096879|NCT00731822|9711087|FG000|Overall Study|Protocol Violation|1
6096880|NCT00731822|9711088|FG001|Overall Study|Protocol Violation|0
6096881|NCT00731822|9711087|FG000|Overall Study|Lost to Follow-up|1
6096882|NCT00731822|9711088|FG001|Overall Study|Lost to Follow-up|0
6096883|NCT00731939|9711103|FG000|Overall Study|Adverse Event|6
6096884|NCT00731939|9711103|FG000|Overall Study|Lost to Follow-up|15
6096885|NCT00731939|9711103|FG000|Overall Study|Not implanted with study device|9
6096886|NCT00731939|9711103|FG000|Overall Study|Withdrawal by Subject|2
6096887|NCT00731939|9711103|FG000|Overall Study|Did not meet enrollment criteria|2
6096888|NCT00732069|9711111|FG000|Washout After First Study Drug|Adverse Event|1
6096889|NCT00732069|9711112|FG001|Washout After First Study Drug|Adverse Event|0
6096890|NCT00732069|9711113|FG002|Washout After First Study Drug|Adverse Event|0
6096891|NCT00732069|9711114|FG003|Washout After First Study Drug|Adverse Event|0
6096892|NCT00732069|9711115|FG004|Washout After First Study Drug|Adverse Event|0
6096893|NCT00732069|9711116|FG005|Washout After First Study Drug|Adverse Event|0
6203452|NCT01514136|9864398|FG000|Test Period 2; Test A*|Adverse Event|0
6203453|NCT01514136|9864399|FG001|Test Period 2; Test A*|Adverse Event|0
6203454|NCT01514136|9864400|FG002|Test Period 2; Test A*|Adverse Event|0
6203455|NCT01514136|9864401|FG003|Test Period 2; Test A*|Adverse Event|0
6203456|NCT01514136|9864402|FG004|Test Period 2; Test A*|Adverse Event|1
6203457|NCT01514136|9864403|FG005|Test Period 2; Test A*|Adverse Event|0
6203458|NCT01514136|9864404|FG006|Test Period 2; Test A*|Adverse Event|0
6203459|NCT01514136|9864405|FG007|Test Period 2; Test A*|Adverse Event|0
6203460|NCT01514136|9864398|FG000|Test Period 2; Test A*|Holiday|0
6203461|NCT01514136|9864399|FG001|Test Period 2; Test A*|Holiday|0
6203462|NCT01514136|9864400|FG002|Test Period 2; Test A*|Holiday|0
6203463|NCT01514136|9864401|FG003|Test Period 2; Test A*|Holiday|0
6203464|NCT01514136|9864402|FG004|Test Period 2; Test A*|Holiday|1
6203465|NCT01514136|9864403|FG005|Test Period 2; Test A*|Holiday|0
6203466|NCT01514136|9864404|FG006|Test Period 2; Test A*|Holiday|0
6203467|NCT01514136|9864405|FG007|Test Period 2; Test A*|Holiday|0
6203468|NCT01514136|9864398|FG000|Test Period 2; Test B*|Withdrawal by Subject|0
6203469|NCT01514136|9864399|FG001|Test Period 2; Test B*|Withdrawal by Subject|0
6203470|NCT01514136|9864400|FG002|Test Period 2; Test B*|Withdrawal by Subject|0
6203471|NCT01514136|9864401|FG003|Test Period 2; Test B*|Withdrawal by Subject|0
6203472|NCT01514136|9864402|FG004|Test Period 2; Test B*|Withdrawal by Subject|0
6203473|NCT01514136|9864403|FG005|Test Period 2; Test B*|Withdrawal by Subject|2
6203474|NCT01514136|9864404|FG006|Test Period 2; Test B*|Withdrawal by Subject|0
6203475|NCT01514136|9864405|FG007|Test Period 2; Test B*|Withdrawal by Subject|0
6203476|NCT01514136|9864398|FG000|Test Period 2; Test C*|Withdrawal by Subject|0
6284510|NCT02326272|9996342|FG014|Open-label Period (Week 48 to Week 144)|Withdrawal by Subject|2
6284511|NCT02326272|9996328|FG000|Open-label Period (Week 48 to Week 144)|Did not achieve PASI50|0
6284512|NCT02326272|9996329|FG001|Open-label Period (Week 48 to Week 144)|Did not achieve PASI50|0
6284513|NCT02326272|9996330|FG002|Open-label Period (Week 48 to Week 144)|Did not achieve PASI50|0
6284514|NCT02326272|9996331|FG003|Open-label Period (Week 48 to Week 144)|Did not achieve PASI50|0
6284515|NCT02326272|9996332|FG004|Open-label Period (Week 48 to Week 144)|Did not achieve PASI50|0
6284516|NCT02326272|9996333|FG005|Open-label Period (Week 48 to Week 144)|Did not achieve PASI50|0
6284517|NCT02326272|9996334|FG006|Open-label Period (Week 48 to Week 144)|Did not achieve PASI50|0
6284518|NCT02326272|9996335|FG007|Open-label Period (Week 48 to Week 144)|Did not achieve PASI50|0
6284519|NCT02326272|9996336|FG008|Open-label Period (Week 48 to Week 144)|Did not achieve PASI50|0
6284520|NCT02326272|9996337|FG009|Open-label Period (Week 48 to Week 144)|Did not achieve PASI50|0
6284521|NCT02326272|9996338|FG010|Open-label Period (Week 48 to Week 144)|Did not achieve PASI50|0
6284522|NCT02326272|9996339|FG011|Open-label Period (Week 48 to Week 144)|Did not achieve PASI50|1
6284523|NCT02326272|9996340|FG012|Open-label Period (Week 48 to Week 144)|Did not achieve PASI50|3
6284524|NCT02326272|9996341|FG013|Open-label Period (Week 48 to Week 144)|Did not achieve PASI50|0
6284525|NCT02326272|9996342|FG014|Open-label Period (Week 48 to Week 144)|Did not achieve PASI50|3
6284526|NCT02326272|9996328|FG000|Open-label Period (Week 48 to Week 144)|Loss of efficacy|0
6284527|NCT02326272|9996329|FG001|Open-label Period (Week 48 to Week 144)|Loss of efficacy|0
6284528|NCT02326272|9996330|FG002|Open-label Period (Week 48 to Week 144)|Loss of efficacy|0
6284529|NCT02326272|9996331|FG003|Open-label Period (Week 48 to Week 144)|Loss of efficacy|0
6284530|NCT02326272|9996332|FG004|Open-label Period (Week 48 to Week 144)|Loss of efficacy|0
6284531|NCT02326272|9996333|FG005|Open-label Period (Week 48 to Week 144)|Loss of efficacy|0
6284532|NCT02326272|9996334|FG006|Open-label Period (Week 48 to Week 144)|Loss of efficacy|0
6284533|NCT02326272|9996335|FG007|Open-label Period (Week 48 to Week 144)|Loss of efficacy|0
6284534|NCT02326272|9996336|FG008|Open-label Period (Week 48 to Week 144)|Loss of efficacy|0
6284535|NCT02326272|9996337|FG009|Open-label Period (Week 48 to Week 144)|Loss of efficacy|0
6284536|NCT02326272|9996338|FG010|Open-label Period (Week 48 to Week 144)|Loss of efficacy|0
6284537|NCT02326272|9996339|FG011|Open-label Period (Week 48 to Week 144)|Loss of efficacy|1
6284538|NCT02326272|9996340|FG012|Open-label Period (Week 48 to Week 144)|Loss of efficacy|0
6284539|NCT02326272|9996341|FG013|Open-label Period (Week 48 to Week 144)|Loss of efficacy|0
6284540|NCT02326272|9996342|FG014|Open-label Period (Week 48 to Week 144)|Loss of efficacy|0
6284541|NCT02326272|9996328|FG000|Open-label Period (Week 48 to Week 144)|Pregnancy|0
6284542|NCT02326272|9996329|FG001|Open-label Period (Week 48 to Week 144)|Pregnancy|0
6284543|NCT02326272|9996330|FG002|Open-label Period (Week 48 to Week 144)|Pregnancy|0
6284544|NCT02326272|9996331|FG003|Open-label Period (Week 48 to Week 144)|Pregnancy|0
6284545|NCT02326272|9996332|FG004|Open-label Period (Week 48 to Week 144)|Pregnancy|0
6096894|NCT00732160|9711128|FG000|Overall Study|Adverse Event|1
6096895|NCT00732160|9711129|FG001|Overall Study|Adverse Event|0
6096896|NCT00732160|9711130|FG002|Overall Study|Adverse Event|1
6096897|NCT00732160|9711131|FG003|Overall Study|Adverse Event|1
6096898|NCT00732160|9711128|FG000|Overall Study|scheduling|4
6096899|NCT00732160|9711129|FG001|Overall Study|scheduling|4
6096900|NCT00732160|9711130|FG002|Overall Study|scheduling|2
6096901|NCT00732160|9711131|FG003|Overall Study|scheduling|1
6096902|NCT00732199|9711143|FG000|Overall Study|Withdrawal by Subject|25
6096903|NCT00732199|9711144|FG001|Overall Study|Withdrawal by Subject|18
6096904|NCT00732199|9711143|FG000|Overall Study|sleep apnea, inadequate signals/sleep|9
6096905|NCT00732199|9711144|FG001|Overall Study|sleep apnea, inadequate signals/sleep|8
6096906|NCT00732238|9711176|FG000|Overall Study|Bacteremia|4
6096907|NCT00732238|9711177|FG001|Overall Study|Bacteremia|1
6096908|NCT00732238|9711176|FG000|Overall Study|Asymptomatic bacteriuria|1
6096909|NCT00732238|9711177|FG001|Overall Study|Asymptomatic bacteriuria|0
6096910|NCT00732251|9711185|FG000|Overall Study|Lost to Follow-up|3
6096911|NCT00732251|9711185|FG000|Overall Study|Withdrawal by Subject|3
6096912|NCT00732251|9711185|FG000|Overall Study|Early Term due to Site Closure|1
6096913|NCT00732303|9711189|FG000|Overall Study|Study Terminated|2
6096914|NCT00732472|9711197|FG000|Overall Study|Adverse Event|0
6096915|NCT00732472|9711198|FG001|Overall Study|Adverse Event|1
6096916|NCT00732472|9711199|FG002|Overall Study|Adverse Event|1
6096917|NCT00732472|9711200|FG003|Overall Study|Adverse Event|1
6096918|NCT00732472|9711197|FG000|Overall Study|Protocol Violation|0
6096919|NCT00732472|9711198|FG001|Overall Study|Protocol Violation|0
6096920|NCT00732472|9711199|FG002|Overall Study|Protocol Violation|0
6096921|NCT00732472|9711200|FG003|Overall Study|Protocol Violation|1
6096922|NCT00732472|9711197|FG000|Overall Study|Withdrawal by Subject|0
6096923|NCT00732472|9711198|FG001|Overall Study|Withdrawal by Subject|2
6096924|NCT00732472|9711199|FG002|Overall Study|Withdrawal by Subject|0
6096925|NCT00732472|9711200|FG003|Overall Study|Withdrawal by Subject|1
6096926|NCT00732498|9711211|FG000|Overall Study|Ineligible|1
6096927|NCT00732498|9711211|FG000|Overall Study|Adverse Event|2
6096928|NCT00732498|9711211|FG000|Overall Study|Physician Decision|3
6096929|NCT00732615|9711217|FG000|Overall Study|Withdrawal by Subject|3
6096930|NCT00732615|9711218|FG001|Overall Study|Withdrawal by Subject|1
6096931|NCT00732615|9711217|FG000|Overall Study|Lost to Follow-up|0
6096932|NCT00732615|9711218|FG001|Overall Study|Lost to Follow-up|1
6096933|NCT00732615|9711217|FG000|Overall Study|Adverse Event|0
6096934|NCT00732615|9711218|FG001|Overall Study|Adverse Event|2
6096935|NCT00732615|9711217|FG000|Overall Study|Physician Decision|3
6096936|NCT00732615|9711218|FG001|Overall Study|Physician Decision|0
6096937|NCT00732615|9711217|FG000|Overall Study|Non-Compliance, Subject/Physician Dec.|1
6096938|NCT00732615|9711218|FG001|Overall Study|Non-Compliance, Subject/Physician Dec.|1
6096939|NCT00732641|9711227|FG000|Overall Study|Relapse or Progressive Disease|65
6096940|NCT00732641|9711228|FG001|Overall Study|Relapse or Progressive Disease|101
6096941|NCT00732641|9711227|FG000|Overall Study|Serious Adverse Events|12
6096942|NCT00732641|9711228|FG001|Overall Study|Serious Adverse Events|3
6096943|NCT00732641|9711227|FG000|Overall Study|Physician Decision|6
6096944|NCT00732641|9711228|FG001|Overall Study|Physician Decision|0
6096945|NCT00732641|9711227|FG000|Overall Study|Withdrawal by Subject|4
6096946|NCT00732641|9711228|FG001|Overall Study|Withdrawal by Subject|2
6096947|NCT00732641|9711227|FG000|Overall Study|Unable to Complete|1
6096948|NCT00732641|9711228|FG001|Overall Study|Unable to Complete|1
6096949|NCT00732641|9711227|FG000|Overall Study|Other|18
6096950|NCT00732641|9711228|FG001|Overall Study|Other|5
6096951|NCT00732758|9711249|FG000|Overall Study|Lost to Follow-up|8
6096952|NCT00732758|9711250|FG001|Overall Study|Lost to Follow-up|16
6096953|NCT00732875|9711256|FG000|Overall Study|Adverse Event|16
6096954|NCT00732875|9711256|FG000|Overall Study|Withdrawal by Subject|6
6096955|NCT00732875|9711256|FG000|Overall Study|Lack of Efficacy|13
6096956|NCT00732940|9711271|FG000|Overall Study|Withdrawal by Subject|1
6096957|NCT00732940|9711272|FG001|Overall Study|Withdrawal by Subject|2
6096958|NCT00732940|9711271|FG000|Overall Study|Adverse Event|0
6096959|NCT00732940|9711272|FG001|Overall Study|Adverse Event|1
6096960|NCT00732940|9711271|FG000|Overall Study|Lost to Follow-up|1
6096961|NCT00732940|9711272|FG001|Overall Study|Lost to Follow-up|0
6096962|NCT00732992|9711280|FG000|Overall Study|Adverse Event|1
6096963|NCT00732992|9711281|FG001|Overall Study|Adverse Event|1
6096964|NCT00732992|9711280|FG000|Overall Study|Objective Progression or Relapse|3
6096965|NCT00732992|9711281|FG001|Overall Study|Objective Progression or Relapse|5
6096966|NCT00732992|9711280|FG000|Overall Study|Global Deterioration of Health Status|1
6096967|NCT00732992|9711281|FG001|Overall Study|Global Deterioration of Health Status|0
6096968|NCT00732992|9711280|FG000|Overall Study|Withdrawal by Subject|1
6096969|NCT00732992|9711281|FG001|Overall Study|Withdrawal by Subject|0
6096970|NCT00733226|9711309|FG000|Overall Study|Withdrawal by Subject|1
6096971|NCT00733226|9711310|FG001|Overall Study|Withdrawal by Subject|0
6096972|NCT00733226|9711309|FG000|Overall Study|Lost to Follow-up|2
6096973|NCT00733226|9711310|FG001|Overall Study|Lost to Follow-up|0
6096974|NCT00733226|9711309|FG000|Overall Study|moved to another place|2
6096975|NCT00733226|9711310|FG001|Overall Study|moved to another place|0
6096976|NCT00733291|9711323|FG000|Washout Period, 3 Days (+/-1 Day)|Failed inc criteria Second Intervention|1
6096977|NCT00733291|9711324|FG001|Washout Period, 3 Days (+/-1 Day)|Failed inc criteria Second Intervention|0
6096978|NCT00733291|9711325|FG002|Washout Period, 3 Days (+/-1 Day)|Failed inc criteria Second Intervention|0
6096979|NCT00733291|9711326|FG003|Washout Period, 3 Days (+/-1 Day)|Failed inc criteria Second Intervention|0
6096980|NCT00733304|9711340|FG000|Overall Study|Adverse Event|3
6096981|NCT00733304|9711341|FG001|Overall Study|Adverse Event|0
6096982|NCT00733304|9711342|FG002|Overall Study|Adverse Event|0
6096983|NCT00733304|9711340|FG000|Overall Study|Lack of Efficacy|0
6096984|NCT00733304|9711341|FG001|Overall Study|Lack of Efficacy|0
6096985|NCT00733304|9711342|FG002|Overall Study|Lack of Efficacy|2
6096986|NCT00733304|9711340|FG000|Overall Study|Lost to Follow-up|0
6096987|NCT00733304|9711341|FG001|Overall Study|Lost to Follow-up|1
6096988|NCT00733304|9711342|FG002|Overall Study|Lost to Follow-up|0
6096989|NCT00733304|9711340|FG000|Overall Study|Physician Decision|3
6096990|NCT00733304|9711341|FG001|Overall Study|Physician Decision|1
6096991|NCT00733304|9711342|FG002|Overall Study|Physician Decision|3
6096992|NCT00733304|9711340|FG000|Overall Study|Withdrawal by Subject|1
6096993|NCT00733304|9711341|FG001|Overall Study|Withdrawal by Subject|1
6096994|NCT00733304|9711342|FG002|Overall Study|Withdrawal by Subject|0
6096995|NCT00733369|9711377|FG000|Overall Study|Lost to Follow-up|2
6096996|NCT00733369|9711378|FG001|Overall Study|Lost to Follow-up|1
6096997|NCT00733369|9711377|FG000|Overall Study|Adverse Event|4
6096998|NCT00733369|9711378|FG001|Overall Study|Adverse Event|4
6096999|NCT00733369|9711377|FG000|Overall Study|Protocol Violation|4
6097000|NCT00733369|9711378|FG001|Overall Study|Protocol Violation|4
6097001|NCT00733408|9711384|FG000|Overall Study|Adverse Event|4
6097002|NCT00733421|9711390|FG000|Overall Study|Withdrawal by Subject|1
6097003|NCT00733421|9711391|FG001|Overall Study|Withdrawal by Subject|1
6097004|NCT00733499|9711399|FG000|Pre-operative|Protocol Violation|0
6097005|NCT00733499|9711400|FG001|Pre-operative|Protocol Violation|1
6097006|NCT00733499|9711399|FG000|3 Months Follow-up|Death|1
6097007|NCT00733499|9711400|FG001|3 Months Follow-up|Death|2
6097008|NCT00733499|9711399|FG000|6 Months Follow-up|Death|0
6097009|NCT00733499|9711400|FG001|6 Months Follow-up|Death|2
6097010|NCT00733499|9711399|FG000|6 Months Follow-up|Adverse Event|0
6097011|NCT00733499|9711400|FG001|6 Months Follow-up|Adverse Event|1
6097012|NCT00733499|9711399|FG000|12 Months Follow-up|Death|2
6097013|NCT00733499|9711400|FG001|12 Months Follow-up|Death|1
6097014|NCT00733499|9711399|FG000|24 Months Follow-up|Death|0
6097015|NCT00733499|9711400|FG001|24 Months Follow-up|Death|1
6097016|NCT00733499|9711399|FG000|5 Year Followup|Adverse Event|2
6097017|NCT00733499|9711400|FG001|5 Year Followup|Adverse Event|2
6097018|NCT00733499|9711399|FG000|5 Year Followup|Non device related AE|0
6097019|NCT00733499|9711400|FG001|5 Year Followup|Non device related AE|1
6203477|NCT01514136|9864399|FG001|Test Period 2; Test C*|Withdrawal by Subject|0
6203478|NCT01514136|9864400|FG002|Test Period 2; Test C*|Withdrawal by Subject|0
6203479|NCT01514136|9864401|FG003|Test Period 2; Test C*|Withdrawal by Subject|0
6203480|NCT01514136|9864402|FG004|Test Period 2; Test C*|Withdrawal by Subject|0
6203481|NCT01514136|9864403|FG005|Test Period 2; Test C*|Withdrawal by Subject|0
6203482|NCT01514136|9864404|FG006|Test Period 2; Test C*|Withdrawal by Subject|1
6203483|NCT01514136|9864405|FG007|Test Period 2; Test C*|Withdrawal by Subject|0
6284546|NCT02326272|9996333|FG005|Open-label Period (Week 48 to Week 144)|Pregnancy|0
6284547|NCT02326272|9996334|FG006|Open-label Period (Week 48 to Week 144)|Pregnancy|0
6284548|NCT02326272|9996335|FG007|Open-label Period (Week 48 to Week 144)|Pregnancy|0
6284549|NCT02326272|9996336|FG008|Open-label Period (Week 48 to Week 144)|Pregnancy|0
6284550|NCT02326272|9996337|FG009|Open-label Period (Week 48 to Week 144)|Pregnancy|0
6284551|NCT02326272|9996338|FG010|Open-label Period (Week 48 to Week 144)|Pregnancy|0
6284552|NCT02326272|9996339|FG011|Open-label Period (Week 48 to Week 144)|Pregnancy|0
6284553|NCT02326272|9996340|FG012|Open-label Period (Week 48 to Week 144)|Pregnancy|1
6284554|NCT02326272|9996341|FG013|Open-label Period (Week 48 to Week 144)|Pregnancy|0
6284555|NCT02326272|9996342|FG014|Open-label Period (Week 48 to Week 144)|Pregnancy|0
6284556|NCT02326298|9996354|FG000|Initial Period (Week 0 to Week 16)|Adverse Event|0
6284557|NCT02326298|9996355|FG001|Initial Period (Week 0 to Week 16)|Adverse Event|0
6284558|NCT02326298|9996356|FG002|Initial Period (Week 0 to Week 16)|Adverse Event|1
6097020|NCT00733499|9711399|FG000|5 Year Followup|Revision of Study Implant|0
6097021|NCT00733499|9711400|FG001|5 Year Followup|Revision of Study Implant|1
6097022|NCT00733499|9711399|FG000|5 Year Followup|Lost to Follow-up|2
6097023|NCT00733499|9711400|FG001|5 Year Followup|Lost to Follow-up|0
6097024|NCT00733499|9711399|FG000|5 Year Followup|Death|13
6097025|NCT00733499|9711400|FG001|5 Year Followup|Death|19
6097026|NCT00733499|9711399|FG000|5 Year Followup|missing, unable to locate|0
6097027|NCT00733499|9711400|FG001|5 Year Followup|missing, unable to locate|1
6097028|NCT00733499|9711399|FG000|5 Year Followup|Withdrawal by Subject|4
6097029|NCT00733499|9711400|FG001|5 Year Followup|Withdrawal by Subject|1
6097030|NCT00733499|9711399|FG000|10 Year Followup|Death|9
6097031|NCT00733499|9711400|FG001|10 Year Followup|Death|7
6097032|NCT00733499|9711399|FG000|10 Year Followup|Adverse Event|3
6097033|NCT00733499|9711400|FG001|10 Year Followup|Adverse Event|3
6097034|NCT00733499|9711399|FG000|10 Year Followup|Lost to Follow-up|3
6097035|NCT00733499|9711400|FG001|10 Year Followup|Lost to Follow-up|2
6097036|NCT00733499|9711399|FG000|10 Year Followup|Withdrawal by Subject|5
6097037|NCT00733499|9711400|FG001|10 Year Followup|Withdrawal by Subject|5
6097038|NCT00733499|9711399|FG000|10 Year Followup|missing, unable to locate|0
6097039|NCT00733499|9711400|FG001|10 Year Followup|missing, unable to locate|2
6097040|NCT00733746|9711410|FG000|Overall Study|Ineligible|5
6203484|NCT01514136|9864398|FG000|Test Period 2; Test C*|holiday|0
6203485|NCT01514136|9864399|FG001|Test Period 2; Test C*|holiday|0
6203486|NCT01514136|9864400|FG002|Test Period 2; Test C*|holiday|0
6203487|NCT01514136|9864401|FG003|Test Period 2; Test C*|holiday|0
6203488|NCT01514136|9864402|FG004|Test Period 2; Test C*|holiday|0
6203489|NCT01514136|9864403|FG005|Test Period 2; Test C*|holiday|0
6284559|NCT02326298|9996357|FG003|Initial Period (Week 0 to Week 16)|Adverse Event|0
6284560|NCT02326298|9996358|FG004|Initial Period (Week 0 to Week 16)|Adverse Event|0
6284561|NCT02326298|9996359|FG005|Initial Period (Week 0 to Week 16)|Adverse Event|0
6284562|NCT02326298|9996360|FG006|Initial Period (Week 0 to Week 16)|Adverse Event|0
6284563|NCT02326298|9996361|FG007|Initial Period (Week 0 to Week 16)|Adverse Event|0
6284564|NCT02326298|9996362|FG008|Initial Period (Week 0 to Week 16)|Adverse Event|0
6284565|NCT02326298|9996363|FG009|Initial Period (Week 0 to Week 16)|Adverse Event|0
6284566|NCT02326298|9996364|FG010|Initial Period (Week 0 to Week 16)|Adverse Event|0
6284567|NCT02326298|9996365|FG011|Initial Period (Week 0 to Week 16)|Adverse Event|0
6284568|NCT02326298|9996366|FG012|Initial Period (Week 0 to Week 16)|Adverse Event|0
6284569|NCT02326298|9996367|FG013|Initial Period (Week 0 to Week 16)|Adverse Event|0
6284570|NCT02326298|9996354|FG000|Initial Period (Week 0 to Week 16)|Lack of Efficacy|1
6284571|NCT02326298|9996355|FG001|Initial Period (Week 0 to Week 16)|Lack of Efficacy|0
6284572|NCT02326298|9996356|FG002|Initial Period (Week 0 to Week 16)|Lack of Efficacy|0
6284573|NCT02326298|9996357|FG003|Initial Period (Week 0 to Week 16)|Lack of Efficacy|0
6284574|NCT02326298|9996358|FG004|Initial Period (Week 0 to Week 16)|Lack of Efficacy|0
6284575|NCT02326298|9996359|FG005|Initial Period (Week 0 to Week 16)|Lack of Efficacy|0
6284576|NCT02326298|9996360|FG006|Initial Period (Week 0 to Week 16)|Lack of Efficacy|0
6284577|NCT02326298|9996361|FG007|Initial Period (Week 0 to Week 16)|Lack of Efficacy|0
6284578|NCT02326298|9996362|FG008|Initial Period (Week 0 to Week 16)|Lack of Efficacy|0
6284579|NCT02326298|9996363|FG009|Initial Period (Week 0 to Week 16)|Lack of Efficacy|0
6284580|NCT02326298|9996364|FG010|Initial Period (Week 0 to Week 16)|Lack of Efficacy|0
6284581|NCT02326298|9996365|FG011|Initial Period (Week 0 to Week 16)|Lack of Efficacy|0
6284582|NCT02326298|9996366|FG012|Initial Period (Week 0 to Week 16)|Lack of Efficacy|0
6284583|NCT02326298|9996367|FG013|Initial Period (Week 0 to Week 16)|Lack of Efficacy|0
6284584|NCT02326298|9996354|FG000|Initial Period (Week 0 to Week 16)|Lost to Follow-up|1
6284585|NCT02326298|9996355|FG001|Initial Period (Week 0 to Week 16)|Lost to Follow-up|1
6284586|NCT02326298|9996356|FG002|Initial Period (Week 0 to Week 16)|Lost to Follow-up|0
6284587|NCT02326298|9996357|FG003|Initial Period (Week 0 to Week 16)|Lost to Follow-up|0
6284588|NCT02326298|9996358|FG004|Initial Period (Week 0 to Week 16)|Lost to Follow-up|0
6284589|NCT02326298|9996359|FG005|Initial Period (Week 0 to Week 16)|Lost to Follow-up|0
6284590|NCT02326298|9996360|FG006|Initial Period (Week 0 to Week 16)|Lost to Follow-up|0
6284591|NCT02326298|9996361|FG007|Initial Period (Week 0 to Week 16)|Lost to Follow-up|0
6284592|NCT02326298|9996362|FG008|Initial Period (Week 0 to Week 16)|Lost to Follow-up|0
6284593|NCT02326298|9996363|FG009|Initial Period (Week 0 to Week 16)|Lost to Follow-up|0
6284594|NCT02326298|9996364|FG010|Initial Period (Week 0 to Week 16)|Lost to Follow-up|0
6284595|NCT02326298|9996365|FG011|Initial Period (Week 0 to Week 16)|Lost to Follow-up|0
6284596|NCT02326298|9996366|FG012|Initial Period (Week 0 to Week 16)|Lost to Follow-up|0
6284597|NCT02326298|9996367|FG013|Initial Period (Week 0 to Week 16)|Lost to Follow-up|0
6284598|NCT02326298|9996354|FG000|Initial Period (Week 0 to Week 16)|Withdrawal by Subject|3
6284599|NCT02326298|9996355|FG001|Initial Period (Week 0 to Week 16)|Withdrawal by Subject|2
6284600|NCT02326298|9996356|FG002|Initial Period (Week 0 to Week 16)|Withdrawal by Subject|0
6284601|NCT02326298|9996357|FG003|Initial Period (Week 0 to Week 16)|Withdrawal by Subject|0
6284602|NCT02326298|9996358|FG004|Initial Period (Week 0 to Week 16)|Withdrawal by Subject|0
6284603|NCT02326298|9996359|FG005|Initial Period (Week 0 to Week 16)|Withdrawal by Subject|0
6284604|NCT02326298|9996360|FG006|Initial Period (Week 0 to Week 16)|Withdrawal by Subject|0
6284605|NCT02326298|9996361|FG007|Initial Period (Week 0 to Week 16)|Withdrawal by Subject|0
6284606|NCT02326298|9996362|FG008|Initial Period (Week 0 to Week 16)|Withdrawal by Subject|0
6284607|NCT02326298|9996363|FG009|Initial Period (Week 0 to Week 16)|Withdrawal by Subject|0
6284608|NCT02326298|9996364|FG010|Initial Period (Week 0 to Week 16)|Withdrawal by Subject|0
6284609|NCT02326298|9996365|FG011|Initial Period (Week 0 to Week 16)|Withdrawal by Subject|0
6284610|NCT02326298|9996366|FG012|Initial Period (Week 0 to Week 16)|Withdrawal by Subject|0
6284611|NCT02326298|9996367|FG013|Initial Period (Week 0 to Week 16)|Withdrawal by Subject|0
6284612|NCT02326298|9996354|FG000|Initial Period (Week 0 to Week 16)|Adverse event after completing wk16|0
6284613|NCT02326298|9996355|FG001|Initial Period (Week 0 to Week 16)|Adverse event after completing wk16|0
6284614|NCT02326298|9996356|FG002|Initial Period (Week 0 to Week 16)|Adverse event after completing wk16|2
6284615|NCT02326298|9996357|FG003|Initial Period (Week 0 to Week 16)|Adverse event after completing wk16|0
6284616|NCT02326298|9996358|FG004|Initial Period (Week 0 to Week 16)|Adverse event after completing wk16|0
6284617|NCT02326298|9996359|FG005|Initial Period (Week 0 to Week 16)|Adverse event after completing wk16|0
6284618|NCT02326298|9996360|FG006|Initial Period (Week 0 to Week 16)|Adverse event after completing wk16|0
6284619|NCT02326298|9996361|FG007|Initial Period (Week 0 to Week 16)|Adverse event after completing wk16|0
6284620|NCT02326298|9996362|FG008|Initial Period (Week 0 to Week 16)|Adverse event after completing wk16|0
6097041|NCT00733824|9711419|FG000|Phase I|Withdrawal by Subject|1
6097042|NCT00733824|9711420|FG001|Phase I|Withdrawal by Subject|0
6097043|NCT00733824|9711421|FG002|Phase I|Withdrawal by Subject|0
6097044|NCT00733824|9711422|FG003|Phase I|Withdrawal by Subject|0
6097045|NCT00733824|9711423|FG004|Phase I|Withdrawal by Subject|0
6097046|NCT00733902|9711441|FG000|Overall Study|Death|0
6097047|NCT00733902|9711442|FG001|Overall Study|Death|0
6097048|NCT00733902|9711443|FG002|Overall Study|Death|0
6097049|NCT00733902|9711444|FG003|Overall Study|Death|1
6097050|NCT00733902|9711441|FG000|Overall Study|Adverse Event|3
6097051|NCT00733902|9711442|FG001|Overall Study|Adverse Event|4
6097052|NCT00733902|9711443|FG002|Overall Study|Adverse Event|7
6097053|NCT00733902|9711444|FG003|Overall Study|Adverse Event|11
6097054|NCT00733902|9711441|FG000|Overall Study|Lack of Efficacy|56
6097055|NCT00733902|9711442|FG001|Overall Study|Lack of Efficacy|21
6097056|NCT00733902|9711443|FG002|Overall Study|Lack of Efficacy|34
6097057|NCT00733902|9711444|FG003|Overall Study|Lack of Efficacy|23
6097058|NCT00733902|9711441|FG000|Overall Study|Protocol Violation|4
6097059|NCT00733902|9711442|FG001|Overall Study|Protocol Violation|6
6097060|NCT00733902|9711443|FG002|Overall Study|Protocol Violation|3
6097061|NCT00733902|9711444|FG003|Overall Study|Protocol Violation|3
6097062|NCT00733902|9711441|FG000|Overall Study|Withdrawal by Subject|10
6097063|NCT00733902|9711442|FG001|Overall Study|Withdrawal by Subject|5
6097064|NCT00733902|9711443|FG002|Overall Study|Withdrawal by Subject|4
6097065|NCT00733902|9711444|FG003|Overall Study|Withdrawal by Subject|16
6097066|NCT00733902|9711441|FG000|Overall Study|Entered extension study|89
6097067|NCT00733902|9711442|FG001|Overall Study|Entered extension study|124
6097068|NCT00733902|9711443|FG002|Overall Study|Entered extension study|111
6097069|NCT00733902|9711444|FG003|Overall Study|Entered extension study|109
6097070|NCT00733902|9711441|FG000|Overall Study|Randomized but not treated|2
6097071|NCT00733902|9711442|FG001|Overall Study|Randomized but not treated|2
6097072|NCT00733902|9711443|FG002|Overall Study|Randomized but not treated|2
6097073|NCT00733902|9711444|FG003|Overall Study|Randomized but not treated|1
6097074|NCT00733954|9711456|FG000|Overall Study|Lost to Follow-up|5
6097075|NCT00733954|9711457|FG001|Overall Study|Lost to Follow-up|2
6097076|NCT00733954|9711456|FG000|Overall Study|Protocol Violation|1
6097077|NCT00733954|9711457|FG001|Overall Study|Protocol Violation|0
6097078|NCT00733954|9711456|FG000|Overall Study|Withdrawal by Subject|2
6097079|NCT00733954|9711457|FG001|Overall Study|Withdrawal by Subject|0
6097080|NCT00733980|9711465|FG000|Overall Study|Adverse Event|5
6097081|NCT00733980|9711466|FG001|Overall Study|Adverse Event|2
6097082|NCT00733980|9711465|FG000|Overall Study|Lack of Efficacy|0
6097083|NCT00733980|9711466|FG001|Overall Study|Lack of Efficacy|1
6097084|NCT00733980|9711465|FG000|Overall Study|Protocol Violation|2
6097085|NCT00733980|9711466|FG001|Overall Study|Protocol Violation|1
6097086|NCT00733980|9711465|FG000|Overall Study|Protocol defined stopping criteria reach|1
6097087|NCT00733980|9711466|FG001|Overall Study|Protocol defined stopping criteria reach|1
6097088|NCT00733980|9711465|FG000|Overall Study|Lost to Follow-up|6
6097089|NCT00733980|9711466|FG001|Overall Study|Lost to Follow-up|11
6097090|NCT00733980|9711465|FG000|Overall Study|Physician Decision|2
6097091|NCT00733980|9711466|FG001|Overall Study|Physician Decision|3
6097092|NCT00733980|9711465|FG000|Overall Study|Withdrawal by Subject|6
6097093|NCT00733980|9711466|FG001|Overall Study|Withdrawal by Subject|2
6097094|NCT00734032|9711491|FG000|Overall Study|Adverse Event|0
6097095|NCT00734032|9711492|FG001|Overall Study|Adverse Event|1
6097096|NCT00734032|9711493|FG002|Overall Study|Adverse Event|0
6097097|NCT00734032|9711494|FG003|Overall Study|Adverse Event|0
6097098|NCT00734071|9711506|FG000|Overall Study|Adverse Event|4
6097099|NCT00734071|9711507|FG001|Overall Study|Adverse Event|3
6097100|NCT00734071|9711506|FG000|Overall Study|Lack of Efficacy|3
6097101|NCT00734071|9711507|FG001|Overall Study|Lack of Efficacy|1
6097102|NCT00734071|9711506|FG000|Overall Study|Noncompliance|2
6097103|NCT00734071|9711507|FG001|Overall Study|Noncompliance|2
6097104|NCT00734071|9711506|FG000|Overall Study|Protocol Deviations|3
6097105|NCT00734071|9711507|FG001|Overall Study|Protocol Deviations|4
6097106|NCT00734071|9711506|FG000|Overall Study|Voluntary Withdrawal|9
6097107|NCT00734071|9711507|FG001|Overall Study|Voluntary Withdrawal|7
6097108|NCT00734071|9711506|FG000|Overall Study|Lost to Follow-up|16
6097109|NCT00734071|9711507|FG001|Overall Study|Lost to Follow-up|8
6097110|NCT00734071|9711506|FG000|Overall Study|Other|1
6097111|NCT00734071|9711507|FG001|Overall Study|Other|2
6097112|NCT00734097|9711513|FG000|Screening|Protocol Violation|12
6097113|NCT00734097|9711513|FG000|Screening|Withdrawal by Subject|5
6097114|NCT00734097|9711513|FG000|Screening|Lost to Follow-up|2
6097115|NCT00734097|9711513|FG000|Screening|Unconfirmed pregnancy|1
6097116|NCT00734097|9711513|FG000|Open Label|Lost to Follow-up|7
6097117|NCT00734097|9711513|FG000|Open Label|Withdrawal by Subject|5
6097118|NCT00734097|9711513|FG000|Open Label|Protocol Violation|4
6097119|NCT00734149|9711517|FG000|Overall Study|Withdrawal by Subject|1
6097120|NCT00734162|9711527|FG000|Randomized Phase (Through Week 72)|Investigator's Discretion|0
6097121|NCT00734162|9711528|FG001|Randomized Phase (Through Week 72)|Investigator's Discretion|1
6097122|NCT00734162|9711529|FG002|Randomized Phase (Through Week 72)|Investigator's Discretion|0
6097123|NCT00734162|9711530|FG003|Randomized Phase (Through Week 72)|Investigator's Discretion|2
6097124|NCT00734162|9711527|FG000|Randomized Phase (Through Week 72)|Per protocol ALT elevation|0
6097125|NCT00734162|9711528|FG001|Randomized Phase (Through Week 72)|Per protocol ALT elevation|0
6097126|NCT00734162|9711529|FG002|Randomized Phase (Through Week 72)|Per protocol ALT elevation|0
6097127|NCT00734162|9711530|FG003|Randomized Phase (Through Week 72)|Per protocol ALT elevation|2
6097128|NCT00734162|9711527|FG000|Open-Label Phase|Safety, Tolerability or Efficacy Reasons|1
6097129|NCT00734162|9711528|FG001|Open-Label Phase|Safety, Tolerability or Efficacy Reasons|0
6097130|NCT00734162|9711529|FG002|Open-Label Phase|Safety, Tolerability or Efficacy Reasons|0
6097131|NCT00734162|9711530|FG003|Open-Label Phase|Safety, Tolerability or Efficacy Reasons|0
6097132|NCT00734162|9711527|FG000|Open-Label Phase|Withdrew Consent|1
6097133|NCT00734162|9711528|FG001|Open-Label Phase|Withdrew Consent|0
6097134|NCT00734162|9711529|FG002|Open-Label Phase|Withdrew Consent|1
6097135|NCT00734162|9711530|FG003|Open-Label Phase|Withdrew Consent|1
6097136|NCT00734162|9711527|FG000|Open-Label Phase|Lost to Follow-up|1
6097137|NCT00734162|9711528|FG001|Open-Label Phase|Lost to Follow-up|2
6097138|NCT00734162|9711529|FG002|Open-Label Phase|Lost to Follow-up|0
6097139|NCT00734162|9711530|FG003|Open-Label Phase|Lost to Follow-up|1
6097140|NCT00734162|9711527|FG000|Open-Label Phase|Did Not Meet Entrance Criteria|0
6097141|NCT00734162|9711528|FG001|Open-Label Phase|Did Not Meet Entrance Criteria|0
6097142|NCT00734162|9711529|FG002|Open-Label Phase|Did Not Meet Entrance Criteria|0
6097143|NCT00734162|9711530|FG003|Open-Label Phase|Did Not Meet Entrance Criteria|1
6097144|NCT00734214|9711546|FG000|Overall Study|Withdrawal by Subject|3
6097145|NCT00734214|9711547|FG001|Overall Study|Withdrawal by Subject|4
6097146|NCT00734214|9711546|FG000|Overall Study|MD withdrawal|1
6097147|NCT00734214|9711547|FG001|Overall Study|MD withdrawal|0
6097148|NCT00734474|9711608|FG000|Overall Study|Entry Criteria Not Met|0
6097149|NCT00734474|9711609|FG001|Overall Study|Entry Criteria Not Met|0
6097150|NCT00734474|9711610|FG002|Overall Study|Entry Criteria Not Met|5
6097151|NCT00734474|9711611|FG003|Overall Study|Entry Criteria Not Met|0
6097152|NCT00734474|9711612|FG004|Overall Study|Entry Criteria Not Met|3
6097153|NCT00734474|9711613|FG005|Overall Study|Entry Criteria Not Met|1
6097154|NCT00734474|9711614|FG006|Overall Study|Entry Criteria Not Met|0
6097155|NCT00734474|9711615|FG007|Overall Study|Entry Criteria Not Met|1
6097156|NCT00734474|9711616|FG008|Overall Study|Entry Criteria Not Met|1
6097157|NCT00734474|9711608|FG000|Overall Study|Lost to Follow-up|1
6097158|NCT00734474|9711609|FG001|Overall Study|Lost to Follow-up|0
6097159|NCT00734474|9711610|FG002|Overall Study|Lost to Follow-up|13
6097160|NCT00734474|9711611|FG003|Overall Study|Lost to Follow-up|0
6097161|NCT00734474|9711612|FG004|Overall Study|Lost to Follow-up|11
6097162|NCT00734474|9711613|FG005|Overall Study|Lost to Follow-up|1
6097163|NCT00734474|9711614|FG006|Overall Study|Lost to Follow-up|0
6097164|NCT00734474|9711615|FG007|Overall Study|Lost to Follow-up|9
6097165|NCT00734474|9711616|FG008|Overall Study|Lost to Follow-up|4
6097166|NCT00734474|9711608|FG000|Overall Study|Withdrawal by Subject|2
6097167|NCT00734474|9711609|FG001|Overall Study|Withdrawal by Subject|1
6097168|NCT00734474|9711610|FG002|Overall Study|Withdrawal by Subject|18
6097169|NCT00734474|9711611|FG003|Overall Study|Withdrawal by Subject|0
6097170|NCT00734474|9711612|FG004|Overall Study|Withdrawal by Subject|24
6097171|NCT00734474|9711613|FG005|Overall Study|Withdrawal by Subject|2
6097172|NCT00734474|9711614|FG006|Overall Study|Withdrawal by Subject|0
6097173|NCT00734474|9711615|FG007|Overall Study|Withdrawal by Subject|36
6097174|NCT00734474|9711616|FG008|Overall Study|Withdrawal by Subject|21
6097175|NCT00734474|9711608|FG000|Overall Study|Physician Decision|0
6097176|NCT00734474|9711609|FG001|Overall Study|Physician Decision|0
6097177|NCT00734474|9711610|FG002|Overall Study|Physician Decision|4
6097178|NCT00734474|9711611|FG003|Overall Study|Physician Decision|1
6097179|NCT00734474|9711612|FG004|Overall Study|Physician Decision|11
6097180|NCT00734474|9711613|FG005|Overall Study|Physician Decision|0
6097181|NCT00734474|9711614|FG006|Overall Study|Physician Decision|0
6097182|NCT00734474|9711615|FG007|Overall Study|Physician Decision|9
6097183|NCT00734474|9711616|FG008|Overall Study|Physician Decision|9
6097184|NCT00734474|9711608|FG000|Overall Study|Adverse Event|4
6097185|NCT00734474|9711609|FG001|Overall Study|Adverse Event|4
6097186|NCT00734474|9711610|FG002|Overall Study|Adverse Event|63
6097187|NCT00734474|9711611|FG003|Overall Study|Adverse Event|1
6097188|NCT00734474|9711612|FG004|Overall Study|Adverse Event|64
6097189|NCT00734474|9711613|FG005|Overall Study|Adverse Event|0
6097190|NCT00734474|9711614|FG006|Overall Study|Adverse Event|1
6097191|NCT00734474|9711615|FG007|Overall Study|Adverse Event|65
6097192|NCT00734474|9711616|FG008|Overall Study|Adverse Event|39
6097193|NCT00734474|9711608|FG000|Overall Study|Protocol Violation|0
6097194|NCT00734474|9711609|FG001|Overall Study|Protocol Violation|0
6097195|NCT00734474|9711610|FG002|Overall Study|Protocol Violation|4
6097196|NCT00734474|9711611|FG003|Overall Study|Protocol Violation|0
6097197|NCT00734474|9711612|FG004|Overall Study|Protocol Violation|3
6097198|NCT00734474|9711613|FG005|Overall Study|Protocol Violation|0
6097199|NCT00734474|9711614|FG006|Overall Study|Protocol Violation|0
6097200|NCT00734474|9711615|FG007|Overall Study|Protocol Violation|3
6097201|NCT00734474|9711616|FG008|Overall Study|Protocol Violation|1
6097202|NCT00734474|9711608|FG000|Overall Study|Sponsor Decision, Arm Discontinued|8
6097203|NCT00734474|9711609|FG001|Overall Study|Sponsor Decision, Arm Discontinued|25
6097204|NCT00734474|9711610|FG002|Overall Study|Sponsor Decision, Arm Discontinued|0
6097205|NCT00734474|9711611|FG003|Overall Study|Sponsor Decision, Arm Discontinued|8
6097206|NCT00734474|9711612|FG004|Overall Study|Sponsor Decision, Arm Discontinued|0
6097207|NCT00734474|9711613|FG005|Overall Study|Sponsor Decision, Arm Discontinued|21
6097208|NCT00734474|9711614|FG006|Overall Study|Sponsor Decision, Arm Discontinued|23
6097209|NCT00734474|9711615|FG007|Overall Study|Sponsor Decision, Arm Discontinued|0
6097210|NCT00734474|9711616|FG008|Overall Study|Sponsor Decision, Arm Discontinued|0
6097211|NCT00734474|9711608|FG000|Overall Study|Sponsor Decision|0
6097212|NCT00734474|9711609|FG001|Overall Study|Sponsor Decision|0
6097213|NCT00734474|9711610|FG002|Overall Study|Sponsor Decision|0
6097214|NCT00734474|9711611|FG003|Overall Study|Sponsor Decision|0
6097215|NCT00734474|9711612|FG004|Overall Study|Sponsor Decision|2
6097216|NCT00734474|9711613|FG005|Overall Study|Sponsor Decision|0
6097217|NCT00734474|9711614|FG006|Overall Study|Sponsor Decision|0
6097218|NCT00734474|9711615|FG007|Overall Study|Sponsor Decision|0
6097219|NCT00734474|9711616|FG008|Overall Study|Sponsor Decision|0
6097220|NCT00734474|9711608|FG000|Overall Study|Death|0
6097221|NCT00734474|9711609|FG001|Overall Study|Death|0
6097222|NCT00734474|9711610|FG002|Overall Study|Death|1
6097223|NCT00734474|9711611|FG003|Overall Study|Death|0
6097224|NCT00734474|9711612|FG004|Overall Study|Death|0
6097225|NCT00734474|9711613|FG005|Overall Study|Death|0
6097226|NCT00734474|9711614|FG006|Overall Study|Death|0
6097227|NCT00734474|9711615|FG007|Overall Study|Death|2
6097228|NCT00734474|9711616|FG008|Overall Study|Death|1
6097229|NCT00734474|9711608|FG000|Overall Study|Lack of Efficacy|0
6097230|NCT00734474|9711609|FG001|Overall Study|Lack of Efficacy|0
6097231|NCT00734474|9711610|FG002|Overall Study|Lack of Efficacy|4
6097232|NCT00734474|9711611|FG003|Overall Study|Lack of Efficacy|0
6097233|NCT00734474|9711612|FG004|Overall Study|Lack of Efficacy|0
6097234|NCT00734474|9711613|FG005|Overall Study|Lack of Efficacy|0
6097235|NCT00734474|9711614|FG006|Overall Study|Lack of Efficacy|0
6097236|NCT00734474|9711615|FG007|Overall Study|Lack of Efficacy|4
6097237|NCT00734474|9711616|FG008|Overall Study|Lack of Efficacy|6
6097238|NCT00734539|9711648|FG000|Main Study|Death|33
6097239|NCT00734539|9711649|FG001|Main Study|Death|32
6097240|NCT00734539|9711648|FG000|Main Study|Physician Decision|2
6097241|NCT00734539|9711649|FG001|Main Study|Physician Decision|0
6097242|NCT00734539|9711648|FG000|Main Study|Withdrawal by Subject|1
6097243|NCT00734539|9711649|FG001|Main Study|Withdrawal by Subject|3
6203490|NCT01514136|9864404|FG006|Test Period 2; Test C*|holiday|1
6203491|NCT01514136|9864405|FG007|Test Period 2; Test C*|holiday|0
6203492|NCT01514136|9864398|FG000|Test Period 2; Test C*|Protocol Violation|0
6203493|NCT01514136|9864399|FG001|Test Period 2; Test C*|Protocol Violation|0
6203494|NCT01514136|9864400|FG002|Test Period 2; Test C*|Protocol Violation|0
6203495|NCT01514136|9864401|FG003|Test Period 2; Test C*|Protocol Violation|0
6203496|NCT01514136|9864402|FG004|Test Period 2; Test C*|Protocol Violation|0
6203497|NCT01514136|9864403|FG005|Test Period 2; Test C*|Protocol Violation|0
6203498|NCT01514136|9864404|FG006|Test Period 2; Test C*|Protocol Violation|1
6203499|NCT01514136|9864405|FG007|Test Period 2; Test C*|Protocol Violation|0
6203500|NCT01514201|9864460|FG000|PHASE I: Veliparib + Radiation Therapy|Lack of Efficacy|1
6203501|NCT01514201|9864461|FG001|PHASE I: Veliparib + Radiation Therapy|Lack of Efficacy|0
6203502|NCT01514201|9864462|FG002|PHASE I: Veliparib + Radiation Therapy|Lack of Efficacy|0
6203503|NCT01514201|9864463|FG003|PHASE I: Veliparib + Radiation Therapy|Lack of Efficacy|0
6203504|NCT01514201|9864460|FG000|PHASE I: Maintenance With Veliparib/TMZ|Adverse Event|0
6203505|NCT01514201|9864461|FG001|PHASE I: Maintenance With Veliparib/TMZ|Adverse Event|1
6203506|NCT01514201|9864462|FG002|PHASE I: Maintenance With Veliparib/TMZ|Adverse Event|1
6203507|NCT01514201|9864463|FG003|PHASE I: Maintenance With Veliparib/TMZ|Adverse Event|0
6203508|NCT01514201|9864460|FG000|PHASE I: Maintenance With Veliparib/TMZ|Lack of Efficacy|4
6097244|NCT00734539|9711648|FG000|Main Study|Enrolled in error; ineligible|1
6097245|NCT00734539|9711649|FG001|Main Study|Enrolled in error; ineligible|0
6097246|NCT00734578|9711661|FG000|Overall Study|Adverse Event|4
6097247|NCT00734578|9711662|FG001|Overall Study|Adverse Event|6
6097248|NCT00734578|9711663|FG002|Overall Study|Adverse Event|1
6097249|NCT00734578|9711661|FG000|Overall Study|Protocol Violation|8
6097250|NCT00734578|9711662|FG001|Overall Study|Protocol Violation|6
6097251|NCT00734578|9711663|FG002|Overall Study|Protocol Violation|3
6097252|NCT00734578|9711661|FG000|Overall Study|Withdrawal by Subject|7
6097253|NCT00734578|9711662|FG001|Overall Study|Withdrawal by Subject|8
6097254|NCT00734578|9711663|FG002|Overall Study|Withdrawal by Subject|11
6097255|NCT00734578|9711661|FG000|Overall Study|Lost to Follow-up|9
6097256|NCT00734578|9711662|FG001|Overall Study|Lost to Follow-up|3
6097257|NCT00734578|9711663|FG002|Overall Study|Lost to Follow-up|5
6097258|NCT00734578|9711661|FG000|Overall Study|Lack of Efficacy|3
6097259|NCT00734578|9711662|FG001|Overall Study|Lack of Efficacy|2
6097260|NCT00734578|9711663|FG002|Overall Study|Lack of Efficacy|5
6097261|NCT00734578|9711661|FG000|Overall Study|Randomized in error|1
6097262|NCT00734578|9711662|FG001|Overall Study|Randomized in error|0
6097263|NCT00734578|9711663|FG002|Overall Study|Randomized in error|0
6097264|NCT00734578|9711661|FG000|Overall Study|Exclusion criteria|1
6097265|NCT00734578|9711662|FG001|Overall Study|Exclusion criteria|0
6097266|NCT00734578|9711663|FG002|Overall Study|Exclusion criteria|0
6097267|NCT00734591|9711673|FG000|Screening for Prospective Period|Site did not participate|1604
6097268|NCT00734591|9711674|FG001|Screening for Prospective Period|Site did not participate|1488
6097269|NCT00734591|9711673|FG000|Screening for Prospective Period|Patient at partic. site not enrolled|913
6097270|NCT00734591|9711674|FG001|Screening for Prospective Period|Patient at partic. site not enrolled|803
6097271|NCT00734591|9711673|FG000|Prospective Period|Withdrawal by Subject|11
6097272|NCT00734591|9711674|FG001|Prospective Period|Withdrawal by Subject|9
6097273|NCT00734591|9711673|FG000|Prospective Period|Lost to Follow-up|37
6097274|NCT00734591|9711674|FG001|Prospective Period|Lost to Follow-up|33
6097275|NCT00734591|9711673|FG000|Prospective Period|Study Terminated|1
6097276|NCT00734591|9711674|FG001|Prospective Period|Study Terminated|0
6097277|NCT00734591|9711673|FG000|Prospective Period|Other|2
6097278|NCT00734591|9711674|FG001|Prospective Period|Other|2
6097279|NCT00734604|9711686|FG000|Overall Study|Adverse Event|0
6097280|NCT00734604|9711687|FG001|Overall Study|Adverse Event|2
6097281|NCT00734604|9711688|FG002|Overall Study|Adverse Event|0
6097282|NCT00734604|9711689|FG003|Overall Study|Adverse Event|2
6097283|NCT00734604|9711690|FG004|Overall Study|Adverse Event|1
6097284|NCT00734604|9711691|FG005|Overall Study|Adverse Event|1
6097285|NCT00734604|9711686|FG000|Overall Study|Serious Adverse Event|1
6097286|NCT00734604|9711687|FG001|Overall Study|Serious Adverse Event|0
6097287|NCT00734604|9711688|FG002|Overall Study|Serious Adverse Event|1
6097288|NCT00734604|9711689|FG003|Overall Study|Serious Adverse Event|2
6097289|NCT00734604|9711690|FG004|Overall Study|Serious Adverse Event|0
6097290|NCT00734604|9711691|FG005|Overall Study|Serious Adverse Event|1
6097291|NCT00734604|9711686|FG000|Overall Study|Lost to Follow-up|1
6097292|NCT00734604|9711687|FG001|Overall Study|Lost to Follow-up|2
6097293|NCT00734604|9711688|FG002|Overall Study|Lost to Follow-up|2
6097294|NCT00734604|9711689|FG003|Overall Study|Lost to Follow-up|4
6097295|NCT00734604|9711690|FG004|Overall Study|Lost to Follow-up|2
6097296|NCT00734604|9711691|FG005|Overall Study|Lost to Follow-up|3
6097297|NCT00734604|9711686|FG000|Overall Study|Physician Decision|0
6097298|NCT00734604|9711687|FG001|Overall Study|Physician Decision|1
6097299|NCT00734604|9711688|FG002|Overall Study|Physician Decision|1
6097300|NCT00734604|9711689|FG003|Overall Study|Physician Decision|0
6097301|NCT00734604|9711690|FG004|Overall Study|Physician Decision|0
6097302|NCT00734604|9711691|FG005|Overall Study|Physician Decision|0
6097303|NCT00734604|9711686|FG000|Overall Study|Protocol Violation|0
6097304|NCT00734604|9711687|FG001|Overall Study|Protocol Violation|2
6097305|NCT00734604|9711688|FG002|Overall Study|Protocol Violation|0
6203509|NCT01514201|9864461|FG001|PHASE I: Maintenance With Veliparib/TMZ|Lack of Efficacy|4
6203510|NCT01514201|9864462|FG002|PHASE I: Maintenance With Veliparib/TMZ|Lack of Efficacy|5
6203511|NCT01514201|9864463|FG003|PHASE I: Maintenance With Veliparib/TMZ|Lack of Efficacy|0
6203512|NCT01514201|9864460|FG000|PHASE I: Maintenance With Veliparib/TMZ|Withdrawal by Subject|1
6203513|NCT01514201|9864461|FG001|PHASE I: Maintenance With Veliparib/TMZ|Withdrawal by Subject|1
6203514|NCT01514201|9864462|FG002|PHASE I: Maintenance With Veliparib/TMZ|Withdrawal by Subject|0
6203515|NCT01514201|9864463|FG003|PHASE I: Maintenance With Veliparib/TMZ|Withdrawal by Subject|0
6203516|NCT01514201|9864460|FG000|PHASE II: Veliparib + Radiation Therapy|Ineligible|0
6203517|NCT01514201|9864461|FG001|PHASE II: Veliparib + Radiation Therapy|Ineligible|0
6203518|NCT01514201|9864462|FG002|PHASE II: Veliparib + Radiation Therapy|Ineligible|0
6203519|NCT01514201|9864463|FG003|PHASE II: Veliparib + Radiation Therapy|Ineligible|1
6203520|NCT01514201|9864460|FG000|PHASE II: Veliparib + Radiation Therapy|Adverse Event|0
6203521|NCT01514201|9864461|FG001|PHASE II: Veliparib + Radiation Therapy|Adverse Event|0
6203522|NCT01514201|9864462|FG002|PHASE II: Veliparib + Radiation Therapy|Adverse Event|0
6203523|NCT01514201|9864463|FG003|PHASE II: Veliparib + Radiation Therapy|Adverse Event|2
6203524|NCT01514201|9864460|FG000|PHASE II: Veliparib + Radiation Therapy|Death|0
6203525|NCT01514201|9864461|FG001|PHASE II: Veliparib + Radiation Therapy|Death|0
6203526|NCT01514201|9864462|FG002|PHASE II: Veliparib + Radiation Therapy|Death|0
6203527|NCT01514201|9864463|FG003|PHASE II: Veliparib + Radiation Therapy|Death|1
6203528|NCT01514201|9864460|FG000|PHASE II: Veliparib + Radiation Therapy|Lack of Efficacy|0
6203529|NCT01514201|9864461|FG001|PHASE II: Veliparib + Radiation Therapy|Lack of Efficacy|0
6203530|NCT01514201|9864462|FG002|PHASE II: Veliparib + Radiation Therapy|Lack of Efficacy|0
6203531|NCT01514201|9864463|FG003|PHASE II: Veliparib + Radiation Therapy|Lack of Efficacy|2
6203532|NCT01514201|9864460|FG000|PHASE II: Veliparib + Radiation Therapy|Withdrawal by Subject|0
6203533|NCT01514201|9864461|FG001|PHASE II: Veliparib + Radiation Therapy|Withdrawal by Subject|0
6203534|NCT01514201|9864462|FG002|PHASE II: Veliparib + Radiation Therapy|Withdrawal by Subject|0
6203535|NCT01514201|9864463|FG003|PHASE II: Veliparib + Radiation Therapy|Withdrawal by Subject|6
6203536|NCT01514201|9864460|FG000|PHASE II: Maintenance With Veliparib/TMZ|Adverse Event|0
6203537|NCT01514201|9864461|FG001|PHASE II: Maintenance With Veliparib/TMZ|Adverse Event|0
6203538|NCT01514201|9864462|FG002|PHASE II: Maintenance With Veliparib/TMZ|Adverse Event|0
6203539|NCT01514201|9864463|FG003|PHASE II: Maintenance With Veliparib/TMZ|Adverse Event|4
6203540|NCT01514201|9864460|FG000|PHASE II: Maintenance With Veliparib/TMZ|Withdrawal by Subject|0
6203541|NCT01514201|9864461|FG001|PHASE II: Maintenance With Veliparib/TMZ|Withdrawal by Subject|0
6203542|NCT01514201|9864462|FG002|PHASE II: Maintenance With Veliparib/TMZ|Withdrawal by Subject|0
6203543|NCT01514201|9864463|FG003|PHASE II: Maintenance With Veliparib/TMZ|Withdrawal by Subject|7
6203544|NCT01514201|9864460|FG000|PHASE II: Maintenance With Veliparib/TMZ|Lack of Efficacy|0
6203545|NCT01514201|9864461|FG001|PHASE II: Maintenance With Veliparib/TMZ|Lack of Efficacy|0
6203546|NCT01514201|9864462|FG002|PHASE II: Maintenance With Veliparib/TMZ|Lack of Efficacy|0
6097306|NCT00734604|9711689|FG003|Overall Study|Protocol Violation|0
6097307|NCT00734604|9711690|FG004|Overall Study|Protocol Violation|1
6097308|NCT00734604|9711691|FG005|Overall Study|Protocol Violation|0
6097309|NCT00734604|9711686|FG000|Overall Study|Sponsor Decision|1
6097310|NCT00734604|9711687|FG001|Overall Study|Sponsor Decision|2
6097311|NCT00734604|9711688|FG002|Overall Study|Sponsor Decision|1
6097312|NCT00734604|9711689|FG003|Overall Study|Sponsor Decision|0
6097313|NCT00734604|9711690|FG004|Overall Study|Sponsor Decision|2
6097314|NCT00734604|9711691|FG005|Overall Study|Sponsor Decision|0
6097315|NCT00734604|9711686|FG000|Overall Study|Withdrawal by Subject|0
6097316|NCT00734604|9711687|FG001|Overall Study|Withdrawal by Subject|2
6097317|NCT00734604|9711688|FG002|Overall Study|Withdrawal by Subject|0
6097318|NCT00734604|9711689|FG003|Overall Study|Withdrawal by Subject|1
6097319|NCT00734604|9711690|FG004|Overall Study|Withdrawal by Subject|2
6097320|NCT00734604|9711691|FG005|Overall Study|Withdrawal by Subject|1
6097321|NCT00734604|9711686|FG000|Overall Study|Lack of Efficacy|0
6097322|NCT00734604|9711687|FG001|Overall Study|Lack of Efficacy|1
6097323|NCT00734604|9711688|FG002|Overall Study|Lack of Efficacy|1
6097324|NCT00734604|9711689|FG003|Overall Study|Lack of Efficacy|0
6097325|NCT00734604|9711690|FG004|Overall Study|Lack of Efficacy|0
6097326|NCT00734604|9711691|FG005|Overall Study|Lack of Efficacy|0
6097327|NCT00734617|9711704|FG000|Overall Study|Adverse Event|4
6097328|NCT00734617|9711705|FG001|Overall Study|Adverse Event|7
6097329|NCT00734617|9711704|FG000|Overall Study|Withdrawal by Subject|103
6097330|NCT00734617|9711705|FG001|Overall Study|Withdrawal by Subject|95
6097331|NCT00734630|9711713|FG000|Overall Study|Lack of Efficacy|4
6097332|NCT00734630|9711714|FG001|Overall Study|Lack of Efficacy|4
6097333|NCT00734630|9711713|FG000|Overall Study|Withdrawal by Subject|7
6097334|NCT00734630|9711714|FG001|Overall Study|Withdrawal by Subject|9
6097335|NCT00734630|9711713|FG000|Overall Study|Lost to Follow-up|13
6097336|NCT00734630|9711714|FG001|Overall Study|Lost to Follow-up|7
6097337|NCT00734630|9711713|FG000|Overall Study|Protocol Violation|0
6097338|NCT00734630|9711714|FG001|Overall Study|Protocol Violation|3
6097339|NCT00734630|9711713|FG000|Overall Study|Inclusion/Exclusion criteria not met|0
6097340|NCT00734630|9711714|FG001|Overall Study|Inclusion/Exclusion criteria not met|1
6097341|NCT00734630|9711713|FG000|Overall Study|Adverse Event|3
6097342|NCT00734630|9711714|FG001|Overall Study|Adverse Event|6
6097343|NCT00734630|9711713|FG000|Overall Study|Randomized in Error|0
6097344|NCT00734630|9711714|FG001|Overall Study|Randomized in Error|1
6097345|NCT00734630|9711713|FG000|Overall Study|Tested Positive for Illegal Drug Use|1
6097346|NCT00734630|9711714|FG001|Overall Study|Tested Positive for Illegal Drug Use|1
6097347|NCT00734630|9711713|FG000|Overall Study|Poor Compliance|1
6097348|NCT00734630|9711714|FG001|Overall Study|Poor Compliance|1
6097349|NCT00734656|9711720|FG000|Lab Session 1|Withdrawal by Subject|2
6097350|NCT00734656|9711721|FG001|Lab Session 1|Withdrawal by Subject|0
6097351|NCT00734656|9711722|FG002|Lab Session 1|Withdrawal by Subject|0
6097352|NCT00734656|9711723|FG003|Lab Session 1|Withdrawal by Subject|0
6097353|NCT00734656|9711720|FG000|Washout 1|Withdrawal by Subject|1
6097354|NCT00734656|9711721|FG001|Washout 1|Withdrawal by Subject|5
6097355|NCT00734656|9711722|FG002|Washout 1|Withdrawal by Subject|2
6097356|NCT00734656|9711723|FG003|Washout 1|Withdrawal by Subject|3
6097357|NCT00734656|9711720|FG000|Lab Session 2|Withdrawal by Subject|1
6097358|NCT00734656|9711721|FG001|Lab Session 2|Withdrawal by Subject|0
6097359|NCT00734656|9711722|FG002|Lab Session 2|Withdrawal by Subject|0
6097360|NCT00734656|9711723|FG003|Lab Session 2|Withdrawal by Subject|1
6097361|NCT00734656|9711720|FG000|Washout 2|Withdrawal by Subject|1
6097362|NCT00734656|9711721|FG001|Washout 2|Withdrawal by Subject|1
6097363|NCT00734656|9711722|FG002|Washout 2|Withdrawal by Subject|1
6097364|NCT00734656|9711723|FG003|Washout 2|Withdrawal by Subject|0
6097365|NCT00734656|9711720|FG000|Washout 3|Withdrawal by Subject|1
6097366|NCT00734656|9711721|FG001|Washout 3|Withdrawal by Subject|0
6097367|NCT00734656|9711722|FG002|Washout 3|Withdrawal by Subject|0
6097368|NCT00734656|9711723|FG003|Washout 3|Withdrawal by Subject|1
6097369|NCT00734656|9711720|FG000|Lab Session 4|Withdrawal by Subject|0
6097370|NCT00734656|9711721|FG001|Lab Session 4|Withdrawal by Subject|0
6097371|NCT00734656|9711722|FG002|Lab Session 4|Withdrawal by Subject|0
6097372|NCT00734656|9711723|FG003|Lab Session 4|Withdrawal by Subject|1
6097373|NCT00734747|9711738|FG000|SRS Procedure|No staples placed|3
6097374|NCT00734747|9711738|FG000|6 Month Follow-up|Did not meet inclusion criteria|3
6097375|NCT00734851|9711751|FG000|Overall Study|Withdrawal by Subject|2
6097376|NCT00734851|9711751|FG000|Overall Study|Lost to Follow-up|1
6097377|NCT00734851|9711751|FG000|Overall Study|Physician Decision|18
6097378|NCT00734929|9711766|FG000|Overall Study|Lost to Follow-up|1
6097379|NCT00734929|9711767|FG001|Overall Study|Lost to Follow-up|2
6097380|NCT00734929|9711766|FG000|Overall Study|No intervention/ screen fail|5
6097381|NCT00734929|9711767|FG001|Overall Study|No intervention/ screen fail|3
6097382|NCT00734994|9711784|FG000|Overall Study|Withdrawal by Subject|1
6097383|NCT00735007|9711789|FG000|Overall Study|Adverse Event|4
6097384|NCT00735007|9711789|FG000|Overall Study|Protocol Violation|1
6097385|NCT00735072|9711795|FG000|Overall Study|interrupted study med during ARV change|1
6097386|NCT00735072|9711796|FG001|Overall Study|interrupted study med during ARV change|0
6097387|NCT00735072|9711795|FG000|Overall Study|Subject interrupted ARVs (non-adherence)|0
6097388|NCT00735072|9711796|FG001|Overall Study|Subject interrupted ARVs (non-adherence)|1
6203547|NCT01514201|9864463|FG003|PHASE II: Maintenance With Veliparib/TMZ|Lack of Efficacy|22
6097389|NCT00735371|9711813|FG000|Overall Study|Adverse Event|3
6097390|NCT00735371|9711814|FG001|Overall Study|Adverse Event|3
6097391|NCT00735371|9711815|FG002|Overall Study|Adverse Event|4
6097392|NCT00735371|9711816|FG003|Overall Study|Adverse Event|1
6097393|NCT00735371|9711813|FG000|Overall Study|Protocol Violation|2
6097394|NCT00735371|9711814|FG001|Overall Study|Protocol Violation|2
6097395|NCT00735371|9711815|FG002|Overall Study|Protocol Violation|0
6097396|NCT00735371|9711816|FG003|Overall Study|Protocol Violation|3
6097397|NCT00735371|9711813|FG000|Overall Study|Withdrawal by Subject|0
6097398|NCT00735371|9711814|FG001|Overall Study|Withdrawal by Subject|2
6097399|NCT00735371|9711815|FG002|Overall Study|Withdrawal by Subject|2
6097400|NCT00735371|9711816|FG003|Overall Study|Withdrawal by Subject|0
6097401|NCT00735371|9711813|FG000|Overall Study|Lost to Follow-up|1
6097402|NCT00735371|9711814|FG001|Overall Study|Lost to Follow-up|1
6097403|NCT00735371|9711815|FG002|Overall Study|Lost to Follow-up|3
6097404|NCT00735371|9711816|FG003|Overall Study|Lost to Follow-up|1
6097405|NCT00735371|9711813|FG000|Overall Study|Lack of Efficacy|4
6097406|NCT00735371|9711814|FG001|Overall Study|Lack of Efficacy|2
6097407|NCT00735371|9711815|FG002|Overall Study|Lack of Efficacy|0
6097408|NCT00735371|9711816|FG003|Overall Study|Lack of Efficacy|4
6097409|NCT00735371|9711813|FG000|Overall Study|Sponsor Decision|3
6097410|NCT00735371|9711814|FG001|Overall Study|Sponsor Decision|1
6097411|NCT00735371|9711815|FG002|Overall Study|Sponsor Decision|0
6097412|NCT00735371|9711816|FG003|Overall Study|Sponsor Decision|1
6097413|NCT00735371|9711813|FG000|Overall Study|Protocol Violation|0
6097414|NCT00735371|9711814|FG001|Overall Study|Protocol Violation|1
6097415|NCT00735371|9711815|FG002|Overall Study|Protocol Violation|2
6097416|NCT00735371|9711816|FG003|Overall Study|Protocol Violation|0
6097417|NCT00735371|9711813|FG000|Overall Study|Prior Vyvanse Exposure|1
6097418|NCT00735371|9711814|FG001|Overall Study|Prior Vyvanse Exposure|1
6097419|NCT00735371|9711815|FG002|Overall Study|Prior Vyvanse Exposure|0
6097420|NCT00735371|9711816|FG003|Overall Study|Prior Vyvanse Exposure|0
6097421|NCT00735371|9711813|FG000|Overall Study|Exclusion criteria|1
6097422|NCT00735371|9711814|FG001|Overall Study|Exclusion criteria|0
6097423|NCT00735371|9711815|FG002|Overall Study|Exclusion criteria|0
6097424|NCT00735371|9711816|FG003|Overall Study|Exclusion criteria|0
6097425|NCT00735397|9711826|FG000|Overall Study|Adverse Event|194
6097426|NCT00735397|9711826|FG000|Overall Study|Lost to Follow-up|33
6097427|NCT00735397|9711826|FG000|Overall Study|Participant choice|252
6097428|NCT00735397|9711826|FG000|Overall Study|Inadequate therapeutic effect|202
6097429|NCT00735397|9711826|FG000|Overall Study|Administrative/Other|502
6097430|NCT00735475|9711862|FG000|Overall Study|Adverse Event|0
6097431|NCT00735475|9711863|FG001|Overall Study|Adverse Event|1
6097432|NCT00735475|9711862|FG000|Overall Study|Death|1
6097433|NCT00735475|9711863|FG001|Overall Study|Death|1
6097434|NCT00735475|9711862|FG000|Overall Study|Lost to Follow-up|3
6097435|NCT00735475|9711863|FG001|Overall Study|Lost to Follow-up|3
6097436|NCT00735475|9711862|FG000|Overall Study|Physician Decision|0
6097437|NCT00735475|9711863|FG001|Overall Study|Physician Decision|1
6097438|NCT00735475|9711862|FG000|Overall Study|Withdrawal by Subject|4
6097439|NCT00735475|9711863|FG001|Overall Study|Withdrawal by Subject|5
6203548|NCT01514240|9864485|FG000|Overall Study|Adverse Event|4
6203549|NCT01514240|9864486|FG001|Overall Study|Adverse Event|4
6203550|NCT01514240|9864485|FG000|Overall Study|Subject Decision|2
6203551|NCT01514240|9864486|FG001|Overall Study|Subject Decision|7
6203552|NCT01514357|9864515|FG000|Overall Study|Screen failure|2
6203553|NCT01514357|9864516|FG001|Overall Study|Screen failure|0
6203554|NCT01514357|9864515|FG000|Overall Study|Withdrawal by Subject|2
6203555|NCT01514357|9864516|FG001|Overall Study|Withdrawal by Subject|0
6203556|NCT01514370|9864524|FG000|Overall Study|Protocol Violation|2
6203557|NCT01514370|9864525|FG001|Overall Study|Protocol Violation|3
6203558|NCT01514370|9864524|FG000|Overall Study|Lost to Follow-up|0
6203559|NCT01514370|9864525|FG001|Overall Study|Lost to Follow-up|2
6203560|NCT01514370|9864524|FG000|Overall Study|Withdrawal by Subject|2
6203561|NCT01514370|9864525|FG001|Overall Study|Withdrawal by Subject|1
6203562|NCT01514370|9864524|FG000|Overall Study|Adverse Event|1
6203563|NCT01514370|9864525|FG001|Overall Study|Adverse Event|3
6203564|NCT01514370|9864524|FG000|Overall Study|Other|6
6203565|NCT01514370|9864525|FG001|Overall Study|Other|7
6203566|NCT01514422|9864542|FG000|Overall Study|Lost to Follow-up|1
6203567|NCT01514448|9864548|FG000|Overall Study|Death|7
6203568|NCT01514448|9864549|FG001|Overall Study|Death|8
6203569|NCT01514448|9864548|FG000|Overall Study|Withdrawal by Subject|2
6203570|NCT01514448|9864549|FG001|Overall Study|Withdrawal by Subject|0
6203571|NCT01514448|9864548|FG000|Overall Study|Lost to Follow-up|2
6203572|NCT01514448|9864549|FG001|Overall Study|Lost to Follow-up|0
6203573|NCT01514448|9864548|FG000|Overall Study|New Cancer Therapy|1
6203574|NCT01514448|9864549|FG001|Overall Study|New Cancer Therapy|0
6203575|NCT01514461|9864559|FG000|Overall Study|Adverse Event|2
6203576|NCT01514461|9864560|FG001|Overall Study|Adverse Event|1
6203577|NCT01514461|9864561|FG002|Overall Study|Adverse Event|3
6203578|NCT01514461|9864559|FG000|Overall Study|Physician Decision|1
6203579|NCT01514461|9864560|FG001|Overall Study|Physician Decision|1
6203580|NCT01514461|9864561|FG002|Overall Study|Physician Decision|0
6203581|NCT01514461|9864559|FG000|Overall Study|Patient/guardian decision|1
6203582|NCT01514461|9864560|FG001|Overall Study|Patient/guardian decision|1
6203583|NCT01514461|9864561|FG002|Overall Study|Patient/guardian decision|1
6097440|NCT00735644|9711878|FG000|Overall Study|Did not receive study vaccine|0
6097441|NCT00735644|9711879|FG001|Overall Study|Did not receive study vaccine|1
6097442|NCT00735644|9711880|FG002|Overall Study|Did not receive study vaccine|0
6097443|NCT00735644|9711881|FG003|Overall Study|Did not receive study vaccine|0
6097444|NCT00735644|9711882|FG004|Overall Study|Did not receive study vaccine|0
6097445|NCT00735644|9711878|FG000|Overall Study|Withdrawal by Subject|0
6097446|NCT00735644|9711879|FG001|Overall Study|Withdrawal by Subject|1
6097447|NCT00735644|9711880|FG002|Overall Study|Withdrawal by Subject|1
6097448|NCT00735644|9711881|FG003|Overall Study|Withdrawal by Subject|1
6097449|NCT00735644|9711882|FG004|Overall Study|Withdrawal by Subject|0
6097450|NCT00735696|9711910|FG000|Overall Study|Withdrawal by Subject|1
6097451|NCT00735696|9711910|FG000|Overall Study|Enrolled but never Treated|1
6097452|NCT00735709|9711918|FG000|Overall Study|Adverse Event|2
6097453|NCT00735709|9711919|FG001|Overall Study|Adverse Event|3
6097454|NCT00735709|9711920|FG002|Overall Study|Adverse Event|1
6097455|NCT00735709|9711921|FG003|Overall Study|Adverse Event|5
6097456|NCT00735709|9711918|FG000|Overall Study|Lack of Efficacy|8
6203584|NCT01514461|9864559|FG000|Overall Study|Death|1
6203585|NCT01514461|9864560|FG001|Overall Study|Death|0
6203586|NCT01514461|9864561|FG002|Overall Study|Death|0
6203587|NCT01514760|9864589|FG000|Overall Study|Lost to Follow-up|2
6203588|NCT01514864|9864604|FG000|Overall Study|Disease progression|7
6203589|NCT01514864|9864605|FG001|Overall Study|Disease progression|5
6203590|NCT01514864|9864604|FG000|Overall Study|Study drug toxicity|2
6203591|NCT01514864|9864605|FG001|Overall Study|Study drug toxicity|0
6203592|NCT01515189|9864652|FG000|Induction|Disease Progression|109
6203593|NCT01515189|9864653|FG001|Induction|Disease Progression|155
6203594|NCT01515189|9864652|FG000|Induction|Study drug toxicity|86
6203595|NCT01515189|9864653|FG001|Induction|Study drug toxicity|36
6203596|NCT01515189|9864652|FG000|Induction|Death|24
6203597|NCT01515189|9864653|FG001|Induction|Death|17
6203598|NCT01515189|9864652|FG000|Induction|Adverse Event|14
6203599|NCT01515189|9864653|FG001|Induction|Adverse Event|9
6203600|NCT01515189|9864652|FG000|Induction|Withdrawal by Subject|3
6203601|NCT01515189|9864653|FG001|Induction|Withdrawal by Subject|9
6203602|NCT01515189|9864652|FG000|Induction|No longer meets study criteria|0
6203603|NCT01515189|9864653|FG001|Induction|No longer meets study criteria|2
6203604|NCT01515189|9864652|FG000|Induction|Lost to Follow-up|1
6203605|NCT01515189|9864653|FG001|Induction|Lost to Follow-up|0
6203606|NCT01515189|9864652|FG000|Induction|Other|0
6203607|NCT01515189|9864653|FG001|Induction|Other|4
6203608|NCT01515189|9864652|FG000|First Re-Induction Phase|Disease progression|6
6203609|NCT01515189|9864653|FG001|First Re-Induction Phase|Disease progression|14
6203610|NCT01515189|9864652|FG000|First Re-Induction Phase|Study drug toxicity|5
6203611|NCT01515189|9864653|FG001|First Re-Induction Phase|Study drug toxicity|0
6203612|NCT01515189|9864652|FG000|First Re-Induction Phase|Withdrawal by Subject|1
6203613|NCT01515189|9864653|FG001|First Re-Induction Phase|Withdrawal by Subject|1
6203614|NCT01515189|9864652|FG000|First Re-Induction Phase|No longer meets study criteria|1
6203615|NCT01515189|9864653|FG001|First Re-Induction Phase|No longer meets study criteria|0
6203616|NCT01515189|9864652|FG000|First Re-Induction Phase|Other|1
6203617|NCT01515189|9864653|FG001|First Re-Induction Phase|Other|0
6203618|NCT01515319|9864669|FG000|Overall Study|Withdrawal by Subject|0
6203619|NCT01515319|9864670|FG001|Overall Study|Withdrawal by Subject|0
6203620|NCT01515319|9864671|FG002|Overall Study|Withdrawal by Subject|0
6203621|NCT01515319|9864672|FG003|Overall Study|Withdrawal by Subject|0
6203622|NCT01515319|9864673|FG004|Overall Study|Withdrawal by Subject|0
6203623|NCT01515319|9864674|FG005|Overall Study|Withdrawal by Subject|0
6203624|NCT01515319|9864675|FG006|Overall Study|Withdrawal by Subject|1
6203625|NCT01515319|9864676|FG007|Overall Study|Withdrawal by Subject|0
6203626|NCT01515319|9864677|FG008|Overall Study|Withdrawal by Subject|0
6203627|NCT01515319|9864678|FG009|Overall Study|Withdrawal by Subject|0
6203628|NCT01515319|9864669|FG000|Overall Study|Adverse Event|0
6203629|NCT01515319|9864670|FG001|Overall Study|Adverse Event|0
6203630|NCT01515319|9864671|FG002|Overall Study|Adverse Event|0
6203631|NCT01515319|9864672|FG003|Overall Study|Adverse Event|0
6203632|NCT01515319|9864673|FG004|Overall Study|Adverse Event|0
6203633|NCT01515319|9864674|FG005|Overall Study|Adverse Event|0
6203634|NCT01515319|9864675|FG006|Overall Study|Adverse Event|0
6203635|NCT01515319|9864676|FG007|Overall Study|Adverse Event|0
6203636|NCT01515319|9864677|FG008|Overall Study|Adverse Event|3
6203637|NCT01515319|9864678|FG009|Overall Study|Adverse Event|0
6203638|NCT01515319|9864669|FG000|Overall Study|Protocol Violation|0
6203639|NCT01515319|9864670|FG001|Overall Study|Protocol Violation|0
6203640|NCT01515319|9864671|FG002|Overall Study|Protocol Violation|0
6203641|NCT01515319|9864672|FG003|Overall Study|Protocol Violation|0
6203642|NCT01515319|9864673|FG004|Overall Study|Protocol Violation|0
6203643|NCT01515319|9864674|FG005|Overall Study|Protocol Violation|0
6284621|NCT02326298|9996363|FG009|Initial Period (Week 0 to Week 16)|Adverse event after completing wk16|0
6284622|NCT02326298|9996364|FG010|Initial Period (Week 0 to Week 16)|Adverse event after completing wk16|0
6284623|NCT02326298|9996365|FG011|Initial Period (Week 0 to Week 16)|Adverse event after completing wk16|0
6097457|NCT00735709|9711919|FG001|Overall Study|Lack of Efficacy|4
6097458|NCT00735709|9711920|FG002|Overall Study|Lack of Efficacy|2
6203644|NCT01515319|9864675|FG006|Overall Study|Protocol Violation|0
6203645|NCT01515319|9864676|FG007|Overall Study|Protocol Violation|0
6097459|NCT00735709|9711921|FG003|Overall Study|Lack of Efficacy|3
6097460|NCT00735709|9711918|FG000|Overall Study|Noncompliance|0
6097461|NCT00735709|9711919|FG001|Overall Study|Noncompliance|0
6097462|NCT00735709|9711920|FG002|Overall Study|Noncompliance|1
6097463|NCT00735709|9711921|FG003|Overall Study|Noncompliance|0
6097464|NCT00735709|9711918|FG000|Overall Study|Protocol deviations|1
6097465|NCT00735709|9711919|FG001|Overall Study|Protocol deviations|2
6097466|NCT00735709|9711920|FG002|Overall Study|Protocol deviations|1
6097467|NCT00735709|9711921|FG003|Overall Study|Protocol deviations|1
6097468|NCT00735709|9711918|FG000|Overall Study|Voluntary Withdrawal|1
6097469|NCT00735709|9711919|FG001|Overall Study|Voluntary Withdrawal|3
6097470|NCT00735709|9711920|FG002|Overall Study|Voluntary Withdrawal|5
6097471|NCT00735709|9711921|FG003|Overall Study|Voluntary Withdrawal|7
6097472|NCT00735709|9711918|FG000|Overall Study|Lost to Follow-up|0
6097473|NCT00735709|9711919|FG001|Overall Study|Lost to Follow-up|1
6097474|NCT00735709|9711920|FG002|Overall Study|Lost to Follow-up|1
6097475|NCT00735709|9711921|FG003|Overall Study|Lost to Follow-up|1
6097476|NCT00735709|9711918|FG000|Overall Study|Excluded medication|1
6097477|NCT00735709|9711919|FG001|Overall Study|Excluded medication|0
6097478|NCT00735709|9711920|FG002|Overall Study|Excluded medication|0
6097479|NCT00735709|9711921|FG003|Overall Study|Excluded medication|1
6097480|NCT00735878|9711958|FG000|Phase I- Dose Determination|Withdrawal by Subject|0
6097481|NCT00735878|9711959|FG001|Phase I- Dose Determination|Withdrawal by Subject|0
6097482|NCT00735878|9711960|FG002|Phase I- Dose Determination|Withdrawal by Subject|1
6097483|NCT00735904|9711971|FG000|Overall Study|Adverse Event|3
6097484|NCT00735904|9711971|FG000|Overall Study|Death|20
6097485|NCT00735904|9711971|FG000|Overall Study|Protocol Violation|1
6097486|NCT00735904|9711971|FG000|Overall Study|Withdrawal by Subject|1
6097487|NCT00735904|9711971|FG000|Overall Study|Study Terminated by Sponsor|5
6097488|NCT00735904|9711971|FG000|Overall Study|Other|8
6097489|NCT00735943|9711979|FG000|Overall Study|Lost to Follow-up|1
6097490|NCT00735943|9711979|FG000|Overall Study|Adverse Event|1
6097491|NCT00736034|9711987|FG000|Overall Study|Adverse Event|2
6097492|NCT00736099|9712003|FG000|Overall Study|Adverse Event|61
6097493|NCT00736099|9712004|FG001|Overall Study|Adverse Event|18
6097494|NCT00736099|9712003|FG000|Overall Study|Protocol Violation|10
6097495|NCT00736099|9712004|FG001|Overall Study|Protocol Violation|4
6097496|NCT00736099|9712003|FG000|Overall Study|Lost to Follow-up|12
6097497|NCT00736099|9712004|FG001|Overall Study|Lost to Follow-up|5
6097498|NCT00736099|9712003|FG000|Overall Study|Withdrawal by Subject|42
6097499|NCT00736099|9712004|FG001|Overall Study|Withdrawal by Subject|13
6097500|NCT00736099|9712003|FG000|Overall Study|Lack of Efficacy|15
6097501|NCT00736099|9712004|FG001|Overall Study|Lack of Efficacy|8
6097502|NCT00736099|9712003|FG000|Overall Study|Other reason|43
6097503|NCT00736099|9712004|FG001|Overall Study|Other reason|10
6097504|NCT00736190|9712019|FG000|Overall Study|Pregnancy|1
6097505|NCT00736190|9712019|FG000|Overall Study|Withdrawal by Subject|1
6097506|NCT00736190|9712019|FG000|Overall Study|Adverse Event|1
6097507|NCT00736255|9712043|FG000|Overall Study|Adverse Event|1
6097508|NCT00736255|9712044|FG001|Overall Study|Adverse Event|0
6097509|NCT00736255|9712043|FG000|Overall Study|Physician Decision|1
6097510|NCT00736255|9712044|FG001|Overall Study|Physician Decision|0
6097511|NCT00736255|9712043|FG000|Overall Study|Non-compliance|1
6097512|NCT00736255|9712044|FG001|Overall Study|Non-compliance|1
6097513|NCT00736333|9712050|FG000|Overall Study|Did Not Receive Drug or Not Documented|7
6097514|NCT00736333|9712050|FG000|Overall Study|Data Missing|2
6097515|NCT00736333|9712050|FG000|Overall Study|Tumor Progression|75
6097516|NCT00736333|9712050|FG000|Overall Study|Toxicity|6
6097517|NCT00736333|9712050|FG000|Overall Study|Withdrawal by Subject|10
6097518|NCT00736333|9712050|FG000|Overall Study|Death|7
6097519|NCT00736333|9712050|FG000|Overall Study|Other|4
6097520|NCT00736450|9712054|FG000|Overall Study|Not ABC gene eligible|19
6097521|NCT00736450|9712054|FG000|Overall Study|Withdrawal by Subject|5
6097522|NCT00736450|9712054|FG000|Overall Study|Physician Decision|1
6097523|NCT00736476|9712060|FG000|Overall Study|Adverse Event|1
6097524|NCT00736476|9712061|FG001|Overall Study|Adverse Event|0
6097525|NCT00736489|9712073|FG000|Period 1|Lost to Follow-up|1
6097526|NCT00736489|9712074|FG001|Period 1|Lost to Follow-up|0
6097527|NCT00736489|9712075|FG002|Period 1|Lost to Follow-up|0
6097528|NCT00736489|9712076|FG003|Period 1|Lost to Follow-up|0
6097529|NCT00736489|9712077|FG004|Period 1|Lost to Follow-up|0
6097530|NCT00736489|9712078|FG005|Period 1|Lost to Follow-up|0
6097531|NCT00736489|9712073|FG000|Period 1|Withdrawal by Subject|0
6097532|NCT00736489|9712074|FG001|Period 1|Withdrawal by Subject|0
6097533|NCT00736489|9712075|FG002|Period 1|Withdrawal by Subject|0
6097534|NCT00736489|9712076|FG003|Period 1|Withdrawal by Subject|0
6097535|NCT00736489|9712077|FG004|Period 1|Withdrawal by Subject|0
6097536|NCT00736489|9712078|FG005|Period 1|Withdrawal by Subject|1
6097537|NCT00736502|9712092|FG000|Overall Study|Adverse Event|22
6097538|NCT00736502|9712092|FG000|Overall Study|Lack of Efficacy|16
6097539|NCT00736502|9712092|FG000|Overall Study|Lost to Follow-up|27
6097540|NCT00736645|9712120|FG000|Overall Study|Adverse Event|0
6097541|NCT00736645|9712121|FG001|Overall Study|Adverse Event|2
6097542|NCT00736645|9712122|FG002|Overall Study|Adverse Event|0
6097543|NCT00736645|9712123|FG003|Overall Study|Adverse Event|0
6097544|NCT00736723|9712135|FG000|Overall Study|Withdrawal by Subject|4
6097545|NCT00736723|9712136|FG001|Overall Study|Withdrawal by Subject|3
6097546|NCT00736840|9712142|FG000|Overall Study|Lost to Follow-up|13
6097547|NCT00736853|9712146|FG000|Open-Label Period|Physician Decision|2
6097548|NCT00736853|9712147|FG001|Open-Label Period|Physician Decision|0
6097549|NCT00736853|9712148|FG002|Open-Label Period|Physician Decision|0
6097550|NCT00736853|9712146|FG000|Open-Label Period|Adverse Event|31
6097551|NCT00736853|9712147|FG001|Open-Label Period|Adverse Event|0
6097552|NCT00736853|9712148|FG002|Open-Label Period|Adverse Event|0
6097553|NCT00736853|9712146|FG000|Open-Label Period|Withdrawal by Subject|16
6097554|NCT00736853|9712147|FG001|Open-Label Period|Withdrawal by Subject|0
6097555|NCT00736853|9712148|FG002|Open-Label Period|Withdrawal by Subject|0
6097556|NCT00736853|9712146|FG000|Open-Label Period|Started but not treated|42
6097557|NCT00736853|9712147|FG001|Open-Label Period|Started but not treated|0
6097558|NCT00736853|9712148|FG002|Open-Label Period|Started but not treated|0
6097559|NCT00736853|9712146|FG000|Open-Label Period|Failed to meet the transfer criteria|40
6097560|NCT00736853|9712147|FG001|Open-Label Period|Failed to meet the transfer criteria|0
6097561|NCT00736853|9712148|FG002|Open-Label Period|Failed to meet the transfer criteria|0
6097562|NCT00736853|9712146|FG000|Open-Label Period|Unable to attend hospital appointments|1
6097563|NCT00736853|9712147|FG001|Open-Label Period|Unable to attend hospital appointments|0
6097564|NCT00736853|9712148|FG002|Open-Label Period|Unable to attend hospital appointments|0
6097565|NCT00736853|9712146|FG000|Double-Blind Period|Lack of Efficacy|0
6097566|NCT00736853|9712147|FG001|Double-Blind Period|Lack of Efficacy|19
6097567|NCT00736853|9712148|FG002|Double-Blind Period|Lack of Efficacy|42
6097568|NCT00736853|9712146|FG000|Double-Blind Period|Adverse Event|0
6097569|NCT00736853|9712147|FG001|Double-Blind Period|Adverse Event|3
6097570|NCT00736853|9712148|FG002|Double-Blind Period|Adverse Event|2
6097571|NCT00736853|9712146|FG000|Double-Blind Period|Withdrawal by Subject|0
6097572|NCT00736853|9712147|FG001|Double-Blind Period|Withdrawal by Subject|1
6097573|NCT00736853|9712148|FG002|Double-Blind Period|Withdrawal by Subject|4
6097574|NCT00736853|9712146|FG000|Double-Blind Period|Ineligible to participate the study|0
6097575|NCT00736853|9712147|FG001|Double-Blind Period|Ineligible to participate the study|1
6097576|NCT00736853|9712148|FG002|Double-Blind Period|Ineligible to participate the study|0
6097577|NCT00736879|9712161|FG000|Double Blind Treatment Period|Lack of Efficacy|1
6097578|NCT00736879|9712162|FG001|Double Blind Treatment Period|Lack of Efficacy|0
6097579|NCT00736879|9712163|FG002|Double Blind Treatment Period|Lack of Efficacy|0
6097580|NCT00736879|9712164|FG003|Double Blind Treatment Period|Lack of Efficacy|0
6097581|NCT00736879|9712161|FG000|Double Blind Treatment Period|Adverse Event|0
6097582|NCT00736879|9712162|FG001|Double Blind Treatment Period|Adverse Event|1
6097583|NCT00736879|9712163|FG002|Double Blind Treatment Period|Adverse Event|1
6097584|NCT00736879|9712164|FG003|Double Blind Treatment Period|Adverse Event|0
6097585|NCT00736879|9712161|FG000|Double Blind Treatment Period|Withdrawal by Subject|2
6097586|NCT00736879|9712162|FG001|Double Blind Treatment Period|Withdrawal by Subject|1
6097587|NCT00736879|9712163|FG002|Double Blind Treatment Period|Withdrawal by Subject|3
6097588|NCT00736879|9712164|FG003|Double Blind Treatment Period|Withdrawal by Subject|3
6097589|NCT00736879|9712161|FG000|Double Blind Treatment Period|Lost to Follow-up|0
6097590|NCT00736879|9712162|FG001|Double Blind Treatment Period|Lost to Follow-up|0
6097591|NCT00736879|9712163|FG002|Double Blind Treatment Period|Lost to Follow-up|2
6097592|NCT00736879|9712164|FG003|Double Blind Treatment Period|Lost to Follow-up|1
6097593|NCT00736879|9712161|FG000|Double Blind Treatment Period|Poor non-compliance|0
6097594|NCT00736879|9712162|FG001|Double Blind Treatment Period|Poor non-compliance|0
6097595|NCT00736879|9712163|FG002|Double Blind Treatment Period|Poor non-compliance|1
6097596|NCT00736879|9712164|FG003|Double Blind Treatment Period|Poor non-compliance|1
6097597|NCT00736879|9712161|FG000|Double Blind Treatment Period|No longer met criteria|0
6097598|NCT00736879|9712162|FG001|Double Blind Treatment Period|No longer met criteria|1
6097599|NCT00736879|9712163|FG002|Double Blind Treatment Period|No longer met criteria|0
6097600|NCT00736879|9712164|FG003|Double Blind Treatment Period|No longer met criteria|0
6097601|NCT00736879|9712161|FG000|Double Blind Treatment Period|non-specified|0
6097602|NCT00736879|9712162|FG001|Double Blind Treatment Period|non-specified|1
6097603|NCT00736879|9712163|FG002|Double Blind Treatment Period|non-specified|0
6097604|NCT00736879|9712164|FG003|Double Blind Treatment Period|non-specified|0
6097605|NCT00736879|9712161|FG000|Follow up Period - No Drug Treatment|Withdrawal by Subject|0
6097606|NCT00736879|9712162|FG001|Follow up Period - No Drug Treatment|Withdrawal by Subject|1
6097607|NCT00736879|9712163|FG002|Follow up Period - No Drug Treatment|Withdrawal by Subject|0
6097608|NCT00736879|9712164|FG003|Follow up Period - No Drug Treatment|Withdrawal by Subject|0
6097609|NCT00736879|9712161|FG000|Follow up Period - No Drug Treatment|non-specified|1
6097610|NCT00736879|9712162|FG001|Follow up Period - No Drug Treatment|non-specified|2
6097611|NCT00736879|9712163|FG002|Follow up Period - No Drug Treatment|non-specified|0
6097612|NCT00736879|9712164|FG003|Follow up Period - No Drug Treatment|non-specified|0
6097613|NCT00736944|9712177|FG000|Induction|Death|1
6097614|NCT00736944|9712177|FG000|Definitive Treatment|Physician Decision|1
6097615|NCT00736957|9712184|FG000|Overall Study|Adverse Event|43
6097616|NCT00736957|9712184|FG000|Overall Study|Withdrawal by Subject|49
6097617|NCT00736957|9712184|FG000|Overall Study|violation of eligibility criteria|2
6097618|NCT00736957|9712184|FG000|Overall Study|did not attend hospital appointments|1
6097619|NCT00736957|9712184|FG000|Overall Study|not eligible for Treatment Period I|22
6097620|NCT00736957|9712184|FG000|Overall Study|Physician Decision|5
6097621|NCT00736996|9712191|FG000|Overall Study|Lost to Follow-up|1
6097622|NCT00736996|9712192|FG001|Overall Study|Lost to Follow-up|9
6097623|NCT00736996|9712193|FG002|Overall Study|Lost to Follow-up|2
6097624|NCT00737048|9712204|FG000|Overall Study|Physician Decision|0
6097625|NCT00737048|9712205|FG001|Overall Study|Physician Decision|0
6097626|NCT00737048|9712206|FG002|Overall Study|Physician Decision|1
6097627|NCT00737048|9712204|FG000|Overall Study|Adverse Event|0
6097628|NCT00737048|9712205|FG001|Overall Study|Adverse Event|1
6097629|NCT00737048|9712206|FG002|Overall Study|Adverse Event|0
6097630|NCT00737048|9712204|FG000|Overall Study|Worsening of the symptoms|3
6097631|NCT00737048|9712205|FG001|Overall Study|Worsening of the symptoms|5
6097632|NCT00737048|9712206|FG002|Overall Study|Worsening of the symptoms|3
6097633|NCT00737061|9712214|FG000|Waiting Period|Lost to Follow-up|6
6097634|NCT00737061|9712214|FG000|Waiting Period|Withdrawal by Subject|1
6097635|NCT00737061|9712214|FG000|Waiting Period|Bilateral placement failure|34
6097636|NCT00737061|9712214|FG000|Waiting Period|Deemed patent following HSG|26
6097637|NCT00737061|9712214|FG000|Waiting Period|Alternative contraception failure|3
6097638|NCT00737061|9712214|FG000|Waiting Period|Elected surgical tubal ligation|5
6097639|NCT00737061|9712214|FG000|1 Year Wearing Period|Lost to Follow-up|11
6097640|NCT00737061|9712214|FG000|1 Year Wearing Period|Withdrawal by Subject|2
6097641|NCT00737061|9712214|FG000|1 Year Wearing Period|Discontinued reilance|3
6097642|NCT00737061|9712214|FG000|1 Year Wearing Period|Terminated for protocol non-compliance|1
6097643|NCT00737100|9712221|FG000|Overall Study|Adverse Event|6
6097644|NCT00737100|9712222|FG001|Overall Study|Adverse Event|5
6097645|NCT00737100|9712223|FG002|Overall Study|Adverse Event|3
6097646|NCT00737100|9712221|FG000|Overall Study|Lost to Follow-up|0
6097647|NCT00737100|9712222|FG001|Overall Study|Lost to Follow-up|1
6097648|NCT00737100|9712223|FG002|Overall Study|Lost to Follow-up|0
6097649|NCT00737100|9712221|FG000|Overall Study|Withdrawal by Subject|0
6097650|NCT00737100|9712222|FG001|Overall Study|Withdrawal by Subject|0
6097651|NCT00737100|9712223|FG002|Overall Study|Withdrawal by Subject|3
6097652|NCT00737100|9712221|FG000|Overall Study|Reason discontinued not explained above|1
6097653|NCT00737100|9712222|FG001|Overall Study|Reason discontinued not explained above|1
6097654|NCT00737100|9712223|FG002|Overall Study|Reason discontinued not explained above|1
6097655|NCT00737438|9712261|FG000|Overall Study|Withdrawal by Subject|2
6097656|NCT00737438|9712261|FG000|Overall Study|Patient ineligible|1
6097657|NCT00737464|9712265|FG000|Overall Study|Adverse Event|1
6097658|NCT00737464|9712265|FG000|Overall Study|Death|6
6097659|NCT00737464|9712265|FG000|Overall Study|Other - Failure to Return|1
6097660|NCT00737464|9712265|FG000|Overall Study|Refused Treatment / Withdrew Consent|6
6097661|NCT00737464|9712265|FG000|Overall Study|Other reasons|4
6097662|NCT00737477|9712269|FG000|Overall Study|Adverse Event|9
6203646|NCT01515319|9864677|FG008|Overall Study|Protocol Violation|2
6203647|NCT01515319|9864678|FG009|Overall Study|Protocol Violation|0
6203648|NCT01515423|9864718|FG000|Open Label Phase|Adverse Event|57
6203649|NCT01515423|9864719|FG001|Open Label Phase|Adverse Event|0
6203650|NCT01515423|9864720|FG002|Open Label Phase|Adverse Event|0
6203651|NCT01515423|9864718|FG000|Open Label Phase|Death|2
6203652|NCT01515423|9864719|FG001|Open Label Phase|Death|0
6203653|NCT01515423|9864720|FG002|Open Label Phase|Death|0
6203654|NCT01515423|9864718|FG000|Open Label Phase|Lack of Efficacy|117
6203655|NCT01515423|9864719|FG001|Open Label Phase|Lack of Efficacy|0
6203656|NCT01515423|9864720|FG002|Open Label Phase|Lack of Efficacy|0
6203657|NCT01515423|9864718|FG000|Open Label Phase|Lost to Follow-up|21
6203658|NCT01515423|9864719|FG001|Open Label Phase|Lost to Follow-up|0
6203659|NCT01515423|9864720|FG002|Open Label Phase|Lost to Follow-up|0
6203660|NCT01515423|9864718|FG000|Open Label Phase|Withdrawal by Subject|118
6203661|NCT01515423|9864719|FG001|Open Label Phase|Withdrawal by Subject|0
6203662|NCT01515423|9864720|FG002|Open Label Phase|Withdrawal by Subject|0
6203663|NCT01515423|9864718|FG000|Open Label Phase|excluded from DB Phase|70
6203664|NCT01515423|9864719|FG001|Open Label Phase|excluded from DB Phase|0
6203665|NCT01515423|9864720|FG002|Open Label Phase|excluded from DB Phase|0
6203666|NCT01515423|9864718|FG000|Open Label Phase|Other|28
6203667|NCT01515423|9864719|FG001|Open Label Phase|Other|0
6203668|NCT01515423|9864720|FG002|Open Label Phase|Other|0
6203669|NCT01515423|9864718|FG000|DOUBLE BLIND|Adverse Event|0
6203670|NCT01515423|9864719|FG001|DOUBLE BLIND|Adverse Event|15
6203671|NCT01515423|9864720|FG002|DOUBLE BLIND|Adverse Event|13
6203672|NCT01515423|9864718|FG000|DOUBLE BLIND|Death|0
6203673|NCT01515423|9864719|FG001|DOUBLE BLIND|Death|1
6203674|NCT01515423|9864720|FG002|DOUBLE BLIND|Death|2
6203675|NCT01515423|9864718|FG000|DOUBLE BLIND|Lost to Follow-up|0
6203676|NCT01515423|9864719|FG001|DOUBLE BLIND|Lost to Follow-up|7
6203677|NCT01515423|9864720|FG002|DOUBLE BLIND|Lost to Follow-up|12
6203678|NCT01515423|9864718|FG000|DOUBLE BLIND|Pregnancy|0
6203679|NCT01515423|9864719|FG001|DOUBLE BLIND|Pregnancy|2
6203680|NCT01515423|9864720|FG002|DOUBLE BLIND|Pregnancy|0
6203681|NCT01515423|9864718|FG000|DOUBLE BLIND|Withdrawal by Subject|0
6203682|NCT01515423|9864719|FG001|DOUBLE BLIND|Withdrawal by Subject|50
6097663|NCT00737477|9712269|FG000|Overall Study|Death|9
6097664|NCT00737477|9712269|FG000|Overall Study|Treatment Refusal|1
6097665|NCT00737477|9712269|FG000|Overall Study|Withdrawal by Subject|1
6097666|NCT00737477|9712269|FG000|Overall Study|Renal Transplantation|10
6203683|NCT01515423|9864720|FG002|DOUBLE BLIND|Withdrawal by Subject|53
6097667|NCT00737477|9712269|FG000|Overall Study|Other|4
6097668|NCT00737529|9712273|FG000|Overall Study|Disease Progression|95
6097669|NCT00737529|9712273|FG000|Overall Study|Adverse Event|24
6097670|NCT00737529|9712273|FG000|Overall Study|Withdrawal by Subject|5
6097671|NCT00737529|9712273|FG000|Overall Study|Death|4
6097672|NCT00737529|9712273|FG000|Overall Study|Protocol Violation|1
6097673|NCT00737529|9712273|FG000|Overall Study|Other|4
6097674|NCT00737568|9712279|FG000|Treatment Period Through Week 240|Investigator's Discretion|6
6097675|NCT00737568|9712280|FG001|Treatment Period Through Week 240|Investigator's Discretion|5
6097676|NCT00737568|9712279|FG000|Treatment Period Through Week 240|Withdrew Consent|5
6097677|NCT00737568|9712280|FG001|Treatment Period Through Week 240|Withdrew Consent|6
6097678|NCT00737568|9712279|FG000|Treatment Period Through Week 240|Safety, Tolerability, or Efficacy Reason|3
6097679|NCT00737568|9712280|FG001|Treatment Period Through Week 240|Safety, Tolerability, or Efficacy Reason|4
6097680|NCT00737568|9712279|FG000|Treatment Period Through Week 240|Lost to Follow-up|3
6097681|NCT00737568|9712280|FG001|Treatment Period Through Week 240|Lost to Follow-up|3
6097682|NCT00737568|9712279|FG000|Treatment Period Through Week 240|Protocol Violation|2
6097683|NCT00737568|9712280|FG001|Treatment Period Through Week 240|Protocol Violation|3
6097684|NCT00737568|9712279|FG000|Treatment Period Through Week 240|Study Discontinued by Sponsor|1
6097685|NCT00737568|9712280|FG001|Treatment Period Through Week 240|Study Discontinued by Sponsor|0
6097686|NCT00737568|9712279|FG000|Treatment-Free Follow-up (TFFU) Period|Started Commercial Therapy|25
6097687|NCT00737568|9712280|FG001|Treatment-Free Follow-up (TFFU) Period|Started Commercial Therapy|17
6097688|NCT00737568|9712279|FG000|Treatment-Free Follow-up (TFFU) Period|Death|0
6097689|NCT00737568|9712280|FG001|Treatment-Free Follow-up (TFFU) Period|Death|1
6097690|NCT00737568|9712279|FG000|Treatment-Free Follow-up (TFFU) Period|Withdrew Consent|1
6097691|NCT00737568|9712280|FG001|Treatment-Free Follow-up (TFFU) Period|Withdrew Consent|0
6097692|NCT00737633|9712288|FG000|Overall Study|Study terminated by sponsor|44
6097693|NCT00737633|9712289|FG001|Overall Study|Study terminated by sponsor|55
6097694|NCT00737633|9712288|FG000|Overall Study|Lost to Follow-up|0
6097695|NCT00737633|9712289|FG001|Overall Study|Lost to Follow-up|1
6097696|NCT00737633|9712288|FG000|Overall Study|protocol non-compliance|0
6097697|NCT00737633|9712289|FG001|Overall Study|protocol non-compliance|1
6097698|NCT00737672|9712297|FG000|Overall Study|Graft Abandonment|48
6097699|NCT00737672|9712298|FG001|Overall Study|Graft Abandonment|56
6097700|NCT00737672|9712297|FG000|Overall Study|Death|23
6097701|NCT00737672|9712298|FG001|Overall Study|Death|22
6097702|NCT00737672|9712297|FG000|Overall Study|Withdrawal by Subject|1
6097703|NCT00737672|9712298|FG001|Overall Study|Withdrawal by Subject|2
6097704|NCT00737672|9712297|FG000|Overall Study|Lost to Follow-up|1
6097705|NCT00737672|9712298|FG001|Overall Study|Lost to Follow-up|0
6097706|NCT00737672|9712297|FG000|Overall Study|Miscellaneous|7
6097707|NCT00737672|9712298|FG001|Overall Study|Miscellaneous|1
6097708|NCT00737672|9712297|FG000|Overall Study|Physician Decision|0
6097709|NCT00737672|9712298|FG001|Overall Study|Physician Decision|2
6097710|NCT00737698|9712307|FG000|Overall Study|Withdrawal by Subject|6
6097711|NCT00737698|9712308|FG001|Overall Study|Withdrawal by Subject|5
6097712|NCT00737698|9712309|FG002|Overall Study|Withdrawal by Subject|3
6097713|NCT00737698|9712307|FG000|Overall Study|Death|0
6097714|NCT00737698|9712308|FG001|Overall Study|Death|0
6097715|NCT00737698|9712309|FG002|Overall Study|Death|1
6097716|NCT00737711|9712317|FG000|Overall Study|Adverse Event|2
6097717|NCT00737711|9712317|FG000|Overall Study|Death|8
6097718|NCT00737711|9712317|FG000|Overall Study|Failure to return|4
6097719|NCT00737711|9712317|FG000|Overall Study|Protocol Violation|1
6097720|NCT00737711|9712317|FG000|Overall Study|Withdrawal by Subject|5
6097721|NCT00737711|9712317|FG000|Overall Study|Blood transfusion|6
6097722|NCT00737711|9712317|FG000|Overall Study|Other|5
6097723|NCT00738062|9712367|FG000|Open Label Treatment|Lack of Efficacy|5
6097724|NCT00738062|9712368|FG001|Open Label Treatment|Lack of Efficacy|0
6097725|NCT00738062|9712369|FG002|Open Label Treatment|Lack of Efficacy|0
6097726|NCT00738062|9712367|FG000|Open Label Treatment|Adverse Event|11
6097727|NCT00738062|9712368|FG001|Open Label Treatment|Adverse Event|0
6097728|NCT00738062|9712369|FG002|Open Label Treatment|Adverse Event|0
6097729|NCT00738062|9712367|FG000|Open Label Treatment|Protocol Violation|2
6097730|NCT00738062|9712368|FG001|Open Label Treatment|Protocol Violation|0
6097731|NCT00738062|9712369|FG002|Open Label Treatment|Protocol Violation|0
6097732|NCT00738062|9712367|FG000|Open Label Treatment|Withdrawal by Subject|9
6097733|NCT00738062|9712368|FG001|Open Label Treatment|Withdrawal by Subject|0
6097734|NCT00738062|9712369|FG002|Open Label Treatment|Withdrawal by Subject|0
6097735|NCT00738062|9712367|FG000|Open Label Treatment|Investigator Decision|1
6097736|NCT00738062|9712368|FG001|Open Label Treatment|Investigator Decision|0
6097737|NCT00738062|9712369|FG002|Open Label Treatment|Investigator Decision|0
6097738|NCT00738062|9712367|FG000|Open-Label Extension|Adverse Event|5
6097739|NCT00738062|9712368|FG001|Open-Label Extension|Adverse Event|0
6097740|NCT00738062|9712369|FG002|Open-Label Extension|Adverse Event|0
6097741|NCT00738062|9712367|FG000|Open-Label Extension|Physician Decision|1
6097742|NCT00738062|9712368|FG001|Open-Label Extension|Physician Decision|0
6097743|NCT00738062|9712369|FG002|Open-Label Extension|Physician Decision|0
6097744|NCT00738062|9712367|FG000|Open-Label Extension|Lack of Efficacy|2
6097745|NCT00738062|9712368|FG001|Open-Label Extension|Lack of Efficacy|0
6097746|NCT00738062|9712369|FG002|Open-Label Extension|Lack of Efficacy|0
6097747|NCT00738062|9712367|FG000|Open-Label Extension|Withdrawal by Subject|6
6097748|NCT00738062|9712368|FG001|Open-Label Extension|Withdrawal by Subject|0
6097749|NCT00738062|9712369|FG002|Open-Label Extension|Withdrawal by Subject|0
6097750|NCT00738062|9712367|FG000|Open-Label Extension|Protocol Violation|1
6097751|NCT00738062|9712368|FG001|Open-Label Extension|Protocol Violation|0
6097752|NCT00738062|9712369|FG002|Open-Label Extension|Protocol Violation|0
6097753|NCT00738062|9712367|FG000|Open-Label Extension|Study Terminated|2
6097754|NCT00738062|9712368|FG001|Open-Label Extension|Study Terminated|0
6097755|NCT00738062|9712369|FG002|Open-Label Extension|Study Terminated|0
6097756|NCT00738101|9712378|FG000|Overall Study|Physician Decision|5
6097757|NCT00738101|9712378|FG000|Overall Study|Death|1
6097758|NCT00738101|9712378|FG000|Overall Study|Repeat enrollment|1
6097759|NCT00738283|9712382|FG000|Overall Study|Death|1
6097760|NCT00738283|9712382|FG000|Overall Study|Transfer to another facility|2
6097761|NCT00738283|9712382|FG000|Overall Study|Discharge home prior to end of study|1
6097762|NCT00738374|9712394|FG000|Induction Treatment Phase|Adverse Event|14
6097763|NCT00738374|9712395|FG001|Induction Treatment Phase|Adverse Event|0
6097764|NCT00738374|9712396|FG002|Induction Treatment Phase|Adverse Event|0
6097765|NCT00738374|9712397|FG003|Induction Treatment Phase|Adverse Event|0
6097766|NCT00738374|9712394|FG000|Induction Treatment Phase|Disease progression/relapse/stable|4
6097767|NCT00738374|9712395|FG001|Induction Treatment Phase|Disease progression/relapse/stable|0
6097768|NCT00738374|9712396|FG002|Induction Treatment Phase|Disease progression/relapse/stable|0
6097769|NCT00738374|9712397|FG003|Induction Treatment Phase|Disease progression/relapse/stable|0
6097770|NCT00738374|9712394|FG000|Induction Treatment Phase|Physician Decision|2
6097771|NCT00738374|9712395|FG001|Induction Treatment Phase|Physician Decision|0
6097772|NCT00738374|9712396|FG002|Induction Treatment Phase|Physician Decision|0
6097773|NCT00738374|9712397|FG003|Induction Treatment Phase|Physician Decision|0
6097774|NCT00738374|9712394|FG000|Induction Treatment Phase|Protocol Violation|2
6097775|NCT00738374|9712395|FG001|Induction Treatment Phase|Protocol Violation|0
6097776|NCT00738374|9712396|FG002|Induction Treatment Phase|Protocol Violation|0
6097777|NCT00738374|9712397|FG003|Induction Treatment Phase|Protocol Violation|0
6097778|NCT00738374|9712394|FG000|Induction Treatment Phase|Non-compliance|1
6097779|NCT00738374|9712395|FG001|Induction Treatment Phase|Non-compliance|0
6097780|NCT00738374|9712396|FG002|Induction Treatment Phase|Non-compliance|0
6097781|NCT00738374|9712397|FG003|Induction Treatment Phase|Non-compliance|0
6097782|NCT00738374|9712394|FG000|Induction Treatment Phase|Withdrawal by Subject|1
6097783|NCT00738374|9712395|FG001|Induction Treatment Phase|Withdrawal by Subject|0
6097784|NCT00738374|9712396|FG002|Induction Treatment Phase|Withdrawal by Subject|0
6097785|NCT00738374|9712397|FG003|Induction Treatment Phase|Withdrawal by Subject|0
6097786|NCT00738374|9712394|FG000|Maintenance Treatment/Observation Phase|Adverse Event|0
6097787|NCT00738374|9712395|FG001|Maintenance Treatment/Observation Phase|Adverse Event|1
6097788|NCT00738374|9712396|FG002|Maintenance Treatment/Observation Phase|Adverse Event|2
6097789|NCT00738374|9712397|FG003|Maintenance Treatment/Observation Phase|Adverse Event|0
6097790|NCT00738374|9712394|FG000|Maintenance Treatment/Observation Phase|Disease progression/relapse/stable|0
6097791|NCT00738374|9712395|FG001|Maintenance Treatment/Observation Phase|Disease progression/relapse/stable|4
6097792|NCT00738374|9712396|FG002|Maintenance Treatment/Observation Phase|Disease progression/relapse/stable|5
6097793|NCT00738374|9712397|FG003|Maintenance Treatment/Observation Phase|Disease progression/relapse/stable|11
6097794|NCT00738374|9712394|FG000|Maintenance Treatment/Observation Phase|Withdrawal by Subject|0
6097795|NCT00738374|9712395|FG001|Maintenance Treatment/Observation Phase|Withdrawal by Subject|0
6097796|NCT00738374|9712396|FG002|Maintenance Treatment/Observation Phase|Withdrawal by Subject|0
6097797|NCT00738374|9712397|FG003|Maintenance Treatment/Observation Phase|Withdrawal by Subject|1
6097798|NCT00738374|9712394|FG000|Maintenance Treatment/Observation Phase|Protocol Violation|0
6097799|NCT00738374|9712395|FG001|Maintenance Treatment/Observation Phase|Protocol Violation|1
6097800|NCT00738374|9712396|FG002|Maintenance Treatment/Observation Phase|Protocol Violation|0
6097801|NCT00738374|9712397|FG003|Maintenance Treatment/Observation Phase|Protocol Violation|0
6097802|NCT00738374|9712394|FG000|Maintenance Treatment/Observation Phase|Other|0
6097803|NCT00738374|9712395|FG001|Maintenance Treatment/Observation Phase|Other|1
6097804|NCT00738374|9712396|FG002|Maintenance Treatment/Observation Phase|Other|0
6097805|NCT00738374|9712397|FG003|Maintenance Treatment/Observation Phase|Other|0
6097806|NCT00738400|9712408|FG000|Overall Study|Adverse Event|3
6097807|NCT00738400|9712409|FG001|Overall Study|Adverse Event|1
6097808|NCT00738400|9712408|FG000|Overall Study|Withdrawal by Subject|0
6097809|NCT00738400|9712409|FG001|Overall Study|Withdrawal by Subject|1
6097810|NCT00738400|9712408|FG000|Overall Study|Lack of Efficacy|0
6097811|NCT00738400|9712409|FG001|Overall Study|Lack of Efficacy|1
6097812|NCT00738400|9712408|FG000|Overall Study|Lost to Follow-up|0
6097813|NCT00738400|9712409|FG001|Overall Study|Lost to Follow-up|3
6097814|NCT00738400|9712408|FG000|Overall Study|Protocol Violation|1
6097815|NCT00738400|9712409|FG001|Overall Study|Protocol Violation|0
6097816|NCT00738400|9712408|FG000|Overall Study|Non-compliant with study medication|0
6097817|NCT00738400|9712409|FG001|Overall Study|Non-compliant with study medication|1
6203684|NCT01515423|9864718|FG000|DOUBLE BLIND|Other|0
6097818|NCT00738530|9712426|FG000|Overall Study|Death|220
6097819|NCT00738530|9712427|FG001|Overall Study|Death|224
6097820|NCT00738530|9712426|FG000|Overall Study|Lost to Follow-up|8
6203685|NCT01515423|9864719|FG001|DOUBLE BLIND|Other|6
6097821|NCT00738530|9712427|FG001|Overall Study|Lost to Follow-up|6
6097822|NCT00738530|9712426|FG000|Overall Study|Withdrawal by Subject|6
6097823|NCT00738530|9712427|FG001|Overall Study|Withdrawal by Subject|8
6097824|NCT00738673|9712439|FG000|Overall Study|Adverse Event|1
6097825|NCT00738673|9712440|FG001|Overall Study|Adverse Event|0
6097826|NCT00738673|9712439|FG000|Overall Study|Lack of Efficacy|19
6097827|NCT00738673|9712440|FG001|Overall Study|Lack of Efficacy|8
6097828|NCT00738673|9712439|FG000|Overall Study|Protocol Violation|1
6097829|NCT00738673|9712440|FG001|Overall Study|Protocol Violation|2
6097830|NCT00738673|9712439|FG000|Overall Study|Withdrawal by Subject|3
6097831|NCT00738673|9712440|FG001|Overall Study|Withdrawal by Subject|1
6097832|NCT00738699|9712448|FG000|Overall Study|Withdrawal by Subject|5
6097833|NCT00738699|9712449|FG001|Overall Study|Withdrawal by Subject|0
6097834|NCT00738699|9712448|FG000|Overall Study|Lost to Follow-up|1
6097835|NCT00738699|9712449|FG001|Overall Study|Lost to Follow-up|0
6097836|NCT00738699|9712448|FG000|Overall Study|Death|144
6097837|NCT00738699|9712449|FG001|Overall Study|Death|68
6097838|NCT00738699|9712448|FG000|Overall Study|Discontinuation of study by Sponsor|123
6097839|NCT00738699|9712449|FG001|Overall Study|Discontinuation of study by Sponsor|72
6097840|NCT00738699|9712448|FG000|Overall Study|Other|2
6097841|NCT00738699|9712449|FG001|Overall Study|Other|0
6097842|NCT00738881|9712457|FG000|Overall Study|Withdrawal by Subject|0
6097843|NCT00738881|9712458|FG001|Overall Study|Withdrawal by Subject|2
6097844|NCT00738894|9712466|FG000|Overall Study|Lost to Follow-up|23
6097845|NCT00738894|9712467|FG001|Overall Study|Lost to Follow-up|13
6097846|NCT00738894|9712466|FG000|Overall Study|Withdrawal by Subject|10
6097847|NCT00738894|9712467|FG001|Overall Study|Withdrawal by Subject|15
6097848|NCT00738894|9712466|FG000|Overall Study|Physician Decision|4
6097849|NCT00738894|9712467|FG001|Overall Study|Physician Decision|5
6097850|NCT00738894|9712466|FG000|Overall Study|Death|2
6097851|NCT00738894|9712467|FG001|Overall Study|Death|0
6097852|NCT00739102|9712473|FG000|Overall Study|Death|5
6097853|NCT00739102|9712473|FG000|Overall Study|Withdrawal by Subject|10
6097854|NCT00739297|9712477|FG000|First Washout Period of 4-7 Days|Adverse Event|0
6097855|NCT00739297|9712478|FG001|First Washout Period of 4-7 Days|Adverse Event|0
6097856|NCT00739297|9712479|FG002|First Washout Period of 4-7 Days|Adverse Event|0
6097857|NCT00739297|9712480|FG003|First Washout Period of 4-7 Days|Adverse Event|2
6097858|NCT00739297|9712481|FG004|First Washout Period of 4-7 Days|Adverse Event|0
6097859|NCT00739297|9712482|FG005|First Washout Period of 4-7 Days|Adverse Event|0
6097860|NCT00739297|9712483|FG006|First Washout Period of 4-7 Days|Adverse Event|2
6097861|NCT00739297|9712477|FG000|Fourth Intervention(Visit 9 to Visit 10)|Patient unable to attend last visit|0
6097862|NCT00739297|9712478|FG001|Fourth Intervention(Visit 9 to Visit 10)|Patient unable to attend last visit|0
6097863|NCT00739297|9712479|FG002|Fourth Intervention(Visit 9 to Visit 10)|Patient unable to attend last visit|0
6097864|NCT00739297|9712480|FG003|Fourth Intervention(Visit 9 to Visit 10)|Patient unable to attend last visit|0
6097865|NCT00739297|9712481|FG004|Fourth Intervention(Visit 9 to Visit 10)|Patient unable to attend last visit|0
6097866|NCT00739297|9712482|FG005|Fourth Intervention(Visit 9 to Visit 10)|Patient unable to attend last visit|1
6097867|NCT00739297|9712483|FG006|Fourth Intervention(Visit 9 to Visit 10)|Patient unable to attend last visit|1
6097868|NCT00739310|9712499|FG000|Overall Study|Poor adherance to prescribed therapy|4
6097869|NCT00739310|9712499|FG000|Overall Study|Withdrawal by Subject|1
6097870|NCT00739310|9712499|FG000|Overall Study|Lost to Follow-up|2
6097871|NCT00739596|9712524|FG000|Overall Study|Adverse Event|12
6097872|NCT00739596|9712525|FG001|Overall Study|Adverse Event|6
6097873|NCT00739596|9712524|FG000|Overall Study|Unsatisfactory Therapeutic Effect|4
6097874|NCT00739596|9712525|FG001|Overall Study|Unsatisfactory Therapeutic Effect|0
6097875|NCT00739596|9712524|FG000|Overall Study|Patient Withdrew Consent|8
6097876|NCT00739596|9712525|FG001|Overall Study|Patient Withdrew Consent|8
6097877|NCT00739596|9712524|FG000|Overall Study|Lost to Follow-up|0
6097878|NCT00739596|9712525|FG001|Overall Study|Lost to Follow-up|2
6097879|NCT00739596|9712524|FG000|Overall Study|Protocol Deviation|1
6097880|NCT00739596|9712525|FG001|Overall Study|Protocol Deviation|1
6097881|NCT00739648|9712533|FG000|Overall Study|Adverse Event|3
6097882|NCT00739648|9712534|FG001|Overall Study|Adverse Event|15
6097883|NCT00739648|9712533|FG000|Overall Study|Withdrawal by Subject|13
6097884|NCT00739648|9712534|FG001|Overall Study|Withdrawal by Subject|25
6097885|NCT00739648|9712533|FG000|Overall Study|Lost to Follow-up|4
6097886|NCT00739648|9712534|FG001|Overall Study|Lost to Follow-up|7
6097887|NCT00739648|9712533|FG000|Overall Study|Death|2
6097888|NCT00739648|9712534|FG001|Overall Study|Death|0
6097889|NCT00739648|9712533|FG000|Overall Study|Do not know|4
6097890|NCT00739648|9712534|FG001|Overall Study|Do not know|6
6097891|NCT00739661|9712546|FG000|Overall Study|Adverse Event|2
6097892|NCT00739661|9712547|FG001|Overall Study|Adverse Event|0
6097893|NCT00739661|9712546|FG000|Overall Study|Physician decision to withdraw patient|1
6097894|NCT00739661|9712547|FG001|Overall Study|Physician decision to withdraw patient|0
6097895|NCT00739661|9712546|FG000|Overall Study|Patient decision to withdraw|9
6097896|NCT00739661|9712547|FG001|Overall Study|Patient decision to withdraw|4
6097897|NCT00739661|9712546|FG000|Overall Study|Disease progression, radiographic|33
6097898|NCT00739661|9712547|FG001|Overall Study|Disease progression, radiographic|37
6097899|NCT00739661|9712546|FG000|Overall Study|Reason for discontinuation not available|1
6097900|NCT00739661|9712547|FG001|Overall Study|Reason for discontinuation not available|1
6097901|NCT00739908|9712593|FG000|Overall Study|Adverse Event|5
6097902|NCT00739908|9712594|FG001|Overall Study|Adverse Event|6
6097903|NCT00739908|9712593|FG000|Overall Study|Withdrawal by Subject|4
6097904|NCT00739908|9712594|FG001|Overall Study|Withdrawal by Subject|2
6097905|NCT00739908|9712593|FG000|Overall Study|Lost to Follow-up|14
6097906|NCT00739908|9712594|FG001|Overall Study|Lost to Follow-up|9
6097907|NCT00739908|9712593|FG000|Overall Study|Non-Compliance With Study Procedures|2
6097908|NCT00739908|9712594|FG001|Overall Study|Non-Compliance With Study Procedures|3
6097909|NCT00739908|9712593|FG000|Overall Study|Non-Compliance With Study Medication|0
6097910|NCT00739908|9712594|FG001|Overall Study|Non-Compliance With Study Medication|3
6097911|NCT00739908|9712593|FG000|Overall Study|Lack of Efficacy|0
6097912|NCT00739908|9712594|FG001|Overall Study|Lack of Efficacy|1
6097913|NCT00739908|9712593|FG000|Overall Study|Relocation|0
6097914|NCT00739908|9712594|FG001|Overall Study|Relocation|1
6097915|NCT00739934|9712602|FG000|Voriconazole IV|Adverse Event|6
6097916|NCT00739934|9712602|FG000|Voriconazole Oral|Other|3
6097917|NCT00739973|9712624|FG000|Single-blind Period (2 to 4 Weeks)|Adverse Event|35
6097918|NCT00739973|9712625|FG001|Single-blind Period (2 to 4 Weeks)|Adverse Event|0
6097919|NCT00739973|9712626|FG002|Single-blind Period (2 to 4 Weeks)|Adverse Event|0
6097920|NCT00739973|9712627|FG003|Single-blind Period (2 to 4 Weeks)|Adverse Event|0
6097921|NCT00739973|9712628|FG004|Single-blind Period (2 to 4 Weeks)|Adverse Event|0
6097922|NCT00739973|9712629|FG005|Single-blind Period (2 to 4 Weeks)|Adverse Event|0
6097923|NCT00739973|9712630|FG006|Single-blind Period (2 to 4 Weeks)|Adverse Event|0
6097924|NCT00739973|9712631|FG007|Single-blind Period (2 to 4 Weeks)|Adverse Event|0
6097925|NCT00739973|9712632|FG008|Single-blind Period (2 to 4 Weeks)|Adverse Event|0
6203686|NCT01515423|9864720|FG002|DOUBLE BLIND|Other|12
6203687|NCT01515423|9864718|FG000|DOUBLE BLIND|Blind broken by investigator|0
6203688|NCT01515423|9864719|FG001|DOUBLE BLIND|Blind broken by investigator|1
6203689|NCT01515423|9864720|FG002|DOUBLE BLIND|Blind broken by investigator|0
6203690|NCT01515475|9864731|FG000|Overall Study|Lost to Follow-up|20
6203691|NCT01515475|9864732|FG001|Overall Study|Lost to Follow-up|15
6203692|NCT01515475|9864733|FG002|Overall Study|Lost to Follow-up|12
6203693|NCT01515475|9864734|FG003|Overall Study|Lost to Follow-up|12
6203694|NCT01515865|9864790|FG000|Part A (Open-label)|Other|3
6203695|NCT01515865|9864791|FG001|Part A (Open-label)|Other|0
6203696|NCT01515865|9864792|FG002|Part A (Open-label)|Other|0
6203697|NCT01515865|9864790|FG000|Part B (Open-label)|Withdrawal by Subject|1
6203698|NCT01515865|9864791|FG001|Part B (Open-label)|Withdrawal by Subject|0
6203699|NCT01515865|9864792|FG002|Part B (Open-label)|Withdrawal by Subject|0
6203700|NCT01515865|9864790|FG000|Part B (Open-label)|Other|1
6203701|NCT01515865|9864791|FG001|Part B (Open-label)|Other|0
6203702|NCT01515865|9864792|FG002|Part B (Open-label)|Other|0
6284624|NCT02326298|9996366|FG012|Initial Period (Week 0 to Week 16)|Adverse event after completing wk16|0
6284625|NCT02326298|9996367|FG013|Initial Period (Week 0 to Week 16)|Adverse event after completing wk16|0
6284626|NCT02326298|9996354|FG000|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|0
6284627|NCT02326298|9996355|FG001|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|0
6284628|NCT02326298|9996356|FG002|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|0
6284629|NCT02326298|9996357|FG003|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|0
6284630|NCT02326298|9996358|FG004|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|0
6284631|NCT02326298|9996359|FG005|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|1
6284632|NCT02326298|9996360|FG006|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|3
6284633|NCT02326298|9996361|FG007|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|1
6284634|NCT02326298|9996362|FG008|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|1
6284635|NCT02326298|9996363|FG009|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|1
6284636|NCT02326298|9996364|FG010|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|0
6284637|NCT02326298|9996365|FG011|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|0
6284638|NCT02326298|9996366|FG012|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|0
6284639|NCT02326298|9996367|FG013|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|0
6284640|NCT02326298|9996354|FG000|Maintenance Period (Week 16 to Week 48)|Patient did not achieve PASI50 response|0
6284641|NCT02326298|9996355|FG001|Maintenance Period (Week 16 to Week 48)|Patient did not achieve PASI50 response|0
6284642|NCT02326298|9996356|FG002|Maintenance Period (Week 16 to Week 48)|Patient did not achieve PASI50 response|0
6284643|NCT02326298|9996357|FG003|Maintenance Period (Week 16 to Week 48)|Patient did not achieve PASI50 response|0
6284644|NCT02326298|9996358|FG004|Maintenance Period (Week 16 to Week 48)|Patient did not achieve PASI50 response|0
6284645|NCT02326298|9996359|FG005|Maintenance Period (Week 16 to Week 48)|Patient did not achieve PASI50 response|1
6284646|NCT02326298|9996360|FG006|Maintenance Period (Week 16 to Week 48)|Patient did not achieve PASI50 response|2
6284647|NCT02326298|9996361|FG007|Maintenance Period (Week 16 to Week 48)|Patient did not achieve PASI50 response|0
6284648|NCT02326298|9996362|FG008|Maintenance Period (Week 16 to Week 48)|Patient did not achieve PASI50 response|4
6284649|NCT02326298|9996363|FG009|Maintenance Period (Week 16 to Week 48)|Patient did not achieve PASI50 response|0
6284650|NCT02326298|9996364|FG010|Maintenance Period (Week 16 to Week 48)|Patient did not achieve PASI50 response|0
6284651|NCT02326298|9996365|FG011|Maintenance Period (Week 16 to Week 48)|Patient did not achieve PASI50 response|0
6284652|NCT02326298|9996366|FG012|Maintenance Period (Week 16 to Week 48)|Patient did not achieve PASI50 response|0
6284653|NCT02326298|9996367|FG013|Maintenance Period (Week 16 to Week 48)|Patient did not achieve PASI50 response|0
6097926|NCT00739973|9712624|FG000|Single-blind Period (2 to 4 Weeks)|Abnormal laboratory value(s)|38
6097927|NCT00739973|9712625|FG001|Single-blind Period (2 to 4 Weeks)|Abnormal laboratory value(s)|0
6097928|NCT00739973|9712626|FG002|Single-blind Period (2 to 4 Weeks)|Abnormal laboratory value(s)|0
6097929|NCT00739973|9712627|FG003|Single-blind Period (2 to 4 Weeks)|Abnormal laboratory value(s)|0
6097930|NCT00739973|9712628|FG004|Single-blind Period (2 to 4 Weeks)|Abnormal laboratory value(s)|0
6097931|NCT00739973|9712629|FG005|Single-blind Period (2 to 4 Weeks)|Abnormal laboratory value(s)|0
6097932|NCT00739973|9712630|FG006|Single-blind Period (2 to 4 Weeks)|Abnormal laboratory value(s)|0
6097933|NCT00739973|9712631|FG007|Single-blind Period (2 to 4 Weeks)|Abnormal laboratory value(s)|0
6097934|NCT00739973|9712632|FG008|Single-blind Period (2 to 4 Weeks)|Abnormal laboratory value(s)|0
6097935|NCT00739973|9712624|FG000|Single-blind Period (2 to 4 Weeks)|Abnormal test procedure result(s)|810
6097936|NCT00739973|9712625|FG001|Single-blind Period (2 to 4 Weeks)|Abnormal test procedure result(s)|0
6097937|NCT00739973|9712626|FG002|Single-blind Period (2 to 4 Weeks)|Abnormal test procedure result(s)|0
6097938|NCT00739973|9712627|FG003|Single-blind Period (2 to 4 Weeks)|Abnormal test procedure result(s)|0
6097939|NCT00739973|9712628|FG004|Single-blind Period (2 to 4 Weeks)|Abnormal test procedure result(s)|0
6097940|NCT00739973|9712629|FG005|Single-blind Period (2 to 4 Weeks)|Abnormal test procedure result(s)|0
6097941|NCT00739973|9712630|FG006|Single-blind Period (2 to 4 Weeks)|Abnormal test procedure result(s)|0
6097942|NCT00739973|9712631|FG007|Single-blind Period (2 to 4 Weeks)|Abnormal test procedure result(s)|0
6097943|NCT00739973|9712632|FG008|Single-blind Period (2 to 4 Weeks)|Abnormal test procedure result(s)|0
6097944|NCT00739973|9712624|FG000|Single-blind Period (2 to 4 Weeks)|Patient withdrew consent|86
6097945|NCT00739973|9712625|FG001|Single-blind Period (2 to 4 Weeks)|Patient withdrew consent|0
6097946|NCT00739973|9712626|FG002|Single-blind Period (2 to 4 Weeks)|Patient withdrew consent|0
6097947|NCT00739973|9712627|FG003|Single-blind Period (2 to 4 Weeks)|Patient withdrew consent|0
6097948|NCT00739973|9712628|FG004|Single-blind Period (2 to 4 Weeks)|Patient withdrew consent|0
6097949|NCT00739973|9712629|FG005|Single-blind Period (2 to 4 Weeks)|Patient withdrew consent|0
6097950|NCT00739973|9712630|FG006|Single-blind Period (2 to 4 Weeks)|Patient withdrew consent|0
6097951|NCT00739973|9712631|FG007|Single-blind Period (2 to 4 Weeks)|Patient withdrew consent|0
6097952|NCT00739973|9712632|FG008|Single-blind Period (2 to 4 Weeks)|Patient withdrew consent|0
6097953|NCT00739973|9712624|FG000|Single-blind Period (2 to 4 Weeks)|Lost to Follow-up|17
6097954|NCT00739973|9712625|FG001|Single-blind Period (2 to 4 Weeks)|Lost to Follow-up|0
6097955|NCT00739973|9712626|FG002|Single-blind Period (2 to 4 Weeks)|Lost to Follow-up|0
6097956|NCT00739973|9712627|FG003|Single-blind Period (2 to 4 Weeks)|Lost to Follow-up|0
6097957|NCT00739973|9712628|FG004|Single-blind Period (2 to 4 Weeks)|Lost to Follow-up|0
6097958|NCT00739973|9712629|FG005|Single-blind Period (2 to 4 Weeks)|Lost to Follow-up|0
6097959|NCT00739973|9712630|FG006|Single-blind Period (2 to 4 Weeks)|Lost to Follow-up|0
6097960|NCT00739973|9712631|FG007|Single-blind Period (2 to 4 Weeks)|Lost to Follow-up|0
6097961|NCT00739973|9712632|FG008|Single-blind Period (2 to 4 Weeks)|Lost to Follow-up|0
6097962|NCT00739973|9712624|FG000|Single-blind Period (2 to 4 Weeks)|Administrative problems|12
6097963|NCT00739973|9712625|FG001|Single-blind Period (2 to 4 Weeks)|Administrative problems|0
6097964|NCT00739973|9712626|FG002|Single-blind Period (2 to 4 Weeks)|Administrative problems|0
6097965|NCT00739973|9712627|FG003|Single-blind Period (2 to 4 Weeks)|Administrative problems|0
6097966|NCT00739973|9712628|FG004|Single-blind Period (2 to 4 Weeks)|Administrative problems|0
6097967|NCT00739973|9712629|FG005|Single-blind Period (2 to 4 Weeks)|Administrative problems|0
6097968|NCT00739973|9712630|FG006|Single-blind Period (2 to 4 Weeks)|Administrative problems|0
6097969|NCT00739973|9712631|FG007|Single-blind Period (2 to 4 Weeks)|Administrative problems|0
6097970|NCT00739973|9712632|FG008|Single-blind Period (2 to 4 Weeks)|Administrative problems|0
6097971|NCT00739973|9712624|FG000|Single-blind Period (2 to 4 Weeks)|Protocol deviation|11
6097972|NCT00739973|9712625|FG001|Single-blind Period (2 to 4 Weeks)|Protocol deviation|0
6097973|NCT00739973|9712626|FG002|Single-blind Period (2 to 4 Weeks)|Protocol deviation|0
6097974|NCT00739973|9712627|FG003|Single-blind Period (2 to 4 Weeks)|Protocol deviation|0
6097975|NCT00739973|9712628|FG004|Single-blind Period (2 to 4 Weeks)|Protocol deviation|0
6097976|NCT00739973|9712629|FG005|Single-blind Period (2 to 4 Weeks)|Protocol deviation|0
6097977|NCT00739973|9712630|FG006|Single-blind Period (2 to 4 Weeks)|Protocol deviation|0
6097978|NCT00739973|9712631|FG007|Single-blind Period (2 to 4 Weeks)|Protocol deviation|0
6097979|NCT00739973|9712632|FG008|Single-blind Period (2 to 4 Weeks)|Protocol deviation|0
6097980|NCT00739973|9712624|FG000|Double-blind:Randomized Period (8 Weeks)|Adverse Event|3
6097981|NCT00739973|9712625|FG001|Double-blind:Randomized Period (8 Weeks)|Adverse Event|3
6097982|NCT00739973|9712626|FG002|Double-blind:Randomized Period (8 Weeks)|Adverse Event|1
6097983|NCT00739973|9712627|FG003|Double-blind:Randomized Period (8 Weeks)|Adverse Event|2
6097984|NCT00739973|9712628|FG004|Double-blind:Randomized Period (8 Weeks)|Adverse Event|7
6097985|NCT00739973|9712629|FG005|Double-blind:Randomized Period (8 Weeks)|Adverse Event|3
6097986|NCT00739973|9712630|FG006|Double-blind:Randomized Period (8 Weeks)|Adverse Event|4
6097987|NCT00739973|9712631|FG007|Double-blind:Randomized Period (8 Weeks)|Adverse Event|1
6097988|NCT00739973|9712632|FG008|Double-blind:Randomized Period (8 Weeks)|Adverse Event|4
6097989|NCT00739973|9712624|FG000|Double-blind:Randomized Period (8 Weeks)|Abnormal laboratory values|0
6097990|NCT00739973|9712625|FG001|Double-blind:Randomized Period (8 Weeks)|Abnormal laboratory values|0
6097991|NCT00739973|9712626|FG002|Double-blind:Randomized Period (8 Weeks)|Abnormal laboratory values|0
6097992|NCT00739973|9712627|FG003|Double-blind:Randomized Period (8 Weeks)|Abnormal laboratory values|0
6097993|NCT00739973|9712628|FG004|Double-blind:Randomized Period (8 Weeks)|Abnormal laboratory values|1
6097994|NCT00739973|9712629|FG005|Double-blind:Randomized Period (8 Weeks)|Abnormal laboratory values|0
6097995|NCT00739973|9712630|FG006|Double-blind:Randomized Period (8 Weeks)|Abnormal laboratory values|0
6097996|NCT00739973|9712631|FG007|Double-blind:Randomized Period (8 Weeks)|Abnormal laboratory values|1
6097997|NCT00739973|9712632|FG008|Double-blind:Randomized Period (8 Weeks)|Abnormal laboratory values|0
6097998|NCT00739973|9712624|FG000|Double-blind:Randomized Period (8 Weeks)|Abnormal test procedure results|1
6097999|NCT00739973|9712625|FG001|Double-blind:Randomized Period (8 Weeks)|Abnormal test procedure results|1
6098000|NCT00739973|9712626|FG002|Double-blind:Randomized Period (8 Weeks)|Abnormal test procedure results|0
6098001|NCT00739973|9712627|FG003|Double-blind:Randomized Period (8 Weeks)|Abnormal test procedure results|0
6098002|NCT00739973|9712628|FG004|Double-blind:Randomized Period (8 Weeks)|Abnormal test procedure results|0
6098003|NCT00739973|9712629|FG005|Double-blind:Randomized Period (8 Weeks)|Abnormal test procedure results|0
6098004|NCT00739973|9712630|FG006|Double-blind:Randomized Period (8 Weeks)|Abnormal test procedure results|0
6098005|NCT00739973|9712631|FG007|Double-blind:Randomized Period (8 Weeks)|Abnormal test procedure results|0
6098006|NCT00739973|9712632|FG008|Double-blind:Randomized Period (8 Weeks)|Abnormal test procedure results|0
6098007|NCT00739973|9712624|FG000|Double-blind:Randomized Period (8 Weeks)|Unsatisfactory therapeutic effect|17
6098008|NCT00739973|9712625|FG001|Double-blind:Randomized Period (8 Weeks)|Unsatisfactory therapeutic effect|8
6098009|NCT00739973|9712626|FG002|Double-blind:Randomized Period (8 Weeks)|Unsatisfactory therapeutic effect|8
6098010|NCT00739973|9712627|FG003|Double-blind:Randomized Period (8 Weeks)|Unsatisfactory therapeutic effect|4
6098011|NCT00739973|9712628|FG004|Double-blind:Randomized Period (8 Weeks)|Unsatisfactory therapeutic effect|2
6098012|NCT00739973|9712629|FG005|Double-blind:Randomized Period (8 Weeks)|Unsatisfactory therapeutic effect|2
6098013|NCT00739973|9712630|FG006|Double-blind:Randomized Period (8 Weeks)|Unsatisfactory therapeutic effect|1
6098014|NCT00739973|9712631|FG007|Double-blind:Randomized Period (8 Weeks)|Unsatisfactory therapeutic effect|1
6098015|NCT00739973|9712632|FG008|Double-blind:Randomized Period (8 Weeks)|Unsatisfactory therapeutic effect|2
6098016|NCT00739973|9712624|FG000|Double-blind:Randomized Period (8 Weeks)|Patient no longer needs study drug|0
6098017|NCT00739973|9712625|FG001|Double-blind:Randomized Period (8 Weeks)|Patient no longer needs study drug|0
6098018|NCT00739973|9712626|FG002|Double-blind:Randomized Period (8 Weeks)|Patient no longer needs study drug|1
6098019|NCT00739973|9712627|FG003|Double-blind:Randomized Period (8 Weeks)|Patient no longer needs study drug|0
6098020|NCT00739973|9712628|FG004|Double-blind:Randomized Period (8 Weeks)|Patient no longer needs study drug|0
6098021|NCT00739973|9712629|FG005|Double-blind:Randomized Period (8 Weeks)|Patient no longer needs study drug|0
6098022|NCT00739973|9712630|FG006|Double-blind:Randomized Period (8 Weeks)|Patient no longer needs study drug|0
6098023|NCT00739973|9712631|FG007|Double-blind:Randomized Period (8 Weeks)|Patient no longer needs study drug|0
6098024|NCT00739973|9712632|FG008|Double-blind:Randomized Period (8 Weeks)|Patient no longer needs study drug|0
6098025|NCT00739973|9712624|FG000|Double-blind:Randomized Period (8 Weeks)|Patient withdrew consent|4
6098026|NCT00739973|9712625|FG001|Double-blind:Randomized Period (8 Weeks)|Patient withdrew consent|2
6098027|NCT00739973|9712626|FG002|Double-blind:Randomized Period (8 Weeks)|Patient withdrew consent|4
6098028|NCT00739973|9712627|FG003|Double-blind:Randomized Period (8 Weeks)|Patient withdrew consent|3
6098029|NCT00739973|9712628|FG004|Double-blind:Randomized Period (8 Weeks)|Patient withdrew consent|4
6098030|NCT00739973|9712629|FG005|Double-blind:Randomized Period (8 Weeks)|Patient withdrew consent|4
6098031|NCT00739973|9712630|FG006|Double-blind:Randomized Period (8 Weeks)|Patient withdrew consent|3
6098032|NCT00739973|9712631|FG007|Double-blind:Randomized Period (8 Weeks)|Patient withdrew consent|2
6098033|NCT00739973|9712632|FG008|Double-blind:Randomized Period (8 Weeks)|Patient withdrew consent|4
6098034|NCT00739973|9712624|FG000|Double-blind:Randomized Period (8 Weeks)|Lost to Follow-up|0
6098035|NCT00739973|9712625|FG001|Double-blind:Randomized Period (8 Weeks)|Lost to Follow-up|2
6098036|NCT00739973|9712626|FG002|Double-blind:Randomized Period (8 Weeks)|Lost to Follow-up|4
6098037|NCT00739973|9712627|FG003|Double-blind:Randomized Period (8 Weeks)|Lost to Follow-up|1
6098038|NCT00739973|9712628|FG004|Double-blind:Randomized Period (8 Weeks)|Lost to Follow-up|2
6098039|NCT00739973|9712629|FG005|Double-blind:Randomized Period (8 Weeks)|Lost to Follow-up|2
6098040|NCT00739973|9712630|FG006|Double-blind:Randomized Period (8 Weeks)|Lost to Follow-up|0
6098041|NCT00739973|9712631|FG007|Double-blind:Randomized Period (8 Weeks)|Lost to Follow-up|3
6098042|NCT00739973|9712632|FG008|Double-blind:Randomized Period (8 Weeks)|Lost to Follow-up|1
6098043|NCT00739973|9712624|FG000|Double-blind:Randomized Period (8 Weeks)|Administrative problems|0
6098044|NCT00739973|9712625|FG001|Double-blind:Randomized Period (8 Weeks)|Administrative problems|0
6098045|NCT00739973|9712626|FG002|Double-blind:Randomized Period (8 Weeks)|Administrative problems|0
6098046|NCT00739973|9712627|FG003|Double-blind:Randomized Period (8 Weeks)|Administrative problems|0
6098047|NCT00739973|9712628|FG004|Double-blind:Randomized Period (8 Weeks)|Administrative problems|0
6098048|NCT00739973|9712629|FG005|Double-blind:Randomized Period (8 Weeks)|Administrative problems|0
6098049|NCT00739973|9712630|FG006|Double-blind:Randomized Period (8 Weeks)|Administrative problems|1
6098050|NCT00739973|9712631|FG007|Double-blind:Randomized Period (8 Weeks)|Administrative problems|0
6098051|NCT00739973|9712632|FG008|Double-blind:Randomized Period (8 Weeks)|Administrative problems|0
6098052|NCT00739973|9712624|FG000|Double-blind:Randomized Period (8 Weeks)|Protocol deviation|5
6098053|NCT00739973|9712625|FG001|Double-blind:Randomized Period (8 Weeks)|Protocol deviation|3
6098054|NCT00739973|9712626|FG002|Double-blind:Randomized Period (8 Weeks)|Protocol deviation|1
6098055|NCT00739973|9712627|FG003|Double-blind:Randomized Period (8 Weeks)|Protocol deviation|2
6098056|NCT00739973|9712628|FG004|Double-blind:Randomized Period (8 Weeks)|Protocol deviation|3
6098057|NCT00739973|9712629|FG005|Double-blind:Randomized Period (8 Weeks)|Protocol deviation|1
6098058|NCT00739973|9712630|FG006|Double-blind:Randomized Period (8 Weeks)|Protocol deviation|2
6098059|NCT00739973|9712631|FG007|Double-blind:Randomized Period (8 Weeks)|Protocol deviation|2
6098060|NCT00739973|9712632|FG008|Double-blind:Randomized Period (8 Weeks)|Protocol deviation|3
6098061|NCT00739973|9712624|FG000|Double-blind:Randomized Period (8 Weeks)|Discont. single-blind, Mis- randomized|0
6098062|NCT00739973|9712625|FG001|Double-blind:Randomized Period (8 Weeks)|Discont. single-blind, Mis- randomized|1
6098063|NCT00739973|9712626|FG002|Double-blind:Randomized Period (8 Weeks)|Discont. single-blind, Mis- randomized|0
6098064|NCT00739973|9712627|FG003|Double-blind:Randomized Period (8 Weeks)|Discont. single-blind, Mis- randomized|0
6098065|NCT00739973|9712628|FG004|Double-blind:Randomized Period (8 Weeks)|Discont. single-blind, Mis- randomized|0
6098066|NCT00739973|9712629|FG005|Double-blind:Randomized Period (8 Weeks)|Discont. single-blind, Mis- randomized|0
6098067|NCT00739973|9712630|FG006|Double-blind:Randomized Period (8 Weeks)|Discont. single-blind, Mis- randomized|2
6098068|NCT00739973|9712631|FG007|Double-blind:Randomized Period (8 Weeks)|Discont. single-blind, Mis- randomized|0
6098069|NCT00739973|9712632|FG008|Double-blind:Randomized Period (8 Weeks)|Discont. single-blind, Mis- randomized|0
6098070|NCT00740051|9712676|FG000|Overall Study|Lack of Efficacy|2
6098071|NCT00740051|9712677|FG001|Overall Study|Lack of Efficacy|5
6098072|NCT00740051|9712676|FG000|Overall Study|Adverse Event|1
6098073|NCT00740051|9712677|FG001|Overall Study|Adverse Event|4
6098074|NCT00740051|9712676|FG000|Overall Study|Protocol Violation|2
6098075|NCT00740051|9712677|FG001|Overall Study|Protocol Violation|6
6098076|NCT00740051|9712676|FG000|Overall Study|Lost to Follow-up|3
6098077|NCT00740051|9712677|FG001|Overall Study|Lost to Follow-up|8
6098078|NCT00740051|9712676|FG000|Overall Study|Withdrawal by Subject|6
6098079|NCT00740051|9712677|FG001|Overall Study|Withdrawal by Subject|8
6098080|NCT00740051|9712676|FG000|Overall Study|Other reason (not specified)|4
6098081|NCT00740051|9712677|FG001|Overall Study|Other reason (not specified)|1
6098082|NCT00740220|9712702|FG000|Overall Study|screen failures (non-COPD patients)|9
6098083|NCT00740584|9712715|FG000|Overall Study|Withdrawal by Subject|1
6098084|NCT00740636|9712722|FG000|Overall Study|Adverse Event|0
6098085|NCT00740636|9712723|FG001|Overall Study|Adverse Event|2
6098086|NCT00740636|9712722|FG000|Overall Study|Patient Ineligible|0
6098087|NCT00740636|9712723|FG001|Overall Study|Patient Ineligible|1
6098088|NCT00740636|9712722|FG000|Overall Study|Patient Not Treated|0
6098089|NCT00740636|9712723|FG001|Overall Study|Patient Not Treated|1
6098090|NCT00740636|9712722|FG000|Overall Study|Progressive Disease|1
6098091|NCT00740636|9712723|FG001|Overall Study|Progressive Disease|0
6098092|NCT00740636|9712722|FG000|Overall Study|Death|1
6098093|NCT00740636|9712723|FG001|Overall Study|Death|0
6098094|NCT00740714|9712732|FG000|Overall Study|Withdrawal by Subject|17
6098095|NCT00740714|9712733|FG001|Overall Study|Withdrawal by Subject|19
6098096|NCT00740714|9712734|FG002|Overall Study|Withdrawal by Subject|29
6098097|NCT00740779|9712745|FG000|Overall Study|Adverse Event|4
6098098|NCT00740779|9712746|FG001|Overall Study|Adverse Event|6
6098099|NCT00740779|9712747|FG002|Overall Study|Adverse Event|3
6098100|NCT00740779|9712745|FG000|Overall Study|Protocol Violation|1
6098101|NCT00740779|9712746|FG001|Overall Study|Protocol Violation|1
6098102|NCT00740779|9712747|FG002|Overall Study|Protocol Violation|1
6098103|NCT00740779|9712745|FG000|Overall Study|Lack of Efficacy|0
6098104|NCT00740779|9712746|FG001|Overall Study|Lack of Efficacy|0
6098105|NCT00740779|9712747|FG002|Overall Study|Lack of Efficacy|2
6098106|NCT00740779|9712745|FG000|Overall Study|Withdrawal by Subject|2
6098107|NCT00740779|9712746|FG001|Overall Study|Withdrawal by Subject|4
6098108|NCT00740779|9712747|FG002|Overall Study|Withdrawal by Subject|2
6098109|NCT00740779|9712745|FG000|Overall Study|Lost to Follow-up|2
6098110|NCT00740779|9712746|FG001|Overall Study|Lost to Follow-up|3
6098111|NCT00740779|9712747|FG002|Overall Study|Lost to Follow-up|5
6098112|NCT00740792|9712759|FG000|Overall Study|Adverse Event|3
6098113|NCT00740792|9712760|FG001|Overall Study|Adverse Event|1
6098114|NCT00740792|9712761|FG002|Overall Study|Adverse Event|1
6098115|NCT00740792|9712762|FG003|Overall Study|Adverse Event|3
6098116|NCT00740792|9712759|FG000|Overall Study|Lack of Efficacy|1
6098117|NCT00740792|9712760|FG001|Overall Study|Lack of Efficacy|1
6098118|NCT00740792|9712761|FG002|Overall Study|Lack of Efficacy|0
6098119|NCT00740792|9712762|FG003|Overall Study|Lack of Efficacy|3
6098120|NCT00740792|9712759|FG000|Overall Study|Lost to Follow-up|2
6098121|NCT00740792|9712760|FG001|Overall Study|Lost to Follow-up|1
6098122|NCT00740792|9712761|FG002|Overall Study|Lost to Follow-up|0
6098123|NCT00740792|9712762|FG003|Overall Study|Lost to Follow-up|0
6098124|NCT00740792|9712759|FG000|Overall Study|Protocol Violation|0
6098125|NCT00740792|9712760|FG001|Overall Study|Protocol Violation|1
6098126|NCT00740792|9712761|FG002|Overall Study|Protocol Violation|0
6098127|NCT00740792|9712762|FG003|Overall Study|Protocol Violation|2
6098128|NCT00740792|9712759|FG000|Overall Study|Withdrawal by Subject|1
6098129|NCT00740792|9712760|FG001|Overall Study|Withdrawal by Subject|1
6098130|NCT00740792|9712761|FG002|Overall Study|Withdrawal by Subject|0
6098131|NCT00740792|9712762|FG003|Overall Study|Withdrawal by Subject|0
6098132|NCT00740792|9712759|FG000|Overall Study|administrative|3
6098133|NCT00740792|9712760|FG001|Overall Study|administrative|3
6098134|NCT00740792|9712761|FG002|Overall Study|administrative|8
6098135|NCT00740792|9712762|FG003|Overall Study|administrative|2
6098136|NCT00740857|9712788|FG000|Overall Study|Withdrawal by Subject|1
6098137|NCT00740857|9712789|FG001|Overall Study|Withdrawal by Subject|0
6098138|NCT00740857|9712790|FG002|Overall Study|Withdrawal by Subject|0
6098139|NCT00740870|9712798|FG000|Overall Study|Not Catheterized|4
6098140|NCT00740870|9712798|FG000|Overall Study|Further testing contraindicated implant|17
6098141|NCT00741013|9712808|FG000|Overall Study|Adverse Event|1
6098142|NCT00741013|9712809|FG001|Overall Study|Adverse Event|0
6098143|NCT00741013|9712810|FG002|Overall Study|Adverse Event|0
6098144|NCT00741013|9712808|FG000|Overall Study|Withdrawal by Subject|0
6098145|NCT00741013|9712809|FG001|Overall Study|Withdrawal by Subject|0
6098146|NCT00741013|9712810|FG002|Overall Study|Withdrawal by Subject|1
6098147|NCT00741013|9712808|FG000|Overall Study|Discovered failed screen after enrolled|0
6098148|NCT00741013|9712809|FG001|Overall Study|Discovered failed screen after enrolled|2
6098149|NCT00741013|9712810|FG002|Overall Study|Discovered failed screen after enrolled|0
6098150|NCT00741039|9712826|FG000|Overall Study|Patient non-compliance|2
6098151|NCT00741039|9712827|FG001|Overall Study|Patient non-compliance|0
6203703|NCT01516008|9864836|FG000|Overall Study|Adverse Event|0
6203704|NCT01516008|9864837|FG001|Overall Study|Adverse Event|2
6203705|NCT01516008|9864838|FG002|Overall Study|Adverse Event|7
6203706|NCT01516008|9864836|FG000|Overall Study|Lack of Efficacy|44
6203707|NCT01516008|9864837|FG001|Overall Study|Lack of Efficacy|14
6203708|NCT01516008|9864838|FG002|Overall Study|Lack of Efficacy|10
6203709|NCT01516008|9864836|FG000|Overall Study|Protocol Violation|1
6203710|NCT01516008|9864837|FG001|Overall Study|Protocol Violation|0
6203711|NCT01516008|9864838|FG002|Overall Study|Protocol Violation|0
6203712|NCT01516008|9864836|FG000|Overall Study|Reason not specified|0
6203713|NCT01516008|9864837|FG001|Overall Study|Reason not specified|0
6203714|NCT01516008|9864838|FG002|Overall Study|Reason not specified|1
6203715|NCT01516437|9864868|FG000|Overall Study|Reason not specified|0
6203716|NCT01516437|9864869|FG001|Overall Study|Reason not specified|0
6203717|NCT01516437|9864870|FG002|Overall Study|Reason not specified|1
6203718|NCT01516437|9864871|FG003|Overall Study|Reason not specified|1
6203719|NCT01516736|9864907|FG000|Overall Study|Withdrawal by Subject|10
6203720|NCT01516736|9864908|FG001|Overall Study|Withdrawal by Subject|4
6203721|NCT01516736|9864907|FG000|Overall Study|Adverse Event|4
6203722|NCT01516736|9864908|FG001|Overall Study|Adverse Event|5
6203723|NCT01516736|9864907|FG000|Overall Study|Death|3
6203724|NCT01516736|9864908|FG001|Overall Study|Death|1
6203725|NCT01516736|9864907|FG000|Overall Study|Physician Decision|2
6203726|NCT01516736|9864908|FG001|Overall Study|Physician Decision|1
6203727|NCT01516736|9864907|FG000|Overall Study|Lack of Efficacy|1
6203728|NCT01516736|9864908|FG001|Overall Study|Lack of Efficacy|0
6203729|NCT01516736|9864907|FG000|Overall Study|Protocol Violation|0
6203730|NCT01516736|9864908|FG001|Overall Study|Protocol Violation|1
6203731|NCT01516736|9864907|FG000|Overall Study|Other (not specified)|0
6203732|NCT01516736|9864908|FG001|Overall Study|Other (not specified)|1
6203733|NCT01516749|9864914|FG000|Active Therapy|Lost to Follow-up|1
6203734|NCT01516749|9864914|FG000|Follow-up Off Therapy|Lost to Follow-up|1
6203735|NCT01516879|9864920|FG000|Overall Study|Withdrawal by Subject|9
6203736|NCT01516879|9864921|FG001|Overall Study|Withdrawal by Subject|11
6203737|NCT01516879|9864920|FG000|Overall Study|Death|0
6203738|NCT01516879|9864921|FG001|Overall Study|Death|2
6203739|NCT01516879|9864920|FG000|Overall Study|Lost to Follow-up|2
6203740|NCT01516879|9864921|FG001|Overall Study|Lost to Follow-up|11
6203741|NCT01516879|9864920|FG000|Overall Study|Other|5
6203742|NCT01516879|9864921|FG001|Overall Study|Other|10
6203743|NCT01516892|9864927|FG000|Overall Study|Adverse Event|25
6203744|NCT01516892|9864927|FG000|Overall Study|Lack of Efficacy|35
6203745|NCT01516892|9864927|FG000|Overall Study|Pregnancy|5
6203746|NCT01516892|9864927|FG000|Overall Study|Lost to Follow-up|82
6203747|NCT01516892|9864927|FG000|Overall Study|Subject Withdrew Consent|92
6203748|NCT01516892|9864927|FG000|Overall Study|Protocol Violation|60
6203749|NCT01516892|9864927|FG000|Overall Study|Other Miscellaneous Reasons|43
6203750|NCT01516892|9864927|FG000|Overall Study|Missing|1
6203751|NCT01516970|9864948|FG000|Overall Study|Lost to Follow-up|7
6203752|NCT01516970|9864949|FG001|Overall Study|Lost to Follow-up|8
6203753|NCT01516970|9864948|FG000|Overall Study|Adverse Event|1
6203754|NCT01516970|9864949|FG001|Overall Study|Adverse Event|5
6203755|NCT01516970|9864948|FG000|Overall Study|Withdrawal by Subject|1
6203756|NCT01516970|9864949|FG001|Overall Study|Withdrawal by Subject|1
6203757|NCT01516970|9864948|FG000|Overall Study|Other|9
6203758|NCT01516970|9864949|FG001|Overall Study|Other|7
6203759|NCT01517178|9864964|FG000|Period 1|Adverse Event|1
6203760|NCT01517178|9864965|FG001|Period 1|Adverse Event|2
6203761|NCT01517178|9864964|FG000|Period 1|Lack of Efficacy|0
6203762|NCT01517178|9864965|FG001|Period 1|Lack of Efficacy|1
6203763|NCT01517178|9864964|FG000|Period 1|E.g. study termination|3
6203764|NCT01517178|9864965|FG001|Period 1|E.g. study termination|1
6203765|NCT01517178|9864964|FG000|Period 1|Withdrawal by Subject|0
6203766|NCT01517178|9864965|FG001|Period 1|Withdrawal by Subject|1
6203767|NCT01517178|9864964|FG000|Period 2|Adverse Event|1
6203768|NCT01517178|9864965|FG001|Period 2|Adverse Event|0
6098152|NCT00741091|9712833|FG000|Overall Study|Death|13
6098153|NCT00741091|9712833|FG000|Overall Study|Lost to Follow-up|16
6098154|NCT00741091|9712833|FG000|Overall Study|Withdrawal by Subject|6
6098155|NCT00741091|9712833|FG000|Overall Study|Missed Visit|22
6098156|NCT00741260|9712863|FG000|Overall Study|Disease Progression|3
6098157|NCT00741260|9712864|FG001|Overall Study|Disease Progression|5
6098158|NCT00741260|9712865|FG002|Overall Study|Disease Progression|3
6098159|NCT00741260|9712866|FG003|Overall Study|Disease Progression|3
6098160|NCT00741260|9712867|FG004|Overall Study|Disease Progression|5
6098161|NCT00741260|9712868|FG005|Overall Study|Disease Progression|37
6098162|NCT00741260|9712869|FG006|Overall Study|Disease Progression|4
6098163|NCT00741260|9712863|FG000|Overall Study|Death|0
6098164|NCT00741260|9712864|FG001|Overall Study|Death|1
6098165|NCT00741260|9712865|FG002|Overall Study|Death|0
6098166|NCT00741260|9712866|FG003|Overall Study|Death|1
6098167|NCT00741260|9712867|FG004|Overall Study|Death|2
6098168|NCT00741260|9712868|FG005|Overall Study|Death|2
6098169|NCT00741260|9712869|FG006|Overall Study|Death|1
6098170|NCT00741260|9712863|FG000|Overall Study|Withdrawal by Subject|0
6098171|NCT00741260|9712864|FG001|Overall Study|Withdrawal by Subject|0
6098172|NCT00741260|9712865|FG002|Overall Study|Withdrawal by Subject|0
6098173|NCT00741260|9712866|FG003|Overall Study|Withdrawal by Subject|0
6098174|NCT00741260|9712867|FG004|Overall Study|Withdrawal by Subject|1
6098175|NCT00741260|9712868|FG005|Overall Study|Withdrawal by Subject|3
6098176|NCT00741260|9712869|FG006|Overall Study|Withdrawal by Subject|1
6098177|NCT00741260|9712863|FG000|Overall Study|Physician Decision|1
6098178|NCT00741260|9712864|FG001|Overall Study|Physician Decision|1
6203769|NCT01517178|9864964|FG000|Period 2|Withdrawal by Subject|3
6203770|NCT01517178|9864965|FG001|Period 2|Withdrawal by Subject|0
6203771|NCT01517178|9864964|FG000|Period 2|E.g. study termination|2
6203772|NCT01517178|9864965|FG001|Period 2|E.g. study termination|2
6203773|NCT01517282|9864975|FG000|Overall Study|Consent withdrawn|0
6098179|NCT00741260|9712865|FG002|Overall Study|Physician Decision|0
6098180|NCT00741260|9712866|FG003|Overall Study|Physician Decision|0
6098181|NCT00741260|9712867|FG004|Overall Study|Physician Decision|0
6098182|NCT00741260|9712868|FG005|Overall Study|Physician Decision|0
6098183|NCT00741260|9712869|FG006|Overall Study|Physician Decision|0
6098184|NCT00741260|9712863|FG000|Overall Study|Other|2
6098185|NCT00741260|9712864|FG001|Overall Study|Other|1
6098186|NCT00741260|9712865|FG002|Overall Study|Other|1
6098187|NCT00741260|9712866|FG003|Overall Study|Other|2
6098188|NCT00741260|9712867|FG004|Overall Study|Other|1
6098189|NCT00741260|9712868|FG005|Overall Study|Other|3
6098190|NCT00741260|9712869|FG006|Overall Study|Other|1
6098191|NCT00741286|9712905|FG000|Overall Study|Lost to Follow-up|15
6098192|NCT00741286|9712906|FG001|Overall Study|Lost to Follow-up|10
6098193|NCT00741286|9712905|FG000|Overall Study|Adverse Event|1
6098194|NCT00741286|9712906|FG001|Overall Study|Adverse Event|6
6098195|NCT00741286|9712905|FG000|Overall Study|Protocol Violation|3
6098196|NCT00741286|9712906|FG001|Overall Study|Protocol Violation|2
6098197|NCT00741286|9712905|FG000|Overall Study|Primary Outcome|1
6098198|NCT00741286|9712906|FG001|Overall Study|Primary Outcome|1
6098199|NCT00741338|9712914|FG000|Overall Study|Adverse Event|0
6098200|NCT00741338|9712915|FG001|Overall Study|Adverse Event|1
6098201|NCT00741598|9712957|FG000|Overall Study|Lost to Follow-up|3
6098202|NCT00741598|9712958|FG001|Overall Study|Lost to Follow-up|4
6098203|NCT00741598|9712957|FG000|Overall Study|Lack of Efficacy|1
6098204|NCT00741598|9712958|FG001|Overall Study|Lack of Efficacy|2
6098205|NCT00741598|9712957|FG000|Overall Study|Physician Decision|1
6098206|NCT00741598|9712958|FG001|Overall Study|Physician Decision|1
6098207|NCT00741598|9712957|FG000|Overall Study|Pregnancy|1
6098208|NCT00741598|9712958|FG001|Overall Study|Pregnancy|0
6098209|NCT00741598|9712957|FG000|Overall Study|Withdrawal by Subject|3
6098210|NCT00741598|9712958|FG001|Overall Study|Withdrawal by Subject|2
6098211|NCT00741611|9712968|FG000|Overall Study|Death|0
6098212|NCT00741611|9712969|FG001|Overall Study|Death|0
6098213|NCT00741611|9712970|FG002|Overall Study|Death|1
6098214|NCT00741611|9712968|FG000|Overall Study|Withdrawal by Subject|0
6098215|NCT00741611|9712969|FG001|Overall Study|Withdrawal by Subject|2
6098216|NCT00741611|9712970|FG002|Overall Study|Withdrawal by Subject|2
6098217|NCT00741819|9712979|FG000|Overall Study|Adverse Event|3
6098218|NCT00741819|9712979|FG000|Overall Study|Withdrawal by Subject|3
6098219|NCT00741819|9712979|FG000|Overall Study|Death|1
6098220|NCT00741819|9712979|FG000|Overall Study|Disease progression|1
6098221|NCT00741936|9712996|FG000|Overall Study|Lost to Follow-up|1
6098222|NCT00741936|9712997|FG001|Overall Study|Lost to Follow-up|1
6098223|NCT00741936|9712996|FG000|Overall Study|Adverse Event|3
6098224|NCT00741936|9712997|FG001|Overall Study|Adverse Event|4
6098225|NCT00741936|9712996|FG000|Overall Study|Pregnancy|0
6098226|NCT00741936|9712997|FG001|Overall Study|Pregnancy|1
6098227|NCT00741936|9712996|FG000|Overall Study|Protocol Violation|2
6098228|NCT00741936|9712997|FG001|Overall Study|Protocol Violation|0
6098229|NCT00741936|9712996|FG000|Overall Study|Lack of Efficacy|0
6098230|NCT00741936|9712997|FG001|Overall Study|Lack of Efficacy|2
6098231|NCT00741936|9712996|FG000|Overall Study|Low compliance|3
6098232|NCT00741936|9712997|FG001|Overall Study|Low compliance|0
6098233|NCT00742001|9713006|FG000|Overall Study|Withdrawn; health exclusion (flu)|0
6203774|NCT01517282|9864976|FG001|Overall Study|Consent withdrawn|1
6203775|NCT01517282|9864977|FG002|Overall Study|Consent withdrawn|1
6098234|NCT00742001|9713007|FG001|Overall Study|Withdrawn; health exclusion (flu)|0
6098235|NCT00742001|9713008|FG002|Overall Study|Withdrawn; health exclusion (flu)|1
6098236|NCT00742027|9713019|FG000|Overall Study|Disease Progression|76
6098237|NCT00742027|9713019|FG000|Overall Study|New Cancer Therapy|19
6098238|NCT00742027|9713019|FG000|Overall Study|Withdrawal by Subject|18
6098239|NCT00742027|9713019|FG000|Overall Study|Death|7
6098240|NCT00742027|9713019|FG000|Overall Study|Lost to Follow-up|4
6098241|NCT00742027|9713019|FG000|Overall Study|Follow up Phase Completed As Per Protocol|2
6098242|NCT00742027|9713019|FG000|Overall Study|Missing|2
6098243|NCT00742027|9713019|FG000|Overall Study|Administrative Problems|1
6098244|NCT00742079|9713029|FG000|Overall Study|Lost to Follow-up|0
6098245|NCT00742079|9713030|FG001|Overall Study|Lost to Follow-up|1
6098246|NCT00742183|9713047|FG000|Overall Study|Adverse Event|2
6098247|NCT00742183|9713048|FG001|Overall Study|Adverse Event|2
6098248|NCT00742183|9713047|FG000|Overall Study|Death|1
6098249|NCT00742183|9713048|FG001|Overall Study|Death|0
6098250|NCT00742183|9713047|FG000|Overall Study|Physician Decision|0
6098251|NCT00742183|9713048|FG001|Overall Study|Physician Decision|2
6098252|NCT00742183|9713047|FG000|Overall Study|Lost to Follow-up|4
6098253|NCT00742183|9713048|FG001|Overall Study|Lost to Follow-up|4
6098254|NCT00742183|9713047|FG000|Overall Study|Required skin-graft|1
6098255|NCT00742183|9713048|FG001|Overall Study|Required skin-graft|1
6098256|NCT00742183|9713047|FG000|Overall Study|Withdrawal by Subject|1
6098257|NCT00742183|9713048|FG001|Overall Study|Withdrawal by Subject|0
6098258|NCT00742183|9713047|FG000|Overall Study|Lack of Efficacy|0
6098259|NCT00742183|9713048|FG001|Overall Study|Lack of Efficacy|3
6098260|NCT00742209|9713059|FG000|Overall Study|Adverse Event|11
6098261|NCT00742209|9713060|FG001|Overall Study|Adverse Event|4
6098262|NCT00742209|9713061|FG002|Overall Study|Adverse Event|17
6098263|NCT00742209|9713062|FG003|Overall Study|Adverse Event|16
6098264|NCT00742209|9713063|FG004|Overall Study|Adverse Event|13
6098265|NCT00742209|9713059|FG000|Overall Study|Participant Withdrew Consent|8
6098266|NCT00742209|9713060|FG001|Overall Study|Participant Withdrew Consent|4
6098267|NCT00742209|9713061|FG002|Overall Study|Participant Withdrew Consent|14
6098268|NCT00742209|9713062|FG003|Overall Study|Participant Withdrew Consent|7
6098269|NCT00742209|9713063|FG004|Overall Study|Participant Withdrew Consent|4
6098270|NCT00742209|9713059|FG000|Overall Study|Protocol Violation|6
6098271|NCT00742209|9713060|FG001|Overall Study|Protocol Violation|5
6098272|NCT00742209|9713061|FG002|Overall Study|Protocol Violation|4
6098273|NCT00742209|9713062|FG003|Overall Study|Protocol Violation|5
6098274|NCT00742209|9713063|FG004|Overall Study|Protocol Violation|3
6098275|NCT00742209|9713059|FG000|Overall Study|Lost to Follow-up|3
6098276|NCT00742209|9713060|FG001|Overall Study|Lost to Follow-up|4
6098277|NCT00742209|9713061|FG002|Overall Study|Lost to Follow-up|5
6098278|NCT00742209|9713062|FG003|Overall Study|Lost to Follow-up|5
6098279|NCT00742209|9713063|FG004|Overall Study|Lost to Follow-up|3
6098280|NCT00742209|9713059|FG000|Overall Study|Lack of Efficacy|6
6098281|NCT00742209|9713060|FG001|Overall Study|Lack of Efficacy|1
6098282|NCT00742209|9713061|FG002|Overall Study|Lack of Efficacy|1
6098283|NCT00742209|9713062|FG003|Overall Study|Lack of Efficacy|3
6098284|NCT00742209|9713063|FG004|Overall Study|Lack of Efficacy|1
6098285|NCT00742209|9713059|FG000|Overall Study|Investigator Discretion|0
6098286|NCT00742209|9713060|FG001|Overall Study|Investigator Discretion|0
6098287|NCT00742209|9713061|FG002|Overall Study|Investigator Discretion|5
6098288|NCT00742209|9713062|FG003|Overall Study|Investigator Discretion|1
6098289|NCT00742209|9713063|FG004|Overall Study|Investigator Discretion|1
6098290|NCT00742235|9713078|FG000|Overall Study|Lost to Follow-up|0
6098291|NCT00742235|9713079|FG001|Overall Study|Lost to Follow-up|31
6098292|NCT00742274|9713087|FG000|Overall Study|Death|1
6098293|NCT00742274|9713088|FG001|Overall Study|Death|0
6098294|NCT00742274|9713087|FG000|Overall Study|Withdrawal by Subject|1
6098295|NCT00742274|9713088|FG001|Overall Study|Withdrawal by Subject|2
6098296|NCT00742274|9713087|FG000|Overall Study|Removed for medical reasons|1
6098297|NCT00742274|9713088|FG001|Overall Study|Removed for medical reasons|1
6098298|NCT00742326|9713105|FG000|Overall Study|Physician Decision|0
6098299|NCT00742326|9713106|FG001|Overall Study|Physician Decision|1
6098300|NCT00742391|9713114|FG000|Overall Study|Adverse Event|2
6098301|NCT00742391|9713115|FG001|Overall Study|Adverse Event|1
6098302|NCT00742391|9713114|FG000|Overall Study|Lost to Follow-up|1
6098303|NCT00742391|9713115|FG001|Overall Study|Lost to Follow-up|0
6098304|NCT00742391|9713114|FG000|Overall Study|Protocol Violation|1
6098305|NCT00742391|9713115|FG001|Overall Study|Protocol Violation|0
6098306|NCT00742417|9713123|FG000|Randomized|Withdrawal by legal representative|0
6098307|NCT00742417|9713124|FG001|Randomized|Withdrawal by legal representative|1
6098308|NCT00742417|9713123|FG000|Randomized|Withdrawal by Subject|1
6098309|NCT00742417|9713124|FG001|Randomized|Withdrawal by Subject|0
6098310|NCT00742417|9713123|FG000|Randomized|Physician Decision|1
6098311|NCT00742417|9713124|FG001|Randomized|Physician Decision|0
6098312|NCT00742417|9713123|FG000|Intensive Period|Withdrawal by Subject|1
6098313|NCT00742417|9713124|FG001|Intensive Period|Withdrawal by Subject|1
6098314|NCT00742417|9713123|FG000|Intensive Period|Adverse Event|2
6098315|NCT00742417|9713124|FG001|Intensive Period|Adverse Event|0
6098316|NCT00742508|9713143|FG000|8-Week Primary Evaluation Period|Adverse Event|2
6098317|NCT00742508|9713144|FG001|8-Week Primary Evaluation Period|Adverse Event|4
6098318|NCT00742508|9713143|FG000|8-Week Primary Evaluation Period|Protocol Violation|1
6098319|NCT00742508|9713144|FG001|8-Week Primary Evaluation Period|Protocol Violation|0
6098320|NCT00742508|9713143|FG000|8-Week Primary Evaluation Period|Met Protocol-defined Stopping Criteria|8
6098321|NCT00742508|9713144|FG001|8-Week Primary Evaluation Period|Met Protocol-defined Stopping Criteria|5
6098322|NCT00742508|9713143|FG000|8-Week Primary Evaluation Period|Withdrawal by Subject|0
6098323|NCT00742508|9713144|FG001|8-Week Primary Evaluation Period|Withdrawal by Subject|2
6098324|NCT00742508|9713143|FG000|4-Week Exploratory Evaluation Period|Met Protocol-defined Stopping Criteria|0
6098325|NCT00742508|9713144|FG001|4-Week Exploratory Evaluation Period|Met Protocol-defined Stopping Criteria|1
6098326|NCT00742560|9713155|FG000|Overall Study|Adverse Event|0
6098327|NCT00742560|9713156|FG001|Overall Study|Adverse Event|0
6098328|NCT00742560|9713157|FG002|Overall Study|Adverse Event|1
6098329|NCT00742560|9713158|FG003|Overall Study|Adverse Event|1
6098330|NCT00742560|9713159|FG004|Overall Study|Adverse Event|1
6098331|NCT00742560|9713155|FG000|Overall Study|Death|0
6098332|NCT00742560|9713156|FG001|Overall Study|Death|2
6098333|NCT00742560|9713157|FG002|Overall Study|Death|0
6098334|NCT00742560|9713158|FG003|Overall Study|Death|2
6098335|NCT00742560|9713159|FG004|Overall Study|Death|3
6098336|NCT00742560|9713155|FG000|Overall Study|Subject's Decision|1
6098337|NCT00742560|9713156|FG001|Overall Study|Subject's Decision|0
6098338|NCT00742560|9713157|FG002|Overall Study|Subject's Decision|2
6098339|NCT00742560|9713158|FG003|Overall Study|Subject's Decision|3
6098340|NCT00742560|9713159|FG004|Overall Study|Subject's Decision|3
6098341|NCT00742560|9713155|FG000|Overall Study|Investigator's Decision|0
6098342|NCT00742560|9713156|FG001|Overall Study|Investigator's Decision|0
6098343|NCT00742560|9713157|FG002|Overall Study|Investigator's Decision|4
6098344|NCT00742560|9713158|FG003|Overall Study|Investigator's Decision|1
6098345|NCT00742560|9713159|FG004|Overall Study|Investigator's Decision|0
6098346|NCT00742560|9713155|FG000|Overall Study|Disease Progression|1
6098347|NCT00742560|9713156|FG001|Overall Study|Disease Progression|0
6098348|NCT00742560|9713157|FG002|Overall Study|Disease Progression|5
6098349|NCT00742560|9713158|FG003|Overall Study|Disease Progression|17
6098350|NCT00742560|9713159|FG004|Overall Study|Disease Progression|16
6098351|NCT00742560|9713155|FG000|Overall Study|New Multiple Myeloma Therapy|1
6098352|NCT00742560|9713156|FG001|Overall Study|New Multiple Myeloma Therapy|0
6098353|NCT00742560|9713157|FG002|Overall Study|New Multiple Myeloma Therapy|2
6098354|NCT00742560|9713158|FG003|Overall Study|New Multiple Myeloma Therapy|3
6098355|NCT00742560|9713159|FG004|Overall Study|New Multiple Myeloma Therapy|4
6098356|NCT00742560|9713155|FG000|Overall Study|Other|0
6098357|NCT00742560|9713156|FG001|Overall Study|Other|1
6098358|NCT00742560|9713157|FG002|Overall Study|Other|8
6098359|NCT00742560|9713158|FG003|Overall Study|Other|9
6098360|NCT00742560|9713159|FG004|Overall Study|Other|9
6098361|NCT00742560|9713155|FG000|Overall Study|MIssing|0
6098362|NCT00742560|9713156|FG001|Overall Study|MIssing|0
6098363|NCT00742560|9713157|FG002|Overall Study|MIssing|0
6098364|NCT00742560|9713158|FG003|Overall Study|MIssing|0
6098365|NCT00742560|9713159|FG004|Overall Study|MIssing|1
6098366|NCT00742625|9713199|FG000|Remission Induction|Progression|6
6098367|NCT00742625|9713199|FG000|Remission Induction|Failed induction|8
6098368|NCT00742625|9713199|FG000|Remission Induction|Adverse Event|3
6098369|NCT00742625|9713199|FG000|Remission Induction|Death|10
6098370|NCT00742625|9713199|FG000|Remission Induction|Refusal|5
6098371|NCT00742625|9713199|FG000|Remission Induction|Non protocol treatment|17
6098372|NCT00742625|9713199|FG000|Remission Induction|Other, not specified|5
6098373|NCT00742625|9713199|FG000|Consolidation|Progression|5
6098374|NCT00742625|9713199|FG000|Consolidation|Adverse Event|1
6098375|NCT00742625|9713199|FG000|Consolidation|Death|1
6098376|NCT00742625|9713199|FG000|Consolidation|Refused|1
6098377|NCT00742625|9713199|FG000|Consolidation|Non protocol therapy|13
6098378|NCT00742781|9713206|FG000|Overall Study|Withdrawal by Subject|3
6098379|NCT00742859|9713215|FG000|Overall Study|Adverse Event|5
6098380|NCT00742859|9713216|FG001|Overall Study|Adverse Event|6
6098381|NCT00742859|9713217|FG002|Overall Study|Adverse Event|3
6098382|NCT00742859|9713218|FG003|Overall Study|Adverse Event|1
6098383|NCT00742859|9713215|FG000|Overall Study|Death|1
6098384|NCT00742859|9713216|FG001|Overall Study|Death|0
6098385|NCT00742859|9713217|FG002|Overall Study|Death|0
6098386|NCT00742859|9713218|FG003|Overall Study|Death|1
6098387|NCT00742859|9713215|FG000|Overall Study|Physician Decision|1
6098388|NCT00742859|9713216|FG001|Overall Study|Physician Decision|2
6098389|NCT00742859|9713217|FG002|Overall Study|Physician Decision|0
6098390|NCT00742859|9713218|FG003|Overall Study|Physician Decision|0
6098391|NCT00742859|9713215|FG000|Overall Study|Withdrawal by Subject|4
6098392|NCT00742859|9713216|FG001|Overall Study|Withdrawal by Subject|2
6098393|NCT00742859|9713217|FG002|Overall Study|Withdrawal by Subject|4
6098394|NCT00742859|9713218|FG003|Overall Study|Withdrawal by Subject|1
6098395|NCT00742859|9713215|FG000|Overall Study|Endpoint|0
6098396|NCT00742859|9713216|FG001|Overall Study|Endpoint|1
6098397|NCT00742859|9713217|FG002|Overall Study|Endpoint|1
6098398|NCT00742859|9713218|FG003|Overall Study|Endpoint|2
6098399|NCT00742859|9713215|FG000|Overall Study|Amendment 2 patient off study drug >4wks|0
6098400|NCT00742859|9713216|FG001|Overall Study|Amendment 2 patient off study drug >4wks|1
6098401|NCT00742859|9713217|FG002|Overall Study|Amendment 2 patient off study drug >4wks|1
6098402|NCT00742859|9713218|FG003|Overall Study|Amendment 2 patient off study drug >4wks|0
6098403|NCT00742859|9713215|FG000|Overall Study|Sponsor req visit schedule noncompliance|0
6098404|NCT00742859|9713216|FG001|Overall Study|Sponsor req visit schedule noncompliance|0
6098405|NCT00742859|9713217|FG002|Overall Study|Sponsor req visit schedule noncompliance|0
6098406|NCT00742859|9713218|FG003|Overall Study|Sponsor req visit schedule noncompliance|1
6098407|NCT00742859|9713215|FG000|Overall Study|Sponsor request patient out of town|0
6098408|NCT00742859|9713216|FG001|Overall Study|Sponsor request patient out of town|0
6098409|NCT00742859|9713217|FG002|Overall Study|Sponsor request patient out of town|1
6098410|NCT00742859|9713218|FG003|Overall Study|Sponsor request patient out of town|1
6098411|NCT00742859|9713215|FG000|Overall Study|Site error|0
6098412|NCT00742859|9713216|FG001|Overall Study|Site error|0
6098413|NCT00742859|9713217|FG002|Overall Study|Site error|1
6098414|NCT00742859|9713218|FG003|Overall Study|Site error|1
6098415|NCT00742885|9713239|FG000|Overall Study|Lost to Follow-up|1
6098416|NCT00742885|9713240|FG001|Overall Study|Lost to Follow-up|0
6098417|NCT00742924|9713253|FG000|Overall Study|Adverse Event|0
6098418|NCT00742924|9713254|FG001|Overall Study|Adverse Event|0
6098419|NCT00742924|9713255|FG002|Overall Study|Adverse Event|1
6098420|NCT00742924|9713256|FG003|Overall Study|Adverse Event|1
6098421|NCT00742924|9713253|FG000|Overall Study|Lack of Efficacy|5
6098422|NCT00742924|9713254|FG001|Overall Study|Lack of Efficacy|1
6098423|NCT00742924|9713255|FG002|Overall Study|Lack of Efficacy|2
6098424|NCT00742924|9713256|FG003|Overall Study|Lack of Efficacy|4
6098425|NCT00742924|9713253|FG000|Overall Study|Physician Decision|0
6098426|NCT00742924|9713254|FG001|Overall Study|Physician Decision|0
6098427|NCT00742924|9713255|FG002|Overall Study|Physician Decision|0
6098428|NCT00742924|9713256|FG003|Overall Study|Physician Decision|1
6098429|NCT00742924|9713253|FG000|Overall Study|Withdrawal by Subject|0
6098430|NCT00742924|9713254|FG001|Overall Study|Withdrawal by Subject|1
6098431|NCT00742924|9713255|FG002|Overall Study|Withdrawal by Subject|1
6098432|NCT00742924|9713256|FG003|Overall Study|Withdrawal by Subject|0
6098433|NCT00743106|9713281|FG000|Overall Study|Met intraoperative exclusion criterion|8
6098434|NCT00743106|9713282|FG001|Overall Study|Met intraoperative exclusion criterion|5
6098435|NCT00743119|9713288|FG000|Overall Study|unreliable|3
6098436|NCT00743119|9713288|FG000|Overall Study|Withdrawal by Subject|1
6098437|NCT00743145|9713300|FG000|Overall Study|Withdrawal by Subject|1
6098438|NCT00743145|9713300|FG000|Overall Study|Adverse Event|2
6098439|NCT00743145|9713300|FG000|Overall Study|Pregnancy|1
6098440|NCT00743249|9713316|FG000|Overall Study|Adverse Event|0
6098441|NCT00743249|9713317|FG001|Overall Study|Adverse Event|4
6098442|NCT00743249|9713316|FG000|Overall Study|Patient Decision Unrelated to Ad Event|0
6098443|NCT00743249|9713317|FG001|Overall Study|Patient Decision Unrelated to Ad Event|1
6098444|NCT00743249|9713316|FG000|Overall Study|Unsuccessful insertion of stent|2
6098445|NCT00743249|9713317|FG001|Overall Study|Unsuccessful insertion of stent|1
6098446|NCT00743275|9713329|FG000|Overall Study|Protocol Violation|0
6098447|NCT00743275|9713330|FG001|Overall Study|Protocol Violation|1
6098448|NCT00743288|9713336|FG000|Overall Study|Adverse Event|1
6098449|NCT00743288|9713337|FG001|Overall Study|Adverse Event|1
6098450|NCT00743288|9713338|FG002|Overall Study|Adverse Event|2
6098451|NCT00743288|9713339|FG003|Overall Study|Adverse Event|2
6098452|NCT00743288|9713340|FG004|Overall Study|Adverse Event|1
6098453|NCT00743288|9713341|FG005|Overall Study|Adverse Event|1
6098454|NCT00743288|9713342|FG006|Overall Study|Adverse Event|2
6098455|NCT00743288|9713336|FG000|Overall Study|Withdrawal by Subject|0
6098456|NCT00743288|9713337|FG001|Overall Study|Withdrawal by Subject|0
6098457|NCT00743288|9713338|FG002|Overall Study|Withdrawal by Subject|1
6098458|NCT00743288|9713339|FG003|Overall Study|Withdrawal by Subject|0
6098459|NCT00743288|9713340|FG004|Overall Study|Withdrawal by Subject|0
6098460|NCT00743288|9713341|FG005|Overall Study|Withdrawal by Subject|1
6098461|NCT00743288|9713342|FG006|Overall Study|Withdrawal by Subject|1
6098462|NCT00743288|9713336|FG000|Overall Study|Progressive disease (PD)|2
6098463|NCT00743288|9713337|FG001|Overall Study|Progressive disease (PD)|0
6098464|NCT00743288|9713338|FG002|Overall Study|Progressive disease (PD)|1
6098465|NCT00743288|9713339|FG003|Overall Study|Progressive disease (PD)|4
6098466|NCT00743288|9713340|FG004|Overall Study|Progressive disease (PD)|5
6098467|NCT00743288|9713341|FG005|Overall Study|Progressive disease (PD)|3
6098468|NCT00743288|9713342|FG006|Overall Study|Progressive disease (PD)|6
6098469|NCT00743288|9713336|FG000|Overall Study|Worsening of condition (Not PD)|0
6098470|NCT00743288|9713337|FG001|Overall Study|Worsening of condition (Not PD)|2
6098471|NCT00743288|9713338|FG002|Overall Study|Worsening of condition (Not PD)|1
6098472|NCT00743288|9713339|FG003|Overall Study|Worsening of condition (Not PD)|1
6098473|NCT00743288|9713340|FG004|Overall Study|Worsening of condition (Not PD)|0
6098474|NCT00743288|9713341|FG005|Overall Study|Worsening of condition (Not PD)|0
6098475|NCT00743288|9713342|FG006|Overall Study|Worsening of condition (Not PD)|0
6098476|NCT00743340|9713353|FG000|Overall Study|Study medication non-compliance|1
6098477|NCT00743340|9713353|FG000|Overall Study|Lost to Follow-up|1
6098478|NCT00743340|9713353|FG000|Overall Study|Withdrawal from the Study|5
6098479|NCT00743340|9713353|FG000|Overall Study|Protocol Violation|1
6098480|NCT00743340|9713353|FG000|Overall Study|Virologic failure|8
6098481|NCT00743340|9713353|FG000|Overall Study|Pregnancy|1
6098482|NCT00743340|9713353|FG000|Overall Study|Rolled over to other Gilead Study|23
6098483|NCT00743340|9713353|FG000|Overall Study|Participant Relocated|1
6098484|NCT00743366|9713357|FG000|Intervention 1 (8 Days)|Withdrawal by Subject|3
6098485|NCT00743366|9713358|FG001|Intervention 1 (8 Days)|Withdrawal by Subject|3
6098486|NCT00743431|9713364|FG000|Overall Study|Toxicity|6
6098487|NCT00743431|9713364|FG000|Overall Study|Tumor progression|56
6098488|NCT00743431|9713364|FG000|Overall Study|Withdrawal by Subject|13
6098489|NCT00743431|9713364|FG000|Overall Study|Death|9
6098490|NCT00743431|9713364|FG000|Overall Study|Reason for discontinuation not specified|29
6098491|NCT00743431|9713364|FG000|Overall Study|No documentation available|13
6098492|NCT00743444|9713368|FG000|First Intervention|Catheter placement problems|0
6098493|NCT00743444|9713369|FG001|First Intervention|Catheter placement problems|1
6098494|NCT00743444|9713368|FG000|Washout Period|Adverse Event|0
6098495|NCT00743444|9713369|FG001|Washout Period|Adverse Event|1
6098496|NCT00743483|9713375|FG000|Baseline Period|Physician Decision|1
6098497|NCT00743483|9713375|FG000|Treatment Period|Adverse Event|1
6098498|NCT00743509|9713379|FG000|Overall Study|Withdrawal by Subject|2
6098499|NCT00743652|9713392|FG000|Overall Study|Parent/Legal Guardian Request|3
6098500|NCT00743652|9713393|FG001|Overall Study|Parent/Legal Guardian Request|2
6098501|NCT00743652|9713394|FG002|Overall Study|Parent/Legal Guardian Request|2
6098502|NCT00743652|9713395|FG003|Overall Study|Parent/Legal Guardian Request|2
6098503|NCT00743652|9713396|FG004|Overall Study|Parent/Legal Guardian Request|0
6098504|NCT00743652|9713392|FG000|Overall Study|Adverse Event|3
6098505|NCT00743652|9713393|FG001|Overall Study|Adverse Event|0
6098506|NCT00743652|9713394|FG002|Overall Study|Adverse Event|0
6098507|NCT00743652|9713395|FG003|Overall Study|Adverse Event|0
6098508|NCT00743652|9713396|FG004|Overall Study|Adverse Event|0
6098509|NCT00743652|9713392|FG000|Overall Study|Death|2
6098510|NCT00743652|9713393|FG001|Overall Study|Death|0
6098511|NCT00743652|9713394|FG002|Overall Study|Death|0
6098512|NCT00743652|9713395|FG003|Overall Study|Death|0
6098513|NCT00743652|9713396|FG004|Overall Study|Death|0
6098514|NCT00743652|9713392|FG000|Overall Study|Investigator Request|0
6098515|NCT00743652|9713393|FG001|Overall Study|Investigator Request|0
6098516|NCT00743652|9713394|FG002|Overall Study|Investigator Request|0
6098517|NCT00743652|9713395|FG003|Overall Study|Investigator Request|2
6098518|NCT00743652|9713396|FG004|Overall Study|Investigator Request|0
6098519|NCT00743652|9713392|FG000|Overall Study|Other|1
6098520|NCT00743652|9713393|FG001|Overall Study|Other|1
6098521|NCT00743652|9713394|FG002|Overall Study|Other|0
6098522|NCT00743652|9713395|FG003|Overall Study|Other|0
6098523|NCT00743652|9713396|FG004|Overall Study|Other|0
6098524|NCT00743652|9713392|FG000|Overall Study|Lost to Follow-up|1
6098525|NCT00743652|9713393|FG001|Overall Study|Lost to Follow-up|0
6098526|NCT00743652|9713394|FG002|Overall Study|Lost to Follow-up|0
6098527|NCT00743652|9713395|FG003|Overall Study|Lost to Follow-up|0
6098528|NCT00743652|9713396|FG004|Overall Study|Lost to Follow-up|0
6098529|NCT00744042|9713438|FG000|Overall Study|Withdrawal by Subject|1
6098530|NCT00744055|9713450|FG000|Overall Study|Withdrawal by Subject|6
6098531|NCT00744055|9713451|FG001|Overall Study|Withdrawal by Subject|9
6098532|NCT00744055|9713450|FG000|Overall Study|Lack of Efficacy|0
6098533|NCT00744055|9713451|FG001|Overall Study|Lack of Efficacy|1
6098534|NCT00744055|9713450|FG000|Overall Study|Physician Decision|0
6098535|NCT00744055|9713451|FG001|Overall Study|Physician Decision|2
6098536|NCT00744055|9713450|FG000|Overall Study|Protocol Violation|1
6098537|NCT00744055|9713451|FG001|Overall Study|Protocol Violation|1
6098538|NCT00744055|9713450|FG000|Overall Study|Lost to Follow-up|0
6098539|NCT00744055|9713451|FG001|Overall Study|Lost to Follow-up|1
6098540|NCT00744237|9713476|FG000|Overall Study|Lack of Efficacy|1
6098541|NCT00744237|9713477|FG001|Overall Study|Lack of Efficacy|1
6098542|NCT00744237|9713478|FG002|Overall Study|Lack of Efficacy|0
6098543|NCT00744237|9713476|FG000|Overall Study|Withdrawal by Subject|9
6098544|NCT00744237|9713477|FG001|Overall Study|Withdrawal by Subject|5
6098545|NCT00744237|9713478|FG002|Overall Study|Withdrawal by Subject|3
6098546|NCT00744237|9713476|FG000|Overall Study|Lost to Follow-up|1
6098547|NCT00744237|9713477|FG001|Overall Study|Lost to Follow-up|1
6098548|NCT00744237|9713478|FG002|Overall Study|Lost to Follow-up|1
6098549|NCT00744237|9713476|FG000|Overall Study|Protocol Violation|3
6098550|NCT00744237|9713477|FG001|Overall Study|Protocol Violation|4
6098551|NCT00744237|9713478|FG002|Overall Study|Protocol Violation|3
6098552|NCT00744237|9713476|FG000|Overall Study|Inclusion/Exclusion criteria not met|1
6098553|NCT00744237|9713477|FG001|Overall Study|Inclusion/Exclusion criteria not met|0
6098554|NCT00744237|9713478|FG002|Overall Study|Inclusion/Exclusion criteria not met|0
6098555|NCT00744237|9713476|FG000|Overall Study|Dosing Error|1
6098556|NCT00744237|9713477|FG001|Overall Study|Dosing Error|0
6098557|NCT00744237|9713478|FG002|Overall Study|Dosing Error|1
6098558|NCT00744237|9713476|FG000|Overall Study|Study Drug Error|1
6098559|NCT00744237|9713477|FG001|Overall Study|Study Drug Error|0
6098560|NCT00744237|9713478|FG002|Overall Study|Study Drug Error|0
6098561|NCT00744237|9713476|FG000|Overall Study|Prohibited Concomitant Medication|0
6098562|NCT00744237|9713477|FG001|Overall Study|Prohibited Concomitant Medication|0
6098563|NCT00744237|9713478|FG002|Overall Study|Prohibited Concomitant Medication|1
6098564|NCT00744237|9713476|FG000|Overall Study|Poor Compliance|0
6098565|NCT00744237|9713477|FG001|Overall Study|Poor Compliance|2
6098566|NCT00744237|9713478|FG002|Overall Study|Poor Compliance|0
6098567|NCT00744237|9713476|FG000|Overall Study|Administrative. Site Closed|1
6098568|NCT00744237|9713477|FG001|Overall Study|Administrative. Site Closed|1
6098569|NCT00744237|9713478|FG002|Overall Study|Administrative. Site Closed|1
6098570|NCT00744237|9713476|FG000|Overall Study|Adverse Event|9
6098571|NCT00744237|9713477|FG001|Overall Study|Adverse Event|13
6098572|NCT00744237|9713478|FG002|Overall Study|Adverse Event|5
6098573|NCT00744263|9713488|FG000|Overall Study|Death|3006
6098574|NCT00744263|9713489|FG001|Overall Study|Death|3005
6098575|NCT00744263|9713488|FG000|Overall Study|Lost to Follow-up|2038
6098576|NCT00744263|9713489|FG001|Overall Study|Lost to Follow-up|2135
6098577|NCT00744263|9713488|FG000|Overall Study|Withdrawal by Subject|166
6098578|NCT00744263|9713489|FG001|Overall Study|Withdrawal by Subject|150
6098579|NCT00744263|9713488|FG000|Overall Study|Physician Decision|20
6098580|NCT00744263|9713489|FG001|Overall Study|Physician Decision|23
6098581|NCT00744263|9713488|FG000|Overall Study|Protocol Violation|3
6098582|NCT00744263|9713489|FG001|Overall Study|Protocol Violation|5
6098583|NCT00744263|9713488|FG000|Overall Study|Adverse Event|1
6098584|NCT00744263|9713489|FG001|Overall Study|Adverse Event|0
6098585|NCT00744263|9713488|FG000|Overall Study|Other|2
6098586|NCT00744263|9713489|FG001|Overall Study|Other|2
6098587|NCT00744328|9713500|FG000|Overall Study|Lost to Follow-up|2
6098588|NCT00744328|9713501|FG001|Overall Study|Lost to Follow-up|5
6098589|NCT00744328|9713502|FG002|Overall Study|Lost to Follow-up|3
6098590|NCT00744328|9713500|FG000|Overall Study|Withdrawal by Subject|5
6098591|NCT00744328|9713501|FG001|Overall Study|Withdrawal by Subject|3
6098592|NCT00744328|9713502|FG002|Overall Study|Withdrawal by Subject|4
6098593|NCT00744328|9713500|FG000|Overall Study|Found ineligible after randomization|0
6098594|NCT00744328|9713501|FG001|Overall Study|Found ineligible after randomization|0
6098595|NCT00744328|9713502|FG002|Overall Study|Found ineligible after randomization|1
6098596|NCT00744471|9713524|FG000|Overall Study|Randomized but not treated|1
6098597|NCT00744471|9713525|FG001|Overall Study|Randomized but not treated|1
6098598|NCT00744471|9713526|FG002|Overall Study|Randomized but not treated|4
6098599|NCT00744471|9713527|FG003|Overall Study|Randomized but not treated|0
6098600|NCT00744471|9713524|FG000|Overall Study|Death|0
6098601|NCT00744471|9713525|FG001|Overall Study|Death|0
6098602|NCT00744471|9713526|FG002|Overall Study|Death|0
6098603|NCT00744471|9713527|FG003|Overall Study|Death|1
6098604|NCT00744471|9713524|FG000|Overall Study|Adverse Event|6
6098605|NCT00744471|9713525|FG001|Overall Study|Adverse Event|7
6098606|NCT00744471|9713526|FG002|Overall Study|Adverse Event|5
6098607|NCT00744471|9713527|FG003|Overall Study|Adverse Event|9
6098608|NCT00744471|9713524|FG000|Overall Study|Withdrawal by Subject|9
6098609|NCT00744471|9713525|FG001|Overall Study|Withdrawal by Subject|9
6098610|NCT00744471|9713526|FG002|Overall Study|Withdrawal by Subject|15
6098611|NCT00744471|9713527|FG003|Overall Study|Withdrawal by Subject|12
6098612|NCT00744471|9713524|FG000|Overall Study|Protocol Violation|1
6098613|NCT00744471|9713525|FG001|Overall Study|Protocol Violation|4
6098614|NCT00744471|9713526|FG002|Overall Study|Protocol Violation|1
6098615|NCT00744471|9713527|FG003|Overall Study|Protocol Violation|2
6098616|NCT00744471|9713524|FG000|Overall Study|Entered extension study|41
6098617|NCT00744471|9713525|FG001|Overall Study|Entered extension study|84
6098618|NCT00744471|9713526|FG002|Overall Study|Entered extension study|100
6098619|NCT00744471|9713527|FG003|Overall Study|Entered extension study|91
6098620|NCT00744471|9713524|FG000|Overall Study|Other|2
6098621|NCT00744471|9713525|FG001|Overall Study|Other|3
6098622|NCT00744471|9713526|FG002|Overall Study|Other|6
6098623|NCT00744471|9713527|FG003|Overall Study|Other|2
6098624|NCT00744471|9713524|FG000|Overall Study|Lack of Efficacy|83
6098625|NCT00744471|9713525|FG001|Overall Study|Lack of Efficacy|37
6098626|NCT00744471|9713526|FG002|Overall Study|Lack of Efficacy|19
6098627|NCT00744471|9713527|FG003|Overall Study|Lack of Efficacy|31
6098628|NCT00744471|9713524|FG000|Overall Study|Lost to Follow-up|0
6098629|NCT00744471|9713525|FG001|Overall Study|Lost to Follow-up|0
6098630|NCT00744471|9713526|FG002|Overall Study|Lost to Follow-up|2
6098631|NCT00744471|9713527|FG003|Overall Study|Lost to Follow-up|0
6098632|NCT00744497|9713539|FG000|Overall Study|Withdrawal by Subject|21
6098633|NCT00744497|9713540|FG001|Overall Study|Withdrawal by Subject|18
6098634|NCT00744497|9713539|FG000|Overall Study|Death|11
6098635|NCT00744497|9713540|FG001|Overall Study|Death|9
6098636|NCT00744497|9713539|FG000|Overall Study|Lost to Follow-up|4
6098637|NCT00744497|9713540|FG001|Overall Study|Lost to Follow-up|2
6098638|NCT00744497|9713539|FG000|Overall Study|Poor compliance/noncompliance|9
6098639|NCT00744497|9713540|FG001|Overall Study|Poor compliance/noncompliance|5
6098640|NCT00744497|9713539|FG000|Overall Study|No longer meets study criteria|7
6098641|NCT00744497|9713540|FG001|Overall Study|No longer meets study criteria|3
6098642|NCT00744497|9713539|FG000|Overall Study|Administrative Reason By Sponsor|25
6098643|NCT00744497|9713540|FG001|Overall Study|Administrative Reason By Sponsor|8
6098644|NCT00744497|9713539|FG000|Overall Study|Disease progression|312
6098645|NCT00744497|9713540|FG001|Overall Study|Disease progression|219
6098646|NCT00744497|9713539|FG000|Overall Study|Study drug toxicity|68
6098647|NCT00744497|9713540|FG001|Overall Study|Study drug toxicity|141
6098648|NCT00744497|9713539|FG000|Overall Study|Adverse event unrelated to study drug|78
6098649|NCT00744497|9713540|FG001|Overall Study|Adverse event unrelated to study drug|122
6098650|NCT00744497|9713539|FG000|Overall Study|Patient requested to stop study drug|65
6098651|NCT00744497|9713540|FG001|Overall Study|Patient requested to stop study drug|80
6098652|NCT00744497|9713539|FG000|Overall Study|Maximum clinical benefit|141
6098653|NCT00744497|9713540|FG001|Overall Study|Maximum clinical benefit|142
6098654|NCT00744497|9713539|FG000|Overall Study|Not defined|19
6098655|NCT00744497|9713540|FG001|Overall Study|Not defined|13
6098656|NCT00744523|9713548|FG000|30 Days After the Procedure|Insufficient follow-up|0
6098657|NCT00744523|9713549|FG001|30 Days After the Procedure|Insufficient follow-up|5
6098658|NCT00744627|9713559|FG000|Overall Study|Adverse Event|6
6098659|NCT00744627|9713560|FG001|Overall Study|Adverse Event|9
6098660|NCT00744627|9713559|FG000|Overall Study|Lack of Efficacy|7
6098661|NCT00744627|9713560|FG001|Overall Study|Lack of Efficacy|3
6098662|NCT00744627|9713559|FG000|Overall Study|Noncompliance|0
6098663|NCT00744627|9713560|FG001|Overall Study|Noncompliance|1
6098664|NCT00744627|9713559|FG000|Overall Study|Protocol Deviations|0
6098665|NCT00744627|9713560|FG001|Overall Study|Protocol Deviations|2
6098666|NCT00744627|9713559|FG000|Overall Study|Voluntary Withdrawal|9
6098667|NCT00744627|9713560|FG001|Overall Study|Voluntary Withdrawal|6
6098668|NCT00744627|9713559|FG000|Overall Study|Lost to Follow-up|2
6098669|NCT00744627|9713560|FG001|Overall Study|Lost to Follow-up|1
6098670|NCT00744627|9713559|FG000|Overall Study|Other|1
6098671|NCT00744627|9713560|FG001|Overall Study|Other|0
6098672|NCT00744653|9713566|FG000|Overall Study|antineoplastic treatment|11
6098673|NCT00744653|9713566|FG000|Overall Study|Death|1
6098674|NCT00744653|9713566|FG000|Overall Study|Lost to Follow-up|1
6098675|NCT00744653|9713566|FG000|Overall Study|Physician Decision|3
6098676|NCT00744757|9713575|FG000|Overall Study|Objective disease progression|7
6098677|NCT00744757|9713575|FG000|Overall Study|Physician Decision|5
6098678|NCT00744757|9713575|FG000|Overall Study|Withdrawal by Subject|1
6098679|NCT00744757|9713575|FG000|Overall Study|Death|6
6098680|NCT00744757|9713575|FG000|Overall Study|Adverse Event|2
6098681|NCT00744796|9713579|FG000|Post-Operative 6-9 Months|Lost to Follow-up|12
6098682|NCT00744861|9713596|FG000|Feasibility Stage 1|Withdrawal by Subject|1
6098683|NCT00744861|9713597|FG001|Feasibility Stage 1|Withdrawal by Subject|1
6098684|NCT00744861|9713598|FG002|Feasibility Stage 1|Withdrawal by Subject|0
6098685|NCT00744861|9713599|FG003|Feasibility Stage 1|Withdrawal by Subject|0
6098686|NCT00744861|9713596|FG000|Feasibility Stage 1|Pregnancy|0
6098687|NCT00744861|9713597|FG001|Feasibility Stage 1|Pregnancy|1
6098688|NCT00744861|9713598|FG002|Feasibility Stage 1|Pregnancy|0
6098689|NCT00744861|9713599|FG003|Feasibility Stage 1|Pregnancy|0
6098690|NCT00744861|9713596|FG000|Pivotal Stage 2|Adverse Event|0
6098691|NCT00744861|9713597|FG001|Pivotal Stage 2|Adverse Event|0
6098692|NCT00744861|9713598|FG002|Pivotal Stage 2|Adverse Event|6
6098693|NCT00744861|9713599|FG003|Pivotal Stage 2|Adverse Event|11
6098694|NCT00744861|9713596|FG000|Pivotal Stage 2|Death|0
6098695|NCT00744861|9713597|FG001|Pivotal Stage 2|Death|0
6098696|NCT00744861|9713598|FG002|Pivotal Stage 2|Death|0
6098697|NCT00744861|9713599|FG003|Pivotal Stage 2|Death|1
6098698|NCT00744861|9713596|FG000|Pivotal Stage 2|Lost to Follow-up|0
6098699|NCT00744861|9713597|FG001|Pivotal Stage 2|Lost to Follow-up|0
6098700|NCT00744861|9713598|FG002|Pivotal Stage 2|Lost to Follow-up|13
6098701|NCT00744861|9713599|FG003|Pivotal Stage 2|Lost to Follow-up|14
6098702|NCT00744861|9713596|FG000|Pivotal Stage 2|Physician Decision|0
6098703|NCT00744861|9713597|FG001|Pivotal Stage 2|Physician Decision|0
6098704|NCT00744861|9713598|FG002|Pivotal Stage 2|Physician Decision|3
6098705|NCT00744861|9713599|FG003|Pivotal Stage 2|Physician Decision|1
6098706|NCT00744861|9713596|FG000|Pivotal Stage 2|Protocol Violation|0
6098707|NCT00744861|9713597|FG001|Pivotal Stage 2|Protocol Violation|0
6098708|NCT00744861|9713598|FG002|Pivotal Stage 2|Protocol Violation|0
6098709|NCT00744861|9713599|FG003|Pivotal Stage 2|Protocol Violation|1
6098710|NCT00744861|9713596|FG000|Pivotal Stage 2|Withdrawal by Subject|0
6098711|NCT00744861|9713597|FG001|Pivotal Stage 2|Withdrawal by Subject|0
6098712|NCT00744861|9713598|FG002|Pivotal Stage 2|Withdrawal by Subject|20
6098713|NCT00744861|9713599|FG003|Pivotal Stage 2|Withdrawal by Subject|14
6098714|NCT00744861|9713596|FG000|Pivotal Stage 2|Study Terminated by Sponsor|0
6098715|NCT00744861|9713597|FG001|Pivotal Stage 2|Study Terminated by Sponsor|0
6098716|NCT00744861|9713598|FG002|Pivotal Stage 2|Study Terminated by Sponsor|60
6098717|NCT00744861|9713599|FG003|Pivotal Stage 2|Study Terminated by Sponsor|63
6098718|NCT00744874|9713607|FG000|Overall Study|Lost to Follow-up|1
6098719|NCT00744874|9713607|FG000|Overall Study|Withdrawal by Subject|1
6098720|NCT00744874|9713607|FG000|Overall Study|Study Device not available at procedure|1
6098721|NCT00744874|9713607|FG000|Overall Study|Unable to accomodate schedule|1
6098722|NCT00744939|9713622|FG000|Overall Study|Withdrawal by Subject|9
6098723|NCT00744939|9713622|FG000|Overall Study|Protocol Violation|13
6098724|NCT00744939|9713622|FG000|Overall Study|Death|24
6098725|NCT00744939|9713622|FG000|Overall Study|distance|4
6098726|NCT00744939|9713622|FG000|Overall Study|Lost to Follow-up|12
6098727|NCT00744939|9713622|FG000|Overall Study|Medical history exclusionary|1
6098728|NCT00744939|9713622|FG000|Overall Study|Did not receive Magnevist|7
6098729|NCT00744939|9713622|FG000|Overall Study|Failed inclusion/exclusion criteria|19
6098730|NCT00744939|9713622|FG000|Overall Study|coma|1
6098731|NCT00744939|9713622|FG000|Overall Study|incorrect race|1
6098732|NCT00744978|9713645|FG000|Period 1|Lost to Follow-up|1
6098733|NCT00744978|9713646|FG001|Period 1|Lost to Follow-up|0
6098734|NCT00744978|9713645|FG000|Period 1|Withdrawal by Subject|0
6098735|NCT00744978|9713646|FG001|Period 1|Withdrawal by Subject|2
6098736|NCT00744978|9713645|FG000|Period 1|Other|0
6098737|NCT00744978|9713646|FG001|Period 1|Other|2
6098738|NCT00744978|9713645|FG000|Period 1|Adverse Event|4
6098739|NCT00744978|9713646|FG001|Period 1|Adverse Event|0
6098740|NCT00744978|9713645|FG000|Period 1|Randomized but not Treated|1
6098741|NCT00744978|9713646|FG001|Period 1|Randomized but not Treated|1
6098742|NCT00744978|9713645|FG000|Period 2|Adverse Event|0
6098743|NCT00744978|9713646|FG001|Period 2|Adverse Event|1
6098744|NCT00744991|9713652|FG000|Overall Study|Progressive Disease|11
6098745|NCT00744991|9713652|FG000|Overall Study|Withdrawal by Subject|8
6098746|NCT00744991|9713652|FG000|Overall Study|Physician Decision|3
6098747|NCT00744991|9713652|FG000|Overall Study|Adverse Event|2
6098748|NCT00744991|9713652|FG000|Overall Study|Protocol Entry Criteria Unmet|1
6098749|NCT00745095|9713665|FG000|Overall Study|Declined to participate|1
6098750|NCT00745095|9713666|FG001|Overall Study|Declined to participate|0
6203776|NCT01517282|9864978|FG003|Overall Study|Consent withdrawn|1
6203777|NCT01517282|9864975|FG000|Overall Study|Physician Decision|1
6203778|NCT01517282|9864976|FG001|Overall Study|Physician Decision|0
6203779|NCT01517282|9864977|FG002|Overall Study|Physician Decision|0
6203780|NCT01517282|9864978|FG003|Overall Study|Physician Decision|0
6203781|NCT01517295|9864990|FG000|Overall Study|Physician Decision|1
6203782|NCT01517295|9864991|FG001|Overall Study|Physician Decision|0
6203783|NCT01517373|9865002|FG000|Run-in Period|Death|1
6203784|NCT01517373|9865003|FG001|Run-in Period|Death|0
6284654|NCT02326298|9996354|FG000|Maintenance Period (Week 16 to Week 48)|Patient cannot attend visits|0
6284655|NCT02326298|9996355|FG001|Maintenance Period (Week 16 to Week 48)|Patient cannot attend visits|0
6284656|NCT02326298|9996356|FG002|Maintenance Period (Week 16 to Week 48)|Patient cannot attend visits|0
6284657|NCT02326298|9996357|FG003|Maintenance Period (Week 16 to Week 48)|Patient cannot attend visits|0
6284658|NCT02326298|9996358|FG004|Maintenance Period (Week 16 to Week 48)|Patient cannot attend visits|0
6284659|NCT02326298|9996359|FG005|Maintenance Period (Week 16 to Week 48)|Patient cannot attend visits|1
6284660|NCT02326298|9996360|FG006|Maintenance Period (Week 16 to Week 48)|Patient cannot attend visits|0
6284661|NCT02326298|9996361|FG007|Maintenance Period (Week 16 to Week 48)|Patient cannot attend visits|0
6284662|NCT02326298|9996362|FG008|Maintenance Period (Week 16 to Week 48)|Patient cannot attend visits|0
6284663|NCT02326298|9996363|FG009|Maintenance Period (Week 16 to Week 48)|Patient cannot attend visits|0
6284664|NCT02326298|9996364|FG010|Maintenance Period (Week 16 to Week 48)|Patient cannot attend visits|0
6284665|NCT02326298|9996365|FG011|Maintenance Period (Week 16 to Week 48)|Patient cannot attend visits|0
6284666|NCT02326298|9996366|FG012|Maintenance Period (Week 16 to Week 48)|Patient cannot attend visits|0
6284667|NCT02326298|9996367|FG013|Maintenance Period (Week 16 to Week 48)|Patient cannot attend visits|0
6284668|NCT02326298|9996354|FG000|Maintenance Period (Week 16 to Week 48)|Pregnancy|0
6284669|NCT02326298|9996355|FG001|Maintenance Period (Week 16 to Week 48)|Pregnancy|0
6284670|NCT02326298|9996356|FG002|Maintenance Period (Week 16 to Week 48)|Pregnancy|0
6284671|NCT02326298|9996357|FG003|Maintenance Period (Week 16 to Week 48)|Pregnancy|0
6284672|NCT02326298|9996358|FG004|Maintenance Period (Week 16 to Week 48)|Pregnancy|0
6284673|NCT02326298|9996359|FG005|Maintenance Period (Week 16 to Week 48)|Pregnancy|0
6284674|NCT02326298|9996360|FG006|Maintenance Period (Week 16 to Week 48)|Pregnancy|1
6284675|NCT02326298|9996361|FG007|Maintenance Period (Week 16 to Week 48)|Pregnancy|0
6284676|NCT02326298|9996362|FG008|Maintenance Period (Week 16 to Week 48)|Pregnancy|0
6284677|NCT02326298|9996363|FG009|Maintenance Period (Week 16 to Week 48)|Pregnancy|0
6284678|NCT02326298|9996364|FG010|Maintenance Period (Week 16 to Week 48)|Pregnancy|0
6284679|NCT02326298|9996365|FG011|Maintenance Period (Week 16 to Week 48)|Pregnancy|0
6284680|NCT02326298|9996366|FG012|Maintenance Period (Week 16 to Week 48)|Pregnancy|0
6284681|NCT02326298|9996367|FG013|Maintenance Period (Week 16 to Week 48)|Pregnancy|0
6284682|NCT02326298|9996354|FG000|Maintenance Period (Week 16 to Week 48)|No valid reason stated by patient|0
6284683|NCT02326298|9996355|FG001|Maintenance Period (Week 16 to Week 48)|No valid reason stated by patient|0
6284684|NCT02326298|9996356|FG002|Maintenance Period (Week 16 to Week 48)|No valid reason stated by patient|0
6284685|NCT02326298|9996357|FG003|Maintenance Period (Week 16 to Week 48)|No valid reason stated by patient|0
6284686|NCT02326298|9996358|FG004|Maintenance Period (Week 16 to Week 48)|No valid reason stated by patient|0
6284687|NCT02326298|9996359|FG005|Maintenance Period (Week 16 to Week 48)|No valid reason stated by patient|0
6284688|NCT02326298|9996360|FG006|Maintenance Period (Week 16 to Week 48)|No valid reason stated by patient|0
6284689|NCT02326298|9996361|FG007|Maintenance Period (Week 16 to Week 48)|No valid reason stated by patient|1
6284690|NCT02326298|9996362|FG008|Maintenance Period (Week 16 to Week 48)|No valid reason stated by patient|0
6284691|NCT02326298|9996363|FG009|Maintenance Period (Week 16 to Week 48)|No valid reason stated by patient|0
6284692|NCT02326298|9996364|FG010|Maintenance Period (Week 16 to Week 48)|No valid reason stated by patient|0
6284693|NCT02326298|9996365|FG011|Maintenance Period (Week 16 to Week 48)|No valid reason stated by patient|0
6284694|NCT02326298|9996366|FG012|Maintenance Period (Week 16 to Week 48)|No valid reason stated by patient|0
6284695|NCT02326298|9996367|FG013|Maintenance Period (Week 16 to Week 48)|No valid reason stated by patient|0
6284696|NCT02326298|9996354|FG000|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|0
6284697|NCT02326298|9996355|FG001|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|0
6284698|NCT02326298|9996356|FG002|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|0
6284699|NCT02326298|9996357|FG003|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|0
6284700|NCT02326298|9996358|FG004|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|0
6284701|NCT02326298|9996359|FG005|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|0
6284702|NCT02326298|9996360|FG006|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|1
6284703|NCT02326298|9996361|FG007|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|2
6203785|NCT01517373|9865004|FG002|Run-in Period|Death|0
6098751|NCT00745095|9713667|FG002|Overall Study|Declined to participate|0
6098752|NCT00745095|9713668|FG003|Overall Study|Declined to participate|0
6098753|NCT00745095|9713669|FG004|Overall Study|Declined to participate|92
6098754|NCT00745095|9713670|FG005|Overall Study|Declined to participate|95
6098755|NCT00745095|9713665|FG000|Overall Study|Ineligible due to GFR criteria|0
6098756|NCT00745095|9713666|FG001|Overall Study|Ineligible due to GFR criteria|2
6098757|NCT00745095|9713667|FG002|Overall Study|Ineligible due to GFR criteria|3
6098758|NCT00745095|9713668|FG003|Overall Study|Ineligible due to GFR criteria|3
6098759|NCT00745095|9713669|FG004|Overall Study|Ineligible due to GFR criteria|30
6098760|NCT00745095|9713670|FG005|Overall Study|Ineligible due to GFR criteria|28
6098761|NCT00745121|9713689|FG000|Overall Study|Death|3
6098762|NCT00745121|9713690|FG001|Overall Study|Death|0
6098763|NCT00745121|9713689|FG000|Overall Study|Adverse Event|1
6098764|NCT00745121|9713690|FG001|Overall Study|Adverse Event|0
6098765|NCT00745121|9713689|FG000|Overall Study|Lost to Follow-up|1
6098766|NCT00745121|9713690|FG001|Overall Study|Lost to Follow-up|0
6098767|NCT00745121|9713689|FG000|Overall Study|Withdrawal by Subject|4
6098768|NCT00745121|9713690|FG001|Overall Study|Withdrawal by Subject|2
6098769|NCT00745251|9713698|FG000|Overall Study|Adverse Event|1
6098770|NCT00745251|9713699|FG001|Overall Study|Adverse Event|2
6098771|NCT00745251|9713698|FG000|Overall Study|Withdrawal by Subject|1
6098772|NCT00745251|9713699|FG001|Overall Study|Withdrawal by Subject|1
6098773|NCT00745368|9713714|FG000|Overall Study|Unable to provide sample|3
6098774|NCT00745420|9713718|FG000|Overall Study|Ineligible|1
6098775|NCT00745498|9713725|FG000|Overall Study|Lost to Follow-up|1
6098776|NCT00745498|9713726|FG001|Overall Study|Lost to Follow-up|1
6098777|NCT00745498|9713727|FG002|Overall Study|Lost to Follow-up|3
6098778|NCT00745498|9713725|FG000|Overall Study|Injection of intravitreal silicone oil o|3
6098779|NCT00745498|9713726|FG001|Overall Study|Injection of intravitreal silicone oil o|4
6098780|NCT00745498|9713727|FG002|Overall Study|Injection of intravitreal silicone oil o|4
6098781|NCT00745498|9713725|FG000|Overall Study|Non-PDR related VH|0
6098782|NCT00745498|9713726|FG001|Overall Study|Non-PDR related VH|1
6098783|NCT00745498|9713727|FG002|Overall Study|Non-PDR related VH|1
6098784|NCT00745498|9713725|FG000|Overall Study|Edophthalmitis after preoperative IVB|1
6098785|NCT00745498|9713726|FG001|Overall Study|Edophthalmitis after preoperative IVB|0
6098786|NCT00745498|9713727|FG002|Overall Study|Edophthalmitis after preoperative IVB|0
6098787|NCT00745615|9713739|FG000|Double-Blind Extension (36 Weeks)|Withdrawal by Subject|3
6098788|NCT00745615|9713740|FG001|Double-Blind Extension (36 Weeks)|Withdrawal by Subject|1
6098789|NCT00745615|9713741|FG002|Double-Blind Extension (36 Weeks)|Withdrawal by Subject|0
6098790|NCT00745615|9713742|FG003|Double-Blind Extension (36 Weeks)|Withdrawal by Subject|4
6098791|NCT00745615|9713743|FG004|Double-Blind Extension (36 Weeks)|Withdrawal by Subject|0
6098792|NCT00745615|9713744|FG005|Double-Blind Extension (36 Weeks)|Withdrawal by Subject|0
6098793|NCT00745615|9713739|FG000|Double-Blind Extension (36 Weeks)|Physician Decision|0
6098794|NCT00745615|9713740|FG001|Double-Blind Extension (36 Weeks)|Physician Decision|1
6098795|NCT00745615|9713741|FG002|Double-Blind Extension (36 Weeks)|Physician Decision|0
6098796|NCT00745615|9713742|FG003|Double-Blind Extension (36 Weeks)|Physician Decision|0
6098797|NCT00745615|9713743|FG004|Double-Blind Extension (36 Weeks)|Physician Decision|0
6098798|NCT00745615|9713744|FG005|Double-Blind Extension (36 Weeks)|Physician Decision|0
6098799|NCT00745615|9713739|FG000|Double-Blind Extension (36 Weeks)|Adverse Event|2
6098800|NCT00745615|9713740|FG001|Double-Blind Extension (36 Weeks)|Adverse Event|3
6098801|NCT00745615|9713741|FG002|Double-Blind Extension (36 Weeks)|Adverse Event|1
6098802|NCT00745615|9713742|FG003|Double-Blind Extension (36 Weeks)|Adverse Event|1
6098803|NCT00745615|9713743|FG004|Double-Blind Extension (36 Weeks)|Adverse Event|0
6098804|NCT00745615|9713744|FG005|Double-Blind Extension (36 Weeks)|Adverse Event|0
6098805|NCT00745615|9713739|FG000|Double-Blind Extension (36 Weeks)|Pregnancy|0
6098806|NCT00745615|9713740|FG001|Double-Blind Extension (36 Weeks)|Pregnancy|1
6098807|NCT00745615|9713741|FG002|Double-Blind Extension (36 Weeks)|Pregnancy|0
6098808|NCT00745615|9713742|FG003|Double-Blind Extension (36 Weeks)|Pregnancy|0
6098809|NCT00745615|9713743|FG004|Double-Blind Extension (36 Weeks)|Pregnancy|0
6098810|NCT00745615|9713744|FG005|Double-Blind Extension (36 Weeks)|Pregnancy|0
6098811|NCT00745615|9713739|FG000|Double-Blind Extension (36 Weeks)|Other Than Specified|0
6098812|NCT00745615|9713740|FG001|Double-Blind Extension (36 Weeks)|Other Than Specified|1
6098813|NCT00745615|9713741|FG002|Double-Blind Extension (36 Weeks)|Other Than Specified|0
6098814|NCT00745615|9713742|FG003|Double-Blind Extension (36 Weeks)|Other Than Specified|0
6098815|NCT00745615|9713743|FG004|Double-Blind Extension (36 Weeks)|Other Than Specified|0
6098816|NCT00745615|9713744|FG005|Double-Blind Extension (36 Weeks)|Other Than Specified|0
6098817|NCT00745615|9713739|FG000|Open-Label (up to Approx 10.5 Years)|Study Terminated by Sponsor|0
6098818|NCT00745615|9713740|FG001|Open-Label (up to Approx 10.5 Years)|Study Terminated by Sponsor|0
6098819|NCT00745615|9713741|FG002|Open-Label (up to Approx 10.5 Years)|Study Terminated by Sponsor|0
6098820|NCT00745615|9713742|FG003|Open-Label (up to Approx 10.5 Years)|Study Terminated by Sponsor|0
6098821|NCT00745615|9713743|FG004|Open-Label (up to Approx 10.5 Years)|Study Terminated by Sponsor|50
6098822|NCT00745615|9713744|FG005|Open-Label (up to Approx 10.5 Years)|Study Terminated by Sponsor|50
6098823|NCT00745615|9713739|FG000|Open-Label (up to Approx 10.5 Years)|Withdrawal by Subject|0
6098824|NCT00745615|9713740|FG001|Open-Label (up to Approx 10.5 Years)|Withdrawal by Subject|0
6098825|NCT00745615|9713741|FG002|Open-Label (up to Approx 10.5 Years)|Withdrawal by Subject|0
6098826|NCT00745615|9713742|FG003|Open-Label (up to Approx 10.5 Years)|Withdrawal by Subject|0
6098827|NCT00745615|9713743|FG004|Open-Label (up to Approx 10.5 Years)|Withdrawal by Subject|19
6098828|NCT00745615|9713744|FG005|Open-Label (up to Approx 10.5 Years)|Withdrawal by Subject|19
6098829|NCT00745615|9713739|FG000|Open-Label (up to Approx 10.5 Years)|Physician Decision|0
6098830|NCT00745615|9713740|FG001|Open-Label (up to Approx 10.5 Years)|Physician Decision|0
6098831|NCT00745615|9713741|FG002|Open-Label (up to Approx 10.5 Years)|Physician Decision|0
6098832|NCT00745615|9713742|FG003|Open-Label (up to Approx 10.5 Years)|Physician Decision|0
6098833|NCT00745615|9713743|FG004|Open-Label (up to Approx 10.5 Years)|Physician Decision|9
6098834|NCT00745615|9713744|FG005|Open-Label (up to Approx 10.5 Years)|Physician Decision|11
6098835|NCT00745615|9713739|FG000|Open-Label (up to Approx 10.5 Years)|Adverse Event|0
6203786|NCT01517373|9865005|FG003|Run-in Period|Death|0
6203787|NCT01517373|9865006|FG004|Run-in Period|Death|0
6203788|NCT01517373|9865007|FG005|Run-in Period|Death|0
6203789|NCT01517373|9865002|FG000|Run-in Period|Adverse Event|5
6203790|NCT01517373|9865003|FG001|Run-in Period|Adverse Event|0
6203791|NCT01517373|9865004|FG002|Run-in Period|Adverse Event|0
6203792|NCT01517373|9865005|FG003|Run-in Period|Adverse Event|0
6203793|NCT01517373|9865006|FG004|Run-in Period|Adverse Event|0
6203794|NCT01517373|9865007|FG005|Run-in Period|Adverse Event|0
6098836|NCT00745615|9713740|FG001|Open-Label (up to Approx 10.5 Years)|Adverse Event|0
6098837|NCT00745615|9713741|FG002|Open-Label (up to Approx 10.5 Years)|Adverse Event|0
6098838|NCT00745615|9713742|FG003|Open-Label (up to Approx 10.5 Years)|Adverse Event|0
6098839|NCT00745615|9713743|FG004|Open-Label (up to Approx 10.5 Years)|Adverse Event|2
6098840|NCT00745615|9713744|FG005|Open-Label (up to Approx 10.5 Years)|Adverse Event|8
6098841|NCT00745615|9713739|FG000|Open-Label (up to Approx 10.5 Years)|Pregnancy|0
6098842|NCT00745615|9713740|FG001|Open-Label (up to Approx 10.5 Years)|Pregnancy|0
6098843|NCT00745615|9713741|FG002|Open-Label (up to Approx 10.5 Years)|Pregnancy|0
6098844|NCT00745615|9713742|FG003|Open-Label (up to Approx 10.5 Years)|Pregnancy|0
6098845|NCT00745615|9713743|FG004|Open-Label (up to Approx 10.5 Years)|Pregnancy|2
6098846|NCT00745615|9713744|FG005|Open-Label (up to Approx 10.5 Years)|Pregnancy|5
6098847|NCT00745615|9713739|FG000|Open-Label (up to Approx 10.5 Years)|Lost to Follow-up|0
6098848|NCT00745615|9713740|FG001|Open-Label (up to Approx 10.5 Years)|Lost to Follow-up|0
6098849|NCT00745615|9713741|FG002|Open-Label (up to Approx 10.5 Years)|Lost to Follow-up|0
6098850|NCT00745615|9713742|FG003|Open-Label (up to Approx 10.5 Years)|Lost to Follow-up|0
6098851|NCT00745615|9713743|FG004|Open-Label (up to Approx 10.5 Years)|Lost to Follow-up|1
6098852|NCT00745615|9713744|FG005|Open-Label (up to Approx 10.5 Years)|Lost to Follow-up|3
6098853|NCT00745615|9713739|FG000|Open-Label (up to Approx 10.5 Years)|Lack of Efficacy|0
6098854|NCT00745615|9713740|FG001|Open-Label (up to Approx 10.5 Years)|Lack of Efficacy|0
6098855|NCT00745615|9713741|FG002|Open-Label (up to Approx 10.5 Years)|Lack of Efficacy|0
6098856|NCT00745615|9713742|FG003|Open-Label (up to Approx 10.5 Years)|Lack of Efficacy|0
6098857|NCT00745615|9713743|FG004|Open-Label (up to Approx 10.5 Years)|Lack of Efficacy|0
6098858|NCT00745615|9713744|FG005|Open-Label (up to Approx 10.5 Years)|Lack of Efficacy|1
6098859|NCT00745615|9713739|FG000|Open-Label (up to Approx 10.5 Years)|Death|0
6098860|NCT00745615|9713740|FG001|Open-Label (up to Approx 10.5 Years)|Death|0
6098861|NCT00745615|9713741|FG002|Open-Label (up to Approx 10.5 Years)|Death|0
6203795|NCT01517373|9865002|FG000|Run-in Period|Did not meet eligibility criteria|34
6203796|NCT01517373|9865003|FG001|Run-in Period|Did not meet eligibility criteria|0
6203797|NCT01517373|9865004|FG002|Run-in Period|Did not meet eligibility criteria|0
6203798|NCT01517373|9865005|FG003|Run-in Period|Did not meet eligibility criteria|0
6203799|NCT01517373|9865006|FG004|Run-in Period|Did not meet eligibility criteria|0
6203800|NCT01517373|9865007|FG005|Run-in Period|Did not meet eligibility criteria|0
6203801|NCT01517373|9865002|FG000|Run-in Period|Lost to Follow-up|1
6203802|NCT01517373|9865003|FG001|Run-in Period|Lost to Follow-up|0
6203803|NCT01517373|9865004|FG002|Run-in Period|Lost to Follow-up|0
6203804|NCT01517373|9865005|FG003|Run-in Period|Lost to Follow-up|0
6098862|NCT00745615|9713742|FG003|Open-Label (up to Approx 10.5 Years)|Death|0
6098863|NCT00745615|9713743|FG004|Open-Label (up to Approx 10.5 Years)|Death|0
6098864|NCT00745615|9713744|FG005|Open-Label (up to Approx 10.5 Years)|Death|1
6098865|NCT00745615|9713739|FG000|Open-Label (up to Approx 10.5 Years)|Other Than Specified|0
6098866|NCT00745615|9713740|FG001|Open-Label (up to Approx 10.5 Years)|Other Than Specified|0
6098867|NCT00745615|9713741|FG002|Open-Label (up to Approx 10.5 Years)|Other Than Specified|0
6203805|NCT01517373|9865006|FG004|Run-in Period|Lost to Follow-up|0
6203806|NCT01517373|9865007|FG005|Run-in Period|Lost to Follow-up|0
6203807|NCT01517373|9865002|FG000|Run-in Period|Withdrawal by Subject|12
6203808|NCT01517373|9865003|FG001|Run-in Period|Withdrawal by Subject|0
6203809|NCT01517373|9865004|FG002|Run-in Period|Withdrawal by Subject|0
6203810|NCT01517373|9865005|FG003|Run-in Period|Withdrawal by Subject|0
6203811|NCT01517373|9865006|FG004|Run-in Period|Withdrawal by Subject|0
6203812|NCT01517373|9865007|FG005|Run-in Period|Withdrawal by Subject|0
6203813|NCT01517373|9865002|FG000|Run-in Period|Sponsor Decision|3
6203814|NCT01517373|9865003|FG001|Run-in Period|Sponsor Decision|0
6203815|NCT01517373|9865004|FG002|Run-in Period|Sponsor Decision|0
6203816|NCT01517373|9865005|FG003|Run-in Period|Sponsor Decision|0
6203817|NCT01517373|9865006|FG004|Run-in Period|Sponsor Decision|0
6203818|NCT01517373|9865007|FG005|Run-in Period|Sponsor Decision|0
6203819|NCT01517373|9865002|FG000|Run-in Period|Other|1
6203820|NCT01517373|9865003|FG001|Run-in Period|Other|0
6203821|NCT01517373|9865004|FG002|Run-in Period|Other|0
6203822|NCT01517373|9865005|FG003|Run-in Period|Other|0
6203823|NCT01517373|9865006|FG004|Run-in Period|Other|0
6203824|NCT01517373|9865007|FG005|Run-in Period|Other|0
6203825|NCT01517373|9865002|FG000|Treatment Period|Adverse Event|0
6203826|NCT01517373|9865003|FG001|Treatment Period|Adverse Event|0
6203827|NCT01517373|9865004|FG002|Treatment Period|Adverse Event|0
6203828|NCT01517373|9865005|FG003|Treatment Period|Adverse Event|0
6203829|NCT01517373|9865006|FG004|Treatment Period|Adverse Event|0
6203830|NCT01517373|9865007|FG005|Treatment Period|Adverse Event|2
6203831|NCT01517373|9865002|FG000|Treatment Period|Lost to Follow-up|0
6203832|NCT01517373|9865003|FG001|Treatment Period|Lost to Follow-up|0
6284704|NCT02326298|9996362|FG008|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|0
6284705|NCT02326298|9996363|FG009|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|0
6284706|NCT02326298|9996364|FG010|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|0
6284707|NCT02326298|9996365|FG011|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|0
6284708|NCT02326298|9996366|FG012|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|0
6284709|NCT02326298|9996367|FG013|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|0
6284710|NCT02326298|9996354|FG000|Maintenance Period (Week 16 to Week 48)|Adverse Event|0
6284711|NCT02326298|9996355|FG001|Maintenance Period (Week 16 to Week 48)|Adverse Event|0
6284712|NCT02326298|9996356|FG002|Maintenance Period (Week 16 to Week 48)|Adverse Event|0
6284713|NCT02326298|9996357|FG003|Maintenance Period (Week 16 to Week 48)|Adverse Event|0
6284714|NCT02326298|9996358|FG004|Maintenance Period (Week 16 to Week 48)|Adverse Event|0
6284715|NCT02326298|9996359|FG005|Maintenance Period (Week 16 to Week 48)|Adverse Event|0
6284716|NCT02326298|9996360|FG006|Maintenance Period (Week 16 to Week 48)|Adverse Event|0
6284717|NCT02326298|9996361|FG007|Maintenance Period (Week 16 to Week 48)|Adverse Event|1
6284718|NCT02326298|9996362|FG008|Maintenance Period (Week 16 to Week 48)|Adverse Event|0
6284719|NCT02326298|9996363|FG009|Maintenance Period (Week 16 to Week 48)|Adverse Event|0
6284720|NCT02326298|9996364|FG010|Maintenance Period (Week 16 to Week 48)|Adverse Event|0
6284721|NCT02326298|9996365|FG011|Maintenance Period (Week 16 to Week 48)|Adverse Event|0
6284722|NCT02326298|9996366|FG012|Maintenance Period (Week 16 to Week 48)|Adverse Event|0
6284723|NCT02326298|9996367|FG013|Maintenance Period (Week 16 to Week 48)|Adverse Event|0
6284724|NCT02326298|9996354|FG000|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50 after week 48|0
6284725|NCT02326298|9996355|FG001|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50 after week 48|0
6284726|NCT02326298|9996356|FG002|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50 after week 48|0
6284727|NCT02326298|9996357|FG003|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50 after week 48|0
6284728|NCT02326298|9996358|FG004|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50 after week 48|0
6284729|NCT02326298|9996359|FG005|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50 after week 48|2
6284730|NCT02326298|9996360|FG006|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50 after week 48|0
6284731|NCT02326298|9996361|FG007|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50 after week 48|0
6284732|NCT02326298|9996362|FG008|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50 after week 48|0
6284733|NCT02326298|9996363|FG009|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50 after week 48|0
6284734|NCT02326298|9996364|FG010|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50 after week 48|0
6284735|NCT02326298|9996365|FG011|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50 after week 48|0
6284736|NCT02326298|9996366|FG012|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50 after week 48|0
6284737|NCT02326298|9996367|FG013|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50 after week 48|0
6284738|NCT02326298|9996354|FG000|Open-label Period (Week 48 to Week 144)|Death|0
6284739|NCT02326298|9996355|FG001|Open-label Period (Week 48 to Week 144)|Death|0
6284740|NCT02326298|9996356|FG002|Open-label Period (Week 48 to Week 144)|Death|0
6284741|NCT02326298|9996357|FG003|Open-label Period (Week 48 to Week 144)|Death|0
6284742|NCT02326298|9996358|FG004|Open-label Period (Week 48 to Week 144)|Death|0
6284743|NCT02326298|9996359|FG005|Open-label Period (Week 48 to Week 144)|Death|0
6284744|NCT02326298|9996360|FG006|Open-label Period (Week 48 to Week 144)|Death|0
6284745|NCT02326298|9996361|FG007|Open-label Period (Week 48 to Week 144)|Death|0
6284746|NCT02326298|9996362|FG008|Open-label Period (Week 48 to Week 144)|Death|0
6284747|NCT02326298|9996363|FG009|Open-label Period (Week 48 to Week 144)|Death|0
6284748|NCT02326298|9996364|FG010|Open-label Period (Week 48 to Week 144)|Death|0
6284749|NCT02326298|9996365|FG011|Open-label Period (Week 48 to Week 144)|Death|1
6284750|NCT02326298|9996366|FG012|Open-label Period (Week 48 to Week 144)|Death|0
6284751|NCT02326298|9996367|FG013|Open-label Period (Week 48 to Week 144)|Death|0
6284752|NCT02326298|9996354|FG000|Open-label Period (Week 48 to Week 144)|Adverse Event|0
6284753|NCT02326298|9996355|FG001|Open-label Period (Week 48 to Week 144)|Adverse Event|0
6284754|NCT02326298|9996356|FG002|Open-label Period (Week 48 to Week 144)|Adverse Event|0
6284755|NCT02326298|9996357|FG003|Open-label Period (Week 48 to Week 144)|Adverse Event|0
6203833|NCT01517373|9865004|FG002|Treatment Period|Lost to Follow-up|1
6203834|NCT01517373|9865005|FG003|Treatment Period|Lost to Follow-up|1
6284756|NCT02326298|9996358|FG004|Open-label Period (Week 48 to Week 144)|Adverse Event|0
6284757|NCT02326298|9996359|FG005|Open-label Period (Week 48 to Week 144)|Adverse Event|0
6284758|NCT02326298|9996360|FG006|Open-label Period (Week 48 to Week 144)|Adverse Event|0
6098868|NCT00745615|9713742|FG003|Open-Label (up to Approx 10.5 Years)|Other Than Specified|0
6098869|NCT00745615|9713743|FG004|Open-Label (up to Approx 10.5 Years)|Other Than Specified|8
6098870|NCT00745615|9713744|FG005|Open-Label (up to Approx 10.5 Years)|Other Than Specified|10
6098871|NCT00745823|9713758|FG000|Overall Study|Adverse Event|5
6098872|NCT00745823|9713759|FG001|Overall Study|Adverse Event|3
6098873|NCT00745823|9713758|FG000|Overall Study|Lack of Efficacy|20
6098874|NCT00745823|9713759|FG001|Overall Study|Lack of Efficacy|6
6098875|NCT00745823|9713758|FG000|Overall Study|Lost to Follow-up|10
6098876|NCT00745823|9713759|FG001|Overall Study|Lost to Follow-up|11
6098877|NCT00745823|9713758|FG000|Overall Study|Physician Decision|10
6098878|NCT00745823|9713759|FG001|Overall Study|Physician Decision|5
6098879|NCT00745823|9713758|FG000|Overall Study|Pregnancy|0
6098880|NCT00745823|9713759|FG001|Overall Study|Pregnancy|4
6098881|NCT00745823|9713758|FG000|Overall Study|Withdrawal by Subject|14
6098882|NCT00745823|9713759|FG001|Overall Study|Withdrawal by Subject|8
6098883|NCT00745823|9713758|FG000|Overall Study|Study Terminated by Sponsor|326
6098884|NCT00745823|9713759|FG001|Overall Study|Study Terminated by Sponsor|349
6098885|NCT00745849|9713767|FG000|First Intervention|Withdrawal by Subject|0
6098886|NCT00745849|9713768|FG001|First Intervention|Withdrawal by Subject|1
6098887|NCT00745849|9713767|FG000|First Intervention|Lost to Follow-up|1
6098888|NCT00745849|9713768|FG001|First Intervention|Lost to Follow-up|1
6098889|NCT00745849|9713767|FG000|Second Intervention|Lost to Follow-up|2
6098890|NCT00745849|9713768|FG001|Second Intervention|Lost to Follow-up|1
6098891|NCT00745875|9713776|FG000|Overall Study|Continuing study treatment|4
6098892|NCT00745875|9713777|FG001|Overall Study|Continuing study treatment|4
6098893|NCT00745901|9713785|FG000|Overall Study|Adverse Event|3
6098894|NCT00745901|9713786|FG001|Overall Study|Adverse Event|4
6098895|NCT00745901|9713785|FG000|Overall Study|Protocol Violation|0
6098896|NCT00745901|9713786|FG001|Overall Study|Protocol Violation|1
6098897|NCT00745901|9713785|FG000|Overall Study|Withdrawal by Subject|1
6098898|NCT00745901|9713786|FG001|Overall Study|Withdrawal by Subject|0
6098899|NCT00745901|9713785|FG000|Overall Study|Lost to Follow-up|7
6098900|NCT00745901|9713786|FG001|Overall Study|Lost to Follow-up|4
6098901|NCT00745901|9713785|FG000|Overall Study|Pregnancy|2
6098902|NCT00745901|9713786|FG001|Overall Study|Pregnancy|4
6098903|NCT00745901|9713785|FG000|Overall Study|Lack of compliance|2
6098904|NCT00745901|9713786|FG001|Overall Study|Lack of compliance|2
6098905|NCT00745901|9713785|FG000|Overall Study|Patient's next menses did not start with|1
6098906|NCT00745901|9713786|FG001|Overall Study|Patient's next menses did not start with|0
6098907|NCT00745901|9713785|FG000|Overall Study|Results of Pap smear at Vis 1 malignant|0
6098908|NCT00745901|9713786|FG001|Overall Study|Results of Pap smear at Vis 1 malignant|2
6098909|NCT00745901|9713785|FG000|Overall Study|Chlamydia test at Visit 1 was positive|1
6098910|NCT00745901|9713786|FG001|Overall Study|Chlamydia test at Visit 1 was positive|1
6098911|NCT00745901|9713785|FG000|Overall Study|Patient didn't take any study medication|7
6098912|NCT00745901|9713786|FG001|Overall Study|Patient didn't take any study medication|3
6098913|NCT00746096|9713803|FG000|Overall Study|Adverse Event|1
6098914|NCT00746096|9713804|FG001|Overall Study|Adverse Event|0
6098915|NCT00746096|9713803|FG000|Overall Study|Withdrawal by Subject|5
6098916|NCT00746096|9713804|FG001|Overall Study|Withdrawal by Subject|1
6098917|NCT00746096|9713803|FG000|Overall Study|Lost to Follow-up|2
6098918|NCT00746096|9713804|FG001|Overall Study|Lost to Follow-up|1
6098919|NCT00746096|9713803|FG000|Overall Study|Protocol Violation|1
6098920|NCT00746096|9713804|FG001|Overall Study|Protocol Violation|0
6098921|NCT00746096|9713803|FG000|Overall Study|No study drug treatment|1
6098922|NCT00746096|9713804|FG001|Overall Study|No study drug treatment|1
6098923|NCT00746252|9713830|FG000|Overall Study|weight gain >7.5 %|1
6098924|NCT00746252|9713831|FG001|Overall Study|weight gain >7.5 %|2
6098925|NCT00746330|9713841|FG000|Period 1|Abnormal test procedure result|0
6098926|NCT00746330|9713842|FG001|Period 1|Abnormal test procedure result|0
6098927|NCT00746330|9713843|FG002|Period 1|Abnormal test procedure result|1
6098928|NCT00746330|9713844|FG003|Period 1|Abnormal test procedure result|0
6098929|NCT00746356|9713855|FG000|Overall Study|Withdrawal by Subject|2
6098930|NCT00746356|9713856|FG001|Overall Study|Withdrawal by Subject|3
6098931|NCT00746356|9713855|FG000|Overall Study|Death|7
6098932|NCT00746356|9713856|FG001|Overall Study|Death|3
6098933|NCT00746356|9713855|FG000|Overall Study|Lost to Follow-up|1
6098934|NCT00746356|9713856|FG001|Overall Study|Lost to Follow-up|0
6098935|NCT00746356|9713855|FG000|Overall Study|Removal of Device|0
6098936|NCT00746356|9713856|FG001|Overall Study|Removal of Device|1
6098937|NCT00746356|9713855|FG000|Overall Study|Patient relocated|1
6098938|NCT00746356|9713856|FG001|Overall Study|Patient relocated|0
6203835|NCT01517373|9865006|FG004|Treatment Period|Lost to Follow-up|0
6203836|NCT01517373|9865007|FG005|Treatment Period|Lost to Follow-up|0
6203837|NCT01517373|9865002|FG000|Treatment Period|Withdrawal by Subject|0
6203838|NCT01517373|9865003|FG001|Treatment Period|Withdrawal by Subject|3
6203839|NCT01517373|9865004|FG002|Treatment Period|Withdrawal by Subject|2
6203840|NCT01517373|9865005|FG003|Treatment Period|Withdrawal by Subject|2
6203841|NCT01517373|9865006|FG004|Treatment Period|Withdrawal by Subject|2
6203842|NCT01517373|9865007|FG005|Treatment Period|Withdrawal by Subject|3
6203843|NCT01517373|9865002|FG000|Treatment Period|Other|0
6098939|NCT00746551|9713901|FG000|At Gestational Age of 36 Weeks|Lost to Follow-up|2
6098940|NCT00746551|9713902|FG001|At Gestational Age of 36 Weeks|Lost to Follow-up|4
6098941|NCT00746551|9713901|FG000|At Delivery (GA of 39 Weeks)|Lost to Follow-up|9
6098942|NCT00746551|9713902|FG001|At Delivery (GA of 39 Weeks)|Lost to Follow-up|7
6098943|NCT00746551|9713901|FG000|At Delivery (GA of 39 Weeks)|preterm delivery, delivery elesewhere|6
6098944|NCT00746551|9713902|FG001|At Delivery (GA of 39 Weeks)|preterm delivery, delivery elesewhere|8
6098945|NCT00746564|9713908|FG000|Overall Study|Required Pacemaker/ICD Implant|2
6098946|NCT00746733|9713937|FG000|Second Intervention|Adverse Event|1
6098947|NCT00746733|9713938|FG001|Second Intervention|Adverse Event|0
6098948|NCT00746733|9713937|FG000|Third Intervention|Withdrawal by Subject|1
6098949|NCT00746733|9713938|FG001|Third Intervention|Withdrawal by Subject|1
6098950|NCT00746785|9713954|FG000|Overall Study|Lost to Follow-up|29
6098951|NCT00746785|9713955|FG001|Overall Study|Lost to Follow-up|25
6098952|NCT00746785|9713956|FG002|Overall Study|Lost to Follow-up|27
6098953|NCT00746798|9713968|FG000|Overall Study|Protocol Violation|0
6098954|NCT00746798|9713969|FG001|Overall Study|Protocol Violation|1
6098955|NCT00746798|9713970|FG002|Overall Study|Protocol Violation|0
6098956|NCT00746798|9713971|FG003|Overall Study|Protocol Violation|0
6098957|NCT00746798|9713968|FG000|Overall Study|Withdrawal by Subject|0
6098958|NCT00746798|9713969|FG001|Overall Study|Withdrawal by Subject|1
6098959|NCT00746798|9713970|FG002|Overall Study|Withdrawal by Subject|1
6098960|NCT00746798|9713971|FG003|Overall Study|Withdrawal by Subject|0
6098961|NCT00746798|9713968|FG000|Overall Study|Death|0
6098962|NCT00746798|9713969|FG001|Overall Study|Death|0
6098963|NCT00746798|9713970|FG002|Overall Study|Death|2
6098964|NCT00746798|9713971|FG003|Overall Study|Death|0
6098965|NCT00746798|9713968|FG000|Overall Study|Participant unable to return for visit|1
6098966|NCT00746798|9713969|FG001|Overall Study|Participant unable to return for visit|0
6098967|NCT00746798|9713970|FG002|Overall Study|Participant unable to return for visit|0
6098968|NCT00746798|9713971|FG003|Overall Study|Participant unable to return for visit|0
6098969|NCT00746941|9714005|FG000|Overall Study|Death|2
6098970|NCT00746941|9714006|FG001|Overall Study|Death|0
6098971|NCT00746941|9714007|FG002|Overall Study|Death|0
6098972|NCT00746941|9714008|FG003|Overall Study|Death|6
6098973|NCT00746941|9714005|FG000|Overall Study|Physician Decision|0
6098974|NCT00746941|9714006|FG001|Overall Study|Physician Decision|0
6098975|NCT00746941|9714007|FG002|Overall Study|Physician Decision|2
6098976|NCT00746941|9714008|FG003|Overall Study|Physician Decision|0
6098977|NCT00746941|9714005|FG000|Overall Study|Withdrawal by Subject|3
6098978|NCT00746941|9714006|FG001|Overall Study|Withdrawal by Subject|0
6098979|NCT00746941|9714007|FG002|Overall Study|Withdrawal by Subject|0
6098980|NCT00746941|9714008|FG003|Overall Study|Withdrawal by Subject|2
6098981|NCT00746941|9714005|FG000|Overall Study|Other, reason not provided|2
6098982|NCT00746941|9714006|FG001|Overall Study|Other, reason not provided|4
6098983|NCT00746941|9714007|FG002|Overall Study|Other, reason not provided|0
6098984|NCT00746941|9714008|FG003|Overall Study|Other, reason not provided|4
6098985|NCT00746941|9714005|FG000|Overall Study|Adverse Event|0
6098986|NCT00746941|9714006|FG001|Overall Study|Adverse Event|0
6098987|NCT00746941|9714007|FG002|Overall Study|Adverse Event|0
6098988|NCT00746941|9714008|FG003|Overall Study|Adverse Event|1
6098989|NCT00747006|9714028|FG000|Overall Study|Adverse Event|1
6098990|NCT00747006|9714029|FG001|Overall Study|Adverse Event|0
6098991|NCT00747006|9714030|FG002|Overall Study|Adverse Event|0
6098992|NCT00747006|9714028|FG000|Overall Study|Lost to Follow-up|0
6098993|NCT00747006|9714029|FG001|Overall Study|Lost to Follow-up|1
6098994|NCT00747006|9714030|FG002|Overall Study|Lost to Follow-up|0
6098995|NCT00747006|9714028|FG000|Overall Study|Physician Decision|2
6098996|NCT00747006|9714029|FG001|Overall Study|Physician Decision|0
6098997|NCT00747006|9714030|FG002|Overall Study|Physician Decision|1
6098998|NCT00747149|9714043|FG000|Overall Study|Adverse Event|0
6098999|NCT00747149|9714044|FG001|Overall Study|Adverse Event|15
6099000|NCT00747149|9714043|FG000|Overall Study|Lost to Follow-up|0
6099001|NCT00747149|9714044|FG001|Overall Study|Lost to Follow-up|10
6099002|NCT00747149|9714043|FG000|Overall Study|Withdrawal by Subject|0
6099003|NCT00747149|9714044|FG001|Overall Study|Withdrawal by Subject|6
6099004|NCT00747149|9714043|FG000|Overall Study|Did not receive treatment|0
6099005|NCT00747149|9714044|FG001|Overall Study|Did not receive treatment|1
6099006|NCT00747149|9714043|FG000|Overall Study|Incorrect enrollment|0
6099007|NCT00747149|9714044|FG001|Overall Study|Incorrect enrollment|6
6099008|NCT00747149|9714043|FG000|Overall Study|Severe non-compliance to protocol|0
6099009|NCT00747149|9714044|FG001|Overall Study|Severe non-compliance to protocol|1
6099010|NCT00747149|9714043|FG000|Overall Study|Not reported|1
6099011|NCT00747149|9714044|FG001|Overall Study|Not reported|4
6099012|NCT00747227|9714067|FG000|Overall Study|Death|3
6099013|NCT00747227|9714068|FG001|Overall Study|Death|1
6099014|NCT00747227|9714067|FG000|Overall Study|Withdrawal by Subject|1
6099015|NCT00747227|9714068|FG001|Overall Study|Withdrawal by Subject|0
6099016|NCT00747227|9714067|FG000|Overall Study|Lost to Follow-up|1
6099017|NCT00747227|9714068|FG001|Overall Study|Lost to Follow-up|2
6099018|NCT00747227|9714067|FG000|Overall Study|Illness|1
6099019|NCT00747227|9714068|FG001|Overall Study|Illness|1
6099020|NCT00747344|9714076|FG000|Controlled Period|Adverse Event|3
6099021|NCT00747344|9714077|FG001|Controlled Period|Adverse Event|0
6099022|NCT00747344|9714078|FG002|Controlled Period|Adverse Event|0
6099023|NCT00747344|9714079|FG003|Controlled Period|Adverse Event|0
6099024|NCT00747344|9714076|FG000|Controlled Period|Lack of Efficacy|2
6099025|NCT00747344|9714077|FG001|Controlled Period|Lack of Efficacy|1
6099026|NCT00747344|9714078|FG002|Controlled Period|Lack of Efficacy|0
6099027|NCT00747344|9714079|FG003|Controlled Period|Lack of Efficacy|0
6099028|NCT00747344|9714076|FG000|Controlled Period|Other|0
6099029|NCT00747344|9714077|FG001|Controlled Period|Other|3
6099030|NCT00747344|9714078|FG002|Controlled Period|Other|0
6099031|NCT00747344|9714079|FG003|Controlled Period|Other|0
6099032|NCT00747344|9714076|FG000|After Controlled Period|Adverse Event|0
6099033|NCT00747344|9714077|FG001|After Controlled Period|Adverse Event|0
6099034|NCT00747344|9714078|FG002|After Controlled Period|Adverse Event|0
6099035|NCT00747344|9714079|FG003|After Controlled Period|Adverse Event|1
6099036|NCT00747435|9714087|FG000|Overall Study|Lost to Follow-up|2
6099037|NCT00747435|9714087|FG000|Overall Study|Withdrawal by Subject|3
6099038|NCT00747435|9714087|FG000|Overall Study|Still undergoing follow up|1
6099039|NCT00747474|9714091|FG000|Cohort 8 (40 mg/m^2) Period|with efficacy and continued treatment|0
6099040|NCT00747474|9714092|FG001|Cohort 8 (40 mg/m^2) Period|with efficacy and continued treatment|0
6099041|NCT00747474|9714093|FG002|Cohort 8 (40 mg/m^2) Period|with efficacy and continued treatment|0
6099042|NCT00747474|9714094|FG003|Cohort 8 (40 mg/m^2) Period|with efficacy and continued treatment|0
6099043|NCT00747474|9714095|FG004|Cohort 8 (40 mg/m^2) Period|with efficacy and continued treatment|0
6203844|NCT01517373|9865003|FG001|Treatment Period|Other|0
6203845|NCT01517373|9865004|FG002|Treatment Period|Other|0
6099044|NCT00747474|9714096|FG005|Cohort 8 (40 mg/m^2) Period|with efficacy and continued treatment|0
6099045|NCT00747474|9714097|FG006|Cohort 8 (40 mg/m^2) Period|with efficacy and continued treatment|0
6099046|NCT00747474|9714098|FG007|Cohort 8 (40 mg/m^2) Period|with efficacy and continued treatment|1
6099047|NCT00747474|9714099|FG008|Cohort 8 (40 mg/m^2) Period|with efficacy and continued treatment|0
6099048|NCT00747474|9714100|FG009|Cohort 8 (40 mg/m^2) Period|with efficacy and continued treatment|0
6099049|NCT00747474|9714101|FG010|Cohort 8 (40 mg/m^2) Period|with efficacy and continued treatment|0
6099050|NCT00747474|9714102|FG011|Cohort 8 (40 mg/m^2) Period|with efficacy and continued treatment|0
6099051|NCT00747565|9714113|FG000|Overall Study|Withdrawal by Subject|10
6099052|NCT00747565|9714114|FG001|Overall Study|Withdrawal by Subject|6
6099053|NCT00747565|9714113|FG000|Overall Study|Lost to Follow-up|4
6099054|NCT00747565|9714114|FG001|Overall Study|Lost to Follow-up|1
6099055|NCT00747617|9714122|FG000|Overall Study|Lost to Follow-up|3
6099056|NCT00747617|9714123|FG001|Overall Study|Lost to Follow-up|1
6099057|NCT00747643|9714131|FG000|Overall Study|Withdrawal by Subject|36
6099058|NCT00747643|9714132|FG001|Overall Study|Withdrawal by Subject|27
6099059|NCT00747812|9714153|FG000|Overall Study|Research Site Staff Relocation|5
6099060|NCT00747812|9714154|FG001|Overall Study|Research Site Staff Relocation|3
6099061|NCT00748033|9714162|FG000|Overall Study|Adverse Event|0
6099062|NCT00748033|9714163|FG001|Overall Study|Adverse Event|1
6099063|NCT00748098|9714186|FG000|First Treatment Intervention Period|Adverse Event|1
6099064|NCT00748098|9714187|FG001|First Treatment Intervention Period|Adverse Event|1
6099065|NCT00748098|9714186|FG000|First Treatment Intervention Period|Protocol Violation|1
6099066|NCT00748098|9714187|FG001|First Treatment Intervention Period|Protocol Violation|0
6099067|NCT00748098|9714186|FG000|First Treatment Intervention Period|Lost to Follow-up|1
6099068|NCT00748098|9714187|FG001|First Treatment Intervention Period|Lost to Follow-up|0
6099069|NCT00748098|9714186|FG000|First Treatment Intervention Period|Withdrawal by Subject|2
6099070|NCT00748098|9714187|FG001|First Treatment Intervention Period|Withdrawal by Subject|0
6099071|NCT00748098|9714186|FG000|First Taper Period|Protocol Violation|1
6099072|NCT00748098|9714187|FG001|First Taper Period|Protocol Violation|0
6099073|NCT00748098|9714186|FG000|First Taper Period|Withdrawal by Subject|2
6099074|NCT00748098|9714187|FG001|First Taper Period|Withdrawal by Subject|0
6099075|NCT00748098|9714186|FG000|First Taper Period|Protocol Stopping Criteria Met|0
6099076|NCT00748098|9714187|FG001|First Taper Period|Protocol Stopping Criteria Met|1
6099077|NCT00748098|9714186|FG000|1-Week Washout Period|Adverse Event|0
6099078|NCT00748098|9714187|FG001|1-Week Washout Period|Adverse Event|1
6099079|NCT00748098|9714186|FG000|1-Week Washout Period|Withdrawal by Subject|2
6099080|NCT00748098|9714187|FG001|1-Week Washout Period|Withdrawal by Subject|0
6099081|NCT00748098|9714186|FG000|Second Treatment Intervention Period|Adverse Event|4
6203846|NCT01517373|9865005|FG003|Treatment Period|Other|0
6203847|NCT01517373|9865006|FG004|Treatment Period|Other|1
6203848|NCT01517373|9865007|FG005|Treatment Period|Other|0
6203849|NCT01517373|9865002|FG000|Treatment Period|Protocol Violation|0
6203850|NCT01517373|9865003|FG001|Treatment Period|Protocol Violation|0
6203851|NCT01517373|9865004|FG002|Treatment Period|Protocol Violation|0
5980503|NCT02733042|9569323|FG003|Treatment Period|Progressive Disease|1
6099082|NCT00748098|9714187|FG001|Second Treatment Intervention Period|Adverse Event|1
6099083|NCT00748098|9714186|FG000|Second Treatment Intervention Period|Lost to Follow-up|1
6099084|NCT00748098|9714187|FG001|Second Treatment Intervention Period|Lost to Follow-up|1
6099085|NCT00748098|9714186|FG000|Second Treatment Intervention Period|Withdrawal by Subject|1
6099086|NCT00748098|9714187|FG001|Second Treatment Intervention Period|Withdrawal by Subject|1
6203852|NCT01517373|9865005|FG003|Treatment Period|Protocol Violation|0
6203853|NCT01517373|9865006|FG004|Treatment Period|Protocol Violation|1
6099087|NCT00748189|9714196|FG000|Overall Study|Death|99
6099088|NCT00748189|9714197|FG001|Overall Study|Death|84
6099089|NCT00748189|9714196|FG000|Overall Study|Withdrawal by Subject|23
6099090|NCT00748189|9714197|FG001|Overall Study|Withdrawal by Subject|29
6099091|NCT00748189|9714196|FG000|Overall Study|Physician Decision|16
6099092|NCT00748189|9714197|FG001|Overall Study|Physician Decision|5
6099093|NCT00748189|9714196|FG000|Overall Study|Lost to Follow-up|8
6099094|NCT00748189|9714197|FG001|Overall Study|Lost to Follow-up|15
6099095|NCT00748189|9714196|FG000|Overall Study|Study terminated by Sponsor|70
6099096|NCT00748189|9714197|FG001|Overall Study|Study terminated by Sponsor|79
6099097|NCT00748215|9714210|FG000|Overall Study|Withdrawal by Subject|7
6099098|NCT00748215|9714211|FG001|Overall Study|Withdrawal by Subject|7
6099099|NCT00748215|9714210|FG000|Overall Study|Treatment change|2
6099100|NCT00748215|9714211|FG001|Overall Study|Treatment change|1
6099101|NCT00748215|9714210|FG000|Overall Study|Change in patient condition|0
6099102|NCT00748215|9714211|FG001|Overall Study|Change in patient condition|3
6099103|NCT00748215|9714210|FG000|Overall Study|Non-compliant|0
6099104|NCT00748215|9714211|FG001|Overall Study|Non-compliant|2
6099105|NCT00748215|9714210|FG000|Overall Study|Adverse Event|0
6099106|NCT00748215|9714211|FG001|Overall Study|Adverse Event|5
6099107|NCT00748241|9714217|FG000|Overall Study|Implant failure|1
6099108|NCT00748241|9714217|FG000|Overall Study|Lost to Follow-up|5
6099109|NCT00748241|9714217|FG000|Overall Study|Death|2
6099110|NCT00748540|9714230|FG000|Overall Study|Physician Decision|1
6099111|NCT00748553|9714236|FG000|Overall Study|Adverse Event|0
6099112|NCT00748553|9714237|FG001|Overall Study|Adverse Event|1
6099113|NCT00748553|9714236|FG000|Overall Study|disease progression|2
6099114|NCT00748553|9714237|FG001|Overall Study|disease progression|0
6099115|NCT00748553|9714236|FG000|Overall Study|noncompliance|1
6099116|NCT00748553|9714237|FG001|Overall Study|noncompliance|0
6099117|NCT00748566|9714242|FG000|Overall Study|Adverse Event|49
6099118|NCT00748566|9714242|FG000|Overall Study|Death|1
6099119|NCT00748566|9714242|FG000|Overall Study|Lack of Efficacy|12
6099120|NCT00748566|9714242|FG000|Overall Study|Lost to Follow-up|1
6099121|NCT00748566|9714242|FG000|Overall Study|Protocol Violation|13
6099122|NCT00748566|9714242|FG000|Overall Study|Withdrawal by Subject|22
6099123|NCT00748566|9714242|FG000|Overall Study|Study terminated by sponsor|5
6099124|NCT00748566|9714242|FG000|Overall Study|Other|9
6099125|NCT00748709|9714256|FG000|Overall Study|Progressive disease|15
6099126|NCT00748709|9714256|FG000|Overall Study|Drug reducing Toxity|2
6099127|NCT00748709|9714256|FG000|Overall Study|Other Adverse Event|1
6099128|NCT00748709|9714256|FG000|Overall Study|Withdrawal by Subject|1
6099129|NCT00748709|9714256|FG000|Overall Study|Other Reasons|1
6099130|NCT00748969|9714286|FG000|Overall Study|Withdrawal by Subject|1
6099131|NCT00748969|9714287|FG001|Overall Study|Withdrawal by Subject|0
6099132|NCT00748969|9714286|FG000|Overall Study|Withdrawal by Subject|0
6099133|NCT00748969|9714287|FG001|Overall Study|Withdrawal by Subject|1
6099134|NCT00749190|9714323|FG000|Overall Study|Adverse Event|0
6099135|NCT00749190|9714324|FG001|Overall Study|Adverse Event|2
6099136|NCT00749190|9714325|FG002|Overall Study|Adverse Event|0
6099137|NCT00749190|9714326|FG003|Overall Study|Adverse Event|4
6099138|NCT00749190|9714327|FG004|Overall Study|Adverse Event|0
6099139|NCT00749190|9714328|FG005|Overall Study|Adverse Event|3
6099140|NCT00749190|9714329|FG006|Overall Study|Adverse Event|0
6099141|NCT00749190|9714323|FG000|Overall Study|Lack of Efficacy|3
6099142|NCT00749190|9714324|FG001|Overall Study|Lack of Efficacy|1
6099143|NCT00749190|9714325|FG002|Overall Study|Lack of Efficacy|1
6099144|NCT00749190|9714326|FG003|Overall Study|Lack of Efficacy|0
6099145|NCT00749190|9714327|FG004|Overall Study|Lack of Efficacy|0
6099146|NCT00749190|9714328|FG005|Overall Study|Lack of Efficacy|1
6099147|NCT00749190|9714329|FG006|Overall Study|Lack of Efficacy|0
6099148|NCT00749190|9714323|FG000|Overall Study|Withdrawal by Subject|2
6099149|NCT00749190|9714324|FG001|Overall Study|Withdrawal by Subject|1
6099150|NCT00749190|9714325|FG002|Overall Study|Withdrawal by Subject|0
6099151|NCT00749190|9714326|FG003|Overall Study|Withdrawal by Subject|0
6099152|NCT00749190|9714327|FG004|Overall Study|Withdrawal by Subject|0
6099153|NCT00749190|9714328|FG005|Overall Study|Withdrawal by Subject|1
6099154|NCT00749190|9714329|FG006|Overall Study|Withdrawal by Subject|0
6099155|NCT00749190|9714323|FG000|Overall Study|Protocol Violation|0
6099156|NCT00749190|9714324|FG001|Overall Study|Protocol Violation|1
6099157|NCT00749190|9714325|FG002|Overall Study|Protocol Violation|0
6099158|NCT00749190|9714326|FG003|Overall Study|Protocol Violation|0
6099159|NCT00749190|9714327|FG004|Overall Study|Protocol Violation|0
6099160|NCT00749190|9714328|FG005|Overall Study|Protocol Violation|0
6099161|NCT00749190|9714329|FG006|Overall Study|Protocol Violation|1
6099162|NCT00749190|9714323|FG000|Overall Study|Other reason not defined above|0
6099163|NCT00749190|9714324|FG001|Overall Study|Other reason not defined above|0
6099164|NCT00749190|9714325|FG002|Overall Study|Other reason not defined above|0
6099165|NCT00749190|9714326|FG003|Overall Study|Other reason not defined above|1
6099166|NCT00749190|9714327|FG004|Overall Study|Other reason not defined above|0
6099167|NCT00749190|9714328|FG005|Overall Study|Other reason not defined above|0
6099168|NCT00749190|9714329|FG006|Overall Study|Other reason not defined above|0
6099169|NCT00749203|9714352|FG000|no Infusion at Week 1|Lost to Follow-up|0
6099170|NCT00749203|9714353|FG001|no Infusion at Week 1|Lost to Follow-up|1
6099171|NCT00749203|9714352|FG000|no Infusion at Week 1|Withdrawal by Subject|0
6099172|NCT00749203|9714353|FG001|no Infusion at Week 1|Withdrawal by Subject|1
6099173|NCT00749203|9714352|FG000|no Infusion at Week 1|delayed-onset sedation|0
6099174|NCT00749203|9714353|FG001|no Infusion at Week 1|delayed-onset sedation|1
6099175|NCT00749203|9714352|FG000|no Infusion at Week 1|low baseline PTSD symptoms level|0
6099176|NCT00749203|9714353|FG001|no Infusion at Week 1|low baseline PTSD symptoms level|1
6099177|NCT00749203|9714352|FG000|Second Infusion at 2 Weeks|Protocol Violation|0
6099178|NCT00749203|9714353|FG001|Second Infusion at 2 Weeks|Protocol Violation|1
6099179|NCT00749203|9714352|FG000|Second Infusion at 2 Weeks|pt felt uncomfortable after infusion|0
6099180|NCT00749203|9714353|FG001|Second Infusion at 2 Weeks|pt felt uncomfortable after infusion|1
6099181|NCT00749398|9714374|FG000|Overall Study|Lack of Efficacy|7
6099182|NCT00749398|9714374|FG000|Overall Study|Adverse Event|4
6099183|NCT00749398|9714374|FG000|Overall Study|Serious adverse event|11
6099184|NCT00749398|9714374|FG000|Overall Study|Withdrawal by Subject|17
6099185|NCT00749398|9714374|FG000|Overall Study|Lost to Follow-up|11
6099186|NCT00749398|9714374|FG000|Overall Study|Reason not specified|2
6099187|NCT00749398|9714374|FG000|Overall Study|Unknown reason|1
6099188|NCT00749411|9714380|FG000|Overall Study|Adverse Event|0
6099189|NCT00749411|9714381|FG001|Overall Study|Adverse Event|2
6099190|NCT00749411|9714380|FG000|Overall Study|Lack of Efficacy|0
6099191|NCT00749411|9714381|FG001|Overall Study|Lack of Efficacy|1
6099192|NCT00749411|9714380|FG000|Overall Study|Protocol Violation|1
6099193|NCT00749411|9714381|FG001|Overall Study|Protocol Violation|1
6099194|NCT00749411|9714380|FG000|Overall Study|Protocol-defined stopping criteria|0
6099195|NCT00749411|9714381|FG001|Overall Study|Protocol-defined stopping criteria|1
6099196|NCT00749463|9714390|FG000|Overall Study|Adverse Event|0
6099197|NCT00749463|9714391|FG001|Overall Study|Adverse Event|4
6099198|NCT00749463|9714392|FG002|Overall Study|Adverse Event|1
6099199|NCT00749463|9714390|FG000|Overall Study|Withdrawal by Subject|1
6099200|NCT00749463|9714391|FG001|Overall Study|Withdrawal by Subject|0
6099201|NCT00749463|9714392|FG002|Overall Study|Withdrawal by Subject|0
6099202|NCT00749580|9714411|FG000|Overall Study|Lost to Follow-up|4
6099203|NCT00749580|9714412|FG001|Overall Study|Lost to Follow-up|8
6099204|NCT00749580|9714411|FG000|Overall Study|Adverse Event|0
6099205|NCT00749580|9714412|FG001|Overall Study|Adverse Event|1
6099206|NCT00749684|9714440|FG000|Overall Study|Death|1
6099207|NCT00749684|9714440|FG000|Overall Study|Adverse Event|27
6099208|NCT00749684|9714440|FG000|Overall Study|Participant's Wish|10
6099209|NCT00749684|9714440|FG000|Overall Study|Not Documented|1
6099210|NCT00749684|9714440|FG000|Overall Study|Progressive Desease|31
6099211|NCT00749684|9714440|FG000|Overall Study|Therapy according to protocol + AE|2
6099212|NCT00749684|9714440|FG000|Overall Study|AE+discontinuation on participants wish|1
6099213|NCT00749684|9714440|FG000|Overall Study|Missing|9
6099214|NCT00749775|9714453|FG000|Overall Study|Protocol Violation|24
6099215|NCT00749775|9714453|FG000|Overall Study|Lost to Follow-up|36
6099216|NCT00749775|9714453|FG000|Overall Study|No visit after first day of treatment|44
6099217|NCT00749775|9714453|FG000|Overall Study|No drug administration|3
6099218|NCT00749892|9714479|FG000|Overall Study|Withdrawal by Subject|3
6099219|NCT00749944|9714496|FG000|Overall Study|Lost to Follow-up|2
6099220|NCT00749944|9714497|FG001|Overall Study|Lost to Follow-up|1
6099221|NCT00749944|9714496|FG000|Overall Study|Other|1
6099222|NCT00749944|9714497|FG001|Overall Study|Other|0
6099223|NCT00749944|9714496|FG000|Overall Study|Withdrawal by Subject|2
6099224|NCT00749944|9714497|FG001|Overall Study|Withdrawal by Subject|0
6203854|NCT01517373|9865007|FG005|Treatment Period|Protocol Violation|0
6203855|NCT01517373|9865002|FG000|Treatment Period|Lack of Efficacy|0
6203856|NCT01517373|9865003|FG001|Treatment Period|Lack of Efficacy|1
6203857|NCT01517373|9865004|FG002|Treatment Period|Lack of Efficacy|1
6203858|NCT01517373|9865005|FG003|Treatment Period|Lack of Efficacy|3
6203859|NCT01517373|9865006|FG004|Treatment Period|Lack of Efficacy|2
6203860|NCT01517373|9865007|FG005|Treatment Period|Lack of Efficacy|0
6203861|NCT01517373|9865002|FG000|Treatment Period|Medication error without AEs|0
6203862|NCT01517373|9865003|FG001|Treatment Period|Medication error without AEs|0
6203863|NCT01517373|9865004|FG002|Treatment Period|Medication error without AEs|2
6203864|NCT01517373|9865005|FG003|Treatment Period|Medication error without AEs|1
6203865|NCT01517373|9865006|FG004|Treatment Period|Medication error without AEs|0
6203866|NCT01517373|9865007|FG005|Treatment Period|Medication error without AEs|2
6203867|NCT01517412|9865022|FG000|Overall Study|Adverse Event|10
6203868|NCT01517412|9865023|FG001|Overall Study|Adverse Event|11
6203869|NCT01517412|9865022|FG000|Overall Study|Lack of Efficacy|10
6203870|NCT01517412|9865023|FG001|Overall Study|Lack of Efficacy|5
6203871|NCT01517412|9865022|FG000|Overall Study|Poor compliance to protocol|8
6203872|NCT01517412|9865023|FG001|Overall Study|Poor compliance to protocol|3
6203873|NCT01517412|9865022|FG000|Overall Study|Other than specified above|8
6203874|NCT01517412|9865023|FG001|Overall Study|Other than specified above|5
6203875|NCT01517750|9865037|FG000|Overall Study|Lost to Follow-up|1
6203876|NCT01517750|9865038|FG001|Overall Study|Lost to Follow-up|2
6203877|NCT01517750|9865039|FG002|Overall Study|Lost to Follow-up|4
6203878|NCT01517750|9865040|FG003|Overall Study|Lost to Follow-up|1
6203879|NCT01517867|9865056|FG000|Overall Study|never started treatment|29
6203880|NCT01517867|9865057|FG001|Overall Study|never started treatment|32
6203881|NCT01517867|9865056|FG000|Overall Study|Withdrawal by Subject|34
6203882|NCT01517867|9865057|FG001|Overall Study|Withdrawal by Subject|30
6099225|NCT00749996|9714516|FG000|Overall Study|Lost to Follow-up|7
6099226|NCT00749996|9714517|FG001|Overall Study|Lost to Follow-up|4
6099227|NCT00749996|9714516|FG000|Overall Study|Withdrawal by Subject|5
6099228|NCT00749996|9714517|FG001|Overall Study|Withdrawal by Subject|4
6099229|NCT00749996|9714516|FG000|Overall Study|Protocol Violation|2
6099230|NCT00749996|9714517|FG001|Overall Study|Protocol Violation|3
6099231|NCT00749996|9714516|FG000|Overall Study|Physician Decision|2
6099232|NCT00749996|9714517|FG001|Overall Study|Physician Decision|0
6099233|NCT00749996|9714516|FG000|Overall Study|Pregnancy|0
6099234|NCT00749996|9714517|FG001|Overall Study|Pregnancy|2
6099235|NCT00749996|9714516|FG000|Overall Study|Adverse Event|1
6099236|NCT00749996|9714517|FG001|Overall Study|Adverse Event|0
6099237|NCT00749996|9714516|FG000|Overall Study|Death|1
6099238|NCT00749996|9714517|FG001|Overall Study|Death|0
6099239|NCT00750061|9714525|FG000|Overall Study|Adverse Event|2
6099240|NCT00750061|9714526|FG001|Overall Study|Adverse Event|0
6099241|NCT00750061|9714525|FG000|Overall Study|Withdrawal by Subject|0
6099242|NCT00750061|9714526|FG001|Overall Study|Withdrawal by Subject|1
6099243|NCT00750061|9714525|FG000|Overall Study|Physician Decision|0
6099244|NCT00750061|9714526|FG001|Overall Study|Physician Decision|1
6099245|NCT00750139|9714536|FG000|Overall Study|Adverse Event|1
6099246|NCT00750139|9714537|FG001|Overall Study|Adverse Event|2
6099247|NCT00750139|9714538|FG002|Overall Study|Adverse Event|0
6099248|NCT00750139|9714539|FG003|Overall Study|Adverse Event|1
6099249|NCT00750139|9714536|FG000|Overall Study|Lost to Follow-up|17
6099250|NCT00750139|9714537|FG001|Overall Study|Lost to Follow-up|12
6099251|NCT00750139|9714538|FG002|Overall Study|Lost to Follow-up|15
6099252|NCT00750139|9714539|FG003|Overall Study|Lost to Follow-up|6
6099253|NCT00750139|9714536|FG000|Overall Study|Withdrawal by Subject|3
6099254|NCT00750139|9714537|FG001|Overall Study|Withdrawal by Subject|2
6099255|NCT00750139|9714538|FG002|Overall Study|Withdrawal by Subject|6
6099256|NCT00750139|9714539|FG003|Overall Study|Withdrawal by Subject|2
6099257|NCT00750139|9714536|FG000|Overall Study|Physician Decision|1
6099258|NCT00750139|9714537|FG001|Overall Study|Physician Decision|1
6099259|NCT00750139|9714538|FG002|Overall Study|Physician Decision|0
6099260|NCT00750139|9714539|FG003|Overall Study|Physician Decision|0
6099261|NCT00750139|9714536|FG000|Overall Study|Non-compliance|1
6099262|NCT00750139|9714537|FG001|Overall Study|Non-compliance|0
6099263|NCT00750139|9714538|FG002|Overall Study|Non-compliance|1
6099264|NCT00750139|9714539|FG003|Overall Study|Non-compliance|3
6099265|NCT00750139|9714536|FG000|Overall Study|Termination by sponsor|4
6099266|NCT00750139|9714537|FG001|Overall Study|Termination by sponsor|0
6099267|NCT00750139|9714538|FG002|Overall Study|Termination by sponsor|0
6099268|NCT00750139|9714539|FG003|Overall Study|Termination by sponsor|1
6099269|NCT00750139|9714536|FG000|Overall Study|Non-specific|62
6099270|NCT00750139|9714537|FG001|Overall Study|Non-specific|42
6099271|NCT00750139|9714538|FG002|Overall Study|Non-specific|79
6099272|NCT00750139|9714539|FG003|Overall Study|Non-specific|33
6099273|NCT00750152|9714553|FG000|Overall Study|Adverse Event|2
6099274|NCT00750152|9714554|FG001|Overall Study|Adverse Event|1
6099275|NCT00750152|9714553|FG000|Overall Study|Lost to Follow-up|8
6099276|NCT00750152|9714554|FG001|Overall Study|Lost to Follow-up|13
6099277|NCT00750152|9714553|FG000|Overall Study|Withdrawal by Subject|3
6099278|NCT00750152|9714554|FG001|Overall Study|Withdrawal by Subject|3
6099279|NCT00750152|9714553|FG000|Overall Study|Physician Decision|1
6099280|NCT00750152|9714554|FG001|Overall Study|Physician Decision|1
6099281|NCT00750152|9714553|FG000|Overall Study|Non-compliance|0
6099282|NCT00750152|9714554|FG001|Overall Study|Non-compliance|1
6099283|NCT00750152|9714553|FG000|Overall Study|Termination by sponsor|1
6099284|NCT00750152|9714554|FG001|Overall Study|Termination by sponsor|0
6099285|NCT00750152|9714553|FG000|Overall Study|Other|7
6203883|NCT01517867|9865056|FG000|Overall Study|Still in treatment at study end|0
6099286|NCT00750152|9714554|FG001|Overall Study|Other|8
6099287|NCT00750269|9714578|FG000|Overall Study|Protocol Violation|0
6099288|NCT00750269|9714579|FG001|Overall Study|Protocol Violation|1
6099289|NCT00750269|9714580|FG002|Overall Study|Protocol Violation|1
6099290|NCT00750269|9714581|FG003|Overall Study|Protocol Violation|2
6099291|NCT00750269|9714582|FG004|Overall Study|Protocol Violation|4
6099292|NCT00750269|9714578|FG000|Overall Study|Withdrawal by Subject|0
6099293|NCT00750269|9714579|FG001|Overall Study|Withdrawal by Subject|0
6099294|NCT00750269|9714580|FG002|Overall Study|Withdrawal by Subject|2
6099295|NCT00750269|9714581|FG003|Overall Study|Withdrawal by Subject|2
6099296|NCT00750269|9714582|FG004|Overall Study|Withdrawal by Subject|2
6099297|NCT00750269|9714578|FG000|Overall Study|Physician Decision|0
6099298|NCT00750269|9714579|FG001|Overall Study|Physician Decision|0
6099299|NCT00750269|9714580|FG002|Overall Study|Physician Decision|0
6099300|NCT00750269|9714581|FG003|Overall Study|Physician Decision|0
6099301|NCT00750269|9714582|FG004|Overall Study|Physician Decision|2
6203884|NCT01517867|9865057|FG001|Overall Study|Still in treatment at study end|3
6099302|NCT00750269|9714578|FG000|Overall Study|Patient too large for positioning|0
6099303|NCT00750269|9714579|FG001|Overall Study|Patient too large for positioning|0
6099304|NCT00750269|9714580|FG002|Overall Study|Patient too large for positioning|1
6099305|NCT00750269|9714581|FG003|Overall Study|Patient too large for positioning|0
6099306|NCT00750269|9714582|FG004|Overall Study|Patient too large for positioning|0
6099307|NCT00750269|9714578|FG000|Overall Study|Site error|0
6099308|NCT00750269|9714579|FG001|Overall Study|Site error|0
6099309|NCT00750269|9714580|FG002|Overall Study|Site error|0
6099310|NCT00750269|9714581|FG003|Overall Study|Site error|1
6099311|NCT00750269|9714582|FG004|Overall Study|Site error|0
6099312|NCT00750269|9714578|FG000|Overall Study|SBRT plan could not be drawn|0
6099313|NCT00750269|9714579|FG001|Overall Study|SBRT plan could not be drawn|0
6099314|NCT00750269|9714580|FG002|Overall Study|SBRT plan could not be drawn|0
6099315|NCT00750269|9714581|FG003|Overall Study|SBRT plan could not be drawn|0
6099316|NCT00750269|9714582|FG004|Overall Study|SBRT plan could not be drawn|1
6099317|NCT00750269|9714578|FG000|Overall Study|Fiducials could not be placed|0
6099318|NCT00750269|9714579|FG001|Overall Study|Fiducials could not be placed|0
6099319|NCT00750269|9714580|FG002|Overall Study|Fiducials could not be placed|0
6099320|NCT00750269|9714581|FG003|Overall Study|Fiducials could not be placed|0
6099321|NCT00750269|9714582|FG004|Overall Study|Fiducials could not be placed|1
6099322|NCT00750308|9714632|FG000|First Treatment|Adverse Event|0
6099323|NCT00750308|9714633|FG001|First Treatment|Adverse Event|1
6099324|NCT00750308|9714634|FG002|First Treatment|Adverse Event|0
6099325|NCT00750308|9714635|FG003|First Treatment|Adverse Event|0
6099326|NCT00750308|9714636|FG004|First Treatment|Adverse Event|0
6099327|NCT00750308|9714637|FG005|First Treatment|Adverse Event|0
6099328|NCT00750308|9714638|FG006|First Treatment|Adverse Event|0
6099329|NCT00750308|9714639|FG007|First Treatment|Adverse Event|0
6099330|NCT00750308|9714640|FG008|First Treatment|Adverse Event|0
6099331|NCT00750308|9714641|FG009|First Treatment|Adverse Event|0
6099332|NCT00750308|9714642|FG010|First Treatment|Adverse Event|1
6099333|NCT00750308|9714643|FG011|First Treatment|Adverse Event|1
6099334|NCT00750308|9714632|FG000|First Treatment|Withdrawal by Subject|0
6099335|NCT00750308|9714633|FG001|First Treatment|Withdrawal by Subject|0
6099336|NCT00750308|9714634|FG002|First Treatment|Withdrawal by Subject|0
6099337|NCT00750308|9714635|FG003|First Treatment|Withdrawal by Subject|1
6099338|NCT00750308|9714636|FG004|First Treatment|Withdrawal by Subject|0
6099339|NCT00750308|9714637|FG005|First Treatment|Withdrawal by Subject|0
6099340|NCT00750308|9714638|FG006|First Treatment|Withdrawal by Subject|0
6099341|NCT00750308|9714639|FG007|First Treatment|Withdrawal by Subject|1
6099342|NCT00750308|9714640|FG008|First Treatment|Withdrawal by Subject|0
6099343|NCT00750308|9714641|FG009|First Treatment|Withdrawal by Subject|0
6099344|NCT00750308|9714642|FG010|First Treatment|Withdrawal by Subject|0
6099345|NCT00750308|9714643|FG011|First Treatment|Withdrawal by Subject|0
6099346|NCT00750308|9714632|FG000|Second Treatment|Adverse Event|0
6099347|NCT00750308|9714633|FG001|Second Treatment|Adverse Event|0
6099348|NCT00750308|9714634|FG002|Second Treatment|Adverse Event|0
6099349|NCT00750308|9714635|FG003|Second Treatment|Adverse Event|0
6099350|NCT00750308|9714636|FG004|Second Treatment|Adverse Event|0
6099351|NCT00750308|9714637|FG005|Second Treatment|Adverse Event|1
6099352|NCT00750308|9714638|FG006|Second Treatment|Adverse Event|0
6099353|NCT00750308|9714639|FG007|Second Treatment|Adverse Event|0
6099354|NCT00750308|9714640|FG008|Second Treatment|Adverse Event|1
6099355|NCT00750308|9714641|FG009|Second Treatment|Adverse Event|0
6099356|NCT00750308|9714642|FG010|Second Treatment|Adverse Event|0
6099357|NCT00750308|9714643|FG011|Second Treatment|Adverse Event|0
6099358|NCT00750308|9714632|FG000|Second Treatment|Withdrawal by Subject|0
6099359|NCT00750308|9714633|FG001|Second Treatment|Withdrawal by Subject|0
6099360|NCT00750308|9714634|FG002|Second Treatment|Withdrawal by Subject|0
6099361|NCT00750308|9714635|FG003|Second Treatment|Withdrawal by Subject|0
6099362|NCT00750308|9714636|FG004|Second Treatment|Withdrawal by Subject|1
6099363|NCT00750308|9714637|FG005|Second Treatment|Withdrawal by Subject|0
6099364|NCT00750308|9714638|FG006|Second Treatment|Withdrawal by Subject|0
6099365|NCT00750308|9714639|FG007|Second Treatment|Withdrawal by Subject|0
6099366|NCT00750308|9714640|FG008|Second Treatment|Withdrawal by Subject|0
6099367|NCT00750308|9714641|FG009|Second Treatment|Withdrawal by Subject|0
6099368|NCT00750308|9714642|FG010|Second Treatment|Withdrawal by Subject|0
6099369|NCT00750308|9714643|FG011|Second Treatment|Withdrawal by Subject|0
6099370|NCT00750308|9714632|FG000|Third Treatment|Withdrawal by Subject|0
6099371|NCT00750308|9714633|FG001|Third Treatment|Withdrawal by Subject|1
6099372|NCT00750308|9714634|FG002|Third Treatment|Withdrawal by Subject|0
6099373|NCT00750308|9714635|FG003|Third Treatment|Withdrawal by Subject|0
6099374|NCT00750308|9714636|FG004|Third Treatment|Withdrawal by Subject|0
6099375|NCT00750308|9714637|FG005|Third Treatment|Withdrawal by Subject|0
6099376|NCT00750308|9714638|FG006|Third Treatment|Withdrawal by Subject|0
6099377|NCT00750308|9714639|FG007|Third Treatment|Withdrawal by Subject|0
6099378|NCT00750308|9714640|FG008|Third Treatment|Withdrawal by Subject|0
6099379|NCT00750308|9714641|FG009|Third Treatment|Withdrawal by Subject|0
6099380|NCT00750308|9714642|FG010|Third Treatment|Withdrawal by Subject|0
6099381|NCT00750308|9714643|FG011|Third Treatment|Withdrawal by Subject|0
6099382|NCT00750438|9714699|FG000|Overall Study|Protocol Violation|4
6099383|NCT00750438|9714700|FG001|Overall Study|Protocol Violation|1
6099384|NCT00750438|9714699|FG000|Overall Study|Physician Decision|2
6099385|NCT00750438|9714700|FG001|Overall Study|Physician Decision|2
6099386|NCT00750438|9714699|FG000|Overall Study|Withdrawal by Subject|1
6099387|NCT00750438|9714700|FG001|Overall Study|Withdrawal by Subject|1
6099388|NCT00750737|9714708|FG000|Overall Study|Withdrawal by Subject|3
6099389|NCT00750737|9714709|FG001|Overall Study|Withdrawal by Subject|3
6099390|NCT00750867|9714728|FG000|Overall Study|Adverse Event|2
6099391|NCT00750880|9714732|FG000|Overall Study|Adverse Event|76
6099392|NCT00750880|9714732|FG000|Overall Study|Death|4
6099393|NCT00750880|9714732|FG000|Overall Study|Lack of Efficacy|46
6099394|NCT00750880|9714732|FG000|Overall Study|Lost to Follow-up|10
6099395|NCT00750880|9714732|FG000|Overall Study|Protocol Violation|15
6099396|NCT00750880|9714732|FG000|Overall Study|Withdrawal by Subject|33
6099397|NCT00750880|9714732|FG000|Overall Study|Physician Decision|20
6099398|NCT00750880|9714732|FG000|Overall Study|Administrative|11
6099399|NCT00750893|9714737|FG000|Overall Study|Adverse Event|5
6099400|NCT00750893|9714737|FG000|Overall Study|Withdrawal by Subject|10
6099401|NCT00750893|9714737|FG000|Overall Study|Lost to Follow-up|510
6099402|NCT00750893|9714737|FG000|Overall Study|Other|17
6099403|NCT00750919|9714741|FG000|Overall Study|Adverse Event|9
6099404|NCT00750919|9714741|FG000|Overall Study|Withdrawal by Subject|1
6099405|NCT00750919|9714741|FG000|Overall Study|Lack of Efficacy|8
6099406|NCT00750919|9714741|FG000|Overall Study|Could not cooperate, unrelated to trial|4
6099407|NCT00750919|9714741|FG000|Overall Study|Other|36
6099408|NCT00751023|9714747|FG000|Overall Study|Lost to Follow-up|11
6099409|NCT00751023|9714748|FG001|Overall Study|Lost to Follow-up|7
6099410|NCT00751036|9714756|FG000|Overall Study|Disease Progression|28
6099411|NCT00751036|9714757|FG001|Overall Study|Disease Progression|29
6099412|NCT00751036|9714756|FG000|Overall Study|Adverse Event|6
6099413|NCT00751036|9714757|FG001|Overall Study|Adverse Event|4
6099414|NCT00751036|9714756|FG000|Overall Study|Administrative Problems|3
6099415|NCT00751036|9714757|FG001|Overall Study|Administrative Problems|4
6099416|NCT00751036|9714756|FG000|Overall Study|Withdrawal by Subject|5
6099417|NCT00751036|9714757|FG001|Overall Study|Withdrawal by Subject|2
6099418|NCT00751036|9714756|FG000|Overall Study|Death|3
6099419|NCT00751036|9714757|FG001|Overall Study|Death|3
6099420|NCT00751036|9714756|FG000|Overall Study|Lost to Follow-up|0
6099421|NCT00751036|9714757|FG001|Overall Study|Lost to Follow-up|1
6099422|NCT00751036|9714756|FG000|Overall Study|Protocol Violation|1
6099423|NCT00751036|9714757|FG001|Overall Study|Protocol Violation|0
6099424|NCT00751036|9714756|FG000|Overall Study|Missing end of Treatment Page|2
6099425|NCT00751036|9714757|FG001|Overall Study|Missing end of Treatment Page|3
6099426|NCT00751101|9714765|FG000|Overall Study|Withdrawal by Subject|1
6099427|NCT00751101|9714766|FG001|Overall Study|Withdrawal by Subject|0
6099428|NCT00751101|9714765|FG000|Overall Study|No HFS / Never Started Patch/|0
6099429|NCT00751101|9714766|FG001|Overall Study|No HFS / Never Started Patch/|4
6099430|NCT00751101|9714765|FG000|Overall Study|Never began capecitabine|1
6099431|NCT00751101|9714766|FG001|Overall Study|Never began capecitabine|0
6099432|NCT00751101|9714765|FG000|Overall Study|Physician Decision|0
6099433|NCT00751101|9714766|FG001|Overall Study|Physician Decision|1
6099434|NCT00751114|9714778|FG000|Overall Study|Adverse Event|2
6099435|NCT00751114|9714779|FG001|Overall Study|Adverse Event|4
6099436|NCT00751114|9714778|FG000|Overall Study|Protocol Violation|8
6099437|NCT00751114|9714779|FG001|Overall Study|Protocol Violation|9
6099438|NCT00751114|9714778|FG000|Overall Study|Withdrawal by Subject|9
6099439|NCT00751114|9714779|FG001|Overall Study|Withdrawal by Subject|4
6099440|NCT00751114|9714778|FG000|Overall Study|Lost to Follow-up|4
6099441|NCT00751114|9714779|FG001|Overall Study|Lost to Follow-up|7
6099442|NCT00751114|9714778|FG000|Overall Study|Lack of Efficacy|0
6099443|NCT00751114|9714779|FG001|Overall Study|Lack of Efficacy|7
6099444|NCT00751114|9714778|FG000|Overall Study|Not Treated|13
6099445|NCT00751114|9714779|FG001|Overall Study|Not Treated|1
6099446|NCT00751114|9714778|FG000|Overall Study|Out of country for 2 months|1
6099447|NCT00751114|9714779|FG001|Overall Study|Out of country for 2 months|0
6099448|NCT00751114|9714778|FG000|Overall Study|Move to another city|1
6099449|NCT00751114|9714779|FG001|Overall Study|Move to another city|0
6099450|NCT00751140|9714785|FG000|Overall Study|benign angioma excluded from analysis|1
6099451|NCT00751296|9714803|FG000|Overall Study|Adverse Event|2
6099452|NCT00751348|9714809|FG000|Overall Study|Withdrawal by Subject|5
6203885|NCT01517893|9865065|FG000|Overall Study|Withdrawal by Subject|3
6203886|NCT01517893|9865066|FG001|Overall Study|Withdrawal by Subject|0
6203887|NCT01517984|9865075|FG000|Overall Study|Lost to Follow-up|0
6203888|NCT01517984|9865076|FG001|Overall Study|Lost to Follow-up|1
6203889|NCT01517984|9865077|FG002|Overall Study|Lost to Follow-up|0
6203890|NCT01517984|9865078|FG003|Overall Study|Lost to Follow-up|0
6203891|NCT01517984|9865075|FG000|Overall Study|Withdrawal by Subject|1
6203892|NCT01517984|9865076|FG001|Overall Study|Withdrawal by Subject|8
6203893|NCT01517984|9865077|FG002|Overall Study|Withdrawal by Subject|4
6203894|NCT01517984|9865078|FG003|Overall Study|Withdrawal by Subject|1
6099453|NCT00751348|9714810|FG001|Overall Study|Withdrawal by Subject|2
6099454|NCT00751348|9714809|FG000|Overall Study|Migration from study area|1
6099455|NCT00751348|9714810|FG001|Overall Study|Migration from study area|0
6099456|NCT00751400|9714816|FG000|Overall Study|Lost to Follow-up|10
6099457|NCT00751621|9714829|FG000|Overall Study|Adverse Event|1
6099458|NCT00751621|9714829|FG000|Overall Study|Withdrawal by Subject|1
6099459|NCT00751621|9714829|FG000|Overall Study|Subject moved to another country|1
6203895|NCT01517984|9865075|FG000|Overall Study|Screen Failure|4
6203896|NCT01517984|9865076|FG001|Overall Study|Screen Failure|0
6203897|NCT01517984|9865077|FG002|Overall Study|Screen Failure|0
6203898|NCT01517984|9865078|FG003|Overall Study|Screen Failure|0
6203899|NCT01517984|9865075|FG000|Overall Study|Ineligible for randomization|0
6203900|NCT01517984|9865076|FG001|Overall Study|Ineligible for randomization|14
6099460|NCT00751621|9714829|FG000|Overall Study|Poor adherence to asthma treatment|1
6099461|NCT00751790|9714849|FG000|Overall Study|Lost to Follow-up|1
6099462|NCT00751790|9714849|FG000|Overall Study|Death|3
6099463|NCT00751790|9714849|FG000|Overall Study|Withdrawal by Subject|1
6099464|NCT00751881|9714856|FG000|Core Treatment Period|Not treated|1
6099465|NCT00751881|9714857|FG001|Core Treatment Period|Not treated|1
6099466|NCT00751881|9714858|FG002|Core Treatment Period|Not treated|2
6099467|NCT00751881|9714856|FG000|Core Treatment Period|Adverse Event|26
6099468|NCT00751881|9714857|FG001|Core Treatment Period|Adverse Event|54
6099469|NCT00751881|9714858|FG002|Core Treatment Period|Adverse Event|58
6099470|NCT00751881|9714856|FG000|Core Treatment Period|Lack of Efficacy|37
6099471|NCT00751881|9714857|FG001|Core Treatment Period|Lack of Efficacy|30
6099472|NCT00751881|9714858|FG002|Core Treatment Period|Lack of Efficacy|20
6099473|NCT00751881|9714856|FG000|Core Treatment Period|Poor compliance to protocol|15
6099474|NCT00751881|9714857|FG001|Core Treatment Period|Poor compliance to protocol|3
6099475|NCT00751881|9714858|FG002|Core Treatment Period|Poor compliance to protocol|4
6099476|NCT00751881|9714856|FG000|Core Treatment Period|Lost to Follow-up|6
6099477|NCT00751881|9714857|FG001|Core Treatment Period|Lost to Follow-up|4
6099478|NCT00751881|9714858|FG002|Core Treatment Period|Lost to Follow-up|3
6099479|NCT00751881|9714856|FG000|Core Treatment Period|Other: protocol deviation|3
6099480|NCT00751881|9714857|FG001|Core Treatment Period|Other: protocol deviation|3
6099481|NCT00751881|9714858|FG002|Core Treatment Period|Other: protocol deviation|7
6099482|NCT00751881|9714856|FG000|Core Treatment Period|Other: wish to parent|5
6099483|NCT00751881|9714857|FG001|Core Treatment Period|Other: wish to parent|7
6099484|NCT00751881|9714858|FG002|Core Treatment Period|Other: wish to parent|4
6099485|NCT00751881|9714856|FG000|Core Treatment Period|Other: personal/family constraints|6
6099486|NCT00751881|9714857|FG001|Core Treatment Period|Other: personal/family constraints|7
6099487|NCT00751881|9714858|FG002|Core Treatment Period|Other: personal/family constraints|10
6099488|NCT00751881|9714856|FG000|Core Treatment Period|Other: MS treatment change|6
6099489|NCT00751881|9714857|FG001|Core Treatment Period|Other: MS treatment change|4
6203901|NCT01517984|9865077|FG002|Overall Study|Ineligible for randomization|0
6203902|NCT01517984|9865078|FG003|Overall Study|Ineligible for randomization|0
6203903|NCT01518153|9865085|FG000|Stem Cell Transplant|Active graft-vs-host disease (GvHD)|5
6203904|NCT01518153|9865086|FG001|Stem Cell Transplant|Active graft-vs-host disease (GvHD)|0
6203905|NCT01518153|9865087|FG002|Stem Cell Transplant|Active graft-vs-host disease (GvHD)|0
6203906|NCT01518153|9865085|FG000|Stem Cell Transplant|Death|2
6203907|NCT01518153|9865086|FG001|Stem Cell Transplant|Death|0
6203908|NCT01518153|9865087|FG002|Stem Cell Transplant|Death|0
6203909|NCT01518153|9865085|FG000|Stem Cell Transplant|Secondary graft failure|1
6203910|NCT01518153|9865086|FG001|Stem Cell Transplant|Secondary graft failure|0
6203911|NCT01518153|9865087|FG002|Stem Cell Transplant|Secondary graft failure|0
6203912|NCT01518153|9865085|FG000|Stem Cell Transplant|Adverse Event|1
6203913|NCT01518153|9865086|FG001|Stem Cell Transplant|Adverse Event|0
6203914|NCT01518153|9865087|FG002|Stem Cell Transplant|Adverse Event|0
6203915|NCT01518153|9865085|FG000|Donor Lymphocyte Infusion|Death|0
6203916|NCT01518153|9865086|FG001|Donor Lymphocyte Infusion|Death|2
6203917|NCT01518153|9865087|FG002|Donor Lymphocyte Infusion|Death|1
6203918|NCT01518192|9865098|FG000|Overall Study|Lost to Follow-up|29
6203919|NCT01518192|9865099|FG001|Overall Study|Lost to Follow-up|26
6203920|NCT01518192|9865100|FG002|Overall Study|Lost to Follow-up|35
6203921|NCT01518244|9865114|FG000|Overall Study|Adverse Event|3
6203922|NCT01518257|9865120|FG000|Overall Study|Lost to Follow-up|1
6203923|NCT01518257|9865121|FG001|Overall Study|Lost to Follow-up|0
6203924|NCT01518257|9865120|FG000|Overall Study|Other Miscellaneous Reason|1
6203925|NCT01518257|9865121|FG001|Overall Study|Other Miscellaneous Reason|0
6203926|NCT01518309|9865131|FG000|Overall Study|Adverse Event|6
6203927|NCT01518309|9865131|FG000|Overall Study|Death|6
6203928|NCT01518309|9865131|FG000|Overall Study|Lack of Efficacy|7
6203929|NCT01518309|9865131|FG000|Overall Study|Withdrawal by Subject|6
6203930|NCT01518309|9865131|FG000|Overall Study|Physician Decision|3
6203931|NCT01518309|9865131|FG000|Overall Study|Sponsor Decision|2
6203932|NCT01518309|9865131|FG000|Overall Study|Not in Predefined Categories|9
6203933|NCT01518322|9865135|FG000|Overall Study|FeNO measurement was missing|13
6203934|NCT01518374|9865144|FG000|Overall Study|Withdrawal by Subject|2
6203935|NCT01518374|9865144|FG000|Overall Study|Protocol Violation|3
6203936|NCT01518374|9865144|FG000|Overall Study|Lost to Follow-up|2
6203937|NCT01518699|9865158|FG000|Period 2|Protocol Violation|1
6203938|NCT01518699|9865159|FG001|Period 2|Protocol Violation|1
6203939|NCT01518699|9865160|FG002|Period 2|Protocol Violation|0
6203940|NCT01518699|9865161|FG003|Period 2|Protocol Violation|0
6099490|NCT00751881|9714858|FG002|Core Treatment Period|Other: MS treatment change|4
6099491|NCT00751881|9714856|FG000|Core Treatment Period|Other: tolerability complaints|2
6099492|NCT00751881|9714857|FG001|Core Treatment Period|Other: tolerability complaints|0
6099493|NCT00751881|9714858|FG002|Core Treatment Period|Other: tolerability complaints|0
6099494|NCT00751881|9714856|FG000|Core Treatment Period|Other:participant's decision/unspecified|19
6099495|NCT00751881|9714857|FG001|Core Treatment Period|Other:participant's decision/unspecified|22
6099496|NCT00751881|9714858|FG002|Core Treatment Period|Other:participant's decision/unspecified|16
6203941|NCT01518699|9865162|FG004|Period 2|Protocol Violation|0
6203942|NCT01518699|9865163|FG005|Period 2|Protocol Violation|0
6203943|NCT01518699|9865158|FG000|Period 2|Lost to Follow-up|0
6099497|NCT00751881|9714856|FG000|Extension Study Period|Adverse Event|18
6099498|NCT00751881|9714857|FG001|Extension Study Period|Adverse Event|20
6099499|NCT00751881|9714858|FG002|Extension Study Period|Adverse Event|21
6099500|NCT00751881|9714856|FG000|Extension Study Period|Lack of Efficacy|14
6099501|NCT00751881|9714857|FG001|Extension Study Period|Lack of Efficacy|10
6099502|NCT00751881|9714858|FG002|Extension Study Period|Lack of Efficacy|20
6099503|NCT00751881|9714856|FG000|Extension Study Period|Lost to Follow-up|4
6099504|NCT00751881|9714857|FG001|Extension Study Period|Lost to Follow-up|9
6099505|NCT00751881|9714858|FG002|Extension Study Period|Lost to Follow-up|6
6099506|NCT00751881|9714856|FG000|Extension Study Period|Poor Compliance to Protocol|3
6099507|NCT00751881|9714857|FG001|Extension Study Period|Poor Compliance to Protocol|2
6099508|NCT00751881|9714858|FG002|Extension Study Period|Poor Compliance to Protocol|1
6099509|NCT00751881|9714856|FG000|Extension Study Period|Other than specified above|26
6099510|NCT00751881|9714857|FG001|Extension Study Period|Other than specified above|30
6099511|NCT00751881|9714858|FG002|Extension Study Period|Other than specified above|18
6099512|NCT00751998|9714880|FG000|Overall Study|Lost to Follow-up|7
6099513|NCT00751998|9714880|FG000|Overall Study|Death|11
6099514|NCT00751998|9714880|FG000|Overall Study|Withdrawal by Subject|2
6099515|NCT00752089|9714884|FG000|Overall Study|Adverse Event|1
6099516|NCT00752089|9714884|FG000|Overall Study|Protocol Deviation|2
6099517|NCT00752089|9714884|FG000|Overall Study|Could not attend visit 9|1
6099518|NCT00752089|9714884|FG000|Overall Study|Not capable of wearing partial denture|1
6099519|NCT00752089|9714884|FG000|Overall Study|Cannot continue the study|1
6099520|NCT00752128|9714904|FG000|Overall Study|Withdrawal by Subject|4
6203944|NCT01518699|9865159|FG001|Period 2|Lost to Follow-up|1
6203945|NCT01518699|9865160|FG002|Period 2|Lost to Follow-up|0
6203946|NCT01518699|9865161|FG003|Period 2|Lost to Follow-up|0
6203947|NCT01518699|9865162|FG004|Period 2|Lost to Follow-up|0
6203948|NCT01518699|9865163|FG005|Period 2|Lost to Follow-up|0
6203949|NCT01518699|9865158|FG000|Period 2|Adverse Event|1
6203950|NCT01518699|9865159|FG001|Period 2|Adverse Event|0
6203951|NCT01518699|9865160|FG002|Period 2|Adverse Event|0
6203952|NCT01518699|9865161|FG003|Period 2|Adverse Event|0
6203953|NCT01518699|9865162|FG004|Period 2|Adverse Event|0
6203954|NCT01518699|9865163|FG005|Period 2|Adverse Event|0
6203955|NCT01518946|9865180|FG000|Open-label Phase|Other|4
6203956|NCT01518946|9865181|FG001|Open-label Phase|Other|0
6203957|NCT01518946|9865182|FG002|Open-label Phase|Other|0
6203958|NCT01518946|9865180|FG000|Randomized Phase (First Intervention)|Other|0
6203959|NCT01518946|9865181|FG001|Randomized Phase (First Intervention)|Other|1
6203960|NCT01518946|9865182|FG002|Randomized Phase (First Intervention)|Other|0
6203961|NCT01518972|9865191|FG000|Overall Study|Lost to Follow-up|2
6203962|NCT01518972|9865192|FG001|Overall Study|Lost to Follow-up|1
6203963|NCT01518972|9865191|FG000|Overall Study|Withdrawal by Subject|1
6203964|NCT01518972|9865192|FG001|Overall Study|Withdrawal by Subject|0
6203965|NCT01518972|9865191|FG000|Overall Study|Moved from area|1
6203966|NCT01518972|9865192|FG001|Overall Study|Moved from area|0
6203967|NCT01518972|9865191|FG000|Overall Study|Transportation problems|1
6203968|NCT01518972|9865192|FG001|Overall Study|Transportation problems|0
6203969|NCT01518972|9865191|FG000|Overall Study|Exclusionary medical condition|1
6203970|NCT01518972|9865192|FG001|Overall Study|Exclusionary medical condition|0
6203971|NCT01518972|9865191|FG000|Overall Study|Missed safety visits|0
6203972|NCT01518972|9865192|FG001|Overall Study|Missed safety visits|1
6203973|NCT01518972|9865191|FG000|Overall Study|Exclusionary medication|0
6203974|NCT01518972|9865192|FG001|Overall Study|Exclusionary medication|1
6203975|NCT01518972|9865191|FG000|Overall Study|Declined medication starting on day 12|0
6203976|NCT01518972|9865192|FG001|Overall Study|Declined medication starting on day 12|1
6203977|NCT01519089|9865209|FG000|Overall Study|Adverse Event|4
6203978|NCT01519089|9865210|FG001|Overall Study|Adverse Event|4
6203979|NCT01519089|9865209|FG000|Overall Study|Lack of Efficacy|0
6203980|NCT01519089|9865210|FG001|Overall Study|Lack of Efficacy|2
6203981|NCT01519089|9865209|FG000|Overall Study|Lost to Follow-up|1
6203982|NCT01519089|9865210|FG001|Overall Study|Lost to Follow-up|0
6203983|NCT01519089|9865209|FG000|Overall Study|Withdrawal by Subject|0
6203984|NCT01519089|9865210|FG001|Overall Study|Withdrawal by Subject|2
6203985|NCT01519089|9865209|FG000|Overall Study|Other|2
6203986|NCT01519089|9865210|FG001|Overall Study|Other|6
6203987|NCT01519089|9865209|FG000|Overall Study|Not received study drug|0
6203988|NCT01519089|9865210|FG001|Overall Study|Not received study drug|1
6203989|NCT01519167|9865220|FG000|Overall Study|Diagnostic/TherapeuticProcedureCompleted|0
6203990|NCT01519167|9865221|FG001|Overall Study|Diagnostic/TherapeuticProcedureCompleted|3
6203991|NCT01519167|9865220|FG000|Overall Study|Adverse Event|0
6203992|NCT01519167|9865221|FG001|Overall Study|Adverse Event|1
6203993|NCT01519167|9865220|FG000|Overall Study|Lack of Efficacy|0
6203994|NCT01519167|9865221|FG001|Overall Study|Lack of Efficacy|1
6203995|NCT01519167|9865220|FG000|Overall Study|Medical condition changes&deep sedation|0
6203996|NCT01519167|9865221|FG001|Overall Study|Medical condition changes&deep sedation|2
6203997|NCT01519167|9865220|FG000|Overall Study|Physician Decision|0
6203998|NCT01519167|9865221|FG001|Overall Study|Physician Decision|1
6203999|NCT01519206|9865227|FG000|Overall Study|Lost to Follow-up|3
6204000|NCT01519206|9865227|FG000|Overall Study|Missed Visit|2
6204001|NCT01519245|9865240|FG000|Overall Study|Met exclusion criteria, not analysed|1
6099521|NCT00752206|9714911|FG000|Overall Study|Disease progression|8
6099522|NCT00752206|9714912|FG001|Overall Study|Disease progression|11
6099523|NCT00752206|9714911|FG000|Overall Study|Pregnancy|1
6099524|NCT00752206|9714912|FG001|Overall Study|Pregnancy|0
6099525|NCT00752219|9714920|FG000|Overall Study|Clinical failure|0
6099526|NCT00752219|9714921|FG001|Overall Study|Clinical failure|1
6099527|NCT00752219|9714920|FG000|Overall Study|Adverse Event|5
6099528|NCT00752219|9714921|FG001|Overall Study|Adverse Event|3
6099529|NCT00752219|9714920|FG000|Overall Study|Protocol deviation|1
6099530|NCT00752219|9714921|FG001|Overall Study|Protocol deviation|0
6099531|NCT00752219|9714920|FG000|Overall Study|Lost to Follow-up|1
6099532|NCT00752219|9714921|FG001|Overall Study|Lost to Follow-up|2
6099533|NCT00752219|9714920|FG000|Overall Study|Randomized but not treated|1
6099534|NCT00752219|9714921|FG001|Overall Study|Randomized but not treated|0
6099535|NCT00752219|9714920|FG000|Overall Study|Other|3
6099536|NCT00752219|9714921|FG001|Overall Study|Other|0
6099537|NCT00752232|9714934|FG000|Overall Study|Protocol Violation|0
6099538|NCT00752232|9714935|FG001|Overall Study|Protocol Violation|0
6099539|NCT00752232|9714936|FG002|Overall Study|Protocol Violation|0
6099540|NCT00752232|9714937|FG003|Overall Study|Protocol Violation|0
6099541|NCT00752232|9714938|FG004|Overall Study|Protocol Violation|0
6099542|NCT00752232|9714939|FG005|Overall Study|Protocol Violation|1
6099543|NCT00752232|9714940|FG006|Overall Study|Protocol Violation|0
6099544|NCT00752232|9714934|FG000|Overall Study|Caregiver request|2
6099545|NCT00752232|9714935|FG001|Overall Study|Caregiver request|0
6099546|NCT00752232|9714936|FG002|Overall Study|Caregiver request|0
6099547|NCT00752232|9714937|FG003|Overall Study|Caregiver request|0
6099548|NCT00752232|9714938|FG004|Overall Study|Caregiver request|1
6099549|NCT00752232|9714939|FG005|Overall Study|Caregiver request|0
6099550|NCT00752232|9714940|FG006|Overall Study|Caregiver request|0
6099551|NCT00752232|9714934|FG000|Overall Study|Investigator request|0
6099552|NCT00752232|9714935|FG001|Overall Study|Investigator request|0
6099553|NCT00752232|9714936|FG002|Overall Study|Investigator request|0
6099554|NCT00752232|9714937|FG003|Overall Study|Investigator request|0
6099555|NCT00752232|9714938|FG004|Overall Study|Investigator request|1
6099556|NCT00752232|9714939|FG005|Overall Study|Investigator request|0
6099557|NCT00752232|9714940|FG006|Overall Study|Investigator request|0
6099558|NCT00752232|9714934|FG000|Overall Study|Subject request|0
6099559|NCT00752232|9714935|FG001|Overall Study|Subject request|0
6099560|NCT00752232|9714936|FG002|Overall Study|Subject request|1
6099561|NCT00752232|9714937|FG003|Overall Study|Subject request|0
6099562|NCT00752232|9714938|FG004|Overall Study|Subject request|0
6099563|NCT00752232|9714939|FG005|Overall Study|Subject request|0
6099564|NCT00752232|9714940|FG006|Overall Study|Subject request|0
6099565|NCT00752232|9714934|FG000|Overall Study|Group home admission|0
6099566|NCT00752232|9714935|FG001|Overall Study|Group home admission|0
6099567|NCT00752232|9714936|FG002|Overall Study|Group home admission|0
6099568|NCT00752232|9714937|FG003|Overall Study|Group home admission|1
6099569|NCT00752232|9714938|FG004|Overall Study|Group home admission|0
6099570|NCT00752232|9714939|FG005|Overall Study|Group home admission|0
6099571|NCT00752232|9714940|FG006|Overall Study|Group home admission|0
6099572|NCT00752232|9714934|FG000|Overall Study|Caregiver could not attend the subject|0
6099573|NCT00752232|9714935|FG001|Overall Study|Caregiver could not attend the subject|0
6099574|NCT00752232|9714936|FG002|Overall Study|Caregiver could not attend the subject|0
6099575|NCT00752232|9714937|FG003|Overall Study|Caregiver could not attend the subject|0
6099576|NCT00752232|9714938|FG004|Overall Study|Caregiver could not attend the subject|1
6099577|NCT00752232|9714939|FG005|Overall Study|Caregiver could not attend the subject|0
6099578|NCT00752232|9714940|FG006|Overall Study|Caregiver could not attend the subject|0
6099579|NCT00752557|9714960|FG000|Overall Study|Withdrawal by Subject|4
6099580|NCT00752557|9714961|FG001|Overall Study|Withdrawal by Subject|3
6099581|NCT00752557|9714962|FG002|Overall Study|Withdrawal by Subject|3
6099582|NCT00752557|9714960|FG000|Overall Study|Unspecified resaons|0
6099583|NCT00752557|9714961|FG001|Overall Study|Unspecified resaons|2
6099584|NCT00752557|9714962|FG002|Overall Study|Unspecified resaons|2
6099585|NCT00752557|9714960|FG000|Overall Study|Lost to Follow-up|1
6099586|NCT00752557|9714961|FG001|Overall Study|Lost to Follow-up|0
6099587|NCT00752557|9714962|FG002|Overall Study|Lost to Follow-up|1
6099588|NCT00752609|9714974|FG000|Overall Study|Adverse Event|2
6099589|NCT00752609|9714975|FG001|Overall Study|Adverse Event|2
6099590|NCT00752609|9714974|FG000|Overall Study|Withdrawal by Subject|3
6099591|NCT00752609|9714975|FG001|Overall Study|Withdrawal by Subject|0
6099592|NCT00752609|9714974|FG000|Overall Study|Physician Decision|1
6099593|NCT00752609|9714975|FG001|Overall Study|Physician Decision|0
6099594|NCT00752609|9714974|FG000|Overall Study|Death|1
6099595|NCT00752609|9714975|FG001|Overall Study|Death|0
6099596|NCT00752609|9714974|FG000|Overall Study|Met exclusion criteria|1
6099597|NCT00752609|9714975|FG001|Overall Study|Met exclusion criteria|0
6099598|NCT00752609|9714974|FG000|Overall Study|Received Aranesp in error|1
6099599|NCT00752609|9714975|FG001|Overall Study|Received Aranesp in error|0
6099600|NCT00752622|9714984|FG000|Induction Phase|Adverse Event|3
6099601|NCT00752622|9714984|FG000|Induction Phase|Other|3
6099602|NCT00752622|9714984|FG000|Induction Phase|Non-responder|14
6099603|NCT00752622|9714984|FG000|Induction Phase|Withdrawal by Subject|1
6099604|NCT00752622|9714984|FG000|Induction Phase|Premature study termination|14
6099605|NCT00752622|9714984|FG000|Observational Phase|Premature Study Termination|36
6099606|NCT00752622|9714984|FG000|Observational Phase|Non-responder|2
6099607|NCT00752622|9714984|FG000|Observational Phase|Withdrawal by Subject|2
6099608|NCT00752622|9714984|FG000|Observational Phase|Adverse Event|1
6099609|NCT00752622|9714984|FG000|Observational Phase|Other|2
6099610|NCT00752622|9714984|FG000|Interventional Phase|Non-responder|2
6099611|NCT00752622|9714984|FG000|Interventional Phase|Physician Decision|1
6099612|NCT00752622|9714984|FG000|Interventional Phase|Premature Study Termination|5
6099613|NCT00752726|9714991|FG000|Overall Study|Lost to Follow-up|2
6099614|NCT00752726|9714992|FG001|Overall Study|Lost to Follow-up|1
6099615|NCT00752726|9714991|FG000|Overall Study|Adverse Event|3
6099616|NCT00752726|9714992|FG001|Overall Study|Adverse Event|0
6099617|NCT00752726|9714991|FG000|Overall Study|Withdrawal by Subject|5
6099618|NCT00752726|9714992|FG001|Overall Study|Withdrawal by Subject|10
6099619|NCT00752726|9714991|FG000|Overall Study|Other Reason|1
6099620|NCT00752726|9714992|FG001|Overall Study|Other Reason|2
6099621|NCT00752791|9714998|FG000|Overall Study|Adverse Event|7
6099622|NCT00752791|9714998|FG000|Overall Study|Withdrawal by Subject|1
6099623|NCT00752791|9714998|FG000|Overall Study|Physician Decision|1
6099624|NCT00752791|9714998|FG000|Overall Study|Death|1
6099625|NCT00752791|9714998|FG000|Overall Study|Renal transplant|3
6099626|NCT00752791|9714998|FG000|Overall Study|Switched to hemodialysis|2
6099627|NCT00752791|9714998|FG000|Overall Study|Protocol deviation|1
6099628|NCT00752856|9715004|FG000|Overall Study|randomized but did not do viral kinetics|0
6099629|NCT00752856|9715005|FG001|Overall Study|randomized but did not do viral kinetics|1
6099630|NCT00752895|9715013|FG000|Overall Study|Withdrawal by Subject|8
6099631|NCT00752895|9715014|FG001|Overall Study|Withdrawal by Subject|3
6099632|NCT00753012|9715037|FG000|Overall Study|Ineligible, abnormal cardiac histo|1
6099633|NCT00753012|9715038|FG001|Overall Study|Ineligible, abnormal cardiac histo|0
6099634|NCT00753012|9715037|FG000|Overall Study|Adverse Event|2
6099635|NCT00753012|9715038|FG001|Overall Study|Adverse Event|0
6099636|NCT00753012|9715037|FG000|Overall Study|Withdrawal by Subject|0
6099637|NCT00753012|9715038|FG001|Overall Study|Withdrawal by Subject|1
6099638|NCT00753012|9715037|FG000|Overall Study|Lost to Follow-up|4
6099639|NCT00753012|9715038|FG001|Overall Study|Lost to Follow-up|0
6099640|NCT00753012|9715037|FG000|Overall Study|Confounded endpoint data|1
6099641|NCT00753012|9715038|FG001|Overall Study|Confounded endpoint data|0
6099642|NCT00753272|9715064|FG000|Overall Study|Adverse Event|878
6099643|NCT00753272|9715065|FG001|Overall Study|Adverse Event|869
6204002|NCT01519245|9865241|FG001|Overall Study|Met exclusion criteria, not analysed|2
6204003|NCT01519323|9865281|FG000|Overall Study|Death|3
6204004|NCT01519323|9865282|FG001|Overall Study|Death|2
6204005|NCT01519323|9865281|FG000|Overall Study|Study terminated by sponsor|0
6204006|NCT01519323|9865282|FG001|Overall Study|Study terminated by sponsor|1
6204007|NCT01519427|9865303|FG000|Overall Study|disease progression|2
6284759|NCT02326298|9996361|FG007|Open-label Period (Week 48 to Week 144)|Adverse Event|0
6284760|NCT02326298|9996362|FG008|Open-label Period (Week 48 to Week 144)|Adverse Event|0
6284761|NCT02326298|9996363|FG009|Open-label Period (Week 48 to Week 144)|Adverse Event|0
6284762|NCT02326298|9996364|FG010|Open-label Period (Week 48 to Week 144)|Adverse Event|0
6284763|NCT02326298|9996365|FG011|Open-label Period (Week 48 to Week 144)|Adverse Event|3
6284764|NCT02326298|9996366|FG012|Open-label Period (Week 48 to Week 144)|Adverse Event|3
6284765|NCT02326298|9996367|FG013|Open-label Period (Week 48 to Week 144)|Adverse Event|0
6284766|NCT02326298|9996354|FG000|Open-label Period (Week 48 to Week 144)|Lack of Efficacy|0
6284767|NCT02326298|9996355|FG001|Open-label Period (Week 48 to Week 144)|Lack of Efficacy|0
6284768|NCT02326298|9996356|FG002|Open-label Period (Week 48 to Week 144)|Lack of Efficacy|0
6284769|NCT02326298|9996357|FG003|Open-label Period (Week 48 to Week 144)|Lack of Efficacy|0
6284770|NCT02326298|9996358|FG004|Open-label Period (Week 48 to Week 144)|Lack of Efficacy|0
6284771|NCT02326298|9996359|FG005|Open-label Period (Week 48 to Week 144)|Lack of Efficacy|0
6284772|NCT02326298|9996360|FG006|Open-label Period (Week 48 to Week 144)|Lack of Efficacy|0
6284773|NCT02326298|9996361|FG007|Open-label Period (Week 48 to Week 144)|Lack of Efficacy|0
6284774|NCT02326298|9996362|FG008|Open-label Period (Week 48 to Week 144)|Lack of Efficacy|0
6284775|NCT02326298|9996363|FG009|Open-label Period (Week 48 to Week 144)|Lack of Efficacy|0
6284776|NCT02326298|9996364|FG010|Open-label Period (Week 48 to Week 144)|Lack of Efficacy|0
6284777|NCT02326298|9996365|FG011|Open-label Period (Week 48 to Week 144)|Lack of Efficacy|1
6284778|NCT02326298|9996366|FG012|Open-label Period (Week 48 to Week 144)|Lack of Efficacy|1
6284779|NCT02326298|9996367|FG013|Open-label Period (Week 48 to Week 144)|Lack of Efficacy|0
6284780|NCT02326298|9996354|FG000|Open-label Period (Week 48 to Week 144)|Protocol Violation|0
6284781|NCT02326298|9996355|FG001|Open-label Period (Week 48 to Week 144)|Protocol Violation|0
6099644|NCT00753272|9715064|FG000|Overall Study|Protocol Violation|28
6099645|NCT00753272|9715065|FG001|Overall Study|Protocol Violation|46
6099646|NCT00753272|9715064|FG000|Overall Study|Withdrawal by Subject|2481
6099647|NCT00753272|9715065|FG001|Overall Study|Withdrawal by Subject|2407
6204008|NCT01519518|9865327|FG000|Overall Study|Consent not available|7
6204009|NCT01519518|9865328|FG001|Overall Study|Consent not available|10
6204010|NCT01519635|9865345|FG000|Overall Study|Withdrawal by Subject|0
6204011|NCT01519635|9865346|FG001|Overall Study|Withdrawal by Subject|1
6204012|NCT01519635|9865345|FG000|Overall Study|No possibility to put a catheter|1
6204013|NCT01519635|9865346|FG001|Overall Study|No possibility to put a catheter|2
6099648|NCT00753272|9715064|FG000|Overall Study|Lost to Follow-up|491
6099649|NCT00753272|9715065|FG001|Overall Study|Lost to Follow-up|497
6099650|NCT00753272|9715064|FG000|Overall Study|Other|1104
6099651|NCT00753272|9715065|FG001|Overall Study|Other|1088
6099652|NCT00753415|9715102|FG000|Part A|Disease progression|1
6099653|NCT00753415|9715103|FG001|Part A|Disease progression|0
6099654|NCT00753415|9715104|FG002|Part A|Disease progression|1
6099655|NCT00753415|9715105|FG003|Part A|Disease progression|2
6099656|NCT00753415|9715106|FG004|Part A|Disease progression|0
6099657|NCT00753415|9715107|FG005|Part A|Disease progression|0
6099658|NCT00753415|9715108|FG006|Part A|Disease progression|0
6099659|NCT00753415|9715109|FG007|Part A|Disease progression|0
6099660|NCT00753415|9715110|FG008|Part A|Disease progression|0
6099661|NCT00753415|9715111|FG009|Part A|Disease progression|0
6099662|NCT00753415|9715102|FG000|Part A|Withdrawal by Subject|0
6099663|NCT00753415|9715103|FG001|Part A|Withdrawal by Subject|0
6099664|NCT00753415|9715104|FG002|Part A|Withdrawal by Subject|1
6099665|NCT00753415|9715105|FG003|Part A|Withdrawal by Subject|0
6099666|NCT00753415|9715106|FG004|Part A|Withdrawal by Subject|0
6099667|NCT00753415|9715107|FG005|Part A|Withdrawal by Subject|0
6099668|NCT00753415|9715108|FG006|Part A|Withdrawal by Subject|0
6099669|NCT00753415|9715109|FG007|Part A|Withdrawal by Subject|0
6099670|NCT00753415|9715110|FG008|Part A|Withdrawal by Subject|0
6099671|NCT00753415|9715111|FG009|Part A|Withdrawal by Subject|0
6099672|NCT00753415|9715102|FG000|Part B|Lost to Follow-up|0
6099673|NCT00753415|9715103|FG001|Part B|Lost to Follow-up|0
6099674|NCT00753415|9715104|FG002|Part B|Lost to Follow-up|0
6099675|NCT00753415|9715105|FG003|Part B|Lost to Follow-up|0
6099676|NCT00753415|9715106|FG004|Part B|Lost to Follow-up|0
6099677|NCT00753415|9715107|FG005|Part B|Lost to Follow-up|0
6099678|NCT00753415|9715108|FG006|Part B|Lost to Follow-up|0
6099679|NCT00753415|9715109|FG007|Part B|Lost to Follow-up|1
6099680|NCT00753415|9715110|FG008|Part B|Lost to Follow-up|1
6099681|NCT00753415|9715111|FG009|Part B|Lost to Follow-up|0
6099682|NCT00753415|9715102|FG000|Part B|Disease progression|0
6099683|NCT00753415|9715103|FG001|Part B|Disease progression|0
6099684|NCT00753415|9715104|FG002|Part B|Disease progression|0
6099685|NCT00753415|9715105|FG003|Part B|Disease progression|0
6099686|NCT00753415|9715106|FG004|Part B|Disease progression|0
6099687|NCT00753415|9715107|FG005|Part B|Disease progression|0
6099688|NCT00753415|9715108|FG006|Part B|Disease progression|0
6099689|NCT00753415|9715109|FG007|Part B|Disease progression|0
6099690|NCT00753415|9715110|FG008|Part B|Disease progression|2
6099691|NCT00753415|9715111|FG009|Part B|Disease progression|1
6099692|NCT00753454|9715135|FG000|Overall Study|Adverse Event|4
6099693|NCT00753454|9715135|FG000|Overall Study|Lack of Efficacy|1
6099694|NCT00753454|9715135|FG000|Overall Study|Lost to Follow-up|3
6099695|NCT00753454|9715135|FG000|Overall Study|Withdrawal by Subject|5
6099696|NCT00753454|9715135|FG000|Overall Study|Investigator Decision|1
6099697|NCT00753506|9715141|FG000|Overall Study|Withdrawal by Subject|4
6099698|NCT00753506|9715142|FG001|Overall Study|Withdrawal by Subject|1
6099699|NCT00753506|9715141|FG000|Overall Study|Lost to Follow-up|2
6099700|NCT00753506|9715142|FG001|Overall Study|Lost to Follow-up|0
6099701|NCT00753506|9715141|FG000|Overall Study|Other reason|1
6099702|NCT00753506|9715142|FG001|Overall Study|Other reason|1
6099703|NCT00753519|9715150|FG000|Overall Study|Withdrawal by Subject|0
6099704|NCT00753519|9715151|FG001|Overall Study|Withdrawal by Subject|2
6099705|NCT00753623|9715161|FG000|Phase I (14 Days)|Withdrawal by Subject|1
6099706|NCT00753623|9715162|FG001|Phase I (14 Days)|Withdrawal by Subject|1
6099707|NCT00753623|9715161|FG000|Phase I (14 Days)|Physician Decision|1
6099708|NCT00753623|9715162|FG001|Phase I (14 Days)|Physician Decision|2
6099709|NCT00753623|9715161|FG000|Phase I (14 Days)|Adverse Event|0
6099710|NCT00753623|9715162|FG001|Phase I (14 Days)|Adverse Event|1
6099711|NCT00753623|9715161|FG000|Washout (7 Days)|Physician Decision|1
6099712|NCT00753623|9715162|FG001|Washout (7 Days)|Physician Decision|0
6099713|NCT00753623|9715161|FG000|Phase II (14 Days)|Physician Decision|0
6099714|NCT00753623|9715162|FG001|Phase II (14 Days)|Physician Decision|1
6099715|NCT00753649|9715174|FG000|Overall Study|Migrated/moved from study area|1
6099716|NCT00753649|9715175|FG001|Overall Study|Migrated/moved from study area|0
6099717|NCT00753649|9715174|FG000|Overall Study|Lost to follow-up-incomplete vaccination|3
6099718|NCT00753649|9715175|FG001|Overall Study|Lost to follow-up-incomplete vaccination|0
6099719|NCT00753649|9715174|FG000|Overall Study|Lost to follow-up-complete vaccination|1
6099720|NCT00753649|9715175|FG001|Overall Study|Lost to follow-up-complete vaccination|0
6099721|NCT00753649|9715174|FG000|Overall Study|Protocol Violation|2
6099722|NCT00753649|9715175|FG001|Overall Study|Protocol Violation|0
6099723|NCT00753675|9715184|FG000|Overall Study|other reason|11
6099724|NCT00753675|9715185|FG001|Overall Study|other reason|12
6099725|NCT00753675|9715186|FG002|Overall Study|other reason|13
6099726|NCT00753675|9715184|FG000|Overall Study|Death|1
6099727|NCT00753675|9715185|FG001|Overall Study|Death|2
6099728|NCT00753675|9715186|FG002|Overall Study|Death|4
6204014|NCT01519661|9865361|FG000|Overall Study|Protocol deviation|6
6204015|NCT01519661|9865361|FG000|Overall Study|Lost to Follow-up|3
6204016|NCT01519661|9865361|FG000|Overall Study|Withdrawal by Subject|17
6099729|NCT00753675|9715184|FG000|Overall Study|Adverse Event|11
6099730|NCT00753675|9715185|FG001|Overall Study|Adverse Event|9
6099731|NCT00753675|9715186|FG002|Overall Study|Adverse Event|4
6099732|NCT00753675|9715184|FG000|Overall Study|Objective progression of disease|35
6099733|NCT00753675|9715185|FG001|Overall Study|Objective progression of disease|35
6099734|NCT00753675|9715186|FG002|Overall Study|Objective progression of disease|35
6099735|NCT00753675|9715184|FG000|Overall Study|Withdrawal by Subject|0
6099736|NCT00753675|9715185|FG001|Overall Study|Withdrawal by Subject|1
6099737|NCT00753675|9715186|FG002|Overall Study|Withdrawal by Subject|0
6099738|NCT00753675|9715184|FG000|Overall Study|Lost to Follow-up|1
6099739|NCT00753675|9715185|FG001|Overall Study|Lost to Follow-up|0
6099740|NCT00753675|9715186|FG002|Overall Study|Lost to Follow-up|0
6099741|NCT00753688|9715196|FG000|Overall Study|Death|102
6099742|NCT00753688|9715197|FG001|Overall Study|Death|203
6099743|NCT00753688|9715196|FG000|Overall Study|Missing|4
6099744|NCT00753688|9715197|FG001|Overall Study|Missing|9
6099745|NCT00753688|9715196|FG000|Overall Study|Participant Withdrew Consent|2
6099746|NCT00753688|9715197|FG001|Overall Study|Participant Withdrew Consent|2
6099747|NCT00753688|9715196|FG000|Overall Study|Ongoing - in Follow-up|15
6099748|NCT00753688|9715197|FG001|Overall Study|Ongoing - in Follow-up|31
6099749|NCT00753688|9715196|FG000|Overall Study|Adverse Event|0
6099750|NCT00753688|9715197|FG001|Overall Study|Adverse Event|1
6099751|NCT00753714|9715205|FG000|Overall Study|Lack of Efficacy|21
6099752|NCT00753714|9715206|FG001|Overall Study|Lack of Efficacy|34
6099753|NCT00753714|9715205|FG000|Overall Study|Adverse Event|26
6099754|NCT00753714|9715206|FG001|Overall Study|Adverse Event|18
6099755|NCT00753714|9715205|FG000|Overall Study|Protocol Violation|1
6099756|NCT00753714|9715206|FG001|Overall Study|Protocol Violation|0
6099757|NCT00753714|9715205|FG000|Overall Study|Lost to Follow-up|0
6099758|NCT00753714|9715206|FG001|Overall Study|Lost to Follow-up|1
6099759|NCT00753714|9715205|FG000|Overall Study|Withdrawal by Subject|2
6099760|NCT00753714|9715206|FG001|Overall Study|Withdrawal by Subject|1
6099761|NCT00753714|9715205|FG000|Overall Study|Death|3
6099762|NCT00753714|9715206|FG001|Overall Study|Death|3
6099763|NCT00753714|9715205|FG000|Overall Study|Other|7
6099764|NCT00753714|9715206|FG001|Overall Study|Other|5
6099765|NCT00753766|9715217|FG000|Overall Study|Physician Decision|1
6099766|NCT00753766|9715218|FG001|Overall Study|Physician Decision|0
6099767|NCT00753896|9715225|FG000|Overall Study|Adverse Event|4
6099768|NCT00753896|9715225|FG000|Overall Study|Death|1
6099769|NCT00753896|9715225|FG000|Overall Study|Lost to Follow-up|2
6099770|NCT00753896|9715225|FG000|Overall Study|Protocol Violation|1
6099771|NCT00753896|9715225|FG000|Overall Study|Withdrawal by Subject|4
6099772|NCT00753896|9715225|FG000|Overall Study|Entry Criteria Not Met|4
6099773|NCT00753922|9715233|FG000|Overall Study|Lost to Follow-up|155
6099774|NCT00753922|9715234|FG001|Overall Study|Lost to Follow-up|24
6099775|NCT00753922|9715235|FG002|Overall Study|Lost to Follow-up|28
6099776|NCT00753922|9715236|FG003|Overall Study|Lost to Follow-up|5
6099777|NCT00753922|9715233|FG000|Overall Study|Withdrawal by Subject|9
6099778|NCT00753922|9715234|FG001|Overall Study|Withdrawal by Subject|11
6099779|NCT00753922|9715235|FG002|Overall Study|Withdrawal by Subject|4
6099780|NCT00753922|9715236|FG003|Overall Study|Withdrawal by Subject|2
6099781|NCT00753922|9715233|FG000|Overall Study|Patient Non-compliance|55
6099782|NCT00753922|9715234|FG001|Overall Study|Patient Non-compliance|22
6099783|NCT00753922|9715235|FG002|Overall Study|Patient Non-compliance|14
6099784|NCT00753922|9715236|FG003|Overall Study|Patient Non-compliance|11
6099785|NCT00753922|9715233|FG000|Overall Study|Patients Not Completing Visit|11
6099786|NCT00753922|9715234|FG001|Overall Study|Patients Not Completing Visit|0
6099787|NCT00753922|9715235|FG002|Overall Study|Patients Not Completing Visit|1
6099788|NCT00753922|9715236|FG003|Overall Study|Patients Not Completing Visit|0
6099789|NCT00753922|9715233|FG000|Overall Study|Death|2
6099790|NCT00753922|9715234|FG001|Overall Study|Death|23
6099791|NCT00753922|9715235|FG002|Overall Study|Death|2
6099792|NCT00753922|9715236|FG003|Overall Study|Death|1
6099793|NCT00753922|9715233|FG000|Overall Study|Discontinuation Due to Explantation|14
6099794|NCT00753922|9715234|FG001|Overall Study|Discontinuation Due to Explantation|14
6099795|NCT00753922|9715235|FG002|Overall Study|Discontinuation Due to Explantation|14
6099796|NCT00753922|9715236|FG003|Overall Study|Discontinuation Due to Explantation|4
6099797|NCT00754065|9715270|FG000|Overall Study|Never received treatment|12
6099798|NCT00754065|9715271|FG001|Overall Study|Never received treatment|2
6099799|NCT00754065|9715270|FG000|Overall Study|Adverse Event|19
6099800|NCT00754065|9715271|FG001|Overall Study|Adverse Event|25
6099801|NCT00754065|9715270|FG000|Overall Study|Lost to Follow-up|7
6099802|NCT00754065|9715271|FG001|Overall Study|Lost to Follow-up|11
6099803|NCT00754065|9715270|FG000|Overall Study|Protocol Violation|12
6099804|NCT00754065|9715271|FG001|Overall Study|Protocol Violation|10
6099805|NCT00754065|9715270|FG000|Overall Study|Withdrawal by Subject|4
6099806|NCT00754065|9715271|FG001|Overall Study|Withdrawal by Subject|5
6099807|NCT00754065|9715270|FG000|Overall Study|Pregnancy|6
6099808|NCT00754065|9715271|FG001|Overall Study|Pregnancy|0
6099809|NCT00754065|9715270|FG000|Overall Study|Reason not specified or unknown, etc.|21
6099810|NCT00754065|9715271|FG001|Overall Study|Reason not specified or unknown, etc.|27
6099811|NCT00754234|9715324|FG000|Overall Study|Withdrawal by Subject|3
6099812|NCT00754325|9715343|FG000|Initial Treatment|Continuing Active Treatment|4
6099813|NCT00754325|9715344|FG001|Initial Treatment|Continuing Active Treatment|5
6099814|NCT00754325|9715343|FG000|Initial Treatment|Adverse Event|7
6099815|NCT00754325|9715344|FG001|Initial Treatment|Adverse Event|6
6099816|NCT00754325|9715343|FG000|Initial Treatment|Withdrawal by Subject|2
6099817|NCT00754325|9715344|FG001|Initial Treatment|Withdrawal by Subject|2
6099818|NCT00754325|9715343|FG000|Initial Treatment|Physician Decision|2
6099819|NCT00754325|9715344|FG001|Initial Treatment|Physician Decision|0
6099820|NCT00754325|9715343|FG000|Initial Treatment|Sponsor Request|0
6099821|NCT00754325|9715344|FG001|Initial Treatment|Sponsor Request|1
6099822|NCT00754325|9715343|FG000|Initial Treatment|Disease Progression|35
6099823|NCT00754325|9715344|FG001|Initial Treatment|Disease Progression|35
6099824|NCT00754338|9715355|FG000|First Intervention for Phase1&Phase2|Withdrawal by Subject|0
6099825|NCT00754338|9715356|FG001|First Intervention for Phase1&Phase2|Withdrawal by Subject|3
6099826|NCT00754338|9715357|FG002|First Intervention for Phase1&Phase2|Withdrawal by Subject|3
6099827|NCT00754338|9715358|FG003|First Intervention for Phase1&Phase2|Withdrawal by Subject|0
6099828|NCT00754338|9715355|FG000|Second Intervention for Phase1&Phase2|Withdrawal by Subject|0
6099829|NCT00754338|9715356|FG001|Second Intervention for Phase1&Phase2|Withdrawal by Subject|1
6099830|NCT00754338|9715357|FG002|Second Intervention for Phase1&Phase2|Withdrawal by Subject|0
6099831|NCT00754338|9715358|FG003|Second Intervention for Phase1&Phase2|Withdrawal by Subject|1
6099832|NCT00754390|9715381|FG000|Ca/Phytate Test Meal 1 (Randomized)|Withdrawal by Subject|3
6099833|NCT00754390|9715381|FG000|Ca/Phytate Test Meal 1 (Randomized)|Protocol Violation|2
6099834|NCT00754390|9715381|FG000|Ca/Phytate Test Meal 3 (Randomized)|Protocol Violation|1
6099835|NCT00754390|9715381|FG000|Ca/Phytate Test Meal 4 (Randomized)|Protocol Violation|1
6099836|NCT00754442|9715390|FG000|Overall Study|Withdrawal by Subject|5
6099837|NCT00754442|9715391|FG001|Overall Study|Withdrawal by Subject|3
6099838|NCT00754559|9715432|FG000|Overall Study|Adverse Event|15
6099839|NCT00754559|9715432|FG000|Overall Study|Protocol Violation|11
6099840|NCT00754559|9715432|FG000|Overall Study|Lack of Efficacy|10
6099841|NCT00754559|9715432|FG000|Overall Study|Lost to Follow-up|2
6099842|NCT00754559|9715432|FG000|Overall Study|Administrative reason|1
6099843|NCT00754559|9715432|FG000|Overall Study|Other|5
6099844|NCT00754559|9715432|FG000|Overall Study|Withdrawal by Subject|3
6099845|NCT00754572|9715439|FG000|Overall Study|Adverse Event|19
6099846|NCT00754572|9715439|FG000|Overall Study|Other|39
6099847|NCT00754572|9715439|FG000|Overall Study|Protocol Violation|3
6099848|NCT00754572|9715439|FG000|Overall Study|Withdrawal by Subject|3
6099849|NCT00754572|9715439|FG000|Overall Study|Lack of Efficacy|2
6099850|NCT00754572|9715439|FG000|Overall Study|Death|1
6099851|NCT00754572|9715439|FG000|Overall Study|Administrative Reason|3
6099852|NCT00754572|9715439|FG000|Overall Study|Lost to Follow-up|1
6099853|NCT00754624|9715443|FG000|Overall Study|Adverse Event|16
6099854|NCT00754624|9715443|FG000|Overall Study|Death|1
6099855|NCT00754624|9715443|FG000|Overall Study|Physician Decision|8
6099856|NCT00754624|9715443|FG000|Overall Study|Protocol Violation|1
6099857|NCT00754624|9715443|FG000|Overall Study|Withdrawal by Subject|28
6099858|NCT00754624|9715443|FG000|Overall Study|Various|12
6099859|NCT00754624|9715443|FG000|Overall Study|Lost to Follow-up|3
6099860|NCT00754650|9715447|FG000|Overall Study|Disease Progression|2
6099861|NCT00754741|9715454|FG000|Overall Study|Died or disenrolled|57
6099862|NCT00754741|9715455|FG001|Overall Study|Died or disenrolled|69
6099863|NCT00754741|9715456|FG002|Overall Study|Died or disenrolled|54
6099864|NCT00754936|9715486|FG000|Overall Study|Lost to Follow-up|3
6099865|NCT00754936|9715486|FG000|Overall Study|Physician Decision|1
6099866|NCT00754936|9715486|FG000|Overall Study|Withdrawal by Subject|2
6099867|NCT00754936|9715486|FG000|Overall Study|Side Effects|3
6099868|NCT00754936|9715486|FG000|Overall Study|Inter-current medical events|3
6099869|NCT00755079|9715501|FG000|Overall Study|Lost to Follow-up|1
6099870|NCT00755079|9715502|FG001|Overall Study|Lost to Follow-up|3
6099871|NCT00755079|9715501|FG000|Overall Study|Adverse Event|0
6099872|NCT00755079|9715502|FG001|Overall Study|Adverse Event|1
6099873|NCT00755079|9715501|FG000|Overall Study|Withdrawal by Subject|0
6099874|NCT00755079|9715502|FG001|Overall Study|Withdrawal by Subject|2
6099875|NCT00755105|9715511|FG000|Overall Study|Withdrawal by Subject|9
6099876|NCT00755105|9715512|FG001|Overall Study|Withdrawal by Subject|11
6099877|NCT00755105|9715513|FG002|Overall Study|Withdrawal by Subject|4
6099878|NCT00755183|9715532|FG000|Overall Study|Adverse Event|5
6099879|NCT00755183|9715533|FG001|Overall Study|Adverse Event|2
6099880|NCT00755183|9715532|FG000|Overall Study|Protocol Violation|0
6099881|NCT00755183|9715533|FG001|Overall Study|Protocol Violation|1
6099882|NCT00755183|9715532|FG000|Overall Study|Withdrawal by Subject|0
6099883|NCT00755183|9715533|FG001|Overall Study|Withdrawal by Subject|2
6099884|NCT00755183|9715532|FG000|Overall Study|Administrative|2
6099885|NCT00755183|9715533|FG001|Overall Study|Administrative|1
6099886|NCT00755196|9715541|FG000|Overall Study|Lost to Follow-up|1
6099887|NCT00755196|9715541|FG000|Overall Study|Lack of Efficiency|1
6099888|NCT00755222|9715548|FG000|Overall Study|Withdrawal by Subject|4
6099889|NCT00755222|9715549|FG001|Overall Study|Withdrawal by Subject|2
6099890|NCT00755222|9715548|FG000|Overall Study|Adverse Event|2
6099891|NCT00755222|9715549|FG001|Overall Study|Adverse Event|0
6099892|NCT00755222|9715548|FG000|Overall Study|Protocol Violation|2
6099893|NCT00755222|9715549|FG001|Overall Study|Protocol Violation|0
6099894|NCT00755326|9715575|FG000|Overall Study|Lost to Follow-up|2
6099895|NCT00755326|9715576|FG001|Overall Study|Lost to Follow-up|3
6099896|NCT00755417|9715586|FG000|Overall Study|Adverse Event|28
6099897|NCT00755417|9715587|FG001|Overall Study|Adverse Event|20
6099898|NCT00755417|9715588|FG002|Overall Study|Adverse Event|7
6099899|NCT00755417|9715586|FG000|Overall Study|Lack of Efficacy|8
6099900|NCT00755417|9715587|FG001|Overall Study|Lack of Efficacy|4
6099901|NCT00755417|9715588|FG002|Overall Study|Lack of Efficacy|9
6099902|NCT00755417|9715586|FG000|Overall Study|Protocol Violation|2
6099903|NCT00755417|9715587|FG001|Overall Study|Protocol Violation|1
6099904|NCT00755417|9715588|FG002|Overall Study|Protocol Violation|1
6099905|NCT00755417|9715586|FG000|Overall Study|Lost to Follow-up|3
6099906|NCT00755417|9715587|FG001|Overall Study|Lost to Follow-up|0
6099907|NCT00755417|9715588|FG002|Overall Study|Lost to Follow-up|1
6099908|NCT00755417|9715586|FG000|Overall Study|Withdrawal by Subject|12
6099909|NCT00755417|9715587|FG001|Overall Study|Withdrawal by Subject|12
6099910|NCT00755417|9715588|FG002|Overall Study|Withdrawal by Subject|12
6099911|NCT00755417|9715586|FG000|Overall Study|Not specified or missing data|9
6099912|NCT00755417|9715587|FG001|Overall Study|Not specified or missing data|18
6099913|NCT00755417|9715588|FG002|Overall Study|Not specified or missing data|12
6099914|NCT00755716|9715599|FG000|Overall Study|Adverse Event|1
6099915|NCT00755716|9715600|FG001|Overall Study|Adverse Event|4
6099916|NCT00755716|9715601|FG002|Overall Study|Adverse Event|1
6099917|NCT00755716|9715599|FG000|Overall Study|Lack of Efficacy|2
6099918|NCT00755716|9715600|FG001|Overall Study|Lack of Efficacy|0
6099919|NCT00755716|9715601|FG002|Overall Study|Lack of Efficacy|0
6099920|NCT00755716|9715599|FG000|Overall Study|Lost to Follow-up|5
6099921|NCT00755716|9715600|FG001|Overall Study|Lost to Follow-up|3
6099922|NCT00755716|9715601|FG002|Overall Study|Lost to Follow-up|1
6099923|NCT00755716|9715599|FG000|Overall Study|work schedule issues|0
6099924|NCT00755716|9715600|FG001|Overall Study|work schedule issues|1
6099925|NCT00755716|9715601|FG002|Overall Study|work schedule issues|1
6204017|NCT01519661|9865361|FG000|Overall Study|Lack of Efficacy|6
6204018|NCT01519661|9865361|FG000|Overall Study|Adverse Event|29
6204019|NCT01519674|9865369|FG000|Overall Study|Adverse Event|3
6204020|NCT01519674|9865370|FG001|Overall Study|Adverse Event|3
6204021|NCT01519674|9865371|FG002|Overall Study|Adverse Event|0
6204022|NCT01519674|9865369|FG000|Overall Study|Lack of Efficacy|1
6204023|NCT01519674|9865370|FG001|Overall Study|Lack of Efficacy|1
6204024|NCT01519674|9865371|FG002|Overall Study|Lack of Efficacy|1
6204025|NCT01519674|9865369|FG000|Overall Study|Protocol Violation|0
6204026|NCT01519674|9865370|FG001|Overall Study|Protocol Violation|3
6204027|NCT01519674|9865371|FG002|Overall Study|Protocol Violation|1
6204028|NCT01519674|9865369|FG000|Overall Study|Withdrawal Criteria|7
6204029|NCT01519674|9865370|FG001|Overall Study|Withdrawal Criteria|2
6204030|NCT01519674|9865371|FG002|Overall Study|Withdrawal Criteria|7
6204031|NCT01519674|9865369|FG000|Overall Study|Unsclassified|10
6204032|NCT01519674|9865370|FG001|Overall Study|Unsclassified|4
6204033|NCT01519674|9865371|FG002|Overall Study|Unsclassified|3
6204034|NCT01519700|9865383|FG000|Overall Study|Death|1
6204035|NCT01519700|9865384|FG001|Overall Study|Death|0
6204036|NCT01519700|9865385|FG002|Overall Study|Death|0
6204037|NCT01519700|9865386|FG003|Overall Study|Death|0
6204038|NCT01519700|9865383|FG000|Overall Study|Lost to Follow-up|0
6204039|NCT01519700|9865384|FG001|Overall Study|Lost to Follow-up|0
6204040|NCT01519700|9865385|FG002|Overall Study|Lost to Follow-up|1
6204041|NCT01519700|9865386|FG003|Overall Study|Lost to Follow-up|1
6204042|NCT01519700|9865383|FG000|Overall Study|Physician Decision|1
6204043|NCT01519700|9865384|FG001|Overall Study|Physician Decision|1
6204044|NCT01519700|9865385|FG002|Overall Study|Physician Decision|3
6204045|NCT01519700|9865386|FG003|Overall Study|Physician Decision|0
6204046|NCT01519700|9865383|FG000|Overall Study|Withdrawal by Subject|5
6204047|NCT01519700|9865384|FG001|Overall Study|Withdrawal by Subject|3
6204048|NCT01519700|9865385|FG002|Overall Study|Withdrawal by Subject|3
6204049|NCT01519700|9865386|FG003|Overall Study|Withdrawal by Subject|2
6204050|NCT01519700|9865383|FG000|Overall Study|Other Reason|2
6204051|NCT01519700|9865384|FG001|Overall Study|Other Reason|2
6204052|NCT01519700|9865385|FG002|Overall Study|Other Reason|0
6204053|NCT01519700|9865386|FG003|Overall Study|Other Reason|4
6204054|NCT01519765|9865417|FG000|Overall Study|Adverse Event|0
6204055|NCT01519765|9865418|FG001|Overall Study|Adverse Event|1
6204056|NCT01519765|9865417|FG000|Overall Study|Lack of Efficacy|2
6204057|NCT01519765|9865418|FG001|Overall Study|Lack of Efficacy|0
6204058|NCT01519765|9865417|FG000|Overall Study|Protocol Violation|1
6204059|NCT01519765|9865418|FG001|Overall Study|Protocol Violation|0
6204060|NCT01519765|9865417|FG000|Overall Study|Withdrawal by Subject|0
6204061|NCT01519765|9865418|FG001|Overall Study|Withdrawal by Subject|1
6204062|NCT01519778|9865425|FG000|Overall Study|Withdrawal by Subject|3
6204063|NCT01519778|9865425|FG000|Overall Study|Lost to Follow-up|10
6204064|NCT01519778|9865425|FG000|Overall Study|Physician Decision|1
6204065|NCT01519791|9865431|FG000|Overall Study|SAE,non-fatal + AE,non-serious non-fatal|2
6204066|NCT01519791|9865432|FG001|Overall Study|SAE,non-fatal + AE,non-serious non-fatal|1
6204067|NCT01519791|9865431|FG000|Overall Study|Protocol Violation|6
6204068|NCT01519791|9865432|FG001|Overall Study|Protocol Violation|19
6204069|NCT01519791|9865431|FG000|Overall Study|Other Reason|87
6204070|NCT01519791|9865432|FG001|Overall Study|Other Reason|222
6204071|NCT01519791|9865431|FG000|Overall Study|subjects randomized in error|2
6204072|NCT01519791|9865432|FG001|Overall Study|subjects randomized in error|0
6204073|NCT01519791|9865431|FG000|Overall Study|Lack of Efficacy|16
6099926|NCT00755807|9715624|FG000|Acute Phase|Adverse Event|16
6204074|NCT01519791|9865432|FG001|Overall Study|Lack of Efficacy|20
6099927|NCT00755807|9715625|FG001|Acute Phase|Adverse Event|5
6099928|NCT00755807|9715624|FG000|Acute Phase|Protocol Violation|1
6099929|NCT00755807|9715625|FG001|Acute Phase|Protocol Violation|3
6099930|NCT00755807|9715624|FG000|Acute Phase|Withdrawal by Subject|1
6099931|NCT00755807|9715625|FG001|Acute Phase|Withdrawal by Subject|2
6099932|NCT00755807|9715624|FG000|Acute Phase|Lack of Efficacy|0
6099933|NCT00755807|9715625|FG001|Acute Phase|Lack of Efficacy|1
6099934|NCT00755807|9715624|FG000|Acute Phase|Physician Decision|0
6099935|NCT00755807|9715625|FG001|Acute Phase|Physician Decision|1
6099936|NCT00755807|9715624|FG000|Open-label Extension Phase|Adverse Event|7
6099937|NCT00755807|9715625|FG001|Open-label Extension Phase|Adverse Event|7
6099938|NCT00755807|9715624|FG000|Open-label Extension Phase|Protocol Violation|5
6099939|NCT00755807|9715625|FG001|Open-label Extension Phase|Protocol Violation|2
6099940|NCT00755807|9715624|FG000|Open-label Extension Phase|Lack of Efficacy|3
6099941|NCT00755807|9715625|FG001|Open-label Extension Phase|Lack of Efficacy|3
6099942|NCT00755807|9715624|FG000|Open-label Extension Phase|Withdrawal by Subject|1
6099943|NCT00755807|9715625|FG001|Open-label Extension Phase|Withdrawal by Subject|3
6099944|NCT00755807|9715624|FG000|Open-label Extension Phase|Lost to Follow-up|2
6099945|NCT00755807|9715625|FG001|Open-label Extension Phase|Lost to Follow-up|0
6099946|NCT00755807|9715624|FG000|Open-label Extension Phase|Sponsor Decision|0
6099947|NCT00755807|9715625|FG001|Open-label Extension Phase|Sponsor Decision|1
6099948|NCT00755846|9715641|FG000|Overall Study|Adverse Event|0
6099949|NCT00755846|9715642|FG001|Overall Study|Adverse Event|0
6099950|NCT00755846|9715643|FG002|Overall Study|Adverse Event|0
6099951|NCT00755846|9715644|FG003|Overall Study|Adverse Event|1
6099952|NCT00755846|9715645|FG004|Overall Study|Adverse Event|3
6099953|NCT00755846|9715646|FG005|Overall Study|Adverse Event|2
6099954|NCT00755846|9715641|FG000|Overall Study|Protocol Violation|1
6099955|NCT00755846|9715642|FG001|Overall Study|Protocol Violation|1
6099956|NCT00755846|9715643|FG002|Overall Study|Protocol Violation|1
6099957|NCT00755846|9715644|FG003|Overall Study|Protocol Violation|1
6099958|NCT00755846|9715645|FG004|Overall Study|Protocol Violation|1
6099959|NCT00755846|9715646|FG005|Overall Study|Protocol Violation|1
6099960|NCT00755846|9715641|FG000|Overall Study|Lost to Follow-up|0
6099961|NCT00755846|9715642|FG001|Overall Study|Lost to Follow-up|2
6099962|NCT00755846|9715643|FG002|Overall Study|Lost to Follow-up|1
6099963|NCT00755846|9715644|FG003|Overall Study|Lost to Follow-up|0
6099964|NCT00755846|9715645|FG004|Overall Study|Lost to Follow-up|4
6099965|NCT00755846|9715646|FG005|Overall Study|Lost to Follow-up|2
6099966|NCT00755846|9715641|FG000|Overall Study|Withdrawal by Subject|2
6099967|NCT00755846|9715642|FG001|Overall Study|Withdrawal by Subject|3
6099968|NCT00755846|9715643|FG002|Overall Study|Withdrawal by Subject|5
6099969|NCT00755846|9715644|FG003|Overall Study|Withdrawal by Subject|2
6099970|NCT00755846|9715645|FG004|Overall Study|Withdrawal by Subject|0
6099971|NCT00755846|9715646|FG005|Overall Study|Withdrawal by Subject|1
6099972|NCT00755846|9715641|FG000|Overall Study|Hyperglycemic Rescue|21
6099973|NCT00755846|9715642|FG001|Overall Study|Hyperglycemic Rescue|7
6099974|NCT00755846|9715643|FG002|Overall Study|Hyperglycemic Rescue|5
6099975|NCT00755846|9715644|FG003|Overall Study|Hyperglycemic Rescue|8
6099976|NCT00755846|9715645|FG004|Overall Study|Hyperglycemic Rescue|8
6099977|NCT00755846|9715646|FG005|Overall Study|Hyperglycemic Rescue|7
6099978|NCT00755846|9715641|FG000|Overall Study|Physician Decision|1
6099979|NCT00755846|9715642|FG001|Overall Study|Physician Decision|3
6099980|NCT00755846|9715643|FG002|Overall Study|Physician Decision|0
6099981|NCT00755846|9715644|FG003|Overall Study|Physician Decision|1
6099982|NCT00755846|9715645|FG004|Overall Study|Physician Decision|0
6099983|NCT00755846|9715646|FG005|Overall Study|Physician Decision|1
6099984|NCT00755846|9715641|FG000|Overall Study|Administrative Error|0
6099985|NCT00755846|9715642|FG001|Overall Study|Administrative Error|1
6099986|NCT00755846|9715643|FG002|Overall Study|Administrative Error|0
6099987|NCT00755846|9715644|FG003|Overall Study|Administrative Error|0
6099988|NCT00755846|9715645|FG004|Overall Study|Administrative Error|0
6099989|NCT00755846|9715646|FG005|Overall Study|Administrative Error|0
6099990|NCT00755846|9715641|FG000|Overall Study|Participant Non-compliance|0
6099991|NCT00755846|9715642|FG001|Overall Study|Participant Non-compliance|0
6099992|NCT00755846|9715643|FG002|Overall Study|Participant Non-compliance|0
6099993|NCT00755846|9715644|FG003|Overall Study|Participant Non-compliance|0
6099994|NCT00755846|9715645|FG004|Overall Study|Participant Non-compliance|1
6099995|NCT00755846|9715646|FG005|Overall Study|Participant Non-compliance|0
6099996|NCT00755937|9715669|FG000|Recruitment|Unknown if infliximab received|164
6099997|NCT00755937|9715669|FG000|Observational Follow-up|Lost to Follow-up|148
6099998|NCT00756002|9715675|FG000|Double-Blind Treatment Period|Lack of Efficacy|1
6099999|NCT00756002|9715676|FG001|Double-Blind Treatment Period|Lack of Efficacy|1
6100000|NCT00756002|9715675|FG000|Double-Blind Treatment Period|Lost to Follow-up|0
6100001|NCT00756002|9715676|FG001|Double-Blind Treatment Period|Lost to Follow-up|1
6100002|NCT00756002|9715675|FG000|Double-Blind Treatment Period|Withdrawal by Subject|6
6100003|NCT00756002|9715676|FG001|Double-Blind Treatment Period|Withdrawal by Subject|6
6100004|NCT00756002|9715675|FG000|Double-Blind Treatment Period|Protocol Violation|6
6100005|NCT00756002|9715676|FG001|Double-Blind Treatment Period|Protocol Violation|5
6100006|NCT00756002|9715675|FG000|Double-Blind Treatment Period|Other|2
6100007|NCT00756002|9715676|FG001|Double-Blind Treatment Period|Other|2
6100008|NCT00756275|9715714|FG000|Overall Study|Lost to Follow-up|25
6100009|NCT00756275|9715715|FG001|Overall Study|Lost to Follow-up|21
6100010|NCT00756275|9715714|FG000|Overall Study|Withdrawal by Subject|4
6100011|NCT00756275|9715715|FG001|Overall Study|Withdrawal by Subject|7
6100012|NCT00756314|9715723|FG000|Overall Study|Lost to Follow-up|2
6100013|NCT00756314|9715724|FG001|Overall Study|Lost to Follow-up|59
6100014|NCT00756444|9715732|FG000|Overall Study|Adverse Event|1
6100015|NCT00756444|9715733|FG001|Overall Study|Adverse Event|1
6100016|NCT00756444|9715732|FG000|Overall Study|Withdrawal by Subject|6
6100017|NCT00756444|9715733|FG001|Overall Study|Withdrawal by Subject|8
6100018|NCT00756444|9715732|FG000|Overall Study|Lost to Follow-up|0
6100019|NCT00756444|9715733|FG001|Overall Study|Lost to Follow-up|1
6204075|NCT01519791|9865431|FG000|Overall Study|SAE, non-fatal|6
6204076|NCT01519791|9865432|FG001|Overall Study|SAE, non-fatal|22
6204077|NCT01519791|9865431|FG000|Overall Study|AE, serious fatal|0
6204078|NCT01519791|9865432|FG001|Overall Study|AE, serious fatal|1
6204079|NCT01519791|9865431|FG000|Overall Study|SAE, fatal + SAE, non-fatal|0
6204080|NCT01519791|9865432|FG001|Overall Study|SAE, fatal + SAE, non-fatal|1
6204081|NCT01519791|9865431|FG000|Overall Study|AE, non-serious non-fatal|12
6204082|NCT01519791|9865432|FG001|Overall Study|AE, non-serious non-fatal|31
6204083|NCT01519791|9865431|FG000|Overall Study|Withdrawal by Subject|15
6204084|NCT01519791|9865432|FG001|Overall Study|Withdrawal by Subject|37
6204085|NCT01519791|9865431|FG000|Overall Study|Lost to Follow-up|6
6204086|NCT01519791|9865432|FG001|Overall Study|Lost to Follow-up|14
6204087|NCT01519817|9865440|FG000|Overall Study|Withdrawal by Subject|1
6204088|NCT01519817|9865441|FG001|Overall Study|Withdrawal by Subject|0
6204089|NCT01519817|9865442|FG002|Overall Study|Withdrawal by Subject|0
6204090|NCT01519817|9865443|FG003|Overall Study|Withdrawal by Subject|0
6204091|NCT01519817|9865440|FG000|Overall Study|Off study due to infection|0
6204092|NCT01519817|9865441|FG001|Overall Study|Off study due to infection|0
6204093|NCT01519817|9865442|FG002|Overall Study|Off study due to infection|0
6204094|NCT01519817|9865443|FG003|Overall Study|Off study due to infection|1
6204095|NCT01519869|9865453|FG000|Overall Study|Lost to Follow-up|1
6204096|NCT01519921|9865468|FG000|Overall Study|Adverse Event|10
6204097|NCT01519921|9865469|FG001|Overall Study|Adverse Event|9
6204098|NCT01519921|9865468|FG000|Overall Study|Lack of Efficacy|4
6204099|NCT01519921|9865469|FG001|Overall Study|Lack of Efficacy|3
6204100|NCT01519921|9865468|FG000|Overall Study|Withdrawal by Subject|3
6204101|NCT01519921|9865469|FG001|Overall Study|Withdrawal by Subject|0
6204102|NCT01519921|9865468|FG000|Overall Study|Lost to Follow-up|2
6204103|NCT01519921|9865469|FG001|Overall Study|Lost to Follow-up|1
6204104|NCT01519921|9865468|FG000|Overall Study|Treatment refusal|2
6204105|NCT01519921|9865469|FG001|Overall Study|Treatment refusal|1
6204106|NCT01519921|9865468|FG000|Overall Study|High alanine aminotransferase (ALT)|0
6204107|NCT01519921|9865469|FG001|Overall Study|High alanine aminotransferase (ALT)|1
6204108|NCT01519934|9865475|FG000|Overall Study|Lost to Follow-up|3
6204109|NCT01519947|9865483|FG000|Overall Study|Death|0
6204110|NCT01519947|9865484|FG001|Overall Study|Death|0
6204111|NCT01519947|9865485|FG002|Overall Study|Death|0
6204112|NCT01519947|9865486|FG003|Overall Study|Death|1
6204113|NCT01519947|9865483|FG000|Overall Study|Protocol Violation|0
6204114|NCT01519947|9865484|FG001|Overall Study|Protocol Violation|0
6204115|NCT01519947|9865485|FG002|Overall Study|Protocol Violation|2
6204116|NCT01519947|9865486|FG003|Overall Study|Protocol Violation|1
6204117|NCT01519947|9865483|FG000|Overall Study|Peritoneal Dialysis Needed|0
6204118|NCT01519947|9865484|FG001|Overall Study|Peritoneal Dialysis Needed|1
6204119|NCT01519947|9865485|FG002|Overall Study|Peritoneal Dialysis Needed|0
6204120|NCT01519947|9865486|FG003|Overall Study|Peritoneal Dialysis Needed|0
6204121|NCT01519947|9865483|FG000|Overall Study|Development of Anemia|0
6204122|NCT01519947|9865484|FG001|Overall Study|Development of Anemia|1
6204123|NCT01519947|9865485|FG002|Overall Study|Development of Anemia|0
6204124|NCT01519947|9865486|FG003|Overall Study|Development of Anemia|1
6204125|NCT01519947|9865483|FG000|Overall Study|Blood Transfusion|0
6204126|NCT01519947|9865484|FG001|Overall Study|Blood Transfusion|1
6204127|NCT01519947|9865485|FG002|Overall Study|Blood Transfusion|1
6204128|NCT01519947|9865486|FG003|Overall Study|Blood Transfusion|0
6204129|NCT01519947|9865483|FG000|Overall Study|Withdrawal by Subject|0
6204130|NCT01519947|9865484|FG001|Overall Study|Withdrawal by Subject|1
6204131|NCT01519947|9865485|FG002|Overall Study|Withdrawal by Subject|0
6204132|NCT01519947|9865486|FG003|Overall Study|Withdrawal by Subject|1
6204133|NCT01519947|9865483|FG000|Overall Study|Lost to Follow-up|0
5980504|NCT02733042|9569324|FG004|Treatment Period|Progressive Disease|1
6204134|NCT01519947|9865484|FG001|Overall Study|Lost to Follow-up|0
6204135|NCT01519947|9865485|FG002|Overall Study|Lost to Follow-up|3
6204136|NCT01519947|9865486|FG003|Overall Study|Lost to Follow-up|2
6204137|NCT01519947|9865483|FG000|Overall Study|Poor Response|1
6204138|NCT01519947|9865484|FG001|Overall Study|Poor Response|0
6204139|NCT01519947|9865485|FG002|Overall Study|Poor Response|0
6204140|NCT01519947|9865486|FG003|Overall Study|Poor Response|1
6204141|NCT01519947|9865483|FG000|Overall Study|Adverse Event|1
6204142|NCT01519947|9865484|FG001|Overall Study|Adverse Event|0
6204143|NCT01519947|9865485|FG002|Overall Study|Adverse Event|1
6204144|NCT01519947|9865486|FG003|Overall Study|Adverse Event|1
6204145|NCT01520324|9865509|FG000|Overall Study|Subject discontinued (moderate illness)|1
6204146|NCT01520363|9865515|FG000|Overall Study|Withdrawal by Subject|2
6204147|NCT01520363|9865516|FG001|Overall Study|Withdrawal by Subject|0
6100020|NCT00756444|9715732|FG000|Overall Study|Death|5
6100021|NCT00756444|9715733|FG001|Overall Study|Death|4
6100022|NCT00756444|9715732|FG000|Overall Study|Disease Progression|2
6100023|NCT00756444|9715733|FG001|Overall Study|Disease Progression|7
6100024|NCT00756444|9715732|FG000|Overall Study|Ineligibility Determined|1
6100025|NCT00756444|9715733|FG001|Overall Study|Ineligibility Determined|0
6100026|NCT00756457|9715742|FG000|Overall Study|Lost to Follow-up|1
6100027|NCT00756457|9715743|FG001|Overall Study|Lost to Follow-up|2
6100028|NCT00756470|9715765|FG000|Overall Study|Withdrawal by Subject|1
6100029|NCT00756470|9715765|FG000|Overall Study|Adverse Event|4
6100030|NCT00756652|9715812|FG000|Original Phase|Withdrawal by Subject|864
6100031|NCT00756652|9715813|FG001|Original Phase|Withdrawal by Subject|23
6100032|NCT00756652|9715812|FG000|Original Phase|Lost to Follow-up|601
6100033|NCT00756652|9715813|FG001|Original Phase|Lost to Follow-up|0
6100034|NCT00756652|9715812|FG000|Original Phase|Other Discontinuation|797
6100035|NCT00756652|9715813|FG001|Original Phase|Other Discontinuation|5
6100036|NCT00756652|9715812|FG000|Original Phase|Participant Noncompliance|18622
6100037|NCT00756652|9715813|FG001|Original Phase|Participant Noncompliance|424
6100038|NCT00756652|9715812|FG000|Original Phase|Unknown Discontinuation Reason|2
6100039|NCT00756652|9715813|FG001|Original Phase|Unknown Discontinuation Reason|0
6100040|NCT00756652|9715812|FG000|Original Phase|Participants without data|3259
6100041|NCT00756652|9715813|FG001|Original Phase|Participants without data|466
6100042|NCT00756652|9715812|FG000|Original Phase|Death|168
6100043|NCT00756652|9715813|FG001|Original Phase|Death|1
6100044|NCT00756652|9715812|FG000|Original Phase|Not due for F/U at Phase One closure|11076
6100045|NCT00756652|9715813|FG001|Original Phase|Not due for F/U at Phase One closure|2
6100046|NCT00756652|9715812|FG000|Re-Op Phase|Withdrawal by Subject|62
6100047|NCT00756652|9715813|FG001|Re-Op Phase|Withdrawal by Subject|0
6100048|NCT00756652|9715812|FG000|Re-Op Phase|Death|6
6100049|NCT00756652|9715813|FG001|Re-Op Phase|Death|0
6100050|NCT00756652|9715812|FG000|Re-Op Phase|Lost to Follow-up|340
6100051|NCT00756652|9715813|FG001|Re-Op Phase|Lost to Follow-up|0
6100052|NCT00756652|9715812|FG000|Re-Op Phase|Site Closed|2454
6100053|NCT00756652|9715813|FG001|Re-Op Phase|Site Closed|0
6100054|NCT00756652|9715812|FG000|Re-Op Phase|Withdrawn after explant|14
6100055|NCT00756652|9715813|FG001|Re-Op Phase|Withdrawn after explant|0
6100056|NCT00756717|9715822|FG000|Overall Study|Withdrawal by Subject|2
6100057|NCT00756730|9715828|FG000|Overall Study|discontinued due to rash prior to week 4|0
6100058|NCT00756730|9715829|FG001|Overall Study|discontinued due to rash prior to week 4|1
6100059|NCT00756730|9715828|FG000|Overall Study|persistent low-level viremmia|0
6100060|NCT00756730|9715829|FG001|Overall Study|persistent low-level viremmia|1
6100061|NCT00756886|9715837|FG000|Overall Study|Lost to Follow-up|1
6100062|NCT00756886|9715838|FG001|Overall Study|Lost to Follow-up|0
6100063|NCT00756886|9715837|FG000|Overall Study|Adverse Event|0
6100064|NCT00756886|9715838|FG001|Overall Study|Adverse Event|3
6100065|NCT00756886|9715837|FG000|Overall Study|Lack of Efficacy|1
6100066|NCT00756886|9715838|FG001|Overall Study|Lack of Efficacy|0
6100067|NCT00756886|9715837|FG000|Overall Study|Ineligible|9
6100068|NCT00756886|9715838|FG001|Overall Study|Ineligible|4
6100069|NCT00757003|9715862|FG000|Overall Study|Death|33
6100070|NCT00757003|9715862|FG000|Overall Study|Lost to Follow-up|9
6100071|NCT00757003|9715862|FG000|Overall Study|Withdrawal by Subject|4
6100072|NCT00757003|9715862|FG000|Overall Study|Surgically explanted|2
6100073|NCT00757003|9715862|FG000|Overall Study|Not implanted|1
6100074|NCT00757172|9715867|FG000|Overall Study|Withdrawal by Subject|4
6100075|NCT00757172|9715867|FG000|Overall Study|Physician Decision|3
6100076|NCT00757172|9715867|FG000|Overall Study|Progression|4
6100077|NCT00757237|9715873|FG000|Overall Study|Lost to Follow-up|0
6100078|NCT00757237|9715874|FG001|Overall Study|Lost to Follow-up|1
6100079|NCT00757237|9715873|FG000|Overall Study|Protocol Violation|0
6100080|NCT00757237|9715874|FG001|Overall Study|Protocol Violation|2
6100081|NCT00757237|9715873|FG000|Overall Study|Physician Decision|2
6100082|NCT00757237|9715874|FG001|Overall Study|Physician Decision|3
6100083|NCT00757237|9715873|FG000|Overall Study|Withdrawal by Subject|8
6100084|NCT00757237|9715874|FG001|Overall Study|Withdrawal by Subject|12
6100085|NCT00757237|9715873|FG000|Overall Study|Safety or Tolerability|3
6100086|NCT00757237|9715874|FG001|Overall Study|Safety or Tolerability|5
6100087|NCT00757237|9715873|FG000|Overall Study|Other|0
6100088|NCT00757237|9715874|FG001|Overall Study|Other|2
6100089|NCT00757588|9715888|FG000|Period 1: Short-term (24-week) Phase|Lack of Efficacy|3
6100090|NCT00757588|9715889|FG001|Period 1: Short-term (24-week) Phase|Lack of Efficacy|2
6100091|NCT00757588|9715888|FG000|Period 1: Short-term (24-week) Phase|Adverse Event|6
6100092|NCT00757588|9715889|FG001|Period 1: Short-term (24-week) Phase|Adverse Event|3
6100093|NCT00757588|9715888|FG000|Period 1: Short-term (24-week) Phase|Withdrawal by Subject|13
6100094|NCT00757588|9715889|FG001|Period 1: Short-term (24-week) Phase|Withdrawal by Subject|5
6100095|NCT00757588|9715888|FG000|Period 1: Short-term (24-week) Phase|Death|1
6100096|NCT00757588|9715889|FG001|Period 1: Short-term (24-week) Phase|Death|0
6100097|NCT00757588|9715888|FG000|Period 1: Short-term (24-week) Phase|Lost to Follow-up|3
6100098|NCT00757588|9715889|FG001|Period 1: Short-term (24-week) Phase|Lost to Follow-up|5
6100099|NCT00757588|9715888|FG000|Period 1: Short-term (24-week) Phase|Poor compliance or noncompliance|5
6100100|NCT00757588|9715889|FG001|Period 1: Short-term (24-week) Phase|Poor compliance or noncompliance|1
6100101|NCT00757588|9715888|FG000|Period 1: Short-term (24-week) Phase|No longer meets study criteria|5
6100102|NCT00757588|9715889|FG001|Period 1: Short-term (24-week) Phase|No longer meets study criteria|0
6100103|NCT00757588|9715888|FG000|Period 1: Short-term (24-week) Phase|Other|0
6100104|NCT00757588|9715889|FG001|Period 1: Short-term (24-week) Phase|Other|1
6100105|NCT00757588|9715888|FG000|Period 2: Long-term (52-week) Phase|Lack of Efficacy|1
6100106|NCT00757588|9715889|FG001|Period 2: Long-term (52-week) Phase|Lack of Efficacy|0
6100107|NCT00757588|9715888|FG000|Period 2: Long-term (52-week) Phase|Adverse Event|4
6100108|NCT00757588|9715889|FG001|Period 2: Long-term (52-week) Phase|Adverse Event|0
6100109|NCT00757588|9715888|FG000|Period 2: Long-term (52-week) Phase|Withdrawal by Subject|4
6100110|NCT00757588|9715889|FG001|Period 2: Long-term (52-week) Phase|Withdrawal by Subject|2
6100111|NCT00757588|9715888|FG000|Period 2: Long-term (52-week) Phase|Lost to Follow-up|1
6100112|NCT00757588|9715889|FG001|Period 2: Long-term (52-week) Phase|Lost to Follow-up|1
6100113|NCT00757588|9715888|FG000|Period 2: Long-term (52-week) Phase|Poor or noncompliance|5
6100114|NCT00757588|9715889|FG001|Period 2: Long-term (52-week) Phase|Poor or noncompliance|2
6100115|NCT00757588|9715888|FG000|Period 2: Long-term (52-week) Phase|Pregnancy|1
6100116|NCT00757588|9715889|FG001|Period 2: Long-term (52-week) Phase|Pregnancy|0
6100117|NCT00757588|9715888|FG000|Period 2: Long-term (52-week) Phase|No longer meets study criteria|5
6100118|NCT00757588|9715889|FG001|Period 2: Long-term (52-week) Phase|No longer meets study criteria|4
6100119|NCT00757588|9715888|FG000|Period 2: Long-term (52-week) Phase|Other|1
6100120|NCT00757588|9715889|FG001|Period 2: Long-term (52-week) Phase|Other|0
6204148|NCT01520402|9865546|FG000|Overall Study|Withdrawal by Subject|2
6204149|NCT01520402|9865546|FG000|Overall Study|Physician Decision|3
6204150|NCT01520506|9865577|FG000|Overall Study|Missed Visit|4
6204151|NCT01520506|9865577|FG000|Overall Study|Lost to Follow-up|1
6204152|NCT01520506|9865577|FG000|Overall Study|Withdrawal by Subject|1
6204153|NCT01520870|9865653|FG000|Overall Study|Withdrawal by Subject|2
6204154|NCT01520909|9865659|FG000|Part 1 (Randomized Period)|Adverse Event|1
6204155|NCT01520909|9865660|FG001|Part 1 (Randomized Period)|Adverse Event|2
6204156|NCT01520909|9865661|FG002|Part 1 (Randomized Period)|Adverse Event|0
6204157|NCT01520909|9865659|FG000|Part 2 (Open-Label Period)-Eltrombopag|Adverse Event|0
6204158|NCT01520909|9865660|FG001|Part 2 (Open-Label Period)-Eltrombopag|Adverse Event|0
6204159|NCT01520909|9865661|FG002|Part 2 (Open-Label Period)-Eltrombopag|Adverse Event|4
6204160|NCT01520909|9865659|FG000|Part 2 (Open-Label Period)-Eltrombopag|Lack of Efficacy|0
6204161|NCT01520909|9865660|FG001|Part 2 (Open-Label Period)-Eltrombopag|Lack of Efficacy|0
6204162|NCT01520909|9865661|FG002|Part 2 (Open-Label Period)-Eltrombopag|Lack of Efficacy|2
6204163|NCT01520909|9865659|FG000|Part 2 (Open-Label Period)-Eltrombopag|Withdrawal by parent or guardian|0
6204164|NCT01520909|9865660|FG001|Part 2 (Open-Label Period)-Eltrombopag|Withdrawal by parent or guardian|0
6204165|NCT01520909|9865661|FG002|Part 2 (Open-Label Period)-Eltrombopag|Withdrawal by parent or guardian|1
6204166|NCT01520922|9865683|FG000|Treatment Phase|Physician Decision|2
6204167|NCT01520922|9865684|FG001|Treatment Phase|Physician Decision|1
6204168|NCT01520922|9865683|FG000|Treatment Phase|Progression|0
6204169|NCT01520922|9865684|FG001|Treatment Phase|Progression|2
6204170|NCT01520922|9865683|FG000|Treatment Phase|Adverse Event|3
6204171|NCT01520922|9865684|FG001|Treatment Phase|Adverse Event|5
6204172|NCT01520922|9865683|FG000|Follow up|Lost to Follow-up|0
6204173|NCT01520922|9865684|FG001|Follow up|Lost to Follow-up|1
6204174|NCT01520922|9865683|FG000|Survival Follow-up|Withdrawal by Subject|1
6204175|NCT01520922|9865684|FG001|Survival Follow-up|Withdrawal by Subject|0
6204176|NCT01520987|9865698|FG000|Overall Study|Withdrawal by Subject|1
6204177|NCT01520987|9865699|FG001|Overall Study|Withdrawal by Subject|0
6204178|NCT01520987|9865700|FG002|Overall Study|Withdrawal by Subject|0
6204179|NCT01520987|9865701|FG003|Overall Study|Withdrawal by Subject|0
6204180|NCT01520987|9865702|FG004|Overall Study|Withdrawal by Subject|0
6204181|NCT01520987|9865703|FG005|Overall Study|Withdrawal by Subject|1
6204182|NCT01520987|9865704|FG006|Overall Study|Withdrawal by Subject|0
6204183|NCT01520987|9865705|FG007|Overall Study|Withdrawal by Subject|0
6204184|NCT01521117|9865730|FG000|First Intervention (6 Weeks)|Adverse Event|5
6204185|NCT01521117|9865731|FG001|First Intervention (6 Weeks)|Adverse Event|1
6204186|NCT01521117|9865730|FG000|First Intervention (6 Weeks)|Scheduling Issues|0
6204187|NCT01521117|9865731|FG001|First Intervention (6 Weeks)|Scheduling Issues|2
6204188|NCT01521117|9865730|FG000|Second Intervention (6 Weeks)|Adverse Event|0
6204189|NCT01521117|9865731|FG001|Second Intervention (6 Weeks)|Adverse Event|3
6204190|NCT01521364|9865746|FG000|Linezolid + 250mg Claritromycin (wk 2&3)|Protocol Violation|1
6204191|NCT01521364|9865746|FG000|Linezolid + 500mg Claritromycin (wk 4&5)|Withdrawal by Subject|1
6204192|NCT01521494|9865762|FG000|Overall Study|Adverse Event|1
6204193|NCT01521494|9865763|FG001|Overall Study|Adverse Event|2
6204194|NCT01521494|9865764|FG002|Overall Study|Adverse Event|9
6204195|NCT01521494|9865765|FG003|Overall Study|Adverse Event|6
6204196|NCT01521494|9865766|FG004|Overall Study|Adverse Event|2
6204197|NCT01521494|9865762|FG000|Overall Study|Lack of Efficacy|0
6204198|NCT01521494|9865763|FG001|Overall Study|Lack of Efficacy|0
6204199|NCT01521494|9865764|FG002|Overall Study|Lack of Efficacy|0
6204200|NCT01521494|9865765|FG003|Overall Study|Lack of Efficacy|0
6204201|NCT01521494|9865766|FG004|Overall Study|Lack of Efficacy|2
6204202|NCT01521494|9865762|FG000|Overall Study|Withdrawal by Subject|1
6204203|NCT01521494|9865763|FG001|Overall Study|Withdrawal by Subject|1
6100121|NCT00757705|9715949|FG000|Overall Study|Adverse Event|19
6100122|NCT00757705|9715949|FG000|Overall Study|Lost to Follow-up|16
6100123|NCT00757705|9715949|FG000|Overall Study|Withdrawal by Subject|25
6100124|NCT00757705|9715949|FG000|Overall Study|Insufficient Response|26
6100125|NCT00757705|9715949|FG000|Overall Study|Ineligible to continue|8
6100126|NCT00757705|9715949|FG000|Overall Study|Non-compliant|9
6100127|NCT00757705|9715949|FG000|Overall Study|Other|18
6100128|NCT00757783|9715955|FG000|Overall Study|Adverse Event|0
6100129|NCT00757783|9715956|FG001|Overall Study|Adverse Event|2
6100130|NCT00757783|9715955|FG000|Overall Study|Lost to Follow-up|1
6100131|NCT00757783|9715956|FG001|Overall Study|Lost to Follow-up|1
6100132|NCT00757783|9715955|FG000|Overall Study|Protocol Violation|1
6100133|NCT00757783|9715956|FG001|Overall Study|Protocol Violation|0
6100134|NCT00757783|9715955|FG000|Overall Study|Withdrawal by Subject|2
6100135|NCT00757783|9715956|FG001|Overall Study|Withdrawal by Subject|1
6100136|NCT00757783|9715955|FG000|Overall Study|Other|1
6100137|NCT00757783|9715956|FG001|Overall Study|Other|2
6100138|NCT00757848|9715976|FG000|Overall Study|Voluntary discontinuation|1
6100139|NCT00757848|9715977|FG001|Overall Study|Voluntary discontinuation|0
6100140|NCT00757848|9715976|FG000|Overall Study|Adverse Event|1
6100141|NCT00757848|9715977|FG001|Overall Study|Adverse Event|2
6100142|NCT00757848|9715976|FG000|Overall Study|Incorrect enrolment|1
6100143|NCT00757848|9715977|FG001|Overall Study|Incorrect enrolment|0
6100144|NCT00758043|9715987|FG000|Overall Study|Adverse Event|1
6100145|NCT00758043|9715988|FG001|Overall Study|Adverse Event|20
6100146|NCT00758043|9715989|FG002|Overall Study|Adverse Event|12
6100147|NCT00758043|9715990|FG003|Overall Study|Adverse Event|62
6100148|NCT00758043|9715987|FG000|Overall Study|Lack of Efficacy|0
6100149|NCT00758043|9715988|FG001|Overall Study|Lack of Efficacy|6
6100150|NCT00758043|9715989|FG002|Overall Study|Lack of Efficacy|18
6100151|NCT00758043|9715990|FG003|Overall Study|Lack of Efficacy|12
6100152|NCT00758043|9715987|FG000|Overall Study|Refused Further Treatment|0
6100153|NCT00758043|9715988|FG001|Overall Study|Refused Further Treatment|11
6100154|NCT00758043|9715989|FG002|Overall Study|Refused Further Treatment|5
6100155|NCT00758043|9715990|FG003|Overall Study|Refused Further Treatment|8
6100156|NCT00758043|9715987|FG000|Overall Study|Lost to Follow-up|0
6100157|NCT00758043|9715988|FG001|Overall Study|Lost to Follow-up|2
6100158|NCT00758043|9715989|FG002|Overall Study|Lost to Follow-up|2
6100159|NCT00758043|9715990|FG003|Overall Study|Lost to Follow-up|5
6100160|NCT00758043|9715987|FG000|Overall Study|Withdrawal by Subject|0
6100161|NCT00758043|9715988|FG001|Overall Study|Withdrawal by Subject|1
6100162|NCT00758043|9715989|FG002|Overall Study|Withdrawal by Subject|1
6100163|NCT00758043|9715990|FG003|Overall Study|Withdrawal by Subject|4
6100164|NCT00758043|9715987|FG000|Overall Study|Required Prohibited Medication|0
6100165|NCT00758043|9715988|FG001|Overall Study|Required Prohibited Medication|0
6100166|NCT00758043|9715989|FG002|Overall Study|Required Prohibited Medication|1
6100167|NCT00758043|9715990|FG003|Overall Study|Required Prohibited Medication|3
6100168|NCT00758043|9715987|FG000|Overall Study|Non-Compliant With study Drug|0
6100169|NCT00758043|9715988|FG001|Overall Study|Non-Compliant With study Drug|0
6100170|NCT00758043|9715989|FG002|Overall Study|Non-Compliant With study Drug|0
6100171|NCT00758043|9715990|FG003|Overall Study|Non-Compliant With study Drug|1
6100172|NCT00758043|9715987|FG000|Overall Study|Other Reasons|0
6100173|NCT00758043|9715988|FG001|Overall Study|Other Reasons|1
6100174|NCT00758043|9715989|FG002|Overall Study|Other Reasons|0
6100175|NCT00758043|9715990|FG003|Overall Study|Other Reasons|5
6100176|NCT00758069|9716009|FG000|Overall Study|Lack of Efficacy|0
6100177|NCT00758069|9716010|FG001|Overall Study|Lack of Efficacy|0
6100178|NCT00758069|9716011|FG002|Overall Study|Lack of Efficacy|1
6100179|NCT00758069|9716009|FG000|Overall Study|Incorrect Study Drug|1
6100180|NCT00758069|9716010|FG001|Overall Study|Incorrect Study Drug|0
6100181|NCT00758069|9716011|FG002|Overall Study|Incorrect Study Drug|0
6100182|NCT00758160|9716019|FG000|Overall Study|No Longer Requires Study Medication|4
6100183|NCT00758160|9716019|FG000|Overall Study|Administration Problems|3
6100184|NCT00758160|9716019|FG000|Overall Study|Adverse Event|15
6100185|NCT00758160|9716019|FG000|Overall Study|Lack of Efficacy|10
6100186|NCT00758160|9716019|FG000|Overall Study|Lost to Follow-up|14
6100187|NCT00758160|9716019|FG000|Overall Study|Protocol Violation|12
6100188|NCT00758160|9716019|FG000|Overall Study|Withdrawal by Subject|8
6100189|NCT00758264|9716030|FG000|Active Phase|Withdrawal by Subject|0
6100190|NCT00758264|9716031|FG001|Active Phase|Withdrawal by Subject|0
6100191|NCT00758264|9716032|FG002|Active Phase|Withdrawal by Subject|1
6100192|NCT00758264|9716030|FG000|Active Phase|Lost to Follow-up|1
6100193|NCT00758264|9716031|FG001|Active Phase|Lost to Follow-up|0
6100194|NCT00758264|9716032|FG002|Active Phase|Lost to Follow-up|0
6100195|NCT00758264|9716030|FG000|Active Phase|Other|0
6100196|NCT00758264|9716031|FG001|Active Phase|Other|0
6100197|NCT00758264|9716032|FG002|Active Phase|Other|4
6100198|NCT00758394|9716053|FG000|2nd Intervention Order|Lost to Follow-up|0
6100199|NCT00758394|9716054|FG001|2nd Intervention Order|Lost to Follow-up|1
6100200|NCT00758394|9716055|FG002|2nd Intervention Order|Lost to Follow-up|0
6100201|NCT00758394|9716056|FG003|2nd Intervention Order|Lost to Follow-up|0
6100202|NCT00758394|9716053|FG000|3rd Intervention|Lost to Follow-up|1
6100203|NCT00758394|9716054|FG001|3rd Intervention|Lost to Follow-up|0
6100204|NCT00758394|9716055|FG002|3rd Intervention|Lost to Follow-up|0
6100205|NCT00758394|9716056|FG003|3rd Intervention|Lost to Follow-up|1
6204204|NCT01521494|9865764|FG002|Overall Study|Withdrawal by Subject|0
6204205|NCT01521494|9865765|FG003|Overall Study|Withdrawal by Subject|2
6204206|NCT01521494|9865766|FG004|Overall Study|Withdrawal by Subject|0
6204207|NCT01521494|9865762|FG000|Overall Study|Decrease in serum phosphate|0
6204208|NCT01521494|9865763|FG001|Overall Study|Decrease in serum phosphate|2
6204209|NCT01521494|9865764|FG002|Overall Study|Decrease in serum phosphate|3
6204210|NCT01521494|9865765|FG003|Overall Study|Decrease in serum phosphate|12
6204211|NCT01521494|9865766|FG004|Overall Study|Decrease in serum phosphate|0
6204212|NCT01521494|9865762|FG000|Overall Study|Decrease in serum calcium|0
6204213|NCT01521494|9865763|FG001|Overall Study|Decrease in serum calcium|0
6204214|NCT01521494|9865764|FG002|Overall Study|Decrease in serum calcium|0
6204215|NCT01521494|9865765|FG003|Overall Study|Decrease in serum calcium|1
6204216|NCT01521494|9865766|FG004|Overall Study|Decrease in serum calcium|1
6204217|NCT01521494|9865762|FG000|Overall Study|Physician Decision|0
6204218|NCT01521494|9865763|FG001|Overall Study|Physician Decision|0
6204219|NCT01521494|9865764|FG002|Overall Study|Physician Decision|0
6204220|NCT01521494|9865765|FG003|Overall Study|Physician Decision|0
6204221|NCT01521494|9865766|FG004|Overall Study|Physician Decision|2
6204222|NCT01521507|9865780|FG000|Stage 1: Randomized Design|Device did not fit, No Treatment|2
6204223|NCT01521507|9865781|FG001|Stage 1: Randomized Design|Device did not fit, No Treatment|0
6204224|NCT01521507|9865780|FG000|Stage 1: Randomized Design|Withdrawal by Subject|1
6204225|NCT01521507|9865781|FG001|Stage 1: Randomized Design|Withdrawal by Subject|3
6204226|NCT01521507|9865780|FG000|Stage 1: Randomized Design|Lost to Follow-up|0
6204227|NCT01521507|9865781|FG001|Stage 1: Randomized Design|Lost to Follow-up|2
6204228|NCT01521507|9865780|FG000|Stage 2: Observational Design|Device did not fit, No Treatment|0
6204229|NCT01521507|9865781|FG001|Stage 2: Observational Design|Device did not fit, No Treatment|1
6204230|NCT01521507|9865780|FG000|Stage 2: Observational Design|Withdrawal by Subject|3
6204231|NCT01521507|9865781|FG001|Stage 2: Observational Design|Withdrawal by Subject|1
6204232|NCT01521507|9865780|FG000|Stage 2: Observational Design|Physician Decision|1
6204233|NCT01521507|9865781|FG001|Stage 2: Observational Design|Physician Decision|0
6204234|NCT01521559|9865805|FG000|Overall Study|Adverse Event|0
6204235|NCT01521559|9865806|FG001|Overall Study|Adverse Event|4
6204236|NCT01521559|9865805|FG000|Overall Study|Death|1
6204237|NCT01521559|9865806|FG001|Overall Study|Death|0
6204238|NCT01521559|9865805|FG000|Overall Study|Withdrawal by Subject|9
6204239|NCT01521559|9865806|FG001|Overall Study|Withdrawal by Subject|11
6204240|NCT01521559|9865805|FG000|Overall Study|Lost to Follow-up|3
6204241|NCT01521559|9865806|FG001|Overall Study|Lost to Follow-up|1
6204242|NCT01521559|9865805|FG000|Overall Study|Protocol Violation|1
6204243|NCT01521559|9865806|FG001|Overall Study|Protocol Violation|0
6204244|NCT01521559|9865805|FG000|Overall Study|Other|1
6204245|NCT01521559|9865806|FG001|Overall Study|Other|2
6204246|NCT01521884|9865842|FG000|Overall Study|Non Responders|10
6204247|NCT01521884|9865842|FG000|Overall Study|Adverse Event|5
6204248|NCT01521884|9865842|FG000|Overall Study|Pregnancy|1
6204249|NCT01521884|9865842|FG000|Overall Study|Withdrawal by Subject|1
6204250|NCT01521884|9865842|FG000|Overall Study|Physician Decision|2
6204251|NCT01521884|9865842|FG000|Overall Study|Protocol Violation|3
6204252|NCT01521884|9865842|FG000|Overall Study|Participant non-eligible|1
6204253|NCT01521884|9865842|FG000|Overall Study|Lost to Follow-up|4
6204254|NCT01521897|9865846|FG000|Overall Study|Protocol Violation|18
6204255|NCT01521897|9865846|FG000|Overall Study|Lost to Follow-up|5
6204256|NCT01521923|9865854|FG000|Overall Study|AE, serious fatal|1
6204257|NCT01521923|9865855|FG001|Overall Study|AE, serious fatal|0
6204258|NCT01521923|9865856|FG002|Overall Study|AE, serious fatal|0
6204259|NCT01521923|9865857|FG003|Overall Study|AE, serious fatal|0
6204260|NCT01521923|9865854|FG000|Overall Study|SAE, non-fatal|0
6204261|NCT01521923|9865855|FG001|Overall Study|SAE, non-fatal|2
6204262|NCT01521923|9865856|FG002|Overall Study|SAE, non-fatal|2
6204263|NCT01521923|9865857|FG003|Overall Study|SAE, non-fatal|0
6204264|NCT01521923|9865854|FG000|Overall Study|AE, non-serious, non-fatal|1
6204265|NCT01521923|9865855|FG001|Overall Study|AE, non-serious, non-fatal|3
6204266|NCT01521923|9865856|FG002|Overall Study|AE, non-serious, non-fatal|6
6204267|NCT01521923|9865857|FG003|Overall Study|AE, non-serious, non-fatal|2
6204268|NCT01521923|9865854|FG000|Overall Study|SAE, nonfatal + AE, non-serious nonfatal|0
6204269|NCT01521923|9865855|FG001|Overall Study|SAE, nonfatal + AE, non-serious nonfatal|0
6204270|NCT01521923|9865856|FG002|Overall Study|SAE, nonfatal + AE, non-serious nonfatal|0
6204271|NCT01521923|9865857|FG003|Overall Study|SAE, nonfatal + AE, non-serious nonfatal|1
6204272|NCT01521923|9865854|FG000|Overall Study|Lack of Efficacy|1
6204273|NCT01521923|9865855|FG001|Overall Study|Lack of Efficacy|1
6204274|NCT01521923|9865856|FG002|Overall Study|Lack of Efficacy|0
6100206|NCT00758459|9716077|FG000|Overall Study|Adverse Event|3
6204275|NCT01521923|9865857|FG003|Overall Study|Lack of Efficacy|0
6204276|NCT01521923|9865854|FG000|Overall Study|Protocol Violation|0
6204277|NCT01521923|9865855|FG001|Overall Study|Protocol Violation|0
6204278|NCT01521923|9865856|FG002|Overall Study|Protocol Violation|1
6204279|NCT01521923|9865857|FG003|Overall Study|Protocol Violation|0
6204280|NCT01521923|9865854|FG000|Overall Study|Lost to Follow-up|1
6204281|NCT01521923|9865855|FG001|Overall Study|Lost to Follow-up|0
6204282|NCT01521923|9865856|FG002|Overall Study|Lost to Follow-up|2
6204283|NCT01521923|9865857|FG003|Overall Study|Lost to Follow-up|1
6204284|NCT01521923|9865854|FG000|Overall Study|Withdrawal by Subject|1
6100207|NCT00758459|9716078|FG001|Overall Study|Adverse Event|2
6100208|NCT00758459|9716077|FG000|Overall Study|Protocol Violation|0
6100209|NCT00758459|9716078|FG001|Overall Study|Protocol Violation|1
6100210|NCT00758459|9716077|FG000|Overall Study|Withdrawal by Subject|0
6100211|NCT00758459|9716078|FG001|Overall Study|Withdrawal by Subject|1
6100212|NCT00758485|9716086|FG000|Overall Study|Lost to Follow-up|0
6100213|NCT00758485|9716087|FG001|Overall Study|Lost to Follow-up|1
6100214|NCT00758485|9716086|FG000|Overall Study|Not Treated|1
6100215|NCT00758485|9716087|FG001|Overall Study|Not Treated|2
6100216|NCT00758498|9716097|FG000|Overall Study|Adverse Event|2
6100217|NCT00758498|9716098|FG001|Overall Study|Adverse Event|2
6100218|NCT00758498|9716099|FG002|Overall Study|Adverse Event|3
6100219|NCT00758498|9716097|FG000|Overall Study|Subject legally detained out of state|1
6100220|NCT00758498|9716098|FG001|Overall Study|Subject legally detained out of state|0
6100221|NCT00758498|9716099|FG002|Overall Study|Subject legally detained out of state|0
6100222|NCT00758498|9716097|FG000|Overall Study|Withdrawal by Subject|0
6100223|NCT00758498|9716098|FG001|Overall Study|Withdrawal by Subject|0
6100224|NCT00758498|9716099|FG002|Overall Study|Withdrawal by Subject|1
6100225|NCT00758498|9716097|FG000|Overall Study|Noncompliance to study procedures|0
6100226|NCT00758498|9716098|FG001|Overall Study|Noncompliance to study procedures|0
6100227|NCT00758498|9716099|FG002|Overall Study|Noncompliance to study procedures|1
6100228|NCT00758524|9716113|FG000|Core Period (Week 0 to Week 8)|Lack of Efficacy|3
6100229|NCT00758524|9716114|FG001|Core Period (Week 0 to Week 8)|Lack of Efficacy|2
6100230|NCT00758524|9716115|FG002|Core Period (Week 0 to Week 8)|Lack of Efficacy|4
6100231|NCT00758524|9716116|FG003|Core Period (Week 0 to Week 8)|Lack of Efficacy|0
6100232|NCT00758524|9716117|FG004|Core Period (Week 0 to Week 8)|Lack of Efficacy|3
6100233|NCT00758524|9716118|FG005|Core Period (Week 0 to Week 8)|Lack of Efficacy|5
6100234|NCT00758524|9716119|FG006|Core Period (Week 0 to Week 8)|Lack of Efficacy|0
6100235|NCT00758524|9716120|FG007|Core Period (Week 0 to Week 8)|Lack of Efficacy|0
6100236|NCT00758524|9716121|FG008|Core Period (Week 0 to Week 8)|Lack of Efficacy|0
6100237|NCT00758524|9716122|FG009|Core Period (Week 0 to Week 8)|Lack of Efficacy|0
6100238|NCT00758524|9716123|FG010|Core Period (Week 0 to Week 8)|Lack of Efficacy|0
6100239|NCT00758524|9716124|FG011|Core Period (Week 0 to Week 8)|Lack of Efficacy|0
6100240|NCT00758524|9716125|FG012|Core Period (Week 0 to Week 8)|Lack of Efficacy|0
6100241|NCT00758524|9716126|FG013|Core Period (Week 0 to Week 8)|Lack of Efficacy|0
6100242|NCT00758524|9716127|FG014|Core Period (Week 0 to Week 8)|Lack of Efficacy|0
6100243|NCT00758524|9716128|FG015|Core Period (Week 0 to Week 8)|Lack of Efficacy|0
6100244|NCT00758524|9716129|FG016|Core Period (Week 0 to Week 8)|Lack of Efficacy|0
6100245|NCT00758524|9716113|FG000|Core Period (Week 0 to Week 8)|Withdrawal by Subject|3
6100246|NCT00758524|9716114|FG001|Core Period (Week 0 to Week 8)|Withdrawal by Subject|0
6100247|NCT00758524|9716115|FG002|Core Period (Week 0 to Week 8)|Withdrawal by Subject|2
6100248|NCT00758524|9716116|FG003|Core Period (Week 0 to Week 8)|Withdrawal by Subject|3
6100249|NCT00758524|9716117|FG004|Core Period (Week 0 to Week 8)|Withdrawal by Subject|1
6100250|NCT00758524|9716118|FG005|Core Period (Week 0 to Week 8)|Withdrawal by Subject|3
6100251|NCT00758524|9716119|FG006|Core Period (Week 0 to Week 8)|Withdrawal by Subject|0
6100252|NCT00758524|9716120|FG007|Core Period (Week 0 to Week 8)|Withdrawal by Subject|0
6100253|NCT00758524|9716121|FG008|Core Period (Week 0 to Week 8)|Withdrawal by Subject|0
6100254|NCT00758524|9716122|FG009|Core Period (Week 0 to Week 8)|Withdrawal by Subject|0
6100255|NCT00758524|9716123|FG010|Core Period (Week 0 to Week 8)|Withdrawal by Subject|0
6100256|NCT00758524|9716124|FG011|Core Period (Week 0 to Week 8)|Withdrawal by Subject|0
6100257|NCT00758524|9716125|FG012|Core Period (Week 0 to Week 8)|Withdrawal by Subject|0
6100258|NCT00758524|9716126|FG013|Core Period (Week 0 to Week 8)|Withdrawal by Subject|0
6100259|NCT00758524|9716127|FG014|Core Period (Week 0 to Week 8)|Withdrawal by Subject|0
6100260|NCT00758524|9716128|FG015|Core Period (Week 0 to Week 8)|Withdrawal by Subject|0
6100261|NCT00758524|9716129|FG016|Core Period (Week 0 to Week 8)|Withdrawal by Subject|0
6100262|NCT00758524|9716113|FG000|Core Period (Week 0 to Week 8)|Adverse Event|2
6100263|NCT00758524|9716114|FG001|Core Period (Week 0 to Week 8)|Adverse Event|1
6100264|NCT00758524|9716115|FG002|Core Period (Week 0 to Week 8)|Adverse Event|1
6100265|NCT00758524|9716116|FG003|Core Period (Week 0 to Week 8)|Adverse Event|3
6100266|NCT00758524|9716117|FG004|Core Period (Week 0 to Week 8)|Adverse Event|2
6100267|NCT00758524|9716118|FG005|Core Period (Week 0 to Week 8)|Adverse Event|1
6100268|NCT00758524|9716119|FG006|Core Period (Week 0 to Week 8)|Adverse Event|0
6100269|NCT00758524|9716120|FG007|Core Period (Week 0 to Week 8)|Adverse Event|0
6100270|NCT00758524|9716121|FG008|Core Period (Week 0 to Week 8)|Adverse Event|0
6100271|NCT00758524|9716122|FG009|Core Period (Week 0 to Week 8)|Adverse Event|0
6100272|NCT00758524|9716123|FG010|Core Period (Week 0 to Week 8)|Adverse Event|0
6100273|NCT00758524|9716124|FG011|Core Period (Week 0 to Week 8)|Adverse Event|0
6100274|NCT00758524|9716125|FG012|Core Period (Week 0 to Week 8)|Adverse Event|0
6100275|NCT00758524|9716126|FG013|Core Period (Week 0 to Week 8)|Adverse Event|0
6100276|NCT00758524|9716127|FG014|Core Period (Week 0 to Week 8)|Adverse Event|0
6100277|NCT00758524|9716128|FG015|Core Period (Week 0 to Week 8)|Adverse Event|0
6100278|NCT00758524|9716129|FG016|Core Period (Week 0 to Week 8)|Adverse Event|0
6100279|NCT00758524|9716113|FG000|Core Period (Week 0 to Week 8)|Lost to Follow-up|0
6100280|NCT00758524|9716114|FG001|Core Period (Week 0 to Week 8)|Lost to Follow-up|2
6100281|NCT00758524|9716115|FG002|Core Period (Week 0 to Week 8)|Lost to Follow-up|1
6100282|NCT00758524|9716116|FG003|Core Period (Week 0 to Week 8)|Lost to Follow-up|0
6100283|NCT00758524|9716117|FG004|Core Period (Week 0 to Week 8)|Lost to Follow-up|2
6100284|NCT00758524|9716118|FG005|Core Period (Week 0 to Week 8)|Lost to Follow-up|1
6100285|NCT00758524|9716119|FG006|Core Period (Week 0 to Week 8)|Lost to Follow-up|0
6100286|NCT00758524|9716120|FG007|Core Period (Week 0 to Week 8)|Lost to Follow-up|0
6100287|NCT00758524|9716121|FG008|Core Period (Week 0 to Week 8)|Lost to Follow-up|0
6100288|NCT00758524|9716122|FG009|Core Period (Week 0 to Week 8)|Lost to Follow-up|0
6100289|NCT00758524|9716123|FG010|Core Period (Week 0 to Week 8)|Lost to Follow-up|0
6100290|NCT00758524|9716124|FG011|Core Period (Week 0 to Week 8)|Lost to Follow-up|0
6100291|NCT00758524|9716125|FG012|Core Period (Week 0 to Week 8)|Lost to Follow-up|0
6100292|NCT00758524|9716126|FG013|Core Period (Week 0 to Week 8)|Lost to Follow-up|0
6100293|NCT00758524|9716127|FG014|Core Period (Week 0 to Week 8)|Lost to Follow-up|0
6100294|NCT00758524|9716128|FG015|Core Period (Week 0 to Week 8)|Lost to Follow-up|0
6100295|NCT00758524|9716129|FG016|Core Period (Week 0 to Week 8)|Lost to Follow-up|0
6100296|NCT00758524|9716113|FG000|Core Period (Week 0 to Week 8)|Administrative Problems|0
6100297|NCT00758524|9716114|FG001|Core Period (Week 0 to Week 8)|Administrative Problems|0
6100298|NCT00758524|9716115|FG002|Core Period (Week 0 to Week 8)|Administrative Problems|1
6100299|NCT00758524|9716116|FG003|Core Period (Week 0 to Week 8)|Administrative Problems|1
6100300|NCT00758524|9716117|FG004|Core Period (Week 0 to Week 8)|Administrative Problems|0
6100301|NCT00758524|9716118|FG005|Core Period (Week 0 to Week 8)|Administrative Problems|0
6100302|NCT00758524|9716119|FG006|Core Period (Week 0 to Week 8)|Administrative Problems|0
6100303|NCT00758524|9716120|FG007|Core Period (Week 0 to Week 8)|Administrative Problems|0
6100304|NCT00758524|9716121|FG008|Core Period (Week 0 to Week 8)|Administrative Problems|0
6100305|NCT00758524|9716122|FG009|Core Period (Week 0 to Week 8)|Administrative Problems|0
6100306|NCT00758524|9716123|FG010|Core Period (Week 0 to Week 8)|Administrative Problems|0
6100307|NCT00758524|9716124|FG011|Core Period (Week 0 to Week 8)|Administrative Problems|0
6100308|NCT00758524|9716125|FG012|Core Period (Week 0 to Week 8)|Administrative Problems|0
6100309|NCT00758524|9716126|FG013|Core Period (Week 0 to Week 8)|Administrative Problems|0
6100310|NCT00758524|9716127|FG014|Core Period (Week 0 to Week 8)|Administrative Problems|0
6100311|NCT00758524|9716128|FG015|Core Period (Week 0 to Week 8)|Administrative Problems|0
6100312|NCT00758524|9716129|FG016|Core Period (Week 0 to Week 8)|Administrative Problems|0
6100313|NCT00758524|9716113|FG000|Core Period (Week 0 to Week 8)|Abnormal Laboratory Values|0
6100314|NCT00758524|9716114|FG001|Core Period (Week 0 to Week 8)|Abnormal Laboratory Values|0
6100315|NCT00758524|9716115|FG002|Core Period (Week 0 to Week 8)|Abnormal Laboratory Values|0
6100316|NCT00758524|9716116|FG003|Core Period (Week 0 to Week 8)|Abnormal Laboratory Values|0
6100317|NCT00758524|9716117|FG004|Core Period (Week 0 to Week 8)|Abnormal Laboratory Values|1
6100318|NCT00758524|9716118|FG005|Core Period (Week 0 to Week 8)|Abnormal Laboratory Values|0
6100319|NCT00758524|9716119|FG006|Core Period (Week 0 to Week 8)|Abnormal Laboratory Values|0
6100320|NCT00758524|9716120|FG007|Core Period (Week 0 to Week 8)|Abnormal Laboratory Values|0
6100321|NCT00758524|9716121|FG008|Core Period (Week 0 to Week 8)|Abnormal Laboratory Values|0
6100322|NCT00758524|9716122|FG009|Core Period (Week 0 to Week 8)|Abnormal Laboratory Values|0
6100323|NCT00758524|9716123|FG010|Core Period (Week 0 to Week 8)|Abnormal Laboratory Values|0
6100324|NCT00758524|9716124|FG011|Core Period (Week 0 to Week 8)|Abnormal Laboratory Values|0
6100325|NCT00758524|9716125|FG012|Core Period (Week 0 to Week 8)|Abnormal Laboratory Values|0
6100326|NCT00758524|9716126|FG013|Core Period (Week 0 to Week 8)|Abnormal Laboratory Values|0
6100327|NCT00758524|9716127|FG014|Core Period (Week 0 to Week 8)|Abnormal Laboratory Values|0
6100328|NCT00758524|9716128|FG015|Core Period (Week 0 to Week 8)|Abnormal Laboratory Values|0
6100329|NCT00758524|9716129|FG016|Core Period (Week 0 to Week 8)|Abnormal Laboratory Values|0
6100330|NCT00758524|9716113|FG000|Core Period (Week 0 to Week 8)|Abnormal Test Procedure Results|0
6100331|NCT00758524|9716114|FG001|Core Period (Week 0 to Week 8)|Abnormal Test Procedure Results|1
6204285|NCT01521923|9865855|FG001|Overall Study|Withdrawal by Subject|1
6204286|NCT01521923|9865856|FG002|Overall Study|Withdrawal by Subject|1
6204287|NCT01521923|9865857|FG003|Overall Study|Withdrawal by Subject|2
6204288|NCT01521923|9865854|FG000|Overall Study|Other|2
6284782|NCT02326298|9996356|FG002|Open-label Period (Week 48 to Week 144)|Protocol Violation|0
6284783|NCT02326298|9996357|FG003|Open-label Period (Week 48 to Week 144)|Protocol Violation|0
6284784|NCT02326298|9996358|FG004|Open-label Period (Week 48 to Week 144)|Protocol Violation|0
6284785|NCT02326298|9996359|FG005|Open-label Period (Week 48 to Week 144)|Protocol Violation|0
6284786|NCT02326298|9996360|FG006|Open-label Period (Week 48 to Week 144)|Protocol Violation|0
6284787|NCT02326298|9996361|FG007|Open-label Period (Week 48 to Week 144)|Protocol Violation|0
6284788|NCT02326298|9996362|FG008|Open-label Period (Week 48 to Week 144)|Protocol Violation|0
6284789|NCT02326298|9996363|FG009|Open-label Period (Week 48 to Week 144)|Protocol Violation|0
6284790|NCT02326298|9996364|FG010|Open-label Period (Week 48 to Week 144)|Protocol Violation|0
6284791|NCT02326298|9996365|FG011|Open-label Period (Week 48 to Week 144)|Protocol Violation|0
6284792|NCT02326298|9996366|FG012|Open-label Period (Week 48 to Week 144)|Protocol Violation|0
6284793|NCT02326298|9996367|FG013|Open-label Period (Week 48 to Week 144)|Protocol Violation|2
6284794|NCT02326298|9996354|FG000|Open-label Period (Week 48 to Week 144)|Withdrawal by Subject|0
6284795|NCT02326298|9996355|FG001|Open-label Period (Week 48 to Week 144)|Withdrawal by Subject|0
6284796|NCT02326298|9996356|FG002|Open-label Period (Week 48 to Week 144)|Withdrawal by Subject|0
6204289|NCT01521923|9865855|FG001|Overall Study|Other|1
6100332|NCT00758524|9716115|FG002|Core Period (Week 0 to Week 8)|Abnormal Test Procedure Results|0
6204290|NCT01521923|9865856|FG002|Overall Study|Other|3
6204291|NCT01521923|9865857|FG003|Overall Study|Other|6
6204292|NCT01521923|9865854|FG000|Overall Study|AE, captured in Period 1|0
6204293|NCT01521923|9865855|FG001|Overall Study|AE, captured in Period 1|1
6204294|NCT01521923|9865856|FG002|Overall Study|AE, captured in Period 1|0
6204295|NCT01521923|9865857|FG003|Overall Study|AE, captured in Period 1|1
6284797|NCT02326298|9996357|FG003|Open-label Period (Week 48 to Week 144)|Withdrawal by Subject|0
6284798|NCT02326298|9996358|FG004|Open-label Period (Week 48 to Week 144)|Withdrawal by Subject|0
6284799|NCT02326298|9996359|FG005|Open-label Period (Week 48 to Week 144)|Withdrawal by Subject|0
6284800|NCT02326298|9996360|FG006|Open-label Period (Week 48 to Week 144)|Withdrawal by Subject|0
6284801|NCT02326298|9996361|FG007|Open-label Period (Week 48 to Week 144)|Withdrawal by Subject|0
6284802|NCT02326298|9996362|FG008|Open-label Period (Week 48 to Week 144)|Withdrawal by Subject|0
6284803|NCT02326298|9996363|FG009|Open-label Period (Week 48 to Week 144)|Withdrawal by Subject|0
6284804|NCT02326298|9996364|FG010|Open-label Period (Week 48 to Week 144)|Withdrawal by Subject|0
6284805|NCT02326298|9996365|FG011|Open-label Period (Week 48 to Week 144)|Withdrawal by Subject|7
6284806|NCT02326298|9996366|FG012|Open-label Period (Week 48 to Week 144)|Withdrawal by Subject|2
6284807|NCT02326298|9996367|FG013|Open-label Period (Week 48 to Week 144)|Withdrawal by Subject|1
6284808|NCT02326298|9996354|FG000|Open-label Period (Week 48 to Week 144)|Did not achieve PASI50|0
6284809|NCT02326298|9996355|FG001|Open-label Period (Week 48 to Week 144)|Did not achieve PASI50|0
6284810|NCT02326298|9996356|FG002|Open-label Period (Week 48 to Week 144)|Did not achieve PASI50|0
6284811|NCT02326298|9996357|FG003|Open-label Period (Week 48 to Week 144)|Did not achieve PASI50|0
6284812|NCT02326298|9996358|FG004|Open-label Period (Week 48 to Week 144)|Did not achieve PASI50|0
6284813|NCT02326298|9996359|FG005|Open-label Period (Week 48 to Week 144)|Did not achieve PASI50|0
6284814|NCT02326298|9996360|FG006|Open-label Period (Week 48 to Week 144)|Did not achieve PASI50|0
6284815|NCT02326298|9996361|FG007|Open-label Period (Week 48 to Week 144)|Did not achieve PASI50|0
6284816|NCT02326298|9996362|FG008|Open-label Period (Week 48 to Week 144)|Did not achieve PASI50|0
6284817|NCT02326298|9996363|FG009|Open-label Period (Week 48 to Week 144)|Did not achieve PASI50|0
6284818|NCT02326298|9996364|FG010|Open-label Period (Week 48 to Week 144)|Did not achieve PASI50|0
6284819|NCT02326298|9996365|FG011|Open-label Period (Week 48 to Week 144)|Did not achieve PASI50|2
6284820|NCT02326298|9996366|FG012|Open-label Period (Week 48 to Week 144)|Did not achieve PASI50|7
6284821|NCT02326298|9996367|FG013|Open-label Period (Week 48 to Week 144)|Did not achieve PASI50|3
6284822|NCT02326298|9996354|FG000|Open-label Period (Week 48 to Week 144)|Lost to Follow-up|0
6284823|NCT02326298|9996355|FG001|Open-label Period (Week 48 to Week 144)|Lost to Follow-up|0
6284824|NCT02326298|9996356|FG002|Open-label Period (Week 48 to Week 144)|Lost to Follow-up|0
6284825|NCT02326298|9996357|FG003|Open-label Period (Week 48 to Week 144)|Lost to Follow-up|0
6284826|NCT02326298|9996358|FG004|Open-label Period (Week 48 to Week 144)|Lost to Follow-up|0
6284827|NCT02326298|9996359|FG005|Open-label Period (Week 48 to Week 144)|Lost to Follow-up|0
6284828|NCT02326298|9996360|FG006|Open-label Period (Week 48 to Week 144)|Lost to Follow-up|0
6284829|NCT02326298|9996361|FG007|Open-label Period (Week 48 to Week 144)|Lost to Follow-up|0
6284830|NCT02326298|9996362|FG008|Open-label Period (Week 48 to Week 144)|Lost to Follow-up|0
6284831|NCT02326298|9996363|FG009|Open-label Period (Week 48 to Week 144)|Lost to Follow-up|0
6284832|NCT02326298|9996364|FG010|Open-label Period (Week 48 to Week 144)|Lost to Follow-up|0
6284833|NCT02326298|9996365|FG011|Open-label Period (Week 48 to Week 144)|Lost to Follow-up|6
6284834|NCT02326298|9996366|FG012|Open-label Period (Week 48 to Week 144)|Lost to Follow-up|6
6284835|NCT02326298|9996367|FG013|Open-label Period (Week 48 to Week 144)|Lost to Follow-up|3
6284836|NCT02326467|9996387|FG000|Overall Study|Withdrawal by Subject|1
6284837|NCT02326597|9996394|FG000|Overall Study|Lost to Follow-up|42
6284838|NCT02326597|9996395|FG001|Overall Study|Lost to Follow-up|32
6284839|NCT02326883|9996423|FG000|Overall Study|Disenrolled or died prior to first follow-up day - not included in outcome or adverse event counts|84
6284840|NCT02326883|9996424|FG001|Overall Study|Disenrolled or died prior to first follow-up day - not included in outcome or adverse event counts|85
6284841|NCT02326883|9996425|FG002|Overall Study|Disenrolled or died prior to first follow-up day - not included in outcome or adverse event counts|69
6284842|NCT02327013|9996436|FG000|Overall Study|Adverse Event|4
6284843|NCT02327013|9996437|FG001|Overall Study|Adverse Event|4
6284844|NCT02327013|9996438|FG002|Overall Study|Adverse Event|3
6284845|NCT02327013|9996439|FG003|Overall Study|Adverse Event|0
6284846|NCT02327013|9996440|FG004|Overall Study|Adverse Event|1
6284847|NCT02327013|9996436|FG000|Overall Study|Lack of Efficacy|2
6284848|NCT02327013|9996437|FG001|Overall Study|Lack of Efficacy|0
6284849|NCT02327013|9996438|FG002|Overall Study|Lack of Efficacy|5
6284850|NCT02327013|9996439|FG003|Overall Study|Lack of Efficacy|0
6284851|NCT02327013|9996440|FG004|Overall Study|Lack of Efficacy|1
6284852|NCT02327013|9996436|FG000|Overall Study|Non-compliance with IMP|1
6284853|NCT02327013|9996437|FG001|Overall Study|Non-compliance with IMP|2
6284854|NCT02327013|9996438|FG002|Overall Study|Non-compliance with IMP|7
6284855|NCT02327013|9996439|FG003|Overall Study|Non-compliance with IMP|0
6284856|NCT02327013|9996440|FG004|Overall Study|Non-compliance with IMP|0
6284857|NCT02327013|9996436|FG000|Overall Study|Withdrawal of Consent|1
6284858|NCT02327013|9996437|FG001|Overall Study|Withdrawal of Consent|0
6284859|NCT02327013|9996438|FG002|Overall Study|Withdrawal of Consent|3
6284860|NCT02327013|9996439|FG003|Overall Study|Withdrawal of Consent|0
6100333|NCT00758524|9716116|FG003|Core Period (Week 0 to Week 8)|Abnormal Test Procedure Results|0
6100334|NCT00758524|9716117|FG004|Core Period (Week 0 to Week 8)|Abnormal Test Procedure Results|0
6100335|NCT00758524|9716118|FG005|Core Period (Week 0 to Week 8)|Abnormal Test Procedure Results|0
6100336|NCT00758524|9716119|FG006|Core Period (Week 0 to Week 8)|Abnormal Test Procedure Results|0
6100337|NCT00758524|9716120|FG007|Core Period (Week 0 to Week 8)|Abnormal Test Procedure Results|0
6100338|NCT00758524|9716121|FG008|Core Period (Week 0 to Week 8)|Abnormal Test Procedure Results|0
6100339|NCT00758524|9716122|FG009|Core Period (Week 0 to Week 8)|Abnormal Test Procedure Results|0
6100340|NCT00758524|9716123|FG010|Core Period (Week 0 to Week 8)|Abnormal Test Procedure Results|0
6100341|NCT00758524|9716124|FG011|Core Period (Week 0 to Week 8)|Abnormal Test Procedure Results|0
6100342|NCT00758524|9716125|FG012|Core Period (Week 0 to Week 8)|Abnormal Test Procedure Results|0
6100343|NCT00758524|9716126|FG013|Core Period (Week 0 to Week 8)|Abnormal Test Procedure Results|0
6100344|NCT00758524|9716127|FG014|Core Period (Week 0 to Week 8)|Abnormal Test Procedure Results|0
6100345|NCT00758524|9716128|FG015|Core Period (Week 0 to Week 8)|Abnormal Test Procedure Results|0
6100346|NCT00758524|9716129|FG016|Core Period (Week 0 to Week 8)|Abnormal Test Procedure Results|0
6100347|NCT00758524|9716113|FG000|Core Period (Week 0 to Week 8)|Reason not Specified|0
6100348|NCT00758524|9716114|FG001|Core Period (Week 0 to Week 8)|Reason not Specified|1
6100349|NCT00758524|9716115|FG002|Core Period (Week 0 to Week 8)|Reason not Specified|0
6100350|NCT00758524|9716116|FG003|Core Period (Week 0 to Week 8)|Reason not Specified|0
6100351|NCT00758524|9716117|FG004|Core Period (Week 0 to Week 8)|Reason not Specified|0
6100352|NCT00758524|9716118|FG005|Core Period (Week 0 to Week 8)|Reason not Specified|0
6100353|NCT00758524|9716119|FG006|Core Period (Week 0 to Week 8)|Reason not Specified|0
6100354|NCT00758524|9716120|FG007|Core Period (Week 0 to Week 8)|Reason not Specified|0
6100355|NCT00758524|9716121|FG008|Core Period (Week 0 to Week 8)|Reason not Specified|0
6100356|NCT00758524|9716122|FG009|Core Period (Week 0 to Week 8)|Reason not Specified|0
6100357|NCT00758524|9716123|FG010|Core Period (Week 0 to Week 8)|Reason not Specified|0
6100358|NCT00758524|9716124|FG011|Core Period (Week 0 to Week 8)|Reason not Specified|0
6100359|NCT00758524|9716125|FG012|Core Period (Week 0 to Week 8)|Reason not Specified|0
6100360|NCT00758524|9716126|FG013|Core Period (Week 0 to Week 8)|Reason not Specified|0
6100361|NCT00758524|9716127|FG014|Core Period (Week 0 to Week 8)|Reason not Specified|0
6100362|NCT00758524|9716128|FG015|Core Period (Week 0 to Week 8)|Reason not Specified|0
6100363|NCT00758524|9716129|FG016|Core Period (Week 0 to Week 8)|Reason not Specified|0
6100364|NCT00758524|9716113|FG000|Withdrawal Period (Week 8 to Week 9)|Unsatisfactory Therapeutic Effect|0
6100365|NCT00758524|9716114|FG001|Withdrawal Period (Week 8 to Week 9)|Unsatisfactory Therapeutic Effect|0
6100366|NCT00758524|9716115|FG002|Withdrawal Period (Week 8 to Week 9)|Unsatisfactory Therapeutic Effect|0
6100367|NCT00758524|9716116|FG003|Withdrawal Period (Week 8 to Week 9)|Unsatisfactory Therapeutic Effect|0
6100368|NCT00758524|9716117|FG004|Withdrawal Period (Week 8 to Week 9)|Unsatisfactory Therapeutic Effect|0
6100369|NCT00758524|9716118|FG005|Withdrawal Period (Week 8 to Week 9)|Unsatisfactory Therapeutic Effect|0
6100370|NCT00758524|9716119|FG006|Withdrawal Period (Week 8 to Week 9)|Unsatisfactory Therapeutic Effect|0
6100371|NCT00758524|9716120|FG007|Withdrawal Period (Week 8 to Week 9)|Unsatisfactory Therapeutic Effect|0
6100372|NCT00758524|9716121|FG008|Withdrawal Period (Week 8 to Week 9)|Unsatisfactory Therapeutic Effect|2
6100373|NCT00758524|9716122|FG009|Withdrawal Period (Week 8 to Week 9)|Unsatisfactory Therapeutic Effect|0
6100374|NCT00758524|9716123|FG010|Withdrawal Period (Week 8 to Week 9)|Unsatisfactory Therapeutic Effect|0
6100375|NCT00758524|9716124|FG011|Withdrawal Period (Week 8 to Week 9)|Unsatisfactory Therapeutic Effect|0
6100376|NCT00758524|9716125|FG012|Withdrawal Period (Week 8 to Week 9)|Unsatisfactory Therapeutic Effect|0
6100377|NCT00758524|9716126|FG013|Withdrawal Period (Week 8 to Week 9)|Unsatisfactory Therapeutic Effect|0
6100378|NCT00758524|9716127|FG014|Withdrawal Period (Week 8 to Week 9)|Unsatisfactory Therapeutic Effect|0
6100379|NCT00758524|9716128|FG015|Withdrawal Period (Week 8 to Week 9)|Unsatisfactory Therapeutic Effect|0
6100380|NCT00758524|9716129|FG016|Withdrawal Period (Week 8 to Week 9)|Unsatisfactory Therapeutic Effect|0
6100381|NCT00758524|9716113|FG000|Withdrawal Period (Week 8 to Week 9)|Lost to Follow-up|0
6100382|NCT00758524|9716114|FG001|Withdrawal Period (Week 8 to Week 9)|Lost to Follow-up|0
6100383|NCT00758524|9716115|FG002|Withdrawal Period (Week 8 to Week 9)|Lost to Follow-up|0
6100384|NCT00758524|9716116|FG003|Withdrawal Period (Week 8 to Week 9)|Lost to Follow-up|0
6100385|NCT00758524|9716117|FG004|Withdrawal Period (Week 8 to Week 9)|Lost to Follow-up|0
6100386|NCT00758524|9716118|FG005|Withdrawal Period (Week 8 to Week 9)|Lost to Follow-up|0
6100387|NCT00758524|9716119|FG006|Withdrawal Period (Week 8 to Week 9)|Lost to Follow-up|1
6100388|NCT00758524|9716120|FG007|Withdrawal Period (Week 8 to Week 9)|Lost to Follow-up|0
6100389|NCT00758524|9716121|FG008|Withdrawal Period (Week 8 to Week 9)|Lost to Follow-up|0
6100390|NCT00758524|9716122|FG009|Withdrawal Period (Week 8 to Week 9)|Lost to Follow-up|0
6100391|NCT00758524|9716123|FG010|Withdrawal Period (Week 8 to Week 9)|Lost to Follow-up|0
6100392|NCT00758524|9716124|FG011|Withdrawal Period (Week 8 to Week 9)|Lost to Follow-up|0
6100393|NCT00758524|9716125|FG012|Withdrawal Period (Week 8 to Week 9)|Lost to Follow-up|0
6100394|NCT00758524|9716126|FG013|Withdrawal Period (Week 8 to Week 9)|Lost to Follow-up|0
6100395|NCT00758524|9716127|FG014|Withdrawal Period (Week 8 to Week 9)|Lost to Follow-up|0
6100396|NCT00758524|9716128|FG015|Withdrawal Period (Week 8 to Week 9)|Lost to Follow-up|0
6100397|NCT00758524|9716129|FG016|Withdrawal Period (Week 8 to Week 9)|Lost to Follow-up|0
6100398|NCT00758589|9716184|FG000|Overall Study|Adverse Event|3
6100399|NCT00758589|9716185|FG001|Overall Study|Adverse Event|2
6100400|NCT00758589|9716186|FG002|Overall Study|Adverse Event|5
6100401|NCT00758589|9716187|FG003|Overall Study|Adverse Event|4
6100402|NCT00758589|9716184|FG000|Overall Study|Withdrawal by Subject|0
6100403|NCT00758589|9716185|FG001|Overall Study|Withdrawal by Subject|1
6100404|NCT00758589|9716186|FG002|Overall Study|Withdrawal by Subject|1
6100405|NCT00758589|9716187|FG003|Overall Study|Withdrawal by Subject|1
6100406|NCT00758589|9716184|FG000|Overall Study|Palm stopped to work|0
6100407|NCT00758589|9716185|FG001|Overall Study|Palm stopped to work|0
6100408|NCT00758589|9716186|FG002|Overall Study|Palm stopped to work|0
6100409|NCT00758589|9716187|FG003|Overall Study|Palm stopped to work|1
6100410|NCT00758602|9716199|FG000|Overall Study|Adverse Event|11
6100411|NCT00758602|9716200|FG001|Overall Study|Adverse Event|10
6100412|NCT00758602|9716199|FG000|Overall Study|Lost to Follow-up|4
6100413|NCT00758602|9716200|FG001|Overall Study|Lost to Follow-up|3
6100414|NCT00758602|9716199|FG000|Overall Study|Withdrawal by Subject|1
6100415|NCT00758602|9716200|FG001|Overall Study|Withdrawal by Subject|3
6100416|NCT00758602|9716199|FG000|Overall Study|Protocol Violation|0
6100417|NCT00758602|9716200|FG001|Overall Study|Protocol Violation|2
6100418|NCT00758602|9716199|FG000|Overall Study|Death|0
6100419|NCT00758602|9716200|FG001|Overall Study|Death|1
6100420|NCT00758602|9716199|FG000|Overall Study|Reason not specified|3
6100421|NCT00758602|9716200|FG001|Overall Study|Reason not specified|3
6100422|NCT00758680|9716217|FG000|Overall Study|Adverse Event|0
6100423|NCT00758680|9716218|FG001|Overall Study|Adverse Event|0
6100424|NCT00758680|9716219|FG002|Overall Study|Adverse Event|0
6100425|NCT00758680|9716220|FG003|Overall Study|Adverse Event|0
6100426|NCT00758680|9716221|FG004|Overall Study|Adverse Event|0
6100427|NCT00758680|9716222|FG005|Overall Study|Adverse Event|0
6100428|NCT00758680|9716223|FG006|Overall Study|Adverse Event|0
6100429|NCT00758680|9716224|FG007|Overall Study|Adverse Event|1
6100430|NCT00758680|9716225|FG008|Overall Study|Adverse Event|0
6100431|NCT00758680|9716226|FG009|Overall Study|Adverse Event|1
6100432|NCT00758680|9716217|FG000|Overall Study|Laboratory Adverse Event|0
6100433|NCT00758680|9716218|FG001|Overall Study|Laboratory Adverse Event|0
6100434|NCT00758680|9716219|FG002|Overall Study|Laboratory Adverse Event|0
6100435|NCT00758680|9716220|FG003|Overall Study|Laboratory Adverse Event|0
6100436|NCT00758680|9716221|FG004|Overall Study|Laboratory Adverse Event|0
6100437|NCT00758680|9716222|FG005|Overall Study|Laboratory Adverse Event|0
6100438|NCT00758680|9716223|FG006|Overall Study|Laboratory Adverse Event|0
6100439|NCT00758680|9716224|FG007|Overall Study|Laboratory Adverse Event|0
6100440|NCT00758680|9716225|FG008|Overall Study|Laboratory Adverse Event|1
6100441|NCT00758680|9716226|FG009|Overall Study|Laboratory Adverse Event|0
6100442|NCT00758680|9716217|FG000|Overall Study|Withdrawal by Subject|0
6100443|NCT00758680|9716218|FG001|Overall Study|Withdrawal by Subject|0
6100444|NCT00758680|9716219|FG002|Overall Study|Withdrawal by Subject|0
6100445|NCT00758680|9716220|FG003|Overall Study|Withdrawal by Subject|0
6100446|NCT00758680|9716221|FG004|Overall Study|Withdrawal by Subject|0
6100447|NCT00758680|9716222|FG005|Overall Study|Withdrawal by Subject|0
6100448|NCT00758680|9716223|FG006|Overall Study|Withdrawal by Subject|1
6100449|NCT00758680|9716224|FG007|Overall Study|Withdrawal by Subject|0
6100450|NCT00758680|9716225|FG008|Overall Study|Withdrawal by Subject|1
6100451|NCT00758680|9716226|FG009|Overall Study|Withdrawal by Subject|0
6100452|NCT00758706|9716251|FG000|Overall Study|Adverse Event|4
6100453|NCT00758706|9716252|FG001|Overall Study|Adverse Event|4
6100454|NCT00758771|9716310|FG000|Overall Study|Withdrawal by Subject|1
6100455|NCT00758771|9716311|FG001|Overall Study|Withdrawal by Subject|1
6100456|NCT00758771|9716310|FG000|Overall Study|Did not meet eligibility criteria|2
6100457|NCT00758771|9716311|FG001|Overall Study|Did not meet eligibility criteria|4
6100458|NCT00759031|9716344|FG000|First Intervention (1 Day)|Physician Decision|1
6100459|NCT00759031|9716345|FG001|First Intervention (1 Day)|Physician Decision|0
6100460|NCT00759031|9716344|FG000|First Intervention (1 Day)|Withdrawal by Subject|0
6100461|NCT00759031|9716345|FG001|First Intervention (1 Day)|Withdrawal by Subject|1
6100462|NCT00759031|9716344|FG000|First Intervention (1 Day)|Screening failure|1
6100463|NCT00759031|9716345|FG001|First Intervention (1 Day)|Screening failure|0
6100464|NCT00759109|9716357|FG000|Overall Study|Adverse Event|17
6100465|NCT00759109|9716358|FG001|Overall Study|Adverse Event|12
6100466|NCT00759109|9716357|FG000|Overall Study|Inability to comply|1
6100467|NCT00759109|9716358|FG001|Overall Study|Inability to comply|1
6100468|NCT00759109|9716357|FG000|Overall Study|Withdrawal by Subject|9
6100469|NCT00759109|9716358|FG001|Overall Study|Withdrawal by Subject|5
6100470|NCT00759109|9716357|FG000|Overall Study|Death|4
6100471|NCT00759109|9716358|FG001|Overall Study|Death|3
6100472|NCT00759109|9716357|FG000|Overall Study|Lost to Follow-up|4
6100473|NCT00759109|9716358|FG001|Overall Study|Lost to Follow-up|6
6100474|NCT00759109|9716357|FG000|Overall Study|Started new therapy|2
6100475|NCT00759109|9716358|FG001|Overall Study|Started new therapy|6
6100476|NCT00759109|9716357|FG000|Overall Study|HCV RNA negative|1
6100477|NCT00759109|9716358|FG001|Overall Study|HCV RNA negative|0
6100478|NCT00759109|9716357|FG000|Overall Study|Participant moved to a different city|0
6100479|NCT00759109|9716358|FG001|Overall Study|Participant moved to a different city|1
6100480|NCT00759109|9716357|FG000|Overall Study|Participant had a liver transplant|0
6100481|NCT00759109|9716358|FG001|Overall Study|Participant had a liver transplant|1
6100482|NCT00759109|9716357|FG000|Overall Study|Lost during study|1
6100483|NCT00759109|9716358|FG001|Overall Study|Lost during study|0
6100484|NCT00759148|9716366|FG000|Overall Study|Adverse Event|1
6100485|NCT00759148|9716367|FG001|Overall Study|Adverse Event|6
6100486|NCT00759148|9716366|FG000|Overall Study|Withdrawal by Subject|3
6100487|NCT00759148|9716367|FG001|Overall Study|Withdrawal by Subject|7
6100488|NCT00759148|9716366|FG000|Overall Study|Lost to Follow-up|3
6100489|NCT00759148|9716367|FG001|Overall Study|Lost to Follow-up|9
6100490|NCT00759148|9716366|FG000|Overall Study|Treatment Failure|6
6100491|NCT00759148|9716367|FG001|Overall Study|Treatment Failure|10
6100492|NCT00759148|9716366|FG000|Overall Study|Reason not given|1
6100493|NCT00759148|9716367|FG001|Overall Study|Reason not given|0
6100494|NCT00759174|9716382|FG000|Overall Study|Other|0
6100495|NCT00759174|9716383|FG001|Overall Study|Other|2
6100496|NCT00759356|9716423|FG000|Overall Study|Adverse Event|0
6100497|NCT00759356|9716424|FG001|Overall Study|Adverse Event|1
6100498|NCT00759356|9716423|FG000|Overall Study|Withdrawal by Subject|0
6100499|NCT00759356|9716424|FG001|Overall Study|Withdrawal by Subject|2
6100500|NCT00759356|9716423|FG000|Overall Study|Subject was unable to return|1
6100501|NCT00759356|9716424|FG001|Overall Study|Subject was unable to return|0
6100502|NCT00759395|9716432|FG000|Overall Study|Adverse Event|1
6100503|NCT00759395|9716433|FG001|Overall Study|Adverse Event|0
6100504|NCT00759395|9716432|FG000|Overall Study|Withdrawal by Subject|1
6100505|NCT00759395|9716433|FG001|Overall Study|Withdrawal by Subject|0
6100506|NCT00759395|9716432|FG000|Overall Study|Lack of Efficacy|0
6100507|NCT00759395|9716433|FG001|Overall Study|Lack of Efficacy|2
6100508|NCT00759564|9716476|FG000|Washout Period (at Least 14 Days)|Adverse Event|0
6100509|NCT00759564|9716477|FG001|Washout Period (at Least 14 Days)|Adverse Event|0
6100510|NCT00759564|9716478|FG002|Washout Period (at Least 14 Days)|Adverse Event|0
6100511|NCT00759564|9716479|FG003|Washout Period (at Least 14 Days)|Adverse Event|0
6100512|NCT00759564|9716480|FG004|Washout Period (at Least 14 Days)|Adverse Event|1
6100513|NCT00759655|9716520|FG000|Overall Study|Termination of the study by sponsor|1
6100514|NCT00759681|9716535|FG000|Overall Study|Death|2
6100515|NCT00759681|9716536|FG001|Overall Study|Death|5
6100516|NCT00759681|9716535|FG000|Overall Study|Lost to Follow-up|8
6100517|NCT00759681|9716536|FG001|Overall Study|Lost to Follow-up|5
6100518|NCT00759759|9716549|FG000|Overall Study|didn't return for period 2|1
6100519|NCT00759759|9716550|FG001|Overall Study|didn't return for period 2|0
6100520|NCT00759759|9716549|FG000|Overall Study|Didn't receive drug in period 2|1
6100521|NCT00759759|9716550|FG001|Overall Study|Didn't receive drug in period 2|0
6100522|NCT00759759|9716549|FG000|Overall Study|Withdrawal by Subject|2
6100523|NCT00759759|9716550|FG001|Overall Study|Withdrawal by Subject|1
6100524|NCT00759785|9716567|FG000|Overall Study|Participant sample not evaluable|11
6100525|NCT00759785|9716568|FG001|Overall Study|Participant sample not evaluable|2
6100526|NCT00759785|9716567|FG000|Overall Study|Participant sample lost|0
6100527|NCT00759785|9716568|FG001|Overall Study|Participant sample lost|1
6100528|NCT00759785|9716567|FG000|Overall Study|Protocol Violation|1
6100529|NCT00759785|9716568|FG001|Overall Study|Protocol Violation|0
6100530|NCT00759785|9716567|FG000|Overall Study|Physician Decision|0
6100531|NCT00759785|9716568|FG001|Overall Study|Physician Decision|1
6100532|NCT00759785|9716567|FG000|Overall Study|Withdrawal by Subject|0
6100533|NCT00759785|9716568|FG001|Overall Study|Withdrawal by Subject|1
6100534|NCT00759863|9716589|FG000|Overall Study|Death, moved, or lost contact|20
6100535|NCT00759863|9716590|FG001|Overall Study|Death, moved, or lost contact|18
6100536|NCT00759876|9716596|FG000|Overall Study|Sponsor terminated study early|36
6100537|NCT00759902|9716602|FG000|Overall Study|Adverse Event|0
6100538|NCT00759902|9716603|FG001|Overall Study|Adverse Event|1
6100539|NCT00759915|9716611|FG000|Overall Study|Withdrawal by Subject|1
6100540|NCT00759915|9716612|FG001|Overall Study|Withdrawal by Subject|0
6100541|NCT00759915|9716611|FG000|Overall Study|Adverse Event|0
6100542|NCT00759915|9716612|FG001|Overall Study|Adverse Event|1
6100543|NCT00759941|9716620|FG000|Overall Study|Use of medication|1
6100544|NCT00759941|9716621|FG001|Overall Study|Use of medication|0
6100545|NCT00759941|9716620|FG000|Overall Study|Adverse Event|1
6100546|NCT00759941|9716621|FG001|Overall Study|Adverse Event|0
6100547|NCT00759941|9716620|FG000|Overall Study|Exited in error by site|1
6100548|NCT00759941|9716621|FG001|Overall Study|Exited in error by site|1
6100549|NCT00759954|9716629|FG000|Overall Study|Personal reason|1
6100550|NCT00759954|9716630|FG001|Overall Study|Personal reason|0
6100551|NCT00759954|9716629|FG000|Overall Study|Adverse Event|1
6100552|NCT00759954|9716630|FG001|Overall Study|Adverse Event|2
6100553|NCT00760084|9716667|FG000|Overall Study|Physician Decision|5
6100554|NCT00760084|9716667|FG000|Overall Study|Withdrawal by Subject|2
6100555|NCT00760084|9716667|FG000|Overall Study|Progressive Disease|3
6100556|NCT00760214|9716674|FG000|Overall Study|Adverse Event|8
6100557|NCT00760214|9716675|FG001|Overall Study|Adverse Event|9
6100558|NCT00760214|9716676|FG002|Overall Study|Adverse Event|12
6100559|NCT00760214|9716674|FG000|Overall Study|Protocol Violation|3
6100560|NCT00760214|9716675|FG001|Overall Study|Protocol Violation|0
6100561|NCT00760214|9716676|FG002|Overall Study|Protocol Violation|3
6100562|NCT00760214|9716674|FG000|Overall Study|Lost to Follow-up|0
6100563|NCT00760214|9716675|FG001|Overall Study|Lost to Follow-up|0
6100564|NCT00760214|9716676|FG002|Overall Study|Lost to Follow-up|1
6100565|NCT00760214|9716674|FG000|Overall Study|Withdrawal by Subject|12
6100566|NCT00760214|9716675|FG001|Overall Study|Withdrawal by Subject|14
6100567|NCT00760214|9716676|FG002|Overall Study|Withdrawal by Subject|13
6100568|NCT00760214|9716674|FG000|Overall Study|Lack of Efficacy|3
6100569|NCT00760214|9716675|FG001|Overall Study|Lack of Efficacy|2
6100570|NCT00760214|9716676|FG002|Overall Study|Lack of Efficacy|4
6100571|NCT00760214|9716674|FG000|Overall Study|Pregnancy|0
6100572|NCT00760214|9716675|FG001|Overall Study|Pregnancy|0
6100573|NCT00760214|9716676|FG002|Overall Study|Pregnancy|1
6100574|NCT00760214|9716674|FG000|Overall Study|Physician Decision|1
6100575|NCT00760214|9716675|FG001|Overall Study|Physician Decision|1
6100576|NCT00760214|9716676|FG002|Overall Study|Physician Decision|1
6100577|NCT00760214|9716674|FG000|Overall Study|Other|3
6100578|NCT00760214|9716675|FG001|Overall Study|Other|4
6100579|NCT00760214|9716676|FG002|Overall Study|Other|6
6100580|NCT00760266|9716686|FG000|Overall Study|Adverse Event|13
6100581|NCT00760266|9716687|FG001|Overall Study|Adverse Event|7
6100582|NCT00760266|9716686|FG000|Overall Study|Abnormal laboratory value(s)|1
6100583|NCT00760266|9716687|FG001|Overall Study|Abnormal laboratory value(s)|0
6100584|NCT00760266|9716686|FG000|Overall Study|Abnormal test procedure result(s)|1
6100585|NCT00760266|9716687|FG001|Overall Study|Abnormal test procedure result(s)|0
6100586|NCT00760266|9716686|FG000|Overall Study|Lack of Efficacy|2
6100587|NCT00760266|9716687|FG001|Overall Study|Lack of Efficacy|2
6100588|NCT00760266|9716686|FG000|Overall Study|Protocol deviation|2
6100589|NCT00760266|9716687|FG001|Overall Study|Protocol deviation|4
6100590|NCT00760266|9716686|FG000|Overall Study|Patient withdrew consent|3
6100591|NCT00760266|9716687|FG001|Overall Study|Patient withdrew consent|3
6100592|NCT00760266|9716686|FG000|Overall Study|Lost to Follow-up|2
6100593|NCT00760266|9716687|FG001|Overall Study|Lost to Follow-up|1
6100594|NCT00760266|9716686|FG000|Overall Study|Administrative Problems|0
6100595|NCT00760266|9716687|FG001|Overall Study|Administrative Problems|1
6100596|NCT00760383|9716695|FG000|Overall Study|moved away; withdrew; medical reasons|5
6100597|NCT00760383|9716696|FG001|Overall Study|moved away; withdrew; medical reasons|7
6100598|NCT00760474|9716711|FG000|Period 1 (P1)|Discontinued then re-entered|1
6100599|NCT00760474|9716712|FG001|Period 1 (P1)|Discontinued then re-entered|1
6100600|NCT00760474|9716711|FG000|Placebo Washout Period|Other|0
6100601|NCT00760474|9716712|FG001|Placebo Washout Period|Other|1
6100602|NCT00760474|9716711|FG000|Period 2 (P2)|Lost to Follow-up|1
6100603|NCT00760474|9716712|FG001|Period 2 (P2)|Lost to Follow-up|0
6100604|NCT00760474|9716711|FG000|Period 2 (P2)|Adverse Event|0
6100605|NCT00760474|9716712|FG001|Period 2 (P2)|Adverse Event|1
6100606|NCT00760487|9716719|FG000|Overall Study|Unilateral implantation|3
6100607|NCT00760513|9716725|FG000|Overall Study|Withdrawal by Subject|5
6100608|NCT00760513|9716726|FG001|Overall Study|Withdrawal by Subject|7
6100609|NCT00760552|9716752|FG000|Overall Study|Death|2
6100610|NCT00760552|9716753|FG001|Overall Study|Death|0
6100611|NCT00760552|9716752|FG000|Overall Study|Lost to Follow-up|11
6100612|NCT00760552|9716753|FG001|Overall Study|Lost to Follow-up|10
6100613|NCT00760617|9716784|FG000|Overall Study|Adverse Event|5
6100614|NCT00760617|9716785|FG001|Overall Study|Adverse Event|2
6100615|NCT00760617|9716786|FG002|Overall Study|Adverse Event|0
6100616|NCT00760617|9716784|FG000|Overall Study|Lost to Follow-up|0
6100617|NCT00760617|9716785|FG001|Overall Study|Lost to Follow-up|0
6100618|NCT00760617|9716786|FG002|Overall Study|Lost to Follow-up|5
6100619|NCT00760669|9716794|FG000|Overall Study|Not assessed for overall improvement|18
6100620|NCT00760669|9716794|FG000|Overall Study|Participants missing efficacy assessment|6
6100621|NCT00760669|9716794|FG000|Overall Study|Participants with overlapping cases|1
6100622|NCT00760669|9716794|FG000|Overall Study|Took drug before entering in contract|5
6100623|NCT00760747|9716800|FG000|Study Period II|Adverse Event|3
6100624|NCT00760747|9716801|FG001|Study Period II|Adverse Event|4
6100625|NCT00760747|9716800|FG000|Study Period II|Lack of Efficacy|0
6100626|NCT00760747|9716801|FG001|Study Period II|Lack of Efficacy|6
6100627|NCT00760747|9716800|FG000|Study Period II|Parent/Caregiver Decision|3
6100628|NCT00760747|9716801|FG001|Study Period II|Parent/Caregiver Decision|0
6100629|NCT00760747|9716800|FG000|Study Period II|Protocol Violation|6
6100630|NCT00760747|9716801|FG001|Study Period II|Protocol Violation|3
6100631|NCT00760747|9716800|FG000|Study Period II|Withdrawal by Subject|1
6100632|NCT00760747|9716801|FG001|Study Period II|Withdrawal by Subject|0
6100633|NCT00760747|9716800|FG000|Study Period II|No drug administered|0
6100634|NCT00760747|9716801|FG001|Study Period II|No drug administered|1
6100635|NCT00760747|9716800|FG000|Study Period III|Adverse Event|1
6100636|NCT00760747|9716801|FG001|Study Period III|Adverse Event|0
6100637|NCT00760747|9716800|FG000|Study Period III|Lack of Efficacy|1
6100638|NCT00760747|9716801|FG001|Study Period III|Lack of Efficacy|0
6100639|NCT00760747|9716800|FG000|Study Period III|Parent/Caregiver Decision|0
6100640|NCT00760747|9716801|FG001|Study Period III|Parent/Caregiver Decision|1
6100641|NCT00760747|9716800|FG000|Study Period III|Protocol Violation|1
6100642|NCT00760747|9716801|FG001|Study Period III|Protocol Violation|1
6100643|NCT00760747|9716800|FG000|Study Period III|Physician Decision|0
6100644|NCT00760747|9716801|FG001|Study Period III|Physician Decision|1
6100645|NCT00760838|9716809|FG000|Overall Study|Adverse Event|1
6100646|NCT00760838|9716810|FG001|Overall Study|Adverse Event|1
6100647|NCT00760838|9716809|FG000|Overall Study|Lack of Efficacy|1
6100648|NCT00760838|9716810|FG001|Overall Study|Lack of Efficacy|0
6100649|NCT00760838|9716809|FG000|Overall Study|Lost to Follow-up|2
6100650|NCT00760838|9716810|FG001|Overall Study|Lost to Follow-up|0
6100651|NCT00760838|9716809|FG000|Overall Study|Withdrawal by Subject|1
6100652|NCT00760838|9716810|FG001|Overall Study|Withdrawal by Subject|1
6100653|NCT00760877|9716818|FG000|Overall Study|Protocol Violation|1
6100654|NCT00760877|9716819|FG001|Overall Study|Protocol Violation|0
6100655|NCT00760877|9716818|FG000|Overall Study|Non-compliance with protocol treatment|2
6100656|NCT00760877|9716819|FG001|Overall Study|Non-compliance with protocol treatment|1
6100657|NCT00760877|9716818|FG000|Overall Study|Pregnancy|1
6100658|NCT00760877|9716819|FG001|Overall Study|Pregnancy|4
6100659|NCT00760877|9716818|FG000|Overall Study|Death|2
6100660|NCT00760877|9716819|FG001|Overall Study|Death|1
6100661|NCT00760877|9716818|FG000|Overall Study|Withdrawal by Subject|7
6100662|NCT00760877|9716819|FG001|Overall Study|Withdrawal by Subject|3
6100663|NCT00760877|9716818|FG000|Overall Study|Adverse Event|19
6100664|NCT00760877|9716819|FG001|Overall Study|Adverse Event|12
6100665|NCT00760877|9716818|FG000|Overall Study|Participant diagnosed with AML|0
6100666|NCT00760877|9716819|FG001|Overall Study|Participant diagnosed with AML|1
6100667|NCT00760877|9716818|FG000|Overall Study|Participant not eligible to cross-over|0
6100668|NCT00760877|9716819|FG001|Overall Study|Participant not eligible to cross-over|1
6100669|NCT00760877|9716818|FG000|Overall Study|Physician Decision|1
6100670|NCT00760877|9716819|FG001|Overall Study|Physician Decision|2
6100671|NCT00760877|9716818|FG000|Overall Study|Participants transferred to AMN107A2408|11
6100672|NCT00760877|9716819|FG001|Overall Study|Participants transferred to AMN107A2408|1
6100673|NCT00760877|9716818|FG000|Overall Study|Treatment failure|1
6100674|NCT00760877|9716819|FG001|Overall Study|Treatment failure|0
6100675|NCT00760929|9716830|FG000|Overall Study|Adverse Event|2
6100676|NCT00760929|9716831|FG001|Overall Study|Adverse Event|0
6100677|NCT00760929|9716832|FG002|Overall Study|Adverse Event|6
6100678|NCT00760929|9716833|FG003|Overall Study|Adverse Event|10
6100679|NCT00760929|9716830|FG000|Overall Study|Lack of Efficacy|0
6100680|NCT00760929|9716831|FG001|Overall Study|Lack of Efficacy|2
6100681|NCT00760929|9716832|FG002|Overall Study|Lack of Efficacy|1
6100682|NCT00760929|9716833|FG003|Overall Study|Lack of Efficacy|0
6100683|NCT00760929|9716830|FG000|Overall Study|Withdrawal by Subject|1
6100684|NCT00760929|9716831|FG001|Overall Study|Withdrawal by Subject|0
6100685|NCT00760929|9716832|FG002|Overall Study|Withdrawal by Subject|9
6100686|NCT00760929|9716833|FG003|Overall Study|Withdrawal by Subject|1
6100687|NCT00760929|9716830|FG000|Overall Study|Lost to Follow-up|0
6100688|NCT00760929|9716831|FG001|Overall Study|Lost to Follow-up|0
6100689|NCT00760929|9716832|FG002|Overall Study|Lost to Follow-up|1
6100690|NCT00760929|9716833|FG003|Overall Study|Lost to Follow-up|0
6100691|NCT00760929|9716830|FG000|Overall Study|Progression of Disease|21
6100692|NCT00760929|9716831|FG001|Overall Study|Progression of Disease|26
6100693|NCT00760929|9716832|FG002|Overall Study|Progression of Disease|38
6100694|NCT00760929|9716833|FG003|Overall Study|Progression of Disease|42
6100695|NCT00760929|9716830|FG000|Overall Study|Other|2
6100696|NCT00760929|9716831|FG001|Overall Study|Other|0
6100697|NCT00760929|9716832|FG002|Overall Study|Other|2
6100698|NCT00760929|9716833|FG003|Overall Study|Other|1
6100699|NCT00760929|9716830|FG000|Overall Study|Death|0
6100700|NCT00760929|9716831|FG001|Overall Study|Death|0
6100701|NCT00760929|9716832|FG002|Overall Study|Death|1
6100702|NCT00760929|9716833|FG003|Overall Study|Death|0
6100703|NCT00760929|9716830|FG000|Overall Study|Violation of Selection Criteria at Entry|0
6100704|NCT00760929|9716831|FG001|Overall Study|Violation of Selection Criteria at Entry|0
6100705|NCT00760929|9716832|FG002|Overall Study|Violation of Selection Criteria at Entry|0
6100706|NCT00760929|9716833|FG003|Overall Study|Violation of Selection Criteria at Entry|1
6100707|NCT00760994|9716845|FG000|Overall Study|Lost to Follow-up|4
6100708|NCT00760994|9716846|FG001|Overall Study|Lost to Follow-up|4
6100709|NCT00760994|9716847|FG002|Overall Study|Lost to Follow-up|3
6100710|NCT00761150|9716901|FG000|Open-label Period|Adverse Event|36
6100711|NCT00761150|9716902|FG001|Open-label Period|Adverse Event|0
6100712|NCT00761150|9716903|FG002|Open-label Period|Adverse Event|0
6100713|NCT00761150|9716901|FG000|Open-label Period|Did not meet DB randomization criteria|11
6100714|NCT00761150|9716902|FG001|Open-label Period|Did not meet DB randomization criteria|0
6100715|NCT00761150|9716903|FG002|Open-label Period|Did not meet DB randomization criteria|0
6100716|NCT00761150|9716901|FG000|Open-label Period|Lost to Follow-up|7
6100717|NCT00761150|9716902|FG001|Open-label Period|Lost to Follow-up|0
6100718|NCT00761150|9716903|FG002|Open-label Period|Lost to Follow-up|0
6100719|NCT00761150|9716901|FG000|Open-label Period|Lack of Efficacy|4
6100720|NCT00761150|9716902|FG001|Open-label Period|Lack of Efficacy|0
6100721|NCT00761150|9716903|FG002|Open-label Period|Lack of Efficacy|0
6100722|NCT00761150|9716901|FG000|Open-label Period|Withdrawal by Subject|5
6100723|NCT00761150|9716902|FG001|Open-label Period|Withdrawal by Subject|0
6100724|NCT00761150|9716903|FG002|Open-label Period|Withdrawal by Subject|0
6100725|NCT00761150|9716901|FG000|Open-label Period|Noncompliance|2
6100726|NCT00761150|9716902|FG001|Open-label Period|Noncompliance|0
6100727|NCT00761150|9716903|FG002|Open-label Period|Noncompliance|0
6100728|NCT00761150|9716901|FG000|Open-label Period|Other|5
6100729|NCT00761150|9716902|FG001|Open-label Period|Other|0
6100730|NCT00761150|9716903|FG002|Open-label Period|Other|0
6100731|NCT00761150|9716901|FG000|Double-blind Period|Lack of Efficacy|0
6100732|NCT00761150|9716902|FG001|Double-blind Period|Lack of Efficacy|2
6100733|NCT00761150|9716903|FG002|Double-blind Period|Lack of Efficacy|19
6100734|NCT00761150|9716901|FG000|Double-blind Period|Adverse Event|0
6100735|NCT00761150|9716902|FG001|Double-blind Period|Adverse Event|3
6100736|NCT00761150|9716903|FG002|Double-blind Period|Adverse Event|3
6100737|NCT00761150|9716901|FG000|Double-blind Period|Withdrawal by Subject|0
6100738|NCT00761150|9716902|FG001|Double-blind Period|Withdrawal by Subject|3
6100739|NCT00761150|9716903|FG002|Double-blind Period|Withdrawal by Subject|2
6100740|NCT00761150|9716901|FG000|Double-blind Period|Lost to Follow-up|0
6100741|NCT00761150|9716902|FG001|Double-blind Period|Lost to Follow-up|2
6100742|NCT00761150|9716903|FG002|Double-blind Period|Lost to Follow-up|1
6100743|NCT00761150|9716901|FG000|Double-blind Period|Did not meet DB randomization criteria|0
6100744|NCT00761150|9716902|FG001|Double-blind Period|Did not meet DB randomization criteria|0
6100745|NCT00761150|9716903|FG002|Double-blind Period|Did not meet DB randomization criteria|1
6100746|NCT00761150|9716901|FG000|Double-blind Period|Noncompliance|0
6100747|NCT00761150|9716902|FG001|Double-blind Period|Noncompliance|1
6100748|NCT00761150|9716903|FG002|Double-blind Period|Noncompliance|0
6100749|NCT00761150|9716901|FG000|Double-blind Period|Other|0
6100750|NCT00761150|9716902|FG001|Double-blind Period|Other|3
6100751|NCT00761150|9716903|FG002|Double-blind Period|Other|3
6100752|NCT00761189|9716910|FG000|Overall Study|Adverse Event|42
6100753|NCT00761189|9716910|FG000|Overall Study|Lack of Efficacy|45
6100754|NCT00761189|9716910|FG000|Overall Study|Lost to Follow-up|36
6100755|NCT00761189|9716910|FG000|Overall Study|Withdrawal by Subject|49
6100756|NCT00761189|9716910|FG000|Overall Study|Other|13
6100757|NCT00761215|9716926|FG000|Overall Study|Randomized but didn't receive drug|1
6100758|NCT00761215|9716927|FG001|Overall Study|Randomized but didn't receive drug|1
6100759|NCT00761215|9716928|FG002|Overall Study|Randomized but didn't receive drug|2
6100760|NCT00761215|9716926|FG000|Overall Study|Lost to Follow-up|6
6100761|NCT00761215|9716927|FG001|Overall Study|Lost to Follow-up|3
6100762|NCT00761215|9716928|FG002|Overall Study|Lost to Follow-up|6
6100763|NCT00761215|9716926|FG000|Overall Study|Withdrawal by Subject|1
6100764|NCT00761215|9716927|FG001|Overall Study|Withdrawal by Subject|0
6100765|NCT00761215|9716928|FG002|Overall Study|Withdrawal by Subject|0
6100766|NCT00761215|9716926|FG000|Overall Study|Bacteremia|1
6100767|NCT00761215|9716927|FG001|Overall Study|Bacteremia|0
6100768|NCT00761215|9716928|FG002|Overall Study|Bacteremia|0
6100769|NCT00761267|9716942|FG000|Overall Study|Death|1
6100770|NCT00761267|9716943|FG001|Overall Study|Death|2
6100771|NCT00761267|9716944|FG002|Overall Study|Death|5
6100772|NCT00761267|9716942|FG000|Overall Study|Lost to Follow-up|0
6100773|NCT00761267|9716943|FG001|Overall Study|Lost to Follow-up|0
6100774|NCT00761267|9716944|FG002|Overall Study|Lost to Follow-up|1
6100775|NCT00761267|9716942|FG000|Overall Study|Randomized but not treated|1
6100776|NCT00761267|9716943|FG001|Overall Study|Randomized but not treated|1
6100777|NCT00761267|9716944|FG002|Overall Study|Randomized but not treated|0
6100778|NCT00761267|9716942|FG000|Overall Study|Withdrawal by Subject|0
6100779|NCT00761267|9716943|FG001|Overall Study|Withdrawal by Subject|1
6100780|NCT00761267|9716944|FG002|Overall Study|Withdrawal by Subject|0
6100781|NCT00761280|9716965|FG000|Randomization to First Dose|Withdrawal by Subject|0
6100782|NCT00761280|9716966|FG001|Randomization to First Dose|Withdrawal by Subject|2
6100783|NCT00761280|9716965|FG000|Randomization to First Dose|Sponsor decision|1
6100784|NCT00761280|9716966|FG001|Randomization to First Dose|Sponsor decision|0
6100785|NCT00761280|9716965|FG000|Randomization to First Dose|Other|1
6100786|NCT00761280|9716966|FG001|Randomization to First Dose|Other|0
6100787|NCT00761280|9716965|FG000|First Dose to End of Study|End of trial|5
6100788|NCT00761280|9716966|FG001|First Dose to End of Study|End of trial|5
6100789|NCT00761280|9716965|FG000|First Dose to End of Study|Progressive disease|5
6100790|NCT00761280|9716966|FG001|First Dose to End of Study|Progressive disease|3
6100791|NCT00761280|9716965|FG000|First Dose to End of Study|Sponsor decision|1
6100792|NCT00761280|9716966|FG001|First Dose to End of Study|Sponsor decision|2
6100793|NCT00761280|9716965|FG000|First Dose to End of Study|Death|1
6100794|NCT00761280|9716966|FG001|First Dose to End of Study|Death|0
6100795|NCT00761280|9716965|FG000|First Dose to End of Study|Lost to Follow-up|0
6100796|NCT00761280|9716966|FG001|First Dose to End of Study|Lost to Follow-up|1
6100797|NCT00761306|9716972|FG000|Overall Study|Adverse Event|5
6100798|NCT00761306|9716972|FG000|Overall Study|Lack of Efficacy|4
6100799|NCT00761306|9716972|FG000|Overall Study|Protocol Violation|2
6100800|NCT00761306|9716972|FG000|Overall Study|Withdrawal of Consent|3
6100801|NCT00761306|9716972|FG000|Overall Study|Lost to Follow-up|1
6100802|NCT00761306|9716972|FG000|Overall Study|Administrative or Other Reasons|5
6100803|NCT00761319|9716978|FG000|Overall Study|Protocol Violation|21
6100804|NCT00761319|9716979|FG001|Overall Study|Protocol Violation|14
6100805|NCT00761319|9716978|FG000|Overall Study|Adverse Event|11
6100806|NCT00761319|9716979|FG001|Overall Study|Adverse Event|7
6100807|NCT00761319|9716978|FG000|Overall Study|Withdrawal by Subject|8
6100808|NCT00761319|9716979|FG001|Overall Study|Withdrawal by Subject|7
6100809|NCT00761319|9716978|FG000|Overall Study|Noncompliance|4
6100810|NCT00761319|9716979|FG001|Overall Study|Noncompliance|3
6100811|NCT00761319|9716978|FG000|Overall Study|Lost to Follow-up|1
6100812|NCT00761319|9716979|FG001|Overall Study|Lost to Follow-up|1
6100813|NCT00761319|9716978|FG000|Overall Study|Nonspecified|2
6100814|NCT00761319|9716979|FG001|Overall Study|Nonspecified|2
6100815|NCT00761319|9716978|FG000|Overall Study|Missing|1
6100816|NCT00761319|9716979|FG001|Overall Study|Missing|0
6100817|NCT00761462|9716991|FG000|Treatment|Subjects never received study medication|23
6100818|NCT00761462|9716992|FG001|Treatment|Subjects never received study medication|12
6100819|NCT00761462|9716991|FG000|2 or 5 Years Long-term Safety Follow-up|Death|4
6100820|NCT00761462|9716992|FG001|2 or 5 Years Long-term Safety Follow-up|Death|0
6100821|NCT00761462|9716991|FG000|2 or 5 Years Long-term Safety Follow-up|Lost to Follow-up|75
6100822|NCT00761462|9716992|FG001|2 or 5 Years Long-term Safety Follow-up|Lost to Follow-up|30
6100823|NCT00761462|9716991|FG000|2 or 5 Years Long-term Safety Follow-up|Withdrawal by Subject|75
6100824|NCT00761462|9716992|FG001|2 or 5 Years Long-term Safety Follow-up|Withdrawal by Subject|21
6100825|NCT00761514|9716998|FG000|Overall Study|Adverse Event|1
6100826|NCT00761514|9716998|FG000|Overall Study|Withdrawal by Subject|2
6100827|NCT00761514|9716998|FG000|Overall Study|Lost to Follow-up|1
6100828|NCT00761514|9716998|FG000|Overall Study|Health insurance didn't cover study drug|1
6100829|NCT00761514|9716998|FG000|Overall Study|Problem complying with study visit|1
6100830|NCT00761514|9716998|FG000|Overall Study|Unable to pay for medications|1
6100831|NCT00761579|9717002|FG000|Overall Study|Adverse Event|10
6100832|NCT00761579|9717002|FG000|Overall Study|Death|2
6100833|NCT00761579|9717002|FG000|Overall Study|Lack of Efficacy|21
6100834|NCT00761579|9717002|FG000|Overall Study|Lost to Follow-up|16
6100835|NCT00761579|9717002|FG000|Overall Study|Pregnancy|1
6100836|NCT00761579|9717002|FG000|Overall Study|Withdrawal by Subject|34
6100837|NCT00761579|9717002|FG000|Overall Study|Lack of compliance|2
6100838|NCT00761579|9717002|FG000|Overall Study|Protocol deviation|1
6100839|NCT00761579|9717002|FG000|Overall Study|Drug overdose|1
6100840|NCT00761579|9717002|FG000|Overall Study|Aggravation of depression|1
6100841|NCT00761579|9717002|FG000|Overall Study|Aggravation of symptoms by changing drug|1
6100842|NCT00761579|9717002|FG000|Overall Study|Lost survey form|1
6204296|NCT01522235|9865885|FG000|Overall Study|Physician Decision|1
6204297|NCT01522235|9865886|FG001|Overall Study|Physician Decision|1
6204298|NCT01522248|9865898|FG000|Overall Study|Lost to Follow-up|1
6204299|NCT01522248|9865899|FG001|Overall Study|Lost to Follow-up|0
6204300|NCT01522404|9865926|FG000|First Intervention (up to Week 29)|Withdrawal by Subject|1
6204301|NCT01522404|9865927|FG001|First Intervention (up to Week 29)|Withdrawal by Subject|0
6204302|NCT01522404|9865926|FG000|First Intervention (up to Week 29)|Adverse Event|1
6204303|NCT01522404|9865927|FG001|First Intervention (up to Week 29)|Adverse Event|0
6204304|NCT01522404|9865926|FG000|Second Intervention (up to Week 58)|Withdrawal by Subject|1
6284861|NCT02327013|9996440|FG004|Overall Study|Withdrawal of Consent|0
6284862|NCT02327013|9996436|FG000|Overall Study|Lost to Follow-up|2
6284863|NCT02327013|9996437|FG001|Overall Study|Lost to Follow-up|4
6284864|NCT02327013|9996438|FG002|Overall Study|Lost to Follow-up|5
6284865|NCT02327013|9996439|FG003|Overall Study|Lost to Follow-up|0
6284866|NCT02327013|9996440|FG004|Overall Study|Lost to Follow-up|0
6284867|NCT02327013|9996436|FG000|Overall Study|Administrative or other reason(s)|1
6284868|NCT02327013|9996437|FG001|Overall Study|Administrative or other reason(s)|5
6284869|NCT02327013|9996438|FG002|Overall Study|Administrative or other reason(s)|11
6284870|NCT02327013|9996439|FG003|Overall Study|Administrative or other reason(s)|1
6284871|NCT02327013|9996440|FG004|Overall Study|Administrative or other reason(s)|1
6284872|NCT02327013|9996436|FG000|Overall Study|Protocol Violation|0
6284873|NCT02327013|9996437|FG001|Overall Study|Protocol Violation|0
6284874|NCT02327013|9996438|FG002|Overall Study|Protocol Violation|3
6284875|NCT02327013|9996439|FG003|Overall Study|Protocol Violation|0
6284876|NCT02327013|9996440|FG004|Overall Study|Protocol Violation|1
6284877|NCT02327013|9996436|FG000|Overall Study|Withdrawal before treatment|2
6284878|NCT02327013|9996437|FG001|Overall Study|Withdrawal before treatment|1
6284879|NCT02327013|9996438|FG002|Overall Study|Withdrawal before treatment|5
6284880|NCT02327013|9996439|FG003|Overall Study|Withdrawal before treatment|0
6284881|NCT02327013|9996440|FG004|Overall Study|Withdrawal before treatment|0
6284882|NCT02327130|9996473|FG000|Overall Study|Discharged in less than 5 days|5
6284883|NCT02327130|9996473|FG000|Overall Study|Physician Decision|2
6284884|NCT02327130|9996473|FG000|Overall Study|Unable to provide breath sample|1
6284885|NCT02327130|9996473|FG000|Overall Study|Incorrectly place ventilator adaptor|1
6284886|NCT02327130|9996473|FG000|Overall Study|Met exclusion criteria|3
6284887|NCT02327169|9996502|FG000|Overall Study|Progressive Disease|1
6284888|NCT02327169|9996503|FG001|Overall Study|Progressive Disease|3
6284889|NCT02327169|9996504|FG002|Overall Study|Progressive Disease|4
6284890|NCT02327169|9996505|FG003|Overall Study|Progressive Disease|3
6284891|NCT02327169|9996506|FG004|Overall Study|Progressive Disease|4
6284892|NCT02327169|9996507|FG005|Overall Study|Progressive Disease|3
6284893|NCT02327169|9996508|FG006|Overall Study|Progressive Disease|3
6284894|NCT02327169|9996509|FG007|Overall Study|Progressive Disease|3
6284895|NCT02327169|9996510|FG008|Overall Study|Progressive Disease|4
6284896|NCT02327169|9996511|FG009|Overall Study|Progressive Disease|4
6284897|NCT02327169|9996512|FG010|Overall Study|Progressive Disease|4
6284898|NCT02327169|9996513|FG011|Overall Study|Progressive Disease|3
6284899|NCT02327169|9996514|FG012|Overall Study|Progressive Disease|1
6284900|NCT02327169|9996515|FG013|Overall Study|Progressive Disease|3
6284901|NCT02327169|9996516|FG014|Overall Study|Progressive Disease|3
6284902|NCT02327169|9996502|FG000|Overall Study|Adverse Event|2
6284903|NCT02327169|9996503|FG001|Overall Study|Adverse Event|0
6284904|NCT02327169|9996504|FG002|Overall Study|Adverse Event|1
6284905|NCT02327169|9996505|FG003|Overall Study|Adverse Event|0
6284906|NCT02327169|9996506|FG004|Overall Study|Adverse Event|1
6284907|NCT02327169|9996507|FG005|Overall Study|Adverse Event|0
6100843|NCT00761579|9717002|FG000|Overall Study|Intake of prohibited concomitant drug|1
6100844|NCT00761605|9717017|FG000|Overall Study|Adverse Event|26
6100845|NCT00761605|9717017|FG000|Overall Study|Death|2
6100846|NCT00761605|9717017|FG000|Overall Study|Lack of Efficacy|26
6100847|NCT00761605|9717017|FG000|Overall Study|Lost to Follow-up|29
6100848|NCT00761605|9717017|FG000|Overall Study|Withdrawal by Subject|37
6100849|NCT00761605|9717017|FG000|Overall Study|Other|21
6100850|NCT00761631|9717029|FG000|Overall Study|Parent/legal guardian request|8
6100851|NCT00761631|9717030|FG001|Overall Study|Parent/legal guardian request|3
6100852|NCT00761631|9717031|FG002|Overall Study|Parent/legal guardian request|8
6100853|NCT00761631|9717032|FG003|Overall Study|Parent/legal guardian request|0
6100854|NCT00761631|9717033|FG004|Overall Study|Parent/legal guardian request|5
6100855|NCT00761631|9717034|FG005|Overall Study|Parent/legal guardian request|0
6100856|NCT00761631|9717029|FG000|Overall Study|Lost to Follow-up|2
6100857|NCT00761631|9717030|FG001|Overall Study|Lost to Follow-up|4
6100858|NCT00761631|9717031|FG002|Overall Study|Lost to Follow-up|7
6100859|NCT00761631|9717032|FG003|Overall Study|Lost to Follow-up|1
6100860|NCT00761631|9717033|FG004|Overall Study|Lost to Follow-up|6
6100861|NCT00761631|9717034|FG005|Overall Study|Lost to Follow-up|1
6100862|NCT00761631|9717029|FG000|Overall Study|Protocol Violation|2
6100863|NCT00761631|9717030|FG001|Overall Study|Protocol Violation|0
6100864|NCT00761631|9717031|FG002|Overall Study|Protocol Violation|0
6100865|NCT00761631|9717032|FG003|Overall Study|Protocol Violation|1
6100866|NCT00761631|9717033|FG004|Overall Study|Protocol Violation|5
6100867|NCT00761631|9717034|FG005|Overall Study|Protocol Violation|1
6100868|NCT00761631|9717029|FG000|Overall Study|Randomized, not treated|1
6100869|NCT00761631|9717030|FG001|Overall Study|Randomized, not treated|0
6100870|NCT00761631|9717031|FG002|Overall Study|Randomized, not treated|0
6100871|NCT00761631|9717032|FG003|Overall Study|Randomized, not treated|0
6100872|NCT00761631|9717033|FG004|Overall Study|Randomized, not treated|0
6100873|NCT00761631|9717034|FG005|Overall Study|Randomized, not treated|0
6100874|NCT00761631|9717029|FG000|Overall Study|Failed to return|1
6204305|NCT01522404|9865927|FG001|Second Intervention (up to Week 58)|Withdrawal by Subject|0
6204306|NCT01522443|9865956|FG000|Overall Study|No longer receiving clinical benefit|36
6204307|NCT01522443|9865957|FG001|Overall Study|No longer receiving clinical benefit|28
6204308|NCT01522443|9865956|FG000|Overall Study|Adverse Event|10
6204309|NCT01522443|9865957|FG001|Overall Study|Adverse Event|15
6204310|NCT01522443|9865956|FG000|Overall Study|Withdrawal by Subject|5
6204311|NCT01522443|9865957|FG001|Overall Study|Withdrawal by Subject|8
6204312|NCT01522443|9865956|FG000|Overall Study|No study treatment given|1
6204313|NCT01522443|9865957|FG001|Overall Study|No study treatment given|1
6204314|NCT01522443|9865956|FG000|Overall Study|Other|1
6204315|NCT01522443|9865957|FG001|Overall Study|Other|3
6204316|NCT01522456|9865963|FG000|Overall Study|Adverse Event|2
6204317|NCT01522456|9865963|FG000|Overall Study|Lost to Follow-up|2
6204318|NCT01522456|9865963|FG000|Overall Study|Withdrawal by Subject|2
6204319|NCT01522456|9865963|FG000|Overall Study|Pregnancy|1
6204320|NCT01522456|9865963|FG000|Overall Study|Tolerability Assessment|1
6204321|NCT01522651|9865979|FG000|Overall Study|Adverse Event|3
6204322|NCT01522651|9865980|FG001|Overall Study|Adverse Event|4
6204323|NCT01522651|9865981|FG002|Overall Study|Adverse Event|4
6204324|NCT01522651|9865982|FG003|Overall Study|Adverse Event|5
6204325|NCT01522651|9865983|FG004|Overall Study|Adverse Event|4
6204326|NCT01522651|9865979|FG000|Overall Study|Cardioversion|1
6204327|NCT01522651|9865980|FG001|Overall Study|Cardioversion|0
6204328|NCT01522651|9865981|FG002|Overall Study|Cardioversion|0
6204329|NCT01522651|9865982|FG003|Overall Study|Cardioversion|0
6204330|NCT01522651|9865983|FG004|Overall Study|Cardioversion|0
6204331|NCT01522651|9865979|FG000|Overall Study|Device Malfunction|0
6204332|NCT01522651|9865980|FG001|Overall Study|Device Malfunction|1
6204333|NCT01522651|9865981|FG002|Overall Study|Device Malfunction|0
6204334|NCT01522651|9865982|FG003|Overall Study|Device Malfunction|0
6204335|NCT01522651|9865983|FG004|Overall Study|Device Malfunction|0
6204336|NCT01522651|9865979|FG000|Overall Study|Investigator's Discretion|0
6204337|NCT01522651|9865980|FG001|Overall Study|Investigator's Discretion|1
6204338|NCT01522651|9865981|FG002|Overall Study|Investigator's Discretion|0
6204339|NCT01522651|9865982|FG003|Overall Study|Investigator's Discretion|0
6204340|NCT01522651|9865983|FG004|Overall Study|Investigator's Discretion|0
6204341|NCT01522651|9865979|FG000|Overall Study|Protocol Violation|3
6204342|NCT01522651|9865980|FG001|Overall Study|Protocol Violation|0
6204343|NCT01522651|9865981|FG002|Overall Study|Protocol Violation|0
6204344|NCT01522651|9865982|FG003|Overall Study|Protocol Violation|0
6204345|NCT01522651|9865983|FG004|Overall Study|Protocol Violation|0
6204346|NCT01522651|9865979|FG000|Overall Study|Reason Not Specified|0
6204347|NCT01522651|9865980|FG001|Overall Study|Reason Not Specified|0
6100875|NCT00761631|9717030|FG001|Overall Study|Failed to return|0
6100876|NCT00761631|9717031|FG002|Overall Study|Failed to return|1
6100877|NCT00761631|9717032|FG003|Overall Study|Failed to return|1
6100878|NCT00761631|9717033|FG004|Overall Study|Failed to return|5
6100879|NCT00761631|9717034|FG005|Overall Study|Failed to return|2
6100880|NCT00761631|9717029|FG000|Overall Study|Physician Decision|1
6204348|NCT01522651|9865981|FG002|Overall Study|Reason Not Specified|0
6204349|NCT01522651|9865982|FG003|Overall Study|Reason Not Specified|1
6204350|NCT01522651|9865983|FG004|Overall Study|Reason Not Specified|0
6204351|NCT01522651|9865979|FG000|Overall Study|Participant Non-Compliance|1
6204352|NCT01522651|9865980|FG001|Overall Study|Participant Non-Compliance|0
6100881|NCT00761631|9717030|FG001|Overall Study|Physician Decision|0
6100882|NCT00761631|9717031|FG002|Overall Study|Physician Decision|0
6100883|NCT00761631|9717032|FG003|Overall Study|Physician Decision|0
6100884|NCT00761631|9717033|FG004|Overall Study|Physician Decision|0
6100885|NCT00761631|9717034|FG005|Overall Study|Physician Decision|0
6100886|NCT00761631|9717029|FG000|Overall Study|Other|0
6100887|NCT00761631|9717030|FG001|Overall Study|Other|0
6100888|NCT00761631|9717031|FG002|Overall Study|Other|0
6100889|NCT00761631|9717032|FG003|Overall Study|Other|0
6100890|NCT00761631|9717033|FG004|Overall Study|Other|1
6100891|NCT00761631|9717034|FG005|Overall Study|Other|1
6204353|NCT01522651|9865981|FG002|Overall Study|Participant Non-Compliance|0
6204354|NCT01522651|9865982|FG003|Overall Study|Participant Non-Compliance|0
6204355|NCT01522651|9865983|FG004|Overall Study|Participant Non-Compliance|0
6204356|NCT01522651|9865979|FG000|Overall Study|Withdrew Consent|1
6204357|NCT01522651|9865980|FG001|Overall Study|Withdrew Consent|1
6204358|NCT01522651|9865981|FG002|Overall Study|Withdrew Consent|0
6204359|NCT01522651|9865982|FG003|Overall Study|Withdrew Consent|1
6204360|NCT01522651|9865983|FG004|Overall Study|Withdrew Consent|1
6204361|NCT01522651|9865979|FG000|Overall Study|Randomized but Never Treated|0
6204362|NCT01522651|9865980|FG001|Overall Study|Randomized but Never Treated|1
6204363|NCT01522651|9865981|FG002|Overall Study|Randomized but Never Treated|0
6204364|NCT01522651|9865982|FG003|Overall Study|Randomized but Never Treated|1
6204365|NCT01522651|9865983|FG004|Overall Study|Randomized but Never Treated|1
6204366|NCT01522950|9866025|FG000|Overall Study|Withdrawal by Subject|3
6204367|NCT01522950|9866026|FG001|Overall Study|Withdrawal by Subject|2
6204368|NCT01522950|9866027|FG002|Overall Study|Withdrawal by Subject|1
6204369|NCT01522950|9866025|FG000|Overall Study|Adverse Event|3
6204370|NCT01522950|9866026|FG001|Overall Study|Adverse Event|1
6204371|NCT01522950|9866027|FG002|Overall Study|Adverse Event|1
6204372|NCT01522950|9866025|FG000|Overall Study|Protocol Violation|0
6204373|NCT01522950|9866026|FG001|Overall Study|Protocol Violation|0
6204374|NCT01522950|9866027|FG002|Overall Study|Protocol Violation|2
6204375|NCT01522950|9866025|FG000|Overall Study|Death|0
6204376|NCT01522950|9866026|FG001|Overall Study|Death|1
6204377|NCT01522950|9866027|FG002|Overall Study|Death|1
6204378|NCT01522950|9866025|FG000|Overall Study|Study Medication Sensitivity|0
6204379|NCT01522950|9866026|FG001|Overall Study|Study Medication Sensitivity|1
6204380|NCT01522950|9866027|FG002|Overall Study|Study Medication Sensitivity|0
6204381|NCT01523275|9866052|FG000|Overall Study|Lost to Follow-up|1
6204382|NCT01523275|9866053|FG001|Overall Study|Lost to Follow-up|2
6204383|NCT01523275|9866052|FG000|Overall Study|Withdrawal by Subject|1
6204384|NCT01523275|9866053|FG001|Overall Study|Withdrawal by Subject|0
6204385|NCT01523301|9866061|FG000|Overall Study|Adverse Event|25
6204386|NCT01523301|9866062|FG001|Overall Study|Adverse Event|16
6204387|NCT01523301|9866061|FG000|Overall Study|Lack of Efficacy|0
6204388|NCT01523301|9866062|FG001|Overall Study|Lack of Efficacy|2
6204389|NCT01523301|9866061|FG000|Overall Study|Protocol Violation|3
6204390|NCT01523301|9866062|FG001|Overall Study|Protocol Violation|4
6204391|NCT01523301|9866061|FG000|Overall Study|Lost to Follow-up|1
6204392|NCT01523301|9866062|FG001|Overall Study|Lost to Follow-up|0
6204393|NCT01523301|9866061|FG000|Overall Study|Withdrawal by Subject|6
6204394|NCT01523301|9866062|FG001|Overall Study|Withdrawal by Subject|8
6204395|NCT01523301|9866061|FG000|Overall Study|Other Reason|0
6204396|NCT01523301|9866062|FG001|Overall Study|Other Reason|2
6204397|NCT01523366|9866070|FG000|Treatment Period 1|Withdrawal by Subject|1
6204398|NCT01523366|9866071|FG001|Treatment Period 1|Withdrawal by Subject|0
6204399|NCT01523366|9866070|FG000|Treatment Period 2|Not completed at least 7 days treatment|1
6204400|NCT01523366|9866071|FG001|Treatment Period 2|Not completed at least 7 days treatment|0
6204401|NCT01523392|9866081|FG000|Treatment Period 1|Withdrawal by Subject|2
6204402|NCT01523392|9866082|FG001|Treatment Period 1|Withdrawal by Subject|0
6204403|NCT01523392|9866081|FG000|Treatment Period 1|Did not complete 7-9 days of treatment.|1
6204404|NCT01523392|9866082|FG001|Treatment Period 1|Did not complete 7-9 days of treatment.|0
6204405|NCT01523392|9866081|FG000|Washout Period - 10 to 14 Days|Adverse Event|1
6204406|NCT01523392|9866082|FG001|Washout Period - 10 to 14 Days|Adverse Event|0
6204407|NCT01523457|9866092|FG000|Overall Study|Withdrawal by Subject|7
6204408|NCT01523457|9866093|FG001|Overall Study|Withdrawal by Subject|2
6204409|NCT01523587|9866122|FG000|Overall Study|Other than listed|5
6204410|NCT01523587|9866123|FG001|Overall Study|Other than listed|5
6204411|NCT01523587|9866122|FG000|Overall Study|Worsening of underlying cancer disease|19
6204412|NCT01523587|9866123|FG001|Overall Study|Worsening of underlying cancer disease|34
6204413|NCT01523587|9866122|FG000|Overall Study|Adverse Event|68
6204414|NCT01523587|9866123|FG001|Overall Study|Adverse Event|52
6204415|NCT01523587|9866122|FG000|Overall Study|Protocol Violation|5
6204416|NCT01523587|9866123|FG001|Overall Study|Protocol Violation|3
6204417|NCT01523587|9866122|FG000|Overall Study|Lost to Follow-up|2
6204418|NCT01523587|9866123|FG001|Overall Study|Lost to Follow-up|2
6204419|NCT01523587|9866122|FG000|Overall Study|Withdrawal by Subject|28
6204420|NCT01523587|9866123|FG001|Overall Study|Withdrawal by Subject|20
6204421|NCT01523587|9866122|FG000|Overall Study|Withdrew due to Progressive disease|265
6204422|NCT01523587|9866123|FG001|Overall Study|Withdrew due to Progressive disease|279
6204423|NCT01523587|9866122|FG000|Overall Study|Randomised but bot treated|6
6204424|NCT01523587|9866123|FG001|Overall Study|Randomised but bot treated|2
6100892|NCT00761657|9717066|FG000|Part 1 (up to Day 57)|Adverse Event|0
6100893|NCT00761657|9717067|FG001|Part 1 (up to Day 57)|Adverse Event|0
6100894|NCT00761657|9717068|FG002|Part 1 (up to Day 57)|Adverse Event|0
6100895|NCT00761657|9717069|FG003|Part 1 (up to Day 57)|Adverse Event|1
6100896|NCT00761657|9717070|FG004|Part 1 (up to Day 57)|Adverse Event|0
6100897|NCT00761657|9717071|FG005|Part 1 (up to Day 57)|Adverse Event|0
6100898|NCT00761657|9717072|FG006|Part 1 (up to Day 57)|Adverse Event|0
6100899|NCT00761657|9717073|FG007|Part 1 (up to Day 57)|Adverse Event|0
6100900|NCT00761657|9717074|FG008|Part 1 (up to Day 57)|Adverse Event|0
6100901|NCT00761657|9717066|FG000|Part 1 (up to Day 57)|Withdrawal by Subject|0
6100902|NCT00761657|9717067|FG001|Part 1 (up to Day 57)|Withdrawal by Subject|0
6100903|NCT00761657|9717068|FG002|Part 1 (up to Day 57)|Withdrawal by Subject|1
6100904|NCT00761657|9717069|FG003|Part 1 (up to Day 57)|Withdrawal by Subject|1
6100905|NCT00761657|9717070|FG004|Part 1 (up to Day 57)|Withdrawal by Subject|0
6100906|NCT00761657|9717071|FG005|Part 1 (up to Day 57)|Withdrawal by Subject|0
6100907|NCT00761657|9717072|FG006|Part 1 (up to Day 57)|Withdrawal by Subject|0
6100908|NCT00761657|9717073|FG007|Part 1 (up to Day 57)|Withdrawal by Subject|0
6100909|NCT00761657|9717074|FG008|Part 1 (up to Day 57)|Withdrawal by Subject|0
6100910|NCT00761657|9717066|FG000|Part 1 (up to Day 57)|Sponsor Decision|0
6100911|NCT00761657|9717067|FG001|Part 1 (up to Day 57)|Sponsor Decision|0
6100912|NCT00761657|9717068|FG002|Part 1 (up to Day 57)|Sponsor Decision|3
6100913|NCT00761657|9717069|FG003|Part 1 (up to Day 57)|Sponsor Decision|4
6100914|NCT00761657|9717070|FG004|Part 1 (up to Day 57)|Sponsor Decision|0
6100915|NCT00761657|9717071|FG005|Part 1 (up to Day 57)|Sponsor Decision|0
6284908|NCT02327169|9996508|FG006|Overall Study|Adverse Event|0
6100916|NCT00761657|9717072|FG006|Part 1 (up to Day 57)|Sponsor Decision|1
6100917|NCT00761657|9717073|FG007|Part 1 (up to Day 57)|Sponsor Decision|1
6100918|NCT00761657|9717074|FG008|Part 1 (up to Day 57)|Sponsor Decision|1
6204425|NCT01523743|9866152|FG000|Period 1|Adverse Event|1
6204426|NCT01523743|9866153|FG001|Period 1|Adverse Event|0
6204427|NCT01523743|9866152|FG000|Period 1|Withdrawal by Subject|6
6204428|NCT01523743|9866153|FG001|Period 1|Withdrawal by Subject|2
6204429|NCT01523743|9866152|FG000|Period 1|Lost to Follow-up|1
6204430|NCT01523743|9866153|FG001|Period 1|Lost to Follow-up|0
6204431|NCT01523743|9866152|FG000|Period 1|Lack of Efficacy|1
6204432|NCT01523743|9866153|FG001|Period 1|Lack of Efficacy|0
6204433|NCT01523743|9866152|FG000|Period 1|Felt unable to empty bladder|1
6204434|NCT01523743|9866153|FG001|Period 1|Felt unable to empty bladder|0
6204435|NCT01523743|9866152|FG000|Period 2|Withdrawal by Subject|0
6204436|NCT01523743|9866153|FG001|Period 2|Withdrawal by Subject|2
6204437|NCT01523743|9866152|FG000|Period 2|Adverse Event|1
6204438|NCT01523743|9866153|FG001|Period 2|Adverse Event|0
6204439|NCT01523756|9866159|FG000|Baseline Period|Adverse Event|0
6204440|NCT01523756|9866160|FG001|Baseline Period|Adverse Event|1
6204441|NCT01523756|9866159|FG000|Test Period 1|Adverse Event|1
6204442|NCT01523756|9866160|FG001|Test Period 1|Adverse Event|0
6204443|NCT01523756|9866159|FG000|Test Period 2|Withdrawal by Subject|0
6204444|NCT01523756|9866160|FG001|Test Period 2|Withdrawal by Subject|1
6204445|NCT01523873|9866225|FG000|Overall Study|Protocol Violation|422
6204446|NCT01523886|9866233|FG000|Overall Study|surgery cancelled|0
6204447|NCT01523886|9866234|FG001|Overall Study|surgery cancelled|1
6204448|NCT01524133|9866270|FG000|Treatment Phase|Withdrawal by Subject|13
6204449|NCT01524133|9866271|FG001|Treatment Phase|Withdrawal by Subject|28
6204450|NCT01524133|9866272|FG002|Treatment Phase|Withdrawal by Subject|31
6204451|NCT01524133|9866270|FG000|Treatment Phase|Physician Decision|6
6204452|NCT01524133|9866271|FG001|Treatment Phase|Physician Decision|3
6204453|NCT01524133|9866272|FG002|Treatment Phase|Physician Decision|3
6204454|NCT01524133|9866270|FG000|Treatment Phase|Lost to Follow-up|0
6204455|NCT01524133|9866271|FG001|Treatment Phase|Lost to Follow-up|1
6204456|NCT01524133|9866272|FG002|Treatment Phase|Lost to Follow-up|2
6204457|NCT01524133|9866270|FG000|Overall Study 52 Weeks|Withdrawal by Subject|4
6204458|NCT01524133|9866271|FG001|Overall Study 52 Weeks|Withdrawal by Subject|5
6204459|NCT01524133|9866272|FG002|Overall Study 52 Weeks|Withdrawal by Subject|10
6204460|NCT01524133|9866270|FG000|Overall Study 52 Weeks|Physician Decision|1
6284909|NCT02327169|9996509|FG007|Overall Study|Adverse Event|0
6284910|NCT02327169|9996510|FG008|Overall Study|Adverse Event|0
6284911|NCT02327169|9996511|FG009|Overall Study|Adverse Event|2
6284912|NCT02327169|9996512|FG010|Overall Study|Adverse Event|0
6284913|NCT02327169|9996513|FG011|Overall Study|Adverse Event|3
6100919|NCT00761657|9717066|FG000|Part 2 (up to Day 114)|Adverse Event|0
6100920|NCT00761657|9717067|FG001|Part 2 (up to Day 114)|Adverse Event|0
6100921|NCT00761657|9717068|FG002|Part 2 (up to Day 114)|Adverse Event|0
6100922|NCT00761657|9717069|FG003|Part 2 (up to Day 114)|Adverse Event|0
6204461|NCT01524133|9866271|FG001|Overall Study 52 Weeks|Physician Decision|0
6284914|NCT02327169|9996514|FG012|Overall Study|Adverse Event|0
6100923|NCT00761657|9717070|FG004|Part 2 (up to Day 114)|Adverse Event|0
6100924|NCT00761657|9717071|FG005|Part 2 (up to Day 114)|Adverse Event|0
6100925|NCT00761657|9717072|FG006|Part 2 (up to Day 114)|Adverse Event|0
6100926|NCT00761657|9717073|FG007|Part 2 (up to Day 114)|Adverse Event|0
6100927|NCT00761657|9717074|FG008|Part 2 (up to Day 114)|Adverse Event|1
6100928|NCT00761735|9717104|FG000|Overall Study|Lost to Follow-up|6
6204462|NCT01524133|9866272|FG002|Overall Study 52 Weeks|Physician Decision|2
6204463|NCT01524133|9866270|FG000|Overall Study 52 Weeks|Lost to Follow-up|16
6100929|NCT00761735|9717104|FG000|Overall Study|Withdrawal by Subject|6
6100930|NCT00761735|9717104|FG000|Overall Study|Non-compliance with protocol|1
6100931|NCT00761735|9717104|FG000|Overall Study|Administrative|1
6100932|NCT00761748|9717112|FG000|First Intervention (21 +/- 3 Days)|Adverse Event|3
6100933|NCT00761748|9717113|FG001|First Intervention (21 +/- 3 Days)|Adverse Event|0
6100934|NCT00761748|9717112|FG000|First Intervention (21 +/- 3 Days)|Lost to Follow-up|0
6100935|NCT00761748|9717113|FG001|First Intervention (21 +/- 3 Days)|Lost to Follow-up|3
6100936|NCT00761761|9717121|FG000|Overall Study|Lost to Follow-up|3
6204464|NCT01524133|9866271|FG001|Overall Study 52 Weeks|Lost to Follow-up|15
6204465|NCT01524133|9866272|FG002|Overall Study 52 Weeks|Lost to Follow-up|15
6204466|NCT01524198|9866282|FG000|Overall Study|Protocol Violation|8
6204467|NCT01524198|9866283|FG001|Overall Study|Protocol Violation|6
6204468|NCT01524198|9866282|FG000|Overall Study|Withdrawal by Subject|15
6204469|NCT01524198|9866283|FG001|Overall Study|Withdrawal by Subject|10
6204470|NCT01524224|9866297|FG000|Overall Study|Progressive Disease|1
6204471|NCT01524224|9866298|FG001|Overall Study|Progressive Disease|0
6204472|NCT01524224|9866299|FG002|Overall Study|Progressive Disease|2
6204473|NCT01524224|9866300|FG003|Overall Study|Progressive Disease|1
6204474|NCT01524224|9866301|FG004|Overall Study|Progressive Disease|2
6204475|NCT01524224|9866302|FG005|Overall Study|Progressive Disease|1
6204476|NCT01524224|9866303|FG006|Overall Study|Progressive Disease|1
6204477|NCT01524224|9866304|FG007|Overall Study|Progressive Disease|5
6204478|NCT01524224|9866297|FG000|Overall Study|Withdrawal by Subject|2
6204479|NCT01524224|9866298|FG001|Overall Study|Withdrawal by Subject|0
6204480|NCT01524224|9866299|FG002|Overall Study|Withdrawal by Subject|0
6204481|NCT01524224|9866300|FG003|Overall Study|Withdrawal by Subject|0
6204482|NCT01524224|9866301|FG004|Overall Study|Withdrawal by Subject|0
6204483|NCT01524224|9866302|FG005|Overall Study|Withdrawal by Subject|0
6204484|NCT01524224|9866303|FG006|Overall Study|Withdrawal by Subject|2
6204485|NCT01524224|9866304|FG007|Overall Study|Withdrawal by Subject|0
6204486|NCT01524224|9866297|FG000|Overall Study|Adverse Event|0
6204487|NCT01524224|9866298|FG001|Overall Study|Adverse Event|1
6204488|NCT01524224|9866299|FG002|Overall Study|Adverse Event|0
6204489|NCT01524224|9866300|FG003|Overall Study|Adverse Event|0
6204490|NCT01524224|9866301|FG004|Overall Study|Adverse Event|0
6204491|NCT01524224|9866302|FG005|Overall Study|Adverse Event|1
6204492|NCT01524224|9866303|FG006|Overall Study|Adverse Event|0
6204493|NCT01524224|9866304|FG007|Overall Study|Adverse Event|0
6204494|NCT01524224|9866297|FG000|Overall Study|Physician Decision|0
6204495|NCT01524224|9866298|FG001|Overall Study|Physician Decision|0
6204496|NCT01524224|9866299|FG002|Overall Study|Physician Decision|0
6204497|NCT01524224|9866300|FG003|Overall Study|Physician Decision|1
6204498|NCT01524224|9866301|FG004|Overall Study|Physician Decision|1
6204499|NCT01524224|9866302|FG005|Overall Study|Physician Decision|0
6204500|NCT01524224|9866303|FG006|Overall Study|Physician Decision|0
6204501|NCT01524224|9866304|FG007|Overall Study|Physician Decision|1
6204502|NCT01524224|9866297|FG000|Overall Study|Sponsor Decision|0
6204503|NCT01524224|9866298|FG001|Overall Study|Sponsor Decision|0
6204504|NCT01524224|9866299|FG002|Overall Study|Sponsor Decision|0
6204505|NCT01524224|9866300|FG003|Overall Study|Sponsor Decision|0
6204506|NCT01524224|9866301|FG004|Overall Study|Sponsor Decision|1
6204507|NCT01524224|9866302|FG005|Overall Study|Sponsor Decision|0
6204508|NCT01524224|9866303|FG006|Overall Study|Sponsor Decision|0
6204509|NCT01524224|9866304|FG007|Overall Study|Sponsor Decision|0
6204510|NCT01524289|9866324|FG000|Overall Study|Lost to Follow-up|0
6204511|NCT01524289|9866325|FG001|Overall Study|Lost to Follow-up|1
6204512|NCT01524289|9866324|FG000|Overall Study|Physician Decision|1
6204513|NCT01524289|9866325|FG001|Overall Study|Physician Decision|0
6204514|NCT01524289|9866324|FG000|Overall Study|Protocol Violation|5
6204515|NCT01524289|9866325|FG001|Overall Study|Protocol Violation|1
6204516|NCT01524289|9866324|FG000|Overall Study|Withdrawal by Subject|11
6204517|NCT01524289|9866325|FG001|Overall Study|Withdrawal by Subject|7
6204518|NCT01524289|9866324|FG000|Overall Study|Adverse Event|12
6204519|NCT01524289|9866325|FG001|Overall Study|Adverse Event|5
6204520|NCT01524289|9866324|FG000|Overall Study|Did not take study medication|1
6204521|NCT01524289|9866325|FG001|Overall Study|Did not take study medication|0
6204522|NCT01524627|9866348|FG000|Overall Study|Physician Decision|0
6204523|NCT01524627|9866349|FG001|Overall Study|Physician Decision|1
6204524|NCT01524627|9866348|FG000|Overall Study|Lost to Follow-up|1
6204525|NCT01524627|9866349|FG001|Overall Study|Lost to Follow-up|1
6204526|NCT01524679|9866357|FG000|Overall Study|Lost to Follow-up|1
6204527|NCT01524679|9866358|FG001|Overall Study|Lost to Follow-up|4
6204528|NCT01524679|9866357|FG000|Overall Study|Withdrawal by Subject|4
6204529|NCT01524679|9866358|FG001|Overall Study|Withdrawal by Subject|4
6204530|NCT01524679|9866357|FG000|Overall Study|Adverse Event|9
6204531|NCT01524679|9866358|FG001|Overall Study|Adverse Event|0
6204532|NCT01524679|9866357|FG000|Overall Study|Protocol Violation|1
6204533|NCT01524679|9866358|FG001|Overall Study|Protocol Violation|0
6204534|NCT01524679|9866357|FG000|Overall Study|Lack of Efficacy|2
6204535|NCT01524679|9866358|FG001|Overall Study|Lack of Efficacy|0
6204536|NCT01524679|9866357|FG000|Overall Study|e.g.wish for children, relocation|6
6204537|NCT01524679|9866358|FG001|Overall Study|e.g.wish for children, relocation|1
6204538|NCT01524692|9866364|FG000|Overall Study|Withdrawal by Subject|3
6204539|NCT01524770|9866369|FG000|First Intervention|Withdrawal by Subject|1
6204540|NCT01524770|9866370|FG001|First Intervention|Withdrawal by Subject|0
6100937|NCT00761761|9717122|FG001|Overall Study|Lost to Follow-up|1
6100938|NCT00761761|9717121|FG000|Overall Study|Withdrawal by Subject|3
6100939|NCT00761761|9717122|FG001|Overall Study|Withdrawal by Subject|0
6100940|NCT00761774|9717130|FG000|Overall Study|Adverse Event|17
6100941|NCT00761774|9717130|FG000|Overall Study|Lack of Efficacy|37
6100942|NCT00761774|9717130|FG000|Overall Study|Lost to Follow-up|2
6100943|NCT00761774|9717130|FG000|Overall Study|Withdrawal by Subject|9
6100944|NCT00761774|9717130|FG000|Overall Study|Non-compliance|4
6100945|NCT00761774|9717130|FG000|Overall Study|End of study|2
6100946|NCT00761774|9717130|FG000|Overall Study|Reclassification of seizures|1
6100947|NCT00761774|9717130|FG000|Overall Study|Medical decision to read SUSAR reports|1
6100948|NCT00761774|9717130|FG000|Overall Study|Sponsor decision|1
6100949|NCT00761774|9717130|FG000|Overall Study|Investigator clinical judgement|1
6100950|NCT00761774|9717130|FG000|Overall Study|Patient moved out of study area|1
6100951|NCT00761774|9717130|FG000|Overall Study|Coordinator leaving site|1
6100952|NCT00761774|9717130|FG000|Overall Study|Subject IP non-compliance|1
6100953|NCT00761774|9717130|FG000|Overall Study|IP stopped by hospital physician|1
6100954|NCT00761865|9717147|FG000|Overall Study|Lost to Follow-up|8
6100955|NCT00761865|9717148|FG001|Overall Study|Lost to Follow-up|7
6100956|NCT00761891|9717154|FG000|Overall Study|Withdrawal by Subject|10
6100957|NCT00761956|9717174|FG000|Overall Study|Lost to Follow-up|6
6100958|NCT00761956|9717175|FG001|Overall Study|Lost to Follow-up|11
6100959|NCT00761956|9717174|FG000|Overall Study|Withdrawal by Subject|3
6100960|NCT00761956|9717175|FG001|Overall Study|Withdrawal by Subject|8
6100961|NCT00761956|9717174|FG000|Overall Study|Death|0
6100962|NCT00761956|9717175|FG001|Overall Study|Death|1
6100963|NCT00761956|9717174|FG000|Overall Study|Adverse Event|26
6100964|NCT00761956|9717175|FG001|Overall Study|Adverse Event|34
6100965|NCT00761969|9717183|FG000|Overall Study|Death|112
6100966|NCT00761969|9717184|FG001|Overall Study|Death|47
6100967|NCT00761969|9717183|FG000|Overall Study|Lost to Follow-up|88
6100968|NCT00761969|9717184|FG001|Overall Study|Lost to Follow-up|93
6100969|NCT00762034|9717201|FG000|Induction Period|Protocol Violation|1
6100970|NCT00762034|9717202|FG001|Induction Period|Protocol Violation|2
6100971|NCT00762034|9717201|FG000|Induction Period|Entry Criterion Not Met|12
6100972|NCT00762034|9717202|FG001|Induction Period|Entry Criterion Not Met|11
6100973|NCT00762034|9717201|FG000|Induction Period|Adverse Event|27
6100974|NCT00762034|9717202|FG001|Induction Period|Adverse Event|38
6100975|NCT00762034|9717201|FG000|Induction Period|Lost to Follow-up|1
6100976|NCT00762034|9717202|FG001|Induction Period|Lost to Follow-up|1
6100977|NCT00762034|9717201|FG000|Induction Period|Progressive Disease|73
6100978|NCT00762034|9717202|FG001|Induction Period|Progressive Disease|55
6100979|NCT00762034|9717201|FG000|Induction Period|Physician Decision|21
6100980|NCT00762034|9717202|FG001|Induction Period|Physician Decision|20
6100981|NCT00762034|9717201|FG000|Induction Period|Withdrawal by Subject|15
6100982|NCT00762034|9717202|FG001|Induction Period|Withdrawal by Subject|19
6100983|NCT00762034|9717201|FG000|Induction Period|Deaths Not Due to Study Disease|19
6100984|NCT00762034|9717202|FG001|Induction Period|Deaths Not Due to Study Disease|14
6100985|NCT00762034|9717201|FG000|Induction Period|Deaths Due to Study Disease|9
6100986|NCT00762034|9717202|FG001|Induction Period|Deaths Due to Study Disease|9
6100987|NCT00762034|9717201|FG000|Maintenance Period|Protocol Violation|1
6100988|NCT00762034|9717202|FG001|Maintenance Period|Protocol Violation|3
6100989|NCT00762034|9717201|FG000|Maintenance Period|Entry Criterion Not Met|0
6100990|NCT00762034|9717202|FG001|Maintenance Period|Entry Criterion Not Met|2
6100991|NCT00762034|9717201|FG000|Maintenance Period|Adverse Event|42
6100992|NCT00762034|9717202|FG001|Maintenance Period|Adverse Event|26
6100993|NCT00762034|9717201|FG000|Maintenance Period|Progressive Disease|186
6100994|NCT00762034|9717202|FG001|Maintenance Period|Progressive Disease|224
6100995|NCT00762034|9717201|FG000|Maintenance Period|Physician Decision|25
6100996|NCT00762034|9717202|FG001|Maintenance Period|Physician Decision|20
6100997|NCT00762034|9717201|FG000|Maintenance Period|Withdrawal by Subject|34
6100998|NCT00762034|9717202|FG001|Maintenance Period|Withdrawal by Subject|14
6100999|NCT00762034|9717201|FG000|Maintenance Period|Death not due to study disease|2
6101000|NCT00762034|9717202|FG001|Maintenance Period|Death not due to study disease|5
6101001|NCT00762034|9717201|FG000|Maintenance Period|Death due to study disease|3
6101002|NCT00762034|9717202|FG001|Maintenance Period|Death due to study disease|3
6101003|NCT00762034|9717201|FG000|Maintenance Period|Other|1
6101004|NCT00762034|9717202|FG001|Maintenance Period|Other|1
6101005|NCT00762073|9717220|FG000|Overall Study|Lack of Efficacy|1
6101006|NCT00762073|9717221|FG001|Overall Study|Lack of Efficacy|1
6101007|NCT00762073|9717222|FG002|Overall Study|Lack of Efficacy|0
6101008|NCT00762073|9717223|FG003|Overall Study|Lack of Efficacy|0
6101009|NCT00762073|9717220|FG000|Overall Study|Adverse Event|1
6101010|NCT00762073|9717221|FG001|Overall Study|Adverse Event|0
6101011|NCT00762073|9717222|FG002|Overall Study|Adverse Event|1
6101012|NCT00762073|9717223|FG003|Overall Study|Adverse Event|1
6101013|NCT00762073|9717220|FG000|Overall Study|Significant Subject Noncompliance|0
6101014|NCT00762073|9717221|FG001|Overall Study|Significant Subject Noncompliance|1
6101015|NCT00762073|9717222|FG002|Overall Study|Significant Subject Noncompliance|0
6101016|NCT00762073|9717223|FG003|Overall Study|Significant Subject Noncompliance|1
6101017|NCT00762073|9717220|FG000|Overall Study|Withdrawal by Subject|1
6101018|NCT00762073|9717221|FG001|Overall Study|Withdrawal by Subject|2
6101019|NCT00762073|9717222|FG002|Overall Study|Withdrawal by Subject|1
6101020|NCT00762073|9717223|FG003|Overall Study|Withdrawal by Subject|1
6101021|NCT00762073|9717220|FG000|Overall Study|Not on treatment for >/= 77 days|1
6101022|NCT00762073|9717221|FG001|Overall Study|Not on treatment for >/= 77 days|0
6101023|NCT00762073|9717222|FG002|Overall Study|Not on treatment for >/= 77 days|0
6101024|NCT00762073|9717223|FG003|Overall Study|Not on treatment for >/= 77 days|0
6101025|NCT00762086|9717242|FG000|Overall Study|Adverse Event|2
6101026|NCT00762086|9717243|FG001|Overall Study|Adverse Event|0
6101027|NCT00762086|9717242|FG000|Overall Study|Lost to Follow-up|0
6101028|NCT00762086|9717243|FG001|Overall Study|Lost to Follow-up|2
6101029|NCT00762086|9717242|FG000|Overall Study|Non compliance|1
6101030|NCT00762086|9717243|FG001|Overall Study|Non compliance|0
6101031|NCT00762086|9717242|FG000|Overall Study|Withdrawal by Subject|2
6101032|NCT00762086|9717243|FG001|Overall Study|Withdrawal by Subject|2
6101033|NCT00762086|9717242|FG000|Overall Study|Ineligible to participate in the study|1
6101034|NCT00762086|9717243|FG001|Overall Study|Ineligible to participate in the study|0
6101035|NCT00762164|9717251|FG000|Overall Study|Lost to Follow-up|1
6101036|NCT00762164|9717252|FG001|Overall Study|Lost to Follow-up|1
6101037|NCT00762164|9717251|FG000|Overall Study|Discontinued medication|2
6101038|NCT00762164|9717252|FG001|Overall Study|Discontinued medication|0
6101039|NCT00762164|9717251|FG000|Overall Study|Withdrawal by Subject|0
6101040|NCT00762164|9717252|FG001|Overall Study|Withdrawal by Subject|1
6101041|NCT00762229|9717280|FG000|Overall Study|Lost to Follow-up|1
6101042|NCT00762229|9717281|FG001|Overall Study|Lost to Follow-up|1
6101043|NCT00762229|9717280|FG000|Overall Study|did not recveive intervention|0
6101044|NCT00762229|9717281|FG001|Overall Study|did not recveive intervention|1
6101045|NCT00762268|9717289|FG000|Overall Study|Withdrawal by Subject|3
6101046|NCT00762268|9717290|FG001|Overall Study|Withdrawal by Subject|3
6101047|NCT00762359|9717335|FG000|Overall Study|Adverse Event|20
6101048|NCT00762359|9717336|FG001|Overall Study|Adverse Event|23
6101049|NCT00762359|9717335|FG000|Overall Study|Protocol Violation|21
6101050|NCT00762359|9717336|FG001|Overall Study|Protocol Violation|13
6101051|NCT00762359|9717335|FG000|Overall Study|Withdrawal by Subject|13
6101052|NCT00762359|9717336|FG001|Overall Study|Withdrawal by Subject|10
6101053|NCT00762359|9717335|FG000|Overall Study|Lack of Efficacy|0
6101054|NCT00762359|9717336|FG001|Overall Study|Lack of Efficacy|4
6101055|NCT00762359|9717335|FG000|Overall Study|Institution closed|2
6101056|NCT00762359|9717336|FG001|Overall Study|Institution closed|3
6101057|NCT00762359|9717335|FG000|Overall Study|Physician Decision|2
6101058|NCT00762359|9717336|FG001|Overall Study|Physician Decision|3
6101059|NCT00762359|9717335|FG000|Overall Study|Removal|0
6101060|NCT00762359|9717336|FG001|Overall Study|Removal|1
6101061|NCT00762359|9717335|FG000|Overall Study|Withdrew consent|1
6101062|NCT00762359|9717336|FG001|Overall Study|Withdrew consent|0
6101063|NCT00762372|9717345|FG000|Overall Study|Adverse Event|1
6101064|NCT00762372|9717346|FG001|Overall Study|Adverse Event|0
6101065|NCT00762372|9717347|FG002|Overall Study|Adverse Event|0
6101066|NCT00762385|9717361|FG000|First Intervention|Lens Issue|1
6101067|NCT00762385|9717362|FG001|First Intervention|Lens Issue|1
6101068|NCT00762385|9717361|FG000|First Intervention|Lost to Follow-up|0
6101069|NCT00762385|9717362|FG001|First Intervention|Lost to Follow-up|2
6101070|NCT00762385|9717361|FG000|First Intervention|Ineligible|1
6101071|NCT00762385|9717362|FG001|First Intervention|Ineligible|0
6101072|NCT00762385|9717361|FG000|First Intervention|Protocol Violation|0
6101073|NCT00762385|9717362|FG001|First Intervention|Protocol Violation|1
6101074|NCT00762385|9717361|FG000|Second Intervention|Protocol Violation|3
6101075|NCT00762385|9717362|FG001|Second Intervention|Protocol Violation|3
6101076|NCT00762411|9717373|FG000|Initial Treatment|Death|7
6101077|NCT00762411|9717374|FG001|Initial Treatment|Death|6
6101078|NCT00762411|9717373|FG000|Initial Treatment|Adverse Event|132
6101079|NCT00762411|9717374|FG001|Initial Treatment|Adverse Event|40
6101080|NCT00762411|9717373|FG000|Initial Treatment|Protocol Violation|4
6101081|NCT00762411|9717374|FG001|Initial Treatment|Protocol Violation|1
6101082|NCT00762411|9717373|FG000|Initial Treatment|Withdrawal by Subject|65
6101083|NCT00762411|9717374|FG001|Initial Treatment|Withdrawal by Subject|52
6101084|NCT00762411|9717373|FG000|Initial Treatment|Physician Decision|1
6101085|NCT00762411|9717374|FG001|Initial Treatment|Physician Decision|0
6101086|NCT00762411|9717373|FG000|Initial Treatment|Sponsor Decision|293
6101087|NCT00762411|9717374|FG001|Initial Treatment|Sponsor Decision|401
6101088|NCT00762411|9717373|FG000|Initial Treatment|Lost to Follow-up|5
6101089|NCT00762411|9717374|FG001|Initial Treatment|Lost to Follow-up|0
6101090|NCT00762411|9717373|FG000|Initial Treatment|Caregiver Decision|21
6101091|NCT00762411|9717374|FG001|Initial Treatment|Caregiver Decision|16
6101092|NCT00762411|9717373|FG000|Initial Treatment|Abnormal Lab/ECG Result|6
6101093|NCT00762411|9717374|FG001|Initial Treatment|Abnormal Lab/ECG Result|4
6101094|NCT00762411|9717373|FG000|Initial Treatment|Entry Criteria Exclusion|0
6101095|NCT00762411|9717374|FG001|Initial Treatment|Entry Criteria Exclusion|1
6101096|NCT00762411|9717373|FG000|Delayed Start|Adverse Event|0
6101097|NCT00762411|9717374|FG001|Delayed Start|Adverse Event|4
6101098|NCT00762411|9717373|FG000|Delayed Start|Protocol Violation|0
6101099|NCT00762411|9717374|FG001|Delayed Start|Protocol Violation|1
6101100|NCT00762411|9717373|FG000|Delayed Start|Sponsor Decision|16
6101101|NCT00762411|9717374|FG001|Delayed Start|Sponsor Decision|20
6101102|NCT00762411|9717373|FG000|Delayed Start|Caregiver Decision|1
6101103|NCT00762411|9717374|FG001|Delayed Start|Caregiver Decision|1
6101104|NCT00762411|9717373|FG000|Safety Follow Up (SFU)-Optional|Death|1
6101105|NCT00762411|9717374|FG001|Safety Follow Up (SFU)-Optional|Death|8
6101106|NCT00762411|9717373|FG000|Safety Follow Up (SFU)-Optional|Adverse Event|0
6101107|NCT00762411|9717374|FG001|Safety Follow Up (SFU)-Optional|Adverse Event|1
6101108|NCT00762411|9717373|FG000|Safety Follow Up (SFU)-Optional|Withdrawal by Subject|21
6101109|NCT00762411|9717374|FG001|Safety Follow Up (SFU)-Optional|Withdrawal by Subject|46
6101110|NCT00762411|9717373|FG000|Safety Follow Up (SFU)-Optional|Lost to Follow-up|6
6101111|NCT00762411|9717374|FG001|Safety Follow Up (SFU)-Optional|Lost to Follow-up|1
6101112|NCT00762411|9717373|FG000|Safety Follow Up (SFU)-Optional|Caregiver Decision|8
6101113|NCT00762411|9717374|FG001|Safety Follow Up (SFU)-Optional|Caregiver Decision|8
6101114|NCT00762411|9717373|FG000|Safety Follow Up (SFU)-Optional|No safety visit or SFU|48
6101115|NCT00762411|9717374|FG001|Safety Follow Up (SFU)-Optional|No safety visit or SFU|54
6101116|NCT00762463|9717408|FG000|Double-blind Phase (Baseline to Week 6)|Insufficient clinical response|2
6101117|NCT00762463|9717409|FG001|Double-blind Phase (Baseline to Week 6)|Insufficient clinical response|2
6101118|NCT00762463|9717410|FG002|Double-blind Phase (Baseline to Week 6)|Insufficient clinical response|0
6101119|NCT00762463|9717411|FG003|Double-blind Phase (Baseline to Week 6)|Insufficient clinical response|0
6101120|NCT00762463|9717408|FG000|Double-blind Phase (Baseline to Week 6)|No longer willing to participate|3
6101121|NCT00762463|9717409|FG001|Double-blind Phase (Baseline to Week 6)|No longer willing to participate|4
6101122|NCT00762463|9717410|FG002|Double-blind Phase (Baseline to Week 6)|No longer willing to participate|0
6101123|NCT00762463|9717411|FG003|Double-blind Phase (Baseline to Week 6)|No longer willing to participate|0
6101124|NCT00762463|9717408|FG000|Double-blind Phase (Baseline to Week 6)|Adverse Event|2
6101125|NCT00762463|9717409|FG001|Double-blind Phase (Baseline to Week 6)|Adverse Event|4
6101126|NCT00762463|9717410|FG002|Double-blind Phase (Baseline to Week 6)|Adverse Event|0
6101127|NCT00762463|9717411|FG003|Double-blind Phase (Baseline to Week 6)|Adverse Event|0
6101128|NCT00762463|9717408|FG000|Enrollment in Extension Phase (Week 6)|Did not sign 2nd informed consent form|4
6101129|NCT00762463|9717409|FG001|Enrollment in Extension Phase (Week 6)|Did not sign 2nd informed consent form|1
6101130|NCT00762463|9717410|FG002|Enrollment in Extension Phase (Week 6)|Did not sign 2nd informed consent form|0
6101131|NCT00762463|9717411|FG003|Enrollment in Extension Phase (Week 6)|Did not sign 2nd informed consent form|0
6101132|NCT00762463|9717408|FG000|Extension Phase (Week 6 to Week 12)|Lost to Follow-up|1
6101133|NCT00762463|9717409|FG001|Extension Phase (Week 6 to Week 12)|Lost to Follow-up|0
6101134|NCT00762463|9717410|FG002|Extension Phase (Week 6 to Week 12)|Lost to Follow-up|1
6101135|NCT00762463|9717411|FG003|Extension Phase (Week 6 to Week 12)|Lost to Follow-up|0
6101136|NCT00762463|9717408|FG000|Extension Phase (Week 6 to Week 12)|Insufficient clinical response|1
6101137|NCT00762463|9717409|FG001|Extension Phase (Week 6 to Week 12)|Insufficient clinical response|1
6101138|NCT00762463|9717410|FG002|Extension Phase (Week 6 to Week 12)|Insufficient clinical response|0
6101139|NCT00762463|9717411|FG003|Extension Phase (Week 6 to Week 12)|Insufficient clinical response|1
6101140|NCT00762463|9717408|FG000|Extension Phase (Week 6 to Week 12)|No longer willing to participate|1
6101141|NCT00762463|9717409|FG001|Extension Phase (Week 6 to Week 12)|No longer willing to participate|0
6101142|NCT00762463|9717410|FG002|Extension Phase (Week 6 to Week 12)|No longer willing to participate|3
6101143|NCT00762463|9717411|FG003|Extension Phase (Week 6 to Week 12)|No longer willing to participate|0
6101144|NCT00762463|9717408|FG000|Extension Phase (Week 6 to Week 12)|Other|0
6101145|NCT00762463|9717409|FG001|Extension Phase (Week 6 to Week 12)|Other|0
6101146|NCT00762463|9717410|FG002|Extension Phase (Week 6 to Week 12)|Other|0
6101147|NCT00762463|9717411|FG003|Extension Phase (Week 6 to Week 12)|Other|1
6101148|NCT00762476|9717426|FG000|Overall Study|Adverse Event|7
6101149|NCT00762476|9717427|FG001|Overall Study|Adverse Event|1
6101150|NCT00762476|9717426|FG000|Overall Study|Lost to Follow-up|2
6101151|NCT00762476|9717427|FG001|Overall Study|Lost to Follow-up|0
6101152|NCT00762476|9717426|FG000|Overall Study|Protocol Violation|5
6101153|NCT00762476|9717427|FG001|Overall Study|Protocol Violation|6
6101154|NCT00762476|9717426|FG000|Overall Study|Physician Decision|2
6101155|NCT00762476|9717427|FG001|Overall Study|Physician Decision|14
6101156|NCT00762476|9717426|FG000|Overall Study|Withdrawal by Subject|6
6101157|NCT00762476|9717427|FG001|Overall Study|Withdrawal by Subject|12
6101158|NCT00762476|9717426|FG000|Overall Study|antibiotic use|0
6101159|NCT00762476|9717427|FG001|Overall Study|antibiotic use|1
6101160|NCT00762476|9717426|FG000|Overall Study|non-compliance with study visits|0
6101161|NCT00762476|9717427|FG001|Overall Study|non-compliance with study visits|2
6101162|NCT00762476|9717426|FG000|Overall Study|Seasonal allergies|1
6101163|NCT00762476|9717427|FG001|Overall Study|Seasonal allergies|0
6101164|NCT00762502|9717437|FG000|Baseline to Month 3 (Period 1)|Adverse Event|4
6101165|NCT00762502|9717438|FG001|Baseline to Month 3 (Period 1)|Adverse Event|3
6101166|NCT00762502|9717439|FG002|Baseline to Month 3 (Period 1)|Adverse Event|6
6101167|NCT00762502|9717437|FG000|Baseline to Month 3 (Period 1)|Lost to Follow-up|6
6101168|NCT00762502|9717438|FG001|Baseline to Month 3 (Period 1)|Lost to Follow-up|3
6101169|NCT00762502|9717439|FG002|Baseline to Month 3 (Period 1)|Lost to Follow-up|13
6101170|NCT00762502|9717437|FG000|Month 3 to Month 6 (Period 2)|Pregnancy|0
6101171|NCT00762502|9717438|FG001|Month 3 to Month 6 (Period 2)|Pregnancy|1
6101172|NCT00762502|9717439|FG002|Month 3 to Month 6 (Period 2)|Pregnancy|0
6101173|NCT00762606|9717465|FG000|Overall Study|Lost to Follow-up|18
6101174|NCT00762606|9717466|FG001|Overall Study|Lost to Follow-up|13
6101175|NCT00762762|9717503|FG000|Overall Study|Did not report for appointments|8
6101176|NCT00762762|9717504|FG001|Overall Study|Did not report for appointments|10
6204541|NCT01524770|9866369|FG000|First Intervention|Adverse Event|1
6204542|NCT01524770|9866370|FG001|First Intervention|Adverse Event|1
6204543|NCT01524770|9866369|FG000|First Intervention|Protocol Violation|1
6204544|NCT01524770|9866370|FG001|First Intervention|Protocol Violation|0
6204545|NCT01524783|9866378|FG000|Blinded Period|Adverse Event|64
6204546|NCT01524783|9866379|FG001|Blinded Period|Adverse Event|7
6204547|NCT01524783|9866380|FG002|Blinded Period|Adverse Event|0
6204548|NCT01524783|9866378|FG000|Blinded Period|Disease Progression|89
6204549|NCT01524783|9866379|FG001|Blinded Period|Disease Progression|75
6204550|NCT01524783|9866380|FG002|Blinded Period|Disease Progression|0
6204551|NCT01524783|9866378|FG000|Blinded Period|Withdrawal by Subject|19
6204552|NCT01524783|9866379|FG001|Blinded Period|Withdrawal by Subject|6
6204553|NCT01524783|9866380|FG002|Blinded Period|Withdrawal by Subject|0
6204554|NCT01524783|9866378|FG000|Blinded Period|Protocol deviation|2
6204555|NCT01524783|9866379|FG001|Blinded Period|Protocol deviation|1
6204556|NCT01524783|9866380|FG002|Blinded Period|Protocol deviation|0
6204557|NCT01524783|9866378|FG000|Blinded Period|Death|5
6204558|NCT01524783|9866379|FG001|Blinded Period|Death|2
6204559|NCT01524783|9866380|FG002|Blinded Period|Death|0
6204560|NCT01524783|9866378|FG000|Open-label Period|Disease progression|13
6204561|NCT01524783|9866379|FG001|Open-label Period|Disease progression|0
6204562|NCT01524783|9866380|FG002|Open-label Period|Disease progression|2
6204563|NCT01524783|9866378|FG000|Open-label Period|Administrative problems|5
6204564|NCT01524783|9866379|FG001|Open-label Period|Administrative problems|0
6204565|NCT01524783|9866380|FG002|Open-label Period|Administrative problems|2
6204566|NCT01524783|9866378|FG000|Open-label Period|Adverse Event|5
6204567|NCT01524783|9866379|FG001|Open-label Period|Adverse Event|0
6204568|NCT01524783|9866380|FG002|Open-label Period|Adverse Event|1
6204569|NCT01524783|9866378|FG000|Open-label Period|Withdrawal by Subject|2
6204570|NCT01524783|9866379|FG001|Open-label Period|Withdrawal by Subject|0
6204571|NCT01524783|9866380|FG002|Open-label Period|Withdrawal by Subject|1
6204572|NCT01524783|9866378|FG000|Open-label Period|Protocol deviation|1
6204573|NCT01524783|9866379|FG001|Open-label Period|Protocol deviation|0
6204574|NCT01524783|9866380|FG002|Open-label Period|Protocol deviation|0
6204575|NCT01524796|9866392|FG000|Overall Study|Adverse Event|13
6204576|NCT01524796|9866392|FG000|Overall Study|Lack of Efficacy|3
6204577|NCT01524796|9866392|FG000|Overall Study|Lost to Follow-up|1
6204578|NCT01524796|9866392|FG000|Overall Study|The price|1
6204579|NCT01524796|9866392|FG000|Overall Study|Withdrawal by Subject|4
6204580|NCT01524796|9866392|FG000|Overall Study|Move|1
6204581|NCT01524796|9866392|FG000|Overall Study|Deterioration of pains|1
6204582|NCT01524796|9866392|FG000|Overall Study|Gall stone surgery|1
6204583|NCT01524796|9866392|FG000|Overall Study|Nervous about confidentiality|1
6204584|NCT01524796|9866392|FG000|Overall Study|Switch to carbamazapine|1
6204585|NCT01524796|9866392|FG000|Overall Study|Adverse Event and Lack of Efficacy|1
6204586|NCT01524887|9866399|FG000|Overall Study|Withdrawal by Subject|6
6204587|NCT01524887|9866400|FG001|Overall Study|Withdrawal by Subject|2
6204588|NCT01524887|9866401|FG002|Overall Study|Withdrawal by Subject|3
6204589|NCT01524887|9866399|FG000|Overall Study|Adverse Event|5
6204590|NCT01524887|9866400|FG001|Overall Study|Adverse Event|1
6204591|NCT01524887|9866401|FG002|Overall Study|Adverse Event|1
6204592|NCT01524887|9866399|FG000|Overall Study|Protocol Violation|0
6204593|NCT01524887|9866400|FG001|Overall Study|Protocol Violation|0
6204594|NCT01524887|9866401|FG002|Overall Study|Protocol Violation|1
6204595|NCT01524887|9866399|FG000|Overall Study|Study termination|73
6204596|NCT01524887|9866400|FG001|Overall Study|Study termination|87
6204597|NCT01524887|9866401|FG002|Overall Study|Study termination|79
6204598|NCT01524887|9866399|FG000|Overall Study|Withdrawal by Caregiver|0
6204599|NCT01524887|9866400|FG001|Overall Study|Withdrawal by Caregiver|0
6204600|NCT01524887|9866401|FG002|Overall Study|Withdrawal by Caregiver|2
6204601|NCT01524887|9866399|FG000|Overall Study|Use of prohibited medication|1
6204602|NCT01524887|9866400|FG001|Overall Study|Use of prohibited medication|0
6204603|NCT01524887|9866401|FG002|Overall Study|Use of prohibited medication|0
6204604|NCT01524900|9866414|FG000|Overall Study|Lost to Follow-up|3
6204605|NCT01524900|9866415|FG001|Overall Study|Lost to Follow-up|12
6204606|NCT01524900|9866416|FG002|Overall Study|Lost to Follow-up|1
6204607|NCT01524900|9866417|FG003|Overall Study|Lost to Follow-up|0
6204608|NCT01524900|9866418|FG004|Overall Study|Lost to Follow-up|0
6204609|NCT01524900|9866414|FG000|Overall Study|Other reason than stated above|1
5980505|NCT02733042|9569325|FG005|Treatment Period|Progressive Disease|3
6204610|NCT01524900|9866415|FG001|Overall Study|Other reason than stated above|1
6204611|NCT01524900|9866416|FG002|Overall Study|Other reason than stated above|0
6204612|NCT01524900|9866417|FG003|Overall Study|Other reason than stated above|0
6204613|NCT01524900|9866418|FG004|Overall Study|Other reason than stated above|0
6204614|NCT01524900|9866414|FG000|Overall Study|No reason documented|2
6204615|NCT01524900|9866415|FG001|Overall Study|No reason documented|1
6204616|NCT01524900|9866416|FG002|Overall Study|No reason documented|0
6204617|NCT01524900|9866417|FG003|Overall Study|No reason documented|1
6204618|NCT01524900|9866418|FG004|Overall Study|No reason documented|0
6101177|NCT00762788|9717516|FG000|Overall Study|Lost to Follow-up|26
6101178|NCT00762788|9717517|FG001|Overall Study|Lost to Follow-up|37
6101179|NCT00762788|9717518|FG002|Overall Study|Lost to Follow-up|21
6101180|NCT00762788|9717519|FG003|Overall Study|Lost to Follow-up|26
6101181|NCT00762788|9717520|FG004|Overall Study|Lost to Follow-up|13
6101182|NCT00762788|9717521|FG005|Overall Study|Lost to Follow-up|21
6101183|NCT00762892|9717546|FG000|Overall Study|Lost to Follow-up|2
6101184|NCT00762892|9717547|FG001|Overall Study|Lost to Follow-up|5
6101185|NCT00762892|9717546|FG000|Overall Study|Withdrawal by Subject|0
6101186|NCT00762892|9717547|FG001|Overall Study|Withdrawal by Subject|1
6101187|NCT00762892|9717546|FG000|Overall Study|Death|1
6101188|NCT00762892|9717547|FG001|Overall Study|Death|0
6101189|NCT00762892|9717546|FG000|Overall Study|Pregnancy|1
6101190|NCT00762892|9717547|FG001|Overall Study|Pregnancy|0
6101191|NCT00762892|9717546|FG000|Overall Study|Incarceration|1
6101192|NCT00762892|9717547|FG001|Overall Study|Incarceration|0
6101193|NCT00762970|9717560|FG000|Overall Study|Withdrawal by Subject|7
6101194|NCT00762970|9717561|FG001|Overall Study|Withdrawal by Subject|4
6101195|NCT00762970|9717562|FG002|Overall Study|Withdrawal by Subject|0
6101196|NCT00762970|9717560|FG000|Overall Study|Protocol Violation|3
6101197|NCT00762970|9717561|FG001|Overall Study|Protocol Violation|1
6101198|NCT00762970|9717562|FG002|Overall Study|Protocol Violation|1
6101199|NCT00762970|9717560|FG000|Overall Study|Lost to Follow-up|1
6101200|NCT00762970|9717561|FG001|Overall Study|Lost to Follow-up|2
6101201|NCT00762970|9717562|FG002|Overall Study|Lost to Follow-up|0
6101202|NCT00762970|9717560|FG000|Overall Study|Difficulty of handling lens|1
6101203|NCT00762970|9717561|FG001|Overall Study|Difficulty of handling lens|2
6101204|NCT00762970|9717562|FG002|Overall Study|Difficulty of handling lens|0
6101205|NCT00762996|9717570|FG000|Period One|Protocol Violation|0
6101206|NCT00762996|9717571|FG001|Period One|Protocol Violation|0
6101207|NCT00762996|9717572|FG002|Period One|Protocol Violation|1
6101208|NCT00762996|9717573|FG003|Period One|Protocol Violation|0
6101209|NCT00762996|9717570|FG000|Period One|ineligible|0
6101210|NCT00762996|9717571|FG001|Period One|ineligible|0
6101211|NCT00762996|9717572|FG002|Period One|ineligible|1
6101212|NCT00762996|9717573|FG003|Period One|ineligible|1
6101213|NCT00762996|9717570|FG000|Period One|Adverse Event|0
6101214|NCT00762996|9717571|FG001|Period One|Adverse Event|0
6101215|NCT00762996|9717572|FG002|Period One|Adverse Event|1
6101216|NCT00762996|9717573|FG003|Period One|Adverse Event|0
6101217|NCT00762996|9717570|FG000|Period One|Withdrawal by Subject|0
6101218|NCT00762996|9717571|FG001|Period One|Withdrawal by Subject|0
6101219|NCT00762996|9717572|FG002|Period One|Withdrawal by Subject|1
6101220|NCT00762996|9717573|FG003|Period One|Withdrawal by Subject|0
6101221|NCT00763035|9717581|FG000|First Intervention|Did not meeting inclusion/exclusion|1
6101222|NCT00763035|9717582|FG001|First Intervention|Did not meeting inclusion/exclusion|0
6101223|NCT00763035|9717581|FG000|First Intervention|Adverse Event|0
6101224|NCT00763035|9717582|FG001|First Intervention|Adverse Event|1
6101225|NCT00763035|9717581|FG000|Second Intervention|Adverse Event|1
6101226|NCT00763035|9717582|FG001|Second Intervention|Adverse Event|0
6101227|NCT00763035|9717581|FG000|Second Intervention|Physician Decision|2
6101228|NCT00763035|9717582|FG001|Second Intervention|Physician Decision|0
6101229|NCT00763139|9717606|FG000|Overall Study|Adverse Event|4
6101230|NCT00763139|9717607|FG001|Overall Study|Adverse Event|2
6101231|NCT00763139|9717606|FG000|Overall Study|Withdrawal by Subject|0
6204619|NCT01524913|9866434|FG000|Overall Study|Lost to Follow-up|4
6204620|NCT01524913|9866435|FG001|Overall Study|Lost to Follow-up|0
6204621|NCT01524913|9866436|FG002|Overall Study|Lost to Follow-up|0
6204622|NCT01524978|9866455|FG000|Overall Study|Other|16
6284915|NCT02327169|9996515|FG013|Overall Study|Adverse Event|2
6284916|NCT02327169|9996516|FG014|Overall Study|Adverse Event|1
6284917|NCT02327169|9996502|FG000|Overall Study|Symptomatic Deterioration|0
6284918|NCT02327169|9996503|FG001|Overall Study|Symptomatic Deterioration|0
6284919|NCT02327169|9996504|FG002|Overall Study|Symptomatic Deterioration|1
6284920|NCT02327169|9996505|FG003|Overall Study|Symptomatic Deterioration|0
6284921|NCT02327169|9996506|FG004|Overall Study|Symptomatic Deterioration|1
6284922|NCT02327169|9996507|FG005|Overall Study|Symptomatic Deterioration|1
6284923|NCT02327169|9996508|FG006|Overall Study|Symptomatic Deterioration|0
6284924|NCT02327169|9996509|FG007|Overall Study|Symptomatic Deterioration|0
6284925|NCT02327169|9996510|FG008|Overall Study|Symptomatic Deterioration|2
6284926|NCT02327169|9996511|FG009|Overall Study|Symptomatic Deterioration|1
6284927|NCT02327169|9996512|FG010|Overall Study|Symptomatic Deterioration|0
6284928|NCT02327169|9996513|FG011|Overall Study|Symptomatic Deterioration|0
6284929|NCT02327169|9996514|FG012|Overall Study|Symptomatic Deterioration|0
6101232|NCT00763139|9717607|FG001|Overall Study|Withdrawal by Subject|1
6101233|NCT00763139|9717606|FG000|Overall Study|med change not allowed by protocol|1
6101234|NCT00763139|9717607|FG001|Overall Study|med change not allowed by protocol|0
6101235|NCT00763256|9717632|FG000|Overall Study|Didn't return for appointments|7
6204623|NCT01524978|9866456|FG001|Overall Study|Other|2
6204624|NCT01524978|9866457|FG002|Overall Study|Other|1
6101236|NCT00763256|9717633|FG001|Overall Study|Didn't return for appointments|10
6204625|NCT01524978|9866458|FG003|Overall Study|Other|2
6204626|NCT01524978|9866459|FG004|Overall Study|Other|1
6204627|NCT01524978|9866460|FG005|Overall Study|Other|3
6101237|NCT00763269|9717641|FG000|Overall Study|Lost to Follow-up|12
6204628|NCT01524978|9866461|FG006|Overall Study|Other|17
6204629|NCT01524978|9866462|FG007|Overall Study|Other|1
6101238|NCT00763269|9717642|FG001|Overall Study|Lost to Follow-up|13
6101239|NCT00763282|9717650|FG000|Overall Study|Withdrawal by Subject|6
6101240|NCT00763282|9717651|FG001|Overall Study|Withdrawal by Subject|5
6101241|NCT00763282|9717650|FG000|Overall Study|Death|4
6101242|NCT00763282|9717651|FG001|Overall Study|Death|3
6101243|NCT00763282|9717650|FG000|Overall Study|Lost to Follow-up|22
6101244|NCT00763282|9717651|FG001|Overall Study|Lost to Follow-up|26
6101245|NCT00763321|9717662|FG000|Open-label Period|Adverse Event|24
6101246|NCT00763321|9717663|FG001|Open-label Period|Adverse Event|0
6101247|NCT00763321|9717664|FG002|Open-label Period|Adverse Event|0
6101248|NCT00763321|9717662|FG000|Open-label Period|Lost to Follow-up|14
6101249|NCT00763321|9717663|FG001|Open-label Period|Lost to Follow-up|0
6101250|NCT00763321|9717664|FG002|Open-label Period|Lost to Follow-up|0
6101251|NCT00763321|9717662|FG000|Open-label Period|Withdrawal by Subject|7
6101252|NCT00763321|9717663|FG001|Open-label Period|Withdrawal by Subject|0
6101253|NCT00763321|9717664|FG002|Open-label Period|Withdrawal by Subject|0
6101254|NCT00763321|9717662|FG000|Open-label Period|Subject noncompliant|7
6101255|NCT00763321|9717663|FG001|Open-label Period|Subject noncompliant|0
6101256|NCT00763321|9717664|FG002|Open-label Period|Subject noncompliant|0
6101257|NCT00763321|9717662|FG000|Open-label Period|Did not meet DB randomization criteria|5
6101258|NCT00763321|9717663|FG001|Open-label Period|Did not meet DB randomization criteria|0
6101259|NCT00763321|9717664|FG002|Open-label Period|Did not meet DB randomization criteria|0
6101260|NCT00763321|9717662|FG000|Open-label Period|Lack of Efficacy|2
6101261|NCT00763321|9717663|FG001|Open-label Period|Lack of Efficacy|0
6101262|NCT00763321|9717664|FG002|Open-label Period|Lack of Efficacy|0
6101263|NCT00763321|9717662|FG000|Open-label Period|Other|4
6101264|NCT00763321|9717663|FG001|Open-label Period|Other|0
6101265|NCT00763321|9717664|FG002|Open-label Period|Other|0
6101266|NCT00763321|9717662|FG000|Double-blind Period|Lack of Efficacy|0
6101267|NCT00763321|9717663|FG001|Double-blind Period|Lack of Efficacy|9
6101268|NCT00763321|9717664|FG002|Double-blind Period|Lack of Efficacy|17
6101269|NCT00763321|9717662|FG000|Double-blind Period|Adverse Event|0
6101270|NCT00763321|9717663|FG001|Double-blind Period|Adverse Event|4
6101271|NCT00763321|9717664|FG002|Double-blind Period|Adverse Event|4
6101272|NCT00763321|9717662|FG000|Double-blind Period|Lost to Follow-up|0
6101273|NCT00763321|9717663|FG001|Double-blind Period|Lost to Follow-up|4
6101274|NCT00763321|9717664|FG002|Double-blind Period|Lost to Follow-up|2
6101275|NCT00763321|9717662|FG000|Double-blind Period|Withdrawal by Subject|0
6101276|NCT00763321|9717663|FG001|Double-blind Period|Withdrawal by Subject|2
6101277|NCT00763321|9717664|FG002|Double-blind Period|Withdrawal by Subject|3
6101278|NCT00763321|9717662|FG000|Double-blind Period|Other|0
6101279|NCT00763321|9717663|FG001|Double-blind Period|Other|2
6101280|NCT00763321|9717664|FG002|Double-blind Period|Other|3
6101281|NCT00763386|9717686|FG000|Overall Study|Adverse Event|43
6101282|NCT00763386|9717687|FG001|Overall Study|Adverse Event|33
6101283|NCT00763386|9717686|FG000|Overall Study|Death|1
6101284|NCT00763386|9717687|FG001|Overall Study|Death|2
6101285|NCT00763386|9717686|FG000|Overall Study|Lost to Follow-up|3
6101286|NCT00763386|9717687|FG001|Overall Study|Lost to Follow-up|3
6101287|NCT00763386|9717686|FG000|Overall Study|Withdrawal by Subject|0
6101288|NCT00763386|9717687|FG001|Overall Study|Withdrawal by Subject|1
6101289|NCT00763386|9717686|FG000|Overall Study|CRF missing|0
6101290|NCT00763386|9717687|FG001|Overall Study|CRF missing|1
6101291|NCT00763386|9717686|FG000|Overall Study|Study Prosthesis Removed|1
6101292|NCT00763386|9717687|FG001|Overall Study|Study Prosthesis Removed|0
6101293|NCT00763451|9717706|FG000|Overall Study|Adverse Event|4
6101294|NCT00763451|9717707|FG001|Overall Study|Adverse Event|6
6101295|NCT00763451|9717708|FG002|Overall Study|Adverse Event|19
6101296|NCT00763451|9717709|FG003|Overall Study|Adverse Event|14
6101297|NCT00763451|9717706|FG000|Overall Study|Lack of Efficacy|1
6101298|NCT00763451|9717707|FG001|Overall Study|Lack of Efficacy|4
6101299|NCT00763451|9717708|FG002|Overall Study|Lack of Efficacy|3
6101300|NCT00763451|9717709|FG003|Overall Study|Lack of Efficacy|2
6101301|NCT00763451|9717706|FG000|Overall Study|Withdrawal by Subject|1
6101302|NCT00763451|9717707|FG001|Overall Study|Withdrawal by Subject|6
6101303|NCT00763451|9717708|FG002|Overall Study|Withdrawal by Subject|9
6101304|NCT00763451|9717709|FG003|Overall Study|Withdrawal by Subject|7
6101305|NCT00763451|9717706|FG000|Overall Study|Protocol Violation|0
6101306|NCT00763451|9717707|FG001|Overall Study|Protocol Violation|0
6101307|NCT00763451|9717708|FG002|Overall Study|Protocol Violation|1
6101308|NCT00763451|9717709|FG003|Overall Study|Protocol Violation|0
6101309|NCT00763451|9717706|FG000|Overall Study|Poor Compliance to Protocol|1
6101310|NCT00763451|9717707|FG001|Overall Study|Poor Compliance to Protocol|1
6101311|NCT00763451|9717708|FG002|Overall Study|Poor Compliance to Protocol|2
6101312|NCT00763451|9717709|FG003|Overall Study|Poor Compliance to Protocol|2
6101313|NCT00763451|9717706|FG000|Overall Study|Familial and Personal Reasons|5
6101314|NCT00763451|9717707|FG001|Overall Study|Familial and Personal Reasons|3
6101315|NCT00763451|9717708|FG002|Overall Study|Familial and Personal Reasons|5
6101316|NCT00763451|9717709|FG003|Overall Study|Familial and Personal Reasons|4
6101317|NCT00763451|9717706|FG000|Overall Study|Randomized but not Treated|1
6101318|NCT00763451|9717707|FG001|Overall Study|Randomized but not Treated|1
6101319|NCT00763451|9717708|FG002|Overall Study|Randomized but not Treated|0
6101320|NCT00763451|9717709|FG003|Overall Study|Randomized but not Treated|0
6101321|NCT00763451|9717706|FG000|Overall Study|Study Site Reason|0
6101322|NCT00763451|9717707|FG001|Overall Study|Study Site Reason|1
6101323|NCT00763451|9717708|FG002|Overall Study|Study Site Reason|1
6101324|NCT00763451|9717709|FG003|Overall Study|Study Site Reason|1
6101325|NCT00763698|9717724|FG000|Overall Study|Unsuccessful Implant|5
6101326|NCT00763698|9717724|FG000|Overall Study|Death|4
6101327|NCT00763698|9717724|FG000|Overall Study|Withdrawal by Subject|1
6101328|NCT00763815|9717735|FG000|Overall Study|Adverse Event|14
6101329|NCT00763815|9717736|FG001|Overall Study|Adverse Event|29
6101330|NCT00763815|9717735|FG000|Overall Study|Lack of Efficacy|10
6101331|NCT00763815|9717736|FG001|Overall Study|Lack of Efficacy|11
6101332|NCT00763815|9717735|FG000|Overall Study|Poor Compliance to Protocol|6
6101333|NCT00763815|9717736|FG001|Overall Study|Poor Compliance to Protocol|6
6101334|NCT00763815|9717735|FG000|Overall Study|Lost to Follow-up|2
6101335|NCT00763815|9717736|FG001|Overall Study|Lost to Follow-up|4
6101336|NCT00763815|9717735|FG000|Overall Study|Early Termination|1
6101337|NCT00763815|9717736|FG001|Overall Study|Early Termination|0
6101338|NCT00763815|9717735|FG000|Overall Study|Familial and Personal Reasons|9
6101339|NCT00763815|9717736|FG001|Overall Study|Familial and Personal Reasons|16
6101340|NCT00763815|9717735|FG000|Overall Study|Physician Decision|1
6101341|NCT00763815|9717736|FG001|Overall Study|Physician Decision|0
6101342|NCT00763815|9717735|FG000|Overall Study|Withdrawal by Subject|7
6101343|NCT00763815|9717736|FG001|Overall Study|Withdrawal by Subject|12
6101344|NCT00763815|9717735|FG000|Overall Study|Protocol Violation|2
6101345|NCT00763815|9717736|FG001|Overall Study|Protocol Violation|5
6101346|NCT00763815|9717735|FG000|Overall Study|Sponsor's Decision|0
6101347|NCT00763815|9717736|FG001|Overall Study|Sponsor's Decision|1
6101348|NCT00763958|9717757|FG000|Overall Study|did not meet final criteria|4
6101349|NCT00763958|9717758|FG001|Overall Study|did not meet final criteria|4
6101350|NCT00763958|9717757|FG000|Overall Study|Lost to Follow-up|10
6101351|NCT00763958|9717758|FG001|Overall Study|Lost to Follow-up|2
6101352|NCT00763958|9717757|FG000|Overall Study|Believed they were receiving placebo|0
6101353|NCT00763958|9717758|FG001|Overall Study|Believed they were receiving placebo|5
6101354|NCT00763971|9717768|FG000|Overall Study|Adverse Event|5
6101355|NCT00763971|9717769|FG001|Overall Study|Adverse Event|2
6101356|NCT00763971|9717770|FG002|Overall Study|Adverse Event|4
6101357|NCT00763971|9717768|FG000|Overall Study|Protocol Violation|3
6101358|NCT00763971|9717769|FG001|Overall Study|Protocol Violation|3
6101359|NCT00763971|9717770|FG002|Overall Study|Protocol Violation|2
6101360|NCT00763971|9717768|FG000|Overall Study|Withdrawal by Subject|4
6101361|NCT00763971|9717769|FG001|Overall Study|Withdrawal by Subject|5
6101362|NCT00763971|9717770|FG002|Overall Study|Withdrawal by Subject|5
6101363|NCT00763971|9717768|FG000|Overall Study|Lost to Follow-up|0
6101364|NCT00763971|9717769|FG001|Overall Study|Lost to Follow-up|1
6101365|NCT00763971|9717770|FG002|Overall Study|Lost to Follow-up|0
6101366|NCT00763971|9717768|FG000|Overall Study|Lack of Efficacy|11
6101367|NCT00763971|9717769|FG001|Overall Study|Lack of Efficacy|22
6101368|NCT00763971|9717770|FG002|Overall Study|Lack of Efficacy|54
6101369|NCT00763971|9717768|FG000|Overall Study|Unable to swallow capsule|2
6101370|NCT00763971|9717769|FG001|Overall Study|Unable to swallow capsule|1
6101371|NCT00763971|9717770|FG002|Overall Study|Unable to swallow capsule|1
6101372|NCT00763971|9717768|FG000|Overall Study|Personal reason|3
6101373|NCT00763971|9717769|FG001|Overall Study|Personal reason|0
6101374|NCT00763971|9717770|FG002|Overall Study|Personal reason|0
6101375|NCT00763971|9717768|FG000|Overall Study|Exclusion criteria met|1
6101376|NCT00763971|9717769|FG001|Overall Study|Exclusion criteria met|0
6101377|NCT00763971|9717770|FG002|Overall Study|Exclusion criteria met|0
6101378|NCT00763971|9717768|FG000|Overall Study|Sponsor decision|1
6101379|NCT00763971|9717769|FG001|Overall Study|Sponsor decision|0
6101380|NCT00763971|9717770|FG002|Overall Study|Sponsor decision|0
6101381|NCT00763971|9717768|FG000|Overall Study|Due to holiday season|2
6101382|NCT00763971|9717769|FG001|Overall Study|Due to holiday season|0
6101383|NCT00763971|9717770|FG002|Overall Study|Due to holiday season|1
6101384|NCT00763971|9717768|FG000|Overall Study|Randomization error|0
6101385|NCT00763971|9717769|FG001|Overall Study|Randomization error|0
6101386|NCT00763971|9717770|FG002|Overall Study|Randomization error|1
6101387|NCT00763971|9717768|FG000|Overall Study|Medical monitor decision|0
6101388|NCT00763971|9717769|FG001|Overall Study|Medical monitor decision|0
6101389|NCT00763971|9717770|FG002|Overall Study|Medical monitor decision|1
6101390|NCT00763971|9717768|FG000|Overall Study|Moved to another country|0
6101391|NCT00763971|9717769|FG001|Overall Study|Moved to another country|1
6101392|NCT00763971|9717770|FG002|Overall Study|Moved to another country|0
6101393|NCT00763971|9717768|FG000|Overall Study|Subject wanted dose reduction|0
6101394|NCT00763971|9717769|FG001|Overall Study|Subject wanted dose reduction|1
6101395|NCT00763971|9717770|FG002|Overall Study|Subject wanted dose reduction|0
6101396|NCT00763971|9717768|FG000|Overall Study|Lack of availability|0
6101397|NCT00763971|9717769|FG001|Overall Study|Lack of availability|1
6101398|NCT00763971|9717770|FG002|Overall Study|Lack of availability|0
6101399|NCT00763971|9717768|FG000|Overall Study|Performed final visit on phone|0
6101400|NCT00763971|9717769|FG001|Overall Study|Performed final visit on phone|1
6101401|NCT00763971|9717770|FG002|Overall Study|Performed final visit on phone|0
6101402|NCT00763971|9717768|FG000|Overall Study|Participation in 489-326 required|1
6101403|NCT00763971|9717769|FG001|Overall Study|Participation in 489-326 required|0
6101404|NCT00763971|9717770|FG002|Overall Study|Participation in 489-326 required|0
6101405|NCT00764322|9717784|FG000|Overall Study|Withdrawal by Subject|11
6101406|NCT00764322|9717784|FG000|Overall Study|No CYP2D6 genotyping|9
6101407|NCT00764361|9717803|FG000|Overall Study|Withdrawal by Subject|2
6101408|NCT00764361|9717804|FG001|Overall Study|Withdrawal by Subject|3
6101409|NCT00764361|9717803|FG000|Overall Study|Adverse Event|0
6101410|NCT00764361|9717804|FG001|Overall Study|Adverse Event|1
6101411|NCT00764465|9717816|FG000|Overall Study|Adverse Event|2
6101412|NCT00764465|9717817|FG001|Overall Study|Adverse Event|0
6101413|NCT00764465|9717818|FG002|Overall Study|Adverse Event|0
6101414|NCT00764465|9717819|FG003|Overall Study|Adverse Event|1
6101415|NCT00764465|9717820|FG004|Overall Study|Adverse Event|1
6101416|NCT00764465|9717821|FG005|Overall Study|Adverse Event|1
6101417|NCT00764465|9717816|FG000|Overall Study|Withdrawal by Subject|0
6101418|NCT00764465|9717817|FG001|Overall Study|Withdrawal by Subject|1
6101419|NCT00764465|9717818|FG002|Overall Study|Withdrawal by Subject|1
6101420|NCT00764465|9717819|FG003|Overall Study|Withdrawal by Subject|0
6101421|NCT00764465|9717820|FG004|Overall Study|Withdrawal by Subject|0
6101422|NCT00764465|9717821|FG005|Overall Study|Withdrawal by Subject|0
6101423|NCT00764491|9717840|FG000|Overall Study|Lost to Follow-up|35
6101424|NCT00764491|9717841|FG001|Overall Study|Lost to Follow-up|17
6101425|NCT00764504|9717850|FG000|Overall Study|Death|12
6101426|NCT00764504|9717851|FG001|Overall Study|Death|6
6101427|NCT00764504|9717852|FG002|Overall Study|Death|13
6101428|NCT00764504|9717850|FG000|Overall Study|Revision of Device|12
6101429|NCT00764504|9717851|FG001|Overall Study|Revision of Device|23
6101430|NCT00764504|9717852|FG002|Overall Study|Revision of Device|14
6101431|NCT00764504|9717850|FG000|Overall Study|Physician Decision|1
6101432|NCT00764504|9717851|FG001|Overall Study|Physician Decision|0
6101433|NCT00764504|9717852|FG002|Overall Study|Physician Decision|0
6101434|NCT00764504|9717850|FG000|Overall Study|Withdrawal by Subject|1
6101435|NCT00764504|9717851|FG001|Overall Study|Withdrawal by Subject|7
6101436|NCT00764504|9717852|FG002|Overall Study|Withdrawal by Subject|4
6101437|NCT00764504|9717850|FG000|Overall Study|Lost to Follow-up|40
6101438|NCT00764504|9717851|FG001|Overall Study|Lost to Follow-up|34
6101439|NCT00764504|9717852|FG002|Overall Study|Lost to Follow-up|72
6101440|NCT00764517|9717862|FG000|Overall Study|Adverse Event|9
6101441|NCT00764517|9717863|FG001|Overall Study|Adverse Event|3
6101442|NCT00764517|9717862|FG000|Overall Study|Death|3
6101443|NCT00764517|9717863|FG001|Overall Study|Death|11
6101444|NCT00764517|9717862|FG000|Overall Study|Physician Decision|3
6101445|NCT00764517|9717863|FG001|Overall Study|Physician Decision|0
6101446|NCT00764660|9717871|FG000|Overall Study|Adverse Event|6
6101447|NCT00764660|9717872|FG001|Overall Study|Adverse Event|3
6101448|NCT00764660|9717871|FG000|Overall Study|Lost to Follow-up|3
6101449|NCT00764660|9717872|FG001|Overall Study|Lost to Follow-up|4
6101450|NCT00764660|9717871|FG000|Overall Study|Withdrawal by Subject|7
6101451|NCT00764660|9717872|FG001|Overall Study|Withdrawal by Subject|3
6101452|NCT00764660|9717871|FG000|Overall Study|Noncompliance With Protocol|5
6101453|NCT00764660|9717872|FG001|Overall Study|Noncompliance With Protocol|1
6101454|NCT00764660|9717871|FG000|Overall Study|Did Not Meet Protocol Eligibility|1
6101455|NCT00764660|9717872|FG001|Overall Study|Did Not Meet Protocol Eligibility|0
6101456|NCT00764673|9717878|FG000|Overall Study|Death|1
6101457|NCT00764673|9717878|FG000|Overall Study|Lost to Follow-up|3
6101458|NCT00764673|9717878|FG000|Overall Study|Withdrawal by Subject|6
6101459|NCT00764673|9717878|FG000|Overall Study|Revision of Device|2
6101460|NCT00764751|9717901|FG000|Overall Study|Adverse Event|1
6101461|NCT00764751|9717902|FG001|Overall Study|Adverse Event|1
6101462|NCT00764751|9717901|FG000|Overall Study|Psoriasis flare up on the scalp|1
6101463|NCT00764751|9717902|FG001|Overall Study|Psoriasis flare up on the scalp|0
6101464|NCT00764790|9717916|FG000|Overall Study|Protocol Violation|0
6101465|NCT00764790|9717917|FG001|Overall Study|Protocol Violation|0
6101466|NCT00764790|9717918|FG002|Overall Study|Protocol Violation|1
6204630|NCT01524978|9866463|FG008|Overall Study|Other|2
6204631|NCT01524978|9866464|FG009|Overall Study|Other|2
6204632|NCT01524978|9866465|FG010|Overall Study|Other|5
6204633|NCT01524978|9866455|FG000|Overall Study|Withdrawal by Subject|12
6204634|NCT01524978|9866456|FG001|Overall Study|Withdrawal by Subject|0
6204635|NCT01524978|9866457|FG002|Overall Study|Withdrawal by Subject|1
6204636|NCT01524978|9866458|FG003|Overall Study|Withdrawal by Subject|1
6204637|NCT01524978|9866459|FG004|Overall Study|Withdrawal by Subject|3
6204638|NCT01524978|9866460|FG005|Overall Study|Withdrawal by Subject|1
6204639|NCT01524978|9866461|FG006|Overall Study|Withdrawal by Subject|6
6204640|NCT01524978|9866462|FG007|Overall Study|Withdrawal by Subject|2
6204641|NCT01524978|9866463|FG008|Overall Study|Withdrawal by Subject|4
6204642|NCT01524978|9866464|FG009|Overall Study|Withdrawal by Subject|0
6204643|NCT01524978|9866465|FG010|Overall Study|Withdrawal by Subject|5
6101467|NCT00764790|9717916|FG000|Overall Study|Withdrawal by Subject|10
6101468|NCT00764790|9717917|FG001|Overall Study|Withdrawal by Subject|12
6101469|NCT00764790|9717918|FG002|Overall Study|Withdrawal by Subject|6
6101470|NCT00764790|9717916|FG000|Overall Study|Lost to Follow-up|28
6204644|NCT01524978|9866455|FG000|Overall Study|Lost to Follow-up|0
6204645|NCT01524978|9866456|FG001|Overall Study|Lost to Follow-up|0
6101471|NCT00764790|9717917|FG001|Overall Study|Lost to Follow-up|29
6101472|NCT00764790|9717918|FG002|Overall Study|Lost to Follow-up|23
6101473|NCT00764868|9717926|FG000|Overall Study|Adverse Event|18
6101474|NCT00764868|9717926|FG000|Overall Study|Withdrawal by Subject|31
6101475|NCT00764868|9717926|FG000|Overall Study|Non-compliance|16
6101476|NCT00764868|9717926|FG000|Overall Study|Lost to Follow-up|25
6101477|NCT00764868|9717926|FG000|Overall Study|Lack of Efficacy|5
6101478|NCT00764868|9717926|FG000|Overall Study|Subject moved|7
6101479|NCT00764868|9717926|FG000|Overall Study|Pregnancy|3
6101480|NCT00764868|9717926|FG000|Overall Study|Prohibited medication|1
6101481|NCT00764868|9717926|FG000|Overall Study|Out of town|1
6101482|NCT00764868|9717926|FG000|Overall Study|Misuse and compliance of study drug|1
6101483|NCT00764868|9717926|FG000|Overall Study|Subject sent to boarding school|1
6101484|NCT00764868|9717926|FG000|Overall Study|Met an exclusion criteria|1
6101485|NCT00764868|9717926|FG000|Overall Study|Positive drug screen|2
6101486|NCT00764868|9717926|FG000|Overall Study|Sponsor requested withdrawal|1
6101487|NCT00764881|9717932|FG000|Overall Study|Adverse Event|5
6101488|NCT00764881|9717933|FG001|Overall Study|Adverse Event|1
6101489|NCT00764881|9717932|FG000|Overall Study|Withdrawal by Subject|1
6101490|NCT00764881|9717933|FG001|Overall Study|Withdrawal by Subject|3
6101491|NCT00764881|9717932|FG000|Overall Study|Protocol Violation|2
6101492|NCT00764881|9717933|FG001|Overall Study|Protocol Violation|2
6101493|NCT00764881|9717932|FG000|Overall Study|Lost to Follow-up|2
6101494|NCT00764881|9717933|FG001|Overall Study|Lost to Follow-up|0
6101495|NCT00764881|9717932|FG000|Overall Study|Noncompliant|1
6101496|NCT00764881|9717933|FG001|Overall Study|Noncompliant|0
6101497|NCT00764881|9717932|FG000|Overall Study|Accidentally discontinued study drug|1
6101498|NCT00764881|9717933|FG001|Overall Study|Accidentally discontinued study drug|0
6101499|NCT00764881|9717932|FG000|Overall Study|Wished to become pregnant|1
6101500|NCT00764881|9717933|FG001|Overall Study|Wished to become pregnant|0
6101501|NCT00764881|9717932|FG000|Overall Study|Carcinoma detected|1
6101502|NCT00764881|9717933|FG001|Overall Study|Carcinoma detected|0
6101503|NCT00764881|9717932|FG000|Overall Study|Possibly noncompliant (study drug)|0
6101504|NCT00764881|9717933|FG001|Overall Study|Possibly noncompliant (study drug)|2
6101505|NCT00764881|9717932|FG000|Overall Study|no treatment or no observation|2
6101506|NCT00764881|9717933|FG001|Overall Study|no treatment or no observation|2
6101507|NCT00764946|9717942|FG000|Overall Study|Lack of Efficacy|1
6101508|NCT00764946|9717943|FG001|Overall Study|Lack of Efficacy|0
6101509|NCT00764946|9717944|FG002|Overall Study|Lack of Efficacy|0
6101510|NCT00764946|9717942|FG000|Overall Study|Lost to Follow-up|3
6101511|NCT00764946|9717943|FG001|Overall Study|Lost to Follow-up|4
6101512|NCT00764946|9717944|FG002|Overall Study|Lost to Follow-up|0
6101513|NCT00764946|9717942|FG000|Overall Study|Physician Decision|2
6101514|NCT00764946|9717943|FG001|Overall Study|Physician Decision|4
6101515|NCT00764946|9717944|FG002|Overall Study|Physician Decision|0
6101516|NCT00764946|9717942|FG000|Overall Study|Adverse Event|3
6101517|NCT00764946|9717943|FG001|Overall Study|Adverse Event|2
6101518|NCT00764946|9717944|FG002|Overall Study|Adverse Event|1
6101519|NCT00764946|9717942|FG000|Overall Study|Withdrawal by Subject|3
6101520|NCT00764946|9717943|FG001|Overall Study|Withdrawal by Subject|6
6101521|NCT00764946|9717944|FG002|Overall Study|Withdrawal by Subject|2
6101522|NCT00764946|9717942|FG000|Overall Study|Never Treated|1
6101523|NCT00764946|9717943|FG001|Overall Study|Never Treated|1
6101524|NCT00764946|9717944|FG002|Overall Study|Never Treated|1
6101525|NCT00765037|9717958|FG000|Overall Study|Lost to Follow-up|5
6101526|NCT00765037|9717958|FG000|Overall Study|Adverse Event|1
6101527|NCT00765063|9717962|FG000|Overall Study|Lack of Efficacy|5
6101528|NCT00765063|9717962|FG000|Overall Study|Withdrawal by Subject|1
6101529|NCT00765063|9717962|FG000|Overall Study|Other|16
6101530|NCT00765063|9717962|FG000|Overall Study|Protocol Violation|6
6101531|NCT00765063|9717962|FG000|Overall Study|Adverse Event|4
6101532|NCT00765076|9717969|FG000|Overall Study|Adverse Event|1
6101533|NCT00765076|9717970|FG001|Overall Study|Adverse Event|0
6101534|NCT00765076|9717971|FG002|Overall Study|Adverse Event|0
6101535|NCT00765076|9717969|FG000|Overall Study|Withdrawal by Subject|0
6101536|NCT00765076|9717970|FG001|Overall Study|Withdrawal by Subject|0
6101537|NCT00765076|9717971|FG002|Overall Study|Withdrawal by Subject|1
6101538|NCT00765102|9717979|FG000|Overall Study|Progressive disease|18
6101539|NCT00765102|9717979|FG000|Overall Study|Adverse Event|6
6101540|NCT00765102|9717979|FG000|Overall Study|Physician Decision|4
6101541|NCT00765102|9717979|FG000|Overall Study|Withdrawal by Subject|2
6101542|NCT00765102|9717979|FG000|Overall Study|Protocol Violation|1
6101543|NCT00765245|9718019|FG000|Overall Study|disease progression|3
6101544|NCT00765245|9718020|FG001|Overall Study|disease progression|2
6101545|NCT00765245|9718019|FG000|Overall Study|Withdrawal by Subject|3
6101546|NCT00765245|9718020|FG001|Overall Study|Withdrawal by Subject|0
6101547|NCT00765245|9718019|FG000|Overall Study|Adverse Event|5
6101548|NCT00765245|9718020|FG001|Overall Study|Adverse Event|0
6101549|NCT00765245|9718019|FG000|Overall Study|Physician Decision|1
6101550|NCT00765245|9718020|FG001|Overall Study|Physician Decision|0
6101551|NCT00765245|9718019|FG000|Overall Study|Death|1
6101552|NCT00765245|9718020|FG001|Overall Study|Death|0
6101553|NCT00765336|9718028|FG000|Overall Study|Protocol Violation|4
6101554|NCT00765336|9718029|FG001|Overall Study|Protocol Violation|2
6284930|NCT02327169|9996515|FG013|Overall Study|Symptomatic Deterioration|2
6101555|NCT00765336|9718028|FG000|Overall Study|Withdrawal by Subject|6
6101556|NCT00765336|9718029|FG001|Overall Study|Withdrawal by Subject|4
6101557|NCT00765336|9718028|FG000|Overall Study|Lost to Follow-up|7
6101558|NCT00765336|9718029|FG001|Overall Study|Lost to Follow-up|9
6101559|NCT00765336|9718028|FG000|Overall Study|Adverse Event|2
6101560|NCT00765336|9718029|FG001|Overall Study|Adverse Event|1
6101561|NCT00765362|9718035|FG000|Overall Study|Death|9
6101562|NCT00765362|9718035|FG000|Overall Study|Adverse Event|2
6101563|NCT00765362|9718035|FG000|Overall Study|Protocol Violation|18
6101564|NCT00765362|9718035|FG000|Overall Study|Withdrawal by Subject|13
6101565|NCT00765362|9718035|FG000|Overall Study|Lost to Follow-up|95
6101566|NCT00765388|9718045|FG000|Period 1|Lack of Efficacy|1
6101567|NCT00765388|9718046|FG001|Period 1|Lack of Efficacy|2
6101568|NCT00765388|9718045|FG000|Period 1|Lost to Follow-up|0
6101569|NCT00765388|9718046|FG001|Period 1|Lost to Follow-up|1
6101570|NCT00765388|9718045|FG000|Period 1|Herpes Zoster|0
6101571|NCT00765388|9718046|FG001|Period 1|Herpes Zoster|1
6101572|NCT00765388|9718045|FG000|Period 1|Hip operation|0
6101573|NCT00765388|9718046|FG001|Period 1|Hip operation|1
6101574|NCT00765674|9718083|FG000|Overall Study|Adverse Event|7
6101575|NCT00765674|9718084|FG001|Overall Study|Adverse Event|2
6101576|NCT00765674|9718085|FG002|Overall Study|Adverse Event|8
6101577|NCT00765674|9718086|FG003|Overall Study|Adverse Event|11
6101578|NCT00765674|9718083|FG000|Overall Study|Abnormal Laboratory Value(s)|0
6101579|NCT00765674|9718084|FG001|Overall Study|Abnormal Laboratory Value(s)|0
6101580|NCT00765674|9718085|FG002|Overall Study|Abnormal Laboratory Value(s)|1
6101581|NCT00765674|9718086|FG003|Overall Study|Abnormal Laboratory Value(s)|0
6101582|NCT00765674|9718083|FG000|Overall Study|Abnormal Test Procedure Result(s)|1
6101583|NCT00765674|9718084|FG001|Overall Study|Abnormal Test Procedure Result(s)|3
6101584|NCT00765674|9718085|FG002|Overall Study|Abnormal Test Procedure Result(s)|1
6101585|NCT00765674|9718086|FG003|Overall Study|Abnormal Test Procedure Result(s)|2
6101586|NCT00765674|9718083|FG000|Overall Study|Lack of Efficacy|2
6101587|NCT00765674|9718084|FG001|Overall Study|Lack of Efficacy|3
6101588|NCT00765674|9718085|FG002|Overall Study|Lack of Efficacy|1
6101589|NCT00765674|9718086|FG003|Overall Study|Lack of Efficacy|2
6101590|NCT00765674|9718083|FG000|Overall Study|Protocol Violation|2
6101591|NCT00765674|9718084|FG001|Overall Study|Protocol Violation|0
6101592|NCT00765674|9718085|FG002|Overall Study|Protocol Violation|1
6101593|NCT00765674|9718086|FG003|Overall Study|Protocol Violation|0
6101594|NCT00765674|9718083|FG000|Overall Study|Withdrawal by Subject|5
6101595|NCT00765674|9718084|FG001|Overall Study|Withdrawal by Subject|7
6101596|NCT00765674|9718085|FG002|Overall Study|Withdrawal by Subject|3
6101597|NCT00765674|9718086|FG003|Overall Study|Withdrawal by Subject|8
6101598|NCT00765674|9718083|FG000|Overall Study|Lost to Follow-up|4
6101599|NCT00765674|9718084|FG001|Overall Study|Lost to Follow-up|6
6101600|NCT00765674|9718085|FG002|Overall Study|Lost to Follow-up|2
6101601|NCT00765674|9718086|FG003|Overall Study|Lost to Follow-up|1
6101602|NCT00765674|9718083|FG000|Overall Study|Randomized in Error - No Study Drug|0
6101603|NCT00765674|9718084|FG001|Overall Study|Randomized in Error - No Study Drug|1
6101604|NCT00765674|9718085|FG002|Overall Study|Randomized in Error - No Study Drug|0
6101605|NCT00765674|9718086|FG003|Overall Study|Randomized in Error - No Study Drug|1
6101606|NCT00765726|9718096|FG000|Overall Study|Withdrawal by Subject|1
6101607|NCT00765726|9718096|FG000|Overall Study|Discontinuation of study by sponsor|8
6101608|NCT00765817|9718102|FG000|Overall Study|Adverse Event|13
6101609|NCT00765817|9718103|FG001|Overall Study|Adverse Event|1
6101610|NCT00765817|9718102|FG000|Overall Study|Death|0
6101611|NCT00765817|9718103|FG001|Overall Study|Death|1
6101612|NCT00765817|9718102|FG000|Overall Study|Entry criteria not met|2
6101613|NCT00765817|9718103|FG001|Overall Study|Entry criteria not met|2
6101614|NCT00765817|9718102|FG000|Overall Study|Loss of glucose control|0
6101615|NCT00765817|9718103|FG001|Overall Study|Loss of glucose control|2
6101616|NCT00765817|9718102|FG000|Overall Study|Lost to Follow-up|1
6101617|NCT00765817|9718103|FG001|Overall Study|Lost to Follow-up|3
6101618|NCT00765817|9718102|FG000|Overall Study|Physician Decision|2
6101619|NCT00765817|9718103|FG001|Overall Study|Physician Decision|1
6101620|NCT00765817|9718102|FG000|Overall Study|Protocol Violation|1
6101621|NCT00765817|9718103|FG001|Overall Study|Protocol Violation|1
6101622|NCT00765817|9718102|FG000|Overall Study|Subject decision|7
6101623|NCT00765817|9718103|FG001|Overall Study|Subject decision|11
6101624|NCT00765843|9718112|FG000|Overall Study|Lost to Follow-up|1
6101625|NCT00765843|9718113|FG001|Overall Study|Lost to Follow-up|3
6101626|NCT00765843|9718114|FG002|Overall Study|Lost to Follow-up|2
6101627|NCT00765843|9718112|FG000|Overall Study|did not return to receive intervention|0
6101628|NCT00765843|9718113|FG001|Overall Study|did not return to receive intervention|1
6101629|NCT00765843|9718114|FG002|Overall Study|did not return to receive intervention|0
6101630|NCT00765843|9718112|FG000|Overall Study|Adverse Event|0
6101631|NCT00765843|9718113|FG001|Overall Study|Adverse Event|0
6101632|NCT00765843|9718114|FG002|Overall Study|Adverse Event|1
6204646|NCT01524978|9866457|FG002|Overall Study|Lost to Follow-up|3
6204647|NCT01524978|9866458|FG003|Overall Study|Lost to Follow-up|0
6204648|NCT01524978|9866459|FG004|Overall Study|Lost to Follow-up|1
6204649|NCT01524978|9866460|FG005|Overall Study|Lost to Follow-up|1
6204650|NCT01524978|9866461|FG006|Overall Study|Lost to Follow-up|2
6204651|NCT01524978|9866462|FG007|Overall Study|Lost to Follow-up|0
6204652|NCT01524978|9866463|FG008|Overall Study|Lost to Follow-up|1
6101633|NCT00765882|9718132|FG000|Overall Study|Adverse Event|10
6101634|NCT00765882|9718133|FG001|Overall Study|Adverse Event|21
6101635|NCT00765882|9718134|FG002|Overall Study|Adverse Event|20
6101636|NCT00765882|9718132|FG000|Overall Study|Lack of Efficacy|4
6101637|NCT00765882|9718133|FG001|Overall Study|Lack of Efficacy|0
6101638|NCT00765882|9718134|FG002|Overall Study|Lack of Efficacy|1
6101639|NCT00765882|9718132|FG000|Overall Study|Protocol Violation|4
6101640|NCT00765882|9718133|FG001|Overall Study|Protocol Violation|3
6101641|NCT00765882|9718134|FG002|Overall Study|Protocol Violation|1
6101642|NCT00765882|9718132|FG000|Overall Study|Withdrawal by Subject|2
6101643|NCT00765882|9718133|FG001|Overall Study|Withdrawal by Subject|6
6101644|NCT00765882|9718134|FG002|Overall Study|Withdrawal by Subject|6
6101645|NCT00765882|9718132|FG000|Overall Study|Lost to Follow-up|1
6101646|NCT00765882|9718133|FG001|Overall Study|Lost to Follow-up|9
6101647|NCT00765882|9718134|FG002|Overall Study|Lost to Follow-up|6
6101648|NCT00765882|9718132|FG000|Overall Study|Other Reason|3
6101649|NCT00765882|9718133|FG001|Overall Study|Other Reason|1
6101650|NCT00765882|9718134|FG002|Overall Study|Other Reason|2
6101651|NCT00765999|9718157|FG000|Overall Study|Adverse Event|203
6101652|NCT00765999|9718157|FG000|Overall Study|Insufficient Therapeutic Response|100
6101653|NCT00765999|9718157|FG000|Overall Study|Protocol Violation|95
6101654|NCT00765999|9718157|FG000|Overall Study|Consent Withdrawn|202
6101655|NCT00765999|9718157|FG000|Overall Study|Lost to Follow-up|131
6101656|NCT00765999|9718157|FG000|Overall Study|Study Terminated by Sponsor|2
6101657|NCT00765999|9718157|FG000|Overall Study|Other Miscellaneous Reasons|51
6101658|NCT00766038|9718165|FG000|Overall Study|Lost to Follow-up|15
6101659|NCT00766038|9718166|FG001|Overall Study|Lost to Follow-up|14
6101660|NCT00766051|9718176|FG000|Overall Study|Withdrawal by Subject|2
6101661|NCT00766051|9718177|FG001|Overall Study|Withdrawal by Subject|0
6101662|NCT00766090|9718187|FG000|Treatment Period 1 (28 Days)|Lost to Follow-up|0
6101663|NCT00766090|9718188|FG001|Treatment Period 1 (28 Days)|Lost to Follow-up|0
6101664|NCT00766090|9718189|FG002|Treatment Period 1 (28 Days)|Lost to Follow-up|0
6101665|NCT00766090|9718190|FG003|Treatment Period 1 (28 Days)|Lost to Follow-up|0
6101666|NCT00766090|9718191|FG004|Treatment Period 1 (28 Days)|Lost to Follow-up|0
6101667|NCT00766090|9718192|FG005|Treatment Period 1 (28 Days)|Lost to Follow-up|0
6101668|NCT00766090|9718193|FG006|Treatment Period 1 (28 Days)|Lost to Follow-up|0
6101669|NCT00766090|9718194|FG007|Treatment Period 1 (28 Days)|Lost to Follow-up|0
6101670|NCT00766090|9718195|FG008|Treatment Period 1 (28 Days)|Lost to Follow-up|1
6101671|NCT00766090|9718196|FG009|Treatment Period 1 (28 Days)|Lost to Follow-up|0
6101672|NCT00766090|9718197|FG010|Treatment Period 1 (28 Days)|Lost to Follow-up|0
6101673|NCT00766090|9718198|FG011|Treatment Period 1 (28 Days)|Lost to Follow-up|0
6204653|NCT01524978|9866464|FG009|Overall Study|Lost to Follow-up|1
6204654|NCT01524978|9866465|FG010|Overall Study|Lost to Follow-up|1
6204655|NCT01524978|9866455|FG000|Overall Study|Death|34
6204656|NCT01524978|9866456|FG001|Overall Study|Death|2
6204657|NCT01524978|9866457|FG002|Overall Study|Death|5
6204658|NCT01524978|9866458|FG003|Overall Study|Death|24
6204659|NCT01524978|9866459|FG004|Overall Study|Death|4
6204660|NCT01524978|9866460|FG005|Overall Study|Death|4
6204661|NCT01524978|9866461|FG006|Overall Study|Death|1
6204662|NCT01524978|9866462|FG007|Overall Study|Death|9
6204663|NCT01524978|9866463|FG008|Overall Study|Death|5
6204664|NCT01524978|9866464|FG009|Overall Study|Death|6
6204665|NCT01524978|9866465|FG010|Overall Study|Death|17
6204666|NCT01524991|9866480|FG000|Overall Study|Adverse Event|12
6204667|NCT01524991|9866480|FG000|Overall Study|Death|1
6204668|NCT01524991|9866480|FG000|Overall Study|Disease ProgressionDu|17
6204669|NCT01524991|9866480|FG000|Overall Study|Other complicating disease|1
6204670|NCT01524991|9866480|FG000|Overall Study|Withdrawal by Subject|2
6204671|NCT01524991|9866480|FG000|Overall Study|Symptomatic Deterioration|1
6204672|NCT01525082|9866484|FG000|Overall Study|Death|1
6204673|NCT01525225|9866500|FG000|Enrollment|No longer met study criteria|1
6204674|NCT01525225|9866500|FG000|Enrollment|Other|1
6204675|NCT01525238|9866507|FG000|Overall Study|Withdrawal by Subject|1
6204676|NCT01525238|9866508|FG001|Overall Study|Withdrawal by Subject|0
6204677|NCT01525238|9866509|FG002|Overall Study|Withdrawal by Subject|0
6204678|NCT01525407|9866519|FG000|Overall Study|Change in recipient treatment plan|2
6204679|NCT01525407|9866520|FG001|Overall Study|Change in recipient treatment plan|2
6204680|NCT01525407|9866519|FG000|Overall Study|Withdrawal by Subject|0
6204681|NCT01525407|9866520|FG001|Overall Study|Withdrawal by Subject|1
6204682|NCT01525407|9866519|FG000|Overall Study|Transplant was delayed|0
6204683|NCT01525407|9866520|FG001|Overall Study|Transplant was delayed|1
6204684|NCT01525407|9866519|FG000|Overall Study|Delay in Transplant|1
6204685|NCT01525407|9866520|FG001|Overall Study|Delay in Transplant|0
6204686|NCT01525550|9866537|FG000|Overall Study|Lost to Follow-up|8
6204687|NCT01525550|9866538|FG001|Overall Study|Lost to Follow-up|2
6204688|NCT01525550|9866537|FG000|Overall Study|Death|19
6204689|NCT01525550|9866538|FG001|Overall Study|Death|28
6204690|NCT01525550|9866537|FG000|Overall Study|Other|0
6204691|NCT01525550|9866538|FG001|Overall Study|Other|4
6204692|NCT01525550|9866537|FG000|Overall Study|Sponsor's Decision|30
6204693|NCT01525550|9866538|FG001|Overall Study|Sponsor's Decision|11
6204694|NCT01525550|9866537|FG000|Overall Study|Withdrawal by Subject|4
6204695|NCT01525550|9866538|FG001|Overall Study|Withdrawal by Subject|0
6204696|NCT01525589|9866551|FG000|Overall Study|Non-treatment-related AE|1
6101674|NCT00766090|9718187|FG000|Treatment Period 1 (28 Days)|Lack of Efficacy|2
6101675|NCT00766090|9718188|FG001|Treatment Period 1 (28 Days)|Lack of Efficacy|0
6101676|NCT00766090|9718189|FG002|Treatment Period 1 (28 Days)|Lack of Efficacy|0
6101677|NCT00766090|9718190|FG003|Treatment Period 1 (28 Days)|Lack of Efficacy|0
6101678|NCT00766090|9718191|FG004|Treatment Period 1 (28 Days)|Lack of Efficacy|0
6101679|NCT00766090|9718192|FG005|Treatment Period 1 (28 Days)|Lack of Efficacy|0
6101680|NCT00766090|9718193|FG006|Treatment Period 1 (28 Days)|Lack of Efficacy|0
6101681|NCT00766090|9718194|FG007|Treatment Period 1 (28 Days)|Lack of Efficacy|0
6101682|NCT00766090|9718195|FG008|Treatment Period 1 (28 Days)|Lack of Efficacy|0
6101683|NCT00766090|9718196|FG009|Treatment Period 1 (28 Days)|Lack of Efficacy|0
6101684|NCT00766090|9718197|FG010|Treatment Period 1 (28 Days)|Lack of Efficacy|0
6101685|NCT00766090|9718198|FG011|Treatment Period 1 (28 Days)|Lack of Efficacy|0
6101686|NCT00766090|9718187|FG000|Treatment Period 1 (28 Days)|Withdrawal by Subject|1
6101687|NCT00766090|9718188|FG001|Treatment Period 1 (28 Days)|Withdrawal by Subject|0
6101688|NCT00766090|9718189|FG002|Treatment Period 1 (28 Days)|Withdrawal by Subject|0
6101689|NCT00766090|9718190|FG003|Treatment Period 1 (28 Days)|Withdrawal by Subject|1
6101690|NCT00766090|9718191|FG004|Treatment Period 1 (28 Days)|Withdrawal by Subject|0
6101691|NCT00766090|9718192|FG005|Treatment Period 1 (28 Days)|Withdrawal by Subject|0
6101692|NCT00766090|9718193|FG006|Treatment Period 1 (28 Days)|Withdrawal by Subject|0
6101693|NCT00766090|9718194|FG007|Treatment Period 1 (28 Days)|Withdrawal by Subject|0
6101694|NCT00766090|9718195|FG008|Treatment Period 1 (28 Days)|Withdrawal by Subject|0
6101695|NCT00766090|9718196|FG009|Treatment Period 1 (28 Days)|Withdrawal by Subject|0
6101696|NCT00766090|9718197|FG010|Treatment Period 1 (28 Days)|Withdrawal by Subject|0
6101697|NCT00766090|9718198|FG011|Treatment Period 1 (28 Days)|Withdrawal by Subject|0
6101698|NCT00766090|9718187|FG000|Washout Period 1 (14 Days)|Protocol Violation|0
6101699|NCT00766090|9718188|FG001|Washout Period 1 (14 Days)|Protocol Violation|0
6101700|NCT00766090|9718189|FG002|Washout Period 1 (14 Days)|Protocol Violation|1
6101701|NCT00766090|9718190|FG003|Washout Period 1 (14 Days)|Protocol Violation|0
6101702|NCT00766090|9718191|FG004|Washout Period 1 (14 Days)|Protocol Violation|0
6101703|NCT00766090|9718192|FG005|Washout Period 1 (14 Days)|Protocol Violation|0
6101704|NCT00766090|9718193|FG006|Washout Period 1 (14 Days)|Protocol Violation|0
6101705|NCT00766090|9718194|FG007|Washout Period 1 (14 Days)|Protocol Violation|0
6101706|NCT00766090|9718195|FG008|Washout Period 1 (14 Days)|Protocol Violation|0
6101707|NCT00766090|9718196|FG009|Washout Period 1 (14 Days)|Protocol Violation|0
6101708|NCT00766090|9718197|FG010|Washout Period 1 (14 Days)|Protocol Violation|0
6101709|NCT00766090|9718198|FG011|Washout Period 1 (14 Days)|Protocol Violation|0
6101710|NCT00766090|9718187|FG000|Treatment Period 2 (28 Days)|Lost to Follow-up|0
6101711|NCT00766090|9718188|FG001|Treatment Period 2 (28 Days)|Lost to Follow-up|0
6101712|NCT00766090|9718189|FG002|Treatment Period 2 (28 Days)|Lost to Follow-up|0
6101713|NCT00766090|9718190|FG003|Treatment Period 2 (28 Days)|Lost to Follow-up|0
6101714|NCT00766090|9718191|FG004|Treatment Period 2 (28 Days)|Lost to Follow-up|2
6101715|NCT00766090|9718192|FG005|Treatment Period 2 (28 Days)|Lost to Follow-up|0
6101716|NCT00766090|9718193|FG006|Treatment Period 2 (28 Days)|Lost to Follow-up|0
6101717|NCT00766090|9718194|FG007|Treatment Period 2 (28 Days)|Lost to Follow-up|0
6101718|NCT00766090|9718195|FG008|Treatment Period 2 (28 Days)|Lost to Follow-up|0
6101719|NCT00766090|9718196|FG009|Treatment Period 2 (28 Days)|Lost to Follow-up|0
6101720|NCT00766090|9718197|FG010|Treatment Period 2 (28 Days)|Lost to Follow-up|0
6101721|NCT00766090|9718198|FG011|Treatment Period 2 (28 Days)|Lost to Follow-up|0
6101722|NCT00766090|9718187|FG000|Treatment Period 2 (28 Days)|Lack of Efficacy|0
6101723|NCT00766090|9718188|FG001|Treatment Period 2 (28 Days)|Lack of Efficacy|0
6101724|NCT00766090|9718189|FG002|Treatment Period 2 (28 Days)|Lack of Efficacy|1
6101725|NCT00766090|9718190|FG003|Treatment Period 2 (28 Days)|Lack of Efficacy|0
6101726|NCT00766090|9718191|FG004|Treatment Period 2 (28 Days)|Lack of Efficacy|0
6101727|NCT00766090|9718192|FG005|Treatment Period 2 (28 Days)|Lack of Efficacy|0
6101728|NCT00766090|9718193|FG006|Treatment Period 2 (28 Days)|Lack of Efficacy|0
6101729|NCT00766090|9718194|FG007|Treatment Period 2 (28 Days)|Lack of Efficacy|0
6101730|NCT00766090|9718195|FG008|Treatment Period 2 (28 Days)|Lack of Efficacy|0
6101731|NCT00766090|9718196|FG009|Treatment Period 2 (28 Days)|Lack of Efficacy|0
6101732|NCT00766090|9718197|FG010|Treatment Period 2 (28 Days)|Lack of Efficacy|0
6101733|NCT00766090|9718198|FG011|Treatment Period 2 (28 Days)|Lack of Efficacy|0
6101734|NCT00766090|9718187|FG000|Washout Period 2 (14 Days)|Physician Decision|0
6101735|NCT00766090|9718188|FG001|Washout Period 2 (14 Days)|Physician Decision|0
6101736|NCT00766090|9718189|FG002|Washout Period 2 (14 Days)|Physician Decision|1
6101737|NCT00766090|9718190|FG003|Washout Period 2 (14 Days)|Physician Decision|0
6101738|NCT00766090|9718191|FG004|Washout Period 2 (14 Days)|Physician Decision|0
6101739|NCT00766090|9718192|FG005|Washout Period 2 (14 Days)|Physician Decision|0
6204697|NCT01525589|9866552|FG001|Overall Study|Non-treatment-related AE|0
6204698|NCT01525589|9866553|FG002|Overall Study|Non-treatment-related AE|0
6204699|NCT01525589|9866551|FG000|Overall Study|Progressive disease|48
6204700|NCT01525589|9866552|FG001|Overall Study|Progressive disease|15
6204701|NCT01525589|9866553|FG002|Overall Study|Progressive disease|29
6204702|NCT01525589|9866551|FG000|Overall Study|Never treated|2
6204703|NCT01525589|9866552|FG001|Overall Study|Never treated|0
6204704|NCT01525589|9866553|FG002|Overall Study|Never treated|0
6284931|NCT02327169|9996516|FG014|Overall Study|Symptomatic Deterioration|1
6101740|NCT00766090|9718193|FG006|Washout Period 2 (14 Days)|Physician Decision|0
6101741|NCT00766090|9718194|FG007|Washout Period 2 (14 Days)|Physician Decision|0
6101742|NCT00766090|9718195|FG008|Washout Period 2 (14 Days)|Physician Decision|0
6101743|NCT00766090|9718196|FG009|Washout Period 2 (14 Days)|Physician Decision|0
6101744|NCT00766090|9718197|FG010|Washout Period 2 (14 Days)|Physician Decision|0
6101745|NCT00766090|9718198|FG011|Washout Period 2 (14 Days)|Physician Decision|0
6101746|NCT00766090|9718187|FG000|Treatment Period 3 (28 Days)|Protocol Violation|0
6101747|NCT00766090|9718188|FG001|Treatment Period 3 (28 Days)|Protocol Violation|0
6101748|NCT00766090|9718189|FG002|Treatment Period 3 (28 Days)|Protocol Violation|0
6101749|NCT00766090|9718190|FG003|Treatment Period 3 (28 Days)|Protocol Violation|0
6101750|NCT00766090|9718191|FG004|Treatment Period 3 (28 Days)|Protocol Violation|0
6101751|NCT00766090|9718192|FG005|Treatment Period 3 (28 Days)|Protocol Violation|1
6101752|NCT00766090|9718193|FG006|Treatment Period 3 (28 Days)|Protocol Violation|0
6101753|NCT00766090|9718194|FG007|Treatment Period 3 (28 Days)|Protocol Violation|0
6101754|NCT00766090|9718195|FG008|Treatment Period 3 (28 Days)|Protocol Violation|0
6101755|NCT00766090|9718196|FG009|Treatment Period 3 (28 Days)|Protocol Violation|0
6101756|NCT00766090|9718197|FG010|Treatment Period 3 (28 Days)|Protocol Violation|0
6101757|NCT00766090|9718198|FG011|Treatment Period 3 (28 Days)|Protocol Violation|0
6101758|NCT00766090|9718187|FG000|Treatment Period 3 (28 Days)|Lack of Efficacy|0
6101759|NCT00766090|9718188|FG001|Treatment Period 3 (28 Days)|Lack of Efficacy|1
6101760|NCT00766090|9718189|FG002|Treatment Period 3 (28 Days)|Lack of Efficacy|0
6101761|NCT00766090|9718190|FG003|Treatment Period 3 (28 Days)|Lack of Efficacy|1
6101762|NCT00766090|9718191|FG004|Treatment Period 3 (28 Days)|Lack of Efficacy|0
6101763|NCT00766090|9718192|FG005|Treatment Period 3 (28 Days)|Lack of Efficacy|0
6101764|NCT00766090|9718193|FG006|Treatment Period 3 (28 Days)|Lack of Efficacy|0
6101765|NCT00766090|9718194|FG007|Treatment Period 3 (28 Days)|Lack of Efficacy|0
6101766|NCT00766090|9718195|FG008|Treatment Period 3 (28 Days)|Lack of Efficacy|0
6101767|NCT00766090|9718196|FG009|Treatment Period 3 (28 Days)|Lack of Efficacy|0
6204705|NCT01525589|9866551|FG000|Overall Study|Physician Decision|4
6204706|NCT01525589|9866552|FG001|Overall Study|Physician Decision|2
6204707|NCT01525589|9866553|FG002|Overall Study|Physician Decision|2
6284932|NCT02327169|9996502|FG000|Overall Study|Reason Not Specified|0
6284933|NCT02327169|9996503|FG001|Overall Study|Reason Not Specified|0
6284934|NCT02327169|9996504|FG002|Overall Study|Reason Not Specified|1
6284935|NCT02327169|9996505|FG003|Overall Study|Reason Not Specified|0
6284936|NCT02327169|9996506|FG004|Overall Study|Reason Not Specified|0
6284937|NCT02327169|9996507|FG005|Overall Study|Reason Not Specified|0
6284938|NCT02327169|9996508|FG006|Overall Study|Reason Not Specified|0
6284939|NCT02327169|9996509|FG007|Overall Study|Reason Not Specified|0
6284940|NCT02327169|9996510|FG008|Overall Study|Reason Not Specified|0
6284941|NCT02327169|9996511|FG009|Overall Study|Reason Not Specified|1
6284942|NCT02327169|9996512|FG010|Overall Study|Reason Not Specified|2
6284943|NCT02327169|9996513|FG011|Overall Study|Reason Not Specified|1
6284944|NCT02327169|9996514|FG012|Overall Study|Reason Not Specified|0
6284945|NCT02327169|9996515|FG013|Overall Study|Reason Not Specified|0
6284946|NCT02327169|9996516|FG014|Overall Study|Reason Not Specified|2
6284947|NCT02327169|9996502|FG000|Overall Study|Withdrawal by Subject|1
6284948|NCT02327169|9996503|FG001|Overall Study|Withdrawal by Subject|0
6284949|NCT02327169|9996504|FG002|Overall Study|Withdrawal by Subject|0
6284950|NCT02327169|9996505|FG003|Overall Study|Withdrawal by Subject|0
6284951|NCT02327169|9996506|FG004|Overall Study|Withdrawal by Subject|1
6284952|NCT02327169|9996507|FG005|Overall Study|Withdrawal by Subject|0
6284953|NCT02327169|9996508|FG006|Overall Study|Withdrawal by Subject|0
6284954|NCT02327169|9996509|FG007|Overall Study|Withdrawal by Subject|1
6284955|NCT02327169|9996510|FG008|Overall Study|Withdrawal by Subject|0
6284956|NCT02327169|9996511|FG009|Overall Study|Withdrawal by Subject|0
6284957|NCT02327169|9996512|FG010|Overall Study|Withdrawal by Subject|0
6284958|NCT02327169|9996513|FG011|Overall Study|Withdrawal by Subject|0
6284959|NCT02327169|9996514|FG012|Overall Study|Withdrawal by Subject|0
6284960|NCT02327169|9996515|FG013|Overall Study|Withdrawal by Subject|0
6284961|NCT02327169|9996516|FG014|Overall Study|Withdrawal by Subject|3
6284962|NCT02327169|9996502|FG000|Overall Study|Lost to Follow-up|0
6284963|NCT02327169|9996503|FG001|Overall Study|Lost to Follow-up|0
6284964|NCT02327169|9996504|FG002|Overall Study|Lost to Follow-up|0
6284965|NCT02327169|9996505|FG003|Overall Study|Lost to Follow-up|0
6284966|NCT02327169|9996506|FG004|Overall Study|Lost to Follow-up|1
6284967|NCT02327169|9996507|FG005|Overall Study|Lost to Follow-up|0
6284968|NCT02327169|9996508|FG006|Overall Study|Lost to Follow-up|0
6284969|NCT02327169|9996509|FG007|Overall Study|Lost to Follow-up|0
6284970|NCT02327169|9996510|FG008|Overall Study|Lost to Follow-up|0
6284971|NCT02327169|9996511|FG009|Overall Study|Lost to Follow-up|0
6284972|NCT02327169|9996512|FG010|Overall Study|Lost to Follow-up|0
6284973|NCT02327169|9996513|FG011|Overall Study|Lost to Follow-up|0
6204708|NCT01525589|9866551|FG000|Overall Study|Death|0
6204709|NCT01525589|9866552|FG001|Overall Study|Death|0
6204710|NCT01525589|9866553|FG002|Overall Study|Death|2
6204711|NCT01525589|9866551|FG000|Overall Study|Treatment-related AE|1
6204712|NCT01525589|9866552|FG001|Overall Study|Treatment-related AE|1
6204713|NCT01525589|9866553|FG002|Overall Study|Treatment-related AE|2
6204714|NCT01525589|9866551|FG000|Overall Study|Other reasons|0
6101768|NCT00766090|9718197|FG010|Treatment Period 3 (28 Days)|Lack of Efficacy|0
6101769|NCT00766090|9718198|FG011|Treatment Period 3 (28 Days)|Lack of Efficacy|1
6101770|NCT00766090|9718187|FG000|Treatment Period 3 (28 Days)|Lost to Follow-up|0
6101771|NCT00766090|9718188|FG001|Treatment Period 3 (28 Days)|Lost to Follow-up|0
6101772|NCT00766090|9718189|FG002|Treatment Period 3 (28 Days)|Lost to Follow-up|0
6101773|NCT00766090|9718190|FG003|Treatment Period 3 (28 Days)|Lost to Follow-up|0
6101774|NCT00766090|9718191|FG004|Treatment Period 3 (28 Days)|Lost to Follow-up|1
6101775|NCT00766090|9718192|FG005|Treatment Period 3 (28 Days)|Lost to Follow-up|0
6101776|NCT00766090|9718193|FG006|Treatment Period 3 (28 Days)|Lost to Follow-up|0
6101777|NCT00766090|9718194|FG007|Treatment Period 3 (28 Days)|Lost to Follow-up|0
6101778|NCT00766090|9718195|FG008|Treatment Period 3 (28 Days)|Lost to Follow-up|0
6101779|NCT00766090|9718196|FG009|Treatment Period 3 (28 Days)|Lost to Follow-up|0
6101780|NCT00766090|9718197|FG010|Treatment Period 3 (28 Days)|Lost to Follow-up|0
6101781|NCT00766090|9718198|FG011|Treatment Period 3 (28 Days)|Lost to Follow-up|0
6101782|NCT00766142|9718219|FG000|Overall Study|Protocol Violation|4
6101783|NCT00766363|9718227|FG000|Overall Study|Withdrawal by Subject|1
6101784|NCT00766363|9718228|FG001|Overall Study|Withdrawal by Subject|0
6101785|NCT00766363|9718229|FG002|Overall Study|Withdrawal by Subject|0
6101786|NCT00766363|9718230|FG003|Overall Study|Withdrawal by Subject|0
6101787|NCT00766363|9718227|FG000|Overall Study|Adverse Event Prior to Randomization|0
6101788|NCT00766363|9718228|FG001|Overall Study|Adverse Event Prior to Randomization|1
6101789|NCT00766363|9718229|FG002|Overall Study|Adverse Event Prior to Randomization|0
6101790|NCT00766363|9718230|FG003|Overall Study|Adverse Event Prior to Randomization|0
6101791|NCT00766376|9718241|FG000|Overall Study|Withdrawal by Subject|27
6101792|NCT00766415|9718247|FG000|Overall Study|Withdrawal by Subject|0
6101793|NCT00766415|9718248|FG001|Overall Study|Withdrawal by Subject|1
6101794|NCT00766467|9718256|FG000|Overall Study|Withdrawal by Subject|7
6101795|NCT00766467|9718257|FG001|Overall Study|Withdrawal by Subject|2
6101796|NCT00766467|9718256|FG000|Overall Study|Adverse Event|1
6101797|NCT00766467|9718257|FG001|Overall Study|Adverse Event|1
6101798|NCT00766467|9718256|FG000|Overall Study|Protocol Violation|2
6101799|NCT00766467|9718257|FG001|Overall Study|Protocol Violation|4
6101800|NCT00766467|9718256|FG000|Overall Study|Tumor Progression on Study|0
6101801|NCT00766467|9718257|FG001|Overall Study|Tumor Progression on Study|1
6101802|NCT00766467|9718256|FG000|Overall Study|Physician Decision|1
6101803|NCT00766467|9718257|FG001|Overall Study|Physician Decision|0
6101804|NCT00766493|9718263|FG000|30 Days Post-Procedure|Discontinued|7
6101805|NCT00766493|9718263|FG000|30 Days Post-Procedure|Missed Visit - Phone Contact f/u|4
6101806|NCT00766493|9718263|FG000|30 Days Post-Procedure|Missed Visit - No Phone Contact|1
6101807|NCT00766506|9718269|FG000|Overall Study|Use rescue medication after 3 hours|3
6101808|NCT00766506|9718270|FG001|Overall Study|Use rescue medication after 3 hours|0
6101809|NCT00766506|9718269|FG000|Overall Study|Other|2
6101810|NCT00766506|9718270|FG001|Overall Study|Other|2
6101811|NCT00766532|9718276|FG000|Overall Study|Protocol Violation|2
6101812|NCT00766597|9718280|FG000|Overall Study|Unexpected closure of study|4
6101813|NCT00766597|9718280|FG000|Overall Study|Without CCR5-tropic virus|5
6101814|NCT00766675|9718290|FG000|Overall Study|Adverse Event|16
6101815|NCT00766675|9718290|FG000|Overall Study|Lost to Follow-up|2
6101816|NCT00766675|9718290|FG000|Overall Study|Withdrawal by Subject|11
6101817|NCT00766675|9718290|FG000|Overall Study|Protocol Violation|8
6101818|NCT00766675|9718290|FG000|Overall Study|Participant took prohibited medication|1
6101819|NCT00766675|9718290|FG000|Overall Study|Receive other anti-neoplastic treatment|1
6101820|NCT00766675|9718290|FG000|Overall Study|Insufficient therapy|1
6101821|NCT00766831|9718310|FG000|Overall Study|Withdrawal by Subject|4
6101822|NCT00766831|9718310|FG000|Overall Study|Lost to Follow-up|3
6101823|NCT00766831|9718310|FG000|Overall Study|Adverse Event|20
6101824|NCT00766831|9718310|FG000|Overall Study|Protocol Violation|15
6101825|NCT00766831|9718310|FG000|Overall Study|Physician Decision|5
6101826|NCT00766831|9718310|FG000|Overall Study|Withdrawal of consent|26
6101827|NCT00766831|9718310|FG000|Overall Study|Non cooperation by participants|14
6101828|NCT00766831|9718310|FG000|Overall Study|Other|28
6101829|NCT00767000|9718319|FG000|54-week Study|Adverse Event|4
6101830|NCT00767000|9718320|FG001|54-week Study|Adverse Event|6
6101831|NCT00767000|9718321|FG002|54-week Study|Adverse Event|6
6101832|NCT00767000|9718322|FG003|54-week Study|Adverse Event|8
6101833|NCT00767000|9718323|FG004|54-week Study|Adverse Event|4
6101834|NCT00767000|9718319|FG000|54-week Study|Creaninine/creatinine clearance|2
6101835|NCT00767000|9718320|FG001|54-week Study|Creaninine/creatinine clearance|1
6101836|NCT00767000|9718321|FG002|54-week Study|Creaninine/creatinine clearance|2
6101837|NCT00767000|9718322|FG003|54-week Study|Creaninine/creatinine clearance|2
6101838|NCT00767000|9718323|FG004|54-week Study|Creaninine/creatinine clearance|4
6101839|NCT00767000|9718319|FG000|54-week Study|Hyperglycemia|0
6101840|NCT00767000|9718320|FG001|54-week Study|Hyperglycemia|0
6101841|NCT00767000|9718321|FG002|54-week Study|Hyperglycemia|1
6101842|NCT00767000|9718322|FG003|54-week Study|Hyperglycemia|0
6101843|NCT00767000|9718323|FG004|54-week Study|Hyperglycemia|1
6101844|NCT00767000|9718319|FG000|54-week Study|Hypoglycemia|0
6101845|NCT00767000|9718320|FG001|54-week Study|Hypoglycemia|1
6101846|NCT00767000|9718321|FG002|54-week Study|Hypoglycemia|0
6101847|NCT00767000|9718322|FG003|54-week Study|Hypoglycemia|0
6101848|NCT00767000|9718323|FG004|54-week Study|Hypoglycemia|0
6101849|NCT00767000|9718319|FG000|54-week Study|Interruption of study medication|0
6101850|NCT00767000|9718320|FG001|54-week Study|Interruption of study medication|0
6101851|NCT00767000|9718321|FG002|54-week Study|Interruption of study medication|1
6101852|NCT00767000|9718322|FG003|54-week Study|Interruption of study medication|0
6101853|NCT00767000|9718323|FG004|54-week Study|Interruption of study medication|0
6101854|NCT00767000|9718319|FG000|54-week Study|Lack of Efficacy|2
6101855|NCT00767000|9718320|FG001|54-week Study|Lack of Efficacy|0
6101856|NCT00767000|9718321|FG002|54-week Study|Lack of Efficacy|1
6101857|NCT00767000|9718322|FG003|54-week Study|Lack of Efficacy|0
6101858|NCT00767000|9718323|FG004|54-week Study|Lack of Efficacy|5
6101859|NCT00767000|9718319|FG000|54-week Study|Lost to Follow-up|4
6101860|NCT00767000|9718320|FG001|54-week Study|Lost to Follow-up|0
6101861|NCT00767000|9718321|FG002|54-week Study|Lost to Follow-up|1
6101862|NCT00767000|9718322|FG003|54-week Study|Lost to Follow-up|4
6101863|NCT00767000|9718323|FG004|54-week Study|Lost to Follow-up|2
6101864|NCT00767000|9718319|FG000|54-week Study|Physician Decision|4
6101865|NCT00767000|9718320|FG001|54-week Study|Physician Decision|0
6101866|NCT00767000|9718321|FG002|54-week Study|Physician Decision|1
6101867|NCT00767000|9718322|FG003|54-week Study|Physician Decision|1
6101868|NCT00767000|9718323|FG004|54-week Study|Physician Decision|1
6101869|NCT00767000|9718319|FG000|54-week Study|Progressive disease|0
6101870|NCT00767000|9718320|FG001|54-week Study|Progressive disease|0
6101871|NCT00767000|9718321|FG002|54-week Study|Progressive disease|1
6101872|NCT00767000|9718322|FG003|54-week Study|Progressive disease|0
6101873|NCT00767000|9718323|FG004|54-week Study|Progressive disease|0
6101874|NCT00767000|9718319|FG000|54-week Study|Protocol Violation|0
6101875|NCT00767000|9718320|FG001|54-week Study|Protocol Violation|0
6101876|NCT00767000|9718321|FG002|54-week Study|Protocol Violation|1
6101877|NCT00767000|9718322|FG003|54-week Study|Protocol Violation|2
6101878|NCT00767000|9718323|FG004|54-week Study|Protocol Violation|0
6101879|NCT00767000|9718319|FG000|54-week Study|Withdrawal by Subject|2
6101880|NCT00767000|9718320|FG001|54-week Study|Withdrawal by Subject|3
6101881|NCT00767000|9718321|FG002|54-week Study|Withdrawal by Subject|5
6101882|NCT00767000|9718322|FG003|54-week Study|Withdrawal by Subject|11
6101883|NCT00767000|9718323|FG004|54-week Study|Withdrawal by Subject|13
6101884|NCT00767000|9718319|FG000|54-week Study|Study terminated by sponsor|90
6101885|NCT00767000|9718320|FG001|54-week Study|Study terminated by sponsor|102
6101886|NCT00767000|9718321|FG002|54-week Study|Study terminated by sponsor|89
6101887|NCT00767000|9718322|FG003|54-week Study|Study terminated by sponsor|196
6101888|NCT00767000|9718323|FG004|54-week Study|Study terminated by sponsor|194
6101889|NCT00767000|9718319|FG000|54-week Study|Reason not reported|0
6101890|NCT00767000|9718320|FG001|54-week Study|Reason not reported|0
6101891|NCT00767000|9718321|FG002|54-week Study|Reason not reported|0
6101892|NCT00767000|9718322|FG003|54-week Study|Reason not reported|1
6101893|NCT00767000|9718323|FG004|54-week Study|Reason not reported|0
6101894|NCT00767000|9718319|FG000|Optional 104-week Extension|Study terminated by sponsor|7
6101895|NCT00767000|9718320|FG001|Optional 104-week Extension|Study terminated by sponsor|3
6101896|NCT00767000|9718321|FG002|Optional 104-week Extension|Study terminated by sponsor|7
6101897|NCT00767000|9718322|FG003|Optional 104-week Extension|Study terminated by sponsor|2
6101898|NCT00767000|9718323|FG004|Optional 104-week Extension|Study terminated by sponsor|4
6101899|NCT00767039|9718337|FG000|Overall Study|Death|5
6101900|NCT00767039|9718338|FG001|Overall Study|Death|2
6101901|NCT00767104|9718346|FG000|Overall Study|Lost to Follow-up|1
6101902|NCT00767104|9718347|FG001|Overall Study|Lost to Follow-up|2
6101903|NCT00767325|9718355|FG000|Overall Study|Lack of Efficacy|2
6101904|NCT00767325|9718355|FG000|Overall Study|Adverse Event|7
6101905|NCT00767325|9718355|FG000|Overall Study|Lost to Follow-up|3
6101906|NCT00767325|9718355|FG000|Overall Study|No longer met study criteria|2
6101907|NCT00767325|9718355|FG000|Overall Study|Missed visit due to family reasons|1
6101908|NCT00767455|9718385|FG000|Overall Study|Investigator error|19
6101909|NCT00767520|9718417|FG000|Overall Study|Participants still on treatment|11
6101910|NCT00767520|9718418|FG001|Overall Study|Participants still on treatment|15
6101911|NCT00767520|9718417|FG000|Overall Study|Randomized in error and Never treated|0
6101912|NCT00767520|9718418|FG001|Overall Study|Randomized in error and Never treated|2
6101913|NCT00767676|9718439|FG000|Overall Study|Investigator error|54
6101914|NCT00767806|9718466|FG000|Overall Study|Adverse Event|30
6101915|NCT00767806|9718467|FG001|Overall Study|Adverse Event|11
6101916|NCT00767806|9718466|FG000|Overall Study|Withdrawal by Subject|8
6101917|NCT00767806|9718467|FG001|Overall Study|Withdrawal by Subject|13
6101918|NCT00767806|9718466|FG000|Overall Study|Protocol Violation|6
6101919|NCT00767806|9718467|FG001|Overall Study|Protocol Violation|5
6101920|NCT00767806|9718466|FG000|Overall Study|Lack of Efficacy|1
6101921|NCT00767806|9718467|FG001|Overall Study|Lack of Efficacy|9
6101922|NCT00767806|9718466|FG000|Overall Study|Physician Decision|4
6101923|NCT00767806|9718467|FG001|Overall Study|Physician Decision|3
6101924|NCT00767806|9718466|FG000|Overall Study|Lost to Follow-up|1
6101925|NCT00767806|9718467|FG001|Overall Study|Lost to Follow-up|4
6101926|NCT00767806|9718466|FG000|Overall Study|Entry Criteria Not Met|1
6101927|NCT00767806|9718467|FG001|Overall Study|Entry Criteria Not Met|1
6101928|NCT00767806|9718466|FG000|Overall Study|Sponsor Decision|0
6101929|NCT00767806|9718467|FG001|Overall Study|Sponsor Decision|1
6101930|NCT00767819|9718476|FG000|Overall Study|Unsatisfactory therapeutic effect|18
6101931|NCT00767819|9718477|FG001|Overall Study|Unsatisfactory therapeutic effect|14
6101932|NCT00767819|9718478|FG002|Overall Study|Unsatisfactory therapeutic effect|0
6101933|NCT00767819|9718476|FG000|Overall Study|Withdrawal by Subject|1
6101934|NCT00767819|9718477|FG001|Overall Study|Withdrawal by Subject|1
6101935|NCT00767819|9718478|FG002|Overall Study|Withdrawal by Subject|0
6101936|NCT00767819|9718476|FG000|Overall Study|Administrative problems|0
6101937|NCT00767819|9718477|FG001|Overall Study|Administrative problems|1
6101938|NCT00767819|9718478|FG002|Overall Study|Administrative problems|0
6101939|NCT00767819|9718476|FG000|Overall Study|Death|2
6101940|NCT00767819|9718477|FG001|Overall Study|Death|3
6101941|NCT00767819|9718478|FG002|Overall Study|Death|0
6101942|NCT00767819|9718476|FG000|Overall Study|Adverse Event|2
6101943|NCT00767819|9718477|FG001|Overall Study|Adverse Event|0
6101944|NCT00767819|9718478|FG002|Overall Study|Adverse Event|0
6101945|NCT00767819|9718476|FG000|Overall Study|Abnormal lab values|1
6101946|NCT00767819|9718477|FG001|Overall Study|Abnormal lab values|0
6101947|NCT00767819|9718478|FG002|Overall Study|Abnormal lab values|0
6101948|NCT00767819|9718476|FG000|Overall Study|Lost to Follow-up|1
6101949|NCT00767819|9718477|FG001|Overall Study|Lost to Follow-up|0
6101950|NCT00767819|9718478|FG002|Overall Study|Lost to Follow-up|0
6101951|NCT00768053|9718486|FG000|Overall Study|Adverse Event|10
6101952|NCT00768053|9718486|FG000|Overall Study|Lost to Follow-up|1
6101953|NCT00768066|9718493|FG000|Overall Study|Did not receive study product injection.|3
6101954|NCT00768066|9718494|FG001|Overall Study|Did not receive study product injection.|3
6101955|NCT00768066|9718495|FG002|Overall Study|Did not receive study product injection.|0
6101956|NCT00768079|9718506|FG000|Overall Study|Lost to Follow-up|2
6101957|NCT00768079|9718507|FG001|Overall Study|Lost to Follow-up|0
6101958|NCT00768079|9718508|FG002|Overall Study|Lost to Follow-up|4
6101959|NCT00768079|9718506|FG000|Overall Study|Participant incarcerated|0
6101960|NCT00768079|9718507|FG001|Overall Study|Participant incarcerated|1
6101961|NCT00768079|9718508|FG002|Overall Study|Participant incarcerated|0
6101962|NCT00768144|9718522|FG000|Overall Study|Adverse Event|13
6101963|NCT00768144|9718522|FG000|Overall Study|Progressive Disease|21
6101964|NCT00768144|9718522|FG000|Overall Study|Patient or MD Decision to End Treatment|1
6101965|NCT00768144|9718522|FG000|Overall Study|Pt Withdrew Consent|1
6101966|NCT00768222|9718528|FG000|Overall Study|Lost to Follow-up|1
6101967|NCT00768222|9718529|FG001|Overall Study|Lost to Follow-up|1
6101968|NCT00768222|9718528|FG000|Overall Study|Withdrawal by Subject|3
6101969|NCT00768222|9718529|FG001|Overall Study|Withdrawal by Subject|1
6101970|NCT00768222|9718528|FG000|Overall Study|Protocol Violation|0
6101971|NCT00768222|9718529|FG001|Overall Study|Protocol Violation|2
6101972|NCT00768300|9718574|FG000|Overall Study|Randomized but not treated|1
6101973|NCT00768300|9718575|FG001|Overall Study|Randomized but not treated|1
6101974|NCT00768300|9718574|FG000|Overall Study|Adverse Event|10
6101975|NCT00768300|9718575|FG001|Overall Study|Adverse Event|2
6101976|NCT00768300|9718574|FG000|Overall Study|Protocol Violation|6
6101977|NCT00768300|9718575|FG001|Overall Study|Protocol Violation|1
6101978|NCT00768300|9718574|FG000|Overall Study|Withdrawal by Subject|13
6101979|NCT00768300|9718575|FG001|Overall Study|Withdrawal by Subject|7
6101980|NCT00768300|9718574|FG000|Overall Study|Physician Decision|2
6101981|NCT00768300|9718575|FG001|Overall Study|Physician Decision|3
6101982|NCT00768300|9718574|FG000|Overall Study|Study discontinued by Sponsor|271
6101983|NCT00768300|9718575|FG001|Overall Study|Study discontinued by Sponsor|140
6101984|NCT00768300|9718574|FG000|Overall Study|Death|21
6101985|NCT00768300|9718575|FG001|Overall Study|Death|5
6101986|NCT00768300|9718574|FG000|Overall Study|Subject moved to pursue lung transplant|1
6101987|NCT00768300|9718575|FG001|Overall Study|Subject moved to pursue lung transplant|1
6101988|NCT00768300|9718574|FG000|Overall Study|Screen failure following randomization|1
6101989|NCT00768300|9718575|FG001|Overall Study|Screen failure following randomization|0
6101990|NCT00768300|9718574|FG000|Overall Study|Received lung transplant|1
6101991|NCT00768300|9718575|FG001|Overall Study|Received lung transplant|1
6101992|NCT00768300|9718574|FG000|Overall Study|Lost to Follow-up|0
6101993|NCT00768300|9718575|FG001|Overall Study|Lost to Follow-up|1
6101994|NCT00768300|9718574|FG000|Overall Study|Began prohibited concomitant medication|0
6101995|NCT00768300|9718575|FG001|Overall Study|Began prohibited concomitant medication|1
6101996|NCT00768300|9718574|FG000|Overall Study|Treated but never dosed with Study drug|1
6101997|NCT00768300|9718575|FG001|Overall Study|Treated but never dosed with Study drug|0
6101998|NCT00768300|9718574|FG000|Overall Study|Missing data|1
6101999|NCT00768300|9718575|FG001|Overall Study|Missing data|0
6102000|NCT00768430|9718583|FG000|7 Day Endpoint|Withdrawal by Subject|2
6102001|NCT00768430|9718584|FG001|7 Day Endpoint|Withdrawal by Subject|3
6102002|NCT00768469|9718592|FG000|Overall Study|Adverse Event|0
6102003|NCT00768469|9718593|FG001|Overall Study|Adverse Event|2
6102004|NCT00768469|9718592|FG000|Overall Study|Disease Progression|3
6102005|NCT00768469|9718593|FG001|Overall Study|Disease Progression|4
6102006|NCT00768469|9718592|FG000|Overall Study|Withdrawal by Subject|0
6102007|NCT00768469|9718593|FG001|Overall Study|Withdrawal by Subject|1
6102008|NCT00768560|9718613|FG000|Intervention Set 1|Adverse Event|0
6102009|NCT00768560|9718614|FG001|Intervention Set 1|Adverse Event|1
6102010|NCT00768560|9718615|FG002|Intervention Set 1|Adverse Event|0
6102011|NCT00768560|9718616|FG003|Intervention Set 1|Adverse Event|0
6102012|NCT00768560|9718617|FG004|Intervention Set 1|Adverse Event|0
6102013|NCT00768560|9718618|FG005|Intervention Set 1|Adverse Event|0
6102014|NCT00768651|9718639|FG000|Overall Study|Withdrawal by Subject|1
6102015|NCT00768664|9718644|FG000|Overall Study|Death|57
6102016|NCT00768664|9718644|FG000|Overall Study|Lost to Follow-up|2
6102017|NCT00768664|9718644|FG000|Overall Study|Other|9
6102018|NCT00768664|9718644|FG000|Overall Study|Participant refused|1
6102019|NCT00768755|9718664|FG000|Phase 1|Death|6
6102020|NCT00768755|9718665|FG001|Phase 1|Death|0
6102021|NCT00768755|9718666|FG002|Phase 1|Death|0
6102022|NCT00768755|9718667|FG003|Phase 1|Death|0
6102023|NCT00768755|9718664|FG000|Phase 1|Other|4
6102024|NCT00768755|9718665|FG001|Phase 1|Other|0
6102025|NCT00768755|9718666|FG002|Phase 1|Other|0
6102026|NCT00768755|9718667|FG003|Phase 1|Other|0
6102027|NCT00768755|9718664|FG000|Phase 2|Death|0
6102028|NCT00768755|9718665|FG001|Phase 2|Death|37
6102029|NCT00768755|9718666|FG002|Phase 2|Death|48
6102030|NCT00768755|9718667|FG003|Phase 2|Death|31
6102031|NCT00768755|9718664|FG000|Phase 2|Protocol Violation|0
6102032|NCT00768755|9718665|FG001|Phase 2|Protocol Violation|2
6102033|NCT00768755|9718666|FG002|Phase 2|Protocol Violation|0
6102034|NCT00768755|9718667|FG003|Phase 2|Protocol Violation|1
6102035|NCT00768755|9718664|FG000|Phase 2|Lost to Follow-up|0
6102036|NCT00768755|9718665|FG001|Phase 2|Lost to Follow-up|1
6102037|NCT00768755|9718666|FG002|Phase 2|Lost to Follow-up|1
6102038|NCT00768755|9718667|FG003|Phase 2|Lost to Follow-up|4
6102039|NCT00768755|9718664|FG000|Phase 2|Withdrawal by Subject|0
6102040|NCT00768755|9718665|FG001|Phase 2|Withdrawal by Subject|1
6102041|NCT00768755|9718666|FG002|Phase 2|Withdrawal by Subject|0
6102042|NCT00768755|9718667|FG003|Phase 2|Withdrawal by Subject|1
6102043|NCT00768755|9718664|FG000|Phase 2|Other|0
6102044|NCT00768755|9718665|FG001|Phase 2|Other|1
6102045|NCT00768755|9718666|FG002|Phase 2|Other|2
6102046|NCT00768755|9718667|FG003|Phase 2|Other|4
6102047|NCT00768755|9718664|FG000|Phase 2|Study Terminated by Sponsor|0
6102048|NCT00768755|9718665|FG001|Phase 2|Study Terminated by Sponsor|13
6102049|NCT00768755|9718666|FG002|Phase 2|Study Terminated by Sponsor|7
6102050|NCT00768755|9718667|FG003|Phase 2|Study Terminated by Sponsor|14
6102051|NCT00768755|9718664|FG000|Phase 2|Randomized but not treated|0
6102052|NCT00768755|9718665|FG001|Phase 2|Randomized but not treated|0
6102053|NCT00768755|9718666|FG002|Phase 2|Randomized but not treated|0
6102054|NCT00768755|9718667|FG003|Phase 2|Randomized but not treated|2
6102055|NCT00768898|9718676|FG000|Overall Study|Unrelated injury|1
6102056|NCT00768898|9718676|FG000|Overall Study|Headache|1
6102057|NCT00768989|9718687|FG000|Prior to Week 24|Withdrawal by Subject|1
6102058|NCT00768989|9718688|FG001|Prior to Week 24|Withdrawal by Subject|0
6102059|NCT00768989|9718687|FG000|Prior to Week 24|Adverse Event|3
6102060|NCT00768989|9718688|FG001|Prior to Week 24|Adverse Event|0
6102061|NCT00768989|9718687|FG000|Prior to Week 24|Lost to Follow-up|0
6102062|NCT00768989|9718688|FG001|Prior to Week 24|Lost to Follow-up|1
6102063|NCT00768989|9718687|FG000|Prior to Week 24|Protocol Violation|0
6102064|NCT00768989|9718688|FG001|Prior to Week 24|Protocol Violation|2
6102065|NCT00768989|9718687|FG000|Week 24 to Prior to Week 36|Adverse Event|1
6102066|NCT00768989|9718688|FG001|Week 24 to Prior to Week 36|Adverse Event|0
6102067|NCT00768989|9718687|FG000|Week 24 to Prior to Week 36|Lack of Efficacy|6
6102068|NCT00768989|9718688|FG001|Week 24 to Prior to Week 36|Lack of Efficacy|0
6102069|NCT00768989|9718687|FG000|Week 24 to Prior to Week 36|Withdrawal by Subject|1
6102070|NCT00768989|9718688|FG001|Week 24 to Prior to Week 36|Withdrawal by Subject|0
6102071|NCT00768989|9718687|FG000|On or After Week 36|Lack of Efficacy|1
6102072|NCT00768989|9718688|FG001|On or After Week 36|Lack of Efficacy|0
6102073|NCT00768989|9718687|FG000|On or After Week 36|Adverse Event|0
6102074|NCT00768989|9718688|FG001|On or After Week 36|Adverse Event|1
6102075|NCT00768989|9718687|FG000|On or After Week 36|Lost to Follow-up|1
6102076|NCT00768989|9718688|FG001|On or After Week 36|Lost to Follow-up|0
6204715|NCT01525589|9866552|FG001|Overall Study|Other reasons|1
6204716|NCT01525589|9866553|FG002|Overall Study|Other reasons|0
6204717|NCT01525589|9866551|FG000|Overall Study|Withdrawal by Subject|0
6204718|NCT01525589|9866552|FG001|Overall Study|Withdrawal by Subject|1
6204719|NCT01525589|9866553|FG002|Overall Study|Withdrawal by Subject|0
6204720|NCT01525602|9866569|FG000|Overall Study|Adverse Event|1
6204721|NCT01525602|9866570|FG001|Overall Study|Adverse Event|0
6204722|NCT01525602|9866571|FG002|Overall Study|Adverse Event|1
6204723|NCT01525602|9866572|FG003|Overall Study|Adverse Event|1
6204724|NCT01525602|9866573|FG004|Overall Study|Adverse Event|3
6204725|NCT01525602|9866574|FG005|Overall Study|Adverse Event|3
6204726|NCT01525602|9866575|FG006|Overall Study|Adverse Event|0
6204727|NCT01525602|9866576|FG007|Overall Study|Adverse Event|1
6204728|NCT01525602|9866569|FG000|Overall Study|Disease progression|6
6102077|NCT00768989|9718687|FG000|On or After Week 36|Poor Compliance|1
6102078|NCT00768989|9718688|FG001|On or After Week 36|Poor Compliance|0
6102079|NCT00768989|9718687|FG000|On or After Week 36|Protocol Violation|1
6102080|NCT00768989|9718688|FG001|On or After Week 36|Protocol Violation|0
6102081|NCT00768989|9718687|FG000|On or After Week 36|Did not attend termination visit|2
6102082|NCT00768989|9718688|FG001|On or After Week 36|Did not attend termination visit|0
6102083|NCT00768989|9718687|FG000|On or After Week 36|Sponsor Termination|45
6102084|NCT00768989|9718688|FG001|On or After Week 36|Sponsor Termination|26
6102085|NCT00769067|9718707|FG000|Overall Study|Death|89
6204729|NCT01525602|9866570|FG001|Overall Study|Disease progression|3
6204730|NCT01525602|9866571|FG002|Overall Study|Disease progression|2
6204731|NCT01525602|9866572|FG003|Overall Study|Disease progression|5
6102086|NCT00769067|9718708|FG001|Overall Study|Death|86
6102087|NCT00769067|9718707|FG000|Overall Study|Lost to Follow-up|3
6102088|NCT00769067|9718708|FG001|Overall Study|Lost to Follow-up|1
6102089|NCT00769067|9718707|FG000|Overall Study|Study terminated by sponsor|1
6102090|NCT00769067|9718708|FG001|Overall Study|Study terminated by sponsor|3
6102091|NCT00769067|9718707|FG000|Overall Study|Other|1
6102092|NCT00769067|9718708|FG001|Overall Study|Other|3
6102093|NCT00769067|9718707|FG000|Overall Study|Withdrawal by Subject|0
6102094|NCT00769067|9718708|FG001|Overall Study|Withdrawal by Subject|1
6102095|NCT00769119|9718717|FG000|Overall Study|Voluntary discontinuation|0
6102096|NCT00769119|9718718|FG001|Overall Study|Voluntary discontinuation|2
6102097|NCT00769119|9718717|FG000|Overall Study|Adverse Event|1
6204732|NCT01525602|9866573|FG004|Overall Study|Disease progression|22
6204733|NCT01525602|9866574|FG005|Overall Study|Disease progression|2
6204734|NCT01525602|9866575|FG006|Overall Study|Disease progression|3
6204735|NCT01525602|9866576|FG007|Overall Study|Disease progression|3
6204736|NCT01525602|9866569|FG000|Overall Study|Clinical progression|2
6204737|NCT01525602|9866570|FG001|Overall Study|Clinical progression|0
6204738|NCT01525602|9866571|FG002|Overall Study|Clinical progression|0
6204739|NCT01525602|9866572|FG003|Overall Study|Clinical progression|0
6204740|NCT01525602|9866573|FG004|Overall Study|Clinical progression|0
6204741|NCT01525602|9866574|FG005|Overall Study|Clinical progression|0
6204742|NCT01525602|9866575|FG006|Overall Study|Clinical progression|1
6204743|NCT01525602|9866576|FG007|Overall Study|Clinical progression|1
6204744|NCT01525602|9866569|FG000|Overall Study|Non-compliance|0
6204745|NCT01525602|9866570|FG001|Overall Study|Non-compliance|0
6204746|NCT01525602|9866571|FG002|Overall Study|Non-compliance|0
6204747|NCT01525602|9866572|FG003|Overall Study|Non-compliance|0
6204748|NCT01525602|9866573|FG004|Overall Study|Non-compliance|1
6204749|NCT01525602|9866574|FG005|Overall Study|Non-compliance|0
6204750|NCT01525602|9866575|FG006|Overall Study|Non-compliance|0
6204751|NCT01525602|9866576|FG007|Overall Study|Non-compliance|0
6204752|NCT01525602|9866569|FG000|Overall Study|Withdrawal by Subject|0
6204753|NCT01525602|9866570|FG001|Overall Study|Withdrawal by Subject|0
6204754|NCT01525602|9866571|FG002|Overall Study|Withdrawal by Subject|0
6204755|NCT01525602|9866572|FG003|Overall Study|Withdrawal by Subject|0
6204756|NCT01525602|9866573|FG004|Overall Study|Withdrawal by Subject|3
6204757|NCT01525602|9866574|FG005|Overall Study|Withdrawal by Subject|1
6204758|NCT01525602|9866575|FG006|Overall Study|Withdrawal by Subject|0
6204759|NCT01525602|9866576|FG007|Overall Study|Withdrawal by Subject|1
6204760|NCT01525602|9866569|FG000|Overall Study|Physician Decision|0
6204761|NCT01525602|9866570|FG001|Overall Study|Physician Decision|0
6204762|NCT01525602|9866571|FG002|Overall Study|Physician Decision|0
6204763|NCT01525602|9866572|FG003|Overall Study|Physician Decision|0
6204764|NCT01525602|9866573|FG004|Overall Study|Physician Decision|3
6204765|NCT01525602|9866574|FG005|Overall Study|Physician Decision|0
6204766|NCT01525602|9866575|FG006|Overall Study|Physician Decision|1
6204767|NCT01525602|9866576|FG007|Overall Study|Physician Decision|0
6204768|NCT01525602|9866569|FG000|Overall Study|Death|0
6204769|NCT01525602|9866570|FG001|Overall Study|Death|0
6204770|NCT01525602|9866571|FG002|Overall Study|Death|0
6204771|NCT01525602|9866572|FG003|Overall Study|Death|0
6204772|NCT01525602|9866573|FG004|Overall Study|Death|1
6204773|NCT01525602|9866574|FG005|Overall Study|Death|1
6204774|NCT01525602|9866575|FG006|Overall Study|Death|0
6204775|NCT01525602|9866576|FG007|Overall Study|Death|0
6204776|NCT01525602|9866569|FG000|Overall Study|Unqualified based on biopsy; not dosed|0
6204777|NCT01525602|9866570|FG001|Overall Study|Unqualified based on biopsy; not dosed|0
6204778|NCT01525602|9866571|FG002|Overall Study|Unqualified based on biopsy; not dosed|0
6204779|NCT01525602|9866572|FG003|Overall Study|Unqualified based on biopsy; not dosed|0
6204780|NCT01525602|9866573|FG004|Overall Study|Unqualified based on biopsy; not dosed|0
6204781|NCT01525602|9866574|FG005|Overall Study|Unqualified based on biopsy; not dosed|0
6204782|NCT01525602|9866575|FG006|Overall Study|Unqualified based on biopsy; not dosed|1
6204783|NCT01525602|9866576|FG007|Overall Study|Unqualified based on biopsy; not dosed|1
6204784|NCT01525615|9866604|FG000|Overall Study|Adverse Event|11
6204785|NCT01525615|9866605|FG001|Overall Study|Adverse Event|7
6204786|NCT01525615|9866606|FG002|Overall Study|Adverse Event|5
6204787|NCT01525615|9866604|FG000|Overall Study|Lost to Follow-up|1
6204788|NCT01525615|9866605|FG001|Overall Study|Lost to Follow-up|0
6204789|NCT01525615|9866606|FG002|Overall Study|Lost to Follow-up|0
6204790|NCT01525615|9866604|FG000|Overall Study|Withdrawal by Subject|1
6204791|NCT01525615|9866605|FG001|Overall Study|Withdrawal by Subject|0
6204792|NCT01525615|9866606|FG002|Overall Study|Withdrawal by Subject|0
6204793|NCT01525615|9866604|FG000|Overall Study|Other reason not described above|1
6204794|NCT01525615|9866605|FG001|Overall Study|Other reason not described above|0
6204795|NCT01525615|9866606|FG002|Overall Study|Other reason not described above|1
6204796|NCT01525628|9866619|FG000|Overall Study|Adverse Event|1
6204797|NCT01525628|9866620|FG001|Overall Study|Adverse Event|1
6204798|NCT01525628|9866621|FG002|Overall Study|Adverse Event|2
6102098|NCT00769119|9718718|FG001|Overall Study|Adverse Event|1
6102099|NCT00769119|9718717|FG000|Overall Study|Disallowed medication|1
6204799|NCT01525628|9866622|FG003|Overall Study|Adverse Event|0
6204800|NCT01525628|9866623|FG004|Overall Study|Adverse Event|1
6102100|NCT00769119|9718718|FG001|Overall Study|Disallowed medication|0
6102101|NCT00769132|9718724|FG000|Period 1|Adverse Event|1
6102102|NCT00769132|9718725|FG001|Period 1|Adverse Event|0
6102103|NCT00769132|9718726|FG002|Period 1|Adverse Event|0
6102104|NCT00769132|9718727|FG003|Period 1|Adverse Event|1
6102105|NCT00769132|9718724|FG000|Period 2|Withdrawal by Subject|0
6102106|NCT00769132|9718725|FG001|Period 2|Withdrawal by Subject|0
6102107|NCT00769132|9718726|FG002|Period 2|Withdrawal by Subject|0
6102108|NCT00769132|9718727|FG003|Period 2|Withdrawal by Subject|1
6102109|NCT00769132|9718724|FG000|Period 3|Withdrawal by Subject|1
6102110|NCT00769132|9718725|FG001|Period 3|Withdrawal by Subject|0
6102111|NCT00769132|9718726|FG002|Period 3|Withdrawal by Subject|0
6102112|NCT00769132|9718727|FG003|Period 3|Withdrawal by Subject|0
6102113|NCT00769132|9718724|FG000|Period 4|Withdrawal by Subject|0
6102114|NCT00769132|9718725|FG001|Period 4|Withdrawal by Subject|1
6102115|NCT00769132|9718726|FG002|Period 4|Withdrawal by Subject|0
6102116|NCT00769132|9718727|FG003|Period 4|Withdrawal by Subject|0
6102117|NCT00769184|9718737|FG000|Corticosteroid + LCD/ +Placebo (2 Weeks)|Adverse Event|1
6102118|NCT00769184|9718738|FG001|Corticosteroid + LCD/ +Placebo (2 Weeks)|Adverse Event|0
6102119|NCT00769184|9718737|FG000|Corticosteroid + LCD/ +Placebo (2 Weeks)|Lost to Follow-up|0
6102120|NCT00769184|9718738|FG001|Corticosteroid + LCD/ +Placebo (2 Weeks)|Lost to Follow-up|1
6102121|NCT00769184|9718737|FG000|No Treatment (6 Weeks)|Adverse Event|1
6102122|NCT00769184|9718738|FG001|No Treatment (6 Weeks)|Adverse Event|1
6102123|NCT00769483|9718765|FG000|Overall Study|Withdrawal by Subject|0
6102124|NCT00769483|9718766|FG001|Overall Study|Withdrawal by Subject|1
6102125|NCT00769483|9718767|FG002|Overall Study|Withdrawal by Subject|0
6102126|NCT00769483|9718768|FG003|Overall Study|Withdrawal by Subject|0
6102127|NCT00769483|9718769|FG004|Overall Study|Withdrawal by Subject|1
6102128|NCT00769483|9718770|FG005|Overall Study|Withdrawal by Subject|0
6102129|NCT00769561|9718788|FG000|Overall Study|Withdrawal by Subject|2
6102130|NCT00769561|9718789|FG001|Overall Study|Withdrawal by Subject|2
6102131|NCT00769561|9718788|FG000|Overall Study|Lost to Follow-up|1
6102132|NCT00769561|9718789|FG001|Overall Study|Lost to Follow-up|3
6102133|NCT00769704|9718809|FG000|Overall Study|Lost to Follow-up|3
6102134|NCT00769704|9718810|FG001|Overall Study|Lost to Follow-up|2
6102135|NCT00769704|9718809|FG000|Overall Study|Death|95
6102136|NCT00769704|9718810|FG001|Overall Study|Death|190
6102137|NCT00769704|9718809|FG000|Overall Study|Withdrawal by Subject|12
6102138|NCT00769704|9718810|FG001|Overall Study|Withdrawal by Subject|5
6102139|NCT00769704|9718809|FG000|Overall Study|Other|1
6102140|NCT00769704|9718810|FG001|Overall Study|Other|2
6102141|NCT00769860|9718823|FG000|Overall Study|Withdrawal by Subject|2
6102142|NCT00769860|9718824|FG001|Overall Study|Withdrawal by Subject|0
6102143|NCT00770029|9718849|FG000|Overall Study|Lost to Follow-up|2
6102144|NCT00770029|9718850|FG001|Overall Study|Lost to Follow-up|0
6102145|NCT00770029|9718849|FG000|Overall Study|Withdrawal by Subject|3
6102146|NCT00770029|9718850|FG001|Overall Study|Withdrawal by Subject|3
6102147|NCT00770029|9718849|FG000|Overall Study|Adverse Event|1
6102148|NCT00770029|9718850|FG001|Overall Study|Adverse Event|0
6102149|NCT00770120|9718856|FG000|Overall Study|Progression|31
6102150|NCT00770120|9718856|FG000|Overall Study|Adverse Event|11
6102151|NCT00770120|9718856|FG000|Overall Study|Not Protocol Specified|11
6102152|NCT00770120|9718856|FG000|Overall Study|Death|3
6102153|NCT00770120|9718856|FG000|Overall Study|Withdrawal by Subject|2
6102154|NCT00770120|9718856|FG000|Overall Study|Ineligible|1
6102155|NCT00770120|9718856|FG000|Overall Study|Never Received Treatment/Not Analyzable|1
6102156|NCT00770120|9718856|FG000|Overall Study|Reason under Review|1
6102157|NCT00770146|9718880|FG000|Treatment Period|Withdrawal by Subject|6
6102158|NCT00770146|9718881|FG001|Treatment Period|Withdrawal by Subject|13
6102159|NCT00770146|9718880|FG000|Treatment Period|Adverse Event|2
6102160|NCT00770146|9718881|FG001|Treatment Period|Adverse Event|26
6102161|NCT00770146|9718880|FG000|Treatment Period|Other|1
6102162|NCT00770146|9718881|FG001|Treatment Period|Other|5
6102163|NCT00770146|9718880|FG000|Treatment Period|Protocol non-compliance|0
6102164|NCT00770146|9718881|FG001|Treatment Period|Protocol non-compliance|1
6102165|NCT00770146|9718880|FG000|Follow-up Period|Withdrawal by Subject|7
6102166|NCT00770146|9718881|FG001|Follow-up Period|Withdrawal by Subject|13
6102167|NCT00770146|9718880|FG000|Follow-up Period|Adverse Event|0
6102168|NCT00770146|9718881|FG001|Follow-up Period|Adverse Event|2
6102169|NCT00770146|9718880|FG000|Follow-up Period|Other|4
6102170|NCT00770146|9718881|FG001|Follow-up Period|Other|5
6102171|NCT00770211|9718889|FG000|Overall Study|Lost to Follow-up|1
6102172|NCT00770211|9718890|FG001|Overall Study|Lost to Follow-up|0
6102173|NCT00770211|9718889|FG000|Overall Study|Withdrawal by Subject|0
6102174|NCT00770211|9718890|FG001|Overall Study|Withdrawal by Subject|2
6102175|NCT00770224|9718896|FG000|Step 1: Induction|Adverse Event|3
6102176|NCT00770224|9718897|FG001|Step 1: Induction|Adverse Event|0
6102177|NCT00770224|9718896|FG000|Step 1: Induction|Refusal unrelated to adverse event|6
6102178|NCT00770224|9718897|FG001|Step 1: Induction|Refusal unrelated to adverse event|0
6102179|NCT00770224|9718896|FG000|Step 1: Induction|Other reason not protocol specified|2
6102180|NCT00770224|9718897|FG001|Step 1: Induction|Other reason not protocol specified|0
6102181|NCT00770224|9718896|FG000|Step 1: Induction|Ineligible|2
6102182|NCT00770224|9718897|FG001|Step 1: Induction|Ineligible|0
6102183|NCT00770224|9718896|FG000|Step 1: Induction|No protocol treatment given|1
6102184|NCT00770224|9718897|FG001|Step 1: Induction|No protocol treatment given|0
6102185|NCT00770224|9718896|FG000|Step 2: Maintenance|Adverse Event|0
6102186|NCT00770224|9718897|FG001|Step 2: Maintenance|Adverse Event|10
6102187|NCT00770224|9718896|FG000|Step 2: Maintenance|Refusal unrelated to adverse event|0
6102188|NCT00770224|9718897|FG001|Step 2: Maintenance|Refusal unrelated to adverse event|8
6102189|NCT00770224|9718896|FG000|Step 2: Maintenance|Progression/relapse|0
6102190|NCT00770224|9718897|FG001|Step 2: Maintenance|Progression/relapse|1
6102191|NCT00770224|9718896|FG000|Step 2: Maintenance|Death|0
6102192|NCT00770224|9718897|FG001|Step 2: Maintenance|Death|2
6102193|NCT00770224|9718896|FG000|Step 2: Maintenance|Other reason not protocol specified|0
6102194|NCT00770224|9718897|FG001|Step 2: Maintenance|Other reason not protocol specified|7
6102195|NCT00770224|9718896|FG000|Step 2: Maintenance|Ineligible|0
6102196|NCT00770224|9718897|FG001|Step 2: Maintenance|Ineligible|2
6102197|NCT00770289|9718904|FG000|Overall Study|Other|6
6102198|NCT00770315|9718917|FG000|Overall Study|Adverse Event|11
6102199|NCT00770315|9718918|FG001|Overall Study|Adverse Event|17
6102200|NCT00770315|9718919|FG002|Overall Study|Adverse Event|16
6102201|NCT00770315|9718920|FG003|Overall Study|Adverse Event|6
6102202|NCT00770315|9718917|FG000|Overall Study|Lost to Follow-up|9
6102203|NCT00770315|9718918|FG001|Overall Study|Lost to Follow-up|5
6102204|NCT00770315|9718919|FG002|Overall Study|Lost to Follow-up|10
6102205|NCT00770315|9718920|FG003|Overall Study|Lost to Follow-up|3
6102206|NCT00770315|9718917|FG000|Overall Study|Withdrawal by Subject|13
6102207|NCT00770315|9718918|FG001|Overall Study|Withdrawal by Subject|17
6102208|NCT00770315|9718919|FG002|Overall Study|Withdrawal by Subject|24
6102209|NCT00770315|9718920|FG003|Overall Study|Withdrawal by Subject|20
6102210|NCT00770315|9718917|FG000|Overall Study|Noncompliance with Protocol|7
6102211|NCT00770315|9718918|FG001|Overall Study|Noncompliance with Protocol|4
6102212|NCT00770315|9718919|FG002|Overall Study|Noncompliance with Protocol|7
6102213|NCT00770315|9718920|FG003|Overall Study|Noncompliance with Protocol|9
6102214|NCT00770328|9718932|FG000|Overall Study|Adverse Event|11
6102215|NCT00770328|9718933|FG001|Overall Study|Adverse Event|2
6102216|NCT00770328|9718932|FG000|Overall Study|Lost to Follow-up|2
6102217|NCT00770328|9718933|FG001|Overall Study|Lost to Follow-up|2
6102218|NCT00770341|9718942|FG000|Overall Study|Did not meet eligibility criteria|1
6102219|NCT00770341|9718943|FG001|Overall Study|Did not meet eligibility criteria|0
6102220|NCT00770341|9718944|FG002|Overall Study|Did not meet eligibility criteria|0
6102221|NCT00770341|9718942|FG000|Overall Study|Withdrawal by Subject|0
6102222|NCT00770341|9718943|FG001|Overall Study|Withdrawal by Subject|1
6102223|NCT00770341|9718944|FG002|Overall Study|Withdrawal by Subject|0
6102224|NCT00770341|9718942|FG000|Overall Study|Clinical Adverse Event|3
6102225|NCT00770341|9718943|FG001|Overall Study|Clinical Adverse Event|1
6102226|NCT00770341|9718944|FG002|Overall Study|Clinical Adverse Event|2
6102227|NCT00770341|9718942|FG000|Overall Study|Laboratory adverse event|3
6102228|NCT00770341|9718943|FG001|Overall Study|Laboratory adverse event|3
6102229|NCT00770341|9718944|FG002|Overall Study|Laboratory adverse event|0
6102230|NCT00770341|9718942|FG000|Overall Study|Lack of Efficacy|3
6102231|NCT00770341|9718943|FG001|Overall Study|Lack of Efficacy|0
6102232|NCT00770341|9718944|FG002|Overall Study|Lack of Efficacy|1
6102233|NCT00770341|9718942|FG000|Overall Study|Other|1
6102234|NCT00770341|9718943|FG001|Overall Study|Other|0
6102235|NCT00770341|9718944|FG002|Overall Study|Other|0
6102236|NCT00770341|9718942|FG000|Overall Study|Not treated|1
6102237|NCT00770341|9718943|FG001|Overall Study|Not treated|0
6102238|NCT00770341|9718944|FG002|Overall Study|Not treated|0
6102239|NCT00770367|9718955|FG000|First Intervention|Withdrawal by Subject|0
6102240|NCT00770367|9718956|FG001|First Intervention|Withdrawal by Subject|2
6102241|NCT00770367|9718955|FG000|Washout Period of 4 Weeks|Withdrawal by Subject|0
6102242|NCT00770367|9718956|FG001|Washout Period of 4 Weeks|Withdrawal by Subject|1
6102243|NCT00770367|9718955|FG000|Second Intervention|Lost to Follow-up|2
6102244|NCT00770367|9718956|FG001|Second Intervention|Lost to Follow-up|0
6102245|NCT00770432|9718966|FG000|Overall Study|Other|4
6102246|NCT00770432|9718967|FG001|Overall Study|Other|6
6102247|NCT00770432|9718966|FG000|Overall Study|Non-compliance|0
6102248|NCT00770432|9718967|FG001|Overall Study|Non-compliance|1
6102249|NCT00770484|9718975|FG000|Overall Study|Withdrawal by Subject|1
6102250|NCT00770484|9718976|FG001|Overall Study|Withdrawal by Subject|0
6102251|NCT00770510|9718982|FG000|Overall Study|Lost to Follow-up|2
6102252|NCT00770510|9718982|FG000|Overall Study|Pregnancy|1
6102253|NCT00770510|9718982|FG000|Overall Study|Withdrawal by Subject|2
6102254|NCT00770562|9718996|FG000|Overall Study|Did not take treatment|1
6102255|NCT00770562|9718997|FG001|Overall Study|Did not take treatment|1
6102256|NCT00770588|9719006|FG000|Overall Study|Adverse Event|9
6102257|NCT00770588|9719007|FG001|Overall Study|Adverse Event|2
6102258|NCT00770588|9719006|FG000|Overall Study|Death caused by progression of disease|70
6102259|NCT00770588|9719007|FG001|Overall Study|Death caused by progression of disease|91
6102260|NCT00770588|9719006|FG000|Overall Study|Lost to Follow-up|1
6102261|NCT00770588|9719007|FG001|Overall Study|Lost to Follow-up|1
6102262|NCT00770588|9719006|FG000|Overall Study|Withdrawal by Subject|1
6102263|NCT00770588|9719007|FG001|Overall Study|Withdrawal by Subject|1
6102264|NCT00770601|9719014|FG000|Overall Study|Withdrawal by Subject|1
6102265|NCT00770653|9719020|FG000|Overall Study|Adverse Event|13
6102266|NCT00770653|9719021|FG001|Overall Study|Adverse Event|5
6102267|NCT00770653|9719020|FG000|Overall Study|Protocol Violation|8
6102268|NCT00770653|9719021|FG001|Overall Study|Protocol Violation|6
6102269|NCT00770653|9719020|FG000|Overall Study|Withdrawal by Subject|4
6102270|NCT00770653|9719021|FG001|Overall Study|Withdrawal by Subject|7
6102271|NCT00770653|9719020|FG000|Overall Study|Lack of Compliance|1
6102272|NCT00770653|9719021|FG001|Overall Study|Lack of Compliance|4
6102273|NCT00770653|9719020|FG000|Overall Study|Worsening of Glycosolated Hemoglobin|2
6102274|NCT00770653|9719021|FG001|Overall Study|Worsening of Glycosolated Hemoglobin|2
6102275|NCT00770653|9719020|FG000|Overall Study|Fasting Glucose > 240 mg/dL|2
6102276|NCT00770653|9719021|FG001|Overall Study|Fasting Glucose > 240 mg/dL|1
6102277|NCT00770653|9719020|FG000|Overall Study|> Three Moderate Hypoglycemic Episodes|0
6102278|NCT00770653|9719021|FG001|Overall Study|> Three Moderate Hypoglycemic Episodes|2
6102279|NCT00770653|9719020|FG000|Overall Study|Lost to Follow-up|1
6102280|NCT00770653|9719021|FG001|Overall Study|Lost to Follow-up|2
6102281|NCT00770653|9719020|FG000|Overall Study|Physician Decision|1
6102282|NCT00770653|9719021|FG001|Overall Study|Physician Decision|0
6102283|NCT00770679|9719027|FG000|Overall Study|Lost to Follow-up|3
6102284|NCT00770679|9719027|FG000|Overall Study|Follow-up LDL measurement not collected|3
6102285|NCT00770692|9719035|FG000|Overall Study|Withdrawal by Subject|7
6102286|NCT00770692|9719036|FG001|Overall Study|Withdrawal by Subject|9
6102287|NCT00770692|9719037|FG002|Overall Study|Withdrawal by Subject|9
6102288|NCT00770692|9719038|FG003|Overall Study|Withdrawal by Subject|6
6102289|NCT00770692|9719035|FG000|Overall Study|Adverse Event|3
6102290|NCT00770692|9719036|FG001|Overall Study|Adverse Event|0
6102291|NCT00770692|9719037|FG002|Overall Study|Adverse Event|4
6204801|NCT01525628|9866619|FG000|Overall Study|Lack of Efficacy|0
6204802|NCT01525628|9866620|FG001|Overall Study|Lack of Efficacy|2
6204803|NCT01525628|9866621|FG002|Overall Study|Lack of Efficacy|2
6204804|NCT01525628|9866622|FG003|Overall Study|Lack of Efficacy|1
6204805|NCT01525628|9866623|FG004|Overall Study|Lack of Efficacy|2
6204806|NCT01525628|9866619|FG000|Overall Study|Protocol Violation|0
6204807|NCT01525628|9866620|FG001|Overall Study|Protocol Violation|0
6204808|NCT01525628|9866621|FG002|Overall Study|Protocol Violation|1
6204809|NCT01525628|9866622|FG003|Overall Study|Protocol Violation|0
6204810|NCT01525628|9866623|FG004|Overall Study|Protocol Violation|0
6204811|NCT01525628|9866619|FG000|Overall Study|Lost to Follow-up|1
6204812|NCT01525628|9866620|FG001|Overall Study|Lost to Follow-up|1
6204813|NCT01525628|9866621|FG002|Overall Study|Lost to Follow-up|0
6204814|NCT01525628|9866622|FG003|Overall Study|Lost to Follow-up|0
6204815|NCT01525628|9866623|FG004|Overall Study|Lost to Follow-up|0
6204816|NCT01525628|9866619|FG000|Overall Study|Withdrawal by Subject|0
6204817|NCT01525628|9866620|FG001|Overall Study|Withdrawal by Subject|1
6204818|NCT01525628|9866621|FG002|Overall Study|Withdrawal by Subject|0
6204819|NCT01525628|9866622|FG003|Overall Study|Withdrawal by Subject|0
6204820|NCT01525628|9866623|FG004|Overall Study|Withdrawal by Subject|0
6204821|NCT01525628|9866619|FG000|Overall Study|Other reason not defined above|0
6204822|NCT01525628|9866620|FG001|Overall Study|Other reason not defined above|0
6204823|NCT01525628|9866621|FG002|Overall Study|Other reason not defined above|0
6204824|NCT01525628|9866622|FG003|Overall Study|Other reason not defined above|3
6204825|NCT01525628|9866623|FG004|Overall Study|Other reason not defined above|0
6204826|NCT01525641|9866637|FG000|Overall Study|Case report form not collected|25
6204827|NCT01525641|9866637|FG000|Overall Study|No visit since the first visit|16
6204828|NCT01525641|9866637|FG000|Overall Study|Adverse Event|73
6204829|NCT01525641|9866637|FG000|Overall Study|Lack of Efficacy|24
6204830|NCT01525641|9866637|FG000|Overall Study|Improvement|5
6204831|NCT01525641|9866637|FG000|Overall Study|Lost to follow-up (relocation)|1
6204832|NCT01525641|9866637|FG000|Overall Study|Lost to follow-up (Unknown reason)|10
6204833|NCT01525641|9866637|FG000|Overall Study|Lost to follow-up (Changing hospital)|19
6204834|NCT01525641|9866637|FG000|Overall Study|Other than stated above|7
6204835|NCT01525849|9866658|FG000|Overall Study|Lost to Follow-up|3
6204836|NCT01525849|9866659|FG001|Overall Study|Lost to Follow-up|2
6204837|NCT01525849|9866658|FG000|Overall Study|Withdrawal by Subject|1
6204838|NCT01525849|9866659|FG001|Overall Study|Withdrawal by Subject|9
6204839|NCT01525849|9866658|FG000|Overall Study|Unrelated medical issue (not treated)|1
6204840|NCT01525849|9866659|FG001|Overall Study|Unrelated medical issue (not treated)|2
6204841|NCT01525849|9866658|FG000|Overall Study|Anatomic exclusion criteria identified|0
6204842|NCT01525849|9866659|FG001|Overall Study|Anatomic exclusion criteria identified|3
6204843|NCT01525875|9866671|FG000|Placebo-controlled Period|Withdrawal by Subject|1
6204844|NCT01525875|9866672|FG001|Placebo-controlled Period|Withdrawal by Subject|2
6204845|NCT01525875|9866671|FG000|Open-label Period|Lost to Follow-up|0
6204846|NCT01525875|9866672|FG001|Open-label Period|Lost to Follow-up|2
6204847|NCT01526057|9866681|FG000|Overall Study|Withdrawal by Subject|3
6204848|NCT01526057|9866682|FG001|Overall Study|Withdrawal by Subject|2
6204849|NCT01526057|9866683|FG002|Overall Study|Withdrawal by Subject|2
6204850|NCT01526057|9866681|FG000|Overall Study|Adverse Event|3
6204851|NCT01526057|9866682|FG001|Overall Study|Adverse Event|1
6204852|NCT01526057|9866683|FG002|Overall Study|Adverse Event|1
6204853|NCT01526057|9866681|FG000|Overall Study|Death|1
6204854|NCT01526057|9866682|FG001|Overall Study|Death|0
6204855|NCT01526057|9866683|FG002|Overall Study|Death|0
6204856|NCT01526057|9866681|FG000|Overall Study|Lost to Follow-up|1
6204857|NCT01526057|9866682|FG001|Overall Study|Lost to Follow-up|0
6204858|NCT01526057|9866683|FG002|Overall Study|Lost to Follow-up|1
6102292|NCT00770692|9719038|FG003|Overall Study|Adverse Event|4
6102293|NCT00770692|9719035|FG000|Overall Study|Investigator judgment|2
6102294|NCT00770692|9719036|FG001|Overall Study|Investigator judgment|0
6102295|NCT00770692|9719037|FG002|Overall Study|Investigator judgment|1
6102296|NCT00770692|9719038|FG003|Overall Study|Investigator judgment|1
6102297|NCT00770770|9719054|FG000|Overall Study|Lost to Follow-up|1
6102298|NCT00770770|9719055|FG001|Overall Study|Lost to Follow-up|0
6102299|NCT00770770|9719054|FG000|Overall Study|Withdrawal by Subject|1
6102300|NCT00770770|9719055|FG001|Overall Study|Withdrawal by Subject|0
6102301|NCT00770770|9719054|FG000|Overall Study|Death|0
6102302|NCT00770770|9719055|FG001|Overall Study|Death|1
6102303|NCT00770770|9719054|FG000|Overall Study|Study Terminated|8
6102304|NCT00770770|9719055|FG001|Overall Study|Study Terminated|0
6102305|NCT00770913|9719082|FG000|Overall Study|Adverse Event|1
6102306|NCT00770913|9719083|FG001|Overall Study|Adverse Event|3
6102307|NCT00770913|9719084|FG002|Overall Study|Adverse Event|6
6102308|NCT00770913|9719082|FG000|Overall Study|Refusal to continue participation|6
6102309|NCT00770913|9719083|FG001|Overall Study|Refusal to continue participation|4
6102310|NCT00770913|9719084|FG002|Overall Study|Refusal to continue participation|5
6102311|NCT00770913|9719082|FG000|Overall Study|Physician Decision|0
6102312|NCT00770913|9719083|FG001|Overall Study|Physician Decision|1
6102313|NCT00770913|9719084|FG002|Overall Study|Physician Decision|1
6102314|NCT00770913|9719082|FG000|Overall Study|Protocol Violation|3
6102315|NCT00770913|9719083|FG001|Overall Study|Protocol Violation|0
6102316|NCT00770913|9719084|FG002|Overall Study|Protocol Violation|1
6102317|NCT00770913|9719082|FG000|Overall Study|Incorrect drug was allocated|1
6102318|NCT00770913|9719083|FG001|Overall Study|Incorrect drug was allocated|0
6102319|NCT00770913|9719084|FG002|Overall Study|Incorrect drug was allocated|0
6102320|NCT00770991|9719094|FG000|Overall Study|Physician Decision|2
6102321|NCT00770991|9719095|FG001|Overall Study|Physician Decision|0
6102322|NCT00770991|9719094|FG000|Overall Study|Withdrawal by Subject|1
6102323|NCT00770991|9719095|FG001|Overall Study|Withdrawal by Subject|0
6102324|NCT00770991|9719094|FG000|Overall Study|Adverse Event|1
6102325|NCT00770991|9719095|FG001|Overall Study|Adverse Event|5
6102326|NCT00770991|9719094|FG000|Overall Study|Pregnancy|1
6102327|NCT00770991|9719095|FG001|Overall Study|Pregnancy|0
6102328|NCT00771030|9719113|FG000|Overall Study|Adverse Event|0
6102329|NCT00771030|9719114|FG001|Overall Study|Adverse Event|1
6102330|NCT00771030|9719115|FG002|Overall Study|Adverse Event|0
6102331|NCT00771030|9719116|FG003|Overall Study|Adverse Event|0
6102332|NCT00771030|9719117|FG004|Overall Study|Adverse Event|0
6102333|NCT00771030|9719118|FG005|Overall Study|Adverse Event|0
6102334|NCT00771030|9719119|FG006|Overall Study|Adverse Event|0
6204859|NCT01526057|9866681|FG000|Overall Study|Other|1
6204860|NCT01526057|9866682|FG001|Overall Study|Other|0
6204861|NCT01526057|9866683|FG002|Overall Study|Other|1
6204862|NCT01526057|9866681|FG000|Overall Study|Protocol Violation|0
6204863|NCT01526057|9866682|FG001|Overall Study|Protocol Violation|0
6204864|NCT01526057|9866683|FG002|Overall Study|Protocol Violation|1
6204865|NCT01526148|9866693|FG000|Overall Study|Adverse Event|6
6204866|NCT01526148|9866694|FG001|Overall Study|Adverse Event|5
6204867|NCT01526148|9866693|FG000|Overall Study|Lost to Follow-up|3
6204868|NCT01526148|9866694|FG001|Overall Study|Lost to Follow-up|6
6204869|NCT01526148|9866693|FG000|Overall Study|Withdrawal by Subject|2
6204870|NCT01526148|9866694|FG001|Overall Study|Withdrawal by Subject|0
6204871|NCT01526148|9866693|FG000|Overall Study|Unstable Medical Condition|1
6204872|NCT01526148|9866694|FG001|Overall Study|Unstable Medical Condition|0
6204873|NCT01526148|9866693|FG000|Overall Study|Unable to discontinue concomitant med|1
6204874|NCT01526148|9866694|FG001|Overall Study|Unable to discontinue concomitant med|0
6204875|NCT01526148|9866693|FG000|Overall Study|Moved out of state|1
6204876|NCT01526148|9866694|FG001|Overall Study|Moved out of state|0
6204877|NCT01526148|9866693|FG000|Overall Study|Incarcerated|0
6204878|NCT01526148|9866694|FG001|Overall Study|Incarcerated|2
6204879|NCT01526551|9866752|FG000|Overall Study|Lack of returned parental consent form|424
6204880|NCT01526733|9866777|FG000|Phase 1|Protocol Violation|1
6204881|NCT01526733|9866778|FG001|Phase 1|Protocol Violation|0
6204882|NCT01526733|9866777|FG000|Phase 1|Withdrawal by Subject|1
6204883|NCT01526733|9866778|FG001|Phase 1|Withdrawal by Subject|1
6204884|NCT01526785|9866785|FG000|Overall Study|Study Terminated by Sponsor|8
6204885|NCT01526785|9866785|FG000|Overall Study|Death|2
6204886|NCT01526785|9866785|FG000|Overall Study|Physician Decision|1
6204887|NCT01526785|9866785|FG000|Overall Study|Withdrawal by Subject|2
6204888|NCT01526889|9866791|FG000|Treatment Period|Adverse Event|2
6284974|NCT02327169|9996514|FG012|Overall Study|Lost to Follow-up|0
6204889|NCT01526889|9866792|FG001|Treatment Period|Adverse Event|0
6204890|NCT01526889|9866791|FG000|Treatment Extension Period|Administrative problems|1
6204891|NCT01526889|9866792|FG001|Treatment Extension Period|Administrative problems|0
6204892|NCT01526928|9866811|FG000|Overall Study|Progressive Disease|35
6204893|NCT01526928|9866812|FG001|Overall Study|Progressive Disease|17
6204894|NCT01526928|9866813|FG002|Overall Study|Progressive Disease|150
6204895|NCT01526928|9866814|FG003|Overall Study|Progressive Disease|182
6204896|NCT01526928|9866815|FG004|Overall Study|Progressive Disease|76
6204897|NCT01526928|9866816|FG005|Overall Study|Progressive Disease|4
6204898|NCT01526928|9866811|FG000|Overall Study|Adverse Event|2
6204899|NCT01526928|9866812|FG001|Overall Study|Adverse Event|1
6102335|NCT00771472|9719184|FG000|Overall Study|Physician Decision|2
6102336|NCT00771472|9719185|FG001|Overall Study|Physician Decision|3
6102337|NCT00771472|9719184|FG000|Overall Study|Progressive Disease|3
6102338|NCT00771472|9719185|FG001|Overall Study|Progressive Disease|1
6102339|NCT00771472|9719184|FG000|Overall Study|Protocol Violation|1
6102340|NCT00771472|9719185|FG001|Overall Study|Protocol Violation|0
6102341|NCT00771615|9719256|FG000|Overall Study|Withdrawal by Subject|0
6102342|NCT00771615|9719257|FG001|Overall Study|Withdrawal by Subject|1
6102343|NCT00771615|9719258|FG002|Overall Study|Withdrawal by Subject|0
6102344|NCT00771615|9719259|FG003|Overall Study|Withdrawal by Subject|0
6102345|NCT00771615|9719260|FG004|Overall Study|Withdrawal by Subject|0
6102346|NCT00771615|9719261|FG005|Overall Study|Withdrawal by Subject|0
6102347|NCT00771615|9719262|FG006|Overall Study|Withdrawal by Subject|0
6102348|NCT00771615|9719263|FG007|Overall Study|Withdrawal by Subject|1
6102349|NCT00771615|9719264|FG008|Overall Study|Withdrawal by Subject|0
6102350|NCT00771615|9719256|FG000|Overall Study|Lost to Follow-up|1
6102351|NCT00771615|9719257|FG001|Overall Study|Lost to Follow-up|1
6102352|NCT00771615|9719258|FG002|Overall Study|Lost to Follow-up|1
6102353|NCT00771615|9719259|FG003|Overall Study|Lost to Follow-up|1
6102354|NCT00771615|9719260|FG004|Overall Study|Lost to Follow-up|0
6102355|NCT00771615|9719261|FG005|Overall Study|Lost to Follow-up|1
6102356|NCT00771615|9719262|FG006|Overall Study|Lost to Follow-up|1
6102357|NCT00771615|9719263|FG007|Overall Study|Lost to Follow-up|0
6102358|NCT00771615|9719264|FG008|Overall Study|Lost to Follow-up|0
6102359|NCT00771667|9719297|FG000|Induction Phase|Adverse Event|5
6102360|NCT00771667|9719298|FG001|Induction Phase|Adverse Event|2
6102361|NCT00771667|9719299|FG002|Induction Phase|Adverse Event|4
6102362|NCT00771667|9719300|FG003|Induction Phase|Adverse Event|1
6102363|NCT00771667|9719301|FG004|Induction Phase|Adverse Event|0
6102364|NCT00771667|9719302|FG005|Induction Phase|Adverse Event|0
6102365|NCT00771667|9719303|FG006|Induction Phase|Adverse Event|0
6102366|NCT00771667|9719304|FG007|Induction Phase|Adverse Event|0
6102367|NCT00771667|9719305|FG008|Induction Phase|Adverse Event|0
6102368|NCT00771667|9719306|FG009|Induction Phase|Adverse Event|0
6102369|NCT00771667|9719297|FG000|Induction Phase|Lack of Efficacy|9
6102370|NCT00771667|9719298|FG001|Induction Phase|Lack of Efficacy|2
6102371|NCT00771667|9719299|FG002|Induction Phase|Lack of Efficacy|4
6102372|NCT00771667|9719300|FG003|Induction Phase|Lack of Efficacy|3
6102373|NCT00771667|9719301|FG004|Induction Phase|Lack of Efficacy|0
6102374|NCT00771667|9719302|FG005|Induction Phase|Lack of Efficacy|0
6102375|NCT00771667|9719303|FG006|Induction Phase|Lack of Efficacy|0
6102376|NCT00771667|9719304|FG007|Induction Phase|Lack of Efficacy|0
6102377|NCT00771667|9719305|FG008|Induction Phase|Lack of Efficacy|0
6102378|NCT00771667|9719306|FG009|Induction Phase|Lack of Efficacy|0
6102379|NCT00771667|9719297|FG000|Induction Phase|Lost to Follow-up|1
6102380|NCT00771667|9719298|FG001|Induction Phase|Lost to Follow-up|0
6102381|NCT00771667|9719299|FG002|Induction Phase|Lost to Follow-up|1
6102382|NCT00771667|9719300|FG003|Induction Phase|Lost to Follow-up|0
6102383|NCT00771667|9719301|FG004|Induction Phase|Lost to Follow-up|0
6102384|NCT00771667|9719302|FG005|Induction Phase|Lost to Follow-up|0
6102385|NCT00771667|9719303|FG006|Induction Phase|Lost to Follow-up|0
6102386|NCT00771667|9719304|FG007|Induction Phase|Lost to Follow-up|0
6102387|NCT00771667|9719305|FG008|Induction Phase|Lost to Follow-up|0
6102388|NCT00771667|9719306|FG009|Induction Phase|Lost to Follow-up|0
6102389|NCT00771667|9719297|FG000|Induction Phase|Other|4
6102390|NCT00771667|9719298|FG001|Induction Phase|Other|6
6102391|NCT00771667|9719299|FG002|Induction Phase|Other|3
6102392|NCT00771667|9719300|FG003|Induction Phase|Other|4
6102393|NCT00771667|9719301|FG004|Induction Phase|Other|0
6102394|NCT00771667|9719302|FG005|Induction Phase|Other|0
6102395|NCT00771667|9719303|FG006|Induction Phase|Other|0
6102396|NCT00771667|9719304|FG007|Induction Phase|Other|0
6102397|NCT00771667|9719305|FG008|Induction Phase|Other|0
6102398|NCT00771667|9719306|FG009|Induction Phase|Other|0
6102399|NCT00771667|9719297|FG000|Maintenance Phase|Adverse Event|0
6102400|NCT00771667|9719298|FG001|Maintenance Phase|Adverse Event|0
6102401|NCT00771667|9719299|FG002|Maintenance Phase|Adverse Event|0
6102402|NCT00771667|9719300|FG003|Maintenance Phase|Adverse Event|0
6102403|NCT00771667|9719301|FG004|Maintenance Phase|Adverse Event|1
6102404|NCT00771667|9719302|FG005|Maintenance Phase|Adverse Event|3
6102405|NCT00771667|9719303|FG006|Maintenance Phase|Adverse Event|5
6102406|NCT00771667|9719304|FG007|Maintenance Phase|Adverse Event|1
6102407|NCT00771667|9719305|FG008|Maintenance Phase|Adverse Event|8
6102408|NCT00771667|9719306|FG009|Maintenance Phase|Adverse Event|7
6102409|NCT00771667|9719297|FG000|Maintenance Phase|Lack of Efficacy|0
6102410|NCT00771667|9719298|FG001|Maintenance Phase|Lack of Efficacy|0
6102411|NCT00771667|9719299|FG002|Maintenance Phase|Lack of Efficacy|0
6102412|NCT00771667|9719300|FG003|Maintenance Phase|Lack of Efficacy|0
6102413|NCT00771667|9719301|FG004|Maintenance Phase|Lack of Efficacy|1
6102414|NCT00771667|9719302|FG005|Maintenance Phase|Lack of Efficacy|3
6102415|NCT00771667|9719303|FG006|Maintenance Phase|Lack of Efficacy|3
6102416|NCT00771667|9719304|FG007|Maintenance Phase|Lack of Efficacy|2
6102417|NCT00771667|9719305|FG008|Maintenance Phase|Lack of Efficacy|11
6102418|NCT00771667|9719306|FG009|Maintenance Phase|Lack of Efficacy|7
6102419|NCT00771667|9719297|FG000|Maintenance Phase|Other|0
6102420|NCT00771667|9719298|FG001|Maintenance Phase|Other|0
6102421|NCT00771667|9719299|FG002|Maintenance Phase|Other|0
6102422|NCT00771667|9719300|FG003|Maintenance Phase|Other|0
6102423|NCT00771667|9719301|FG004|Maintenance Phase|Other|0
6102424|NCT00771667|9719302|FG005|Maintenance Phase|Other|1
6102425|NCT00771667|9719303|FG006|Maintenance Phase|Other|2
6102426|NCT00771667|9719304|FG007|Maintenance Phase|Other|2
6102427|NCT00771667|9719305|FG008|Maintenance Phase|Other|3
6102428|NCT00771667|9719306|FG009|Maintenance Phase|Other|3
6102429|NCT00771758|9719336|FG000|Overall Study|Adverse Event|2
6102430|NCT00771758|9719337|FG001|Overall Study|Adverse Event|8
6102431|NCT00771758|9719338|FG002|Overall Study|Adverse Event|1
6102432|NCT00771758|9719336|FG000|Overall Study|Lack of Efficacy|0
6102433|NCT00771758|9719337|FG001|Overall Study|Lack of Efficacy|2
6102434|NCT00771758|9719338|FG002|Overall Study|Lack of Efficacy|1
6102435|NCT00771758|9719336|FG000|Overall Study|Lost to Follow-up|1
6102436|NCT00771758|9719337|FG001|Overall Study|Lost to Follow-up|0
6102437|NCT00771758|9719338|FG002|Overall Study|Lost to Follow-up|0
6102438|NCT00771758|9719336|FG000|Overall Study|Protocol Violation|1
6102439|NCT00771758|9719337|FG001|Overall Study|Protocol Violation|0
6102440|NCT00771758|9719338|FG002|Overall Study|Protocol Violation|0
6102441|NCT00771758|9719336|FG000|Overall Study|Withdrawal by Subject|1
6102442|NCT00771758|9719337|FG001|Overall Study|Withdrawal by Subject|0
6102443|NCT00771758|9719338|FG002|Overall Study|Withdrawal by Subject|0
6102444|NCT00771758|9719336|FG000|Overall Study|Other|3
6102445|NCT00771758|9719337|FG001|Overall Study|Other|2
6102446|NCT00771758|9719338|FG002|Overall Study|Other|0
6102447|NCT00771810|9719366|FG000|Overall Study|Adverse Event|3
6102448|NCT00771810|9719367|FG001|Overall Study|Adverse Event|0
6102449|NCT00771810|9719368|FG002|Overall Study|Adverse Event|2
6102450|NCT00771810|9719366|FG000|Overall Study|Lost to Follow-up|0
6102451|NCT00771810|9719367|FG001|Overall Study|Lost to Follow-up|0
6102452|NCT00771810|9719368|FG002|Overall Study|Lost to Follow-up|1
6102453|NCT00771810|9719366|FG000|Overall Study|Physician Decision|1
6102454|NCT00771810|9719367|FG001|Overall Study|Physician Decision|2
6102455|NCT00771810|9719368|FG002|Overall Study|Physician Decision|2
6102456|NCT00771810|9719366|FG000|Overall Study|Protocol Violation|0
6102457|NCT00771810|9719367|FG001|Overall Study|Protocol Violation|1
6102458|NCT00771810|9719368|FG002|Overall Study|Protocol Violation|1
6102459|NCT00771810|9719366|FG000|Overall Study|Withdrawal by Subject|1
6102460|NCT00771810|9719367|FG001|Overall Study|Withdrawal by Subject|2
6102461|NCT00771810|9719368|FG002|Overall Study|Withdrawal by Subject|0
6102462|NCT00771810|9719366|FG000|Overall Study|Other|0
6102463|NCT00771810|9719367|FG001|Overall Study|Other|0
6102464|NCT00771810|9719368|FG002|Overall Study|Other|1
6102465|NCT00771849|9719379|FG000|Overall Study|Lost to Follow-up|1
6102466|NCT00771849|9719380|FG001|Overall Study|Lost to Follow-up|2
6102467|NCT00771849|9719379|FG000|Overall Study|Withdrawal by Subject|1
6102468|NCT00771849|9719380|FG001|Overall Study|Withdrawal by Subject|1
6102469|NCT00771849|9719379|FG000|Overall Study|Not vaccinated|0
6102470|NCT00771849|9719380|FG001|Overall Study|Not vaccinated|1
6102471|NCT00771901|9719402|FG000|Overall Study|Dissat w/# of study medication (40/day)|0
6102472|NCT00771901|9719403|FG001|Overall Study|Dissat w/# of study medication (40/day)|0
6102473|NCT00771901|9719404|FG002|Overall Study|Dissat w/# of study medication (40/day)|4
6102474|NCT00771914|9719416|FG000|Overall Study|Physician Decision|0
6102475|NCT00771914|9719417|FG001|Overall Study|Physician Decision|0
6102476|NCT00771914|9719418|FG002|Overall Study|Physician Decision|0
6102477|NCT00771914|9719419|FG003|Overall Study|Physician Decision|1
6102478|NCT00771914|9719416|FG000|Overall Study|Lost to Follow-up|0
6102479|NCT00771914|9719417|FG001|Overall Study|Lost to Follow-up|0
6102480|NCT00771914|9719418|FG002|Overall Study|Lost to Follow-up|0
6102481|NCT00771914|9719419|FG003|Overall Study|Lost to Follow-up|1
6102482|NCT00771927|9719431|FG000|Overall Study|Adverse Event|100
6102483|NCT00771927|9719432|FG001|Overall Study|Adverse Event|105
6102484|NCT00771927|9719431|FG000|Overall Study|Lack of Efficacy|70
6102485|NCT00771927|9719432|FG001|Overall Study|Lack of Efficacy|42
6102486|NCT00771927|9719431|FG000|Overall Study|Lost to Follow-up|46
6102487|NCT00771927|9719432|FG001|Overall Study|Lost to Follow-up|46
6102488|NCT00771927|9719431|FG000|Overall Study|Withdrawal by Subject|16
6102489|NCT00771927|9719432|FG001|Overall Study|Withdrawal by Subject|17
6102490|NCT00771927|9719431|FG000|Overall Study|Other reason|23
6102491|NCT00771927|9719432|FG001|Overall Study|Other reason|27
6102492|NCT00771953|9719440|FG000|Overall Study|Adverse Event|5
6102493|NCT00771953|9719441|FG001|Overall Study|Adverse Event|3
6102494|NCT00771953|9719440|FG000|Overall Study|Death|2
6102495|NCT00771953|9719441|FG001|Overall Study|Death|2
6102496|NCT00771953|9719440|FG000|Overall Study|Progression before active Tx|1
6102497|NCT00771953|9719441|FG001|Overall Study|Progression before active Tx|2
6102498|NCT00771953|9719440|FG000|Overall Study|Sponsor decision|1
6102499|NCT00771953|9719441|FG001|Overall Study|Sponsor decision|0
6102500|NCT00771953|9719440|FG000|Overall Study|Other complicating disease|1
6102501|NCT00771953|9719441|FG001|Overall Study|Other complicating disease|0
6102502|NCT00771953|9719440|FG000|Overall Study|Withdrawal by Subject|0
6102503|NCT00771953|9719441|FG001|Overall Study|Withdrawal by Subject|3
6102504|NCT00772005|9719453|FG000|Overall Study|Adverse Event|9
6102505|NCT00772005|9719454|FG001|Overall Study|Adverse Event|14
6102506|NCT00772005|9719455|FG002|Overall Study|Adverse Event|10
6102507|NCT00772005|9719456|FG003|Overall Study|Adverse Event|13
6102508|NCT00772005|9719453|FG000|Overall Study|Lack of Efficacy|0
6102509|NCT00772005|9719454|FG001|Overall Study|Lack of Efficacy|1
6102510|NCT00772005|9719455|FG002|Overall Study|Lack of Efficacy|0
6102511|NCT00772005|9719456|FG003|Overall Study|Lack of Efficacy|0
6102512|NCT00772005|9719453|FG000|Overall Study|Withdrawal by Subject|3
6102513|NCT00772005|9719454|FG001|Overall Study|Withdrawal by Subject|7
6102514|NCT00772005|9719455|FG002|Overall Study|Withdrawal by Subject|10
6102515|NCT00772005|9719456|FG003|Overall Study|Withdrawal by Subject|2
6102516|NCT00772005|9719453|FG000|Overall Study|Protocol Violation|2
6102517|NCT00772005|9719454|FG001|Overall Study|Protocol Violation|4
6102518|NCT00772005|9719455|FG002|Overall Study|Protocol Violation|1
6102519|NCT00772005|9719456|FG003|Overall Study|Protocol Violation|6
6102520|NCT00772005|9719453|FG000|Overall Study|Lost to Follow-up|7
6102521|NCT00772005|9719454|FG001|Overall Study|Lost to Follow-up|3
6102522|NCT00772005|9719455|FG002|Overall Study|Lost to Follow-up|6
6102523|NCT00772005|9719456|FG003|Overall Study|Lost to Follow-up|3
6102524|NCT00772005|9719453|FG000|Overall Study|Non-compliance with study procedures|1
6102525|NCT00772005|9719454|FG001|Overall Study|Non-compliance with study procedures|1
6102526|NCT00772005|9719455|FG002|Overall Study|Non-compliance with study procedures|0
6102527|NCT00772005|9719456|FG003|Overall Study|Non-compliance with study procedures|1
6102528|NCT00772005|9719453|FG000|Overall Study|Non-compliance with drug administration|3
6102529|NCT00772005|9719454|FG001|Overall Study|Non-compliance with drug administration|0
6102530|NCT00772005|9719455|FG002|Overall Study|Non-compliance with drug administration|1
6102531|NCT00772005|9719456|FG003|Overall Study|Non-compliance with drug administration|1
6102532|NCT00772031|9719468|FG000|Overall Study|Early termination of trial|12
6102533|NCT00772031|9719469|FG001|Overall Study|Early termination of trial|10
6102534|NCT00772031|9719468|FG000|Overall Study|Lost to Follow-up|20
6102535|NCT00772031|9719469|FG001|Overall Study|Lost to Follow-up|33
6102536|NCT00772070|9719483|FG000|Overall Study|Lost to Follow-up|0
6102537|NCT00772070|9719484|FG001|Overall Study|Lost to Follow-up|8
6102538|NCT00772070|9719483|FG000|Overall Study|Withdrawal by Subject|0
6102539|NCT00772070|9719484|FG001|Overall Study|Withdrawal by Subject|2
6102540|NCT00772070|9719483|FG000|Overall Study|Vaccination error-wrong dose/expired lot|2
6102541|NCT00772070|9719484|FG001|Overall Study|Vaccination error-wrong dose/expired lot|0
6102542|NCT00772109|9719494|FG000|Overall Study|Serious adverse event|1
6102543|NCT00772109|9719495|FG001|Overall Study|Serious adverse event|0
6102544|NCT00772109|9719496|FG002|Overall Study|Serious adverse event|1
6102545|NCT00772109|9719497|FG003|Overall Study|Serious adverse event|0
6102546|NCT00772109|9719494|FG000|Overall Study|Protocol Violation|5
6102547|NCT00772109|9719495|FG001|Overall Study|Protocol Violation|8
6102548|NCT00772109|9719496|FG002|Overall Study|Protocol Violation|7
6102549|NCT00772109|9719497|FG003|Overall Study|Protocol Violation|6
6102550|NCT00772109|9719494|FG000|Overall Study|Lost to Follow-up|7
6102551|NCT00772109|9719495|FG001|Overall Study|Lost to Follow-up|3
6102552|NCT00772109|9719496|FG002|Overall Study|Lost to Follow-up|5
6102553|NCT00772109|9719497|FG003|Overall Study|Lost to Follow-up|9
6102554|NCT00772109|9719494|FG000|Overall Study|Withdrawal by Subject|8
6102555|NCT00772109|9719495|FG001|Overall Study|Withdrawal by Subject|8
6102556|NCT00772109|9719496|FG002|Overall Study|Withdrawal by Subject|6
6102557|NCT00772109|9719497|FG003|Overall Study|Withdrawal by Subject|16
6102558|NCT00772148|9719509|FG000|Pharmacokinetic Phase (14 Days)|Adverse Event|3
6102559|NCT00772148|9719510|FG001|Pharmacokinetic Phase (14 Days)|Adverse Event|1
6102560|NCT00772148|9719509|FG000|Pharmacokinetic Phase (14 Days)|Withdrawal by Subject|3
6102561|NCT00772148|9719510|FG001|Pharmacokinetic Phase (14 Days)|Withdrawal by Subject|5
6102562|NCT00772148|9719509|FG000|Pharmacokinetic Phase (14 Days)|Administrative/other|2
6102563|NCT00772148|9719510|FG001|Pharmacokinetic Phase (14 Days)|Administrative/other|0
6102564|NCT00772148|9719509|FG000|Maintenance Phase (Week 52)|Death|2
6102565|NCT00772148|9719510|FG001|Maintenance Phase (Week 52)|Death|2
6102566|NCT00772148|9719509|FG000|Maintenance Phase (Week 52)|Adverse Event|1
6102567|NCT00772148|9719510|FG001|Maintenance Phase (Week 52)|Adverse Event|0
6102568|NCT00772148|9719509|FG000|Maintenance Phase (Week 52)|Withdrawal by Subject|0
6102569|NCT00772148|9719510|FG001|Maintenance Phase (Week 52)|Withdrawal by Subject|1
6102570|NCT00772148|9719509|FG000|Maintenance Phase (Week 52)|Administrative/other|1
6102571|NCT00772148|9719510|FG001|Maintenance Phase (Week 52)|Administrative/other|2
6102572|NCT00772330|9719520|FG000|Overall Study|Lost to Follow-up|3
6102573|NCT00772369|9719527|FG000|Overall Study|Did not return record release form|1
6102574|NCT00772382|9719531|FG000|Overall Study|Adverse Event|19
6102575|NCT00772382|9719531|FG000|Overall Study|Death|6
6204900|NCT01526928|9866813|FG002|Overall Study|Adverse Event|29
6204901|NCT01526928|9866814|FG003|Overall Study|Adverse Event|40
6204902|NCT01526928|9866815|FG004|Overall Study|Adverse Event|13
6204903|NCT01526928|9866816|FG005|Overall Study|Adverse Event|2
6204904|NCT01526928|9866811|FG000|Overall Study|Death|0
6204905|NCT01526928|9866812|FG001|Overall Study|Death|0
6204906|NCT01526928|9866813|FG002|Overall Study|Death|3
6204907|NCT01526928|9866814|FG003|Overall Study|Death|0
6204908|NCT01526928|9866815|FG004|Overall Study|Death|0
6204909|NCT01526928|9866816|FG005|Overall Study|Death|0
6204910|NCT01526928|9866811|FG000|Overall Study|Withdrawal by Subject|1
6204911|NCT01526928|9866812|FG001|Overall Study|Withdrawal by Subject|0
6204912|NCT01526928|9866813|FG002|Overall Study|Withdrawal by Subject|13
6204913|NCT01526928|9866814|FG003|Overall Study|Withdrawal by Subject|11
6204914|NCT01526928|9866815|FG004|Overall Study|Withdrawal by Subject|3
6102576|NCT00772382|9719531|FG000|Overall Study|Lack of Efficacy|4
6102577|NCT00772382|9719531|FG000|Overall Study|Physician Decision|5
6102578|NCT00772382|9719531|FG000|Overall Study|Protocol Violation|1
6102579|NCT00772382|9719531|FG000|Overall Study|Withdrawal by Subject|10
6102580|NCT00772382|9719531|FG000|Overall Study|Other Reasons|10
6102581|NCT00772447|9719537|FG000|Overall Study|Withdrawal by Subject|9
6102582|NCT00772447|9719538|FG001|Overall Study|Withdrawal by Subject|5
6102583|NCT00772447|9719537|FG000|Overall Study|Physician Decision|4
6102584|NCT00772447|9719538|FG001|Overall Study|Physician Decision|8
6102585|NCT00772447|9719537|FG000|Overall Study|Lost to Follow-up|2
6102586|NCT00772447|9719538|FG001|Overall Study|Lost to Follow-up|4
6102587|NCT00772447|9719537|FG000|Overall Study|incorrect enrolment|3
6102588|NCT00772447|9719538|FG001|Overall Study|incorrect enrolment|4
6102589|NCT00772447|9719537|FG000|Overall Study|Protocol Violation|0
6102590|NCT00772447|9719538|FG001|Overall Study|Protocol Violation|1
6102591|NCT00772447|9719537|FG000|Overall Study|all others|2
6102592|NCT00772447|9719538|FG001|Overall Study|all others|2
6102593|NCT00772538|9719547|FG000|Overall Study|Adverse Event|6
6102594|NCT00772538|9719548|FG001|Overall Study|Adverse Event|6
6102595|NCT00772538|9719547|FG000|Overall Study|Protocol Violation|3
6102596|NCT00772538|9719548|FG001|Overall Study|Protocol Violation|3
6102597|NCT00772538|9719547|FG000|Overall Study|Lost to Follow-up|1
6102598|NCT00772538|9719548|FG001|Overall Study|Lost to Follow-up|1
6102599|NCT00772538|9719547|FG000|Overall Study|Withdrawal by Subject|3
6102600|NCT00772538|9719548|FG001|Overall Study|Withdrawal by Subject|8
6102601|NCT00772538|9719547|FG000|Overall Study|Lack of Efficacy|0
6102602|NCT00772538|9719548|FG001|Overall Study|Lack of Efficacy|1
6102603|NCT00772538|9719547|FG000|Overall Study|Other|7
6102604|NCT00772538|9719548|FG001|Overall Study|Other|7
6102605|NCT00772577|9719556|FG000|Overall Study|Adverse Event|6
6102606|NCT00772577|9719557|FG001|Overall Study|Adverse Event|3
6102607|NCT00772577|9719556|FG000|Overall Study|Abnormal laboratory values|0
6102608|NCT00772577|9719557|FG001|Overall Study|Abnormal laboratory values|1
6102609|NCT00772577|9719556|FG000|Overall Study|Unsatisfactory therapeutic effect|0
6102610|NCT00772577|9719557|FG001|Overall Study|Unsatisfactory therapeutic effect|8
6102611|NCT00772577|9719556|FG000|Overall Study|Patient withdrew consent|8
6102612|NCT00772577|9719557|FG001|Overall Study|Patient withdrew consent|5
6102613|NCT00772577|9719556|FG000|Overall Study|Lost to Follow-up|4
6102614|NCT00772577|9719557|FG001|Overall Study|Lost to Follow-up|3
6102615|NCT00772577|9719556|FG000|Overall Study|Administrative problems|2
6102616|NCT00772577|9719557|FG001|Overall Study|Administrative problems|1
6102617|NCT00772577|9719556|FG000|Overall Study|Protocol Deviation|3
6102618|NCT00772577|9719557|FG001|Overall Study|Protocol Deviation|2
6102619|NCT00772603|9719583|FG000|Overall Study|Withdrawal by Subject|11
6102620|NCT00772603|9719584|FG001|Overall Study|Withdrawal by Subject|10
6102621|NCT00772603|9719585|FG002|Overall Study|Withdrawal by Subject|6
6102622|NCT00772603|9719583|FG000|Overall Study|Adverse Event|37
6102623|NCT00772603|9719584|FG001|Overall Study|Adverse Event|18
6102624|NCT00772603|9719585|FG002|Overall Study|Adverse Event|10
6102625|NCT00772603|9719583|FG000|Overall Study|Subject Non-compliance|1
6102626|NCT00772603|9719584|FG001|Overall Study|Subject Non-compliance|6
6102627|NCT00772603|9719585|FG002|Overall Study|Subject Non-compliance|4
6102628|NCT00772603|9719583|FG000|Overall Study|Protocol Violation|0
6102629|NCT00772603|9719584|FG001|Overall Study|Protocol Violation|1
6102630|NCT00772603|9719585|FG002|Overall Study|Protocol Violation|1
6102631|NCT00772603|9719583|FG000|Overall Study|Lost to Follow-up|1
6102632|NCT00772603|9719584|FG001|Overall Study|Lost to Follow-up|5
6102633|NCT00772603|9719585|FG002|Overall Study|Lost to Follow-up|2
6102634|NCT00772603|9719583|FG000|Overall Study|Physician Decision|0
6102635|NCT00772603|9719584|FG001|Overall Study|Physician Decision|0
6102636|NCT00772603|9719585|FG002|Overall Study|Physician Decision|1
6102637|NCT00772603|9719583|FG000|Overall Study|Other|2
6102638|NCT00772603|9719584|FG001|Overall Study|Other|0
6102639|NCT00772603|9719585|FG002|Overall Study|Other|2
6102640|NCT00772629|9719598|FG000|Overall Study|Subject was not vaccinated|1
6102641|NCT00772629|9719599|FG001|Overall Study|Subject was not vaccinated|0
6102642|NCT00772668|9719605|FG000|Overall Study|Physician Decision|3
6102643|NCT00772707|9719610|FG000|Overall Study|Withdrawn|3
6102644|NCT00772889|9719622|FG000|Overall Study|Adverse Event|7
6102645|NCT00772889|9719623|FG001|Overall Study|Adverse Event|4
6102646|NCT00772889|9719624|FG002|Overall Study|Adverse Event|0
6102647|NCT00772889|9719622|FG000|Overall Study|Withdrawal by Subject|9
6102648|NCT00772889|9719623|FG001|Overall Study|Withdrawal by Subject|8
6102649|NCT00772889|9719624|FG002|Overall Study|Withdrawal by Subject|9
6102650|NCT00772889|9719622|FG000|Overall Study|Lost to Follow-up|6
6102651|NCT00772889|9719623|FG001|Overall Study|Lost to Follow-up|6
6102652|NCT00772889|9719624|FG002|Overall Study|Lost to Follow-up|7
6102653|NCT00772928|9719638|FG000|Overall Study|Lost to Follow-up|9
6102654|NCT00772928|9719639|FG001|Overall Study|Lost to Follow-up|6
6102655|NCT00772928|9719638|FG000|Overall Study|Protocol Violation|10
6102656|NCT00772928|9719639|FG001|Overall Study|Protocol Violation|12
6102657|NCT00772928|9719638|FG000|Overall Study|Withdrawal by Subject|25
6102658|NCT00772928|9719639|FG001|Overall Study|Withdrawal by Subject|22
6102659|NCT00772928|9719638|FG000|Overall Study|Did not receive vaccine|0
6102660|NCT00772928|9719639|FG001|Overall Study|Did not receive vaccine|1
6102661|NCT00772941|9719645|FG000|Overall Study|CRFs not available|195
6102662|NCT00772941|9719645|FG000|Overall Study|Study not completed|16
6102663|NCT00772941|9719645|FG000|Overall Study|Missed Visits|374
6102664|NCT00772941|9719645|FG000|Overall Study|Poor Compliance|7
6102665|NCT00772941|9719645|FG000|Overall Study|GPSP Violation|90
6102666|NCT00772954|9719675|FG000|Overall Study|Adverse Event|0
6102667|NCT00772954|9719676|FG001|Overall Study|Adverse Event|0
6102668|NCT00772954|9719677|FG002|Overall Study|Adverse Event|1
6102669|NCT00772967|9719685|FG000|Crossover Treatment 1|Adverse Event (Pain)|0
6102670|NCT00772967|9719686|FG001|Crossover Treatment 1|Adverse Event (Pain)|0
6102671|NCT00772967|9719687|FG002|Crossover Treatment 1|Adverse Event (Pain)|0
6102672|NCT00772967|9719688|FG003|Crossover Treatment 1|Adverse Event (Pain)|1
6102673|NCT00772967|9719689|FG004|Crossover Treatment 1|Adverse Event (Pain)|0
6102674|NCT00772967|9719690|FG005|Crossover Treatment 1|Adverse Event (Pain)|0
6102675|NCT00772967|9719685|FG000|Break 1 (4-7 Days)|Withdrawal by Subject|0
6102676|NCT00772967|9719686|FG001|Break 1 (4-7 Days)|Withdrawal by Subject|1
6102677|NCT00772967|9719687|FG002|Break 1 (4-7 Days)|Withdrawal by Subject|0
6102678|NCT00772967|9719688|FG003|Break 1 (4-7 Days)|Withdrawal by Subject|0
6102679|NCT00772967|9719689|FG004|Break 1 (4-7 Days)|Withdrawal by Subject|0
6102680|NCT00772967|9719690|FG005|Break 1 (4-7 Days)|Withdrawal by Subject|0
6102681|NCT00772967|9719685|FG000|Crossover Treatment 3|Adverse Event|0
6102682|NCT00772967|9719686|FG001|Crossover Treatment 3|Adverse Event|0
6102683|NCT00772967|9719687|FG002|Crossover Treatment 3|Adverse Event|0
6102684|NCT00772967|9719688|FG003|Crossover Treatment 3|Adverse Event|0
6102685|NCT00772967|9719689|FG004|Crossover Treatment 3|Adverse Event|1
6102686|NCT00772967|9719690|FG005|Crossover Treatment 3|Adverse Event|0
6102687|NCT00773097|9719698|FG000|Overall Study|Withdrawal by Subject|1
6102688|NCT00773097|9719698|FG000|Overall Study|Physician Decision|6
6204915|NCT01526928|9866816|FG005|Overall Study|Withdrawal by Subject|0
6204916|NCT01526928|9866811|FG000|Overall Study|Physician Decision|0
6204917|NCT01526928|9866812|FG001|Overall Study|Physician Decision|0
6204918|NCT01526928|9866813|FG002|Overall Study|Physician Decision|2
6204919|NCT01526928|9866814|FG003|Overall Study|Physician Decision|5
6204920|NCT01526928|9866815|FG004|Overall Study|Physician Decision|0
6204921|NCT01526928|9866816|FG005|Overall Study|Physician Decision|0
6204922|NCT01526928|9866811|FG000|Overall Study|Other Reason|0
6204923|NCT01526928|9866812|FG001|Overall Study|Other Reason|1
6204924|NCT01526928|9866813|FG002|Overall Study|Other Reason|11
6204925|NCT01526928|9866814|FG003|Overall Study|Other Reason|4
6204926|NCT01526928|9866815|FG004|Overall Study|Other Reason|1
6204927|NCT01526928|9866816|FG005|Overall Study|Other Reason|0
6204928|NCT01526928|9866811|FG000|Overall Study|Lost to Follow-up|0
6204929|NCT01526928|9866812|FG001|Overall Study|Lost to Follow-up|0
6204930|NCT01526928|9866813|FG002|Overall Study|Lost to Follow-up|0
6204931|NCT01526928|9866814|FG003|Overall Study|Lost to Follow-up|1
6204932|NCT01526928|9866815|FG004|Overall Study|Lost to Follow-up|0
6204933|NCT01526928|9866816|FG005|Overall Study|Lost to Follow-up|0
6204934|NCT01526928|9866811|FG000|Overall Study|Protocol Deviation|0
6204935|NCT01526928|9866812|FG001|Overall Study|Protocol Deviation|0
6204936|NCT01526928|9866813|FG002|Overall Study|Protocol Deviation|0
6284975|NCT02327169|9996515|FG013|Overall Study|Lost to Follow-up|0
6284976|NCT02327169|9996516|FG014|Overall Study|Lost to Follow-up|0
6284977|NCT02327260|9996561|FG000|Overall Study|Lost to Follow-up|2
6284978|NCT02327260|9996562|FG001|Overall Study|Lost to Follow-up|3
6284979|NCT02327260|9996563|FG002|Overall Study|Lost to Follow-up|2
6284980|NCT02327260|9996561|FG000|Overall Study|invalid phone number|1
6284981|NCT02327260|9996562|FG001|Overall Study|invalid phone number|1
6284982|NCT02327260|9996563|FG002|Overall Study|invalid phone number|0
6284983|NCT02327260|9996561|FG000|Overall Study|non-adherence to protocol|2
6284984|NCT02327260|9996562|FG001|Overall Study|non-adherence to protocol|0
6284985|NCT02327260|9996563|FG002|Overall Study|non-adherence to protocol|0
6284986|NCT02327260|9996561|FG000|Overall Study|cognitive concerns|1
6284987|NCT02327260|9996562|FG001|Overall Study|cognitive concerns|0
6284988|NCT02327260|9996563|FG002|Overall Study|cognitive concerns|0
6284989|NCT02327325|9996575|FG000|Overall Study|Withdrawal by Subject|1
6284990|NCT02327325|9996576|FG001|Overall Study|Withdrawal by Subject|4
6284991|NCT02327325|9996577|FG002|Overall Study|Withdrawal by Subject|4
6284992|NCT02327325|9996575|FG000|Overall Study|Excluded by Study Team|0
6284993|NCT02327325|9996576|FG001|Overall Study|Excluded by Study Team|0
6284994|NCT02327325|9996577|FG002|Overall Study|Excluded by Study Team|1
6284995|NCT02328027|9996608|FG000|Overall Study|Withdrawal by Subject|0
6284996|NCT02328027|9996609|FG001|Overall Study|Withdrawal by Subject|1
6284997|NCT02328040|9996616|FG000|First Intervention (2 Days)|Withdrawal by Subject|1
6284998|NCT02328040|9996617|FG001|First Intervention (2 Days)|Withdrawal by Subject|1
6284999|NCT02328326|9996625|FG000|Overall Study|Withdrawal by Subject|10
6285000|NCT02328326|9996626|FG001|Overall Study|Withdrawal by Subject|3
6285001|NCT02328326|9996625|FG000|Overall Study|Death|2
6285002|NCT02328326|9996626|FG001|Overall Study|Death|1
6285003|NCT02328326|9996625|FG000|Overall Study|Lost to Follow-up|10
6285004|NCT02328326|9996626|FG001|Overall Study|Lost to Follow-up|4
6285005|NCT02328547|9996649|FG000|First Intervention (12 Weeks)|Lost to Follow-up|1
6285006|NCT02328547|9996650|FG001|First Intervention (12 Weeks)|Lost to Follow-up|0
6102689|NCT00773136|9719702|FG000|Overall Study|Physician Decision|2
6204937|NCT01526928|9866814|FG003|Overall Study|Protocol Deviation|2
6102690|NCT00773175|9719709|FG000|Overall Study|Adverse Event|2
6102691|NCT00773175|9719710|FG001|Overall Study|Adverse Event|0
6102692|NCT00773175|9719709|FG000|Overall Study|Consent Withdrawn|0
6102693|NCT00773175|9719710|FG001|Overall Study|Consent Withdrawn|2
6102694|NCT00773253|9719723|FG000|First Intervention (Week 0-24)|Frontalis Test Negative|0
6102695|NCT00773253|9719724|FG001|First Intervention (Week 0-24)|Frontalis Test Negative|1
6102696|NCT00773279|9719732|FG000|Period 1|Adverse Event|2
6102697|NCT00773279|9719733|FG001|Period 1|Adverse Event|1
6102698|NCT00773279|9719732|FG000|Period 1|Lack of Efficacy|0
6102699|NCT00773279|9719733|FG001|Period 1|Lack of Efficacy|2
6102700|NCT00773279|9719732|FG000|Period 1|Unclassified|5
6102701|NCT00773279|9719733|FG001|Period 1|Unclassified|1
6102702|NCT00773279|9719732|FG000|Period 2|Adverse Event|0
6102703|NCT00773279|9719733|FG001|Period 2|Adverse Event|1
6102704|NCT00773279|9719732|FG000|Period 2|Lack of Efficacy|1
6102705|NCT00773279|9719733|FG001|Period 2|Lack of Efficacy|0
6102706|NCT00773279|9719732|FG000|Period 2|Protocol Violation|0
6102707|NCT00773279|9719733|FG001|Period 2|Protocol Violation|3
6102708|NCT00773279|9719732|FG000|Period 2|Unclassified|2
6102709|NCT00773279|9719733|FG001|Period 2|Unclassified|2
6102710|NCT00773292|9719740|FG000|Treatment 48 Weeks|Adverse Event|1
6102711|NCT00773292|9719740|FG000|Treatment 48 Weeks|Lack of Efficacy|1
6102712|NCT00773383|9719753|FG000|Overall Study|Adverse Event|4
6102713|NCT00773383|9719753|FG000|Overall Study|Death|1
6102714|NCT00773383|9719753|FG000|Overall Study|Progression of Disease|23
6102715|NCT00773383|9719753|FG000|Overall Study|Other|2
6102716|NCT00773383|9719753|FG000|Overall Study|No study dose received|1
6102717|NCT00773461|9719776|FG000|Overall Study|Adverse Event|1
6102718|NCT00773461|9719777|FG001|Overall Study|Adverse Event|3
6102719|NCT00773461|9719776|FG000|Overall Study|Withdrawal by Subject|4
6285007|NCT02328547|9996649|FG000|First Intervention (12 Weeks)|Withdrawal by Subject|2
6285008|NCT02328547|9996650|FG001|First Intervention (12 Weeks)|Withdrawal by Subject|0
6285009|NCT02328937|9996683|FG000|Period 1|Lost to Follow-up|0
6285010|NCT02328937|9996684|FG001|Period 1|Lost to Follow-up|0
6285011|NCT02328937|9996685|FG002|Period 1|Lost to Follow-up|0
6285012|NCT02328937|9996686|FG003|Period 1|Lost to Follow-up|1
6285013|NCT02328937|9996687|FG004|Period 1|Lost to Follow-up|0
6285014|NCT02328937|9996688|FG005|Period 1|Lost to Follow-up|0
6285015|NCT02328937|9996683|FG000|Period 2|Adverse Event|0
6285016|NCT02328937|9996684|FG001|Period 2|Adverse Event|0
6285017|NCT02328937|9996685|FG002|Period 2|Adverse Event|1
6285018|NCT02328937|9996686|FG003|Period 2|Adverse Event|0
6285019|NCT02328937|9996687|FG004|Period 2|Adverse Event|0
6285020|NCT02328937|9996688|FG005|Period 2|Adverse Event|0
6285021|NCT02329223|9996708|FG000|Overall Study|Withdrawal by Subject|1
6285022|NCT02329223|9996709|FG001|Overall Study|Withdrawal by Subject|2
6285023|NCT02329223|9996710|FG002|Overall Study|Withdrawal by Subject|5
6285024|NCT02329223|9996708|FG000|Overall Study|Physician Decision|0
6285025|NCT02329223|9996709|FG001|Overall Study|Physician Decision|0
6285026|NCT02329223|9996710|FG002|Overall Study|Physician Decision|1
6285027|NCT02329223|9996708|FG000|Overall Study|Adverse Event|0
6285028|NCT02329223|9996709|FG001|Overall Study|Adverse Event|1
6285029|NCT02329223|9996710|FG002|Overall Study|Adverse Event|0
6102720|NCT00773461|9719777|FG001|Overall Study|Withdrawal by Subject|1
6102721|NCT00773513|9719790|FG000|Overall Study|Renal Transplant|254
6102722|NCT00773513|9719791|FG001|Overall Study|Renal Transplant|263
6102723|NCT00773513|9719790|FG000|Overall Study|Adverse Event / Intercurrent Illness|40
6102724|NCT00773513|9719791|FG001|Overall Study|Adverse Event / Intercurrent Illness|48
6102725|NCT00773513|9719790|FG000|Overall Study|Withdrew Consent|68
6102726|NCT00773513|9719791|FG001|Overall Study|Withdrew Consent|69
6102727|NCT00773513|9719790|FG000|Overall Study|Refused Treatment / Did not Cooperate|26
6102728|NCT00773513|9719791|FG001|Overall Study|Refused Treatment / Did not Cooperate|32
6102729|NCT00773513|9719790|FG000|Overall Study|Failure to Return|22
6102730|NCT00773513|9719791|FG001|Overall Study|Failure to Return|8
6102731|NCT00773513|9719790|FG000|Overall Study|Insufficient Therapeutic Response|1
6102732|NCT00773513|9719791|FG001|Overall Study|Insufficient Therapeutic Response|18
6102733|NCT00773513|9719790|FG000|Overall Study|Reason Not Specified|159
6102734|NCT00773513|9719791|FG001|Overall Study|Reason Not Specified|126
6102735|NCT00773513|9719790|FG000|Overall Study|Death|531
6102736|NCT00773513|9719791|FG001|Overall Study|Death|545
6102737|NCT00773734|9719805|FG000|Core: Placebo Controlled Phase Week 0-16|Adverse Event|5
6102738|NCT00773734|9719806|FG001|Core: Placebo Controlled Phase Week 0-16|Adverse Event|1
6102739|NCT00773734|9719807|FG002|Core: Placebo Controlled Phase Week 0-16|Adverse Event|8
6102740|NCT00773734|9719808|FG003|Core: Placebo Controlled Phase Week 0-16|Adverse Event|10
6102741|NCT00773734|9719809|FG004|Core: Placebo Controlled Phase Week 0-16|Adverse Event|0
6102742|NCT00773734|9719810|FG005|Core: Placebo Controlled Phase Week 0-16|Adverse Event|0
6102743|NCT00773734|9719805|FG000|Core: Placebo Controlled Phase Week 0-16|Lack of Efficacy|4
6285030|NCT02329431|9996720|FG000|Overall Study|Lost to Follow-up|20
6102744|NCT00773734|9719806|FG001|Core: Placebo Controlled Phase Week 0-16|Lack of Efficacy|3
6102745|NCT00773734|9719807|FG002|Core: Placebo Controlled Phase Week 0-16|Lack of Efficacy|2
6102746|NCT00773734|9719808|FG003|Core: Placebo Controlled Phase Week 0-16|Lack of Efficacy|2
6102747|NCT00773734|9719809|FG004|Core: Placebo Controlled Phase Week 0-16|Lack of Efficacy|0
6285031|NCT02329431|9996721|FG001|Overall Study|Lost to Follow-up|13
6285032|NCT02329730|9996753|FG000|Overall Study|Protocol Violation|0
6102748|NCT00773734|9719810|FG005|Core: Placebo Controlled Phase Week 0-16|Lack of Efficacy|0
6102749|NCT00773734|9719805|FG000|Core: Placebo Controlled Phase Week 0-16|Withdrawal by Subject|2
6102750|NCT00773734|9719806|FG001|Core: Placebo Controlled Phase Week 0-16|Withdrawal by Subject|2
6102751|NCT00773734|9719807|FG002|Core: Placebo Controlled Phase Week 0-16|Withdrawal by Subject|6
6102752|NCT00773734|9719808|FG003|Core: Placebo Controlled Phase Week 0-16|Withdrawal by Subject|4
6102753|NCT00773734|9719809|FG004|Core: Placebo Controlled Phase Week 0-16|Withdrawal by Subject|0
6102754|NCT00773734|9719810|FG005|Core: Placebo Controlled Phase Week 0-16|Withdrawal by Subject|0
6102755|NCT00773734|9719805|FG000|Core: Placebo Controlled Phase Week 0-16|Death|1
6102756|NCT00773734|9719806|FG001|Core: Placebo Controlled Phase Week 0-16|Death|0
6102757|NCT00773734|9719807|FG002|Core: Placebo Controlled Phase Week 0-16|Death|0
6102758|NCT00773734|9719808|FG003|Core: Placebo Controlled Phase Week 0-16|Death|0
6102759|NCT00773734|9719809|FG004|Core: Placebo Controlled Phase Week 0-16|Death|0
6102760|NCT00773734|9719810|FG005|Core: Placebo Controlled Phase Week 0-16|Death|0
6102761|NCT00773734|9719805|FG000|Core: Placebo Controlled Phase Week 0-16|Lost to Follow-up|2
6102762|NCT00773734|9719806|FG001|Core: Placebo Controlled Phase Week 0-16|Lost to Follow-up|0
6102763|NCT00773734|9719807|FG002|Core: Placebo Controlled Phase Week 0-16|Lost to Follow-up|0
6102764|NCT00773734|9719808|FG003|Core: Placebo Controlled Phase Week 0-16|Lost to Follow-up|1
6102765|NCT00773734|9719809|FG004|Core: Placebo Controlled Phase Week 0-16|Lost to Follow-up|0
6102766|NCT00773734|9719810|FG005|Core: Placebo Controlled Phase Week 0-16|Lost to Follow-up|0
6102767|NCT00773734|9719805|FG000|Core: Placebo Controlled Phase Week 0-16|Protocol Violation|1
6102768|NCT00773734|9719806|FG001|Core: Placebo Controlled Phase Week 0-16|Protocol Violation|3
6102769|NCT00773734|9719807|FG002|Core: Placebo Controlled Phase Week 0-16|Protocol Violation|4
6102770|NCT00773734|9719808|FG003|Core: Placebo Controlled Phase Week 0-16|Protocol Violation|0
6102771|NCT00773734|9719809|FG004|Core: Placebo Controlled Phase Week 0-16|Protocol Violation|0
6102772|NCT00773734|9719810|FG005|Core: Placebo Controlled Phase Week 0-16|Protocol Violation|0
6102773|NCT00773734|9719805|FG000|Core: Placebo Controlled Phase Week 0-16|Other|1
6102774|NCT00773734|9719806|FG001|Core: Placebo Controlled Phase Week 0-16|Other|1
6102775|NCT00773734|9719807|FG002|Core: Placebo Controlled Phase Week 0-16|Other|1
6102776|NCT00773734|9719808|FG003|Core: Placebo Controlled Phase Week 0-16|Other|1
6102777|NCT00773734|9719809|FG004|Core: Placebo Controlled Phase Week 0-16|Other|0
6102778|NCT00773734|9719810|FG005|Core: Placebo Controlled Phase Week 0-16|Other|0
6102779|NCT00773734|9719805|FG000|Core: Active Treatment Phase Week 16-24|Adverse Event|0
6102780|NCT00773734|9719806|FG001|Core: Active Treatment Phase Week 16-24|Adverse Event|4
6102781|NCT00773734|9719807|FG002|Core: Active Treatment Phase Week 16-24|Adverse Event|0
6102782|NCT00773734|9719808|FG003|Core: Active Treatment Phase Week 16-24|Adverse Event|0
6102783|NCT00773734|9719809|FG004|Core: Active Treatment Phase Week 16-24|Adverse Event|1
6102784|NCT00773734|9719810|FG005|Core: Active Treatment Phase Week 16-24|Adverse Event|2
6102785|NCT00773734|9719805|FG000|Core: Active Treatment Phase Week 16-24|Lack of Efficacy|0
6102786|NCT00773734|9719806|FG001|Core: Active Treatment Phase Week 16-24|Lack of Efficacy|4
6102787|NCT00773734|9719807|FG002|Core: Active Treatment Phase Week 16-24|Lack of Efficacy|4
6102788|NCT00773734|9719808|FG003|Core: Active Treatment Phase Week 16-24|Lack of Efficacy|1
6102789|NCT00773734|9719809|FG004|Core: Active Treatment Phase Week 16-24|Lack of Efficacy|0
6102790|NCT00773734|9719810|FG005|Core: Active Treatment Phase Week 16-24|Lack of Efficacy|0
6102791|NCT00773734|9719805|FG000|Core: Active Treatment Phase Week 16-24|Withdrawal by Subject|0
6102792|NCT00773734|9719806|FG001|Core: Active Treatment Phase Week 16-24|Withdrawal by Subject|1
6102793|NCT00773734|9719807|FG002|Core: Active Treatment Phase Week 16-24|Withdrawal by Subject|1
6102794|NCT00773734|9719808|FG003|Core: Active Treatment Phase Week 16-24|Withdrawal by Subject|0
6102795|NCT00773734|9719809|FG004|Core: Active Treatment Phase Week 16-24|Withdrawal by Subject|0
6102796|NCT00773734|9719810|FG005|Core: Active Treatment Phase Week 16-24|Withdrawal by Subject|2
6102797|NCT00773734|9719805|FG000|Core: Active Treatment Phase Week 16-24|Lost to Follow-up|0
6102798|NCT00773734|9719806|FG001|Core: Active Treatment Phase Week 16-24|Lost to Follow-up|1
6102799|NCT00773734|9719807|FG002|Core: Active Treatment Phase Week 16-24|Lost to Follow-up|1
6102800|NCT00773734|9719808|FG003|Core: Active Treatment Phase Week 16-24|Lost to Follow-up|0
6102801|NCT00773734|9719809|FG004|Core: Active Treatment Phase Week 16-24|Lost to Follow-up|0
6102802|NCT00773734|9719810|FG005|Core: Active Treatment Phase Week 16-24|Lost to Follow-up|0
6102803|NCT00773734|9719805|FG000|Core: Active Treatment Phase Week 16-24|Protocol Violation|0
6102804|NCT00773734|9719806|FG001|Core: Active Treatment Phase Week 16-24|Protocol Violation|1
6102805|NCT00773734|9719807|FG002|Core: Active Treatment Phase Week 16-24|Protocol Violation|1
6102806|NCT00773734|9719808|FG003|Core: Active Treatment Phase Week 16-24|Protocol Violation|1
6102807|NCT00773734|9719809|FG004|Core: Active Treatment Phase Week 16-24|Protocol Violation|0
6102808|NCT00773734|9719810|FG005|Core: Active Treatment Phase Week 16-24|Protocol Violation|1
6102809|NCT00773734|9719805|FG000|Core: Active Treatment Phase Week 16-24|Other|0
6102810|NCT00773734|9719806|FG001|Core: Active Treatment Phase Week 16-24|Other|1
6102811|NCT00773734|9719807|FG002|Core: Active Treatment Phase Week 16-24|Other|0
6102812|NCT00773734|9719808|FG003|Core: Active Treatment Phase Week 16-24|Other|0
6102813|NCT00773734|9719809|FG004|Core: Active Treatment Phase Week 16-24|Other|0
6102814|NCT00773734|9719810|FG005|Core: Active Treatment Phase Week 16-24|Other|0
6102815|NCT00773734|9719805|FG000|Extension: Active Treatment Week 24-52|Adverse Event|0
6102816|NCT00773734|9719806|FG001|Extension: Active Treatment Week 24-52|Adverse Event|0
6102817|NCT00773734|9719807|FG002|Extension: Active Treatment Week 24-52|Adverse Event|0
6102818|NCT00773734|9719808|FG003|Extension: Active Treatment Week 24-52|Adverse Event|0
6102819|NCT00773734|9719809|FG004|Extension: Active Treatment Week 24-52|Adverse Event|2
6102820|NCT00773734|9719810|FG005|Extension: Active Treatment Week 24-52|Adverse Event|1
6102821|NCT00773734|9719805|FG000|Extension: Active Treatment Week 24-52|Lack of Efficacy|0
6102822|NCT00773734|9719806|FG001|Extension: Active Treatment Week 24-52|Lack of Efficacy|8
6102823|NCT00773734|9719807|FG002|Extension: Active Treatment Week 24-52|Lack of Efficacy|10
6102824|NCT00773734|9719808|FG003|Extension: Active Treatment Week 24-52|Lack of Efficacy|3
6102825|NCT00773734|9719809|FG004|Extension: Active Treatment Week 24-52|Lack of Efficacy|1
6102826|NCT00773734|9719810|FG005|Extension: Active Treatment Week 24-52|Lack of Efficacy|2
6102827|NCT00773734|9719805|FG000|Extension: Active Treatment Week 24-52|Withdrawal by Subject|0
6102828|NCT00773734|9719806|FG001|Extension: Active Treatment Week 24-52|Withdrawal by Subject|3
6102829|NCT00773734|9719807|FG002|Extension: Active Treatment Week 24-52|Withdrawal by Subject|1
6102830|NCT00773734|9719808|FG003|Extension: Active Treatment Week 24-52|Withdrawal by Subject|2
6102831|NCT00773734|9719809|FG004|Extension: Active Treatment Week 24-52|Withdrawal by Subject|2
6102832|NCT00773734|9719810|FG005|Extension: Active Treatment Week 24-52|Withdrawal by Subject|3
6102833|NCT00773734|9719805|FG000|Extension: Active Treatment Week 24-52|Lost to Follow-up|0
6102834|NCT00773734|9719806|FG001|Extension: Active Treatment Week 24-52|Lost to Follow-up|2
6102835|NCT00773734|9719807|FG002|Extension: Active Treatment Week 24-52|Lost to Follow-up|5
6102836|NCT00773734|9719808|FG003|Extension: Active Treatment Week 24-52|Lost to Follow-up|3
6102837|NCT00773734|9719809|FG004|Extension: Active Treatment Week 24-52|Lost to Follow-up|0
6102838|NCT00773734|9719810|FG005|Extension: Active Treatment Week 24-52|Lost to Follow-up|1
6102839|NCT00773734|9719805|FG000|Extension: Active Treatment Week 24-52|Other|0
6102840|NCT00773734|9719806|FG001|Extension: Active Treatment Week 24-52|Other|0
6102841|NCT00773734|9719807|FG002|Extension: Active Treatment Week 24-52|Other|1
6102842|NCT00773734|9719808|FG003|Extension: Active Treatment Week 24-52|Other|2
6102843|NCT00773734|9719809|FG004|Extension: Active Treatment Week 24-52|Other|0
6102844|NCT00773734|9719810|FG005|Extension: Active Treatment Week 24-52|Other|1
6102845|NCT00773734|9719805|FG000|LTE Period: Week 52 to 6 Years|Adverse Event|0
6102846|NCT00773734|9719806|FG001|LTE Period: Week 52 to 6 Years|Adverse Event|0
6102847|NCT00773734|9719807|FG002|LTE Period: Week 52 to 6 Years|Adverse Event|0
6102848|NCT00773734|9719808|FG003|LTE Period: Week 52 to 6 Years|Adverse Event|1
6102849|NCT00773734|9719809|FG004|LTE Period: Week 52 to 6 Years|Adverse Event|0
6102850|NCT00773734|9719810|FG005|LTE Period: Week 52 to 6 Years|Adverse Event|0
6102851|NCT00773734|9719805|FG000|LTE Period: Week 52 to 6 Years|Lack of Efficacy|0
6102852|NCT00773734|9719806|FG001|LTE Period: Week 52 to 6 Years|Lack of Efficacy|0
6102853|NCT00773734|9719807|FG002|LTE Period: Week 52 to 6 Years|Lack of Efficacy|2
6102854|NCT00773734|9719808|FG003|LTE Period: Week 52 to 6 Years|Lack of Efficacy|4
6102855|NCT00773734|9719809|FG004|LTE Period: Week 52 to 6 Years|Lack of Efficacy|0
6102856|NCT00773734|9719810|FG005|LTE Period: Week 52 to 6 Years|Lack of Efficacy|0
6102857|NCT00773734|9719805|FG000|LTE Period: Week 52 to 6 Years|Withdrawal by Subject|0
6102858|NCT00773734|9719806|FG001|LTE Period: Week 52 to 6 Years|Withdrawal by Subject|0
6102859|NCT00773734|9719807|FG002|LTE Period: Week 52 to 6 Years|Withdrawal by Subject|6
6102860|NCT00773734|9719808|FG003|LTE Period: Week 52 to 6 Years|Withdrawal by Subject|3
6102861|NCT00773734|9719809|FG004|LTE Period: Week 52 to 6 Years|Withdrawal by Subject|0
6102862|NCT00773734|9719810|FG005|LTE Period: Week 52 to 6 Years|Withdrawal by Subject|0
6102863|NCT00773734|9719805|FG000|LTE Period: Week 52 to 6 Years|Lost to Follow-up|0
6102864|NCT00773734|9719806|FG001|LTE Period: Week 52 to 6 Years|Lost to Follow-up|0
6102865|NCT00773734|9719807|FG002|LTE Period: Week 52 to 6 Years|Lost to Follow-up|4
6102866|NCT00773734|9719808|FG003|LTE Period: Week 52 to 6 Years|Lost to Follow-up|4
6102867|NCT00773734|9719809|FG004|LTE Period: Week 52 to 6 Years|Lost to Follow-up|0
6102868|NCT00773734|9719810|FG005|LTE Period: Week 52 to 6 Years|Lost to Follow-up|0
6102869|NCT00773747|9719869|FG000|Overall Study|Lack of Efficacy|112
6102870|NCT00773747|9719870|FG001|Overall Study|Lack of Efficacy|144
6102871|NCT00773747|9719869|FG000|Overall Study|Physician Decision|26
6102872|NCT00773747|9719870|FG001|Overall Study|Physician Decision|18
6102873|NCT00773747|9719869|FG000|Overall Study|Lost to Follow-up|0
6102874|NCT00773747|9719870|FG001|Overall Study|Lost to Follow-up|1
6102875|NCT00773747|9719869|FG000|Overall Study|Protocol Violation|2
6102876|NCT00773747|9719870|FG001|Overall Study|Protocol Violation|2
6102877|NCT00773747|9719869|FG000|Overall Study|Withdrawal by Subject|89
6102878|NCT00773747|9719870|FG001|Overall Study|Withdrawal by Subject|61
6102879|NCT00773747|9719869|FG000|Overall Study|Adverse Event|61
6102880|NCT00773747|9719870|FG001|Overall Study|Adverse Event|62
6102881|NCT00773747|9719869|FG000|Overall Study|Death|5
6102882|NCT00773747|9719870|FG001|Overall Study|Death|8
6102883|NCT00773747|9719869|FG000|Overall Study|Not Treated|2
6102884|NCT00773747|9719870|FG001|Overall Study|Not Treated|0
6204938|NCT01526928|9866815|FG004|Overall Study|Protocol Deviation|0
6204939|NCT01526928|9866816|FG005|Overall Study|Protocol Deviation|0
6204940|NCT01526928|9866811|FG000|Overall Study|Missing|0
6204941|NCT01526928|9866812|FG001|Overall Study|Missing|0
6204942|NCT01526928|9866813|FG002|Overall Study|Missing|1
6204943|NCT01526928|9866814|FG003|Overall Study|Missing|0
6204944|NCT01526928|9866815|FG004|Overall Study|Missing|2
6102885|NCT00773838|9719884|FG000|Overall Study|Adverse Event|29
6102886|NCT00773838|9719884|FG000|Overall Study|Lost to Follow-up|1
6102887|NCT00773838|9719884|FG000|Overall Study|Physician Decision|8
6102888|NCT00773838|9719884|FG000|Overall Study|Progressive Disease|82
6102889|NCT00773838|9719884|FG000|Overall Study|Protocol Violation|2
6102890|NCT00773838|9719884|FG000|Overall Study|Withdrawal by Subject|21
6102891|NCT00773968|9719892|FG000|Overall Study|Adverse Event|2
6102892|NCT00773968|9719892|FG000|Overall Study|Death|1
6102893|NCT00773968|9719892|FG000|Overall Study|Failure to Return|2
6102894|NCT00773968|9719892|FG000|Overall Study|Lack of Efficacy|3
6102895|NCT00773968|9719892|FG000|Overall Study|Protocol Violation|1
6102896|NCT00773968|9719892|FG000|Overall Study|Withdrawal by Subject|11
6102897|NCT00773968|9719892|FG000|Overall Study|Screen Failure|17
6102898|NCT00773968|9719892|FG000|Overall Study|Other|8
6102899|NCT00774046|9719896|FG000|Screening|Not eligible|56
6102900|NCT00774046|9719896|FG000|Enrollment|Desired other therapy/refused|28
6102901|NCT00774046|9719896|FG000|Stem Cell Mobilization|Count too low (2), sudden death (1)|3
6102902|NCT00774397|9719946|FG000|Overall Study|Adverse Event|1
6102903|NCT00774397|9719947|FG001|Overall Study|Adverse Event|3
6102904|NCT00774397|9719948|FG002|Overall Study|Adverse Event|16
6102905|NCT00774397|9719949|FG003|Overall Study|Adverse Event|8
6102906|NCT00774397|9719950|FG004|Overall Study|Adverse Event|8
6102907|NCT00774397|9719951|FG005|Overall Study|Adverse Event|3
6102908|NCT00774397|9719952|FG006|Overall Study|Adverse Event|16
6102909|NCT00774397|9719946|FG000|Overall Study|Lack of Efficacy|11
6102910|NCT00774397|9719947|FG001|Overall Study|Lack of Efficacy|4
6102911|NCT00774397|9719948|FG002|Overall Study|Lack of Efficacy|5
6102912|NCT00774397|9719949|FG003|Overall Study|Lack of Efficacy|3
6102913|NCT00774397|9719950|FG004|Overall Study|Lack of Efficacy|27
6102914|NCT00774397|9719951|FG005|Overall Study|Lack of Efficacy|15
6102915|NCT00774397|9719952|FG006|Overall Study|Lack of Efficacy|9
6102916|NCT00774397|9719946|FG000|Overall Study|Protocol Violation|0
6102917|NCT00774397|9719947|FG001|Overall Study|Protocol Violation|1
6102918|NCT00774397|9719948|FG002|Overall Study|Protocol Violation|3
6102919|NCT00774397|9719949|FG003|Overall Study|Protocol Violation|1
6102920|NCT00774397|9719950|FG004|Overall Study|Protocol Violation|2
6102921|NCT00774397|9719951|FG005|Overall Study|Protocol Violation|1
6102922|NCT00774397|9719952|FG006|Overall Study|Protocol Violation|0
6102923|NCT00774397|9719946|FG000|Overall Study|Lost to Follow-up|0
6102924|NCT00774397|9719947|FG001|Overall Study|Lost to Follow-up|1
6102925|NCT00774397|9719948|FG002|Overall Study|Lost to Follow-up|1
6102926|NCT00774397|9719949|FG003|Overall Study|Lost to Follow-up|1
6102927|NCT00774397|9719950|FG004|Overall Study|Lost to Follow-up|0
6102928|NCT00774397|9719951|FG005|Overall Study|Lost to Follow-up|1
6102929|NCT00774397|9719952|FG006|Overall Study|Lost to Follow-up|0
6102930|NCT00774397|9719946|FG000|Overall Study|Refused to continue trial medication|1
6102931|NCT00774397|9719947|FG001|Overall Study|Refused to continue trial medication|3
6102932|NCT00774397|9719948|FG002|Overall Study|Refused to continue trial medication|2
6102933|NCT00774397|9719949|FG003|Overall Study|Refused to continue trial medication|2
6102934|NCT00774397|9719950|FG004|Overall Study|Refused to continue trial medication|6
6102935|NCT00774397|9719951|FG005|Overall Study|Refused to continue trial medication|2
6102936|NCT00774397|9719952|FG006|Overall Study|Refused to continue trial medication|3
6102937|NCT00774397|9719946|FG000|Overall Study|Not treated|0
6102938|NCT00774397|9719947|FG001|Overall Study|Not treated|0
6102939|NCT00774397|9719948|FG002|Overall Study|Not treated|0
6102940|NCT00774397|9719949|FG003|Overall Study|Not treated|0
6102941|NCT00774397|9719950|FG004|Overall Study|Not treated|1
6102942|NCT00774397|9719951|FG005|Overall Study|Not treated|0
6102943|NCT00774397|9719952|FG006|Overall Study|Not treated|1
6102944|NCT00774397|9719946|FG000|Overall Study|Other than those stated above|1
6102945|NCT00774397|9719947|FG001|Overall Study|Other than those stated above|1
6102946|NCT00774397|9719948|FG002|Overall Study|Other than those stated above|3
6102947|NCT00774397|9719949|FG003|Overall Study|Other than those stated above|2
6102948|NCT00774397|9719950|FG004|Overall Study|Other than those stated above|2
6102949|NCT00774397|9719951|FG005|Overall Study|Other than those stated above|0
6102950|NCT00774397|9719952|FG006|Overall Study|Other than those stated above|1
6102951|NCT00774566|9719977|FG000|Overall Study|Protocol Violation|18
6102952|NCT00774566|9719978|FG001|Overall Study|Protocol Violation|15
6102953|NCT00774748|9719993|FG000|Overall Study|Lost to Follow-up|3
6102954|NCT00774787|9720001|FG000|Overall Study|Lost to Follow-up|1
6102955|NCT00774800|9720005|FG000|Intervention 4|Withdrawal by Subject|1
6102956|NCT00774852|9720017|FG000|Overall Study|Adverse Event|9
6102957|NCT00774852|9720018|FG001|Overall Study|Adverse Event|6
6102958|NCT00774852|9720017|FG000|Overall Study|Death|2
6102959|NCT00774852|9720018|FG001|Overall Study|Death|1
6102960|NCT00774852|9720017|FG000|Overall Study|Lack of Efficacy|3
6102961|NCT00774852|9720018|FG001|Overall Study|Lack of Efficacy|7
6102962|NCT00774852|9720017|FG000|Overall Study|Lost to Follow-up|9
6102963|NCT00774852|9720018|FG001|Overall Study|Lost to Follow-up|5
6102964|NCT00774852|9720017|FG000|Overall Study|Physician Decision|2
6102965|NCT00774852|9720018|FG001|Overall Study|Physician Decision|6
6102966|NCT00774852|9720017|FG000|Overall Study|Pregnancy|1
6102967|NCT00774852|9720018|FG001|Overall Study|Pregnancy|2
6102968|NCT00774852|9720017|FG000|Overall Study|Withdrawal by Subject|2
6102969|NCT00774852|9720018|FG001|Overall Study|Withdrawal by Subject|2
6102970|NCT00774852|9720017|FG000|Overall Study|Non-responder|15
6102971|NCT00774852|9720018|FG001|Overall Study|Non-responder|11
6102972|NCT00774852|9720017|FG000|Overall Study|Subject non-compliance|0
6102973|NCT00774852|9720018|FG001|Overall Study|Subject non-compliance|1
6102974|NCT00774852|9720017|FG000|Overall Study|Protocol Violation|1
6102975|NCT00774852|9720018|FG001|Overall Study|Protocol Violation|0
6102976|NCT00774852|9720017|FG000|Overall Study|Subject received prohibited medication|1
6102977|NCT00774852|9720018|FG001|Overall Study|Subject received prohibited medication|0
6102978|NCT00774930|9720036|FG000|DB Phase|Early Roll Over (ERO) to IOL phase|11
6102979|NCT00774930|9720037|FG001|DB Phase|Early Roll Over (ERO) to IOL phase|12
6102980|NCT00774930|9720036|FG000|DB Phase|Adverse Event|1
6102981|NCT00774930|9720037|FG001|DB Phase|Adverse Event|2
6102982|NCT00774930|9720036|FG000|DB Phase|Subject Decision|1
6102983|NCT00774930|9720037|FG001|DB Phase|Subject Decision|5
6102984|NCT00774930|9720036|FG000|DB Phase|Sponsor Decision|0
6102985|NCT00774930|9720037|FG001|DB Phase|Sponsor Decision|1
6102986|NCT00774930|9720036|FG000|DB Phase|Disease Progression|1
6102987|NCT00774930|9720037|FG001|DB Phase|Disease Progression|1
6102988|NCT00774930|9720036|FG000|DB Phase|Started Nonprotocol Radiation therapy|0
6102989|NCT00774930|9720037|FG001|DB Phase|Started Nonprotocol Radiation therapy|1
6102990|NCT00774930|9720036|FG000|IOL Phase|Adverse Event|1
6102991|NCT00774930|9720037|FG001|IOL Phase|Adverse Event|1
6102992|NCT00774930|9720036|FG000|IOL Phase|Subject Decision|4
6102993|NCT00774930|9720037|FG001|IOL Phase|Subject Decision|3
6102994|NCT00774930|9720036|FG000|IOL Phase|Physician Decision|3
6102995|NCT00774930|9720037|FG001|IOL Phase|Physician Decision|2
6102996|NCT00774930|9720036|FG000|IOL Phase|Sponsor Decision|1
6102997|NCT00774930|9720037|FG001|IOL Phase|Sponsor Decision|0
6102998|NCT00774930|9720036|FG000|IOL Phase|Disease Progression|2
6102999|NCT00774930|9720037|FG001|IOL Phase|Disease Progression|1
6103000|NCT00774930|9720036|FG000|IOL Phase|Subject Consumed Prohibited Medication|1
6103001|NCT00774930|9720037|FG001|IOL Phase|Subject Consumed Prohibited Medication|0
6103002|NCT00774930|9720036|FG000|IOL Phase|Peptide Receptor Radionuclide Therapy|0
6103003|NCT00774930|9720037|FG001|IOL Phase|Peptide Receptor Radionuclide Therapy|1
6103004|NCT00774930|9720036|FG000|IOL Phase|Other|1
6103005|NCT00774930|9720037|FG001|IOL Phase|Other|0
6103006|NCT00774930|9720036|FG000|IOL Phase|Brain radiation|0
6103007|NCT00774930|9720037|FG001|IOL Phase|Brain radiation|1
6103008|NCT00774930|9720036|FG000|LTOLE Phase|Adverse Event|7
6103009|NCT00774930|9720037|FG001|LTOLE Phase|Adverse Event|3
6103010|NCT00774930|9720036|FG000|LTOLE Phase|Subject decision|0
6103011|NCT00774930|9720037|FG001|LTOLE Phase|Subject decision|5
6103012|NCT00774930|9720036|FG000|LTOLE Phase|Physician Decision|4
6103013|NCT00774930|9720037|FG001|LTOLE Phase|Physician Decision|1
6103014|NCT00774930|9720036|FG000|LTOLE Phase|Sponsor decision|2
6103015|NCT00774930|9720037|FG001|LTOLE Phase|Sponsor decision|1
6103016|NCT00774930|9720036|FG000|LTOLE Phase|Disease Progression|2
6103017|NCT00774930|9720037|FG001|LTOLE Phase|Disease Progression|5
6103018|NCT00774930|9720036|FG000|LTOLE Phase|Tumour Progression of Hepatic Metastases|0
6103019|NCT00774930|9720037|FG001|LTOLE Phase|Tumour Progression of Hepatic Metastases|1
6103020|NCT00774930|9720036|FG000|LTOLE Phase|Proton Pump Inhibitor Dose Adjusted|0
6103021|NCT00774930|9720037|FG001|LTOLE Phase|Proton Pump Inhibitor Dose Adjusted|1
6103022|NCT00774995|9720049|FG000|Overall Study|Protocol Violation|0
6103023|NCT00774995|9720050|FG001|Overall Study|Protocol Violation|0
6103024|NCT00774995|9720051|FG002|Overall Study|Protocol Violation|1
6103025|NCT00774995|9720052|FG003|Overall Study|Protocol Violation|0
6103026|NCT00775021|9720062|FG000|First Intervention|Lost to Follow-up|1
6103027|NCT00775021|9720063|FG001|First Intervention|Lost to Follow-up|0
6103028|NCT00775021|9720062|FG000|Second Intervention|Adverse Event|0
6103029|NCT00775021|9720063|FG001|Second Intervention|Adverse Event|1
6103030|NCT00775138|9720073|FG000|Overall Study|Withdrawal by Subject|0
6103031|NCT00775138|9720074|FG001|Overall Study|Withdrawal by Subject|0
6103032|NCT00775138|9720075|FG002|Overall Study|Withdrawal by Subject|2
6103033|NCT00775138|9720076|FG003|Overall Study|Withdrawal by Subject|2
6103034|NCT00775138|9720073|FG000|Overall Study|Adverse Event|0
6103035|NCT00775138|9720074|FG001|Overall Study|Adverse Event|0
6103036|NCT00775138|9720075|FG002|Overall Study|Adverse Event|1
6103037|NCT00775138|9720076|FG003|Overall Study|Adverse Event|0
6103038|NCT00775203|9720090|FG000|Overall Study|Adverse Event|25
6103039|NCT00775203|9720091|FG001|Overall Study|Adverse Event|6
6103040|NCT00775203|9720090|FG000|Overall Study|Lack of Efficacy|8
6103041|NCT00775203|9720091|FG001|Overall Study|Lack of Efficacy|9
6103042|NCT00775203|9720090|FG000|Overall Study|Withdrawal by Subject|11
6103043|NCT00775203|9720091|FG001|Overall Study|Withdrawal by Subject|9
6103044|NCT00775203|9720090|FG000|Overall Study|Lost to Follow-up|11
6103045|NCT00775203|9720091|FG001|Overall Study|Lost to Follow-up|15
6103046|NCT00775203|9720090|FG000|Overall Study|Administrative reason|2
6103047|NCT00775203|9720091|FG001|Overall Study|Administrative reason|0
6103048|NCT00775203|9720090|FG000|Overall Study|Noncompliance|4
6103049|NCT00775203|9720091|FG001|Overall Study|Noncompliance|2
6103050|NCT00775203|9720090|FG000|Overall Study|Protocol Violation|0
6103051|NCT00775203|9720091|FG001|Overall Study|Protocol Violation|1
6103052|NCT00775203|9720090|FG000|Overall Study|Entered other study|1
6103053|NCT00775203|9720091|FG001|Overall Study|Entered other study|0
6103054|NCT00775203|9720090|FG000|Overall Study|Physician Decision|0
6103055|NCT00775203|9720091|FG001|Overall Study|Physician Decision|1
6103056|NCT00775268|9720108|FG000|Baseline|Drug not synthesize dose|1
6103057|NCT00775268|9720109|FG001|Baseline|Drug not synthesize dose|0
6103058|NCT00775268|9720108|FG000|Baseline|Not treated-ineligible per CT|0
6103059|NCT00775268|9720109|FG001|Baseline|Not treated-ineligible per CT|1
6103060|NCT00775268|9720108|FG000|After 2 Cycles|Participant refused to be scanned further|1
6103061|NCT00775268|9720109|FG001|After 2 Cycles|Participant refused to be scanned further|0
6103062|NCT00775268|9720108|FG000|After Completion|Participant missed scan appointment|1
6103063|NCT00775268|9720109|FG001|After Completion|Participant missed scan appointment|0
6103064|NCT00775437|9720134|FG000|Overall Study|Loss of efficacy|2
6103065|NCT00775437|9720134|FG000|Overall Study|Withdrawal by Subject|3
6103066|NCT00775437|9720134|FG000|Overall Study|Lost to Follow-up|1
6103067|NCT00775450|9720143|FG000|Overall Study|Serious Adverse Event|2
6103068|NCT00775450|9720144|FG001|Overall Study|Serious Adverse Event|0
6103069|NCT00775450|9720145|FG002|Overall Study|Serious Adverse Event|0
6103070|NCT00775450|9720146|FG003|Overall Study|Serious Adverse Event|0
6103071|NCT00775450|9720147|FG004|Overall Study|Serious Adverse Event|0
6103072|NCT00775450|9720143|FG000|Overall Study|Protocol Violation|0
6103073|NCT00775450|9720144|FG001|Overall Study|Protocol Violation|0
6103074|NCT00775450|9720145|FG002|Overall Study|Protocol Violation|0
6103075|NCT00775450|9720146|FG003|Overall Study|Protocol Violation|0
6103076|NCT00775450|9720147|FG004|Overall Study|Protocol Violation|1
6103077|NCT00775450|9720143|FG000|Overall Study|Withdrawal by Subject|1
6103078|NCT00775450|9720144|FG001|Overall Study|Withdrawal by Subject|0
6103079|NCT00775450|9720145|FG002|Overall Study|Withdrawal by Subject|0
6103080|NCT00775450|9720146|FG003|Overall Study|Withdrawal by Subject|0
6103081|NCT00775450|9720147|FG004|Overall Study|Withdrawal by Subject|1
6103082|NCT00775463|9720161|FG000|Overall Study|Withdrawal by Subject|0
6103083|NCT00775463|9720162|FG001|Overall Study|Withdrawal by Subject|1
6103084|NCT00775463|9720161|FG000|Overall Study|Adverse Event|7
6103085|NCT00775463|9720162|FG001|Overall Study|Adverse Event|9
6103086|NCT00775463|9720161|FG000|Overall Study|Protocol Violation|2
6103087|NCT00775463|9720162|FG001|Overall Study|Protocol Violation|2
6103088|NCT00775463|9720161|FG000|Overall Study|Lost to Follow-up|1
6103089|NCT00775463|9720162|FG001|Overall Study|Lost to Follow-up|0
6103090|NCT00775463|9720161|FG000|Overall Study|Lack of Efficacy|1
6103091|NCT00775463|9720162|FG001|Overall Study|Lack of Efficacy|1
6103092|NCT00775528|9720175|FG000|Overall Study|Protocol Violation|1
6103093|NCT00775593|9720179|FG000|Overall Study|Unmet eligibility criteria|6
6103094|NCT00775593|9720179|FG000|Overall Study|Death|1
6103095|NCT00775606|9720185|FG000|Overall Study|Study sponsor terminated funding|3
6103096|NCT00775606|9720186|FG001|Overall Study|Study sponsor terminated funding|0
6103097|NCT00775983|9720269|FG000|Overall Study|Protocol Violation|1
6103098|NCT00775983|9720270|FG001|Overall Study|Protocol Violation|2
6103099|NCT00776009|9720282|FG000|Period 1: First Intervention|Withdrawal by Subject|0
6103100|NCT00776009|9720283|FG001|Period 1: First Intervention|Withdrawal by Subject|0
6103101|NCT00776009|9720284|FG002|Period 1: First Intervention|Withdrawal by Subject|1
6103102|NCT00776009|9720285|FG003|Period 1: First Intervention|Withdrawal by Subject|0
6103103|NCT00776009|9720286|FG004|Period 1: First Intervention|Withdrawal by Subject|1
6103104|NCT00776009|9720287|FG005|Period 1: First Intervention|Withdrawal by Subject|0
6103105|NCT00776009|9720282|FG000|Period 1: First Intervention|Protocol Violation|0
6103106|NCT00776009|9720283|FG001|Period 1: First Intervention|Protocol Violation|1
6103107|NCT00776009|9720284|FG002|Period 1: First Intervention|Protocol Violation|0
6103108|NCT00776009|9720285|FG003|Period 1: First Intervention|Protocol Violation|0
6103109|NCT00776009|9720286|FG004|Period 1: First Intervention|Protocol Violation|1
6103110|NCT00776009|9720287|FG005|Period 1: First Intervention|Protocol Violation|0
6103111|NCT00776009|9720282|FG000|Period 2: Second Intervention|Withdrawal by Subject|0
6103112|NCT00776009|9720283|FG001|Period 2: Second Intervention|Withdrawal by Subject|0
6103113|NCT00776009|9720284|FG002|Period 2: Second Intervention|Withdrawal by Subject|0
6103114|NCT00776009|9720285|FG003|Period 2: Second Intervention|Withdrawal by Subject|0
6103115|NCT00776009|9720286|FG004|Period 2: Second Intervention|Withdrawal by Subject|0
6103116|NCT00776009|9720287|FG005|Period 2: Second Intervention|Withdrawal by Subject|1
6103117|NCT00776009|9720282|FG000|Period 2: Second Intervention|Protocol Violation|1
6103118|NCT00776009|9720283|FG001|Period 2: Second Intervention|Protocol Violation|0
6103119|NCT00776009|9720284|FG002|Period 2: Second Intervention|Protocol Violation|1
6103120|NCT00776009|9720285|FG003|Period 2: Second Intervention|Protocol Violation|0
6103121|NCT00776009|9720286|FG004|Period 2: Second Intervention|Protocol Violation|0
6103122|NCT00776009|9720287|FG005|Period 2: Second Intervention|Protocol Violation|0
6103123|NCT00776009|9720282|FG000|Period 3: Third Intervention|Withdrawal by Subject|1
6103124|NCT00776009|9720283|FG001|Period 3: Third Intervention|Withdrawal by Subject|0
6103125|NCT00776009|9720284|FG002|Period 3: Third Intervention|Withdrawal by Subject|0
6103126|NCT00776009|9720285|FG003|Period 3: Third Intervention|Withdrawal by Subject|0
6103127|NCT00776009|9720286|FG004|Period 3: Third Intervention|Withdrawal by Subject|0
6103128|NCT00776009|9720287|FG005|Period 3: Third Intervention|Withdrawal by Subject|0
6103129|NCT00776230|9720298|FG000|Overall Study|Lost to Follow-up|2
6103130|NCT00776230|9720299|FG001|Overall Study|Lost to Follow-up|1
6103131|NCT00776230|9720300|FG002|Overall Study|Lost to Follow-up|5
6103132|NCT00776230|9720298|FG000|Overall Study|Not vaccinated at Day 0|1
6285033|NCT02329730|9996754|FG001|Overall Study|Protocol Violation|0
6103133|NCT00776230|9720299|FG001|Overall Study|Not vaccinated at Day 0|0
6103134|NCT00776230|9720300|FG002|Overall Study|Not vaccinated at Day 0|0
6103135|NCT00776230|9720298|FG000|Overall Study|Withdrawal by Subject|0
6103136|NCT00776230|9720299|FG001|Overall Study|Withdrawal by Subject|1
6103137|NCT00776230|9720300|FG002|Overall Study|Withdrawal by Subject|0
6103138|NCT00776230|9720298|FG000|Overall Study|Subject missed Visit 4|0
6103139|NCT00776230|9720299|FG001|Overall Study|Subject missed Visit 4|1
6103140|NCT00776230|9720300|FG002|Overall Study|Subject missed Visit 4|0
6103141|NCT00776659|9720323|FG000|Overall Study|Lost to Follow-up|15
6103142|NCT00776659|9720323|FG000|Overall Study|Withdrawal by Subject|10
6103143|NCT00776659|9720323|FG000|Overall Study|Study Terminated by Sponsor|1
6103144|NCT00776789|9720329|FG000|Overall Study|Consent refusal|2
6103145|NCT00776789|9720330|FG001|Overall Study|Consent refusal|2
6103146|NCT00776789|9720329|FG000|Overall Study|Poor quality video|1
6103147|NCT00776789|9720330|FG001|Overall Study|Poor quality video|1
6204945|NCT01526928|9866816|FG005|Overall Study|Missing|0
6204946|NCT01527006|9866874|FG000|Core Study|Adverse Event|0
6204947|NCT01527006|9866875|FG001|Core Study|Adverse Event|2
6204948|NCT01527006|9866874|FG000|Core Study|Lost to Follow-up|0
6204949|NCT01527006|9866875|FG001|Core Study|Lost to Follow-up|1
6204950|NCT01527006|9866874|FG000|Core Study|Subject Choice|1
6204951|NCT01527006|9866875|FG001|Core Study|Subject Choice|0
6204952|NCT01527006|9866874|FG000|Core Study|Inadequate Therapeutic Effect|1
6204953|NCT01527006|9866875|FG001|Core Study|Inadequate Therapeutic Effect|0
6204954|NCT01527006|9866874|FG000|Core Study|Withdrawal by Subject|0
6204955|NCT01527006|9866875|FG001|Core Study|Withdrawal by Subject|1
6204956|NCT01527006|9866874|FG000|Core Study|Other|0
6204957|NCT01527006|9866875|FG001|Core Study|Other|2
6204958|NCT01527006|9866874|FG000|Extension Phase|Adverse Event|4
6204959|NCT01527006|9866875|FG001|Extension Phase|Adverse Event|2
6204960|NCT01527006|9866874|FG000|Extension Phase|Lost to Follow-up|0
6204961|NCT01527006|9866875|FG001|Extension Phase|Lost to Follow-up|1
6204962|NCT01527006|9866874|FG000|Extension Phase|Subject Choice|1
6204963|NCT01527006|9866875|FG001|Extension Phase|Subject Choice|1
6204964|NCT01527006|9866874|FG000|Extension Phase|Inadequate therapeutic effect|1
6204965|NCT01527006|9866875|FG001|Extension Phase|Inadequate therapeutic effect|1
6204966|NCT01527006|9866874|FG000|Extension Phase|Other|0
6204967|NCT01527006|9866875|FG001|Extension Phase|Other|3
6204968|NCT01527110|9866900|FG000|Overall Study|Adverse Event|1
6204969|NCT01527357|9866915|FG000|Overall Study|Death|8
6204970|NCT01527357|9866916|FG001|Overall Study|Death|2
6204971|NCT01527357|9866915|FG000|Overall Study|Lost to Follow-up|6
6204972|NCT01527357|9866916|FG001|Overall Study|Lost to Follow-up|4
6204973|NCT01527357|9866915|FG000|Overall Study|Withdrew Consent|1
6204974|NCT01527357|9866916|FG001|Overall Study|Withdrew Consent|1
6204975|NCT01527357|9866915|FG000|Overall Study|Non-compliance|0
6204976|NCT01527357|9866916|FG001|Overall Study|Non-compliance|1
6204977|NCT01527357|9866915|FG000|Overall Study|No Day 29 Visit|0
6204978|NCT01527357|9866916|FG001|Overall Study|No Day 29 Visit|1
6204979|NCT01527357|9866915|FG000|Overall Study|Did Not Receive Treatment|2
6204980|NCT01527357|9866916|FG001|Overall Study|Did Not Receive Treatment|0
6204981|NCT01527370|9866922|FG000|Overall Study|Withdrawal by Subject|4
6204982|NCT01527370|9866922|FG000|Overall Study|Physician Decision|1
6204983|NCT01527370|9866922|FG000|Overall Study|Death|1
6204984|NCT01527383|9866928|FG000|Overall Study|Adverse Event|5
6204985|NCT01527383|9866929|FG001|Overall Study|Adverse Event|0
6204986|NCT01527383|9866928|FG000|Overall Study|Lost to Follow-up|3
6204987|NCT01527383|9866929|FG001|Overall Study|Lost to Follow-up|0
6204988|NCT01527383|9866928|FG000|Overall Study|Physician Decision|2
6204989|NCT01527383|9866929|FG001|Overall Study|Physician Decision|0
6204990|NCT01527383|9866928|FG000|Overall Study|Pregnancy|1
6204991|NCT01527383|9866929|FG001|Overall Study|Pregnancy|0
6204992|NCT01527383|9866928|FG000|Overall Study|Protocol Violation|1
6204993|NCT01527383|9866929|FG001|Overall Study|Protocol Violation|0
6204994|NCT01527383|9866928|FG000|Overall Study|Screen failure|1
6204995|NCT01527383|9866929|FG001|Overall Study|Screen failure|0
6204996|NCT01527383|9866928|FG000|Overall Study|Participant moved|0
6285034|NCT02329730|9996755|FG002|Overall Study|Protocol Violation|0
6285035|NCT02329730|9996756|FG003|Overall Study|Protocol Violation|0
6204997|NCT01527383|9866929|FG001|Overall Study|Participant moved|1
6204998|NCT01527383|9866928|FG000|Overall Study|Withdrawal by Subject|2
6204999|NCT01527383|9866929|FG001|Overall Study|Withdrawal by Subject|3
6205000|NCT01527487|9866937|FG000|Overall Study|MD Discretion/Lack of Efficacy|3
6205001|NCT01527487|9866938|FG001|Overall Study|MD Discretion/Lack of Efficacy|4
6205002|NCT01527487|9866937|FG000|Overall Study|Disease Progression|4
6205003|NCT01527487|9866938|FG001|Overall Study|Disease Progression|1
6205004|NCT01527487|9866937|FG000|Overall Study|Adverse Event|1
6205005|NCT01527487|9866938|FG001|Overall Study|Adverse Event|1
6205006|NCT01527487|9866937|FG000|Overall Study|Death|0
6205007|NCT01527487|9866938|FG001|Overall Study|Death|1
6205008|NCT01527500|9866953|FG000|Part A|Administrative|11
6205009|NCT01527500|9866954|FG001|Part A|Administrative|7
6205010|NCT01527500|9866953|FG000|Part A|Adverse Event|4
6205011|NCT01527500|9866954|FG001|Part A|Adverse Event|2
6205012|NCT01527500|9866953|FG000|Part A|Death|4
6205013|NCT01527500|9866954|FG001|Part A|Death|1
6205014|NCT01527500|9866953|FG000|Part A|Lost to Follow-up|0
6205015|NCT01527500|9866954|FG001|Part A|Lost to Follow-up|1
6103148|NCT00776919|9720342|FG000|Overall Study|Withdrawal by Subject|16
6103149|NCT00776919|9720343|FG001|Overall Study|Withdrawal by Subject|14
6103150|NCT00776919|9720344|FG002|Overall Study|Withdrawal by Subject|15
6103151|NCT00776919|9720345|FG003|Overall Study|Withdrawal by Subject|26
6103152|NCT00776919|9720342|FG000|Overall Study|Lost to Follow-up|8
6103153|NCT00776919|9720343|FG001|Overall Study|Lost to Follow-up|12
6103154|NCT00776919|9720344|FG002|Overall Study|Lost to Follow-up|11
6103155|NCT00776919|9720345|FG003|Overall Study|Lost to Follow-up|8
6103156|NCT00776919|9720342|FG000|Overall Study|Adverse Event|1
6103157|NCT00776919|9720343|FG001|Overall Study|Adverse Event|0
6103158|NCT00776919|9720344|FG002|Overall Study|Adverse Event|2
6103159|NCT00776919|9720345|FG003|Overall Study|Adverse Event|2
6103160|NCT00776919|9720342|FG000|Overall Study|Protocol Violation|1
6103161|NCT00776919|9720343|FG001|Overall Study|Protocol Violation|2
6103162|NCT00776919|9720344|FG002|Overall Study|Protocol Violation|0
6103163|NCT00776919|9720345|FG003|Overall Study|Protocol Violation|1
6103164|NCT00776919|9720342|FG000|Overall Study|Other: Lack of Efficacy/Lost Medication|1
6103165|NCT00776919|9720343|FG001|Overall Study|Other: Lack of Efficacy/Lost Medication|5
6103166|NCT00776919|9720344|FG002|Overall Study|Other: Lack of Efficacy/Lost Medication|4
6103167|NCT00776919|9720345|FG003|Overall Study|Other: Lack of Efficacy/Lost Medication|2
6103168|NCT00776984|9720357|FG000|Overall Study|Adverse Event|8
6103169|NCT00776984|9720358|FG001|Overall Study|Adverse Event|2
6103170|NCT00776984|9720357|FG000|Overall Study|Protocol Violation|4
6205016|NCT01527500|9866953|FG000|Part A|Protocol Deviation|9
6205017|NCT01527500|9866954|FG001|Part A|Protocol Deviation|2
6205018|NCT01527500|9866953|FG000|Part A|Withdrawal by Subject|2
6205019|NCT01527500|9866954|FG001|Part A|Withdrawal by Subject|0
6205020|NCT01527500|9866953|FG000|Part B|Adverse Event|1
6205021|NCT01527500|9866954|FG001|Part B|Adverse Event|0
6205022|NCT01527682|9866981|FG000|Overall Study|Protocol Violation|8
6205023|NCT01528033|9866987|FG000|Primary Endpoint Assessment ITT|Withdrawal by Subject|8
6205024|NCT01528033|9866988|FG001|Primary Endpoint Assessment ITT|Withdrawal by Subject|7
6205025|NCT01528033|9866987|FG000|Primary Endpoint Assessment ITT|No or deliquent informed consent|3
6205026|NCT01528033|9866988|FG001|Primary Endpoint Assessment ITT|No or deliquent informed consent|3
6205027|NCT01528033|9866987|FG000|Primary Endpoint Assessment ITT|Death|2
6205028|NCT01528033|9866988|FG001|Primary Endpoint Assessment ITT|Death|2
6205029|NCT01528033|9866987|FG000|Primary Endpoint Assessment ITT|Physician Decision|2
6205030|NCT01528033|9866988|FG001|Primary Endpoint Assessment ITT|Physician Decision|1
6205031|NCT01528033|9866987|FG000|Primary Endpoint Assessment ITT|No post baseline documentation|2
6205032|NCT01528033|9866988|FG001|Primary Endpoint Assessment ITT|No post baseline documentation|2
6205033|NCT01528033|9866987|FG000|Follow Up|No data available|46
6205034|NCT01528033|9866988|FG001|Follow Up|No data available|44
6205035|NCT01528072|9866994|FG000|Overall Study|Withdrawal by Subject|5
6205036|NCT01528072|9866994|FG000|Overall Study|Physician Decision|1
6205037|NCT01528072|9866994|FG000|Overall Study|Determined not eligible by AEAC|1
6205038|NCT01528072|9866994|FG000|Overall Study|Missed Visit|2
6205039|NCT01528072|9866994|FG000|Overall Study|Lost to Follow-up|5
6205040|NCT01528072|9866994|FG000|Overall Study|Explanted|2
6205041|NCT01528072|9866994|FG000|Overall Study|Site Closure|4
6205042|NCT01528072|9866994|FG000|Overall Study|Death|2
6205043|NCT01528072|9866994|FG000|Overall Study|Early Termination of Study|52
6205044|NCT01528215|9867039|FG000|Enrollment to 1 Year Follow-up|Adverse Event|4
6205045|NCT01528215|9867040|FG001|Enrollment to 1 Year Follow-up|Adverse Event|1
6205046|NCT01528215|9867039|FG000|1 Year Follow-up to 5 Year Follow-up|Adverse Event|2
6205047|NCT01528215|9867040|FG001|1 Year Follow-up to 5 Year Follow-up|Adverse Event|2
6205048|NCT01528215|9867039|FG000|1 Year Follow-up to 5 Year Follow-up|Lost to Follow-up|10
6205049|NCT01528215|9867040|FG001|1 Year Follow-up to 5 Year Follow-up|Lost to Follow-up|13
6205050|NCT01528215|9867039|FG000|1 Year Follow-up to 5 Year Follow-up|Withdrawal by Subject|3
6205051|NCT01528215|9867040|FG001|1 Year Follow-up to 5 Year Follow-up|Withdrawal by Subject|0
6205052|NCT01528254|9867057|FG000|Overall Study|Administrative problems|96
6205053|NCT01528254|9867058|FG001|Overall Study|Administrative problems|94
6205054|NCT01528254|9867057|FG000|Overall Study|Adverse Event|28
6205055|NCT01528254|9867058|FG001|Overall Study|Adverse Event|44
6205056|NCT01528254|9867057|FG000|Overall Study|Lost to Follow-up|17
6205057|NCT01528254|9867058|FG001|Overall Study|Lost to Follow-up|24
6205058|NCT01528254|9867057|FG000|Overall Study|Death|13
6205059|NCT01528254|9867058|FG001|Overall Study|Death|9
6205060|NCT01528254|9867057|FG000|Overall Study|Protocol deviation|9
6205061|NCT01528254|9867058|FG001|Overall Study|Protocol deviation|19
6205062|NCT01528254|9867057|FG000|Overall Study|New therapy for study indication|8
6205063|NCT01528254|9867058|FG001|Overall Study|New therapy for study indication|6
6205064|NCT01528254|9867057|FG000|Overall Study|Unsatisfactory therapeutic effect|6
6205065|NCT01528254|9867058|FG001|Overall Study|Unsatisfactory therapeutic effect|8
6205066|NCT01528254|9867057|FG000|Overall Study|Withdrawal by Subject|5
6205067|NCT01528254|9867058|FG001|Overall Study|Withdrawal by Subject|4
6205068|NCT01528254|9867057|FG000|Overall Study|Abnormal laboratory value(s)|3
6103171|NCT00776984|9720358|FG001|Overall Study|Protocol Violation|2
6103172|NCT00776984|9720357|FG000|Overall Study|Lost to Follow-up|2
6103173|NCT00776984|9720358|FG001|Overall Study|Lost to Follow-up|0
6103174|NCT00776984|9720357|FG000|Overall Study|Withdrawal by Subject|12
6205069|NCT01528254|9867058|FG001|Overall Study|Abnormal laboratory value(s)|7
6103175|NCT00776984|9720358|FG001|Overall Study|Withdrawal by Subject|7
6103176|NCT00776984|9720357|FG000|Overall Study|Lack of Efficacy|0
6103177|NCT00776984|9720358|FG001|Overall Study|Lack of Efficacy|1
6103178|NCT00776984|9720357|FG000|Overall Study|Other|5
6103179|NCT00776984|9720358|FG001|Overall Study|Other|9
6103180|NCT00776997|9720364|FG000|Overall Study|Adverse Event|2
6103181|NCT00777023|9720371|FG000|Overall Study|Adverse Event|15
6103182|NCT00777023|9720372|FG001|Overall Study|Adverse Event|21
6103183|NCT00777023|9720373|FG002|Overall Study|Adverse Event|8
6103184|NCT00777023|9720371|FG000|Overall Study|Lack of Efficacy|1
6103185|NCT00777023|9720372|FG001|Overall Study|Lack of Efficacy|0
6103186|NCT00777023|9720373|FG002|Overall Study|Lack of Efficacy|14
6103187|NCT00777023|9720371|FG000|Overall Study|Protocol Violation|2
6103188|NCT00777023|9720372|FG001|Overall Study|Protocol Violation|1
6103189|NCT00777023|9720373|FG002|Overall Study|Protocol Violation|1
6103190|NCT00777023|9720371|FG000|Overall Study|Lost to Follow-up|2
6103191|NCT00777023|9720372|FG001|Overall Study|Lost to Follow-up|3
6103192|NCT00777023|9720373|FG002|Overall Study|Lost to Follow-up|3
6103193|NCT00777023|9720371|FG000|Overall Study|Death|0
6103194|NCT00777023|9720372|FG001|Overall Study|Death|1
6103195|NCT00777023|9720373|FG002|Overall Study|Death|0
6103196|NCT00777023|9720371|FG000|Overall Study|Withdrawal by Subject|7
6103197|NCT00777023|9720372|FG001|Overall Study|Withdrawal by Subject|7
6103198|NCT00777023|9720373|FG002|Overall Study|Withdrawal by Subject|8
6103199|NCT00777023|9720371|FG000|Overall Study|Missing data|1
6103200|NCT00777023|9720372|FG001|Overall Study|Missing data|1
6103201|NCT00777023|9720373|FG002|Overall Study|Missing data|0
6103202|NCT00777023|9720371|FG000|Overall Study|Reasons not specified|4
6103203|NCT00777023|9720372|FG001|Overall Study|Reasons not specified|4
6103204|NCT00777023|9720373|FG002|Overall Study|Reasons not specified|2
6103205|NCT00777023|9720371|FG000|Overall Study|Last dose date unknown|3
6103206|NCT00777023|9720372|FG001|Overall Study|Last dose date unknown|3
6103207|NCT00777023|9720373|FG002|Overall Study|Last dose date unknown|1
6103208|NCT00777049|9720383|FG000|Overall Study|Withdrawal by Subject|1
6103209|NCT00777049|9720384|FG001|Overall Study|Withdrawal by Subject|0
6103210|NCT00777049|9720383|FG000|Overall Study|No treatment (elevated liver enzymes)|0
6103211|NCT00777049|9720384|FG001|Overall Study|No treatment (elevated liver enzymes)|1
6103212|NCT00777088|9720399|FG000|Overall Study|PED Treatment not attempted|1
6103213|NCT00777101|9720406|FG000|Overall Study|Death|48
6103214|NCT00777101|9720407|FG001|Overall Study|Death|43
6103215|NCT00777101|9720406|FG000|Overall Study|Withdrawal by Subject|11
6103216|NCT00777101|9720407|FG001|Overall Study|Withdrawal by Subject|6
6103217|NCT00777101|9720406|FG000|Overall Study|Lost to Follow-up|2
6103218|NCT00777101|9720407|FG001|Overall Study|Lost to Follow-up|1
6103219|NCT00777101|9720406|FG000|Overall Study|Discontinuation of Study by Sponsor|1
6103220|NCT00777101|9720407|FG001|Overall Study|Discontinuation of Study by Sponsor|0
6103221|NCT00777101|9720406|FG000|Overall Study|Failed to Return|0
6103222|NCT00777101|9720407|FG001|Overall Study|Failed to Return|1
6103223|NCT00777153|9720417|FG000|Overall Study|Lost to Follow-up|1
6103224|NCT00777153|9720418|FG001|Overall Study|Lost to Follow-up|1
6103225|NCT00777153|9720419|FG002|Overall Study|Lost to Follow-up|0
6103226|NCT00777153|9720417|FG000|Overall Study|Death|85
6103227|NCT00777153|9720418|FG001|Overall Study|Death|73
6103228|NCT00777153|9720419|FG002|Overall Study|Death|33
6103229|NCT00777153|9720417|FG000|Overall Study|Withdrawal by Subject|3
6103230|NCT00777153|9720418|FG001|Overall Study|Withdrawal by Subject|4
6103231|NCT00777153|9720419|FG002|Overall Study|Withdrawal by Subject|3
6103232|NCT00777153|9720417|FG000|Overall Study|Incorrect enrol/elig crit not fulfilled|1
6103233|NCT00777153|9720418|FG001|Overall Study|Incorrect enrol/elig crit not fulfilled|5
6103234|NCT00777153|9720419|FG002|Overall Study|Incorrect enrol/elig crit not fulfilled|1
6103235|NCT00777205|9720442|FG000|Overall Study|Lost to Follow-up|25
6103236|NCT00777205|9720443|FG001|Overall Study|Lost to Follow-up|9
6103237|NCT00777205|9720442|FG000|Overall Study|Withdrawal by Subject|6
6103238|NCT00777205|9720443|FG001|Overall Study|Withdrawal by Subject|4
6103239|NCT00777205|9720442|FG000|Overall Study|Death|0
6103240|NCT00777205|9720443|FG001|Overall Study|Death|2
6103241|NCT00777205|9720442|FG000|Overall Study|Protocol Violation|0
6103242|NCT00777205|9720443|FG001|Overall Study|Protocol Violation|56
6103243|NCT00777257|9720454|FG000|Overall Study|Adverse Event|3
6103244|NCT00777257|9720455|FG001|Overall Study|Adverse Event|1
6103245|NCT00777257|9720456|FG002|Overall Study|Adverse Event|0
6103246|NCT00777257|9720454|FG000|Overall Study|Lost to Follow-up|3
6103247|NCT00777257|9720455|FG001|Overall Study|Lost to Follow-up|3
6103248|NCT00777257|9720456|FG002|Overall Study|Lost to Follow-up|2
6103249|NCT00777257|9720454|FG000|Overall Study|Protocol Violation|2
6103250|NCT00777257|9720455|FG001|Overall Study|Protocol Violation|2
6103251|NCT00777257|9720456|FG002|Overall Study|Protocol Violation|2
6103252|NCT00777257|9720454|FG000|Overall Study|Withdrawal by Subject|3
6103253|NCT00777257|9720455|FG001|Overall Study|Withdrawal by Subject|6
6103254|NCT00777257|9720456|FG002|Overall Study|Withdrawal by Subject|5
6103255|NCT00777296|9720468|FG000|Overall Study|Adverse Event|0
6103256|NCT00777296|9720469|FG001|Overall Study|Adverse Event|1
6103257|NCT00777296|9720470|FG002|Overall Study|Adverse Event|0
6103258|NCT00777296|9720471|FG003|Overall Study|Adverse Event|1
6103259|NCT00777296|9720468|FG000|Overall Study|Withdrawal by Subject|1
6103260|NCT00777296|9720469|FG001|Overall Study|Withdrawal by Subject|0
6103261|NCT00777296|9720470|FG002|Overall Study|Withdrawal by Subject|0
6103262|NCT00777296|9720471|FG003|Overall Study|Withdrawal by Subject|0
6103263|NCT00777296|9720468|FG000|Overall Study|CRF form not completed|0
6103264|NCT00777296|9720469|FG001|Overall Study|CRF form not completed|0
6103265|NCT00777296|9720470|FG002|Overall Study|CRF form not completed|2
6103266|NCT00777296|9720471|FG003|Overall Study|CRF form not completed|0
6103267|NCT00777491|9720504|FG000|Overall Study|Protocol Violation|0
6103268|NCT00777491|9720505|FG001|Overall Study|Protocol Violation|2
6103269|NCT00777491|9720504|FG000|Overall Study|Did not receive any protocol treatment|2
6103270|NCT00777491|9720505|FG001|Overall Study|Did not receive any protocol treatment|0
6103271|NCT00777556|9720511|FG000|Overall Study|Inappropriate self-selection|34
6103272|NCT00777556|9720511|FG000|Overall Study|Dispensed but did not use product|12
6103273|NCT00777556|9720511|FG000|Overall Study|Did not complete all 3 follow-up visits|20
6103274|NCT00777608|9720517|FG000|Overall Study|Lost to Follow-up|1
6103275|NCT00777608|9720518|FG001|Overall Study|Lost to Follow-up|1
6103276|NCT00777608|9720517|FG000|Overall Study|Withdrawal by Subject|1
6103277|NCT00777608|9720518|FG001|Overall Study|Withdrawal by Subject|3
6103278|NCT00777608|9720517|FG000|Overall Study|Protocol Violation|1
6103279|NCT00777608|9720518|FG001|Overall Study|Protocol Violation|0
6103280|NCT00777608|9720517|FG000|Overall Study|Investigator Decision|1
6103281|NCT00777608|9720518|FG001|Overall Study|Investigator Decision|2
6103282|NCT00777803|9720559|FG000|Overall Study|Lost to Follow-up|12
6103283|NCT00777803|9720560|FG001|Overall Study|Lost to Follow-up|5
6103284|NCT00777803|9720559|FG000|Overall Study|Adverse Event|1
6103285|NCT00777803|9720560|FG001|Overall Study|Adverse Event|0
6103286|NCT00777803|9720559|FG000|Overall Study|Non-compliance|2
6103287|NCT00777803|9720560|FG001|Overall Study|Non-compliance|2
6103288|NCT00777829|9720566|FG000|Overall Study|Withdrawal by Subject|0
6103289|NCT00777829|9720567|FG001|Overall Study|Withdrawal by Subject|2
6103290|NCT00777920|9720581|FG000|Overall Study|Adverse Event|39
6103291|NCT00777920|9720581|FG000|Overall Study|Withdrawal of Consent|4
6103292|NCT00777920|9720581|FG000|Overall Study|Lost to Follow-up|1
6103293|NCT00777920|9720581|FG000|Overall Study|Investigator's discretion|1
6103294|NCT00777920|9720581|FG000|Overall Study|Clinical status did not improve|1
6103295|NCT00777920|9720581|FG000|Overall Study|Other, not specified|4
6103296|NCT00777946|9720588|FG000|Overall Study|Adverse Event|11
6103297|NCT00777946|9720589|FG001|Overall Study|Adverse Event|1
6103298|NCT00777946|9720590|FG002|Overall Study|Adverse Event|3
6103299|NCT00777946|9720588|FG000|Overall Study|Lack of Efficacy|0
6103300|NCT00777946|9720589|FG001|Overall Study|Lack of Efficacy|0
6103301|NCT00777946|9720590|FG002|Overall Study|Lack of Efficacy|9
6103302|NCT00777946|9720588|FG000|Overall Study|Condition no longer required study drug|1
6103303|NCT00777946|9720589|FG001|Overall Study|Condition no longer required study drug|0
6103304|NCT00777946|9720590|FG002|Overall Study|Condition no longer required study drug|0
6103305|NCT00777946|9720588|FG000|Overall Study|Patient withdrew consent|3
6103306|NCT00777946|9720589|FG001|Overall Study|Patient withdrew consent|2
6103307|NCT00777946|9720590|FG002|Overall Study|Patient withdrew consent|3
6103308|NCT00777946|9720588|FG000|Overall Study|Lost to Follow-up|3
6103309|NCT00777946|9720589|FG001|Overall Study|Lost to Follow-up|1
6103310|NCT00777946|9720590|FG002|Overall Study|Lost to Follow-up|0
6103311|NCT00777946|9720588|FG000|Overall Study|Protocol deviation|2
6103312|NCT00777946|9720589|FG001|Overall Study|Protocol deviation|1
6103313|NCT00777946|9720590|FG002|Overall Study|Protocol deviation|1
6103314|NCT00777946|9720588|FG000|Overall Study|Randomized in error|1
6103315|NCT00777946|9720589|FG001|Overall Study|Randomized in error|1
6103316|NCT00777946|9720590|FG002|Overall Study|Randomized in error|0
6103317|NCT00778102|9720600|FG000|Overall Study|Adverse Event|8
6103318|NCT00778102|9720601|FG001|Overall Study|Adverse Event|5
6103319|NCT00778102|9720600|FG000|Overall Study|Death|1
6103320|NCT00778102|9720601|FG001|Overall Study|Death|1
6205070|NCT01528254|9867057|FG000|Overall Study|Abnormal test procedure result(s)|1
6205071|NCT01528254|9867058|FG001|Overall Study|Abnormal test procedure result(s)|0
6205072|NCT01528254|9867057|FG000|Overall Study|No longer requires study drug|1
6205073|NCT01528254|9867058|FG001|Overall Study|No longer requires study drug|1
6285036|NCT02329730|9996757|FG004|Overall Study|Protocol Violation|2
6285037|NCT02329730|9996758|FG005|Overall Study|Protocol Violation|2
6285038|NCT02329730|9996759|FG006|Overall Study|Protocol Violation|0
6285039|NCT02329730|9996760|FG007|Overall Study|Protocol Violation|0
6285040|NCT02329730|9996761|FG008|Overall Study|Protocol Violation|0
6285041|NCT02329730|9996762|FG009|Overall Study|Protocol Violation|0
6285042|NCT02329730|9996763|FG010|Overall Study|Protocol Violation|0
6285043|NCT02329730|9996764|FG011|Overall Study|Protocol Violation|0
6285044|NCT02329730|9996753|FG000|Overall Study|Withdrawal by Subject|0
6285045|NCT02329730|9996754|FG001|Overall Study|Withdrawal by Subject|0
6285046|NCT02329730|9996755|FG002|Overall Study|Withdrawal by Subject|0
6103321|NCT00778102|9720600|FG000|Overall Study|Lost to Follow-up|1
6103322|NCT00778102|9720601|FG001|Overall Study|Lost to Follow-up|0
6103323|NCT00778102|9720600|FG000|Overall Study|Violation of Selection Criteria|1
6285047|NCT02329730|9996756|FG003|Overall Study|Withdrawal by Subject|0
6285048|NCT02329730|9996757|FG004|Overall Study|Withdrawal by Subject|1
6103324|NCT00778102|9720601|FG001|Overall Study|Violation of Selection Criteria|1
6103325|NCT00778102|9720600|FG000|Overall Study|Protocol Violation|0
6103326|NCT00778102|9720601|FG001|Overall Study|Protocol Violation|1
6103327|NCT00778102|9720600|FG000|Overall Study|Refused Treatment|2
6103328|NCT00778102|9720601|FG001|Overall Study|Refused Treatment|3
6103329|NCT00778102|9720600|FG000|Overall Study|Withdrawal by Subject|1
6103330|NCT00778102|9720601|FG001|Overall Study|Withdrawal by Subject|1
6103331|NCT00778102|9720600|FG000|Overall Study|Administrative Reason|7
6103332|NCT00778102|9720601|FG001|Overall Study|Administrative Reason|10
6103333|NCT00778258|9720629|FG000|Overall Study|Adverse Event|1
6103334|NCT00778258|9720630|FG001|Overall Study|Adverse Event|0
6103335|NCT00778258|9720631|FG002|Overall Study|Adverse Event|0
6103336|NCT00778258|9720632|FG003|Overall Study|Adverse Event|0
6103337|NCT00778258|9720633|FG004|Overall Study|Adverse Event|0
6103338|NCT00778258|9720634|FG005|Overall Study|Adverse Event|1
6103339|NCT00778258|9720635|FG006|Overall Study|Adverse Event|0
6103340|NCT00778258|9720636|FG007|Overall Study|Adverse Event|0
6103341|NCT00778258|9720637|FG008|Overall Study|Adverse Event|0
6103342|NCT00778258|9720629|FG000|Overall Study|Lost to Follow-up|0
6103343|NCT00778258|9720630|FG001|Overall Study|Lost to Follow-up|0
6103344|NCT00778258|9720631|FG002|Overall Study|Lost to Follow-up|2
6103345|NCT00778258|9720632|FG003|Overall Study|Lost to Follow-up|0
6103346|NCT00778258|9720633|FG004|Overall Study|Lost to Follow-up|0
6103347|NCT00778258|9720634|FG005|Overall Study|Lost to Follow-up|3
6103348|NCT00778258|9720635|FG006|Overall Study|Lost to Follow-up|2
6103349|NCT00778258|9720636|FG007|Overall Study|Lost to Follow-up|2
6103350|NCT00778258|9720637|FG008|Overall Study|Lost to Follow-up|0
6103351|NCT00778258|9720629|FG000|Overall Study|Withdrawal by Subject|6
6103352|NCT00778258|9720630|FG001|Overall Study|Withdrawal by Subject|2
6103353|NCT00778258|9720631|FG002|Overall Study|Withdrawal by Subject|8
6103354|NCT00778258|9720632|FG003|Overall Study|Withdrawal by Subject|2
6103355|NCT00778258|9720633|FG004|Overall Study|Withdrawal by Subject|0
6103356|NCT00778258|9720634|FG005|Overall Study|Withdrawal by Subject|6
6103357|NCT00778258|9720635|FG006|Overall Study|Withdrawal by Subject|12
6103358|NCT00778258|9720636|FG007|Overall Study|Withdrawal by Subject|12
6103359|NCT00778258|9720637|FG008|Overall Study|Withdrawal by Subject|4
6103360|NCT00778258|9720629|FG000|Overall Study|New Contraindication|0
6103361|NCT00778258|9720630|FG001|Overall Study|New Contraindication|0
6103362|NCT00778258|9720631|FG002|Overall Study|New Contraindication|0
6103363|NCT00778258|9720632|FG003|Overall Study|New Contraindication|0
6103364|NCT00778258|9720633|FG004|Overall Study|New Contraindication|0
6103365|NCT00778258|9720634|FG005|Overall Study|New Contraindication|0
6103366|NCT00778258|9720635|FG006|Overall Study|New Contraindication|0
6103367|NCT00778258|9720636|FG007|Overall Study|New Contraindication|1
6103368|NCT00778258|9720637|FG008|Overall Study|New Contraindication|0
6103369|NCT00778258|9720629|FG000|Overall Study|Non-compliance|0
6103370|NCT00778258|9720630|FG001|Overall Study|Non-compliance|0
6103371|NCT00778258|9720631|FG002|Overall Study|Non-compliance|0
6103372|NCT00778258|9720632|FG003|Overall Study|Non-compliance|1
6103373|NCT00778258|9720633|FG004|Overall Study|Non-compliance|0
6103374|NCT00778258|9720634|FG005|Overall Study|Non-compliance|0
6103375|NCT00778258|9720635|FG006|Overall Study|Non-compliance|0
6103376|NCT00778258|9720636|FG007|Overall Study|Non-compliance|0
6103377|NCT00778258|9720637|FG008|Overall Study|Non-compliance|0
6103378|NCT00778258|9720629|FG000|Overall Study|Other|0
6103379|NCT00778258|9720630|FG001|Overall Study|Other|0
6103380|NCT00778258|9720631|FG002|Overall Study|Other|0
6103381|NCT00778258|9720632|FG003|Overall Study|Other|0
6103382|NCT00778258|9720633|FG004|Overall Study|Other|0
6103383|NCT00778258|9720634|FG005|Overall Study|Other|0
6103384|NCT00778258|9720635|FG006|Overall Study|Other|1
6103385|NCT00778258|9720636|FG007|Overall Study|Other|0
6103386|NCT00778258|9720637|FG008|Overall Study|Other|0
6103387|NCT00778336|9720678|FG000|Index Procedure-Discharge|Death|6
6103388|NCT00778336|9720679|FG001|Index Procedure-Discharge|Death|3
6103389|NCT00778336|9720680|FG002|Index Procedure-Discharge|Death|2
6103390|NCT00778336|9720681|FG003|Index Procedure-Discharge|Death|0
6103391|NCT00778336|9720678|FG000|3 Month Follow Up|Lost to Follow-up|15
6103392|NCT00778336|9720679|FG001|3 Month Follow Up|Lost to Follow-up|20
6103393|NCT00778336|9720680|FG002|3 Month Follow Up|Lost to Follow-up|3
6103394|NCT00778336|9720681|FG003|3 Month Follow Up|Lost to Follow-up|0
6103395|NCT00778336|9720678|FG000|3 Month Follow Up|Death|8
6103396|NCT00778336|9720679|FG001|3 Month Follow Up|Death|3
6103397|NCT00778336|9720680|FG002|3 Month Follow Up|Death|2
6103398|NCT00778336|9720681|FG003|3 Month Follow Up|Death|0
6103399|NCT00778375|9720691|FG000|Overall Study|Ineligible|3
6103400|NCT00778622|9720700|FG000|Overall Study|Adverse Event|5
6103401|NCT00778622|9720701|FG001|Overall Study|Adverse Event|4
6103402|NCT00778622|9720702|FG002|Overall Study|Adverse Event|7
6103403|NCT00778622|9720700|FG000|Overall Study|Withdrawal by Subject|4
6103404|NCT00778622|9720701|FG001|Overall Study|Withdrawal by Subject|5
6103405|NCT00778622|9720702|FG002|Overall Study|Withdrawal by Subject|5
6103406|NCT00778622|9720700|FG000|Overall Study|Lost to Follow-up|3
6103407|NCT00778622|9720701|FG001|Overall Study|Lost to Follow-up|3
6103408|NCT00778622|9720702|FG002|Overall Study|Lost to Follow-up|2
6103409|NCT00778622|9720700|FG000|Overall Study|Protocol Violation|0
6103410|NCT00778622|9720701|FG001|Overall Study|Protocol Violation|3
6103411|NCT00778622|9720702|FG002|Overall Study|Protocol Violation|0
6103412|NCT00778622|9720700|FG000|Overall Study|Lack of Efficacy|2
6103413|NCT00778622|9720701|FG001|Overall Study|Lack of Efficacy|0
6103414|NCT00778622|9720702|FG002|Overall Study|Lack of Efficacy|0
6103415|NCT00778622|9720700|FG000|Overall Study|immigration|1
6103416|NCT00778622|9720701|FG001|Overall Study|immigration|0
6103417|NCT00778622|9720702|FG002|Overall Study|immigration|0
6103418|NCT00778622|9720700|FG000|Overall Study|Other|1
6103419|NCT00778622|9720701|FG001|Overall Study|Other|0
6103420|NCT00778622|9720702|FG002|Overall Study|Other|1
6103421|NCT00778817|9720723|FG000|Overall Study|Adverse Event|2
6103422|NCT00778817|9720723|FG000|Overall Study|Withdrawal by Subject|2
6103423|NCT00778830|9720729|FG000|Overall Study|Ongoing at data cut-off|0
6103424|NCT00778830|9720730|FG001|Overall Study|Ongoing at data cut-off|1
6103425|NCT00778895|9720743|FG000|Active Phase|Adverse Event|3
6103426|NCT00778895|9720744|FG001|Active Phase|Adverse Event|1
6103427|NCT00778895|9720745|FG002|Active Phase|Adverse Event|0
6103428|NCT00778895|9720743|FG000|Active Phase|Withdrawal by Subject|1
6103429|NCT00778895|9720744|FG001|Active Phase|Withdrawal by Subject|4
6103430|NCT00778895|9720745|FG002|Active Phase|Withdrawal by Subject|0
6103431|NCT00778895|9720743|FG000|Active Phase|Lost to Follow-up|1
6103432|NCT00778895|9720744|FG001|Active Phase|Lost to Follow-up|1
6103433|NCT00778895|9720745|FG002|Active Phase|Lost to Follow-up|0
6103434|NCT00778895|9720743|FG000|Active Phase|Other|2
6103435|NCT00778895|9720744|FG001|Active Phase|Other|0
6103436|NCT00778895|9720745|FG002|Active Phase|Other|0
6103437|NCT00778895|9720743|FG000|ESFU Phase|Adverse Event|2
6103438|NCT00778895|9720744|FG001|ESFU Phase|Adverse Event|1
6103439|NCT00778895|9720745|FG002|ESFU Phase|Adverse Event|0
6103440|NCT00778895|9720743|FG000|ESFU Phase|Withdrawal by Subject|1
6103441|NCT00778895|9720744|FG001|ESFU Phase|Withdrawal by Subject|4
6103442|NCT00778895|9720745|FG002|ESFU Phase|Withdrawal by Subject|0
6103443|NCT00778895|9720743|FG000|ESFU Phase|Lost to Follow-up|6
6103444|NCT00778895|9720744|FG001|ESFU Phase|Lost to Follow-up|7
6103445|NCT00778895|9720745|FG002|ESFU Phase|Lost to Follow-up|2
6103446|NCT00778895|9720743|FG000|ESFU Phase|Other|2
6103447|NCT00778895|9720744|FG001|ESFU Phase|Other|0
6103448|NCT00778895|9720745|FG002|ESFU Phase|Other|0
6103449|NCT00778921|9720757|FG000|Overall Study|Adverse Event|9
6103450|NCT00778921|9720758|FG001|Overall Study|Adverse Event|10
6103451|NCT00778921|9720759|FG002|Overall Study|Adverse Event|14
6103452|NCT00778921|9720757|FG000|Overall Study|Abnormal Laboratory Value(s)|1
6103453|NCT00778921|9720758|FG001|Overall Study|Abnormal Laboratory Value(s)|0
6103454|NCT00778921|9720759|FG002|Overall Study|Abnormal Laboratory Value(s)|0
6103455|NCT00778921|9720757|FG000|Overall Study|Abnormal Test Procedure Result(s)|0
6103456|NCT00778921|9720758|FG001|Overall Study|Abnormal Test Procedure Result(s)|0
6103457|NCT00778921|9720759|FG002|Overall Study|Abnormal Test Procedure Result(s)|2
6103458|NCT00778921|9720757|FG000|Overall Study|Unsatisfactory therapeutic response|1
6103459|NCT00778921|9720758|FG001|Overall Study|Unsatisfactory therapeutic response|1
6103460|NCT00778921|9720759|FG002|Overall Study|Unsatisfactory therapeutic response|1
6103461|NCT00778921|9720757|FG000|Overall Study|Patient No Longer Requires Study Drug|0
6205074|NCT01528345|9867080|FG000|Overall Study|Adverse Event|10
6205075|NCT01528345|9867081|FG001|Overall Study|Adverse Event|1
6205076|NCT01528345|9867080|FG000|Overall Study|Death|1
6285049|NCT02329730|9996758|FG005|Overall Study|Withdrawal by Subject|0
6285050|NCT02329730|9996759|FG006|Overall Study|Withdrawal by Subject|1
6285051|NCT02329730|9996760|FG007|Overall Study|Withdrawal by Subject|1
6285052|NCT02329730|9996761|FG008|Overall Study|Withdrawal by Subject|1
6285053|NCT02329730|9996762|FG009|Overall Study|Withdrawal by Subject|1
6285054|NCT02329730|9996763|FG010|Overall Study|Withdrawal by Subject|0
6285055|NCT02329730|9996764|FG011|Overall Study|Withdrawal by Subject|0
6285056|NCT02329743|9996785|FG000|Overall Study|Adverse Event|1
6285057|NCT02329743|9996786|FG001|Overall Study|Adverse Event|1
6285058|NCT02329743|9996787|FG002|Overall Study|Adverse Event|3
6285059|NCT02329743|9996785|FG000|Overall Study|Lost to Follow-up|1
6285060|NCT02329743|9996786|FG001|Overall Study|Lost to Follow-up|0
6285061|NCT02329743|9996787|FG002|Overall Study|Lost to Follow-up|1
6285062|NCT02329743|9996785|FG000|Overall Study|Withdrawal by Subject|4
6285063|NCT02329743|9996786|FG001|Overall Study|Withdrawal by Subject|4
6285064|NCT02329743|9996787|FG002|Overall Study|Withdrawal by Subject|1
6285065|NCT02329743|9996785|FG000|Overall Study|Other|0
6285066|NCT02329743|9996786|FG001|Overall Study|Other|2
6285067|NCT02329743|9996787|FG002|Overall Study|Other|3
6285068|NCT02330055|9996806|FG000|Overall Study|technical issues|2
6285069|NCT02330055|9996807|FG001|Overall Study|technical issues|0
6285070|NCT02330055|9996806|FG000|Overall Study|participant forgot to wear device|5
6285071|NCT02330055|9996807|FG001|Overall Study|participant forgot to wear device|5
6285072|NCT02330055|9996806|FG000|Overall Study|data for less than 60 minutes|3
6285073|NCT02330055|9996807|FG001|Overall Study|data for less than 60 minutes|3
6285074|NCT02330055|9996806|FG000|Overall Study|participant did not sleep|0
6285075|NCT02330055|9996807|FG001|Overall Study|participant did not sleep|1
6103462|NCT00778921|9720758|FG001|Overall Study|Patient No Longer Requires Study Drug|1
6103463|NCT00778921|9720759|FG002|Overall Study|Patient No Longer Requires Study Drug|0
6103464|NCT00778921|9720757|FG000|Overall Study|Patient withdrew request|3
6103465|NCT00778921|9720758|FG001|Overall Study|Patient withdrew request|1
6103466|NCT00778921|9720759|FG002|Overall Study|Patient withdrew request|6
6103467|NCT00778921|9720757|FG000|Overall Study|Lost to Follow-up|0
6103468|NCT00778921|9720758|FG001|Overall Study|Lost to Follow-up|2
6103469|NCT00778921|9720759|FG002|Overall Study|Lost to Follow-up|1
6103470|NCT00778921|9720757|FG000|Overall Study|Administrative Problems|1
6103471|NCT00778921|9720758|FG001|Overall Study|Administrative Problems|2
6103472|NCT00778921|9720759|FG002|Overall Study|Administrative Problems|0
6103473|NCT00778921|9720757|FG000|Overall Study|Protocol Violation|3
6103474|NCT00778921|9720758|FG001|Overall Study|Protocol Violation|0
6103475|NCT00778921|9720759|FG002|Overall Study|Protocol Violation|2
6103476|NCT00778921|9720757|FG000|Overall Study|Not treated|0
6103477|NCT00778921|9720758|FG001|Overall Study|Not treated|2
6103478|NCT00778921|9720759|FG002|Overall Study|Not treated|2
6103479|NCT00779025|9720767|FG000|Overall Study|Withdrawal by Subject|1
6103480|NCT00779142|9720780|FG000|Overall Study|Screen Failures|3
6103481|NCT00779246|9720796|FG000|Overall Study|Missing sufficient data for analysis|33
6103482|NCT00779246|9720797|FG001|Overall Study|Missing sufficient data for analysis|53
6103483|NCT00779259|9720803|FG000|Quinine Alone|Adverse Event|2
6103484|NCT00779324|9720848|FG000|Overall Study|Lost to Follow-up|2
6103485|NCT00779324|9720849|FG001|Overall Study|Lost to Follow-up|1
6103486|NCT00779324|9720848|FG000|Overall Study|Withdrawal by Subject|4
6103487|NCT00779324|9720849|FG001|Overall Study|Withdrawal by Subject|2
6103488|NCT00779324|9720848|FG000|Overall Study|Missed visit|1
6103489|NCT00779324|9720849|FG001|Overall Study|Missed visit|1
6103490|NCT00779402|9720857|FG000|Treatment Phase 1|Disease Progression|1
6103491|NCT00779402|9720858|FG001|Treatment Phase 1|Disease Progression|0
6103492|NCT00779402|9720857|FG000|Treatment Phase 1|Adverse Event|2
6103493|NCT00779402|9720858|FG001|Treatment Phase 1|Adverse Event|0
6103494|NCT00779402|9720857|FG000|Treatment Phase 1|Protocol Violation|1
6103495|NCT00779402|9720858|FG001|Treatment Phase 1|Protocol Violation|0
6103496|NCT00779402|9720857|FG000|Treatment Phase 1|Patient Refused to Continue|17
6103497|NCT00779402|9720858|FG001|Treatment Phase 1|Patient Refused to Continue|2
6103498|NCT00779402|9720857|FG000|Treatment Phase 1|Lost to Follow-up|0
6103499|NCT00779402|9720858|FG001|Treatment Phase 1|Lost to Follow-up|1
6103500|NCT00779402|9720857|FG000|Treatment Phase 1|Death|0
6103501|NCT00779402|9720858|FG001|Treatment Phase 1|Death|1
6103502|NCT00779402|9720857|FG000|Treatment Phase 1|Intercurrent Illness|1
6103503|NCT00779402|9720858|FG001|Treatment Phase 1|Intercurrent Illness|1
6103504|NCT00779402|9720857|FG000|Treatment Phase 1|Withdrawal by Subject|1
6103505|NCT00779402|9720858|FG001|Treatment Phase 1|Withdrawal by Subject|0
6103506|NCT00779402|9720857|FG000|Treatment Phase 1|Other|4
6103507|NCT00779402|9720858|FG001|Treatment Phase 1|Other|2
6103508|NCT00779402|9720857|FG000|Treatment Phase 1|Closure of Study|3
6103509|NCT00779402|9720858|FG001|Treatment Phase 1|Closure of Study|2
6103510|NCT00779402|9720857|FG000|Treatment Phase 1|Completed Protocol Visits|3
6103511|NCT00779402|9720858|FG001|Treatment Phase 1|Completed Protocol Visits|6
6103512|NCT00779402|9720857|FG000|Surveillance Phase|Protocol Violation|0
6103513|NCT00779402|9720858|FG001|Surveillance Phase|Protocol Violation|1
6103514|NCT00779402|9720857|FG000|Surveillance Phase|Patient refused to continue|22
6103515|NCT00779402|9720858|FG001|Surveillance Phase|Patient refused to continue|14
6103516|NCT00779402|9720857|FG000|Surveillance Phase|Lost to Follow-up|2
6103517|NCT00779402|9720858|FG001|Surveillance Phase|Lost to Follow-up|1
6103518|NCT00779402|9720857|FG000|Surveillance Phase|Death|0
6103519|NCT00779402|9720858|FG001|Surveillance Phase|Death|1
6103520|NCT00779402|9720857|FG000|Surveillance Phase|Intercurrent Illness|2
6103521|NCT00779402|9720858|FG001|Surveillance Phase|Intercurrent Illness|0
6103522|NCT00779402|9720857|FG000|Surveillance Phase|Other|5
6103523|NCT00779402|9720858|FG001|Surveillance Phase|Other|5
6103524|NCT00779402|9720857|FG000|Surveillance Phase|Withdrawal by Subject|4
6103525|NCT00779402|9720858|FG001|Surveillance Phase|Withdrawal by Subject|1
6103526|NCT00779402|9720857|FG000|Surveillance Phase|Closure of study|5
6103527|NCT00779402|9720858|FG001|Surveillance Phase|Closure of study|6
6103528|NCT00779402|9720857|FG000|Surveillance Phase|Completed Protocol Visits|3
6103529|NCT00779402|9720858|FG001|Surveillance Phase|Completed Protocol Visits|2
6103530|NCT00779402|9720857|FG000|Long-term Follow-up|Patient refused to continue|2
6103531|NCT00779402|9720858|FG001|Long-term Follow-up|Patient refused to continue|0
6103532|NCT00779402|9720857|FG000|Long-term Follow-up|Other|5
6103533|NCT00779402|9720858|FG001|Long-term Follow-up|Other|0
6103534|NCT00779402|9720857|FG000|Long-term Follow-up|Closure of Study|8
6103535|NCT00779402|9720858|FG001|Long-term Follow-up|Closure of Study|4
6103536|NCT00779402|9720857|FG000|Long-term Follow-up|Completed Protocol Visits|6
6103537|NCT00779402|9720858|FG001|Long-term Follow-up|Completed Protocol Visits|2
6103538|NCT00779467|9720868|FG000|Overall Study|Lack of Efficacy|11
6103539|NCT00779467|9720869|FG001|Overall Study|Lack of Efficacy|2
6103540|NCT00779467|9720870|FG002|Overall Study|Lack of Efficacy|6
6103541|NCT00779467|9720871|FG003|Overall Study|Lack of Efficacy|11
6103542|NCT00779467|9720868|FG000|Overall Study|failed inclusion criteria|3
6103543|NCT00779467|9720869|FG001|Overall Study|failed inclusion criteria|3
6103544|NCT00779467|9720870|FG002|Overall Study|failed inclusion criteria|1
6103545|NCT00779467|9720871|FG003|Overall Study|failed inclusion criteria|2
6103546|NCT00779467|9720868|FG000|Overall Study|missing data|1
6103547|NCT00779467|9720869|FG001|Overall Study|missing data|0
6103548|NCT00779467|9720870|FG002|Overall Study|missing data|1
6103549|NCT00779467|9720871|FG003|Overall Study|missing data|4
6103550|NCT00779467|9720868|FG000|Overall Study|technical issue|0
6103551|NCT00779467|9720869|FG001|Overall Study|technical issue|0
6103552|NCT00779467|9720870|FG002|Overall Study|technical issue|2
6103553|NCT00779467|9720871|FG003|Overall Study|technical issue|1
6103554|NCT00779467|9720868|FG000|Overall Study|unavailable research staff|0
6103555|NCT00779467|9720869|FG001|Overall Study|unavailable research staff|0
6103556|NCT00779467|9720870|FG002|Overall Study|unavailable research staff|0
6103557|NCT00779467|9720871|FG003|Overall Study|unavailable research staff|1
6103558|NCT00779506|9720881|FG000|Overall Study|Screening Failed|2
6103559|NCT00779506|9720881|FG000|Overall Study|Adverse Event|4
6103560|NCT00779506|9720881|FG000|Overall Study|Lack of Efficacy|11
6103561|NCT00779506|9720881|FG000|Overall Study|Protocol Violation|5
6103562|NCT00779506|9720881|FG000|Overall Study|Withdrawal by Subject|6
6103563|NCT00779506|9720881|FG000|Overall Study|Lost to Follow-up|1
6103564|NCT00779584|9720903|FG000|Overall Study|Protocol Violation|0
6103565|NCT00779584|9720904|FG001|Overall Study|Protocol Violation|0
6103566|NCT00779584|9720905|FG002|Overall Study|Protocol Violation|0
6103567|NCT00779584|9720906|FG003|Overall Study|Protocol Violation|0
6103568|NCT00779584|9720907|FG004|Overall Study|Protocol Violation|0
6103569|NCT00779584|9720908|FG005|Overall Study|Protocol Violation|1
6103570|NCT00779584|9720909|FG006|Overall Study|Protocol Violation|0
6103571|NCT00779584|9720910|FG007|Overall Study|Protocol Violation|0
6103572|NCT00779584|9720911|FG008|Overall Study|Protocol Violation|0
6103573|NCT00779584|9720903|FG000|Overall Study|Withdrawal by Subject|1
6103574|NCT00779584|9720904|FG001|Overall Study|Withdrawal by Subject|1
6103575|NCT00779584|9720905|FG002|Overall Study|Withdrawal by Subject|2
6103576|NCT00779584|9720906|FG003|Overall Study|Withdrawal by Subject|0
6103577|NCT00779584|9720907|FG004|Overall Study|Withdrawal by Subject|0
6103578|NCT00779584|9720908|FG005|Overall Study|Withdrawal by Subject|2
6103579|NCT00779584|9720909|FG006|Overall Study|Withdrawal by Subject|1
6103580|NCT00779584|9720910|FG007|Overall Study|Withdrawal by Subject|0
6103581|NCT00779584|9720911|FG008|Overall Study|Withdrawal by Subject|0
6103582|NCT00779584|9720903|FG000|Overall Study|Lost to Follow-up|0
6103583|NCT00779584|9720904|FG001|Overall Study|Lost to Follow-up|0
6103584|NCT00779584|9720905|FG002|Overall Study|Lost to Follow-up|0
6103585|NCT00779584|9720906|FG003|Overall Study|Lost to Follow-up|0
6103586|NCT00779584|9720907|FG004|Overall Study|Lost to Follow-up|1
6103587|NCT00779584|9720908|FG005|Overall Study|Lost to Follow-up|0
6103588|NCT00779584|9720909|FG006|Overall Study|Lost to Follow-up|0
6103589|NCT00779584|9720910|FG007|Overall Study|Lost to Follow-up|0
6103590|NCT00779584|9720911|FG008|Overall Study|Lost to Follow-up|0
6103591|NCT00779584|9720903|FG000|Overall Study|Progression of Disease|0
6103592|NCT00779584|9720904|FG001|Overall Study|Progression of Disease|1
6103593|NCT00779584|9720905|FG002|Overall Study|Progression of Disease|2
6103594|NCT00779584|9720906|FG003|Overall Study|Progression of Disease|6
6103595|NCT00779584|9720907|FG004|Overall Study|Progression of Disease|5
6103596|NCT00779584|9720908|FG005|Overall Study|Progression of Disease|1
6103597|NCT00779584|9720909|FG006|Overall Study|Progression of Disease|4
6103598|NCT00779584|9720910|FG007|Overall Study|Progression of Disease|2
6103599|NCT00779584|9720911|FG008|Overall Study|Progression of Disease|1
6103600|NCT00779584|9720903|FG000|Overall Study|Adverse Event|1
6103601|NCT00779584|9720904|FG001|Overall Study|Adverse Event|0
6103602|NCT00779584|9720905|FG002|Overall Study|Adverse Event|2
6103603|NCT00779584|9720906|FG003|Overall Study|Adverse Event|0
6103604|NCT00779584|9720907|FG004|Overall Study|Adverse Event|0
6103605|NCT00779584|9720908|FG005|Overall Study|Adverse Event|0
6103606|NCT00779584|9720909|FG006|Overall Study|Adverse Event|2
6103607|NCT00779584|9720910|FG007|Overall Study|Adverse Event|1
6103608|NCT00779584|9720911|FG008|Overall Study|Adverse Event|1
6103609|NCT00779584|9720903|FG000|Overall Study|Symptomatic Deterioration|1
6103610|NCT00779584|9720904|FG001|Overall Study|Symptomatic Deterioration|1
6103611|NCT00779584|9720905|FG002|Overall Study|Symptomatic Deterioration|1
6103612|NCT00779584|9720906|FG003|Overall Study|Symptomatic Deterioration|0
6103613|NCT00779584|9720907|FG004|Overall Study|Symptomatic Deterioration|0
6103614|NCT00779584|9720908|FG005|Overall Study|Symptomatic Deterioration|1
6103615|NCT00779584|9720909|FG006|Overall Study|Symptomatic Deterioration|1
6103616|NCT00779584|9720910|FG007|Overall Study|Symptomatic Deterioration|0
6103617|NCT00779584|9720911|FG008|Overall Study|Symptomatic Deterioration|0
6103618|NCT00779584|9720903|FG000|Overall Study|Ongoing in Study|0
6103619|NCT00779584|9720904|FG001|Overall Study|Ongoing in Study|0
6103620|NCT00779584|9720905|FG002|Overall Study|Ongoing in Study|0
6103621|NCT00779584|9720906|FG003|Overall Study|Ongoing in Study|0
6103622|NCT00779584|9720907|FG004|Overall Study|Ongoing in Study|1
6103623|NCT00779584|9720908|FG005|Overall Study|Ongoing in Study|1
6103624|NCT00779584|9720909|FG006|Overall Study|Ongoing in Study|0
6103625|NCT00779584|9720910|FG007|Overall Study|Ongoing in Study|0
6103626|NCT00779584|9720911|FG008|Overall Study|Ongoing in Study|0
6103627|NCT00779675|9720931|FG000|Treatment Period|Adverse Event|87
6103628|NCT00779675|9720931|FG000|Treatment Period|Treatment Failure|80
6103629|NCT00779675|9720931|FG000|Treatment Period|Transferred to Another Study|38
6103630|NCT00779675|9720931|FG000|Treatment Period|Lost to Follow-up|23
6103631|NCT00779675|9720931|FG000|Treatment Period|Withdrawal by Subject|46
6103632|NCT00779675|9720931|FG000|Treatment Period|Protocol Violation|54
6103633|NCT00779675|9720931|FG000|Treatment Period|Did Not Meet Protocol Eligibility|1
6103634|NCT00779675|9720931|FG000|Treatment Period|Administrative|3
6103635|NCT00779675|9720931|FG000|Extended Treatment Period|Reasons unrelated to study treatment|9
6103636|NCT00779675|9720931|FG000|Extended Treatment Period|Protocol Violation|13
6103637|NCT00779675|9720931|FG000|Extended Treatment Period|Adverse Event|6
6103638|NCT00779675|9720931|FG000|Extended Treatment Period|Treatment Failure|11
6103639|NCT00779675|9720931|FG000|Extended Treatment Period|Protocol defined clinical event|1
6103640|NCT00779675|9720931|FG000|Extended Treatment Period|Lost to Follow-up|6
6103641|NCT00779766|9720945|FG000|Month 24|Serious Adverse Event|2
6103642|NCT00779766|9720946|FG001|Month 24|Serious Adverse Event|3
6103643|NCT00779766|9720945|FG000|Month 24|Adverse Event|3
6103644|NCT00779766|9720946|FG001|Month 24|Adverse Event|3
6103645|NCT00779766|9720945|FG000|Month 24|Protocol Violation|3
6103646|NCT00779766|9720946|FG001|Month 24|Protocol Violation|1
6103647|NCT00779766|9720945|FG000|Month 24|Withdrawal by Subject|159
6103648|NCT00779766|9720946|FG001|Month 24|Withdrawal by Subject|127
6103649|NCT00779766|9720945|FG000|Month 24|Migrated/moved from study area|138
6103650|NCT00779766|9720946|FG001|Month 24|Migrated/moved from study area|162
6103651|NCT00779766|9720945|FG000|Month 24|Lost to Follow-up|9
6103652|NCT00779766|9720946|FG001|Month 24|Lost to Follow-up|9
6103653|NCT00779766|9720945|FG000|Month 24|Other|18
6103654|NCT00779766|9720946|FG001|Month 24|Other|27
6103655|NCT00779766|9720945|FG000|Month 48|Withdrawal by Subject|68
6103656|NCT00779766|9720946|FG001|Month 48|Withdrawal by Subject|63
6103657|NCT00779766|9720945|FG000|Month 48|Migrated/moved from study area|76
6103658|NCT00779766|9720946|FG001|Month 48|Migrated/moved from study area|75
6103659|NCT00779766|9720945|FG000|Month 48|Lost to Follow-up|29
6103660|NCT00779766|9720946|FG001|Month 48|Lost to Follow-up|30
6103661|NCT00779766|9720945|FG000|Month 48|Other|1
6103662|NCT00779766|9720946|FG001|Month 48|Other|0
6103663|NCT00779766|9720945|FG000|Month 72|Withdrawal by Subject|55
6103664|NCT00779766|9720946|FG001|Month 72|Withdrawal by Subject|71
6103665|NCT00779766|9720945|FG000|Month 72|Migrated/moved from study area|124
6103666|NCT00779766|9720946|FG001|Month 72|Migrated/moved from study area|109
6103667|NCT00779766|9720945|FG000|Month 72|Lost to Follow-up|6
6103668|NCT00779766|9720946|FG001|Month 72|Lost to Follow-up|8
6103669|NCT00779766|9720945|FG000|Month 72|Other|0
6103670|NCT00779766|9720946|FG001|Month 72|Other|1
6103671|NCT00779779|9720953|FG000|Overall Study|Adverse Event|1
6103672|NCT00779779|9720953|FG000|Overall Study|Protocol Violation|14
6103673|NCT00779779|9720953|FG000|Overall Study|Withdrawal by Subject|4
6103674|NCT00779779|9720953|FG000|Overall Study|Lost to Follow-up|5
6103675|NCT00779857|9720957|FG000|Overall Study|Death|1
6103676|NCT00779857|9720957|FG000|Overall Study|Withdrawal by Subject|3
6103677|NCT00779857|9720957|FG000|Overall Study|Missed Visit|2
6103678|NCT00779909|9720978|FG000|Overall Study|Lost to Follow-up|1
6103679|NCT00779909|9720979|FG001|Overall Study|Lost to Follow-up|0
6103680|NCT00779909|9720980|FG002|Overall Study|Lost to Follow-up|0
6103681|NCT00779909|9720981|FG003|Overall Study|Lost to Follow-up|1
6103682|NCT00779909|9720978|FG000|Overall Study|Withdrawal by Subject|0
6103683|NCT00779909|9720979|FG001|Overall Study|Withdrawal by Subject|1
6103684|NCT00779909|9720980|FG002|Overall Study|Withdrawal by Subject|0
6103685|NCT00779909|9720981|FG003|Overall Study|Withdrawal by Subject|0
6103686|NCT00780143|9721007|FG000|Overall Study|Progressive disease|1
6103687|NCT00780143|9721007|FG000|Overall Study|Toxicity|1
6103688|NCT00780143|9721007|FG000|Overall Study|Adverse Event|1
6103689|NCT00780273|9721024|FG000|Overall Study|Death|1
6103690|NCT00780273|9721024|FG000|Overall Study|Lost to Follow-up|1
6103691|NCT00780416|9721044|FG000|Overall Study|Physician Decision|3
6103692|NCT00780416|9721045|FG001|Overall Study|Physician Decision|3
6103693|NCT00780416|9721044|FG000|Overall Study|Protocol Violation|1
6103694|NCT00780416|9721045|FG001|Overall Study|Protocol Violation|0
6103695|NCT00780416|9721044|FG000|Overall Study|Withdrawal by Subject|8
6103696|NCT00780416|9721045|FG001|Overall Study|Withdrawal by Subject|6
6103697|NCT00780559|9721066|FG000|Overall Study|Lost to Follow-up|2
6205077|NCT01528345|9867081|FG001|Overall Study|Death|1
6205078|NCT01528345|9867080|FG000|Overall Study|Non-compliance with study treatment|1
6205079|NCT01528345|9867081|FG001|Overall Study|Non-compliance with study treatment|0
6205080|NCT01528345|9867080|FG000|Overall Study|Progressive Disease|26
6205081|NCT01528345|9867081|FG001|Overall Study|Progressive Disease|40
6205082|NCT01528345|9867080|FG000|Overall Study|Study Terminated by Sponsor|4
6205083|NCT01528345|9867081|FG001|Overall Study|Study Terminated by Sponsor|8
6285076|NCT02330081|9996813|FG000|Overall Study|Adverse Event|1
6285077|NCT02330081|9996813|FG000|Overall Study|Donation did not meet criteria|1
6285078|NCT02330081|9996813|FG000|Overall Study|Protocol Violation|6
6285079|NCT02330549|9996871|FG000|Overall Study|Adverse Event|1
6285080|NCT02330549|9996872|FG001|Overall Study|Adverse Event|0
6285081|NCT02330549|9996871|FG000|Overall Study|Subject withdrew consent|2
6285082|NCT02330549|9996872|FG001|Overall Study|Subject withdrew consent|1
6103698|NCT00780559|9721067|FG001|Overall Study|Lost to Follow-up|7
6103699|NCT00780559|9721066|FG000|Overall Study|Death|1
6103700|NCT00780559|9721067|FG001|Overall Study|Death|0
6103701|NCT00780910|9721126|FG000|Overall Study|Adverse Event|2
6205084|NCT01528345|9867080|FG000|Overall Study|Subject/Guardian Decision|5
6205085|NCT01528345|9867081|FG001|Overall Study|Subject/Guardian Decision|0
6103702|NCT00780975|9721139|FG000|Overall Study|Progressive disease|3
6103703|NCT00780975|9721139|FG000|Overall Study|Toxicity|5
6103704|NCT00781274|9721152|FG000|Overall Study|Withdrawal by Subject|2
6103705|NCT00781326|9721156|FG000|Phase I|Adverse Event|1
6103706|NCT00781326|9721156|FG000|Phase I|Withdrawal by Subject|1
6103707|NCT00781326|9721156|FG000|Phase I|Physician Decision|2
6103708|NCT00781365|9721162|FG000|Overall Study|Withdrawal by Subject|13
6103709|NCT00781365|9721163|FG001|Overall Study|Withdrawal by Subject|8
6103710|NCT00781365|9721162|FG000|Overall Study|Did Not Attend Visit|20
6103711|NCT00781365|9721163|FG001|Overall Study|Did Not Attend Visit|28
6103712|NCT00781365|9721162|FG000|Overall Study|Language barrier|1
6103713|NCT00781365|9721163|FG001|Overall Study|Language barrier|0
6103714|NCT00781391|9721172|FG000|Overall Study|never received study drug|24
6103715|NCT00781391|9721173|FG001|Overall Study|never received study drug|23
6103716|NCT00781391|9721174|FG002|Overall Study|never received study drug|32
6103717|NCT00781391|9721172|FG000|Overall Study|Protocol Violation|19
6103718|NCT00781391|9721173|FG001|Overall Study|Protocol Violation|17
6103719|NCT00781391|9721174|FG002|Overall Study|Protocol Violation|20
6103720|NCT00781391|9721172|FG000|Overall Study|Death|789
6103721|NCT00781391|9721173|FG001|Overall Study|Death|730
6103722|NCT00781391|9721174|FG002|Overall Study|Death|706
6103723|NCT00781391|9721172|FG000|Overall Study|Withdrawal by Subject|47
6103724|NCT00781391|9721173|FG001|Overall Study|Withdrawal by Subject|37
6103725|NCT00781391|9721174|FG002|Overall Study|Withdrawal by Subject|25
6103726|NCT00781391|9721172|FG000|Overall Study|Lost to Follow-up|0
6103727|NCT00781391|9721173|FG001|Overall Study|Lost to Follow-up|0
6103728|NCT00781391|9721174|FG002|Overall Study|Lost to Follow-up|1
6103729|NCT00781456|9721184|FG000|Overall Study|Adverse Event|3
6103730|NCT00781456|9721185|FG001|Overall Study|Adverse Event|3
6103731|NCT00781456|9721184|FG000|Overall Study|Withdrawal by Subject|3
6103732|NCT00781456|9721185|FG001|Overall Study|Withdrawal by Subject|5
6103733|NCT00781456|9721184|FG000|Overall Study|Protocol Violation|4
6103734|NCT00781456|9721185|FG001|Overall Study|Protocol Violation|1
6103735|NCT00781456|9721184|FG000|Overall Study|Noncompliance With Protocol|1
6103736|NCT00781456|9721185|FG001|Overall Study|Noncompliance With Protocol|1
6103737|NCT00781456|9721184|FG000|Overall Study|Lost to Follow-up|10
6103738|NCT00781456|9721185|FG001|Overall Study|Lost to Follow-up|5
6103739|NCT00781456|9721184|FG000|Overall Study|Other Reason, Unknown|0
6103740|NCT00781456|9721185|FG001|Overall Study|Other Reason, Unknown|1
6103741|NCT00781599|9721204|FG000|Overall Study|Lost to Follow-up|7
6103742|NCT00781599|9721205|FG001|Overall Study|Lost to Follow-up|4
6103743|NCT00781768|9721213|FG000|Overall Study|Not transplanted.|0
6103744|NCT00781768|9721214|FG001|Overall Study|Not transplanted.|2
6103745|NCT00781859|9721222|FG000|Overall Study|Adverse Event|2
6103746|NCT00781859|9721223|FG001|Overall Study|Adverse Event|2
6103747|NCT00781859|9721222|FG000|Overall Study|Withdrawal by Subject|8
6205086|NCT01528605|9867097|FG000|Overall Study|Lost to Follow-up|1
6205087|NCT01528605|9867098|FG001|Overall Study|Lost to Follow-up|0
6205088|NCT01528605|9867099|FG002|Overall Study|Lost to Follow-up|1
6205089|NCT01528605|9867100|FG003|Overall Study|Lost to Follow-up|1
6205090|NCT01528605|9867101|FG004|Overall Study|Lost to Follow-up|0
6205091|NCT01528605|9867102|FG005|Overall Study|Lost to Follow-up|0
6205092|NCT01528605|9867097|FG000|Overall Study|Death|1
6205093|NCT01528605|9867098|FG001|Overall Study|Death|0
6205094|NCT01528605|9867099|FG002|Overall Study|Death|0
6205095|NCT01528605|9867100|FG003|Overall Study|Death|0
6205096|NCT01528605|9867101|FG004|Overall Study|Death|0
6205097|NCT01528605|9867102|FG005|Overall Study|Death|0
6205098|NCT01528709|9867118|FG000|Overall Study|Death|2
6205099|NCT01528709|9867119|FG001|Overall Study|Death|0
6205100|NCT01528709|9867118|FG000|Overall Study|Withdrawal by Subject|10
6205101|NCT01528709|9867119|FG001|Overall Study|Withdrawal by Subject|15
6205102|NCT01528709|9867118|FG000|Overall Study|allergy|1
6205103|NCT01528709|9867119|FG001|Overall Study|allergy|0
6205104|NCT01528735|9867127|FG000|Treatment Period 1: Faldap/Del/RBV|Adverse Event|1
6205105|NCT01528735|9867128|FG001|Treatment Period 1: Faldap/Del/RBV|Adverse Event|1
6205106|NCT01528735|9867127|FG000|Treatment Period 2: Faldap/PegIFN/RBV|Withdrawal by Subject|1
6205107|NCT01528735|9867128|FG001|Treatment Period 2: Faldap/PegIFN/RBV|Withdrawal by Subject|0
6205108|NCT01528787|9867140|FG000|Overall Study|Withdrawal by Subject|0
6205109|NCT01528787|9867141|FG001|Overall Study|Withdrawal by Subject|0
6205110|NCT01528787|9867142|FG002|Overall Study|Withdrawal by Subject|0
6205111|NCT01528787|9867143|FG003|Overall Study|Withdrawal by Subject|1
6205112|NCT01528787|9867140|FG000|Overall Study|Family Emergency|0
6205113|NCT01528787|9867141|FG001|Overall Study|Family Emergency|0
6205114|NCT01528787|9867142|FG002|Overall Study|Family Emergency|1
6205115|NCT01528787|9867143|FG003|Overall Study|Family Emergency|0
6205116|NCT01528969|9867172|FG000|Overall Study|absent from the school at baseline|2
6205117|NCT01528969|9867173|FG001|Overall Study|absent from the school at baseline|0
6205118|NCT01529034|9867179|FG000|Overall Study|Discontinued prior to study treatment|14
6205119|NCT01529034|9867179|FG000|Overall Study|Site closure|62
6205120|NCT01529034|9867179|FG000|Overall Study|Study termination|29
6205121|NCT01529034|9867179|FG000|Overall Study|Withdrawal by Subject|25
6205122|NCT01529034|9867179|FG000|Overall Study|No treated SCs within protocol window|13
6103748|NCT00781859|9721223|FG001|Overall Study|Withdrawal by Subject|4
6103749|NCT00781859|9721222|FG000|Overall Study|Lost to Follow-up|6
6103750|NCT00781859|9721223|FG001|Overall Study|Lost to Follow-up|3
6103751|NCT00781859|9721222|FG000|Overall Study|Death|3
6103752|NCT00781859|9721223|FG001|Overall Study|Death|0
6103753|NCT00781885|9721229|FG000|Overall Study|Physician Decision|1
6103754|NCT00781911|9721244|FG000|Overall Study|Adverse Event|4
6103755|NCT00781911|9721245|FG001|Overall Study|Adverse Event|4
6103756|NCT00781911|9721244|FG000|Overall Study|Withdrawal by Subject|1
6103757|NCT00781911|9721245|FG001|Overall Study|Withdrawal by Subject|2
6103758|NCT00781911|9721244|FG000|Overall Study|Physician Decision|0
6103759|NCT00781911|9721245|FG001|Overall Study|Physician Decision|2
6103760|NCT00781911|9721244|FG000|Overall Study|Sponsor Decision|1
6103761|NCT00781911|9721245|FG001|Overall Study|Sponsor Decision|0
6103762|NCT00781937|9721255|FG000|Main Trial Period Through Week 56|Adverse Event|18
6103763|NCT00781937|9721256|FG001|Main Trial Period Through Week 56|Adverse Event|18
6103764|NCT00781937|9721255|FG000|Main Trial Period Through Week 56|Lack of Efficacy|0
6103765|NCT00781937|9721256|FG001|Main Trial Period Through Week 56|Lack of Efficacy|2
6103766|NCT00781937|9721255|FG000|Main Trial Period Through Week 56|Protocol Violation|8
6103767|NCT00781937|9721256|FG001|Main Trial Period Through Week 56|Protocol Violation|5
6103768|NCT00781937|9721255|FG000|Main Trial Period Through Week 56|Withdrawal by Subject|17
6103769|NCT00781937|9721256|FG001|Main Trial Period Through Week 56|Withdrawal by Subject|24
6103770|NCT00781937|9721255|FG000|Main Trial Period Through Week 56|Unclassified|10
6103771|NCT00781937|9721256|FG001|Main Trial Period Through Week 56|Unclassified|15
6103772|NCT00781937|9721255|FG000|Follow up Period (Week 56-68)|Protocol Violation|1
6103773|NCT00781937|9721256|FG001|Follow up Period (Week 56-68)|Protocol Violation|1
6103774|NCT00781937|9721255|FG000|Follow up Period (Week 56-68)|Unclassified|5
6103775|NCT00781937|9721256|FG001|Follow up Period (Week 56-68)|Unclassified|4
6103776|NCT00781963|9721274|FG000|Overall Study|Death|3
6103777|NCT00781963|9721275|FG001|Overall Study|Death|0
6103778|NCT00781963|9721274|FG000|Overall Study|Lost to Follow-up|2
6103779|NCT00781963|9721275|FG001|Overall Study|Lost to Follow-up|1
6103780|NCT00781963|9721274|FG000|Overall Study|Withdrawal by Subject|3
6103781|NCT00781963|9721275|FG001|Overall Study|Withdrawal by Subject|1
6103782|NCT00781963|9721274|FG000|Overall Study|Refused follow-up|9
6103783|NCT00781963|9721275|FG001|Overall Study|Refused follow-up|0
6103784|NCT00782067|9721281|FG000|Overall Study|Adverse Event|35
6103785|NCT00782067|9721281|FG000|Overall Study|Subject withdrew consent|11
6103786|NCT00782067|9721281|FG000|Overall Study|Lost to Follow-up|2
6103787|NCT00782067|9721281|FG000|Overall Study|Administrative problems|14
6103788|NCT00782067|9721281|FG000|Overall Study|Death|9
6103789|NCT00782067|9721281|FG000|Overall Study|Disease progression|43
6103790|NCT00782067|9721281|FG000|Overall Study|Protocol deviation|2
6103791|NCT00782171|9721287|FG000|Overall Study|Lost to Follow-up|2
6103792|NCT00782171|9721288|FG001|Overall Study|Lost to Follow-up|2
6103793|NCT00782171|9721287|FG000|Overall Study|Withdrawal by Subject|2
6103794|NCT00782171|9721288|FG001|Overall Study|Withdrawal by Subject|1
6103795|NCT00782171|9721287|FG000|Overall Study|complications|3
6103796|NCT00782171|9721288|FG001|Overall Study|complications|1
6103797|NCT00782171|9721287|FG000|Overall Study|others|7
6103798|NCT00782171|9721288|FG001|Overall Study|others|9
6103799|NCT00782171|9721287|FG000|Overall Study|not eligible|8
6103800|NCT00782171|9721288|FG001|Overall Study|not eligible|6
6103801|NCT00782210|9721297|FG000|Overall Study|Adverse Event|21
6103802|NCT00782210|9721298|FG001|Overall Study|Adverse Event|17
6103803|NCT00782210|9721299|FG002|Overall Study|Adverse Event|16
6103804|NCT00782210|9721297|FG000|Overall Study|Lost to Follow-up|2
6103805|NCT00782210|9721298|FG001|Overall Study|Lost to Follow-up|1
6103806|NCT00782210|9721299|FG002|Overall Study|Lost to Follow-up|2
6103807|NCT00782210|9721297|FG000|Overall Study|Withdrawal by Subject|11
6103808|NCT00782210|9721298|FG001|Overall Study|Withdrawal by Subject|8
6103809|NCT00782210|9721299|FG002|Overall Study|Withdrawal by Subject|11
6103810|NCT00782210|9721297|FG000|Overall Study|Non compliance with protocol|0
6103811|NCT00782210|9721298|FG001|Overall Study|Non compliance with protocol|3
6103812|NCT00782210|9721299|FG002|Overall Study|Non compliance with protocol|2
6103813|NCT00782210|9721297|FG000|Overall Study|Lack of Efficacy|13
6103814|NCT00782210|9721298|FG001|Overall Study|Lack of Efficacy|4
6103815|NCT00782210|9721299|FG002|Overall Study|Lack of Efficacy|1
6103816|NCT00782210|9721297|FG000|Overall Study|Other reason not described above|3
6103817|NCT00782210|9721298|FG001|Overall Study|Other reason not described above|2
6103818|NCT00782210|9721299|FG002|Overall Study|Other reason not described above|3
6103819|NCT00782275|9721316|FG000|Overall Study|Adverse Event|11
6103820|NCT00782275|9721316|FG000|Overall Study|Withdrawal by Subject|1
6103821|NCT00782275|9721316|FG000|Overall Study|Progressive Disease|21
6103822|NCT00782275|9721316|FG000|Overall Study|Physician Decision|4
6103823|NCT00782275|9721316|FG000|Overall Study|Not started treatment|1
6103824|NCT00782275|9721316|FG000|Overall Study|Other|3
6103825|NCT00782340|9721323|FG000|Open Label Titration|Adverse Event|12
6103826|NCT00782340|9721324|FG001|Open Label Titration|Adverse Event|0
6103827|NCT00782340|9721325|FG002|Open Label Titration|Adverse Event|0
6103828|NCT00782340|9721323|FG000|Open Label Titration|Treatment failure|50
6103829|NCT00782340|9721324|FG001|Open Label Titration|Treatment failure|0
6103830|NCT00782340|9721325|FG002|Open Label Titration|Treatment failure|0
6103831|NCT00782340|9721323|FG000|Open Label Titration|Protocol Violation|5
6103832|NCT00782340|9721324|FG001|Open Label Titration|Protocol Violation|0
6103833|NCT00782340|9721325|FG002|Open Label Titration|Protocol Violation|0
6103834|NCT00782340|9721323|FG000|Open Label Titration|Withdrawal by Subject|5
6103835|NCT00782340|9721324|FG001|Open Label Titration|Withdrawal by Subject|0
6103836|NCT00782340|9721325|FG002|Open Label Titration|Withdrawal by Subject|0
6103837|NCT00782340|9721323|FG000|Open Label Titration|Enrollment capped|16
6103838|NCT00782340|9721324|FG001|Open Label Titration|Enrollment capped|0
6103839|NCT00782340|9721325|FG002|Open Label Titration|Enrollment capped|0
6103840|NCT00782340|9721323|FG000|Open Label Titration|Did not meet responder criteria|2
6103841|NCT00782340|9721324|FG001|Open Label Titration|Did not meet responder criteria|0
6103842|NCT00782340|9721325|FG002|Open Label Titration|Did not meet responder criteria|0
6103843|NCT00782340|9721323|FG000|Open Label Titration|Lost to Follow-up|5
6103844|NCT00782340|9721324|FG001|Open Label Titration|Lost to Follow-up|0
6103845|NCT00782340|9721325|FG002|Open Label Titration|Lost to Follow-up|0
6103846|NCT00782340|9721323|FG000|Open Label Titration|Randomized in error|6
6103847|NCT00782340|9721324|FG001|Open Label Titration|Randomized in error|0
6103848|NCT00782340|9721325|FG002|Open Label Titration|Randomized in error|0
6103849|NCT00782418|9721336|FG000|Period 1 Procedure/Treatment Groups|Adverse Event|1
6103850|NCT00782418|9721337|FG001|Period 1 Procedure/Treatment Groups|Adverse Event|0
6103851|NCT00782418|9721338|FG002|Period 1 Procedure/Treatment Groups|Adverse Event|0
6103852|NCT00782418|9721339|FG003|Period 1 Procedure/Treatment Groups|Adverse Event|0
6103853|NCT00782418|9721340|FG004|Period 1 Procedure/Treatment Groups|Adverse Event|0
6103854|NCT00782418|9721341|FG005|Period 1 Procedure/Treatment Groups|Adverse Event|0
6103855|NCT00782418|9721342|FG006|Period 1 Procedure/Treatment Groups|Adverse Event|0
6103856|NCT00782418|9721336|FG000|Period 1 Procedure/Treatment Groups|Study placed on temporary hold|1
6103857|NCT00782418|9721337|FG001|Period 1 Procedure/Treatment Groups|Study placed on temporary hold|0
6103858|NCT00782418|9721338|FG002|Period 1 Procedure/Treatment Groups|Study placed on temporary hold|0
6103859|NCT00782418|9721339|FG003|Period 1 Procedure/Treatment Groups|Study placed on temporary hold|0
6103860|NCT00782418|9721340|FG004|Period 1 Procedure/Treatment Groups|Study placed on temporary hold|1
6103861|NCT00782418|9721341|FG005|Period 1 Procedure/Treatment Groups|Study placed on temporary hold|1
6103862|NCT00782418|9721342|FG006|Period 1 Procedure/Treatment Groups|Study placed on temporary hold|0
6103863|NCT00782496|9721358|FG000|Overall Study|Lost to Follow-up|14
6103864|NCT00782496|9721359|FG001|Overall Study|Lost to Follow-up|15
6205123|NCT01529034|9867179|FG000|Overall Study|Noncompliance|8
6205124|NCT01529034|9867179|FG000|Overall Study|Caregiver no longer available|7
6205125|NCT01529034|9867179|FG000|Overall Study|Adverse Event|4
6205126|NCT01529034|9867179|FG000|Overall Study|Protocol Violation|4
6205127|NCT01529034|9867179|FG000|Overall Study|Lack of Efficacy|4
6205128|NCT01529034|9867179|FG000|Overall Study|Investigator no longer available|2
6205129|NCT01529034|9867179|FG000|Overall Study|Study drug not available|2
6205130|NCT01529112|9867196|FG000|Overall Study|Adverse Event|2
6205131|NCT01529112|9867197|FG001|Overall Study|Adverse Event|0
6205132|NCT01529112|9867196|FG000|Overall Study|Death|59
6205133|NCT01529112|9867197|FG001|Overall Study|Death|38
6205134|NCT01529112|9867196|FG000|Overall Study|Protocol Violation|1
6205135|NCT01529112|9867197|FG001|Overall Study|Protocol Violation|0
6205136|NCT01529112|9867196|FG000|Overall Study|Withdrawal by Subject|7
6205137|NCT01529112|9867197|FG001|Overall Study|Withdrawal by Subject|3
6205138|NCT01529268|9867209|FG000|Overall Study|Lost to Follow-up|9
6205139|NCT01529268|9867210|FG001|Overall Study|Lost to Follow-up|3
6205140|NCT01529268|9867209|FG000|Overall Study|Moved|3
6205141|NCT01529268|9867210|FG001|Overall Study|Moved|0
6205142|NCT01529346|9867221|FG000|Overall Study|Lost to Follow-up|2
6205143|NCT01529346|9867222|FG001|Overall Study|Lost to Follow-up|0
6205144|NCT01529346|9867223|FG002|Overall Study|Lost to Follow-up|1
6205145|NCT01529346|9867224|FG003|Overall Study|Lost to Follow-up|0
6205146|NCT01529346|9867225|FG004|Overall Study|Lost to Follow-up|0
6205147|NCT01529346|9867221|FG000|Overall Study|Other|0
6205148|NCT01529346|9867222|FG001|Overall Study|Other|1
6205149|NCT01529346|9867223|FG002|Overall Study|Other|1
6205150|NCT01529346|9867224|FG003|Overall Study|Other|0
6205151|NCT01529346|9867225|FG004|Overall Study|Other|0
6205152|NCT01529385|9867240|FG000|Overall Study|Lost to Follow-up|2
6205153|NCT01529385|9867241|FG001|Overall Study|Lost to Follow-up|1
6205154|NCT01529515|9867278|FG000|TRANSITION PHASE|Adverse Event|16
6205155|NCT01529515|9867279|FG001|TRANSITION PHASE|Adverse Event|0
6205156|NCT01529515|9867280|FG002|TRANSITION PHASE|Adverse Event|0
6205157|NCT01529515|9867281|FG003|TRANSITION PHASE|Adverse Event|0
6205158|NCT01529515|9867278|FG000|TRANSITION PHASE|Death|1
6205159|NCT01529515|9867279|FG001|TRANSITION PHASE|Death|0
6205160|NCT01529515|9867280|FG002|TRANSITION PHASE|Death|0
6205161|NCT01529515|9867281|FG003|TRANSITION PHASE|Death|0
6205162|NCT01529515|9867278|FG000|TRANSITION PHASE|Lack of Efficacy|19
6205163|NCT01529515|9867279|FG001|TRANSITION PHASE|Lack of Efficacy|0
6205164|NCT01529515|9867280|FG002|TRANSITION PHASE|Lack of Efficacy|0
6205165|NCT01529515|9867281|FG003|TRANSITION PHASE|Lack of Efficacy|0
6205166|NCT01529515|9867278|FG000|TRANSITION PHASE|Lost to Follow-up|19
6205167|NCT01529515|9867279|FG001|TRANSITION PHASE|Lost to Follow-up|0
6205168|NCT01529515|9867280|FG002|TRANSITION PHASE|Lost to Follow-up|0
6205169|NCT01529515|9867281|FG003|TRANSITION PHASE|Lost to Follow-up|0
6205170|NCT01529515|9867278|FG000|TRANSITION PHASE|Protocol Violation|4
6205171|NCT01529515|9867279|FG001|TRANSITION PHASE|Protocol Violation|0
6205172|NCT01529515|9867280|FG002|TRANSITION PHASE|Protocol Violation|0
6205173|NCT01529515|9867281|FG003|TRANSITION PHASE|Protocol Violation|0
6205174|NCT01529515|9867278|FG000|TRANSITION PHASE|Withdrawal by Subject|51
6205175|NCT01529515|9867279|FG001|TRANSITION PHASE|Withdrawal by Subject|0
6103865|NCT00782509|9721369|FG000|Overall Study|Adverse Event|20
6103866|NCT00782509|9721370|FG001|Overall Study|Adverse Event|10
6103867|NCT00782509|9721371|FG002|Overall Study|Adverse Event|20
6103868|NCT00782509|9721369|FG000|Overall Study|Lost to Follow-up|1
6103869|NCT00782509|9721370|FG001|Overall Study|Lost to Follow-up|2
6103870|NCT00782509|9721371|FG002|Overall Study|Lost to Follow-up|3
6103871|NCT00782509|9721369|FG000|Overall Study|Withdrawal by Subject|3
6103872|NCT00782509|9721370|FG001|Overall Study|Withdrawal by Subject|5
6103873|NCT00782509|9721371|FG002|Overall Study|Withdrawal by Subject|8
6103874|NCT00782509|9721369|FG000|Overall Study|Non compliance with protocol|2
6103875|NCT00782509|9721370|FG001|Overall Study|Non compliance with protocol|0
6103876|NCT00782509|9721371|FG002|Overall Study|Non compliance with protocol|0
6103877|NCT00782509|9721369|FG000|Overall Study|Other reasons not stated above|5
6103878|NCT00782509|9721370|FG001|Overall Study|Other reasons not stated above|2
6103879|NCT00782509|9721371|FG002|Overall Study|Other reasons not stated above|3
6103880|NCT00782509|9721369|FG000|Overall Study|Lack of Efficacy|10
6103881|NCT00782509|9721370|FG001|Overall Study|Lack of Efficacy|5
6103882|NCT00782509|9721371|FG002|Overall Study|Lack of Efficacy|2
6103883|NCT00782626|9721386|FG000|Overall Study|Adverse Event|1
6103884|NCT00782626|9721386|FG000|Overall Study|Progressive Disease|5
6103885|NCT00782626|9721386|FG000|Overall Study|Other Complicating Disease|1
6103886|NCT00782717|9721403|FG000|Overall Study|Adverse Event|2
6103887|NCT00782717|9721404|FG001|Overall Study|Adverse Event|5
6103888|NCT00782717|9721403|FG000|Overall Study|Patient decision unrelated to AE|6
6103889|NCT00782717|9721404|FG001|Overall Study|Patient decision unrelated to AE|3
6103890|NCT00782717|9721403|FG000|Overall Study|Noncompliance|2
6103891|NCT00782717|9721404|FG001|Overall Study|Noncompliance|1
6103892|NCT00782717|9721403|FG000|Overall Study|Treatment failure|3
6103893|NCT00782717|9721404|FG001|Overall Study|Treatment failure|14
6103894|NCT00782717|9721403|FG000|Overall Study|Enrollment close prior to surgery|1
6103895|NCT00782717|9721404|FG001|Overall Study|Enrollment close prior to surgery|0
6103896|NCT00782717|9721403|FG000|Overall Study|Did not meet entrance criteria|1
6103897|NCT00782717|9721404|FG001|Overall Study|Did not meet entrance criteria|3
6103898|NCT00782717|9721403|FG000|Overall Study|Exited in error|0
6103899|NCT00782717|9721404|FG001|Overall Study|Exited in error|2
6103900|NCT00782795|9721416|FG000|Overall Study|Withdrawal by Subject|1
6103901|NCT00782795|9721417|FG001|Overall Study|Withdrawal by Subject|2
6103902|NCT00782834|9721447|FG000|Treatment Phase|fibrous tumor not GIST|1
6103903|NCT00783094|9721454|FG000|Randomized Double-Blind Treatment Period|Adverse Event|4
6103904|NCT00783094|9721455|FG001|Randomized Double-Blind Treatment Period|Adverse Event|5
6103905|NCT00783094|9721456|FG002|Randomized Double-Blind Treatment Period|Adverse Event|5
6103906|NCT00783094|9721454|FG000|Randomized Double-Blind Treatment Period|Lack of Efficacy|0
6103907|NCT00783094|9721455|FG001|Randomized Double-Blind Treatment Period|Lack of Efficacy|2
6103908|NCT00783094|9721456|FG002|Randomized Double-Blind Treatment Period|Lack of Efficacy|1
6103909|NCT00783094|9721454|FG000|Randomized Double-Blind Treatment Period|Physician Decision|0
6103910|NCT00783094|9721455|FG001|Randomized Double-Blind Treatment Period|Physician Decision|2
6103911|NCT00783094|9721456|FG002|Randomized Double-Blind Treatment Period|Physician Decision|0
6103912|NCT00783094|9721454|FG000|Randomized Double-Blind Treatment Period|Protocol Violation|1
6103913|NCT00783094|9721455|FG001|Randomized Double-Blind Treatment Period|Protocol Violation|2
6103914|NCT00783094|9721456|FG002|Randomized Double-Blind Treatment Period|Protocol Violation|1
6103915|NCT00783094|9721454|FG000|Randomized Double-Blind Treatment Period|Withdrawal by Subject|2
6103916|NCT00783094|9721455|FG001|Randomized Double-Blind Treatment Period|Withdrawal by Subject|1
6103917|NCT00783094|9721456|FG002|Randomized Double-Blind Treatment Period|Withdrawal by Subject|2
6103918|NCT00783094|9721454|FG000|Open-Label Extension Period|Adverse Event|12
6103919|NCT00783094|9721455|FG001|Open-Label Extension Period|Adverse Event|7
6103920|NCT00783094|9721456|FG002|Open-Label Extension Period|Adverse Event|16
6103921|NCT00783094|9721454|FG000|Open-Label Extension Period|Death|0
6103922|NCT00783094|9721455|FG001|Open-Label Extension Period|Death|0
6103923|NCT00783094|9721456|FG002|Open-Label Extension Period|Death|1
6103924|NCT00783094|9721454|FG000|Open-Label Extension Period|Protocol Violation|4
6103925|NCT00783094|9721455|FG001|Open-Label Extension Period|Protocol Violation|5
6103926|NCT00783094|9721456|FG002|Open-Label Extension Period|Protocol Violation|7
6103927|NCT00783094|9721454|FG000|Open-Label Extension Period|Withdrawal by Subject|1
6103928|NCT00783094|9721455|FG001|Open-Label Extension Period|Withdrawal by Subject|1
6103929|NCT00783094|9721456|FG002|Open-Label Extension Period|Withdrawal by Subject|3
6103930|NCT00783094|9721454|FG000|Open-Label Extension Period|Physician Decision|4
6103931|NCT00783094|9721455|FG001|Open-Label Extension Period|Physician Decision|2
6103932|NCT00783094|9721456|FG002|Open-Label Extension Period|Physician Decision|3
6103933|NCT00783094|9721454|FG000|Open-Label Extension Period|Lack of Efficacy|1
6103934|NCT00783094|9721455|FG001|Open-Label Extension Period|Lack of Efficacy|4
6103935|NCT00783094|9721456|FG002|Open-Label Extension Period|Lack of Efficacy|0
6103936|NCT00783198|9721470|FG000|Overall Study|Adverse Event|15
6103937|NCT00783198|9721471|FG001|Overall Study|Adverse Event|19
6103938|NCT00783198|9721472|FG002|Overall Study|Adverse Event|3
6103939|NCT00783198|9721470|FG000|Overall Study|Lost to Follow-up|11
6103940|NCT00783198|9721471|FG001|Overall Study|Lost to Follow-up|1
6103941|NCT00783198|9721472|FG002|Overall Study|Lost to Follow-up|7
6103942|NCT00783198|9721470|FG000|Overall Study|Withdrawal by Subject|22
6103943|NCT00783198|9721471|FG001|Overall Study|Withdrawal by Subject|14
6103944|NCT00783198|9721472|FG002|Overall Study|Withdrawal by Subject|20
6103945|NCT00783198|9721470|FG000|Overall Study|Noncompliance with protocol|7
6103946|NCT00783198|9721471|FG001|Overall Study|Noncompliance with protocol|7
6103947|NCT00783198|9721472|FG002|Overall Study|Noncompliance with protocol|10
6103948|NCT00783198|9721470|FG000|Overall Study|Did not meet protocol eligibility|0
6103949|NCT00783198|9721471|FG001|Overall Study|Did not meet protocol eligibility|1
6103950|NCT00783198|9721472|FG002|Overall Study|Did not meet protocol eligibility|0
6103951|NCT00783198|9721470|FG000|Overall Study|Administrative|2
6103952|NCT00783198|9721471|FG001|Overall Study|Administrative|1
6103953|NCT00783198|9721472|FG002|Overall Study|Administrative|2
6103954|NCT00783289|9721484|FG000|Overall Study|Protocol Violation|0
6103955|NCT00783289|9721485|FG001|Overall Study|Protocol Violation|1
6103956|NCT00783289|9721486|FG002|Overall Study|Protocol Violation|0
6103957|NCT00783289|9721487|FG003|Overall Study|Protocol Violation|0
6103958|NCT00783302|9721500|FG000|Overall Study|Lost to Follow-up|17
6103959|NCT00783302|9721500|FG000|Overall Study|Technical Problems|11
6103960|NCT00783302|9721500|FG000|Overall Study|Protocol Violation|3
6103961|NCT00783302|9721500|FG000|Overall Study|Physician Decision|1
6103962|NCT00783302|9721500|FG000|Overall Study|Withdrawal by Subject|3
6103963|NCT00783432|9721529|FG000|Overall Study|Adverse Event|22
6103964|NCT00783432|9721530|FG001|Overall Study|Adverse Event|17
6103965|NCT00783432|9721529|FG000|Overall Study|Lack of Efficacy|20
6103966|NCT00783432|9721530|FG001|Overall Study|Lack of Efficacy|21
6103967|NCT00783432|9721529|FG000|Overall Study|Lost to Follow-up|11
6103968|NCT00783432|9721530|FG001|Overall Study|Lost to Follow-up|6
6103969|NCT00783432|9721529|FG000|Overall Study|Withdrawal by Subject|23
6103970|NCT00783432|9721530|FG001|Overall Study|Withdrawal by Subject|20
6103971|NCT00783432|9721529|FG000|Overall Study|subject moved|3
6103972|NCT00783432|9721530|FG001|Overall Study|subject moved|5
6103973|NCT00783432|9721529|FG000|Overall Study|Protocol Violation|6
6103974|NCT00783432|9721530|FG001|Overall Study|Protocol Violation|9
6103975|NCT00783692|9721556|FG000|Induction Phase|Adverse Event|7
6103976|NCT00783692|9721557|FG001|Induction Phase|Adverse Event|9
6103977|NCT00783692|9721558|FG002|Induction Phase|Adverse Event|24
6103978|NCT00783692|9721559|FG003|Induction Phase|Adverse Event|0
6103979|NCT00783692|9721560|FG004|Induction Phase|Adverse Event|0
6103980|NCT00783692|9721561|FG005|Induction Phase|Adverse Event|0
6103981|NCT00783692|9721562|FG006|Induction Phase|Adverse Event|0
6103982|NCT00783692|9721556|FG000|Induction Phase|Protocol Violation|0
6103983|NCT00783692|9721557|FG001|Induction Phase|Protocol Violation|0
6103984|NCT00783692|9721558|FG002|Induction Phase|Protocol Violation|1
6103985|NCT00783692|9721559|FG003|Induction Phase|Protocol Violation|0
6103986|NCT00783692|9721560|FG004|Induction Phase|Protocol Violation|0
6103987|NCT00783692|9721561|FG005|Induction Phase|Protocol Violation|0
6103988|NCT00783692|9721562|FG006|Induction Phase|Protocol Violation|0
6103989|NCT00783692|9721556|FG000|Induction Phase|Lack of Efficacy|1
6103990|NCT00783692|9721557|FG001|Induction Phase|Lack of Efficacy|3
6103991|NCT00783692|9721558|FG002|Induction Phase|Lack of Efficacy|28
6103992|NCT00783692|9721559|FG003|Induction Phase|Lack of Efficacy|0
6103993|NCT00783692|9721560|FG004|Induction Phase|Lack of Efficacy|0
6103994|NCT00783692|9721561|FG005|Induction Phase|Lack of Efficacy|0
6103995|NCT00783692|9721562|FG006|Induction Phase|Lack of Efficacy|0
6103996|NCT00783692|9721556|FG000|Induction Phase|Withdrawal by Subject|3
6103997|NCT00783692|9721557|FG001|Induction Phase|Withdrawal by Subject|9
6103998|NCT00783692|9721558|FG002|Induction Phase|Withdrawal by Subject|16
6103999|NCT00783692|9721559|FG003|Induction Phase|Withdrawal by Subject|0
6104000|NCT00783692|9721560|FG004|Induction Phase|Withdrawal by Subject|0
6104001|NCT00783692|9721561|FG005|Induction Phase|Withdrawal by Subject|0
6104002|NCT00783692|9721562|FG006|Induction Phase|Withdrawal by Subject|0
6104003|NCT00783692|9721556|FG000|Induction Phase|Lost to Follow-up|0
6104004|NCT00783692|9721557|FG001|Induction Phase|Lost to Follow-up|0
6104005|NCT00783692|9721558|FG002|Induction Phase|Lost to Follow-up|3
6104006|NCT00783692|9721559|FG003|Induction Phase|Lost to Follow-up|0
6104007|NCT00783692|9721560|FG004|Induction Phase|Lost to Follow-up|0
6104008|NCT00783692|9721561|FG005|Induction Phase|Lost to Follow-up|0
6104009|NCT00783692|9721562|FG006|Induction Phase|Lost to Follow-up|0
6104010|NCT00783692|9721556|FG000|Induction Phase|Other|0
6104011|NCT00783692|9721557|FG001|Induction Phase|Other|0
6104012|NCT00783692|9721558|FG002|Induction Phase|Other|2
6104013|NCT00783692|9721559|FG003|Induction Phase|Other|0
6104014|NCT00783692|9721560|FG004|Induction Phase|Other|0
6104015|NCT00783692|9721561|FG005|Induction Phase|Other|0
6104016|NCT00783692|9721562|FG006|Induction Phase|Other|0
6104017|NCT00783692|9721556|FG000|Maintenance Phase|Adverse Event|7
6104018|NCT00783692|9721557|FG001|Maintenance Phase|Adverse Event|0
6104019|NCT00783692|9721558|FG002|Maintenance Phase|Adverse Event|0
6104020|NCT00783692|9721559|FG003|Maintenance Phase|Adverse Event|15
6104021|NCT00783692|9721560|FG004|Maintenance Phase|Adverse Event|12
6104022|NCT00783692|9721561|FG005|Maintenance Phase|Adverse Event|9
6104023|NCT00783692|9721562|FG006|Maintenance Phase|Adverse Event|38
6104024|NCT00783692|9721556|FG000|Maintenance Phase|Protocol Violation|0
6104025|NCT00783692|9721557|FG001|Maintenance Phase|Protocol Violation|0
6104026|NCT00783692|9721558|FG002|Maintenance Phase|Protocol Violation|0
6104027|NCT00783692|9721559|FG003|Maintenance Phase|Protocol Violation|1
6104028|NCT00783692|9721560|FG004|Maintenance Phase|Protocol Violation|2
6104029|NCT00783692|9721561|FG005|Maintenance Phase|Protocol Violation|3
6104030|NCT00783692|9721562|FG006|Maintenance Phase|Protocol Violation|4
6104031|NCT00783692|9721556|FG000|Maintenance Phase|Lack of Efficacy|79
6104032|NCT00783692|9721557|FG001|Maintenance Phase|Lack of Efficacy|0
6104033|NCT00783692|9721558|FG002|Maintenance Phase|Lack of Efficacy|0
6104034|NCT00783692|9721559|FG003|Maintenance Phase|Lack of Efficacy|64
6104035|NCT00783692|9721560|FG004|Maintenance Phase|Lack of Efficacy|58
6104036|NCT00783692|9721561|FG005|Maintenance Phase|Lack of Efficacy|48
6104037|NCT00783692|9721562|FG006|Maintenance Phase|Lack of Efficacy|177
6104038|NCT00783692|9721556|FG000|Maintenance Phase|Withdrawal by Subject|7
6104039|NCT00783692|9721557|FG001|Maintenance Phase|Withdrawal by Subject|0
6104040|NCT00783692|9721558|FG002|Maintenance Phase|Withdrawal by Subject|0
6104041|NCT00783692|9721559|FG003|Maintenance Phase|Withdrawal by Subject|7
6104042|NCT00783692|9721560|FG004|Maintenance Phase|Withdrawal by Subject|6
6104043|NCT00783692|9721561|FG005|Maintenance Phase|Withdrawal by Subject|9
6104044|NCT00783692|9721562|FG006|Maintenance Phase|Withdrawal by Subject|24
6104045|NCT00783692|9721556|FG000|Maintenance Phase|Lost to Follow-up|2
6104046|NCT00783692|9721557|FG001|Maintenance Phase|Lost to Follow-up|0
6104047|NCT00783692|9721558|FG002|Maintenance Phase|Lost to Follow-up|0
6104048|NCT00783692|9721559|FG003|Maintenance Phase|Lost to Follow-up|1
6104049|NCT00783692|9721560|FG004|Maintenance Phase|Lost to Follow-up|3
6104050|NCT00783692|9721561|FG005|Maintenance Phase|Lost to Follow-up|2
6104051|NCT00783692|9721562|FG006|Maintenance Phase|Lost to Follow-up|5
6104052|NCT00783692|9721556|FG000|Maintenance Phase|Other|0
6104053|NCT00783692|9721557|FG001|Maintenance Phase|Other|0
6104054|NCT00783692|9721558|FG002|Maintenance Phase|Other|0
6104055|NCT00783692|9721559|FG003|Maintenance Phase|Other|1
6104056|NCT00783692|9721560|FG004|Maintenance Phase|Other|0
6104057|NCT00783692|9721561|FG005|Maintenance Phase|Other|1
6104058|NCT00783692|9721562|FG006|Maintenance Phase|Other|1
6104059|NCT00783705|9721577|FG000|Overall Study|Adverse Event|2
6104060|NCT00783705|9721578|FG001|Overall Study|Adverse Event|0
6104061|NCT00783705|9721577|FG000|Overall Study|Withdrawal by Subject|3
6104062|NCT00783705|9721578|FG001|Overall Study|Withdrawal by Subject|2
6104063|NCT00783705|9721577|FG000|Overall Study|Lost to Follow-up|1
6104064|NCT00783705|9721578|FG001|Overall Study|Lost to Follow-up|3
6104065|NCT00783718|9721587|FG000|Induction Phase|Adverse Event|4
6104066|NCT00783718|9721588|FG001|Induction Phase|Adverse Event|0
6104067|NCT00783718|9721589|FG002|Induction Phase|Adverse Event|7
6104068|NCT00783718|9721590|FG003|Induction Phase|Adverse Event|0
6104069|NCT00783718|9721591|FG004|Induction Phase|Adverse Event|0
6104070|NCT00783718|9721592|FG005|Induction Phase|Adverse Event|0
6104071|NCT00783718|9721593|FG006|Induction Phase|Adverse Event|0
6104072|NCT00783718|9721587|FG000|Induction Phase|Protocol Violation|1
6104073|NCT00783718|9721588|FG001|Induction Phase|Protocol Violation|1
6104074|NCT00783718|9721589|FG002|Induction Phase|Protocol Violation|6
6104075|NCT00783718|9721590|FG003|Induction Phase|Protocol Violation|0
6104076|NCT00783718|9721591|FG004|Induction Phase|Protocol Violation|0
6104077|NCT00783718|9721592|FG005|Induction Phase|Protocol Violation|0
6104078|NCT00783718|9721593|FG006|Induction Phase|Protocol Violation|0
6104079|NCT00783718|9721587|FG000|Induction Phase|Lack of Efficacy|5
6104080|NCT00783718|9721588|FG001|Induction Phase|Lack of Efficacy|2
6104081|NCT00783718|9721589|FG002|Induction Phase|Lack of Efficacy|14
6104082|NCT00783718|9721590|FG003|Induction Phase|Lack of Efficacy|0
6104083|NCT00783718|9721591|FG004|Induction Phase|Lack of Efficacy|0
6104084|NCT00783718|9721592|FG005|Induction Phase|Lack of Efficacy|0
6104085|NCT00783718|9721593|FG006|Induction Phase|Lack of Efficacy|0
6104086|NCT00783718|9721587|FG000|Induction Phase|Withdrawal by Subject|3
6104087|NCT00783718|9721588|FG001|Induction Phase|Withdrawal by Subject|4
6104088|NCT00783718|9721589|FG002|Induction Phase|Withdrawal by Subject|8
6104089|NCT00783718|9721590|FG003|Induction Phase|Withdrawal by Subject|0
6104090|NCT00783718|9721591|FG004|Induction Phase|Withdrawal by Subject|0
6104091|NCT00783718|9721592|FG005|Induction Phase|Withdrawal by Subject|0
6104092|NCT00783718|9721593|FG006|Induction Phase|Withdrawal by Subject|0
6104093|NCT00783718|9721587|FG000|Induction Phase|Lost to Follow-up|1
6104094|NCT00783718|9721588|FG001|Induction Phase|Lost to Follow-up|0
6104095|NCT00783718|9721589|FG002|Induction Phase|Lost to Follow-up|1
6104096|NCT00783718|9721590|FG003|Induction Phase|Lost to Follow-up|0
6104097|NCT00783718|9721591|FG004|Induction Phase|Lost to Follow-up|0
6104098|NCT00783718|9721592|FG005|Induction Phase|Lost to Follow-up|0
6104099|NCT00783718|9721593|FG006|Induction Phase|Lost to Follow-up|0
6104100|NCT00783718|9721587|FG000|Maintenance Phase|Adverse Event|12
6104101|NCT00783718|9721588|FG001|Maintenance Phase|Adverse Event|0
6104102|NCT00783718|9721589|FG002|Maintenance Phase|Adverse Event|0
6104103|NCT00783718|9721590|FG003|Maintenance Phase|Adverse Event|15
6104104|NCT00783718|9721591|FG004|Maintenance Phase|Adverse Event|7
6104105|NCT00783718|9721592|FG005|Maintenance Phase|Adverse Event|6
6104106|NCT00783718|9721593|FG006|Maintenance Phase|Adverse Event|16
6104107|NCT00783718|9721587|FG000|Maintenance Phase|Protocol Violation|1
6104108|NCT00783718|9721588|FG001|Maintenance Phase|Protocol Violation|0
6104109|NCT00783718|9721589|FG002|Maintenance Phase|Protocol Violation|0
6104110|NCT00783718|9721590|FG003|Maintenance Phase|Protocol Violation|0
6104111|NCT00783718|9721591|FG004|Maintenance Phase|Protocol Violation|0
6104112|NCT00783718|9721592|FG005|Maintenance Phase|Protocol Violation|0
6104113|NCT00783718|9721593|FG006|Maintenance Phase|Protocol Violation|2
6104114|NCT00783718|9721587|FG000|Maintenance Phase|Lack of Efficacy|83
6104115|NCT00783718|9721588|FG001|Maintenance Phase|Lack of Efficacy|0
6104116|NCT00783718|9721589|FG002|Maintenance Phase|Lack of Efficacy|0
6104117|NCT00783718|9721590|FG003|Maintenance Phase|Lack of Efficacy|61
6104118|NCT00783718|9721591|FG004|Maintenance Phase|Lack of Efficacy|31
6104119|NCT00783718|9721592|FG005|Maintenance Phase|Lack of Efficacy|33
6104120|NCT00783718|9721593|FG006|Maintenance Phase|Lack of Efficacy|155
6104121|NCT00783718|9721587|FG000|Maintenance Phase|Withdrawal by Subject|6
6104122|NCT00783718|9721588|FG001|Maintenance Phase|Withdrawal by Subject|0
6104123|NCT00783718|9721589|FG002|Maintenance Phase|Withdrawal by Subject|0
6104124|NCT00783718|9721590|FG003|Maintenance Phase|Withdrawal by Subject|2
6104125|NCT00783718|9721591|FG004|Maintenance Phase|Withdrawal by Subject|5
6104126|NCT00783718|9721592|FG005|Maintenance Phase|Withdrawal by Subject|2
6104127|NCT00783718|9721593|FG006|Maintenance Phase|Withdrawal by Subject|20
6104128|NCT00783718|9721587|FG000|Maintenance Phase|Lost to Follow-up|3
6104129|NCT00783718|9721588|FG001|Maintenance Phase|Lost to Follow-up|0
6104130|NCT00783718|9721589|FG002|Maintenance Phase|Lost to Follow-up|0
6104131|NCT00783718|9721590|FG003|Maintenance Phase|Lost to Follow-up|0
6104132|NCT00783718|9721591|FG004|Maintenance Phase|Lost to Follow-up|2
6104133|NCT00783718|9721592|FG005|Maintenance Phase|Lost to Follow-up|0
6104134|NCT00783718|9721593|FG006|Maintenance Phase|Lost to Follow-up|2
6104135|NCT00783796|9721603|FG000|Overall Study|Did not receive any stent|4
6104136|NCT00783796|9721603|FG000|Overall Study|Received non-XIENCE V stent|1
6104137|NCT00783796|9721603|FG000|Overall Study|Received commercial XIENCE V stent|1
6104138|NCT00783835|9721609|FG000|Overall Study|Adverse Event|3
6104139|NCT00783835|9721609|FG000|Overall Study|Medical Criteria|1
6104140|NCT00783835|9721609|FG000|Overall Study|Withdrawal by Subject|2
6104141|NCT00783835|9721609|FG000|Overall Study|Lost to Follow-up|1
6104142|NCT00783835|9721609|FG000|Overall Study|Participant not Adherent|3
6104143|NCT00784134|9721654|FG000|Overall Study|Lost to Follow-up|3
6104144|NCT00784134|9721655|FG001|Overall Study|Lost to Follow-up|6
6104145|NCT00784147|9721663|FG000|Overall Study|Lost to Follow-up|2
6104146|NCT00784147|9721664|FG001|Overall Study|Lost to Follow-up|4
6104147|NCT00784147|9721663|FG000|Overall Study|Withdrawal by Subject|1
6104148|NCT00784147|9721664|FG001|Overall Study|Withdrawal by Subject|3
6104149|NCT00784147|9721663|FG000|Overall Study|Physician Decision|2
6104150|NCT00784147|9721664|FG001|Overall Study|Physician Decision|1
6104151|NCT00784147|9721663|FG000|Overall Study|Protocol Violation|1
6104152|NCT00784147|9721664|FG001|Overall Study|Protocol Violation|1
6104153|NCT00784147|9721663|FG000|Overall Study|Death|2
6104154|NCT00784147|9721664|FG001|Overall Study|Death|0
6104155|NCT00784238|9721691|FG000|Overall Study|Adverse Event|14
6104156|NCT00784238|9721691|FG000|Overall Study|Death|2
6104157|NCT00784238|9721691|FG000|Overall Study|Lack of Efficacy|33
6104158|NCT00784238|9721691|FG000|Overall Study|Lost to Follow-up|29
6104159|NCT00784238|9721691|FG000|Overall Study|Pregnancy|1
6104160|NCT00784238|9721691|FG000|Overall Study|Withdrawal by Subject|26
6104161|NCT00784238|9721691|FG000|Overall Study|Other|14
6104162|NCT00784277|9721702|FG000|IR Treatment|Adverse Event|4
6104163|NCT00784277|9721703|FG001|IR Treatment|Adverse Event|8
6104164|NCT00784277|9721704|FG002|IR Treatment|Adverse Event|19
6104165|NCT00784277|9721705|FG003|IR Treatment|Adverse Event|35
6104166|NCT00784277|9721706|FG004|IR Treatment|Adverse Event|0
6104167|NCT00784277|9721707|FG005|IR Treatment|Adverse Event|0
6104168|NCT00784277|9721708|FG006|IR Treatment|Adverse Event|0
6104169|NCT00784277|9721702|FG000|IR Treatment|Lack of Efficacy|4
6104170|NCT00784277|9721703|FG001|IR Treatment|Lack of Efficacy|4
6104171|NCT00784277|9721704|FG002|IR Treatment|Lack of Efficacy|1
6104172|NCT00784277|9721705|FG003|IR Treatment|Lack of Efficacy|0
6104173|NCT00784277|9721706|FG004|IR Treatment|Lack of Efficacy|0
6104174|NCT00784277|9721707|FG005|IR Treatment|Lack of Efficacy|0
6104175|NCT00784277|9721708|FG006|IR Treatment|Lack of Efficacy|0
6104176|NCT00784277|9721702|FG000|IR Treatment|Lost to Follow-up|1
6104177|NCT00784277|9721703|FG001|IR Treatment|Lost to Follow-up|0
6104178|NCT00784277|9721704|FG002|IR Treatment|Lost to Follow-up|1
6104179|NCT00784277|9721705|FG003|IR Treatment|Lost to Follow-up|0
6104180|NCT00784277|9721706|FG004|IR Treatment|Lost to Follow-up|0
6104181|NCT00784277|9721707|FG005|IR Treatment|Lost to Follow-up|0
6104182|NCT00784277|9721708|FG006|IR Treatment|Lost to Follow-up|0
6104183|NCT00784277|9721702|FG000|IR Treatment|Withdrawal by Subject|5
6104184|NCT00784277|9721703|FG001|IR Treatment|Withdrawal by Subject|1
6104185|NCT00784277|9721704|FG002|IR Treatment|Withdrawal by Subject|4
6104186|NCT00784277|9721705|FG003|IR Treatment|Withdrawal by Subject|6
6104187|NCT00784277|9721706|FG004|IR Treatment|Withdrawal by Subject|0
6104188|NCT00784277|9721707|FG005|IR Treatment|Withdrawal by Subject|0
6104189|NCT00784277|9721708|FG006|IR Treatment|Withdrawal by Subject|0
6104190|NCT00784277|9721702|FG000|IR Treatment|Resolution Of Pain|0
6104191|NCT00784277|9721703|FG001|IR Treatment|Resolution Of Pain|1
6104192|NCT00784277|9721704|FG002|IR Treatment|Resolution Of Pain|0
6104193|NCT00784277|9721705|FG003|IR Treatment|Resolution Of Pain|0
6104194|NCT00784277|9721706|FG004|IR Treatment|Resolution Of Pain|0
6104195|NCT00784277|9721707|FG005|IR Treatment|Resolution Of Pain|0
6104196|NCT00784277|9721708|FG006|IR Treatment|Resolution Of Pain|0
6104197|NCT00784277|9721702|FG000|IR Treatment|Other|2
6104198|NCT00784277|9721703|FG001|IR Treatment|Other|3
6104199|NCT00784277|9721704|FG002|IR Treatment|Other|3
6104200|NCT00784277|9721705|FG003|IR Treatment|Other|2
6104201|NCT00784277|9721706|FG004|IR Treatment|Other|0
6104202|NCT00784277|9721707|FG005|IR Treatment|Other|0
6104203|NCT00784277|9721708|FG006|IR Treatment|Other|0
6104204|NCT00784277|9721702|FG000|ER Treatment|Adverse Event|0
6104205|NCT00784277|9721703|FG001|ER Treatment|Adverse Event|0
6104206|NCT00784277|9721704|FG002|ER Treatment|Adverse Event|0
6104207|NCT00784277|9721705|FG003|ER Treatment|Adverse Event|0
6104208|NCT00784277|9721706|FG004|ER Treatment|Adverse Event|1
6104209|NCT00784277|9721707|FG005|ER Treatment|Adverse Event|7
6104210|NCT00784277|9721708|FG006|ER Treatment|Adverse Event|7
6104211|NCT00784277|9721702|FG000|ER Treatment|Lack of Efficacy|0
6104212|NCT00784277|9721703|FG001|ER Treatment|Lack of Efficacy|0
6104213|NCT00784277|9721704|FG002|ER Treatment|Lack of Efficacy|0
6104214|NCT00784277|9721705|FG003|ER Treatment|Lack of Efficacy|0
6104215|NCT00784277|9721706|FG004|ER Treatment|Lack of Efficacy|3
6104216|NCT00784277|9721707|FG005|ER Treatment|Lack of Efficacy|4
6104217|NCT00784277|9721708|FG006|ER Treatment|Lack of Efficacy|0
6104218|NCT00784277|9721702|FG000|ER Treatment|Lost to Follow-up|0
6104219|NCT00784277|9721703|FG001|ER Treatment|Lost to Follow-up|0
6104220|NCT00784277|9721704|FG002|ER Treatment|Lost to Follow-up|0
6104221|NCT00784277|9721705|FG003|ER Treatment|Lost to Follow-up|0
6104222|NCT00784277|9721706|FG004|ER Treatment|Lost to Follow-up|0
6104223|NCT00784277|9721707|FG005|ER Treatment|Lost to Follow-up|2
6104224|NCT00784277|9721708|FG006|ER Treatment|Lost to Follow-up|0
6104225|NCT00784277|9721702|FG000|ER Treatment|Withdrawal by Subject|0
6104226|NCT00784277|9721703|FG001|ER Treatment|Withdrawal by Subject|0
6104227|NCT00784277|9721704|FG002|ER Treatment|Withdrawal by Subject|0
6104228|NCT00784277|9721705|FG003|ER Treatment|Withdrawal by Subject|0
6104229|NCT00784277|9721706|FG004|ER Treatment|Withdrawal by Subject|2
6104230|NCT00784277|9721707|FG005|ER Treatment|Withdrawal by Subject|5
6104231|NCT00784277|9721708|FG006|ER Treatment|Withdrawal by Subject|3
6104232|NCT00784277|9721702|FG000|ER Treatment|Study Medication Non-Compliant|0
6104233|NCT00784277|9721703|FG001|ER Treatment|Study Medication Non-Compliant|0
6104234|NCT00784277|9721704|FG002|ER Treatment|Study Medication Non-Compliant|0
6104235|NCT00784277|9721705|FG003|ER Treatment|Study Medication Non-Compliant|0
6104236|NCT00784277|9721706|FG004|ER Treatment|Study Medication Non-Compliant|2
6104237|NCT00784277|9721707|FG005|ER Treatment|Study Medication Non-Compliant|3
6104238|NCT00784277|9721708|FG006|ER Treatment|Study Medication Non-Compliant|3
6104239|NCT00784277|9721702|FG000|ER Treatment|Other|0
6104240|NCT00784277|9721703|FG001|ER Treatment|Other|0
6104241|NCT00784277|9721704|FG002|ER Treatment|Other|0
6104242|NCT00784277|9721705|FG003|ER Treatment|Other|0
6104243|NCT00784277|9721706|FG004|ER Treatment|Other|1
6104244|NCT00784277|9721707|FG005|ER Treatment|Other|3
6104245|NCT00784277|9721708|FG006|ER Treatment|Other|2
6104246|NCT00784368|9721734|FG000|Overall Study|Physician Decision|0
6104247|NCT00784368|9721735|FG001|Overall Study|Physician Decision|0
6104248|NCT00784368|9721736|FG002|Overall Study|Physician Decision|6
6104249|NCT00784368|9721734|FG000|Overall Study|Lack of Efficacy|2
6104250|NCT00784368|9721735|FG001|Overall Study|Lack of Efficacy|0
6104251|NCT00784368|9721736|FG002|Overall Study|Lack of Efficacy|1
6104252|NCT00784368|9721734|FG000|Overall Study|Adverse Event|6
6104253|NCT00784368|9721735|FG001|Overall Study|Adverse Event|9
6104254|NCT00784368|9721736|FG002|Overall Study|Adverse Event|2
6104255|NCT00784368|9721734|FG000|Overall Study|Diagnosis of fever|0
6104256|NCT00784368|9721735|FG001|Overall Study|Diagnosis of fever|0
6104257|NCT00784368|9721736|FG002|Overall Study|Diagnosis of fever|1
6104258|NCT00784368|9721734|FG000|Overall Study|Worsening of complications|0
6104259|NCT00784368|9721735|FG001|Overall Study|Worsening of complications|0
6104260|NCT00784368|9721736|FG002|Overall Study|Worsening of complications|1
6104261|NCT00784368|9721734|FG000|Overall Study|Worsening of symptoms|0
6104262|NCT00784368|9721735|FG001|Overall Study|Worsening of symptoms|1
6104263|NCT00784368|9721736|FG002|Overall Study|Worsening of symptoms|0
6104264|NCT00784368|9721734|FG000|Overall Study|Withdrawal of informed consent|0
6104265|NCT00784368|9721735|FG001|Overall Study|Withdrawal of informed consent|1
6104266|NCT00784368|9721736|FG002|Overall Study|Withdrawal of informed consent|0
6104267|NCT00784459|9721749|FG000|Overall Study|Adverse Event|0
6104268|NCT00784459|9721750|FG001|Overall Study|Adverse Event|2
6104269|NCT00784550|9721762|FG000|Overall Study|Adverse Event|12
6104270|NCT00784550|9721763|FG001|Overall Study|Adverse Event|10
6104271|NCT00784550|9721762|FG000|Overall Study|Lack of Efficacy|0
6104272|NCT00784550|9721763|FG001|Overall Study|Lack of Efficacy|1
6104273|NCT00784550|9721762|FG000|Overall Study|Protocol Violation|10
6104274|NCT00784550|9721763|FG001|Overall Study|Protocol Violation|10
6104275|NCT00784550|9721762|FG000|Overall Study|Lost to Follow-up|8
6104276|NCT00784550|9721763|FG001|Overall Study|Lost to Follow-up|5
6104277|NCT00784550|9721762|FG000|Overall Study|Physician Decision|2
6104278|NCT00784550|9721763|FG001|Overall Study|Physician Decision|3
6104279|NCT00784550|9721762|FG000|Overall Study|Withdrawal by Subject|4
6104280|NCT00784550|9721763|FG001|Overall Study|Withdrawal by Subject|13
6104281|NCT00784563|9721772|FG000|Years 1 & 2|Withdrawal by Subject|3
6104282|NCT00784563|9721773|FG001|Years 1 & 2|Withdrawal by Subject|2
6104283|NCT00784563|9721774|FG002|Years 1 & 2|Withdrawal by Subject|0
6104284|NCT00784563|9721772|FG000|Years 1 & 2|Adverse Event|0
6104285|NCT00784563|9721773|FG001|Years 1 & 2|Adverse Event|3
6104286|NCT00784563|9721774|FG002|Years 1 & 2|Adverse Event|0
6104287|NCT00784563|9721772|FG000|Year 3|Withdrawal by Subject|0
6205176|NCT01529515|9867280|FG002|TRANSITION PHASE|Withdrawal by Subject|0
6205177|NCT01529515|9867281|FG003|TRANSITION PHASE|Withdrawal by Subject|0
6205178|NCT01529515|9867278|FG000|TRANSITION PHASE|Failed Maintenance Phase Criteria|8
6205179|NCT01529515|9867279|FG001|TRANSITION PHASE|Failed Maintenance Phase Criteria|0
6205180|NCT01529515|9867280|FG002|TRANSITION PHASE|Failed Maintenance Phase Criteria|0
6285083|NCT02330549|9996871|FG000|Overall Study|Failure to meet randomization criteria|1
6285084|NCT02330549|9996872|FG001|Overall Study|Failure to meet randomization criteria|0
6285085|NCT02331368|9996960|FG000|Overall Study|Withdrawal by Subject|3
6285086|NCT02331394|9996964|FG000|Overall Study|Disease progression|1
6285087|NCT02331446|9996983|FG000|Overall Study|Lost to Follow-up|2
5980506|NCT02733042|9569326|FG006|Treatment Period|Progressive Disease|0
5980507|NCT02733042|9569327|FG007|Treatment Period|Progressive Disease|3
5980508|NCT02733042|9569328|FG008|Treatment Period|Progressive Disease|3
5980509|NCT02733042|9569329|FG009|Treatment Period|Progressive Disease|0
5980510|NCT02733042|9569330|FG010|Treatment Period|Progressive Disease|2
5980511|NCT02733042|9569331|FG011|Treatment Period|Progressive Disease|2
5980512|NCT02733042|9569332|FG012|Treatment Period|Progressive Disease|8
5980513|NCT02733042|9569333|FG013|Treatment Period|Progressive Disease|1
5980514|NCT02733042|9569334|FG014|Treatment Period|Progressive Disease|4
5980515|NCT02733042|9569335|FG015|Treatment Period|Progressive Disease|7
5980516|NCT02733042|9569336|FG016|Treatment Period|Progressive Disease|2
5980517|NCT02733042|9569337|FG017|Treatment Period|Progressive Disease|3
5980518|NCT02733042|9569338|FG018|Treatment Period|Progressive Disease|4
5980519|NCT02733042|9569320|FG000|Treatment Period|Withdrawal by Subject|0
5980520|NCT02733042|9569321|FG001|Treatment Period|Withdrawal by Subject|1
5980521|NCT02733042|9569322|FG002|Treatment Period|Withdrawal by Subject|2
5980522|NCT02733042|9569323|FG003|Treatment Period|Withdrawal by Subject|1
5980523|NCT02733042|9569324|FG004|Treatment Period|Withdrawal by Subject|0
5980524|NCT02733042|9569325|FG005|Treatment Period|Withdrawal by Subject|0
5980525|NCT02733042|9569326|FG006|Treatment Period|Withdrawal by Subject|0
5980526|NCT02733042|9569327|FG007|Treatment Period|Withdrawal by Subject|0
5980527|NCT02733042|9569328|FG008|Treatment Period|Withdrawal by Subject|1
5980528|NCT02733042|9569329|FG009|Treatment Period|Withdrawal by Subject|1
5980529|NCT02733042|9569330|FG010|Treatment Period|Withdrawal by Subject|0
5980530|NCT02733042|9569331|FG011|Treatment Period|Withdrawal by Subject|2
5980531|NCT02733042|9569332|FG012|Treatment Period|Withdrawal by Subject|1
5980532|NCT02733042|9569333|FG013|Treatment Period|Withdrawal by Subject|1
5980533|NCT02733042|9569334|FG014|Treatment Period|Withdrawal by Subject|0
5980534|NCT02733042|9569335|FG015|Treatment Period|Withdrawal by Subject|0
5980535|NCT02733042|9569336|FG016|Treatment Period|Withdrawal by Subject|0
5980536|NCT02733042|9569337|FG017|Treatment Period|Withdrawal by Subject|0
5980537|NCT02733042|9569338|FG018|Treatment Period|Withdrawal by Subject|0
5980538|NCT02733042|9569320|FG000|Treatment Period|Other|0
5980539|NCT02733042|9569321|FG001|Treatment Period|Other|0
5980540|NCT02733042|9569322|FG002|Treatment Period|Other|1
5980541|NCT02733042|9569323|FG003|Treatment Period|Other|0
5980542|NCT02733042|9569324|FG004|Treatment Period|Other|0
5980543|NCT02733042|9569325|FG005|Treatment Period|Other|0
5980544|NCT02733042|9569326|FG006|Treatment Period|Other|0
5980545|NCT02733042|9569327|FG007|Treatment Period|Other|0
5980546|NCT02733042|9569328|FG008|Treatment Period|Other|0
5980547|NCT02733042|9569329|FG009|Treatment Period|Other|1
5980548|NCT02733042|9569330|FG010|Treatment Period|Other|1
5980549|NCT02733042|9569331|FG011|Treatment Period|Other|0
5980550|NCT02733042|9569332|FG012|Treatment Period|Other|0
6104288|NCT00784563|9721773|FG001|Year 3|Withdrawal by Subject|0
6104289|NCT00784563|9721774|FG002|Year 3|Withdrawal by Subject|2
6104290|NCT00784563|9721772|FG000|Year 3|Adverse Event|0
6104291|NCT00784563|9721773|FG001|Year 3|Adverse Event|0
6104292|NCT00784563|9721774|FG002|Year 3|Adverse Event|1
6104293|NCT00784654|9721793|FG000|Open-Label Period (Non-Randomized)|Adverse Event|44
6104294|NCT00784654|9721794|FG001|Open-Label Period (Non-Randomized)|Adverse Event|0
6104295|NCT00784654|9721795|FG002|Open-Label Period (Non-Randomized)|Adverse Event|0
6104296|NCT00784654|9721793|FG000|Open-Label Period (Non-Randomized)|Withdrawal by Subject|22
6104297|NCT00784654|9721794|FG001|Open-Label Period (Non-Randomized)|Withdrawal by Subject|0
6104298|NCT00784654|9721795|FG002|Open-Label Period (Non-Randomized)|Withdrawal by Subject|0
6104299|NCT00784654|9721793|FG000|Open-Label Period (Non-Randomized)|Lack of Efficacy|21
6205181|NCT01529515|9867281|FG003|TRANSITION PHASE|Failed Maintenance Phase Criteria|0
6205182|NCT01529515|9867278|FG000|TRANSITION PHASE|Other|9
6205183|NCT01529515|9867279|FG001|TRANSITION PHASE|Other|0
6205184|NCT01529515|9867280|FG002|TRANSITION PHASE|Other|0
6205185|NCT01529515|9867281|FG003|TRANSITION PHASE|Other|0
6205186|NCT01529515|9867278|FG000|MAINTENANCE PHASE|Adverse Event|0
6205187|NCT01529515|9867279|FG001|MAINTENANCE PHASE|Adverse Event|10
6205188|NCT01529515|9867280|FG002|MAINTENANCE PHASE|Adverse Event|0
6205189|NCT01529515|9867281|FG003|MAINTENANCE PHASE|Adverse Event|0
6205190|NCT01529515|9867278|FG000|MAINTENANCE PHASE|Lack of Efficacy|0
6205191|NCT01529515|9867279|FG001|MAINTENANCE PHASE|Lack of Efficacy|9
5980551|NCT02733042|9569333|FG013|Treatment Period|Other|0
5980552|NCT02733042|9569334|FG014|Treatment Period|Other|0
5980553|NCT02733042|9569335|FG015|Treatment Period|Other|1
6104300|NCT00784654|9721794|FG001|Open-Label Period (Non-Randomized)|Lack of Efficacy|0
6104301|NCT00784654|9721795|FG002|Open-Label Period (Non-Randomized)|Lack of Efficacy|0
6104302|NCT00784654|9721793|FG000|Open-Label Period (Non-Randomized)|Lost to Follow-up|11
6104303|NCT00784654|9721794|FG001|Open-Label Period (Non-Randomized)|Lost to Follow-up|0
6104304|NCT00784654|9721795|FG002|Open-Label Period (Non-Randomized)|Lost to Follow-up|0
6104305|NCT00784654|9721793|FG000|Open-Label Period (Non-Randomized)|Protocol Violation|7
6104306|NCT00784654|9721794|FG001|Open-Label Period (Non-Randomized)|Protocol Violation|0
6104307|NCT00784654|9721795|FG002|Open-Label Period (Non-Randomized)|Protocol Violation|0
6104308|NCT00784654|9721793|FG000|Open-Label Period (Non-Randomized)|Mother is a drug addict|1
6104309|NCT00784654|9721794|FG001|Open-Label Period (Non-Randomized)|Mother is a drug addict|0
6104310|NCT00784654|9721795|FG002|Open-Label Period (Non-Randomized)|Mother is a drug addict|0
6104311|NCT00784654|9721793|FG000|Open-Label Period (Non-Randomized)|Decision of medical monitor|1
6104312|NCT00784654|9721794|FG001|Open-Label Period (Non-Randomized)|Decision of medical monitor|0
6104313|NCT00784654|9721795|FG002|Open-Label Period (Non-Randomized)|Decision of medical monitor|0
6104314|NCT00784654|9721793|FG000|Open-Label Period (Non-Randomized)|Home situation intolerable|1
6104315|NCT00784654|9721794|FG001|Open-Label Period (Non-Randomized)|Home situation intolerable|0
6104316|NCT00784654|9721795|FG002|Open-Label Period (Non-Randomized)|Home situation intolerable|0
6104317|NCT00784654|9721793|FG000|Open-Label Period (Non-Randomized)|ADHD-RS score too high for Random Phase|1
6104318|NCT00784654|9721794|FG001|Open-Label Period (Non-Randomized)|ADHD-RS score too high for Random Phase|0
6104319|NCT00784654|9721795|FG002|Open-Label Period (Non-Randomized)|ADHD-RS score too high for Random Phase|0
6104320|NCT00784654|9721793|FG000|Open-Label Period (Non-Randomized)|Met stopping criteria for CGI-S score|1
6104321|NCT00784654|9721794|FG001|Open-Label Period (Non-Randomized)|Met stopping criteria for CGI-S score|0
6104322|NCT00784654|9721795|FG002|Open-Label Period (Non-Randomized)|Met stopping criteria for CGI-S score|0
6104323|NCT00784654|9721793|FG000|Open-Label Period (Non-Randomized)|Did not provide end of study page|1
6104324|NCT00784654|9721794|FG001|Open-Label Period (Non-Randomized)|Did not provide end of study page|0
6104325|NCT00784654|9721795|FG002|Open-Label Period (Non-Randomized)|Did not provide end of study page|0
6104326|NCT00784654|9721793|FG000|Randomized Withdrawal Period|Met relapse criteria per investigator|0
6104327|NCT00784654|9721794|FG001|Randomized Withdrawal Period|Met relapse criteria per investigator|8
6104328|NCT00784654|9721795|FG002|Randomized Withdrawal Period|Met relapse criteria per investigator|35
6104329|NCT00784654|9721793|FG000|Randomized Withdrawal Period|Lack of Efficacy|0
6104330|NCT00784654|9721794|FG001|Randomized Withdrawal Period|Lack of Efficacy|5
6104331|NCT00784654|9721795|FG002|Randomized Withdrawal Period|Lack of Efficacy|18
6104332|NCT00784654|9721793|FG000|Randomized Withdrawal Period|Withdrawal by Subject|0
6104333|NCT00784654|9721794|FG001|Randomized Withdrawal Period|Withdrawal by Subject|1
6104334|NCT00784654|9721795|FG002|Randomized Withdrawal Period|Withdrawal by Subject|7
6104335|NCT00784654|9721793|FG000|Randomized Withdrawal Period|Protocol Violation|0
6104336|NCT00784654|9721794|FG001|Randomized Withdrawal Period|Protocol Violation|2
6104337|NCT00784654|9721795|FG002|Randomized Withdrawal Period|Protocol Violation|1
6104338|NCT00784654|9721793|FG000|Randomized Withdrawal Period|Adverse Event|0
6104339|NCT00784654|9721794|FG001|Randomized Withdrawal Period|Adverse Event|1
6104340|NCT00784654|9721795|FG002|Randomized Withdrawal Period|Adverse Event|1
6104341|NCT00784654|9721793|FG000|Randomized Withdrawal Period|Did not complete a visit|0
6104342|NCT00784654|9721794|FG001|Randomized Withdrawal Period|Did not complete a visit|1
6104343|NCT00784654|9721795|FG002|Randomized Withdrawal Period|Did not complete a visit|0
6104344|NCT00784654|9721793|FG000|Randomized Withdrawal Period|Family reasons|0
6104345|NCT00784654|9721794|FG001|Randomized Withdrawal Period|Family reasons|0
6104346|NCT00784654|9721795|FG002|Randomized Withdrawal Period|Family reasons|1
6104347|NCT00784693|9721808|FG000|Overall Study|Lost to Follow-up|0
6104348|NCT00784693|9721809|FG001|Overall Study|Lost to Follow-up|1
6104349|NCT00784693|9721808|FG000|Overall Study|Lack of Efficacy|1
6104350|NCT00784693|9721809|FG001|Overall Study|Lack of Efficacy|1
6104351|NCT00784693|9721808|FG000|Overall Study|Withdrawal by Subject|0
6104352|NCT00784693|9721809|FG001|Overall Study|Withdrawal by Subject|4
6104353|NCT00784693|9721808|FG000|Overall Study|Randomized but not Treated|1
6104354|NCT00784693|9721809|FG001|Overall Study|Randomized but not Treated|0
6104355|NCT00784693|9721808|FG000|Overall Study|Other|1
6104356|NCT00784693|9721809|FG001|Overall Study|Other|0
6104357|NCT00784719|9721822|FG000|Overall Study|Adverse Event|0
6104358|NCT00784719|9721823|FG001|Overall Study|Adverse Event|2
6104359|NCT00784719|9721824|FG002|Overall Study|Adverse Event|0
6104360|NCT00784719|9721825|FG003|Overall Study|Adverse Event|0
6104361|NCT00784719|9721826|FG004|Overall Study|Adverse Event|1
6104362|NCT00784719|9721827|FG005|Overall Study|Adverse Event|1
6104363|NCT00784719|9721828|FG006|Overall Study|Adverse Event|1
6104364|NCT00784719|9721822|FG000|Overall Study|Lost to Follow-up|0
6104365|NCT00784719|9721823|FG001|Overall Study|Lost to Follow-up|0
6205192|NCT01529515|9867280|FG002|MAINTENANCE PHASE|Lack of Efficacy|0
6205193|NCT01529515|9867281|FG003|MAINTENANCE PHASE|Lack of Efficacy|0
6205194|NCT01529515|9867278|FG000|MAINTENANCE PHASE|Lost to Follow-up|0
6205195|NCT01529515|9867279|FG001|MAINTENANCE PHASE|Lost to Follow-up|5
6205196|NCT01529515|9867280|FG002|MAINTENANCE PHASE|Lost to Follow-up|0
6205197|NCT01529515|9867281|FG003|MAINTENANCE PHASE|Lost to Follow-up|0
6104366|NCT00784719|9721824|FG002|Overall Study|Lost to Follow-up|0
6104367|NCT00784719|9721825|FG003|Overall Study|Lost to Follow-up|0
6104368|NCT00784719|9721826|FG004|Overall Study|Lost to Follow-up|1
6104369|NCT00784719|9721827|FG005|Overall Study|Lost to Follow-up|1
6104370|NCT00784719|9721828|FG006|Overall Study|Lost to Follow-up|0
6104371|NCT00784719|9721822|FG000|Overall Study|Other|2
6104372|NCT00784719|9721823|FG001|Overall Study|Other|1
6104373|NCT00784719|9721824|FG002|Overall Study|Other|1
6104374|NCT00784719|9721825|FG003|Overall Study|Other|0
6104375|NCT00784719|9721826|FG004|Overall Study|Other|2
6104376|NCT00784719|9721827|FG005|Overall Study|Other|1
6104377|NCT00784719|9721828|FG006|Overall Study|Other|3
6104378|NCT00784719|9721822|FG000|Overall Study|Withdrawal by Subject|1
6104379|NCT00784719|9721823|FG001|Overall Study|Withdrawal by Subject|0
6104380|NCT00784719|9721824|FG002|Overall Study|Withdrawal by Subject|0
6104381|NCT00784719|9721825|FG003|Overall Study|Withdrawal by Subject|0
6104382|NCT00784719|9721826|FG004|Overall Study|Withdrawal by Subject|2
6104383|NCT00784719|9721827|FG005|Overall Study|Withdrawal by Subject|0
6104384|NCT00784719|9721828|FG006|Overall Study|Withdrawal by Subject|1
6104385|NCT00784758|9721846|FG000|Overall Study|Withdrawal by Subject|3
6104386|NCT00784758|9721847|FG001|Overall Study|Withdrawal by Subject|0
6104387|NCT00784758|9721846|FG000|Overall Study|Adverse Event|1
6104388|NCT00784758|9721847|FG001|Overall Study|Adverse Event|0
6104389|NCT00784784|9721857|FG000|Overall Study|Withdrawal by Subject|2
6104390|NCT00784784|9721858|FG001|Overall Study|Withdrawal by Subject|2
6104391|NCT00784810|9721866|FG000|Overall Study|Adverse Event|32
6104392|NCT00784810|9721867|FG001|Overall Study|Adverse Event|20
6104393|NCT00784810|9721866|FG000|Overall Study|Lack of Efficacy|14
6104394|NCT00784810|9721867|FG001|Overall Study|Lack of Efficacy|11
6104395|NCT00784810|9721866|FG000|Overall Study|Withdrawal by Subject|11
6104396|NCT00784810|9721867|FG001|Overall Study|Withdrawal by Subject|9
6104397|NCT00784810|9721866|FG000|Overall Study|Administrative|5
6104398|NCT00784810|9721867|FG001|Overall Study|Administrative|8
6104399|NCT00784810|9721866|FG000|Overall Study|Lost to Follow-up|1
6104400|NCT00784810|9721867|FG001|Overall Study|Lost to Follow-up|1
6104401|NCT00784836|9721873|FG000|Overall Study|Early Study Termination|3
6104402|NCT00784875|9721885|FG000|Period A - Baseline|Entry Criteria Not Met|0
6104403|NCT00784875|9721886|FG001|Period A - Baseline|Entry Criteria Not Met|0
6104404|NCT00784875|9721887|FG002|Period A - Baseline|Entry Criteria Not Met|0
6104405|NCT00784875|9721888|FG003|Period A - Baseline|Entry Criteria Not Met|5
6104406|NCT00784875|9721885|FG000|Period A - Baseline|Adverse Event|0
6104407|NCT00784875|9721886|FG001|Period A - Baseline|Adverse Event|0
6104408|NCT00784875|9721887|FG002|Period A - Baseline|Adverse Event|0
6104409|NCT00784875|9721888|FG003|Period A - Baseline|Adverse Event|8
6104410|NCT00784875|9721885|FG000|Period A - Baseline|Protocol Violation|0
6104411|NCT00784875|9721886|FG001|Period A - Baseline|Protocol Violation|0
6104412|NCT00784875|9721887|FG002|Period A - Baseline|Protocol Violation|0
6104413|NCT00784875|9721888|FG003|Period A - Baseline|Protocol Violation|25
6104414|NCT00784875|9721885|FG000|Period A - Baseline|Withdrawal by Subject|0
6104415|NCT00784875|9721886|FG001|Period A - Baseline|Withdrawal by Subject|0
6104416|NCT00784875|9721887|FG002|Period A - Baseline|Withdrawal by Subject|0
6104417|NCT00784875|9721888|FG003|Period A - Baseline|Withdrawal by Subject|27
6104418|NCT00784875|9721885|FG000|Period A - Baseline|Physician Decision|0
6104419|NCT00784875|9721886|FG001|Period A - Baseline|Physician Decision|0
6104420|NCT00784875|9721887|FG002|Period A - Baseline|Physician Decision|0
6104421|NCT00784875|9721888|FG003|Period A - Baseline|Physician Decision|2
6104422|NCT00784875|9721885|FG000|Period A - Baseline|Sponsor Decision|0
6104423|NCT00784875|9721886|FG001|Period A - Baseline|Sponsor Decision|0
6104424|NCT00784875|9721887|FG002|Period A - Baseline|Sponsor Decision|0
6104425|NCT00784875|9721888|FG003|Period A - Baseline|Sponsor Decision|113
6104426|NCT00784875|9721885|FG000|Period A - Baseline|Lost to Follow-up|0
6104427|NCT00784875|9721886|FG001|Period A - Baseline|Lost to Follow-up|0
6104428|NCT00784875|9721887|FG002|Period A - Baseline|Lost to Follow-up|0
6104429|NCT00784875|9721888|FG003|Period A - Baseline|Lost to Follow-up|2
6104430|NCT00784875|9721885|FG000|Period B - Efficacy Endpoint|Entry Criteria Not Met|0
6104431|NCT00784875|9721886|FG001|Period B - Efficacy Endpoint|Entry Criteria Not Met|0
6104432|NCT00784875|9721887|FG002|Period B - Efficacy Endpoint|Entry Criteria Not Met|2
6104433|NCT00784875|9721888|FG003|Period B - Efficacy Endpoint|Entry Criteria Not Met|1
6104434|NCT00784875|9721885|FG000|Period B - Efficacy Endpoint|Adverse Event|0
6104435|NCT00784875|9721886|FG001|Period B - Efficacy Endpoint|Adverse Event|3
6104436|NCT00784875|9721887|FG002|Period B - Efficacy Endpoint|Adverse Event|2
6104437|NCT00784875|9721888|FG003|Period B - Efficacy Endpoint|Adverse Event|1
6104438|NCT00784875|9721885|FG000|Period B - Efficacy Endpoint|Protocol Violation|1
6104439|NCT00784875|9721886|FG001|Period B - Efficacy Endpoint|Protocol Violation|1
6104440|NCT00784875|9721887|FG002|Period B - Efficacy Endpoint|Protocol Violation|2
6104441|NCT00784875|9721888|FG003|Period B - Efficacy Endpoint|Protocol Violation|3
6104442|NCT00784875|9721885|FG000|Period B - Efficacy Endpoint|Lack of Efficacy|0
6104443|NCT00784875|9721886|FG001|Period B - Efficacy Endpoint|Lack of Efficacy|1
6104444|NCT00784875|9721887|FG002|Period B - Efficacy Endpoint|Lack of Efficacy|0
6104445|NCT00784875|9721888|FG003|Period B - Efficacy Endpoint|Lack of Efficacy|0
6104446|NCT00784875|9721885|FG000|Period B - Efficacy Endpoint|Withdrawal by Subject|4
6104447|NCT00784875|9721886|FG001|Period B - Efficacy Endpoint|Withdrawal by Subject|1
6104448|NCT00784875|9721887|FG002|Period B - Efficacy Endpoint|Withdrawal by Subject|1
6104449|NCT00784875|9721888|FG003|Period B - Efficacy Endpoint|Withdrawal by Subject|2
6104450|NCT00784875|9721885|FG000|Period B - Efficacy Endpoint|Physician Decision|0
6104451|NCT00784875|9721886|FG001|Period B - Efficacy Endpoint|Physician Decision|0
6104452|NCT00784875|9721887|FG002|Period B - Efficacy Endpoint|Physician Decision|1
6104453|NCT00784875|9721888|FG003|Period B - Efficacy Endpoint|Physician Decision|0
6104454|NCT00784875|9721885|FG000|Period B - Efficacy Endpoint|Sponsor Decision|9
6104455|NCT00784875|9721886|FG001|Period B - Efficacy Endpoint|Sponsor Decision|6
6104456|NCT00784875|9721887|FG002|Period B - Efficacy Endpoint|Sponsor Decision|12
6104457|NCT00784875|9721888|FG003|Period B - Efficacy Endpoint|Sponsor Decision|12
6104458|NCT00784875|9721885|FG000|Period B - Efficacy Endpoint|Lost to Follow-up|0
6104459|NCT00784875|9721886|FG001|Period B - Efficacy Endpoint|Lost to Follow-up|0
6104460|NCT00784875|9721887|FG002|Period B - Efficacy Endpoint|Lost to Follow-up|1
6104461|NCT00784875|9721888|FG003|Period B - Efficacy Endpoint|Lost to Follow-up|0
6104462|NCT00784875|9721885|FG000|Period C|Adverse Event|1
6104463|NCT00784875|9721886|FG001|Period C|Adverse Event|0
6104464|NCT00784875|9721887|FG002|Period C|Adverse Event|4
6104465|NCT00784875|9721888|FG003|Period C|Adverse Event|2
6104466|NCT00784875|9721885|FG000|Period C|Protocol Violation|0
6104467|NCT00784875|9721886|FG001|Period C|Protocol Violation|0
6104468|NCT00784875|9721887|FG002|Period C|Protocol Violation|1
6104469|NCT00784875|9721888|FG003|Period C|Protocol Violation|2
6104470|NCT00784875|9721885|FG000|Period C|Lack of Efficacy|0
6104471|NCT00784875|9721886|FG001|Period C|Lack of Efficacy|0
6104472|NCT00784875|9721887|FG002|Period C|Lack of Efficacy|1
6104473|NCT00784875|9721888|FG003|Period C|Lack of Efficacy|0
6104474|NCT00784875|9721885|FG000|Period C|Withdrawal by Subject|1
6104475|NCT00784875|9721886|FG001|Period C|Withdrawal by Subject|1
6104476|NCT00784875|9721887|FG002|Period C|Withdrawal by Subject|2
6104477|NCT00784875|9721888|FG003|Period C|Withdrawal by Subject|0
6104478|NCT00784875|9721885|FG000|Period C|Physician Decision|0
6104479|NCT00784875|9721886|FG001|Period C|Physician Decision|0
6104480|NCT00784875|9721887|FG002|Period C|Physician Decision|1
6104481|NCT00784875|9721888|FG003|Period C|Physician Decision|1
6104482|NCT00784875|9721885|FG000|Period C|Sponsor Decision|5
6104483|NCT00784875|9721886|FG001|Period C|Sponsor Decision|5
6104484|NCT00784875|9721887|FG002|Period C|Sponsor Decision|4
6104485|NCT00784875|9721888|FG003|Period C|Sponsor Decision|2
6104486|NCT00784875|9721885|FG000|Period D|Adverse Event|0
6104487|NCT00784875|9721886|FG001|Period D|Adverse Event|2
6104488|NCT00784875|9721887|FG002|Period D|Adverse Event|2
6104489|NCT00784875|9721888|FG003|Period D|Adverse Event|0
6104490|NCT00784875|9721885|FG000|Period D|Protocol Violation|1
6104491|NCT00784875|9721886|FG001|Period D|Protocol Violation|0
6104492|NCT00784875|9721887|FG002|Period D|Protocol Violation|0
6104493|NCT00784875|9721888|FG003|Period D|Protocol Violation|0
6104494|NCT00784875|9721885|FG000|Period D|Withdrawal by Subject|2
6104495|NCT00784875|9721886|FG001|Period D|Withdrawal by Subject|0
6104496|NCT00784875|9721887|FG002|Period D|Withdrawal by Subject|2
6104497|NCT00784875|9721888|FG003|Period D|Withdrawal by Subject|0
6104498|NCT00784875|9721885|FG000|Period D|Physician Decision|0
6104499|NCT00784875|9721886|FG001|Period D|Physician Decision|1
6104500|NCT00784875|9721887|FG002|Period D|Physician Decision|0
6104501|NCT00784875|9721888|FG003|Period D|Physician Decision|0
6104502|NCT00784875|9721885|FG000|Period D|Sponsor Decision|1
6104503|NCT00784875|9721886|FG001|Period D|Sponsor Decision|1
6104504|NCT00784875|9721887|FG002|Period D|Sponsor Decision|1
6104505|NCT00784875|9721888|FG003|Period D|Sponsor Decision|0
6104506|NCT00784875|9721885|FG000|Period D|Lost to Follow-up|1
6104507|NCT00784875|9721886|FG001|Period D|Lost to Follow-up|0
6104508|NCT00784875|9721887|FG002|Period D|Lost to Follow-up|1
6104509|NCT00784875|9721888|FG003|Period D|Lost to Follow-up|1
6104510|NCT00784927|9721911|FG000|Overall Study|Cancel Prior to Initiating Treatment|1
6104511|NCT00784927|9721911|FG000|Overall Study|Protocol Violation|1
6104512|NCT00784927|9721911|FG000|Overall Study|Ineligible|1
6104513|NCT00784979|9721916|FG000|Overall Study|incomplete data|6
6104514|NCT00785044|9721920|FG000|Overall Study|Dosed at non-participating sites|152
6104515|NCT00785044|9721920|FG000|Overall Study|Death|77
6104516|NCT00785044|9721920|FG000|Overall Study|Lost to Follow-up|266
6104517|NCT00785044|9721920|FG000|Overall Study|Withdrawal by Subject|1
6104518|NCT00785213|9721925|FG000|Quinine Sulfate Alone|Adverse Event|4
6104519|NCT00785213|9721925|FG000|Rosiglitazone With Quinine Sulfate|Adverse Event|1
6104520|NCT00785486|9721932|FG000|Midazolam Alone|Withdrawal by Subject|1
6104521|NCT00785512|9721955|FG000|Overall Study|Inclusion/Exclusion not meet|0
6104522|NCT00785512|9721956|FG001|Overall Study|Inclusion/Exclusion not meet|0
6104523|NCT00785512|9721955|FG000|Overall Study|Adverse Event|0
6104524|NCT00785512|9721956|FG001|Overall Study|Adverse Event|0
6104525|NCT00785512|9721955|FG000|Overall Study|Lack of Efficacy|0
6104526|NCT00785512|9721956|FG001|Overall Study|Lack of Efficacy|2
6104527|NCT00785512|9721955|FG000|Overall Study|Withdrawal by Subject|0
6104528|NCT00785512|9721956|FG001|Overall Study|Withdrawal by Subject|1
6104529|NCT00785512|9721955|FG000|Overall Study|Lost to Follow-up|3
6104530|NCT00785512|9721956|FG001|Overall Study|Lost to Follow-up|0
6104531|NCT00785512|9721955|FG000|Overall Study|Precedure Refused|0
6104532|NCT00785512|9721956|FG001|Overall Study|Precedure Refused|0
6104533|NCT00785512|9721955|FG000|Overall Study|IVRS Programing Error|0
6104534|NCT00785512|9721956|FG001|Overall Study|IVRS Programing Error|0
6104535|NCT00785512|9721955|FG000|Overall Study|Physician Decision|0
6104536|NCT00785512|9721956|FG001|Overall Study|Physician Decision|0
6104537|NCT00785512|9721955|FG000|Overall Study|Lack of compliance|0
6104538|NCT00785512|9721956|FG001|Overall Study|Lack of compliance|1
6104539|NCT00785538|9721967|FG000|Treatment Period|Adverse Event|1
6104540|NCT00785538|9721968|FG001|Treatment Period|Adverse Event|2
6104541|NCT00785538|9721969|FG002|Treatment Period|Adverse Event|2
6104542|NCT00785538|9721970|FG003|Treatment Period|Adverse Event|0
6104543|NCT00785538|9721967|FG000|Treatment Period|Withdrawal by Subject|0
6104544|NCT00785538|9721968|FG001|Treatment Period|Withdrawal by Subject|0
6104545|NCT00785538|9721969|FG002|Treatment Period|Withdrawal by Subject|0
6104546|NCT00785538|9721970|FG003|Treatment Period|Withdrawal by Subject|1
6104547|NCT00785577|9721986|FG000|Study Period 2: Therapy Phase|Adverse Event|5
6104548|NCT00785577|9721987|FG001|Study Period 2: Therapy Phase|Adverse Event|7
6104549|NCT00785577|9721988|FG002|Study Period 2: Therapy Phase|Adverse Event|14
6104550|NCT00785577|9721989|FG003|Study Period 2: Therapy Phase|Adverse Event|10
6104551|NCT00785577|9721990|FG004|Study Period 2: Therapy Phase|Adverse Event|17
6104552|NCT00785577|9721986|FG000|Study Period 2: Therapy Phase|Lack of Efficacy|0
6104553|NCT00785577|9721987|FG001|Study Period 2: Therapy Phase|Lack of Efficacy|0
6104554|NCT00785577|9721988|FG002|Study Period 2: Therapy Phase|Lack of Efficacy|0
6104555|NCT00785577|9721989|FG003|Study Period 2: Therapy Phase|Lack of Efficacy|0
6104556|NCT00785577|9721990|FG004|Study Period 2: Therapy Phase|Lack of Efficacy|1
6104557|NCT00785577|9721986|FG000|Study Period 2: Therapy Phase|Lost to Follow-up|0
6104558|NCT00785577|9721987|FG001|Study Period 2: Therapy Phase|Lost to Follow-up|0
6104559|NCT00785577|9721988|FG002|Study Period 2: Therapy Phase|Lost to Follow-up|0
6104560|NCT00785577|9721989|FG003|Study Period 2: Therapy Phase|Lost to Follow-up|1
6104561|NCT00785577|9721990|FG004|Study Period 2: Therapy Phase|Lost to Follow-up|0
6104562|NCT00785577|9721986|FG000|Study Period 2: Therapy Phase|Physician Decision|1
6104563|NCT00785577|9721987|FG001|Study Period 2: Therapy Phase|Physician Decision|0
6104564|NCT00785577|9721988|FG002|Study Period 2: Therapy Phase|Physician Decision|0
6104565|NCT00785577|9721989|FG003|Study Period 2: Therapy Phase|Physician Decision|0
6104566|NCT00785577|9721990|FG004|Study Period 2: Therapy Phase|Physician Decision|0
6104567|NCT00785577|9721986|FG000|Study Period 2: Therapy Phase|Protocol Violation|1
6104568|NCT00785577|9721987|FG001|Study Period 2: Therapy Phase|Protocol Violation|1
6104569|NCT00785577|9721988|FG002|Study Period 2: Therapy Phase|Protocol Violation|1
6104570|NCT00785577|9721989|FG003|Study Period 2: Therapy Phase|Protocol Violation|0
6104571|NCT00785577|9721990|FG004|Study Period 2: Therapy Phase|Protocol Violation|1
6104572|NCT00785577|9721986|FG000|Study Period 2: Therapy Phase|Withdrawal by Subject|2
6104573|NCT00785577|9721987|FG001|Study Period 2: Therapy Phase|Withdrawal by Subject|1
6104574|NCT00785577|9721988|FG002|Study Period 2: Therapy Phase|Withdrawal by Subject|1
6104575|NCT00785577|9721989|FG003|Study Period 2: Therapy Phase|Withdrawal by Subject|0
6104576|NCT00785577|9721990|FG004|Study Period 2: Therapy Phase|Withdrawal by Subject|1
6104577|NCT00785577|9721986|FG000|Study Period 2: Therapy Phase|Entry Criteria Exclusion|1
6104578|NCT00785577|9721987|FG001|Study Period 2: Therapy Phase|Entry Criteria Exclusion|0
6104579|NCT00785577|9721988|FG002|Study Period 2: Therapy Phase|Entry Criteria Exclusion|1
6104580|NCT00785577|9721989|FG003|Study Period 2: Therapy Phase|Entry Criteria Exclusion|1
6104581|NCT00785577|9721990|FG004|Study Period 2: Therapy Phase|Entry Criteria Exclusion|0
6104582|NCT00785577|9721986|FG000|Study Period 2: Therapy Phase|Sponsor Decision|1
6104583|NCT00785577|9721987|FG001|Study Period 2: Therapy Phase|Sponsor Decision|0
6104584|NCT00785577|9721988|FG002|Study Period 2: Therapy Phase|Sponsor Decision|1
6104585|NCT00785577|9721989|FG003|Study Period 2: Therapy Phase|Sponsor Decision|1
6104586|NCT00785577|9721990|FG004|Study Period 2: Therapy Phase|Sponsor Decision|0
6104587|NCT00785577|9721986|FG000|Study Period 3: 1-Week Washout Phase|Adverse Event|0
6104588|NCT00785577|9721987|FG001|Study Period 3: 1-Week Washout Phase|Adverse Event|0
6104589|NCT00785577|9721988|FG002|Study Period 3: 1-Week Washout Phase|Adverse Event|0
6104590|NCT00785577|9721989|FG003|Study Period 3: 1-Week Washout Phase|Adverse Event|1
6104591|NCT00785577|9721990|FG004|Study Period 3: 1-Week Washout Phase|Adverse Event|0
6104592|NCT00785577|9721986|FG000|Study Period 3: 1-Week Washout Phase|Death|0
6104593|NCT00785577|9721987|FG001|Study Period 3: 1-Week Washout Phase|Death|0
6104594|NCT00785577|9721988|FG002|Study Period 3: 1-Week Washout Phase|Death|0
6104595|NCT00785577|9721989|FG003|Study Period 3: 1-Week Washout Phase|Death|0
6104596|NCT00785577|9721990|FG004|Study Period 3: 1-Week Washout Phase|Death|1
6104597|NCT00785629|9722016|FG000|Overall Study|Adverse Event|2
6104598|NCT00785629|9722017|FG001|Overall Study|Adverse Event|1
6104599|NCT00785629|9722018|FG002|Overall Study|Adverse Event|1
6104600|NCT00785629|9722019|FG003|Overall Study|Adverse Event|5
6104601|NCT00785629|9722016|FG000|Overall Study|Protocol Violation|1
6104602|NCT00785629|9722017|FG001|Overall Study|Protocol Violation|2
6104603|NCT00785629|9722018|FG002|Overall Study|Protocol Violation|4
6104604|NCT00785629|9722019|FG003|Overall Study|Protocol Violation|5
6104605|NCT00785629|9722016|FG000|Overall Study|administrative decision|5
6104606|NCT00785629|9722017|FG001|Overall Study|administrative decision|1
6104607|NCT00785629|9722018|FG002|Overall Study|administrative decision|3
6104608|NCT00785629|9722019|FG003|Overall Study|administrative decision|4
6104609|NCT00785629|9722016|FG000|Overall Study|Withdrawal by Subject|0
6104610|NCT00785629|9722017|FG001|Overall Study|Withdrawal by Subject|1
6104611|NCT00785629|9722018|FG002|Overall Study|Withdrawal by Subject|2
6104612|NCT00785629|9722019|FG003|Overall Study|Withdrawal by Subject|2
6104613|NCT00785707|9722027|FG000|Overall Study|Lost to Follow-up|7
6104614|NCT00785785|9722037|FG000|Core Phase up to 36 Months|Patients didn't receive 1st line therapy|3
6104615|NCT00785785|9722038|FG001|Core Phase up to 36 Months|Patients didn't receive 1st line therapy|4
6104616|NCT00785785|9722037|FG000|Core Phase up to 36 Months|Adverse Event|31
6104617|NCT00785785|9722038|FG001|Core Phase up to 36 Months|Adverse Event|21
6104618|NCT00785785|9722037|FG000|Core Phase up to 36 Months|Abnormal laboratory value|1
6104619|NCT00785785|9722038|FG001|Core Phase up to 36 Months|Abnormal laboratory value|0
6104620|NCT00785785|9722037|FG000|Core Phase up to 36 Months|Abnormal test procedure result|2
6104621|NCT00785785|9722038|FG001|Core Phase up to 36 Months|Abnormal test procedure result|2
6104622|NCT00785785|9722037|FG000|Core Phase up to 36 Months|Withdrawal by Subject|16
6104623|NCT00785785|9722038|FG001|Core Phase up to 36 Months|Withdrawal by Subject|17
6104624|NCT00785785|9722037|FG000|Core Phase up to 36 Months|Lost to Follow-up|3
6104625|NCT00785785|9722038|FG001|Core Phase up to 36 Months|Lost to Follow-up|7
6104626|NCT00785785|9722037|FG000|Core Phase up to 36 Months|Administrative problems|3
6104627|NCT00785785|9722038|FG001|Core Phase up to 36 Months|Administrative problems|3
6104628|NCT00785785|9722037|FG000|Core Phase up to 36 Months|Death|5
6104629|NCT00785785|9722038|FG001|Core Phase up to 36 Months|Death|8
6104630|NCT00785785|9722037|FG000|Core Phase up to 36 Months|Disease progression|139
6104631|NCT00785785|9722038|FG001|Core Phase up to 36 Months|Disease progression|119
6104632|NCT00785785|9722037|FG000|Core Phase up to 36 Months|Protocol deviation|5
6104633|NCT00785785|9722038|FG001|Core Phase up to 36 Months|Protocol deviation|6
6104634|NCT00785785|9722037|FG000|Core Phase up to 36 Months|Study terminated by sponsor|116
6104635|NCT00785785|9722038|FG001|Core Phase up to 36 Months|Study terminated by sponsor|133
6104636|NCT00785785|9722037|FG000|Optional Extension Phase|Adverse Event|4
6104637|NCT00785785|9722038|FG001|Optional Extension Phase|Adverse Event|5
6104638|NCT00785785|9722037|FG000|Optional Extension Phase|Withdrawal by Subject|6
6104639|NCT00785785|9722038|FG001|Optional Extension Phase|Withdrawal by Subject|6
6104640|NCT00785785|9722037|FG000|Optional Extension Phase|Lost to Follow-up|1
6104641|NCT00785785|9722038|FG001|Optional Extension Phase|Lost to Follow-up|0
6104642|NCT00785785|9722037|FG000|Optional Extension Phase|Administrative problems|2
6104643|NCT00785785|9722038|FG001|Optional Extension Phase|Administrative problems|0
6104644|NCT00785785|9722037|FG000|Optional Extension Phase|Death|1
6104645|NCT00785785|9722038|FG001|Optional Extension Phase|Death|5
6104646|NCT00785785|9722037|FG000|Optional Extension Phase|Disease progression|22
6104647|NCT00785785|9722038|FG001|Optional Extension Phase|Disease progression|70
6104648|NCT00785785|9722037|FG000|Optional Extension Phase|Protocol deviation|0
6104649|NCT00785785|9722038|FG001|Optional Extension Phase|Protocol deviation|2
6104650|NCT00785785|9722037|FG000|Optional Extension Phase|Study terminated by sponsor|3
6104651|NCT00785785|9722038|FG001|Optional Extension Phase|Study terminated by sponsor|37
6104652|NCT00785928|9722053|FG000|Treatment Phase|Adverse Event|1
6104653|NCT00785928|9722054|FG001|Treatment Phase|Adverse Event|1
6104654|NCT00785928|9722055|FG002|Treatment Phase|Adverse Event|2
6104655|NCT00785928|9722056|FG003|Treatment Phase|Adverse Event|0
6104656|NCT00785928|9722057|FG004|Treatment Phase|Adverse Event|0
6104657|NCT00785928|9722058|FG005|Treatment Phase|Adverse Event|0
6104658|NCT00785928|9722059|FG006|Treatment Phase|Adverse Event|2
6104659|NCT00785928|9722053|FG000|Treatment Phase|Inadequate Response|0
6104660|NCT00785928|9722054|FG001|Treatment Phase|Inadequate Response|1
6104661|NCT00785928|9722055|FG002|Treatment Phase|Inadequate Response|0
6104662|NCT00785928|9722056|FG003|Treatment Phase|Inadequate Response|0
6104663|NCT00785928|9722057|FG004|Treatment Phase|Inadequate Response|0
6104664|NCT00785928|9722058|FG005|Treatment Phase|Inadequate Response|0
6104665|NCT00785928|9722059|FG006|Treatment Phase|Inadequate Response|0
6104666|NCT00785928|9722053|FG000|Treatment Phase|Lack of Efficacy|0
6104667|NCT00785928|9722054|FG001|Treatment Phase|Lack of Efficacy|1
6104668|NCT00785928|9722055|FG002|Treatment Phase|Lack of Efficacy|1
6104669|NCT00785928|9722056|FG003|Treatment Phase|Lack of Efficacy|0
6104670|NCT00785928|9722057|FG004|Treatment Phase|Lack of Efficacy|0
6104671|NCT00785928|9722058|FG005|Treatment Phase|Lack of Efficacy|0
6104672|NCT00785928|9722059|FG006|Treatment Phase|Lack of Efficacy|0
6104673|NCT00785928|9722053|FG000|Treatment Phase|Physician Decision|0
6104674|NCT00785928|9722054|FG001|Treatment Phase|Physician Decision|0
6104675|NCT00785928|9722055|FG002|Treatment Phase|Physician Decision|0
6104676|NCT00785928|9722056|FG003|Treatment Phase|Physician Decision|0
6104677|NCT00785928|9722057|FG004|Treatment Phase|Physician Decision|1
6104678|NCT00785928|9722058|FG005|Treatment Phase|Physician Decision|0
6104679|NCT00785928|9722059|FG006|Treatment Phase|Physician Decision|0
6104680|NCT00785928|9722053|FG000|Treatment Phase|Sponsor Decision|1
6104681|NCT00785928|9722054|FG001|Treatment Phase|Sponsor Decision|0
6104682|NCT00785928|9722055|FG002|Treatment Phase|Sponsor Decision|0
6104683|NCT00785928|9722056|FG003|Treatment Phase|Sponsor Decision|0
6104684|NCT00785928|9722057|FG004|Treatment Phase|Sponsor Decision|0
6104685|NCT00785928|9722058|FG005|Treatment Phase|Sponsor Decision|0
6104686|NCT00785928|9722059|FG006|Treatment Phase|Sponsor Decision|1
6104687|NCT00785928|9722053|FG000|Treatment Phase|Withdrawal by Subject|1
6104688|NCT00785928|9722054|FG001|Treatment Phase|Withdrawal by Subject|2
6104689|NCT00785928|9722055|FG002|Treatment Phase|Withdrawal by Subject|0
6104690|NCT00785928|9722056|FG003|Treatment Phase|Withdrawal by Subject|0
6104691|NCT00785928|9722057|FG004|Treatment Phase|Withdrawal by Subject|1
6104692|NCT00785928|9722058|FG005|Treatment Phase|Withdrawal by Subject|0
6104693|NCT00785928|9722059|FG006|Treatment Phase|Withdrawal by Subject|0
6104694|NCT00785980|9722097|FG000|7 Day Washout Period|Protocol Violation|3
6104695|NCT00786032|9722115|FG000|Overall Study|Death|4
6104696|NCT00786032|9722115|FG000|Overall Study|Withdrawal by Subject|14
6104697|NCT00786032|9722115|FG000|Overall Study|Did not complete in the timeframe|6
6104698|NCT00786188|9722123|FG000|Overall Study|Adverse Event|3
6104699|NCT00786188|9722124|FG001|Overall Study|Adverse Event|1
6104700|NCT00786188|9722123|FG000|Overall Study|Withdrawal by Subject|2
6104701|NCT00786188|9722124|FG001|Overall Study|Withdrawal by Subject|0
6104702|NCT00786409|9722132|FG000|Overall Study|Withdrawal by Subject|2
6104703|NCT00786409|9722132|FG000|Overall Study|Adverse Event|2
6104704|NCT00786409|9722132|FG000|Overall Study|Pregnancy|2
6104705|NCT00786409|9722132|FG000|Overall Study|Lost to Follow-up|1
6104706|NCT00786422|9722136|FG000|Rivaroxaban Treatment|Death|2
6104707|NCT00786422|9722136|FG000|Rivaroxaban Treatment|Final visit earlier than planned|3
6104708|NCT00786422|9722136|FG000|Rivaroxaban Treatment|Lack of Efficacy|1
6104709|NCT00786422|9722136|FG000|Rivaroxaban Treatment|Physician Decision|1
6104710|NCT00786422|9722136|FG000|Rivaroxaban Treatment|Withdrawal by Subject|1
6104711|NCT00786422|9722136|FG000|Rivaroxaban Treatment|Non-compliance with study drug treatment|1
6205198|NCT01529515|9867278|FG000|MAINTENANCE PHASE|Protocol Violation|0
6205199|NCT01529515|9867279|FG001|MAINTENANCE PHASE|Protocol Violation|12
6205200|NCT01529515|9867280|FG002|MAINTENANCE PHASE|Protocol Violation|0
6205201|NCT01529515|9867281|FG003|MAINTENANCE PHASE|Protocol Violation|0
6205202|NCT01529515|9867278|FG000|MAINTENANCE PHASE|Withdrawal by Subject|0
6205203|NCT01529515|9867279|FG001|MAINTENANCE PHASE|Withdrawal by Subject|15
6205204|NCT01529515|9867280|FG002|MAINTENANCE PHASE|Withdrawal by Subject|0
6205205|NCT01529515|9867281|FG003|MAINTENANCE PHASE|Withdrawal by Subject|0
6205206|NCT01529515|9867278|FG000|MAINTENANCE PHASE|Failed Randomization Criteria|0
6205207|NCT01529515|9867279|FG001|MAINTENANCE PHASE|Failed Randomization Criteria|13
6205208|NCT01529515|9867280|FG002|MAINTENANCE PHASE|Failed Randomization Criteria|0
6205209|NCT01529515|9867281|FG003|MAINTENANCE PHASE|Failed Randomization Criteria|0
6205210|NCT01529515|9867278|FG000|MAINTENANCE PHASE|Other|0
6205211|NCT01529515|9867279|FG001|MAINTENANCE PHASE|Other|10
6205212|NCT01529515|9867280|FG002|MAINTENANCE PHASE|Other|0
6205213|NCT01529515|9867281|FG003|MAINTENANCE PHASE|Other|0
6205214|NCT01529515|9867278|FG000|DOUBLE BLIND PHASE|Adverse Event|0
6205215|NCT01529515|9867279|FG001|DOUBLE BLIND PHASE|Adverse Event|0
6205216|NCT01529515|9867280|FG002|DOUBLE BLIND PHASE|Adverse Event|1
6205217|NCT01529515|9867281|FG003|DOUBLE BLIND PHASE|Adverse Event|0
6205218|NCT01529515|9867278|FG000|DOUBLE BLIND PHASE|Lost to Follow-up|0
6205219|NCT01529515|9867279|FG001|DOUBLE BLIND PHASE|Lost to Follow-up|0
6205220|NCT01529515|9867280|FG002|DOUBLE BLIND PHASE|Lost to Follow-up|1
6205221|NCT01529515|9867281|FG003|DOUBLE BLIND PHASE|Lost to Follow-up|3
6205222|NCT01529515|9867278|FG000|DOUBLE BLIND PHASE|Pregnancy|0
6205223|NCT01529515|9867279|FG001|DOUBLE BLIND PHASE|Pregnancy|0
6205224|NCT01529515|9867280|FG002|DOUBLE BLIND PHASE|Pregnancy|1
6205225|NCT01529515|9867281|FG003|DOUBLE BLIND PHASE|Pregnancy|0
6205226|NCT01529515|9867278|FG000|DOUBLE BLIND PHASE|Withdrawal by Subject|0
6205227|NCT01529515|9867279|FG001|DOUBLE BLIND PHASE|Withdrawal by Subject|0
6205228|NCT01529515|9867280|FG002|DOUBLE BLIND PHASE|Withdrawal by Subject|10
6205229|NCT01529515|9867281|FG003|DOUBLE BLIND PHASE|Withdrawal by Subject|7
6205230|NCT01529515|9867278|FG000|DOUBLE BLIND PHASE|Protocol Violation|0
6205231|NCT01529515|9867279|FG001|DOUBLE BLIND PHASE|Protocol Violation|0
6205232|NCT01529515|9867280|FG002|DOUBLE BLIND PHASE|Protocol Violation|1
6205233|NCT01529515|9867281|FG003|DOUBLE BLIND PHASE|Protocol Violation|0
6205234|NCT01529515|9867278|FG000|DOUBLE BLIND PHASE|Other|0
6205235|NCT01529515|9867279|FG001|DOUBLE BLIND PHASE|Other|0
6205236|NCT01529515|9867280|FG002|DOUBLE BLIND PHASE|Other|9
6205237|NCT01529515|9867281|FG003|DOUBLE BLIND PHASE|Other|2
6205238|NCT01529606|9867290|FG000|Overall Study|Lost to Follow-up|21
6205239|NCT01529606|9867291|FG001|Overall Study|Lost to Follow-up|18
6205240|NCT01529632|9867299|FG000|Overall Study|Administrative problem|2
6205241|NCT01529632|9867300|FG001|Overall Study|Administrative problem|1
6205242|NCT01529632|9867299|FG000|Overall Study|Protocol Violation|0
6205243|NCT01529632|9867300|FG001|Overall Study|Protocol Violation|1
6205244|NCT01529632|9867299|FG000|Overall Study|Adverse Event|1
6205245|NCT01529632|9867300|FG001|Overall Study|Adverse Event|1
6205246|NCT01529645|9867316|FG000|Overall Study|Lost to Follow-up|0
6205247|NCT01529645|9867317|FG001|Overall Study|Lost to Follow-up|1
6205248|NCT01529645|9867318|FG002|Overall Study|Lost to Follow-up|1
6205249|NCT01529645|9867319|FG003|Overall Study|Lost to Follow-up|1
6205250|NCT01529645|9867320|FG004|Overall Study|Lost to Follow-up|1
6205251|NCT01529645|9867321|FG005|Overall Study|Lost to Follow-up|0
6205252|NCT01529645|9867322|FG006|Overall Study|Lost to Follow-up|2
6205253|NCT01529645|9867323|FG007|Overall Study|Lost to Follow-up|0
6205254|NCT01529645|9867324|FG008|Overall Study|Lost to Follow-up|1
6205255|NCT01529645|9867325|FG009|Overall Study|Lost to Follow-up|0
6205256|NCT01529645|9867316|FG000|Overall Study|SAE - Premature contractions|0
6205257|NCT01529645|9867317|FG001|Overall Study|SAE - Premature contractions|0
6205258|NCT01529645|9867318|FG002|Overall Study|SAE - Premature contractions|1
6104712|NCT00786422|9722136|FG000|Rivaroxaban Treatment|Adverse Event|2
6104713|NCT00786422|9722136|FG000|Follow-up Period|Death|1
6104714|NCT00786422|9722136|FG000|Follow-up Period|End-of-study done up to 4 days early|2
6104715|NCT00786474|9722144|FG000|Overall Study|Death|5
6104716|NCT00786474|9722145|FG001|Overall Study|Death|4
6104717|NCT00786474|9722144|FG000|Overall Study|Withdrawal by Subject|23
6104718|NCT00786474|9722145|FG001|Overall Study|Withdrawal by Subject|31
6104719|NCT00786474|9722144|FG000|Overall Study|Lost to Follow-up|3
6104720|NCT00786474|9722145|FG001|Overall Study|Lost to Follow-up|3
6104721|NCT00786474|9722144|FG000|Overall Study|Physician Decision|2
6104722|NCT00786474|9722145|FG001|Overall Study|Physician Decision|1
6104723|NCT00786474|9722144|FG000|Overall Study|Other|4
6104724|NCT00786474|9722145|FG001|Overall Study|Other|4
6104725|NCT00786565|9722168|FG000|Enrollment Prior to Surgery|Site Closed|3
6104726|NCT00786565|9722168|FG000|Enrollment Prior to Surgery|Protocol Violation|3
6104727|NCT00786565|9722168|FG000|Post Surgery|Abnormal macular pucker|1
6104728|NCT00786565|9722168|FG000|Post Surgery|Adapt AO implanted posterior side up|1
6104729|NCT00786799|9722185|FG000|Overall Study|Lost to Follow-up|1
6104730|NCT00786799|9722186|FG001|Overall Study|Lost to Follow-up|1
6104731|NCT00786838|9722206|FG000|Overall Study|Physician Decision|4
6285088|NCT02331446|9996984|FG001|Overall Study|Lost to Follow-up|1
6285089|NCT02331446|9996985|FG002|Overall Study|Lost to Follow-up|0
6285090|NCT02331446|9996986|FG003|Overall Study|Lost to Follow-up|1
6285091|NCT02331446|9996983|FG000|Overall Study|Personal Problem|2
6285092|NCT02331446|9996984|FG001|Overall Study|Personal Problem|0
6285093|NCT02331446|9996985|FG002|Overall Study|Personal Problem|0
6285094|NCT02331446|9996986|FG003|Overall Study|Personal Problem|0
6285095|NCT02331446|9996983|FG000|Overall Study|Disease|0
6104732|NCT00786838|9722206|FG000|Overall Study|Death|4
6104733|NCT00786838|9722206|FG000|Overall Study|Adverse Event|6
6104734|NCT00786838|9722206|FG000|Overall Study|Progressive disease|31
6104735|NCT00786838|9722206|FG000|Overall Study|Withdrawal by Subject|4
6104736|NCT00786864|9722217|FG000|Overall Study|Lost to Follow-up|0
6104737|NCT00786864|9722218|FG001|Overall Study|Lost to Follow-up|1
6104738|NCT00786864|9722217|FG000|Overall Study|Sustained serious back injury|1
6104739|NCT00786864|9722218|FG001|Overall Study|Sustained serious back injury|0
6104740|NCT00787137|9722265|FG000|Overall Study|Study Termination|0
6104741|NCT00787137|9722266|FG001|Overall Study|Study Termination|0
6104742|NCT00787137|9722267|FG002|Overall Study|Study Termination|1
6104743|NCT00787150|9722278|FG000|Overall Study|Adverse Event|4
6104744|NCT00787150|9722279|FG001|Overall Study|Adverse Event|4
6104745|NCT00787150|9722280|FG002|Overall Study|Adverse Event|4
6104746|NCT00787150|9722278|FG000|Overall Study|Physician Decision|1
6205259|NCT01529645|9867319|FG003|Overall Study|SAE - Premature contractions|0
6205260|NCT01529645|9867320|FG004|Overall Study|SAE - Premature contractions|0
6205261|NCT01529645|9867321|FG005|Overall Study|SAE - Premature contractions|0
6205262|NCT01529645|9867322|FG006|Overall Study|SAE - Premature contractions|0
6205263|NCT01529645|9867323|FG007|Overall Study|SAE - Premature contractions|0
6205264|NCT01529645|9867324|FG008|Overall Study|SAE - Premature contractions|0
6205265|NCT01529645|9867325|FG009|Overall Study|SAE - Premature contractions|0
6205266|NCT01529645|9867316|FG000|Overall Study|Withdrawal by Subject|2
6205267|NCT01529645|9867317|FG001|Overall Study|Withdrawal by Subject|0
6205268|NCT01529645|9867318|FG002|Overall Study|Withdrawal by Subject|0
6205269|NCT01529645|9867319|FG003|Overall Study|Withdrawal by Subject|1
6205270|NCT01529645|9867320|FG004|Overall Study|Withdrawal by Subject|1
6205271|NCT01529645|9867321|FG005|Overall Study|Withdrawal by Subject|1
6205272|NCT01529645|9867322|FG006|Overall Study|Withdrawal by Subject|0
6205273|NCT01529645|9867323|FG007|Overall Study|Withdrawal by Subject|0
6205274|NCT01529645|9867324|FG008|Overall Study|Withdrawal by Subject|0
6205275|NCT01529645|9867325|FG009|Overall Study|Withdrawal by Subject|0
6205276|NCT01529749|9867359|FG000|Overall Study|Lost to Follow-up|0
6205277|NCT01529749|9867360|FG001|Overall Study|Lost to Follow-up|1
6205278|NCT01529749|9867361|FG002|Overall Study|Lost to Follow-up|1
6205279|NCT01529749|9867362|FG003|Overall Study|Lost to Follow-up|0
6205280|NCT01529749|9867359|FG000|Overall Study|Physician Decision|0
6205281|NCT01529749|9867360|FG001|Overall Study|Physician Decision|0
6205282|NCT01529749|9867361|FG002|Overall Study|Physician Decision|0
6205283|NCT01529749|9867362|FG003|Overall Study|Physician Decision|1
6205284|NCT01529749|9867359|FG000|Overall Study|Withdrawal by Subject|0
6205285|NCT01529749|9867360|FG001|Overall Study|Withdrawal by Subject|1
6205286|NCT01529749|9867361|FG002|Overall Study|Withdrawal by Subject|1
6205287|NCT01529749|9867362|FG003|Overall Study|Withdrawal by Subject|0
6205288|NCT01529749|9867359|FG000|Overall Study|Protocol Violation|0
6205289|NCT01529749|9867360|FG001|Overall Study|Protocol Violation|0
6205290|NCT01529749|9867361|FG002|Overall Study|Protocol Violation|0
6205291|NCT01529749|9867362|FG003|Overall Study|Protocol Violation|1
6205292|NCT01530256|9867407|FG000|Overall Study|Death|2
6205293|NCT01530334|9867411|FG000|Overall Study|Adverse Event|3
6205294|NCT01530334|9867411|FG000|Overall Study|unknown reason|1
6205295|NCT01530334|9867411|FG000|Overall Study|Progressive disease|47
6205296|NCT01530464|9867442|FG000|Washout (24h)|Withdrawal by Subject|1
6205297|NCT01530464|9867443|FG001|Washout (24h)|Withdrawal by Subject|0
6205298|NCT01530464|9867442|FG000|Washout (24h)|Withdrawal by Subject|0
6285096|NCT02331446|9996984|FG001|Overall Study|Disease|2
6285097|NCT02331446|9996985|FG002|Overall Study|Disease|2
6104747|NCT00787150|9722279|FG001|Overall Study|Physician Decision|2
6104748|NCT00787150|9722280|FG002|Overall Study|Physician Decision|1
6104749|NCT00787150|9722278|FG000|Overall Study|Withdrawal by Subject|2
6104750|NCT00787150|9722279|FG001|Overall Study|Withdrawal by Subject|1
6104751|NCT00787150|9722280|FG002|Overall Study|Withdrawal by Subject|0
6104752|NCT00787150|9722278|FG000|Overall Study|Dosing incorrect study durg|2
6104753|NCT00787150|9722279|FG001|Overall Study|Dosing incorrect study durg|0
6104754|NCT00787150|9722280|FG002|Overall Study|Dosing incorrect study durg|0
6104755|NCT00787189|9722292|FG000|Overall Study|Lost to Follow-up|2
6104756|NCT00787189|9722293|FG001|Overall Study|Lost to Follow-up|2
6104757|NCT00787202|9722304|FG000|Overall Study|Adverse Event|3
6104758|NCT00787202|9722305|FG001|Overall Study|Adverse Event|2
6104759|NCT00787202|9722306|FG002|Overall Study|Adverse Event|0
6104760|NCT00787202|9722307|FG003|Overall Study|Adverse Event|0
6104761|NCT00787202|9722308|FG004|Overall Study|Adverse Event|2
6104762|NCT00787202|9722304|FG000|Overall Study|Lack of Efficacy|5
6104763|NCT00787202|9722305|FG001|Overall Study|Lack of Efficacy|6
6104764|NCT00787202|9722306|FG002|Overall Study|Lack of Efficacy|5
6104765|NCT00787202|9722307|FG003|Overall Study|Lack of Efficacy|2
6104766|NCT00787202|9722308|FG004|Overall Study|Lack of Efficacy|1
6104767|NCT00787202|9722304|FG000|Overall Study|Lost to Follow-up|1
6104768|NCT00787202|9722305|FG001|Overall Study|Lost to Follow-up|0
6104769|NCT00787202|9722306|FG002|Overall Study|Lost to Follow-up|0
6104770|NCT00787202|9722307|FG003|Overall Study|Lost to Follow-up|0
6104771|NCT00787202|9722308|FG004|Overall Study|Lost to Follow-up|0
6104772|NCT00787202|9722304|FG000|Overall Study|Withdrawal by Subject|2
6104773|NCT00787202|9722305|FG001|Overall Study|Withdrawal by Subject|2
6104774|NCT00787202|9722306|FG002|Overall Study|Withdrawal by Subject|2
6104775|NCT00787202|9722307|FG003|Overall Study|Withdrawal by Subject|0
6104776|NCT00787202|9722308|FG004|Overall Study|Withdrawal by Subject|0
6104777|NCT00787202|9722304|FG000|Overall Study|Protocol Violation|2
6104778|NCT00787202|9722305|FG001|Overall Study|Protocol Violation|1
6104779|NCT00787202|9722306|FG002|Overall Study|Protocol Violation|0
6104780|NCT00787202|9722307|FG003|Overall Study|Protocol Violation|0
6104781|NCT00787202|9722308|FG004|Overall Study|Protocol Violation|1
6104782|NCT00787202|9722304|FG000|Overall Study|Randomized, not treated|1
6104783|NCT00787202|9722305|FG001|Overall Study|Randomized, not treated|0
6104784|NCT00787202|9722306|FG002|Overall Study|Randomized, not treated|0
6104785|NCT00787202|9722307|FG003|Overall Study|Randomized, not treated|0
6104786|NCT00787202|9722308|FG004|Overall Study|Randomized, not treated|0
6104787|NCT00787254|9722339|FG000|Overall Study|Adverse Event|24
6104788|NCT00787254|9722340|FG001|Overall Study|Adverse Event|23
6104789|NCT00787254|9722339|FG000|Overall Study|Protocol Violation|26
6104790|NCT00787254|9722340|FG001|Overall Study|Protocol Violation|23
6104791|NCT00787254|9722339|FG000|Overall Study|Withdrawal by Subject|16
6104792|NCT00787254|9722340|FG001|Overall Study|Withdrawal by Subject|11
6104793|NCT00787254|9722339|FG000|Overall Study|Lack of Efficacy|4
6104794|NCT00787254|9722340|FG001|Overall Study|Lack of Efficacy|15
6104795|NCT00787254|9722339|FG000|Overall Study|NSAIDs discontinuation|1
6104796|NCT00787254|9722340|FG001|Overall Study|NSAIDs discontinuation|2
6104797|NCT00787254|9722339|FG000|Overall Study|Institution closed|1
6104798|NCT00787254|9722340|FG001|Overall Study|Institution closed|0
6104799|NCT00787254|9722339|FG000|Overall Study|Physician Decision|4
6104800|NCT00787254|9722340|FG001|Overall Study|Physician Decision|8
6104801|NCT00787267|9722346|FG000|Overall Study|Screen failure/Ineligible|10
6104802|NCT00787267|9722346|FG000|Overall Study|No Reason Provided|1
6104803|NCT00787267|9722346|FG000|Overall Study|Withdrawal by Subject|1
6104804|NCT00787319|9722350|FG000|Overall Study|Lost to Follow-up|2
6104805|NCT00787319|9722350|FG000|Overall Study|Withdrawal by Subject|15
6104806|NCT00787319|9722350|FG000|Overall Study|Adverse Event|3
6104807|NCT00787319|9722350|FG000|Overall Study|Objective progression or relapse|30
6104808|NCT00787319|9722350|FG000|Overall Study|Lack of Efficacy|1
6104809|NCT00787319|9722350|FG000|Overall Study|Budget exhausted/exceeded|1
6104810|NCT00787319|9722350|FG000|Overall Study|Unresponsiveness to visit invitation|1
6104811|NCT00787319|9722350|FG000|Overall Study|No health insurance reimbursement|2
6104812|NCT00787319|9722350|FG000|Overall Study|Stabilized disease findings|3
6104813|NCT00787319|9722350|FG000|Overall Study|Inactive disease|5
6104814|NCT00787527|9722363|FG000|Overall Study|Toxicity|3
6104815|NCT00787566|9722374|FG000|Overall Study|AE related to chemotherapy|0
6104816|NCT00787566|9722375|FG001|Overall Study|AE related to chemotherapy|1
6104817|NCT00787566|9722376|FG002|Overall Study|AE related to chemotherapy|0
6104818|NCT00787605|9722386|FG000|Overall Study|Administrative Problems|3
6104819|NCT00787605|9722387|FG001|Overall Study|Administrative Problems|0
6104820|NCT00787605|9722386|FG000|Overall Study|Adverse Event|14
6104821|NCT00787605|9722387|FG001|Overall Study|Adverse Event|25
6104822|NCT00787605|9722386|FG000|Overall Study|Lost to Follow-up|3
6104823|NCT00787605|9722387|FG001|Overall Study|Lost to Follow-up|6
6104824|NCT00787605|9722386|FG000|Overall Study|Protocol Violation|7
6104825|NCT00787605|9722387|FG001|Overall Study|Protocol Violation|3
6104826|NCT00787605|9722386|FG000|Overall Study|Withdrawal by Subject|6
6104827|NCT00787605|9722387|FG001|Overall Study|Withdrawal by Subject|13
6104828|NCT00787605|9722386|FG000|Overall Study|Lack of Efficacy|13
6104829|NCT00787605|9722387|FG001|Overall Study|Lack of Efficacy|9
6104830|NCT00787644|9722395|FG000|Overall Study|Lost to Follow-up|1
6104831|NCT00787644|9722396|FG001|Overall Study|Lost to Follow-up|1
6104832|NCT00787644|9722395|FG000|Overall Study|Withdrawal by Subject|1
6104833|NCT00787644|9722396|FG001|Overall Study|Withdrawal by Subject|1
6104834|NCT00787787|9722413|FG000|Overall Study|Lack of Efficacy|4
6104835|NCT00787787|9722413|FG000|Overall Study|Adverse Event|3
6104836|NCT00787800|9722419|FG000|Overall Study|Withdrawal by Subject|3
6104837|NCT00787800|9722420|FG001|Overall Study|Withdrawal by Subject|5
6104838|NCT00787800|9722419|FG000|Overall Study|Death|0
6104839|NCT00787800|9722420|FG001|Overall Study|Death|2
6104840|NCT00787839|9722427|FG000|Overall Study|Failure to have the OGTT was most common|404
6104841|NCT00787891|9722459|FG000|Short-term Double-blind Phase (Part 1)|Adverse Event|1
6104842|NCT00787891|9722460|FG001|Short-term Double-blind Phase (Part 1)|Adverse Event|2
6104843|NCT00787891|9722459|FG000|Short-term Double-blind Phase (Part 1)|Lost to Follow-up|2
6104844|NCT00787891|9722460|FG001|Short-term Double-blind Phase (Part 1)|Lost to Follow-up|2
6104845|NCT00787891|9722459|FG000|Short-term Double-blind Phase (Part 1)|Protocol Violation|0
6104846|NCT00787891|9722460|FG001|Short-term Double-blind Phase (Part 1)|Protocol Violation|1
6104847|NCT00787891|9722459|FG000|Short-term Double-blind Phase (Part 1)|Physician Decision|1
6104848|NCT00787891|9722460|FG001|Short-term Double-blind Phase (Part 1)|Physician Decision|0
6104849|NCT00787891|9722459|FG000|Short-term Double-blind Phase (Part 1)|Withdrawal by Subject|6
6104850|NCT00787891|9722460|FG001|Short-term Double-blind Phase (Part 1)|Withdrawal by Subject|2
6104851|NCT00787891|9722459|FG000|Short-term Double-blind Phase (Part 1)|Other|0
6104852|NCT00787891|9722460|FG001|Short-term Double-blind Phase (Part 1)|Other|2
6104853|NCT00787891|9722459|FG000|Maintenance Double-blind Phase (Part 2)|Adverse Event|0
6104854|NCT00787891|9722460|FG001|Maintenance Double-blind Phase (Part 2)|Adverse Event|1
6104855|NCT00787891|9722459|FG000|Maintenance Double-blind Phase (Part 2)|Non-Compliance With Study Drug|1
6104856|NCT00787891|9722460|FG001|Maintenance Double-blind Phase (Part 2)|Non-Compliance With Study Drug|1
6104857|NCT00787891|9722459|FG000|Maintenance Double-blind Phase (Part 2)|Withdrawal by Subject|1
6104858|NCT00787891|9722460|FG001|Maintenance Double-blind Phase (Part 2)|Withdrawal by Subject|3
6104859|NCT00787891|9722459|FG000|Maintenance Double-blind Phase (Part 2)|Other|5
6104860|NCT00787891|9722460|FG001|Maintenance Double-blind Phase (Part 2)|Other|2
6104861|NCT00787930|9722477|FG000|Continuation Treatment -- up to 12 Month|Withdrawal by Subject|3
6104862|NCT00788073|9722506|FG000|STX209 Then Placebo|Adverse Event|1
6104863|NCT00788073|9722507|FG001|STX209 Then Placebo|Adverse Event|0
6104864|NCT00788073|9722506|FG000|STX209 Then Placebo|Lost to Follow-up|0
6104865|NCT00788073|9722507|FG001|STX209 Then Placebo|Lost to Follow-up|1
6104866|NCT00788073|9722506|FG000|STX209 Then Placebo|Withdrawal by Subject|0
6104867|NCT00788073|9722507|FG001|STX209 Then Placebo|Withdrawal by Subject|1
6104868|NCT00788073|9722506|FG000|STX209 Then Placebo|unable to return due to travel|0
6104869|NCT00788073|9722507|FG001|STX209 Then Placebo|unable to return due to travel|1
6104870|NCT00788073|9722506|FG000|Placebo Then STX209|Adverse Event|2
6104871|NCT00788073|9722507|FG001|Placebo Then STX209|Adverse Event|0
6104872|NCT00788073|9722506|FG000|Placebo Then STX209|Protocol Violation|0
6104873|NCT00788073|9722507|FG001|Placebo Then STX209|Protocol Violation|1
6205299|NCT01530464|9867443|FG001|Washout (24h)|Withdrawal by Subject|1
6205300|NCT01531153|9867468|FG000|Overall Study|Withdrawal by Subject|10
6205301|NCT01531153|9867469|FG001|Overall Study|Withdrawal by Subject|9
6205302|NCT01531153|9867470|FG002|Overall Study|Withdrawal by Subject|15
6205303|NCT01531205|9867481|FG000|Overall Study|Did not proceed to surgery|1
6205304|NCT01531673|9867518|FG000|Overall Study|Non-Compliance|0
6205305|NCT01531673|9867519|FG001|Overall Study|Non-Compliance|0
6205306|NCT01531673|9867520|FG002|Overall Study|Non-Compliance|0
6205307|NCT01531673|9867521|FG003|Overall Study|Non-Compliance|0
6205308|NCT01531673|9867522|FG004|Overall Study|Non-Compliance|0
6205309|NCT01531673|9867523|FG005|Overall Study|Non-Compliance|1
6205310|NCT01531673|9867524|FG006|Overall Study|Non-Compliance|0
6205311|NCT01531673|9867525|FG007|Overall Study|Non-Compliance|0
6205312|NCT01531673|9867526|FG008|Overall Study|Non-Compliance|0
6205313|NCT01531673|9867527|FG009|Overall Study|Non-Compliance|0
6205314|NCT01531673|9867528|FG010|Overall Study|Non-Compliance|0
6205315|NCT01531673|9867529|FG011|Overall Study|Non-Compliance|0
6205316|NCT01531673|9867530|FG012|Overall Study|Non-Compliance|0
6205317|NCT01531673|9867518|FG000|Overall Study|Adverse Event|0
6205318|NCT01531673|9867519|FG001|Overall Study|Adverse Event|1
6205319|NCT01531673|9867520|FG002|Overall Study|Adverse Event|0
6205320|NCT01531673|9867521|FG003|Overall Study|Adverse Event|0
6205321|NCT01531673|9867522|FG004|Overall Study|Adverse Event|0
6205322|NCT01531673|9867523|FG005|Overall Study|Adverse Event|0
6285098|NCT02331446|9996986|FG003|Overall Study|Disease|1
6285099|NCT02331446|9996983|FG000|Overall Study|Physician Decision|0
6205323|NCT01531673|9867524|FG006|Overall Study|Adverse Event|0
6205324|NCT01531673|9867525|FG007|Overall Study|Adverse Event|0
6205325|NCT01531673|9867526|FG008|Overall Study|Adverse Event|0
6205326|NCT01531673|9867527|FG009|Overall Study|Adverse Event|0
6205327|NCT01531673|9867528|FG010|Overall Study|Adverse Event|0
6205328|NCT01531673|9867529|FG011|Overall Study|Adverse Event|0
6285100|NCT02331446|9996984|FG001|Overall Study|Physician Decision|1
6205329|NCT01531673|9867530|FG012|Overall Study|Adverse Event|0
6205330|NCT01531673|9867518|FG000|Overall Study|Lost to Follow-up|0
6205331|NCT01531673|9867519|FG001|Overall Study|Lost to Follow-up|0
6205332|NCT01531673|9867520|FG002|Overall Study|Lost to Follow-up|0
6205333|NCT01531673|9867521|FG003|Overall Study|Lost to Follow-up|0
6104874|NCT00788372|9722520|FG000|Period 1 (up to 4 Weeks)|Adverse Event|18
6104875|NCT00788372|9722520|FG000|Period 1 (up to 4 Weeks)|Ineligible for transfer to period 2|9
6104876|NCT00788372|9722520|FG000|Period 1 (up to 4 Weeks)|Withdrawal of informed consent|4
6104877|NCT00788372|9722520|FG000|Period 2 (Week 4 to Week 52)|Adverse Event|13
6104878|NCT00788372|9722520|FG000|Period 2 (Week 4 to Week 52)|Physician Decision|9
6104879|NCT00788372|9722520|FG000|Period 2 (Week 4 to Week 52)|Withdrawal of informed consent|9
6104880|NCT00788372|9722520|FG000|Period 2 (Week 4 to Week 52)|Aggravated symptoms|1
6104881|NCT00788593|9722524|FG000|Placebo Run-in Phase|Adverse Event|2
6104882|NCT00788593|9722525|FG001|Placebo Run-in Phase|Adverse Event|0
6104883|NCT00788593|9722526|FG002|Placebo Run-in Phase|Adverse Event|0
6104884|NCT00788593|9722524|FG000|Placebo Run-in Phase|Withdrawal by Subject|2
6104885|NCT00788593|9722525|FG001|Placebo Run-in Phase|Withdrawal by Subject|0
6104886|NCT00788593|9722526|FG002|Placebo Run-in Phase|Withdrawal by Subject|0
6104887|NCT00788593|9722524|FG000|Placebo Run-in Phase|Protocol Violation|2
6104888|NCT00788593|9722525|FG001|Placebo Run-in Phase|Protocol Violation|0
6104889|NCT00788593|9722526|FG002|Placebo Run-in Phase|Protocol Violation|0
6104890|NCT00788593|9722524|FG000|First Intervention Period|Adverse Event|0
6104891|NCT00788593|9722525|FG001|First Intervention Period|Adverse Event|1
6104892|NCT00788593|9722526|FG002|First Intervention Period|Adverse Event|0
6104893|NCT00788593|9722524|FG000|Second Intervention Period|Lost to Follow-up|0
6104894|NCT00788593|9722525|FG001|Second Intervention Period|Lost to Follow-up|1
6104895|NCT00788593|9722526|FG002|Second Intervention Period|Lost to Follow-up|0
6104896|NCT00788593|9722524|FG000|Second Intervention Period|Other|0
6104897|NCT00788593|9722525|FG001|Second Intervention Period|Other|0
6104898|NCT00788593|9722526|FG002|Second Intervention Period|Other|1
6104899|NCT00788697|9722536|FG000|Overall Study|No study drug administered|12
6104900|NCT00788697|9722536|FG000|Overall Study|Training Patients|74
6104901|NCT00788697|9722536|FG000|Overall Study|no truth standard procedure available|5
6104902|NCT00788697|9722536|FG000|Overall Study|Technically inadequate truth standard|1
6104903|NCT00788697|9722536|FG000|Overall Study|Indeterminate diagnosis from truth stand|17
6104904|NCT00788775|9722550|FG000|Overall Study|Progressive Disease|8
6104905|NCT00788775|9722551|FG001|Overall Study|Progressive Disease|6
6104906|NCT00788775|9722550|FG000|Overall Study|Withdrawal by Subject|0
6104907|NCT00788775|9722551|FG001|Overall Study|Withdrawal by Subject|2
6104908|NCT00788775|9722550|FG000|Overall Study|Patient Non-Compliance|1
6104909|NCT00788775|9722551|FG001|Overall Study|Patient Non-Compliance|0
6104910|NCT00788775|9722550|FG000|Overall Study|Patient's measurable disease resected.|1
6104911|NCT00788775|9722551|FG001|Overall Study|Patient's measurable disease resected.|0
6104912|NCT00788827|9722557|FG000|Overall Study|Lack of Efficacy|2
6205334|NCT01531673|9867522|FG004|Overall Study|Lost to Follow-up|1
6205335|NCT01531673|9867523|FG005|Overall Study|Lost to Follow-up|0
6205336|NCT01531673|9867524|FG006|Overall Study|Lost to Follow-up|0
6205337|NCT01531673|9867525|FG007|Overall Study|Lost to Follow-up|0
6205338|NCT01531673|9867526|FG008|Overall Study|Lost to Follow-up|0
6205339|NCT01531673|9867527|FG009|Overall Study|Lost to Follow-up|0
6205340|NCT01531673|9867528|FG010|Overall Study|Lost to Follow-up|0
6205341|NCT01531673|9867529|FG011|Overall Study|Lost to Follow-up|0
6205342|NCT01531673|9867530|FG012|Overall Study|Lost to Follow-up|0
6205343|NCT01531673|9867518|FG000|Overall Study|Other|0
6205344|NCT01531673|9867519|FG001|Overall Study|Other|0
6205345|NCT01531673|9867520|FG002|Overall Study|Other|0
6205346|NCT01531673|9867521|FG003|Overall Study|Other|1
6205347|NCT01531673|9867522|FG004|Overall Study|Other|0
6285101|NCT02331446|9996985|FG002|Overall Study|Physician Decision|0
6285102|NCT02331446|9996986|FG003|Overall Study|Physician Decision|1
6285103|NCT02331446|9996983|FG000|Overall Study|Lost before baseline analysis|0
6285104|NCT02331446|9996984|FG001|Overall Study|Lost before baseline analysis|1
6285105|NCT02331446|9996985|FG002|Overall Study|Lost before baseline analysis|1
6285106|NCT02331446|9996986|FG003|Overall Study|Lost before baseline analysis|0
6285107|NCT02331680|9997008|FG000|Overall Study|Adverse Event|3
6285108|NCT02331680|9997009|FG001|Overall Study|Adverse Event|0
6285109|NCT02331680|9997010|FG002|Overall Study|Adverse Event|2
6285110|NCT02331680|9997008|FG000|Overall Study|Physician Decision|1
6285111|NCT02331680|9997009|FG001|Overall Study|Physician Decision|1
6285112|NCT02331680|9997010|FG002|Overall Study|Physician Decision|2
6285113|NCT02331680|9997008|FG000|Overall Study|Withdrawal by Subject|0
6285114|NCT02331680|9997009|FG001|Overall Study|Withdrawal by Subject|1
6285115|NCT02331680|9997010|FG002|Overall Study|Withdrawal by Subject|2
6285116|NCT02331680|9997008|FG000|Overall Study|Met withdrawal criteria|2
6285117|NCT02331680|9997009|FG001|Overall Study|Met withdrawal criteria|2
6285118|NCT02331680|9997010|FG002|Overall Study|Met withdrawal criteria|5
6285119|NCT02331680|9997008|FG000|Overall Study|Non-compliance with study drug|0
6285120|NCT02331680|9997009|FG001|Overall Study|Non-compliance with study drug|0
6285121|NCT02331680|9997010|FG002|Overall Study|Non-compliance with study drug|1
6285122|NCT02331680|9997008|FG000|Overall Study|Protocol Violation|0
6285123|NCT02331680|9997009|FG001|Overall Study|Protocol Violation|0
6285124|NCT02331680|9997010|FG002|Overall Study|Protocol Violation|3
6285125|NCT02332239|9997033|FG000|Overall Study|Lost to Follow-up|4
6285126|NCT02332239|9997034|FG001|Overall Study|Lost to Follow-up|6
6285127|NCT02332291|9997044|FG000|Phase 1: Blinded Escitalopram or Placebo|Adverse Event|3
6285128|NCT02332291|9997045|FG001|Phase 1: Blinded Escitalopram or Placebo|Adverse Event|5
6104913|NCT00788957|9722576|FG000|Part 1|Death|8
6104914|NCT00788957|9722577|FG001|Part 1|Death|0
6104915|NCT00788957|9722578|FG002|Part 1|Death|0
6104916|NCT00788957|9722579|FG003|Part 1|Death|0
6104917|NCT00788957|9722580|FG004|Part 1|Death|0
6104918|NCT00788957|9722581|FG005|Part 1|Death|0
6104919|NCT00788957|9722576|FG000|Part 1|Lost to Follow-up|1
6104920|NCT00788957|9722577|FG001|Part 1|Lost to Follow-up|0
6104921|NCT00788957|9722578|FG002|Part 1|Lost to Follow-up|0
6104922|NCT00788957|9722579|FG003|Part 1|Lost to Follow-up|0
6104923|NCT00788957|9722580|FG004|Part 1|Lost to Follow-up|0
6104924|NCT00788957|9722581|FG005|Part 1|Lost to Follow-up|0
6104925|NCT00788957|9722576|FG000|Part 2|Withdrawal by Subject|0
6104926|NCT00788957|9722577|FG001|Part 2|Withdrawal by Subject|9
6104927|NCT00788957|9722578|FG002|Part 2|Withdrawal by Subject|5
6104928|NCT00788957|9722579|FG003|Part 2|Withdrawal by Subject|3
6104929|NCT00788957|9722580|FG004|Part 2|Withdrawal by Subject|0
6104930|NCT00788957|9722581|FG005|Part 2|Withdrawal by Subject|0
6104931|NCT00788957|9722576|FG000|Part 2|Death|0
6104932|NCT00788957|9722577|FG001|Part 2|Death|32
6104933|NCT00788957|9722578|FG002|Part 2|Death|35
6104934|NCT00788957|9722579|FG003|Part 2|Death|37
6104935|NCT00788957|9722580|FG004|Part 2|Death|0
6104936|NCT00788957|9722581|FG005|Part 2|Death|0
6104937|NCT00788957|9722576|FG000|Part 2|Lost to Follow-up|0
6104938|NCT00788957|9722577|FG001|Part 2|Lost to Follow-up|0
6104939|NCT00788957|9722578|FG002|Part 2|Lost to Follow-up|3
6104940|NCT00788957|9722579|FG003|Part 2|Lost to Follow-up|0
6104941|NCT00788957|9722580|FG004|Part 2|Lost to Follow-up|0
6104942|NCT00788957|9722581|FG005|Part 2|Lost to Follow-up|0
6104943|NCT00788957|9722576|FG000|Part 2|On-study at time of data cut-off|0
6104944|NCT00788957|9722577|FG001|Part 2|On-study at time of data cut-off|1
6104945|NCT00788957|9722578|FG002|Part 2|On-study at time of data cut-off|1
6104946|NCT00788957|9722579|FG003|Part 2|On-study at time of data cut-off|1
6104947|NCT00788957|9722580|FG004|Part 2|On-study at time of data cut-off|0
6104948|NCT00788957|9722581|FG005|Part 2|On-study at time of data cut-off|0
6104949|NCT00788957|9722576|FG000|Part 3|Withdrawal by Subject|0
6104950|NCT00788957|9722577|FG001|Part 3|Withdrawal by Subject|0
6104951|NCT00788957|9722578|FG002|Part 3|Withdrawal by Subject|0
6104952|NCT00788957|9722579|FG003|Part 3|Withdrawal by Subject|0
6104953|NCT00788957|9722580|FG004|Part 3|Withdrawal by Subject|0
6104954|NCT00788957|9722581|FG005|Part 3|Withdrawal by Subject|2
6104955|NCT00788957|9722576|FG000|Part 3|Death|0
6104956|NCT00788957|9722577|FG001|Part 3|Death|0
6104957|NCT00788957|9722578|FG002|Part 3|Death|0
6104958|NCT00788957|9722579|FG003|Part 3|Death|0
6104959|NCT00788957|9722580|FG004|Part 3|Death|8
6104960|NCT00788957|9722581|FG005|Part 3|Death|9
6104961|NCT00788957|9722576|FG000|Part 3|On-study at time of data cut-off|0
6104962|NCT00788957|9722577|FG001|Part 3|On-study at time of data cut-off|0
6104963|NCT00788957|9722578|FG002|Part 3|On-study at time of data cut-off|0
6104964|NCT00788957|9722579|FG003|Part 3|On-study at time of data cut-off|0
6104965|NCT00788957|9722580|FG004|Part 3|On-study at time of data cut-off|1
6104966|NCT00788957|9722581|FG005|Part 3|On-study at time of data cut-off|0
6104967|NCT00789035|9722603|FG000|Overall Study|Adverse Event|0
6104968|NCT00789035|9722604|FG001|Overall Study|Adverse Event|2
6104969|NCT00789035|9722605|FG002|Overall Study|Adverse Event|0
6104970|NCT00789035|9722606|FG003|Overall Study|Adverse Event|1
6104971|NCT00789035|9722607|FG004|Overall Study|Adverse Event|3
6104972|NCT00789035|9722603|FG000|Overall Study|Lack of Efficacy|3
6104973|NCT00789035|9722604|FG001|Overall Study|Lack of Efficacy|0
6104974|NCT00789035|9722605|FG002|Overall Study|Lack of Efficacy|0
6104975|NCT00789035|9722606|FG003|Overall Study|Lack of Efficacy|0
6104976|NCT00789035|9722607|FG004|Overall Study|Lack of Efficacy|2
6104977|NCT00789035|9722603|FG000|Overall Study|Protocol Violation|1
6104978|NCT00789035|9722604|FG001|Overall Study|Protocol Violation|0
6104979|NCT00789035|9722605|FG002|Overall Study|Protocol Violation|0
6104980|NCT00789035|9722606|FG003|Overall Study|Protocol Violation|0
6104981|NCT00789035|9722607|FG004|Overall Study|Protocol Violation|0
6104982|NCT00789035|9722603|FG000|Overall Study|Withdrawal by Subject|0
6104983|NCT00789035|9722604|FG001|Overall Study|Withdrawal by Subject|2
6104984|NCT00789035|9722605|FG002|Overall Study|Withdrawal by Subject|0
6104985|NCT00789035|9722606|FG003|Overall Study|Withdrawal by Subject|0
6104986|NCT00789035|9722607|FG004|Overall Study|Withdrawal by Subject|0
6104987|NCT00789035|9722603|FG000|Overall Study|Other reason not defined above|2
6104988|NCT00789035|9722604|FG001|Overall Study|Other reason not defined above|3
6104989|NCT00789035|9722605|FG002|Overall Study|Other reason not defined above|1
6104990|NCT00789035|9722606|FG003|Overall Study|Other reason not defined above|0
6104991|NCT00789035|9722607|FG004|Overall Study|Other reason not defined above|1
6104992|NCT00789191|9722641|FG000|Overall Study|Adverse Event|2
6104993|NCT00789191|9722642|FG001|Overall Study|Adverse Event|4
6104994|NCT00789191|9722641|FG000|Overall Study|Lack of Efficacy|0
6104995|NCT00789191|9722642|FG001|Overall Study|Lack of Efficacy|5
6104996|NCT00789191|9722641|FG000|Overall Study|Protocol Violation|5
6104997|NCT00789191|9722642|FG001|Overall Study|Protocol Violation|3
6104998|NCT00789191|9722641|FG000|Overall Study|Withdrawal Criteria|2
6104999|NCT00789191|9722642|FG001|Overall Study|Withdrawal Criteria|4
6105000|NCT00789191|9722641|FG000|Overall Study|Unclassified|5
6105001|NCT00789191|9722642|FG001|Overall Study|Unclassified|3
6105002|NCT00789321|9722662|FG000|Overall Study|Adverse Event|0
6105003|NCT00789321|9722663|FG001|Overall Study|Adverse Event|1
6105004|NCT00789360|9722671|FG000|Overall Study|Protocol Violation|3
6105005|NCT00789360|9722672|FG001|Overall Study|Protocol Violation|1
6105006|NCT00789373|9722679|FG000|Induction|Adverse Event|64
6105007|NCT00789373|9722680|FG001|Induction|Adverse Event|0
6105008|NCT00789373|9722681|FG002|Induction|Adverse Event|0
6105009|NCT00789373|9722679|FG000|Induction|Death Due to study disease|24
6105010|NCT00789373|9722680|FG001|Induction|Death Due to study disease|0
6105011|NCT00789373|9722681|FG002|Induction|Death Due to study disease|0
6105012|NCT00789373|9722679|FG000|Induction|Death due to adverse event|19
6105013|NCT00789373|9722680|FG001|Induction|Death due to adverse event|0
6105014|NCT00789373|9722681|FG002|Induction|Death due to adverse event|0
6105015|NCT00789373|9722679|FG000|Induction|Death due to toxicity|11
6105016|NCT00789373|9722680|FG001|Induction|Death due to toxicity|0
6105017|NCT00789373|9722681|FG002|Induction|Death due to toxicity|0
6105018|NCT00789373|9722679|FG000|Induction|Death due to procedure|1
6105019|NCT00789373|9722680|FG001|Induction|Death due to procedure|0
6105020|NCT00789373|9722681|FG002|Induction|Death due to procedure|0
6105021|NCT00789373|9722679|FG000|Induction|Investigator decision|7
6105022|NCT00789373|9722680|FG001|Induction|Investigator decision|0
6105023|NCT00789373|9722681|FG002|Induction|Investigator decision|0
6105024|NCT00789373|9722679|FG000|Induction|Protocol entry criteria not met|9
6105025|NCT00789373|9722680|FG001|Induction|Protocol entry criteria not met|0
6105026|NCT00789373|9722681|FG002|Induction|Protocol entry criteria not met|0
6105027|NCT00789373|9722679|FG000|Induction|Lost to Follow-up|6
6105028|NCT00789373|9722680|FG001|Induction|Lost to Follow-up|0
6105029|NCT00789373|9722681|FG002|Induction|Lost to Follow-up|0
6105030|NCT00789373|9722679|FG000|Induction|Protocol Violation|1
6105031|NCT00789373|9722680|FG001|Induction|Protocol Violation|0
6105032|NCT00789373|9722681|FG002|Induction|Protocol Violation|0
6105033|NCT00789373|9722679|FG000|Induction|Progressive Disease|220
6105034|NCT00789373|9722680|FG001|Induction|Progressive Disease|0
6105035|NCT00789373|9722681|FG002|Induction|Progressive Disease|0
6105036|NCT00789373|9722679|FG000|Induction|Withdrawal by Subject|37
6105037|NCT00789373|9722680|FG001|Induction|Withdrawal by Subject|0
6105038|NCT00789373|9722681|FG002|Induction|Withdrawal by Subject|0
6105039|NCT00789373|9722679|FG000|Maintenance|Adverse Event|0
6105040|NCT00789373|9722680|FG001|Maintenance|Adverse Event|65
6105041|NCT00789373|9722681|FG002|Maintenance|Adverse Event|12
6105042|NCT00789373|9722679|FG000|Maintenance|Death due to study disease|0
6105043|NCT00789373|9722680|FG001|Maintenance|Death due to study disease|3
6105044|NCT00789373|9722681|FG002|Maintenance|Death due to study disease|1
6105045|NCT00789373|9722679|FG000|Maintenance|Death due to adverse event|0
6105046|NCT00789373|9722680|FG001|Maintenance|Death due to adverse event|4
6105047|NCT00789373|9722681|FG002|Maintenance|Death due to adverse event|1
6105048|NCT00789373|9722679|FG000|Maintenance|Death due to toxicity|0
6105049|NCT00789373|9722680|FG001|Maintenance|Death due to toxicity|1
6105050|NCT00789373|9722681|FG002|Maintenance|Death due to toxicity|2
6105051|NCT00789373|9722679|FG000|Maintenance|Investigator Decision|0
6105052|NCT00789373|9722680|FG001|Maintenance|Investigator Decision|4
6105053|NCT00789373|9722681|FG002|Maintenance|Investigator Decision|2
6105054|NCT00789373|9722679|FG000|Maintenance|Protocol entry criteria not met|0
6105055|NCT00789373|9722680|FG001|Maintenance|Protocol entry criteria not met|2
6105056|NCT00789373|9722681|FG002|Maintenance|Protocol entry criteria not met|0
6105057|NCT00789373|9722679|FG000|Maintenance|Lost to Follow-up|0
6105058|NCT00789373|9722680|FG001|Maintenance|Lost to Follow-up|2
6105059|NCT00789373|9722681|FG002|Maintenance|Lost to Follow-up|0
6105060|NCT00789373|9722679|FG000|Maintenance|Progressive Disease|0
6105061|NCT00789373|9722680|FG001|Maintenance|Progressive Disease|253
6105062|NCT00789373|9722681|FG002|Maintenance|Progressive Disease|152
6105063|NCT00789373|9722679|FG000|Maintenance|Withdrawal by Subject|0
6105064|NCT00789373|9722680|FG001|Maintenance|Withdrawal by Subject|21
6105065|NCT00789373|9722681|FG002|Maintenance|Withdrawal by Subject|8
6105066|NCT00789373|9722679|FG000|Maintenance|Sponsor Decision|0
6105067|NCT00789373|9722680|FG001|Maintenance|Sponsor Decision|0
6105068|NCT00789373|9722681|FG002|Maintenance|Sponsor Decision|2
6105069|NCT00789373|9722679|FG000|Maintenance|Participants On-Going at Data Cut-Off|0
6105070|NCT00789373|9722680|FG001|Maintenance|Participants On-Going at Data Cut-Off|4
6105071|NCT00789373|9722681|FG002|Maintenance|Participants On-Going at Data Cut-Off|0
6105072|NCT00789477|9722710|FG000|Overall Study|Withdrawal by Subject|2
6105073|NCT00789477|9722711|FG001|Overall Study|Withdrawal by Subject|1
6105074|NCT00789477|9722712|FG002|Overall Study|Withdrawal by Subject|3
6105075|NCT00789477|9722713|FG003|Overall Study|Withdrawal by Subject|2
6105076|NCT00789477|9722714|FG004|Overall Study|Withdrawal by Subject|3
6105077|NCT00789477|9722710|FG000|Overall Study|Protocol Violation|1
6105078|NCT00789477|9722711|FG001|Overall Study|Protocol Violation|0
6105079|NCT00789477|9722712|FG002|Overall Study|Protocol Violation|0
6105080|NCT00789477|9722713|FG003|Overall Study|Protocol Violation|1
6105081|NCT00789477|9722714|FG004|Overall Study|Protocol Violation|0
6105082|NCT00789477|9722710|FG000|Overall Study|Adverse Event|3
6105083|NCT00789477|9722711|FG001|Overall Study|Adverse Event|3
6105084|NCT00789477|9722712|FG002|Overall Study|Adverse Event|1
6105085|NCT00789477|9722713|FG003|Overall Study|Adverse Event|0
6105086|NCT00789477|9722714|FG004|Overall Study|Adverse Event|0
6105087|NCT00789477|9722710|FG000|Overall Study|Death|1
6105088|NCT00789477|9722711|FG001|Overall Study|Death|1
6105089|NCT00789477|9722712|FG002|Overall Study|Death|2
6105090|NCT00789477|9722713|FG003|Overall Study|Death|2
6105091|NCT00789477|9722714|FG004|Overall Study|Death|0
6105092|NCT00789477|9722710|FG000|Overall Study|Lost to Follow-up|0
6105093|NCT00789477|9722711|FG001|Overall Study|Lost to Follow-up|1
6105094|NCT00789477|9722712|FG002|Overall Study|Lost to Follow-up|4
6105095|NCT00789477|9722713|FG003|Overall Study|Lost to Follow-up|2
6105096|NCT00789477|9722714|FG004|Overall Study|Lost to Follow-up|4
6105097|NCT00789477|9722710|FG000|Overall Study|Lack of Efficacy|2
6105098|NCT00789477|9722711|FG001|Overall Study|Lack of Efficacy|0
6105099|NCT00789477|9722712|FG002|Overall Study|Lack of Efficacy|0
6105100|NCT00789477|9722713|FG003|Overall Study|Lack of Efficacy|0
6105101|NCT00789477|9722714|FG004|Overall Study|Lack of Efficacy|0
6105102|NCT00789477|9722710|FG000|Overall Study|Other|2
6105103|NCT00789477|9722711|FG001|Overall Study|Other|0
6105104|NCT00789477|9722712|FG002|Overall Study|Other|1
6105105|NCT00789477|9722713|FG003|Overall Study|Other|3
6105106|NCT00789477|9722714|FG004|Overall Study|Other|0
6105107|NCT00789529|9722730|FG000|Overall Study|Withdrawal by Subject|0
6105108|NCT00789529|9722731|FG001|Overall Study|Withdrawal by Subject|1
6105109|NCT00789529|9722730|FG000|Overall Study|Other Reason|1
6105110|NCT00789529|9722731|FG001|Overall Study|Other Reason|0
6105111|NCT00789555|9722740|FG000|Overall Study|Protocol Amendment|78
6105112|NCT00789555|9722741|FG001|Overall Study|Protocol Amendment|76
6105113|NCT00789555|9722742|FG002|Overall Study|Protocol Amendment|80
6105114|NCT00789555|9722740|FG000|Overall Study|Adverse Event|17
6105115|NCT00789555|9722741|FG001|Overall Study|Adverse Event|7
6105116|NCT00789555|9722742|FG002|Overall Study|Adverse Event|10
6105117|NCT00789555|9722740|FG000|Overall Study|Lost to Follow-up|9
6105118|NCT00789555|9722741|FG001|Overall Study|Lost to Follow-up|10
6105119|NCT00789555|9722742|FG002|Overall Study|Lost to Follow-up|18
6105120|NCT00789555|9722740|FG000|Overall Study|Patient decision unnrelated to adv event|38
6105121|NCT00789555|9722741|FG001|Overall Study|Patient decision unnrelated to adv event|29
6105122|NCT00789555|9722742|FG002|Overall Study|Patient decision unnrelated to adv event|26
6105123|NCT00789555|9722740|FG000|Overall Study|Treatment failure|11
6105124|NCT00789555|9722741|FG001|Overall Study|Treatment failure|8
6105125|NCT00789555|9722742|FG002|Overall Study|Treatment failure|12
6105126|NCT00789555|9722740|FG000|Overall Study|Protocol Violation|6
6105127|NCT00789555|9722741|FG001|Overall Study|Protocol Violation|9
6105128|NCT00789555|9722742|FG002|Overall Study|Protocol Violation|13
6105129|NCT00789581|9722752|FG000|AC Therapy|Adverse Event|2
6105130|NCT00789581|9722753|FG001|AC Therapy|Adverse Event|3
6105131|NCT00789581|9722752|FG000|AC Therapy|Withdrawal by Subject|4
6105132|NCT00789581|9722753|FG001|AC Therapy|Withdrawal by Subject|7
6105133|NCT00789581|9722752|FG000|AC Therapy|Disease recurrence|3
6105134|NCT00789581|9722753|FG001|AC Therapy|Disease recurrence|1
6105135|NCT00789581|9722752|FG000|AC Therapy|Intercurrent Illness|1
6105136|NCT00789581|9722753|FG001|AC Therapy|Intercurrent Illness|0
6105137|NCT00789581|9722752|FG000|AC Therapy|Never Treated|1
6105138|NCT00789581|9722753|FG001|AC Therapy|Never Treated|4
6105139|NCT00789581|9722752|FG000|AC Therapy|Other|0
6105140|NCT00789581|9722753|FG001|AC Therapy|Other|2
6105141|NCT00789581|9722752|FG000|Adjuvant Therapy|Never treated|2
6105142|NCT00789581|9722753|FG001|Adjuvant Therapy|Never treated|2
6105143|NCT00789581|9722752|FG000|Adjuvant Therapy|Adverse Event|20
6105144|NCT00789581|9722753|FG001|Adjuvant Therapy|Adverse Event|44
6105145|NCT00789581|9722752|FG000|Adjuvant Therapy|Withdrawal by Subject|14
6105146|NCT00789581|9722753|FG001|Adjuvant Therapy|Withdrawal by Subject|5
6105147|NCT00789581|9722752|FG000|Adjuvant Therapy|Disease recurrence|2
6105148|NCT00789581|9722753|FG001|Adjuvant Therapy|Disease recurrence|1
6105149|NCT00789581|9722752|FG000|Adjuvant Therapy|Intercurrent Illness|1
6105150|NCT00789581|9722753|FG001|Adjuvant Therapy|Intercurrent Illness|3
6105151|NCT00789581|9722752|FG000|Adjuvant Therapy|Protocol Violation|1
6105152|NCT00789581|9722753|FG001|Adjuvant Therapy|Protocol Violation|1
6105153|NCT00789581|9722752|FG000|Adjuvant Therapy|Other|0
6105154|NCT00789581|9722753|FG001|Adjuvant Therapy|Other|1
6105155|NCT00789698|9722777|FG000|Overall Study|Lack of Efficacy|10
6105156|NCT00789698|9722778|FG001|Overall Study|Lack of Efficacy|4
6105157|NCT00789698|9722779|FG002|Overall Study|Lack of Efficacy|5
6105158|NCT00789698|9722780|FG003|Overall Study|Lack of Efficacy|18
6105159|NCT00789698|9722777|FG000|Overall Study|Adverse Event|5
6105160|NCT00789698|9722778|FG001|Overall Study|Adverse Event|5
6105161|NCT00789698|9722779|FG002|Overall Study|Adverse Event|3
6105162|NCT00789698|9722780|FG003|Overall Study|Adverse Event|4
6105163|NCT00789698|9722777|FG000|Overall Study|Lost to Follow-up|5
6105164|NCT00789698|9722778|FG001|Overall Study|Lost to Follow-up|5
6105165|NCT00789698|9722779|FG002|Overall Study|Lost to Follow-up|2
6105166|NCT00789698|9722780|FG003|Overall Study|Lost to Follow-up|9
6105167|NCT00789698|9722777|FG000|Overall Study|Protocol Violation|6
6105168|NCT00789698|9722778|FG001|Overall Study|Protocol Violation|1
6105169|NCT00789698|9722779|FG002|Overall Study|Protocol Violation|2
6105170|NCT00789698|9722780|FG003|Overall Study|Protocol Violation|1
6105171|NCT00789698|9722777|FG000|Overall Study|Withdrawal by Subject|14
6105172|NCT00789698|9722778|FG001|Overall Study|Withdrawal by Subject|15
6105173|NCT00789698|9722779|FG002|Overall Study|Withdrawal by Subject|12
6105174|NCT00789698|9722780|FG003|Overall Study|Withdrawal by Subject|19
6105175|NCT00789698|9722777|FG000|Overall Study|Administrative|0
6105176|NCT00789698|9722778|FG001|Overall Study|Administrative|3
6105177|NCT00789698|9722779|FG002|Overall Study|Administrative|3
6105178|NCT00789698|9722780|FG003|Overall Study|Administrative|1
6105179|NCT00789737|9722800|FG000|Overall Study|Withdrawal by Subject|13
6105180|NCT00789737|9722801|FG001|Overall Study|Withdrawal by Subject|22
6105181|NCT00789737|9722800|FG000|Overall Study|Lost to Follow-up|10
6105182|NCT00789737|9722801|FG001|Overall Study|Lost to Follow-up|14
6105183|NCT00789737|9722800|FG000|Overall Study|Adverse Event|8
6105184|NCT00789737|9722801|FG001|Overall Study|Adverse Event|8
6105185|NCT00789737|9722800|FG000|Overall Study|Protocol Violation|3
6105186|NCT00789737|9722801|FG001|Overall Study|Protocol Violation|0
6105187|NCT00789737|9722800|FG000|Overall Study|Lack of Efficacy|3
6105188|NCT00789737|9722801|FG001|Overall Study|Lack of Efficacy|0
6105189|NCT00789737|9722800|FG000|Overall Study|hyperglycemia that met protocol-specifie|0
6105190|NCT00789737|9722801|FG001|Overall Study|hyperglycemia that met protocol-specifie|4
6105191|NCT00789737|9722800|FG000|Overall Study|Other|11
6105192|NCT00789737|9722801|FG001|Overall Study|Other|7
6105193|NCT00789815|9722843|FG000|Overall Study|Protocol Violation|6
6105194|NCT00789815|9722844|FG001|Overall Study|Protocol Violation|1
6105195|NCT00789815|9722843|FG000|Overall Study|Intubation due to massive bleeding|1
6105196|NCT00789815|9722844|FG001|Overall Study|Intubation due to massive bleeding|0
6105197|NCT00789828|9722852|FG000|Core Period (48 Weeks)|Administrative problems|0
6105198|NCT00789828|9722853|FG001|Core Period (48 Weeks)|Administrative problems|1
6105199|NCT00789828|9722852|FG000|Core Period (48 Weeks)|Withdrawal by Subject|0
6105200|NCT00789828|9722853|FG001|Core Period (48 Weeks)|Withdrawal by Subject|4
6105201|NCT00789828|9722852|FG000|Core Period (48 Weeks)|Lost to Follow-up|0
6105202|NCT00789828|9722853|FG001|Core Period (48 Weeks)|Lost to Follow-up|1
6105203|NCT00789828|9722852|FG000|Open-label Extension Period (4 Years)|Adverse Event|10
6105204|NCT00789828|9722853|FG001|Open-label Extension Period (4 Years)|Adverse Event|0
6105205|NCT00789828|9722852|FG000|Open-label Extension Period (4 Years)|Withdrawal by Subject|6
6105206|NCT00789828|9722853|FG001|Open-label Extension Period (4 Years)|Withdrawal by Subject|0
6105207|NCT00789828|9722852|FG000|Open-label Extension Period (4 Years)|Lost to Follow-up|3
6105208|NCT00789828|9722853|FG001|Open-label Extension Period (4 Years)|Lost to Follow-up|0
6105209|NCT00789828|9722852|FG000|Open-label Extension Period (4 Years)|Administrative problems|7
6105210|NCT00789828|9722853|FG001|Open-label Extension Period (4 Years)|Administrative problems|0
6105211|NCT00789828|9722852|FG000|Open-label Extension Period (4 Years)|Death|1
6105212|NCT00789828|9722853|FG001|Open-label Extension Period (4 Years)|Death|0
6105213|NCT00789828|9722852|FG000|Open-label Extension Period (4 Years)|Disease progression|1
6105214|NCT00789828|9722853|FG001|Open-label Extension Period (4 Years)|Disease progression|0
6105215|NCT00789828|9722852|FG000|Open-label Extension Period (4 Years)|New treatment for indication under study|1
6105216|NCT00789828|9722853|FG001|Open-label Extension Period (4 Years)|New treatment for indication under study|0
6105217|NCT00789854|9722865|FG000|Overall Study|Adverse Event|28
6105218|NCT00789854|9722866|FG001|Overall Study|Adverse Event|23
6105219|NCT00789854|9722867|FG002|Overall Study|Adverse Event|18
6105220|NCT00789854|9722865|FG000|Overall Study|Lost to Follow-up|1
6105221|NCT00789854|9722866|FG001|Overall Study|Lost to Follow-up|1
6105222|NCT00789854|9722867|FG002|Overall Study|Lost to Follow-up|4
6105223|NCT00789854|9722865|FG000|Overall Study|Withdrawal by Subject|9
6105224|NCT00789854|9722866|FG001|Overall Study|Withdrawal by Subject|6
6105225|NCT00789854|9722867|FG002|Overall Study|Withdrawal by Subject|17
6105226|NCT00789854|9722865|FG000|Overall Study|Eligibility criteria not fulfilled|2
6105227|NCT00789854|9722866|FG001|Overall Study|Eligibility criteria not fulfilled|5
6105228|NCT00789854|9722867|FG002|Overall Study|Eligibility criteria not fulfilled|1
6105229|NCT00789854|9722865|FG000|Overall Study|Severe non-compliance to the protocol|3
6105230|NCT00789854|9722866|FG001|Overall Study|Severe non-compliance to the protocol|0
6105231|NCT00789854|9722867|FG002|Overall Study|Severe non-compliance to the protocol|0
6105232|NCT00789854|9722865|FG000|Overall Study|Safety reasons|0
6105233|NCT00789854|9722866|FG001|Overall Study|Safety reasons|0
6105234|NCT00789854|9722867|FG002|Overall Study|Safety reasons|2
6105235|NCT00789854|9722865|FG000|Overall Study|Other|6
6105236|NCT00789854|9722866|FG001|Overall Study|Other|0
6105237|NCT00789854|9722867|FG002|Overall Study|Other|5
6105238|NCT00789880|9722895|FG000|Overall Study|Adverse Event|0
6105239|NCT00789880|9722896|FG001|Overall Study|Adverse Event|0
6105240|NCT00789880|9722897|FG002|Overall Study|Adverse Event|0
6105241|NCT00789880|9722898|FG003|Overall Study|Adverse Event|0
6105242|NCT00789880|9722899|FG004|Overall Study|Adverse Event|1
6105243|NCT00789880|9722900|FG005|Overall Study|Adverse Event|0
6105244|NCT00789880|9722895|FG000|Overall Study|Protocol Violation|0
6105245|NCT00789880|9722896|FG001|Overall Study|Protocol Violation|1
6105246|NCT00789880|9722897|FG002|Overall Study|Protocol Violation|0
6105247|NCT00789880|9722898|FG003|Overall Study|Protocol Violation|1
6105248|NCT00789880|9722899|FG004|Overall Study|Protocol Violation|0
6105249|NCT00789880|9722900|FG005|Overall Study|Protocol Violation|0
6105250|NCT00789880|9722895|FG000|Overall Study|Withdrawal by Subject|1
6105251|NCT00789880|9722896|FG001|Overall Study|Withdrawal by Subject|0
6105252|NCT00789880|9722897|FG002|Overall Study|Withdrawal by Subject|0
6105253|NCT00789880|9722898|FG003|Overall Study|Withdrawal by Subject|0
6105254|NCT00789880|9722899|FG004|Overall Study|Withdrawal by Subject|2
6105255|NCT00789880|9722900|FG005|Overall Study|Withdrawal by Subject|0
6105256|NCT00789958|9722914|FG000|Overall Study|Adverse Event|3
6105257|NCT00789958|9722914|FG000|Overall Study|Withdrawal by Subject|4
6105258|NCT00789958|9722914|FG000|Overall Study|Progression|3
6105259|NCT00789958|9722914|FG000|Overall Study|not protocol specified|1
6105260|NCT00789958|9722914|FG000|Overall Study|Not eligible/not analyzable|26
6105261|NCT00790023|9722932|FG000|Overall Study|Adverse Event|2
6105262|NCT00790023|9722933|FG001|Overall Study|Adverse Event|1
6105263|NCT00790023|9722934|FG002|Overall Study|Adverse Event|4
6105264|NCT00790023|9722932|FG000|Overall Study|Protocol Violation|2
6105265|NCT00790023|9722933|FG001|Overall Study|Protocol Violation|4
6105266|NCT00790023|9722934|FG002|Overall Study|Protocol Violation|2
6105267|NCT00790023|9722932|FG000|Overall Study|Withdrawal by Subject|2
6105268|NCT00790023|9722933|FG001|Overall Study|Withdrawal by Subject|0
6105269|NCT00790023|9722934|FG002|Overall Study|Withdrawal by Subject|6
6105270|NCT00790023|9722932|FG000|Overall Study|Lost to Follow-up|0
6105271|NCT00790023|9722933|FG001|Overall Study|Lost to Follow-up|0
6105272|NCT00790023|9722934|FG002|Overall Study|Lost to Follow-up|1
6105273|NCT00790023|9722932|FG000|Overall Study|Other|5
6105274|NCT00790023|9722933|FG001|Overall Study|Other|5
6105275|NCT00790023|9722934|FG002|Overall Study|Other|8
6105276|NCT00790036|9722945|FG000|Overall Study|Abnormal lab values|3
6105277|NCT00790036|9722946|FG001|Overall Study|Abnormal lab values|2
6105278|NCT00790036|9722945|FG000|Overall Study|Administrative problems|5
6105279|NCT00790036|9722946|FG001|Overall Study|Administrative problems|9
6105280|NCT00790036|9722945|FG000|Overall Study|Adverse Event|113
6105281|NCT00790036|9722946|FG001|Overall Study|Adverse Event|44
6105282|NCT00790036|9722945|FG000|Overall Study|Death|1
6105283|NCT00790036|9722946|FG001|Overall Study|Death|0
6105284|NCT00790036|9722945|FG000|Overall Study|Disease progression|24
6105285|NCT00790036|9722946|FG001|Overall Study|Disease progression|48
6105286|NCT00790036|9722945|FG000|Overall Study|Lost to Follow-up|1
6105287|NCT00790036|9722946|FG001|Overall Study|Lost to Follow-up|2
6105288|NCT00790036|9722945|FG000|Overall Study|Protocol Violation|10
6105289|NCT00790036|9722946|FG001|Overall Study|Protocol Violation|2
6105290|NCT00790036|9722945|FG000|Overall Study|Withdrawal by Subject|18
6105291|NCT00790036|9722946|FG001|Overall Study|Withdrawal by Subject|7
6105292|NCT00790036|9722945|FG000|Overall Study|Subject/guardian decision|20
6105293|NCT00790036|9722946|FG001|Overall Study|Subject/guardian decision|7
6105294|NCT00790088|9722975|FG000|Overall Study|Protocol Violation|11
6105295|NCT00790088|9722975|FG000|Overall Study|Withdrawal by Subject|17
6105296|NCT00790088|9722975|FG000|Overall Study|Lost to Follow-up|7
6105297|NCT00790088|9722975|FG000|Overall Study|Physician Decision|4
6105298|NCT00790205|9723000|FG000|Overall Study|Lost to Follow-up|61
6105299|NCT00790205|9723001|FG001|Overall Study|Lost to Follow-up|71
6105300|NCT00790205|9723000|FG000|Overall Study|Withdrawal by Subject|299
6105301|NCT00790205|9723001|FG001|Overall Study|Withdrawal by Subject|363
6105302|NCT00790296|9723022|FG000|Overall Study|Did not meet study eligibility criteria|1
6105303|NCT00790296|9723023|FG001|Overall Study|Did not meet study eligibility criteria|1
6105304|NCT00790296|9723022|FG000|Overall Study|Adverse Event|0
6105305|NCT00790296|9723023|FG001|Overall Study|Adverse Event|1
6105306|NCT00790400|9723040|FG000|Double-blind Period (Core Phase)|Protocol Violation|1
6105307|NCT00790400|9723041|FG001|Double-blind Period (Core Phase)|Protocol Violation|0
6105308|NCT00790400|9723040|FG000|Double-blind Period (Core Phase)|Progressive disease|0
6105309|NCT00790400|9723041|FG001|Double-blind Period (Core Phase)|Progressive disease|9
6105310|NCT00790400|9723040|FG000|Double-blind Period (Core Phase)|Adverse Event|2
6105311|NCT00790400|9723041|FG001|Double-blind Period (Core Phase)|Adverse Event|4
6105312|NCT00790400|9723040|FG000|Double-blind Period (Core Phase)|Abnormal lab value (s)|1
6105313|NCT00790400|9723041|FG001|Double-blind Period (Core Phase)|Abnormal lab value (s)|0
6105314|NCT00790400|9723040|FG000|Double-blind Period (Core Phase)|Withdrawal by Subject|1
6105315|NCT00790400|9723041|FG001|Double-blind Period (Core Phase)|Withdrawal by Subject|0
6105316|NCT00790400|9723040|FG000|Double-blind Period (Core Phase)|Administrative problems|1
6105317|NCT00790400|9723041|FG001|Double-blind Period (Core Phase)|Administrative problems|0
6105318|NCT00790400|9723040|FG000|Double-blind Period (Core Phase)|Death|1
6105319|NCT00790400|9723041|FG001|Double-blind Period (Core Phase)|Death|0
6105320|NCT00790400|9723040|FG000|Everolimus Period (Core or Extension)|Adverse Event|9
6105321|NCT00790400|9723041|FG001|Everolimus Period (Core or Extension)|Adverse Event|0
6105322|NCT00790400|9723040|FG000|Everolimus Period (Core or Extension)|Abnormal lab value (s)|1
6105323|NCT00790400|9723041|FG001|Everolimus Period (Core or Extension)|Abnormal lab value (s)|0
6105324|NCT00790400|9723040|FG000|Everolimus Period (Core or Extension)|Withdrawal by Subject|7
6105325|NCT00790400|9723041|FG001|Everolimus Period (Core or Extension)|Withdrawal by Subject|0
6105326|NCT00790400|9723040|FG000|Everolimus Period (Core or Extension)|Lost to Follow-up|1
6105327|NCT00790400|9723041|FG001|Everolimus Period (Core or Extension)|Lost to Follow-up|0
6105328|NCT00790400|9723040|FG000|Everolimus Period (Core or Extension)|Administrative problems|2
6205348|NCT01531673|9867523|FG005|Overall Study|Other|0
6205349|NCT01531673|9867524|FG006|Overall Study|Other|0
6205350|NCT01531673|9867525|FG007|Overall Study|Other|0
6205351|NCT01531673|9867526|FG008|Overall Study|Other|0
6205352|NCT01531673|9867527|FG009|Overall Study|Other|1
6205353|NCT01531673|9867528|FG010|Overall Study|Other|0
6205354|NCT01531673|9867529|FG011|Overall Study|Other|0
6205355|NCT01531673|9867530|FG012|Overall Study|Other|0
6205356|NCT01531725|9867582|FG000|Overall Study|Protocol Violation|5
6105329|NCT00790400|9723041|FG001|Everolimus Period (Core or Extension)|Administrative problems|0
6105330|NCT00790400|9723040|FG000|Everolimus Period (Core or Extension)|Death|1
6105331|NCT00790400|9723041|FG001|Everolimus Period (Core or Extension)|Death|0
6105332|NCT00790400|9723040|FG000|Everolimus Period (Core or Extension)|Disease progression|5
6105333|NCT00790400|9723041|FG001|Everolimus Period (Core or Extension)|Disease progression|0
6205357|NCT01531894|9867604|FG000|Overall Study|Physician Decision|8
6205358|NCT01531894|9867604|FG000|Overall Study|Death|1
6205359|NCT01531998|9867617|FG000|Overall Study|Withdrawal by Subject|3
6205360|NCT01532388|9867671|FG000|3-month Follow-up|Lost to Follow-up|68
6105334|NCT00790400|9723040|FG000|Everolimus Period (Core or Extension)|Protocol Violation|1
6105335|NCT00790400|9723041|FG001|Everolimus Period (Core or Extension)|Protocol Violation|0
6105336|NCT00790400|9723040|FG000|Everolimus Period (Core or Extension)|New treatment|2
6105337|NCT00790400|9723041|FG001|Everolimus Period (Core or Extension)|New treatment|0
6105338|NCT00790556|9723050|FG000|Treatment Period 1|Physician Decision|1
6105339|NCT00790556|9723051|FG001|Treatment Period 1|Physician Decision|0
6105340|NCT00790556|9723050|FG000|Treatment Period 1|Withdrawal by Subject|1
6105341|NCT00790556|9723051|FG001|Treatment Period 1|Withdrawal by Subject|0
6105342|NCT00790569|9723060|FG000|End of Treatment (6 Month Interview)|Lost to Follow-up|20
6105343|NCT00790569|9723061|FG001|End of Treatment (6 Month Interview)|Lost to Follow-up|8
6105344|NCT00790569|9723062|FG002|End of Treatment (6 Month Interview)|Lost to Follow-up|20
6105345|NCT00790569|9723060|FG000|End of Treatment (6 Month Interview)|Death|0
6105346|NCT00790569|9723061|FG001|End of Treatment (6 Month Interview)|Death|2
6105347|NCT00790569|9723062|FG002|End of Treatment (6 Month Interview)|Death|1
6105348|NCT00790569|9723060|FG000|End of Treatment (6 Month Interview)|Hospitalized|2
6105349|NCT00790569|9723061|FG001|End of Treatment (6 Month Interview)|Hospitalized|0
6105350|NCT00790569|9723062|FG002|End of Treatment (6 Month Interview)|Hospitalized|0
6105351|NCT00790569|9723060|FG000|End of Treatment (6 Month Interview)|Residential Treatment|0
6105352|NCT00790569|9723061|FG001|End of Treatment (6 Month Interview)|Residential Treatment|0
6105353|NCT00790569|9723062|FG002|End of Treatment (6 Month Interview)|Residential Treatment|2
6105354|NCT00790569|9723060|FG000|End of Treatment (6 Month Interview)|Incarcerated|0
6105355|NCT00790569|9723061|FG001|End of Treatment (6 Month Interview)|Incarcerated|0
6105356|NCT00790569|9723062|FG002|End of Treatment (6 Month Interview)|Incarcerated|3
6105357|NCT00790569|9723060|FG000|End of Study (12 Month Interview)|Lost to Follow-up|66
6105358|NCT00790569|9723061|FG001|End of Study (12 Month Interview)|Lost to Follow-up|19
6105359|NCT00790569|9723062|FG002|End of Study (12 Month Interview)|Lost to Follow-up|50
6105360|NCT00790582|9723072|FG000|Overall Study|Death|14
6105361|NCT00790582|9723073|FG001|Overall Study|Death|32
6105362|NCT00790582|9723072|FG000|Overall Study|Physician Decision|7
6105363|NCT00790582|9723073|FG001|Overall Study|Physician Decision|1
6105364|NCT00790582|9723072|FG000|Overall Study|Lost to Follow-up|3
6105365|NCT00790582|9723073|FG001|Overall Study|Lost to Follow-up|3
6105366|NCT00790582|9723072|FG000|Overall Study|Withdrawal by Subject|7
6105367|NCT00790582|9723073|FG001|Overall Study|Withdrawal by Subject|51
6105368|NCT00790647|9723081|FG000|Overall Study|Adverse Event|1
6105369|NCT00790751|9723128|FG000|Overall Study|Protocol non-compliance|16
6105370|NCT00790751|9723129|FG001|Overall Study|Protocol non-compliance|16
6105371|NCT00790751|9723130|FG002|Overall Study|Protocol non-compliance|10
6105372|NCT00790751|9723131|FG003|Overall Study|Protocol non-compliance|11
6105373|NCT00790751|9723128|FG000|Overall Study|Lost to Follow-up|4
6105374|NCT00790751|9723129|FG001|Overall Study|Lost to Follow-up|9
6105375|NCT00790751|9723130|FG002|Overall Study|Lost to Follow-up|4
6105376|NCT00790751|9723131|FG003|Overall Study|Lost to Follow-up|5
6105377|NCT00790751|9723128|FG000|Overall Study|Adverse Event|5
6105378|NCT00790751|9723129|FG001|Overall Study|Adverse Event|3
6105379|NCT00790751|9723130|FG002|Overall Study|Adverse Event|5
6105380|NCT00790751|9723131|FG003|Overall Study|Adverse Event|4
6105381|NCT00790751|9723128|FG000|Overall Study|Requirement for restricted medication|0
6105382|NCT00790751|9723129|FG001|Overall Study|Requirement for restricted medication|2
6105383|NCT00790751|9723130|FG002|Overall Study|Requirement for restricted medication|0
6105384|NCT00790751|9723131|FG003|Overall Study|Requirement for restricted medication|0
6105385|NCT00790751|9723128|FG000|Overall Study|Death|0
6105386|NCT00790751|9723129|FG001|Overall Study|Death|0
6105387|NCT00790751|9723130|FG002|Overall Study|Death|1
6105388|NCT00790751|9723131|FG003|Overall Study|Death|0
6105389|NCT00790751|9723128|FG000|Overall Study|Physician Decision|0
6105390|NCT00790751|9723129|FG001|Overall Study|Physician Decision|0
6105391|NCT00790751|9723130|FG002|Overall Study|Physician Decision|0
6105392|NCT00790751|9723131|FG003|Overall Study|Physician Decision|1
6105393|NCT00790790|9723144|FG000|Study Period 2: Therapy Phase|Adverse Event|3
6105394|NCT00790790|9723145|FG001|Study Period 2: Therapy Phase|Adverse Event|16
6105395|NCT00790790|9723146|FG002|Study Period 2: Therapy Phase|Adverse Event|16
6105396|NCT00790790|9723144|FG000|Study Period 2: Therapy Phase|Protocol Violation|1
6105397|NCT00790790|9723145|FG001|Study Period 2: Therapy Phase|Protocol Violation|1
6105398|NCT00790790|9723146|FG002|Study Period 2: Therapy Phase|Protocol Violation|0
6105399|NCT00790790|9723144|FG000|Study Period 2: Therapy Phase|Withdrawal by Subject|7
6105400|NCT00790790|9723145|FG001|Study Period 2: Therapy Phase|Withdrawal by Subject|0
6105401|NCT00790790|9723146|FG002|Study Period 2: Therapy Phase|Withdrawal by Subject|2
6205361|NCT01532388|9867672|FG001|3-month Follow-up|Lost to Follow-up|68
6105402|NCT00790790|9723144|FG000|Study Period 2: Therapy Phase|Lack of Efficacy|1
6105403|NCT00790790|9723145|FG001|Study Period 2: Therapy Phase|Lack of Efficacy|0
6105404|NCT00790790|9723146|FG002|Study Period 2: Therapy Phase|Lack of Efficacy|3
6105405|NCT00790790|9723144|FG000|Study Period 2: Therapy Phase|Physician Decision|0
6105406|NCT00790790|9723145|FG001|Study Period 2: Therapy Phase|Physician Decision|1
6105407|NCT00790790|9723146|FG002|Study Period 2: Therapy Phase|Physician Decision|0
6105408|NCT00790842|9723162|FG000|Dose Level 1|Adverse Event|1
6105409|NCT00790842|9723163|FG001|Dose Level 1|Adverse Event|0
6105410|NCT00790842|9723164|FG002|Dose Level 1|Adverse Event|0
6105411|NCT00790842|9723165|FG003|Dose Level 1|Adverse Event|2
6105412|NCT00790842|9723166|FG004|Dose Level 1|Adverse Event|0
6105413|NCT00790842|9723167|FG005|Dose Level 1|Adverse Event|0
6105414|NCT00790842|9723168|FG006|Dose Level 1|Adverse Event|0
6105415|NCT00790842|9723169|FG007|Dose Level 1|Adverse Event|1
6105416|NCT00790842|9723170|FG008|Dose Level 1|Adverse Event|0
6105417|NCT00790842|9723171|FG009|Dose Level 1|Adverse Event|0
6105418|NCT00790842|9723172|FG010|Dose Level 1|Adverse Event|0
6105419|NCT00790842|9723162|FG000|Dose Level 1|Physician Decision|1
6105420|NCT00790842|9723163|FG001|Dose Level 1|Physician Decision|0
6105421|NCT00790842|9723164|FG002|Dose Level 1|Physician Decision|0
6105422|NCT00790842|9723165|FG003|Dose Level 1|Physician Decision|0
6105423|NCT00790842|9723166|FG004|Dose Level 1|Physician Decision|0
6105424|NCT00790842|9723167|FG005|Dose Level 1|Physician Decision|0
6105425|NCT00790842|9723168|FG006|Dose Level 1|Physician Decision|0
6105426|NCT00790842|9723169|FG007|Dose Level 1|Physician Decision|1
6105427|NCT00790842|9723170|FG008|Dose Level 1|Physician Decision|0
6105428|NCT00790842|9723171|FG009|Dose Level 1|Physician Decision|0
6105429|NCT00790842|9723172|FG010|Dose Level 1|Physician Decision|0
6105430|NCT00790842|9723162|FG000|Dose Level 1|Withdrawal by Subject|1
6105431|NCT00790842|9723163|FG001|Dose Level 1|Withdrawal by Subject|0
6105432|NCT00790842|9723164|FG002|Dose Level 1|Withdrawal by Subject|0
6105433|NCT00790842|9723165|FG003|Dose Level 1|Withdrawal by Subject|0
6105434|NCT00790842|9723166|FG004|Dose Level 1|Withdrawal by Subject|0
6105435|NCT00790842|9723167|FG005|Dose Level 1|Withdrawal by Subject|0
6105436|NCT00790842|9723168|FG006|Dose Level 1|Withdrawal by Subject|0
6105437|NCT00790842|9723169|FG007|Dose Level 1|Withdrawal by Subject|0
6105438|NCT00790842|9723170|FG008|Dose Level 1|Withdrawal by Subject|0
6105439|NCT00790842|9723171|FG009|Dose Level 1|Withdrawal by Subject|0
6105440|NCT00790842|9723172|FG010|Dose Level 1|Withdrawal by Subject|0
6105441|NCT00790842|9723162|FG000|Dose Level 2|Death|0
6105442|NCT00790842|9723163|FG001|Dose Level 2|Death|1
6105443|NCT00790842|9723164|FG002|Dose Level 2|Death|0
6105444|NCT00790842|9723165|FG003|Dose Level 2|Death|0
6105445|NCT00790842|9723166|FG004|Dose Level 2|Death|1
6105446|NCT00790842|9723167|FG005|Dose Level 2|Death|0
6105447|NCT00790842|9723168|FG006|Dose Level 2|Death|0
6105448|NCT00790842|9723169|FG007|Dose Level 2|Death|0
6105449|NCT00790842|9723170|FG008|Dose Level 2|Death|0
6105450|NCT00790842|9723171|FG009|Dose Level 2|Death|0
6105451|NCT00790842|9723172|FG010|Dose Level 2|Death|0
6105452|NCT00790842|9723162|FG000|Dose Level 2|Physician Decision|0
6105453|NCT00790842|9723163|FG001|Dose Level 2|Physician Decision|1
6105454|NCT00790842|9723164|FG002|Dose Level 2|Physician Decision|0
6105455|NCT00790842|9723165|FG003|Dose Level 2|Physician Decision|0
6105456|NCT00790842|9723166|FG004|Dose Level 2|Physician Decision|0
6105457|NCT00790842|9723167|FG005|Dose Level 2|Physician Decision|0
6105458|NCT00790842|9723168|FG006|Dose Level 2|Physician Decision|0
6105459|NCT00790842|9723169|FG007|Dose Level 2|Physician Decision|0
6105460|NCT00790842|9723170|FG008|Dose Level 2|Physician Decision|0
6105461|NCT00790842|9723171|FG009|Dose Level 2|Physician Decision|0
6105462|NCT00790842|9723172|FG010|Dose Level 2|Physician Decision|0
6105463|NCT00790842|9723162|FG000|Dose Level 2|Withdrawal by Subject|0
6105464|NCT00790842|9723163|FG001|Dose Level 2|Withdrawal by Subject|1
6105465|NCT00790842|9723164|FG002|Dose Level 2|Withdrawal by Subject|0
6105466|NCT00790842|9723165|FG003|Dose Level 2|Withdrawal by Subject|0
6105467|NCT00790842|9723166|FG004|Dose Level 2|Withdrawal by Subject|0
6105468|NCT00790842|9723167|FG005|Dose Level 2|Withdrawal by Subject|0
6105469|NCT00790842|9723168|FG006|Dose Level 2|Withdrawal by Subject|0
6105470|NCT00790842|9723169|FG007|Dose Level 2|Withdrawal by Subject|0
6105471|NCT00790842|9723170|FG008|Dose Level 2|Withdrawal by Subject|0
6205362|NCT01532388|9867671|FG000|6-month Follow-up|Lost to Follow-up|74
6105472|NCT00790842|9723171|FG009|Dose Level 2|Withdrawal by Subject|0
6105473|NCT00790842|9723172|FG010|Dose Level 2|Withdrawal by Subject|0
6105474|NCT00790842|9723162|FG000|Dose Level 2|Intercurrent Illness/Other Treatment|0
6105475|NCT00790842|9723163|FG001|Dose Level 2|Intercurrent Illness/Other Treatment|0
6105476|NCT00790842|9723164|FG002|Dose Level 2|Intercurrent Illness/Other Treatment|0
6105477|NCT00790842|9723165|FG003|Dose Level 2|Intercurrent Illness/Other Treatment|0
6105478|NCT00790842|9723166|FG004|Dose Level 2|Intercurrent Illness/Other Treatment|0
6105479|NCT00790842|9723167|FG005|Dose Level 2|Intercurrent Illness/Other Treatment|0
6105480|NCT00790842|9723168|FG006|Dose Level 2|Intercurrent Illness/Other Treatment|0
6105481|NCT00790842|9723169|FG007|Dose Level 2|Intercurrent Illness/Other Treatment|0
6105482|NCT00790842|9723170|FG008|Dose Level 2|Intercurrent Illness/Other Treatment|2
6105483|NCT00790842|9723171|FG009|Dose Level 2|Intercurrent Illness/Other Treatment|0
6105484|NCT00790842|9723172|FG010|Dose Level 2|Intercurrent Illness/Other Treatment|0
6105485|NCT00790842|9723162|FG000|Dose Level 3|Adverse Event|0
6105486|NCT00790842|9723163|FG001|Dose Level 3|Adverse Event|0
6105487|NCT00790842|9723164|FG002|Dose Level 3|Adverse Event|1
6105488|NCT00790842|9723165|FG003|Dose Level 3|Adverse Event|0
6105489|NCT00790842|9723166|FG004|Dose Level 3|Adverse Event|0
6105490|NCT00790842|9723167|FG005|Dose Level 3|Adverse Event|0
6105491|NCT00790842|9723168|FG006|Dose Level 3|Adverse Event|0
6105492|NCT00790842|9723169|FG007|Dose Level 3|Adverse Event|0
6105493|NCT00790842|9723170|FG008|Dose Level 3|Adverse Event|0
6105494|NCT00790842|9723171|FG009|Dose Level 3|Adverse Event|0
6105495|NCT00790842|9723172|FG010|Dose Level 3|Adverse Event|0
6105496|NCT00790842|9723162|FG000|Dose Level 3|Withdrawal by Subject|0
6105497|NCT00790842|9723163|FG001|Dose Level 3|Withdrawal by Subject|0
6105498|NCT00790842|9723164|FG002|Dose Level 3|Withdrawal by Subject|3
6105499|NCT00790842|9723165|FG003|Dose Level 3|Withdrawal by Subject|0
6105500|NCT00790842|9723166|FG004|Dose Level 3|Withdrawal by Subject|0
6105501|NCT00790842|9723167|FG005|Dose Level 3|Withdrawal by Subject|0
6105502|NCT00790842|9723168|FG006|Dose Level 3|Withdrawal by Subject|0
6105503|NCT00790842|9723169|FG007|Dose Level 3|Withdrawal by Subject|0
6105504|NCT00790842|9723170|FG008|Dose Level 3|Withdrawal by Subject|0
6105505|NCT00790842|9723171|FG009|Dose Level 3|Withdrawal by Subject|2
6105506|NCT00790842|9723172|FG010|Dose Level 3|Withdrawal by Subject|0
6105507|NCT00790842|9723162|FG000|Dose Level 3|Intercurrent Illness/Alternative Therapy|0
6105508|NCT00790842|9723163|FG001|Dose Level 3|Intercurrent Illness/Alternative Therapy|0
6105509|NCT00790842|9723164|FG002|Dose Level 3|Intercurrent Illness/Alternative Therapy|0
6105510|NCT00790842|9723165|FG003|Dose Level 3|Intercurrent Illness/Alternative Therapy|0
6105511|NCT00790842|9723166|FG004|Dose Level 3|Intercurrent Illness/Alternative Therapy|0
6105512|NCT00790842|9723167|FG005|Dose Level 3|Intercurrent Illness/Alternative Therapy|1
6105513|NCT00790842|9723168|FG006|Dose Level 3|Intercurrent Illness/Alternative Therapy|0
6105514|NCT00790842|9723169|FG007|Dose Level 3|Intercurrent Illness/Alternative Therapy|0
6105515|NCT00790842|9723170|FG008|Dose Level 3|Intercurrent Illness/Alternative Therapy|0
6105516|NCT00790842|9723171|FG009|Dose Level 3|Intercurrent Illness/Alternative Therapy|0
6105517|NCT00790842|9723172|FG010|Dose Level 3|Intercurrent Illness/Alternative Therapy|0
6105518|NCT00790842|9723162|FG000|Dose Level 3|Ineligible/Withdrew before Treatment|0
6105519|NCT00790842|9723163|FG001|Dose Level 3|Ineligible/Withdrew before Treatment|0
6105520|NCT00790842|9723164|FG002|Dose Level 3|Ineligible/Withdrew before Treatment|1
6105521|NCT00790842|9723165|FG003|Dose Level 3|Ineligible/Withdrew before Treatment|0
6105522|NCT00790842|9723166|FG004|Dose Level 3|Ineligible/Withdrew before Treatment|0
6105523|NCT00790842|9723167|FG005|Dose Level 3|Ineligible/Withdrew before Treatment|0
6105524|NCT00790842|9723168|FG006|Dose Level 3|Ineligible/Withdrew before Treatment|0
6105525|NCT00790842|9723169|FG007|Dose Level 3|Ineligible/Withdrew before Treatment|0
6105526|NCT00790842|9723170|FG008|Dose Level 3|Ineligible/Withdrew before Treatment|0
6105527|NCT00790842|9723171|FG009|Dose Level 3|Ineligible/Withdrew before Treatment|0
6105528|NCT00790842|9723172|FG010|Dose Level 3|Ineligible/Withdrew before Treatment|0
6105529|NCT00790842|9723162|FG000|Dose Level 4|Adverse Event|0
6105530|NCT00790842|9723163|FG001|Dose Level 4|Adverse Event|0
6105531|NCT00790842|9723164|FG002|Dose Level 4|Adverse Event|0
6105532|NCT00790842|9723165|FG003|Dose Level 4|Adverse Event|0
6105533|NCT00790842|9723166|FG004|Dose Level 4|Adverse Event|0
6105534|NCT00790842|9723167|FG005|Dose Level 4|Adverse Event|0
6105535|NCT00790842|9723168|FG006|Dose Level 4|Adverse Event|1
6105536|NCT00790842|9723169|FG007|Dose Level 4|Adverse Event|0
6105537|NCT00790842|9723170|FG008|Dose Level 4|Adverse Event|0
6105538|NCT00790842|9723171|FG009|Dose Level 4|Adverse Event|0
6105539|NCT00790842|9723172|FG010|Dose Level 4|Adverse Event|0
6105540|NCT00790842|9723162|FG000|Dose Level 4|Physician Decision|0
6105541|NCT00790842|9723163|FG001|Dose Level 4|Physician Decision|0
6105542|NCT00790842|9723164|FG002|Dose Level 4|Physician Decision|0
6105543|NCT00790842|9723165|FG003|Dose Level 4|Physician Decision|0
6105544|NCT00790842|9723166|FG004|Dose Level 4|Physician Decision|0
6105545|NCT00790842|9723167|FG005|Dose Level 4|Physician Decision|0
6105546|NCT00790842|9723168|FG006|Dose Level 4|Physician Decision|1
6105547|NCT00790842|9723169|FG007|Dose Level 4|Physician Decision|0
6105548|NCT00790842|9723170|FG008|Dose Level 4|Physician Decision|0
6105549|NCT00790842|9723171|FG009|Dose Level 4|Physician Decision|0
6105550|NCT00790842|9723172|FG010|Dose Level 4|Physician Decision|1
6105551|NCT00790842|9723162|FG000|Dose Level 4|Withdrawal by Subject|0
6105552|NCT00790842|9723163|FG001|Dose Level 4|Withdrawal by Subject|0
6105553|NCT00790842|9723164|FG002|Dose Level 4|Withdrawal by Subject|0
6105554|NCT00790842|9723165|FG003|Dose Level 4|Withdrawal by Subject|0
6105555|NCT00790842|9723166|FG004|Dose Level 4|Withdrawal by Subject|0
6105556|NCT00790842|9723167|FG005|Dose Level 4|Withdrawal by Subject|0
6105557|NCT00790842|9723168|FG006|Dose Level 4|Withdrawal by Subject|0
6105558|NCT00790842|9723169|FG007|Dose Level 4|Withdrawal by Subject|0
6105559|NCT00790842|9723170|FG008|Dose Level 4|Withdrawal by Subject|0
6105560|NCT00790842|9723171|FG009|Dose Level 4|Withdrawal by Subject|0
6105561|NCT00790842|9723172|FG010|Dose Level 4|Withdrawal by Subject|1
6105562|NCT00790842|9723162|FG000|Expansion Cohort|Adverse Event|0
6105563|NCT00790842|9723163|FG001|Expansion Cohort|Adverse Event|0
6105564|NCT00790842|9723164|FG002|Expansion Cohort|Adverse Event|0
6105565|NCT00790842|9723165|FG003|Expansion Cohort|Adverse Event|0
6105566|NCT00790842|9723166|FG004|Expansion Cohort|Adverse Event|0
6105567|NCT00790842|9723167|FG005|Expansion Cohort|Adverse Event|0
6105568|NCT00790842|9723168|FG006|Expansion Cohort|Adverse Event|1
6105569|NCT00790842|9723169|FG007|Expansion Cohort|Adverse Event|0
6105570|NCT00790842|9723170|FG008|Expansion Cohort|Adverse Event|0
6105571|NCT00790842|9723171|FG009|Expansion Cohort|Adverse Event|0
6105572|NCT00790842|9723172|FG010|Expansion Cohort|Adverse Event|0
6105573|NCT00790842|9723162|FG000|Expansion Cohort|Death|0
6105574|NCT00790842|9723163|FG001|Expansion Cohort|Death|0
6105575|NCT00790842|9723164|FG002|Expansion Cohort|Death|2
6105576|NCT00790842|9723165|FG003|Expansion Cohort|Death|0
6105577|NCT00790842|9723166|FG004|Expansion Cohort|Death|0
6105578|NCT00790842|9723167|FG005|Expansion Cohort|Death|0
6105579|NCT00790842|9723168|FG006|Expansion Cohort|Death|0
6105580|NCT00790842|9723169|FG007|Expansion Cohort|Death|0
6105581|NCT00790842|9723170|FG008|Expansion Cohort|Death|0
6105582|NCT00790842|9723171|FG009|Expansion Cohort|Death|0
6105583|NCT00790842|9723172|FG010|Expansion Cohort|Death|0
6105584|NCT00790842|9723162|FG000|Expansion Cohort|Physician Decision|0
6105585|NCT00790842|9723163|FG001|Expansion Cohort|Physician Decision|0
6105586|NCT00790842|9723164|FG002|Expansion Cohort|Physician Decision|1
6105587|NCT00790842|9723165|FG003|Expansion Cohort|Physician Decision|0
6105588|NCT00790842|9723166|FG004|Expansion Cohort|Physician Decision|0
6105589|NCT00790842|9723167|FG005|Expansion Cohort|Physician Decision|0
6105590|NCT00790842|9723168|FG006|Expansion Cohort|Physician Decision|0
6105591|NCT00790842|9723169|FG007|Expansion Cohort|Physician Decision|0
6105592|NCT00790842|9723170|FG008|Expansion Cohort|Physician Decision|0
6105593|NCT00790842|9723171|FG009|Expansion Cohort|Physician Decision|0
6105594|NCT00790842|9723172|FG010|Expansion Cohort|Physician Decision|0
6205363|NCT01532388|9867672|FG001|6-month Follow-up|Lost to Follow-up|66
6205364|NCT01532388|9867671|FG000|12-month Follow-up|Lost to Follow-up|69
6285129|NCT02332291|9997044|FG000|Phase 1: Blinded Escitalopram or Placebo|Worsening Depression|0
6285130|NCT02332291|9997045|FG001|Phase 1: Blinded Escitalopram or Placebo|Worsening Depression|4
6285131|NCT02332291|9997044|FG000|Phase 1: Blinded Escitalopram or Placebo|Withdrawal by Subject|1
6285132|NCT02332291|9997045|FG001|Phase 1: Blinded Escitalopram or Placebo|Withdrawal by Subject|0
6285133|NCT02332291|9997044|FG000|Phase 2: Open-Label Bupropion|Adverse Event|2
6285134|NCT02332291|9997045|FG001|Phase 2: Open-Label Bupropion|Adverse Event|7
6105595|NCT00790842|9723162|FG000|Expansion Cohort|Withdrawal by Subject|0
6105596|NCT00790842|9723163|FG001|Expansion Cohort|Withdrawal by Subject|0
6105597|NCT00790842|9723164|FG002|Expansion Cohort|Withdrawal by Subject|3
6205365|NCT01532388|9867672|FG001|12-month Follow-up|Lost to Follow-up|67
6205366|NCT01532414|9867681|FG000|Overall Study|Lost to Follow-up|3
6205367|NCT01532414|9867682|FG001|Overall Study|Lost to Follow-up|0
6205368|NCT01532414|9867683|FG002|Overall Study|Lost to Follow-up|1
6205369|NCT01532414|9867681|FG000|Overall Study|Withdrawal by Subject|3
6205370|NCT01532414|9867682|FG001|Overall Study|Withdrawal by Subject|0
6205371|NCT01532414|9867683|FG002|Overall Study|Withdrawal by Subject|0
6205372|NCT01532414|9867681|FG000|Overall Study|No V6 semen sample|0
6205373|NCT01532414|9867682|FG001|Overall Study|No V6 semen sample|1
6205374|NCT01532414|9867683|FG002|Overall Study|No V6 semen sample|0
6205375|NCT01532414|9867681|FG000|Overall Study|Adverse Event|0
6205376|NCT01532414|9867682|FG001|Overall Study|Adverse Event|1
6205377|NCT01532414|9867683|FG002|Overall Study|Adverse Event|1
6205378|NCT01532414|9867681|FG000|Overall Study|Unable to complete 24 hour PK|0
6205379|NCT01532414|9867682|FG001|Overall Study|Unable to complete 24 hour PK|0
6205380|NCT01532414|9867683|FG002|Overall Study|Unable to complete 24 hour PK|1
6205381|NCT01532414|9867681|FG000|Overall Study|Withdrawn by sponsor|1
6205382|NCT01532414|9867682|FG001|Overall Study|Withdrawn by sponsor|0
6205383|NCT01532414|9867683|FG002|Overall Study|Withdrawn by sponsor|0
6205384|NCT01532570|9867704|FG000|Overall Study|Lack of Efficacy|1
6205385|NCT01532570|9867705|FG001|Overall Study|Lack of Efficacy|0
6205386|NCT01532570|9867706|FG002|Overall Study|Lack of Efficacy|0
6205387|NCT01532570|9867707|FG003|Overall Study|Lack of Efficacy|0
6205388|NCT01532570|9867704|FG000|Overall Study|Withdrawal by Subject|0
6205389|NCT01532570|9867705|FG001|Overall Study|Withdrawal by Subject|1
6205390|NCT01532570|9867706|FG002|Overall Study|Withdrawal by Subject|0
6205391|NCT01532570|9867707|FG003|Overall Study|Withdrawal by Subject|0
6205392|NCT01532648|9867726|FG000|Overall Study|Lost to Follow-up|3
6205393|NCT01532648|9867727|FG001|Overall Study|Lost to Follow-up|4
6205394|NCT01532648|9867726|FG000|Overall Study|Lack of Efficacy|4
6205395|NCT01532648|9867727|FG001|Overall Study|Lack of Efficacy|1
6205396|NCT01532648|9867726|FG000|Overall Study|Protocol Violation|1
6205397|NCT01532648|9867727|FG001|Overall Study|Protocol Violation|1
6205398|NCT01532648|9867726|FG000|Overall Study|Adverse Event|12
6205399|NCT01532648|9867727|FG001|Overall Study|Adverse Event|9
6205400|NCT01532648|9867726|FG000|Overall Study|Withdrawal by Subject|16
6205401|NCT01532648|9867727|FG001|Overall Study|Withdrawal by Subject|2
6205402|NCT01532687|9867735|FG000|Overall Study|Death|2
6205403|NCT01532687|9867736|FG001|Overall Study|Death|0
6205404|NCT01532687|9867735|FG000|Overall Study|Adverse Event|6
6205405|NCT01532687|9867736|FG001|Overall Study|Adverse Event|1
6205406|NCT01532687|9867735|FG000|Overall Study|Withdrawal by Subject|1
6105598|NCT00790842|9723165|FG003|Expansion Cohort|Withdrawal by Subject|0
6105599|NCT00790842|9723166|FG004|Expansion Cohort|Withdrawal by Subject|0
6105600|NCT00790842|9723167|FG005|Expansion Cohort|Withdrawal by Subject|0
6105601|NCT00790842|9723168|FG006|Expansion Cohort|Withdrawal by Subject|0
6105602|NCT00790842|9723169|FG007|Expansion Cohort|Withdrawal by Subject|0
6105603|NCT00790842|9723170|FG008|Expansion Cohort|Withdrawal by Subject|0
6105604|NCT00790842|9723171|FG009|Expansion Cohort|Withdrawal by Subject|0
6105605|NCT00790842|9723172|FG010|Expansion Cohort|Withdrawal by Subject|0
6105606|NCT00790842|9723162|FG000|Expansion Cohort|Study Closure|0
6105607|NCT00790842|9723163|FG001|Expansion Cohort|Study Closure|0
6105608|NCT00790842|9723164|FG002|Expansion Cohort|Study Closure|1
6105609|NCT00790842|9723165|FG003|Expansion Cohort|Study Closure|0
6105610|NCT00790842|9723166|FG004|Expansion Cohort|Study Closure|0
6105611|NCT00790842|9723167|FG005|Expansion Cohort|Study Closure|0
6105612|NCT00790842|9723168|FG006|Expansion Cohort|Study Closure|0
6105613|NCT00790842|9723169|FG007|Expansion Cohort|Study Closure|0
6105614|NCT00790842|9723170|FG008|Expansion Cohort|Study Closure|0
6105615|NCT00790842|9723171|FG009|Expansion Cohort|Study Closure|0
6105616|NCT00790842|9723172|FG010|Expansion Cohort|Study Closure|0
6105617|NCT00790868|9723227|FG000|Overall Study|Withdrawal by Subject|4
6105618|NCT00790868|9723228|FG001|Overall Study|Withdrawal by Subject|5
6105619|NCT00790868|9723227|FG000|Overall Study|Lost to Follow-up|2
6105620|NCT00790868|9723228|FG001|Overall Study|Lost to Follow-up|12
6105621|NCT00790907|9723239|FG000|Overall Study|Adverse Event|9
6205407|NCT01532687|9867736|FG001|Overall Study|Withdrawal by Subject|0
6205408|NCT01532687|9867735|FG000|Overall Study|Physician Decision|2
6205409|NCT01532687|9867736|FG001|Overall Study|Physician Decision|1
6205410|NCT01532687|9867735|FG000|Overall Study|Protocol-defined delay > 3 weeks|3
6205411|NCT01532687|9867736|FG001|Overall Study|Protocol-defined delay > 3 weeks|0
6205412|NCT01532869|9867758|FG000|Blinded-Treatment Period (Up to Week 24)|Death|0
6205413|NCT01532869|9867759|FG001|Blinded-Treatment Period (Up to Week 24)|Death|1
6205414|NCT01532869|9867758|FG000|Blinded-Treatment Period (Up to Week 24)|Adverse Event|2
6205415|NCT01532869|9867759|FG001|Blinded-Treatment Period (Up to Week 24)|Adverse Event|3
6205416|NCT01532869|9867758|FG000|Blinded-Treatment Period (Up to Week 24)|Lost to Follow-up|0
6205417|NCT01532869|9867759|FG001|Blinded-Treatment Period (Up to Week 24)|Lost to Follow-up|1
6205418|NCT01532869|9867758|FG000|Blinded-Treatment Period (Up to Week 24)|Non-compliance|1
6205419|NCT01532869|9867759|FG001|Blinded-Treatment Period (Up to Week 24)|Non-compliance|0
6205420|NCT01532869|9867758|FG000|Blinded-Treatment Period (Up to Week 24)|Lack of Efficacy|1
6205421|NCT01532869|9867759|FG001|Blinded-Treatment Period (Up to Week 24)|Lack of Efficacy|1
6205422|NCT01532869|9867758|FG000|Blinded-Treatment Period (Up to Week 24)|Withdrawal by Subject|4
6205423|NCT01532869|9867759|FG001|Blinded-Treatment Period (Up to Week 24)|Withdrawal by Subject|2
6205424|NCT01532869|9867758|FG000|Blinded-Treatment Period (Up to Week 48)|Death|0
6205425|NCT01532869|9867759|FG001|Blinded-Treatment Period (Up to Week 48)|Death|3
6205426|NCT01532869|9867758|FG000|Blinded-Treatment Period (Up to Week 48)|Adverse Event|4
6205427|NCT01532869|9867759|FG001|Blinded-Treatment Period (Up to Week 48)|Adverse Event|5
6205428|NCT01532869|9867758|FG000|Blinded-Treatment Period (Up to Week 48)|Lost to Follow-up|0
6205429|NCT01532869|9867759|FG001|Blinded-Treatment Period (Up to Week 48)|Lost to Follow-up|1
6205430|NCT01532869|9867758|FG000|Blinded-Treatment Period (Up to Week 48)|Non-Compliance|1
6205431|NCT01532869|9867759|FG001|Blinded-Treatment Period (Up to Week 48)|Non-Compliance|0
6205432|NCT01532869|9867758|FG000|Blinded-Treatment Period (Up to Week 48)|Lack of Efficacy|0
6205433|NCT01532869|9867759|FG001|Blinded-Treatment Period (Up to Week 48)|Lack of Efficacy|1
6205434|NCT01532869|9867758|FG000|Blinded-Treatment Period (Up to Week 48)|Withdrawal by Subject|5
6205435|NCT01532869|9867759|FG001|Blinded-Treatment Period (Up to Week 48)|Withdrawal by Subject|3
6205436|NCT01532869|9867758|FG000|Blinded-Treatment Period (Up to Week 48)|Physician Decision|1
6205437|NCT01532869|9867759|FG001|Blinded-Treatment Period (Up to Week 48)|Physician Decision|0
6205438|NCT01532869|9867758|FG000|Open-label Period (Week 48 to Week 96)|Adverse Event|4
6205439|NCT01532869|9867759|FG001|Open-label Period (Week 48 to Week 96)|Adverse Event|1
6205440|NCT01532869|9867758|FG000|Open-label Period (Week 48 to Week 96)|Non-compliance|1
6205441|NCT01532869|9867759|FG001|Open-label Period (Week 48 to Week 96)|Non-compliance|0
6205442|NCT01532869|9867758|FG000|Open-label Period (Week 48 to Week 96)|Lack of Efficacy|1
6205443|NCT01532869|9867759|FG001|Open-label Period (Week 48 to Week 96)|Lack of Efficacy|1
6205444|NCT01532869|9867758|FG000|Open-label Period (Week 48 to Week 96)|Withdrawal by Subject|1
6205445|NCT01532869|9867759|FG001|Open-label Period (Week 48 to Week 96)|Withdrawal by Subject|1
6205446|NCT01532908|9867772|FG000|Overall Study|Not Transplanted|1
6205447|NCT01532908|9867773|FG001|Overall Study|Not Transplanted|0
6205448|NCT01532921|9867779|FG000|Overall Study|Death|3
6205449|NCT01532921|9867779|FG000|Overall Study|Withdrawal by Subject|2
6205450|NCT01532921|9867779|FG000|Overall Study|Lost to Follow-up|3
6205451|NCT01532921|9867779|FG000|Overall Study|Physician Decision|7
6205452|NCT01532921|9867779|FG000|Overall Study|Device was explanted during procedure|1
6205453|NCT01532934|9867789|FG000|Overall Study|Lost to Follow-up|11
6205454|NCT01532934|9867790|FG001|Overall Study|Lost to Follow-up|11
6205455|NCT01532934|9867789|FG000|Overall Study|In controlled environment|3
6205456|NCT01532934|9867790|FG001|Overall Study|In controlled environment|2
6205457|NCT01532986|9867842|FG000|Overall Study|Death|9
6205458|NCT01532986|9867843|FG001|Overall Study|Death|9
6105622|NCT00790907|9723240|FG001|Overall Study|Adverse Event|7
6105623|NCT00790907|9723241|FG002|Overall Study|Adverse Event|6
6105624|NCT00790907|9723239|FG000|Overall Study|Physician Decision|304
6105625|NCT00790907|9723240|FG001|Overall Study|Physician Decision|271
6105626|NCT00790907|9723241|FG002|Overall Study|Physician Decision|255
6105627|NCT00790907|9723239|FG000|Overall Study|Withdrawal by Subject|1
6105628|NCT00790907|9723240|FG001|Overall Study|Withdrawal by Subject|7
6105629|NCT00790907|9723241|FG002|Overall Study|Withdrawal by Subject|5
6105630|NCT00790907|9723239|FG000|Overall Study|Bleeding Event|11
6105631|NCT00790907|9723240|FG001|Overall Study|Bleeding Event|16
6105632|NCT00790907|9723241|FG002|Overall Study|Bleeding Event|21
6105633|NCT00790907|9723239|FG000|Overall Study|Required Protocol-prohibited Therapy|17
6105634|NCT00790907|9723240|FG001|Overall Study|Required Protocol-prohibited Therapy|5
6105635|NCT00790907|9723241|FG002|Overall Study|Required Protocol-prohibited Therapy|7
6105636|NCT00790907|9723239|FG000|Overall Study|Qualifying Condition Not Present|29
6105637|NCT00790907|9723240|FG001|Overall Study|Qualifying Condition Not Present|14
6105638|NCT00790907|9723241|FG002|Overall Study|Qualifying Condition Not Present|16
6105639|NCT00790907|9723239|FG000|Overall Study|Verbatim Reason on the Case Report Form|74
6105640|NCT00790907|9723240|FG001|Overall Study|Verbatim Reason on the Case Report Form|20
6105641|NCT00790907|9723241|FG002|Overall Study|Verbatim Reason on the Case Report Form|29
6105642|NCT00790907|9723239|FG000|Overall Study|Did Not Receive Study Drug|10
6105643|NCT00790907|9723240|FG001|Overall Study|Did Not Receive Study Drug|0
6105644|NCT00790907|9723241|FG002|Overall Study|Did Not Receive Study Drug|0
6105645|NCT00791128|9723270|FG000|Overall Study|Adverse Event|4
6105646|NCT00791128|9723270|FG000|Overall Study|Device migration|2
6105647|NCT00791128|9723270|FG000|Overall Study|non-compliance by subject|2
6105648|NCT00791128|9723270|FG000|Overall Study|abdominal tumor, unrelated to device|1
6105649|NCT00791258|9723287|FG000|Overall Study|Adverse Event|87
6105650|NCT00791258|9723287|FG000|Overall Study|Lost to Follow-up|18
6105651|NCT00791258|9723287|FG000|Overall Study|Protocol Violation|109
6105652|NCT00791258|9723287|FG000|Overall Study|Withdrawal by Subject|40
6105653|NCT00791258|9723287|FG000|Overall Study|Did not take medication for >3 days|1
6105654|NCT00791258|9723287|FG000|Overall Study|subject left area|2
6105655|NCT00791258|9723287|FG000|Overall Study|non-compliance|3
6105656|NCT00791258|9723287|FG000|Overall Study|Subject incarcerated|1
6105657|NCT00791258|9723287|FG000|Overall Study|Subject required restricted medication|1
6105658|NCT00791258|9723287|FG000|Overall Study|Lack of Efficacy|1
6105659|NCT00791388|9723305|FG000|Period 1 - 50 mg Dose Group|Withdrawal by Subject|0
6105660|NCT00791388|9723306|FG001|Period 1 - 50 mg Dose Group|Withdrawal by Subject|1
6105661|NCT00791388|9723307|FG002|Period 1 - 50 mg Dose Group|Withdrawal by Subject|0
6105662|NCT00791388|9723308|FG003|Period 1 - 50 mg Dose Group|Withdrawal by Subject|0
6105663|NCT00791388|9723309|FG004|Period 1 - 50 mg Dose Group|Withdrawal by Subject|0
6105664|NCT00791388|9723305|FG000|Period 2 - 100 mg Dose Group|Withdrawal by Subject|1
6105665|NCT00791388|9723306|FG001|Period 2 - 100 mg Dose Group|Withdrawal by Subject|0
6105666|NCT00791388|9723307|FG002|Period 2 - 100 mg Dose Group|Withdrawal by Subject|0
6105667|NCT00791388|9723308|FG003|Period 2 - 100 mg Dose Group|Withdrawal by Subject|0
6105668|NCT00791388|9723309|FG004|Period 2 - 100 mg Dose Group|Withdrawal by Subject|0
6105669|NCT00791388|9723305|FG000|Period 4 - 400 mg Dose Group|Adverse Event|0
6105670|NCT00791388|9723306|FG001|Period 4 - 400 mg Dose Group|Adverse Event|0
6105671|NCT00791388|9723307|FG002|Period 4 - 400 mg Dose Group|Adverse Event|0
6105672|NCT00791388|9723308|FG003|Period 4 - 400 mg Dose Group|Adverse Event|0
6105673|NCT00791388|9723309|FG004|Period 4 - 400 mg Dose Group|Adverse Event|4
6105674|NCT00791479|9723327|FG000|Overall Study|Dose Discontinued per Sponsor Decision|0
6105675|NCT00791479|9723328|FG001|Overall Study|Dose Discontinued per Sponsor Decision|0
6105676|NCT00791479|9723329|FG002|Overall Study|Dose Discontinued per Sponsor Decision|0
6105677|NCT00791479|9723330|FG003|Overall Study|Dose Discontinued per Sponsor Decision|0
6105678|NCT00791479|9723331|FG004|Overall Study|Dose Discontinued per Sponsor Decision|3
6105679|NCT00791479|9723332|FG005|Overall Study|Dose Discontinued per Sponsor Decision|0
6105680|NCT00791479|9723327|FG000|Overall Study|Adverse Event|0
6105681|NCT00791479|9723328|FG001|Overall Study|Adverse Event|1
6105682|NCT00791479|9723329|FG002|Overall Study|Adverse Event|0
6105683|NCT00791479|9723330|FG003|Overall Study|Adverse Event|2
6105684|NCT00791479|9723331|FG004|Overall Study|Adverse Event|0
6105685|NCT00791479|9723332|FG005|Overall Study|Adverse Event|1
6105686|NCT00791479|9723327|FG000|Overall Study|Lost to Follow-up|0
6105687|NCT00791479|9723328|FG001|Overall Study|Lost to Follow-up|1
6105688|NCT00791479|9723329|FG002|Overall Study|Lost to Follow-up|0
6105689|NCT00791479|9723330|FG003|Overall Study|Lost to Follow-up|0
6105690|NCT00791479|9723331|FG004|Overall Study|Lost to Follow-up|0
6105691|NCT00791479|9723332|FG005|Overall Study|Lost to Follow-up|1
6105692|NCT00791479|9723327|FG000|Overall Study|Protocol Violation|2
6105693|NCT00791479|9723328|FG001|Overall Study|Protocol Violation|1
6105694|NCT00791479|9723329|FG002|Overall Study|Protocol Violation|0
6105695|NCT00791479|9723330|FG003|Overall Study|Protocol Violation|1
6105696|NCT00791479|9723331|FG004|Overall Study|Protocol Violation|0
6105697|NCT00791479|9723332|FG005|Overall Study|Protocol Violation|0
6105698|NCT00791479|9723327|FG000|Overall Study|Withdrawal by Subject|0
6105699|NCT00791479|9723328|FG001|Overall Study|Withdrawal by Subject|0
6105700|NCT00791479|9723329|FG002|Overall Study|Withdrawal by Subject|0
6105701|NCT00791479|9723330|FG003|Overall Study|Withdrawal by Subject|1
6105702|NCT00791479|9723331|FG004|Overall Study|Withdrawal by Subject|0
6105703|NCT00791479|9723332|FG005|Overall Study|Withdrawal by Subject|1
6105704|NCT00791492|9723355|FG000|Overall Study|Withdrawal by Subject|1
6105705|NCT00791492|9723356|FG001|Overall Study|Withdrawal by Subject|2
6105706|NCT00791492|9723355|FG000|Overall Study|Liver transplantation|5
6105707|NCT00791492|9723356|FG001|Overall Study|Liver transplantation|1
6105708|NCT00791518|9723362|FG000|Overall Study|Protocol Violation|93
6105709|NCT00791557|9723381|FG000|Overall Study|Adverse Event|1
6105710|NCT00791648|9723387|FG000|Overall Study|Physician Decision|0
6105711|NCT00791648|9723388|FG001|Overall Study|Physician Decision|1
6105712|NCT00791648|9723387|FG000|Overall Study|Withdrawal by Subject|0
6105713|NCT00791648|9723388|FG001|Overall Study|Withdrawal by Subject|1
6105714|NCT00791661|9723397|FG000|7 Day Wash-out|Adverse Event|0
6105715|NCT00791661|9723398|FG001|7 Day Wash-out|Adverse Event|0
6105716|NCT00791661|9723399|FG002|7 Day Wash-out|Adverse Event|1
6105717|NCT00791661|9723397|FG000|7 Day Wash-out|Abnormal Clinical Laboratory Test|0
6105718|NCT00791661|9723398|FG001|7 Day Wash-out|Abnormal Clinical Laboratory Test|0
6105719|NCT00791661|9723399|FG002|7 Day Wash-out|Abnormal Clinical Laboratory Test|1
6105720|NCT00791700|9723427|FG000|Overall Study|Insufficient clinical response|1
6105721|NCT00791700|9723428|FG001|Overall Study|Insufficient clinical response|4
6105722|NCT00791700|9723429|FG002|Overall Study|Insufficient clinical response|1
6105723|NCT00791700|9723430|FG003|Overall Study|Insufficient clinical response|8
6105724|NCT00791700|9723427|FG000|Overall Study|No longer willing to participate|1
6105725|NCT00791700|9723428|FG001|Overall Study|No longer willing to participate|1
6105726|NCT00791700|9723429|FG002|Overall Study|No longer willing to participate|0
6105727|NCT00791700|9723430|FG003|Overall Study|No longer willing to participate|8
6105728|NCT00791700|9723427|FG000|Overall Study|Non-compliance with study treatment|0
6105729|NCT00791700|9723428|FG001|Overall Study|Non-compliance with study treatment|2
6105730|NCT00791700|9723429|FG002|Overall Study|Non-compliance with study treatment|0
6105731|NCT00791700|9723430|FG003|Overall Study|Non-compliance with study treatment|4
6105732|NCT00791700|9723427|FG000|Overall Study|Withdrawn due to pregnancy|0
6105733|NCT00791700|9723428|FG001|Overall Study|Withdrawn due to pregnancy|0
6105734|NCT00791700|9723429|FG002|Overall Study|Withdrawn due to pregnancy|0
6105735|NCT00791700|9723430|FG003|Overall Study|Withdrawn due to pregnancy|1
6105736|NCT00791700|9723427|FG000|Overall Study|Other|0
6105737|NCT00791700|9723428|FG001|Overall Study|Other|1
6105738|NCT00791700|9723429|FG002|Overall Study|Other|0
6105739|NCT00791700|9723430|FG003|Overall Study|Other|1
6105740|NCT00791700|9723427|FG000|Overall Study|Death|0
6105741|NCT00791700|9723428|FG001|Overall Study|Death|0
6105742|NCT00791700|9723429|FG002|Overall Study|Death|0
6105743|NCT00791700|9723430|FG003|Overall Study|Death|1
6105744|NCT00791700|9723427|FG000|Overall Study|Lost to Follow-up|4
6105745|NCT00791700|9723428|FG001|Overall Study|Lost to Follow-up|3
6105746|NCT00791700|9723429|FG002|Overall Study|Lost to Follow-up|4
6105747|NCT00791700|9723430|FG003|Overall Study|Lost to Follow-up|6
6105748|NCT00791700|9723427|FG000|Overall Study|Adverse Event|0
6105749|NCT00791700|9723428|FG001|Overall Study|Adverse Event|0
6105750|NCT00791700|9723429|FG002|Overall Study|Adverse Event|1
6105751|NCT00791700|9723430|FG003|Overall Study|Adverse Event|1
6105752|NCT00791765|9723453|FG000|Weeks 1 to 12|Adverse Event|0
6105753|NCT00791765|9723454|FG001|Weeks 1 to 12|Adverse Event|1
6105754|NCT00791765|9723453|FG000|Weeks 1 to 12|Lost to Follow-up|1
6105755|NCT00791765|9723454|FG001|Weeks 1 to 12|Lost to Follow-up|0
6105756|NCT00791765|9723453|FG000|Weeks 1 to 12|Withdrawal by Subject|3
6105757|NCT00791765|9723454|FG001|Weeks 1 to 12|Withdrawal by Subject|0
6105758|NCT00791765|9723453|FG000|Weeks 1 to 12|Physician Decision|1
6105759|NCT00791765|9723454|FG001|Weeks 1 to 12|Physician Decision|0
6105760|NCT00791765|9723453|FG000|Weeks 1 to 12|Disease progression|3
6105761|NCT00791765|9723454|FG001|Weeks 1 to 12|Disease progression|0
6105762|NCT00791765|9723453|FG000|Weeks 1 to 12|Ineligibility determined|0
6105763|NCT00791765|9723454|FG001|Weeks 1 to 12|Ineligibility determined|3
6105764|NCT00791765|9723453|FG000|Weeks 13 to 24|Protocol deviation|2
6105765|NCT00791765|9723454|FG001|Weeks 13 to 24|Protocol deviation|0
6105766|NCT00791765|9723453|FG000|Weeks 13 to 24|Adverse Event|0
6105767|NCT00791765|9723454|FG001|Weeks 13 to 24|Adverse Event|3
6105768|NCT00791765|9723453|FG000|Weeks 13 to 24|Withdrawal by Subject|2
6105769|NCT00791765|9723454|FG001|Weeks 13 to 24|Withdrawal by Subject|1
6105770|NCT00791765|9723453|FG000|Weeks 13 to 24|Disease progression|0
6105771|NCT00791765|9723454|FG001|Weeks 13 to 24|Disease progression|1
6105772|NCT00791765|9723453|FG000|Weeks 13 to 24|Lost to Follow-up|1
6105773|NCT00791765|9723454|FG001|Weeks 13 to 24|Lost to Follow-up|2
6105774|NCT00791765|9723453|FG000|Weeks 13 to 24|Other|0
6105775|NCT00791765|9723454|FG001|Weeks 13 to 24|Other|1
6105776|NCT00791778|9723462|FG000|Double-blind Treatment|Adverse Event|49
6105777|NCT00791778|9723463|FG001|Double-blind Treatment|Adverse Event|9
6105778|NCT00791778|9723462|FG000|Double-blind Treatment|Physician Decision|6
6105779|NCT00791778|9723463|FG001|Double-blind Treatment|Physician Decision|26
6105780|NCT00791778|9723462|FG000|Double-blind Treatment|Protocol Violation|0
6105781|NCT00791778|9723463|FG001|Double-blind Treatment|Protocol Violation|4
6105782|NCT00791778|9723462|FG000|Double-blind Treatment|Withdrawal by Subject|20
6105783|NCT00791778|9723463|FG001|Double-blind Treatment|Withdrawal by Subject|9
6105784|NCT00791778|9723462|FG000|Double-blind Treatment|Non-compliant with study medication|2
6105785|NCT00791778|9723463|FG001|Double-blind Treatment|Non-compliant with study medication|0
6105786|NCT00791778|9723462|FG000|Follow-up|Withdrawal by Subject|3
6105787|NCT00791778|9723463|FG001|Follow-up|Withdrawal by Subject|0
6105788|NCT00791778|9723462|FG000|Follow-up|Lost to Follow-up|2
6105789|NCT00791778|9723463|FG001|Follow-up|Lost to Follow-up|1
6105790|NCT00791921|9723488|FG000|Overall Study|Protocol planed|24
6105791|NCT00791921|9723489|FG001|Overall Study|Protocol planed|88
6105792|NCT00791921|9723488|FG000|Overall Study|Withdrawal by Subject|1
6105793|NCT00791921|9723489|FG001|Overall Study|Withdrawal by Subject|2
6105794|NCT00791921|9723488|FG000|Overall Study|Adverse Event|8
6105795|NCT00791921|9723489|FG001|Overall Study|Adverse Event|2
6105796|NCT00791921|9723488|FG000|Overall Study|Lack of Efficacy|0
6105797|NCT00791921|9723489|FG001|Overall Study|Lack of Efficacy|2
6105798|NCT00791921|9723488|FG000|Overall Study|Lack of study drug administration|1
6105799|NCT00791921|9723489|FG001|Overall Study|Lack of study drug administration|1
6105800|NCT00791921|9723488|FG000|Overall Study|Reason other than those above|0
6105801|NCT00791921|9723489|FG001|Overall Study|Reason other than those above|1
6105802|NCT00791934|9723495|FG000|Overall Study|Withdrawal by Subject|2
6105803|NCT00791934|9723495|FG000|Overall Study|Did not consent for extended follow-up|13
6105804|NCT00791999|9723512|FG000|Overall Study|Protocol planed withdrawal|14
6105805|NCT00791999|9723513|FG001|Overall Study|Protocol planed withdrawal|11
6105806|NCT00791999|9723514|FG002|Overall Study|Protocol planed withdrawal|11
6105807|NCT00791999|9723515|FG003|Overall Study|Protocol planed withdrawal|45
6105808|NCT00791999|9723512|FG000|Overall Study|Withdrawal by Subject|0
6105809|NCT00791999|9723513|FG001|Overall Study|Withdrawal by Subject|1
6105810|NCT00791999|9723514|FG002|Overall Study|Withdrawal by Subject|0
6105811|NCT00791999|9723515|FG003|Overall Study|Withdrawal by Subject|2
6105812|NCT00791999|9723512|FG000|Overall Study|Protocol Violation|3
6105813|NCT00791999|9723513|FG001|Overall Study|Protocol Violation|0
6105814|NCT00791999|9723514|FG002|Overall Study|Protocol Violation|1
6105815|NCT00791999|9723515|FG003|Overall Study|Protocol Violation|0
6105816|NCT00791999|9723512|FG000|Overall Study|Adverse Event|3
6105817|NCT00791999|9723513|FG001|Overall Study|Adverse Event|3
6105818|NCT00791999|9723514|FG002|Overall Study|Adverse Event|7
6105819|NCT00791999|9723515|FG003|Overall Study|Adverse Event|3
6105820|NCT00791999|9723512|FG000|Overall Study|Lack of Efficacy|0
6105821|NCT00791999|9723513|FG001|Overall Study|Lack of Efficacy|1
6105822|NCT00791999|9723514|FG002|Overall Study|Lack of Efficacy|0
6105823|NCT00791999|9723515|FG003|Overall Study|Lack of Efficacy|2
6105824|NCT00791999|9723512|FG000|Overall Study|Reason other than those above|1
6105825|NCT00791999|9723513|FG001|Overall Study|Reason other than those above|0
6105826|NCT00791999|9723514|FG002|Overall Study|Reason other than those above|1
6105827|NCT00791999|9723515|FG003|Overall Study|Reason other than those above|0
6105828|NCT00792103|9723529|FG000|Overall Study|Enrolled, not treated|15
6105829|NCT00792103|9723529|FG000|Overall Study|Lost to Follow-up|17
6105830|NCT00792103|9723529|FG000|Overall Study|Adverse Event|25
6105831|NCT00792103|9723529|FG000|Overall Study|Withdrawal by Subject|52
6105832|NCT00792103|9723529|FG000|Overall Study|Protocol Violation|10
6105833|NCT00792103|9723529|FG000|Overall Study|Did not apply 6 patches in 1st 3 mths|14
6105834|NCT00792298|9723537|FG000|Treatment Period 1|Adverse Event|0
6105835|NCT00792298|9723538|FG001|Treatment Period 1|Adverse Event|1
6105836|NCT00792298|9723539|FG002|Treatment Period 1|Adverse Event|0
6105837|NCT00792298|9723540|FG003|Treatment Period 1|Adverse Event|1
6105838|NCT00792298|9723541|FG004|Treatment Period 1|Adverse Event|0
6105839|NCT00792298|9723542|FG005|Treatment Period 1|Adverse Event|1
6105840|NCT00792298|9723543|FG006|Treatment Period 1|Adverse Event|1
6105841|NCT00792298|9723544|FG007|Treatment Period 1|Adverse Event|0
6105842|NCT00792298|9723537|FG000|Treatment Period 1|Lack of Efficacy|0
6105843|NCT00792298|9723538|FG001|Treatment Period 1|Lack of Efficacy|0
6105844|NCT00792298|9723539|FG002|Treatment Period 1|Lack of Efficacy|1
6105845|NCT00792298|9723540|FG003|Treatment Period 1|Lack of Efficacy|0
6105846|NCT00792298|9723541|FG004|Treatment Period 1|Lack of Efficacy|0
6105847|NCT00792298|9723542|FG005|Treatment Period 1|Lack of Efficacy|0
6105848|NCT00792298|9723543|FG006|Treatment Period 1|Lack of Efficacy|0
6105849|NCT00792298|9723544|FG007|Treatment Period 1|Lack of Efficacy|0
6105850|NCT00792298|9723537|FG000|Treatment Period 1|Withdrawal by Subject|1
6105851|NCT00792298|9723538|FG001|Treatment Period 1|Withdrawal by Subject|0
6105852|NCT00792298|9723539|FG002|Treatment Period 1|Withdrawal by Subject|1
6105853|NCT00792298|9723540|FG003|Treatment Period 1|Withdrawal by Subject|2
6105854|NCT00792298|9723541|FG004|Treatment Period 1|Withdrawal by Subject|0
6105855|NCT00792298|9723542|FG005|Treatment Period 1|Withdrawal by Subject|2
6205459|NCT01532986|9867842|FG000|Overall Study|Withdrawal by Subject|7
6205460|NCT01532986|9867843|FG001|Overall Study|Withdrawal by Subject|10
6105856|NCT00792298|9723543|FG006|Treatment Period 1|Withdrawal by Subject|1
6105857|NCT00792298|9723544|FG007|Treatment Period 1|Withdrawal by Subject|0
6105858|NCT00792298|9723537|FG000|Treatment Period 1|Lost to Follow-up|0
6105859|NCT00792298|9723538|FG001|Treatment Period 1|Lost to Follow-up|0
6105860|NCT00792298|9723539|FG002|Treatment Period 1|Lost to Follow-up|0
6105861|NCT00792298|9723540|FG003|Treatment Period 1|Lost to Follow-up|0
6105862|NCT00792298|9723541|FG004|Treatment Period 1|Lost to Follow-up|0
6105863|NCT00792298|9723542|FG005|Treatment Period 1|Lost to Follow-up|0
6105864|NCT00792298|9723543|FG006|Treatment Period 1|Lost to Follow-up|1
6105865|NCT00792298|9723544|FG007|Treatment Period 1|Lost to Follow-up|0
6105866|NCT00792298|9723537|FG000|Treatment Period 1|Physician Decision|0
6105867|NCT00792298|9723538|FG001|Treatment Period 1|Physician Decision|0
6105868|NCT00792298|9723539|FG002|Treatment Period 1|Physician Decision|0
6105869|NCT00792298|9723540|FG003|Treatment Period 1|Physician Decision|1
6105870|NCT00792298|9723541|FG004|Treatment Period 1|Physician Decision|0
6105871|NCT00792298|9723542|FG005|Treatment Period 1|Physician Decision|0
6105872|NCT00792298|9723543|FG006|Treatment Period 1|Physician Decision|1
6105873|NCT00792298|9723544|FG007|Treatment Period 1|Physician Decision|0
6105874|NCT00792298|9723537|FG000|Treatment Period 1|Protocol Violation|0
6105875|NCT00792298|9723538|FG001|Treatment Period 1|Protocol Violation|0
6105876|NCT00792298|9723539|FG002|Treatment Period 1|Protocol Violation|0
6105877|NCT00792298|9723540|FG003|Treatment Period 1|Protocol Violation|0
6105878|NCT00792298|9723541|FG004|Treatment Period 1|Protocol Violation|0
6105879|NCT00792298|9723542|FG005|Treatment Period 1|Protocol Violation|0
6105880|NCT00792298|9723543|FG006|Treatment Period 1|Protocol Violation|0
6105881|NCT00792298|9723544|FG007|Treatment Period 1|Protocol Violation|1
6105882|NCT00792298|9723537|FG000|Washout|Adverse Event|0
6105883|NCT00792298|9723538|FG001|Washout|Adverse Event|0
6105884|NCT00792298|9723539|FG002|Washout|Adverse Event|0
6105885|NCT00792298|9723540|FG003|Washout|Adverse Event|0
6105886|NCT00792298|9723541|FG004|Washout|Adverse Event|0
6105887|NCT00792298|9723542|FG005|Washout|Adverse Event|1
6105888|NCT00792298|9723543|FG006|Washout|Adverse Event|0
6105889|NCT00792298|9723544|FG007|Washout|Adverse Event|0
6105890|NCT00792298|9723537|FG000|Washout|Withdrawal by Subject|0
6105891|NCT00792298|9723538|FG001|Washout|Withdrawal by Subject|0
6105892|NCT00792298|9723539|FG002|Washout|Withdrawal by Subject|1
6105893|NCT00792298|9723540|FG003|Washout|Withdrawal by Subject|0
6105894|NCT00792298|9723541|FG004|Washout|Withdrawal by Subject|0
6105895|NCT00792298|9723542|FG005|Washout|Withdrawal by Subject|1
6105896|NCT00792298|9723543|FG006|Washout|Withdrawal by Subject|0
6105897|NCT00792298|9723544|FG007|Washout|Withdrawal by Subject|0
6105898|NCT00792298|9723537|FG000|Treatment Period 2|Lack of Efficacy|0
6105899|NCT00792298|9723538|FG001|Treatment Period 2|Lack of Efficacy|0
6105900|NCT00792298|9723539|FG002|Treatment Period 2|Lack of Efficacy|0
6105901|NCT00792298|9723540|FG003|Treatment Period 2|Lack of Efficacy|0
6105902|NCT00792298|9723541|FG004|Treatment Period 2|Lack of Efficacy|1
6105903|NCT00792298|9723542|FG005|Treatment Period 2|Lack of Efficacy|0
6105904|NCT00792298|9723543|FG006|Treatment Period 2|Lack of Efficacy|0
6105905|NCT00792298|9723544|FG007|Treatment Period 2|Lack of Efficacy|0
6105906|NCT00792298|9723537|FG000|Treatment Period 2|Physician Decision|0
6105907|NCT00792298|9723538|FG001|Treatment Period 2|Physician Decision|0
6105908|NCT00792298|9723539|FG002|Treatment Period 2|Physician Decision|0
6105909|NCT00792298|9723540|FG003|Treatment Period 2|Physician Decision|0
6105910|NCT00792298|9723541|FG004|Treatment Period 2|Physician Decision|0
6105911|NCT00792298|9723542|FG005|Treatment Period 2|Physician Decision|0
6105912|NCT00792298|9723543|FG006|Treatment Period 2|Physician Decision|1
6105913|NCT00792298|9723544|FG007|Treatment Period 2|Physician Decision|0
6105914|NCT00792298|9723537|FG000|Treatment Period 2|Pregnancy|0
6105915|NCT00792298|9723538|FG001|Treatment Period 2|Pregnancy|0
6105916|NCT00792298|9723539|FG002|Treatment Period 2|Pregnancy|1
6105917|NCT00792298|9723540|FG003|Treatment Period 2|Pregnancy|0
6105918|NCT00792298|9723541|FG004|Treatment Period 2|Pregnancy|0
6105919|NCT00792298|9723542|FG005|Treatment Period 2|Pregnancy|0
6105920|NCT00792298|9723543|FG006|Treatment Period 2|Pregnancy|0
6105921|NCT00792298|9723544|FG007|Treatment Period 2|Pregnancy|0
6105922|NCT00792298|9723537|FG000|Treatment Period 2|Withdrawal by Subject|1
6105923|NCT00792298|9723538|FG001|Treatment Period 2|Withdrawal by Subject|1
6105924|NCT00792298|9723539|FG002|Treatment Period 2|Withdrawal by Subject|0
6105925|NCT00792298|9723540|FG003|Treatment Period 2|Withdrawal by Subject|2
6105926|NCT00792298|9723541|FG004|Treatment Period 2|Withdrawal by Subject|1
6105927|NCT00792298|9723542|FG005|Treatment Period 2|Withdrawal by Subject|0
6105928|NCT00792298|9723543|FG006|Treatment Period 2|Withdrawal by Subject|0
6105929|NCT00792298|9723544|FG007|Treatment Period 2|Withdrawal by Subject|2
6105930|NCT00792467|9723570|FG000|Overall Study|progression of disease|17
6105931|NCT00792467|9723570|FG000|Overall Study|Adverse Event|1
6105932|NCT00792467|9723570|FG000|Overall Study|patient request|1
6105933|NCT00792467|9723570|FG000|Overall Study|Lost to Follow-up|1
6105934|NCT00792467|9723570|FG000|Overall Study|Patient achieved a PR and allogenic transplant was performed|1
6105935|NCT00792467|9723570|FG000|Overall Study|Patient in CR and HLA-matched donor available. Allogenic SCT performed|1
6105936|NCT00792571|9723575|FG000|Overall Study|Death|1
6105937|NCT00792571|9723575|FG000|Overall Study|Adverse Event|4
6105938|NCT00792571|9723575|FG000|Overall Study|Withdrawal by Subject|1
6105939|NCT00792571|9723575|FG000|Overall Study|Other|4
6105940|NCT00792623|9723583|FG000|Overall Study|Adverse Event|2
6105941|NCT00792623|9723583|FG000|Overall Study|Withdrawal by Subject|5
6105942|NCT00792636|9723591|FG000|Overall Study|Protocol Violation|17
6105943|NCT00792636|9723592|FG001|Overall Study|Protocol Violation|23
6105944|NCT00792636|9723593|FG002|Overall Study|Protocol Violation|20
6105945|NCT00792636|9723591|FG000|Overall Study|Met Protocol-defined Stopping Criteria|19
6105946|NCT00792636|9723592|FG001|Overall Study|Met Protocol-defined Stopping Criteria|20
6105947|NCT00792636|9723593|FG002|Overall Study|Met Protocol-defined Stopping Criteria|20
6105948|NCT00792636|9723591|FG000|Overall Study|Lost to Follow-up|13
6105949|NCT00792636|9723592|FG001|Overall Study|Lost to Follow-up|19
6105950|NCT00792636|9723593|FG002|Overall Study|Lost to Follow-up|14
6105951|NCT00792636|9723591|FG000|Overall Study|Withdrew Consent|10
6105952|NCT00792636|9723592|FG001|Overall Study|Withdrew Consent|13
6105953|NCT00792636|9723593|FG002|Overall Study|Withdrew Consent|9
6105954|NCT00792636|9723591|FG000|Overall Study|Lack of Efficacy|3
6105955|NCT00792636|9723592|FG001|Overall Study|Lack of Efficacy|4
6105956|NCT00792636|9723593|FG002|Overall Study|Lack of Efficacy|13
6105957|NCT00792636|9723591|FG000|Overall Study|Adverse Event|4
6105958|NCT00792636|9723592|FG001|Overall Study|Adverse Event|2
6105959|NCT00792636|9723593|FG002|Overall Study|Adverse Event|3
6105960|NCT00792636|9723591|FG000|Overall Study|Investigator Discretion|2
6105961|NCT00792636|9723592|FG001|Overall Study|Investigator Discretion|0
6105962|NCT00792636|9723593|FG002|Overall Study|Investigator Discretion|2
6105963|NCT00792701|9723618|FG000|Overall Study|Adverse Event|0
6105964|NCT00792701|9723619|FG001|Overall Study|Adverse Event|22
6105965|NCT00792701|9723618|FG000|Overall Study|Ineligible|1
6105966|NCT00792701|9723619|FG001|Overall Study|Ineligible|3
6105967|NCT00792701|9723618|FG000|Overall Study|Withdrawal by Subject|1
6105968|NCT00792701|9723619|FG001|Overall Study|Withdrawal by Subject|19
6105969|NCT00792701|9723618|FG000|Overall Study|Not protocol specified|17
6105970|NCT00792701|9723619|FG001|Overall Study|Not protocol specified|0
6105971|NCT00792805|9723630|FG000|Overall Study|Adverse Event|12
6105972|NCT00792805|9723631|FG001|Overall Study|Adverse Event|10
6105973|NCT00792805|9723632|FG002|Overall Study|Adverse Event|10
6105974|NCT00792805|9723630|FG000|Overall Study|Subject withdrew consent|5
6105975|NCT00792805|9723631|FG001|Overall Study|Subject withdrew consent|6
6105976|NCT00792805|9723632|FG002|Overall Study|Subject withdrew consent|5
6105977|NCT00792805|9723630|FG000|Overall Study|Administrative problems|2
6105978|NCT00792805|9723631|FG001|Overall Study|Administrative problems|0
6105979|NCT00792805|9723632|FG002|Overall Study|Administrative problems|4
6105980|NCT00792805|9723630|FG000|Overall Study|Abnormal test procedure result(s)|1
6105981|NCT00792805|9723631|FG001|Overall Study|Abnormal test procedure result(s)|2
6105982|NCT00792805|9723632|FG002|Overall Study|Abnormal test procedure result(s)|0
6105983|NCT00792805|9723630|FG000|Overall Study|Unsatisfactory therapeutic effect|1
6105984|NCT00792805|9723631|FG001|Overall Study|Unsatisfactory therapeutic effect|6
6105985|NCT00792805|9723632|FG002|Overall Study|Unsatisfactory therapeutic effect|6
6105986|NCT00792805|9723630|FG000|Overall Study|Lost to Follow-up|1
6105987|NCT00792805|9723631|FG001|Overall Study|Lost to Follow-up|1
6105988|NCT00792805|9723632|FG002|Overall Study|Lost to Follow-up|6
6105989|NCT00792805|9723630|FG000|Overall Study|Abnormal laboratory value(s)|0
6105990|NCT00792805|9723631|FG001|Overall Study|Abnormal laboratory value(s)|0
6105991|NCT00792805|9723632|FG002|Overall Study|Abnormal laboratory value(s)|1
6105992|NCT00792805|9723630|FG000|Overall Study|Protocol deviation|0
6105993|NCT00792805|9723631|FG001|Overall Study|Protocol deviation|1
6105994|NCT00792805|9723632|FG002|Overall Study|Protocol deviation|1
6105995|NCT00792909|9723643|FG000|Overall Study|Withdrawal by Subject|0
6105996|NCT00792909|9723644|FG001|Overall Study|Withdrawal by Subject|1
6105997|NCT00792909|9723645|FG002|Overall Study|Withdrawal by Subject|0
6105998|NCT00792935|9723677|FG000|Overall Study|Adverse Event|2
6105999|NCT00792935|9723678|FG001|Overall Study|Adverse Event|1
6106000|NCT00792935|9723677|FG000|Overall Study|Lost to Follow-up|0
6106001|NCT00792935|9723678|FG001|Overall Study|Lost to Follow-up|1
6106002|NCT00792935|9723677|FG000|Overall Study|Protocol Violation|2
6106003|NCT00792935|9723678|FG001|Overall Study|Protocol Violation|0
6106004|NCT00792935|9723677|FG000|Overall Study|Withdrawal by Subject|0
6106005|NCT00792935|9723678|FG001|Overall Study|Withdrawal by Subject|1
6106006|NCT00793104|9723684|FG000|Overall Study|Lost to Follow-up|1
6106007|NCT00793182|9723690|FG000|Overall Study|Adverse Event|0
6106008|NCT00793182|9723691|FG001|Overall Study|Adverse Event|1
6205461|NCT01532986|9867842|FG000|Overall Study|Physician Decision|7
6205462|NCT01532986|9867843|FG001|Overall Study|Physician Decision|5
6205463|NCT01532999|9867852|FG000|Overall Study|Lost to Follow-up|14
6205464|NCT01532999|9867853|FG001|Overall Study|Lost to Follow-up|8
6205465|NCT01532999|9867852|FG000|Overall Study|Physician Decision|1
6205466|NCT01532999|9867853|FG001|Overall Study|Physician Decision|2
6205467|NCT01532999|9867852|FG000|Overall Study|Withdrawal by Subject|5
6205468|NCT01532999|9867853|FG001|Overall Study|Withdrawal by Subject|0
6205469|NCT01532999|9867852|FG000|Overall Study|Relocated|2
6205470|NCT01532999|9867853|FG001|Overall Study|Relocated|0
6205471|NCT01532999|9867852|FG000|Overall Study|should not have been randomized|1
6205472|NCT01532999|9867853|FG001|Overall Study|should not have been randomized|0
6205473|NCT01532999|9867852|FG000|Overall Study|substantial noncompliance|2
6205474|NCT01532999|9867853|FG001|Overall Study|substantial noncompliance|0
6205475|NCT01532999|9867852|FG000|Overall Study|no show for week 9 assessments|6
6205476|NCT01532999|9867853|FG001|Overall Study|no show for week 9 assessments|4
6205477|NCT01532999|9867852|FG000|Overall Study|Adverse Event|0
6205478|NCT01532999|9867853|FG001|Overall Study|Adverse Event|1
6205479|NCT01532999|9867852|FG000|Overall Study|incarcerated|0
6205480|NCT01532999|9867853|FG001|Overall Study|incarcerated|1
6205481|NCT01532999|9867852|FG000|Overall Study|New job|0
6205482|NCT01532999|9867853|FG001|Overall Study|New job|2
6205483|NCT01533181|9867904|FG000|Overall Study|Disease progression pre-active treatment|0
6205484|NCT01533181|9867905|FG001|Overall Study|Disease progression pre-active treatment|1
6205485|NCT01533181|9867904|FG000|Overall Study|Patient withdrawal pre-active treatment|1
6285135|NCT02332291|9997044|FG000|Phase 2: Open-Label Bupropion|Worsening Depression|0
6285136|NCT02332291|9997045|FG001|Phase 2: Open-Label Bupropion|Worsening Depression|1
6285137|NCT02332291|9997044|FG000|Phase 2: Open-Label Bupropion|Lost to Follow-up|1
6285138|NCT02332291|9997045|FG001|Phase 2: Open-Label Bupropion|Lost to Follow-up|0
6285139|NCT02332707|9997073|FG000|Overall Study|Adverse Event|0
6285140|NCT02332707|9997074|FG001|Overall Study|Adverse Event|0
6285141|NCT02332707|9997075|FG002|Overall Study|Adverse Event|0
6285142|NCT02332707|9997076|FG003|Overall Study|Adverse Event|0
6285143|NCT02332707|9997077|FG004|Overall Study|Adverse Event|0
6285144|NCT02332707|9997078|FG005|Overall Study|Adverse Event|0
6285145|NCT02332707|9997079|FG006|Overall Study|Adverse Event|0
6285146|NCT02332707|9997080|FG007|Overall Study|Adverse Event|0
6285147|NCT02332707|9997081|FG008|Overall Study|Adverse Event|0
6285148|NCT02332707|9997082|FG009|Overall Study|Adverse Event|0
6285149|NCT02332707|9997083|FG010|Overall Study|Adverse Event|0
6285150|NCT02332707|9997084|FG011|Overall Study|Adverse Event|0
6285151|NCT02332707|9997085|FG012|Overall Study|Adverse Event|1
6285152|NCT02332707|9997086|FG013|Overall Study|Adverse Event|0
6285153|NCT02332707|9997087|FG014|Overall Study|Adverse Event|0
6285154|NCT02332707|9997088|FG015|Overall Study|Adverse Event|0
6285155|NCT02332707|9997089|FG016|Overall Study|Adverse Event|0
6285156|NCT02332707|9997090|FG017|Overall Study|Adverse Event|0
6285157|NCT02332707|9997073|FG000|Overall Study|Lost to Follow-up|0
6285158|NCT02332707|9997074|FG001|Overall Study|Lost to Follow-up|0
6285159|NCT02332707|9997075|FG002|Overall Study|Lost to Follow-up|0
6285160|NCT02332707|9997076|FG003|Overall Study|Lost to Follow-up|0
6285161|NCT02332707|9997077|FG004|Overall Study|Lost to Follow-up|0
6285162|NCT02332707|9997078|FG005|Overall Study|Lost to Follow-up|1
6285163|NCT02332707|9997079|FG006|Overall Study|Lost to Follow-up|0
6285164|NCT02332707|9997080|FG007|Overall Study|Lost to Follow-up|0
6285165|NCT02332707|9997081|FG008|Overall Study|Lost to Follow-up|0
6285166|NCT02332707|9997082|FG009|Overall Study|Lost to Follow-up|0
6285167|NCT02332707|9997083|FG010|Overall Study|Lost to Follow-up|2
6285168|NCT02332707|9997084|FG011|Overall Study|Lost to Follow-up|0
6285169|NCT02332707|9997085|FG012|Overall Study|Lost to Follow-up|3
6285170|NCT02332707|9997086|FG013|Overall Study|Lost to Follow-up|0
6285171|NCT02332707|9997087|FG014|Overall Study|Lost to Follow-up|0
6285172|NCT02332707|9997088|FG015|Overall Study|Lost to Follow-up|0
6285173|NCT02332707|9997089|FG016|Overall Study|Lost to Follow-up|0
6285174|NCT02332707|9997090|FG017|Overall Study|Lost to Follow-up|0
6285175|NCT02332707|9997073|FG000|Overall Study|Physician Decision|0
6285176|NCT02332707|9997074|FG001|Overall Study|Physician Decision|0
6285177|NCT02332707|9997075|FG002|Overall Study|Physician Decision|0
6285178|NCT02332707|9997076|FG003|Overall Study|Physician Decision|1
6285179|NCT02332707|9997077|FG004|Overall Study|Physician Decision|0
6285180|NCT02332707|9997078|FG005|Overall Study|Physician Decision|0
6285181|NCT02332707|9997079|FG006|Overall Study|Physician Decision|0
6285182|NCT02332707|9997080|FG007|Overall Study|Physician Decision|0
5980554|NCT02733042|9569336|FG016|Treatment Period|Other|0
5980555|NCT02733042|9569337|FG017|Treatment Period|Other|1
5980556|NCT02733042|9569338|FG018|Treatment Period|Other|0
5980557|NCT02733042|9569320|FG000|Treatment Period|Ongoing on Assigned Treatment|0
5980558|NCT02733042|9569321|FG001|Treatment Period|Ongoing on Assigned Treatment|0
5980559|NCT02733042|9569322|FG002|Treatment Period|Ongoing on Assigned Treatment|0
5980560|NCT02733042|9569323|FG003|Treatment Period|Ongoing on Assigned Treatment|0
5980561|NCT02733042|9569324|FG004|Treatment Period|Ongoing on Assigned Treatment|3
5980562|NCT02733042|9569325|FG005|Treatment Period|Ongoing on Assigned Treatment|0
5980563|NCT02733042|9569326|FG006|Treatment Period|Ongoing on Assigned Treatment|0
5980564|NCT02733042|9569327|FG007|Treatment Period|Ongoing on Assigned Treatment|0
5980565|NCT02733042|9569328|FG008|Treatment Period|Ongoing on Assigned Treatment|0
5980566|NCT02733042|9569329|FG009|Treatment Period|Ongoing on Assigned Treatment|8
6205486|NCT01533181|9867905|FG001|Overall Study|Patient withdrawal pre-active treatment|0
6205487|NCT01533246|9867920|FG000|Overall Study|Adverse Event|1
6205488|NCT01533246|9867920|FG000|Overall Study|Withdrawal by Subject|1
6205489|NCT01533428|9867930|FG000|Overall Study|Adverse Event|0
6205490|NCT01533428|9867931|FG001|Overall Study|Adverse Event|1
6205491|NCT01533428|9867930|FG000|Overall Study|Lost to Follow-up|2
6205492|NCT01533428|9867931|FG001|Overall Study|Lost to Follow-up|1
6205493|NCT01533428|9867930|FG000|Overall Study|Withdrawal by Subject|7
6205494|NCT01533428|9867931|FG001|Overall Study|Withdrawal by Subject|6
5980567|NCT02733042|9569330|FG010|Treatment Period|Ongoing on Assigned Treatment|4
5980568|NCT02733042|9569331|FG011|Treatment Period|Ongoing on Assigned Treatment|0
5980569|NCT02733042|9569332|FG012|Treatment Period|Ongoing on Assigned Treatment|0
5980570|NCT02733042|9569333|FG013|Treatment Period|Ongoing on Assigned Treatment|0
5980571|NCT02733042|9569334|FG014|Treatment Period|Ongoing on Assigned Treatment|0
5980572|NCT02733042|9569335|FG015|Treatment Period|Ongoing on Assigned Treatment|0
5980573|NCT02733042|9569336|FG016|Treatment Period|Ongoing on Assigned Treatment|0
5980574|NCT02733042|9569337|FG017|Treatment Period|Ongoing on Assigned Treatment|0
6106009|NCT00793325|9723697|FG000|Overall Study|Protocol Violation|18
6106010|NCT00793325|9723697|FG000|Overall Study|Lost to Follow-up|1
6106011|NCT00793403|9723720|FG000|Overall Study|Other|73
6106012|NCT00793546|9723736|FG000|Overall Study|Death|3
6106013|NCT00793546|9723737|FG001|Overall Study|Death|0
6106014|NCT00793546|9723736|FG000|Overall Study|Lost to Follow-up|1
6106015|NCT00793546|9723737|FG001|Overall Study|Lost to Follow-up|0
6106016|NCT00793546|9723736|FG000|Overall Study|Withdrawal by Subject|1
6106017|NCT00793546|9723737|FG001|Overall Study|Withdrawal by Subject|1
6106018|NCT00793546|9723736|FG000|Overall Study|Study Terminated by Sponsor|8
6106019|NCT00793546|9723737|FG001|Overall Study|Study Terminated by Sponsor|27
6106020|NCT00793546|9723736|FG000|Overall Study|Other|1
6106021|NCT00793546|9723737|FG001|Overall Study|Other|0
6106022|NCT00793585|9723751|FG000|Overall Study|Adverse Event|1
6106023|NCT00793585|9723752|FG001|Overall Study|Adverse Event|1
6106024|NCT00793585|9723751|FG000|Overall Study|Protocol Violation|1
6106025|NCT00793585|9723752|FG001|Overall Study|Protocol Violation|2
6106026|NCT00793598|9723763|FG000|Overall Study|Patient Request|0
6106027|NCT00793598|9723764|FG001|Overall Study|Patient Request|1
6106028|NCT00793598|9723765|FG002|Overall Study|Patient Request|0
6106029|NCT00793598|9723766|FG003|Overall Study|Patient Request|0
6106030|NCT00793598|9723767|FG004|Overall Study|Patient Request|0
6106031|NCT00793598|9723768|FG005|Overall Study|Patient Request|0
6106032|NCT00793598|9723769|FG006|Overall Study|Patient Request|0
6106033|NCT00793598|9723770|FG007|Overall Study|Patient Request|0
6106034|NCT00793598|9723763|FG000|Overall Study|Protocol Violation|0
6106035|NCT00793598|9723764|FG001|Overall Study|Protocol Violation|0
6106036|NCT00793598|9723765|FG002|Overall Study|Protocol Violation|0
6106037|NCT00793598|9723766|FG003|Overall Study|Protocol Violation|0
6106038|NCT00793598|9723767|FG004|Overall Study|Protocol Violation|0
6106039|NCT00793598|9723768|FG005|Overall Study|Protocol Violation|0
6106040|NCT00793598|9723769|FG006|Overall Study|Protocol Violation|0
6106041|NCT00793598|9723770|FG007|Overall Study|Protocol Violation|1
6106042|NCT00793598|9723763|FG000|Overall Study|Subject not dosed|0
6106043|NCT00793598|9723764|FG001|Overall Study|Subject not dosed|0
6106044|NCT00793598|9723765|FG002|Overall Study|Subject not dosed|0
6106045|NCT00793598|9723766|FG003|Overall Study|Subject not dosed|0
6106046|NCT00793598|9723767|FG004|Overall Study|Subject not dosed|0
6106047|NCT00793598|9723768|FG005|Overall Study|Subject not dosed|1
6106048|NCT00793598|9723769|FG006|Overall Study|Subject not dosed|0
6106049|NCT00793598|9723770|FG007|Overall Study|Subject not dosed|0
6106050|NCT00793624|9723805|FG000|Overall Study|Adverse Event|18
6106051|NCT00793624|9723806|FG001|Overall Study|Adverse Event|16
6106052|NCT00793624|9723807|FG002|Overall Study|Adverse Event|15
6106053|NCT00793624|9723808|FG003|Overall Study|Adverse Event|20
6106054|NCT00793624|9723805|FG000|Overall Study|Lost to Follow-up|2
6106055|NCT00793624|9723806|FG001|Overall Study|Lost to Follow-up|2
6106056|NCT00793624|9723807|FG002|Overall Study|Lost to Follow-up|4
6106057|NCT00793624|9723808|FG003|Overall Study|Lost to Follow-up|0
6106058|NCT00793624|9723805|FG000|Overall Study|Withdrawal by Subject|20
6106059|NCT00793624|9723806|FG001|Overall Study|Withdrawal by Subject|9
6106060|NCT00793624|9723807|FG002|Overall Study|Withdrawal by Subject|11
6106061|NCT00793624|9723808|FG003|Overall Study|Withdrawal by Subject|14
6106062|NCT00793624|9723805|FG000|Overall Study|Lack of Efficacy|9
6106063|NCT00793624|9723806|FG001|Overall Study|Lack of Efficacy|2
6106064|NCT00793624|9723807|FG002|Overall Study|Lack of Efficacy|1
6106065|NCT00793624|9723808|FG003|Overall Study|Lack of Efficacy|3
6106066|NCT00793624|9723805|FG000|Overall Study|Non compliance with protocol|2
6106067|NCT00793624|9723806|FG001|Overall Study|Non compliance with protocol|3
6106068|NCT00793624|9723807|FG002|Overall Study|Non compliance with protocol|2
6106069|NCT00793624|9723808|FG003|Overall Study|Non compliance with protocol|3
6106070|NCT00793624|9723805|FG000|Overall Study|Other reason not described above|6
6106071|NCT00793624|9723806|FG001|Overall Study|Other reason not described above|4
6106072|NCT00793624|9723807|FG002|Overall Study|Other reason not described above|6
6106073|NCT00793624|9723808|FG003|Overall Study|Other reason not described above|3
6106074|NCT00793780|9723839|FG000|Overall Study|Withdrawal by Subject|2
6106075|NCT00793780|9723840|FG001|Overall Study|Withdrawal by Subject|1
6106076|NCT00793793|9723858|FG000|Overall Study|Adverse Event|0
6106077|NCT00793793|9723859|FG001|Overall Study|Adverse Event|0
6106078|NCT00793793|9723860|FG002|Overall Study|Adverse Event|1
6106079|NCT00793793|9723861|FG003|Overall Study|Adverse Event|1
6106080|NCT00793793|9723862|FG004|Overall Study|Adverse Event|0
6106081|NCT00793793|9723863|FG005|Overall Study|Adverse Event|1
6106082|NCT00793793|9723864|FG006|Overall Study|Adverse Event|2
6106083|NCT00793793|9723865|FG007|Overall Study|Adverse Event|0
6106084|NCT00793793|9723866|FG008|Overall Study|Adverse Event|0
6106085|NCT00793793|9723867|FG009|Overall Study|Adverse Event|0
6106086|NCT00793793|9723868|FG010|Overall Study|Adverse Event|0
6106087|NCT00793793|9723869|FG011|Overall Study|Adverse Event|2
6106088|NCT00793793|9723858|FG000|Overall Study|Protocol Violation|0
6106089|NCT00793793|9723859|FG001|Overall Study|Protocol Violation|0
6106090|NCT00793793|9723860|FG002|Overall Study|Protocol Violation|0
6106091|NCT00793793|9723861|FG003|Overall Study|Protocol Violation|1
6106092|NCT00793793|9723862|FG004|Overall Study|Protocol Violation|0
6106093|NCT00793793|9723863|FG005|Overall Study|Protocol Violation|0
6106094|NCT00793793|9723864|FG006|Overall Study|Protocol Violation|0
6106095|NCT00793793|9723865|FG007|Overall Study|Protocol Violation|0
6106096|NCT00793793|9723866|FG008|Overall Study|Protocol Violation|0
6106097|NCT00793793|9723867|FG009|Overall Study|Protocol Violation|0
6106098|NCT00793793|9723868|FG010|Overall Study|Protocol Violation|0
6106099|NCT00793793|9723869|FG011|Overall Study|Protocol Violation|0
6106100|NCT00793793|9723858|FG000|Overall Study|Lost to Follow-up|0
6106101|NCT00793793|9723859|FG001|Overall Study|Lost to Follow-up|0
6106102|NCT00793793|9723860|FG002|Overall Study|Lost to Follow-up|1
6106103|NCT00793793|9723861|FG003|Overall Study|Lost to Follow-up|0
6106104|NCT00793793|9723862|FG004|Overall Study|Lost to Follow-up|0
6106105|NCT00793793|9723863|FG005|Overall Study|Lost to Follow-up|0
6106106|NCT00793793|9723864|FG006|Overall Study|Lost to Follow-up|0
6106107|NCT00793793|9723865|FG007|Overall Study|Lost to Follow-up|0
6106108|NCT00793793|9723866|FG008|Overall Study|Lost to Follow-up|1
6106109|NCT00793793|9723867|FG009|Overall Study|Lost to Follow-up|3
6106110|NCT00793793|9723868|FG010|Overall Study|Lost to Follow-up|1
6106111|NCT00793793|9723869|FG011|Overall Study|Lost to Follow-up|0
6106112|NCT00793793|9723858|FG000|Overall Study|Withdrawal by Subject|0
6106113|NCT00793793|9723859|FG001|Overall Study|Withdrawal by Subject|0
6106114|NCT00793793|9723860|FG002|Overall Study|Withdrawal by Subject|0
6106115|NCT00793793|9723861|FG003|Overall Study|Withdrawal by Subject|0
6106116|NCT00793793|9723862|FG004|Overall Study|Withdrawal by Subject|1
6106117|NCT00793793|9723863|FG005|Overall Study|Withdrawal by Subject|0
6106118|NCT00793793|9723864|FG006|Overall Study|Withdrawal by Subject|0
6106119|NCT00793793|9723865|FG007|Overall Study|Withdrawal by Subject|0
6106120|NCT00793793|9723866|FG008|Overall Study|Withdrawal by Subject|1
6106121|NCT00793793|9723867|FG009|Overall Study|Withdrawal by Subject|0
6106122|NCT00793793|9723868|FG010|Overall Study|Withdrawal by Subject|0
6106123|NCT00793793|9723869|FG011|Overall Study|Withdrawal by Subject|0
6106124|NCT00793793|9723858|FG000|Overall Study|reason not specified|0
6106125|NCT00793793|9723859|FG001|Overall Study|reason not specified|1
6106126|NCT00793793|9723860|FG002|Overall Study|reason not specified|0
6106127|NCT00793793|9723861|FG003|Overall Study|reason not specified|1
6106128|NCT00793793|9723862|FG004|Overall Study|reason not specified|1
6106129|NCT00793793|9723863|FG005|Overall Study|reason not specified|1
6106130|NCT00793793|9723864|FG006|Overall Study|reason not specified|2
6106131|NCT00793793|9723865|FG007|Overall Study|reason not specified|0
6106132|NCT00793793|9723866|FG008|Overall Study|reason not specified|7
6106133|NCT00793793|9723867|FG009|Overall Study|reason not specified|6
6106134|NCT00793793|9723868|FG010|Overall Study|reason not specified|2
6106135|NCT00793793|9723869|FG011|Overall Study|reason not specified|4
6106136|NCT00793819|9723917|FG000|Overall Study|Adverse Event|8
6106137|NCT00793819|9723918|FG001|Overall Study|Adverse Event|4
6106138|NCT00793819|9723917|FG000|Overall Study|Lack of Efficacy|1
6106139|NCT00793819|9723918|FG001|Overall Study|Lack of Efficacy|1
6106140|NCT00793819|9723917|FG000|Overall Study|Withdrawal by Subject|4
6106141|NCT00793819|9723918|FG001|Overall Study|Withdrawal by Subject|3
6106142|NCT00793819|9723917|FG000|Overall Study|Lost to Follow-up|1
6106143|NCT00793819|9723918|FG001|Overall Study|Lost to Follow-up|1
6106144|NCT00793871|9723924|FG000|Overall Study|Death|50
6106145|NCT00793871|9723924|FG000|Overall Study|Lost to Follow-up|3
6106146|NCT00793871|9723924|FG000|Overall Study|Study terminated by the Sponsor|7
6106147|NCT00793910|9723930|FG000|Overall Study|discarded study pills|0
6106148|NCT00793910|9723931|FG001|Overall Study|discarded study pills|1
6106149|NCT00793910|9723930|FG000|Overall Study|did not pick up medications|1
6106150|NCT00793910|9723931|FG001|Overall Study|did not pick up medications|1
6106151|NCT00793910|9723930|FG000|Overall Study|ineligible based on entry criteria|2
6106152|NCT00793910|9723931|FG001|Overall Study|ineligible based on entry criteria|3
6106153|NCT00793910|9723930|FG000|Overall Study|decided to undergo LASIK instead of PRK|2
6106154|NCT00793910|9723931|FG001|Overall Study|decided to undergo LASIK instead of PRK|1
6106155|NCT00793910|9723930|FG000|Overall Study|Withdrawal by Subject|0
6106156|NCT00793910|9723931|FG001|Overall Study|Withdrawal by Subject|1
6106157|NCT00794040|9723939|FG000|Overall Study|Withdrawal by Subject|3
6106158|NCT00794040|9723940|FG001|Overall Study|Withdrawal by Subject|4
6106159|NCT00794040|9723939|FG000|Overall Study|Physician Decision|0
6106160|NCT00794040|9723940|FG001|Overall Study|Physician Decision|1
6106161|NCT00794118|9723946|FG000|Overall Study|Lost to Follow-up|16
6106162|NCT00794118|9723946|FG000|Overall Study|Withdrawal by Subject|9
6106163|NCT00794118|9723946|FG000|Overall Study|Changed hospital center|2
6106164|NCT00794157|9723962|FG000|Overall Study|Adverse Event|4
6106165|NCT00794157|9723963|FG001|Overall Study|Adverse Event|1
6106166|NCT00794157|9723964|FG002|Overall Study|Adverse Event|8
6106167|NCT00794157|9723962|FG000|Overall Study|Subject withdrew consent|2
6106168|NCT00794157|9723963|FG001|Overall Study|Subject withdrew consent|0
6106169|NCT00794157|9723964|FG002|Overall Study|Subject withdrew consent|3
6106170|NCT00794157|9723962|FG000|Overall Study|Lost to Follow-up|2
6106171|NCT00794157|9723963|FG001|Overall Study|Lost to Follow-up|0
6106172|NCT00794157|9723964|FG002|Overall Study|Lost to Follow-up|1
6106173|NCT00794157|9723962|FG000|Overall Study|Unsatisfactory therapeutic effect|1
6106174|NCT00794157|9723963|FG001|Overall Study|Unsatisfactory therapeutic effect|0
6106175|NCT00794157|9723964|FG002|Overall Study|Unsatisfactory therapeutic effect|2
6106176|NCT00794157|9723962|FG000|Overall Study|Administrative problems|1
6106177|NCT00794157|9723963|FG001|Overall Study|Administrative problems|7
6106178|NCT00794157|9723964|FG002|Overall Study|Administrative problems|4
6106179|NCT00794157|9723962|FG000|Overall Study|Abnormal test procedure result(s)|0
6106180|NCT00794157|9723963|FG001|Overall Study|Abnormal test procedure result(s)|1
6106181|NCT00794157|9723964|FG002|Overall Study|Abnormal test procedure result(s)|0
6106182|NCT00794157|9723962|FG000|Overall Study|Protocol deviation|0
6106183|NCT00794157|9723963|FG001|Overall Study|Protocol deviation|1
6106184|NCT00794157|9723964|FG002|Overall Study|Protocol deviation|1
6106185|NCT00794196|9723983|FG000|Overall Study|Lost to Follow-up|5
6106186|NCT00794196|9723984|FG001|Overall Study|Lost to Follow-up|23
6106187|NCT00794339|9724003|FG000|Overall Study|Withdrawal by Subject|3
6106188|NCT00794339|9724003|FG000|Overall Study|Ineligible|4
6106189|NCT00794339|9724003|FG000|Overall Study|Tx prior to ATSM|3
6106190|NCT00794339|9724003|FG000|Overall Study|ATSM imaging not complete or inadequate|3
6106191|NCT00794339|9724003|FG000|Overall Study|Tx not per protocol|1
6106192|NCT00794365|9724024|FG000|Overall Study|Lost to Follow-up|38
6106193|NCT00794365|9724024|FG000|Overall Study|Other|17
6106194|NCT00794365|9724024|FG000|Overall Study|Poor Compliance|11
6106195|NCT00794365|9724024|FG000|Overall Study|Adverse Event|10
6106196|NCT00794365|9724024|FG000|Overall Study|Lack of Efficacy|3
6205495|NCT01533493|9867939|FG000|Overall Study|Adverse Event|2
6205496|NCT01533493|9867940|FG001|Overall Study|Adverse Event|1
6205497|NCT01533493|9867939|FG000|Overall Study|Withdrawal by Subject|1
6205498|NCT01533493|9867940|FG001|Overall Study|Withdrawal by Subject|2
6205499|NCT01533493|9867939|FG000|Overall Study|Lost to Follow-up|2
6205500|NCT01533493|9867940|FG001|Overall Study|Lost to Follow-up|0
6205501|NCT01533688|9867958|FG000|Overall Study|Withdrawal by Subject|5
6205502|NCT01533688|9867959|FG001|Overall Study|Withdrawal by Subject|4
6205503|NCT01533688|9867960|FG002|Overall Study|Withdrawal by Subject|3
6205504|NCT01533688|9867958|FG000|Overall Study|Medically unstable|1
6205505|NCT01533688|9867959|FG001|Overall Study|Medically unstable|3
6205506|NCT01533688|9867960|FG002|Overall Study|Medically unstable|3
6205507|NCT01533688|9867958|FG000|Overall Study|Had colonoscopy at outside hospital|2
6205508|NCT01533688|9867959|FG001|Overall Study|Had colonoscopy at outside hospital|3
6205509|NCT01533688|9867960|FG002|Overall Study|Had colonoscopy at outside hospital|2
6205510|NCT01533922|9867970|FG000|Overall Study|Adverse Event|5
6205511|NCT01533922|9867971|FG001|Overall Study|Adverse Event|8
6205512|NCT01533922|9867972|FG002|Overall Study|Adverse Event|6
6205513|NCT01533922|9867973|FG003|Overall Study|Adverse Event|3
6205514|NCT01533922|9867974|FG004|Overall Study|Adverse Event|4
6205515|NCT01533922|9867970|FG000|Overall Study|Lack of Efficacy|0
6205516|NCT01533922|9867971|FG001|Overall Study|Lack of Efficacy|0
6205517|NCT01533922|9867972|FG002|Overall Study|Lack of Efficacy|1
6205518|NCT01533922|9867973|FG003|Overall Study|Lack of Efficacy|0
6205519|NCT01533922|9867974|FG004|Overall Study|Lack of Efficacy|0
6205520|NCT01533922|9867970|FG000|Overall Study|Protocol Violation|0
6205521|NCT01533922|9867971|FG001|Overall Study|Protocol Violation|3
6205522|NCT01533922|9867972|FG002|Overall Study|Protocol Violation|0
6205523|NCT01533922|9867973|FG003|Overall Study|Protocol Violation|0
6205524|NCT01533922|9867974|FG004|Overall Study|Protocol Violation|1
6205525|NCT01533922|9867970|FG000|Overall Study|Withdrawal by Subject|3
6205526|NCT01533922|9867971|FG001|Overall Study|Withdrawal by Subject|1
6205527|NCT01533922|9867972|FG002|Overall Study|Withdrawal by Subject|2
6205528|NCT01533922|9867973|FG003|Overall Study|Withdrawal by Subject|2
6205529|NCT01533922|9867974|FG004|Overall Study|Withdrawal by Subject|1
6205530|NCT01533922|9867970|FG000|Overall Study|Other reason not defined above|2
6205531|NCT01533922|9867971|FG001|Overall Study|Other reason not defined above|0
6205532|NCT01533922|9867972|FG002|Overall Study|Other reason not defined above|1
6285183|NCT02332707|9997081|FG008|Overall Study|Physician Decision|0
6285184|NCT02332707|9997082|FG009|Overall Study|Physician Decision|0
6285185|NCT02332707|9997083|FG010|Overall Study|Physician Decision|0
6285186|NCT02332707|9997084|FG011|Overall Study|Physician Decision|0
6285187|NCT02332707|9997085|FG012|Overall Study|Physician Decision|1
6285188|NCT02332707|9997086|FG013|Overall Study|Physician Decision|0
6285189|NCT02332707|9997087|FG014|Overall Study|Physician Decision|0
6285190|NCT02332707|9997088|FG015|Overall Study|Physician Decision|0
6285191|NCT02332707|9997089|FG016|Overall Study|Physician Decision|0
6285192|NCT02332707|9997090|FG017|Overall Study|Physician Decision|0
6285193|NCT02332707|9997073|FG000|Overall Study|Withdrawal by Subject|0
6285194|NCT02332707|9997074|FG001|Overall Study|Withdrawal by Subject|0
6285195|NCT02332707|9997075|FG002|Overall Study|Withdrawal by Subject|1
6285196|NCT02332707|9997076|FG003|Overall Study|Withdrawal by Subject|0
6285197|NCT02332707|9997077|FG004|Overall Study|Withdrawal by Subject|0
6285198|NCT02332707|9997078|FG005|Overall Study|Withdrawal by Subject|0
6285199|NCT02332707|9997079|FG006|Overall Study|Withdrawal by Subject|0
6285200|NCT02332707|9997080|FG007|Overall Study|Withdrawal by Subject|0
6285201|NCT02332707|9997081|FG008|Overall Study|Withdrawal by Subject|0
6285202|NCT02332707|9997082|FG009|Overall Study|Withdrawal by Subject|3
6205533|NCT01533922|9867973|FG003|Overall Study|Other reason not defined above|0
6205534|NCT01533922|9867974|FG004|Overall Study|Other reason not defined above|0
6285203|NCT02332707|9997083|FG010|Overall Study|Withdrawal by Subject|0
6285204|NCT02332707|9997084|FG011|Overall Study|Withdrawal by Subject|0
6285205|NCT02332707|9997085|FG012|Overall Study|Withdrawal by Subject|0
6106197|NCT00794417|9724032|FG000|Phase 1: Baseline (Day 1) up to Day 751|Death|0
6106198|NCT00794417|9724033|FG001|Phase 1: Baseline (Day 1) up to Day 751|Death|0
6106199|NCT00794417|9724034|FG002|Phase 1: Baseline (Day 1) up to Day 751|Death|2
6106200|NCT00794417|9724035|FG003|Phase 1: Baseline (Day 1) up to Day 751|Death|0
6106201|NCT00794417|9724032|FG000|Phase 1: Baseline (Day 1) up to Day 751|Other un-specified|3
6106202|NCT00794417|9724033|FG001|Phase 1: Baseline (Day 1) up to Day 751|Other un-specified|3
6106203|NCT00794417|9724034|FG002|Phase 1: Baseline (Day 1) up to Day 751|Other un-specified|1
6106204|NCT00794417|9724035|FG003|Phase 1: Baseline (Day 1) up to Day 751|Other un-specified|0
6106205|NCT00794417|9724032|FG000|Phase 2: Baseline (Day 421) to Day 972|Death|0
6106206|NCT00794417|9724033|FG001|Phase 2: Baseline (Day 421) to Day 972|Death|0
6106207|NCT00794417|9724034|FG002|Phase 2: Baseline (Day 421) to Day 972|Death|0
6106208|NCT00794417|9724035|FG003|Phase 2: Baseline (Day 421) to Day 972|Death|7
6106209|NCT00794417|9724032|FG000|Phase 2: Baseline (Day 421) to Day 972|Physician Decision|0
6106210|NCT00794417|9724033|FG001|Phase 2: Baseline (Day 421) to Day 972|Physician Decision|0
6106211|NCT00794417|9724034|FG002|Phase 2: Baseline (Day 421) to Day 972|Physician Decision|0
6106212|NCT00794417|9724035|FG003|Phase 2: Baseline (Day 421) to Day 972|Physician Decision|11
6106213|NCT00794417|9724032|FG000|Phase 2: Baseline (Day 421) to Day 972|Withdrawal by Subject|0
6106214|NCT00794417|9724033|FG001|Phase 2: Baseline (Day 421) to Day 972|Withdrawal by Subject|0
6106215|NCT00794417|9724034|FG002|Phase 2: Baseline (Day 421) to Day 972|Withdrawal by Subject|0
6106216|NCT00794417|9724035|FG003|Phase 2: Baseline (Day 421) to Day 972|Withdrawal by Subject|4
6106217|NCT00794417|9724032|FG000|Phase 2: Baseline (Day 421) to Day 972|Other unspecified|0
6106218|NCT00794417|9724033|FG001|Phase 2: Baseline (Day 421) to Day 972|Other unspecified|0
6106219|NCT00794417|9724034|FG002|Phase 2: Baseline (Day 421) to Day 972|Other unspecified|0
6106220|NCT00794417|9724035|FG003|Phase 2: Baseline (Day 421) to Day 972|Other unspecified|13
6106221|NCT00794573|9724079|FG000|Overall Study|Death|3
6106222|NCT00794573|9724080|FG001|Overall Study|Death|0
6106223|NCT00794573|9724079|FG000|Overall Study|Withdrawal by Subject|9
6106224|NCT00794573|9724080|FG001|Overall Study|Withdrawal by Subject|12
6106225|NCT00794573|9724079|FG000|Overall Study|Lost to Follow-up|26
6106226|NCT00794573|9724080|FG001|Overall Study|Lost to Follow-up|33
6106227|NCT00794664|9724088|FG000|Treatment Period|Withdrawal by Subject|0
6106228|NCT00794664|9724089|FG001|Treatment Period|Withdrawal by Subject|2
6106229|NCT00794664|9724088|FG000|Treatment Period|Protocol non-compliance|0
6106230|NCT00794664|9724089|FG001|Treatment Period|Protocol non-compliance|1
6106231|NCT00794664|9724088|FG000|Treatment Period|Other|0
6106232|NCT00794664|9724089|FG001|Treatment Period|Other|1
6106233|NCT00794664|9724088|FG000|Treatment Period|Adverse Event|1
6106234|NCT00794664|9724089|FG001|Treatment Period|Adverse Event|8
6106235|NCT00794664|9724088|FG000|Follow-up Period|Other|1
6106236|NCT00794664|9724089|FG001|Follow-up Period|Other|2
6106237|NCT00794664|9724088|FG000|Follow-up Period|Withdrawal by Subject|0
6106238|NCT00794664|9724089|FG001|Follow-up Period|Withdrawal by Subject|2
6106239|NCT00794664|9724088|FG000|Follow-up Period|Protocol non-compliance|0
6106240|NCT00794664|9724089|FG001|Follow-up Period|Protocol non-compliance|1
6106241|NCT00794820|9724095|FG000|Overall Study|Adverse Event|11
6106242|NCT00794820|9724095|FG000|Overall Study|Secondary Malignancies|2
6106243|NCT00794820|9724095|FG000|Overall Study|Resistant Disease|2
6106244|NCT00794820|9724095|FG000|Overall Study|Ineligible/Screen Failure|1
6106245|NCT00794950|9724099|FG000|BCG Induction|Withdrawal by Subject|2
6106246|NCT00794950|9724099|FG000|BCG Induction|ineligible|3
6106247|NCT00794950|9724099|FG000|BCG Induction|noncompliant w. BCG|1
6106248|NCT00794950|9724099|FG000|BCG Induction|Adverse Event|1
6106249|NCT00794950|9724099|FG000|Beginning Sunitinib Treatment|cystectomy|5
6106250|NCT00794950|9724099|FG000|Beginning Sunitinib Treatment|Physician Decision|5
6106251|NCT00794950|9724099|FG000|Beginning Sunitinib Treatment|Withdrawal by Subject|1
6106252|NCT00794950|9724099|FG000|Beginning Sunitinib Treatment|Lost to Follow-up|1
6106253|NCT00794963|9724106|FG000|Overall Study|Withdrawal by Subject|1
6106254|NCT00794963|9724107|FG001|Overall Study|Withdrawal by Subject|4
6106255|NCT00795132|9724122|FG000|Overall Study|Death|1
6106256|NCT00795132|9724122|FG000|Overall Study|Relapse|2
6106257|NCT00795184|9724169|FG000|Overall Study|Tissue sampling incomplete/conclusive|8
6106258|NCT00795184|9724170|FG001|Overall Study|Tissue sampling incomplete/conclusive|13
6106259|NCT00795509|9724232|FG000|Overall Study|Protocol Violation|31
6106260|NCT00795535|9724236|FG000|Overall Study|incomplete data and technical problems|20
6106261|NCT00795600|9724242|FG000|Overall Study|Adverse Event|1
6106262|NCT00795600|9724243|FG001|Overall Study|Adverse Event|1
6106263|NCT00795600|9724242|FG000|Overall Study|Protocol Violation|1
6106264|NCT00795600|9724243|FG001|Overall Study|Protocol Violation|2
6106265|NCT00795600|9724242|FG000|Overall Study|Withdrawal by Subject|1
6106266|NCT00795600|9724243|FG001|Overall Study|Withdrawal by Subject|0
6106267|NCT00795600|9724242|FG000|Overall Study|Unclassified|1
6106268|NCT00795600|9724243|FG001|Overall Study|Unclassified|1
6106269|NCT00795639|9724251|FG000|Overall Study|Death|1
6106270|NCT00795639|9724252|FG001|Overall Study|Death|6
6106271|NCT00795639|9724251|FG000|Overall Study|Withdrawal by Subject|1
6106272|NCT00795639|9724252|FG001|Overall Study|Withdrawal by Subject|3
6106273|NCT00795639|9724251|FG000|Overall Study|Pregnancy|1
6106274|NCT00795639|9724252|FG001|Overall Study|Pregnancy|0
6106275|NCT00795639|9724251|FG000|Overall Study|Adverse Event|5
6106276|NCT00795639|9724252|FG001|Overall Study|Adverse Event|2
6106277|NCT00795639|9724251|FG000|Overall Study|Other|0
6106278|NCT00795639|9724252|FG001|Overall Study|Other|2
6106279|NCT00795639|9724251|FG000|Overall Study|Terminated by sponsor|13
6106280|NCT00795639|9724252|FG001|Overall Study|Terminated by sponsor|12
6106281|NCT00795639|9724251|FG000|Overall Study|Randomized and not treated|0
6106282|NCT00795639|9724252|FG001|Overall Study|Randomized and not treated|1
6106283|NCT00795704|9724260|FG000|Overall Study|Withdrawal by Subject|3
6106284|NCT00795704|9724261|FG001|Overall Study|Withdrawal by Subject|2
6106285|NCT00795704|9724260|FG000|Overall Study|Adverse Event|1
6106286|NCT00795704|9724261|FG001|Overall Study|Adverse Event|1
6106287|NCT00795717|9724269|FG000|Phase I Followed by Wash Out x 4 Weeks|alcohol treatment|1
6106288|NCT00795717|9724270|FG001|Phase I Followed by Wash Out x 4 Weeks|alcohol treatment|0
6106289|NCT00795717|9724269|FG000|Phase I Followed by Wash Out x 4 Weeks|Adverse Event|1
6106290|NCT00795717|9724270|FG001|Phase I Followed by Wash Out x 4 Weeks|Adverse Event|1
6106291|NCT00795717|9724269|FG000|Phase I Followed by Wash Out x 4 Weeks|Lost to Follow-up|0
6106292|NCT00795717|9724270|FG001|Phase I Followed by Wash Out x 4 Weeks|Lost to Follow-up|1
6106293|NCT00795717|9724269|FG000|Phase II|too busy|0
6106294|NCT00795717|9724270|FG001|Phase II|too busy|1
6106295|NCT00795821|9724283|FG000|Acute Treatment Phase|Adverse Event|23
6106296|NCT00795821|9724284|FG001|Acute Treatment Phase|Adverse Event|4
6106297|NCT00795821|9724283|FG000|Acute Treatment Phase|Death|1
6106298|NCT00795821|9724284|FG001|Acute Treatment Phase|Death|0
6106299|NCT00795821|9724283|FG000|Acute Treatment Phase|Lack of Efficacy|5
6106300|NCT00795821|9724284|FG001|Acute Treatment Phase|Lack of Efficacy|2
6106301|NCT00795821|9724283|FG000|Acute Treatment Phase|Lost to Follow-up|9
6106302|NCT00795821|9724284|FG001|Acute Treatment Phase|Lost to Follow-up|12
6106303|NCT00795821|9724283|FG000|Acute Treatment Phase|Physician Decision|1
6106304|NCT00795821|9724284|FG001|Acute Treatment Phase|Physician Decision|1
6106305|NCT00795821|9724283|FG000|Acute Treatment Phase|Protocol Violation|1
6106306|NCT00795821|9724284|FG001|Acute Treatment Phase|Protocol Violation|2
6106307|NCT00795821|9724283|FG000|Acute Treatment Phase|Withdrawal by Subject|16
6106308|NCT00795821|9724284|FG001|Acute Treatment Phase|Withdrawal by Subject|10
6106309|NCT00795821|9724283|FG000|Long-term Extension Phase|Adverse Event|25
6106310|NCT00795821|9724284|FG001|Long-term Extension Phase|Adverse Event|32
6106311|NCT00795821|9724283|FG000|Long-term Extension Phase|Lack of Efficacy|16
6106312|NCT00795821|9724284|FG001|Long-term Extension Phase|Lack of Efficacy|12
6106313|NCT00795821|9724283|FG000|Long-term Extension Phase|Lost to Follow-up|20
6106314|NCT00795821|9724284|FG001|Long-term Extension Phase|Lost to Follow-up|16
6106315|NCT00795821|9724283|FG000|Long-term Extension Phase|Physician Decision|1
6106316|NCT00795821|9724284|FG001|Long-term Extension Phase|Physician Decision|2
6106317|NCT00795821|9724283|FG000|Long-term Extension Phase|Protocol Violation|3
6106318|NCT00795821|9724284|FG001|Long-term Extension Phase|Protocol Violation|5
6106319|NCT00795821|9724283|FG000|Long-term Extension Phase|Withdrawal by Subject|25
6106320|NCT00795821|9724284|FG001|Long-term Extension Phase|Withdrawal by Subject|25
6106321|NCT00795821|9724283|FG000|Taper Phase|Adverse Event|2
6106322|NCT00795821|9724284|FG001|Taper Phase|Adverse Event|0
6106323|NCT00795821|9724283|FG000|Taper Phase|Lost to Follow-up|1
6106324|NCT00795821|9724284|FG001|Taper Phase|Lost to Follow-up|0
6106325|NCT00795821|9724283|FG000|Taper Phase|Physician Decision|2
6106326|NCT00795821|9724284|FG001|Taper Phase|Physician Decision|0
6106327|NCT00795821|9724283|FG000|Taper Phase|Withdrawal by Subject|4
6106328|NCT00795821|9724284|FG001|Taper Phase|Withdrawal by Subject|0
6106329|NCT00795886|9724300|FG000|Overall Study|Death|10
6106330|NCT00795951|9724305|FG000|Overall Study|Lost to Follow-up|1
6106331|NCT00795951|9724305|FG000|Overall Study|Withdrawal by Subject|1
6106332|NCT00796003|9724312|FG000|Overall Study|Disease Progression|2
6106333|NCT00796003|9724313|FG001|Overall Study|Disease Progression|13
6106334|NCT00796003|9724312|FG000|Overall Study|Adverse Event|1
6106335|NCT00796003|9724313|FG001|Overall Study|Adverse Event|7
6106336|NCT00796003|9724312|FG000|Overall Study|Specified organ function not met|0
6106337|NCT00796003|9724313|FG001|Overall Study|Specified organ function not met|1
6106338|NCT00796003|9724312|FG000|Overall Study|Physician Decision|0
6106339|NCT00796003|9724313|FG001|Overall Study|Physician Decision|4
6106340|NCT00796003|9724312|FG000|Overall Study|Withdrawal by Subject|0
6205535|NCT01533935|9867986|FG000|Overall Study|Adverse Event|5
6205536|NCT01533935|9867987|FG001|Overall Study|Adverse Event|7
6205537|NCT01533935|9867988|FG002|Overall Study|Adverse Event|1
6205538|NCT01533935|9867989|FG003|Overall Study|Adverse Event|5
6106341|NCT00796003|9724313|FG001|Overall Study|Withdrawal by Subject|1
6106342|NCT00796003|9724312|FG000|Overall Study|Other|0
6106343|NCT00796003|9724313|FG001|Overall Study|Other|1
6106344|NCT00796003|9724312|FG000|Overall Study|Participants Not treated|0
6106345|NCT00796003|9724313|FG001|Overall Study|Participants Not treated|2
6106346|NCT00796120|9724324|FG000|Overall Study|Death|3
6106347|NCT00796120|9724325|FG001|Overall Study|Death|0
6106348|NCT00796120|9724324|FG000|Overall Study|Adverse Event|11
6106349|NCT00796120|9724325|FG001|Overall Study|Adverse Event|6
6106350|NCT00796120|9724324|FG000|Overall Study|Progressive disease|22
6106351|NCT00796120|9724325|FG001|Overall Study|Progressive disease|13
6106352|NCT00796120|9724324|FG000|Overall Study|Participant refusal|3
6106353|NCT00796120|9724325|FG001|Overall Study|Participant refusal|4
6106354|NCT00796120|9724324|FG000|Overall Study|Other|6
6205539|NCT01533935|9867990|FG004|Overall Study|Adverse Event|3
6106355|NCT00796120|9724325|FG001|Overall Study|Other|17
6106356|NCT00796120|9724324|FG000|Overall Study|Physician Decision|16
6106357|NCT00796120|9724325|FG001|Overall Study|Physician Decision|17
6106358|NCT00796120|9724324|FG000|Overall Study|Randomized but not treated|0
6106359|NCT00796120|9724325|FG001|Overall Study|Randomized but not treated|3
6106360|NCT00796224|9724333|FG000|Overall Study|Adverse Event|1
6106361|NCT00796224|9724334|FG001|Overall Study|Adverse Event|0
6106362|NCT00796224|9724333|FG000|Overall Study|Protocol Violation|0
6106363|NCT00796224|9724334|FG001|Overall Study|Protocol Violation|1
6106364|NCT00796315|9724352|FG000|Overall Study|Protocol Violation|0
6106365|NCT00796315|9724353|FG001|Overall Study|Protocol Violation|1
6106366|NCT00796315|9724354|FG002|Overall Study|Protocol Violation|0
6106367|NCT00796328|9724365|FG000|Overall Study|experienced hypotension requiring tx|6
6106368|NCT00796367|9724372|FG000|Overall Study|Adverse Event|6
6106369|NCT00796367|9724373|FG001|Overall Study|Adverse Event|4
6106370|NCT00796367|9724374|FG002|Overall Study|Adverse Event|7
6205540|NCT01533935|9867986|FG000|Overall Study|Protocol Violation|0
6205541|NCT01533935|9867987|FG001|Overall Study|Protocol Violation|2
6205542|NCT01533935|9867988|FG002|Overall Study|Protocol Violation|0
6205543|NCT01533935|9867989|FG003|Overall Study|Protocol Violation|0
6205544|NCT01533935|9867990|FG004|Overall Study|Protocol Violation|0
6205545|NCT01533935|9867986|FG000|Overall Study|Lost to Follow-up|0
6205546|NCT01533935|9867987|FG001|Overall Study|Lost to Follow-up|0
6205547|NCT01533935|9867988|FG002|Overall Study|Lost to Follow-up|1
6205548|NCT01533935|9867989|FG003|Overall Study|Lost to Follow-up|0
6205549|NCT01533935|9867990|FG004|Overall Study|Lost to Follow-up|0
6205550|NCT01533935|9867986|FG000|Overall Study|Withdrawal by Subject|0
6205551|NCT01533935|9867987|FG001|Overall Study|Withdrawal by Subject|4
6285206|NCT02332707|9997086|FG013|Overall Study|Withdrawal by Subject|0
6285207|NCT02332707|9997087|FG014|Overall Study|Withdrawal by Subject|0
6285208|NCT02332707|9997088|FG015|Overall Study|Withdrawal by Subject|0
6285209|NCT02332707|9997089|FG016|Overall Study|Withdrawal by Subject|0
6285210|NCT02332707|9997090|FG017|Overall Study|Withdrawal by Subject|0
6285211|NCT02332720|9997151|FG000|Part A and Part B|Lost to Follow-up|1
6285212|NCT02332720|9997152|FG001|Part A and Part B|Lost to Follow-up|0
6285213|NCT02332720|9997153|FG002|Part A and Part B|Lost to Follow-up|0
6285214|NCT02332720|9997154|FG003|Part A and Part B|Lost to Follow-up|0
6285215|NCT02332720|9997155|FG004|Part A and Part B|Lost to Follow-up|0
6285216|NCT02332720|9997156|FG005|Part A and Part B|Lost to Follow-up|2
6285217|NCT02332720|9997157|FG006|Part A and Part B|Lost to Follow-up|1
6285218|NCT02332720|9997158|FG007|Part A and Part B|Lost to Follow-up|1
6285219|NCT02332720|9997159|FG008|Part A and Part B|Lost to Follow-up|0
6285220|NCT02332720|9997160|FG009|Part A and Part B|Lost to Follow-up|0
6285221|NCT02332720|9997161|FG010|Part A and Part B|Lost to Follow-up|0
6285222|NCT02332720|9997162|FG011|Part A and Part B|Lost to Follow-up|0
6285223|NCT02332720|9997163|FG012|Part A and Part B|Lost to Follow-up|0
6285224|NCT02332720|9997164|FG013|Part A and Part B|Lost to Follow-up|0
6285225|NCT02332720|9997165|FG014|Part A and Part B|Lost to Follow-up|0
6285226|NCT02332720|9997166|FG015|Part A and Part B|Lost to Follow-up|1
6285227|NCT02332720|9997167|FG016|Part A and Part B|Lost to Follow-up|0
6285228|NCT02332720|9997168|FG017|Part A and Part B|Lost to Follow-up|0
6285229|NCT02332720|9997169|FG018|Part A and Part B|Lost to Follow-up|0
6285230|NCT02332720|9997170|FG019|Part A and Part B|Lost to Follow-up|0
6285231|NCT02332720|9997171|FG020|Part A and Part B|Lost to Follow-up|0
6285232|NCT02332720|9997172|FG021|Part A and Part B|Lost to Follow-up|0
6285233|NCT02332720|9997173|FG022|Part A and Part B|Lost to Follow-up|0
6285234|NCT02332720|9997151|FG000|Part A and Part B|Adverse Event|0
6285235|NCT02332720|9997152|FG001|Part A and Part B|Adverse Event|0
6285236|NCT02332720|9997153|FG002|Part A and Part B|Adverse Event|0
6285237|NCT02332720|9997154|FG003|Part A and Part B|Adverse Event|0
6285238|NCT02332720|9997155|FG004|Part A and Part B|Adverse Event|0
6285239|NCT02332720|9997156|FG005|Part A and Part B|Adverse Event|0
6285240|NCT02332720|9997157|FG006|Part A and Part B|Adverse Event|0
6285241|NCT02332720|9997158|FG007|Part A and Part B|Adverse Event|0
6285242|NCT02332720|9997159|FG008|Part A and Part B|Adverse Event|0
6285243|NCT02332720|9997160|FG009|Part A and Part B|Adverse Event|0
6285244|NCT02332720|9997161|FG010|Part A and Part B|Adverse Event|0
6285245|NCT02332720|9997162|FG011|Part A and Part B|Adverse Event|0
6285246|NCT02332720|9997163|FG012|Part A and Part B|Adverse Event|0
6285247|NCT02332720|9997164|FG013|Part A and Part B|Adverse Event|0
6285248|NCT02332720|9997165|FG014|Part A and Part B|Adverse Event|0
6285249|NCT02332720|9997166|FG015|Part A and Part B|Adverse Event|0
6106371|NCT00796367|9724372|FG000|Overall Study|Lost to Follow-up|5
6106372|NCT00796367|9724373|FG001|Overall Study|Lost to Follow-up|4
6106373|NCT00796367|9724374|FG002|Overall Study|Lost to Follow-up|21
6106374|NCT00796367|9724372|FG000|Overall Study|Withdrawal by Subject|9
6285250|NCT02332720|9997167|FG016|Part A and Part B|Adverse Event|0
6285251|NCT02332720|9997168|FG017|Part A and Part B|Adverse Event|1
6285252|NCT02332720|9997169|FG018|Part A and Part B|Adverse Event|0
6285253|NCT02332720|9997170|FG019|Part A and Part B|Adverse Event|0
6285254|NCT02332720|9997171|FG020|Part A and Part B|Adverse Event|0
6285255|NCT02332720|9997172|FG021|Part A and Part B|Adverse Event|0
6285256|NCT02332720|9997173|FG022|Part A and Part B|Adverse Event|0
6106375|NCT00796367|9724373|FG001|Overall Study|Withdrawal by Subject|11
6205552|NCT01533935|9867988|FG002|Overall Study|Withdrawal by Subject|5
6106376|NCT00796367|9724374|FG002|Overall Study|Withdrawal by Subject|12
6106377|NCT00796367|9724372|FG000|Overall Study|Lack of Efficacy|2
6106378|NCT00796367|9724373|FG001|Overall Study|Lack of Efficacy|1
6106379|NCT00796367|9724374|FG002|Overall Study|Lack of Efficacy|0
6106380|NCT00796367|9724372|FG000|Overall Study|non compliance|3
6106381|NCT00796367|9724373|FG001|Overall Study|non compliance|1
6106382|NCT00796367|9724374|FG002|Overall Study|non compliance|1
6106383|NCT00796367|9724372|FG000|Overall Study|Pregnancy|1
6106384|NCT00796367|9724373|FG001|Overall Study|Pregnancy|0
6106385|NCT00796367|9724374|FG002|Overall Study|Pregnancy|1
6106386|NCT00796367|9724372|FG000|Overall Study|Requirement for restricted medication|2
6106387|NCT00796367|9724373|FG001|Overall Study|Requirement for restricted medication|0
6106388|NCT00796367|9724374|FG002|Overall Study|Requirement for restricted medication|2
6106389|NCT00796367|9724372|FG000|Overall Study|other|2
6106390|NCT00796367|9724373|FG001|Overall Study|other|4
6106391|NCT00796367|9724374|FG002|Overall Study|other|3
6106392|NCT00796419|9724384|FG000|Overall Study|Death|0
6106393|NCT00796419|9724385|FG001|Overall Study|Death|1
6106394|NCT00796445|9724393|FG000|Overall Study|Protocol Violation|5
6106395|NCT00796445|9724394|FG001|Overall Study|Protocol Violation|3
6106396|NCT00796445|9724393|FG000|Overall Study|Adverse event, serious fatal|10
6106397|NCT00796445|9724394|FG001|Overall Study|Adverse event, serious fatal|5
6106398|NCT00796445|9724393|FG000|Overall Study|Adverse event, non-fatal|4
6106399|NCT00796445|9724394|FG001|Overall Study|Adverse event, non-fatal|0
6106400|NCT00796445|9724393|FG000|Overall Study|Disease progression/recurrence|537
6106401|NCT00796445|9724394|FG001|Overall Study|Disease progression/recurrence|268
6106402|NCT00796445|9724393|FG000|Overall Study|Other|10
6106403|NCT00796445|9724394|FG001|Overall Study|Other|7
6106404|NCT00796445|9724393|FG000|Overall Study|Withdrawal by Subject|18
6106405|NCT00796445|9724394|FG001|Overall Study|Withdrawal by Subject|9
6106406|NCT00796445|9724393|FG000|Overall Study|Invalid Informed Consent Form|1
6106407|NCT00796445|9724394|FG001|Overall Study|Invalid Informed Consent Form|0
6106408|NCT00796549|9724408|FG000|Overall Study|Adverse Event|11
6106409|NCT00796549|9724408|FG000|Overall Study|not entered|149
6106410|NCT00796549|9724408|FG000|Overall Study|Other|2
6106411|NCT00796549|9724408|FG000|Overall Study|Progressive disease|56
6106412|NCT00796562|9724414|FG000|Overall Study|Death|49
6106413|NCT00796614|9724422|FG000|Overall Study|Adverse Event|1
6106414|NCT00796614|9724423|FG001|Overall Study|Adverse Event|2
6106415|NCT00796614|9724424|FG002|Overall Study|Adverse Event|0
6106416|NCT00796614|9724425|FG003|Overall Study|Adverse Event|0
6205553|NCT01533935|9867989|FG003|Overall Study|Withdrawal by Subject|2
6205554|NCT01533935|9867990|FG004|Overall Study|Withdrawal by Subject|4
6205555|NCT01533935|9867986|FG000|Overall Study|Other reason not defined above|1
6205556|NCT01533935|9867987|FG001|Overall Study|Other reason not defined above|0
6205557|NCT01533935|9867988|FG002|Overall Study|Other reason not defined above|1
6205558|NCT01533935|9867989|FG003|Overall Study|Other reason not defined above|0
6205559|NCT01533935|9867990|FG004|Overall Study|Other reason not defined above|1
6205560|NCT01534078|9868028|FG000|Overall Study|Death|1
6205561|NCT01534078|9868028|FG000|Overall Study|Withdrawal by Subject|1
6205562|NCT01534182|9868034|FG000|Overall Study|Administrative problems|1
6205563|NCT01534182|9868035|FG001|Overall Study|Administrative problems|0
6205564|NCT01534182|9868034|FG000|Overall Study|Withdrawal by Subject|4
6205565|NCT01534182|9868035|FG001|Overall Study|Withdrawal by Subject|7
6205566|NCT01534182|9868034|FG000|Overall Study|Adverse Event|7
6205567|NCT01534182|9868035|FG001|Overall Study|Adverse Event|3
6205568|NCT01534195|9868044|FG000|Overall Study|Withdrawal by Subject|1
6205569|NCT01534195|9868045|FG001|Overall Study|Withdrawal by Subject|1
6205570|NCT01534208|9868053|FG000|Overall Study|Lost to Follow-up|19
6205571|NCT01534208|9868054|FG001|Overall Study|Lost to Follow-up|14
6205572|NCT01534208|9868053|FG000|Overall Study|Withdrawal by Subject|6
6205573|NCT01534208|9868054|FG001|Overall Study|Withdrawal by Subject|20
6205574|NCT01534208|9868053|FG000|Overall Study|Adverse Event|15
6205575|NCT01534208|9868054|FG001|Overall Study|Adverse Event|8
6205576|NCT01534208|9868053|FG000|Overall Study|Physician Decision|2
6205577|NCT01534208|9868054|FG001|Overall Study|Physician Decision|0
6205578|NCT01534208|9868053|FG000|Overall Study|Lack of Efficacy|0
6205579|NCT01534208|9868054|FG001|Overall Study|Lack of Efficacy|3
6205580|NCT01534208|9868053|FG000|Overall Study|Protocol Violation|2
6205581|NCT01534208|9868054|FG001|Overall Study|Protocol Violation|2
6205582|NCT01534208|9868053|FG000|Overall Study|Sponsor decision|4
6285257|NCT02332720|9997151|FG000|Part A and Part B|Physician Decision|0
6106417|NCT00796614|9724422|FG000|Overall Study|Protocol Violation|0
6106418|NCT00796614|9724423|FG001|Overall Study|Protocol Violation|0
6205583|NCT01534208|9868054|FG001|Overall Study|Sponsor decision|1
6205584|NCT01534208|9868053|FG000|Overall Study|Subject relocation|2
6205585|NCT01534208|9868054|FG001|Overall Study|Subject relocation|0
6205586|NCT01534208|9868053|FG000|Overall Study|Lab assessment|2
6106419|NCT00796614|9724424|FG002|Overall Study|Protocol Violation|2
6106420|NCT00796614|9724425|FG003|Overall Study|Protocol Violation|0
6106421|NCT00796614|9724422|FG000|Overall Study|Lost to Follow-up|2
6106422|NCT00796614|9724423|FG001|Overall Study|Lost to Follow-up|2
6205587|NCT01534208|9868054|FG001|Overall Study|Lab assessment|1
6106423|NCT00796614|9724424|FG002|Overall Study|Lost to Follow-up|1
6106424|NCT00796614|9724425|FG003|Overall Study|Lost to Follow-up|0
6106425|NCT00796614|9724422|FG000|Overall Study|Withdrawal by Subject|1
6106426|NCT00796614|9724423|FG001|Overall Study|Withdrawal by Subject|0
6106427|NCT00796614|9724424|FG002|Overall Study|Withdrawal by Subject|0
6106428|NCT00796614|9724425|FG003|Overall Study|Withdrawal by Subject|1
6106429|NCT00796614|9724422|FG000|Overall Study|Other than stated|1
6106430|NCT00796614|9724423|FG001|Overall Study|Other than stated|0
6106431|NCT00796614|9724424|FG002|Overall Study|Other than stated|0
6106432|NCT00796614|9724425|FG003|Overall Study|Other than stated|0
6106433|NCT00796653|9724448|FG000|Overall Study|Adverse Event|19
6106434|NCT00796653|9724449|FG001|Overall Study|Adverse Event|16
6106435|NCT00796653|9724450|FG002|Overall Study|Adverse Event|16
6106436|NCT00796653|9724451|FG003|Overall Study|Adverse Event|16
6106437|NCT00796653|9724448|FG000|Overall Study|Lost to Follow-up|2
6106438|NCT00796653|9724449|FG001|Overall Study|Lost to Follow-up|1
6106439|NCT00796653|9724450|FG002|Overall Study|Lost to Follow-up|2
6106440|NCT00796653|9724451|FG003|Overall Study|Lost to Follow-up|3
6106441|NCT00796653|9724448|FG000|Overall Study|Withdrawal by Subject|16
6106442|NCT00796653|9724449|FG001|Overall Study|Withdrawal by Subject|8
6106443|NCT00796653|9724450|FG002|Overall Study|Withdrawal by Subject|8
6106444|NCT00796653|9724451|FG003|Overall Study|Withdrawal by Subject|13
6106445|NCT00796653|9724448|FG000|Overall Study|Lack of Efficacy|8
6106446|NCT00796653|9724449|FG001|Overall Study|Lack of Efficacy|1
6106447|NCT00796653|9724450|FG002|Overall Study|Lack of Efficacy|3
6106448|NCT00796653|9724451|FG003|Overall Study|Lack of Efficacy|2
6106449|NCT00796653|9724448|FG000|Overall Study|Non compliance with protocol|2
6106450|NCT00796653|9724449|FG001|Overall Study|Non compliance with protocol|2
6106451|NCT00796653|9724450|FG002|Overall Study|Non compliance with protocol|0
6106452|NCT00796653|9724451|FG003|Overall Study|Non compliance with protocol|2
6106453|NCT00796653|9724448|FG000|Overall Study|Other reason not described above|4
6106454|NCT00796653|9724449|FG001|Overall Study|Other reason not described above|9
6106455|NCT00796653|9724450|FG002|Overall Study|Other reason not described above|7
6106456|NCT00796653|9724451|FG003|Overall Study|Other reason not described above|4
6106457|NCT00796666|9724471|FG000|Overall Study|Death|2
6106458|NCT00796666|9724472|FG001|Overall Study|Death|4
6106459|NCT00796666|9724471|FG000|Overall Study|Withdrawal by Subject|2
6106460|NCT00796666|9724472|FG001|Overall Study|Withdrawal by Subject|0
6106461|NCT00796666|9724471|FG000|Overall Study|Adverse Event|7
6106462|NCT00796666|9724472|FG001|Overall Study|Adverse Event|5
6106463|NCT00796666|9724471|FG000|Overall Study|Protocol Violation|1
6106464|NCT00796666|9724472|FG001|Overall Study|Protocol Violation|0
6106465|NCT00796666|9724471|FG000|Overall Study|Other|1
6106466|NCT00796666|9724472|FG001|Overall Study|Other|0
6106467|NCT00796666|9724471|FG000|Overall Study|Terminated by sponsor|53
6106468|NCT00796666|9724472|FG001|Overall Study|Terminated by sponsor|55
6106469|NCT00796666|9724471|FG000|Overall Study|Randomized and not treated|1
6106470|NCT00796666|9724472|FG001|Overall Study|Randomized and not treated|0
6106471|NCT00796718|9724497|FG000|Overall Study|Adverse Event|2
6106472|NCT00796718|9724497|FG000|Overall Study|Exclusion Criteria|1
6106473|NCT00796718|9724497|FG000|Overall Study|Lost to Follow-up|5
6106474|NCT00796718|9724497|FG000|Overall Study|Withdrawal by Informed Consent|1
6106475|NCT00796757|9724516|FG000|Overall Study|Withdrawal by Subject|14
6106476|NCT00796757|9724516|FG000|Overall Study|Death|61
6106477|NCT00796757|9724516|FG000|Overall Study|Protocol Violation|1
6106478|NCT00796757|9724516|FG000|Overall Study|Participant noncompliance|1
6106479|NCT00796757|9724516|FG000|Overall Study|Investigator's decision|2
6106480|NCT00796757|9724516|FG000|Overall Study|Other|7
6106481|NCT00796822|9724522|FG000|Overall Study|Lost to Follow-up|2
6106482|NCT00796822|9724523|FG001|Overall Study|Lost to Follow-up|0
6106483|NCT00796822|9724522|FG000|Overall Study|Adverse Event|1
6106484|NCT00796822|9724523|FG001|Overall Study|Adverse Event|0
6106485|NCT00796978|9724538|FG000|Overall Study|Cardiac adverse event|5
6106486|NCT00796978|9724538|FG000|Overall Study|Adverse Event|4
6106487|NCT00796978|9724538|FG000|Overall Study|Withdrawal by Subject|3
6106488|NCT00796991|9724545|FG000|Overall Study|Adverse Event|0
6106489|NCT00796991|9724546|FG001|Overall Study|Adverse Event|0
6106490|NCT00796991|9724547|FG002|Overall Study|Adverse Event|1
6106491|NCT00796991|9724545|FG000|Overall Study|Death|2
6106492|NCT00796991|9724546|FG001|Overall Study|Death|0
6106493|NCT00796991|9724547|FG002|Overall Study|Death|0
6106494|NCT00796991|9724545|FG000|Overall Study|Disease Progression|10
6106495|NCT00796991|9724546|FG001|Overall Study|Disease Progression|9
6106496|NCT00796991|9724547|FG002|Overall Study|Disease Progression|7
6106497|NCT00796991|9724545|FG000|Overall Study|Study Drug Toxicity|3
6106498|NCT00796991|9724546|FG001|Overall Study|Study Drug Toxicity|3
6106499|NCT00796991|9724547|FG002|Overall Study|Study Drug Toxicity|5
6106500|NCT00796991|9724545|FG000|Overall Study|Withdrawal by Subject|0
6106501|NCT00796991|9724546|FG001|Overall Study|Withdrawal by Subject|0
6106502|NCT00796991|9724547|FG002|Overall Study|Withdrawal by Subject|1
6106503|NCT00797108|9724558|FG000|Overall Study|Adverse Event|1
6106504|NCT00797108|9724559|FG001|Overall Study|Adverse Event|0
6106505|NCT00797108|9724560|FG002|Overall Study|Adverse Event|3
6106506|NCT00797108|9724558|FG000|Overall Study|Did Not Meet Entrance Criteria|0
6106507|NCT00797108|9724559|FG001|Overall Study|Did Not Meet Entrance Criteria|1
6106508|NCT00797108|9724560|FG002|Overall Study|Did Not Meet Entrance Criteria|0
6106509|NCT00797108|9724558|FG000|Overall Study|Global Deterioration of Health Status|0
6106510|NCT00797108|9724559|FG001|Overall Study|Global Deterioration of Health Status|1
6106511|NCT00797108|9724560|FG002|Overall Study|Global Deterioration of Health Status|0
6106512|NCT00797108|9724558|FG000|Overall Study|Lack of Efficacy|1
6106513|NCT00797108|9724559|FG001|Overall Study|Lack of Efficacy|0
6106514|NCT00797108|9724560|FG002|Overall Study|Lack of Efficacy|1
6106515|NCT00797108|9724558|FG000|Overall Study|Other|0
6106516|NCT00797108|9724559|FG001|Overall Study|Other|0
6106517|NCT00797108|9724560|FG002|Overall Study|Other|2
6106518|NCT00797108|9724558|FG000|Overall Study|Randomized but not Treated|2
6106519|NCT00797108|9724559|FG001|Overall Study|Randomized but not Treated|0
6106520|NCT00797108|9724560|FG002|Overall Study|Randomized but not Treated|0
6106521|NCT00797225|9724576|FG000|Weeks 1 to 12|Adverse Event|0
6106522|NCT00797225|9724577|FG001|Weeks 1 to 12|Adverse Event|0
6106523|NCT00797225|9724578|FG002|Weeks 1 to 12|Adverse Event|1
6106524|NCT00797225|9724579|FG003|Weeks 1 to 12|Adverse Event|0
6106525|NCT00797225|9724580|FG004|Weeks 1 to 12|Adverse Event|0
6106526|NCT00797225|9724581|FG005|Weeks 1 to 12|Adverse Event|0
6106527|NCT00797225|9724582|FG006|Weeks 1 to 12|Adverse Event|0
6106528|NCT00797225|9724583|FG007|Weeks 1 to 12|Adverse Event|0
6106529|NCT00797225|9724576|FG000|Weeks 1 to 12|Non-compliance|0
6106530|NCT00797225|9724577|FG001|Weeks 1 to 12|Non-compliance|1
6106531|NCT00797225|9724578|FG002|Weeks 1 to 12|Non-compliance|0
6106532|NCT00797225|9724579|FG003|Weeks 1 to 12|Non-compliance|0
6106533|NCT00797225|9724580|FG004|Weeks 1 to 12|Non-compliance|0
6106534|NCT00797225|9724581|FG005|Weeks 1 to 12|Non-compliance|0
6106535|NCT00797225|9724582|FG006|Weeks 1 to 12|Non-compliance|0
6106536|NCT00797225|9724583|FG007|Weeks 1 to 12|Non-compliance|0
6106537|NCT00797225|9724576|FG000|Weeks 1 to 12|Lack of Efficacy|1
6106538|NCT00797225|9724577|FG001|Weeks 1 to 12|Lack of Efficacy|0
6106539|NCT00797225|9724578|FG002|Weeks 1 to 12|Lack of Efficacy|0
6106540|NCT00797225|9724579|FG003|Weeks 1 to 12|Lack of Efficacy|0
6205588|NCT01534208|9868053|FG000|Overall Study|Eligibility error|3
6205589|NCT01534208|9868054|FG001|Overall Study|Eligibility error|0
6205590|NCT01534208|9868053|FG000|Overall Study|PCP decision|1
6205591|NCT01534208|9868054|FG001|Overall Study|PCP decision|0
6205592|NCT01534208|9868053|FG000|Overall Study|Needed prohibited meds|1
6205593|NCT01534208|9868054|FG001|Overall Study|Needed prohibited meds|0
6205594|NCT01534260|9868062|FG000|Overall Study|Adverse Event|1
6205595|NCT01534260|9868063|FG001|Overall Study|Adverse Event|8
6205596|NCT01534260|9868062|FG000|Overall Study|Death|2
6205597|NCT01534260|9868063|FG001|Overall Study|Death|0
6205598|NCT01534260|9868062|FG000|Overall Study|Lack of Efficacy|1
6205599|NCT01534260|9868063|FG001|Overall Study|Lack of Efficacy|1
6205600|NCT01534260|9868062|FG000|Overall Study|Withdrawal by Subject|1
6205601|NCT01534260|9868063|FG001|Overall Study|Withdrawal by Subject|3
6205602|NCT01534260|9868062|FG000|Overall Study|Disease Progression|8
6205603|NCT01534260|9868063|FG001|Overall Study|Disease Progression|6
6205604|NCT01534260|9868062|FG000|Overall Study|Physician Decision|3
6205605|NCT01534260|9868063|FG001|Overall Study|Physician Decision|1
6205606|NCT01534260|9868062|FG000|Overall Study|No treatment, per protocol|0
6205607|NCT01534260|9868063|FG001|Overall Study|No treatment, per protocol|1
6205608|NCT01534273|9868073|FG000|Period 1|Physician Decision|0
6205609|NCT01534273|9868074|FG001|Period 1|Physician Decision|0
6205610|NCT01534273|9868075|FG002|Period 1|Physician Decision|0
6205611|NCT01534273|9868076|FG003|Period 1|Physician Decision|1
6205612|NCT01534273|9868077|FG004|Period 1|Physician Decision|0
6205613|NCT01534273|9868078|FG005|Period 1|Physician Decision|0
6205614|NCT01534273|9868079|FG006|Period 1|Physician Decision|0
6205615|NCT01534351|9868103|FG000|Overall Study|Study Terminated Early|1
6205616|NCT01534351|9868104|FG001|Overall Study|Study Terminated Early|0
6205617|NCT01534351|9868105|FG002|Overall Study|Study Terminated Early|0
6205618|NCT01534520|9868134|FG000|Overall Study|Adverse Event|0
6205619|NCT01534520|9868135|FG001|Overall Study|Adverse Event|1
6205620|NCT01534533|9868149|FG000|Overall Study|Lost to Follow-up|3
6205621|NCT01534533|9868150|FG001|Overall Study|Lost to Follow-up|0
6205622|NCT01534533|9868151|FG002|Overall Study|Lost to Follow-up|4
6205623|NCT01534533|9868152|FG003|Overall Study|Lost to Follow-up|3
6205624|NCT01534533|9868149|FG000|Overall Study|Withdrawal by Subject|5
6205625|NCT01534533|9868150|FG001|Overall Study|Withdrawal by Subject|3
6285258|NCT02332720|9997152|FG001|Part A and Part B|Physician Decision|0
6205626|NCT01534533|9868151|FG002|Overall Study|Withdrawal by Subject|4
6205627|NCT01534533|9868152|FG003|Overall Study|Withdrawal by Subject|1
6205628|NCT01534637|9868164|FG000|Overall Study|Physician Decision|3
6205629|NCT01534637|9868164|FG000|Overall Study|Lack of Efficacy|3
6205630|NCT01534637|9868164|FG000|Overall Study|Withdrawal by Subject|1
6205631|NCT01534637|9868164|FG000|Overall Study|Adverse Event|1
6205632|NCT01534637|9868164|FG000|Overall Study|Liver Mets before treatment|1
6205633|NCT01534663|9868170|FG000|Overall Study|Lost to Follow-up|0
6205634|NCT01534663|9868171|FG001|Overall Study|Lost to Follow-up|2
6205635|NCT01534663|9868170|FG000|Overall Study|Adverse Event|2
6205636|NCT01534663|9868171|FG001|Overall Study|Adverse Event|1
6106541|NCT00797225|9724580|FG004|Weeks 1 to 12|Lack of Efficacy|0
6106542|NCT00797225|9724581|FG005|Weeks 1 to 12|Lack of Efficacy|0
6106543|NCT00797225|9724582|FG006|Weeks 1 to 12|Lack of Efficacy|0
6106544|NCT00797225|9724583|FG007|Weeks 1 to 12|Lack of Efficacy|0
6205637|NCT01534962|9868201|FG000|Overall Study|Randomized but did not start treatment|2
6106545|NCT00797225|9724576|FG000|Weeks 1 to 12|Sponsor Decision|1
6106546|NCT00797225|9724577|FG001|Weeks 1 to 12|Sponsor Decision|0
6106547|NCT00797225|9724578|FG002|Weeks 1 to 12|Sponsor Decision|0
6106548|NCT00797225|9724579|FG003|Weeks 1 to 12|Sponsor Decision|0
6106549|NCT00797225|9724580|FG004|Weeks 1 to 12|Sponsor Decision|0
6106550|NCT00797225|9724581|FG005|Weeks 1 to 12|Sponsor Decision|0
6106551|NCT00797225|9724582|FG006|Weeks 1 to 12|Sponsor Decision|0
6106552|NCT00797225|9724583|FG007|Weeks 1 to 12|Sponsor Decision|0
6106553|NCT00797225|9724576|FG000|Weeks 13 to 24|Non-compliance|0
6106554|NCT00797225|9724577|FG001|Weeks 13 to 24|Non-compliance|2
6106555|NCT00797225|9724578|FG002|Weeks 13 to 24|Non-compliance|0
6106556|NCT00797225|9724579|FG003|Weeks 13 to 24|Non-compliance|0
6106557|NCT00797225|9724580|FG004|Weeks 13 to 24|Non-compliance|0
6106558|NCT00797225|9724581|FG005|Weeks 13 to 24|Non-compliance|0
6106559|NCT00797225|9724582|FG006|Weeks 13 to 24|Non-compliance|0
6106560|NCT00797225|9724583|FG007|Weeks 13 to 24|Non-compliance|0
6106561|NCT00797225|9724576|FG000|Weeks 13 to 24|Withdrawal by Subject|0
6106562|NCT00797225|9724577|FG001|Weeks 13 to 24|Withdrawal by Subject|1
6106563|NCT00797225|9724578|FG002|Weeks 13 to 24|Withdrawal by Subject|1
6106564|NCT00797225|9724579|FG003|Weeks 13 to 24|Withdrawal by Subject|0
6106565|NCT00797225|9724580|FG004|Weeks 13 to 24|Withdrawal by Subject|0
6106566|NCT00797225|9724581|FG005|Weeks 13 to 24|Withdrawal by Subject|0
6106567|NCT00797225|9724582|FG006|Weeks 13 to 24|Withdrawal by Subject|0
6106568|NCT00797225|9724583|FG007|Weeks 13 to 24|Withdrawal by Subject|0
6106569|NCT00797225|9724576|FG000|Weeks 13 to 24|Lost to Follow-up|0
6106570|NCT00797225|9724577|FG001|Weeks 13 to 24|Lost to Follow-up|0
6106571|NCT00797225|9724578|FG002|Weeks 13 to 24|Lost to Follow-up|1
6106572|NCT00797225|9724579|FG003|Weeks 13 to 24|Lost to Follow-up|0
6106573|NCT00797225|9724580|FG004|Weeks 13 to 24|Lost to Follow-up|1
6106574|NCT00797225|9724581|FG005|Weeks 13 to 24|Lost to Follow-up|0
6106575|NCT00797225|9724582|FG006|Weeks 13 to 24|Lost to Follow-up|0
6106576|NCT00797225|9724583|FG007|Weeks 13 to 24|Lost to Follow-up|0
6106577|NCT00797225|9724576|FG000|Weeks 13 to 24|Adverse Event|0
6106578|NCT00797225|9724577|FG001|Weeks 13 to 24|Adverse Event|1
6106579|NCT00797225|9724578|FG002|Weeks 13 to 24|Adverse Event|0
6106580|NCT00797225|9724579|FG003|Weeks 13 to 24|Adverse Event|0
6106581|NCT00797225|9724580|FG004|Weeks 13 to 24|Adverse Event|0
6106582|NCT00797225|9724581|FG005|Weeks 13 to 24|Adverse Event|0
6106583|NCT00797225|9724582|FG006|Weeks 13 to 24|Adverse Event|1
6106584|NCT00797225|9724583|FG007|Weeks 13 to 24|Adverse Event|0
6106585|NCT00797225|9724576|FG000|Weeks 13 to 24|Sponsor Decision|0
6106586|NCT00797225|9724577|FG001|Weeks 13 to 24|Sponsor Decision|0
6106587|NCT00797225|9724578|FG002|Weeks 13 to 24|Sponsor Decision|0
6106588|NCT00797225|9724579|FG003|Weeks 13 to 24|Sponsor Decision|0
6106589|NCT00797225|9724580|FG004|Weeks 13 to 24|Sponsor Decision|0
6106590|NCT00797225|9724581|FG005|Weeks 13 to 24|Sponsor Decision|0
6106591|NCT00797225|9724582|FG006|Weeks 13 to 24|Sponsor Decision|1
6106592|NCT00797225|9724583|FG007|Weeks 13 to 24|Sponsor Decision|0
6106593|NCT00797316|9724611|FG000|Overall Study|Administrative problems|1
6106594|NCT00797316|9724612|FG001|Overall Study|Administrative problems|0
6106595|NCT00797316|9724611|FG000|Overall Study|Adverse Event|5
6106596|NCT00797316|9724612|FG001|Overall Study|Adverse Event|3
6106597|NCT00797316|9724611|FG000|Overall Study|Lost to Follow-up|4
6106598|NCT00797316|9724612|FG001|Overall Study|Lost to Follow-up|8
6106599|NCT00797316|9724611|FG000|Overall Study|Protocol Deviation|1
6106600|NCT00797316|9724612|FG001|Overall Study|Protocol Deviation|2
6106601|NCT00797316|9724611|FG000|Overall Study|Patient withdrew consent|12
6106602|NCT00797316|9724612|FG001|Overall Study|Patient withdrew consent|6
6106603|NCT00797316|9724611|FG000|Overall Study|Unsatisfactory therapeutic effect|0
6106604|NCT00797316|9724612|FG001|Overall Study|Unsatisfactory therapeutic effect|13
6106605|NCT00797511|9724626|FG000|Overall Study|Withdrawal by Subject|1
6106606|NCT00797563|9724631|FG000|Overall Study|Adverse Event|1
6106607|NCT00797667|9724638|FG000|Overall Study|Lack of Efficacy|0
6106608|NCT00797667|9724639|FG001|Overall Study|Lack of Efficacy|1
6106609|NCT00797667|9724640|FG002|Overall Study|Lack of Efficacy|0
6106610|NCT00797667|9724638|FG000|Overall Study|Lost to Follow-up|8
6106611|NCT00797667|9724639|FG001|Overall Study|Lost to Follow-up|12
6106612|NCT00797667|9724640|FG002|Overall Study|Lost to Follow-up|2
6106613|NCT00797667|9724638|FG000|Overall Study|Physician Decision|3
6106614|NCT00797667|9724639|FG001|Overall Study|Physician Decision|1
6106615|NCT00797667|9724640|FG002|Overall Study|Physician Decision|0
6106616|NCT00797667|9724638|FG000|Overall Study|Pregnancy|2
6106617|NCT00797667|9724639|FG001|Overall Study|Pregnancy|0
6106618|NCT00797667|9724640|FG002|Overall Study|Pregnancy|0
6106619|NCT00797667|9724638|FG000|Overall Study|Protocol Violation|2
6106620|NCT00797667|9724639|FG001|Overall Study|Protocol Violation|7
6106621|NCT00797667|9724640|FG002|Overall Study|Protocol Violation|0
6106622|NCT00797667|9724638|FG000|Overall Study|Study Terminated by Sponsor|217
6106623|NCT00797667|9724639|FG001|Overall Study|Study Terminated by Sponsor|216
6106624|NCT00797667|9724640|FG002|Overall Study|Study Terminated by Sponsor|115
6106625|NCT00797667|9724638|FG000|Overall Study|Withdrawal by Subject|9
6106626|NCT00797667|9724639|FG001|Overall Study|Withdrawal by Subject|14
6106627|NCT00797667|9724640|FG002|Overall Study|Withdrawal by Subject|2
6106628|NCT00797667|9724638|FG000|Overall Study|Adverse Event|19
6106629|NCT00797667|9724639|FG001|Overall Study|Adverse Event|8
6106630|NCT00797667|9724640|FG002|Overall Study|Adverse Event|8
6106631|NCT00797732|9724650|FG000|Overall Study|Withdrawal by Subject|3
6106632|NCT00797732|9724651|FG001|Overall Study|Withdrawal by Subject|3
6106633|NCT00797732|9724652|FG002|Overall Study|Withdrawal by Subject|0
6106634|NCT00797732|9724650|FG000|Overall Study|Lost to Follow-up|1
6106635|NCT00797732|9724651|FG001|Overall Study|Lost to Follow-up|0
6106636|NCT00797732|9724652|FG002|Overall Study|Lost to Follow-up|0
6106637|NCT00797732|9724650|FG000|Overall Study|Death|1
6106638|NCT00797732|9724651|FG001|Overall Study|Death|0
6106639|NCT00797732|9724652|FG002|Overall Study|Death|0
6106640|NCT00797732|9724650|FG000|Overall Study|Not meet inclusion criteria|0
6106641|NCT00797732|9724651|FG001|Overall Study|Not meet inclusion criteria|0
6205638|NCT01534962|9868202|FG001|Overall Study|Randomized but did not start treatment|0
6205639|NCT01534962|9868203|FG002|Overall Study|Randomized but did not start treatment|0
6205640|NCT01534962|9868204|FG003|Overall Study|Randomized but did not start treatment|1
6205641|NCT01534962|9868201|FG000|Overall Study|Discontinued at AF recurrence|35
6205642|NCT01534962|9868202|FG001|Overall Study|Discontinued at AF recurrence|26
6205643|NCT01534962|9868203|FG002|Overall Study|Discontinued at AF recurrence|24
6205644|NCT01534962|9868204|FG003|Overall Study|Discontinued at AF recurrence|31
6285259|NCT02332720|9997153|FG002|Part A and Part B|Physician Decision|0
6285260|NCT02332720|9997154|FG003|Part A and Part B|Physician Decision|0
6285261|NCT02332720|9997155|FG004|Part A and Part B|Physician Decision|0
6285262|NCT02332720|9997156|FG005|Part A and Part B|Physician Decision|0
6285263|NCT02332720|9997157|FG006|Part A and Part B|Physician Decision|0
6285264|NCT02332720|9997158|FG007|Part A and Part B|Physician Decision|0
6285265|NCT02332720|9997159|FG008|Part A and Part B|Physician Decision|0
6285266|NCT02332720|9997160|FG009|Part A and Part B|Physician Decision|0
6285267|NCT02332720|9997161|FG010|Part A and Part B|Physician Decision|0
6285268|NCT02332720|9997162|FG011|Part A and Part B|Physician Decision|0
6285269|NCT02332720|9997163|FG012|Part A and Part B|Physician Decision|0
6285270|NCT02332720|9997164|FG013|Part A and Part B|Physician Decision|0
6285271|NCT02332720|9997165|FG014|Part A and Part B|Physician Decision|0
6285272|NCT02332720|9997166|FG015|Part A and Part B|Physician Decision|0
6285273|NCT02332720|9997167|FG016|Part A and Part B|Physician Decision|0
6285274|NCT02332720|9997168|FG017|Part A and Part B|Physician Decision|0
6285275|NCT02332720|9997169|FG018|Part A and Part B|Physician Decision|1
6285276|NCT02332720|9997170|FG019|Part A and Part B|Physician Decision|0
6285277|NCT02332720|9997171|FG020|Part A and Part B|Physician Decision|0
6285278|NCT02332720|9997172|FG021|Part A and Part B|Physician Decision|0
6285279|NCT02332720|9997173|FG022|Part A and Part B|Physician Decision|0
6285280|NCT02332720|9997151|FG000|Part A and Part B|Withdrawal by Subject|0
6285281|NCT02332720|9997152|FG001|Part A and Part B|Withdrawal by Subject|0
6285282|NCT02332720|9997153|FG002|Part A and Part B|Withdrawal by Subject|0
6285283|NCT02332720|9997154|FG003|Part A and Part B|Withdrawal by Subject|0
6285284|NCT02332720|9997155|FG004|Part A and Part B|Withdrawal by Subject|0
6285285|NCT02332720|9997156|FG005|Part A and Part B|Withdrawal by Subject|1
6285286|NCT02332720|9997157|FG006|Part A and Part B|Withdrawal by Subject|0
6285287|NCT02332720|9997158|FG007|Part A and Part B|Withdrawal by Subject|0
6285288|NCT02332720|9997159|FG008|Part A and Part B|Withdrawal by Subject|0
6285289|NCT02332720|9997160|FG009|Part A and Part B|Withdrawal by Subject|0
6285290|NCT02332720|9997161|FG010|Part A and Part B|Withdrawal by Subject|0
6285291|NCT02332720|9997162|FG011|Part A and Part B|Withdrawal by Subject|0
6285292|NCT02332720|9997163|FG012|Part A and Part B|Withdrawal by Subject|0
6285293|NCT02332720|9997164|FG013|Part A and Part B|Withdrawal by Subject|0
6285294|NCT02332720|9997165|FG014|Part A and Part B|Withdrawal by Subject|0
6285295|NCT02332720|9997166|FG015|Part A and Part B|Withdrawal by Subject|0
6285296|NCT02332720|9997167|FG016|Part A and Part B|Withdrawal by Subject|0
6285297|NCT02332720|9997168|FG017|Part A and Part B|Withdrawal by Subject|0
6285298|NCT02332720|9997169|FG018|Part A and Part B|Withdrawal by Subject|0
6285299|NCT02332720|9997170|FG019|Part A and Part B|Withdrawal by Subject|1
6285300|NCT02332720|9997171|FG020|Part A and Part B|Withdrawal by Subject|0
6285301|NCT02332720|9997172|FG021|Part A and Part B|Withdrawal by Subject|0
6285302|NCT02332720|9997173|FG022|Part A and Part B|Withdrawal by Subject|0
6285303|NCT02332798|9997238|FG000|Overall Study|Unwilling to Participate in Study|0
6285304|NCT02332798|9997239|FG001|Overall Study|Unwilling to Participate in Study|1
6285305|NCT02332798|9997240|FG002|Overall Study|Unwilling to Participate in Study|1
6285306|NCT02332798|9997238|FG000|Overall Study|Positive Urine Drug Test|0
6285307|NCT02332798|9997239|FG001|Overall Study|Positive Urine Drug Test|1
6285308|NCT02332798|9997240|FG002|Overall Study|Positive Urine Drug Test|0
6285309|NCT02332798|9997238|FG000|Overall Study|Abnormal Laboratory Findings|1
6285310|NCT02332798|9997239|FG001|Overall Study|Abnormal Laboratory Findings|0
6285311|NCT02332798|9997240|FG002|Overall Study|Abnormal Laboratory Findings|0
6285312|NCT02332824|9997254|FG000|Overall Study|Pretreatment Event/Adverse Event|4
6285313|NCT02332824|9997255|FG001|Overall Study|Pretreatment Event/Adverse Event|0
6285314|NCT02332824|9997256|FG002|Overall Study|Pretreatment Event/Adverse Event|1
6285315|NCT02332824|9997257|FG003|Overall Study|Pretreatment Event/Adverse Event|1
6285316|NCT02332824|9997258|FG004|Overall Study|Pretreatment Event/Adverse Event|4
6285317|NCT02332824|9997259|FG005|Overall Study|Pretreatment Event/Adverse Event|1
6285318|NCT02332824|9997254|FG000|Overall Study|Voluntary Withdrawal|1
6285319|NCT02332824|9997255|FG001|Overall Study|Voluntary Withdrawal|0
6285320|NCT02332824|9997256|FG002|Overall Study|Voluntary Withdrawal|0
6106642|NCT00797732|9724652|FG002|Overall Study|Not meet inclusion criteria|7
6106643|NCT00797732|9724650|FG000|Overall Study|Excluded due to time constraints|0
6106644|NCT00797732|9724651|FG001|Overall Study|Excluded due to time constraints|0
6106645|NCT00797732|9724652|FG002|Overall Study|Excluded due to time constraints|24
6106646|NCT00797732|9724650|FG000|Overall Study|Refused to Participate|0
6106647|NCT00797732|9724651|FG001|Overall Study|Refused to Participate|0
6106648|NCT00797732|9724652|FG002|Overall Study|Refused to Participate|123
6106649|NCT00797823|9724670|FG000|First Period (Initial Randomization)|Physician Decision|1
6106650|NCT00797823|9724671|FG001|First Period (Initial Randomization)|Physician Decision|0
6106651|NCT00797823|9724672|FG002|First Period (Initial Randomization)|Physician Decision|0
6106652|NCT00797862|9724682|FG000|Overall Study|Adverse Event|86
6106653|NCT00797862|9724683|FG001|Overall Study|Adverse Event|44
6106654|NCT00797862|9724684|FG002|Overall Study|Adverse Event|58
6106655|NCT00797862|9724682|FG000|Overall Study|Abnormal Test Procedure Result|0
6106656|NCT00797862|9724683|FG001|Overall Study|Abnormal Test Procedure Result|1
6106657|NCT00797862|9724684|FG002|Overall Study|Abnormal Test Procedure Result|1
6106658|NCT00797862|9724682|FG000|Overall Study|Lack of Efficacy|1
6106659|NCT00797862|9724683|FG001|Overall Study|Lack of Efficacy|7
6106660|NCT00797862|9724684|FG002|Overall Study|Lack of Efficacy|6
6106661|NCT00797862|9724682|FG000|Overall Study|No longer required study medication|1
6106662|NCT00797862|9724683|FG001|Overall Study|No longer required study medication|0
6106663|NCT00797862|9724684|FG002|Overall Study|No longer required study medication|0
6106664|NCT00797862|9724682|FG000|Overall Study|Withdrawal by Subject|14
6106665|NCT00797862|9724683|FG001|Overall Study|Withdrawal by Subject|7
6106666|NCT00797862|9724684|FG002|Overall Study|Withdrawal by Subject|7
6106667|NCT00797862|9724682|FG000|Overall Study|Lost to Follow-up|11
6106668|NCT00797862|9724683|FG001|Overall Study|Lost to Follow-up|0
6106669|NCT00797862|9724684|FG002|Overall Study|Lost to Follow-up|5
6106670|NCT00797862|9724682|FG000|Overall Study|Administrative Problem|4
6106671|NCT00797862|9724683|FG001|Overall Study|Administrative Problem|0
6205645|NCT01535040|9868257|FG000|Overall Study|Physician Decision|0
6205646|NCT01535040|9868258|FG001|Overall Study|Physician Decision|1
6205647|NCT01535040|9868257|FG000|Overall Study|Withdrawal by Subject|13
6205648|NCT01535040|9868258|FG001|Overall Study|Withdrawal by Subject|10
6205649|NCT01535040|9868257|FG000|Overall Study|Never Started|9
6205650|NCT01535040|9868258|FG001|Overall Study|Never Started|4
6205651|NCT01535040|9868257|FG000|Overall Study|Toxicity|7
6205652|NCT01535040|9868258|FG001|Overall Study|Toxicity|5
6205653|NCT01535040|9868257|FG000|Overall Study|Multiple Reasons|1
6205654|NCT01535040|9868258|FG001|Overall Study|Multiple Reasons|1
6205655|NCT01535053|9868266|FG000|Overall Study|Ineligible|1
6205656|NCT01535053|9868267|FG001|Overall Study|Ineligible|2
6205657|NCT01535222|9868283|FG000|Overall Study|Inclusion/exclusion|0
6205658|NCT01535222|9868284|FG001|Overall Study|Inclusion/exclusion|0
6205659|NCT01535222|9868285|FG002|Overall Study|Inclusion/exclusion|1
6205660|NCT01535222|9868286|FG003|Overall Study|Inclusion/exclusion|0
6205661|NCT01535222|9868287|FG004|Overall Study|Inclusion/exclusion|0
6205662|NCT01535222|9868288|FG005|Overall Study|Inclusion/exclusion|0
6205663|NCT01535235|9868304|FG000|Overall Study|Adverse Event|1
6205664|NCT01535235|9868305|FG001|Overall Study|Adverse Event|0
6205665|NCT01535261|9868311|FG000|Overall Study|Physician Decision|8
6205666|NCT01535261|9868311|FG000|Overall Study|Protocol Violation|3
6205667|NCT01535261|9868311|FG000|Overall Study|Death|5
6205668|NCT01535261|9868311|FG000|Overall Study|Lost to Follow-up|8
6205669|NCT01535261|9868311|FG000|Overall Study|Withdrawal by Subject|14
6205670|NCT01535261|9868311|FG000|Overall Study|Adverse Event|12
6205671|NCT01535287|9868317|FG000|Overall Study|drug not prepared in time|5
6205672|NCT01535287|9868318|FG001|Overall Study|drug not prepared in time|6
6205673|NCT01535443|9868351|FG000|Overall Study|Physician Decision|3
6205674|NCT01535560|9868358|FG000|Overall Study|Adverse Event|12
6205675|NCT01535560|9868359|FG001|Overall Study|Adverse Event|7
6205676|NCT01535560|9868358|FG000|Overall Study|Lost to Follow-up|1
6205677|NCT01535560|9868359|FG001|Overall Study|Lost to Follow-up|3
6205678|NCT01535560|9868358|FG000|Overall Study|Subj Decision Unrel to an Adverse Event|3
6205679|NCT01535560|9868359|FG001|Overall Study|Subj Decision Unrel to an Adverse Event|1
6205680|NCT01535560|9868358|FG000|Overall Study|Treatment Failure|21
6205681|NCT01535560|9868359|FG001|Overall Study|Treatment Failure|83
6205682|NCT01535560|9868358|FG000|Overall Study|Other|0
6205683|NCT01535560|9868359|FG001|Overall Study|Other|1
6205684|NCT01535560|9868358|FG000|Overall Study|Randomized in Error|0
6205685|NCT01535560|9868359|FG001|Overall Study|Randomized in Error|1
6205686|NCT01535599|9868380|FG000|Overall Study|Adverse Event|6
6205687|NCT01535599|9868381|FG001|Overall Study|Adverse Event|15
6205688|NCT01535599|9868380|FG000|Overall Study|Lost to Follow-up|3
6205689|NCT01535599|9868381|FG001|Overall Study|Lost to Follow-up|4
6205690|NCT01535599|9868380|FG000|Overall Study|Subj Decision Unrelated to Adverse Event|4
6205691|NCT01535599|9868381|FG001|Overall Study|Subj Decision Unrelated to Adverse Event|3
6205692|NCT01535599|9868380|FG000|Overall Study|Treatment Failure|33
6205693|NCT01535599|9868381|FG001|Overall Study|Treatment Failure|66
6205694|NCT01535599|9868380|FG000|Overall Study|BL Culture + for Group A Strep|0
6205695|NCT01535599|9868381|FG001|Overall Study|BL Culture + for Group A Strep|1
6205696|NCT01535599|9868380|FG000|Overall Study|BL Culture + for Yeast//Fungi|0
6205697|NCT01535599|9868381|FG001|Overall Study|BL Culture + for Yeast//Fungi|1
6106672|NCT00797862|9724684|FG002|Overall Study|Administrative Problem|0
6106673|NCT00797862|9724682|FG000|Overall Study|Protocol Violation|4
6106674|NCT00797862|9724683|FG001|Overall Study|Protocol Violation|6
6106675|NCT00797862|9724684|FG002|Overall Study|Protocol Violation|8
6106676|NCT00797862|9724682|FG000|Overall Study|Mis-randomized|3
6106677|NCT00797862|9724683|FG001|Overall Study|Mis-randomized|3
6106678|NCT00797862|9724684|FG002|Overall Study|Mis-randomized|1
6106679|NCT00797966|9724696|FG000|Phase A|Lost to Follow-up|0
6106680|NCT00797966|9724697|FG001|Phase A|Lost to Follow-up|0
6106681|NCT00797966|9724698|FG002|Phase A|Lost to Follow-up|0
6106682|NCT00797966|9724699|FG003|Phase A|Lost to Follow-up|0
6106683|NCT00797966|9724700|FG004|Phase A|Lost to Follow-up|33
6106684|NCT00797966|9724701|FG005|Phase A|Lost to Follow-up|0
6106685|NCT00797966|9724696|FG000|Phase A|Adverse Event|0
6106686|NCT00797966|9724697|FG001|Phase A|Adverse Event|0
6106687|NCT00797966|9724698|FG002|Phase A|Adverse Event|0
6106688|NCT00797966|9724699|FG003|Phase A|Adverse Event|0
6106689|NCT00797966|9724700|FG004|Phase A|Adverse Event|46
6106690|NCT00797966|9724701|FG005|Phase A|Adverse Event|0
6106691|NCT00797966|9724696|FG000|Phase A|Met withdrawal criteria|0
6106692|NCT00797966|9724697|FG001|Phase A|Met withdrawal criteria|0
6106693|NCT00797966|9724698|FG002|Phase A|Met withdrawal criteria|0
6106694|NCT00797966|9724699|FG003|Phase A|Met withdrawal criteria|0
6106695|NCT00797966|9724700|FG004|Phase A|Met withdrawal criteria|4
6106696|NCT00797966|9724701|FG005|Phase A|Met withdrawal criteria|0
6106697|NCT00797966|9724696|FG000|Phase A|Physician Decision|0
6106698|NCT00797966|9724697|FG001|Phase A|Physician Decision|0
6106699|NCT00797966|9724698|FG002|Phase A|Physician Decision|0
6106700|NCT00797966|9724699|FG003|Phase A|Physician Decision|0
6106701|NCT00797966|9724700|FG004|Phase A|Physician Decision|13
6106702|NCT00797966|9724701|FG005|Phase A|Physician Decision|0
6106703|NCT00797966|9724696|FG000|Phase A|Withdrawal by Subject|0
6106704|NCT00797966|9724697|FG001|Phase A|Withdrawal by Subject|0
6106705|NCT00797966|9724698|FG002|Phase A|Withdrawal by Subject|0
6106706|NCT00797966|9724699|FG003|Phase A|Withdrawal by Subject|0
6106707|NCT00797966|9724700|FG004|Phase A|Withdrawal by Subject|33
6106708|NCT00797966|9724701|FG005|Phase A|Withdrawal by Subject|0
6106709|NCT00797966|9724696|FG000|Phase A|Protocol deviation|0
6106710|NCT00797966|9724697|FG001|Phase A|Protocol deviation|0
6106711|NCT00797966|9724698|FG002|Phase A|Protocol deviation|0
6106712|NCT00797966|9724699|FG003|Phase A|Protocol deviation|0
6106713|NCT00797966|9724700|FG004|Phase A|Protocol deviation|56
6106714|NCT00797966|9724701|FG005|Phase A|Protocol deviation|0
6106715|NCT00797966|9724696|FG000|Phase B|Lost to Follow-up|0
6106716|NCT00797966|9724697|FG001|Phase B|Lost to Follow-up|1
6106717|NCT00797966|9724698|FG002|Phase B|Lost to Follow-up|3
6106718|NCT00797966|9724699|FG003|Phase B|Lost to Follow-up|0
6106719|NCT00797966|9724700|FG004|Phase B|Lost to Follow-up|0
6106720|NCT00797966|9724701|FG005|Phase B|Lost to Follow-up|0
6106721|NCT00797966|9724696|FG000|Phase B|Adverse Event|2
6106722|NCT00797966|9724697|FG001|Phase B|Adverse Event|1
6106723|NCT00797966|9724698|FG002|Phase B|Adverse Event|3
6106724|NCT00797966|9724699|FG003|Phase B|Adverse Event|1
6106725|NCT00797966|9724700|FG004|Phase B|Adverse Event|0
6106726|NCT00797966|9724701|FG005|Phase B|Adverse Event|0
6106727|NCT00797966|9724696|FG000|Phase B|Met Withdrawal Criteria|3
6106728|NCT00797966|9724697|FG001|Phase B|Met Withdrawal Criteria|3
6106729|NCT00797966|9724698|FG002|Phase B|Met Withdrawal Criteria|6
6106730|NCT00797966|9724699|FG003|Phase B|Met Withdrawal Criteria|1
6106731|NCT00797966|9724700|FG004|Phase B|Met Withdrawal Criteria|0
6106732|NCT00797966|9724701|FG005|Phase B|Met Withdrawal Criteria|0
6106733|NCT00797966|9724696|FG000|Phase B|Physician Decision|1
6106734|NCT00797966|9724697|FG001|Phase B|Physician Decision|0
6106735|NCT00797966|9724698|FG002|Phase B|Physician Decision|3
6106736|NCT00797966|9724699|FG003|Phase B|Physician Decision|1
6106737|NCT00797966|9724700|FG004|Phase B|Physician Decision|0
6106738|NCT00797966|9724701|FG005|Phase B|Physician Decision|0
6106739|NCT00797966|9724696|FG000|Phase B|Withdrawal by Subject|1
6106740|NCT00797966|9724697|FG001|Phase B|Withdrawal by Subject|4
6106741|NCT00797966|9724698|FG002|Phase B|Withdrawal by Subject|3
6106742|NCT00797966|9724699|FG003|Phase B|Withdrawal by Subject|3
6106743|NCT00797966|9724700|FG004|Phase B|Withdrawal by Subject|0
6106744|NCT00797966|9724701|FG005|Phase B|Withdrawal by Subject|0
6106745|NCT00797966|9724696|FG000|Phase B|Protocol Deviation|4
6106746|NCT00797966|9724697|FG001|Phase B|Protocol Deviation|8
6106747|NCT00797966|9724698|FG002|Phase B|Protocol Deviation|2
6106748|NCT00797966|9724699|FG003|Phase B|Protocol Deviation|6
6106749|NCT00797966|9724700|FG004|Phase B|Protocol Deviation|0
6106750|NCT00797966|9724701|FG005|Phase B|Protocol Deviation|0
6106751|NCT00797966|9724696|FG000|Phase B|Lack of Efficacy|0
6106752|NCT00797966|9724697|FG001|Phase B|Lack of Efficacy|1
6106753|NCT00797966|9724698|FG002|Phase B|Lack of Efficacy|1
6106754|NCT00797966|9724699|FG003|Phase B|Lack of Efficacy|4
6106755|NCT00797966|9724700|FG004|Phase B|Lack of Efficacy|0
6106756|NCT00797966|9724701|FG005|Phase B|Lack of Efficacy|0
6106757|NCT00797966|9724696|FG000|Phase A+|Lost to Follow-up|0
6106758|NCT00797966|9724697|FG001|Phase A+|Lost to Follow-up|0
6106759|NCT00797966|9724698|FG002|Phase A+|Lost to Follow-up|0
6106760|NCT00797966|9724699|FG003|Phase A+|Lost to Follow-up|0
6106761|NCT00797966|9724700|FG004|Phase A+|Lost to Follow-up|0
6106762|NCT00797966|9724701|FG005|Phase A+|Lost to Follow-up|9
6106763|NCT00797966|9724696|FG000|Phase A+|Met withdrawal criteria|0
6106764|NCT00797966|9724697|FG001|Phase A+|Met withdrawal criteria|0
6106765|NCT00797966|9724698|FG002|Phase A+|Met withdrawal criteria|0
6106766|NCT00797966|9724699|FG003|Phase A+|Met withdrawal criteria|0
6106767|NCT00797966|9724700|FG004|Phase A+|Met withdrawal criteria|0
6106768|NCT00797966|9724701|FG005|Phase A+|Met withdrawal criteria|5
6106769|NCT00797966|9724696|FG000|Phase A+|Withdrawal by Subject|0
6106770|NCT00797966|9724697|FG001|Phase A+|Withdrawal by Subject|0
6106771|NCT00797966|9724698|FG002|Phase A+|Withdrawal by Subject|0
6106772|NCT00797966|9724699|FG003|Phase A+|Withdrawal by Subject|0
6106773|NCT00797966|9724700|FG004|Phase A+|Withdrawal by Subject|0
6106774|NCT00797966|9724701|FG005|Phase A+|Withdrawal by Subject|6
6106775|NCT00797966|9724696|FG000|Phase A+|Adverse Event|0
6106776|NCT00797966|9724697|FG001|Phase A+|Adverse Event|0
6106777|NCT00797966|9724698|FG002|Phase A+|Adverse Event|0
6106778|NCT00797966|9724699|FG003|Phase A+|Adverse Event|0
6106779|NCT00797966|9724700|FG004|Phase A+|Adverse Event|0
6106780|NCT00797966|9724701|FG005|Phase A+|Adverse Event|4
6106781|NCT00797966|9724696|FG000|Phase A+|Protocol deviation|0
6106782|NCT00797966|9724697|FG001|Phase A+|Protocol deviation|0
6106783|NCT00797966|9724698|FG002|Phase A+|Protocol deviation|0
6106784|NCT00797966|9724699|FG003|Phase A+|Protocol deviation|0
6106785|NCT00797966|9724700|FG004|Phase A+|Protocol deviation|0
6106786|NCT00797966|9724701|FG005|Phase A+|Protocol deviation|4
6106787|NCT00798096|9724730|FG000|Overall Study|Ongoing|2
6106788|NCT00798135|9724734|FG000|Overall Study|Disease progression, relapse|11
6106789|NCT00798135|9724734|FG000|Overall Study|Disease progression, refractory|1
6106790|NCT00798135|9724734|FG000|Overall Study|Physician Decision|1
6106791|NCT00798161|9724745|FG000|Overall Study|Adverse Event|3
6106792|NCT00798161|9724746|FG001|Overall Study|Adverse Event|4
6106793|NCT00798161|9724747|FG002|Overall Study|Adverse Event|6
6106794|NCT00798161|9724748|FG003|Overall Study|Adverse Event|6
6106795|NCT00798161|9724749|FG004|Overall Study|Adverse Event|5
6106796|NCT00798161|9724750|FG005|Overall Study|Adverse Event|2
6106797|NCT00798161|9724751|FG006|Overall Study|Adverse Event|4
6106798|NCT00798161|9724745|FG000|Overall Study|Protocol Violation|2
6106799|NCT00798161|9724746|FG001|Overall Study|Protocol Violation|1
6106800|NCT00798161|9724747|FG002|Overall Study|Protocol Violation|3
6106801|NCT00798161|9724748|FG003|Overall Study|Protocol Violation|3
6106802|NCT00798161|9724749|FG004|Overall Study|Protocol Violation|3
6106803|NCT00798161|9724750|FG005|Overall Study|Protocol Violation|2
6106804|NCT00798161|9724751|FG006|Overall Study|Protocol Violation|0
6106805|NCT00798161|9724745|FG000|Overall Study|Lost to Follow-up|1
6106806|NCT00798161|9724746|FG001|Overall Study|Lost to Follow-up|3
6106807|NCT00798161|9724747|FG002|Overall Study|Lost to Follow-up|4
6106808|NCT00798161|9724748|FG003|Overall Study|Lost to Follow-up|3
6106809|NCT00798161|9724749|FG004|Overall Study|Lost to Follow-up|4
6106810|NCT00798161|9724750|FG005|Overall Study|Lost to Follow-up|0
6106811|NCT00798161|9724751|FG006|Overall Study|Lost to Follow-up|0
6106812|NCT00798161|9724745|FG000|Overall Study|Withdrawal by Subject|5
6106813|NCT00798161|9724746|FG001|Overall Study|Withdrawal by Subject|4
6106814|NCT00798161|9724747|FG002|Overall Study|Withdrawal by Subject|5
6106815|NCT00798161|9724748|FG003|Overall Study|Withdrawal by Subject|4
6106816|NCT00798161|9724749|FG004|Overall Study|Withdrawal by Subject|2
6106817|NCT00798161|9724750|FG005|Overall Study|Withdrawal by Subject|3
6106818|NCT00798161|9724751|FG006|Overall Study|Withdrawal by Subject|1
6106819|NCT00798161|9724745|FG000|Overall Study|Other reason (incl. lack of efficacy)|7
6106820|NCT00798161|9724746|FG001|Overall Study|Other reason (incl. lack of efficacy)|5
6106821|NCT00798161|9724747|FG002|Overall Study|Other reason (incl. lack of efficacy)|3
6106822|NCT00798161|9724748|FG003|Overall Study|Other reason (incl. lack of efficacy)|5
6106823|NCT00798161|9724749|FG004|Overall Study|Other reason (incl. lack of efficacy)|2
6106824|NCT00798161|9724750|FG005|Overall Study|Other reason (incl. lack of efficacy)|4
6106825|NCT00798161|9724751|FG006|Overall Study|Other reason (incl. lack of efficacy)|5
6106826|NCT00798174|9724767|FG000|Overall Study|inability to implant azygos coil|3
6106827|NCT00798174|9724768|FG001|Overall Study|inability to implant azygos coil|3
6106828|NCT00798174|9724767|FG000|Overall Study|Inability to sedate for DFT testing|1
6106829|NCT00798174|9724768|FG001|Overall Study|Inability to sedate for DFT testing|0
6106830|NCT00798304|9724775|FG000|Overall Study|Adverse Event|0
6106831|NCT00798304|9724776|FG001|Overall Study|Adverse Event|1
6106832|NCT00798304|9724777|FG002|Overall Study|Adverse Event|1
6106833|NCT00798304|9724775|FG000|Overall Study|Discontinuation by Sponsor|14
6106834|NCT00798304|9724776|FG001|Overall Study|Discontinuation by Sponsor|21
6106835|NCT00798304|9724777|FG002|Overall Study|Discontinuation by Sponsor|9
6106836|NCT00798317|9724787|FG000|Overall Study|Physician Decision|0
6106837|NCT00798317|9724788|FG001|Overall Study|Physician Decision|1
6106838|NCT00798317|9724787|FG000|Overall Study|Withdrawal by Subject|5
6106839|NCT00798317|9724788|FG001|Overall Study|Withdrawal by Subject|4
6106840|NCT00798317|9724787|FG000|Overall Study|Lost to Follow-up|2
6106841|NCT00798317|9724788|FG001|Overall Study|Lost to Follow-up|2
6106842|NCT00798317|9724787|FG000|Overall Study|Adverse Event|2
6106843|NCT00798317|9724788|FG001|Overall Study|Adverse Event|0
6106844|NCT00798317|9724787|FG000|Overall Study|Death|1
6106845|NCT00798317|9724788|FG001|Overall Study|Death|0
6106846|NCT00798369|9724800|FG000|Overall Study|Subject withdrew consent|0
6106847|NCT00798369|9724801|FG001|Overall Study|Subject withdrew consent|0
6106848|NCT00798369|9724802|FG002|Overall Study|Subject withdrew consent|1
6106849|NCT00798369|9724803|FG003|Overall Study|Subject withdrew consent|1
6106850|NCT00798369|9724804|FG004|Overall Study|Subject withdrew consent|0
6106851|NCT00798369|9724805|FG005|Overall Study|Subject withdrew consent|2
6106852|NCT00798369|9724800|FG000|Overall Study|Lost to Follow-up|1
6106853|NCT00798369|9724801|FG001|Overall Study|Lost to Follow-up|1
6106854|NCT00798369|9724802|FG002|Overall Study|Lost to Follow-up|1
6205698|NCT01535599|9868380|FG000|Overall Study|Randomized in Error|2
6205699|NCT01535599|9868381|FG001|Overall Study|Randomized in Error|4
6205700|NCT01535599|9868380|FG000|Overall Study|Did not use product|1
6205701|NCT01535599|9868381|FG001|Overall Study|Did not use product|0
6205702|NCT01535599|9868380|FG000|Overall Study|Other|1
6205703|NCT01535599|9868381|FG001|Overall Study|Other|0
6205704|NCT01535599|9868380|FG000|Overall Study|Stopped medication|0
6205705|NCT01535599|9868381|FG001|Overall Study|Stopped medication|1
6205706|NCT01535599|9868380|FG000|Overall Study|Noncompliance|0
6205707|NCT01535599|9868381|FG001|Overall Study|Noncompliance|1
6205708|NCT01535638|9868387|FG000|Treatment 1 (Single Dose)|Protocol Violation|0
6205709|NCT01535638|9868388|FG001|Treatment 1 (Single Dose)|Protocol Violation|0
6205710|NCT01535638|9868389|FG002|Treatment 1 (Single Dose)|Protocol Violation|0
6205711|NCT01535638|9868390|FG003|Treatment 1 (Single Dose)|Protocol Violation|0
6205712|NCT01535638|9868391|FG004|Treatment 1 (Single Dose)|Protocol Violation|0
6205713|NCT01535638|9868392|FG005|Treatment 1 (Single Dose)|Protocol Violation|1
6205714|NCT01535638|9868387|FG000|Treatment 3 (Single Dose)|Protocol Violation|0
6205715|NCT01535638|9868388|FG001|Treatment 3 (Single Dose)|Protocol Violation|0
6205716|NCT01535638|9868389|FG002|Treatment 3 (Single Dose)|Protocol Violation|0
6205717|NCT01535638|9868390|FG003|Treatment 3 (Single Dose)|Protocol Violation|1
6205718|NCT01535638|9868391|FG004|Treatment 3 (Single Dose)|Protocol Violation|0
6205719|NCT01535638|9868392|FG005|Treatment 3 (Single Dose)|Protocol Violation|0
6205720|NCT01535729|9868409|FG000|Overall Study|Withdrawal by Subject|2
6205721|NCT01535729|9868409|FG000|Overall Study|Disease progression|230
6205722|NCT01535729|9868409|FG000|Overall Study|Discontinued treatment|25
6205723|NCT01535729|9868409|FG000|Overall Study|Lost to Follow-up|8
6205724|NCT01535729|9868409|FG000|Overall Study|Death|52
6205725|NCT01535729|9868409|FG000|Overall Study|Other|19
6205726|NCT01535729|9868409|FG000|Overall Study|Did not sign informed consent|1
6205727|NCT01535729|9868409|FG000|Overall Study|No previous chemotherapy|33
6205728|NCT01535729|9868409|FG000|Overall Study|NSCLC grade IV histology not confirmed|20
6205729|NCT01535729|9868409|FG000|Overall Study|Protocol Violation|11
6205730|NCT01535729|9868409|FG000|Overall Study|Screening failure|1
6205731|NCT01535729|9868409|FG000|Overall Study|Not treated|9
6205732|NCT01535729|9868409|FG000|Overall Study|No participant record available|5
6205733|NCT01536067|9868457|FG000|Overall Study|Disease Progression|1
6205734|NCT01536093|9868463|FG000|Overall Study|Death|1
6205735|NCT01536093|9868464|FG001|Overall Study|Death|2
6205736|NCT01536093|9868463|FG000|Overall Study|absence of maternal colostrum|2
6205737|NCT01536093|9868464|FG001|Overall Study|absence of maternal colostrum|0
6205738|NCT01536093|9868463|FG000|Overall Study|Withdrawal by Subject|0
6205739|NCT01536093|9868464|FG001|Overall Study|Withdrawal by Subject|1
6205740|NCT01536119|9868472|FG000|Overall Study|Lost to Follow-up|17
6205741|NCT01536119|9868473|FG001|Overall Study|Lost to Follow-up|14
6205742|NCT01536145|9868479|FG000|Overall Study|Progressive disease|3
6205743|NCT01536145|9868480|FG001|Overall Study|Progressive disease|4
6205744|NCT01536145|9868481|FG002|Overall Study|Progressive disease|1
6205745|NCT01536145|9868482|FG003|Overall Study|Progressive disease|2
6205746|NCT01536145|9868483|FG004|Overall Study|Progressive disease|1
6205747|NCT01536145|9868484|FG005|Overall Study|Progressive disease|2
6205748|NCT01536145|9868485|FG006|Overall Study|Progressive disease|1
6205749|NCT01536145|9868486|FG007|Overall Study|Progressive disease|2
6205750|NCT01536145|9868487|FG008|Overall Study|Progressive disease|1
6205751|NCT01536145|9868488|FG009|Overall Study|Progressive disease|3
6205752|NCT01536145|9868489|FG010|Overall Study|Progressive disease|3
6205753|NCT01536145|9868479|FG000|Overall Study|Withdrawal by Subject|0
6205754|NCT01536145|9868480|FG001|Overall Study|Withdrawal by Subject|0
6205755|NCT01536145|9868481|FG002|Overall Study|Withdrawal by Subject|1
6205756|NCT01536145|9868482|FG003|Overall Study|Withdrawal by Subject|0
6205757|NCT01536145|9868483|FG004|Overall Study|Withdrawal by Subject|0
6205758|NCT01536145|9868484|FG005|Overall Study|Withdrawal by Subject|1
6205759|NCT01536145|9868485|FG006|Overall Study|Withdrawal by Subject|0
6205760|NCT01536145|9868486|FG007|Overall Study|Withdrawal by Subject|0
6205761|NCT01536145|9868487|FG008|Overall Study|Withdrawal by Subject|2
6205762|NCT01536145|9868488|FG009|Overall Study|Withdrawal by Subject|0
6205763|NCT01536145|9868489|FG010|Overall Study|Withdrawal by Subject|2
6205764|NCT01536145|9868479|FG000|Overall Study|Other|0
6205765|NCT01536145|9868480|FG001|Overall Study|Other|0
6205766|NCT01536145|9868481|FG002|Overall Study|Other|0
6205767|NCT01536145|9868482|FG003|Overall Study|Other|0
6205768|NCT01536145|9868483|FG004|Overall Study|Other|1
6205769|NCT01536145|9868484|FG005|Overall Study|Other|0
6205770|NCT01536145|9868485|FG006|Overall Study|Other|0
6106855|NCT00798369|9724803|FG003|Overall Study|Lost to Follow-up|0
6205771|NCT01536145|9868486|FG007|Overall Study|Other|0
6205772|NCT01536145|9868487|FG008|Overall Study|Other|0
6205773|NCT01536145|9868488|FG009|Overall Study|Other|3
6205774|NCT01536145|9868489|FG010|Overall Study|Other|2
6106856|NCT00798369|9724804|FG004|Overall Study|Lost to Follow-up|1
6106857|NCT00798369|9724805|FG005|Overall Study|Lost to Follow-up|0
6106858|NCT00798369|9724800|FG000|Overall Study|Adminstrative problems|0
6106859|NCT00798369|9724801|FG001|Overall Study|Adminstrative problems|0
6106860|NCT00798369|9724802|FG002|Overall Study|Adminstrative problems|0
6106861|NCT00798369|9724803|FG003|Overall Study|Adminstrative problems|0
6106862|NCT00798369|9724804|FG004|Overall Study|Adminstrative problems|0
6106863|NCT00798369|9724805|FG005|Overall Study|Adminstrative problems|1
6106864|NCT00798434|9724822|FG000|Double-Blind|Adverse Event|22
6106865|NCT00798434|9724823|FG001|Double-Blind|Adverse Event|46
6106866|NCT00798434|9724822|FG000|Double-Blind|Death|0
6106867|NCT00798434|9724823|FG001|Double-Blind|Death|1
6106868|NCT00798434|9724822|FG000|Double-Blind|Lost to Follow-up|1
6106869|NCT00798434|9724823|FG001|Double-Blind|Lost to Follow-up|0
6106870|NCT00798434|9724822|FG000|Double-Blind|Lack of Efficacy|8
6106871|NCT00798434|9724823|FG001|Double-Blind|Lack of Efficacy|12
6106872|NCT00798434|9724822|FG000|Double-Blind|Withdrawal by Subject|17
6106873|NCT00798434|9724823|FG001|Double-Blind|Withdrawal by Subject|14
6106874|NCT00798434|9724822|FG000|Double-Blind|Protocol Violation|1
6106875|NCT00798434|9724823|FG001|Double-Blind|Protocol Violation|4
6106876|NCT00798434|9724822|FG000|Double-Blind|Did Not Meet Entrance Criteria|2
6106877|NCT00798434|9724823|FG001|Double-Blind|Did Not Meet Entrance Criteria|1
6106878|NCT00798434|9724822|FG000|Double-Blind|Other|1
6106879|NCT00798434|9724823|FG001|Double-Blind|Other|0
6106880|NCT00798434|9724822|FG000|Double-Blind|Not Treated|3
6106881|NCT00798434|9724823|FG001|Double-Blind|Not Treated|6
6106882|NCT00798434|9724822|FG000|Open-Label|Adverse Event|33
6106883|NCT00798434|9724823|FG001|Open-Label|Adverse Event|11
6106884|NCT00798434|9724822|FG000|Open-Label|Lack of Efficacy|5
6106885|NCT00798434|9724823|FG001|Open-Label|Lack of Efficacy|11
6106886|NCT00798434|9724822|FG000|Open-Label|Withdrawal by Subject|2
6106887|NCT00798434|9724823|FG001|Open-Label|Withdrawal by Subject|7
6106888|NCT00798434|9724822|FG000|Open-Label|Protocol Violation|1
6106889|NCT00798434|9724823|FG001|Open-Label|Protocol Violation|0
6205775|NCT01536145|9868479|FG000|Overall Study|Death|0
6205776|NCT01536145|9868480|FG001|Overall Study|Death|0
6205777|NCT01536145|9868481|FG002|Overall Study|Death|0
6205778|NCT01536145|9868482|FG003|Overall Study|Death|0
6205779|NCT01536145|9868483|FG004|Overall Study|Death|0
6205780|NCT01536145|9868484|FG005|Overall Study|Death|0
6205781|NCT01536145|9868485|FG006|Overall Study|Death|1
6205782|NCT01536145|9868486|FG007|Overall Study|Death|0
6205783|NCT01536145|9868487|FG008|Overall Study|Death|0
6205784|NCT01536145|9868488|FG009|Overall Study|Death|0
6205785|NCT01536145|9868489|FG010|Overall Study|Death|0
6205786|NCT01536145|9868479|FG000|Overall Study|Adverse Event|0
6205787|NCT01536145|9868480|FG001|Overall Study|Adverse Event|0
6205788|NCT01536145|9868481|FG002|Overall Study|Adverse Event|0
6205789|NCT01536145|9868482|FG003|Overall Study|Adverse Event|0
6205790|NCT01536145|9868483|FG004|Overall Study|Adverse Event|0
6205791|NCT01536145|9868484|FG005|Overall Study|Adverse Event|0
6205792|NCT01536145|9868485|FG006|Overall Study|Adverse Event|0
6205793|NCT01536145|9868486|FG007|Overall Study|Adverse Event|2
6205794|NCT01536145|9868487|FG008|Overall Study|Adverse Event|0
6205795|NCT01536145|9868488|FG009|Overall Study|Adverse Event|0
6205796|NCT01536145|9868489|FG010|Overall Study|Adverse Event|3
6205797|NCT01536171|9868520|FG000|Overall Study|Withdrawal by Subject|1
6205798|NCT01536262|9868546|FG000|Overall Study|Adverse Event|6
6205799|NCT01536262|9868547|FG001|Overall Study|Adverse Event|1
6205800|NCT01536262|9868548|FG002|Overall Study|Adverse Event|2
6205801|NCT01536262|9868546|FG000|Overall Study|Withdrawal by Subject|1
6205802|NCT01536262|9868547|FG001|Overall Study|Withdrawal by Subject|1
6205803|NCT01536262|9868548|FG002|Overall Study|Withdrawal by Subject|0
6205804|NCT01536262|9868546|FG000|Overall Study|Other than stated above|1
6205805|NCT01536262|9868547|FG001|Overall Study|Other than stated above|0
6205806|NCT01536262|9868548|FG002|Overall Study|Other than stated above|0
6205807|NCT01536379|9868568|FG000|Overall Study|Adverse Event|1
6205808|NCT01536379|9868569|FG001|Overall Study|Adverse Event|2
6205809|NCT01536379|9868568|FG000|Overall Study|Withdrawal by Subject|1
6205810|NCT01536379|9868569|FG001|Overall Study|Withdrawal by Subject|1
6205811|NCT01536392|9868577|FG000|Overall Study|Adverse Event|2
6205812|NCT01536392|9868578|FG001|Overall Study|Adverse Event|2
6205813|NCT01536392|9868577|FG000|Overall Study|Physician Decision|2
6205814|NCT01536392|9868578|FG001|Overall Study|Physician Decision|3
6205815|NCT01536392|9868577|FG000|Overall Study|Withdrawal by Subject|3
6205816|NCT01536392|9868578|FG001|Overall Study|Withdrawal by Subject|6
6205817|NCT01536392|9868577|FG000|Overall Study|Non Compliance|3
6205818|NCT01536392|9868578|FG001|Overall Study|Non Compliance|4
6205819|NCT01536392|9868577|FG000|Overall Study|Completed therapy early|3
6205820|NCT01536392|9868578|FG001|Overall Study|Completed therapy early|0
6205821|NCT01536405|9868586|FG000|Randomization to Visit 1 (Vaccination 1)|Not vaccinated|8
6205822|NCT01536405|9868587|FG001|Randomization to Visit 1 (Vaccination 1)|Not vaccinated|4
6205823|NCT01536405|9868586|FG000|Visit 1 (Vaccination 1) to Visit 2|Withdrawal by Subject|12
6205824|NCT01536405|9868587|FG001|Visit 1 (Vaccination 1) to Visit 2|Withdrawal by Subject|18
6205825|NCT01536405|9868586|FG000|Visit 1 (Vaccination 1) to Visit 2|Lost to Follow-up|20
6285321|NCT02332824|9997257|FG003|Overall Study|Voluntary Withdrawal|0
6106890|NCT00798434|9724822|FG000|Open-Label|Other|1
6106891|NCT00798434|9724823|FG001|Open-Label|Other|2
6106892|NCT00798434|9724822|FG000|Open-Label|Not Treated|0
6106893|NCT00798434|9724823|FG001|Open-Label|Not Treated|1
6205826|NCT01536405|9868587|FG001|Visit 1 (Vaccination 1) to Visit 2|Lost to Follow-up|22
6205827|NCT01536405|9868586|FG000|Visit 2 to Visit 3 (Vaccination 2)|Withdrawal by Subject|17
6205828|NCT01536405|9868587|FG001|Visit 2 to Visit 3 (Vaccination 2)|Withdrawal by Subject|13
6205829|NCT01536405|9868586|FG000|Visit 2 to Visit 3 (Vaccination 2)|Adverse Event|3
6205830|NCT01536405|9868587|FG001|Visit 2 to Visit 3 (Vaccination 2)|Adverse Event|3
6205831|NCT01536405|9868586|FG000|Visit 2 to Visit 3 (Vaccination 2)|Lost to Follow-up|9
6205832|NCT01536405|9868587|FG001|Visit 2 to Visit 3 (Vaccination 2)|Lost to Follow-up|10
6205833|NCT01536405|9868586|FG000|Visit 2 to Visit 3 (Vaccination 2)|Protocol Violation|2
6205834|NCT01536405|9868587|FG001|Visit 2 to Visit 3 (Vaccination 2)|Protocol Violation|2
6205835|NCT01536405|9868586|FG000|Visit 3 (Vaccination 2) to Visit 4|Withdrawal by Subject|3
6205836|NCT01536405|9868587|FG001|Visit 3 (Vaccination 2) to Visit 4|Withdrawal by Subject|2
6205837|NCT01536405|9868586|FG000|Visit 3 (Vaccination 2) to Visit 4|Adverse Event|1
6205838|NCT01536405|9868587|FG001|Visit 3 (Vaccination 2) to Visit 4|Adverse Event|0
6205839|NCT01536405|9868586|FG000|Visit 3 (Vaccination 2) to Visit 4|Lost to Follow-up|16
6205840|NCT01536405|9868587|FG001|Visit 3 (Vaccination 2) to Visit 4|Lost to Follow-up|14
6205841|NCT01536405|9868586|FG000|Visit 4 to Extended Study Follow-up|Withdrawal by Subject|0
6205842|NCT01536405|9868587|FG001|Visit 4 to Extended Study Follow-up|Withdrawal by Subject|2
6205843|NCT01536405|9868586|FG000|Visit 4 to Extended Study Follow-up|Adverse Event|0
6205844|NCT01536405|9868587|FG001|Visit 4 to Extended Study Follow-up|Adverse Event|1
6205845|NCT01536405|9868586|FG000|Visit 4 to Extended Study Follow-up|Lost to Follow-up|20
6205846|NCT01536405|9868587|FG001|Visit 4 to Extended Study Follow-up|Lost to Follow-up|20
6205847|NCT01536418|9868595|FG000|Overall Study|Protocol Violation|2
6205848|NCT01536418|9868596|FG001|Overall Study|Protocol Violation|3
6205849|NCT01536418|9868595|FG000|Overall Study|Physician Decision|1
6205850|NCT01536418|9868596|FG001|Overall Study|Physician Decision|3
6205851|NCT01536418|9868595|FG000|Overall Study|Study closed/terminated|41
6205852|NCT01536418|9868596|FG001|Overall Study|Study closed/terminated|37
6205853|NCT01536418|9868595|FG000|Overall Study|Lack of Efficacy|10
6205854|NCT01536418|9868596|FG001|Overall Study|Lack of Efficacy|16
6205855|NCT01536418|9868595|FG000|Overall Study|Adverse Event|9
6205856|NCT01536418|9868596|FG001|Overall Study|Adverse Event|4
6205857|NCT01536418|9868595|FG000|Overall Study|Met Liver Chemistry Stopping criteria|1
6205858|NCT01536418|9868596|FG001|Overall Study|Met Liver Chemistry Stopping criteria|0
6205859|NCT01536418|9868595|FG000|Overall Study|Withdrawal by Subject|5
6205860|NCT01536418|9868596|FG001|Overall Study|Withdrawal by Subject|3
6205861|NCT01536535|9868616|FG000|Overall Study|Withdrawal by Subject|10
6205862|NCT01536535|9868617|FG001|Overall Study|Withdrawal by Subject|5
6205863|NCT01536535|9868616|FG000|Overall Study|Lost to Follow-up|4
6205864|NCT01536535|9868617|FG001|Overall Study|Lost to Follow-up|6
6205865|NCT01536535|9868616|FG000|Overall Study|Physician Decision|1
6205866|NCT01536535|9868617|FG001|Overall Study|Physician Decision|1
6205867|NCT01536535|9868616|FG000|Overall Study|Participant moved|0
6205868|NCT01536535|9868617|FG001|Overall Study|Participant moved|1
6205869|NCT01536561|9868624|FG000|Dosimetric and Therapeutic Treatment|Progressive Disease|40
6205870|NCT01536561|9868624|FG000|Dosimetric and Therapeutic Treatment|Received Alternate Treatment|2
6205871|NCT01536561|9868624|FG000|Dosimetric and Therapeutic Treatment|Adverse Event|1
6205872|NCT01536561|9868624|FG000|Dosimetric and Therapeutic Treatment|Lost to Follow-up|1
6205873|NCT01536561|9868624|FG000|Dosimetric and Therapeutic Treatment|Death|2
6205874|NCT01536561|9868624|FG000|Dosimetric and Therapeutic Treatment|Enrolled in Study BEX104526|13
6205875|NCT01536574|9868633|FG000|Overall Study|Adverse Event|4
6205876|NCT01536574|9868634|FG001|Overall Study|Adverse Event|5
6205877|NCT01536574|9868633|FG000|Overall Study|Withdrawal by Subject|1
6205878|NCT01536574|9868634|FG001|Overall Study|Withdrawal by Subject|2
6205879|NCT01536574|9868633|FG000|Overall Study|Lack of Efficacy|1
6205880|NCT01536574|9868634|FG001|Overall Study|Lack of Efficacy|0
6205881|NCT01536587|9868640|FG000|Overall Study|Adverse Event|2
6205882|NCT01536704|9868644|FG000|Washout Period 1|Withdrawal by Subject|1
6205883|NCT01536704|9868645|FG001|Washout Period 1|Withdrawal by Subject|2
6205884|NCT01536704|9868646|FG002|Washout Period 1|Withdrawal by Subject|0
6205885|NCT01536704|9868647|FG003|Washout Period 1|Withdrawal by Subject|0
6205886|NCT01536704|9868644|FG000|Washout Period 2|Adverse Event|1
6205887|NCT01536704|9868645|FG001|Washout Period 2|Adverse Event|0
6205888|NCT01536704|9868646|FG002|Washout Period 2|Adverse Event|0
6205889|NCT01536704|9868647|FG003|Washout Period 2|Adverse Event|0
6205890|NCT01536704|9868644|FG000|Washout Period 2|Withdrawal by Subject|0
6205891|NCT01536704|9868645|FG001|Washout Period 2|Withdrawal by Subject|0
6205892|NCT01536704|9868646|FG002|Washout Period 2|Withdrawal by Subject|0
6205893|NCT01536704|9868647|FG003|Washout Period 2|Withdrawal by Subject|1
6205894|NCT01536704|9868644|FG000|Period 3|Adverse Event|0
6205895|NCT01536704|9868645|FG001|Period 3|Adverse Event|0
6205896|NCT01536704|9868646|FG002|Period 3|Adverse Event|0
6205897|NCT01536704|9868647|FG003|Period 3|Adverse Event|1
6205898|NCT01536704|9868644|FG000|Washout Period 3|Adverse Event|0
6205899|NCT01536704|9868645|FG001|Washout Period 3|Adverse Event|0
6205900|NCT01536704|9868646|FG002|Washout Period 3|Adverse Event|1
6205901|NCT01536704|9868647|FG003|Washout Period 3|Adverse Event|0
6205902|NCT01536795|9868663|FG000|Overall Study|Lost to Follow-up|0
6106894|NCT00798603|9724847|FG000|Overall Study|Still on treatment as of 11/6/2012|1
6106895|NCT00798603|9724847|FG000|Overall Study|Withdrawal by Subject|10
6106896|NCT00798603|9724847|FG000|Overall Study|Adverse Event|22
6106897|NCT00798603|9724847|FG000|Overall Study|Physician Decision|1
6106898|NCT00798603|9724847|FG000|Overall Study|Lack of insurance coverage|1
6106899|NCT00798655|9724851|FG000|Overall Study|Did not receive at least one dose of pan|2
6106900|NCT00798694|9724857|FG000|Overall Study|Lost to Follow-up|1
6106901|NCT00798694|9724858|FG001|Overall Study|Lost to Follow-up|1
6106902|NCT00798694|9724857|FG000|Overall Study|Physician Decision|1
6106903|NCT00798694|9724858|FG001|Overall Study|Physician Decision|0
6106904|NCT00798707|9724873|FG000|Overall Study|Adverse Event|6
6106905|NCT00798707|9724874|FG001|Overall Study|Adverse Event|8
6106906|NCT00798707|9724875|FG002|Overall Study|Adverse Event|8
6106907|NCT00798707|9724873|FG000|Overall Study|Failed to return|2
6106908|NCT00798707|9724874|FG001|Overall Study|Failed to return|2
6106909|NCT00798707|9724875|FG002|Overall Study|Failed to return|0
6106910|NCT00798707|9724873|FG000|Overall Study|Investigator|0
6106911|NCT00798707|9724874|FG001|Overall Study|Investigator|1
6106912|NCT00798707|9724875|FG002|Overall Study|Investigator|2
6106913|NCT00798707|9724873|FG000|Overall Study|Lack of Efficacy|2
6106914|NCT00798707|9724874|FG001|Overall Study|Lack of Efficacy|2
6106915|NCT00798707|9724875|FG002|Overall Study|Lack of Efficacy|1
6106916|NCT00798707|9724873|FG000|Overall Study|Lost to Follow-up|5
6106917|NCT00798707|9724874|FG001|Overall Study|Lost to Follow-up|6
6106918|NCT00798707|9724875|FG002|Overall Study|Lost to Follow-up|6
6106919|NCT00798707|9724873|FG000|Overall Study|Other|0
6106920|NCT00798707|9724874|FG001|Overall Study|Other|1
6106921|NCT00798707|9724875|FG002|Overall Study|Other|0
6106922|NCT00798707|9724873|FG000|Overall Study|Protocol Violation|4
6106923|NCT00798707|9724874|FG001|Overall Study|Protocol Violation|0
6106924|NCT00798707|9724875|FG002|Overall Study|Protocol Violation|2
6106925|NCT00798707|9724873|FG000|Overall Study|Withdrawal by Subject|3
6106926|NCT00798707|9724874|FG001|Overall Study|Withdrawal by Subject|8
6106927|NCT00798707|9724875|FG002|Overall Study|Withdrawal by Subject|2
6106928|NCT00798707|9724873|FG000|Overall Study|Randomized not treated|4
6106929|NCT00798707|9724874|FG001|Overall Study|Randomized not treated|5
6106930|NCT00798707|9724875|FG002|Overall Study|Randomized not treated|1
6106931|NCT00798759|9724889|FG000|Overall Study|Adverse Event|3
6106932|NCT00798759|9724890|FG001|Overall Study|Adverse Event|3
6106933|NCT00798759|9724889|FG000|Overall Study|Lost to Follow-up|1
6106934|NCT00798759|9724890|FG001|Overall Study|Lost to Follow-up|1
6106935|NCT00798759|9724889|FG000|Overall Study|Protocol Violation|4
6106936|NCT00798759|9724890|FG001|Overall Study|Protocol Violation|8
6106937|NCT00798759|9724889|FG000|Overall Study|Other|0
6106938|NCT00798759|9724890|FG001|Overall Study|Other|1
6106939|NCT00798889|9724896|FG000|Overall Study|Adverse Event|53
6106940|NCT00798889|9724896|FG000|Overall Study|Protocol Violation|2
6106941|NCT00798889|9724896|FG000|Overall Study|Withdrawal by Subject|31
6106942|NCT00798889|9724896|FG000|Overall Study|Lost to Follow-up|1
6106943|NCT00798889|9724896|FG000|Overall Study|Lack of Efficacy|213
6106944|NCT00798889|9724896|FG000|Overall Study|Decision of Sponsor|11
6106945|NCT00798889|9724896|FG000|Overall Study|Enrolled, Not treated|3
6106946|NCT00798967|9724902|FG000|Overall Study|Adverse Event|2
6106947|NCT00798967|9724903|FG001|Overall Study|Adverse Event|3
6106948|NCT00798967|9724902|FG000|Overall Study|Withdrawal by Subject|0
6106949|NCT00798967|9724903|FG001|Overall Study|Withdrawal by Subject|1
6106950|NCT00798967|9724902|FG000|Overall Study|Physician Decision|1
6106951|NCT00798967|9724903|FG001|Overall Study|Physician Decision|0
6106952|NCT00798967|9724902|FG000|Overall Study|Randomized in error by site|1
6106953|NCT00798967|9724903|FG001|Overall Study|Randomized in error by site|0
6106954|NCT00799383|9724916|FG000|Overall Study|Protocol Violation|1
6106955|NCT00799383|9724917|FG001|Overall Study|Protocol Violation|1
6106956|NCT00799383|9724916|FG000|Overall Study|Adverse Event|0
6106957|NCT00799383|9724917|FG001|Overall Study|Adverse Event|1
6106958|NCT00799383|9724916|FG000|Overall Study|Lost to Follow-up|1
6106959|NCT00799383|9724917|FG001|Overall Study|Lost to Follow-up|2
6106960|NCT00799383|9724916|FG000|Overall Study|Urinary Calcium/Creatinine > 0.2|1
6106961|NCT00799383|9724917|FG001|Overall Study|Urinary Calcium/Creatinine > 0.2|1
6106962|NCT00799383|9724916|FG000|Overall Study|Withdrawal by Subject|0
6106963|NCT00799383|9724917|FG001|Overall Study|Withdrawal by Subject|1
6106964|NCT00799409|9724926|FG000|Overall Study|Withdrawal by Subject|1
6106965|NCT00799409|9724927|FG001|Overall Study|Withdrawal by Subject|0
6106966|NCT00799409|9724928|FG002|Overall Study|Withdrawal by Subject|0
6106967|NCT00799409|9724926|FG000|Overall Study|Lost to Follow-up|1
6106968|NCT00799409|9724927|FG001|Overall Study|Lost to Follow-up|0
6106969|NCT00799409|9724928|FG002|Overall Study|Lost to Follow-up|0
6285322|NCT02332824|9997258|FG004|Overall Study|Voluntary Withdrawal|0
6106970|NCT00799409|9724926|FG000|Overall Study|Optimal Dose Not Achieved|2
6285323|NCT02332824|9997259|FG005|Overall Study|Voluntary Withdrawal|0
6106971|NCT00799409|9724927|FG001|Overall Study|Optimal Dose Not Achieved|0
6106972|NCT00799409|9724928|FG002|Overall Study|Optimal Dose Not Achieved|0
6106973|NCT00799409|9724926|FG000|Overall Study|Failure to follow study protocol)|1
6106974|NCT00799409|9724927|FG001|Overall Study|Failure to follow study protocol)|0
6106975|NCT00799409|9724928|FG002|Overall Study|Failure to follow study protocol)|0
6106976|NCT00799409|9724926|FG000|Overall Study|Did not attend lab school day 1|1
6106977|NCT00799409|9724927|FG001|Overall Study|Did not attend lab school day 1|0
6106978|NCT00799409|9724928|FG002|Overall Study|Did not attend lab school day 1|0
6106979|NCT00799409|9724926|FG000|Overall Study|medication compliance|1
6106980|NCT00799409|9724927|FG001|Overall Study|medication compliance|0
6106981|NCT00799409|9724928|FG002|Overall Study|medication compliance|0
6106982|NCT00799422|9724936|FG000|First Week of Wear|Lost to Follow-up|0
6106983|NCT00799422|9724937|FG001|First Week of Wear|Lost to Follow-up|0
6106984|NCT00799422|9724938|FG002|First Week of Wear|Lost to Follow-up|1
6106985|NCT00799422|9724939|FG003|First Week of Wear|Lost to Follow-up|0
6106986|NCT00799422|9724940|FG004|First Week of Wear|Lost to Follow-up|0
6106987|NCT00799422|9724941|FG005|First Week of Wear|Lost to Follow-up|0
6106988|NCT00799422|9724936|FG000|First Week of Wear|Adverse Event|0
6106989|NCT00799422|9724937|FG001|First Week of Wear|Adverse Event|0
6106990|NCT00799422|9724938|FG002|First Week of Wear|Adverse Event|0
6106991|NCT00799422|9724939|FG003|First Week of Wear|Adverse Event|1
6106992|NCT00799422|9724940|FG004|First Week of Wear|Adverse Event|0
6106993|NCT00799422|9724941|FG005|First Week of Wear|Adverse Event|0
6106994|NCT00799487|9724965|FG000|Dose Adjustment Period|Lost to Follow-up|1
6106995|NCT00799487|9724966|FG001|Dose Adjustment Period|Lost to Follow-up|0
6106996|NCT00799487|9724967|FG002|Dose Adjustment Period|Lost to Follow-up|0
6106997|NCT00799487|9724965|FG000|Dose Adjustment Period|Adverse Event|2
6106998|NCT00799487|9724966|FG001|Dose Adjustment Period|Adverse Event|0
6106999|NCT00799487|9724967|FG002|Dose Adjustment Period|Adverse Event|0
6107000|NCT00799487|9724965|FG000|Dose Adjustment Period|Optimal Dose Not Achieved|8
6107001|NCT00799487|9724966|FG001|Dose Adjustment Period|Optimal Dose Not Achieved|0
6107002|NCT00799487|9724967|FG002|Dose Adjustment Period|Optimal Dose Not Achieved|0
6107003|NCT00799487|9724965|FG000|Dose Adjustment Period|Investigator Discretion|2
6107004|NCT00799487|9724966|FG001|Dose Adjustment Period|Investigator Discretion|0
6107005|NCT00799487|9724967|FG002|Dose Adjustment Period|Investigator Discretion|0
6107006|NCT00799487|9724965|FG000|Dose Adjustment Period|Withdrawal by Subject|3
6107007|NCT00799487|9724966|FG001|Dose Adjustment Period|Withdrawal by Subject|0
6107008|NCT00799487|9724967|FG002|Dose Adjustment Period|Withdrawal by Subject|0
6107009|NCT00799487|9724965|FG000|Dose Adjustment Period|Parent to home school child (exclusion)|1
6107010|NCT00799487|9724966|FG001|Dose Adjustment Period|Parent to home school child (exclusion)|0
6107011|NCT00799487|9724967|FG002|Dose Adjustment Period|Parent to home school child (exclusion)|0
6107012|NCT00799487|9724965|FG000|Dose Adjustment Period|Child too young (exclusion)|1
6107013|NCT00799487|9724966|FG001|Dose Adjustment Period|Child too young (exclusion)|0
6107014|NCT00799487|9724967|FG002|Dose Adjustment Period|Child too young (exclusion)|0
6107015|NCT00799487|9724965|FG000|Dose Adjustment Period|Missed laboratory day 1|1
6107016|NCT00799487|9724966|FG001|Dose Adjustment Period|Missed laboratory day 1|0
6107017|NCT00799487|9724967|FG002|Dose Adjustment Period|Missed laboratory day 1|0
6107018|NCT00799487|9724965|FG000|Dose Adjustment Period|ADHD RS-IV rating scale >85th percentile|2
6107019|NCT00799487|9724966|FG001|Dose Adjustment Period|ADHD RS-IV rating scale >85th percentile|0
6107020|NCT00799487|9724967|FG002|Dose Adjustment Period|ADHD RS-IV rating scale >85th percentile|0
6107021|NCT00799487|9724965|FG000|Double-Blind Assessment Period|Lost to Follow-up|0
6107022|NCT00799487|9724966|FG001|Double-Blind Assessment Period|Lost to Follow-up|0
6107023|NCT00799487|9724967|FG002|Double-Blind Assessment Period|Lost to Follow-up|1
6107024|NCT00799487|9724965|FG000|Double-Blind Assessment Period|Subject was out of the state|0
6107025|NCT00799487|9724966|FG001|Double-Blind Assessment Period|Subject was out of the state|0
6107026|NCT00799487|9724967|FG002|Double-Blind Assessment Period|Subject was out of the state|1
6107027|NCT00799487|9724965|FG000|Double-Blind Assessment Period|Overslept and missed lab day 2|0
6107028|NCT00799487|9724966|FG001|Double-Blind Assessment Period|Overslept and missed lab day 2|1
6107029|NCT00799487|9724967|FG002|Double-Blind Assessment Period|Overslept and missed lab day 2|0
6107030|NCT00799591|9724982|FG000|Overall Study|De-escalation of doses|20
6107031|NCT00799591|9724982|FG000|Overall Study|Death|14
6107032|NCT00799591|9724982|FG000|Overall Study|Technical failure|12
6107033|NCT00799591|9724982|FG000|Overall Study|Resistant germ|11
6107034|NCT00799591|9724982|FG000|Overall Study|New infection|4
6107035|NCT00799591|9724982|FG000|Overall Study|Resistance germ and technical failure|2
6107036|NCT00799591|9724982|FG000|Overall Study|Persistance of fever undetermined origin|1
6107037|NCT00799591|9724982|FG000|Overall Study|Antibiotic changed, no apparent reason|1
6107038|NCT00799591|9724982|FG000|Overall Study|Infectious origin not probable|1
6107039|NCT00799617|9725001|FG000|Main Testosterone Trial|Randomized in error|1
6107040|NCT00799617|9725002|FG001|Main Testosterone Trial|Randomized in error|1
6107041|NCT00799617|9725001|FG000|Main Testosterone Trial|Lost to Follow-up|18
6107042|NCT00799617|9725002|FG001|Main Testosterone Trial|Lost to Follow-up|20
6107043|NCT00799617|9725001|FG000|Sexual Funtion Trial|Lost to Follow-up|12
6107044|NCT00799617|9725002|FG001|Sexual Funtion Trial|Lost to Follow-up|14
6107045|NCT00799617|9725001|FG000|Sexual Funtion Trial|No Baseline Data|4
6107046|NCT00799617|9725002|FG001|Sexual Funtion Trial|No Baseline Data|7
6107047|NCT00799617|9725001|FG000|Physical Function Trial|Lost to Follow-up|6
6107048|NCT00799617|9725002|FG001|Physical Function Trial|Lost to Follow-up|11
6107049|NCT00799617|9725001|FG000|Vitality Trial|Lost to Follow-up|7
6107050|NCT00799617|9725002|FG001|Vitality Trial|Lost to Follow-up|22
6205903|NCT01536795|9868664|FG001|Overall Study|Lost to Follow-up|2
6205904|NCT01536795|9868663|FG000|Overall Study|Lack of Efficacy|1
6205905|NCT01536795|9868664|FG001|Overall Study|Lack of Efficacy|0
6107051|NCT00799617|9725001|FG000|Cardiovascular Trial|Month 12 scan not available|15
6107052|NCT00799617|9725002|FG001|Cardiovascular Trial|Month 12 scan not available|15
6107053|NCT00799617|9725001|FG000|Cardiovascular Trial|Baseline scan not analyzable|0
6107054|NCT00799617|9725002|FG001|Cardiovascular Trial|Baseline scan not analyzable|2
6107055|NCT00799617|9725001|FG000|Bone Trial|Month 12 scan not available|6
6107056|NCT00799617|9725002|FG001|Bone Trial|Month 12 scan not available|16
6107057|NCT00799617|9725001|FG000|Cognitive Function Trial|Lost to Follow-up|0
6107058|NCT00799617|9725002|FG001|Cognitive Function Trial|Lost to Follow-up|1
6107059|NCT00799617|9725001|FG000|Anemia Trial|Withdrawal by Subject|3
6107060|NCT00799617|9725002|FG001|Anemia Trial|Withdrawal by Subject|3
6107061|NCT00799708|9725021|FG000|Overall Study|non-compliance|1
6107062|NCT00799708|9725022|FG001|Overall Study|non-compliance|0
6107063|NCT00799708|9725023|FG002|Overall Study|non-compliance|0
6107064|NCT00799825|9725045|FG000|Overall Study|Adverse Event|1
6107065|NCT00799825|9725045|FG000|Overall Study|Withdrawal by Subject|6
6107066|NCT00799825|9725045|FG000|Overall Study|Lost to Follow-up|38
6107067|NCT00799825|9725045|FG000|Overall Study|Pregnancy|3
6107068|NCT00799903|9725051|FG000|Overall Study|Investigator Site Closed|25
6107069|NCT00799903|9725052|FG001|Overall Study|Investigator Site Closed|23
6107070|NCT00799903|9725051|FG000|Overall Study|Withdrawal by Subject|179
6107071|NCT00799903|9725052|FG001|Overall Study|Withdrawal by Subject|175
6107072|NCT00799903|9725051|FG000|Overall Study|Lost to Follow-up|69
6107073|NCT00799903|9725052|FG001|Overall Study|Lost to Follow-up|80
6107074|NCT00800176|9725078|FG000|Overall Study|Adverse Event|2
6107075|NCT00800176|9725079|FG001|Overall Study|Adverse Event|1
6107076|NCT00800176|9725080|FG002|Overall Study|Adverse Event|0
6107077|NCT00800176|9725081|FG003|Overall Study|Adverse Event|2
6107078|NCT00800176|9725082|FG004|Overall Study|Adverse Event|1
6107079|NCT00800176|9725083|FG005|Overall Study|Adverse Event|1
6107080|NCT00800176|9725078|FG000|Overall Study|Refused treatment|3
6107081|NCT00800176|9725079|FG001|Overall Study|Refused treatment|2
6107082|NCT00800176|9725080|FG002|Overall Study|Refused treatment|0
6107083|NCT00800176|9725081|FG003|Overall Study|Refused treatment|0
6107084|NCT00800176|9725082|FG004|Overall Study|Refused treatment|1
6107085|NCT00800176|9725083|FG005|Overall Study|Refused treatment|4
6107086|NCT00800176|9725078|FG000|Overall Study|Failure to return|3
6107087|NCT00800176|9725079|FG001|Overall Study|Failure to return|3
6107088|NCT00800176|9725080|FG002|Overall Study|Failure to return|0
6107089|NCT00800176|9725081|FG003|Overall Study|Failure to return|2
6107090|NCT00800176|9725082|FG004|Overall Study|Failure to return|0
6107091|NCT00800176|9725083|FG005|Overall Study|Failure to return|0
6107092|NCT00800176|9725078|FG000|Overall Study|Other|1
6107093|NCT00800176|9725079|FG001|Overall Study|Other|0
6107094|NCT00800176|9725080|FG002|Overall Study|Other|0
6107095|NCT00800176|9725081|FG003|Overall Study|Other|0
6107096|NCT00800176|9725082|FG004|Overall Study|Other|2
6107097|NCT00800176|9725083|FG005|Overall Study|Other|0
6107098|NCT00800202|9725099|FG000|Overall Study|Adverse Event|7
6107099|NCT00800202|9725100|FG001|Overall Study|Adverse Event|6
6107100|NCT00800202|9725099|FG000|Overall Study|Death|1
6107101|NCT00800202|9725100|FG001|Overall Study|Death|0
6107102|NCT00800202|9725099|FG000|Overall Study|Other|5
6107103|NCT00800202|9725100|FG001|Overall Study|Other|0
6107104|NCT00800202|9725099|FG000|Overall Study|Disease Progression|54
6107105|NCT00800202|9725100|FG001|Overall Study|Disease Progression|18
6107106|NCT00800384|9725121|FG000|Overall Study|Withdrawal by Subject|24
6107107|NCT00800384|9725122|FG001|Overall Study|Withdrawal by Subject|17
6107108|NCT00800384|9725121|FG000|Overall Study|Lost to Follow-up|17
6107109|NCT00800384|9725122|FG001|Overall Study|Lost to Follow-up|26
6107110|NCT00800436|9725136|FG000|Overall Study|Withdrawal by Subject|0
6107111|NCT00800436|9725137|FG001|Overall Study|Withdrawal by Subject|0
6107112|NCT00800436|9725138|FG002|Overall Study|Withdrawal by Subject|1
6107113|NCT00800436|9725139|FG003|Overall Study|Withdrawal by Subject|1
6107114|NCT00800436|9725140|FG004|Overall Study|Withdrawal by Subject|0
6107115|NCT00800436|9725141|FG005|Overall Study|Withdrawal by Subject|0
6107116|NCT00800436|9725142|FG006|Overall Study|Withdrawal by Subject|0
6107117|NCT00800540|9725158|FG000|Period One: 6 Weeks|Noncompliance|1
6107118|NCT00800540|9725159|FG001|Period One: 6 Weeks|Noncompliance|0
6107119|NCT00800540|9725158|FG000|Period One: 6 Weeks|Pt Decision Unrelated to Adverse Event|0
6107120|NCT00800540|9725159|FG001|Period One: 6 Weeks|Pt Decision Unrelated to Adverse Event|1
6107121|NCT00800540|9725158|FG000|Period 2: 6 Weeks|Adverse Event|0
6107122|NCT00800540|9725159|FG001|Period 2: 6 Weeks|Adverse Event|1
6107123|NCT00800683|9725167|FG000|Overall Study|Adverse Event|11
6107124|NCT00800683|9725168|FG001|Overall Study|Adverse Event|8
6107125|NCT00800683|9725167|FG000|Overall Study|Lost to Follow-up|3
6107126|NCT00800683|9725168|FG001|Overall Study|Lost to Follow-up|1
6107127|NCT00800683|9725167|FG000|Overall Study|Withdrawal by Subject|1
6107128|NCT00800683|9725168|FG001|Overall Study|Withdrawal by Subject|7
6107129|NCT00800683|9725167|FG000|Overall Study|Lack of Efficacy|1
6107130|NCT00800683|9725168|FG001|Overall Study|Lack of Efficacy|1
6107131|NCT00800683|9725167|FG000|Overall Study|Other|1
6107132|NCT00800683|9725168|FG001|Overall Study|Other|2
6107133|NCT00800735|9725174|FG000|Overall Study|Administrative/Other|2
6107134|NCT00800735|9725174|FG000|Overall Study|Insufficient Therapeutic Response|2
6205906|NCT01536860|9868670|FG000|Washout Period (3 Days)|Lost to Follow-up|1
6107135|NCT00800735|9725174|FG000|Overall Study|Violation of Selection Criteria at Entry|7
6107136|NCT00800735|9725174|FG000|Overall Study|Withdrew Consent|3
6107137|NCT00800982|9725193|FG000|Overall Study|Lost to Follow-up|1
6107138|NCT00800982|9725194|FG001|Overall Study|Lost to Follow-up|2
6107139|NCT00800982|9725193|FG000|Overall Study|Withdrawal by Subject|0
6107140|NCT00800982|9725194|FG001|Overall Study|Withdrawal by Subject|1
6107141|NCT00800982|9725193|FG000|Overall Study|Patient moved out of state|1
6107142|NCT00800982|9725194|FG001|Overall Study|Patient moved out of state|0
6107143|NCT00801099|9725200|FG000|Overall Study|Lost to Follow-up|101
6107144|NCT00801229|9725223|FG000|Signed Consent|Withdrawal by Subject|2
6107145|NCT00801229|9725224|FG001|Signed Consent|Withdrawal by Subject|2
6107146|NCT00801229|9725223|FG000|Signed Consent|Found Ineligible|1
6107147|NCT00801229|9725224|FG001|Signed Consent|Found Ineligible|1
6107148|NCT00801229|9725223|FG000|Received Study Drug/Placebo|Elevated SGOT level|1
6107149|NCT00801229|9725224|FG001|Received Study Drug/Placebo|Elevated SGOT level|0
6107150|NCT00801229|9725223|FG000|Received Study Drug/Placebo|Sub-threshold ADHD|0
6107151|NCT00801229|9725224|FG001|Received Study Drug/Placebo|Sub-threshold ADHD|1
6107152|NCT00801229|9725223|FG000|Received Study Drug/Placebo|Simulator sickness|1
6107153|NCT00801229|9725224|FG001|Received Study Drug/Placebo|Simulator sickness|1
6107154|NCT00801229|9725223|FG000|Received Study Drug/Placebo|Withdrawal by Subject|1
6107155|NCT00801229|9725224|FG001|Received Study Drug/Placebo|Withdrawal by Subject|0
6107156|NCT00801229|9725223|FG000|Received Study Drug/Placebo|Lost to Follow-up|0
6107157|NCT00801229|9725224|FG001|Received Study Drug/Placebo|Lost to Follow-up|1
6107158|NCT00801229|9725223|FG000|Received Study Drug/Placebo|Adverse Event|1
6107159|NCT00801229|9725224|FG001|Received Study Drug/Placebo|Adverse Event|1
6107160|NCT00801242|9725230|FG000|Overall Study|Adverse Event|10
6107161|NCT00801242|9725230|FG000|Overall Study|Withdrawal by Subject|13
6107162|NCT00801242|9725230|FG000|Overall Study|Protocol Violation|5
6107163|NCT00801242|9725230|FG000|Overall Study|Physician Decision|3
6107164|NCT00801242|9725230|FG000|Overall Study|Lost to Follow-up|1
6107165|NCT00801242|9725230|FG000|Overall Study|Miscellaneous reasons|20
6107166|NCT00801632|9725273|FG000|Overall Study|Re-transplant|1
6107167|NCT00801892|9725314|FG000|Main Study Period|Withdrawal by Subject|0
6107168|NCT00801892|9725315|FG001|Main Study Period|Withdrawal by Subject|1
6107169|NCT00801892|9725314|FG000|Sham Crossover Period|Lost to Follow-up|0
6107170|NCT00801892|9725315|FG001|Sham Crossover Period|Lost to Follow-up|2
6107171|NCT00801983|9725325|FG000|Period 1|Lost to Follow-up|2
6107172|NCT00801983|9725326|FG001|Period 1|Lost to Follow-up|0
6107173|NCT00801983|9725325|FG000|Period 1|Withdrawal by Subject|2
6107174|NCT00801983|9725326|FG001|Period 1|Withdrawal by Subject|8
6107175|NCT00801983|9725325|FG000|Period 2|Withdrawal by Subject|2
6107176|NCT00801983|9725326|FG001|Period 2|Withdrawal by Subject|1
6107177|NCT00802074|9725338|FG000|Overall Study|Adverse Event|1
6107178|NCT00802074|9725339|FG001|Overall Study|Adverse Event|1
6107179|NCT00802074|9725340|FG002|Overall Study|Adverse Event|1
6107180|NCT00802074|9725341|FG003|Overall Study|Adverse Event|0
6107181|NCT00802074|9725342|FG004|Overall Study|Adverse Event|0
6107182|NCT00802074|9725343|FG005|Overall Study|Adverse Event|0
6107183|NCT00802074|9725338|FG000|Overall Study|Withdrawal by Subject|1
6107184|NCT00802074|9725339|FG001|Overall Study|Withdrawal by Subject|0
6107185|NCT00802074|9725340|FG002|Overall Study|Withdrawal by Subject|0
6107186|NCT00802074|9725341|FG003|Overall Study|Withdrawal by Subject|0
6107187|NCT00802074|9725342|FG004|Overall Study|Withdrawal by Subject|0
6107188|NCT00802074|9725343|FG005|Overall Study|Withdrawal by Subject|0
6107189|NCT00802178|9725383|FG000|Overall Study|Lack of Efficacy|36
6107190|NCT00802178|9725383|FG000|Overall Study|Insufficient tolerability (IT)|17
6107191|NCT00802178|9725383|FG000|Overall Study|Withdrawal by Subject|18
6107192|NCT00802178|9725383|FG000|Overall Study|Other|32
6107193|NCT00802178|9725383|FG000|Overall Study|Lack of efficacy and patient wish|1
6107194|NCT00802178|9725383|FG000|Overall Study|IT and patient wish|8
6107195|NCT00802178|9725383|FG000|Overall Study|Patients wish and other reason|1
6107196|NCT00802360|9725403|FG000|Overall Study|Stimulation failure|4
6107197|NCT00802360|9725404|FG001|Overall Study|Stimulation failure|0
6107198|NCT00802360|9725405|FG002|Overall Study|Stimulation failure|3
6107199|NCT00802360|9725406|FG003|Overall Study|Stimulation failure|3
6107200|NCT00802360|9725403|FG000|Overall Study|Inadequate number of oocytes retrieved|0
6107201|NCT00802360|9725404|FG001|Overall Study|Inadequate number of oocytes retrieved|0
6107202|NCT00802360|9725405|FG002|Overall Study|Inadequate number of oocytes retrieved|0
6107203|NCT00802360|9725406|FG003|Overall Study|Inadequate number of oocytes retrieved|1
6107204|NCT00802360|9725403|FG000|Overall Study|Cycle cancelled|0
6107205|NCT00802360|9725404|FG001|Overall Study|Cycle cancelled|1
6205907|NCT01536860|9868671|FG001|Washout Period (3 Days)|Lost to Follow-up|0
6205908|NCT01536860|9868672|FG002|Washout Period (3 Days)|Lost to Follow-up|0
6107206|NCT00802360|9725405|FG002|Overall Study|Cycle cancelled|1
6107207|NCT00802360|9725406|FG003|Overall Study|Cycle cancelled|1
6107208|NCT00802360|9725403|FG000|Overall Study|Risk of ovarian hyperstimulation syndrom|0
6107209|NCT00802360|9725404|FG001|Overall Study|Risk of ovarian hyperstimulation syndrom|0
6107210|NCT00802360|9725405|FG002|Overall Study|Risk of ovarian hyperstimulation syndrom|0
6107211|NCT00802360|9725406|FG003|Overall Study|Risk of ovarian hyperstimulation syndrom|1
6107212|NCT00802360|9725403|FG000|Overall Study|No positive serum pregnancy|17
6107213|NCT00802360|9725404|FG001|Overall Study|No positive serum pregnancy|20
6107214|NCT00802360|9725405|FG002|Overall Study|No positive serum pregnancy|14
6107215|NCT00802360|9725406|FG003|Overall Study|No positive serum pregnancy|10
6107216|NCT00802360|9725403|FG000|Overall Study|Pregnancy not confirmed by ultrasound|1
6107217|NCT00802360|9725404|FG001|Overall Study|Pregnancy not confirmed by ultrasound|0
6205909|NCT01536951|9868712|FG000|First Intervention and Washout Period 1|Withdrawal by Subject|0
6205910|NCT01536951|9868713|FG001|First Intervention and Washout Period 1|Withdrawal by Subject|0
6205911|NCT01536951|9868714|FG002|First Intervention and Washout Period 1|Withdrawal by Subject|1
6205912|NCT01536951|9868715|FG003|First Intervention and Washout Period 1|Withdrawal by Subject|0
6205913|NCT01536951|9868716|FG004|First Intervention and Washout Period 1|Withdrawal by Subject|0
6205914|NCT01536951|9868717|FG005|First Intervention and Washout Period 1|Withdrawal by Subject|0
6205915|NCT01536951|9868718|FG006|First Intervention and Washout Period 1|Withdrawal by Subject|0
6205916|NCT01536951|9868719|FG007|First Intervention and Washout Period 1|Withdrawal by Subject|0
6205917|NCT01536951|9868720|FG008|First Intervention and Washout Period 1|Withdrawal by Subject|0
6205918|NCT01536951|9868712|FG000|Second Intervention and Washout Period 2|Adverse Event|0
6205919|NCT01536951|9868713|FG001|Second Intervention and Washout Period 2|Adverse Event|0
6205920|NCT01536951|9868714|FG002|Second Intervention and Washout Period 2|Adverse Event|0
6205921|NCT01536951|9868715|FG003|Second Intervention and Washout Period 2|Adverse Event|0
6205922|NCT01536951|9868716|FG004|Second Intervention and Washout Period 2|Adverse Event|0
6205923|NCT01536951|9868717|FG005|Second Intervention and Washout Period 2|Adverse Event|0
6205924|NCT01536951|9868718|FG006|Second Intervention and Washout Period 2|Adverse Event|0
6205925|NCT01536951|9868719|FG007|Second Intervention and Washout Period 2|Adverse Event|1
6205926|NCT01536951|9868720|FG008|Second Intervention and Washout Period 2|Adverse Event|0
6205927|NCT01537042|9868749|FG000|Overall Study|Adverse Event|0
6205928|NCT01537042|9868750|FG001|Overall Study|Adverse Event|2
6205929|NCT01537042|9868749|FG000|Overall Study|Lack of Efficacy|0
6205930|NCT01537042|9868750|FG001|Overall Study|Lack of Efficacy|1
6205931|NCT01537042|9868749|FG000|Overall Study|Protocol Violation|0
6205932|NCT01537042|9868750|FG001|Overall Study|Protocol Violation|1
6205933|NCT01537042|9868749|FG000|Overall Study|Other|0
6205934|NCT01537042|9868750|FG001|Overall Study|Other|1
6205935|NCT01537068|9868762|FG000|Overall Study|Lost to Follow-up|2
6205936|NCT01537068|9868763|FG001|Overall Study|Lost to Follow-up|1
6285324|NCT02332824|9997254|FG000|Overall Study|Inconvenient schedule|1
6285325|NCT02332824|9997255|FG001|Overall Study|Inconvenient schedule|1
6285326|NCT02332824|9997256|FG002|Overall Study|Inconvenient schedule|0
6285327|NCT02332824|9997257|FG003|Overall Study|Inconvenient schedule|0
6285328|NCT02332824|9997258|FG004|Overall Study|Inconvenient schedule|0
6285329|NCT02332824|9997259|FG005|Overall Study|Inconvenient schedule|0
6285330|NCT02332824|9997254|FG000|Overall Study|Transfer|0
6285331|NCT02332824|9997255|FG001|Overall Study|Transfer|0
6285332|NCT02332824|9997256|FG002|Overall Study|Transfer|1
6285333|NCT02332824|9997257|FG003|Overall Study|Transfer|1
6285334|NCT02332824|9997258|FG004|Overall Study|Transfer|0
6285335|NCT02332824|9997259|FG005|Overall Study|Transfer|0
6285336|NCT02332876|9997284|FG000|Overall Study|Lost to Follow-up|1
6285337|NCT02332876|9997285|FG001|Overall Study|Lost to Follow-up|1
6285338|NCT02332889|9997291|FG000|Overall Study|Physician Decision|1
6285339|NCT02332915|9997301|FG000|Overall Study|Moved out of region|3
6285340|NCT02332915|9997302|FG001|Overall Study|Moved out of region|0
6285341|NCT02332915|9997301|FG000|Overall Study|Unrelated illness|1
6285342|NCT02332915|9997302|FG001|Overall Study|Unrelated illness|1
6285343|NCT02332915|9997301|FG000|Overall Study|Travel distance prohibitive|0
6285344|NCT02332915|9997302|FG001|Overall Study|Travel distance prohibitive|1
6285345|NCT02332915|9997301|FG000|Overall Study|did not meet inclusion criteria|2
6285346|NCT02332915|9997302|FG001|Overall Study|did not meet inclusion criteria|4
6285347|NCT02333331|9997337|FG000|Overall Study|Adverse Event|1
6285348|NCT02333331|9997338|FG001|Overall Study|Adverse Event|0
6285349|NCT02333331|9997339|FG002|Overall Study|Adverse Event|4
6285350|NCT02333331|9997340|FG003|Overall Study|Adverse Event|1
6285351|NCT02333331|9997337|FG000|Overall Study|Death|0
6285352|NCT02333331|9997338|FG001|Overall Study|Death|0
6285353|NCT02333331|9997339|FG002|Overall Study|Death|2
6285354|NCT02333331|9997340|FG003|Overall Study|Death|0
6285355|NCT02333331|9997337|FG000|Overall Study|Lost to Follow-up|0
6285356|NCT02333331|9997338|FG001|Overall Study|Lost to Follow-up|0
6285357|NCT02333331|9997339|FG002|Overall Study|Lost to Follow-up|1
6285358|NCT02333331|9997340|FG003|Overall Study|Lost to Follow-up|0
6285359|NCT02333331|9997337|FG000|Overall Study|Physician Decision|0
6285360|NCT02333331|9997338|FG001|Overall Study|Physician Decision|1
6285361|NCT02333331|9997339|FG002|Overall Study|Physician Decision|0
6285362|NCT02333331|9997340|FG003|Overall Study|Physician Decision|0
6285363|NCT02333331|9997337|FG000|Overall Study|Protocol Deviation|0
6285364|NCT02333331|9997338|FG001|Overall Study|Protocol Deviation|3
6285365|NCT02333331|9997339|FG002|Overall Study|Protocol Deviation|2
6285366|NCT02333331|9997340|FG003|Overall Study|Protocol Deviation|1
6285367|NCT02333331|9997337|FG000|Overall Study|Patient/Guardian Decision|1
6285368|NCT02333331|9997338|FG001|Overall Study|Patient/Guardian Decision|2
6285369|NCT02333331|9997339|FG002|Overall Study|Patient/Guardian Decision|9
6285370|NCT02333331|9997340|FG003|Overall Study|Patient/Guardian Decision|1
6285371|NCT02333383|9997350|FG000|Overall Study|Adalimumab discontinuation|21
6285372|NCT02333383|9997350|FG000|Overall Study|Lost to Follow-up|15
6107218|NCT00802360|9725405|FG002|Overall Study|Pregnancy not confirmed by ultrasound|1
6205937|NCT01537068|9868762|FG000|Overall Study|Adverse Event|0
6205938|NCT01537068|9868763|FG001|Overall Study|Adverse Event|1
6205939|NCT01537068|9868762|FG000|Overall Study|Withdrawal by Subject|1
6205940|NCT01537068|9868763|FG001|Overall Study|Withdrawal by Subject|1
6205941|NCT01537068|9868762|FG000|Overall Study|Lack of Efficacy|1
6205942|NCT01537068|9868763|FG001|Overall Study|Lack of Efficacy|0
6205943|NCT01537081|9868772|FG000|Overall Study|Adverse Event|5
6205944|NCT01537081|9868773|FG001|Overall Study|Adverse Event|2
6205945|NCT01537081|9868774|FG002|Overall Study|Adverse Event|2
6205946|NCT01537081|9868772|FG000|Overall Study|Lack of Efficacy|2
6285373|NCT02333383|9997350|FG000|Overall Study|Withdrawal by Subject|3
6285374|NCT02333383|9997350|FG000|Overall Study|Transfer to another hospital|2
6285375|NCT02333487|9997357|FG000|Overall Study|Adverse Event|0
6285376|NCT02333487|9997358|FG001|Overall Study|Adverse Event|2
6285377|NCT02333487|9997359|FG002|Overall Study|Adverse Event|0
6205947|NCT01537081|9868773|FG001|Overall Study|Lack of Efficacy|1
6205948|NCT01537081|9868774|FG002|Overall Study|Lack of Efficacy|0
6205949|NCT01537081|9868772|FG000|Overall Study|Lost to Follow-up|17
6205950|NCT01537081|9868773|FG001|Overall Study|Lost to Follow-up|15
6205951|NCT01537081|9868774|FG002|Overall Study|Lost to Follow-up|9
6205952|NCT01537081|9868772|FG000|Overall Study|Protocol Violation|3
6107219|NCT00802360|9725406|FG003|Overall Study|Pregnancy not confirmed by ultrasound|0
6107220|NCT00802360|9725403|FG000|Overall Study|Pregnancy loss/miscarriage|0
6107221|NCT00802360|9725404|FG001|Overall Study|Pregnancy loss/miscarriage|2
6107222|NCT00802360|9725405|FG002|Overall Study|Pregnancy loss/miscarriage|0
6107223|NCT00802360|9725406|FG003|Overall Study|Pregnancy loss/miscarriage|3
6107224|NCT00802360|9725403|FG000|Overall Study|Other|2
6107225|NCT00802360|9725404|FG001|Overall Study|Other|3
6107226|NCT00802360|9725405|FG002|Overall Study|Other|6
6107227|NCT00802360|9725406|FG003|Overall Study|Other|3
6107228|NCT00802438|9725427|FG000|Overall Study|Screen Failure|20
6107229|NCT00802438|9725427|FG000|Overall Study|Withdrawal by Subject|7
6107230|NCT00802438|9725427|FG000|Overall Study|Physician Decision|1
6107231|NCT00802464|9725435|FG000|Month 0 - Month 8|Adverse Event|0
6107232|NCT00802464|9725436|FG001|Month 0 - Month 8|Adverse Event|1
6107233|NCT00802464|9725437|FG002|Month 0 - Month 8|Adverse Event|1
6107234|NCT00802464|9725438|FG003|Month 0 - Month 8|Adverse Event|2
6107235|NCT00802464|9725435|FG000|Month 0 - Month 8|Protocol Violation|0
6107236|NCT00802464|9725436|FG001|Month 0 - Month 8|Protocol Violation|0
6107237|NCT00802464|9725437|FG002|Month 0 - Month 8|Protocol Violation|1
6107238|NCT00802464|9725438|FG003|Month 0 - Month 8|Protocol Violation|0
6107239|NCT00802464|9725435|FG000|Month 0 - Month 8|Withdrawal by Subject|0
6107240|NCT00802464|9725436|FG001|Month 0 - Month 8|Withdrawal by Subject|1
6107241|NCT00802464|9725437|FG002|Month 0 - Month 8|Withdrawal by Subject|2
6107242|NCT00802464|9725438|FG003|Month 0 - Month 8|Withdrawal by Subject|5
6107243|NCT00802464|9725435|FG000|Month 0 - Month 8|Lost to Follow-up|0
6107244|NCT00802464|9725436|FG001|Month 0 - Month 8|Lost to Follow-up|1
6107245|NCT00802464|9725437|FG002|Month 0 - Month 8|Lost to Follow-up|2
6107246|NCT00802464|9725438|FG003|Month 0 - Month 8|Lost to Follow-up|2
6107247|NCT00802464|9725435|FG000|Month 0 - Month 8|Other|0
6107248|NCT00802464|9725436|FG001|Month 0 - Month 8|Other|0
6107249|NCT00802464|9725437|FG002|Month 0 - Month 8|Other|1
6107250|NCT00802464|9725438|FG003|Month 0 - Month 8|Other|0
6107251|NCT00802464|9725435|FG000|Month 8 - Month 14|Adverse Event|0
6107252|NCT00802464|9725436|FG001|Month 8 - Month 14|Adverse Event|1
6107253|NCT00802464|9725437|FG002|Month 8 - Month 14|Adverse Event|0
6107254|NCT00802464|9725438|FG003|Month 8 - Month 14|Adverse Event|0
6107255|NCT00802464|9725435|FG000|Month 8 - Month 14|Withdrawal by Subject|1
6107256|NCT00802464|9725436|FG001|Month 8 - Month 14|Withdrawal by Subject|1
6107257|NCT00802464|9725437|FG002|Month 8 - Month 14|Withdrawal by Subject|0
6107258|NCT00802464|9725438|FG003|Month 8 - Month 14|Withdrawal by Subject|0
6107259|NCT00802464|9725435|FG000|Month 8 - Month 14|Lost to Follow-up|0
6107260|NCT00802464|9725436|FG001|Month 8 - Month 14|Lost to Follow-up|0
6107261|NCT00802464|9725437|FG002|Month 8 - Month 14|Lost to Follow-up|1
6107262|NCT00802464|9725438|FG003|Month 8 - Month 14|Lost to Follow-up|0
6107263|NCT00802529|9725465|FG000|Overall Study|Lost to Follow-up|0
6107264|NCT00802529|9725466|FG001|Overall Study|Lost to Follow-up|1
6107265|NCT00802672|9725484|FG000|Overall Study|Lack of fungal pathogen at baseline|56
6107266|NCT00802672|9725485|FG001|Overall Study|Lack of fungal pathogen at baseline|43
6107267|NCT00802672|9725486|FG002|Overall Study|Lack of fungal pathogen at baseline|25
6205953|NCT01537081|9868773|FG001|Overall Study|Protocol Violation|2
6205954|NCT01537081|9868774|FG002|Overall Study|Protocol Violation|2
6205955|NCT01537081|9868772|FG000|Overall Study|Withdrawal by Subject|6
6205956|NCT01537081|9868773|FG001|Overall Study|Withdrawal by Subject|11
6205957|NCT01537081|9868774|FG002|Overall Study|Withdrawal by Subject|3
6205958|NCT01537081|9868772|FG000|Overall Study|Physician Decision|5
6205959|NCT01537081|9868773|FG001|Overall Study|Physician Decision|6
6205960|NCT01537081|9868774|FG002|Overall Study|Physician Decision|0
6205961|NCT01537081|9868772|FG000|Overall Study|Sponsor decision|0
6205962|NCT01537081|9868773|FG001|Overall Study|Sponsor decision|1
6205963|NCT01537081|9868774|FG002|Overall Study|Sponsor decision|0
6205964|NCT01537081|9868772|FG000|Overall Study|Assigned but never dosed|1
6205965|NCT01537081|9868773|FG001|Overall Study|Assigned but never dosed|0
6205966|NCT01537081|9868774|FG002|Overall Study|Assigned but never dosed|0
6205967|NCT01537120|9868783|FG000|8 Weeks Washout|Inclusion/exclusion criteria not met|1
6205968|NCT01537120|9868783|FG000|3 Weeks Placebo|Withdrawal by Subject|1
6205969|NCT01537133|9868793|FG000|Overall Study|Withdrawal by Subject|2
6205970|NCT01537133|9868794|FG001|Overall Study|Withdrawal by Subject|0
6205971|NCT01537133|9868795|FG002|Overall Study|Withdrawal by Subject|0
6205972|NCT01537133|9868796|FG003|Overall Study|Withdrawal by Subject|0
6205973|NCT01537133|9868793|FG000|Overall Study|Lost to Follow-up|1
6205974|NCT01537133|9868794|FG001|Overall Study|Lost to Follow-up|0
6205975|NCT01537133|9868795|FG002|Overall Study|Lost to Follow-up|0
6205976|NCT01537133|9868796|FG003|Overall Study|Lost to Follow-up|0
6205977|NCT01537198|9868823|FG000|Overall Study|RSV infection|2
6205978|NCT01537198|9868823|FG000|Overall Study|Adverse Event|4
6205979|NCT01537198|9868823|FG000|Overall Study|No Further Visits to the Clinic|37
6205980|NCT01537198|9868823|FG000|Overall Study|Other|111
6205981|NCT01537211|9868829|FG000|Overall Study|Lost to Follow-up|0
6107268|NCT00802672|9725484|FG000|Overall Study|Adverse Event|1
6107269|NCT00802672|9725485|FG001|Overall Study|Adverse Event|1
6205982|NCT01537211|9868830|FG001|Overall Study|Lost to Follow-up|1
6205983|NCT01537393|9868868|FG000|Overall Study|Exclude prior to study|32
6205984|NCT01537393|9868869|FG001|Overall Study|Exclude prior to study|44
6205985|NCT01537393|9868868|FG000|Overall Study|Death|20
6107270|NCT00802672|9725486|FG002|Overall Study|Adverse Event|1
6107271|NCT00802672|9725484|FG000|Overall Study|Protocol Violation|2
6107272|NCT00802672|9725485|FG001|Overall Study|Protocol Violation|1
6107273|NCT00802672|9725486|FG002|Overall Study|Protocol Violation|1
6107274|NCT00802672|9725484|FG000|Overall Study|Lost to Follow-up|5
6107275|NCT00802672|9725485|FG001|Overall Study|Lost to Follow-up|5
6107276|NCT00802672|9725486|FG002|Overall Study|Lost to Follow-up|3
6107277|NCT00802672|9725484|FG000|Overall Study|Withdrawal by Subject|1
6107278|NCT00802672|9725485|FG001|Overall Study|Withdrawal by Subject|1
6107279|NCT00802672|9725486|FG002|Overall Study|Withdrawal by Subject|2
6107280|NCT00802672|9725484|FG000|Overall Study|other|3
6107281|NCT00802672|9725485|FG001|Overall Study|other|1
6107282|NCT00802672|9725486|FG002|Overall Study|other|2
6107283|NCT00802737|9725506|FG000|Overall Study|Withdrawn due to Disease Progression|9
6107284|NCT00802737|9725507|FG001|Overall Study|Withdrawn due to Disease Progression|3
6107285|NCT00802737|9725508|FG002|Overall Study|Withdrawn due to Disease Progression|0
6107286|NCT00802737|9725506|FG000|Overall Study|Death|6
6107287|NCT00802737|9725507|FG001|Overall Study|Death|5
6107288|NCT00802737|9725508|FG002|Overall Study|Death|1
6107289|NCT00802737|9725506|FG000|Overall Study|Adverse Event|1
6107290|NCT00802737|9725507|FG001|Overall Study|Adverse Event|0
6107291|NCT00802737|9725508|FG002|Overall Study|Adverse Event|0
6107292|NCT00802737|9725506|FG000|Overall Study|Received Prohibited Therapy|1
6107293|NCT00802737|9725507|FG001|Overall Study|Received Prohibited Therapy|0
6107294|NCT00802737|9725508|FG002|Overall Study|Received Prohibited Therapy|0
6107295|NCT00802737|9725506|FG000|Overall Study|Ongoing CLL-Treatment|0
6107296|NCT00802737|9725507|FG001|Overall Study|Ongoing CLL-Treatment|1
6107297|NCT00802737|9725508|FG002|Overall Study|Ongoing CLL-Treatment|0
6107298|NCT00802737|9725506|FG000|Overall Study|Participant too Unwell|0
6107299|NCT00802737|9725507|FG001|Overall Study|Participant too Unwell|2
6107300|NCT00802737|9725508|FG002|Overall Study|Participant too Unwell|0
6107301|NCT00802841|9725519|FG000|Overall Study|Administrative problems|1
6107302|NCT00802841|9725520|FG001|Overall Study|Administrative problems|0
6107303|NCT00802841|9725519|FG000|Overall Study|Lost to Follow-up|2
6107304|NCT00802841|9725520|FG001|Overall Study|Lost to Follow-up|1
6205986|NCT01537393|9868869|FG001|Overall Study|Death|32
6205987|NCT01537393|9868868|FG000|Overall Study|Withdrawal by Subject|18
6205988|NCT01537393|9868869|FG001|Overall Study|Withdrawal by Subject|17
6205989|NCT01537393|9868868|FG000|Overall Study|Lost to Follow-up|53
6205990|NCT01537393|9868869|FG001|Overall Study|Lost to Follow-up|48
6205991|NCT01537393|9868868|FG000|Overall Study|Failure - Regrafted|28
5980575|NCT02733042|9569338|FG018|Treatment Period|Ongoing on Assigned Treatment|1
5980576|NCT02733042|9569320|FG000|Treatment Period|Death|0
5980577|NCT02733042|9569321|FG001|Treatment Period|Death|0
5980578|NCT02733042|9569322|FG002|Treatment Period|Death|0
5980579|NCT02733042|9569323|FG003|Treatment Period|Death|0
5980580|NCT02733042|9569324|FG004|Treatment Period|Death|0
5980581|NCT02733042|9569325|FG005|Treatment Period|Death|0
5980582|NCT02733042|9569326|FG006|Treatment Period|Death|1
5980583|NCT02733042|9569327|FG007|Treatment Period|Death|0
5980584|NCT02733042|9569328|FG008|Treatment Period|Death|1
5980585|NCT02733042|9569329|FG009|Treatment Period|Death|0
5980586|NCT02733042|9569330|FG010|Treatment Period|Death|1
5980587|NCT02733042|9569331|FG011|Treatment Period|Death|0
5980588|NCT02733042|9569332|FG012|Treatment Period|Death|0
5980589|NCT02733042|9569333|FG013|Treatment Period|Death|0
5980590|NCT02733042|9569334|FG014|Treatment Period|Death|1
5980591|NCT02733042|9569335|FG015|Treatment Period|Death|2
5980592|NCT02733042|9569336|FG016|Treatment Period|Death|0
6285378|NCT02333630|9997370|FG000|Overall Study|Lost to Follow-up|5
6285379|NCT02333630|9997371|FG001|Overall Study|Lost to Follow-up|2
6285380|NCT02334215|9997397|FG000|Overall Study|Death|1
6285381|NCT02334215|9997398|FG001|Overall Study|Death|1
6285382|NCT02334215|9997399|FG002|Overall Study|Death|0
6285383|NCT02334215|9997397|FG000|Overall Study|Lost to Follow-up|1
6285384|NCT02334215|9997398|FG001|Overall Study|Lost to Follow-up|0
6285385|NCT02334215|9997399|FG002|Overall Study|Lost to Follow-up|4
6285386|NCT02334215|9997397|FG000|Overall Study|Withdrawal by Subject|2
6285387|NCT02334215|9997398|FG001|Overall Study|Withdrawal by Subject|2
5980593|NCT02733042|9569337|FG017|Treatment Period|Death|0
5980594|NCT02733042|9569338|FG018|Treatment Period|Death|0
5980595|NCT02733042|9569320|FG000|Follow-up Period|Ongoing on Follow-up|2
5980596|NCT02733042|9569321|FG001|Follow-up Period|Ongoing on Follow-up|2
5980597|NCT02733042|9569322|FG002|Follow-up Period|Ongoing on Follow-up|4
6107305|NCT00802841|9725519|FG000|Overall Study|Death|1
6107306|NCT00802841|9725520|FG001|Overall Study|Death|2
6107307|NCT00802841|9725519|FG000|Overall Study|Adverse Event|8
6107308|NCT00802841|9725520|FG001|Overall Study|Adverse Event|2
6205992|NCT01537393|9868869|FG001|Overall Study|Failure - Regrafted|43
6205993|NCT01537393|9868868|FG000|Overall Study|Failure - Not regrafted|2
6205994|NCT01537393|9868869|FG001|Overall Study|Failure - Not regrafted|6
6205995|NCT01537393|9868868|FG000|Overall Study|Censored (severe event unrelated to PT)|1
6205996|NCT01537393|9868869|FG001|Overall Study|Censored (severe event unrelated to PT)|1
6205997|NCT01537432|9868886|FG000|Overall Study|Lost to Follow-up|3
6107309|NCT00802841|9725519|FG000|Overall Study|Disease progression|7
6107310|NCT00802841|9725520|FG001|Overall Study|Disease progression|3
6285388|NCT02334215|9997399|FG002|Overall Study|Withdrawal by Subject|1
6107311|NCT00802841|9725519|FG000|Overall Study|Withdrawal by Subject|9
6107312|NCT00802841|9725520|FG001|Overall Study|Withdrawal by Subject|5
6107313|NCT00802841|9725519|FG000|Overall Study|Protocol deviation|2
6107314|NCT00802841|9725520|FG001|Overall Study|Protocol deviation|6
6107315|NCT00802841|9725519|FG000|Overall Study|Treatment duration completed|66
6107316|NCT00802841|9725520|FG001|Overall Study|Treatment duration completed|76
6107317|NCT00802867|9725532|FG000|Overall Study|Lost to Follow-up|6
6107318|NCT00802867|9725532|FG000|Overall Study|Protocol Violation|6
6107319|NCT00802867|9725532|FG000|Overall Study|Withdrawal by Subject|1
6107320|NCT00802945|9725556|FG000|Overall Study|Death|27
6107321|NCT00802945|9725557|FG001|Overall Study|Death|23
6107322|NCT00802945|9725556|FG000|Overall Study|Terminated by sponsor|8
6107323|NCT00802945|9725557|FG001|Overall Study|Terminated by sponsor|12
6107324|NCT00803023|9725587|FG000|Overall Study|Adverse Event|5
6107325|NCT00803023|9725588|FG001|Overall Study|Adverse Event|4
6107326|NCT00803023|9725589|FG002|Overall Study|Adverse Event|8
6107327|NCT00803023|9725590|FG003|Overall Study|Adverse Event|6
6107328|NCT00803023|9725587|FG000|Overall Study|Withdrawal by Subject|0
6107329|NCT00803023|9725588|FG001|Overall Study|Withdrawal by Subject|2
6107330|NCT00803023|9725589|FG002|Overall Study|Withdrawal by Subject|0
6107331|NCT00803023|9725590|FG003|Overall Study|Withdrawal by Subject|0
6107332|NCT00803023|9725587|FG000|Overall Study|Lost to Follow-up|0
6107333|NCT00803023|9725588|FG001|Overall Study|Lost to Follow-up|1
6107334|NCT00803023|9725589|FG002|Overall Study|Lost to Follow-up|2
6107335|NCT00803023|9725590|FG003|Overall Study|Lost to Follow-up|1
6107336|NCT00803023|9725587|FG000|Overall Study|Lack of Efficacy|0
6107337|NCT00803023|9725588|FG001|Overall Study|Lack of Efficacy|1
6107338|NCT00803023|9725589|FG002|Overall Study|Lack of Efficacy|1
6107339|NCT00803023|9725590|FG003|Overall Study|Lack of Efficacy|1
6107340|NCT00803049|9725604|FG000|Overall Study|Adverse Event|21
6107341|NCT00803049|9725605|FG001|Overall Study|Adverse Event|33
6107342|NCT00803049|9725606|FG002|Overall Study|Adverse Event|13
6107343|NCT00803049|9725607|FG003|Overall Study|Adverse Event|27
6107344|NCT00803049|9725604|FG000|Overall Study|Lack of Efficacy|10
6107345|NCT00803049|9725605|FG001|Overall Study|Lack of Efficacy|19
6107346|NCT00803049|9725606|FG002|Overall Study|Lack of Efficacy|6
6107347|NCT00803049|9725607|FG003|Overall Study|Lack of Efficacy|13
6107348|NCT00803049|9725604|FG000|Overall Study|Lost to Follow-up|0
6107349|NCT00803049|9725605|FG001|Overall Study|Lost to Follow-up|2
6107350|NCT00803049|9725606|FG002|Overall Study|Lost to Follow-up|0
6107351|NCT00803049|9725607|FG003|Overall Study|Lost to Follow-up|3
6107352|NCT00803049|9725604|FG000|Overall Study|Death|2
6107353|NCT00803049|9725605|FG001|Overall Study|Death|1
6107354|NCT00803049|9725606|FG002|Overall Study|Death|0
6107355|NCT00803049|9725607|FG003|Overall Study|Death|2
6107356|NCT00803049|9725604|FG000|Overall Study|Progressive Disease|6
6107357|NCT00803049|9725605|FG001|Overall Study|Progressive Disease|10
6107358|NCT00803049|9725606|FG002|Overall Study|Progressive Disease|6
6107359|NCT00803049|9725607|FG003|Overall Study|Progressive Disease|6
6107360|NCT00803049|9725604|FG000|Overall Study|Withdrawal by Subject|19
6107361|NCT00803049|9725605|FG001|Overall Study|Withdrawal by Subject|43
6107362|NCT00803049|9725606|FG002|Overall Study|Withdrawal by Subject|16
6107363|NCT00803049|9725607|FG003|Overall Study|Withdrawal by Subject|44
6107364|NCT00803049|9725604|FG000|Overall Study|Protocol Violation|0
6107365|NCT00803049|9725605|FG001|Overall Study|Protocol Violation|1
6107366|NCT00803049|9725606|FG002|Overall Study|Protocol Violation|1
6107367|NCT00803049|9725607|FG003|Overall Study|Protocol Violation|0
6107368|NCT00803049|9725604|FG000|Overall Study|Randomized and Not Treated|0
6107369|NCT00803049|9725605|FG001|Overall Study|Randomized and Not Treated|0
6107370|NCT00803049|9725606|FG002|Overall Study|Randomized and Not Treated|0
6107371|NCT00803049|9725607|FG003|Overall Study|Randomized and Not Treated|2
6107372|NCT00803049|9725604|FG000|Overall Study|Other than Specified Above|3
6107373|NCT00803049|9725605|FG001|Overall Study|Other than Specified Above|9
6107374|NCT00803049|9725606|FG002|Overall Study|Other than Specified Above|2
6107375|NCT00803049|9725607|FG003|Overall Study|Other than Specified Above|5
6107376|NCT00803101|9725636|FG000|Overall Study|Death / Serious Adverse Event|4
6107377|NCT00803101|9725637|FG001|Overall Study|Death / Serious Adverse Event|6
6107378|NCT00803101|9725636|FG000|Overall Study|Withdrawal by Subject|6
6107379|NCT00803101|9725637|FG001|Overall Study|Withdrawal by Subject|4
6205998|NCT01537432|9868887|FG001|Overall Study|Lost to Follow-up|1
6107380|NCT00803101|9725636|FG000|Overall Study|Lost to Follow-up|2
6107381|NCT00803101|9725637|FG001|Overall Study|Lost to Follow-up|2
6107382|NCT00803101|9725636|FG000|Overall Study|Protocol Violation|1
6107383|NCT00803101|9725637|FG001|Overall Study|Protocol Violation|7
6107384|NCT00803101|9725636|FG000|Overall Study|Surgery finished outside protocol window|1
6107385|NCT00803101|9725637|FG001|Overall Study|Surgery finished outside protocol window|1
6107386|NCT00803101|9725636|FG000|Overall Study|Patient died outside SAE report period|1
6107387|NCT00803101|9725637|FG001|Overall Study|Patient died outside SAE report period|0
6107388|NCT00803101|9725636|FG000|Overall Study|Patient did not attend scheduled visit|2
6107389|NCT00803101|9725637|FG001|Overall Study|Patient did not attend scheduled visit|1
6107390|NCT00803101|9725636|FG000|Overall Study|Patient did not have surgery|1
6107391|NCT00803101|9725637|FG001|Overall Study|Patient did not have surgery|1
6107392|NCT00803205|9725645|FG000|Overall Study|Adverse Event|7
6107393|NCT00803205|9725646|FG001|Overall Study|Adverse Event|2
6107394|NCT00803205|9725645|FG000|Overall Study|Lost to Follow-up|1
6107395|NCT00803205|9725646|FG001|Overall Study|Lost to Follow-up|0
6107396|NCT00803205|9725645|FG000|Overall Study|Withdrawal by Subject|9
6107397|NCT00803205|9725646|FG001|Overall Study|Withdrawal by Subject|9
6107398|NCT00803205|9725645|FG000|Overall Study|Physician Decision|1
6107399|NCT00803205|9725646|FG001|Overall Study|Physician Decision|0
6107400|NCT00803205|9725645|FG000|Overall Study|Protocol Violation|1
6107401|NCT00803205|9725646|FG001|Overall Study|Protocol Violation|1
6107402|NCT00803205|9725645|FG000|Overall Study|Medical Monitor Decision|1
6107403|NCT00803205|9725646|FG001|Overall Study|Medical Monitor Decision|0
6107404|NCT00803205|9725645|FG000|Overall Study|Acquired a Lung Infection|0
6107405|NCT00803205|9725646|FG001|Overall Study|Acquired a Lung Infection|1
6107406|NCT00803205|9725645|FG000|Overall Study|Sponsor Decision|0
6107407|NCT00803205|9725646|FG001|Overall Study|Sponsor Decision|1
6107408|NCT00803244|9725654|FG000|Overall Study|Adverse Event|1
6107409|NCT00803244|9725655|FG001|Overall Study|Adverse Event|2
6107410|NCT00803244|9725654|FG000|Overall Study|Withdrawal by Subject|2
6107411|NCT00803244|9725655|FG001|Overall Study|Withdrawal by Subject|3
6107412|NCT00803244|9725654|FG000|Overall Study|Any other reason not above-mentioned|4
6107413|NCT00803244|9725655|FG001|Overall Study|Any other reason not above-mentioned|10
6107414|NCT00803270|9725663|FG000|Overall Study|Lost to Follow-up|1
6107415|NCT00803270|9725664|FG001|Overall Study|Lost to Follow-up|2
6107416|NCT00803361|9725672|FG000|Overall Study|Adverse Event|13
6107417|NCT00803361|9725673|FG001|Overall Study|Adverse Event|3
6107418|NCT00803361|9725672|FG000|Overall Study|Lack of Efficacy|4
6107419|NCT00803361|9725673|FG001|Overall Study|Lack of Efficacy|13
6107420|NCT00803361|9725672|FG000|Overall Study|Lost to Follow-up|1
6107421|NCT00803361|9725673|FG001|Overall Study|Lost to Follow-up|2
6107422|NCT00803361|9725672|FG000|Overall Study|Physician Decision|1
6107423|NCT00803361|9725673|FG001|Overall Study|Physician Decision|0
6107424|NCT00803361|9725672|FG000|Overall Study|Protocol Violation|2
6107425|NCT00803361|9725673|FG001|Overall Study|Protocol Violation|4
6107426|NCT00803361|9725672|FG000|Overall Study|Withdrawal by Subject|5
6107427|NCT00803361|9725673|FG001|Overall Study|Withdrawal by Subject|6
6107428|NCT00803452|9725691|FG000|Overall Study|Adverse Event|0
6107429|NCT00803452|9725692|FG001|Overall Study|Adverse Event|2
6107430|NCT00803452|9725691|FG000|Overall Study|Lost to Follow-up|0
6107431|NCT00803452|9725692|FG001|Overall Study|Lost to Follow-up|3
6107432|NCT00803569|9725707|FG000|Overall Study|Progressive Disease|3
6107433|NCT00803569|9725707|FG000|Overall Study|Noncompliance|1
6107434|NCT00803595|9725714|FG000|Overall Study|Adverse Event|3
6107435|NCT00803595|9725715|FG001|Overall Study|Adverse Event|4
6107436|NCT00803595|9725716|FG002|Overall Study|Adverse Event|1
6107437|NCT00803595|9725714|FG000|Overall Study|Protocol Violation|7
6107438|NCT00803595|9725715|FG001|Overall Study|Protocol Violation|2
6107439|NCT00803595|9725716|FG002|Overall Study|Protocol Violation|12
6107440|NCT00803595|9725714|FG000|Overall Study|Withdrawal by Subject|5
6107441|NCT00803595|9725715|FG001|Overall Study|Withdrawal by Subject|2
6107442|NCT00803595|9725716|FG002|Overall Study|Withdrawal by Subject|3
6107443|NCT00803634|9725726|FG000|Overall Study|Withdrew Consent|1
6107444|NCT00803634|9725727|FG001|Overall Study|Withdrew Consent|0
6107445|NCT00803634|9725726|FG000|Overall Study|Lost to Follow-up|2
6107446|NCT00803634|9725727|FG001|Overall Study|Lost to Follow-up|3
6107447|NCT00803634|9725726|FG000|Overall Study|Death|3
6107448|NCT00803634|9725727|FG001|Overall Study|Death|2
6107449|NCT00803712|9725759|FG000|Overall Study|Noncompliance|3
6107450|NCT00803712|9725760|FG001|Overall Study|Noncompliance|0
6107451|NCT00803712|9725759|FG000|Overall Study|Adverse Event|5
6107452|NCT00803712|9725760|FG001|Overall Study|Adverse Event|0
6107453|NCT00803712|9725759|FG000|Overall Study|Death|8
6107454|NCT00803712|9725760|FG001|Overall Study|Death|7
6107455|NCT00803712|9725759|FG000|Overall Study|Lost to Follow-up|3
6107456|NCT00803712|9725760|FG001|Overall Study|Lost to Follow-up|1
6107457|NCT00803712|9725759|FG000|Overall Study|Withdrawal by Subject|2
6107458|NCT00803712|9725760|FG001|Overall Study|Withdrawal by Subject|4
6107459|NCT00803712|9725759|FG000|Overall Study|"Other in electronic Case Report Form"|0
6107460|NCT00803712|9725760|FG001|Overall Study|"Other in electronic Case Report Form"|1
6107461|NCT00803712|9725759|FG000|Overall Study|Protocol criteria (other)|0
6107462|NCT00803712|9725760|FG001|Overall Study|Protocol criteria (other)|2
6107463|NCT00803712|9725759|FG000|Overall Study|Protocol criteria (renal transplant)|12
6107464|NCT00803712|9725760|FG001|Overall Study|Protocol criteria (renal transplant)|8
6107465|NCT00803712|9725759|FG000|Overall Study|Administrative decision|2
6107466|NCT00803712|9725760|FG001|Overall Study|Administrative decision|3
6107467|NCT00803712|9725759|FG000|Overall Study|Protocol criteria (parathyroidectomy)|1
6107468|NCT00803712|9725760|FG001|Overall Study|Protocol criteria (parathyroidectomy)|1
6107469|NCT00803738|9725768|FG000|Overall Study|Adverse Event|3
6107470|NCT00803738|9725769|FG001|Overall Study|Adverse Event|5
6107471|NCT00803738|9725768|FG000|Overall Study|Lost to Follow-up|4
6107472|NCT00803738|9725769|FG001|Overall Study|Lost to Follow-up|4
6107473|NCT00803738|9725768|FG000|Overall Study|Protocol Violation|18
6107474|NCT00803738|9725769|FG001|Overall Study|Protocol Violation|10
6107475|NCT00803738|9725768|FG000|Overall Study|Withdrawal by Subject|1
6107476|NCT00803738|9725769|FG001|Overall Study|Withdrawal by Subject|4
6107477|NCT00803738|9725768|FG000|Overall Study|Lack of Efficacy|10
6107478|NCT00803738|9725769|FG001|Overall Study|Lack of Efficacy|16
6107479|NCT00803738|9725768|FG000|Overall Study|Negative Baseline Culture of Candida|56
6107480|NCT00803738|9725769|FG001|Overall Study|Negative Baseline Culture of Candida|63
6107481|NCT00803738|9725768|FG000|Overall Study|Positive Results for STD or abnormal PAP|2
6107482|NCT00803738|9725769|FG001|Overall Study|Positive Results for STD or abnormal PAP|8
6107483|NCT00804141|9725797|FG000|Overall Study|Adverse Event|157
6107484|NCT00804141|9725797|FG000|Overall Study|Death|4
6107485|NCT00804141|9725797|FG000|Overall Study|Failed to return|96
6107486|NCT00804141|9725797|FG000|Overall Study|Investigator request|8
6107487|NCT00804141|9725797|FG000|Overall Study|Protocol Violation|85
6107488|NCT00804141|9725797|FG000|Overall Study|Withdrawal by Subject|131
6107489|NCT00804141|9725797|FG000|Overall Study|Lack of Efficacy|46
6107490|NCT00804141|9725797|FG000|Overall Study|Other than specified|30
6107491|NCT00804141|9725797|FG000|Overall Study|Enrolled but not treated|6
6107492|NCT00804193|9725804|FG000|Overall Study|Lack of baseline fungus|32
6107493|NCT00804193|9725805|FG001|Overall Study|Lack of baseline fungus|31
6107494|NCT00804193|9725806|FG002|Overall Study|Lack of baseline fungus|19
6107495|NCT00804193|9725804|FG000|Overall Study|Adverse Event|0
6107496|NCT00804193|9725805|FG001|Overall Study|Adverse Event|0
6107497|NCT00804193|9725806|FG002|Overall Study|Adverse Event|2
6107498|NCT00804193|9725804|FG000|Overall Study|Lack of Efficacy|1
6107499|NCT00804193|9725805|FG001|Overall Study|Lack of Efficacy|1
6107500|NCT00804193|9725806|FG002|Overall Study|Lack of Efficacy|3
6107501|NCT00804193|9725804|FG000|Overall Study|Protocol Violation|0
6107502|NCT00804193|9725805|FG001|Overall Study|Protocol Violation|8
6107503|NCT00804193|9725806|FG002|Overall Study|Protocol Violation|2
6107504|NCT00804193|9725804|FG000|Overall Study|Lost to Follow-up|3
6107505|NCT00804193|9725805|FG001|Overall Study|Lost to Follow-up|3
6107506|NCT00804193|9725806|FG002|Overall Study|Lost to Follow-up|4
6107507|NCT00804193|9725804|FG000|Overall Study|Withdrawal by Subject|3
6107508|NCT00804193|9725805|FG001|Overall Study|Withdrawal by Subject|1
6107509|NCT00804193|9725806|FG002|Overall Study|Withdrawal by Subject|2
6107510|NCT00804570|9725816|FG000|Overall Study|Adverse Event|14
6107511|NCT00804570|9725817|FG001|Overall Study|Adverse Event|7
6107512|NCT00804570|9725816|FG000|Overall Study|Lack of Efficacy|0
6107513|NCT00804570|9725817|FG001|Overall Study|Lack of Efficacy|1
6107514|NCT00804570|9725816|FG000|Overall Study|Lost to Follow-up|18
6107515|NCT00804570|9725817|FG001|Overall Study|Lost to Follow-up|21
6107516|NCT00804570|9725816|FG000|Overall Study|Entry criteria not met|5
6107517|NCT00804570|9725817|FG001|Overall Study|Entry criteria not met|5
6107518|NCT00804570|9725816|FG000|Overall Study|Protocol Violation|12
6107519|NCT00804570|9725817|FG001|Overall Study|Protocol Violation|16
6107520|NCT00804570|9725816|FG000|Overall Study|Physician Decision|1
6107521|NCT00804570|9725817|FG001|Overall Study|Physician Decision|2
6107522|NCT00804570|9725816|FG000|Overall Study|Sponsor decision|1
6107523|NCT00804570|9725817|FG001|Overall Study|Sponsor decision|4
6107524|NCT00804570|9725816|FG000|Overall Study|Withdrawal by Subject|21
6107525|NCT00804570|9725817|FG001|Overall Study|Withdrawal by Subject|38
6205999|NCT01537432|9868886|FG000|Overall Study|Withdrawal by Subject|0
6206000|NCT01537432|9868887|FG001|Overall Study|Withdrawal by Subject|1
6206001|NCT01537432|9868886|FG000|Overall Study|Administrative problems|1
6206002|NCT01537432|9868887|FG001|Overall Study|Administrative problems|0
6206003|NCT01537432|9868886|FG000|Overall Study|Adverse Event|1
6206004|NCT01537432|9868887|FG001|Overall Study|Adverse Event|0
6206005|NCT01537432|9868886|FG000|Overall Study|Unsatisfactory therapeutic effect|1
6206006|NCT01537432|9868887|FG001|Overall Study|Unsatisfactory therapeutic effect|0
6206007|NCT01537549|9868893|FG000|Overall Study|Lost to Follow-up|1
6206008|NCT01537549|9868893|FG000|Overall Study|Withdrawal by Subject|2
6206009|NCT01537783|9868928|FG000|Overall Study|Lost to Follow-up|11
6206010|NCT01537783|9868929|FG001|Overall Study|Lost to Follow-up|2
6206011|NCT01537887|9868948|FG000|Period 1|Physician Decision|0
6206012|NCT01537887|9868949|FG001|Period 1|Physician Decision|0
6206013|NCT01537887|9868950|FG002|Period 1|Physician Decision|0
6206014|NCT01537887|9868951|FG003|Period 1|Physician Decision|0
6206015|NCT01537887|9868952|FG004|Period 1|Physician Decision|1
6206016|NCT01537887|9868953|FG005|Period 1|Physician Decision|1
6206017|NCT01537887|9868948|FG000|Period 1|Did not receive treatment|0
6206018|NCT01537887|9868949|FG001|Period 1|Did not receive treatment|0
6206019|NCT01537887|9868950|FG002|Period 1|Did not receive treatment|1
6206020|NCT01537887|9868951|FG003|Period 1|Did not receive treatment|0
6206021|NCT01537887|9868952|FG004|Period 1|Did not receive treatment|0
6206022|NCT01537887|9868953|FG005|Period 1|Did not receive treatment|0
6206023|NCT01537887|9868948|FG000|Period 2|Withdrawal by Subject|0
5980598|NCT02733042|9569323|FG003|Follow-up Period|Ongoing on Follow-up|2
5980599|NCT02733042|9569324|FG004|Follow-up Period|Ongoing on Follow-up|0
5980600|NCT02733042|9569325|FG005|Follow-up Period|Ongoing on Follow-up|0
5980601|NCT02733042|9569326|FG006|Follow-up Period|Ongoing on Follow-up|0
5980602|NCT02733042|9569327|FG007|Follow-up Period|Ongoing on Follow-up|1
5980603|NCT02733042|9569328|FG008|Follow-up Period|Ongoing on Follow-up|0
5980604|NCT02733042|9569329|FG009|Follow-up Period|Ongoing on Follow-up|2
6206024|NCT01537887|9868949|FG001|Period 2|Withdrawal by Subject|1
6206025|NCT01537887|9868950|FG002|Period 2|Withdrawal by Subject|0
6206026|NCT01537887|9868951|FG003|Period 2|Withdrawal by Subject|0
6206027|NCT01537887|9868952|FG004|Period 2|Withdrawal by Subject|0
6206028|NCT01537887|9868953|FG005|Period 2|Withdrawal by Subject|0
6107526|NCT00804687|9725850|FG000|Period 3: Treatment Period|Positive Drug screen|0
6107527|NCT00804687|9725851|FG001|Period 3: Treatment Period|Positive Drug screen|0
6107528|NCT00804687|9725852|FG002|Period 3: Treatment Period|Positive Drug screen|0
6107529|NCT00804687|9725853|FG003|Period 3: Treatment Period|Positive Drug screen|1
6107530|NCT00804687|9725854|FG004|Period 3: Treatment Period|Positive Drug screen|0
6107531|NCT00804687|9725855|FG005|Period 3: Treatment Period|Positive Drug screen|0
6107532|NCT00804687|9725850|FG000|Period 5: Treatment Period|Withdrawal by Subject|0
6107533|NCT00804687|9725851|FG001|Period 5: Treatment Period|Withdrawal by Subject|0
6107534|NCT00804687|9725852|FG002|Period 5: Treatment Period|Withdrawal by Subject|0
6107535|NCT00804687|9725853|FG003|Period 5: Treatment Period|Withdrawal by Subject|0
6107536|NCT00804687|9725854|FG004|Period 5: Treatment Period|Withdrawal by Subject|1
6107537|NCT00804687|9725855|FG005|Period 5: Treatment Period|Withdrawal by Subject|0
6107538|NCT00804687|9725850|FG000|Period 5: Treatment Period|Positive drugs of abuse|0
6107539|NCT00804687|9725851|FG001|Period 5: Treatment Period|Positive drugs of abuse|0
6107540|NCT00804687|9725852|FG002|Period 5: Treatment Period|Positive drugs of abuse|1
6107541|NCT00804687|9725853|FG003|Period 5: Treatment Period|Positive drugs of abuse|0
6107542|NCT00804687|9725854|FG004|Period 5: Treatment Period|Positive drugs of abuse|0
6107543|NCT00804687|9725855|FG005|Period 5: Treatment Period|Positive drugs of abuse|0
6107544|NCT00804687|9725850|FG000|Period 5: Treatment Period|Positive drug test|1
6107545|NCT00804687|9725851|FG001|Period 5: Treatment Period|Positive drug test|0
6107546|NCT00804687|9725852|FG002|Period 5: Treatment Period|Positive drug test|0
6107547|NCT00804687|9725853|FG003|Period 5: Treatment Period|Positive drug test|0
6107548|NCT00804687|9725854|FG004|Period 5: Treatment Period|Positive drug test|0
6107549|NCT00804687|9725855|FG005|Period 5: Treatment Period|Positive drug test|0
6107550|NCT00804843|9725865|FG000|Overall Study|Protocol Violation|1
6107551|NCT00804843|9725866|FG001|Overall Study|Protocol Violation|0
6107552|NCT00804843|9725865|FG000|Overall Study|Adverse Event|8
6107553|NCT00804843|9725866|FG001|Overall Study|Adverse Event|5
6107554|NCT00804843|9725865|FG000|Overall Study|Withdrawal by Subject|1
6107555|NCT00804843|9725866|FG001|Overall Study|Withdrawal by Subject|2
6107556|NCT00804908|9725876|FG000|Overall Study|Other|115
6107557|NCT00804908|9725877|FG001|Overall Study|Other|116
6107558|NCT00804908|9725878|FG002|Overall Study|Other|114
6107559|NCT00804986|9725905|FG000|Overall Study|Adverse Event|0
6107560|NCT00804986|9725906|FG001|Overall Study|Adverse Event|1
6107561|NCT00804986|9725907|FG002|Overall Study|Adverse Event|2
6107562|NCT00804986|9725908|FG003|Overall Study|Adverse Event|1
6107563|NCT00804986|9725909|FG004|Overall Study|Adverse Event|3
6107564|NCT00804986|9725910|FG005|Overall Study|Adverse Event|0
6107565|NCT00804986|9725905|FG000|Overall Study|Lack of Efficacy|0
6107566|NCT00804986|9725906|FG001|Overall Study|Lack of Efficacy|0
6107567|NCT00804986|9725907|FG002|Overall Study|Lack of Efficacy|0
6107568|NCT00804986|9725908|FG003|Overall Study|Lack of Efficacy|1
6107569|NCT00804986|9725909|FG004|Overall Study|Lack of Efficacy|0
6107570|NCT00804986|9725910|FG005|Overall Study|Lack of Efficacy|3
6107571|NCT00804986|9725905|FG000|Overall Study|Lost to Follow-up|0
6107572|NCT00804986|9725906|FG001|Overall Study|Lost to Follow-up|0
6107573|NCT00804986|9725907|FG002|Overall Study|Lost to Follow-up|0
6107574|NCT00804986|9725908|FG003|Overall Study|Lost to Follow-up|1
6107575|NCT00804986|9725909|FG004|Overall Study|Lost to Follow-up|1
6107576|NCT00804986|9725910|FG005|Overall Study|Lost to Follow-up|3
6107577|NCT00804986|9725905|FG000|Overall Study|Protocol Violation|0
6107578|NCT00804986|9725906|FG001|Overall Study|Protocol Violation|1
6107579|NCT00804986|9725907|FG002|Overall Study|Protocol Violation|0
6107580|NCT00804986|9725908|FG003|Overall Study|Protocol Violation|1
6107581|NCT00804986|9725909|FG004|Overall Study|Protocol Violation|0
6107582|NCT00804986|9725910|FG005|Overall Study|Protocol Violation|0
6107583|NCT00804986|9725905|FG000|Overall Study|Withdrawal by Subject|0
6107584|NCT00804986|9725906|FG001|Overall Study|Withdrawal by Subject|3
6107585|NCT00804986|9725907|FG002|Overall Study|Withdrawal by Subject|0
6107586|NCT00804986|9725908|FG003|Overall Study|Withdrawal by Subject|3
6107587|NCT00804986|9725909|FG004|Overall Study|Withdrawal by Subject|5
6107588|NCT00804986|9725910|FG005|Overall Study|Withdrawal by Subject|3
6107589|NCT00804986|9725905|FG000|Overall Study|Inclusion/Exclusion criteria not met|0
6107590|NCT00804986|9725906|FG001|Overall Study|Inclusion/Exclusion criteria not met|2
6107591|NCT00804986|9725907|FG002|Overall Study|Inclusion/Exclusion criteria not met|0
6107592|NCT00804986|9725908|FG003|Overall Study|Inclusion/Exclusion criteria not met|1
6107593|NCT00804986|9725909|FG004|Overall Study|Inclusion/Exclusion criteria not met|0
6107594|NCT00804986|9725910|FG005|Overall Study|Inclusion/Exclusion criteria not met|1
6107595|NCT00804986|9725905|FG000|Overall Study|Sponsor Decision|0
6107596|NCT00804986|9725906|FG001|Overall Study|Sponsor Decision|1
6107597|NCT00804986|9725907|FG002|Overall Study|Sponsor Decision|0
6107598|NCT00804986|9725908|FG003|Overall Study|Sponsor Decision|0
6107599|NCT00804986|9725909|FG004|Overall Study|Sponsor Decision|0
6107600|NCT00804986|9725910|FG005|Overall Study|Sponsor Decision|0
6107601|NCT00804986|9725905|FG000|Overall Study|Physician Decision|1
6107602|NCT00804986|9725906|FG001|Overall Study|Physician Decision|0
6107603|NCT00804986|9725907|FG002|Overall Study|Physician Decision|0
6107604|NCT00804986|9725908|FG003|Overall Study|Physician Decision|0
6107605|NCT00804986|9725909|FG004|Overall Study|Physician Decision|0
6107606|NCT00804986|9725910|FG005|Overall Study|Physician Decision|0
6107607|NCT00805025|9725941|FG000|Overall Study|Screened but not enrolled/treated|42
6107608|NCT00805025|9725941|FG000|Overall Study|Adverse Event|4
6107609|NCT00805025|9725941|FG000|Overall Study|Withdrawal by Subject|2
6107610|NCT00805025|9725941|FG000|Overall Study|Physician Decision|1
6107611|NCT00805142|9725956|FG000|Titration Period|Adverse Event|3
6107612|NCT00805142|9725957|FG001|Titration Period|Adverse Event|3
6107613|NCT00805142|9725956|FG000|Titration Period|Lack of Efficacy|1
6107614|NCT00805142|9725957|FG001|Titration Period|Lack of Efficacy|1
6107615|NCT00805142|9725956|FG000|Titration Period|Lost to Follow-up|0
6107616|NCT00805142|9725957|FG001|Titration Period|Lost to Follow-up|1
6107617|NCT00805142|9725956|FG000|Titration Period|Disease Progression|2
6107618|NCT00805142|9725957|FG001|Titration Period|Disease Progression|1
6107619|NCT00805142|9725956|FG000|Titration Period|Withdrawal of consent|0
6107620|NCT00805142|9725957|FG001|Titration Period|Withdrawal of consent|1
6107621|NCT00805142|9725956|FG000|Titration Period|Other|0
6107622|NCT00805142|9725957|FG001|Titration Period|Other|3
6107623|NCT00805142|9725956|FG000|Maintenance Period|Adverse Event|0
6107624|NCT00805142|9725957|FG001|Maintenance Period|Adverse Event|1
6107625|NCT00805142|9725956|FG000|Maintenance Period|Other|0
6107626|NCT00805142|9725957|FG001|Maintenance Period|Other|1
6107627|NCT00805194|9725972|FG000|Overall Study|Progressive disease (modified RECIST)|404
6107628|NCT00805194|9725973|FG001|Overall Study|Progressive disease (modified RECIST)|435
6107629|NCT00805194|9725972|FG000|Overall Study|Worsening or AE of underlying disease|64
6107630|NCT00805194|9725973|FG001|Overall Study|Worsening or AE of underlying disease|70
6107631|NCT00805194|9725972|FG000|Overall Study|Other AE|84
6107632|NCT00805194|9725973|FG001|Overall Study|Other AE|73
6107633|NCT00805194|9725972|FG000|Overall Study|Protocol Violation|9
6107634|NCT00805194|9725973|FG001|Overall Study|Protocol Violation|9
6107635|NCT00805194|9725972|FG000|Overall Study|Lost to Follow-up|5
6107636|NCT00805194|9725973|FG001|Overall Study|Lost to Follow-up|5
6107637|NCT00805194|9725972|FG000|Overall Study|Withdrawal by Subject|60
6107638|NCT00805194|9725973|FG001|Overall Study|Withdrawal by Subject|42
6206029|NCT01537887|9868948|FG000|Period 3|Adverse Event|0
6206030|NCT01537887|9868949|FG001|Period 3|Adverse Event|0
6206031|NCT01537887|9868950|FG002|Period 3|Adverse Event|1
6206032|NCT01537887|9868951|FG003|Period 3|Adverse Event|0
6206033|NCT01537887|9868952|FG004|Period 3|Adverse Event|0
6206034|NCT01537887|9868953|FG005|Period 3|Adverse Event|0
6206035|NCT01537887|9868948|FG000|Period 3|Withdrawal by Subject|0
6206036|NCT01537887|9868949|FG001|Period 3|Withdrawal by Subject|1
6206037|NCT01537887|9868950|FG002|Period 3|Withdrawal by Subject|0
6206038|NCT01537887|9868951|FG003|Period 3|Withdrawal by Subject|0
6206039|NCT01537887|9868952|FG004|Period 3|Withdrawal by Subject|0
6206040|NCT01537887|9868953|FG005|Period 3|Withdrawal by Subject|0
6206041|NCT01538199|9868981|FG000|Overall Study|Lost to Follow-up|1
6206042|NCT01538199|9868982|FG001|Overall Study|Lost to Follow-up|2
6206043|NCT01538199|9868983|FG002|Overall Study|Lost to Follow-up|1
6206044|NCT01538199|9868984|FG003|Overall Study|Lost to Follow-up|0
6206045|NCT01538199|9868981|FG000|Overall Study|participant did not have time|1
6206046|NCT01538199|9868982|FG001|Overall Study|participant did not have time|0
6206047|NCT01538199|9868983|FG002|Overall Study|participant did not have time|0
6206048|NCT01538199|9868984|FG003|Overall Study|participant did not have time|2
6206049|NCT01538199|9868981|FG000|Overall Study|Lack of Efficacy|0
6206050|NCT01538199|9868982|FG001|Overall Study|Lack of Efficacy|1
6206051|NCT01538199|9868983|FG002|Overall Study|Lack of Efficacy|0
6107639|NCT00805194|9725972|FG000|Overall Study|Not treated|3
6107640|NCT00805194|9725973|FG001|Overall Study|Not treated|4
6107641|NCT00805194|9725972|FG000|Overall Study|Reasons other than stated above|20
6107642|NCT00805194|9725973|FG001|Overall Study|Reasons other than stated above|16
6107643|NCT00805207|9725993|FG000|Overall Study|Protocol Violation|0
6107644|NCT00805207|9725994|FG001|Overall Study|Protocol Violation|0
6107645|NCT00805207|9725995|FG002|Overall Study|Protocol Violation|1
6107646|NCT00805207|9725996|FG003|Overall Study|Protocol Violation|0
6107647|NCT00805207|9725997|FG004|Overall Study|Protocol Violation|0
6107648|NCT00805207|9725998|FG005|Overall Study|Protocol Violation|0
6107649|NCT00805207|9725999|FG006|Overall Study|Protocol Violation|0
6107650|NCT00805207|9726000|FG007|Overall Study|Protocol Violation|0
6107651|NCT00805207|9726001|FG008|Overall Study|Protocol Violation|0
6107652|NCT00805207|9725993|FG000|Overall Study|Physician Decision|0
6107653|NCT00805207|9725994|FG001|Overall Study|Physician Decision|1
6107654|NCT00805207|9725995|FG002|Overall Study|Physician Decision|0
6107655|NCT00805207|9725996|FG003|Overall Study|Physician Decision|0
6107656|NCT00805207|9725997|FG004|Overall Study|Physician Decision|0
6107657|NCT00805207|9725998|FG005|Overall Study|Physician Decision|1
6107658|NCT00805207|9725999|FG006|Overall Study|Physician Decision|0
6107659|NCT00805207|9726000|FG007|Overall Study|Physician Decision|0
6107660|NCT00805207|9726001|FG008|Overall Study|Physician Decision|0
6107661|NCT00805207|9725993|FG000|Overall Study|Withdrawal by Subject|0
6107662|NCT00805207|9725994|FG001|Overall Study|Withdrawal by Subject|1
6107663|NCT00805207|9725995|FG002|Overall Study|Withdrawal by Subject|0
6107664|NCT00805207|9725996|FG003|Overall Study|Withdrawal by Subject|0
6107665|NCT00805207|9725997|FG004|Overall Study|Withdrawal by Subject|1
6206052|NCT01538199|9868984|FG003|Overall Study|Lack of Efficacy|0
6206053|NCT01538472|9869001|FG000|Overall Study|Disease Progression|3
6206054|NCT01538472|9869001|FG000|Overall Study|Death|1
6206055|NCT01538628|9869016|FG000|Overall Study|Withdrawal by Subject|1
6107666|NCT00805207|9725998|FG005|Overall Study|Withdrawal by Subject|2
6107667|NCT00805207|9725999|FG006|Overall Study|Withdrawal by Subject|0
6107668|NCT00805207|9726000|FG007|Overall Study|Withdrawal by Subject|0
6206056|NCT01538628|9869017|FG001|Overall Study|Withdrawal by Subject|1
6206057|NCT01538628|9869016|FG000|Overall Study|Lost to Follow-up|0
6206058|NCT01538628|9869017|FG001|Overall Study|Lost to Follow-up|1
6206059|NCT01538719|9869026|FG000|Overall Study|Lost to Follow-up|2
6206060|NCT01538719|9869027|FG001|Overall Study|Lost to Follow-up|0
6206061|NCT01539083|9869056|FG000|Before Randomization (VCD Induction)|Withdrawal by Subject|4
6206062|NCT01539083|9869057|FG001|Before Randomization (VCD Induction)|Withdrawal by Subject|0
6206063|NCT01539083|9869058|FG002|Before Randomization (VCD Induction)|Withdrawal by Subject|0
6206064|NCT01539083|9869056|FG000|Before Randomization (VCD Induction)|Adverse Event|14
6206065|NCT01539083|9869057|FG001|Before Randomization (VCD Induction)|Adverse Event|0
6206066|NCT01539083|9869058|FG002|Before Randomization (VCD Induction)|Adverse Event|0
6206067|NCT01539083|9869056|FG000|Before Randomization (VCD Induction)|Death|6
6206068|NCT01539083|9869057|FG001|Before Randomization (VCD Induction)|Death|0
6206069|NCT01539083|9869058|FG002|Before Randomization (VCD Induction)|Death|0
6206070|NCT01539083|9869056|FG000|Before Randomization (VCD Induction)|Protocol Violation|2
6206071|NCT01539083|9869057|FG001|Before Randomization (VCD Induction)|Protocol Violation|0
6285389|NCT02334215|9997397|FG000|Overall Study|Not released from incarceration on time|3
6285390|NCT02334215|9997398|FG001|Overall Study|Not released from incarceration on time|3
6285391|NCT02334215|9997399|FG002|Overall Study|Not released from incarceration on time|3
6285392|NCT02334215|9997397|FG000|Overall Study|Incarcerated|0
6285393|NCT02334215|9997398|FG001|Overall Study|Incarcerated|0
6285394|NCT02334215|9997399|FG002|Overall Study|Incarcerated|7
6285395|NCT02334306|9997424|FG000|Double-blind Period|Adverse Event|0
6285396|NCT02334306|9997425|FG001|Double-blind Period|Adverse Event|1
6285397|NCT02334306|9997424|FG000|Double-blind Period|Withdrawal by Subject|1
6285398|NCT02334306|9997425|FG001|Double-blind Period|Withdrawal by Subject|1
6285399|NCT02334384|9997438|FG000|Overall Study|Lost to Follow-up|1
6285400|NCT02334384|9997439|FG001|Overall Study|Lost to Follow-up|1
6285401|NCT02334423|9997447|FG000|Overall Study|Protocol Violation|10
6285402|NCT02334423|9997448|FG001|Overall Study|Protocol Violation|3
6285403|NCT02334683|9997473|FG000|First 12 Week Period|Lost to Follow-up|1
5980605|NCT02733042|9569330|FG010|Follow-up Period|Ongoing on Follow-up|4
5980606|NCT02733042|9569331|FG011|Follow-up Period|Ongoing on Follow-up|9
5980607|NCT02733042|9569332|FG012|Follow-up Period|Ongoing on Follow-up|1
5980608|NCT02733042|9569333|FG013|Follow-up Period|Ongoing on Follow-up|3
5980609|NCT02733042|9569334|FG014|Follow-up Period|Ongoing on Follow-up|0
5980610|NCT02733042|9569335|FG015|Follow-up Period|Ongoing on Follow-up|0
5980611|NCT02733042|9569336|FG016|Follow-up Period|Ongoing on Follow-up|0
5980612|NCT02733042|9569337|FG017|Follow-up Period|Ongoing on Follow-up|1
5980613|NCT02733042|9569338|FG018|Follow-up Period|Ongoing on Follow-up|0
5980614|NCT02733042|9569320|FG000|Follow-up Period|Death|1
5980615|NCT02733042|9569321|FG001|Follow-up Period|Death|1
5980616|NCT02733042|9569322|FG002|Follow-up Period|Death|2
5980617|NCT02733042|9569323|FG003|Follow-up Period|Death|0
5980618|NCT02733042|9569324|FG004|Follow-up Period|Death|1
5980619|NCT02733042|9569325|FG005|Follow-up Period|Death|2
5980620|NCT02733042|9569326|FG006|Follow-up Period|Death|0
5980621|NCT02733042|9569327|FG007|Follow-up Period|Death|3
5980622|NCT02733042|9569328|FG008|Follow-up Period|Death|3
5980623|NCT02733042|9569329|FG009|Follow-up Period|Death|0
5980624|NCT02733042|9569330|FG010|Follow-up Period|Death|0
5980625|NCT02733042|9569331|FG011|Follow-up Period|Death|0
5980626|NCT02733042|9569332|FG012|Follow-up Period|Death|8
5980627|NCT02733042|9569333|FG013|Follow-up Period|Death|1
5980628|NCT02733042|9569334|FG014|Follow-up Period|Death|1
5980629|NCT02733042|9569335|FG015|Follow-up Period|Death|4
5980630|NCT02733042|9569336|FG016|Follow-up Period|Death|0
5980631|NCT02733042|9569337|FG017|Follow-up Period|Death|1
5980632|NCT02733042|9569338|FG018|Follow-up Period|Death|2
5980633|NCT02733042|9569320|FG000|Follow-up Period|Other|0
5980634|NCT02733042|9569321|FG001|Follow-up Period|Other|0
5980635|NCT02733042|9569322|FG002|Follow-up Period|Other|0
5980636|NCT02733042|9569323|FG003|Follow-up Period|Other|1
5980637|NCT02733042|9569324|FG004|Follow-up Period|Other|0
5980638|NCT02733042|9569325|FG005|Follow-up Period|Other|0
5980639|NCT02733042|9569326|FG006|Follow-up Period|Other|0
5980640|NCT02733042|9569327|FG007|Follow-up Period|Other|0
5980641|NCT02733042|9569328|FG008|Follow-up Period|Other|0
5980642|NCT02733042|9569329|FG009|Follow-up Period|Other|0
5980643|NCT02733042|9569330|FG010|Follow-up Period|Other|0
5980644|NCT02733042|9569331|FG011|Follow-up Period|Other|0
5980645|NCT02733042|9569332|FG012|Follow-up Period|Other|0
5980646|NCT02733042|9569333|FG013|Follow-up Period|Other|0
5980647|NCT02733042|9569334|FG014|Follow-up Period|Other|0
5980648|NCT02733042|9569335|FG015|Follow-up Period|Other|0
5980649|NCT02733042|9569336|FG016|Follow-up Period|Other|0
5980650|NCT02733042|9569337|FG017|Follow-up Period|Other|0
6206072|NCT01539083|9869058|FG002|Before Randomization (VCD Induction)|Protocol Violation|0
6285404|NCT02334683|9997474|FG001|First 12 Week Period|Lost to Follow-up|0
5980651|NCT02733042|9569338|FG018|Follow-up Period|Other|0
5980652|NCT02733042|9569320|FG000|Follow-up Period|Withdrawal by Subject|0
5980653|NCT02733042|9569321|FG001|Follow-up Period|Withdrawal by Subject|0
5980654|NCT02733042|9569322|FG002|Follow-up Period|Withdrawal by Subject|0
6107669|NCT00805207|9726001|FG008|Overall Study|Withdrawal by Subject|0
6107670|NCT00805285|9726025|FG000|Overall Study|Lack of Efficacy|1
6107671|NCT00805389|9726034|FG000|Overall Study|Adverse Event|0
6107672|NCT00805389|9726035|FG001|Overall Study|Adverse Event|0
6107673|NCT00805389|9726036|FG002|Overall Study|Adverse Event|1
6107674|NCT00805389|9726037|FG003|Overall Study|Adverse Event|2
6107675|NCT00805389|9726038|FG004|Overall Study|Adverse Event|0
6107676|NCT00805389|9726034|FG000|Overall Study|Lost to Follow-up|4
6107677|NCT00805389|9726035|FG001|Overall Study|Lost to Follow-up|3
6107678|NCT00805389|9726036|FG002|Overall Study|Lost to Follow-up|6
6107679|NCT00805389|9726037|FG003|Overall Study|Lost to Follow-up|10
6107680|NCT00805389|9726038|FG004|Overall Study|Lost to Follow-up|9
6107681|NCT00805389|9726034|FG000|Overall Study|Protocol Violation|0
6107682|NCT00805389|9726035|FG001|Overall Study|Protocol Violation|0
6107683|NCT00805389|9726036|FG002|Overall Study|Protocol Violation|1
6107684|NCT00805389|9726037|FG003|Overall Study|Protocol Violation|0
6107685|NCT00805389|9726038|FG004|Overall Study|Protocol Violation|0
6107686|NCT00805389|9726034|FG000|Overall Study|Withdrawal by Subject|3
6107687|NCT00805389|9726035|FG001|Overall Study|Withdrawal by Subject|2
6107688|NCT00805389|9726036|FG002|Overall Study|Withdrawal by Subject|4
6107689|NCT00805389|9726037|FG003|Overall Study|Withdrawal by Subject|5
6107690|NCT00805389|9726038|FG004|Overall Study|Withdrawal by Subject|4
6107691|NCT00805441|9726062|FG000|Overall Study|Adverse Event|5
6107692|NCT00805441|9726063|FG001|Overall Study|Adverse Event|2
6107693|NCT00805441|9726062|FG000|Overall Study|Lack of Efficacy|0
6107694|NCT00805441|9726063|FG001|Overall Study|Lack of Efficacy|2
6107695|NCT00805441|9726062|FG000|Overall Study|Protocol Violation|4
6107696|NCT00805441|9726063|FG001|Overall Study|Protocol Violation|8
6107697|NCT00805441|9726062|FG000|Overall Study|Lost to Follow-up|10
6107698|NCT00805441|9726063|FG001|Overall Study|Lost to Follow-up|13
6107699|NCT00805441|9726062|FG000|Overall Study|Withdrawal by Subject|15
6107700|NCT00805441|9726063|FG001|Overall Study|Withdrawal by Subject|9
6107701|NCT00805441|9726062|FG000|Overall Study|Physician Decision|0
6107702|NCT00805441|9726063|FG001|Overall Study|Physician Decision|1
6107703|NCT00805441|9726062|FG000|Overall Study|Acute Alcohol Withdrawal|0
6107704|NCT00805441|9726063|FG001|Overall Study|Acute Alcohol Withdrawal|1
6107705|NCT00805467|9726073|FG000|Overall Study|Lack of Efficacy|0
6107706|NCT00805467|9726074|FG001|Overall Study|Lack of Efficacy|8
6107707|NCT00805467|9726075|FG002|Overall Study|Lack of Efficacy|13
6107708|NCT00805467|9726076|FG003|Overall Study|Lack of Efficacy|86
6107709|NCT00805467|9726073|FG000|Overall Study|Lost to Follow-up|0
6107710|NCT00805467|9726074|FG001|Overall Study|Lost to Follow-up|1
6107711|NCT00805467|9726075|FG002|Overall Study|Lost to Follow-up|7
6107712|NCT00805467|9726076|FG003|Overall Study|Lost to Follow-up|21
6107713|NCT00805467|9726073|FG000|Overall Study|Withdrawal by Subject|0
6107714|NCT00805467|9726074|FG001|Overall Study|Withdrawal by Subject|6
6107715|NCT00805467|9726075|FG002|Overall Study|Withdrawal by Subject|45
6107716|NCT00805467|9726076|FG003|Overall Study|Withdrawal by Subject|50
6107717|NCT00805467|9726073|FG000|Overall Study|Protocol Violation|0
6107718|NCT00805467|9726074|FG001|Overall Study|Protocol Violation|3
6107719|NCT00805467|9726075|FG002|Overall Study|Protocol Violation|0
6107720|NCT00805467|9726076|FG003|Overall Study|Protocol Violation|5
6107721|NCT00805467|9726073|FG000|Overall Study|Adverse Event|0
6107722|NCT00805467|9726074|FG001|Overall Study|Adverse Event|13
6107723|NCT00805467|9726075|FG002|Overall Study|Adverse Event|26
6107724|NCT00805467|9726076|FG003|Overall Study|Adverse Event|57
6107725|NCT00805467|9726073|FG000|Overall Study|Death|0
6107726|NCT00805467|9726074|FG001|Overall Study|Death|2
6107727|NCT00805467|9726075|FG002|Overall Study|Death|7
6107728|NCT00805467|9726076|FG003|Overall Study|Death|5
6107729|NCT00805467|9726073|FG000|Overall Study|Physician Decision|0
6107730|NCT00805467|9726074|FG001|Overall Study|Physician Decision|1
6107731|NCT00805467|9726075|FG002|Overall Study|Physician Decision|2
6107732|NCT00805467|9726076|FG003|Overall Study|Physician Decision|6
6107733|NCT00805467|9726073|FG000|Overall Study|Not reported|0
6107734|NCT00805467|9726074|FG001|Overall Study|Not reported|0
6107735|NCT00805467|9726075|FG002|Overall Study|Not reported|3
6107736|NCT00805467|9726076|FG003|Overall Study|Not reported|7
6107737|NCT00805480|9726090|FG000|Overall Study|Withdrawal by Subject|13
6107738|NCT00805480|9726091|FG001|Overall Study|Withdrawal by Subject|5
6107739|NCT00805480|9726092|FG002|Overall Study|Withdrawal by Subject|11
6107740|NCT00805480|9726093|FG003|Overall Study|Withdrawal by Subject|5
6107741|NCT00805480|9726090|FG000|Overall Study|Lost to Follow-up|1
6107742|NCT00805480|9726091|FG001|Overall Study|Lost to Follow-up|2
6107743|NCT00805480|9726092|FG002|Overall Study|Lost to Follow-up|0
6107744|NCT00805480|9726093|FG003|Overall Study|Lost to Follow-up|0
6107745|NCT00805480|9726090|FG000|Overall Study|Adverse Event|0
6107746|NCT00805480|9726091|FG001|Overall Study|Adverse Event|0
6107747|NCT00805480|9726092|FG002|Overall Study|Adverse Event|1
6107748|NCT00805480|9726093|FG003|Overall Study|Adverse Event|0
6107749|NCT00805532|9726121|FG000|Overall Study|invalid data|0
6107750|NCT00805532|9726122|FG001|Overall Study|invalid data|1
6107751|NCT00805545|9726132|FG000|Overall Study|Protocol Violation|3
6107752|NCT00805545|9726133|FG001|Overall Study|Protocol Violation|2
6107753|NCT00805545|9726132|FG000|Overall Study|Protocol Violation|3
6107754|NCT00805545|9726133|FG001|Overall Study|Protocol Violation|1
6107755|NCT00805675|9726142|FG000|Overall Study|Adverse Event|0
6107756|NCT00805675|9726143|FG001|Overall Study|Adverse Event|0
6107757|NCT00805675|9726144|FG002|Overall Study|Adverse Event|1
6107758|NCT00805740|9726154|FG000|Overall Study|Death|7
6107759|NCT00805740|9726155|FG001|Overall Study|Death|4
6107760|NCT00805740|9726154|FG000|Overall Study|Withdrawal by Subject|1
6107761|NCT00805740|9726155|FG001|Overall Study|Withdrawal by Subject|0
6107762|NCT00805740|9726154|FG000|Overall Study|Lost to Follow-up|1
6107763|NCT00805740|9726155|FG001|Overall Study|Lost to Follow-up|0
6206073|NCT01539083|9869056|FG000|Before Randomization (VCD Induction)|Physician Decision|14
6206074|NCT01539083|9869057|FG001|Before Randomization (VCD Induction)|Physician Decision|0
6206075|NCT01539083|9869058|FG002|Before Randomization (VCD Induction)|Physician Decision|0
6206076|NCT01539083|9869056|FG000|Before Randomization (VCD Induction)|Progressive Disease|8
6206077|NCT01539083|9869057|FG001|Before Randomization (VCD Induction)|Progressive Disease|0
6206078|NCT01539083|9869058|FG002|Before Randomization (VCD Induction)|Progressive Disease|0
6206079|NCT01539083|9869056|FG000|Before Randomization (VCD Induction)|Other|5
6206080|NCT01539083|9869057|FG001|Before Randomization (VCD Induction)|Other|0
6206081|NCT01539083|9869058|FG002|Before Randomization (VCD Induction)|Other|0
6206082|NCT01539083|9869056|FG000|After Randomization (TP and VTP)|Physician Decision|0
6206083|NCT01539083|9869057|FG001|After Randomization (TP and VTP)|Physician Decision|0
6206084|NCT01539083|9869058|FG002|After Randomization (TP and VTP)|Physician Decision|1
6206085|NCT01539083|9869056|FG000|After Randomization (TP and VTP)|Other|0
6206086|NCT01539083|9869057|FG001|After Randomization (TP and VTP)|Other|1
6206087|NCT01539083|9869058|FG002|After Randomization (TP and VTP)|Other|1
6206088|NCT01539083|9869056|FG000|After Randomization (TP and VTP)|Adverse Event|0
6206089|NCT01539083|9869057|FG001|After Randomization (TP and VTP)|Adverse Event|1
6206090|NCT01539083|9869058|FG002|After Randomization (TP and VTP)|Adverse Event|1
6206091|NCT01539083|9869056|FG000|After Randomization (TP and VTP)|Lost to Follow-up|0
6206092|NCT01539083|9869057|FG001|After Randomization (TP and VTP)|Lost to Follow-up|2
6206093|NCT01539083|9869058|FG002|After Randomization (TP and VTP)|Lost to Follow-up|2
6206094|NCT01539083|9869056|FG000|After Randomization (TP and VTP)|Withdrawal by Subject|0
6206095|NCT01539083|9869057|FG001|After Randomization (TP and VTP)|Withdrawal by Subject|5
6206096|NCT01539083|9869058|FG002|After Randomization (TP and VTP)|Withdrawal by Subject|4
6206097|NCT01539083|9869056|FG000|After Randomization (TP and VTP)|Progressive Disease|0
6206098|NCT01539083|9869057|FG001|After Randomization (TP and VTP)|Progressive Disease|6
6206099|NCT01539083|9869058|FG002|After Randomization (TP and VTP)|Progressive Disease|3
6206100|NCT01539083|9869056|FG000|After Randomization (TP and VTP)|Death|0
6206101|NCT01539083|9869057|FG001|After Randomization (TP and VTP)|Death|6
6206102|NCT01539083|9869058|FG002|After Randomization (TP and VTP)|Death|11
6206103|NCT01539239|9869076|FG000|Overall Study|Death|5
6206104|NCT01539239|9869077|FG001|Overall Study|Death|5
6206105|NCT01539239|9869076|FG000|Overall Study|Lost to Follow-up|7
6206106|NCT01539239|9869077|FG001|Overall Study|Lost to Follow-up|12
6206107|NCT01539291|9869086|FG000|Study GS-US-312-0116|Adverse Event|9
6206108|NCT01539291|9869087|FG001|Study GS-US-312-0116|Adverse Event|0
6206109|NCT01539291|9869088|FG002|Study GS-US-312-0116|Adverse Event|0
6206110|NCT01539291|9869089|FG003|Study GS-US-312-0116|Adverse Event|0
6206111|NCT01539291|9869086|FG000|Study GS-US-312-0116|Physician Decision|1
6206112|NCT01539291|9869087|FG001|Study GS-US-312-0116|Physician Decision|0
6206113|NCT01539291|9869088|FG002|Study GS-US-312-0116|Physician Decision|0
6206114|NCT01539291|9869089|FG003|Study GS-US-312-0116|Physician Decision|0
6206115|NCT01539291|9869086|FG000|Study GS-US-312-0116|Withdrawal by Subject|12
6206116|NCT01539291|9869087|FG001|Study GS-US-312-0116|Withdrawal by Subject|0
6206117|NCT01539291|9869088|FG002|Study GS-US-312-0116|Withdrawal by Subject|0
6206118|NCT01539291|9869089|FG003|Study GS-US-312-0116|Withdrawal by Subject|0
6206119|NCT01539291|9869086|FG000|Study GS-US-312-0116|Study Terminated by Sponsor|2
6206120|NCT01539291|9869087|FG001|Study GS-US-312-0116|Study Terminated by Sponsor|0
6206121|NCT01539291|9869088|FG002|Study GS-US-312-0116|Study Terminated by Sponsor|0
6206122|NCT01539291|9869089|FG003|Study GS-US-312-0116|Study Terminated by Sponsor|0
6206123|NCT01539291|9869086|FG000|Study GS-US-312-0116|Other|1
6206124|NCT01539291|9869087|FG001|Study GS-US-312-0116|Other|0
6206125|NCT01539291|9869088|FG002|Study GS-US-312-0116|Other|0
6206126|NCT01539291|9869089|FG003|Study GS-US-312-0116|Other|0
6206127|NCT01539291|9869086|FG000|Study GS-US-312-0117|Adverse Event|22
6206128|NCT01539291|9869087|FG001|Study GS-US-312-0117|Adverse Event|1
6206129|NCT01539291|9869088|FG002|Study GS-US-312-0117|Adverse Event|9
6206130|NCT01539291|9869089|FG003|Study GS-US-312-0117|Adverse Event|12
6206131|NCT01539291|9869086|FG000|Study GS-US-312-0117|Physician Decision|9
6206132|NCT01539291|9869087|FG001|Study GS-US-312-0117|Physician Decision|0
6206133|NCT01539291|9869088|FG002|Study GS-US-312-0117|Physician Decision|6
6206134|NCT01539291|9869089|FG003|Study GS-US-312-0117|Physician Decision|4
6206135|NCT01539291|9869086|FG000|Study GS-US-312-0117|Withdrawal by Subject|5
6206136|NCT01539291|9869087|FG001|Study GS-US-312-0117|Withdrawal by Subject|0
6206137|NCT01539291|9869088|FG002|Study GS-US-312-0117|Withdrawal by Subject|6
6206138|NCT01539291|9869089|FG003|Study GS-US-312-0117|Withdrawal by Subject|4
6206139|NCT01539291|9869086|FG000|Study GS-US-312-0117|Study Terminated by Sponsor|3
6206140|NCT01539291|9869087|FG001|Study GS-US-312-0117|Study Terminated by Sponsor|0
6206141|NCT01539291|9869088|FG002|Study GS-US-312-0117|Study Terminated by Sponsor|0
6206142|NCT01539291|9869089|FG003|Study GS-US-312-0117|Study Terminated by Sponsor|5
6107764|NCT00805740|9726154|FG000|Overall Study|Randomized, but not treated|2
6107765|NCT00805740|9726155|FG001|Overall Study|Randomized, but not treated|0
6107766|NCT00805766|9726161|FG000|Screening Period|Adverse Event|1
6107767|NCT00805766|9726161|FG000|Screening Period|Lack of Efficacy|2
6107768|NCT00805766|9726161|FG000|Screening Period|Pregnancy|1
6107769|NCT00805766|9726161|FG000|Screening Period|Responder|2
6107770|NCT00805766|9726161|FG000|Increased Dose Period|Adverse Event|4
6107771|NCT00805766|9726161|FG000|Increased Dose Period|Lack of Efficacy|7
6107772|NCT00805766|9726161|FG000|Increased Dose Period|Pregnancy|1
6107773|NCT00805766|9726161|FG000|Increased Dose Period|Withdrawal by Subject|1
6107774|NCT00805792|9726169|FG000|Overall Study|Death|3
6107775|NCT00805792|9726169|FG000|Overall Study|Lost to Follow-up|2
6107776|NCT00805935|9726186|FG000|Overall Study|Stimulation Failure|1
6107777|NCT00805935|9726187|FG001|Overall Study|Stimulation Failure|5
6107778|NCT00805935|9726188|FG002|Overall Study|Stimulation Failure|2
6107779|NCT00805935|9726189|FG003|Overall Study|Stimulation Failure|2
6107780|NCT00805935|9726186|FG000|Overall Study|Cycle cancelled|0
6107781|NCT00805935|9726187|FG001|Overall Study|Cycle cancelled|0
6107782|NCT00805935|9726188|FG002|Overall Study|Cycle cancelled|2
6107783|NCT00805935|9726189|FG003|Overall Study|Cycle cancelled|0
6107784|NCT00805935|9726186|FG000|Overall Study|Cycle cancellation for risk of OHSS|1
6107785|NCT00805935|9726187|FG001|Overall Study|Cycle cancellation for risk of OHSS|0
6107786|NCT00805935|9726188|FG002|Overall Study|Cycle cancellation for risk of OHSS|1
6107787|NCT00805935|9726189|FG003|Overall Study|Cycle cancellation for risk of OHSS|0
6107788|NCT00805935|9726186|FG000|Overall Study|Ovarian hyperstimulation syndrome(OHSS)|0
6107789|NCT00805935|9726187|FG001|Overall Study|Ovarian hyperstimulation syndrome(OHSS)|0
6107790|NCT00805935|9726188|FG002|Overall Study|Ovarian hyperstimulation syndrome(OHSS)|0
6107791|NCT00805935|9726189|FG003|Overall Study|Ovarian hyperstimulation syndrome(OHSS)|1
6107792|NCT00805935|9726186|FG000|Overall Study|Lost to Follow-up|1
6107793|NCT00805935|9726187|FG001|Overall Study|Lost to Follow-up|0
6206143|NCT01539291|9869086|FG000|Study GS-US-312-0117|Other|2
6107794|NCT00805935|9726188|FG002|Overall Study|Lost to Follow-up|0
6107795|NCT00805935|9726189|FG003|Overall Study|Lost to Follow-up|0
6107796|NCT00805935|9726186|FG000|Overall Study|No positive serum pregnancy|8
6107797|NCT00805935|9726187|FG001|Overall Study|No positive serum pregnancy|7
6107798|NCT00805935|9726188|FG002|Overall Study|No positive serum pregnancy|6
6107799|NCT00805935|9726189|FG003|Overall Study|No positive serum pregnancy|5
6107800|NCT00805935|9726186|FG000|Overall Study|Pregnancy not confirmed by ultrasound|0
6107801|NCT00805935|9726187|FG001|Overall Study|Pregnancy not confirmed by ultrasound|0
6107802|NCT00805935|9726188|FG002|Overall Study|Pregnancy not confirmed by ultrasound|0
6107803|NCT00805935|9726189|FG003|Overall Study|Pregnancy not confirmed by ultrasound|1
6107804|NCT00805935|9726186|FG000|Overall Study|Pregnancy loss/miscarriage|2
6107805|NCT00805935|9726187|FG001|Overall Study|Pregnancy loss/miscarriage|0
6107806|NCT00805935|9726188|FG002|Overall Study|Pregnancy loss/miscarriage|0
6107807|NCT00805935|9726189|FG003|Overall Study|Pregnancy loss/miscarriage|0
6107808|NCT00805935|9726186|FG000|Overall Study|Biochemical pregnancy|0
6107809|NCT00805935|9726187|FG001|Overall Study|Biochemical pregnancy|1
6107810|NCT00805935|9726188|FG002|Overall Study|Biochemical pregnancy|0
6107811|NCT00805935|9726189|FG003|Overall Study|Biochemical pregnancy|0
6107812|NCT00805935|9726186|FG000|Overall Study|Chemical pregnancy|0
6107813|NCT00805935|9726187|FG001|Overall Study|Chemical pregnancy|5
6107814|NCT00805935|9726188|FG002|Overall Study|Chemical pregnancy|3
6107815|NCT00805935|9726189|FG003|Overall Study|Chemical pregnancy|2
6107816|NCT00805935|9726186|FG000|Overall Study|Ectopic pregnancy|0
6107817|NCT00805935|9726187|FG001|Overall Study|Ectopic pregnancy|0
6107818|NCT00805935|9726188|FG002|Overall Study|Ectopic pregnancy|1
6107819|NCT00805935|9726189|FG003|Overall Study|Ectopic pregnancy|0
6107820|NCT00805935|9726186|FG000|Overall Study|Serious Adverse Event-congenital anomaly|0
6107821|NCT00805935|9726187|FG001|Overall Study|Serious Adverse Event-congenital anomaly|1
6107822|NCT00805935|9726188|FG002|Overall Study|Serious Adverse Event-congenital anomaly|0
6107823|NCT00805935|9726189|FG003|Overall Study|Serious Adverse Event-congenital anomaly|0
6107824|NCT00806026|9726217|FG000|Overall Study|Death|0
6107825|NCT00806026|9726218|FG001|Overall Study|Death|0
6107826|NCT00806026|9726219|FG002|Overall Study|Death|0
6107827|NCT00806026|9726220|FG003|Overall Study|Death|1
6107828|NCT00806026|9726221|FG004|Overall Study|Death|0
6107829|NCT00806026|9726222|FG005|Overall Study|Death|0
6107830|NCT00806026|9726217|FG000|Overall Study|Did not meet entrance criteria|4
6107831|NCT00806026|9726218|FG001|Overall Study|Did not meet entrance criteria|1
6107832|NCT00806026|9726219|FG002|Overall Study|Did not meet entrance criteria|2
6107833|NCT00806026|9726220|FG003|Overall Study|Did not meet entrance criteria|1
6107834|NCT00806026|9726221|FG004|Overall Study|Did not meet entrance criteria|0
6107835|NCT00806026|9726222|FG005|Overall Study|Did not meet entrance criteria|0
6107836|NCT00806026|9726217|FG000|Overall Study|Lack of Efficacy|5
6107837|NCT00806026|9726218|FG001|Overall Study|Lack of Efficacy|18
6107838|NCT00806026|9726219|FG002|Overall Study|Lack of Efficacy|13
6107839|NCT00806026|9726220|FG003|Overall Study|Lack of Efficacy|4
6107840|NCT00806026|9726221|FG004|Overall Study|Lack of Efficacy|8
6107841|NCT00806026|9726222|FG005|Overall Study|Lack of Efficacy|7
6107842|NCT00806026|9726217|FG000|Overall Study|Lost to Follow-up|8
6107843|NCT00806026|9726218|FG001|Overall Study|Lost to Follow-up|15
6107844|NCT00806026|9726219|FG002|Overall Study|Lost to Follow-up|8
6107845|NCT00806026|9726220|FG003|Overall Study|Lost to Follow-up|2
6107846|NCT00806026|9726221|FG004|Overall Study|Lost to Follow-up|6
6107847|NCT00806026|9726222|FG005|Overall Study|Lost to Follow-up|6
6107848|NCT00806026|9726217|FG000|Overall Study|Withdrawal by Subject|14
6107849|NCT00806026|9726218|FG001|Overall Study|Withdrawal by Subject|17
6107850|NCT00806026|9726219|FG002|Overall Study|Withdrawal by Subject|9
6107851|NCT00806026|9726220|FG003|Overall Study|Withdrawal by Subject|2
6107852|NCT00806026|9726221|FG004|Overall Study|Withdrawal by Subject|5
6107853|NCT00806026|9726222|FG005|Overall Study|Withdrawal by Subject|3
6107854|NCT00806026|9726217|FG000|Overall Study|Other|3
6107855|NCT00806026|9726218|FG001|Overall Study|Other|6
6107856|NCT00806026|9726219|FG002|Overall Study|Other|8
6107857|NCT00806026|9726220|FG003|Overall Study|Other|2
6107858|NCT00806026|9726221|FG004|Overall Study|Other|0
6107859|NCT00806026|9726222|FG005|Overall Study|Other|4
6107860|NCT00806026|9726217|FG000|Overall Study|Protocol Violation|6
6107861|NCT00806026|9726218|FG001|Overall Study|Protocol Violation|9
6107862|NCT00806026|9726219|FG002|Overall Study|Protocol Violation|9
6107863|NCT00806026|9726220|FG003|Overall Study|Protocol Violation|0
6107864|NCT00806026|9726221|FG004|Overall Study|Protocol Violation|2
6107865|NCT00806026|9726222|FG005|Overall Study|Protocol Violation|3
6107866|NCT00806026|9726217|FG000|Overall Study|Adverse Event|52
6107867|NCT00806026|9726218|FG001|Overall Study|Adverse Event|35
6107868|NCT00806026|9726219|FG002|Overall Study|Adverse Event|44
6107869|NCT00806026|9726220|FG003|Overall Study|Adverse Event|17
6107870|NCT00806026|9726221|FG004|Overall Study|Adverse Event|9
6107871|NCT00806026|9726222|FG005|Overall Study|Adverse Event|9
6107872|NCT00806156|9726245|FG000|Overall Study|Death|35
6107873|NCT00806156|9726246|FG001|Overall Study|Death|95
6107874|NCT00806156|9726245|FG000|Overall Study|Did not meet eligibility criteria|1
6107875|NCT00806156|9726246|FG001|Overall Study|Did not meet eligibility criteria|0
6107876|NCT00806156|9726245|FG000|Overall Study|Study terminated by Sponsor|2
6107877|NCT00806156|9726246|FG001|Overall Study|Study terminated by Sponsor|40
6107878|NCT00806156|9726245|FG000|Overall Study|Consent withdrawn by subject|1
6107879|NCT00806156|9726246|FG001|Overall Study|Consent withdrawn by subject|3
6107880|NCT00806156|9726245|FG000|Overall Study|Lost to Follow-up|0
6107881|NCT00806156|9726246|FG001|Overall Study|Lost to Follow-up|1
6107882|NCT00806195|9726268|FG000|Overall Study|Death|6
6107883|NCT00806195|9726269|FG001|Overall Study|Death|0
6107884|NCT00806195|9726270|FG002|Overall Study|Death|1
6107885|NCT00806195|9726271|FG003|Overall Study|Death|0
6285405|NCT02334683|9997473|FG000|Second 12 Week Period|Adverse Event|0
6285406|NCT02334683|9997474|FG001|Second 12 Week Period|Adverse Event|1
6285407|NCT02334748|9997480|FG000|Overall Study|Adverse Event|1
6285408|NCT02334748|9997480|FG000|Overall Study|Inclusion in the CACZ8852306 study|1
6285409|NCT02334748|9997480|FG000|Overall Study|Patient no longer required study drug|2
6285410|NCT02334748|9997480|FG000|Overall Study|Lack of Efficacy|4
6285411|NCT02335346|9997615|FG000|Overall Study|Adverse Event|11
6107886|NCT00806195|9726268|FG000|Overall Study|Adverse Event|25
6107887|NCT00806195|9726269|FG001|Overall Study|Adverse Event|5
6107888|NCT00806195|9726270|FG002|Overall Study|Adverse Event|11
6107889|NCT00806195|9726271|FG003|Overall Study|Adverse Event|2
6107890|NCT00806195|9726268|FG000|Overall Study|Withdrawal by Subject|119
6107891|NCT00806195|9726269|FG001|Overall Study|Withdrawal by Subject|31
6107892|NCT00806195|9726270|FG002|Overall Study|Withdrawal by Subject|76
6107893|NCT00806195|9726271|FG003|Overall Study|Withdrawal by Subject|35
6107894|NCT00806195|9726268|FG000|Overall Study|Lost to Follow-up|217
6107895|NCT00806195|9726269|FG001|Overall Study|Lost to Follow-up|66
6107896|NCT00806195|9726270|FG002|Overall Study|Lost to Follow-up|90
6107897|NCT00806195|9726271|FG003|Overall Study|Lost to Follow-up|34
6107898|NCT00806195|9726268|FG000|Overall Study|Inappropriate Enrollment|0
6107899|NCT00806195|9726269|FG001|Overall Study|Inappropriate Enrollment|1
6107900|NCT00806195|9726270|FG002|Overall Study|Inappropriate Enrollment|0
6107901|NCT00806195|9726271|FG003|Overall Study|Inappropriate Enrollment|0
6107902|NCT00806195|9726268|FG000|Overall Study|Administrative Reason|113
6107903|NCT00806195|9726269|FG001|Overall Study|Administrative Reason|35
6107904|NCT00806195|9726270|FG002|Overall Study|Administrative Reason|66
6107905|NCT00806195|9726271|FG003|Overall Study|Administrative Reason|26
6107906|NCT00806195|9726268|FG000|Overall Study|Protocol Violation|34
6107907|NCT00806195|9726269|FG001|Overall Study|Protocol Violation|24
6107908|NCT00806195|9726270|FG002|Overall Study|Protocol Violation|26
6107909|NCT00806195|9726271|FG003|Overall Study|Protocol Violation|9
6107910|NCT00806260|9726306|FG000|Period 1 (1 Day)|Adverse Event|0
6107911|NCT00806260|9726307|FG001|Period 1 (1 Day)|Adverse Event|0
6107912|NCT00806260|9726308|FG002|Period 1 (1 Day)|Adverse Event|0
6107913|NCT00806260|9726309|FG003|Period 1 (1 Day)|Adverse Event|0
6107914|NCT00806260|9726310|FG004|Period 1 (1 Day)|Adverse Event|3
6107915|NCT00806260|9726311|FG005|Period 1 (1 Day)|Adverse Event|0
6107916|NCT00806260|9726306|FG000|Period 2|Adverse Event|0
6107917|NCT00806260|9726307|FG001|Period 2|Adverse Event|0
6107918|NCT00806260|9726308|FG002|Period 2|Adverse Event|0
6107919|NCT00806260|9726309|FG003|Period 2|Adverse Event|1
6107920|NCT00806260|9726310|FG004|Period 2|Adverse Event|0
6107921|NCT00806260|9726311|FG005|Period 2|Adverse Event|0
6107922|NCT00806260|9726306|FG000|Period 2|Protocol Violation|1
6107923|NCT00806260|9726307|FG001|Period 2|Protocol Violation|0
6107924|NCT00806260|9726308|FG002|Period 2|Protocol Violation|1
6107925|NCT00806260|9726309|FG003|Period 2|Protocol Violation|0
6107926|NCT00806260|9726310|FG004|Period 2|Protocol Violation|0
6107927|NCT00806260|9726311|FG005|Period 2|Protocol Violation|0
6107928|NCT00806260|9726306|FG000|Period 2|Need to take concomitant medication|1
6107929|NCT00806260|9726307|FG001|Period 2|Need to take concomitant medication|0
6107930|NCT00806260|9726308|FG002|Period 2|Need to take concomitant medication|0
6107931|NCT00806260|9726309|FG003|Period 2|Need to take concomitant medication|0
6107932|NCT00806260|9726310|FG004|Period 2|Need to take concomitant medication|0
6107933|NCT00806260|9726311|FG005|Period 2|Need to take concomitant medication|0
6107934|NCT00806260|9726306|FG000|Period 2|sponsor request|0
6107935|NCT00806260|9726307|FG001|Period 2|sponsor request|0
6107936|NCT00806260|9726308|FG002|Period 2|sponsor request|1
6107937|NCT00806260|9726309|FG003|Period 2|sponsor request|1
6107938|NCT00806260|9726310|FG004|Period 2|sponsor request|0
6107939|NCT00806260|9726311|FG005|Period 2|sponsor request|0
6107940|NCT00806260|9726306|FG000|Period 3|Protocol Violation|0
6107941|NCT00806260|9726307|FG001|Period 3|Protocol Violation|1
6107942|NCT00806260|9726308|FG002|Period 3|Protocol Violation|1
6107943|NCT00806260|9726309|FG003|Period 3|Protocol Violation|0
6107944|NCT00806260|9726310|FG004|Period 3|Protocol Violation|0
6107945|NCT00806260|9726311|FG005|Period 3|Protocol Violation|0
6107946|NCT00806260|9726306|FG000|Period 3|Pregnancy|1
6107947|NCT00806260|9726307|FG001|Period 3|Pregnancy|0
6107948|NCT00806260|9726308|FG002|Period 3|Pregnancy|0
6107949|NCT00806260|9726309|FG003|Period 3|Pregnancy|0
6107950|NCT00806260|9726310|FG004|Period 3|Pregnancy|0
6107951|NCT00806260|9726311|FG005|Period 3|Pregnancy|0
6107952|NCT00806286|9726326|FG000|Overall Study|Adverse Event|5
6107953|NCT00806286|9726327|FG001|Overall Study|Adverse Event|2
6107954|NCT00806286|9726328|FG002|Overall Study|Adverse Event|0
6107955|NCT00806286|9726326|FG000|Overall Study|Disease progression|31
6107956|NCT00806286|9726327|FG001|Overall Study|Disease progression|38
6107957|NCT00806286|9726328|FG002|Overall Study|Disease progression|1
6107958|NCT00806286|9726326|FG000|Overall Study|Death|1
6107959|NCT00806286|9726327|FG001|Overall Study|Death|6
6107960|NCT00806286|9726328|FG002|Overall Study|Death|0
6107961|NCT00806286|9726326|FG000|Overall Study|Lost to Follow-up|0
6107962|NCT00806286|9726327|FG001|Overall Study|Lost to Follow-up|1
6107963|NCT00806286|9726328|FG002|Overall Study|Lost to Follow-up|0
6107964|NCT00806286|9726326|FG000|Overall Study|Withdrawal by Subject|8
6107965|NCT00806286|9726327|FG001|Overall Study|Withdrawal by Subject|3
6107966|NCT00806286|9726328|FG002|Overall Study|Withdrawal by Subject|1
6107967|NCT00806286|9726326|FG000|Overall Study|Physician Decision|2
6107968|NCT00806286|9726327|FG001|Overall Study|Physician Decision|2
6107969|NCT00806286|9726328|FG002|Overall Study|Physician Decision|0
6107970|NCT00806286|9726326|FG000|Overall Study|Due to a variety of reasons|7
6107971|NCT00806286|9726327|FG001|Overall Study|Due to a variety of reasons|2
6107972|NCT00806286|9726328|FG002|Overall Study|Due to a variety of reasons|1
6107973|NCT00806351|9726338|FG000|Overall Study|Death|5
6107974|NCT00806351|9726339|FG001|Overall Study|Death|4
6107975|NCT00806442|9726345|FG000|Overall Study|Lost to Follow-up|3
6107976|NCT00806442|9726346|FG001|Overall Study|Lost to Follow-up|2
6107977|NCT00806442|9726345|FG000|Overall Study|Withdrawal by Subject|1
6107978|NCT00806442|9726346|FG001|Overall Study|Withdrawal by Subject|5
6107979|NCT00806494|9726354|FG000|Overall Study|Adverse Event|29
6107980|NCT00806494|9726354|FG000|Overall Study|Lack of Efficacy|6
6107981|NCT00806494|9726354|FG000|Overall Study|Lost to Follow-up|10
6107982|NCT00806494|9726354|FG000|Overall Study|Other|30
6107983|NCT00806494|9726354|FG000|Overall Study|Withdrawal by Subject|5
6107984|NCT00806546|9726359|FG000|Overall Study|Enrolled, not treated|35
6107985|NCT00806546|9726359|FG000|Overall Study|Lost to Follow-up|32
6107986|NCT00806546|9726359|FG000|Overall Study|Adverse Event|74
6107987|NCT00806546|9726359|FG000|Overall Study|Withdrawal by Subject|75
6107988|NCT00806546|9726359|FG000|Overall Study|Protocol Violation|49
6107989|NCT00806546|9726359|FG000|Overall Study|Various|42
6107990|NCT00806585|9726368|FG000|Overall Study|Study terminated by Sponsor|0
6107991|NCT00806585|9726369|FG001|Overall Study|Study terminated by Sponsor|0
6107992|NCT00806585|9726370|FG002|Overall Study|Study terminated by Sponsor|1
6107993|NCT00806585|9726371|FG003|Overall Study|Study terminated by Sponsor|2
6107994|NCT00806585|9726372|FG004|Overall Study|Study terminated by Sponsor|0
6107995|NCT00806585|9726368|FG000|Overall Study|Protocol Violation|3
6107996|NCT00806585|9726369|FG001|Overall Study|Protocol Violation|1
6107997|NCT00806585|9726370|FG002|Overall Study|Protocol Violation|2
6107998|NCT00806585|9726371|FG003|Overall Study|Protocol Violation|0
6107999|NCT00806585|9726372|FG004|Overall Study|Protocol Violation|0
6108000|NCT00806585|9726368|FG000|Overall Study|Physician Decision|0
6108001|NCT00806585|9726369|FG001|Overall Study|Physician Decision|2
6108002|NCT00806585|9726370|FG002|Overall Study|Physician Decision|3
6108003|NCT00806585|9726371|FG003|Overall Study|Physician Decision|0
6108004|NCT00806585|9726372|FG004|Overall Study|Physician Decision|1
6108005|NCT00806585|9726368|FG000|Overall Study|Lost to Follow-up|2
6108006|NCT00806585|9726369|FG001|Overall Study|Lost to Follow-up|1
6108007|NCT00806585|9726370|FG002|Overall Study|Lost to Follow-up|2
6108008|NCT00806585|9726371|FG003|Overall Study|Lost to Follow-up|2
6108009|NCT00806585|9726372|FG004|Overall Study|Lost to Follow-up|5
6108010|NCT00806585|9726368|FG000|Overall Study|Lack of Efficacy|1
6108011|NCT00806585|9726369|FG001|Overall Study|Lack of Efficacy|0
6108012|NCT00806585|9726370|FG002|Overall Study|Lack of Efficacy|0
6108013|NCT00806585|9726371|FG003|Overall Study|Lack of Efficacy|0
6108014|NCT00806585|9726372|FG004|Overall Study|Lack of Efficacy|0
6108015|NCT00806585|9726368|FG000|Overall Study|Adverse Event|1
6108016|NCT00806585|9726369|FG001|Overall Study|Adverse Event|5
6108017|NCT00806585|9726370|FG002|Overall Study|Adverse Event|3
6108018|NCT00806585|9726371|FG003|Overall Study|Adverse Event|4
6108019|NCT00806585|9726372|FG004|Overall Study|Adverse Event|2
6108020|NCT00806585|9726368|FG000|Overall Study|Withdrawal by Subject|10
6108021|NCT00806585|9726369|FG001|Overall Study|Withdrawal by Subject|8
6108022|NCT00806585|9726370|FG002|Overall Study|Withdrawal by Subject|9
6108023|NCT00806585|9726371|FG003|Overall Study|Withdrawal by Subject|3
6108024|NCT00806585|9726372|FG004|Overall Study|Withdrawal by Subject|11
6108025|NCT00806585|9726368|FG000|Overall Study|Completion status unknown|15
6108026|NCT00806585|9726369|FG001|Overall Study|Completion status unknown|14
6108027|NCT00806585|9726370|FG002|Overall Study|Completion status unknown|12
6108028|NCT00806585|9726371|FG003|Overall Study|Completion status unknown|4
6108029|NCT00806585|9726372|FG004|Overall Study|Completion status unknown|12
6108030|NCT00806624|9726391|FG000|Overall Study|Adverse Event|2
6108031|NCT00806624|9726392|FG001|Overall Study|Adverse Event|8
6108032|NCT00806624|9726393|FG002|Overall Study|Adverse Event|0
6108033|NCT00806624|9726391|FG000|Overall Study|Death|0
6108034|NCT00806624|9726392|FG001|Overall Study|Death|1
6108035|NCT00806624|9726393|FG002|Overall Study|Death|1
6108036|NCT00806624|9726391|FG000|Overall Study|Lost to Follow-up|1
6108037|NCT00806624|9726392|FG001|Overall Study|Lost to Follow-up|0
6108038|NCT00806624|9726393|FG002|Overall Study|Lost to Follow-up|1
6108039|NCT00806624|9726391|FG000|Overall Study|Withdrawal by Subject|6
6108040|NCT00806624|9726392|FG001|Overall Study|Withdrawal by Subject|3
6108041|NCT00806624|9726393|FG002|Overall Study|Withdrawal by Subject|3
6108042|NCT00806624|9726391|FG000|Overall Study|discontinued before start of treatment|0
6108043|NCT00806624|9726392|FG001|Overall Study|discontinued before start of treatment|0
6108044|NCT00806624|9726393|FG002|Overall Study|discontinued before start of treatment|1
6206144|NCT01539291|9869087|FG001|Study GS-US-312-0117|Other|1
6206145|NCT01539291|9869088|FG002|Study GS-US-312-0117|Other|1
6206146|NCT01539291|9869089|FG003|Study GS-US-312-0117|Other|1
6206147|NCT01539317|9869108|FG000|Overall Study|Screening Error. Deleted from analysis.|1
6206148|NCT01539317|9869109|FG001|Overall Study|Screening Error. Deleted from analysis.|0
6206149|NCT01539512|9869120|FG000|Overall Study|Adverse Event|9
6206150|NCT01539512|9869121|FG001|Overall Study|Adverse Event|7
6206151|NCT01539512|9869120|FG000|Overall Study|Physician Decision|1
6206152|NCT01539512|9869121|FG001|Overall Study|Physician Decision|1
6206153|NCT01539512|9869120|FG000|Overall Study|Withdrawal by Subject|12
6206154|NCT01539512|9869121|FG001|Overall Study|Withdrawal by Subject|5
6206155|NCT01539512|9869120|FG000|Overall Study|Richter's Transformation|1
6206156|NCT01539512|9869121|FG001|Overall Study|Richter's Transformation|0
6206157|NCT01539525|9869130|FG000|Overall Study|Lost to Follow-up|19
6206158|NCT01539525|9869131|FG001|Overall Study|Lost to Follow-up|12
6206159|NCT01539525|9869132|FG002|Overall Study|Lost to Follow-up|11
6206160|NCT01539525|9869130|FG000|Overall Study|Withdrawal by Subject|0
6206161|NCT01539525|9869131|FG001|Overall Study|Withdrawal by Subject|3
6206162|NCT01539525|9869132|FG002|Overall Study|Withdrawal by Subject|2
6206163|NCT01539525|9869130|FG000|Overall Study|Protocol Violation|1
6206164|NCT01539525|9869131|FG001|Overall Study|Protocol Violation|1
6206165|NCT01539525|9869132|FG002|Overall Study|Protocol Violation|4
6206166|NCT01539538|9869145|FG000|Overall Study|Adverse Event|13
6206167|NCT01539538|9869146|FG001|Overall Study|Adverse Event|18
6206168|NCT01539538|9869145|FG000|Overall Study|Lack of Efficacy|13
6206169|NCT01539538|9869146|FG001|Overall Study|Lack of Efficacy|16
6206170|NCT01539538|9869145|FG000|Overall Study|Withdrawal by Subject|2
6206171|NCT01539538|9869146|FG001|Overall Study|Withdrawal by Subject|3
6206172|NCT01539538|9869145|FG000|Overall Study|PCA no longer required or PCA problem|3
6206173|NCT01539538|9869146|FG001|Overall Study|PCA no longer required or PCA problem|7
6206174|NCT01539642|9869154|FG000|Overall Study|Lack of Efficacy|20
6206175|NCT01539642|9869155|FG001|Overall Study|Lack of Efficacy|18
6206176|NCT01539642|9869154|FG000|Overall Study|Patient ready for early discharge|8
6206177|NCT01539642|9869155|FG001|Overall Study|Patient ready for early discharge|7
6206178|NCT01539642|9869154|FG000|Overall Study|Adverse Event|6
6206179|NCT01539642|9869155|FG001|Overall Study|Adverse Event|4
6206180|NCT01539642|9869154|FG000|Overall Study|Withdrawal by Subject|2
6206181|NCT01539642|9869155|FG001|Overall Study|Withdrawal by Subject|2
6206182|NCT01539759|9869170|FG000|Overall Study|Lost to Follow-up|6
6206183|NCT01539759|9869171|FG001|Overall Study|Lost to Follow-up|8
6206184|NCT01539837|9869180|FG000|Overall Study|reduce neutrophil level|0
6206185|NCT01539837|9869181|FG001|Overall Study|reduce neutrophil level|1
6206186|NCT01539837|9869182|FG002|Overall Study|reduce neutrophil level|1
6206187|NCT01539837|9869180|FG000|Overall Study|bad compliance|0
6206188|NCT01539837|9869181|FG001|Overall Study|bad compliance|0
6206189|NCT01539837|9869182|FG002|Overall Study|bad compliance|1
6206190|NCT01540474|9869278|FG000|Vaccination Period|Lost to Follow-up|0
6206191|NCT01540474|9869279|FG001|Vaccination Period|Lost to Follow-up|1
6108045|NCT00806819|9726417|FG000|Overall Study|progressive disease (modified RECIST )|217
6108046|NCT00806819|9726418|FG001|Overall Study|progressive disease (modified RECIST )|216
6108047|NCT00806819|9726417|FG000|Overall Study|Worsening or AE of underlying disease|18
6108048|NCT00806819|9726418|FG001|Overall Study|Worsening or AE of underlying disease|25
6108049|NCT00806819|9726417|FG000|Overall Study|Other AE|38
6108050|NCT00806819|9726418|FG001|Overall Study|Other AE|40
6108051|NCT00806819|9726417|FG000|Overall Study|Protocol Violation|9
6108052|NCT00806819|9726418|FG001|Overall Study|Protocol Violation|4
6108053|NCT00806819|9726417|FG000|Overall Study|Lost to Follow-up|1
6108054|NCT00806819|9726418|FG001|Overall Study|Lost to Follow-up|0
6108055|NCT00806819|9726417|FG000|Overall Study|Withdrawal by Subject|32
6108056|NCT00806819|9726418|FG001|Overall Study|Withdrawal by Subject|29
6108057|NCT00806819|9726417|FG000|Overall Study|Not treated|6
6108058|NCT00806819|9726418|FG001|Overall Study|Not treated|3
6108059|NCT00806819|9726417|FG000|Overall Study|Reasons other than stated above|25
6108060|NCT00806819|9726418|FG001|Overall Study|Reasons other than stated above|41
6108061|NCT00806988|9726427|FG000|Overall Study|Death|15
6108062|NCT00806988|9726428|FG001|Overall Study|Death|16
6108063|NCT00806988|9726427|FG000|Overall Study|Withdrawal by Subject|8
6108064|NCT00806988|9726428|FG001|Overall Study|Withdrawal by Subject|8
6108065|NCT00806988|9726427|FG000|Overall Study|Lost to Follow-up|4
6108066|NCT00806988|9726428|FG001|Overall Study|Lost to Follow-up|19
6108067|NCT00807001|9726439|FG000|Overall Study|Non-compliance|0
6108068|NCT00807001|9726440|FG001|Overall Study|Non-compliance|1
6108069|NCT00807001|9726441|FG002|Overall Study|Non-compliance|0
6108070|NCT00807001|9726442|FG003|Overall Study|Non-compliance|0
6108071|NCT00807001|9726443|FG004|Overall Study|Non-compliance|0
6108072|NCT00807014|9726457|FG000|Overall Study|Participant Considered Disease Cured|13
6108073|NCT00807014|9726458|FG001|Overall Study|Participant Considered Disease Cured|2
6108074|NCT00807014|9726457|FG000|Overall Study|Participant Considered Disease Not Cured|2
6108075|NCT00807014|9726458|FG001|Overall Study|Participant Considered Disease Not Cured|7
6108076|NCT00807014|9726457|FG000|Overall Study|Protocol Violation|2
6108077|NCT00807014|9726458|FG001|Overall Study|Protocol Violation|8
6108078|NCT00807014|9726457|FG000|Overall Study|Adverse Event|0
6108079|NCT00807014|9726458|FG001|Overall Study|Adverse Event|2
6108080|NCT00807014|9726457|FG000|Overall Study|Lost to Follow-up|9
6108081|NCT00807014|9726458|FG001|Overall Study|Lost to Follow-up|7
6108082|NCT00807014|9726457|FG000|Overall Study|Recovery|1
6108083|NCT00807014|9726458|FG001|Overall Study|Recovery|0
6108084|NCT00807014|9726457|FG000|Overall Study|Missed Visit 2 Due to Personal Reasons|0
6108085|NCT00807014|9726458|FG001|Overall Study|Missed Visit 2 Due to Personal Reasons|1
6108086|NCT00807040|9726466|FG000|Overall Study|Death|24
6108087|NCT00807040|9726467|FG001|Overall Study|Death|29
6108088|NCT00807040|9726466|FG000|Overall Study|Withdrawal by Subject|8
6108089|NCT00807040|9726467|FG001|Overall Study|Withdrawal by Subject|6
6108090|NCT00807040|9726466|FG000|Overall Study|Lost to Follow-up|4
6108091|NCT00807040|9726467|FG001|Overall Study|Lost to Follow-up|6
6108092|NCT00807092|9726475|FG000|Overall Study|Adverse Event|0
6108093|NCT00807092|9726476|FG001|Overall Study|Adverse Event|1
6108094|NCT00807092|9726475|FG000|Overall Study|Protocol Violation|0
6108095|NCT00807092|9726476|FG001|Overall Study|Protocol Violation|2
6108096|NCT00807092|9726475|FG000|Overall Study|Withdrawal by Subject|1
6108097|NCT00807092|9726476|FG001|Overall Study|Withdrawal by Subject|0
6108098|NCT00807092|9726475|FG000|Overall Study|CGMS data collection failed|0
6108099|NCT00807092|9726476|FG001|Overall Study|CGMS data collection failed|1
6108100|NCT00807144|9726484|FG000|Overall Study|Lost to Follow-up|0
6108101|NCT00807144|9726485|FG001|Overall Study|Lost to Follow-up|1
6108102|NCT00807235|9726506|FG000|Overall Study|Adverse Event|1
6108103|NCT00807235|9726507|FG001|Overall Study|Adverse Event|0
6108104|NCT00807248|9726517|FG000|Overall Study|Adverse Event|1
6108105|NCT00807248|9726518|FG001|Overall Study|Adverse Event|2
6108106|NCT00807248|9726519|FG002|Overall Study|Adverse Event|2
6108107|NCT00807248|9726520|FG003|Overall Study|Adverse Event|6
6108108|NCT00807248|9726517|FG000|Overall Study|Lack of Efficacy|14
6108109|NCT00807248|9726518|FG001|Overall Study|Lack of Efficacy|4
6108110|NCT00807248|9726519|FG002|Overall Study|Lack of Efficacy|8
6108111|NCT00807248|9726520|FG003|Overall Study|Lack of Efficacy|3
6108112|NCT00807248|9726517|FG000|Overall Study|Protocol Violation|0
6108113|NCT00807248|9726518|FG001|Overall Study|Protocol Violation|1
6108114|NCT00807248|9726519|FG002|Overall Study|Protocol Violation|1
6108115|NCT00807248|9726520|FG003|Overall Study|Protocol Violation|0
6108116|NCT00807248|9726517|FG000|Overall Study|Withdrawal of Consent|5
6108117|NCT00807248|9726518|FG001|Overall Study|Withdrawal of Consent|5
6108118|NCT00807248|9726519|FG002|Overall Study|Withdrawal of Consent|5
6108119|NCT00807248|9726520|FG003|Overall Study|Withdrawal of Consent|5
6108120|NCT00807248|9726517|FG000|Overall Study|Lost to Follow-up|1
6108121|NCT00807248|9726518|FG001|Overall Study|Lost to Follow-up|0
6108122|NCT00807248|9726519|FG002|Overall Study|Lost to Follow-up|0
6108123|NCT00807248|9726520|FG003|Overall Study|Lost to Follow-up|0
6108124|NCT00807248|9726517|FG000|Overall Study|Other Reason|0
6108125|NCT00807248|9726518|FG001|Overall Study|Other Reason|0
6108126|NCT00807248|9726519|FG002|Overall Study|Other Reason|2
6108127|NCT00807248|9726520|FG003|Overall Study|Other Reason|0
6108128|NCT00807495|9726539|FG000|Overall Study|Adverse Event|6
6108129|NCT00807495|9726540|FG001|Overall Study|Adverse Event|3
6108130|NCT00807495|9726541|FG002|Overall Study|Adverse Event|1
6108131|NCT00807495|9726542|FG003|Overall Study|Adverse Event|1
6108132|NCT00807495|9726543|FG004|Overall Study|Adverse Event|2
6108133|NCT00807495|9726539|FG000|Overall Study|Withdrawal by Patient|2
6108134|NCT00807495|9726540|FG001|Overall Study|Withdrawal by Patient|0
6108135|NCT00807495|9726541|FG002|Overall Study|Withdrawal by Patient|1
6108136|NCT00807495|9726542|FG003|Overall Study|Withdrawal by Patient|0
6108137|NCT00807495|9726543|FG004|Overall Study|Withdrawal by Patient|0
6108138|NCT00807495|9726539|FG000|Overall Study|Reason Not Specified|0
6108139|NCT00807495|9726540|FG001|Overall Study|Reason Not Specified|3
6108140|NCT00807495|9726541|FG002|Overall Study|Reason Not Specified|2
6108141|NCT00807495|9726542|FG003|Overall Study|Reason Not Specified|0
6108142|NCT00807495|9726543|FG004|Overall Study|Reason Not Specified|3
6108143|NCT00807573|9726564|FG000|Overall Study|Withdrawal by Subject|1
6108144|NCT00807573|9726564|FG000|Overall Study|Adverse Event|1
6108145|NCT00807599|9726579|FG000|Overall Study|Not treated on protocol study|0
6108146|NCT00807599|9726580|FG001|Overall Study|Not treated on protocol study|0
6108147|NCT00807599|9726581|FG002|Overall Study|Not treated on protocol study|2
6108148|NCT00807599|9726579|FG000|Overall Study|Adverse Event|0
6108149|NCT00807599|9726580|FG001|Overall Study|Adverse Event|0
6108150|NCT00807599|9726581|FG002|Overall Study|Adverse Event|5
6108151|NCT00807599|9726579|FG000|Overall Study|Inadequate response to induction|0
6108152|NCT00807599|9726580|FG001|Overall Study|Inadequate response to induction|0
6108153|NCT00807599|9726581|FG002|Overall Study|Inadequate response to induction|9
6108154|NCT00807599|9726579|FG000|Overall Study|Withdrawal by Subject|0
6108155|NCT00807599|9726580|FG001|Overall Study|Withdrawal by Subject|0
6108156|NCT00807599|9726581|FG002|Overall Study|Withdrawal by Subject|1
6108157|NCT00807742|9726599|FG000|Overall Study|Death|9
6108158|NCT00807742|9726600|FG001|Overall Study|Death|2
6108159|NCT00807742|9726599|FG000|Overall Study|Withdrawal by Subject|2
6108160|NCT00807742|9726600|FG001|Overall Study|Withdrawal by Subject|1
6108161|NCT00807742|9726599|FG000|Overall Study|Lost to Follow-up|35
6108162|NCT00807742|9726600|FG001|Overall Study|Lost to Follow-up|51
6108163|NCT00807846|9726617|FG000|Overall Study|Adverse Event|5
6108164|NCT00807846|9726618|FG001|Overall Study|Adverse Event|0
6108165|NCT00807846|9726617|FG000|Overall Study|Lack of Efficacy|2
6108166|NCT00807846|9726618|FG001|Overall Study|Lack of Efficacy|0
6108167|NCT00807846|9726617|FG000|Overall Study|Protocol Violation|2
6108168|NCT00807846|9726618|FG001|Overall Study|Protocol Violation|1
6108169|NCT00807846|9726617|FG000|Overall Study|Withdrawal by Subject|2
6108170|NCT00807846|9726618|FG001|Overall Study|Withdrawal by Subject|1
6108171|NCT00807846|9726617|FG000|Overall Study|Other|1
6108172|NCT00807846|9726618|FG001|Overall Study|Other|2
6108173|NCT00807885|9726633|FG000|Overall Study|Lost to Follow-up|0
6108174|NCT00807885|9726634|FG001|Overall Study|Lost to Follow-up|0
6108175|NCT00807885|9726635|FG002|Overall Study|Lost to Follow-up|0
6108176|NCT00807885|9726636|FG003|Overall Study|Lost to Follow-up|0
6108177|NCT00807885|9726637|FG004|Overall Study|Lost to Follow-up|0
6108178|NCT00807885|9726638|FG005|Overall Study|Lost to Follow-up|1
6108179|NCT00807885|9726639|FG006|Overall Study|Lost to Follow-up|0
6108180|NCT00807885|9726640|FG007|Overall Study|Lost to Follow-up|0
6108181|NCT00807885|9726641|FG008|Overall Study|Lost to Follow-up|0
6108182|NCT00807937|9726665|FG000|Overall Study|Adverse Event|12
6108183|NCT00807937|9726666|FG001|Overall Study|Adverse Event|12
6108184|NCT00807937|9726667|FG002|Overall Study|Adverse Event|5
6108185|NCT00807937|9726668|FG003|Overall Study|Adverse Event|4
6108186|NCT00807937|9726665|FG000|Overall Study|Protocol Violation|4
6108187|NCT00807937|9726666|FG001|Overall Study|Protocol Violation|5
6108188|NCT00807937|9726667|FG002|Overall Study|Protocol Violation|3
6108189|NCT00807937|9726668|FG003|Overall Study|Protocol Violation|3
6108190|NCT00807937|9726665|FG000|Overall Study|Withdrawal by Subject|5
6108191|NCT00807937|9726666|FG001|Overall Study|Withdrawal by Subject|4
6108192|NCT00807937|9726667|FG002|Overall Study|Withdrawal by Subject|1
6108193|NCT00807937|9726668|FG003|Overall Study|Withdrawal by Subject|4
6108194|NCT00807937|9726665|FG000|Overall Study|Lost to Follow-up|4
6108195|NCT00807937|9726666|FG001|Overall Study|Lost to Follow-up|0
6108196|NCT00807937|9726667|FG002|Overall Study|Lost to Follow-up|2
6108197|NCT00807937|9726668|FG003|Overall Study|Lost to Follow-up|1
6108198|NCT00807937|9726665|FG000|Overall Study|Lack of Efficacy|0
6108199|NCT00807937|9726666|FG001|Overall Study|Lack of Efficacy|0
6108200|NCT00807937|9726667|FG002|Overall Study|Lack of Efficacy|1
6108201|NCT00807937|9726668|FG003|Overall Study|Lack of Efficacy|2
6108202|NCT00807937|9726665|FG000|Overall Study|Intake of prohibited medicine|0
6108203|NCT00807937|9726666|FG001|Overall Study|Intake of prohibited medicine|0
6108204|NCT00807937|9726667|FG002|Overall Study|Intake of prohibited medicine|2
6108205|NCT00807937|9726668|FG003|Overall Study|Intake of prohibited medicine|0
6108206|NCT00807937|9726665|FG000|Overall Study|All other reasons (not provided)|2
6108207|NCT00807937|9726666|FG001|Overall Study|All other reasons (not provided)|4
6108208|NCT00807937|9726667|FG002|Overall Study|All other reasons (not provided)|0
6108209|NCT00807937|9726668|FG003|Overall Study|All other reasons (not provided)|1
6108210|NCT00808015|9726687|FG000|Overall Study|Death|1
6108211|NCT00808015|9726687|FG000|Overall Study|Lack of Efficacy|58
6108212|NCT00808015|9726687|FG000|Overall Study|Lost to Follow-up|76
6108213|NCT00808015|9726687|FG000|Overall Study|Participants not willing to participate|158
6108214|NCT00808015|9726687|FG000|Overall Study|Adverse Event|22
6108215|NCT00808015|9726687|FG000|Overall Study|Other|25
6108216|NCT00808015|9726687|FG000|Overall Study|Enrolled but not treated|4
6108217|NCT00808028|9726695|FG000|Stage 1 (6 Months)|Withdrawal by Subject|3
6108218|NCT00808028|9726696|FG001|Stage 1 (6 Months)|Withdrawal by Subject|0
6108219|NCT00808028|9726697|FG002|Stage 1 (6 Months)|Withdrawal by Subject|2
6108220|NCT00808028|9726698|FG003|Stage 1 (6 Months)|Withdrawal by Subject|5
6108221|NCT00808028|9726695|FG000|Stage 1 (6 Months)|Other|1
6108222|NCT00808028|9726696|FG001|Stage 1 (6 Months)|Other|0
6108223|NCT00808028|9726697|FG002|Stage 1 (6 Months)|Other|2
6108224|NCT00808028|9726698|FG003|Stage 1 (6 Months)|Other|4
6108225|NCT00808028|9726695|FG000|Stage 1 (6 Months)|Parent/legal guardian request|0
6108226|NCT00808028|9726696|FG001|Stage 1 (6 Months)|Parent/legal guardian request|1
6108227|NCT00808028|9726697|FG002|Stage 1 (6 Months)|Parent/legal guardian request|1
6206192|NCT01540474|9869280|FG002|Vaccination Period|Lost to Follow-up|0
6206193|NCT01540474|9869281|FG003|Vaccination Period|Lost to Follow-up|0
6206194|NCT01540487|9869294|FG000|Overall Study|Protocol Violation|1
6206195|NCT01540487|9869295|FG001|Overall Study|Protocol Violation|0
6206196|NCT01540565|9869309|FG000|Overall Study|Ineligible|2
6206197|NCT01540838|9869379|FG000|Overall Study|Open nasogastric tube|9
6206198|NCT01540838|9869380|FG001|Overall Study|Open nasogastric tube|7
6206199|NCT01540838|9869379|FG000|Overall Study|Treatment doses missing|8
6206200|NCT01540838|9869380|FG001|Overall Study|Treatment doses missing|12
6206201|NCT01540838|9869379|FG000|Overall Study|Additional antibiotic treatment|1
6206202|NCT01540838|9869380|FG001|Overall Study|Additional antibiotic treatment|2
6206203|NCT01540838|9869379|FG000|Overall Study|Died before treatment initiation|1
6206204|NCT01540838|9869380|FG001|Overall Study|Died before treatment initiation|1
6206205|NCT01540838|9869379|FG000|Overall Study|Not BM. Other treatment|3
6206206|NCT01540838|9869380|FG001|Overall Study|Not BM. Other treatment|1
6206207|NCT01540851|9869388|FG000|Overall Study|Lost to Follow-up|14
6206208|NCT01540851|9869389|FG001|Overall Study|Lost to Follow-up|15
6206209|NCT01540851|9869388|FG000|Overall Study|Withdrawal by Subject|7
6206210|NCT01540851|9869389|FG001|Overall Study|Withdrawal by Subject|3
6285412|NCT02335346|9997615|FG000|Overall Study|Withdrawal by Subject|1
6285413|NCT02335450|9997619|FG000|Overall Study|Pregnancy|1
6285414|NCT02335489|9997629|FG000|Overall Study|Sponsor terminated study|4
6285415|NCT02335489|9997629|FG000|Overall Study|Lost to Follow-up|1
6285416|NCT02335489|9997629|FG000|Overall Study|Withdrawal by Subject|2
6285417|NCT02335489|9997629|FG000|Overall Study|Physician Decision|2
6285418|NCT02335489|9997629|FG000|Overall Study|Lack of Efficacy|1
6285419|NCT02335983|9997656|FG000|Overall Study|Sponsor Decision|0
6285420|NCT02335983|9997657|FG001|Overall Study|Sponsor Decision|0
6285421|NCT02335983|9997658|FG002|Overall Study|Sponsor Decision|1
6285422|NCT02335983|9997659|FG003|Overall Study|Sponsor Decision|1
6285423|NCT02335983|9997660|FG004|Overall Study|Sponsor Decision|0
6285424|NCT02335983|9997661|FG005|Overall Study|Sponsor Decision|1
6285425|NCT02335983|9997656|FG000|Overall Study|Withdrawal by Subject|3
6285426|NCT02335983|9997657|FG001|Overall Study|Withdrawal by Subject|2
6285427|NCT02335983|9997658|FG002|Overall Study|Withdrawal by Subject|2
6285428|NCT02335983|9997659|FG003|Overall Study|Withdrawal by Subject|1
6285429|NCT02335983|9997660|FG004|Overall Study|Withdrawal by Subject|3
6285430|NCT02335983|9997661|FG005|Overall Study|Withdrawal by Subject|9
6285431|NCT02335983|9997656|FG000|Overall Study|Death|0
6285432|NCT02335983|9997657|FG001|Overall Study|Death|0
6285433|NCT02335983|9997658|FG002|Overall Study|Death|2
6285434|NCT02335983|9997659|FG003|Overall Study|Death|0
6285435|NCT02335983|9997660|FG004|Overall Study|Death|0
6285436|NCT02335983|9997661|FG005|Overall Study|Death|0
6285437|NCT02335983|9997656|FG000|Overall Study|Lost to Follow-up|0
6285438|NCT02335983|9997657|FG001|Overall Study|Lost to Follow-up|0
6285439|NCT02335983|9997658|FG002|Overall Study|Lost to Follow-up|0
6285440|NCT02335983|9997659|FG003|Overall Study|Lost to Follow-up|0
6285441|NCT02335983|9997660|FG004|Overall Study|Lost to Follow-up|0
6285442|NCT02335983|9997661|FG005|Overall Study|Lost to Follow-up|1
6285443|NCT02335983|9997656|FG000|Overall Study|Protocol Specified Criteria|5
6285444|NCT02335983|9997657|FG001|Overall Study|Protocol Specified Criteria|7
6285445|NCT02335983|9997658|FG002|Overall Study|Protocol Specified Criteria|27
6285446|NCT02335983|9997659|FG003|Overall Study|Protocol Specified Criteria|7
6285447|NCT02335983|9997660|FG004|Overall Study|Protocol Specified Criteria|5
6285448|NCT02335983|9997661|FG005|Overall Study|Protocol Specified Criteria|21
6285449|NCT02336074|9997686|FG000|Overall Study|Adverse Event|0
6285450|NCT02336074|9997687|FG001|Overall Study|Adverse Event|2
6285451|NCT02336165|9997703|FG000|Overall Study|Death|3
6285452|NCT02336165|9997704|FG001|Overall Study|Death|0
6285453|NCT02336165|9997705|FG002|Overall Study|Death|0
6285454|NCT02336165|9997706|FG003|Overall Study|Death|0
6285455|NCT02336165|9997707|FG004|Overall Study|Death|1
6285456|NCT02336165|9997703|FG000|Overall Study|Physician Decision|2
6285457|NCT02336165|9997704|FG001|Overall Study|Physician Decision|2
6285458|NCT02336165|9997705|FG002|Overall Study|Physician Decision|1
6285459|NCT02336165|9997706|FG003|Overall Study|Physician Decision|1
6285460|NCT02336165|9997707|FG004|Overall Study|Physician Decision|0
6285461|NCT02336165|9997703|FG000|Overall Study|Withdrawal by Subject|0
6285462|NCT02336165|9997704|FG001|Overall Study|Withdrawal by Subject|0
6285463|NCT02336165|9997705|FG002|Overall Study|Withdrawal by Subject|1
6285464|NCT02336165|9997706|FG003|Overall Study|Withdrawal by Subject|0
6285465|NCT02336165|9997707|FG004|Overall Study|Withdrawal by Subject|1
6108228|NCT00808028|9726698|FG003|Stage 1 (6 Months)|Parent/legal guardian request|3
6108229|NCT00808028|9726695|FG000|Stage 1 (6 Months)|Adverse Event|0
6108230|NCT00808028|9726696|FG001|Stage 1 (6 Months)|Adverse Event|0
6108231|NCT00808028|9726697|FG002|Stage 1 (6 Months)|Adverse Event|1
6108232|NCT00808028|9726698|FG003|Stage 1 (6 Months)|Adverse Event|2
6108233|NCT00808028|9726695|FG000|Stage 1 (6 Months)|Lost to Follow-up|1
6108234|NCT00808028|9726696|FG001|Stage 1 (6 Months)|Lost to Follow-up|0
6108235|NCT00808028|9726697|FG002|Stage 1 (6 Months)|Lost to Follow-up|1
6108236|NCT00808028|9726698|FG003|Stage 1 (6 Months)|Lost to Follow-up|0
6108237|NCT00808028|9726695|FG000|Stage 1 (6 Months)|Protocol Violation|0
6108238|NCT00808028|9726696|FG001|Stage 1 (6 Months)|Protocol Violation|0
6108239|NCT00808028|9726697|FG002|Stage 1 (6 Months)|Protocol Violation|0
6108240|NCT00808028|9726698|FG003|Stage 1 (6 Months)|Protocol Violation|1
6108241|NCT00808028|9726695|FG000|Stage 2 (Followed up to 48 Months )|Withdrawal by Subject|6
6108242|NCT00808028|9726696|FG001|Stage 2 (Followed up to 48 Months )|Withdrawal by Subject|0
6108243|NCT00808028|9726697|FG002|Stage 2 (Followed up to 48 Months )|Withdrawal by Subject|9
6108244|NCT00808028|9726698|FG003|Stage 2 (Followed up to 48 Months )|Withdrawal by Subject|11
6108245|NCT00808028|9726695|FG000|Stage 2 (Followed up to 48 Months )|Protocol Violation|0
6108246|NCT00808028|9726696|FG001|Stage 2 (Followed up to 48 Months )|Protocol Violation|0
6108247|NCT00808028|9726697|FG002|Stage 2 (Followed up to 48 Months )|Protocol Violation|1
6108248|NCT00808028|9726698|FG003|Stage 2 (Followed up to 48 Months )|Protocol Violation|0
6108249|NCT00808028|9726695|FG000|Stage 2 (Followed up to 48 Months )|Lost to Follow-up|2
6108250|NCT00808028|9726696|FG001|Stage 2 (Followed up to 48 Months )|Lost to Follow-up|0
6108251|NCT00808028|9726697|FG002|Stage 2 (Followed up to 48 Months )|Lost to Follow-up|8
6108252|NCT00808028|9726698|FG003|Stage 2 (Followed up to 48 Months )|Lost to Follow-up|7
6108253|NCT00808028|9726695|FG000|Stage 2 (Followed up to 48 Months )|Failed to return|2
6108254|NCT00808028|9726696|FG001|Stage 2 (Followed up to 48 Months )|Failed to return|0
6108255|NCT00808028|9726697|FG002|Stage 2 (Followed up to 48 Months )|Failed to return|5
6108256|NCT00808028|9726698|FG003|Stage 2 (Followed up to 48 Months )|Failed to return|4
6108257|NCT00808028|9726695|FG000|Stage 2 (Followed up to 48 Months )|Adverse Event|1
6108258|NCT00808028|9726696|FG001|Stage 2 (Followed up to 48 Months )|Adverse Event|0
6108259|NCT00808028|9726697|FG002|Stage 2 (Followed up to 48 Months )|Adverse Event|1
6108260|NCT00808028|9726698|FG003|Stage 2 (Followed up to 48 Months )|Adverse Event|0
6108261|NCT00808028|9726695|FG000|Stage 2 (Followed up to 48 Months )|Other|0
6108262|NCT00808028|9726696|FG001|Stage 2 (Followed up to 48 Months )|Other|0
6108263|NCT00808028|9726697|FG002|Stage 2 (Followed up to 48 Months )|Other|1
6108264|NCT00808028|9726698|FG003|Stage 2 (Followed up to 48 Months )|Other|1
6108265|NCT00808028|9726695|FG000|Stage 2 (Followed up to 48 Months )|Parent's or guardian request|0
6108266|NCT00808028|9726696|FG001|Stage 2 (Followed up to 48 Months )|Parent's or guardian request|0
6108267|NCT00808028|9726697|FG002|Stage 2 (Followed up to 48 Months )|Parent's or guardian request|2
6108268|NCT00808028|9726698|FG003|Stage 2 (Followed up to 48 Months )|Parent's or guardian request|0
6108269|NCT00808028|9726695|FG000|Stage 2 (Followed up to 48 Months )|Death|0
6108270|NCT00808028|9726696|FG001|Stage 2 (Followed up to 48 Months )|Death|0
6108271|NCT00808028|9726697|FG002|Stage 2 (Followed up to 48 Months )|Death|1
6108272|NCT00808028|9726698|FG003|Stage 2 (Followed up to 48 Months )|Death|0
6108273|NCT00808028|9726695|FG000|Stage 2 (Followed up to 48 Months )|Non-compliance|0
6108274|NCT00808028|9726696|FG001|Stage 2 (Followed up to 48 Months )|Non-compliance|0
6108275|NCT00808028|9726697|FG002|Stage 2 (Followed up to 48 Months )|Non-compliance|1
6108276|NCT00808028|9726698|FG003|Stage 2 (Followed up to 48 Months )|Non-compliance|0
6108277|NCT00808067|9726720|FG000|Overall Study|Major/minor bleed|30
6108278|NCT00808067|9726721|FG001|Overall Study|Major/minor bleed|44
6108279|NCT00808067|9726720|FG000|Overall Study|Outcome event - other|33
6108280|NCT00808067|9726721|FG001|Overall Study|Outcome event - other|25
6108281|NCT00808067|9726720|FG000|Overall Study|Adverse Event|111
6108282|NCT00808067|9726721|FG001|Overall Study|Adverse Event|121
6108283|NCT00808067|9726720|FG000|Overall Study|Hospitalization (not including surgery)|18
6108284|NCT00808067|9726721|FG001|Overall Study|Hospitalization (not including surgery)|17
6108285|NCT00808067|9726720|FG000|Overall Study|Hospitalization due to surgery|37
6108286|NCT00808067|9726721|FG001|Overall Study|Hospitalization due to surgery|40
6108287|NCT00808067|9726720|FG000|Overall Study|Reduced creatinine clearance|53
6108288|NCT00808067|9726721|FG001|Overall Study|Reduced creatinine clearance|55
6108289|NCT00808067|9726720|FG000|Overall Study|Elevated LFT results|7
6108290|NCT00808067|9726721|FG001|Overall Study|Elevated LFT results|3
6108291|NCT00808067|9726720|FG000|Overall Study|Patient refused to take study medication|65
6108292|NCT00808067|9726721|FG001|Overall Study|Patient refused to take study medication|76
6108293|NCT00808067|9726720|FG000|Overall Study|Missing|1
6108294|NCT00808067|9726721|FG001|Overall Study|Missing|0
6108295|NCT00808067|9726720|FG000|Overall Study|Death|1
6108296|NCT00808067|9726721|FG001|Overall Study|Death|1
6108297|NCT00808067|9726720|FG000|Overall Study|Procedure|6
6108298|NCT00808067|9726721|FG001|Overall Study|Procedure|7
6108299|NCT00808067|9726720|FG000|Overall Study|Withdrawal by Subject|21
6108300|NCT00808067|9726721|FG001|Overall Study|Withdrawal by Subject|25
6108301|NCT00808067|9726720|FG000|Overall Study|Site closed|4
6108302|NCT00808067|9726721|FG001|Overall Study|Site closed|3
6108303|NCT00808067|9726720|FG000|Overall Study|Physician Decision|47
6108304|NCT00808067|9726721|FG001|Overall Study|Physician Decision|38
6108305|NCT00808067|9726720|FG000|Overall Study|Protocol Violation|3
6108306|NCT00808067|9726721|FG001|Overall Study|Protocol Violation|11
6108307|NCT00808067|9726720|FG000|Overall Study|Patient elected|7
6108308|NCT00808067|9726721|FG001|Overall Study|Patient elected|9
6108309|NCT00808067|9726720|FG000|Overall Study|Site closed for cause|19
6108310|NCT00808067|9726721|FG001|Overall Study|Site closed for cause|19
6108311|NCT00808067|9726720|FG000|Overall Study|Other reason not defined above|5
6108312|NCT00808067|9726721|FG001|Overall Study|Other reason not defined above|5
6108313|NCT00808067|9726720|FG000|Overall Study|Excluded from analysis|13
6108314|NCT00808067|9726721|FG001|Overall Study|Excluded from analysis|19
6108315|NCT00808132|9726732|FG000|Overall Study|Adverse Event|34
6108316|NCT00808132|9726733|FG001|Overall Study|Adverse Event|33
6108317|NCT00808132|9726734|FG002|Overall Study|Adverse Event|16
6108318|NCT00808132|9726735|FG003|Overall Study|Adverse Event|31
6108319|NCT00808132|9726736|FG004|Overall Study|Adverse Event|33
6108320|NCT00808132|9726732|FG000|Overall Study|Death|0
6108321|NCT00808132|9726733|FG001|Overall Study|Death|0
6108322|NCT00808132|9726734|FG002|Overall Study|Death|0
6108323|NCT00808132|9726735|FG003|Overall Study|Death|0
6108324|NCT00808132|9726736|FG004|Overall Study|Death|1
6108325|NCT00808132|9726732|FG000|Overall Study|Physician Decision|0
6108326|NCT00808132|9726733|FG001|Overall Study|Physician Decision|1
6108327|NCT00808132|9726734|FG002|Overall Study|Physician Decision|0
6108328|NCT00808132|9726735|FG003|Overall Study|Physician Decision|0
6108329|NCT00808132|9726736|FG004|Overall Study|Physician Decision|0
6108330|NCT00808132|9726732|FG000|Overall Study|Lost to Follow-up|8
6108331|NCT00808132|9726733|FG001|Overall Study|Lost to Follow-up|10
6108332|NCT00808132|9726734|FG002|Overall Study|Lost to Follow-up|11
6108333|NCT00808132|9726735|FG003|Overall Study|Lost to Follow-up|8
6108334|NCT00808132|9726736|FG004|Overall Study|Lost to Follow-up|9
6108335|NCT00808132|9726732|FG000|Overall Study|Protocol Violation|8
6108336|NCT00808132|9726733|FG001|Overall Study|Protocol Violation|9
6108337|NCT00808132|9726734|FG002|Overall Study|Protocol Violation|4
6108338|NCT00808132|9726735|FG003|Overall Study|Protocol Violation|9
6108339|NCT00808132|9726736|FG004|Overall Study|Protocol Violation|5
6108340|NCT00808132|9726732|FG000|Overall Study|Withdrawal by Subject|27
6108341|NCT00808132|9726733|FG001|Overall Study|Withdrawal by Subject|18
6108342|NCT00808132|9726734|FG002|Overall Study|Withdrawal by Subject|2
6108343|NCT00808132|9726735|FG003|Overall Study|Withdrawal by Subject|7
6108344|NCT00808132|9726736|FG004|Overall Study|Withdrawal by Subject|16
6108345|NCT00808132|9726732|FG000|Overall Study|Other|6
6108346|NCT00808132|9726733|FG001|Overall Study|Other|4
6108347|NCT00808132|9726734|FG002|Overall Study|Other|6
6108348|NCT00808132|9726735|FG003|Overall Study|Other|2
6108349|NCT00808132|9726736|FG004|Overall Study|Other|15
6108350|NCT00808132|9726732|FG000|Overall Study|Randomized, but not treated|10
6108351|NCT00808132|9726733|FG001|Overall Study|Randomized, but not treated|7
6108352|NCT00808132|9726734|FG002|Overall Study|Randomized, but not treated|9
6108353|NCT00808132|9726735|FG003|Overall Study|Randomized, but not treated|8
6108354|NCT00808132|9726736|FG004|Overall Study|Randomized, but not treated|9
6108355|NCT00808132|9726732|FG000|Overall Study|Unsatisfactory response|5
6108356|NCT00808132|9726733|FG001|Overall Study|Unsatisfactory response|6
6108357|NCT00808132|9726734|FG002|Overall Study|Unsatisfactory response|6
6108358|NCT00808132|9726735|FG003|Overall Study|Unsatisfactory response|4
6108359|NCT00808132|9726736|FG004|Overall Study|Unsatisfactory response|12
6108360|NCT00808210|9726750|FG000|Study Period + 48 Weeks of Follow-up|Sponsor decision to terminate study|3
6108361|NCT00808210|9726751|FG001|Study Period + 48 Weeks of Follow-up|Sponsor decision to terminate study|7
6108362|NCT00808210|9726750|FG000|Study Period + 48 Weeks of Follow-up|Other reasons outside Sponsor decision|6
6108363|NCT00808210|9726751|FG001|Study Period + 48 Weeks of Follow-up|Other reasons outside Sponsor decision|2
6108364|NCT00808210|9726750|FG000|Double-Blind TX Period|Adverse Event|0
6108365|NCT00808210|9726751|FG001|Double-Blind TX Period|Adverse Event|1
6108366|NCT00808210|9726750|FG000|Double-Blind TX Period|Sponsor decision to terminate study|1
6108367|NCT00808210|9726751|FG001|Double-Blind TX Period|Sponsor decision to terminate study|1
6108368|NCT00808210|9726750|FG000|Double-Blind TX Period|Other reasons outside Sponsor decision|1
6108369|NCT00808210|9726751|FG001|Double-Blind TX Period|Other reasons outside Sponsor decision|1
6108370|NCT00808210|9726750|FG000|Open Label Ocrelizumab Treatment Period|Sponsor decision to terminate study|9
6108371|NCT00808210|9726751|FG001|Open Label Ocrelizumab Treatment Period|Sponsor decision to terminate study|4
6108372|NCT00808236|9726759|FG000|Overall Study|Was not resuscitated|50
6108373|NCT00808236|9726760|FG001|Overall Study|Was not resuscitated|56
6108374|NCT00808236|9726759|FG000|Overall Study|Pre-defined exclusion|13
6108375|NCT00808236|9726760|FG001|Overall Study|Pre-defined exclusion|3
6108376|NCT00808236|9726759|FG000|Overall Study|Lost to Follow-up|1
6108377|NCT00808236|9726760|FG001|Overall Study|Lost to Follow-up|1
6108378|NCT00808236|9726759|FG000|Overall Study|Physician Decision|0
6108379|NCT00808236|9726760|FG001|Overall Study|Physician Decision|1
6108380|NCT00808236|9726759|FG000|Overall Study|Death|18
6108381|NCT00808236|9726760|FG001|Overall Study|Death|30
6108382|NCT00808249|9726770|FG000|Overall Study|Adverse Event|4
6108383|NCT00808249|9726771|FG001|Overall Study|Adverse Event|7
6108384|NCT00808249|9726772|FG002|Overall Study|Adverse Event|10
6108385|NCT00808249|9726773|FG003|Overall Study|Adverse Event|6
6108386|NCT00808249|9726770|FG000|Overall Study|Lost to Follow-up|2
6108387|NCT00808249|9726771|FG001|Overall Study|Lost to Follow-up|3
6108388|NCT00808249|9726772|FG002|Overall Study|Lost to Follow-up|3
6108389|NCT00808249|9726773|FG003|Overall Study|Lost to Follow-up|5
6108390|NCT00808249|9726770|FG000|Overall Study|Withdrawal by Subject|4
6108391|NCT00808249|9726771|FG001|Overall Study|Withdrawal by Subject|0
6108392|NCT00808249|9726772|FG002|Overall Study|Withdrawal by Subject|2
6108393|NCT00808249|9726773|FG003|Overall Study|Withdrawal by Subject|4
6108394|NCT00808249|9726770|FG000|Overall Study|Protocol Violation|3
6108395|NCT00808249|9726771|FG001|Overall Study|Protocol Violation|3
6108396|NCT00808249|9726772|FG002|Overall Study|Protocol Violation|3
6108397|NCT00808249|9726773|FG003|Overall Study|Protocol Violation|0
6108398|NCT00808249|9726770|FG000|Overall Study|Lack of Efficacy|1
6108399|NCT00808249|9726771|FG001|Overall Study|Lack of Efficacy|1
6108400|NCT00808249|9726772|FG002|Overall Study|Lack of Efficacy|0
6108401|NCT00808249|9726773|FG003|Overall Study|Lack of Efficacy|0
6108402|NCT00808249|9726770|FG000|Overall Study|study specific discontinuation criteria|1
6108403|NCT00808249|9726771|FG001|Overall Study|study specific discontinuation criteria|0
6108404|NCT00808249|9726772|FG002|Overall Study|study specific discontinuation criteria|1
6108405|NCT00808249|9726773|FG003|Overall Study|study specific discontinuation criteria|0
6108406|NCT00808249|9726770|FG000|Overall Study|All other reasons|2
6108407|NCT00808249|9726771|FG001|Overall Study|All other reasons|1
6108408|NCT00808249|9726772|FG002|Overall Study|All other reasons|3
6108409|NCT00808249|9726773|FG003|Overall Study|All other reasons|1
6108410|NCT00808444|9726807|FG000|Overall Study|Withdrawal by Subject|1
6108411|NCT00808444|9726808|FG001|Overall Study|Withdrawal by Subject|0
6108412|NCT00808444|9726807|FG000|Overall Study|Lost to Follow-up|0
6108413|NCT00808444|9726808|FG001|Overall Study|Lost to Follow-up|1
6108414|NCT00808483|9726829|FG000|From 3 to 5 Months After Surgery|Withdrawal by Subject|1
6108415|NCT00808483|9726830|FG001|From 3 to 5 Months After Surgery|Withdrawal by Subject|1
6108416|NCT00808483|9726829|FG000|From 3 to 5 Months After Surgery|Lack of Efficacy|1
6108417|NCT00808483|9726830|FG001|From 3 to 5 Months After Surgery|Lack of Efficacy|0
6108418|NCT00808483|9726829|FG000|From 5 Months to 12 Months|Lack of Efficacy|1
6108419|NCT00808483|9726830|FG001|From 5 Months to 12 Months|Lack of Efficacy|0
6108420|NCT00808509|9726845|FG000|Randomized Phase|Did not meet eligibility criteria|1
6108421|NCT00808509|9726846|FG001|Randomized Phase|Did not meet eligibility criteria|0
6108422|NCT00808509|9726845|FG000|Randomized Phase|Reduced methotrexate dose|1
6108423|NCT00808509|9726846|FG001|Randomized Phase|Reduced methotrexate dose|2
6108424|NCT00808509|9726845|FG000|Randomized Phase|Patient refused rescue therapy|0
6108425|NCT00808509|9726846|FG001|Randomized Phase|Patient refused rescue therapy|3
6108426|NCT00808639|9726854|FG000|Overall Study|Disease progression before surgery.|1
6108427|NCT00808665|9726860|FG000|Overall Study|Withdrawal by Subject|1
6108428|NCT00808665|9726861|FG001|Overall Study|Withdrawal by Subject|0
6108429|NCT00808665|9726860|FG000|Overall Study|only required minimally invasive surgery|1
6108430|NCT00808665|9726861|FG001|Overall Study|only required minimally invasive surgery|0
6108431|NCT00808665|9726860|FG000|Overall Study|surgery cancelled|1
6108432|NCT00808665|9726861|FG001|Overall Study|surgery cancelled|0
6108433|NCT00808665|9726860|FG000|Overall Study|required an additional procedure|0
6108434|NCT00808665|9726861|FG001|Overall Study|required an additional procedure|1
6108435|NCT00808665|9726860|FG000|Overall Study|Physician Decision|3
6108436|NCT00808665|9726861|FG001|Overall Study|Physician Decision|1
6108437|NCT00808665|9726860|FG000|Overall Study|Medication stopped by resident|0
6108438|NCT00808665|9726861|FG001|Overall Study|Medication stopped by resident|1
6108439|NCT00808808|9726870|FG000|Overall Study|Vaccinated; survey not completed|131
6108440|NCT00808808|9726871|FG001|Overall Study|Vaccinated; survey not completed|169
6108441|NCT00808808|9726872|FG002|Overall Study|Vaccinated; survey not completed|302
6108442|NCT00808808|9726870|FG000|Overall Study|Employee was not vaccinated.|2686
6108443|NCT00808808|9726871|FG001|Overall Study|Employee was not vaccinated.|2268
6108444|NCT00808808|9726872|FG002|Overall Study|Employee was not vaccinated.|2255
6108445|NCT00809094|9726904|FG000|Overall Study|Lost to Follow-up|0
6108446|NCT00809094|9726905|FG001|Overall Study|Lost to Follow-up|1
6108447|NCT00809133|9726925|FG000|Overall Study|Progressive disease|2
6108448|NCT00809133|9726926|FG001|Overall Study|Progressive disease|5
6108449|NCT00809133|9726927|FG002|Overall Study|Progressive disease|5
6108450|NCT00809133|9726928|FG003|Overall Study|Progressive disease|3
6108451|NCT00809133|9726929|FG004|Overall Study|Progressive disease|4
6108452|NCT00809133|9726930|FG005|Overall Study|Progressive disease|1
6108453|NCT00809133|9726931|FG006|Overall Study|Progressive disease|3
6108454|NCT00809133|9726932|FG007|Overall Study|Progressive disease|3
6108455|NCT00809133|9726933|FG008|Overall Study|Progressive disease|3
6108456|NCT00809133|9726934|FG009|Overall Study|Progressive disease|9
6108457|NCT00809133|9726935|FG010|Overall Study|Progressive disease|5
6108458|NCT00809133|9726936|FG011|Overall Study|Progressive disease|7
6108459|NCT00809133|9726937|FG012|Overall Study|Progressive disease|5
6108460|NCT00809133|9726938|FG013|Overall Study|Progressive disease|4
6108461|NCT00809133|9726925|FG000|Overall Study|Dose Limiting Toxicity (DLT)|0
6108462|NCT00809133|9726926|FG001|Overall Study|Dose Limiting Toxicity (DLT)|0
6108463|NCT00809133|9726927|FG002|Overall Study|Dose Limiting Toxicity (DLT)|0
6108464|NCT00809133|9726928|FG003|Overall Study|Dose Limiting Toxicity (DLT)|0
6108465|NCT00809133|9726929|FG004|Overall Study|Dose Limiting Toxicity (DLT)|0
6108466|NCT00809133|9726930|FG005|Overall Study|Dose Limiting Toxicity (DLT)|1
6108467|NCT00809133|9726931|FG006|Overall Study|Dose Limiting Toxicity (DLT)|1
6108468|NCT00809133|9726932|FG007|Overall Study|Dose Limiting Toxicity (DLT)|1
6108469|NCT00809133|9726933|FG008|Overall Study|Dose Limiting Toxicity (DLT)|0
6108470|NCT00809133|9726934|FG009|Overall Study|Dose Limiting Toxicity (DLT)|0
6108471|NCT00809133|9726935|FG010|Overall Study|Dose Limiting Toxicity (DLT)|0
6108472|NCT00809133|9726936|FG011|Overall Study|Dose Limiting Toxicity (DLT)|0
6108473|NCT00809133|9726937|FG012|Overall Study|Dose Limiting Toxicity (DLT)|0
6108474|NCT00809133|9726938|FG013|Overall Study|Dose Limiting Toxicity (DLT)|2
6108475|NCT00809133|9726925|FG000|Overall Study|Other adverse event|1
6108476|NCT00809133|9726926|FG001|Overall Study|Other adverse event|1
6108477|NCT00809133|9726927|FG002|Overall Study|Other adverse event|1
6108478|NCT00809133|9726928|FG003|Overall Study|Other adverse event|0
6108479|NCT00809133|9726929|FG004|Overall Study|Other adverse event|0
6108480|NCT00809133|9726930|FG005|Overall Study|Other adverse event|3
6108481|NCT00809133|9726931|FG006|Overall Study|Other adverse event|2
6108482|NCT00809133|9726932|FG007|Overall Study|Other adverse event|4
6108483|NCT00809133|9726933|FG008|Overall Study|Other adverse event|0
6108484|NCT00809133|9726934|FG009|Overall Study|Other adverse event|0
6108485|NCT00809133|9726935|FG010|Overall Study|Other adverse event|1
6108486|NCT00809133|9726936|FG011|Overall Study|Other adverse event|1
6108487|NCT00809133|9726937|FG012|Overall Study|Other adverse event|0
6108488|NCT00809133|9726938|FG013|Overall Study|Other adverse event|1
6108489|NCT00809133|9726925|FG000|Overall Study|Lost to Follow-up|0
6108490|NCT00809133|9726926|FG001|Overall Study|Lost to Follow-up|0
6108491|NCT00809133|9726927|FG002|Overall Study|Lost to Follow-up|0
6108492|NCT00809133|9726928|FG003|Overall Study|Lost to Follow-up|0
6108493|NCT00809133|9726929|FG004|Overall Study|Lost to Follow-up|0
6108494|NCT00809133|9726930|FG005|Overall Study|Lost to Follow-up|1
6108495|NCT00809133|9726931|FG006|Overall Study|Lost to Follow-up|0
6108496|NCT00809133|9726932|FG007|Overall Study|Lost to Follow-up|0
6108497|NCT00809133|9726933|FG008|Overall Study|Lost to Follow-up|0
6108498|NCT00809133|9726934|FG009|Overall Study|Lost to Follow-up|0
6108499|NCT00809133|9726935|FG010|Overall Study|Lost to Follow-up|0
6108500|NCT00809133|9726936|FG011|Overall Study|Lost to Follow-up|0
6108501|NCT00809133|9726937|FG012|Overall Study|Lost to Follow-up|0
6108502|NCT00809133|9726938|FG013|Overall Study|Lost to Follow-up|0
6108503|NCT00809133|9726925|FG000|Overall Study|Consent withdrawn|0
6108504|NCT00809133|9726926|FG001|Overall Study|Consent withdrawn|0
6108505|NCT00809133|9726927|FG002|Overall Study|Consent withdrawn|0
6108506|NCT00809133|9726928|FG003|Overall Study|Consent withdrawn|0
6108507|NCT00809133|9726929|FG004|Overall Study|Consent withdrawn|1
6108508|NCT00809133|9726930|FG005|Overall Study|Consent withdrawn|0
6108509|NCT00809133|9726931|FG006|Overall Study|Consent withdrawn|0
6108510|NCT00809133|9726932|FG007|Overall Study|Consent withdrawn|0
6108511|NCT00809133|9726933|FG008|Overall Study|Consent withdrawn|0
6108512|NCT00809133|9726934|FG009|Overall Study|Consent withdrawn|0
6108513|NCT00809133|9726935|FG010|Overall Study|Consent withdrawn|0
6108514|NCT00809133|9726936|FG011|Overall Study|Consent withdrawn|0
6108515|NCT00809133|9726937|FG012|Overall Study|Consent withdrawn|0
6108516|NCT00809133|9726938|FG013|Overall Study|Consent withdrawn|0
6108517|NCT00809133|9726925|FG000|Overall Study|Other not mentioned above|0
6108518|NCT00809133|9726926|FG001|Overall Study|Other not mentioned above|1
6108519|NCT00809133|9726927|FG002|Overall Study|Other not mentioned above|0
6108520|NCT00809133|9726928|FG003|Overall Study|Other not mentioned above|0
6108521|NCT00809133|9726929|FG004|Overall Study|Other not mentioned above|0
6108522|NCT00809133|9726930|FG005|Overall Study|Other not mentioned above|1
6108523|NCT00809133|9726931|FG006|Overall Study|Other not mentioned above|0
6108524|NCT00809133|9726932|FG007|Overall Study|Other not mentioned above|0
6108525|NCT00809133|9726933|FG008|Overall Study|Other not mentioned above|0
6108526|NCT00809133|9726934|FG009|Overall Study|Other not mentioned above|0
6108527|NCT00809133|9726935|FG010|Overall Study|Other not mentioned above|0
6108528|NCT00809133|9726936|FG011|Overall Study|Other not mentioned above|0
6108529|NCT00809133|9726937|FG012|Overall Study|Other not mentioned above|0
6108530|NCT00809133|9726938|FG013|Overall Study|Other not mentioned above|0
6108531|NCT00809159|9726994|FG000|Part 1|Adverse Event|1
6108532|NCT00809159|9726995|FG001|Part 1|Adverse Event|1
6108533|NCT00809159|9726996|FG002|Part 1|Adverse Event|0
6108534|NCT00809159|9726997|FG003|Part 1|Adverse Event|0
6108535|NCT00809159|9726998|FG004|Part 1|Adverse Event|0
6108536|NCT00809159|9726999|FG005|Part 1|Adverse Event|0
6108537|NCT00809159|9726994|FG000|Part 1|Lost to Follow-up|1
6108538|NCT00809159|9726995|FG001|Part 1|Lost to Follow-up|0
6108539|NCT00809159|9726996|FG002|Part 1|Lost to Follow-up|0
6108540|NCT00809159|9726997|FG003|Part 1|Lost to Follow-up|0
6108541|NCT00809159|9726998|FG004|Part 1|Lost to Follow-up|0
6108542|NCT00809159|9726999|FG005|Part 1|Lost to Follow-up|0
6285466|NCT02336165|9997703|FG000|Overall Study|Adverse Event|4
6108543|NCT00809159|9726994|FG000|Part 1|Withdrawal by Subject|3
6108544|NCT00809159|9726995|FG001|Part 1|Withdrawal by Subject|1
6108545|NCT00809159|9726996|FG002|Part 1|Withdrawal by Subject|0
6108546|NCT00809159|9726997|FG003|Part 1|Withdrawal by Subject|0
6108547|NCT00809159|9726998|FG004|Part 1|Withdrawal by Subject|0
6108548|NCT00809159|9726999|FG005|Part 1|Withdrawal by Subject|0
6108549|NCT00809159|9726994|FG000|Part 1|Unsatisfactory therapeutic effect|3
6108550|NCT00809159|9726995|FG001|Part 1|Unsatisfactory therapeutic effect|1
6108551|NCT00809159|9726996|FG002|Part 1|Unsatisfactory therapeutic effect|0
6108552|NCT00809159|9726997|FG003|Part 1|Unsatisfactory therapeutic effect|0
6108553|NCT00809159|9726998|FG004|Part 1|Unsatisfactory therapeutic effect|0
6108554|NCT00809159|9726999|FG005|Part 1|Unsatisfactory therapeutic effect|0
6108555|NCT00809159|9726994|FG000|Part 1 and 2|Unsatisfactory therapeutic effect|0
6108556|NCT00809159|9726995|FG001|Part 1 and 2|Unsatisfactory therapeutic effect|0
6108557|NCT00809159|9726996|FG002|Part 1 and 2|Unsatisfactory therapeutic effect|4
6108558|NCT00809159|9726997|FG003|Part 1 and 2|Unsatisfactory therapeutic effect|3
6108559|NCT00809159|9726998|FG004|Part 1 and 2|Unsatisfactory therapeutic effect|5
6108560|NCT00809159|9726999|FG005|Part 1 and 2|Unsatisfactory therapeutic effect|1
6108561|NCT00809159|9726994|FG000|Part 1 and 2|Administrative problems|0
6108562|NCT00809159|9726995|FG001|Part 1 and 2|Administrative problems|0
6108563|NCT00809159|9726996|FG002|Part 1 and 2|Administrative problems|0
6108564|NCT00809159|9726997|FG003|Part 1 and 2|Administrative problems|1
6108565|NCT00809159|9726998|FG004|Part 1 and 2|Administrative problems|0
6108566|NCT00809159|9726999|FG005|Part 1 and 2|Administrative problems|0
6108567|NCT00809159|9726994|FG000|Part 1 and 2|Adverse Event|0
6108568|NCT00809159|9726995|FG001|Part 1 and 2|Adverse Event|0
6108569|NCT00809159|9726996|FG002|Part 1 and 2|Adverse Event|1
6108570|NCT00809159|9726997|FG003|Part 1 and 2|Adverse Event|0
6108571|NCT00809159|9726998|FG004|Part 1 and 2|Adverse Event|1
6108572|NCT00809159|9726999|FG005|Part 1 and 2|Adverse Event|1
6108573|NCT00809159|9726994|FG000|Part 1 and 2|Lost to Follow-up|0
6108574|NCT00809159|9726995|FG001|Part 1 and 2|Lost to Follow-up|0
6108575|NCT00809159|9726996|FG002|Part 1 and 2|Lost to Follow-up|1
6108576|NCT00809159|9726997|FG003|Part 1 and 2|Lost to Follow-up|1
6108577|NCT00809159|9726998|FG004|Part 1 and 2|Lost to Follow-up|0
6108578|NCT00809159|9726999|FG005|Part 1 and 2|Lost to Follow-up|0
6108579|NCT00809159|9726994|FG000|Part 1 and 2|Withdrawal by Subject|0
6108580|NCT00809159|9726995|FG001|Part 1 and 2|Withdrawal by Subject|0
6108581|NCT00809159|9726996|FG002|Part 1 and 2|Withdrawal by Subject|4
6108582|NCT00809159|9726997|FG003|Part 1 and 2|Withdrawal by Subject|0
6108583|NCT00809159|9726998|FG004|Part 1 and 2|Withdrawal by Subject|0
6108584|NCT00809159|9726999|FG005|Part 1 and 2|Withdrawal by Subject|1
6108585|NCT00809328|9727022|FG000|Overall Study|Lack of Efficacy|18
6108586|NCT00809328|9727022|FG000|Overall Study|Adverse Event|6
6108587|NCT00809328|9727022|FG000|Overall Study|Protocol Violation|3
6108588|NCT00809328|9727022|FG000|Overall Study|Withdrawal by Subject|2
6108589|NCT00809354|9727036|FG000|Overall Study|Adverse Event|32
6108590|NCT00809354|9727037|FG001|Overall Study|Adverse Event|45
6108591|NCT00809354|9727038|FG002|Overall Study|Adverse Event|37
6108592|NCT00809354|9727039|FG003|Overall Study|Adverse Event|53
6108593|NCT00809354|9727040|FG004|Overall Study|Adverse Event|26
6108594|NCT00809354|9727041|FG005|Overall Study|Adverse Event|33
6108595|NCT00809354|9727042|FG006|Overall Study|Adverse Event|44
6108596|NCT00809354|9727043|FG007|Overall Study|Adverse Event|40
6108597|NCT00809354|9727044|FG008|Overall Study|Adverse Event|46
6108598|NCT00809354|9727045|FG009|Overall Study|Adverse Event|26
6108599|NCT00809354|9727036|FG000|Overall Study|Lack of Efficacy|23
6108600|NCT00809354|9727037|FG001|Overall Study|Lack of Efficacy|23
6108601|NCT00809354|9727038|FG002|Overall Study|Lack of Efficacy|22
6108602|NCT00809354|9727039|FG003|Overall Study|Lack of Efficacy|15
6108603|NCT00809354|9727040|FG004|Overall Study|Lack of Efficacy|40
6108604|NCT00809354|9727041|FG005|Overall Study|Lack of Efficacy|19
6108605|NCT00809354|9727042|FG006|Overall Study|Lack of Efficacy|21
6108606|NCT00809354|9727043|FG007|Overall Study|Lack of Efficacy|15
6108607|NCT00809354|9727044|FG008|Overall Study|Lack of Efficacy|18
6108608|NCT00809354|9727045|FG009|Overall Study|Lack of Efficacy|38
6108609|NCT00809354|9727036|FG000|Overall Study|Lost to Follow-up|10
6108610|NCT00809354|9727037|FG001|Overall Study|Lost to Follow-up|11
6108611|NCT00809354|9727038|FG002|Overall Study|Lost to Follow-up|8
6108612|NCT00809354|9727039|FG003|Overall Study|Lost to Follow-up|13
6108613|NCT00809354|9727040|FG004|Overall Study|Lost to Follow-up|6
6108614|NCT00809354|9727041|FG005|Overall Study|Lost to Follow-up|2
6108615|NCT00809354|9727042|FG006|Overall Study|Lost to Follow-up|0
6108616|NCT00809354|9727043|FG007|Overall Study|Lost to Follow-up|5
6108617|NCT00809354|9727044|FG008|Overall Study|Lost to Follow-up|4
6108618|NCT00809354|9727045|FG009|Overall Study|Lost to Follow-up|0
6108619|NCT00809354|9727036|FG000|Overall Study|Protocol Violation|7
6108620|NCT00809354|9727037|FG001|Overall Study|Protocol Violation|14
6108621|NCT00809354|9727038|FG002|Overall Study|Protocol Violation|14
6108622|NCT00809354|9727039|FG003|Overall Study|Protocol Violation|12
6206211|NCT01540981|9869399|FG000|Overall Study|Withdrawal by Subject|1
6206212|NCT01540981|9869400|FG001|Overall Study|Withdrawal by Subject|0
6206213|NCT01541215|9869408|FG000|Treatment Period (52 Weeks)|Withdrawal criteria|6
6206214|NCT01541215|9869409|FG001|Treatment Period (52 Weeks)|Withdrawal criteria|8
6206215|NCT01541215|9869408|FG000|Treatment Period (52 Weeks)|Non-compliance|4
6206216|NCT01541215|9869409|FG001|Treatment Period (52 Weeks)|Non-compliance|4
6206217|NCT01541215|9869408|FG000|Treatment Period (52 Weeks)|Adverse Event|0
6206218|NCT01541215|9869409|FG001|Treatment Period (52 Weeks)|Adverse Event|1
6108623|NCT00809354|9727040|FG004|Overall Study|Protocol Violation|14
6108624|NCT00809354|9727041|FG005|Overall Study|Protocol Violation|6
6108625|NCT00809354|9727042|FG006|Overall Study|Protocol Violation|4
6108626|NCT00809354|9727043|FG007|Overall Study|Protocol Violation|6
6108627|NCT00809354|9727044|FG008|Overall Study|Protocol Violation|9
6108628|NCT00809354|9727045|FG009|Overall Study|Protocol Violation|3
6108629|NCT00809354|9727036|FG000|Overall Study|Withdrawal by Subject|32
6108630|NCT00809354|9727037|FG001|Overall Study|Withdrawal by Subject|27
6108631|NCT00809354|9727038|FG002|Overall Study|Withdrawal by Subject|31
6108632|NCT00809354|9727039|FG003|Overall Study|Withdrawal by Subject|33
6108633|NCT00809354|9727040|FG004|Overall Study|Withdrawal by Subject|34
6108634|NCT00809354|9727041|FG005|Overall Study|Withdrawal by Subject|29
6108635|NCT00809354|9727042|FG006|Overall Study|Withdrawal by Subject|27
6108636|NCT00809354|9727043|FG007|Overall Study|Withdrawal by Subject|19
6108637|NCT00809354|9727044|FG008|Overall Study|Withdrawal by Subject|18
6108638|NCT00809354|9727045|FG009|Overall Study|Withdrawal by Subject|20
6108639|NCT00809354|9727036|FG000|Overall Study|Other|10
6108640|NCT00809354|9727037|FG001|Overall Study|Other|2
6108641|NCT00809354|9727038|FG002|Overall Study|Other|7
6108642|NCT00809354|9727039|FG003|Overall Study|Other|10
6108643|NCT00809354|9727040|FG004|Overall Study|Other|5
6108644|NCT00809354|9727041|FG005|Overall Study|Other|3
6108645|NCT00809354|9727042|FG006|Overall Study|Other|2
6108646|NCT00809354|9727043|FG007|Overall Study|Other|3
6108647|NCT00809354|9727044|FG008|Overall Study|Other|4
6108648|NCT00809354|9727045|FG009|Overall Study|Other|3
6108649|NCT00809354|9727036|FG000|Overall Study|Study terminated by sponsor|138
6108650|NCT00809354|9727037|FG001|Overall Study|Study terminated by sponsor|134
6108651|NCT00809354|9727038|FG002|Overall Study|Study terminated by sponsor|129
6108652|NCT00809354|9727039|FG003|Overall Study|Study terminated by sponsor|120
6108653|NCT00809354|9727040|FG004|Overall Study|Study terminated by sponsor|126
6108654|NCT00809354|9727041|FG005|Overall Study|Study terminated by sponsor|133
6108655|NCT00809354|9727042|FG006|Overall Study|Study terminated by sponsor|124
6108656|NCT00809354|9727043|FG007|Overall Study|Study terminated by sponsor|148
6108657|NCT00809354|9727044|FG008|Overall Study|Study terminated by sponsor|127
6108658|NCT00809354|9727045|FG009|Overall Study|Study terminated by sponsor|135
6108659|NCT00809354|9727036|FG000|Overall Study|Withdrawn due to pregnancy|0
6108660|NCT00809354|9727037|FG001|Overall Study|Withdrawn due to pregnancy|1
6108661|NCT00809354|9727038|FG002|Overall Study|Withdrawn due to pregnancy|0
6108662|NCT00809354|9727039|FG003|Overall Study|Withdrawn due to pregnancy|0
6108663|NCT00809354|9727040|FG004|Overall Study|Withdrawn due to pregnancy|0
6108664|NCT00809354|9727041|FG005|Overall Study|Withdrawn due to pregnancy|0
6108665|NCT00809354|9727042|FG006|Overall Study|Withdrawn due to pregnancy|0
6108666|NCT00809354|9727043|FG007|Overall Study|Withdrawn due to pregnancy|0
6108667|NCT00809354|9727044|FG008|Overall Study|Withdrawn due to pregnancy|0
6108668|NCT00809354|9727045|FG009|Overall Study|Withdrawn due to pregnancy|0
6108669|NCT00809354|9727036|FG000|Overall Study|Randomized but not Treated|3
6108670|NCT00809354|9727037|FG001|Overall Study|Randomized but not Treated|1
6108671|NCT00809354|9727038|FG002|Overall Study|Randomized but not Treated|6
6108672|NCT00809354|9727039|FG003|Overall Study|Randomized but not Treated|0
6108673|NCT00809354|9727040|FG004|Overall Study|Randomized but not Treated|5
6108674|NCT00809354|9727041|FG005|Overall Study|Randomized but not Treated|0
6108675|NCT00809354|9727042|FG006|Overall Study|Randomized but not Treated|1
6108676|NCT00809354|9727043|FG007|Overall Study|Randomized but not Treated|1
6108677|NCT00809354|9727044|FG008|Overall Study|Randomized but not Treated|2
6108678|NCT00809354|9727045|FG009|Overall Study|Randomized but not Treated|1
6108679|NCT00809354|9727036|FG000|Overall Study|Death|0
6108680|NCT00809354|9727037|FG001|Overall Study|Death|0
6108681|NCT00809354|9727038|FG002|Overall Study|Death|0
6108682|NCT00809354|9727039|FG003|Overall Study|Death|0
6108683|NCT00809354|9727040|FG004|Overall Study|Death|0
6108684|NCT00809354|9727041|FG005|Overall Study|Death|0
6108685|NCT00809354|9727042|FG006|Overall Study|Death|0
6108686|NCT00809354|9727043|FG007|Overall Study|Death|1
6108687|NCT00809354|9727044|FG008|Overall Study|Death|0
6108688|NCT00809354|9727045|FG009|Overall Study|Death|0
6108689|NCT00809445|9727075|FG000|1 Month Follow-up|Lost contact|1
6108690|NCT00809445|9727076|FG001|1 Month Follow-up|Lost contact|2
6108691|NCT00809445|9727077|FG002|1 Month Follow-up|Lost contact|1
6108692|NCT00809445|9727075|FG000|1 Month Follow-up|Withdrew consent|1
6108693|NCT00809445|9727076|FG001|1 Month Follow-up|Withdrew consent|1
6108694|NCT00809445|9727077|FG002|1 Month Follow-up|Withdrew consent|1
6108695|NCT00809445|9727075|FG000|1 Month Follow-up|Death|0
6108696|NCT00809445|9727076|FG001|1 Month Follow-up|Death|1
6108697|NCT00809445|9727077|FG002|1 Month Follow-up|Death|1
6108698|NCT00809445|9727075|FG000|1 Month Follow-up|Incarcerated|0
6108699|NCT00809445|9727076|FG001|1 Month Follow-up|Incarcerated|0
6108700|NCT00809445|9727077|FG002|1 Month Follow-up|Incarcerated|1
6108701|NCT00809445|9727075|FG000|6 Month Follow-up|Lost contact|16
6108702|NCT00809445|9727076|FG001|6 Month Follow-up|Lost contact|14
6108703|NCT00809445|9727077|FG002|6 Month Follow-up|Lost contact|14
6108704|NCT00809445|9727075|FG000|6 Month Follow-up|Death|2
6108705|NCT00809445|9727076|FG001|6 Month Follow-up|Death|1
6108706|NCT00809445|9727077|FG002|6 Month Follow-up|Death|1
6108707|NCT00809445|9727075|FG000|6 Month Follow-up|Incarcerated|6
6108708|NCT00809445|9727076|FG001|6 Month Follow-up|Incarcerated|8
6108709|NCT00809445|9727077|FG002|6 Month Follow-up|Incarcerated|8
6108710|NCT00809445|9727075|FG000|6 Month Follow-up|Withdrew consent|0
6108711|NCT00809445|9727076|FG001|6 Month Follow-up|Withdrew consent|0
6108712|NCT00809445|9727077|FG002|6 Month Follow-up|Withdrew consent|1
6108713|NCT00809471|9727088|FG000|Overall Study|Protocol non-compliance|15
6206219|NCT01541215|9869408|FG000|Treatment Period (52 Weeks)|Unclassified|0
6108714|NCT00809471|9727089|FG001|Overall Study|Protocol non-compliance|15
6108715|NCT00809471|9727090|FG002|Overall Study|Protocol non-compliance|6
6108716|NCT00809471|9727088|FG000|Overall Study|Lost to Follow-up|4
6108717|NCT00809471|9727089|FG001|Overall Study|Lost to Follow-up|2
6108718|NCT00809471|9727090|FG002|Overall Study|Lost to Follow-up|9
6108719|NCT00809471|9727088|FG000|Overall Study|Adverse Event|0
6108720|NCT00809471|9727089|FG001|Overall Study|Adverse Event|2
6108721|NCT00809471|9727090|FG002|Overall Study|Adverse Event|2
6108722|NCT00809471|9727088|FG000|Overall Study|Requirement for restricted medication|1
6108723|NCT00809471|9727089|FG001|Overall Study|Requirement for restricted medication|1
6108724|NCT00809471|9727090|FG002|Overall Study|Requirement for restricted medication|0
6108725|NCT00809614|9727109|FG000|Overall Study|Lack of Efficacy|2
6108726|NCT00809614|9727110|FG001|Overall Study|Lack of Efficacy|3
6108727|NCT00809614|9727109|FG000|Overall Study|Withdrawal by Subject|1
6108728|NCT00809614|9727110|FG001|Overall Study|Withdrawal by Subject|1
6108729|NCT00809757|9727119|FG000|Overall Study|Adverse Event|2
6108730|NCT00809757|9727120|FG001|Overall Study|Adverse Event|3
6108731|NCT00809757|9727121|FG002|Overall Study|Adverse Event|3
6108732|NCT00809757|9727119|FG000|Overall Study|Lost to Follow-up|0
6108733|NCT00809757|9727120|FG001|Overall Study|Lost to Follow-up|0
6108734|NCT00809757|9727121|FG002|Overall Study|Lost to Follow-up|1
6108735|NCT00809757|9727119|FG000|Overall Study|Protocol Violation|1
6108736|NCT00809757|9727120|FG001|Overall Study|Protocol Violation|1
6108737|NCT00809757|9727121|FG002|Overall Study|Protocol Violation|1
6108738|NCT00809757|9727119|FG000|Overall Study|Withdrawal by Subject|2
6108739|NCT00809757|9727120|FG001|Overall Study|Withdrawal by Subject|1
6108740|NCT00809757|9727121|FG002|Overall Study|Withdrawal by Subject|3
6108741|NCT00809757|9727119|FG000|Overall Study|Subject Uncooperative|1
6108742|NCT00809757|9727120|FG001|Overall Study|Subject Uncooperative|0
6108743|NCT00809757|9727121|FG002|Overall Study|Subject Uncooperative|2
6108744|NCT00809757|9727119|FG000|Overall Study|Noncompliance with Medication|0
6108745|NCT00809757|9727120|FG001|Overall Study|Noncompliance with Medication|0
6108746|NCT00809757|9727121|FG002|Overall Study|Noncompliance with Medication|1
6108747|NCT00809783|9727138|FG000|Overall Study|Death|1
6108748|NCT00809783|9727139|FG001|Overall Study|Death|0
6108749|NCT00809783|9727140|FG002|Overall Study|Death|0
6108750|NCT00809783|9727138|FG000|Overall Study|Adverse Event|34
6108751|NCT00809783|9727139|FG001|Overall Study|Adverse Event|52
6108752|NCT00809783|9727140|FG002|Overall Study|Adverse Event|71
6108753|NCT00809783|9727138|FG000|Overall Study|Lack of Efficacy|39
6108754|NCT00809783|9727139|FG001|Overall Study|Lack of Efficacy|52
6108755|NCT00809783|9727140|FG002|Overall Study|Lack of Efficacy|63
6108756|NCT00809783|9727138|FG000|Overall Study|Lost to Follow-up|0
6108757|NCT00809783|9727139|FG001|Overall Study|Lost to Follow-up|3
6108758|NCT00809783|9727140|FG002|Overall Study|Lost to Follow-up|4
6108759|NCT00809783|9727138|FG000|Overall Study|Withdrawal by Subject|47
6108760|NCT00809783|9727139|FG001|Overall Study|Withdrawal by Subject|72
6108761|NCT00809783|9727140|FG002|Overall Study|Withdrawal by Subject|64
6108762|NCT00809783|9727138|FG000|Overall Study|Protocol Violation|2
6108763|NCT00809783|9727139|FG001|Overall Study|Protocol Violation|6
6108764|NCT00809783|9727140|FG002|Overall Study|Protocol Violation|5
6108765|NCT00809783|9727138|FG000|Overall Study|Randomized, but not treated|3
6108766|NCT00809783|9727139|FG001|Overall Study|Randomized, but not treated|0
6108767|NCT00809783|9727140|FG002|Overall Study|Randomized, but not treated|2
6108768|NCT00809783|9727138|FG000|Overall Study|Study Terminated by Sponsor|378
6108769|NCT00809783|9727139|FG001|Overall Study|Study Terminated by Sponsor|626
6108770|NCT00809783|9727140|FG002|Overall Study|Study Terminated by Sponsor|565
6108771|NCT00809783|9727138|FG000|Overall Study|Other|21
6108772|NCT00809783|9727139|FG001|Overall Study|Other|21
6108773|NCT00809783|9727140|FG002|Overall Study|Other|16
6108774|NCT00809835|9727161|FG000|Overall Study|Lost to Follow-up|7
6108775|NCT00809835|9727162|FG001|Overall Study|Lost to Follow-up|6
6108776|NCT00809835|9727163|FG002|Overall Study|Lost to Follow-up|10
6108777|NCT00809835|9727164|FG003|Overall Study|Lost to Follow-up|2
6108778|NCT00809835|9727161|FG000|Overall Study|Withdrawal by Subject|1
6108779|NCT00809835|9727162|FG001|Overall Study|Withdrawal by Subject|1
6108780|NCT00809835|9727163|FG002|Overall Study|Withdrawal by Subject|1
6108781|NCT00809835|9727164|FG003|Overall Study|Withdrawal by Subject|0
6206220|NCT01541215|9869409|FG001|Treatment Period (52 Weeks)|Unclassified|3
6206221|NCT01541215|9869408|FG000|Follow up 1 (Weeks 53-104)|Lost to Follow-up|1
6206222|NCT01541215|9869409|FG001|Follow up 1 (Weeks 53-104)|Lost to Follow-up|0
6206223|NCT01541215|9869408|FG000|Follow up 1 (Weeks 53-104)|Withdrawal by Subject|1
6206224|NCT01541215|9869409|FG001|Follow up 1 (Weeks 53-104)|Withdrawal by Subject|0
6206225|NCT01541254|9869419|FG000|Overall Study|Withdrawal by Subject|1
6206226|NCT01541254|9869419|FG000|Overall Study|excluded - metal allergy|1
6206227|NCT01541254|9869419|FG000|Overall Study|enrolled after study closed|1
6206228|NCT01541254|9869419|FG000|Overall Study|GI bleed prior to procedure|1
6206229|NCT01541254|9869419|FG000|Overall Study|stent not required|1
6206230|NCT01541254|9869419|FG000|Overall Study|alternate stent used|1
6206231|NCT01541371|9869428|FG000|Overall Study|Withdrawal by Subject|14
6206232|NCT01541371|9869428|FG000|Overall Study|Lost to Follow-up|21
6206233|NCT01541371|9869428|FG000|Overall Study|Adverse Event|15
6206234|NCT01541371|9869428|FG000|Overall Study|Lack of Efficacy|12
6206235|NCT01541371|9869428|FG000|Overall Study|Protocol Violation|6
6108782|NCT00809926|9727198|FG000|Overall Study|Adverse Event|18
6108783|NCT00809926|9727199|FG001|Overall Study|Adverse Event|10
6108784|NCT00809926|9727198|FG000|Overall Study|Unsatisfactory therapeutic effect|3
6108785|NCT00809926|9727199|FG001|Overall Study|Unsatisfactory therapeutic effect|3
6108786|NCT00809926|9727198|FG000|Overall Study|Patient withdrew consent|8
6108787|NCT00809926|9727199|FG001|Overall Study|Patient withdrew consent|6
6108788|NCT00809926|9727198|FG000|Overall Study|Lost to Follow-up|2
6108789|NCT00809926|9727199|FG001|Overall Study|Lost to Follow-up|1
6108790|NCT00809926|9727198|FG000|Overall Study|Administrative Problems|0
6108791|NCT00809926|9727199|FG001|Overall Study|Administrative Problems|1
6108792|NCT00809926|9727198|FG000|Overall Study|Protocol deviation|0
6108793|NCT00809926|9727199|FG001|Overall Study|Protocol deviation|2
6108794|NCT00809965|9727208|FG000|Overall Study|Death|194
6108795|NCT00809965|9727209|FG001|Overall Study|Death|147
6108796|NCT00809965|9727210|FG002|Overall Study|Death|196
6108797|NCT00809965|9727208|FG000|Overall Study|Lost to Follow-up|17
6108798|NCT00809965|9727209|FG001|Overall Study|Lost to Follow-up|10
6108799|NCT00809965|9727210|FG002|Overall Study|Lost to Follow-up|18
6108800|NCT00809965|9727208|FG000|Overall Study|Withdrawal by Subject|405
6108801|NCT00809965|9727209|FG001|Overall Study|Withdrawal by Subject|448
6108802|NCT00809965|9727210|FG002|Overall Study|Withdrawal by Subject|441
6108803|NCT00809965|9727208|FG000|Overall Study|Other Reason|167
6108804|NCT00809965|9727209|FG001|Overall Study|Other Reason|170
6108805|NCT00809965|9727210|FG002|Overall Study|Other Reason|189
6108806|NCT00810043|9727220|FG000|Overall Study|Withdrawal by Subject|1
6108807|NCT00810043|9727221|FG001|Overall Study|Withdrawal by Subject|0
6108808|NCT00810043|9727222|FG002|Overall Study|Withdrawal by Subject|2
6108809|NCT00810043|9727220|FG000|Overall Study|Lost to Follow-up|1
6108810|NCT00810043|9727221|FG001|Overall Study|Lost to Follow-up|0
6108811|NCT00810043|9727222|FG002|Overall Study|Lost to Follow-up|0
6108812|NCT00810043|9727220|FG000|Overall Study|Physician Decision|0
6108813|NCT00810043|9727221|FG001|Overall Study|Physician Decision|0
6108814|NCT00810043|9727222|FG002|Overall Study|Physician Decision|2
6108815|NCT00810043|9727220|FG000|Overall Study|Death|2
6108816|NCT00810043|9727221|FG001|Overall Study|Death|0
6108817|NCT00810043|9727222|FG002|Overall Study|Death|0
6108818|NCT00810043|9727220|FG000|Overall Study|Unrelated medical problem|0
6108819|NCT00810043|9727221|FG001|Overall Study|Unrelated medical problem|1
6108820|NCT00810043|9727222|FG002|Overall Study|Unrelated medical problem|0
6108821|NCT00810043|9727220|FG000|Overall Study|Non-medical problem|0
6108822|NCT00810043|9727221|FG001|Overall Study|Non-medical problem|0
6108823|NCT00810043|9727222|FG002|Overall Study|Non-medical problem|1
6108824|NCT00810043|9727220|FG000|Overall Study|No longer met enrollment criteria|0
6108825|NCT00810043|9727221|FG001|Overall Study|No longer met enrollment criteria|0
6108826|NCT00810043|9727222|FG002|Overall Study|No longer met enrollment criteria|3
6108827|NCT00810069|9727233|FG000|Lead-in Period I|Adverse Event|43
6108828|NCT00810069|9727234|FG001|Lead-in Period I|Adverse Event|0
6108829|NCT00810069|9727235|FG002|Lead-in Period I|Adverse Event|0
6108830|NCT00810069|9727233|FG000|Lead-in Period I|Lack of Efficacy|1
6108831|NCT00810069|9727234|FG001|Lead-in Period I|Lack of Efficacy|0
6108832|NCT00810069|9727235|FG002|Lead-in Period I|Lack of Efficacy|0
6108833|NCT00810069|9727233|FG000|Lead-in Period I|Lost to Follow-up|19
6108834|NCT00810069|9727234|FG001|Lead-in Period I|Lost to Follow-up|0
6108835|NCT00810069|9727235|FG002|Lead-in Period I|Lost to Follow-up|0
6108836|NCT00810069|9727233|FG000|Lead-in Period I|Physician Decision|1
6108837|NCT00810069|9727234|FG001|Lead-in Period I|Physician Decision|0
6108838|NCT00810069|9727235|FG002|Lead-in Period I|Physician Decision|0
6108839|NCT00810069|9727233|FG000|Lead-in Period I|Protocol Violation|1
6108840|NCT00810069|9727234|FG001|Lead-in Period I|Protocol Violation|0
6108841|NCT00810069|9727235|FG002|Lead-in Period I|Protocol Violation|0
6108842|NCT00810069|9727233|FG000|Lead-in Period I|Withdrawal by Subject|46
6108843|NCT00810069|9727234|FG001|Lead-in Period I|Withdrawal by Subject|0
6108844|NCT00810069|9727235|FG002|Lead-in Period I|Withdrawal by Subject|0
6108845|NCT00810069|9727233|FG000|Lead-in Period I|Protocol entry criterion not met|5
6108846|NCT00810069|9727234|FG001|Lead-in Period I|Protocol entry criterion not met|0
6108847|NCT00810069|9727235|FG002|Lead-in Period I|Protocol entry criterion not met|0
6108848|NCT00810069|9727233|FG000|Lead-in Period I|Randomization criteria not met|158
6108849|NCT00810069|9727234|FG001|Lead-in Period I|Randomization criteria not met|0
6108850|NCT00810069|9727235|FG002|Lead-in Period I|Randomization criteria not met|0
6108851|NCT00810069|9727233|FG000|Double-Blind Period II|Adverse Event|0
6108852|NCT00810069|9727234|FG001|Double-Blind Period II|Adverse Event|9
6108853|NCT00810069|9727235|FG002|Double-Blind Period II|Adverse Event|8
6108854|NCT00810069|9727233|FG000|Double-Blind Period II|Lack of Efficacy|0
6108855|NCT00810069|9727234|FG001|Double-Blind Period II|Lack of Efficacy|7
6108856|NCT00810069|9727235|FG002|Double-Blind Period II|Lack of Efficacy|12
6108857|NCT00810069|9727233|FG000|Double-Blind Period II|Lost to Follow-up|0
6108858|NCT00810069|9727234|FG001|Double-Blind Period II|Lost to Follow-up|9
6108859|NCT00810069|9727235|FG002|Double-Blind Period II|Lost to Follow-up|9
6108860|NCT00810069|9727233|FG000|Double-Blind Period II|Physician Decision|0
6108861|NCT00810069|9727234|FG001|Double-Blind Period II|Physician Decision|0
6108862|NCT00810069|9727235|FG002|Double-Blind Period II|Physician Decision|1
6108863|NCT00810069|9727233|FG000|Double-Blind Period II|Withdrawal by Subject|0
6108864|NCT00810069|9727234|FG001|Double-Blind Period II|Withdrawal by Subject|21
6108865|NCT00810069|9727235|FG002|Double-Blind Period II|Withdrawal by Subject|35
6108866|NCT00810069|9727233|FG000|Double-Blind Period II|Protocol entry criterion not met|0
6108867|NCT00810069|9727234|FG001|Double-Blind Period II|Protocol entry criterion not met|0
6108868|NCT00810069|9727235|FG002|Double-Blind Period II|Protocol entry criterion not met|1
6108869|NCT00810069|9727233|FG000|Double-Blind Period II|Clinical relapse|0
6108870|NCT00810069|9727234|FG001|Double-Blind Period II|Clinical relapse|3
6108871|NCT00810069|9727235|FG002|Double-Blind Period II|Clinical relapse|0
6108872|NCT00810069|9727233|FG000|Double-Blind Period II|Protocol Violation|0
6108873|NCT00810069|9727234|FG001|Double-Blind Period II|Protocol Violation|7
6108874|NCT00810069|9727235|FG002|Double-Blind Period II|Protocol Violation|6
6108875|NCT00810082|9727246|FG000|Overall Study|Lost to Follow-up|0
6108876|NCT00810082|9727247|FG001|Overall Study|Lost to Follow-up|4
6108877|NCT00810108|9727259|FG000|Overall Study|Withdrawal by Subject|1
6108878|NCT00810108|9727260|FG001|Overall Study|Withdrawal by Subject|0
6108879|NCT00810199|9727267|FG000|Overall Study|Adverse Event|24
6108880|NCT00810199|9727268|FG001|Overall Study|Adverse Event|26
6108881|NCT00810199|9727267|FG000|Overall Study|Death|4
6108882|NCT00810199|9727268|FG001|Overall Study|Death|6
6108883|NCT00810199|9727267|FG000|Overall Study|Withdrew consent|9
6108884|NCT00810199|9727268|FG001|Overall Study|Withdrew consent|12
6108885|NCT00810199|9727267|FG000|Overall Study|Insufficient therapeutic response|5
6108886|NCT00810199|9727268|FG001|Overall Study|Insufficient therapeutic response|14
6108887|NCT00810199|9727267|FG000|Overall Study|Refused treatment/Did not cooperate|7
6108888|NCT00810199|9727268|FG001|Overall Study|Refused treatment/Did not cooperate|7
6108889|NCT00810199|9727267|FG000|Overall Study|Administrative/Other|5
6108890|NCT00810199|9727268|FG001|Overall Study|Administrative/Other|6
6108891|NCT00810199|9727267|FG000|Overall Study|Protocol Violation|2
6108892|NCT00810199|9727268|FG001|Overall Study|Protocol Violation|6
6108893|NCT00810199|9727267|FG000|Overall Study|Failure to return|1
6108894|NCT00810199|9727268|FG001|Overall Study|Failure to return|4
6108895|NCT00810199|9727267|FG000|Overall Study|Did not receive study drug|2
6108896|NCT00810199|9727268|FG001|Overall Study|Did not receive study drug|1
6108897|NCT00810264|9727280|FG000|Overall Study|Lost to Follow-up|191
6108898|NCT00810264|9727280|FG000|Overall Study|Withdrawal by subject or physician|721
6108899|NCT00810264|9727280|FG000|Overall Study|Death|641
6108900|NCT00810277|9727288|FG000|Overall Study|Adverse Event|1
6108901|NCT00810342|9727302|FG000|Month 1 Follow-up|Lost to Follow-up|4
6108902|NCT00810342|9727303|FG001|Month 1 Follow-up|Lost to Follow-up|2
6206236|NCT01541371|9869428|FG000|Overall Study|Study medication non-compliance|3
6206237|NCT01541371|9869428|FG000|Overall Study|Other|6
6206238|NCT01541644|9869458|FG000|Overall Study|Withdrawal by Subject|3
6206239|NCT01541748|9869471|FG000|Overall Study|Lost to Follow-up|17
6206240|NCT01541748|9869471|FG000|Overall Study|Moved out of state|1
6206241|NCT01541748|9869471|FG000|Overall Study|Withdrawal by Subject|7
6206242|NCT01541748|9869471|FG000|Overall Study|Screen failure|5
6206243|NCT01541748|9869471|FG000|Overall Study|Did not receive study device|1
6206244|NCT01541826|9869487|FG000|Overall Study|Lost to Follow-up|2
6206245|NCT01541826|9869488|FG001|Overall Study|Lost to Follow-up|3
6206246|NCT01541826|9869489|FG002|Overall Study|Lost to Follow-up|0
6206247|NCT01541826|9869487|FG000|Overall Study|Withdrawal by Subject|2
6206248|NCT01541826|9869488|FG001|Overall Study|Withdrawal by Subject|0
6206249|NCT01541826|9869489|FG002|Overall Study|Withdrawal by Subject|0
6206250|NCT01541865|9869497|FG000|Overall Study|Lost to Follow-up|11
6206251|NCT01541865|9869497|FG000|Overall Study|Withdrawal by Subject|9
6206252|NCT01541865|9869497|FG000|Overall Study|Adverse Event|1
6206253|NCT01541865|9869497|FG000|Overall Study|Protocol Violation|1
6206254|NCT01541917|9869515|FG000|Overall Study|Lost to Follow-up|2
6206255|NCT01541917|9869516|FG001|Overall Study|Lost to Follow-up|2
6206256|NCT01541917|9869515|FG000|Overall Study|Withdrawal by Subject|13
6206257|NCT01541917|9869516|FG001|Overall Study|Withdrawal by Subject|7
6206258|NCT01541930|9869525|FG000|Overall Study|Withdrawal by Subject|1
6206259|NCT01541969|9869542|FG000|Double-blind (0-12 Weeks)|Dominant pitch match not possible|0
6206260|NCT01541969|9869543|FG001|Double-blind (0-12 Weeks)|Dominant pitch match not possible|1
6206261|NCT01541969|9869542|FG000|Double-blind (0-12 Weeks)|Pitch shifted out of fitting range|1
6206262|NCT01541969|9869543|FG001|Double-blind (0-12 Weeks)|Pitch shifted out of fitting range|1
6206263|NCT01541969|9869542|FG000|Double-blind (0-12 Weeks)|Withdrawal by Subject|2
6206264|NCT01541969|9869543|FG001|Double-blind (0-12 Weeks)|Withdrawal by Subject|0
6206265|NCT01541969|9869542|FG000|Double-blind (0-12 Weeks)|Lost to Follow-up|1
6285467|NCT02336165|9997704|FG001|Overall Study|Adverse Event|1
6285468|NCT02336165|9997705|FG002|Overall Study|Adverse Event|2
6108903|NCT00810342|9727302|FG000|Month 1 Follow-up|Pregnancy|1
6108904|NCT00810342|9727303|FG001|Month 1 Follow-up|Pregnancy|0
6108905|NCT00810342|9727302|FG000|6-month Follow-up|Lost to Follow-up|18
6108906|NCT00810342|9727303|FG001|6-month Follow-up|Lost to Follow-up|6
6108907|NCT00810342|9727302|FG000|6-month Follow-up|Pregnancy|6
6285469|NCT02336165|9997706|FG003|Overall Study|Adverse Event|4
6285470|NCT02336165|9997707|FG004|Overall Study|Adverse Event|1
6285471|NCT02336165|9997703|FG000|Overall Study|Progressive disease|23
6285472|NCT02336165|9997704|FG001|Overall Study|Progressive disease|22
6108908|NCT00810342|9727303|FG001|6-month Follow-up|Pregnancy|2
6108909|NCT00810342|9727302|FG000|12-month Followup|Pregnancy|9
6285473|NCT02336165|9997705|FG002|Overall Study|Progressive disease|27
6206266|NCT01541969|9869543|FG001|Double-blind (0-12 Weeks)|Lost to Follow-up|0
6108910|NCT00810342|9727303|FG001|12-month Followup|Pregnancy|10
6108911|NCT00810342|9727302|FG000|12-month Followup|Lost to Follow-up|3
6108912|NCT00810342|9727303|FG001|12-month Followup|Lost to Follow-up|1
6108913|NCT00810355|9727314|FG000|Overall Study|Lost to Follow-up|13
6108914|NCT00810355|9727315|FG001|Overall Study|Lost to Follow-up|17
6108915|NCT00810355|9727316|FG002|Overall Study|Lost to Follow-up|11
6108916|NCT00810355|9727314|FG000|Overall Study|Withdrawal by Subject|1
6108917|NCT00810355|9727315|FG001|Overall Study|Withdrawal by Subject|0
6108918|NCT00810355|9727316|FG002|Overall Study|Withdrawal by Subject|0
6108919|NCT00810368|9727326|FG000|Overall Study|Lost to Follow-up|4
6108920|NCT00810368|9727327|FG001|Overall Study|Lost to Follow-up|2
6108921|NCT00810368|9727326|FG000|Overall Study|Lack of Efficacy|2
6108922|NCT00810368|9727327|FG001|Overall Study|Lack of Efficacy|0
6108923|NCT00810394|9727335|FG000|Overall Study|Withdrawal by Subject|3
6108924|NCT00810407|9727339|FG000|Overall Study|Protocol Violation|3
6108925|NCT00810407|9727339|FG000|Overall Study|No Visit After First Day of Treatment|3
6108926|NCT00810511|9727360|FG000|Overall Study|Protocol Violation|0
6108927|NCT00810511|9727361|FG001|Overall Study|Protocol Violation|1
6108928|NCT00810511|9727360|FG000|Overall Study|Lack of Efficacy|9
6108929|NCT00810511|9727361|FG001|Overall Study|Lack of Efficacy|1
6108930|NCT00810511|9727360|FG000|Overall Study|death in the family|0
6108931|NCT00810511|9727361|FG001|Overall Study|death in the family|1
6108932|NCT00810511|9727360|FG000|Overall Study|Lost to Follow-up|1
6108933|NCT00810511|9727361|FG001|Overall Study|Lost to Follow-up|0
6108934|NCT00810511|9727360|FG000|Overall Study|deposits on contact lens|0
6108935|NCT00810511|9727361|FG001|Overall Study|deposits on contact lens|1
6108936|NCT00810602|9727371|FG000|Overall Study|Withdrawal by Subject|8
6108937|NCT00810602|9727372|FG001|Overall Study|Withdrawal by Subject|3
6108938|NCT00810615|9727378|FG000|Overall Study|Withdrawal by Subject|1
6108939|NCT00810615|9727379|FG001|Overall Study|Withdrawal by Subject|1
6108940|NCT00810641|9727400|FG000|Overall Study|Withdrawal by Subject|0
6108941|NCT00810641|9727401|FG001|Overall Study|Withdrawal by Subject|1
6108942|NCT00810641|9727402|FG002|Overall Study|Withdrawal by Subject|2
6108943|NCT00810693|9727413|FG000|Treatment Period|Adverse Event|8
6108944|NCT00810693|9727414|FG001|Treatment Period|Adverse Event|1
6206267|NCT01541969|9869542|FG000|Double-blind (0-12 Weeks)|Adverse Event|2
6206268|NCT01541969|9869543|FG001|Double-blind (0-12 Weeks)|Adverse Event|0
6206269|NCT01541969|9869542|FG000|Open Label Extension (12-36 Weeks)|Pitch shifted out of fitting range|1
6206270|NCT01541969|9869543|FG001|Open Label Extension (12-36 Weeks)|Pitch shifted out of fitting range|1
6206271|NCT01541969|9869542|FG000|Open Label Extension (12-36 Weeks)|Prescription adjusted: tones inaudible|1
6206272|NCT01541969|9869543|FG001|Open Label Extension (12-36 Weeks)|Prescription adjusted: tones inaudible|0
6206273|NCT01541969|9869542|FG000|Open Label Extension (12-36 Weeks)|Withdrawal by Subject|1
6206274|NCT01541969|9869543|FG001|Open Label Extension (12-36 Weeks)|Withdrawal by Subject|1
6206275|NCT01541969|9869542|FG000|Open Label Extension (12-36 Weeks)|Lost to Follow-up|6
6206276|NCT01541969|9869543|FG001|Open Label Extension (12-36 Weeks)|Lost to Follow-up|8
6206277|NCT01541969|9869542|FG000|Open Label Extension (12-36 Weeks)|Adverse Event|2
6206278|NCT01541969|9869543|FG001|Open Label Extension (12-36 Weeks)|Adverse Event|3
6206279|NCT01542034|9869554|FG000|Overall Study|Consent Withdrawn (Subject Convenience)|20
6206280|NCT01542034|9869555|FG001|Overall Study|Consent Withdrawn (Subject Convenience)|12
6206281|NCT01542034|9869554|FG000|Overall Study|Administrative decision|0
6206282|NCT01542034|9869555|FG001|Overall Study|Administrative decision|3
6206283|NCT01542034|9869554|FG000|Overall Study|Subject Noncompliance|1
6206284|NCT01542034|9869555|FG001|Overall Study|Subject Noncompliance|0
6206285|NCT01542034|9869554|FG000|Overall Study|Adverse Event|2
6206286|NCT01542034|9869555|FG001|Overall Study|Adverse Event|2
6206287|NCT01542034|9869554|FG000|Overall Study|Lost to Follow-up|7
6206288|NCT01542034|9869555|FG001|Overall Study|Lost to Follow-up|6
6206289|NCT01542528|9869619|FG000|Overall Study|Lost to Follow-up|2
6206290|NCT01542528|9869620|FG001|Overall Study|Lost to Follow-up|1
6206291|NCT01542528|9869619|FG000|Overall Study|Physician Decision|1
6206292|NCT01542528|9869620|FG001|Overall Study|Physician Decision|0
6206293|NCT01542528|9869619|FG000|Overall Study|Withdrawal by Subject|9
6206294|NCT01542528|9869620|FG001|Overall Study|Withdrawal by Subject|6
6206295|NCT01542632|9869641|FG000|Overall Study|Withdrawal of Consent|0
6206296|NCT01542632|9869642|FG001|Overall Study|Withdrawal of Consent|0
6206297|NCT01542632|9869643|FG002|Overall Study|Withdrawal of Consent|0
6108945|NCT00810693|9727415|FG002|Treatment Period|Adverse Event|7
6108946|NCT00810693|9727413|FG000|Treatment Period|Death|0
6108947|NCT00810693|9727414|FG001|Treatment Period|Death|1
6206298|NCT01542632|9869644|FG003|Overall Study|Withdrawal of Consent|2
6206299|NCT01542632|9869645|FG004|Overall Study|Withdrawal of Consent|3
6206300|NCT01542632|9869646|FG005|Overall Study|Withdrawal of Consent|0
6206301|NCT01542632|9869641|FG000|Overall Study|Adverse Event|0
6206302|NCT01542632|9869642|FG001|Overall Study|Adverse Event|0
6108948|NCT00810693|9727415|FG002|Treatment Period|Death|2
6108949|NCT00810693|9727413|FG000|Treatment Period|Lack of Efficacy|0
6108950|NCT00810693|9727414|FG001|Treatment Period|Lack of Efficacy|0
6108951|NCT00810693|9727415|FG002|Treatment Period|Lack of Efficacy|1
6108952|NCT00810693|9727413|FG000|Treatment Period|Lost to Follow-up|1
6108953|NCT00810693|9727414|FG001|Treatment Period|Lost to Follow-up|0
6206303|NCT01542632|9869643|FG002|Overall Study|Adverse Event|1
6108954|NCT00810693|9727415|FG002|Treatment Period|Lost to Follow-up|0
6108955|NCT00810693|9727413|FG000|Treatment Period|Non-compliance|1
6108956|NCT00810693|9727414|FG001|Treatment Period|Non-compliance|0
6108957|NCT00810693|9727415|FG002|Treatment Period|Non-compliance|0
6285474|NCT02336165|9997706|FG003|Overall Study|Progressive disease|24
6285475|NCT02336165|9997707|FG004|Overall Study|Progressive disease|19
6285476|NCT02336165|9997703|FG000|Overall Study|Non-compliance|1
6285477|NCT02336165|9997704|FG001|Overall Study|Non-compliance|0
6285478|NCT02336165|9997705|FG002|Overall Study|Non-compliance|0
6285479|NCT02336165|9997706|FG003|Overall Study|Non-compliance|1
6285480|NCT02336165|9997707|FG004|Overall Study|Non-compliance|0
6285481|NCT02336165|9997703|FG000|Overall Study|Other|1
6285482|NCT02336165|9997704|FG001|Overall Study|Other|0
6285483|NCT02336165|9997705|FG002|Overall Study|Other|0
6285484|NCT02336165|9997706|FG003|Overall Study|Other|1
6285485|NCT02336165|9997707|FG004|Overall Study|Other|0
6285486|NCT02336178|9997723|FG000|Overall Study|Lost to Follow-up|1
6108958|NCT00810693|9727413|FG000|Treatment Period|Protocol Violation|1
6108959|NCT00810693|9727414|FG001|Treatment Period|Protocol Violation|2
6108960|NCT00810693|9727415|FG002|Treatment Period|Protocol Violation|2
6108961|NCT00810693|9727413|FG000|Treatment Period|Withdrawal by Subject|6
6108962|NCT00810693|9727414|FG001|Treatment Period|Withdrawal by Subject|2
6108963|NCT00810693|9727415|FG002|Treatment Period|Withdrawal by Subject|3
6108964|NCT00810693|9727413|FG000|Treatment Period|Not treated|0
6108965|NCT00810693|9727414|FG001|Treatment Period|Not treated|1
6108966|NCT00810693|9727415|FG002|Treatment Period|Not treated|1
6108967|NCT00810693|9727413|FG000|Follow-up Period (FUP)|Adverse Event|3
6108968|NCT00810693|9727414|FG001|Follow-up Period (FUP)|Adverse Event|1
6108969|NCT00810693|9727415|FG002|Follow-up Period (FUP)|Adverse Event|1
6108970|NCT00810693|9727413|FG000|Follow-up Period (FUP)|Death|2
6108971|NCT00810693|9727414|FG001|Follow-up Period (FUP)|Death|0
6108972|NCT00810693|9727415|FG002|Follow-up Period (FUP)|Death|1
6108973|NCT00810693|9727413|FG000|Follow-up Period (FUP)|Lost to Follow-up|1
6108974|NCT00810693|9727414|FG001|Follow-up Period (FUP)|Lost to Follow-up|0
6108975|NCT00810693|9727415|FG002|Follow-up Period (FUP)|Lost to Follow-up|2
6108976|NCT00810693|9727413|FG000|Follow-up Period (FUP)|Protocol Violation|0
6108977|NCT00810693|9727414|FG001|Follow-up Period (FUP)|Protocol Violation|1
6108978|NCT00810693|9727415|FG002|Follow-up Period (FUP)|Protocol Violation|0
6108979|NCT00810693|9727413|FG000|Follow-up Period (FUP)|Withdrawal by Subject|2
6108980|NCT00810693|9727414|FG001|Follow-up Period (FUP)|Withdrawal by Subject|1
6108981|NCT00810693|9727415|FG002|Follow-up Period (FUP)|Withdrawal by Subject|0
6108982|NCT00810810|9727450|FG000|Overall Study|Withdrawal by Subject|0
6108983|NCT00810810|9727451|FG001|Overall Study|Withdrawal by Subject|8
6108984|NCT00810810|9727452|FG002|Overall Study|Withdrawal by Subject|10
6108985|NCT00810810|9727453|FG003|Overall Study|Withdrawal by Subject|8
6108986|NCT00810810|9727450|FG000|Overall Study|Physician Decision|0
6108987|NCT00810810|9727451|FG001|Overall Study|Physician Decision|3
6108988|NCT00810810|9727452|FG002|Overall Study|Physician Decision|1
6108989|NCT00810810|9727453|FG003|Overall Study|Physician Decision|5
6108990|NCT00810901|9727478|FG000|Overall Study|Lost to Follow-up|88
6108991|NCT00810901|9727479|FG001|Overall Study|Lost to Follow-up|58
6108992|NCT00811018|9727485|FG000|Overall Study|Additional Chronic Treatment|31
6108993|NCT00811018|9727485|FG000|Overall Study|Adverse Event|79
6108994|NCT00811018|9727485|FG000|Overall Study|Death|147
6108995|NCT00811018|9727485|FG000|Overall Study|ALT/AST >3x UNL, Bilirubin >2xUNL|4
6108996|NCT00811018|9727485|FG000|Overall Study|ALT/AST >5x Upper Limit of Normal (ULN)|70
6108997|NCT00811018|9727485|FG000|Overall Study|Investigator Decision|57
6108998|NCT00811018|9727485|FG000|Overall Study|Lost to Follow-up|19
6108999|NCT00811018|9727485|FG000|Overall Study|Pregnancy|6
6109000|NCT00811018|9727485|FG000|Overall Study|Sponsor Decision|450
6109001|NCT00811018|9727485|FG000|Overall Study|Withdrawal by Subject|70
6206304|NCT01542632|9869644|FG003|Overall Study|Adverse Event|0
6206305|NCT01542632|9869645|FG004|Overall Study|Adverse Event|0
6206306|NCT01542632|9869646|FG005|Overall Study|Adverse Event|0
6206307|NCT01542632|9869641|FG000|Overall Study|Lost to Follow-up|0
6206308|NCT01542632|9869642|FG001|Overall Study|Lost to Follow-up|1
6206309|NCT01542632|9869643|FG002|Overall Study|Lost to Follow-up|0
6206310|NCT01542632|9869644|FG003|Overall Study|Lost to Follow-up|0
6206311|NCT01542632|9869645|FG004|Overall Study|Lost to Follow-up|0
6206312|NCT01542632|9869646|FG005|Overall Study|Lost to Follow-up|0
6206313|NCT01542632|9869641|FG000|Overall Study|Sponsor/Investigator Decision|0
6206314|NCT01542632|9869642|FG001|Overall Study|Sponsor/Investigator Decision|0
6206315|NCT01542632|9869643|FG002|Overall Study|Sponsor/Investigator Decision|0
6206316|NCT01542632|9869644|FG003|Overall Study|Sponsor/Investigator Decision|0
6206317|NCT01542632|9869645|FG004|Overall Study|Sponsor/Investigator Decision|1
6206318|NCT01542632|9869646|FG005|Overall Study|Sponsor/Investigator Decision|0
6206319|NCT01542788|9869684|FG000|Overall Study|Randomized but Not Treated|2
6206320|NCT01542788|9869685|FG001|Overall Study|Randomized but Not Treated|0
6206321|NCT01542788|9869684|FG000|Overall Study|Lack of Efficacy|41
6206322|NCT01542788|9869685|FG001|Overall Study|Lack of Efficacy|71
6285487|NCT02336178|9997723|FG000|Overall Study|Protocol Violation|1
6285488|NCT02336178|9997723|FG000|Overall Study|Withdrawal by Subject|1
6206323|NCT01542788|9869684|FG000|Overall Study|Lost to Follow-up|5
6285489|NCT02336178|9997723|FG000|Overall Study|Other|1
6285490|NCT02336282|9997735|FG000|Overall Study|Unrelated illness|1
6109002|NCT00811018|9727485|FG000|Overall Study|WHO FC deterioration and 6MWD decrease|9
6109003|NCT00811018|9727485|FG000|Overall Study|Other|26
6109004|NCT00811057|9727492|FG000|Overall Study|Protocol Violation|5
6109005|NCT00811057|9727493|FG001|Overall Study|Protocol Violation|10
6109006|NCT00811057|9727494|FG002|Overall Study|Protocol Violation|10
6109007|NCT00811070|9727508|FG000|Overall Study|Death|0
6109008|NCT00811070|9727509|FG001|Overall Study|Death|0
6109009|NCT00811070|9727510|FG002|Overall Study|Death|0
6109010|NCT00811070|9727511|FG003|Overall Study|Death|2
6109011|NCT00811070|9727512|FG004|Overall Study|Death|5
6109012|NCT00811070|9727513|FG005|Overall Study|Death|0
6109013|NCT00811070|9727508|FG000|Overall Study|Other|1
6109014|NCT00811070|9727509|FG001|Overall Study|Other|0
6109015|NCT00811070|9727510|FG002|Overall Study|Other|0
6109016|NCT00811070|9727511|FG003|Overall Study|Other|0
6109017|NCT00811070|9727512|FG004|Overall Study|Other|0
6109018|NCT00811070|9727513|FG005|Overall Study|Other|0
6109019|NCT00811070|9727508|FG000|Overall Study|Withdrawal by Subject|0
6109020|NCT00811070|9727509|FG001|Overall Study|Withdrawal by Subject|1
6109021|NCT00811070|9727510|FG002|Overall Study|Withdrawal by Subject|0
6109022|NCT00811070|9727511|FG003|Overall Study|Withdrawal by Subject|0
6109023|NCT00811070|9727512|FG004|Overall Study|Withdrawal by Subject|0
6109024|NCT00811070|9727513|FG005|Overall Study|Withdrawal by Subject|0
6109025|NCT00811070|9727508|FG000|Overall Study|Physician Decision|0
6109026|NCT00811070|9727509|FG001|Overall Study|Physician Decision|0
6109027|NCT00811070|9727510|FG002|Overall Study|Physician Decision|0
6109028|NCT00811070|9727511|FG003|Overall Study|Physician Decision|0
6109029|NCT00811070|9727512|FG004|Overall Study|Physician Decision|0
6109030|NCT00811070|9727513|FG005|Overall Study|Physician Decision|1
6109031|NCT00811135|9727529|FG000|Overall Study|Adverse Event/Intercurrent Illness|8
6109032|NCT00811135|9727529|FG000|Overall Study|Death|3
6109033|NCT00811135|9727529|FG000|Overall Study|Protocol Violation|2
6109034|NCT00811135|9727529|FG000|Overall Study|Violation of Selection Criteria|1
6109035|NCT00811135|9727529|FG000|Overall Study|Refused Treatment|1
6109036|NCT00811135|9727529|FG000|Overall Study|Withdrawal by Subject|3
6109037|NCT00811135|9727529|FG000|Overall Study|Administrative/Other Unspecified|11
6109038|NCT00811135|9727529|FG000|Overall Study|Ongoing|59
6109039|NCT00811174|9727533|FG000|Overall Study|Protocol Violation|2
6109040|NCT00811174|9727533|FG000|Overall Study|Sponsors Decision|1
6109041|NCT00811187|9727539|FG000|Overall Study|Unable to place device / procedure abort|3
6109042|NCT00811187|9727540|FG001|Overall Study|Unable to place device / procedure abort|3
6109043|NCT00811252|9727549|FG000|Overall Study|Adverse Event|6
6109044|NCT00811252|9727550|FG001|Overall Study|Adverse Event|10
6109045|NCT00811252|9727551|FG002|Overall Study|Adverse Event|15
6109046|NCT00811252|9727549|FG000|Overall Study|Lack of Efficacy|7
6109047|NCT00811252|9727550|FG001|Overall Study|Lack of Efficacy|2
6109048|NCT00811252|9727551|FG002|Overall Study|Lack of Efficacy|0
6109049|NCT00811252|9727549|FG000|Overall Study|Protocol Violation|3
6109050|NCT00811252|9727550|FG001|Overall Study|Protocol Violation|3
6109051|NCT00811252|9727551|FG002|Overall Study|Protocol Violation|2
6109052|NCT00811252|9727549|FG000|Overall Study|Withdrawal of Consent|1
6109053|NCT00811252|9727550|FG001|Overall Study|Withdrawal of Consent|2
6109054|NCT00811252|9727551|FG002|Overall Study|Withdrawal of Consent|2
6109055|NCT00811252|9727549|FG000|Overall Study|Lost to Follow-up|0
6109056|NCT00811252|9727550|FG001|Overall Study|Lost to Follow-up|0
6109057|NCT00811252|9727551|FG002|Overall Study|Lost to Follow-up|2
6109058|NCT00811252|9727549|FG000|Overall Study|Administrative or Other Reasons|0
6109059|NCT00811252|9727550|FG001|Overall Study|Administrative or Other Reasons|3
6109060|NCT00811252|9727551|FG002|Overall Study|Administrative or Other Reasons|2
6109061|NCT00811395|9727580|FG000|Extension Treatment|Adverse Event|1
6109062|NCT00811395|9727581|FG001|Extension Treatment|Adverse Event|2
6109063|NCT00811395|9727582|FG002|Extension Treatment|Adverse Event|2
6109064|NCT00811395|9727583|FG003|Extension Treatment|Adverse Event|2
6109065|NCT00811395|9727584|FG004|Extension Treatment|Adverse Event|0
6109066|NCT00811395|9727585|FG005|Extension Treatment|Adverse Event|1
6109067|NCT00811395|9727580|FG000|Extension Treatment|Progressive disease|1
6109068|NCT00811395|9727581|FG001|Extension Treatment|Progressive disease|1
6109069|NCT00811395|9727582|FG002|Extension Treatment|Progressive disease|0
6109070|NCT00811395|9727583|FG003|Extension Treatment|Progressive disease|0
6109071|NCT00811395|9727584|FG004|Extension Treatment|Progressive disease|0
6109072|NCT00811395|9727585|FG005|Extension Treatment|Progressive disease|0
6109073|NCT00811395|9727580|FG000|Extension Treatment|Participant did not wish to continue|0
6109074|NCT00811395|9727581|FG001|Extension Treatment|Participant did not wish to continue|3
6109075|NCT00811395|9727582|FG002|Extension Treatment|Participant did not wish to continue|0
6109076|NCT00811395|9727583|FG003|Extension Treatment|Participant did not wish to continue|1
6109077|NCT00811395|9727584|FG004|Extension Treatment|Participant did not wish to continue|0
6109078|NCT00811395|9727585|FG005|Extension Treatment|Participant did not wish to continue|1
6109079|NCT00811395|9727580|FG000|Extension Treatment|Other than above|0
6109080|NCT00811395|9727581|FG001|Extension Treatment|Other than above|0
6109081|NCT00811395|9727582|FG002|Extension Treatment|Other than above|1
6109082|NCT00811395|9727583|FG003|Extension Treatment|Other than above|0
6109083|NCT00811395|9727584|FG004|Extension Treatment|Other than above|0
6109084|NCT00811395|9727585|FG005|Extension Treatment|Other than above|0
6109085|NCT00811473|9727612|FG000|Overall Study|Adverse Event|3
6109086|NCT00811473|9727613|FG001|Overall Study|Adverse Event|12
6109087|NCT00811473|9727612|FG000|Overall Study|Lost to Follow-up|5
6109088|NCT00811473|9727613|FG001|Overall Study|Lost to Follow-up|1
6109089|NCT00811473|9727612|FG000|Overall Study|Withdrawal by Subject|2
6109090|NCT00811473|9727613|FG001|Overall Study|Withdrawal by Subject|4
6109091|NCT00811473|9727612|FG000|Overall Study|Severe non-compliance to protocol|2
6109092|NCT00811473|9727613|FG001|Overall Study|Severe non-compliance to protocol|4
6109093|NCT00811473|9727612|FG000|Overall Study|Lack of therapeutic response|4
6109094|NCT00811473|9727613|FG001|Overall Study|Lack of therapeutic response|1
6109095|NCT00811473|9727612|FG000|Overall Study|Condition under investigation worsened|1
6109096|NCT00811473|9727613|FG001|Overall Study|Condition under investigation worsened|3
6109097|NCT00811473|9727612|FG000|Overall Study|Other 2|4
6109098|NCT00811473|9727613|FG001|Overall Study|Other 2|1
6109099|NCT00811473|9727612|FG000|Overall Study|Incorrect Enrollment|1
6109100|NCT00811473|9727613|FG001|Overall Study|Incorrect Enrollment|0
6109101|NCT00811473|9727612|FG000|Overall Study|Safety Reasons|1
6109102|NCT00811473|9727613|FG001|Overall Study|Safety Reasons|0
6109103|NCT00811577|9727630|FG000|Overall Study|Lost to Follow-up|7
6109104|NCT00811577|9727631|FG001|Overall Study|Lost to Follow-up|1
6109105|NCT00811577|9727630|FG000|Overall Study|Withdrawal by Subject|3
6109106|NCT00811577|9727631|FG001|Overall Study|Withdrawal by Subject|0
6109107|NCT00811642|9727680|FG000|Overall Study|Adverse Event|3
6109108|NCT00811642|9727680|FG000|Overall Study|Protocol Violation|1
6109109|NCT00811642|9727680|FG000|Overall Study|Death|2
6109110|NCT00811642|9727680|FG000|Overall Study|Withdrawal by Subject|7
6109111|NCT00811642|9727680|FG000|Overall Study|Cumulative use of antifungal agent|2
6109112|NCT00811655|9727684|FG000|Overall Study|Physician Decision|1
6109113|NCT00811720|9727690|FG000|All Randomised Patients|Did not receive placebo/nalmefene|2
6109114|NCT00811720|9727691|FG001|All Randomised Patients|Did not receive placebo/nalmefene|4
6109115|NCT00811720|9727690|FG000|All Treated Patients|Adverse Event|20
6109116|NCT00811720|9727691|FG001|All Treated Patients|Adverse Event|62
6109117|NCT00811720|9727690|FG000|All Treated Patients|Lack of Efficacy|22
6109118|NCT00811720|9727691|FG001|All Treated Patients|Lack of Efficacy|18
6109119|NCT00811720|9727690|FG000|All Treated Patients|Non-compliance|0
6109120|NCT00811720|9727691|FG001|All Treated Patients|Non-compliance|14
6109121|NCT00811720|9727690|FG000|All Treated Patients|Protocol Violation|9
6109122|NCT00811720|9727691|FG001|All Treated Patients|Protocol Violation|16
6109123|NCT00811720|9727690|FG000|All Treated Patients|Withdrawal by Subject|28
6109124|NCT00811720|9727691|FG001|All Treated Patients|Withdrawal by Subject|34
6109125|NCT00811720|9727690|FG000|All Treated Patients|Lost to Follow-up|10
6109126|NCT00811720|9727691|FG001|All Treated Patients|Lost to Follow-up|16
6109127|NCT00811720|9727690|FG000|All Treated Patients|Other Reason|7
6109128|NCT00811720|9727691|FG001|All Treated Patients|Other Reason|4
6109129|NCT00811733|9727699|FG000|Overall Study|Investigator Discretion|10
6109130|NCT00811733|9727700|FG001|Overall Study|Investigator Discretion|8
6109131|NCT00811733|9727699|FG000|Overall Study|Withdrawal by Subject|1
6109132|NCT00811733|9727700|FG001|Overall Study|Withdrawal by Subject|2
6109133|NCT00811928|9727718|FG000|Overall Study|AEs and SAEs Including Death|7
6109134|NCT00811928|9727719|FG001|Overall Study|AEs and SAEs Including Death|11
6109135|NCT00811928|9727718|FG000|Overall Study|Withdrawal by Subject|18
6109136|NCT00811928|9727719|FG001|Overall Study|Withdrawal by Subject|12
6109137|NCT00811928|9727718|FG000|Overall Study|Did Not Take Study Drug|3
6109138|NCT00811928|9727719|FG001|Overall Study|Did Not Take Study Drug|0
6109139|NCT00811928|9727718|FG000|Overall Study|Without Primary Efficacy Endpoint Data|7
6109140|NCT00811928|9727719|FG001|Overall Study|Without Primary Efficacy Endpoint Data|4
6109141|NCT00811928|9727718|FG000|Overall Study|Investigator Decision|2
6109142|NCT00811928|9727719|FG001|Overall Study|Investigator Decision|1
6109143|NCT00811928|9727718|FG000|Overall Study|Poor Compliance|2
6109144|NCT00811928|9727719|FG001|Overall Study|Poor Compliance|5
6109145|NCT00811941|9727727|FG000|All Randomised Patients|Did not receive placebo/nalmefene|2
6109146|NCT00811941|9727728|FG001|All Randomised Patients|Did not receive placebo/nalmefene|8
6109147|NCT00811941|9727727|FG000|All Treated Patients|Adverse Event|2
6109148|NCT00811941|9727728|FG001|All Treated Patients|Adverse Event|43
6109149|NCT00811941|9727727|FG000|All Treated Patients|Lack of Efficacy|2
6109150|NCT00811941|9727728|FG001|All Treated Patients|Lack of Efficacy|3
6109151|NCT00811941|9727727|FG000|All Treated Patients|Non-compliance|1
6109152|NCT00811941|9727728|FG001|All Treated Patients|Non-compliance|8
6109153|NCT00811941|9727727|FG000|All Treated Patients|Protocol Violation|5
6109154|NCT00811941|9727728|FG001|All Treated Patients|Protocol Violation|17
6109155|NCT00811941|9727727|FG000|All Treated Patients|Withdrawal by Subject|35
6109156|NCT00811941|9727728|FG001|All Treated Patients|Withdrawal by Subject|94
6109157|NCT00811941|9727727|FG000|All Treated Patients|Lost to Follow-up|3
6109158|NCT00811941|9727728|FG001|All Treated Patients|Lost to Follow-up|12
6109159|NCT00811941|9727727|FG000|All Treated Patients|Other Reason|4
6109160|NCT00811941|9727728|FG001|All Treated Patients|Other Reason|14
6109161|NCT00811954|9727737|FG000|Overall Study|Death|10
6109162|NCT00811954|9727738|FG001|Overall Study|Death|6
6109163|NCT00811954|9727739|FG002|Overall Study|Death|13
6109164|NCT00811954|9727737|FG000|Overall Study|Lost to Follow-up|29
6109165|NCT00811954|9727738|FG001|Overall Study|Lost to Follow-up|23
6109166|NCT00811954|9727739|FG002|Overall Study|Lost to Follow-up|34
6109167|NCT00811954|9727737|FG000|Overall Study|Not able to get to clinic|28
6109168|NCT00811954|9727738|FG001|Overall Study|Not able to get to clinic|35
6109169|NCT00811954|9727739|FG002|Overall Study|Not able to get to clinic|30
6109170|NCT00811954|9727737|FG000|Overall Study|Not willing to adhere to requirements|12
6109171|NCT00811954|9727738|FG001|Overall Study|Not willing to adhere to requirements|2
6109172|NCT00811954|9727739|FG002|Overall Study|Not willing to adhere to requirements|16
6109173|NCT00811954|9727737|FG000|Overall Study|Withdraw consent prior study completion|4
6109174|NCT00811954|9727738|FG001|Overall Study|Withdraw consent prior study completion|6
6109175|NCT00811954|9727739|FG002|Overall Study|Withdraw consent prior study completion|5
6109176|NCT00811954|9727737|FG000|Overall Study|Site Closure|4
6109177|NCT00811954|9727738|FG001|Overall Study|Site Closure|0
6109178|NCT00811954|9727739|FG002|Overall Study|Site Closure|1
6109179|NCT00811954|9727737|FG000|Overall Study|Severe Debilitation|2
6109180|NCT00811954|9727738|FG001|Overall Study|Severe Debilitation|0
6109181|NCT00811954|9727739|FG002|Overall Study|Severe Debilitation|1
6109182|NCT00811954|9727737|FG000|Overall Study|Complete Protocol: No follow-up|0
6109183|NCT00811954|9727738|FG001|Overall Study|Complete Protocol: No follow-up|0
6109184|NCT00811954|9727739|FG002|Overall Study|Complete Protocol: No follow-up|1
6109185|NCT00812097|9727751|FG000|Overall Study|Death|3
6109186|NCT00812097|9727752|FG001|Overall Study|Death|10
6109187|NCT00812097|9727753|FG002|Overall Study|Death|3
6109188|NCT00812097|9727754|FG003|Overall Study|Death|3
6109189|NCT00812097|9727751|FG000|Overall Study|Withdrawal by Subject|14
6109190|NCT00812097|9727752|FG001|Overall Study|Withdrawal by Subject|12
6109191|NCT00812097|9727753|FG002|Overall Study|Withdrawal by Subject|8
6109192|NCT00812097|9727754|FG003|Overall Study|Withdrawal by Subject|2
6109193|NCT00812097|9727751|FG000|Overall Study|Lost to Follow-up|90
6109194|NCT00812097|9727752|FG001|Overall Study|Lost to Follow-up|14
6109195|NCT00812097|9727753|FG002|Overall Study|Lost to Follow-up|17
6109196|NCT00812097|9727754|FG003|Overall Study|Lost to Follow-up|5
6109197|NCT00812097|9727751|FG000|Overall Study|Explantation of study device(s)|27
6109198|NCT00812097|9727752|FG001|Overall Study|Explantation of study device(s)|29
6109199|NCT00812097|9727753|FG002|Overall Study|Explantation of study device(s)|14
6109200|NCT00812097|9727754|FG003|Overall Study|Explantation of study device(s)|20
6109201|NCT00812097|9727751|FG000|Overall Study|Unknown reasons and patient/doctor moves|111
6109202|NCT00812097|9727752|FG001|Overall Study|Unknown reasons and patient/doctor moves|24
6109203|NCT00812097|9727753|FG002|Overall Study|Unknown reasons and patient/doctor moves|15
6109204|NCT00812097|9727754|FG003|Overall Study|Unknown reasons and patient/doctor moves|5
6109205|NCT00812253|9727770|FG000|Overall Study|Withdrawal by Subject|3
6109206|NCT00812253|9727771|FG001|Overall Study|Withdrawal by Subject|2
6109207|NCT00812253|9727770|FG000|Overall Study|Protocol Violation|1
6109208|NCT00812253|9727771|FG001|Overall Study|Protocol Violation|1
6109209|NCT00812253|9727770|FG000|Overall Study|Lost to Follow-up|2
6109210|NCT00812253|9727771|FG001|Overall Study|Lost to Follow-up|0
6109211|NCT00812331|9727782|FG000|Overall Study|Adverse Event|1
6109212|NCT00812331|9727783|FG001|Overall Study|Adverse Event|0
6109213|NCT00812331|9727784|FG002|Overall Study|Adverse Event|0
6109214|NCT00812331|9727785|FG003|Overall Study|Adverse Event|0
6109215|NCT00812331|9727786|FG004|Overall Study|Adverse Event|0
6109216|NCT00812461|9727796|FG000|All Randomised Patients|Did not receive placebo/nalmefene|23
6109217|NCT00812461|9727797|FG001|All Randomised Patients|Did not receive placebo/nalmefene|17
6109218|NCT00812461|9727796|FG000|All Treated Patients|Adverse Event|8
6109219|NCT00812461|9727797|FG001|All Treated Patients|Adverse Event|15
6109220|NCT00812461|9727796|FG000|All Treated Patients|Lack of Efficacy|13
6109221|NCT00812461|9727797|FG001|All Treated Patients|Lack of Efficacy|7
6109222|NCT00812461|9727796|FG000|All Treated Patients|Non-compliance|6
6109223|NCT00812461|9727797|FG001|All Treated Patients|Non-compliance|9
6109224|NCT00812461|9727796|FG000|All Treated Patients|Protocol Violation|36
6109225|NCT00812461|9727797|FG001|All Treated Patients|Protocol Violation|27
6109226|NCT00812461|9727796|FG000|All Treated Patients|Withdrawal by Subject|45
6109227|NCT00812461|9727797|FG001|All Treated Patients|Withdrawal by Subject|54
6109228|NCT00812461|9727796|FG000|All Treated Patients|Lost to Follow-up|11
6109229|NCT00812461|9727797|FG001|All Treated Patients|Lost to Follow-up|14
6109230|NCT00812461|9727796|FG000|All Treated Patients|Other Reason|13
6109231|NCT00812461|9727797|FG001|All Treated Patients|Other Reason|21
6109232|NCT00812487|9727805|FG000|Overall Study|Lost to Follow-up|2
6109233|NCT00812487|9727806|FG001|Overall Study|Lost to Follow-up|0
6109234|NCT00812487|9727805|FG000|Overall Study|Withdrawal by Subject|3
6109235|NCT00812487|9727806|FG001|Overall Study|Withdrawal by Subject|2
6109236|NCT00812487|9727805|FG000|Overall Study|Transfer to ICU prior to intervention|1
6109237|NCT00812487|9727806|FG001|Overall Study|Transfer to ICU prior to intervention|0
6109238|NCT00812487|9727805|FG000|Overall Study|Protocol Violation|0
6109239|NCT00812487|9727806|FG001|Overall Study|Protocol Violation|1
6109240|NCT00812565|9727820|FG000|Overall Study|Did Not Receive Study Medication|1
6109241|NCT00812565|9727821|FG001|Overall Study|Did Not Receive Study Medication|1
6109242|NCT00812565|9727822|FG002|Overall Study|Did Not Receive Study Medication|0
6109243|NCT00812565|9727823|FG003|Overall Study|Did Not Receive Study Medication|0
6109244|NCT00812565|9727824|FG004|Overall Study|Did Not Receive Study Medication|0
6109245|NCT00812565|9727825|FG005|Overall Study|Did Not Receive Study Medication|0
6109246|NCT00812565|9727826|FG006|Overall Study|Did Not Receive Study Medication|0
6109247|NCT00812565|9727827|FG007|Overall Study|Did Not Receive Study Medication|0
6109248|NCT00812565|9727820|FG000|Overall Study|Adverse Event|0
6109249|NCT00812565|9727821|FG001|Overall Study|Adverse Event|0
6109250|NCT00812565|9727822|FG002|Overall Study|Adverse Event|0
6109251|NCT00812565|9727823|FG003|Overall Study|Adverse Event|2
6109252|NCT00812565|9727824|FG004|Overall Study|Adverse Event|0
6109253|NCT00812565|9727825|FG005|Overall Study|Adverse Event|0
6109254|NCT00812565|9727826|FG006|Overall Study|Adverse Event|0
6109255|NCT00812565|9727827|FG007|Overall Study|Adverse Event|1
6109256|NCT00812565|9727820|FG000|Overall Study|Did Not Come to Study Visit|1
6109257|NCT00812565|9727821|FG001|Overall Study|Did Not Come to Study Visit|0
6109258|NCT00812565|9727822|FG002|Overall Study|Did Not Come to Study Visit|0
6109259|NCT00812565|9727823|FG003|Overall Study|Did Not Come to Study Visit|0
6109260|NCT00812565|9727824|FG004|Overall Study|Did Not Come to Study Visit|0
6109261|NCT00812565|9727825|FG005|Overall Study|Did Not Come to Study Visit|0
6109262|NCT00812565|9727826|FG006|Overall Study|Did Not Come to Study Visit|0
6109263|NCT00812565|9727827|FG007|Overall Study|Did Not Come to Study Visit|0
6109264|NCT00812565|9727820|FG000|Overall Study|Withdrawal of Consent|1
6109265|NCT00812565|9727821|FG001|Overall Study|Withdrawal of Consent|0
6109266|NCT00812565|9727822|FG002|Overall Study|Withdrawal of Consent|0
6109267|NCT00812565|9727823|FG003|Overall Study|Withdrawal of Consent|0
6109268|NCT00812565|9727824|FG004|Overall Study|Withdrawal of Consent|1
6109269|NCT00812565|9727825|FG005|Overall Study|Withdrawal of Consent|0
6109270|NCT00812565|9727826|FG006|Overall Study|Withdrawal of Consent|0
6109271|NCT00812565|9727827|FG007|Overall Study|Withdrawal of Consent|0
6109272|NCT00812565|9727820|FG000|Overall Study|Reason Not Specified|0
6109273|NCT00812565|9727821|FG001|Overall Study|Reason Not Specified|0
6109274|NCT00812565|9727822|FG002|Overall Study|Reason Not Specified|0
6109275|NCT00812565|9727823|FG003|Overall Study|Reason Not Specified|0
6109276|NCT00812565|9727824|FG004|Overall Study|Reason Not Specified|0
6109277|NCT00812565|9727825|FG005|Overall Study|Reason Not Specified|1
6109278|NCT00812565|9727826|FG006|Overall Study|Reason Not Specified|0
6109279|NCT00812565|9727827|FG007|Overall Study|Reason Not Specified|0
6109280|NCT00812812|9727856|FG000|Overall Study|Adverse Event|2
6109281|NCT00812812|9727857|FG001|Overall Study|Adverse Event|1
6109282|NCT00812812|9727856|FG000|Overall Study|Lack of Efficacy|1
6109283|NCT00812812|9727857|FG001|Overall Study|Lack of Efficacy|0
6109284|NCT00812812|9727856|FG000|Overall Study|Lost to Follow-up|0
6109285|NCT00812812|9727857|FG001|Overall Study|Lost to Follow-up|1
6109286|NCT00812812|9727856|FG000|Overall Study|Withdrawal by Subject|0
6109287|NCT00812812|9727857|FG001|Overall Study|Withdrawal by Subject|2
6109288|NCT00812929|9727891|FG000|Washout Period 1 (7 Days)|Physician Decision|0
6109289|NCT00812929|9727892|FG001|Washout Period 1 (7 Days)|Physician Decision|0
6109290|NCT00812929|9727893|FG002|Washout Period 1 (7 Days)|Physician Decision|1
6109291|NCT00812929|9727894|FG003|Washout Period 1 (7 Days)|Physician Decision|0
6109292|NCT00812929|9727895|FG004|Washout Period 1 (7 Days)|Physician Decision|0
6109293|NCT00812929|9727896|FG005|Washout Period 1 (7 Days)|Physician Decision|0
6109294|NCT00812929|9727897|FG006|Washout Period 1 (7 Days)|Physician Decision|0
6109295|NCT00812929|9727898|FG007|Washout Period 1 (7 Days)|Physician Decision|0
6109296|NCT00812929|9727899|FG008|Washout Period 1 (7 Days)|Physician Decision|0
6109297|NCT00812929|9727900|FG009|Washout Period 1 (7 Days)|Physician Decision|0
6109298|NCT00812929|9727891|FG000|Washout Period 2 (7 Days)|Physician Decision|0
6109299|NCT00812929|9727892|FG001|Washout Period 2 (7 Days)|Physician Decision|0
6109300|NCT00812929|9727893|FG002|Washout Period 2 (7 Days)|Physician Decision|0
6109301|NCT00812929|9727894|FG003|Washout Period 2 (7 Days)|Physician Decision|0
6109302|NCT00812929|9727895|FG004|Washout Period 2 (7 Days)|Physician Decision|0
6109303|NCT00812929|9727896|FG005|Washout Period 2 (7 Days)|Physician Decision|0
6109304|NCT00812929|9727897|FG006|Washout Period 2 (7 Days)|Physician Decision|0
6109305|NCT00812929|9727898|FG007|Washout Period 2 (7 Days)|Physician Decision|0
6109306|NCT00812929|9727899|FG008|Washout Period 2 (7 Days)|Physician Decision|0
6109307|NCT00812929|9727900|FG009|Washout Period 2 (7 Days)|Physician Decision|1
6109308|NCT00812929|9727891|FG000|Washout Period 3 (7 Days)|Adverse Event|0
6109309|NCT00812929|9727892|FG001|Washout Period 3 (7 Days)|Adverse Event|0
6109310|NCT00812929|9727893|FG002|Washout Period 3 (7 Days)|Adverse Event|0
6109311|NCT00812929|9727894|FG003|Washout Period 3 (7 Days)|Adverse Event|0
6109312|NCT00812929|9727895|FG004|Washout Period 3 (7 Days)|Adverse Event|0
6109313|NCT00812929|9727896|FG005|Washout Period 3 (7 Days)|Adverse Event|1
6109314|NCT00812929|9727897|FG006|Washout Period 3 (7 Days)|Adverse Event|0
6109315|NCT00812929|9727898|FG007|Washout Period 3 (7 Days)|Adverse Event|0
6109316|NCT00812929|9727899|FG008|Washout Period 3 (7 Days)|Adverse Event|0
6109317|NCT00812929|9727900|FG009|Washout Period 3 (7 Days)|Adverse Event|0
6109318|NCT00812955|9727921|FG000|Overall Study|Adverse Event|7
6109319|NCT00812955|9727922|FG001|Overall Study|Adverse Event|6
6285491|NCT02336282|9997735|FG000|Overall Study|Uncomfortable with technology|1
6109320|NCT00812955|9727923|FG002|Overall Study|Adverse Event|3
6109321|NCT00812955|9727924|FG003|Overall Study|Adverse Event|4
6109322|NCT00812955|9727921|FG000|Overall Study|Lost to Follow-up|2
6109323|NCT00812955|9727922|FG001|Overall Study|Lost to Follow-up|1
6109324|NCT00812955|9727923|FG002|Overall Study|Lost to Follow-up|1
6109325|NCT00812955|9727924|FG003|Overall Study|Lost to Follow-up|2
6109326|NCT00812955|9727921|FG000|Overall Study|Withdrawal by Subject|1
6109327|NCT00812955|9727922|FG001|Overall Study|Withdrawal by Subject|0
6109328|NCT00812955|9727923|FG002|Overall Study|Withdrawal by Subject|1
6109329|NCT00812955|9727924|FG003|Overall Study|Withdrawal by Subject|2
6109330|NCT00812955|9727921|FG000|Overall Study|randomized in error|0
6109331|NCT00812955|9727922|FG001|Overall Study|randomized in error|0
6109332|NCT00812955|9727923|FG002|Overall Study|randomized in error|1
6109333|NCT00812955|9727924|FG003|Overall Study|randomized in error|0
6109334|NCT00812968|9727938|FG000|Overall Study|Relapse after erythroid response|6
6109335|NCT00812968|9727938|FG000|Overall Study|Disease progression|1
6109336|NCT00812968|9727938|FG000|Overall Study|No further treatment required|1
6109337|NCT00812968|9727938|FG000|Overall Study|Study closed due to marketing approval|3
6109338|NCT00812981|9727946|FG000|Overall Study|Other|0
6109339|NCT00812981|9727947|FG001|Overall Study|Other|1
6109340|NCT00813098|9727956|FG000|Overall Study|Adverse Event|2
6109341|NCT00813098|9727957|FG001|Overall Study|Adverse Event|4
6109342|NCT00813098|9727958|FG002|Overall Study|Adverse Event|1
6109343|NCT00813098|9727956|FG000|Overall Study|Withdrawal by Subject|0
6109344|NCT00813098|9727957|FG001|Overall Study|Withdrawal by Subject|1
6109345|NCT00813098|9727958|FG002|Overall Study|Withdrawal by Subject|0
6109346|NCT00813098|9727956|FG000|Overall Study|Inability to complete study procedures|1
6109347|NCT00813098|9727957|FG001|Overall Study|Inability to complete study procedures|0
6109348|NCT00813098|9727958|FG002|Overall Study|Inability to complete study procedures|0
6109349|NCT00813098|9727956|FG000|Overall Study|Lost to Follow-up|0
6109350|NCT00813098|9727957|FG001|Overall Study|Lost to Follow-up|1
6109351|NCT00813098|9727958|FG002|Overall Study|Lost to Follow-up|0
6109352|NCT00813098|9727956|FG000|Overall Study|Protocol Violation|0
6109353|NCT00813098|9727957|FG001|Overall Study|Protocol Violation|0
6109354|NCT00813098|9727958|FG002|Overall Study|Protocol Violation|1
6109355|NCT00813098|9727956|FG000|Overall Study|Principal Investigator decision|0
6109356|NCT00813098|9727957|FG001|Overall Study|Principal Investigator decision|1
6109357|NCT00813098|9727958|FG002|Overall Study|Principal Investigator decision|0
6109358|NCT00813098|9727956|FG000|Overall Study|Withdrew Consent|0
6109359|NCT00813098|9727957|FG001|Overall Study|Withdrew Consent|1
6109360|NCT00813098|9727958|FG002|Overall Study|Withdrew Consent|0
6109361|NCT00813124|9727975|FG000|Overall Study|Death|2
6109362|NCT00813124|9727975|FG000|Overall Study|Ineligible - Participants did not received Azacytidine|9
6109363|NCT00813124|9727975|FG000|Overall Study|Withdrawal by Subject|1
6109364|NCT00813150|9727981|FG000|Treatment Period|Adverse Event|16
6109365|NCT00813150|9727982|FG001|Treatment Period|Adverse Event|15
6109366|NCT00813150|9727981|FG000|Treatment Period|Death|2
6109367|NCT00813150|9727982|FG001|Treatment Period|Death|0
6109368|NCT00813150|9727981|FG000|Treatment Period|Progressive disease|1
6109369|NCT00813150|9727982|FG001|Treatment Period|Progressive disease|0
6109370|NCT00813150|9727981|FG000|Treatment Period|Complete response|0
6109371|NCT00813150|9727982|FG001|Treatment Period|Complete response|1
6109372|NCT00813150|9727981|FG000|Treatment Period|Stable disease|1
6109373|NCT00813150|9727982|FG001|Treatment Period|Stable disease|2
6109374|NCT00813150|9727981|FG000|Treatment Period|Protocol Violation|3
6109375|NCT00813150|9727982|FG001|Treatment Period|Protocol Violation|4
6109376|NCT00813150|9727981|FG000|Treatment Period|Withdrawal by Subject|5
6109377|NCT00813150|9727982|FG001|Treatment Period|Withdrawal by Subject|3
6109378|NCT00813150|9727981|FG000|Treatment Period|Non compliance|0
6109379|NCT00813150|9727982|FG001|Treatment Period|Non compliance|1
6109380|NCT00813150|9727981|FG000|Treatment Period|Reason not specified|3
6109381|NCT00813150|9727982|FG001|Treatment Period|Reason not specified|4
6109382|NCT00813150|9727981|FG000|Treatment Period|Data not available|1
6109383|NCT00813150|9727982|FG001|Treatment Period|Data not available|2
6109384|NCT00813150|9727981|FG000|Long Term Follow-up|Death|0
6109385|NCT00813150|9727982|FG001|Long Term Follow-up|Death|4
6109386|NCT00813150|9727981|FG000|Long Term Follow-up|Other|0
6109387|NCT00813150|9727982|FG001|Long Term Follow-up|Other|3
6109388|NCT00813150|9727981|FG000|Long Term Follow-up|Lost to Follow-up|2
6109389|NCT00813150|9727982|FG001|Long Term Follow-up|Lost to Follow-up|0
6109390|NCT00813150|9727981|FG000|Long Term Follow-up|Progression/Relapse|22
6109391|NCT00813150|9727982|FG001|Long Term Follow-up|Progression/Relapse|24
6109392|NCT00813293|9728001|FG000|Overall Study|Intercurrent illness|1
6109393|NCT00813293|9728002|FG001|Overall Study|Intercurrent illness|0
6109394|NCT00813293|9728001|FG000|Overall Study|Adverse Event|0
6285492|NCT02336282|9997735|FG000|Overall Study|Lost to Follow-up|1
6109395|NCT00813293|9728002|FG001|Overall Study|Adverse Event|1
6109396|NCT00813358|9728017|FG000|Overall Study|Death|32
6109397|NCT00813358|9728017|FG000|Overall Study|Lost to Follow-up|12
6109398|NCT00813358|9728017|FG000|Overall Study|other endpoints|5
6109399|NCT00813358|9728017|FG000|Overall Study|Withdrawal by Subject|20
6109400|NCT00813488|9728021|FG000|Titration Period 1|Adverse Event|6
6109401|NCT00813488|9728022|FG001|Titration Period 1|Adverse Event|1
6109402|NCT00813488|9728021|FG000|Titration Period 1|Lack of Efficacy|9
6109403|NCT00813488|9728022|FG001|Titration Period 1|Lack of Efficacy|7
6109404|NCT00813488|9728021|FG000|Titration Period 1|Withdrawal by Subject|2
6109405|NCT00813488|9728022|FG001|Titration Period 1|Withdrawal by Subject|2
6109406|NCT00813488|9728021|FG000|Titration Period 1|Protocol Violation|4
6109407|NCT00813488|9728022|FG001|Titration Period 1|Protocol Violation|3
6109408|NCT00813488|9728021|FG000|Titration Period 1|Non-compliance to study medication|4
6109409|NCT00813488|9728022|FG001|Titration Period 1|Non-compliance to study medication|1
6109410|NCT00813488|9728021|FG000|Titration Period 1|Non-compliance to study procedures|2
6109411|NCT00813488|9728022|FG001|Titration Period 1|Non-compliance to study procedures|2
6109412|NCT00813488|9728021|FG000|Titration Period 1|Technical Difficulties|0
6109413|NCT00813488|9728022|FG001|Titration Period 1|Technical Difficulties|1
6109414|NCT00813488|9728021|FG000|Titration Period 2|Adverse Event|2
6109415|NCT00813488|9728022|FG001|Titration Period 2|Adverse Event|3
6109416|NCT00813488|9728021|FG000|Titration Period 2|Lack of Efficacy|8
6109417|NCT00813488|9728022|FG001|Titration Period 2|Lack of Efficacy|4
6109418|NCT00813488|9728021|FG000|Titration Period 2|Protocol Violation|3
6109419|NCT00813488|9728022|FG001|Titration Period 2|Protocol Violation|2
6109420|NCT00813488|9728021|FG000|Titration Period 2|Lost to Follow-up|1
6109421|NCT00813488|9728022|FG001|Titration Period 2|Lost to Follow-up|0
6109422|NCT00813488|9728021|FG000|Titration Period 2|Non-compliance with study procedures|2
6109423|NCT00813488|9728022|FG001|Titration Period 2|Non-compliance with study procedures|1
6109424|NCT00813488|9728021|FG000|Double-blind Treatment Period 1|Adverse Event|1
6109425|NCT00813488|9728022|FG001|Double-blind Treatment Period 1|Adverse Event|1
6109426|NCT00813488|9728021|FG000|Double-blind Treatment Period 1|Withdrawal by Subject|0
6109427|NCT00813488|9728022|FG001|Double-blind Treatment Period 1|Withdrawal by Subject|1
6109428|NCT00813488|9728021|FG000|Double-blind Treatment Period 1|Protocol Violation|0
6109429|NCT00813488|9728022|FG001|Double-blind Treatment Period 1|Protocol Violation|2
6109430|NCT00813488|9728021|FG000|Double-blind Treatment Period 1|Lost to Follow-up|0
6109431|NCT00813488|9728022|FG001|Double-blind Treatment Period 1|Lost to Follow-up|1
6109432|NCT00813488|9728021|FG000|Double-blind Treatment Period 2|Adverse Event|1
6109433|NCT00813488|9728022|FG001|Double-blind Treatment Period 2|Adverse Event|0
6109434|NCT00813488|9728021|FG000|Double-blind Treatment Period 2|Withdrawal by Subject|1
6109435|NCT00813488|9728022|FG001|Double-blind Treatment Period 2|Withdrawal by Subject|1
6109436|NCT00813488|9728021|FG000|Double-blind Treatment Period 2|Protocol Violation|2
6109437|NCT00813488|9728022|FG001|Double-blind Treatment Period 2|Protocol Violation|0
6109438|NCT00813488|9728021|FG000|Double-blind Treatment Period 2|Other|1
6109439|NCT00813488|9728022|FG001|Double-blind Treatment Period 2|Other|0
6109440|NCT00813488|9728021|FG000|Open-label Extension|Adverse Event|1
6109441|NCT00813488|9728022|FG001|Open-label Extension|Adverse Event|2
6109442|NCT00813488|9728021|FG000|Open-label Extension|Lack of Efficacy|3
6109443|NCT00813488|9728022|FG001|Open-label Extension|Lack of Efficacy|0
6109444|NCT00813488|9728021|FG000|Open-label Extension|Withdrawal by Subject|0
6109445|NCT00813488|9728022|FG001|Open-label Extension|Withdrawal by Subject|2
6109446|NCT00813488|9728021|FG000|Open-label Extension|Protocol Violation|1
6109447|NCT00813488|9728022|FG001|Open-label Extension|Protocol Violation|2
6109448|NCT00813488|9728021|FG000|Open-label Extension|Non-compliance study medication|4
6109449|NCT00813488|9728022|FG001|Open-label Extension|Non-compliance study medication|0
6109450|NCT00813488|9728021|FG000|Open-label Extension|Non-compliance study procedures|2
6109451|NCT00813488|9728022|FG001|Open-label Extension|Non-compliance study procedures|1
6109452|NCT00813488|9728021|FG000|Open-label Extension|Other|1
6109453|NCT00813488|9728022|FG001|Open-label Extension|Other|0
6109454|NCT00813592|9728032|FG000|Overall Study|Disease assessment was not completed per|2
6109455|NCT00813709|9728040|FG000|Double Blind Period|Adverse Event|4
6109456|NCT00813709|9728041|FG001|Double Blind Period|Adverse Event|1
6109457|NCT00813709|9728042|FG002|Double Blind Period|Adverse Event|4
6109458|NCT00813709|9728043|FG003|Double Blind Period|Adverse Event|0
6109459|NCT00813709|9728044|FG004|Double Blind Period|Adverse Event|0
6109460|NCT00813709|9728045|FG005|Double Blind Period|Adverse Event|0
6109461|NCT00813709|9728040|FG000|Double Blind Period|Lost to Follow-up|3
6109462|NCT00813709|9728041|FG001|Double Blind Period|Lost to Follow-up|2
6109463|NCT00813709|9728042|FG002|Double Blind Period|Lost to Follow-up|2
6109464|NCT00813709|9728043|FG003|Double Blind Period|Lost to Follow-up|0
6109465|NCT00813709|9728044|FG004|Double Blind Period|Lost to Follow-up|0
6109466|NCT00813709|9728045|FG005|Double Blind Period|Lost to Follow-up|0
6109467|NCT00813709|9728040|FG000|Double Blind Period|Switched to open label phase|9
6109468|NCT00813709|9728041|FG001|Double Blind Period|Switched to open label phase|26
6109469|NCT00813709|9728042|FG002|Double Blind Period|Switched to open label phase|18
6206324|NCT01542788|9869685|FG001|Overall Study|Lost to Follow-up|0
6109470|NCT00813709|9728043|FG003|Double Blind Period|Switched to open label phase|0
6109471|NCT00813709|9728044|FG004|Double Blind Period|Switched to open label phase|0
6109472|NCT00813709|9728045|FG005|Double Blind Period|Switched to open label phase|0
6109473|NCT00813709|9728040|FG000|Double Blind Period|Randomized but not treated|1
6109474|NCT00813709|9728041|FG001|Double Blind Period|Randomized but not treated|3
6109475|NCT00813709|9728042|FG002|Double Blind Period|Randomized but not treated|1
6109476|NCT00813709|9728043|FG003|Double Blind Period|Randomized but not treated|0
6109477|NCT00813709|9728044|FG004|Double Blind Period|Randomized but not treated|0
6109478|NCT00813709|9728045|FG005|Double Blind Period|Randomized but not treated|0
6109479|NCT00813709|9728040|FG000|Double Blind Period|Other|14
6109480|NCT00813709|9728041|FG001|Double Blind Period|Other|9
6109481|NCT00813709|9728042|FG002|Double Blind Period|Other|6
6109482|NCT00813709|9728043|FG003|Double Blind Period|Other|0
6109483|NCT00813709|9728044|FG004|Double Blind Period|Other|0
6109484|NCT00813709|9728045|FG005|Double Blind Period|Other|0
6109485|NCT00813709|9728040|FG000|Open Label Period|Adverse Event|0
6109486|NCT00813709|9728041|FG001|Open Label Period|Adverse Event|0
6109487|NCT00813709|9728042|FG002|Open Label Period|Adverse Event|0
6109488|NCT00813709|9728043|FG003|Open Label Period|Adverse Event|5
6109489|NCT00813709|9728044|FG004|Open Label Period|Adverse Event|4
6109490|NCT00813709|9728045|FG005|Open Label Period|Adverse Event|3
6109491|NCT00813709|9728040|FG000|Open Label Period|Lack of Efficacy|0
6109492|NCT00813709|9728041|FG001|Open Label Period|Lack of Efficacy|0
6109493|NCT00813709|9728042|FG002|Open Label Period|Lack of Efficacy|0
6109494|NCT00813709|9728043|FG003|Open Label Period|Lack of Efficacy|3
6109495|NCT00813709|9728044|FG004|Open Label Period|Lack of Efficacy|1
6109496|NCT00813709|9728045|FG005|Open Label Period|Lack of Efficacy|1
6109497|NCT00813709|9728040|FG000|Open Label Period|Randomized but not treated|0
6109498|NCT00813709|9728041|FG001|Open Label Period|Randomized but not treated|0
6109499|NCT00813709|9728042|FG002|Open Label Period|Randomized but not treated|0
6109500|NCT00813709|9728043|FG003|Open Label Period|Randomized but not treated|1
6109501|NCT00813709|9728044|FG004|Open Label Period|Randomized but not treated|0
6109502|NCT00813709|9728045|FG005|Open Label Period|Randomized but not treated|1
6109503|NCT00813709|9728040|FG000|Open Label Period|Other|0
6109504|NCT00813709|9728041|FG001|Open Label Period|Other|0
6109505|NCT00813709|9728042|FG002|Open Label Period|Other|0
6109506|NCT00813709|9728043|FG003|Open Label Period|Other|11
6109507|NCT00813709|9728044|FG004|Open Label Period|Other|5
6109508|NCT00813709|9728045|FG005|Open Label Period|Other|6
6109509|NCT00813748|9728076|FG000|Skin Test Substudy|Physician Decision|0
6109510|NCT00813748|9728077|FG001|Skin Test Substudy|Physician Decision|1
6109511|NCT00813761|9728087|FG000|Phase 1 (Baseline to 4 Weeks)|Pregnancy|2
6109512|NCT00813761|9728088|FG001|Phase 1 (Baseline to 4 Weeks)|Pregnancy|0
6109513|NCT00813761|9728089|FG002|Phase 1 (Baseline to 4 Weeks)|Pregnancy|0
6109514|NCT00813761|9728090|FG003|Phase 1 (Baseline to 4 Weeks)|Pregnancy|0
6109515|NCT00813761|9728087|FG000|Phase 1 (Baseline to 4 Weeks)|Lost to Follow-up|0
6109516|NCT00813761|9728088|FG001|Phase 1 (Baseline to 4 Weeks)|Lost to Follow-up|0
6109517|NCT00813761|9728089|FG002|Phase 1 (Baseline to 4 Weeks)|Lost to Follow-up|3
6109518|NCT00813761|9728090|FG003|Phase 1 (Baseline to 4 Weeks)|Lost to Follow-up|1
6109519|NCT00813761|9728087|FG000|Phase 1 (Baseline to 4 Weeks)|Protocol Violation|1
6109520|NCT00813761|9728088|FG001|Phase 1 (Baseline to 4 Weeks)|Protocol Violation|1
6109521|NCT00813761|9728089|FG002|Phase 1 (Baseline to 4 Weeks)|Protocol Violation|1
6109522|NCT00813761|9728090|FG003|Phase 1 (Baseline to 4 Weeks)|Protocol Violation|0
6109523|NCT00813761|9728087|FG000|Phase 1 (Baseline to 4 Weeks)|poor vision|0
6109524|NCT00813761|9728088|FG001|Phase 1 (Baseline to 4 Weeks)|poor vision|0
6109525|NCT00813761|9728089|FG002|Phase 1 (Baseline to 4 Weeks)|poor vision|3
6109526|NCT00813761|9728090|FG003|Phase 1 (Baseline to 4 Weeks)|poor vision|0
6109527|NCT00813761|9728087|FG000|Phase 1 (Baseline to 4 Weeks)|poor comfort|1
6109528|NCT00813761|9728088|FG001|Phase 1 (Baseline to 4 Weeks)|poor comfort|1
6109529|NCT00813761|9728089|FG002|Phase 1 (Baseline to 4 Weeks)|poor comfort|5
6109530|NCT00813761|9728090|FG003|Phase 1 (Baseline to 4 Weeks)|poor comfort|1
6109531|NCT00813761|9728087|FG000|Phase 1 (Baseline to 4 Weeks)|Withdrawal by Subject|0
6109532|NCT00813761|9728088|FG001|Phase 1 (Baseline to 4 Weeks)|Withdrawal by Subject|1
6109533|NCT00813761|9728089|FG002|Phase 1 (Baseline to 4 Weeks)|Withdrawal by Subject|0
6109534|NCT00813761|9728090|FG003|Phase 1 (Baseline to 4 Weeks)|Withdrawal by Subject|0
6109535|NCT00813761|9728087|FG000|Phase 2 (4 Weeks to 24 Weeks)|Adverse Event|2
6109536|NCT00813761|9728088|FG001|Phase 2 (4 Weeks to 24 Weeks)|Adverse Event|3
6109537|NCT00813761|9728089|FG002|Phase 2 (4 Weeks to 24 Weeks)|Adverse Event|0
6109538|NCT00813761|9728090|FG003|Phase 2 (4 Weeks to 24 Weeks)|Adverse Event|0
6109539|NCT00813761|9728087|FG000|Phase 2 (4 Weeks to 24 Weeks)|Lost to Follow-up|3
6109540|NCT00813761|9728088|FG001|Phase 2 (4 Weeks to 24 Weeks)|Lost to Follow-up|0
6109541|NCT00813761|9728089|FG002|Phase 2 (4 Weeks to 24 Weeks)|Lost to Follow-up|2
6109542|NCT00813761|9728090|FG003|Phase 2 (4 Weeks to 24 Weeks)|Lost to Follow-up|1
6109543|NCT00813761|9728087|FG000|Phase 2 (4 Weeks to 24 Weeks)|Protocol Violation|0
6109544|NCT00813761|9728088|FG001|Phase 2 (4 Weeks to 24 Weeks)|Protocol Violation|1
6109545|NCT00813761|9728089|FG002|Phase 2 (4 Weeks to 24 Weeks)|Protocol Violation|0
6109546|NCT00813761|9728090|FG003|Phase 2 (4 Weeks to 24 Weeks)|Protocol Violation|1
6109547|NCT00813761|9728087|FG000|Phase 2 (4 Weeks to 24 Weeks)|Poor vision|1
6109548|NCT00813761|9728088|FG001|Phase 2 (4 Weeks to 24 Weeks)|Poor vision|1
6109549|NCT00813761|9728089|FG002|Phase 2 (4 Weeks to 24 Weeks)|Poor vision|1
6109550|NCT00813761|9728090|FG003|Phase 2 (4 Weeks to 24 Weeks)|Poor vision|0
6109551|NCT00813761|9728087|FG000|Phase 2 (4 Weeks to 24 Weeks)|Poor comfort|1
6109552|NCT00813761|9728088|FG001|Phase 2 (4 Weeks to 24 Weeks)|Poor comfort|4
6109553|NCT00813761|9728089|FG002|Phase 2 (4 Weeks to 24 Weeks)|Poor comfort|0
6109554|NCT00813761|9728090|FG003|Phase 2 (4 Weeks to 24 Weeks)|Poor comfort|3
6109555|NCT00813761|9728087|FG000|Phase 2 (4 Weeks to 24 Weeks)|Randomization strata filled|9
6109556|NCT00813761|9728088|FG001|Phase 2 (4 Weeks to 24 Weeks)|Randomization strata filled|0
6109557|NCT00813761|9728089|FG002|Phase 2 (4 Weeks to 24 Weeks)|Randomization strata filled|6
6109558|NCT00813761|9728090|FG003|Phase 2 (4 Weeks to 24 Weeks)|Randomization strata filled|0
6109559|NCT00813800|9728106|FG000|Overall Study|Screen Failure after Consent|2
6109560|NCT00813800|9728106|FG000|Overall Study|Adverse Event|1
6109561|NCT00813800|9728106|FG000|Overall Study|Worsening of depression|2
6109562|NCT00813800|9728106|FG000|Overall Study|Physician Decision|1
6109563|NCT00813813|9728112|FG000|Overall Study|Withdrawal by Subject|1
6109564|NCT00813813|9728113|FG001|Overall Study|Withdrawal by Subject|1
6109565|NCT00813813|9728112|FG000|Overall Study|Lost to Follow-up|2
6109566|NCT00813813|9728113|FG001|Overall Study|Lost to Follow-up|7
6109567|NCT00813813|9728112|FG000|Overall Study|Other|0
6109568|NCT00813813|9728113|FG001|Overall Study|Other|1
6109569|NCT00813865|9728119|FG000|Overall Study|Failure to Respond|3
6109570|NCT00813865|9728119|FG000|Overall Study|Lost to Follow-up|3
6109571|NCT00813865|9728119|FG000|Overall Study|Withdrawal by Subject|1
6109572|NCT00813904|9728123|FG000|Overall Study|Death|1
6109573|NCT00813917|9728129|FG000|Overall Study|Adverse Event|0
6109574|NCT00813917|9728130|FG001|Overall Study|Adverse Event|1
6109575|NCT00813917|9728129|FG000|Overall Study|Withdrawal by Subject|3
6109576|NCT00813917|9728130|FG001|Overall Study|Withdrawal by Subject|4
6109577|NCT00813917|9728129|FG000|Overall Study|Lost to Follow-up|3
6109578|NCT00813917|9728130|FG001|Overall Study|Lost to Follow-up|1
6109579|NCT00813943|9728139|FG000|Overall Study|Ongoing at cut-off date|5
6109580|NCT00813943|9728140|FG001|Overall Study|Ongoing at cut-off date|5
6109581|NCT00813943|9728141|FG002|Overall Study|Ongoing at cut-off date|3
6109582|NCT00813995|9728158|FG000|Overall Study|Clinical adverse event|9
6109583|NCT00813995|9728159|FG001|Overall Study|Clinical adverse event|3
6109584|NCT00813995|9728158|FG000|Overall Study|Laboratory adverse event|0
6109585|NCT00813995|9728159|FG001|Overall Study|Laboratory adverse event|2
6109586|NCT00813995|9728158|FG000|Overall Study|Lack of Efficacy|1
6109587|NCT00813995|9728159|FG001|Overall Study|Lack of Efficacy|0
6109588|NCT00813995|9728158|FG000|Overall Study|Lost to Follow-up|4
6109589|NCT00813995|9728159|FG001|Overall Study|Lost to Follow-up|2
6109590|NCT00813995|9728158|FG000|Overall Study|Other reason|2
6109591|NCT00813995|9728159|FG001|Overall Study|Other reason|2
6109592|NCT00813995|9728158|FG000|Overall Study|Protocol Violation|3
6109593|NCT00813995|9728159|FG001|Overall Study|Protocol Violation|2
6109594|NCT00813995|9728158|FG000|Overall Study|Subject moved|4
6109595|NCT00813995|9728159|FG001|Overall Study|Subject moved|0
6109596|NCT00813995|9728158|FG000|Overall Study|Withdrawal by Subject|0
6109597|NCT00813995|9728159|FG001|Overall Study|Withdrawal by Subject|5
6109598|NCT00814164|9728180|FG000|Overall Study|Progression|7
6109599|NCT00814164|9728180|FG000|Overall Study|not stated|7
6109600|NCT00814164|9728180|FG000|Overall Study|Death|5
6109601|NCT00814307|9728213|FG000|Overall Study|Randomized but not treated|1
6109602|NCT00814307|9728214|FG001|Overall Study|Randomized but not treated|0
6109603|NCT00814307|9728215|FG002|Overall Study|Randomized but not treated|0
6109604|NCT00814307|9728216|FG003|Overall Study|Randomized but not treated|0
6109605|NCT00814307|9728213|FG000|Overall Study|Adverse Event|3
6109606|NCT00814307|9728214|FG001|Overall Study|Adverse Event|9
6109607|NCT00814307|9728215|FG002|Overall Study|Adverse Event|3
6109608|NCT00814307|9728216|FG003|Overall Study|Adverse Event|2
6109609|NCT00814307|9728213|FG000|Overall Study|Lack of Efficacy|1
6109610|NCT00814307|9728214|FG001|Overall Study|Lack of Efficacy|1
6109611|NCT00814307|9728215|FG002|Overall Study|Lack of Efficacy|3
6109612|NCT00814307|9728216|FG003|Overall Study|Lack of Efficacy|4
6109613|NCT00814307|9728213|FG000|Overall Study|Other|1
6109614|NCT00814307|9728214|FG001|Overall Study|Other|2
6109615|NCT00814307|9728215|FG002|Overall Study|Other|0
6206325|NCT01542788|9869684|FG000|Overall Study|Death|3
6206326|NCT01542788|9869685|FG001|Overall Study|Death|0
6206327|NCT01542788|9869684|FG000|Overall Study|Protocol Violation|2
6206328|NCT01542788|9869685|FG001|Overall Study|Protocol Violation|0
6206329|NCT01542788|9869684|FG000|Overall Study|Physician Decision|1
6206330|NCT01542788|9869685|FG001|Overall Study|Physician Decision|0
6206331|NCT01542788|9869684|FG000|Overall Study|Withdrawal by Subject|1
6206332|NCT01542788|9869685|FG001|Overall Study|Withdrawal by Subject|0
6206333|NCT01543087|9869727|FG000|Stage 1 (48 Months)|Lost to Follow-up|3
6206334|NCT01543087|9869728|FG001|Stage 1 (48 Months)|Lost to Follow-up|4
6206335|NCT01543087|9869729|FG002|Stage 1 (48 Months)|Lost to Follow-up|12
6206336|NCT01543087|9869730|FG003|Stage 1 (48 Months)|Lost to Follow-up|0
6206337|NCT01543087|9869731|FG004|Stage 1 (48 Months)|Lost to Follow-up|0
6206338|NCT01543087|9869732|FG005|Stage 1 (48 Months)|Lost to Follow-up|0
6206339|NCT01543087|9869727|FG000|Stage 1 (48 Months)|No longer met eligibility criteria|1
6206340|NCT01543087|9869728|FG001|Stage 1 (48 Months)|No longer met eligibility criteria|0
6206341|NCT01543087|9869729|FG002|Stage 1 (48 Months)|No longer met eligibility criteria|1
6206342|NCT01543087|9869730|FG003|Stage 1 (48 Months)|No longer met eligibility criteria|2
6206343|NCT01543087|9869731|FG004|Stage 1 (48 Months)|No longer met eligibility criteria|0
6206344|NCT01543087|9869732|FG005|Stage 1 (48 Months)|No longer met eligibility criteria|0
6206345|NCT01543087|9869727|FG000|Stage 1 (48 Months)|No longer willing to participate|5
6206346|NCT01543087|9869728|FG001|Stage 1 (48 Months)|No longer willing to participate|3
6206347|NCT01543087|9869729|FG002|Stage 1 (48 Months)|No longer willing to participate|18
6206348|NCT01543087|9869730|FG003|Stage 1 (48 Months)|No longer willing to participate|6
6206349|NCT01543087|9869731|FG004|Stage 1 (48 Months)|No longer willing to participate|3
6206350|NCT01543087|9869732|FG005|Stage 1 (48 Months)|No longer willing to participate|0
6206351|NCT01543087|9869727|FG000|Stage 1 (48 Months)|Other than specified|5
6206352|NCT01543087|9869728|FG001|Stage 1 (48 Months)|Other than specified|0
6206353|NCT01543087|9869729|FG002|Stage 1 (48 Months)|Other than specified|9
6206354|NCT01543087|9869730|FG003|Stage 1 (48 Months)|Other than specified|0
6109616|NCT00814307|9728216|FG003|Overall Study|Other|1
6109617|NCT00814307|9728213|FG000|Overall Study|Protocol Violation|2
6109618|NCT00814307|9728214|FG001|Overall Study|Protocol Violation|8
6109619|NCT00814307|9728215|FG002|Overall Study|Protocol Violation|1
6206355|NCT01543087|9869731|FG004|Stage 1 (48 Months)|Other than specified|0
6206356|NCT01543087|9869732|FG005|Stage 1 (48 Months)|Other than specified|0
6206357|NCT01543087|9869727|FG000|Stage 1 (48 Months)|Protocol Violation|0
6206358|NCT01543087|9869728|FG001|Stage 1 (48 Months)|Protocol Violation|3
6206359|NCT01543087|9869729|FG002|Stage 1 (48 Months)|Protocol Violation|0
6206360|NCT01543087|9869730|FG003|Stage 1 (48 Months)|Protocol Violation|0
6206361|NCT01543087|9869731|FG004|Stage 1 (48 Months)|Protocol Violation|0
6206362|NCT01543087|9869732|FG005|Stage 1 (48 Months)|Protocol Violation|0
6206363|NCT01543087|9869727|FG000|Booster Stage (26 Months)|Withdrawal before booster vaccination|0
6206364|NCT01543087|9869728|FG001|Booster Stage (26 Months)|Withdrawal before booster vaccination|1
6206365|NCT01543087|9869729|FG002|Booster Stage (26 Months)|Withdrawal before booster vaccination|0
6206366|NCT01543087|9869730|FG003|Booster Stage (26 Months)|Withdrawal before booster vaccination|0
6206367|NCT01543087|9869731|FG004|Booster Stage (26 Months)|Withdrawal before booster vaccination|2
6206368|NCT01543087|9869732|FG005|Booster Stage (26 Months)|Withdrawal before booster vaccination|0
6206369|NCT01543087|9869727|FG000|Booster Stage (26 Months)|Lost to Follow-up|0
6206370|NCT01543087|9869728|FG001|Booster Stage (26 Months)|Lost to Follow-up|0
6206371|NCT01543087|9869729|FG002|Booster Stage (26 Months)|Lost to Follow-up|1
6206372|NCT01543087|9869730|FG003|Booster Stage (26 Months)|Lost to Follow-up|0
6206373|NCT01543087|9869731|FG004|Booster Stage (26 Months)|Lost to Follow-up|0
6206374|NCT01543087|9869732|FG005|Booster Stage (26 Months)|Lost to Follow-up|0
6206375|NCT01543152|9869773|FG000|Overall Study|Withdrawal by Subject|0
6206376|NCT01543152|9869774|FG001|Overall Study|Withdrawal by Subject|2
6206377|NCT01543152|9869775|FG002|Overall Study|Withdrawal by Subject|0
6206378|NCT01543152|9869776|FG003|Overall Study|Withdrawal by Subject|0
6206379|NCT01543152|9869777|FG004|Overall Study|Withdrawal by Subject|0
6206380|NCT01543204|9869801|FG000|Overall Study|Non-compliance|1
6206381|NCT01543204|9869801|FG000|Overall Study|Adverse Event|1
6206382|NCT01543204|9869801|FG000|Overall Study|Withdrawal by Subject|4
6206383|NCT01543204|9869801|FG000|Overall Study|Requirement for Alternative Therapy|1
6206384|NCT01543204|9869801|FG000|Overall Study|Lost to Follow-up|1
6206385|NCT01543490|9869811|FG000|Overall Study|Adverse Event|4
6206386|NCT01543490|9869812|FG001|Overall Study|Adverse Event|0
6206387|NCT01543490|9869811|FG000|Overall Study|Physician Decision|1
6206388|NCT01543490|9869812|FG001|Overall Study|Physician Decision|0
6206389|NCT01543490|9869811|FG000|Overall Study|Lack of Efficacy|3
6206390|NCT01543490|9869812|FG001|Overall Study|Lack of Efficacy|3
6206391|NCT01543490|9869811|FG000|Overall Study|Lost to Follow-up|5
6206392|NCT01543490|9869812|FG001|Overall Study|Lost to Follow-up|0
6206393|NCT01543490|9869811|FG000|Overall Study|Withdrawal by Subject|2
6206394|NCT01543490|9869812|FG001|Overall Study|Withdrawal by Subject|0
6206395|NCT01543490|9869811|FG000|Overall Study|Other-Various Administrative Reasons|1
6206396|NCT01543490|9869812|FG001|Overall Study|Other-Various Administrative Reasons|2
6206397|NCT01543503|9869820|FG000|Overall Study|Lost to Follow-up|32
6206398|NCT01543503|9869821|FG001|Overall Study|Lost to Follow-up|36
6206399|NCT01543503|9869820|FG000|Overall Study|Adverse Event|9
6206400|NCT01543503|9869821|FG001|Overall Study|Adverse Event|13
6206401|NCT01543503|9869820|FG000|Overall Study|Lack of Efficacy|4
6206402|NCT01543503|9869821|FG001|Overall Study|Lack of Efficacy|16
6206403|NCT01543503|9869820|FG000|Overall Study|Participant withdrew informed consent|8
6206404|NCT01543503|9869821|FG001|Overall Study|Participant withdrew informed consent|10
6206405|NCT01543503|9869820|FG000|Overall Study|Change of jobs|0
6206406|NCT01543503|9869821|FG001|Overall Study|Change of jobs|1
6206407|NCT01543503|9869820|FG000|Overall Study|Intolerance to the biologic treatment|0
6206408|NCT01543503|9869821|FG001|Overall Study|Intolerance to the biologic treatment|1
6206409|NCT01543503|9869820|FG000|Overall Study|Probable overlap of RA with fibromyalgia|1
6206410|NCT01543503|9869821|FG001|Overall Study|Probable overlap of RA with fibromyalgia|0
6206411|NCT01543503|9869820|FG000|Overall Study|Participant did not complete last visit|0
6206412|NCT01543503|9869821|FG001|Overall Study|Participant did not complete last visit|2
6206413|NCT01543503|9869820|FG000|Overall Study|Refused to continue treatment|7
6206414|NCT01543503|9869821|FG001|Overall Study|Refused to continue treatment|0
6206415|NCT01543503|9869820|FG000|Overall Study|Incorrect medication received|1
6206416|NCT01543503|9869821|FG001|Overall Study|Incorrect medication received|0
6206417|NCT01543503|9869820|FG000|Overall Study|Participant moved to another city|2
6206418|NCT01543503|9869821|FG001|Overall Study|Participant moved to another city|0
6206419|NCT01543503|9869820|FG000|Overall Study|Participant will not return for visits|0
6206420|NCT01543503|9869821|FG001|Overall Study|Participant will not return for visits|2
6206421|NCT01543503|9869820|FG000|Overall Study|Participant transferred to another city|1
6206422|NCT01543503|9869821|FG001|Overall Study|Participant transferred to another city|0
6206423|NCT01543503|9869820|FG000|Overall Study|Participant moved to Scotland|1
6206424|NCT01543503|9869821|FG001|Overall Study|Participant moved to Scotland|0
6206425|NCT01543503|9869820|FG000|Overall Study|Participant decision to stop treatment|1
6206426|NCT01543503|9869821|FG001|Overall Study|Participant decision to stop treatment|0
6206427|NCT01543503|9869820|FG000|Overall Study|Investigator did not wish to participate|1
6206428|NCT01543503|9869821|FG001|Overall Study|Investigator did not wish to participate|1
6206429|NCT01543503|9869820|FG000|Overall Study|Participant recruited after closing date|0
6109620|NCT00814307|9728216|FG003|Overall Study|Protocol Violation|1
6109621|NCT00814307|9728213|FG000|Overall Study|Withdrawal by Subject|4
6109622|NCT00814307|9728214|FG001|Overall Study|Withdrawal by Subject|6
6109623|NCT00814307|9728215|FG002|Overall Study|Withdrawal by Subject|0
6109624|NCT00814307|9728216|FG003|Overall Study|Withdrawal by Subject|2
6109625|NCT00814307|9728213|FG000|Overall Study|Death|0
6109626|NCT00814307|9728214|FG001|Overall Study|Death|1
6109627|NCT00814307|9728215|FG002|Overall Study|Death|0
6109628|NCT00814307|9728216|FG003|Overall Study|Death|0
6206430|NCT01543503|9869821|FG001|Overall Study|Participant recruited after closing date|1
6206431|NCT01543503|9869820|FG000|Overall Study|Site stopped participation|5
6206432|NCT01543503|9869821|FG001|Overall Study|Site stopped participation|1
6206433|NCT01543503|9869820|FG000|Overall Study|Participant did not attend a visit|1
6206434|NCT01543503|9869821|FG001|Overall Study|Participant did not attend a visit|0
6206435|NCT01543503|9869820|FG000|Overall Study|Moved to other rheumatologic site|0
6206436|NCT01543503|9869821|FG001|Overall Study|Moved to other rheumatologic site|1
6206437|NCT01543503|9869820|FG000|Overall Study|Participant consented to another study|0
6206438|NCT01543503|9869821|FG001|Overall Study|Participant consented to another study|2
6206439|NCT01543503|9869820|FG000|Overall Study|Participant went to United States|1
6206440|NCT01543503|9869821|FG001|Overall Study|Participant went to United States|0
6206441|NCT01543503|9869820|FG000|Overall Study|Screen failure|1
6206442|NCT01543503|9869821|FG001|Overall Study|Screen failure|0
6206443|NCT01543685|9869847|FG000|Overall Study|Lack of Efficacy|1
6206444|NCT01543685|9869848|FG001|Overall Study|Lack of Efficacy|2
6206445|NCT01543685|9869849|FG002|Overall Study|Lack of Efficacy|2
6206446|NCT01543685|9869850|FG003|Overall Study|Lack of Efficacy|0
6206447|NCT01543685|9869851|FG004|Overall Study|Lack of Efficacy|2
6206448|NCT01543685|9869847|FG000|Overall Study|Adverse Event|2
6285493|NCT02336282|9997735|FG000|Overall Study|Not enough time to complete sessions|2
6285494|NCT02336373|9997751|FG000|Overall Study|Protocol closed early|4
6285495|NCT02336373|9997751|FG000|Overall Study|Physician Decision|14
6285496|NCT02336451|9997766|FG000|Overall Study|Adverse Event|1
6285497|NCT02336451|9997767|FG001|Overall Study|Adverse Event|2
6285498|NCT02336451|9997768|FG002|Overall Study|Adverse Event|0
6285499|NCT02336451|9997769|FG003|Overall Study|Adverse Event|6
6285500|NCT02336451|9997770|FG004|Overall Study|Adverse Event|4
6285501|NCT02336451|9997766|FG000|Overall Study|Death|6
6285502|NCT02336451|9997767|FG001|Overall Study|Death|2
6285503|NCT02336451|9997768|FG002|Overall Study|Death|3
6285504|NCT02336451|9997769|FG003|Overall Study|Death|6
6285505|NCT02336451|9997770|FG004|Overall Study|Death|6
6285506|NCT02336451|9997766|FG000|Overall Study|Physician Decision|9
6285507|NCT02336451|9997767|FG001|Overall Study|Physician Decision|6
6285508|NCT02336451|9997768|FG002|Overall Study|Physician Decision|7
6285509|NCT02336451|9997769|FG003|Overall Study|Physician Decision|16
6285510|NCT02336451|9997770|FG004|Overall Study|Physician Decision|3
6285511|NCT02336451|9997766|FG000|Overall Study|Progressive disease|23
6285512|NCT02336451|9997767|FG001|Overall Study|Progressive disease|26
6285513|NCT02336451|9997768|FG002|Overall Study|Progressive disease|2
6285514|NCT02336451|9997769|FG003|Overall Study|Progressive disease|14
6285515|NCT02336451|9997770|FG004|Overall Study|Progressive disease|4
6285516|NCT02336451|9997766|FG000|Overall Study|Protocol Violation|1
6285517|NCT02336451|9997767|FG001|Overall Study|Protocol Violation|0
6285518|NCT02336451|9997768|FG002|Overall Study|Protocol Violation|0
6285519|NCT02336451|9997769|FG003|Overall Study|Protocol Violation|0
6285520|NCT02336451|9997770|FG004|Overall Study|Protocol Violation|0
6285521|NCT02336451|9997766|FG000|Overall Study|Patient/guardian decision|2
6285522|NCT02336451|9997767|FG001|Overall Study|Patient/guardian decision|4
6285523|NCT02336451|9997768|FG002|Overall Study|Patient/guardian decision|0
6285524|NCT02336451|9997769|FG003|Overall Study|Patient/guardian decision|2
6285525|NCT02336451|9997770|FG004|Overall Study|Patient/guardian decision|1
6285526|NCT02336555|9997786|FG000|Treatment Period 1 (28 Days)|Withdrawal by Subject|0
6285527|NCT02336555|9997787|FG001|Treatment Period 1 (28 Days)|Withdrawal by Subject|1
6285528|NCT02336555|9997786|FG000|Treatment Period 1 (28 Days)|Physician Decision|2
6285529|NCT02336555|9997787|FG001|Treatment Period 1 (28 Days)|Physician Decision|0
6285530|NCT02336555|9997786|FG000|Treatment Period 2 (28 Days)|Adverse Event|0
6285531|NCT02336555|9997787|FG001|Treatment Period 2 (28 Days)|Adverse Event|1
6285532|NCT02336607|9997817|FG000|Overall Study|Physician Decision|1
6285533|NCT02336607|9997818|FG001|Overall Study|Physician Decision|4
6285534|NCT02336607|9997819|FG002|Overall Study|Physician Decision|3
6285535|NCT02336607|9997820|FG003|Overall Study|Physician Decision|15
6285536|NCT02336607|9997817|FG000|Overall Study|Lack of Efficacy|1
6285537|NCT02336607|9997818|FG001|Overall Study|Lack of Efficacy|0
6285538|NCT02336607|9997819|FG002|Overall Study|Lack of Efficacy|0
6285539|NCT02336607|9997820|FG003|Overall Study|Lack of Efficacy|2
6109629|NCT00814320|9728230|FG000|Epoch 1 (IV Treatment)|Withdrawal by Subject|1
6109630|NCT00814320|9728231|FG001|Epoch 1 (IV Treatment)|Withdrawal by Subject|0
6109631|NCT00814320|9728230|FG000|Epoch 1 (IV Treatment)|Participant missed 2 consecutive doses|0
6206449|NCT01543685|9869848|FG001|Overall Study|Adverse Event|1
6206450|NCT01543685|9869849|FG002|Overall Study|Adverse Event|0
6206451|NCT01543685|9869850|FG003|Overall Study|Adverse Event|0
6206452|NCT01543685|9869851|FG004|Overall Study|Adverse Event|2
6285540|NCT02336607|9997817|FG000|Overall Study|Lost to Follow-up|2
6285541|NCT02336607|9997818|FG001|Overall Study|Lost to Follow-up|1
6109632|NCT00814320|9728231|FG001|Epoch 1 (IV Treatment)|Participant missed 2 consecutive doses|2
6109633|NCT00814320|9728230|FG000|Between Epoch 1 (IV) and Epoch 2 Ramp-up|Withdrawal by Subject|0
6109634|NCT00814320|9728231|FG001|Between Epoch 1 (IV) and Epoch 2 Ramp-up|Withdrawal by Subject|1
6109635|NCT00814320|9728230|FG000|"Epoch 2 Ramp-up (Ramp-up)"|Adverse Event|1
6109636|NCT00814320|9728231|FG001|"Epoch 2 Ramp-up (Ramp-up)"|Adverse Event|0
6109637|NCT00814320|9728230|FG000|"Epoch 2 Ramp-up (Ramp-up)"|Geographic Factor|1
6109638|NCT00814320|9728231|FG001|"Epoch 2 Ramp-up (Ramp-up)"|Geographic Factor|0
6109639|NCT00814320|9728230|FG000|Epoch 2 After Ramp-up (SC/rHuPH20)|Adverse Event|1
6109640|NCT00814320|9728231|FG001|Epoch 2 After Ramp-up (SC/rHuPH20)|Adverse Event|4
6109641|NCT00814320|9728230|FG000|Epoch 2 After Ramp-up (SC/rHuPH20)|Withdrawal by Subject|2
6109642|NCT00814320|9728231|FG001|Epoch 2 After Ramp-up (SC/rHuPH20)|Withdrawal by Subject|1
6109643|NCT00814320|9728230|FG000|Epoch 2 After Ramp-up (SC/rHuPH20)|Lost to Follow-up|0
6109644|NCT00814320|9728231|FG001|Epoch 2 After Ramp-up (SC/rHuPH20)|Lost to Follow-up|1
6109645|NCT00814320|9728230|FG000|Epoch 2 After Ramp-up (SC/rHuPH20)|Subject Felt Increased Infections on SC|0
6109646|NCT00814320|9728231|FG001|Epoch 2 After Ramp-up (SC/rHuPH20)|Subject Felt Increased Infections on SC|1
6109647|NCT00814320|9728230|FG000|Epoch 2 After Ramp-up (SC/rHuPH20)|Switched to safety follow-up|0
6109648|NCT00814320|9728231|FG001|Epoch 2 After Ramp-up (SC/rHuPH20)|Switched to safety follow-up|3
6109649|NCT00814346|9728256|FG000|Double-blind Phase (4 Weeks)|Adverse Event|0
6109650|NCT00814346|9728257|FG001|Double-blind Phase (4 Weeks)|Adverse Event|1
6109651|NCT00814346|9728256|FG000|Double-blind Phase (4 Weeks)|Not otherwise specified|0
6109652|NCT00814346|9728257|FG001|Double-blind Phase (4 Weeks)|Not otherwise specified|2
6109653|NCT00814346|9728256|FG000|Open Phase (17 Months)|Adverse Event|5
6109654|NCT00814346|9728257|FG001|Open Phase (17 Months)|Adverse Event|0
6109655|NCT00814346|9728256|FG000|Open Phase (17 Months)|Consent|2
6109656|NCT00814346|9728257|FG001|Open Phase (17 Months)|Consent|0
6109657|NCT00814346|9728256|FG000|Open Phase (17 Months)|Lost to Follow-up|2
6109658|NCT00814346|9728257|FG001|Open Phase (17 Months)|Lost to Follow-up|0
6109659|NCT00814346|9728256|FG000|Open Phase (17 Months)|Not otherwise specified|1
6109660|NCT00814346|9728257|FG001|Open Phase (17 Months)|Not otherwise specified|0
6109661|NCT00814463|9728276|FG000|Overall Study|Lost to Follow-up|1
6109662|NCT00814489|9728284|FG000|Overall Study|Other|2
6109663|NCT00814489|9728285|FG001|Overall Study|Other|0
6109664|NCT00814489|9728286|FG002|Overall Study|Other|1
6109665|NCT00814502|9728298|FG000|Overall Study|Adverse Event|1
6109666|NCT00814502|9728299|FG001|Overall Study|Adverse Event|0
6109667|NCT00814502|9728298|FG000|Overall Study|Withdrawal by Subject|0
6109668|NCT00814502|9728299|FG001|Overall Study|Withdrawal by Subject|2
6206453|NCT01543776|9869865|FG000|Overall Study|Withdrawal by Subject|2
6206454|NCT01543776|9869866|FG001|Overall Study|Withdrawal by Subject|2
6206455|NCT01543828|9869874|FG000|Treatment 2|Lost to Follow-up|1
6206456|NCT01543828|9869875|FG001|Treatment 2|Lost to Follow-up|0
6206457|NCT01543958|9869883|FG000|Overall Study|Loss to follow-up|3
6206458|NCT01543958|9869883|FG000|Overall Study|ART initiation|1
6206459|NCT01544114|9869913|FG000|Overall Study|Withdrawal by Subject|0
6206460|NCT01544114|9869914|FG001|Overall Study|Withdrawal by Subject|0
6206461|NCT01544114|9869915|FG002|Overall Study|Withdrawal by Subject|3
6206462|NCT01544114|9869913|FG000|Overall Study|Lost to Follow-up|0
6206463|NCT01544114|9869914|FG001|Overall Study|Lost to Follow-up|2
6206464|NCT01544114|9869915|FG002|Overall Study|Lost to Follow-up|0
6206465|NCT01544114|9869913|FG000|Overall Study|Adverse Event|1
6206466|NCT01544114|9869914|FG001|Overall Study|Adverse Event|1
6206467|NCT01544114|9869915|FG002|Overall Study|Adverse Event|2
6206468|NCT01544114|9869913|FG000|Overall Study|Protocol Violation|0
6206469|NCT01544114|9869914|FG001|Overall Study|Protocol Violation|1
6206470|NCT01544114|9869915|FG002|Overall Study|Protocol Violation|0
6206471|NCT01544153|9869929|FG000|Overall Study|Under 18|0
6206472|NCT01544153|9869930|FG001|Overall Study|Under 18|1
6206473|NCT01544153|9869931|FG002|Overall Study|Under 18|0
6206474|NCT01544153|9869932|FG003|Overall Study|Under 18|0
6206475|NCT01544153|9869929|FG000|Overall Study|Non-smoker|0
6206476|NCT01544153|9869930|FG001|Overall Study|Non-smoker|0
6206477|NCT01544153|9869931|FG002|Overall Study|Non-smoker|1
6206478|NCT01544153|9869932|FG003|Overall Study|Non-smoker|0
6206479|NCT01544179|9869951|FG000|Overall Study|Death|50
6206480|NCT01544179|9869952|FG001|Overall Study|Death|37
6206481|NCT01544179|9869951|FG000|Overall Study|Lost to Follow-up|0
6206482|NCT01544179|9869952|FG001|Overall Study|Lost to Follow-up|1
6206483|NCT01544179|9869951|FG000|Overall Study|Adverse Event|0
6206484|NCT01544179|9869952|FG001|Overall Study|Adverse Event|1
6206485|NCT01544179|9869951|FG000|Overall Study|Withdrawal by Subject|12
6206486|NCT01544179|9869952|FG001|Overall Study|Withdrawal by Subject|7
6206487|NCT01544179|9869951|FG000|Overall Study|Eligibility criteria not fulfilled|1
6206488|NCT01544179|9869952|FG001|Overall Study|Eligibility criteria not fulfilled|0
6206489|NCT01544309|9869960|FG000|Overall Study|Withdrawal by Subject|12
6206490|NCT01544309|9869961|FG001|Overall Study|Withdrawal by Subject|7
6206491|NCT01544309|9869960|FG000|Overall Study|Protocol Violation|2
6206492|NCT01544309|9869961|FG001|Overall Study|Protocol Violation|1
6206493|NCT01544309|9869960|FG000|Overall Study|Physician Decision|4
6206494|NCT01544309|9869961|FG001|Overall Study|Physician Decision|1
6206495|NCT01544309|9869960|FG000|Overall Study|Not performed pre-dose examination|1
6206496|NCT01544309|9869961|FG001|Overall Study|Not performed pre-dose examination|2
6109669|NCT00814580|9728309|FG000|Overall Study|Adverse Event|6
6109670|NCT00814580|9728310|FG001|Overall Study|Adverse Event|15
6109671|NCT00814580|9728309|FG000|Overall Study|Lack of Efficacy|18
6109672|NCT00814580|9728310|FG001|Overall Study|Lack of Efficacy|25
6109673|NCT00814580|9728309|FG000|Overall Study|Protocol Violation|2
6109674|NCT00814580|9728310|FG001|Overall Study|Protocol Violation|0
6109675|NCT00814580|9728309|FG000|Overall Study|Withdrawal by Subject|2
6109676|NCT00814580|9728310|FG001|Overall Study|Withdrawal by Subject|2
6109677|NCT00814580|9728309|FG000|Overall Study|Other|1
6109678|NCT00814580|9728310|FG001|Overall Study|Other|3
6109679|NCT00814580|9728309|FG000|Overall Study|Did Not Take Drug|2
6109680|NCT00814580|9728310|FG001|Overall Study|Did Not Take Drug|2
6109681|NCT00814632|9728328|FG000|Overall Study|Lack of Efficacy|2
6109682|NCT00814658|9728334|FG000|Overall Study|Lost to Follow-up|0
6109683|NCT00814658|9728335|FG001|Overall Study|Lost to Follow-up|1
6109684|NCT00814658|9728334|FG000|Overall Study|Physician Decision|1
6109685|NCT00814658|9728335|FG001|Overall Study|Physician Decision|0
6109686|NCT00814658|9728334|FG000|Overall Study|Adverse Event|3
6109687|NCT00814658|9728335|FG001|Overall Study|Adverse Event|3
6109688|NCT00814710|9728374|FG000|Overall Study|Adverse Event|1
6109689|NCT00814710|9728375|FG001|Overall Study|Adverse Event|0
6109690|NCT00814710|9728374|FG000|Overall Study|Lost to Follow-up|7
6109691|NCT00814710|9728375|FG001|Overall Study|Lost to Follow-up|3
6109692|NCT00814801|9728399|FG000|Overall Study|Adverse Event|15
6109693|NCT00814801|9728400|FG001|Overall Study|Adverse Event|16
6109694|NCT00814801|9728401|FG002|Overall Study|Adverse Event|19
6109695|NCT00814801|9728399|FG000|Overall Study|Withdrawal by Subject|9
6109696|NCT00814801|9728400|FG001|Overall Study|Withdrawal by Subject|11
6109697|NCT00814801|9728401|FG002|Overall Study|Withdrawal by Subject|14
6109698|NCT00814801|9728399|FG000|Overall Study|Inappropriate as a subject|1
6109699|NCT00814801|9728400|FG001|Overall Study|Inappropriate as a subject|1
6109700|NCT00814801|9728401|FG002|Overall Study|Inappropriate as a subject|1
6109701|NCT00814801|9728399|FG000|Overall Study|Change of patients for CIBIC plus-J|1
6109702|NCT00814801|9728400|FG001|Overall Study|Change of patients for CIBIC plus-J|1
6206497|NCT01544309|9869960|FG000|Overall Study|Administered prohibit prior medication|1
6206498|NCT01544309|9869961|FG001|Overall Study|Administered prohibit prior medication|0
6206499|NCT01544335|9869969|FG000|Overall Study|Lost to Follow-up|27
6206500|NCT01544335|9869969|FG000|Overall Study|Death|4
6206501|NCT01544335|9869969|FG000|Overall Study|Disease progression|3
6206502|NCT01544335|9869969|FG000|Overall Study|Baseline Measurements not Available|19
6206503|NCT01544348|9869981|FG000|Overall Study|Lost to Follow-up|1
6285542|NCT02336607|9997819|FG002|Overall Study|Lost to Follow-up|0
6285543|NCT02336607|9997820|FG003|Overall Study|Lost to Follow-up|21
6285544|NCT02336607|9997817|FG000|Overall Study|Protocol Violation|0
6285545|NCT02336607|9997818|FG001|Overall Study|Protocol Violation|1
6285546|NCT02336607|9997819|FG002|Overall Study|Protocol Violation|1
6285547|NCT02336607|9997820|FG003|Overall Study|Protocol Violation|3
6285548|NCT02336607|9997817|FG000|Overall Study|Adverse Event|0
6285549|NCT02336607|9997818|FG001|Overall Study|Adverse Event|2
6285550|NCT02336607|9997819|FG002|Overall Study|Adverse Event|2
6285551|NCT02336607|9997820|FG003|Overall Study|Adverse Event|26
6285552|NCT02336607|9997817|FG000|Overall Study|Withdrawal by Subject|0
6285553|NCT02336607|9997818|FG001|Overall Study|Withdrawal by Subject|2
6285554|NCT02336607|9997819|FG002|Overall Study|Withdrawal by Subject|0
6285555|NCT02336607|9997820|FG003|Overall Study|Withdrawal by Subject|20
6285556|NCT02336737|9997830|FG000|Overall Study|Withdrawal by Subject|5
6285557|NCT02336737|9997830|FG000|Overall Study|Physician Decision|8
6285558|NCT02336815|9997837|FG000|Overall Study|Disease Progression|45
6285559|NCT02336815|9997838|FG001|Overall Study|Disease Progression|70
6285560|NCT02336815|9997837|FG000|Overall Study|Adverse Event|18
6285561|NCT02336815|9997838|FG001|Overall Study|Adverse Event|39
6285562|NCT02336815|9997837|FG000|Overall Study|Physician Decision|11
6285563|NCT02336815|9997838|FG001|Overall Study|Physician Decision|4
6285564|NCT02336815|9997837|FG000|Overall Study|Withdrawal by Subject|3
6285565|NCT02336815|9997838|FG001|Overall Study|Withdrawal by Subject|2
6285566|NCT02336815|9997837|FG000|Overall Study|Lost to Follow-up|1
6285567|NCT02336815|9997838|FG001|Overall Study|Lost to Follow-up|3
6285568|NCT02336815|9997837|FG000|Overall Study|Other|1
6285569|NCT02336815|9997838|FG001|Overall Study|Other|5
6285570|NCT02337361|9997877|FG000|3-month Follow-up|Lost to Follow-up|19
6285571|NCT02337361|9997878|FG001|3-month Follow-up|Lost to Follow-up|14
6285572|NCT02337361|9997877|FG000|6-month Follow-up|Lost to Follow-up|2
6285573|NCT02337361|9997878|FG001|6-month Follow-up|Lost to Follow-up|4
6285574|NCT02337387|9997889|FG000|Overall Study|Adverse Event|0
6285575|NCT02337387|9997890|FG001|Overall Study|Adverse Event|1
6285576|NCT02337387|9997891|FG002|Overall Study|Adverse Event|0
6285577|NCT02337387|9997892|FG003|Overall Study|Adverse Event|0
6285578|NCT02337387|9997889|FG000|Overall Study|Sponsor Decision to Terminate Study|14
6285579|NCT02337387|9997890|FG001|Overall Study|Sponsor Decision to Terminate Study|7
6285580|NCT02337387|9997891|FG002|Overall Study|Sponsor Decision to Terminate Study|3
6285581|NCT02337387|9997892|FG003|Overall Study|Sponsor Decision to Terminate Study|3
6109703|NCT00814801|9728401|FG002|Overall Study|Change of patients for CIBIC plus-J|0
6109704|NCT00814801|9728399|FG000|Overall Study|Missing or change of caregiver|6
6206504|NCT01544348|9869982|FG001|Overall Study|Lost to Follow-up|0
6206505|NCT01544348|9869983|FG002|Overall Study|Lost to Follow-up|0
6109705|NCT00814801|9728400|FG001|Overall Study|Missing or change of caregiver|2
6109706|NCT00814801|9728401|FG002|Overall Study|Missing or change of caregiver|4
6109707|NCT00814801|9728399|FG000|Overall Study|Non-compliance|0
6109708|NCT00814801|9728400|FG001|Overall Study|Non-compliance|1
6109709|NCT00814801|9728401|FG002|Overall Study|Non-compliance|1
6109710|NCT00814801|9728399|FG000|Overall Study|Other|2
6109711|NCT00814801|9728400|FG001|Overall Study|Other|6
6109712|NCT00814801|9728401|FG002|Overall Study|Other|4
6109713|NCT00814879|9728411|FG000|By Week 24|Cancer Diagnosis|1
6109714|NCT00814879|9728412|FG001|By Week 24|Cancer Diagnosis|0
6109715|NCT00814879|9728411|FG000|By Week 24|Incarceration|0
6109716|NCT00814879|9728412|FG001|By Week 24|Incarceration|1
6109717|NCT00814879|9728411|FG000|By Week 48|Lost to Follow-up|2
6109718|NCT00814879|9728412|FG001|By Week 48|Lost to Follow-up|2
6109719|NCT00814879|9728411|FG000|By Week 48|Death|0
6109720|NCT00814879|9728412|FG001|By Week 48|Death|1
6109721|NCT00815191|9728449|FG000|Overall Study|Protocol Violation|1
6109722|NCT00815191|9728450|FG001|Overall Study|Protocol Violation|1
6109723|NCT00815295|9728459|FG000|Overall Study|Cetuximab hypersensitivity reaction|0
6109724|NCT00815295|9728460|FG001|Overall Study|Cetuximab hypersensitivity reaction|1
6109725|NCT00815295|9728461|FG002|Overall Study|Cetuximab hypersensitivity reaction|3
6109726|NCT00815308|9728469|FG000|Overall Study|Adverse Event|4
6109727|NCT00815308|9728469|FG000|Overall Study|Withdrawal by Subject|0
6109728|NCT00815308|9728469|FG000|Overall Study|Protocol Violation|6
6109729|NCT00815516|9728499|FG000|Overall Study|Death|3
6109730|NCT00815516|9728500|FG001|Overall Study|Death|1
6109731|NCT00815516|9728499|FG000|Overall Study|Physician Decision|1
6109732|NCT00815516|9728500|FG001|Overall Study|Physician Decision|0
6109733|NCT00815659|9728506|FG000|Overall Study|Adverse Event|9
6109734|NCT00815659|9728506|FG000|Overall Study|Withdrawal by Subject|9
6109735|NCT00815659|9728506|FG000|Overall Study|Lost to Follow-up|4
6109736|NCT00815659|9728506|FG000|Overall Study|Protocol Violation|1
6109737|NCT00815919|9728539|FG000|Overall Study|Unrelated Fungal Infection|1
6109738|NCT00815919|9728539|FG000|Overall Study|AML Relapse|1
6109739|NCT00815919|9728539|FG000|Overall Study|Lack of Efficacy|2
6109740|NCT00816023|9728558|FG000|Overall Study|Lost to Follow-up|1
6109741|NCT00816023|9728559|FG001|Overall Study|Lost to Follow-up|1
6109742|NCT00816023|9728560|FG002|Overall Study|Lost to Follow-up|0
6109743|NCT00816023|9728561|FG003|Overall Study|Lost to Follow-up|0
6109744|NCT00816023|9728558|FG000|Overall Study|Withdrawal by Subject|1
6109745|NCT00816023|9728559|FG001|Overall Study|Withdrawal by Subject|0
6109746|NCT00816023|9728560|FG002|Overall Study|Withdrawal by Subject|0
6109747|NCT00816023|9728561|FG003|Overall Study|Withdrawal by Subject|0
6109748|NCT00816023|9728558|FG000|Overall Study|Physician Decision|0
6109749|NCT00816023|9728559|FG001|Overall Study|Physician Decision|0
6109750|NCT00816023|9728560|FG002|Overall Study|Physician Decision|1
6109751|NCT00816023|9728561|FG003|Overall Study|Physician Decision|0
6109752|NCT00816023|9728558|FG000|Overall Study|assessments complete prior to window|1
6109753|NCT00816023|9728559|FG001|Overall Study|assessments complete prior to window|1
6109754|NCT00816023|9728560|FG002|Overall Study|assessments complete prior to window|2
6109755|NCT00816023|9728561|FG003|Overall Study|assessments complete prior to window|1
6109756|NCT00816023|9728558|FG000|Overall Study|Randomized Not Treated|6
6109757|NCT00816023|9728559|FG001|Overall Study|Randomized Not Treated|4
6109758|NCT00816023|9728560|FG002|Overall Study|Randomized Not Treated|6
6109759|NCT00816023|9728561|FG003|Overall Study|Randomized Not Treated|11
6109760|NCT00816036|9728573|FG000|Overall Study|Death|47
6109761|NCT00816036|9728574|FG001|Overall Study|Death|28
6109762|NCT00816036|9728573|FG000|Overall Study|Lost to Follow-up|75
6109763|NCT00816036|9728574|FG001|Overall Study|Lost to Follow-up|57
6109764|NCT00816036|9728573|FG000|Overall Study|Withdrawal by Subject|54
6109765|NCT00816036|9728574|FG001|Overall Study|Withdrawal by Subject|23
6109766|NCT00816166|9728600|FG000|Overall Study|Lost to Follow-up|6
6109767|NCT00816166|9728601|FG001|Overall Study|Lost to Follow-up|10
6109768|NCT00816166|9728600|FG000|Overall Study|Death|4
6109769|NCT00816166|9728601|FG001|Overall Study|Death|2
6109770|NCT00816361|9728618|FG000|Overall Study|Withdrawal by Subject|0
6109771|NCT00816361|9728619|FG001|Overall Study|Withdrawal by Subject|0
6109772|NCT00816361|9728620|FG002|Overall Study|Withdrawal by Subject|0
6109773|NCT00816361|9728621|FG003|Overall Study|Withdrawal by Subject|0
6109774|NCT00816361|9728622|FG004|Overall Study|Withdrawal by Subject|1
6109775|NCT00816361|9728623|FG005|Overall Study|Withdrawal by Subject|2
6109776|NCT00816361|9728624|FG006|Overall Study|Withdrawal by Subject|0
6109777|NCT00816361|9728625|FG007|Overall Study|Withdrawal by Subject|2
6109778|NCT00816361|9728626|FG008|Overall Study|Withdrawal by Subject|1
6109779|NCT00816361|9728618|FG000|Overall Study|Death|4
6109780|NCT00816361|9728619|FG001|Overall Study|Death|3
6109781|NCT00816361|9728620|FG002|Overall Study|Death|3
6109782|NCT00816361|9728621|FG003|Overall Study|Death|3
6109783|NCT00816361|9728622|FG004|Overall Study|Death|1
6109784|NCT00816361|9728623|FG005|Overall Study|Death|1
6109785|NCT00816361|9728624|FG006|Overall Study|Death|3
6109786|NCT00816361|9728625|FG007|Overall Study|Death|7
6109787|NCT00816361|9728626|FG008|Overall Study|Death|8
6109788|NCT00816361|9728618|FG000|Overall Study|Other|0
6109789|NCT00816361|9728619|FG001|Overall Study|Other|0
6109790|NCT00816361|9728620|FG002|Overall Study|Other|0
6109791|NCT00816361|9728621|FG003|Overall Study|Other|0
6109792|NCT00816361|9728622|FG004|Overall Study|Other|0
6109793|NCT00816361|9728623|FG005|Overall Study|Other|0
6109794|NCT00816361|9728624|FG006|Overall Study|Other|0
6109795|NCT00816361|9728625|FG007|Overall Study|Other|0
6109796|NCT00816361|9728626|FG008|Overall Study|Other|1
6109797|NCT00816400|9728656|FG000|Overall Study|Death|2
6109798|NCT00816400|9728657|FG001|Overall Study|Death|3
6109799|NCT00816400|9728658|FG002|Overall Study|Death|3
6109800|NCT00816400|9728659|FG003|Overall Study|Death|3
6109801|NCT00816400|9728660|FG004|Overall Study|Death|2
6109802|NCT00816400|9728661|FG005|Overall Study|Death|3
6109803|NCT00816400|9728662|FG006|Overall Study|Death|2
6109804|NCT00816400|9728663|FG007|Overall Study|Death|5
6109805|NCT00816400|9728664|FG008|Overall Study|Death|6
6109806|NCT00816400|9728656|FG000|Overall Study|In hospice care at the end of the study|0
6109807|NCT00816400|9728657|FG001|Overall Study|In hospice care at the end of the study|0
6109808|NCT00816400|9728658|FG002|Overall Study|In hospice care at the end of the study|2
6109809|NCT00816400|9728659|FG003|Overall Study|In hospice care at the end of the study|0
6109810|NCT00816400|9728660|FG004|Overall Study|In hospice care at the end of the study|0
6109811|NCT00816400|9728661|FG005|Overall Study|In hospice care at the end of the study|0
6109812|NCT00816400|9728662|FG006|Overall Study|In hospice care at the end of the study|0
6109813|NCT00816400|9728663|FG007|Overall Study|In hospice care at the end of the study|0
6109814|NCT00816400|9728664|FG008|Overall Study|In hospice care at the end of the study|0
6109815|NCT00816556|9728688|FG000|Overall Study|Adverse Event|1
6109816|NCT00816556|9728689|FG001|Overall Study|Adverse Event|1
6109817|NCT00816556|9728690|FG002|Overall Study|Adverse Event|1
6109818|NCT00816556|9728688|FG000|Overall Study|Withdrawal by Subject|1
6109819|NCT00816556|9728689|FG001|Overall Study|Withdrawal by Subject|1
6109820|NCT00816556|9728690|FG002|Overall Study|Withdrawal by Subject|1
6109821|NCT00816556|9728688|FG000|Overall Study|Lost to Follow-up|0
6109822|NCT00816556|9728689|FG001|Overall Study|Lost to Follow-up|0
6109823|NCT00816556|9728690|FG002|Overall Study|Lost to Follow-up|1
6109824|NCT00816595|9728700|FG000|Overall Study|Withdrawal by Subject|2
6109825|NCT00816595|9728701|FG001|Overall Study|Withdrawal by Subject|0
6109826|NCT00817063|9728740|FG000|Overall Study|Adverse Event|32
6109827|NCT00817063|9728741|FG001|Overall Study|Adverse Event|13
6109828|NCT00817063|9728740|FG000|Overall Study|Death|1
6109829|NCT00817063|9728741|FG001|Overall Study|Death|1
6109830|NCT00817063|9728740|FG000|Overall Study|Lack of Efficacy|33
6109831|NCT00817063|9728741|FG001|Overall Study|Lack of Efficacy|86
6109832|NCT00817063|9728740|FG000|Overall Study|Failure to Return|13
6109833|NCT00817063|9728741|FG001|Overall Study|Failure to Return|12
6109834|NCT00817063|9728740|FG000|Overall Study|Violation of Selection at Entry|7
6109835|NCT00817063|9728741|FG001|Overall Study|Violation of Selection at Entry|4
6109836|NCT00817063|9728740|FG000|Overall Study|Protocol Violation|3
6109837|NCT00817063|9728741|FG001|Overall Study|Protocol Violation|8
6109838|NCT00817063|9728740|FG000|Overall Study|Withdrawal by Subject|17
6109839|NCT00817063|9728741|FG001|Overall Study|Withdrawal by Subject|37
6109840|NCT00817063|9728740|FG000|Overall Study|Early Improvement|19
6109841|NCT00817063|9728741|FG001|Overall Study|Early Improvement|4
6109842|NCT00817063|9728740|FG000|Overall Study|Administrative|10
6109843|NCT00817063|9728741|FG001|Overall Study|Administrative|4
6109844|NCT00817063|9728740|FG000|Overall Study|Abnormality of Laboratory Test|2
6109845|NCT00817063|9728741|FG001|Overall Study|Abnormality of Laboratory Test|1
6109846|NCT00817089|9728751|FG000|First Alcohol Challenge|Lost to Follow-up|0
6109847|NCT00817089|9728752|FG001|First Alcohol Challenge|Lost to Follow-up|0
6109848|NCT00817089|9728753|FG002|First Alcohol Challenge|Lost to Follow-up|0
6109849|NCT00817089|9728754|FG003|First Alcohol Challenge|Lost to Follow-up|1
6285582|NCT02337478|9997906|FG000|Overall Study|Lack of Efficacy|5
6285583|NCT02337491|9997912|FG000|Overall Study|Death|1
6109850|NCT00817089|9728751|FG000|Second Alcohol Challenge|Lost to Follow-up|0
6109851|NCT00817089|9728752|FG001|Second Alcohol Challenge|Lost to Follow-up|1
6109852|NCT00817089|9728753|FG002|Second Alcohol Challenge|Lost to Follow-up|0
6109853|NCT00817089|9728754|FG003|Second Alcohol Challenge|Lost to Follow-up|0
6109854|NCT00817206|9728770|FG000|Overall Study|Adverse Event|10
6109855|NCT00817206|9728771|FG001|Overall Study|Adverse Event|3
6109856|NCT00817206|9728770|FG000|Overall Study|Protocol Violation|0
6109857|NCT00817206|9728771|FG001|Overall Study|Protocol Violation|2
6109858|NCT00817206|9728770|FG000|Overall Study|Lost to Follow-up|0
6109859|NCT00817206|9728771|FG001|Overall Study|Lost to Follow-up|1
6109860|NCT00817206|9728770|FG000|Overall Study|Death|2
6109861|NCT00817206|9728771|FG001|Overall Study|Death|0
6109862|NCT00817206|9728770|FG000|Overall Study|Withdrawal by Subject|7
6109863|NCT00817206|9728771|FG001|Overall Study|Withdrawal by Subject|3
6109864|NCT00817206|9728770|FG000|Overall Study|Physician Decision|2
6109865|NCT00817206|9728771|FG001|Overall Study|Physician Decision|0
6285584|NCT02337491|9997913|FG001|Overall Study|Death|1
6285585|NCT02337491|9997912|FG000|Overall Study|Adverse Event|0
6109866|NCT00817336|9728783|FG000|Overall Study|Withdrawal by Subject|1
6109867|NCT00817336|9728784|FG001|Overall Study|Withdrawal by Subject|1
6109868|NCT00817414|9728794|FG000|Overall Study|Adverse Event|1
6109869|NCT00817414|9728795|FG001|Overall Study|Adverse Event|1
6109870|NCT00817414|9728796|FG002|Overall Study|Adverse Event|1
6109871|NCT00817414|9728797|FG003|Overall Study|Adverse Event|0
6109872|NCT00817414|9728798|FG004|Overall Study|Adverse Event|0
6109873|NCT00817414|9728794|FG000|Overall Study|Low Adrenocorticotropic Hormone (ACTH)- Stimulated Cortisol|0
6109874|NCT00817414|9728795|FG001|Overall Study|Low Adrenocorticotropic Hormone (ACTH)- Stimulated Cortisol|1
6109875|NCT00817414|9728796|FG002|Overall Study|Low Adrenocorticotropic Hormone (ACTH)- Stimulated Cortisol|2
6109876|NCT00817414|9728797|FG003|Overall Study|Low Adrenocorticotropic Hormone (ACTH)- Stimulated Cortisol|4
6109877|NCT00817414|9728798|FG004|Overall Study|Low Adrenocorticotropic Hormone (ACTH)- Stimulated Cortisol|0
6109878|NCT00817414|9728794|FG000|Overall Study|Withdrawal by Subject|1
6109879|NCT00817414|9728795|FG001|Overall Study|Withdrawal by Subject|1
6109880|NCT00817414|9728796|FG002|Overall Study|Withdrawal by Subject|0
6109881|NCT00817414|9728797|FG003|Overall Study|Withdrawal by Subject|0
6109882|NCT00817414|9728798|FG004|Overall Study|Withdrawal by Subject|0
6109883|NCT00817414|9728794|FG000|Overall Study|Lost to Follow-up|0
6109884|NCT00817414|9728795|FG001|Overall Study|Lost to Follow-up|0
6109885|NCT00817414|9728796|FG002|Overall Study|Lost to Follow-up|1
6109886|NCT00817414|9728797|FG003|Overall Study|Lost to Follow-up|1
6109887|NCT00817414|9728798|FG004|Overall Study|Lost to Follow-up|1
6109888|NCT00817414|9728794|FG000|Overall Study|Dose Arm Exceeds Maximum Tolerated Dose (MTD)|0
6109889|NCT00817414|9728795|FG001|Overall Study|Dose Arm Exceeds Maximum Tolerated Dose (MTD)|0
6109890|NCT00817414|9728796|FG002|Overall Study|Dose Arm Exceeds Maximum Tolerated Dose (MTD)|0
6109891|NCT00817414|9728797|FG003|Overall Study|Dose Arm Exceeds Maximum Tolerated Dose (MTD)|7
6109892|NCT00817414|9728798|FG004|Overall Study|Dose Arm Exceeds Maximum Tolerated Dose (MTD)|0
6109893|NCT00817414|9728794|FG000|Overall Study|Protocol Violation|0
6109894|NCT00817414|9728795|FG001|Overall Study|Protocol Violation|0
6109895|NCT00817414|9728796|FG002|Overall Study|Protocol Violation|0
6109896|NCT00817414|9728797|FG003|Overall Study|Protocol Violation|0
6109897|NCT00817414|9728798|FG004|Overall Study|Protocol Violation|1
6109898|NCT00817479|9728817|FG000|Overall Study|Physician Decision|1
6109899|NCT00817479|9728818|FG001|Overall Study|Physician Decision|1
6109900|NCT00817531|9728824|FG000|Overall Study|Adverse Event|1
6109901|NCT00817531|9728824|FG000|Overall Study|Lack of Efficacy|1
6109902|NCT00817635|9728837|FG000|Overall Study|Adverse Event|1
6109903|NCT00817635|9728838|FG001|Overall Study|Adverse Event|0
6109904|NCT00817635|9728839|FG002|Overall Study|Adverse Event|0
6109905|NCT00817635|9728840|FG003|Overall Study|Adverse Event|1
6109906|NCT00817635|9728841|FG004|Overall Study|Adverse Event|1
6109907|NCT00817635|9728837|FG000|Overall Study|Abnormal Laboratory Value(s)|1
6109908|NCT00817635|9728838|FG001|Overall Study|Abnormal Laboratory Value(s)|1
6109909|NCT00817635|9728839|FG002|Overall Study|Abnormal Laboratory Value(s)|0
6109910|NCT00817635|9728840|FG003|Overall Study|Abnormal Laboratory Value(s)|0
6109911|NCT00817635|9728841|FG004|Overall Study|Abnormal Laboratory Value(s)|1
6109912|NCT00817635|9728837|FG000|Overall Study|Withdrawal by Subject|2
6109913|NCT00817635|9728838|FG001|Overall Study|Withdrawal by Subject|1
6109914|NCT00817635|9728839|FG002|Overall Study|Withdrawal by Subject|0
6109915|NCT00817635|9728840|FG003|Overall Study|Withdrawal by Subject|1
6109916|NCT00817635|9728841|FG004|Overall Study|Withdrawal by Subject|2
6109917|NCT00817635|9728837|FG000|Overall Study|Lost to Follow-up|0
6109918|NCT00817635|9728838|FG001|Overall Study|Lost to Follow-up|1
6109919|NCT00817635|9728839|FG002|Overall Study|Lost to Follow-up|0
6109920|NCT00817635|9728840|FG003|Overall Study|Lost to Follow-up|1
6109921|NCT00817635|9728841|FG004|Overall Study|Lost to Follow-up|0
6109922|NCT00817635|9728837|FG000|Overall Study|Administrative Problems|0
6109923|NCT00817635|9728838|FG001|Overall Study|Administrative Problems|0
6109924|NCT00817635|9728839|FG002|Overall Study|Administrative Problems|0
6109925|NCT00817635|9728840|FG003|Overall Study|Administrative Problems|0
6109926|NCT00817635|9728841|FG004|Overall Study|Administrative Problems|1
6109927|NCT00817635|9728837|FG000|Overall Study|Protocol Violation|5
6109928|NCT00817635|9728838|FG001|Overall Study|Protocol Violation|1
6109929|NCT00817635|9728839|FG002|Overall Study|Protocol Violation|3
6109930|NCT00817635|9728840|FG003|Overall Study|Protocol Violation|2
6109931|NCT00817635|9728841|FG004|Overall Study|Protocol Violation|3
6109932|NCT00817778|9728862|FG000|Overall Study|Adverse Event|1
6109933|NCT00817778|9728863|FG001|Overall Study|Adverse Event|0
6109934|NCT00817778|9728862|FG000|Overall Study|Withdrawal by Subject|1
6109935|NCT00817778|9728863|FG001|Overall Study|Withdrawal by Subject|1
6109936|NCT00817778|9728862|FG000|Overall Study|Protocol Violation|0
6109937|NCT00817778|9728863|FG001|Overall Study|Protocol Violation|1
6109938|NCT00817778|9728862|FG000|Overall Study|Study-specific discontinuation criteria|0
6109939|NCT00817778|9728863|FG001|Overall Study|Study-specific discontinuation criteria|1
6109940|NCT00817778|9728862|FG000|Overall Study|Poor venous access|1
6285586|NCT02337491|9997913|FG001|Overall Study|Adverse Event|1
6109941|NCT00817778|9728863|FG001|Overall Study|Poor venous access|0
6109942|NCT00818168|9728899|FG000|Overall Study|Lack of Efficacy|18
6109943|NCT00818168|9728899|FG000|Overall Study|Pregnancy|2
6109944|NCT00818168|9728899|FG000|Overall Study|Withdrawal by Subject|16
6109945|NCT00818168|9728899|FG000|Overall Study|Lost to Follow-up|7
6109946|NCT00818168|9728899|FG000|Overall Study|Adverse Event|19
6109947|NCT00818168|9728899|FG000|Overall Study|Reason for Non-completion Not reported|6
6109948|NCT00818168|9728899|FG000|Overall Study|Participant Moved|2
6109949|NCT00818207|9728905|FG000|Overall Study|Adverse Event|6
6109950|NCT00818207|9728906|FG001|Overall Study|Adverse Event|0
6109951|NCT00818207|9728905|FG000|Overall Study|Lost to Follow-up|160
6109952|NCT00818207|9728906|FG001|Overall Study|Lost to Follow-up|146
6109953|NCT00818207|9728905|FG000|Overall Study|Multiple reasons|11
6109954|NCT00818207|9728906|FG001|Overall Study|Multiple reasons|12
6109955|NCT00818207|9728905|FG000|Overall Study|Withdrawal by Subject|42
6109956|NCT00818207|9728906|FG001|Overall Study|Withdrawal by Subject|104
6109957|NCT00818207|9728905|FG000|Overall Study|Death|3
6109958|NCT00818207|9728906|FG001|Overall Study|Death|5
6109959|NCT00818246|9728912|FG000|Overall Study|Impossible to match pictures|5
6109960|NCT00818259|9728923|FG000|Part I|Withdrawal by Subject|1
6109961|NCT00818259|9728924|FG001|Part I|Withdrawal by Subject|0
6109962|NCT00818259|9728925|FG002|Part I|Withdrawal by Subject|0
6109963|NCT00818259|9728926|FG003|Part I|Withdrawal by Subject|0
6109964|NCT00818259|9728927|FG004|Part I|Withdrawal by Subject|0
6109965|NCT00818259|9728928|FG005|Part I|Withdrawal by Subject|0
6109966|NCT00818259|9728929|FG006|Part I|Withdrawal by Subject|0
6109967|NCT00818259|9728930|FG007|Part I|Withdrawal by Subject|0
6109968|NCT00818259|9728931|FG008|Part I|Withdrawal by Subject|0
6109969|NCT00818259|9728923|FG000|Part II|Physician Decision|0
6109970|NCT00818259|9728924|FG001|Part II|Physician Decision|0
6109971|NCT00818259|9728925|FG002|Part II|Physician Decision|1
6109972|NCT00818259|9728926|FG003|Part II|Physician Decision|0
6109973|NCT00818259|9728927|FG004|Part II|Physician Decision|0
6109974|NCT00818259|9728928|FG005|Part II|Physician Decision|0
6109975|NCT00818259|9728929|FG006|Part II|Physician Decision|0
6109976|NCT00818259|9728930|FG007|Part II|Physician Decision|0
6109977|NCT00818259|9728931|FG008|Part II|Physician Decision|0
6109978|NCT00818259|9728923|FG000|Part II|Lack of Efficacy|0
6109979|NCT00818259|9728924|FG001|Part II|Lack of Efficacy|0
6109980|NCT00818259|9728925|FG002|Part II|Lack of Efficacy|0
6109981|NCT00818259|9728926|FG003|Part II|Lack of Efficacy|1
6109982|NCT00818259|9728927|FG004|Part II|Lack of Efficacy|0
6109983|NCT00818259|9728928|FG005|Part II|Lack of Efficacy|0
6109984|NCT00818259|9728929|FG006|Part II|Lack of Efficacy|0
6109985|NCT00818259|9728930|FG007|Part II|Lack of Efficacy|0
6109986|NCT00818259|9728931|FG008|Part II|Lack of Efficacy|0
6109987|NCT00818259|9728923|FG000|Part II|Not Treated|0
6109988|NCT00818259|9728924|FG001|Part II|Not Treated|0
6109989|NCT00818259|9728925|FG002|Part II|Not Treated|0
6109990|NCT00818259|9728926|FG003|Part II|Not Treated|1
6109991|NCT00818259|9728927|FG004|Part II|Not Treated|0
6109992|NCT00818259|9728928|FG005|Part II|Not Treated|0
6109993|NCT00818259|9728929|FG006|Part II|Not Treated|0
6109994|NCT00818259|9728930|FG007|Part II|Not Treated|0
6109995|NCT00818259|9728931|FG008|Part II|Not Treated|0
6109996|NCT00818259|9728923|FG000|Part IV|Physician Decision|0
6109997|NCT00818259|9728924|FG001|Part IV|Physician Decision|0
6109998|NCT00818259|9728925|FG002|Part IV|Physician Decision|0
6109999|NCT00818259|9728926|FG003|Part IV|Physician Decision|0
6110000|NCT00818259|9728927|FG004|Part IV|Physician Decision|0
6110001|NCT00818259|9728928|FG005|Part IV|Physician Decision|1
6110002|NCT00818259|9728929|FG006|Part IV|Physician Decision|0
6110003|NCT00818259|9728930|FG007|Part IV|Physician Decision|0
6110004|NCT00818259|9728931|FG008|Part IV|Physician Decision|0
6110005|NCT00818259|9728923|FG000|Part V|Adverse Event|0
6110006|NCT00818259|9728924|FG001|Part V|Adverse Event|0
6110007|NCT00818259|9728925|FG002|Part V|Adverse Event|0
6110008|NCT00818259|9728926|FG003|Part V|Adverse Event|0
6110009|NCT00818259|9728927|FG004|Part V|Adverse Event|0
6110010|NCT00818259|9728928|FG005|Part V|Adverse Event|0
6110011|NCT00818259|9728929|FG006|Part V|Adverse Event|0
6110012|NCT00818259|9728930|FG007|Part V|Adverse Event|1
6110013|NCT00818259|9728931|FG008|Part V|Adverse Event|0
6110014|NCT00818389|9728971|FG000|Overall Study|Death|1
6110015|NCT00818389|9728972|FG001|Overall Study|Death|3
6110016|NCT00818389|9728971|FG000|Overall Study|ALS Disease Progression|1
6110017|NCT00818389|9728972|FG001|Overall Study|ALS Disease Progression|0
6110018|NCT00818389|9728971|FG000|Overall Study|Withdrawal by Subject|2
6110019|NCT00818389|9728972|FG001|Overall Study|Withdrawal by Subject|2
6110020|NCT00818389|9728971|FG000|Overall Study|Adverse Event|0
6110021|NCT00818389|9728972|FG001|Overall Study|Adverse Event|1
6110022|NCT00818441|9728980|FG000|Overall Study|Death|69
6110023|NCT00818441|9728981|FG001|Overall Study|Death|26
6110024|NCT00818441|9728980|FG000|Overall Study|Other|5
6110025|NCT00818441|9728981|FG001|Overall Study|Other|0
6110026|NCT00818441|9728980|FG000|Overall Study|Lost to Follow-up|2
6110027|NCT00818441|9728981|FG001|Overall Study|Lost to Follow-up|1
6110028|NCT00818441|9728980|FG000|Overall Study|Withdrawal by Subject|2
6110029|NCT00818441|9728981|FG001|Overall Study|Withdrawal by Subject|0
6110030|NCT00818441|9728980|FG000|Overall Study|Adverse Event|0
6110031|NCT00818441|9728981|FG001|Overall Study|Adverse Event|1
6110032|NCT00818441|9728980|FG000|Overall Study|Study terminated by sponsor|11
6110033|NCT00818441|9728981|FG001|Overall Study|Study terminated by sponsor|2
6110034|NCT00818454|9728988|FG000|Treatment Period 1|Adverse Event|0
6110035|NCT00818454|9728989|FG001|Treatment Period 1|Adverse Event|1
6110036|NCT00818454|9728990|FG002|Treatment Period 1|Adverse Event|0
6110037|NCT00818454|9728991|FG003|Treatment Period 1|Adverse Event|0
6110038|NCT00818454|9728988|FG000|Treatment Period 1|Other|3
6110039|NCT00818454|9728989|FG001|Treatment Period 1|Other|0
6110040|NCT00818454|9728990|FG002|Treatment Period 1|Other|0
6110041|NCT00818454|9728991|FG003|Treatment Period 1|Other|0
6110042|NCT00818454|9728988|FG000|Washout Period of 1 Week|Adverse Event|1
6110043|NCT00818454|9728989|FG001|Washout Period of 1 Week|Adverse Event|1
6110044|NCT00818454|9728990|FG002|Washout Period of 1 Week|Adverse Event|0
6110045|NCT00818454|9728991|FG003|Washout Period of 1 Week|Adverse Event|0
6110046|NCT00818454|9728988|FG000|Washout Period of 1 Week|Protocol Violation|2
6110047|NCT00818454|9728989|FG001|Washout Period of 1 Week|Protocol Violation|0
6110048|NCT00818454|9728990|FG002|Washout Period of 1 Week|Protocol Violation|0
6110049|NCT00818454|9728991|FG003|Washout Period of 1 Week|Protocol Violation|0
6110050|NCT00818454|9728988|FG000|Washout Period of 1 Week|Other|1
6110051|NCT00818454|9728989|FG001|Washout Period of 1 Week|Other|2
6110052|NCT00818454|9728990|FG002|Washout Period of 1 Week|Other|0
6110053|NCT00818454|9728991|FG003|Washout Period of 1 Week|Other|0
6110054|NCT00818454|9728988|FG000|Treatment Period 2|Other|2
6110055|NCT00818454|9728989|FG001|Treatment Period 2|Other|1
6110056|NCT00818454|9728990|FG002|Treatment Period 2|Other|0
6110057|NCT00818454|9728991|FG003|Treatment Period 2|Other|0
6110058|NCT00818454|9728988|FG000|Treatment Period 3|Adverse Event|0
6110059|NCT00818454|9728989|FG001|Treatment Period 3|Adverse Event|0
6110060|NCT00818454|9728990|FG002|Treatment Period 3|Adverse Event|0
6110061|NCT00818454|9728991|FG003|Treatment Period 3|Adverse Event|1
6110062|NCT00818519|9729003|FG000|Overall Study|Adverse Event|2
6110063|NCT00818519|9729004|FG001|Overall Study|Adverse Event|2
6110064|NCT00818519|9729003|FG000|Overall Study|Lost to Follow-up|4
6110065|NCT00818519|9729004|FG001|Overall Study|Lost to Follow-up|6
6110066|NCT00818519|9729003|FG000|Overall Study|Protocol Violation|2
6110067|NCT00818519|9729004|FG001|Overall Study|Protocol Violation|1
6110068|NCT00818519|9729003|FG000|Overall Study|Pregnancy|0
6110069|NCT00818519|9729004|FG001|Overall Study|Pregnancy|1
6110070|NCT00818519|9729003|FG000|Overall Study|Withdrawal by Subject|4
6110071|NCT00818519|9729004|FG001|Overall Study|Withdrawal by Subject|9
6110072|NCT00818519|9729003|FG000|Overall Study|participant recovered completely|1
6110073|NCT00818519|9729004|FG001|Overall Study|participant recovered completely|0
6110074|NCT00818519|9729003|FG000|Overall Study|participant will leave for long tme|1
6110075|NCT00818519|9729004|FG001|Overall Study|participant will leave for long tme|0
6110076|NCT00818623|9729018|FG000|Overall Study|Adverse Event|1
6110077|NCT00818623|9729019|FG001|Overall Study|Adverse Event|0
6110078|NCT00818623|9729020|FG002|Overall Study|Adverse Event|1
6110079|NCT00818623|9729021|FG003|Overall Study|Adverse Event|0
6110080|NCT00818623|9729022|FG004|Overall Study|Adverse Event|0
6110081|NCT00818623|9729023|FG005|Overall Study|Adverse Event|1
6110082|NCT00818623|9729024|FG006|Overall Study|Adverse Event|0
6110083|NCT00818623|9729025|FG007|Overall Study|Adverse Event|0
6110084|NCT00818623|9729018|FG000|Overall Study|Bad prostate specific antigen response|0
6110085|NCT00818623|9729019|FG001|Overall Study|Bad prostate specific antigen response|3
6110086|NCT00818623|9729020|FG002|Overall Study|Bad prostate specific antigen response|2
6110087|NCT00818623|9729021|FG003|Overall Study|Bad prostate specific antigen response|5
6110088|NCT00818623|9729022|FG004|Overall Study|Bad prostate specific antigen response|0
6110089|NCT00818623|9729023|FG005|Overall Study|Bad prostate specific antigen response|1
6110090|NCT00818623|9729024|FG006|Overall Study|Bad prostate specific antigen response|0
6110091|NCT00818623|9729025|FG007|Overall Study|Bad prostate specific antigen response|0
6110092|NCT00818623|9729018|FG000|Overall Study|Withdrawal by Subject|0
6110093|NCT00818623|9729019|FG001|Overall Study|Withdrawal by Subject|1
6110094|NCT00818623|9729020|FG002|Overall Study|Withdrawal by Subject|1
6110095|NCT00818623|9729021|FG003|Overall Study|Withdrawal by Subject|0
6110096|NCT00818623|9729022|FG004|Overall Study|Withdrawal by Subject|0
6110097|NCT00818623|9729023|FG005|Overall Study|Withdrawal by Subject|1
6110098|NCT00818623|9729024|FG006|Overall Study|Withdrawal by Subject|1
6110099|NCT00818623|9729025|FG007|Overall Study|Withdrawal by Subject|1
6110100|NCT00818623|9729018|FG000|Overall Study|Protocol Violation|1
6110101|NCT00818623|9729019|FG001|Overall Study|Protocol Violation|0
6110102|NCT00818623|9729020|FG002|Overall Study|Protocol Violation|0
6110103|NCT00818623|9729021|FG003|Overall Study|Protocol Violation|0
6110104|NCT00818623|9729022|FG004|Overall Study|Protocol Violation|1
6110105|NCT00818623|9729023|FG005|Overall Study|Protocol Violation|0
6110106|NCT00818623|9729024|FG006|Overall Study|Protocol Violation|1
6110107|NCT00818623|9729025|FG007|Overall Study|Protocol Violation|0
6110108|NCT00818623|9729018|FG000|Overall Study|Need of additional treatment|0
6110109|NCT00818623|9729019|FG001|Overall Study|Need of additional treatment|0
6110110|NCT00818623|9729020|FG002|Overall Study|Need of additional treatment|0
6110111|NCT00818623|9729021|FG003|Overall Study|Need of additional treatment|0
6110112|NCT00818623|9729022|FG004|Overall Study|Need of additional treatment|1
6110113|NCT00818623|9729023|FG005|Overall Study|Need of additional treatment|0
6110114|NCT00818623|9729024|FG006|Overall Study|Need of additional treatment|0
6110115|NCT00818623|9729025|FG007|Overall Study|Need of additional treatment|0
6110116|NCT00818623|9729018|FG000|Overall Study|Lack of trial drug at site|0
6110117|NCT00818623|9729019|FG001|Overall Study|Lack of trial drug at site|0
6110118|NCT00818623|9729020|FG002|Overall Study|Lack of trial drug at site|0
6110119|NCT00818623|9729021|FG003|Overall Study|Lack of trial drug at site|0
6110120|NCT00818623|9729022|FG004|Overall Study|Lack of trial drug at site|2
6110121|NCT00818623|9729023|FG005|Overall Study|Lack of trial drug at site|0
6206506|NCT01544348|9869984|FG003|Overall Study|Lost to Follow-up|0
6206507|NCT01544348|9869985|FG004|Overall Study|Lost to Follow-up|0
6206508|NCT01544348|9869986|FG005|Overall Study|Lost to Follow-up|0
6110122|NCT00818623|9729024|FG006|Overall Study|Lack of trial drug at site|1
6206509|NCT01544348|9869987|FG006|Overall Study|Lost to Follow-up|1
6206510|NCT01544348|9869988|FG007|Overall Study|Lost to Follow-up|0
6206511|NCT01544348|9869981|FG000|Overall Study|Withdrawal by Subject|1
6206512|NCT01544348|9869982|FG001|Overall Study|Withdrawal by Subject|0
6206513|NCT01544348|9869983|FG002|Overall Study|Withdrawal by Subject|0
6206514|NCT01544348|9869984|FG003|Overall Study|Withdrawal by Subject|0
6285587|NCT02337491|9997912|FG000|Overall Study|Withdrawal by Subject|3
6285588|NCT02337491|9997913|FG001|Overall Study|Withdrawal by Subject|0
6285589|NCT02337491|9997912|FG000|Overall Study|Progressive Disease|44
6285590|NCT02337491|9997913|FG001|Overall Study|Progressive Disease|28
6285591|NCT02337491|9997912|FG000|Overall Study|On Treatment|2
6285592|NCT02337491|9997913|FG001|Overall Study|On Treatment|0
6285593|NCT02337907|9997943|FG000|Overall Study|Other than listed|1
6285594|NCT02337907|9997944|FG001|Overall Study|Other than listed|0
6285595|NCT02337907|9997945|FG002|Overall Study|Other than listed|0
6285596|NCT02337907|9997946|FG003|Overall Study|Other than listed|1
6285597|NCT02337907|9997947|FG004|Overall Study|Other than listed|1
6285598|NCT02337907|9997948|FG005|Overall Study|Other than listed|0
6285599|NCT02337907|9997943|FG000|Overall Study|Withdrawal by Subject|2
6285600|NCT02337907|9997944|FG001|Overall Study|Withdrawal by Subject|3
6285601|NCT02337907|9997945|FG002|Overall Study|Withdrawal by Subject|0
6285602|NCT02337907|9997946|FG003|Overall Study|Withdrawal by Subject|2
6285603|NCT02337907|9997947|FG004|Overall Study|Withdrawal by Subject|5
6285604|NCT02337907|9997948|FG005|Overall Study|Withdrawal by Subject|0
6285605|NCT02337907|9997943|FG000|Overall Study|Lost to Follow-up|0
6285606|NCT02337907|9997944|FG001|Overall Study|Lost to Follow-up|0
6285607|NCT02337907|9997945|FG002|Overall Study|Lost to Follow-up|0
6285608|NCT02337907|9997946|FG003|Overall Study|Lost to Follow-up|0
6285609|NCT02337907|9997947|FG004|Overall Study|Lost to Follow-up|0
6285610|NCT02337907|9997948|FG005|Overall Study|Lost to Follow-up|1
6285611|NCT02337907|9997943|FG000|Overall Study|Adverse Event|1
6285612|NCT02337907|9997944|FG001|Overall Study|Adverse Event|1
6285613|NCT02337907|9997945|FG002|Overall Study|Adverse Event|1
6285614|NCT02337907|9997946|FG003|Overall Study|Adverse Event|1
6285615|NCT02337907|9997947|FG004|Overall Study|Adverse Event|4
6285616|NCT02337907|9997948|FG005|Overall Study|Adverse Event|0
6285617|NCT02337946|9997972|FG000|Protocol Treatment 1 Period|Adverse Event|7
6285618|NCT02337946|9997973|FG001|Protocol Treatment 1 Period|Adverse Event|0
6285619|NCT02337946|9997974|FG002|Protocol Treatment 1 Period|Adverse Event|0
6285620|NCT02337946|9997972|FG000|Protocol Treatment 1 Period|Major Protocol Deviation|1
6285621|NCT02337946|9997973|FG001|Protocol Treatment 1 Period|Major Protocol Deviation|0
6285622|NCT02337946|9997974|FG002|Protocol Treatment 1 Period|Major Protocol Deviation|0
6285623|NCT02337946|9997972|FG000|Protocol Treatment 1 Period|Voluntary Withdrawal|6
6285624|NCT02337946|9997973|FG001|Protocol Treatment 1 Period|Voluntary Withdrawal|0
6285625|NCT02337946|9997974|FG002|Protocol Treatment 1 Period|Voluntary Withdrawal|0
6285626|NCT02337946|9997972|FG000|Protocol Treatment 1 Period|Lack of Efficacy|15
6285627|NCT02337946|9997973|FG001|Protocol Treatment 1 Period|Lack of Efficacy|0
6285628|NCT02337946|9997974|FG002|Protocol Treatment 1 Period|Lack of Efficacy|0
6285629|NCT02337946|9997972|FG000|Protocol Treatment 1 Period|Death During Protocol Treatment|3
6285630|NCT02337946|9997973|FG001|Protocol Treatment 1 Period|Death During Protocol Treatment|0
6285631|NCT02337946|9997974|FG002|Protocol Treatment 1 Period|Death During Protocol Treatment|0
6285632|NCT02337946|9997972|FG000|Protocol Treatment 1 Period|Surgery Aimed at Curative Resection|9
6285633|NCT02337946|9997973|FG001|Protocol Treatment 1 Period|Surgery Aimed at Curative Resection|0
6285634|NCT02337946|9997974|FG002|Protocol Treatment 1 Period|Surgery Aimed at Curative Resection|0
6285635|NCT02337946|9997972|FG000|Protocol Treatment 1 Period|Did not Meet Entrance Criteria|1
6285636|NCT02337946|9997973|FG001|Protocol Treatment 1 Period|Did not Meet Entrance Criteria|0
6285637|NCT02337946|9997974|FG002|Protocol Treatment 1 Period|Did not Meet Entrance Criteria|0
6206515|NCT01544348|9869985|FG004|Overall Study|Withdrawal by Subject|1
6206516|NCT01544348|9869986|FG005|Overall Study|Withdrawal by Subject|2
6206517|NCT01544348|9869987|FG006|Overall Study|Withdrawal by Subject|1
6206518|NCT01544348|9869988|FG007|Overall Study|Withdrawal by Subject|0
6206519|NCT01544348|9869981|FG000|Overall Study|Physician Decision|0
6206520|NCT01544348|9869982|FG001|Overall Study|Physician Decision|0
6206521|NCT01544348|9869983|FG002|Overall Study|Physician Decision|0
6206522|NCT01544348|9869984|FG003|Overall Study|Physician Decision|0
6206523|NCT01544348|9869985|FG004|Overall Study|Physician Decision|0
6206524|NCT01544348|9869986|FG005|Overall Study|Physician Decision|1
6206525|NCT01544348|9869987|FG006|Overall Study|Physician Decision|0
6206526|NCT01544348|9869988|FG007|Overall Study|Physician Decision|0
6206527|NCT01544478|9870034|FG000|Overall Study|Adverse Event|1
6206528|NCT01544478|9870034|FG000|Overall Study|Death|1
6206529|NCT01544478|9870034|FG000|Overall Study|Lost to Follow-up|48
6206530|NCT01544478|9870034|FG000|Overall Study|Physician Decision|15
6206531|NCT01544478|9870034|FG000|Overall Study|Pregnancy|1
6110123|NCT00818623|9729025|FG007|Overall Study|Lack of trial drug at site|0
6206532|NCT01544478|9870034|FG000|Overall Study|Withdrawal by Subject|52
6206533|NCT01544491|9870040|FG000|Overall Study|Withdrawal by Subject|3
6206534|NCT01544491|9870041|FG001|Overall Study|Withdrawal by Subject|2
6206535|NCT01544491|9870040|FG000|Overall Study|Lost to Follow-up|0
6206536|NCT01544491|9870041|FG001|Overall Study|Lost to Follow-up|1
6110124|NCT00818623|9729018|FG000|Overall Study|Disease progression|0
6110125|NCT00818623|9729019|FG001|Overall Study|Disease progression|0
6110126|NCT00818623|9729020|FG002|Overall Study|Disease progression|0
6110127|NCT00818623|9729021|FG003|Overall Study|Disease progression|0
6110128|NCT00818623|9729022|FG004|Overall Study|Disease progression|0
6110129|NCT00818623|9729023|FG005|Overall Study|Disease progression|0
6110130|NCT00818623|9729024|FG006|Overall Study|Disease progression|1
6110131|NCT00818623|9729025|FG007|Overall Study|Disease progression|0
6110132|NCT00818649|9729043|FG000|Overall Study|Declining performance status|2
6110133|NCT00818649|9729043|FG000|Overall Study|Unrelated hip fracture-unable to proceed|1
6110134|NCT00818649|9729043|FG000|Overall Study|Adverse Event|1
6110135|NCT00818662|9729052|FG000|Overall Study|Adverse Event|5
6110136|NCT00818662|9729053|FG001|Overall Study|Adverse Event|14
6110137|NCT00818662|9729054|FG002|Overall Study|Adverse Event|4
6110138|NCT00818662|9729055|FG003|Overall Study|Adverse Event|3
6110139|NCT00818662|9729052|FG000|Overall Study|Withdrawal by Subject|5
6110140|NCT00818662|9729053|FG001|Overall Study|Withdrawal by Subject|4
6110141|NCT00818662|9729054|FG002|Overall Study|Withdrawal by Subject|2
6110142|NCT00818662|9729055|FG003|Overall Study|Withdrawal by Subject|2
6110143|NCT00818662|9729052|FG000|Overall Study|Death|1
6110144|NCT00818662|9729053|FG001|Overall Study|Death|3
6110145|NCT00818662|9729054|FG002|Overall Study|Death|0
6110146|NCT00818662|9729055|FG003|Overall Study|Death|0
6110147|NCT00818662|9729052|FG000|Overall Study|Physician Decision|1
6110148|NCT00818662|9729053|FG001|Overall Study|Physician Decision|0
6110149|NCT00818662|9729054|FG002|Overall Study|Physician Decision|0
6110150|NCT00818662|9729055|FG003|Overall Study|Physician Decision|0
6110151|NCT00818662|9729052|FG000|Overall Study|Lost to Follow-up|0
6110152|NCT00818662|9729053|FG001|Overall Study|Lost to Follow-up|0
6110153|NCT00818662|9729054|FG002|Overall Study|Lost to Follow-up|0
6110154|NCT00818662|9729055|FG003|Overall Study|Lost to Follow-up|1
6110155|NCT00818662|9729052|FG000|Overall Study|Unwilling or Unable to Participate|4
6110156|NCT00818662|9729053|FG001|Overall Study|Unwilling or Unable to Participate|6
6110157|NCT00818662|9729054|FG002|Overall Study|Unwilling or Unable to Participate|2
6110158|NCT00818662|9729055|FG003|Overall Study|Unwilling or Unable to Participate|4
6110159|NCT00818662|9729052|FG000|Overall Study|Protocol Violation|1
6110160|NCT00818662|9729053|FG001|Overall Study|Protocol Violation|1
6110161|NCT00818662|9729054|FG002|Overall Study|Protocol Violation|0
6110162|NCT00818662|9729055|FG003|Overall Study|Protocol Violation|0
6110163|NCT00818662|9729052|FG000|Overall Study|Requires a Prohibited Medication|1
6110164|NCT00818662|9729053|FG001|Overall Study|Requires a Prohibited Medication|0
6110165|NCT00818662|9729054|FG002|Overall Study|Requires a Prohibited Medication|0
6110166|NCT00818662|9729055|FG003|Overall Study|Requires a Prohibited Medication|0
6110167|NCT00818662|9729052|FG000|Overall Study|Safety Risk|1
6110168|NCT00818662|9729053|FG001|Overall Study|Safety Risk|1
6110169|NCT00818662|9729054|FG002|Overall Study|Safety Risk|0
6110170|NCT00818662|9729055|FG003|Overall Study|Safety Risk|1
6110171|NCT00818662|9729052|FG000|Overall Study|Study Partner Unwilling or Unable|3
6110172|NCT00818662|9729053|FG001|Overall Study|Study Partner Unwilling or Unable|2
6110173|NCT00818662|9729054|FG002|Overall Study|Study Partner Unwilling or Unable|1
6110174|NCT00818662|9729055|FG003|Overall Study|Study Partner Unwilling or Unable|1
6110175|NCT00818662|9729052|FG000|Overall Study|Participant's health declined|0
6110176|NCT00818662|9729053|FG001|Overall Study|Participant's health declined|0
6110177|NCT00818662|9729054|FG002|Overall Study|Participant's health declined|0
6110178|NCT00818662|9729055|FG003|Overall Study|Participant's health declined|1
6110179|NCT00818662|9729052|FG000|Overall Study|Caregiver to pursue other treatment|0
6110180|NCT00818662|9729053|FG001|Overall Study|Caregiver to pursue other treatment|1
6110181|NCT00818662|9729054|FG002|Overall Study|Caregiver to pursue other treatment|0
6110182|NCT00818662|9729055|FG003|Overall Study|Caregiver to pursue other treatment|0
6110183|NCT00818662|9729052|FG000|Overall Study|Moving out of state|0
6110184|NCT00818662|9729053|FG001|Overall Study|Moving out of state|0
6110185|NCT00818662|9729054|FG002|Overall Study|Moving out of state|0
6110186|NCT00818662|9729055|FG003|Overall Study|Moving out of state|1
6110187|NCT00818662|9729052|FG000|Overall Study|Declined move to another study site|1
6110188|NCT00818662|9729053|FG001|Overall Study|Declined move to another study site|0
6110189|NCT00818662|9729054|FG002|Overall Study|Declined move to another study site|0
6110190|NCT00818662|9729055|FG003|Overall Study|Declined move to another study site|0
6110191|NCT00818662|9729052|FG000|Overall Study|Change in living situation|0
6110192|NCT00818662|9729053|FG001|Overall Study|Change in living situation|0
6110193|NCT00818662|9729054|FG002|Overall Study|Change in living situation|0
6110194|NCT00818662|9729055|FG003|Overall Study|Change in living situation|1
6110195|NCT00818662|9729052|FG000|Overall Study|Study partner decision|0
6110196|NCT00818662|9729053|FG001|Overall Study|Study partner decision|0
6110197|NCT00818662|9729054|FG002|Overall Study|Study partner decision|0
6110198|NCT00818662|9729055|FG003|Overall Study|Study partner decision|1
6110199|NCT00818662|9729052|FG000|Overall Study|Admitted to long term nursing care|0
6110200|NCT00818662|9729053|FG001|Overall Study|Admitted to long term nursing care|1
6110201|NCT00818662|9729054|FG002|Overall Study|Admitted to long term nursing care|0
6110202|NCT00818662|9729055|FG003|Overall Study|Admitted to long term nursing care|0
6110203|NCT00818753|9729069|FG000|Overall Study|Protocol Violation|1
6110204|NCT00818753|9729070|FG001|Overall Study|Protocol Violation|0
6110205|NCT00818753|9729071|FG002|Overall Study|Protocol Violation|0
6110206|NCT00818753|9729069|FG000|Overall Study|Other reason (not specified)|0
6110207|NCT00818753|9729070|FG001|Overall Study|Other reason (not specified)|0
6110208|NCT00818753|9729071|FG002|Overall Study|Other reason (not specified)|1
6110209|NCT00818753|9729069|FG000|Overall Study|Randomised and not treated|2
6110210|NCT00818753|9729070|FG001|Overall Study|Randomised and not treated|0
6110211|NCT00818753|9729071|FG002|Overall Study|Randomised and not treated|0
6110212|NCT00818766|9729081|FG000|Overall Study|Could not be Contacted on Day 28|11
6110213|NCT00818766|9729082|FG001|Overall Study|Could not be Contacted on Day 28|10
6110214|NCT00818766|9729081|FG000|Overall Study|Death|1
6110215|NCT00818766|9729082|FG001|Overall Study|Death|0
6110216|NCT00818766|9729081|FG000|Overall Study|Did not Receive Allocated Intervention|3
6110217|NCT00818766|9729082|FG001|Overall Study|Did not Receive Allocated Intervention|0
6110218|NCT00818779|9729090|FG000|Overall Study|Protocol Violation|1
6110219|NCT00818779|9729091|FG001|Overall Study|Protocol Violation|0
6110220|NCT00818779|9729090|FG000|Overall Study|Lost to Follow-up|1
6110221|NCT00818779|9729091|FG001|Overall Study|Lost to Follow-up|0
6110222|NCT00818779|9729090|FG000|Overall Study|Adverse Event|4
6110223|NCT00818779|9729091|FG001|Overall Study|Adverse Event|1
6110224|NCT00818883|9729110|FG000|Overall Study|Adverse Event|28
6110225|NCT00818883|9729111|FG001|Overall Study|Adverse Event|19
6110226|NCT00818883|9729110|FG000|Overall Study|Protocol Violation|2
6110227|NCT00818883|9729111|FG001|Overall Study|Protocol Violation|2
6110228|NCT00818883|9729110|FG000|Overall Study|Lost to Follow-up|3
6110229|NCT00818883|9729111|FG001|Overall Study|Lost to Follow-up|2
6110230|NCT00818883|9729110|FG000|Overall Study|Withdrawal by Subject|16
6110231|NCT00818883|9729111|FG001|Overall Study|Withdrawal by Subject|14
6110232|NCT00818883|9729110|FG000|Overall Study|Lack of Efficacy|0
6110233|NCT00818883|9729111|FG001|Overall Study|Lack of Efficacy|2
6110234|NCT00818883|9729110|FG000|Overall Study|Other|2
6110235|NCT00818883|9729111|FG001|Overall Study|Other|7
6285638|NCT02337946|9997972|FG000|Protocol Treatment 1 Period|Reason not specified|8
6285639|NCT02337946|9997973|FG001|Protocol Treatment 1 Period|Reason not specified|0
6285640|NCT02337946|9997974|FG002|Protocol Treatment 1 Period|Reason not specified|0
6285641|NCT02337946|9997972|FG000|In-between Period|Without Informed Consent|1
6285642|NCT02337946|9997973|FG001|In-between Period|Without Informed Consent|0
6285643|NCT02337946|9997974|FG002|In-between Period|Without Informed Consent|0
6285644|NCT02337946|9997972|FG000|Protocol Treatment 2 Period|Adverse Event|0
6285645|NCT02337946|9997973|FG001|Protocol Treatment 2 Period|Adverse Event|9
6285646|NCT02337946|9997974|FG002|Protocol Treatment 2 Period|Adverse Event|9
6285647|NCT02337946|9997972|FG000|Protocol Treatment 2 Period|Voluntary Withdrawal|0
6285648|NCT02337946|9997973|FG001|Protocol Treatment 2 Period|Voluntary Withdrawal|3
6285649|NCT02337946|9997974|FG002|Protocol Treatment 2 Period|Voluntary Withdrawal|1
6285650|NCT02337946|9997972|FG000|Protocol Treatment 2 Period|Lack of Efficacy|0
6110236|NCT00819013|9729125|FG000|Overall Study|Not meeting continuing study eligibility|2
6110237|NCT00819013|9729126|FG001|Overall Study|Not meeting continuing study eligibility|1
6110238|NCT00819013|9729127|FG002|Overall Study|Not meeting continuing study eligibility|2
6110239|NCT00819013|9729128|FG003|Overall Study|Not meeting continuing study eligibility|1
6110240|NCT00819013|9729125|FG000|Overall Study|Adverse Event|0
6110241|NCT00819013|9729126|FG001|Overall Study|Adverse Event|0
6110242|NCT00819013|9729127|FG002|Overall Study|Adverse Event|1
6110243|NCT00819013|9729128|FG003|Overall Study|Adverse Event|0
6110244|NCT00819013|9729125|FG000|Overall Study|Withdrawal by Subject|1
6110245|NCT00819013|9729126|FG001|Overall Study|Withdrawal by Subject|0
6110246|NCT00819013|9729127|FG002|Overall Study|Withdrawal by Subject|1
6110247|NCT00819013|9729128|FG003|Overall Study|Withdrawal by Subject|0
6110248|NCT00819013|9729125|FG000|Overall Study|Lost to Follow-up|0
6110249|NCT00819013|9729126|FG001|Overall Study|Lost to Follow-up|0
6110250|NCT00819013|9729127|FG002|Overall Study|Lost to Follow-up|1
6110251|NCT00819013|9729128|FG003|Overall Study|Lost to Follow-up|2
6110252|NCT00819013|9729125|FG000|Overall Study|Death|0
6110253|NCT00819013|9729126|FG001|Overall Study|Death|0
6110254|NCT00819013|9729127|FG002|Overall Study|Death|0
6110255|NCT00819013|9729128|FG003|Overall Study|Death|1
6110256|NCT00819039|9729141|FG000|Overall Study|Physician Decision|1
6110257|NCT00819039|9729142|FG001|Overall Study|Physician Decision|0
6110258|NCT00819039|9729143|FG002|Overall Study|Physician Decision|1
6110259|NCT00819039|9729141|FG000|Overall Study|Protocol Violation|1
6110260|NCT00819039|9729142|FG001|Overall Study|Protocol Violation|0
6110261|NCT00819039|9729143|FG002|Overall Study|Protocol Violation|0
6110262|NCT00819052|9729155|FG000|Overall Study|Adverse Event|0
6110263|NCT00819052|9729156|FG001|Overall Study|Adverse Event|5
6110264|NCT00819052|9729155|FG000|Overall Study|Protocol Violation|1
6110265|NCT00819052|9729156|FG001|Overall Study|Protocol Violation|2
6110266|NCT00819052|9729155|FG000|Overall Study|Lost to Follow-up|1
6110267|NCT00819052|9729156|FG001|Overall Study|Lost to Follow-up|2
6110268|NCT00819052|9729155|FG000|Overall Study|Withdrawal by Subject|1
6110269|NCT00819052|9729156|FG001|Overall Study|Withdrawal by Subject|2
6110270|NCT00819052|9729155|FG000|Overall Study|Lack of Efficacy|1
6110271|NCT00819052|9729156|FG001|Overall Study|Lack of Efficacy|1
6110272|NCT00819052|9729155|FG000|Overall Study|Pregnancy|1
6110273|NCT00819052|9729156|FG001|Overall Study|Pregnancy|2
6110274|NCT00819052|9729155|FG000|Overall Study|Death or events leading to death|1
6110275|NCT00819052|9729156|FG001|Overall Study|Death or events leading to death|0
6110276|NCT00819091|9729167|FG000|Overall Study|Adverse Event|3
6110277|NCT00819091|9729168|FG001|Overall Study|Adverse Event|5
6110278|NCT00819091|9729167|FG000|Overall Study|Protocol Violation|0
6110279|NCT00819091|9729168|FG001|Overall Study|Protocol Violation|1
6110280|NCT00819091|9729167|FG000|Overall Study|Lost to Follow-up|2
6110281|NCT00819091|9729168|FG001|Overall Study|Lost to Follow-up|0
6110282|NCT00819091|9729167|FG000|Overall Study|Withdrawal by Subject|1
6110283|NCT00819091|9729168|FG001|Overall Study|Withdrawal by Subject|2
6110284|NCT00819091|9729167|FG000|Overall Study|Other|1
6110285|NCT00819091|9729168|FG001|Overall Study|Other|2
6110286|NCT00819156|9729180|FG000|Overall Study|Adverse Event|1
6110287|NCT00819156|9729181|FG001|Overall Study|Adverse Event|4
6110288|NCT00819156|9729182|FG002|Overall Study|Adverse Event|2
6110289|NCT00819156|9729183|FG003|Overall Study|Adverse Event|1
6110290|NCT00819156|9729184|FG004|Overall Study|Adverse Event|2
6110291|NCT00819156|9729185|FG005|Overall Study|Adverse Event|3
6110292|NCT00819156|9729180|FG000|Overall Study|Withdrawal by Subject|0
6110293|NCT00819156|9729181|FG001|Overall Study|Withdrawal by Subject|3
6110294|NCT00819156|9729182|FG002|Overall Study|Withdrawal by Subject|2
6110295|NCT00819156|9729183|FG003|Overall Study|Withdrawal by Subject|0
6110296|NCT00819156|9729184|FG004|Overall Study|Withdrawal by Subject|1
6110297|NCT00819156|9729185|FG005|Overall Study|Withdrawal by Subject|0
6110298|NCT00819156|9729180|FG000|Overall Study|Protocol Violation|1
6110299|NCT00819156|9729181|FG001|Overall Study|Protocol Violation|0
6110300|NCT00819156|9729182|FG002|Overall Study|Protocol Violation|1
6110301|NCT00819156|9729183|FG003|Overall Study|Protocol Violation|0
6110302|NCT00819156|9729184|FG004|Overall Study|Protocol Violation|0
6110303|NCT00819156|9729185|FG005|Overall Study|Protocol Violation|1
6110304|NCT00819156|9729180|FG000|Overall Study|Lost to Follow-up|0
6110305|NCT00819156|9729181|FG001|Overall Study|Lost to Follow-up|1
6110306|NCT00819156|9729182|FG002|Overall Study|Lost to Follow-up|0
6110307|NCT00819156|9729183|FG003|Overall Study|Lost to Follow-up|0
6110308|NCT00819156|9729184|FG004|Overall Study|Lost to Follow-up|0
6206537|NCT01544491|9870040|FG000|Overall Study|administrative problems|2
6206538|NCT01544491|9870041|FG001|Overall Study|administrative problems|0
6206539|NCT01544582|9870050|FG000|Screening/Eligibility|Initiated Different CHC Treatment|1
6206540|NCT01544582|9870051|FG001|Screening/Eligibility|Initiated Different CHC Treatment|0
6206541|NCT01544582|9870052|FG002|Screening/Eligibility|Initiated Different CHC Treatment|0
6206542|NCT01544582|9870053|FG003|Screening/Eligibility|Initiated Different CHC Treatment|0
6206543|NCT01544582|9870050|FG000|Screening/Eligibility|Eligibility Criteria Not Met|33
6206544|NCT01544582|9870051|FG001|Screening/Eligibility|Eligibility Criteria Not Met|0
6206545|NCT01544582|9870052|FG002|Screening/Eligibility|Eligibility Criteria Not Met|0
6206546|NCT01544582|9870053|FG003|Screening/Eligibility|Eligibility Criteria Not Met|0
6206547|NCT01544582|9870050|FG000|Analysis Population|Participant Refuses to Continue Study|0
6206548|NCT01544582|9870051|FG001|Analysis Population|Participant Refuses to Continue Study|15
6206549|NCT01544582|9870052|FG002|Analysis Population|Participant Refuses to Continue Study|17
6206550|NCT01544582|9870053|FG003|Analysis Population|Participant Refuses to Continue Study|4
6206551|NCT01544582|9870050|FG000|Analysis Population|Physician Decision|0
6206552|NCT01544582|9870051|FG001|Analysis Population|Physician Decision|13
6206553|NCT01544582|9870052|FG002|Analysis Population|Physician Decision|10
6206554|NCT01544582|9870053|FG003|Analysis Population|Physician Decision|9
6206555|NCT01544582|9870050|FG000|Analysis Population|Safety Reason|0
6206556|NCT01544582|9870051|FG001|Analysis Population|Safety Reason|33
6206557|NCT01544582|9870052|FG002|Analysis Population|Safety Reason|31
6206558|NCT01544582|9870053|FG003|Analysis Population|Safety Reason|8
6206559|NCT01544582|9870050|FG000|Analysis Population|Effectiveness Reason|0
6206560|NCT01544582|9870051|FG001|Analysis Population|Effectiveness Reason|48
6206561|NCT01544582|9870052|FG002|Analysis Population|Effectiveness Reason|29
6206562|NCT01544582|9870053|FG003|Analysis Population|Effectiveness Reason|12
6206563|NCT01544582|9870050|FG000|Analysis Population|New Contraindication-Alcohol Abuse|0
6206564|NCT01544582|9870051|FG001|Analysis Population|New Contraindication-Alcohol Abuse|0
6206565|NCT01544582|9870052|FG002|Analysis Population|New Contraindication-Alcohol Abuse|0
6206566|NCT01544582|9870053|FG003|Analysis Population|New Contraindication-Alcohol Abuse|1
6206567|NCT01544582|9870050|FG000|Analysis Population|Lost to Follow-up|0
6206568|NCT01544582|9870051|FG001|Analysis Population|Lost to Follow-up|6
6206569|NCT01544582|9870052|FG002|Analysis Population|Lost to Follow-up|6
6206570|NCT01544582|9870053|FG003|Analysis Population|Lost to Follow-up|5
6206571|NCT01544582|9870050|FG000|Analysis Population|Bad Tolerance to Treatment|0
6206572|NCT01544582|9870051|FG001|Analysis Population|Bad Tolerance to Treatment|0
6206573|NCT01544582|9870052|FG002|Analysis Population|Bad Tolerance to Treatment|2
6206574|NCT01544582|9870053|FG003|Analysis Population|Bad Tolerance to Treatment|0
6206575|NCT01544582|9870050|FG000|Analysis Population|Did Not Meet Inclusion Criteria|0
6206576|NCT01544582|9870051|FG001|Analysis Population|Did Not Meet Inclusion Criteria|0
6206577|NCT01544582|9870052|FG002|Analysis Population|Did Not Meet Inclusion Criteria|3
6206578|NCT01544582|9870053|FG003|Analysis Population|Did Not Meet Inclusion Criteria|0
6206579|NCT01544582|9870050|FG000|Analysis Population|Intolerance|0
6110309|NCT00819156|9729185|FG005|Overall Study|Lost to Follow-up|2
6110310|NCT00819156|9729180|FG000|Overall Study|Testosterone >1ng/ml from Day 28+|5
6110311|NCT00819156|9729181|FG001|Overall Study|Testosterone >1ng/ml from Day 28+|2
6206580|NCT01544582|9870051|FG001|Analysis Population|Intolerance|1
6110312|NCT00819156|9729182|FG002|Overall Study|Testosterone >1ng/ml from Day 28+|1
6110313|NCT00819156|9729183|FG003|Overall Study|Testosterone >1ng/ml from Day 28+|1
6110314|NCT00819156|9729184|FG004|Overall Study|Testosterone >1ng/ml from Day 28+|1
6110315|NCT00819156|9729185|FG005|Overall Study|Testosterone >1ng/ml from Day 28+|2
6110316|NCT00819156|9729180|FG000|Overall Study|Testosterone >=.5ng/ml 2 visits|3
6110317|NCT00819156|9729181|FG001|Overall Study|Testosterone >=.5ng/ml 2 visits|0
6110318|NCT00819156|9729182|FG002|Overall Study|Testosterone >=.5ng/ml 2 visits|0
6110319|NCT00819156|9729183|FG003|Overall Study|Testosterone >=.5ng/ml 2 visits|0
6110320|NCT00819156|9729184|FG004|Overall Study|Testosterone >=.5ng/ml 2 visits|1
6110321|NCT00819156|9729185|FG005|Overall Study|Testosterone >=.5ng/ml 2 visits|0
6110322|NCT00819156|9729180|FG000|Overall Study|Prostate-specific antigen progression|0
6110323|NCT00819156|9729181|FG001|Overall Study|Prostate-specific antigen progression|0
6110324|NCT00819156|9729182|FG002|Overall Study|Prostate-specific antigen progression|0
6110325|NCT00819156|9729183|FG003|Overall Study|Prostate-specific antigen progression|0
6110326|NCT00819156|9729184|FG004|Overall Study|Prostate-specific antigen progression|1
6110327|NCT00819156|9729185|FG005|Overall Study|Prostate-specific antigen progression|0
6110328|NCT00819234|9729220|FG000|Overall Study|Withdrawal by Subject|8
6110329|NCT00819234|9729221|FG001|Overall Study|Withdrawal by Subject|13
6110330|NCT00819234|9729222|FG002|Overall Study|Withdrawal by Subject|6
6110331|NCT00819234|9729223|FG003|Overall Study|Withdrawal by Subject|3
6110332|NCT00819234|9729224|FG004|Overall Study|Withdrawal by Subject|0
6110333|NCT00819234|9729225|FG005|Overall Study|Withdrawal by Subject|4
6110334|NCT00819234|9729226|FG006|Overall Study|Withdrawal by Subject|4
6206581|NCT01544582|9870052|FG002|Analysis Population|Intolerance|0
6206582|NCT01544582|9870053|FG003|Analysis Population|Intolerance|0
6206583|NCT01544582|9870050|FG000|Analysis Population|Liver Transplantation|0
6206584|NCT01544582|9870051|FG001|Analysis Population|Liver Transplantation|0
6206585|NCT01544582|9870052|FG002|Analysis Population|Liver Transplantation|1
6206586|NCT01544582|9870053|FG003|Analysis Population|Liver Transplantation|0
6206587|NCT01544582|9870050|FG000|Analysis Population|No Social Insurance|0
6206588|NCT01544582|9870051|FG001|Analysis Population|No Social Insurance|0
6206589|NCT01544582|9870052|FG002|Analysis Population|No Social Insurance|1
6206590|NCT01544582|9870053|FG003|Analysis Population|No Social Insurance|0
6206591|NCT01544582|9870050|FG000|Analysis Population|Poor Adherence|0
6206592|NCT01544582|9870051|FG001|Analysis Population|Poor Adherence|0
6206593|NCT01544582|9870052|FG002|Analysis Population|Poor Adherence|1
6206594|NCT01544582|9870053|FG003|Analysis Population|Poor Adherence|0
6206595|NCT01544582|9870050|FG000|Analysis Population|Poor Participant Compliance|0
6206596|NCT01544582|9870051|FG001|Analysis Population|Poor Participant Compliance|1
6206597|NCT01544582|9870052|FG002|Analysis Population|Poor Participant Compliance|0
6206598|NCT01544582|9870053|FG003|Analysis Population|Poor Participant Compliance|0
6206599|NCT01544582|9870050|FG000|Analysis Population|Programmed Surgery|0
6206600|NCT01544582|9870051|FG001|Analysis Population|Programmed Surgery|1
6206601|NCT01544582|9870052|FG002|Analysis Population|Programmed Surgery|0
6206602|NCT01544582|9870053|FG003|Analysis Population|Programmed Surgery|0
6206603|NCT01544582|9870050|FG000|Analysis Population|Participant in Jail|0
6206604|NCT01544582|9870051|FG001|Analysis Population|Participant in Jail|0
6206605|NCT01544582|9870052|FG002|Analysis Population|Participant in Jail|1
6206606|NCT01544582|9870053|FG003|Analysis Population|Participant in Jail|0
6206607|NCT01544595|9870072|FG000|Status at Week 68|Adverse Event|3
6206608|NCT01544595|9870073|FG001|Status at Week 68|Adverse Event|2
6206609|NCT01544595|9870074|FG002|Status at Week 68|Adverse Event|1
6206610|NCT01544595|9870075|FG003|Status at Week 68|Adverse Event|0
6206611|NCT01544595|9870076|FG004|Status at Week 68|Adverse Event|0
6206612|NCT01544595|9870077|FG005|Status at Week 68|Adverse Event|0
6206613|NCT01544595|9870072|FG000|Status at Week 68|Lack of Efficacy|1
6206614|NCT01544595|9870073|FG001|Status at Week 68|Lack of Efficacy|0
6206615|NCT01544595|9870074|FG002|Status at Week 68|Lack of Efficacy|0
6206616|NCT01544595|9870075|FG003|Status at Week 68|Lack of Efficacy|0
6206617|NCT01544595|9870076|FG004|Status at Week 68|Lack of Efficacy|0
6206618|NCT01544595|9870077|FG005|Status at Week 68|Lack of Efficacy|0
6206619|NCT01544595|9870072|FG000|Status at Week 68|Lost to Follow-up|1
6206620|NCT01544595|9870073|FG001|Status at Week 68|Lost to Follow-up|1
6206621|NCT01544595|9870074|FG002|Status at Week 68|Lost to Follow-up|0
6206622|NCT01544595|9870075|FG003|Status at Week 68|Lost to Follow-up|0
6206623|NCT01544595|9870076|FG004|Status at Week 68|Lost to Follow-up|0
6206624|NCT01544595|9870077|FG005|Status at Week 68|Lost to Follow-up|0
6206625|NCT01544595|9870072|FG000|Status at Week 68|Non-compliance with study treatment|1
6206626|NCT01544595|9870073|FG001|Status at Week 68|Non-compliance with study treatment|0
6206627|NCT01544595|9870074|FG002|Status at Week 68|Non-compliance with study treatment|0
6206628|NCT01544595|9870075|FG003|Status at Week 68|Non-compliance with study treatment|1
6206629|NCT01544595|9870076|FG004|Status at Week 68|Non-compliance with study treatment|0
6206630|NCT01544595|9870077|FG005|Status at Week 68|Non-compliance with study treatment|0
6206631|NCT01544595|9870072|FG000|Status at Week 68|Protocol Violation|2
6206632|NCT01544595|9870073|FG001|Status at Week 68|Protocol Violation|0
6206633|NCT01544595|9870074|FG002|Status at Week 68|Protocol Violation|1
6206634|NCT01544595|9870075|FG003|Status at Week 68|Protocol Violation|1
6206635|NCT01544595|9870076|FG004|Status at Week 68|Protocol Violation|0
6110335|NCT00819234|9729227|FG007|Overall Study|Withdrawal by Subject|8
6110336|NCT00819234|9729228|FG008|Overall Study|Withdrawal by Subject|5
6110337|NCT00819234|9729229|FG009|Overall Study|Withdrawal by Subject|3
6110338|NCT00819234|9729220|FG000|Overall Study|Adverse Event|0
6110339|NCT00819234|9729221|FG001|Overall Study|Adverse Event|0
6110340|NCT00819234|9729222|FG002|Overall Study|Adverse Event|1
6110341|NCT00819234|9729223|FG003|Overall Study|Adverse Event|0
6110342|NCT00819234|9729224|FG004|Overall Study|Adverse Event|0
6110343|NCT00819234|9729225|FG005|Overall Study|Adverse Event|2
6110344|NCT00819234|9729226|FG006|Overall Study|Adverse Event|0
6110345|NCT00819234|9729227|FG007|Overall Study|Adverse Event|0
6110346|NCT00819234|9729228|FG008|Overall Study|Adverse Event|0
6110347|NCT00819234|9729229|FG009|Overall Study|Adverse Event|0
6110348|NCT00819234|9729220|FG000|Overall Study|Physician Decision|0
6110349|NCT00819234|9729221|FG001|Overall Study|Physician Decision|0
6110350|NCT00819234|9729222|FG002|Overall Study|Physician Decision|0
6110351|NCT00819234|9729223|FG003|Overall Study|Physician Decision|1
6110352|NCT00819234|9729224|FG004|Overall Study|Physician Decision|0
6110353|NCT00819234|9729225|FG005|Overall Study|Physician Decision|0
6110354|NCT00819234|9729226|FG006|Overall Study|Physician Decision|0
6110355|NCT00819234|9729227|FG007|Overall Study|Physician Decision|0
6110356|NCT00819234|9729228|FG008|Overall Study|Physician Decision|0
6110357|NCT00819234|9729229|FG009|Overall Study|Physician Decision|2
6110358|NCT00819234|9729220|FG000|Overall Study|Protocol Violation|0
6110359|NCT00819234|9729221|FG001|Overall Study|Protocol Violation|0
6110360|NCT00819234|9729222|FG002|Overall Study|Protocol Violation|1
6110361|NCT00819234|9729223|FG003|Overall Study|Protocol Violation|0
6110362|NCT00819234|9729224|FG004|Overall Study|Protocol Violation|0
6110363|NCT00819234|9729225|FG005|Overall Study|Protocol Violation|0
6110364|NCT00819234|9729226|FG006|Overall Study|Protocol Violation|0
6110365|NCT00819234|9729227|FG007|Overall Study|Protocol Violation|0
6110366|NCT00819234|9729228|FG008|Overall Study|Protocol Violation|0
6110367|NCT00819234|9729229|FG009|Overall Study|Protocol Violation|0
6110368|NCT00819234|9729220|FG000|Overall Study|Lost to Follow-up|2
6110369|NCT00819234|9729221|FG001|Overall Study|Lost to Follow-up|2
6110370|NCT00819234|9729222|FG002|Overall Study|Lost to Follow-up|0
6110371|NCT00819234|9729223|FG003|Overall Study|Lost to Follow-up|2
6110372|NCT00819234|9729224|FG004|Overall Study|Lost to Follow-up|1
6110373|NCT00819234|9729225|FG005|Overall Study|Lost to Follow-up|1
6110374|NCT00819234|9729226|FG006|Overall Study|Lost to Follow-up|1
6110375|NCT00819234|9729227|FG007|Overall Study|Lost to Follow-up|1
6110376|NCT00819234|9729228|FG008|Overall Study|Lost to Follow-up|1
6110377|NCT00819234|9729229|FG009|Overall Study|Lost to Follow-up|2
6110378|NCT00819247|9729287|FG000|Overall Study|Adverse Event|0
6110379|NCT00819247|9729288|FG001|Overall Study|Adverse Event|5
6110380|NCT00819247|9729289|FG002|Overall Study|Adverse Event|3
6110381|NCT00819247|9729287|FG000|Overall Study|Insufficient testosterone response|5
6110382|NCT00819247|9729288|FG001|Overall Study|Insufficient testosterone response|8
6110383|NCT00819247|9729289|FG002|Overall Study|Insufficient testosterone response|10
6110384|NCT00819247|9729287|FG000|Overall Study|Withdrawal by Subject|1
6110385|NCT00819247|9729288|FG001|Overall Study|Withdrawal by Subject|0
6110386|NCT00819247|9729289|FG002|Overall Study|Withdrawal by Subject|0
6110387|NCT00819247|9729287|FG000|Overall Study|Protocol Violation|1
6110388|NCT00819247|9729288|FG001|Overall Study|Protocol Violation|0
6110389|NCT00819247|9729289|FG002|Overall Study|Protocol Violation|1
6110390|NCT00819247|9729287|FG000|Overall Study|Mistakenly withdrawn|0
6110391|NCT00819247|9729288|FG001|Overall Study|Mistakenly withdrawn|1
6110392|NCT00819247|9729289|FG002|Overall Study|Mistakenly withdrawn|0
6110393|NCT00819247|9729287|FG000|Overall Study|Bad prostate-specific antigen response|3
6110394|NCT00819247|9729288|FG001|Overall Study|Bad prostate-specific antigen response|2
6110395|NCT00819247|9729289|FG002|Overall Study|Bad prostate-specific antigen response|0
6110396|NCT00819247|9729287|FG000|Overall Study|Other|1
6110397|NCT00819247|9729288|FG001|Overall Study|Other|0
6110398|NCT00819247|9729289|FG002|Overall Study|Other|0
6110399|NCT00819390|9729316|FG000|Overall Study|Lost to Follow-up|1
6110400|NCT00819390|9729317|FG001|Overall Study|Lost to Follow-up|1
6206636|NCT01544595|9870077|FG005|Status at Week 68|Protocol Violation|0
6206637|NCT01544595|9870072|FG000|Status at Week 68|Technical problems|1
6206638|NCT01544595|9870073|FG001|Status at Week 68|Technical problems|0
6206639|NCT01544595|9870074|FG002|Status at Week 68|Technical problems|0
6206640|NCT01544595|9870075|FG003|Status at Week 68|Technical problems|1
6206641|NCT01544595|9870076|FG004|Status at Week 68|Technical problems|0
6206642|NCT01544595|9870077|FG005|Status at Week 68|Technical problems|0
6206643|NCT01544595|9870072|FG000|Status at Week 68|Withdrawal by Subject|0
6206644|NCT01544595|9870073|FG001|Status at Week 68|Withdrawal by Subject|1
6206645|NCT01544595|9870074|FG002|Status at Week 68|Withdrawal by Subject|1
6206646|NCT01544595|9870075|FG003|Status at Week 68|Withdrawal by Subject|2
6110401|NCT00819390|9729318|FG002|Overall Study|Lost to Follow-up|0
6110402|NCT00819390|9729319|FG003|Overall Study|Lost to Follow-up|0
6110403|NCT00819390|9729316|FG000|Overall Study|Withdrawal by Subject|2
6110404|NCT00819390|9729317|FG001|Overall Study|Withdrawal by Subject|0
6110405|NCT00819390|9729318|FG002|Overall Study|Withdrawal by Subject|0
6110406|NCT00819390|9729319|FG003|Overall Study|Withdrawal by Subject|0
6110407|NCT00819390|9729316|FG000|Overall Study|Adverse Event|0
6206647|NCT01544595|9870076|FG004|Status at Week 68|Withdrawal by Subject|0
6110408|NCT00819390|9729317|FG001|Overall Study|Adverse Event|0
6110409|NCT00819390|9729318|FG002|Overall Study|Adverse Event|1
6110410|NCT00819390|9729319|FG003|Overall Study|Adverse Event|0
6110411|NCT00819585|9729353|FG000|Core Study|Adverse Event|2
6110412|NCT00819585|9729354|FG001|Core Study|Adverse Event|1
6110413|NCT00819585|9729355|FG002|Core Study|Adverse Event|1
6110414|NCT00819585|9729356|FG003|Core Study|Adverse Event|4
6110415|NCT00819585|9729357|FG004|Core Study|Adverse Event|1
6110416|NCT00819585|9729358|FG005|Core Study|Adverse Event|0
6110417|NCT00819585|9729359|FG006|Core Study|Adverse Event|2
6110418|NCT00819585|9729360|FG007|Core Study|Adverse Event|0
6110419|NCT00819585|9729361|FG008|Core Study|Adverse Event|0
6110420|NCT00819585|9729362|FG009|Core Study|Adverse Event|0
6110421|NCT00819585|9729363|FG010|Core Study|Adverse Event|0
6110422|NCT00819585|9729353|FG000|Core Study|Abnormal Laboratory Value(s)|2
6110423|NCT00819585|9729354|FG001|Core Study|Abnormal Laboratory Value(s)|0
6110424|NCT00819585|9729355|FG002|Core Study|Abnormal Laboratory Value(s)|0
6110425|NCT00819585|9729356|FG003|Core Study|Abnormal Laboratory Value(s)|0
6110426|NCT00819585|9729357|FG004|Core Study|Abnormal Laboratory Value(s)|0
6110427|NCT00819585|9729358|FG005|Core Study|Abnormal Laboratory Value(s)|0
6110428|NCT00819585|9729359|FG006|Core Study|Abnormal Laboratory Value(s)|0
6110429|NCT00819585|9729360|FG007|Core Study|Abnormal Laboratory Value(s)|0
6110430|NCT00819585|9729361|FG008|Core Study|Abnormal Laboratory Value(s)|0
6110431|NCT00819585|9729362|FG009|Core Study|Abnormal Laboratory Value(s)|0
6110432|NCT00819585|9729363|FG010|Core Study|Abnormal Laboratory Value(s)|0
6110433|NCT00819585|9729353|FG000|Core Study|Unsatisfactory Therapeutic Effect|0
6110434|NCT00819585|9729354|FG001|Core Study|Unsatisfactory Therapeutic Effect|1
6110435|NCT00819585|9729355|FG002|Core Study|Unsatisfactory Therapeutic Effect|0
6110436|NCT00819585|9729356|FG003|Core Study|Unsatisfactory Therapeutic Effect|0
6110437|NCT00819585|9729357|FG004|Core Study|Unsatisfactory Therapeutic Effect|0
6110438|NCT00819585|9729358|FG005|Core Study|Unsatisfactory Therapeutic Effect|0
6110439|NCT00819585|9729359|FG006|Core Study|Unsatisfactory Therapeutic Effect|1
6110440|NCT00819585|9729360|FG007|Core Study|Unsatisfactory Therapeutic Effect|0
6110441|NCT00819585|9729361|FG008|Core Study|Unsatisfactory Therapeutic Effect|0
6110442|NCT00819585|9729362|FG009|Core Study|Unsatisfactory Therapeutic Effect|0
6110443|NCT00819585|9729363|FG010|Core Study|Unsatisfactory Therapeutic Effect|0
6110444|NCT00819585|9729353|FG000|Core Study|Subject No Longer Requires Study Drug|0
6110445|NCT00819585|9729354|FG001|Core Study|Subject No Longer Requires Study Drug|0
6110446|NCT00819585|9729355|FG002|Core Study|Subject No Longer Requires Study Drug|0
6110447|NCT00819585|9729356|FG003|Core Study|Subject No Longer Requires Study Drug|0
6110448|NCT00819585|9729357|FG004|Core Study|Subject No Longer Requires Study Drug|1
6110449|NCT00819585|9729358|FG005|Core Study|Subject No Longer Requires Study Drug|0
6110450|NCT00819585|9729359|FG006|Core Study|Subject No Longer Requires Study Drug|0
6110451|NCT00819585|9729360|FG007|Core Study|Subject No Longer Requires Study Drug|0
6110452|NCT00819585|9729361|FG008|Core Study|Subject No Longer Requires Study Drug|0
6110453|NCT00819585|9729362|FG009|Core Study|Subject No Longer Requires Study Drug|0
6110454|NCT00819585|9729363|FG010|Core Study|Subject No Longer Requires Study Drug|0
6110455|NCT00819585|9729353|FG000|Core Study|Subject Withdrew Consent|0
6110456|NCT00819585|9729354|FG001|Core Study|Subject Withdrew Consent|3
6110457|NCT00819585|9729355|FG002|Core Study|Subject Withdrew Consent|2
6110458|NCT00819585|9729356|FG003|Core Study|Subject Withdrew Consent|1
6110459|NCT00819585|9729357|FG004|Core Study|Subject Withdrew Consent|0
6110460|NCT00819585|9729358|FG005|Core Study|Subject Withdrew Consent|0
6110461|NCT00819585|9729359|FG006|Core Study|Subject Withdrew Consent|3
6110462|NCT00819585|9729360|FG007|Core Study|Subject Withdrew Consent|0
6110463|NCT00819585|9729361|FG008|Core Study|Subject Withdrew Consent|0
6110464|NCT00819585|9729362|FG009|Core Study|Subject Withdrew Consent|0
6110465|NCT00819585|9729363|FG010|Core Study|Subject Withdrew Consent|0
6110466|NCT00819585|9729353|FG000|Core Study|Lost to Follow-up|2
6110467|NCT00819585|9729354|FG001|Core Study|Lost to Follow-up|1
6110468|NCT00819585|9729355|FG002|Core Study|Lost to Follow-up|2
6110469|NCT00819585|9729356|FG003|Core Study|Lost to Follow-up|0
6110470|NCT00819585|9729357|FG004|Core Study|Lost to Follow-up|1
6110471|NCT00819585|9729358|FG005|Core Study|Lost to Follow-up|1
6110472|NCT00819585|9729359|FG006|Core Study|Lost to Follow-up|1
6110473|NCT00819585|9729360|FG007|Core Study|Lost to Follow-up|0
6110474|NCT00819585|9729361|FG008|Core Study|Lost to Follow-up|0
6110475|NCT00819585|9729362|FG009|Core Study|Lost to Follow-up|0
6110476|NCT00819585|9729363|FG010|Core Study|Lost to Follow-up|0
6110477|NCT00819585|9729353|FG000|Core Study|Administrative Problems|0
6110478|NCT00819585|9729354|FG001|Core Study|Administrative Problems|0
6110479|NCT00819585|9729355|FG002|Core Study|Administrative Problems|0
6110480|NCT00819585|9729356|FG003|Core Study|Administrative Problems|0
6110481|NCT00819585|9729357|FG004|Core Study|Administrative Problems|0
6110482|NCT00819585|9729358|FG005|Core Study|Administrative Problems|0
6110483|NCT00819585|9729359|FG006|Core Study|Administrative Problems|2
6110484|NCT00819585|9729360|FG007|Core Study|Administrative Problems|0
6110485|NCT00819585|9729361|FG008|Core Study|Administrative Problems|0
6110486|NCT00819585|9729362|FG009|Core Study|Administrative Problems|0
6110487|NCT00819585|9729363|FG010|Core Study|Administrative Problems|0
6110488|NCT00819585|9729353|FG000|Core Study|Death|0
6110489|NCT00819585|9729354|FG001|Core Study|Death|0
6110490|NCT00819585|9729355|FG002|Core Study|Death|0
6110491|NCT00819585|9729356|FG003|Core Study|Death|0
6110492|NCT00819585|9729357|FG004|Core Study|Death|0
6110493|NCT00819585|9729358|FG005|Core Study|Death|0
6110494|NCT00819585|9729359|FG006|Core Study|Death|1
6110495|NCT00819585|9729360|FG007|Core Study|Death|0
6110496|NCT00819585|9729361|FG008|Core Study|Death|0
6110497|NCT00819585|9729362|FG009|Core Study|Death|0
6110498|NCT00819585|9729363|FG010|Core Study|Death|0
6110499|NCT00819585|9729353|FG000|Core Study|Protocol Violation|0
6110500|NCT00819585|9729354|FG001|Core Study|Protocol Violation|0
6110501|NCT00819585|9729355|FG002|Core Study|Protocol Violation|1
6110502|NCT00819585|9729356|FG003|Core Study|Protocol Violation|0
6110503|NCT00819585|9729357|FG004|Core Study|Protocol Violation|0
6110504|NCT00819585|9729358|FG005|Core Study|Protocol Violation|1
6110505|NCT00819585|9729359|FG006|Core Study|Protocol Violation|3
6110506|NCT00819585|9729360|FG007|Core Study|Protocol Violation|0
6110507|NCT00819585|9729361|FG008|Core Study|Protocol Violation|0
6110508|NCT00819585|9729362|FG009|Core Study|Protocol Violation|0
6110509|NCT00819585|9729363|FG010|Core Study|Protocol Violation|0
6110510|NCT00819585|9729353|FG000|Extension Study|Abnormal Laboratory Value(s)|0
6110511|NCT00819585|9729354|FG001|Extension Study|Abnormal Laboratory Value(s)|0
6110512|NCT00819585|9729355|FG002|Extension Study|Abnormal Laboratory Value(s)|0
6110513|NCT00819585|9729356|FG003|Extension Study|Abnormal Laboratory Value(s)|0
6110514|NCT00819585|9729357|FG004|Extension Study|Abnormal Laboratory Value(s)|0
6110515|NCT00819585|9729358|FG005|Extension Study|Abnormal Laboratory Value(s)|0
6110516|NCT00819585|9729359|FG006|Extension Study|Abnormal Laboratory Value(s)|0
6110517|NCT00819585|9729360|FG007|Extension Study|Abnormal Laboratory Value(s)|0
6110518|NCT00819585|9729361|FG008|Extension Study|Abnormal Laboratory Value(s)|1
6110519|NCT00819585|9729362|FG009|Extension Study|Abnormal Laboratory Value(s)|0
6110520|NCT00819585|9729363|FG010|Extension Study|Abnormal Laboratory Value(s)|0
6110521|NCT00819585|9729353|FG000|Extension Study|Subject Withdrew Consent|0
6110522|NCT00819585|9729354|FG001|Extension Study|Subject Withdrew Consent|0
6110523|NCT00819585|9729355|FG002|Extension Study|Subject Withdrew Consent|0
6110524|NCT00819585|9729356|FG003|Extension Study|Subject Withdrew Consent|0
6110525|NCT00819585|9729357|FG004|Extension Study|Subject Withdrew Consent|0
6110526|NCT00819585|9729358|FG005|Extension Study|Subject Withdrew Consent|0
6110527|NCT00819585|9729359|FG006|Extension Study|Subject Withdrew Consent|0
6110528|NCT00819585|9729360|FG007|Extension Study|Subject Withdrew Consent|0
6110529|NCT00819585|9729361|FG008|Extension Study|Subject Withdrew Consent|3
6110530|NCT00819585|9729362|FG009|Extension Study|Subject Withdrew Consent|0
6110531|NCT00819585|9729363|FG010|Extension Study|Subject Withdrew Consent|1
6110532|NCT00819585|9729353|FG000|Extension Study|Lost to Follow-up|0
6110533|NCT00819585|9729354|FG001|Extension Study|Lost to Follow-up|0
6110534|NCT00819585|9729355|FG002|Extension Study|Lost to Follow-up|0
6110535|NCT00819585|9729356|FG003|Extension Study|Lost to Follow-up|0
6110536|NCT00819585|9729357|FG004|Extension Study|Lost to Follow-up|0
6110537|NCT00819585|9729358|FG005|Extension Study|Lost to Follow-up|0
6110538|NCT00819585|9729359|FG006|Extension Study|Lost to Follow-up|0
6110539|NCT00819585|9729360|FG007|Extension Study|Lost to Follow-up|0
6110540|NCT00819585|9729361|FG008|Extension Study|Lost to Follow-up|2
6110541|NCT00819585|9729362|FG009|Extension Study|Lost to Follow-up|1
6110542|NCT00819585|9729363|FG010|Extension Study|Lost to Follow-up|1
6110543|NCT00819585|9729353|FG000|Extension Study|Death|0
6110544|NCT00819585|9729354|FG001|Extension Study|Death|0
6110545|NCT00819585|9729355|FG002|Extension Study|Death|0
6110546|NCT00819585|9729356|FG003|Extension Study|Death|0
6110547|NCT00819585|9729357|FG004|Extension Study|Death|0
6110548|NCT00819585|9729358|FG005|Extension Study|Death|0
6110549|NCT00819585|9729359|FG006|Extension Study|Death|0
6206648|NCT01544595|9870077|FG005|Status at Week 68|Withdrawal by Subject|0
6206649|NCT01544595|9870072|FG000|Status at Week 68|Moved to treatment period ≤ wk 68|30
6206650|NCT01544595|9870073|FG001|Status at Week 68|Moved to treatment period ≤ wk 68|13
6206651|NCT01544595|9870074|FG002|Status at Week 68|Moved to treatment period ≤ wk 68|60
6206652|NCT01544595|9870075|FG003|Status at Week 68|Moved to treatment period ≤ wk 68|46
6206653|NCT01544595|9870076|FG004|Status at Week 68|Moved to treatment period ≤ wk 68|0
6110550|NCT00819585|9729360|FG007|Extension Study|Death|0
6110551|NCT00819585|9729361|FG008|Extension Study|Death|2
6110552|NCT00819585|9729362|FG009|Extension Study|Death|0
6110553|NCT00819585|9729363|FG010|Extension Study|Death|0
6110554|NCT00819741|9729406|FG000|Overall Study|Adverse Event|5
6110555|NCT00819741|9729407|FG001|Overall Study|Adverse Event|2
6110556|NCT00819741|9729406|FG000|Overall Study|Lack of Efficacy|0
6110557|NCT00819741|9729407|FG001|Overall Study|Lack of Efficacy|2
6110558|NCT00819741|9729406|FG000|Overall Study|Lost to Follow-up|3
6110559|NCT00819741|9729407|FG001|Overall Study|Lost to Follow-up|1
6110560|NCT00819741|9729406|FG000|Overall Study|Protocol Violation|3
6110561|NCT00819741|9729407|FG001|Overall Study|Protocol Violation|4
6110562|NCT00819741|9729406|FG000|Overall Study|Withdrawal by Subject|2
6110563|NCT00819741|9729407|FG001|Overall Study|Withdrawal by Subject|2
6110564|NCT00819741|9729406|FG000|Overall Study|Unclassified|6
6110565|NCT00819741|9729407|FG001|Overall Study|Unclassified|0
6110566|NCT00819741|9729406|FG000|Overall Study|Reasons unknown|3
6110567|NCT00819741|9729407|FG001|Overall Study|Reasons unknown|3
6110568|NCT00819767|9729415|FG000|Overall Study|Unsatisfactory therapeutic effect|1
6110569|NCT00819767|9729416|FG001|Overall Study|Unsatisfactory therapeutic effect|2
6110570|NCT00819780|9729424|FG000|Overall Study|Did not receive study drug|3
6110571|NCT00819780|9729425|FG001|Overall Study|Did not receive study drug|4
6110572|NCT00819780|9729424|FG000|Overall Study|Still in treatment|25
6110573|NCT00819780|9729425|FG001|Overall Study|Still in treatment|17
6110574|NCT00819910|9729440|FG000|Overall Study|Adverse Event|0
6110575|NCT00819910|9729441|FG001|Overall Study|Adverse Event|0
6110576|NCT00819910|9729442|FG002|Overall Study|Adverse Event|2
6110577|NCT00819910|9729443|FG003|Overall Study|Adverse Event|1
6110578|NCT00819910|9729440|FG000|Overall Study|Withdrawal by Subject|1
6110579|NCT00819910|9729441|FG001|Overall Study|Withdrawal by Subject|1
6110580|NCT00819910|9729442|FG002|Overall Study|Withdrawal by Subject|1
6110581|NCT00819910|9729443|FG003|Overall Study|Withdrawal by Subject|0
6110582|NCT00819910|9729440|FG000|Overall Study|Lost to Follow-up|1
6110583|NCT00819910|9729441|FG001|Overall Study|Lost to Follow-up|0
6110584|NCT00819910|9729442|FG002|Overall Study|Lost to Follow-up|0
6110585|NCT00819910|9729443|FG003|Overall Study|Lost to Follow-up|0
6110586|NCT00820040|9729455|FG000|Overall Study|Death|1
6110587|NCT00820040|9729455|FG000|Overall Study|Sponsor terminated study|1
6110588|NCT00820040|9729455|FG000|Overall Study|Screen failure|1
6110589|NCT00820170|9729464|FG000|Overall Study|Adverse Event|0
6110590|NCT00820170|9729465|FG001|Overall Study|Adverse Event|0
6110591|NCT00820170|9729466|FG002|Overall Study|Adverse Event|0
6110592|NCT00820170|9729467|FG003|Overall Study|Adverse Event|0
6110593|NCT00820170|9729468|FG004|Overall Study|Adverse Event|2
6110594|NCT00820170|9729464|FG000|Overall Study|Progressive Disease|0
6110595|NCT00820170|9729465|FG001|Overall Study|Progressive Disease|0
6110596|NCT00820170|9729466|FG002|Overall Study|Progressive Disease|0
6110597|NCT00820170|9729467|FG003|Overall Study|Progressive Disease|0
6110598|NCT00820170|9729468|FG004|Overall Study|Progressive Disease|2
6110599|NCT00820222|9729487|FG000|Overall Study|Lost to Follow-up|10
6110600|NCT00820222|9729488|FG001|Overall Study|Lost to Follow-up|9
6110601|NCT00820222|9729487|FG000|Overall Study|Withdrawal by Subject|19
6110602|NCT00820222|9729488|FG001|Overall Study|Withdrawal by Subject|21
6110603|NCT00820222|9729487|FG000|Overall Study|Physician Decision|93
6110604|NCT00820222|9729488|FG001|Overall Study|Physician Decision|88
6110605|NCT00820222|9729487|FG000|Overall Study|Sponsor Terminated Study|43
6110606|NCT00820222|9729488|FG001|Overall Study|Sponsor Terminated Study|65
6110607|NCT00820222|9729487|FG000|Overall Study|Unkown|11
6110608|NCT00820222|9729488|FG001|Overall Study|Unkown|7
6110609|NCT00820248|9729509|FG000|Overall Study|No treated|4
6110610|NCT00820248|9729510|FG001|Overall Study|No treated|1
6206654|NCT01544595|9870077|FG005|Status at Week 68|Moved to treatment period ≤ wk 68|0
6206655|NCT01544595|9870072|FG000|Status at Week 156|Withdrawal by Subject|9
6206656|NCT01544595|9870073|FG001|Status at Week 156|Withdrawal by Subject|10
6206657|NCT01544595|9870074|FG002|Status at Week 156|Withdrawal by Subject|4
6206658|NCT01544595|9870075|FG003|Status at Week 156|Withdrawal by Subject|9
6206659|NCT01544595|9870076|FG004|Status at Week 156|Withdrawal by Subject|20
6206660|NCT01544595|9870077|FG005|Status at Week 156|Withdrawal by Subject|6
6206661|NCT01544595|9870072|FG000|Status at Week 156|Adverse Event|9
6206662|NCT01544595|9870073|FG001|Status at Week 156|Adverse Event|11
6206663|NCT01544595|9870074|FG002|Status at Week 156|Adverse Event|1
6206664|NCT01544595|9870075|FG003|Status at Week 156|Adverse Event|3
6206665|NCT01544595|9870076|FG004|Status at Week 156|Adverse Event|4
6206666|NCT01544595|9870077|FG005|Status at Week 156|Adverse Event|2
6206667|NCT01544595|9870072|FG000|Status at Week 156|Lost to Follow-up|4
6206668|NCT01544595|9870073|FG001|Status at Week 156|Lost to Follow-up|4
6206669|NCT01544595|9870074|FG002|Status at Week 156|Lost to Follow-up|0
6206670|NCT01544595|9870075|FG003|Status at Week 156|Lost to Follow-up|1
6206671|NCT01544595|9870076|FG004|Status at Week 156|Lost to Follow-up|4
6206672|NCT01544595|9870077|FG005|Status at Week 156|Lost to Follow-up|1
6206673|NCT01544595|9870072|FG000|Status at Week 156|Non-compliance with study treatement|0
6206674|NCT01544595|9870073|FG001|Status at Week 156|Non-compliance with study treatement|1
6206675|NCT01544595|9870074|FG002|Status at Week 156|Non-compliance with study treatement|0
6206676|NCT01544595|9870075|FG003|Status at Week 156|Non-compliance with study treatement|1
6206677|NCT01544595|9870076|FG004|Status at Week 156|Non-compliance with study treatement|0
6206678|NCT01544595|9870077|FG005|Status at Week 156|Non-compliance with study treatement|1
6206679|NCT01544595|9870072|FG000|Status at Week 156|Physician Decision|0
6206680|NCT01544595|9870073|FG001|Status at Week 156|Physician Decision|3
6206681|NCT01544595|9870074|FG002|Status at Week 156|Physician Decision|1
6206682|NCT01544595|9870075|FG003|Status at Week 156|Physician Decision|0
6206683|NCT01544595|9870076|FG004|Status at Week 156|Physician Decision|0
6206684|NCT01544595|9870077|FG005|Status at Week 156|Physician Decision|0
6206685|NCT01544595|9870072|FG000|Status at Week 156|Pregnancy|2
6206686|NCT01544595|9870073|FG001|Status at Week 156|Pregnancy|3
6206687|NCT01544595|9870074|FG002|Status at Week 156|Pregnancy|0
6206688|NCT01544595|9870075|FG003|Status at Week 156|Pregnancy|0
6206689|NCT01544595|9870076|FG004|Status at Week 156|Pregnancy|0
6206690|NCT01544595|9870077|FG005|Status at Week 156|Pregnancy|0
6206691|NCT01544595|9870072|FG000|Status at Week 156|Protocol Violation|3
6206692|NCT01544595|9870073|FG001|Status at Week 156|Protocol Violation|1
6206693|NCT01544595|9870074|FG002|Status at Week 156|Protocol Violation|2
6206694|NCT01544595|9870075|FG003|Status at Week 156|Protocol Violation|2
6206695|NCT01544595|9870076|FG004|Status at Week 156|Protocol Violation|0
6206696|NCT01544595|9870077|FG005|Status at Week 156|Protocol Violation|0
6110611|NCT00820599|9729556|FG000|Overall Study|Death|129
6110612|NCT00820599|9729556|FG000|Overall Study|Withdrawal by Subject|2
6110613|NCT00820755|9729582|FG000|Period 1: Combination Therapy Phase|Adverse Event|77
6110614|NCT00820755|9729583|FG001|Period 1: Combination Therapy Phase|Adverse Event|0
6110615|NCT00820755|9729584|FG002|Period 1: Combination Therapy Phase|Adverse Event|0
6110616|NCT00820755|9729582|FG000|Period 1: Combination Therapy Phase|Death|28
6110617|NCT00820755|9729583|FG001|Period 1: Combination Therapy Phase|Death|0
6110618|NCT00820755|9729584|FG002|Period 1: Combination Therapy Phase|Death|0
6110619|NCT00820755|9729582|FG000|Period 1: Combination Therapy Phase|Protocol Violation|4
6110620|NCT00820755|9729583|FG001|Period 1: Combination Therapy Phase|Protocol Violation|0
6110621|NCT00820755|9729584|FG002|Period 1: Combination Therapy Phase|Protocol Violation|0
6110622|NCT00820755|9729582|FG000|Period 1: Combination Therapy Phase|Lost to Follow-up|1
6110623|NCT00820755|9729583|FG001|Period 1: Combination Therapy Phase|Lost to Follow-up|0
6110624|NCT00820755|9729584|FG002|Period 1: Combination Therapy Phase|Lost to Follow-up|0
6110625|NCT00820755|9729582|FG000|Period 1: Combination Therapy Phase|Withdrawal by Subject|21
6110626|NCT00820755|9729583|FG001|Period 1: Combination Therapy Phase|Withdrawal by Subject|0
6110627|NCT00820755|9729584|FG002|Period 1: Combination Therapy Phase|Withdrawal by Subject|0
6110628|NCT00820755|9729582|FG000|Period 1: Combination Therapy Phase|Progressive disease|114
6110629|NCT00820755|9729583|FG001|Period 1: Combination Therapy Phase|Progressive disease|0
6110630|NCT00820755|9729584|FG002|Period 1: Combination Therapy Phase|Progressive disease|0
6110631|NCT00820755|9729582|FG000|Period 1: Combination Therapy Phase|Sympt. deterioration w/o PD by imaging|14
6110632|NCT00820755|9729583|FG001|Period 1: Combination Therapy Phase|Sympt. deterioration w/o PD by imaging|0
6110633|NCT00820755|9729584|FG002|Period 1: Combination Therapy Phase|Sympt. deterioration w/o PD by imaging|0
6110634|NCT00820755|9729582|FG000|Period 1: Combination Therapy Phase|Other|11
6110635|NCT00820755|9729583|FG001|Period 1: Combination Therapy Phase|Other|0
6110636|NCT00820755|9729584|FG002|Period 1: Combination Therapy Phase|Other|0
6110637|NCT00820755|9729582|FG000|Period 2: Maintenance Therapy Phase|Investigational study phase ongoing|0
6110638|NCT00820755|9729583|FG001|Period 2: Maintenance Therapy Phase|Investigational study phase ongoing|45
6110639|NCT00820755|9729584|FG002|Period 2: Maintenance Therapy Phase|Investigational study phase ongoing|45
6110640|NCT00820898|9729596|FG000|Overall Study|Inelgible - wrong primary site|1
6110641|NCT00821015|9729606|FG000|Overall Study|Lost to Follow-up|12
6110642|NCT00821093|9729621|FG000|Overall Study|Adverse Event|20
6110643|NCT00821093|9729622|FG001|Overall Study|Adverse Event|12
6110644|NCT00821093|9729621|FG000|Overall Study|Withdrawal by Subject|9
6110645|NCT00821093|9729622|FG001|Overall Study|Withdrawal by Subject|13
6110646|NCT00821093|9729621|FG000|Overall Study|Lost to Follow-up|9
6110647|NCT00821093|9729622|FG001|Overall Study|Lost to Follow-up|3
6110648|NCT00821093|9729621|FG000|Overall Study|Protocol deviation|3
6110649|NCT00821093|9729622|FG001|Overall Study|Protocol deviation|6
6110650|NCT00821093|9729621|FG000|Overall Study|Abnormal laboratory value(s)|2
6110651|NCT00821093|9729622|FG001|Overall Study|Abnormal laboratory value(s)|0
6110652|NCT00821093|9729621|FG000|Overall Study|Lack of Efficacy|2
6110653|NCT00821093|9729622|FG001|Overall Study|Lack of Efficacy|2
6110654|NCT00821093|9729621|FG000|Overall Study|Death|2
6110655|NCT00821093|9729622|FG001|Overall Study|Death|1
6110656|NCT00821093|9729621|FG000|Overall Study|Abnormal test procedure result(s)|1
6110657|NCT00821093|9729622|FG001|Overall Study|Abnormal test procedure result(s)|1
6110658|NCT00821093|9729621|FG000|Overall Study|Administrative problems|1
6110659|NCT00821093|9729622|FG001|Overall Study|Administrative problems|2
6206697|NCT01544595|9870072|FG000|Status at Week 156|Technical problems|3
6206698|NCT01544595|9870073|FG001|Status at Week 156|Technical problems|1
6206699|NCT01544595|9870074|FG002|Status at Week 156|Technical problems|0
6206700|NCT01544595|9870075|FG003|Status at Week 156|Technical problems|1
6206701|NCT01544595|9870076|FG004|Status at Week 156|Technical problems|0
6206702|NCT01544595|9870077|FG005|Status at Week 156|Technical problems|0
6206703|NCT01544595|9870072|FG000|Status at Week 156|Moved to treatment period ≤ wk 156|86
6206704|NCT01544595|9870073|FG001|Status at Week 156|Moved to treatment period ≤ wk 156|44
6206705|NCT01544595|9870074|FG002|Status at Week 156|Moved to treatment period ≤ wk 156|131
6206706|NCT01544595|9870075|FG003|Status at Week 156|Moved to treatment period ≤ wk 156|145
6206707|NCT01544595|9870076|FG004|Status at Week 156|Moved to treatment period ≤ wk 156|0
6206708|NCT01544595|9870077|FG005|Status at Week 156|Moved to treatment period ≤ wk 156|0
6206709|NCT01544595|9870072|FG000|Status at Week 156|Lack of Efficacy|1
6206710|NCT01544595|9870073|FG001|Status at Week 156|Lack of Efficacy|0
6206711|NCT01544595|9870074|FG002|Status at Week 156|Lack of Efficacy|1
6206712|NCT01544595|9870075|FG003|Status at Week 156|Lack of Efficacy|4
6206713|NCT01544595|9870076|FG004|Status at Week 156|Lack of Efficacy|10
6206714|NCT01544595|9870077|FG005|Status at Week 156|Lack of Efficacy|5
6206715|NCT01544920|9870097|FG000|Overall Study|Adverse Event|0
6206716|NCT01544920|9870098|FG001|Overall Study|Adverse Event|3
6206717|NCT01544920|9870097|FG000|Overall Study|Death|0
6206718|NCT01544920|9870098|FG001|Overall Study|Death|1
6206719|NCT01544920|9870097|FG000|Overall Study|Lost to Follow-up|11
6206720|NCT01544920|9870098|FG001|Overall Study|Lost to Follow-up|12
6206721|NCT01544920|9870097|FG000|Overall Study|Protocol Violation|0
6206722|NCT01544920|9870098|FG001|Overall Study|Protocol Violation|2
6206723|NCT01544920|9870097|FG000|Overall Study|Physician Decision|4
6206724|NCT01544920|9870098|FG001|Overall Study|Physician Decision|1
6110660|NCT04187989|9729652|FG000|Overall Study - 3-Month Follow-Up|Lost to Follow-up|6
6110661|NCT04187989|9729653|FG001|Overall Study - 3-Month Follow-Up|Lost to Follow-up|8
6110662|NCT04187989|9729652|FG000|Overall Study - 6-Month Follow-Up|Lost to Follow-up|8
6110663|NCT04187989|9729653|FG001|Overall Study - 6-Month Follow-Up|Lost to Follow-up|8
6110664|NCT04109118|9729659|FG000|Overall Study|Lost to Follow-up|3
6110665|NCT04045132|9729666|FG000|Overall Study|Lost to Follow-up|3
6110666|NCT04045132|9729667|FG001|Overall Study|Lost to Follow-up|7
6110667|NCT03846219|9729678|FG000|Overall Study|Withdrawal by Subject|3
6110668|NCT03846219|9729679|FG001|Overall Study|Withdrawal by Subject|2
6110669|NCT03846219|9729680|FG002|Overall Study|Withdrawal by Subject|2
6110670|NCT03846219|9729678|FG000|Overall Study|Fulfilled hepatoxicity-related stopping rules|0
6110671|NCT03846219|9729679|FG001|Overall Study|Fulfilled hepatoxicity-related stopping rules|2
6110672|NCT03846219|9729680|FG002|Overall Study|Fulfilled hepatoxicity-related stopping rules|1
6110673|NCT03846219|9729678|FG000|Overall Study|Physician Decision|0
6110674|NCT03846219|9729679|FG001|Overall Study|Physician Decision|0
6110675|NCT03846219|9729680|FG002|Overall Study|Physician Decision|2
6110676|NCT03606668|9729722|FG000|Overall Study|Screen Failure|1
6110677|NCT03606668|9729722|FG000|Overall Study|Lost to Follow-up|1
6110678|NCT03575897|9729728|FG000|Overall Study|Lost to Follow-up|12
6110679|NCT03575897|9729729|FG001|Overall Study|Lost to Follow-up|13
6110680|NCT03343626|9729743|FG000|Overall Study|Lost to Follow-up|4
6110681|NCT03343626|9729744|FG001|Overall Study|Lost to Follow-up|3
6110682|NCT03343626|9729745|FG002|Overall Study|Lost to Follow-up|2
6110683|NCT03343626|9729746|FG003|Overall Study|Lost to Follow-up|5
6110684|NCT03343626|9729747|FG004|Overall Study|Lost to Follow-up|4
6110685|NCT03343626|9729748|FG005|Overall Study|Lost to Follow-up|4
6110686|NCT03343626|9729749|FG006|Overall Study|Lost to Follow-up|4
6110687|NCT03343626|9729750|FG007|Overall Study|Lost to Follow-up|7
6110688|NCT03343626|9729743|FG000|Overall Study|Withdrawal of Consent|2
6110689|NCT03343626|9729744|FG001|Overall Study|Withdrawal of Consent|1
6110690|NCT03343626|9729745|FG002|Overall Study|Withdrawal of Consent|0
6110691|NCT03343626|9729746|FG003|Overall Study|Withdrawal of Consent|3
6206725|NCT01544920|9870097|FG000|Overall Study|Withdrawal by Subject|4
6206726|NCT01544920|9870098|FG001|Overall Study|Withdrawal by Subject|4
6206727|NCT01545076|9870115|FG000|IgPro10 Restabilization Period|Adverse Event|4
6206728|NCT01545076|9870116|FG001|IgPro10 Restabilization Period|Adverse Event|0
6206729|NCT01545076|9870117|FG002|IgPro10 Restabilization Period|Adverse Event|0
6206730|NCT01545076|9870118|FG003|IgPro10 Restabilization Period|Adverse Event|0
6206731|NCT01545076|9870119|FG004|IgPro10 Restabilization Period|Adverse Event|0
6206732|NCT01545076|9870115|FG000|IgPro10 Restabilization Period|Physician Decision|2
6206733|NCT01545076|9870116|FG001|IgPro10 Restabilization Period|Physician Decision|0
6206734|NCT01545076|9870117|FG002|IgPro10 Restabilization Period|Physician Decision|0
6206735|NCT01545076|9870118|FG003|IgPro10 Restabilization Period|Physician Decision|0
6206736|NCT01545076|9870119|FG004|IgPro10 Restabilization Period|Physician Decision|0
6206737|NCT01545076|9870115|FG000|IgPro10 Restabilization Period|Protocol Violation|1
6206738|NCT01545076|9870116|FG001|IgPro10 Restabilization Period|Protocol Violation|0
6206739|NCT01545076|9870117|FG002|IgPro10 Restabilization Period|Protocol Violation|0
6206740|NCT01545076|9870118|FG003|IgPro10 Restabilization Period|Protocol Violation|0
6206741|NCT01545076|9870119|FG004|IgPro10 Restabilization Period|Protocol Violation|0
6206742|NCT01545076|9870115|FG000|IgPro10 Restabilization Period|Failure to meet randomization criteria|22
6206743|NCT01545076|9870116|FG001|IgPro10 Restabilization Period|Failure to meet randomization criteria|0
6206744|NCT01545076|9870117|FG002|IgPro10 Restabilization Period|Failure to meet randomization criteria|0
6206745|NCT01545076|9870118|FG003|IgPro10 Restabilization Period|Failure to meet randomization criteria|0
6206746|NCT01545076|9870119|FG004|IgPro10 Restabilization Period|Failure to meet randomization criteria|0
6206747|NCT01545076|9870115|FG000|IgPro10 Restabilization Period|Withdrawal by Subject|7
6206748|NCT01545076|9870116|FG001|IgPro10 Restabilization Period|Withdrawal by Subject|0
6206749|NCT01545076|9870117|FG002|IgPro10 Restabilization Period|Withdrawal by Subject|0
6206750|NCT01545076|9870118|FG003|IgPro10 Restabilization Period|Withdrawal by Subject|0
6206751|NCT01545076|9870119|FG004|IgPro10 Restabilization Period|Withdrawal by Subject|0
6206752|NCT01545076|9870115|FG000|IgPro20 Subcutaneous Treatment Period|Physician Decision|0
6206753|NCT01545076|9870116|FG001|IgPro20 Subcutaneous Treatment Period|Physician Decision|0
6206754|NCT01545076|9870117|FG002|IgPro20 Subcutaneous Treatment Period|Physician Decision|0
6206755|NCT01545076|9870118|FG003|IgPro20 Subcutaneous Treatment Period|Physician Decision|1
6206756|NCT01545076|9870119|FG004|IgPro20 Subcutaneous Treatment Period|Physician Decision|0
6206757|NCT01545076|9870115|FG000|IgPro20 Subcutaneous Treatment Period|Lack of Efficacy|0
6110692|NCT03343626|9729747|FG004|Overall Study|Withdrawal of Consent|3
6110693|NCT03343626|9729748|FG005|Overall Study|Withdrawal of Consent|1
6110694|NCT03343626|9729749|FG006|Overall Study|Withdrawal of Consent|1
6110695|NCT03343626|9729750|FG007|Overall Study|Withdrawal of Consent|2
6110696|NCT03343626|9729743|FG000|Overall Study|Reason not Specified|0
6110697|NCT03343626|9729744|FG001|Overall Study|Reason not Specified|1
6110698|NCT03343626|9729745|FG002|Overall Study|Reason not Specified|0
6110699|NCT03343626|9729746|FG003|Overall Study|Reason not Specified|0
6110700|NCT03343626|9729747|FG004|Overall Study|Reason not Specified|0
6110701|NCT03343626|9729748|FG005|Overall Study|Reason not Specified|0
6110702|NCT03343626|9729749|FG006|Overall Study|Reason not Specified|0
6110703|NCT03343626|9729750|FG007|Overall Study|Reason not Specified|1
6110704|NCT03343626|9729743|FG000|Overall Study|Data Entry Error|0
6110705|NCT03343626|9729744|FG001|Overall Study|Data Entry Error|0
6110706|NCT03343626|9729745|FG002|Overall Study|Data Entry Error|0
6110707|NCT03343626|9729746|FG003|Overall Study|Data Entry Error|0
6110708|NCT03343626|9729747|FG004|Overall Study|Data Entry Error|0
6110709|NCT03343626|9729748|FG005|Overall Study|Data Entry Error|0
6110710|NCT03343626|9729749|FG006|Overall Study|Data Entry Error|0
6110711|NCT03343626|9729750|FG007|Overall Study|Data Entry Error|1
6110712|NCT02807363|9729805|FG000|Dosing Period|Adverse Event|0
6110713|NCT02807363|9729806|FG001|Dosing Period|Adverse Event|1
6110714|NCT02807363|9729807|FG002|Dosing Period|Adverse Event|0
6110715|NCT02807363|9729808|FG003|Dosing Period|Adverse Event|0
6110716|NCT02756403|9729824|FG000|Overall Study|Unable to swallow medication|0
6110717|NCT02756403|9729825|FG001|Overall Study|Unable to swallow medication|1
6110718|NCT02756403|9729826|FG002|Overall Study|Unable to swallow medication|1
6110719|NCT02756403|9729827|FG003|Overall Study|Unable to swallow medication|1
6110720|NCT02756403|9729824|FG000|Overall Study|Did not complete Procedure|0
6110721|NCT02756403|9729825|FG001|Overall Study|Did not complete Procedure|1
6110722|NCT02756403|9729826|FG002|Overall Study|Did not complete Procedure|0
6110723|NCT02756403|9729827|FG003|Overall Study|Did not complete Procedure|0
6110724|NCT02756403|9729824|FG000|Overall Study|Changed Mind About Procedure|0
6110725|NCT02756403|9729825|FG001|Overall Study|Changed Mind About Procedure|0
6110726|NCT02756403|9729826|FG002|Overall Study|Changed Mind About Procedure|1
6110727|NCT02756403|9729827|FG003|Overall Study|Changed Mind About Procedure|0
6110728|NCT02756403|9729824|FG000|Overall Study|Protocol Violation|0
6110729|NCT02756403|9729825|FG001|Overall Study|Protocol Violation|1
6110730|NCT02756403|9729826|FG002|Overall Study|Protocol Violation|0
6110731|NCT02756403|9729827|FG003|Overall Study|Protocol Violation|1
6110732|NCT02751502|9729837|FG000|Overall Study|Lack of funding|4
6206758|NCT01545076|9870116|FG001|IgPro20 Subcutaneous Treatment Period|Lack of Efficacy|10
6206759|NCT01545076|9870117|FG002|IgPro20 Subcutaneous Treatment Period|Lack of Efficacy|18
6206760|NCT01545076|9870118|FG003|IgPro20 Subcutaneous Treatment Period|Lack of Efficacy|32
6206761|NCT01545076|9870119|FG004|IgPro20 Subcutaneous Treatment Period|Lack of Efficacy|0
6206762|NCT01545076|9870115|FG000|IgPro20 Subcutaneous Treatment Period|Adverse Event|0
6206763|NCT01545076|9870116|FG001|IgPro20 Subcutaneous Treatment Period|Adverse Event|1
6206764|NCT01545076|9870117|FG002|IgPro20 Subcutaneous Treatment Period|Adverse Event|1
6206765|NCT01545076|9870118|FG003|IgPro20 Subcutaneous Treatment Period|Adverse Event|0
6206766|NCT01545076|9870119|FG004|IgPro20 Subcutaneous Treatment Period|Adverse Event|0
6206767|NCT01545076|9870115|FG000|IgPro20 Subcutaneous Treatment Period|Withdrawal by Subject|0
6206768|NCT01545076|9870116|FG001|IgPro20 Subcutaneous Treatment Period|Withdrawal by Subject|8
6206769|NCT01545076|9870117|FG002|IgPro20 Subcutaneous Treatment Period|Withdrawal by Subject|2
6206770|NCT01545076|9870118|FG003|IgPro20 Subcutaneous Treatment Period|Withdrawal by Subject|3
6206771|NCT01545076|9870119|FG004|IgPro20 Subcutaneous Treatment Period|Withdrawal by Subject|0
6206772|NCT01545375|9870181|FG000|Overall Study|Adverse Event|2
6206773|NCT01545375|9870182|FG001|Overall Study|Adverse Event|1
6206774|NCT01545375|9870181|FG000|Overall Study|Lost to Follow-up|34
6206775|NCT01545375|9870182|FG001|Overall Study|Lost to Follow-up|31
6206776|NCT01545375|9870181|FG000|Overall Study|Protocol Violation|3
6206777|NCT01545375|9870182|FG001|Overall Study|Protocol Violation|3
6206778|NCT01545375|9870181|FG000|Overall Study|Withdrawal by Subject|58
6206779|NCT01545375|9870182|FG001|Overall Study|Withdrawal by Subject|55
6206780|NCT01545388|9870191|FG000|Overall Study|Adverse Event|2
6206781|NCT01545388|9870192|FG001|Overall Study|Adverse Event|4
6206782|NCT01545388|9870193|FG002|Overall Study|Adverse Event|1
6206783|NCT01545388|9870191|FG000|Overall Study|Lack of Efficacy|3
6206784|NCT01545388|9870192|FG001|Overall Study|Lack of Efficacy|2
6206785|NCT01545388|9870193|FG002|Overall Study|Lack of Efficacy|5
6206786|NCT01545388|9870191|FG000|Overall Study|Participant moved or relocated|1
6206787|NCT01545388|9870192|FG001|Overall Study|Participant moved or relocated|0
6206788|NCT01545388|9870193|FG002|Overall Study|Participant moved or relocated|0
6206789|NCT01545388|9870191|FG000|Overall Study|Withdrawal by Subject|1
6206790|NCT01545388|9870192|FG001|Overall Study|Withdrawal by Subject|4
6206791|NCT01545388|9870193|FG002|Overall Study|Withdrawal by Subject|2
6206792|NCT01545388|9870191|FG000|Overall Study|Other|1
6206793|NCT01545388|9870192|FG001|Overall Study|Other|1
6206794|NCT01545388|9870193|FG002|Overall Study|Other|0
6206795|NCT01545817|9870297|FG000|Pazopanib|Disease progression|51
6206796|NCT01545817|9870298|FG001|Pazopanib|Disease progression|0
6206797|NCT01545817|9870297|FG000|Pazopanib|Adverse Event|19
6206798|NCT01545817|9870298|FG001|Pazopanib|Adverse Event|0
6206799|NCT01545817|9870297|FG000|Pazopanib|Other reason|4
6206800|NCT01545817|9870298|FG001|Pazopanib|Other reason|0
6206801|NCT01545817|9870297|FG000|Everolimus|Other reason|0
6206802|NCT01545817|9870298|FG001|Everolimus|Other reason|7
6206803|NCT01545817|9870297|FG000|Everolimus|Disease progression|0
6206804|NCT01545817|9870298|FG001|Everolimus|Disease progression|25
6206805|NCT01545817|9870297|FG000|Everolimus|Adverse Event|0
6206806|NCT01545817|9870298|FG001|Everolimus|Adverse Event|6
6206807|NCT01545934|9870324|FG000|Overall Study|Withdrawal by Subject|4
6206808|NCT01545934|9870325|FG001|Overall Study|Withdrawal by Subject|3
6110733|NCT02285062|9729869|FG000|Overall Study|Withdrawal by Subject|12
6110734|NCT02285062|9729870|FG001|Overall Study|Withdrawal by Subject|17
6110735|NCT02285062|9729869|FG000|Overall Study|Death|58
6110736|NCT02285062|9729870|FG001|Overall Study|Death|62
6110737|NCT02285062|9729869|FG000|Overall Study|Lost to Follow-up|8
6110738|NCT02285062|9729870|FG001|Overall Study|Lost to Follow-up|5
6110739|NCT02264977|9729876|FG000|Overall Study|Death|3
6110740|NCT02264977|9729876|FG000|Overall Study|Withdrawal by Subject|1
6110741|NCT02264977|9729876|FG000|Overall Study|Physician Decision|1
6110742|NCT01981096|9729882|FG000|Overall Study|Parent illness|1
6110743|NCT01981096|9729883|FG001|Overall Study|Parent illness|0
6110744|NCT01981096|9729882|FG000|Overall Study|Withdrawal by Subject|0
6110745|NCT01981096|9729883|FG001|Overall Study|Withdrawal by Subject|1
6110746|NCT01981096|9729882|FG000|Overall Study|Lost to Follow-up|2
6110747|NCT01981096|9729883|FG001|Overall Study|Lost to Follow-up|0
6110748|NCT01935336|9729893|FG000|Overall Study|Adverse Event|1
6110749|NCT01935336|9729894|FG001|Overall Study|Adverse Event|0
6110750|NCT01935336|9729895|FG002|Overall Study|Adverse Event|0
6110751|NCT01935336|9729896|FG003|Overall Study|Adverse Event|0
6110752|NCT01935336|9729893|FG000|Overall Study|Progressive disease|5
6110753|NCT01935336|9729894|FG001|Overall Study|Progressive disease|3
6206809|NCT01545934|9870324|FG000|Overall Study|Lost to Follow-up|1
6206810|NCT01545934|9870325|FG001|Overall Study|Lost to Follow-up|0
6206811|NCT01546038|9870338|FG000|Overall Study|Death|15
6206812|NCT01546038|9870339|FG001|Overall Study|Death|6
6206813|NCT01546038|9870340|FG002|Overall Study|Death|4
6206814|NCT01546038|9870341|FG003|Overall Study|Death|2
6206815|NCT01546038|9870342|FG004|Overall Study|Death|9
6206816|NCT01546038|9870343|FG005|Overall Study|Death|3
6206817|NCT01546038|9870344|FG006|Overall Study|Death|46
6206818|NCT01546038|9870345|FG007|Overall Study|Death|76
6206819|NCT01546038|9870346|FG008|Overall Study|Death|39
6206820|NCT01546038|9870338|FG000|Overall Study|Lost to Follow-up|0
6206821|NCT01546038|9870339|FG001|Overall Study|Lost to Follow-up|0
6206822|NCT01546038|9870340|FG002|Overall Study|Lost to Follow-up|0
6206823|NCT01546038|9870341|FG003|Overall Study|Lost to Follow-up|0
6206824|NCT01546038|9870342|FG004|Overall Study|Lost to Follow-up|1
6206825|NCT01546038|9870343|FG005|Overall Study|Lost to Follow-up|0
6206826|NCT01546038|9870344|FG006|Overall Study|Lost to Follow-up|2
6206827|NCT01546038|9870345|FG007|Overall Study|Lost to Follow-up|1
6206828|NCT01546038|9870346|FG008|Overall Study|Lost to Follow-up|0
6206829|NCT01546038|9870338|FG000|Overall Study|Withdrawal by Subject|1
6206830|NCT01546038|9870339|FG001|Overall Study|Withdrawal by Subject|0
6206831|NCT01546038|9870340|FG002|Overall Study|Withdrawal by Subject|0
6206832|NCT01546038|9870341|FG003|Overall Study|Withdrawal by Subject|1
6206833|NCT01546038|9870342|FG004|Overall Study|Withdrawal by Subject|0
6206834|NCT01546038|9870343|FG005|Overall Study|Withdrawal by Subject|1
6206835|NCT01546038|9870344|FG006|Overall Study|Withdrawal by Subject|3
6206836|NCT01546038|9870345|FG007|Overall Study|Withdrawal by Subject|3
6206837|NCT01546038|9870346|FG008|Overall Study|Withdrawal by Subject|1
6206838|NCT01546038|9870338|FG000|Overall Study|: Randomized, not treated|0
6206839|NCT01546038|9870339|FG001|Overall Study|: Randomized, not treated|0
6206840|NCT01546038|9870340|FG002|Overall Study|: Randomized, not treated|0
6206841|NCT01546038|9870341|FG003|Overall Study|: Randomized, not treated|0
6206842|NCT01546038|9870342|FG004|Overall Study|: Randomized, not treated|0
6206843|NCT01546038|9870343|FG005|Overall Study|: Randomized, not treated|0
6206844|NCT01546038|9870344|FG006|Overall Study|: Randomized, not treated|2
6206845|NCT01546038|9870345|FG007|Overall Study|: Randomized, not treated|4
6206846|NCT01546038|9870346|FG008|Overall Study|: Randomized, not treated|3
6206847|NCT01546142|9870398|FG000|Overall Study|Consent Withdrawn (Subject Convenience)|15
6206848|NCT01546142|9870399|FG001|Overall Study|Consent Withdrawn (Subject Convenience)|15
6206849|NCT01546142|9870398|FG000|Overall Study|Subject Noncompliance|1
6206850|NCT01546142|9870399|FG001|Overall Study|Subject Noncompliance|1
6206851|NCT01546142|9870398|FG000|Overall Study|Adverse Event|6
6206852|NCT01546142|9870399|FG001|Overall Study|Adverse Event|3
6206853|NCT01546142|9870398|FG000|Overall Study|Lost to Follow-up|20
6206854|NCT01546142|9870399|FG001|Overall Study|Lost to Follow-up|15
6206855|NCT01546142|9870398|FG000|Overall Study|Consent Withdrawn (Subject Discomfort)|1
6206856|NCT01546142|9870399|FG001|Overall Study|Consent Withdrawn (Subject Discomfort)|0
6206857|NCT01546142|9870398|FG000|Overall Study|Subject Randomized but Not Treated|1
6206858|NCT01546142|9870399|FG001|Overall Study|Subject Randomized but Not Treated|0
6206859|NCT01546155|9870405|FG000|Overall Study|could not tolerate long scan duration|3
6206860|NCT01546168|9870411|FG000|Overall Study|Lost to Follow-up|1
6206861|NCT01546168|9870412|FG001|Overall Study|Lost to Follow-up|0
6206862|NCT01546168|9870411|FG000|Overall Study|Withdrawal by Subject|1
6206863|NCT01546168|9870412|FG001|Overall Study|Withdrawal by Subject|0
6206864|NCT01546168|9870411|FG000|Overall Study|ineligible after signing consent|2
6206865|NCT01546168|9870412|FG001|Overall Study|ineligible after signing consent|0
6206866|NCT01546519|9870452|FG000|Overall Study|Adverse Event|0
6206867|NCT01546519|9870453|FG001|Overall Study|Adverse Event|0
6110754|NCT01935336|9729895|FG002|Overall Study|Progressive disease|47
6206868|NCT01546519|9870454|FG002|Overall Study|Adverse Event|1
6206869|NCT01546519|9870455|FG003|Overall Study|Adverse Event|1
6206870|NCT01546519|9870452|FG000|Overall Study|Death|0
6206871|NCT01546519|9870453|FG001|Overall Study|Death|1
6110755|NCT01935336|9729896|FG003|Overall Study|Progressive disease|66
6110756|NCT01712490|9729914|FG000|Overall Study|Ongoing|601
6110757|NCT01712490|9729915|FG001|Overall Study|Ongoing|586
6110758|NCT01712490|9729914|FG000|Overall Study|Other|11
6110759|NCT01712490|9729915|FG001|Overall Study|Other|11
6110760|NCT01712490|9729914|FG000|Overall Study|Withdrawal by Subject|36
6110761|NCT01712490|9729915|FG001|Overall Study|Withdrawal by Subject|44
6110762|NCT01712490|9729914|FG000|Overall Study|Lost to Follow-up|16
6110763|NCT01712490|9729915|FG001|Overall Study|Lost to Follow-up|29
6110764|NCT01702805|9729923|FG000|Overall Study|Data withdrawn prior to hospital discharge|3
6110765|NCT01702805|9729924|FG001|Overall Study|Data withdrawn prior to hospital discharge|7
6110766|NCT01702805|9729923|FG000|Overall Study|Incomplete Follow-up|18
6110767|NCT01702805|9729924|FG001|Overall Study|Incomplete Follow-up|15
6110768|NCT01702805|9729923|FG000|Overall Study|Vital Status Assessment Only|40
6110769|NCT01702805|9729924|FG001|Overall Study|Vital Status Assessment Only|39
6110770|NCT01702805|9729923|FG000|Overall Study|Lost to Follow-up|5
6110771|NCT01702805|9729924|FG001|Overall Study|Lost to Follow-up|5
6110772|NCT01499160|9729930|FG000|Overall Study|Adverse Event|1
6110773|NCT01499160|9729930|FG000|Overall Study|Withdrawal by Subject|1
6110774|NCT01061151|9729972|FG000|Protocol Version 2.0: 04/2011-09/2012|Protocol Violation|2
6110775|NCT01061151|9729973|FG001|Protocol Version 2.0: 04/2011-09/2012|Protocol Violation|0
6110776|NCT01061151|9729974|FG002|Protocol Version 2.0: 04/2011-09/2012|Protocol Violation|0
6110777|NCT01061151|9729975|FG003|Protocol Version 2.0: 04/2011-09/2012|Protocol Violation|1
6110778|NCT01061151|9729972|FG000|Protocol Version 2.0: 04/2011-09/2012|Death|6
6110779|NCT01061151|9729973|FG001|Protocol Version 2.0: 04/2011-09/2012|Death|9
6110780|NCT01061151|9729974|FG002|Protocol Version 2.0: 04/2011-09/2012|Death|1
6110781|NCT01061151|9729975|FG003|Protocol Version 2.0: 04/2011-09/2012|Death|2
6110782|NCT01061151|9729972|FG000|Protocol Version 2.0: 04/2011-09/2012|Withdrawal by Subject|89
6110783|NCT01061151|9729973|FG001|Protocol Version 2.0: 04/2011-09/2012|Withdrawal by Subject|82
6206872|NCT01546519|9870454|FG002|Overall Study|Death|3
6206873|NCT01546519|9870455|FG003|Overall Study|Death|1
6206874|NCT01546519|9870452|FG000|Overall Study|related to disease progression|2
6206875|NCT01546519|9870453|FG001|Overall Study|related to disease progression|2
6206876|NCT01546519|9870454|FG002|Overall Study|related to disease progression|2
6206877|NCT01546519|9870455|FG003|Overall Study|related to disease progression|1
6206878|NCT01546519|9870452|FG000|Overall Study|Physician Decision|6
6206879|NCT01546519|9870453|FG001|Overall Study|Physician Decision|5
6206880|NCT01546519|9870454|FG002|Overall Study|Physician Decision|2
6206881|NCT01546519|9870455|FG003|Overall Study|Physician Decision|3
6206882|NCT01546519|9870452|FG000|Overall Study|Withdrawal by Subject|1
6206883|NCT01546519|9870453|FG001|Overall Study|Withdrawal by Subject|0
6206884|NCT01546519|9870454|FG002|Overall Study|Withdrawal by Subject|0
6206885|NCT01546519|9870455|FG003|Overall Study|Withdrawal by Subject|0
6206886|NCT01546623|9870471|FG000|Overall Study|Adverse Event|2
6206887|NCT01546623|9870472|FG001|Overall Study|Adverse Event|3
6206888|NCT01546623|9870471|FG000|Overall Study|Major Protocol Deviation|1
6206889|NCT01546623|9870472|FG001|Overall Study|Major Protocol Deviation|1
6206890|NCT01546623|9870471|FG000|Overall Study|High Prostate specific antigen|2
6206891|NCT01546623|9870472|FG001|Overall Study|High Prostate specific antigen|1
6206892|NCT01546623|9870471|FG000|Overall Study|Did Not Receive Study Drug|1
6206893|NCT01546623|9870472|FG001|Overall Study|Did Not Receive Study Drug|1
6206894|NCT01546649|9870489|FG000|Overall Study|Adverse Event|4
6206895|NCT01546649|9870490|FG001|Overall Study|Adverse Event|5
6206896|NCT01546649|9870489|FG000|Overall Study|Protocol Violation|1
6206897|NCT01546649|9870490|FG001|Overall Study|Protocol Violation|0
6206898|NCT01546649|9870489|FG000|Overall Study|Lack of Efficacy|1
6206899|NCT01546649|9870490|FG001|Overall Study|Lack of Efficacy|0
6206900|NCT01546649|9870489|FG000|Overall Study|Recurrence|1
6206901|NCT01546649|9870490|FG001|Overall Study|Recurrence|1
6206902|NCT01546649|9870489|FG000|Overall Study|Discovery of secondary cancer|0
6206903|NCT01546649|9870490|FG001|Overall Study|Discovery of secondary cancer|1
6206904|NCT01546649|9870489|FG000|Overall Study|Withdrawal by Subject|1
6206905|NCT01546649|9870490|FG001|Overall Study|Withdrawal by Subject|2
6206906|NCT01546688|9870507|FG000|Overall Study|Adverse Event|0
6206907|NCT01546688|9870508|FG001|Overall Study|Adverse Event|4
6206908|NCT01546688|9870507|FG000|Overall Study|Withdrawal by Subject|2
6206909|NCT01546688|9870508|FG001|Overall Study|Withdrawal by Subject|1
6206910|NCT01546688|9870507|FG000|Overall Study|Lack of Efficacy|1
6206911|NCT01546688|9870508|FG001|Overall Study|Lack of Efficacy|0
6206912|NCT01546857|9870516|FG000|Overall Study|Withdrawal by Subject|2
6110784|NCT01061151|9729974|FG002|Protocol Version 2.0: 04/2011-09/2012|Withdrawal by Subject|2
6110785|NCT01061151|9729975|FG003|Protocol Version 2.0: 04/2011-09/2012|Withdrawal by Subject|10
6110786|NCT01061151|9729972|FG000|Protocol Version 2.0: 04/2011-09/2012|Lost to Follow-up|73
6206913|NCT01546857|9870517|FG001|Overall Study|Withdrawal by Subject|3
6206914|NCT01546922|9870524|FG000|First Period of 10 Weeks|Protocol Violation|3
6206915|NCT01546922|9870525|FG001|First Period of 10 Weeks|Protocol Violation|1
6110787|NCT01061151|9729973|FG001|Protocol Version 2.0: 04/2011-09/2012|Lost to Follow-up|65
6206916|NCT01546922|9870524|FG000|First Period of 10 Weeks|Withdrawal by Subject|1
6206917|NCT01546922|9870525|FG001|First Period of 10 Weeks|Withdrawal by Subject|1
6206918|NCT01546922|9870524|FG000|First Period of 10 Weeks|Investigator's judgment|1
6110788|NCT01061151|9729974|FG002|Protocol Version 2.0: 04/2011-09/2012|Lost to Follow-up|2
6110789|NCT01061151|9729975|FG003|Protocol Version 2.0: 04/2011-09/2012|Lost to Follow-up|10
6110790|NCT01061151|9729972|FG000|Protocol Version 2.0: 04/2011-09/2012|Site Closure|15
6110791|NCT01061151|9729973|FG001|Protocol Version 2.0: 04/2011-09/2012|Site Closure|19
6110792|NCT01061151|9729974|FG002|Protocol Version 2.0: 04/2011-09/2012|Site Closure|1
6110793|NCT01061151|9729975|FG003|Protocol Version 2.0: 04/2011-09/2012|Site Closure|0
6110794|NCT01061151|9729972|FG000|Protocol Version 2.0: 04/2011-09/2012|Subject Unable to Get to Clinic|44
6110795|NCT01061151|9729973|FG001|Protocol Version 2.0: 04/2011-09/2012|Subject Unable to Get to Clinic|61
6110796|NCT01061151|9729974|FG002|Protocol Version 2.0: 04/2011-09/2012|Subject Unable to Get to Clinic|2
6110797|NCT01061151|9729975|FG003|Protocol Version 2.0: 04/2011-09/2012|Subject Unable to Get to Clinic|5
6110798|NCT01061151|9729972|FG000|Protocol Version 2.0: 04/2011-09/2012|Other Reason|3
6110799|NCT01061151|9729973|FG001|Protocol Version 2.0: 04/2011-09/2012|Other Reason|5
6110800|NCT01061151|9729974|FG002|Protocol Version 2.0: 04/2011-09/2012|Other Reason|1
6110801|NCT01061151|9729975|FG003|Protocol Version 2.0: 04/2011-09/2012|Other Reason|0
6110802|NCT01061151|9729972|FG000|Protocol Version 3.0: 10/2012-10/2014|Protocol Violation|0
6110803|NCT01061151|9729973|FG001|Protocol Version 3.0: 10/2012-10/2014|Protocol Violation|0
6110804|NCT01061151|9729974|FG002|Protocol Version 3.0: 10/2012-10/2014|Protocol Violation|2
6110805|NCT01061151|9729975|FG003|Protocol Version 3.0: 10/2012-10/2014|Protocol Violation|4
6110806|NCT01061151|9729972|FG000|Protocol Version 3.0: 10/2012-10/2014|Adverse Event|1
6110807|NCT01061151|9729973|FG001|Protocol Version 3.0: 10/2012-10/2014|Adverse Event|0
6110808|NCT01061151|9729974|FG002|Protocol Version 3.0: 10/2012-10/2014|Adverse Event|0
6110809|NCT01061151|9729975|FG003|Protocol Version 3.0: 10/2012-10/2014|Adverse Event|0
6110810|NCT01061151|9729972|FG000|Protocol Version 3.0: 10/2012-10/2014|Death|3
6110811|NCT01061151|9729973|FG001|Protocol Version 3.0: 10/2012-10/2014|Death|5
6110812|NCT01061151|9729974|FG002|Protocol Version 3.0: 10/2012-10/2014|Death|1
6110813|NCT01061151|9729975|FG003|Protocol Version 3.0: 10/2012-10/2014|Death|1
6110814|NCT01061151|9729972|FG000|Protocol Version 3.0: 10/2012-10/2014|Withdrawal by Subject|54
6110815|NCT01061151|9729973|FG001|Protocol Version 3.0: 10/2012-10/2014|Withdrawal by Subject|52
6110816|NCT01061151|9729974|FG002|Protocol Version 3.0: 10/2012-10/2014|Withdrawal by Subject|31
6110817|NCT01061151|9729975|FG003|Protocol Version 3.0: 10/2012-10/2014|Withdrawal by Subject|3
6110818|NCT01061151|9729972|FG000|Protocol Version 3.0: 10/2012-10/2014|Lost to Follow-up|49
6110819|NCT01061151|9729973|FG001|Protocol Version 3.0: 10/2012-10/2014|Lost to Follow-up|36
6110820|NCT01061151|9729974|FG002|Protocol Version 3.0: 10/2012-10/2014|Lost to Follow-up|25
6110821|NCT01061151|9729975|FG003|Protocol Version 3.0: 10/2012-10/2014|Lost to Follow-up|4
6110822|NCT01061151|9729972|FG000|Protocol Version 3.0: 10/2012-10/2014|Site Closure|12
6110823|NCT01061151|9729973|FG001|Protocol Version 3.0: 10/2012-10/2014|Site Closure|11
6110824|NCT01061151|9729974|FG002|Protocol Version 3.0: 10/2012-10/2014|Site Closure|2
6110825|NCT01061151|9729975|FG003|Protocol Version 3.0: 10/2012-10/2014|Site Closure|0
6110826|NCT01061151|9729972|FG000|Protocol Version 3.0: 10/2012-10/2014|Subject Unable to Get to Clinic|28
6110827|NCT01061151|9729973|FG001|Protocol Version 3.0: 10/2012-10/2014|Subject Unable to Get to Clinic|26
6110828|NCT01061151|9729974|FG002|Protocol Version 3.0: 10/2012-10/2014|Subject Unable to Get to Clinic|15
6110829|NCT01061151|9729975|FG003|Protocol Version 3.0: 10/2012-10/2014|Subject Unable to Get to Clinic|5
6110830|NCT01061151|9729972|FG000|Protocol Version 3.0: 10/2012-10/2014|Other Reason|5
6110831|NCT01061151|9729973|FG001|Protocol Version 3.0: 10/2012-10/2014|Other Reason|8
6110832|NCT01061151|9729974|FG002|Protocol Version 3.0: 10/2012-10/2014|Other Reason|1
6110833|NCT01061151|9729975|FG003|Protocol Version 3.0: 10/2012-10/2014|Other Reason|3
6110834|NCT00981058|9729997|FG000|Overall Study|Adverse Event|1
6110835|NCT00981058|9729998|FG001|Overall Study|Adverse Event|1
6110836|NCT00981058|9729997|FG000|Overall Study|Progressive Disease|61
6110837|NCT00981058|9729998|FG001|Overall Study|Progressive Disease|49
6110838|NCT00981058|9729997|FG000|Overall Study|Lost to Follow-up|16
6110839|NCT00981058|9729998|FG001|Overall Study|Lost to Follow-up|15
6110840|NCT00981058|9729997|FG000|Overall Study|New Anticancer Therapy|6
6110841|NCT00981058|9729998|FG001|Overall Study|New Anticancer Therapy|6
6110842|NCT00981058|9729997|FG000|Overall Study|Noncompliance|1
6110843|NCT00981058|9729998|FG001|Overall Study|Noncompliance|0
6110844|NCT00981058|9729997|FG000|Overall Study|Radiologist Error|0
6110845|NCT00981058|9729998|FG001|Overall Study|Radiologist Error|1
6110846|NCT00981058|9729997|FG000|Overall Study|Randomization Error|1
6110847|NCT00981058|9729998|FG001|Overall Study|Randomization Error|2
6110848|NCT00981058|9729997|FG000|Overall Study|Withdrawal by Subject|25
6110849|NCT00981058|9729998|FG001|Overall Study|Withdrawal by Subject|23
6110850|NCT00981058|9729997|FG000|Overall Study|On study treatment at conclusion|9
6110851|NCT00981058|9729998|FG001|Overall Study|On study treatment at conclusion|0
6110852|NCT00885495|9730006|FG000|Overall Study|Adverse Event|1
6110853|NCT00885495|9730007|FG001|Overall Study|Adverse Event|2
6110854|NCT00885495|9730006|FG000|Overall Study|Protocol Violation|0
6110855|NCT00885495|9730007|FG001|Overall Study|Protocol Violation|1
6110856|NCT00885495|9730006|FG000|Overall Study|Withdrawal by Subject|1
6110857|NCT00885495|9730007|FG001|Overall Study|Withdrawal by Subject|0
6110858|NCT00084799|9730020|FG000|Overall Study|Disease Progression|1
6110859|NCT00084799|9730021|FG001|Overall Study|Disease Progression|0
6110860|NCT00821236|9730030|FG000|Overall Study|Lost to Follow-up|3
6110861|NCT00821327|9730038|FG000|Overall Study|Adverse Event|13
6110862|NCT00821327|9730038|FG000|Overall Study|Patient Request|1
6110863|NCT00821327|9730038|FG000|Overall Study|Investigator Request|2
6110864|NCT00821327|9730038|FG000|Overall Study|Sponsor Request|1
6110865|NCT00821327|9730038|FG000|Overall Study|Disease Progression|13
6110866|NCT00821327|9730038|FG000|Overall Study|Other/Unknown|5
6110867|NCT00821431|9730044|FG000|Overall Study|Adverse Event|6
6110868|NCT00821431|9730045|FG001|Overall Study|Adverse Event|3
6110869|NCT00821431|9730044|FG000|Overall Study|Withdrawal by Subject|5
6110870|NCT00821431|9730045|FG001|Overall Study|Withdrawal by Subject|0
6110871|NCT00821431|9730044|FG000|Overall Study|Lost to Follow-up|1
6110872|NCT00821431|9730045|FG001|Overall Study|Lost to Follow-up|0
6110873|NCT00821431|9730044|FG000|Overall Study|Protocol Violation|3
6110874|NCT00821431|9730045|FG001|Overall Study|Protocol Violation|1
6110875|NCT00821431|9730044|FG000|Overall Study|Physician Decision|0
6110876|NCT00821431|9730045|FG001|Overall Study|Physician Decision|1
6110877|NCT00821509|9730054|FG000|Overall Study|Withdrawal by Subject|12
6110878|NCT00821509|9730055|FG001|Overall Study|Withdrawal by Subject|11
6110879|NCT00821509|9730056|FG002|Overall Study|Withdrawal by Subject|34
6110880|NCT00821678|9730077|FG000|Overall Study|Withdrawal by Subject|8
6110881|NCT00821678|9730078|FG001|Overall Study|Withdrawal by Subject|0
6110882|NCT00821678|9730077|FG000|Overall Study|Lost to Follow-up|13
6110883|NCT00821678|9730078|FG001|Overall Study|Lost to Follow-up|12
6110884|NCT00821678|9730077|FG000|Overall Study|Death|0
6110885|NCT00821678|9730078|FG001|Overall Study|Death|2
6110886|NCT00821873|9730110|FG000|Overall Study|Lost to Follow-up|4
6110887|NCT00822172|9730144|FG000|Overall Study|Adverse Event|10
6110888|NCT00822172|9730145|FG001|Overall Study|Adverse Event|12
6110889|NCT00822172|9730144|FG000|Overall Study|Death|1
6110890|NCT00822172|9730145|FG001|Overall Study|Death|0
6110891|NCT00822172|9730144|FG000|Overall Study|Lost to Follow-up|3
6110892|NCT00822172|9730145|FG001|Overall Study|Lost to Follow-up|1
6110893|NCT00822172|9730144|FG000|Overall Study|Withdrawal by Subject|1
6110894|NCT00822172|9730145|FG001|Overall Study|Withdrawal by Subject|4
6110895|NCT00822172|9730144|FG000|Overall Study|site closed|0
6110896|NCT00822172|9730145|FG001|Overall Study|site closed|1
6110897|NCT00822172|9730144|FG000|Overall Study|Other|0
6110898|NCT00822172|9730145|FG001|Overall Study|Other|1
6110899|NCT00822237|9730174|FG000|Dose 1 Vaccination|Not vaccinated|3
6110900|NCT00822237|9730175|FG001|Dose 1 Vaccination|Not vaccinated|0
6110901|NCT00822237|9730174|FG000|Dose 1 Vaccination|Withdrawal by Subject|13
6110902|NCT00822237|9730175|FG001|Dose 1 Vaccination|Withdrawal by Subject|14
6110903|NCT00822237|9730174|FG000|Dose 1 Vaccination|Lost to Follow-up|9
6110904|NCT00822237|9730175|FG001|Dose 1 Vaccination|Lost to Follow-up|12
6110905|NCT00822237|9730174|FG000|Dose 2 Vaccination|Withdrawal by Subject|2
6110906|NCT00822237|9730175|FG001|Dose 2 Vaccination|Withdrawal by Subject|2
6110907|NCT00822237|9730174|FG000|Dose 2 Vaccination|Lost to Follow-up|2
6110908|NCT00822237|9730175|FG001|Dose 2 Vaccination|Lost to Follow-up|9
6110909|NCT00822692|9730243|FG000|Overall Study|Lost to Follow-up|17
6110910|NCT00822692|9730244|FG001|Overall Study|Lost to Follow-up|25
6110911|NCT00822770|9730261|FG000|Overall Study|Not treated|1
6110912|NCT00822770|9730262|FG001|Overall Study|Not treated|0
6110913|NCT00822770|9730261|FG000|Overall Study|Complication/Incomplete treatment|1
6110914|NCT00822770|9730262|FG001|Overall Study|Complication/Incomplete treatment|0
6110915|NCT00822770|9730261|FG000|Overall Study|Death|1
6110916|NCT00822770|9730262|FG001|Overall Study|Death|1
6110917|NCT00822900|9730270|FG000|Overall Study|Withdrawal by Subject|14
6110918|NCT00822900|9730271|FG001|Overall Study|Withdrawal by Subject|14
6110919|NCT00822900|9730270|FG000|Overall Study|Lost to Follow-up|9
6110920|NCT00822900|9730271|FG001|Overall Study|Lost to Follow-up|9
6285651|NCT02337946|9997973|FG001|Protocol Treatment 2 Period|Lack of Efficacy|29
6285652|NCT02337946|9997974|FG002|Protocol Treatment 2 Period|Lack of Efficacy|29
6285653|NCT02337946|9997972|FG000|Protocol Treatment 2 Period|Death During Protocol Treatment|0
6285654|NCT02337946|9997973|FG001|Protocol Treatment 2 Period|Death During Protocol Treatment|1
6285655|NCT02337946|9997974|FG002|Protocol Treatment 2 Period|Death During Protocol Treatment|0
6110921|NCT00822900|9730270|FG000|Overall Study|Death|83
6110922|NCT00822900|9730271|FG001|Overall Study|Death|69
6110923|NCT00822900|9730270|FG000|Overall Study|Became a ward of the state|2
6110924|NCT00822900|9730271|FG001|Overall Study|Became a ward of the state|1
6110925|NCT00822926|9730279|FG000|Second Injection Visit|Lost to Follow-up|1
6110926|NCT00822926|9730280|FG001|Second Injection Visit|Lost to Follow-up|0
6110927|NCT00822926|9730279|FG000|Second Injection Visit|Withdrawal by Subject|0
6110928|NCT00822926|9730280|FG001|Second Injection Visit|Withdrawal by Subject|1
6110929|NCT00823134|9730311|FG000|Overall Study|Invalid measurement|1
6110930|NCT00823199|9730316|FG000|Overall Study|Withdrawal by Subject|2
6110931|NCT00823212|9730323|FG000|Overall Study|Death|8
6110932|NCT00823212|9730324|FG001|Overall Study|Death|10
6110933|NCT00823212|9730323|FG000|Overall Study|Withdrawal by Subject|6
6110934|NCT00823212|9730324|FG001|Overall Study|Withdrawal by Subject|1
6110935|NCT00823212|9730323|FG000|Overall Study|Incarcerated|0
6110936|NCT00823212|9730324|FG001|Overall Study|Incarcerated|1
6110937|NCT00823212|9730323|FG000|Overall Study|Missed 12-month visit|21
6110938|NCT00823212|9730324|FG001|Overall Study|Missed 12-month visit|21
6110939|NCT00823264|9730334|FG000|Overall Study|Protocol Violation|2
6110940|NCT00823264|9730335|FG001|Overall Study|Protocol Violation|0
6110941|NCT00823472|9730357|FG000|Overall Study|Physician Decision|24
6110942|NCT00823472|9730358|FG001|Overall Study|Physician Decision|28
6110943|NCT00823615|9730364|FG000|Period 2|Lost to Follow-up|2
6110944|NCT00823615|9730365|FG001|Period 2|Lost to Follow-up|0
6110945|NCT00823615|9730364|FG000|Period 2|Time/Job Conflict|1
6110946|NCT00823615|9730365|FG001|Period 2|Time/Job Conflict|2
6110947|NCT00823719|9730373|FG000|Overall Study|Adverse Event|1
6110948|NCT00823719|9730374|FG001|Overall Study|Adverse Event|2
6110949|NCT00823719|9730373|FG000|Overall Study|Physician Decision|1
6110950|NCT00823719|9730374|FG001|Overall Study|Physician Decision|4
6110951|NCT00823719|9730373|FG000|Overall Study|Withdrawal by Subject|0
6110952|NCT00823719|9730374|FG001|Overall Study|Withdrawal by Subject|1
6110953|NCT00823719|9730373|FG000|Overall Study|Disease Progression|4
6110954|NCT00823719|9730374|FG001|Overall Study|Disease Progression|4
6110955|NCT00823823|9730392|FG000|Overall Study|Lost to Follow-up|3
6110956|NCT00823823|9730393|FG001|Overall Study|Lost to Follow-up|1
6110957|NCT00823823|9730392|FG000|Overall Study|Protocol Violation|5
6110958|NCT00823823|9730393|FG001|Overall Study|Protocol Violation|5
6110959|NCT00823836|9730401|FG000|NV and PR/XR Switching Phases|Adverse Event|22
6110960|NCT00823836|9730402|FG001|NV and PR/XR Switching Phases|Adverse Event|21
6110961|NCT00823836|9730401|FG000|NV and PR/XR Switching Phases|Protocol Violation|1
6110962|NCT00823836|9730402|FG001|NV and PR/XR Switching Phases|Protocol Violation|1
6110963|NCT00823836|9730401|FG000|NV and PR/XR Switching Phases|Physician Decision|5
6110964|NCT00823836|9730402|FG001|NV and PR/XR Switching Phases|Physician Decision|2
6110965|NCT00823836|9730401|FG000|NV and PR/XR Switching Phases|Withdrawal by Subject|4
6110966|NCT00823836|9730402|FG001|NV and PR/XR Switching Phases|Withdrawal by Subject|5
6110967|NCT00823836|9730401|FG000|Long-term Phase|Adverse Event|3
6110968|NCT00823836|9730402|FG001|Long-term Phase|Adverse Event|2
6110969|NCT00823836|9730401|FG000|Long-term Phase|Physician Decision|1
6110970|NCT00823836|9730402|FG001|Long-term Phase|Physician Decision|2
6110971|NCT00823836|9730401|FG000|Long-term Phase|Withdrawal by Subject|1
6110972|NCT00823836|9730402|FG001|Long-term Phase|Withdrawal by Subject|1
6206919|NCT01546922|9870525|FG001|First Period of 10 Weeks|Investigator's judgment|0
6206920|NCT01546922|9870524|FG000|Second Period of 10 Weeks|Protocol Violation|3
6206921|NCT01546922|9870525|FG001|Second Period of 10 Weeks|Protocol Violation|1
6206922|NCT01546922|9870524|FG000|Second Period of 10 Weeks|Withdrawal by Subject|0
6206923|NCT01546922|9870525|FG001|Second Period of 10 Weeks|Withdrawal by Subject|2
6285656|NCT02337946|9997972|FG000|Protocol Treatment 2 Period|Surgery Aimed at Curative Resection|0
6285657|NCT02337946|9997973|FG001|Protocol Treatment 2 Period|Surgery Aimed at Curative Resection|5
6285658|NCT02337946|9997974|FG002|Protocol Treatment 2 Period|Surgery Aimed at Curative Resection|7
6285659|NCT02337946|9997972|FG000|Protocol Treatment 2 Period|Reason not specified|0
6285660|NCT02337946|9997973|FG001|Protocol Treatment 2 Period|Reason not specified|4
6285661|NCT02337946|9997974|FG002|Protocol Treatment 2 Period|Reason not specified|4
6285662|NCT02338154|9997999|FG000|Overall Study|Death|46
6285663|NCT02338154|9997999|FG000|Overall Study|Valve Implant Failure|17
6285664|NCT02338154|9997999|FG000|Overall Study|Valve Explant|11
6285665|NCT02338154|9997999|FG000|Overall Study|Withdrawal by Subject or by Investigator|10
6285666|NCT02338154|9997999|FG000|Overall Study|Lost to Follow-up|8
6285667|NCT02338154|9997999|FG000|Overall Study|Other Reason|3
6285668|NCT02338154|9997999|FG000|Overall Study|Patients Without Exit Form|47
6285669|NCT02338154|9997999|FG000|Overall Study|Missing Exit Reason on Exit Form|1
6285670|NCT02338193|9998014|FG000|Overall Study|Withdrawal by Subject|0
6285671|NCT02338193|9998015|FG001|Overall Study|Withdrawal by Subject|0
6285672|NCT02338193|9998016|FG002|Overall Study|Withdrawal by Subject|2
6285673|NCT02338193|9998014|FG000|Overall Study|Pregnancy|0
6285674|NCT02338193|9998015|FG001|Overall Study|Pregnancy|1
6285675|NCT02338193|9998016|FG002|Overall Study|Pregnancy|1
6285676|NCT02338193|9998014|FG000|Overall Study|Noncompliant with visits|2
6285677|NCT02338193|9998015|FG001|Overall Study|Noncompliant with visits|2
6285678|NCT02338193|9998016|FG002|Overall Study|Noncompliant with visits|7
6285679|NCT02338193|9998014|FG000|Overall Study|moved out of state|0
6285680|NCT02338193|9998015|FG001|Overall Study|moved out of state|1
6285681|NCT02338193|9998016|FG002|Overall Study|moved out of state|0
6285682|NCT02338193|9998014|FG000|Overall Study|intolerant of side effects|1
6285683|NCT02338193|9998015|FG001|Overall Study|intolerant of side effects|0
6285684|NCT02338193|9998016|FG002|Overall Study|intolerant of side effects|0
6285685|NCT02338362|9998037|FG000|Overall Study|Withdrawal by Subject|1
6285686|NCT02338362|9998038|FG001|Overall Study|Withdrawal by Subject|1
6285687|NCT02338492|9998044|FG000|Overall Study|Death|32
6285688|NCT02338492|9998044|FG000|Overall Study|Adverse Event|3
6285689|NCT02338492|9998044|FG000|Overall Study|Lost to Follow-up|4
6285690|NCT02338492|9998044|FG000|Overall Study|Reason not captured above|6
6285691|NCT02338843|9998056|FG000|Overall Study|Adverse Event|2
6285692|NCT02338843|9998057|FG001|Overall Study|Adverse Event|1
6285693|NCT02338843|9998056|FG000|Overall Study|Death|40
5980655|NCT02733042|9569323|FG003|Follow-up Period|Withdrawal by Subject|0
6206924|NCT01547130|9870542|FG000|Overall Study|Lost to Follow-up|9
6206925|NCT01547130|9870543|FG001|Overall Study|Lost to Follow-up|5
6206926|NCT01547286|9870566|FG000|Overall Study|Did not meet all eligibility criteria|1
6206927|NCT01547286|9870566|FG000|Overall Study|Physician Decision|1
6206928|NCT01547299|9870573|FG000|Overall Study|Withdrawal by Subject|2
6285694|NCT02338843|9998057|FG001|Overall Study|Death|53
6110973|NCT00823901|9730413|FG000|Overall Study|Adverse Event|1
6110974|NCT00823901|9730414|FG001|Overall Study|Adverse Event|1
6110975|NCT00823901|9730413|FG000|Overall Study|Lack of Efficacy|1
6110976|NCT00823901|9730414|FG001|Overall Study|Lack of Efficacy|0
6110977|NCT00823901|9730413|FG000|Overall Study|Lost to Follow-up|2
6206929|NCT01547299|9870574|FG001|Overall Study|Withdrawal by Subject|2
6206930|NCT01547390|9870582|FG000|Overall Study|Withdrawal by Subject|10
6206931|NCT01547390|9870583|FG001|Overall Study|Withdrawal by Subject|7
6206932|NCT01547390|9870582|FG000|Overall Study|termination of pregnancy|0
6206933|NCT01547390|9870583|FG001|Overall Study|termination of pregnancy|1
6206934|NCT01547390|9870582|FG000|Overall Study|Lost to Follow-up|0
6206935|NCT01547390|9870583|FG001|Overall Study|Lost to Follow-up|2
6206936|NCT01547390|9870582|FG000|Overall Study|Adverse Event|3
6206937|NCT01547390|9870583|FG001|Overall Study|Adverse Event|0
6206938|NCT01547598|9870591|FG000|Overall Study|Withdrew consent|1
6206939|NCT01547598|9870592|FG001|Overall Study|Withdrew consent|1
6206940|NCT01547598|9870591|FG000|Overall Study|Lost to Follow-up|1
6206941|NCT01547598|9870592|FG001|Overall Study|Lost to Follow-up|1
6206942|NCT01547598|9870591|FG000|Overall Study|Adverse Event|1
6206943|NCT01547598|9870592|FG001|Overall Study|Adverse Event|1
6206944|NCT01547598|9870591|FG000|Overall Study|Protocol Violation|1
6206945|NCT01547598|9870592|FG001|Overall Study|Protocol Violation|1
6206946|NCT01547598|9870591|FG000|Overall Study|Other Miscellaneous Reasons|2
6206947|NCT01547598|9870592|FG001|Overall Study|Other Miscellaneous Reasons|1
6206948|NCT01547780|9870617|FG000|Baseline PET Scan|Physician Decision|1
6206949|NCT01547780|9870618|FG001|Baseline PET Scan|Physician Decision|0
6206950|NCT01547780|9870619|FG002|Baseline PET Scan|Physician Decision|1
6206951|NCT01547780|9870620|FG003|Baseline PET Scan|Physician Decision|0
6206952|NCT01547780|9870617|FG000|Baseline PET Scan|Withdrawal by Subject|2
6206953|NCT01547780|9870618|FG001|Baseline PET Scan|Withdrawal by Subject|0
6206954|NCT01547780|9870619|FG002|Baseline PET Scan|Withdrawal by Subject|1
6206955|NCT01547780|9870620|FG003|Baseline PET Scan|Withdrawal by Subject|0
6285695|NCT02338843|9998056|FG000|Overall Study|Physician Decision|1
6285696|NCT02338843|9998057|FG001|Overall Study|Physician Decision|0
6285697|NCT02338843|9998056|FG000|Overall Study|Withdrawal by Subject|0
6285698|NCT02338843|9998057|FG001|Overall Study|Withdrawal by Subject|2
6285699|NCT02338843|9998056|FG000|Overall Study|Subject Recovered|0
6285700|NCT02338843|9998057|FG001|Overall Study|Subject Recovered|2
6285701|NCT02338843|9998056|FG000|Overall Study|Discontinued prior to randomizat|1
6285702|NCT02338843|9998057|FG001|Overall Study|Discontinued prior to randomizat|0
6285703|NCT02338882|9998065|FG000|Overall Study|Death|1
6285704|NCT02338882|9998066|FG001|Overall Study|Death|0
6285705|NCT02338882|9998065|FG000|Overall Study|Lost to Follow-up|6
6285706|NCT02338882|9998066|FG001|Overall Study|Lost to Follow-up|3
6285707|NCT02338999|9998172|FG000|First Intervention|Withdrawal by Subject|3
6285708|NCT02338999|9998173|FG001|First Intervention|Withdrawal by Subject|1
6285709|NCT02338999|9998172|FG000|Washout Period|Withdrawal by Subject|0
6285710|NCT02338999|9998173|FG001|Washout Period|Withdrawal by Subject|2
6285711|NCT02338999|9998172|FG000|Second Intervention|Withdrawal by Subject|0
6285712|NCT02338999|9998173|FG001|Second Intervention|Withdrawal by Subject|2
6285713|NCT02339155|9998185|FG000|Overall Study|Adverse Event|0
6285714|NCT02339155|9998186|FG001|Overall Study|Adverse Event|6
6285715|NCT02339155|9998185|FG000|Overall Study|Death|1
6285716|NCT02339155|9998186|FG001|Overall Study|Death|1
6285717|NCT02339155|9998185|FG000|Overall Study|Lost to Follow-up|8
6285718|NCT02339155|9998186|FG001|Overall Study|Lost to Follow-up|9
6285719|NCT02339155|9998185|FG000|Overall Study|Physician Decision|2
6285720|NCT02339155|9998186|FG001|Overall Study|Physician Decision|1
6285721|NCT02339155|9998185|FG000|Overall Study|Withdrawal by Subject|4
6285722|NCT02339155|9998186|FG001|Overall Study|Withdrawal by Subject|4
6285723|NCT02339285|9998209|FG000|Overall Study|Withdrawal by Subject|0
6285724|NCT02339285|9998210|FG001|Overall Study|Withdrawal by Subject|1
6285725|NCT02339285|9998211|FG002|Overall Study|Withdrawal by Subject|1
6285726|NCT02339285|9998209|FG000|Overall Study|Lost to Follow-up|1
6285727|NCT02339285|9998210|FG001|Overall Study|Lost to Follow-up|1
6285728|NCT02339285|9998211|FG002|Overall Study|Lost to Follow-up|1
6285729|NCT02339285|9998209|FG000|Overall Study|Protocol Deviation|0
6285730|NCT02339285|9998210|FG001|Overall Study|Protocol Deviation|1
6285731|NCT02339285|9998211|FG002|Overall Study|Protocol Deviation|0
6285732|NCT02339506|9998235|FG000|Period 1 (Placebo or Cosyntropin)|Withdrawal by Subject|0
6285733|NCT02339506|9998236|FG001|Period 1 (Placebo or Cosyntropin)|Withdrawal by Subject|1
6285734|NCT02339506|9998235|FG000|Washout (Period 2)|Withdrawal by Subject|2
6285735|NCT02339506|9998236|FG001|Washout (Period 2)|Withdrawal by Subject|0
6285736|NCT02339584|9998253|FG000|Overall Study|Adverse Event|11
6285737|NCT02339584|9998254|FG001|Overall Study|Adverse Event|7
6285738|NCT02339584|9998253|FG000|Overall Study|Lack of Efficacy|0
6285739|NCT02339584|9998254|FG001|Overall Study|Lack of Efficacy|1
6285740|NCT02339584|9998253|FG000|Overall Study|Physician Decision|1
6285741|NCT02339584|9998254|FG001|Overall Study|Physician Decision|2
6285742|NCT02339584|9998253|FG000|Overall Study|Protocol Violation|1
6285743|NCT02339584|9998254|FG001|Overall Study|Protocol Violation|1
6285744|NCT02339584|9998253|FG000|Overall Study|Withdrawal by Subject|2
6285745|NCT02339584|9998254|FG001|Overall Study|Withdrawal by Subject|4
6110978|NCT00823901|9730414|FG001|Overall Study|Lost to Follow-up|1
6110979|NCT00823979|9730427|FG000|Overall Study|Lack of Efficacy|13
6110980|NCT00823979|9730428|FG001|Overall Study|Lack of Efficacy|16
6110981|NCT00823979|9730429|FG002|Overall Study|Lack of Efficacy|9
6110982|NCT00823979|9730427|FG000|Overall Study|Lost to Follow-up|2
6110983|NCT00823979|9730428|FG001|Overall Study|Lost to Follow-up|1
6110984|NCT00823979|9730429|FG002|Overall Study|Lost to Follow-up|0
6110985|NCT00823979|9730427|FG000|Overall Study|Withdrawal by Subject|2
6110986|NCT00823979|9730428|FG001|Overall Study|Withdrawal by Subject|3
6110987|NCT00823979|9730429|FG002|Overall Study|Withdrawal by Subject|2
6110988|NCT00823979|9730427|FG000|Overall Study|Protocol Violation|1
6110989|NCT00823979|9730428|FG001|Overall Study|Protocol Violation|1
6110990|NCT00823979|9730429|FG002|Overall Study|Protocol Violation|0
6110991|NCT00823979|9730427|FG000|Overall Study|Pregnancy|0
6110992|NCT00823979|9730428|FG001|Overall Study|Pregnancy|1
6110993|NCT00823979|9730429|FG002|Overall Study|Pregnancy|0
6110994|NCT00823979|9730427|FG000|Overall Study|Adverse Event|0
6110995|NCT00823979|9730428|FG001|Overall Study|Adverse Event|2
6110996|NCT00823979|9730429|FG002|Overall Study|Adverse Event|4
6110997|NCT00823979|9730427|FG000|Overall Study|Other|2
6110998|NCT00823979|9730428|FG001|Overall Study|Other|0
6110999|NCT00823979|9730429|FG002|Overall Study|Other|1
6111000|NCT00823979|9730427|FG000|Overall Study|Randomized but not Treated|4
6111001|NCT00823979|9730428|FG001|Overall Study|Randomized but not Treated|3
6111002|NCT00823979|9730429|FG002|Overall Study|Randomized but not Treated|1
6111003|NCT00823979|9730427|FG000|Overall Study|Study Terminated by Sponsor|5
6111004|NCT00823979|9730428|FG001|Overall Study|Study Terminated by Sponsor|5
6111005|NCT00823979|9730429|FG002|Overall Study|Study Terminated by Sponsor|7
6111006|NCT00824005|9730439|FG000|Overall Study|Death|0
6111007|NCT00824005|9730440|FG001|Overall Study|Death|1
6111008|NCT00824005|9730439|FG000|Overall Study|Lost to Follow-up|0
6111009|NCT00824005|9730440|FG001|Overall Study|Lost to Follow-up|1
6111010|NCT00824161|9730472|FG000|Overall Study|Withdrawal by Subject|1
6111011|NCT00824161|9730472|FG000|Overall Study|Screen Failure|1
6111012|NCT00824265|9730479|FG000|Treatment Phase|Adverse Event,non-fatal|50
6111013|NCT00824265|9730480|FG001|Treatment Phase|Adverse Event,non-fatal|52
6111014|NCT00824265|9730479|FG000|Treatment Phase|Protocol Violation|1
6111015|NCT00824265|9730480|FG001|Treatment Phase|Protocol Violation|0
6111016|NCT00824265|9730479|FG000|Treatment Phase|Lost to Follow-up|1
6111017|NCT00824265|9730480|FG001|Treatment Phase|Lost to Follow-up|1
6111018|NCT00824265|9730479|FG000|Treatment Phase|Physician Decision|6
6111019|NCT00824265|9730480|FG001|Treatment Phase|Physician Decision|12
6111020|NCT00824265|9730479|FG000|Treatment Phase|Withdrawal by Subject|6
6111021|NCT00824265|9730480|FG001|Treatment Phase|Withdrawal by Subject|15
6111022|NCT00824265|9730479|FG000|Follow-up Phase|w/drew consent, no f/u, or MD choice|18
6111023|NCT00824265|9730480|FG001|Follow-up Phase|w/drew consent, no f/u, or MD choice|31
6111024|NCT00824265|9730479|FG000|Survival Follow-up Phase|w/drew consent, no f/u, or MD choice|9
6111025|NCT00824265|9730480|FG001|Survival Follow-up Phase|w/drew consent, no f/u, or MD choice|16
6111026|NCT00824291|9730492|FG000|Overall Study|Adverse Event|15
6111027|NCT00824291|9730493|FG001|Overall Study|Adverse Event|6
6111028|NCT00824291|9730492|FG000|Overall Study|Discontinuation of Study by Sponsor|1
6111029|NCT00824291|9730493|FG001|Overall Study|Discontinuation of Study by Sponsor|2
6111030|NCT00824291|9730492|FG000|Overall Study|Lost to Follow-up|11
6111031|NCT00824291|9730493|FG001|Overall Study|Lost to Follow-up|9
6111032|NCT00824291|9730492|FG000|Overall Study|Non-compliance|1
6111033|NCT00824291|9730493|FG001|Overall Study|Non-compliance|1
6111034|NCT00824291|9730492|FG000|Overall Study|Protocol Violation|4
6111035|NCT00824291|9730493|FG001|Overall Study|Protocol Violation|1
6111036|NCT00824291|9730492|FG000|Overall Study|Withdrawal by Subject|14
6111037|NCT00824291|9730493|FG001|Overall Study|Withdrawal by Subject|8
6111038|NCT00824291|9730492|FG000|Overall Study|Lack of Efficacy|7
6111039|NCT00824291|9730493|FG001|Overall Study|Lack of Efficacy|8
6111040|NCT00824291|9730492|FG000|Overall Study|Participant on prohibited medication|1
6111041|NCT00824291|9730493|FG001|Overall Study|Participant on prohibited medication|0
6111042|NCT00824369|9730505|FG000|Overall Study|Nolonger willing to participate in study|1
6111043|NCT00824369|9730506|FG001|Overall Study|Nolonger willing to participate in study|0
6111044|NCT00824369|9730507|FG002|Overall Study|Nolonger willing to participate in study|1
6111045|NCT00824369|9730508|FG003|Overall Study|Nolonger willing to participate in study|2
6111046|NCT00824369|9730509|FG004|Overall Study|Nolonger willing to participate in study|0
6111047|NCT00824369|9730510|FG005|Overall Study|Nolonger willing to participate in study|1
6111048|NCT00824369|9730505|FG000|Overall Study|Lost to Follow-up|0
6111049|NCT00824369|9730506|FG001|Overall Study|Lost to Follow-up|0
6111050|NCT00824369|9730507|FG002|Overall Study|Lost to Follow-up|0
6111051|NCT00824369|9730508|FG003|Overall Study|Lost to Follow-up|0
6111052|NCT00824369|9730509|FG004|Overall Study|Lost to Follow-up|1
6111053|NCT00824369|9730510|FG005|Overall Study|Lost to Follow-up|0
6111054|NCT00824382|9730528|FG000|Overall Study|Adverse Event|4
6111055|NCT00824382|9730529|FG001|Overall Study|Adverse Event|1
6111056|NCT00824382|9730530|FG002|Overall Study|Adverse Event|1
6206956|NCT01548287|9870648|FG000|Screening|No reason provided|0
6111057|NCT00824382|9730531|FG003|Overall Study|Adverse Event|4
6111058|NCT00824382|9730528|FG000|Overall Study|Protocol Violation|1
6111059|NCT00824382|9730529|FG001|Overall Study|Protocol Violation|0
6111060|NCT00824382|9730530|FG002|Overall Study|Protocol Violation|0
6206957|NCT01548287|9870649|FG001|Screening|No reason provided|0
6111061|NCT00824382|9730531|FG003|Overall Study|Protocol Violation|1
6111062|NCT00824382|9730528|FG000|Overall Study|Investigator's decision|0
6111063|NCT00824382|9730529|FG001|Overall Study|Investigator's decision|1
6111064|NCT00824382|9730530|FG002|Overall Study|Investigator's decision|2
6111065|NCT00824382|9730531|FG003|Overall Study|Investigator's decision|0
6111066|NCT00824408|9730548|FG000|Run-in Phase|Progressive disease|4
6111067|NCT00824408|9730549|FG001|Run-in Phase|Progressive disease|4
6111068|NCT00824408|9730550|FG002|Run-in Phase|Progressive disease|0
6111069|NCT00824408|9730551|FG003|Run-in Phase|Progressive disease|0
6111070|NCT00824408|9730552|FG004|Run-in Phase|Progressive disease|0
6111071|NCT00824408|9730548|FG000|Run-in Phase|Adverse Event|1
6111072|NCT00824408|9730549|FG001|Run-in Phase|Adverse Event|1
6111073|NCT00824408|9730550|FG002|Run-in Phase|Adverse Event|0
6111074|NCT00824408|9730551|FG003|Run-in Phase|Adverse Event|0
6111075|NCT00824408|9730552|FG004|Run-in Phase|Adverse Event|0
6111076|NCT00824408|9730548|FG000|Run-in Phase|Refused to continue medication|1
6111077|NCT00824408|9730549|FG001|Run-in Phase|Refused to continue medication|0
6111078|NCT00824408|9730550|FG002|Run-in Phase|Refused to continue medication|0
6111079|NCT00824408|9730551|FG003|Run-in Phase|Refused to continue medication|0
6111080|NCT00824408|9730552|FG004|Run-in Phase|Refused to continue medication|0
6111081|NCT00824408|9730548|FG000|Run-in Phase|Other reason not defined above|0
6111082|NCT00824408|9730549|FG001|Run-in Phase|Other reason not defined above|1
6111083|NCT00824408|9730550|FG002|Run-in Phase|Other reason not defined above|0
6111084|NCT00824408|9730551|FG003|Run-in Phase|Other reason not defined above|0
6111085|NCT00824408|9730552|FG004|Run-in Phase|Other reason not defined above|0
6111086|NCT00824408|9730548|FG000|Randomized Phase|Not treated|0
6111087|NCT00824408|9730549|FG001|Randomized Phase|Not treated|0
6111088|NCT00824408|9730550|FG002|Randomized Phase|Not treated|1
6111089|NCT00824408|9730551|FG003|Randomized Phase|Not treated|1
6111090|NCT00824408|9730552|FG004|Randomized Phase|Not treated|1
6111091|NCT00824408|9730548|FG000|Randomized Phase|Progressive disease|0
6111092|NCT00824408|9730549|FG001|Randomized Phase|Progressive disease|0
6111093|NCT00824408|9730550|FG002|Randomized Phase|Progressive disease|25
6111094|NCT00824408|9730551|FG003|Randomized Phase|Progressive disease|36
6111095|NCT00824408|9730552|FG004|Randomized Phase|Progressive disease|34
6111096|NCT00824408|9730548|FG000|Randomized Phase|Adverse Event|0
6111097|NCT00824408|9730549|FG001|Randomized Phase|Adverse Event|0
6111098|NCT00824408|9730550|FG002|Randomized Phase|Adverse Event|4
6111099|NCT00824408|9730551|FG003|Randomized Phase|Adverse Event|5
6111100|NCT00824408|9730552|FG004|Randomized Phase|Adverse Event|5
6111101|NCT00824408|9730548|FG000|Randomized Phase|Refused to continue medication|0
6111102|NCT00824408|9730549|FG001|Randomized Phase|Refused to continue medication|0
6111103|NCT00824408|9730550|FG002|Randomized Phase|Refused to continue medication|2
6111104|NCT00824408|9730551|FG003|Randomized Phase|Refused to continue medication|2
6111105|NCT00824408|9730552|FG004|Randomized Phase|Refused to continue medication|2
6111106|NCT00824408|9730548|FG000|Randomized Phase|Other reason not defined above|0
6206958|NCT01548287|9870650|FG002|Screening|No reason provided|0
6206959|NCT01548287|9870651|FG003|Screening|No reason provided|0
6206960|NCT01548287|9870652|FG004|Screening|No reason provided|9
6206961|NCT01548287|9870648|FG000|Screening|Did not meet eligibility criteria|0
6206962|NCT01548287|9870649|FG001|Screening|Did not meet eligibility criteria|0
6206963|NCT01548287|9870650|FG002|Screening|Did not meet eligibility criteria|0
6206964|NCT01548287|9870651|FG003|Screening|Did not meet eligibility criteria|0
6206965|NCT01548287|9870652|FG004|Screening|Did not meet eligibility criteria|74
6206966|NCT01548287|9870648|FG000|Randomized Period|Did not meet inclusion criteria|0
6206967|NCT01548287|9870649|FG001|Randomized Period|Did not meet inclusion criteria|0
6206968|NCT01548287|9870650|FG002|Randomized Period|Did not meet inclusion criteria|2
6206969|NCT01548287|9870651|FG003|Randomized Period|Did not meet inclusion criteria|0
6206970|NCT01548287|9870652|FG004|Randomized Period|Did not meet inclusion criteria|0
6206971|NCT01548287|9870648|FG000|Randomized Period|Adverse Event|0
6206972|NCT01548287|9870649|FG001|Randomized Period|Adverse Event|2
6206973|NCT01548287|9870650|FG002|Randomized Period|Adverse Event|5
6206974|NCT01548287|9870651|FG003|Randomized Period|Adverse Event|0
6206975|NCT01548287|9870652|FG004|Randomized Period|Adverse Event|0
6206976|NCT01548404|9870673|FG000|Overall Study|Adverse Event|3
6206977|NCT01548404|9870674|FG001|Overall Study|Adverse Event|1
6206978|NCT01548404|9870673|FG000|Overall Study|Physician Decision|2
6206979|NCT01548404|9870674|FG001|Overall Study|Physician Decision|1
6206980|NCT01548404|9870673|FG000|Overall Study|Inadequate response to study treatment|23
6206981|NCT01548404|9870674|FG001|Overall Study|Inadequate response to study treatment|7
6206982|NCT01548404|9870673|FG000|Overall Study|Lost to Follow-up|2
6206983|NCT01548404|9870674|FG001|Overall Study|Lost to Follow-up|0
6111107|NCT00824408|9730549|FG001|Randomized Phase|Other reason not defined above|0
6111108|NCT00824408|9730550|FG002|Randomized Phase|Other reason not defined above|4
6111109|NCT00824408|9730551|FG003|Randomized Phase|Other reason not defined above|2
6111110|NCT00824408|9730552|FG004|Randomized Phase|Other reason not defined above|4
6111111|NCT00824421|9730573|FG000|Overall Study|Adverse Event|6
6111112|NCT00824421|9730574|FG001|Overall Study|Adverse Event|6
6111113|NCT00824421|9730575|FG002|Overall Study|Adverse Event|6
6111114|NCT00824421|9730573|FG000|Overall Study|Death|0
6111115|NCT00824421|9730574|FG001|Overall Study|Death|1
6206984|NCT01548404|9870673|FG000|Overall Study|Withdrawal by Subject|0
6111116|NCT00824421|9730575|FG002|Overall Study|Death|0
6111117|NCT00824421|9730573|FG000|Overall Study|Lack of Efficacy|5
6111118|NCT00824421|9730574|FG001|Overall Study|Lack of Efficacy|7
6111119|NCT00824421|9730575|FG002|Overall Study|Lack of Efficacy|4
6111120|NCT00824421|9730573|FG000|Overall Study|Lost to Follow-up|2
6111121|NCT00824421|9730574|FG001|Overall Study|Lost to Follow-up|3
6111122|NCT00824421|9730575|FG002|Overall Study|Lost to Follow-up|0
6111123|NCT00824421|9730573|FG000|Overall Study|Pregnancy|1
6111124|NCT00824421|9730574|FG001|Overall Study|Pregnancy|0
6111125|NCT00824421|9730575|FG002|Overall Study|Pregnancy|1
6111126|NCT00824421|9730573|FG000|Overall Study|Withdrawal by Subject|2
6111127|NCT00824421|9730574|FG001|Overall Study|Withdrawal by Subject|3
6111128|NCT00824421|9730575|FG002|Overall Study|Withdrawal by Subject|3
6111129|NCT00824421|9730573|FG000|Overall Study|Randomized but not Treated|1
6111130|NCT00824421|9730574|FG001|Overall Study|Randomized but not Treated|1
6111131|NCT00824421|9730575|FG002|Overall Study|Randomized but not Treated|0
6111132|NCT00824421|9730573|FG000|Overall Study|Other|0
6111133|NCT00824421|9730574|FG001|Overall Study|Other|1
6111134|NCT00824421|9730575|FG002|Overall Study|Other|0
6111135|NCT00824473|9730624|FG000|Overall Study|Adverse Event|4
6111136|NCT00824473|9730625|FG001|Overall Study|Adverse Event|5
6111137|NCT00824473|9730624|FG000|Overall Study|Lack of Efficacy|2
6111138|NCT00824473|9730625|FG001|Overall Study|Lack of Efficacy|2
6111139|NCT00824473|9730624|FG000|Overall Study|Protocol Violation|2
6111140|NCT00824473|9730625|FG001|Overall Study|Protocol Violation|0
6111141|NCT00824473|9730624|FG000|Overall Study|Non-Compliance|4
6111142|NCT00824473|9730625|FG001|Overall Study|Non-Compliance|2
6111143|NCT00824473|9730624|FG000|Overall Study|Withdrawal by Subject|2
6111144|NCT00824473|9730625|FG001|Overall Study|Withdrawal by Subject|3
6111145|NCT00824473|9730624|FG000|Overall Study|Other|1
6111146|NCT00824473|9730625|FG001|Overall Study|Other|1
6111147|NCT00824564|9730647|FG000|Overall Study|Lost to Follow-up|5
6111148|NCT00824564|9730648|FG001|Overall Study|Lost to Follow-up|7
6111149|NCT00824564|9730647|FG000|Overall Study|Withdrawal by Subject|1
6111150|NCT00824564|9730648|FG001|Overall Study|Withdrawal by Subject|1
6111151|NCT00824564|9730647|FG000|Overall Study|Other|1
6111152|NCT00824564|9730648|FG001|Overall Study|Other|2
6111153|NCT00824564|9730647|FG000|Overall Study|Randomized, but not treated|1
6111154|NCT00824564|9730648|FG001|Overall Study|Randomized, but not treated|0
6111155|NCT00824616|9730656|FG000|Overall Study|Adverse Event|2
6111156|NCT00824616|9730657|FG001|Overall Study|Adverse Event|1
6111157|NCT00824616|9730656|FG000|Overall Study|Creatinine/Creatinine Clearance|0
6111158|NCT00824616|9730657|FG001|Overall Study|Creatinine/Creatinine Clearance|2
6111159|NCT00824616|9730656|FG000|Overall Study|Hyperglycemia|1
6111160|NCT00824616|9730657|FG001|Overall Study|Hyperglycemia|1
6111161|NCT00824616|9730656|FG000|Overall Study|Lack of Efficacy|2
6111162|NCT00824616|9730657|FG001|Overall Study|Lack of Efficacy|1
6111163|NCT00824616|9730656|FG000|Overall Study|Lost to Follow-up|0
6111164|NCT00824616|9730657|FG001|Overall Study|Lost to Follow-up|1
6111165|NCT00824616|9730656|FG000|Overall Study|Withdrawal by Subject|1
6111166|NCT00824616|9730657|FG001|Overall Study|Withdrawal by Subject|1
6111167|NCT00824655|9730665|FG000|Toddler Dose (12 Months of Age)|Adverse Event|1
6111168|NCT00824655|9730666|FG001|Toddler Dose (12 Months of Age)|Adverse Event|0
6111169|NCT00824655|9730665|FG000|Toddler Dose (12 Months of Age)|Parent/legal guardian request|1
6111170|NCT00824655|9730666|FG001|Toddler Dose (12 Months of Age)|Parent/legal guardian request|0
6111171|NCT00824720|9730677|FG000|Overall Study|failed plug insertion|3
6111172|NCT00824720|9730678|FG001|Overall Study|failed plug insertion|1
6111173|NCT00824720|9730679|FG002|Overall Study|failed plug insertion|0
6111174|NCT00824720|9730677|FG000|Overall Study|Protocol Violation|0
6111175|NCT00824720|9730678|FG001|Overall Study|Protocol Violation|0
6111176|NCT00824720|9730679|FG002|Overall Study|Protocol Violation|1
6111177|NCT00824772|9730697|FG000|Overall Study|Withdrawal by Subject|8
6111178|NCT00824850|9730712|FG000|Overall Study|Withdrawal by Subject|0
6111179|NCT00824850|9730713|FG001|Overall Study|Withdrawal by Subject|1
6111180|NCT00824993|9730727|FG000|Overall Study|Withdrawal by Subject|1
6111181|NCT00824993|9730728|FG001|Overall Study|Withdrawal by Subject|1
6111182|NCT00824993|9730727|FG000|Overall Study|Malignancy Relapse|9
6111183|NCT00824993|9730728|FG001|Overall Study|Malignancy Relapse|10
6111184|NCT00824993|9730727|FG000|Overall Study|Rapid Bone Loss|0
6111185|NCT00824993|9730728|FG001|Overall Study|Rapid Bone Loss|1
6111186|NCT00824993|9730727|FG000|Overall Study|Non-Compliant|2
6111187|NCT00824993|9730728|FG001|Overall Study|Non-Compliant|1
6111188|NCT00824993|9730727|FG000|Overall Study|Insurance Issue|2
6111189|NCT00824993|9730728|FG001|Overall Study|Insurance Issue|1
6111190|NCT00824993|9730727|FG000|Overall Study|Death|0
6111191|NCT00824993|9730728|FG001|Overall Study|Death|3
6111192|NCT00825162|9730737|FG000|Overall Study|Withdrawal by Subject|11
6111193|NCT00825162|9730738|FG001|Overall Study|Withdrawal by Subject|13
6111194|NCT00825162|9730739|FG002|Overall Study|Withdrawal by Subject|3
6111195|NCT00825162|9730737|FG000|Overall Study|Lost to Follow-up|9
6111196|NCT00825162|9730738|FG001|Overall Study|Lost to Follow-up|6
6111197|NCT00825162|9730739|FG002|Overall Study|Lost to Follow-up|3
6111198|NCT00825162|9730737|FG000|Overall Study|Physician Decision|2
6111199|NCT00825162|9730738|FG001|Overall Study|Physician Decision|0
6111200|NCT00825162|9730739|FG002|Overall Study|Physician Decision|0
6111201|NCT00825162|9730737|FG000|Overall Study|Move away from the study area|1
6111202|NCT00825162|9730738|FG001|Overall Study|Move away from the study area|0
6111203|NCT00825162|9730739|FG002|Overall Study|Move away from the study area|0
6111204|NCT00825162|9730737|FG000|Overall Study|Unable to attend the study visit|5
6111205|NCT00825162|9730738|FG001|Overall Study|Unable to attend the study visit|2
6111206|NCT00825162|9730739|FG002|Overall Study|Unable to attend the study visit|0
6111207|NCT00825175|9730754|FG000|Overall Study|Withdrawal by Subject|0
6111208|NCT00825175|9730755|FG001|Overall Study|Withdrawal by Subject|5
6111209|NCT00825305|9730772|FG000|Overall Study|Adverse Event|1
6111210|NCT00825305|9730773|FG001|Overall Study|Adverse Event|1
6111211|NCT00825305|9730772|FG000|Overall Study|Withdrawal by Subject|6
6111212|NCT00825305|9730773|FG001|Overall Study|Withdrawal by Subject|12
6111213|NCT00825305|9730772|FG000|Overall Study|Inappropriate inclusion|1
6111214|NCT00825305|9730773|FG001|Overall Study|Inappropriate inclusion|0
6111215|NCT00825305|9730772|FG000|Overall Study|Protocol Violation|9
6111216|NCT00825305|9730773|FG001|Overall Study|Protocol Violation|9
6111217|NCT00825305|9730772|FG000|Overall Study|Can not be classified|0
6111218|NCT00825305|9730773|FG001|Overall Study|Can not be classified|1
6111219|NCT00825682|9730847|FG000|Overall Study|personal reasons/ inconvenience|13
6111220|NCT00825682|9730848|FG001|Overall Study|personal reasons/ inconvenience|5
6111221|NCT00825812|9730875|FG000|Overall Study|Never entered follow up|0
6111222|NCT00825812|9730876|FG001|Overall Study|Never entered follow up|0
6111223|NCT00825812|9730877|FG002|Overall Study|Never entered follow up|0
6111224|NCT00825812|9730878|FG003|Overall Study|Never entered follow up|1
6111225|NCT00825812|9730875|FG000|Overall Study|Adverse Event|0
6111226|NCT00825812|9730876|FG001|Overall Study|Adverse Event|0
6111227|NCT00825812|9730877|FG002|Overall Study|Adverse Event|0
6111228|NCT00825812|9730878|FG003|Overall Study|Adverse Event|1
6111229|NCT00825812|9730875|FG000|Overall Study|Subject withdrew consent|0
6111230|NCT00825812|9730876|FG001|Overall Study|Subject withdrew consent|0
6111231|NCT00825812|9730877|FG002|Overall Study|Subject withdrew consent|3
6111232|NCT00825812|9730878|FG003|Overall Study|Subject withdrew consent|2
6111233|NCT00825812|9730875|FG000|Overall Study|Non-compliance with protocol|0
6111234|NCT00825812|9730876|FG001|Overall Study|Non-compliance with protocol|0
6111235|NCT00825812|9730877|FG002|Overall Study|Non-compliance with protocol|0
6111236|NCT00825812|9730878|FG003|Overall Study|Non-compliance with protocol|1
6111237|NCT00825812|9730875|FG000|Overall Study|Administrative|0
6111238|NCT00825812|9730876|FG001|Overall Study|Administrative|1
6111239|NCT00825812|9730877|FG002|Overall Study|Administrative|3
6111240|NCT00825812|9730878|FG003|Overall Study|Administrative|5
6111241|NCT00825825|9730888|FG000|First Medication Period (14 Days)|Adverse Event|1
6111242|NCT00825825|9730889|FG001|First Medication Period (14 Days)|Adverse Event|0
6111243|NCT00825825|9730890|FG002|First Medication Period (14 Days)|Adverse Event|0
6111244|NCT00825825|9730891|FG003|First Medication Period (14 Days)|Adverse Event|0
6111245|NCT00825825|9730892|FG004|First Medication Period (14 Days)|Adverse Event|0
6111246|NCT00825825|9730893|FG005|First Medication Period (14 Days)|Adverse Event|1
6111247|NCT00825825|9730888|FG000|First Medication Period (14 Days)|Physician Decision|2
6111248|NCT00825825|9730889|FG001|First Medication Period (14 Days)|Physician Decision|0
6111249|NCT00825825|9730890|FG002|First Medication Period (14 Days)|Physician Decision|1
6111250|NCT00825825|9730891|FG003|First Medication Period (14 Days)|Physician Decision|0
6111251|NCT00825825|9730892|FG004|First Medication Period (14 Days)|Physician Decision|0
6111252|NCT00825825|9730893|FG005|First Medication Period (14 Days)|Physician Decision|1
6111253|NCT00825825|9730888|FG000|Second Medication Period (14 Days)|Physician Decision|1
6111254|NCT00825825|9730889|FG001|Second Medication Period (14 Days)|Physician Decision|0
6111255|NCT00825825|9730890|FG002|Second Medication Period (14 Days)|Physician Decision|0
6111256|NCT00825825|9730891|FG003|Second Medication Period (14 Days)|Physician Decision|2
6111257|NCT00825825|9730892|FG004|Second Medication Period (14 Days)|Physician Decision|0
6111258|NCT00825825|9730893|FG005|Second Medication Period (14 Days)|Physician Decision|0
6111259|NCT00825825|9730888|FG000|Second Medication Period (14 Days)|Protocol Violation|1
6111260|NCT00825825|9730889|FG001|Second Medication Period (14 Days)|Protocol Violation|0
6111261|NCT00825825|9730890|FG002|Second Medication Period (14 Days)|Protocol Violation|0
6111262|NCT00825825|9730891|FG003|Second Medication Period (14 Days)|Protocol Violation|0
6111263|NCT00825825|9730892|FG004|Second Medication Period (14 Days)|Protocol Violation|1
6111264|NCT00825825|9730893|FG005|Second Medication Period (14 Days)|Protocol Violation|0
6111265|NCT00825825|9730888|FG000|Third Medication Period (14 Days)|Adverse Event|0
6111266|NCT00825825|9730889|FG001|Third Medication Period (14 Days)|Adverse Event|1
6111267|NCT00825825|9730890|FG002|Third Medication Period (14 Days)|Adverse Event|0
6111268|NCT00825825|9730891|FG003|Third Medication Period (14 Days)|Adverse Event|0
6111269|NCT00825825|9730892|FG004|Third Medication Period (14 Days)|Adverse Event|0
6111270|NCT00825825|9730893|FG005|Third Medication Period (14 Days)|Adverse Event|0
6111271|NCT00825825|9730888|FG000|Third Medication Period (14 Days)|Protocol Violation|0
6111272|NCT00825825|9730889|FG001|Third Medication Period (14 Days)|Protocol Violation|0
6111273|NCT00825825|9730890|FG002|Third Medication Period (14 Days)|Protocol Violation|0
6111274|NCT00825825|9730891|FG003|Third Medication Period (14 Days)|Protocol Violation|0
6111275|NCT00825825|9730892|FG004|Third Medication Period (14 Days)|Protocol Violation|0
6111276|NCT00825825|9730893|FG005|Third Medication Period (14 Days)|Protocol Violation|2
6111277|NCT00825825|9730888|FG000|Third Medication Period (14 Days)|poor data quality|0
6111278|NCT00825825|9730889|FG001|Third Medication Period (14 Days)|poor data quality|1
6111279|NCT00825825|9730890|FG002|Third Medication Period (14 Days)|poor data quality|0
6111280|NCT00825825|9730891|FG003|Third Medication Period (14 Days)|poor data quality|0
6111281|NCT00825825|9730892|FG004|Third Medication Period (14 Days)|poor data quality|0
6111282|NCT00825825|9730893|FG005|Third Medication Period (14 Days)|poor data quality|0
6111283|NCT00825916|9730903|FG000|Overall Study|Lost to Follow-up|4
6111284|NCT00825916|9730904|FG001|Overall Study|Lost to Follow-up|2
6111285|NCT00825916|9730905|FG002|Overall Study|Lost to Follow-up|1
6111286|NCT00825994|9730946|FG000|Overall Study|Withdrawal by Subject|2
6111287|NCT00825994|9730946|FG000|Overall Study|Lost to Follow-up|1
6111288|NCT00825994|9730946|FG000|Overall Study|Protocol Violation|1
6111289|NCT00825994|9730946|FG000|Overall Study|Placebo Responder at V2|1
6111290|NCT00826111|9730964|FG000|Overall Study|Lost to Follow-up|0
6111291|NCT00826111|9730965|FG001|Overall Study|Lost to Follow-up|1
6111292|NCT00826111|9730964|FG000|Overall Study|Protocol Violation|1
6111293|NCT00826111|9730965|FG001|Overall Study|Protocol Violation|0
6111294|NCT00826111|9730964|FG000|Overall Study|Withdrawal by Subject|5
6111295|NCT00826111|9730965|FG001|Overall Study|Withdrawal by Subject|0
6111296|NCT00826111|9730964|FG000|Overall Study|Physician Decision|1
6111297|NCT00826111|9730965|FG001|Overall Study|Physician Decision|1
6111298|NCT00826176|9730991|FG000|Overall Study|Lost to Follow-up|1
6111299|NCT00826176|9730992|FG001|Overall Study|Lost to Follow-up|0
6111300|NCT00826176|9730991|FG000|Overall Study|Subject Withdrew Consent|3
6111301|NCT00826176|9730992|FG001|Overall Study|Subject Withdrew Consent|0
6111302|NCT00826176|9730991|FG000|Overall Study|Administrative|9
6111303|NCT00826176|9730992|FG001|Overall Study|Administrative|0
6206985|NCT01548404|9870674|FG001|Overall Study|Withdrawal by Subject|3
6206986|NCT01548404|9870673|FG000|Overall Study|Other than specified above|0
6206987|NCT01548404|9870674|FG001|Overall Study|Other than specified above|2
6206988|NCT01548417|9870683|FG000|Overall Study|Withdrawal by Subject|0
6206989|NCT01548417|9870684|FG001|Overall Study|Withdrawal by Subject|2
6206990|NCT01548573|9870690|FG000|Overall Study|Death|3
6206991|NCT01548573|9870690|FG000|Overall Study|Withdrawal by Subject|2
6206992|NCT01548599|9870697|FG000|Overall Study|Lost to Follow-up|0
6285746|NCT02339909|9998272|FG000|Overall Study|Became ineligible after randomisation|89
6285747|NCT02339909|9998273|FG001|Overall Study|Became ineligible after randomisation|63
6285748|NCT02339909|9998274|FG002|Overall Study|Became ineligible after randomisation|71
6285749|NCT02340000|9998284|FG000|Time Period 1|Withdrawal by Subject|6
6285750|NCT02340000|9998285|FG001|Time Period 1|Withdrawal by Subject|8
6285751|NCT02340000|9998284|FG000|Time Period 1|Lost to Follow-up|6
6285752|NCT02340000|9998285|FG001|Time Period 1|Lost to Follow-up|7
6285753|NCT02340000|9998284|FG000|Time Period 2|Withdrawal by Subject|9
6111304|NCT00826228|9731007|FG000|Overall Study|Withdrawal by Subject|1
6111305|NCT00826241|9731012|FG000|Overall Study|Withdrawal from Follow-up|1
6111306|NCT00826241|9731012|FG000|Overall Study|Withdrew consent|2
6111307|NCT00826241|9731012|FG000|Overall Study|Death|4
6111308|NCT00826241|9731012|FG000|Overall Study|Non-reportable(not qualify as Gr. 5 SAE)|1
6111309|NCT00826241|9731012|FG000|Overall Study|Non-compliance|1
6111310|NCT00826241|9731012|FG000|Overall Study|Progression of disease|1
6111311|NCT00826241|9731012|FG000|Overall Study|Patient refused follow-up|3
6111312|NCT00826241|9731012|FG000|Overall Study|Lost to Follow-up|9
6111313|NCT00826241|9731012|FG000|Overall Study|Could not obtain records|1
6111314|NCT00826241|9731012|FG000|Overall Study|Screen failure|2
6111315|NCT00826241|9731012|FG000|Overall Study|Pt unable to proceed to registration|1
6111316|NCT00826241|9731012|FG000|Overall Study|Pt opt not to proceed w/trmt|1
6111317|NCT00826267|9731019|FG000|Overall Study|Other Adverse Event|1
6111318|NCT00826267|9731020|FG001|Overall Study|Other Adverse Event|0
6111319|NCT00826267|9731021|FG002|Overall Study|Other Adverse Event|0
6111320|NCT00826280|9731033|FG000|Overall Study|Randomized but drug not received|1
6111321|NCT00826280|9731034|FG001|Overall Study|Randomized but drug not received|0
6111322|NCT00826280|9731035|FG002|Overall Study|Randomized but drug not received|1
6111323|NCT00826280|9731033|FG000|Overall Study|Adverse Event|1
6111324|NCT00826280|9731034|FG001|Overall Study|Adverse Event|3
6111325|NCT00826280|9731035|FG002|Overall Study|Adverse Event|0
6111326|NCT00826280|9731033|FG000|Overall Study|Lost to Follow-up|0
6111327|NCT00826280|9731034|FG001|Overall Study|Lost to Follow-up|1
6111328|NCT00826280|9731035|FG002|Overall Study|Lost to Follow-up|0
6206993|NCT01548599|9870698|FG001|Overall Study|Lost to Follow-up|1
6206994|NCT01548599|9870697|FG000|Overall Study|Withdrawal by Subject|4
6111329|NCT00826280|9731033|FG000|Overall Study|Sponsor discontinued subject or study|1
6111330|NCT00826280|9731034|FG001|Overall Study|Sponsor discontinued subject or study|0
6111331|NCT00826280|9731035|FG002|Overall Study|Sponsor discontinued subject or study|0
6111332|NCT00826280|9731033|FG000|Overall Study|Reversible ischemic defect not present|43
6111333|NCT00826280|9731034|FG001|Overall Study|Reversible ischemic defect not present|40
6111334|NCT00826280|9731035|FG002|Overall Study|Reversible ischemic defect not present|44
6111335|NCT00826280|9731033|FG000|Overall Study|Interpretation Failure|1
6111336|NCT00826280|9731034|FG001|Overall Study|Interpretation Failure|0
6111337|NCT00826280|9731035|FG002|Overall Study|Interpretation Failure|0
6111338|NCT00826280|9731033|FG000|Overall Study|Machine Failure|1
6111339|NCT00826280|9731034|FG001|Overall Study|Machine Failure|1
6111340|NCT00826280|9731035|FG002|Overall Study|Machine Failure|0
6111341|NCT00826280|9731033|FG000|Overall Study|One or more non-interpretable scan|0
6111342|NCT00826280|9731034|FG001|Overall Study|One or more non-interpretable scan|1
6111343|NCT00826280|9731035|FG002|Overall Study|One or more non-interpretable scan|1
6111344|NCT00826449|9731045|FG000|Overall Study|Disease Progression|4
6111345|NCT00826449|9731045|FG000|Overall Study|Withdrawal by Subject|1
6111346|NCT00826514|9731052|FG000|Overall Study|Adverse Event|1
6111347|NCT00826514|9731053|FG001|Overall Study|Adverse Event|1
6111348|NCT00826514|9731052|FG000|Overall Study|Lack of Efficacy|0
6111349|NCT00826514|9731053|FG001|Overall Study|Lack of Efficacy|1
6111350|NCT00826514|9731052|FG000|Overall Study|Withdrawal by Subject|2
6111351|NCT00826514|9731053|FG001|Overall Study|Withdrawal by Subject|3
6111352|NCT00826540|9731059|FG000|Overall Study|ineligible|3
6111353|NCT00826540|9731059|FG000|Overall Study|Withdrawal by Subject|1
6111354|NCT00826618|9731063|FG000|Overall Study|Withdrawal by Subject|1
6111355|NCT00826748|9731070|FG000|Overall Study|Withdrawal by Subject|0
6111356|NCT00826748|9731071|FG001|Overall Study|Withdrawal by Subject|0
6111357|NCT00826748|9731072|FG002|Overall Study|Withdrawal by Subject|2
6111358|NCT00826748|9731070|FG000|Overall Study|Physician Decision|0
6111359|NCT00826748|9731071|FG001|Overall Study|Physician Decision|0
6111360|NCT00826748|9731072|FG002|Overall Study|Physician Decision|1
6111361|NCT00826748|9731070|FG000|Overall Study|Samples Did Not pass QC|0
6111362|NCT00826748|9731071|FG001|Overall Study|Samples Did Not pass QC|0
6111363|NCT00826748|9731072|FG002|Overall Study|Samples Did Not pass QC|1
6111364|NCT00826943|9731084|FG000|Overall Study|Withdrawal by Subject|0
6111365|NCT00826943|9731085|FG001|Overall Study|Withdrawal by Subject|0
6111366|NCT00826943|9731086|FG002|Overall Study|Withdrawal by Subject|0
6111367|NCT00826943|9731087|FG003|Overall Study|Withdrawal by Subject|0
6111368|NCT00826943|9731088|FG004|Overall Study|Withdrawal by Subject|1
6111369|NCT00826943|9731089|FG005|Overall Study|Withdrawal by Subject|0
6111370|NCT00827112|9731112|FG000|Overall Study|Adverse Event|2
6111371|NCT00827112|9731113|FG001|Overall Study|Adverse Event|0
6111372|NCT00827112|9731112|FG000|Overall Study|Lack of Efficacy|2
6111373|NCT00827112|9731113|FG001|Overall Study|Lack of Efficacy|0
6111374|NCT00827112|9731112|FG000|Overall Study|Lost to Follow-up|3
6111375|NCT00827112|9731113|FG001|Overall Study|Lost to Follow-up|2
6111376|NCT00827112|9731112|FG000|Overall Study|Pregnancy|0
6111377|NCT00827112|9731113|FG001|Overall Study|Pregnancy|1
6111378|NCT00827112|9731112|FG000|Overall Study|Protocol Violation|0
6111379|NCT00827112|9731113|FG001|Overall Study|Protocol Violation|2
6111380|NCT00827112|9731112|FG000|Overall Study|Withdrawal by Subject|2
6111381|NCT00827112|9731113|FG001|Overall Study|Withdrawal by Subject|1
6111382|NCT00827112|9731112|FG000|Overall Study|Randomized but not treated|5
6111383|NCT00827112|9731113|FG001|Overall Study|Randomized but not treated|3
6111384|NCT00827112|9731112|FG000|Overall Study|Other|1
6111385|NCT00827112|9731113|FG001|Overall Study|Other|3
6111386|NCT00827242|9731121|FG000|Overall Study|Withdrawal by Subject|2
6111387|NCT00827242|9731122|FG001|Overall Study|Withdrawal by Subject|4
6111388|NCT00827242|9731121|FG000|Overall Study|Protocol Violation|1
6111389|NCT00827242|9731122|FG001|Overall Study|Protocol Violation|3
6111390|NCT00827242|9731121|FG000|Overall Study|Lost to Follow-up|0
6111391|NCT00827242|9731122|FG001|Overall Study|Lost to Follow-up|3
6111392|NCT00827242|9731121|FG000|Overall Study|Adverse Event Excluding Death|2
6111393|NCT00827242|9731122|FG001|Overall Study|Adverse Event Excluding Death|1
6111394|NCT00827242|9731121|FG000|Overall Study|Entry Criteria Not Met|4
6111395|NCT00827242|9731122|FG001|Overall Study|Entry Criteria Not Met|1
6111396|NCT00827242|9731121|FG000|Overall Study|Physician Decision|2
6111397|NCT00827242|9731122|FG001|Overall Study|Physician Decision|0
6111398|NCT00827242|9731121|FG000|Overall Study|Death|1
6111399|NCT00827242|9731122|FG001|Overall Study|Death|0
6111400|NCT00827242|9731121|FG000|Overall Study|Lack of Efficacy|1
6111401|NCT00827242|9731122|FG001|Overall Study|Lack of Efficacy|0
6111402|NCT00827359|9731132|FG000|Overall Study|Progressive Diseas|19
6111403|NCT00827359|9731132|FG000|Overall Study|Unacceptable Toxicity|5
6111404|NCT00827359|9731132|FG000|Overall Study|Ineligible|1
6111405|NCT00827372|9731136|FG000|Overall Study|Adverse Event|5
6111406|NCT00827372|9731136|FG000|Overall Study|Lack of Efficacy|3
6111407|NCT00827502|9731141|FG000|Overall Study|randomized but not treated|11
6111408|NCT00827502|9731141|FG000|Overall Study|Adverse Event|1
6111409|NCT00827502|9731141|FG000|Overall Study|Lost to Follow-up|4
6111410|NCT00827502|9731141|FG000|Overall Study|Withdrawal by Subject|5
6111411|NCT00827541|9731147|FG000|Overall Study|Exitus|1
6111412|NCT00827541|9731148|FG001|Overall Study|Exitus|8
6111413|NCT00827541|9731147|FG000|Overall Study|Other|1
6111414|NCT00827541|9731148|FG001|Overall Study|Other|3
6111415|NCT00827541|9731147|FG000|Overall Study|Pathogen not susceptible|1
6111416|NCT00827541|9731148|FG001|Overall Study|Pathogen not susceptible|0
6111417|NCT00827541|9731147|FG000|Overall Study|Lack of effectiveness|1
6111418|NCT00827541|9731148|FG001|Overall Study|Lack of effectiveness|0
6111419|NCT00827606|9731156|FG000|Overall Study|Protocol Violation|4
6111420|NCT00827606|9731157|FG001|Overall Study|Protocol Violation|3
6206995|NCT01548599|9870698|FG001|Overall Study|Withdrawal by Subject|0
6111421|NCT00827606|9731156|FG000|Overall Study|Lost to Follow-up|3
6111422|NCT00827606|9731157|FG001|Overall Study|Lost to Follow-up|1
6111423|NCT00827606|9731156|FG000|Overall Study|Withdrawal by Subject|7
6111424|NCT00827606|9731157|FG001|Overall Study|Withdrawal by Subject|6
6111425|NCT00827606|9731156|FG000|Overall Study|Pregnancy|0
6111426|NCT00827606|9731157|FG001|Overall Study|Pregnancy|1
6111427|NCT00827606|9731156|FG000|Overall Study|Other|5
6111428|NCT00827606|9731157|FG001|Overall Study|Other|13
6111429|NCT00827606|9731156|FG000|Overall Study|LDL below 2.59 mmol/L|4
6111430|NCT00827606|9731157|FG001|Overall Study|LDL below 2.59 mmol/L|12
6111431|NCT00827606|9731156|FG000|Overall Study|Adverse Event|4
6111432|NCT00827606|9731157|FG001|Overall Study|Adverse Event|2
6111433|NCT00827632|9731171|FG000|Overall Study|Lost to Follow-up|8
6111434|NCT00827632|9731172|FG001|Overall Study|Lost to Follow-up|12
6111435|NCT00827632|9731171|FG000|Overall Study|Early withdrawal|14
6111436|NCT00827632|9731172|FG001|Overall Study|Early withdrawal|11
6111437|NCT00827775|9731180|FG000|Overall Study|Withdrawal by Subject|0
6111438|NCT00827775|9731181|FG001|Overall Study|Withdrawal by Subject|5
6111439|NCT00827827|9731189|FG000|Overall Study|Lost to Follow-up|3
6111440|NCT00827827|9731190|FG001|Overall Study|Lost to Follow-up|0
6111441|NCT00827827|9731189|FG000|Overall Study|Fall at home- hospitalization|1
6111442|NCT00827827|9731190|FG001|Overall Study|Fall at home- hospitalization|0
6111443|NCT00827827|9731189|FG000|Overall Study|Another cerebrovascular accident (CVA)|1
6111444|NCT00827827|9731190|FG001|Overall Study|Another cerebrovascular accident (CVA)|0
6111445|NCT00827827|9731189|FG000|Overall Study|Gout|1
6111446|NCT00827827|9731190|FG001|Overall Study|Gout|0
6111447|NCT00827827|9731189|FG000|Overall Study|Transportation issues|1
6111448|NCT00827827|9731190|FG001|Overall Study|Transportation issues|0
6111449|NCT00827827|9731189|FG000|Overall Study|Burned with water at home|1
6111450|NCT00827827|9731190|FG001|Overall Study|Burned with water at home|0
6111451|NCT00827918|9731200|FG000|Overall Study|Adverse Event|4
6111452|NCT00827918|9731201|FG001|Overall Study|Adverse Event|0
6111453|NCT00827918|9731202|FG002|Overall Study|Adverse Event|0
6111454|NCT00827918|9731200|FG000|Overall Study|Lack of Efficacy|16
6111455|NCT00827918|9731201|FG001|Overall Study|Lack of Efficacy|4
6111456|NCT00827918|9731202|FG002|Overall Study|Lack of Efficacy|15
6111457|NCT00827918|9731200|FG000|Overall Study|Physician Decision|1
6111458|NCT00827918|9731201|FG001|Overall Study|Physician Decision|0
6111459|NCT00827918|9731202|FG002|Overall Study|Physician Decision|0
6111460|NCT00827918|9731200|FG000|Overall Study|Pregnancy|0
6111461|NCT00827918|9731201|FG001|Overall Study|Pregnancy|1
6111462|NCT00827918|9731202|FG002|Overall Study|Pregnancy|0
6111463|NCT00827918|9731200|FG000|Overall Study|Progressive Disease|1
6111464|NCT00827918|9731201|FG001|Overall Study|Progressive Disease|1
6111465|NCT00827918|9731202|FG002|Overall Study|Progressive Disease|0
6111466|NCT00827918|9731200|FG000|Overall Study|Protocol Violation|0
6111467|NCT00827918|9731201|FG001|Overall Study|Protocol Violation|1
6206996|NCT01548599|9870697|FG000|Overall Study|Death|2
6206997|NCT01548599|9870698|FG001|Overall Study|Death|1
6206998|NCT01548638|9870707|FG000|Overall Study|Protocol Violation|3
6206999|NCT01548638|9870707|FG000|Overall Study|Withdrawal by Subject|1
6207000|NCT01548768|9870747|FG000|Overall Study|Withdrawal by Subject|0
6207001|NCT01548768|9870748|FG001|Overall Study|Withdrawal by Subject|2
6207002|NCT01548768|9870749|FG002|Overall Study|Withdrawal by Subject|1
6207003|NCT01548768|9870750|FG003|Overall Study|Withdrawal by Subject|0
6207004|NCT01548768|9870747|FG000|Overall Study|Physician Decision|1
6207005|NCT01548768|9870748|FG001|Overall Study|Physician Decision|0
6207006|NCT01548768|9870749|FG002|Overall Study|Physician Decision|0
6207007|NCT01548768|9870750|FG003|Overall Study|Physician Decision|0
6207008|NCT01548768|9870747|FG000|Overall Study|Adverse Event|0
6207009|NCT01548768|9870748|FG001|Overall Study|Adverse Event|0
6207010|NCT01548768|9870749|FG002|Overall Study|Adverse Event|0
6207011|NCT01548768|9870750|FG003|Overall Study|Adverse Event|1
6207012|NCT01548768|9870747|FG000|Overall Study|Non-Compliance|0
6207013|NCT01548768|9870748|FG001|Overall Study|Non-Compliance|0
6207014|NCT01548768|9870749|FG002|Overall Study|Non-Compliance|0
6207015|NCT01548768|9870750|FG003|Overall Study|Non-Compliance|3
6207016|NCT01549002|9870776|FG000|Overall Study|Excessive pain|0
6207017|NCT01549002|9870777|FG001|Overall Study|Excessive pain|2
6207018|NCT01549002|9870776|FG000|Overall Study|Moderate sedation required|0
6207019|NCT01549002|9870777|FG001|Overall Study|Moderate sedation required|2
6207020|NCT01549041|9870785|FG000|Overall Study|Lack of Efficacy|2
6207021|NCT01549041|9870786|FG001|Overall Study|Lack of Efficacy|4
6207022|NCT01549041|9870785|FG000|Overall Study|Adverse Event|0
6207023|NCT01549041|9870786|FG001|Overall Study|Adverse Event|4
6207024|NCT01549275|9870803|FG000|Overall Study|Lost to Follow-up|1
6207025|NCT01549275|9870804|FG001|Overall Study|Lost to Follow-up|0
6207026|NCT01549392|9870838|FG000|Overall Study|Withdrawal by Subject|1
6207027|NCT01549392|9870839|FG001|Overall Study|Withdrawal by Subject|0
6111468|NCT00827918|9731202|FG002|Overall Study|Protocol Violation|0
6111469|NCT00827918|9731200|FG000|Overall Study|Withdrawal by Subject|6
6111470|NCT00827918|9731201|FG001|Overall Study|Withdrawal by Subject|2
6111471|NCT00827918|9731202|FG002|Overall Study|Withdrawal by Subject|6
5980656|NCT02733042|9569324|FG004|Follow-up Period|Withdrawal by Subject|0
6111472|NCT00827931|9731212|FG000|Overall Study|Death|3
6207028|NCT01549613|9870867|FG000|Overall Study|Lost to Follow-up|11
6207029|NCT01549613|9870868|FG001|Overall Study|Lost to Follow-up|11
6207030|NCT01549652|9870877|FG000|Overall Study|Did Not Receive Allocated Intervention|0
6207031|NCT01549652|9870878|FG001|Overall Study|Did Not Receive Allocated Intervention|0
6207032|NCT01549652|9870879|FG002|Overall Study|Did Not Receive Allocated Intervention|2
6111473|NCT00827931|9731213|FG001|Overall Study|Death|5
6111474|NCT00827931|9731212|FG000|Overall Study|Adverse Event|1
6111475|NCT00827931|9731213|FG001|Overall Study|Adverse Event|0
6111476|NCT00827931|9731212|FG000|Overall Study|Lost to Follow-up|1
6111477|NCT00827931|9731213|FG001|Overall Study|Lost to Follow-up|0
6111478|NCT00827931|9731212|FG000|Overall Study|Withdrawal by Subject|0
6111479|NCT00827931|9731213|FG001|Overall Study|Withdrawal by Subject|1
6111480|NCT00827931|9731212|FG000|Overall Study|Other|1
6111481|NCT00827931|9731213|FG001|Overall Study|Other|0
6111482|NCT00828009|9731237|FG000|Step 1 - Chemo RT/Consolidation Chemo|Adverse Event|10
6111483|NCT00828009|9731237|FG000|Step 1 - Chemo RT/Consolidation Chemo|Death|2
6111484|NCT00828009|9731237|FG000|Step 1 - Chemo RT/Consolidation Chemo|Withdrawal by Subject|3
6111485|NCT00828009|9731237|FG000|Step 1 - Chemo RT/Consolidation Chemo|Progressive disease|11
6111486|NCT00828009|9731237|FG000|Step 1 - Chemo RT/Consolidation Chemo|Complicating disease|1
6111487|NCT00828009|9731237|FG000|Step 1 - Chemo RT/Consolidation Chemo|No show/Patient moved|2
6111488|NCT00828009|9731237|FG000|Step 1 - Chemo RT/Consolidation Chemo|Never started therapy|2
6111489|NCT00828009|9731237|FG000|Step 2 - Maintenance Therapy|Progressive disease|12
6111490|NCT00828009|9731237|FG000|Step 2 - Maintenance Therapy|Adverse Event|13
6111491|NCT00828009|9731237|FG000|Step 2 - Maintenance Therapy|Death|1
6111492|NCT00828009|9731237|FG000|Step 2 - Maintenance Therapy|Withdrawal by Subject|4
6111493|NCT00828009|9731237|FG000|Step 2 - Maintenance Therapy|Complicating disease|2
6111494|NCT00828009|9731237|FG000|Step 2 - Maintenance Therapy|Other|1
6111495|NCT00828113|9731271|FG000|Overall Study|Withdrawal by Subject|27
6111496|NCT00828113|9731272|FG001|Overall Study|Withdrawal by Subject|26
6111497|NCT00828113|9731271|FG000|Overall Study|Lost to Follow-up|3
6111498|NCT00828113|9731272|FG001|Overall Study|Lost to Follow-up|5
6207033|NCT01549652|9870880|FG003|Overall Study|Did Not Receive Allocated Intervention|0
6207034|NCT01549652|9870877|FG000|Overall Study|Study Drug Titration Failure|5
6207035|NCT01549652|9870878|FG001|Overall Study|Study Drug Titration Failure|6
6207036|NCT01549652|9870879|FG002|Overall Study|Study Drug Titration Failure|0
6207037|NCT01549652|9870880|FG003|Overall Study|Study Drug Titration Failure|0
6207038|NCT01549652|9870877|FG000|Overall Study|Withdrawal Effect|0
6207039|NCT01549652|9870878|FG001|Overall Study|Withdrawal Effect|2
6207040|NCT01549652|9870879|FG002|Overall Study|Withdrawal Effect|0
6207041|NCT01549652|9870880|FG003|Overall Study|Withdrawal Effect|0
6207042|NCT01549652|9870877|FG000|Overall Study|Did Not Return Due to Withdrawal Effect|5
6207043|NCT01549652|9870878|FG001|Overall Study|Did Not Return Due to Withdrawal Effect|1
6207044|NCT01549652|9870879|FG002|Overall Study|Did Not Return Due to Withdrawal Effect|0
6207045|NCT01549652|9870880|FG003|Overall Study|Did Not Return Due to Withdrawal Effect|0
6207046|NCT01549652|9870877|FG000|Overall Study|Problem with Infusion|1
6207047|NCT01549652|9870878|FG001|Overall Study|Problem with Infusion|0
6207048|NCT01549652|9870879|FG002|Overall Study|Problem with Infusion|0
6207049|NCT01549652|9870880|FG003|Overall Study|Problem with Infusion|0
6207050|NCT01549652|9870877|FG000|Overall Study|Titration Non-Compliance|1
6207051|NCT01549652|9870878|FG001|Overall Study|Titration Non-Compliance|3
6207052|NCT01549652|9870879|FG002|Overall Study|Titration Non-Compliance|4
6207053|NCT01549652|9870880|FG003|Overall Study|Titration Non-Compliance|5
6207054|NCT01549652|9870877|FG000|Overall Study|Titration Side Effects|0
6207055|NCT01549652|9870878|FG001|Overall Study|Titration Side Effects|0
6207056|NCT01549652|9870879|FG002|Overall Study|Titration Side Effects|6
6207057|NCT01549652|9870880|FG003|Overall Study|Titration Side Effects|3
6207058|NCT01549652|9870877|FG000|Overall Study|Withdrawal by Subject|0
6285754|NCT02340000|9998285|FG001|Time Period 2|Withdrawal by Subject|7
6285755|NCT02340000|9998284|FG000|Time Period 2|Lost to Follow-up|10
6285756|NCT02340000|9998285|FG001|Time Period 2|Lost to Follow-up|8
6285757|NCT02340078|9998298|FG000|Overall Study|Protocol Violation|1
6285758|NCT02340520|9998355|FG000|Overall Study|Lost to Follow-up|1
6285759|NCT02340520|9998355|FG000|Overall Study|Patient did not take drug as specified|1
6285760|NCT02340520|9998355|FG000|Overall Study|Withdrawal by Subject|1
6285761|NCT02340663|9998361|FG000|Overall Study|Lost to Follow-up|1
6285762|NCT02340663|9998362|FG001|Overall Study|Lost to Follow-up|0
6285763|NCT02340663|9998361|FG000|Overall Study|Protocol Violation|1
6285764|NCT02340663|9998362|FG001|Overall Study|Protocol Violation|0
6285765|NCT02340663|9998361|FG000|Overall Study|Withdrawal by Subject|3
6285766|NCT02340663|9998362|FG001|Overall Study|Withdrawal by Subject|1
6285767|NCT02340780|9998404|FG000|Overall Study|Ineligible|1
6285768|NCT02340806|9998410|FG000|Overall Study|Protocol Violation|2
6285769|NCT02340806|9998411|FG001|Overall Study|Protocol Violation|0
6285770|NCT02340806|9998410|FG000|Overall Study|epidural catheter replaced|2
6285771|NCT02340806|9998411|FG001|Overall Study|epidural catheter replaced|1
6285772|NCT02340806|9998410|FG000|Overall Study|history of chronic pain medication|1
6285773|NCT02340806|9998411|FG001|Overall Study|history of chronic pain medication|0
6285774|NCT02340806|9998410|FG000|Overall Study|re-dose < 90 min of CSE|1
6285775|NCT02340806|9998411|FG001|Overall Study|re-dose < 90 min of CSE|3
6285776|NCT02340819|9998417|FG000|Overall Study|Adverse Event|1
6285777|NCT02340819|9998417|FG000|Overall Study|Withdrawal by Subject|2
6111499|NCT00828139|9731282|FG000|Overall Study|Adverse Event|8
6111500|NCT00828139|9731283|FG001|Overall Study|Adverse Event|1
6111501|NCT00828139|9731284|FG002|Overall Study|Adverse Event|10
6111502|NCT00828139|9731285|FG003|Overall Study|Adverse Event|5
6111503|NCT00828139|9731282|FG000|Overall Study|Death|2
6111504|NCT00828139|9731283|FG001|Overall Study|Death|1
6111505|NCT00828139|9731284|FG002|Overall Study|Death|0
6111506|NCT00828139|9731285|FG003|Overall Study|Death|2
6111507|NCT00828139|9731282|FG000|Overall Study|Refusal unrelated to toxicity|3
6111508|NCT00828139|9731283|FG001|Overall Study|Refusal unrelated to toxicity|4
6111509|NCT00828139|9731284|FG002|Overall Study|Refusal unrelated to toxicity|5
6111510|NCT00828139|9731285|FG003|Overall Study|Refusal unrelated to toxicity|3
6111511|NCT00828139|9731282|FG000|Overall Study|Disease Progression|24
6111512|NCT00828139|9731283|FG001|Overall Study|Disease Progression|33
6111513|NCT00828139|9731284|FG002|Overall Study|Disease Progression|35
6111514|NCT00828139|9731285|FG003|Overall Study|Disease Progression|39
6111515|NCT00828139|9731282|FG000|Overall Study|Other|4
6111516|NCT00828139|9731283|FG001|Overall Study|Other|2
6111517|NCT00828139|9731284|FG002|Overall Study|Other|5
6111518|NCT00828139|9731285|FG003|Overall Study|Other|2
6111519|NCT00828204|9731317|FG000|Main Study: Prior to Study Suspension|Adverse Event|1
6111520|NCT00828204|9731318|FG001|Main Study: Prior to Study Suspension|Adverse Event|0
6111521|NCT00828204|9731317|FG000|Main Study: Prior to Study Suspension|Subject Was Withdrawn|2
6111522|NCT00828204|9731318|FG001|Main Study: Prior to Study Suspension|Subject Was Withdrawn|0
6111523|NCT00828204|9731317|FG000|Main Study: Prior to Study Suspension|Study Suspension|11
6111524|NCT00828204|9731318|FG001|Main Study: Prior to Study Suspension|Study Suspension|0
6111525|NCT00828204|9731317|FG000|Main Study: After Study Restart|Adverse Event|0
6111526|NCT00828204|9731318|FG001|Main Study: After Study Restart|Adverse Event|2
6111527|NCT00828204|9731317|FG000|Main Study: After Study Restart|Noncompliance|0
6111528|NCT00828204|9731318|FG001|Main Study: After Study Restart|Noncompliance|1
6111529|NCT00828204|9731317|FG000|Extension Study|Lost to Follow-up|0
6111530|NCT00828204|9731318|FG001|Extension Study|Lost to Follow-up|1
6111531|NCT00828204|9731317|FG000|Extension Study|Physician Decision|0
6111532|NCT00828204|9731318|FG001|Extension Study|Physician Decision|2
6111533|NCT00828451|9731352|FG000|Overall Study|Death|2
6111534|NCT00828451|9731352|FG000|Overall Study|Lack of intravenous line|7
6111535|NCT00828451|9731352|FG000|Overall Study|Withdrawal by Subject|1
6111536|NCT00828451|9731352|FG000|Overall Study|Deterioration in clinical status|1
6111537|NCT00828464|9731356|FG000|Overall Study|Withdrawal by Subject|1
6207059|NCT01549652|9870878|FG001|Overall Study|Withdrawal by Subject|0
6285778|NCT02340819|9998417|FG000|Overall Study|Discontinued with other reason|1
6285779|NCT02340949|9998423|FG000|Overall Study|Adverse Event|4
6285780|NCT02340949|9998424|FG001|Overall Study|Adverse Event|2
6285781|NCT02340949|9998423|FG000|Overall Study|Withdrawal by Subject|2
6285782|NCT02340949|9998424|FG001|Overall Study|Withdrawal by Subject|0
6285783|NCT02340949|9998423|FG000|Overall Study|Progression disease|6
6285784|NCT02340949|9998424|FG001|Overall Study|Progression disease|2
6285785|NCT02340949|9998423|FG000|Overall Study|Death|3
6285786|NCT02340949|9998424|FG001|Overall Study|Death|0
6285787|NCT02340949|9998423|FG000|Overall Study|Physician Decision|1
6285788|NCT02340949|9998424|FG001|Overall Study|Physician Decision|0
6285789|NCT02340962|9998432|FG000|Overall Study|Lost to Follow-up|1
6285790|NCT02340962|9998433|FG001|Overall Study|Lost to Follow-up|0
6285791|NCT02340975|9998445|FG000|Overall Study|Death|6
6285792|NCT02340975|9998446|FG001|Overall Study|Death|23
6285793|NCT02340975|9998447|FG002|Overall Study|Death|21
6285794|NCT02340975|9998448|FG003|Overall Study|Death|7
6285795|NCT02340975|9998449|FG004|Overall Study|Death|21
6285796|NCT02340975|9998450|FG005|Overall Study|Death|13
6285797|NCT02340975|9998445|FG000|Overall Study|Lost to Follow-up|0
6285798|NCT02340975|9998446|FG001|Overall Study|Lost to Follow-up|0
6285799|NCT02340975|9998447|FG002|Overall Study|Lost to Follow-up|0
6285800|NCT02340975|9998448|FG003|Overall Study|Lost to Follow-up|0
6111538|NCT00828516|9731360|FG000|Clinical Phase: Series 1|Withdrawal by Subject|2
6111539|NCT00828568|9731376|FG000|Randomized|Withdrawal by Subject|1
6111540|NCT00828568|9731377|FG001|Randomized|Withdrawal by Subject|0
6111541|NCT00828568|9731378|FG002|Randomized|Withdrawal by Subject|2
6111542|NCT00828568|9731376|FG000|Treated - Received at Least One Dose|Adverse Event|11
6111543|NCT00828568|9731377|FG001|Treated - Received at Least One Dose|Adverse Event|8
6111544|NCT00828568|9731378|FG002|Treated - Received at Least One Dose|Adverse Event|1
6111545|NCT00828568|9731376|FG000|Treated - Received at Least One Dose|Withdrawal by Subject|9
6207060|NCT01549652|9870879|FG002|Overall Study|Withdrawal by Subject|5
6207061|NCT01549652|9870880|FG003|Overall Study|Withdrawal by Subject|3
6207062|NCT01549860|9870888|FG000|Overall Study|Withdrawal by Subject|1
6207063|NCT01549860|9870889|FG001|Overall Study|Withdrawal by Subject|0
6207064|NCT01549860|9870888|FG000|Overall Study|Physician Decision|1
6207065|NCT01549860|9870889|FG001|Overall Study|Physician Decision|1
6207066|NCT01549873|9870897|FG000|Overall Study|Physician Decision|0
6207067|NCT01549873|9870898|FG001|Overall Study|Physician Decision|1
6207068|NCT01549886|9870906|FG000|Overall Study|Sponsor's decision|2
6285801|NCT02340975|9998449|FG004|Overall Study|Lost to Follow-up|2
5980657|NCT02733042|9569325|FG005|Follow-up Period|Withdrawal by Subject|0
6111546|NCT00828568|9731377|FG001|Treated - Received at Least One Dose|Withdrawal by Subject|11
6111547|NCT00828568|9731378|FG002|Treated - Received at Least One Dose|Withdrawal by Subject|0
6207069|NCT01549886|9870907|FG001|Overall Study|Sponsor's decision|3
6285802|NCT02340975|9998450|FG005|Overall Study|Lost to Follow-up|0
6285803|NCT02340975|9998445|FG000|Overall Study|Withdrawal by Subject|0
6111548|NCT00828568|9731376|FG000|Treated - Received at Least One Dose|Lost to Follow-up|1
6111549|NCT00828568|9731377|FG001|Treated - Received at Least One Dose|Lost to Follow-up|5
6111550|NCT00828568|9731378|FG002|Treated - Received at Least One Dose|Lost to Follow-up|1
6111551|NCT00828568|9731376|FG000|Treated - Received at Least One Dose|Protocol Violation|9
6111552|NCT00828568|9731377|FG001|Treated - Received at Least One Dose|Protocol Violation|5
6111553|NCT00828568|9731378|FG002|Treated - Received at Least One Dose|Protocol Violation|3
6111554|NCT00828672|9731389|FG000|Study Treatment|Lost to Follow-up|1
6111555|NCT00828672|9731390|FG001|Study Treatment|Lost to Follow-up|0
6111556|NCT00828672|9731389|FG000|Study Treatment|Adverse Event|0
6111557|NCT00828672|9731390|FG001|Study Treatment|Adverse Event|1
6111558|NCT00828672|9731389|FG000|Study Treatment|Complete response, no surgery|1
6111559|NCT00828672|9731390|FG001|Study Treatment|Complete response, no surgery|1
6111560|NCT00828672|9731389|FG000|Post-surgery (<30 Days)|No central review materials|0
6111561|NCT00828672|9731390|FG001|Post-surgery (<30 Days)|No central review materials|1
6111562|NCT00828711|9731399|FG000|Overall Study|Lost to Follow-up|1
6111563|NCT00828711|9731400|FG001|Overall Study|Lost to Follow-up|0
6111564|NCT00828711|9731401|FG002|Overall Study|Lost to Follow-up|0
6111565|NCT00828750|9731409|FG000|Overall Study|Lack of Efficacy|3
6111566|NCT00828750|9731409|FG000|Overall Study|Normal PC Remained While No Treatment|1
6111567|NCT00828945|9731429|FG000|Overall Study|Death|4
6111568|NCT00828945|9731429|FG000|Overall Study|Participant was missing|1
6111569|NCT00828945|9731429|FG000|Overall Study|Other|36
6207070|NCT01549951|9870924|FG000|Overall Study|Adverse Event|15
6207071|NCT01549951|9870924|FG000|Overall Study|Withdrawal by Subject|2
6207072|NCT01549951|9870924|FG000|Overall Study|Unsatisfactory therapeutic response|1
6207073|NCT01549951|9870924|FG000|Overall Study|Progressive disease|29
6207074|NCT01549951|9870924|FG000|Overall Study|Symptomatic deterioration|1
6207075|NCT01549951|9870924|FG000|Overall Study|Other|2
6207076|NCT01549964|9870932|FG000|24-Week Treatment Period|Study Terminated by Sponsor|50
6207077|NCT01549964|9870933|FG001|24-Week Treatment Period|Study Terminated by Sponsor|104
6207078|NCT01549964|9870934|FG002|24-Week Treatment Period|Study Terminated by Sponsor|104
6207079|NCT01549964|9870935|FG003|24-Week Treatment Period|Study Terminated by Sponsor|105
6207080|NCT01549964|9870932|FG000|24-Week Treatment Period|Voluntary Withdrawal|6
6207081|NCT01549964|9870933|FG001|24-Week Treatment Period|Voluntary Withdrawal|3
6207082|NCT01549964|9870934|FG002|24-Week Treatment Period|Voluntary Withdrawal|3
6207083|NCT01549964|9870935|FG003|24-Week Treatment Period|Voluntary Withdrawal|8
6207084|NCT01549964|9870932|FG000|24-Week Treatment Period|Pretreatment Event/Adverse Event|1
6207085|NCT01549964|9870933|FG001|24-Week Treatment Period|Pretreatment Event/Adverse Event|4
6207086|NCT01549964|9870934|FG002|24-Week Treatment Period|Pretreatment Event/Adverse Event|4
6207087|NCT01549964|9870935|FG003|24-Week Treatment Period|Pretreatment Event/Adverse Event|4
6207088|NCT01549964|9870932|FG000|24-Week Treatment Period|Lost to Follow-up|1
6207089|NCT01549964|9870933|FG001|24-Week Treatment Period|Lost to Follow-up|0
6207090|NCT01549964|9870934|FG002|24-Week Treatment Period|Lost to Follow-up|1
6207091|NCT01549964|9870935|FG003|24-Week Treatment Period|Lost to Follow-up|2
6207092|NCT01549964|9870932|FG000|24-Week Treatment Period|Lack of Efficacy|1
6207093|NCT01549964|9870933|FG001|24-Week Treatment Period|Lack of Efficacy|0
6207094|NCT01549964|9870934|FG002|24-Week Treatment Period|Lack of Efficacy|1
6207095|NCT01549964|9870935|FG003|24-Week Treatment Period|Lack of Efficacy|1
6207096|NCT01549964|9870932|FG000|24-Week Treatment Period|Other|1
6207097|NCT01549964|9870933|FG001|24-Week Treatment Period|Other|0
6207098|NCT01549964|9870934|FG002|24-Week Treatment Period|Other|1
6207099|NCT01549964|9870935|FG003|24-Week Treatment Period|Other|0
6207100|NCT01549964|9870932|FG000|24-Week Treatment Period|Metformin/Sitagliptin Contraindication|0
6207101|NCT01549964|9870933|FG001|24-Week Treatment Period|Metformin/Sitagliptin Contraindication|0
6207102|NCT01549964|9870934|FG002|24-Week Treatment Period|Metformin/Sitagliptin Contraindication|1
6207103|NCT01549964|9870935|FG003|24-Week Treatment Period|Metformin/Sitagliptin Contraindication|0
6207104|NCT01549964|9870932|FG000|24-Week Treatment Period|Randomized but Not Treated|0
6207105|NCT01549964|9870933|FG001|24-Week Treatment Period|Randomized but Not Treated|0
6285804|NCT02340975|9998446|FG001|Overall Study|Withdrawal by Subject|0
6285805|NCT02340975|9998447|FG002|Overall Study|Withdrawal by Subject|3
6285806|NCT02340975|9998448|FG003|Overall Study|Withdrawal by Subject|3
6285807|NCT02340975|9998449|FG004|Overall Study|Withdrawal by Subject|2
6285808|NCT02340975|9998450|FG005|Overall Study|Withdrawal by Subject|0
6285809|NCT02340975|9998445|FG000|Overall Study|Other|0
6285810|NCT02340975|9998446|FG001|Overall Study|Other|4
6285811|NCT02340975|9998447|FG002|Overall Study|Other|0
6285812|NCT02340975|9998448|FG003|Overall Study|Other|2
6285813|NCT02340975|9998449|FG004|Overall Study|Other|0
6285814|NCT02340975|9998450|FG005|Overall Study|Other|6
6285815|NCT02341417|9998477|FG000|Overall Study|Withdrawal by Subject|0
6285816|NCT02341417|9998478|FG001|Overall Study|Withdrawal by Subject|2
6285817|NCT02341417|9998479|FG002|Overall Study|Withdrawal by Subject|0
6285818|NCT02341417|9998477|FG000|Overall Study|Decision by sponsor|2
6285819|NCT02341417|9998478|FG001|Overall Study|Decision by sponsor|0
6285820|NCT02341417|9998479|FG002|Overall Study|Decision by sponsor|0
6207106|NCT01549964|9870934|FG002|24-Week Treatment Period|Randomized but Not Treated|0
6207107|NCT01549964|9870935|FG003|24-Week Treatment Period|Randomized but Not Treated|1
6285821|NCT02341417|9998477|FG000|Overall Study|Death|0
6285822|NCT02341417|9998478|FG001|Overall Study|Death|0
6111570|NCT00828984|9731436|FG000|Overall Study|Adverse Event|2
6111571|NCT00828984|9731437|FG001|Overall Study|Adverse Event|3
6111572|NCT00828984|9731438|FG002|Overall Study|Adverse Event|0
6111573|NCT00828984|9731436|FG000|Overall Study|Lost to Follow-up|5
6111574|NCT00828984|9731437|FG001|Overall Study|Lost to Follow-up|3
6111575|NCT00828984|9731438|FG002|Overall Study|Lost to Follow-up|1
6111576|NCT00828984|9731436|FG000|Overall Study|Withdrawal by Subject|4
6111577|NCT00828984|9731437|FG001|Overall Study|Withdrawal by Subject|4
6111578|NCT00828984|9731438|FG002|Overall Study|Withdrawal by Subject|4
6111579|NCT00828984|9731436|FG000|Overall Study|Ineligable|1
6111580|NCT00828984|9731437|FG001|Overall Study|Ineligable|2
6111581|NCT00828984|9731438|FG002|Overall Study|Ineligable|0
6111582|NCT00828984|9731436|FG000|Overall Study|Medical Contraindication|0
6207108|NCT01549964|9870932|FG000|24-Week Treatment Period|Completion Status Unknown|1
6207109|NCT01549964|9870933|FG001|24-Week Treatment Period|Completion Status Unknown|0
6207110|NCT01549964|9870934|FG002|24-Week Treatment Period|Completion Status Unknown|1
6207111|NCT01549964|9870935|FG003|24-Week Treatment Period|Completion Status Unknown|0
6207112|NCT01549964|9870932|FG000|80-Week Extension Period|Pregnancy|0
6207113|NCT01549964|9870933|FG001|80-Week Extension Period|Pregnancy|0
6207114|NCT01549964|9870934|FG002|80-Week Extension Period|Pregnancy|1
6207115|NCT01549964|9870935|FG003|80-Week Extension Period|Pregnancy|0
6207116|NCT01549964|9870932|FG000|80-Week Extension Period|Study Terminated by Sponsor|65
6207117|NCT01549964|9870933|FG001|80-Week Extension Period|Study Terminated by Sponsor|137
6207118|NCT01549964|9870934|FG002|80-Week Extension Period|Study Terminated by Sponsor|132
6207119|NCT01549964|9870935|FG003|80-Week Extension Period|Study Terminated by Sponsor|132
6207120|NCT01549964|9870932|FG000|80-Week Extension Period|Voluntary Withdrawal|0
6207121|NCT01549964|9870933|FG001|80-Week Extension Period|Voluntary Withdrawal|1
6207122|NCT01549964|9870934|FG002|80-Week Extension Period|Voluntary Withdrawal|4
6207123|NCT01549964|9870935|FG003|80-Week Extension Period|Voluntary Withdrawal|2
6207124|NCT01549964|9870932|FG000|80-Week Extension Period|Lost to Follow-up|1
6207125|NCT01549964|9870933|FG001|80-Week Extension Period|Lost to Follow-up|0
6207126|NCT01549964|9870934|FG002|80-Week Extension Period|Lost to Follow-up|2
6207127|NCT01549964|9870935|FG003|80-Week Extension Period|Lost to Follow-up|1
6207128|NCT01549964|9870932|FG000|80-Week Extension Period|Pretreatment Event/Adverse Event|0
6207129|NCT01549964|9870933|FG001|80-Week Extension Period|Pretreatment Event/Adverse Event|0
6207130|NCT01549964|9870934|FG002|80-Week Extension Period|Pretreatment Event/Adverse Event|1
6207131|NCT01549964|9870935|FG003|80-Week Extension Period|Pretreatment Event/Adverse Event|2
6207132|NCT01550744|9871009|FG000|Open-Label|Lost to Follow-up|7
6207133|NCT01550744|9871010|FG001|Open-Label|Lost to Follow-up|0
6207134|NCT01550744|9871011|FG002|Open-Label|Lost to Follow-up|0
6207135|NCT01550744|9871009|FG000|Open-Label|Withdrawal by Subject|13
6207136|NCT01550744|9871010|FG001|Open-Label|Withdrawal by Subject|0
6207137|NCT01550744|9871011|FG002|Open-Label|Withdrawal by Subject|0
6207138|NCT01550744|9871009|FG000|Open-Label|Adverse Event|11
6207139|NCT01550744|9871010|FG001|Open-Label|Adverse Event|0
6207140|NCT01550744|9871011|FG002|Open-Label|Adverse Event|0
6207141|NCT01550744|9871009|FG000|Open-Label|Lack of Efficacy|4
6207142|NCT01550744|9871010|FG001|Open-Label|Lack of Efficacy|0
6207143|NCT01550744|9871011|FG002|Open-Label|Lack of Efficacy|0
6207144|NCT01550744|9871009|FG000|Open-Label|Protocol Violation|4
6207145|NCT01550744|9871010|FG001|Open-Label|Protocol Violation|0
6207146|NCT01550744|9871011|FG002|Open-Label|Protocol Violation|0
6207147|NCT01550744|9871009|FG000|Open-Label|Not all 3 study drug injections received|2
6207148|NCT01550744|9871010|FG001|Open-Label|Not all 3 study drug injections received|0
6207149|NCT01550744|9871011|FG002|Open-Label|Not all 3 study drug injections received|0
6207150|NCT01550744|9871009|FG000|Open-Label|Static PGA-cleared/minimal not achieved|58
6207151|NCT01550744|9871010|FG001|Open-Label|Static PGA-cleared/minimal not achieved|0
6207152|NCT01550744|9871011|FG002|Open-Label|Static PGA-cleared/minimal not achieved|0
6207153|NCT01550744|9871009|FG000|Open-Label|Other|1
6207154|NCT01550744|9871010|FG001|Open-Label|Other|0
6207155|NCT01550744|9871011|FG002|Open-Label|Other|0
6207156|NCT01550744|9871009|FG000|Double-Blind|Lost to Follow-up|0
6207157|NCT01550744|9871010|FG001|Double-Blind|Lost to Follow-up|6
6207158|NCT01550744|9871011|FG002|Double-Blind|Lost to Follow-up|12
6207159|NCT01550744|9871009|FG000|Double-Blind|Withdrawal by Subject|0
6207160|NCT01550744|9871010|FG001|Double-Blind|Withdrawal by Subject|2
6207161|NCT01550744|9871011|FG002|Double-Blind|Withdrawal by Subject|15
6207162|NCT01550744|9871009|FG000|Double-Blind|Adverse Event|0
6207163|NCT01550744|9871010|FG001|Double-Blind|Adverse Event|4
6207164|NCT01550744|9871011|FG002|Double-Blind|Adverse Event|15
6207165|NCT01550744|9871009|FG000|Double-Blind|Death|0
6207166|NCT01550744|9871010|FG001|Double-Blind|Death|1
6207167|NCT01550744|9871011|FG002|Double-Blind|Death|0
6207168|NCT01550744|9871009|FG000|Double-Blind|Lack of Efficacy|0
6285823|NCT02341417|9998479|FG002|Overall Study|Death|1
6285824|NCT02341456|9998491|FG000|Overall Study|Disease progression|2
6285825|NCT02341456|9998492|FG001|Overall Study|Disease progression|3
6285826|NCT02341456|9998493|FG002|Overall Study|Disease progression|1
6111583|NCT00828984|9731437|FG001|Overall Study|Medical Contraindication|1
6111584|NCT00828984|9731438|FG002|Overall Study|Medical Contraindication|0
6111585|NCT00828984|9731436|FG000|Overall Study|Noncompliant|1
6111586|NCT00828984|9731437|FG001|Overall Study|Noncompliant|2
6111587|NCT00828984|9731438|FG002|Overall Study|Noncompliant|3
6111588|NCT00828984|9731436|FG000|Overall Study|ConMed|1
6111589|NCT00828984|9731437|FG001|Overall Study|ConMed|1
6111590|NCT00828984|9731438|FG002|Overall Study|ConMed|1
6111591|NCT00829010|9731451|FG000|Overall Study|Adverse Event|1
6111592|NCT00829010|9731452|FG001|Overall Study|Adverse Event|0
6111593|NCT00829010|9731453|FG002|Overall Study|Adverse Event|0
6111594|NCT00829010|9731454|FG003|Overall Study|Adverse Event|0
6111595|NCT00829010|9731455|FG004|Overall Study|Adverse Event|0
6111596|NCT00829010|9731451|FG000|Overall Study|Withdrawal by Subject|0
6111597|NCT00829010|9731452|FG001|Overall Study|Withdrawal by Subject|1
6111598|NCT00829010|9731453|FG002|Overall Study|Withdrawal by Subject|1
6111599|NCT00829010|9731454|FG003|Overall Study|Withdrawal by Subject|0
6111600|NCT00829010|9731455|FG004|Overall Study|Withdrawal by Subject|2
6111601|NCT00829010|9731451|FG000|Overall Study|Lost to Follow-up|1
6111602|NCT00829010|9731452|FG001|Overall Study|Lost to Follow-up|0
6111603|NCT00829010|9731453|FG002|Overall Study|Lost to Follow-up|2
6111604|NCT00829010|9731454|FG003|Overall Study|Lost to Follow-up|0
6111605|NCT00829010|9731455|FG004|Overall Study|Lost to Follow-up|0
6111606|NCT00829010|9731451|FG000|Overall Study|Fatality|5
6111607|NCT00829010|9731452|FG001|Overall Study|Fatality|4
6111608|NCT00829010|9731453|FG002|Overall Study|Fatality|0
6285827|NCT02341456|9998491|FG000|Overall Study|Death|1
6285828|NCT02341456|9998492|FG001|Overall Study|Death|1
6285829|NCT02341456|9998493|FG002|Overall Study|Death|1
6285830|NCT02341456|9998491|FG000|Overall Study|Withdrawal by Subject|0
6285831|NCT02341456|9998492|FG001|Overall Study|Withdrawal by Subject|1
6285832|NCT02341456|9998493|FG002|Overall Study|Withdrawal by Subject|1
6285833|NCT02341456|9998491|FG000|Overall Study|Moved to local access programme.|0
6285834|NCT02341456|9998492|FG001|Overall Study|Moved to local access programme.|1
6285835|NCT02341456|9998493|FG002|Overall Study|Moved to local access programme.|1
6285836|NCT02341456|9998491|FG000|Overall Study|Physician Decision|1
6285837|NCT02341456|9998492|FG001|Overall Study|Physician Decision|0
6111609|NCT00829010|9731454|FG003|Overall Study|Fatality|3
6111610|NCT00829010|9731455|FG004|Overall Study|Fatality|0
6111611|NCT00829010|9731451|FG000|Overall Study|Migrated/Moved from study area|3
6111612|NCT00829010|9731452|FG001|Overall Study|Migrated/Moved from study area|4
6111613|NCT00829010|9731453|FG002|Overall Study|Migrated/Moved from study area|0
6111614|NCT00829010|9731454|FG003|Overall Study|Migrated/Moved from study area|5
6111615|NCT00829010|9731455|FG004|Overall Study|Migrated/Moved from study area|0
6207169|NCT01550744|9871010|FG001|Double-Blind|Lack of Efficacy|2
6207170|NCT01550744|9871011|FG002|Double-Blind|Lack of Efficacy|8
6207171|NCT01550744|9871009|FG000|Double-Blind|Protocol Violation|0
6207172|NCT01550744|9871010|FG001|Double-Blind|Protocol Violation|0
6207173|NCT01550744|9871011|FG002|Double-Blind|Protocol Violation|4
6207174|NCT01550744|9871009|FG000|Double-Blind|Pregnancy|0
6207175|NCT01550744|9871010|FG001|Double-Blind|Pregnancy|0
6207176|NCT01550744|9871011|FG002|Double-Blind|Pregnancy|3
6207177|NCT01550744|9871009|FG000|Double-Blind|Other|0
6207178|NCT01550744|9871010|FG001|Double-Blind|Other|2
6207179|NCT01550744|9871011|FG002|Double-Blind|Other|10
6207180|NCT01550757|9871022|FG000|Overall Study|Lost to Follow-up|21
6207181|NCT01550757|9871023|FG001|Overall Study|Lost to Follow-up|14
6207182|NCT01550757|9871024|FG002|Overall Study|Lost to Follow-up|42
6207183|NCT01550757|9871025|FG003|Overall Study|Lost to Follow-up|53
6207184|NCT01550757|9871022|FG000|Overall Study|Withdrawal by Subject|2
6207185|NCT01550757|9871023|FG001|Overall Study|Withdrawal by Subject|0
6207186|NCT01550757|9871024|FG002|Overall Study|Withdrawal by Subject|3
6207187|NCT01550757|9871025|FG003|Overall Study|Withdrawal by Subject|1
6207188|NCT01550965|9871048|FG000|Overall Study|Adverse Event|26
6207189|NCT01550965|9871048|FG000|Overall Study|Withdrawal by Subject|10
6207190|NCT01550965|9871048|FG000|Overall Study|Lost to Follow-up|2
6207191|NCT01550965|9871048|FG000|Overall Study|Lack of Efficacy|59
6207192|NCT01550965|9871048|FG000|Overall Study|Other|13
6207193|NCT01551173|9871072|FG000|Overall Study|Withdrawal by Subject|11
6207194|NCT01551173|9871073|FG001|Overall Study|Withdrawal by Subject|16
6207195|NCT01551173|9871072|FG000|Overall Study|Adverse Event|7
6207196|NCT01551173|9871073|FG001|Overall Study|Adverse Event|6
6207197|NCT01551173|9871072|FG000|Overall Study|Lost to Follow-up|5
6207198|NCT01551173|9871073|FG001|Overall Study|Lost to Follow-up|7
6207199|NCT01551173|9871072|FG000|Overall Study|Other|5
6207200|NCT01551173|9871073|FG001|Overall Study|Other|3
6207201|NCT01551212|9871095|FG000|Overall Study|Graft loss/Retransplantation|0
6207202|NCT01551212|9871096|FG001|Overall Study|Graft loss/Retransplantation|1
6207203|NCT01551212|9871095|FG000|Overall Study|Administrative problems|1
6207204|NCT01551212|9871096|FG001|Overall Study|Administrative problems|2
6207205|NCT01551212|9871095|FG000|Overall Study|Lost to Follow-up|0
6207206|NCT01551212|9871096|FG001|Overall Study|Lost to Follow-up|1
6285838|NCT02341456|9998493|FG002|Overall Study|Physician Decision|0
6207207|NCT01551212|9871095|FG000|Overall Study|Protocol Violation|0
6207208|NCT01551212|9871096|FG001|Overall Study|Protocol Violation|1
6207209|NCT01551212|9871095|FG000|Overall Study|Withdrawal by Subject|0
6207210|NCT01551212|9871096|FG001|Overall Study|Withdrawal by Subject|7
6207211|NCT01551212|9871095|FG000|Overall Study|Death|2
6207212|NCT01551212|9871096|FG001|Overall Study|Death|4
6207213|NCT01551212|9871095|FG000|Overall Study|Never Received Study Treatment|2
6111616|NCT00829166|9731482|FG000|Overall Study|Death|305
6111617|NCT00829166|9731483|FG001|Overall Study|Death|333
6207214|NCT01551212|9871096|FG001|Overall Study|Never Received Study Treatment|4
6207215|NCT01551303|9871113|FG000|Overall Study|failed awareness check on vision test|4
6207216|NCT01551303|9871114|FG001|Overall Study|failed awareness check on vision test|7
6207217|NCT01551355|9871126|FG000|Overall Study|Lost to Follow-up|51
6207218|NCT01551355|9871127|FG001|Overall Study|Lost to Follow-up|49
6207219|NCT01551355|9871128|FG002|Overall Study|Lost to Follow-up|34
6207220|NCT01551355|9871129|FG003|Overall Study|Lost to Follow-up|24
6207221|NCT01551355|9871130|FG004|Overall Study|Lost to Follow-up|9
6207222|NCT01551355|9871131|FG005|Overall Study|Lost to Follow-up|6
6207223|NCT01551420|9871141|FG000|In-laboratory (Part A)|Lost to Follow-up|2
6207224|NCT01551420|9871142|FG001|In-laboratory (Part A)|Lost to Follow-up|1
6207225|NCT01551420|9871141|FG000|In-laboratory (Part A)|Withdrawal by Subject|2
6207226|NCT01551420|9871142|FG001|In-laboratory (Part A)|Withdrawal by Subject|0
6207227|NCT01551420|9871141|FG000|In-laboratory (Part A)|Scheduling conflict|2
6207228|NCT01551420|9871142|FG001|In-laboratory (Part A)|Scheduling conflict|1
6207229|NCT01551420|9871141|FG000|Screened for Part B Eligibility|Declined participation|8
6207230|NCT01551420|9871142|FG001|Screened for Part B Eligibility|Declined participation|1
6207231|NCT01551420|9871141|FG000|Screened for Part B Eligibility|Deemed ineligible by staff|1
6285839|NCT02341482|9998501|FG000|Overall Study|Adverse Event|1
5980658|NCT02733042|9569326|FG006|Follow-up Period|Withdrawal by Subject|0
5980659|NCT02733042|9569327|FG007|Follow-up Period|Withdrawal by Subject|0
5980660|NCT02733042|9569328|FG008|Follow-up Period|Withdrawal by Subject|1
5980661|NCT02733042|9569329|FG009|Follow-up Period|Withdrawal by Subject|0
5980662|NCT02733042|9569330|FG010|Follow-up Period|Withdrawal by Subject|1
5980663|NCT02733042|9569331|FG011|Follow-up Period|Withdrawal by Subject|0
5980664|NCT02733042|9569332|FG012|Follow-up Period|Withdrawal by Subject|0
5980665|NCT02733042|9569333|FG013|Follow-up Period|Withdrawal by Subject|0
5980666|NCT02733042|9569334|FG014|Follow-up Period|Withdrawal by Subject|0
5980667|NCT02733042|9569335|FG015|Follow-up Period|Withdrawal by Subject|1
5980668|NCT02733042|9569336|FG016|Follow-up Period|Withdrawal by Subject|0
5980669|NCT02733042|9569337|FG017|Follow-up Period|Withdrawal by Subject|0
5980670|NCT02733042|9569338|FG018|Follow-up Period|Withdrawal by Subject|0
5980671|NCT02574286|9569399|FG000|Overall Study|Adverse Event|3
5980672|NCT02574286|9569399|FG000|Overall Study|Withdrawal by Subject|2
5980673|NCT02471144|9569407|FG000|Induction Period (Up to Week 12)|Adverse Event|0
5980674|NCT02471144|9569408|FG001|Induction Period (Up to Week 12)|Adverse Event|1
5980675|NCT02471144|9569409|FG002|Induction Period (Up to Week 12)|Adverse Event|1
5980676|NCT02471144|9569410|FG003|Induction Period (Up to Week 12)|Adverse Event|0
5980677|NCT02471144|9569411|FG004|Induction Period (Up to Week 12)|Adverse Event|0
5980678|NCT02471144|9569412|FG005|Induction Period (Up to Week 12)|Adverse Event|0
5980679|NCT02471144|9569413|FG006|Induction Period (Up to Week 12)|Adverse Event|0
5980680|NCT02471144|9569414|FG007|Induction Period (Up to Week 12)|Adverse Event|0
5980681|NCT02471144|9569415|FG008|Induction Period (Up to Week 12)|Adverse Event|0
5980682|NCT02471144|9569416|FG009|Induction Period (Up to Week 12)|Adverse Event|0
5980683|NCT02471144|9569417|FG010|Induction Period (Up to Week 12)|Adverse Event|0
5980684|NCT02471144|9569407|FG000|Induction Period (Up to Week 12)|Lack of Efficacy|0
5980685|NCT02471144|9569408|FG001|Induction Period (Up to Week 12)|Lack of Efficacy|0
5980686|NCT02471144|9569409|FG002|Induction Period (Up to Week 12)|Lack of Efficacy|0
5980687|NCT02471144|9569410|FG003|Induction Period (Up to Week 12)|Lack of Efficacy|1
5980688|NCT02471144|9569411|FG004|Induction Period (Up to Week 12)|Lack of Efficacy|0
5980689|NCT02471144|9569412|FG005|Induction Period (Up to Week 12)|Lack of Efficacy|0
5980690|NCT02471144|9569413|FG006|Induction Period (Up to Week 12)|Lack of Efficacy|0
5980691|NCT02471144|9569414|FG007|Induction Period (Up to Week 12)|Lack of Efficacy|0
5980692|NCT02471144|9569415|FG008|Induction Period (Up to Week 12)|Lack of Efficacy|0
5980693|NCT02471144|9569416|FG009|Induction Period (Up to Week 12)|Lack of Efficacy|0
5980694|NCT02471144|9569417|FG010|Induction Period (Up to Week 12)|Lack of Efficacy|0
5980695|NCT02471144|9569407|FG000|Induction Period (Up to Week 12)|Protocol Deviation|0
5980696|NCT02471144|9569408|FG001|Induction Period (Up to Week 12)|Protocol Deviation|0
5980697|NCT02471144|9569409|FG002|Induction Period (Up to Week 12)|Protocol Deviation|1
5980698|NCT02471144|9569410|FG003|Induction Period (Up to Week 12)|Protocol Deviation|0
5980699|NCT02471144|9569411|FG004|Induction Period (Up to Week 12)|Protocol Deviation|0
5980700|NCT02471144|9569412|FG005|Induction Period (Up to Week 12)|Protocol Deviation|0
5980701|NCT02471144|9569413|FG006|Induction Period (Up to Week 12)|Protocol Deviation|0
6063191|NCT00505414|9664574|FG001|Titration Phase|Death|0
6111618|NCT00829166|9731482|FG000|Overall Study|Lost to Follow-up|5
6111619|NCT00829166|9731483|FG001|Overall Study|Lost to Follow-up|4
6111620|NCT00829166|9731482|FG000|Overall Study|Physician's Decision|4
6111621|NCT00829166|9731483|FG001|Overall Study|Physician's Decision|3
6111622|NCT00829166|9731482|FG000|Overall Study|Subject's Decision|41
6207232|NCT01551420|9871142|FG001|Screened for Part B Eligibility|Deemed ineligible by staff|2
6207233|NCT01551420|9871141|FG000|Home Use (Part B)|Withdrawal by Subject|6
6207234|NCT01551420|9871142|FG001|Home Use (Part B)|Withdrawal by Subject|0
6111623|NCT00829166|9731483|FG001|Overall Study|Subject's Decision|55
6207235|NCT01551420|9871141|FG000|Home Use (Part B)|Withdrawal by staff|0
6207236|NCT01551420|9871142|FG001|Home Use (Part B)|Withdrawal by staff|1
6207237|NCT01551693|9871150|FG000|Overall Study|Disease Progression|1
6207238|NCT01551693|9871151|FG001|Overall Study|Disease Progression|0
6207239|NCT01551693|9871150|FG000|Overall Study|Adverse Event|0
6207240|NCT01551693|9871151|FG001|Overall Study|Adverse Event|1
6207241|NCT01551693|9871150|FG000|Overall Study|Withdrawal by Subject|0
6207242|NCT01551693|9871151|FG001|Overall Study|Withdrawal by Subject|1
6207243|NCT01551745|9871157|FG000|Overall Study|Withdrawal by Subject|1
6207244|NCT01551745|9871157|FG000|Overall Study|Disease Progression|2
6207245|NCT01551758|9871163|FG000|Overall Study|Adverse Event|29
6207246|NCT01551758|9871164|FG001|Overall Study|Adverse Event|43
6207247|NCT01551758|9871163|FG000|Overall Study|Lack of Efficacy|0
6207248|NCT01551758|9871164|FG001|Overall Study|Lack of Efficacy|1
6207249|NCT01551758|9871163|FG000|Overall Study|Protocol Violation|5
6207250|NCT01551758|9871164|FG001|Overall Study|Protocol Violation|6
6207251|NCT01551758|9871163|FG000|Overall Study|Met Protocol-defined stopping criteria|8
6207252|NCT01551758|9871164|FG001|Overall Study|Met Protocol-defined stopping criteria|10
6207253|NCT01551758|9871163|FG000|Overall Study|Lost to Follow-up|29
6207254|NCT01551758|9871164|FG001|Overall Study|Lost to Follow-up|25
6207255|NCT01551758|9871163|FG000|Overall Study|Physician Decision|9
6207256|NCT01551758|9871164|FG001|Overall Study|Physician Decision|3
6207257|NCT01551758|9871163|FG000|Overall Study|Withdrawal by Subject|14
6207258|NCT01551758|9871164|FG001|Overall Study|Withdrawal by Subject|17
6207259|NCT01552057|9871192|FG000|Overall Study|Adverse Event|14
6207260|NCT01552057|9871193|FG001|Overall Study|Adverse Event|15
6207261|NCT01552057|9871192|FG000|Overall Study|Lack of Efficacy|8
6207262|NCT01552057|9871193|FG001|Overall Study|Lack of Efficacy|23
6207263|NCT01552057|9871192|FG000|Overall Study|Withdrawal by Subject|5
6207264|NCT01552057|9871193|FG001|Overall Study|Withdrawal by Subject|8
6207265|NCT01552057|9871192|FG000|Overall Study|Entry Criteria Not Met|2
6207266|NCT01552057|9871193|FG001|Overall Study|Entry Criteria Not Met|2
6207267|NCT01552057|9871192|FG000|Overall Study|Physician Decision|1
6207268|NCT01552057|9871193|FG001|Overall Study|Physician Decision|0
6207269|NCT01552369|9871228|FG000|Overall Study|Did not consent to extended follow up|8
6207270|NCT01552369|9871229|FG001|Overall Study|Did not consent to extended follow up|9
6207271|NCT01552408|9871239|FG000|Overall Study|Lost to Follow-up|2
6207272|NCT01552408|9871240|FG001|Overall Study|Lost to Follow-up|0
6207273|NCT01552408|9871239|FG000|Overall Study|Relocation|0
6207274|NCT01552408|9871240|FG001|Overall Study|Relocation|1
6207275|NCT01552408|9871239|FG000|Overall Study|Withdrawal by Subject|2
6207276|NCT01552408|9871240|FG001|Overall Study|Withdrawal by Subject|1
6207277|NCT01552603|9871247|FG000|Overall Study|Physician Decision|1
6207278|NCT01552681|9871253|FG000|Overall Study|Withdrawal by Subject|4
6207279|NCT01552681|9871254|FG001|Overall Study|Withdrawal by Subject|0
6207280|NCT01552681|9871253|FG000|Overall Study|Physician Decision|1
6207281|NCT01552681|9871254|FG001|Overall Study|Physician Decision|0
6207282|NCT01552681|9871253|FG000|Overall Study|Subject moved away|0
6207283|NCT01552681|9871254|FG001|Overall Study|Subject moved away|1
6207284|NCT01552694|9871262|FG000|Overall Study|Lost to Follow-up|0
6207285|NCT01552694|9871263|FG001|Overall Study|Lost to Follow-up|1
6207286|NCT01552694|9871262|FG000|Overall Study|Protocol Violation|0
6207287|NCT01552694|9871263|FG001|Overall Study|Protocol Violation|1
6207288|NCT01552772|9871269|FG000|Overall Study|Lost to Follow-up|2
6207289|NCT01552772|9871269|FG000|Overall Study|Adverse Event|1
6207290|NCT01552772|9871269|FG000|Overall Study|Protocol Deviation|1
6207291|NCT01552902|9871301|FG000|Overall Study|Adverse Event|1
6207292|NCT01552902|9871302|FG001|Overall Study|Adverse Event|15
6207293|NCT01552902|9871303|FG002|Overall Study|Adverse Event|14
6207294|NCT01552902|9871301|FG000|Overall Study|Protocol Violation|3
6207295|NCT01552902|9871302|FG001|Overall Study|Protocol Violation|3
6207296|NCT01552902|9871303|FG002|Overall Study|Protocol Violation|3
6207297|NCT01552902|9871301|FG000|Overall Study|Lack of Efficacy|4
6207298|NCT01552902|9871302|FG001|Overall Study|Lack of Efficacy|3
6207299|NCT01552902|9871303|FG002|Overall Study|Lack of Efficacy|1
6207300|NCT01552902|9871301|FG000|Overall Study|Withdrawal by Subject|1
6207301|NCT01552902|9871302|FG001|Overall Study|Withdrawal by Subject|9
6207302|NCT01552902|9871303|FG002|Overall Study|Withdrawal by Subject|6
6207303|NCT01552902|9871301|FG000|Overall Study|Lost to Follow-up|1
6207304|NCT01552902|9871302|FG001|Overall Study|Lost to Follow-up|3
6207305|NCT01552902|9871303|FG002|Overall Study|Lost to Follow-up|6
6207306|NCT01552902|9871301|FG000|Overall Study|Other|3
6207307|NCT01552902|9871302|FG001|Overall Study|Other|4
6207308|NCT01552902|9871303|FG002|Overall Study|Other|3
6207309|NCT01552915|9871314|FG000|Overall Study|Adverse Event|3
6207310|NCT01552915|9871315|FG001|Overall Study|Adverse Event|14
6207311|NCT01552915|9871316|FG002|Overall Study|Adverse Event|3
6207312|NCT01552915|9871314|FG000|Overall Study|Lost to Follow-up|4
6207313|NCT01552915|9871315|FG001|Overall Study|Lost to Follow-up|6
6207314|NCT01552915|9871316|FG002|Overall Study|Lost to Follow-up|5
6207315|NCT01552915|9871314|FG000|Overall Study|Withdrawal by Subject|6
6207316|NCT01552915|9871315|FG001|Overall Study|Withdrawal by Subject|4
6207317|NCT01552915|9871316|FG002|Overall Study|Withdrawal by Subject|5
6207318|NCT01552915|9871314|FG000|Overall Study|Protocol Violation|0
6207319|NCT01552915|9871315|FG001|Overall Study|Protocol Violation|4
6111624|NCT00829166|9731482|FG000|Overall Study|Sponsor's Decision|137
6111625|NCT00829166|9731483|FG001|Overall Study|Sponsor's Decision|98
6111626|NCT00829166|9731482|FG000|Overall Study|Reason Not Specified|3
6111627|NCT00829166|9731483|FG001|Overall Study|Reason Not Specified|3
6111628|NCT00829179|9731490|FG000|Overall Study|Withdrawal by Subject|1
6111629|NCT00829244|9731496|FG000|Overall Study|Adverse Event|1
6111630|NCT00829244|9731497|FG001|Overall Study|Adverse Event|3
6111631|NCT00829244|9731496|FG000|Overall Study|Protocol Violation|1
6111632|NCT00829244|9731497|FG001|Overall Study|Protocol Violation|0
6111633|NCT00829244|9731496|FG000|Overall Study|Lack of ovarian response to stimulation|9
6111634|NCT00829244|9731497|FG001|Overall Study|Lack of ovarian response to stimulation|5
6111635|NCT00829244|9731496|FG000|Overall Study|Ovarian hyperstimulation syndrome (OHSS)|1
6111636|NCT00829244|9731497|FG001|Overall Study|Ovarian hyperstimulation syndrome (OHSS)|6
6111637|NCT00829244|9731496|FG000|Overall Study|No fertilization|2
6111638|NCT00829244|9731497|FG001|Overall Study|No fertilization|2
6111639|NCT00829244|9731496|FG000|Overall Study|All embryos discarded|0
6111640|NCT00829244|9731497|FG001|Overall Study|All embryos discarded|3
6111641|NCT00829244|9731496|FG000|Overall Study|No embryo cleavage|0
6111642|NCT00829244|9731497|FG001|Overall Study|No embryo cleavage|2
6111643|NCT00829283|9731505|FG000|Overall Study|Lost to Follow-up|7
6111644|NCT00829283|9731506|FG001|Overall Study|Lost to Follow-up|25
6111645|NCT00829296|9731514|FG000|Overall Study|Adverse Event|5
6111646|NCT00829296|9731515|FG001|Overall Study|Adverse Event|4
6111647|NCT00829387|9731523|FG000|Overall Study|Withdrawal by Subject|2
6111648|NCT00829387|9731524|FG001|Overall Study|Withdrawal by Subject|3
6111649|NCT00829387|9731523|FG000|Overall Study|Disqualified by PI|1
6111650|NCT00829387|9731524|FG001|Overall Study|Disqualified by PI|0
6111651|NCT00829413|9731530|FG000|Overall Study|No study drug admimnistered|13
6111652|NCT00829413|9731530|FG000|Overall Study|Training Patients|67
6111653|NCT00829413|9731530|FG000|Overall Study|No truth standard procedure available|9
6111654|NCT00829413|9731530|FG000|Overall Study|Technically inadequate truth standard|2
6111655|NCT00829413|9731530|FG000|Overall Study|Indeterminate diagnosis from truth stand|3
6111656|NCT00829439|9731541|FG000|Overall Study|Adverse Event|0
6111657|NCT00829439|9731542|FG001|Overall Study|Adverse Event|0
6111658|NCT00829439|9731543|FG002|Overall Study|Adverse Event|1
6111659|NCT00829439|9731544|FG003|Overall Study|Adverse Event|0
6111660|NCT00829621|9731550|FG000|Overall Study|Death|1
6111661|NCT00829621|9731551|FG001|Overall Study|Death|0
6111662|NCT00829621|9731550|FG000|Overall Study|Lost to Follow-up|3
6111663|NCT00829621|9731551|FG001|Overall Study|Lost to Follow-up|4
6111664|NCT00829829|9731565|FG000|Overall Study|Protocol Violation|0
6111665|NCT00829829|9731566|FG001|Overall Study|Protocol Violation|3
6111666|NCT00829829|9731567|FG002|Overall Study|Protocol Violation|0
6111667|NCT00829829|9731565|FG000|Overall Study|Adverse Event|4
6111668|NCT00829829|9731566|FG001|Overall Study|Adverse Event|4
6111669|NCT00829829|9731567|FG002|Overall Study|Adverse Event|3
6111670|NCT00829829|9731565|FG000|Overall Study|Withdrawal by Subject|8
6111671|NCT00829829|9731566|FG001|Overall Study|Withdrawal by Subject|4
6111672|NCT00829829|9731567|FG002|Overall Study|Withdrawal by Subject|2
6111673|NCT00829829|9731565|FG000|Overall Study|Decision by the Sponsor|1
6111674|NCT00829829|9731566|FG001|Overall Study|Decision by the Sponsor|0
6111675|NCT00829829|9731567|FG002|Overall Study|Decision by the Sponsor|2
6111676|NCT00829829|9731565|FG000|Overall Study|Lost to Follow-up|7
6111677|NCT00829829|9731566|FG001|Overall Study|Lost to Follow-up|3
6111678|NCT00829829|9731567|FG002|Overall Study|Lost to Follow-up|3
6111679|NCT00829829|9731565|FG000|Overall Study|Other than specified above|2
6111680|NCT00829829|9731566|FG001|Overall Study|Other than specified above|2
6111681|NCT00829829|9731567|FG002|Overall Study|Other than specified above|1
6111682|NCT00829933|9731580|FG000|Overall Study|Adverse Event|2
6111683|NCT00829933|9731581|FG001|Overall Study|Adverse Event|3
6111684|NCT00829933|9731582|FG002|Overall Study|Adverse Event|2
6111685|NCT00829933|9731583|FG003|Overall Study|Adverse Event|1
6111686|NCT00829933|9731580|FG000|Overall Study|Death|0
6111687|NCT00829933|9731581|FG001|Overall Study|Death|0
6111688|NCT00829933|9731582|FG002|Overall Study|Death|1
6111689|NCT00829933|9731583|FG003|Overall Study|Death|1
6111690|NCT00829933|9731580|FG000|Overall Study|Lack of Efficacy|0
6111691|NCT00829933|9731581|FG001|Overall Study|Lack of Efficacy|1
6111692|NCT00829933|9731582|FG002|Overall Study|Lack of Efficacy|0
6111693|NCT00829933|9731583|FG003|Overall Study|Lack of Efficacy|0
6111694|NCT00829933|9731580|FG000|Overall Study|Physician Decision|5
6111695|NCT00829933|9731581|FG001|Overall Study|Physician Decision|7
6111696|NCT00829933|9731582|FG002|Overall Study|Physician Decision|8
6111697|NCT00829933|9731583|FG003|Overall Study|Physician Decision|1
6111698|NCT00829933|9731580|FG000|Overall Study|Pregnancy|0
6111699|NCT00829933|9731581|FG001|Overall Study|Pregnancy|0
6111700|NCT00829933|9731582|FG002|Overall Study|Pregnancy|0
6111701|NCT00829933|9731583|FG003|Overall Study|Pregnancy|2
6111702|NCT00829933|9731580|FG000|Overall Study|Protocol Violation|2
6111703|NCT00829933|9731581|FG001|Overall Study|Protocol Violation|1
6111704|NCT00829933|9731582|FG002|Overall Study|Protocol Violation|0
6111705|NCT00829933|9731583|FG003|Overall Study|Protocol Violation|0
6111706|NCT00829933|9731580|FG000|Overall Study|withdrew before treatment started|5
6111707|NCT00829933|9731581|FG001|Overall Study|withdrew before treatment started|1
6111708|NCT00829933|9731582|FG002|Overall Study|withdrew before treatment started|2
6111709|NCT00829933|9731583|FG003|Overall Study|withdrew before treatment started|9
6111710|NCT00830037|9731604|FG000|Overall Study|Withdrawal by Subject|2
6111711|NCT00830037|9731605|FG001|Overall Study|Withdrawal by Subject|3
6111712|NCT00830037|9731604|FG000|Overall Study|Lost to Follow-up|1
6111713|NCT00830037|9731605|FG001|Overall Study|Lost to Follow-up|2
6111714|NCT00830037|9731604|FG000|Overall Study|Active when terminated by DSMB|15
6111715|NCT00830037|9731605|FG001|Overall Study|Active when terminated by DSMB|14
6111716|NCT00830063|9731615|FG000|Overall Study|Adverse Event|7
6111717|NCT00830063|9731616|FG001|Overall Study|Adverse Event|13
6111718|NCT00830063|9731617|FG002|Overall Study|Adverse Event|16
6111719|NCT00830063|9731618|FG003|Overall Study|Adverse Event|13
6111720|NCT00830063|9731615|FG000|Overall Study|Death|1
6111721|NCT00830063|9731616|FG001|Overall Study|Death|0
6111722|NCT00830063|9731617|FG002|Overall Study|Death|0
6111723|NCT00830063|9731618|FG003|Overall Study|Death|0
6111724|NCT00830063|9731615|FG000|Overall Study|Lost to Follow-up|0
6111725|NCT00830063|9731616|FG001|Overall Study|Lost to Follow-up|0
6111726|NCT00830063|9731617|FG002|Overall Study|Lost to Follow-up|3
6111727|NCT00830063|9731618|FG003|Overall Study|Lost to Follow-up|1
6111728|NCT00830063|9731615|FG000|Overall Study|Preferred Time Entry in Extension Study|119
6111729|NCT00830063|9731616|FG001|Overall Study|Preferred Time Entry in Extension Study|139
6111730|NCT00830063|9731617|FG002|Overall Study|Preferred Time Entry in Extension Study|127
6207320|NCT01552915|9871316|FG002|Overall Study|Protocol Violation|4
6207321|NCT01552915|9871314|FG000|Overall Study|Lack of Efficacy|8
6207322|NCT01552915|9871315|FG001|Overall Study|Lack of Efficacy|1
6207323|NCT01552915|9871316|FG002|Overall Study|Lack of Efficacy|4
6207324|NCT01552915|9871314|FG000|Overall Study|Other|2
6207325|NCT01552915|9871315|FG001|Overall Study|Other|0
6207326|NCT01552915|9871316|FG002|Overall Study|Other|6
6207327|NCT01552928|9871328|FG000|Period 3|Adverse Event|0
6207328|NCT01552928|9871329|FG001|Period 3|Adverse Event|0
6207329|NCT01552928|9871330|FG002|Period 3|Adverse Event|1
6207330|NCT01552928|9871331|FG003|Period 3|Adverse Event|0
6207331|NCT01552954|9871350|FG000|Overall Study|Adverse Event|1
6207332|NCT01552954|9871351|FG001|Overall Study|Adverse Event|2
6207333|NCT01552954|9871350|FG000|Overall Study|Lost to Follow-up|1
6207334|NCT01552954|9871351|FG001|Overall Study|Lost to Follow-up|1
6207335|NCT01552954|9871350|FG000|Overall Study|Withdrawal by Subject|1
6207336|NCT01552954|9871351|FG001|Overall Study|Withdrawal by Subject|1
6207337|NCT01552954|9871350|FG000|Overall Study|Protocol Violation|1
6207338|NCT01552954|9871351|FG001|Overall Study|Protocol Violation|2
6207339|NCT01552954|9871350|FG000|Overall Study|diagnosed DM|1
6207340|NCT01552954|9871351|FG001|Overall Study|diagnosed DM|0
6207341|NCT01553084|9871377|FG000|Overall Study|Withdrawal by Subject|15
6207342|NCT01553084|9871378|FG001|Overall Study|Withdrawal by Subject|13
6207343|NCT01553084|9871379|FG002|Overall Study|Withdrawal by Subject|35
6207344|NCT01553136|9871391|FG000|Overall Study|Adverse Event|3
6207345|NCT01553136|9871392|FG001|Overall Study|Adverse Event|2
6207346|NCT01553136|9871391|FG000|Overall Study|Withdrawal by Subject|2
6207347|NCT01553136|9871392|FG001|Overall Study|Withdrawal by Subject|3
6207348|NCT01553136|9871391|FG000|Overall Study|Lost to Follow-up|4
6207349|NCT01553136|9871392|FG001|Overall Study|Lost to Follow-up|10
6207350|NCT01553136|9871391|FG000|Overall Study|Physician Decision|2
6207351|NCT01553136|9871392|FG001|Overall Study|Physician Decision|3
6207352|NCT01553136|9871391|FG000|Overall Study|Scheduling Difficulties|5
6207353|NCT01553136|9871392|FG001|Overall Study|Scheduling Difficulties|4
6207354|NCT01553188|9871402|FG000|Overall Study|Patient choice|1
6207355|NCT01553188|9871403|FG001|Overall Study|Patient choice|0
6207356|NCT01553188|9871404|FG002|Overall Study|Patient choice|0
6207357|NCT01553188|9871405|FG003|Overall Study|Patient choice|0
6207358|NCT01553188|9871402|FG000|Overall Study|Intercurrent illness and adverse event|0
6207359|NCT01553188|9871403|FG001|Overall Study|Intercurrent illness and adverse event|1
6207360|NCT01553188|9871404|FG002|Overall Study|Intercurrent illness and adverse event|2
6207361|NCT01553188|9871405|FG003|Overall Study|Intercurrent illness and adverse event|0
6207362|NCT01553279|9871429|FG000|Part 1 (Infant Vaccinations)|Lost to Follow-up|1
6207363|NCT01553279|9871430|FG001|Part 1 (Infant Vaccinations)|Lost to Follow-up|0
6207364|NCT01553279|9871429|FG000|Part 1 (Infant Vaccinations)|Withdrawal by Subject|1
6207365|NCT01553279|9871430|FG001|Part 1 (Infant Vaccinations)|Withdrawal by Subject|1
6207366|NCT01553279|9871429|FG000|Interim Period|Withdrawal by Subject|2
6207367|NCT01553279|9871430|FG001|Interim Period|Withdrawal by Subject|2
6207368|NCT01553279|9871429|FG000|Interim Period|Lost to Follow-up|1
6207369|NCT01553279|9871430|FG001|Interim Period|Lost to Follow-up|0
6207370|NCT01553279|9871429|FG000|Period 2: Toddler Vaccinations|Withdrawal by Subject|0
6111731|NCT00830063|9731618|FG003|Overall Study|Preferred Time Entry in Extension Study|126
6111732|NCT00830063|9731615|FG000|Overall Study|Lack of Efficacy|51
6111733|NCT00830063|9731616|FG001|Overall Study|Lack of Efficacy|23
6111734|NCT00830063|9731617|FG002|Overall Study|Lack of Efficacy|25
6111735|NCT00830063|9731618|FG003|Overall Study|Lack of Efficacy|32
6111736|NCT00830063|9731615|FG000|Overall Study|Other|5
6111737|NCT00830063|9731616|FG001|Overall Study|Other|5
6111738|NCT00830063|9731617|FG002|Overall Study|Other|8
6207371|NCT01553279|9871430|FG001|Period 2: Toddler Vaccinations|Withdrawal by Subject|5
6207372|NCT01553279|9871429|FG000|Period 2: Toddler Vaccinations|Lost to Follow-up|3
6207373|NCT01553279|9871430|FG001|Period 2: Toddler Vaccinations|Lost to Follow-up|2
6111739|NCT00830063|9731618|FG003|Overall Study|Other|6
6111740|NCT00830063|9731615|FG000|Overall Study|Withdrawal by Subject|16
6111741|NCT00830063|9731616|FG001|Overall Study|Withdrawal by Subject|10
6111742|NCT00830063|9731617|FG002|Overall Study|Withdrawal by Subject|16
6111743|NCT00830063|9731618|FG003|Overall Study|Withdrawal by Subject|13
6111744|NCT00830063|9731615|FG000|Overall Study|Protocol Violation|1
6111745|NCT00830063|9731616|FG001|Overall Study|Protocol Violation|0
6111746|NCT00830063|9731617|FG002|Overall Study|Protocol Violation|3
6111747|NCT00830063|9731618|FG003|Overall Study|Protocol Violation|2
6111748|NCT00830063|9731615|FG000|Overall Study|Randomized But Not Treated|0
6111749|NCT00830063|9731616|FG001|Overall Study|Randomized But Not Treated|2
6111750|NCT00830063|9731617|FG002|Overall Study|Randomized But Not Treated|0
6111751|NCT00830063|9731618|FG003|Overall Study|Randomized But Not Treated|2
6111752|NCT00830115|9731637|FG000|Overall Study|Adverse Event|2
6111753|NCT00830115|9731637|FG000|Overall Study|Improvement/recovery|1
6111754|NCT00830128|9731643|FG000|Overall Study|Adverse Event|5
6111755|NCT00830128|9731643|FG000|Overall Study|Lack of Efficacy|7
6111756|NCT00830128|9731643|FG000|Overall Study|Protocol Violation|1
6111757|NCT00830128|9731643|FG000|Overall Study|Withdrawal by Subject|2
6111758|NCT00830128|9731643|FG000|Overall Study|Family obligation|1
6111759|NCT00830128|9731643|FG000|Overall Study|Relocation|1
6111760|NCT00830128|9731643|FG000|Overall Study|Work obligation|1
6111761|NCT00830128|9731643|FG000|Overall Study|Operating a vehicle|1
6111762|NCT00830167|9731649|FG000|Overall Study|Lack of Efficacy|26
6111763|NCT00830167|9731650|FG001|Overall Study|Lack of Efficacy|10
6111764|NCT00830167|9731649|FG000|Overall Study|Adverse Event|8
6111765|NCT00830167|9731650|FG001|Overall Study|Adverse Event|24
6111766|NCT00830167|9731649|FG000|Overall Study|Not meeting entrance criteria|2
6111767|NCT00830167|9731650|FG001|Overall Study|Not meeting entrance criteria|5
6111768|NCT00830167|9731649|FG000|Overall Study|Withdrawal by Subject|2
6111769|NCT00830167|9731650|FG001|Overall Study|Withdrawal by Subject|0
6111770|NCT00830167|9731649|FG000|Overall Study|Lost to Follow-up|0
6111771|NCT00830167|9731650|FG001|Overall Study|Lost to Follow-up|1
6111772|NCT00830167|9731649|FG000|Overall Study|Protocol Violation|0
6111773|NCT00830167|9731650|FG001|Overall Study|Protocol Violation|1
6111774|NCT00830167|9731649|FG000|Overall Study|Other|2
6111775|NCT00830167|9731650|FG001|Overall Study|Other|2
6111776|NCT00830180|9731656|FG000|Overall Study|Adverse Event|6
6111777|NCT00830180|9731656|FG000|Overall Study|Death|11
6111778|NCT00830180|9731656|FG000|Overall Study|Insufficient clinical response|1
6111779|NCT00830180|9731656|FG000|Overall Study|Withdrawal by Subject|5
6111780|NCT00830180|9731656|FG000|Overall Study|Progressive disease|2
6111781|NCT00830180|9731656|FG000|Overall Study|Other - Unspecified|1
6111782|NCT00830375|9731688|FG000|Overall Study|Lost to Follow-up|1
6111783|NCT00830440|9731698|FG000|Overall Study|Protocol Violation|1
6111784|NCT00830440|9731699|FG001|Overall Study|Protocol Violation|0
6111785|NCT00830440|9731698|FG000|Overall Study|Withdrawal by Subject|1
6111786|NCT00830440|9731699|FG001|Overall Study|Withdrawal by Subject|0
6111787|NCT00830440|9731698|FG000|Overall Study|unsuccessful procedure|4
6111788|NCT00830440|9731699|FG001|Overall Study|unsuccessful procedure|0
6111789|NCT00830440|9731698|FG000|Overall Study|Adverse Event|2
6111790|NCT00830440|9731699|FG001|Overall Study|Adverse Event|0
6111791|NCT00830518|9731708|FG000|Overall Study|Progressive Disease|18
6111792|NCT00830518|9731709|FG001|Overall Study|Progressive Disease|8
6111793|NCT00830518|9731708|FG000|Overall Study|Symptomatic Deterioration|4
6111794|NCT00830518|9731709|FG001|Overall Study|Symptomatic Deterioration|1
6111795|NCT00830518|9731708|FG000|Overall Study|Adverse Event|14
6111796|NCT00830518|9731709|FG001|Overall Study|Adverse Event|1
6111797|NCT00830518|9731708|FG000|Overall Study|Withdrawal by Patient|2
6111798|NCT00830518|9731709|FG001|Overall Study|Withdrawal by Patient|0
6111799|NCT00830518|9731708|FG000|Overall Study|Reason not Specified|8
6111800|NCT00830518|9731709|FG001|Overall Study|Reason not Specified|1
6111801|NCT00830765|9731731|FG000|Overall Study|Protocol Violation|3
6111802|NCT00830765|9731732|FG001|Overall Study|Protocol Violation|2
6111803|NCT00830804|9731762|FG000|Overall Study|Lost to Follow-up|4
6111804|NCT00830804|9731762|FG000|Overall Study|Death|1
6111805|NCT00830804|9731762|FG000|Overall Study|Unable to get to clinic|7
6111806|NCT00830804|9731762|FG000|Overall Study|Consent withdrawn|2
6111807|NCT00830804|9731762|FG000|Overall Study|Unwilling to adhere to study requirement|1
6111808|NCT00830869|9731779|FG000|Period 1: Part 1|Symptomatic deterioration|0
6111809|NCT00830869|9731780|FG001|Period 1: Part 1|Symptomatic deterioration|0
6111810|NCT00830869|9731781|FG002|Period 1: Part 1|Symptomatic deterioration|0
6111811|NCT00830869|9731782|FG003|Period 1: Part 1|Symptomatic deterioration|1
6111812|NCT00830869|9731783|FG004|Period 1: Part 1|Symptomatic deterioration|0
6111813|NCT00830869|9731784|FG005|Period 1: Part 1|Symptomatic deterioration|1
6111814|NCT00830869|9731785|FG006|Period 1: Part 1|Symptomatic deterioration|1
6111815|NCT00830869|9731786|FG007|Period 1: Part 1|Symptomatic deterioration|0
6111816|NCT00830869|9731787|FG008|Period 1: Part 1|Symptomatic deterioration|0
6111817|NCT00830869|9731788|FG009|Period 1: Part 1|Symptomatic deterioration|0
6111818|NCT00830869|9731789|FG010|Period 1: Part 1|Symptomatic deterioration|0
6111819|NCT00830869|9731790|FG011|Period 1: Part 1|Symptomatic deterioration|0
6111820|NCT00830869|9731779|FG000|Period 1: Part 1|Withdrawal by Subject|0
6111821|NCT00830869|9731780|FG001|Period 1: Part 1|Withdrawal by Subject|1
6111822|NCT00830869|9731781|FG002|Period 1: Part 1|Withdrawal by Subject|0
6111823|NCT00830869|9731782|FG003|Period 1: Part 1|Withdrawal by Subject|0
6207374|NCT01553318|9871445|FG000|Overall Study|Protocol Violation|3
6207375|NCT01553318|9871446|FG001|Overall Study|Protocol Violation|2
6207376|NCT01553591|9871461|FG000|Overall Study|Voluntarily withdrew|94
6207377|NCT01553591|9871462|FG001|Overall Study|Voluntarily withdrew|79
6207378|NCT01553591|9871463|FG002|Overall Study|Voluntarily withdrew|96
6207379|NCT01553591|9871461|FG000|Overall Study|Adverse Event|36
6207380|NCT01553591|9871462|FG001|Overall Study|Adverse Event|45
6207381|NCT01553591|9871463|FG002|Overall Study|Adverse Event|16
6207382|NCT01553591|9871461|FG000|Overall Study|Lost to Follow-up|25
6207383|NCT01553591|9871462|FG001|Overall Study|Lost to Follow-up|23
6285840|NCT02342171|9998554|FG000|Overall Study|Death|4
6285841|NCT02342171|9998555|FG001|Overall Study|Death|87
6285842|NCT02342171|9998554|FG000|Overall Study|Received favipiravir|10
6285843|NCT02342171|9998555|FG001|Overall Study|Received favipiravir|0
6285844|NCT02342171|9998554|FG000|Overall Study|Missing cycle treshold value|1
6285845|NCT02342171|9998555|FG001|Overall Study|Missing cycle treshold value|0
6285846|NCT02342171|9998554|FG000|Overall Study|Unknown outcome|0
6285847|NCT02342171|9998555|FG001|Overall Study|Unknown outcome|1
6285848|NCT02342171|9998554|FG000|Overall Study|Missing age data|0
6285849|NCT02342171|9998555|FG001|Overall Study|Missing age data|1
6285850|NCT02342223|9998569|FG000|Overall Study|Lost to Follow-up|1
6285851|NCT02342288|9998575|FG000|Overall Study|no protocol anesthesiologist available|3
6285852|NCT02342288|9998576|FG001|Overall Study|no protocol anesthesiologist available|2
6285853|NCT02342288|9998575|FG000|Overall Study|anesthesia leak in system|1
6285854|NCT02342288|9998576|FG001|Overall Study|anesthesia leak in system|0
6285855|NCT02342288|9998575|FG000|Overall Study|Withdrawal by Subject|1
6285856|NCT02342288|9998576|FG001|Overall Study|Withdrawal by Subject|0
6285857|NCT02342288|9998575|FG000|Overall Study|coordinator contaminated with blood|0
6285858|NCT02342288|9998576|FG001|Overall Study|coordinator contaminated with blood|1
6285859|NCT02342288|9998575|FG000|Overall Study|subject cannot tolerate numbing drops|0
6285860|NCT02342288|9998576|FG001|Overall Study|subject cannot tolerate numbing drops|1
6285861|NCT02342288|9998575|FG000|Overall Study|coordinator not available|0
6285862|NCT02342288|9998576|FG001|Overall Study|coordinator not available|2
6285863|NCT02342418|9998686|FG000|Overall Study|Adverse Event|0
6285864|NCT02342418|9998687|FG001|Overall Study|Adverse Event|1
6285865|NCT02342548|9998700|FG000|Overall Study|Adverse Event|12
6285866|NCT02342548|9998701|FG001|Overall Study|Adverse Event|17
6285867|NCT02342548|9998702|FG002|Overall Study|Adverse Event|13
6285868|NCT02342548|9998700|FG000|Overall Study|Lost to Follow-up|0
6285869|NCT02342548|9998701|FG001|Overall Study|Lost to Follow-up|1
6285870|NCT02342548|9998702|FG002|Overall Study|Lost to Follow-up|0
6285871|NCT02342548|9998700|FG000|Overall Study|Study terminated by sponsor|20
6285872|NCT02342548|9998701|FG001|Overall Study|Study terminated by sponsor|39
6285873|NCT02342548|9998702|FG002|Overall Study|Study terminated by sponsor|25
6285874|NCT02342548|9998700|FG000|Overall Study|Protocol Violation|0
6285875|NCT02342548|9998701|FG001|Overall Study|Protocol Violation|1
6285876|NCT02342548|9998702|FG002|Overall Study|Protocol Violation|0
6285877|NCT02342548|9998700|FG000|Overall Study|Withdrawal by Subject|1
6111824|NCT00830869|9731783|FG004|Period 1: Part 1|Withdrawal by Subject|0
6111825|NCT00830869|9731784|FG005|Period 1: Part 1|Withdrawal by Subject|0
6111826|NCT00830869|9731785|FG006|Period 1: Part 1|Withdrawal by Subject|0
6111827|NCT00830869|9731786|FG007|Period 1: Part 1|Withdrawal by Subject|0
6111828|NCT00830869|9731787|FG008|Period 1: Part 1|Withdrawal by Subject|0
6111829|NCT00830869|9731788|FG009|Period 1: Part 1|Withdrawal by Subject|0
6111830|NCT00830869|9731789|FG010|Period 1: Part 1|Withdrawal by Subject|0
6111831|NCT00830869|9731790|FG011|Period 1: Part 1|Withdrawal by Subject|0
6111832|NCT00830869|9731779|FG000|Period 1: Part 1|Adverse Event|0
6111833|NCT00830869|9731780|FG001|Period 1: Part 1|Adverse Event|0
6111834|NCT00830869|9731781|FG002|Period 1: Part 1|Adverse Event|0
6111835|NCT00830869|9731782|FG003|Period 1: Part 1|Adverse Event|0
6111836|NCT00830869|9731783|FG004|Period 1: Part 1|Adverse Event|0
6111837|NCT00830869|9731784|FG005|Period 1: Part 1|Adverse Event|1
6111838|NCT00830869|9731785|FG006|Period 1: Part 1|Adverse Event|1
6111839|NCT00830869|9731786|FG007|Period 1: Part 1|Adverse Event|0
6111840|NCT00830869|9731787|FG008|Period 1: Part 1|Adverse Event|0
6111841|NCT00830869|9731788|FG009|Period 1: Part 1|Adverse Event|0
6111842|NCT00830869|9731789|FG010|Period 1: Part 1|Adverse Event|0
6111843|NCT00830869|9731790|FG011|Period 1: Part 1|Adverse Event|0
6111844|NCT00830869|9731779|FG000|Period 1: Part 1|Progressive disease|1
6111845|NCT00830869|9731780|FG001|Period 1: Part 1|Progressive disease|0
6111846|NCT00830869|9731781|FG002|Period 1: Part 1|Progressive disease|1
6111847|NCT00830869|9731782|FG003|Period 1: Part 1|Progressive disease|6
6285878|NCT02342548|9998701|FG001|Overall Study|Withdrawal by Subject|3
6111848|NCT00830869|9731783|FG004|Period 1: Part 1|Progressive disease|4
6111849|NCT00830869|9731784|FG005|Period 1: Part 1|Progressive disease|4
6111850|NCT00830869|9731785|FG006|Period 1: Part 1|Progressive disease|1
6111851|NCT00830869|9731786|FG007|Period 1: Part 1|Progressive disease|0
6111852|NCT00830869|9731787|FG008|Period 1: Part 1|Progressive disease|0
6111853|NCT00830869|9731788|FG009|Period 1: Part 1|Progressive disease|0
6111854|NCT00830869|9731789|FG010|Period 1: Part 1|Progressive disease|0
6207384|NCT01553591|9871463|FG002|Overall Study|Lost to Follow-up|16
6111855|NCT00830869|9731790|FG011|Period 1: Part 1|Progressive disease|0
6111856|NCT00830869|9731779|FG000|Period 2: Part 2|Protocol Violation|0
6111857|NCT00830869|9731780|FG001|Period 2: Part 2|Protocol Violation|0
6111858|NCT00830869|9731781|FG002|Period 2: Part 2|Protocol Violation|0
6111859|NCT00830869|9731782|FG003|Period 2: Part 2|Protocol Violation|0
6111860|NCT00830869|9731783|FG004|Period 2: Part 2|Protocol Violation|0
6111861|NCT00830869|9731784|FG005|Period 2: Part 2|Protocol Violation|0
6111862|NCT00830869|9731785|FG006|Period 2: Part 2|Protocol Violation|0
6111863|NCT00830869|9731786|FG007|Period 2: Part 2|Protocol Violation|1
6111864|NCT00830869|9731787|FG008|Period 2: Part 2|Protocol Violation|0
6111865|NCT00830869|9731788|FG009|Period 2: Part 2|Protocol Violation|1
6111866|NCT00830869|9731789|FG010|Period 2: Part 2|Protocol Violation|0
6111867|NCT00830869|9731790|FG011|Period 2: Part 2|Protocol Violation|0
6111868|NCT00830869|9731779|FG000|Period 2: Part 2|Withdrawal by Subject|0
6111869|NCT00830869|9731780|FG001|Period 2: Part 2|Withdrawal by Subject|0
6111870|NCT00830869|9731781|FG002|Period 2: Part 2|Withdrawal by Subject|0
6111871|NCT00830869|9731782|FG003|Period 2: Part 2|Withdrawal by Subject|0
6111872|NCT00830869|9731783|FG004|Period 2: Part 2|Withdrawal by Subject|0
6111873|NCT00830869|9731784|FG005|Period 2: Part 2|Withdrawal by Subject|0
6111874|NCT00830869|9731785|FG006|Period 2: Part 2|Withdrawal by Subject|0
6111875|NCT00830869|9731786|FG007|Period 2: Part 2|Withdrawal by Subject|1
6111876|NCT00830869|9731787|FG008|Period 2: Part 2|Withdrawal by Subject|2
6111877|NCT00830869|9731788|FG009|Period 2: Part 2|Withdrawal by Subject|1
6111878|NCT00830869|9731789|FG010|Period 2: Part 2|Withdrawal by Subject|0
6111879|NCT00830869|9731790|FG011|Period 2: Part 2|Withdrawal by Subject|1
6111880|NCT00830869|9731779|FG000|Period 2: Part 2|Adverse Event|0
6111881|NCT00830869|9731780|FG001|Period 2: Part 2|Adverse Event|0
6207385|NCT01553591|9871461|FG000|Overall Study|Physician decision: other|11
6207386|NCT01553591|9871462|FG001|Overall Study|Physician decision: other|14
6207387|NCT01553591|9871463|FG002|Overall Study|Physician decision: other|16
6207388|NCT01553591|9871461|FG000|Overall Study|Physician decision: lack of efficacy|2
6207389|NCT01553591|9871462|FG001|Overall Study|Physician decision: lack of efficacy|3
6207390|NCT01553591|9871463|FG002|Overall Study|Physician decision: lack of efficacy|7
6207391|NCT01553591|9871461|FG000|Overall Study|Protocol Violation|3
6207392|NCT01553591|9871462|FG001|Overall Study|Protocol Violation|4
6207393|NCT01553591|9871463|FG002|Overall Study|Protocol Violation|4
6207394|NCT01553591|9871461|FG000|Overall Study|Sponsor decision|1
6207395|NCT01553591|9871462|FG001|Overall Study|Sponsor decision|0
6207396|NCT01553591|9871463|FG002|Overall Study|Sponsor decision|3
6207397|NCT01553591|9871461|FG000|Overall Study|Randomized and never dispensed drug|0
6207398|NCT01553591|9871462|FG001|Overall Study|Randomized and never dispensed drug|1
6207399|NCT01553591|9871463|FG002|Overall Study|Randomized and never dispensed drug|0
6207400|NCT01553747|9871483|FG000|Overall Study|Protocol Violation|0
6207401|NCT01553747|9871484|FG001|Overall Study|Protocol Violation|2
6207402|NCT01553747|9871485|FG002|Overall Study|Protocol Violation|0
6207403|NCT01553747|9871483|FG000|Overall Study|Voluntarily withdrew|70
6207404|NCT01553747|9871484|FG001|Overall Study|Voluntarily withdrew|66
6207405|NCT01553747|9871485|FG002|Overall Study|Voluntarily withdrew|74
6207406|NCT01553747|9871483|FG000|Overall Study|Adverse event or SAE|32
6207407|NCT01553747|9871484|FG001|Overall Study|Adverse event or SAE|28
6207408|NCT01553747|9871485|FG002|Overall Study|Adverse event or SAE|19
6207409|NCT01553747|9871483|FG000|Overall Study|Physician decision: other|10
6207410|NCT01553747|9871484|FG001|Overall Study|Physician decision: other|8
6207411|NCT01553747|9871485|FG002|Overall Study|Physician decision: other|7
6207412|NCT01553747|9871483|FG000|Overall Study|Lost to Follow-up|11
6207413|NCT01553747|9871484|FG001|Overall Study|Lost to Follow-up|5
6207414|NCT01553747|9871485|FG002|Overall Study|Lost to Follow-up|6
6207415|NCT01553747|9871483|FG000|Overall Study|Sponsor decision, specify|7
6207416|NCT01553747|9871484|FG001|Overall Study|Sponsor decision, specify|5
6207417|NCT01553747|9871485|FG002|Overall Study|Sponsor decision, specify|0
6207418|NCT01553747|9871483|FG000|Overall Study|Physician decision: lack of efficacy|1
6207419|NCT01553747|9871484|FG001|Overall Study|Physician decision: lack of efficacy|5
6207420|NCT01553747|9871485|FG002|Overall Study|Physician decision: lack of efficacy|3
6207421|NCT01553851|9871496|FG000|Overall Study|Adverse Event|2
6207422|NCT01553851|9871496|FG000|Overall Study|constipation|1
6207423|NCT01553916|9871500|FG000|Overall Study|Withdrawal by Subject|2
6207424|NCT01553916|9871500|FG000|Overall Study|Pre-treatment MRI metastatic disease|1
6207425|NCT01554176|9871506|FG000|Treatment Phase|Protocol Violation|1
6207426|NCT01554176|9871507|FG001|Treatment Phase|Protocol Violation|2
6207427|NCT01554176|9871508|FG002|Treatment Phase|Protocol Violation|0
6207428|NCT01554176|9871509|FG003|Treatment Phase|Protocol Violation|0
6285879|NCT02342548|9998702|FG002|Overall Study|Withdrawal by Subject|4
6207429|NCT01554176|9871510|FG004|Treatment Phase|Protocol Violation|0
6285880|NCT02342548|9998700|FG000|Overall Study|Other|1
6285881|NCT02342548|9998701|FG001|Overall Study|Other|1
6111882|NCT00830869|9731781|FG002|Period 2: Part 2|Adverse Event|0
6207430|NCT01554176|9871506|FG000|Treatment Phase|Physician Decision|1
6207431|NCT01554176|9871507|FG001|Treatment Phase|Physician Decision|1
6207432|NCT01554176|9871508|FG002|Treatment Phase|Physician Decision|0
6207433|NCT01554176|9871509|FG003|Treatment Phase|Physician Decision|0
6207434|NCT01554176|9871510|FG004|Treatment Phase|Physician Decision|0
6111883|NCT00830869|9731782|FG003|Period 2: Part 2|Adverse Event|0
6111884|NCT00830869|9731783|FG004|Period 2: Part 2|Adverse Event|0
6111885|NCT00830869|9731784|FG005|Period 2: Part 2|Adverse Event|0
6111886|NCT00830869|9731785|FG006|Period 2: Part 2|Adverse Event|0
6111887|NCT00830869|9731786|FG007|Period 2: Part 2|Adverse Event|4
6111888|NCT00830869|9731787|FG008|Period 2: Part 2|Adverse Event|3
6111889|NCT00830869|9731788|FG009|Period 2: Part 2|Adverse Event|2
6111890|NCT00830869|9731789|FG010|Period 2: Part 2|Adverse Event|2
6111891|NCT00830869|9731790|FG011|Period 2: Part 2|Adverse Event|0
6111892|NCT00830869|9731779|FG000|Period 2: Part 2|Symptomatic Deterioration|0
6111893|NCT00830869|9731780|FG001|Period 2: Part 2|Symptomatic Deterioration|0
6111894|NCT00830869|9731781|FG002|Period 2: Part 2|Symptomatic Deterioration|0
6111895|NCT00830869|9731782|FG003|Period 2: Part 2|Symptomatic Deterioration|0
6111896|NCT00830869|9731783|FG004|Period 2: Part 2|Symptomatic Deterioration|0
6111897|NCT00830869|9731784|FG005|Period 2: Part 2|Symptomatic Deterioration|0
6111898|NCT00830869|9731785|FG006|Period 2: Part 2|Symptomatic Deterioration|0
6111899|NCT00830869|9731786|FG007|Period 2: Part 2|Symptomatic Deterioration|0
6111900|NCT00830869|9731787|FG008|Period 2: Part 2|Symptomatic Deterioration|6
6111901|NCT00830869|9731788|FG009|Period 2: Part 2|Symptomatic Deterioration|3
6111902|NCT00830869|9731789|FG010|Period 2: Part 2|Symptomatic Deterioration|1
6111903|NCT00830869|9731790|FG011|Period 2: Part 2|Symptomatic Deterioration|4
6111904|NCT00830869|9731779|FG000|Period 2: Part 2|Progressive disease|0
6207435|NCT01554176|9871506|FG000|Treatment Phase|Lack of Efficacy|0
6207436|NCT01554176|9871507|FG001|Treatment Phase|Lack of Efficacy|1
6207437|NCT01554176|9871508|FG002|Treatment Phase|Lack of Efficacy|0
6207438|NCT01554176|9871509|FG003|Treatment Phase|Lack of Efficacy|0
6207439|NCT01554176|9871510|FG004|Treatment Phase|Lack of Efficacy|0
6207440|NCT01554176|9871506|FG000|Treatment Phase|Adverse event, non-fatal|1
6207441|NCT01554176|9871507|FG001|Treatment Phase|Adverse event, non-fatal|1
6207442|NCT01554176|9871508|FG002|Treatment Phase|Adverse event, non-fatal|0
6207443|NCT01554176|9871509|FG003|Treatment Phase|Adverse event, non-fatal|0
6207444|NCT01554176|9871510|FG004|Treatment Phase|Adverse event, non-fatal|0
6207445|NCT01554176|9871506|FG000|Treatment Phase|Non-compliance with study drug|1
6207446|NCT01554176|9871507|FG001|Treatment Phase|Non-compliance with study drug|0
6207447|NCT01554176|9871508|FG002|Treatment Phase|Non-compliance with study drug|0
6207448|NCT01554176|9871509|FG003|Treatment Phase|Non-compliance with study drug|0
6207449|NCT01554176|9871510|FG004|Treatment Phase|Non-compliance with study drug|0
6207450|NCT01554176|9871506|FG000|Treatment Phase|Withdrawal by Subject|1
6207451|NCT01554176|9871507|FG001|Treatment Phase|Withdrawal by Subject|0
6207452|NCT01554176|9871508|FG002|Treatment Phase|Withdrawal by Subject|0
6207453|NCT01554176|9871509|FG003|Treatment Phase|Withdrawal by Subject|0
6207454|NCT01554176|9871510|FG004|Treatment Phase|Withdrawal by Subject|0
6285882|NCT02342548|9998702|FG002|Overall Study|Other|1
6285883|NCT02342639|9998720|FG000|Overall Study|Acute illness, unrelated to study drug|2
6285884|NCT02342639|9998721|FG001|Overall Study|Acute illness, unrelated to study drug|3
6285885|NCT02342639|9998720|FG000|Overall Study|Protocol Violation|0
6285886|NCT02342639|9998721|FG001|Overall Study|Protocol Violation|2
6285887|NCT02342678|9998731|FG000|Overall Study|Lost to Follow-up|0
6285888|NCT02342678|9998732|FG001|Overall Study|Lost to Follow-up|1
6285889|NCT02342678|9998731|FG000|Overall Study|Too busy to complete study|0
6285890|NCT02342678|9998732|FG001|Overall Study|Too busy to complete study|2
6285891|NCT02342678|9998731|FG000|Overall Study|Family illness/emergency|0
6285892|NCT02342678|9998732|FG001|Overall Study|Family illness/emergency|1
6285893|NCT02342678|9998731|FG000|Overall Study|Illness/medical reason|1
6285894|NCT02342678|9998732|FG001|Overall Study|Illness/medical reason|1
6285895|NCT02342704|9998740|FG000|Overall Study|Physician Decision|0
6285896|NCT02342704|9998741|FG001|Overall Study|Physician Decision|3
6285897|NCT02342704|9998740|FG000|Overall Study|Sponsor Termination|49
6285898|NCT02342704|9998741|FG001|Overall Study|Sponsor Termination|43
6285899|NCT02342704|9998740|FG000|Overall Study|Other|0
6285900|NCT02342704|9998741|FG001|Overall Study|Other|1
6285901|NCT02342704|9998740|FG000|Overall Study|Withdrawal by Subject|1
6285902|NCT02342704|9998741|FG001|Overall Study|Withdrawal by Subject|0
6285903|NCT02342704|9998740|FG000|Overall Study|Lost to Follow-up|2
6285904|NCT02342704|9998741|FG001|Overall Study|Lost to Follow-up|1
6285905|NCT02342704|9998740|FG000|Overall Study|Adverse Event|1
6285906|NCT02342704|9998741|FG001|Overall Study|Adverse Event|3
6285907|NCT02342743|9998747|FG000|Baseline Period|Withdrawal by Subject|3
6285908|NCT02342743|9998747|FG000|Baseline Period|Lost to Follow-up|2
6285909|NCT02342743|9998747|FG000|Baseline Period|Change in prophylactic medication|3
6285910|NCT02342743|9998747|FG000|Baseline Period|Screening failure regarding baseline|7
6285911|NCT02342743|9998747|FG000|Treatment Period|Withdrawal by Subject|2
6285912|NCT02342743|9998747|FG000|Treatment Period|Lost to Follow-up|8
6111905|NCT00830869|9731780|FG001|Period 2: Part 2|Progressive disease|0
6111906|NCT00830869|9731781|FG002|Period 2: Part 2|Progressive disease|0
6111907|NCT00830869|9731782|FG003|Period 2: Part 2|Progressive disease|0
6285913|NCT02342743|9998747|FG000|Treatment Period|Change in prophylactic medication|1
6285914|NCT02342886|9998756|FG000|Overall Study|Treatment non-compliance|1
6285915|NCT02342886|9998757|FG001|Overall Study|Treatment non-compliance|0
6285916|NCT02342886|9998758|FG002|Overall Study|Treatment non-compliance|0
6285917|NCT02342886|9998759|FG003|Overall Study|Treatment non-compliance|1
6111908|NCT00830869|9731783|FG004|Period 2: Part 2|Progressive disease|0
6111909|NCT00830869|9731784|FG005|Period 2: Part 2|Progressive disease|0
6111910|NCT00830869|9731785|FG006|Period 2: Part 2|Progressive disease|0
6111911|NCT00830869|9731786|FG007|Period 2: Part 2|Progressive disease|14
6111912|NCT00830869|9731787|FG008|Period 2: Part 2|Progressive disease|11
6111913|NCT00830869|9731788|FG009|Period 2: Part 2|Progressive disease|12
6111914|NCT00830869|9731789|FG010|Period 2: Part 2|Progressive disease|8
6111915|NCT00830869|9731790|FG011|Period 2: Part 2|Progressive disease|15
6111916|NCT00830869|9731779|FG000|Period 2: Part 2|Other|0
6111917|NCT00830869|9731780|FG001|Period 2: Part 2|Other|0
6111918|NCT00830869|9731781|FG002|Period 2: Part 2|Other|0
6111919|NCT00830869|9731782|FG003|Period 2: Part 2|Other|0
6111920|NCT00830869|9731783|FG004|Period 2: Part 2|Other|0
6111921|NCT00830869|9731784|FG005|Period 2: Part 2|Other|0
6111922|NCT00830869|9731785|FG006|Period 2: Part 2|Other|0
6111923|NCT00830869|9731786|FG007|Period 2: Part 2|Other|0
6111924|NCT00830869|9731787|FG008|Period 2: Part 2|Other|0
6111925|NCT00830869|9731788|FG009|Period 2: Part 2|Other|1
6111926|NCT00830869|9731789|FG010|Period 2: Part 2|Other|0
6111927|NCT00830869|9731790|FG011|Period 2: Part 2|Other|0
6111928|NCT00830947|9731819|FG000|Overall Study|Lost to Follow-up|4
6111929|NCT00830947|9731820|FG001|Overall Study|Lost to Follow-up|4
6111930|NCT00830960|9731832|FG000|Overall Study|Death|5
6111931|NCT00830960|9731833|FG001|Overall Study|Death|4
6111932|NCT00830960|9731834|FG002|Overall Study|Death|3
6111933|NCT00830960|9731835|FG003|Overall Study|Death|2
6111934|NCT00830960|9731836|FG004|Overall Study|Death|6
6111935|NCT00830960|9731837|FG005|Overall Study|Death|1
6111936|NCT00830960|9731832|FG000|Overall Study|Lost to Follow-up|1
6111937|NCT00830960|9731833|FG001|Overall Study|Lost to Follow-up|1
6111938|NCT00830960|9731834|FG002|Overall Study|Lost to Follow-up|1
6111939|NCT00830960|9731835|FG003|Overall Study|Lost to Follow-up|0
6111940|NCT00830960|9731836|FG004|Overall Study|Lost to Follow-up|0
6111941|NCT00830960|9731837|FG005|Overall Study|Lost to Follow-up|1
6207455|NCT01554176|9871506|FG000|Treatment Phase|Lost to Follow-up|3
6207456|NCT01554176|9871507|FG001|Treatment Phase|Lost to Follow-up|0
6207457|NCT01554176|9871508|FG002|Treatment Phase|Lost to Follow-up|0
6207458|NCT01554176|9871509|FG003|Treatment Phase|Lost to Follow-up|0
6207459|NCT01554176|9871510|FG004|Treatment Phase|Lost to Follow-up|0
6207460|NCT01554176|9871506|FG000|Run-out Phase|Protocol Violation|0
6207461|NCT01554176|9871507|FG001|Run-out Phase|Protocol Violation|0
6207462|NCT01554176|9871508|FG002|Run-out Phase|Protocol Violation|0
6207463|NCT01554176|9871509|FG003|Run-out Phase|Protocol Violation|1
6207464|NCT01554176|9871510|FG004|Run-out Phase|Protocol Violation|0
6207465|NCT01554241|9871526|FG000|Overall Study|Death|3
6207466|NCT01554241|9871527|FG001|Overall Study|Death|1
6207467|NCT01554241|9871528|FG002|Overall Study|Death|1
6207468|NCT01554241|9871529|FG003|Overall Study|Death|0
6207469|NCT01554241|9871526|FG000|Overall Study|protocol specified renal stone|0
6285918|NCT02342886|9998760|FG004|Overall Study|Treatment non-compliance|0
6285919|NCT02342886|9998756|FG000|Overall Study|Late exclusion: rifampicin resistance|1
6285920|NCT02342886|9998757|FG001|Overall Study|Late exclusion: rifampicin resistance|0
6285921|NCT02342886|9998758|FG002|Overall Study|Late exclusion: rifampicin resistance|0
6285922|NCT02342886|9998759|FG003|Overall Study|Late exclusion: rifampicin resistance|0
6285923|NCT02342886|9998760|FG004|Overall Study|Late exclusion: rifampicin resistance|0
6285924|NCT02342886|9998756|FG000|Overall Study|Adverse event/specific toxicity|4
6285925|NCT02342886|9998757|FG001|Overall Study|Adverse event/specific toxicity|3
6285926|NCT02342886|9998758|FG002|Overall Study|Adverse event/specific toxicity|11
6285927|NCT02342886|9998759|FG003|Overall Study|Adverse event/specific toxicity|2
6285928|NCT02342886|9998760|FG004|Overall Study|Adverse event/specific toxicity|1
6285929|NCT02342886|9998756|FG000|Overall Study|Lost to Follow-up|1
6285930|NCT02342886|9998757|FG001|Overall Study|Lost to Follow-up|0
6285931|NCT02342886|9998758|FG002|Overall Study|Lost to Follow-up|0
6285932|NCT02342886|9998759|FG003|Overall Study|Lost to Follow-up|0
6285933|NCT02342886|9998760|FG004|Overall Study|Lost to Follow-up|0
6285934|NCT02342886|9998756|FG000|Overall Study|Death|1
6285935|NCT02342886|9998757|FG001|Overall Study|Death|2
6285936|NCT02342886|9998758|FG002|Overall Study|Death|1
6285937|NCT02342886|9998759|FG003|Overall Study|Death|0
6285938|NCT02342886|9998760|FG004|Overall Study|Death|1
6285939|NCT02342886|9998756|FG000|Overall Study|Withdrawal by Subject|0
6285940|NCT02342886|9998757|FG001|Overall Study|Withdrawal by Subject|1
6285941|NCT02342886|9998758|FG002|Overall Study|Withdrawal by Subject|0
6285942|NCT02342886|9998759|FG003|Overall Study|Withdrawal by Subject|1
6285943|NCT02342886|9998760|FG004|Overall Study|Withdrawal by Subject|0
6285944|NCT02342886|9998756|FG000|Overall Study|Investigator/sponsor decision|0
6285945|NCT02342886|9998757|FG001|Overall Study|Investigator/sponsor decision|2
6285946|NCT02342886|9998758|FG002|Overall Study|Investigator/sponsor decision|0
6285947|NCT02342886|9998759|FG003|Overall Study|Investigator/sponsor decision|3
6285948|NCT02342886|9998760|FG004|Overall Study|Investigator/sponsor decision|1
6285949|NCT02342886|9998756|FG000|Overall Study|Pregnancy|0
6111942|NCT00830960|9731832|FG000|Overall Study|Withdrawal by Subject|19
6111943|NCT00830960|9731833|FG001|Overall Study|Withdrawal by Subject|19
6111944|NCT00830960|9731834|FG002|Overall Study|Withdrawal by Subject|18
6111945|NCT00830960|9731835|FG003|Overall Study|Withdrawal by Subject|23
6111946|NCT00830960|9731836|FG004|Overall Study|Withdrawal by Subject|16
6111947|NCT00830960|9731837|FG005|Overall Study|Withdrawal by Subject|21
6111948|NCT00830960|9731832|FG000|Overall Study|Sponsor Decision|1
6111949|NCT00830960|9731833|FG001|Overall Study|Sponsor Decision|2
6111950|NCT00830960|9731834|FG002|Overall Study|Sponsor Decision|3
6111951|NCT00830960|9731835|FG003|Overall Study|Sponsor Decision|4
6111952|NCT00830960|9731836|FG004|Overall Study|Sponsor Decision|5
6111953|NCT00830960|9731837|FG005|Overall Study|Sponsor Decision|7
6111954|NCT00830960|9731832|FG000|Overall Study|No study drug received|7
6111955|NCT00830960|9731833|FG001|Overall Study|No study drug received|2
6111956|NCT00830960|9731834|FG002|Overall Study|No study drug received|4
6111957|NCT00830960|9731835|FG003|Overall Study|No study drug received|3
6111958|NCT00830960|9731836|FG004|Overall Study|No study drug received|5
6111959|NCT00830960|9731837|FG005|Overall Study|No study drug received|7
6111960|NCT00831129|9731876|FG000|Overall Study|Adverse Event|0
6111961|NCT00831129|9731877|FG001|Overall Study|Adverse Event|1
6111962|NCT00831129|9731876|FG000|Overall Study|9 lost to follow-up reasons uknown|0
6111963|NCT00831129|9731877|FG001|Overall Study|9 lost to follow-up reasons uknown|9
6111964|NCT00831181|9731883|FG000|Overall Study|Adverse Event|12
6111965|NCT00831233|9731890|FG000|Overall Study|Adverse Event|0
6111966|NCT00831233|9731891|FG001|Overall Study|Adverse Event|1
6111967|NCT00831233|9731890|FG000|Overall Study|Protocol Violation|1
6111968|NCT00831233|9731891|FG001|Overall Study|Protocol Violation|0
6111969|NCT00831233|9731890|FG000|Overall Study|Selection Criteria Not Met|2
6111970|NCT00831233|9731891|FG001|Overall Study|Selection Criteria Not Met|0
6111971|NCT00831311|9731916|FG000|Overall Study|Definitive Contraindication|3
6111972|NCT00831311|9731917|FG001|Overall Study|Definitive Contraindication|3
6111973|NCT00831311|9731916|FG000|Overall Study|Lost to Follow-up|3
6111974|NCT00831311|9731917|FG001|Overall Study|Lost to Follow-up|0
6111975|NCT00831311|9731916|FG000|Overall Study|Physician Decision|0
6111976|NCT00831311|9731917|FG001|Overall Study|Physician Decision|1
6111977|NCT00831311|9731916|FG000|Overall Study|Withdrawal by Subject|6
6111978|NCT00831311|9731917|FG001|Overall Study|Withdrawal by Subject|4
6111979|NCT00831389|9731926|FG000|Overall Study|Withdrawal by Subject|0
6111980|NCT00831389|9731927|FG001|Overall Study|Withdrawal by Subject|1
6111981|NCT00831415|9731933|FG000|Overall Study|Adverse Event|14
6111982|NCT00831415|9731933|FG000|Overall Study|Failed to return|3
6111983|NCT00831415|9731933|FG000|Overall Study|Physician Decision|6
6111984|NCT00831415|9731933|FG000|Overall Study|Lost to Follow-up|9
6111985|NCT00831415|9731933|FG000|Overall Study|Protocol Violation|3
6111986|NCT00831415|9731933|FG000|Overall Study|Withdrawal by Subject|35
6111987|NCT00831415|9731933|FG000|Overall Study|Unsatisfactory response - Efficacy|4
6111988|NCT00831415|9731933|FG000|Overall Study|Death|1
6111989|NCT00831441|9731943|FG000|Randomized|Death|82
6111990|NCT00831441|9731944|FG001|Randomized|Death|81
6111991|NCT00831441|9731943|FG000|Randomized|Adverse Event|248
6111992|NCT00831441|9731944|FG001|Randomized|Adverse Event|321
6111993|NCT00831441|9731943|FG000|Randomized|Emergency procedure|2
6111994|NCT00831441|9731944|FG001|Randomized|Emergency procedure|2
6111995|NCT00831441|9731943|FG000|Randomized|Elective procedure|26
6111996|NCT00831441|9731944|FG001|Randomized|Elective procedure|25
6111997|NCT00831441|9731943|FG000|Randomized|Physician Decision|26
6207470|NCT01554241|9871527|FG001|Overall Study|protocol specified renal stone|0
6207471|NCT01554241|9871528|FG002|Overall Study|protocol specified renal stone|0
6207472|NCT01554241|9871529|FG003|Overall Study|protocol specified renal stone|1
6207473|NCT01554241|9871526|FG000|Overall Study|protocol specified change in eGFR|0
6207474|NCT01554241|9871527|FG001|Overall Study|protocol specified change in eGFR|0
6207475|NCT01554241|9871528|FG002|Overall Study|protocol specified change in eGFR|1
6207476|NCT01554241|9871529|FG003|Overall Study|protocol specified change in eGFR|0
6207477|NCT01554241|9871526|FG000|Overall Study|Withdrawal by Subject|0
6207478|NCT01554241|9871527|FG001|Overall Study|Withdrawal by Subject|0
6207479|NCT01554241|9871528|FG002|Overall Study|Withdrawal by Subject|2
6207480|NCT01554241|9871529|FG003|Overall Study|Withdrawal by Subject|0
6207481|NCT01554514|9871564|FG000|Overall Study|1 patient ineligible with congenital TTP|1
6207482|NCT01554514|9871564|FG000|Overall Study|Physician Decision|1
6207483|NCT01554527|9871571|FG000|Overall Study|Withdrawal by Subject|1
6207484|NCT01554527|9871572|FG001|Overall Study|Withdrawal by Subject|0
6207485|NCT01554527|9871573|FG002|Overall Study|Withdrawal by Subject|3
6207486|NCT01554527|9871571|FG000|Overall Study|Lost to Follow-up|0
6207487|NCT01554527|9871572|FG001|Overall Study|Lost to Follow-up|0
6207488|NCT01554527|9871573|FG002|Overall Study|Lost to Follow-up|4
6207489|NCT01554527|9871571|FG000|Overall Study|Physician Decision|0
6207490|NCT01554527|9871572|FG001|Overall Study|Physician Decision|0
6207491|NCT01554527|9871573|FG002|Overall Study|Physician Decision|1
6207492|NCT01554579|9871584|FG000|Overall Study|Adverse Event|6
6207493|NCT01554579|9871585|FG001|Overall Study|Adverse Event|25
6207494|NCT01554579|9871584|FG000|Overall Study|Lack of Efficacy|2
6207495|NCT01554579|9871585|FG001|Overall Study|Lack of Efficacy|1
6207496|NCT01554579|9871584|FG000|Overall Study|Withdrawal by Subject|2
6207497|NCT01554579|9871585|FG001|Overall Study|Withdrawal by Subject|1
6207498|NCT01554618|9871594|FG000|Randomized Through Start of Treatment|Adverse Event|1
6111998|NCT00831441|9731944|FG001|Randomized|Physician Decision|35
6111999|NCT00831441|9731943|FG000|Randomized|No longer met criteria|13
6112000|NCT00831441|9731944|FG001|Randomized|No longer met criteria|19
6112001|NCT00831441|9731943|FG000|Randomized|Withdrawal by Subject|178
6112002|NCT00831441|9731944|FG001|Randomized|Withdrawal by Subject|212
6112003|NCT00831441|9731943|FG000|Randomized|Lost to Follow-up|26
6112004|NCT00831441|9731944|FG001|Randomized|Lost to Follow-up|35
6112005|NCT00831441|9731943|FG000|Randomized|Administrative reason by sponsor|2780
6112006|NCT00831441|9731944|FG001|Randomized|Administrative reason by sponsor|2671
6112007|NCT00831441|9731943|FG000|Randomized|poor/non-compliance|30
6112008|NCT00831441|9731944|FG001|Randomized|poor/non-compliance|38
6112009|NCT00831441|9731943|FG000|Randomized|non-specified|276
6112010|NCT00831441|9731944|FG001|Randomized|non-specified|266
6112011|NCT00831441|9731943|FG000|Follow Up (30 Days)|Withdrawal by Subject|41
6112012|NCT00831441|9731944|FG001|Follow Up (30 Days)|Withdrawal by Subject|34
6207499|NCT01554618|9871595|FG001|Randomized Through Start of Treatment|Adverse Event|0
6207500|NCT01554618|9871594|FG000|Controlled Assessment Period|Lost to Follow-up|2
6207501|NCT01554618|9871595|FG001|Controlled Assessment Period|Lost to Follow-up|1
6207502|NCT01554618|9871594|FG000|Controlled Assessment Period|Withdrawal by Subject|6
6207503|NCT01554618|9871595|FG001|Controlled Assessment Period|Withdrawal by Subject|0
6207504|NCT01554618|9871594|FG000|Open-Label Extension Period|Withdrawal by Subject|2
6207505|NCT01554618|9871595|FG001|Open-Label Extension Period|Withdrawal by Subject|3
6207506|NCT01554618|9871594|FG000|Open-Label Extension Period|Physician Decision|0
6207507|NCT01554618|9871595|FG001|Open-Label Extension Period|Physician Decision|1
6207508|NCT01554618|9871594|FG000|Open-Label Extension Period|Lost to Follow-up|1
6207509|NCT01554618|9871595|FG001|Open-Label Extension Period|Lost to Follow-up|1
6207510|NCT01554904|9871631|FG000|Overall Study|Withdrawal by Subject|3
6207511|NCT01554904|9871631|FG000|Overall Study|Had sleep apnea on Home Study 1|1
6285950|NCT02342886|9998757|FG001|Overall Study|Pregnancy|0
6285951|NCT02342886|9998758|FG002|Overall Study|Pregnancy|2
6285952|NCT02342886|9998759|FG003|Overall Study|Pregnancy|0
6285953|NCT02342886|9998760|FG004|Overall Study|Pregnancy|0
6285954|NCT02342886|9998756|FG000|Overall Study|Late exclusion: pyrazinamide resistance|0
6285955|NCT02342886|9998757|FG001|Overall Study|Late exclusion: pyrazinamide resistance|0
6285956|NCT02342886|9998758|FG002|Overall Study|Late exclusion: pyrazinamide resistance|1
6285957|NCT02342886|9998759|FG003|Overall Study|Late exclusion: pyrazinamide resistance|0
6285958|NCT02342886|9998760|FG004|Overall Study|Late exclusion: pyrazinamide resistance|0
6285959|NCT02342886|9998756|FG000|Overall Study|Protocol Violation|0
6285960|NCT02342886|9998757|FG001|Overall Study|Protocol Violation|0
6285961|NCT02342886|9998758|FG002|Overall Study|Protocol Violation|0
6285962|NCT02342886|9998759|FG003|Overall Study|Protocol Violation|2
6285963|NCT02342886|9998760|FG004|Overall Study|Protocol Violation|0
6285964|NCT02343003|9998774|FG000|Overall Study|Withdrawal by Subject|9
6285965|NCT02343003|9998775|FG001|Overall Study|Withdrawal by Subject|4
6285966|NCT02343003|9998774|FG000|Overall Study|Lost to Follow-up|5
6285967|NCT02343003|9998775|FG001|Overall Study|Lost to Follow-up|1
6285968|NCT02343003|9998774|FG000|Overall Study|Protocol Violation|1
6285969|NCT02343003|9998775|FG001|Overall Study|Protocol Violation|0
6285970|NCT02343003|9998774|FG000|Overall Study|Death|0
6285971|NCT02343003|9998775|FG001|Overall Study|Death|1
6285972|NCT02343003|9998774|FG000|Overall Study|exclusion criteria met|1
6285973|NCT02343003|9998775|FG001|Overall Study|exclusion criteria met|1
6112013|NCT00831441|9731943|FG000|Follow Up (30 Days)|Lost to Follow-up|13
6112014|NCT00831441|9731944|FG001|Follow Up (30 Days)|Lost to Follow-up|27
6112015|NCT00831441|9731943|FG000|Follow Up (30 Days)|Death|63
6112016|NCT00831441|9731944|FG001|Follow Up (30 Days)|Death|86
6112017|NCT00831441|9731943|FG000|Follow Up (30 Days)|non-specified|16
6112018|NCT00831441|9731944|FG001|Follow Up (30 Days)|non-specified|26
6112019|NCT00831441|9731943|FG000|Follow Up (30 Days)|missing end of study status|0
6112020|NCT00831441|9731944|FG001|Follow Up (30 Days)|missing end of study status|1
6112021|NCT00831493|9731955|FG000|Overall Study|Intractable nausea and vomiting|1
6112022|NCT00831701|9731970|FG000|Overall Study|Withdrawal by Subject|2
6112023|NCT00831701|9731971|FG001|Overall Study|Withdrawal by Subject|0
6112024|NCT00831701|9731970|FG000|Overall Study|Stone expulsion before first medication|2
6112025|NCT00831701|9731971|FG001|Overall Study|Stone expulsion before first medication|2
6112026|NCT00831701|9731970|FG000|Overall Study|Lost to Follow-up|1
6112027|NCT00831701|9731971|FG001|Overall Study|Lost to Follow-up|3
6112028|NCT00831779|9731998|FG000|Overall Study|Lost to Follow-up|1
6112029|NCT00831779|9731999|FG001|Overall Study|Lost to Follow-up|0
6112030|NCT00831779|9731998|FG000|Overall Study|No longer met criteria|0
6112031|NCT00831779|9731999|FG001|Overall Study|No longer met criteria|1
6112032|NCT00831792|9732005|FG000|Overall Study|Not Eligible|3
6112033|NCT00831792|9732005|FG000|Overall Study|Adverse Event|1
6112034|NCT00831792|9732005|FG000|Overall Study|Death|1
6112035|NCT00831792|9732005|FG000|Overall Study|Lack of Efficacy|1
6112036|NCT00831844|9732019|FG000|Overall Study|Adverse Event|2
6112037|NCT00831844|9732020|FG001|Overall Study|Adverse Event|0
6112038|NCT00831844|9732021|FG002|Overall Study|Adverse Event|0
6112039|NCT00831844|9732022|FG003|Overall Study|Adverse Event|0
6112040|NCT00831844|9732023|FG004|Overall Study|Adverse Event|1
6112041|NCT00831844|9732024|FG005|Overall Study|Adverse Event|1
6285974|NCT02343003|9998774|FG000|Overall Study|terminated by sponsor|2
6285975|NCT02343003|9998775|FG001|Overall Study|terminated by sponsor|0
6285976|NCT02343406|9998823|FG000|Overall Study|Progressive disease|72
6285977|NCT02343406|9998824|FG001|Overall Study|Progressive disease|70
6285978|NCT02343406|9998825|FG002|Overall Study|Progressive disease|43
6112042|NCT00831844|9732025|FG006|Overall Study|Adverse Event|2
6112043|NCT00831844|9732026|FG007|Overall Study|Adverse Event|0
6112044|NCT00831844|9732027|FG008|Overall Study|Adverse Event|0
6112045|NCT00831844|9732028|FG009|Overall Study|Adverse Event|0
6112046|NCT00831844|9732019|FG000|Overall Study|Death|0
6112047|NCT00831844|9732020|FG001|Overall Study|Death|0
6112048|NCT00831844|9732021|FG002|Overall Study|Death|0
6112049|NCT00831844|9732022|FG003|Overall Study|Death|1
6112050|NCT00831844|9732023|FG004|Overall Study|Death|0
6112051|NCT00831844|9732024|FG005|Overall Study|Death|0
6112052|NCT00831844|9732025|FG006|Overall Study|Death|0
6112053|NCT00831844|9732026|FG007|Overall Study|Death|0
6112054|NCT00831844|9732027|FG008|Overall Study|Death|0
6112055|NCT00831844|9732028|FG009|Overall Study|Death|0
6112056|NCT00831844|9732019|FG000|Overall Study|Lack of Efficacy|8
6112057|NCT00831844|9732020|FG001|Overall Study|Lack of Efficacy|10
6112058|NCT00831844|9732021|FG002|Overall Study|Lack of Efficacy|15
6112059|NCT00831844|9732022|FG003|Overall Study|Lack of Efficacy|8
6112060|NCT00831844|9732023|FG004|Overall Study|Lack of Efficacy|11
6112061|NCT00831844|9732024|FG005|Overall Study|Lack of Efficacy|17
6112062|NCT00831844|9732025|FG006|Overall Study|Lack of Efficacy|8
6112063|NCT00831844|9732026|FG007|Overall Study|Lack of Efficacy|9
6112064|NCT00831844|9732027|FG008|Overall Study|Lack of Efficacy|7
6112065|NCT00831844|9732028|FG009|Overall Study|Lack of Efficacy|0
6112066|NCT00831844|9732019|FG000|Overall Study|Physician Decision|0
6112067|NCT00831844|9732020|FG001|Overall Study|Physician Decision|1
6112068|NCT00831844|9732021|FG002|Overall Study|Physician Decision|3
6112069|NCT00831844|9732022|FG003|Overall Study|Physician Decision|1
6112070|NCT00831844|9732023|FG004|Overall Study|Physician Decision|1
6112071|NCT00831844|9732024|FG005|Overall Study|Physician Decision|1
6112072|NCT00831844|9732025|FG006|Overall Study|Physician Decision|0
6112073|NCT00831844|9732026|FG007|Overall Study|Physician Decision|0
6112074|NCT00831844|9732027|FG008|Overall Study|Physician Decision|1
6112075|NCT00831844|9732028|FG009|Overall Study|Physician Decision|0
6112076|NCT00831844|9732019|FG000|Overall Study|Withdrawal by Subject|0
6112077|NCT00831844|9732020|FG001|Overall Study|Withdrawal by Subject|0
6112078|NCT00831844|9732021|FG002|Overall Study|Withdrawal by Subject|1
6112079|NCT00831844|9732022|FG003|Overall Study|Withdrawal by Subject|0
6112080|NCT00831844|9732023|FG004|Overall Study|Withdrawal by Subject|0
6112081|NCT00831844|9732024|FG005|Overall Study|Withdrawal by Subject|0
6112082|NCT00831844|9732025|FG006|Overall Study|Withdrawal by Subject|0
6112083|NCT00831844|9732026|FG007|Overall Study|Withdrawal by Subject|1
6112084|NCT00831844|9732027|FG008|Overall Study|Withdrawal by Subject|1
6112085|NCT00831844|9732028|FG009|Overall Study|Withdrawal by Subject|0
6112086|NCT00831844|9732019|FG000|Overall Study|Ineligible|0
6112087|NCT00831844|9732020|FG001|Overall Study|Ineligible|1
6112088|NCT00831844|9732021|FG002|Overall Study|Ineligible|1
6112089|NCT00831844|9732022|FG003|Overall Study|Ineligible|0
6112090|NCT00831844|9732023|FG004|Overall Study|Ineligible|1
6112091|NCT00831844|9732024|FG005|Overall Study|Ineligible|0
6112092|NCT00831844|9732025|FG006|Overall Study|Ineligible|0
6112093|NCT00831844|9732026|FG007|Overall Study|Ineligible|0
6112094|NCT00831844|9732027|FG008|Overall Study|Ineligible|0
6112095|NCT00831844|9732028|FG009|Overall Study|Ineligible|0
6112096|NCT00832000|9732059|FG000|Overall Study|Adverse Event|2
6112097|NCT00832000|9732060|FG001|Overall Study|Adverse Event|0
6112098|NCT00832000|9732059|FG000|Overall Study|Withdrawal by Subject|1
6112099|NCT00832000|9732060|FG001|Overall Study|Withdrawal by Subject|0
6112100|NCT00832000|9732059|FG000|Overall Study|No calls to IVR in either period|1
6112101|NCT00832000|9732060|FG001|Overall Study|No calls to IVR in either period|1
6112102|NCT00832000|9732059|FG000|Overall Study|No calls to IVR in period 2|2
6112103|NCT00832000|9732060|FG001|Overall Study|No calls to IVR in period 2|0
6112104|NCT00832078|9732095|FG000|Test Day 1-2 Period|Lack of Efficacy|0
6112105|NCT00832078|9732096|FG001|Test Day 1-2 Period|Lack of Efficacy|2
6112106|NCT00832078|9732095|FG000|Test Day 2 - 2 Period|Lack of Efficacy|1
6112107|NCT00832078|9732096|FG001|Test Day 2 - 2 Period|Lack of Efficacy|0
6112108|NCT00832091|9732104|FG000|Overall Study|Adverse Event|1
6112109|NCT00832091|9732105|FG001|Overall Study|Adverse Event|1
6112110|NCT00832091|9732104|FG000|Overall Study|Protocol Violation|1
6112111|NCT00832091|9732105|FG001|Overall Study|Protocol Violation|0
6112112|NCT00832091|9732104|FG000|Overall Study|Withdrawal by Subject|2
6112113|NCT00832091|9732105|FG001|Overall Study|Withdrawal by Subject|1
6112114|NCT00832091|9732104|FG000|Overall Study|Prohibited Medication|1
6112115|NCT00832091|9732105|FG001|Overall Study|Prohibited Medication|0
6112116|NCT00832117|9732113|FG000|Overall Study|Death|1
6112117|NCT00832117|9732113|FG000|Overall Study|Disease Progression|11
6112118|NCT00832377|9732137|FG000|Overall Study|Protocol Violation|1
6112119|NCT00832416|9732158|FG000|Overall Study|Lack of Efficacy|17
6112120|NCT00832416|9732159|FG001|Overall Study|Lack of Efficacy|15
6112121|NCT00832416|9732160|FG002|Overall Study|Lack of Efficacy|13
6112122|NCT00832416|9732161|FG003|Overall Study|Lack of Efficacy|52
6112123|NCT00832416|9732158|FG000|Overall Study|Withdrawal by Subject|5
6112124|NCT00832416|9732159|FG001|Overall Study|Withdrawal by Subject|7
6112125|NCT00832416|9732160|FG002|Overall Study|Withdrawal by Subject|2
6112126|NCT00832416|9732161|FG003|Overall Study|Withdrawal by Subject|10
6112127|NCT00832416|9732158|FG000|Overall Study|Physician Decision|2
6112128|NCT00832416|9732159|FG001|Overall Study|Physician Decision|12
6112129|NCT00832416|9732160|FG002|Overall Study|Physician Decision|5
6112130|NCT00832416|9732161|FG003|Overall Study|Physician Decision|10
6112131|NCT00832416|9732158|FG000|Overall Study|Administrative|0
6112132|NCT00832416|9732159|FG001|Overall Study|Administrative|0
6112133|NCT00832416|9732160|FG002|Overall Study|Administrative|0
6112134|NCT00832416|9732161|FG003|Overall Study|Administrative|1
6112135|NCT00832416|9732158|FG000|Overall Study|Adverse Event|21
6112136|NCT00832416|9732159|FG001|Overall Study|Adverse Event|19
6112137|NCT00832416|9732160|FG002|Overall Study|Adverse Event|41
6207512|NCT01555125|9871642|FG000|Induction Period|Lost to Follow-up|0
6207513|NCT01555125|9871643|FG001|Induction Period|Lost to Follow-up|2
6207514|NCT01555125|9871644|FG002|Induction Period|Lost to Follow-up|0
6207515|NCT01555125|9871645|FG003|Induction Period|Lost to Follow-up|0
6207516|NCT01555125|9871646|FG004|Induction Period|Lost to Follow-up|0
6207517|NCT01555125|9871642|FG000|Induction Period|Adverse Event|0
6207518|NCT01555125|9871643|FG001|Induction Period|Adverse Event|1
6207519|NCT01555125|9871644|FG002|Induction Period|Adverse Event|0
6207520|NCT01555125|9871645|FG003|Induction Period|Adverse Event|0
6207521|NCT01555125|9871646|FG004|Induction Period|Adverse Event|1
6207522|NCT01555125|9871642|FG000|Induction Period|Subject / guardian decision|0
6207523|NCT01555125|9871643|FG001|Induction Period|Subject / guardian decision|0
6207524|NCT01555125|9871644|FG002|Induction Period|Subject / guardian decision|0
6207525|NCT01555125|9871645|FG003|Induction Period|Subject / guardian decision|0
6207526|NCT01555125|9871646|FG004|Induction Period|Subject / guardian decision|2
6207527|NCT01555125|9871642|FG000|Induction Period|Death|1
6207528|NCT01555125|9871643|FG001|Induction Period|Death|0
6207529|NCT01555125|9871644|FG002|Induction Period|Death|0
6207530|NCT01555125|9871645|FG003|Induction Period|Death|0
6207531|NCT01555125|9871646|FG004|Induction Period|Death|0
6207532|NCT01555125|9871642|FG000|Maintenance Period|Adverse Event|1
6207533|NCT01555125|9871643|FG001|Maintenance Period|Adverse Event|1
6207534|NCT01555125|9871644|FG002|Maintenance Period|Adverse Event|0
6207535|NCT01555125|9871645|FG003|Maintenance Period|Adverse Event|0
6207536|NCT01555125|9871646|FG004|Maintenance Period|Adverse Event|0
6207537|NCT01555125|9871642|FG000|Maintenance Period|Subject / guardian decision|1
6207538|NCT01555125|9871643|FG001|Maintenance Period|Subject / guardian decision|2
6207539|NCT01555125|9871644|FG002|Maintenance Period|Subject / guardian decision|0
6207540|NCT01555125|9871645|FG003|Maintenance Period|Subject / guardian decision|0
6207541|NCT01555125|9871646|FG004|Maintenance Period|Subject / guardian decision|0
6207542|NCT01555125|9871642|FG000|Maintenance Period|Lost to Follow-up|2
6207543|NCT01555125|9871643|FG001|Maintenance Period|Lost to Follow-up|0
6207544|NCT01555125|9871644|FG002|Maintenance Period|Lost to Follow-up|0
6207545|NCT01555125|9871645|FG003|Maintenance Period|Lost to Follow-up|1
6207546|NCT01555125|9871646|FG004|Maintenance Period|Lost to Follow-up|0
6207547|NCT01555125|9871642|FG000|Maintenance Period|Lack of Efficacy|6
6207548|NCT01555125|9871643|FG001|Maintenance Period|Lack of Efficacy|1
6207549|NCT01555125|9871644|FG002|Maintenance Period|Lack of Efficacy|3
6207550|NCT01555125|9871645|FG003|Maintenance Period|Lack of Efficacy|0
6207551|NCT01555125|9871646|FG004|Maintenance Period|Lack of Efficacy|0
6207552|NCT01555125|9871642|FG000|Maintenance Period|Physician Decision|0
6207553|NCT01555125|9871643|FG001|Maintenance Period|Physician Decision|0
6207554|NCT01555125|9871644|FG002|Maintenance Period|Physician Decision|1
6207555|NCT01555125|9871645|FG003|Maintenance Period|Physician Decision|0
6207556|NCT01555125|9871646|FG004|Maintenance Period|Physician Decision|0
6207557|NCT01555125|9871642|FG000|Maintenance Period|Death|0
6207558|NCT01555125|9871643|FG001|Maintenance Period|Death|0
6207559|NCT01555125|9871644|FG002|Maintenance Period|Death|0
6207560|NCT01555125|9871645|FG003|Maintenance Period|Death|1
6207561|NCT01555125|9871646|FG004|Maintenance Period|Death|0
6207562|NCT01555125|9871642|FG000|Extension|Adverse Event|1
6207563|NCT01555125|9871643|FG001|Extension|Adverse Event|2
6207564|NCT01555125|9871644|FG002|Extension|Adverse Event|1
6207565|NCT01555125|9871645|FG003|Extension|Adverse Event|1
6207566|NCT01555125|9871646|FG004|Extension|Adverse Event|0
6112138|NCT00832416|9732161|FG003|Overall Study|Adverse Event|10
6112139|NCT00832416|9732158|FG000|Overall Study|Death|1
6112140|NCT00832416|9732159|FG001|Overall Study|Death|0
6112141|NCT00832416|9732160|FG002|Overall Study|Death|0
6112142|NCT00832416|9732161|FG003|Overall Study|Death|0
6112143|NCT00832585|9732171|FG000|Overall Study|Withdrawal by Subject|1
6112144|NCT00832585|9732171|FG000|Overall Study|Lost to Follow-up|1
6112145|NCT00832650|9732182|FG000|Overall Study|Randomized but not treated|0
6112146|NCT00832650|9732183|FG001|Overall Study|Randomized but not treated|0
6112147|NCT00832650|9732184|FG002|Overall Study|Randomized but not treated|1
6112148|NCT00832780|9732203|FG000|Overall Study|Death|16
6112149|NCT00832780|9732203|FG000|Overall Study|Lost to Follow-up|4
6112150|NCT00832780|9732203|FG000|Overall Study|no reason given|2
6207567|NCT01555125|9871642|FG000|Extension|Protocol deviation|1
6207568|NCT01555125|9871643|FG001|Extension|Protocol deviation|0
6207569|NCT01555125|9871644|FG002|Extension|Protocol deviation|0
6207570|NCT01555125|9871645|FG003|Extension|Protocol deviation|0
6112151|NCT00832780|9732203|FG000|Overall Study|other complicating condition|2
6207571|NCT01555125|9871646|FG004|Extension|Protocol deviation|0
6207572|NCT01555125|9871642|FG000|Extension|Lack of Efficacy|7
6112152|NCT00832780|9732203|FG000|Overall Study|Physician Decision|1
6112153|NCT00832819|9732210|FG000|Overall Study|Adverse Event|0
6207573|NCT01555125|9871643|FG001|Extension|Lack of Efficacy|6
6207574|NCT01555125|9871644|FG002|Extension|Lack of Efficacy|3
6112154|NCT00832819|9732211|FG001|Overall Study|Adverse Event|1
6112155|NCT00832819|9732212|FG002|Overall Study|Adverse Event|0
6112156|NCT00832819|9732210|FG000|Overall Study|Protocol Violation|0
6112157|NCT00832819|9732211|FG001|Overall Study|Protocol Violation|0
6112158|NCT00832819|9732212|FG002|Overall Study|Protocol Violation|1
6112159|NCT00832975|9732222|FG000|Overall Study|Lost to Follow-up|7
6112160|NCT00832975|9732222|FG000|Overall Study|Protocol Violation|6
6112161|NCT00832975|9732222|FG000|Overall Study|Death|5
6112162|NCT00832975|9732222|FG000|Overall Study|Physician Decision|4
6112163|NCT00832975|9732222|FG000|Overall Study|Withdrawal by Subject|3
6112164|NCT00832975|9732222|FG000|Overall Study|Other reasons|14
6112165|NCT00833027|9732226|FG000|Overall Study|Adverse Event|33
6112166|NCT00833027|9732226|FG000|Overall Study|Death|1
6112167|NCT00833027|9732226|FG000|Overall Study|Lack of Efficacy|12
6112168|NCT00833027|9732226|FG000|Overall Study|Lost to Follow-up|24
6112169|NCT00833027|9732226|FG000|Overall Study|Protocol Violation|115
6112170|NCT00833027|9732226|FG000|Overall Study|Withdrawal by Subject|16
6112171|NCT00833027|9732226|FG000|Overall Study|Missing|10
6112172|NCT00833040|9732230|FG000|Overall Study|Adverse Event|0
6112173|NCT00833040|9732231|FG001|Overall Study|Adverse Event|0
6112174|NCT00833040|9732232|FG002|Overall Study|Adverse Event|0
6112175|NCT00833040|9732233|FG003|Overall Study|Adverse Event|0
6112176|NCT00833040|9732234|FG004|Overall Study|Adverse Event|0
6112177|NCT00833040|9732235|FG005|Overall Study|Adverse Event|1
6112178|NCT00833053|9732242|FG000|Overall Study|Adverse Event|4
6112179|NCT00833053|9732243|FG001|Overall Study|Adverse Event|0
6112180|NCT00833053|9732242|FG000|Overall Study|Treatment Failure|3
6112181|NCT00833053|9732243|FG001|Overall Study|Treatment Failure|1
6112182|NCT00833053|9732242|FG000|Overall Study|Withdrawal by Subject|0
6112183|NCT00833053|9732243|FG001|Overall Study|Withdrawal by Subject|1
6112184|NCT00833053|9732242|FG000|Overall Study|Protocol Violation|2
6112185|NCT00833053|9732243|FG001|Overall Study|Protocol Violation|1
6112186|NCT00833092|9732251|FG000|Overall Study|Withdrawal by Subject|2
6112187|NCT00833092|9732252|FG001|Overall Study|Withdrawal by Subject|3
6112188|NCT00833092|9732251|FG000|Overall Study|Protocol Violation|2
6112189|NCT00833092|9732252|FG001|Overall Study|Protocol Violation|1
6112190|NCT00833092|9732251|FG000|Overall Study|Diarrhea|0
6112191|NCT00833092|9732252|FG001|Overall Study|Diarrhea|2
6112192|NCT00833092|9732251|FG000|Overall Study|constipation|0
6112193|NCT00833092|9732252|FG001|Overall Study|constipation|1
6112194|NCT00833105|9732258|FG000|Overall Study|Withdrawal by Subject|1
6112195|NCT00833105|9732258|FG000|Overall Study|Adverse Event|2
6112196|NCT00833248|9732266|FG000|Overall Study|Adverse Event|3
6112197|NCT00833248|9732267|FG001|Overall Study|Adverse Event|0
6112198|NCT00833248|9732266|FG000|Overall Study|Protocol Violation|1
6112199|NCT00833248|9732267|FG001|Overall Study|Protocol Violation|2
6112200|NCT00833248|9732266|FG000|Overall Study|Withdrawal by Subject|0
6112201|NCT00833248|9732267|FG001|Overall Study|Withdrawal by Subject|1
6112202|NCT00833261|9732273|FG000|Overall Study|Withdrawal by Subject|4
6112203|NCT00833417|9732288|FG000|Overall Study|Adverse Event|5
6112204|NCT00833417|9732289|FG001|Overall Study|Adverse Event|16
6112205|NCT00833417|9732288|FG000|Overall Study|Death|1
6112206|NCT00833417|9732289|FG001|Overall Study|Death|3
6112207|NCT00833417|9732288|FG000|Overall Study|Lost to Follow-up|1
6207575|NCT01555125|9871645|FG003|Extension|Lack of Efficacy|0
6207576|NCT01555125|9871646|FG004|Extension|Lack of Efficacy|0
6207577|NCT01555125|9871642|FG000|Extension|Lost to Follow-up|2
6207578|NCT01555125|9871643|FG001|Extension|Lost to Follow-up|1
6207579|NCT01555125|9871644|FG002|Extension|Lost to Follow-up|2
6207580|NCT01555125|9871645|FG003|Extension|Lost to Follow-up|0
6207581|NCT01555125|9871646|FG004|Extension|Lost to Follow-up|0
6207582|NCT01555125|9871642|FG000|Extension|Study terminated by sponsor|32
6207583|NCT01555125|9871643|FG001|Extension|Study terminated by sponsor|33
6207584|NCT01555125|9871644|FG002|Extension|Study terminated by sponsor|16
6207585|NCT01555125|9871645|FG003|Extension|Study terminated by sponsor|20
6207586|NCT01555125|9871646|FG004|Extension|Study terminated by sponsor|0
6207587|NCT01555125|9871642|FG000|Extension|Subject/guardian decision|1
6207588|NCT01555125|9871643|FG001|Extension|Subject/guardian decision|9
6207589|NCT01555125|9871644|FG002|Extension|Subject/guardian decision|1
6207590|NCT01555125|9871645|FG003|Extension|Subject/guardian decision|0
6285979|NCT02343406|9998826|FG003|Overall Study|Progressive disease|15
6285980|NCT02343406|9998827|FG004|Overall Study|Progressive disease|5
6112208|NCT00833417|9732289|FG001|Overall Study|Lost to Follow-up|2
6112209|NCT00833417|9732288|FG000|Overall Study|Physician Decision to Withdraw Patient|3
6112210|NCT00833417|9732289|FG001|Overall Study|Physician Decision to Withdraw Patient|7
6112211|NCT00833417|9732288|FG000|Overall Study|Patient Decision to Withdraw|4
6112212|NCT00833417|9732289|FG001|Overall Study|Patient Decision to Withdraw|23
6112213|NCT00833417|9732288|FG000|Overall Study|Sponsor Decision to Terminate Study|1
6207591|NCT01555125|9871646|FG004|Extension|Subject/guardian decision|0
6207592|NCT01555125|9871642|FG000|Extension|Technical Problems|1
6207593|NCT01555125|9871643|FG001|Extension|Technical Problems|0
6112214|NCT00833417|9732289|FG001|Overall Study|Sponsor Decision to Terminate Study|2
6112215|NCT00833417|9732288|FG000|Overall Study|Disease Progression|18
6112216|NCT00833417|9732289|FG001|Overall Study|Disease Progression|17
6207594|NCT01555125|9871644|FG002|Extension|Technical Problems|0
6207595|NCT01555125|9871645|FG003|Extension|Technical Problems|1
6112217|NCT00833417|9732288|FG000|Overall Study|Reason Not Specified|0
6112218|NCT00833417|9732289|FG001|Overall Study|Reason Not Specified|1
6112219|NCT00833469|9732307|FG000|Overall Study|Withdrawal by Subject|1
6112220|NCT00833469|9732307|FG000|Overall Study|Lost to Follow-up|1
6112221|NCT00833482|9732313|FG000|Days 11-20|Adverse Event|0
6112222|NCT00833482|9732314|FG001|Days 11-20|Adverse Event|2
6112223|NCT00833482|9732315|FG002|Days 11-20|Adverse Event|0
6112224|NCT00833482|9732316|FG003|Days 11-20|Adverse Event|0
6112225|NCT00833482|9732317|FG004|Days 11-20|Adverse Event|0
6112226|NCT00833482|9732318|FG005|Days 11-20|Adverse Event|0
6112227|NCT00833482|9732313|FG000|Days 11-20|Withdrawal by Subject|0
6112228|NCT00833482|9732314|FG001|Days 11-20|Withdrawal by Subject|1
6112229|NCT00833482|9732315|FG002|Days 11-20|Withdrawal by Subject|0
6112230|NCT00833482|9732316|FG003|Days 11-20|Withdrawal by Subject|0
6112231|NCT00833482|9732317|FG004|Days 11-20|Withdrawal by Subject|0
6112232|NCT00833482|9732318|FG005|Days 11-20|Withdrawal by Subject|0
6112233|NCT00833482|9732313|FG000|Days 21-30|Adverse Event|0
6112234|NCT00833482|9732314|FG001|Days 21-30|Adverse Event|0
6112235|NCT00833482|9732315|FG002|Days 21-30|Adverse Event|1
6112236|NCT00833482|9732316|FG003|Days 21-30|Adverse Event|0
6112237|NCT00833482|9732317|FG004|Days 21-30|Adverse Event|0
6112238|NCT00833482|9732318|FG005|Days 21-30|Adverse Event|0
6112239|NCT00833482|9732313|FG000|Days 21-30|Withdrawal by Subject|0
6112240|NCT00833482|9732314|FG001|Days 21-30|Withdrawal by Subject|0
6112241|NCT00833482|9732315|FG002|Days 21-30|Withdrawal by Subject|0
6112242|NCT00833482|9732316|FG003|Days 21-30|Withdrawal by Subject|0
6112243|NCT00833482|9732317|FG004|Days 21-30|Withdrawal by Subject|1
6112244|NCT00833482|9732318|FG005|Days 21-30|Withdrawal by Subject|0
6112245|NCT00833547|9732342|FG000|Overall Study|Withdrawal by Subject|2
6112246|NCT00833547|9732343|FG001|Overall Study|Withdrawal by Subject|2
6112247|NCT00833560|9732349|FG000|Overall Study|Toxicity|13
6112248|NCT00833560|9732349|FG000|Overall Study|Adverse Event|11
6112249|NCT00833560|9732349|FG000|Overall Study|Protocol Violation|6
6112250|NCT00833560|9732349|FG000|Overall Study|Lack of Efficacy|4
6112251|NCT00833560|9732349|FG000|Overall Study|Death|2
6112252|NCT00833560|9732349|FG000|Overall Study|Pregression of other disease|1
6207596|NCT01555125|9871646|FG004|Extension|Technical Problems|0
6207597|NCT01555125|9871642|FG000|Follow-Up Period|Lost to Follow-up|1
6207598|NCT01555125|9871643|FG001|Follow-Up Period|Lost to Follow-up|0
6207599|NCT01555125|9871644|FG002|Follow-Up Period|Lost to Follow-up|0
6207600|NCT01555125|9871645|FG003|Follow-Up Period|Lost to Follow-up|0
6207601|NCT01555125|9871646|FG004|Follow-Up Period|Lost to Follow-up|0
6207602|NCT01555125|9871642|FG000|Follow-Up Period|Subject / guardian decision|3
6207603|NCT01555125|9871643|FG001|Follow-Up Period|Subject / guardian decision|1
6207604|NCT01555125|9871644|FG002|Follow-Up Period|Subject / guardian decision|1
6207605|NCT01555125|9871645|FG003|Follow-Up Period|Subject / guardian decision|1
6207606|NCT01555125|9871646|FG004|Follow-Up Period|Subject / guardian decision|0
6207607|NCT01555138|9871663|FG000|Overall Study|Death|0
6207608|NCT01555138|9871664|FG001|Overall Study|Death|1
6207609|NCT01555138|9871663|FG000|Overall Study|Lost to Follow-up|1
6207610|NCT01555138|9871664|FG001|Overall Study|Lost to Follow-up|0
6207611|NCT01555138|9871663|FG000|Overall Study|Abnormal Lab reults|1
6207612|NCT01555138|9871664|FG001|Overall Study|Abnormal Lab reults|3
6207613|NCT01555138|9871663|FG000|Overall Study|Lack of Efficacy|2
6207614|NCT01555138|9871664|FG001|Overall Study|Lack of Efficacy|2
6207615|NCT01555138|9871663|FG000|Overall Study|Protocol Violation|5
6207616|NCT01555138|9871664|FG001|Overall Study|Protocol Violation|3
6207617|NCT01555138|9871663|FG000|Overall Study|Administrative problems|8
6207618|NCT01555138|9871664|FG001|Overall Study|Administrative problems|0
6207619|NCT01555138|9871663|FG000|Overall Study|Withdrawal by Subject|16
6207620|NCT01555138|9871664|FG001|Overall Study|Withdrawal by Subject|15
6207621|NCT01555138|9871663|FG000|Overall Study|Adverse Event|14
6207622|NCT01555138|9871664|FG001|Overall Study|Adverse Event|14
6207623|NCT01555151|9871674|FG000|Overall Study|Withdrawal by Subject|6
6207624|NCT01555151|9871675|FG001|Overall Study|Withdrawal by Subject|2
6207625|NCT01555151|9871676|FG002|Overall Study|Withdrawal by Subject|0
6207626|NCT01555151|9871677|FG003|Overall Study|Withdrawal by Subject|2
6207627|NCT01555151|9871674|FG000|Overall Study|Administrative|3
6112253|NCT00833560|9732349|FG000|Overall Study|Other|5
6207628|NCT01555151|9871675|FG001|Overall Study|Administrative|1
6207629|NCT01555151|9871676|FG002|Overall Study|Administrative|2
6207630|NCT01555151|9871677|FG003|Overall Study|Administrative|0
6207631|NCT01555151|9871674|FG000|Overall Study|Protocol Violation|3
6207632|NCT01555151|9871675|FG001|Overall Study|Protocol Violation|3
6207633|NCT01555151|9871676|FG002|Overall Study|Protocol Violation|3
6207634|NCT01555151|9871677|FG003|Overall Study|Protocol Violation|5
6207635|NCT01555151|9871674|FG000|Overall Study|Adverse Event|1
6207636|NCT01555151|9871675|FG001|Overall Study|Adverse Event|2
6207637|NCT01555151|9871676|FG002|Overall Study|Adverse Event|1
6112254|NCT00833638|9732356|FG000|Phase 2: Double-blind Treatment Phase|Adverse Event|1
6112255|NCT00833638|9732357|FG001|Phase 2: Double-blind Treatment Phase|Adverse Event|2
6112256|NCT00833638|9732358|FG002|Phase 2: Double-blind Treatment Phase|Adverse Event|0
6112257|NCT00833638|9732356|FG000|Phase 2: Double-blind Treatment Phase|Entry Criteria Not Met|3
6112258|NCT00833638|9732357|FG001|Phase 2: Double-blind Treatment Phase|Entry Criteria Not Met|2
6207638|NCT01555151|9871677|FG003|Overall Study|Adverse Event|2
6207639|NCT01555151|9871674|FG000|Overall Study|Lost to Follow-up|0
6112259|NCT00833638|9732358|FG002|Phase 2: Double-blind Treatment Phase|Entry Criteria Not Met|1
6112260|NCT00833638|9732356|FG000|Phase 2: Double-blind Treatment Phase|Lost to Follow-up|1
6112261|NCT00833638|9732357|FG001|Phase 2: Double-blind Treatment Phase|Lost to Follow-up|2
6112262|NCT00833638|9732358|FG002|Phase 2: Double-blind Treatment Phase|Lost to Follow-up|1
6112263|NCT00833638|9732356|FG000|Phase 2: Double-blind Treatment Phase|Physician Decision|1
6112264|NCT00833638|9732357|FG001|Phase 2: Double-blind Treatment Phase|Physician Decision|0
6112265|NCT00833638|9732358|FG002|Phase 2: Double-blind Treatment Phase|Physician Decision|0
6112266|NCT00833638|9732356|FG000|Phase 2: Double-blind Treatment Phase|Protocol Violation|3
6112267|NCT00833638|9732357|FG001|Phase 2: Double-blind Treatment Phase|Protocol Violation|3
6112268|NCT00833638|9732358|FG002|Phase 2: Double-blind Treatment Phase|Protocol Violation|3
6112269|NCT00833638|9732356|FG000|Phase 2: Double-blind Treatment Phase|Sponsor Decision|0
6112270|NCT00833638|9732357|FG001|Phase 2: Double-blind Treatment Phase|Sponsor Decision|0
6112271|NCT00833638|9732358|FG002|Phase 2: Double-blind Treatment Phase|Sponsor Decision|2
6112272|NCT00833638|9732356|FG000|Phase 2: Double-blind Treatment Phase|Withdrawal by Subject|1
6112273|NCT00833638|9732357|FG001|Phase 2: Double-blind Treatment Phase|Withdrawal by Subject|1
6112274|NCT00833638|9732358|FG002|Phase 2: Double-blind Treatment Phase|Withdrawal by Subject|2
6112275|NCT00833638|9732356|FG000|Phase 3: Open-label Extension Phase|Lost to Follow-up|1
6112276|NCT00833638|9732357|FG001|Phase 3: Open-label Extension Phase|Lost to Follow-up|2
6112277|NCT00833638|9732358|FG002|Phase 3: Open-label Extension Phase|Lost to Follow-up|0
6112278|NCT00833638|9732356|FG000|Phase 3: Open-label Extension Phase|Protocol Violation|0
6112279|NCT00833638|9732357|FG001|Phase 3: Open-label Extension Phase|Protocol Violation|1
6112280|NCT00833638|9732358|FG002|Phase 3: Open-label Extension Phase|Protocol Violation|2
6112281|NCT00833690|9732377|FG000|Overall Study|Withdrawal by Subject|1
6112282|NCT00833690|9732378|FG001|Overall Study|Withdrawal by Subject|0
6112283|NCT00833690|9732379|FG002|Overall Study|Withdrawal by Subject|0
6112284|NCT00833690|9732377|FG000|Overall Study|Discontinued study drug|3
6112285|NCT00833690|9732378|FG001|Overall Study|Discontinued study drug|2
6112286|NCT00833690|9732379|FG002|Overall Study|Discontinued study drug|0
6112287|NCT00833703|9732389|FG000|Overall Study|Parent(s)/guardian(s)'s request|0
6112288|NCT00833703|9732390|FG001|Overall Study|Parent(s)/guardian(s)'s request|1
6112289|NCT00833755|9732400|FG000|Overall Study|Physician Decision|4
6112290|NCT00833755|9732401|FG001|Overall Study|Physician Decision|4
6112291|NCT00833755|9732402|FG002|Overall Study|Physician Decision|2
6112292|NCT00833755|9732403|FG003|Overall Study|Physician Decision|6
6112293|NCT00833755|9732400|FG000|Overall Study|Subject had scheduling issues|0
6112294|NCT00833755|9732401|FG001|Overall Study|Subject had scheduling issues|1
6207640|NCT01555151|9871675|FG001|Overall Study|Lost to Follow-up|0
6207641|NCT01555151|9871676|FG002|Overall Study|Lost to Follow-up|0
6207642|NCT01555151|9871677|FG003|Overall Study|Lost to Follow-up|1
6207643|NCT01555164|9871690|FG000|Overall Study|Adverse Event|5
6207644|NCT01555164|9871691|FG001|Overall Study|Adverse Event|7
6207645|NCT01555164|9871690|FG000|Overall Study|Hyperglycemia|0
6207646|NCT01555164|9871691|FG001|Overall Study|Hyperglycemia|1
6207647|NCT01555164|9871690|FG000|Overall Study|Investigator's Discretion|2
6207648|NCT01555164|9871691|FG001|Overall Study|Investigator's Discretion|2
6207649|NCT01555164|9871690|FG000|Overall Study|Lost to Follow-up|4
6207650|NCT01555164|9871691|FG001|Overall Study|Lost to Follow-up|3
6207651|NCT01555164|9871690|FG000|Overall Study|Protocol Violation|9
6207652|NCT01555164|9871691|FG001|Overall Study|Protocol Violation|5
6207653|NCT01555164|9871690|FG000|Overall Study|Subject Non-compliance|14
6207654|NCT01555164|9871691|FG001|Overall Study|Subject Non-compliance|6
6207655|NCT01555164|9871690|FG000|Overall Study|Subject Withdrew Consent|6
6207656|NCT01555164|9871691|FG001|Overall Study|Subject Withdrew Consent|11
6207657|NCT01555463|9871699|FG000|Treatment|Adverse Event|6
6207658|NCT01555463|9871700|FG001|Treatment|Adverse Event|12
6207659|NCT01555463|9871699|FG000|Treatment|Withdrawal by Subject|24
6207660|NCT01555463|9871700|FG001|Treatment|Withdrawal by Subject|36
6207661|NCT01555463|9871699|FG000|Treatment|Lost to Follow-up|28
6207662|NCT01555463|9871700|FG001|Treatment|Lost to Follow-up|23
6207663|NCT01555463|9871699|FG000|Treatment|Protocol Violation|4
6207664|NCT01555463|9871700|FG001|Treatment|Protocol Violation|5
6207665|NCT01555463|9871699|FG000|Treatment|Other reason|2
6207666|NCT01555463|9871700|FG001|Treatment|Other reason|3
6207667|NCT01555463|9871699|FG000|Follow up|Adverse Event|2
6207668|NCT01555463|9871700|FG001|Follow up|Adverse Event|5
6207669|NCT01555463|9871699|FG000|Follow up|Death|0
6207670|NCT01555463|9871700|FG001|Follow up|Death|1
6207671|NCT01555463|9871699|FG000|Follow up|Withdrawal by Subject|22
6207672|NCT01555463|9871700|FG001|Follow up|Withdrawal by Subject|22
6207673|NCT01555463|9871699|FG000|Follow up|Lost to Follow-up|9
6207674|NCT01555463|9871700|FG001|Follow up|Lost to Follow-up|10
6207675|NCT01555463|9871699|FG000|Follow up|Protocol Violation|2
6207676|NCT01555463|9871700|FG001|Follow up|Protocol Violation|4
6207677|NCT01555463|9871699|FG000|Follow up|Other reason|3
6207678|NCT01555463|9871700|FG001|Follow up|Other reason|3
6207679|NCT01555671|9871730|FG000|Overall Study|Physician Decision|20
6207680|NCT01555671|9871731|FG001|Overall Study|Physician Decision|25
6207681|NCT01555762|9871766|FG000|Overall Study|No information on Bevacizumab intake|11
6207682|NCT01555762|9871766|FG000|Overall Study|Missing start date of infusion|8
6285981|NCT02343406|9998823|FG000|Overall Study|Adverse Event|6
6112295|NCT00833755|9732402|FG002|Overall Study|Subject had scheduling issues|0
6112296|NCT00833755|9732403|FG003|Overall Study|Subject had scheduling issues|0
6112297|NCT00833794|9732424|FG000|Open-label Phase|Adverse Event|225
6112298|NCT00833794|9732425|FG001|Open-label Phase|Adverse Event|0
6112299|NCT00833794|9732424|FG000|Open-label Phase|Lack of Efficacy|28
6112300|NCT00833794|9732425|FG001|Open-label Phase|Lack of Efficacy|0
6112301|NCT00833794|9732424|FG000|Open-label Phase|Withdrawal by Subject|48
6112302|NCT00833794|9732425|FG001|Open-label Phase|Withdrawal by Subject|0
6112303|NCT00833794|9732424|FG000|Open-label Phase|Physician Decision|20
6112304|NCT00833794|9732425|FG001|Open-label Phase|Physician Decision|0
6112305|NCT00833794|9732424|FG000|Open-label Phase|Administrative reason|1
6112306|NCT00833794|9732425|FG001|Open-label Phase|Administrative reason|0
6112307|NCT00833794|9732424|FG000|Open-label Phase|Protocol Violation|47
6112308|NCT00833794|9732425|FG001|Open-label Phase|Protocol Violation|0
6112309|NCT00833794|9732424|FG000|Open-label Phase|Did not complete wash-out period|12
6112310|NCT00833794|9732425|FG001|Open-label Phase|Did not complete wash-out period|0
6112311|NCT00833794|9732424|FG000|Open-label Phase|enrolled in error (immediately D/C)|1
6112312|NCT00833794|9732425|FG001|Open-label Phase|enrolled in error (immediately D/C)|0
6112313|NCT00833794|9732424|FG000|Double-blind Phase|Adverse Event|44
6112314|NCT00833794|9732425|FG001|Double-blind Phase|Adverse Event|11
6112315|NCT00833794|9732424|FG000|Double-blind Phase|Lack of Efficacy|34
6112316|NCT00833794|9732425|FG001|Double-blind Phase|Lack of Efficacy|22
6112317|NCT00833794|9732424|FG000|Double-blind Phase|Withdrawal by Subject|23
6112318|NCT00833794|9732425|FG001|Double-blind Phase|Withdrawal by Subject|6
6112319|NCT00833794|9732424|FG000|Double-blind Phase|Physician Decision|4
6112320|NCT00833794|9732425|FG001|Double-blind Phase|Physician Decision|7
6112321|NCT00833794|9732424|FG000|Double-blind Phase|Administrative reason|1
6112322|NCT00833794|9732425|FG001|Double-blind Phase|Administrative reason|3
6112323|NCT00833833|9732439|FG000|Phase 1 (as of 01 April 2011)|Still active in study|0
6112324|NCT00833833|9732440|FG001|Phase 1 (as of 01 April 2011)|Still active in study|0
6112325|NCT00833833|9732441|FG002|Phase 1 (as of 01 April 2011)|Still active in study|2
6112326|NCT00833833|9732442|FG003|Phase 1 (as of 01 April 2011)|Still active in study|2
6112327|NCT00833833|9732443|FG004|Phase 1 (as of 01 April 2011)|Still active in study|0
6112328|NCT00833833|9732444|FG005|Phase 1 (as of 01 April 2011)|Still active in study|0
6112329|NCT00833833|9732439|FG000|Phase 1 (as of 01 April 2011)|Withdrawal by Subject|1
6112330|NCT00833833|9732440|FG001|Phase 1 (as of 01 April 2011)|Withdrawal by Subject|1
6112331|NCT00833833|9732441|FG002|Phase 1 (as of 01 April 2011)|Withdrawal by Subject|2
6112332|NCT00833833|9732442|FG003|Phase 1 (as of 01 April 2011)|Withdrawal by Subject|2
6112333|NCT00833833|9732443|FG004|Phase 1 (as of 01 April 2011)|Withdrawal by Subject|0
6112334|NCT00833833|9732444|FG005|Phase 1 (as of 01 April 2011)|Withdrawal by Subject|0
6112335|NCT00833833|9732439|FG000|Phase 1 (as of 01 April 2011)|Adverse Event|1
6112336|NCT00833833|9732440|FG001|Phase 1 (as of 01 April 2011)|Adverse Event|0
6112337|NCT00833833|9732441|FG002|Phase 1 (as of 01 April 2011)|Adverse Event|2
6112338|NCT00833833|9732442|FG003|Phase 1 (as of 01 April 2011)|Adverse Event|1
6112339|NCT00833833|9732443|FG004|Phase 1 (as of 01 April 2011)|Adverse Event|0
6112340|NCT00833833|9732444|FG005|Phase 1 (as of 01 April 2011)|Adverse Event|0
6112341|NCT00833833|9732439|FG000|Phase 1 (as of 01 April 2011)|Death|0
6112342|NCT00833833|9732440|FG001|Phase 1 (as of 01 April 2011)|Death|1
6112343|NCT00833833|9732441|FG002|Phase 1 (as of 01 April 2011)|Death|2
6112344|NCT00833833|9732442|FG003|Phase 1 (as of 01 April 2011)|Death|0
6112345|NCT00833833|9732443|FG004|Phase 1 (as of 01 April 2011)|Death|0
6112346|NCT00833833|9732444|FG005|Phase 1 (as of 01 April 2011)|Death|0
6112347|NCT00833833|9732439|FG000|Phase 1 (as of 01 April 2011)|Disease progression - unconfirmed|1
6112348|NCT00833833|9732440|FG001|Phase 1 (as of 01 April 2011)|Disease progression - unconfirmed|0
6112349|NCT00833833|9732441|FG002|Phase 1 (as of 01 April 2011)|Disease progression - unconfirmed|1
6112350|NCT00833833|9732442|FG003|Phase 1 (as of 01 April 2011)|Disease progression - unconfirmed|0
6112351|NCT00833833|9732443|FG004|Phase 1 (as of 01 April 2011)|Disease progression - unconfirmed|0
6112352|NCT00833833|9732444|FG005|Phase 1 (as of 01 April 2011)|Disease progression - unconfirmed|0
6112353|NCT00833833|9732439|FG000|Phase 1 (as of 01 April 2011)|Other|1
6112354|NCT00833833|9732440|FG001|Phase 1 (as of 01 April 2011)|Other|3
6112355|NCT00833833|9732441|FG002|Phase 1 (as of 01 April 2011)|Other|0
6112356|NCT00833833|9732442|FG003|Phase 1 (as of 01 April 2011)|Other|1
6207683|NCT01555762|9871766|FG000|Overall Study|75 years old or more ticked No|1
6207684|NCT01555762|9871766|FG000|Overall Study|Treatment with Bevacizumab ticked No|24
6207685|NCT01555762|9871766|FG000|Overall Study|Death linked to progression of disease|165
6207686|NCT01555762|9871766|FG000|Overall Study|Lost follow-up/moved house/changed team|35
6207687|NCT01555762|9871766|FG000|Overall Study|Investigator's decision|10
6207688|NCT01555762|9871766|FG000|Overall Study|Participant not wishing to continue|5
6207689|NCT01555762|9871766|FG000|Overall Study|Missing data|1
6207690|NCT01555762|9871766|FG000|Overall Study|Death linked to an adverse event|14
6207691|NCT01555931|9871772|FG000|Overall Study|Lost to Follow-up|2
6207692|NCT01555931|9871773|FG001|Overall Study|Lost to Follow-up|5
6207693|NCT01555983|9871788|FG000|Overall Study|Withdrawal by Subject|1
6207694|NCT01555983|9871789|FG001|Overall Study|Withdrawal by Subject|0
6207695|NCT01555983|9871790|FG002|Overall Study|Withdrawal by Subject|0
6207696|NCT01555983|9871791|FG003|Overall Study|Withdrawal by Subject|0
6112357|NCT00833833|9732443|FG004|Phase 1 (as of 01 April 2011)|Other|0
6112358|NCT00833833|9732444|FG005|Phase 1 (as of 01 April 2011)|Other|0
6112359|NCT00833833|9732439|FG000|Phase 2 (as of 01 April 2011)|Still active in study|0
6112360|NCT00833833|9732440|FG001|Phase 2 (as of 01 April 2011)|Still active in study|0
6112361|NCT00833833|9732441|FG002|Phase 2 (as of 01 April 2011)|Still active in study|0
6112362|NCT00833833|9732442|FG003|Phase 2 (as of 01 April 2011)|Still active in study|0
6112363|NCT00833833|9732443|FG004|Phase 2 (as of 01 April 2011)|Still active in study|23
6112364|NCT00833833|9732444|FG005|Phase 2 (as of 01 April 2011)|Still active in study|22
6112365|NCT00833833|9732439|FG000|Phase 2 (as of 01 April 2011)|Adverse Event|0
6112366|NCT00833833|9732440|FG001|Phase 2 (as of 01 April 2011)|Adverse Event|0
6112367|NCT00833833|9732441|FG002|Phase 2 (as of 01 April 2011)|Adverse Event|0
6112368|NCT00833833|9732442|FG003|Phase 2 (as of 01 April 2011)|Adverse Event|0
6112369|NCT00833833|9732443|FG004|Phase 2 (as of 01 April 2011)|Adverse Event|8
6112370|NCT00833833|9732444|FG005|Phase 2 (as of 01 April 2011)|Adverse Event|13
6112371|NCT00833833|9732439|FG000|Phase 2 (as of 01 April 2011)|Death|0
6112372|NCT00833833|9732440|FG001|Phase 2 (as of 01 April 2011)|Death|0
6112373|NCT00833833|9732441|FG002|Phase 2 (as of 01 April 2011)|Death|0
6112374|NCT00833833|9732442|FG003|Phase 2 (as of 01 April 2011)|Death|0
6112375|NCT00833833|9732443|FG004|Phase 2 (as of 01 April 2011)|Death|8
6112376|NCT00833833|9732444|FG005|Phase 2 (as of 01 April 2011)|Death|9
6112377|NCT00833833|9732439|FG000|Phase 2 (as of 01 April 2011)|Disease progression - unconfirmed|0
6112378|NCT00833833|9732440|FG001|Phase 2 (as of 01 April 2011)|Disease progression - unconfirmed|0
6112379|NCT00833833|9732441|FG002|Phase 2 (as of 01 April 2011)|Disease progression - unconfirmed|0
6112380|NCT00833833|9732442|FG003|Phase 2 (as of 01 April 2011)|Disease progression - unconfirmed|0
6112381|NCT00833833|9732443|FG004|Phase 2 (as of 01 April 2011)|Disease progression - unconfirmed|7
6112382|NCT00833833|9732444|FG005|Phase 2 (as of 01 April 2011)|Disease progression - unconfirmed|6
6112383|NCT00833833|9732439|FG000|Phase 2 (as of 01 April 2011)|Withdrawal by Subject|0
6112384|NCT00833833|9732440|FG001|Phase 2 (as of 01 April 2011)|Withdrawal by Subject|0
6112385|NCT00833833|9732441|FG002|Phase 2 (as of 01 April 2011)|Withdrawal by Subject|0
6112386|NCT00833833|9732442|FG003|Phase 2 (as of 01 April 2011)|Withdrawal by Subject|0
6112387|NCT00833833|9732443|FG004|Phase 2 (as of 01 April 2011)|Withdrawal by Subject|5
6112388|NCT00833833|9732444|FG005|Phase 2 (as of 01 April 2011)|Withdrawal by Subject|7
6112389|NCT00833833|9732439|FG000|Phase 2 (as of 01 April 2011)|Other|0
6112390|NCT00833833|9732440|FG001|Phase 2 (as of 01 April 2011)|Other|0
6112391|NCT00833833|9732441|FG002|Phase 2 (as of 01 April 2011)|Other|0
6112392|NCT00833833|9732442|FG003|Phase 2 (as of 01 April 2011)|Other|0
6112393|NCT00833833|9732443|FG004|Phase 2 (as of 01 April 2011)|Other|4
6112394|NCT00833833|9732444|FG005|Phase 2 (as of 01 April 2011)|Other|3
6112395|NCT00833833|9732439|FG000|Phase 2 (as of 01 April 2011)|Lost to Follow-up|0
6112396|NCT00833833|9732440|FG001|Phase 2 (as of 01 April 2011)|Lost to Follow-up|0
6112397|NCT00833833|9732441|FG002|Phase 2 (as of 01 April 2011)|Lost to Follow-up|0
6112398|NCT00833833|9732442|FG003|Phase 2 (as of 01 April 2011)|Lost to Follow-up|0
6112399|NCT00833833|9732443|FG004|Phase 2 (as of 01 April 2011)|Lost to Follow-up|0
6112400|NCT00833833|9732444|FG005|Phase 2 (as of 01 April 2011)|Lost to Follow-up|1
6112401|NCT00833898|9732466|FG000|Overall Study|Withdrawal by Subject|33
6112402|NCT00833898|9732467|FG001|Overall Study|Withdrawal by Subject|27
6112403|NCT00833898|9732466|FG000|Overall Study|Lost to Follow-up|7
6112404|NCT00833898|9732467|FG001|Overall Study|Lost to Follow-up|7
6112405|NCT00833898|9732466|FG000|Overall Study|Patient did not receive transplant|0
6112406|NCT00833898|9732467|FG001|Overall Study|Patient did not receive transplant|2
6112407|NCT00833911|9732473|FG000|Titration|Adverse Event|18
6112408|NCT00833911|9732473|FG000|Titration|Withdrawal by Subject|3
6112409|NCT00833911|9732473|FG000|Maintenance Phase I|Adverse Event|73
6112410|NCT00833911|9732473|FG000|Maintenance Phase I|Withdrawal by Subject|11
6112411|NCT00833911|9732473|FG000|Maintenance Phase I|Physician Decision|10
6112412|NCT00833911|9732473|FG000|Maintenance Phase I|Lack of Efficacy|4
6112413|NCT00833911|9732473|FG000|Maintenance Phase II|Adverse Event|6
6112414|NCT00833911|9732473|FG000|Maintenance Phase II|Physician Decision|2
6112415|NCT00833911|9732473|FG000|Maintenance Phase II|Withdrawal by Subject|1
6112416|NCT00833911|9732473|FG000|Maintenance Phase II|Lack of Efficacy|1
6112417|NCT00833924|9732481|FG000|Overall Study|Death|21
6112418|NCT00833924|9732481|FG000|Overall Study|Conversion|2
6112419|NCT00833924|9732481|FG000|Overall Study|Lost to Follow-up|2
6112420|NCT00833924|9732481|FG000|Overall Study|Withdrawal by Subject|13
6112421|NCT00833924|9732481|FG000|Overall Study|In study follow-up|71
6207697|NCT01555983|9871792|FG004|Overall Study|Withdrawal by Subject|1
6207698|NCT01555983|9871793|FG005|Overall Study|Withdrawal by Subject|1
6207699|NCT01556165|9871818|FG000|Overall Study|Adverse Event|5
6207700|NCT01556165|9871819|FG001|Overall Study|Adverse Event|3
6207701|NCT01556165|9871818|FG000|Overall Study|Protocol Violation|0
6207702|NCT01556165|9871819|FG001|Overall Study|Protocol Violation|3
6207703|NCT01556165|9871818|FG000|Overall Study|Withdrawal of Consent|7
6207704|NCT01556165|9871819|FG001|Overall Study|Withdrawal of Consent|1
6207705|NCT01556438|9871881|FG000|Overall Study|Adverse Event|4
6207706|NCT01556438|9871882|FG001|Overall Study|Adverse Event|2
6207707|NCT01556438|9871881|FG000|Overall Study|Sponsor Decision|0
6207708|NCT01556438|9871882|FG001|Overall Study|Sponsor Decision|2
6207709|NCT01556438|9871881|FG000|Overall Study|Progressive Disease|0
6112422|NCT00833976|9732485|FG000|Overall Study|Withdrawal by Subject|5
6112423|NCT00833976|9732485|FG000|Overall Study|Lost to Follow-up|4
6112424|NCT00833976|9732485|FG000|Overall Study|Did not meet eligibility criteria|41
6112425|NCT00833976|9732485|FG000|Overall Study|Physician Decision|1
6112426|NCT00833989|9732493|FG000|Overall Study|Physician Decision|0
6112427|NCT00833989|9732494|FG001|Overall Study|Physician Decision|0
6112428|NCT00833989|9732495|FG002|Overall Study|Physician Decision|0
6112429|NCT00833989|9732496|FG003|Overall Study|Physician Decision|1
6112430|NCT00833989|9732493|FG000|Overall Study|Withdrawal by Subject|3
6112431|NCT00833989|9732494|FG001|Overall Study|Withdrawal by Subject|0
6112432|NCT00833989|9732495|FG002|Overall Study|Withdrawal by Subject|1
6112433|NCT00833989|9732496|FG003|Overall Study|Withdrawal by Subject|1
6112434|NCT00834041|9732511|FG000|Overall Study|Withdrawal by Subject|1
6112435|NCT00834041|9732512|FG001|Overall Study|Withdrawal by Subject|0
6112436|NCT00834041|9732511|FG000|Overall Study|Lost to Follow-up|0
6112437|NCT00834041|9732512|FG001|Overall Study|Lost to Follow-up|1
6112438|NCT00834080|9732518|FG000|Overall Study|Adverse Event|7
6112439|NCT00834080|9732518|FG000|Overall Study|Lost to Follow-up|7
6112440|NCT00834080|9732518|FG000|Overall Study|Withdrawal by Subject|5
6112441|NCT00834080|9732518|FG000|Overall Study|Other - Pregnancy|1
6112442|NCT00834080|9732518|FG000|Overall Study|Other - False positive tests of the UDS|1
6112443|NCT00834080|9732518|FG000|Overall Study|Physician Decision|1
6112444|NCT00834080|9732518|FG000|Overall Study|Subject Relocated|1
6112445|NCT00834366|9732569|FG000|Treatment Period 1|Adverse Event|1
6112446|NCT00834366|9732570|FG001|Treatment Period 1|Adverse Event|1
6112447|NCT00834834|9732620|FG000|Overall Study|Withdrawal by Subject|4
6112448|NCT00834834|9732621|FG001|Overall Study|Withdrawal by Subject|3
6207710|NCT01556438|9871882|FG001|Overall Study|Progressive Disease|6
6207711|NCT01556438|9871881|FG000|Overall Study|Death|0
6207712|NCT01556438|9871882|FG001|Overall Study|Death|1
6207713|NCT01556763|9871951|FG000|Overall Study|Withdrawal by Subject|0
6207714|NCT01556763|9871952|FG001|Overall Study|Withdrawal by Subject|1
6207715|NCT01556763|9871953|FG002|Overall Study|Withdrawal by Subject|0
6207716|NCT01556932|9871967|FG000|Time Point 60 Minutes|Withdrawal by Subject|1
6207717|NCT01556932|9871968|FG001|Time Point 60 Minutes|Withdrawal by Subject|1
6207718|NCT01556997|9871976|FG000|Overall Study|Adverse Event|10
6207719|NCT01556997|9871977|FG001|Overall Study|Adverse Event|12
6207720|NCT01556997|9871978|FG002|Overall Study|Adverse Event|12
6207721|NCT01556997|9871976|FG000|Overall Study|Lost to Follow-up|6
6207722|NCT01556997|9871977|FG001|Overall Study|Lost to Follow-up|6
6207723|NCT01556997|9871978|FG002|Overall Study|Lost to Follow-up|4
6207724|NCT01556997|9871976|FG000|Overall Study|Physician Decision|1
6207725|NCT01556997|9871977|FG001|Overall Study|Physician Decision|1
6207726|NCT01556997|9871978|FG002|Overall Study|Physician Decision|1
6207727|NCT01556997|9871976|FG000|Overall Study|Withdrawal by Subject|7
6207728|NCT01556997|9871977|FG001|Overall Study|Withdrawal by Subject|6
6207729|NCT01556997|9871978|FG002|Overall Study|Withdrawal by Subject|8
6207730|NCT01556997|9871976|FG000|Overall Study|Other|2
6207731|NCT01556997|9871977|FG001|Overall Study|Other|3
6207732|NCT01556997|9871978|FG002|Overall Study|Other|7
6207733|NCT01557166|9871988|FG000|Overall Study|Adverse Event|20
6207734|NCT01557166|9871989|FG001|Overall Study|Adverse Event|6
6207735|NCT01557166|9871988|FG000|Overall Study|Lack of Efficacy|2
6207736|NCT01557166|9871989|FG001|Overall Study|Lack of Efficacy|1
6207737|NCT01557166|9871988|FG000|Overall Study|Protocol Violation|8
6207738|NCT01557166|9871989|FG001|Overall Study|Protocol Violation|5
6207739|NCT01557166|9871988|FG000|Overall Study|Withdrawn consent|12
6207740|NCT01557166|9871989|FG001|Overall Study|Withdrawn consent|20
6207741|NCT01557166|9871988|FG000|Overall Study|Target dose not tolerated|1
6207742|NCT01557166|9871989|FG001|Overall Study|Target dose not tolerated|0
6207743|NCT01557166|9871988|FG000|Overall Study|Psychiatric disorder|1
6207744|NCT01557166|9871989|FG001|Overall Study|Psychiatric disorder|0
6207745|NCT01557166|9871988|FG000|Overall Study|Unclassified|2
6207746|NCT01557166|9871989|FG001|Overall Study|Unclassified|5
6207747|NCT01557244|9872000|FG000|Active Comparator/Efficacy Phase:12Weeks|Adverse Event|2
6207748|NCT01557244|9872001|FG001|Active Comparator/Efficacy Phase:12Weeks|Adverse Event|0
6207749|NCT01557244|9872002|FG002|Active Comparator/Efficacy Phase:12Weeks|Adverse Event|0
6112449|NCT00834899|9732646|FG000|Overall Study|Withdrawal by Subject|1
6112450|NCT00834899|9732647|FG001|Overall Study|Withdrawal by Subject|1
6112451|NCT00834912|9732659|FG000|Treatment Period 1|Adverse Event|0
6112452|NCT00834912|9732660|FG001|Treatment Period 1|Adverse Event|1
6112453|NCT00834912|9732661|FG002|Treatment Period 1|Adverse Event|0
6112454|NCT00834912|9732662|FG003|Treatment Period 1|Adverse Event|1
6112455|NCT00834912|9732663|FG004|Treatment Period 1|Adverse Event|0
6112456|NCT00834912|9732664|FG005|Treatment Period 1|Adverse Event|0
6207750|NCT01557244|9872003|FG003|Active Comparator/Efficacy Phase:12Weeks|Adverse Event|0
6207751|NCT01557244|9872004|FG004|Active Comparator/Efficacy Phase:12Weeks|Adverse Event|0
6207752|NCT01557244|9872005|FG005|Active Comparator/Efficacy Phase:12Weeks|Adverse Event|2
6207753|NCT01557244|9872006|FG006|Active Comparator/Efficacy Phase:12Weeks|Adverse Event|0
6207754|NCT01557244|9872000|FG000|Active Comparator/Efficacy Phase:12Weeks|Protocol Violation|2
6207755|NCT01557244|9872001|FG001|Active Comparator/Efficacy Phase:12Weeks|Protocol Violation|0
6112457|NCT00834912|9732659|FG000|Treatment Period 2|Withdrawal by Subject|0
6207756|NCT01557244|9872002|FG002|Active Comparator/Efficacy Phase:12Weeks|Protocol Violation|1
6207757|NCT01557244|9872003|FG003|Active Comparator/Efficacy Phase:12Weeks|Protocol Violation|0
6207758|NCT01557244|9872004|FG004|Active Comparator/Efficacy Phase:12Weeks|Protocol Violation|0
6207759|NCT01557244|9872005|FG005|Active Comparator/Efficacy Phase:12Weeks|Protocol Violation|0
6207760|NCT01557244|9872006|FG006|Active Comparator/Efficacy Phase:12Weeks|Protocol Violation|0
6207761|NCT01557244|9872000|FG000|Active Comparator/Efficacy Phase:12Weeks|Lost to Follow-up|1
6207762|NCT01557244|9872001|FG001|Active Comparator/Efficacy Phase:12Weeks|Lost to Follow-up|0
6207763|NCT01557244|9872002|FG002|Active Comparator/Efficacy Phase:12Weeks|Lost to Follow-up|0
6207764|NCT01557244|9872003|FG003|Active Comparator/Efficacy Phase:12Weeks|Lost to Follow-up|0
6207765|NCT01557244|9872004|FG004|Active Comparator/Efficacy Phase:12Weeks|Lost to Follow-up|0
6207766|NCT01557244|9872005|FG005|Active Comparator/Efficacy Phase:12Weeks|Lost to Follow-up|0
6207767|NCT01557244|9872006|FG006|Active Comparator/Efficacy Phase:12Weeks|Lost to Follow-up|0
6207768|NCT01557244|9872000|FG000|Active Comparator/Efficacy Phase:12Weeks|Withdrawal By Parent/Guardian|2
6207769|NCT01557244|9872001|FG001|Active Comparator/Efficacy Phase:12Weeks|Withdrawal By Parent/Guardian|0
6207770|NCT01557244|9872002|FG002|Active Comparator/Efficacy Phase:12Weeks|Withdrawal By Parent/Guardian|0
6207771|NCT01557244|9872003|FG003|Active Comparator/Efficacy Phase:12Weeks|Withdrawal By Parent/Guardian|0
6207772|NCT01557244|9872004|FG004|Active Comparator/Efficacy Phase:12Weeks|Withdrawal By Parent/Guardian|0
6207773|NCT01557244|9872005|FG005|Active Comparator/Efficacy Phase:12Weeks|Withdrawal By Parent/Guardian|3
6207774|NCT01557244|9872006|FG006|Active Comparator/Efficacy Phase:12Weeks|Withdrawal By Parent/Guardian|0
6207775|NCT01557244|9872000|FG000|Active Comparator/Efficacy Phase:12Weeks|Medication Error Without Associated AEs|0
6207776|NCT01557244|9872001|FG001|Active Comparator/Efficacy Phase:12Weeks|Medication Error Without Associated AEs|1
6207777|NCT01557244|9872002|FG002|Active Comparator/Efficacy Phase:12Weeks|Medication Error Without Associated AEs|0
6207778|NCT01557244|9872003|FG003|Active Comparator/Efficacy Phase:12Weeks|Medication Error Without Associated AEs|0
6207779|NCT01557244|9872004|FG004|Active Comparator/Efficacy Phase:12Weeks|Medication Error Without Associated AEs|0
6207780|NCT01557244|9872005|FG005|Active Comparator/Efficacy Phase:12Weeks|Medication Error Without Associated AEs|0
6207781|NCT01557244|9872006|FG006|Active Comparator/Efficacy Phase:12Weeks|Medication Error Without Associated AEs|0
6207782|NCT01557244|9872000|FG000|Active Comparator/Efficacy Phase:12Weeks|Insufficient Clinical Response|0
6207783|NCT01557244|9872001|FG001|Active Comparator/Efficacy Phase:12Weeks|Insufficient Clinical Response|0
6207784|NCT01557244|9872002|FG002|Active Comparator/Efficacy Phase:12Weeks|Insufficient Clinical Response|0
6207785|NCT01557244|9872003|FG003|Active Comparator/Efficacy Phase:12Weeks|Insufficient Clinical Response|0
6207786|NCT01557244|9872004|FG004|Active Comparator/Efficacy Phase:12Weeks|Insufficient Clinical Response|0
6207787|NCT01557244|9872005|FG005|Active Comparator/Efficacy Phase:12Weeks|Insufficient Clinical Response|1
6207788|NCT01557244|9872006|FG006|Active Comparator/Efficacy Phase:12Weeks|Insufficient Clinical Response|1
6207789|NCT01557244|9872000|FG000|Active Comparator/Efficacy Phase:12Weeks|Failure to Meet Randomization Criteria|0
6207790|NCT01557244|9872001|FG001|Active Comparator/Efficacy Phase:12Weeks|Failure to Meet Randomization Criteria|1
6285982|NCT02343406|9998824|FG001|Overall Study|Adverse Event|8
6285983|NCT02343406|9998825|FG002|Overall Study|Adverse Event|6
6285984|NCT02343406|9998826|FG003|Overall Study|Adverse Event|3
6285985|NCT02343406|9998827|FG004|Overall Study|Adverse Event|0
6285986|NCT02343406|9998823|FG000|Overall Study|Withdrawal by Subject|6
6285987|NCT02343406|9998824|FG001|Overall Study|Withdrawal by Subject|4
6285988|NCT02343406|9998825|FG002|Overall Study|Withdrawal by Subject|8
6285989|NCT02343406|9998826|FG003|Overall Study|Withdrawal by Subject|3
6285990|NCT02343406|9998827|FG004|Overall Study|Withdrawal by Subject|0
6285991|NCT02343406|9998823|FG000|Overall Study|Death|2
6285992|NCT02343406|9998824|FG001|Overall Study|Death|1
6285993|NCT02343406|9998825|FG002|Overall Study|Death|0
6285994|NCT02343406|9998826|FG003|Overall Study|Death|0
6285995|NCT02343406|9998827|FG004|Overall Study|Death|0
6285996|NCT02343406|9998823|FG000|Overall Study|Start of a new anti-cancer treatment|0
6285997|NCT02343406|9998824|FG001|Overall Study|Start of a new anti-cancer treatment|1
6285998|NCT02343406|9998825|FG002|Overall Study|Start of a new anti-cancer treatment|0
6285999|NCT02343406|9998826|FG003|Overall Study|Start of a new anti-cancer treatment|1
6286000|NCT02343406|9998827|FG004|Overall Study|Start of a new anti-cancer treatment|0
6286001|NCT02343406|9998823|FG000|Overall Study|Other primary malignancy|0
6286002|NCT02343406|9998824|FG001|Overall Study|Other primary malignancy|1
6286003|NCT02343406|9998825|FG002|Overall Study|Other primary malignancy|0
6286004|NCT02343406|9998826|FG003|Overall Study|Other primary malignancy|0
6286005|NCT02343406|9998827|FG004|Overall Study|Other primary malignancy|0
6286006|NCT02343406|9998823|FG000|Overall Study|Other, not specified|2
6286007|NCT02343406|9998824|FG001|Overall Study|Other, not specified|1
6286008|NCT02343406|9998825|FG002|Overall Study|Other, not specified|1
6286009|NCT02343406|9998826|FG003|Overall Study|Other, not specified|4
6286010|NCT02343406|9998827|FG004|Overall Study|Other, not specified|0
6286011|NCT02343458|9998842|FG000|Overall Study|Adverse Event|15
6286012|NCT02343458|9998843|FG001|Overall Study|Adverse Event|14
6286013|NCT02343458|9998844|FG002|Overall Study|Adverse Event|15
6286014|NCT02343458|9998845|FG003|Overall Study|Adverse Event|3
6286015|NCT02343458|9998842|FG000|Overall Study|Lack of Efficacy|3
6286016|NCT02343458|9998843|FG001|Overall Study|Lack of Efficacy|8
6112458|NCT00834912|9732660|FG001|Treatment Period 2|Withdrawal by Subject|0
6112459|NCT00834912|9732661|FG002|Treatment Period 2|Withdrawal by Subject|1
6112460|NCT00834912|9732662|FG003|Treatment Period 2|Withdrawal by Subject|0
6112461|NCT00834912|9732663|FG004|Treatment Period 2|Withdrawal by Subject|1
6112462|NCT00834912|9732664|FG005|Treatment Period 2|Withdrawal by Subject|0
6112463|NCT00835068|9732683|FG000|Overall Study|Death|1
6112464|NCT00835068|9732684|FG001|Overall Study|Death|0
6112465|NCT00835068|9732683|FG000|Overall Study|Adverse Event|0
6112466|NCT00835068|9732684|FG001|Overall Study|Adverse Event|1
6112467|NCT00835068|9732683|FG000|Overall Study|Other|8
6112468|NCT00835068|9732684|FG001|Overall Study|Other|0
6112469|NCT00835068|9732683|FG000|Overall Study|Withdrawal by Subject|1
6112470|NCT00835068|9732684|FG001|Overall Study|Withdrawal by Subject|0
6112471|NCT00835120|9732690|FG000|Overall Study|Lack of Efficacy|1
6112472|NCT00835120|9732690|FG000|Overall Study|Lost to Follow-up|3
6112473|NCT00835120|9732690|FG000|Overall Study|Adverse Event|2
6112474|NCT00835120|9732690|FG000|Overall Study|Withdrawal by Subject|2
6112475|NCT00835237|9732733|FG000|Overall Study|Lost to Follow-up|4
6112476|NCT00835237|9732734|FG001|Overall Study|Lost to Follow-up|0
6112477|NCT00835237|9732733|FG000|Overall Study|Withdrawal by Subject|2
6112478|NCT00835237|9732734|FG001|Overall Study|Withdrawal by Subject|0
6112479|NCT00835341|9732742|FG000|Overall Study|Lost to Follow-up|3
6112480|NCT00835341|9732743|FG001|Overall Study|Lost to Follow-up|12
6112481|NCT00835380|9732749|FG000|Overall Study|Withdrawal by Subject|2
6112482|NCT00835731|9732768|FG000|Overall Study|Withdrawal by Subject|1
6112483|NCT00835731|9732769|FG001|Overall Study|Withdrawal by Subject|0
6112484|NCT00835731|9732768|FG000|Overall Study|Physician Decision|1
6112485|NCT00835731|9732769|FG001|Overall Study|Physician Decision|1
6112486|NCT00835770|9732777|FG000|Overall Study|MS Relapse|17
6112487|NCT00835770|9732778|FG001|Overall Study|MS Relapse|23
6112488|NCT00835770|9732777|FG000|Overall Study|MS Progression|14
6112489|NCT00835770|9732778|FG001|Overall Study|MS Progression|9
6112490|NCT00835770|9732777|FG000|Overall Study|Adverse Event|113
6112491|NCT00835770|9732778|FG001|Overall Study|Adverse Event|124
6112492|NCT00835770|9732777|FG000|Overall Study|Lost to Follow-up|22
6112493|NCT00835770|9732778|FG001|Overall Study|Lost to Follow-up|19
6112494|NCT00835770|9732777|FG000|Overall Study|Consent Withdrawn|144
6112495|NCT00835770|9732778|FG001|Overall Study|Consent Withdrawn|156
6112496|NCT00835770|9732777|FG000|Overall Study|Investigator Decision|42
6112497|NCT00835770|9732778|FG001|Overall Study|Investigator Decision|42
6112498|NCT00835770|9732777|FG000|Overall Study|Participant Non-Compliance|11
6112499|NCT00835770|9732778|FG001|Overall Study|Participant Non-Compliance|9
6112500|NCT00835770|9732777|FG000|Overall Study|Death|4
6112501|NCT00835770|9732778|FG001|Overall Study|Death|6
6112502|NCT00835770|9732777|FG000|Overall Study|Other|115
6112503|NCT00835770|9732778|FG001|Overall Study|Other|104
6112504|NCT00835770|9732777|FG000|Overall Study|Other|2
6112505|NCT00835770|9732778|FG001|Overall Study|Other|1
6112506|NCT00835978|9732821|FG000|Overall Study|Death|33
6112507|NCT00835978|9732822|FG001|Overall Study|Death|40
6112508|NCT00835978|9732823|FG002|Overall Study|Death|49
6112509|NCT00835978|9732824|FG003|Overall Study|Death|4
6112510|NCT00835978|9732821|FG000|Overall Study|Lost to Follow-up|3
6112511|NCT00835978|9732822|FG001|Overall Study|Lost to Follow-up|4
6112512|NCT00835978|9732823|FG002|Overall Study|Lost to Follow-up|2
6112513|NCT00835978|9732824|FG003|Overall Study|Lost to Follow-up|1
6112514|NCT00835978|9732821|FG000|Overall Study|Other|5
6112515|NCT00835978|9732822|FG001|Overall Study|Other|1
6112516|NCT00835978|9732823|FG002|Overall Study|Other|8
6112517|NCT00835978|9732824|FG003|Overall Study|Other|0
6207791|NCT01557244|9872002|FG002|Active Comparator/Efficacy Phase:12Weeks|Failure to Meet Randomization Criteria|1
6207792|NCT01557244|9872003|FG003|Active Comparator/Efficacy Phase:12Weeks|Failure to Meet Randomization Criteria|0
6207793|NCT01557244|9872004|FG004|Active Comparator/Efficacy Phase:12Weeks|Failure to Meet Randomization Criteria|0
6207794|NCT01557244|9872005|FG005|Active Comparator/Efficacy Phase:12Weeks|Failure to Meet Randomization Criteria|1
6207795|NCT01557244|9872006|FG006|Active Comparator/Efficacy Phase:12Weeks|Failure to Meet Randomization Criteria|0
6207796|NCT01557244|9872000|FG000|Active Comparator/Efficacy Phase:12Weeks|Other|2
6207797|NCT01557244|9872001|FG001|Active Comparator/Efficacy Phase:12Weeks|Other|0
6207798|NCT01557244|9872002|FG002|Active Comparator/Efficacy Phase:12Weeks|Other|2
6207799|NCT01557244|9872003|FG003|Active Comparator/Efficacy Phase:12Weeks|Other|0
6207800|NCT01557244|9872004|FG004|Active Comparator/Efficacy Phase:12Weeks|Other|0
6286017|NCT02343458|9998844|FG002|Overall Study|Lack of Efficacy|4
6286018|NCT02343458|9998845|FG003|Overall Study|Lack of Efficacy|8
6286019|NCT02343458|9998842|FG000|Overall Study|Withdrawal by Subject|18
6286020|NCT02343458|9998843|FG001|Overall Study|Withdrawal by Subject|17
6286021|NCT02343458|9998844|FG002|Overall Study|Withdrawal by Subject|23
6112518|NCT00835978|9732821|FG000|Overall Study|Objective progression or relapse|2
6112519|NCT00835978|9732822|FG001|Overall Study|Objective progression or relapse|0
6112520|NCT00835978|9732823|FG002|Overall Study|Objective progression or relapse|1
6112521|NCT00835978|9732824|FG003|Overall Study|Objective progression or relapse|0
6112522|NCT00835978|9732821|FG000|Overall Study|Adverse Event|1
6112523|NCT00835978|9732822|FG001|Overall Study|Adverse Event|0
6112524|NCT00835978|9732823|FG002|Overall Study|Adverse Event|1
6112525|NCT00835978|9732824|FG003|Overall Study|Adverse Event|0
6112526|NCT00835978|9732821|FG000|Overall Study|Withdrawal by Subject|0
6112527|NCT00835978|9732822|FG001|Overall Study|Withdrawal by Subject|3
6112528|NCT00835978|9732823|FG002|Overall Study|Withdrawal by Subject|0
6112529|NCT00835978|9732824|FG003|Overall Study|Withdrawal by Subject|5
6112530|NCT00835978|9732821|FG000|Overall Study|Study terminated by sponsor|12
6112531|NCT00835978|9732822|FG001|Overall Study|Study terminated by sponsor|8
6112532|NCT00835978|9732823|FG002|Overall Study|Study terminated by sponsor|30
6112533|NCT00835978|9732824|FG003|Overall Study|Study terminated by sponsor|0
6112534|NCT00836095|9732845|FG000|Overall Study|Physician Decision|0
6112535|NCT00836095|9732846|FG001|Overall Study|Physician Decision|3
6112536|NCT00836186|9732852|FG000|Overall Study|Blood could not be drawn|1
6112537|NCT00836277|9732857|FG000|Overall Study|Not evaluable for response|6
6112538|NCT00836498|9732898|FG000|Overall Study|Adverse Event|1
6112539|NCT00836498|9732899|FG001|Overall Study|Adverse Event|0
6112540|NCT00836498|9732898|FG000|Overall Study|Lost to Follow-up|1
6112541|NCT00836498|9732899|FG001|Overall Study|Lost to Follow-up|0
6112542|NCT00836498|9732898|FG000|Overall Study|Withdrawal by Subject|2
6112543|NCT00836498|9732899|FG001|Overall Study|Withdrawal by Subject|1
6112544|NCT00836589|9732906|FG000|Overall Study|Lost to Follow-up|246
6112545|NCT00836589|9732906|FG000|Overall Study|Death|429
6112546|NCT00836589|9732906|FG000|Overall Study|Withdrawal by Subject or Physician|591
6112547|NCT00836693|9732928|FG000|Overall Study|Adverse Event|4
6112548|NCT00836693|9732929|FG001|Overall Study|Adverse Event|1
6112549|NCT00836693|9732928|FG000|Overall Study|Sponsor Decision|0
6112550|NCT00836693|9732929|FG001|Overall Study|Sponsor Decision|1
6112551|NCT00836693|9732928|FG000|Overall Study|Physician Decision|2
6112552|NCT00836693|9732929|FG001|Overall Study|Physician Decision|0
6112553|NCT00836693|9732928|FG000|Overall Study|Withdrawal by Subject|9
6112554|NCT00836693|9732929|FG001|Overall Study|Withdrawal by Subject|4
6112555|NCT00836693|9732928|FG000|Overall Study|Protocol Violation|1
6112556|NCT00836693|9732929|FG001|Overall Study|Protocol Violation|0
6112557|NCT00836693|9732928|FG000|Overall Study|Lost to Follow-up|1
6112558|NCT00836693|9732929|FG001|Overall Study|Lost to Follow-up|0
6112559|NCT00836745|9732939|FG000|Overall Study|Death|2
6112560|NCT00836745|9732939|FG000|Overall Study|Lost to Follow-up|10
6112561|NCT00836745|9732939|FG000|Overall Study|Adverse Event|3
6112562|NCT00836745|9732939|FG000|Overall Study|Objective progression or relapse|4
6112563|NCT00836745|9732939|FG000|Overall Study|Other|2
6207801|NCT01557244|9872005|FG005|Active Comparator/Efficacy Phase:12Weeks|Other|0
6207802|NCT01557244|9872006|FG006|Active Comparator/Efficacy Phase:12Weeks|Other|0
6207803|NCT01557244|9872000|FG000|Safety Extension Phase: 12 Weeks|Adverse Event|1
6207804|NCT01557244|9872001|FG001|Safety Extension Phase: 12 Weeks|Adverse Event|1
6207805|NCT01557244|9872002|FG002|Safety Extension Phase: 12 Weeks|Adverse Event|0
6207806|NCT01557244|9872003|FG003|Safety Extension Phase: 12 Weeks|Adverse Event|0
6207807|NCT01557244|9872004|FG004|Safety Extension Phase: 12 Weeks|Adverse Event|0
6286022|NCT02343458|9998845|FG003|Overall Study|Withdrawal by Subject|14
6286023|NCT02343458|9998842|FG000|Overall Study|Physician Decision|1
6286024|NCT02343458|9998843|FG001|Overall Study|Physician Decision|4
6286025|NCT02343458|9998844|FG002|Overall Study|Physician Decision|2
6286026|NCT02343458|9998845|FG003|Overall Study|Physician Decision|2
6286027|NCT02343458|9998842|FG000|Overall Study|Lost to Follow-up|5
6286028|NCT02343458|9998843|FG001|Overall Study|Lost to Follow-up|5
6286029|NCT02343458|9998844|FG002|Overall Study|Lost to Follow-up|3
6286030|NCT02343458|9998845|FG003|Overall Study|Lost to Follow-up|1
6286031|NCT02343458|9998842|FG000|Overall Study|Protocol Violation|2
6286032|NCT02343458|9998843|FG001|Overall Study|Protocol Violation|5
6286033|NCT02343458|9998844|FG002|Overall Study|Protocol Violation|2
6286034|NCT02343458|9998845|FG003|Overall Study|Protocol Violation|2
6286035|NCT02343458|9998842|FG000|Overall Study|Protocol Specified Criteria|17
6286036|NCT02343458|9998843|FG001|Overall Study|Protocol Specified Criteria|13
6286037|NCT02343458|9998844|FG002|Overall Study|Protocol Specified Criteria|14
6286038|NCT02343458|9998845|FG003|Overall Study|Protocol Specified Criteria|8
6286039|NCT02343939|9998882|FG000|Overall Study|Death|0
6286040|NCT02343939|9998883|FG001|Overall Study|Death|15
6286041|NCT02343939|9998884|FG002|Overall Study|Death|4
6286042|NCT02343939|9998885|FG003|Overall Study|Death|2
6286043|NCT02343939|9998886|FG004|Overall Study|Death|5
6286044|NCT02343939|9998887|FG005|Overall Study|Death|11
6286045|NCT02343939|9998888|FG006|Overall Study|Death|8
6286046|NCT02343939|9998889|FG007|Overall Study|Death|22
6286047|NCT02343939|9998890|FG008|Overall Study|Death|1
6286048|NCT02343939|9998882|FG000|Overall Study|Study terminated by sponsor|0
6286049|NCT02343939|9998883|FG001|Overall Study|Study terminated by sponsor|27
6286050|NCT02343939|9998884|FG002|Overall Study|Study terminated by sponsor|0
6286051|NCT02343939|9998885|FG003|Overall Study|Study terminated by sponsor|1
6112564|NCT00836810|9732951|FG000|Overall Study|New diagnosis|1
6112565|NCT00836810|9732952|FG001|Overall Study|New diagnosis|0
6286052|NCT02343939|9998886|FG004|Overall Study|Study terminated by sponsor|1
6286053|NCT02343939|9998887|FG005|Overall Study|Study terminated by sponsor|5
6286054|NCT02343939|9998888|FG006|Overall Study|Study terminated by sponsor|3
6286055|NCT02343939|9998889|FG007|Overall Study|Study terminated by sponsor|4
6286056|NCT02343939|9998890|FG008|Overall Study|Study terminated by sponsor|0
6112566|NCT00836875|9732960|FG000|Overall Study|Death|3
6112567|NCT00836875|9732961|FG001|Overall Study|Death|2
6112568|NCT00836875|9732960|FG000|Overall Study|Withdrawal by Subject|0
6112569|NCT00836875|9732961|FG001|Overall Study|Withdrawal by Subject|1
6112570|NCT00836927|9732989|FG000|Overall Study|Progressive disease|2
6112571|NCT00836927|9732990|FG001|Overall Study|Progressive disease|0
6112572|NCT00836927|9732991|FG002|Overall Study|Progressive disease|0
6112573|NCT00836927|9732992|FG003|Overall Study|Progressive disease|1
6112574|NCT00836927|9732993|FG004|Overall Study|Progressive disease|1
6112575|NCT00836927|9732989|FG000|Overall Study|Withdrawal by Subject|1
6112576|NCT00836927|9732990|FG001|Overall Study|Withdrawal by Subject|0
6207808|NCT01557244|9872005|FG005|Safety Extension Phase: 12 Weeks|Adverse Event|1
6207809|NCT01557244|9872006|FG006|Safety Extension Phase: 12 Weeks|Adverse Event|0
6207810|NCT01557244|9872000|FG000|Safety Extension Phase: 12 Weeks|Withdrawal By Parent/Guardian|1
6207811|NCT01557244|9872001|FG001|Safety Extension Phase: 12 Weeks|Withdrawal By Parent/Guardian|1
6207812|NCT01557244|9872002|FG002|Safety Extension Phase: 12 Weeks|Withdrawal By Parent/Guardian|0
6207813|NCT01557244|9872003|FG003|Safety Extension Phase: 12 Weeks|Withdrawal By Parent/Guardian|0
6207814|NCT01557244|9872004|FG004|Safety Extension Phase: 12 Weeks|Withdrawal By Parent/Guardian|0
6207815|NCT01557244|9872005|FG005|Safety Extension Phase: 12 Weeks|Withdrawal By Parent/Guardian|0
6207816|NCT01557244|9872006|FG006|Safety Extension Phase: 12 Weeks|Withdrawal By Parent/Guardian|0
6207817|NCT01557244|9872000|FG000|Safety Extension Phase: 12 Weeks|Medication Error Without Associated AEs|0
6207818|NCT01557244|9872001|FG001|Safety Extension Phase: 12 Weeks|Medication Error Without Associated AEs|0
6207819|NCT01557244|9872002|FG002|Safety Extension Phase: 12 Weeks|Medication Error Without Associated AEs|0
6207820|NCT01557244|9872003|FG003|Safety Extension Phase: 12 Weeks|Medication Error Without Associated AEs|1
6207821|NCT01557244|9872004|FG004|Safety Extension Phase: 12 Weeks|Medication Error Without Associated AEs|0
6207822|NCT01557244|9872005|FG005|Safety Extension Phase: 12 Weeks|Medication Error Without Associated AEs|0
6207823|NCT01557244|9872006|FG006|Safety Extension Phase: 12 Weeks|Medication Error Without Associated AEs|0
6207824|NCT01557244|9872000|FG000|Safety Extension Phase: 12 Weeks|Insufficient Clinical Response|1
6207825|NCT01557244|9872001|FG001|Safety Extension Phase: 12 Weeks|Insufficient Clinical Response|2
6207826|NCT01557244|9872002|FG002|Safety Extension Phase: 12 Weeks|Insufficient Clinical Response|0
6207827|NCT01557244|9872003|FG003|Safety Extension Phase: 12 Weeks|Insufficient Clinical Response|0
6207828|NCT01557244|9872004|FG004|Safety Extension Phase: 12 Weeks|Insufficient Clinical Response|0
6207829|NCT01557244|9872005|FG005|Safety Extension Phase: 12 Weeks|Insufficient Clinical Response|0
6207830|NCT01557244|9872006|FG006|Safety Extension Phase: 12 Weeks|Insufficient Clinical Response|0
6207831|NCT01557283|9872034|FG000|Overall Study|Lost to Follow-up|7
6207832|NCT01557283|9872034|FG000|Overall Study|Non-responder|19
6207833|NCT01557283|9872034|FG000|Overall Study|Adverse Event|7
6207834|NCT01557283|9872034|FG000|Overall Study|Lack of Efficacy|1
6207835|NCT01557283|9872034|FG000|Overall Study|Non-compliance|1
6207836|NCT01557283|9872034|FG000|Overall Study|Withdrawal by Subject|1
6207837|NCT01557283|9872034|FG000|Overall Study|Participant's weight too high for dose|1
6207838|NCT01557283|9872034|FG000|Overall Study|Worsening of psoriasis|1
6207839|NCT01557283|9872034|FG000|Overall Study|Other|6
6207840|NCT01557348|9872049|FG000|Overall Study|Adverse Event|6
6207841|NCT01557348|9872050|FG001|Overall Study|Adverse Event|16
6207842|NCT01557348|9872049|FG000|Overall Study|Infusion reaction event|5
6207843|NCT01557348|9872050|FG001|Overall Study|Infusion reaction event|5
6207844|NCT01557348|9872049|FG000|Overall Study|Death|7
6207845|NCT01557348|9872050|FG001|Overall Study|Death|4
6207846|NCT01557348|9872049|FG000|Overall Study|Insufficient Therapeutic Response|13
6207847|NCT01557348|9872050|FG001|Overall Study|Insufficient Therapeutic Response|28
6207848|NCT01557348|9872049|FG000|Overall Study|Withdrawal by Subject|5
6207849|NCT01557348|9872050|FG001|Overall Study|Withdrawal by Subject|4
6207850|NCT01557348|9872049|FG000|Overall Study|Lost to Follow-up|26
6207851|NCT01557348|9872050|FG001|Overall Study|Lost to Follow-up|22
6207852|NCT01557348|9872049|FG000|Overall Study|Administrative|18
6207853|NCT01557348|9872050|FG001|Overall Study|Administrative|11
6207854|NCT01557400|9872057|FG000|Overall Study|Transitioned to Commercial Drug Product|40
6207855|NCT01557400|9872057|FG000|Overall Study|Adverse Event|3
6207856|NCT01557400|9872057|FG000|Overall Study|Lost to Follow-up|5
6207857|NCT01557400|9872057|FG000|Overall Study|Withdrawal by Subject|9
6207858|NCT01557504|9872068|FG000|Overall Study|Physician Decision|1
6207859|NCT01557504|9872069|FG001|Overall Study|Physician Decision|0
6207860|NCT01557517|9872083|FG000|Overall Study|Death|1
6207861|NCT01557517|9872084|FG001|Overall Study|Death|0
6207862|NCT01557517|9872083|FG000|Overall Study|Refused further treatment|0
6207863|NCT01557517|9872084|FG001|Overall Study|Refused further treatment|2
6207864|NCT01557517|9872083|FG000|Overall Study|Adverse Event|0
6207865|NCT01557517|9872084|FG001|Overall Study|Adverse Event|2
6207866|NCT01557517|9872083|FG000|Overall Study|Pt declined before treatment started|1
6207867|NCT01557517|9872084|FG001|Overall Study|Pt declined before treatment started|0
6207868|NCT01557569|9872099|FG000|Overall Study|Adverse Event|2
6207869|NCT01557569|9872100|FG001|Overall Study|Adverse Event|0
6207870|NCT01557569|9872099|FG000|Overall Study|high blood pressure|0
6207871|NCT01557569|9872100|FG001|Overall Study|high blood pressure|1
6207872|NCT01557569|9872099|FG000|Overall Study|Withdrawal by Subject|3
6207873|NCT01557569|9872100|FG001|Overall Study|Withdrawal by Subject|5
6207874|NCT01557569|9872099|FG000|Overall Study|noncompliance with rules of residential|0
6207875|NCT01557569|9872100|FG001|Overall Study|noncompliance with rules of residential|1
6207876|NCT01557582|9872106|FG000|Overall Study|Protocol Violation|4
6207877|NCT01557582|9872106|FG000|Overall Study|Operator error|2
6112577|NCT00836927|9732991|FG002|Overall Study|Withdrawal by Subject|0
6112578|NCT00836927|9732992|FG003|Overall Study|Withdrawal by Subject|0
6112579|NCT00836927|9732993|FG004|Overall Study|Withdrawal by Subject|0
6112580|NCT00836953|9733007|FG000|Overall Study|Withdrawal by Subject|1
6112581|NCT00836953|9733007|FG000|Overall Study|Lost to Follow-up|1
6112582|NCT00837096|9733017|FG000|Overall Study|Physician Decision|1
6112583|NCT00837096|9733018|FG001|Overall Study|Physician Decision|1
6112584|NCT00837096|9733017|FG000|Overall Study|Not reported|9
6112585|NCT00837096|9733018|FG001|Overall Study|Not reported|8
6112586|NCT00837148|9733024|FG000|Overall Study|Adverse Event|1
6112587|NCT00837148|9733024|FG000|Overall Study|Death|1
6112588|NCT00837161|9733028|FG000|Overall Study|refused hysterectomy|2
6112589|NCT00837213|9733038|FG000|Overall Study|Lost to Follow-up|3
6112590|NCT00837213|9733039|FG001|Overall Study|Lost to Follow-up|2
6112591|NCT00837213|9733038|FG000|Overall Study|Withdrawal by Subject|2
6112592|NCT00837213|9733039|FG001|Overall Study|Withdrawal by Subject|2
6112593|NCT00837213|9733038|FG000|Overall Study|not stated|1
6112594|NCT00837213|9733039|FG001|Overall Study|not stated|1
6112595|NCT00837330|9733051|FG000|Overall Study|Lost to Follow-up|1
6112596|NCT00837330|9733052|FG001|Overall Study|Lost to Follow-up|3
6112597|NCT00837434|9733060|FG000|Overall Study|Physician Decision|3
6112598|NCT00837434|9733061|FG001|Overall Study|Physician Decision|0
6112599|NCT00837434|9733060|FG000|Overall Study|Lost to Follow-up|1
6112600|NCT00837434|9733061|FG001|Overall Study|Lost to Follow-up|1
6112601|NCT00837434|9733060|FG000|Overall Study|Withdrawn by sponsor/regulatory agency|1
6112602|NCT00837434|9733061|FG001|Overall Study|Withdrawn by sponsor/regulatory agency|0
6207878|NCT01557842|9872136|FG000|Overall Study|Lost to Follow-up|0
6207879|NCT01557842|9872137|FG001|Overall Study|Lost to Follow-up|1
6207880|NCT01557842|9872136|FG000|Overall Study|Death|1
6207881|NCT01557842|9872137|FG001|Overall Study|Death|0
6207882|NCT01557842|9872136|FG000|Overall Study|Lack of Efficacy|0
6207883|NCT01557842|9872137|FG001|Overall Study|Lack of Efficacy|1
6207884|NCT01557842|9872136|FG000|Overall Study|Not Meet Inclusion/Exclusion Criteria|3
6207885|NCT01557842|9872137|FG001|Overall Study|Not Meet Inclusion/Exclusion Criteria|0
6207886|NCT01557842|9872136|FG000|Overall Study|Study Terminated by Sponsor|3
6207887|NCT01557842|9872137|FG001|Overall Study|Study Terminated by Sponsor|4
6207888|NCT01557842|9872136|FG000|Overall Study|Not Ablated|2
6207889|NCT01557842|9872137|FG001|Overall Study|Not Ablated|0
6207890|NCT01557920|9872162|FG000|Overall Study|Withdrawal by Subject|2
6207891|NCT01557920|9872163|FG001|Overall Study|Withdrawal by Subject|3
6207892|NCT01557920|9872162|FG000|Overall Study|Lack of Efficacy|1
6207893|NCT01557920|9872163|FG001|Overall Study|Lack of Efficacy|0
6207894|NCT01557946|9872198|FG000|Overall Study|Adverse Event|3
6207895|NCT01557946|9872199|FG001|Overall Study|Adverse Event|0
6207896|NCT01558089|9872230|FG000|Overall Study|Adverse Event|1
6207897|NCT01558089|9872230|FG000|Overall Study|Lack of Efficacy|1
6207898|NCT01558089|9872230|FG000|Overall Study|Lost to Follow-up|5
6207899|NCT01558089|9872230|FG000|Overall Study|Withdrawal by Subject|6
6207900|NCT01558271|9872241|FG000|Overall Study|Adverse Event|6
6207901|NCT01558271|9872242|FG001|Overall Study|Adverse Event|3
6207902|NCT01558271|9872243|FG002|Overall Study|Adverse Event|4
6207903|NCT01558271|9872241|FG000|Overall Study|Lost to Follow-up|1
6207904|NCT01558271|9872242|FG001|Overall Study|Lost to Follow-up|0
6207905|NCT01558271|9872243|FG002|Overall Study|Lost to Follow-up|0
6207906|NCT01558271|9872241|FG000|Overall Study|Protocol Violation|1
6207907|NCT01558271|9872242|FG001|Overall Study|Protocol Violation|0
6207908|NCT01558271|9872243|FG002|Overall Study|Protocol Violation|0
6207909|NCT01558271|9872241|FG000|Overall Study|Withdrawal by Subject|10
6207910|NCT01558271|9872242|FG001|Overall Study|Withdrawal by Subject|6
6207911|NCT01558271|9872243|FG002|Overall Study|Withdrawal by Subject|12
6207912|NCT01558271|9872241|FG000|Overall Study|Physician Decision|0
6207913|NCT01558271|9872242|FG001|Overall Study|Physician Decision|2
6207914|NCT01558271|9872243|FG002|Overall Study|Physician Decision|1
6207915|NCT01558297|9872258|FG000|Overall Study|Withdrawal by Subject|2
6207916|NCT01558297|9872259|FG001|Overall Study|Withdrawal by Subject|2
6207917|NCT01558297|9872260|FG002|Overall Study|Withdrawal by Subject|1
6207918|NCT01558596|9872270|FG000|Overall Study|Withdrawal by Subject|1
6207919|NCT01558596|9872271|FG001|Overall Study|Withdrawal by Subject|0
6207920|NCT01558596|9872270|FG000|Overall Study|surgery elsewhere or cancelled|1
6207921|NCT01558596|9872271|FG001|Overall Study|surgery elsewhere or cancelled|1
6207922|NCT01558596|9872270|FG000|Overall Study|Protocol Violation|1
6207923|NCT01558596|9872271|FG001|Overall Study|Protocol Violation|0
6207924|NCT01558635|9872277|FG000|Overall Study|Death|1
6207925|NCT01558635|9872277|FG000|Overall Study|Withdrawal by Subject|2
6207926|NCT01558635|9872277|FG000|Overall Study|Physician Decision|1
6112603|NCT00837434|9733060|FG000|Overall Study|Noncompliant|2
6207927|NCT01558635|9872277|FG000|Overall Study|Subject received other treatment|1
6207928|NCT01558635|9872277|FG000|Overall Study|Reveal XT was explanted|1
6207929|NCT01558674|9872294|FG000|Part 1|Study Terminated by Sponsor|10
6207930|NCT01558674|9872295|FG001|Part 1|Study Terminated by Sponsor|0
6207931|NCT01558674|9872294|FG000|Part 1|Withdrawal by Subject|1
6207932|NCT01558674|9872295|FG001|Part 1|Withdrawal by Subject|0
6207933|NCT01558739|9872323|FG000|Overall Study|Adverse Event|7
6207934|NCT01558739|9872323|FG000|Overall Study|Withdrawal by Subject|2
6207935|NCT01558739|9872323|FG000|Overall Study|Death|3
6112604|NCT00837434|9733061|FG001|Overall Study|Noncompliant|0
6112605|NCT00837434|9733060|FG000|Overall Study|Baseline assessments not done in time|1
6112606|NCT00837434|9733061|FG001|Overall Study|Baseline assessments not done in time|0
6112607|NCT00837434|9733060|FG000|Overall Study|Unable to obtain study drug|1
6112608|NCT00837434|9733061|FG001|Overall Study|Unable to obtain study drug|0
6112609|NCT00837473|9733072|FG000|Overall Study|Lost to Follow-up|1
6112610|NCT00837473|9733072|FG000|Overall Study|Withdrawal by Subject|2
6112611|NCT00837486|9733078|FG000|Blinded-treatment Phase|Physician Decision|1
6112612|NCT00837486|9733079|FG001|Blinded-treatment Phase|Physician Decision|0
6112613|NCT00837486|9733078|FG000|Long-term Follow-up Phase - Open Label|Physician Decision|2
6112614|NCT00837486|9733079|FG001|Long-term Follow-up Phase - Open Label|Physician Decision|0
6112615|NCT00837486|9733078|FG000|Long-term Follow-up Phase - Open Label|Withdrawal by Subject|2
6112616|NCT00837486|9733079|FG001|Long-term Follow-up Phase - Open Label|Withdrawal by Subject|0
6112617|NCT00837486|9733078|FG000|Long-term Follow-up Phase - Open Label|Death|1
6112618|NCT00837486|9733079|FG001|Long-term Follow-up Phase - Open Label|Death|0
6112619|NCT00837577|9733096|FG000|Double-blind Period|Clinical Adverse Event|1
6112620|NCT00837577|9733097|FG001|Double-blind Period|Clinical Adverse Event|0
6112621|NCT00837577|9733096|FG000|Double-blind Period|Withdrawal by Subject|1
6112622|NCT00837577|9733097|FG001|Double-blind Period|Withdrawal by Subject|0
6112623|NCT00837577|9733096|FG000|Open-label Period|Clinical Adverse Event|2
6112624|NCT00837577|9733097|FG001|Open-label Period|Clinical Adverse Event|2
6112625|NCT00837577|9733096|FG000|Open-label Period|Laboratory Adverse Event|0
6112626|NCT00837577|9733097|FG001|Open-label Period|Laboratory Adverse Event|1
6112627|NCT00837577|9733096|FG000|Open-label Period|Lack of Efficacy|4
6112628|NCT00837577|9733097|FG001|Open-label Period|Lack of Efficacy|3
6112629|NCT00837577|9733096|FG000|Open-label Period|Withdrawal by Subject|1
6207936|NCT01558739|9872323|FG000|Overall Study|Disease Progression|4
6207937|NCT01558739|9872323|FG000|Overall Study|Protocol Violation|1
6207938|NCT01558752|9872329|FG000|Overall Study|Physician Decision|2
6207939|NCT01558752|9872330|FG001|Overall Study|Physician Decision|0
6207940|NCT01559012|9872349|FG000|Overall Study|Withdrawal by Subject|0
6207941|NCT01559012|9872350|FG001|Overall Study|Withdrawal by Subject|1
6207942|NCT01559090|9872387|FG000|Stage I|Withdrawal by Subject|2
6207943|NCT01559090|9872388|FG001|Stage I|Withdrawal by Subject|2
6207944|NCT01559090|9872389|FG002|Stage I|Withdrawal by Subject|3
6207945|NCT01559090|9872387|FG000|Stage II|Withdrawal by Subject|1
6207946|NCT01559090|9872388|FG001|Stage II|Withdrawal by Subject|0
6207947|NCT01559090|9872389|FG002|Stage II|Withdrawal by Subject|0
6207948|NCT01559116|9872397|FG000|Overall Study|Adverse Event|10
6207949|NCT01559116|9872397|FG000|Overall Study|Lack of Efficacy|1
6207950|NCT01559116|9872397|FG000|Overall Study|Lost to Follow-up|1
6207951|NCT01559116|9872397|FG000|Overall Study|Protocol Violation|1
6207952|NCT01559116|9872397|FG000|Overall Study|Withdrawal by Subject|4
6207953|NCT01559116|9872397|FG000|Overall Study|other than stated above|9
6207954|NCT01559129|9872416|FG000|Treatment Phase|Adverse Event|0
6207955|NCT01559129|9872417|FG001|Treatment Phase|Adverse Event|2
6207956|NCT01559129|9872416|FG000|Treatment Phase|Progressive Disease|1
6207957|NCT01559129|9872417|FG001|Treatment Phase|Progressive Disease|1
6207958|NCT01559129|9872416|FG000|Treatment Phase|Lack of Efficacy|0
6207959|NCT01559129|9872417|FG001|Treatment Phase|Lack of Efficacy|1
6207960|NCT01559129|9872416|FG000|Treatment Phase|Study Terminated by Sponsor|3
6207961|NCT01559129|9872417|FG001|Treatment Phase|Study Terminated by Sponsor|2
6207962|NCT01559129|9872416|FG000|Treatment Phase|Protocol Exclusion Criteria|1
6207963|NCT01559129|9872417|FG001|Treatment Phase|Protocol Exclusion Criteria|0
6207964|NCT01559129|9872416|FG000|Treatment Phase|Did Not Receive Study Drug|0
6207965|NCT01559129|9872417|FG001|Treatment Phase|Did Not Receive Study Drug|1
6207966|NCT01559129|9872416|FG000|Open-label Extension Period|Adverse Event|1
6207967|NCT01559129|9872417|FG001|Open-label Extension Period|Adverse Event|0
6207968|NCT01559129|9872416|FG000|Open-label Extension Period|Study Terminated by Sponsor|5
6207969|NCT01559129|9872417|FG001|Open-label Extension Period|Study Terminated by Sponsor|2
6207970|NCT01559259|9872434|FG000|Overall Study|Withdrawal by Subject|0
6207971|NCT01559259|9872435|FG001|Overall Study|Withdrawal by Subject|0
6207972|NCT01559259|9872436|FG002|Overall Study|Withdrawal by Subject|0
6207973|NCT01559259|9872437|FG003|Overall Study|Withdrawal by Subject|1
6207974|NCT01559259|9872438|FG004|Overall Study|Withdrawal by Subject|0
6207975|NCT01559259|9872434|FG000|Overall Study|Adverse Event|0
6207976|NCT01559259|9872435|FG001|Overall Study|Adverse Event|1
6207977|NCT01559259|9872436|FG002|Overall Study|Adverse Event|1
6207978|NCT01559259|9872437|FG003|Overall Study|Adverse Event|0
6207979|NCT01559259|9872438|FG004|Overall Study|Adverse Event|0
6207980|NCT01559311|9872453|FG000|Overall Study|Protocol Violation|0
6207981|NCT01559311|9872454|FG001|Overall Study|Protocol Violation|0
6207982|NCT01559311|9872455|FG002|Overall Study|Protocol Violation|2
6286057|NCT02343939|9998882|FG000|Overall Study|Withdrew consent|3
6207983|NCT01559311|9872453|FG000|Overall Study|Difficulty in cannulating the lateral ve|1
6207984|NCT01559311|9872454|FG001|Overall Study|Difficulty in cannulating the lateral ve|0
6207985|NCT01559311|9872455|FG002|Overall Study|Difficulty in cannulating the lateral ve|0
6207986|NCT01559311|9872453|FG000|Overall Study|Withdrawal by Subject|2
6207987|NCT01559311|9872454|FG001|Overall Study|Withdrawal by Subject|1
6207988|NCT01559311|9872455|FG002|Overall Study|Withdrawal by Subject|0
6112630|NCT00837577|9733097|FG001|Open-label Period|Withdrawal by Subject|2
6112631|NCT00837577|9733096|FG000|Open-label Period|Other Reason|1
6112632|NCT00837577|9733097|FG001|Open-label Period|Other Reason|1
6112633|NCT00837616|9733119|FG000|Overall Study|Withdrawal by Subject|0
6112634|NCT00837616|9733120|FG001|Overall Study|Withdrawal by Subject|1
6112635|NCT00837694|9733132|FG000|Overall Study|Lost to Follow-up|2
6112636|NCT00837694|9733133|FG001|Overall Study|Lost to Follow-up|0
6112637|NCT00837694|9733134|FG002|Overall Study|Lost to Follow-up|2
6112638|NCT00837694|9733135|FG003|Overall Study|Lost to Follow-up|1
6112639|NCT00837694|9733136|FG004|Overall Study|Lost to Follow-up|1
6112640|NCT00837694|9733137|FG005|Overall Study|Lost to Follow-up|1
6112641|NCT00837759|9733151|FG000|Overall Study|Protocol Violation|3
6112642|NCT00837759|9733151|FG000|Overall Study|Lost to Follow-up|1
6112643|NCT00837811|9733158|FG000|Overall Study|Adverse Event|4
6112644|NCT00837811|9733159|FG001|Overall Study|Adverse Event|6
6112645|NCT00837811|9733160|FG002|Overall Study|Adverse Event|0
6112646|NCT00837811|9733158|FG000|Overall Study|Death|1
6112647|NCT00837811|9733159|FG001|Overall Study|Death|1
6112648|NCT00837811|9733160|FG002|Overall Study|Death|0
6112649|NCT00837811|9733158|FG000|Overall Study|Lack of Efficacy|0
6112650|NCT00837811|9733159|FG001|Overall Study|Lack of Efficacy|11
6112651|NCT00837811|9733160|FG002|Overall Study|Lack of Efficacy|0
6112652|NCT00837811|9733158|FG000|Overall Study|Lost to Follow-up|1
6112653|NCT00837811|9733159|FG001|Overall Study|Lost to Follow-up|3
6112654|NCT00837811|9733160|FG002|Overall Study|Lost to Follow-up|0
6112655|NCT00837811|9733158|FG000|Overall Study|Physician Decision|0
6112656|NCT00837811|9733159|FG001|Overall Study|Physician Decision|2
6112657|NCT00837811|9733160|FG002|Overall Study|Physician Decision|1
6112658|NCT00837811|9733158|FG000|Overall Study|Withdrawal by Subject|1
6112659|NCT00837811|9733159|FG001|Overall Study|Withdrawal by Subject|9
6112660|NCT00837811|9733160|FG002|Overall Study|Withdrawal by Subject|0
6112661|NCT00837811|9733158|FG000|Overall Study|Sponsor Decision|0
6112662|NCT00837811|9733159|FG001|Overall Study|Sponsor Decision|2
6112663|NCT00837811|9733160|FG002|Overall Study|Sponsor Decision|0
6112664|NCT00837876|9733187|FG000|Overall Study|Death|2
6112665|NCT00837876|9733187|FG000|Overall Study|Adverse Event|7
6112666|NCT00837876|9733187|FG000|Overall Study|Physician Decision|1
6112667|NCT00837876|9733187|FG000|Overall Study|Withdrawal by Subject|3
6112668|NCT00837876|9733187|FG000|Overall Study|disease progression|24
6112669|NCT00837967|9733201|FG000|Washout Period of 7 - 14 Days|Adverse Event|2
6112670|NCT00837967|9733202|FG001|Washout Period of 7 - 14 Days|Adverse Event|0
6112671|NCT00838097|9733223|FG000|Overall Study|Ineligibility determined|6
6112672|NCT00838097|9733223|FG000|Overall Study|Adverse Event|2
6112673|NCT00838097|9733223|FG000|Overall Study|Withdrawal by Subject|3
6112674|NCT00838097|9733223|FG000|Overall Study|Requirement for alternative therapy|2
6112675|NCT00838097|9733223|FG000|Overall Study|Physician Decision|4
6112676|NCT00838097|9733223|FG000|Overall Study|Lost to Follow-up|11
6112677|NCT00838097|9733223|FG000|Overall Study|Death|6
6112678|NCT00838097|9733223|FG000|Overall Study|Protocol-specified criteria|142
6112679|NCT00838110|9733229|FG000|Overall Study|Death|0
6112680|NCT00838110|9733230|FG001|Overall Study|Death|0
6112681|NCT00838110|9733231|FG002|Overall Study|Death|1
6112682|NCT00838110|9733232|FG003|Overall Study|Death|2
6112683|NCT00838110|9733229|FG000|Overall Study|Adverse Event|11
6112684|NCT00838110|9733230|FG001|Overall Study|Adverse Event|10
6112685|NCT00838110|9733231|FG002|Overall Study|Adverse Event|8
6112686|NCT00838110|9733232|FG003|Overall Study|Adverse Event|7
6207989|NCT01559311|9872453|FG000|Overall Study|Death|0
6207990|NCT01559311|9872454|FG001|Overall Study|Death|2
6207991|NCT01559311|9872455|FG002|Overall Study|Death|3
6207992|NCT01559311|9872453|FG000|Overall Study|Lost to Follow-up|0
6207993|NCT01559311|9872454|FG001|Overall Study|Lost to Follow-up|3
6207994|NCT01559311|9872455|FG002|Overall Study|Lost to Follow-up|2
6207995|NCT01559311|9872453|FG000|Overall Study|Adverse Event|0
6207996|NCT01559311|9872454|FG001|Overall Study|Adverse Event|0
6207997|NCT01559311|9872455|FG002|Overall Study|Adverse Event|1
6207998|NCT01559389|9872465|FG000|Overall Study|Withdrawal by Subject|20
6207999|NCT01559389|9872466|FG001|Overall Study|Withdrawal by Subject|20
6208000|NCT01559454|9872478|FG000|Overall Study|Lost to Follow-up|3
6208001|NCT01559454|9872479|FG001|Overall Study|Lost to Follow-up|2
6208002|NCT01559454|9872478|FG000|Overall Study|Withdrawal by Subject|0
6112687|NCT00838110|9733229|FG000|Overall Study|Withdrawal by Subject|5
6112688|NCT00838110|9733230|FG001|Overall Study|Withdrawal by Subject|6
6112689|NCT00838110|9733231|FG002|Overall Study|Withdrawal by Subject|3
6112690|NCT00838110|9733232|FG003|Overall Study|Withdrawal by Subject|4
6112691|NCT00838110|9733229|FG000|Overall Study|Other|3
6112692|NCT00838110|9733230|FG001|Overall Study|Other|3
6112693|NCT00838110|9733231|FG002|Overall Study|Other|3
6112694|NCT00838110|9733232|FG003|Overall Study|Other|2
6112695|NCT00838110|9733229|FG000|Overall Study|Protocol Violation|0
6112696|NCT00838110|9733230|FG001|Overall Study|Protocol Violation|2
6112697|NCT00838110|9733231|FG002|Overall Study|Protocol Violation|1
6112698|NCT00838110|9733232|FG003|Overall Study|Protocol Violation|1
6112699|NCT00838110|9733229|FG000|Overall Study|Lost to Follow-up|3
6208003|NCT01559454|9872479|FG001|Overall Study|Withdrawal by Subject|1
6112700|NCT00838110|9733230|FG001|Overall Study|Lost to Follow-up|0
6112701|NCT00838110|9733231|FG002|Overall Study|Lost to Follow-up|0
6112702|NCT00838110|9733232|FG003|Overall Study|Lost to Follow-up|0
6112703|NCT00838110|9733229|FG000|Overall Study|Did not meet eligibility criteria|0
6112704|NCT00838110|9733230|FG001|Overall Study|Did not meet eligibility criteria|0
6112705|NCT00838110|9733231|FG002|Overall Study|Did not meet eligibility criteria|1
6112706|NCT00838110|9733232|FG003|Overall Study|Did not meet eligibility criteria|2
6112707|NCT00838110|9733229|FG000|Overall Study|Randomized but not treated|0
6208004|NCT01559454|9872478|FG000|Overall Study|Physician Decision|0
6208005|NCT01559454|9872479|FG001|Overall Study|Physician Decision|1
6208006|NCT01559454|9872478|FG000|Overall Study|Protocol Violation|0
6208007|NCT01559454|9872479|FG001|Overall Study|Protocol Violation|1
6208008|NCT01559454|9872478|FG000|Overall Study|Lack of Efficacy|0
6208009|NCT01559454|9872479|FG001|Overall Study|Lack of Efficacy|1
6208010|NCT01559675|9872506|FG000|Overall Study|Protocol Violation|1
6112708|NCT00838110|9733230|FG001|Overall Study|Randomized but not treated|1
6112709|NCT00838110|9733231|FG002|Overall Study|Randomized but not treated|0
6112710|NCT00838110|9733232|FG003|Overall Study|Randomized but not treated|0
6112711|NCT00838201|9733261|FG000|Overall Study|Investigator decision, or other reasons|2
6112712|NCT00838201|9733262|FG001|Overall Study|Investigator decision, or other reasons|3
6112713|NCT00838201|9733261|FG000|Overall Study|Noncompliance|0
6112714|NCT00838201|9733262|FG001|Overall Study|Noncompliance|1
6112715|NCT00838201|9733261|FG000|Overall Study|Administrative decision|1
6112716|NCT00838201|9733262|FG001|Overall Study|Administrative decision|2
6112717|NCT00838201|9733261|FG000|Overall Study|Disease progression|3
6112718|NCT00838201|9733262|FG001|Overall Study|Disease progression|3
6112719|NCT00838201|9733261|FG000|Overall Study|Consent withdrawn|16
6112720|NCT00838201|9733262|FG001|Overall Study|Consent withdrawn|19
6112721|NCT00838201|9733261|FG000|Overall Study|Lost to Follow-up|4
6112722|NCT00838201|9733262|FG001|Overall Study|Lost to Follow-up|3
6208011|NCT01559675|9872507|FG001|Overall Study|Protocol Violation|2
6208012|NCT01559675|9872506|FG000|Overall Study|2nd operation on same patient excluded|14
6208013|NCT01559675|9872507|FG001|Overall Study|2nd operation on same patient excluded|12
6208014|NCT01559844|9872513|FG000|Overall Study|Consent Withdrawn|7
6208015|NCT01559844|9872513|FG000|Overall Study|Death|5
6208016|NCT01559844|9872513|FG000|Overall Study|Efficacy Failure|10
6208017|NCT01559844|9872513|FG000|Overall Study|No Longer A Transplant Candidate|3
6208018|NCT01560234|9872562|FG000|Overall Study|Lost to Follow-up|3
6208019|NCT01560234|9872563|FG001|Overall Study|Lost to Follow-up|0
6208020|NCT01560234|9872564|FG002|Overall Study|Lost to Follow-up|1
6208021|NCT01560234|9872565|FG003|Overall Study|Lost to Follow-up|0
6208022|NCT01560234|9872566|FG004|Overall Study|Lost to Follow-up|0
6208023|NCT01560234|9872567|FG005|Overall Study|Lost to Follow-up|2
6208024|NCT01560234|9872568|FG006|Overall Study|Lost to Follow-up|0
6208025|NCT01560234|9872569|FG007|Overall Study|Lost to Follow-up|2
6208026|NCT01560403|9872603|FG000|Overall Study|Lost to Follow-up|0
6208027|NCT01560403|9872604|FG001|Overall Study|Lost to Follow-up|1
6208028|NCT01560416|9872612|FG000|Randomized Phase|Crossover Participants|7
6208029|NCT01560416|9872613|FG001|Randomized Phase|Crossover Participants|0
6208030|NCT01560429|9872623|FG000|Overall Study|Protocol Violation|3
6208031|NCT01560429|9872624|FG001|Overall Study|Protocol Violation|6
6208032|NCT01560780|9872643|FG000|Overall Study|Death|2
6208033|NCT01560780|9872644|FG001|Overall Study|Death|1
6208034|NCT01560780|9872643|FG000|Overall Study|Patient Preference|11
6208035|NCT01560780|9872644|FG001|Overall Study|Patient Preference|11
6208036|NCT01560819|9872652|FG000|Overall Study|Physician Decision|1
6208037|NCT01560819|9872653|FG001|Overall Study|Physician Decision|0
6208038|NCT01560871|9872659|FG000|Overall Study|transportation issues|2
6208039|NCT01560871|9872660|FG001|Overall Study|transportation issues|1
6208040|NCT01560871|9872659|FG000|Overall Study|relocation|1
6208041|NCT01560871|9872660|FG001|Overall Study|relocation|0
6208042|NCT01560871|9872659|FG000|Overall Study|readmission to a hospital|2
6208043|NCT01560871|9872660|FG001|Overall Study|readmission to a hospital|1
6208044|NCT01560871|9872659|FG000|Overall Study|Lost to Follow-up|1
6208045|NCT01560871|9872660|FG001|Overall Study|Lost to Follow-up|0
6208046|NCT01560949|9872676|FG000|Systemic Phase: mFOLFIRINOX|Adverse Event|6
6208047|NCT01560949|9872676|FG000|Surgery Phase|Physician Decision|3
6208048|NCT01560988|9872692|FG000|First Intervention (Six Weeks)|Lost to Follow-up|7
6208049|NCT01560988|9872693|FG001|First Intervention (Six Weeks)|Lost to Follow-up|4
6208050|NCT01560988|9872692|FG000|First Intervention (Six Weeks)|Withdrawal by Subject|3
6286058|NCT02343939|9998883|FG001|Overall Study|Withdrew consent|6
6286059|NCT02343939|9998884|FG002|Overall Study|Withdrew consent|1
6112723|NCT00838201|9733261|FG000|Overall Study|Adverse Event|5
6112724|NCT00838201|9733262|FG001|Overall Study|Adverse Event|9
6112725|NCT00838201|9733261|FG000|Overall Study|Death|11
6112726|NCT00838201|9733262|FG001|Overall Study|Death|13
6112727|NCT00838331|9733268|FG000|Aged Blood Transfusion|Withdrawal by Subject|9
6112728|NCT00838435|9733272|FG000|PK Sub-Study 2 (4 Weeks)|no postdose blood sample|1
6112729|NCT00838435|9733272|FG000|Safety/Efficacy Sub-Study 1 (6 Months)|Adverse Event|2
6112730|NCT00838435|9733272|FG000|Part 2 (7 Years)|Adverse Event|2
6112731|NCT00838435|9733272|FG000|Part 2 (7 Years)|Lost to Follow-up|2
6208051|NCT01560988|9872693|FG001|First Intervention (Six Weeks)|Withdrawal by Subject|0
6208052|NCT01560988|9872692|FG000|Washout (Six Weeks)|Lost to Follow-up|2
6208053|NCT01560988|9872693|FG001|Washout (Six Weeks)|Lost to Follow-up|2
6208054|NCT01561079|9872722|FG000|Overall Study|Physician Decision|17
6208055|NCT01561079|9872722|FG000|Overall Study|Withdrawal by Subject|59
6112732|NCT00838435|9733272|FG000|Part 2 (7 Years)|Physician Decision|1
6112733|NCT00838435|9733272|FG000|Part 2 (7 Years)|Sponsor Decision|6
6112734|NCT00838435|9733272|FG000|Part 2 (7 Years)|Withdrawal by Subject|5
6112735|NCT00838513|9733279|FG000|Screening Period|Screen Failure|3
6112736|NCT00838513|9733279|FG000|Extension Treatment Period|Death|1
6112737|NCT00838513|9733279|FG000|Post Treatment Period (Patients Who Disc|Death|1
6112738|NCT00838539|9733295|FG000|Overall Study|Disease Progression|2
6112739|NCT00838539|9733296|FG001|Overall Study|Disease Progression|4
6112740|NCT00838539|9733297|FG002|Overall Study|Disease Progression|3
6112741|NCT00838539|9733298|FG003|Overall Study|Disease Progression|2
6112742|NCT00838539|9733299|FG004|Overall Study|Disease Progression|4
6208056|NCT01561079|9872722|FG000|Overall Study|Protocol Violation|2
6208057|NCT01561300|9872765|FG000|Run in on Placebo|Adverse Event|1
6208058|NCT01561300|9872766|FG001|Run in on Placebo|Adverse Event|0
6208059|NCT01561313|9872775|FG000|Overall Study|Withdrawal by Subject|1
6208060|NCT01561313|9872776|FG001|Overall Study|Withdrawal by Subject|0
6208061|NCT01561313|9872775|FG000|Overall Study|Adverse event and withdrawal by subject|1
6208062|NCT01561313|9872776|FG001|Overall Study|Adverse event and withdrawal by subject|0
6208063|NCT01561560|9872791|FG000|First Two Weeks of Wear|Time/job conflict|0
6208064|NCT01561560|9872792|FG001|First Two Weeks of Wear|Time/job conflict|1
6208065|NCT01561560|9872791|FG000|First Two Weeks of Wear|Adverse Event|0
6208066|NCT01561560|9872792|FG001|First Two Weeks of Wear|Adverse Event|1
6208067|NCT01561560|9872791|FG000|Second Two Weeks of Wear|Adverse Event|0
6208068|NCT01561560|9872792|FG001|Second Two Weeks of Wear|Adverse Event|1
6286060|NCT02343939|9998885|FG003|Overall Study|Withdrew consent|2
6286061|NCT02343939|9998886|FG004|Overall Study|Withdrew consent|2
6286062|NCT02343939|9998887|FG005|Overall Study|Withdrew consent|0
6286063|NCT02343939|9998888|FG006|Overall Study|Withdrew consent|0
6286064|NCT02343939|9998889|FG007|Overall Study|Withdrew consent|8
6286065|NCT02343939|9998890|FG008|Overall Study|Withdrew consent|6
6286066|NCT02343939|9998882|FG000|Overall Study|Treatment failure|0
6286067|NCT02343939|9998883|FG001|Overall Study|Treatment failure|0
6286068|NCT02343939|9998884|FG002|Overall Study|Treatment failure|0
6286069|NCT02343939|9998885|FG003|Overall Study|Treatment failure|0
6286070|NCT02343939|9998886|FG004|Overall Study|Treatment failure|0
6286071|NCT02343939|9998887|FG005|Overall Study|Treatment failure|0
6286072|NCT02343939|9998888|FG006|Overall Study|Treatment failure|2
6286073|NCT02343939|9998889|FG007|Overall Study|Treatment failure|1
6286074|NCT02343939|9998890|FG008|Overall Study|Treatment failure|0
6286075|NCT02343939|9998882|FG000|Overall Study|Investigator's discretion|0
6286076|NCT02343939|9998883|FG001|Overall Study|Investigator's discretion|0
6286077|NCT02343939|9998884|FG002|Overall Study|Investigator's discretion|0
6286078|NCT02343939|9998885|FG003|Overall Study|Investigator's discretion|1
6286079|NCT02343939|9998886|FG004|Overall Study|Investigator's discretion|0
6286080|NCT02343939|9998887|FG005|Overall Study|Investigator's discretion|0
6286081|NCT02343939|9998888|FG006|Overall Study|Investigator's discretion|1
6286082|NCT02343939|9998889|FG007|Overall Study|Investigator's discretion|0
6286083|NCT02343939|9998890|FG008|Overall Study|Investigator's discretion|0
6286084|NCT02343939|9998882|FG000|Overall Study|Adverse Event|0
6286085|NCT02343939|9998883|FG001|Overall Study|Adverse Event|0
6286086|NCT02343939|9998884|FG002|Overall Study|Adverse Event|0
6286087|NCT02343939|9998885|FG003|Overall Study|Adverse Event|0
6286088|NCT02343939|9998886|FG004|Overall Study|Adverse Event|0
6286089|NCT02343939|9998887|FG005|Overall Study|Adverse Event|1
6286090|NCT02343939|9998888|FG006|Overall Study|Adverse Event|0
6286091|NCT02343939|9998889|FG007|Overall Study|Adverse Event|0
6286092|NCT02343939|9998890|FG008|Overall Study|Adverse Event|0
6286093|NCT02343939|9998882|FG000|Overall Study|Never Treated With ENTO|0
6286094|NCT02343939|9998883|FG001|Overall Study|Never Treated With ENTO|0
6286095|NCT02343939|9998884|FG002|Overall Study|Never Treated With ENTO|0
6286096|NCT02343939|9998885|FG003|Overall Study|Never Treated With ENTO|0
6286097|NCT02343939|9998886|FG004|Overall Study|Never Treated With ENTO|0
6286098|NCT02343939|9998887|FG005|Overall Study|Never Treated With ENTO|0
6286099|NCT02343939|9998888|FG006|Overall Study|Never Treated With ENTO|1
6286100|NCT02343939|9998889|FG007|Overall Study|Never Treated With ENTO|2
6286101|NCT02343939|9998890|FG008|Overall Study|Never Treated With ENTO|0
6286102|NCT02344004|9998926|FG000|Overall Study|Adverse Event|11
6286103|NCT02344004|9998927|FG001|Overall Study|Adverse Event|1
6286104|NCT02344004|9998926|FG000|Overall Study|Death|9
6286105|NCT02344004|9998927|FG001|Overall Study|Death|7
6286106|NCT02344004|9998926|FG000|Overall Study|Physician Decision|4
6286107|NCT02344004|9998927|FG001|Overall Study|Physician Decision|1
6286108|NCT02344004|9998926|FG000|Overall Study|Withdrawal by Subject|22
6286109|NCT02344004|9998927|FG001|Overall Study|Withdrawal by Subject|5
6286110|NCT02344004|9998926|FG000|Overall Study|Rescue Medication|2
6286111|NCT02344004|9998927|FG001|Overall Study|Rescue Medication|0
6286112|NCT02344004|9998926|FG000|Overall Study|Other Not Specified|12
6286113|NCT02344004|9998927|FG001|Overall Study|Other Not Specified|0
6286114|NCT02344004|9998926|FG000|Overall Study|Protocol Violation|1
6286115|NCT02344004|9998927|FG001|Overall Study|Protocol Violation|0
6286116|NCT02344173|9998934|FG000|Procedure|Ablation Procedure Not Performed|7
6112743|NCT00838539|9733300|FG005|Overall Study|Disease Progression|2
6112744|NCT00838539|9733301|FG006|Overall Study|Disease Progression|3
6286117|NCT02344173|9998934|FG000|12-month Visit|Death|8
6286118|NCT02344173|9998934|FG000|12-month Visit|Withdrawal by Subject|30
6112745|NCT00838539|9733302|FG007|Overall Study|Disease Progression|4
6112746|NCT00838539|9733303|FG008|Overall Study|Disease Progression|4
6112747|NCT00838539|9733304|FG009|Overall Study|Disease Progression|5
6112748|NCT00838539|9733305|FG010|Overall Study|Disease Progression|1
6112749|NCT00838539|9733306|FG011|Overall Study|Disease Progression|4
6112750|NCT00838539|9733295|FG000|Overall Study|Adverse Event|1
6112751|NCT00838539|9733296|FG001|Overall Study|Adverse Event|1
6112752|NCT00838539|9733297|FG002|Overall Study|Adverse Event|1
6112753|NCT00838539|9733298|FG003|Overall Study|Adverse Event|1
6112754|NCT00838539|9733299|FG004|Overall Study|Adverse Event|2
6112755|NCT00838539|9733300|FG005|Overall Study|Adverse Event|1
6112756|NCT00838539|9733301|FG006|Overall Study|Adverse Event|0
6112757|NCT00838539|9733302|FG007|Overall Study|Adverse Event|2
6112758|NCT00838539|9733303|FG008|Overall Study|Adverse Event|0
6112759|NCT00838539|9733304|FG009|Overall Study|Adverse Event|1
6112760|NCT00838539|9733305|FG010|Overall Study|Adverse Event|2
6112761|NCT00838539|9733306|FG011|Overall Study|Adverse Event|0
6112762|NCT00838539|9733295|FG000|Overall Study|Withdrawal by Subject|0
6112763|NCT00838539|9733296|FG001|Overall Study|Withdrawal by Subject|1
6112764|NCT00838539|9733297|FG002|Overall Study|Withdrawal by Subject|0
6112765|NCT00838539|9733298|FG003|Overall Study|Withdrawal by Subject|0
6112766|NCT00838539|9733299|FG004|Overall Study|Withdrawal by Subject|0
6112767|NCT00838539|9733300|FG005|Overall Study|Withdrawal by Subject|0
6112768|NCT00838539|9733301|FG006|Overall Study|Withdrawal by Subject|0
6112769|NCT00838539|9733302|FG007|Overall Study|Withdrawal by Subject|0
6112770|NCT00838539|9733303|FG008|Overall Study|Withdrawal by Subject|0
6112771|NCT00838539|9733304|FG009|Overall Study|Withdrawal by Subject|1
6112772|NCT00838539|9733305|FG010|Overall Study|Withdrawal by Subject|2
6112773|NCT00838539|9733306|FG011|Overall Study|Withdrawal by Subject|0
6112774|NCT00838539|9733295|FG000|Overall Study|Death|0
6112775|NCT00838539|9733296|FG001|Overall Study|Death|0
6112776|NCT00838539|9733297|FG002|Overall Study|Death|0
6112777|NCT00838539|9733298|FG003|Overall Study|Death|0
6112778|NCT00838539|9733299|FG004|Overall Study|Death|0
6112779|NCT00838539|9733300|FG005|Overall Study|Death|0
6112780|NCT00838539|9733301|FG006|Overall Study|Death|1
6112781|NCT00838539|9733302|FG007|Overall Study|Death|0
6112782|NCT00838539|9733303|FG008|Overall Study|Death|0
6112783|NCT00838539|9733304|FG009|Overall Study|Death|0
6112784|NCT00838539|9733305|FG010|Overall Study|Death|0
6112785|NCT00838539|9733306|FG011|Overall Study|Death|0
6112786|NCT00838539|9733295|FG000|Overall Study|Physician Decision|0
6112787|NCT00838539|9733296|FG001|Overall Study|Physician Decision|0
6112788|NCT00838539|9733297|FG002|Overall Study|Physician Decision|0
6112789|NCT00838539|9733298|FG003|Overall Study|Physician Decision|0
6112790|NCT00838539|9733299|FG004|Overall Study|Physician Decision|0
6112791|NCT00838539|9733300|FG005|Overall Study|Physician Decision|0
6112792|NCT00838539|9733301|FG006|Overall Study|Physician Decision|0
6112793|NCT00838539|9733302|FG007|Overall Study|Physician Decision|0
6112794|NCT00838539|9733303|FG008|Overall Study|Physician Decision|1
6112795|NCT00838539|9733304|FG009|Overall Study|Physician Decision|0
6112796|NCT00838539|9733305|FG010|Overall Study|Physician Decision|0
6112797|NCT00838539|9733306|FG011|Overall Study|Physician Decision|0
6112798|NCT00838539|9733295|FG000|Overall Study|Clinical Progression|0
6112799|NCT00838539|9733296|FG001|Overall Study|Clinical Progression|0
6112800|NCT00838539|9733297|FG002|Overall Study|Clinical Progression|0
6112801|NCT00838539|9733298|FG003|Overall Study|Clinical Progression|0
6112802|NCT00838539|9733299|FG004|Overall Study|Clinical Progression|0
6112803|NCT00838539|9733300|FG005|Overall Study|Clinical Progression|0
6112804|NCT00838539|9733301|FG006|Overall Study|Clinical Progression|1
6112805|NCT00838539|9733302|FG007|Overall Study|Clinical Progression|0
6112806|NCT00838539|9733303|FG008|Overall Study|Clinical Progression|0
6112807|NCT00838539|9733304|FG009|Overall Study|Clinical Progression|0
6112808|NCT00838539|9733305|FG010|Overall Study|Clinical Progression|0
6112809|NCT00838539|9733306|FG011|Overall Study|Clinical Progression|0
6112810|NCT00838539|9733295|FG000|Overall Study|Symptomatic Deterioration|0
6112811|NCT00838539|9733296|FG001|Overall Study|Symptomatic Deterioration|0
6112812|NCT00838539|9733297|FG002|Overall Study|Symptomatic Deterioration|1
6112813|NCT00838539|9733298|FG003|Overall Study|Symptomatic Deterioration|1
6112814|NCT00838539|9733299|FG004|Overall Study|Symptomatic Deterioration|0
6112815|NCT00838539|9733300|FG005|Overall Study|Symptomatic Deterioration|1
6112816|NCT00838539|9733301|FG006|Overall Study|Symptomatic Deterioration|0
6112817|NCT00838539|9733302|FG007|Overall Study|Symptomatic Deterioration|0
6112818|NCT00838539|9733303|FG008|Overall Study|Symptomatic Deterioration|0
6112819|NCT00838539|9733304|FG009|Overall Study|Symptomatic Deterioration|1
6112820|NCT00838539|9733305|FG010|Overall Study|Symptomatic Deterioration|0
6112821|NCT00838539|9733306|FG011|Overall Study|Symptomatic Deterioration|0
6112822|NCT00838565|9733352|FG000|Overall Study|Withdrawal by Subject|0
6112823|NCT00838565|9733353|FG001|Overall Study|Withdrawal by Subject|0
6112824|NCT00838565|9733354|FG002|Overall Study|Withdrawal by Subject|1
6112825|NCT00838565|9733355|FG003|Overall Study|Withdrawal by Subject|0
6112826|NCT00838565|9733356|FG004|Overall Study|Withdrawal by Subject|0
6112827|NCT00838565|9733357|FG005|Overall Study|Withdrawal by Subject|2
6112828|NCT00838565|9733352|FG000|Overall Study|Other|0
6112829|NCT00838565|9733353|FG001|Overall Study|Other|2
6112830|NCT00838565|9733354|FG002|Overall Study|Other|0
6112831|NCT00838565|9733355|FG003|Overall Study|Other|0
6112832|NCT00838565|9733356|FG004|Overall Study|Other|0
6112833|NCT00838565|9733357|FG005|Overall Study|Other|0
6112834|NCT00838565|9733352|FG000|Overall Study|Randomized but not Treated|0
6112835|NCT00838565|9733353|FG001|Overall Study|Randomized but not Treated|1
6112836|NCT00838565|9733354|FG002|Overall Study|Randomized but not Treated|0
6112837|NCT00838565|9733355|FG003|Overall Study|Randomized but not Treated|0
6112838|NCT00838565|9733356|FG004|Overall Study|Randomized but not Treated|0
6112839|NCT00838565|9733357|FG005|Overall Study|Randomized but not Treated|0
6112840|NCT00838578|9733376|FG000|Overall Study|Protocol Violation|2
6112841|NCT00838682|9733386|FG000|Overall Study|Lost to Follow-up|21
6112842|NCT00838682|9733387|FG001|Overall Study|Lost to Follow-up|14
6112843|NCT00838682|9733386|FG000|Overall Study|detection of exclusion criteria|4
6112844|NCT00838682|9733387|FG001|Overall Study|detection of exclusion criteria|3
6112845|NCT00838682|9733386|FG000|Overall Study|Protocol Violation|0
6112846|NCT00838682|9733387|FG001|Overall Study|Protocol Violation|1
6112847|NCT00838682|9733386|FG000|Overall Study|Withdrawal by Subject|0
6112848|NCT00838682|9733387|FG001|Overall Study|Withdrawal by Subject|1
6112849|NCT00838903|9733406|FG000|Treatment Period (156 Weeks)|Adverse Event|5
6112850|NCT00838903|9733407|FG001|Treatment Period (156 Weeks)|Adverse Event|13
6112851|NCT00838903|9733408|FG002|Treatment Period (156 Weeks)|Adverse Event|17
6112852|NCT00838903|9733409|FG003|Treatment Period (156 Weeks)|Adverse Event|25
6208069|NCT01561755|9872834|FG000|Overall Study|Lost to Follow-up|0
6208070|NCT01561755|9872835|FG001|Overall Study|Lost to Follow-up|1
6208071|NCT01561898|9872849|FG000|Overall Study|Withdrawal by Subject|0
6208072|NCT01561898|9872850|FG001|Overall Study|Withdrawal by Subject|8
6208073|NCT01561898|9872851|FG002|Overall Study|Withdrawal by Subject|12
6208074|NCT01561898|9872852|FG003|Overall Study|Withdrawal by Subject|5
6208075|NCT01561898|9872849|FG000|Overall Study|Lack of Efficacy|0
6208076|NCT01561898|9872850|FG001|Overall Study|Lack of Efficacy|8
6208077|NCT01561898|9872851|FG002|Overall Study|Lack of Efficacy|10
6208078|NCT01561898|9872852|FG003|Overall Study|Lack of Efficacy|5
6208079|NCT01561898|9872849|FG000|Overall Study|Worsening of complications|0
6208080|NCT01561898|9872850|FG001|Overall Study|Worsening of complications|1
6208081|NCT01561898|9872851|FG002|Overall Study|Worsening of complications|0
6208082|NCT01561898|9872852|FG003|Overall Study|Worsening of complications|0
6208083|NCT01561898|9872849|FG000|Overall Study|Lost to Follow-up|0
6208084|NCT01561898|9872850|FG001|Overall Study|Lost to Follow-up|0
6208085|NCT01561898|9872851|FG002|Overall Study|Lost to Follow-up|1
6208086|NCT01561898|9872852|FG003|Overall Study|Lost to Follow-up|0
6208087|NCT01561898|9872849|FG000|Overall Study|Adverse Event|1
6208088|NCT01561898|9872850|FG001|Overall Study|Adverse Event|19
6208089|NCT01561898|9872851|FG002|Overall Study|Adverse Event|14
6208090|NCT01561898|9872852|FG003|Overall Study|Adverse Event|9
6208091|NCT01561898|9872849|FG000|Overall Study|Physician Decision|1
6208092|NCT01561898|9872850|FG001|Overall Study|Physician Decision|5
6208093|NCT01561898|9872851|FG002|Overall Study|Physician Decision|7
6208094|NCT01561898|9872852|FG003|Overall Study|Physician Decision|1
6208095|NCT01561963|9872860|FG000|Overall Study|Adverse Event|1
6208096|NCT01561976|9872875|FG000|Period 1|Adverse Event|0
6208097|NCT01561976|9872876|FG001|Period 1|Adverse Event|0
6208098|NCT01561976|9872877|FG002|Period 1|Adverse Event|1
6208099|NCT01561976|9872878|FG003|Period 1|Adverse Event|0
6286119|NCT02344173|9998934|FG000|12-month Visit|Lost to Follow-up|58
6286120|NCT02344342|9998994|FG000|Overall Study|Industry partner dropped out|11
6286121|NCT02344342|9998995|FG001|Overall Study|Industry partner dropped out|9
6286122|NCT02344342|9998996|FG002|Overall Study|Industry partner dropped out|14
6286123|NCT02344342|9998997|FG003|Overall Study|Industry partner dropped out|10
6286124|NCT02344576|9999028|FG000|Enrollment|Agreed to Medical Record Review Only|7
6286125|NCT02344576|9999029|FG001|Enrollment|Agreed to Medical Record Review Only|8
6286126|NCT02344576|9999030|FG002|Enrollment|Agreed to Medical Record Review Only|0
6286127|NCT02344576|9999031|FG003|Enrollment|Agreed to Medical Record Review Only|0
6286128|NCT02344576|9999028|FG000|1-Month Follow-Up|Death|13
6286129|NCT02344576|9999029|FG001|1-Month Follow-Up|Death|8
6286130|NCT02344576|9999030|FG002|1-Month Follow-Up|Death|0
6286131|NCT02344576|9999031|FG003|1-Month Follow-Up|Death|0
6286132|NCT02344576|9999028|FG000|1-Month Follow-Up|Withdrawal by Subject|3
6286133|NCT02344576|9999029|FG001|1-Month Follow-Up|Withdrawal by Subject|14
6286134|NCT02344576|9999030|FG002|1-Month Follow-Up|Withdrawal by Subject|8
6286135|NCT02344576|9999031|FG003|1-Month Follow-Up|Withdrawal by Subject|10
6286136|NCT02344576|9999028|FG000|1-Month Follow-Up|Lost to Follow-up|2
6286137|NCT02344576|9999029|FG001|1-Month Follow-Up|Lost to Follow-up|5
6286138|NCT02344576|9999030|FG002|1-Month Follow-Up|Lost to Follow-up|11
6286139|NCT02344576|9999031|FG003|1-Month Follow-Up|Lost to Follow-up|3
6286140|NCT02344576|9999028|FG000|6-Month Follow-Up|Death|14
6286141|NCT02344576|9999029|FG001|6-Month Follow-Up|Death|14
6286142|NCT02344576|9999030|FG002|6-Month Follow-Up|Death|0
6286143|NCT02344576|9999031|FG003|6-Month Follow-Up|Death|0
6286144|NCT02344576|9999028|FG000|6-Month Follow-Up|Withdrawal by Subject|1
6286145|NCT02344576|9999029|FG001|6-Month Follow-Up|Withdrawal by Subject|0
6112853|NCT00838903|9733406|FG000|Treatment Period (156 Weeks)|Protocol Violation|1
6112854|NCT00838903|9733407|FG001|Treatment Period (156 Weeks)|Protocol Violation|6
6112855|NCT00838903|9733408|FG002|Treatment Period (156 Weeks)|Protocol Violation|6
6112856|NCT00838903|9733409|FG003|Treatment Period (156 Weeks)|Protocol Violation|5
6112857|NCT00838903|9733406|FG000|Treatment Period (156 Weeks)|Noncompliance|9
6112858|NCT00838903|9733407|FG001|Treatment Period (156 Weeks)|Noncompliance|13
6112859|NCT00838903|9733408|FG002|Treatment Period (156 Weeks)|Noncompliance|12
6112860|NCT00838903|9733409|FG003|Treatment Period (156 Weeks)|Noncompliance|6
6112861|NCT00838903|9733406|FG000|Treatment Period (156 Weeks)|Severe or Repeated Hypoglycaemia|0
6112862|NCT00838903|9733407|FG001|Treatment Period (156 Weeks)|Severe or Repeated Hypoglycaemia|0
6112863|NCT00838903|9733408|FG002|Treatment Period (156 Weeks)|Severe or Repeated Hypoglycaemia|1
6112864|NCT00838903|9733409|FG003|Treatment Period (156 Weeks)|Severe or Repeated Hypoglycaemia|0
6112865|NCT00838903|9733406|FG000|Treatment Period (156 Weeks)|Lost to Follow-up|4
6112866|NCT00838903|9733407|FG001|Treatment Period (156 Weeks)|Lost to Follow-up|16
6112867|NCT00838903|9733408|FG002|Treatment Period (156 Weeks)|Lost to Follow-up|15
6112868|NCT00838903|9733409|FG003|Treatment Period (156 Weeks)|Lost to Follow-up|13
6112869|NCT00838903|9733406|FG000|Treatment Period (156 Weeks)|Withdrawal by Subject|20
6112870|NCT00838903|9733407|FG001|Treatment Period (156 Weeks)|Withdrawal by Subject|55
6112871|NCT00838903|9733408|FG002|Treatment Period (156 Weeks)|Withdrawal by Subject|56
6112872|NCT00838903|9733409|FG003|Treatment Period (156 Weeks)|Withdrawal by Subject|53
6112873|NCT00838903|9733406|FG000|Treatment Period (156 Weeks)|Physician Decision|1
6112874|NCT00838903|9733407|FG001|Treatment Period (156 Weeks)|Physician Decision|2
6112875|NCT00838903|9733408|FG002|Treatment Period (156 Weeks)|Physician Decision|1
6112876|NCT00838903|9733409|FG003|Treatment Period (156 Weeks)|Physician Decision|2
6112877|NCT00838903|9733406|FG000|Treatment Period (156 Weeks)|Termination of Study/Site by GSK|3
6112878|NCT00838903|9733407|FG001|Treatment Period (156 Weeks)|Termination of Study/Site by GSK|5
6112879|NCT00838903|9733408|FG002|Treatment Period (156 Weeks)|Termination of Study/Site by GSK|5
6112880|NCT00838903|9733409|FG003|Treatment Period (156 Weeks)|Termination of Study/Site by GSK|4
6112881|NCT00838903|9733406|FG000|Treatment Period (156 Weeks)|Patient and PI Decision to Discontinue|0
6112882|NCT00838903|9733407|FG001|Treatment Period (156 Weeks)|Patient and PI Decision to Discontinue|1
6112883|NCT00838903|9733408|FG002|Treatment Period (156 Weeks)|Patient and PI Decision to Discontinue|0
6112884|NCT00838903|9733409|FG003|Treatment Period (156 Weeks)|Patient and PI Decision to Discontinue|0
6112885|NCT00838903|9733406|FG000|Treatment Period (156 Weeks)|Poor Glycemic Control|0
6112886|NCT00838903|9733407|FG001|Treatment Period (156 Weeks)|Poor Glycemic Control|0
6112887|NCT00838903|9733408|FG002|Treatment Period (156 Weeks)|Poor Glycemic Control|0
6112888|NCT00838903|9733409|FG003|Treatment Period (156 Weeks)|Poor Glycemic Control|1
6112889|NCT00838903|9733406|FG000|Treatment Period (156 Weeks)|Poor Therapeutic Response|1
6112890|NCT00838903|9733407|FG001|Treatment Period (156 Weeks)|Poor Therapeutic Response|0
6112891|NCT00838903|9733408|FG002|Treatment Period (156 Weeks)|Poor Therapeutic Response|0
6112892|NCT00838903|9733409|FG003|Treatment Period (156 Weeks)|Poor Therapeutic Response|0
6112893|NCT00838903|9733406|FG000|Treatment Period (156 Weeks)|Pregnancy|0
6112894|NCT00838903|9733407|FG001|Treatment Period (156 Weeks)|Pregnancy|0
6112895|NCT00838903|9733408|FG002|Treatment Period (156 Weeks)|Pregnancy|1
6112896|NCT00838903|9733409|FG003|Treatment Period (156 Weeks)|Pregnancy|0
6112897|NCT00838903|9733406|FG000|Treatment Period (156 Weeks)|PI Decided for Safety Purpose|0
6112898|NCT00838903|9733407|FG001|Treatment Period (156 Weeks)|PI Decided for Safety Purpose|0
6112899|NCT00838903|9733408|FG002|Treatment Period (156 Weeks)|PI Decided for Safety Purpose|1
6112900|NCT00838903|9733409|FG003|Treatment Period (156 Weeks)|PI Decided for Safety Purpose|0
6112901|NCT00838903|9733406|FG000|Treatment Period (156 Weeks)|Site closed|0
6112902|NCT00838903|9733407|FG001|Treatment Period (156 Weeks)|Site closed|0
6112903|NCT00838903|9733408|FG002|Treatment Period (156 Weeks)|Site closed|1
6112904|NCT00838903|9733409|FG003|Treatment Period (156 Weeks)|Site closed|0
6112905|NCT00838903|9733406|FG000|Treatment Period (156 Weeks)|Site Closed and Subject Withdrew Consent|1
6112906|NCT00838903|9733407|FG001|Treatment Period (156 Weeks)|Site Closed and Subject Withdrew Consent|0
6112907|NCT00838903|9733408|FG002|Treatment Period (156 Weeks)|Site Closed and Subject Withdrew Consent|0
6112908|NCT00838903|9733409|FG003|Treatment Period (156 Weeks)|Site Closed and Subject Withdrew Consent|0
6112909|NCT00838903|9733406|FG000|Treatment Period (156 Weeks)|Subject Migrated to Other Country|0
6112910|NCT00838903|9733407|FG001|Treatment Period (156 Weeks)|Subject Migrated to Other Country|1
6208100|NCT01561976|9872879|FG004|Period 1|Adverse Event|0
6208101|NCT01561976|9872880|FG005|Period 1|Adverse Event|0
6208102|NCT01561976|9872875|FG000|Washout Period 1 (7 Days)|Adverse Event|0
6208103|NCT01561976|9872876|FG001|Washout Period 1 (7 Days)|Adverse Event|0
6208104|NCT01561976|9872877|FG002|Washout Period 1 (7 Days)|Adverse Event|0
6208105|NCT01561976|9872878|FG003|Washout Period 1 (7 Days)|Adverse Event|1
6208106|NCT01561976|9872879|FG004|Washout Period 1 (7 Days)|Adverse Event|0
6208107|NCT01561976|9872880|FG005|Washout Period 1 (7 Days)|Adverse Event|0
6208108|NCT01561976|9872875|FG000|Washout Period 1 (7 Days)|Withdrawal by Subject|0
6208109|NCT01561976|9872876|FG001|Washout Period 1 (7 Days)|Withdrawal by Subject|0
6208110|NCT01561976|9872877|FG002|Washout Period 1 (7 Days)|Withdrawal by Subject|0
6208111|NCT01561976|9872878|FG003|Washout Period 1 (7 Days)|Withdrawal by Subject|0
6208112|NCT01561976|9872879|FG004|Washout Period 1 (7 Days)|Withdrawal by Subject|0
6208113|NCT01561976|9872880|FG005|Washout Period 1 (7 Days)|Withdrawal by Subject|1
6208114|NCT01561976|9872875|FG000|Washout Period 2 (7 Days)|Non-compliance|1
6112911|NCT00838903|9733408|FG002|Treatment Period (156 Weeks)|Subject Migrated to Other Country|0
6208115|NCT01561976|9872876|FG001|Washout Period 2 (7 Days)|Non-compliance|0
6112912|NCT00838903|9733409|FG003|Treatment Period (156 Weeks)|Subject Migrated to Other Country|1
6112913|NCT00838903|9733406|FG000|Treatment Period (156 Weeks)|Missing Active Treatment Status|1
6112914|NCT00838903|9733407|FG001|Treatment Period (156 Weeks)|Missing Active Treatment Status|0
6112915|NCT00838903|9733408|FG002|Treatment Period (156 Weeks)|Missing Active Treatment Status|0
6112916|NCT00838903|9733409|FG003|Treatment Period (156 Weeks)|Missing Active Treatment Status|0
6112917|NCT00838903|9733406|FG000|Follow-up Period (8 Weeks)|Adverse Event|0
6112918|NCT00838903|9733407|FG001|Follow-up Period (8 Weeks)|Adverse Event|0
6112919|NCT00838903|9733408|FG002|Follow-up Period (8 Weeks)|Adverse Event|3
6112920|NCT00838903|9733409|FG003|Follow-up Period (8 Weeks)|Adverse Event|1
6112921|NCT00838903|9733406|FG000|Follow-up Period (8 Weeks)|Noncompliance|2
6112922|NCT00838903|9733407|FG001|Follow-up Period (8 Weeks)|Noncompliance|8
6112923|NCT00838903|9733408|FG002|Follow-up Period (8 Weeks)|Noncompliance|5
6112924|NCT00838903|9733409|FG003|Follow-up Period (8 Weeks)|Noncompliance|5
6112925|NCT00838903|9733406|FG000|Follow-up Period (8 Weeks)|Lost to Follow-up|6
6112926|NCT00838903|9733407|FG001|Follow-up Period (8 Weeks)|Lost to Follow-up|28
6112927|NCT00838903|9733408|FG002|Follow-up Period (8 Weeks)|Lost to Follow-up|22
6112928|NCT00838903|9733409|FG003|Follow-up Period (8 Weeks)|Lost to Follow-up|24
6112929|NCT00838903|9733406|FG000|Follow-up Period (8 Weeks)|Did Not Enter Follow-up Period|5
6112930|NCT00838903|9733407|FG001|Follow-up Period (8 Weeks)|Did Not Enter Follow-up Period|7
6112931|NCT00838903|9733408|FG002|Follow-up Period (8 Weeks)|Did Not Enter Follow-up Period|12
6112932|NCT00838903|9733409|FG003|Follow-up Period (8 Weeks)|Did Not Enter Follow-up Period|7
6112933|NCT00838903|9733406|FG000|Follow-up Period (8 Weeks)|Subject Withdrawn from Follow-up|8
6112934|NCT00838903|9733407|FG001|Follow-up Period (8 Weeks)|Subject Withdrawn from Follow-up|13
6112935|NCT00838903|9733408|FG002|Follow-up Period (8 Weeks)|Subject Withdrawn from Follow-up|14
6112936|NCT00838903|9733409|FG003|Follow-up Period (8 Weeks)|Subject Withdrawn from Follow-up|14
6112937|NCT00838903|9733406|FG000|Follow-up Period (8 Weeks)|Physician Decision|1
6112938|NCT00838903|9733407|FG001|Follow-up Period (8 Weeks)|Physician Decision|1
6112939|NCT00838903|9733408|FG002|Follow-up Period (8 Weeks)|Physician Decision|1
6112940|NCT00838903|9733409|FG003|Follow-up Period (8 Weeks)|Physician Decision|1
6112941|NCT00838903|9733406|FG000|Follow-up Period (8 Weeks)|Termination of Study/Site by GSK|3
6112942|NCT00838903|9733407|FG001|Follow-up Period (8 Weeks)|Termination of Study/Site by GSK|4
6112943|NCT00838903|9733408|FG002|Follow-up Period (8 Weeks)|Termination of Study/Site by GSK|6
6112944|NCT00838903|9733409|FG003|Follow-up Period (8 Weeks)|Termination of Study/Site by GSK|4
6112945|NCT00838903|9733406|FG000|Follow-up Period (8 Weeks)|ICF Withdrawn|0
6112946|NCT00838903|9733407|FG001|Follow-up Period (8 Weeks)|ICF Withdrawn|1
6112947|NCT00838903|9733408|FG002|Follow-up Period (8 Weeks)|ICF Withdrawn|0
6112948|NCT00838903|9733409|FG003|Follow-up Period (8 Weeks)|ICF Withdrawn|0
6112949|NCT00838903|9733406|FG000|Follow-up Period (8 Weeks)|Investigator Stopped Study at Site|0
6112950|NCT00838903|9733407|FG001|Follow-up Period (8 Weeks)|Investigator Stopped Study at Site|1
6112951|NCT00838903|9733408|FG002|Follow-up Period (8 Weeks)|Investigator Stopped Study at Site|0
6112952|NCT00838903|9733409|FG003|Follow-up Period (8 Weeks)|Investigator Stopped Study at Site|0
6112953|NCT00838903|9733406|FG000|Follow-up Period (8 Weeks)|Subject Moved out of Town|0
6112954|NCT00838903|9733407|FG001|Follow-up Period (8 Weeks)|Subject Moved out of Town|0
6112955|NCT00838903|9733408|FG002|Follow-up Period (8 Weeks)|Subject Moved out of Town|0
6112956|NCT00838903|9733409|FG003|Follow-up Period (8 Weeks)|Subject Moved out of Town|1
6208116|NCT01561976|9872877|FG002|Washout Period 2 (7 Days)|Non-compliance|1
6286146|NCT02344576|9999030|FG002|6-Month Follow-Up|Withdrawal by Subject|1
6286147|NCT02344576|9999031|FG003|6-Month Follow-Up|Withdrawal by Subject|2
6286148|NCT02344576|9999028|FG000|6-Month Follow-Up|Lost to Follow-up|4
6286149|NCT02344576|9999029|FG001|6-Month Follow-Up|Lost to Follow-up|5
6286150|NCT02344576|9999030|FG002|6-Month Follow-Up|Lost to Follow-up|13
6286151|NCT02344576|9999031|FG003|6-Month Follow-Up|Lost to Follow-up|6
6286152|NCT02344745|9999054|FG000|Overall Study|Data collection sheets were lost|2
6286153|NCT02344745|9999055|FG001|Overall Study|Data collection sheets were lost|0
6286154|NCT02345161|9999074|FG000|Overall Study|Withdrawal by Subject|25
6286155|NCT02345161|9999075|FG001|Overall Study|Withdrawal by Subject|33
6286156|NCT02345161|9999074|FG000|Overall Study|Adverse Event|16
6286157|NCT02345161|9999075|FG001|Overall Study|Adverse Event|19
6286158|NCT02345161|9999074|FG000|Overall Study|Physician Decision|4
6286159|NCT02345161|9999075|FG001|Overall Study|Physician Decision|4
6286160|NCT02345161|9999074|FG000|Overall Study|Lost to Follow-up|0
6286161|NCT02345161|9999075|FG001|Overall Study|Lost to Follow-up|1
6286162|NCT02345226|9999088|FG000|Double-Blind Phase|Adverse Event|5
6286163|NCT02345226|9999089|FG001|Double-Blind Phase|Adverse Event|6
6286164|NCT02345226|9999088|FG000|Double-Blind Phase|Death|3
6286165|NCT02345226|9999089|FG001|Double-Blind Phase|Death|0
6286166|NCT02345226|9999088|FG000|Double-Blind Phase|Pregnancy|0
6286167|NCT02345226|9999089|FG001|Double-Blind Phase|Pregnancy|1
6286168|NCT02345226|9999088|FG000|Double-Blind Phase|Lack of Efficacy|1
6112957|NCT00838903|9733406|FG000|Follow-up Period (8 Weeks)|Missing|1
6286169|NCT02345226|9999089|FG001|Double-Blind Phase|Lack of Efficacy|0
6286170|NCT02345226|9999088|FG000|Double-Blind Phase|Investigator's Discretion|4
6286171|NCT02345226|9999089|FG001|Double-Blind Phase|Investigator's Discretion|3
6286172|NCT02345226|9999088|FG000|Double-Blind Phase|Non-Compliance with Study Drug|1
6286173|NCT02345226|9999089|FG001|Double-Blind Phase|Non-Compliance with Study Drug|2
6112958|NCT00838903|9733407|FG001|Follow-up Period (8 Weeks)|Missing|2
6112959|NCT00838903|9733408|FG002|Follow-up Period (8 Weeks)|Missing|1
6112960|NCT00838903|9733409|FG003|Follow-up Period (8 Weeks)|Missing|1
6112961|NCT00838916|9733421|FG000|Treatment Period (156 Weeks)|Adverse Event|50
6112962|NCT00838916|9733422|FG001|Treatment Period (156 Weeks)|Adverse Event|11
6112963|NCT00838916|9733421|FG000|Treatment Period (156 Weeks)|Protocol Violation|12
6112964|NCT00838916|9733422|FG001|Treatment Period (156 Weeks)|Protocol Violation|3
6112965|NCT00838916|9733421|FG000|Treatment Period (156 Weeks)|Noncompliance|21
6112966|NCT00838916|9733422|FG001|Treatment Period (156 Weeks)|Noncompliance|14
6112967|NCT00838916|9733421|FG000|Treatment Period (156 Weeks)|Severe or Repeated Hypoglycaemia|1
6112968|NCT00838916|9733422|FG001|Treatment Period (156 Weeks)|Severe or Repeated Hypoglycaemia|0
6112969|NCT00838916|9733421|FG000|Treatment Period (156 Weeks)|Lost to Follow-up|19
6112970|NCT00838916|9733422|FG001|Treatment Period (156 Weeks)|Lost to Follow-up|18
6112971|NCT00838916|9733421|FG000|Treatment Period (156 Weeks)|Withdrawal by Subject|81
6112972|NCT00838916|9733422|FG001|Treatment Period (156 Weeks)|Withdrawal by Subject|29
6112973|NCT00838916|9733421|FG000|Treatment Period (156 Weeks)|Physician Decision|6
6112974|NCT00838916|9733422|FG001|Treatment Period (156 Weeks)|Physician Decision|1
6112975|NCT00838916|9733421|FG000|Treatment Period (156 Weeks)|Termination of Study/Site by GSK|1
6112976|NCT00838916|9733422|FG001|Treatment Period (156 Weeks)|Termination of Study/Site by GSK|0
6112977|NCT00838916|9733421|FG000|Treatment Period (156 Weeks)|Missing|3
6112978|NCT00838916|9733422|FG001|Treatment Period (156 Weeks)|Missing|1
6112979|NCT00838916|9733421|FG000|Treatment Period (156 Weeks)|Pregnancy|2
6112980|NCT00838916|9733422|FG001|Treatment Period (156 Weeks)|Pregnancy|0
6112981|NCT00838916|9733421|FG000|Follow-up Period (8 Weeks)|Adverse Event|10
6112982|NCT00838916|9733422|FG001|Follow-up Period (8 Weeks)|Adverse Event|5
6112983|NCT00838916|9733421|FG000|Follow-up Period (8 Weeks)|Noncompliance|6
6112984|NCT00838916|9733422|FG001|Follow-up Period (8 Weeks)|Noncompliance|5
6112985|NCT00838916|9733421|FG000|Follow-up Period (8 Weeks)|Lost to Follow-up|38
6112986|NCT00838916|9733422|FG001|Follow-up Period (8 Weeks)|Lost to Follow-up|22
6112987|NCT00838916|9733421|FG000|Follow-up Period (8 Weeks)|Did not Enter Follow-up Period|7
6112988|NCT00838916|9733422|FG001|Follow-up Period (8 Weeks)|Did not Enter Follow-up Period|7
6112989|NCT00838916|9733421|FG000|Follow-up Period (8 Weeks)|Withdrawn from Follow-up Participation|26
6112990|NCT00838916|9733422|FG001|Follow-up Period (8 Weeks)|Withdrawn from Follow-up Participation|12
6112991|NCT00838916|9733421|FG000|Follow-up Period (8 Weeks)|Physician Decision|2
6112992|NCT00838916|9733422|FG001|Follow-up Period (8 Weeks)|Physician Decision|0
6112993|NCT00838916|9733421|FG000|Follow-up Period (8 Weeks)|Termination of Study/Site by GSK|2
6112994|NCT00838916|9733422|FG001|Follow-up Period (8 Weeks)|Termination of Study/Site by GSK|0
6112995|NCT00838916|9733421|FG000|Follow-up Period (8 Weeks)|Withdrawal by Subject|2
6112996|NCT00838916|9733422|FG001|Follow-up Period (8 Weeks)|Withdrawal by Subject|0
6112997|NCT00838916|9733421|FG000|Follow-up Period (8 Weeks)|Missing|3
6112998|NCT00838916|9733422|FG001|Follow-up Period (8 Weeks)|Missing|0
6112999|NCT00838929|9733431|FG000|Overall Study|Protocol Violation|0
6113000|NCT00838929|9733432|FG001|Overall Study|Protocol Violation|1
6113001|NCT00838929|9733433|FG002|Overall Study|Protocol Violation|0
6113002|NCT00838929|9733431|FG000|Overall Study|Disease progression|0
6113003|NCT00838929|9733432|FG001|Overall Study|Disease progression|2
6113004|NCT00838929|9733433|FG002|Overall Study|Disease progression|1
6113005|NCT00839072|9733439|FG000|First Intervention Period|Withdrawal by Subject|1
6113006|NCT00839072|9733440|FG001|First Intervention Period|Withdrawal by Subject|0
6113007|NCT00839072|9733439|FG000|First Intervention Period|Adverse Event|1
6113008|NCT00839072|9733440|FG001|First Intervention Period|Adverse Event|1
6113009|NCT00839072|9733439|FG000|Second Intervention Period|Withdrawal by Subject|1
6113010|NCT00839072|9733440|FG001|Second Intervention Period|Withdrawal by Subject|0
6113011|NCT00839098|9733449|FG000|Overall Study|Withdrawal by Subject|2
6113012|NCT00839098|9733450|FG001|Overall Study|Withdrawal by Subject|1
6113013|NCT00839098|9733451|FG002|Overall Study|Withdrawal by Subject|7
6113014|NCT00839254|9733476|FG000|Overall Study|Protocol Violation|0
6113015|NCT00839254|9733477|FG001|Overall Study|Protocol Violation|1
6113016|NCT00839254|9733478|FG002|Overall Study|Protocol Violation|1
6113017|NCT00839254|9733479|FG003|Overall Study|Protocol Violation|1
6113018|NCT00839254|9733480|FG004|Overall Study|Protocol Violation|0
6113019|NCT00839254|9733481|FG005|Overall Study|Protocol Violation|0
6113020|NCT00839254|9733482|FG006|Overall Study|Protocol Violation|1
6113021|NCT00839254|9733483|FG007|Overall Study|Protocol Violation|2
6113022|NCT00839254|9733476|FG000|Overall Study|Physician Decision|0
6208117|NCT01561976|9872878|FG003|Washout Period 2 (7 Days)|Non-compliance|0
6208118|NCT01561976|9872879|FG004|Washout Period 2 (7 Days)|Non-compliance|0
6208119|NCT01561976|9872880|FG005|Washout Period 2 (7 Days)|Non-compliance|0
6208120|NCT01562028|9872890|FG000|Overall Study|Withdrawal by Subject|1
6208121|NCT01562028|9872891|FG001|Overall Study|Withdrawal by Subject|1
6208122|NCT01562028|9872890|FG000|Overall Study|Lost to Follow-up|2
6208123|NCT01562028|9872891|FG001|Overall Study|Lost to Follow-up|1
6208124|NCT01562275|9872923|FG000|Stage 1|Adverse Event|0
6208125|NCT01562275|9872924|FG001|Stage 1|Adverse Event|0
6286174|NCT02345226|9999088|FG000|Double-Blind Phase|Withdrew Consent|41
6286175|NCT02345226|9999089|FG001|Double-Blind Phase|Withdrew Consent|39
6286176|NCT02345226|9999088|FG000|Double-Blind Phase|Lost to Follow-up|12
6286177|NCT02345226|9999089|FG001|Double-Blind Phase|Lost to Follow-up|16
6113023|NCT00839254|9733477|FG001|Overall Study|Physician Decision|1
6113024|NCT00839254|9733478|FG002|Overall Study|Physician Decision|0
6113025|NCT00839254|9733479|FG003|Overall Study|Physician Decision|0
6113026|NCT00839254|9733480|FG004|Overall Study|Physician Decision|0
6113027|NCT00839254|9733481|FG005|Overall Study|Physician Decision|0
6113028|NCT00839254|9733482|FG006|Overall Study|Physician Decision|0
6113029|NCT00839254|9733483|FG007|Overall Study|Physician Decision|1
6113030|NCT00839254|9733476|FG000|Overall Study|Wrong treatment number allocation|0
6113031|NCT00839254|9733477|FG001|Overall Study|Wrong treatment number allocation|1
6113032|NCT00839254|9733478|FG002|Overall Study|Wrong treatment number allocation|0
6113033|NCT00839254|9733479|FG003|Overall Study|Wrong treatment number allocation|0
6113034|NCT00839254|9733480|FG004|Overall Study|Wrong treatment number allocation|0
6113035|NCT00839254|9733481|FG005|Overall Study|Wrong treatment number allocation|1
6113036|NCT00839254|9733482|FG006|Overall Study|Wrong treatment number allocation|0
6113037|NCT00839254|9733483|FG007|Overall Study|Wrong treatment number allocation|0
6113038|NCT00839254|9733476|FG000|Overall Study|Adverse Event|12
6113039|NCT00839254|9733477|FG001|Overall Study|Adverse Event|6
6113040|NCT00839254|9733478|FG002|Overall Study|Adverse Event|3
6113041|NCT00839254|9733479|FG003|Overall Study|Adverse Event|5
6113042|NCT00839254|9733480|FG004|Overall Study|Adverse Event|2
6113043|NCT00839254|9733481|FG005|Overall Study|Adverse Event|1
6113044|NCT00839254|9733482|FG006|Overall Study|Adverse Event|0
6113045|NCT00839254|9733483|FG007|Overall Study|Adverse Event|1
6113046|NCT00839254|9733476|FG000|Overall Study|Withdrawal by Subject|87
6113047|NCT00839254|9733477|FG001|Overall Study|Withdrawal by Subject|53
6113048|NCT00839254|9733478|FG002|Overall Study|Withdrawal by Subject|54
6113049|NCT00839254|9733479|FG003|Overall Study|Withdrawal by Subject|32
6113050|NCT00839254|9733480|FG004|Overall Study|Withdrawal by Subject|27
6113051|NCT00839254|9733481|FG005|Overall Study|Withdrawal by Subject|15
6113052|NCT00839254|9733482|FG006|Overall Study|Withdrawal by Subject|22
6113053|NCT00839254|9733483|FG007|Overall Study|Withdrawal by Subject|9
6113054|NCT00839254|9733476|FG000|Overall Study|Wrong group allocation|0
6113055|NCT00839254|9733477|FG001|Overall Study|Wrong group allocation|0
6113056|NCT00839254|9733478|FG002|Overall Study|Wrong group allocation|0
6113057|NCT00839254|9733479|FG003|Overall Study|Wrong group allocation|0
6113058|NCT00839254|9733480|FG004|Overall Study|Wrong group allocation|0
6113059|NCT00839254|9733481|FG005|Overall Study|Wrong group allocation|0
6113060|NCT00839254|9733482|FG006|Overall Study|Wrong group allocation|1
6113061|NCT00839254|9733483|FG007|Overall Study|Wrong group allocation|0
6113062|NCT00839254|9733476|FG000|Overall Study|Parents wanted pneumococcal vaccine|1
6113063|NCT00839254|9733477|FG001|Overall Study|Parents wanted pneumococcal vaccine|0
6113064|NCT00839254|9733478|FG002|Overall Study|Parents wanted pneumococcal vaccine|0
6113065|NCT00839254|9733479|FG003|Overall Study|Parents wanted pneumococcal vaccine|0
6113066|NCT00839254|9733480|FG004|Overall Study|Parents wanted pneumococcal vaccine|0
6113067|NCT00839254|9733481|FG005|Overall Study|Parents wanted pneumococcal vaccine|1
6113068|NCT00839254|9733482|FG006|Overall Study|Parents wanted pneumococcal vaccine|0
6113069|NCT00839254|9733483|FG007|Overall Study|Parents wanted pneumococcal vaccine|0
6113070|NCT00839254|9733476|FG000|Overall Study|Withdrawn due to non-compliance|2
6113071|NCT00839254|9733477|FG001|Overall Study|Withdrawn due to non-compliance|0
6113072|NCT00839254|9733478|FG002|Overall Study|Withdrawn due to non-compliance|0
6113073|NCT00839254|9733479|FG003|Overall Study|Withdrawn due to non-compliance|0
6113074|NCT00839254|9733480|FG004|Overall Study|Withdrawn due to non-compliance|0
6113075|NCT00839254|9733481|FG005|Overall Study|Withdrawn due to non-compliance|0
6113076|NCT00839254|9733482|FG006|Overall Study|Withdrawn due to non-compliance|0
6113077|NCT00839254|9733483|FG007|Overall Study|Withdrawn due to non-compliance|0
6113078|NCT00839254|9733476|FG000|Overall Study|Lost to Follow-up|51
6113079|NCT00839254|9733477|FG001|Overall Study|Lost to Follow-up|30
6113080|NCT00839254|9733478|FG002|Overall Study|Lost to Follow-up|32
6113081|NCT00839254|9733479|FG003|Overall Study|Lost to Follow-up|24
6113082|NCT00839254|9733480|FG004|Overall Study|Lost to Follow-up|8
6113083|NCT00839254|9733481|FG005|Overall Study|Lost to Follow-up|8
6113084|NCT00839254|9733482|FG006|Overall Study|Lost to Follow-up|4
6113085|NCT00839254|9733483|FG007|Overall Study|Lost to Follow-up|2
6113086|NCT00839306|9733534|FG000|Overall Study|Adverse Event|3
6113087|NCT00839306|9733535|FG001|Overall Study|Adverse Event|5
6113088|NCT00839306|9733534|FG000|Overall Study|Lost to Follow-up|6
6113089|NCT00839306|9733535|FG001|Overall Study|Lost to Follow-up|9
6208126|NCT01562275|9872925|FG002|Stage 1|Adverse Event|0
6208127|NCT01562275|9872926|FG003|Stage 1|Adverse Event|1
6208128|NCT01562275|9872927|FG004|Stage 1|Adverse Event|1
6208129|NCT01562275|9872928|FG005|Stage 1|Adverse Event|0
6113090|NCT00839306|9733534|FG000|Overall Study|Withdrawal by Subject|5
6113091|NCT00839306|9733535|FG001|Overall Study|Withdrawal by Subject|7
6113092|NCT00839306|9733534|FG000|Overall Study|Lack of Efficacy|5
6113093|NCT00839306|9733535|FG001|Overall Study|Lack of Efficacy|4
6113094|NCT00839306|9733534|FG000|Overall Study|Other|6
6113095|NCT00839306|9733535|FG001|Overall Study|Other|18
6208130|NCT01562275|9872929|FG006|Stage 1|Adverse Event|0
6208131|NCT01562275|9872930|FG007|Stage 1|Adverse Event|0
6208132|NCT01562275|9872931|FG008|Stage 1|Adverse Event|0
6208133|NCT01562275|9872932|FG009|Stage 1|Adverse Event|1
6208134|NCT01562275|9872933|FG010|Stage 1|Adverse Event|0
6208135|NCT01562275|9872934|FG011|Stage 1|Adverse Event|0
6113096|NCT00839332|9733566|FG000|Phase 1|Disease Progression|38
6113097|NCT00839332|9733567|FG001|Phase 1|Disease Progression|0
6113098|NCT00839332|9733568|FG002|Phase 1|Disease Progression|0
6113099|NCT00839332|9733566|FG000|Phase 1|Adverse Event|6
6113100|NCT00839332|9733567|FG001|Phase 1|Adverse Event|0
6113101|NCT00839332|9733568|FG002|Phase 1|Adverse Event|0
6113102|NCT00839332|9733566|FG000|Phase 1|Withdrawal by Subject|4
6113103|NCT00839332|9733567|FG001|Phase 1|Withdrawal by Subject|0
6113104|NCT00839332|9733568|FG002|Phase 1|Withdrawal by Subject|0
6113105|NCT00839332|9733566|FG000|Phase 1|Physician Decision|2
6113106|NCT00839332|9733567|FG001|Phase 1|Physician Decision|0
6113107|NCT00839332|9733568|FG002|Phase 1|Physician Decision|0
6113108|NCT00839332|9733566|FG000|Phase 2|Protocol Violation|0
6113109|NCT00839332|9733567|FG001|Phase 2|Protocol Violation|1
6113110|NCT00839332|9733568|FG002|Phase 2|Protocol Violation|0
6208136|NCT01562275|9872935|FG012|Stage 1|Adverse Event|0
6208137|NCT01562275|9872923|FG000|Stage 1|Death|1
6208138|NCT01562275|9872924|FG001|Stage 1|Death|0
6208139|NCT01562275|9872925|FG002|Stage 1|Death|0
6208140|NCT01562275|9872926|FG003|Stage 1|Death|0
6208141|NCT01562275|9872927|FG004|Stage 1|Death|0
6208142|NCT01562275|9872928|FG005|Stage 1|Death|0
6208143|NCT01562275|9872929|FG006|Stage 1|Death|0
6208144|NCT01562275|9872930|FG007|Stage 1|Death|0
6208145|NCT01562275|9872931|FG008|Stage 1|Death|0
6208146|NCT01562275|9872932|FG009|Stage 1|Death|0
6208147|NCT01562275|9872933|FG010|Stage 1|Death|0
6208148|NCT01562275|9872934|FG011|Stage 1|Death|0
6208149|NCT01562275|9872935|FG012|Stage 1|Death|0
6208150|NCT01562275|9872923|FG000|Stage 1|Non Compliance|0
6208151|NCT01562275|9872924|FG001|Stage 1|Non Compliance|0
6208152|NCT01562275|9872925|FG002|Stage 1|Non Compliance|1
6208153|NCT01562275|9872926|FG003|Stage 1|Non Compliance|0
6208154|NCT01562275|9872927|FG004|Stage 1|Non Compliance|0
6208155|NCT01562275|9872928|FG005|Stage 1|Non Compliance|0
6208156|NCT01562275|9872929|FG006|Stage 1|Non Compliance|0
6208157|NCT01562275|9872930|FG007|Stage 1|Non Compliance|0
6208158|NCT01562275|9872931|FG008|Stage 1|Non Compliance|0
6208159|NCT01562275|9872932|FG009|Stage 1|Non Compliance|0
6208160|NCT01562275|9872933|FG010|Stage 1|Non Compliance|0
6208161|NCT01562275|9872934|FG011|Stage 1|Non Compliance|0
6208162|NCT01562275|9872935|FG012|Stage 1|Non Compliance|0
6208163|NCT01562275|9872923|FG000|Stage 1|Physician Decision|0
6208164|NCT01562275|9872924|FG001|Stage 1|Physician Decision|0
6208165|NCT01562275|9872925|FG002|Stage 1|Physician Decision|0
6208166|NCT01562275|9872926|FG003|Stage 1|Physician Decision|0
6208167|NCT01562275|9872927|FG004|Stage 1|Physician Decision|1
6208168|NCT01562275|9872928|FG005|Stage 1|Physician Decision|0
6208169|NCT01562275|9872929|FG006|Stage 1|Physician Decision|1
6208170|NCT01562275|9872930|FG007|Stage 1|Physician Decision|0
6208171|NCT01562275|9872931|FG008|Stage 1|Physician Decision|1
6208172|NCT01562275|9872932|FG009|Stage 1|Physician Decision|0
6208173|NCT01562275|9872933|FG010|Stage 1|Physician Decision|0
6208174|NCT01562275|9872934|FG011|Stage 1|Physician Decision|0
6208175|NCT01562275|9872935|FG012|Stage 1|Physician Decision|0
6208176|NCT01562275|9872923|FG000|Stage 1|Progression of Disease|2
6208177|NCT01562275|9872924|FG001|Stage 1|Progression of Disease|6
6208178|NCT01562275|9872925|FG002|Stage 1|Progression of Disease|2
6208179|NCT01562275|9872926|FG003|Stage 1|Progression of Disease|1
6208180|NCT01562275|9872927|FG004|Stage 1|Progression of Disease|2
6208181|NCT01562275|9872928|FG005|Stage 1|Progression of Disease|4
6208182|NCT01562275|9872929|FG006|Stage 1|Progression of Disease|1
6208183|NCT01562275|9872930|FG007|Stage 1|Progression of Disease|7
6208184|NCT01562275|9872931|FG008|Stage 1|Progression of Disease|2
6208185|NCT01562275|9872932|FG009|Stage 1|Progression of Disease|5
6208186|NCT01562275|9872933|FG010|Stage 1|Progression of Disease|3
6208187|NCT01562275|9872934|FG011|Stage 1|Progression of Disease|0
6208188|NCT01562275|9872935|FG012|Stage 1|Progression of Disease|0
6208189|NCT01562275|9872923|FG000|Stage 1|Withdrawal by Subject|0
6208190|NCT01562275|9872924|FG001|Stage 1|Withdrawal by Subject|1
6208191|NCT01562275|9872925|FG002|Stage 1|Withdrawal by Subject|0
6208192|NCT01562275|9872926|FG003|Stage 1|Withdrawal by Subject|2
5980702|NCT02471144|9569414|FG007|Induction Period (Up to Week 12)|Protocol Deviation|0
6113111|NCT00839332|9733566|FG000|Phase 2|Disease Progression|0
6113112|NCT00839332|9733567|FG001|Phase 2|Disease Progression|46
6113113|NCT00839332|9733568|FG002|Phase 2|Disease Progression|21
6113114|NCT00839332|9733566|FG000|Phase 2|Adverse Event|0
6208193|NCT01562275|9872927|FG004|Stage 1|Withdrawal by Subject|0
6208194|NCT01562275|9872928|FG005|Stage 1|Withdrawal by Subject|0
6208195|NCT01562275|9872929|FG006|Stage 1|Withdrawal by Subject|1
6208196|NCT01562275|9872930|FG007|Stage 1|Withdrawal by Subject|0
6208197|NCT01562275|9872931|FG008|Stage 1|Withdrawal by Subject|0
6208198|NCT01562275|9872932|FG009|Stage 1|Withdrawal by Subject|1
6208199|NCT01562275|9872933|FG010|Stage 1|Withdrawal by Subject|0
6208200|NCT01562275|9872934|FG011|Stage 1|Withdrawal by Subject|0
6208201|NCT01562275|9872935|FG012|Stage 1|Withdrawal by Subject|0
6208202|NCT01562275|9872923|FG000|Stage 2|Death|0
6208203|NCT01562275|9872924|FG001|Stage 2|Death|0
6208204|NCT01562275|9872925|FG002|Stage 2|Death|0
6208205|NCT01562275|9872926|FG003|Stage 2|Death|0
6208206|NCT01562275|9872927|FG004|Stage 2|Death|0
6208207|NCT01562275|9872928|FG005|Stage 2|Death|0
6208208|NCT01562275|9872929|FG006|Stage 2|Death|0
6113115|NCT00839332|9733567|FG001|Phase 2|Adverse Event|8
6113116|NCT00839332|9733568|FG002|Phase 2|Adverse Event|6
6113117|NCT00839332|9733566|FG000|Phase 2|Death|0
6113118|NCT00839332|9733567|FG001|Phase 2|Death|4
6113119|NCT00839332|9733568|FG002|Phase 2|Death|2
6113120|NCT00839332|9733566|FG000|Phase 2|Withdrawal by Subject|0
6113121|NCT00839332|9733567|FG001|Phase 2|Withdrawal by Subject|5
6113122|NCT00839332|9733568|FG002|Phase 2|Withdrawal by Subject|8
6113123|NCT00839332|9733566|FG000|Phase 2|Physician Decision|0
6113124|NCT00839332|9733567|FG001|Phase 2|Physician Decision|4
6113125|NCT00839332|9733568|FG002|Phase 2|Physician Decision|1
6113126|NCT00839332|9733566|FG000|Phase 2|Lost to Follow-up|0
6113127|NCT00839332|9733567|FG001|Phase 2|Lost to Follow-up|0
6113128|NCT00839332|9733568|FG002|Phase 2|Lost to Follow-up|1
6113129|NCT00839423|9733581|FG000|Overall Study|Adverse Event|4
6113130|NCT00839423|9733582|FG001|Overall Study|Adverse Event|3
6113131|NCT00839423|9733583|FG002|Overall Study|Adverse Event|7
6113132|NCT00839423|9733584|FG003|Overall Study|Adverse Event|16
6113133|NCT00839423|9733581|FG000|Overall Study|Lack of Efficacy|6
6113134|NCT00839423|9733582|FG001|Overall Study|Lack of Efficacy|6
6113135|NCT00839423|9733583|FG002|Overall Study|Lack of Efficacy|3
6113136|NCT00839423|9733584|FG003|Overall Study|Lack of Efficacy|2
6113137|NCT00839423|9733581|FG000|Overall Study|Non-compliance|0
6113138|NCT00839423|9733582|FG001|Overall Study|Non-compliance|0
6113139|NCT00839423|9733583|FG002|Overall Study|Non-compliance|0
6113140|NCT00839423|9733584|FG003|Overall Study|Non-compliance|1
6113141|NCT00839423|9733581|FG000|Overall Study|Protocol Violation|0
6113142|NCT00839423|9733582|FG001|Overall Study|Protocol Violation|1
6113143|NCT00839423|9733583|FG002|Overall Study|Protocol Violation|2
6113144|NCT00839423|9733584|FG003|Overall Study|Protocol Violation|0
6113145|NCT00839423|9733581|FG000|Overall Study|Withdrawal of consent|4
6113146|NCT00839423|9733582|FG001|Overall Study|Withdrawal of consent|0
6113147|NCT00839423|9733583|FG002|Overall Study|Withdrawal of consent|4
6113148|NCT00839423|9733584|FG003|Overall Study|Withdrawal of consent|1
6113149|NCT00839423|9733581|FG000|Overall Study|Lost to Follow-up|1
6113150|NCT00839423|9733582|FG001|Overall Study|Lost to Follow-up|0
6113151|NCT00839423|9733583|FG002|Overall Study|Lost to Follow-up|1
6113152|NCT00839423|9733584|FG003|Overall Study|Lost to Follow-up|0
6113153|NCT00839423|9733581|FG000|Overall Study|Administrative or other reasons|3
6113154|NCT00839423|9733582|FG001|Overall Study|Administrative or other reasons|0
6113155|NCT00839423|9733583|FG002|Overall Study|Administrative or other reasons|1
6113156|NCT00839423|9733584|FG003|Overall Study|Administrative or other reasons|0
6113157|NCT00839436|9733597|FG000|Overall Study|Developed exclusionary condition|1
6113158|NCT00839436|9733598|FG001|Overall Study|Developed exclusionary condition|0
6113159|NCT00839436|9733599|FG002|Overall Study|Developed exclusionary condition|0
6113160|NCT00839436|9733597|FG000|Overall Study|Withdrawal by Subject|0
6113161|NCT00839436|9733598|FG001|Overall Study|Withdrawal by Subject|1
6113162|NCT00839436|9733599|FG002|Overall Study|Withdrawal by Subject|0
6113163|NCT00839436|9733597|FG000|Overall Study|Study drug no longer available|0
6113164|NCT00839436|9733598|FG001|Overall Study|Study drug no longer available|0
6113165|NCT00839436|9733599|FG002|Overall Study|Study drug no longer available|1
6113166|NCT00839527|9733610|FG000|Treatment Period (TP) (156 Weeks)|Adverse Event|11
6113167|NCT00839527|9733611|FG001|Treatment Period (TP) (156 Weeks)|Adverse Event|29
6113168|NCT00839527|9733612|FG002|Treatment Period (TP) (156 Weeks)|Adverse Event|22
6208209|NCT01562275|9872930|FG007|Stage 2|Death|0
6208210|NCT01562275|9872931|FG008|Stage 2|Death|0
6208211|NCT01562275|9872932|FG009|Stage 2|Death|0
6208212|NCT01562275|9872933|FG010|Stage 2|Death|0
6208213|NCT01562275|9872934|FG011|Stage 2|Death|2
6208214|NCT01562275|9872935|FG012|Stage 2|Death|1
6208215|NCT01562275|9872923|FG000|Stage 2|Progression of Disease|0
6208216|NCT01562275|9872924|FG001|Stage 2|Progression of Disease|0
6208217|NCT01562275|9872925|FG002|Stage 2|Progression of Disease|0
6208218|NCT01562275|9872926|FG003|Stage 2|Progression of Disease|0
6208219|NCT01562275|9872927|FG004|Stage 2|Progression of Disease|0
6208220|NCT01562275|9872928|FG005|Stage 2|Progression of Disease|0
6208221|NCT01562275|9872929|FG006|Stage 2|Progression of Disease|0
6113169|NCT00839527|9733610|FG000|Treatment Period (TP) (156 Weeks)|Protocol Violation|4
6113170|NCT00839527|9733611|FG001|Treatment Period (TP) (156 Weeks)|Protocol Violation|7
6208222|NCT01562275|9872930|FG007|Stage 2|Progression of Disease|0
6208223|NCT01562275|9872931|FG008|Stage 2|Progression of Disease|0
6113171|NCT00839527|9733612|FG002|Treatment Period (TP) (156 Weeks)|Protocol Violation|1
6113172|NCT00839527|9733610|FG000|Treatment Period (TP) (156 Weeks)|Noncompliance|5
6113173|NCT00839527|9733611|FG001|Treatment Period (TP) (156 Weeks)|Noncompliance|6
6113174|NCT00839527|9733612|FG002|Treatment Period (TP) (156 Weeks)|Noncompliance|16
6113175|NCT00839527|9733610|FG000|Treatment Period (TP) (156 Weeks)|Lost to Follow-up|3
6113176|NCT00839527|9733611|FG001|Treatment Period (TP) (156 Weeks)|Lost to Follow-up|12
6113177|NCT00839527|9733612|FG002|Treatment Period (TP) (156 Weeks)|Lost to Follow-up|7
6113178|NCT00839527|9733610|FG000|Treatment Period (TP) (156 Weeks)|Withdrawal by Subject|32
6113179|NCT00839527|9733611|FG001|Treatment Period (TP) (156 Weeks)|Withdrawal by Subject|46
6113180|NCT00839527|9733612|FG002|Treatment Period (TP) (156 Weeks)|Withdrawal by Subject|64
6208224|NCT01562275|9872932|FG009|Stage 2|Progression of Disease|0
6208225|NCT01562275|9872933|FG010|Stage 2|Progression of Disease|0
6208226|NCT01562275|9872934|FG011|Stage 2|Progression of Disease|12
6113181|NCT00839527|9733610|FG000|Treatment Period (TP) (156 Weeks)|Physician Decision|1
6113182|NCT00839527|9733611|FG001|Treatment Period (TP) (156 Weeks)|Physician Decision|6
6113183|NCT00839527|9733612|FG002|Treatment Period (TP) (156 Weeks)|Physician Decision|1
6113184|NCT00839527|9733610|FG000|Treatment Period (TP) (156 Weeks)|Termination of Site by Sponsor|3
6113185|NCT00839527|9733611|FG001|Treatment Period (TP) (156 Weeks)|Termination of Site by Sponsor|8
6113186|NCT00839527|9733612|FG002|Treatment Period (TP) (156 Weeks)|Termination of Site by Sponsor|5
6113187|NCT00839527|9733610|FG000|Treatment Period (TP) (156 Weeks)|Missing|0
6113188|NCT00839527|9733611|FG001|Treatment Period (TP) (156 Weeks)|Missing|1
6113189|NCT00839527|9733612|FG002|Treatment Period (TP) (156 Weeks)|Missing|0
6113190|NCT00839527|9733610|FG000|Treatment Period (TP) (156 Weeks)|Persistant Elevated HbA1c Results|0
6113191|NCT00839527|9733611|FG001|Treatment Period (TP) (156 Weeks)|Persistant Elevated HbA1c Results|0
6113192|NCT00839527|9733612|FG002|Treatment Period (TP) (156 Weeks)|Persistant Elevated HbA1c Results|1
6113193|NCT00839527|9733610|FG000|Treatment Period (TP) (156 Weeks)|Pregnancy|0
6113194|NCT00839527|9733611|FG001|Treatment Period (TP) (156 Weeks)|Pregnancy|1
6113195|NCT00839527|9733612|FG002|Treatment Period (TP) (156 Weeks)|Pregnancy|1
6113196|NCT00839527|9733610|FG000|Treatment Period (TP) (156 Weeks)|Site Closed|1
6113197|NCT00839527|9733611|FG001|Treatment Period (TP) (156 Weeks)|Site Closed|2
6113198|NCT00839527|9733612|FG002|Treatment Period (TP) (156 Weeks)|Site Closed|0
6113199|NCT00839527|9733610|FG000|Treatment Period (TP) (156 Weeks)|Sponsor Decision on Blinding|0
6113200|NCT00839527|9733611|FG001|Treatment Period (TP) (156 Weeks)|Sponsor Decision on Blinding|0
6113201|NCT00839527|9733612|FG002|Treatment Period (TP) (156 Weeks)|Sponsor Decision on Blinding|1
6113202|NCT00839527|9733610|FG000|Follow-up Period (FUP) (8 Weeks)|Adverse Event|1
6113203|NCT00839527|9733611|FG001|Follow-up Period (FUP) (8 Weeks)|Adverse Event|2
6113204|NCT00839527|9733612|FG002|Follow-up Period (FUP) (8 Weeks)|Adverse Event|1
6113205|NCT00839527|9733610|FG000|Follow-up Period (FUP) (8 Weeks)|Noncompliance|1
6113206|NCT00839527|9733611|FG001|Follow-up Period (FUP) (8 Weeks)|Noncompliance|0
6113207|NCT00839527|9733612|FG002|Follow-up Period (FUP) (8 Weeks)|Noncompliance|5
6113208|NCT00839527|9733610|FG000|Follow-up Period (FUP) (8 Weeks)|Lost to Follow-up|8
6113209|NCT00839527|9733611|FG001|Follow-up Period (FUP) (8 Weeks)|Lost to Follow-up|20
6113210|NCT00839527|9733612|FG002|Follow-up Period (FUP) (8 Weeks)|Lost to Follow-up|29
6208227|NCT01562275|9872935|FG012|Stage 2|Progression of Disease|4
6208228|NCT01562314|9872967|FG000|Overall Study|Adverse Event|10
6208229|NCT01562314|9872968|FG001|Overall Study|Adverse Event|5
6208230|NCT01562314|9872967|FG000|Overall Study|Met Withdrawal Criteria|3
6208231|NCT01562314|9872968|FG001|Overall Study|Met Withdrawal Criteria|2
6208232|NCT01562314|9872967|FG000|Overall Study|Withdrawal by Subject|0
6208233|NCT01562314|9872968|FG001|Overall Study|Withdrawal by Subject|1
6208234|NCT01562327|9872974|FG000|Overall Study|Adverse Event|2
6208235|NCT01562327|9872974|FG000|Overall Study|Lack of Efficacy|1
6113211|NCT00839527|9733610|FG000|Follow-up Period (FUP) (8 Weeks)|Withdrawal by Subject|12
6113212|NCT00839527|9733611|FG001|Follow-up Period (FUP) (8 Weeks)|Withdrawal by Subject|21
6113213|NCT00839527|9733612|FG002|Follow-up Period (FUP) (8 Weeks)|Withdrawal by Subject|19
6113214|NCT00839527|9733610|FG000|Follow-up Period (FUP) (8 Weeks)|Physician Decision|0
6113215|NCT00839527|9733611|FG001|Follow-up Period (FUP) (8 Weeks)|Physician Decision|0
6113216|NCT00839527|9733612|FG002|Follow-up Period (FUP) (8 Weeks)|Physician Decision|1
6208236|NCT01562327|9872974|FG000|Overall Study|Participant drop-out|1
6208237|NCT01562327|9872974|FG000|Overall Study|Infusion not received at 6 month window|4
6208238|NCT01562444|9873003|FG000|Overall Study|Did not meet entry criteria|2
6208239|NCT01562444|9873004|FG001|Overall Study|Did not meet entry criteria|0
6208240|NCT01562444|9873005|FG002|Overall Study|Did not meet entry criteria|3
6208241|NCT01562444|9873003|FG000|Overall Study|Did not comply with blood draw schedule|1
6208242|NCT01562444|9873004|FG001|Overall Study|Did not comply with blood draw schedule|0
6208243|NCT01562444|9873005|FG002|Overall Study|Did not comply with blood draw schedule|1
6208244|NCT01562444|9873003|FG000|Overall Study|Unavailable serological results|0
6208245|NCT01562444|9873004|FG001|Overall Study|Unavailable serological results|2
6208246|NCT01562444|9873005|FG002|Overall Study|Unavailable serological results|2
6208247|NCT01562444|9873003|FG000|Overall Study|Protocol forbidden concomitant vaccine|1
6208248|NCT01562444|9873004|FG001|Overall Study|Protocol forbidden concomitant vaccine|0
6208249|NCT01562444|9873005|FG002|Overall Study|Protocol forbidden concomitant vaccine|1
6208250|NCT01562444|9873003|FG000|Overall Study|Protocol forbidden medication|1
6208251|NCT01562444|9873004|FG001|Overall Study|Protocol forbidden medication|0
6208252|NCT01562444|9873005|FG002|Overall Study|Protocol forbidden medication|0
6208253|NCT01562548|9873017|FG000|Overall Study|Lost to Follow-up|0
6208254|NCT01562548|9873018|FG001|Overall Study|Lost to Follow-up|0
6208255|NCT01562548|9873019|FG002|Overall Study|Lost to Follow-up|1
6208256|NCT01562548|9873020|FG003|Overall Study|Lost to Follow-up|0
6208257|NCT01562613|9873032|FG000|Overall Study|Lost to Follow-up|2
6208258|NCT01562613|9873032|FG000|Overall Study|Withdrawal by Subject|2
6208259|NCT01562743|9873045|FG000|Overall Study|Adverse Event|29
6208260|NCT01562743|9873045|FG000|Overall Study|Lack of Efficacy|3
6208261|NCT01562743|9873045|FG000|Overall Study|Withdrawal by Subject|13
6208262|NCT01562743|9873045|FG000|Overall Study|Protocol Violation|1
6208263|NCT01562743|9873045|FG000|Overall Study|Discontinuation criteria|2
6208264|NCT01562743|9873045|FG000|Overall Study|Lost to Follow-up|2
6113217|NCT00839527|9733610|FG000|Follow-up Period (FUP) (8 Weeks)|Termination of Study by Sponsor|3
6113218|NCT00839527|9733611|FG001|Follow-up Period (FUP) (8 Weeks)|Termination of Study by Sponsor|10
6113219|NCT00839527|9733612|FG002|Follow-up Period (FUP) (8 Weeks)|Termination of Study by Sponsor|5
6113220|NCT00839527|9733610|FG000|Follow-up Period (FUP) (8 Weeks)|Informed Consent Recalled by Participant|1
6113221|NCT00839527|9733611|FG001|Follow-up Period (FUP) (8 Weeks)|Informed Consent Recalled by Participant|0
6113222|NCT00839527|9733612|FG002|Follow-up Period (FUP) (8 Weeks)|Informed Consent Recalled by Participant|0
6113223|NCT00839527|9733610|FG000|Follow-up Period (FUP) (8 Weeks)|Investigator Closed Study at Site|1
6113224|NCT00839527|9733611|FG001|Follow-up Period (FUP) (8 Weeks)|Investigator Closed Study at Site|0
6113225|NCT00839527|9733612|FG002|Follow-up Period (FUP) (8 Weeks)|Investigator Closed Study at Site|0
6113226|NCT00839527|9733610|FG000|Follow-up Period (FUP) (8 Weeks)|Site Closed|0
6113227|NCT00839527|9733611|FG001|Follow-up Period (FUP) (8 Weeks)|Site Closed|1
6113228|NCT00839527|9733612|FG002|Follow-up Period (FUP) (8 Weeks)|Site Closed|0
6113229|NCT00839527|9733610|FG000|Follow-up Period (FUP) (8 Weeks)|Site Closing and Withdrew Consent|1
6113230|NCT00839527|9733611|FG001|Follow-up Period (FUP) (8 Weeks)|Site Closing and Withdrew Consent|0
6113231|NCT00839527|9733612|FG002|Follow-up Period (FUP) (8 Weeks)|Site Closing and Withdrew Consent|1
6113232|NCT00839527|9733610|FG000|Follow-up Period (FUP) (8 Weeks)|Unable to Complete Follow-up|0
6113233|NCT00839527|9733611|FG001|Follow-up Period (FUP) (8 Weeks)|Unable to Complete Follow-up|1
6113234|NCT00839527|9733612|FG002|Follow-up Period (FUP) (8 Weeks)|Unable to Complete Follow-up|0
6113235|NCT00839527|9733610|FG000|Follow-up Period (FUP) (8 Weeks)|Missing Follow-up Status|0
6113236|NCT00839527|9733611|FG001|Follow-up Period (FUP) (8 Weeks)|Missing Follow-up Status|1
6113237|NCT00839527|9733612|FG002|Follow-up Period (FUP) (8 Weeks)|Missing Follow-up Status|1
6113238|NCT00839800|9733637|FG000|Overall Study|Adverse Event|8
6113239|NCT00839800|9733638|FG001|Overall Study|Adverse Event|12
6113240|NCT00839800|9733637|FG000|Overall Study|Lost to Follow-up|31
6113241|NCT00839800|9733638|FG001|Overall Study|Lost to Follow-up|26
6113242|NCT00839800|9733637|FG000|Overall Study|Withdrawal by Subject|28
6113243|NCT00839800|9733638|FG001|Overall Study|Withdrawal by Subject|34
6113244|NCT00839800|9733637|FG000|Overall Study|Incorrect Enrolment|3
6113245|NCT00839800|9733638|FG001|Overall Study|Incorrect Enrolment|3
6113246|NCT00839800|9733637|FG000|Overall Study|Study-Specific Discontinuation Criteria|6
6113247|NCT00839800|9733638|FG001|Overall Study|Study-Specific Discontinuation Criteria|13
6113248|NCT00839800|9733637|FG000|Overall Study|Safety Reasons|2
6113249|NCT00839800|9733638|FG001|Overall Study|Safety Reasons|1
6113250|NCT00839800|9733637|FG000|Overall Study|Other|8
6113251|NCT00839800|9733638|FG001|Overall Study|Other|14
6113252|NCT00839800|9733637|FG000|Overall Study|Severe Non-Compliance to Protocol|7
6113253|NCT00839800|9733638|FG001|Overall Study|Severe Non-Compliance to Protocol|7
6113254|NCT00839852|9733644|FG000|Overall Study|Adverse Event|10
6113255|NCT00839852|9733644|FG000|Overall Study|Insufficient Therapeutic Response|3
6113256|NCT00839852|9733644|FG000|Overall Study|Protocol Violation|9
6113257|NCT00839852|9733644|FG000|Overall Study|Withdrawal of Consent|16
6113258|NCT00839852|9733644|FG000|Overall Study|Lost to Follow-up|7
6113259|NCT00839852|9733644|FG000|Overall Study|Lack of Compliance While in Jail|1
6113260|NCT00839852|9733644|FG000|Overall Study|Pregnancy|1
6113261|NCT00839917|9733650|FG000|Overall Study|Lost to Follow-up|1
6113262|NCT00839917|9733651|FG001|Overall Study|Lost to Follow-up|0
6113263|NCT00839917|9733650|FG000|Overall Study|Did not receive vaccine|0
6113264|NCT00839917|9733651|FG001|Overall Study|Did not receive vaccine|1
6113265|NCT00839956|9733657|FG000|Overall Study|Adverse Event|2
6113266|NCT00839956|9733657|FG000|Overall Study|Lack of Efficacy|6
6113267|NCT00839956|9733657|FG000|Overall Study|Physician Decision|1
6113268|NCT00839956|9733657|FG000|Overall Study|Withdrawal by Subject|3
6113269|NCT00840034|9733674|FG000|Acute Treatment Phase|Adverse Event|6
6113270|NCT00840034|9733675|FG001|Acute Treatment Phase|Adverse Event|8
6113271|NCT00840034|9733674|FG000|Acute Treatment Phase|Lack of Efficacy|2
6113272|NCT00840034|9733675|FG001|Acute Treatment Phase|Lack of Efficacy|0
6113273|NCT00840034|9733674|FG000|Acute Treatment Phase|Lost to Follow-up|5
6113274|NCT00840034|9733675|FG001|Acute Treatment Phase|Lost to Follow-up|12
6113275|NCT00840034|9733674|FG000|Acute Treatment Phase|Physician Decision|0
6113276|NCT00840034|9733675|FG001|Acute Treatment Phase|Physician Decision|1
6113277|NCT00840034|9733674|FG000|Acute Treatment Phase|Protocol Violation|2
6113278|NCT00840034|9733675|FG001|Acute Treatment Phase|Protocol Violation|4
6113279|NCT00840034|9733674|FG000|Acute Treatment Phase|Withdrawal by Subject|6
6113280|NCT00840034|9733675|FG001|Acute Treatment Phase|Withdrawal by Subject|11
6113281|NCT00840034|9733674|FG000|Taper Phase|Adverse Event|1
6113282|NCT00840034|9733675|FG001|Taper Phase|Adverse Event|0
6113283|NCT00840034|9733674|FG000|Taper Phase|Lost to Follow-up|1
6113284|NCT00840034|9733675|FG001|Taper Phase|Lost to Follow-up|1
6113285|NCT00840034|9733674|FG000|Taper Phase|Withdrawal by Subject|1
6113286|NCT00840034|9733675|FG001|Taper Phase|Withdrawal by Subject|1
6113287|NCT00840060|9733685|FG000|Overall Study|Withdrawal by Subject|1
6113288|NCT00840060|9733686|FG001|Overall Study|Withdrawal by Subject|0
6113289|NCT00840060|9733685|FG000|Overall Study|Change in emotional/behavioral status|0
6113290|NCT00840060|9733686|FG001|Overall Study|Change in emotional/behavioral status|1
6113291|NCT00840086|9733692|FG000|Overall Study|Adverse Event|1
6113292|NCT00840086|9733692|FG000|Overall Study|Protocol Violation|2
6113293|NCT00840086|9733692|FG000|Overall Study|Lost to Follow-up|1
6113294|NCT00840294|9733701|FG000|Overall Study|Withdrawal by Subject|2
6113295|NCT00840294|9733702|FG001|Overall Study|Withdrawal by Subject|1
6113296|NCT00840294|9733701|FG000|Overall Study|Protocol Violation|1
6113297|NCT00840294|9733702|FG001|Overall Study|Protocol Violation|3
6113298|NCT00840294|9733701|FG000|Overall Study|Illness|0
6113299|NCT00840294|9733702|FG001|Overall Study|Illness|1
6113300|NCT00840450|9733712|FG000|Overall Study|Adverse Event|1
6113301|NCT00840450|9733712|FG000|Overall Study|Lack of Efficacy|2
6113302|NCT00840463|9733718|FG000|Overall Study|Adverse Event|1
6113303|NCT00840463|9733719|FG001|Overall Study|Adverse Event|0
6113304|NCT00840658|9733729|FG000|Overall Study|Death|2
6113305|NCT00840658|9733730|FG001|Overall Study|Death|2
6113306|NCT00840658|9733731|FG002|Overall Study|Death|3
6113307|NCT00840658|9733732|FG003|Overall Study|Death|3
6113308|NCT00840658|9733729|FG000|Overall Study|Lost to Follow-up|3
6113309|NCT00840658|9733730|FG001|Overall Study|Lost to Follow-up|1
6113310|NCT00840658|9733731|FG002|Overall Study|Lost to Follow-up|2
6113311|NCT00840658|9733732|FG003|Overall Study|Lost to Follow-up|1
6113312|NCT00840749|9733748|FG000|Overall Study|Death|1
6113313|NCT00840749|9733749|FG001|Overall Study|Death|2
6113314|NCT00840749|9733748|FG000|Overall Study|not treated on study arm|11
6113315|NCT00840749|9733749|FG001|Overall Study|not treated on study arm|11
6113316|NCT00840749|9733748|FG000|Overall Study|study closed|19
6113317|NCT00840749|9733749|FG001|Overall Study|study closed|14
6113318|NCT00840970|9733755|FG000|Overall Study|Adverse Event|0
6113319|NCT00840970|9733756|FG001|Overall Study|Adverse Event|0
6113320|NCT00840970|9733757|FG002|Overall Study|Adverse Event|1
6113321|NCT00840996|9733769|FG000|Overall Study|Withdrawal by Subject|1
6113322|NCT00840996|9733770|FG001|Overall Study|Withdrawal by Subject|0
6113323|NCT00841100|9733785|FG000|Phase 1 (28 Days)|Adverse Event|1
6113324|NCT00841100|9733785|FG000|Phase 1 (28 Days)|Participant non-compliance|2
6113325|NCT00841321|9733810|FG000|Overall Study|Lost to Follow-up|1
6113326|NCT00841321|9733811|FG001|Overall Study|Lost to Follow-up|1
6113327|NCT00841321|9733810|FG000|Overall Study|Adverse Event|0
6113328|NCT00841321|9733811|FG001|Overall Study|Adverse Event|2
6208265|NCT01562743|9873045|FG000|Overall Study|Physician Decision|2
6208266|NCT01562782|9873055|FG000|Overall Study|Withdrawal by Subject|3
6208267|NCT01562782|9873056|FG001|Overall Study|Withdrawal by Subject|3
6208268|NCT01562782|9873055|FG000|Overall Study|screen failure|1
6208269|NCT01562782|9873056|FG001|Overall Study|screen failure|2
6208270|NCT01562873|9873062|FG000|Overall Study|Disease Progression per RECIST|10
6208271|NCT01562873|9873063|FG001|Overall Study|Disease Progression per RECIST|0
6208272|NCT01562873|9873062|FG000|Overall Study|Adverse Event|1
6208273|NCT01562873|9873063|FG001|Overall Study|Adverse Event|0
6208274|NCT01562873|9873062|FG000|Overall Study|Clinical Disease Progression|9
6208275|NCT01562873|9873063|FG001|Overall Study|Clinical Disease Progression|0
6208276|NCT01562873|9873062|FG000|Overall Study|Clinical PD and adverse event|1
6208277|NCT01562873|9873063|FG001|Overall Study|Clinical PD and adverse event|0
6208278|NCT01563029|9873085|FG000|Overall Study|Adverse Event|1
6208279|NCT01563029|9873086|FG001|Overall Study|Adverse Event|0
6208280|NCT01563029|9873087|FG002|Overall Study|Adverse Event|1
6208281|NCT01563029|9873088|FG003|Overall Study|Adverse Event|2
6208282|NCT01563029|9873089|FG004|Overall Study|Adverse Event|1
6208283|NCT01563029|9873085|FG000|Overall Study|Lack of Efficacy|42
6208284|NCT01563029|9873086|FG001|Overall Study|Lack of Efficacy|16
6208285|NCT01563029|9873087|FG002|Overall Study|Lack of Efficacy|23
6208286|NCT01563029|9873088|FG003|Overall Study|Lack of Efficacy|21
6208287|NCT01563029|9873089|FG004|Overall Study|Lack of Efficacy|19
6208288|NCT01563029|9873085|FG000|Overall Study|Protocol Violation|1
6208289|NCT01563029|9873086|FG001|Overall Study|Protocol Violation|2
6208290|NCT01563029|9873087|FG002|Overall Study|Protocol Violation|3
6208291|NCT01563029|9873088|FG003|Overall Study|Protocol Violation|1
6208292|NCT01563029|9873089|FG004|Overall Study|Protocol Violation|3
6208293|NCT01563029|9873085|FG000|Overall Study|Protocol defined stopping criteria|1
6208294|NCT01563029|9873086|FG001|Overall Study|Protocol defined stopping criteria|0
6208295|NCT01563029|9873087|FG002|Overall Study|Protocol defined stopping criteria|0
6208296|NCT01563029|9873088|FG003|Overall Study|Protocol defined stopping criteria|0
6208297|NCT01563029|9873089|FG004|Overall Study|Protocol defined stopping criteria|0
6208298|NCT01563029|9873085|FG000|Overall Study|Lost to Follow-up|1
6208299|NCT01563029|9873086|FG001|Overall Study|Lost to Follow-up|0
6208300|NCT01563029|9873087|FG002|Overall Study|Lost to Follow-up|1
6208301|NCT01563029|9873088|FG003|Overall Study|Lost to Follow-up|1
6113329|NCT00841568|9733835|FG000|Overall Study|Adverse Event|1
6113330|NCT00841568|9733835|FG000|Overall Study|Death|1
6113331|NCT00841568|9733835|FG000|Overall Study|Withdrawal by Subject|2
6113332|NCT00841568|9733835|FG000|Overall Study|Creatinine over the withdrawal criteria|1
6113333|NCT00841672|9733845|FG000|Overall Study|Adverse Event|7
6113334|NCT00841672|9733846|FG001|Overall Study|Adverse Event|16
6113335|NCT00841672|9733845|FG000|Overall Study|Abnormal test procedure result(s)|0
6208302|NCT01563029|9873089|FG004|Overall Study|Lost to Follow-up|1
6208303|NCT01563029|9873085|FG000|Overall Study|Physician Decision|3
6208304|NCT01563029|9873086|FG001|Overall Study|Physician Decision|5
6208305|NCT01563029|9873087|FG002|Overall Study|Physician Decision|2
6208306|NCT01563029|9873088|FG003|Overall Study|Physician Decision|4
6208307|NCT01563029|9873089|FG004|Overall Study|Physician Decision|2
6113336|NCT00841672|9733846|FG001|Overall Study|Abnormal test procedure result(s)|1
6113337|NCT00841672|9733845|FG000|Overall Study|Subject withdrew consent|2
6113338|NCT00841672|9733846|FG001|Overall Study|Subject withdrew consent|4
6113339|NCT00841672|9733845|FG000|Overall Study|Lost to Follow-up|1
6113340|NCT00841672|9733846|FG001|Overall Study|Lost to Follow-up|1
6113341|NCT00841672|9733845|FG000|Overall Study|Administrative problems|9
6113342|NCT00841672|9733846|FG001|Overall Study|Administrative problems|9
6113343|NCT00841672|9733845|FG000|Overall Study|Misrandomized|1
6113344|NCT00841672|9733846|FG001|Overall Study|Misrandomized|0
6113345|NCT00841672|9733845|FG000|Overall Study|Protocol Deviation|0
6113346|NCT00841672|9733846|FG001|Overall Study|Protocol Deviation|1
6113347|NCT00841763|9733854|FG000|Overall Study|Withdrawal by Subject|60
6113348|NCT00841763|9733855|FG001|Overall Study|Withdrawal by Subject|17
6113349|NCT00841763|9733856|FG002|Overall Study|Withdrawal by Subject|4
6113350|NCT00841763|9733857|FG003|Overall Study|Withdrawal by Subject|1
6113351|NCT00841763|9733854|FG000|Overall Study|Adverse Event|9
6113352|NCT00841763|9733855|FG001|Overall Study|Adverse Event|10
6113353|NCT00841763|9733856|FG002|Overall Study|Adverse Event|3
6113354|NCT00841763|9733857|FG003|Overall Study|Adverse Event|2
6113355|NCT00841763|9733854|FG000|Overall Study|Lost to Follow-up|63
6113356|NCT00841763|9733855|FG001|Overall Study|Lost to Follow-up|25
6113357|NCT00841763|9733856|FG002|Overall Study|Lost to Follow-up|0
6113358|NCT00841763|9733857|FG003|Overall Study|Lost to Follow-up|0
6113359|NCT00841763|9733854|FG000|Overall Study|Protocol Violation|20
6113360|NCT00841763|9733855|FG001|Overall Study|Protocol Violation|3
6113361|NCT00841763|9733856|FG002|Overall Study|Protocol Violation|1
6113362|NCT00841763|9733857|FG003|Overall Study|Protocol Violation|0
6113363|NCT00841763|9733854|FG000|Overall Study|Administrative Reasons|3
6113364|NCT00841763|9733855|FG001|Overall Study|Administrative Reasons|1
6113365|NCT00841763|9733856|FG002|Overall Study|Administrative Reasons|0
6113366|NCT00841763|9733857|FG003|Overall Study|Administrative Reasons|0
6113367|NCT00841763|9733854|FG000|Overall Study|Unable to Classify|7
6113368|NCT00841763|9733855|FG001|Overall Study|Unable to Classify|1
6113369|NCT00841763|9733856|FG002|Overall Study|Unable to Classify|0
6113370|NCT00841763|9733857|FG003|Overall Study|Unable to Classify|0
6113371|NCT00841776|9733904|FG000|Overall Study|Lack of Efficacy|0
6113372|NCT00841776|9733905|FG001|Overall Study|Lack of Efficacy|1
6113373|NCT00841776|9733904|FG000|Overall Study|Lost to Follow-up|2
6113374|NCT00841776|9733905|FG001|Overall Study|Lost to Follow-up|1
6113375|NCT00841776|9733904|FG000|Overall Study|Withdrawal by Subject|0
6113376|NCT00841776|9733905|FG001|Overall Study|Withdrawal by Subject|1
6113377|NCT00841906|9733924|FG000|Overall Study|Withdrawal by Subject|2
6113378|NCT00841906|9733925|FG001|Overall Study|Withdrawal by Subject|0
6113379|NCT00842153|9733965|FG000|Overall Study|Adverse Event|0
6113380|NCT00842153|9733966|FG001|Overall Study|Adverse Event|1
6113381|NCT00842153|9733965|FG000|Overall Study|Lost to Follow-up|1
6113382|NCT00842153|9733966|FG001|Overall Study|Lost to Follow-up|2
6113383|NCT00842244|9733976|FG000|Overall Study|Death|3
6113384|NCT00842244|9733976|FG000|Overall Study|Withdrawal by Subject|1
6113385|NCT00842244|9733976|FG000|Overall Study|Other|17
6113386|NCT00842257|9733983|FG000|Overall Study|Adverse Event|1
6113387|NCT00842309|9733993|FG000|Overall Study|Withdrawal by Subject|3
6113388|NCT00842309|9733994|FG001|Overall Study|Withdrawal by Subject|1
6113389|NCT00842348|9734008|FG000|Patients Randomised in Study 726|Did not enter Study 729|59
6113390|NCT00842348|9734009|FG001|Patients Randomised in Study 726|Did not enter Study 729|56
6113391|NCT00842348|9734008|FG000|Study 729|Disease progression/death|19
6113392|NCT00842348|9734009|FG001|Study 729|Disease progression/death|30
6113393|NCT00842348|9734008|FG000|Study 729|Adverse Event|1
6113394|NCT00842348|9734009|FG001|Study 729|Adverse Event|1
6113395|NCT00842348|9734008|FG000|Study 729|Protocol Violation|1
6113396|NCT00842348|9734009|FG001|Study 729|Protocol Violation|1
6113397|NCT00842348|9734008|FG000|Study 729|Withdrawal by Subject|2
6113398|NCT00842348|9734009|FG001|Study 729|Withdrawal by Subject|4
6113399|NCT00842348|9734008|FG000|Study 729|Due to Sponsor stopping the study|1
6113400|NCT00842348|9734009|FG001|Study 729|Due to Sponsor stopping the study|1
6113401|NCT00842348|9734008|FG000|Study 729|Due to non-availability of IP|0
6208308|NCT01563029|9873085|FG000|Overall Study|Withdrawal by Subject|4
6208309|NCT01563029|9873086|FG001|Overall Study|Withdrawal by Subject|1
6208310|NCT01563029|9873087|FG002|Overall Study|Withdrawal by Subject|3
6208311|NCT01563029|9873088|FG003|Overall Study|Withdrawal by Subject|4
6113402|NCT00842348|9734009|FG001|Study 729|Due to non-availability of IP|1
6113403|NCT00842348|9734008|FG000|Study 729|Sponsor's decision|1
6113404|NCT00842348|9734009|FG001|Study 729|Sponsor's decision|0
6113405|NCT00842348|9734008|FG000|Study 729|Surgical resection|1
6113406|NCT00842348|9734009|FG001|Study 729|Surgical resection|0
6113407|NCT00842361|9734021|FG000|Overall Study|Protocol Violation|1
6113408|NCT00842361|9734022|FG001|Overall Study|Protocol Violation|0
6113409|NCT00842361|9734021|FG000|Overall Study|Unclassified|0
6208312|NCT01563029|9873089|FG004|Overall Study|Withdrawal by Subject|3
6113410|NCT00842361|9734022|FG001|Overall Study|Unclassified|2
6113411|NCT00842543|9734032|FG000|Overall Study|Withdrawal by Subject|2
6113412|NCT00842543|9734033|FG001|Overall Study|Withdrawal by Subject|0
6113413|NCT00842543|9734034|FG002|Overall Study|Withdrawal by Subject|3
6113414|NCT00842543|9734035|FG003|Overall Study|Withdrawal by Subject|4
6113415|NCT00842712|9734071|FG000|Safety Run-in Part|Adverse Event|0
6113416|NCT00842712|9734072|FG001|Safety Run-in Part|Adverse Event|1
6113417|NCT00842712|9734073|FG002|Safety Run-in Part|Adverse Event|0
6113418|NCT00842712|9734074|FG003|Safety Run-in Part|Adverse Event|0
6113419|NCT00842712|9734075|FG004|Safety Run-in Part|Adverse Event|0
6113420|NCT00842712|9734076|FG005|Safety Run-in Part|Adverse Event|0
6113421|NCT00842712|9734077|FG006|Safety Run-in Part|Adverse Event|0
6113422|NCT00842712|9734071|FG000|Safety Run-in Part|Progressive disease|3
6113423|NCT00842712|9734072|FG001|Safety Run-in Part|Progressive disease|1
6113424|NCT00842712|9734073|FG002|Safety Run-in Part|Progressive disease|0
6113425|NCT00842712|9734074|FG003|Safety Run-in Part|Progressive disease|1
6113426|NCT00842712|9734075|FG004|Safety Run-in Part|Progressive disease|0
6113427|NCT00842712|9734076|FG005|Safety Run-in Part|Progressive disease|0
6113428|NCT00842712|9734077|FG006|Safety Run-in Part|Progressive disease|0
6113429|NCT00842712|9734071|FG000|Randomized Part|Randomized but not treated|0
6113430|NCT00842712|9734072|FG001|Randomized Part|Randomized but not treated|0
6113431|NCT00842712|9734073|FG002|Randomized Part|Randomized but not treated|0
6113432|NCT00842712|9734074|FG003|Randomized Part|Randomized but not treated|0
6113433|NCT00842712|9734075|FG004|Randomized Part|Randomized but not treated|0
6113434|NCT00842712|9734076|FG005|Randomized Part|Randomized but not treated|1
6113435|NCT00842712|9734077|FG006|Randomized Part|Randomized but not treated|4
6113436|NCT00842712|9734071|FG000|Randomized Part|Ongoing at cut-off date|0
6113437|NCT00842712|9734072|FG001|Randomized Part|Ongoing at cut-off date|0
6113438|NCT00842712|9734073|FG002|Randomized Part|Ongoing at cut-off date|0
6113439|NCT00842712|9734074|FG003|Randomized Part|Ongoing at cut-off date|0
6113440|NCT00842712|9734075|FG004|Randomized Part|Ongoing at cut-off date|0
6113441|NCT00842712|9734076|FG005|Randomized Part|Ongoing at cut-off date|0
6113442|NCT00842712|9734077|FG006|Randomized Part|Ongoing at cut-off date|2
6113443|NCT00842829|9734112|FG000|Dose Titration Period|Adverse Event|11
6113444|NCT00842829|9734113|FG001|Dose Titration Period|Adverse Event|10
6113445|NCT00842829|9734114|FG002|Dose Titration Period|Adverse Event|0
6113446|NCT00842829|9734112|FG000|Dose Titration Period|Lack of Efficacy|4
6113447|NCT00842829|9734113|FG001|Dose Titration Period|Lack of Efficacy|1
6113448|NCT00842829|9734114|FG002|Dose Titration Period|Lack of Efficacy|0
6113449|NCT00842829|9734112|FG000|Dose Titration Period|Unstable persistent cancer pain|1
6113450|NCT00842829|9734113|FG001|Dose Titration Period|Unstable persistent cancer pain|0
6113451|NCT00842829|9734114|FG002|Dose Titration Period|Unstable persistent cancer pain|0
6113452|NCT00842829|9734112|FG000|Dose Titration Period|Withdrawal by Subject|2
6208313|NCT01563172|9873122|FG000|Overall Study|Adverse Event|5
6208314|NCT01563172|9873122|FG000|Overall Study|Lost to Follow-up|2
6208315|NCT01563172|9873122|FG000|Overall Study|Other (Protocol deviation)|5
6208316|NCT01563172|9873122|FG000|Overall Study|Other (Not specified)|1
6208317|NCT01563185|9873137|FG000|Overall Study|Withdrawal by Subject|1
6208318|NCT01563185|9873137|FG000|Overall Study|Non-Compliance with study drug|1
6208319|NCT01563237|9873145|FG000|Overall Study|Lost to Follow-up|6
6208320|NCT01563237|9873146|FG001|Overall Study|Lost to Follow-up|0
6208321|NCT01563237|9873145|FG000|Overall Study|Withdrawal by Subject|1
6208322|NCT01563237|9873146|FG001|Overall Study|Withdrawal by Subject|0
6208323|NCT01563237|9873145|FG000|Overall Study|Adverse Event|1
6208324|NCT01563237|9873146|FG001|Overall Study|Adverse Event|0
6208325|NCT01563237|9873145|FG000|Overall Study|Medical Reasons|1
6208326|NCT01563237|9873146|FG001|Overall Study|Medical Reasons|0
6208327|NCT01563237|9873145|FG000|Overall Study|Death|1
6208328|NCT01563237|9873146|FG001|Overall Study|Death|0
6208329|NCT01563354|9873154|FG000|Core Phase|Adverse Event|5
6208330|NCT01563354|9873155|FG001|Core Phase|Adverse Event|15
6208331|NCT01563354|9873156|FG002|Core Phase|Adverse Event|13
6208332|NCT01563354|9873154|FG000|Core Phase|Withdrawal by Subject|1
6208333|NCT01563354|9873155|FG001|Core Phase|Withdrawal by Subject|0
6208334|NCT01563354|9873156|FG002|Core Phase|Withdrawal by Subject|3
6208335|NCT01563354|9873154|FG000|Core Phase|Lost to Follow-up|1
6208336|NCT01563354|9873155|FG001|Core Phase|Lost to Follow-up|0
6208337|NCT01563354|9873156|FG002|Core Phase|Lost to Follow-up|0
6208338|NCT01563354|9873154|FG000|Core Phase|Death|1
6208339|NCT01563354|9873155|FG001|Core Phase|Death|5
6208340|NCT01563354|9873156|FG002|Core Phase|Death|2
6208341|NCT01563354|9873154|FG000|Core Phase|Diseasse progression|18
6208342|NCT01563354|9873155|FG001|Core Phase|Diseasse progression|7
5980703|NCT02471144|9569415|FG008|Induction Period (Up to Week 12)|Protocol Deviation|0
5980704|NCT02471144|9569416|FG009|Induction Period (Up to Week 12)|Protocol Deviation|0
5980705|NCT02471144|9569417|FG010|Induction Period (Up to Week 12)|Protocol Deviation|0
5980706|NCT02471144|9569407|FG000|Induction Period (Up to Week 12)|Subject/Guardian Decision|1
5980707|NCT02471144|9569408|FG001|Induction Period (Up to Week 12)|Subject/Guardian Decision|1
5980708|NCT02471144|9569409|FG002|Induction Period (Up to Week 12)|Subject/Guardian Decision|0
5980709|NCT02471144|9569410|FG003|Induction Period (Up to Week 12)|Subject/Guardian Decision|0
6113453|NCT00842829|9734113|FG001|Dose Titration Period|Withdrawal by Subject|6
6113454|NCT00842829|9734114|FG002|Dose Titration Period|Withdrawal by Subject|0
6113455|NCT00842829|9734112|FG000|Dose Titration Period|Other|5
6113456|NCT00842829|9734113|FG001|Dose Titration Period|Other|4
6113457|NCT00842829|9734114|FG002|Dose Titration Period|Other|0
6113458|NCT00842829|9734112|FG000|Dose Titration Period|Non-compliance to study procedures|1
6208343|NCT01563354|9873156|FG002|Core Phase|Diseasse progression|8
6208344|NCT01563354|9873154|FG000|Core Phase|Protocol deviation|2
5980710|NCT02471144|9569411|FG004|Induction Period (Up to Week 12)|Subject/Guardian Decision|0
5980711|NCT02471144|9569412|FG005|Induction Period (Up to Week 12)|Subject/Guardian Decision|0
6063192|NCT00505414|9664575|FG002|Titration Phase|Death|0
6113459|NCT00842829|9734113|FG001|Dose Titration Period|Non-compliance to study procedures|1
6113460|NCT00842829|9734114|FG002|Dose Titration Period|Non-compliance to study procedures|0
6113461|NCT00842829|9734112|FG000|Dose Titration Period|Non-compliance to study drug|2
6113462|NCT00842829|9734113|FG001|Dose Titration Period|Non-compliance to study drug|1
6208345|NCT01563354|9873155|FG001|Core Phase|Protocol deviation|0
6208346|NCT01563354|9873156|FG002|Core Phase|Protocol deviation|0
6208347|NCT01563354|9873154|FG000|Core Phase|PI decision - did not enter extension|0
6208348|NCT01563354|9873155|FG001|Core Phase|PI decision - did not enter extension|1
6208349|NCT01563354|9873156|FG002|Core Phase|PI decision - did not enter extension|0
6208350|NCT01563354|9873154|FG000|Core Phase|Worsening of clinical condition - did not enter extension|1
6208351|NCT01563354|9873155|FG001|Core Phase|Worsening of clinical condition - did not enter extension|0
6208352|NCT01563354|9873156|FG002|Core Phase|Worsening of clinical condition - did not enter extension|0
6208353|NCT01563354|9873154|FG000|Extension Phase|Adverse Event|0
6208354|NCT01563354|9873155|FG001|Extension Phase|Adverse Event|3
6208355|NCT01563354|9873156|FG002|Extension Phase|Adverse Event|2
6208356|NCT01563354|9873154|FG000|Extension Phase|Withdrawal by Subject|0
6208357|NCT01563354|9873155|FG001|Extension Phase|Withdrawal by Subject|1
6208358|NCT01563354|9873156|FG002|Extension Phase|Withdrawal by Subject|0
6208359|NCT01563354|9873154|FG000|Extension Phase|Administration problems|3
6208360|NCT01563354|9873155|FG001|Extension Phase|Administration problems|2
6208361|NCT01563354|9873156|FG002|Extension Phase|Administration problems|3
6208362|NCT01563354|9873154|FG000|Extension Phase|Disease progression|9
6208363|NCT01563354|9873155|FG001|Extension Phase|Disease progression|8
6208364|NCT01563354|9873156|FG002|Extension Phase|Disease progression|10
6208365|NCT01563536|9873187|FG000|Overall Study|Withdrawal by Subject|0
6208366|NCT01563536|9873188|FG001|Overall Study|Withdrawal by Subject|2
6208367|NCT01563536|9873187|FG000|Overall Study|Lost to Follow-up|1
6208368|NCT01563536|9873188|FG001|Overall Study|Lost to Follow-up|0
6208369|NCT01563913|9873196|FG000|Overall Study|Physician Decision|1
6208370|NCT01563913|9873197|FG001|Overall Study|Physician Decision|0
6208371|NCT01563913|9873196|FG000|Overall Study|Spouse Passed Away|1
6208372|NCT01563913|9873197|FG001|Overall Study|Spouse Passed Away|0
6208373|NCT01563978|9873205|FG000|Overall Study|Physician Decision|1
6208374|NCT01563978|9873206|FG001|Overall Study|Physician Decision|0
6208375|NCT01563978|9873205|FG000|Overall Study|Lost to Follow-up|1
6208376|NCT01563978|9873206|FG001|Overall Study|Lost to Follow-up|0
6208377|NCT01563978|9873205|FG000|Overall Study|Dev. of study specific discont. criteria|1
6208378|NCT01563978|9873206|FG001|Overall Study|Dev. of study specific discont. criteria|0
6208379|NCT01563978|9873205|FG000|Overall Study|Adverse Event|1
6208380|NCT01563978|9873206|FG001|Overall Study|Adverse Event|2
6208381|NCT01564277|9873214|FG000|Overall Study|Protocol Violation|0
6208382|NCT01564277|9873215|FG001|Overall Study|Protocol Violation|1
6208383|NCT01564277|9873214|FG000|Overall Study|Physician Decision|1
6208384|NCT01564277|9873215|FG001|Overall Study|Physician Decision|0
6208385|NCT01564394|9873223|FG000|Overall Study|Withdrawal by Subject|6
6208386|NCT01564394|9873224|FG001|Overall Study|Withdrawal by Subject|10
6208387|NCT01564407|9873235|FG000|Overall Study|Lost to Follow-up|0
6208388|NCT01564407|9873236|FG001|Overall Study|Lost to Follow-up|1
6208389|NCT01564407|9873237|FG002|Overall Study|Lost to Follow-up|0
6208390|NCT01564407|9873238|FG003|Overall Study|Lost to Follow-up|0
6208391|NCT01564407|9873239|FG004|Overall Study|Lost to Follow-up|0
6208392|NCT01564407|9873235|FG000|Overall Study|Withdrawal by Subject|0
6208393|NCT01564407|9873236|FG001|Overall Study|Withdrawal by Subject|1
6208394|NCT01564407|9873237|FG002|Overall Study|Withdrawal by Subject|0
6208395|NCT01564407|9873238|FG003|Overall Study|Withdrawal by Subject|0
6208396|NCT01564407|9873239|FG004|Overall Study|Withdrawal by Subject|0
6208397|NCT01564407|9873235|FG000|Overall Study|funding lost, study ended|0
6208398|NCT01564407|9873236|FG001|Overall Study|funding lost, study ended|0
6208399|NCT01564407|9873237|FG002|Overall Study|funding lost, study ended|0
6208400|NCT01564407|9873238|FG003|Overall Study|funding lost, study ended|1
6208401|NCT01564407|9873239|FG004|Overall Study|funding lost, study ended|0
6208402|NCT01564459|9873263|FG000|Run-In|Adverse Event|7
6208403|NCT01564459|9873264|FG001|Run-In|Adverse Event|0
6208404|NCT01564459|9873265|FG002|Run-In|Adverse Event|0
6208405|NCT01564459|9873263|FG000|Run-In|Lost to Follow-up|1
6208406|NCT01564459|9873264|FG001|Run-In|Lost to Follow-up|0
6063193|NCT00505414|9664576|FG003|Titration Phase|Death|2
6063194|NCT00505414|9664577|FG004|Titration Phase|Death|0
6063195|NCT00505414|9664573|FG000|Titration Phase|Lack of Efficacy|0
6063196|NCT00505414|9664574|FG001|Titration Phase|Lack of Efficacy|0
6063197|NCT00505414|9664575|FG002|Titration Phase|Lack of Efficacy|0
6063198|NCT00505414|9664576|FG003|Titration Phase|Lack of Efficacy|10
6063199|NCT00505414|9664577|FG004|Titration Phase|Lack of Efficacy|1
6063200|NCT00505414|9664573|FG000|Titration Phase|Protocol Violation|0
6063201|NCT00505414|9664574|FG001|Titration Phase|Protocol Violation|0
6063202|NCT00505414|9664575|FG002|Titration Phase|Protocol Violation|0
6063203|NCT00505414|9664576|FG003|Titration Phase|Protocol Violation|0
6063204|NCT00505414|9664577|FG004|Titration Phase|Protocol Violation|1
6063205|NCT00505414|9664573|FG000|Titration Phase|Withdrawal by Subject|0
6113463|NCT00842829|9734114|FG002|Dose Titration Period|Non-compliance to study drug|0
6113464|NCT00842829|9734112|FG000|Treatment Period|Adverse Event|0
6113465|NCT00842829|9734113|FG001|Treatment Period|Adverse Event|0
6113466|NCT00842829|9734114|FG002|Treatment Period|Adverse Event|15
6113467|NCT00842829|9734112|FG000|Treatment Period|Lack of Efficacy|0
6113468|NCT00842829|9734113|FG001|Treatment Period|Lack of Efficacy|0
6113469|NCT00842829|9734114|FG002|Treatment Period|Lack of Efficacy|6
6113470|NCT00842829|9734112|FG000|Treatment Period|Unstable persistent cancer pain|0
6113471|NCT00842829|9734113|FG001|Treatment Period|Unstable persistent cancer pain|0
6113472|NCT00842829|9734114|FG002|Treatment Period|Unstable persistent cancer pain|5
6113473|NCT00842829|9734112|FG000|Treatment Period|Withdrawal by Subject|0
6113474|NCT00842829|9734113|FG001|Treatment Period|Withdrawal by Subject|0
6113475|NCT00842829|9734114|FG002|Treatment Period|Withdrawal by Subject|11
6113476|NCT00842829|9734112|FG000|Treatment Period|Consistently >4 BTP episodes daily|0
6113477|NCT00842829|9734113|FG001|Treatment Period|Consistently >4 BTP episodes daily|0
6113478|NCT00842829|9734114|FG002|Treatment Period|Consistently >4 BTP episodes daily|1
6113479|NCT00842829|9734112|FG000|Treatment Period|Protocol Violation|0
6113480|NCT00842829|9734113|FG001|Treatment Period|Protocol Violation|0
6113481|NCT00842829|9734114|FG002|Treatment Period|Protocol Violation|2
6113482|NCT00842829|9734112|FG000|Treatment Period|Other|0
6113483|NCT00842829|9734113|FG001|Treatment Period|Other|0
6113484|NCT00842829|9734114|FG002|Treatment Period|Other|18
6113485|NCT00842829|9734112|FG000|Treatment Period|Non-compliance to study procedures|0
6113486|NCT00842829|9734113|FG001|Treatment Period|Non-compliance to study procedures|0
6113487|NCT00842829|9734114|FG002|Treatment Period|Non-compliance to study procedures|4
6113488|NCT00842829|9734112|FG000|Treatment Period|Unclear completion status|0
6208407|NCT01564459|9873265|FG002|Run-In|Lost to Follow-up|0
6208408|NCT01564459|9873263|FG000|Run-In|Non-compliance with study drug|2
6208409|NCT01564459|9873264|FG001|Run-In|Non-compliance with study drug|0
6208410|NCT01564459|9873265|FG002|Run-In|Non-compliance with study drug|0
6208411|NCT01564459|9873263|FG000|Run-In|Protocol Violation|1
6208412|NCT01564459|9873264|FG001|Run-In|Protocol Violation|0
6208413|NCT01564459|9873265|FG002|Run-In|Protocol Violation|0
6208414|NCT01564459|9873263|FG000|Run-In|Withdrawal by Subject|1
6208415|NCT01564459|9873264|FG001|Run-In|Withdrawal by Subject|0
6208416|NCT01564459|9873265|FG002|Run-In|Withdrawal by Subject|0
6208417|NCT01564459|9873263|FG000|Double-blind Treatment|Adverse Event|0
6208418|NCT01564459|9873264|FG001|Double-blind Treatment|Adverse Event|0
6208419|NCT01564459|9873265|FG002|Double-blind Treatment|Adverse Event|1
6208420|NCT01564758|9873312|FG000|Overall Study|Death|8
6208421|NCT01564758|9873312|FG000|Overall Study|Adverse Event|3
6208422|NCT01564758|9873312|FG000|Overall Study|Other|3
6208423|NCT01564784|9873318|FG000|Overall Study|Other|1
6208424|NCT01564784|9873319|FG001|Overall Study|Other|0
6208425|NCT01564784|9873318|FG000|Overall Study|Subject refused further follow-up|1
6208426|NCT01564784|9873319|FG001|Overall Study|Subject refused further follow-up|6
6208427|NCT01564784|9873318|FG000|Overall Study|Lost to Follow-up|1
6208428|NCT01564784|9873319|FG001|Overall Study|Lost to Follow-up|1
6208429|NCT01564784|9873318|FG000|Overall Study|Death|131
6208430|NCT01564784|9873319|FG001|Overall Study|Death|126
6208431|NCT01564862|9873328|FG000|Overall Study|Pretreatment Event or Adverse Event|6
6286178|NCT02345226|9999088|FG000|Double-Blind Phase|Randomized but Never Treated|2
6286179|NCT02345226|9999089|FG001|Double-Blind Phase|Randomized but Never Treated|4
6286180|NCT02345226|9999088|FG000|Open-Label Extension Phase|Lost to Follow-up|0
6286181|NCT02345226|9999089|FG001|Open-Label Extension Phase|Lost to Follow-up|1
6286182|NCT02345252|9999099|FG000|Double-Blind Phase|Adverse Event|2
6286183|NCT02345252|9999100|FG001|Double-Blind Phase|Adverse Event|3
6286184|NCT02345252|9999099|FG000|Double-Blind Phase|Death|1
6286185|NCT02345252|9999100|FG001|Double-Blind Phase|Death|2
6286186|NCT02345252|9999099|FG000|Double-Blind Phase|Lack of Efficacy|1
6286187|NCT02345252|9999100|FG001|Double-Blind Phase|Lack of Efficacy|0
6286188|NCT02345252|9999099|FG000|Double-Blind Phase|Investigator's Discretion|4
6286189|NCT02345252|9999100|FG001|Double-Blind Phase|Investigator's Discretion|6
6286190|NCT02345252|9999099|FG000|Double-Blind Phase|Non-Compliance with Study Drug|1
6286191|NCT02345252|9999100|FG001|Double-Blind Phase|Non-Compliance with Study Drug|2
6286192|NCT02345252|9999099|FG000|Double-Blind Phase|Protocol Violation|2
6286193|NCT02345252|9999100|FG001|Double-Blind Phase|Protocol Violation|1
6286194|NCT02345252|9999099|FG000|Double-Blind Phase|Withdrew Consent|21
6286195|NCT02345252|9999100|FG001|Double-Blind Phase|Withdrew Consent|23
6286196|NCT02345252|9999099|FG000|Double-Blind Phase|Lost to Follow-up|8
6286197|NCT02345252|9999100|FG001|Double-Blind Phase|Lost to Follow-up|10
6286198|NCT02345252|9999099|FG000|Double-Blind Phase|Randomized but Never Treated|0
6286199|NCT02345252|9999100|FG001|Double-Blind Phase|Randomized but Never Treated|2
6286200|NCT02345330|9999108|FG000|Overall Study|Death|1
6286201|NCT02345330|9999108|FG000|Overall Study|Progressive Disease|2
6113489|NCT00842829|9734113|FG001|Treatment Period|Unclear completion status|0
6113490|NCT00842829|9734114|FG002|Treatment Period|Unclear completion status|1
6113491|NCT00842829|9734112|FG000|Continuation Period|Adverse Event|0
6113492|NCT00842829|9734113|FG001|Continuation Period|Adverse Event|0
6113493|NCT00842829|9734114|FG002|Continuation Period|Adverse Event|32
6286202|NCT02345434|9999114|FG000|Overall Study|Deceased (excluded from intervention and analysis)|5
6286203|NCT02345434|9999115|FG001|Overall Study|Deceased (excluded from intervention and analysis)|2
6113494|NCT00842829|9734112|FG000|Continuation Period|Lack of Efficacy|0
6113495|NCT00842829|9734113|FG001|Continuation Period|Lack of Efficacy|0
6113496|NCT00842829|9734114|FG002|Continuation Period|Lack of Efficacy|6
6113497|NCT00842829|9734112|FG000|Continuation Period|Unstable persistent cancer pain|0
6113498|NCT00842829|9734113|FG001|Continuation Period|Unstable persistent cancer pain|0
6113499|NCT00842829|9734114|FG002|Continuation Period|Unstable persistent cancer pain|3
6113500|NCT00842829|9734112|FG000|Continuation Period|Withdrawal by Subject|0
6113501|NCT00842829|9734113|FG001|Continuation Period|Withdrawal by Subject|0
6113502|NCT00842829|9734114|FG002|Continuation Period|Withdrawal by Subject|10
6113503|NCT00842829|9734112|FG000|Continuation Period|Other|0
6113504|NCT00842829|9734113|FG001|Continuation Period|Other|0
6113505|NCT00842829|9734114|FG002|Continuation Period|Other|7
6113506|NCT00842829|9734112|FG000|Continuation Period|Non-compliance to study procedures|0
6113507|NCT00842829|9734113|FG001|Continuation Period|Non-compliance to study procedures|0
6113508|NCT00842829|9734114|FG002|Continuation Period|Non-compliance to study procedures|2
6113509|NCT00842829|9734112|FG000|Continuation Period|Non-compliance to study drug|0
6113510|NCT00842829|9734113|FG001|Continuation Period|Non-compliance to study drug|0
6113511|NCT00842829|9734114|FG002|Continuation Period|Non-compliance to study drug|1
6113512|NCT00842985|9734135|FG000|Screening|Did not meet entrance requirements|27
6113513|NCT00842985|9734135|FG000|First Intervention|Withdrawal by Subject|3
6113514|NCT00842985|9734135|FG000|First Intervention|Protocol Violation|3
6113515|NCT00842985|9734135|FG000|Washout Period of GE 4 Days|Withdrawal by Subject|2
6113516|NCT00842985|9734135|FG000|Washout Period of GE 4 Days|Withdrawal by Subject|2
6113517|NCT00843024|9734146|FG000|Single-blind Placebo Run-In Phase|Did not meet continuation criteria|79
6113518|NCT00843024|9734147|FG001|Single-blind Placebo Run-In Phase|Did not meet continuation criteria|74
6113519|NCT00843024|9734148|FG002|Single-blind Placebo Run-In Phase|Did not meet continuation criteria|0
6113520|NCT00843024|9734149|FG003|Single-blind Placebo Run-In Phase|Did not meet continuation criteria|0
6113521|NCT00843024|9734150|FG004|Single-blind Placebo Run-In Phase|Did not meet continuation criteria|0
6113522|NCT00843024|9734151|FG005|Single-blind Placebo Run-In Phase|Did not meet continuation criteria|0
6113523|NCT00843024|9734146|FG000|Single-blind Placebo Run-In Phase|Lost to Follow-up|36
6113524|NCT00843024|9734147|FG001|Single-blind Placebo Run-In Phase|Lost to Follow-up|31
6113525|NCT00843024|9734148|FG002|Single-blind Placebo Run-In Phase|Lost to Follow-up|0
6113526|NCT00843024|9734149|FG003|Single-blind Placebo Run-In Phase|Lost to Follow-up|0
6113527|NCT00843024|9734150|FG004|Single-blind Placebo Run-In Phase|Lost to Follow-up|0
6113528|NCT00843024|9734151|FG005|Single-blind Placebo Run-In Phase|Lost to Follow-up|0
6113529|NCT00843024|9734146|FG000|Single-blind Placebo Run-In Phase|Withdrawal by Subject|19
6113530|NCT00843024|9734147|FG001|Single-blind Placebo Run-In Phase|Withdrawal by Subject|18
6113531|NCT00843024|9734148|FG002|Single-blind Placebo Run-In Phase|Withdrawal by Subject|0
6113532|NCT00843024|9734149|FG003|Single-blind Placebo Run-In Phase|Withdrawal by Subject|0
6208432|NCT01564862|9873329|FG001|Overall Study|Pretreatment Event or Adverse Event|12
6208433|NCT01564862|9873330|FG002|Overall Study|Pretreatment Event or Adverse Event|6
6208434|NCT01564862|9873328|FG000|Overall Study|Major Protocol Deviation|3
6208435|NCT01564862|9873329|FG001|Overall Study|Major Protocol Deviation|3
6208436|NCT01564862|9873330|FG002|Overall Study|Major Protocol Deviation|4
6208437|NCT01564862|9873328|FG000|Overall Study|Lost to Follow-up|10
6208438|NCT01564862|9873329|FG001|Overall Study|Lost to Follow-up|8
6208439|NCT01564862|9873330|FG002|Overall Study|Lost to Follow-up|6
6208440|NCT01564862|9873328|FG000|Overall Study|Voluntary Withdrawal|9
6208441|NCT01564862|9873329|FG001|Overall Study|Voluntary Withdrawal|6
6208442|NCT01564862|9873330|FG002|Overall Study|Voluntary Withdrawal|8
6208443|NCT01564862|9873328|FG000|Overall Study|Lack of Efficacy|1
6208444|NCT01564862|9873329|FG001|Overall Study|Lack of Efficacy|5
6208445|NCT01564862|9873330|FG002|Overall Study|Lack of Efficacy|6
6208446|NCT01564862|9873328|FG000|Overall Study|Other reason(s)|1
6208447|NCT01564862|9873329|FG001|Overall Study|Other reason(s)|0
6208448|NCT01564862|9873330|FG002|Overall Study|Other reason(s)|0
6208449|NCT01565083|9873360|FG000|Overall Study|Withdrawal by Subject|6
6208450|NCT01565083|9873361|FG001|Overall Study|Withdrawal by Subject|4
6208451|NCT01565083|9873360|FG000|Overall Study|Lost to Follow-up|2
6208452|NCT01565083|9873361|FG001|Overall Study|Lost to Follow-up|7
6208453|NCT01565083|9873360|FG000|Overall Study|Death|22
6208454|NCT01565083|9873361|FG001|Overall Study|Death|23
6208455|NCT01565083|9873360|FG000|Overall Study|Other|3
6208456|NCT01565083|9873361|FG001|Overall Study|Other|5
6208457|NCT01565148|9873371|FG000|Overall Study|Withdrawal by Subject|1
6208458|NCT01565148|9873372|FG001|Overall Study|Withdrawal by Subject|1
6208459|NCT01565148|9873373|FG002|Overall Study|Withdrawal by Subject|1
6208460|NCT01565148|9873374|FG003|Overall Study|Withdrawal by Subject|2
6208461|NCT01565148|9873371|FG000|Overall Study|Lost to Follow-up|4
6208462|NCT01565148|9873372|FG001|Overall Study|Lost to Follow-up|4
6208463|NCT01565148|9873373|FG002|Overall Study|Lost to Follow-up|0
6208464|NCT01565148|9873374|FG003|Overall Study|Lost to Follow-up|3
6208465|NCT01565148|9873371|FG000|Overall Study|Rescue Therapy|8
6113533|NCT00843024|9734150|FG004|Single-blind Placebo Run-In Phase|Withdrawal by Subject|0
6113534|NCT00843024|9734151|FG005|Single-blind Placebo Run-In Phase|Withdrawal by Subject|0
6113535|NCT00843024|9734146|FG000|Single-blind Placebo Run-In Phase|Protocol Violation|4
6113536|NCT00843024|9734147|FG001|Single-blind Placebo Run-In Phase|Protocol Violation|5
6113537|NCT00843024|9734148|FG002|Single-blind Placebo Run-In Phase|Protocol Violation|0
6113538|NCT00843024|9734149|FG003|Single-blind Placebo Run-In Phase|Protocol Violation|0
6113539|NCT00843024|9734150|FG004|Single-blind Placebo Run-In Phase|Protocol Violation|0
6113540|NCT00843024|9734151|FG005|Single-blind Placebo Run-In Phase|Protocol Violation|0
6113541|NCT00843024|9734146|FG000|Single-blind Placebo Run-In Phase|Physician Decision|2
6113542|NCT00843024|9734147|FG001|Single-blind Placebo Run-In Phase|Physician Decision|6
6113543|NCT00843024|9734148|FG002|Single-blind Placebo Run-In Phase|Physician Decision|0
6113544|NCT00843024|9734149|FG003|Single-blind Placebo Run-In Phase|Physician Decision|0
6113545|NCT00843024|9734150|FG004|Single-blind Placebo Run-In Phase|Physician Decision|0
6113546|NCT00843024|9734151|FG005|Single-blind Placebo Run-In Phase|Physician Decision|0
6113547|NCT00843024|9734146|FG000|Single-blind Placebo Run-In Phase|Adverse Event|0
6113548|NCT00843024|9734147|FG001|Single-blind Placebo Run-In Phase|Adverse Event|1
6113549|NCT00843024|9734148|FG002|Single-blind Placebo Run-In Phase|Adverse Event|0
6113550|NCT00843024|9734149|FG003|Single-blind Placebo Run-In Phase|Adverse Event|0
6113551|NCT00843024|9734150|FG004|Single-blind Placebo Run-In Phase|Adverse Event|0
6113552|NCT00843024|9734151|FG005|Single-blind Placebo Run-In Phase|Adverse Event|0
6113553|NCT00843024|9734146|FG000|Single-blind Placebo Run-In Phase|Other|0
6113554|NCT00843024|9734147|FG001|Single-blind Placebo Run-In Phase|Other|1
6113555|NCT00843024|9734148|FG002|Single-blind Placebo Run-In Phase|Other|0
6208466|NCT01565148|9873372|FG001|Overall Study|Rescue Therapy|5
6208467|NCT01565148|9873373|FG002|Overall Study|Rescue Therapy|5
6208468|NCT01565148|9873374|FG003|Overall Study|Rescue Therapy|8
6208469|NCT01565148|9873371|FG000|Overall Study|Death|0
6208470|NCT01565148|9873372|FG001|Overall Study|Death|0
6208471|NCT01565148|9873373|FG002|Overall Study|Death|1
6208472|NCT01565148|9873374|FG003|Overall Study|Death|0
6208473|NCT01565148|9873371|FG000|Overall Study|Physician Decision|2
6208474|NCT01565148|9873372|FG001|Overall Study|Physician Decision|5
6208475|NCT01565148|9873373|FG002|Overall Study|Physician Decision|0
6208476|NCT01565148|9873374|FG003|Overall Study|Physician Decision|0
6208477|NCT01565291|9873390|FG000|Overall Study|Withdrawal by Subject|1
6208478|NCT01565291|9873391|FG001|Overall Study|Withdrawal by Subject|0
6208479|NCT01565343|9873418|FG000|Overall Study|Administrative decision/technical issues|1
6208480|NCT01565343|9873419|FG001|Overall Study|Administrative decision/technical issues|0
6208481|NCT01565343|9873420|FG002|Overall Study|Administrative decision/technical issues|0
6208482|NCT01565499|9873442|FG000|Overall Study|Physician Decision|1
6208483|NCT01565499|9873442|FG000|Overall Study|Adverse Event|5
6208484|NCT01565499|9873442|FG000|Overall Study|Withdrawal by Subject|2
6208485|NCT01565564|9873466|FG000|Overall Study|Lost to Follow-up|5
6208486|NCT01565564|9873467|FG001|Overall Study|Lost to Follow-up|1
6208487|NCT01565642|9873479|FG000|Overall Study|Withdrawal by Subject|2
6208488|NCT01565642|9873480|FG001|Overall Study|Withdrawal by Subject|1
6208489|NCT01565668|9873488|FG000|Overall Study|Death|2
6208490|NCT01565668|9873489|FG001|Overall Study|Death|1
6208491|NCT01565668|9873488|FG000|Overall Study|Lack of Efficacy|4
6286204|NCT02345512|9999130|FG000|Overall Study|Adverse Event|1
6286205|NCT02345512|9999130|FG000|Overall Study|Withdrawal by Subject|1
6286206|NCT02345811|9999152|FG000|First Intervention|Withdrawal by Subject|1
6286207|NCT02345811|9999153|FG001|First Intervention|Withdrawal by Subject|1
6286208|NCT02345889|9999165|FG000|Overall Study|Inadequate Bowel Prep|17
6286209|NCT02345889|9999166|FG001|Overall Study|Inadequate Bowel Prep|16
6286210|NCT02345889|9999167|FG002|Overall Study|Inadequate Bowel Prep|18
6286211|NCT02345889|9999168|FG003|Overall Study|Inadequate Bowel Prep|14
6286212|NCT02345889|9999165|FG000|Overall Study|Polyposis identified during procedure|1
6286213|NCT02345889|9999166|FG001|Overall Study|Polyposis identified during procedure|1
6286214|NCT02345889|9999167|FG002|Overall Study|Polyposis identified during procedure|0
6286215|NCT02345889|9999168|FG003|Overall Study|Polyposis identified during procedure|1
6286216|NCT02345889|9999165|FG000|Overall Study|Recognized ineligible post-randomization|1
6286217|NCT02345889|9999166|FG001|Overall Study|Recognized ineligible post-randomization|0
6286218|NCT02345889|9999167|FG002|Overall Study|Recognized ineligible post-randomization|2
6286219|NCT02345889|9999168|FG003|Overall Study|Recognized ineligible post-randomization|1
6286220|NCT02345889|9999165|FG000|Overall Study|Ulcerative Colitis identified|1
6286221|NCT02345889|9999166|FG001|Overall Study|Ulcerative Colitis identified|0
6286222|NCT02345889|9999167|FG002|Overall Study|Ulcerative Colitis identified|0
6286223|NCT02345889|9999168|FG003|Overall Study|Ulcerative Colitis identified|0
6286224|NCT02345889|9999165|FG000|Overall Study|Cecum not intubated|1
6286225|NCT02345889|9999166|FG001|Overall Study|Cecum not intubated|0
6286226|NCT02345889|9999167|FG002|Overall Study|Cecum not intubated|0
6286227|NCT02345889|9999168|FG003|Overall Study|Cecum not intubated|0
6286228|NCT02346136|9999180|FG000|Overall Study|Withdrawal by Subject|7
6286229|NCT02346136|9999181|FG001|Overall Study|Withdrawal by Subject|5
6286230|NCT02346136|9999180|FG000|Overall Study|Death|1
6286231|NCT02346136|9999181|FG001|Overall Study|Death|0
6286232|NCT02346136|9999180|FG000|Overall Study|Study termination|14
6286233|NCT02346136|9999181|FG001|Overall Study|Study termination|18
6286234|NCT02346240|9999191|FG000|Initial Period (Baseline to Week 16)|Adverse Event|0
6208492|NCT01565668|9873489|FG001|Overall Study|Lack of Efficacy|2
6208493|NCT01565668|9873488|FG000|Overall Study|Participant went on Hospice Care|1
6208494|NCT01565668|9873489|FG001|Overall Study|Participant went on Hospice Care|0
6113556|NCT00843024|9734149|FG003|Single-blind Placebo Run-In Phase|Other|0
6113557|NCT00843024|9734150|FG004|Single-blind Placebo Run-In Phase|Other|0
6113558|NCT00843024|9734151|FG005|Single-blind Placebo Run-In Phase|Other|0
6113559|NCT00843024|9734146|FG000|Double-blind Treatment Phase|No opportunity to treat migraine|0
6113560|NCT00843024|9734147|FG001|Double-blind Treatment Phase|No opportunity to treat migraine|0
6113561|NCT00843024|9734148|FG002|Double-blind Treatment Phase|No opportunity to treat migraine|20
6113562|NCT00843024|9734149|FG003|Double-blind Treatment Phase|No opportunity to treat migraine|10
6113563|NCT00843024|9734150|FG004|Double-blind Treatment Phase|No opportunity to treat migraine|13
6113564|NCT00843024|9734151|FG005|Double-blind Treatment Phase|No opportunity to treat migraine|14
6113565|NCT00843024|9734146|FG000|Double-blind Treatment Phase|Lost to Follow-up|0
6113566|NCT00843024|9734147|FG001|Double-blind Treatment Phase|Lost to Follow-up|0
6113567|NCT00843024|9734148|FG002|Double-blind Treatment Phase|Lost to Follow-up|8
6113568|NCT00843024|9734149|FG003|Double-blind Treatment Phase|Lost to Follow-up|4
6113569|NCT00843024|9734150|FG004|Double-blind Treatment Phase|Lost to Follow-up|4
6113570|NCT00843024|9734151|FG005|Double-blind Treatment Phase|Lost to Follow-up|4
6113571|NCT00843024|9734146|FG000|Double-blind Treatment Phase|Withdrawal by Subject|0
6113572|NCT00843024|9734147|FG001|Double-blind Treatment Phase|Withdrawal by Subject|0
6113573|NCT00843024|9734148|FG002|Double-blind Treatment Phase|Withdrawal by Subject|0
6113574|NCT00843024|9734149|FG003|Double-blind Treatment Phase|Withdrawal by Subject|6
6113575|NCT00843024|9734150|FG004|Double-blind Treatment Phase|Withdrawal by Subject|0
6113576|NCT00843024|9734151|FG005|Double-blind Treatment Phase|Withdrawal by Subject|2
6113577|NCT00843024|9734146|FG000|Double-blind Treatment Phase|Protocol Violation|0
6113578|NCT00843024|9734147|FG001|Double-blind Treatment Phase|Protocol Violation|0
6113579|NCT00843024|9734148|FG002|Double-blind Treatment Phase|Protocol Violation|3
6113580|NCT00843024|9734149|FG003|Double-blind Treatment Phase|Protocol Violation|0
6113581|NCT00843024|9734150|FG004|Double-blind Treatment Phase|Protocol Violation|0
6113582|NCT00843024|9734151|FG005|Double-blind Treatment Phase|Protocol Violation|3
6113583|NCT00843024|9734146|FG000|Double-blind Treatment Phase|Physician Decision|0
6113584|NCT00843024|9734147|FG001|Double-blind Treatment Phase|Physician Decision|0
6113585|NCT00843024|9734148|FG002|Double-blind Treatment Phase|Physician Decision|0
6113586|NCT00843024|9734149|FG003|Double-blind Treatment Phase|Physician Decision|3
6113587|NCT00843024|9734150|FG004|Double-blind Treatment Phase|Physician Decision|1
6113588|NCT00843024|9734151|FG005|Double-blind Treatment Phase|Physician Decision|1
6113589|NCT00843024|9734146|FG000|Double-blind Treatment Phase|Adverse Event|0
6113590|NCT00843024|9734147|FG001|Double-blind Treatment Phase|Adverse Event|0
6113591|NCT00843024|9734148|FG002|Double-blind Treatment Phase|Adverse Event|0
6113592|NCT00843024|9734149|FG003|Double-blind Treatment Phase|Adverse Event|0
6113593|NCT00843024|9734150|FG004|Double-blind Treatment Phase|Adverse Event|1
6113594|NCT00843024|9734151|FG005|Double-blind Treatment Phase|Adverse Event|1
6113595|NCT00843024|9734146|FG000|Double-blind Treatment Phase|Lack of Efficacy|0
6113596|NCT00843024|9734147|FG001|Double-blind Treatment Phase|Lack of Efficacy|0
6113597|NCT00843024|9734148|FG002|Double-blind Treatment Phase|Lack of Efficacy|0
6113598|NCT00843024|9734149|FG003|Double-blind Treatment Phase|Lack of Efficacy|0
6113599|NCT00843024|9734150|FG004|Double-blind Treatment Phase|Lack of Efficacy|1
6113600|NCT00843024|9734151|FG005|Double-blind Treatment Phase|Lack of Efficacy|0
6113601|NCT00843115|9734164|FG000|Overall Study|Death|4
6113602|NCT00843115|9734164|FG000|Overall Study|Adverse Event|30
6113603|NCT00843115|9734164|FG000|Overall Study|Lost to Follow-up|4
6113604|NCT00843115|9734164|FG000|Overall Study|Withdrawal by Subject|17
6113605|NCT00843115|9734164|FG000|Overall Study|Family wanted meds stopped|1
6113606|NCT00843115|9734164|FG000|Overall Study|Family does not want continuation|1
6113607|NCT00843115|9734164|FG000|Overall Study|Patient forgot to take meds|1
6113608|NCT00843115|9734164|FG000|Overall Study|Does not meet entrance criteria|1
6113609|NCT00843115|9734164|FG000|Overall Study|Physician Decision|1
6113610|NCT00843115|9734164|FG000|Overall Study|Family discontinued meds|1
6113611|NCT00843115|9734164|FG000|Overall Study|patient took for 2 days then stopped|1
6113612|NCT00843115|9734164|FG000|Overall Study|patient never took the medication|1
6113613|NCT00843115|9734164|FG000|Overall Study|hospitalized due to deterioration|1
6113614|NCT00843115|9734164|FG000|Overall Study|week 12 not done|1
6113615|NCT00843115|9734164|FG000|Overall Study|Syndrome De Glissement|1
6113616|NCT00843167|9734170|FG000|Treatment Period|Adverse Event|1
6113617|NCT00843167|9734171|FG001|Treatment Period|Adverse Event|5
6113618|NCT00843167|9734170|FG000|Treatment Period|Withdrawal by Subject|2
6113619|NCT00843167|9734171|FG001|Treatment Period|Withdrawal by Subject|3
6113620|NCT00843193|9734192|FG000|Overall Study|Adverse Event|2
6113621|NCT00843193|9734193|FG001|Overall Study|Adverse Event|4
6113622|NCT00843193|9734192|FG000|Overall Study|Lack of Efficacy|1
6113623|NCT00843193|9734193|FG001|Overall Study|Lack of Efficacy|1
6113624|NCT00843193|9734192|FG000|Overall Study|Protocol Violation|1
6113625|NCT00843193|9734193|FG001|Overall Study|Protocol Violation|2
6113626|NCT00843193|9734192|FG000|Overall Study|Lost to Follow-up|1
6113627|NCT00843193|9734193|FG001|Overall Study|Lost to Follow-up|0
6113628|NCT00843193|9734192|FG000|Overall Study|Physician Decision|0
6113629|NCT00843193|9734193|FG001|Overall Study|Physician Decision|1
6113630|NCT00843193|9734192|FG000|Overall Study|Withdrawal by Subject|3
6113631|NCT00843193|9734193|FG001|Overall Study|Withdrawal by Subject|3
6113632|NCT00843284|9734200|FG000|Overall Study|Adverse Event|39
6113633|NCT00843284|9734200|FG000|Overall Study|Lack of Efficacy|5
6113634|NCT00843284|9734200|FG000|Overall Study|Lost to Follow-up|11
6113635|NCT00843284|9734200|FG000|Overall Study|Other|10
6113636|NCT00843284|9734200|FG000|Overall Study|Withdrawal by Subject|4
6113637|NCT00843284|9734200|FG000|Overall Study|Death|3
6113638|NCT00843492|9734243|FG000|Overall Study|Adverse Event|0
6113639|NCT00843492|9734244|FG001|Overall Study|Adverse Event|3
6113640|NCT00843492|9734243|FG000|Overall Study|Lost to Follow-up|4
6113641|NCT00843492|9734244|FG001|Overall Study|Lost to Follow-up|4
6113642|NCT00843492|9734243|FG000|Overall Study|Withdrawal by Subject|0
6208495|NCT01565668|9873488|FG000|Overall Study|Adverse Event|6
6208496|NCT01565668|9873489|FG001|Overall Study|Adverse Event|1
6208497|NCT01565668|9873488|FG000|Overall Study|Randomized, but never received drug|0
6208498|NCT01565668|9873489|FG001|Overall Study|Randomized, but never received drug|2
6208499|NCT01565668|9873488|FG000|Overall Study|Progressive disease|13
6208500|NCT01565668|9873489|FG001|Overall Study|Progressive disease|14
6208501|NCT01565668|9873488|FG000|Overall Study|Withdrawal by Subject|1
6208502|NCT01565668|9873489|FG001|Overall Study|Withdrawal by Subject|3
6208503|NCT01565668|9873488|FG000|Overall Study|HSCT Transplant|11
6208504|NCT01565668|9873489|FG001|Overall Study|HSCT Transplant|15
6208505|NCT01565694|9873495|FG000|Dose-Titration Period|Adverse Event|4
6208506|NCT01565694|9873495|FG000|Dose-Titration Period|Protocol Violation|10
6208507|NCT01565694|9873495|FG000|Fixed-Dose Assessment Period|Withdrawal by Subject|4
6208508|NCT01565707|9873503|FG000|Overall Study|Adverse Event|1
6208509|NCT01565707|9873504|FG001|Overall Study|Adverse Event|6
6208510|NCT01565707|9873505|FG002|Overall Study|Adverse Event|2
6208511|NCT01565707|9873506|FG003|Overall Study|Adverse Event|1
6208512|NCT01565707|9873503|FG000|Overall Study|Lost to Follow-up|1
6208513|NCT01565707|9873504|FG001|Overall Study|Lost to Follow-up|0
6208514|NCT01565707|9873505|FG002|Overall Study|Lost to Follow-up|0
6208515|NCT01565707|9873506|FG003|Overall Study|Lost to Follow-up|0
6208516|NCT01565707|9873503|FG000|Overall Study|Protocol Violation|1
6208517|NCT01565707|9873504|FG001|Overall Study|Protocol Violation|0
6208518|NCT01565707|9873505|FG002|Overall Study|Protocol Violation|0
6208519|NCT01565707|9873506|FG003|Overall Study|Protocol Violation|1
6208520|NCT01565707|9873503|FG000|Overall Study|Withdrawal by Subject|3
6208521|NCT01565707|9873504|FG001|Overall Study|Withdrawal by Subject|1
6208522|NCT01565707|9873505|FG002|Overall Study|Withdrawal by Subject|1
6208523|NCT01565707|9873506|FG003|Overall Study|Withdrawal by Subject|1
6208524|NCT01565707|9873503|FG000|Overall Study|Randomized but not evaluable|2
6208525|NCT01565707|9873504|FG001|Overall Study|Randomized but not evaluable|0
6208526|NCT01565707|9873505|FG002|Overall Study|Randomized but not evaluable|0
6208527|NCT01565707|9873506|FG003|Overall Study|Randomized but not evaluable|0
6208528|NCT01565707|9873503|FG000|Overall Study|Miscellaneous|1
6208529|NCT01565707|9873504|FG001|Overall Study|Miscellaneous|1
6208530|NCT01565707|9873505|FG002|Overall Study|Miscellaneous|0
6208531|NCT01565707|9873506|FG003|Overall Study|Miscellaneous|2
6208532|NCT01565850|9873525|FG000|Overall Study|Adverse Event|0
6208533|NCT01565850|9873526|FG001|Overall Study|Adverse Event|1
6208534|NCT01565850|9873525|FG000|Overall Study|Lost to Follow-up|12
6208535|NCT01565850|9873526|FG001|Overall Study|Lost to Follow-up|4
6208536|NCT01565850|9873525|FG000|Overall Study|Investigator's Discretion|2
6208537|NCT01565850|9873526|FG001|Overall Study|Investigator's Discretion|1
6208538|NCT01565850|9873525|FG000|Overall Study|Participant noncompliance|2
6208539|NCT01565850|9873526|FG001|Overall Study|Participant noncompliance|0
6208540|NCT01565850|9873525|FG000|Overall Study|Withdrew Consent|4
6208541|NCT01565850|9873526|FG001|Overall Study|Withdrew Consent|2
6208542|NCT01565889|9873538|FG000|Part A|Withdrawal by Subject|1
6208543|NCT01565889|9873539|FG001|Part A|Withdrawal by Subject|0
6208544|NCT01565889|9873540|FG002|Part A|Withdrawal by Subject|0
6208545|NCT01565889|9873541|FG003|Part A|Withdrawal by Subject|0
6208546|NCT01565889|9873542|FG004|Part A|Withdrawal by Subject|0
6286235|NCT02346240|9999192|FG001|Initial Period (Baseline to Week 16)|Adverse Event|4
6286236|NCT02346240|9999193|FG002|Initial Period (Baseline to Week 16)|Adverse Event|1
6286237|NCT02346240|9999194|FG003|Initial Period (Baseline to Week 16)|Adverse Event|1
6286238|NCT02346240|9999195|FG004|Initial Period (Baseline to Week 16)|Adverse Event|0
6208547|NCT01565889|9873543|FG005|Part A|Withdrawal by Subject|0
6208548|NCT01565889|9873538|FG000|Part B|Withdrawal by Subject|0
6208549|NCT01565889|9873539|FG001|Part B|Withdrawal by Subject|0
6208550|NCT01565889|9873540|FG002|Part B|Withdrawal by Subject|0
6208551|NCT01565889|9873541|FG003|Part B|Withdrawal by Subject|0
6208552|NCT01565889|9873542|FG004|Part B|Withdrawal by Subject|0
6208553|NCT01565889|9873543|FG005|Part B|Withdrawal by Subject|1
6208554|NCT01565889|9873538|FG000|Part B|Lack of Efficacy|0
6113643|NCT00843492|9734244|FG001|Overall Study|Withdrawal by Subject|4
6113644|NCT00843492|9734243|FG000|Overall Study|Immobilization Stopped|1
6208555|NCT01565889|9873539|FG001|Part B|Lack of Efficacy|0
6208556|NCT01565889|9873540|FG002|Part B|Lack of Efficacy|0
6208557|NCT01565889|9873541|FG003|Part B|Lack of Efficacy|0
6208558|NCT01565889|9873542|FG004|Part B|Lack of Efficacy|0
6208559|NCT01565889|9873543|FG005|Part B|Lack of Efficacy|2
6208560|NCT01565889|9873538|FG000|Part B|Lost to Follow-up|0
6208561|NCT01565889|9873539|FG001|Part B|Lost to Follow-up|0
6208562|NCT01565889|9873540|FG002|Part B|Lost to Follow-up|0
6208563|NCT01565889|9873541|FG003|Part B|Lost to Follow-up|0
6113645|NCT00843492|9734244|FG001|Overall Study|Immobilization Stopped|0
6113646|NCT00843492|9734243|FG000|Overall Study|Investigator/Orthopedic Surgeon Decision|1
6113647|NCT00843492|9734244|FG001|Overall Study|Investigator/Orthopedic Surgeon Decision|1
6113648|NCT00843492|9734243|FG000|Overall Study|Orthopedic Surgery|0
6113649|NCT00843492|9734244|FG001|Overall Study|Orthopedic Surgery|2
6113650|NCT00843492|9734243|FG000|Overall Study|Visit Not Performed|1
6113651|NCT00843492|9734244|FG001|Overall Study|Visit Not Performed|0
6113652|NCT00843492|9734243|FG000|Overall Study|Deep-vein Thrombosis|1
6113653|NCT00843492|9734244|FG001|Overall Study|Deep-vein Thrombosis|0
6113654|NCT00843518|9734252|FG000|Period 2 (Double-blind Treatment)|Adverse Event|5
6113655|NCT00843518|9734253|FG001|Period 2 (Double-blind Treatment)|Adverse Event|3
6113656|NCT00843518|9734252|FG000|Period 2 (Double-blind Treatment)|Death|0
6113657|NCT00843518|9734253|FG001|Period 2 (Double-blind Treatment)|Death|1
6113658|NCT00843518|9734252|FG000|Period 2 (Double-blind Treatment)|Lost to Follow-up|2
6113659|NCT00843518|9734253|FG001|Period 2 (Double-blind Treatment)|Lost to Follow-up|3
6113660|NCT00843518|9734252|FG000|Period 2 (Double-blind Treatment)|Physician Decision|2
6113661|NCT00843518|9734253|FG001|Period 2 (Double-blind Treatment)|Physician Decision|1
6113662|NCT00843518|9734252|FG000|Period 2 (Double-blind Treatment)|Protocol Violation|2
6113663|NCT00843518|9734253|FG001|Period 2 (Double-blind Treatment)|Protocol Violation|5
6113664|NCT00843518|9734252|FG000|Period 2 (Double-blind Treatment)|Withdrawal by Subject|2
6113665|NCT00843518|9734253|FG001|Period 2 (Double-blind Treatment)|Withdrawal by Subject|0
6113666|NCT00843518|9734252|FG000|Period 2 (Double-blind Treatment)|Caregiver decision|7
6113667|NCT00843518|9734253|FG001|Period 2 (Double-blind Treatment)|Caregiver decision|7
6113668|NCT00843635|9734283|FG000|Overall Study|Adverse Event|2
6113669|NCT00843635|9734284|FG001|Overall Study|Adverse Event|2
6113670|NCT00843635|9734285|FG002|Overall Study|Adverse Event|0
6113671|NCT00843726|9734308|FG000|Overall Study|Death|1
6113672|NCT00843726|9734309|FG001|Overall Study|Death|0
6113673|NCT00843726|9734308|FG000|Overall Study|Withdrawal by Subject|0
6113674|NCT00843726|9734309|FG001|Overall Study|Withdrawal by Subject|1
6113675|NCT00843778|9734316|FG000|Overall Study|Adverse Event|15
6113676|NCT00843778|9734316|FG000|Overall Study|Lack of Efficacy|14
6113677|NCT00843778|9734316|FG000|Overall Study|Loss of efficacy|2
6113678|NCT00843778|9734316|FG000|Overall Study|Withdrawal by Subject|4
6113679|NCT00843843|9734322|FG000|Overall Study|Physician Decision|1
6113680|NCT00843843|9734323|FG001|Overall Study|Physician Decision|1
6113681|NCT00843843|9734322|FG000|Overall Study|Protocol Violation|1
6113682|NCT00843843|9734323|FG001|Overall Study|Protocol Violation|1
6113683|NCT00843856|9734331|FG000|Overall Study|Lost to Follow-up|1
6113684|NCT00843856|9734332|FG001|Overall Study|Lost to Follow-up|2
6113685|NCT00844194|9734358|FG000|Overall Study|Adverse Event|17
6113686|NCT00844194|9734359|FG001|Overall Study|Adverse Event|5
6113687|NCT00844194|9734358|FG000|Overall Study|Protocol Violation|1
6113688|NCT00844194|9734359|FG001|Overall Study|Protocol Violation|1
6113689|NCT00844194|9734358|FG000|Overall Study|Lost to Follow-up|1
6113690|NCT00844194|9734359|FG001|Overall Study|Lost to Follow-up|1
6113691|NCT00844194|9734358|FG000|Overall Study|Withdrawal by Subject|2
6113692|NCT00844194|9734359|FG001|Overall Study|Withdrawal by Subject|1
6113693|NCT00844194|9734358|FG000|Overall Study|Lack of Efficacy|3
6113694|NCT00844194|9734359|FG001|Overall Study|Lack of Efficacy|0
6113695|NCT00844194|9734358|FG000|Overall Study|Other reason (not specified)|1
6113696|NCT00844194|9734359|FG001|Overall Study|Other reason (not specified)|0
6113697|NCT00844376|9734373|FG000|Period 1: First Intervention|Withdrawal by Subject|1
6113698|NCT00844376|9734374|FG001|Period 1: First Intervention|Withdrawal by Subject|0
6113699|NCT00844415|9734380|FG000|Overall Study|Withdrawal by Subject|1
6113700|NCT00844428|9734385|FG000|Screening Period|Screen Failure|3
6113701|NCT00844428|9734385|FG000|Extension Treatment Period|Death|1
6113702|NCT00844428|9734385|FG000|Post Treatment Period (Patients Who Disc|Death|1
6113703|NCT00844519|9734391|FG000|Overall Study|Withdrawal by Subject|1
6113704|NCT00844519|9734392|FG001|Overall Study|Withdrawal by Subject|1
6113705|NCT00844519|9734391|FG000|Overall Study|Adverse Event|1
6113706|NCT00844519|9734392|FG001|Overall Study|Adverse Event|0
6113707|NCT00844532|9734398|FG000|Overall Study|Death|16
6113708|NCT00844532|9734398|FG000|Overall Study|Withdrawal by Subject|16
6113709|NCT00844532|9734398|FG000|Overall Study|Lost to Follow-up|7
6113710|NCT00844545|9734402|FG000|Treatment Period (26 Weeks)|Adverse Event|1
6113711|NCT00844545|9734402|FG000|Treatment Period (26 Weeks)|Protocol Violation|1
6113712|NCT00844545|9734402|FG000|Extension Treatment Period|Adverse Event|2
6113713|NCT00844545|9734402|FG000|Post Treatment Period|Withdrawal by Subject|1
6113714|NCT00844558|9734409|FG000|Overall Study|Withdrawal by Subject|9
6113715|NCT00844558|9734410|FG001|Overall Study|Withdrawal by Subject|2
6113716|NCT00844558|9734409|FG000|Overall Study|Death|1
6113717|NCT00844558|9734410|FG001|Overall Study|Death|0
6113718|NCT00844558|9734409|FG000|Overall Study|Protocol Violation|1
6113719|NCT00844558|9734410|FG001|Overall Study|Protocol Violation|1
6113720|NCT00844558|9734409|FG000|Overall Study|Lost to Follow-up|0
6113721|NCT00844558|9734410|FG001|Overall Study|Lost to Follow-up|1
6113722|NCT00844558|9734409|FG000|Overall Study|Physician Decision|1
6113723|NCT00844558|9734410|FG001|Overall Study|Physician Decision|0
6113724|NCT00844597|9734427|FG000|Overall Study|Adverse Event|0
6113725|NCT00844597|9734428|FG001|Overall Study|Adverse Event|0
6113726|NCT00844597|9734429|FG002|Overall Study|Adverse Event|0
6113727|NCT00844597|9734430|FG003|Overall Study|Adverse Event|1
6113728|NCT00844597|9734431|FG004|Overall Study|Adverse Event|0
6113729|NCT00844597|9734432|FG005|Overall Study|Adverse Event|0
6113730|NCT00844649|9734450|FG000|Overall Study|Progressive Disease|196
6113731|NCT00844649|9734451|FG001|Overall Study|Progressive Disease|245
6113732|NCT00844649|9734450|FG000|Overall Study|Adverse Event|128
6113733|NCT00844649|9734451|FG001|Overall Study|Adverse Event|73
6113734|NCT00844649|9734450|FG000|Overall Study|Physician Decision|25
6113735|NCT00844649|9734451|FG001|Overall Study|Physician Decision|18
6113736|NCT00844649|9734450|FG000|Overall Study|Protocol Violation|10
6113737|NCT00844649|9734451|FG001|Overall Study|Protocol Violation|6
6208564|NCT01565889|9873542|FG004|Part B|Lost to Follow-up|0
6208565|NCT01565889|9873543|FG005|Part B|Lost to Follow-up|1
6208566|NCT01565928|9873578|FG000|Overall Study|Adverse Event|3
6208567|NCT01565928|9873578|FG000|Overall Study|Other|3
6208568|NCT01565928|9873578|FG000|Overall Study|Progressive Disease|13
6208569|NCT01565928|9873578|FG000|Overall Study|Withdrawal by Subject|1
6208570|NCT01565928|9873578|FG000|Overall Study|Death|2
6208571|NCT01565941|9873587|FG000|Overall Study|Withdrawn by parent/guardian|3
6208572|NCT01565941|9873588|FG001|Overall Study|Withdrawn by parent/guardian|2
6208573|NCT01565941|9873587|FG000|Overall Study|Randomized; did not receive intevention|8
6208574|NCT01565941|9873588|FG001|Overall Study|Randomized; did not receive intevention|2
6208575|NCT01565980|9873598|FG000|Overall Study|Death|1
6208576|NCT01565980|9873599|FG001|Overall Study|Death|0
6208577|NCT01565980|9873598|FG000|Overall Study|Lost to Follow-up|1
6208578|NCT01565980|9873599|FG001|Overall Study|Lost to Follow-up|0
6208579|NCT01565980|9873598|FG000|Overall Study|health complications|1
6208580|NCT01565980|9873599|FG001|Overall Study|health complications|1
6208581|NCT01565980|9873598|FG000|Overall Study|stopped medical treatment|1
6208582|NCT01565980|9873599|FG001|Overall Study|stopped medical treatment|0
6208583|NCT01565980|9873598|FG000|Overall Study|Withdrawal by Subject|0
6208584|NCT01565980|9873599|FG001|Overall Study|Withdrawal by Subject|3
6208585|NCT01565993|9873611|FG000|Overall Study|Physician Decision|0
6208586|NCT01565993|9873612|FG001|Overall Study|Physician Decision|3
6208587|NCT01566214|9873641|FG000|Overall Study|Lost to Follow-up|3
6286239|NCT02346240|9999196|FG005|Initial Period (Baseline to Week 16)|Adverse Event|0
6286240|NCT02346240|9999197|FG006|Initial Period (Baseline to Week 16)|Adverse Event|0
6286241|NCT02346240|9999198|FG007|Initial Period (Baseline to Week 16)|Adverse Event|0
6286242|NCT02346240|9999199|FG008|Initial Period (Baseline to Week 16)|Adverse Event|0
6286243|NCT02346240|9999200|FG009|Initial Period (Baseline to Week 16)|Adverse Event|0
6286244|NCT02346240|9999201|FG010|Initial Period (Baseline to Week 16)|Adverse Event|0
6286245|NCT02346240|9999202|FG011|Initial Period (Baseline to Week 16)|Adverse Event|0
6286246|NCT02346240|9999203|FG012|Initial Period (Baseline to Week 16)|Adverse Event|0
6286247|NCT02346240|9999204|FG013|Initial Period (Baseline to Week 16)|Adverse Event|0
6286248|NCT02346240|9999205|FG014|Initial Period (Baseline to Week 16)|Adverse Event|0
6286249|NCT02346240|9999206|FG015|Initial Period (Baseline to Week 16)|Adverse Event|0
6286250|NCT02346240|9999207|FG016|Initial Period (Baseline to Week 16)|Adverse Event|0
6286251|NCT02346240|9999208|FG017|Initial Period (Baseline to Week 16)|Adverse Event|0
6286252|NCT02346240|9999209|FG018|Initial Period (Baseline to Week 16)|Adverse Event|0
6286253|NCT02346240|9999210|FG019|Initial Period (Baseline to Week 16)|Adverse Event|0
6286254|NCT02346240|9999211|FG020|Initial Period (Baseline to Week 16)|Adverse Event|0
6208588|NCT01566214|9873642|FG001|Overall Study|Lost to Follow-up|0
6286255|NCT02346240|9999212|FG021|Initial Period (Baseline to Week 16)|Adverse Event|0
6286256|NCT02346240|9999213|FG022|Initial Period (Baseline to Week 16)|Adverse Event|0
6286257|NCT02346240|9999214|FG023|Initial Period (Baseline to Week 16)|Adverse Event|0
6286258|NCT02346240|9999191|FG000|Initial Period (Baseline to Week 16)|Lack of Efficacy|0
6286259|NCT02346240|9999192|FG001|Initial Period (Baseline to Week 16)|Lack of Efficacy|1
6286260|NCT02346240|9999193|FG002|Initial Period (Baseline to Week 16)|Lack of Efficacy|0
6286261|NCT02346240|9999194|FG003|Initial Period (Baseline to Week 16)|Lack of Efficacy|0
6286262|NCT02346240|9999195|FG004|Initial Period (Baseline to Week 16)|Lack of Efficacy|0
6286263|NCT02346240|9999196|FG005|Initial Period (Baseline to Week 16)|Lack of Efficacy|0
6286264|NCT02346240|9999197|FG006|Initial Period (Baseline to Week 16)|Lack of Efficacy|0
6113738|NCT00844649|9734450|FG000|Overall Study|Withdrawal by Subject|28
6208589|NCT01566435|9873666|FG000|ACF Definitive Chemoradiation-cisplatin|Withdrawal by Subject|1
6208590|NCT01566604|9873735|FG000|Overall Study|Patient's inability to use the device|1
6208591|NCT01566604|9873736|FG001|Overall Study|Patient's inability to use the device|0
6208592|NCT01566604|9873735|FG000|Overall Study|Administrative problems|1
6208593|NCT01566604|9873736|FG001|Overall Study|Administrative problems|0
6208594|NCT01566604|9873735|FG000|Overall Study|Lack of Efficacy|1
6208595|NCT01566604|9873736|FG001|Overall Study|Lack of Efficacy|2
6208596|NCT01566604|9873735|FG000|Overall Study|Protocol deviation|2
6208597|NCT01566604|9873736|FG001|Overall Study|Protocol deviation|0
6208598|NCT01566604|9873735|FG000|Overall Study|Abnormal laboratory value|2
6208599|NCT01566604|9873736|FG001|Overall Study|Abnormal laboratory value|0
6208600|NCT01566604|9873735|FG000|Overall Study|Death|4
6208601|NCT01566604|9873736|FG001|Overall Study|Death|1
6208602|NCT01566604|9873735|FG000|Overall Study|Adverse Event|4
6208603|NCT01566604|9873736|FG001|Overall Study|Adverse Event|2
6208604|NCT01566604|9873735|FG000|Overall Study|Withdrawal by Subject|9
6113739|NCT00844649|9734451|FG001|Overall Study|Withdrawal by Subject|39
6113740|NCT00844649|9734450|FG000|Overall Study|Other|7
6113741|NCT00844649|9734451|FG001|Overall Study|Other|10
6113742|NCT00844649|9734450|FG000|Overall Study|Withdrew prior to starting treatment|11
6113743|NCT00844649|9734451|FG001|Overall Study|Withdrew prior to starting treatment|27
6113744|NCT00844753|9734467|FG000|Overall Study|Lack of Efficacy|1
6113745|NCT00844753|9734468|FG001|Overall Study|Lack of Efficacy|0
6113746|NCT00844753|9734469|FG002|Overall Study|Lack of Efficacy|2
6113747|NCT00844753|9734470|FG003|Overall Study|Lack of Efficacy|2
6113748|NCT00844753|9734467|FG000|Overall Study|Adverse Event|3
6113749|NCT00844753|9734468|FG001|Overall Study|Adverse Event|2
6113750|NCT00844753|9734469|FG002|Overall Study|Adverse Event|5
6113751|NCT00844753|9734470|FG003|Overall Study|Adverse Event|5
6113752|NCT00844753|9734467|FG000|Overall Study|Lost to Follow-up|1
6113753|NCT00844753|9734468|FG001|Overall Study|Lost to Follow-up|1
6113754|NCT00844753|9734469|FG002|Overall Study|Lost to Follow-up|0
6113755|NCT00844753|9734470|FG003|Overall Study|Lost to Follow-up|1
6113756|NCT00844753|9734467|FG000|Overall Study|could not swallow medication|2
6113757|NCT00844753|9734468|FG001|Overall Study|could not swallow medication|0
6113758|NCT00844753|9734469|FG002|Overall Study|could not swallow medication|0
6113759|NCT00844753|9734470|FG003|Overall Study|could not swallow medication|0
6113760|NCT00844753|9734467|FG000|Overall Study|Withdrawal by Subject|1
6113761|NCT00844753|9734468|FG001|Overall Study|Withdrawal by Subject|0
6113762|NCT00844753|9734469|FG002|Overall Study|Withdrawal by Subject|0
6113763|NCT00844753|9734470|FG003|Overall Study|Withdrawal by Subject|3
6113764|NCT00844805|9734480|FG000|Treatment Phase|Adverse Event|5
6113765|NCT00844805|9734481|FG001|Treatment Phase|Adverse Event|1
6113766|NCT00844805|9734482|FG002|Treatment Phase|Adverse Event|0
6113767|NCT00844805|9734483|FG003|Treatment Phase|Adverse Event|0
6113768|NCT00844805|9734480|FG000|Treatment Phase|Withdrawal by Subject|3
6113769|NCT00844805|9734481|FG001|Treatment Phase|Withdrawal by Subject|4
6113770|NCT00844805|9734482|FG002|Treatment Phase|Withdrawal by Subject|0
6113771|NCT00844805|9734483|FG003|Treatment Phase|Withdrawal by Subject|0
6113772|NCT00844805|9734480|FG000|Treatment Phase|Noncompliance With Protocol|1
6113773|NCT00844805|9734481|FG001|Treatment Phase|Noncompliance With Protocol|0
6113774|NCT00844805|9734482|FG002|Treatment Phase|Noncompliance With Protocol|0
6113775|NCT00844805|9734483|FG003|Treatment Phase|Noncompliance With Protocol|0
6113776|NCT00844805|9734480|FG000|Treatment Phase|Did Not Meet Protocol Eligibility|1
6113777|NCT00844805|9734481|FG001|Treatment Phase|Did Not Meet Protocol Eligibility|2
6113778|NCT00844805|9734482|FG002|Treatment Phase|Did Not Meet Protocol Eligibility|0
6113779|NCT00844805|9734483|FG003|Treatment Phase|Did Not Meet Protocol Eligibility|0
6113780|NCT00844805|9734480|FG000|Follow-Up Phase|Adverse Event|0
6113781|NCT00844805|9734481|FG001|Follow-Up Phase|Adverse Event|0
6113782|NCT00844805|9734482|FG002|Follow-Up Phase|Adverse Event|1
6113783|NCT00844805|9734483|FG003|Follow-Up Phase|Adverse Event|0
6113784|NCT00844805|9734480|FG000|Follow-Up Phase|Withdrawal by Subject|0
6113785|NCT00844805|9734481|FG001|Follow-Up Phase|Withdrawal by Subject|0
6113786|NCT00844805|9734482|FG002|Follow-Up Phase|Withdrawal by Subject|6
6113787|NCT00844805|9734483|FG003|Follow-Up Phase|Withdrawal by Subject|3
6113788|NCT00844805|9734480|FG000|Follow-Up Phase|Noncompliance With Protocol|0
6113789|NCT00844805|9734481|FG001|Follow-Up Phase|Noncompliance With Protocol|0
6113790|NCT00844805|9734482|FG002|Follow-Up Phase|Noncompliance With Protocol|0
6113791|NCT00844805|9734483|FG003|Follow-Up Phase|Noncompliance With Protocol|1
6113792|NCT00844805|9734480|FG000|Follow-Up Phase|Relapse/Recurrence|0
6113793|NCT00844805|9734481|FG001|Follow-Up Phase|Relapse/Recurrence|0
6113794|NCT00844805|9734482|FG002|Follow-Up Phase|Relapse/Recurrence|2
6113795|NCT00844805|9734483|FG003|Follow-Up Phase|Relapse/Recurrence|4
6113796|NCT00844805|9734480|FG000|Follow-Up Phase|Did Not Meet Protocol Eligibility|0
6113797|NCT00844805|9734481|FG001|Follow-Up Phase|Did Not Meet Protocol Eligibility|0
6113798|NCT00844805|9734482|FG002|Follow-Up Phase|Did Not Meet Protocol Eligibility|0
6113799|NCT00844805|9734483|FG003|Follow-Up Phase|Did Not Meet Protocol Eligibility|1
6208605|NCT01566604|9873736|FG001|Overall Study|Withdrawal by Subject|6
6208606|NCT01566721|9873763|FG000|Treatment Period|Withdrawal by Subject|35
6208607|NCT01566721|9873764|FG001|Treatment Period|Withdrawal by Subject|9
6208608|NCT01566721|9873763|FG000|Treatment Period|Disease Progression/Recurrence|37
6208609|NCT01566721|9873764|FG001|Treatment Period|Disease Progression/Recurrence|13
6208610|NCT01566721|9873763|FG000|Treatment Period|Investigator/Sponsor Decision|6
6208611|NCT01566721|9873764|FG001|Treatment Period|Investigator/Sponsor Decision|3
6208612|NCT01566721|9873763|FG000|Treatment Period|Other|13
6208613|NCT01566721|9873764|FG001|Treatment Period|Other|2
6208614|NCT01566721|9873763|FG000|Treatment Period|Lack of Compliance|5
6208615|NCT01566721|9873764|FG001|Treatment Period|Lack of Compliance|1
6208616|NCT01566721|9873763|FG000|Treatment Period|Adverse Event|100
6208617|NCT01566721|9873764|FG001|Treatment Period|Adverse Event|30
6286265|NCT02346240|9999198|FG007|Initial Period (Baseline to Week 16)|Lack of Efficacy|0
6286266|NCT02346240|9999199|FG008|Initial Period (Baseline to Week 16)|Lack of Efficacy|0
6286267|NCT02346240|9999200|FG009|Initial Period (Baseline to Week 16)|Lack of Efficacy|0
6113800|NCT00844831|9734494|FG000|Overall Study|Withdrawal by Subject|4
6113801|NCT00844831|9734494|FG000|Overall Study|Adverse Event|1
6113802|NCT00844831|9734494|FG000|Overall Study|Physician Decision|1
6113803|NCT00844844|9734502|FG000|Treatment Period (26 Weeks)|Adverse Event|1
6113804|NCT00844844|9734502|FG000|Treatment Period (26 Weeks)|Protocol Violation|1
6113805|NCT00844844|9734502|FG000|Extension Treatment Period|Adverse Event|2
6113806|NCT00844844|9734502|FG000|Post Treatment Period|Withdrawal by Subject|1
6113807|NCT00844857|9734508|FG000|Overall Study|Adverse Event|24
6113808|NCT00844857|9734509|FG001|Overall Study|Adverse Event|5
6113809|NCT00844857|9734508|FG000|Overall Study|Sponsor Decision|1
6113810|NCT00844857|9734509|FG001|Overall Study|Sponsor Decision|1
6113811|NCT00844857|9734508|FG000|Overall Study|Physician Decision|2
6113812|NCT00844857|9734509|FG001|Overall Study|Physician Decision|0
6113813|NCT00844857|9734508|FG000|Overall Study|Parent/Caregiver Decision|6
6113814|NCT00844857|9734509|FG001|Overall Study|Parent/Caregiver Decision|2
6113815|NCT00844857|9734508|FG000|Overall Study|Withdrawal by Subject|8
6113816|NCT00844857|9734509|FG001|Overall Study|Withdrawal by Subject|7
6113817|NCT00844857|9734508|FG000|Overall Study|Protocol Violation|6
6113818|NCT00844857|9734509|FG001|Overall Study|Protocol Violation|0
6113819|NCT00844857|9734508|FG000|Overall Study|Lack of Efficacy|5
6113820|NCT00844857|9734509|FG001|Overall Study|Lack of Efficacy|5
6113821|NCT00844857|9734508|FG000|Overall Study|Clinical Relapse|0
6113822|NCT00844857|9734509|FG001|Overall Study|Clinical Relapse|1
6113823|NCT00844857|9734508|FG000|Overall Study|Entry Criteria Not Met|0
6113824|NCT00844857|9734509|FG001|Overall Study|Entry Criteria Not Met|1
6113825|NCT00844857|9734508|FG000|Overall Study|Lost to Follow-up|2
6113826|NCT00844857|9734509|FG001|Overall Study|Lost to Follow-up|3
6113827|NCT00844857|9734508|FG000|Overall Study|Did Not Take Study Drug|3
6113828|NCT00844857|9734509|FG001|Overall Study|Did Not Take Study Drug|1
6113829|NCT00844857|9734508|FG000|Overall Study|Good Clinical Practice Violations|21
6113830|NCT00844857|9734509|FG001|Overall Study|Good Clinical Practice Violations|11
6113831|NCT00844883|9734518|FG000|Overall Study|Bridged to liver transplant|3
6113832|NCT00844883|9734518|FG000|Overall Study|Bridged to resection|1
6113833|NCT00844896|9734524|FG000|Overall Study|Lost to Follow-up|12
6113834|NCT00844896|9734525|FG001|Overall Study|Lost to Follow-up|16
6113835|NCT00844896|9734524|FG000|Overall Study|Parents did not have time to complete|0
6113836|NCT00844896|9734525|FG001|Overall Study|Parents did not have time to complete|1
6113837|NCT00845065|9734564|FG000|Overall Study|Adverse Event|3
6113838|NCT00845065|9734565|FG001|Overall Study|Adverse Event|23
6113839|NCT00845065|9734564|FG000|Overall Study|Lack of Efficacy|43
6113840|NCT00845065|9734565|FG001|Overall Study|Lack of Efficacy|21
6113841|NCT00845065|9734564|FG000|Overall Study|Non-Medical Reasons|1
6113842|NCT00845065|9734565|FG001|Overall Study|Non-Medical Reasons|11
6113843|NCT00845182|9734585|FG000|Overall Study|Lost to Follow-up|3
6113844|NCT00845182|9734586|FG001|Overall Study|Lost to Follow-up|3
6113845|NCT00845182|9734587|FG002|Overall Study|Lost to Follow-up|4
6113846|NCT00845182|9734585|FG000|Overall Study|Adverse Event|0
6208618|NCT01566721|9873763|FG000|Treatment Period|Pregnancy|1
6208619|NCT01566721|9873764|FG001|Treatment Period|Pregnancy|0
6208620|NCT01566721|9873763|FG000|Safety Follow-up|Physician Decision|6
6208621|NCT01566721|9873764|FG001|Safety Follow-up|Physician Decision|4
6208622|NCT01566721|9873763|FG000|Safety Follow-up|Lost to Follow-up|101
6208623|NCT01566721|9873764|FG001|Safety Follow-up|Lost to Follow-up|48
6208624|NCT01566721|9873763|FG000|Safety Follow-up|Withdrawal by Subject|155
6208625|NCT01566721|9873764|FG001|Safety Follow-up|Withdrawal by Subject|49
6208626|NCT01566721|9873763|FG000|Safety Follow-up|Death|28
6208627|NCT01566721|9873764|FG001|Safety Follow-up|Death|4
6208628|NCT01566721|9873763|FG000|Safety Follow-up|Non-compliance|7
6208629|NCT01566721|9873764|FG001|Safety Follow-up|Non-compliance|3
6208630|NCT01566721|9873763|FG000|Safety Follow-up|Protocol Violation|7
6208631|NCT01566721|9873764|FG001|Safety Follow-up|Protocol Violation|0
6208632|NCT01566721|9873763|FG000|Safety Follow-up|Site closure|2
6208633|NCT01566721|9873764|FG001|Safety Follow-up|Site closure|3
6113847|NCT00845182|9734586|FG001|Overall Study|Adverse Event|1
6113848|NCT00845182|9734587|FG002|Overall Study|Adverse Event|1
6113849|NCT00845182|9734585|FG000|Overall Study|Physician Decision|0
6113850|NCT00845182|9734586|FG001|Overall Study|Physician Decision|0
6113851|NCT00845182|9734587|FG002|Overall Study|Physician Decision|1
6208634|NCT01566721|9873763|FG000|Safety Follow-up|Erroneous reporting or late reporting|2
6208635|NCT01566721|9873764|FG001|Safety Follow-up|Erroneous reporting or late reporting|0
6208636|NCT01566721|9873763|FG000|Safety Follow-up|Missing|7
6208637|NCT01566721|9873764|FG001|Safety Follow-up|Missing|2
6208638|NCT01566721|9873763|FG000|Safety Follow-up|Disease progression /disease recurrence|223
6208639|NCT01566721|9873764|FG001|Safety Follow-up|Disease progression /disease recurrence|90
6208640|NCT01566721|9873763|FG000|Safety Follow-up|Sponsor decision|1
6208641|NCT01566721|9873764|FG001|Safety Follow-up|Sponsor decision|0
6208642|NCT01566721|9873763|FG000|Safety Follow-up|Adverse Event|8
6208643|NCT01566721|9873764|FG001|Safety Follow-up|Adverse Event|4
6208644|NCT01566773|9873777|FG000|Overall Study|Protocol specified criteria|4
6208645|NCT01566773|9873777|FG000|Overall Study|Protocol Violation|4
6208646|NCT01566773|9873777|FG000|Overall Study|Withdrawal by Subject|9
6208647|NCT01566773|9873777|FG000|Overall Study|Administrative reason|1
6208648|NCT01566773|9873777|FG000|Overall Study|Adverse Event|10
6208649|NCT01566773|9873777|FG000|Overall Study|Physician Decision|2
6208650|NCT01566981|9873808|FG000|Overall Study|Lost to Follow-up|5
6208651|NCT01566981|9873809|FG001|Overall Study|Lost to Follow-up|8
6208652|NCT01567085|9873834|FG000|Overall Study|Death|6
6113852|NCT00845429|9734611|FG000|Overall Study|Protocol Violation|5
6113853|NCT00845429|9734612|FG001|Overall Study|Protocol Violation|4
6113854|NCT00845429|9734613|FG002|Overall Study|Protocol Violation|7
6113855|NCT00845429|9734611|FG000|Overall Study|Lost to Follow-up|7
6113856|NCT00845429|9734612|FG001|Overall Study|Lost to Follow-up|9
6113857|NCT00845429|9734613|FG002|Overall Study|Lost to Follow-up|10
6113858|NCT00845429|9734611|FG000|Overall Study|Withdrawal by Subject|2
6113859|NCT00845429|9734612|FG001|Overall Study|Withdrawal by Subject|2
6113860|NCT00845429|9734613|FG002|Overall Study|Withdrawal by Subject|2
6113861|NCT00845429|9734611|FG000|Overall Study|Serious adverse event|0
6113862|NCT00845429|9734612|FG001|Overall Study|Serious adverse event|0
6113863|NCT00845429|9734613|FG002|Overall Study|Serious adverse event|1
6113864|NCT00845520|9734642|FG000|Overall Study|Death|1
6113865|NCT00845520|9734643|FG001|Overall Study|Death|2
6113866|NCT00845520|9734644|FG002|Overall Study|Death|0
6208653|NCT01567085|9873834|FG000|Overall Study|Adverse Event|6
6208654|NCT01567085|9873834|FG000|Overall Study|Lost to Follow-up|3
6208655|NCT01567085|9873834|FG000|Overall Study|Graft loss|2
6208656|NCT01567085|9873834|FG000|Overall Study|Renal transplantectomy|1
6208657|NCT01567085|9873834|FG000|Overall Study|Returned to chronic dialysis|1
6208658|NCT01567085|9873834|FG000|Overall Study|Terminal chronic kidney dysfunction|1
6208659|NCT01567163|9873847|FG000|Overall Study|Progressive Disease|2
6208660|NCT01567163|9873847|FG000|Overall Study|Lost to Follow-up|2
6208661|NCT01567306|9873862|FG000|Overall Study|Protocol Violation|2
6208662|NCT01567306|9873863|FG001|Overall Study|Protocol Violation|2
6208663|NCT01567306|9873864|FG002|Overall Study|Protocol Violation|0
6208664|NCT01567306|9873865|FG003|Overall Study|Protocol Violation|3
6208665|NCT01567306|9873866|FG004|Overall Study|Protocol Violation|1
6208666|NCT01567306|9873867|FG005|Overall Study|Protocol Violation|1
6208667|NCT01567306|9873862|FG000|Overall Study|Change site living|1
6208668|NCT01567306|9873863|FG001|Overall Study|Change site living|0
6208669|NCT01567306|9873864|FG002|Overall Study|Change site living|0
6208670|NCT01567306|9873865|FG003|Overall Study|Change site living|0
6208671|NCT01567306|9873866|FG004|Overall Study|Change site living|0
6208672|NCT01567306|9873867|FG005|Overall Study|Change site living|0
6208673|NCT01567306|9873862|FG000|Overall Study|Adverse Event|0
6208674|NCT01567306|9873863|FG001|Overall Study|Adverse Event|0
6208675|NCT01567306|9873864|FG002|Overall Study|Adverse Event|0
6208676|NCT01567306|9873865|FG003|Overall Study|Adverse Event|2
6208677|NCT01567306|9873866|FG004|Overall Study|Adverse Event|4
6208678|NCT01567306|9873867|FG005|Overall Study|Adverse Event|1
6208679|NCT01567306|9873862|FG000|Overall Study|Lost to Follow-up|0
6208680|NCT01567306|9873863|FG001|Overall Study|Lost to Follow-up|0
6208681|NCT01567306|9873864|FG002|Overall Study|Lost to Follow-up|0
6208682|NCT01567306|9873865|FG003|Overall Study|Lost to Follow-up|0
6208683|NCT01567306|9873866|FG004|Overall Study|Lost to Follow-up|2
6208684|NCT01567306|9873867|FG005|Overall Study|Lost to Follow-up|0
6208685|NCT01567306|9873862|FG000|Overall Study|Withdrawal by Subject|0
6208686|NCT01567306|9873863|FG001|Overall Study|Withdrawal by Subject|0
6208687|NCT01567306|9873864|FG002|Overall Study|Withdrawal by Subject|0
6208688|NCT01567306|9873865|FG003|Overall Study|Withdrawal by Subject|0
6208689|NCT01567306|9873866|FG004|Overall Study|Withdrawal by Subject|0
6208690|NCT01567306|9873867|FG005|Overall Study|Withdrawal by Subject|1
6208691|NCT01567462|9873887|FG000|Overall Study|Withdrawal by Subject|4
6208692|NCT01567462|9873888|FG001|Overall Study|Withdrawal by Subject|7
6208693|NCT01567527|9873896|FG000|Conversion Phase.|Protocol deviation|3
6208694|NCT01567527|9873897|FG001|Conversion Phase.|Protocol deviation|0
6208695|NCT01567527|9873898|FG002|Conversion Phase.|Protocol deviation|0
6208696|NCT01567527|9873899|FG003|Conversion Phase.|Protocol deviation|0
6113867|NCT00845520|9734642|FG000|Overall Study|Lost to Follow-up|1
6113868|NCT00845520|9734643|FG001|Overall Study|Lost to Follow-up|0
6113869|NCT00845520|9734644|FG002|Overall Study|Lost to Follow-up|0
6113870|NCT00845520|9734642|FG000|Overall Study|Adverse Event|0
6113871|NCT00845520|9734643|FG001|Overall Study|Adverse Event|0
6113872|NCT00845520|9734644|FG002|Overall Study|Adverse Event|1
6113873|NCT00845650|9734664|FG000|Overall Study|Withdrawal by Subject|0
6113874|NCT00845650|9734665|FG001|Overall Study|Withdrawal by Subject|0
6113875|NCT00845650|9734666|FG002|Overall Study|Withdrawal by Subject|0
6113876|NCT00845650|9734667|FG003|Overall Study|Withdrawal by Subject|0
6113877|NCT00845650|9734668|FG004|Overall Study|Withdrawal by Subject|2
6113878|NCT00845650|9734669|FG005|Overall Study|Withdrawal by Subject|0
6113879|NCT00845650|9734664|FG000|Overall Study|Lost to Follow-up|0
6113880|NCT00845650|9734665|FG001|Overall Study|Lost to Follow-up|0
6113881|NCT00845650|9734666|FG002|Overall Study|Lost to Follow-up|3
6113882|NCT00845650|9734667|FG003|Overall Study|Lost to Follow-up|1
6208697|NCT01567527|9873900|FG004|Conversion Phase.|Protocol deviation|0
6208698|NCT01567527|9873896|FG000|Conversion Phase.|Met withdrawal criteria|10
6208699|NCT01567527|9873897|FG001|Conversion Phase.|Met withdrawal criteria|0
6208700|NCT01567527|9873898|FG002|Conversion Phase.|Met withdrawal criteria|0
6208701|NCT01567527|9873899|FG003|Conversion Phase.|Met withdrawal criteria|0
6208702|NCT01567527|9873900|FG004|Conversion Phase.|Met withdrawal criteria|0
6208703|NCT01567527|9873896|FG000|Conversion Phase.|Withdrawal by Subject|32
6113883|NCT00845650|9734668|FG004|Overall Study|Lost to Follow-up|0
6113884|NCT00845650|9734669|FG005|Overall Study|Lost to Follow-up|1
6208704|NCT01567527|9873897|FG001|Conversion Phase.|Withdrawal by Subject|0
6113885|NCT00845650|9734664|FG000|Overall Study|Sponsor hold on dosing|0
6113886|NCT00845650|9734665|FG001|Overall Study|Sponsor hold on dosing|0
6113887|NCT00845650|9734666|FG002|Overall Study|Sponsor hold on dosing|0
6113888|NCT00845650|9734667|FG003|Overall Study|Sponsor hold on dosing|0
6113889|NCT00845650|9734668|FG004|Overall Study|Sponsor hold on dosing|1
6113890|NCT00845650|9734669|FG005|Overall Study|Sponsor hold on dosing|1
6113891|NCT00845650|9734664|FG000|Overall Study|Unable to access IV line|1
6113892|NCT00845650|9734665|FG001|Overall Study|Unable to access IV line|0
6113893|NCT00845650|9734666|FG002|Overall Study|Unable to access IV line|0
6113894|NCT00845650|9734667|FG003|Overall Study|Unable to access IV line|0
6113895|NCT00845650|9734668|FG004|Overall Study|Unable to access IV line|0
6113896|NCT00845650|9734669|FG005|Overall Study|Unable to access IV line|0
6113897|NCT00845676|9734694|FG000|Overall Study|Virologic breakthrough at week 20|1
6113898|NCT00845676|9734694|FG000|Overall Study|Adverse Event|1
6113899|NCT00845728|9734701|FG000|Overall Study|Abnormal laboratory value (s)|2
6113900|NCT00845728|9734702|FG001|Overall Study|Abnormal laboratory value (s)|2
6113901|NCT00845728|9734701|FG000|Overall Study|Patient's inability to use the device|4
6113902|NCT00845728|9734702|FG001|Overall Study|Patient's inability to use the device|6
6113903|NCT00845728|9734701|FG000|Overall Study|Abnormal test procedure result (s)|7
6113904|NCT00845728|9734702|FG001|Overall Study|Abnormal test procedure result (s)|2
6113905|NCT00845728|9734701|FG000|Overall Study|Lost to Follow-up|22
6113906|NCT00845728|9734702|FG001|Overall Study|Lost to Follow-up|13
6113907|NCT00845728|9734701|FG000|Overall Study|Death|24
6113908|NCT00845728|9734702|FG001|Overall Study|Death|26
6113909|NCT00845728|9734701|FG000|Overall Study|Administrative Problems|34
6113910|NCT00845728|9734702|FG001|Overall Study|Administrative Problems|26
6113911|NCT00845728|9734701|FG000|Overall Study|Protocol Violation|36
6113912|NCT00845728|9734702|FG001|Overall Study|Protocol Violation|24
6113913|NCT00845728|9734701|FG000|Overall Study|Lack of Efficacy|51
6113914|NCT00845728|9734702|FG001|Overall Study|Lack of Efficacy|39
6113915|NCT00845728|9734701|FG000|Overall Study|Adverse Event|101
6113916|NCT00845728|9734702|FG001|Overall Study|Adverse Event|96
6113917|NCT00845728|9734701|FG000|Overall Study|Withdrawal by Subject|105
6113918|NCT00845728|9734702|FG001|Overall Study|Withdrawal by Subject|108
6113919|NCT00845832|9734711|FG000|Treatment Period|Adverse Event|0
6113920|NCT00845832|9734712|FG001|Treatment Period|Adverse Event|2
6113921|NCT00845832|9734713|FG002|Treatment Period|Adverse Event|0
6113922|NCT00845832|9734711|FG000|Treatment Period|Protocol Violation|1
6113923|NCT00845832|9734712|FG001|Treatment Period|Protocol Violation|1
6113924|NCT00845832|9734713|FG002|Treatment Period|Protocol Violation|0
6113925|NCT00845832|9734711|FG000|Safety Follow-Up|Withdrawal by Subject|1
6113926|NCT00845832|9734712|FG001|Safety Follow-Up|Withdrawal by Subject|0
6113927|NCT00845832|9734713|FG002|Safety Follow-Up|Withdrawal by Subject|0
6113928|NCT00845832|9734711|FG000|Extended Safety Follow-Up|Withdrawal by Subject|0
6113929|NCT00845832|9734712|FG001|Extended Safety Follow-Up|Withdrawal by Subject|0
6113930|NCT00845832|9734713|FG002|Extended Safety Follow-Up|Withdrawal by Subject|7
6113931|NCT00845858|9734724|FG000|Overall Study|Withdrawal by Subject|5
6113932|NCT00845858|9734725|FG001|Overall Study|Withdrawal by Subject|1
6113933|NCT00845858|9734726|FG002|Overall Study|Withdrawal by Subject|1
6113934|NCT00845858|9734724|FG000|Overall Study|Adverse Event|3
6113935|NCT00845858|9734725|FG001|Overall Study|Adverse Event|8
6113936|NCT00845858|9734726|FG002|Overall Study|Adverse Event|4
6113937|NCT00845858|9734724|FG000|Overall Study|Protocol Violation|0
6113938|NCT00845858|9734725|FG001|Overall Study|Protocol Violation|0
6113939|NCT00845858|9734726|FG002|Overall Study|Protocol Violation|1
6113940|NCT00845858|9734724|FG000|Overall Study|not eligible|0
6113941|NCT00845858|9734725|FG001|Overall Study|not eligible|3
6113942|NCT00845858|9734726|FG002|Overall Study|not eligible|2
6113943|NCT00845871|9734737|FG000|Assessment Period|Adverse Event|2
6113944|NCT00845871|9734737|FG000|Assessment Period|Abnormal laboratory values|1
6113945|NCT00845871|9734737|FG000|Assessment Period|Abnormal test procedure results|1
6113946|NCT00845871|9734737|FG000|Assessment Period|Patient withdrew consent|3
6113947|NCT00845897|9734764|FG000|Overall Study|Lost to Follow-up|1
6113948|NCT00845897|9734765|FG001|Overall Study|Lost to Follow-up|1
6113949|NCT00845897|9734766|FG002|Overall Study|Lost to Follow-up|0
6113950|NCT00845897|9734764|FG000|Overall Study|Withdrawal by Subject|0
6113951|NCT00845897|9734765|FG001|Overall Study|Withdrawal by Subject|3
6113952|NCT00845897|9734766|FG002|Overall Study|Withdrawal by Subject|2
6113953|NCT00845897|9734764|FG000|Overall Study|Ulcer did not heal|1
6113954|NCT00845897|9734765|FG001|Overall Study|Ulcer did not heal|0
6113955|NCT00845897|9734766|FG002|Overall Study|Ulcer did not heal|1
6113956|NCT00845897|9734764|FG000|Overall Study|Too ill to participate|0
6113957|NCT00845897|9734765|FG001|Overall Study|Too ill to participate|1
6113958|NCT00845897|9734766|FG002|Overall Study|Too ill to participate|0
6113959|NCT00846027|9734783|FG000|Overall Study|Death|3
6113960|NCT00846027|9734783|FG000|Overall Study|Disease Progression|30
6113961|NCT00846027|9734783|FG000|Overall Study|Toxicity|12
6113962|NCT00846027|9734783|FG000|Overall Study|Patient Decision|7
6113963|NCT00846027|9734783|FG000|Overall Study|Investigator Discretion|29
6113964|NCT00846027|9734783|FG000|Overall Study|Protocol Violation|2
6113965|NCT00846027|9734783|FG000|Overall Study|Subject Not Treated|7
6113966|NCT00846040|9734790|FG000|Baseline: Days 1-5|Withdrawal by Subject|1
6113967|NCT00846040|9734791|FG001|Baseline: Days 1-5|Withdrawal by Subject|0
6113968|NCT00846040|9734792|FG002|Baseline: Days 1-5|Withdrawal by Subject|0
6113969|NCT00846040|9734790|FG000|Washout: 2 Weeks to 10 Weeks|Withdrawal by Subject|0
6113970|NCT00846040|9734791|FG001|Washout: 2 Weeks to 10 Weeks|Withdrawal by Subject|2
6113971|NCT00846040|9734792|FG002|Washout: 2 Weeks to 10 Weeks|Withdrawal by Subject|0
6113972|NCT00846053|9734803|FG000|Overall Study|Physician Decision|3
6113973|NCT00846053|9734804|FG001|Overall Study|Physician Decision|0
6113974|NCT00846365|9734834|FG000|Overall Study|Adverse Event|20
6113975|NCT00846365|9734835|FG001|Overall Study|Adverse Event|30
6113976|NCT00846365|9734836|FG002|Overall Study|Adverse Event|11
6208705|NCT01567527|9873898|FG002|Conversion Phase.|Withdrawal by Subject|0
6208706|NCT01567527|9873899|FG003|Conversion Phase.|Withdrawal by Subject|0
6208707|NCT01567527|9873900|FG004|Conversion Phase.|Withdrawal by Subject|0
6208708|NCT01567527|9873896|FG000|Conversion Phase.|Lost to Follow-up|16
6208709|NCT01567527|9873897|FG001|Conversion Phase.|Lost to Follow-up|0
6208710|NCT01567527|9873898|FG002|Conversion Phase.|Lost to Follow-up|0
6208711|NCT01567527|9873899|FG003|Conversion Phase.|Lost to Follow-up|0
6208712|NCT01567527|9873900|FG004|Conversion Phase.|Lost to Follow-up|0
6208713|NCT01567527|9873896|FG000|Conversion Phase.|Lack of Efficacy|2
6208714|NCT01567527|9873897|FG001|Conversion Phase.|Lack of Efficacy|0
6208715|NCT01567527|9873898|FG002|Conversion Phase.|Lack of Efficacy|0
6208716|NCT01567527|9873899|FG003|Conversion Phase.|Lack of Efficacy|0
6208717|NCT01567527|9873900|FG004|Conversion Phase.|Lack of Efficacy|0
6208718|NCT01567527|9873896|FG000|Conversion Phase.|Adverse Event|33
6208719|NCT01567527|9873897|FG001|Conversion Phase.|Adverse Event|0
6208720|NCT01567527|9873898|FG002|Conversion Phase.|Adverse Event|0
6208721|NCT01567527|9873899|FG003|Conversion Phase.|Adverse Event|0
6208722|NCT01567527|9873900|FG004|Conversion Phase.|Adverse Event|0
6208723|NCT01567527|9873896|FG000|Conversion Phase.|Withdrawn by the investigator|3
6208724|NCT01567527|9873897|FG001|Conversion Phase.|Withdrawn by the investigator|0
6208725|NCT01567527|9873898|FG002|Conversion Phase.|Withdrawn by the investigator|0
6208726|NCT01567527|9873899|FG003|Conversion Phase.|Withdrawn by the investigator|0
6208727|NCT01567527|9873900|FG004|Conversion Phase.|Withdrawn by the investigator|0
6208728|NCT01567527|9873896|FG000|Oral Aripiprazole Stabilization Phase.|Met withdrawal criteria|0
6208729|NCT01567527|9873897|FG001|Oral Aripiprazole Stabilization Phase.|Met withdrawal criteria|41
6208730|NCT01567527|9873898|FG002|Oral Aripiprazole Stabilization Phase.|Met withdrawal criteria|0
6208731|NCT01567527|9873899|FG003|Oral Aripiprazole Stabilization Phase.|Met withdrawal criteria|0
6208732|NCT01567527|9873900|FG004|Oral Aripiprazole Stabilization Phase.|Met withdrawal criteria|0
6208733|NCT01567527|9873896|FG000|Oral Aripiprazole Stabilization Phase.|Withdrawal by Subject|0
6208734|NCT01567527|9873897|FG001|Oral Aripiprazole Stabilization Phase.|Withdrawal by Subject|45
6208735|NCT01567527|9873898|FG002|Oral Aripiprazole Stabilization Phase.|Withdrawal by Subject|0
5980712|NCT02471144|9569413|FG006|Induction Period (Up to Week 12)|Subject/Guardian Decision|0
5980713|NCT02471144|9569414|FG007|Induction Period (Up to Week 12)|Subject/Guardian Decision|0
5980714|NCT02471144|9569415|FG008|Induction Period (Up to Week 12)|Subject/Guardian Decision|0
5980715|NCT02471144|9569416|FG009|Induction Period (Up to Week 12)|Subject/Guardian Decision|0
5980716|NCT02471144|9569417|FG010|Induction Period (Up to Week 12)|Subject/Guardian Decision|0
5980717|NCT02471144|9569407|FG000|Maintenance Period (Week 12 to Week 52)|Adverse Event|0
5980718|NCT02471144|9569408|FG001|Maintenance Period (Week 12 to Week 52)|Adverse Event|0
5980719|NCT02471144|9569409|FG002|Maintenance Period (Week 12 to Week 52)|Adverse Event|0
5980720|NCT02471144|9569410|FG003|Maintenance Period (Week 12 to Week 52)|Adverse Event|0
5980721|NCT02471144|9569411|FG004|Maintenance Period (Week 12 to Week 52)|Adverse Event|1
5980722|NCT02471144|9569412|FG005|Maintenance Period (Week 12 to Week 52)|Adverse Event|0
5980723|NCT02471144|9569413|FG006|Maintenance Period (Week 12 to Week 52)|Adverse Event|1
5980724|NCT02471144|9569414|FG007|Maintenance Period (Week 12 to Week 52)|Adverse Event|0
5980725|NCT02471144|9569415|FG008|Maintenance Period (Week 12 to Week 52)|Adverse Event|1
5980726|NCT02471144|9569416|FG009|Maintenance Period (Week 12 to Week 52)|Adverse Event|0
5980727|NCT02471144|9569417|FG010|Maintenance Period (Week 12 to Week 52)|Adverse Event|0
5980728|NCT02471144|9569407|FG000|Maintenance Period (Week 12 to Week 52)|Lack of Efficacy|0
5980729|NCT02471144|9569408|FG001|Maintenance Period (Week 12 to Week 52)|Lack of Efficacy|0
5980730|NCT02471144|9569409|FG002|Maintenance Period (Week 12 to Week 52)|Lack of Efficacy|0
5980731|NCT02471144|9569410|FG003|Maintenance Period (Week 12 to Week 52)|Lack of Efficacy|0
5980732|NCT02471144|9569411|FG004|Maintenance Period (Week 12 to Week 52)|Lack of Efficacy|0
5980733|NCT02471144|9569412|FG005|Maintenance Period (Week 12 to Week 52)|Lack of Efficacy|1
6113977|NCT00846365|9734834|FG000|Overall Study|Protocol Violation|5
6113978|NCT00846365|9734835|FG001|Overall Study|Protocol Violation|4
6113979|NCT00846365|9734836|FG002|Overall Study|Protocol Violation|0
6113980|NCT00846365|9734834|FG000|Overall Study|Lost to Follow-up|8
6113981|NCT00846365|9734835|FG001|Overall Study|Lost to Follow-up|2
6113982|NCT00846365|9734836|FG002|Overall Study|Lost to Follow-up|5
6113983|NCT00846365|9734834|FG000|Overall Study|Withdrawal by Subject|11
6113984|NCT00846365|9734835|FG001|Overall Study|Withdrawal by Subject|11
6113985|NCT00846365|9734836|FG002|Overall Study|Withdrawal by Subject|9
5980734|NCT02471144|9569413|FG006|Maintenance Period (Week 12 to Week 52)|Lack of Efficacy|0
5980735|NCT02471144|9569414|FG007|Maintenance Period (Week 12 to Week 52)|Lack of Efficacy|0
5980736|NCT02471144|9569415|FG008|Maintenance Period (Week 12 to Week 52)|Lack of Efficacy|3
6113986|NCT00846365|9734834|FG000|Overall Study|Pregnancy|1
6113987|NCT00846365|9734835|FG001|Overall Study|Pregnancy|0
6208736|NCT01567527|9873899|FG003|Oral Aripiprazole Stabilization Phase.|Withdrawal by Subject|0
6208737|NCT01567527|9873900|FG004|Oral Aripiprazole Stabilization Phase.|Withdrawal by Subject|0
6208738|NCT01567527|9873896|FG000|Oral Aripiprazole Stabilization Phase.|Lost to Follow-up|0
6208739|NCT01567527|9873897|FG001|Oral Aripiprazole Stabilization Phase.|Lost to Follow-up|44
6286268|NCT02346240|9999201|FG010|Initial Period (Baseline to Week 16)|Lack of Efficacy|0
6286269|NCT02346240|9999202|FG011|Initial Period (Baseline to Week 16)|Lack of Efficacy|0
6286270|NCT02346240|9999203|FG012|Initial Period (Baseline to Week 16)|Lack of Efficacy|0
6286271|NCT02346240|9999204|FG013|Initial Period (Baseline to Week 16)|Lack of Efficacy|0
6286272|NCT02346240|9999205|FG014|Initial Period (Baseline to Week 16)|Lack of Efficacy|0
6286273|NCT02346240|9999206|FG015|Initial Period (Baseline to Week 16)|Lack of Efficacy|0
6286274|NCT02346240|9999207|FG016|Initial Period (Baseline to Week 16)|Lack of Efficacy|0
6286275|NCT02346240|9999208|FG017|Initial Period (Baseline to Week 16)|Lack of Efficacy|0
6286276|NCT02346240|9999209|FG018|Initial Period (Baseline to Week 16)|Lack of Efficacy|0
6286277|NCT02346240|9999210|FG019|Initial Period (Baseline to Week 16)|Lack of Efficacy|0
6286278|NCT02346240|9999211|FG020|Initial Period (Baseline to Week 16)|Lack of Efficacy|0
6286279|NCT02346240|9999212|FG021|Initial Period (Baseline to Week 16)|Lack of Efficacy|0
6286280|NCT02346240|9999213|FG022|Initial Period (Baseline to Week 16)|Lack of Efficacy|0
6286281|NCT02346240|9999214|FG023|Initial Period (Baseline to Week 16)|Lack of Efficacy|0
6286282|NCT02346240|9999191|FG000|Initial Period (Baseline to Week 16)|Protocol Violation|0
6286283|NCT02346240|9999192|FG001|Initial Period (Baseline to Week 16)|Protocol Violation|1
6286284|NCT02346240|9999193|FG002|Initial Period (Baseline to Week 16)|Protocol Violation|0
6286285|NCT02346240|9999194|FG003|Initial Period (Baseline to Week 16)|Protocol Violation|0
6286286|NCT02346240|9999195|FG004|Initial Period (Baseline to Week 16)|Protocol Violation|0
6286287|NCT02346240|9999196|FG005|Initial Period (Baseline to Week 16)|Protocol Violation|0
6286288|NCT02346240|9999197|FG006|Initial Period (Baseline to Week 16)|Protocol Violation|0
6286289|NCT02346240|9999198|FG007|Initial Period (Baseline to Week 16)|Protocol Violation|0
6286290|NCT02346240|9999199|FG008|Initial Period (Baseline to Week 16)|Protocol Violation|0
6286291|NCT02346240|9999200|FG009|Initial Period (Baseline to Week 16)|Protocol Violation|0
6286292|NCT02346240|9999201|FG010|Initial Period (Baseline to Week 16)|Protocol Violation|0
6286293|NCT02346240|9999202|FG011|Initial Period (Baseline to Week 16)|Protocol Violation|0
6286294|NCT02346240|9999203|FG012|Initial Period (Baseline to Week 16)|Protocol Violation|0
6286295|NCT02346240|9999204|FG013|Initial Period (Baseline to Week 16)|Protocol Violation|0
6286296|NCT02346240|9999205|FG014|Initial Period (Baseline to Week 16)|Protocol Violation|0
6286297|NCT02346240|9999206|FG015|Initial Period (Baseline to Week 16)|Protocol Violation|0
5980737|NCT02471144|9569416|FG009|Maintenance Period (Week 12 to Week 52)|Lack of Efficacy|0
5980738|NCT02471144|9569417|FG010|Maintenance Period (Week 12 to Week 52)|Lack of Efficacy|0
5980739|NCT02471144|9569407|FG000|Maintenance Period (Week 12 to Week 52)|Pregnancy|0
5980740|NCT02471144|9569408|FG001|Maintenance Period (Week 12 to Week 52)|Pregnancy|0
5980741|NCT02471144|9569409|FG002|Maintenance Period (Week 12 to Week 52)|Pregnancy|0
5980742|NCT02471144|9569410|FG003|Maintenance Period (Week 12 to Week 52)|Pregnancy|0
5980743|NCT02471144|9569411|FG004|Maintenance Period (Week 12 to Week 52)|Pregnancy|0
5980744|NCT02471144|9569412|FG005|Maintenance Period (Week 12 to Week 52)|Pregnancy|0
5980745|NCT02471144|9569413|FG006|Maintenance Period (Week 12 to Week 52)|Pregnancy|0
5980746|NCT02471144|9569414|FG007|Maintenance Period (Week 12 to Week 52)|Pregnancy|0
6113988|NCT00846365|9734836|FG002|Overall Study|Pregnancy|0
6208740|NCT01567527|9873898|FG002|Oral Aripiprazole Stabilization Phase.|Lost to Follow-up|0
6208741|NCT01567527|9873899|FG003|Oral Aripiprazole Stabilization Phase.|Lost to Follow-up|0
6208742|NCT01567527|9873900|FG004|Oral Aripiprazole Stabilization Phase.|Lost to Follow-up|0
6208743|NCT01567527|9873896|FG000|Oral Aripiprazole Stabilization Phase.|Lack of Efficacy|0
6208744|NCT01567527|9873897|FG001|Oral Aripiprazole Stabilization Phase.|Lack of Efficacy|12
6208745|NCT01567527|9873898|FG002|Oral Aripiprazole Stabilization Phase.|Lack of Efficacy|0
6208746|NCT01567527|9873899|FG003|Oral Aripiprazole Stabilization Phase.|Lack of Efficacy|0
6208747|NCT01567527|9873900|FG004|Oral Aripiprazole Stabilization Phase.|Lack of Efficacy|0
6208748|NCT01567527|9873896|FG000|Oral Aripiprazole Stabilization Phase.|Adverse Event|0
6208749|NCT01567527|9873897|FG001|Oral Aripiprazole Stabilization Phase.|Adverse Event|63
6208750|NCT01567527|9873898|FG002|Oral Aripiprazole Stabilization Phase.|Adverse Event|0
6208751|NCT01567527|9873899|FG003|Oral Aripiprazole Stabilization Phase.|Adverse Event|0
6208752|NCT01567527|9873900|FG004|Oral Aripiprazole Stabilization Phase.|Adverse Event|0
6208753|NCT01567527|9873896|FG000|Oral Aripiprazole Stabilization Phase.|Withdrawn by the investigator|0
6208754|NCT01567527|9873897|FG001|Oral Aripiprazole Stabilization Phase.|Withdrawn by the investigator|2
6208755|NCT01567527|9873898|FG002|Oral Aripiprazole Stabilization Phase.|Withdrawn by the investigator|0
6208756|NCT01567527|9873899|FG003|Oral Aripiprazole Stabilization Phase.|Withdrawn by the investigator|0
6208757|NCT01567527|9873900|FG004|Oral Aripiprazole Stabilization Phase.|Withdrawn by the investigator|0
6208758|NCT01567527|9873896|FG000|IM Depot Stabilization.|Protocol deviation|0
5980747|NCT02471144|9569415|FG008|Maintenance Period (Week 12 to Week 52)|Pregnancy|1
5980748|NCT02471144|9569416|FG009|Maintenance Period (Week 12 to Week 52)|Pregnancy|0
5980749|NCT02471144|9569417|FG010|Maintenance Period (Week 12 to Week 52)|Pregnancy|0
5980750|NCT02471144|9569407|FG000|Maintenance Period (Week 12 to Week 52)|Protocol Deviation|0
6286298|NCT02346240|9999207|FG016|Initial Period (Baseline to Week 16)|Protocol Violation|0
6286299|NCT02346240|9999208|FG017|Initial Period (Baseline to Week 16)|Protocol Violation|0
6113989|NCT00846365|9734834|FG000|Overall Study|Lack of Efficacy|1
6113990|NCT00846365|9734835|FG001|Overall Study|Lack of Efficacy|1
6113991|NCT00846365|9734836|FG002|Overall Study|Lack of Efficacy|2
6113992|NCT00846365|9734834|FG000|Overall Study|Other|9
6113993|NCT00846365|9734835|FG001|Overall Study|Other|1
6113994|NCT00846365|9734836|FG002|Overall Study|Other|6
6113995|NCT00846391|9734847|FG000|Overall Study|Physician Decision|0
6113996|NCT00846391|9734848|FG001|Overall Study|Physician Decision|0
6113997|NCT00846391|9734849|FG002|Overall Study|Physician Decision|1
6113998|NCT00846391|9734847|FG000|Overall Study|Study Terminated by Sponsor|1
6113999|NCT00846391|9734848|FG001|Overall Study|Study Terminated by Sponsor|2
6114000|NCT00846391|9734849|FG002|Overall Study|Study Terminated by Sponsor|2
6114001|NCT00846495|9734864|FG000|Overall Study|Lost to Follow-up|1
6114002|NCT00846495|9734865|FG001|Overall Study|Lost to Follow-up|0
6114003|NCT00846495|9734864|FG000|Overall Study|Adverse Event|5
6114004|NCT00846495|9734865|FG001|Overall Study|Adverse Event|1
6114005|NCT00846495|9734864|FG000|Overall Study|Lack of Efficacy|1
6114006|NCT00846495|9734865|FG001|Overall Study|Lack of Efficacy|2
6114007|NCT00846495|9734864|FG000|Overall Study|Physician Decision|1
6114008|NCT00846495|9734865|FG001|Overall Study|Physician Decision|0
6114009|NCT00846521|9734871|FG000|Overall Study|Withdrawal by Subject|5
6114010|NCT00846521|9734871|FG000|Overall Study|Did not meet OGTT/ CGMS criteria|5
6114011|NCT00846521|9734871|FG000|Overall Study|Protocol Violation|1
6114012|NCT00846586|9734895|FG000|Overall Study|Adverse Event|20
6114013|NCT00846586|9734896|FG001|Overall Study|Adverse Event|10
6114014|NCT00846586|9734895|FG000|Overall Study|Subject withdrew consent|8
6114015|NCT00846586|9734896|FG001|Overall Study|Subject withdrew consent|10
6114016|NCT00846586|9734895|FG000|Overall Study|Administrative problems|5
6114017|NCT00846586|9734896|FG001|Overall Study|Administrative problems|4
6114018|NCT00846586|9734895|FG000|Overall Study|Death|2
6114019|NCT00846586|9734896|FG001|Overall Study|Death|0
6114020|NCT00846586|9734895|FG000|Overall Study|Protocol deviation|2
6114021|NCT00846586|9734896|FG001|Overall Study|Protocol deviation|6
6114022|NCT00846586|9734895|FG000|Overall Study|Abnormal test procedure result(s)|1
6114023|NCT00846586|9734896|FG001|Overall Study|Abnormal test procedure result(s)|0
6114024|NCT00846586|9734895|FG000|Overall Study|Lost to Follow-up|1
6114025|NCT00846586|9734896|FG001|Overall Study|Lost to Follow-up|4
6114026|NCT00846586|9734895|FG000|Overall Study|Unsatisfactory therapeutic effect|0
6114027|NCT00846586|9734896|FG001|Overall Study|Unsatisfactory therapeutic effect|1
6114028|NCT00846742|9734913|FG000|Overall Study|Withdrawal by Subject|1
6114029|NCT00846768|9734918|FG000|Overall Study|Adverse Event|0
6114030|NCT00846768|9734919|FG001|Overall Study|Adverse Event|1
6114031|NCT00846768|9734920|FG002|Overall Study|Adverse Event|0
6114032|NCT00846768|9734921|FG003|Overall Study|Adverse Event|0
6114033|NCT00846807|9734931|FG000|Overall Study|Adverse Event|270
6114034|NCT00846807|9734931|FG000|Overall Study|Lost to Follow-up|94
6114035|NCT00846807|9734931|FG000|Overall Study|Withdrawal by Subject|56
6114036|NCT00846807|9734931|FG000|Overall Study|Non compliant with European label|7
6114037|NCT00846807|9734931|FG000|Overall Study|Switch to other anticoagulants|89
6114038|NCT00846807|9734931|FG000|Overall Study|No prescription after hospital discharge|56
6114039|NCT00846807|9734931|FG000|Overall Study|Other|60
6114040|NCT00846846|9734935|FG000|Overall Study|Death|56
6114041|NCT00846846|9734935|FG000|Overall Study|Withdrawal by Subject|19
6114042|NCT00847015|9734939|FG000|Overall Study|Withdrawal by Subject|1
6114043|NCT00847015|9734939|FG000|Overall Study|declined any surgery|1
6114044|NCT00847015|9734939|FG000|Overall Study|partial cystectomy vs radical cystectomy|1
6114045|NCT00847132|9734945|FG000|Overall Study|Death|1
6114046|NCT00847132|9734946|FG001|Overall Study|Death|1
6208759|NCT01567527|9873897|FG001|IM Depot Stabilization.|Protocol deviation|0
6208760|NCT01567527|9873898|FG002|IM Depot Stabilization.|Protocol deviation|5
6208761|NCT01567527|9873899|FG003|IM Depot Stabilization.|Protocol deviation|0
6208762|NCT01567527|9873900|FG004|IM Depot Stabilization.|Protocol deviation|0
6208763|NCT01567527|9873896|FG000|IM Depot Stabilization.|Met withdrawal criteria|0
6208764|NCT01567527|9873897|FG001|IM Depot Stabilization.|Met withdrawal criteria|0
6208765|NCT01567527|9873898|FG002|IM Depot Stabilization.|Met withdrawal criteria|26
6208766|NCT01567527|9873899|FG003|IM Depot Stabilization.|Met withdrawal criteria|0
6208767|NCT01567527|9873900|FG004|IM Depot Stabilization.|Met withdrawal criteria|0
6208768|NCT01567527|9873896|FG000|IM Depot Stabilization.|Withdrawal by Subject|0
6208769|NCT01567527|9873897|FG001|IM Depot Stabilization.|Withdrawal by Subject|0
6208770|NCT01567527|9873898|FG002|IM Depot Stabilization.|Withdrawal by Subject|56
6208771|NCT01567527|9873899|FG003|IM Depot Stabilization.|Withdrawal by Subject|0
6114047|NCT00847145|9734960|FG000|Overall Study|AE or Death|0
6208772|NCT01567527|9873900|FG004|IM Depot Stabilization.|Withdrawal by Subject|0
6114048|NCT00847145|9734961|FG001|Overall Study|AE or Death|1
6114049|NCT00847145|9734962|FG002|Overall Study|AE or Death|1
6114050|NCT00847145|9734963|FG003|Overall Study|AE or Death|0
6114051|NCT00847145|9734964|FG004|Overall Study|AE or Death|0
6114052|NCT00847145|9734965|FG005|Overall Study|AE or Death|0
6114053|NCT00847145|9734966|FG006|Overall Study|AE or Death|0
6114054|NCT00847145|9734967|FG007|Overall Study|AE or Death|0
6114055|NCT00847145|9734960|FG000|Overall Study|Withdrawal by Subject|3
6114056|NCT00847145|9734961|FG001|Overall Study|Withdrawal by Subject|4
6114057|NCT00847145|9734962|FG002|Overall Study|Withdrawal by Subject|6
6114058|NCT00847145|9734963|FG003|Overall Study|Withdrawal by Subject|1
6114059|NCT00847145|9734964|FG004|Overall Study|Withdrawal by Subject|0
6114060|NCT00847145|9734965|FG005|Overall Study|Withdrawal by Subject|0
6114061|NCT00847145|9734966|FG006|Overall Study|Withdrawal by Subject|1
6114062|NCT00847145|9734967|FG007|Overall Study|Withdrawal by Subject|1
6114063|NCT00847145|9734960|FG000|Overall Study|Lost to Follow-up|3
6114064|NCT00847145|9734961|FG001|Overall Study|Lost to Follow-up|1
6114065|NCT00847145|9734962|FG002|Overall Study|Lost to Follow-up|1
6114066|NCT00847145|9734963|FG003|Overall Study|Lost to Follow-up|0
6114067|NCT00847145|9734964|FG004|Overall Study|Lost to Follow-up|4
6114068|NCT00847145|9734965|FG005|Overall Study|Lost to Follow-up|4
6114069|NCT00847145|9734966|FG006|Overall Study|Lost to Follow-up|8
6114070|NCT00847145|9734967|FG007|Overall Study|Lost to Follow-up|2
6114071|NCT00847145|9734960|FG000|Overall Study|Inappropriate enrollment|0
6114072|NCT00847145|9734961|FG001|Overall Study|Inappropriate enrollment|0
6114073|NCT00847145|9734962|FG002|Overall Study|Inappropriate enrollment|0
6114074|NCT00847145|9734963|FG003|Overall Study|Inappropriate enrollment|0
6114075|NCT00847145|9734964|FG004|Overall Study|Inappropriate enrollment|1
6114076|NCT00847145|9734965|FG005|Overall Study|Inappropriate enrollment|0
6114077|NCT00847145|9734966|FG006|Overall Study|Inappropriate enrollment|0
6114078|NCT00847145|9734967|FG007|Overall Study|Inappropriate enrollment|0
6114079|NCT00847145|9734960|FG000|Overall Study|Protocol Violation|0
6114080|NCT00847145|9734961|FG001|Overall Study|Protocol Violation|0
6114081|NCT00847145|9734962|FG002|Overall Study|Protocol Violation|3
6114082|NCT00847145|9734963|FG003|Overall Study|Protocol Violation|0
6114083|NCT00847145|9734964|FG004|Overall Study|Protocol Violation|1
6208773|NCT01567527|9873896|FG000|IM Depot Stabilization.|Sponsor discontinued study|0
6208774|NCT01567527|9873897|FG001|IM Depot Stabilization.|Sponsor discontinued study|0
6208775|NCT01567527|9873898|FG002|IM Depot Stabilization.|Sponsor discontinued study|1
6208776|NCT01567527|9873899|FG003|IM Depot Stabilization.|Sponsor discontinued study|0
6114084|NCT00847145|9734965|FG005|Overall Study|Protocol Violation|0
6114085|NCT00847145|9734966|FG006|Overall Study|Protocol Violation|0
6114086|NCT00847145|9734967|FG007|Overall Study|Protocol Violation|1
6114087|NCT00847197|9735001|FG000|Overall Study|Adverse Event|21
6114088|NCT00847197|9735002|FG001|Overall Study|Adverse Event|3
6114089|NCT00847197|9735001|FG000|Overall Study|Protocol Violation|0
6114090|NCT00847197|9735002|FG001|Overall Study|Protocol Violation|1
6114091|NCT00847197|9735001|FG000|Overall Study|Withdrawal by Subject|3
6114092|NCT00847197|9735002|FG001|Overall Study|Withdrawal by Subject|1
6114093|NCT00847301|9735026|FG000|Overall Study|Adverse Event|35
6114094|NCT00847301|9735026|FG000|Overall Study|Switch to other anticoagulants|16
6114095|NCT00847301|9735026|FG000|Overall Study|Lost to Follow-up|1
6114096|NCT00847301|9735026|FG000|Overall Study|No prescription after hospital discharge|1
6114097|NCT00847301|9735026|FG000|Overall Study|Other reason not defined above|1
6114098|NCT00847379|9735033|FG000|Overall Study|Study terminated by Sponsor|59
6114099|NCT00847379|9735034|FG001|Overall Study|Study terminated by Sponsor|57
6114100|NCT00847379|9735035|FG002|Overall Study|Study terminated by Sponsor|57
6114101|NCT00847535|9735049|FG000|Overall Study|Withdrawal by Subject|2
6114102|NCT00847535|9735050|FG001|Overall Study|Withdrawal by Subject|1
6114103|NCT00847535|9735051|FG002|Overall Study|Withdrawal by Subject|1
6114104|NCT00847535|9735049|FG000|Overall Study|Lost to Follow-up|0
6114105|NCT00847535|9735050|FG001|Overall Study|Lost to Follow-up|1
6114106|NCT00847535|9735051|FG002|Overall Study|Lost to Follow-up|0
6114107|NCT00847561|9735058|FG000|Overall Study|Withdrawal by Subject|4
6114108|NCT00847561|9735059|FG001|Overall Study|Withdrawal by Subject|3
6114109|NCT00847561|9735058|FG000|Overall Study|Unable to schedule|9
6114110|NCT00847561|9735059|FG001|Overall Study|Unable to schedule|1
6114111|NCT00847613|9735078|FG000|Overall Study|Ongoing at cut-off date|250
6114112|NCT00847613|9735079|FG001|Overall Study|Ongoing at cut-off date|265
6114113|NCT00847613|9735080|FG002|Overall Study|Ongoing at cut-off date|64
6114114|NCT00847613|9735081|FG003|Overall Study|Ongoing at cut-off date|64
6114115|NCT00847613|9735078|FG000|Overall Study|Death|1
6114116|NCT00847613|9735079|FG001|Overall Study|Death|1
6114117|NCT00847613|9735080|FG002|Overall Study|Death|0
6114118|NCT00847613|9735081|FG003|Overall Study|Death|0
6114119|NCT00847613|9735078|FG000|Overall Study|Adverse Event|36
6114120|NCT00847613|9735079|FG001|Overall Study|Adverse Event|26
6114121|NCT00847613|9735080|FG002|Overall Study|Adverse Event|5
6114122|NCT00847613|9735081|FG003|Overall Study|Adverse Event|6
6114123|NCT00847613|9735078|FG000|Overall Study|Lack of Efficacy|7
6114124|NCT00847613|9735079|FG001|Overall Study|Lack of Efficacy|3
6114125|NCT00847613|9735080|FG002|Overall Study|Lack of Efficacy|3
6114126|NCT00847613|9735081|FG003|Overall Study|Lack of Efficacy|1
6208777|NCT01567527|9873900|FG004|IM Depot Stabilization.|Sponsor discontinued study|0
6208778|NCT01567527|9873896|FG000|IM Depot Stabilization.|Lost to Follow-up|0
6208779|NCT01567527|9873897|FG001|IM Depot Stabilization.|Lost to Follow-up|0
6208780|NCT01567527|9873898|FG002|IM Depot Stabilization.|Lost to Follow-up|21
6208781|NCT01567527|9873899|FG003|IM Depot Stabilization.|Lost to Follow-up|0
6208782|NCT01567527|9873900|FG004|IM Depot Stabilization.|Lost to Follow-up|0
6208783|NCT01567527|9873896|FG000|IM Depot Stabilization.|Lack of Efficacy|0
6208784|NCT01567527|9873897|FG001|IM Depot Stabilization.|Lack of Efficacy|0
6114127|NCT00847613|9735078|FG000|Overall Study|Study terminated by Sponsor|1
6114128|NCT00847613|9735079|FG001|Overall Study|Study terminated by Sponsor|0
6114129|NCT00847613|9735080|FG002|Overall Study|Study terminated by Sponsor|2
6114130|NCT00847613|9735081|FG003|Overall Study|Study terminated by Sponsor|1
6114131|NCT00847613|9735078|FG000|Overall Study|Lost to Follow-up|5
6114132|NCT00847613|9735079|FG001|Overall Study|Lost to Follow-up|0
6114133|NCT00847613|9735080|FG002|Overall Study|Lost to Follow-up|0
6114134|NCT00847613|9735081|FG003|Overall Study|Lost to Follow-up|3
6114135|NCT00847613|9735078|FG000|Overall Study|Protocol Violation|6
6114136|NCT00847613|9735079|FG001|Overall Study|Protocol Violation|6
6114137|NCT00847613|9735080|FG002|Overall Study|Protocol Violation|3
6114138|NCT00847613|9735081|FG003|Overall Study|Protocol Violation|1
6114139|NCT00847613|9735078|FG000|Overall Study|Pregnancy|1
6114140|NCT00847613|9735079|FG001|Overall Study|Pregnancy|1
6114141|NCT00847613|9735080|FG002|Overall Study|Pregnancy|0
6114142|NCT00847613|9735081|FG003|Overall Study|Pregnancy|0
6114143|NCT00847613|9735078|FG000|Overall Study|Site closure|1
6114144|NCT00847613|9735079|FG001|Overall Study|Site closure|0
6114145|NCT00847613|9735080|FG002|Overall Study|Site closure|0
6114146|NCT00847613|9735081|FG003|Overall Study|Site closure|1
6114147|NCT00847613|9735078|FG000|Overall Study|Withdrawal by Subject|8
6114148|NCT00847613|9735079|FG001|Overall Study|Withdrawal by Subject|11
6114149|NCT00847613|9735080|FG002|Overall Study|Withdrawal by Subject|2
6114150|NCT00847613|9735081|FG003|Overall Study|Withdrawal by Subject|2
6114151|NCT00847613|9735078|FG000|Overall Study|Participant moved|4
6114152|NCT00847613|9735079|FG001|Overall Study|Participant moved|1
6114153|NCT00847613|9735080|FG002|Overall Study|Participant moved|0
6208785|NCT01567527|9873898|FG002|IM Depot Stabilization.|Lack of Efficacy|7
6208786|NCT01567527|9873899|FG003|IM Depot Stabilization.|Lack of Efficacy|0
6208787|NCT01567527|9873900|FG004|IM Depot Stabilization.|Lack of Efficacy|0
6208788|NCT01567527|9873896|FG000|IM Depot Stabilization.|Adverse Event|0
6208789|NCT01567527|9873897|FG001|IM Depot Stabilization.|Adverse Event|0
6208790|NCT01567527|9873898|FG002|IM Depot Stabilization.|Adverse Event|37
6208791|NCT01567527|9873899|FG003|IM Depot Stabilization.|Adverse Event|0
6208792|NCT01567527|9873900|FG004|IM Depot Stabilization.|Adverse Event|0
6208793|NCT01567527|9873896|FG000|IM Depot Stabilization.|Withdrawn by the investigator|0
6208794|NCT01567527|9873897|FG001|IM Depot Stabilization.|Withdrawn by the investigator|0
6208795|NCT01567527|9873898|FG002|IM Depot Stabilization.|Withdrawn by the investigator|6
6208796|NCT01567527|9873899|FG003|IM Depot Stabilization.|Withdrawn by the investigator|0
6208797|NCT01567527|9873900|FG004|IM Depot Stabilization.|Withdrawn by the investigator|0
6208798|NCT01567527|9873896|FG000|Double-blind, Placebo-controlled Phase|Protocol deviation|0
6208799|NCT01567527|9873897|FG001|Double-blind, Placebo-controlled Phase|Protocol deviation|0
6286300|NCT02346240|9999209|FG018|Initial Period (Baseline to Week 16)|Protocol Violation|0
6286301|NCT02346240|9999210|FG019|Initial Period (Baseline to Week 16)|Protocol Violation|0
6286302|NCT02346240|9999211|FG020|Initial Period (Baseline to Week 16)|Protocol Violation|0
6286303|NCT02346240|9999212|FG021|Initial Period (Baseline to Week 16)|Protocol Violation|0
6286304|NCT02346240|9999213|FG022|Initial Period (Baseline to Week 16)|Protocol Violation|0
6286305|NCT02346240|9999214|FG023|Initial Period (Baseline to Week 16)|Protocol Violation|0
6286306|NCT02346240|9999191|FG000|Initial Period (Baseline to Week 16)|Lost to Follow-up|1
6286307|NCT02346240|9999192|FG001|Initial Period (Baseline to Week 16)|Lost to Follow-up|2
6286308|NCT02346240|9999193|FG002|Initial Period (Baseline to Week 16)|Lost to Follow-up|1
6286309|NCT02346240|9999194|FG003|Initial Period (Baseline to Week 16)|Lost to Follow-up|3
6286310|NCT02346240|9999195|FG004|Initial Period (Baseline to Week 16)|Lost to Follow-up|0
6286311|NCT02346240|9999196|FG005|Initial Period (Baseline to Week 16)|Lost to Follow-up|0
6286312|NCT02346240|9999197|FG006|Initial Period (Baseline to Week 16)|Lost to Follow-up|0
6286313|NCT02346240|9999198|FG007|Initial Period (Baseline to Week 16)|Lost to Follow-up|0
6286314|NCT02346240|9999199|FG008|Initial Period (Baseline to Week 16)|Lost to Follow-up|0
6286315|NCT02346240|9999200|FG009|Initial Period (Baseline to Week 16)|Lost to Follow-up|0
6286316|NCT02346240|9999201|FG010|Initial Period (Baseline to Week 16)|Lost to Follow-up|0
6286317|NCT02346240|9999202|FG011|Initial Period (Baseline to Week 16)|Lost to Follow-up|0
6286318|NCT02346240|9999203|FG012|Initial Period (Baseline to Week 16)|Lost to Follow-up|0
6286319|NCT02346240|9999204|FG013|Initial Period (Baseline to Week 16)|Lost to Follow-up|0
6286320|NCT02346240|9999205|FG014|Initial Period (Baseline to Week 16)|Lost to Follow-up|0
6286321|NCT02346240|9999206|FG015|Initial Period (Baseline to Week 16)|Lost to Follow-up|0
6286322|NCT02346240|9999207|FG016|Initial Period (Baseline to Week 16)|Lost to Follow-up|0
6286323|NCT02346240|9999208|FG017|Initial Period (Baseline to Week 16)|Lost to Follow-up|0
6286324|NCT02346240|9999209|FG018|Initial Period (Baseline to Week 16)|Lost to Follow-up|0
6286325|NCT02346240|9999210|FG019|Initial Period (Baseline to Week 16)|Lost to Follow-up|0
6286326|NCT02346240|9999211|FG020|Initial Period (Baseline to Week 16)|Lost to Follow-up|0
6286327|NCT02346240|9999212|FG021|Initial Period (Baseline to Week 16)|Lost to Follow-up|0
6286328|NCT02346240|9999213|FG022|Initial Period (Baseline to Week 16)|Lost to Follow-up|0
6286329|NCT02346240|9999214|FG023|Initial Period (Baseline to Week 16)|Lost to Follow-up|0
6286330|NCT02346240|9999191|FG000|Initial Period (Baseline to Week 16)|Withdrawal by Subject|1
6286331|NCT02346240|9999192|FG001|Initial Period (Baseline to Week 16)|Withdrawal by Subject|2
6114154|NCT00847613|9735081|FG003|Overall Study|Participant moved|0
6114155|NCT00847613|9735078|FG000|Overall Study|Sponsor request|0
6114156|NCT00847613|9735079|FG001|Overall Study|Sponsor request|1
6114157|NCT00847613|9735080|FG002|Overall Study|Sponsor request|0
6114158|NCT00847613|9735081|FG003|Overall Study|Sponsor request|0
6114159|NCT00847613|9735078|FG000|Overall Study|Randomized, but not treated|0
6114160|NCT00847613|9735079|FG001|Overall Study|Randomized, but not treated|3
6114161|NCT00847613|9735080|FG002|Overall Study|Randomized, but not treated|0
6114162|NCT00847613|9735081|FG003|Overall Study|Randomized, but not treated|0
6114163|NCT00847613|9735078|FG000|Overall Study|Other|1
6114164|NCT00847613|9735079|FG001|Overall Study|Other|1
6114165|NCT00847613|9735080|FG002|Overall Study|Other|2
6114166|NCT00847613|9735081|FG003|Overall Study|Other|0
6114167|NCT00847626|9735109|FG000|Overall Study|Adverse Event|10
6114168|NCT00847626|9735110|FG001|Overall Study|Adverse Event|10
6114169|NCT00847626|9735111|FG002|Overall Study|Adverse Event|6
6114170|NCT00847626|9735112|FG003|Overall Study|Adverse Event|19
6114171|NCT00847626|9735113|FG004|Overall Study|Adverse Event|11
6114172|NCT00847626|9735114|FG005|Overall Study|Adverse Event|22
6114173|NCT00847626|9735115|FG006|Overall Study|Adverse Event|4
6114174|NCT00847626|9735116|FG007|Overall Study|Adverse Event|6
6114175|NCT00847626|9735117|FG008|Overall Study|Adverse Event|3
6114176|NCT00847626|9735118|FG009|Overall Study|Adverse Event|6
6114177|NCT00847626|9735119|FG010|Overall Study|Adverse Event|6
6114178|NCT00847626|9735109|FG000|Overall Study|Protocol Violation|2
6114179|NCT00847626|9735110|FG001|Overall Study|Protocol Violation|1
6114180|NCT00847626|9735111|FG002|Overall Study|Protocol Violation|2
6114181|NCT00847626|9735112|FG003|Overall Study|Protocol Violation|1
6114182|NCT00847626|9735113|FG004|Overall Study|Protocol Violation|1
6114183|NCT00847626|9735114|FG005|Overall Study|Protocol Violation|1
6114184|NCT00847626|9735115|FG006|Overall Study|Protocol Violation|1
6114185|NCT00847626|9735116|FG007|Overall Study|Protocol Violation|1
6114186|NCT00847626|9735117|FG008|Overall Study|Protocol Violation|0
6114187|NCT00847626|9735118|FG009|Overall Study|Protocol Violation|1
6114188|NCT00847626|9735119|FG010|Overall Study|Protocol Violation|1
6114189|NCT00847626|9735109|FG000|Overall Study|Lost to Follow-up|0
6114190|NCT00847626|9735110|FG001|Overall Study|Lost to Follow-up|1
6114191|NCT00847626|9735111|FG002|Overall Study|Lost to Follow-up|1
6114192|NCT00847626|9735112|FG003|Overall Study|Lost to Follow-up|1
6114193|NCT00847626|9735113|FG004|Overall Study|Lost to Follow-up|0
6114194|NCT00847626|9735114|FG005|Overall Study|Lost to Follow-up|3
6114195|NCT00847626|9735115|FG006|Overall Study|Lost to Follow-up|1
6114196|NCT00847626|9735116|FG007|Overall Study|Lost to Follow-up|3
6114197|NCT00847626|9735117|FG008|Overall Study|Lost to Follow-up|1
6114198|NCT00847626|9735118|FG009|Overall Study|Lost to Follow-up|0
6114199|NCT00847626|9735119|FG010|Overall Study|Lost to Follow-up|1
6114200|NCT00847626|9735109|FG000|Overall Study|Withdrawal by Subject|5
6114201|NCT00847626|9735110|FG001|Overall Study|Withdrawal by Subject|5
6114202|NCT00847626|9735111|FG002|Overall Study|Withdrawal by Subject|3
6114203|NCT00847626|9735112|FG003|Overall Study|Withdrawal by Subject|8
6114204|NCT00847626|9735113|FG004|Overall Study|Withdrawal by Subject|12
6114205|NCT00847626|9735114|FG005|Overall Study|Withdrawal by Subject|9
6114206|NCT00847626|9735115|FG006|Overall Study|Withdrawal by Subject|8
6114207|NCT00847626|9735116|FG007|Overall Study|Withdrawal by Subject|4
6114208|NCT00847626|9735117|FG008|Overall Study|Withdrawal by Subject|4
6114209|NCT00847626|9735118|FG009|Overall Study|Withdrawal by Subject|5
6114210|NCT00847626|9735119|FG010|Overall Study|Withdrawal by Subject|2
6114211|NCT00847626|9735109|FG000|Overall Study|Lack of Efficacy|3
6114212|NCT00847626|9735110|FG001|Overall Study|Lack of Efficacy|1
6114213|NCT00847626|9735111|FG002|Overall Study|Lack of Efficacy|0
6114214|NCT00847626|9735112|FG003|Overall Study|Lack of Efficacy|1
6114215|NCT00847626|9735113|FG004|Overall Study|Lack of Efficacy|2
6114216|NCT00847626|9735114|FG005|Overall Study|Lack of Efficacy|0
6114217|NCT00847626|9735115|FG006|Overall Study|Lack of Efficacy|6
6114218|NCT00847626|9735116|FG007|Overall Study|Lack of Efficacy|2
6114219|NCT00847626|9735117|FG008|Overall Study|Lack of Efficacy|5
6114220|NCT00847626|9735118|FG009|Overall Study|Lack of Efficacy|1
6114221|NCT00847626|9735119|FG010|Overall Study|Lack of Efficacy|7
6114222|NCT00847626|9735109|FG000|Overall Study|Other|1
6114223|NCT00847626|9735110|FG001|Overall Study|Other|5
6114224|NCT00847626|9735111|FG002|Overall Study|Other|4
6114225|NCT00847626|9735112|FG003|Overall Study|Other|1
6114226|NCT00847626|9735113|FG004|Overall Study|Other|2
6114227|NCT00847626|9735114|FG005|Overall Study|Other|2
6114228|NCT00847626|9735115|FG006|Overall Study|Other|2
6114229|NCT00847626|9735116|FG007|Overall Study|Other|3
6114230|NCT00847626|9735117|FG008|Overall Study|Other|1
6114231|NCT00847626|9735118|FG009|Overall Study|Other|1
6114232|NCT00847626|9735119|FG010|Overall Study|Other|3
6114233|NCT00847665|9735148|FG000|Overall Study|Withdrawal by Subject|1
6114234|NCT00847665|9735149|FG001|Overall Study|Withdrawal by Subject|0
6114235|NCT00847704|9735155|FG000|Overall Study|Withdrawal by Subject|1
6114236|NCT00847730|9735159|FG000|Overall Study|Multiple interruptions in therapy|8
6114237|NCT00847808|9735163|FG000|Overall Study|Adverse Event|7
6114238|NCT00847808|9735163|FG000|Overall Study|Protocol Violation|1
6114239|NCT00847808|9735163|FG000|Overall Study|Lost to Follow-up|1
6114240|NCT00847808|9735163|FG000|Overall Study|Withdrawal by Subject|4
6114241|NCT00847808|9735163|FG000|Overall Study|Participant Reported Lack of Efficacy|1
6114242|NCT00847808|9735163|FG000|Overall Study|Participant Took Excluded Medication|1
6114243|NCT00847886|9735169|FG000|Overall Study|Adverse Event|0
6114244|NCT00847886|9735170|FG001|Overall Study|Adverse Event|1
6114245|NCT00847912|9735178|FG000|Overall Study|Protocol Violation|6
6114246|NCT00847912|9735179|FG001|Overall Study|Protocol Violation|7
6114247|NCT00847912|9735178|FG000|Overall Study|Withdrawal by Subject|3
6114248|NCT00847912|9735179|FG001|Overall Study|Withdrawal by Subject|6
6114249|NCT00848042|9735210|FG000|Overall Study|Death|1
6114250|NCT00848042|9735211|FG001|Overall Study|Death|2
6114251|NCT00848042|9735212|FG002|Overall Study|Death|0
6114252|NCT00848042|9735210|FG000|Overall Study|Other Therapy|3
6114253|NCT00848042|9735211|FG001|Overall Study|Other Therapy|0
6114254|NCT00848042|9735212|FG002|Overall Study|Other Therapy|0
6114255|NCT00848081|9735222|FG000|Overall Study|Adverse Event|6
6114256|NCT00848081|9735223|FG001|Overall Study|Adverse Event|7
6114257|NCT00848081|9735222|FG000|Overall Study|Protocol Violation|8
6114258|NCT00848081|9735223|FG001|Overall Study|Protocol Violation|5
6114259|NCT00848081|9735222|FG000|Overall Study|Lost to Follow-up|1
6114260|NCT00848081|9735223|FG001|Overall Study|Lost to Follow-up|0
6114261|NCT00848081|9735222|FG000|Overall Study|Physician Decision|0
6208800|NCT01567527|9873898|FG002|Double-blind, Placebo-controlled Phase|Protocol deviation|0
6208801|NCT01567527|9873899|FG003|Double-blind, Placebo-controlled Phase|Protocol deviation|1
6208802|NCT01567527|9873900|FG004|Double-blind, Placebo-controlled Phase|Protocol deviation|1
6208803|NCT01567527|9873896|FG000|Double-blind, Placebo-controlled Phase|Recurrence of any mood episode with AE|0
6208804|NCT01567527|9873897|FG001|Double-blind, Placebo-controlled Phase|Recurrence of any mood episode with AE|0
6208805|NCT01567527|9873898|FG002|Double-blind, Placebo-controlled Phase|Recurrence of any mood episode with AE|0
6208806|NCT01567527|9873899|FG003|Double-blind, Placebo-controlled Phase|Recurrence of any mood episode with AE|16
6208807|NCT01567527|9873900|FG004|Double-blind, Placebo-controlled Phase|Recurrence of any mood episode with AE|33
6208808|NCT01567527|9873896|FG000|Double-blind, Placebo-controlled Phase|Met withdrawal criteria|0
6208809|NCT01567527|9873897|FG001|Double-blind, Placebo-controlled Phase|Met withdrawal criteria|0
6208810|NCT01567527|9873898|FG002|Double-blind, Placebo-controlled Phase|Met withdrawal criteria|0
6208811|NCT01567527|9873899|FG003|Double-blind, Placebo-controlled Phase|Met withdrawal criteria|4
6286332|NCT02346240|9999193|FG002|Initial Period (Baseline to Week 16)|Withdrawal by Subject|3
6286333|NCT02346240|9999194|FG003|Initial Period (Baseline to Week 16)|Withdrawal by Subject|2
6286334|NCT02346240|9999195|FG004|Initial Period (Baseline to Week 16)|Withdrawal by Subject|0
6286335|NCT02346240|9999196|FG005|Initial Period (Baseline to Week 16)|Withdrawal by Subject|0
6286336|NCT02346240|9999197|FG006|Initial Period (Baseline to Week 16)|Withdrawal by Subject|0
6286337|NCT02346240|9999198|FG007|Initial Period (Baseline to Week 16)|Withdrawal by Subject|0
6286338|NCT02346240|9999199|FG008|Initial Period (Baseline to Week 16)|Withdrawal by Subject|0
6286339|NCT02346240|9999200|FG009|Initial Period (Baseline to Week 16)|Withdrawal by Subject|0
6286340|NCT02346240|9999201|FG010|Initial Period (Baseline to Week 16)|Withdrawal by Subject|0
6286341|NCT02346240|9999202|FG011|Initial Period (Baseline to Week 16)|Withdrawal by Subject|0
6286342|NCT02346240|9999203|FG012|Initial Period (Baseline to Week 16)|Withdrawal by Subject|0
6286343|NCT02346240|9999204|FG013|Initial Period (Baseline to Week 16)|Withdrawal by Subject|0
6286344|NCT02346240|9999205|FG014|Initial Period (Baseline to Week 16)|Withdrawal by Subject|0
5980751|NCT02471144|9569408|FG001|Maintenance Period (Week 12 to Week 52)|Protocol Deviation|0
5980752|NCT02471144|9569409|FG002|Maintenance Period (Week 12 to Week 52)|Protocol Deviation|0
5980753|NCT02471144|9569410|FG003|Maintenance Period (Week 12 to Week 52)|Protocol Deviation|0
5980754|NCT02471144|9569411|FG004|Maintenance Period (Week 12 to Week 52)|Protocol Deviation|0
5980755|NCT02471144|9569412|FG005|Maintenance Period (Week 12 to Week 52)|Protocol Deviation|0
5980756|NCT02471144|9569413|FG006|Maintenance Period (Week 12 to Week 52)|Protocol Deviation|0
5980757|NCT02471144|9569414|FG007|Maintenance Period (Week 12 to Week 52)|Protocol Deviation|2
5980758|NCT02471144|9569415|FG008|Maintenance Period (Week 12 to Week 52)|Protocol Deviation|1
5980759|NCT02471144|9569416|FG009|Maintenance Period (Week 12 to Week 52)|Protocol Deviation|0
5980760|NCT02471144|9569417|FG010|Maintenance Period (Week 12 to Week 52)|Protocol Deviation|0
5980761|NCT02471144|9569407|FG000|Extension Period (Week 52 to Week 236)|Lack of Efficacy|0
5980762|NCT02471144|9569408|FG001|Extension Period (Week 52 to Week 236)|Lack of Efficacy|0
5980763|NCT02471144|9569409|FG002|Extension Period (Week 52 to Week 236)|Lack of Efficacy|0
5980764|NCT02471144|9569410|FG003|Extension Period (Week 52 to Week 236)|Lack of Efficacy|0
5980765|NCT02471144|9569411|FG004|Extension Period (Week 52 to Week 236)|Lack of Efficacy|0
5980766|NCT02471144|9569412|FG005|Extension Period (Week 52 to Week 236)|Lack of Efficacy|0
5980767|NCT02471144|9569413|FG006|Extension Period (Week 52 to Week 236)|Lack of Efficacy|0
5980768|NCT02471144|9569414|FG007|Extension Period (Week 52 to Week 236)|Lack of Efficacy|0
5980769|NCT02471144|9569415|FG008|Extension Period (Week 52 to Week 236)|Lack of Efficacy|0
5980770|NCT02471144|9569416|FG009|Extension Period (Week 52 to Week 236)|Lack of Efficacy|5
5980771|NCT02471144|9569417|FG010|Extension Period (Week 52 to Week 236)|Lack of Efficacy|2
6114262|NCT00848081|9735223|FG001|Overall Study|Physician Decision|3
5980772|NCT02471144|9569407|FG000|Extension Period (Week 52 to Week 236)|Pregnancy|0
5980773|NCT02471144|9569408|FG001|Extension Period (Week 52 to Week 236)|Pregnancy|0
5980774|NCT02471144|9569409|FG002|Extension Period (Week 52 to Week 236)|Pregnancy|0
6114263|NCT00848081|9735222|FG000|Overall Study|Withdrawal by Subject|5
6114264|NCT00848081|9735223|FG001|Overall Study|Withdrawal by Subject|3
6114265|NCT00848107|9735229|FG000|Overall Study|Lost to Follow-up|2
6114266|NCT00848107|9735229|FG000|Overall Study|Withdrawal by Subject|8
6114267|NCT00848107|9735229|FG000|Overall Study|Adverse Event|9
6114268|NCT00848107|9735229|FG000|Overall Study|Death|1
6114269|NCT00848107|9735229|FG000|Overall Study|Pregnancy|1
6114270|NCT00848120|9735233|FG000|Overall Study|Adverse Event|1
6114271|NCT00848198|9735262|FG000|Overall Study|Incomplete Case Report Forms|15
6114272|NCT00848211|9735274|FG000|Overall Study|Protocol Violation|0
6114273|NCT00848211|9735275|FG001|Overall Study|Protocol Violation|1
6114274|NCT00848211|9735276|FG002|Overall Study|Protocol Violation|1
6114275|NCT00848211|9735277|FG003|Overall Study|Protocol Violation|0
6114276|NCT00848211|9735274|FG000|Overall Study|Adverse Event|0
6114277|NCT00848211|9735275|FG001|Overall Study|Adverse Event|0
6114278|NCT00848211|9735276|FG002|Overall Study|Adverse Event|0
6114279|NCT00848211|9735277|FG003|Overall Study|Adverse Event|0
6114280|NCT00848250|9735293|FG000|Overall Study|surgery was completed without cardiopulm|0
6114281|NCT00848250|9735294|FG001|Overall Study|surgery was completed without cardiopulm|1
6114282|NCT00848354|9735303|FG000|Phase 1|Adverse Event|5
6114283|NCT00848354|9735304|FG001|Phase 1|Adverse Event|4
6114284|NCT00848354|9735303|FG000|Phase 1|Discontinuation of study by sponsor|2
6114285|NCT00848354|9735304|FG001|Phase 1|Discontinuation of study by sponsor|1
6114286|NCT00848354|9735303|FG000|Phase 1|Failed to return|0
6114287|NCT00848354|9735304|FG001|Phase 1|Failed to return|1
6114288|NCT00848354|9735303|FG000|Phase 1|Lost to Follow-up|1
6114289|NCT00848354|9735304|FG001|Phase 1|Lost to Follow-up|1
6114290|NCT00848354|9735303|FG000|Phase 1|Unspecified Reason|1
6114291|NCT00848354|9735304|FG001|Phase 1|Unspecified Reason|1
6114292|NCT00848354|9735303|FG000|Phase 1|Protocol Violation|1
6114293|NCT00848354|9735304|FG001|Phase 1|Protocol Violation|1
6114294|NCT00848354|9735303|FG000|Phase 1|Withdrawal by Subject|2
6114295|NCT00848354|9735304|FG001|Phase 1|Withdrawal by Subject|4
6114296|NCT00848354|9735303|FG000|Phase 1|Lack of Efficacy|0
6114297|NCT00848354|9735304|FG001|Phase 1|Lack of Efficacy|1
6114298|NCT00848354|9735303|FG000|Phase 2 Year 1|Adverse Event|7
6114299|NCT00848354|9735304|FG001|Phase 2 Year 1|Adverse Event|2
6114300|NCT00848354|9735303|FG000|Phase 2 Year 1|Death|1
6114301|NCT00848354|9735304|FG001|Phase 2 Year 1|Death|0
6114302|NCT00848354|9735303|FG000|Phase 2 Year 1|Failed to Return|1
6114303|NCT00848354|9735304|FG001|Phase 2 Year 1|Failed to Return|1
6114304|NCT00848354|9735303|FG000|Phase 2 Year 1|Lost to Follow-up|1
6114305|NCT00848354|9735304|FG001|Phase 2 Year 1|Lost to Follow-up|0
6114306|NCT00848354|9735303|FG000|Phase 2 Year 1|Unspecified Reason|3
6114307|NCT00848354|9735304|FG001|Phase 2 Year 1|Unspecified Reason|0
6114308|NCT00848354|9735303|FG000|Phase 2 Year 1|Protocol Violation|4
6114309|NCT00848354|9735304|FG001|Phase 2 Year 1|Protocol Violation|1
6114310|NCT00848354|9735303|FG000|Phase 2 Year 1|Subject Request|1
6114311|NCT00848354|9735304|FG001|Phase 2 Year 1|Subject Request|2
6114312|NCT00848354|9735303|FG000|Phase 2 Year 2|Adverse Event|12
6114313|NCT00848354|9735304|FG001|Phase 2 Year 2|Adverse Event|2
6208812|NCT01567527|9873900|FG004|Double-blind, Placebo-controlled Phase|Met withdrawal criteria|7
6208813|NCT01567527|9873896|FG000|Double-blind, Placebo-controlled Phase|AE without recurrence of any moodepisode|0
6208814|NCT01567527|9873897|FG001|Double-blind, Placebo-controlled Phase|AE without recurrence of any moodepisode|0
6208815|NCT01567527|9873898|FG002|Double-blind, Placebo-controlled Phase|AE without recurrence of any moodepisode|0
6114314|NCT00848354|9735303|FG000|Phase 2 Year 2|Death|2
6114315|NCT00848354|9735304|FG001|Phase 2 Year 2|Death|0
6114316|NCT00848354|9735303|FG000|Phase 2 Year 2|Failed to return|3
6114317|NCT00848354|9735304|FG001|Phase 2 Year 2|Failed to return|0
6114318|NCT00848354|9735303|FG000|Phase 2 Year 2|Lost to Follow-up|1
6114319|NCT00848354|9735304|FG001|Phase 2 Year 2|Lost to Follow-up|3
6114320|NCT00848354|9735303|FG000|Phase 2 Year 2|Unspecified Reason|1
6114321|NCT00848354|9735304|FG001|Phase 2 Year 2|Unspecified Reason|0
6114322|NCT00848354|9735303|FG000|Phase 2 Year 2|Protocol Violation|1
6114323|NCT00848354|9735304|FG001|Phase 2 Year 2|Protocol Violation|1
6114324|NCT00848354|9735303|FG000|Phase 2 Year 2|Subject Request|1
6114325|NCT00848354|9735304|FG001|Phase 2 Year 2|Subject Request|1
6114326|NCT00848354|9735303|FG000|Phase 2 Year 2|Unsatisfactory Response - Efficacy|2
6114327|NCT00848354|9735304|FG001|Phase 2 Year 2|Unsatisfactory Response - Efficacy|0
6114328|NCT00848393|9735328|FG000|Overall Study|Protocol Violation|0
6114329|NCT00848393|9735329|FG001|Overall Study|Protocol Violation|0
6114330|NCT00848393|9735330|FG002|Overall Study|Protocol Violation|1
6114331|NCT00848393|9735328|FG000|Overall Study|surgical complications unrelated to stud|0
6114332|NCT00848393|9735329|FG001|Overall Study|surgical complications unrelated to stud|0
6114333|NCT00848393|9735330|FG002|Overall Study|surgical complications unrelated to stud|2
6114334|NCT00848484|9735344|FG000|First Intervention (Treatment Period 1)|Adverse Event|2
6114335|NCT00848484|9735345|FG001|First Intervention (Treatment Period 1)|Adverse Event|1
6114336|NCT00848484|9735344|FG000|First Intervention (Treatment Period 1)|Physician Decision|0
6114337|NCT00848484|9735345|FG001|First Intervention (Treatment Period 1)|Physician Decision|1
6114338|NCT00848484|9735344|FG000|First Intervention (Treatment Period 1)|Withdrawal by Subject|0
6114339|NCT00848484|9735345|FG001|First Intervention (Treatment Period 1)|Withdrawal by Subject|1
6114340|NCT00848484|9735344|FG000|Washout Period of Two Weeks|Withdrawal by Subject|0
6114341|NCT00848484|9735345|FG001|Washout Period of Two Weeks|Withdrawal by Subject|3
6114342|NCT00848484|9735344|FG000|Second Intervention (Treatment Period 2)|Lost to Follow-up|0
6114343|NCT00848484|9735345|FG001|Second Intervention (Treatment Period 2)|Lost to Follow-up|1
6114344|NCT00848497|9735353|FG000|Overall Study|Screen failure|2
6114345|NCT00848497|9735354|FG001|Overall Study|Screen failure|0
6114346|NCT00848497|9735353|FG000|Overall Study|Withdrawal by Subject|0
6114347|NCT00848497|9735354|FG001|Overall Study|Withdrawal by Subject|1
6114348|NCT00848536|9735381|FG000|Overall Study|Adverse Event|2
6114349|NCT00848536|9735382|FG001|Overall Study|Adverse Event|2
6114350|NCT00848536|9735381|FG000|Overall Study|Withdrawal by Subject|0
6114351|NCT00848536|9735382|FG001|Overall Study|Withdrawal by Subject|1
6114352|NCT00848536|9735381|FG000|Overall Study|Protocol Violation|0
6114353|NCT00848536|9735382|FG001|Overall Study|Protocol Violation|1
6114354|NCT00848536|9735381|FG000|Overall Study|Noncompliance|1
6114355|NCT00848536|9735382|FG001|Overall Study|Noncompliance|0
6114356|NCT00848536|9735381|FG000|Overall Study|Inadequate Control of IOP|1
6114357|NCT00848536|9735382|FG001|Overall Study|Inadequate Control of IOP|1
6114358|NCT00848536|9735381|FG000|Overall Study|Patient Moved|0
6114359|NCT00848536|9735382|FG001|Overall Study|Patient Moved|2
6114360|NCT00848549|9735390|FG000|E2090-E044-310 (Base Study) Disposition|Adverse Event|31
6114361|NCT00848549|9735391|FG001|E2090-E044-310 (Base Study) Disposition|Adverse Event|35
6114362|NCT00848549|9735390|FG000|E2090-E044-310 (Base Study) Disposition|Withdrawal by Subject|35
6114363|NCT00848549|9735391|FG001|E2090-E044-310 (Base Study) Disposition|Withdrawal by Subject|24
6114364|NCT00848549|9735390|FG000|E2090-E044-310 (Base Study) Disposition|Lack of Efficacy|23
6114365|NCT00848549|9735391|FG001|E2090-E044-310 (Base Study) Disposition|Lack of Efficacy|23
6208816|NCT01567527|9873899|FG003|Double-blind, Placebo-controlled Phase|AE without recurrence of any moodepisode|7
6208817|NCT01567527|9873900|FG004|Double-blind, Placebo-controlled Phase|AE without recurrence of any moodepisode|1
6208818|NCT01567527|9873896|FG000|Double-blind, Placebo-controlled Phase|Withdrawal by Subject|0
6286345|NCT02346240|9999206|FG015|Initial Period (Baseline to Week 16)|Withdrawal by Subject|0
6286346|NCT02346240|9999207|FG016|Initial Period (Baseline to Week 16)|Withdrawal by Subject|0
6286347|NCT02346240|9999208|FG017|Initial Period (Baseline to Week 16)|Withdrawal by Subject|0
6286348|NCT02346240|9999209|FG018|Initial Period (Baseline to Week 16)|Withdrawal by Subject|0
6286349|NCT02346240|9999210|FG019|Initial Period (Baseline to Week 16)|Withdrawal by Subject|0
6286350|NCT02346240|9999211|FG020|Initial Period (Baseline to Week 16)|Withdrawal by Subject|0
6286351|NCT02346240|9999212|FG021|Initial Period (Baseline to Week 16)|Withdrawal by Subject|0
6286352|NCT02346240|9999213|FG022|Initial Period (Baseline to Week 16)|Withdrawal by Subject|0
6286353|NCT02346240|9999214|FG023|Initial Period (Baseline to Week 16)|Withdrawal by Subject|0
6286354|NCT02346240|9999191|FG000|Initial Period (Baseline to Week 16)|Non-compliance|0
6286355|NCT02346240|9999192|FG001|Initial Period (Baseline to Week 16)|Non-compliance|1
6286356|NCT02346240|9999193|FG002|Initial Period (Baseline to Week 16)|Non-compliance|0
6286357|NCT02346240|9999194|FG003|Initial Period (Baseline to Week 16)|Non-compliance|1
6286358|NCT02346240|9999195|FG004|Initial Period (Baseline to Week 16)|Non-compliance|0
6286359|NCT02346240|9999196|FG005|Initial Period (Baseline to Week 16)|Non-compliance|0
6286360|NCT02346240|9999197|FG006|Initial Period (Baseline to Week 16)|Non-compliance|0
6286361|NCT02346240|9999198|FG007|Initial Period (Baseline to Week 16)|Non-compliance|0
6286362|NCT02346240|9999199|FG008|Initial Period (Baseline to Week 16)|Non-compliance|0
6286363|NCT02346240|9999200|FG009|Initial Period (Baseline to Week 16)|Non-compliance|0
6286364|NCT02346240|9999201|FG010|Initial Period (Baseline to Week 16)|Non-compliance|0
6286365|NCT02346240|9999202|FG011|Initial Period (Baseline to Week 16)|Non-compliance|0
6286366|NCT02346240|9999203|FG012|Initial Period (Baseline to Week 16)|Non-compliance|0
6286367|NCT02346240|9999204|FG013|Initial Period (Baseline to Week 16)|Non-compliance|0
6286368|NCT02346240|9999205|FG014|Initial Period (Baseline to Week 16)|Non-compliance|0
6114366|NCT00848549|9735390|FG000|E2090-E044-310 (Base Study) Disposition|Protocol Violation|3
6114367|NCT00848549|9735391|FG001|E2090-E044-310 (Base Study) Disposition|Protocol Violation|8
6114368|NCT00848549|9735390|FG000|E2090-E044-310 (Base Study) Disposition|Physician Decision|4
6114369|NCT00848549|9735391|FG001|E2090-E044-310 (Base Study) Disposition|Physician Decision|5
6114370|NCT00848549|9735390|FG000|E2090-E044-310 (Base Study) Disposition|Lost to Follow-up|21
6114371|NCT00848549|9735391|FG001|E2090-E044-310 (Base Study) Disposition|Lost to Follow-up|11
6208819|NCT01567527|9873897|FG001|Double-blind, Placebo-controlled Phase|Withdrawal by Subject|0
6208820|NCT01567527|9873898|FG002|Double-blind, Placebo-controlled Phase|Withdrawal by Subject|0
6208821|NCT01567527|9873899|FG003|Double-blind, Placebo-controlled Phase|Withdrawal by Subject|13
6208822|NCT01567527|9873900|FG004|Double-blind, Placebo-controlled Phase|Withdrawal by Subject|10
6208823|NCT01567527|9873896|FG000|Double-blind, Placebo-controlled Phase|Sponsor discontinued study|0
6208824|NCT01567527|9873897|FG001|Double-blind, Placebo-controlled Phase|Sponsor discontinued study|0
6208825|NCT01567527|9873898|FG002|Double-blind, Placebo-controlled Phase|Sponsor discontinued study|0
6208826|NCT01567527|9873899|FG003|Double-blind, Placebo-controlled Phase|Sponsor discontinued study|1
6208827|NCT01567527|9873900|FG004|Double-blind, Placebo-controlled Phase|Sponsor discontinued study|3
6208828|NCT01567527|9873896|FG000|Double-blind, Placebo-controlled Phase|Recurrence of any mood episode withoutAE|0
6208829|NCT01567527|9873897|FG001|Double-blind, Placebo-controlled Phase|Recurrence of any mood episode withoutAE|0
6208830|NCT01567527|9873898|FG002|Double-blind, Placebo-controlled Phase|Recurrence of any mood episode withoutAE|0
6208831|NCT01567527|9873899|FG003|Double-blind, Placebo-controlled Phase|Recurrence of any mood episode withoutAE|19
6114372|NCT00848549|9735390|FG000|E2090-E044-310 (Base Study) Disposition|Other|4
6114373|NCT00848549|9735391|FG001|E2090-E044-310 (Base Study) Disposition|Other|3
6114374|NCT00848549|9735390|FG000|E2090-E044-310 (Base Study) Transition|Chose not to enter 314 Extension study|24
6114375|NCT00848549|9735391|FG001|E2090-E044-310 (Base Study) Transition|Chose not to enter 314 Extension study|34
6114376|NCT00848549|9735390|FG000|E2090-E044-314 (Extension Study)|Adverse Event|2
6114377|NCT00848549|9735391|FG001|E2090-E044-314 (Extension Study)|Adverse Event|1
6114378|NCT00848549|9735390|FG000|E2090-E044-314 (Extension Study)|Protocol Violation|1
6114379|NCT00848549|9735391|FG001|E2090-E044-314 (Extension Study)|Protocol Violation|2
6114380|NCT00848549|9735390|FG000|E2090-E044-314 (Extension Study)|Withdrawal by Subject|8
6114381|NCT00848549|9735391|FG001|E2090-E044-314 (Extension Study)|Withdrawal by Subject|12
6114382|NCT00848549|9735390|FG000|E2090-E044-314 (Extension Study)|Lack of Efficacy|1
6114383|NCT00848549|9735391|FG001|E2090-E044-314 (Extension Study)|Lack of Efficacy|1
6114384|NCT00848549|9735390|FG000|E2090-E044-314 (Extension Study)|Physician Decision|0
6114385|NCT00848549|9735391|FG001|E2090-E044-314 (Extension Study)|Physician Decision|2
6114386|NCT00848549|9735390|FG000|E2090-E044-314 (Extension Study)|Other|5
6114387|NCT00848549|9735391|FG001|E2090-E044-314 (Extension Study)|Other|6
6114388|NCT00848718|9735412|FG000|Overall Study|Adverse Event|2
6114389|NCT00848718|9735413|FG001|Overall Study|Adverse Event|2
6114390|NCT00848718|9735414|FG002|Overall Study|Adverse Event|1
6114391|NCT00848718|9735415|FG003|Overall Study|Adverse Event|1
6114392|NCT00848718|9735416|FG004|Overall Study|Adverse Event|1
6114393|NCT00848718|9735417|FG005|Overall Study|Adverse Event|0
6114394|NCT00848718|9735418|FG006|Overall Study|Adverse Event|0
6114395|NCT00848718|9735419|FG007|Overall Study|Adverse Event|1
6114396|NCT00848718|9735420|FG008|Overall Study|Adverse Event|1
6114397|NCT00848718|9735421|FG009|Overall Study|Adverse Event|0
6114398|NCT00848718|9735422|FG010|Overall Study|Adverse Event|0
6114399|NCT00848718|9735423|FG011|Overall Study|Adverse Event|0
6114400|NCT00848718|9735424|FG012|Overall Study|Adverse Event|2
6114401|NCT00848718|9735412|FG000|Overall Study|Lack of Efficacy|0
6114402|NCT00848718|9735413|FG001|Overall Study|Lack of Efficacy|0
6114403|NCT00848718|9735414|FG002|Overall Study|Lack of Efficacy|1
6114404|NCT00848718|9735415|FG003|Overall Study|Lack of Efficacy|0
6114405|NCT00848718|9735416|FG004|Overall Study|Lack of Efficacy|0
6114406|NCT00848718|9735417|FG005|Overall Study|Lack of Efficacy|0
6114407|NCT00848718|9735418|FG006|Overall Study|Lack of Efficacy|1
6114408|NCT00848718|9735419|FG007|Overall Study|Lack of Efficacy|0
6114409|NCT00848718|9735420|FG008|Overall Study|Lack of Efficacy|0
6114410|NCT00848718|9735421|FG009|Overall Study|Lack of Efficacy|0
6114411|NCT00848718|9735422|FG010|Overall Study|Lack of Efficacy|0
6114412|NCT00848718|9735423|FG011|Overall Study|Lack of Efficacy|0
6208832|NCT01567527|9873900|FG004|Double-blind, Placebo-controlled Phase|Recurrence of any mood episode withoutAE|35
6208833|NCT01567527|9873896|FG000|Double-blind, Placebo-controlled Phase|Lost to Follow-up|0
6208834|NCT01567527|9873897|FG001|Double-blind, Placebo-controlled Phase|Lost to Follow-up|0
6208835|NCT01567527|9873898|FG002|Double-blind, Placebo-controlled Phase|Lost to Follow-up|0
6208836|NCT01567527|9873899|FG003|Double-blind, Placebo-controlled Phase|Lost to Follow-up|8
6208837|NCT01567527|9873900|FG004|Double-blind, Placebo-controlled Phase|Lost to Follow-up|5
6286369|NCT02346240|9999206|FG015|Initial Period (Baseline to Week 16)|Non-compliance|0
6286370|NCT02346240|9999207|FG016|Initial Period (Baseline to Week 16)|Non-compliance|0
6286371|NCT02346240|9999208|FG017|Initial Period (Baseline to Week 16)|Non-compliance|0
6286372|NCT02346240|9999209|FG018|Initial Period (Baseline to Week 16)|Non-compliance|0
6286373|NCT02346240|9999210|FG019|Initial Period (Baseline to Week 16)|Non-compliance|0
6286374|NCT02346240|9999211|FG020|Initial Period (Baseline to Week 16)|Non-compliance|0
6286375|NCT02346240|9999212|FG021|Initial Period (Baseline to Week 16)|Non-compliance|0
6286376|NCT02346240|9999213|FG022|Initial Period (Baseline to Week 16)|Non-compliance|0
6286377|NCT02346240|9999214|FG023|Initial Period (Baseline to Week 16)|Non-compliance|0
6286378|NCT02346240|9999191|FG000|Initial Period (Baseline to Week 16)|Subject missed 3 visits|0
6286379|NCT02346240|9999192|FG001|Initial Period (Baseline to Week 16)|Subject missed 3 visits|0
6286380|NCT02346240|9999193|FG002|Initial Period (Baseline to Week 16)|Subject missed 3 visits|1
6286381|NCT02346240|9999194|FG003|Initial Period (Baseline to Week 16)|Subject missed 3 visits|0
6286382|NCT02346240|9999195|FG004|Initial Period (Baseline to Week 16)|Subject missed 3 visits|0
6286383|NCT02346240|9999196|FG005|Initial Period (Baseline to Week 16)|Subject missed 3 visits|0
6286384|NCT02346240|9999197|FG006|Initial Period (Baseline to Week 16)|Subject missed 3 visits|0
6286385|NCT02346240|9999198|FG007|Initial Period (Baseline to Week 16)|Subject missed 3 visits|0
6286386|NCT02346240|9999199|FG008|Initial Period (Baseline to Week 16)|Subject missed 3 visits|0
6286387|NCT02346240|9999200|FG009|Initial Period (Baseline to Week 16)|Subject missed 3 visits|0
6286388|NCT02346240|9999201|FG010|Initial Period (Baseline to Week 16)|Subject missed 3 visits|0
6286389|NCT02346240|9999202|FG011|Initial Period (Baseline to Week 16)|Subject missed 3 visits|0
6286390|NCT02346240|9999203|FG012|Initial Period (Baseline to Week 16)|Subject missed 3 visits|0
6286391|NCT02346240|9999204|FG013|Initial Period (Baseline to Week 16)|Subject missed 3 visits|0
6286392|NCT02346240|9999205|FG014|Initial Period (Baseline to Week 16)|Subject missed 3 visits|0
6286393|NCT02346240|9999206|FG015|Initial Period (Baseline to Week 16)|Subject missed 3 visits|0
6286394|NCT02346240|9999207|FG016|Initial Period (Baseline to Week 16)|Subject missed 3 visits|0
6114413|NCT00848718|9735424|FG012|Overall Study|Lack of Efficacy|0
6114414|NCT00848718|9735412|FG000|Overall Study|Physician Decision|0
6114415|NCT00848718|9735413|FG001|Overall Study|Physician Decision|1
6114416|NCT00848718|9735414|FG002|Overall Study|Physician Decision|0
6114417|NCT00848718|9735415|FG003|Overall Study|Physician Decision|0
6114418|NCT00848718|9735416|FG004|Overall Study|Physician Decision|1
6114419|NCT00848718|9735417|FG005|Overall Study|Physician Decision|1
6114420|NCT00848718|9735418|FG006|Overall Study|Physician Decision|0
6114421|NCT00848718|9735419|FG007|Overall Study|Physician Decision|0
6114422|NCT00848718|9735420|FG008|Overall Study|Physician Decision|1
6114423|NCT00848718|9735421|FG009|Overall Study|Physician Decision|2
6114424|NCT00848718|9735422|FG010|Overall Study|Physician Decision|0
6114425|NCT00848718|9735423|FG011|Overall Study|Physician Decision|0
6114426|NCT00848718|9735424|FG012|Overall Study|Physician Decision|1
6114427|NCT00848718|9735412|FG000|Overall Study|Progressive disease before treatment|1
6114428|NCT00848718|9735413|FG001|Overall Study|Progressive disease before treatment|5
6114429|NCT00848718|9735414|FG002|Overall Study|Progressive disease before treatment|1
6114430|NCT00848718|9735415|FG003|Overall Study|Progressive disease before treatment|3
6114431|NCT00848718|9735416|FG004|Overall Study|Progressive disease before treatment|4
6114432|NCT00848718|9735417|FG005|Overall Study|Progressive disease before treatment|4
6114433|NCT00848718|9735418|FG006|Overall Study|Progressive disease before treatment|2
6208838|NCT01567826|9873911|FG000|Overall Study|Lost to Follow-up|3
6208839|NCT01567826|9873912|FG001|Overall Study|Lost to Follow-up|2
6208840|NCT01567852|9873930|FG000|Overall Study|Withdrawal by Subject|3
6208841|NCT01567852|9873931|FG001|Overall Study|Withdrawal by Subject|6
6208842|NCT01567852|9873930|FG000|Overall Study|ECT discontinued|1
6208843|NCT01567852|9873931|FG001|Overall Study|ECT discontinued|1
6208844|NCT01567865|9873941|FG000|Evaluated for Immunogenicity|Sero+ for anti-JEV at Visit 1|0
6208845|NCT01567865|9873942|FG001|Evaluated for Immunogenicity|Sero+ for anti-JEV at Visit 1|1
6208846|NCT01567865|9873943|FG002|Evaluated for Immunogenicity|Sero+ for anti-JEV at Visit 1|3
6208847|NCT01567865|9873944|FG003|Evaluated for Immunogenicity|Sero+ for anti-JEV at Visit 1|2
6208848|NCT01567865|9873941|FG000|Evaluated for Immunogenicity|Missing blood sample|17
6208849|NCT01567865|9873942|FG001|Evaluated for Immunogenicity|Missing blood sample|24
6286395|NCT02346240|9999208|FG017|Initial Period (Baseline to Week 16)|Subject missed 3 visits|0
6286396|NCT02346240|9999209|FG018|Initial Period (Baseline to Week 16)|Subject missed 3 visits|0
6286397|NCT02346240|9999210|FG019|Initial Period (Baseline to Week 16)|Subject missed 3 visits|0
6286398|NCT02346240|9999211|FG020|Initial Period (Baseline to Week 16)|Subject missed 3 visits|0
6286399|NCT02346240|9999212|FG021|Initial Period (Baseline to Week 16)|Subject missed 3 visits|0
6286400|NCT02346240|9999213|FG022|Initial Period (Baseline to Week 16)|Subject missed 3 visits|0
6286401|NCT02346240|9999214|FG023|Initial Period (Baseline to Week 16)|Subject missed 3 visits|0
6286402|NCT02346240|9999191|FG000|Maintenance Period (Week 16 to Week 48)|Adverse Event|0
6286403|NCT02346240|9999192|FG001|Maintenance Period (Week 16 to Week 48)|Adverse Event|0
6286404|NCT02346240|9999193|FG002|Maintenance Period (Week 16 to Week 48)|Adverse Event|0
6286405|NCT02346240|9999194|FG003|Maintenance Period (Week 16 to Week 48)|Adverse Event|0
6286406|NCT02346240|9999195|FG004|Maintenance Period (Week 16 to Week 48)|Adverse Event|0
6286407|NCT02346240|9999196|FG005|Maintenance Period (Week 16 to Week 48)|Adverse Event|0
6286408|NCT02346240|9999197|FG006|Maintenance Period (Week 16 to Week 48)|Adverse Event|0
6286409|NCT02346240|9999198|FG007|Maintenance Period (Week 16 to Week 48)|Adverse Event|1
6286410|NCT02346240|9999199|FG008|Maintenance Period (Week 16 to Week 48)|Adverse Event|2
6286411|NCT02346240|9999200|FG009|Maintenance Period (Week 16 to Week 48)|Adverse Event|0
6286412|NCT02346240|9999201|FG010|Maintenance Period (Week 16 to Week 48)|Adverse Event|0
6286413|NCT02346240|9999202|FG011|Maintenance Period (Week 16 to Week 48)|Adverse Event|0
6286414|NCT02346240|9999203|FG012|Maintenance Period (Week 16 to Week 48)|Adverse Event|0
6286415|NCT02346240|9999204|FG013|Maintenance Period (Week 16 to Week 48)|Adverse Event|1
6286416|NCT02346240|9999205|FG014|Maintenance Period (Week 16 to Week 48)|Adverse Event|4
6286417|NCT02346240|9999206|FG015|Maintenance Period (Week 16 to Week 48)|Adverse Event|1
6286418|NCT02346240|9999207|FG016|Maintenance Period (Week 16 to Week 48)|Adverse Event|2
6286419|NCT02346240|9999208|FG017|Maintenance Period (Week 16 to Week 48)|Adverse Event|0
6286420|NCT02346240|9999209|FG018|Maintenance Period (Week 16 to Week 48)|Adverse Event|0
6286421|NCT02346240|9999210|FG019|Maintenance Period (Week 16 to Week 48)|Adverse Event|0
6286422|NCT02346240|9999211|FG020|Maintenance Period (Week 16 to Week 48)|Adverse Event|0
6286423|NCT02346240|9999212|FG021|Maintenance Period (Week 16 to Week 48)|Adverse Event|0
6286424|NCT02346240|9999213|FG022|Maintenance Period (Week 16 to Week 48)|Adverse Event|0
6286425|NCT02346240|9999214|FG023|Maintenance Period (Week 16 to Week 48)|Adverse Event|0
6286426|NCT02346240|9999191|FG000|Maintenance Period (Week 16 to Week 48)|Lack of Efficacy|0
6286427|NCT02346240|9999192|FG001|Maintenance Period (Week 16 to Week 48)|Lack of Efficacy|0
6286428|NCT02346240|9999193|FG002|Maintenance Period (Week 16 to Week 48)|Lack of Efficacy|0
6286429|NCT02346240|9999194|FG003|Maintenance Period (Week 16 to Week 48)|Lack of Efficacy|0
6286430|NCT02346240|9999195|FG004|Maintenance Period (Week 16 to Week 48)|Lack of Efficacy|0
6286431|NCT02346240|9999196|FG005|Maintenance Period (Week 16 to Week 48)|Lack of Efficacy|0
6286432|NCT02346240|9999197|FG006|Maintenance Period (Week 16 to Week 48)|Lack of Efficacy|0
6114434|NCT00848718|9735419|FG007|Overall Study|Progressive disease before treatment|1
6114435|NCT00848718|9735420|FG008|Overall Study|Progressive disease before treatment|2
6114436|NCT00848718|9735421|FG009|Overall Study|Progressive disease before treatment|7
6114437|NCT00848718|9735422|FG010|Overall Study|Progressive disease before treatment|3
6114438|NCT00848718|9735423|FG011|Overall Study|Progressive disease before treatment|6
6114439|NCT00848718|9735424|FG012|Overall Study|Progressive disease before treatment|2
6114440|NCT00848718|9735412|FG000|Overall Study|Protocol Violation|0
6114441|NCT00848718|9735413|FG001|Overall Study|Protocol Violation|1
6114442|NCT00848718|9735414|FG002|Overall Study|Protocol Violation|0
6114443|NCT00848718|9735415|FG003|Overall Study|Protocol Violation|0
6114444|NCT00848718|9735416|FG004|Overall Study|Protocol Violation|0
6114445|NCT00848718|9735417|FG005|Overall Study|Protocol Violation|0
6114446|NCT00848718|9735418|FG006|Overall Study|Protocol Violation|0
6114447|NCT00848718|9735419|FG007|Overall Study|Protocol Violation|1
6114448|NCT00848718|9735420|FG008|Overall Study|Protocol Violation|0
6114449|NCT00848718|9735421|FG009|Overall Study|Protocol Violation|0
6114450|NCT00848718|9735422|FG010|Overall Study|Protocol Violation|0
6208850|NCT01567865|9873943|FG002|Evaluated for Immunogenicity|Missing blood sample|16
6208851|NCT01567865|9873944|FG003|Evaluated for Immunogenicity|Missing blood sample|28
6208852|NCT01568034|9873986|FG000|Overall Study|Withdrawal by Subject|1
6208853|NCT01568034|9873987|FG001|Overall Study|Withdrawal by Subject|0
6208854|NCT01568034|9873988|FG002|Overall Study|Withdrawal by Subject|0
6208855|NCT01568034|9873989|FG003|Overall Study|Withdrawal by Subject|0
6208856|NCT01568047|9874003|FG000|Overall Study|Ineligibility|1
6208857|NCT01568047|9874004|FG001|Overall Study|Ineligibility|0
6208858|NCT01568047|9874005|FG002|Overall Study|Ineligibility|0
6208859|NCT01568047|9874006|FG003|Overall Study|Ineligibility|0
6208860|NCT01568047|9874003|FG000|Overall Study|Withdrawal by Subject|0
6208861|NCT01568047|9874004|FG001|Overall Study|Withdrawal by Subject|1
6208862|NCT01568047|9874005|FG002|Overall Study|Withdrawal by Subject|0
6208863|NCT01568047|9874006|FG003|Overall Study|Withdrawal by Subject|0
6208864|NCT01568047|9874003|FG000|Overall Study|Adverse Event|0
6208865|NCT01568047|9874004|FG001|Overall Study|Adverse Event|0
6208866|NCT01568047|9874005|FG002|Overall Study|Adverse Event|1
6208867|NCT01568047|9874006|FG003|Overall Study|Adverse Event|1
6208868|NCT01568112|9874041|FG000|Overall Study|Randomized But Not Treated|0
6208869|NCT01568112|9874042|FG001|Overall Study|Randomized But Not Treated|1
6208870|NCT01568112|9874043|FG002|Overall Study|Randomized But Not Treated|0
6208871|NCT01568112|9874044|FG003|Overall Study|Randomized But Not Treated|0
6208872|NCT01568112|9874041|FG000|Overall Study|Withdrew due to Adverse Event|2
6208873|NCT01568112|9874042|FG001|Overall Study|Withdrew due to Adverse Event|4
6208874|NCT01568112|9874043|FG002|Overall Study|Withdrew due to Adverse Event|6
6208875|NCT01568112|9874044|FG003|Overall Study|Withdrew due to Adverse Event|3
6208876|NCT01568112|9874041|FG000|Overall Study|Lost to Follow-up|0
6208877|NCT01568112|9874042|FG001|Overall Study|Lost to Follow-up|0
6208878|NCT01568112|9874043|FG002|Overall Study|Lost to Follow-up|0
6208879|NCT01568112|9874044|FG003|Overall Study|Lost to Follow-up|1
6208880|NCT01568112|9874041|FG000|Overall Study|Withdrawal by Subject|2
6208881|NCT01568112|9874042|FG001|Overall Study|Withdrawal by Subject|3
6208882|NCT01568112|9874043|FG002|Overall Study|Withdrawal by Subject|0
6208883|NCT01568112|9874044|FG003|Overall Study|Withdrawal by Subject|7
6208884|NCT01568112|9874041|FG000|Overall Study|Withdrawal by Physician|1
6208885|NCT01568112|9874042|FG001|Overall Study|Withdrawal by Physician|0
6208886|NCT01568112|9874043|FG002|Overall Study|Withdrawal by Physician|1
6208887|NCT01568112|9874044|FG003|Overall Study|Withdrawal by Physician|1
6208888|NCT01568320|9874064|FG000|Overall Study|Death|20
6208889|NCT01568320|9874064|FG000|Overall Study|Lost to Follow-up|9
6208890|NCT01568320|9874064|FG000|Overall Study|Withdrawal by Subject|10
6208891|NCT01568320|9874064|FG000|Overall Study|Conversion to open repair|1
6208892|NCT01568320|9874064|FG000|Overall Study|Patient fell outside of the consented window, data outside of the consented 5-year was not collected|1
6208893|NCT01568593|9874087|FG000|Overall Study|Lack of Efficacy|4
6208894|NCT01568593|9874088|FG001|Overall Study|Lack of Efficacy|1
6208895|NCT01568593|9874087|FG000|Overall Study|Adverse Event|3
6208896|NCT01568593|9874088|FG001|Overall Study|Adverse Event|2
6208897|NCT01568866|9874109|FG000|Overall Study|Disease Progression|208
6208898|NCT01568866|9874110|FG001|Overall Study|Disease Progression|183
6208899|NCT01568866|9874109|FG000|Overall Study|Adverse Event|94
6208900|NCT01568866|9874110|FG001|Overall Study|Adverse Event|96
6208901|NCT01568866|9874109|FG000|Overall Study|Patient Request|55
6208902|NCT01568866|9874110|FG001|Overall Study|Patient Request|71
6208903|NCT01568866|9874109|FG000|Overall Study|Physician Decision|40
6208904|NCT01568866|9874110|FG001|Overall Study|Physician Decision|32
6208905|NCT01568866|9874109|FG000|Overall Study|Withdrawal by Subject|19
6208906|NCT01568866|9874110|FG001|Overall Study|Withdrawal by Subject|11
6208907|NCT01568866|9874109|FG000|Overall Study|Death|10
6208908|NCT01568866|9874110|FG001|Overall Study|Death|18
6208909|NCT01568866|9874109|FG000|Overall Study|Protocol Non-compliance|2
6208910|NCT01568866|9874110|FG001|Overall Study|Protocol Non-compliance|4
6208911|NCT01568866|9874109|FG000|Overall Study|Lost to Follow-up|1
6208912|NCT01568866|9874110|FG001|Overall Study|Lost to Follow-up|0
6208913|NCT01568866|9874109|FG000|Overall Study|Randomized but Not Dosed|9
6208914|NCT01568866|9874110|FG001|Overall Study|Randomized but Not Dosed|1
6114451|NCT00848718|9735423|FG011|Overall Study|Protocol Violation|0
6208915|NCT01568892|9874118|FG000|Open-label Phase|Adverse Event|2
6208916|NCT01568892|9874119|FG001|Open-label Phase|Adverse Event|0
6114452|NCT00848718|9735424|FG012|Overall Study|Protocol Violation|1
6114453|NCT00848718|9735412|FG000|Overall Study|Withdrawal by Subject|1
6114454|NCT00848718|9735413|FG001|Overall Study|Withdrawal by Subject|0
6114455|NCT00848718|9735414|FG002|Overall Study|Withdrawal by Subject|0
6114456|NCT00848718|9735415|FG003|Overall Study|Withdrawal by Subject|1
6114457|NCT00848718|9735416|FG004|Overall Study|Withdrawal by Subject|0
6114458|NCT00848718|9735417|FG005|Overall Study|Withdrawal by Subject|0
6114459|NCT00848718|9735418|FG006|Overall Study|Withdrawal by Subject|0
6114460|NCT00848718|9735419|FG007|Overall Study|Withdrawal by Subject|0
6114461|NCT00848718|9735420|FG008|Overall Study|Withdrawal by Subject|0
6114462|NCT00848718|9735421|FG009|Overall Study|Withdrawal by Subject|0
6114463|NCT00848718|9735422|FG010|Overall Study|Withdrawal by Subject|1
6114464|NCT00848718|9735423|FG011|Overall Study|Withdrawal by Subject|0
6114465|NCT00848718|9735424|FG012|Overall Study|Withdrawal by Subject|0
6114466|NCT00848718|9735412|FG000|Overall Study|Progressive disease during treatment|3
6114467|NCT00848718|9735413|FG001|Overall Study|Progressive disease during treatment|0
6114468|NCT00848718|9735414|FG002|Overall Study|Progressive disease during treatment|3
6114469|NCT00848718|9735415|FG003|Overall Study|Progressive disease during treatment|0
6114470|NCT00848718|9735416|FG004|Overall Study|Progressive disease during treatment|0
6114471|NCT00848718|9735417|FG005|Overall Study|Progressive disease during treatment|0
6114472|NCT00848718|9735418|FG006|Overall Study|Progressive disease during treatment|0
6114473|NCT00848718|9735419|FG007|Overall Study|Progressive disease during treatment|2
6114474|NCT00848718|9735420|FG008|Overall Study|Progressive disease during treatment|0
6114475|NCT00848718|9735421|FG009|Overall Study|Progressive disease during treatment|0
6114476|NCT00848718|9735422|FG010|Overall Study|Progressive disease during treatment|0
6114477|NCT00848718|9735423|FG011|Overall Study|Progressive disease during treatment|0
6114478|NCT00848718|9735424|FG012|Overall Study|Progressive disease during treatment|2
6114479|NCT00848926|9735475|FG000|Treatment Period|Progressive disease|45
6114480|NCT00848926|9735475|FG000|Treatment Period|Adverse Event|20
6114481|NCT00848926|9735475|FG000|Treatment Period|Physician Decision|12
6208917|NCT01568892|9874118|FG000|Open-label Phase|Lack of Efficacy|4
6208918|NCT01568892|9874119|FG001|Open-label Phase|Lack of Efficacy|2
6208919|NCT01568892|9874118|FG000|Open-label Phase|Lost to Follow-up|0
6208920|NCT01568892|9874119|FG001|Open-label Phase|Lost to Follow-up|1
6208921|NCT01569022|9874148|FG000|First Intervention|Lost to Follow-up|2
6208922|NCT01569022|9874149|FG001|First Intervention|Lost to Follow-up|1
6208923|NCT01569022|9874148|FG000|Second Intervention|Lost to Follow-up|2
6208924|NCT01569022|9874149|FG001|Second Intervention|Lost to Follow-up|2
6208925|NCT01569074|9874162|FG000|Overall Study|Study stopped|6
6208926|NCT01569074|9874163|FG001|Overall Study|Study stopped|6
6286433|NCT02346240|9999198|FG007|Maintenance Period (Week 16 to Week 48)|Lack of Efficacy|0
6286434|NCT02346240|9999199|FG008|Maintenance Period (Week 16 to Week 48)|Lack of Efficacy|0
6286435|NCT02346240|9999200|FG009|Maintenance Period (Week 16 to Week 48)|Lack of Efficacy|0
6286436|NCT02346240|9999201|FG010|Maintenance Period (Week 16 to Week 48)|Lack of Efficacy|0
6286437|NCT02346240|9999202|FG011|Maintenance Period (Week 16 to Week 48)|Lack of Efficacy|0
6286438|NCT02346240|9999203|FG012|Maintenance Period (Week 16 to Week 48)|Lack of Efficacy|0
6286439|NCT02346240|9999204|FG013|Maintenance Period (Week 16 to Week 48)|Lack of Efficacy|1
6286440|NCT02346240|9999205|FG014|Maintenance Period (Week 16 to Week 48)|Lack of Efficacy|0
6286441|NCT02346240|9999206|FG015|Maintenance Period (Week 16 to Week 48)|Lack of Efficacy|3
6286442|NCT02346240|9999207|FG016|Maintenance Period (Week 16 to Week 48)|Lack of Efficacy|0
6286443|NCT02346240|9999208|FG017|Maintenance Period (Week 16 to Week 48)|Lack of Efficacy|0
6286444|NCT02346240|9999209|FG018|Maintenance Period (Week 16 to Week 48)|Lack of Efficacy|0
6286445|NCT02346240|9999210|FG019|Maintenance Period (Week 16 to Week 48)|Lack of Efficacy|0
6286446|NCT02346240|9999211|FG020|Maintenance Period (Week 16 to Week 48)|Lack of Efficacy|0
6286447|NCT02346240|9999212|FG021|Maintenance Period (Week 16 to Week 48)|Lack of Efficacy|0
6286448|NCT02346240|9999213|FG022|Maintenance Period (Week 16 to Week 48)|Lack of Efficacy|0
6286449|NCT02346240|9999214|FG023|Maintenance Period (Week 16 to Week 48)|Lack of Efficacy|0
6286450|NCT02346240|9999191|FG000|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|0
6286451|NCT02346240|9999192|FG001|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|0
6286452|NCT02346240|9999193|FG002|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|0
6286453|NCT02346240|9999194|FG003|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|0
6286454|NCT02346240|9999195|FG004|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|0
6286455|NCT02346240|9999196|FG005|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|0
6286456|NCT02346240|9999197|FG006|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|0
6286457|NCT02346240|9999198|FG007|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|0
6286458|NCT02346240|9999199|FG008|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|0
6286459|NCT02346240|9999200|FG009|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|0
6286460|NCT02346240|9999201|FG010|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|0
6286461|NCT02346240|9999202|FG011|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|0
6286462|NCT02346240|9999203|FG012|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|0
6286463|NCT02346240|9999204|FG013|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|0
6286464|NCT02346240|9999205|FG014|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|1
6286465|NCT02346240|9999206|FG015|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|0
6114482|NCT00848926|9735475|FG000|Treatment Period|Withdrawal by Subject|7
6114483|NCT00848926|9735475|FG000|Follow-up Period|Lost to Follow-up|7
6114484|NCT00848926|9735475|FG000|Follow-up Period|Withdrawal by Subject|3
6114485|NCT00848926|9735475|FG000|Follow-up Period|Other|2
6114486|NCT00848965|9735479|FG000|Overall Study|Adverse Event|1
6114487|NCT00848965|9735479|FG000|Overall Study|Withdrawal by Subject|1
6114488|NCT00849017|9735494|FG000|Treatment Period (156 Weeks)|Adverse Event|5
6114489|NCT00849017|9735495|FG001|Treatment Period (156 Weeks)|Adverse Event|6
6114490|NCT00849017|9735496|FG002|Treatment Period (156 Weeks)|Adverse Event|15
6114491|NCT00849017|9735494|FG000|Treatment Period (156 Weeks)|Noncompliance|3
6114492|NCT00849017|9735495|FG001|Treatment Period (156 Weeks)|Noncompliance|3
6114493|NCT00849017|9735496|FG002|Treatment Period (156 Weeks)|Noncompliance|4
6114494|NCT00849017|9735494|FG000|Treatment Period (156 Weeks)|Lost to Follow-up|10
6114495|NCT00849017|9735495|FG001|Treatment Period (156 Weeks)|Lost to Follow-up|7
6114496|NCT00849017|9735496|FG002|Treatment Period (156 Weeks)|Lost to Follow-up|8
6114497|NCT00849017|9735494|FG000|Treatment Period (156 Weeks)|Withdrawal by Subject|18
6114498|NCT00849017|9735495|FG001|Treatment Period (156 Weeks)|Withdrawal by Subject|14
6114499|NCT00849017|9735496|FG002|Treatment Period (156 Weeks)|Withdrawal by Subject|11
6114500|NCT00849017|9735494|FG000|Treatment Period (156 Weeks)|Physician Decision|0
6114501|NCT00849017|9735495|FG001|Treatment Period (156 Weeks)|Physician Decision|2
6114502|NCT00849017|9735496|FG002|Treatment Period (156 Weeks)|Physician Decision|1
6114503|NCT00849017|9735494|FG000|Treatment Period (156 Weeks)|Termination of Study/ Site by GSK|3
6114504|NCT00849017|9735495|FG001|Treatment Period (156 Weeks)|Termination of Study/ Site by GSK|1
6114505|NCT00849017|9735496|FG002|Treatment Period (156 Weeks)|Termination of Study/ Site by GSK|1
6114506|NCT00849017|9735494|FG000|Treatment Period (156 Weeks)|Increased Calcitonin|1
6208927|NCT01569074|9874164|FG002|Overall Study|Study stopped|8
6208928|NCT01569074|9874165|FG003|Overall Study|Study stopped|7
6208929|NCT01569074|9874166|FG004|Overall Study|Study stopped|7
6208930|NCT01569074|9874162|FG000|Overall Study|Study-specific discontinuation criteria|0
6208931|NCT01569074|9874163|FG001|Overall Study|Study-specific discontinuation criteria|1
6208932|NCT01569074|9874164|FG002|Overall Study|Study-specific discontinuation criteria|0
6208933|NCT01569074|9874165|FG003|Overall Study|Study-specific discontinuation criteria|0
6208934|NCT01569074|9874166|FG004|Overall Study|Study-specific discontinuation criteria|0
6208935|NCT01569074|9874162|FG000|Overall Study|Severe non-compliance to protocol|0
6208936|NCT01569074|9874163|FG001|Overall Study|Severe non-compliance to protocol|0
6208937|NCT01569074|9874164|FG002|Overall Study|Severe non-compliance to protocol|1
6208938|NCT01569074|9874165|FG003|Overall Study|Severe non-compliance to protocol|0
6208939|NCT01569074|9874166|FG004|Overall Study|Severe non-compliance to protocol|0
6208940|NCT01569074|9874162|FG000|Overall Study|eg change in circumstances|0
6208941|NCT01569074|9874163|FG001|Overall Study|eg change in circumstances|2
6208942|NCT01569074|9874164|FG002|Overall Study|eg change in circumstances|0
6208943|NCT01569074|9874165|FG003|Overall Study|eg change in circumstances|1
6208944|NCT01569074|9874166|FG004|Overall Study|eg change in circumstances|1
6208945|NCT01569074|9874162|FG000|Overall Study|Adverse Event|1
6208946|NCT01569074|9874163|FG001|Overall Study|Adverse Event|0
6208947|NCT01569074|9874164|FG002|Overall Study|Adverse Event|3
6208948|NCT01569074|9874165|FG003|Overall Study|Adverse Event|0
6208949|NCT01569074|9874166|FG004|Overall Study|Adverse Event|0
6208950|NCT01569152|9874227|FG000|Phase IIa, Period 1|Early Escape|5
6208951|NCT01569152|9874228|FG001|Phase IIa, Period 1|Early Escape|22
6208952|NCT01569152|9874229|FG002|Phase IIa, Period 1|Early Escape|0
6208953|NCT01569152|9874227|FG000|Phase IIa, Period 1|Adverse Event|4
6208954|NCT01569152|9874228|FG001|Phase IIa, Period 1|Adverse Event|0
6208955|NCT01569152|9874229|FG002|Phase IIa, Period 1|Adverse Event|0
6208956|NCT01569152|9874227|FG000|Phase IIa, Period 1|Lost to Follow-up|1
6208957|NCT01569152|9874228|FG001|Phase IIa, Period 1|Lost to Follow-up|0
6208958|NCT01569152|9874229|FG002|Phase IIa, Period 1|Lost to Follow-up|0
6208959|NCT01569152|9874227|FG000|Phase IIa, Period 1|Study Terminated by Sponsor|9
6208960|NCT01569152|9874228|FG001|Phase IIa, Period 1|Study Terminated by Sponsor|8
6208961|NCT01569152|9874229|FG002|Phase IIa, Period 1|Study Terminated by Sponsor|0
6208962|NCT01569152|9874227|FG000|Phase IIa, Period 1|Protocol Violation|0
6208963|NCT01569152|9874228|FG001|Phase IIa, Period 1|Protocol Violation|1
6208964|NCT01569152|9874229|FG002|Phase IIa, Period 1|Protocol Violation|0
6208965|NCT01569152|9874227|FG000|Phase IIa, Period 1|Withdrawal by Subject|2
6208966|NCT01569152|9874228|FG001|Phase IIa, Period 1|Withdrawal by Subject|1
6208967|NCT01569152|9874229|FG002|Phase IIa, Period 1|Withdrawal by Subject|0
6208968|NCT01569152|9874227|FG000|Safety Extension, Period 3|Adverse Event|0
6208969|NCT01569152|9874228|FG001|Safety Extension, Period 3|Adverse Event|0
6208970|NCT01569152|9874229|FG002|Safety Extension, Period 3|Adverse Event|4
6208971|NCT01569152|9874227|FG000|Safety Extension, Period 3|Withdrawal by Subject|0
6208972|NCT01569152|9874228|FG001|Safety Extension, Period 3|Withdrawal by Subject|0
6208973|NCT01569152|9874229|FG002|Safety Extension, Period 3|Withdrawal by Subject|2
6208974|NCT01569152|9874227|FG000|Safety Extension, Period 3|Physician Decision|0
6208975|NCT01569152|9874228|FG001|Safety Extension, Period 3|Physician Decision|0
6208976|NCT01569152|9874229|FG002|Safety Extension, Period 3|Physician Decision|2
6208977|NCT01569152|9874227|FG000|Safety Extension, Period 3|Study terminated by Sponsor|0
6208978|NCT01569152|9874228|FG001|Safety Extension, Period 3|Study terminated by Sponsor|0
6208979|NCT01569152|9874229|FG002|Safety Extension, Period 3|Study terminated by Sponsor|47
6114507|NCT00849017|9735495|FG001|Treatment Period (156 Weeks)|Increased Calcitonin|0
6114508|NCT00849017|9735496|FG002|Treatment Period (156 Weeks)|Increased Calcitonin|0
6114509|NCT00849017|9735494|FG000|Treatment Period (156 Weeks)|Physician Discontinued-Thrombocytopenia|1
6114510|NCT00849017|9735495|FG001|Treatment Period (156 Weeks)|Physician Discontinued-Thrombocytopenia|0
6114511|NCT00849017|9735496|FG002|Treatment Period (156 Weeks)|Physician Discontinued-Thrombocytopenia|0
6114512|NCT00849017|9735494|FG000|Treatment Period (156 Weeks)|Participant Moved to Africa|1
6114513|NCT00849017|9735495|FG001|Treatment Period (156 Weeks)|Participant Moved to Africa|0
6114514|NCT00849017|9735496|FG002|Treatment Period (156 Weeks)|Participant Moved to Africa|0
6114515|NCT00849017|9735494|FG000|Treatment Period (156 Weeks)|Pregnancy|1
6114516|NCT00849017|9735495|FG001|Treatment Period (156 Weeks)|Pregnancy|0
6114517|NCT00849017|9735496|FG002|Treatment Period (156 Weeks)|Pregnancy|1
6114518|NCT00849017|9735494|FG000|Treatment Period (156 Weeks)|Participant Decided to Move Out of State|0
6114519|NCT00849017|9735495|FG001|Treatment Period (156 Weeks)|Participant Decided to Move Out of State|0
6114520|NCT00849017|9735496|FG002|Treatment Period (156 Weeks)|Participant Decided to Move Out of State|1
6114521|NCT00849017|9735494|FG000|Follow-up Period (8 Weeks)|Adverse Event|1
6114522|NCT00849017|9735495|FG001|Follow-up Period (8 Weeks)|Adverse Event|0
6114523|NCT00849017|9735496|FG002|Follow-up Period (8 Weeks)|Adverse Event|0
6114524|NCT00849017|9735494|FG000|Follow-up Period (8 Weeks)|Noncompliance|2
6114525|NCT00849017|9735495|FG001|Follow-up Period (8 Weeks)|Noncompliance|1
6114526|NCT00849017|9735496|FG002|Follow-up Period (8 Weeks)|Noncompliance|0
6114527|NCT00849017|9735494|FG000|Follow-up Period (8 Weeks)|Lost to Follow-up|13
6114528|NCT00849017|9735495|FG001|Follow-up Period (8 Weeks)|Lost to Follow-up|12
6114529|NCT00849017|9735496|FG002|Follow-up Period (8 Weeks)|Lost to Follow-up|16
6114530|NCT00849017|9735494|FG000|Follow-up Period (8 Weeks)|Did Not Enter Follow-up Period|1
6114531|NCT00849017|9735495|FG001|Follow-up Period (8 Weeks)|Did Not Enter Follow-up Period|1
6114532|NCT00849017|9735496|FG002|Follow-up Period (8 Weeks)|Did Not Enter Follow-up Period|4
6114533|NCT00849017|9735494|FG000|Follow-up Period (8 Weeks)|Withdrawal by Subject|4
6114534|NCT00849017|9735495|FG001|Follow-up Period (8 Weeks)|Withdrawal by Subject|2
6114535|NCT00849017|9735496|FG002|Follow-up Period (8 Weeks)|Withdrawal by Subject|3
6114536|NCT00849017|9735494|FG000|Follow-up Period (8 Weeks)|Physician Decision|0
6114537|NCT00849017|9735495|FG001|Follow-up Period (8 Weeks)|Physician Decision|1
6114538|NCT00849017|9735496|FG002|Follow-up Period (8 Weeks)|Physician Decision|1
6208980|NCT01569295|9874251|FG000|Overall Study|Progressive Disease|75
6208981|NCT01569295|9874252|FG001|Overall Study|Progressive Disease|139
6208982|NCT01569295|9874251|FG000|Overall Study|Adverse Event|39
6208983|NCT01569295|9874252|FG001|Overall Study|Adverse Event|14
6208984|NCT01569295|9874251|FG000|Overall Study|Withdrawal by Subject|25
6208985|NCT01569295|9874252|FG001|Overall Study|Withdrawal by Subject|12
6208986|NCT01569295|9874251|FG000|Overall Study|Death|19
6208987|NCT01569295|9874252|FG001|Overall Study|Death|15
6208988|NCT01569295|9874251|FG000|Overall Study|Physician Decision|13
6208989|NCT01569295|9874252|FG001|Overall Study|Physician Decision|18
6208990|NCT01569295|9874251|FG000|Overall Study|Study Terminated by Sponsor|24
6208991|NCT01569295|9874252|FG001|Overall Study|Study Terminated by Sponsor|2
6208992|NCT01569295|9874251|FG000|Overall Study|Other Reason not Specified|3
6208993|NCT01569295|9874252|FG001|Overall Study|Other Reason not Specified|5
6208994|NCT01569295|9874251|FG000|Overall Study|Non-Compliance with Study Drug|6
6208995|NCT01569295|9874252|FG001|Overall Study|Non-Compliance with Study Drug|1
6208996|NCT01569295|9874251|FG000|Overall Study|Other Anticancer/Experimental Therapy|2
6208997|NCT01569295|9874252|FG001|Overall Study|Other Anticancer/Experimental Therapy|2
6114539|NCT00849017|9735494|FG000|Follow-up Period (8 Weeks)|Termination of Study/ Site by GSK|3
6208998|NCT01569295|9874251|FG000|Overall Study|Lost to Follow-up|1
6208999|NCT01569295|9874252|FG001|Overall Study|Lost to Follow-up|1
6209000|NCT01569438|9874261|FG000|Overall Study|Lack of Efficacy|1
6209001|NCT01569438|9874262|FG001|Overall Study|Lack of Efficacy|2
6209002|NCT01569438|9874261|FG000|Overall Study|Withdrawal by Subject|0
6209003|NCT01569438|9874262|FG001|Overall Study|Withdrawal by Subject|3
6209004|NCT01569438|9874261|FG000|Overall Study|Adverse Event|2
6209005|NCT01569438|9874262|FG001|Overall Study|Adverse Event|15
6209006|NCT01569438|9874261|FG000|Overall Study|Protocol Violation|2
6209007|NCT01569438|9874262|FG001|Overall Study|Protocol Violation|0
6209008|NCT01569438|9874261|FG000|Overall Study|Decrease of GFR greater than 30 ml/min|1
6209009|NCT01569438|9874262|FG001|Overall Study|Decrease of GFR greater than 30 ml/min|0
6209010|NCT01569438|9874261|FG000|Overall Study|Sponsor/Physician decision|1
6209011|NCT01569438|9874262|FG001|Overall Study|Sponsor/Physician decision|1
6209012|NCT01569438|9874261|FG000|Overall Study|Unable to adhere to study schedule|0
6209013|NCT01569438|9874262|FG001|Overall Study|Unable to adhere to study schedule|1
6209014|NCT01569464|9874281|FG000|Overall Study|Adverse Event|4
6209015|NCT01569464|9874282|FG001|Overall Study|Adverse Event|0
6209016|NCT01569464|9874281|FG000|Overall Study|Lack of Efficacy|1
6209017|NCT01569464|9874282|FG001|Overall Study|Lack of Efficacy|0
6114540|NCT00849017|9735495|FG001|Follow-up Period (8 Weeks)|Termination of Study/ Site by GSK|1
6209018|NCT01569464|9874281|FG000|Overall Study|Protocol Violation|1
6209019|NCT01569464|9874282|FG001|Overall Study|Protocol Violation|0
6209020|NCT01569464|9874281|FG000|Overall Study|Lost to Follow-up|2
6209021|NCT01569464|9874282|FG001|Overall Study|Lost to Follow-up|3
6209022|NCT01569464|9874281|FG000|Overall Study|Withdrawal by Subject|1
6114541|NCT00849017|9735496|FG002|Follow-up Period (8 Weeks)|Termination of Study/ Site by GSK|1
6114542|NCT00849017|9735494|FG000|Follow-up Period (8 Weeks)|Participant Relocating to Africa|1
6114543|NCT00849017|9735495|FG001|Follow-up Period (8 Weeks)|Participant Relocating to Africa|0
6209023|NCT01569464|9874282|FG001|Overall Study|Withdrawal by Subject|1
6209024|NCT01569464|9874281|FG000|Overall Study|Other|1
6209025|NCT01569464|9874282|FG001|Overall Study|Other|1
6209026|NCT01569568|9874301|FG000|Overall Study|Physician Decision|0
6209027|NCT01569568|9874302|FG001|Overall Study|Physician Decision|2
6209028|NCT01569594|9874308|FG000|Overall Study|Physician Decision|4
6209029|NCT01569594|9874308|FG000|Overall Study|Death|13
6209030|NCT01569594|9874308|FG000|Overall Study|Lost to Follow-up|22
6209031|NCT01569594|9874308|FG000|Overall Study|Adverse Event|2
6209032|NCT01569594|9874308|FG000|Overall Study|Withdrawal by Subject|13
6209033|NCT01569594|9874308|FG000|Overall Study|Other|4
6209034|NCT01569594|9874308|FG000|Overall Study|No ECM used|9
6209035|NCT01569763|9874327|FG000|Overall Study|Lack of Efficacy|2
6209036|NCT01569763|9874328|FG001|Overall Study|Lack of Efficacy|7
6209037|NCT01569763|9874327|FG000|Overall Study|Adverse Event|1
6209038|NCT01569763|9874328|FG001|Overall Study|Adverse Event|0
6209039|NCT01569841|9874362|FG000|Period A (6 Weeks)|Withdrawal by Subject|0
6209040|NCT01569841|9874363|FG001|Period A (6 Weeks)|Withdrawal by Subject|1
6209041|NCT01570192|9874382|FG000|Overall Study|no qualifying organism|6
6209042|NCT01570192|9874383|FG001|Overall Study|no qualifying organism|12
6209043|NCT01570192|9874382|FG000|Overall Study|changed to palliative care|1
6209044|NCT01570192|9874383|FG001|Overall Study|changed to palliative care|0
6209045|NCT01570192|9874382|FG000|Overall Study|Physician Decision|0
6209046|NCT01570192|9874383|FG001|Overall Study|Physician Decision|1
6209047|NCT01570244|9874394|FG000|Microgynon+Faldaprevir|Adverse Event|1
6209048|NCT01570283|9874403|FG000|Cohort 1: Dose Level 1|Death|0
6209049|NCT01570283|9874404|FG001|Cohort 1: Dose Level 1|Death|1
6209050|NCT01570283|9874405|FG002|Cohort 1: Dose Level 1|Death|0
6209051|NCT01570283|9874406|FG003|Cohort 1: Dose Level 1|Death|0
6209052|NCT01570283|9874407|FG004|Cohort 1: Dose Level 1|Death|0
6209053|NCT01570283|9874408|FG005|Cohort 1: Dose Level 1|Death|0
6209054|NCT01570283|9874403|FG000|Cohort 1: Dose Level 1|Received other hematopoietic cells|0
6209055|NCT01570283|9874404|FG001|Cohort 1: Dose Level 1|Received other hematopoietic cells|1
6209056|NCT01570283|9874405|FG002|Cohort 1: Dose Level 1|Received other hematopoietic cells|0
6209057|NCT01570283|9874406|FG003|Cohort 1: Dose Level 1|Received other hematopoietic cells|0
6209058|NCT01570283|9874407|FG004|Cohort 1: Dose Level 1|Received other hematopoietic cells|0
6209059|NCT01570283|9874408|FG005|Cohort 1: Dose Level 1|Received other hematopoietic cells|0
6209060|NCT01570283|9874403|FG000|Cohort 2: Dose Level 2|Death|0
6209061|NCT01570283|9874404|FG001|Cohort 2: Dose Level 2|Death|0
6209062|NCT01570283|9874405|FG002|Cohort 2: Dose Level 2|Death|1
6209063|NCT01570283|9874406|FG003|Cohort 2: Dose Level 2|Death|0
6209064|NCT01570283|9874407|FG004|Cohort 2: Dose Level 2|Death|0
6209065|NCT01570283|9874408|FG005|Cohort 2: Dose Level 2|Death|0
6209066|NCT01570283|9874403|FG000|Cohort 2: Dose Level 2|Received other hematopoietic cells|0
6209067|NCT01570283|9874404|FG001|Cohort 2: Dose Level 2|Received other hematopoietic cells|0
6209068|NCT01570283|9874405|FG002|Cohort 2: Dose Level 2|Received other hematopoietic cells|0
6209069|NCT01570283|9874406|FG003|Cohort 2: Dose Level 2|Received other hematopoietic cells|1
6209070|NCT01570283|9874407|FG004|Cohort 2: Dose Level 2|Received other hematopoietic cells|0
6209071|NCT01570283|9874408|FG005|Cohort 2: Dose Level 2|Received other hematopoietic cells|0
6209072|NCT01570283|9874403|FG000|Cohort 3: Dose Level 3|Death|0
6209073|NCT01570283|9874404|FG001|Cohort 3: Dose Level 3|Death|0
6209074|NCT01570283|9874405|FG002|Cohort 3: Dose Level 3|Death|0
6209075|NCT01570283|9874406|FG003|Cohort 3: Dose Level 3|Death|0
6209076|NCT01570283|9874407|FG004|Cohort 3: Dose Level 3|Death|0
6209077|NCT01570283|9874408|FG005|Cohort 3: Dose Level 3|Death|1
6209078|NCT01570283|9874403|FG000|Cohort 3: Dose Level 3|Received other hematopoietic cells|0
6209079|NCT01570283|9874404|FG001|Cohort 3: Dose Level 3|Received other hematopoietic cells|0
6209080|NCT01570283|9874405|FG002|Cohort 3: Dose Level 3|Received other hematopoietic cells|0
6209081|NCT01570283|9874406|FG003|Cohort 3: Dose Level 3|Received other hematopoietic cells|0
6209082|NCT01570283|9874407|FG004|Cohort 3: Dose Level 3|Received other hematopoietic cells|0
6209083|NCT01570283|9874408|FG005|Cohort 3: Dose Level 3|Received other hematopoietic cells|1
6209084|NCT01570309|9874424|FG000|Overall Study|Withdrawal by Subject|3
6209085|NCT01570309|9874425|FG001|Overall Study|Withdrawal by Subject|3
6209086|NCT01570361|9874441|FG000|Overall Study|Subject discontinued|1
6209087|NCT01570361|9874442|FG001|Overall Study|Subject discontinued|2
6209088|NCT01570361|9874441|FG000|Overall Study|Sponsor closing the study|51
6209089|NCT01570361|9874442|FG001|Overall Study|Sponsor closing the study|50
6209090|NCT01570361|9874441|FG000|Overall Study|Subject excluded|5
6209091|NCT01570361|9874442|FG001|Overall Study|Subject excluded|3
6209092|NCT01570361|9874441|FG000|Overall Study|Subject withdrew consent|14
6209093|NCT01570361|9874442|FG001|Overall Study|Subject withdrew consent|9
6209094|NCT01570361|9874441|FG000|Overall Study|Adverse Event|2
6209095|NCT01570361|9874442|FG001|Overall Study|Adverse Event|1
6209096|NCT01570361|9874441|FG000|Overall Study|Lost to Follow-up|4
6209097|NCT01570361|9874442|FG001|Overall Study|Lost to Follow-up|4
6209098|NCT01570361|9874441|FG000|Overall Study|Death|5
6209099|NCT01570361|9874442|FG001|Overall Study|Death|4
6209100|NCT01570361|9874441|FG000|Overall Study|Other|0
6114544|NCT00849017|9735496|FG002|Follow-up Period (8 Weeks)|Participant Relocating to Africa|0
6114545|NCT00849056|9735510|FG000|Treatment Period (TP) (156 Weeks)|Adverse Event|13
6114546|NCT00849056|9735511|FG001|Treatment Period (TP) (156 Weeks)|Adverse Event|11
6114547|NCT00849056|9735510|FG000|Treatment Period (TP) (156 Weeks)|Protocol Violation|3
6114548|NCT00849056|9735511|FG001|Treatment Period (TP) (156 Weeks)|Protocol Violation|6
6114549|NCT00849056|9735510|FG000|Treatment Period (TP) (156 Weeks)|Noncompliance|3
6114550|NCT00849056|9735511|FG001|Treatment Period (TP) (156 Weeks)|Noncompliance|3
6114551|NCT00849056|9735510|FG000|Treatment Period (TP) (156 Weeks)|Lost to Follow-up|7
6114552|NCT00849056|9735511|FG001|Treatment Period (TP) (156 Weeks)|Lost to Follow-up|5
6114553|NCT00849056|9735510|FG000|Treatment Period (TP) (156 Weeks)|Withdrawal by Subject|31
6114554|NCT00849056|9735511|FG001|Treatment Period (TP) (156 Weeks)|Withdrawal by Subject|18
6209101|NCT01570361|9874442|FG001|Overall Study|Other|2
6209102|NCT01570387|9874455|FG000|Overall Study|Adverse Event|1
6209103|NCT01570387|9874456|FG001|Overall Study|Adverse Event|0
6209104|NCT01570387|9874457|FG002|Overall Study|Adverse Event|0
6209105|NCT01570387|9874458|FG003|Overall Study|Adverse Event|0
6209106|NCT01570387|9874455|FG000|Overall Study|Death|0
6209107|NCT01570387|9874456|FG001|Overall Study|Death|0
6209108|NCT01570387|9874457|FG002|Overall Study|Death|0
6209109|NCT01570387|9874458|FG003|Overall Study|Death|1
6209110|NCT01570387|9874455|FG000|Overall Study|Withdrawal by Subject|0
6209111|NCT01570387|9874456|FG001|Overall Study|Withdrawal by Subject|0
6209112|NCT01570387|9874457|FG002|Overall Study|Withdrawal by Subject|0
6209113|NCT01570387|9874458|FG003|Overall Study|Withdrawal by Subject|1
6209114|NCT01570491|9874467|FG000|Overall Study|Lost to Follow-up|3
6286466|NCT02346240|9999207|FG016|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|0
6286467|NCT02346240|9999208|FG017|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|0
6286468|NCT02346240|9999209|FG018|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|0
6286469|NCT02346240|9999210|FG019|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|0
6286470|NCT02346240|9999211|FG020|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|0
6286471|NCT02346240|9999212|FG021|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|0
6286472|NCT02346240|9999213|FG022|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|0
6286473|NCT02346240|9999214|FG023|Maintenance Period (Week 16 to Week 48)|Lost to Follow-up|0
6286474|NCT02346240|9999191|FG000|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|0
6286475|NCT02346240|9999192|FG001|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|0
6286476|NCT02346240|9999193|FG002|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|0
6286477|NCT02346240|9999194|FG003|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|0
6286478|NCT02346240|9999195|FG004|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|0
6286479|NCT02346240|9999196|FG005|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|1
6286480|NCT02346240|9999197|FG006|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|1
6286481|NCT02346240|9999198|FG007|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|1
6286482|NCT02346240|9999199|FG008|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|1
6286483|NCT02346240|9999200|FG009|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|0
6286484|NCT02346240|9999201|FG010|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|1
6286485|NCT02346240|9999202|FG011|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|2
6286486|NCT02346240|9999203|FG012|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|0
6209115|NCT01570491|9874468|FG001|Overall Study|Lost to Follow-up|1
6209116|NCT01570491|9874467|FG000|Overall Study|treatment: not given or discontinued|2
6209117|NCT01570491|9874468|FG001|Overall Study|treatment: not given or discontinued|0
6209118|NCT01570686|9874476|FG000|Overall Study|Abnormal test procedure result(s)|1
6209119|NCT01570686|9874477|FG001|Overall Study|Abnormal test procedure result(s)|1
6209120|NCT01570686|9874476|FG000|Overall Study|Administrative problems|0
6209121|NCT01570686|9874477|FG001|Overall Study|Administrative problems|1
6209122|NCT01570686|9874476|FG000|Overall Study|Adverse Event|8
6209123|NCT01570686|9874477|FG001|Overall Study|Adverse Event|6
6209124|NCT01570686|9874476|FG000|Overall Study|Lost to Follow-up|4
6209125|NCT01570686|9874477|FG001|Overall Study|Lost to Follow-up|3
6209126|NCT01570686|9874476|FG000|Overall Study|Protocol Deviation|3
6209127|NCT01570686|9874477|FG001|Overall Study|Protocol Deviation|0
6209128|NCT01570686|9874476|FG000|Overall Study|Withdrawal by Subject|4
6209129|NCT01570686|9874477|FG001|Overall Study|Withdrawal by Subject|4
6209130|NCT01570686|9874476|FG000|Overall Study|Unsatisfactory therapeutic effect|2
6209131|NCT01570686|9874477|FG001|Overall Study|Unsatisfactory therapeutic effect|1
6209132|NCT01570751|9874485|FG000|Period A (16 Weeks)|Protocol Violation|1
6209133|NCT01570751|9874486|FG001|Period A (16 Weeks)|Protocol Violation|1
6209134|NCT01570751|9874485|FG000|Period A (16 Weeks)|Withdrawal criteria|0
6209135|NCT01570751|9874486|FG001|Period A (16 Weeks)|Withdrawal criteria|1
6209136|NCT01570751|9874485|FG000|Period A (16 Weeks)|Unclassified|2
6209137|NCT01570751|9874486|FG001|Period A (16 Weeks)|Unclassified|3
6209138|NCT01570751|9874485|FG000|Period B (16 Weeks)|Adverse Event|1
6209139|NCT01570751|9874486|FG001|Period B (16 Weeks)|Adverse Event|0
6209140|NCT01570751|9874485|FG000|Period B (16 Weeks)|Protocol Violation|0
6209141|NCT01570751|9874486|FG001|Period B (16 Weeks)|Protocol Violation|1
6209142|NCT01570868|9874505|FG000|Overall Study|Adverse Event|8
6209143|NCT01570868|9874506|FG001|Overall Study|Adverse Event|1
6209144|NCT01570868|9874505|FG000|Overall Study|FDA Recommendation|23
6114555|NCT00849056|9735510|FG000|Treatment Period (TP) (156 Weeks)|Physician Decision|3
6114556|NCT00849056|9735511|FG001|Treatment Period (TP) (156 Weeks)|Physician Decision|3
6114557|NCT00849056|9735510|FG000|Treatment Period (TP) (156 Weeks)|Termination of Study/Site by GSK|1
6114558|NCT00849056|9735511|FG001|Treatment Period (TP) (156 Weeks)|Termination of Study/Site by GSK|4
6114559|NCT00849056|9735510|FG000|Treatment Period (TP) (156 Weeks)|Calcitonin Out of Range|1
6114560|NCT00849056|9735511|FG001|Treatment Period (TP) (156 Weeks)|Calcitonin Out of Range|0
6114561|NCT00849056|9735510|FG000|Treatment Period (TP) (156 Weeks)|Pregnancy|1
6114562|NCT00849056|9735511|FG001|Treatment Period (TP) (156 Weeks)|Pregnancy|0
6114563|NCT00849056|9735510|FG000|Follow-up Period (FUP) (8 Weeks)|Adverse Event|1
6114564|NCT00849056|9735511|FG001|Follow-up Period (FUP) (8 Weeks)|Adverse Event|3
6114565|NCT00849056|9735510|FG000|Follow-up Period (FUP) (8 Weeks)|Noncompliance|0
6114566|NCT00849056|9735511|FG001|Follow-up Period (FUP) (8 Weeks)|Noncompliance|1
6114567|NCT00849056|9735510|FG000|Follow-up Period (FUP) (8 Weeks)|Lost to Follow-up|14
6114568|NCT00849056|9735511|FG001|Follow-up Period (FUP) (8 Weeks)|Lost to Follow-up|9
6114569|NCT00849056|9735510|FG000|Follow-up Period (FUP) (8 Weeks)|Withdrawal by Subject|9
6114570|NCT00849056|9735511|FG001|Follow-up Period (FUP) (8 Weeks)|Withdrawal by Subject|7
6114571|NCT00849056|9735510|FG000|Follow-up Period (FUP) (8 Weeks)|Physician Decision|1
6114572|NCT00849056|9735511|FG001|Follow-up Period (FUP) (8 Weeks)|Physician Decision|1
6114573|NCT00849056|9735510|FG000|Follow-up Period (FUP) (8 Weeks)|Termination of Study/Site by GSK|1
6114574|NCT00849056|9735511|FG001|Follow-up Period (FUP) (8 Weeks)|Termination of Study/Site by GSK|4
6114575|NCT00849056|9735510|FG000|Follow-up Period (FUP) (8 Weeks)|Early Termination|1
6114576|NCT00849056|9735511|FG001|Follow-up Period (FUP) (8 Weeks)|Early Termination|0
6114577|NCT00849108|9735520|FG000|Cohort 1 Dose Ranging and Dose Interval|Withdrawal by Subject|1
6114578|NCT00849108|9735521|FG001|Cohort 1 Dose Ranging and Dose Interval|Withdrawal by Subject|0
6114579|NCT00849108|9735520|FG000|Cohort 2 Efficacy|Adverse Event|0
6114580|NCT00849108|9735521|FG001|Cohort 2 Efficacy|Adverse Event|1
6114581|NCT00849108|9735520|FG000|Cohort 2 Efficacy|Other|0
6114582|NCT00849108|9735521|FG001|Cohort 2 Efficacy|Other|9
6114583|NCT00849147|9735538|FG000|Overall Study|Withdrawal by Subject|1
6114584|NCT00849147|9735538|FG000|Overall Study|Protocol Violation|2
6114585|NCT00849147|9735538|FG000|Overall Study|Disease Relapse/Progression|2
6114586|NCT00849186|9735542|FG000|Overall Study|Adverse Event|2
6114587|NCT00849186|9735542|FG000|Overall Study|Withdrawal by Subject|1
6114588|NCT00849186|9735542|FG000|Overall Study|not treated|6
6114589|NCT00849186|9735542|FG000|Overall Study|Other|1
6114590|NCT00849212|9735547|FG000|Overall Study|Lack of Efficacy|1
6114591|NCT00849212|9735547|FG000|Overall Study|Withdrawal by Subject|3
6114592|NCT00849212|9735547|FG000|Overall Study|Adverse Event|2
6114593|NCT00849212|9735547|FG000|Overall Study|Miscellaneous|1
6114594|NCT00849290|9735558|FG000|Overall Study|Adverse Event|3
6114595|NCT00849290|9735558|FG000|Overall Study|Death|14
6114596|NCT00849290|9735558|FG000|Overall Study|Withdrawal by Subject|11
6209145|NCT01570868|9874506|FG001|Overall Study|FDA Recommendation|3
6209146|NCT01570868|9874505|FG000|Overall Study|Physician Decision|10
6209147|NCT01570868|9874506|FG001|Overall Study|Physician Decision|4
6209148|NCT01570868|9874505|FG000|Overall Study|Lost to Follow-up|1
6209149|NCT01570868|9874506|FG001|Overall Study|Lost to Follow-up|0
6209150|NCT01570868|9874505|FG000|Overall Study|Withdrawal by Subject|1
6209151|NCT01570868|9874506|FG001|Overall Study|Withdrawal by Subject|0
6209152|NCT01571232|9874518|FG000|Overall Study|Lost to Follow-up|0
6209153|NCT01571232|9874519|FG001|Overall Study|Lost to Follow-up|1
6209154|NCT01571232|9874518|FG000|Overall Study|Withdrawal by Subject|1
6209155|NCT01571232|9874519|FG001|Overall Study|Withdrawal by Subject|0
6209156|NCT01571284|9874526|FG000|Overall Study|Participant's decision|84
6209157|NCT01571284|9874526|FG000|Overall Study|Lost to Follow-up|3
6209158|NCT01571284|9874526|FG000|Overall Study|Enrolled but not treated|2
6209159|NCT01571284|9874526|FG000|Overall Study|Other than specified above|80
6209160|NCT01571362|9874530|FG000|Open-Label Conversion + Titration Period|Withdrawal by Subject|11
6209161|NCT01571362|9874531|FG001|Open-Label Conversion + Titration Period|Withdrawal by Subject|0
6209162|NCT01571362|9874532|FG002|Open-Label Conversion + Titration Period|Withdrawal by Subject|0
6209163|NCT01571362|9874530|FG000|Open-Label Conversion + Titration Period|Protocol Violation|7
6114597|NCT00849290|9735558|FG000|Overall Study|Lost to Follow-up|2
6114598|NCT00849290|9735558|FG000|Overall Study|Protocol Violation|5
6114599|NCT00849290|9735558|FG000|Overall Study|Disease Progression|20
6114600|NCT00849381|9735562|FG000|Overall Study|Adverse Event|1
6114601|NCT00849381|9735562|FG000|Overall Study|Lost to Follow-up|129
6114602|NCT00849381|9735562|FG000|Overall Study|Protocol Violation|5
6114603|NCT00849381|9735562|FG000|Overall Study|Withdrawal by Subject|6
6114604|NCT00849381|9735562|FG000|Overall Study|Other|4
6114605|NCT00849472|9735566|FG000|Doxorubicin and Cyclophosphamide (AC)|Disease Progression|2
6114606|NCT00849472|9735566|FG000|Doxorubicin and Cyclophosphamide (AC)|Adverse Event|1
6114607|NCT00849472|9735566|FG000|Doxorubicin and Cyclophosphamide (AC)|Withdrawal by Subject|1
6114608|NCT00849472|9735566|FG000|Doxorubicin and Cyclophosphamide (AC)|Physician Decision|1
6114609|NCT00849472|9735566|FG000|Doxorubicin and Cyclophosphamide (AC)|Participant Moved|1
6114610|NCT00849472|9735566|FG000|Weekly Paclitaxel|Disease Progression|1
6114611|NCT00849472|9735566|FG000|Weekly Paclitaxel|Adverse Event|11
6114612|NCT00849472|9735566|FG000|Weekly Paclitaxel|Withdrawal by Subject|1
6114613|NCT00849472|9735566|FG000|Weekly Paclitaxel|Physician Decision|3
6114614|NCT00849472|9735566|FG000|Pazopanib Presurgery Treatment (PPT)|Adverse Event|52
6114615|NCT00849472|9735566|FG000|Pazopanib Presurgery Treatment (PPT)|Withdrawal by Subject|4
6114616|NCT00849472|9735566|FG000|Pazopanib Presurgery Treatment (PPT)|Physician Decision|1
6114617|NCT00849472|9735566|FG000|Pazopanib Presurgery Treatment (PPT)|Never Started Pre-operative Pazopanib|1
6114618|NCT00849472|9735566|FG000|Pazopanib Postsurgery Treatment|Adverse Event|19
6114619|NCT00849472|9735566|FG000|Pazopanib Postsurgery Treatment|Withdrawal by Subject|5
6114620|NCT00849472|9735566|FG000|Pazopanib Postsurgery Treatment|Moved|1
6114621|NCT00849472|9735566|FG000|Pazopanib Postsurgery Treatment|Site Thought Treatment Was Completed|1
6114622|NCT00849680|9735579|FG000|Overall Study|Adverse Event|0
6114623|NCT00849680|9735580|FG001|Overall Study|Adverse Event|0
6114624|NCT00849680|9735581|FG002|Overall Study|Adverse Event|0
6114625|NCT00849680|9735582|FG003|Overall Study|Adverse Event|0
6114626|NCT00849680|9735583|FG004|Overall Study|Adverse Event|0
6114627|NCT00849680|9735584|FG005|Overall Study|Adverse Event|0
6114628|NCT00849680|9735585|FG006|Overall Study|Adverse Event|2
6114629|NCT00849680|9735586|FG007|Overall Study|Adverse Event|0
6114630|NCT00849680|9735579|FG000|Overall Study|Lost to Follow-up|7
6114631|NCT00849680|9735580|FG001|Overall Study|Lost to Follow-up|3
6114632|NCT00849680|9735581|FG002|Overall Study|Lost to Follow-up|12
6114633|NCT00849680|9735582|FG003|Overall Study|Lost to Follow-up|11
6114634|NCT00849680|9735583|FG004|Overall Study|Lost to Follow-up|8
6114635|NCT00849680|9735584|FG005|Overall Study|Lost to Follow-up|11
6114636|NCT00849680|9735585|FG006|Overall Study|Lost to Follow-up|12
6114637|NCT00849680|9735586|FG007|Overall Study|Lost to Follow-up|5
6114638|NCT00849680|9735579|FG000|Overall Study|Subject moved|1
6114639|NCT00849680|9735580|FG001|Overall Study|Subject moved|0
6114640|NCT00849680|9735581|FG002|Overall Study|Subject moved|3
6114641|NCT00849680|9735582|FG003|Overall Study|Subject moved|1
6114642|NCT00849680|9735583|FG004|Overall Study|Subject moved|0
6114643|NCT00849680|9735584|FG005|Overall Study|Subject moved|2
6114644|NCT00849680|9735585|FG006|Overall Study|Subject moved|2
6114645|NCT00849680|9735586|FG007|Overall Study|Subject moved|2
6114646|NCT00849680|9735579|FG000|Overall Study|Withdrawal by Subject|2
6114647|NCT00849680|9735580|FG001|Overall Study|Withdrawal by Subject|0
6114648|NCT00849680|9735581|FG002|Overall Study|Withdrawal by Subject|0
6114649|NCT00849680|9735582|FG003|Overall Study|Withdrawal by Subject|2
6114650|NCT00849680|9735583|FG004|Overall Study|Withdrawal by Subject|2
6114651|NCT00849680|9735584|FG005|Overall Study|Withdrawal by Subject|2
6114652|NCT00849680|9735585|FG006|Overall Study|Withdrawal by Subject|1
6114653|NCT00849680|9735586|FG007|Overall Study|Withdrawal by Subject|1
6114654|NCT00849680|9735579|FG000|Overall Study|Subject unable to comply with protocol|1
6114655|NCT00849680|9735580|FG001|Overall Study|Subject unable to comply with protocol|0
6114656|NCT00849680|9735581|FG002|Overall Study|Subject unable to comply with protocol|0
6114657|NCT00849680|9735582|FG003|Overall Study|Subject unable to comply with protocol|0
6114658|NCT00849680|9735583|FG004|Overall Study|Subject unable to comply with protocol|0
6114659|NCT00849680|9735584|FG005|Overall Study|Subject unable to comply with protocol|0
6114660|NCT00849680|9735585|FG006|Overall Study|Subject unable to comply with protocol|0
6114661|NCT00849680|9735586|FG007|Overall Study|Subject unable to comply with protocol|0
6114662|NCT00849693|9735608|FG000|Acute Treatment Phase|Adverse Event|12
6114663|NCT00849693|9735609|FG001|Acute Treatment Phase|Adverse Event|7
6114664|NCT00849693|9735610|FG002|Acute Treatment Phase|Adverse Event|6
6114665|NCT00849693|9735611|FG003|Acute Treatment Phase|Adverse Event|4
6114666|NCT00849693|9735608|FG000|Acute Treatment Phase|Lost to Follow-up|5
6114667|NCT00849693|9735609|FG001|Acute Treatment Phase|Lost to Follow-up|8
6114668|NCT00849693|9735610|FG002|Acute Treatment Phase|Lost to Follow-up|11
6114669|NCT00849693|9735611|FG003|Acute Treatment Phase|Lost to Follow-up|9
6114670|NCT00849693|9735608|FG000|Acute Treatment Phase|Protocol Violation|1
6114671|NCT00849693|9735609|FG001|Acute Treatment Phase|Protocol Violation|5
6114672|NCT00849693|9735610|FG002|Acute Treatment Phase|Protocol Violation|2
6114673|NCT00849693|9735611|FG003|Acute Treatment Phase|Protocol Violation|6
6114674|NCT00849693|9735608|FG000|Acute Treatment Phase|Withdrawal by Subject|5
6114675|NCT00849693|9735609|FG001|Acute Treatment Phase|Withdrawal by Subject|5
6114676|NCT00849693|9735610|FG002|Acute Treatment Phase|Withdrawal by Subject|3
6114677|NCT00849693|9735611|FG003|Acute Treatment Phase|Withdrawal by Subject|8
6114678|NCT00849693|9735608|FG000|Acute Treatment Phase|Parent or caregiver decision|7
6114679|NCT00849693|9735609|FG001|Acute Treatment Phase|Parent or caregiver decision|6
6114680|NCT00849693|9735610|FG002|Acute Treatment Phase|Parent or caregiver decision|7
6114681|NCT00849693|9735611|FG003|Acute Treatment Phase|Parent or caregiver decision|7
6114682|NCT00849693|9735608|FG000|Acute Treatment Phase|Physician Decision|2
6114683|NCT00849693|9735609|FG001|Acute Treatment Phase|Physician Decision|1
6114684|NCT00849693|9735610|FG002|Acute Treatment Phase|Physician Decision|2
6114685|NCT00849693|9735611|FG003|Acute Treatment Phase|Physician Decision|1
6114686|NCT00849693|9735608|FG000|Acute Treatment Phase|Sponsor decision|0
6114687|NCT00849693|9735609|FG001|Acute Treatment Phase|Sponsor decision|0
6114688|NCT00849693|9735610|FG002|Acute Treatment Phase|Sponsor decision|1
6114689|NCT00849693|9735611|FG003|Acute Treatment Phase|Sponsor decision|0
6114690|NCT00849693|9735608|FG000|Acute Treatment Phase|Lack of Efficacy|1
6114691|NCT00849693|9735609|FG001|Acute Treatment Phase|Lack of Efficacy|3
6114692|NCT00849693|9735610|FG002|Acute Treatment Phase|Lack of Efficacy|1
6114693|NCT00849693|9735611|FG003|Acute Treatment Phase|Lack of Efficacy|2
6114694|NCT00849693|9735608|FG000|Extension Phase|Adverse Event|4
6114695|NCT00849693|9735609|FG001|Extension Phase|Adverse Event|6
6114696|NCT00849693|9735610|FG002|Extension Phase|Adverse Event|3
6114697|NCT00849693|9735611|FG003|Extension Phase|Adverse Event|7
6114698|NCT00849693|9735608|FG000|Extension Phase|Lost to Follow-up|7
6114699|NCT00849693|9735609|FG001|Extension Phase|Lost to Follow-up|5
6114700|NCT00849693|9735610|FG002|Extension Phase|Lost to Follow-up|6
6114701|NCT00849693|9735611|FG003|Extension Phase|Lost to Follow-up|6
6114702|NCT00849693|9735608|FG000|Extension Phase|Protocol Violation|0
6114703|NCT00849693|9735609|FG001|Extension Phase|Protocol Violation|3
6114704|NCT00849693|9735610|FG002|Extension Phase|Protocol Violation|2
6114705|NCT00849693|9735611|FG003|Extension Phase|Protocol Violation|3
6114706|NCT00849693|9735608|FG000|Extension Phase|Withdrawal by Subject|6
6114707|NCT00849693|9735609|FG001|Extension Phase|Withdrawal by Subject|9
6114708|NCT00849693|9735610|FG002|Extension Phase|Withdrawal by Subject|10
6114709|NCT00849693|9735611|FG003|Extension Phase|Withdrawal by Subject|15
6114710|NCT00849693|9735608|FG000|Extension Phase|Parent or caregiver decision|9
6114711|NCT00849693|9735609|FG001|Extension Phase|Parent or caregiver decision|4
6114712|NCT00849693|9735610|FG002|Extension Phase|Parent or caregiver decision|10
6114713|NCT00849693|9735611|FG003|Extension Phase|Parent or caregiver decision|5
6114714|NCT00849693|9735608|FG000|Extension Phase|Physician Decision|1
6114715|NCT00849693|9735609|FG001|Extension Phase|Physician Decision|1
6114716|NCT00849693|9735610|FG002|Extension Phase|Physician Decision|2
6114717|NCT00849693|9735611|FG003|Extension Phase|Physician Decision|0
6114718|NCT00849693|9735608|FG000|Extension Phase|Sponsor decision|1
6114719|NCT00849693|9735609|FG001|Extension Phase|Sponsor decision|0
6209164|NCT01571362|9874531|FG001|Open-Label Conversion + Titration Period|Protocol Violation|0
6209165|NCT01571362|9874532|FG002|Open-Label Conversion + Titration Period|Protocol Violation|0
6209166|NCT01571362|9874530|FG000|Open-Label Conversion + Titration Period|Adverse Event|57
6209167|NCT01571362|9874531|FG001|Open-Label Conversion + Titration Period|Adverse Event|0
6209168|NCT01571362|9874532|FG002|Open-Label Conversion + Titration Period|Adverse Event|0
6209169|NCT01571362|9874530|FG000|Open-Label Conversion + Titration Period|Lost to Follow-up|10
6209170|NCT01571362|9874531|FG001|Open-Label Conversion + Titration Period|Lost to Follow-up|0
6209171|NCT01571362|9874532|FG002|Open-Label Conversion + Titration Period|Lost to Follow-up|0
6209172|NCT01571362|9874530|FG000|Open-Label Conversion + Titration Period|Does not meet entrance criteria|41
6209173|NCT01571362|9874531|FG001|Open-Label Conversion + Titration Period|Does not meet entrance criteria|0
6209174|NCT01571362|9874532|FG002|Open-Label Conversion + Titration Period|Does not meet entrance criteria|0
6209175|NCT01571362|9874530|FG000|Open-Label Conversion + Titration Period|Other - unspecified|3
6209176|NCT01571362|9874531|FG001|Open-Label Conversion + Titration Period|Other - unspecified|0
6209177|NCT01571362|9874532|FG002|Open-Label Conversion + Titration Period|Other - unspecified|0
6209178|NCT01571362|9874530|FG000|Double-Blind Treatment Period|Withdrawal by Subject|0
6209179|NCT01571362|9874531|FG001|Double-Blind Treatment Period|Withdrawal by Subject|11
6209180|NCT01571362|9874532|FG002|Double-Blind Treatment Period|Withdrawal by Subject|5
6209181|NCT01571362|9874530|FG000|Double-Blind Treatment Period|Protocol Violation|0
6209182|NCT01571362|9874531|FG001|Double-Blind Treatment Period|Protocol Violation|8
6209183|NCT01571362|9874532|FG002|Double-Blind Treatment Period|Protocol Violation|9
6209184|NCT01571362|9874530|FG000|Double-Blind Treatment Period|Adverse Event|0
6209185|NCT01571362|9874531|FG001|Double-Blind Treatment Period|Adverse Event|9
6209186|NCT01571362|9874532|FG002|Double-Blind Treatment Period|Adverse Event|14
6209187|NCT01571362|9874530|FG000|Double-Blind Treatment Period|Lost to Follow-up|0
6209188|NCT01571362|9874531|FG001|Double-Blind Treatment Period|Lost to Follow-up|3
6209189|NCT01571362|9874532|FG002|Double-Blind Treatment Period|Lost to Follow-up|6
6209190|NCT01571362|9874530|FG000|Double-Blind Treatment Period|Insufficient clinical response|0
6209191|NCT01571362|9874531|FG001|Double-Blind Treatment Period|Insufficient clinical response|16
6209192|NCT01571362|9874532|FG002|Double-Blind Treatment Period|Insufficient clinical response|4
6209193|NCT01571362|9874530|FG000|Double-Blind Treatment Period|Other - unspecified|0
6209194|NCT01571362|9874531|FG001|Double-Blind Treatment Period|Other - unspecified|6
6209195|NCT01571362|9874532|FG002|Double-Blind Treatment Period|Other - unspecified|1
6209196|NCT01571453|9874551|FG000|Overall Study|Adverse Event|14
6209197|NCT01571453|9874552|FG001|Overall Study|Adverse Event|32
6209198|NCT01571453|9874551|FG000|Overall Study|Lack of Efficacy|8
6209199|NCT01571453|9874552|FG001|Overall Study|Lack of Efficacy|3
6209200|NCT01571453|9874551|FG000|Overall Study|Non-compliance|2
6209201|NCT01571453|9874552|FG001|Overall Study|Non-compliance|4
6209202|NCT01571453|9874551|FG000|Overall Study|Protocol Violation|1
6209203|NCT01571453|9874552|FG001|Overall Study|Protocol Violation|5
6209204|NCT01571453|9874551|FG000|Overall Study|Withdrawal of consent|5
6209205|NCT01571453|9874552|FG001|Overall Study|Withdrawal of consent|13
6114720|NCT00849693|9735610|FG002|Extension Phase|Sponsor decision|0
6114721|NCT00849693|9735611|FG003|Extension Phase|Sponsor decision|1
6114722|NCT00849693|9735608|FG000|Extension Phase|Lack of Efficacy|2
6114723|NCT00849693|9735609|FG001|Extension Phase|Lack of Efficacy|2
6114724|NCT00849693|9735610|FG002|Extension Phase|Lack of Efficacy|2
6114725|NCT00849693|9735611|FG003|Extension Phase|Lack of Efficacy|1
6114726|NCT00849875|9735640|FG000|Overall Study|Death|28
6114727|NCT00849875|9735640|FG000|Overall Study|Ongoing (unknown completion status)|11
6114728|NCT00849875|9735640|FG000|Overall Study|Others|6
6114729|NCT00849875|9735640|FG000|Overall Study|Lost to Follow-up|2
6114730|NCT00849901|9735654|FG000|Acute Treatment Phase|Adverse Event|9
6114731|NCT00849901|9735655|FG001|Acute Treatment Phase|Adverse Event|1
6114732|NCT00849901|9735656|FG002|Acute Treatment Phase|Adverse Event|3
6114733|NCT00849901|9735654|FG000|Acute Treatment Phase|Lost to Follow-up|2
6114734|NCT00849901|9735655|FG001|Acute Treatment Phase|Lost to Follow-up|4
6114735|NCT00849901|9735656|FG002|Acute Treatment Phase|Lost to Follow-up|1
6114736|NCT00849901|9735654|FG000|Acute Treatment Phase|Protocol Violation|0
6114737|NCT00849901|9735655|FG001|Acute Treatment Phase|Protocol Violation|2
6114738|NCT00849901|9735656|FG002|Acute Treatment Phase|Protocol Violation|1
6114739|NCT00849901|9735654|FG000|Acute Treatment Phase|Withdrawal by Subject|4
6114740|NCT00849901|9735655|FG001|Acute Treatment Phase|Withdrawal by Subject|10
6114741|NCT00849901|9735656|FG002|Acute Treatment Phase|Withdrawal by Subject|4
6114742|NCT00849901|9735654|FG000|Acute Treatment Phase|Parent or Caregiver Decision|11
6114743|NCT00849901|9735655|FG001|Acute Treatment Phase|Parent or Caregiver Decision|5
6114744|NCT00849901|9735656|FG002|Acute Treatment Phase|Parent or Caregiver Decision|4
6114745|NCT00849901|9735654|FG000|Acute Treatment Phase|Physician Decision|1
6114746|NCT00849901|9735655|FG001|Acute Treatment Phase|Physician Decision|1
6114747|NCT00849901|9735656|FG002|Acute Treatment Phase|Physician Decision|1
6114748|NCT00849901|9735654|FG000|Acute Treatment Phase|Sponsor Decision|1
6114749|NCT00849901|9735655|FG001|Acute Treatment Phase|Sponsor Decision|0
6114750|NCT00849901|9735656|FG002|Acute Treatment Phase|Sponsor Decision|0
6114751|NCT00849901|9735654|FG000|Acute Treatment Phase|Lack of Efficacy|2
6114752|NCT00849901|9735655|FG001|Acute Treatment Phase|Lack of Efficacy|3
6114753|NCT00849901|9735656|FG002|Acute Treatment Phase|Lack of Efficacy|2
6114754|NCT00849901|9735654|FG000|Extension Phase|Adverse Event|2
6114755|NCT00849901|9735655|FG001|Extension Phase|Adverse Event|8
6114756|NCT00849901|9735656|FG002|Extension Phase|Adverse Event|4
6114757|NCT00849901|9735654|FG000|Extension Phase|Lost to Follow-up|3
6114758|NCT00849901|9735655|FG001|Extension Phase|Lost to Follow-up|0
6114759|NCT00849901|9735656|FG002|Extension Phase|Lost to Follow-up|1
6114760|NCT00849901|9735654|FG000|Extension Phase|Protocol Violation|2
6114761|NCT00849901|9735655|FG001|Extension Phase|Protocol Violation|2
6114762|NCT00849901|9735656|FG002|Extension Phase|Protocol Violation|4
6114763|NCT00849901|9735654|FG000|Extension Phase|Withdrawal by Subject|7
6114764|NCT00849901|9735655|FG001|Extension Phase|Withdrawal by Subject|6
6114765|NCT00849901|9735656|FG002|Extension Phase|Withdrawal by Subject|3
6114766|NCT00849901|9735654|FG000|Extension Phase|Parent or Caregiver Decision|10
6114767|NCT00849901|9735655|FG001|Extension Phase|Parent or Caregiver Decision|4
6114768|NCT00849901|9735656|FG002|Extension Phase|Parent or Caregiver Decision|4
6114769|NCT00849901|9735654|FG000|Extension Phase|Physician Decision|1
6114770|NCT00849901|9735655|FG001|Extension Phase|Physician Decision|2
6114771|NCT00849901|9735656|FG002|Extension Phase|Physician Decision|0
6114772|NCT00849901|9735654|FG000|Extension Phase|Lack of Efficacy|2
6114773|NCT00849901|9735655|FG001|Extension Phase|Lack of Efficacy|4
6114774|NCT00849901|9735656|FG002|Extension Phase|Lack of Efficacy|1
6114775|NCT00849940|9735670|FG000|Overall Study|Physician Decision|4
6114776|NCT00850070|9735680|FG000|Overall Study|Lack of Efficacy|1
6114777|NCT00850070|9735681|FG001|Overall Study|Lack of Efficacy|1
6114778|NCT00850070|9735680|FG000|Overall Study|Adverse Event|2
6114779|NCT00850070|9735681|FG001|Overall Study|Adverse Event|0
6114780|NCT00850135|9735701|FG000|Overall Study|Physician Decision|1
6114781|NCT00850200|9735707|FG000|Overall Study|Physician Decision|2
6114782|NCT00850200|9735707|FG000|Overall Study|Did not recieve treatment|2
6114783|NCT00850200|9735707|FG000|Overall Study|Withdrawal by Subject|1
6114784|NCT00850343|9735718|FG000|Overall Study|Withdrawal by Subject|11
6114785|NCT00850343|9735719|FG001|Overall Study|Withdrawal by Subject|0
6114786|NCT00850343|9735720|FG002|Overall Study|Withdrawal by Subject|3
6114787|NCT00850343|9735721|FG003|Overall Study|Withdrawal by Subject|2
6114788|NCT00850343|9735718|FG000|Overall Study|Adverse Event|15
6114789|NCT00850343|9735719|FG001|Overall Study|Adverse Event|2
6114790|NCT00850343|9735720|FG002|Overall Study|Adverse Event|6
6114791|NCT00850343|9735721|FG003|Overall Study|Adverse Event|6
6114792|NCT00850343|9735718|FG000|Overall Study|Pregnancy|0
6114793|NCT00850343|9735719|FG001|Overall Study|Pregnancy|0
6114794|NCT00850343|9735720|FG002|Overall Study|Pregnancy|0
6114795|NCT00850343|9735721|FG003|Overall Study|Pregnancy|1
6209206|NCT01571453|9874551|FG000|Overall Study|Lost to Follow-up|4
6209207|NCT01571453|9874552|FG001|Overall Study|Lost to Follow-up|2
6209208|NCT01571453|9874551|FG000|Overall Study|Administrative or other reason(s)|4
6114796|NCT00850343|9735718|FG000|Overall Study|Lack of Efficacy|17
6114797|NCT00850343|9735719|FG001|Overall Study|Lack of Efficacy|0
6209209|NCT01571453|9874552|FG001|Overall Study|Administrative or other reason(s)|3
6209210|NCT01571596|9874565|FG000|Overall Study|Adverse Event|2
6114798|NCT00850343|9735720|FG002|Overall Study|Lack of Efficacy|3
6114799|NCT00850343|9735721|FG003|Overall Study|Lack of Efficacy|2
6114800|NCT00850343|9735718|FG000|Overall Study|Non-compliance with Study Procedures|1
6114801|NCT00850343|9735719|FG001|Overall Study|Non-compliance with Study Procedures|0
6114802|NCT00850343|9735720|FG002|Overall Study|Non-compliance with Study Procedures|1
6209211|NCT01571596|9874566|FG001|Overall Study|Adverse Event|0
6114803|NCT00850343|9735721|FG003|Overall Study|Non-compliance with Study Procedures|1
6114804|NCT00850343|9735718|FG000|Overall Study|Physician Decision|2
6114805|NCT00850343|9735719|FG001|Overall Study|Physician Decision|1
6114806|NCT00850343|9735720|FG002|Overall Study|Physician Decision|1
6114807|NCT00850343|9735721|FG003|Overall Study|Physician Decision|1
6209212|NCT01571596|9874567|FG002|Overall Study|Adverse Event|0
6209213|NCT01571596|9874565|FG000|Overall Study|Study Terminated by the Sponsor|0
6209214|NCT01571596|9874566|FG001|Overall Study|Study Terminated by the Sponsor|1
6209215|NCT01571596|9874567|FG002|Overall Study|Study Terminated by the Sponsor|1
6209216|NCT01572038|9874577|FG000|Overall Study|Death|648
6209217|NCT01572038|9874577|FG000|Overall Study|Withdrawal by Subject|204
6209218|NCT01572038|9874577|FG000|Overall Study|Lost to Follow-up|81
6209219|NCT01572038|9874577|FG000|Overall Study|Physician Decision|20
6209220|NCT01572038|9874577|FG000|Overall Study|Patient Decision|14
6209221|NCT01572038|9874577|FG000|Overall Study|Progressive Disease|8
6209222|NCT01572038|9874577|FG000|Overall Study|Site Closed Before Completing Form|6
6209223|NCT01572038|9874577|FG000|Overall Study|Enrolled into Another Trial|3
6209224|NCT01572038|9874577|FG000|Overall Study|Participated in Another Trial|3
6209225|NCT01572038|9874577|FG000|Overall Study|Termination by Sponsor|2
6209226|NCT01572038|9874577|FG000|Overall Study|Patient Deterioration|1
6209227|NCT01572038|9874577|FG000|Overall Study|Sponsor Decision|1
6209228|NCT01572389|9874616|FG000|Overall Study|Death|1
6209229|NCT01572389|9874617|FG001|Overall Study|Death|3
6209230|NCT01572389|9874616|FG000|Overall Study|Withdrawal by Subject|14
6209231|NCT01572389|9874617|FG001|Overall Study|Withdrawal by Subject|2
6209232|NCT01572389|9874616|FG000|Overall Study|Lost to Follow-up|25
6209233|NCT01572389|9874617|FG001|Overall Study|Lost to Follow-up|14
6209234|NCT01572389|9874616|FG000|Overall Study|Only A1C or Assessment was Collected|6
6209235|NCT01572389|9874617|FG001|Overall Study|Only A1C or Assessment was Collected|2
6209236|NCT01572727|9874634|FG000|Overall Study|Adverse Event|43
6209237|NCT01572727|9874635|FG001|Overall Study|Adverse Event|15
6209238|NCT01572727|9874634|FG000|Overall Study|Lost to Follow-up|1
6209239|NCT01572727|9874635|FG001|Overall Study|Lost to Follow-up|1
6209240|NCT01572727|9874634|FG000|Overall Study|Physician Decision|23
6209241|NCT01572727|9874635|FG001|Overall Study|Physician Decision|9
6209242|NCT01572727|9874634|FG000|Overall Study|Progressive disease|59
6286487|NCT02346240|9999204|FG013|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|2
6286488|NCT02346240|9999205|FG014|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|5
6286489|NCT02346240|9999206|FG015|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|2
6286490|NCT02346240|9999207|FG016|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|1
6286491|NCT02346240|9999208|FG017|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|0
6286492|NCT02346240|9999209|FG018|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|0
6286493|NCT02346240|9999210|FG019|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|0
6286494|NCT02346240|9999211|FG020|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|0
6286495|NCT02346240|9999212|FG021|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|0
6286496|NCT02346240|9999213|FG022|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|0
6286497|NCT02346240|9999214|FG023|Maintenance Period (Week 16 to Week 48)|Withdrawal by Subject|0
6286498|NCT02346240|9999191|FG000|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50|0
6286499|NCT02346240|9999192|FG001|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50|0
6286500|NCT02346240|9999193|FG002|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50|0
6286501|NCT02346240|9999194|FG003|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50|0
6286502|NCT02346240|9999195|FG004|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50|0
6286503|NCT02346240|9999196|FG005|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50|0
6286504|NCT02346240|9999197|FG006|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50|0
6286505|NCT02346240|9999198|FG007|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50|0
6286506|NCT02346240|9999199|FG008|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50|0
6286507|NCT02346240|9999200|FG009|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50|0
6286508|NCT02346240|9999201|FG010|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50|0
6286509|NCT02346240|9999202|FG011|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50|0
6286510|NCT02346240|9999203|FG012|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50|0
6286511|NCT02346240|9999204|FG013|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50|3
6286512|NCT02346240|9999205|FG014|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50|3
6286513|NCT02346240|9999206|FG015|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50|8
6286514|NCT02346240|9999207|FG016|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50|4
6209243|NCT01572727|9874635|FG001|Overall Study|Progressive disease|82
6209244|NCT01572727|9874634|FG000|Overall Study|Protocol Violation|0
6209245|NCT01572727|9874635|FG001|Overall Study|Protocol Violation|1
6209246|NCT01572727|9874634|FG000|Overall Study|Study terminated by sponsor|61
6209247|NCT01572727|9874635|FG001|Overall Study|Study terminated by sponsor|83
6209248|NCT01572727|9874634|FG000|Overall Study|Parent/guardian decision|14
6209249|NCT01572727|9874635|FG001|Overall Study|Parent/guardian decision|9
6209250|NCT01572727|9874634|FG000|Overall Study|Death|2
6209251|NCT01572727|9874635|FG001|Overall Study|Death|2
6209252|NCT01572727|9874634|FG000|Overall Study|Untreated|4
6209253|NCT01572727|9874635|FG001|Overall Study|Untreated|7
6209254|NCT01572740|9874643|FG000|Overall Study|Adverse Event|1
6114808|NCT00850395|9735731|FG000|Overall Study|Death|1
6114809|NCT00850395|9735731|FG000|Overall Study|Adverse Event|1
6114810|NCT00850395|9735731|FG000|Overall Study|Insufficient clinical response|3
6114811|NCT00850395|9735731|FG000|Overall Study|Other|5
6114812|NCT00850460|9735737|FG000|Overall Study|Lost to Follow-up|4
6114813|NCT00850460|9735738|FG001|Overall Study|Lost to Follow-up|4
6114814|NCT00850499|9735750|FG000|Overall Study|Adverse Event|3
6114815|NCT00850499|9735751|FG001|Overall Study|Adverse Event|1
6114816|NCT00850499|9735750|FG000|Overall Study|Lack of Efficacy|0
6114817|NCT00850499|9735751|FG001|Overall Study|Lack of Efficacy|1
6114818|NCT00850538|9735757|FG000|Overall Study|unable/unwilling to complete MRI|13
6114819|NCT00850538|9735757|FG000|Overall Study|specimen missed due to scheduling error|14
6114820|NCT00850538|9735757|FG000|Overall Study|specimen unusable|7
6114821|NCT00850538|9735757|FG000|Overall Study|Withdrawal by Subject|3
6114822|NCT00850538|9735757|FG000|Overall Study|radiology error|2
6114823|NCT00850538|9735757|FG000|Overall Study|Protocol Violation|2
6114824|NCT00850564|9735761|FG000|Overall Study|Withdrawal by Subject|2
6114825|NCT00850759|9735804|FG000|Overall Study|Lost to Follow-up|7
6114826|NCT00850759|9735805|FG001|Overall Study|Lost to Follow-up|5
6114827|NCT00850759|9735806|FG002|Overall Study|Lost to Follow-up|5
6114828|NCT00850759|9735807|FG003|Overall Study|Lost to Follow-up|3
6114829|NCT00850993|9735828|FG000|Overall Study|Parent/Guardian Voluntarily Withdrew|1
6114830|NCT00850993|9735829|FG001|Overall Study|Parent/Guardian Voluntarily Withdrew|0
6114831|NCT00850993|9735830|FG002|Overall Study|Parent/Guardian Voluntarily Withdrew|0
6114832|NCT00850993|9735831|FG003|Overall Study|Parent/Guardian Voluntarily Withdrew|1
6114833|NCT00851084|9735851|FG000|Overall Study|Randomized but not treated|1
6114834|NCT00851084|9735852|FG001|Overall Study|Randomized but not treated|0
6114835|NCT00851084|9735851|FG000|Overall Study|Adverse Event|26
6114836|NCT00851084|9735852|FG001|Overall Study|Adverse Event|36
6114837|NCT00851084|9735851|FG000|Overall Study|Disease progression|52
6114838|NCT00851084|9735852|FG001|Overall Study|Disease progression|47
6114839|NCT00851084|9735851|FG000|Overall Study|Poor compliance to protocol|1
6114840|NCT00851084|9735852|FG001|Overall Study|Poor compliance to protocol|1
6114841|NCT00851084|9735851|FG000|Overall Study|Physician Decision|13
6114842|NCT00851084|9735852|FG001|Overall Study|Physician Decision|14
6114843|NCT00851084|9735851|FG000|Overall Study|Consent withdrawn|0
6114844|NCT00851084|9735852|FG001|Overall Study|Consent withdrawn|2
6114845|NCT00851084|9735851|FG000|Overall Study|Withdrawal by Subject|11
6114846|NCT00851084|9735852|FG001|Overall Study|Withdrawal by Subject|12
6114847|NCT00851084|9735851|FG000|Overall Study|Metastatic surgery|6
6114848|NCT00851084|9735852|FG001|Overall Study|Metastatic surgery|6
6114849|NCT00851084|9735851|FG000|Overall Study|Other|7
6114850|NCT00851084|9735852|FG001|Overall Study|Other|1
6114851|NCT00851253|9735862|FG000|Overall Study|Disease Progression|1
6114852|NCT00851253|9735863|FG001|Overall Study|Disease Progression|0
6114853|NCT00851318|9735877|FG000|Overall Study|Withdrawal by Subject|7
6114854|NCT00851318|9735878|FG001|Overall Study|Withdrawal by Subject|1
6114855|NCT00851318|9735879|FG002|Overall Study|Withdrawal by Subject|5
6114856|NCT00851318|9735880|FG003|Overall Study|Withdrawal by Subject|3
6114857|NCT00851318|9735877|FG000|Overall Study|Adverse Event|13
6114858|NCT00851318|9735878|FG001|Overall Study|Adverse Event|2
6114859|NCT00851318|9735879|FG002|Overall Study|Adverse Event|9
6114860|NCT00851318|9735880|FG003|Overall Study|Adverse Event|12
6114861|NCT00851318|9735877|FG000|Overall Study|Pregnancy|0
6114862|NCT00851318|9735878|FG001|Overall Study|Pregnancy|0
6114863|NCT00851318|9735879|FG002|Overall Study|Pregnancy|1
6114864|NCT00851318|9735880|FG003|Overall Study|Pregnancy|1
6114865|NCT00851318|9735877|FG000|Overall Study|Lack of Efficacy|8
6114866|NCT00851318|9735878|FG001|Overall Study|Lack of Efficacy|2
6114867|NCT00851318|9735879|FG002|Overall Study|Lack of Efficacy|4
6114868|NCT00851318|9735880|FG003|Overall Study|Lack of Efficacy|2
6114869|NCT00851318|9735877|FG000|Overall Study|Non-compliance with Study Procedures|2
6114870|NCT00851318|9735878|FG001|Overall Study|Non-compliance with Study Procedures|0
6114871|NCT00851318|9735879|FG002|Overall Study|Non-compliance with Study Procedures|1
6114872|NCT00851318|9735880|FG003|Overall Study|Non-compliance with Study Procedures|0
6114873|NCT00851318|9735877|FG000|Overall Study|Physician Decision|0
6114874|NCT00851318|9735878|FG001|Overall Study|Physician Decision|0
6114875|NCT00851318|9735879|FG002|Overall Study|Physician Decision|1
6114876|NCT00851318|9735880|FG003|Overall Study|Physician Decision|1
6114877|NCT00851630|9735910|FG000|Overall Study|Death|2
6114878|NCT00851630|9735911|FG001|Overall Study|Death|1
6114879|NCT00851630|9735910|FG000|Overall Study|Clinical failure|0
6114880|NCT00851630|9735911|FG001|Overall Study|Clinical failure|1
6114881|NCT00851643|9735923|FG000|Base Study (Up to 12 Months)|Withdrawal by Subject|1
6114882|NCT00851643|9735924|FG001|Base Study (Up to 12 Months)|Withdrawal by Subject|0
6114883|NCT00851643|9735925|FG002|Base Study (Up to 12 Months)|Withdrawal by Subject|0
6114884|NCT00851643|9735926|FG003|Base Study (Up to 12 Months)|Withdrawal by Subject|0
6114885|NCT00851643|9735927|FG004|Base Study (Up to 12 Months)|Withdrawal by Subject|0
6114886|NCT00851643|9735928|FG005|Base Study (Up to 12 Months)|Withdrawal by Subject|0
6114887|NCT00851643|9735923|FG000|Base Study (Up to 12 Months)|Other|0
6114888|NCT00851643|9735924|FG001|Base Study (Up to 12 Months)|Other|0
6114889|NCT00851643|9735925|FG002|Base Study (Up to 12 Months)|Other|0
6114890|NCT00851643|9735926|FG003|Base Study (Up to 12 Months)|Other|0
6114891|NCT00851643|9735927|FG004|Base Study (Up to 12 Months)|Other|0
6114892|NCT00851643|9735928|FG005|Base Study (Up to 12 Months)|Other|1
6114893|NCT00851643|9735923|FG000|Extension Study (Up to 36 Months)|Lost to Follow-up|4
6114894|NCT00851643|9735924|FG001|Extension Study (Up to 36 Months)|Lost to Follow-up|2
6114895|NCT00851643|9735925|FG002|Extension Study (Up to 36 Months)|Lost to Follow-up|4
6114896|NCT00851643|9735926|FG003|Extension Study (Up to 36 Months)|Lost to Follow-up|1
6114897|NCT00851643|9735927|FG004|Extension Study (Up to 36 Months)|Lost to Follow-up|2
6114898|NCT00851643|9735928|FG005|Extension Study (Up to 36 Months)|Lost to Follow-up|0
6114899|NCT00851643|9735923|FG000|Extension Study (Up to 36 Months)|Moved|0
6114900|NCT00851643|9735924|FG001|Extension Study (Up to 36 Months)|Moved|2
6114901|NCT00851643|9735925|FG002|Extension Study (Up to 36 Months)|Moved|1
6114902|NCT00851643|9735926|FG003|Extension Study (Up to 36 Months)|Moved|1
6114903|NCT00851643|9735927|FG004|Extension Study (Up to 36 Months)|Moved|0
6114904|NCT00851643|9735928|FG005|Extension Study (Up to 36 Months)|Moved|1
6114905|NCT00851721|9735943|FG000|Overall Study|planned surgery|1
6114906|NCT00851721|9735944|FG001|Overall Study|planned surgery|0
6114907|NCT00851721|9735943|FG000|Overall Study|Death|1
6114908|NCT00851721|9735944|FG001|Overall Study|Death|0
6114909|NCT00851721|9735943|FG000|Overall Study|Adverse Event|0
6114910|NCT00851721|9735944|FG001|Overall Study|Adverse Event|1
6114911|NCT00851786|9735958|FG000|Overall Study|Withdrawal by Subject|0
6114912|NCT00851786|9735959|FG001|Overall Study|Withdrawal by Subject|1
6114913|NCT00851786|9735958|FG000|Overall Study|Protocol Violation|0
6114914|NCT00851786|9735959|FG001|Overall Study|Protocol Violation|1
6114915|NCT00851786|9735958|FG000|Overall Study|Lost to Follow-up|1
6114916|NCT00851786|9735959|FG001|Overall Study|Lost to Follow-up|0
6114917|NCT00851786|9735958|FG000|Overall Study|Incarceration|1
6114918|NCT00851786|9735959|FG001|Overall Study|Incarceration|0
6114919|NCT00851786|9735958|FG000|Overall Study|Site Closure|1
6114920|NCT00851786|9735959|FG001|Overall Study|Site Closure|0
6209255|NCT01572740|9874644|FG001|Overall Study|Adverse Event|1
6209256|NCT01572740|9874643|FG000|Overall Study|Withdrawal by Subject|1
6209257|NCT01572740|9874644|FG001|Overall Study|Withdrawal by Subject|1
6209258|NCT01572740|9874643|FG000|Overall Study|unclassified|4
6286515|NCT02346240|9999208|FG017|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50|0
6286516|NCT02346240|9999209|FG018|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50|0
6286517|NCT02346240|9999210|FG019|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50|0
6286518|NCT02346240|9999211|FG020|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50|0
6286519|NCT02346240|9999212|FG021|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50|0
6286520|NCT02346240|9999213|FG022|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50|0
6286521|NCT02346240|9999214|FG023|Maintenance Period (Week 16 to Week 48)|Did not achieve PASI50|0
6286522|NCT02346240|9999191|FG000|Maintenance Period (Week 16 to Week 48)|Moved out of state|0
6286523|NCT02346240|9999192|FG001|Maintenance Period (Week 16 to Week 48)|Moved out of state|0
6286524|NCT02346240|9999193|FG002|Maintenance Period (Week 16 to Week 48)|Moved out of state|0
6286525|NCT02346240|9999194|FG003|Maintenance Period (Week 16 to Week 48)|Moved out of state|0
6286526|NCT02346240|9999195|FG004|Maintenance Period (Week 16 to Week 48)|Moved out of state|0
6286527|NCT02346240|9999196|FG005|Maintenance Period (Week 16 to Week 48)|Moved out of state|0
6286528|NCT02346240|9999197|FG006|Maintenance Period (Week 16 to Week 48)|Moved out of state|1
6286529|NCT02346240|9999198|FG007|Maintenance Period (Week 16 to Week 48)|Moved out of state|0
6286530|NCT02346240|9999199|FG008|Maintenance Period (Week 16 to Week 48)|Moved out of state|0
6286531|NCT02346240|9999200|FG009|Maintenance Period (Week 16 to Week 48)|Moved out of state|0
6286532|NCT02346240|9999201|FG010|Maintenance Period (Week 16 to Week 48)|Moved out of state|0
6286533|NCT02346240|9999202|FG011|Maintenance Period (Week 16 to Week 48)|Moved out of state|0
6286534|NCT02346240|9999203|FG012|Maintenance Period (Week 16 to Week 48)|Moved out of state|0
6286535|NCT02346240|9999204|FG013|Maintenance Period (Week 16 to Week 48)|Moved out of state|0
6286536|NCT02346240|9999205|FG014|Maintenance Period (Week 16 to Week 48)|Moved out of state|0
6286537|NCT02346240|9999206|FG015|Maintenance Period (Week 16 to Week 48)|Moved out of state|0
6286538|NCT02346240|9999207|FG016|Maintenance Period (Week 16 to Week 48)|Moved out of state|0
6286539|NCT02346240|9999208|FG017|Maintenance Period (Week 16 to Week 48)|Moved out of state|0
6286540|NCT02346240|9999209|FG018|Maintenance Period (Week 16 to Week 48)|Moved out of state|0
6286541|NCT02346240|9999210|FG019|Maintenance Period (Week 16 to Week 48)|Moved out of state|0
6286542|NCT02346240|9999211|FG020|Maintenance Period (Week 16 to Week 48)|Moved out of state|0
6286543|NCT02346240|9999212|FG021|Maintenance Period (Week 16 to Week 48)|Moved out of state|0
6209259|NCT01572740|9874644|FG001|Overall Study|unclassified|3
6209260|NCT01572792|9874655|FG000|Lead-in Study|Lost to Follow-up|5
6209261|NCT01572792|9874656|FG001|Lead-in Study|Lost to Follow-up|9
6209262|NCT01572792|9874657|FG002|Lead-in Study|Lost to Follow-up|4
6209263|NCT01572792|9874658|FG003|Lead-in Study|Lost to Follow-up|2
6209264|NCT01572792|9874659|FG004|Lead-in Study|Lost to Follow-up|4
6209265|NCT01572792|9874655|FG000|Lead-in Study|Withdrawal by Subject|22
6114921|NCT00851786|9735958|FG000|Overall Study|Cannot Adhere to Protocol Requirement|2
6114922|NCT00851786|9735959|FG001|Overall Study|Cannot Adhere to Protocol Requirement|0
6114923|NCT00851799|9735968|FG000|Overall Study|Death|1
6114924|NCT00851799|9735969|FG001|Overall Study|Death|0
6114925|NCT00851799|9735970|FG002|Overall Study|Death|1
6114926|NCT00851799|9735968|FG000|Overall Study|Lost to Follow-up|5
6114927|NCT00851799|9735969|FG001|Overall Study|Lost to Follow-up|3
6114928|NCT00851799|9735970|FG002|Overall Study|Lost to Follow-up|10
6114929|NCT00851799|9735968|FG000|Overall Study|Not able to get to clinic|8
6114930|NCT00851799|9735969|FG001|Overall Study|Not able to get to clinic|5
6114931|NCT00851799|9735970|FG002|Overall Study|Not able to get to clinic|9
6114932|NCT00851799|9735968|FG000|Overall Study|Not willing to adhere to requirements|1
6114933|NCT00851799|9735969|FG001|Overall Study|Not willing to adhere to requirements|2
6114934|NCT00851799|9735970|FG002|Overall Study|Not willing to adhere to requirements|2
6114935|NCT00851799|9735968|FG000|Overall Study|Withdrew consent prior study completion|1
6114936|NCT00851799|9735969|FG001|Overall Study|Withdrew consent prior study completion|2
6114937|NCT00851799|9735970|FG002|Overall Study|Withdrew consent prior study completion|1
6209266|NCT01572792|9874656|FG001|Lead-in Study|Withdrawal by Subject|11
6209267|NCT01572792|9874657|FG002|Lead-in Study|Withdrawal by Subject|12
6209268|NCT01572792|9874658|FG003|Lead-in Study|Withdrawal by Subject|24
6209269|NCT01572792|9874659|FG004|Lead-in Study|Withdrawal by Subject|11
6209270|NCT01572792|9874655|FG000|Lead-in Study|Protocol Violation|19
6209271|NCT01572792|9874656|FG001|Lead-in Study|Protocol Violation|10
6209272|NCT01572792|9874657|FG002|Lead-in Study|Protocol Violation|12
6209273|NCT01572792|9874658|FG003|Lead-in Study|Protocol Violation|13
6209274|NCT01572792|9874659|FG004|Lead-in Study|Protocol Violation|21
6209275|NCT01572792|9874655|FG000|Lead-in Study|Lack of Efficacy|20
6209276|NCT01572792|9874656|FG001|Lead-in Study|Lack of Efficacy|5
6209277|NCT01572792|9874657|FG002|Lead-in Study|Lack of Efficacy|4
6209278|NCT01572792|9874658|FG003|Lead-in Study|Lack of Efficacy|8
6209279|NCT01572792|9874659|FG004|Lead-in Study|Lack of Efficacy|10
6209280|NCT01572792|9874655|FG000|Lead-in Study|Adverse Event|21
6209281|NCT01572792|9874656|FG001|Lead-in Study|Adverse Event|21
6209282|NCT01572792|9874657|FG002|Lead-in Study|Adverse Event|22
6209283|NCT01572792|9874658|FG003|Lead-in Study|Adverse Event|16
6209284|NCT01572792|9874659|FG004|Lead-in Study|Adverse Event|14
6209285|NCT01572792|9874655|FG000|Lead-in Study|Site termination/COPD exacerbation/other|14
6209286|NCT01572792|9874656|FG001|Lead-in Study|Site termination/COPD exacerbation/other|10
6209287|NCT01572792|9874657|FG002|Lead-in Study|Site termination/COPD exacerbation/other|8
6209288|NCT01572792|9874658|FG003|Lead-in Study|Site termination/COPD exacerbation/other|9
6209289|NCT01572792|9874659|FG004|Lead-in Study|Site termination/COPD exacerbation/other|9
6209290|NCT01572792|9874655|FG000|Extension Study|Lost to Follow-up|6
6209291|NCT01572792|9874656|FG001|Extension Study|Lost to Follow-up|2
6209292|NCT01572792|9874657|FG002|Extension Study|Lost to Follow-up|0
6209293|NCT01572792|9874658|FG003|Extension Study|Lost to Follow-up|3
6209294|NCT01572792|9874659|FG004|Extension Study|Lost to Follow-up|3
6209295|NCT01572792|9874655|FG000|Extension Study|Withdrawal by Subject|7
6209296|NCT01572792|9874656|FG001|Extension Study|Withdrawal by Subject|6
6209297|NCT01572792|9874657|FG002|Extension Study|Withdrawal by Subject|11
6209298|NCT01572792|9874658|FG003|Extension Study|Withdrawal by Subject|8
6209299|NCT01572792|9874659|FG004|Extension Study|Withdrawal by Subject|14
6209300|NCT01572792|9874655|FG000|Extension Study|Protocol Violation|0
6209301|NCT01572792|9874656|FG001|Extension Study|Protocol Violation|4
6209302|NCT01572792|9874657|FG002|Extension Study|Protocol Violation|3
6209303|NCT01572792|9874658|FG003|Extension Study|Protocol Violation|4
6209304|NCT01572792|9874659|FG004|Extension Study|Protocol Violation|3
6209305|NCT01572792|9874655|FG000|Extension Study|Lack of Efficacy|2
6209306|NCT01572792|9874656|FG001|Extension Study|Lack of Efficacy|3
6209307|NCT01572792|9874657|FG002|Extension Study|Lack of Efficacy|3
6209308|NCT01572792|9874658|FG003|Extension Study|Lack of Efficacy|2
6209309|NCT01572792|9874659|FG004|Extension Study|Lack of Efficacy|2
6209310|NCT01572792|9874655|FG000|Extension Study|Adverse Event|7
6209311|NCT01572792|9874656|FG001|Extension Study|Adverse Event|6
6209312|NCT01572792|9874657|FG002|Extension Study|Adverse Event|5
6209313|NCT01572792|9874658|FG003|Extension Study|Adverse Event|6
6209314|NCT01572792|9874659|FG004|Extension Study|Adverse Event|4
6209315|NCT01572792|9874655|FG000|Extension Study|Site termination/COPD exacerbation/other|3
6209316|NCT01572792|9874656|FG001|Extension Study|Site termination/COPD exacerbation/other|8
6209317|NCT01572792|9874657|FG002|Extension Study|Site termination/COPD exacerbation/other|4
6209318|NCT01572792|9874658|FG003|Extension Study|Site termination/COPD exacerbation/other|6
6209319|NCT01572792|9874659|FG004|Extension Study|Site termination/COPD exacerbation/other|6
6209320|NCT01572844|9874672|FG000|Overall Study|Physician Decision|1
6209321|NCT01572844|9874673|FG001|Overall Study|Physician Decision|1
6209322|NCT01572909|9874684|FG000|Overall Study|Adverse Event|7
6209323|NCT01572909|9874685|FG001|Overall Study|Adverse Event|2
6209324|NCT01572909|9874684|FG000|Overall Study|Death|3
6209325|NCT01572909|9874685|FG001|Overall Study|Death|1
6209326|NCT01572909|9874684|FG000|Overall Study|Lost to Follow-up|8
6209327|NCT01572909|9874685|FG001|Overall Study|Lost to Follow-up|7
6209328|NCT01572909|9874684|FG000|Overall Study|Physician Decision|1
6209329|NCT01572909|9874685|FG001|Overall Study|Physician Decision|1
6209330|NCT01572909|9874684|FG000|Overall Study|Technical Issues|1
6114938|NCT00851799|9735968|FG000|Overall Study|Severe Debilitation|0
6114939|NCT00851799|9735969|FG001|Overall Study|Severe Debilitation|1
6209331|NCT01572909|9874685|FG001|Overall Study|Technical Issues|0
6209332|NCT01572909|9874684|FG000|Overall Study|Withdrawal by Subject|12
6114940|NCT00851799|9735970|FG002|Overall Study|Severe Debilitation|0
6114941|NCT00851799|9735968|FG000|Overall Study|Completed protocol due to pregnancy|0
6114942|NCT00851799|9735969|FG001|Overall Study|Completed protocol due to pregnancy|0
6114943|NCT00851799|9735970|FG002|Overall Study|Completed protocol due to pregnancy|1
6114944|NCT00851877|9735978|FG000|Phase I-1|Death|1
6114945|NCT00851877|9735979|FG001|Phase I-1|Death|0
6114946|NCT00851877|9735980|FG002|Phase I-1|Death|0
6114947|NCT00851877|9735978|FG000|Phase II|Withdrawal by Subject|0
6114948|NCT00851877|9735979|FG001|Phase II|Withdrawal by Subject|0
6114949|NCT00851877|9735980|FG002|Phase II|Withdrawal by Subject|3
6114950|NCT00851890|9735990|FG000|Overall Study|Lost to Follow-up|0
6114951|NCT00851890|9735991|FG001|Overall Study|Lost to Follow-up|1
6114952|NCT00851890|9735992|FG002|Overall Study|Lost to Follow-up|0
6114953|NCT00851890|9735993|FG003|Overall Study|Lost to Follow-up|1
6114954|NCT00851903|9736003|FG000|Overall Study|Withdrawal by Subject|2
6114955|NCT00852202|9736019|FG000|Overall Study|Adverse Event|2
6114956|NCT00852202|9736020|FG001|Overall Study|Adverse Event|3
6114957|NCT00852202|9736021|FG002|Overall Study|Adverse Event|7
6114958|NCT00852202|9736019|FG000|Overall Study|Lack of Efficacy|4
6114959|NCT00852202|9736020|FG001|Overall Study|Lack of Efficacy|1
6114960|NCT00852202|9736021|FG002|Overall Study|Lack of Efficacy|2
6114961|NCT00852202|9736019|FG000|Overall Study|Protocol Violation|2
6114962|NCT00852202|9736020|FG001|Overall Study|Protocol Violation|2
6114963|NCT00852202|9736021|FG002|Overall Study|Protocol Violation|7
6114964|NCT00852202|9736019|FG000|Overall Study|Withdrawal by Subject|3
6114965|NCT00852202|9736020|FG001|Overall Study|Withdrawal by Subject|1
6114966|NCT00852202|9736021|FG002|Overall Study|Withdrawal by Subject|2
6114967|NCT00852202|9736019|FG000|Overall Study|Lost to Follow-up|5
6114968|NCT00852202|9736020|FG001|Overall Study|Lost to Follow-up|5
6114969|NCT00852202|9736021|FG002|Overall Study|Lost to Follow-up|6
6114970|NCT00852202|9736019|FG000|Overall Study|pregnancy,moving away and surgery|1
6114971|NCT00852202|9736020|FG001|Overall Study|pregnancy,moving away and surgery|0
6114972|NCT00852202|9736021|FG002|Overall Study|pregnancy,moving away and surgery|2
6114973|NCT00852397|9736033|FG000|Overall Study|Adverse Event|4
6114974|NCT00852397|9736034|FG001|Overall Study|Adverse Event|6
6114975|NCT00852397|9736035|FG002|Overall Study|Adverse Event|4
6114976|NCT00852397|9736033|FG000|Overall Study|Death|0
6114977|NCT00852397|9736034|FG001|Overall Study|Death|0
6114978|NCT00852397|9736035|FG002|Overall Study|Death|1
6114979|NCT00852397|9736033|FG000|Overall Study|Withdrawal by Subject|4
6114980|NCT00852397|9736034|FG001|Overall Study|Withdrawal by Subject|1
6114981|NCT00852397|9736035|FG002|Overall Study|Withdrawal by Subject|2
6114982|NCT00852397|9736033|FG000|Overall Study|Study terminated by sponsor|2
6114983|NCT00852397|9736034|FG001|Overall Study|Study terminated by sponsor|1
6114984|NCT00852397|9736035|FG002|Overall Study|Study terminated by sponsor|6
6114985|NCT00852397|9736033|FG000|Overall Study|Difficulty in study site visit|1
6114986|NCT00852397|9736034|FG001|Overall Study|Difficulty in study site visit|0
6114987|NCT00852397|9736035|FG002|Overall Study|Difficulty in study site visit|0
6114988|NCT00852397|9736033|FG000|Overall Study|Protocol Violation|0
6114989|NCT00852397|9736034|FG001|Overall Study|Protocol Violation|0
6114990|NCT00852397|9736035|FG002|Overall Study|Protocol Violation|1
6114991|NCT00852475|9736045|FG000|Overall Study|Lost to Follow-up|3
6114992|NCT00852475|9736046|FG001|Overall Study|Lost to Follow-up|4
6114993|NCT00852540|9736062|FG000|Overall Study|Adverse Event|10
6114994|NCT00852540|9736063|FG001|Overall Study|Adverse Event|3
6114995|NCT00852540|9736062|FG000|Overall Study|Lack of Efficacy|15
6114996|NCT00852540|9736063|FG001|Overall Study|Lack of Efficacy|3
6114997|NCT00852540|9736062|FG000|Overall Study|Protocol Violation|1
6114998|NCT00852540|9736063|FG001|Overall Study|Protocol Violation|2
6114999|NCT00852540|9736062|FG000|Overall Study|Lost to Follow-up|2
6115000|NCT00852540|9736063|FG001|Overall Study|Lost to Follow-up|3
6115001|NCT00852540|9736062|FG000|Overall Study|Investigator Discretion|2
6115002|NCT00852540|9736063|FG001|Overall Study|Investigator Discretion|3
6115003|NCT00852540|9736062|FG000|Overall Study|Withdrawal by Subject|3
6115004|NCT00852540|9736063|FG001|Overall Study|Withdrawal by Subject|1
6115005|NCT00852540|9736062|FG000|Overall Study|Did Not Receive Study Drug|3
6115006|NCT00852540|9736063|FG001|Overall Study|Did Not Receive Study Drug|3
6115007|NCT00852917|9736116|FG000|Overall Study|Adverse Event|13
6115008|NCT00852917|9736117|FG001|Overall Study|Adverse Event|20
6115009|NCT00852917|9736118|FG002|Overall Study|Adverse Event|35
6115010|NCT00852917|9736119|FG003|Overall Study|Adverse Event|17
6115011|NCT00852917|9736116|FG000|Overall Study|Lack of Efficacy|21
6115012|NCT00852917|9736117|FG001|Overall Study|Lack of Efficacy|11
6115013|NCT00852917|9736118|FG002|Overall Study|Lack of Efficacy|11
6115014|NCT00852917|9736119|FG003|Overall Study|Lack of Efficacy|47
6115015|NCT00852917|9736116|FG000|Overall Study|Withdrawal by Subject|4
6115016|NCT00852917|9736117|FG001|Overall Study|Withdrawal by Subject|8
6115017|NCT00852917|9736118|FG002|Overall Study|Withdrawal by Subject|10
6115018|NCT00852917|9736119|FG003|Overall Study|Withdrawal by Subject|9
6115019|NCT00852917|9736116|FG000|Overall Study|Physician Decision|6
6115020|NCT00852917|9736117|FG001|Overall Study|Physician Decision|7
6115021|NCT00852917|9736118|FG002|Overall Study|Physician Decision|2
6115022|NCT00852917|9736119|FG003|Overall Study|Physician Decision|19
6115023|NCT00852917|9736116|FG000|Overall Study|Death|0
6115024|NCT00852917|9736117|FG001|Overall Study|Death|0
6115025|NCT00852917|9736118|FG002|Overall Study|Death|0
6115026|NCT00852917|9736119|FG003|Overall Study|Death|1
6115027|NCT00852930|9736132|FG000|Overall Study|Withdrawal by Subject|1
6115028|NCT00852930|9736133|FG001|Overall Study|Withdrawal by Subject|1
6115029|NCT00852930|9736134|FG002|Overall Study|Withdrawal by Subject|1
6115030|NCT00852930|9736132|FG000|Overall Study|Physician Decision|0
6115031|NCT00852930|9736133|FG001|Overall Study|Physician Decision|0
6115032|NCT00852930|9736134|FG002|Overall Study|Physician Decision|1
6115033|NCT00852969|9736145|FG000|Overall Study|Adverse Event|0
6115034|NCT00852969|9736146|FG001|Overall Study|Adverse Event|1
6115035|NCT00852969|9736145|FG000|Overall Study|Lost to Follow-up|0
6115036|NCT00852969|9736146|FG001|Overall Study|Lost to Follow-up|1
6115037|NCT00852995|9736157|FG000|Overall Study|Adverse Event|1
6115038|NCT00852995|9736158|FG001|Overall Study|Adverse Event|0
6115039|NCT00852995|9736159|FG002|Overall Study|Adverse Event|4
6115040|NCT00852995|9736160|FG003|Overall Study|Adverse Event|0
6115041|NCT00852995|9736161|FG004|Overall Study|Adverse Event|0
6115042|NCT00852995|9736157|FG000|Overall Study|Lost to Follow-up|0
6115043|NCT00852995|9736158|FG001|Overall Study|Lost to Follow-up|1
6115044|NCT00852995|9736159|FG002|Overall Study|Lost to Follow-up|1
6115045|NCT00852995|9736160|FG003|Overall Study|Lost to Follow-up|0
6115046|NCT00852995|9736161|FG004|Overall Study|Lost to Follow-up|0
6115047|NCT00852995|9736157|FG000|Overall Study|Withdrawal by Subject|4
6115048|NCT00852995|9736158|FG001|Overall Study|Withdrawal by Subject|0
6115049|NCT00852995|9736159|FG002|Overall Study|Withdrawal by Subject|0
6115050|NCT00852995|9736160|FG003|Overall Study|Withdrawal by Subject|1
6115051|NCT00852995|9736161|FG004|Overall Study|Withdrawal by Subject|2
6115052|NCT00852995|9736157|FG000|Overall Study|Non-Compliance|0
6115053|NCT00852995|9736158|FG001|Overall Study|Non-Compliance|0
6115054|NCT00852995|9736159|FG002|Overall Study|Non-Compliance|0
6115055|NCT00852995|9736160|FG003|Overall Study|Non-Compliance|2
6115056|NCT00852995|9736161|FG004|Overall Study|Non-Compliance|0
6115057|NCT00852995|9736157|FG000|Overall Study|Progressive Disease|1
6115058|NCT00852995|9736158|FG001|Overall Study|Progressive Disease|0
6115059|NCT00852995|9736159|FG002|Overall Study|Progressive Disease|0
6209333|NCT01572909|9874685|FG001|Overall Study|Withdrawal by Subject|11
6209334|NCT01572909|9874684|FG000|Overall Study|Infarct, comorbidity, Pt refusal of exam|0
6209335|NCT01572909|9874685|FG001|Overall Study|Infarct, comorbidity, Pt refusal of exam|3
6209336|NCT01572922|9874693|FG000|Overall Study|Adverse Event|1
6209337|NCT01572922|9874693|FG000|Overall Study|Protocol Violation|1
6209338|NCT01572922|9874693|FG000|Overall Study|Death|1
6209339|NCT01572948|9874704|FG000|Overall Study|Lost to Follow-up|1
6209340|NCT01572948|9874705|FG001|Overall Study|Lost to Follow-up|0
6209341|NCT01572948|9874704|FG000|Overall Study|unable to contact|0
6209342|NCT01572948|9874705|FG001|Overall Study|unable to contact|1
6209343|NCT01573000|9874717|FG000|Dosimetric and Therapeutic Treatment|Lack of Efficacy|27
6209344|NCT01573000|9874718|FG001|Dosimetric and Therapeutic Treatment|Lack of Efficacy|32
6209345|NCT01573000|9874717|FG000|Dosimetric and Therapeutic Treatment|Lost to Follow-up|4
6209346|NCT01573000|9874718|FG001|Dosimetric and Therapeutic Treatment|Lost to Follow-up|2
6209347|NCT01573000|9874717|FG000|Dosimetric and Therapeutic Treatment|Death|0
6209348|NCT01573000|9874718|FG001|Dosimetric and Therapeutic Treatment|Death|1
6209349|NCT01573000|9874717|FG000|Dosimetric and Therapeutic Treatment|Withdrawal by Subject|2
6209350|NCT01573000|9874718|FG001|Dosimetric and Therapeutic Treatment|Withdrawal by Subject|0
6209351|NCT01573000|9874717|FG000|Dosimetric and Therapeutic Treatment|Received Other Treatment|2
6209352|NCT01573000|9874718|FG001|Dosimetric and Therapeutic Treatment|Received Other Treatment|0
6209353|NCT01573000|9874717|FG000|Crossover Phase|Lack of Efficacy|0
6209354|NCT01573000|9874718|FG001|Crossover Phase|Lack of Efficacy|13
6209355|NCT01573000|9874717|FG000|Crossover Phase|Lost to Follow-up|0
6209356|NCT01573000|9874718|FG001|Crossover Phase|Lost to Follow-up|2
6209357|NCT01573000|9874717|FG000|Crossover Phase|Death|0
6209358|NCT01573000|9874718|FG001|Crossover Phase|Death|3
6209359|NCT01573000|9874717|FG000|Long-Term Follow-Up|Death|3
6209360|NCT01573000|9874718|FG001|Long-Term Follow-Up|Death|0
6209361|NCT01573000|9874717|FG000|Long-Term Follow-Up|Lost to Follow-up|0
6115060|NCT00852995|9736160|FG003|Overall Study|Progressive Disease|2
6115061|NCT00852995|9736161|FG004|Overall Study|Progressive Disease|1
6115062|NCT00852995|9736157|FG000|Overall Study|Physician Decision|1
6115063|NCT00852995|9736158|FG001|Overall Study|Physician Decision|0
6115064|NCT00852995|9736159|FG002|Overall Study|Physician Decision|0
6115065|NCT00852995|9736160|FG003|Overall Study|Physician Decision|0
6115066|NCT00852995|9736161|FG004|Overall Study|Physician Decision|0
6115067|NCT00852995|9736157|FG000|Overall Study|Protocol Violation|0
6115068|NCT00852995|9736158|FG001|Overall Study|Protocol Violation|0
6115069|NCT00852995|9736159|FG002|Overall Study|Protocol Violation|0
6115070|NCT00852995|9736160|FG003|Overall Study|Protocol Violation|0
6115071|NCT00852995|9736161|FG004|Overall Study|Protocol Violation|1
6115072|NCT00852995|9736157|FG000|Overall Study|Moved Out of Area|1
6115073|NCT00852995|9736158|FG001|Overall Study|Moved Out of Area|0
6115074|NCT00852995|9736159|FG002|Overall Study|Moved Out of Area|0
6115075|NCT00852995|9736160|FG003|Overall Study|Moved Out of Area|0
6115076|NCT00852995|9736161|FG004|Overall Study|Moved Out of Area|0
6115077|NCT00853021|9736178|FG000|Overall Study|Adverse Event|2
6115078|NCT00853021|9736178|FG000|Overall Study|Withdrawal by Subject|2
6115079|NCT00853021|9736178|FG000|Overall Study|Death|1
6115080|NCT00853047|9736187|FG000|Core Phase|Participant Request|0
6115081|NCT00853047|9736188|FG001|Core Phase|Participant Request|0
6115082|NCT00853047|9736189|FG002|Core Phase|Participant Request|0
6115083|NCT00853047|9736190|FG003|Core Phase|Participant Request|1
6115084|NCT00853047|9736191|FG004|Core Phase|Participant Request|0
6115085|NCT00853047|9736192|FG005|Core Phase|Participant Request|0
6115086|NCT00853047|9736187|FG000|Open-Label Extension Phase|Participant Request|0
6115087|NCT00853047|9736188|FG001|Open-Label Extension Phase|Participant Request|0
6115088|NCT00853047|9736189|FG002|Open-Label Extension Phase|Participant Request|0
6115089|NCT00853047|9736190|FG003|Open-Label Extension Phase|Participant Request|0
6115090|NCT00853047|9736191|FG004|Open-Label Extension Phase|Participant Request|0
6115091|NCT00853047|9736192|FG005|Open-Label Extension Phase|Participant Request|7
6115092|NCT00853047|9736187|FG000|Open-Label Extension Phase|Lost to Follow-up|0
6115093|NCT00853047|9736188|FG001|Open-Label Extension Phase|Lost to Follow-up|0
6115094|NCT00853047|9736189|FG002|Open-Label Extension Phase|Lost to Follow-up|0
6115095|NCT00853047|9736190|FG003|Open-Label Extension Phase|Lost to Follow-up|0
6115096|NCT00853047|9736191|FG004|Open-Label Extension Phase|Lost to Follow-up|0
6115097|NCT00853047|9736192|FG005|Open-Label Extension Phase|Lost to Follow-up|1
6115098|NCT00853047|9736187|FG000|Open-Label Extension Phase|Transfer to LX1606-302|0
6115099|NCT00853047|9736188|FG001|Open-Label Extension Phase|Transfer to LX1606-302|0
6209362|NCT01573000|9874718|FG001|Long-Term Follow-Up|Lost to Follow-up|1
6209363|NCT01573442|9874806|FG000|Overall Study|Cancels|9
6209364|NCT01573442|9874807|FG001|Overall Study|Cancels|10
6209365|NCT01573624|9874821|FG000|Period 1 : Treatment Period 1 (14 Days)|Adverse Event|0
6209366|NCT01573624|9874822|FG001|Period 1 : Treatment Period 1 (14 Days)|Adverse Event|0
6209367|NCT01573624|9874823|FG002|Period 1 : Treatment Period 1 (14 Days)|Adverse Event|1
6209368|NCT01573624|9874824|FG003|Period 1 : Treatment Period 1 (14 Days)|Adverse Event|0
6209369|NCT01573624|9874825|FG004|Period 1 : Treatment Period 1 (14 Days)|Adverse Event|0
6209370|NCT01573624|9874826|FG005|Period 1 : Treatment Period 1 (14 Days)|Adverse Event|1
6209371|NCT01573624|9874827|FG006|Period 1 : Treatment Period 1 (14 Days)|Adverse Event|0
6209372|NCT01573624|9874821|FG000|Period 1 : Treatment Period 1 (14 Days)|Lack of Efficacy|4
6209373|NCT01573624|9874822|FG001|Period 1 : Treatment Period 1 (14 Days)|Lack of Efficacy|3
6209374|NCT01573624|9874823|FG002|Period 1 : Treatment Period 1 (14 Days)|Lack of Efficacy|6
6209375|NCT01573624|9874824|FG003|Period 1 : Treatment Period 1 (14 Days)|Lack of Efficacy|1
6209376|NCT01573624|9874825|FG004|Period 1 : Treatment Period 1 (14 Days)|Lack of Efficacy|2
6209377|NCT01573624|9874826|FG005|Period 1 : Treatment Period 1 (14 Days)|Lack of Efficacy|0
6209378|NCT01573624|9874827|FG006|Period 1 : Treatment Period 1 (14 Days)|Lack of Efficacy|1
6209379|NCT01573624|9874821|FG000|Period 1 : Treatment Period 1 (14 Days)|Protocol Violation|1
6209380|NCT01573624|9874822|FG001|Period 1 : Treatment Period 1 (14 Days)|Protocol Violation|0
6209381|NCT01573624|9874823|FG002|Period 1 : Treatment Period 1 (14 Days)|Protocol Violation|0
6209382|NCT01573624|9874824|FG003|Period 1 : Treatment Period 1 (14 Days)|Protocol Violation|0
6209383|NCT01573624|9874825|FG004|Period 1 : Treatment Period 1 (14 Days)|Protocol Violation|0
6209384|NCT01573624|9874826|FG005|Period 1 : Treatment Period 1 (14 Days)|Protocol Violation|0
6209385|NCT01573624|9874827|FG006|Period 1 : Treatment Period 1 (14 Days)|Protocol Violation|0
6209386|NCT01573624|9874821|FG000|Period 1 : Treatment Period 1 (14 Days)|Withdrawal by Subject|1
6209387|NCT01573624|9874822|FG001|Period 1 : Treatment Period 1 (14 Days)|Withdrawal by Subject|0
6209388|NCT01573624|9874823|FG002|Period 1 : Treatment Period 1 (14 Days)|Withdrawal by Subject|1
6209389|NCT01573624|9874824|FG003|Period 1 : Treatment Period 1 (14 Days)|Withdrawal by Subject|0
6209390|NCT01573624|9874825|FG004|Period 1 : Treatment Period 1 (14 Days)|Withdrawal by Subject|0
6209391|NCT01573624|9874826|FG005|Period 1 : Treatment Period 1 (14 Days)|Withdrawal by Subject|2
6209392|NCT01573624|9874827|FG006|Period 1 : Treatment Period 1 (14 Days)|Withdrawal by Subject|0
6209393|NCT01573624|9874821|FG000|Period 1 : Treatment Period 1 (14 Days)|Protocol-defined stopping criteria|0
6209394|NCT01573624|9874822|FG001|Period 1 : Treatment Period 1 (14 Days)|Protocol-defined stopping criteria|0
6209395|NCT01573624|9874823|FG002|Period 1 : Treatment Period 1 (14 Days)|Protocol-defined stopping criteria|1
6209396|NCT01573624|9874824|FG003|Period 1 : Treatment Period 1 (14 Days)|Protocol-defined stopping criteria|1
6209397|NCT01573624|9874825|FG004|Period 1 : Treatment Period 1 (14 Days)|Protocol-defined stopping criteria|0
6209398|NCT01573624|9874826|FG005|Period 1 : Treatment Period 1 (14 Days)|Protocol-defined stopping criteria|1
6209399|NCT01573624|9874827|FG006|Period 1 : Treatment Period 1 (14 Days)|Protocol-defined stopping criteria|1
6209400|NCT01573624|9874821|FG000|Period 2 : Washout Period 1 (12-14 Days)|Adverse Event|0
6209401|NCT01573624|9874822|FG001|Period 2 : Washout Period 1 (12-14 Days)|Adverse Event|0
6209402|NCT01573624|9874823|FG002|Period 2 : Washout Period 1 (12-14 Days)|Adverse Event|0
6209403|NCT01573624|9874824|FG003|Period 2 : Washout Period 1 (12-14 Days)|Adverse Event|0
6209404|NCT01573624|9874825|FG004|Period 2 : Washout Period 1 (12-14 Days)|Adverse Event|0
6209405|NCT01573624|9874826|FG005|Period 2 : Washout Period 1 (12-14 Days)|Adverse Event|1
6209406|NCT01573624|9874827|FG006|Period 2 : Washout Period 1 (12-14 Days)|Adverse Event|0
6209407|NCT01573624|9874821|FG000|Period 2 : Washout Period 1 (12-14 Days)|Lack of Efficacy|0
6209408|NCT01573624|9874822|FG001|Period 2 : Washout Period 1 (12-14 Days)|Lack of Efficacy|1
6286544|NCT02346240|9999213|FG022|Maintenance Period (Week 16 to Week 48)|Moved out of state|0
6115100|NCT00853047|9736189|FG002|Open-Label Extension Phase|Transfer to LX1606-302|0
6115101|NCT00853047|9736190|FG003|Open-Label Extension Phase|Transfer to LX1606-302|0
6115102|NCT00853047|9736191|FG004|Open-Label Extension Phase|Transfer to LX1606-302|0
6115103|NCT00853047|9736192|FG005|Open-Label Extension Phase|Transfer to LX1606-302|2
6115104|NCT00853047|9736187|FG000|Open-Label Extension Phase|Investigator Decision|0
6115105|NCT00853047|9736188|FG001|Open-Label Extension Phase|Investigator Decision|0
6115106|NCT00853047|9736189|FG002|Open-Label Extension Phase|Investigator Decision|0
6115107|NCT00853047|9736190|FG003|Open-Label Extension Phase|Investigator Decision|0
6115108|NCT00853047|9736191|FG004|Open-Label Extension Phase|Investigator Decision|0
6115109|NCT00853047|9736192|FG005|Open-Label Extension Phase|Investigator Decision|1
6115110|NCT00853047|9736187|FG000|Open-Label Extension Phase|Reason Not Specified|0
6115111|NCT00853047|9736188|FG001|Open-Label Extension Phase|Reason Not Specified|0
6115112|NCT00853047|9736189|FG002|Open-Label Extension Phase|Reason Not Specified|0
6115113|NCT00853047|9736190|FG003|Open-Label Extension Phase|Reason Not Specified|0
6115114|NCT00853047|9736191|FG004|Open-Label Extension Phase|Reason Not Specified|0
6115115|NCT00853047|9736192|FG005|Open-Label Extension Phase|Reason Not Specified|6
6115116|NCT00853073|9736209|FG000|Overall Study|Withdrawal by Subject|3
6115117|NCT00853073|9736210|FG001|Overall Study|Withdrawal by Subject|2
6115118|NCT00853099|9736219|FG000|Double-blind Period|Adverse Event|7
6115119|NCT00853099|9736220|FG001|Double-blind Period|Adverse Event|9
6115120|NCT00853099|9736221|FG002|Double-blind Period|Adverse Event|13
6115121|NCT00853099|9736222|FG003|Double-blind Period|Adverse Event|0
6115122|NCT00853099|9736219|FG000|Double-blind Period|Withdrawal by Subject|2
6115123|NCT00853099|9736220|FG001|Double-blind Period|Withdrawal by Subject|3
6286545|NCT02346240|9999214|FG023|Maintenance Period (Week 16 to Week 48)|Moved out of state|0
6286546|NCT02346240|9999191|FG000|Maintenance Period (Week 16 to Week 48)|Sponsor decision due to non-compliance|0
6286547|NCT02346240|9999192|FG001|Maintenance Period (Week 16 to Week 48)|Sponsor decision due to non-compliance|0
6286548|NCT02346240|9999193|FG002|Maintenance Period (Week 16 to Week 48)|Sponsor decision due to non-compliance|0
6115124|NCT00853099|9736221|FG002|Double-blind Period|Withdrawal by Subject|0
6115125|NCT00853099|9736222|FG003|Double-blind Period|Withdrawal by Subject|0
6115126|NCT00853099|9736219|FG000|Double-blind Period|Lack of Efficacy|14
6115127|NCT00853099|9736220|FG001|Double-blind Period|Lack of Efficacy|17
6115128|NCT00853099|9736221|FG002|Double-blind Period|Lack of Efficacy|16
6115129|NCT00853099|9736222|FG003|Double-blind Period|Lack of Efficacy|0
6115130|NCT00853099|9736219|FG000|Double-blind Period|Other|0
6115131|NCT00853099|9736220|FG001|Double-blind Period|Other|0
6115132|NCT00853099|9736221|FG002|Double-blind Period|Other|1
6115133|NCT00853099|9736222|FG003|Double-blind Period|Other|0
6115134|NCT00853099|9736219|FG000|Double-blind Period|Mistreated with rescue study drug|0
6115135|NCT00853099|9736220|FG001|Double-blind Period|Mistreated with rescue study drug|0
6115136|NCT00853099|9736221|FG002|Double-blind Period|Mistreated with rescue study drug|1
6115137|NCT00853099|9736222|FG003|Double-blind Period|Mistreated with rescue study drug|0
6115138|NCT00853099|9736219|FG000|Double-blind + Open-label Periods|Lack of Efficacy|0
6115139|NCT00853099|9736220|FG001|Double-blind + Open-label Periods|Lack of Efficacy|0
6115140|NCT00853099|9736221|FG002|Double-blind + Open-label Periods|Lack of Efficacy|0
6115141|NCT00853099|9736222|FG003|Double-blind + Open-label Periods|Lack of Efficacy|74
6115142|NCT00853099|9736219|FG000|Double-blind + Open-label Periods|Adverse Event|0
6115143|NCT00853099|9736220|FG001|Double-blind + Open-label Periods|Adverse Event|0
6115144|NCT00853099|9736221|FG002|Double-blind + Open-label Periods|Adverse Event|0
6115145|NCT00853099|9736222|FG003|Double-blind + Open-label Periods|Adverse Event|47
6115146|NCT00853099|9736219|FG000|Double-blind + Open-label Periods|Withdrawal by Subject|0
6115147|NCT00853099|9736220|FG001|Double-blind + Open-label Periods|Withdrawal by Subject|0
6115148|NCT00853099|9736221|FG002|Double-blind + Open-label Periods|Withdrawal by Subject|0
6115149|NCT00853099|9736222|FG003|Double-blind + Open-label Periods|Withdrawal by Subject|20
6115150|NCT00853099|9736219|FG000|Double-blind + Open-label Periods|Other|0
6115151|NCT00853099|9736220|FG001|Double-blind + Open-label Periods|Other|0
6115152|NCT00853099|9736221|FG002|Double-blind + Open-label Periods|Other|0
6115153|NCT00853099|9736222|FG003|Double-blind + Open-label Periods|Other|6
6115154|NCT00853112|9736239|FG000|Overall Study|Randomized but not treated|0
6115155|NCT00853112|9736240|FG001|Overall Study|Randomized but not treated|1
6115156|NCT00853112|9736241|FG002|Overall Study|Randomized but not treated|0
6115157|NCT00853112|9736242|FG003|Overall Study|Randomized but not treated|2
6115158|NCT00853112|9736243|FG004|Overall Study|Randomized but not treated|0
6115159|NCT00853112|9736244|FG005|Overall Study|Randomized but not treated|0
6115160|NCT00853112|9736245|FG006|Overall Study|Randomized but not treated|1
6115161|NCT00853125|9736261|FG000|Overall Study|Study participant's donor was CMV +|1
6115162|NCT00853151|9736270|FG000|Overall Study|Adverse Event|1
6115163|NCT00853151|9736271|FG001|Overall Study|Adverse Event|4
6115164|NCT00853151|9736272|FG002|Overall Study|Adverse Event|2
6115165|NCT00853151|9736273|FG003|Overall Study|Adverse Event|0
6115166|NCT00853151|9736270|FG000|Overall Study|Inclusion/Exclusion Criteria Not Met|1
6115167|NCT00853151|9736271|FG001|Overall Study|Inclusion/Exclusion Criteria Not Met|0
6115168|NCT00853151|9736272|FG002|Overall Study|Inclusion/Exclusion Criteria Not Met|0
6115169|NCT00853151|9736273|FG003|Overall Study|Inclusion/Exclusion Criteria Not Met|0
6115170|NCT00853151|9736270|FG000|Overall Study|Lost to Follow-up|2
6115171|NCT00853151|9736271|FG001|Overall Study|Lost to Follow-up|0
6115172|NCT00853151|9736272|FG002|Overall Study|Lost to Follow-up|3
6115173|NCT00853151|9736273|FG003|Overall Study|Lost to Follow-up|0
6115174|NCT00853151|9736270|FG000|Overall Study|Death|1
6115175|NCT00853151|9736271|FG001|Overall Study|Death|0
6115176|NCT00853151|9736272|FG002|Overall Study|Death|0
6115177|NCT00853151|9736273|FG003|Overall Study|Death|1
6209409|NCT01573624|9874823|FG002|Period 2 : Washout Period 1 (12-14 Days)|Lack of Efficacy|0
6209410|NCT01573624|9874824|FG003|Period 2 : Washout Period 1 (12-14 Days)|Lack of Efficacy|1
6209411|NCT01573624|9874825|FG004|Period 2 : Washout Period 1 (12-14 Days)|Lack of Efficacy|0
6209412|NCT01573624|9874826|FG005|Period 2 : Washout Period 1 (12-14 Days)|Lack of Efficacy|0
6209413|NCT01573624|9874827|FG006|Period 2 : Washout Period 1 (12-14 Days)|Lack of Efficacy|1
6209414|NCT01573624|9874821|FG000|Period 2 : Washout Period 1 (12-14 Days)|Protocol Violation|1
6209415|NCT01573624|9874822|FG001|Period 2 : Washout Period 1 (12-14 Days)|Protocol Violation|0
6209416|NCT01573624|9874823|FG002|Period 2 : Washout Period 1 (12-14 Days)|Protocol Violation|2
6209417|NCT01573624|9874824|FG003|Period 2 : Washout Period 1 (12-14 Days)|Protocol Violation|1
6209418|NCT01573624|9874825|FG004|Period 2 : Washout Period 1 (12-14 Days)|Protocol Violation|0
6209419|NCT01573624|9874826|FG005|Period 2 : Washout Period 1 (12-14 Days)|Protocol Violation|0
6209420|NCT01573624|9874827|FG006|Period 2 : Washout Period 1 (12-14 Days)|Protocol Violation|0
6209421|NCT01573624|9874821|FG000|Period 2 : Washout Period 1 (12-14 Days)|Physician Decision|0
6209422|NCT01573624|9874822|FG001|Period 2 : Washout Period 1 (12-14 Days)|Physician Decision|0
6209423|NCT01573624|9874823|FG002|Period 2 : Washout Period 1 (12-14 Days)|Physician Decision|0
6209424|NCT01573624|9874824|FG003|Period 2 : Washout Period 1 (12-14 Days)|Physician Decision|0
6209425|NCT01573624|9874825|FG004|Period 2 : Washout Period 1 (12-14 Days)|Physician Decision|0
6209426|NCT01573624|9874826|FG005|Period 2 : Washout Period 1 (12-14 Days)|Physician Decision|1
6209427|NCT01573624|9874827|FG006|Period 2 : Washout Period 1 (12-14 Days)|Physician Decision|0
6209428|NCT01573624|9874821|FG000|Period 2 : Washout Period 1 (12-14 Days)|Withdrawal by Subject|0
6209429|NCT01573624|9874822|FG001|Period 2 : Washout Period 1 (12-14 Days)|Withdrawal by Subject|0
6209430|NCT01573624|9874823|FG002|Period 2 : Washout Period 1 (12-14 Days)|Withdrawal by Subject|0
6209431|NCT01573624|9874824|FG003|Period 2 : Washout Period 1 (12-14 Days)|Withdrawal by Subject|2
6209432|NCT01573624|9874825|FG004|Period 2 : Washout Period 1 (12-14 Days)|Withdrawal by Subject|0
6209433|NCT01573624|9874826|FG005|Period 2 : Washout Period 1 (12-14 Days)|Withdrawal by Subject|0
6209434|NCT01573624|9874827|FG006|Period 2 : Washout Period 1 (12-14 Days)|Withdrawal by Subject|1
6209435|NCT01573624|9874821|FG000|Period 2 : Washout Period 1 (12-14 Days)|Protocol-defined stopping criteria|0
6209436|NCT01573624|9874822|FG001|Period 2 : Washout Period 1 (12-14 Days)|Protocol-defined stopping criteria|0
6209437|NCT01573624|9874823|FG002|Period 2 : Washout Period 1 (12-14 Days)|Protocol-defined stopping criteria|1
6209438|NCT01573624|9874824|FG003|Period 2 : Washout Period 1 (12-14 Days)|Protocol-defined stopping criteria|1
6209439|NCT01573624|9874825|FG004|Period 2 : Washout Period 1 (12-14 Days)|Protocol-defined stopping criteria|0
6209440|NCT01573624|9874826|FG005|Period 2 : Washout Period 1 (12-14 Days)|Protocol-defined stopping criteria|1
6209441|NCT01573624|9874827|FG006|Period 2 : Washout Period 1 (12-14 Days)|Protocol-defined stopping criteria|0
6209442|NCT01573624|9874821|FG000|Period 3 : Treatment Period 2 (14 Days)|Lack of Efficacy|5
6209443|NCT01573624|9874822|FG001|Period 3 : Treatment Period 2 (14 Days)|Lack of Efficacy|4
6209444|NCT01573624|9874823|FG002|Period 3 : Treatment Period 2 (14 Days)|Lack of Efficacy|2
6209445|NCT01573624|9874824|FG003|Period 3 : Treatment Period 2 (14 Days)|Lack of Efficacy|1
6209446|NCT01573624|9874825|FG004|Period 3 : Treatment Period 2 (14 Days)|Lack of Efficacy|3
6209447|NCT01573624|9874826|FG005|Period 3 : Treatment Period 2 (14 Days)|Lack of Efficacy|2
6209448|NCT01573624|9874827|FG006|Period 3 : Treatment Period 2 (14 Days)|Lack of Efficacy|0
6209449|NCT01573624|9874821|FG000|Period 3 : Treatment Period 2 (14 Days)|Protocol Violation|0
6209450|NCT01573624|9874822|FG001|Period 3 : Treatment Period 2 (14 Days)|Protocol Violation|1
6209451|NCT01573624|9874823|FG002|Period 3 : Treatment Period 2 (14 Days)|Protocol Violation|0
6209452|NCT01573624|9874824|FG003|Period 3 : Treatment Period 2 (14 Days)|Protocol Violation|0
6209453|NCT01573624|9874825|FG004|Period 3 : Treatment Period 2 (14 Days)|Protocol Violation|0
6209454|NCT01573624|9874826|FG005|Period 3 : Treatment Period 2 (14 Days)|Protocol Violation|2
6209455|NCT01573624|9874827|FG006|Period 3 : Treatment Period 2 (14 Days)|Protocol Violation|0
6209456|NCT01573624|9874821|FG000|Period 3 : Treatment Period 2 (14 Days)|Physician Decision|1
6209457|NCT01573624|9874822|FG001|Period 3 : Treatment Period 2 (14 Days)|Physician Decision|0
6209458|NCT01573624|9874823|FG002|Period 3 : Treatment Period 2 (14 Days)|Physician Decision|0
6209459|NCT01573624|9874824|FG003|Period 3 : Treatment Period 2 (14 Days)|Physician Decision|0
6209460|NCT01573624|9874825|FG004|Period 3 : Treatment Period 2 (14 Days)|Physician Decision|0
6209461|NCT01573624|9874826|FG005|Period 3 : Treatment Period 2 (14 Days)|Physician Decision|0
6209462|NCT01573624|9874827|FG006|Period 3 : Treatment Period 2 (14 Days)|Physician Decision|0
6209463|NCT01573624|9874821|FG000|Period 3 : Treatment Period 2 (14 Days)|Withdrawal by Subject|0
6209464|NCT01573624|9874822|FG001|Period 3 : Treatment Period 2 (14 Days)|Withdrawal by Subject|1
6209465|NCT01573624|9874823|FG002|Period 3 : Treatment Period 2 (14 Days)|Withdrawal by Subject|1
6209466|NCT01573624|9874824|FG003|Period 3 : Treatment Period 2 (14 Days)|Withdrawal by Subject|0
6209467|NCT01573624|9874825|FG004|Period 3 : Treatment Period 2 (14 Days)|Withdrawal by Subject|0
6209468|NCT01573624|9874826|FG005|Period 3 : Treatment Period 2 (14 Days)|Withdrawal by Subject|1
6209469|NCT01573624|9874827|FG006|Period 3 : Treatment Period 2 (14 Days)|Withdrawal by Subject|0
6115178|NCT00853151|9736270|FG000|Overall Study|Protocol Violation|0
6115179|NCT00853151|9736271|FG001|Overall Study|Protocol Violation|0
6115180|NCT00853151|9736272|FG002|Overall Study|Protocol Violation|0
6115181|NCT00853151|9736273|FG003|Overall Study|Protocol Violation|1
6115182|NCT00853151|9736270|FG000|Overall Study|Withdrawal by Subject|5
6115183|NCT00853151|9736271|FG001|Overall Study|Withdrawal by Subject|4
6115184|NCT00853151|9736272|FG002|Overall Study|Withdrawal by Subject|2
6115185|NCT00853151|9736273|FG003|Overall Study|Withdrawal by Subject|1
6115186|NCT00853151|9736270|FG000|Overall Study|Physician Decision|0
6115187|NCT00853151|9736271|FG001|Overall Study|Physician Decision|2
6115188|NCT00853151|9736272|FG002|Overall Study|Physician Decision|1
6209470|NCT01573624|9874821|FG000|Period 3 : Treatment Period 2 (14 Days)|Protocol-defined stopping criteria|1
6209471|NCT01573624|9874822|FG001|Period 3 : Treatment Period 2 (14 Days)|Protocol-defined stopping criteria|0
6209472|NCT01573624|9874823|FG002|Period 3 : Treatment Period 2 (14 Days)|Protocol-defined stopping criteria|0
6209473|NCT01573624|9874824|FG003|Period 3 : Treatment Period 2 (14 Days)|Protocol-defined stopping criteria|0
6209474|NCT01573624|9874825|FG004|Period 3 : Treatment Period 2 (14 Days)|Protocol-defined stopping criteria|0
6209475|NCT01573624|9874826|FG005|Period 3 : Treatment Period 2 (14 Days)|Protocol-defined stopping criteria|0
6209476|NCT01573624|9874827|FG006|Period 3 : Treatment Period 2 (14 Days)|Protocol-defined stopping criteria|0
6209477|NCT01573624|9874821|FG000|Period 4 : Washout Period 2 (12-14 Days)|Adverse Event|1
6209478|NCT01573624|9874822|FG001|Period 4 : Washout Period 2 (12-14 Days)|Adverse Event|0
6209479|NCT01573624|9874823|FG002|Period 4 : Washout Period 2 (12-14 Days)|Adverse Event|0
6209480|NCT01573624|9874824|FG003|Period 4 : Washout Period 2 (12-14 Days)|Adverse Event|0
6209481|NCT01573624|9874825|FG004|Period 4 : Washout Period 2 (12-14 Days)|Adverse Event|0
6209482|NCT01573624|9874826|FG005|Period 4 : Washout Period 2 (12-14 Days)|Adverse Event|0
6209483|NCT01573624|9874827|FG006|Period 4 : Washout Period 2 (12-14 Days)|Adverse Event|1
6209484|NCT01573624|9874821|FG000|Period 4 : Washout Period 2 (12-14 Days)|Lack of Efficacy|0
6209485|NCT01573624|9874822|FG001|Period 4 : Washout Period 2 (12-14 Days)|Lack of Efficacy|1
6209486|NCT01573624|9874823|FG002|Period 4 : Washout Period 2 (12-14 Days)|Lack of Efficacy|1
6209487|NCT01573624|9874824|FG003|Period 4 : Washout Period 2 (12-14 Days)|Lack of Efficacy|1
6209488|NCT01573624|9874825|FG004|Period 4 : Washout Period 2 (12-14 Days)|Lack of Efficacy|1
6209489|NCT01573624|9874826|FG005|Period 4 : Washout Period 2 (12-14 Days)|Lack of Efficacy|0
6209490|NCT01573624|9874827|FG006|Period 4 : Washout Period 2 (12-14 Days)|Lack of Efficacy|1
6209491|NCT01573624|9874821|FG000|Period 4 : Washout Period 2 (12-14 Days)|Protocol Violation|0
6209492|NCT01573624|9874822|FG001|Period 4 : Washout Period 2 (12-14 Days)|Protocol Violation|1
6209493|NCT01573624|9874823|FG002|Period 4 : Washout Period 2 (12-14 Days)|Protocol Violation|0
6209494|NCT01573624|9874824|FG003|Period 4 : Washout Period 2 (12-14 Days)|Protocol Violation|0
6209495|NCT01573624|9874825|FG004|Period 4 : Washout Period 2 (12-14 Days)|Protocol Violation|0
6209496|NCT01573624|9874826|FG005|Period 4 : Washout Period 2 (12-14 Days)|Protocol Violation|0
6209497|NCT01573624|9874827|FG006|Period 4 : Washout Period 2 (12-14 Days)|Protocol Violation|0
6209498|NCT01573624|9874821|FG000|Period 4 : Washout Period 2 (12-14 Days)|Lost to Follow-up|0
6209499|NCT01573624|9874822|FG001|Period 4 : Washout Period 2 (12-14 Days)|Lost to Follow-up|1
6209500|NCT01573624|9874823|FG002|Period 4 : Washout Period 2 (12-14 Days)|Lost to Follow-up|0
6209501|NCT01573624|9874824|FG003|Period 4 : Washout Period 2 (12-14 Days)|Lost to Follow-up|0
6209502|NCT01573624|9874825|FG004|Period 4 : Washout Period 2 (12-14 Days)|Lost to Follow-up|0
6209503|NCT01573624|9874826|FG005|Period 4 : Washout Period 2 (12-14 Days)|Lost to Follow-up|0
6209504|NCT01573624|9874827|FG006|Period 4 : Washout Period 2 (12-14 Days)|Lost to Follow-up|0
6209505|NCT01573624|9874821|FG000|Period 4 : Washout Period 2 (12-14 Days)|Withdrawal by Subject|0
6209506|NCT01573624|9874822|FG001|Period 4 : Washout Period 2 (12-14 Days)|Withdrawal by Subject|0
6209507|NCT01573624|9874823|FG002|Period 4 : Washout Period 2 (12-14 Days)|Withdrawal by Subject|0
6209508|NCT01573624|9874824|FG003|Period 4 : Washout Period 2 (12-14 Days)|Withdrawal by Subject|0
6209509|NCT01573624|9874825|FG004|Period 4 : Washout Period 2 (12-14 Days)|Withdrawal by Subject|0
6209510|NCT01573624|9874826|FG005|Period 4 : Washout Period 2 (12-14 Days)|Withdrawal by Subject|1
6209511|NCT01573624|9874827|FG006|Period 4 : Washout Period 2 (12-14 Days)|Withdrawal by Subject|1
6209512|NCT01573624|9874821|FG000|Period 4 : Washout Period 2 (12-14 Days)|Protocol-defined stopping criteria|0
6209513|NCT01573624|9874822|FG001|Period 4 : Washout Period 2 (12-14 Days)|Protocol-defined stopping criteria|1
6209514|NCT01573624|9874823|FG002|Period 4 : Washout Period 2 (12-14 Days)|Protocol-defined stopping criteria|1
6209515|NCT01573624|9874824|FG003|Period 4 : Washout Period 2 (12-14 Days)|Protocol-defined stopping criteria|1
6209516|NCT01573624|9874825|FG004|Period 4 : Washout Period 2 (12-14 Days)|Protocol-defined stopping criteria|0
6209517|NCT01573624|9874826|FG005|Period 4 : Washout Period 2 (12-14 Days)|Protocol-defined stopping criteria|1
6209518|NCT01573624|9874827|FG006|Period 4 : Washout Period 2 (12-14 Days)|Protocol-defined stopping criteria|0
6209519|NCT01573624|9874821|FG000|Period 5 : Treatment Period 3 (14 Days)|Lack of Efficacy|2
6209520|NCT01573624|9874822|FG001|Period 5 : Treatment Period 3 (14 Days)|Lack of Efficacy|0
6209521|NCT01573624|9874823|FG002|Period 5 : Treatment Period 3 (14 Days)|Lack of Efficacy|0
6209522|NCT01573624|9874824|FG003|Period 5 : Treatment Period 3 (14 Days)|Lack of Efficacy|0
6209523|NCT01573624|9874825|FG004|Period 5 : Treatment Period 3 (14 Days)|Lack of Efficacy|1
6209524|NCT01573624|9874826|FG005|Period 5 : Treatment Period 3 (14 Days)|Lack of Efficacy|1
6209525|NCT01573624|9874827|FG006|Period 5 : Treatment Period 3 (14 Days)|Lack of Efficacy|4
6115189|NCT00853151|9736273|FG003|Overall Study|Physician Decision|0
6115190|NCT00853151|9736270|FG000|Overall Study|Sponsor Decision|0
6115191|NCT00853151|9736271|FG001|Overall Study|Sponsor Decision|3
6115192|NCT00853151|9736272|FG002|Overall Study|Sponsor Decision|0
6115193|NCT00853151|9736273|FG003|Overall Study|Sponsor Decision|0
6115194|NCT00853242|9736293|FG000|Overall Study|Adverse Event|0
6115195|NCT00853242|9736294|FG001|Overall Study|Adverse Event|1
6115196|NCT00853242|9736295|FG002|Overall Study|Adverse Event|1
6115197|NCT00853242|9736296|FG003|Overall Study|Adverse Event|0
6115198|NCT00853242|9736297|FG004|Overall Study|Adverse Event|3
6115199|NCT00853242|9736298|FG005|Overall Study|Adverse Event|1
6115200|NCT00853242|9736299|FG006|Overall Study|Adverse Event|1
6115201|NCT00853242|9736293|FG000|Overall Study|Noncompliant|0
6115202|NCT00853242|9736294|FG001|Overall Study|Noncompliant|0
6115203|NCT00853242|9736295|FG002|Overall Study|Noncompliant|0
6115204|NCT00853242|9736296|FG003|Overall Study|Noncompliant|0
6115205|NCT00853242|9736297|FG004|Overall Study|Noncompliant|1
6115206|NCT00853242|9736298|FG005|Overall Study|Noncompliant|0
6115207|NCT00853242|9736299|FG006|Overall Study|Noncompliant|0
6115208|NCT00853242|9736293|FG000|Overall Study|Withdrawal by Subject|1
6115209|NCT00853242|9736294|FG001|Overall Study|Withdrawal by Subject|2
6115210|NCT00853242|9736295|FG002|Overall Study|Withdrawal by Subject|0
6115211|NCT00853242|9736296|FG003|Overall Study|Withdrawal by Subject|4
6115212|NCT00853242|9736297|FG004|Overall Study|Withdrawal by Subject|0
6115213|NCT00853242|9736298|FG005|Overall Study|Withdrawal by Subject|0
6115214|NCT00853242|9736299|FG006|Overall Study|Withdrawal by Subject|2
6115215|NCT00853242|9736293|FG000|Overall Study|Other|2
6115216|NCT00853242|9736294|FG001|Overall Study|Other|0
6115217|NCT00853242|9736295|FG002|Overall Study|Other|2
6115218|NCT00853242|9736296|FG003|Overall Study|Other|0
6115219|NCT00853242|9736297|FG004|Overall Study|Other|0
6115220|NCT00853242|9736298|FG005|Overall Study|Other|1
6115221|NCT00853242|9736299|FG006|Overall Study|Other|2
6115222|NCT00853372|9736336|FG000|Overall Study|Death|30
6115223|NCT00853372|9736337|FG001|Overall Study|Death|26
6115224|NCT00853372|9736336|FG000|Overall Study|Lost to Follow-up|1
6115225|NCT00853372|9736337|FG001|Overall Study|Lost to Follow-up|2
6115226|NCT00853372|9736336|FG000|Overall Study|Full Consent Withdrawn|1
6115227|NCT00853372|9736337|FG001|Overall Study|Full Consent Withdrawn|1
6115228|NCT00853385|9736348|FG000|Overall Study|Death|0
6115229|NCT00853385|9736349|FG001|Overall Study|Death|0
6115230|NCT00853385|9736350|FG002|Overall Study|Death|0
6115231|NCT00853385|9736351|FG003|Overall Study|Death|0
6115232|NCT00853385|9736352|FG004|Overall Study|Death|1
6115233|NCT00853385|9736348|FG000|Overall Study|Adverse Event|24
6115234|NCT00853385|9736349|FG001|Overall Study|Adverse Event|24
6115235|NCT00853385|9736350|FG002|Overall Study|Adverse Event|2
6115236|NCT00853385|9736351|FG003|Overall Study|Adverse Event|5
6115237|NCT00853385|9736352|FG004|Overall Study|Adverse Event|22
6115238|NCT00853385|9736348|FG000|Overall Study|Lack of Efficacy|6
6115239|NCT00853385|9736349|FG001|Overall Study|Lack of Efficacy|7
6115240|NCT00853385|9736350|FG002|Overall Study|Lack of Efficacy|3
6115241|NCT00853385|9736351|FG003|Overall Study|Lack of Efficacy|3
6115242|NCT00853385|9736352|FG004|Overall Study|Lack of Efficacy|6
6115243|NCT00853385|9736348|FG000|Overall Study|Lost to Follow-up|2
6115244|NCT00853385|9736349|FG001|Overall Study|Lost to Follow-up|1
6115245|NCT00853385|9736350|FG002|Overall Study|Lost to Follow-up|0
6115246|NCT00853385|9736351|FG003|Overall Study|Lost to Follow-up|0
6115247|NCT00853385|9736352|FG004|Overall Study|Lost to Follow-up|0
6115248|NCT00853385|9736348|FG000|Overall Study|Withdrawal by Subject|4
6115249|NCT00853385|9736349|FG001|Overall Study|Withdrawal by Subject|2
6115250|NCT00853385|9736350|FG002|Overall Study|Withdrawal by Subject|0
6115251|NCT00853385|9736351|FG003|Overall Study|Withdrawal by Subject|1
6115252|NCT00853385|9736352|FG004|Overall Study|Withdrawal by Subject|1
6115253|NCT00853385|9736348|FG000|Overall Study|Other|18
6115254|NCT00853385|9736349|FG001|Overall Study|Other|9
6115255|NCT00853385|9736350|FG002|Overall Study|Other|4
6115256|NCT00853385|9736351|FG003|Overall Study|Other|4
6115257|NCT00853385|9736352|FG004|Overall Study|Other|12
6115258|NCT00853489|9736376|FG000|Overall Study|Lost to Follow-up|5
6115259|NCT00853489|9736377|FG001|Overall Study|Lost to Follow-up|2
6115260|NCT00853580|9736385|FG000|Overall Study|Lost to Follow-up|3
6115261|NCT00853580|9736386|FG001|Overall Study|Lost to Follow-up|5
6115262|NCT00853580|9736385|FG000|Overall Study|Protocol Violation|2
6115263|NCT00853580|9736386|FG001|Overall Study|Protocol Violation|1
6115264|NCT00853580|9736385|FG000|Overall Study|Withdrawal by Subject|2
6115265|NCT00853580|9736386|FG001|Overall Study|Withdrawal by Subject|8
6115266|NCT00853580|9736385|FG000|Overall Study|Commenced contraindicated therapy|0
6115267|NCT00853580|9736386|FG001|Overall Study|Commenced contraindicated therapy|2
6115268|NCT00853593|9736392|FG000|Overall Study|Subjects did not receive a 4396 lead|12
6115269|NCT00853593|9736392|FG000|Overall Study|Model 4396 lead not attempted|29
6115270|NCT00853593|9736392|FG000|Overall Study|Implant not attempted|4
6115271|NCT00853658|9736424|FG000|Overall Study|Death|713
6115272|NCT00853658|9736425|FG001|Overall Study|Death|768
6115273|NCT00853658|9736426|FG002|Overall Study|Death|753
6115274|NCT00853658|9736424|FG000|Overall Study|Lost to Follow-up|11
6115275|NCT00853658|9736425|FG001|Overall Study|Lost to Follow-up|6
6115276|NCT00853658|9736426|FG002|Overall Study|Lost to Follow-up|11
6115277|NCT00853658|9736424|FG000|Overall Study|H.A. Request|26
6115278|NCT00853658|9736425|FG001|Overall Study|H.A. Request|23
6115279|NCT00853658|9736426|FG002|Overall Study|H.A. Request|19
6115280|NCT00853658|9736424|FG000|Overall Study|IRB request|0
6115281|NCT00853658|9736425|FG001|Overall Study|IRB request|0
6115282|NCT00853658|9736426|FG002|Overall Study|IRB request|2
6115283|NCT00853658|9736424|FG000|Overall Study|Vital Status known (alive) at study end|2
6115284|NCT00853658|9736425|FG001|Overall Study|Vital Status known (alive) at study end|3
6115285|NCT00853658|9736426|FG002|Overall Study|Vital Status known (alive) at study end|3
6115286|NCT00853658|9736424|FG000|Overall Study|Vital Status unknown at study end|1
6115287|NCT00853658|9736425|FG001|Overall Study|Vital Status unknown at study end|1
6115288|NCT00853658|9736426|FG002|Overall Study|Vital Status unknown at study end|0
6115289|NCT00853658|9736424|FG000|Overall Study|Vital Status at study end N/A|8
6115290|NCT00853658|9736425|FG001|Overall Study|Vital Status at study end N/A|10
6115291|NCT00853658|9736426|FG002|Overall Study|Vital Status at study end N/A|10
6115292|NCT00853658|9736424|FG000|Overall Study|Patient's request|21
6115293|NCT00853658|9736425|FG001|Overall Study|Patient's request|17
6115294|NCT00853658|9736426|FG002|Overall Study|Patient's request|11
6115295|NCT00853658|9736424|FG000|Overall Study|Missing study completion information|5
6115296|NCT00853658|9736425|FG001|Overall Study|Missing study completion information|4
6115297|NCT00853658|9736426|FG002|Overall Study|Missing study completion information|6
6115298|NCT00853723|9736441|FG000|Overall Study|Adverse Event|3
6209526|NCT01573624|9874821|FG000|Period 5 : Treatment Period 3 (14 Days)|Protocol Violation|0
6209527|NCT01573624|9874822|FG001|Period 5 : Treatment Period 3 (14 Days)|Protocol Violation|1
6209528|NCT01573624|9874823|FG002|Period 5 : Treatment Period 3 (14 Days)|Protocol Violation|0
6209529|NCT01573624|9874824|FG003|Period 5 : Treatment Period 3 (14 Days)|Protocol Violation|0
6209530|NCT01573624|9874825|FG004|Period 5 : Treatment Period 3 (14 Days)|Protocol Violation|0
6209531|NCT01573624|9874826|FG005|Period 5 : Treatment Period 3 (14 Days)|Protocol Violation|1
6209532|NCT01573624|9874827|FG006|Period 5 : Treatment Period 3 (14 Days)|Protocol Violation|0
6209533|NCT01573624|9874821|FG000|Period 5 : Treatment Period 3 (14 Days)|Lost to Follow-up|1
6115299|NCT00853723|9736442|FG001|Overall Study|Adverse Event|4
6115300|NCT00853723|9736443|FG002|Overall Study|Adverse Event|1
6115301|NCT00853723|9736441|FG000|Overall Study|Withdrawal by Subject|2
6115302|NCT00853723|9736442|FG001|Overall Study|Withdrawal by Subject|1
6115303|NCT00853723|9736443|FG002|Overall Study|Withdrawal by Subject|0
6115304|NCT00853723|9736441|FG000|Overall Study|Protocol Violation|1
6115305|NCT00853723|9736442|FG001|Overall Study|Protocol Violation|2
6115306|NCT00853723|9736443|FG002|Overall Study|Protocol Violation|1
6115307|NCT00853749|9736456|FG000|Overall Study|Lost to Follow-up|0
6115308|NCT00853749|9736457|FG001|Overall Study|Lost to Follow-up|1
6115309|NCT00853762|9736467|FG000|Overall Study|Premature Termination|16
6115310|NCT00853762|9736468|FG001|Overall Study|Premature Termination|15
6115311|NCT00853762|9736469|FG002|Overall Study|Premature Termination|14
6115312|NCT00853762|9736470|FG003|Overall Study|Premature Termination|21
6115313|NCT00853762|9736467|FG000|Overall Study|Protocol Violation|0
6115314|NCT00853762|9736468|FG001|Overall Study|Protocol Violation|0
6115315|NCT00853762|9736469|FG002|Overall Study|Protocol Violation|0
6115316|NCT00853762|9736470|FG003|Overall Study|Protocol Violation|1
6115317|NCT00853762|9736467|FG000|Overall Study|Withdrawal by Subject|0
6115318|NCT00853762|9736468|FG001|Overall Study|Withdrawal by Subject|0
6115319|NCT00853762|9736469|FG002|Overall Study|Withdrawal by Subject|1
6115320|NCT00853762|9736470|FG003|Overall Study|Withdrawal by Subject|0
6115321|NCT00853762|9736467|FG000|Overall Study|Other|0
6115322|NCT00853762|9736468|FG001|Overall Study|Other|2
6115323|NCT00853762|9736469|FG002|Overall Study|Other|0
6115324|NCT00853762|9736470|FG003|Overall Study|Other|0
6115325|NCT00853762|9736467|FG000|Overall Study|Randomised but not Treated|0
6115326|NCT00853762|9736468|FG001|Overall Study|Randomised but not Treated|2
6115327|NCT00853762|9736469|FG002|Overall Study|Randomised but not Treated|2
6115328|NCT00853762|9736470|FG003|Overall Study|Randomised but not Treated|0
6115329|NCT00853827|9736482|FG000|Single Blind Period (1 Week)|Other|4
6115330|NCT00853827|9736483|FG001|Single Blind Period (1 Week)|Other|0
6115331|NCT00853827|9736482|FG000|Single Blind Period (1 Week)|Adverse Event|9
6115332|NCT00853827|9736483|FG001|Single Blind Period (1 Week)|Adverse Event|0
6115333|NCT00853827|9736482|FG000|Single Blind Period (1 Week)|Abnormal laboratory value|3
6115334|NCT00853827|9736483|FG001|Single Blind Period (1 Week)|Abnormal laboratory value|0
6115335|NCT00853827|9736482|FG000|Single Blind Period (1 Week)|Abnormal test procedure result|1
6115336|NCT00853827|9736483|FG001|Single Blind Period (1 Week)|Abnormal test procedure result|0
6115337|NCT00853827|9736482|FG000|Single Blind Period (1 Week)|Withdrawal by Subject|9
6115338|NCT00853827|9736483|FG001|Single Blind Period (1 Week)|Withdrawal by Subject|0
6115339|NCT00853827|9736482|FG000|Single Blind Period (1 Week)|Lost to Follow-up|1
6115340|NCT00853827|9736483|FG001|Single Blind Period (1 Week)|Lost to Follow-up|0
6115341|NCT00853827|9736482|FG000|Single Blind Period (1 Week)|Protocol Violation|12
6115342|NCT00853827|9736483|FG001|Single Blind Period (1 Week)|Protocol Violation|0
6115343|NCT00853827|9736482|FG000|Double Blind Period (103 Weeks)|Adverse Event|25
6115344|NCT00853827|9736483|FG001|Double Blind Period (103 Weeks)|Adverse Event|14
6115345|NCT00853827|9736482|FG000|Double Blind Period (103 Weeks)|Abnormal laboratory values|0
6115346|NCT00853827|9736483|FG001|Double Blind Period (103 Weeks)|Abnormal laboratory values|3
6115347|NCT00853827|9736482|FG000|Double Blind Period (103 Weeks)|Lack of Efficacy|1
6115348|NCT00853827|9736483|FG001|Double Blind Period (103 Weeks)|Lack of Efficacy|0
6115349|NCT00853827|9736482|FG000|Double Blind Period (103 Weeks)|Patient's no longer requires study drug|3
6115350|NCT00853827|9736483|FG001|Double Blind Period (103 Weeks)|Patient's no longer requires study drug|1
6115351|NCT00853827|9736482|FG000|Double Blind Period (103 Weeks)|Protocol Violation|2
6115352|NCT00853827|9736483|FG001|Double Blind Period (103 Weeks)|Protocol Violation|1
6115353|NCT00853827|9736482|FG000|Double Blind Period (103 Weeks)|Withdrawal by Subject|19
6115354|NCT00853827|9736483|FG001|Double Blind Period (103 Weeks)|Withdrawal by Subject|18
6115355|NCT00853827|9736482|FG000|Double Blind Period (103 Weeks)|Lost to Follow-up|8
6115356|NCT00853827|9736483|FG001|Double Blind Period (103 Weeks)|Lost to Follow-up|10
6115357|NCT00853827|9736482|FG000|Double Blind Period (103 Weeks)|Administrative problems|45
6115358|NCT00853827|9736483|FG001|Double Blind Period (103 Weeks)|Administrative problems|56
6115359|NCT00853827|9736482|FG000|Double Blind Period (103 Weeks)|Death|1
6115360|NCT00853827|9736483|FG001|Double Blind Period (103 Weeks)|Death|6
6115361|NCT00853905|9736499|FG000|Overall Study|Lost to Follow-up|1
6115362|NCT00853905|9736500|FG001|Overall Study|Lost to Follow-up|3
6115363|NCT00853905|9736499|FG000|Overall Study|Withdrawal by Subject|0
6115364|NCT00853905|9736500|FG001|Overall Study|Withdrawal by Subject|1
6115365|NCT00853905|9736499|FG000|Overall Study|never had surgery|1
6115366|NCT00853905|9736500|FG001|Overall Study|never had surgery|0
6115367|NCT00853957|9736511|FG000|Overall Study|Adverse Event|9
6115368|NCT00853957|9736512|FG001|Overall Study|Adverse Event|3
6115369|NCT00853957|9736511|FG000|Overall Study|Unsatisfactory therapeutic effect|0
6209534|NCT01573624|9874822|FG001|Period 5 : Treatment Period 3 (14 Days)|Lost to Follow-up|0
6209535|NCT01573624|9874823|FG002|Period 5 : Treatment Period 3 (14 Days)|Lost to Follow-up|0
6209536|NCT01573624|9874824|FG003|Period 5 : Treatment Period 3 (14 Days)|Lost to Follow-up|0
6209537|NCT01573624|9874825|FG004|Period 5 : Treatment Period 3 (14 Days)|Lost to Follow-up|0
6209538|NCT01573624|9874826|FG005|Period 5 : Treatment Period 3 (14 Days)|Lost to Follow-up|0
6209539|NCT01573624|9874827|FG006|Period 5 : Treatment Period 3 (14 Days)|Lost to Follow-up|0
6209540|NCT01573624|9874821|FG000|Period 6 : Follow-up Period (7 Days)|Adverse Event|0
6209541|NCT01573624|9874822|FG001|Period 6 : Follow-up Period (7 Days)|Adverse Event|0
6209542|NCT01573624|9874823|FG002|Period 6 : Follow-up Period (7 Days)|Adverse Event|0
6209543|NCT01573624|9874824|FG003|Period 6 : Follow-up Period (7 Days)|Adverse Event|0
6209544|NCT01573624|9874825|FG004|Period 6 : Follow-up Period (7 Days)|Adverse Event|2
6209545|NCT01573624|9874826|FG005|Period 6 : Follow-up Period (7 Days)|Adverse Event|1
6209546|NCT01573624|9874827|FG006|Period 6 : Follow-up Period (7 Days)|Adverse Event|0
6209547|NCT01573624|9874821|FG000|Period 6 : Follow-up Period (7 Days)|Protocol Violation|1
6209548|NCT01573624|9874822|FG001|Period 6 : Follow-up Period (7 Days)|Protocol Violation|0
6209549|NCT01573624|9874823|FG002|Period 6 : Follow-up Period (7 Days)|Protocol Violation|0
6209550|NCT01573624|9874824|FG003|Period 6 : Follow-up Period (7 Days)|Protocol Violation|0
6209551|NCT01573624|9874825|FG004|Period 6 : Follow-up Period (7 Days)|Protocol Violation|0
6209552|NCT01573624|9874826|FG005|Period 6 : Follow-up Period (7 Days)|Protocol Violation|0
6209553|NCT01573624|9874827|FG006|Period 6 : Follow-up Period (7 Days)|Protocol Violation|0
6209554|NCT01573767|9874858|FG000|Overall Study|Adverse Event|0
6209555|NCT01573767|9874859|FG001|Overall Study|Adverse Event|1
6209556|NCT01573767|9874860|FG002|Overall Study|Adverse Event|0
6209557|NCT01573767|9874861|FG003|Overall Study|Adverse Event|1
6209558|NCT01573767|9874858|FG000|Overall Study|Lack of Efficacy|18
6209559|NCT01573767|9874859|FG001|Overall Study|Lack of Efficacy|15
6209560|NCT01573767|9874860|FG002|Overall Study|Lack of Efficacy|12
6209561|NCT01573767|9874861|FG003|Overall Study|Lack of Efficacy|17
6209562|NCT01573767|9874858|FG000|Overall Study|Protocol Violation|3
6209563|NCT01573767|9874859|FG001|Overall Study|Protocol Violation|1
6209564|NCT01573767|9874860|FG002|Overall Study|Protocol Violation|1
6209565|NCT01573767|9874861|FG003|Overall Study|Protocol Violation|3
6209566|NCT01573767|9874858|FG000|Overall Study|Lost to Follow-up|0
6209567|NCT01573767|9874859|FG001|Overall Study|Lost to Follow-up|1
6209568|NCT01573767|9874860|FG002|Overall Study|Lost to Follow-up|1
6209569|NCT01573767|9874861|FG003|Overall Study|Lost to Follow-up|1
6209570|NCT01573767|9874858|FG000|Overall Study|Physician Decision|1
6209571|NCT01573767|9874859|FG001|Overall Study|Physician Decision|2
6209572|NCT01573767|9874860|FG002|Overall Study|Physician Decision|0
6209573|NCT01573767|9874861|FG003|Overall Study|Physician Decision|2
6209574|NCT01573767|9874858|FG000|Overall Study|Withdrawal by Subject|0
6209575|NCT01573767|9874859|FG001|Overall Study|Withdrawal by Subject|1
6209576|NCT01573767|9874860|FG002|Overall Study|Withdrawal by Subject|0
6209577|NCT01573767|9874861|FG003|Overall Study|Withdrawal by Subject|0
6209578|NCT01573910|9874873|FG000|Overall Study|Adverse Event|4
6209579|NCT01573910|9874874|FG001|Overall Study|Adverse Event|4
6115370|NCT00853957|9736512|FG001|Overall Study|Unsatisfactory therapeutic effect|2
6115371|NCT00853957|9736511|FG000|Overall Study|Subject withdrew consent|4
6209580|NCT01573910|9874873|FG000|Overall Study|Lost to Follow-up|2
6209581|NCT01573910|9874874|FG001|Overall Study|Lost to Follow-up|1
6209582|NCT01573910|9874873|FG000|Overall Study|Withdrawal by Subject|0
6209583|NCT01573910|9874874|FG001|Overall Study|Withdrawal by Subject|1
6209584|NCT01573910|9874873|FG000|Overall Study|Protocol Violation|3
6209585|NCT01573910|9874874|FG001|Overall Study|Protocol Violation|0
6209586|NCT01573910|9874873|FG000|Overall Study|Patient decision unrelated to Advs Event|11
6115372|NCT00853957|9736512|FG001|Overall Study|Subject withdrew consent|5
6115373|NCT00853957|9736511|FG000|Overall Study|Lost to Follow-up|1
6115374|NCT00853957|9736512|FG001|Overall Study|Lost to Follow-up|6
6115375|NCT00853957|9736511|FG000|Overall Study|Protocol deviation|0
6115376|NCT00853957|9736512|FG001|Overall Study|Protocol deviation|3
6115377|NCT00853970|9736520|FG000|Overall Study|Withdrawal by Subject|2
6115378|NCT00853970|9736521|FG001|Overall Study|Withdrawal by Subject|1
6115379|NCT00853970|9736520|FG000|Overall Study|Cancelled surgery|4
6115380|NCT00853970|9736521|FG001|Overall Study|Cancelled surgery|2
6115381|NCT00854100|9736549|FG000|Overall Study|Inability to complete the study visits|0
6115382|NCT00854100|9736550|FG001|Overall Study|Inability to complete the study visits|0
6115383|NCT00854100|9736551|FG002|Overall Study|Inability to complete the study visits|1
6115384|NCT00854100|9736549|FG000|Overall Study|Lost to Follow-up|2
6115385|NCT00854100|9736550|FG001|Overall Study|Lost to Follow-up|0
6115386|NCT00854100|9736551|FG002|Overall Study|Lost to Follow-up|3
6115387|NCT00854100|9736549|FG000|Overall Study|Withdrawal by Subject|3
6115388|NCT00854100|9736550|FG001|Overall Study|Withdrawal by Subject|1
6115389|NCT00854100|9736551|FG002|Overall Study|Withdrawal by Subject|2
6115390|NCT00854100|9736549|FG000|Overall Study|Protocol Violation|2
6115391|NCT00854100|9736550|FG001|Overall Study|Protocol Violation|4
6115392|NCT00854100|9736551|FG002|Overall Study|Protocol Violation|3
6115393|NCT00854100|9736549|FG000|Overall Study|Adverse Event|2
6209587|NCT01573910|9874874|FG001|Overall Study|Patient decision unrelated to Advs Event|11
6209588|NCT01574079|9874886|FG000|Overall Study|Physician Decision|0
6209589|NCT01574079|9874887|FG001|Overall Study|Physician Decision|2
6209590|NCT01574079|9874886|FG000|Overall Study|Lost to Follow-up|1
6209591|NCT01574079|9874887|FG001|Overall Study|Lost to Follow-up|0
6209592|NCT01574157|9874909|FG000|Overall Study|Withdrawal by Subject|4
6209593|NCT01574157|9874910|FG001|Overall Study|Withdrawal by Subject|5
6209594|NCT01574157|9874909|FG000|Overall Study|Lost to Follow-up|0
6209595|NCT01574157|9874910|FG001|Overall Study|Lost to Follow-up|3
6209596|NCT01574248|9874933|FG000|Overall Study|Withdrawal by Subject|2
6209597|NCT01574248|9874934|FG001|Overall Study|Withdrawal by Subject|0
6209598|NCT01574248|9874933|FG000|Overall Study|Missing primary endpoint data|1
6209599|NCT01574248|9874934|FG001|Overall Study|Missing primary endpoint data|0
6209600|NCT01574326|9874946|FG000|Overall Study|Randomized but not treated|0
6209601|NCT01574326|9874947|FG001|Overall Study|Randomized but not treated|1
6209602|NCT01574326|9874946|FG000|Overall Study|Withdrawal by Participant|2
6209603|NCT01574326|9874947|FG001|Overall Study|Withdrawal by Participant|4
6209604|NCT01574326|9874946|FG000|Overall Study|Physician Decision|5
6209605|NCT01574326|9874947|FG001|Overall Study|Physician Decision|3
6209606|NCT01574326|9874946|FG000|Overall Study|Adverse Event|1
6115394|NCT00854100|9736550|FG001|Overall Study|Adverse Event|1
6115395|NCT00854100|9736551|FG002|Overall Study|Adverse Event|2
6115396|NCT00854113|9736571|FG000|Overall Study|Adverse Event|0
6115397|NCT00854113|9736572|FG001|Overall Study|Adverse Event|0
6115398|NCT00854113|9736573|FG002|Overall Study|Adverse Event|0
6115399|NCT00854113|9736574|FG003|Overall Study|Adverse Event|0
6115400|NCT00854113|9736575|FG004|Overall Study|Adverse Event|0
6115401|NCT00854113|9736576|FG005|Overall Study|Adverse Event|0
6209607|NCT01574326|9874947|FG001|Overall Study|Adverse Event|3
6209608|NCT01574326|9874946|FG000|Overall Study|Other: Mainly kidney transplant|8
6209609|NCT01574326|9874947|FG001|Overall Study|Other: Mainly kidney transplant|8
6209610|NCT01574352|9874960|FG000|Overall Study|Withdrawal by Subject|6
6209611|NCT01574352|9874961|FG001|Overall Study|Withdrawal by Subject|13
6209612|NCT01574352|9874960|FG000|Overall Study|Injury in non-camp related sport|1
6209613|NCT01574352|9874961|FG001|Overall Study|Injury in non-camp related sport|0
6209614|NCT01574612|9874967|FG000|Overall Study|Adverse Event|3
6209615|NCT01574612|9874967|FG000|Overall Study|non compliant with drug|2
6209616|NCT01574612|9874967|FG000|Overall Study|Withdrawal by Subject|1
6209617|NCT01574612|9874967|FG000|Overall Study|Lost to Follow-up|2
6209618|NCT01574651|9874973|FG000|Overall Study|Lost to Follow-up|2
6209619|NCT01574651|9874974|FG001|Overall Study|Lost to Follow-up|4
6209620|NCT01574651|9874973|FG000|Overall Study|Administrative problems|0
6209621|NCT01574651|9874974|FG001|Overall Study|Administrative problems|1
6209622|NCT01574651|9874973|FG000|Overall Study|Death|3
6209623|NCT01574651|9874974|FG001|Overall Study|Death|3
6209624|NCT01574651|9874973|FG000|Overall Study|Patient's inability to use the device|0
6209625|NCT01574651|9874974|FG001|Overall Study|Patient's inability to use the device|1
6209626|NCT01574651|9874973|FG000|Overall Study|Adverse Event|36
6209627|NCT01574651|9874974|FG001|Overall Study|Adverse Event|27
6209628|NCT01574651|9874973|FG000|Overall Study|Abnormal laboratory value(s)|1
6209629|NCT01574651|9874974|FG001|Overall Study|Abnormal laboratory value(s)|0
6209630|NCT01574651|9874973|FG000|Overall Study|Abnormal test procedure result(s)|1
6209631|NCT01574651|9874974|FG001|Overall Study|Abnormal test procedure result(s)|1
6209632|NCT01574651|9874973|FG000|Overall Study|Unsatisfactory therapeutic effect|6
6209633|NCT01574651|9874974|FG001|Overall Study|Unsatisfactory therapeutic effect|0
6209634|NCT01574651|9874973|FG000|Overall Study|Protocol Violation|3
6209635|NCT01574651|9874974|FG001|Overall Study|Protocol Violation|5
6209636|NCT01574651|9874973|FG000|Overall Study|Withdrawal by Subject|9
6209637|NCT01574651|9874974|FG001|Overall Study|Withdrawal by Subject|10
6115402|NCT00854113|9736577|FG006|Overall Study|Adverse Event|0
6115403|NCT00854113|9736578|FG007|Overall Study|Adverse Event|2
6115404|NCT00854113|9736579|FG008|Overall Study|Adverse Event|0
6115405|NCT00854113|9736580|FG009|Overall Study|Adverse Event|0
6115406|NCT00854113|9736581|FG010|Overall Study|Adverse Event|0
6115407|NCT00854113|9736571|FG000|Overall Study|Withdrawal by Subject|0
6115408|NCT00854113|9736572|FG001|Overall Study|Withdrawal by Subject|0
6115409|NCT00854113|9736573|FG002|Overall Study|Withdrawal by Subject|0
6115410|NCT00854113|9736574|FG003|Overall Study|Withdrawal by Subject|0
6115411|NCT00854113|9736575|FG004|Overall Study|Withdrawal by Subject|0
6115412|NCT00854113|9736576|FG005|Overall Study|Withdrawal by Subject|0
6115413|NCT00854113|9736577|FG006|Overall Study|Withdrawal by Subject|0
6115414|NCT00854113|9736578|FG007|Overall Study|Withdrawal by Subject|1
6115415|NCT00854113|9736579|FG008|Overall Study|Withdrawal by Subject|1
6115416|NCT00854113|9736580|FG009|Overall Study|Withdrawal by Subject|0
6115417|NCT00854113|9736581|FG010|Overall Study|Withdrawal by Subject|0
6115418|NCT00854308|9736607|FG000|Overall Study|Disease progression|42
6115419|NCT00854308|9736608|FG001|Overall Study|Disease progression|50
6115420|NCT00854308|9736607|FG000|Overall Study|Adverse Event|8
6115421|NCT00854308|9736608|FG001|Overall Study|Adverse Event|3
6115422|NCT00854308|9736607|FG000|Overall Study|Death|2
6115423|NCT00854308|9736608|FG001|Overall Study|Death|5
6115424|NCT00854308|9736607|FG000|Overall Study|Physician Decision|6
6115425|NCT00854308|9736608|FG001|Overall Study|Physician Decision|6
6115426|NCT00854308|9736607|FG000|Overall Study|Withdrawal by Subject|4
6115427|NCT00854308|9736608|FG001|Overall Study|Withdrawal by Subject|2
6115428|NCT00854308|9736607|FG000|Overall Study|Sponsor's decision to terminate study|0
6115429|NCT00854308|9736608|FG001|Overall Study|Sponsor's decision to terminate study|1
6115430|NCT00854360|9736618|FG000|Overall Study|Adverse Event|0
6115431|NCT00854360|9736619|FG001|Overall Study|Adverse Event|1
6115432|NCT00854360|9736620|FG002|Overall Study|Adverse Event|2
6115433|NCT00854360|9736621|FG003|Overall Study|Adverse Event|6
6115434|NCT00854360|9736618|FG000|Overall Study|Withdrawal by Subject|0
6115435|NCT00854360|9736619|FG001|Overall Study|Withdrawal by Subject|0
6115436|NCT00854360|9736620|FG002|Overall Study|Withdrawal by Subject|0
6115437|NCT00854360|9736621|FG003|Overall Study|Withdrawal by Subject|1
6115438|NCT00854360|9736618|FG000|Overall Study|Pregnancy|0
6115439|NCT00854360|9736619|FG001|Overall Study|Pregnancy|1
6115440|NCT00854360|9736620|FG002|Overall Study|Pregnancy|0
6115441|NCT00854360|9736621|FG003|Overall Study|Pregnancy|0
6115442|NCT00854360|9736618|FG000|Overall Study|Lack of Efficacy|2
6115443|NCT00854360|9736619|FG001|Overall Study|Lack of Efficacy|1
6115444|NCT00854360|9736620|FG002|Overall Study|Lack of Efficacy|0
6115445|NCT00854360|9736621|FG003|Overall Study|Lack of Efficacy|0
6115446|NCT00854360|9736618|FG000|Overall Study|Other|0
6115447|NCT00854360|9736619|FG001|Overall Study|Other|0
6115448|NCT00854360|9736620|FG002|Overall Study|Other|0
6115449|NCT00854360|9736621|FG003|Overall Study|Other|3
6115450|NCT00854373|9736633|FG000|Overall Study|Withdrawal by Subject|1
6115451|NCT00854373|9736634|FG001|Overall Study|Withdrawal by Subject|3
6115452|NCT00854373|9736633|FG000|Overall Study|Forgot to take study drug|1
6115453|NCT00854373|9736634|FG001|Overall Study|Forgot to take study drug|1
6115454|NCT00854581|9736640|FG000|Induction (Up to Day 21)|Lack of Efficacy|4
6115455|NCT00854581|9736640|FG000|Induction (Up to Day 21)|Death|1
6115456|NCT00854581|9736640|FG000|Induction (Up to Day 21)|Physician Decision|1
6115457|NCT00854581|9736640|FG000|Part 2 Maintenance (Up to 12 Months)|Lack of Efficacy|3
6115458|NCT00854607|9736658|FG000|2 Weeks After Start Anti-fungal Therapy|Diagnosed with Possible IA|65
6115459|NCT00854620|9736669|FG000|Overall Study|Adverse Event|1
6115460|NCT00854724|9736675|FG000|First Intervention|Withdrawal by Subject|1
6115461|NCT00854724|9736676|FG001|First Intervention|Withdrawal by Subject|1
6115462|NCT00854724|9736675|FG000|Washout|Protocol Violation|1
6115463|NCT00854724|9736676|FG001|Washout|Protocol Violation|0
6115464|NCT00854724|9736675|FG000|Washout|Withdrawal by Subject|0
6115465|NCT00854724|9736676|FG001|Washout|Withdrawal by Subject|1
6115466|NCT00854724|9736675|FG000|Second Intervention|Protocol Violation|1
6115467|NCT00854724|9736676|FG001|Second Intervention|Protocol Violation|0
6115468|NCT00854724|9736675|FG000|Second Intervention|Physician Decision|0
6115469|NCT00854724|9736676|FG001|Second Intervention|Physician Decision|1
6115470|NCT00854828|9736686|FG000|Overall Study|Death|1
6115471|NCT00854828|9736687|FG001|Overall Study|Death|0
6115472|NCT00854828|9736688|FG002|Overall Study|Death|0
6115473|NCT00854828|9736689|FG003|Overall Study|Death|0
6115474|NCT00854828|9736686|FG000|Overall Study|Withdrawal by Subject|1
6115475|NCT00854828|9736687|FG001|Overall Study|Withdrawal by Subject|1
6115476|NCT00854828|9736688|FG002|Overall Study|Withdrawal by Subject|0
6115477|NCT00854828|9736689|FG003|Overall Study|Withdrawal by Subject|9
6115478|NCT00854828|9736686|FG000|Overall Study|Missed 24mo visit|1
6115479|NCT00854828|9736687|FG001|Overall Study|Missed 24mo visit|1
6115480|NCT00854828|9736688|FG002|Overall Study|Missed 24mo visit|8
6115481|NCT00854828|9736689|FG003|Overall Study|Missed 24mo visit|8
6115482|NCT00854906|9736699|FG000|Overall Study|One person had no ocular history|1
6115483|NCT00855062|9736721|FG000|Step1|Early Study Closure|5
6115484|NCT00855062|9736722|FG001|Step1|Early Study Closure|7
6115485|NCT00855062|9736721|FG000|Step1|Adverse Event|1
6115486|NCT00855062|9736722|FG001|Step1|Adverse Event|1
6115487|NCT00855062|9736721|FG000|Step1|Protocol Violation|1
6115488|NCT00855062|9736722|FG001|Step1|Protocol Violation|0
6115489|NCT00855062|9736721|FG000|Step1|Pregnancy|1
6115490|NCT00855062|9736722|FG001|Step1|Pregnancy|0
6115491|NCT00855062|9736721|FG000|Step1|Withdrawal by Subject|2
6115492|NCT00855062|9736722|FG001|Step1|Withdrawal by Subject|3
6115493|NCT00855062|9736721|FG000|Step2|Early Study Closure|6
6115494|NCT00855062|9736722|FG001|Step2|Early Study Closure|2
6115495|NCT00855062|9736721|FG000|Step2|Adverse Event|0
6115496|NCT00855062|9736722|FG001|Step2|Adverse Event|3
6115497|NCT00855062|9736721|FG000|Step2|Initiation of antiretroviral therapy/ART|0
6115498|NCT00855062|9736722|FG001|Step2|Initiation of antiretroviral therapy/ART|1
6115499|NCT00855166|9736730|FG000|Overall Study|Adverse Event|0
6115500|NCT00855166|9736731|FG001|Overall Study|Adverse Event|2
6115501|NCT00855166|9736730|FG000|Overall Study|Death|0
6115502|NCT00855166|9736731|FG001|Overall Study|Death|1
6115503|NCT00855166|9736730|FG000|Overall Study|Withdrawal by Subject|1
6115504|NCT00855166|9736731|FG001|Overall Study|Withdrawal by Subject|4
6115505|NCT00855166|9736730|FG000|Overall Study|Poor/non-compliance|2
6115506|NCT00855166|9736731|FG001|Overall Study|Poor/non-compliance|0
6115507|NCT00855166|9736730|FG000|Overall Study|Administrative reasons by sponsor|1
6115508|NCT00855166|9736731|FG001|Overall Study|Administrative reasons by sponsor|0
6115509|NCT00855166|9736730|FG000|Overall Study|Subject no longer meets study criteria|1
6115510|NCT00855166|9736731|FG001|Overall Study|Subject no longer meets study criteria|1
6115511|NCT00855218|9736741|FG000|Overall Study|Adverse Event|43
6115512|NCT00855218|9736742|FG001|Overall Study|Adverse Event|27
6115513|NCT00855218|9736741|FG000|Overall Study|Withdrawal by Subject|10
6115514|NCT00855218|9736742|FG001|Overall Study|Withdrawal by Subject|6
6115515|NCT00855218|9736741|FG000|Overall Study|Physician Decision|18
6115516|NCT00855218|9736742|FG001|Overall Study|Physician Decision|11
6115517|NCT00855218|9736741|FG000|Overall Study|Lost to Follow-up|0
6115518|NCT00855218|9736742|FG001|Overall Study|Lost to Follow-up|1
6115519|NCT00855218|9736741|FG000|Overall Study|Protocol Violation|5
6115520|NCT00855218|9736742|FG001|Overall Study|Protocol Violation|9
6115521|NCT00855218|9736741|FG000|Overall Study|non-compliant with study drug|3
6115522|NCT00855218|9736742|FG001|Overall Study|non-compliant with study drug|1
6115523|NCT00855218|9736741|FG000|Overall Study|patient convenience|2
6115524|NCT00855218|9736742|FG001|Overall Study|patient convenience|0
6115525|NCT00855218|9736741|FG000|Overall Study|technical problems|2
6115526|NCT00855218|9736742|FG001|Overall Study|technical problems|1
6115527|NCT00855218|9736741|FG000|Overall Study|Still treated with study medication|0
6115528|NCT00855218|9736742|FG001|Overall Study|Still treated with study medication|1
6115529|NCT00855218|9736741|FG000|Overall Study|Untreatable disease progression|54
6115530|NCT00855218|9736742|FG001|Overall Study|Untreatable disease progression|67
6115531|NCT00855218|9736741|FG000|Overall Study|Second malignancy|0
6115532|NCT00855218|9736742|FG001|Overall Study|Second malignancy|1
6115533|NCT00855218|9736741|FG000|Overall Study|Progression measurement proven|7
6115534|NCT00855218|9736742|FG001|Overall Study|Progression measurement proven|15
6115535|NCT00855218|9736741|FG000|Overall Study|Clinical endpoint reached|10
6209638|NCT01574703|9874984|FG000|Overall Study|Adverse Event|0
6209639|NCT01574703|9874985|FG001|Overall Study|Adverse Event|2
6209640|NCT01574703|9874986|FG002|Overall Study|Adverse Event|1
6209641|NCT01574703|9874987|FG003|Overall Study|Adverse Event|1
6209642|NCT01574703|9874984|FG000|Overall Study|Protocol Violation|0
6209643|NCT01574703|9874985|FG001|Overall Study|Protocol Violation|0
6209644|NCT01574703|9874986|FG002|Overall Study|Protocol Violation|0
6209645|NCT01574703|9874987|FG003|Overall Study|Protocol Violation|1
6209646|NCT01574703|9874984|FG000|Overall Study|Unspecified Reason|27
6209647|NCT01574703|9874985|FG001|Overall Study|Unspecified Reason|15
6209648|NCT01574703|9874986|FG002|Overall Study|Unspecified Reason|20
6209649|NCT01574703|9874987|FG003|Overall Study|Unspecified Reason|16
6209650|NCT01574703|9874984|FG000|Overall Study|Withdrawal by Subject|53
6209651|NCT01574703|9874985|FG001|Overall Study|Withdrawal by Subject|52
6209652|NCT01574703|9874986|FG002|Overall Study|Withdrawal by Subject|36
6209653|NCT01574703|9874987|FG003|Overall Study|Withdrawal by Subject|61
6209654|NCT01574703|9874984|FG000|Overall Study|Met Withdrawal Criteria|0
6209655|NCT01574703|9874985|FG001|Overall Study|Met Withdrawal Criteria|1
6209656|NCT01574703|9874986|FG002|Overall Study|Met Withdrawal Criteria|1
6209657|NCT01574703|9874987|FG003|Overall Study|Met Withdrawal Criteria|0
6209658|NCT01574703|9874984|FG000|Overall Study|Lost to Follow-up|43
6209659|NCT01574703|9874985|FG001|Overall Study|Lost to Follow-up|41
6209660|NCT01574703|9874986|FG002|Overall Study|Lost to Follow-up|46
6209661|NCT01574703|9874987|FG003|Overall Study|Lost to Follow-up|35
6209662|NCT01574703|9874984|FG000|Overall Study|Death|2
6209663|NCT01574703|9874985|FG001|Overall Study|Death|1
6115536|NCT00855218|9736742|FG001|Overall Study|Clinical endpoint reached|13
6115537|NCT00855309|9736750|FG000|Overall Study|patient never recieved drug|1
6115538|NCT00855309|9736751|FG001|Overall Study|patient never recieved drug|0
6115539|NCT00855335|9736762|FG000|Overall Study|Lost to Follow-up|0
6115540|NCT00855335|9736763|FG001|Overall Study|Lost to Follow-up|0
6115541|NCT00855335|9736764|FG002|Overall Study|Lost to Follow-up|3
6115542|NCT00855335|9736765|FG003|Overall Study|Lost to Follow-up|1
6115543|NCT00855335|9736766|FG004|Overall Study|Lost to Follow-up|0
6115544|NCT00855335|9736762|FG000|Overall Study|Withdrawal by Subject|0
6115545|NCT00855335|9736763|FG001|Overall Study|Withdrawal by Subject|0
6115546|NCT00855335|9736764|FG002|Overall Study|Withdrawal by Subject|0
6115547|NCT00855335|9736765|FG003|Overall Study|Withdrawal by Subject|1
6209664|NCT01574703|9874986|FG002|Overall Study|Death|1
6115548|NCT00855335|9736766|FG004|Overall Study|Withdrawal by Subject|0
6115549|NCT00855335|9736762|FG000|Overall Study|Adverse Event|2
6115550|NCT00855335|9736763|FG001|Overall Study|Adverse Event|0
6115551|NCT00855335|9736764|FG002|Overall Study|Adverse Event|0
6115552|NCT00855335|9736765|FG003|Overall Study|Adverse Event|0
6115553|NCT00855335|9736766|FG004|Overall Study|Adverse Event|0
6115554|NCT00855335|9736762|FG000|Overall Study|Physician Decision|1
6115555|NCT00855335|9736763|FG001|Overall Study|Physician Decision|1
6115556|NCT00855335|9736764|FG002|Overall Study|Physician Decision|0
6115557|NCT00855335|9736765|FG003|Overall Study|Physician Decision|0
6115558|NCT00855335|9736766|FG004|Overall Study|Physician Decision|0
6115559|NCT00855335|9736762|FG000|Overall Study|Other|2
6115560|NCT00855335|9736763|FG001|Overall Study|Other|1
6115561|NCT00855335|9736764|FG002|Overall Study|Other|2
6115562|NCT00855335|9736765|FG003|Overall Study|Other|5
6115563|NCT00855335|9736766|FG004|Overall Study|Other|1
6115564|NCT00855439|9736797|FG000|Overall Study|Withdrawal by Subject|2
6115565|NCT00855439|9736798|FG001|Overall Study|Withdrawal by Subject|0
6115566|NCT00855439|9736797|FG000|Overall Study|Pregnancy|1
6115567|NCT00855439|9736798|FG001|Overall Study|Pregnancy|0
6115568|NCT00855465|9736806|FG000|Treatment Period|Adverse Event|4
6115569|NCT00855465|9736807|FG001|Treatment Period|Adverse Event|2
6209665|NCT01574703|9874987|FG003|Overall Study|Death|0
6209666|NCT01574716|9875002|FG000|Part 1|Death|3
6209667|NCT01574716|9875003|FG001|Part 1|Death|1
6209668|NCT01574716|9875004|FG002|Part 1|Death|8
6209669|NCT01574716|9875005|FG003|Part 1|Death|0
6209670|NCT01574716|9875006|FG004|Part 1|Death|0
6209671|NCT01574716|9875002|FG000|Part 1|Discontinuation of study by sponsor|0
6209672|NCT01574716|9875003|FG001|Part 1|Discontinuation of study by sponsor|0
6209673|NCT01574716|9875004|FG002|Part 1|Discontinuation of study by sponsor|1
6209674|NCT01574716|9875005|FG003|Part 1|Discontinuation of study by sponsor|0
6209675|NCT01574716|9875006|FG004|Part 1|Discontinuation of study by sponsor|0
6209676|NCT01574716|9875002|FG000|Part 1|Withdrawal by Subject|0
6209677|NCT01574716|9875003|FG001|Part 1|Withdrawal by Subject|2
6209678|NCT01574716|9875004|FG002|Part 1|Withdrawal by Subject|0
6209679|NCT01574716|9875005|FG003|Part 1|Withdrawal by Subject|0
6209680|NCT01574716|9875006|FG004|Part 1|Withdrawal by Subject|0
6209681|NCT01574716|9875002|FG000|Part 1|Lost to Follow-up|0
6209682|NCT01574716|9875003|FG001|Part 1|Lost to Follow-up|1
6209683|NCT01574716|9875004|FG002|Part 1|Lost to Follow-up|0
6209684|NCT01574716|9875005|FG003|Part 1|Lost to Follow-up|0
6209685|NCT01574716|9875006|FG004|Part 1|Lost to Follow-up|0
6209686|NCT01574716|9875002|FG000|Part 2|Progressive disease|0
6209687|NCT01574716|9875003|FG001|Part 2|Progressive disease|0
6209688|NCT01574716|9875004|FG002|Part 2|Progressive disease|0
6209689|NCT01574716|9875005|FG003|Part 2|Progressive disease|1
6209690|NCT01574716|9875006|FG004|Part 2|Progressive disease|0
6209691|NCT01574716|9875002|FG000|Part 2|Death|0
6209692|NCT01574716|9875003|FG001|Part 2|Death|0
6209693|NCT01574716|9875004|FG002|Part 2|Death|0
6209694|NCT01574716|9875005|FG003|Part 2|Death|76
6209695|NCT01574716|9875006|FG004|Part 2|Death|35
6209696|NCT01574716|9875002|FG000|Part 2|Discontinuation of study by sponsor|0
6209697|NCT01574716|9875003|FG001|Part 2|Discontinuation of study by sponsor|0
6209698|NCT01574716|9875004|FG002|Part 2|Discontinuation of study by sponsor|0
6209699|NCT01574716|9875005|FG003|Part 2|Discontinuation of study by sponsor|51
6209700|NCT01574716|9875006|FG004|Part 2|Discontinuation of study by sponsor|31
6209701|NCT01574716|9875002|FG000|Part 2|Withdrawal by Subject|0
6209702|NCT01574716|9875003|FG001|Part 2|Withdrawal by Subject|0
6209703|NCT01574716|9875004|FG002|Part 2|Withdrawal by Subject|0
6209704|NCT01574716|9875005|FG003|Part 2|Withdrawal by Subject|5
6209705|NCT01574716|9875006|FG004|Part 2|Withdrawal by Subject|4
6209706|NCT01574716|9875002|FG000|Part 2|Brain metastases|0
6209707|NCT01574716|9875003|FG001|Part 2|Brain metastases|0
6209708|NCT01574716|9875004|FG002|Part 2|Brain metastases|0
6209709|NCT01574716|9875005|FG003|Part 2|Brain metastases|1
6209710|NCT01574716|9875006|FG004|Part 2|Brain metastases|0
6209711|NCT01574716|9875002|FG000|Part 2|Lost to Follow-up|0
6209712|NCT01574716|9875003|FG001|Part 2|Lost to Follow-up|0
6209713|NCT01574716|9875004|FG002|Part 2|Lost to Follow-up|0
6209714|NCT01574716|9875005|FG003|Part 2|Lost to Follow-up|3
6209715|NCT01574716|9875006|FG004|Part 2|Lost to Follow-up|0
6286549|NCT02346240|9999194|FG003|Maintenance Period (Week 16 to Week 48)|Sponsor decision due to non-compliance|0
6286550|NCT02346240|9999195|FG004|Maintenance Period (Week 16 to Week 48)|Sponsor decision due to non-compliance|0
6286551|NCT02346240|9999196|FG005|Maintenance Period (Week 16 to Week 48)|Sponsor decision due to non-compliance|0
6286552|NCT02346240|9999197|FG006|Maintenance Period (Week 16 to Week 48)|Sponsor decision due to non-compliance|0
6286553|NCT02346240|9999198|FG007|Maintenance Period (Week 16 to Week 48)|Sponsor decision due to non-compliance|0
6286554|NCT02346240|9999199|FG008|Maintenance Period (Week 16 to Week 48)|Sponsor decision due to non-compliance|1
6286555|NCT02346240|9999200|FG009|Maintenance Period (Week 16 to Week 48)|Sponsor decision due to non-compliance|0
6286556|NCT02346240|9999201|FG010|Maintenance Period (Week 16 to Week 48)|Sponsor decision due to non-compliance|0
6286557|NCT02346240|9999202|FG011|Maintenance Period (Week 16 to Week 48)|Sponsor decision due to non-compliance|1
6286558|NCT02346240|9999203|FG012|Maintenance Period (Week 16 to Week 48)|Sponsor decision due to non-compliance|0
6115570|NCT00855465|9736806|FG000|Treatment Period|Death|2
6115571|NCT00855465|9736807|FG001|Treatment Period|Death|2
6115572|NCT00855465|9736806|FG000|Treatment Period|Lack of Efficacy|2
6115573|NCT00855465|9736807|FG001|Treatment Period|Lack of Efficacy|1
6209716|NCT01575054|9875023|FG000|Overall Study|Other Reasons|5
6209717|NCT01575054|9875024|FG001|Overall Study|Other Reasons|3
6209718|NCT01575054|9875023|FG000|Overall Study|Protocol Violation|2
6209719|NCT01575054|9875024|FG001|Overall Study|Protocol Violation|1
6209720|NCT01575054|9875023|FG000|Overall Study|Personal Reasons|10
6209721|NCT01575054|9875024|FG001|Overall Study|Personal Reasons|11
6209722|NCT01575054|9875023|FG000|Overall Study|Lost to Follow-up|3
6209723|NCT01575054|9875024|FG001|Overall Study|Lost to Follow-up|3
6209724|NCT01575054|9875023|FG000|Overall Study|Adverse Event|9
6209725|NCT01575054|9875024|FG001|Overall Study|Adverse Event|8
6209726|NCT01575197|9875042|FG000|Overall Study|Migration out of study area|1
6209727|NCT01575197|9875043|FG001|Overall Study|Migration out of study area|5
6209728|NCT01575197|9875044|FG002|Overall Study|Migration out of study area|4
6209729|NCT01575197|9875042|FG000|Overall Study|SAE|0
6209730|NCT01575197|9875043|FG001|Overall Study|SAE|1
6209731|NCT01575197|9875044|FG002|Overall Study|SAE|0
6209732|NCT01575197|9875042|FG000|Overall Study|Lost to Follow-up|0
6209733|NCT01575197|9875043|FG001|Overall Study|Lost to Follow-up|1
6209734|NCT01575197|9875044|FG002|Overall Study|Lost to Follow-up|0
6209735|NCT01575197|9875042|FG000|Overall Study|Withdrawal by Subject|0
6209736|NCT01575197|9875043|FG001|Overall Study|Withdrawal by Subject|1
6209737|NCT01575197|9875044|FG002|Overall Study|Withdrawal by Subject|1
6209738|NCT01575197|9875042|FG000|Overall Study|Protocol Violation|2
6209739|NCT01575197|9875043|FG001|Overall Study|Protocol Violation|1
6209740|NCT01575197|9875044|FG002|Overall Study|Protocol Violation|1
6209741|NCT01575561|9875063|FG000|Overall Study|Adverse Event|9
6209742|NCT01575561|9875063|FG000|Overall Study|Lack of Efficacy|8
6209743|NCT01575561|9875063|FG000|Overall Study|Lost to Follow-up|6
6209744|NCT01575561|9875063|FG000|Overall Study|Protocol Violation|4
6209745|NCT01575561|9875063|FG000|Overall Study|Withdrawal by Subject|11
6209746|NCT01575561|9875063|FG000|Overall Study|administration|1
6209747|NCT01575769|9875075|FG000|Overall Study|Adverse Event|1
6209748|NCT01575769|9875075|FG000|Overall Study|Study terminated by sponsor|40
6209749|NCT01575808|9875083|FG000|Overall Study|Death|2
6209750|NCT01575808|9875084|FG001|Overall Study|Death|0
6209751|NCT01575808|9875083|FG000|Overall Study|Withdrawal by Subject|1
6209752|NCT01575808|9875084|FG001|Overall Study|Withdrawal by Subject|0
6209753|NCT01575834|9875094|FG000|Overall Study|Withdrawal by Subject|352
6209754|NCT01575834|9875095|FG001|Overall Study|Withdrawal by Subject|390
6209755|NCT01575834|9875094|FG000|Overall Study|Death|81
6209756|NCT01575834|9875095|FG001|Overall Study|Death|74
6209757|NCT01575834|9875094|FG000|Overall Study|Other|70
6209758|NCT01575834|9875095|FG001|Overall Study|Other|70
6209759|NCT01575834|9875094|FG000|Overall Study|Adverse Event|63
6209760|NCT01575834|9875095|FG001|Overall Study|Adverse Event|61
6209761|NCT01575834|9875094|FG000|Overall Study|Lost to Follow-up|55
6209762|NCT01575834|9875095|FG001|Overall Study|Lost to Follow-up|68
6209763|NCT01575834|9875094|FG000|Overall Study|Noncompliance|52
6209764|NCT01575834|9875095|FG001|Overall Study|Noncompliance|27
6115574|NCT00855465|9736806|FG000|Treatment Period|Non-compliance|1
6115575|NCT00855465|9736807|FG001|Treatment Period|Non-compliance|0
6115576|NCT00855465|9736806|FG000|Treatment Period|Protocol Violation|2
6115577|NCT00855465|9736807|FG001|Treatment Period|Protocol Violation|0
6115578|NCT00855465|9736806|FG000|Treatment Period|Withdrawal by Subject|2
6115579|NCT00855465|9736807|FG001|Treatment Period|Withdrawal by Subject|0
6115580|NCT00855465|9736806|FG000|Treatment Period|Not treated|1
6115581|NCT00855465|9736807|FG001|Treatment Period|Not treated|0
6115582|NCT00855465|9736806|FG000|Follow-up Period (FUP)|Adverse Event|0
6115583|NCT00855465|9736807|FG001|Follow-up Period (FUP)|Adverse Event|1
6115584|NCT00855465|9736806|FG000|Follow-up Period (FUP)|Death|0
6115585|NCT00855465|9736807|FG001|Follow-up Period (FUP)|Death|1
6115586|NCT00855465|9736806|FG000|Follow-up Period (FUP)|Lost to Follow-up|3
6115587|NCT00855465|9736807|FG001|Follow-up Period (FUP)|Lost to Follow-up|0
6115588|NCT00855465|9736806|FG000|Follow-up Period (FUP)|Withdrawal by Subject|4
6115589|NCT00855465|9736807|FG001|Follow-up Period (FUP)|Withdrawal by Subject|0
6115590|NCT00855465|9736806|FG000|Follow-up Period (FUP)|Missing|1
6115591|NCT00855465|9736807|FG001|Follow-up Period (FUP)|Missing|0
6115592|NCT00855582|9736816|FG000|Overall Study|Adverse Event|2
6115593|NCT00855582|9736817|FG001|Overall Study|Adverse Event|6
6115594|NCT00855582|9736818|FG002|Overall Study|Adverse Event|3
6115595|NCT00855582|9736816|FG000|Overall Study|Death|1
6115596|NCT00855582|9736817|FG001|Overall Study|Death|0
6115597|NCT00855582|9736818|FG002|Overall Study|Death|0
6115598|NCT00855582|9736816|FG000|Overall Study|Lack of Efficacy|1
6115599|NCT00855582|9736817|FG001|Overall Study|Lack of Efficacy|3
6115600|NCT00855582|9736818|FG002|Overall Study|Lack of Efficacy|8
6115601|NCT00855582|9736816|FG000|Overall Study|Lost to Follow-up|1
6115602|NCT00855582|9736817|FG001|Overall Study|Lost to Follow-up|3
6115603|NCT00855582|9736818|FG002|Overall Study|Lost to Follow-up|1
6115604|NCT00855582|9736816|FG000|Overall Study|Physician Decision|0
6209765|NCT01575834|9875094|FG000|Overall Study|Administrative decision|15
6209766|NCT01575834|9875095|FG001|Overall Study|Administrative decision|33
6209767|NCT01575834|9875094|FG000|Overall Study|Ineligibility Determined|5
6209768|NCT01575834|9875095|FG001|Overall Study|Ineligibility Determined|8
6115605|NCT00855582|9736817|FG001|Overall Study|Physician Decision|0
6115606|NCT00855582|9736818|FG002|Overall Study|Physician Decision|1
6115607|NCT00855582|9736816|FG000|Overall Study|Protocol Violation|6
6115608|NCT00855582|9736817|FG001|Overall Study|Protocol Violation|2
6115609|NCT00855582|9736818|FG002|Overall Study|Protocol Violation|6
6115610|NCT00855582|9736816|FG000|Overall Study|Entry Criteria Not Met|8
6115611|NCT00855582|9736817|FG001|Overall Study|Entry Criteria Not Met|6
6115612|NCT00855582|9736818|FG002|Overall Study|Entry Criteria Not Met|3
6115613|NCT00855582|9736816|FG000|Overall Study|Withdrawal by Subject|7
6115614|NCT00855582|9736817|FG001|Overall Study|Withdrawal by Subject|4
6115615|NCT00855582|9736818|FG002|Overall Study|Withdrawal by Subject|8
6115616|NCT00855595|9736831|FG000|Overall Study|Withdrawal by Subject|1
6115617|NCT00855595|9736832|FG001|Overall Study|Withdrawal by Subject|2
6115618|NCT00855595|9736831|FG000|Overall Study|Lost to Follow-up|3
6115619|NCT00855595|9736832|FG001|Overall Study|Lost to Follow-up|3
6115620|NCT00855595|9736831|FG000|Overall Study|Adverse Event|1
6115621|NCT00855595|9736832|FG001|Overall Study|Adverse Event|1
6115622|NCT00855595|9736831|FG000|Overall Study|patient moved out of state|1
6115623|NCT00855595|9736832|FG001|Overall Study|patient moved out of state|0
6115624|NCT00855595|9736831|FG000|Overall Study|patient left country|0
6115625|NCT00855595|9736832|FG001|Overall Study|patient left country|1
6115626|NCT00855738|9736838|FG000|Overall Study|Lost to Follow-up|2
6115627|NCT00855738|9736838|FG000|Overall Study|Adverse Event|1
6115628|NCT00855738|9736838|FG000|Overall Study|Subject Defaulted|1
6209769|NCT01575834|9875094|FG000|Overall Study|Protocol Deviation|4
6209770|NCT01575834|9875095|FG001|Overall Study|Protocol Deviation|3
6209771|NCT01575834|9875094|FG000|Overall Study|Requirement for Alternative Therapy|2
6209772|NCT01575834|9875095|FG001|Overall Study|Requirement for Alternative Therapy|4
6209773|NCT01575860|9875105|FG000|Overall Study|Withdrawal by Subject|1
6209774|NCT01575860|9875105|FG000|Overall Study|Progression Prior to Lenalidomide Maint.|1
6209775|NCT01575873|9875114|FG000|Overall Study|Withdrawal by Subject|15
6209776|NCT01575873|9875115|FG001|Overall Study|Withdrawal by Subject|20
6209777|NCT01575873|9875116|FG002|Overall Study|Withdrawal by Subject|34
6209778|NCT01575873|9875117|FG003|Overall Study|Withdrawal by Subject|34
6209779|NCT01575873|9875114|FG000|Overall Study|Adverse Event|7
6209780|NCT01575873|9875115|FG001|Overall Study|Adverse Event|7
6209781|NCT01575873|9875116|FG002|Overall Study|Adverse Event|9
6209782|NCT01575873|9875117|FG003|Overall Study|Adverse Event|12
6209783|NCT01575873|9875114|FG000|Overall Study|Lost to Follow-up|1
6209784|NCT01575873|9875115|FG001|Overall Study|Lost to Follow-up|3
6209785|NCT01575873|9875116|FG002|Overall Study|Lost to Follow-up|13
6209786|NCT01575873|9875117|FG003|Overall Study|Lost to Follow-up|5
6209787|NCT01575873|9875114|FG000|Overall Study|Death|3
6209788|NCT01575873|9875115|FG001|Overall Study|Death|2
6209789|NCT01575873|9875116|FG002|Overall Study|Death|8
6209790|NCT01575873|9875117|FG003|Overall Study|Death|9
6209791|NCT01575873|9875114|FG000|Overall Study|Noncompliance|1
6209792|NCT01575873|9875115|FG001|Overall Study|Noncompliance|2
6209793|NCT01575873|9875116|FG002|Overall Study|Noncompliance|4
6209794|NCT01575873|9875117|FG003|Overall Study|Noncompliance|3
6209795|NCT01575873|9875114|FG000|Overall Study|Administrative decision|1
6209796|NCT01575873|9875115|FG001|Overall Study|Administrative decision|1
6209797|NCT01575873|9875116|FG002|Overall Study|Administrative decision|1
6209798|NCT01575873|9875117|FG003|Overall Study|Administrative decision|0
6209799|NCT01575873|9875114|FG000|Overall Study|Protocol deviation|0
6209800|NCT01575873|9875115|FG001|Overall Study|Protocol deviation|1
6209801|NCT01575873|9875116|FG002|Overall Study|Protocol deviation|0
6209802|NCT01575873|9875117|FG003|Overall Study|Protocol deviation|1
6209803|NCT01575873|9875114|FG000|Overall Study|Requirement for Alternative Therapy|0
6209804|NCT01575873|9875115|FG001|Overall Study|Requirement for Alternative Therapy|0
6209805|NCT01575873|9875116|FG002|Overall Study|Requirement for Alternative Therapy|1
6209806|NCT01575873|9875117|FG003|Overall Study|Requirement for Alternative Therapy|1
6209807|NCT01575873|9875114|FG000|Overall Study|Other|0
6209808|NCT01575873|9875115|FG001|Overall Study|Other|0
6209809|NCT01575873|9875116|FG002|Overall Study|Other|4
6209810|NCT01575873|9875117|FG003|Overall Study|Other|2
6209811|NCT01575899|9875128|FG000|Overall Study|Lost to Follow-up|3
6209812|NCT01575899|9875129|FG001|Overall Study|Lost to Follow-up|4
6209813|NCT01575899|9875130|FG002|Overall Study|Lost to Follow-up|2
6209814|NCT01575899|9875128|FG000|Overall Study|Protocol Violation|2
6209815|NCT01575899|9875129|FG001|Overall Study|Protocol Violation|1
6209816|NCT01575899|9875130|FG002|Overall Study|Protocol Violation|0
6209817|NCT01576016|9875168|FG000|Lead Safety|Death|132
6115629|NCT00855738|9736838|FG000|Overall Study|Death|1
6115630|NCT00855816|9736846|FG000|Overall Study|Withdrawal by Subject|22
6115631|NCT00855816|9736847|FG001|Overall Study|Withdrawal by Subject|15
6209818|NCT01576016|9875169|FG001|Lead Safety|Death|0
6209819|NCT01576016|9875168|FG000|Lead Safety|Withdrawal by Subject|81
6209820|NCT01576016|9875169|FG001|Lead Safety|Withdrawal by Subject|0
6209821|NCT01576016|9875168|FG000|Lead Safety|System Explanted without Replacement|24
6209822|NCT01576016|9875169|FG001|Lead Safety|System Explanted without Replacement|0
6209823|NCT01576016|9875168|FG000|Lead Safety|Physician Decision|14
6209824|NCT01576016|9875169|FG001|Lead Safety|Physician Decision|0
6209825|NCT01576016|9875168|FG000|Lead Safety|Lost to Follow-up|13
6115632|NCT00855816|9736846|FG000|Overall Study|Lost to Follow-up|3
6209826|NCT01576016|9875169|FG001|Lead Safety|Lost to Follow-up|0
6115633|NCT00855816|9736847|FG001|Overall Study|Lost to Follow-up|5
6115634|NCT00855816|9736846|FG000|Overall Study|Death|1
6209827|NCT01576016|9875168|FG000|Lead Safety|Unsuccessful implant|2
6209828|NCT01576016|9875169|FG001|Lead Safety|Unsuccessful implant|0
6209829|NCT01576016|9875168|FG000|Lead Safety|Sponsor request|1
6209830|NCT01576016|9875169|FG001|Lead Safety|Sponsor request|0
6209831|NCT01576016|9875168|FG000|Lead Safety|Device replaced with CRT-D|1
6209832|NCT01576016|9875169|FG001|Lead Safety|Device replaced with CRT-D|0
6209833|NCT01576016|9875168|FG000|Lead Safety|Patient on Palliative Care|1
6209834|NCT01576016|9875169|FG001|Lead Safety|Patient on Palliative Care|0
6209835|NCT01576016|9875168|FG000|Lead Safety|Patient noncompliance|1
6209836|NCT01576016|9875169|FG001|Lead Safety|Patient noncompliance|0
6209837|NCT01576016|9875168|FG000|Lead Safety|Too far from study site|1
6209838|NCT01576016|9875169|FG001|Lead Safety|Too far from study site|0
6209839|NCT01576016|9875168|FG000|Lead Safety|System deactivated|1
6209840|NCT01576016|9875169|FG001|Lead Safety|System deactivated|0
6209841|NCT01576016|9875168|FG000|Lead Safety|Patient no longer followed by study PI|1
6209842|NCT01576016|9875169|FG001|Lead Safety|Patient no longer followed by study PI|0
6209843|NCT01576016|9875168|FG000|MRI Safety|Withdrawal by Subject|0
6209844|NCT01576016|9875169|FG001|MRI Safety|Withdrawal by Subject|10
6209845|NCT01576016|9875168|FG000|MRI Safety|Non-MRI Compatible Device or Material|0
6209846|NCT01576016|9875169|FG001|MRI Safety|Non-MRI Compatible Device or Material|5
6209847|NCT01576016|9875168|FG000|MRI Safety|Has not yet completed MRI scan|0
6209848|NCT01576016|9875169|FG001|MRI Safety|Has not yet completed MRI scan|56
6209849|NCT01576016|9875168|FG000|MRI Safety|MRI scan not performed at MRI visit|0
6209850|NCT01576016|9875169|FG001|MRI Safety|MRI scan not performed at MRI visit|3
6209851|NCT01576042|9875179|FG000|Overall Study|Physician Decision|2
6209852|NCT01576042|9875180|FG001|Overall Study|Physician Decision|0
6209853|NCT01576146|9875204|FG000|Extension Period 1|Adverse Event|2
6209854|NCT01576146|9875204|FG000|Extension Period 1|Death|2
6209855|NCT01576146|9875204|FG000|Extension Period 1|Physician Decision|2
6209856|NCT01576146|9875204|FG000|Extension Period 1|Withdrawal by Subject|1
6209857|NCT01576146|9875204|FG000|Extension Period 1|Lost to Follow-up|1
6209858|NCT01576146|9875204|FG000|Extension Period 1|Parathyroidectomy|1
6209859|NCT01576146|9875204|FG000|Extension Period 1|Renal Transplant|1
6209860|NCT01576146|9875204|FG000|Extension Period 2|Sponsor Decision|13
6209861|NCT01576146|9875204|FG000|Extension Period 2|Death|1
6209862|NCT01576146|9875204|FG000|Extension Period 2|Adverse Event|1
6209863|NCT01576146|9875204|FG000|Extension Period 2|Renal Transplant|1
6209864|NCT01576146|9875204|FG000|Extension Period 2|Treatment Not Resumed Within 8 Weeks|1
6209865|NCT01576159|9875212|FG000|Overall Study|Withdrawal by Subject|0
6209866|NCT01576159|9875213|FG001|Overall Study|Withdrawal by Subject|1
6209867|NCT01576159|9875214|FG002|Overall Study|Withdrawal by Subject|0
6209868|NCT01576159|9875215|FG003|Overall Study|Withdrawal by Subject|0
6209869|NCT01576159|9875212|FG000|Overall Study|Physician Decision|0
6209870|NCT01576159|9875213|FG001|Overall Study|Physician Decision|0
6209871|NCT01576159|9875214|FG002|Overall Study|Physician Decision|1
6209872|NCT01576159|9875215|FG003|Overall Study|Physician Decision|0
6209873|NCT01576159|9875212|FG000|Overall Study|Lost to Follow-up|0
6209874|NCT01576159|9875213|FG001|Overall Study|Lost to Follow-up|0
6209875|NCT01576159|9875214|FG002|Overall Study|Lost to Follow-up|0
6209876|NCT01576159|9875215|FG003|Overall Study|Lost to Follow-up|1
6115635|NCT00855816|9736847|FG001|Overall Study|Death|0
6115636|NCT00855816|9736846|FG000|Overall Study|Became ineligible|0
6115637|NCT00855816|9736847|FG001|Overall Study|Became ineligible|1
6115638|NCT00855894|9736866|FG000|Overall Study|Death|31
6115639|NCT00855894|9736866|FG000|Overall Study|Patient's decision|1
6115640|NCT00855894|9736866|FG000|Overall Study|Disease progression|1
6115641|NCT00855920|9736873|FG000|Overall Study|Protocol Violation|0
6115642|NCT00855920|9736874|FG001|Overall Study|Protocol Violation|0
6115643|NCT00855920|9736875|FG002|Overall Study|Protocol Violation|2
6115644|NCT00855920|9736873|FG000|Overall Study|Adverse Event|2
6115645|NCT00855920|9736874|FG001|Overall Study|Adverse Event|1
6115646|NCT00855920|9736875|FG002|Overall Study|Adverse Event|1
6115647|NCT00855920|9736873|FG000|Overall Study|Lack of Efficacy|2
6115648|NCT00855920|9736874|FG001|Overall Study|Lack of Efficacy|2
6115649|NCT00855920|9736875|FG002|Overall Study|Lack of Efficacy|2
6115650|NCT00855920|9736873|FG000|Overall Study|Withdrawal by Subject|2
6115651|NCT00855920|9736874|FG001|Overall Study|Withdrawal by Subject|3
6115652|NCT00855920|9736875|FG002|Overall Study|Withdrawal by Subject|2
6115653|NCT00855920|9736873|FG000|Overall Study|Lost to Follow-up|1
6115654|NCT00855920|9736874|FG001|Overall Study|Lost to Follow-up|0
6115655|NCT00855920|9736875|FG002|Overall Study|Lost to Follow-up|2
6115656|NCT00855920|9736873|FG000|Overall Study|Death|0
6115657|NCT00855920|9736874|FG001|Overall Study|Death|1
6209877|NCT01576159|9875212|FG000|Overall Study|Protocol Violation|1
6209878|NCT01576159|9875213|FG001|Overall Study|Protocol Violation|0
6209879|NCT01576159|9875214|FG002|Overall Study|Protocol Violation|0
6209880|NCT01576159|9875215|FG003|Overall Study|Protocol Violation|0
6209881|NCT01576172|9875234|FG000|Overall Study|Ineligible|2
6209882|NCT01576172|9875235|FG001|Overall Study|Ineligible|1
6209883|NCT01576172|9875234|FG000|Overall Study|Withdrawal by Subject|2
6209884|NCT01576172|9875235|FG001|Overall Study|Withdrawal by Subject|0
6115658|NCT00855920|9736875|FG002|Overall Study|Death|0
6209885|NCT01576172|9875234|FG000|Overall Study|Insurance issue|1
6115659|NCT00855920|9736873|FG000|Overall Study|Decision by the sponsor|0
6115660|NCT00855920|9736874|FG001|Overall Study|Decision by the sponsor|1
6115661|NCT00855920|9736875|FG002|Overall Study|Decision by the sponsor|1
6115662|NCT00855920|9736873|FG000|Overall Study|Other than specified above|1
6115663|NCT00855920|9736874|FG001|Overall Study|Other than specified above|1
6115664|NCT00855920|9736875|FG002|Overall Study|Other than specified above|1
6115665|NCT00855933|9736885|FG000|Overall Study|Withdrawal by Subject|0
6115666|NCT00855933|9736886|FG001|Overall Study|Withdrawal by Subject|1
6115667|NCT00855959|9736892|FG000|Overall Study|Adverse Event|2
6115668|NCT00855959|9736892|FG000|Overall Study|Lost to Follow-up|2
6115669|NCT00855959|9736892|FG000|Overall Study|Withdrawal by Subject|3
6115670|NCT00855959|9736892|FG000|Overall Study|Pregnancy|1
6115671|NCT00855959|9736892|FG000|Overall Study|Incorrect enrolment|1
6209886|NCT01576172|9875235|FG001|Overall Study|Insurance issue|0
6209887|NCT01576341|9875253|FG000|Overall Study|Withdrawal by Subject|24
6209888|NCT01576341|9875253|FG000|Overall Study|Adverse Event|10
6209889|NCT01576341|9875253|FG000|Overall Study|Death|21
6209890|NCT01576341|9875253|FG000|Overall Study|Physician Decision|2
6209891|NCT01576341|9875253|FG000|Overall Study|Lost to Follow-up|2
6209892|NCT01576341|9875253|FG000|Overall Study|Kidney transplantation|10
6209893|NCT01576341|9875253|FG000|Overall Study|Protocol Violation|12
6209894|NCT01576341|9875253|FG000|Overall Study|Other|12
6209895|NCT01576367|9875260|FG000|Overall Study|Unsatisfactory therapeutic effect|2
6209896|NCT01576367|9875260|FG000|Overall Study|Moved to commercial use after 6 months|1
6209897|NCT01576406|9875270|FG000|Overall Study|Lost to Follow-up|1
6209898|NCT01576406|9875271|FG001|Overall Study|Lost to Follow-up|2
6209899|NCT01576406|9875272|FG002|Overall Study|Lost to Follow-up|0
6209900|NCT01576406|9875273|FG003|Overall Study|Lost to Follow-up|0
6209901|NCT01576406|9875274|FG004|Overall Study|Lost to Follow-up|0
6209902|NCT01576406|9875275|FG005|Overall Study|Lost to Follow-up|0
6209903|NCT01576406|9875270|FG000|Overall Study|Death|3
6209904|NCT01576406|9875271|FG001|Overall Study|Death|4
6209905|NCT01576406|9875272|FG002|Overall Study|Death|8
6209906|NCT01576406|9875273|FG003|Overall Study|Death|5
6209907|NCT01576406|9875274|FG004|Overall Study|Death|7
6209908|NCT01576406|9875275|FG005|Overall Study|Death|9
6209909|NCT01576406|9875270|FG000|Overall Study|Non-clinical trial supply of Crizotinib|0
6209910|NCT01576406|9875271|FG001|Overall Study|Non-clinical trial supply of Crizotinib|0
6209911|NCT01576406|9875272|FG002|Overall Study|Non-clinical trial supply of Crizotinib|1
6209912|NCT01576406|9875273|FG003|Overall Study|Non-clinical trial supply of Crizotinib|1
6209913|NCT01576406|9875274|FG004|Overall Study|Non-clinical trial supply of Crizotinib|0
6209914|NCT01576406|9875275|FG005|Overall Study|Non-clinical trial supply of Crizotinib|0
6209915|NCT01576406|9875270|FG000|Overall Study|Withdrawal the consent|2
6209916|NCT01576406|9875271|FG001|Overall Study|Withdrawal the consent|2
6209917|NCT01576406|9875272|FG002|Overall Study|Withdrawal the consent|5
6209918|NCT01576406|9875273|FG003|Overall Study|Withdrawal the consent|1
6209919|NCT01576406|9875274|FG004|Overall Study|Withdrawal the consent|1
6209920|NCT01576406|9875275|FG005|Overall Study|Withdrawal the consent|3
6209921|NCT01576406|9875270|FG000|Overall Study|Other|0
6209922|NCT01576406|9875271|FG001|Overall Study|Other|0
6209923|NCT01576406|9875272|FG002|Overall Study|Other|2
6209924|NCT01576406|9875273|FG003|Overall Study|Other|2
6209925|NCT01576406|9875274|FG004|Overall Study|Other|0
6209926|NCT01576406|9875275|FG005|Overall Study|Other|0
6209927|NCT01576484|9875300|FG000|Overall Study|Adverse Event|1
6209928|NCT01576484|9875301|FG001|Overall Study|Adverse Event|1
6209929|NCT01576484|9875300|FG000|Overall Study|Protocol Violation|0
6209930|NCT01576484|9875301|FG001|Overall Study|Protocol Violation|2
6209931|NCT01576484|9875300|FG000|Overall Study|Sponsor Decision|2
6209932|NCT01576484|9875301|FG001|Overall Study|Sponsor Decision|8
6209933|NCT01576484|9875300|FG000|Overall Study|Withdrawal by Subject|0
6209934|NCT01576484|9875301|FG001|Overall Study|Withdrawal by Subject|3
6209935|NCT01576484|9875300|FG000|Overall Study|Other|2
6209936|NCT01576484|9875301|FG001|Overall Study|Other|5
6209937|NCT01576705|9875342|FG000|Overall Study|TSH > 7 mIU/L at baseline|3
6209938|NCT01576705|9875343|FG001|Overall Study|TSH > 7 mIU/L at baseline|7
6209939|NCT01576705|9875344|FG002|Overall Study|TSH > 7 mIU/L at baseline|5
6209940|NCT01576705|9875345|FG003|Overall Study|TSH > 7 mIU/L at baseline|3
6209941|NCT01576705|9875342|FG000|Overall Study|invalid ICF|0
6209942|NCT01576705|9875343|FG001|Overall Study|invalid ICF|1
6209943|NCT01576705|9875344|FG002|Overall Study|invalid ICF|0
6209944|NCT01576705|9875345|FG003|Overall Study|invalid ICF|0
6209945|NCT01576718|9875361|FG000|Pre-Assignment Period (Run-In Placebo)|Inclusion/exclusion criteria|49
6209946|NCT01576718|9875362|FG001|Pre-Assignment Period (Run-In Placebo)|Inclusion/exclusion criteria|0
6209947|NCT01576718|9875363|FG002|Pre-Assignment Period (Run-In Placebo)|Inclusion/exclusion criteria|0
6209948|NCT01576718|9875364|FG003|Pre-Assignment Period (Run-In Placebo)|Inclusion/exclusion criteria|0
6209949|NCT01576718|9875365|FG004|Pre-Assignment Period (Run-In Placebo)|Inclusion/exclusion criteria|0
6209950|NCT01576718|9875366|FG005|Pre-Assignment Period (Run-In Placebo)|Inclusion/exclusion criteria|0
6209951|NCT01576718|9875367|FG006|Pre-Assignment Period (Run-In Placebo)|Inclusion/exclusion criteria|0
6209952|NCT01576718|9875361|FG000|Pre-Assignment Period (Run-In Placebo)|Withdrawal by Subject|17
6209953|NCT01576718|9875362|FG001|Pre-Assignment Period (Run-In Placebo)|Withdrawal by Subject|0
6209954|NCT01576718|9875363|FG002|Pre-Assignment Period (Run-In Placebo)|Withdrawal by Subject|0
6115672|NCT00856180|9736906|FG000|Overall Study|Adverse Event|4
6115673|NCT00856180|9736906|FG000|Overall Study|Progressive Disease|16
6115674|NCT00856193|9736912|FG000|Period 2|Abnormal test procedure results|0
6115675|NCT00856193|9736913|FG001|Period 2|Abnormal test procedure results|1
6115676|NCT00856193|9736912|FG000|Period 2|Lost to Follow-up|0
6115677|NCT00856193|9736913|FG001|Period 2|Lost to Follow-up|1
6115678|NCT00856206|9736921|FG000|Overall Study|Protocol Violation|6
6115679|NCT00856206|9736922|FG001|Overall Study|Protocol Violation|18
6115680|NCT00856206|9736921|FG000|Overall Study|Adverse Event|10
6115681|NCT00856206|9736922|FG001|Overall Study|Adverse Event|46
6115682|NCT00856206|9736921|FG000|Overall Study|Lack of Efficacy|1
6115683|NCT00856206|9736922|FG001|Overall Study|Lack of Efficacy|2
6115684|NCT00856206|9736921|FG000|Overall Study|Withdrawal by Subject|15
6209955|NCT01576718|9875364|FG003|Pre-Assignment Period (Run-In Placebo)|Withdrawal by Subject|0
6209956|NCT01576718|9875365|FG004|Pre-Assignment Period (Run-In Placebo)|Withdrawal by Subject|0
6209957|NCT01576718|9875366|FG005|Pre-Assignment Period (Run-In Placebo)|Withdrawal by Subject|0
6209958|NCT01576718|9875367|FG006|Pre-Assignment Period (Run-In Placebo)|Withdrawal by Subject|0
6286559|NCT02346240|9999204|FG013|Maintenance Period (Week 16 to Week 48)|Sponsor decision due to non-compliance|1
6286560|NCT02346240|9999205|FG014|Maintenance Period (Week 16 to Week 48)|Sponsor decision due to non-compliance|1
6286561|NCT02346240|9999206|FG015|Maintenance Period (Week 16 to Week 48)|Sponsor decision due to non-compliance|0
6286562|NCT02346240|9999207|FG016|Maintenance Period (Week 16 to Week 48)|Sponsor decision due to non-compliance|0
6286563|NCT02346240|9999208|FG017|Maintenance Period (Week 16 to Week 48)|Sponsor decision due to non-compliance|0
6286564|NCT02346240|9999209|FG018|Maintenance Period (Week 16 to Week 48)|Sponsor decision due to non-compliance|0
6286565|NCT02346240|9999210|FG019|Maintenance Period (Week 16 to Week 48)|Sponsor decision due to non-compliance|0
6286566|NCT02346240|9999211|FG020|Maintenance Period (Week 16 to Week 48)|Sponsor decision due to non-compliance|0
6286567|NCT02346240|9999212|FG021|Maintenance Period (Week 16 to Week 48)|Sponsor decision due to non-compliance|0
6286568|NCT02346240|9999213|FG022|Maintenance Period (Week 16 to Week 48)|Sponsor decision due to non-compliance|0
6286569|NCT02346240|9999214|FG023|Maintenance Period (Week 16 to Week 48)|Sponsor decision due to non-compliance|0
6286570|NCT02346240|9999191|FG000|Maintenance Period (Week 16 to Week 48)|Adverse events and alcohol problem|0
6286571|NCT02346240|9999192|FG001|Maintenance Period (Week 16 to Week 48)|Adverse events and alcohol problem|0
6286572|NCT02346240|9999193|FG002|Maintenance Period (Week 16 to Week 48)|Adverse events and alcohol problem|0
6286573|NCT02346240|9999194|FG003|Maintenance Period (Week 16 to Week 48)|Adverse events and alcohol problem|0
6286574|NCT02346240|9999195|FG004|Maintenance Period (Week 16 to Week 48)|Adverse events and alcohol problem|0
6286575|NCT02346240|9999196|FG005|Maintenance Period (Week 16 to Week 48)|Adverse events and alcohol problem|0
6286576|NCT02346240|9999197|FG006|Maintenance Period (Week 16 to Week 48)|Adverse events and alcohol problem|0
6286577|NCT02346240|9999198|FG007|Maintenance Period (Week 16 to Week 48)|Adverse events and alcohol problem|0
6286578|NCT02346240|9999199|FG008|Maintenance Period (Week 16 to Week 48)|Adverse events and alcohol problem|0
6286579|NCT02346240|9999200|FG009|Maintenance Period (Week 16 to Week 48)|Adverse events and alcohol problem|1
6286580|NCT02346240|9999201|FG010|Maintenance Period (Week 16 to Week 48)|Adverse events and alcohol problem|0
6286581|NCT02346240|9999202|FG011|Maintenance Period (Week 16 to Week 48)|Adverse events and alcohol problem|0
6286582|NCT02346240|9999203|FG012|Maintenance Period (Week 16 to Week 48)|Adverse events and alcohol problem|0
6286583|NCT02346240|9999204|FG013|Maintenance Period (Week 16 to Week 48)|Adverse events and alcohol problem|0
6286584|NCT02346240|9999205|FG014|Maintenance Period (Week 16 to Week 48)|Adverse events and alcohol problem|0
6286585|NCT02346240|9999206|FG015|Maintenance Period (Week 16 to Week 48)|Adverse events and alcohol problem|0
6286586|NCT02346240|9999207|FG016|Maintenance Period (Week 16 to Week 48)|Adverse events and alcohol problem|0
6286587|NCT02346240|9999208|FG017|Maintenance Period (Week 16 to Week 48)|Adverse events and alcohol problem|0
6286588|NCT02346240|9999209|FG018|Maintenance Period (Week 16 to Week 48)|Adverse events and alcohol problem|0
6286589|NCT02346240|9999210|FG019|Maintenance Period (Week 16 to Week 48)|Adverse events and alcohol problem|0
6286590|NCT02346240|9999211|FG020|Maintenance Period (Week 16 to Week 48)|Adverse events and alcohol problem|0
6286591|NCT02346240|9999212|FG021|Maintenance Period (Week 16 to Week 48)|Adverse events and alcohol problem|0
6286592|NCT02346240|9999213|FG022|Maintenance Period (Week 16 to Week 48)|Adverse events and alcohol problem|0
6286593|NCT02346240|9999214|FG023|Maintenance Period (Week 16 to Week 48)|Adverse events and alcohol problem|0
6286594|NCT02346240|9999191|FG000|Maintenance Period (Week 16 to Week 48)|Patient's decisions|0
6286595|NCT02346240|9999192|FG001|Maintenance Period (Week 16 to Week 48)|Patient's decisions|0
6286596|NCT02346240|9999193|FG002|Maintenance Period (Week 16 to Week 48)|Patient's decisions|0
6286597|NCT02346240|9999194|FG003|Maintenance Period (Week 16 to Week 48)|Patient's decisions|0
6209959|NCT01576718|9875361|FG000|Pre-Assignment Period (Run-In Placebo)|Randomization criteria not met|166
6209960|NCT01576718|9875362|FG001|Pre-Assignment Period (Run-In Placebo)|Randomization criteria not met|0
6209961|NCT01576718|9875363|FG002|Pre-Assignment Period (Run-In Placebo)|Randomization criteria not met|0
6209962|NCT01576718|9875364|FG003|Pre-Assignment Period (Run-In Placebo)|Randomization criteria not met|0
6209963|NCT01576718|9875365|FG004|Pre-Assignment Period (Run-In Placebo)|Randomization criteria not met|0
6115685|NCT00856206|9736922|FG001|Overall Study|Withdrawal by Subject|36
6115686|NCT00856206|9736921|FG000|Overall Study|Lost to Follow-up|13
6115687|NCT00856206|9736922|FG001|Overall Study|Lost to Follow-up|39
6115688|NCT00856206|9736921|FG000|Overall Study|Death|2
6115689|NCT00856206|9736922|FG001|Overall Study|Death|2
6115690|NCT00856206|9736921|FG000|Overall Study|Decision by the Sponsor|4
6115691|NCT00856206|9736922|FG001|Overall Study|Decision by the Sponsor|8
6115692|NCT00856206|9736921|FG000|Overall Study|Other than specified above|3
6115693|NCT00856206|9736922|FG001|Overall Study|Other than specified above|10
6115694|NCT00856245|9736943|FG000|Overall Study|Was not transplanted|5
6115695|NCT00856284|9736950|FG000|Overall Study|Hyperglycemic rescue|231
6115696|NCT00856284|9736951|FG001|Overall Study|Hyperglycemic rescue|201
6115697|NCT00856284|9736952|FG002|Overall Study|Hyperglycemic rescue|235
6115698|NCT00856284|9736950|FG000|Overall Study|Adverse Event|60
6115699|NCT00856284|9736951|FG001|Overall Study|Adverse Event|74
6115700|NCT00856284|9736952|FG002|Overall Study|Adverse Event|82
6115701|NCT00856284|9736950|FG000|Overall Study|Major protocol deviation|24
6115702|NCT00856284|9736951|FG001|Overall Study|Major protocol deviation|16
6115703|NCT00856284|9736952|FG002|Overall Study|Major protocol deviation|15
6115704|NCT00856284|9736950|FG000|Overall Study|Lost to Follow-up|20
6115705|NCT00856284|9736951|FG001|Overall Study|Lost to Follow-up|22
6115706|NCT00856284|9736952|FG002|Overall Study|Lost to Follow-up|28
6115707|NCT00856284|9736950|FG000|Overall Study|Voluntary withdrawal|48
6115708|NCT00856284|9736951|FG001|Overall Study|Voluntary withdrawal|52
6115709|NCT00856284|9736952|FG002|Overall Study|Voluntary withdrawal|62
6115710|NCT00856284|9736950|FG000|Overall Study|Pregnancy|1
6115711|NCT00856284|9736951|FG001|Overall Study|Pregnancy|2
6115712|NCT00856284|9736952|FG002|Overall Study|Pregnancy|0
6115713|NCT00856284|9736950|FG000|Overall Study|Investigator discretion|9
6115714|NCT00856284|9736951|FG001|Overall Study|Investigator discretion|8
6115715|NCT00856284|9736952|FG002|Overall Study|Investigator discretion|10
6115716|NCT00856284|9736950|FG000|Overall Study|Other|15
6115717|NCT00856284|9736951|FG001|Overall Study|Other|17
6115718|NCT00856284|9736952|FG002|Overall Study|Other|14
6115719|NCT00856284|9736950|FG000|Overall Study|Randomized in error|0
6115720|NCT00856284|9736951|FG001|Overall Study|Randomized in error|0
6115721|NCT00856284|9736952|FG002|Overall Study|Randomized in error|1
6115722|NCT00856297|9736965|FG000|Overall Study|Unable to classify|2
6115723|NCT00856297|9736966|FG001|Overall Study|Unable to classify|0
6115724|NCT00856297|9736967|FG002|Overall Study|Unable to classify|0
6115725|NCT00856297|9736968|FG003|Overall Study|Unable to classify|0
6115726|NCT00856297|9736969|FG004|Overall Study|Unable to classify|0
6115727|NCT00856323|9736986|FG000|Overall Study|Withdrawal by Subject|2
6115728|NCT00856349|9736990|FG000|Overall Study|Death|418
6115729|NCT00856349|9736990|FG000|Overall Study|Withdrawal by Subject|116
6115730|NCT00856349|9736990|FG000|Overall Study|Lost to Follow-up|91
6115731|NCT00856349|9736990|FG000|Overall Study|Protocol Violation|38
6115732|NCT00856349|9736990|FG000|Overall Study|Physician Decision|13
6115733|NCT00856349|9736990|FG000|Overall Study|Subject relocation|104
6115734|NCT00856349|9736990|FG000|Overall Study|Device explant|33
6115735|NCT00856349|9736990|FG000|Overall Study|Site closure|78
6115736|NCT00856349|9736990|FG000|Overall Study|Subject changed Dr, insurance issue, etc|130
6115737|NCT00856375|9736998|FG000|Overall Study|Other|0
6115738|NCT00856375|9736999|FG001|Overall Study|Other|1
6115739|NCT00856375|9736998|FG000|Overall Study|Death|32
6115740|NCT00856375|9736999|FG001|Overall Study|Death|30
6115741|NCT00856375|9736998|FG000|Overall Study|Sponsor Terminated Study|7
6115742|NCT00856375|9736999|FG001|Overall Study|Sponsor Terminated Study|7
6115743|NCT00856375|9736998|FG000|Overall Study|Withdrawal by Subject|2
6115744|NCT00856375|9736999|FG001|Overall Study|Withdrawal by Subject|1
6115745|NCT00856375|9736998|FG000|Overall Study|Lost to Follow-up|1
6115746|NCT00856375|9736999|FG001|Overall Study|Lost to Follow-up|2
6115747|NCT00856388|9737005|FG000|Overall Study|Other|1
6115748|NCT00856492|9737017|FG000|Overall Study|Ineligible or withdrew consent|1
6115749|NCT00856492|9737018|FG001|Overall Study|Ineligible or withdrew consent|1
6115750|NCT00856492|9737019|FG002|Overall Study|Ineligible or withdrew consent|2
6115751|NCT00856518|9737032|FG000|Overall Study|Lost to Follow-up|4
6115752|NCT00856518|9737033|FG001|Overall Study|Lost to Follow-up|2
6115753|NCT00856544|9737045|FG000|Overall Study|Randomized but not treated|3
6115754|NCT00856544|9737046|FG001|Overall Study|Randomized but not treated|0
6115755|NCT00856544|9737047|FG002|Overall Study|Randomized but not treated|0
6115756|NCT00856544|9737048|FG003|Overall Study|Randomized but not treated|0
6115757|NCT00856544|9737045|FG000|Overall Study|Death|0
6115758|NCT00856544|9737046|FG001|Overall Study|Death|2
6115759|NCT00856544|9737047|FG002|Overall Study|Death|0
6115760|NCT00856544|9737048|FG003|Overall Study|Death|0
6115761|NCT00856544|9737045|FG000|Overall Study|Adverse Event|20
6209964|NCT01576718|9875366|FG005|Pre-Assignment Period (Run-In Placebo)|Randomization criteria not met|0
6115762|NCT00856544|9737046|FG001|Overall Study|Adverse Event|29
6115763|NCT00856544|9737047|FG002|Overall Study|Adverse Event|2
6115764|NCT00856544|9737048|FG003|Overall Study|Adverse Event|3
6115765|NCT00856544|9737045|FG000|Overall Study|Lack of Efficacy|16
6115766|NCT00856544|9737046|FG001|Overall Study|Lack of Efficacy|12
6115767|NCT00856544|9737047|FG002|Overall Study|Lack of Efficacy|3
6115768|NCT00856544|9737048|FG003|Overall Study|Lack of Efficacy|3
6115769|NCT00856544|9737045|FG000|Overall Study|Other|9
6115770|NCT00856544|9737046|FG001|Overall Study|Other|16
6115771|NCT00856544|9737047|FG002|Overall Study|Other|1
6115772|NCT00856544|9737048|FG003|Overall Study|Other|6
6115773|NCT00856544|9737045|FG000|Overall Study|Lost to Follow-up|1
6115774|NCT00856544|9737046|FG001|Overall Study|Lost to Follow-up|2
6115775|NCT00856544|9737047|FG002|Overall Study|Lost to Follow-up|2
6209965|NCT01576718|9875367|FG006|Pre-Assignment Period (Run-In Placebo)|Randomization criteria not met|0
6209966|NCT01576718|9875361|FG000|Pre-Assignment Period (Run-In Placebo)|Lost to Follow-up|2
6209967|NCT01576718|9875362|FG001|Pre-Assignment Period (Run-In Placebo)|Lost to Follow-up|0
6209968|NCT01576718|9875363|FG002|Pre-Assignment Period (Run-In Placebo)|Lost to Follow-up|0
6209969|NCT01576718|9875364|FG003|Pre-Assignment Period (Run-In Placebo)|Lost to Follow-up|0
6209970|NCT01576718|9875365|FG004|Pre-Assignment Period (Run-In Placebo)|Lost to Follow-up|0
6209971|NCT01576718|9875366|FG005|Pre-Assignment Period (Run-In Placebo)|Lost to Follow-up|0
6209972|NCT01576718|9875367|FG006|Pre-Assignment Period (Run-In Placebo)|Lost to Follow-up|0
6209973|NCT01576718|9875361|FG000|Pre-Assignment Period (Run-In Placebo)|Other|15
6209974|NCT01576718|9875362|FG001|Pre-Assignment Period (Run-In Placebo)|Other|0
6209975|NCT01576718|9875363|FG002|Pre-Assignment Period (Run-In Placebo)|Other|0
6209976|NCT01576718|9875364|FG003|Pre-Assignment Period (Run-In Placebo)|Other|0
6209977|NCT01576718|9875365|FG004|Pre-Assignment Period (Run-In Placebo)|Other|0
6209978|NCT01576718|9875366|FG005|Pre-Assignment Period (Run-In Placebo)|Other|0
6209979|NCT01576718|9875367|FG006|Pre-Assignment Period (Run-In Placebo)|Other|0
6209980|NCT01576718|9875361|FG000|Treatment Period|Adverse Event|0
6209981|NCT01576718|9875362|FG001|Treatment Period|Adverse Event|1
6209982|NCT01576718|9875363|FG002|Treatment Period|Adverse Event|1
6209983|NCT01576718|9875364|FG003|Treatment Period|Adverse Event|1
6209984|NCT01576718|9875365|FG004|Treatment Period|Adverse Event|1
6209985|NCT01576718|9875366|FG005|Treatment Period|Adverse Event|1
6209986|NCT01576718|9875367|FG006|Treatment Period|Adverse Event|0
6209987|NCT01576718|9875361|FG000|Treatment Period|Withdrawal by Subject|0
6209988|NCT01576718|9875362|FG001|Treatment Period|Withdrawal by Subject|1
6209989|NCT01576718|9875363|FG002|Treatment Period|Withdrawal by Subject|1
6209990|NCT01576718|9875364|FG003|Treatment Period|Withdrawal by Subject|0
6209991|NCT01576718|9875365|FG004|Treatment Period|Withdrawal by Subject|2
6209992|NCT01576718|9875366|FG005|Treatment Period|Withdrawal by Subject|4
6209993|NCT01576718|9875367|FG006|Treatment Period|Withdrawal by Subject|2
6209994|NCT01576718|9875361|FG000|Treatment Period|Physician Decision|0
6209995|NCT01576718|9875362|FG001|Treatment Period|Physician Decision|1
6209996|NCT01576718|9875363|FG002|Treatment Period|Physician Decision|1
6209997|NCT01576718|9875364|FG003|Treatment Period|Physician Decision|1
6209998|NCT01576718|9875365|FG004|Treatment Period|Physician Decision|1
6209999|NCT01576718|9875366|FG005|Treatment Period|Physician Decision|0
6210000|NCT01576718|9875367|FG006|Treatment Period|Physician Decision|0
6210001|NCT01576718|9875361|FG000|Treatment Period|Protocol Violation|0
6210002|NCT01576718|9875362|FG001|Treatment Period|Protocol Violation|5
6210003|NCT01576718|9875363|FG002|Treatment Period|Protocol Violation|4
6210004|NCT01576718|9875364|FG003|Treatment Period|Protocol Violation|10
6210005|NCT01576718|9875365|FG004|Treatment Period|Protocol Violation|6
6210006|NCT01576718|9875366|FG005|Treatment Period|Protocol Violation|8
6210007|NCT01576718|9875367|FG006|Treatment Period|Protocol Violation|12
6210008|NCT01576718|9875361|FG000|Treatment Period|Sponsor request|0
6210009|NCT01576718|9875362|FG001|Treatment Period|Sponsor request|1
6210010|NCT01576718|9875363|FG002|Treatment Period|Sponsor request|0
6210011|NCT01576718|9875364|FG003|Treatment Period|Sponsor request|0
6210012|NCT01576718|9875365|FG004|Treatment Period|Sponsor request|0
6210013|NCT01576718|9875366|FG005|Treatment Period|Sponsor request|1
6210014|NCT01576718|9875367|FG006|Treatment Period|Sponsor request|0
6210015|NCT01576718|9875361|FG000|Treatment Period|Met stopping criteria|0
6210016|NCT01576718|9875362|FG001|Treatment Period|Met stopping criteria|16
6210017|NCT01576718|9875363|FG002|Treatment Period|Met stopping criteria|13
6210018|NCT01576718|9875364|FG003|Treatment Period|Met stopping criteria|19
6286598|NCT02346240|9999195|FG004|Maintenance Period (Week 16 to Week 48)|Patient's decisions|0
6286599|NCT02346240|9999196|FG005|Maintenance Period (Week 16 to Week 48)|Patient's decisions|0
6286600|NCT02346240|9999197|FG006|Maintenance Period (Week 16 to Week 48)|Patient's decisions|0
6286601|NCT02346240|9999198|FG007|Maintenance Period (Week 16 to Week 48)|Patient's decisions|0
6286602|NCT02346240|9999199|FG008|Maintenance Period (Week 16 to Week 48)|Patient's decisions|0
6286603|NCT02346240|9999200|FG009|Maintenance Period (Week 16 to Week 48)|Patient's decisions|0
6286604|NCT02346240|9999201|FG010|Maintenance Period (Week 16 to Week 48)|Patient's decisions|1
6286605|NCT02346240|9999202|FG011|Maintenance Period (Week 16 to Week 48)|Patient's decisions|0
6286606|NCT02346240|9999203|FG012|Maintenance Period (Week 16 to Week 48)|Patient's decisions|0
6286607|NCT02346240|9999204|FG013|Maintenance Period (Week 16 to Week 48)|Patient's decisions|0
6286608|NCT02346240|9999205|FG014|Maintenance Period (Week 16 to Week 48)|Patient's decisions|0
6286609|NCT02346240|9999206|FG015|Maintenance Period (Week 16 to Week 48)|Patient's decisions|0
6286610|NCT02346240|9999207|FG016|Maintenance Period (Week 16 to Week 48)|Patient's decisions|0
6286611|NCT02346240|9999208|FG017|Maintenance Period (Week 16 to Week 48)|Patient's decisions|0
6286612|NCT02346240|9999209|FG018|Maintenance Period (Week 16 to Week 48)|Patient's decisions|0
6286613|NCT02346240|9999210|FG019|Maintenance Period (Week 16 to Week 48)|Patient's decisions|0
6286614|NCT02346240|9999211|FG020|Maintenance Period (Week 16 to Week 48)|Patient's decisions|0
6286615|NCT02346240|9999212|FG021|Maintenance Period (Week 16 to Week 48)|Patient's decisions|0
6115776|NCT00856544|9737048|FG003|Overall Study|Lost to Follow-up|0
6115777|NCT00856544|9737045|FG000|Overall Study|Withdrawal by Subject|8
6115778|NCT00856544|9737046|FG001|Overall Study|Withdrawal by Subject|5
6115779|NCT00856544|9737047|FG002|Overall Study|Withdrawal by Subject|0
6115780|NCT00856544|9737048|FG003|Overall Study|Withdrawal by Subject|1
6115781|NCT00856557|9737072|FG000|Overall Study|No patients with contextual flags|12
6115782|NCT00856557|9737073|FG001|Overall Study|No patients with contextual flags|16
6115783|NCT00856583|9737081|FG000|Overall Study|Lack of Efficacy|389
6115784|NCT00856583|9737082|FG001|Overall Study|Lack of Efficacy|377
6115785|NCT00856583|9737081|FG000|Overall Study|Serious Adverse Event (SAE)|99
6115786|NCT00856583|9737082|FG001|Overall Study|Serious Adverse Event (SAE)|65
6115787|NCT00856583|9737081|FG000|Overall Study|Non-SAE: Mostly Asymptomatic ECGs|393
6115788|NCT00856583|9737082|FG001|Overall Study|Non-SAE: Mostly Asymptomatic ECGs|179
6115789|NCT00856583|9737081|FG000|Overall Study|Non-compliance|305
6115790|NCT00856583|9737082|FG001|Overall Study|Non-compliance|262
6115791|NCT00856583|9737081|FG000|Overall Study|Withdrawal by Subject|1092
6115792|NCT00856583|9737082|FG001|Overall Study|Withdrawal by Subject|919
6115793|NCT00856583|9737081|FG000|Overall Study|Physician Decision|59
6115794|NCT00856583|9737082|FG001|Overall Study|Physician Decision|82
6115795|NCT00856583|9737081|FG000|Overall Study|Pregnancy|14
6115796|NCT00856583|9737082|FG001|Overall Study|Pregnancy|5
6115797|NCT00856583|9737081|FG000|Overall Study|Other|92
6115798|NCT00856583|9737082|FG001|Overall Study|Other|104
6115799|NCT00856583|9737081|FG000|Overall Study|Non-evaluable: Patient on Polytherapy|694
6115800|NCT00856583|9737082|FG001|Overall Study|Non-evaluable: Patient on Polytherapy|604
6115801|NCT00856609|9737090|FG000|Overall Study|Adverse Event|1
6115802|NCT00856609|9737091|FG001|Overall Study|Adverse Event|0
6115803|NCT00856635|9737099|FG000|Overall Study|Lost to Follow-up|2
6115804|NCT00856635|9737100|FG001|Overall Study|Lost to Follow-up|5
6115805|NCT00856635|9737099|FG000|Overall Study|Pregnancy|1
6115806|NCT00856635|9737100|FG001|Overall Study|Pregnancy|0
6115807|NCT00856635|9737099|FG000|Overall Study|Withdrawal by Subject|3
6115808|NCT00856635|9737100|FG001|Overall Study|Withdrawal by Subject|1
6115809|NCT00856635|9737099|FG000|Overall Study|Serious Adverse Event|1
6115810|NCT00856635|9737100|FG001|Overall Study|Serious Adverse Event|0
6115811|NCT00856635|9737099|FG000|Overall Study|Other|1
6115812|NCT00856635|9737100|FG001|Overall Study|Other|0
6115813|NCT00856635|9737099|FG000|Overall Study|Discontinued at Randomization|2
6115814|NCT00856635|9737100|FG001|Overall Study|Discontinued at Randomization|2
6115815|NCT00856661|9737110|FG000|Overall Study|Death|15
6115816|NCT00856661|9737111|FG001|Overall Study|Death|18
6115817|NCT00856661|9737110|FG000|Overall Study|Protocol Violation|2
6115818|NCT00856661|9737111|FG001|Overall Study|Protocol Violation|1
6115819|NCT00856661|9737110|FG000|Overall Study|Withdrawal by Subject|1
6115820|NCT00856661|9737111|FG001|Overall Study|Withdrawal by Subject|2
6115821|NCT00856661|9737110|FG000|Overall Study|Lost to Follow-up|1
6115822|NCT00856661|9737111|FG001|Overall Study|Lost to Follow-up|3
6115823|NCT00856661|9737110|FG000|Overall Study|Physician Judgement|8
6115824|NCT00856661|9737111|FG001|Overall Study|Physician Judgement|5
6115825|NCT00856778|9737137|FG000|Overall Study|Adverse Event|7
6115826|NCT00856778|9737137|FG000|Overall Study|Withdrawal by Subject|10
6115827|NCT00856778|9737137|FG000|Overall Study|Study deviation|2
6210019|NCT01576718|9875365|FG004|Treatment Period|Met stopping criteria|16
6210020|NCT01576718|9875366|FG005|Treatment Period|Met stopping criteria|33
6210021|NCT01576718|9875367|FG006|Treatment Period|Met stopping criteria|15
6210022|NCT01576718|9875361|FG000|Treatment Period|Lost to Follow-up|0
6210023|NCT01576718|9875362|FG001|Treatment Period|Lost to Follow-up|0
6210024|NCT01576718|9875363|FG002|Treatment Period|Lost to Follow-up|0
6210025|NCT01576718|9875364|FG003|Treatment Period|Lost to Follow-up|0
6210026|NCT01576718|9875365|FG004|Treatment Period|Lost to Follow-up|1
6210027|NCT01576718|9875366|FG005|Treatment Period|Lost to Follow-up|0
6210028|NCT01576718|9875367|FG006|Treatment Period|Lost to Follow-up|0
6115828|NCT00856778|9737137|FG000|Overall Study|Lost to Follow-up|5
6115829|NCT00856830|9737149|FG000|Irinotecan & Bendamustine|Death|0
6115830|NCT00856830|9737150|FG001|Irinotecan & Bendamustine|Death|0
6115831|NCT00856830|9737151|FG002|Irinotecan & Bendamustine|Death|0
6115832|NCT00856830|9737152|FG003|Irinotecan & Bendamustine|Death|2
6115833|NCT00856830|9737149|FG000|Irinotecan & Bendamustine|Physician Decision|0
6115834|NCT00856830|9737150|FG001|Irinotecan & Bendamustine|Physician Decision|0
6115835|NCT00856830|9737151|FG002|Irinotecan & Bendamustine|Physician Decision|0
6115836|NCT00856830|9737152|FG003|Irinotecan & Bendamustine|Physician Decision|1
6115837|NCT00856843|9737159|FG000|Overall Study|Withdrawal by Subject|1
6115838|NCT00856843|9737160|FG001|Overall Study|Withdrawal by Subject|5
6115839|NCT00856843|9737159|FG000|Overall Study|Lack of Efficacy|1
6115840|NCT00856843|9737160|FG001|Overall Study|Lack of Efficacy|0
6115841|NCT00856856|9737166|FG000|2-year Clinical Follow-up|Lost to Follow-up|1
6210029|NCT01576718|9875361|FG000|Treatment Period|Noncompliance to study medication|0
6115842|NCT00856856|9737166|FG000|4-year Clinical Follow-up|Missed visit|1
6115843|NCT00856908|9737177|FG000|Overall Study|Lost to Follow-up|1
6115844|NCT00856908|9737178|FG001|Overall Study|Lost to Follow-up|0
6115845|NCT00856973|9737187|FG000|Overall Study|Adverse Event|5
6115846|NCT00856973|9737188|FG001|Overall Study|Adverse Event|5
6115847|NCT00856973|9737189|FG002|Overall Study|Adverse Event|3
6115848|NCT00856973|9737187|FG000|Overall Study|Lost to Follow-up|6
6115849|NCT00856973|9737188|FG001|Overall Study|Lost to Follow-up|3
6115850|NCT00856973|9737189|FG002|Overall Study|Lost to Follow-up|5
6115851|NCT00856973|9737187|FG000|Overall Study|Physician Decision|0
6115852|NCT00856973|9737188|FG001|Overall Study|Physician Decision|3
6115853|NCT00856973|9737189|FG002|Overall Study|Physician Decision|1
6115854|NCT00856973|9737187|FG000|Overall Study|Protocol Violation|1
6115855|NCT00856973|9737188|FG001|Overall Study|Protocol Violation|2
6115856|NCT00856973|9737189|FG002|Overall Study|Protocol Violation|1
6115857|NCT00856973|9737187|FG000|Overall Study|Withdrawal by Subject|13
6115858|NCT00856973|9737188|FG001|Overall Study|Withdrawal by Subject|16
6115859|NCT00856973|9737189|FG002|Overall Study|Withdrawal by Subject|15
6115860|NCT00856973|9737187|FG000|Overall Study|Other|11
6115861|NCT00856973|9737188|FG001|Overall Study|Other|12
6115862|NCT00856973|9737189|FG002|Overall Study|Other|13
6115863|NCT00856986|9737206|FG000|Run-in Period, Weeks -12-0|Adverse Event|0
6115864|NCT00856986|9737207|FG001|Run-in Period, Weeks -12-0|Adverse Event|0
6115865|NCT00856986|9737208|FG002|Run-in Period, Weeks -12-0|Adverse Event|0
6115866|NCT00856986|9737209|FG003|Run-in Period, Weeks -12-0|Adverse Event|92
6210030|NCT01576718|9875362|FG001|Treatment Period|Noncompliance to study medication|0
6210031|NCT01576718|9875363|FG002|Treatment Period|Noncompliance to study medication|0
6210032|NCT01576718|9875364|FG003|Treatment Period|Noncompliance to study medication|0
6210033|NCT01576718|9875365|FG004|Treatment Period|Noncompliance to study medication|0
6210034|NCT01576718|9875366|FG005|Treatment Period|Noncompliance to study medication|1
6210035|NCT01576718|9875367|FG006|Treatment Period|Noncompliance to study medication|1
6210036|NCT01576783|9875383|FG000|Overall Study|Change in Medical Care|1
6210037|NCT01576783|9875384|FG001|Overall Study|Change in Medical Care|0
6210038|NCT01576783|9875383|FG000|Overall Study|Lost to Follow-up|14
6210039|NCT01576783|9875384|FG001|Overall Study|Lost to Follow-up|16
6210040|NCT01576783|9875383|FG000|Overall Study|Withdrawal by Subject|5
6210041|NCT01576783|9875384|FG001|Overall Study|Withdrawal by Subject|1
6210042|NCT01577160|9875425|FG000|Overall Study|Adverse Event|9
6210043|NCT01577160|9875425|FG000|Overall Study|Lack of Efficacy|15
6210044|NCT01577160|9875425|FG000|Overall Study|Lost to Follow-up|40
6210045|NCT01577160|9875425|FG000|Overall Study|Withdrawal by Subject|18
6210046|NCT01577160|9875425|FG000|Overall Study|Subject Uncooperative|7
6210047|NCT01577160|9875425|FG000|Overall Study|Other|9
6210048|NCT01577186|9875429|FG000|Overall Study|Adverse Event|23
6210049|NCT01577186|9875429|FG000|Overall Study|Death|1
6210050|NCT01577186|9875429|FG000|Overall Study|Lost to Follow-up|28
6210051|NCT01577186|9875429|FG000|Overall Study|Withdrawal by Subject|35
6210052|NCT01577186|9875429|FG000|Overall Study|Insufficient Response|18
6210053|NCT01577186|9875429|FG000|Overall Study|Ineligible to Continue|15
6210054|NCT01577186|9875429|FG000|Overall Study|Non-Compliant|8
6210055|NCT01577186|9875429|FG000|Overall Study|Other|2
6210056|NCT01577381|9875455|FG000|Overall Study|Discontinued|2
6210057|NCT01577381|9875456|FG001|Overall Study|Discontinued|1
6210058|NCT01577381|9875457|FG002|Overall Study|Discontinued|2
6210059|NCT01577381|9875458|FG003|Overall Study|Discontinued|2
6210060|NCT01577381|9875455|FG000|Overall Study|Ongoing at Date of Cut-Off|0
6210061|NCT01577381|9875456|FG001|Overall Study|Ongoing at Date of Cut-Off|2
6210062|NCT01577381|9875457|FG002|Overall Study|Ongoing at Date of Cut-Off|1
6210063|NCT01577381|9875458|FG003|Overall Study|Ongoing at Date of Cut-Off|0
6210064|NCT01577745|9875497|FG000|Overall Study|Withdrawal by Subject|0
6210065|NCT01577745|9875498|FG001|Overall Study|Withdrawal by Subject|1
6210066|NCT01577745|9875499|FG002|Overall Study|Withdrawal by Subject|0
6210067|NCT01577745|9875500|FG003|Overall Study|Withdrawal by Subject|3
6210068|NCT01577745|9875501|FG004|Overall Study|Withdrawal by Subject|2
6210069|NCT01577745|9875502|FG005|Overall Study|Withdrawal by Subject|0
6210070|NCT01577745|9875497|FG000|Overall Study|Death|3
6210071|NCT01577745|9875498|FG001|Overall Study|Death|2
6210072|NCT01577745|9875499|FG002|Overall Study|Death|2
6210073|NCT01577745|9875500|FG003|Overall Study|Death|1
6210074|NCT01577745|9875501|FG004|Overall Study|Death|1
6210075|NCT01577745|9875502|FG005|Overall Study|Death|3
6210076|NCT01577745|9875497|FG000|Overall Study|Physician Decision|0
6210077|NCT01577745|9875498|FG001|Overall Study|Physician Decision|0
6210078|NCT01577745|9875499|FG002|Overall Study|Physician Decision|0
6210079|NCT01577745|9875500|FG003|Overall Study|Physician Decision|1
6210080|NCT01577745|9875501|FG004|Overall Study|Physician Decision|1
6210081|NCT01577745|9875502|FG005|Overall Study|Physician Decision|0
6115867|NCT00856986|9737210|FG004|Run-in Period, Weeks -12-0|Adverse Event|0
6115868|NCT00856986|9737206|FG000|Run-in Period, Weeks -12-0|Protocol Violation|0
6115869|NCT00856986|9737207|FG001|Run-in Period, Weeks -12-0|Protocol Violation|0
6115870|NCT00856986|9737208|FG002|Run-in Period, Weeks -12-0|Protocol Violation|0
6210082|NCT01577745|9875497|FG000|Overall Study|Lost to Follow-up|0
6210083|NCT01577745|9875498|FG001|Overall Study|Lost to Follow-up|0
6210084|NCT01577745|9875499|FG002|Overall Study|Lost to Follow-up|0
6210085|NCT01577745|9875500|FG003|Overall Study|Lost to Follow-up|0
6210086|NCT01577745|9875501|FG004|Overall Study|Lost to Follow-up|0
6210087|NCT01577745|9875502|FG005|Overall Study|Lost to Follow-up|1
6210088|NCT01577745|9875497|FG000|Overall Study|Alternative Therapy|0
6210089|NCT01577745|9875498|FG001|Overall Study|Alternative Therapy|0
6115871|NCT00856986|9737209|FG003|Run-in Period, Weeks -12-0|Protocol Violation|24
6115872|NCT00856986|9737210|FG004|Run-in Period, Weeks -12-0|Protocol Violation|0
6210090|NCT01577745|9875499|FG002|Overall Study|Alternative Therapy|0
6115873|NCT00856986|9737206|FG000|Run-in Period, Weeks -12-0|Withdrawal Criteria|0
6115874|NCT00856986|9737207|FG001|Run-in Period, Weeks -12-0|Withdrawal Criteria|0
6115875|NCT00856986|9737208|FG002|Run-in Period, Weeks -12-0|Withdrawal Criteria|0
6115876|NCT00856986|9737209|FG003|Run-in Period, Weeks -12-0|Withdrawal Criteria|10
6115877|NCT00856986|9737210|FG004|Run-in Period, Weeks -12-0|Withdrawal Criteria|0
6115878|NCT00856986|9737206|FG000|Run-in Period, Weeks -12-0|Lost to Follow-up|0
6115879|NCT00856986|9737207|FG001|Run-in Period, Weeks -12-0|Lost to Follow-up|0
6115880|NCT00856986|9737208|FG002|Run-in Period, Weeks -12-0|Lost to Follow-up|0
6115881|NCT00856986|9737209|FG003|Run-in Period, Weeks -12-0|Lost to Follow-up|11
6115882|NCT00856986|9737210|FG004|Run-in Period, Weeks -12-0|Lost to Follow-up|0
6115883|NCT00856986|9737206|FG000|Run-in Period, Weeks -12-0|Lack of Efficacy|0
6115884|NCT00856986|9737207|FG001|Run-in Period, Weeks -12-0|Lack of Efficacy|0
6115885|NCT00856986|9737208|FG002|Run-in Period, Weeks -12-0|Lack of Efficacy|0
6115886|NCT00856986|9737209|FG003|Run-in Period, Weeks -12-0|Lack of Efficacy|6
6115887|NCT00856986|9737210|FG004|Run-in Period, Weeks -12-0|Lack of Efficacy|0
6115888|NCT00856986|9737206|FG000|Run-in Period, Weeks -12-0|Unclassified|0
6115889|NCT00856986|9737207|FG001|Run-in Period, Weeks -12-0|Unclassified|0
6115890|NCT00856986|9737208|FG002|Run-in Period, Weeks -12-0|Unclassified|0
6115891|NCT00856986|9737209|FG003|Run-in Period, Weeks -12-0|Unclassified|24
6115892|NCT00856986|9737210|FG004|Run-in Period, Weeks -12-0|Unclassified|0
6115893|NCT00856986|9737206|FG000|Main Period, Weeks 0-26|Adverse Event|6
6115894|NCT00856986|9737207|FG001|Main Period, Weeks 0-26|Adverse Event|4
6115895|NCT00856986|9737208|FG002|Main Period, Weeks 0-26|Adverse Event|9
6115896|NCT00856986|9737209|FG003|Main Period, Weeks 0-26|Adverse Event|0
6115897|NCT00856986|9737210|FG004|Main Period, Weeks 0-26|Adverse Event|0
6115898|NCT00856986|9737206|FG000|Main Period, Weeks 0-26|Protocol Violation|4
6115899|NCT00856986|9737207|FG001|Main Period, Weeks 0-26|Protocol Violation|5
6115900|NCT00856986|9737208|FG002|Main Period, Weeks 0-26|Protocol Violation|7
6115901|NCT00856986|9737209|FG003|Main Period, Weeks 0-26|Protocol Violation|0
6115902|NCT00856986|9737210|FG004|Main Period, Weeks 0-26|Protocol Violation|0
6115903|NCT00856986|9737206|FG000|Main Period, Weeks 0-26|Withdrawal Criteria|11
6115904|NCT00856986|9737207|FG001|Main Period, Weeks 0-26|Withdrawal Criteria|0
6115905|NCT00856986|9737208|FG002|Main Period, Weeks 0-26|Withdrawal Criteria|3
6115906|NCT00856986|9737209|FG003|Main Period, Weeks 0-26|Withdrawal Criteria|0
6115907|NCT00856986|9737210|FG004|Main Period, Weeks 0-26|Withdrawal Criteria|0
6115908|NCT00856986|9737206|FG000|Main Period, Weeks 0-26|Lost to Follow-up|1
6115909|NCT00856986|9737207|FG001|Main Period, Weeks 0-26|Lost to Follow-up|1
6115910|NCT00856986|9737208|FG002|Main Period, Weeks 0-26|Lost to Follow-up|2
6115911|NCT00856986|9737209|FG003|Main Period, Weeks 0-26|Lost to Follow-up|0
6115912|NCT00856986|9737210|FG004|Main Period, Weeks 0-26|Lost to Follow-up|0
6115913|NCT00856986|9737206|FG000|Main Period, Weeks 0-26|Lack of Efficacy|5
6115914|NCT00856986|9737207|FG001|Main Period, Weeks 0-26|Lack of Efficacy|2
6115915|NCT00856986|9737208|FG002|Main Period, Weeks 0-26|Lack of Efficacy|0
6115916|NCT00856986|9737209|FG003|Main Period, Weeks 0-26|Lack of Efficacy|0
6115917|NCT00856986|9737210|FG004|Main Period, Weeks 0-26|Lack of Efficacy|0
6115918|NCT00856986|9737206|FG000|Main Period, Weeks 0-26|Unclassified|7
6115919|NCT00856986|9737207|FG001|Main Period, Weeks 0-26|Unclassified|6
6115920|NCT00856986|9737208|FG002|Main Period, Weeks 0-26|Unclassified|7
6115921|NCT00856986|9737209|FG003|Main Period, Weeks 0-26|Unclassified|0
6115922|NCT00856986|9737210|FG004|Main Period, Weeks 0-26|Unclassified|0
6115923|NCT00856986|9737206|FG000|Extension Period, Weeks 26-52|Adverse Event|3
6115924|NCT00856986|9737207|FG001|Extension Period, Weeks 26-52|Adverse Event|3
6115925|NCT00856986|9737208|FG002|Extension Period, Weeks 26-52|Adverse Event|10
6115926|NCT00856986|9737209|FG003|Extension Period, Weeks 26-52|Adverse Event|0
6115927|NCT00856986|9737210|FG004|Extension Period, Weeks 26-52|Adverse Event|0
6115928|NCT00856986|9737206|FG000|Extension Period, Weeks 26-52|Protocol Violation|6
6115929|NCT00856986|9737207|FG001|Extension Period, Weeks 26-52|Protocol Violation|2
6115930|NCT00856986|9737208|FG002|Extension Period, Weeks 26-52|Protocol Violation|5
6115931|NCT00856986|9737209|FG003|Extension Period, Weeks 26-52|Protocol Violation|0
6115932|NCT00856986|9737210|FG004|Extension Period, Weeks 26-52|Protocol Violation|0
6115933|NCT00856986|9737206|FG000|Extension Period, Weeks 26-52|Withdrawal Criteria|2
6115934|NCT00856986|9737207|FG001|Extension Period, Weeks 26-52|Withdrawal Criteria|0
6115935|NCT00856986|9737208|FG002|Extension Period, Weeks 26-52|Withdrawal Criteria|8
6115936|NCT00856986|9737209|FG003|Extension Period, Weeks 26-52|Withdrawal Criteria|0
6115937|NCT00856986|9737210|FG004|Extension Period, Weeks 26-52|Withdrawal Criteria|0
6115938|NCT00856986|9737206|FG000|Extension Period, Weeks 26-52|Lost to Follow-up|0
6115939|NCT00856986|9737207|FG001|Extension Period, Weeks 26-52|Lost to Follow-up|5
6115940|NCT00856986|9737208|FG002|Extension Period, Weeks 26-52|Lost to Follow-up|2
6115941|NCT00856986|9737209|FG003|Extension Period, Weeks 26-52|Lost to Follow-up|0
6115942|NCT00856986|9737210|FG004|Extension Period, Weeks 26-52|Lost to Follow-up|0
6115943|NCT00856986|9737206|FG000|Extension Period, Weeks 26-52|Lack of Efficacy|4
6115944|NCT00856986|9737207|FG001|Extension Period, Weeks 26-52|Lack of Efficacy|2
6115945|NCT00856986|9737208|FG002|Extension Period, Weeks 26-52|Lack of Efficacy|2
6115946|NCT00856986|9737209|FG003|Extension Period, Weeks 26-52|Lack of Efficacy|0
6115947|NCT00856986|9737210|FG004|Extension Period, Weeks 26-52|Lack of Efficacy|0
6115948|NCT00856986|9737206|FG000|Extension Period, Weeks 26-52|Unclassified|4
6115949|NCT00856986|9737207|FG001|Extension Period, Weeks 26-52|Unclassified|2
6115950|NCT00856986|9737208|FG002|Extension Period, Weeks 26-52|Unclassified|11
6115951|NCT00856986|9737209|FG003|Extension Period, Weeks 26-52|Unclassified|0
6115952|NCT00856986|9737210|FG004|Extension Period, Weeks 26-52|Unclassified|0
6115953|NCT00856999|9737222|FG000|Overall Study|Withdrawal by Subject|5
6115954|NCT00857207|9737229|FG000|Overall Study|Withdrawal by Subject|13
6115955|NCT00857207|9737230|FG001|Overall Study|Withdrawal by Subject|0
6115956|NCT00857207|9737229|FG000|Overall Study|did not meet inclusion criteria for deficit in inhibition or failed the TOMM|18
6115957|NCT00857207|9737230|FG001|Overall Study|did not meet inclusion criteria for deficit in inhibition or failed the TOMM|0
6115958|NCT00857207|9737229|FG000|Overall Study|Subject chose not to participate after signing consent|3
6210091|NCT01577745|9875500|FG003|Overall Study|Alternative Therapy|1
6210092|NCT01577745|9875501|FG004|Overall Study|Alternative Therapy|1
6210093|NCT01577745|9875502|FG005|Overall Study|Alternative Therapy|0
6210094|NCT01577758|9875521|FG000|Dose Escalation Phase|Adverse Event|0
6210095|NCT01577758|9875522|FG001|Dose Escalation Phase|Adverse Event|0
6210096|NCT01577758|9875523|FG002|Dose Escalation Phase|Adverse Event|0
6210097|NCT01577758|9875524|FG003|Dose Escalation Phase|Adverse Event|0
6210098|NCT01577758|9875525|FG004|Dose Escalation Phase|Adverse Event|0
6210099|NCT01577758|9875526|FG005|Dose Escalation Phase|Adverse Event|2
6210100|NCT01577758|9875527|FG006|Dose Escalation Phase|Adverse Event|1
6210101|NCT01577758|9875528|FG007|Dose Escalation Phase|Adverse Event|0
6210102|NCT01577758|9875521|FG000|Dose Escalation Phase|Symptomatic Deterioration|0
6210103|NCT01577758|9875522|FG001|Dose Escalation Phase|Symptomatic Deterioration|0
6210104|NCT01577758|9875523|FG002|Dose Escalation Phase|Symptomatic Deterioration|1
6210105|NCT01577758|9875524|FG003|Dose Escalation Phase|Symptomatic Deterioration|0
6210106|NCT01577758|9875525|FG004|Dose Escalation Phase|Symptomatic Deterioration|1
6210107|NCT01577758|9875526|FG005|Dose Escalation Phase|Symptomatic Deterioration|1
6210108|NCT01577758|9875527|FG006|Dose Escalation Phase|Symptomatic Deterioration|0
6210109|NCT01577758|9875528|FG007|Dose Escalation Phase|Symptomatic Deterioration|0
6210110|NCT01577758|9875521|FG000|Dose Escalation Phase|Withdrawal by Subject|0
6210111|NCT01577758|9875522|FG001|Dose Escalation Phase|Withdrawal by Subject|0
6210112|NCT01577758|9875523|FG002|Dose Escalation Phase|Withdrawal by Subject|0
6210113|NCT01577758|9875524|FG003|Dose Escalation Phase|Withdrawal by Subject|0
6210114|NCT01577758|9875525|FG004|Dose Escalation Phase|Withdrawal by Subject|0
6210115|NCT01577758|9875526|FG005|Dose Escalation Phase|Withdrawal by Subject|1
6210116|NCT01577758|9875527|FG006|Dose Escalation Phase|Withdrawal by Subject|0
6210117|NCT01577758|9875528|FG007|Dose Escalation Phase|Withdrawal by Subject|0
6210118|NCT01577758|9875521|FG000|Dose Escalation Phase|Progression Disease|2
6210119|NCT01577758|9875522|FG001|Dose Escalation Phase|Progression Disease|2
6210120|NCT01577758|9875523|FG002|Dose Escalation Phase|Progression Disease|1
6210121|NCT01577758|9875524|FG003|Dose Escalation Phase|Progression Disease|2
6210122|NCT01577758|9875525|FG004|Dose Escalation Phase|Progression Disease|5
6210123|NCT01577758|9875526|FG005|Dose Escalation Phase|Progression Disease|0
6210124|NCT01577758|9875527|FG006|Dose Escalation Phase|Progression Disease|0
6210125|NCT01577758|9875528|FG007|Dose Escalation Phase|Progression Disease|0
6210126|NCT01577758|9875521|FG000|mCRC Expansion Phase|Symptomatic Deterioration|0
6210127|NCT01577758|9875522|FG001|mCRC Expansion Phase|Symptomatic Deterioration|0
6210128|NCT01577758|9875523|FG002|mCRC Expansion Phase|Symptomatic Deterioration|0
6210129|NCT01577758|9875524|FG003|mCRC Expansion Phase|Symptomatic Deterioration|0
6210130|NCT01577758|9875525|FG004|mCRC Expansion Phase|Symptomatic Deterioration|0
6210131|NCT01577758|9875526|FG005|mCRC Expansion Phase|Symptomatic Deterioration|0
6210132|NCT01577758|9875527|FG006|mCRC Expansion Phase|Symptomatic Deterioration|0
6210133|NCT01577758|9875528|FG007|mCRC Expansion Phase|Symptomatic Deterioration|4
6210134|NCT01577758|9875521|FG000|mCRC Expansion Phase|Withdrawal by Subject|0
6210135|NCT01577758|9875522|FG001|mCRC Expansion Phase|Withdrawal by Subject|0
6210136|NCT01577758|9875523|FG002|mCRC Expansion Phase|Withdrawal by Subject|0
6210137|NCT01577758|9875524|FG003|mCRC Expansion Phase|Withdrawal by Subject|0
6210138|NCT01577758|9875525|FG004|mCRC Expansion Phase|Withdrawal by Subject|0
6210139|NCT01577758|9875526|FG005|mCRC Expansion Phase|Withdrawal by Subject|0
6210140|NCT01577758|9875527|FG006|mCRC Expansion Phase|Withdrawal by Subject|0
6210141|NCT01577758|9875528|FG007|mCRC Expansion Phase|Withdrawal by Subject|2
6210142|NCT01577758|9875521|FG000|mCRC Expansion Phase|Progression Disease|0
6210143|NCT01577758|9875522|FG001|mCRC Expansion Phase|Progression Disease|0
6210144|NCT01577758|9875523|FG002|mCRC Expansion Phase|Progression Disease|0
6210145|NCT01577758|9875524|FG003|mCRC Expansion Phase|Progression Disease|0
6210146|NCT01577758|9875525|FG004|mCRC Expansion Phase|Progression Disease|0
6210147|NCT01577758|9875526|FG005|mCRC Expansion Phase|Progression Disease|0
6210148|NCT01577758|9875527|FG006|mCRC Expansion Phase|Progression Disease|0
6210149|NCT01577758|9875528|FG007|mCRC Expansion Phase|Progression Disease|19
6210150|NCT01578187|9875576|FG000|Usability Phase|Withdrawal by Subject|1
6210151|NCT01578330|9875608|FG000|Overall Study|Adverse Event|2
6210152|NCT01578330|9875608|FG000|Overall Study|Protocol Violation|5
6210153|NCT01578486|9875612|FG000|Overall Study|Physician Decision|3
6210154|NCT01578486|9875612|FG000|Overall Study|Withdrawal by Subject|2
6210155|NCT01578499|9875618|FG000|Overall Study|Reason not Specified|0
6210156|NCT01578499|9875619|FG001|Overall Study|Reason not Specified|1
6210157|NCT01578499|9875618|FG000|Overall Study|Lost to Follow-up|2
6286616|NCT02346240|9999213|FG022|Maintenance Period (Week 16 to Week 48)|Patient's decisions|0
6115959|NCT00857207|9737230|FG001|Overall Study|Subject chose not to participate after signing consent|0
6115960|NCT00857220|9737237|FG000|Overall Study|Adverse Event|35
6115961|NCT00857220|9737237|FG000|Overall Study|Death|1
6115962|NCT00857220|9737237|FG000|Overall Study|Lack of Efficacy|11
6115963|NCT00857220|9737237|FG000|Overall Study|Lost to Follow-up|30
6115964|NCT00857220|9737237|FG000|Overall Study|Physician Decision|4
6115965|NCT00857220|9737237|FG000|Overall Study|Protocol Violation|16
6115966|NCT00857220|9737237|FG000|Overall Study|Withdrawal by Subject|67
6115967|NCT00857220|9737237|FG000|Overall Study|Clinical Hold|6
6115968|NCT00857220|9737237|FG000|Overall Study|Site Closed|5
6115969|NCT00857220|9737237|FG000|Overall Study|Miscellaneous|8
6115970|NCT00857233|9737241|FG000|Overall Study|Adverse Event|24
6115971|NCT00857233|9737241|FG000|Overall Study|Lack of Efficacy|1
6115972|NCT00857233|9737241|FG000|Overall Study|Non-compliance|1
6115973|NCT00857233|9737241|FG000|Overall Study|Withdrawal of Consent|9
6115974|NCT00857233|9737241|FG000|Overall Study|Lost to Follow-up|4
6115975|NCT00857233|9737241|FG000|Overall Study|Nursing Home Placement|14
6115976|NCT00857233|9737241|FG000|Overall Study|Other Reasons|2
6115977|NCT00857246|9737245|FG000|Induction Regimen|Adverse Event|1
6115978|NCT00857246|9737245|FG000|Induction Regimen|disease-related complications|1
6115979|NCT00857246|9737245|FG000|Induction Regimen|Withdrawal by Subject|1
6115980|NCT00857246|9737245|FG000|Surgery (Curative)|disease progression|6
6115981|NCT00857246|9737245|FG000|ChemoRT|Withdrawal by Subject|1
6115982|NCT00857246|9737245|FG000|ChemoRT|Adverse Event|2
6115983|NCT00857259|9737255|FG000|Overall Study|Protocol Violation|1
6115984|NCT00857259|9737256|FG001|Overall Study|Protocol Violation|0
6115985|NCT00857259|9737257|FG002|Overall Study|Protocol Violation|1
6210158|NCT01578499|9875619|FG001|Overall Study|Lost to Follow-up|1
6210159|NCT01578499|9875618|FG000|Overall Study|Withdrawal by Subject|10
6210160|NCT01578499|9875619|FG001|Overall Study|Withdrawal by Subject|16
6210161|NCT01578499|9875618|FG000|Overall Study|Death|20
6210162|NCT01578499|9875619|FG001|Overall Study|Death|25
6210163|NCT01578499|9875618|FG000|Overall Study|Died and End of Study Page not Completed|2
6210164|NCT01578499|9875619|FG001|Overall Study|Died and End of Study Page not Completed|0
6210165|NCT01578551|9875631|FG000|Overall Study|Adverse Event|1
6210166|NCT01578551|9875632|FG001|Overall Study|Adverse Event|0
6210167|NCT01578850|9875678|FG000|Period 1|Insufficient Clinical Response|1
6210168|NCT01578850|9875679|FG001|Period 1|Insufficient Clinical Response|0
6210169|NCT01578850|9875680|FG002|Period 1|Insufficient Clinical Response|0
6210170|NCT01578850|9875678|FG000|Period 1|Adverse Event|11
6210171|NCT01578850|9875679|FG001|Period 1|Adverse Event|0
6210172|NCT01578850|9875680|FG002|Period 1|Adverse Event|0
6210173|NCT01578850|9875678|FG000|Period 1|Death|1
6210174|NCT01578850|9875679|FG001|Period 1|Death|0
6210175|NCT01578850|9875680|FG002|Period 1|Death|0
6210176|NCT01578850|9875678|FG000|Period 1|Does Not Meet Entrance Criteria|12
6210177|NCT01578850|9875679|FG001|Period 1|Does Not Meet Entrance Criteria|0
6210178|NCT01578850|9875680|FG002|Period 1|Does Not Meet Entrance Criteria|0
6210179|NCT01578850|9875678|FG000|Period 1|Withdrawal by Subject|9
6210180|NCT01578850|9875679|FG001|Period 1|Withdrawal by Subject|0
6115986|NCT00857311|9737280|FG000|Overall Study|Lost to Follow-up|1
6115987|NCT00857311|9737281|FG001|Overall Study|Lost to Follow-up|0
6115988|NCT00857311|9737282|FG002|Overall Study|Lost to Follow-up|0
6210181|NCT01578850|9875680|FG002|Period 1|Withdrawal by Subject|0
6210182|NCT01578850|9875678|FG000|Period 1|Study Terminated by Sponsor|3
6210183|NCT01578850|9875679|FG001|Period 1|Study Terminated by Sponsor|0
6210184|NCT01578850|9875680|FG002|Period 1|Study Terminated by Sponsor|0
6210185|NCT01578850|9875678|FG000|Period 2|Insufficient Clinical Response|0
6210186|NCT01578850|9875679|FG001|Period 2|Insufficient Clinical Response|1
6210187|NCT01578850|9875680|FG002|Period 2|Insufficient Clinical Response|0
6210188|NCT01578850|9875678|FG000|Period 2|Adverse Event|0
6210189|NCT01578850|9875679|FG001|Period 2|Adverse Event|3
6210190|NCT01578850|9875680|FG002|Period 2|Adverse Event|6
6210191|NCT01578850|9875678|FG000|Period 2|Lost to Follow-up|0
6210192|NCT01578850|9875679|FG001|Period 2|Lost to Follow-up|1
6210193|NCT01578850|9875680|FG002|Period 2|Lost to Follow-up|2
6210194|NCT01578850|9875678|FG000|Period 2|Withdrawal by Subject|0
6210195|NCT01578850|9875679|FG001|Period 2|Withdrawal by Subject|2
6210196|NCT01578850|9875680|FG002|Period 2|Withdrawal by Subject|2
6210197|NCT01578850|9875678|FG000|Period 2|Study Terminated by Sponsor|0
6210198|NCT01578850|9875679|FG001|Period 2|Study Terminated by Sponsor|5
6210199|NCT01578850|9875680|FG002|Period 2|Study Terminated by Sponsor|4
6210200|NCT01578850|9875678|FG000|Period 2|Unspecified Reasons|0
6210201|NCT01578850|9875679|FG001|Period 2|Unspecified Reasons|1
6210202|NCT01578850|9875680|FG002|Period 2|Unspecified Reasons|0
6210203|NCT01579006|9875703|FG000|Overall Study|Lack of Efficacy|10
6210204|NCT01579006|9875703|FG000|Overall Study|Adverse Event|13
6210205|NCT01579006|9875703|FG000|Overall Study|Withdrawal by Subject|5
6210206|NCT01579006|9875703|FG000|Overall Study|Non-compliance|3
6210207|NCT01579006|9875703|FG000|Overall Study|Due to participant's health fund|1
6210208|NCT01579006|9875703|FG000|Overall Study|Scheduled surgery|1
6210209|NCT01579318|9875794|FG000|Overall Study|Disease Progression|1
6210210|NCT01579474|9875804|FG000|Overall Study|Adverse Event|1
6210211|NCT01579474|9875805|FG001|Overall Study|Adverse Event|13
6210212|NCT01579474|9875806|FG002|Overall Study|Adverse Event|2
6210213|NCT01579474|9875807|FG003|Overall Study|Adverse Event|0
6115989|NCT00857311|9737283|FG003|Overall Study|Lost to Follow-up|0
6115990|NCT00857389|9737289|FG000|Overall Study|Did not proceed to transplant|2
6115991|NCT00857415|9737295|FG000|Overall Study|Image acquisition failure|2
6115992|NCT00857415|9737296|FG001|Overall Study|Image acquisition failure|0
6115993|NCT00857415|9737295|FG000|Overall Study|Invalid image or not imaged|3
6115994|NCT00857415|9737296|FG001|Overall Study|Invalid image or not imaged|0
6115995|NCT00857415|9737295|FG000|Overall Study|Subject still living at end of study|110
6115996|NCT00857415|9737296|FG001|Overall Study|Subject still living at end of study|0
6115997|NCT00857415|9737295|FG000|Overall Study|Deceased with no autopsy|2
6115998|NCT00857415|9737296|FG001|Overall Study|Deceased with no autopsy|0
6115999|NCT00857454|9737302|FG000|Overall Study|Withdrawal by Subject|2
6116000|NCT00857454|9737302|FG000|Overall Study|Lost to Follow-up|1
6116001|NCT00857454|9737302|FG000|Overall Study|Adverse Event|2
6116002|NCT00857454|9737302|FG000|Overall Study|Total Testosterone >1050 ng/dL|1
6116003|NCT00857454|9737302|FG000|Overall Study|Total Testosterone <300 ng/dL|8
6116004|NCT00857454|9737302|FG000|Overall Study|MTE09 enrollment criteria not met|6
6116005|NCT00857584|9737358|FG000|Overall Study|Lack of Efficacy|1
6116006|NCT00857584|9737359|FG001|Overall Study|Lack of Efficacy|2
6116007|NCT00857584|9737358|FG000|Overall Study|Adverse Event|2
6116008|NCT00857584|9737359|FG001|Overall Study|Adverse Event|2
6116009|NCT00857584|9737358|FG000|Overall Study|Physician Decision|1
6116010|NCT00857584|9737359|FG001|Overall Study|Physician Decision|1
6116011|NCT00857623|9737367|FG000|Overall Study|Adverse Event|5
6116012|NCT00857623|9737368|FG001|Overall Study|Adverse Event|2
6116013|NCT00857623|9737367|FG000|Overall Study|Study-specific discontinuation criteria|5
6116014|NCT00857623|9737368|FG001|Overall Study|Study-specific discontinuation criteria|3
6116015|NCT00857623|9737367|FG000|Overall Study|Withdrawal by Subject|2
6116016|NCT00857623|9737368|FG001|Overall Study|Withdrawal by Subject|1
6116017|NCT00857623|9737367|FG000|Overall Study|Lack of Efficacy|1
6116018|NCT00857623|9737368|FG001|Overall Study|Lack of Efficacy|1
6116019|NCT00857623|9737367|FG000|Overall Study|Severe non-compliance to protocol|1
6116020|NCT00857623|9737368|FG001|Overall Study|Severe non-compliance to protocol|1
6116021|NCT00857623|9737367|FG000|Overall Study|Intake of prohibited medication|0
6116022|NCT00857623|9737368|FG001|Overall Study|Intake of prohibited medication|1
6116023|NCT00857623|9737367|FG000|Overall Study|Positive for HEP C|0
6116024|NCT00857623|9737368|FG001|Overall Study|Positive for HEP C|1
6116025|NCT00857649|9737376|FG000|Overall Study|Adverse Event|15
6116026|NCT00857649|9737377|FG001|Overall Study|Adverse Event|10
6116027|NCT00857649|9737376|FG000|Overall Study|Non-compliance|1
6116028|NCT00857649|9737377|FG001|Overall Study|Non-compliance|1
6116029|NCT00857649|9737376|FG000|Overall Study|Protocol Violation|2
6116030|NCT00857649|9737377|FG001|Overall Study|Protocol Violation|2
6116031|NCT00857649|9737376|FG000|Overall Study|Withdrawal of Consent|10
6116032|NCT00857649|9737377|FG001|Overall Study|Withdrawal of Consent|7
6116033|NCT00857649|9737376|FG000|Overall Study|Nursing Home Placement|2
6116034|NCT00857649|9737377|FG001|Overall Study|Nursing Home Placement|9
6210214|NCT01579474|9875808|FG004|Overall Study|Adverse Event|0
6210215|NCT01579474|9875809|FG005|Overall Study|Adverse Event|1
6210216|NCT01579474|9875804|FG000|Overall Study|Lack of Efficacy|1
6210217|NCT01579474|9875805|FG001|Overall Study|Lack of Efficacy|0
6210218|NCT01579474|9875806|FG002|Overall Study|Lack of Efficacy|0
6210219|NCT01579474|9875807|FG003|Overall Study|Lack of Efficacy|0
6210220|NCT01579474|9875808|FG004|Overall Study|Lack of Efficacy|1
6210221|NCT01579474|9875809|FG005|Overall Study|Lack of Efficacy|0
6210222|NCT01579474|9875804|FG000|Overall Study|Withdrawal by Subject|1
6210223|NCT01579474|9875805|FG001|Overall Study|Withdrawal by Subject|0
6210224|NCT01579474|9875806|FG002|Overall Study|Withdrawal by Subject|0
6210225|NCT01579474|9875807|FG003|Overall Study|Withdrawal by Subject|0
6210226|NCT01579474|9875808|FG004|Overall Study|Withdrawal by Subject|0
6210227|NCT01579474|9875809|FG005|Overall Study|Withdrawal by Subject|0
6210228|NCT01579565|9875833|FG000|Randomized|Adverse Event|1
6210229|NCT01579565|9875834|FG001|Randomized|Adverse Event|3
6210230|NCT01579565|9875833|FG000|Randomized|Withdrawal by Subject|3
6210231|NCT01579565|9875834|FG001|Randomized|Withdrawal by Subject|0
6210232|NCT01579565|9875833|FG000|Randomized|inadequate preoperative pupil dilation|0
6210233|NCT01579565|9875834|FG001|Randomized|inadequate preoperative pupil dilation|1
6210234|NCT01579565|9875833|FG000|Randomized|prohibited preoperative eating|1
6210235|NCT01579565|9875834|FG001|Randomized|prohibited preoperative eating|0
6210236|NCT01579565|9875833|FG000|Randomized|prohibited preoperative medication|0
6210237|NCT01579565|9875834|FG001|Randomized|prohibited preoperative medication|1
6210238|NCT01579565|9875833|FG000|Treated|Physician Decision|0
6210239|NCT01579565|9875834|FG001|Treated|Physician Decision|1
6210240|NCT01579565|9875833|FG000|Treated|Lost to Follow-up|2
6210241|NCT01579565|9875834|FG001|Treated|Lost to Follow-up|1
6116035|NCT00857649|9737376|FG000|Overall Study|Other Reasons|1
6210242|NCT01579565|9875833|FG000|Treated|declined to return for final visit|0
6210243|NCT01579565|9875834|FG001|Treated|declined to return for final visit|1
6210244|NCT01579578|9875844|FG000|Overall Study|Death|4
6210245|NCT01579578|9875845|FG001|Overall Study|Death|1
6116036|NCT00857649|9737377|FG001|Overall Study|Other Reasons|3
6116037|NCT00857766|9737398|FG000|Overall Study|Adverse Event|13
6210246|NCT01579578|9875844|FG000|Overall Study|Lost to Follow-up|1
6210247|NCT01579578|9875845|FG001|Overall Study|Lost to Follow-up|1
6116038|NCT00857766|9737399|FG001|Overall Study|Adverse Event|12
6116039|NCT00857766|9737398|FG000|Overall Study|Protocol Violation|11
6116040|NCT00857766|9737399|FG001|Overall Study|Protocol Violation|11
6116041|NCT00857766|9737398|FG000|Overall Study|Lost to Follow-up|1
6116042|NCT00857766|9737399|FG001|Overall Study|Lost to Follow-up|0
6116043|NCT00857766|9737398|FG000|Overall Study|Investigator Discretion|2
6116044|NCT00857766|9737399|FG001|Overall Study|Investigator Discretion|3
6210248|NCT01579578|9875844|FG000|Overall Study|Withdrawal by Subject|2
6210249|NCT01579578|9875845|FG001|Overall Study|Withdrawal by Subject|1
6210250|NCT01579578|9875844|FG000|Overall Study|Eligibility criteria|3
6210251|NCT01579578|9875845|FG001|Overall Study|Eligibility criteria|9
6210252|NCT01579578|9875844|FG000|Overall Study|Ongoing|3
6210253|NCT01579578|9875845|FG001|Overall Study|Ongoing|0
6210254|NCT01579812|9875869|FG000|Overall Study|Ineligible after treatment start|40
6210255|NCT01579812|9875869|FG000|Overall Study|Patient choice|3
6210256|NCT01579812|9875869|FG000|Overall Study|Noncompliance|3
6210257|NCT01579812|9875869|FG000|Overall Study|Withdrawal by Subject|6
6210258|NCT01579916|9875878|FG000|Overall Study|Lost to Follow-up|6
6210259|NCT01579916|9875879|FG001|Overall Study|Lost to Follow-up|1
6210260|NCT01579916|9875878|FG000|Overall Study|Withdrawal by Subject|1
6210261|NCT01579916|9875879|FG001|Overall Study|Withdrawal by Subject|1
6210262|NCT01579916|9875878|FG000|Overall Study|Death|1
6210263|NCT01579916|9875879|FG001|Overall Study|Death|0
6210264|NCT01580020|9875887|FG000|Overall Study|Lack of Efficacy|0
6210265|NCT01580020|9875888|FG001|Overall Study|Lack of Efficacy|5
6210266|NCT01580020|9875889|FG002|Overall Study|Lack of Efficacy|0
6210267|NCT01580020|9875890|FG003|Overall Study|Lack of Efficacy|1
6210268|NCT01580020|9875887|FG000|Overall Study|Withdrawal by Subject|0
6210269|NCT01580020|9875888|FG001|Overall Study|Withdrawal by Subject|1
6286617|NCT02346240|9999214|FG023|Maintenance Period (Week 16 to Week 48)|Patient's decisions|0
6286618|NCT02346240|9999191|FG000|Maintenance Period (Week 16 to Week 48)|Unavailability due to business trip|0
6286619|NCT02346240|9999192|FG001|Maintenance Period (Week 16 to Week 48)|Unavailability due to business trip|0
6286620|NCT02346240|9999193|FG002|Maintenance Period (Week 16 to Week 48)|Unavailability due to business trip|0
6286621|NCT02346240|9999194|FG003|Maintenance Period (Week 16 to Week 48)|Unavailability due to business trip|0
6286622|NCT02346240|9999195|FG004|Maintenance Period (Week 16 to Week 48)|Unavailability due to business trip|0
6286623|NCT02346240|9999196|FG005|Maintenance Period (Week 16 to Week 48)|Unavailability due to business trip|0
6286624|NCT02346240|9999197|FG006|Maintenance Period (Week 16 to Week 48)|Unavailability due to business trip|0
6286625|NCT02346240|9999198|FG007|Maintenance Period (Week 16 to Week 48)|Unavailability due to business trip|0
6286626|NCT02346240|9999199|FG008|Maintenance Period (Week 16 to Week 48)|Unavailability due to business trip|0
6286627|NCT02346240|9999200|FG009|Maintenance Period (Week 16 to Week 48)|Unavailability due to business trip|0
6286628|NCT02346240|9999201|FG010|Maintenance Period (Week 16 to Week 48)|Unavailability due to business trip|0
6286629|NCT02346240|9999202|FG011|Maintenance Period (Week 16 to Week 48)|Unavailability due to business trip|0
6286630|NCT02346240|9999203|FG012|Maintenance Period (Week 16 to Week 48)|Unavailability due to business trip|0
6286631|NCT02346240|9999204|FG013|Maintenance Period (Week 16 to Week 48)|Unavailability due to business trip|0
6286632|NCT02346240|9999205|FG014|Maintenance Period (Week 16 to Week 48)|Unavailability due to business trip|1
6286633|NCT02346240|9999206|FG015|Maintenance Period (Week 16 to Week 48)|Unavailability due to business trip|0
6286634|NCT02346240|9999207|FG016|Maintenance Period (Week 16 to Week 48)|Unavailability due to business trip|0
6286635|NCT02346240|9999208|FG017|Maintenance Period (Week 16 to Week 48)|Unavailability due to business trip|0
6286636|NCT02346240|9999209|FG018|Maintenance Period (Week 16 to Week 48)|Unavailability due to business trip|0
6286637|NCT02346240|9999210|FG019|Maintenance Period (Week 16 to Week 48)|Unavailability due to business trip|0
6286638|NCT02346240|9999211|FG020|Maintenance Period (Week 16 to Week 48)|Unavailability due to business trip|0
6286639|NCT02346240|9999212|FG021|Maintenance Period (Week 16 to Week 48)|Unavailability due to business trip|0
6286640|NCT02346240|9999213|FG022|Maintenance Period (Week 16 to Week 48)|Unavailability due to business trip|0
5980775|NCT02471144|9569410|FG003|Extension Period (Week 52 to Week 236)|Pregnancy|0
6063206|NCT00505414|9664574|FG001|Titration Phase|Withdrawal by Subject|0
6063207|NCT00505414|9664575|FG002|Titration Phase|Withdrawal by Subject|0
6063208|NCT00505414|9664576|FG003|Titration Phase|Withdrawal by Subject|3
6063209|NCT00505414|9664577|FG004|Titration Phase|Withdrawal by Subject|4
6063210|NCT00505414|9664573|FG000|Titration Phase|Underlying disease and therapy required|0
6063211|NCT00505414|9664574|FG001|Titration Phase|Underlying disease and therapy required|0
6063212|NCT00505414|9664575|FG002|Titration Phase|Underlying disease and therapy required|0
6063213|NCT00505414|9664576|FG003|Titration Phase|Underlying disease and therapy required|7
6063214|NCT00505414|9664577|FG004|Titration Phase|Underlying disease and therapy required|3
6063215|NCT00505414|9664573|FG000|Maintenance Phase|Adverse Event|2
6063216|NCT00505414|9664574|FG001|Maintenance Phase|Adverse Event|2
6063217|NCT00505414|9664575|FG002|Maintenance Phase|Adverse Event|3
6063218|NCT00505414|9664576|FG003|Maintenance Phase|Adverse Event|0
6063219|NCT00505414|9664577|FG004|Maintenance Phase|Adverse Event|0
6063220|NCT00505414|9664573|FG000|Maintenance Phase|Death|2
6063221|NCT00505414|9664574|FG001|Maintenance Phase|Death|0
6063222|NCT00505414|9664575|FG002|Maintenance Phase|Death|1
6063223|NCT00505414|9664576|FG003|Maintenance Phase|Death|0
6116045|NCT00857766|9737398|FG000|Overall Study|Participant Withdrew Consent|4
6116046|NCT00857766|9737399|FG001|Overall Study|Participant Withdrew Consent|4
6116047|NCT00857792|9737405|FG000|Overall Study|inadequate image quality for analysis|12
6116048|NCT00857818|9737411|FG000|Overall Study|Lack of Efficacy|1
6116049|NCT00857818|9737412|FG001|Overall Study|Lack of Efficacy|0
6116050|NCT00857818|9737411|FG000|Overall Study|Adverse Event|3
6116051|NCT00857818|9737412|FG001|Overall Study|Adverse Event|0
6116052|NCT00857818|9737411|FG000|Overall Study|Withdrawal by Subject|0
6116053|NCT00857818|9737412|FG001|Overall Study|Withdrawal by Subject|4
6116054|NCT00857818|9737411|FG000|Overall Study|Sponsor terminated study|6
6116055|NCT00857818|9737412|FG001|Overall Study|Sponsor terminated study|4
6116056|NCT00857818|9737411|FG000|Overall Study|Investigator decision|1
6116057|NCT00857818|9737412|FG001|Overall Study|Investigator decision|0
6116058|NCT00857896|9737430|FG000|Baseline to Week 4|Withdrawal by Subject|1
6116059|NCT00857948|9737439|FG000|Overall Study|Withdrawal by Subject|2
6116060|NCT00857948|9737440|FG001|Overall Study|Withdrawal by Subject|0
6116061|NCT00857948|9737441|FG002|Overall Study|Withdrawal by Subject|0
6116062|NCT00857948|9737442|FG003|Overall Study|Withdrawal by Subject|0
6116063|NCT00857948|9737439|FG000|Overall Study|Protocol Violation|1
6116064|NCT00857948|9737440|FG001|Overall Study|Protocol Violation|0
6116065|NCT00857948|9737441|FG002|Overall Study|Protocol Violation|1
6116066|NCT00857948|9737442|FG003|Overall Study|Protocol Violation|0
6116067|NCT00858117|9737471|FG000|Treatment on Study|Adverse Event|2
6116068|NCT00858117|9737471|FG000|Follow up for 5 Years|Death|4
6116069|NCT00858117|9737471|FG000|Follow up for 5 Years|No further data collected for study|9
6116070|NCT00858143|9737480|FG000|Overall Study|Adverse Event|16
6116071|NCT00858143|9737480|FG000|Overall Study|Lack of Efficacy|4
6116072|NCT00858143|9737480|FG000|Overall Study|Death|7
6116073|NCT00858143|9737480|FG000|Overall Study|Other|23
6116074|NCT00858208|9737484|FG000|Overall Study|Adverse Event|3
6116075|NCT00858208|9737484|FG000|Overall Study|Lost to Follow-up|26
6116076|NCT00858208|9737484|FG000|Overall Study|Participant refused|40
6210270|NCT01580020|9875889|FG002|Overall Study|Withdrawal by Subject|1
6210271|NCT01580020|9875890|FG003|Overall Study|Withdrawal by Subject|0
6210272|NCT01580020|9875887|FG000|Overall Study|Adverse Event|1
6210273|NCT01580020|9875888|FG001|Overall Study|Adverse Event|1
6210274|NCT01580020|9875889|FG002|Overall Study|Adverse Event|1
6210275|NCT01580020|9875890|FG003|Overall Study|Adverse Event|1
6210276|NCT01580020|9875887|FG000|Overall Study|Administrative Problems|0
6210277|NCT01580020|9875888|FG001|Overall Study|Administrative Problems|0
6210278|NCT01580020|9875889|FG002|Overall Study|Administrative Problems|1
6210279|NCT01580020|9875890|FG003|Overall Study|Administrative Problems|0
6210280|NCT01580020|9875887|FG000|Overall Study|Lost to Follow-up|0
6210281|NCT01580020|9875888|FG001|Overall Study|Lost to Follow-up|0
6210282|NCT01580020|9875889|FG002|Overall Study|Lost to Follow-up|1
6210283|NCT01580020|9875890|FG003|Overall Study|Lost to Follow-up|0
6210284|NCT01580293|9875931|FG000|Part A_Main Trial|Adverse Event|0
6210285|NCT01580293|9875932|FG001|Part A_Main Trial|Adverse Event|2
6210286|NCT01580293|9875933|FG002|Part A_Main Trial|Adverse Event|0
6210287|NCT01580293|9875931|FG000|Part A_Main Trial|Withdrawal by Subject|1
6210288|NCT01580293|9875932|FG001|Part A_Main Trial|Withdrawal by Subject|4
6210289|NCT01580293|9875933|FG002|Part A_Main Trial|Withdrawal by Subject|0
6210290|NCT01580293|9875931|FG000|Part A_Main Trial|Non-adherence to the protocol|1
6210291|NCT01580293|9875932|FG001|Part A_Main Trial|Non-adherence to the protocol|0
6210292|NCT01580293|9875933|FG002|Part A_Main Trial|Non-adherence to the protocol|0
6210293|NCT01580293|9875931|FG000|Part A_Extension|Adverse Event|0
6210294|NCT01580293|9875932|FG001|Part A_Extension|Adverse Event|2
6210295|NCT01580293|9875933|FG002|Part A_Extension|Adverse Event|0
6210296|NCT01580293|9875931|FG000|Part A_Extension|Withdrawal by Subject|0
6210297|NCT01580293|9875932|FG001|Part A_Extension|Withdrawal by Subject|3
6286641|NCT02346240|9999214|FG023|Maintenance Period (Week 16 to Week 48)|Unavailability due to business trip|0
6286642|NCT02346240|9999191|FG000|Maintenance Period (Week 16 to Week 48)|Withdrawn by Sponsor|0
6286643|NCT02346240|9999192|FG001|Maintenance Period (Week 16 to Week 48)|Withdrawn by Sponsor|0
6286644|NCT02346240|9999193|FG002|Maintenance Period (Week 16 to Week 48)|Withdrawn by Sponsor|0
6286645|NCT02346240|9999194|FG003|Maintenance Period (Week 16 to Week 48)|Withdrawn by Sponsor|0
6286646|NCT02346240|9999195|FG004|Maintenance Period (Week 16 to Week 48)|Withdrawn by Sponsor|0
6286647|NCT02346240|9999196|FG005|Maintenance Period (Week 16 to Week 48)|Withdrawn by Sponsor|0
6286648|NCT02346240|9999197|FG006|Maintenance Period (Week 16 to Week 48)|Withdrawn by Sponsor|0
6286649|NCT02346240|9999198|FG007|Maintenance Period (Week 16 to Week 48)|Withdrawn by Sponsor|0
6286650|NCT02346240|9999199|FG008|Maintenance Period (Week 16 to Week 48)|Withdrawn by Sponsor|0
6286651|NCT02346240|9999200|FG009|Maintenance Period (Week 16 to Week 48)|Withdrawn by Sponsor|0
6286652|NCT02346240|9999201|FG010|Maintenance Period (Week 16 to Week 48)|Withdrawn by Sponsor|0
6116077|NCT00858208|9737484|FG000|Overall Study|Other|10
6116078|NCT00858234|9737488|FG000|Overall Study|Adverse Event|6
6116079|NCT00858234|9737488|FG000|Overall Study|Progressive disease|2
6116080|NCT00858234|9737488|FG000|Overall Study|Status unknown|1
6116081|NCT00858247|9737494|FG000|Baseline Assessment|Withdrawal by Subject|1
6210298|NCT01580293|9875933|FG002|Part A_Extension|Withdrawal by Subject|0
6210299|NCT01580293|9875931|FG000|Part A_Extension|Lost to Follow-up|0
6210300|NCT01580293|9875932|FG001|Part A_Extension|Lost to Follow-up|1
6116082|NCT00858247|9737495|FG001|Baseline Assessment|Withdrawal by Subject|1
6116083|NCT00858247|9737494|FG000|Baseline Assessment|Poor IV access|1
6116084|NCT00858247|9737495|FG001|Baseline Assessment|Poor IV access|0
6116085|NCT00858247|9737494|FG000|Baseline Assessment|Protocol Violation|0
6116086|NCT00858247|9737495|FG001|Baseline Assessment|Protocol Violation|1
6116087|NCT00858247|9737494|FG000|Week 12 Follow-up|Withdrawal by Subject|0
6116088|NCT00858247|9737495|FG001|Week 12 Follow-up|Withdrawal by Subject|1
6116089|NCT00858364|9737503|FG000|Overall Study|Administrative Decision|3
6116090|NCT00858364|9737504|FG001|Overall Study|Administrative Decision|2
6116091|NCT00858364|9737503|FG000|Overall Study|Adverse Event|5
6116092|NCT00858364|9737504|FG001|Overall Study|Adverse Event|2
6116093|NCT00858364|9737503|FG000|Overall Study|Withdrawal by Subject|44
6116094|NCT00858364|9737504|FG001|Overall Study|Withdrawal by Subject|118
6116095|NCT00858364|9737503|FG000|Overall Study|Ineligibility Determined|1
6116096|NCT00858364|9737504|FG001|Overall Study|Ineligibility Determined|10
6116097|NCT00858364|9737503|FG000|Overall Study|Lost to Follow-up|24
6116098|NCT00858364|9737504|FG001|Overall Study|Lost to Follow-up|54
6116099|NCT00858364|9737503|FG000|Overall Study|Noncompliance|3
6116100|NCT00858364|9737504|FG001|Overall Study|Noncompliance|4
6116101|NCT00858364|9737503|FG000|Overall Study|Protocol Deviation|0
6116102|NCT00858364|9737504|FG001|Overall Study|Protocol Deviation|2
6116103|NCT00858364|9737503|FG000|Overall Study|Other|9
6116104|NCT00858364|9737504|FG001|Overall Study|Other|17
6116105|NCT00858364|9737503|FG000|Overall Study|Missing|1
6210301|NCT01580293|9875933|FG002|Part A_Extension|Lost to Follow-up|0
6210302|NCT01580293|9875931|FG000|Part A_Extension|Other Reason|0
6210303|NCT01580293|9875932|FG001|Part A_Extension|Other Reason|1
6210304|NCT01580293|9875933|FG002|Part A_Extension|Other Reason|0
6210305|NCT01580293|9875931|FG000|Part A_Extension|Completed Japan only|0
6210306|NCT01580293|9875932|FG001|Part A_Extension|Completed Japan only|5
6210307|NCT01580293|9875933|FG002|Part A_Extension|Completed Japan only|0
6210308|NCT01580293|9875931|FG000|Part B|Withdrawal by Subject|0
6210309|NCT01580293|9875932|FG001|Part B|Withdrawal by Subject|0
6210310|NCT01580293|9875933|FG002|Part B|Withdrawal by Subject|1
6210311|NCT01580293|9875931|FG000|Part B|Other reason|0
6210312|NCT01580293|9875932|FG001|Part B|Other reason|0
6210313|NCT01580293|9875933|FG002|Part B|Other reason|1
6210314|NCT01580488|9875994|FG000|Overall Study|Withdrawal by Subject|1
6210315|NCT01580670|9876030|FG000|Maintenance Period (Week 14 to 54)|Adverse Event|1
6210316|NCT01580670|9876030|FG000|Maintenance Period (Week 14 to 54)|Lack of Efficacy|1
6286653|NCT02346240|9999202|FG011|Maintenance Period (Week 16 to Week 48)|Withdrawn by Sponsor|0
6286654|NCT02346240|9999203|FG012|Maintenance Period (Week 16 to Week 48)|Withdrawn by Sponsor|0
6286655|NCT02346240|9999204|FG013|Maintenance Period (Week 16 to Week 48)|Withdrawn by Sponsor|0
6286656|NCT02346240|9999205|FG014|Maintenance Period (Week 16 to Week 48)|Withdrawn by Sponsor|1
6286657|NCT02346240|9999206|FG015|Maintenance Period (Week 16 to Week 48)|Withdrawn by Sponsor|0
6286658|NCT02346240|9999207|FG016|Maintenance Period (Week 16 to Week 48)|Withdrawn by Sponsor|0
6286659|NCT02346240|9999208|FG017|Maintenance Period (Week 16 to Week 48)|Withdrawn by Sponsor|0
6286660|NCT02346240|9999209|FG018|Maintenance Period (Week 16 to Week 48)|Withdrawn by Sponsor|0
6286661|NCT02346240|9999210|FG019|Maintenance Period (Week 16 to Week 48)|Withdrawn by Sponsor|0
6286662|NCT02346240|9999211|FG020|Maintenance Period (Week 16 to Week 48)|Withdrawn by Sponsor|0
6286663|NCT02346240|9999212|FG021|Maintenance Period (Week 16 to Week 48)|Withdrawn by Sponsor|0
6286664|NCT02346240|9999213|FG022|Maintenance Period (Week 16 to Week 48)|Withdrawn by Sponsor|0
6286665|NCT02346240|9999214|FG023|Maintenance Period (Week 16 to Week 48)|Withdrawn by Sponsor|0
6286666|NCT02346240|9999191|FG000|Maintenance Period (Week 16 to Week 48)|Patient request due to non-compliance|0
6286667|NCT02346240|9999192|FG001|Maintenance Period (Week 16 to Week 48)|Patient request due to non-compliance|0
6286668|NCT02346240|9999193|FG002|Maintenance Period (Week 16 to Week 48)|Patient request due to non-compliance|0
6286669|NCT02346240|9999194|FG003|Maintenance Period (Week 16 to Week 48)|Patient request due to non-compliance|0
6286670|NCT02346240|9999195|FG004|Maintenance Period (Week 16 to Week 48)|Patient request due to non-compliance|0
6286671|NCT02346240|9999196|FG005|Maintenance Period (Week 16 to Week 48)|Patient request due to non-compliance|0
6286672|NCT02346240|9999197|FG006|Maintenance Period (Week 16 to Week 48)|Patient request due to non-compliance|0
6286673|NCT02346240|9999198|FG007|Maintenance Period (Week 16 to Week 48)|Patient request due to non-compliance|0
6286674|NCT02346240|9999199|FG008|Maintenance Period (Week 16 to Week 48)|Patient request due to non-compliance|0
6286675|NCT02346240|9999200|FG009|Maintenance Period (Week 16 to Week 48)|Patient request due to non-compliance|0
6286676|NCT02346240|9999201|FG010|Maintenance Period (Week 16 to Week 48)|Patient request due to non-compliance|0
6116106|NCT00858364|9737504|FG001|Overall Study|Missing|1
6116107|NCT00858364|9737503|FG000|Overall Study|Still on-study|114
6116108|NCT00858364|9737504|FG001|Overall Study|Still on-study|247
6116109|NCT00858403|9737519|FG000|Overall Study|Withdrawal by Subject|1
6116110|NCT00858403|9737519|FG000|Overall Study|Death|3
6116111|NCT00858403|9737519|FG000|Overall Study|Disease Progression|1
6116112|NCT00858442|9737525|FG000|Compression:Start to Finish|Lost to Follow-up|1
6210317|NCT01580969|9876047|FG000|Overall Study|Physician Decision|3
6116113|NCT00858442|9737526|FG001|Compression:Start to Finish|Lost to Follow-up|3
6116114|NCT00858637|9737557|FG000|Active Comparison Phase|Adverse Event|14
6116115|NCT00858637|9737558|FG001|Active Comparison Phase|Adverse Event|0
6210318|NCT01580969|9876048|FG001|Overall Study|Physician Decision|0
6116116|NCT00858637|9737559|FG002|Active Comparison Phase|Adverse Event|0
6116117|NCT00858637|9737560|FG003|Active Comparison Phase|Adverse Event|9
6116118|NCT00858637|9737561|FG004|Active Comparison Phase|Adverse Event|0
6116119|NCT00858637|9737562|FG005|Active Comparison Phase|Adverse Event|0
6116120|NCT00858637|9737557|FG000|Active Comparison Phase|Death|1
6116121|NCT00858637|9737558|FG001|Active Comparison Phase|Death|0
6116122|NCT00858637|9737559|FG002|Active Comparison Phase|Death|0
6116123|NCT00858637|9737560|FG003|Active Comparison Phase|Death|1
6116124|NCT00858637|9737561|FG004|Active Comparison Phase|Death|0
6116125|NCT00858637|9737562|FG005|Active Comparison Phase|Death|0
6116126|NCT00858637|9737557|FG000|Active Comparison Phase|Physician Decision|1
6116127|NCT00858637|9737558|FG001|Active Comparison Phase|Physician Decision|0
6116128|NCT00858637|9737559|FG002|Active Comparison Phase|Physician Decision|0
6116129|NCT00858637|9737560|FG003|Active Comparison Phase|Physician Decision|1
6116130|NCT00858637|9737561|FG004|Active Comparison Phase|Physician Decision|0
6116131|NCT00858637|9737562|FG005|Active Comparison Phase|Physician Decision|0
6116132|NCT00858637|9737557|FG000|Active Comparison Phase|Withdrawal by Subject|7
6116133|NCT00858637|9737558|FG001|Active Comparison Phase|Withdrawal by Subject|0
6116134|NCT00858637|9737559|FG002|Active Comparison Phase|Withdrawal by Subject|0
6116135|NCT00858637|9737560|FG003|Active Comparison Phase|Withdrawal by Subject|6
6116136|NCT00858637|9737561|FG004|Active Comparison Phase|Withdrawal by Subject|0
6116137|NCT00858637|9737562|FG005|Active Comparison Phase|Withdrawal by Subject|0
6116138|NCT00858637|9737557|FG000|Active Comparison Phase|Other Reasons|1
6116139|NCT00858637|9737558|FG001|Active Comparison Phase|Other Reasons|0
6116140|NCT00858637|9737559|FG002|Active Comparison Phase|Other Reasons|0
6116141|NCT00858637|9737560|FG003|Active Comparison Phase|Other Reasons|1
6116142|NCT00858637|9737561|FG004|Active Comparison Phase|Other Reasons|0
6116143|NCT00858637|9737562|FG005|Active Comparison Phase|Other Reasons|0
6116144|NCT00858637|9737557|FG000|Placebo-controlled Withdrawal Phase|Death|0
6116145|NCT00858637|9737558|FG001|Placebo-controlled Withdrawal Phase|Death|0
6116146|NCT00858637|9737559|FG002|Placebo-controlled Withdrawal Phase|Death|1
6116147|NCT00858637|9737560|FG003|Placebo-controlled Withdrawal Phase|Death|0
6116148|NCT00858637|9737561|FG004|Placebo-controlled Withdrawal Phase|Death|1
6116149|NCT00858637|9737562|FG005|Placebo-controlled Withdrawal Phase|Death|0
6116150|NCT00858637|9737557|FG000|Placebo-controlled Withdrawal Phase|Withdrawal by Subject|0
6116151|NCT00858637|9737558|FG001|Placebo-controlled Withdrawal Phase|Withdrawal by Subject|0
6116152|NCT00858637|9737559|FG002|Placebo-controlled Withdrawal Phase|Withdrawal by Subject|0
6116153|NCT00858637|9737560|FG003|Placebo-controlled Withdrawal Phase|Withdrawal by Subject|0
6116154|NCT00858637|9737561|FG004|Placebo-controlled Withdrawal Phase|Withdrawal by Subject|0
6116155|NCT00858637|9737562|FG005|Placebo-controlled Withdrawal Phase|Withdrawal by Subject|1
6116156|NCT00858780|9737576|FG000|Open-Label (OL) Run-In(Week-8 to Week 0)|Did not enter double-blind period|18
6116157|NCT00858780|9737577|FG001|Open-Label (OL) Run-In(Week-8 to Week 0)|Did not enter double-blind period|0
6116158|NCT00858780|9737578|FG002|Open-Label (OL) Run-In(Week-8 to Week 0)|Did not enter double-blind period|0
6116159|NCT00858780|9737579|FG003|Open-Label (OL) Run-In(Week-8 to Week 0)|Did not enter double-blind period|0
6210319|NCT01580969|9876049|FG002|Overall Study|Physician Decision|0
6210320|NCT01580995|9876059|FG000|Overall Study|Lost to Follow-up|2
6210321|NCT01580995|9876060|FG001|Overall Study|Lost to Follow-up|2
6210322|NCT01581021|9876078|FG000|Overall Study|Lost to Follow-up|4
6210323|NCT01581021|9876079|FG001|Overall Study|Lost to Follow-up|6
6210324|NCT01581021|9876078|FG000|Overall Study|More than 2 hooks in thoracic|3
6210325|NCT01581021|9876079|FG001|Overall Study|More than 2 hooks in thoracic|0
6210326|NCT01581021|9876078|FG000|Overall Study|Neuromuscular|2
6210327|NCT01581021|9876079|FG001|Overall Study|Neuromuscular|1
6210328|NCT01581021|9876078|FG000|Overall Study|Not Randomized|1
6210329|NCT01581021|9876079|FG001|Overall Study|Not Randomized|2
6210330|NCT01581021|9876078|FG000|Overall Study|Lenke 6 Classification|0
6210331|NCT01581021|9876079|FG001|Overall Study|Lenke 6 Classification|1
6210332|NCT01581021|9876078|FG000|Overall Study|Lack of Efficacy|0
6210333|NCT01581021|9876079|FG001|Overall Study|Lack of Efficacy|1
6210334|NCT01581281|9876088|FG000|Overall Study|Early Study Closure|15
6210335|NCT01581281|9876089|FG001|Overall Study|Early Study Closure|6
6210336|NCT01581281|9876090|FG002|Overall Study|Early Study Closure|12
6286677|NCT02346240|9999202|FG011|Maintenance Period (Week 16 to Week 48)|Patient request due to non-compliance|0
6286678|NCT02346240|9999203|FG012|Maintenance Period (Week 16 to Week 48)|Patient request due to non-compliance|0
6286679|NCT02346240|9999204|FG013|Maintenance Period (Week 16 to Week 48)|Patient request due to non-compliance|0
6286680|NCT02346240|9999205|FG014|Maintenance Period (Week 16 to Week 48)|Patient request due to non-compliance|1
6286681|NCT02346240|9999206|FG015|Maintenance Period (Week 16 to Week 48)|Patient request due to non-compliance|0
6286682|NCT02346240|9999207|FG016|Maintenance Period (Week 16 to Week 48)|Patient request due to non-compliance|0
6286683|NCT02346240|9999208|FG017|Maintenance Period (Week 16 to Week 48)|Patient request due to non-compliance|0
6286684|NCT02346240|9999209|FG018|Maintenance Period (Week 16 to Week 48)|Patient request due to non-compliance|0
6286685|NCT02346240|9999210|FG019|Maintenance Period (Week 16 to Week 48)|Patient request due to non-compliance|0
6286686|NCT02346240|9999211|FG020|Maintenance Period (Week 16 to Week 48)|Patient request due to non-compliance|0
6286687|NCT02346240|9999212|FG021|Maintenance Period (Week 16 to Week 48)|Patient request due to non-compliance|0
6286688|NCT02346240|9999213|FG022|Maintenance Period (Week 16 to Week 48)|Patient request due to non-compliance|0
6116160|NCT00858780|9737580|FG004|Open-Label (OL) Run-In(Week-8 to Week 0)|Did not enter double-blind period|0
6116161|NCT00858780|9737576|FG000|Double-Blind (Week 0 to Failure/Week 48)|Adverse Event|0
6116162|NCT00858780|9737577|FG001|Double-Blind (Week 0 to Failure/Week 48)|Adverse Event|0
6116163|NCT00858780|9737578|FG002|Double-Blind (Week 0 to Failure/Week 48)|Adverse Event|1
6116164|NCT00858780|9737579|FG003|Double-Blind (Week 0 to Failure/Week 48)|Adverse Event|0
6116165|NCT00858780|9737580|FG004|Double-Blind (Week 0 to Failure/Week 48)|Adverse Event|0
6116166|NCT00858780|9737576|FG000|Double-Blind (Week 0 to Failure/Week 48)|Withdrawal by Subject|0
6116167|NCT00858780|9737577|FG001|Double-Blind (Week 0 to Failure/Week 48)|Withdrawal by Subject|1
6116168|NCT00858780|9737578|FG002|Double-Blind (Week 0 to Failure/Week 48)|Withdrawal by Subject|1
6116169|NCT00858780|9737579|FG003|Double-Blind (Week 0 to Failure/Week 48)|Withdrawal by Subject|1
6116170|NCT00858780|9737580|FG004|Double-Blind (Week 0 to Failure/Week 48)|Withdrawal by Subject|0
6116171|NCT00858780|9737576|FG000|Double-Blind (Week 0 to Failure/Week 48)|Other|0
6116172|NCT00858780|9737577|FG001|Double-Blind (Week 0 to Failure/Week 48)|Other|1
6116173|NCT00858780|9737578|FG002|Double-Blind (Week 0 to Failure/Week 48)|Other|0
6116174|NCT00858780|9737579|FG003|Double-Blind (Week 0 to Failure/Week 48)|Other|0
6210337|NCT01581307|9876099|FG000|Overall Study|Withdrawal by Subject|1
6210338|NCT01581593|9876146|FG000|Overall Study|Withdrawal by Subject|1
6210339|NCT01581619|9876154|FG000|Overall Study|Withdrawal by Subject|1
6210340|NCT01581619|9876154|FG000|Overall Study|Lost to Follow-up|1
6210341|NCT01581684|9876187|FG000|Overall Study|Other reason not defined|0
6210342|NCT01581684|9876188|FG001|Overall Study|Other reason not defined|0
6210343|NCT01581684|9876189|FG002|Overall Study|Other reason not defined|0
6286689|NCT02346240|9999214|FG023|Maintenance Period (Week 16 to Week 48)|Patient request due to non-compliance|0
6286690|NCT02346240|9999191|FG000|Open-Label Period (Week 48 to Week 144)|Adverse Event|0
6286691|NCT02346240|9999192|FG001|Open-Label Period (Week 48 to Week 144)|Adverse Event|0
6286692|NCT02346240|9999193|FG002|Open-Label Period (Week 48 to Week 144)|Adverse Event|0
6286693|NCT02346240|9999194|FG003|Open-Label Period (Week 48 to Week 144)|Adverse Event|0
6286694|NCT02346240|9999195|FG004|Open-Label Period (Week 48 to Week 144)|Adverse Event|0
6286695|NCT02346240|9999196|FG005|Open-Label Period (Week 48 to Week 144)|Adverse Event|0
6286696|NCT02346240|9999197|FG006|Open-Label Period (Week 48 to Week 144)|Adverse Event|0
6286697|NCT02346240|9999198|FG007|Open-Label Period (Week 48 to Week 144)|Adverse Event|0
6286698|NCT02346240|9999199|FG008|Open-Label Period (Week 48 to Week 144)|Adverse Event|0
6286699|NCT02346240|9999200|FG009|Open-Label Period (Week 48 to Week 144)|Adverse Event|0
6286700|NCT02346240|9999201|FG010|Open-Label Period (Week 48 to Week 144)|Adverse Event|0
6286701|NCT02346240|9999202|FG011|Open-Label Period (Week 48 to Week 144)|Adverse Event|0
6286702|NCT02346240|9999203|FG012|Open-Label Period (Week 48 to Week 144)|Adverse Event|0
6286703|NCT02346240|9999204|FG013|Open-Label Period (Week 48 to Week 144)|Adverse Event|0
6286704|NCT02346240|9999205|FG014|Open-Label Period (Week 48 to Week 144)|Adverse Event|0
6286705|NCT02346240|9999206|FG015|Open-Label Period (Week 48 to Week 144)|Adverse Event|0
6286706|NCT02346240|9999207|FG016|Open-Label Period (Week 48 to Week 144)|Adverse Event|0
6286707|NCT02346240|9999208|FG017|Open-Label Period (Week 48 to Week 144)|Adverse Event|1
6286708|NCT02346240|9999209|FG018|Open-Label Period (Week 48 to Week 144)|Adverse Event|6
6286709|NCT02346240|9999210|FG019|Open-Label Period (Week 48 to Week 144)|Adverse Event|2
6286710|NCT02346240|9999211|FG020|Open-Label Period (Week 48 to Week 144)|Adverse Event|3
6286711|NCT02346240|9999212|FG021|Open-Label Period (Week 48 to Week 144)|Adverse Event|13
6286712|NCT02346240|9999213|FG022|Open-Label Period (Week 48 to Week 144)|Adverse Event|3
6286713|NCT02346240|9999214|FG023|Open-Label Period (Week 48 to Week 144)|Adverse Event|3
6286714|NCT02346240|9999191|FG000|Open-Label Period (Week 48 to Week 144)|Death|0
6286715|NCT02346240|9999192|FG001|Open-Label Period (Week 48 to Week 144)|Death|0
6286716|NCT02346240|9999193|FG002|Open-Label Period (Week 48 to Week 144)|Death|0
6286717|NCT02346240|9999194|FG003|Open-Label Period (Week 48 to Week 144)|Death|0
6286718|NCT02346240|9999195|FG004|Open-Label Period (Week 48 to Week 144)|Death|0
6286719|NCT02346240|9999196|FG005|Open-Label Period (Week 48 to Week 144)|Death|0
6286720|NCT02346240|9999197|FG006|Open-Label Period (Week 48 to Week 144)|Death|0
6286721|NCT02346240|9999198|FG007|Open-Label Period (Week 48 to Week 144)|Death|0
6286722|NCT02346240|9999199|FG008|Open-Label Period (Week 48 to Week 144)|Death|0
6286723|NCT02346240|9999200|FG009|Open-Label Period (Week 48 to Week 144)|Death|0
6286724|NCT02346240|9999201|FG010|Open-Label Period (Week 48 to Week 144)|Death|0
6286725|NCT02346240|9999202|FG011|Open-Label Period (Week 48 to Week 144)|Death|0
6286726|NCT02346240|9999203|FG012|Open-Label Period (Week 48 to Week 144)|Death|0
6286727|NCT02346240|9999204|FG013|Open-Label Period (Week 48 to Week 144)|Death|0
6286728|NCT02346240|9999205|FG014|Open-Label Period (Week 48 to Week 144)|Death|0
6286729|NCT02346240|9999206|FG015|Open-Label Period (Week 48 to Week 144)|Death|0
6286730|NCT02346240|9999207|FG016|Open-Label Period (Week 48 to Week 144)|Death|0
6286731|NCT02346240|9999208|FG017|Open-Label Period (Week 48 to Week 144)|Death|0
6286732|NCT02346240|9999209|FG018|Open-Label Period (Week 48 to Week 144)|Death|1
6286733|NCT02346240|9999210|FG019|Open-Label Period (Week 48 to Week 144)|Death|1
6286734|NCT02346240|9999211|FG020|Open-Label Period (Week 48 to Week 144)|Death|0
6286735|NCT02346240|9999212|FG021|Open-Label Period (Week 48 to Week 144)|Death|1
6286736|NCT02346240|9999213|FG022|Open-Label Period (Week 48 to Week 144)|Death|0
6116175|NCT00858780|9737580|FG004|Double-Blind (Week 0 to Failure/Week 48)|Other|0
6210344|NCT01581684|9876190|FG003|Overall Study|Other reason not defined|0
6116176|NCT00858780|9737576|FG000|OL Re-Treatment (Failure to Week 48)|Protocol Violation|0
6116177|NCT00858780|9737577|FG001|OL Re-Treatment (Failure to Week 48)|Protocol Violation|0
6116178|NCT00858780|9737578|FG002|OL Re-Treatment (Failure to Week 48)|Protocol Violation|0
6116179|NCT00858780|9737579|FG003|OL Re-Treatment (Failure to Week 48)|Protocol Violation|0
6116180|NCT00858780|9737580|FG004|OL Re-Treatment (Failure to Week 48)|Protocol Violation|1
6116181|NCT00858780|9737576|FG000|OL Re-Treatment (Failure to Week 48)|Other|0
6210345|NCT01581684|9876191|FG004|Overall Study|Other reason not defined|0
6210346|NCT01581684|9876192|FG005|Overall Study|Other reason not defined|0
6210347|NCT01581684|9876193|FG006|Overall Study|Other reason not defined|0
6210348|NCT01581684|9876194|FG007|Overall Study|Other reason not defined|0
6210349|NCT01581684|9876195|FG008|Overall Study|Other reason not defined|1
6210350|NCT01581684|9876196|FG009|Overall Study|Other reason not defined|0
6210351|NCT01581931|9876240|FG000|Washout|Adverse Event|0
6210352|NCT01581931|9876241|FG001|Washout|Adverse Event|1
6210353|NCT01582009|9876251|FG000|Overall Study|Withdrawal by Subject|1
6210354|NCT01582009|9876251|FG000|Overall Study|Physician Decision|1
6210355|NCT01582061|9876257|FG000|Overall Study|Lack of Efficacy|3
6210356|NCT01582061|9876258|FG001|Overall Study|Lack of Efficacy|23
6210357|NCT01582061|9876257|FG000|Overall Study|Adverse Event|12
6210358|NCT01582061|9876258|FG001|Overall Study|Adverse Event|8
6210359|NCT01582061|9876257|FG000|Overall Study|Withdrawal by Subject|10
6210360|NCT01582061|9876258|FG001|Overall Study|Withdrawal by Subject|4
6210361|NCT01582061|9876257|FG000|Overall Study|Abnormal laboratory value(s)|1
6210362|NCT01582061|9876258|FG001|Overall Study|Abnormal laboratory value(s)|0
6210363|NCT01582061|9876257|FG000|Overall Study|Death|0
6210364|NCT01582061|9876258|FG001|Overall Study|Death|1
6116182|NCT00858780|9737577|FG001|OL Re-Treatment (Failure to Week 48)|Other|0
6116183|NCT00858780|9737578|FG002|OL Re-Treatment (Failure to Week 48)|Other|0
6116184|NCT00858780|9737579|FG003|OL Re-Treatment (Failure to Week 48)|Other|0
6116185|NCT00858780|9737580|FG004|OL Re-Treatment (Failure to Week 48)|Other|1
6116186|NCT00858832|9737592|FG000|Overall Study|became ineligible: delivered vaginally|1
6116187|NCT00858832|9737593|FG001|Overall Study|became ineligible: delivered vaginally|0
6116188|NCT00858832|9737592|FG000|Overall Study|Adverse Event|0
6116189|NCT00858832|9737593|FG001|Overall Study|Adverse Event|1
6116190|NCT00858845|9737601|FG000|Overall Study|Patient underwent heart transplant.|0
6116191|NCT00858845|9737602|FG001|Overall Study|Patient underwent heart transplant.|1
6116192|NCT00858988|9737618|FG000|Analysis|Lactulose unable to be detected in urine|2
6116193|NCT00858988|9737619|FG001|Analysis|Lactulose unable to be detected in urine|1
6116194|NCT00859014|9737625|FG000|Overall Study|Death|4
6116195|NCT00859014|9737625|FG000|Overall Study|Lost to Follow-up|1
6116196|NCT00859222|9737676|FG000|Overall Study|Adverse Event|2
6116197|NCT00859222|9737677|FG001|Overall Study|Adverse Event|3
6116198|NCT00859222|9737678|FG002|Overall Study|Adverse Event|6
6116199|NCT00859222|9737679|FG003|Overall Study|Adverse Event|24
6116200|NCT00859222|9737680|FG004|Overall Study|Adverse Event|15
6116201|NCT00859222|9737676|FG000|Overall Study|DLT|1
6116202|NCT00859222|9737677|FG001|Overall Study|DLT|0
6116203|NCT00859222|9737678|FG002|Overall Study|DLT|0
6116204|NCT00859222|9737679|FG003|Overall Study|DLT|0
6116205|NCT00859222|9737680|FG004|Overall Study|DLT|0
6116206|NCT00859313|9737695|FG000|Overall Study|Lack of Efficacy|2
6116207|NCT00859313|9737695|FG000|Overall Study|Adverse Event|1
6116208|NCT00859313|9737695|FG000|Overall Study|staff error|1
6116209|NCT00859456|9737703|FG000|Overall Study|Adverse Event|3
6116210|NCT00859456|9737703|FG000|Overall Study|Progressive disease|2
6116211|NCT00859456|9737703|FG000|Overall Study|Non-compliance|3
6116212|NCT00859469|9737707|FG000|Overall Study|Adverse Event|2
6116213|NCT00859469|9737707|FG000|Overall Study|Lack of Efficacy|9
6116214|NCT00859469|9737707|FG000|Overall Study|Withdrawal by Subject|1
6116215|NCT00859469|9737707|FG000|Overall Study|Death|16
6116216|NCT00859547|9737724|FG000|Overall Study|Lost to Follow-up|1
6116217|NCT00859547|9737724|FG000|Overall Study|Parent withdrew consent|1
6116218|NCT00859573|9737730|FG000|Overall Study|Withdrawal by Subject|4
6116219|NCT00859573|9737731|FG001|Overall Study|Withdrawal by Subject|1
6116220|NCT00859573|9737730|FG000|Overall Study|Physician Decision|1
6116221|NCT00859573|9737731|FG001|Overall Study|Physician Decision|1
6116222|NCT00859586|9737737|FG000|Overall Study|Donors|4
6116223|NCT00859638|9737743|FG000|Overall Study|Lost to Follow-up|6
6116224|NCT00859638|9737744|FG001|Overall Study|Lost to Follow-up|1
6116225|NCT00859638|9737743|FG000|Overall Study|Withdrawal by Subject|3
6116226|NCT00859638|9737744|FG001|Overall Study|Withdrawal by Subject|2
6116227|NCT00859638|9737743|FG000|Overall Study|Ill health|1
6116228|NCT00859638|9737744|FG001|Overall Study|Ill health|1
6116229|NCT00859898|9737767|FG000|Overall Study|Lack of Efficacy|0
6116230|NCT00859898|9737768|FG001|Overall Study|Lack of Efficacy|1
6116231|NCT00859898|9737769|FG002|Overall Study|Lack of Efficacy|1
6116232|NCT00859898|9737767|FG000|Overall Study|Adverse Event|4
6116233|NCT00859898|9737768|FG001|Overall Study|Adverse Event|9
6116234|NCT00859898|9737769|FG002|Overall Study|Adverse Event|8
6116235|NCT00859898|9737767|FG000|Overall Study|Withdrawal by Subject|11
6116236|NCT00859898|9737768|FG001|Overall Study|Withdrawal by Subject|8
6210365|NCT01582061|9876257|FG000|Overall Study|condition no longer requires study drug|1
6210366|NCT01582061|9876258|FG001|Overall Study|condition no longer requires study drug|0
6210367|NCT01582061|9876257|FG000|Overall Study|Lost to Follow-up|1
6116237|NCT00859898|9737769|FG002|Overall Study|Withdrawal by Subject|11
6116238|NCT00859898|9737767|FG000|Overall Study|Death|0
6116239|NCT00859898|9737768|FG001|Overall Study|Death|0
6116240|NCT00859898|9737769|FG002|Overall Study|Death|1
6116241|NCT00859898|9737767|FG000|Overall Study|Lost to Follow-up|10
6116242|NCT00859898|9737768|FG001|Overall Study|Lost to Follow-up|11
6116243|NCT00859898|9737769|FG002|Overall Study|Lost to Follow-up|5
6210368|NCT01582061|9876258|FG001|Overall Study|Lost to Follow-up|0
6210369|NCT01582152|9876285|FG000|Overall Study|Disease Progression|4
6210370|NCT01582152|9876286|FG001|Overall Study|Disease Progression|5
6210371|NCT01582152|9876285|FG000|Overall Study|Adverse Event|2
6210372|NCT01582152|9876286|FG001|Overall Study|Adverse Event|1
6210373|NCT01582178|9876294|FG000|Overall Study|Physician Decision|6
6210374|NCT01582178|9876295|FG001|Overall Study|Physician Decision|5
6210375|NCT01582243|9876301|FG000|Overall Study|Withdrawal by Subject|1
6210376|NCT01582243|9876301|FG000|Overall Study|Adverse Event|1
6210377|NCT01582243|9876301|FG000|Overall Study|Lost to Follow-up|1
6210378|NCT01582282|9876308|FG000|Overall Study|Adverse Event|1
6210379|NCT01582282|9876309|FG001|Overall Study|Adverse Event|1
6210380|NCT01582282|9876310|FG002|Overall Study|Adverse Event|0
6210381|NCT01582282|9876308|FG000|Overall Study|Lost to Follow-up|1
6210382|NCT01582282|9876309|FG001|Overall Study|Lost to Follow-up|0
6210383|NCT01582282|9876310|FG002|Overall Study|Lost to Follow-up|0
6210384|NCT01582282|9876308|FG000|Overall Study|fasting blood glucose outside Protocol|0
6210385|NCT01582282|9876309|FG001|Overall Study|fasting blood glucose outside Protocol|1
6210386|NCT01582282|9876310|FG002|Overall Study|fasting blood glucose outside Protocol|0
6210387|NCT01582308|9876318|FG000|Period 1|Withdrawal by Subject|0
6210388|NCT01582308|9876319|FG001|Period 1|Withdrawal by Subject|0
6210389|NCT01582308|9876320|FG002|Period 1|Withdrawal by Subject|0
6210390|NCT01582308|9876321|FG003|Period 1|Withdrawal by Subject|0
6210391|NCT01582308|9876322|FG004|Period 1|Withdrawal by Subject|0
6210392|NCT01582308|9876323|FG005|Period 1|Withdrawal by Subject|0
6210393|NCT01582308|9876324|FG006|Period 1|Withdrawal by Subject|1
6210394|NCT01582308|9876325|FG007|Period 1|Withdrawal by Subject|0
6210395|NCT01582308|9876326|FG008|Period 1|Withdrawal by Subject|0
6210396|NCT01582308|9876327|FG009|Period 1|Withdrawal by Subject|0
6210397|NCT01582308|9876318|FG000|10-day Washout Following Period 1|Physician Decision|0
6210398|NCT01582308|9876319|FG001|10-day Washout Following Period 1|Physician Decision|0
6210399|NCT01582308|9876320|FG002|10-day Washout Following Period 1|Physician Decision|0
6210400|NCT01582308|9876321|FG003|10-day Washout Following Period 1|Physician Decision|0
6210401|NCT01582308|9876322|FG004|10-day Washout Following Period 1|Physician Decision|1
6210402|NCT01582308|9876323|FG005|10-day Washout Following Period 1|Physician Decision|0
6210403|NCT01582308|9876324|FG006|10-day Washout Following Period 1|Physician Decision|0
6210404|NCT01582308|9876325|FG007|10-day Washout Following Period 1|Physician Decision|0
6210405|NCT01582308|9876326|FG008|10-day Washout Following Period 1|Physician Decision|0
6210406|NCT01582308|9876327|FG009|10-day Washout Following Period 1|Physician Decision|0
6210407|NCT01582308|9876318|FG000|Period 4|Physician Decision|1
6210408|NCT01582308|9876319|FG001|Period 4|Physician Decision|0
6210409|NCT01582308|9876320|FG002|Period 4|Physician Decision|0
6210410|NCT01582308|9876321|FG003|Period 4|Physician Decision|0
6210411|NCT01582308|9876322|FG004|Period 4|Physician Decision|0
6210412|NCT01582308|9876323|FG005|Period 4|Physician Decision|1
6210413|NCT01582308|9876324|FG006|Period 4|Physician Decision|0
6210414|NCT01582308|9876325|FG007|Period 4|Physician Decision|0
6210415|NCT01582308|9876326|FG008|Period 4|Physician Decision|0
6210416|NCT01582308|9876327|FG009|Period 4|Physician Decision|1
6210417|NCT01582451|9876342|FG000|Overall Study|Adverse Event|1
6210418|NCT01582451|9876343|FG001|Overall Study|Adverse Event|3
6210419|NCT01582451|9876342|FG000|Overall Study|Death|3
6210420|NCT01582451|9876343|FG001|Overall Study|Death|3
6210421|NCT01582451|9876342|FG000|Overall Study|Lost to Follow-up|0
6210422|NCT01582451|9876343|FG001|Overall Study|Lost to Follow-up|2
6210423|NCT01582451|9876342|FG000|Overall Study|Protocol Violation|11
6210424|NCT01582451|9876343|FG001|Overall Study|Protocol Violation|3
6210425|NCT01582451|9876342|FG000|Overall Study|Withdrawal by Subject|13
6210426|NCT01582451|9876343|FG001|Overall Study|Withdrawal by Subject|9
6210427|NCT01582451|9876342|FG000|Overall Study|Physician Decision|3
6210428|NCT01582451|9876343|FG001|Overall Study|Physician Decision|0
6210429|NCT01582451|9876342|FG000|Overall Study|Sponsor Decision|1
6210430|NCT01582451|9876343|FG001|Overall Study|Sponsor Decision|0
6210431|NCT01582789|9876369|FG000|Second Intervention (14 Days)|Withdrawal by Subject|1
6210432|NCT01582789|9876370|FG001|Second Intervention (14 Days)|Withdrawal by Subject|0
6210433|NCT01582854|9876380|FG000|Overall Study|Death|8
6210434|NCT01582854|9876381|FG001|Overall Study|Death|5
6116244|NCT00859898|9737767|FG000|Overall Study|poor/non-compliance|2
6116245|NCT00859898|9737768|FG001|Overall Study|poor/non-compliance|0
6210435|NCT01582854|9876380|FG000|Overall Study|Adverse Event|2
6210436|NCT01582854|9876381|FG001|Overall Study|Adverse Event|3
6210437|NCT01582854|9876380|FG000|Overall Study|Withdrawal by Participant|8
6210438|NCT01582854|9876381|FG001|Overall Study|Withdrawal by Participant|11
6210439|NCT01582854|9876380|FG000|Overall Study|Lost to Follow-up|1
6210440|NCT01582854|9876381|FG001|Overall Study|Lost to Follow-up|2
6210441|NCT01582854|9876380|FG000|Overall Study|Physician Decision|0
6210442|NCT01582854|9876381|FG001|Overall Study|Physician Decision|1
6116246|NCT00859898|9737769|FG002|Overall Study|poor/non-compliance|0
6116247|NCT00859898|9737767|FG000|Overall Study|No longer meets criteria|0
6116248|NCT00859898|9737768|FG001|Overall Study|No longer meets criteria|1
6210443|NCT01582854|9876380|FG000|Overall Study|Recurrent Stroke|13
6210444|NCT01582854|9876381|FG001|Overall Study|Recurrent Stroke|8
6210445|NCT01582854|9876380|FG000|Overall Study|Disallowed Concomitant Medication|3
6210446|NCT01582854|9876381|FG001|Overall Study|Disallowed Concomitant Medication|2
6210447|NCT01582854|9876380|FG000|Overall Study|Carotid or Neurosurgery|0
6210448|NCT01582854|9876381|FG001|Overall Study|Carotid or Neurosurgery|1
6210449|NCT01582854|9876380|FG000|Overall Study|General Anaesthesia|0
6210450|NCT01582854|9876381|FG001|Overall Study|General Anaesthesia|1
6210451|NCT01582854|9876380|FG000|Overall Study|Other Miscellaneous Reason|1
6210452|NCT01582854|9876381|FG001|Overall Study|Other Miscellaneous Reason|0
6210453|NCT01582945|9876391|FG000|Overall Study|Intolerable side-effects|1
6210454|NCT01582945|9876391|FG000|Overall Study|Scheduling conflicts|1
6210455|NCT01582971|9876397|FG000|Overall Study|Death|2
6210456|NCT01582971|9876398|FG001|Overall Study|Death|1
6210457|NCT01582971|9876397|FG000|Overall Study|Lost to Follow-up|18
6210458|NCT01582971|9876398|FG001|Overall Study|Lost to Follow-up|21
6210459|NCT01582971|9876397|FG000|Overall Study|Withdrawal by Subject|4
6210460|NCT01582971|9876398|FG001|Overall Study|Withdrawal by Subject|2
6210461|NCT01582971|9876397|FG000|Overall Study|Other|15
6210462|NCT01582971|9876398|FG001|Overall Study|Other|13
6210463|NCT01583166|9876421|FG000|Overall Study|Withdrawal by Subject|4
6210464|NCT01583166|9876422|FG001|Overall Study|Withdrawal by Subject|6
6210465|NCT01583179|9876430|FG000|Overall Study|Screen failure|1
6210466|NCT01583179|9876431|FG001|Overall Study|Screen failure|2
6210467|NCT01583218|9876439|FG000|Overall Study|Withdrawal by Subject|43
6210468|NCT01583218|9876440|FG001|Overall Study|Withdrawal by Subject|29
6210469|NCT01583218|9876439|FG000|Overall Study|Death|206
6210470|NCT01583218|9876440|FG001|Overall Study|Death|211
6210471|NCT01583218|9876439|FG000|Overall Study|Lost to Follow-up|11
6210472|NCT01583218|9876440|FG001|Overall Study|Lost to Follow-up|17
6286737|NCT02346240|9999214|FG023|Open-Label Period (Week 48 to Week 144)|Death|0
6286738|NCT02346240|9999191|FG000|Open-Label Period (Week 48 to Week 144)|Lack of Efficacy|0
6286739|NCT02346240|9999192|FG001|Open-Label Period (Week 48 to Week 144)|Lack of Efficacy|0
6286740|NCT02346240|9999193|FG002|Open-Label Period (Week 48 to Week 144)|Lack of Efficacy|0
5980776|NCT02471144|9569411|FG004|Extension Period (Week 52 to Week 236)|Pregnancy|0
6116249|NCT00859898|9737769|FG002|Overall Study|No longer meets criteria|0
6116250|NCT00859898|9737767|FG000|Overall Study|non-specified|1
6116251|NCT00859898|9737768|FG001|Overall Study|non-specified|1
6116252|NCT00859898|9737769|FG002|Overall Study|non-specified|1
6210473|NCT01583218|9876439|FG000|Overall Study|Adverse event or serious adverse event|3
6210474|NCT01583218|9876440|FG001|Overall Study|Adverse event or serious adverse event|3
6210475|NCT01583218|9876439|FG000|Overall Study|Patient /Family decision|3
6210476|NCT01583218|9876440|FG001|Overall Study|Patient /Family decision|0
6210477|NCT01583218|9876439|FG000|Overall Study|Cannot contact patient directly|1
6210478|NCT01583218|9876440|FG001|Overall Study|Cannot contact patient directly|2
6210479|NCT01583218|9876439|FG000|Overall Study|SOURCE DOCUMENT/COORDINATOR MISSING|0
6210480|NCT01583218|9876440|FG001|Overall Study|SOURCE DOCUMENT/COORDINATOR MISSING|2
6210481|NCT01583218|9876439|FG000|Overall Study|Patient did not wish to attend visits|0
6210482|NCT01583218|9876440|FG001|Overall Study|Patient did not wish to attend visits|1
6210483|NCT01583218|9876439|FG000|Overall Study|Patient randomized but not dosed|17
6210484|NCT01583218|9876440|FG001|Overall Study|Patient randomized but not dosed|16
6210485|NCT01583218|9876439|FG000|Overall Study|Patient was assessed via phone in person|1
6210486|NCT01583218|9876440|FG001|Overall Study|Patient was assessed via phone in person|0
6210487|NCT01583218|9876439|FG000|Overall Study|Patient deemed ineligible after random|2
6210488|NCT01583218|9876440|FG001|Overall Study|Patient deemed ineligible after random|0
6210489|NCT01583218|9876439|FG000|Overall Study|Patient was early terminated from study|0
6210490|NCT01583218|9876440|FG001|Overall Study|Patient was early terminated from study|1
6210491|NCT01583218|9876439|FG000|Overall Study|Patient was randomized due to mistake|1
6210492|NCT01583218|9876440|FG001|Overall Study|Patient was randomized due to mistake|0
6210493|NCT01583218|9876439|FG000|Overall Study|THE SUBJECT MOVED TO ANOTHER PROVINCE|0
6210494|NCT01583218|9876440|FG001|Overall Study|THE SUBJECT MOVED TO ANOTHER PROVINCE|1
6210495|NCT01583218|9876439|FG000|Overall Study|Withdraw of consent on day of random|1
6210496|NCT01583218|9876440|FG001|Overall Study|Withdraw of consent on day of random|0
6210497|NCT01583296|9876448|FG000|Overall Study|Withdrawal by Subject|11
6210498|NCT01583296|9876449|FG001|Overall Study|Withdrawal by Subject|10
6210499|NCT01583374|9876458|FG000|Placebo-controlled Phase (Week 0-24)|Adverse Event|6
6210500|NCT01583374|9876459|FG001|Placebo-controlled Phase (Week 0-24)|Adverse Event|7
6210501|NCT01583374|9876460|FG002|Placebo-controlled Phase (Week 0-24)|Adverse Event|12
6210502|NCT01583374|9876461|FG003|Placebo-controlled Phase (Week 0-24)|Adverse Event|0
6210503|NCT01583374|9876462|FG004|Placebo-controlled Phase (Week 0-24)|Adverse Event|0
6210504|NCT01583374|9876463|FG005|Placebo-controlled Phase (Week 0-24)|Adverse Event|0
6210505|NCT01583374|9876464|FG006|Placebo-controlled Phase (Week 0-24)|Adverse Event|0
6210506|NCT01583374|9876465|FG007|Placebo-controlled Phase (Week 0-24)|Adverse Event|0
6210507|NCT01583374|9876466|FG008|Placebo-controlled Phase (Week 0-24)|Adverse Event|0
6116253|NCT00859937|9737780|FG000|Overall Study|Protocol Violation|1
6116254|NCT00859937|9737781|FG001|Overall Study|Protocol Violation|0
6116255|NCT00860028|9737811|FG000|Placebo Controlled Pretreatment Period|No longer interested in treatment|2
6116256|NCT00860028|9737812|FG001|Placebo Controlled Pretreatment Period|No longer interested in treatment|1
6116257|NCT00860067|9737823|FG000|Overall Study|Lost to Follow-up|46
6116258|NCT00860067|9737824|FG001|Overall Study|Lost to Follow-up|9
6116259|NCT00860067|9737825|FG002|Overall Study|Lost to Follow-up|9
6116260|NCT00860067|9737823|FG000|Overall Study|Withdrawal by Subject|4
6116261|NCT00860067|9737824|FG001|Overall Study|Withdrawal by Subject|0
6116262|NCT00860067|9737825|FG002|Overall Study|Withdrawal by Subject|0
6116263|NCT00860067|9737823|FG000|Overall Study|Pregnancy|1
6116264|NCT00860067|9737824|FG001|Overall Study|Pregnancy|0
6116265|NCT00860067|9737825|FG002|Overall Study|Pregnancy|0
6116266|NCT00860262|9737843|FG000|Overall Study|Adverse Event|9
6116267|NCT00860262|9737844|FG001|Overall Study|Adverse Event|6
6116268|NCT00860262|9737845|FG002|Overall Study|Adverse Event|7
6116269|NCT00860262|9737843|FG000|Overall Study|Protocol Violation|0
6116270|NCT00860262|9737844|FG001|Overall Study|Protocol Violation|1
6116271|NCT00860262|9737845|FG002|Overall Study|Protocol Violation|0
6116272|NCT00860262|9737843|FG000|Overall Study|Lost to Follow-up|2
6116273|NCT00860262|9737844|FG001|Overall Study|Lost to Follow-up|0
6116274|NCT00860262|9737845|FG002|Overall Study|Lost to Follow-up|1
6116275|NCT00860262|9737843|FG000|Overall Study|Withdrawal by Subject|4
6116276|NCT00860262|9737844|FG001|Overall Study|Withdrawal by Subject|8
6116277|NCT00860262|9737845|FG002|Overall Study|Withdrawal by Subject|6
6116278|NCT00860262|9737843|FG000|Overall Study|Lack of Efficacy|0
6116279|NCT00860262|9737844|FG001|Overall Study|Lack of Efficacy|4
6116280|NCT00860262|9737845|FG002|Overall Study|Lack of Efficacy|3
6116281|NCT00860262|9737843|FG000|Overall Study|Other|5
6116282|NCT00860262|9737844|FG001|Overall Study|Other|3
6116283|NCT00860262|9737845|FG002|Overall Study|Other|1
6116284|NCT00860405|9737879|FG000|Overall Study|Main reason: Follow-up data not complete|5
6116285|NCT00860405|9737880|FG001|Overall Study|Main reason: Follow-up data not complete|4
6116286|NCT00860470|9737892|FG000|Overall Study|Death|6
6116287|NCT00860470|9737893|FG001|Overall Study|Death|10
6116288|NCT00860470|9737892|FG000|Overall Study|Moved away|8
6116289|NCT00860470|9737893|FG001|Overall Study|Moved away|10
6116290|NCT00860470|9737892|FG000|Overall Study|Lost to Follow-up|34
6210508|NCT01583374|9876458|FG000|Placebo-controlled Phase (Week 0-24)|Lack of Efficacy|3
6210509|NCT01583374|9876459|FG001|Placebo-controlled Phase (Week 0-24)|Lack of Efficacy|2
6210510|NCT01583374|9876460|FG002|Placebo-controlled Phase (Week 0-24)|Lack of Efficacy|5
6210511|NCT01583374|9876461|FG003|Placebo-controlled Phase (Week 0-24)|Lack of Efficacy|0
6210512|NCT01583374|9876462|FG004|Placebo-controlled Phase (Week 0-24)|Lack of Efficacy|0
6210513|NCT01583374|9876463|FG005|Placebo-controlled Phase (Week 0-24)|Lack of Efficacy|0
6210514|NCT01583374|9876464|FG006|Placebo-controlled Phase (Week 0-24)|Lack of Efficacy|0
6210515|NCT01583374|9876465|FG007|Placebo-controlled Phase (Week 0-24)|Lack of Efficacy|0
6210516|NCT01583374|9876466|FG008|Placebo-controlled Phase (Week 0-24)|Lack of Efficacy|0
6210517|NCT01583374|9876458|FG000|Placebo-controlled Phase (Week 0-24)|Non-compliance with Study Drug|1
6210518|NCT01583374|9876459|FG001|Placebo-controlled Phase (Week 0-24)|Non-compliance with Study Drug|1
6210519|NCT01583374|9876460|FG002|Placebo-controlled Phase (Week 0-24)|Non-compliance with Study Drug|0
6210520|NCT01583374|9876461|FG003|Placebo-controlled Phase (Week 0-24)|Non-compliance with Study Drug|0
6210521|NCT01583374|9876462|FG004|Placebo-controlled Phase (Week 0-24)|Non-compliance with Study Drug|0
6210522|NCT01583374|9876463|FG005|Placebo-controlled Phase (Week 0-24)|Non-compliance with Study Drug|0
6210523|NCT01583374|9876464|FG006|Placebo-controlled Phase (Week 0-24)|Non-compliance with Study Drug|0
6210524|NCT01583374|9876465|FG007|Placebo-controlled Phase (Week 0-24)|Non-compliance with Study Drug|0
6210525|NCT01583374|9876466|FG008|Placebo-controlled Phase (Week 0-24)|Non-compliance with Study Drug|0
6210526|NCT01583374|9876458|FG000|Placebo-controlled Phase (Week 0-24)|Withdrawal by Subject|8
6210527|NCT01583374|9876459|FG001|Placebo-controlled Phase (Week 0-24)|Withdrawal by Subject|3
6210528|NCT01583374|9876460|FG002|Placebo-controlled Phase (Week 0-24)|Withdrawal by Subject|5
6210529|NCT01583374|9876461|FG003|Placebo-controlled Phase (Week 0-24)|Withdrawal by Subject|0
6210530|NCT01583374|9876462|FG004|Placebo-controlled Phase (Week 0-24)|Withdrawal by Subject|0
6210531|NCT01583374|9876463|FG005|Placebo-controlled Phase (Week 0-24)|Withdrawal by Subject|0
6210532|NCT01583374|9876464|FG006|Placebo-controlled Phase (Week 0-24)|Withdrawal by Subject|0
6210533|NCT01583374|9876465|FG007|Placebo-controlled Phase (Week 0-24)|Withdrawal by Subject|0
6210534|NCT01583374|9876466|FG008|Placebo-controlled Phase (Week 0-24)|Withdrawal by Subject|0
6210535|NCT01583374|9876458|FG000|Placebo-controlled Phase (Week 0-24)|Lost to Follow-up|1
6210536|NCT01583374|9876459|FG001|Placebo-controlled Phase (Week 0-24)|Lost to Follow-up|2
6210537|NCT01583374|9876460|FG002|Placebo-controlled Phase (Week 0-24)|Lost to Follow-up|0
6210538|NCT01583374|9876461|FG003|Placebo-controlled Phase (Week 0-24)|Lost to Follow-up|0
6210539|NCT01583374|9876462|FG004|Placebo-controlled Phase (Week 0-24)|Lost to Follow-up|0
6210540|NCT01583374|9876463|FG005|Placebo-controlled Phase (Week 0-24)|Lost to Follow-up|0
6116291|NCT00860470|9737893|FG001|Overall Study|Lost to Follow-up|39
6116292|NCT00860574|9737903|FG000|Overall Study|Death|2
6116293|NCT00860574|9737903|FG000|Overall Study|Relapse|1
6116294|NCT00860743|9737913|FG000|Overall Study|Withdrawal by Subject|3
6116295|NCT00860743|9737914|FG001|Overall Study|Withdrawal by Subject|0
6116296|NCT00860951|9737947|FG000|Overall Study|Withdrawal by Subject|2
6116297|NCT00860951|9737947|FG000|Overall Study|Lost to Follow-up|5
6116298|NCT00861198|9737962|FG000|Overall Study|SpyGlass Failed|5
6116299|NCT00861341|9737970|FG000|Overall Study|Withdrawal by Subject|2
6116300|NCT00861380|9737981|FG000|Overall Study|Withdrawal Information not recorded|8427
6116301|NCT00861380|9737982|FG001|Overall Study|Withdrawal Information not recorded|9112
6116302|NCT00861380|9737983|FG002|Overall Study|Withdrawal Information not recorded|8872
6116303|NCT00861380|9737984|FG003|Overall Study|Withdrawal Information not recorded|3689
6116304|NCT00861380|9737985|FG004|Overall Study|Withdrawal Information not recorded|1812
6116305|NCT00861380|9737986|FG005|Overall Study|Withdrawal Information not recorded|6249
6116306|NCT00861380|9737987|FG006|Overall Study|Withdrawal Information not recorded|3020
6116307|NCT00861471|9738020|FG000|Overall Study|Withdrawal by Subject|1
6116308|NCT00861471|9738020|FG000|Overall Study|Adverse Event|2
6116309|NCT00861471|9738020|FG000|Overall Study|Lack of Efficacy|3
6116310|NCT00861471|9738020|FG000|Overall Study|treatment for lumbar laminectomy|1
6210541|NCT01583374|9876464|FG006|Placebo-controlled Phase (Week 0-24)|Lost to Follow-up|0
6210542|NCT01583374|9876465|FG007|Placebo-controlled Phase (Week 0-24)|Lost to Follow-up|0
6210543|NCT01583374|9876466|FG008|Placebo-controlled Phase (Week 0-24)|Lost to Follow-up|0
6210544|NCT01583374|9876458|FG000|Placebo-controlled Phase (Week 0-24)|Protocol Violation|0
6210545|NCT01583374|9876459|FG001|Placebo-controlled Phase (Week 0-24)|Protocol Violation|0
6210546|NCT01583374|9876460|FG002|Placebo-controlled Phase (Week 0-24)|Protocol Violation|3
6210547|NCT01583374|9876461|FG003|Placebo-controlled Phase (Week 0-24)|Protocol Violation|0
6210548|NCT01583374|9876462|FG004|Placebo-controlled Phase (Week 0-24)|Protocol Violation|0
6210549|NCT01583374|9876463|FG005|Placebo-controlled Phase (Week 0-24)|Protocol Violation|0
6286741|NCT02346240|9999194|FG003|Open-Label Period (Week 48 to Week 144)|Lack of Efficacy|0
6286742|NCT02346240|9999195|FG004|Open-Label Period (Week 48 to Week 144)|Lack of Efficacy|0
6286743|NCT02346240|9999196|FG005|Open-Label Period (Week 48 to Week 144)|Lack of Efficacy|0
6286744|NCT02346240|9999197|FG006|Open-Label Period (Week 48 to Week 144)|Lack of Efficacy|0
6286745|NCT02346240|9999198|FG007|Open-Label Period (Week 48 to Week 144)|Lack of Efficacy|0
6286746|NCT02346240|9999199|FG008|Open-Label Period (Week 48 to Week 144)|Lack of Efficacy|0
6286747|NCT02346240|9999200|FG009|Open-Label Period (Week 48 to Week 144)|Lack of Efficacy|0
6286748|NCT02346240|9999201|FG010|Open-Label Period (Week 48 to Week 144)|Lack of Efficacy|0
6286749|NCT02346240|9999202|FG011|Open-Label Period (Week 48 to Week 144)|Lack of Efficacy|0
6286750|NCT02346240|9999203|FG012|Open-Label Period (Week 48 to Week 144)|Lack of Efficacy|0
6286751|NCT02346240|9999204|FG013|Open-Label Period (Week 48 to Week 144)|Lack of Efficacy|0
6286752|NCT02346240|9999205|FG014|Open-Label Period (Week 48 to Week 144)|Lack of Efficacy|0
6286753|NCT02346240|9999206|FG015|Open-Label Period (Week 48 to Week 144)|Lack of Efficacy|0
6286754|NCT02346240|9999207|FG016|Open-Label Period (Week 48 to Week 144)|Lack of Efficacy|0
6286755|NCT02346240|9999208|FG017|Open-Label Period (Week 48 to Week 144)|Lack of Efficacy|0
6286756|NCT02346240|9999209|FG018|Open-Label Period (Week 48 to Week 144)|Lack of Efficacy|1
6286757|NCT02346240|9999210|FG019|Open-Label Period (Week 48 to Week 144)|Lack of Efficacy|0
6286758|NCT02346240|9999211|FG020|Open-Label Period (Week 48 to Week 144)|Lack of Efficacy|0
6286759|NCT02346240|9999212|FG021|Open-Label Period (Week 48 to Week 144)|Lack of Efficacy|1
6286760|NCT02346240|9999213|FG022|Open-Label Period (Week 48 to Week 144)|Lack of Efficacy|0
6286761|NCT02346240|9999214|FG023|Open-Label Period (Week 48 to Week 144)|Lack of Efficacy|0
6286762|NCT02346240|9999191|FG000|Open-Label Period (Week 48 to Week 144)|Protocol Violation|0
6286763|NCT02346240|9999192|FG001|Open-Label Period (Week 48 to Week 144)|Protocol Violation|0
6286764|NCT02346240|9999193|FG002|Open-Label Period (Week 48 to Week 144)|Protocol Violation|0
6286765|NCT02346240|9999194|FG003|Open-Label Period (Week 48 to Week 144)|Protocol Violation|0
6286766|NCT02346240|9999195|FG004|Open-Label Period (Week 48 to Week 144)|Protocol Violation|0
6286767|NCT02346240|9999196|FG005|Open-Label Period (Week 48 to Week 144)|Protocol Violation|0
6116311|NCT00861471|9738020|FG000|Overall Study|Physician Decision|2
6116312|NCT00861614|9738042|FG000|Overall Study|Disease Progression|182
6116313|NCT00861614|9738043|FG001|Overall Study|Disease Progression|263
6116314|NCT00861614|9738042|FG000|Overall Study|Study Drug Toxicity|79
6116315|NCT00861614|9738043|FG001|Overall Study|Study Drug Toxicity|6
6116316|NCT00861614|9738042|FG000|Overall Study|Death|32
6116317|NCT00861614|9738043|FG001|Overall Study|Death|19
6116318|NCT00861614|9738042|FG000|Overall Study|Adverse Event|27
6116319|NCT00861614|9738043|FG001|Overall Study|Adverse Event|23
6116320|NCT00861614|9738042|FG000|Overall Study|Withdrawal by Subject|34
6116321|NCT00861614|9738043|FG001|Overall Study|Withdrawal by Subject|35
6116322|NCT00861614|9738042|FG000|Overall Study|Other|17
6116323|NCT00861614|9738043|FG001|Overall Study|Other|22
6116324|NCT00861692|9738049|FG000|Overall Study|Death|6
6116325|NCT00861744|9738057|FG000|Overall Study|Adverse Event|0
6116326|NCT00861744|9738058|FG001|Overall Study|Adverse Event|0
6116327|NCT00861744|9738059|FG002|Overall Study|Adverse Event|0
6116328|NCT00861744|9738060|FG003|Overall Study|Adverse Event|1
6116329|NCT00861744|9738057|FG000|Overall Study|Lost to Follow-up|7
6116330|NCT00861744|9738058|FG001|Overall Study|Lost to Follow-up|19
6116331|NCT00861744|9738059|FG002|Overall Study|Lost to Follow-up|17
6116332|NCT00861744|9738060|FG003|Overall Study|Lost to Follow-up|12
6116333|NCT00861744|9738057|FG000|Overall Study|Withdrawal by Subject|10
6116334|NCT00861744|9738058|FG001|Overall Study|Withdrawal by Subject|6
6116335|NCT00861744|9738059|FG002|Overall Study|Withdrawal by Subject|6
6116336|NCT00861744|9738060|FG003|Overall Study|Withdrawal by Subject|19
6116337|NCT00861744|9738057|FG000|Overall Study|Protocol Violation|0
6116338|NCT00861744|9738058|FG001|Overall Study|Protocol Violation|1
6116339|NCT00861744|9738059|FG002|Overall Study|Protocol Violation|0
6116340|NCT00861744|9738060|FG003|Overall Study|Protocol Violation|0
6116341|NCT00861744|9738057|FG000|Overall Study|Migration from study area|0
6116342|NCT00861744|9738058|FG001|Overall Study|Migration from study area|3
6116343|NCT00861744|9738059|FG002|Overall Study|Migration from study area|1
6116344|NCT00861744|9738060|FG003|Overall Study|Migration from study area|0
6116345|NCT00861744|9738057|FG000|Overall Study|Blood draws|0
6116346|NCT00861744|9738058|FG001|Overall Study|Blood draws|0
6116347|NCT00861744|9738059|FG002|Overall Study|Blood draws|0
6116348|NCT00861744|9738060|FG003|Overall Study|Blood draws|1
6116349|NCT00861757|9738074|FG000|Overall Study|Adverse Event|1
6210550|NCT01583374|9876464|FG006|Placebo-controlled Phase (Week 0-24)|Protocol Violation|0
6210551|NCT01583374|9876465|FG007|Placebo-controlled Phase (Week 0-24)|Protocol Violation|0
6210552|NCT01583374|9876466|FG008|Placebo-controlled Phase (Week 0-24)|Protocol Violation|0
6210553|NCT01583374|9876458|FG000|Placebo-controlled Phase (Week 0-24)|Other|0
6210554|NCT01583374|9876459|FG001|Placebo-controlled Phase (Week 0-24)|Other|1
6210555|NCT01583374|9876460|FG002|Placebo-controlled Phase (Week 0-24)|Other|0
6210556|NCT01583374|9876461|FG003|Placebo-controlled Phase (Week 0-24)|Other|0
6210557|NCT01583374|9876462|FG004|Placebo-controlled Phase (Week 0-24)|Other|0
6210558|NCT01583374|9876463|FG005|Placebo-controlled Phase (Week 0-24)|Other|0
6210559|NCT01583374|9876464|FG006|Placebo-controlled Phase (Week 0-24)|Other|0
6210560|NCT01583374|9876465|FG007|Placebo-controlled Phase (Week 0-24)|Other|0
6210561|NCT01583374|9876466|FG008|Placebo-controlled Phase (Week 0-24)|Other|0
6210562|NCT01583374|9876458|FG000|Extension Phase (Weeks 24 to 52)|Lost to Follow-up|0
6210563|NCT01583374|9876459|FG001|Extension Phase (Weeks 24 to 52)|Lost to Follow-up|0
6210564|NCT01583374|9876460|FG002|Extension Phase (Weeks 24 to 52)|Lost to Follow-up|0
6210565|NCT01583374|9876461|FG003|Extension Phase (Weeks 24 to 52)|Lost to Follow-up|0
6210566|NCT01583374|9876462|FG004|Extension Phase (Weeks 24 to 52)|Lost to Follow-up|0
6210567|NCT01583374|9876463|FG005|Extension Phase (Weeks 24 to 52)|Lost to Follow-up|0
6210568|NCT01583374|9876464|FG006|Extension Phase (Weeks 24 to 52)|Lost to Follow-up|0
6286768|NCT02346240|9999197|FG006|Open-Label Period (Week 48 to Week 144)|Protocol Violation|0
6286769|NCT02346240|9999198|FG007|Open-Label Period (Week 48 to Week 144)|Protocol Violation|0
6286770|NCT02346240|9999199|FG008|Open-Label Period (Week 48 to Week 144)|Protocol Violation|0
6286771|NCT02346240|9999200|FG009|Open-Label Period (Week 48 to Week 144)|Protocol Violation|0
6286772|NCT02346240|9999201|FG010|Open-Label Period (Week 48 to Week 144)|Protocol Violation|0
6286773|NCT02346240|9999202|FG011|Open-Label Period (Week 48 to Week 144)|Protocol Violation|0
6286774|NCT02346240|9999203|FG012|Open-Label Period (Week 48 to Week 144)|Protocol Violation|0
6286775|NCT02346240|9999204|FG013|Open-Label Period (Week 48 to Week 144)|Protocol Violation|0
6286776|NCT02346240|9999205|FG014|Open-Label Period (Week 48 to Week 144)|Protocol Violation|0
6286777|NCT02346240|9999206|FG015|Open-Label Period (Week 48 to Week 144)|Protocol Violation|0
6286778|NCT02346240|9999207|FG016|Open-Label Period (Week 48 to Week 144)|Protocol Violation|0
6116350|NCT00861757|9738075|FG001|Overall Study|Adverse Event|5
6116351|NCT00861757|9738076|FG002|Overall Study|Adverse Event|7
6116352|NCT00861757|9738077|FG003|Overall Study|Adverse Event|2
6116353|NCT00861757|9738074|FG000|Overall Study|Entry Criteria Not Met|1
6116354|NCT00861757|9738075|FG001|Overall Study|Entry Criteria Not Met|2
6116355|NCT00861757|9738076|FG002|Overall Study|Entry Criteria Not Met|1
6116356|NCT00861757|9738077|FG003|Overall Study|Entry Criteria Not Met|1
6116357|NCT00861757|9738074|FG000|Overall Study|Lack of Efficacy|3
6116358|NCT00861757|9738075|FG001|Overall Study|Lack of Efficacy|1
6116359|NCT00861757|9738076|FG002|Overall Study|Lack of Efficacy|0
6116360|NCT00861757|9738077|FG003|Overall Study|Lack of Efficacy|1
6116361|NCT00861757|9738074|FG000|Overall Study|Lost to Follow-up|1
6116362|NCT00861757|9738075|FG001|Overall Study|Lost to Follow-up|0
6116363|NCT00861757|9738076|FG002|Overall Study|Lost to Follow-up|1
6116364|NCT00861757|9738077|FG003|Overall Study|Lost to Follow-up|1
6116365|NCT00861757|9738074|FG000|Overall Study|Physician Decision|0
6116366|NCT00861757|9738075|FG001|Overall Study|Physician Decision|0
6116367|NCT00861757|9738076|FG002|Overall Study|Physician Decision|0
6116368|NCT00861757|9738077|FG003|Overall Study|Physician Decision|1
6116369|NCT00861757|9738074|FG000|Overall Study|Protocol Violation|2
6116370|NCT00861757|9738075|FG001|Overall Study|Protocol Violation|2
6116371|NCT00861757|9738076|FG002|Overall Study|Protocol Violation|4
6116372|NCT00861757|9738077|FG003|Overall Study|Protocol Violation|1
6116373|NCT00861757|9738074|FG000|Overall Study|Withdrawal by Subject|1
6286779|NCT02346240|9999208|FG017|Open-Label Period (Week 48 to Week 144)|Protocol Violation|0
6116374|NCT00861757|9738075|FG001|Overall Study|Withdrawal by Subject|5
6116375|NCT00861757|9738076|FG002|Overall Study|Withdrawal by Subject|5
6116376|NCT00861757|9738077|FG003|Overall Study|Withdrawal by Subject|2
6116377|NCT00862082|9738097|FG000|Overall Study|Sponsor decision to terminate the study|5
6116378|NCT00862082|9738098|FG001|Overall Study|Sponsor decision to terminate the study|0
6116379|NCT00862082|9738097|FG000|Overall Study|Withdrawal by Subject|0
6116380|NCT00862082|9738098|FG001|Overall Study|Withdrawal by Subject|1
6116381|NCT00862121|9738113|FG000|Overall Study|Adverse Event|1
6116382|NCT00862121|9738114|FG001|Overall Study|Adverse Event|2
6116383|NCT00862121|9738113|FG000|Overall Study|Lack of Efficacy|0
6116384|NCT00862121|9738114|FG001|Overall Study|Lack of Efficacy|3
6116385|NCT00862121|9738113|FG000|Overall Study|Protocol Violation|0
6116386|NCT00862121|9738114|FG001|Overall Study|Protocol Violation|1
6116387|NCT00862121|9738113|FG000|Overall Study|Exclusion criterion violation|0
6116388|NCT00862121|9738114|FG001|Overall Study|Exclusion criterion violation|1
6116389|NCT00862121|9738113|FG000|Overall Study|Incorrect randomisation|0
6116390|NCT00862121|9738114|FG001|Overall Study|Incorrect randomisation|1
6116391|NCT00862134|9738122|FG000|Overall Study|Death|1
6116392|NCT00862134|9738123|FG001|Overall Study|Death|0
6116393|NCT00862134|9738122|FG000|Overall Study|Physician Decision|0
6116394|NCT00862134|9738123|FG001|Overall Study|Physician Decision|1
6116395|NCT00862134|9738122|FG000|Overall Study|Withdrawal by Subject|1
6116396|NCT00862134|9738123|FG001|Overall Study|Withdrawal by Subject|2
6116397|NCT00862134|9738122|FG000|Overall Study|Sponsor terminated study|5
6116398|NCT00862134|9738123|FG001|Overall Study|Sponsor terminated study|7
6116399|NCT00862134|9738122|FG000|Overall Study|Adverse Event|2
6116400|NCT00862134|9738123|FG001|Overall Study|Adverse Event|2
6116401|NCT00862134|9738122|FG000|Overall Study|Withdrew prior to dosing|2
6116402|NCT00862134|9738123|FG001|Overall Study|Withdrew prior to dosing|0
6116403|NCT00862277|9738137|FG000|Overall Study|Protocol Violation|1
6116404|NCT00862277|9738138|FG001|Overall Study|Protocol Violation|2
6116405|NCT00862277|9738139|FG002|Overall Study|Protocol Violation|5
6116406|NCT00862459|9738154|FG000|Overall Study|Lost to Follow-up|1
6116407|NCT00862459|9738155|FG001|Overall Study|Lost to Follow-up|2
6116408|NCT00862459|9738156|FG002|Overall Study|Lost to Follow-up|2
6116409|NCT00862459|9738154|FG000|Overall Study|Protocol Violation|1
6116410|NCT00862459|9738155|FG001|Overall Study|Protocol Violation|0
6116411|NCT00862459|9738156|FG002|Overall Study|Protocol Violation|0
6116412|NCT00862459|9738154|FG000|Overall Study|Withdrawal by Subject|1
6210569|NCT01583374|9876465|FG007|Extension Phase (Weeks 24 to 52)|Lost to Follow-up|1
6210570|NCT01583374|9876466|FG008|Extension Phase (Weeks 24 to 52)|Lost to Follow-up|0
6210571|NCT01583374|9876458|FG000|Extension Phase (Weeks 24 to 52)|Adverse Event|0
6210572|NCT01583374|9876459|FG001|Extension Phase (Weeks 24 to 52)|Adverse Event|1
6210573|NCT01583374|9876460|FG002|Extension Phase (Weeks 24 to 52)|Adverse Event|2
6210574|NCT01583374|9876461|FG003|Extension Phase (Weeks 24 to 52)|Adverse Event|0
6210575|NCT01583374|9876462|FG004|Extension Phase (Weeks 24 to 52)|Adverse Event|1
6210576|NCT01583374|9876463|FG005|Extension Phase (Weeks 24 to 52)|Adverse Event|1
6210577|NCT01583374|9876464|FG006|Extension Phase (Weeks 24 to 52)|Adverse Event|0
6210578|NCT01583374|9876465|FG007|Extension Phase (Weeks 24 to 52)|Adverse Event|1
6210579|NCT01583374|9876466|FG008|Extension Phase (Weeks 24 to 52)|Adverse Event|0
6210580|NCT01583374|9876458|FG000|Extension Phase (Weeks 24 to 52)|Lack of Efficacy|0
6210581|NCT01583374|9876459|FG001|Extension Phase (Weeks 24 to 52)|Lack of Efficacy|2
6210582|NCT01583374|9876460|FG002|Extension Phase (Weeks 24 to 52)|Lack of Efficacy|0
6210583|NCT01583374|9876461|FG003|Extension Phase (Weeks 24 to 52)|Lack of Efficacy|6
6210584|NCT01583374|9876462|FG004|Extension Phase (Weeks 24 to 52)|Lack of Efficacy|3
6210585|NCT01583374|9876463|FG005|Extension Phase (Weeks 24 to 52)|Lack of Efficacy|2
6210586|NCT01583374|9876464|FG006|Extension Phase (Weeks 24 to 52)|Lack of Efficacy|5
6210587|NCT01583374|9876465|FG007|Extension Phase (Weeks 24 to 52)|Lack of Efficacy|1
6210588|NCT01583374|9876466|FG008|Extension Phase (Weeks 24 to 52)|Lack of Efficacy|2
6210589|NCT01583374|9876458|FG000|Extension Phase (Weeks 24 to 52)|Non-compliance study drug|0
6210590|NCT01583374|9876459|FG001|Extension Phase (Weeks 24 to 52)|Non-compliance study drug|2
6210591|NCT01583374|9876460|FG002|Extension Phase (Weeks 24 to 52)|Non-compliance study drug|1
6210592|NCT01583374|9876461|FG003|Extension Phase (Weeks 24 to 52)|Non-compliance study drug|0
6210593|NCT01583374|9876462|FG004|Extension Phase (Weeks 24 to 52)|Non-compliance study drug|1
6210594|NCT01583374|9876463|FG005|Extension Phase (Weeks 24 to 52)|Non-compliance study drug|0
6210595|NCT01583374|9876464|FG006|Extension Phase (Weeks 24 to 52)|Non-compliance study drug|0
6210596|NCT01583374|9876465|FG007|Extension Phase (Weeks 24 to 52)|Non-compliance study drug|0
6210597|NCT01583374|9876466|FG008|Extension Phase (Weeks 24 to 52)|Non-compliance study drug|0
6210598|NCT01583374|9876458|FG000|Extension Phase (Weeks 24 to 52)|Withdrawal by Subject|0
6210599|NCT01583374|9876459|FG001|Extension Phase (Weeks 24 to 52)|Withdrawal by Subject|0
6210600|NCT01583374|9876460|FG002|Extension Phase (Weeks 24 to 52)|Withdrawal by Subject|1
6210601|NCT01583374|9876461|FG003|Extension Phase (Weeks 24 to 52)|Withdrawal by Subject|0
6210602|NCT01583374|9876462|FG004|Extension Phase (Weeks 24 to 52)|Withdrawal by Subject|1
6210603|NCT01583374|9876463|FG005|Extension Phase (Weeks 24 to 52)|Withdrawal by Subject|2
6210604|NCT01583374|9876464|FG006|Extension Phase (Weeks 24 to 52)|Withdrawal by Subject|0
6210605|NCT01583374|9876465|FG007|Extension Phase (Weeks 24 to 52)|Withdrawal by Subject|0
6210606|NCT01583374|9876466|FG008|Extension Phase (Weeks 24 to 52)|Withdrawal by Subject|0
6210607|NCT01583374|9876458|FG000|Long-Term Extension Phase Weeks 52-260|Adverse Event|0
6116413|NCT00862459|9738155|FG001|Overall Study|Withdrawal by Subject|1
6116414|NCT00862459|9738156|FG002|Overall Study|Withdrawal by Subject|3
6116415|NCT00862459|9738154|FG000|Overall Study|Adverse Event|0
6116416|NCT00862459|9738155|FG001|Overall Study|Adverse Event|1
6116417|NCT00862459|9738156|FG002|Overall Study|Adverse Event|0
6116418|NCT00862459|9738154|FG000|Overall Study|Personal reasons|1
6116419|NCT00862459|9738155|FG001|Overall Study|Personal reasons|0
6116420|NCT00862459|9738156|FG002|Overall Study|Personal reasons|0
6116421|NCT00862459|9738154|FG000|Overall Study|Operation|1
6116422|NCT00862459|9738155|FG001|Overall Study|Operation|1
6116423|NCT00862459|9738156|FG002|Overall Study|Operation|0
6116424|NCT00862459|9738154|FG000|Overall Study|Intravenous (IV) site problems|1
6116425|NCT00862459|9738155|FG001|Overall Study|Intravenous (IV) site problems|0
6116426|NCT00862459|9738156|FG002|Overall Study|Intravenous (IV) site problems|1
6116427|NCT00862459|9738154|FG000|Overall Study|Unable to hold still for imaging|0
6116428|NCT00862459|9738155|FG001|Overall Study|Unable to hold still for imaging|1
6116429|NCT00862459|9738156|FG002|Overall Study|Unable to hold still for imaging|0
6116430|NCT00862459|9738154|FG000|Overall Study|Inclusion/exclusion criteria not met|0
6116431|NCT00862459|9738155|FG001|Overall Study|Inclusion/exclusion criteria not met|1
6116432|NCT00862459|9738156|FG002|Overall Study|Inclusion/exclusion criteria not met|0
6116433|NCT00862459|9738154|FG000|Overall Study|Administrative problems|0
6116434|NCT00862459|9738155|FG001|Overall Study|Administrative problems|1
6116435|NCT00862459|9738156|FG002|Overall Study|Administrative problems|0
6116436|NCT00862641|9738199|FG000|Overall Study|Randomized, but drug not received|1
6116437|NCT00862641|9738200|FG001|Overall Study|Randomized, but drug not received|4
6116438|NCT00862641|9738201|FG002|Overall Study|Randomized, but drug not received|1
6116439|NCT00862641|9738202|FG003|Overall Study|Randomized, but drug not received|4
6116440|NCT00862654|9738216|FG000|Overall Study|Lack of Efficacy|1
6116441|NCT00862654|9738217|FG001|Overall Study|Lack of Efficacy|0
6116442|NCT00862654|9738218|FG002|Overall Study|Lack of Efficacy|1
6116443|NCT00862654|9738219|FG003|Overall Study|Lack of Efficacy|0
6116444|NCT00862654|9738216|FG000|Overall Study|Lost to Follow-up|1
6116445|NCT00862654|9738217|FG001|Overall Study|Lost to Follow-up|2
6116446|NCT00862654|9738218|FG002|Overall Study|Lost to Follow-up|1
6116447|NCT00862654|9738219|FG003|Overall Study|Lost to Follow-up|3
6116448|NCT00862654|9738216|FG000|Overall Study|Adverse Event|0
6116449|NCT00862654|9738217|FG001|Overall Study|Adverse Event|1
6116450|NCT00862654|9738218|FG002|Overall Study|Adverse Event|1
6116451|NCT00862654|9738219|FG003|Overall Study|Adverse Event|0
6116452|NCT00862654|9738216|FG000|Overall Study|Pregnancy|1
6116453|NCT00862654|9738217|FG001|Overall Study|Pregnancy|1
6116454|NCT00862654|9738218|FG002|Overall Study|Pregnancy|0
6116455|NCT00862654|9738219|FG003|Overall Study|Pregnancy|0
6116456|NCT00862654|9738216|FG000|Overall Study|Withdrawal by Subject|2
6116457|NCT00862654|9738217|FG001|Overall Study|Withdrawal by Subject|2
6116458|NCT00862654|9738218|FG002|Overall Study|Withdrawal by Subject|2
6210608|NCT01583374|9876459|FG001|Long-Term Extension Phase Weeks 52-260|Adverse Event|5
6210609|NCT01583374|9876460|FG002|Long-Term Extension Phase Weeks 52-260|Adverse Event|2
6210610|NCT01583374|9876461|FG003|Long-Term Extension Phase Weeks 52-260|Adverse Event|2
6210611|NCT01583374|9876462|FG004|Long-Term Extension Phase Weeks 52-260|Adverse Event|6
6210612|NCT01583374|9876463|FG005|Long-Term Extension Phase Weeks 52-260|Adverse Event|2
6210613|NCT01583374|9876464|FG006|Long-Term Extension Phase Weeks 52-260|Adverse Event|2
6210614|NCT01583374|9876465|FG007|Long-Term Extension Phase Weeks 52-260|Adverse Event|3
6210615|NCT01583374|9876466|FG008|Long-Term Extension Phase Weeks 52-260|Adverse Event|1
6210616|NCT01583374|9876458|FG000|Long-Term Extension Phase Weeks 52-260|Lack of Efficacy|0
6210617|NCT01583374|9876459|FG001|Long-Term Extension Phase Weeks 52-260|Lack of Efficacy|4
6210618|NCT01583374|9876460|FG002|Long-Term Extension Phase Weeks 52-260|Lack of Efficacy|6
6210619|NCT01583374|9876461|FG003|Long-Term Extension Phase Weeks 52-260|Lack of Efficacy|7
6210620|NCT01583374|9876462|FG004|Long-Term Extension Phase Weeks 52-260|Lack of Efficacy|10
6210621|NCT01583374|9876463|FG005|Long-Term Extension Phase Weeks 52-260|Lack of Efficacy|7
6210622|NCT01583374|9876464|FG006|Long-Term Extension Phase Weeks 52-260|Lack of Efficacy|4
6286780|NCT02346240|9999209|FG018|Open-Label Period (Week 48 to Week 144)|Protocol Violation|0
6286781|NCT02346240|9999210|FG019|Open-Label Period (Week 48 to Week 144)|Protocol Violation|0
6286782|NCT02346240|9999211|FG020|Open-Label Period (Week 48 to Week 144)|Protocol Violation|0
6286783|NCT02346240|9999212|FG021|Open-Label Period (Week 48 to Week 144)|Protocol Violation|1
6286784|NCT02346240|9999213|FG022|Open-Label Period (Week 48 to Week 144)|Protocol Violation|0
6286785|NCT02346240|9999214|FG023|Open-Label Period (Week 48 to Week 144)|Protocol Violation|0
6286786|NCT02346240|9999191|FG000|Open-Label Period (Week 48 to Week 144)|Lost to Follow-up|0
6286787|NCT02346240|9999192|FG001|Open-Label Period (Week 48 to Week 144)|Lost to Follow-up|0
6286788|NCT02346240|9999193|FG002|Open-Label Period (Week 48 to Week 144)|Lost to Follow-up|0
6286789|NCT02346240|9999194|FG003|Open-Label Period (Week 48 to Week 144)|Lost to Follow-up|0
6286790|NCT02346240|9999195|FG004|Open-Label Period (Week 48 to Week 144)|Lost to Follow-up|0
6286791|NCT02346240|9999196|FG005|Open-Label Period (Week 48 to Week 144)|Lost to Follow-up|0
6286792|NCT02346240|9999197|FG006|Open-Label Period (Week 48 to Week 144)|Lost to Follow-up|0
6286793|NCT02346240|9999198|FG007|Open-Label Period (Week 48 to Week 144)|Lost to Follow-up|0
6116459|NCT00862654|9738219|FG003|Overall Study|Withdrawal by Subject|3
6116460|NCT00862654|9738216|FG000|Overall Study|Subject mistake|0
6116461|NCT00862654|9738217|FG001|Overall Study|Subject mistake|1
6210623|NCT01583374|9876465|FG007|Long-Term Extension Phase Weeks 52-260|Lack of Efficacy|2
6210624|NCT01583374|9876466|FG008|Long-Term Extension Phase Weeks 52-260|Lack of Efficacy|4
6116462|NCT00862654|9738218|FG002|Overall Study|Subject mistake|0
6116463|NCT00862654|9738219|FG003|Overall Study|Subject mistake|0
6116464|NCT00862654|9738216|FG000|Overall Study|Familly constraint|0
6116465|NCT00862654|9738217|FG001|Overall Study|Familly constraint|1
6116466|NCT00862654|9738218|FG002|Overall Study|Familly constraint|0
6116467|NCT00862654|9738219|FG003|Overall Study|Familly constraint|0
6116468|NCT00862654|9738216|FG000|Overall Study|Never used study drugs|1
6116469|NCT00862654|9738217|FG001|Overall Study|Never used study drugs|0
6116470|NCT00862654|9738218|FG002|Overall Study|Never used study drugs|0
6116471|NCT00862654|9738219|FG003|Overall Study|Never used study drugs|0
6116472|NCT00862654|9738216|FG000|Overall Study|Included after end of inclusions|0
6116473|NCT00862654|9738217|FG001|Overall Study|Included after end of inclusions|0
6116474|NCT00862654|9738218|FG002|Overall Study|Included after end of inclusions|1
6116475|NCT00862654|9738219|FG003|Overall Study|Included after end of inclusions|0
6116476|NCT00862719|9738233|FG000|Overall Study|Disease Progression|5
6116477|NCT00862719|9738234|FG001|Overall Study|Disease Progression|0
6116478|NCT00862719|9738235|FG002|Overall Study|Disease Progression|1
6116479|NCT00862719|9738236|FG003|Overall Study|Disease Progression|0
6116480|NCT00862719|9738233|FG000|Overall Study|Death|5
6116481|NCT00862719|9738234|FG001|Overall Study|Death|6
6116482|NCT00862719|9738235|FG002|Overall Study|Death|1
6116483|NCT00862719|9738236|FG003|Overall Study|Death|1
6116484|NCT00862719|9738233|FG000|Overall Study|Engraftment failure|0
6116485|NCT00862719|9738234|FG001|Overall Study|Engraftment failure|0
6116486|NCT00862719|9738235|FG002|Overall Study|Engraftment failure|1
6116487|NCT00862719|9738236|FG003|Overall Study|Engraftment failure|0
6116488|NCT00862719|9738233|FG000|Overall Study|Veno-Occlusive Disease|0
6116489|NCT00862719|9738234|FG001|Overall Study|Veno-Occlusive Disease|0
6116490|NCT00862719|9738235|FG002|Overall Study|Veno-Occlusive Disease|1
6116491|NCT00862719|9738236|FG003|Overall Study|Veno-Occlusive Disease|0
6116492|NCT00862823|9738268|FG000|First Intervention|Withdrawal by Subject|1
6116493|NCT00862823|9738269|FG001|First Intervention|Withdrawal by Subject|1
6116494|NCT00862836|9738274|FG000|Overall Study|Withdrawal by Subject|1
6116495|NCT00862849|9738278|FG000|Washout 1 (3 to 14 Days)|Withdrawal by Subject|0
6116496|NCT00862849|9738279|FG001|Washout 1 (3 to 14 Days)|Withdrawal by Subject|1
6116497|NCT00862849|9738280|FG002|Washout 1 (3 to 14 Days)|Withdrawal by Subject|0
6116498|NCT00862849|9738281|FG003|Washout 1 (3 to 14 Days)|Withdrawal by Subject|0
6116499|NCT00862849|9738282|FG004|Washout 1 (3 to 14 Days)|Withdrawal by Subject|0
6116500|NCT00862849|9738283|FG005|Washout 1 (3 to 14 Days)|Withdrawal by Subject|0
6116501|NCT00862849|9738278|FG000|Washout 2 (3 to 14 Days)|Protocol Violation|0
6116502|NCT00862849|9738279|FG001|Washout 2 (3 to 14 Days)|Protocol Violation|1
6116503|NCT00862849|9738280|FG002|Washout 2 (3 to 14 Days)|Protocol Violation|0
6116504|NCT00862849|9738281|FG003|Washout 2 (3 to 14 Days)|Protocol Violation|0
6116505|NCT00862849|9738282|FG004|Washout 2 (3 to 14 Days)|Protocol Violation|0
6116506|NCT00862849|9738283|FG005|Washout 2 (3 to 14 Days)|Protocol Violation|0
6116507|NCT00862940|9738293|FG000|Overall Study|Adverse Event|15
6116508|NCT00862940|9738294|FG001|Overall Study|Adverse Event|12
6116509|NCT00862940|9738293|FG000|Overall Study|Lack of Efficacy|1
6116510|NCT00862940|9738294|FG001|Overall Study|Lack of Efficacy|3
6116511|NCT00862940|9738293|FG000|Overall Study|Protocol Violation|2
6116512|NCT00862940|9738294|FG001|Overall Study|Protocol Violation|5
6116513|NCT00862940|9738293|FG000|Overall Study|Withdrawal by Subject|4
6210625|NCT01583374|9876458|FG000|Long-Term Extension Phase Weeks 52-260|Noncomplinace with Study Drug|0
6210626|NCT01583374|9876459|FG001|Long-Term Extension Phase Weeks 52-260|Noncomplinace with Study Drug|0
6210627|NCT01583374|9876460|FG002|Long-Term Extension Phase Weeks 52-260|Noncomplinace with Study Drug|0
6210628|NCT01583374|9876461|FG003|Long-Term Extension Phase Weeks 52-260|Noncomplinace with Study Drug|0
6210629|NCT01583374|9876462|FG004|Long-Term Extension Phase Weeks 52-260|Noncomplinace with Study Drug|1
6210630|NCT01583374|9876463|FG005|Long-Term Extension Phase Weeks 52-260|Noncomplinace with Study Drug|0
6210631|NCT01583374|9876464|FG006|Long-Term Extension Phase Weeks 52-260|Noncomplinace with Study Drug|0
6210632|NCT01583374|9876465|FG007|Long-Term Extension Phase Weeks 52-260|Noncomplinace with Study Drug|1
6210633|NCT01583374|9876466|FG008|Long-Term Extension Phase Weeks 52-260|Noncomplinace with Study Drug|1
6210634|NCT01583374|9876458|FG000|Long-Term Extension Phase Weeks 52-260|Withdrawal by Subject|0
6210635|NCT01583374|9876459|FG001|Long-Term Extension Phase Weeks 52-260|Withdrawal by Subject|11
6210636|NCT01583374|9876460|FG002|Long-Term Extension Phase Weeks 52-260|Withdrawal by Subject|11
6210637|NCT01583374|9876461|FG003|Long-Term Extension Phase Weeks 52-260|Withdrawal by Subject|1
6116514|NCT00862940|9738294|FG001|Overall Study|Withdrawal by Subject|6
6116515|NCT00862940|9738293|FG000|Overall Study|Non-compliance|4
6116516|NCT00862940|9738294|FG001|Overall Study|Non-compliance|0
6116517|NCT00862940|9738293|FG000|Overall Study|Lost to Follow-up|0
6116518|NCT00862940|9738294|FG001|Overall Study|Lost to Follow-up|1
6116519|NCT00862940|9738293|FG000|Overall Study|Administrative or other reason(s)|4
6116520|NCT00862940|9738294|FG001|Overall Study|Administrative or other reason(s)|3
6116521|NCT00862979|9738302|FG000|Overall Study|Adverse Event|6
6116522|NCT00862979|9738303|FG001|Overall Study|Adverse Event|3
6116523|NCT00862979|9738302|FG000|Overall Study|Protocol Violation|0
6116524|NCT00862979|9738303|FG001|Overall Study|Protocol Violation|1
6116525|NCT00862979|9738302|FG000|Overall Study|Patient withdrew consent|2
6116526|NCT00862979|9738303|FG001|Overall Study|Patient withdrew consent|1
6116527|NCT00862979|9738302|FG000|Overall Study|Administrative problems|0
6116528|NCT00862979|9738303|FG001|Overall Study|Administrative problems|1
6116529|NCT00862979|9738302|FG000|Overall Study|Death|0
6116530|NCT00862979|9738303|FG001|Overall Study|Death|1
6116531|NCT00862992|9738312|FG000|Overall Study|Adverse Event|2
6116532|NCT00862992|9738313|FG001|Overall Study|Adverse Event|1
6116533|NCT00862992|9738314|FG002|Overall Study|Adverse Event|1
6116534|NCT00862992|9738312|FG000|Overall Study|Physician Decision|1
6116535|NCT00862992|9738313|FG001|Overall Study|Physician Decision|0
6116536|NCT00862992|9738314|FG002|Overall Study|Physician Decision|0
6116537|NCT00862992|9738312|FG000|Overall Study|Withdrawal by Subject|0
6116538|NCT00862992|9738313|FG001|Overall Study|Withdrawal by Subject|0
6116539|NCT00862992|9738314|FG002|Overall Study|Withdrawal by Subject|2
6116540|NCT00863057|9738326|FG000|Milestones Period 1 (Weeks 0-5)|Adverse Event|1
6116541|NCT00863057|9738327|FG001|Milestones Period 1 (Weeks 0-5)|Adverse Event|1
6116542|NCT00863057|9738328|FG002|Milestones Period 1 (Weeks 0-5)|Adverse Event|0
6116543|NCT00863057|9738329|FG003|Milestones Period 1 (Weeks 0-5)|Adverse Event|1
6116544|NCT00863057|9738326|FG000|Milestones Period 1 (Weeks 0-5)|Physician Decision|0
6116545|NCT00863057|9738327|FG001|Milestones Period 1 (Weeks 0-5)|Physician Decision|1
6116546|NCT00863057|9738328|FG002|Milestones Period 1 (Weeks 0-5)|Physician Decision|0
6116547|NCT00863057|9738329|FG003|Milestones Period 1 (Weeks 0-5)|Physician Decision|0
6116548|NCT00863057|9738326|FG000|Period 2 (Weeks 6-10)|Adverse Event|0
6210638|NCT01583374|9876462|FG004|Long-Term Extension Phase Weeks 52-260|Withdrawal by Subject|12
6210639|NCT01583374|9876463|FG005|Long-Term Extension Phase Weeks 52-260|Withdrawal by Subject|7
6210640|NCT01583374|9876464|FG006|Long-Term Extension Phase Weeks 52-260|Withdrawal by Subject|5
6210641|NCT01583374|9876465|FG007|Long-Term Extension Phase Weeks 52-260|Withdrawal by Subject|3
6210642|NCT01583374|9876466|FG008|Long-Term Extension Phase Weeks 52-260|Withdrawal by Subject|3
6210643|NCT01583374|9876458|FG000|Long-Term Extension Phase Weeks 52-260|Death|0
6210644|NCT01583374|9876459|FG001|Long-Term Extension Phase Weeks 52-260|Death|0
6210645|NCT01583374|9876460|FG002|Long-Term Extension Phase Weeks 52-260|Death|0
6210646|NCT01583374|9876461|FG003|Long-Term Extension Phase Weeks 52-260|Death|0
6210647|NCT01583374|9876462|FG004|Long-Term Extension Phase Weeks 52-260|Death|1
6210648|NCT01583374|9876463|FG005|Long-Term Extension Phase Weeks 52-260|Death|0
6210649|NCT01583374|9876464|FG006|Long-Term Extension Phase Weeks 52-260|Death|1
6210650|NCT01583374|9876465|FG007|Long-Term Extension Phase Weeks 52-260|Death|0
6210651|NCT01583374|9876466|FG008|Long-Term Extension Phase Weeks 52-260|Death|0
6210652|NCT01583374|9876458|FG000|Long-Term Extension Phase Weeks 52-260|Lost to Follow-up|0
6210653|NCT01583374|9876459|FG001|Long-Term Extension Phase Weeks 52-260|Lost to Follow-up|1
6210654|NCT01583374|9876460|FG002|Long-Term Extension Phase Weeks 52-260|Lost to Follow-up|0
6210655|NCT01583374|9876461|FG003|Long-Term Extension Phase Weeks 52-260|Lost to Follow-up|1
6210656|NCT01583374|9876462|FG004|Long-Term Extension Phase Weeks 52-260|Lost to Follow-up|1
6210657|NCT01583374|9876463|FG005|Long-Term Extension Phase Weeks 52-260|Lost to Follow-up|0
6210658|NCT01583374|9876464|FG006|Long-Term Extension Phase Weeks 52-260|Lost to Follow-up|1
6210659|NCT01583374|9876465|FG007|Long-Term Extension Phase Weeks 52-260|Lost to Follow-up|0
6210660|NCT01583374|9876466|FG008|Long-Term Extension Phase Weeks 52-260|Lost to Follow-up|0
6210661|NCT01583374|9876458|FG000|Long-Term Extension Phase Weeks 52-260|Miscellaneous|0
6210662|NCT01583374|9876459|FG001|Long-Term Extension Phase Weeks 52-260|Miscellaneous|5
6210663|NCT01583374|9876460|FG002|Long-Term Extension Phase Weeks 52-260|Miscellaneous|1
6210664|NCT01583374|9876461|FG003|Long-Term Extension Phase Weeks 52-260|Miscellaneous|2
6210665|NCT01583374|9876462|FG004|Long-Term Extension Phase Weeks 52-260|Miscellaneous|0
6210666|NCT01583374|9876463|FG005|Long-Term Extension Phase Weeks 52-260|Miscellaneous|1
6210667|NCT01583374|9876464|FG006|Long-Term Extension Phase Weeks 52-260|Miscellaneous|5
6210668|NCT01583374|9876465|FG007|Long-Term Extension Phase Weeks 52-260|Miscellaneous|0
6210669|NCT01583374|9876466|FG008|Long-Term Extension Phase Weeks 52-260|Miscellaneous|1
6210670|NCT01583530|9876503|FG000|Overall Study|Adverse Event|0
6210671|NCT01583530|9876504|FG001|Overall Study|Adverse Event|0
6210672|NCT01583530|9876505|FG002|Overall Study|Adverse Event|0
6210673|NCT01583530|9876506|FG003|Overall Study|Adverse Event|0
6210674|NCT01583530|9876507|FG004|Overall Study|Adverse Event|0
6210675|NCT01583530|9876508|FG005|Overall Study|Adverse Event|1
6210676|NCT01583530|9876503|FG000|Overall Study|Withdrawal by Subject|0
6210677|NCT01583530|9876504|FG001|Overall Study|Withdrawal by Subject|3
6210678|NCT01583530|9876505|FG002|Overall Study|Withdrawal by Subject|0
6210679|NCT01583530|9876506|FG003|Overall Study|Withdrawal by Subject|1
6210680|NCT01583530|9876507|FG004|Overall Study|Withdrawal by Subject|1
6210681|NCT01583530|9876508|FG005|Overall Study|Withdrawal by Subject|2
6210682|NCT01583530|9876503|FG000|Overall Study|Lost to Follow-up|0
6210683|NCT01583530|9876504|FG001|Overall Study|Lost to Follow-up|0
6210684|NCT01583530|9876505|FG002|Overall Study|Lost to Follow-up|0
6210685|NCT01583530|9876506|FG003|Overall Study|Lost to Follow-up|0
6210686|NCT01583530|9876507|FG004|Overall Study|Lost to Follow-up|3
6210687|NCT01583530|9876508|FG005|Overall Study|Lost to Follow-up|0
6210688|NCT01583530|9876503|FG000|Overall Study|Lack of compliance|0
6210689|NCT01583530|9876504|FG001|Overall Study|Lack of compliance|0
6210690|NCT01583530|9876505|FG002|Overall Study|Lack of compliance|0
6210691|NCT01583530|9876506|FG003|Overall Study|Lack of compliance|0
6210692|NCT01583530|9876507|FG004|Overall Study|Lack of compliance|1
6210693|NCT01583530|9876508|FG005|Overall Study|Lack of compliance|0
6116549|NCT00863057|9738327|FG001|Period 2 (Weeks 6-10)|Adverse Event|1
6116550|NCT00863057|9738328|FG002|Period 2 (Weeks 6-10)|Adverse Event|1
6116551|NCT00863057|9738329|FG003|Period 2 (Weeks 6-10)|Adverse Event|0
6116552|NCT00863057|9738326|FG000|Period 2 (Weeks 6-10)|Physician Decision|0
6116553|NCT00863057|9738327|FG001|Period 2 (Weeks 6-10)|Physician Decision|0
6116554|NCT00863057|9738328|FG002|Period 2 (Weeks 6-10)|Physician Decision|0
6116555|NCT00863057|9738329|FG003|Period 2 (Weeks 6-10)|Physician Decision|1
6116556|NCT00863304|9738387|FG000|Overall Study|Adverse Event|10
6116557|NCT00863304|9738388|FG001|Overall Study|Adverse Event|4
6116558|NCT00863304|9738389|FG002|Overall Study|Adverse Event|14
6116559|NCT00863304|9738390|FG003|Overall Study|Adverse Event|16
6116560|NCT00863304|9738387|FG000|Overall Study|Lost to Follow-up|1
6116561|NCT00863304|9738388|FG001|Overall Study|Lost to Follow-up|5
6116562|NCT00863304|9738389|FG002|Overall Study|Lost to Follow-up|4
6116563|NCT00863304|9738390|FG003|Overall Study|Lost to Follow-up|2
6116564|NCT00863304|9738387|FG000|Overall Study|Lack of Efficacy|57
6116565|NCT00863304|9738388|FG001|Overall Study|Lack of Efficacy|26
6116566|NCT00863304|9738389|FG002|Overall Study|Lack of Efficacy|30
6116567|NCT00863304|9738390|FG003|Overall Study|Lack of Efficacy|28
6116568|NCT00863304|9738387|FG000|Overall Study|Withdrawal by Subject|19
6116569|NCT00863304|9738388|FG001|Overall Study|Withdrawal by Subject|14
6116570|NCT00863304|9738389|FG002|Overall Study|Withdrawal by Subject|20
6116571|NCT00863304|9738390|FG003|Overall Study|Withdrawal by Subject|18
6116572|NCT00863304|9738387|FG000|Overall Study|Other|1
6116573|NCT00863304|9738388|FG001|Overall Study|Other|0
6116574|NCT00863304|9738389|FG002|Overall Study|Other|0
6116575|NCT00863304|9738390|FG003|Overall Study|Other|1
6116576|NCT00863304|9738387|FG000|Overall Study|Protocol Violation|2
6116577|NCT00863304|9738388|FG001|Overall Study|Protocol Violation|6
6116578|NCT00863304|9738389|FG002|Overall Study|Protocol Violation|2
6116579|NCT00863304|9738390|FG003|Overall Study|Protocol Violation|0
6116580|NCT00863304|9738387|FG000|Overall Study|Randomized, but not Treated|3
6116581|NCT00863304|9738388|FG001|Overall Study|Randomized, but not Treated|1
6116582|NCT00863304|9738389|FG002|Overall Study|Randomized, but not Treated|4
6116583|NCT00863304|9738390|FG003|Overall Study|Randomized, but not Treated|1
6116584|NCT00863304|9738387|FG000|Overall Study|Entered extension study|101
6116585|NCT00863304|9738388|FG001|Overall Study|Entered extension study|129
6116586|NCT00863304|9738389|FG002|Overall Study|Entered extension study|113
6116587|NCT00863304|9738390|FG003|Overall Study|Entered extension study|125
6116588|NCT00863317|9738404|FG000|Overall Study|Lost to Follow-up|8
6116589|NCT00863317|9738405|FG001|Overall Study|Lost to Follow-up|9
6116590|NCT00863655|9738436|FG000|Overall Study|Protocol Violation|4
6116591|NCT00863655|9738437|FG001|Overall Study|Protocol Violation|0
6116592|NCT00863655|9738436|FG000|Overall Study|Adverse Event|52
6116593|NCT00863655|9738437|FG001|Overall Study|Adverse Event|8
6116594|NCT00863655|9738436|FG000|Overall Study|Withdrawal by Subject|47
6116595|NCT00863655|9738437|FG001|Overall Study|Withdrawal by Subject|7
6116596|NCT00863655|9738436|FG000|Overall Study|Administrative problems|1
6116597|NCT00863655|9738437|FG001|Overall Study|Administrative problems|0
6116598|NCT00863655|9738436|FG000|Overall Study|Death|7
6116599|NCT00863655|9738437|FG001|Overall Study|Death|1
6116600|NCT00863655|9738436|FG000|Overall Study|New cancer therapy|5
6116601|NCT00863655|9738437|FG001|Overall Study|New cancer therapy|1
6116602|NCT00863655|9738436|FG000|Overall Study|Disease progression|364
6116603|NCT00863655|9738437|FG001|Overall Study|Disease progression|221
6116604|NCT00863655|9738436|FG000|Overall Study|Treatment completed as per protocol|5
6116605|NCT00863655|9738437|FG001|Overall Study|Treatment completed as per protocol|1
6116606|NCT00863681|9738446|FG000|Overall Study|Other|2
6116607|NCT00863681|9738447|FG001|Overall Study|Other|0
6116608|NCT00863681|9738448|FG002|Overall Study|Other|0
6116609|NCT00863681|9738446|FG000|Overall Study|Missing|1
6116610|NCT00863681|9738447|FG001|Overall Study|Missing|0
6116611|NCT00863681|9738448|FG002|Overall Study|Missing|0
6116612|NCT00863681|9738446|FG000|Overall Study|Death|40
6116613|NCT00863681|9738447|FG001|Overall Study|Death|23
6116614|NCT00863681|9738448|FG002|Overall Study|Death|6
6116615|NCT00863681|9738446|FG000|Overall Study|Withdrawal by Subject|12
6116616|NCT00863681|9738447|FG001|Overall Study|Withdrawal by Subject|5
6116617|NCT00863681|9738448|FG002|Overall Study|Withdrawal by Subject|2
6116618|NCT00863681|9738446|FG000|Overall Study|Protocol Violation|2
6116619|NCT00863681|9738447|FG001|Overall Study|Protocol Violation|0
6116620|NCT00863681|9738448|FG002|Overall Study|Protocol Violation|0
6116621|NCT00863681|9738446|FG000|Overall Study|Lost to Follow-up|3
6116622|NCT00863681|9738447|FG001|Overall Study|Lost to Follow-up|0
6116623|NCT00863681|9738448|FG002|Overall Study|Lost to Follow-up|3
6116624|NCT00863681|9738446|FG000|Overall Study|Adverse Event|28
6116625|NCT00863681|9738447|FG001|Overall Study|Adverse Event|10
6116626|NCT00863681|9738448|FG002|Overall Study|Adverse Event|6
6116627|NCT00863681|9738446|FG000|Overall Study|Lack of Efficacy|2
6116628|NCT00863681|9738447|FG001|Overall Study|Lack of Efficacy|2
6116629|NCT00863681|9738448|FG002|Overall Study|Lack of Efficacy|1
6116630|NCT00863681|9738446|FG000|Overall Study|Non-compliance with study drug|1
6116631|NCT00863681|9738447|FG001|Overall Study|Non-compliance with study drug|3
6116632|NCT00863681|9738448|FG002|Overall Study|Non-compliance with study drug|0
6116633|NCT00863707|9738458|FG000|Overall Study|Randomized, but drug not received|4
6116634|NCT00863707|9738459|FG001|Overall Study|Randomized, but drug not received|3
6116635|NCT00863746|9738467|FG000|Treatment|Not treated|4
6116636|NCT00863746|9738468|FG001|Treatment|Not treated|2
6116637|NCT00863746|9738467|FG000|Treatment|Adverse Event|41
6116638|NCT00863746|9738468|FG001|Treatment|Adverse Event|16
6116639|NCT00863746|9738467|FG000|Treatment|non-compliant with study medication|4
6116640|NCT00863746|9738468|FG001|Treatment|non-compliant with study medication|0
6116641|NCT00863746|9738467|FG000|Treatment|Consent withdrawn|15
6116642|NCT00863746|9738468|FG001|Treatment|Consent withdrawn|14
6116643|NCT00863746|9738467|FG000|Treatment|Lost to Follow-up|1
6116644|NCT00863746|9738468|FG001|Treatment|Lost to Follow-up|0
6116645|NCT00863746|9738467|FG000|Treatment|Protocol Violation|5
6116646|NCT00863746|9738468|FG001|Treatment|Protocol Violation|3
6116647|NCT00863746|9738467|FG000|Treatment|Other|1
6116648|NCT00863746|9738468|FG001|Treatment|Other|0
6116649|NCT00863746|9738467|FG000|Survival Follow up|Death|244
6116650|NCT00863746|9738468|FG001|Survival Follow up|Death|271
6116651|NCT00863746|9738467|FG000|Survival Follow up|Lost to Follow-up|2
6116652|NCT00863746|9738468|FG001|Survival Follow up|Lost to Follow-up|1
6210694|NCT01584024|9876582|FG000|Overall Study|Lost to Follow-up|10
6210695|NCT01584024|9876582|FG000|Overall Study|Withdrawal by Subject|3
6210696|NCT01584232|9876589|FG000|Overall Study|Adverse Event|3
6210697|NCT01584232|9876590|FG001|Overall Study|Adverse Event|1
6210698|NCT01584232|9876589|FG000|Overall Study|Withdrawal by Subject|2
6210699|NCT01584232|9876590|FG001|Overall Study|Withdrawal by Subject|1
6210700|NCT01584232|9876589|FG000|Overall Study|Physician Decision|2
6210701|NCT01584232|9876590|FG001|Overall Study|Physician Decision|1
6210702|NCT01584232|9876589|FG000|Overall Study|Lost to Follow-up|1
6210703|NCT01584232|9876590|FG001|Overall Study|Lost to Follow-up|0
6210704|NCT01584440|9876616|FG000|Stage 1 (5 Weeks)|Advised Not to Take Study Medication|1
6210705|NCT01584440|9876617|FG001|Stage 1 (5 Weeks)|Advised Not to Take Study Medication|0
6210706|NCT01584440|9876618|FG002|Stage 1 (5 Weeks)|Advised Not to Take Study Medication|0
6210707|NCT01584440|9876619|FG003|Stage 1 (5 Weeks)|Advised Not to Take Study Medication|0
6210708|NCT01584440|9876620|FG004|Stage 1 (5 Weeks)|Advised Not to Take Study Medication|0
6210709|NCT01584440|9876616|FG000|Stage 1 (5 Weeks)|Adverse Event|5
6210710|NCT01584440|9876617|FG001|Stage 1 (5 Weeks)|Adverse Event|3
6210711|NCT01584440|9876618|FG002|Stage 1 (5 Weeks)|Adverse Event|0
6210712|NCT01584440|9876619|FG003|Stage 1 (5 Weeks)|Adverse Event|0
6210713|NCT01584440|9876620|FG004|Stage 1 (5 Weeks)|Adverse Event|0
6210714|NCT01584440|9876616|FG000|Stage 1 (5 Weeks)|Lost to Follow-up|1
6210715|NCT01584440|9876617|FG001|Stage 1 (5 Weeks)|Lost to Follow-up|0
6210716|NCT01584440|9876618|FG002|Stage 1 (5 Weeks)|Lost to Follow-up|0
6210717|NCT01584440|9876619|FG003|Stage 1 (5 Weeks)|Lost to Follow-up|0
6210718|NCT01584440|9876620|FG004|Stage 1 (5 Weeks)|Lost to Follow-up|0
6210719|NCT01584440|9876616|FG000|Stage 1 (5 Weeks)|Protocol Violation|2
6210720|NCT01584440|9876617|FG001|Stage 1 (5 Weeks)|Protocol Violation|3
6210721|NCT01584440|9876618|FG002|Stage 1 (5 Weeks)|Protocol Violation|0
6210722|NCT01584440|9876619|FG003|Stage 1 (5 Weeks)|Protocol Violation|0
6210723|NCT01584440|9876620|FG004|Stage 1 (5 Weeks)|Protocol Violation|0
6210724|NCT01584440|9876616|FG000|Stage 1 (5 Weeks)|Withdrawal by Subject|1
6210725|NCT01584440|9876617|FG001|Stage 1 (5 Weeks)|Withdrawal by Subject|0
6210726|NCT01584440|9876618|FG002|Stage 1 (5 Weeks)|Withdrawal by Subject|0
6210727|NCT01584440|9876619|FG003|Stage 1 (5 Weeks)|Withdrawal by Subject|0
6210728|NCT01584440|9876620|FG004|Stage 1 (5 Weeks)|Withdrawal by Subject|0
6210729|NCT01584440|9876616|FG000|Stage 1 (5 Weeks)|Withdrawal by Parent/Guardian|0
6210730|NCT01584440|9876617|FG001|Stage 1 (5 Weeks)|Withdrawal by Parent/Guardian|2
6210731|NCT01584440|9876618|FG002|Stage 1 (5 Weeks)|Withdrawal by Parent/Guardian|0
6210732|NCT01584440|9876619|FG003|Stage 1 (5 Weeks)|Withdrawal by Parent/Guardian|0
6210733|NCT01584440|9876620|FG004|Stage 1 (5 Weeks)|Withdrawal by Parent/Guardian|0
6210734|NCT01584440|9876616|FG000|Stage 2 (5 Weeks)|Withdrawal by Subject|0
6210735|NCT01584440|9876617|FG001|Stage 2 (5 Weeks)|Withdrawal by Subject|0
6210736|NCT01584440|9876618|FG002|Stage 2 (5 Weeks)|Withdrawal by Subject|1
6210737|NCT01584440|9876619|FG003|Stage 2 (5 Weeks)|Withdrawal by Subject|2
6210738|NCT01584440|9876620|FG004|Stage 2 (5 Weeks)|Withdrawal by Subject|0
6210739|NCT01584440|9876616|FG000|Stage 2 (5 Weeks)|Adverse Event|0
6210740|NCT01584440|9876617|FG001|Stage 2 (5 Weeks)|Adverse Event|0
6210741|NCT01584440|9876618|FG002|Stage 2 (5 Weeks)|Adverse Event|1
6210742|NCT01584440|9876619|FG003|Stage 2 (5 Weeks)|Adverse Event|2
6210743|NCT01584440|9876620|FG004|Stage 2 (5 Weeks)|Adverse Event|1
6210744|NCT01584440|9876616|FG000|Stage 2 (5 Weeks)|Unable to Return to Site: Rehabilitation|0
6210745|NCT01584440|9876617|FG001|Stage 2 (5 Weeks)|Unable to Return to Site: Rehabilitation|0
6210746|NCT01584440|9876618|FG002|Stage 2 (5 Weeks)|Unable to Return to Site: Rehabilitation|1
6210747|NCT01584440|9876619|FG003|Stage 2 (5 Weeks)|Unable to Return to Site: Rehabilitation|0
6210748|NCT01584440|9876620|FG004|Stage 2 (5 Weeks)|Unable to Return to Site: Rehabilitation|0
6210749|NCT01584648|9876691|FG000|Overall Study|Death|136
6210750|NCT01584648|9876692|FG001|Overall Study|Death|146
6210751|NCT01584648|9876691|FG000|Overall Study|Lost to Follow-up|9
6210752|NCT01584648|9876692|FG001|Overall Study|Lost to Follow-up|9
6210753|NCT01584648|9876691|FG000|Overall Study|Investigator discretion|3
6116653|NCT00863746|9738467|FG000|Survival Follow up|Consent Withdrawn|7
6210754|NCT01584648|9876692|FG001|Overall Study|Investigator discretion|2
5980777|NCT02471144|9569412|FG005|Extension Period (Week 52 to Week 236)|Pregnancy|0
6116654|NCT00863746|9738468|FG001|Survival Follow up|Consent Withdrawn|8
6116655|NCT00863772|9738477|FG000|Overall Study|Adverse Event|1
6116656|NCT00863772|9738478|FG001|Overall Study|Adverse Event|4
6116657|NCT00863772|9738479|FG002|Overall Study|Adverse Event|0
6210755|NCT01584648|9876691|FG000|Overall Study|Withdrew consent|13
6116658|NCT00863772|9738477|FG000|Overall Study|Lack of Efficacy|4
6116659|NCT00863772|9738478|FG001|Overall Study|Lack of Efficacy|2
6116660|NCT00863772|9738479|FG002|Overall Study|Lack of Efficacy|4
6116661|NCT00863772|9738477|FG000|Overall Study|Lost to Follow-up|5
6116662|NCT00863772|9738478|FG001|Overall Study|Lost to Follow-up|1
6116663|NCT00863772|9738479|FG002|Overall Study|Lost to Follow-up|1
6116664|NCT00863772|9738477|FG000|Overall Study|Protocol Violation|2
6116665|NCT00863772|9738478|FG001|Overall Study|Protocol Violation|0
6116666|NCT00863772|9738479|FG002|Overall Study|Protocol Violation|2
6116667|NCT00863772|9738477|FG000|Overall Study|Withdrawal by Subject|4
6116668|NCT00863772|9738478|FG001|Overall Study|Withdrawal by Subject|7
6116669|NCT00863772|9738479|FG002|Overall Study|Withdrawal by Subject|5
6116670|NCT00863772|9738477|FG000|Overall Study|Study terminated by sponsor|44
6116671|NCT00863772|9738478|FG001|Overall Study|Study terminated by sponsor|45
6116672|NCT00863772|9738479|FG002|Overall Study|Study terminated by sponsor|36
6116673|NCT00863772|9738477|FG000|Overall Study|Entered extension study|6
6116674|NCT00863772|9738478|FG001|Overall Study|Entered extension study|4
6116675|NCT00863772|9738479|FG002|Overall Study|Entered extension study|9
6116676|NCT00863772|9738477|FG000|Overall Study|Other|1
6116677|NCT00863772|9738478|FG001|Overall Study|Other|2
6116678|NCT00863772|9738479|FG002|Overall Study|Other|4
6116679|NCT00863772|9738477|FG000|Overall Study|Randomized but not Treated|1
6116680|NCT00863772|9738478|FG001|Overall Study|Randomized but not Treated|0
6116681|NCT00863772|9738479|FG002|Overall Study|Randomized but not Treated|0
6116682|NCT00863798|9738490|FG000|Overall Study|Adverse Event|5
6116683|NCT00863798|9738491|FG001|Overall Study|Adverse Event|2
6116684|NCT00863798|9738492|FG002|Overall Study|Adverse Event|4
6116685|NCT00863798|9738490|FG000|Overall Study|Participant failed to return|2
6116686|NCT00863798|9738491|FG001|Overall Study|Participant failed to return|1
6116687|NCT00863798|9738492|FG002|Overall Study|Participant failed to return|0
6116688|NCT00863798|9738490|FG000|Overall Study|Investigator request|1
6116689|NCT00863798|9738491|FG001|Overall Study|Investigator request|2
6116690|NCT00863798|9738492|FG002|Overall Study|Investigator request|1
6116691|NCT00863798|9738490|FG000|Overall Study|Lack of Efficacy|4
6116692|NCT00863798|9738491|FG001|Overall Study|Lack of Efficacy|3
6116693|NCT00863798|9738492|FG002|Overall Study|Lack of Efficacy|6
6116694|NCT00863798|9738490|FG000|Overall Study|Lost to Follow-up|6
6116695|NCT00863798|9738491|FG001|Overall Study|Lost to Follow-up|9
6116696|NCT00863798|9738492|FG002|Overall Study|Lost to Follow-up|5
6116697|NCT00863798|9738490|FG000|Overall Study|Other|2
6116698|NCT00863798|9738491|FG001|Overall Study|Other|3
6116699|NCT00863798|9738492|FG002|Overall Study|Other|1
6210756|NCT01584648|9876692|FG001|Overall Study|Withdrew consent|4
6210757|NCT01584648|9876691|FG000|Overall Study|Study closed/terminated|50
6210758|NCT01584648|9876692|FG001|Overall Study|Study closed/terminated|23
6210759|NCT01584648|9876691|FG000|Overall Study|Crossover to Dabrafenib + Trametinib|0
6210760|NCT01584648|9876692|FG001|Overall Study|Crossover to Dabrafenib + Trametinib|28
6210761|NCT01584843|9876705|FG000|First Treatment Period|Adverse Event|0
6210762|NCT01584843|9876706|FG001|First Treatment Period|Adverse Event|0
6210763|NCT01584843|9876707|FG002|First Treatment Period|Adverse Event|1
6210764|NCT01584843|9876708|FG003|First Treatment Period|Adverse Event|0
6210765|NCT01584843|9876709|FG004|First Treatment Period|Adverse Event|0
6210766|NCT01584843|9876710|FG005|First Treatment Period|Adverse Event|0
6210767|NCT01584843|9876705|FG000|First Treatment Period|Protocol Violation|0
6210768|NCT01584843|9876706|FG001|First Treatment Period|Protocol Violation|0
6210769|NCT01584843|9876707|FG002|First Treatment Period|Protocol Violation|0
6210770|NCT01584843|9876708|FG003|First Treatment Period|Protocol Violation|0
6210771|NCT01584843|9876709|FG004|First Treatment Period|Protocol Violation|0
6116700|NCT00863798|9738490|FG000|Overall Study|Protocol Violation|0
6116701|NCT00863798|9738491|FG001|Overall Study|Protocol Violation|1
6116702|NCT00863798|9738492|FG002|Overall Study|Protocol Violation|1
6116703|NCT00863798|9738490|FG000|Overall Study|Withdrawal by Subject|8
6116704|NCT00863798|9738491|FG001|Overall Study|Withdrawal by Subject|7
6116705|NCT00863798|9738492|FG002|Overall Study|Withdrawal by Subject|4
6116706|NCT00863798|9738490|FG000|Overall Study|Randomized not treated|4
6116707|NCT00863798|9738491|FG001|Overall Study|Randomized not treated|2
6116708|NCT00863798|9738492|FG002|Overall Study|Randomized not treated|3
6116709|NCT00863928|9738502|FG000|Overall Study|Protocol Violation|26
6116710|NCT00863928|9738503|FG001|Overall Study|Protocol Violation|0
6116711|NCT00863928|9738502|FG000|Overall Study|Withdrawal by Subject|3
6116712|NCT00863928|9738503|FG001|Overall Study|Withdrawal by Subject|0
6116713|NCT00863928|9738502|FG000|Overall Study|surgery cancellation|4
6116714|NCT00863928|9738503|FG001|Overall Study|surgery cancellation|0
6210772|NCT01584843|9876710|FG005|First Treatment Period|Protocol Violation|1
6210773|NCT01584843|9876705|FG000|First Treatment Period|Met Protocol-defined Stopping Criteria|0
6116715|NCT00863928|9738502|FG000|Overall Study|medication allergy|3
6116716|NCT00863928|9738503|FG001|Overall Study|medication allergy|0
6116717|NCT00864097|9738530|FG000|Overall Study|Death|0
6116718|NCT00864097|9738531|FG001|Overall Study|Death|1
6116719|NCT00864097|9738532|FG002|Overall Study|Death|0
6116720|NCT00864097|9738533|FG003|Overall Study|Death|0
6116721|NCT00864097|9738530|FG000|Overall Study|Adverse Event|6
6116722|NCT00864097|9738531|FG001|Overall Study|Adverse Event|8
6116723|NCT00864097|9738532|FG002|Overall Study|Adverse Event|11
6116724|NCT00864097|9738533|FG003|Overall Study|Adverse Event|9
6116725|NCT00864097|9738530|FG000|Overall Study|Lack of Efficacy|9
6116726|NCT00864097|9738531|FG001|Overall Study|Lack of Efficacy|3
6116727|NCT00864097|9738532|FG002|Overall Study|Lack of Efficacy|7
6116728|NCT00864097|9738533|FG003|Overall Study|Lack of Efficacy|2
6116729|NCT00864097|9738530|FG000|Overall Study|Lost to Follow-up|0
6116730|NCT00864097|9738531|FG001|Overall Study|Lost to Follow-up|1
6116731|NCT00864097|9738532|FG002|Overall Study|Lost to Follow-up|0
6116732|NCT00864097|9738533|FG003|Overall Study|Lost to Follow-up|1
6116733|NCT00864097|9738530|FG000|Overall Study|Withdrawal by Subject|15
6116734|NCT00864097|9738531|FG001|Overall Study|Withdrawal by Subject|11
6116735|NCT00864097|9738532|FG002|Overall Study|Withdrawal by Subject|11
6116736|NCT00864097|9738533|FG003|Overall Study|Withdrawal by Subject|12
6116737|NCT00864097|9738530|FG000|Overall Study|Protocol Violation|2
6116738|NCT00864097|9738531|FG001|Overall Study|Protocol Violation|1
6116739|NCT00864097|9738532|FG002|Overall Study|Protocol Violation|0
6116740|NCT00864097|9738533|FG003|Overall Study|Protocol Violation|1
6116741|NCT00864097|9738530|FG000|Overall Study|Terminated by sponsor|105
6116742|NCT00864097|9738531|FG001|Overall Study|Terminated by sponsor|112
6116743|NCT00864097|9738532|FG002|Overall Study|Terminated by sponsor|102
6116744|NCT00864097|9738533|FG003|Overall Study|Terminated by sponsor|99
6116745|NCT00864097|9738530|FG000|Overall Study|Randomized but not treated|2
6116746|NCT00864097|9738531|FG001|Overall Study|Randomized but not treated|0
6116747|NCT00864097|9738532|FG002|Overall Study|Randomized but not treated|1
6116748|NCT00864097|9738533|FG003|Overall Study|Randomized but not treated|0
6116749|NCT00864097|9738530|FG000|Overall Study|Other|0
6116750|NCT00864097|9738531|FG001|Overall Study|Other|0
6116751|NCT00864097|9738532|FG002|Overall Study|Other|0
6116752|NCT00864097|9738533|FG003|Overall Study|Other|1
6116753|NCT00864253|9738554|FG000|Overall Study|Adverse Event|56
6116754|NCT00864253|9738555|FG001|Overall Study|Adverse Event|11
6116755|NCT00864253|9738554|FG000|Overall Study|Unrelated Adverse Event|3
6116756|NCT00864253|9738555|FG001|Overall Study|Unrelated Adverse Event|1
6116757|NCT00864253|9738554|FG000|Overall Study|Physician Decision|11
6116758|NCT00864253|9738555|FG001|Overall Study|Physician Decision|15
6116759|NCT00864253|9738554|FG000|Overall Study|Protocol Violation|0
6116760|NCT00864253|9738555|FG001|Overall Study|Protocol Violation|2
6116761|NCT00864253|9738554|FG000|Overall Study|Lost to Follow-up|1
6116762|NCT00864253|9738555|FG001|Overall Study|Lost to Follow-up|1
6116763|NCT00864253|9738554|FG000|Overall Study|Withdrawal by Subject|18
6116764|NCT00864253|9738555|FG001|Overall Study|Withdrawal by Subject|18
6116765|NCT00864253|9738554|FG000|Overall Study|Death|1
6116766|NCT00864253|9738555|FG001|Overall Study|Death|0
6116767|NCT00864253|9738554|FG000|Overall Study|Ongoing|2
6116768|NCT00864253|9738555|FG001|Overall Study|Ongoing|3
6116769|NCT00864253|9738554|FG000|Overall Study|Untreated|7
6116770|NCT00864253|9738555|FG001|Overall Study|Untreated|7
6116771|NCT00864513|9738576|FG000|Overall Study|Withdrawal by Subject|3
6116772|NCT00864682|9738608|FG000|Overall Study|Protocol Violation|2
6116773|NCT00864682|9738609|FG001|Overall Study|Protocol Violation|1
6116774|NCT00864682|9738610|FG002|Overall Study|Protocol Violation|2
5980778|NCT02471144|9569413|FG006|Extension Period (Week 52 to Week 236)|Pregnancy|0
5980779|NCT02471144|9569414|FG007|Extension Period (Week 52 to Week 236)|Pregnancy|0
5980780|NCT02471144|9569415|FG008|Extension Period (Week 52 to Week 236)|Pregnancy|0
5980781|NCT02471144|9569416|FG009|Extension Period (Week 52 to Week 236)|Pregnancy|2
5980782|NCT02471144|9569417|FG010|Extension Period (Week 52 to Week 236)|Pregnancy|0
5980783|NCT02471144|9569407|FG000|Extension Period (Week 52 to Week 236)|Lost to Follow-up|0
5980784|NCT02471144|9569408|FG001|Extension Period (Week 52 to Week 236)|Lost to Follow-up|0
5980785|NCT02471144|9569409|FG002|Extension Period (Week 52 to Week 236)|Lost to Follow-up|0
5980786|NCT02471144|9569410|FG003|Extension Period (Week 52 to Week 236)|Lost to Follow-up|0
5980787|NCT02471144|9569411|FG004|Extension Period (Week 52 to Week 236)|Lost to Follow-up|0
5980788|NCT02471144|9569412|FG005|Extension Period (Week 52 to Week 236)|Lost to Follow-up|0
5980789|NCT02471144|9569413|FG006|Extension Period (Week 52 to Week 236)|Lost to Follow-up|0
5980790|NCT02471144|9569414|FG007|Extension Period (Week 52 to Week 236)|Lost to Follow-up|0
5980791|NCT02471144|9569415|FG008|Extension Period (Week 52 to Week 236)|Lost to Follow-up|0
5980792|NCT02471144|9569416|FG009|Extension Period (Week 52 to Week 236)|Lost to Follow-up|0
5980793|NCT02471144|9569417|FG010|Extension Period (Week 52 to Week 236)|Lost to Follow-up|2
5980794|NCT02440464|9569435|FG000|Overall Study|Withdrawal by Subject|3
5980795|NCT02440464|9569436|FG001|Overall Study|Withdrawal by Subject|2
5980796|NCT02366728|9569453|FG000|Overall Study|Death|0
5980797|NCT02366728|9569454|FG001|Overall Study|Death|0
5980798|NCT02366728|9569455|FG002|Overall Study|Death|1
6116775|NCT00864721|9738624|FG000|Overall Study|Patient request|11
6116776|NCT00864721|9738624|FG000|Overall Study|Hospitalized|1
6116777|NCT00864721|9738624|FG000|Overall Study|Drug hold/delay more than 4 weeks|1
6116778|NCT00864721|9738624|FG000|Overall Study|Adverse Event|21
6116779|NCT00864851|9738631|FG000|Overall Study|Withdrawal by Subject|0
6116780|NCT00864851|9738632|FG001|Overall Study|Withdrawal by Subject|1
6116781|NCT00864851|9738633|FG002|Overall Study|Withdrawal by Subject|0
6116782|NCT00864851|9738631|FG000|Overall Study|Physician Decision|1
6116783|NCT00864851|9738632|FG001|Overall Study|Physician Decision|0
6116784|NCT00864851|9738633|FG002|Overall Study|Physician Decision|0
6116785|NCT00864851|9738631|FG000|Overall Study|Death|1
6116786|NCT00864851|9738632|FG001|Overall Study|Death|0
6116787|NCT00864851|9738633|FG002|Overall Study|Death|0
6116788|NCT00864851|9738631|FG000|Overall Study|Patient uncooperative|1
6116789|NCT00864851|9738632|FG001|Overall Study|Patient uncooperative|0
6116790|NCT00864851|9738633|FG002|Overall Study|Patient uncooperative|0
6116791|NCT00864916|9738645|FG000|Overall Study|Lost to Follow-up|4
6116792|NCT00864916|9738646|FG001|Overall Study|Lost to Follow-up|4
6116793|NCT00864916|9738645|FG000|Overall Study|Protocol Violation|1
6116794|NCT00864916|9738646|FG001|Overall Study|Protocol Violation|0
6116795|NCT00864916|9738645|FG000|Overall Study|Withdrawal by Subject|1
6116796|NCT00864916|9738646|FG001|Overall Study|Withdrawal by Subject|0
6116797|NCT00865020|9738654|FG000|Overall Study|Withdrawal by Subject|22
6116798|NCT00865020|9738655|FG001|Overall Study|Withdrawal by Subject|16
6116799|NCT00865020|9738654|FG000|Overall Study|Adverse Event|9
6116800|NCT00865020|9738655|FG001|Overall Study|Adverse Event|14
6116801|NCT00865020|9738654|FG000|Overall Study|Abnormal test procedure result(s)|6
6116802|NCT00865020|9738655|FG001|Overall Study|Abnormal test procedure result(s)|8
6116803|NCT00865020|9738654|FG000|Overall Study|Lost to Follow-up|6
6116804|NCT00865020|9738655|FG001|Overall Study|Lost to Follow-up|4
6116805|NCT00865020|9738654|FG000|Overall Study|Protocol deviation|4
6116806|NCT00865020|9738655|FG001|Overall Study|Protocol deviation|1
6116807|NCT00865020|9738654|FG000|Overall Study|Administrative problems|0
6116808|NCT00865020|9738655|FG001|Overall Study|Administrative problems|2
6116809|NCT00865020|9738654|FG000|Overall Study|Abnormal laboratory value(s)|0
6116810|NCT00865020|9738655|FG001|Overall Study|Abnormal laboratory value(s)|1
6116811|NCT00865020|9738654|FG000|Overall Study|Death|0
6116812|NCT00865020|9738655|FG001|Overall Study|Death|1
6116813|NCT00865020|9738654|FG000|Overall Study|Randomized but discontinued|2
6116814|NCT00865020|9738655|FG001|Overall Study|Randomized but discontinued|4
6116815|NCT00865046|9738664|FG000|Overall Study|Lost to Follow-up|1
6116816|NCT00865046|9738665|FG001|Overall Study|Lost to Follow-up|4
6210774|NCT01584843|9876706|FG001|First Treatment Period|Met Protocol-defined Stopping Criteria|0
6210775|NCT01584843|9876707|FG002|First Treatment Period|Met Protocol-defined Stopping Criteria|0
6210776|NCT01584843|9876708|FG003|First Treatment Period|Met Protocol-defined Stopping Criteria|0
6210777|NCT01584843|9876709|FG004|First Treatment Period|Met Protocol-defined Stopping Criteria|0
6210778|NCT01584843|9876710|FG005|First Treatment Period|Met Protocol-defined Stopping Criteria|1
6210779|NCT01584843|9876705|FG000|Second Treatment Period|Withdrawal by Subject|0
6210780|NCT01584843|9876706|FG001|Second Treatment Period|Withdrawal by Subject|0
6210781|NCT01584843|9876707|FG002|Second Treatment Period|Withdrawal by Subject|0
6210782|NCT01584843|9876708|FG003|Second Treatment Period|Withdrawal by Subject|0
6210783|NCT01584843|9876709|FG004|Second Treatment Period|Withdrawal by Subject|0
6210784|NCT01584843|9876710|FG005|Second Treatment Period|Withdrawal by Subject|1
6210785|NCT01585025|9876729|FG000|Overall Study|Withdrawal by Subject|0
6210786|NCT01585025|9876730|FG001|Overall Study|Withdrawal by Subject|3
6210787|NCT01585025|9876731|FG002|Overall Study|Withdrawal by Subject|4
6210788|NCT01585038|9876741|FG000|Overall Study|Adverse Event|2
6210789|NCT01585038|9876742|FG001|Overall Study|Adverse Event|2
6210790|NCT01585155|9876757|FG000|Overall Study|Adverse Event|1
6210791|NCT01585155|9876757|FG000|Overall Study|Lack of Efficacy|2
6210792|NCT01585155|9876757|FG000|Overall Study|Worsening ulcerative colitis|2
6210793|NCT01585168|9876763|FG000|Overall Study|Lost to Follow-up|3
6210794|NCT01585168|9876764|FG001|Overall Study|Lost to Follow-up|1
6210795|NCT01585168|9876765|FG002|Overall Study|Lost to Follow-up|1
6210796|NCT01585168|9876766|FG003|Overall Study|Lost to Follow-up|1
6210797|NCT01585194|9876774|FG000|Overall Study|Withdrawal by Subject|1
6286794|NCT02346240|9999199|FG008|Open-Label Period (Week 48 to Week 144)|Lost to Follow-up|0
6286795|NCT02346240|9999200|FG009|Open-Label Period (Week 48 to Week 144)|Lost to Follow-up|0
6286796|NCT02346240|9999201|FG010|Open-Label Period (Week 48 to Week 144)|Lost to Follow-up|0
6286797|NCT02346240|9999202|FG011|Open-Label Period (Week 48 to Week 144)|Lost to Follow-up|0
6286798|NCT02346240|9999203|FG012|Open-Label Period (Week 48 to Week 144)|Lost to Follow-up|0
6286799|NCT02346240|9999204|FG013|Open-Label Period (Week 48 to Week 144)|Lost to Follow-up|0
6286800|NCT02346240|9999205|FG014|Open-Label Period (Week 48 to Week 144)|Lost to Follow-up|0
6286801|NCT02346240|9999206|FG015|Open-Label Period (Week 48 to Week 144)|Lost to Follow-up|0
6286802|NCT02346240|9999207|FG016|Open-Label Period (Week 48 to Week 144)|Lost to Follow-up|0
6286803|NCT02346240|9999208|FG017|Open-Label Period (Week 48 to Week 144)|Lost to Follow-up|2
6286804|NCT02346240|9999209|FG018|Open-Label Period (Week 48 to Week 144)|Lost to Follow-up|2
6286805|NCT02346240|9999210|FG019|Open-Label Period (Week 48 to Week 144)|Lost to Follow-up|3
6286806|NCT02346240|9999211|FG020|Open-Label Period (Week 48 to Week 144)|Lost to Follow-up|0
6286807|NCT02346240|9999212|FG021|Open-Label Period (Week 48 to Week 144)|Lost to Follow-up|1
6210798|NCT01585194|9876774|FG000|Overall Study|Physician Decision|2
6210799|NCT01585194|9876774|FG000|Overall Study|Lack of insurance|1
6210800|NCT01585246|9876787|FG000|Overall Study|Lost to Follow-up|0
6210801|NCT01585246|9876788|FG001|Overall Study|Lost to Follow-up|0
6210802|NCT01585246|9876789|FG002|Overall Study|Lost to Follow-up|2
6210803|NCT01585246|9876790|FG003|Overall Study|Lost to Follow-up|1
6210804|NCT01585246|9876791|FG004|Overall Study|Lost to Follow-up|0
6210805|NCT01585246|9876787|FG000|Overall Study|Protocol Violation|0
6210806|NCT01585246|9876788|FG001|Overall Study|Protocol Violation|0
6210807|NCT01585246|9876789|FG002|Overall Study|Protocol Violation|0
6210808|NCT01585246|9876790|FG003|Overall Study|Protocol Violation|0
6210809|NCT01585246|9876791|FG004|Overall Study|Protocol Violation|1
6116817|NCT00865046|9738666|FG002|Overall Study|Lost to Follow-up|0
6116818|NCT00865046|9738664|FG000|Overall Study|Death|0
6116819|NCT00865046|9738665|FG001|Overall Study|Death|1
6116820|NCT00865046|9738666|FG002|Overall Study|Death|1
6116821|NCT00865046|9738664|FG000|Overall Study|Withdrawal by Subject|5
6116822|NCT00865046|9738665|FG001|Overall Study|Withdrawal by Subject|0
6116823|NCT00865046|9738666|FG002|Overall Study|Withdrawal by Subject|0
6116824|NCT00865098|9738674|FG000|Overall Study|Progressive disease|1
6116825|NCT00865124|9738681|FG000|Overall Study|Physician Decision|2
6116826|NCT00865124|9738682|FG001|Overall Study|Physician Decision|1
6116827|NCT00865124|9738683|FG002|Overall Study|Physician Decision|0
6116828|NCT00865124|9738681|FG000|Overall Study|Withdrawn consent|2
6116829|NCT00865124|9738682|FG001|Overall Study|Withdrawn consent|0
6116830|NCT00865124|9738683|FG002|Overall Study|Withdrawn consent|0
6116831|NCT00865189|9738693|FG000|Overall Study|Other|1
6116832|NCT00865189|9738694|FG001|Overall Study|Other|2
6116833|NCT00865189|9738693|FG000|Overall Study|Death|4
6116834|NCT00865189|9738694|FG001|Overall Study|Death|11
6116835|NCT00865189|9738693|FG000|Overall Study|Lost to Follow-up|6
6116836|NCT00865189|9738694|FG001|Overall Study|Lost to Follow-up|6
6116837|NCT00865189|9738693|FG000|Overall Study|Withdrawal by Subject|1
6210810|NCT01585246|9876787|FG000|Overall Study|Withdrawal by Subject|0
6210811|NCT01585246|9876788|FG001|Overall Study|Withdrawal by Subject|0
6210812|NCT01585246|9876789|FG002|Overall Study|Withdrawal by Subject|1
6210813|NCT01585246|9876790|FG003|Overall Study|Withdrawal by Subject|2
6210814|NCT01585246|9876791|FG004|Overall Study|Withdrawal by Subject|1
6210815|NCT01585246|9876787|FG000|Overall Study|Other|0
6210816|NCT01585246|9876788|FG001|Overall Study|Other|1
6210817|NCT01585246|9876789|FG002|Overall Study|Other|1
6286808|NCT02346240|9999213|FG022|Open-Label Period (Week 48 to Week 144)|Lost to Follow-up|1
6286809|NCT02346240|9999214|FG023|Open-Label Period (Week 48 to Week 144)|Lost to Follow-up|1
6286810|NCT02346240|9999191|FG000|Open-Label Period (Week 48 to Week 144)|Withdrawal by Subject|0
6286811|NCT02346240|9999192|FG001|Open-Label Period (Week 48 to Week 144)|Withdrawal by Subject|0
6286812|NCT02346240|9999193|FG002|Open-Label Period (Week 48 to Week 144)|Withdrawal by Subject|0
6286813|NCT02346240|9999194|FG003|Open-Label Period (Week 48 to Week 144)|Withdrawal by Subject|0
6286814|NCT02346240|9999195|FG004|Open-Label Period (Week 48 to Week 144)|Withdrawal by Subject|0
6286815|NCT02346240|9999196|FG005|Open-Label Period (Week 48 to Week 144)|Withdrawal by Subject|0
6286816|NCT02346240|9999197|FG006|Open-Label Period (Week 48 to Week 144)|Withdrawal by Subject|0
6286817|NCT02346240|9999198|FG007|Open-Label Period (Week 48 to Week 144)|Withdrawal by Subject|0
6286818|NCT02346240|9999199|FG008|Open-Label Period (Week 48 to Week 144)|Withdrawal by Subject|0
6286819|NCT02346240|9999200|FG009|Open-Label Period (Week 48 to Week 144)|Withdrawal by Subject|0
6286820|NCT02346240|9999201|FG010|Open-Label Period (Week 48 to Week 144)|Withdrawal by Subject|0
6286821|NCT02346240|9999202|FG011|Open-Label Period (Week 48 to Week 144)|Withdrawal by Subject|0
6286822|NCT02346240|9999203|FG012|Open-Label Period (Week 48 to Week 144)|Withdrawal by Subject|0
6286823|NCT02346240|9999204|FG013|Open-Label Period (Week 48 to Week 144)|Withdrawal by Subject|0
6286824|NCT02346240|9999205|FG014|Open-Label Period (Week 48 to Week 144)|Withdrawal by Subject|0
6286825|NCT02346240|9999206|FG015|Open-Label Period (Week 48 to Week 144)|Withdrawal by Subject|0
6286826|NCT02346240|9999207|FG016|Open-Label Period (Week 48 to Week 144)|Withdrawal by Subject|0
6286827|NCT02346240|9999208|FG017|Open-Label Period (Week 48 to Week 144)|Withdrawal by Subject|0
6286828|NCT02346240|9999209|FG018|Open-Label Period (Week 48 to Week 144)|Withdrawal by Subject|4
6286829|NCT02346240|9999210|FG019|Open-Label Period (Week 48 to Week 144)|Withdrawal by Subject|1
6286830|NCT02346240|9999211|FG020|Open-Label Period (Week 48 to Week 144)|Withdrawal by Subject|0
6286831|NCT02346240|9999212|FG021|Open-Label Period (Week 48 to Week 144)|Withdrawal by Subject|10
6286832|NCT02346240|9999213|FG022|Open-Label Period (Week 48 to Week 144)|Withdrawal by Subject|1
6286833|NCT02346240|9999214|FG023|Open-Label Period (Week 48 to Week 144)|Withdrawal by Subject|1
6286834|NCT02346240|9999191|FG000|Open-Label Period (Week 48 to Week 144)|No PASI50 response|0
6286835|NCT02346240|9999192|FG001|Open-Label Period (Week 48 to Week 144)|No PASI50 response|0
6286836|NCT02346240|9999193|FG002|Open-Label Period (Week 48 to Week 144)|No PASI50 response|0
6286837|NCT02346240|9999194|FG003|Open-Label Period (Week 48 to Week 144)|No PASI50 response|0
6286838|NCT02346240|9999195|FG004|Open-Label Period (Week 48 to Week 144)|No PASI50 response|0
6286839|NCT02346240|9999196|FG005|Open-Label Period (Week 48 to Week 144)|No PASI50 response|0
6286840|NCT02346240|9999197|FG006|Open-Label Period (Week 48 to Week 144)|No PASI50 response|0
6286841|NCT02346240|9999198|FG007|Open-Label Period (Week 48 to Week 144)|No PASI50 response|0
6286842|NCT02346240|9999199|FG008|Open-Label Period (Week 48 to Week 144)|No PASI50 response|0
6286843|NCT02346240|9999200|FG009|Open-Label Period (Week 48 to Week 144)|No PASI50 response|0
6286844|NCT02346240|9999201|FG010|Open-Label Period (Week 48 to Week 144)|No PASI50 response|0
6286845|NCT02346240|9999202|FG011|Open-Label Period (Week 48 to Week 144)|No PASI50 response|0
6286846|NCT02346240|9999203|FG012|Open-Label Period (Week 48 to Week 144)|No PASI50 response|0
6286847|NCT02346240|9999204|FG013|Open-Label Period (Week 48 to Week 144)|No PASI50 response|0
6286848|NCT02346240|9999205|FG014|Open-Label Period (Week 48 to Week 144)|No PASI50 response|0
6116838|NCT00865189|9738694|FG001|Overall Study|Withdrawal by Subject|0
6210818|NCT01585246|9876790|FG003|Overall Study|Other|1
6210819|NCT01585246|9876791|FG004|Overall Study|Other|0
6116839|NCT00865280|9738712|FG000|Overall Study|Withdrawal by Subject|4
6116840|NCT00865280|9738713|FG001|Overall Study|Withdrawal by Subject|1
6116841|NCT00865280|9738712|FG000|Overall Study|End of Treatment/Lost to Follow-up|0
6116842|NCT00865280|9738713|FG001|Overall Study|End of Treatment/Lost to Follow-up|1
6116843|NCT00865280|9738712|FG000|Overall Study|Adverse Event/Lost to Follow-up|1
6210820|NCT01585272|9876806|FG000|Overall Study|Adverse Event|22
6210821|NCT01585272|9876806|FG000|Overall Study|Protocol Violation|7
6210822|NCT01585272|9876806|FG000|Overall Study|Withdrawal by Subject|10
6210823|NCT01585298|9876810|FG000|Overall Study|Study completion was not documented.|1
6210824|NCT01585298|9876810|FG000|Overall Study|Protocol deviation|1
6210825|NCT01585298|9876810|FG000|Overall Study|Administrative problems|4
6210826|NCT01585298|9876810|FG000|Overall Study|Lost to Follow-up|2
6210827|NCT01585298|9876810|FG000|Overall Study|Withdrawal by Subject|4
6210828|NCT01585298|9876810|FG000|Overall Study|Abnormal test procedure results|1
6210829|NCT01585298|9876810|FG000|Overall Study|Adverse Event|24
6210830|NCT01585428|9876822|FG000|Overall Study|Death during treatment|1
6210831|NCT01585428|9876823|FG001|Overall Study|Death during treatment|0
6210832|NCT01585558|9876842|FG000|Overall Study|Withdrawal by Subject|4
6210833|NCT01585558|9876843|FG001|Overall Study|Withdrawal by Subject|5
6210834|NCT01585558|9876844|FG002|Overall Study|Withdrawal by Subject|8
6286849|NCT02346240|9999206|FG015|Open-Label Period (Week 48 to Week 144)|No PASI50 response|0
6286850|NCT02346240|9999207|FG016|Open-Label Period (Week 48 to Week 144)|No PASI50 response|0
6286851|NCT02346240|9999208|FG017|Open-Label Period (Week 48 to Week 144)|No PASI50 response|0
6286852|NCT02346240|9999209|FG018|Open-Label Period (Week 48 to Week 144)|No PASI50 response|2
6286853|NCT02346240|9999210|FG019|Open-Label Period (Week 48 to Week 144)|No PASI50 response|0
6286854|NCT02346240|9999211|FG020|Open-Label Period (Week 48 to Week 144)|No PASI50 response|0
6286855|NCT02346240|9999212|FG021|Open-Label Period (Week 48 to Week 144)|No PASI50 response|4
6286856|NCT02346240|9999213|FG022|Open-Label Period (Week 48 to Week 144)|No PASI50 response|2
6286857|NCT02346240|9999214|FG023|Open-Label Period (Week 48 to Week 144)|No PASI50 response|3
6286858|NCT02346240|9999191|FG000|Open-Label Period (Week 48 to Week 144)|No efficacy of study medication|0
6286859|NCT02346240|9999192|FG001|Open-Label Period (Week 48 to Week 144)|No efficacy of study medication|0
6286860|NCT02346240|9999193|FG002|Open-Label Period (Week 48 to Week 144)|No efficacy of study medication|0
6286861|NCT02346240|9999194|FG003|Open-Label Period (Week 48 to Week 144)|No efficacy of study medication|0
6286862|NCT02346240|9999195|FG004|Open-Label Period (Week 48 to Week 144)|No efficacy of study medication|0
6286863|NCT02346240|9999196|FG005|Open-Label Period (Week 48 to Week 144)|No efficacy of study medication|0
6286864|NCT02346240|9999197|FG006|Open-Label Period (Week 48 to Week 144)|No efficacy of study medication|0
6286865|NCT02346240|9999198|FG007|Open-Label Period (Week 48 to Week 144)|No efficacy of study medication|0
6286866|NCT02346240|9999199|FG008|Open-Label Period (Week 48 to Week 144)|No efficacy of study medication|0
6286867|NCT02346240|9999200|FG009|Open-Label Period (Week 48 to Week 144)|No efficacy of study medication|0
6286868|NCT02346240|9999201|FG010|Open-Label Period (Week 48 to Week 144)|No efficacy of study medication|0
6286869|NCT02346240|9999202|FG011|Open-Label Period (Week 48 to Week 144)|No efficacy of study medication|0
6286870|NCT02346240|9999203|FG012|Open-Label Period (Week 48 to Week 144)|No efficacy of study medication|0
6286871|NCT02346240|9999204|FG013|Open-Label Period (Week 48 to Week 144)|No efficacy of study medication|0
6286872|NCT02346240|9999205|FG014|Open-Label Period (Week 48 to Week 144)|No efficacy of study medication|0
6116844|NCT00865280|9738713|FG001|Overall Study|Adverse Event/Lost to Follow-up|0
6116845|NCT00865280|9738712|FG000|Overall Study|Exclusion Condition|1
6116846|NCT00865280|9738713|FG001|Overall Study|Exclusion Condition|0
6116847|NCT00865280|9738712|FG000|Overall Study|Adverse Event|0
6116848|NCT00865280|9738713|FG001|Overall Study|Adverse Event|1
6116849|NCT00865306|9738721|FG000|Controlled Trial|Lost to Follow-up|1
6116850|NCT00865306|9738722|FG001|Controlled Trial|Lost to Follow-up|1
6116851|NCT00865306|9738721|FG000|Controlled Trial|Difficulty commuting|2
6116852|NCT00865306|9738722|FG001|Controlled Trial|Difficulty commuting|0
6116853|NCT00865306|9738721|FG000|Controlled Trial|Improved btw baseline and first session|1
6116854|NCT00865306|9738722|FG001|Controlled Trial|Improved btw baseline and first session|0
6116855|NCT00865306|9738721|FG000|Controlled Trial|Sought treatment for conduct disorder|1
6116856|NCT00865306|9738722|FG001|Controlled Trial|Sought treatment for conduct disorder|0
6116857|NCT00865306|9738721|FG000|Controlled Trial|Withdrawal by Subject|0
6116858|NCT00865306|9738722|FG001|Controlled Trial|Withdrawal by Subject|1
6116859|NCT00865345|9738728|FG000|Overall Study|Withdrawal by Subject|2
6116860|NCT00865566|9738734|FG000|Overall Study|Death|1
6116861|NCT00865566|9738735|FG001|Overall Study|Death|11
6116862|NCT00865566|9738734|FG000|Overall Study|Lost to Follow-up|314
6116863|NCT00865566|9738735|FG001|Overall Study|Lost to Follow-up|315
6116864|NCT00865566|9738734|FG000|Overall Study|Withdrawal by Subject|45
6116865|NCT00865566|9738735|FG001|Overall Study|Withdrawal by Subject|65
6116866|NCT00865566|9738734|FG000|Overall Study|Physician Decision|0
6116867|NCT00865566|9738735|FG001|Overall Study|Physician Decision|1
6116868|NCT00865566|9738734|FG000|Overall Study|Participant relocated|78
6116869|NCT00865566|9738735|FG001|Overall Study|Participant relocated|107
6116870|NCT00865566|9738734|FG000|Overall Study|Participant unable to adhere|27
6116871|NCT00865566|9738735|FG001|Overall Study|Participant unable to adhere|42
6210835|NCT01585558|9876842|FG000|Overall Study|Lost to Follow-up|2
6210836|NCT01585558|9876843|FG001|Overall Study|Lost to Follow-up|0
6116872|NCT00865566|9738734|FG000|Overall Study|Other; N=245 due to early study closure|154
6116873|NCT00865566|9738735|FG001|Overall Study|Other; N=245 due to early study closure|139
6116874|NCT00865566|9738734|FG000|Overall Study|HIV infection|5
6116875|NCT00865566|9738735|FG001|Overall Study|HIV infection|7
6116876|NCT00865709|9738743|FG000|Treatment|Adverse Event|9
6116877|NCT00865709|9738744|FG001|Treatment|Adverse Event|6
6116878|NCT00865709|9738743|FG000|Treatment|Withdrawal by Subject|10
6116879|NCT00865709|9738744|FG001|Treatment|Withdrawal by Subject|7
6116880|NCT00865709|9738743|FG000|Treatment|Physician Decision|3
6116881|NCT00865709|9738744|FG001|Treatment|Physician Decision|2
6116882|NCT00865709|9738743|FG000|Treatment|Surgery|8
6116883|NCT00865709|9738744|FG001|Treatment|Surgery|3
6116884|NCT00865904|9738757|FG000|Overall Study|Randomized but not Treated|2
6116885|NCT00865904|9738758|FG001|Overall Study|Randomized but not Treated|0
6116886|NCT00865904|9738759|FG002|Overall Study|Randomized but not Treated|0
6116887|NCT00865904|9738760|FG003|Overall Study|Randomized but not Treated|1
6116888|NCT00865904|9738761|FG004|Overall Study|Randomized but not Treated|1
6116889|NCT00866047|9738790|FG000|Treatment Period|Progressive disease|13
6116890|NCT00866047|9738790|FG000|Treatment Period|Adverse Event|16
6116891|NCT00866047|9738790|FG000|Treatment Period|Physician Decision|14
6116892|NCT00866047|9738790|FG000|Treatment Period|Withdrawal by Subject|5
6116893|NCT00866047|9738790|FG000|Follow-up Period|Lost to Follow-up|5
6116894|NCT00866177|9738794|FG000|Overall Study|Withdrawal by Subject|1
6210837|NCT01585558|9876844|FG002|Overall Study|Lost to Follow-up|3
6286873|NCT02346240|9999206|FG015|Open-Label Period (Week 48 to Week 144)|No efficacy of study medication|0
6286874|NCT02346240|9999207|FG016|Open-Label Period (Week 48 to Week 144)|No efficacy of study medication|0
6286875|NCT02346240|9999208|FG017|Open-Label Period (Week 48 to Week 144)|No efficacy of study medication|0
6286876|NCT02346240|9999209|FG018|Open-Label Period (Week 48 to Week 144)|No efficacy of study medication|1
6286877|NCT02346240|9999210|FG019|Open-Label Period (Week 48 to Week 144)|No efficacy of study medication|0
6286878|NCT02346240|9999211|FG020|Open-Label Period (Week 48 to Week 144)|No efficacy of study medication|0
6286879|NCT02346240|9999212|FG021|Open-Label Period (Week 48 to Week 144)|No efficacy of study medication|0
6286880|NCT02346240|9999213|FG022|Open-Label Period (Week 48 to Week 144)|No efficacy of study medication|0
6286881|NCT02346240|9999214|FG023|Open-Label Period (Week 48 to Week 144)|No efficacy of study medication|0
6286882|NCT02346370|9999239|FG000|Overall Study|Not treated|1
6286883|NCT02346370|9999240|FG001|Overall Study|Not treated|0
6286884|NCT02346370|9999241|FG002|Overall Study|Not treated|0
6286885|NCT02346370|9999239|FG000|Overall Study|Withdrawal of consent|1
6286886|NCT02346370|9999240|FG001|Overall Study|Withdrawal of consent|0
6286887|NCT02346370|9999241|FG002|Overall Study|Withdrawal of consent|0
6286888|NCT02346370|9999239|FG000|Overall Study|Death|1
6286889|NCT02346370|9999240|FG001|Overall Study|Death|3
6286890|NCT02346370|9999241|FG002|Overall Study|Death|1
6286891|NCT02346370|9999239|FG000|Overall Study|Sponsor discontinued study|5
6286892|NCT02346370|9999240|FG001|Overall Study|Sponsor discontinued study|0
6286893|NCT02346370|9999241|FG002|Overall Study|Sponsor discontinued study|2
6286894|NCT02346370|9999239|FG000|Overall Study|Radiologic progression|0
6286895|NCT02346370|9999240|FG001|Overall Study|Radiologic progression|0
6286896|NCT02346370|9999241|FG002|Overall Study|Radiologic progression|1
6286897|NCT02346370|9999239|FG000|Overall Study|Physician Decision|0
6286898|NCT02346370|9999240|FG001|Overall Study|Physician Decision|1
6286899|NCT02346370|9999241|FG002|Overall Study|Physician Decision|0
6286900|NCT02346708|9999275|FG000|Overall Study|Adverse Event|2
6286901|NCT02346708|9999276|FG001|Overall Study|Adverse Event|0
6116895|NCT00866177|9738794|FG000|Overall Study|Not Treated|151
6116896|NCT00866281|9738800|FG000|Overall Study|Adverse Event|1
6116897|NCT00866281|9738801|FG001|Overall Study|Adverse Event|0
6116898|NCT00866281|9738800|FG000|Overall Study|Withdrawal by participants|3
6116899|NCT00866281|9738801|FG001|Overall Study|Withdrawal by participants|0
6116900|NCT00866281|9738800|FG000|Overall Study|Disease progression|3
6116901|NCT00866281|9738801|FG001|Overall Study|Disease progression|11
6116902|NCT00866281|9738800|FG000|Overall Study|New cancer therapy|0
6116903|NCT00866281|9738801|FG001|Overall Study|New cancer therapy|4
6210838|NCT01585558|9876842|FG000|Overall Study|Adverse Event|3
6210839|NCT01585558|9876843|FG001|Overall Study|Adverse Event|4
6210840|NCT01585558|9876844|FG002|Overall Study|Adverse Event|1
6210841|NCT01585558|9876842|FG000|Overall Study|Protocol Violation|4
6210842|NCT01585558|9876843|FG001|Overall Study|Protocol Violation|3
6210843|NCT01585558|9876844|FG002|Overall Study|Protocol Violation|2
6210844|NCT01585558|9876842|FG000|Overall Study|Lack of Efficacy|0
6210845|NCT01585558|9876843|FG001|Overall Study|Lack of Efficacy|0
6210846|NCT01585558|9876844|FG002|Overall Study|Lack of Efficacy|1
6210847|NCT01585584|9876852|FG000|Overall Study|Lack of Efficacy|1
6210848|NCT01585584|9876852|FG000|Overall Study|Withdrawal by Subject|1
6210849|NCT01585584|9876852|FG000|Overall Study|Physician Decision|2
6210850|NCT01585766|9876866|FG000|Overall Study|Withdrawal by Subject|0
6210851|NCT01585766|9876867|FG001|Overall Study|Withdrawal by Subject|1
6210852|NCT01585766|9876868|FG002|Overall Study|Withdrawal by Subject|1
6210853|NCT01585766|9876869|FG003|Overall Study|Withdrawal by Subject|0
6210854|NCT01585766|9876870|FG004|Overall Study|Withdrawal by Subject|0
6210855|NCT01585766|9876871|FG005|Overall Study|Withdrawal by Subject|0
6210856|NCT01585766|9876866|FG000|Overall Study|Death|0
6210857|NCT01585766|9876867|FG001|Overall Study|Death|1
6116904|NCT00866294|9738813|FG000|Overall Study|Adverse Event|12
6116905|NCT00866294|9738814|FG001|Overall Study|Adverse Event|13
6116906|NCT00866294|9738815|FG002|Overall Study|Adverse Event|9
6116907|NCT00866294|9738813|FG000|Overall Study|Lack of Efficacy|7
6116908|NCT00866294|9738814|FG001|Overall Study|Lack of Efficacy|1
6116909|NCT00866294|9738815|FG002|Overall Study|Lack of Efficacy|0
6116910|NCT00866294|9738813|FG000|Overall Study|Protocol Violation|2
6116911|NCT00866294|9738814|FG001|Overall Study|Protocol Violation|0
6116912|NCT00866294|9738815|FG002|Overall Study|Protocol Violation|0
6116913|NCT00866294|9738813|FG000|Overall Study|Met Protocol-defined Stopping Criteria|5
6116914|NCT00866294|9738814|FG001|Overall Study|Met Protocol-defined Stopping Criteria|1
6116915|NCT00866294|9738815|FG002|Overall Study|Met Protocol-defined Stopping Criteria|1
6116916|NCT00866294|9738813|FG000|Overall Study|Lost to Follow-up|1
6116917|NCT00866294|9738814|FG001|Overall Study|Lost to Follow-up|3
6116918|NCT00866294|9738815|FG002|Overall Study|Lost to Follow-up|0
6116919|NCT00866294|9738813|FG000|Overall Study|Physician Decision|6
6116920|NCT00866294|9738814|FG001|Overall Study|Physician Decision|2
6116921|NCT00866294|9738815|FG002|Overall Study|Physician Decision|1
6116922|NCT00866307|9738831|FG000|Induction|Adverse Event|5
6116923|NCT00866307|9738832|FG001|Induction|Adverse Event|0
6116924|NCT00866307|9738833|FG002|Induction|Adverse Event|0
6286902|NCT02346708|9999275|FG000|Overall Study|Protocol Violation|0
6286903|NCT02346708|9999276|FG001|Overall Study|Protocol Violation|1
6116925|NCT00866307|9738831|FG000|Induction|Death|2
6116926|NCT00866307|9738832|FG001|Induction|Death|0
6116927|NCT00866307|9738833|FG002|Induction|Death|0
6116928|NCT00866307|9738831|FG000|Induction|Physician Decision|5
6116929|NCT00866307|9738832|FG001|Induction|Physician Decision|0
6116930|NCT00866307|9738833|FG002|Induction|Physician Decision|0
6210858|NCT01585766|9876868|FG002|Overall Study|Death|0
6210859|NCT01585766|9876869|FG003|Overall Study|Death|0
6210860|NCT01585766|9876870|FG004|Overall Study|Death|0
6210861|NCT01585766|9876871|FG005|Overall Study|Death|0
6210862|NCT01585766|9876866|FG000|Overall Study|Physician Decision|0
6210863|NCT01585766|9876867|FG001|Overall Study|Physician Decision|0
6210864|NCT01585766|9876868|FG002|Overall Study|Physician Decision|1
6210865|NCT01585766|9876869|FG003|Overall Study|Physician Decision|0
6210866|NCT01585766|9876870|FG004|Overall Study|Physician Decision|0
6210867|NCT01585766|9876871|FG005|Overall Study|Physician Decision|0
6210868|NCT01585831|9876904|FG000|Overall Study|Physician Decision|0
6210869|NCT01585831|9876905|FG001|Overall Study|Physician Decision|1
6210870|NCT01585831|9876904|FG000|Overall Study|Withdrawal by Subject|2
6210871|NCT01585831|9876905|FG001|Overall Study|Withdrawal by Subject|1
6210872|NCT01585961|9876911|FG000|Overall Study|Death|6
6210873|NCT01585961|9876911|FG000|Overall Study|Physician Decision|1
6210874|NCT01585961|9876911|FG000|Overall Study|Decision to use non-study catheter|1
6210875|NCT01585961|9876911|FG000|Overall Study|Withdrawal by Subject|1
6210876|NCT01585961|9876911|FG000|Overall Study|Lost to Follow-up|23
6286904|NCT02346721|9999283|FG000|Overall Study|Withdrew Consent|3
6286905|NCT02346721|9999283|FG000|Overall Study|Lack of Efficacy|1
6286906|NCT02347072|9999297|FG000|Overall Study|Adverse Event|2
6286907|NCT02347072|9999297|FG000|Overall Study|Withdrawal by Subject|6
6286908|NCT02347072|9999297|FG000|Overall Study|Physician Decision|1
6286909|NCT02347072|9999297|FG000|Overall Study|Lost to Follow-up|2
6286910|NCT02347072|9999297|FG000|Overall Study|Protocol Violation|1
6286911|NCT02347072|9999297|FG000|Overall Study|Disc due to Protocol-specified Criteria|6
6286912|NCT02347085|9999305|FG000|Overall Study|Adverse Event|2
6286913|NCT02347085|9999305|FG000|Overall Study|Lack of Efficacy|1
6286914|NCT02347085|9999305|FG000|Overall Study|Withdrawal by Subject|4
6286915|NCT02347085|9999305|FG000|Overall Study|Lost to Follow-up|1
6286916|NCT02347085|9999305|FG000|Overall Study|Protocol Criteria|2
6286917|NCT02347098|9999313|FG000|Overall Study|Death|1
6286918|NCT02347098|9999314|FG001|Overall Study|Death|0
6286919|NCT02347098|9999313|FG000|Overall Study|Withdrawal by Subject|1
6286920|NCT02347098|9999314|FG001|Overall Study|Withdrawal by Subject|0
6286921|NCT02347098|9999313|FG000|Overall Study|Lost to Follow-up|2
6286922|NCT02347098|9999314|FG001|Overall Study|Lost to Follow-up|2
6286923|NCT02347098|9999313|FG000|Overall Study|Refuse Follow-up Visit|1
6286924|NCT02347098|9999314|FG001|Overall Study|Refuse Follow-up Visit|5
6286925|NCT02347098|9999313|FG000|Overall Study|no visit due to illness|2
6286926|NCT02347098|9999314|FG001|Overall Study|no visit due to illness|1
6286927|NCT02347176|9999333|FG000|Overall Study|Lost to Follow-up|2
6286928|NCT02347176|9999334|FG001|Overall Study|Lost to Follow-up|3
6063224|NCT00505414|9664577|FG004|Maintenance Phase|Death|0
6063225|NCT00505414|9664573|FG000|Maintenance Phase|Lack of Efficacy|2
6063226|NCT00505414|9664574|FG001|Maintenance Phase|Lack of Efficacy|1
6063227|NCT00505414|9664575|FG002|Maintenance Phase|Lack of Efficacy|1
6063228|NCT00505414|9664576|FG003|Maintenance Phase|Lack of Efficacy|0
6063229|NCT00505414|9664577|FG004|Maintenance Phase|Lack of Efficacy|0
6063230|NCT00505414|9664573|FG000|Maintenance Phase|Withdrawal by Subject|0
6286929|NCT02347176|9999335|FG002|Overall Study|Lost to Follow-up|1
6063231|NCT00505414|9664574|FG001|Maintenance Phase|Withdrawal by Subject|0
6063232|NCT00505414|9664575|FG002|Maintenance Phase|Withdrawal by Subject|1
6063233|NCT00505414|9664576|FG003|Maintenance Phase|Withdrawal by Subject|0
6210877|NCT01585961|9876911|FG000|Overall Study|Ablation cancelled for slow-heal wound|1
6210878|NCT01585987|9876917|FG000|Randomized|Withdrawal by Subject|0
6116931|NCT00866307|9738831|FG000|Induction|Progressive Disease|1
6116932|NCT00866307|9738832|FG001|Induction|Progressive Disease|0
6116933|NCT00866307|9738833|FG002|Induction|Progressive Disease|0
6116934|NCT00866307|9738831|FG000|Induction|Identification of Patients with Day 29 M|3
6116935|NCT00866307|9738832|FG001|Induction|Identification of Patients with Day 29 M|0
6116936|NCT00866307|9738833|FG002|Induction|Identification of Patients with Day 29 M|0
6116937|NCT00866307|9738831|FG000|Induction|Inadequate cytognetic samples th|1
6116938|NCT00866307|9738832|FG001|Induction|Inadequate cytognetic samples th|0
6116939|NCT00866307|9738833|FG002|Induction|Inadequate cytognetic samples th|0
6116940|NCT00866307|9738831|FG000|Induction|Improper post-induction consent|2
6116941|NCT00866307|9738832|FG001|Induction|Improper post-induction consent|0
6116942|NCT00866307|9738833|FG002|Induction|Improper post-induction consent|0
6116943|NCT00866307|9738831|FG000|Induction|Study was closed at the time|1
6116944|NCT00866307|9738832|FG001|Induction|Study was closed at the time|0
6116945|NCT00866307|9738833|FG002|Induction|Study was closed at the time|0
6116946|NCT00866307|9738831|FG000|Consolidation/Maintenance|Adverse Event|0
6116947|NCT00866307|9738832|FG001|Consolidation/Maintenance|Adverse Event|0
6116948|NCT00866307|9738833|FG002|Consolidation/Maintenance|Adverse Event|8
6116949|NCT00866307|9738831|FG000|Consolidation/Maintenance|Death|0
6116950|NCT00866307|9738832|FG001|Consolidation/Maintenance|Death|0
6116951|NCT00866307|9738833|FG002|Consolidation/Maintenance|Death|1
6116952|NCT00866307|9738831|FG000|Consolidation/Maintenance|Physician Decision|0
6116953|NCT00866307|9738832|FG001|Consolidation/Maintenance|Physician Decision|3
6116954|NCT00866307|9738833|FG002|Consolidation/Maintenance|Physician Decision|2
6116955|NCT00866307|9738831|FG000|Consolidation/Maintenance|Withdrawal by Subject|0
6116956|NCT00866307|9738832|FG001|Consolidation/Maintenance|Withdrawal by Subject|1
6116957|NCT00866307|9738833|FG002|Consolidation/Maintenance|Withdrawal by Subject|1
6116958|NCT00866307|9738831|FG000|Consolidation/Maintenance|Development of 2nd malignant neoplasm|0
6116959|NCT00866307|9738832|FG001|Consolidation/Maintenance|Development of 2nd malignant neoplasm|0
6116960|NCT00866307|9738833|FG002|Consolidation/Maintenance|Development of 2nd malignant neoplasm|2
6116961|NCT00866307|9738831|FG000|Consolidation/Maintenance|Recurrent leukemia following remission|0
6116962|NCT00866307|9738832|FG001|Consolidation/Maintenance|Recurrent leukemia following remission|3
6116963|NCT00866307|9738833|FG002|Consolidation/Maintenance|Recurrent leukemia following remission|1
6116964|NCT00866307|9738831|FG000|Consolidation/Maintenance|Therapy error|0
6116965|NCT00866307|9738832|FG001|Consolidation/Maintenance|Therapy error|1
6116966|NCT00866307|9738833|FG002|Consolidation/Maintenance|Therapy error|0
6116967|NCT00866307|9738831|FG000|Consolidation/Maintenance|Non-compliance|0
6116968|NCT00866307|9738832|FG001|Consolidation/Maintenance|Non-compliance|0
6116969|NCT00866307|9738833|FG002|Consolidation/Maintenance|Non-compliance|1
6116970|NCT00866307|9738831|FG000|Consolidation/Maintenance|Patient moved to non-participating inst|0
6116971|NCT00866307|9738832|FG001|Consolidation/Maintenance|Patient moved to non-participating inst|1
6116972|NCT00866307|9738833|FG002|Consolidation/Maintenance|Patient moved to non-participating inst|0
6116973|NCT00866320|9738839|FG000|Overall Study|Withdrawal by Subject|4
6210879|NCT01585987|9876918|FG001|Randomized|Withdrawal by Subject|4
6210880|NCT01585987|9876917|FG000|Randomized|No longer met criteria|0
6210881|NCT01585987|9876918|FG001|Randomized|No longer met criteria|2
6210882|NCT01585987|9876917|FG000|Treated|Disease Progression|39
6210883|NCT01585987|9876918|FG001|Treated|Disease Progression|36
6210884|NCT01585987|9876917|FG000|Treated|Study Drug Toxicity|9
6210885|NCT01585987|9876918|FG001|Treated|Study Drug Toxicity|5
6210886|NCT01585987|9876917|FG000|Treated|Adverse Event|3
6210887|NCT01585987|9876918|FG001|Treated|Adverse Event|0
6210888|NCT01585987|9876917|FG000|Treated|Withdrawal by Subject|1
6210889|NCT01585987|9876918|FG001|Treated|Withdrawal by Subject|2
6210890|NCT01585987|9876917|FG000|Treated|Death|1
6210891|NCT01585987|9876918|FG001|Treated|Death|0
6210892|NCT01585987|9876917|FG000|Treated|Lost to Follow-up|0
6210893|NCT01585987|9876918|FG001|Treated|Lost to Follow-up|1
6210894|NCT01585987|9876917|FG000|Treated|Maximum Clinical Benefit|0
6210895|NCT01585987|9876918|FG001|Treated|Maximum Clinical Benefit|1
6210896|NCT01585987|9876917|FG000|Treated|Non-Specified|1
6210897|NCT01585987|9876918|FG001|Treated|Non-Specified|2
6210898|NCT01585987|9876917|FG000|Treated|Subject Request|0
6210899|NCT01585987|9876918|FG001|Treated|Subject Request|1
6210900|NCT01585987|9876917|FG000|Treated|Poor/Non-Compliance|0
6210901|NCT01585987|9876918|FG001|Treated|Poor/Non-Compliance|1
6210902|NCT01586156|9876971|FG000|Overall Study|Pregnancy|0
6210903|NCT01586156|9876972|FG001|Overall Study|Pregnancy|1
6210904|NCT01586156|9876973|FG002|Overall Study|Pregnancy|0
6210905|NCT01586195|9876981|FG000|Overall Study|Death|11
6210906|NCT01586195|9876981|FG000|Overall Study|Withdrawal of Consent|5
6210907|NCT01586195|9876981|FG000|Overall Study|Started new anti-melanoma therapy|1
6210908|NCT01586195|9876981|FG000|Overall Study|Reason not specified|9
6210909|NCT01586338|9876994|FG000|Overall Study|Adverse Event|3
6210910|NCT01586338|9876994|FG000|Overall Study|Lost to Follow-up|1
6210911|NCT01586338|9876994|FG000|Overall Study|Withdrawal by participant|3
6210912|NCT01586338|9876994|FG000|Overall Study|Other|1
6210913|NCT01586364|9876998|FG000|Overall Study|Withdrawal by Subject|40
6210914|NCT01586364|9876998|FG000|Overall Study|Adverse Event|37
6210915|NCT01586364|9876998|FG000|Overall Study|Lost to Follow-up|17
6210916|NCT01586364|9876998|FG000|Overall Study|Protocol Violation|16
6210917|NCT01586364|9876998|FG000|Overall Study|Lack of Efficacy|1
6116974|NCT00866320|9738839|FG000|Overall Study|Death|2
6116975|NCT00866333|9738848|FG000|Overall Study|Withdrawal of consent|0
6116976|NCT00866333|9738849|FG001|Overall Study|Withdrawal of consent|1
6116977|NCT00866333|9738850|FG002|Overall Study|Withdrawal of consent|2
6116978|NCT00866333|9738848|FG000|Overall Study|Reason not Specified|3
6116979|NCT00866333|9738849|FG001|Overall Study|Reason not Specified|1
6116980|NCT00866333|9738850|FG002|Overall Study|Reason not Specified|1
6116981|NCT00866333|9738848|FG000|Overall Study|Study Terminated by Sponsor|2
6116982|NCT00866333|9738849|FG001|Overall Study|Study Terminated by Sponsor|5
6116983|NCT00866333|9738850|FG002|Overall Study|Study Terminated by Sponsor|9
6116984|NCT00866359|9738860|FG000|Treatment Phase (Days 1 to 85)|Adverse Event|5
6116985|NCT00866359|9738861|FG001|Treatment Phase (Days 1 to 85)|Adverse Event|4
6116986|NCT00866359|9738862|FG002|Treatment Phase (Days 1 to 85)|Adverse Event|0
6116987|NCT00866359|9738863|FG003|Treatment Phase (Days 1 to 85)|Adverse Event|0
6116988|NCT00866359|9738860|FG000|Treatment Phase (Days 1 to 85)|Lack of Efficacy|3
6116989|NCT00866359|9738861|FG001|Treatment Phase (Days 1 to 85)|Lack of Efficacy|0
6116990|NCT00866359|9738862|FG002|Treatment Phase (Days 1 to 85)|Lack of Efficacy|0
6116991|NCT00866359|9738863|FG003|Treatment Phase (Days 1 to 85)|Lack of Efficacy|0
6116992|NCT00866359|9738860|FG000|Treatment Phase (Days 1 to 85)|Withdrawal by Subject|1
6116993|NCT00866359|9738861|FG001|Treatment Phase (Days 1 to 85)|Withdrawal by Subject|0
6116994|NCT00866359|9738862|FG002|Treatment Phase (Days 1 to 85)|Withdrawal by Subject|0
6116995|NCT00866359|9738863|FG003|Treatment Phase (Days 1 to 85)|Withdrawal by Subject|0
6116996|NCT00866359|9738860|FG000|Treatment Phase (Days 1 to 85)|Protocol Violation|1
6116997|NCT00866359|9738861|FG001|Treatment Phase (Days 1 to 85)|Protocol Violation|1
6116998|NCT00866359|9738862|FG002|Treatment Phase (Days 1 to 85)|Protocol Violation|0
6116999|NCT00866359|9738863|FG003|Treatment Phase (Days 1 to 85)|Protocol Violation|0
6117000|NCT00866359|9738860|FG000|Treatment Phase (Days 1 to 85)|Other|1
6117001|NCT00866359|9738861|FG001|Treatment Phase (Days 1 to 85)|Other|0
6117002|NCT00866359|9738862|FG002|Treatment Phase (Days 1 to 85)|Other|0
6117003|NCT00866359|9738863|FG003|Treatment Phase (Days 1 to 85)|Other|0
6117004|NCT00866359|9738860|FG000|Extension Phase (Day 86 to 169)|Adverse Event|0
6117005|NCT00866359|9738861|FG001|Extension Phase (Day 86 to 169)|Adverse Event|0
6117006|NCT00866359|9738862|FG002|Extension Phase (Day 86 to 169)|Adverse Event|1
6117007|NCT00866359|9738863|FG003|Extension Phase (Day 86 to 169)|Adverse Event|3
6117008|NCT00866606|9738890|FG000|Overall Study|Lost to Follow-up|3
6117009|NCT00866606|9738890|FG000|Overall Study|Adverse Event|1
6117010|NCT00866619|9738898|FG000|Overall Study|Adverse Event|112
6117011|NCT00866619|9738899|FG001|Overall Study|Adverse Event|106
6117012|NCT00866619|9738900|FG002|Overall Study|Adverse Event|47
6117013|NCT00866619|9738901|FG003|Overall Study|Adverse Event|44
6117014|NCT00866619|9738898|FG000|Overall Study|Protocol Violation|2
6117015|NCT00866619|9738899|FG001|Overall Study|Protocol Violation|39
6117016|NCT00866619|9738900|FG002|Overall Study|Protocol Violation|2
6117017|NCT00866619|9738901|FG003|Overall Study|Protocol Violation|17
6117018|NCT00866619|9738898|FG000|Overall Study|Withdrawal by Subject|587
6117019|NCT00866619|9738899|FG001|Overall Study|Withdrawal by Subject|295
6117020|NCT00866619|9738900|FG002|Overall Study|Withdrawal by Subject|272
6117021|NCT00866619|9738901|FG003|Overall Study|Withdrawal by Subject|144
6117022|NCT00866619|9738898|FG000|Overall Study|Lost to Follow-up|1145
6117023|NCT00866619|9738899|FG001|Overall Study|Lost to Follow-up|830
6117024|NCT00866619|9738900|FG002|Overall Study|Lost to Follow-up|568
6117025|NCT00866619|9738901|FG003|Overall Study|Lost to Follow-up|425
6117026|NCT00866658|9738938|FG000|Overall Study|Adverse Event|5
6117027|NCT00866658|9738939|FG001|Overall Study|Adverse Event|14
6117028|NCT00866658|9738938|FG000|Overall Study|Lack of Efficacy|2
6117029|NCT00866658|9738939|FG001|Overall Study|Lack of Efficacy|1
6117030|NCT00866658|9738938|FG000|Overall Study|Withdrawal by Subject|1
6117031|NCT00866658|9738939|FG001|Overall Study|Withdrawal by Subject|0
6117032|NCT00866658|9738938|FG000|Overall Study|Protocol Violation|1
6117033|NCT00866658|9738939|FG001|Overall Study|Protocol Violation|1
6210918|NCT01586364|9876998|FG000|Overall Study|Other-Did not feel better post-treatment|1
6210919|NCT01586364|9876998|FG000|Overall Study|Other-Subject wasn't getting much relief|1
6210920|NCT01586364|9876998|FG000|Overall Study|Other-Site closure due to PI illness|1
6210921|NCT01586364|9876998|FG000|Overall Study|Other-PI discretion, site closing|2
6117034|NCT00866658|9738938|FG000|Overall Study|Familial and Personal Reasons|4
6117035|NCT00866658|9738939|FG001|Overall Study|Familial and Personal Reasons|5
6117036|NCT00866697|9738947|FG000|Overall Study|Study closed/terminated|156
6117037|NCT00866697|9738948|FG001|Overall Study|Study closed/terminated|138
6117038|NCT00866697|9738947|FG000|Overall Study|Lost to Follow-up|22
6117039|NCT00866697|9738948|FG001|Overall Study|Lost to Follow-up|28
6117040|NCT00866697|9738947|FG000|Overall Study|Physician Decision|3
6117041|NCT00866697|9738948|FG001|Overall Study|Physician Decision|5
6117042|NCT00866697|9738947|FG000|Overall Study|Withdrawal by Subject|33
6117043|NCT00866697|9738948|FG001|Overall Study|Withdrawal by Subject|57
6117044|NCT00866723|9738954|FG000|Overall Study|Withdrawal by Subject|1
6117045|NCT00866723|9738954|FG000|Overall Study|Disease Progression|4
6117046|NCT00866775|9738964|FG000|Overall Study|Adverse Event|5
6117047|NCT00866775|9738965|FG001|Overall Study|Adverse Event|19
6117048|NCT00866775|9738964|FG000|Overall Study|Death|1
6117049|NCT00866775|9738965|FG001|Overall Study|Death|0
6117050|NCT00866775|9738964|FG000|Overall Study|Lost to Follow-up|0
6117051|NCT00866775|9738965|FG001|Overall Study|Lost to Follow-up|4
6117052|NCT00866775|9738964|FG000|Overall Study|Physician Decision|0
6117053|NCT00866775|9738965|FG001|Overall Study|Physician Decision|3
6117054|NCT00866775|9738964|FG000|Overall Study|Protocol Violation|3
6117055|NCT00866775|9738965|FG001|Overall Study|Protocol Violation|4
6117056|NCT00866775|9738964|FG000|Overall Study|Withdrawal by Subject|4
6117057|NCT00866775|9738965|FG001|Overall Study|Withdrawal by Subject|4
6117058|NCT00866775|9738964|FG000|Overall Study|met exit criteria|23
6117059|NCT00866775|9738965|FG001|Overall Study|met exit criteria|17
6117060|NCT00866775|9738964|FG000|Overall Study|discontinued due to communication error|0
6117061|NCT00866775|9738965|FG001|Overall Study|discontinued due to communication error|1
6117062|NCT00866788|9738977|FG000|Overall Study|Adverse Event|0
6117063|NCT00866788|9738978|FG001|Overall Study|Adverse Event|2
6117064|NCT00866788|9738979|FG002|Overall Study|Adverse Event|0
6117065|NCT00866788|9738980|FG003|Overall Study|Adverse Event|1
6117066|NCT00866788|9738977|FG000|Overall Study|Lost to Follow-up|1
6117067|NCT00866788|9738978|FG001|Overall Study|Lost to Follow-up|1
6117068|NCT00866788|9738979|FG002|Overall Study|Lost to Follow-up|0
6117069|NCT00866788|9738980|FG003|Overall Study|Lost to Follow-up|2
6117070|NCT00866788|9738977|FG000|Overall Study|Withdrawal by Subject|2
6117071|NCT00866788|9738978|FG001|Overall Study|Withdrawal by Subject|1
6117072|NCT00866788|9738979|FG002|Overall Study|Withdrawal by Subject|0
6117073|NCT00866788|9738980|FG003|Overall Study|Withdrawal by Subject|1
6117074|NCT00866788|9738977|FG000|Overall Study|Pregnancy|0
6117075|NCT00866788|9738978|FG001|Overall Study|Pregnancy|1
6117076|NCT00866788|9738979|FG002|Overall Study|Pregnancy|0
6117077|NCT00866788|9738980|FG003|Overall Study|Pregnancy|0
6117078|NCT00866788|9738977|FG000|Overall Study|Disease progression|3
6117079|NCT00866788|9738978|FG001|Overall Study|Disease progression|1
6210922|NCT01586364|9876998|FG000|Overall Study|Other-Not specified|1
6210923|NCT01586624|9877010|FG000|Overall Study|Adverse Event|3
6210924|NCT01586624|9877011|FG001|Overall Study|Adverse Event|0
6210925|NCT01586624|9877012|FG002|Overall Study|Adverse Event|2
6210926|NCT01586624|9877013|FG003|Overall Study|Adverse Event|1
6210927|NCT01586624|9877014|FG004|Overall Study|Adverse Event|3
6286930|NCT02347176|9999336|FG003|Overall Study|Lost to Follow-up|1
6286931|NCT02347176|9999333|FG000|Overall Study|Withdrawal by Subject|9
6286932|NCT02347176|9999334|FG001|Overall Study|Withdrawal by Subject|5
6286933|NCT02347176|9999335|FG002|Overall Study|Withdrawal by Subject|5
6286934|NCT02347176|9999336|FG003|Overall Study|Withdrawal by Subject|3
6286935|NCT02347176|9999333|FG000|Overall Study|Other|1
6286936|NCT02347176|9999334|FG001|Overall Study|Other|2
6286937|NCT02347176|9999335|FG002|Overall Study|Other|2
6286938|NCT02347176|9999336|FG003|Overall Study|Other|0
6286939|NCT02347189|9999346|FG000|Overall Study|No implant attempted of study device|9
6286940|NCT02347189|9999346|FG000|Overall Study|No primary outcome data available|2
6286941|NCT02347332|9999363|FG000|Overall Study|Not treated|5
6286942|NCT02347332|9999364|FG001|Overall Study|Not treated|2
6286943|NCT02347332|9999363|FG000|Overall Study|Progressive disease|141
6286944|NCT02347332|9999364|FG001|Overall Study|Progressive disease|159
6286945|NCT02347332|9999363|FG000|Overall Study|Adverse Event|50
6286946|NCT02347332|9999364|FG001|Overall Study|Adverse Event|41
6286947|NCT02347332|9999363|FG000|Overall Study|Death (Unknown, Various reasons)|6
6286948|NCT02347332|9999364|FG001|Overall Study|Death (Unknown, Various reasons)|6
6117080|NCT00866788|9738979|FG002|Overall Study|Disease progression|1
6117081|NCT00866788|9738980|FG003|Overall Study|Disease progression|0
6117082|NCT00866788|9738977|FG000|Overall Study|Physician Decision|0
6117083|NCT00866788|9738978|FG001|Overall Study|Physician Decision|0
6117084|NCT00866788|9738979|FG002|Overall Study|Physician Decision|1
6117085|NCT00866788|9738980|FG003|Overall Study|Physician Decision|1
6117086|NCT00866814|9738993|FG000|Overall Study|Lost to Follow-up|12
6117087|NCT00866814|9738993|FG000|Overall Study|Adverse Event|2
6117088|NCT00866814|9738993|FG000|Overall Study|Physician Decision|1
6117089|NCT00866814|9738993|FG000|Overall Study|Death|1
6117090|NCT00866814|9738993|FG000|Overall Study|No longer wished to participate|1
6210928|NCT01586624|9877015|FG005|Overall Study|Adverse Event|3
6210929|NCT01586624|9877016|FG006|Overall Study|Adverse Event|2
6210930|NCT01586624|9877017|FG007|Overall Study|Adverse Event|3
6210931|NCT01586624|9877010|FG000|Overall Study|Physician Decision|0
6210932|NCT01586624|9877011|FG001|Overall Study|Physician Decision|1
6210933|NCT01586624|9877012|FG002|Overall Study|Physician Decision|1
6210934|NCT01586624|9877013|FG003|Overall Study|Physician Decision|0
6210935|NCT01586624|9877014|FG004|Overall Study|Physician Decision|2
6210936|NCT01586624|9877015|FG005|Overall Study|Physician Decision|0
6210937|NCT01586624|9877016|FG006|Overall Study|Physician Decision|1
6210938|NCT01586624|9877017|FG007|Overall Study|Physician Decision|1
6210939|NCT01586624|9877010|FG000|Overall Study|Withdrawal by Subject|0
6210940|NCT01586624|9877011|FG001|Overall Study|Withdrawal by Subject|0
6210941|NCT01586624|9877012|FG002|Overall Study|Withdrawal by Subject|0
6210942|NCT01586624|9877013|FG003|Overall Study|Withdrawal by Subject|1
6210943|NCT01586624|9877014|FG004|Overall Study|Withdrawal by Subject|0
6286949|NCT02347332|9999363|FG000|Overall Study|Protocol Violation|1
6286950|NCT02347332|9999364|FG001|Overall Study|Protocol Violation|1
6286951|NCT02347332|9999363|FG000|Overall Study|Lost to Follow-up|2
6286952|NCT02347332|9999364|FG001|Overall Study|Lost to Follow-up|1
6286953|NCT02347332|9999363|FG000|Overall Study|Physician Decision|4
6117091|NCT00866814|9738993|FG000|Overall Study|Unable to meet follow-up requirements|2
6117092|NCT00866814|9738993|FG000|Overall Study|Moved to area without study site|1
6117093|NCT00867009|9739012|FG000|Induction Period|Nonserious Adverse Event|5
6117094|NCT00867009|9739012|FG000|Induction Period|Serious Adverse Event|10
6117095|NCT00867009|9739012|FG000|Induction Period|Death due to serious adverse event|6
6117096|NCT00867009|9739012|FG000|Induction Period|Death due to Study Disease|4
6117097|NCT00867009|9739012|FG000|Induction Period|Protocol Violation|1
6117098|NCT00867009|9739012|FG000|Induction Period|Withdrawal by Subject|8
6117099|NCT00867009|9739012|FG000|Induction Period|Physician Decision|3
6117100|NCT00867009|9739012|FG000|Induction Period|Progressive Disease (PD)|25
6117101|NCT00867009|9739012|FG000|Maintenance Period|On-going in the Study at Data Cut-off|4
6117102|NCT00867035|9739018|FG000|Baseline to 1 Hour|Withdrawal by Subject|1
6117103|NCT00867035|9739019|FG001|Baseline to 1 Hour|Withdrawal by Subject|1
6117104|NCT00867035|9739018|FG000|Baseline to 1 Week|Withdrawal by Subject|1
6117105|NCT00867035|9739019|FG001|Baseline to 1 Week|Withdrawal by Subject|0
6117106|NCT00867087|9739025|FG000|Overall Study|Other|1
6117107|NCT00867087|9739025|FG000|Overall Study|Withdrawal by Subject|4
6117108|NCT00867087|9739025|FG000|Overall Study|Death|37
6117109|NCT00867113|9739086|FG000|Treatment Period|Adverse Event|15
6117110|NCT00867113|9739086|FG000|Treatment Period|Death|2
6117111|NCT00867113|9739086|FG000|Treatment Period|Withdrawal by Subject|19
6117112|NCT00867113|9739086|FG000|Treatment Period|Lost to Follow-up|3
6117113|NCT00867113|9739086|FG000|Treatment Period|Administrative problems|1
6117114|NCT00867113|9739086|FG000|Treatment Period|Disease progression/relapse|1
6117115|NCT00867113|9739086|FG000|Treatment Period|Protocol Violation|4
6117116|NCT00867113|9739086|FG000|Post Treatment After Survival Follow-up|Death|1
6117117|NCT00867113|9739086|FG000|Post Treatment After Survival Follow-up|Withdrawal by Subject|1
6117118|NCT00867113|9739086|FG000|Post Treatment After Survival Follow-up|Lost to Follow-up|5
6117119|NCT00867113|9739086|FG000|Post Treatment After Survival Follow-up|Administrative problems|4
6117120|NCT00867308|9739122|FG000|Overall Study|Death|1
6117121|NCT00867308|9739123|FG001|Overall Study|Death|0
6117122|NCT00867308|9739122|FG000|Overall Study|Adverse Event|1
6117123|NCT00867308|9739123|FG001|Overall Study|Adverse Event|4
6117124|NCT00867308|9739122|FG000|Overall Study|Lack of Efficacy|6
6117125|NCT00867308|9739123|FG001|Overall Study|Lack of Efficacy|12
6117126|NCT00867308|9739122|FG000|Overall Study|Withdrawal by Subject|1
6117127|NCT00867308|9739123|FG001|Overall Study|Withdrawal by Subject|2
6117128|NCT00867334|9739131|FG000|Overall Study|Withdrawal by Subject|0
6117129|NCT00867334|9739132|FG001|Overall Study|Withdrawal by Subject|1
6117130|NCT00867334|9739131|FG000|Overall Study|Withdrawal by Subject|1
6117131|NCT00867334|9739132|FG001|Overall Study|Withdrawal by Subject|0
6117132|NCT00867334|9739131|FG000|Overall Study|Withdrawal by Subject|1
6117133|NCT00867334|9739132|FG001|Overall Study|Withdrawal by Subject|0
6117134|NCT00867360|9739140|FG000|Overall Study|Withdrawal by Subject|1
6117135|NCT00867360|9739141|FG001|Overall Study|Withdrawal by Subject|0
6117136|NCT00867360|9739140|FG000|Overall Study|Physician Decision|0
6117137|NCT00867360|9739141|FG001|Overall Study|Physician Decision|1
6117138|NCT00867490|9739161|FG000|Phase 1 - Candesartan+HCTZ|Adverse Event|5
6117139|NCT00867490|9739161|FG000|Phase 1 - Candesartan+HCTZ|Withdrawal by Subject|4
6117140|NCT00867490|9739161|FG000|Phase 1 - Candesartan+HCTZ|Administrative Problems|1
6117141|NCT00867490|9739161|FG000|Phase 2 - Aliskiren+HCTZ|Adverse Event|2
6117142|NCT00867490|9739161|FG000|Phase 2 - Aliskiren+HCTZ|Withdrawal by Subject|1
6117143|NCT00867503|9739168|FG000|Overall Study|Withdrawal by Subject|1
6117144|NCT00867815|9739192|FG000|Overall Study|Lost to Follow-up|1
6117145|NCT00868166|9739224|FG000|Overall Study|Death|58
6117146|NCT00868166|9739225|FG001|Overall Study|Death|65
6117147|NCT00868166|9739224|FG000|Overall Study|Withdrawal by Subject|33
6117148|NCT00868166|9739225|FG001|Overall Study|Withdrawal by Subject|25
6117149|NCT00868166|9739224|FG000|Overall Study|Protocol Violation|1
6117150|NCT00868166|9739225|FG001|Overall Study|Protocol Violation|0
6117151|NCT00868166|9739224|FG000|Overall Study|Lost to Follow-up|1
6117152|NCT00868166|9739225|FG001|Overall Study|Lost to Follow-up|3
6117153|NCT00868166|9739224|FG000|Overall Study|Adverse Event|9
6117154|NCT00868166|9739225|FG001|Overall Study|Adverse Event|10
6117155|NCT00868166|9739224|FG000|Overall Study|Lack of efficacy, logistics, unwell|9
6117156|NCT00868166|9739225|FG001|Overall Study|Lack of efficacy, logistics, unwell|10
6117157|NCT00868166|9739224|FG000|Overall Study|Non-compliance with IMP|1
6117158|NCT00868166|9739225|FG001|Overall Study|Non-compliance with IMP|1
6117159|NCT00868192|9739231|FG000|Overall Study|Ineligible|4
6117160|NCT00868231|9739256|FG000|Treatment Period 1|Adverse Event|0
6117161|NCT00868231|9739257|FG001|Treatment Period 1|Adverse Event|0
6117162|NCT00868231|9739258|FG002|Treatment Period 1|Adverse Event|0
6117163|NCT00868231|9739259|FG003|Treatment Period 1|Adverse Event|0
6117164|NCT00868231|9739260|FG004|Treatment Period 1|Adverse Event|1
6117165|NCT00868231|9739261|FG005|Treatment Period 1|Adverse Event|0
6117166|NCT00868231|9739256|FG000|Treatment Period 2|Adverse Event|1
6210944|NCT01586624|9877015|FG005|Overall Study|Withdrawal by Subject|0
6117167|NCT00868231|9739257|FG001|Treatment Period 2|Adverse Event|0
6117168|NCT00868231|9739258|FG002|Treatment Period 2|Adverse Event|0
6117169|NCT00868231|9739259|FG003|Treatment Period 2|Adverse Event|0
6117170|NCT00868231|9739260|FG004|Treatment Period 2|Adverse Event|0
6117171|NCT00868231|9739261|FG005|Treatment Period 2|Adverse Event|0
6117172|NCT00868231|9739256|FG000|Treatment Period 3|Adverse Event|0
6117173|NCT00868231|9739257|FG001|Treatment Period 3|Adverse Event|0
6117174|NCT00868231|9739258|FG002|Treatment Period 3|Adverse Event|1
6117175|NCT00868231|9739259|FG003|Treatment Period 3|Adverse Event|0
6210945|NCT01586624|9877016|FG006|Overall Study|Withdrawal by Subject|0
6210946|NCT01586624|9877017|FG007|Overall Study|Withdrawal by Subject|0
6210947|NCT01586624|9877010|FG000|Overall Study|Evidence of disease progression|1
6210948|NCT01586624|9877011|FG001|Overall Study|Evidence of disease progression|3
6210949|NCT01586624|9877012|FG002|Overall Study|Evidence of disease progression|2
6210950|NCT01586624|9877013|FG003|Overall Study|Evidence of disease progression|5
6210951|NCT01586624|9877014|FG004|Overall Study|Evidence of disease progression|3
6210952|NCT01586624|9877015|FG005|Overall Study|Evidence of disease progression|5
6210953|NCT01586624|9877016|FG006|Overall Study|Evidence of disease progression|4
6210954|NCT01586624|9877017|FG007|Overall Study|Evidence of disease progression|6
6210955|NCT01586624|9877010|FG000|Overall Study|Screen failure (no treatment received)|0
6210956|NCT01586624|9877011|FG001|Overall Study|Screen failure (no treatment received)|0
6210957|NCT01586624|9877012|FG002|Overall Study|Screen failure (no treatment received)|0
6210958|NCT01586624|9877013|FG003|Overall Study|Screen failure (no treatment received)|0
6210959|NCT01586624|9877014|FG004|Overall Study|Screen failure (no treatment received)|0
6210960|NCT01586624|9877015|FG005|Overall Study|Screen failure (no treatment received)|0
6210961|NCT01586624|9877016|FG006|Overall Study|Screen failure (no treatment received)|1
6210962|NCT01586624|9877017|FG007|Overall Study|Screen failure (no treatment received)|0
6210963|NCT01586806|9877052|FG000|Overall Study|Protocol Violation|0
6210964|NCT01586806|9877053|FG001|Overall Study|Protocol Violation|1
6210965|NCT01586806|9877054|FG002|Overall Study|Protocol Violation|0
6210966|NCT01586806|9877052|FG000|Overall Study|Withdrawal by Subject|1
6210967|NCT01586806|9877053|FG001|Overall Study|Withdrawal by Subject|0
6210968|NCT01586806|9877054|FG002|Overall Study|Withdrawal by Subject|0
6210969|NCT01586806|9877052|FG000|Overall Study|Lost to Follow-up|2
6210970|NCT01586806|9877053|FG001|Overall Study|Lost to Follow-up|3
6210971|NCT01586806|9877054|FG002|Overall Study|Lost to Follow-up|2
6210972|NCT01586819|9877064|FG000|Overall Study|Withdrawal by Subject|1
6210973|NCT01586819|9877065|FG001|Overall Study|Withdrawal by Subject|0
6210974|NCT01587001|9877114|FG000|Overall Study|Lost to Follow-up|2
6210975|NCT01587001|9877115|FG001|Overall Study|Lost to Follow-up|0
6117176|NCT00868231|9739260|FG004|Treatment Period 3|Adverse Event|0
6117177|NCT00868231|9739261|FG005|Treatment Period 3|Adverse Event|0
6117178|NCT00868296|9739271|FG000|Overall Study|Adverse Event|0
6117179|NCT00868296|9739272|FG001|Overall Study|Adverse Event|2
6117180|NCT00868296|9739271|FG000|Overall Study|Withdrawal by Subject|0
6117181|NCT00868296|9739272|FG001|Overall Study|Withdrawal by Subject|1
6117182|NCT00868439|9739307|FG000|Overall Study|Adverse Event|4
6117183|NCT00868439|9739308|FG001|Overall Study|Adverse Event|3
6117184|NCT00868439|9739307|FG000|Overall Study|Prot-Specified W/D Criteria (Serum K+)|2
6117185|NCT00868439|9739308|FG001|Overall Study|Prot-Specified W/D Criteria (Serum K+)|3
6117186|NCT00868439|9739307|FG000|Overall Study|Death|0
6117187|NCT00868439|9739308|FG001|Overall Study|Death|1
6117188|NCT00868439|9739307|FG000|Overall Study|Protocol Violation|1
6210976|NCT01587001|9877114|FG000|Overall Study|Insufficient samples to complete testing|4
6210977|NCT01587001|9877115|FG001|Overall Study|Insufficient samples to complete testing|1
6210978|NCT01587014|9877122|FG000|Overall Study|Death|2
6210979|NCT01587079|9877135|FG000|Overall Study|Protocol-specified criteria|9
6210980|NCT01587079|9877135|FG000|Overall Study|Protocol Violation|5
6210981|NCT01587079|9877135|FG000|Overall Study|Lost to Follow-up|2
6210982|NCT01587079|9877135|FG000|Overall Study|Physician Decision|2
6210983|NCT01587079|9877135|FG000|Overall Study|Withdrawal by Subject|7
6210984|NCT01587079|9877135|FG000|Overall Study|Adverse Event|14
6210985|NCT01587118|9877178|FG000|Overall Study|Adverse Event|3
6210986|NCT01587118|9877178|FG000|Overall Study|Lost to Follow-up|2
6210987|NCT01587118|9877178|FG000|Overall Study|Relocation|1
6210988|NCT01587118|9877178|FG000|Overall Study|nonresponse|1
6210989|NCT01587274|9877185|FG000|Overall Study|Lost to Follow-up|4
6210990|NCT01587274|9877186|FG001|Overall Study|Lost to Follow-up|5
6210991|NCT01587274|9877187|FG002|Overall Study|Lost to Follow-up|3
6210992|NCT01587651|9877198|FG000|Overall Study|Adverse Event|0
6210993|NCT01587651|9877199|FG001|Overall Study|Adverse Event|1
6210994|NCT01587651|9877200|FG002|Overall Study|Adverse Event|0
6210995|NCT01587651|9877198|FG000|Overall Study|Protocol Violation|0
6210996|NCT01587651|9877199|FG001|Overall Study|Protocol Violation|1
6210997|NCT01587651|9877200|FG002|Overall Study|Protocol Violation|1
6210998|NCT01587651|9877198|FG000|Overall Study|Withdrawal by Subject|0
6210999|NCT01587651|9877199|FG001|Overall Study|Withdrawal by Subject|1
6211000|NCT01587651|9877200|FG002|Overall Study|Withdrawal by Subject|0
6211001|NCT01587703|9877227|FG000|Part1 QD(Median Exposure of 1.38months)|Physician Decision|1
6211002|NCT01587703|9877228|FG001|Part1 QD(Median Exposure of 1.38months)|Physician Decision|0
6211003|NCT01587703|9877229|FG002|Part1 QD(Median Exposure of 1.38months)|Physician Decision|0
6211004|NCT01587703|9877230|FG003|Part1 QD(Median Exposure of 1.38months)|Physician Decision|0
6117189|NCT00868439|9739308|FG001|Overall Study|Protocol Violation|1
6117190|NCT00868439|9739307|FG000|Overall Study|Physician Decision|1
6117191|NCT00868439|9739308|FG001|Overall Study|Physician Decision|0
6117192|NCT00868439|9739307|FG000|Overall Study|Withdrawal by Subject|0
6117193|NCT00868439|9739308|FG001|Overall Study|Withdrawal by Subject|1
6117194|NCT00868517|9739327|FG000|Overall Study|Withdrawal by Subject|3
6117195|NCT00868517|9739328|FG001|Overall Study|Withdrawal by Subject|3
6117196|NCT00868517|9739329|FG002|Overall Study|Withdrawal by Subject|2
6117197|NCT00868517|9739327|FG000|Overall Study|Protocol Violation|1
6117198|NCT00868517|9739328|FG001|Overall Study|Protocol Violation|1
6117199|NCT00868517|9739329|FG002|Overall Study|Protocol Violation|0
6117200|NCT00868530|9739337|FG000|Overall Study|Adverse Event|3
6117201|NCT00868530|9739337|FG000|Overall Study|Lost to Follow-up|1
6117202|NCT00868608|9739344|FG000|Overall Study|Withdrawal by Subject|3
6117203|NCT00868608|9739345|FG001|Overall Study|Withdrawal by Subject|1
6117204|NCT00868608|9739346|FG002|Overall Study|Withdrawal by Subject|0
6117205|NCT00868608|9739344|FG000|Overall Study|Lost to Follow-up|3
6117206|NCT00868608|9739345|FG001|Overall Study|Lost to Follow-up|0
6117207|NCT00868608|9739346|FG002|Overall Study|Lost to Follow-up|1
6117208|NCT00868608|9739344|FG000|Overall Study|Death|16
6117209|NCT00868608|9739345|FG001|Overall Study|Death|2
6117210|NCT00868608|9739346|FG002|Overall Study|Death|4
6117211|NCT00868608|9739344|FG000|Overall Study|Other - Unspecified|1
6117212|NCT00868608|9739345|FG001|Overall Study|Other - Unspecified|0
6117213|NCT00868608|9739346|FG002|Overall Study|Other - Unspecified|0
6117214|NCT00868790|9739384|FG000|Period 1|Adverse Event|1
6117215|NCT00868790|9739385|FG001|Period 1|Adverse Event|0
6117216|NCT00868790|9739386|FG002|Period 1|Adverse Event|0
6117217|NCT00868790|9739387|FG003|Period 1|Adverse Event|0
6117218|NCT00868790|9739388|FG004|Period 1|Adverse Event|0
6117219|NCT00868790|9739389|FG005|Period 1|Adverse Event|0
6117220|NCT00868790|9739390|FG006|Period 1|Adverse Event|0
6117221|NCT00868790|9739391|FG007|Period 1|Adverse Event|3
6117222|NCT00868790|9739392|FG008|Period 1|Adverse Event|1
6117223|NCT00868790|9739393|FG009|Period 1|Adverse Event|0
6117224|NCT00868790|9739394|FG010|Period 1|Adverse Event|0
6117225|NCT00868790|9739395|FG011|Period 1|Adverse Event|0
6117226|NCT00868790|9739396|FG012|Period 1|Adverse Event|0
6117227|NCT00868790|9739397|FG013|Period 1|Adverse Event|1
6117228|NCT00868790|9739384|FG000|Period 1|Protocol Violation|1
6117229|NCT00868790|9739385|FG001|Period 1|Protocol Violation|0
6117230|NCT00868790|9739386|FG002|Period 1|Protocol Violation|0
6117231|NCT00868790|9739387|FG003|Period 1|Protocol Violation|0
6117232|NCT00868790|9739388|FG004|Period 1|Protocol Violation|0
6117233|NCT00868790|9739389|FG005|Period 1|Protocol Violation|0
6211005|NCT01587703|9877231|FG004|Part1 QD(Median Exposure of 1.38months)|Physician Decision|0
6211006|NCT01587703|9877232|FG005|Part1 QD(Median Exposure of 1.38months)|Physician Decision|0
6211007|NCT01587703|9877233|FG006|Part1 QD(Median Exposure of 1.38months)|Physician Decision|0
6211008|NCT01587703|9877234|FG007|Part1 QD(Median Exposure of 1.38months)|Physician Decision|0
6211009|NCT01587703|9877235|FG008|Part1 QD(Median Exposure of 1.38months)|Physician Decision|0
6211010|NCT01587703|9877236|FG009|Part1 QD(Median Exposure of 1.38months)|Physician Decision|0
6211011|NCT01587703|9877237|FG010|Part1 QD(Median Exposure of 1.38months)|Physician Decision|0
6211012|NCT01587703|9877238|FG011|Part1 QD(Median Exposure of 1.38months)|Physician Decision|0
6211013|NCT01587703|9877239|FG012|Part1 QD(Median Exposure of 1.38months)|Physician Decision|0
6211014|NCT01587703|9877240|FG013|Part1 QD(Median Exposure of 1.38months)|Physician Decision|0
6211015|NCT01587703|9877241|FG014|Part1 QD(Median Exposure of 1.38months)|Physician Decision|0
6211016|NCT01587703|9877242|FG015|Part1 QD(Median Exposure of 1.38months)|Physician Decision|0
6211017|NCT01587703|9877243|FG016|Part1 QD(Median Exposure of 1.38months)|Physician Decision|0
6211018|NCT01587703|9877244|FG017|Part1 QD(Median Exposure of 1.38months)|Physician Decision|0
6211019|NCT01587703|9877245|FG018|Part1 QD(Median Exposure of 1.38months)|Physician Decision|0
6211020|NCT01587703|9877227|FG000|Part1 QD(Median Exposure of 1.38months)|Lost to Follow-up|0
6211021|NCT01587703|9877228|FG001|Part1 QD(Median Exposure of 1.38months)|Lost to Follow-up|0
6211022|NCT01587703|9877229|FG002|Part1 QD(Median Exposure of 1.38months)|Lost to Follow-up|0
6211023|NCT01587703|9877230|FG003|Part1 QD(Median Exposure of 1.38months)|Lost to Follow-up|0
6211024|NCT01587703|9877231|FG004|Part1 QD(Median Exposure of 1.38months)|Lost to Follow-up|0
6211025|NCT01587703|9877232|FG005|Part1 QD(Median Exposure of 1.38months)|Lost to Follow-up|1
6211026|NCT01587703|9877233|FG006|Part1 QD(Median Exposure of 1.38months)|Lost to Follow-up|0
6211027|NCT01587703|9877234|FG007|Part1 QD(Median Exposure of 1.38months)|Lost to Follow-up|2
6211028|NCT01587703|9877235|FG008|Part1 QD(Median Exposure of 1.38months)|Lost to Follow-up|0
6211029|NCT01587703|9877236|FG009|Part1 QD(Median Exposure of 1.38months)|Lost to Follow-up|0
6211030|NCT01587703|9877237|FG010|Part1 QD(Median Exposure of 1.38months)|Lost to Follow-up|0
6211031|NCT01587703|9877238|FG011|Part1 QD(Median Exposure of 1.38months)|Lost to Follow-up|0
6211032|NCT01587703|9877239|FG012|Part1 QD(Median Exposure of 1.38months)|Lost to Follow-up|0
6117234|NCT00868790|9739390|FG006|Period 1|Protocol Violation|0
6117235|NCT00868790|9739391|FG007|Period 1|Protocol Violation|0
6117236|NCT00868790|9739392|FG008|Period 1|Protocol Violation|0
6117237|NCT00868790|9739393|FG009|Period 1|Protocol Violation|0
6117238|NCT00868790|9739394|FG010|Period 1|Protocol Violation|0
6117239|NCT00868790|9739395|FG011|Period 1|Protocol Violation|0
6117240|NCT00868790|9739396|FG012|Period 1|Protocol Violation|0
6117241|NCT00868790|9739397|FG013|Period 1|Protocol Violation|0
6117242|NCT00868790|9739384|FG000|Period 1|Withdrawal by Subject|0
6117243|NCT00868790|9739385|FG001|Period 1|Withdrawal by Subject|1
6117244|NCT00868790|9739386|FG002|Period 1|Withdrawal by Subject|0
6117245|NCT00868790|9739387|FG003|Period 1|Withdrawal by Subject|0
6117246|NCT00868790|9739388|FG004|Period 1|Withdrawal by Subject|0
6117247|NCT00868790|9739389|FG005|Period 1|Withdrawal by Subject|0
6117248|NCT00868790|9739390|FG006|Period 1|Withdrawal by Subject|0
6117249|NCT00868790|9739391|FG007|Period 1|Withdrawal by Subject|0
6117250|NCT00868790|9739392|FG008|Period 1|Withdrawal by Subject|0
6117251|NCT00868790|9739393|FG009|Period 1|Withdrawal by Subject|0
6117252|NCT00868790|9739394|FG010|Period 1|Withdrawal by Subject|0
6117253|NCT00868790|9739395|FG011|Period 1|Withdrawal by Subject|0
6117254|NCT00868790|9739396|FG012|Period 1|Withdrawal by Subject|0
6117255|NCT00868790|9739397|FG013|Period 1|Withdrawal by Subject|1
6117256|NCT00868790|9739384|FG000|Period 1|Abnormal Triglycerides|0
6117257|NCT00868790|9739385|FG001|Period 1|Abnormal Triglycerides|0
6117258|NCT00868790|9739386|FG002|Period 1|Abnormal Triglycerides|0
6117259|NCT00868790|9739387|FG003|Period 1|Abnormal Triglycerides|0
6117260|NCT00868790|9739388|FG004|Period 1|Abnormal Triglycerides|1
6117261|NCT00868790|9739389|FG005|Period 1|Abnormal Triglycerides|0
6117262|NCT00868790|9739390|FG006|Period 1|Abnormal Triglycerides|0
6117263|NCT00868790|9739391|FG007|Period 1|Abnormal Triglycerides|0
6117264|NCT00868790|9739392|FG008|Period 1|Abnormal Triglycerides|0
6117265|NCT00868790|9739393|FG009|Period 1|Abnormal Triglycerides|0
6117266|NCT00868790|9739394|FG010|Period 1|Abnormal Triglycerides|0
6117267|NCT00868790|9739395|FG011|Period 1|Abnormal Triglycerides|0
6117268|NCT00868790|9739396|FG012|Period 1|Abnormal Triglycerides|0
6117269|NCT00868790|9739397|FG013|Period 1|Abnormal Triglycerides|0
6117270|NCT00868790|9739384|FG000|Period 1|Lost to Follow-up|0
6117271|NCT00868790|9739385|FG001|Period 1|Lost to Follow-up|0
6117272|NCT00868790|9739386|FG002|Period 1|Lost to Follow-up|0
6117273|NCT00868790|9739387|FG003|Period 1|Lost to Follow-up|0
6117274|NCT00868790|9739388|FG004|Period 1|Lost to Follow-up|0
6117275|NCT00868790|9739389|FG005|Period 1|Lost to Follow-up|1
6117276|NCT00868790|9739390|FG006|Period 1|Lost to Follow-up|0
6117277|NCT00868790|9739391|FG007|Period 1|Lost to Follow-up|0
6117278|NCT00868790|9739392|FG008|Period 1|Lost to Follow-up|0
6117279|NCT00868790|9739393|FG009|Period 1|Lost to Follow-up|0
6117280|NCT00868790|9739394|FG010|Period 1|Lost to Follow-up|0
6117281|NCT00868790|9739395|FG011|Period 1|Lost to Follow-up|0
6117282|NCT00868790|9739396|FG012|Period 1|Lost to Follow-up|0
6117283|NCT00868790|9739397|FG013|Period 1|Lost to Follow-up|0
6117284|NCT00868790|9739384|FG000|Period 2|Adverse Event|0
6117285|NCT00868790|9739385|FG001|Period 2|Adverse Event|0
6117286|NCT00868790|9739386|FG002|Period 2|Adverse Event|0
6117287|NCT00868790|9739387|FG003|Period 2|Adverse Event|0
6117288|NCT00868790|9739388|FG004|Period 2|Adverse Event|0
6117289|NCT00868790|9739389|FG005|Period 2|Adverse Event|0
6117290|NCT00868790|9739390|FG006|Period 2|Adverse Event|0
6117291|NCT00868790|9739391|FG007|Period 2|Adverse Event|0
6117292|NCT00868790|9739392|FG008|Period 2|Adverse Event|1
6117293|NCT00868790|9739393|FG009|Period 2|Adverse Event|0
6211033|NCT01587703|9877240|FG013|Part1 QD(Median Exposure of 1.38months)|Lost to Follow-up|0
6211034|NCT01587703|9877241|FG014|Part1 QD(Median Exposure of 1.38months)|Lost to Follow-up|0
6211035|NCT01587703|9877242|FG015|Part1 QD(Median Exposure of 1.38months)|Lost to Follow-up|0
6211036|NCT01587703|9877243|FG016|Part1 QD(Median Exposure of 1.38months)|Lost to Follow-up|0
6211037|NCT01587703|9877244|FG017|Part1 QD(Median Exposure of 1.38months)|Lost to Follow-up|0
6211038|NCT01587703|9877245|FG018|Part1 QD(Median Exposure of 1.38months)|Lost to Follow-up|0
6211039|NCT01587703|9877227|FG000|Part1 QD(Median Exposure of 1.38months)|Site closed|0
6211040|NCT01587703|9877228|FG001|Part1 QD(Median Exposure of 1.38months)|Site closed|0
6211041|NCT01587703|9877229|FG002|Part1 QD(Median Exposure of 1.38months)|Site closed|0
6211042|NCT01587703|9877230|FG003|Part1 QD(Median Exposure of 1.38months)|Site closed|0
6211043|NCT01587703|9877231|FG004|Part1 QD(Median Exposure of 1.38months)|Site closed|0
6211044|NCT01587703|9877232|FG005|Part1 QD(Median Exposure of 1.38months)|Site closed|0
6211045|NCT01587703|9877233|FG006|Part1 QD(Median Exposure of 1.38months)|Site closed|2
6211046|NCT01587703|9877234|FG007|Part1 QD(Median Exposure of 1.38months)|Site closed|0
6211047|NCT01587703|9877235|FG008|Part1 QD(Median Exposure of 1.38months)|Site closed|0
6211048|NCT01587703|9877236|FG009|Part1 QD(Median Exposure of 1.38months)|Site closed|0
6211049|NCT01587703|9877237|FG010|Part1 QD(Median Exposure of 1.38months)|Site closed|0
6211050|NCT01587703|9877238|FG011|Part1 QD(Median Exposure of 1.38months)|Site closed|0
6211051|NCT01587703|9877239|FG012|Part1 QD(Median Exposure of 1.38months)|Site closed|0
6211052|NCT01587703|9877240|FG013|Part1 QD(Median Exposure of 1.38months)|Site closed|0
6211053|NCT01587703|9877241|FG014|Part1 QD(Median Exposure of 1.38months)|Site closed|0
6211054|NCT01587703|9877242|FG015|Part1 QD(Median Exposure of 1.38months)|Site closed|0
6211055|NCT01587703|9877243|FG016|Part1 QD(Median Exposure of 1.38months)|Site closed|0
6211056|NCT01587703|9877244|FG017|Part1 QD(Median Exposure of 1.38months)|Site closed|0
6211057|NCT01587703|9877245|FG018|Part1 QD(Median Exposure of 1.38months)|Site closed|0
6211058|NCT01587703|9877227|FG000|Part1 QD(Median Exposure of 1.38months)|Death|2
6117294|NCT00868790|9739394|FG010|Period 2|Adverse Event|0
6117295|NCT00868790|9739395|FG011|Period 2|Adverse Event|0
6117296|NCT00868790|9739396|FG012|Period 2|Adverse Event|0
6117297|NCT00868790|9739397|FG013|Period 2|Adverse Event|0
6117298|NCT00868790|9739384|FG000|Period 2|Lost to Follow-up|0
6117299|NCT00868790|9739385|FG001|Period 2|Lost to Follow-up|1
6117300|NCT00868790|9739386|FG002|Period 2|Lost to Follow-up|0
6117301|NCT00868790|9739387|FG003|Period 2|Lost to Follow-up|0
6117302|NCT00868790|9739388|FG004|Period 2|Lost to Follow-up|0
6117303|NCT00868790|9739389|FG005|Period 2|Lost to Follow-up|1
6117304|NCT00868790|9739390|FG006|Period 2|Lost to Follow-up|0
6117305|NCT00868790|9739391|FG007|Period 2|Lost to Follow-up|0
6117306|NCT00868790|9739392|FG008|Period 2|Lost to Follow-up|0
6117307|NCT00868790|9739393|FG009|Period 2|Lost to Follow-up|0
6117308|NCT00868790|9739394|FG010|Period 2|Lost to Follow-up|0
6117309|NCT00868790|9739395|FG011|Period 2|Lost to Follow-up|0
6117310|NCT00868790|9739396|FG012|Period 2|Lost to Follow-up|0
6117311|NCT00868790|9739397|FG013|Period 2|Lost to Follow-up|0
6117312|NCT00868790|9739384|FG000|Period 2|Withdrawal by Subject|0
6117313|NCT00868790|9739385|FG001|Period 2|Withdrawal by Subject|0
6117314|NCT00868790|9739386|FG002|Period 2|Withdrawal by Subject|0
6117315|NCT00868790|9739387|FG003|Period 2|Withdrawal by Subject|0
6117316|NCT00868790|9739388|FG004|Period 2|Withdrawal by Subject|0
6117317|NCT00868790|9739389|FG005|Period 2|Withdrawal by Subject|0
6117318|NCT00868790|9739390|FG006|Period 2|Withdrawal by Subject|0
6117319|NCT00868790|9739391|FG007|Period 2|Withdrawal by Subject|0
6117320|NCT00868790|9739392|FG008|Period 2|Withdrawal by Subject|1
6117321|NCT00868790|9739393|FG009|Period 2|Withdrawal by Subject|0
6117322|NCT00868790|9739394|FG010|Period 2|Withdrawal by Subject|0
6117323|NCT00868790|9739395|FG011|Period 2|Withdrawal by Subject|0
6117324|NCT00868790|9739396|FG012|Period 2|Withdrawal by Subject|0
6117325|NCT00868790|9739397|FG013|Period 2|Withdrawal by Subject|1
6117326|NCT00868790|9739384|FG000|Period 3|Adverse Event|0
6117327|NCT00868790|9739385|FG001|Period 3|Adverse Event|0
6117328|NCT00868790|9739386|FG002|Period 3|Adverse Event|0
6117329|NCT00868790|9739387|FG003|Period 3|Adverse Event|0
6117330|NCT00868790|9739388|FG004|Period 3|Adverse Event|0
6117331|NCT00868790|9739389|FG005|Period 3|Adverse Event|0
6117332|NCT00868790|9739390|FG006|Period 3|Adverse Event|0
6117333|NCT00868790|9739391|FG007|Period 3|Adverse Event|0
6117334|NCT00868790|9739392|FG008|Period 3|Adverse Event|0
6117335|NCT00868790|9739393|FG009|Period 3|Adverse Event|1
6117336|NCT00868790|9739394|FG010|Period 3|Adverse Event|0
6117337|NCT00868790|9739395|FG011|Period 3|Adverse Event|0
6117338|NCT00868790|9739396|FG012|Period 3|Adverse Event|0
6117339|NCT00868790|9739397|FG013|Period 3|Adverse Event|0
6117340|NCT00868790|9739384|FG000|Period 3|Protocol Violation|0
6117341|NCT00868790|9739385|FG001|Period 3|Protocol Violation|0
6117342|NCT00868790|9739386|FG002|Period 3|Protocol Violation|0
6117343|NCT00868790|9739387|FG003|Period 3|Protocol Violation|0
6117344|NCT00868790|9739388|FG004|Period 3|Protocol Violation|0
6117345|NCT00868790|9739389|FG005|Period 3|Protocol Violation|0
6117346|NCT00868790|9739390|FG006|Period 3|Protocol Violation|0
6117347|NCT00868790|9739391|FG007|Period 3|Protocol Violation|0
6117348|NCT00868790|9739392|FG008|Period 3|Protocol Violation|0
6117349|NCT00868790|9739393|FG009|Period 3|Protocol Violation|0
6117350|NCT00868790|9739394|FG010|Period 3|Protocol Violation|1
6117351|NCT00868790|9739395|FG011|Period 3|Protocol Violation|0
6117352|NCT00868790|9739396|FG012|Period 3|Protocol Violation|0
6117353|NCT00868790|9739397|FG013|Period 3|Protocol Violation|0
6117354|NCT00868790|9739384|FG000|Period 3|Study Terminated by Sponsor|0
6117355|NCT00868790|9739385|FG001|Period 3|Study Terminated by Sponsor|0
6117356|NCT00868790|9739386|FG002|Period 3|Study Terminated by Sponsor|0
6117357|NCT00868790|9739387|FG003|Period 3|Study Terminated by Sponsor|1
6117358|NCT00868790|9739388|FG004|Period 3|Study Terminated by Sponsor|0
6117359|NCT00868790|9739389|FG005|Period 3|Study Terminated by Sponsor|0
6117360|NCT00868790|9739390|FG006|Period 3|Study Terminated by Sponsor|0
6117361|NCT00868790|9739391|FG007|Period 3|Study Terminated by Sponsor|0
6211059|NCT01587703|9877228|FG001|Part1 QD(Median Exposure of 1.38months)|Death|4
6211060|NCT01587703|9877229|FG002|Part1 QD(Median Exposure of 1.38months)|Death|1
6211061|NCT01587703|9877230|FG003|Part1 QD(Median Exposure of 1.38months)|Death|3
6211062|NCT01587703|9877231|FG004|Part1 QD(Median Exposure of 1.38months)|Death|4
6211063|NCT01587703|9877232|FG005|Part1 QD(Median Exposure of 1.38months)|Death|7
6211064|NCT01587703|9877233|FG006|Part1 QD(Median Exposure of 1.38months)|Death|30
6117362|NCT00868790|9739392|FG008|Period 3|Study Terminated by Sponsor|0
6117363|NCT00868790|9739393|FG009|Period 3|Study Terminated by Sponsor|0
6117364|NCT00868790|9739394|FG010|Period 3|Study Terminated by Sponsor|0
6117365|NCT00868790|9739395|FG011|Period 3|Study Terminated by Sponsor|0
6117366|NCT00868790|9739396|FG012|Period 3|Study Terminated by Sponsor|0
6117367|NCT00868790|9739397|FG013|Period 3|Study Terminated by Sponsor|0
6117368|NCT00868790|9739384|FG000|Period 4|Adverse Event|0
6117369|NCT00868790|9739385|FG001|Period 4|Adverse Event|0
6117370|NCT00868790|9739386|FG002|Period 4|Adverse Event|0
6117371|NCT00868790|9739387|FG003|Period 4|Adverse Event|0
6117372|NCT00868790|9739388|FG004|Period 4|Adverse Event|0
6117373|NCT00868790|9739389|FG005|Period 4|Adverse Event|0
6117374|NCT00868790|9739390|FG006|Period 4|Adverse Event|0
6117375|NCT00868790|9739391|FG007|Period 4|Adverse Event|1
6117376|NCT00868790|9739392|FG008|Period 4|Adverse Event|0
6117377|NCT00868790|9739393|FG009|Period 4|Adverse Event|0
6117378|NCT00868790|9739394|FG010|Period 4|Adverse Event|1
6117379|NCT00868790|9739395|FG011|Period 4|Adverse Event|0
6117380|NCT00868790|9739396|FG012|Period 4|Adverse Event|1
6117381|NCT00868790|9739397|FG013|Period 4|Adverse Event|0
6117382|NCT00868790|9739384|FG000|Period 4|Lost to Follow-up|0
6117383|NCT00868790|9739385|FG001|Period 4|Lost to Follow-up|0
6117384|NCT00868790|9739386|FG002|Period 4|Lost to Follow-up|0
6117385|NCT00868790|9739387|FG003|Period 4|Lost to Follow-up|0
6117386|NCT00868790|9739388|FG004|Period 4|Lost to Follow-up|0
6117387|NCT00868790|9739389|FG005|Period 4|Lost to Follow-up|0
6117388|NCT00868790|9739390|FG006|Period 4|Lost to Follow-up|0
6117389|NCT00868790|9739391|FG007|Period 4|Lost to Follow-up|1
6117390|NCT00868790|9739392|FG008|Period 4|Lost to Follow-up|0
6117391|NCT00868790|9739393|FG009|Period 4|Lost to Follow-up|0
6117392|NCT00868790|9739394|FG010|Period 4|Lost to Follow-up|0
6117393|NCT00868790|9739395|FG011|Period 4|Lost to Follow-up|0
6117394|NCT00868790|9739396|FG012|Period 4|Lost to Follow-up|0
6117395|NCT00868790|9739397|FG013|Period 4|Lost to Follow-up|0
6117396|NCT00868790|9739384|FG000|Period 4|Study Terminated by Sponsor|2
6117397|NCT00868790|9739385|FG001|Period 4|Study Terminated by Sponsor|0
6117398|NCT00868790|9739386|FG002|Period 4|Study Terminated by Sponsor|0
6117399|NCT00868790|9739387|FG003|Period 4|Study Terminated by Sponsor|0
6117400|NCT00868790|9739388|FG004|Period 4|Study Terminated by Sponsor|0
6117401|NCT00868790|9739389|FG005|Period 4|Study Terminated by Sponsor|0
6117402|NCT00868790|9739390|FG006|Period 4|Study Terminated by Sponsor|0
6117403|NCT00868790|9739391|FG007|Period 4|Study Terminated by Sponsor|1
6117404|NCT00868790|9739392|FG008|Period 4|Study Terminated by Sponsor|2
6117405|NCT00868790|9739393|FG009|Period 4|Study Terminated by Sponsor|0
6117406|NCT00868790|9739394|FG010|Period 4|Study Terminated by Sponsor|2
6117407|NCT00868790|9739395|FG011|Period 4|Study Terminated by Sponsor|1
6117408|NCT00868790|9739396|FG012|Period 4|Study Terminated by Sponsor|0
6117409|NCT00868790|9739397|FG013|Period 4|Study Terminated by Sponsor|1
6117410|NCT00868790|9739384|FG000|Period 4|Abnormal ALT/AST|0
6117411|NCT00868790|9739385|FG001|Period 4|Abnormal ALT/AST|0
6117412|NCT00868790|9739386|FG002|Period 4|Abnormal ALT/AST|1
6117413|NCT00868790|9739387|FG003|Period 4|Abnormal ALT/AST|0
6117414|NCT00868790|9739388|FG004|Period 4|Abnormal ALT/AST|0
6117415|NCT00868790|9739389|FG005|Period 4|Abnormal ALT/AST|0
6117416|NCT00868790|9739390|FG006|Period 4|Abnormal ALT/AST|0
6117417|NCT00868790|9739391|FG007|Period 4|Abnormal ALT/AST|0
6117418|NCT00868790|9739392|FG008|Period 4|Abnormal ALT/AST|0
6117419|NCT00868790|9739393|FG009|Period 4|Abnormal ALT/AST|0
6117420|NCT00868790|9739394|FG010|Period 4|Abnormal ALT/AST|0
6117421|NCT00868790|9739395|FG011|Period 4|Abnormal ALT/AST|0
6117422|NCT00868790|9739396|FG012|Period 4|Abnormal ALT/AST|0
6117423|NCT00868790|9739397|FG013|Period 4|Abnormal ALT/AST|0
6117424|NCT00868790|9739384|FG000|Post-study|Withdrawal by Subject|0
6117425|NCT00868790|9739385|FG001|Post-study|Withdrawal by Subject|0
6117426|NCT00868790|9739386|FG002|Post-study|Withdrawal by Subject|0
6117427|NCT00868790|9739387|FG003|Post-study|Withdrawal by Subject|0
6117428|NCT00868790|9739388|FG004|Post-study|Withdrawal by Subject|1
6117429|NCT00868790|9739389|FG005|Post-study|Withdrawal by Subject|0
6117430|NCT00868790|9739390|FG006|Post-study|Withdrawal by Subject|0
6117431|NCT00868790|9739391|FG007|Post-study|Withdrawal by Subject|0
6117432|NCT00868790|9739392|FG008|Post-study|Withdrawal by Subject|0
6117433|NCT00868790|9739393|FG009|Post-study|Withdrawal by Subject|0
6117434|NCT00868790|9739394|FG010|Post-study|Withdrawal by Subject|0
6117435|NCT00868790|9739395|FG011|Post-study|Withdrawal by Subject|0
6117436|NCT00868790|9739396|FG012|Post-study|Withdrawal by Subject|0
6117437|NCT00868790|9739397|FG013|Post-study|Withdrawal by Subject|0
6117438|NCT00868790|9739384|FG000|Post-study|Excluded Medication|0
6117439|NCT00868790|9739385|FG001|Post-study|Excluded Medication|0
6117440|NCT00868790|9739386|FG002|Post-study|Excluded Medication|0
6117441|NCT00868790|9739387|FG003|Post-study|Excluded Medication|0
6117442|NCT00868790|9739388|FG004|Post-study|Excluded Medication|0
6117443|NCT00868790|9739389|FG005|Post-study|Excluded Medication|0
6117444|NCT00868790|9739390|FG006|Post-study|Excluded Medication|0
6117445|NCT00868790|9739391|FG007|Post-study|Excluded Medication|2
6117446|NCT00868790|9739392|FG008|Post-study|Excluded Medication|0
6211065|NCT01587703|9877234|FG007|Part1 QD(Median Exposure of 1.38months)|Death|7
6211066|NCT01587703|9877235|FG008|Part1 QD(Median Exposure of 1.38months)|Death|0
6211067|NCT01587703|9877236|FG009|Part1 QD(Median Exposure of 1.38months)|Death|0
6211068|NCT01587703|9877237|FG010|Part1 QD(Median Exposure of 1.38months)|Death|0
6211069|NCT01587703|9877238|FG011|Part1 QD(Median Exposure of 1.38months)|Death|0
6211070|NCT01587703|9877239|FG012|Part1 QD(Median Exposure of 1.38months)|Death|0
6211071|NCT01587703|9877240|FG013|Part1 QD(Median Exposure of 1.38months)|Death|0
6211072|NCT01587703|9877241|FG014|Part1 QD(Median Exposure of 1.38months)|Death|0
6211073|NCT01587703|9877242|FG015|Part1 QD(Median Exposure of 1.38months)|Death|0
6211074|NCT01587703|9877243|FG016|Part1 QD(Median Exposure of 1.38months)|Death|0
6211075|NCT01587703|9877244|FG017|Part1 QD(Median Exposure of 1.38months)|Death|0
6117447|NCT00868790|9739393|FG009|Post-study|Excluded Medication|1
6117448|NCT00868790|9739394|FG010|Post-study|Excluded Medication|0
6117449|NCT00868790|9739395|FG011|Post-study|Excluded Medication|0
6117450|NCT00868790|9739396|FG012|Post-study|Excluded Medication|0
6117451|NCT00868790|9739397|FG013|Post-study|Excluded Medication|0
6117452|NCT00869024|9739419|FG000|Overall Study|Death|2
6211076|NCT01587703|9877245|FG018|Part1 QD(Median Exposure of 1.38months)|Death|0
6117453|NCT00869024|9739420|FG001|Overall Study|Death|3
6117454|NCT00869024|9739419|FG000|Overall Study|Lost to Follow-up|0
6117455|NCT00869024|9739420|FG001|Overall Study|Lost to Follow-up|1
6117456|NCT00869024|9739419|FG000|Overall Study|Protocol Violation|0
6117457|NCT00869024|9739420|FG001|Overall Study|Protocol Violation|1
6117458|NCT00869050|9739426|FG000|Overall Study|Screen Failure|3
6117459|NCT00869089|9739430|FG000|Overall Study|Lost to Follow-up|1
6211077|NCT01587703|9877227|FG000|Part1 BID(Median Exposure of 1.41months)|Death|0
6211078|NCT01587703|9877228|FG001|Part1 BID(Median Exposure of 1.41months)|Death|0
6211079|NCT01587703|9877229|FG002|Part1 BID(Median Exposure of 1.41months)|Death|0
6211080|NCT01587703|9877230|FG003|Part1 BID(Median Exposure of 1.41months)|Death|0
6211081|NCT01587703|9877231|FG004|Part1 BID(Median Exposure of 1.41months)|Death|0
6211082|NCT01587703|9877232|FG005|Part1 BID(Median Exposure of 1.41months)|Death|0
6211083|NCT01587703|9877233|FG006|Part1 BID(Median Exposure of 1.41months)|Death|0
6211084|NCT01587703|9877234|FG007|Part1 BID(Median Exposure of 1.41months)|Death|0
6211085|NCT01587703|9877235|FG008|Part1 BID(Median Exposure of 1.41months)|Death|1
6211086|NCT01587703|9877236|FG009|Part1 BID(Median Exposure of 1.41months)|Death|9
6211087|NCT01587703|9877237|FG010|Part1 BID(Median Exposure of 1.41months)|Death|3
6211088|NCT01587703|9877238|FG011|Part1 BID(Median Exposure of 1.41months)|Death|0
6211089|NCT01587703|9877239|FG012|Part1 BID(Median Exposure of 1.41months)|Death|0
6211090|NCT01587703|9877240|FG013|Part1 BID(Median Exposure of 1.41months)|Death|0
6211091|NCT01587703|9877241|FG014|Part1 BID(Median Exposure of 1.41months)|Death|0
6211092|NCT01587703|9877242|FG015|Part1 BID(Median Exposure of 1.41months)|Death|0
6211093|NCT01587703|9877243|FG016|Part1 BID(Median Exposure of 1.41months)|Death|0
6211094|NCT01587703|9877244|FG017|Part1 BID(Median Exposure of 1.41months)|Death|0
6211095|NCT01587703|9877245|FG018|Part1 BID(Median Exposure of 1.41months)|Death|0
6211096|NCT01587703|9877227|FG000|Part1 BID(Median Exposure of 1.41months)|Withdrawal by Subject|0
6211097|NCT01587703|9877228|FG001|Part1 BID(Median Exposure of 1.41months)|Withdrawal by Subject|0
6211098|NCT01587703|9877229|FG002|Part1 BID(Median Exposure of 1.41months)|Withdrawal by Subject|0
6286954|NCT02347332|9999364|FG001|Overall Study|Physician Decision|3
6286955|NCT02347332|9999363|FG000|Overall Study|Withdrawal by Subject|20
6286956|NCT02347332|9999364|FG001|Overall Study|Withdrawal by Subject|14
6286957|NCT02347332|9999363|FG000|Overall Study|Protocol requirement|1
6286958|NCT02347332|9999364|FG001|Overall Study|Protocol requirement|1
6286959|NCT02347332|9999363|FG000|Overall Study|Switch Post-Trial program|0
6286960|NCT02347332|9999364|FG001|Overall Study|Switch Post-Trial program|1
6286961|NCT02347631|9999423|FG000|First Intervention (2 Months)|Adverse Event|1
6286962|NCT02347631|9999424|FG001|First Intervention (2 Months)|Adverse Event|1
6286963|NCT02347631|9999423|FG000|First Intervention (2 Months)|Pregnancy|1
6286964|NCT02347631|9999424|FG001|First Intervention (2 Months)|Pregnancy|0
6286965|NCT02347631|9999423|FG000|First Intervention (2 Months)|Moved out of area|0
6286966|NCT02347631|9999424|FG001|First Intervention (2 Months)|Moved out of area|2
6286967|NCT02347631|9999423|FG000|First Intervention (2 Months)|Lost to Follow-up|5
6286968|NCT02347631|9999424|FG001|First Intervention (2 Months)|Lost to Follow-up|3
6286969|NCT02347631|9999423|FG000|Washout 2 (1 Month)|Withdrawal by Subject|2
6286970|NCT02347631|9999424|FG001|Washout 2 (1 Month)|Withdrawal by Subject|2
6286971|NCT02347631|9999423|FG000|Washout 2 (1 Month)|Lost to Follow-up|0
6286972|NCT02347631|9999424|FG001|Washout 2 (1 Month)|Lost to Follow-up|1
6286973|NCT02347631|9999423|FG000|Second Intervention (2 Months)|Lost to Follow-up|7
6286974|NCT02347631|9999424|FG001|Second Intervention (2 Months)|Lost to Follow-up|4
6286975|NCT02347631|9999423|FG000|Second Intervention (2 Months)|Withdrawal by Subject|6
6286976|NCT02347631|9999424|FG001|Second Intervention (2 Months)|Withdrawal by Subject|0
6286977|NCT02347657|9999434|FG000|Overall Study|Physician Decision|0
6286978|NCT02347657|9999435|FG001|Overall Study|Physician Decision|1
6286979|NCT02347657|9999434|FG000|Overall Study|Adverse Event|8
6286980|NCT02347657|9999435|FG001|Overall Study|Adverse Event|4
6286981|NCT02347657|9999434|FG000|Overall Study|Withdrawal by Subject|6
6286982|NCT02347657|9999435|FG001|Overall Study|Withdrawal by Subject|7
6286983|NCT02347657|9999434|FG000|Overall Study|Randomized but not treated|1
6286984|NCT02347657|9999435|FG001|Overall Study|Randomized but not treated|0
6286985|NCT02347657|9999434|FG000|Overall Study|Other|3
6286986|NCT02347657|9999435|FG001|Overall Study|Other|3
6286987|NCT02347761|9999445|FG000|All Collected|Death|1
6286988|NCT02347761|9999446|FG001|All Collected|Death|0
6286989|NCT02347761|9999447|FG002|All Collected|Death|0
6286990|NCT02347761|9999445|FG000|All Collected|Lost to Follow-up|3
6117460|NCT00869089|9739430|FG000|Overall Study|Withdrawal by Subject|1
6117461|NCT00869089|9739430|FG000|Overall Study|Screen Fail|1
6117462|NCT00869323|9739471|FG000|Maintenance Therapy|concurrent illness|1
6117463|NCT00869362|9739486|FG000|Overall Study|Death|0
6117464|NCT00869362|9739487|FG001|Overall Study|Death|2
6117465|NCT00869362|9739486|FG000|Overall Study|Lost to Follow-up|1
6117466|NCT00869362|9739487|FG001|Overall Study|Lost to Follow-up|3
6117467|NCT00869401|9739508|FG000|Overall Study|Withdrawal by Subject|0
6117468|NCT00869401|9739509|FG001|Overall Study|Withdrawal by Subject|0
6117469|NCT00869401|9739510|FG002|Overall Study|Withdrawal by Subject|0
6117470|NCT00869401|9739511|FG003|Overall Study|Withdrawal by Subject|5
6117471|NCT00869401|9739512|FG004|Overall Study|Withdrawal by Subject|3
6117472|NCT00869440|9739528|FG000|Overall Study|Withdrawal by Subject|1
6117473|NCT00869440|9739529|FG001|Overall Study|Withdrawal by Subject|0
6117474|NCT00869440|9739530|FG002|Overall Study|Withdrawal by Subject|0
6117475|NCT00869440|9739531|FG003|Overall Study|Withdrawal by Subject|0
6117476|NCT00869440|9739528|FG000|Overall Study|Physician Decision|1
6286991|NCT02347761|9999446|FG001|All Collected|Lost to Follow-up|2
6117477|NCT00869440|9739529|FG001|Overall Study|Physician Decision|1
6117478|NCT00869440|9739530|FG002|Overall Study|Physician Decision|0
6117479|NCT00869440|9739531|FG003|Overall Study|Physician Decision|0
6117480|NCT00869518|9739543|FG000|Overall Study|Lost to Follow-up|1
6117481|NCT00869518|9739544|FG001|Overall Study|Lost to Follow-up|1
6117482|NCT00869557|9739552|FG000|Randomized Phase|Lost to Follow-up|2
6117483|NCT00869557|9739553|FG001|Randomized Phase|Lost to Follow-up|1
6117484|NCT00869557|9739552|FG000|Randomized Phase|Investigator's Discretion|1
6117485|NCT00869557|9739553|FG001|Randomized Phase|Investigator's Discretion|0
6117486|NCT00869557|9739552|FG000|Randomized Phase|Withdrew Consent|0
6117487|NCT00869557|9739553|FG001|Randomized Phase|Withdrew Consent|1
6117488|NCT00869557|9739552|FG000|Extension Phase|Adverse Event|2
6117489|NCT00869557|9739553|FG001|Extension Phase|Adverse Event|2
6117490|NCT00869557|9739552|FG000|Extension Phase|Lack of Efficacy|1
6117491|NCT00869557|9739553|FG001|Extension Phase|Lack of Efficacy|0
6117492|NCT00869557|9739552|FG000|Extension Phase|Lost to Follow-up|3
6117493|NCT00869557|9739553|FG001|Extension Phase|Lost to Follow-up|1
6117494|NCT00869557|9739552|FG000|Extension Phase|Investigator's Discretion|2
6117495|NCT00869557|9739553|FG001|Extension Phase|Investigator's Discretion|0
6117496|NCT00869557|9739552|FG000|Extension Phase|Withdrew Consent|2
6117497|NCT00869557|9739553|FG001|Extension Phase|Withdrew Consent|0
6117498|NCT00869778|9739582|FG000|Overall Study|Adverse Event|2
6117499|NCT00869778|9739583|FG001|Overall Study|Adverse Event|0
6117500|NCT00869778|9739584|FG002|Overall Study|Adverse Event|0
6117501|NCT00869778|9739582|FG000|Overall Study|Withdrawal by Subject|3
6117502|NCT00869778|9739583|FG001|Overall Study|Withdrawal by Subject|4
6117503|NCT00869778|9739584|FG002|Overall Study|Withdrawal by Subject|5
6117504|NCT00869778|9739582|FG000|Overall Study|Pregnancy|1
6117505|NCT00869778|9739583|FG001|Overall Study|Pregnancy|0
6117506|NCT00869778|9739584|FG002|Overall Study|Pregnancy|0
6117507|NCT00869778|9739582|FG000|Overall Study|Protocol Violation|5
6117508|NCT00869778|9739583|FG001|Overall Study|Protocol Violation|3
6117509|NCT00869778|9739584|FG002|Overall Study|Protocol Violation|5
6117510|NCT00869778|9739582|FG000|Overall Study|Unblinding|1
6117511|NCT00869778|9739583|FG001|Overall Study|Unblinding|0
6211099|NCT01587703|9877230|FG003|Part1 BID(Median Exposure of 1.41months)|Withdrawal by Subject|0
6211100|NCT01587703|9877231|FG004|Part1 BID(Median Exposure of 1.41months)|Withdrawal by Subject|0
6211101|NCT01587703|9877232|FG005|Part1 BID(Median Exposure of 1.41months)|Withdrawal by Subject|0
6211102|NCT01587703|9877233|FG006|Part1 BID(Median Exposure of 1.41months)|Withdrawal by Subject|0
6211103|NCT01587703|9877234|FG007|Part1 BID(Median Exposure of 1.41months)|Withdrawal by Subject|0
6211104|NCT01587703|9877235|FG008|Part1 BID(Median Exposure of 1.41months)|Withdrawal by Subject|1
6211105|NCT01587703|9877236|FG009|Part1 BID(Median Exposure of 1.41months)|Withdrawal by Subject|0
6211106|NCT01587703|9877237|FG010|Part1 BID(Median Exposure of 1.41months)|Withdrawal by Subject|1
6211107|NCT01587703|9877238|FG011|Part1 BID(Median Exposure of 1.41months)|Withdrawal by Subject|0
6211108|NCT01587703|9877239|FG012|Part1 BID(Median Exposure of 1.41months)|Withdrawal by Subject|0
6211109|NCT01587703|9877240|FG013|Part1 BID(Median Exposure of 1.41months)|Withdrawal by Subject|0
6211110|NCT01587703|9877241|FG014|Part1 BID(Median Exposure of 1.41months)|Withdrawal by Subject|0
6211111|NCT01587703|9877242|FG015|Part1 BID(Median Exposure of 1.41months)|Withdrawal by Subject|0
6211112|NCT01587703|9877243|FG016|Part1 BID(Median Exposure of 1.41months)|Withdrawal by Subject|0
6211113|NCT01587703|9877244|FG017|Part1 BID(Median Exposure of 1.41months)|Withdrawal by Subject|0
6211114|NCT01587703|9877245|FG018|Part1 BID(Median Exposure of 1.41months)|Withdrawal by Subject|0
6211115|NCT01587703|9877227|FG000|Part1 BID(Median Exposure of 1.41months)|Site closed|0
6211116|NCT01587703|9877228|FG001|Part1 BID(Median Exposure of 1.41months)|Site closed|0
6211117|NCT01587703|9877229|FG002|Part1 BID(Median Exposure of 1.41months)|Site closed|0
6211118|NCT01587703|9877230|FG003|Part1 BID(Median Exposure of 1.41months)|Site closed|0
6211119|NCT01587703|9877231|FG004|Part1 BID(Median Exposure of 1.41months)|Site closed|0
6211120|NCT01587703|9877232|FG005|Part1 BID(Median Exposure of 1.41months)|Site closed|0
6211121|NCT01587703|9877233|FG006|Part1 BID(Median Exposure of 1.41months)|Site closed|0
6211122|NCT01587703|9877234|FG007|Part1 BID(Median Exposure of 1.41months)|Site closed|0
6211123|NCT01587703|9877235|FG008|Part1 BID(Median Exposure of 1.41months)|Site closed|0
6211124|NCT01587703|9877236|FG009|Part1 BID(Median Exposure of 1.41months)|Site closed|1
6211125|NCT01587703|9877237|FG010|Part1 BID(Median Exposure of 1.41months)|Site closed|1
6211126|NCT01587703|9877238|FG011|Part1 BID(Median Exposure of 1.41months)|Site closed|0
6211127|NCT01587703|9877239|FG012|Part1 BID(Median Exposure of 1.41months)|Site closed|0
6211128|NCT01587703|9877240|FG013|Part1 BID(Median Exposure of 1.41months)|Site closed|0
6211129|NCT01587703|9877241|FG014|Part1 BID(Median Exposure of 1.41months)|Site closed|0
6211130|NCT01587703|9877242|FG015|Part1 BID(Median Exposure of 1.41months)|Site closed|0
6211131|NCT01587703|9877243|FG016|Part1 BID(Median Exposure of 1.41months)|Site closed|0
6211132|NCT01587703|9877244|FG017|Part1 BID(Median Exposure of 1.41months)|Site closed|0
6211133|NCT01587703|9877245|FG018|Part1 BID(Median Exposure of 1.41months)|Site closed|0
6211134|NCT01587703|9877227|FG000|Part1 BID(Median Exposure of 1.41months)|Lost to Follow-up|0
6211135|NCT01587703|9877228|FG001|Part1 BID(Median Exposure of 1.41months)|Lost to Follow-up|0
6117512|NCT00869778|9739584|FG002|Overall Study|Unblinding|0
6117513|NCT00869960|9739613|FG000|Overall Study|Lost to Follow-up|2
6117514|NCT00869999|9739617|FG000|Overall Study|Withdrawal by Subject|1
6117515|NCT00869999|9739617|FG000|Overall Study|removed prior to starting therapy|1
6117516|NCT00870103|9739621|FG000|Overall Study|Physician Decision|2
6117517|NCT00870103|9739621|FG000|Overall Study|Lost to Follow-up|2
6117518|NCT00870194|9739627|FG000|Overall Study|Adverse Event|10
6117519|NCT00870194|9739628|FG001|Overall Study|Adverse Event|5
6117520|NCT00870194|9739627|FG000|Overall Study|Lack of Efficacy|0
6117521|NCT00870194|9739628|FG001|Overall Study|Lack of Efficacy|1
6117522|NCT00870194|9739627|FG000|Overall Study|Lost to Follow-up|2
6117523|NCT00870194|9739628|FG001|Overall Study|Lost to Follow-up|0
6117524|NCT00870194|9739627|FG000|Overall Study|Physician Decision|3
6117525|NCT00870194|9739628|FG001|Overall Study|Physician Decision|1
6117526|NCT00870194|9739627|FG000|Overall Study|Protocol Violation|3
6117527|NCT00870194|9739628|FG001|Overall Study|Protocol Violation|3
6117528|NCT00870194|9739627|FG000|Overall Study|Entry Criteria Not Met|1
6117529|NCT00870194|9739628|FG001|Overall Study|Entry Criteria Not Met|2
6117530|NCT00870194|9739627|FG000|Overall Study|Subject Decision|7
6117531|NCT00870194|9739628|FG001|Overall Study|Subject Decision|2
6117532|NCT00870233|9739634|FG000|Overall Study|Withdrawal by Subject|18
6117533|NCT00870233|9739634|FG000|Overall Study|Did not undergo laparotomy|3
6117534|NCT00870233|9739634|FG000|Overall Study|Incompatible internet browser|2
6117535|NCT00870233|9739634|FG000|Overall Study|Death|1
6117536|NCT00870584|9739681|FG000|Overall Study|Adverse Event|3
6117537|NCT00870584|9739682|FG001|Overall Study|Adverse Event|3
6117538|NCT00870584|9739681|FG000|Overall Study|Withdrawal by Subject|6
6117539|NCT00870584|9739682|FG001|Overall Study|Withdrawal by Subject|7
6117540|NCT00870584|9739681|FG000|Overall Study|Lost to Follow-up|5
6117541|NCT00870584|9739682|FG001|Overall Study|Lost to Follow-up|1
6117542|NCT00870584|9739681|FG000|Overall Study|Protocol Deviation|2
6117543|NCT00870584|9739682|FG001|Overall Study|Protocol Deviation|2
6117544|NCT00870727|9739690|FG000|Overall Study|Lost to Follow-up|0
6117545|NCT00870727|9739691|FG001|Overall Study|Lost to Follow-up|1
6117546|NCT00870727|9739690|FG000|Overall Study|Lack of Efficacy|1
6117547|NCT00870727|9739691|FG001|Overall Study|Lack of Efficacy|3
6117548|NCT00870727|9739690|FG000|Overall Study|Adverse Event|0
6117549|NCT00870727|9739691|FG001|Overall Study|Adverse Event|1
6117550|NCT00870740|9739703|FG000|Overall Study|Adverse Event|2
6117551|NCT00870740|9739704|FG001|Overall Study|Adverse Event|1
6117552|NCT00870740|9739705|FG002|Overall Study|Adverse Event|3
6117553|NCT00870740|9739706|FG003|Overall Study|Adverse Event|2
6117554|NCT00870740|9739707|FG004|Overall Study|Adverse Event|1
6117555|NCT00870740|9739708|FG005|Overall Study|Adverse Event|6
6117556|NCT00870740|9739703|FG000|Overall Study|Consent Withdrawn|6
6117557|NCT00870740|9739704|FG001|Overall Study|Consent Withdrawn|3
6117558|NCT00870740|9739705|FG002|Overall Study|Consent Withdrawn|4
6117559|NCT00870740|9739706|FG003|Overall Study|Consent Withdrawn|6
6117560|NCT00870740|9739707|FG004|Overall Study|Consent Withdrawn|6
6117561|NCT00870740|9739708|FG005|Overall Study|Consent Withdrawn|5
6117562|NCT00870740|9739703|FG000|Overall Study|Investigator Decision|2
6117563|NCT00870740|9739704|FG001|Overall Study|Investigator Decision|0
6117564|NCT00870740|9739705|FG002|Overall Study|Investigator Decision|1
6117565|NCT00870740|9739706|FG003|Overall Study|Investigator Decision|0
6117566|NCT00870740|9739707|FG004|Overall Study|Investigator Decision|0
6117567|NCT00870740|9739708|FG005|Overall Study|Investigator Decision|0
6117568|NCT00870740|9739703|FG000|Overall Study|Subject Non-compliance|0
6117569|NCT00870740|9739704|FG001|Overall Study|Subject Non-compliance|0
6117570|NCT00870740|9739705|FG002|Overall Study|Subject Non-compliance|0
6117571|NCT00870740|9739706|FG003|Overall Study|Subject Non-compliance|0
6117572|NCT00870740|9739707|FG004|Overall Study|Subject Non-compliance|0
6117573|NCT00870740|9739708|FG005|Overall Study|Subject Non-compliance|1
6117574|NCT00870740|9739703|FG000|Overall Study|Death|0
6117575|NCT00870740|9739704|FG001|Overall Study|Death|0
6117576|NCT00870740|9739705|FG002|Overall Study|Death|0
6117577|NCT00870740|9739706|FG003|Overall Study|Death|0
6117578|NCT00870740|9739707|FG004|Overall Study|Death|1
6211136|NCT01587703|9877229|FG002|Part1 BID(Median Exposure of 1.41months)|Lost to Follow-up|0
6211137|NCT01587703|9877230|FG003|Part1 BID(Median Exposure of 1.41months)|Lost to Follow-up|0
6211138|NCT01587703|9877231|FG004|Part1 BID(Median Exposure of 1.41months)|Lost to Follow-up|0
6211139|NCT01587703|9877232|FG005|Part1 BID(Median Exposure of 1.41months)|Lost to Follow-up|0
6211140|NCT01587703|9877233|FG006|Part1 BID(Median Exposure of 1.41months)|Lost to Follow-up|0
6211141|NCT01587703|9877234|FG007|Part1 BID(Median Exposure of 1.41months)|Lost to Follow-up|0
6211142|NCT01587703|9877235|FG008|Part1 BID(Median Exposure of 1.41months)|Lost to Follow-up|1
6211143|NCT01587703|9877236|FG009|Part1 BID(Median Exposure of 1.41months)|Lost to Follow-up|0
6211144|NCT01587703|9877237|FG010|Part1 BID(Median Exposure of 1.41months)|Lost to Follow-up|0
6117579|NCT00870740|9739708|FG005|Overall Study|Death|0
6117580|NCT00870740|9739703|FG000|Overall Study|Other|2
6117581|NCT00870740|9739704|FG001|Overall Study|Other|5
6117582|NCT00870740|9739705|FG002|Overall Study|Other|2
6117583|NCT00870740|9739706|FG003|Overall Study|Other|4
6117584|NCT00870740|9739707|FG004|Overall Study|Other|3
6117585|NCT00870740|9739708|FG005|Overall Study|Other|5
6117586|NCT00870870|9739737|FG000|Overall Study|Withdrawal by Subject|0
6117587|NCT00870870|9739738|FG001|Overall Study|Withdrawal by Subject|1
6117588|NCT00870870|9739739|FG002|Overall Study|Withdrawal by Subject|1
6117589|NCT00870870|9739740|FG003|Overall Study|Withdrawal by Subject|3
6117590|NCT00870870|9739737|FG000|Overall Study|Adverse Event|0
6117591|NCT00870870|9739738|FG001|Overall Study|Adverse Event|0
6117592|NCT00870870|9739739|FG002|Overall Study|Adverse Event|2
6117593|NCT00870870|9739740|FG003|Overall Study|Adverse Event|2
6117594|NCT00871000|9739763|FG000|Overall Study|Withdrawal by Subject|1
6117595|NCT00871000|9739764|FG001|Overall Study|Withdrawal by Subject|0
6117596|NCT00871117|9739772|FG000|Overall Study|Lost to Follow-up|5
6117597|NCT00871117|9739773|FG001|Overall Study|Lost to Follow-up|6
6117598|NCT00871117|9739772|FG000|Overall Study|Other|0
6117599|NCT00871117|9739773|FG001|Overall Study|Other|4
6117600|NCT00871169|9739789|FG000|Overall Study|Protocol Violation|1
6117601|NCT00871169|9739789|FG000|Overall Study|Patient did not receive study treatment|2
6117602|NCT00871234|9739793|FG000|Overall Study|Adverse Event|2
6117603|NCT00871234|9739793|FG000|Overall Study|Lost to Follow-up|3
6117604|NCT00871338|9739812|FG000|Prior to Booster|Withdrawal by Subject|1
6117605|NCT00871338|9739813|FG001|Prior to Booster|Withdrawal by Subject|3
6117606|NCT00871338|9739812|FG000|Prior to Booster|Lost to Follow-up|1
6117607|NCT00871338|9739813|FG001|Prior to Booster|Lost to Follow-up|0
6117608|NCT00871377|9739819|FG000|First Intervention (10 Weeks)|Withdrawal by Subject|0
6117609|NCT00871377|9739820|FG001|First Intervention (10 Weeks)|Withdrawal by Subject|0
6117610|NCT00871377|9739821|FG002|First Intervention (10 Weeks)|Withdrawal by Subject|1
6117611|NCT00871377|9739822|FG003|First Intervention (10 Weeks)|Withdrawal by Subject|0
6117612|NCT00871377|9739823|FG004|First Intervention (10 Weeks)|Withdrawal by Subject|0
6117613|NCT00871377|9739824|FG005|First Intervention (10 Weeks)|Withdrawal by Subject|0
6117614|NCT00871377|9739819|FG000|First Intervention (10 Weeks)|Lost to Follow-up|0
6117615|NCT00871377|9739820|FG001|First Intervention (10 Weeks)|Lost to Follow-up|0
6117616|NCT00871377|9739821|FG002|First Intervention (10 Weeks)|Lost to Follow-up|0
6117617|NCT00871377|9739822|FG003|First Intervention (10 Weeks)|Lost to Follow-up|0
6117618|NCT00871377|9739823|FG004|First Intervention (10 Weeks)|Lost to Follow-up|0
6117619|NCT00871377|9739824|FG005|First Intervention (10 Weeks)|Lost to Follow-up|1
6117620|NCT00871377|9739819|FG000|Washout (6 Weeks)|Withdrawal by Subject|1
6117621|NCT00871377|9739820|FG001|Washout (6 Weeks)|Withdrawal by Subject|0
6211145|NCT01587703|9877238|FG011|Part1 BID(Median Exposure of 1.41months)|Lost to Follow-up|0
6211146|NCT01587703|9877239|FG012|Part1 BID(Median Exposure of 1.41months)|Lost to Follow-up|0
6211147|NCT01587703|9877240|FG013|Part1 BID(Median Exposure of 1.41months)|Lost to Follow-up|0
6211148|NCT01587703|9877241|FG014|Part1 BID(Median Exposure of 1.41months)|Lost to Follow-up|0
6211149|NCT01587703|9877242|FG015|Part1 BID(Median Exposure of 1.41months)|Lost to Follow-up|0
6211150|NCT01587703|9877243|FG016|Part1 BID(Median Exposure of 1.41months)|Lost to Follow-up|0
6211151|NCT01587703|9877244|FG017|Part1 BID(Median Exposure of 1.41months)|Lost to Follow-up|0
6211152|NCT01587703|9877245|FG018|Part1 BID(Median Exposure of 1.41months)|Lost to Follow-up|0
6211153|NCT01587703|9877227|FG000|Substudy-P4,Maximum Exposure of 5.5month|Withdrawal by Subject|0
6211154|NCT01587703|9877228|FG001|Substudy-P4,Maximum Exposure of 5.5month|Withdrawal by Subject|0
6211155|NCT01587703|9877229|FG002|Substudy-P4,Maximum Exposure of 5.5month|Withdrawal by Subject|0
6211156|NCT01587703|9877230|FG003|Substudy-P4,Maximum Exposure of 5.5month|Withdrawal by Subject|0
6211157|NCT01587703|9877231|FG004|Substudy-P4,Maximum Exposure of 5.5month|Withdrawal by Subject|0
6211158|NCT01587703|9877232|FG005|Substudy-P4,Maximum Exposure of 5.5month|Withdrawal by Subject|0
6211159|NCT01587703|9877233|FG006|Substudy-P4,Maximum Exposure of 5.5month|Withdrawal by Subject|0
6211160|NCT01587703|9877234|FG007|Substudy-P4,Maximum Exposure of 5.5month|Withdrawal by Subject|0
6211161|NCT01587703|9877235|FG008|Substudy-P4,Maximum Exposure of 5.5month|Withdrawal by Subject|0
6211162|NCT01587703|9877236|FG009|Substudy-P4,Maximum Exposure of 5.5month|Withdrawal by Subject|0
6211163|NCT01587703|9877237|FG010|Substudy-P4,Maximum Exposure of 5.5month|Withdrawal by Subject|0
6211164|NCT01587703|9877238|FG011|Substudy-P4,Maximum Exposure of 5.5month|Withdrawal by Subject|0
6211165|NCT01587703|9877239|FG012|Substudy-P4,Maximum Exposure of 5.5month|Withdrawal by Subject|0
6117622|NCT00871377|9739821|FG002|Washout (6 Weeks)|Withdrawal by Subject|0
6117623|NCT00871377|9739822|FG003|Washout (6 Weeks)|Withdrawal by Subject|0
6117624|NCT00871377|9739823|FG004|Washout (6 Weeks)|Withdrawal by Subject|0
6117625|NCT00871377|9739824|FG005|Washout (6 Weeks)|Withdrawal by Subject|0
6117626|NCT00871377|9739819|FG000|Washout (6 Weeks)|Withdrawal by Subject|0
6117627|NCT00871377|9739820|FG001|Washout (6 Weeks)|Withdrawal by Subject|0
6117628|NCT00871377|9739821|FG002|Washout (6 Weeks)|Withdrawal by Subject|0
6117629|NCT00871377|9739822|FG003|Washout (6 Weeks)|Withdrawal by Subject|0
6117630|NCT00871377|9739823|FG004|Washout (6 Weeks)|Withdrawal by Subject|0
6117631|NCT00871377|9739824|FG005|Washout (6 Weeks)|Withdrawal by Subject|1
6117632|NCT00871377|9739819|FG000|Third Intervention (10 Weeks)|Death|0
6117633|NCT00871377|9739820|FG001|Third Intervention (10 Weeks)|Death|0
6117634|NCT00871377|9739821|FG002|Third Intervention (10 Weeks)|Death|0
6117635|NCT00871377|9739822|FG003|Third Intervention (10 Weeks)|Death|1
6117636|NCT00871377|9739823|FG004|Third Intervention (10 Weeks)|Death|0
6117637|NCT00871377|9739824|FG005|Third Intervention (10 Weeks)|Death|0
6117638|NCT00871403|9739835|FG000|Combination Treatment Phase|Randomized but Not Treated|1
6117639|NCT00871403|9739836|FG001|Combination Treatment Phase|Randomized but Not Treated|1
6117640|NCT00871403|9739837|FG002|Combination Treatment Phase|Randomized but Not Treated|1
6117641|NCT00871403|9739835|FG000|Combination Treatment Phase|Treatment Stopped; Protocol Amendment|8
6117642|NCT00871403|9739836|FG001|Combination Treatment Phase|Treatment Stopped; Protocol Amendment|19
6117643|NCT00871403|9739837|FG002|Combination Treatment Phase|Treatment Stopped; Protocol Amendment|0
6117644|NCT00871403|9739835|FG000|Combination Treatment Phase|Adverse Event|0
6117645|NCT00871403|9739836|FG001|Combination Treatment Phase|Adverse Event|17
6117646|NCT00871403|9739837|FG002|Combination Treatment Phase|Adverse Event|2
6117647|NCT00871403|9739835|FG000|Combination Treatment Phase|Disease Progression|0
6117648|NCT00871403|9739836|FG001|Combination Treatment Phase|Disease Progression|8
6117649|NCT00871403|9739837|FG002|Combination Treatment Phase|Disease Progression|5
6117650|NCT00871403|9739835|FG000|Combination Treatment Phase|Withdrawal by Subject|0
6117651|NCT00871403|9739836|FG001|Combination Treatment Phase|Withdrawal by Subject|3
6117652|NCT00871403|9739837|FG002|Combination Treatment Phase|Withdrawal by Subject|1
6117653|NCT00871403|9739835|FG000|Combination Treatment Phase|Physician Decision|0
6117654|NCT00871403|9739836|FG001|Combination Treatment Phase|Physician Decision|1
6117655|NCT00871403|9739837|FG002|Combination Treatment Phase|Physician Decision|3
6117656|NCT00871403|9739835|FG000|Monotherapy Treatment Phase|Disease Progression|0
6117657|NCT00871403|9739836|FG001|Monotherapy Treatment Phase|Disease Progression|9
6117658|NCT00871403|9739837|FG002|Monotherapy Treatment Phase|Disease Progression|1
6117659|NCT00871403|9739835|FG000|Monotherapy Treatment Phase|Adverse Event|0
6117660|NCT00871403|9739836|FG001|Monotherapy Treatment Phase|Adverse Event|4
6117661|NCT00871403|9739837|FG002|Monotherapy Treatment Phase|Adverse Event|0
6117662|NCT00871429|9739844|FG000|Overall Study|Lost to Follow-up|6
6211166|NCT01587703|9877240|FG013|Substudy-P4,Maximum Exposure of 5.5month|Withdrawal by Subject|0
6211167|NCT01587703|9877241|FG014|Substudy-P4,Maximum Exposure of 5.5month|Withdrawal by Subject|0
6211168|NCT01587703|9877242|FG015|Substudy-P4,Maximum Exposure of 5.5month|Withdrawal by Subject|0
6211169|NCT01587703|9877243|FG016|Substudy-P4,Maximum Exposure of 5.5month|Withdrawal by Subject|0
6211170|NCT01587703|9877244|FG017|Substudy-P4,Maximum Exposure of 5.5month|Withdrawal by Subject|0
6211171|NCT01587703|9877245|FG018|Substudy-P4,Maximum Exposure of 5.5month|Withdrawal by Subject|1
6211172|NCT01587703|9877227|FG000|Substudy-P4,Maximum Exposure of 5.5month|Death|0
6211173|NCT01587703|9877228|FG001|Substudy-P4,Maximum Exposure of 5.5month|Death|0
6211174|NCT01587703|9877229|FG002|Substudy-P4,Maximum Exposure of 5.5month|Death|0
6211175|NCT01587703|9877230|FG003|Substudy-P4,Maximum Exposure of 5.5month|Death|0
6211176|NCT01587703|9877231|FG004|Substudy-P4,Maximum Exposure of 5.5month|Death|0
6211177|NCT01587703|9877232|FG005|Substudy-P4,Maximum Exposure of 5.5month|Death|0
6211178|NCT01587703|9877233|FG006|Substudy-P4,Maximum Exposure of 5.5month|Death|0
6211179|NCT01587703|9877234|FG007|Substudy-P4,Maximum Exposure of 5.5month|Death|0
6211180|NCT01587703|9877235|FG008|Substudy-P4,Maximum Exposure of 5.5month|Death|0
6211181|NCT01587703|9877236|FG009|Substudy-P4,Maximum Exposure of 5.5month|Death|0
6211182|NCT01587703|9877237|FG010|Substudy-P4,Maximum Exposure of 5.5month|Death|0
6211183|NCT01587703|9877238|FG011|Substudy-P4,Maximum Exposure of 5.5month|Death|0
6211184|NCT01587703|9877239|FG012|Substudy-P4,Maximum Exposure of 5.5month|Death|0
6211185|NCT01587703|9877240|FG013|Substudy-P4,Maximum Exposure of 5.5month|Death|0
6211186|NCT01587703|9877241|FG014|Substudy-P4,Maximum Exposure of 5.5month|Death|0
6211187|NCT01587703|9877242|FG015|Substudy-P4,Maximum Exposure of 5.5month|Death|0
6211188|NCT01587703|9877243|FG016|Substudy-P4,Maximum Exposure of 5.5month|Death|0
6211189|NCT01587703|9877244|FG017|Substudy-P4,Maximum Exposure of 5.5month|Death|5
6211190|NCT01587703|9877245|FG018|Substudy-P4,Maximum Exposure of 5.5month|Death|4
6211191|NCT01587703|9877227|FG000|Part2(Median Exposure of 1.41 Months)|Withdrawal by Subject|0
6211192|NCT01587703|9877228|FG001|Part2(Median Exposure of 1.41 Months)|Withdrawal by Subject|0
6211193|NCT01587703|9877229|FG002|Part2(Median Exposure of 1.41 Months)|Withdrawal by Subject|0
6211194|NCT01587703|9877230|FG003|Part2(Median Exposure of 1.41 Months)|Withdrawal by Subject|0
6211195|NCT01587703|9877231|FG004|Part2(Median Exposure of 1.41 Months)|Withdrawal by Subject|0
6211196|NCT01587703|9877232|FG005|Part2(Median Exposure of 1.41 Months)|Withdrawal by Subject|0
6211197|NCT01587703|9877233|FG006|Part2(Median Exposure of 1.41 Months)|Withdrawal by Subject|0
6211198|NCT01587703|9877234|FG007|Part2(Median Exposure of 1.41 Months)|Withdrawal by Subject|0
6211199|NCT01587703|9877235|FG008|Part2(Median Exposure of 1.41 Months)|Withdrawal by Subject|0
6211200|NCT01587703|9877236|FG009|Part2(Median Exposure of 1.41 Months)|Withdrawal by Subject|0
6211201|NCT01587703|9877237|FG010|Part2(Median Exposure of 1.41 Months)|Withdrawal by Subject|0
6211202|NCT01587703|9877238|FG011|Part2(Median Exposure of 1.41 Months)|Withdrawal by Subject|0
6211203|NCT01587703|9877239|FG012|Part2(Median Exposure of 1.41 Months)|Withdrawal by Subject|0
6211204|NCT01587703|9877240|FG013|Part2(Median Exposure of 1.41 Months)|Withdrawal by Subject|0
6211205|NCT01587703|9877241|FG014|Part2(Median Exposure of 1.41 Months)|Withdrawal by Subject|0
6211206|NCT01587703|9877242|FG015|Part2(Median Exposure of 1.41 Months)|Withdrawal by Subject|1
6211207|NCT01587703|9877243|FG016|Part2(Median Exposure of 1.41 Months)|Withdrawal by Subject|0
6211208|NCT01587703|9877244|FG017|Part2(Median Exposure of 1.41 Months)|Withdrawal by Subject|0
6211209|NCT01587703|9877245|FG018|Part2(Median Exposure of 1.41 Months)|Withdrawal by Subject|0
6211210|NCT01587703|9877227|FG000|Part2(Median Exposure of 1.41 Months)|Lost to Follow-up|0
6211211|NCT01587703|9877228|FG001|Part2(Median Exposure of 1.41 Months)|Lost to Follow-up|0
6211212|NCT01587703|9877229|FG002|Part2(Median Exposure of 1.41 Months)|Lost to Follow-up|0
6211213|NCT01587703|9877230|FG003|Part2(Median Exposure of 1.41 Months)|Lost to Follow-up|0
6211214|NCT01587703|9877231|FG004|Part2(Median Exposure of 1.41 Months)|Lost to Follow-up|0
6211215|NCT01587703|9877232|FG005|Part2(Median Exposure of 1.41 Months)|Lost to Follow-up|0
6211216|NCT01587703|9877233|FG006|Part2(Median Exposure of 1.41 Months)|Lost to Follow-up|0
6211217|NCT01587703|9877234|FG007|Part2(Median Exposure of 1.41 Months)|Lost to Follow-up|0
6211218|NCT01587703|9877235|FG008|Part2(Median Exposure of 1.41 Months)|Lost to Follow-up|0
6117663|NCT00871429|9739844|FG000|Overall Study|Withdrawal by Subject|17
6117664|NCT00871429|9739844|FG000|Overall Study|Questionnaire not completed|1
6117665|NCT00871494|9739852|FG000|Overall Study|Protocol Violation|5
6117666|NCT00871494|9739852|FG000|Overall Study|Lack of Efficacy|4
6117667|NCT00871494|9739852|FG000|Overall Study|Adverse Event|4
6117668|NCT00871494|9739852|FG000|Overall Study|Lost to Follow-up|1
6117669|NCT00871572|9739860|FG000|Overall Study|Adverse Event|0
6117670|NCT00871572|9739861|FG001|Overall Study|Adverse Event|2
6117671|NCT00871572|9739862|FG002|Overall Study|Adverse Event|0
6117672|NCT00871572|9739863|FG003|Overall Study|Adverse Event|3
6117673|NCT00871572|9739860|FG000|Overall Study|Investigator Decision|0
6117674|NCT00871572|9739861|FG001|Overall Study|Investigator Decision|1
6117675|NCT00871572|9739862|FG002|Overall Study|Investigator Decision|0
6117676|NCT00871572|9739863|FG003|Overall Study|Investigator Decision|1
6117677|NCT00871572|9739860|FG000|Overall Study|Lost to Follow-up|0
6117678|NCT00871572|9739861|FG001|Overall Study|Lost to Follow-up|1
6117679|NCT00871572|9739862|FG002|Overall Study|Lost to Follow-up|0
6117680|NCT00871572|9739863|FG003|Overall Study|Lost to Follow-up|1
6117681|NCT00871572|9739860|FG000|Overall Study|Protocol Violation|0
6117682|NCT00871572|9739861|FG001|Overall Study|Protocol Violation|0
6117683|NCT00871572|9739862|FG002|Overall Study|Protocol Violation|1
6117684|NCT00871572|9739863|FG003|Overall Study|Protocol Violation|1
6117685|NCT00871572|9739860|FG000|Overall Study|Sponsor Decision|1
6117686|NCT00871572|9739861|FG001|Overall Study|Sponsor Decision|0
6117687|NCT00871572|9739862|FG002|Overall Study|Sponsor Decision|0
6117688|NCT00871572|9739863|FG003|Overall Study|Sponsor Decision|0
6117689|NCT00871572|9739860|FG000|Overall Study|Withdrawal by Subject|1
6117690|NCT00871572|9739861|FG001|Overall Study|Withdrawal by Subject|2
6117691|NCT00871572|9739862|FG002|Overall Study|Withdrawal by Subject|3
6117692|NCT00871572|9739863|FG003|Overall Study|Withdrawal by Subject|1
6211219|NCT01587703|9877236|FG009|Part2(Median Exposure of 1.41 Months)|Lost to Follow-up|0
6211220|NCT01587703|9877237|FG010|Part2(Median Exposure of 1.41 Months)|Lost to Follow-up|0
6211221|NCT01587703|9877238|FG011|Part2(Median Exposure of 1.41 Months)|Lost to Follow-up|1
6211222|NCT01587703|9877239|FG012|Part2(Median Exposure of 1.41 Months)|Lost to Follow-up|0
6211223|NCT01587703|9877240|FG013|Part2(Median Exposure of 1.41 Months)|Lost to Follow-up|0
6211224|NCT01587703|9877241|FG014|Part2(Median Exposure of 1.41 Months)|Lost to Follow-up|2
6211225|NCT01587703|9877242|FG015|Part2(Median Exposure of 1.41 Months)|Lost to Follow-up|0
6211226|NCT01587703|9877243|FG016|Part2(Median Exposure of 1.41 Months)|Lost to Follow-up|0
6211227|NCT01587703|9877244|FG017|Part2(Median Exposure of 1.41 Months)|Lost to Follow-up|0
6211228|NCT01587703|9877245|FG018|Part2(Median Exposure of 1.41 Months)|Lost to Follow-up|0
6211229|NCT01587703|9877227|FG000|Part2(Median Exposure of 1.41 Months)|Site closed|0
6211230|NCT01587703|9877228|FG001|Part2(Median Exposure of 1.41 Months)|Site closed|0
6211231|NCT01587703|9877229|FG002|Part2(Median Exposure of 1.41 Months)|Site closed|0
6211232|NCT01587703|9877230|FG003|Part2(Median Exposure of 1.41 Months)|Site closed|0
6211233|NCT01587703|9877231|FG004|Part2(Median Exposure of 1.41 Months)|Site closed|0
6211234|NCT01587703|9877232|FG005|Part2(Median Exposure of 1.41 Months)|Site closed|0
6211235|NCT01587703|9877233|FG006|Part2(Median Exposure of 1.41 Months)|Site closed|0
6211236|NCT01587703|9877234|FG007|Part2(Median Exposure of 1.41 Months)|Site closed|0
6211237|NCT01587703|9877235|FG008|Part2(Median Exposure of 1.41 Months)|Site closed|0
6211238|NCT01587703|9877236|FG009|Part2(Median Exposure of 1.41 Months)|Site closed|0
6211239|NCT01587703|9877237|FG010|Part2(Median Exposure of 1.41 Months)|Site closed|0
6211240|NCT01587703|9877238|FG011|Part2(Median Exposure of 1.41 Months)|Site closed|2
6211241|NCT01587703|9877239|FG012|Part2(Median Exposure of 1.41 Months)|Site closed|2
6211242|NCT01587703|9877240|FG013|Part2(Median Exposure of 1.41 Months)|Site closed|1
6211243|NCT01587703|9877241|FG014|Part2(Median Exposure of 1.41 Months)|Site closed|1
6211244|NCT01587703|9877242|FG015|Part2(Median Exposure of 1.41 Months)|Site closed|3
6211245|NCT01587703|9877243|FG016|Part2(Median Exposure of 1.41 Months)|Site closed|8
6211246|NCT01587703|9877244|FG017|Part2(Median Exposure of 1.41 Months)|Site closed|0
6211247|NCT01587703|9877245|FG018|Part2(Median Exposure of 1.41 Months)|Site closed|0
6211248|NCT01587703|9877227|FG000|Part2(Median Exposure of 1.41 Months)|Death|0
6211249|NCT01587703|9877228|FG001|Part2(Median Exposure of 1.41 Months)|Death|0
6211250|NCT01587703|9877229|FG002|Part2(Median Exposure of 1.41 Months)|Death|0
6211251|NCT01587703|9877230|FG003|Part2(Median Exposure of 1.41 Months)|Death|0
6211252|NCT01587703|9877231|FG004|Part2(Median Exposure of 1.41 Months)|Death|0
6211253|NCT01587703|9877232|FG005|Part2(Median Exposure of 1.41 Months)|Death|0
6211254|NCT01587703|9877233|FG006|Part2(Median Exposure of 1.41 Months)|Death|0
6211255|NCT01587703|9877234|FG007|Part2(Median Exposure of 1.41 Months)|Death|0
6211256|NCT01587703|9877235|FG008|Part2(Median Exposure of 1.41 Months)|Death|0
6211257|NCT01587703|9877236|FG009|Part2(Median Exposure of 1.41 Months)|Death|0
6211258|NCT01587703|9877237|FG010|Part2(Median Exposure of 1.41 Months)|Death|0
6211259|NCT01587703|9877238|FG011|Part2(Median Exposure of 1.41 Months)|Death|8
6211260|NCT01587703|9877239|FG012|Part2(Median Exposure of 1.41 Months)|Death|12
6211261|NCT01587703|9877240|FG013|Part2(Median Exposure of 1.41 Months)|Death|21
6211262|NCT01587703|9877241|FG014|Part2(Median Exposure of 1.41 Months)|Death|16
6211263|NCT01587703|9877242|FG015|Part2(Median Exposure of 1.41 Months)|Death|17
6211264|NCT01587703|9877243|FG016|Part2(Median Exposure of 1.41 Months)|Death|5
6211265|NCT01587703|9877244|FG017|Part2(Median Exposure of 1.41 Months)|Death|0
6211266|NCT01587703|9877245|FG018|Part2(Median Exposure of 1.41 Months)|Death|0
6117693|NCT00871715|9739891|FG000|Overall Study|Withdrawal by Subject|6
6117694|NCT00871715|9739892|FG001|Overall Study|Withdrawal by Subject|10
6117695|NCT00871715|9739893|FG002|Overall Study|Withdrawal by Subject|15
6117696|NCT00871715|9739891|FG000|Overall Study|Physician Decision|6
6117697|NCT00871715|9739892|FG001|Overall Study|Physician Decision|0
6117698|NCT00871715|9739893|FG002|Overall Study|Physician Decision|2
6117699|NCT00871715|9739891|FG000|Overall Study|Lost to Follow-up|3
6117700|NCT00871715|9739892|FG001|Overall Study|Lost to Follow-up|6
6117701|NCT00871715|9739893|FG002|Overall Study|Lost to Follow-up|9
6117702|NCT00871728|9739902|FG000|Overall Study|Adverse Event|1
6117703|NCT00871728|9739902|FG000|Overall Study|Protocol Violation|7
6117704|NCT00871728|9739902|FG000|Overall Study|Lost to Follow-up|2
6117705|NCT00871728|9739902|FG000|Overall Study|Failed to Visit Hospital|4
6117706|NCT00871728|9739902|FG000|Overall Study|Participant Non-compliance|1
6117707|NCT00871728|9739902|FG000|Overall Study|Withdrawal of Informed Consent|5
6117708|NCT00871741|9739908|FG000|Overall Study|Premature study termination|9
6117709|NCT00871741|9739909|FG001|Overall Study|Premature study termination|7
6117710|NCT00871780|9739915|FG000|Overall Study|Enrolled But Not Treated|6
6117711|NCT00871780|9739915|FG000|Overall Study|Withdrawal by Subject|9
6117712|NCT00871780|9739915|FG000|Overall Study|Adverse Event|6
6117713|NCT00871780|9739915|FG000|Overall Study|Voluntary Discontinuation|4
6117714|NCT00871780|9739915|FG000|Overall Study|Death|1
6117715|NCT00871780|9739915|FG000|Overall Study|Physician Decision|1
6117716|NCT00871858|9739941|FG000|Overall Study|Protocol Violation|3
6117717|NCT00871858|9739942|FG001|Overall Study|Protocol Violation|4
6117718|NCT00871858|9739941|FG000|Overall Study|Adverse Event|1
6117719|NCT00871858|9739942|FG001|Overall Study|Adverse Event|1
6211267|NCT01587703|9877227|FG000|Part2(Median Exposure of 1.41 Months)|Physician Decision|0
6211268|NCT01587703|9877228|FG001|Part2(Median Exposure of 1.41 Months)|Physician Decision|0
6211269|NCT01587703|9877229|FG002|Part2(Median Exposure of 1.41 Months)|Physician Decision|0
6211270|NCT01587703|9877230|FG003|Part2(Median Exposure of 1.41 Months)|Physician Decision|0
6211271|NCT01587703|9877231|FG004|Part2(Median Exposure of 1.41 Months)|Physician Decision|0
6211272|NCT01587703|9877232|FG005|Part2(Median Exposure of 1.41 Months)|Physician Decision|0
6211273|NCT01587703|9877233|FG006|Part2(Median Exposure of 1.41 Months)|Physician Decision|0
6211274|NCT01587703|9877234|FG007|Part2(Median Exposure of 1.41 Months)|Physician Decision|0
6211275|NCT01587703|9877235|FG008|Part2(Median Exposure of 1.41 Months)|Physician Decision|0
6211276|NCT01587703|9877236|FG009|Part2(Median Exposure of 1.41 Months)|Physician Decision|0
6211277|NCT01587703|9877237|FG010|Part2(Median Exposure of 1.41 Months)|Physician Decision|0
6211278|NCT01587703|9877238|FG011|Part2(Median Exposure of 1.41 Months)|Physician Decision|1
6211279|NCT01587703|9877239|FG012|Part2(Median Exposure of 1.41 Months)|Physician Decision|0
6211280|NCT01587703|9877240|FG013|Part2(Median Exposure of 1.41 Months)|Physician Decision|0
6211281|NCT01587703|9877241|FG014|Part2(Median Exposure of 1.41 Months)|Physician Decision|0
6211282|NCT01587703|9877242|FG015|Part2(Median Exposure of 1.41 Months)|Physician Decision|0
6211283|NCT01587703|9877243|FG016|Part2(Median Exposure of 1.41 Months)|Physician Decision|0
6211284|NCT01587703|9877244|FG017|Part2(Median Exposure of 1.41 Months)|Physician Decision|0
6211285|NCT01587703|9877245|FG018|Part2(Median Exposure of 1.41 Months)|Physician Decision|0
6211286|NCT01587885|9877304|FG000|Treatment Period 1|Failure to Return|0
6211287|NCT01587885|9877305|FG001|Treatment Period 1|Failure to Return|1
6211288|NCT01587885|9877304|FG000|Treatment Period 1|Protocol Violation|0
6211289|NCT01587885|9877305|FG001|Treatment Period 1|Protocol Violation|2
6211290|NCT01587898|9877316|FG000|Overall Study|Adverse Event|1
6211291|NCT01587898|9877317|FG001|Overall Study|Adverse Event|1
6211292|NCT01587898|9877318|FG002|Overall Study|Adverse Event|0
6211293|NCT01587898|9877319|FG003|Overall Study|Adverse Event|0
6211294|NCT01587898|9877316|FG000|Overall Study|Protocol Violation|0
6211295|NCT01587898|9877317|FG001|Overall Study|Protocol Violation|2
6211296|NCT01587898|9877318|FG002|Overall Study|Protocol Violation|1
6211297|NCT01587898|9877319|FG003|Overall Study|Protocol Violation|1
6211298|NCT01587898|9877316|FG000|Overall Study|Lost to Follow-up|0
6211299|NCT01587898|9877317|FG001|Overall Study|Lost to Follow-up|0
6211300|NCT01587898|9877318|FG002|Overall Study|Lost to Follow-up|0
6211301|NCT01587898|9877319|FG003|Overall Study|Lost to Follow-up|1
6211302|NCT01587898|9877316|FG000|Overall Study|Withdrawal by Subject|2
6211303|NCT01587898|9877317|FG001|Overall Study|Withdrawal by Subject|1
6211304|NCT01587898|9877318|FG002|Overall Study|Withdrawal by Subject|0
6211305|NCT01587898|9877319|FG003|Overall Study|Withdrawal by Subject|0
6117720|NCT00871858|9739941|FG000|Overall Study|Withdrawal by Subject|1
6117721|NCT00871858|9739942|FG001|Overall Study|Withdrawal by Subject|1
6117722|NCT00871858|9739941|FG000|Overall Study|Lost to Follow-up|0
6117723|NCT00871858|9739942|FG001|Overall Study|Lost to Follow-up|1
6117724|NCT00871871|9739950|FG000|Part I|Adverse Event|0
6117725|NCT00871871|9739951|FG001|Part I|Adverse Event|2
6117726|NCT00871871|9739952|FG002|Part I|Adverse Event|0
6211306|NCT01587898|9877316|FG000|Overall Study|Met haemoglobin stopping criteria|1
6211307|NCT01587898|9877317|FG001|Overall Study|Met haemoglobin stopping criteria|1
6211308|NCT01587898|9877318|FG002|Overall Study|Met haemoglobin stopping criteria|1
6211309|NCT01587898|9877319|FG003|Overall Study|Met haemoglobin stopping criteria|0
6211310|NCT01587924|9877336|FG000|Overall Study|Adverse Event|0
6211311|NCT01587924|9877337|FG001|Overall Study|Adverse Event|2
6117727|NCT00871871|9739953|FG003|Part I|Adverse Event|0
6117728|NCT00871871|9739950|FG000|Part I|Withdrawal by Subject|3
6117729|NCT00871871|9739951|FG001|Part I|Withdrawal by Subject|0
6117730|NCT00871871|9739952|FG002|Part I|Withdrawal by Subject|0
6117731|NCT00871871|9739953|FG003|Part I|Withdrawal by Subject|0
6117732|NCT00871871|9739950|FG000|Part I|Laboratory abnormality|0
6117733|NCT00871871|9739951|FG001|Part I|Laboratory abnormality|1
6117734|NCT00871871|9739952|FG002|Part I|Laboratory abnormality|0
6117735|NCT00871871|9739953|FG003|Part I|Laboratory abnormality|0
6117736|NCT00871871|9739950|FG000|Part II|Lack of Efficacy|0
6117737|NCT00871871|9739951|FG001|Part II|Lack of Efficacy|0
6117738|NCT00871871|9739952|FG002|Part II|Lack of Efficacy|1
6117739|NCT00871871|9739953|FG003|Part II|Lack of Efficacy|0
6117740|NCT00871871|9739950|FG000|Part II|Withdrawal by Subject|0
6117741|NCT00871871|9739951|FG001|Part II|Withdrawal by Subject|0
6117742|NCT00871871|9739952|FG002|Part II|Withdrawal by Subject|2
6117743|NCT00871871|9739953|FG003|Part II|Withdrawal by Subject|1
6117744|NCT00871871|9739950|FG000|Part II|Adverse Event|0
6117745|NCT00871871|9739951|FG001|Part II|Adverse Event|0
6117746|NCT00871871|9739952|FG002|Part II|Adverse Event|1
6117747|NCT00871871|9739953|FG003|Part II|Adverse Event|2
6117748|NCT00871871|9739950|FG000|Part II|Protocol Violation|0
6117749|NCT00871871|9739951|FG001|Part II|Protocol Violation|0
6117750|NCT00871871|9739952|FG002|Part II|Protocol Violation|0
6117751|NCT00871871|9739953|FG003|Part II|Protocol Violation|1
6117752|NCT00871923|9739963|FG000|Overall Study|Death|1
6117753|NCT00871923|9739963|FG000|Overall Study|Withdrawal by Subject|1
6117754|NCT00871975|9739967|FG000|Overall Study|Technical difficulty w155-1ith equipment|3
6117755|NCT00871975|9739967|FG000|Overall Study|Catheters could not be inserted|1
6117756|NCT00871975|9739967|FG000|Overall Study|Patient unable to void/insufficient vol|13
6117757|NCT00871975|9739967|FG000|Overall Study|Motion artifact, tracing uninterpretable|5
6117758|NCT00872001|9739973|FG000|Overall Study|Adverse Event|34
6117759|NCT00872001|9739974|FG001|Overall Study|Adverse Event|23
6117760|NCT00872001|9739973|FG000|Overall Study|Protocol Defined Clinical Event|5
6117761|NCT00872001|9739974|FG001|Overall Study|Protocol Defined Clinical Event|7
6117762|NCT00872001|9739973|FG000|Overall Study|Lost to Follow-up|13
6117763|NCT00872001|9739974|FG001|Overall Study|Lost to Follow-up|12
6211312|NCT01587924|9877338|FG002|Overall Study|Adverse Event|0
6211313|NCT01587924|9877339|FG003|Overall Study|Adverse Event|0
6211314|NCT01587924|9877336|FG000|Overall Study|Protocol Violation|2
6211315|NCT01587924|9877337|FG001|Overall Study|Protocol Violation|1
6211316|NCT01587924|9877338|FG002|Overall Study|Protocol Violation|2
6211317|NCT01587924|9877339|FG003|Overall Study|Protocol Violation|1
6211318|NCT01587924|9877336|FG000|Overall Study|Met Hemoglobin stopping criteria|2
6211319|NCT01587924|9877337|FG001|Overall Study|Met Hemoglobin stopping criteria|0
6211320|NCT01587924|9877338|FG002|Overall Study|Met Hemoglobin stopping criteria|1
6211321|NCT01587924|9877339|FG003|Overall Study|Met Hemoglobin stopping criteria|0
6211322|NCT01587924|9877336|FG000|Overall Study|Withdrawal by Subject|0
6211323|NCT01587924|9877337|FG001|Overall Study|Withdrawal by Subject|1
6211324|NCT01587924|9877338|FG002|Overall Study|Withdrawal by Subject|1
6211325|NCT01587924|9877339|FG003|Overall Study|Withdrawal by Subject|0
6211326|NCT01587989|9877364|FG000|12-Week Open-Label Run-In Period|Physician Decision|7
6211327|NCT01587989|9877365|FG001|12-Week Open-Label Run-In Period|Physician Decision|0
6211328|NCT01587989|9877366|FG002|12-Week Open-Label Run-In Period|Physician Decision|0
6211329|NCT01587989|9877364|FG000|12-Week Open-Label Run-In Period|Withdrawal by Subject|1
6211330|NCT01587989|9877365|FG001|12-Week Open-Label Run-In Period|Withdrawal by Subject|0
6211331|NCT01587989|9877366|FG002|12-Week Open-Label Run-In Period|Withdrawal by Subject|0
6211332|NCT01587989|9877364|FG000|12-Week Open-Label Run-In Period|No EULAR Response|4
6211333|NCT01587989|9877365|FG001|12-Week Open-Label Run-In Period|No EULAR Response|0
6211334|NCT01587989|9877366|FG002|12-Week Open-Label Run-In Period|No EULAR Response|0
6211335|NCT01587989|9877364|FG000|Randomized Study Treatment|Withdrawal by Subject|0
6211336|NCT01587989|9877365|FG001|Randomized Study Treatment|Withdrawal by Subject|1
6211337|NCT01587989|9877366|FG002|Randomized Study Treatment|Withdrawal by Subject|0
6211338|NCT01587989|9877364|FG000|Randomized Study Treatment|Screening failure|0
6211339|NCT01587989|9877365|FG001|Randomized Study Treatment|Screening failure|1
6211340|NCT01587989|9877366|FG002|Randomized Study Treatment|Screening failure|0
6211341|NCT01587989|9877364|FG000|Randomized Study Treatment|Physician Decision|0
6211342|NCT01587989|9877365|FG001|Randomized Study Treatment|Physician Decision|0
6211343|NCT01587989|9877366|FG002|Randomized Study Treatment|Physician Decision|1
6286992|NCT02347761|9999447|FG002|All Collected|Lost to Follow-up|3
6286993|NCT02347761|9999445|FG000|All Collected|Withdrawal by Subject|11
6286994|NCT02347761|9999446|FG001|All Collected|Withdrawal by Subject|11
6286995|NCT02347761|9999447|FG002|All Collected|Withdrawal by Subject|22
6286996|NCT02347761|9999445|FG000|All Collected|invetigator disretion|2
6286997|NCT02347761|9999446|FG001|All Collected|invetigator disretion|0
6286998|NCT02347761|9999447|FG002|All Collected|invetigator disretion|0
6286999|NCT02347761|9999445|FG000|All Collected|instillation site pain|0
6117764|NCT00872001|9739973|FG000|Overall Study|Withdrawal by Subject|18
6117765|NCT00872001|9739974|FG001|Overall Study|Withdrawal by Subject|30
6117766|NCT00872001|9739973|FG000|Overall Study|Protocol Violation|5
6117767|NCT00872001|9739974|FG001|Overall Study|Protocol Violation|8
6117768|NCT00872001|9739973|FG000|Overall Study|Did Not Meet Protocol Eligibility|38
6117769|NCT00872001|9739974|FG001|Overall Study|Did Not Meet Protocol Eligibility|36
6117770|NCT00872001|9739973|FG000|Overall Study|Administrative|23
6117771|NCT00872001|9739974|FG001|Overall Study|Administrative|15
6117772|NCT00872170|9739997|FG000|Overall Study|Adverse Event|1
6117773|NCT00872170|9739998|FG001|Overall Study|Adverse Event|0
6117774|NCT00872521|9740019|FG000|Completed PAD Induction|Patient choice|0
6117775|NCT00872521|9740020|FG001|Completed PAD Induction|Patient choice|1
6117776|NCT00872521|9740021|FG002|Completed PAD Induction|Patient choice|0
6117777|NCT00872521|9740019|FG000|Completed PAD Induction|Disease progression|0
6117778|NCT00872521|9740020|FG001|Completed PAD Induction|Disease progression|2
6117779|NCT00872521|9740021|FG002|Completed PAD Induction|Disease progression|0
6117780|NCT00872521|9740019|FG000|Completed PAD Induction|Adverse Event|4
6117781|NCT00872521|9740020|FG001|Completed PAD Induction|Adverse Event|0
6117782|NCT00872521|9740021|FG002|Completed PAD Induction|Adverse Event|0
6117783|NCT00872521|9740019|FG000|Completed PAD Induction|Death|1
6211344|NCT01588106|9877374|FG000|Overall Study|Withdrawal by Subject|5
6211345|NCT01588106|9877375|FG001|Overall Study|Withdrawal by Subject|4
6211346|NCT01588184|9877396|FG000|Overall Study|Death|1
6211347|NCT01588184|9877397|FG001|Overall Study|Death|0
6211348|NCT01588184|9877398|FG002|Overall Study|Death|0
6211349|NCT01588184|9877399|FG003|Overall Study|Death|1
6211350|NCT01588184|9877400|FG004|Overall Study|Death|1
6211351|NCT01588184|9877401|FG005|Overall Study|Death|1
6211352|NCT01588184|9877396|FG000|Overall Study|Withdrawal by Subject|2
6211353|NCT01588184|9877397|FG001|Overall Study|Withdrawal by Subject|4
6211354|NCT01588184|9877398|FG002|Overall Study|Withdrawal by Subject|0
6211355|NCT01588184|9877399|FG003|Overall Study|Withdrawal by Subject|1
6211356|NCT01588184|9877400|FG004|Overall Study|Withdrawal by Subject|0
6211357|NCT01588184|9877401|FG005|Overall Study|Withdrawal by Subject|0
6211358|NCT01588184|9877396|FG000|Overall Study|Bevacizumab treatment provision changed|0
6211359|NCT01588184|9877397|FG001|Overall Study|Bevacizumab treatment provision changed|6
6211360|NCT01588184|9877398|FG002|Overall Study|Bevacizumab treatment provision changed|2
6211361|NCT01588184|9877399|FG003|Overall Study|Bevacizumab treatment provision changed|0
6211362|NCT01588184|9877400|FG004|Overall Study|Bevacizumab treatment provision changed|1
6211363|NCT01588184|9877401|FG005|Overall Study|Bevacizumab treatment provision changed|3
6211364|NCT01588184|9877396|FG000|Overall Study|multiple reasons|0
6211365|NCT01588184|9877397|FG001|Overall Study|multiple reasons|3
6211366|NCT01588184|9877398|FG002|Overall Study|multiple reasons|0
6211367|NCT01588184|9877399|FG003|Overall Study|multiple reasons|1
6211368|NCT01588184|9877400|FG004|Overall Study|multiple reasons|0
6211369|NCT01588184|9877401|FG005|Overall Study|multiple reasons|0
6211370|NCT01588197|9877417|FG000|Overall Study|Lack of Efficacy|0
6211371|NCT01588197|9877418|FG001|Overall Study|Lack of Efficacy|1
6211372|NCT01588197|9877417|FG000|Overall Study|No MRI|1
6211373|NCT01588197|9877418|FG001|Overall Study|No MRI|0
6211374|NCT01588353|9877440|FG000|Step2|Withdrawal by Subject|0
6211375|NCT01588353|9877441|FG001|Step2|Withdrawal by Subject|1
6211376|NCT01588353|9877442|FG002|Step2|Withdrawal by Subject|0
6211377|NCT01588353|9877440|FG000|Step3|Adverse Event|0
6211378|NCT01588353|9877441|FG001|Step3|Adverse Event|0
6211379|NCT01588353|9877442|FG002|Step3|Adverse Event|2
6211380|NCT01588366|9877454|FG000|Overall Study|Adverse Event|0
6211381|NCT01588366|9877455|FG001|Overall Study|Adverse Event|1
6211382|NCT01588366|9877456|FG002|Overall Study|Adverse Event|0
6211383|NCT01588366|9877457|FG003|Overall Study|Adverse Event|1
6211384|NCT01588366|9877458|FG004|Overall Study|Adverse Event|0
6287000|NCT02347761|9999446|FG001|All Collected|instillation site pain|0
6287001|NCT02347761|9999447|FG002|All Collected|instillation site pain|1
6287002|NCT02347761|9999445|FG000|All Collected|exacerbation of COPD|0
6287003|NCT02347761|9999446|FG001|All Collected|exacerbation of COPD|0
6287004|NCT02347761|9999447|FG002|All Collected|exacerbation of COPD|1
6287005|NCT02347761|9999445|FG000|All Collected|moved/travel|0
6287006|NCT02347761|9999446|FG001|All Collected|moved/travel|1
6287007|NCT02347761|9999447|FG002|All Collected|moved/travel|0
6287008|NCT02347761|9999445|FG000|On Study Treatment|Lack of Efficacy|2
6287009|NCT02347761|9999446|FG001|On Study Treatment|Lack of Efficacy|3
6287010|NCT02347761|9999447|FG002|On Study Treatment|Lack of Efficacy|4
6287011|NCT02347761|9999445|FG000|On Study Treatment|non-compliance with study medication|0
6287012|NCT02347761|9999446|FG001|On Study Treatment|non-compliance with study medication|0
6287013|NCT02347761|9999447|FG002|On Study Treatment|non-compliance with study medication|2
6287014|NCT02347761|9999445|FG000|On Study Treatment|Withdrawal by Subject|7
6287015|NCT02347761|9999446|FG001|On Study Treatment|Withdrawal by Subject|3
6287016|NCT02347761|9999447|FG002|On Study Treatment|Withdrawal by Subject|5
6287017|NCT02347761|9999445|FG000|On Study Treatment|move/travel|2
6287018|NCT02347761|9999446|FG001|On Study Treatment|move/travel|6
6287019|NCT02347761|9999447|FG002|On Study Treatment|move/travel|5
6287020|NCT02347761|9999445|FG000|On Study Treatment|dissastisfaction with device|2
6287021|NCT02347761|9999446|FG001|On Study Treatment|dissastisfaction with device|1
6287022|NCT02347761|9999447|FG002|On Study Treatment|dissastisfaction with device|4
6287023|NCT02347761|9999445|FG000|On Study Treatment|Lost to Follow-up|2
6287024|NCT02347761|9999446|FG001|On Study Treatment|Lost to Follow-up|1
6287025|NCT02347761|9999447|FG002|On Study Treatment|Lost to Follow-up|1
6287026|NCT02347761|9999445|FG000|On Study Treatment|investigator discretion|2
6287027|NCT02347761|9999446|FG001|On Study Treatment|investigator discretion|0
6117784|NCT00872521|9740020|FG001|Completed PAD Induction|Death|1
6117785|NCT00872521|9740021|FG002|Completed PAD Induction|Death|0
6117786|NCT00872521|9740019|FG000|Primary Endpoint Analysis|Other|1
6117787|NCT00872521|9740020|FG001|Primary Endpoint Analysis|Other|2
6117788|NCT00872521|9740021|FG002|Primary Endpoint Analysis|Other|0
6117789|NCT00872521|9740019|FG000|Primary Endpoint Analysis|Patient choice|0
6117790|NCT00872521|9740020|FG001|Primary Endpoint Analysis|Patient choice|1
6117791|NCT00872521|9740021|FG002|Primary Endpoint Analysis|Patient choice|0
6117792|NCT00872521|9740019|FG000|Primary Endpoint Analysis|Efficacy data unavailable|0
6117793|NCT00872521|9740020|FG001|Primary Endpoint Analysis|Efficacy data unavailable|2
6117794|NCT00872521|9740021|FG002|Primary Endpoint Analysis|Efficacy data unavailable|0
6117795|NCT00872521|9740019|FG000|Primary Endpoint Analysis|Patient response missing|0
6117796|NCT00872521|9740020|FG001|Primary Endpoint Analysis|Patient response missing|0
6117797|NCT00872521|9740021|FG002|Primary Endpoint Analysis|Patient response missing|1
6117798|NCT00872521|9740019|FG000|Completed 3-month Follow up|Other|0
6117799|NCT00872521|9740020|FG001|Completed 3-month Follow up|Other|2
6117800|NCT00872521|9740021|FG002|Completed 3-month Follow up|Other|0
6117801|NCT00872521|9740019|FG000|Completed 3-month Follow up|Physician Decision|0
6117802|NCT00872521|9740020|FG001|Completed 3-month Follow up|Physician Decision|1
6117803|NCT00872521|9740021|FG002|Completed 3-month Follow up|Physician Decision|0
6117804|NCT00872521|9740019|FG000|Secondary Endpoint Analysis|Efficacy data unavailable|0
6117805|NCT00872521|9740020|FG001|Secondary Endpoint Analysis|Efficacy data unavailable|2
6117806|NCT00872521|9740021|FG002|Secondary Endpoint Analysis|Efficacy data unavailable|1
6117807|NCT00872599|9740049|FG000|Second Washout Period|Adverse Event|1
6117808|NCT00872599|9740050|FG001|Second Washout Period|Adverse Event|1
6117809|NCT00872898|9740095|FG000|Part Two - Double Blind|Adverse Event|4
6117810|NCT00872898|9740096|FG001|Part Two - Double Blind|Adverse Event|3
6117811|NCT00872898|9740095|FG000|Part Two - Double Blind|Lack of Efficacy|1
6117812|NCT00872898|9740096|FG001|Part Two - Double Blind|Lack of Efficacy|0
6117813|NCT00872898|9740095|FG000|Part Two - Double Blind|Protocol Violation|1
6117814|NCT00872898|9740096|FG001|Part Two - Double Blind|Protocol Violation|0
6117815|NCT00872898|9740095|FG000|Part Two - Double Blind|Withdrawal by Subject|3
6117816|NCT00872898|9740096|FG001|Part Two - Double Blind|Withdrawal by Subject|1
6117817|NCT00872898|9740095|FG000|Part Two - Double Blind|Lost to Follow-up|0
6117818|NCT00872898|9740096|FG001|Part Two - Double Blind|Lost to Follow-up|2
6117819|NCT00872898|9740095|FG000|Part Two - Double Blind|Other reasons|2
6117820|NCT00872898|9740096|FG001|Part Two - Double Blind|Other reasons|0
6117821|NCT00872989|9740107|FG000|Overall Study|Adverse Event|7
6117822|NCT00872989|9740108|FG001|Overall Study|Adverse Event|15
6117823|NCT00872989|9740107|FG000|Overall Study|Withdrawal by Subject|8
6117824|NCT00872989|9740108|FG001|Overall Study|Withdrawal by Subject|5
6117825|NCT00872989|9740107|FG000|Overall Study|Progression/relapse|47
6117826|NCT00872989|9740108|FG001|Overall Study|Progression/relapse|35
6117827|NCT00872989|9740107|FG000|Overall Study|Not protocol specified|3
6117828|NCT00872989|9740108|FG001|Overall Study|Not protocol specified|8
6117829|NCT00873015|9740124|FG000|Overall Study|Withdrawal by Subject|0
6117830|NCT00873015|9740125|FG001|Overall Study|Withdrawal by Subject|1
6117831|NCT00873015|9740126|FG002|Overall Study|Withdrawal by Subject|0
6117832|NCT00873015|9740127|FG003|Overall Study|Withdrawal by Subject|0
6117833|NCT00873041|9740139|FG000|Core Study|Adverse Event|2
6117834|NCT00873041|9740140|FG001|Core Study|Adverse Event|3
6117835|NCT00873041|9740141|FG002|Core Study|Adverse Event|1
6117836|NCT00873041|9740139|FG000|Core Study|Withdrawal by Subject|1
6117837|NCT00873041|9740140|FG001|Core Study|Withdrawal by Subject|2
6117838|NCT00873041|9740141|FG002|Core Study|Withdrawal by Subject|2
6211385|NCT01588366|9877459|FG005|Overall Study|Adverse Event|2
6211386|NCT01588405|9877475|FG000|Overall Study|Adverse Event|1
6211387|NCT01588405|9877475|FG000|Overall Study|Clinical Worsening|1
6211388|NCT01588496|9877535|FG000|Overall Study|Withdrawal by Subject|0
6211389|NCT01588496|9877536|FG001|Overall Study|Withdrawal by Subject|1
6211390|NCT01588496|9877537|FG002|Overall Study|Withdrawal by Subject|0
6211391|NCT01588509|9877547|FG000|Overall Study|Lost to Follow-up|1
6211392|NCT01588509|9877548|FG001|Overall Study|Lost to Follow-up|0
6211393|NCT01588548|9877560|FG000|Overall Study|Withdrawal by Subject|0
6211394|NCT01588548|9877561|FG001|Overall Study|Withdrawal by Subject|1
6211395|NCT01588548|9877562|FG002|Overall Study|Withdrawal by Subject|1
6211396|NCT01588548|9877563|FG003|Overall Study|Withdrawal by Subject|1
6211397|NCT01588548|9877564|FG004|Overall Study|Withdrawal by Subject|2
6211398|NCT01588548|9877565|FG005|Overall Study|Withdrawal by Subject|3
6211399|NCT01588548|9877560|FG000|Overall Study|Adverse Event|0
6211400|NCT01588548|9877561|FG001|Overall Study|Adverse Event|0
6211401|NCT01588548|9877562|FG002|Overall Study|Adverse Event|1
6211402|NCT01588548|9877563|FG003|Overall Study|Adverse Event|2
6211403|NCT01588548|9877564|FG004|Overall Study|Adverse Event|1
6211404|NCT01588548|9877565|FG005|Overall Study|Adverse Event|0
6211405|NCT01588548|9877560|FG000|Overall Study|Condition Under Investigation Worsened|3
6211406|NCT01588548|9877561|FG001|Overall Study|Condition Under Investigation Worsened|6
6211407|NCT01588548|9877562|FG002|Overall Study|Condition Under Investigation Worsened|4
6211408|NCT01588548|9877563|FG003|Overall Study|Condition Under Investigation Worsened|4
6211409|NCT01588548|9877564|FG004|Overall Study|Condition Under Investigation Worsened|3
6211410|NCT01588548|9877565|FG005|Overall Study|Condition Under Investigation Worsened|3
6117839|NCT00873041|9740139|FG000|Core Study|Lost to Follow-up|3
6117840|NCT00873041|9740140|FG001|Core Study|Lost to Follow-up|1
6117841|NCT00873041|9740141|FG002|Core Study|Lost to Follow-up|0
6117842|NCT00873041|9740139|FG000|Core Study|Abnormal laboratory value|0
6117843|NCT00873041|9740140|FG001|Core Study|Abnormal laboratory value|0
6117844|NCT00873041|9740141|FG002|Core Study|Abnormal laboratory value|1
6117845|NCT00873041|9740139|FG000|Core Study|Protocol deviation|1
6117846|NCT00873041|9740140|FG001|Core Study|Protocol deviation|0
6117847|NCT00873041|9740141|FG002|Core Study|Protocol deviation|1
6117848|NCT00873041|9740139|FG000|Extension Study|Adverse Event|1
6117849|NCT00873041|9740140|FG001|Extension Study|Adverse Event|0
6117850|NCT00873041|9740141|FG002|Extension Study|Adverse Event|1
6117851|NCT00873041|9740139|FG000|Extension Study|Administrative reasons|0
6117852|NCT00873041|9740140|FG001|Extension Study|Administrative reasons|0
6117853|NCT00873041|9740141|FG002|Extension Study|Administrative reasons|1
6117854|NCT00873093|9740161|FG000|Overall Study|Adverse Event|0
6117855|NCT00873093|9740162|FG001|Overall Study|Adverse Event|2
6117856|NCT00873093|9740163|FG002|Overall Study|Adverse Event|0
6211411|NCT01588951|9877594|FG000|Overall Study|Ineligible in retrospect|0
6211412|NCT01588951|9877595|FG001|Overall Study|Ineligible in retrospect|0
6211413|NCT01588951|9877596|FG002|Overall Study|Ineligible in retrospect|1
6211414|NCT01588990|9877604|FG000|Phase A|Withdrawal by Subject|5
6211415|NCT01588990|9877604|FG000|Phase A|Physician Decision|11
6211416|NCT01588990|9877604|FG000|Phase A|Other|14
6211417|NCT01588990|9877604|FG000|Phase A|Lost to Follow-up|1
6287028|NCT02347761|9999447|FG002|On Study Treatment|investigator discretion|0
6287029|NCT02347761|9999445|FG000|On Study Treatment|durg not working|0
6287030|NCT02347761|9999446|FG001|On Study Treatment|durg not working|1
6063234|NCT00505414|9664577|FG004|Maintenance Phase|Withdrawal by Subject|0
6117857|NCT00873093|9740164|FG003|Overall Study|Adverse Event|0
6117858|NCT00873093|9740165|FG004|Overall Study|Adverse Event|0
6117859|NCT00873093|9740161|FG000|Overall Study|Death|0
6117860|NCT00873093|9740162|FG001|Overall Study|Death|3
6117861|NCT00873093|9740163|FG002|Overall Study|Death|2
6117862|NCT00873093|9740164|FG003|Overall Study|Death|0
6117863|NCT00873093|9740165|FG004|Overall Study|Death|0
6117864|NCT00873093|9740161|FG000|Overall Study|Physician Decision|0
6117865|NCT00873093|9740162|FG001|Overall Study|Physician Decision|17
6117866|NCT00873093|9740163|FG002|Overall Study|Physician Decision|10
6117867|NCT00873093|9740164|FG003|Overall Study|Physician Decision|10
6117868|NCT00873093|9740165|FG004|Overall Study|Physician Decision|2
6117869|NCT00873093|9740161|FG000|Overall Study|Withdrawal by Subject|1
6211418|NCT01588990|9877604|FG000|Phase A|Death|5
6211419|NCT01588990|9877604|FG000|Phase A|Adverse Event|28
6211420|NCT01588990|9877604|FG000|Phase A|Still on therapy at end of study|6
6211421|NCT01588990|9877604|FG000|Phase B|Adverse Event|2
6211422|NCT01588990|9877604|FG000|Phase B|Still on therapy at end of study|5
6211423|NCT01588990|9877604|FG000|Phase B|Withdrawal by Subject|3
6211424|NCT01588990|9877604|FG000|Phase B|Physician Decision|4
6211425|NCT01588990|9877604|FG000|Phase B|Other|2
6211426|NCT01589094|9877612|FG000|Overall Study|Did not receive treatment|2
6211427|NCT01589185|9877621|FG000|Overall Study|Death|1
6211428|NCT01589185|9877622|FG001|Overall Study|Death|2
6211429|NCT01589185|9877623|FG002|Overall Study|Death|2
6211430|NCT01589185|9877624|FG003|Overall Study|Death|0
6211431|NCT01589185|9877625|FG004|Overall Study|Death|1
6211432|NCT01589185|9877621|FG000|Overall Study|Lost to Follow-up|1
6211433|NCT01589185|9877622|FG001|Overall Study|Lost to Follow-up|0
6211434|NCT01589185|9877623|FG002|Overall Study|Lost to Follow-up|2
6211435|NCT01589185|9877624|FG003|Overall Study|Lost to Follow-up|3
6211436|NCT01589185|9877625|FG004|Overall Study|Lost to Follow-up|0
6211437|NCT01589237|9877642|FG000|Part A (52 Weeks)|Subject/guardian decision|2
6211438|NCT01589237|9877643|FG001|Part A (52 Weeks)|Subject/guardian decision|3
6211439|NCT01589237|9877644|FG002|Part A (52 Weeks)|Subject/guardian decision|2
6211440|NCT01589237|9877645|FG003|Part A (52 Weeks)|Subject/guardian decision|0
6211441|NCT01589237|9877642|FG000|Part B (Planned for 78 Week-terminated)|Subject/guardian decision|0
6211442|NCT01589237|9877643|FG001|Part B (Planned for 78 Week-terminated)|Subject/guardian decision|1
6287031|NCT02347761|9999447|FG002|On Study Treatment|durg not working|1
6063235|NCT00505414|9664573|FG000|Maintenance Phase|underlying disease and therapy required|0
6063236|NCT00505414|9664574|FG001|Maintenance Phase|underlying disease and therapy required|2
6063237|NCT00505414|9664575|FG002|Maintenance Phase|underlying disease and therapy required|2
6063238|NCT00505414|9664576|FG003|Maintenance Phase|underlying disease and therapy required|0
6063239|NCT00505414|9664577|FG004|Maintenance Phase|underlying disease and therapy required|0
6063240|NCT00505622|9664596|FG000|Overall Study|Adverse Event|5
6063241|NCT00505622|9664597|FG001|Overall Study|Adverse Event|6
6063242|NCT00505622|9664598|FG002|Overall Study|Adverse Event|4
6063243|NCT00505622|9664596|FG000|Overall Study|Protocol Violation|1
6063244|NCT00505622|9664597|FG001|Overall Study|Protocol Violation|1
6063245|NCT00505622|9664598|FG002|Overall Study|Protocol Violation|0
6063246|NCT00505622|9664596|FG000|Overall Study|Withdrawal by Subject|0
6063247|NCT00505622|9664597|FG001|Overall Study|Withdrawal by Subject|3
6063248|NCT00505622|9664598|FG002|Overall Study|Withdrawal by Subject|2
6117870|NCT00873093|9740162|FG001|Overall Study|Withdrawal by Subject|4
6211443|NCT01589237|9877644|FG002|Part B (Planned for 78 Week-terminated)|Subject/guardian decision|0
6117871|NCT00873093|9740163|FG002|Overall Study|Withdrawal by Subject|4
6117872|NCT00873093|9740164|FG003|Overall Study|Withdrawal by Subject|0
6117873|NCT00873093|9740165|FG004|Overall Study|Withdrawal by Subject|0
6117874|NCT00873093|9740161|FG000|Overall Study|Ineligible|0
6117875|NCT00873093|9740162|FG001|Overall Study|Ineligible|1
6117876|NCT00873093|9740163|FG002|Overall Study|Ineligible|0
6117877|NCT00873093|9740164|FG003|Overall Study|Ineligible|1
6117878|NCT00873093|9740165|FG004|Overall Study|Ineligible|0
6117879|NCT00873119|9740189|FG000|Overall Study|Patient request|4
6117880|NCT00873119|9740190|FG001|Overall Study|Patient request|2
6117881|NCT00873119|9740189|FG000|Overall Study|Adverse Event|8
6117882|NCT00873119|9740190|FG001|Overall Study|Adverse Event|0
6117883|NCT00873119|9740189|FG000|Overall Study|Progressive disease|26
6117884|NCT00873119|9740190|FG001|Overall Study|Progressive disease|18
6117885|NCT00873119|9740189|FG000|Overall Study|Death|2
6117886|NCT00873119|9740190|FG001|Overall Study|Death|1
6117887|NCT00873119|9740189|FG000|Overall Study|Other|2
6117888|NCT00873119|9740190|FG001|Overall Study|Other|5
6117889|NCT00873119|9740189|FG000|Overall Study|Not treated|2
6117890|NCT00873119|9740190|FG001|Overall Study|Not treated|0
6117891|NCT00873730|9740206|FG000|Overall Study|Protocol Deviation|5
6117892|NCT00873730|9740207|FG001|Overall Study|Protocol Deviation|2
6117893|NCT00873730|9740206|FG000|Overall Study|Adverse Event|0
6117894|NCT00873730|9740207|FG001|Overall Study|Adverse Event|2
6117895|NCT00873730|9740206|FG000|Overall Study|Withdrawal by Subject|0
6117896|NCT00873730|9740207|FG001|Overall Study|Withdrawal by Subject|1
6117897|NCT00873730|9740206|FG000|Overall Study|Sponsor decision|1
6117898|NCT00873730|9740207|FG001|Overall Study|Sponsor decision|0
6117899|NCT00873860|9740230|FG000|Overall Study|Lost to Follow-up|1
6117900|NCT00873860|9740231|FG001|Overall Study|Lost to Follow-up|0
6117901|NCT00873860|9740232|FG002|Overall Study|Lost to Follow-up|0
6117902|NCT00873860|9740233|FG003|Overall Study|Lost to Follow-up|1
6117903|NCT00873860|9740230|FG000|Overall Study|Withdrawal by Subject|1
6117904|NCT00873860|9740231|FG001|Overall Study|Withdrawal by Subject|0
6117905|NCT00873860|9740232|FG002|Overall Study|Withdrawal by Subject|2
6117906|NCT00873860|9740233|FG003|Overall Study|Withdrawal by Subject|0
6117907|NCT00873860|9740230|FG000|Overall Study|Death|1
6117908|NCT00873860|9740231|FG001|Overall Study|Death|0
6117909|NCT00873860|9740232|FG002|Overall Study|Death|0
6117910|NCT00873860|9740233|FG003|Overall Study|Death|0
6117911|NCT00873860|9740230|FG000|Overall Study|Other|1
6117912|NCT00873860|9740231|FG001|Overall Study|Other|0
6117913|NCT00873860|9740232|FG002|Overall Study|Other|1
6117914|NCT00873860|9740233|FG003|Overall Study|Other|0
6117915|NCT00873912|9740265|FG000|Overall Study|Withdrawal by Subject|1
6117916|NCT00873912|9740266|FG001|Overall Study|Withdrawal by Subject|0
6117917|NCT00873912|9740265|FG000|Overall Study|Lost to Follow-up|2
6117918|NCT00873912|9740266|FG001|Overall Study|Lost to Follow-up|0
6117919|NCT00874029|9740272|FG000|Overall Study|Withdrawal by Subject|10
6117920|NCT00874029|9740272|FG000|Overall Study|Pregnancy|4
6117921|NCT00874029|9740272|FG000|Overall Study|Physician Decision|1
6117922|NCT00874029|9740272|FG000|Overall Study|Adverse Event|1
6117923|NCT00874029|9740272|FG000|Overall Study|Lost to Follow-up|5
6117924|NCT00874120|9740292|FG000|First Intervention|Adverse Event|0
6117925|NCT00874120|9740293|FG001|First Intervention|Adverse Event|1
6117926|NCT00874120|9740292|FG000|First Intervention|Withdrawal by Subject|2
6117927|NCT00874120|9740293|FG001|First Intervention|Withdrawal by Subject|0
6117928|NCT00874120|9740292|FG000|First Intervention|Lost to Follow-up|0
6117929|NCT00874120|9740293|FG001|First Intervention|Lost to Follow-up|1
6117930|NCT00874120|9740292|FG000|First Intervention|Protocol Violation|3
6117931|NCT00874120|9740293|FG001|First Intervention|Protocol Violation|0
6117932|NCT00874120|9740292|FG000|First Intervention|positive drug test|1
6117933|NCT00874120|9740293|FG001|First Intervention|positive drug test|0
6117934|NCT00874120|9740292|FG000|Second Intervention|Withdrawal by Subject|1
6117935|NCT00874120|9740293|FG001|Second Intervention|Withdrawal by Subject|0
6211444|NCT01589237|9877645|FG003|Part B (Planned for 78 Week-terminated)|Subject/guardian decision|0
6211445|NCT01589237|9877642|FG000|Part B (Planned for 78 Week-terminated)|Study terminated by sponsor|5
6211446|NCT01589237|9877643|FG001|Part B (Planned for 78 Week-terminated)|Study terminated by sponsor|5
6211447|NCT01589237|9877644|FG002|Part B (Planned for 78 Week-terminated)|Study terminated by sponsor|4
6211448|NCT01589237|9877645|FG003|Part B (Planned for 78 Week-terminated)|Study terminated by sponsor|3
6211449|NCT01589237|9877642|FG000|Part B (Planned for 78 Week-terminated)|Physician Decision|0
6211450|NCT01589237|9877643|FG001|Part B (Planned for 78 Week-terminated)|Physician Decision|0
6211451|NCT01589237|9877644|FG002|Part B (Planned for 78 Week-terminated)|Physician Decision|0
6211452|NCT01589237|9877645|FG003|Part B (Planned for 78 Week-terminated)|Physician Decision|1
6211453|NCT01589445|9877677|FG000|001 (Pioglitazone) -3 Months|Protocol Violation|1
6117936|NCT00874120|9740292|FG000|Second Intervention|Protocol Violation|1
6117937|NCT00874120|9740293|FG001|Second Intervention|Protocol Violation|0
6117938|NCT00874237|9740299|FG000|Overall Study|Physician Decision|0
6117939|NCT00874237|9740300|FG001|Overall Study|Physician Decision|1
6117940|NCT00874237|9740301|FG002|Overall Study|Physician Decision|0
6117941|NCT00874237|9740302|FG003|Overall Study|Physician Decision|0
6117942|NCT00874237|9740303|FG004|Overall Study|Physician Decision|0
6117943|NCT00874237|9740304|FG005|Overall Study|Physician Decision|0
6117944|NCT00874237|9740299|FG000|Overall Study|Withdrawal by Subject|0
6211454|NCT01589445|9877677|FG000|001 (Pioglitazone) -3 Months|Withdrawal by Subject|1
6211455|NCT01589445|9877677|FG000|001 (Pioglitazone) -3 Months|Lost to Follow-up|2
6211456|NCT01589445|9877677|FG000|001 (Pioglitazone) -3 Months|Lack of Efficacy|1
6211457|NCT01589445|9877677|FG000|001 (Pioglitazone) -3 Months|biasedness about the double blind method|2
6211458|NCT01589445|9877677|FG000|002 (Metformin)-3 Months|Lack of Efficacy|1
6211459|NCT01589445|9877677|FG000|002 (Metformin)-3 Months|Lost to Follow-up|2
6211460|NCT01589445|9877677|FG000|002 (Metformin)-3 Months|Protocol Violation|2
6211461|NCT01589445|9877677|FG000|002 (Metformin)-3 Months|Adverse Event|2
6211462|NCT01589445|9877677|FG000|002 (Metformin)-3 Months|Husbands of female patients refrained|2
6211463|NCT01589497|9877694|FG000|Overall Study|Withdrawal by Subject|0
6211464|NCT01589497|9877695|FG001|Overall Study|Withdrawal by Subject|1
6211465|NCT01589497|9877696|FG002|Overall Study|Withdrawal by Subject|0
6211466|NCT01589497|9877697|FG003|Overall Study|Withdrawal by Subject|1
6211467|NCT01589497|9877694|FG000|Overall Study|Death|1
6211468|NCT01589497|9877695|FG001|Overall Study|Death|0
6211469|NCT01589497|9877696|FG002|Overall Study|Death|0
6211470|NCT01589497|9877697|FG003|Overall Study|Death|0
6211471|NCT01589497|9877694|FG000|Overall Study|Pre-entry overnight sputum< 10ML|0
6211472|NCT01589497|9877695|FG001|Overall Study|Pre-entry overnight sputum< 10ML|0
6211473|NCT01589497|9877696|FG002|Overall Study|Pre-entry overnight sputum< 10ML|1
6211474|NCT01589497|9877697|FG003|Overall Study|Pre-entry overnight sputum< 10ML|0
6211475|NCT01589653|9877727|FG000|Overall Study|Protocol Violation|3
6211476|NCT01589653|9877728|FG001|Overall Study|Protocol Violation|1
6211477|NCT01589653|9877727|FG000|Overall Study|Withdrawal criteria|4
6211478|NCT01589653|9877728|FG001|Overall Study|Withdrawal criteria|7
6211479|NCT01589653|9877727|FG000|Overall Study|Unclassified|0
6211480|NCT01589653|9877728|FG001|Overall Study|Unclassified|3
6211481|NCT01589770|9877736|FG000|Overall Study|EGFR <60ml/min|6
6211482|NCT01589770|9877737|FG001|Overall Study|EGFR <60ml/min|4
6211483|NCT01589770|9877736|FG000|Overall Study|claustrophobic when entering cardiac MRI|2
6211484|NCT01589770|9877737|FG001|Overall Study|claustrophobic when entering cardiac MRI|1
6211485|NCT01589822|9877746|FG000|Overall Study|Withdrawal by Subject|1
6211486|NCT01589822|9877747|FG001|Overall Study|Withdrawal by Subject|2
6211487|NCT01589822|9877748|FG002|Overall Study|Withdrawal by Subject|0
6211488|NCT01589822|9877746|FG000|Overall Study|Death|1
6211489|NCT01589822|9877747|FG001|Overall Study|Death|0
6211490|NCT01589822|9877748|FG002|Overall Study|Death|0
6211491|NCT01589822|9877746|FG000|Overall Study|Missed 90 day visit|2
6211492|NCT01589822|9877747|FG001|Overall Study|Missed 90 day visit|1
6211493|NCT01589822|9877748|FG002|Overall Study|Missed 90 day visit|1
6211494|NCT01590017|9877763|FG000|Overall Study|Adverse Event|1
6211495|NCT01590017|9877763|FG000|Overall Study|Withdrawal by Subject|1
6211496|NCT01590017|9877763|FG000|Overall Study|Lack of Efficacy|1
6211497|NCT01590017|9877763|FG000|Overall Study|Physician Decision|1
6211498|NCT01590082|9877769|FG000|Overall Study|Withdrawal by Subject|1
6211499|NCT01590082|9877770|FG001|Overall Study|Withdrawal by Subject|0
6211500|NCT01590082|9877769|FG000|Overall Study|Ineligible|1
6211501|NCT01590082|9877770|FG001|Overall Study|Ineligible|0
6211502|NCT01590212|9877779|FG000|Overall Study|Withdrawal by Subject|2
6211503|NCT01590212|9877780|FG001|Overall Study|Withdrawal by Subject|2
6211504|NCT01590212|9877781|FG002|Overall Study|Withdrawal by Subject|2
6211505|NCT01590212|9877779|FG000|Overall Study|Lost to Follow-up|1
6211506|NCT01590212|9877780|FG001|Overall Study|Lost to Follow-up|2
6211507|NCT01590212|9877781|FG002|Overall Study|Lost to Follow-up|3
6211508|NCT01590433|9877800|FG000|Overall Study|Lost to Follow-up|20
6211509|NCT01590433|9877801|FG001|Overall Study|Lost to Follow-up|8
6211510|NCT01590433|9877800|FG000|Overall Study|Withdrawal by Subject|21
6211511|NCT01590433|9877801|FG001|Overall Study|Withdrawal by Subject|11
6211512|NCT01590433|9877800|FG000|Overall Study|Adverse Event|11
6211513|NCT01590433|9877801|FG001|Overall Study|Adverse Event|3
6211514|NCT01590563|9877812|FG000|Overall Study|simple uterine hyperplasia - not related|1
6211515|NCT01590758|9877819|FG000|Overall Study|Withdrawal by Subject|0
6211516|NCT01590758|9877820|FG001|Overall Study|Withdrawal by Subject|3
6211517|NCT01590758|9877819|FG000|Overall Study|Physician Decision|1
6211518|NCT01590758|9877820|FG001|Overall Study|Physician Decision|2
6211519|NCT01590758|9877819|FG000|Overall Study|Lost to Follow-up|4
6063249|NCT00505622|9664596|FG000|Overall Study|Study termination by sponsor|115
6063250|NCT00505622|9664597|FG001|Overall Study|Study termination by sponsor|98
6063251|NCT00505622|9664598|FG002|Overall Study|Study termination by sponsor|90
6063252|NCT00505661|9664610|FG000|Overall Study|Not Eligible|4
6063253|NCT00505687|9664614|FG000|Overall Study|Important protocol violation|2
6063254|NCT00505687|9664614|FG000|Overall Study|Lack of Efficacy|15
6063255|NCT00505687|9664614|FG000|Overall Study|Adverse Event|48
6063256|NCT00505687|9664614|FG000|Overall Study|Subject withdrew consent|15
6063257|NCT00505687|9664614|FG000|Overall Study|Lost to Follow-up|1
6063258|NCT00505687|9664614|FG000|Overall Study|Other: Underwent Implantation Of DBS|1
6117945|NCT00874237|9740300|FG001|Overall Study|Withdrawal by Subject|0
6211520|NCT01590758|9877820|FG001|Overall Study|Lost to Follow-up|2
6211521|NCT01590771|9877828|FG000|Overall Study|Other Protocol Specified Criteria|5
6211522|NCT01590771|9877829|FG001|Overall Study|Other Protocol Specified Criteria|14
6211523|NCT01590771|9877828|FG000|Overall Study|Withdrawal by Subject|8
6211524|NCT01590771|9877829|FG001|Overall Study|Withdrawal by Subject|15
6117946|NCT00874237|9740301|FG002|Overall Study|Withdrawal by Subject|1
6117947|NCT00874237|9740302|FG003|Overall Study|Withdrawal by Subject|0
6117948|NCT00874237|9740303|FG004|Overall Study|Withdrawal by Subject|0
6117949|NCT00874237|9740304|FG005|Overall Study|Withdrawal by Subject|0
6117950|NCT00874276|9740321|FG000|Overall Study|Withdrawal by Subject|1
6117951|NCT00874276|9740322|FG001|Overall Study|Withdrawal by Subject|1
6117952|NCT00874432|9740334|FG000|Overall Study|Withdrawal by Subject|1
6117953|NCT00874432|9740335|FG001|Overall Study|Withdrawal by Subject|0
6117954|NCT00874432|9740336|FG002|Overall Study|Withdrawal by Subject|0
6117955|NCT00874432|9740337|FG003|Overall Study|Withdrawal by Subject|0
6117956|NCT00874432|9740334|FG000|Overall Study|Physician Decision|1
6117957|NCT00874432|9740335|FG001|Overall Study|Physician Decision|0
6117958|NCT00874432|9740336|FG002|Overall Study|Physician Decision|0
6117959|NCT00874432|9740337|FG003|Overall Study|Physician Decision|0
6117960|NCT00874432|9740334|FG000|Overall Study|Other|1
6117961|NCT00874432|9740335|FG001|Overall Study|Other|2
6117962|NCT00874432|9740336|FG002|Overall Study|Other|8
6117963|NCT00874432|9740337|FG003|Overall Study|Other|3
6117964|NCT00874497|9740351|FG000|Overall Study|Lost to Follow-up|2
6117965|NCT00874497|9740352|FG001|Overall Study|Lost to Follow-up|4
6117966|NCT00874497|9740351|FG000|Overall Study|Adverse Event|9
6117967|NCT00874497|9740352|FG001|Overall Study|Adverse Event|4
6117968|NCT00874497|9740351|FG000|Overall Study|Sponsor Discontinued Trial|7
6117969|NCT00874497|9740352|FG001|Overall Study|Sponsor Discontinued Trial|3
6117970|NCT00874497|9740351|FG000|Overall Study|Met Withdrawal Criteria|4
6117971|NCT00874497|9740352|FG001|Overall Study|Met Withdrawal Criteria|2
6117972|NCT00874497|9740351|FG000|Overall Study|Physician Decision|1
6117973|NCT00874497|9740352|FG001|Overall Study|Physician Decision|1
6117974|NCT00874497|9740351|FG000|Overall Study|Withdrawal by Subject|5
6117975|NCT00874497|9740352|FG001|Overall Study|Withdrawal by Subject|4
6117976|NCT00874549|9740371|FG000|Overall Study|Adverse Event|0
6117977|NCT00874549|9740372|FG001|Overall Study|Adverse Event|0
6117978|NCT00874549|9740373|FG002|Overall Study|Adverse Event|1
6117979|NCT00874549|9740374|FG003|Overall Study|Adverse Event|0
6117980|NCT00874549|9740371|FG000|Overall Study|Protocol Violation|1
6117981|NCT00874549|9740372|FG001|Overall Study|Protocol Violation|0
6117982|NCT00874549|9740373|FG002|Overall Study|Protocol Violation|2
6117983|NCT00874549|9740374|FG003|Overall Study|Protocol Violation|1
6117984|NCT00874549|9740371|FG000|Overall Study|Lost to Follow-up|0
6117985|NCT00874549|9740372|FG001|Overall Study|Lost to Follow-up|0
6117986|NCT00874549|9740373|FG002|Overall Study|Lost to Follow-up|1
6117987|NCT00874549|9740374|FG003|Overall Study|Lost to Follow-up|0
6117988|NCT00874549|9740371|FG000|Overall Study|Withdrawal by Subject|0
6211525|NCT01590771|9877828|FG000|Overall Study|Protocol Violation|1
6211526|NCT01590771|9877829|FG001|Overall Study|Protocol Violation|2
6211527|NCT01590771|9877828|FG000|Overall Study|Lost to Follow-up|1
6211528|NCT01590771|9877829|FG001|Overall Study|Lost to Follow-up|1
6211529|NCT01590771|9877828|FG000|Overall Study|Lack of Efficacy|1
6211530|NCT01590771|9877829|FG001|Overall Study|Lack of Efficacy|0
6211531|NCT01590771|9877828|FG000|Overall Study|Adverse Event|3
6211532|NCT01590771|9877829|FG001|Overall Study|Adverse Event|7
6211533|NCT01590797|9877837|FG000|Overall Study|Adverse Event|4
6211534|NCT01590797|9877838|FG001|Overall Study|Adverse Event|3
6211535|NCT01590797|9877837|FG000|Overall Study|Lack of Efficacy|0
6211536|NCT01590797|9877838|FG001|Overall Study|Lack of Efficacy|2
6211537|NCT01590797|9877837|FG000|Overall Study|Lost to Follow-up|0
6211538|NCT01590797|9877838|FG001|Overall Study|Lost to Follow-up|1
6211539|NCT01590797|9877837|FG000|Overall Study|Protocol Violation|4
6211540|NCT01590797|9877838|FG001|Overall Study|Protocol Violation|1
6211541|NCT01590797|9877837|FG000|Overall Study|Withdrawal by Subject|7
6211542|NCT01590797|9877838|FG001|Overall Study|Withdrawal by Subject|5
6211543|NCT01590797|9877837|FG000|Overall Study|Other Protocol Specified Criteria|2
6211544|NCT01590797|9877838|FG001|Overall Study|Other Protocol Specified Criteria|4
6211545|NCT01590810|9877849|FG000|Overall Study|Physician Decision|0
6211546|NCT01590810|9877850|FG001|Overall Study|Physician Decision|1
6211547|NCT01590810|9877851|FG002|Overall Study|Physician Decision|1
6211548|NCT01590810|9877852|FG003|Overall Study|Physician Decision|0
6211549|NCT01590810|9877853|FG004|Overall Study|Physician Decision|0
6211550|NCT01590888|9877900|FG000|Overall Study|Adverse Event|3
6211551|NCT01590888|9877901|FG001|Overall Study|Adverse Event|0
6211552|NCT01590888|9877902|FG002|Overall Study|Adverse Event|1
6211553|NCT01590888|9877900|FG000|Overall Study|Lost to Follow-up|1
6211554|NCT01590888|9877901|FG001|Overall Study|Lost to Follow-up|0
6117989|NCT00874549|9740372|FG001|Overall Study|Withdrawal by Subject|1
6117990|NCT00874549|9740373|FG002|Overall Study|Withdrawal by Subject|0
6117991|NCT00874549|9740374|FG003|Overall Study|Withdrawal by Subject|1
6211555|NCT01590888|9877902|FG002|Overall Study|Lost to Follow-up|0
6211556|NCT01591330|9877985|FG000|Period 1|Adverse Event|1
6211557|NCT01591330|9877986|FG001|Period 1|Adverse Event|0
6211558|NCT01591330|9877987|FG002|Period 1|Adverse Event|0
6117992|NCT00874731|9740390|FG000|Part 1, Day 1: Placebo|Disease Progression|1
6117993|NCT00874731|9740391|FG001|Part 1, Day 1: Placebo|Disease Progression|0
6117994|NCT00874731|9740392|FG002|Part 1, Day 1: Placebo|Disease Progression|0
6211559|NCT01591330|9877988|FG003|Period 1|Adverse Event|0
6211560|NCT01591330|9877985|FG000|Washout of at Least 3 Days|Withdrawal by Subject|1
6211561|NCT01591330|9877986|FG001|Washout of at Least 3 Days|Withdrawal by Subject|0
6117995|NCT00874731|9740390|FG000|Part 2: Ridaforolimus 40 mg|Adverse Event|0
6117996|NCT00874731|9740391|FG001|Part 2: Ridaforolimus 40 mg|Adverse Event|0
6117997|NCT00874731|9740392|FG002|Part 2: Ridaforolimus 40 mg|Adverse Event|3
6117998|NCT00874731|9740390|FG000|Part 2: Ridaforolimus 40 mg|Disease Progression|0
6117999|NCT00874731|9740391|FG001|Part 2: Ridaforolimus 40 mg|Disease Progression|0
6118000|NCT00874731|9740392|FG002|Part 2: Ridaforolimus 40 mg|Disease Progression|19
6118001|NCT00874770|9740404|FG000|Overall Study|Lack of Efficacy|2
6118002|NCT00874770|9740405|FG001|Overall Study|Lack of Efficacy|0
6118003|NCT00874770|9740406|FG002|Overall Study|Lack of Efficacy|0
6118004|NCT00874770|9740407|FG003|Overall Study|Lack of Efficacy|2
6118005|NCT00874770|9740404|FG000|Overall Study|Adverse Event|1
6118006|NCT00874770|9740405|FG001|Overall Study|Adverse Event|1
6118007|NCT00874770|9740406|FG002|Overall Study|Adverse Event|4
6118008|NCT00874770|9740407|FG003|Overall Study|Adverse Event|2
6118009|NCT00874770|9740404|FG000|Overall Study|Lost to Follow-up|1
6118010|NCT00874770|9740405|FG001|Overall Study|Lost to Follow-up|0
6118011|NCT00874770|9740406|FG002|Overall Study|Lost to Follow-up|0
6118012|NCT00874770|9740407|FG003|Overall Study|Lost to Follow-up|1
6118013|NCT00874770|9740404|FG000|Overall Study|Subject no Longer Meets Study Criteria|1
6118014|NCT00874770|9740405|FG001|Overall Study|Subject no Longer Meets Study Criteria|0
6118015|NCT00874770|9740406|FG002|Overall Study|Subject no Longer Meets Study Criteria|0
6118016|NCT00874770|9740407|FG003|Overall Study|Subject no Longer Meets Study Criteria|0
6118017|NCT00874822|9740427|FG000|Overall Study|excluded by criteria|8
6118018|NCT00874848|9740433|FG000|Overall Study|Adverse Event|13
6118019|NCT00874848|9740434|FG001|Overall Study|Adverse Event|2
6118020|NCT00874848|9740433|FG000|Overall Study|Progressive neoplastic disease|38
6118021|NCT00874848|9740434|FG001|Overall Study|Progressive neoplastic disease|18
6118022|NCT00874848|9740433|FG000|Overall Study|Withdrawal by Subject|7
6118023|NCT00874848|9740434|FG001|Overall Study|Withdrawal by Subject|4
6118024|NCT00874848|9740433|FG000|Overall Study|Noncompliance|1
6118025|NCT00874848|9740434|FG001|Overall Study|Noncompliance|1
6118026|NCT00874848|9740433|FG000|Overall Study|Failure to comply with protocol|0
6118027|NCT00874848|9740434|FG001|Overall Study|Failure to comply with protocol|1
6118028|NCT00874848|9740433|FG000|Overall Study|Physician Decision|0
6118029|NCT00874848|9740434|FG001|Overall Study|Physician Decision|2
6118030|NCT00875017|9740455|FG000|First Intervention|Withdrawal by Subject|1
6118031|NCT00875017|9740456|FG001|First Intervention|Withdrawal by Subject|0
6118032|NCT00875017|9740457|FG002|First Intervention|Withdrawal by Subject|1
6118033|NCT00875017|9740458|FG003|First Intervention|Withdrawal by Subject|0
6118034|NCT00875017|9740459|FG004|First Intervention|Withdrawal by Subject|0
6118035|NCT00875017|9740460|FG005|First Intervention|Withdrawal by Subject|0
6118036|NCT00875017|9740455|FG000|First Intervention|Adverse Event|0
6118037|NCT00875017|9740456|FG001|First Intervention|Adverse Event|0
6118038|NCT00875017|9740457|FG002|First Intervention|Adverse Event|0
6118039|NCT00875017|9740458|FG003|First Intervention|Adverse Event|1
6118040|NCT00875017|9740459|FG004|First Intervention|Adverse Event|0
6118041|NCT00875017|9740460|FG005|First Intervention|Adverse Event|0
6118042|NCT00875017|9740455|FG000|First Intervention|Problems collecting rectal effluent|1
6118043|NCT00875017|9740456|FG001|First Intervention|Problems collecting rectal effluent|0
6118044|NCT00875017|9740457|FG002|First Intervention|Problems collecting rectal effluent|0
6118045|NCT00875017|9740458|FG003|First Intervention|Problems collecting rectal effluent|0
6118046|NCT00875017|9740459|FG004|First Intervention|Problems collecting rectal effluent|0
6118047|NCT00875017|9740460|FG005|First Intervention|Problems collecting rectal effluent|0
6118048|NCT00875017|9740455|FG000|First Intervention|Intolerance to nasogastric tube|0
6118049|NCT00875017|9740456|FG001|First Intervention|Intolerance to nasogastric tube|0
6118050|NCT00875017|9740457|FG002|First Intervention|Intolerance to nasogastric tube|0
6118051|NCT00875017|9740458|FG003|First Intervention|Intolerance to nasogastric tube|0
6118052|NCT00875017|9740459|FG004|First Intervention|Intolerance to nasogastric tube|1
6118053|NCT00875017|9740460|FG005|First Intervention|Intolerance to nasogastric tube|0
6118054|NCT00875017|9740455|FG000|Washout|Problem collecting rectal effluent|0
6118055|NCT00875017|9740456|FG001|Washout|Problem collecting rectal effluent|0
6118056|NCT00875017|9740457|FG002|Washout|Problem collecting rectal effluent|1
6118057|NCT00875017|9740458|FG003|Washout|Problem collecting rectal effluent|0
6118058|NCT00875017|9740459|FG004|Washout|Problem collecting rectal effluent|0
6118059|NCT00875017|9740460|FG005|Washout|Problem collecting rectal effluent|0
6118060|NCT00875017|9740455|FG000|Second Intervention|Adverse Event|0
6118061|NCT00875017|9740456|FG001|Second Intervention|Adverse Event|0
6118062|NCT00875017|9740457|FG002|Second Intervention|Adverse Event|0
6118063|NCT00875017|9740458|FG003|Second Intervention|Adverse Event|1
6118064|NCT00875017|9740459|FG004|Second Intervention|Adverse Event|0
6118065|NCT00875017|9740460|FG005|Second Intervention|Adverse Event|0
6118066|NCT00875017|9740455|FG000|Washout|Problems collecting rectal effluent|0
6118067|NCT00875017|9740456|FG001|Washout|Problems collecting rectal effluent|1
6118068|NCT00875017|9740457|FG002|Washout|Problems collecting rectal effluent|0
6118069|NCT00875017|9740458|FG003|Washout|Problems collecting rectal effluent|0
6118070|NCT00875017|9740459|FG004|Washout|Problems collecting rectal effluent|0
6118071|NCT00875017|9740460|FG005|Washout|Problems collecting rectal effluent|0
6118072|NCT00875017|9740455|FG000|Third Intervention|Adverse Event|0
6118073|NCT00875017|9740456|FG001|Third Intervention|Adverse Event|1
6118074|NCT00875017|9740457|FG002|Third Intervention|Adverse Event|1
6118075|NCT00875017|9740458|FG003|Third Intervention|Adverse Event|0
6118076|NCT00875017|9740459|FG004|Third Intervention|Adverse Event|0
6118077|NCT00875017|9740460|FG005|Third Intervention|Adverse Event|0
6118078|NCT00875017|9740455|FG000|Washout|Withdrawal by Subject|0
6211562|NCT01591330|9877987|FG002|Washout of at Least 3 Days|Withdrawal by Subject|0
6211563|NCT01591330|9877988|FG003|Washout of at Least 3 Days|Withdrawal by Subject|0
6211564|NCT01591330|9877985|FG000|Period 2|Adverse Event|1
6211565|NCT01591330|9877986|FG001|Period 2|Adverse Event|0
6211566|NCT01591330|9877987|FG002|Period 2|Adverse Event|0
6211567|NCT01591330|9877988|FG003|Period 2|Adverse Event|0
6211568|NCT01591382|9878000|FG000|Overall Study|Discharged Prior to Study Completion|2
6211569|NCT01591382|9878001|FG001|Overall Study|Discharged Prior to Study Completion|1
6211570|NCT01591382|9878000|FG000|Overall Study|Participant Opted for Morphine PCA|1
6211571|NCT01591382|9878001|FG001|Overall Study|Participant Opted for Morphine PCA|1
6211572|NCT01591460|9878016|FG000|Overall Study|Adverse Event or Intercurrent Illness|5
6211573|NCT01591460|9878016|FG000|Overall Study|Futility Rule (Week 12)|7
6211574|NCT01591460|9878016|FG000|Overall Study|Futility Rule (Week 24)|3
6211575|NCT01591460|9878016|FG000|Overall Study|Rebound or Breakthrough|3
6211576|NCT01591460|9878016|FG000|Overall Study|Treatment Discontinued by Error|1
6211577|NCT01591460|9878016|FG000|Overall Study|Lost to Follow-up|1
6211578|NCT01591460|9878016|FG000|Overall Study|Noncompliance|1
6211579|NCT01591460|9878016|FG000|Overall Study|Participant Refusal|3
6211580|NCT01591460|9878016|FG000|Overall Study|Withdrawal by Subject|1
6211581|NCT01591460|9878016|FG000|Overall Study|Protocol Violation|1
6211582|NCT01591499|9878028|FG000|Baseline Visit|Withdrawal by Subject|0
6211583|NCT01591499|9878029|FG001|Baseline Visit|Withdrawal by Subject|2
6211584|NCT01591499|9878030|FG002|Baseline Visit|Withdrawal by Subject|0
6211585|NCT01591499|9878031|FG003|Baseline Visit|Withdrawal by Subject|2
6211586|NCT01591499|9878028|FG000|Second Intervention (up to 24 Days)|Withdrawal by Subject|2
6211587|NCT01591499|9878029|FG001|Second Intervention (up to 24 Days)|Withdrawal by Subject|0
6211588|NCT01591499|9878030|FG002|Second Intervention (up to 24 Days)|Withdrawal by Subject|2
6211589|NCT01591499|9878031|FG003|Second Intervention (up to 24 Days)|Withdrawal by Subject|0
6211590|NCT01591499|9878028|FG000|Second Intervention (up to 24 Days)|Lost to Follow-up|4
6211591|NCT01591499|9878029|FG001|Second Intervention (up to 24 Days)|Lost to Follow-up|3
6211592|NCT01591499|9878030|FG002|Second Intervention (up to 24 Days)|Lost to Follow-up|1
6211593|NCT01591499|9878031|FG003|Second Intervention (up to 24 Days)|Lost to Follow-up|3
6211594|NCT01591616|9878055|FG000|Overall Study|Withdrawal by Subject|1
6211595|NCT01591681|9878203|FG000|Overall Study|Didn't meet min hypoglycemia requirement|3
6211596|NCT01591681|9878203|FG000|Overall Study|Failed to use system during run-in|1
6211597|NCT01591785|9878226|FG000|Overall Study|worsening condition|1
6211598|NCT01591785|9878227|FG001|Overall Study|worsening condition|2
6211599|NCT01591785|9878226|FG000|Overall Study|Protocol Violation|2
6211600|NCT01591785|9878227|FG001|Overall Study|Protocol Violation|0
6211601|NCT01591785|9878226|FG000|Overall Study|Lost to Follow-up|1
6211602|NCT01591785|9878227|FG001|Overall Study|Lost to Follow-up|0
6211603|NCT01591863|9878242|FG000|Overall Study|Adverse Event|3
6211604|NCT01591863|9878242|FG000|Overall Study|Withdrawal by Subject|1
6211605|NCT01591863|9878242|FG000|Overall Study|recurrence|9
6211606|NCT01591863|9878242|FG000|Overall Study|Lack of Efficacy|1
6211607|NCT01592045|9878252|FG000|Overall Study|Disease Progression|1
6211608|NCT01592045|9878253|FG001|Overall Study|Disease Progression|1
6211609|NCT01592045|9878252|FG000|Overall Study|Adverse Event|1
6211610|NCT01592045|9878253|FG001|Overall Study|Adverse Event|1
6211611|NCT01592045|9878252|FG000|Overall Study|Withdrawal by Subject|1
6211612|NCT01592045|9878253|FG001|Overall Study|Withdrawal by Subject|0
6211613|NCT01592045|9878252|FG000|Overall Study|Moved out of country|2
6211614|NCT01592045|9878253|FG001|Overall Study|Moved out of country|0
6211615|NCT01592240|9878270|FG000|Overall Study|Adverse Event|1
6211616|NCT01592240|9878271|FG001|Overall Study|Adverse Event|0
6211617|NCT01592240|9878272|FG002|Overall Study|Adverse Event|0
6211618|NCT01592240|9878273|FG003|Overall Study|Adverse Event|1
6211619|NCT01592240|9878274|FG004|Overall Study|Adverse Event|1
6211620|NCT01592240|9878275|FG005|Overall Study|Adverse Event|0
6211621|NCT01592240|9878276|FG006|Overall Study|Adverse Event|0
6211622|NCT01592240|9878270|FG000|Overall Study|Death|0
6211623|NCT01592240|9878271|FG001|Overall Study|Death|1
6211624|NCT01592240|9878272|FG002|Overall Study|Death|0
6211625|NCT01592240|9878273|FG003|Overall Study|Death|0
6063259|NCT00505687|9664614|FG000|Overall Study|Other: Scheduled DBS Surgery|1
6063260|NCT00505687|9664614|FG000|Overall Study|Other: Prolonged Hospitalization|1
6063261|NCT00505687|9664614|FG000|Overall Study|Other: Patches Would Not Stick D/T Sweat|1
6063262|NCT00505687|9664614|FG000|Overall Study|Other: Neupro Given In Hospital|1
6063263|NCT00505687|9664614|FG000|Overall Study|Other: Disease Progression|1
6063264|NCT00505687|9664614|FG000|Overall Study|Other: As Per Sponsor|8
6063265|NCT00505752|9664622|FG000|Overall Study|Adverse Event|1
6063266|NCT00505752|9664623|FG001|Overall Study|Adverse Event|0
6063267|NCT00505752|9664624|FG002|Overall Study|Adverse Event|1
6211626|NCT01592240|9878274|FG004|Overall Study|Death|0
6211627|NCT01592240|9878275|FG005|Overall Study|Death|0
6211628|NCT01592240|9878276|FG006|Overall Study|Death|0
6211629|NCT01592240|9878270|FG000|Overall Study|Lost to Follow-up|1
6118079|NCT00875017|9740456|FG001|Washout|Withdrawal by Subject|0
6118080|NCT00875017|9740457|FG002|Washout|Withdrawal by Subject|0
6118081|NCT00875017|9740458|FG003|Washout|Withdrawal by Subject|0
6118082|NCT00875017|9740459|FG004|Washout|Withdrawal by Subject|1
6118083|NCT00875017|9740460|FG005|Washout|Withdrawal by Subject|0
6118084|NCT00875017|9740455|FG000|Fourth Intervention|Inability to comply with fasting|0
6118085|NCT00875017|9740456|FG001|Fourth Intervention|Inability to comply with fasting|0
6118086|NCT00875017|9740457|FG002|Fourth Intervention|Inability to comply with fasting|0
6118087|NCT00875017|9740458|FG003|Fourth Intervention|Inability to comply with fasting|0
6118088|NCT00875017|9740459|FG004|Fourth Intervention|Inability to comply with fasting|0
6118089|NCT00875017|9740460|FG005|Fourth Intervention|Inability to comply with fasting|1
6118090|NCT00875056|9740476|FG000|Overall Study|Adverse Event|6
6118091|NCT00875056|9740477|FG001|Overall Study|Adverse Event|1
6118092|NCT00875056|9740478|FG002|Overall Study|Adverse Event|2
6118093|NCT00875056|9740476|FG000|Overall Study|Progressive Disease|14
6118094|NCT00875056|9740477|FG001|Overall Study|Progressive Disease|8
6118095|NCT00875056|9740478|FG002|Overall Study|Progressive Disease|3
6118096|NCT00875056|9740476|FG000|Overall Study|Withdrawal by Subject|3
6118097|NCT00875056|9740477|FG001|Overall Study|Withdrawal by Subject|0
6118098|NCT00875056|9740478|FG002|Overall Study|Withdrawal by Subject|1
6118099|NCT00875420|9740526|FG000|Overall Study|Adverse Event|0
6118100|NCT00875420|9740527|FG001|Overall Study|Adverse Event|1
6211630|NCT01592240|9878271|FG001|Overall Study|Lost to Follow-up|3
6118101|NCT00875420|9740528|FG002|Overall Study|Adverse Event|1
6118102|NCT00875420|9740529|FG003|Overall Study|Adverse Event|0
6118103|NCT00875420|9740530|FG004|Overall Study|Adverse Event|0
6118104|NCT00875420|9740526|FG000|Overall Study|Inability to complete study procedures|1
6211631|NCT01592240|9878272|FG002|Overall Study|Lost to Follow-up|1
6211632|NCT01592240|9878273|FG003|Overall Study|Lost to Follow-up|0
6211633|NCT01592240|9878274|FG004|Overall Study|Lost to Follow-up|3
6211634|NCT01592240|9878275|FG005|Overall Study|Lost to Follow-up|2
6211635|NCT01592240|9878276|FG006|Overall Study|Lost to Follow-up|0
6211636|NCT01592240|9878270|FG000|Overall Study|Protocol Violation|0
6211637|NCT01592240|9878271|FG001|Overall Study|Protocol Violation|0
6211638|NCT01592240|9878272|FG002|Overall Study|Protocol Violation|0
6211639|NCT01592240|9878273|FG003|Overall Study|Protocol Violation|0
6211640|NCT01592240|9878274|FG004|Overall Study|Protocol Violation|0
6211641|NCT01592240|9878275|FG005|Overall Study|Protocol Violation|1
6211642|NCT01592240|9878276|FG006|Overall Study|Protocol Violation|0
6211643|NCT01592240|9878270|FG000|Overall Study|Withdrawal by Subject|0
6211644|NCT01592240|9878271|FG001|Overall Study|Withdrawal by Subject|4
6211645|NCT01592240|9878272|FG002|Overall Study|Withdrawal by Subject|4
6211646|NCT01592240|9878273|FG003|Overall Study|Withdrawal by Subject|1
6211647|NCT01592240|9878274|FG004|Overall Study|Withdrawal by Subject|3
6287032|NCT02347761|9999445|FG000|On Study Treatment|Adverse Event|10
6287033|NCT02347761|9999446|FG001|On Study Treatment|Adverse Event|8
6287034|NCT02347761|9999447|FG002|On Study Treatment|Adverse Event|20
6287035|NCT02347774|9999458|FG000|Study Participation|Lost to Follow-up|3
6287036|NCT02347774|9999459|FG001|Study Participation|Lost to Follow-up|6
6287037|NCT02347774|9999460|FG002|Study Participation|Lost to Follow-up|2
6287038|NCT02347774|9999458|FG000|Study Participation|Withdrawal by Subject|8
6287039|NCT02347774|9999459|FG001|Study Participation|Withdrawal by Subject|9
6287040|NCT02347774|9999460|FG002|Study Participation|Withdrawal by Subject|15
6287041|NCT02347774|9999458|FG000|Study Participation|Adverse Event|1
6287042|NCT02347774|9999459|FG001|Study Participation|Adverse Event|4
6287043|NCT02347774|9999460|FG002|Study Participation|Adverse Event|6
6118105|NCT00875420|9740527|FG001|Overall Study|Inability to complete study procedures|0
6118106|NCT00875420|9740528|FG002|Overall Study|Inability to complete study procedures|1
6118107|NCT00875420|9740529|FG003|Overall Study|Inability to complete study procedures|1
6118108|NCT00875420|9740530|FG004|Overall Study|Inability to complete study procedures|1
6118109|NCT00875420|9740526|FG000|Overall Study|Lost to Follow-up|1
6118110|NCT00875420|9740527|FG001|Overall Study|Lost to Follow-up|0
6118111|NCT00875420|9740528|FG002|Overall Study|Lost to Follow-up|0
6118112|NCT00875420|9740529|FG003|Overall Study|Lost to Follow-up|0
6118113|NCT00875420|9740530|FG004|Overall Study|Lost to Follow-up|0
6118114|NCT00875420|9740526|FG000|Overall Study|Personal reason|0
6118115|NCT00875420|9740527|FG001|Overall Study|Personal reason|0
6118116|NCT00875420|9740528|FG002|Overall Study|Personal reason|0
6118117|NCT00875420|9740529|FG003|Overall Study|Personal reason|0
6211648|NCT01592240|9878275|FG005|Overall Study|Withdrawal by Subject|0
6211649|NCT01592240|9878276|FG006|Overall Study|Withdrawal by Subject|2
6211650|NCT01592240|9878270|FG000|Overall Study|Other|0
6287044|NCT02347774|9999458|FG000|Study Participation|withdrew consent|1
6287045|NCT02347774|9999459|FG001|Study Participation|withdrew consent|1
6287046|NCT02347774|9999460|FG002|Study Participation|withdrew consent|1
6287047|NCT02347774|9999458|FG000|Study Participation|Met Prolonged QT criteria|1
6287048|NCT02347774|9999459|FG001|Study Participation|Met Prolonged QT criteria|0
6287049|NCT02347774|9999460|FG002|Study Participation|Met Prolonged QT criteria|0
6118118|NCT00875420|9740530|FG004|Overall Study|Personal reason|1
6118119|NCT00875420|9740526|FG000|Overall Study|Prohibited medication|0
6118120|NCT00875420|9740527|FG001|Overall Study|Prohibited medication|0
6211651|NCT01592240|9878271|FG001|Overall Study|Other|3
6211652|NCT01592240|9878272|FG002|Overall Study|Other|1
6118121|NCT00875420|9740528|FG002|Overall Study|Prohibited medication|0
6118122|NCT00875420|9740529|FG003|Overall Study|Prohibited medication|1
6118123|NCT00875420|9740530|FG004|Overall Study|Prohibited medication|0
6118124|NCT00875420|9740526|FG000|Overall Study|Sponsor decision|0
6118125|NCT00875420|9740527|FG001|Overall Study|Sponsor decision|1
6118126|NCT00875420|9740528|FG002|Overall Study|Sponsor decision|0
6118127|NCT00875420|9740529|FG003|Overall Study|Sponsor decision|0
6118128|NCT00875420|9740530|FG004|Overall Study|Sponsor decision|0
6118129|NCT00875420|9740526|FG000|Overall Study|Withdrawal by Subject|0
6118130|NCT00875420|9740527|FG001|Overall Study|Withdrawal by Subject|0
6118131|NCT00875420|9740528|FG002|Overall Study|Withdrawal by Subject|1
6211653|NCT01592240|9878273|FG003|Overall Study|Other|1
6211654|NCT01592240|9878274|FG004|Overall Study|Other|0
6211655|NCT01592240|9878275|FG005|Overall Study|Other|0
6211656|NCT01592240|9878276|FG006|Overall Study|Other|1
6211657|NCT01592240|9878270|FG000|Overall Study|Did Not Meet Entrance Criteria|1
6211658|NCT01592240|9878271|FG001|Overall Study|Did Not Meet Entrance Criteria|0
6211659|NCT01592240|9878272|FG002|Overall Study|Did Not Meet Entrance Criteria|1
6211660|NCT01592240|9878273|FG003|Overall Study|Did Not Meet Entrance Criteria|0
6211661|NCT01592240|9878274|FG004|Overall Study|Did Not Meet Entrance Criteria|0
6211662|NCT01592240|9878275|FG005|Overall Study|Did Not Meet Entrance Criteria|0
6211663|NCT01592240|9878276|FG006|Overall Study|Did Not Meet Entrance Criteria|0
6211664|NCT01592292|9878299|FG000|Overall Study|Follow-up loss|3
6211665|NCT01592292|9878300|FG001|Overall Study|Follow-up loss|3
6211666|NCT01592292|9878301|FG002|Overall Study|Follow-up loss|1
6211667|NCT01592292|9878302|FG003|Overall Study|Follow-up loss|0
6211668|NCT01592292|9878299|FG000|Overall Study|Withdrew consent|2
6211669|NCT01592292|9878300|FG001|Overall Study|Withdrew consent|1
6211670|NCT01592292|9878301|FG002|Overall Study|Withdrew consent|0
6211671|NCT01592292|9878302|FG003|Overall Study|Withdrew consent|0
6211672|NCT01592292|9878299|FG000|Overall Study|Other|1
6211673|NCT01592292|9878300|FG001|Overall Study|Other|1
6211674|NCT01592292|9878301|FG002|Overall Study|Other|2
6211675|NCT01592292|9878302|FG003|Overall Study|Other|1
6211676|NCT01592344|9878310|FG000|Overall Study|Adverse Event|1
6211677|NCT01592344|9878311|FG001|Overall Study|Adverse Event|1
6211678|NCT01592344|9878310|FG000|Overall Study|Lack of Efficacy|1
6211679|NCT01592344|9878311|FG001|Overall Study|Lack of Efficacy|0
6211680|NCT01592344|9878310|FG000|Overall Study|not available at primary outcome visit|2
6211681|NCT01592344|9878311|FG001|Overall Study|not available at primary outcome visit|4
6211682|NCT01592409|9878329|FG000|Overall Study|Withdrawal by Subject|0
6211683|NCT01592409|9878330|FG001|Overall Study|Withdrawal by Subject|1
6211684|NCT01592695|9878361|FG000|Overall Study|Lost to Follow-up|8
6211685|NCT01592695|9878362|FG001|Overall Study|Lost to Follow-up|4
6211686|NCT01592708|9878370|FG000|Overall Study|Protocol Violation|3
6211687|NCT01592708|9878371|FG001|Overall Study|Protocol Violation|0
6211688|NCT01592747|9878383|FG000|Overall Study|Loss of Therapeutic Response|107
6211689|NCT01592747|9878384|FG001|Overall Study|Loss of Therapeutic Response|108
6211690|NCT01592747|9878385|FG002|Overall Study|Loss of Therapeutic Response|100
6211691|NCT01592747|9878383|FG000|Overall Study|Inclusion/Exclusion criteria not met|0
6211692|NCT01592747|9878384|FG001|Overall Study|Inclusion/Exclusion criteria not met|1
6211693|NCT01592747|9878385|FG002|Overall Study|Inclusion/Exclusion criteria not met|1
6211694|NCT01592747|9878383|FG000|Overall Study|Adverse Event|1
6211695|NCT01592747|9878384|FG001|Overall Study|Adverse Event|0
6211696|NCT01592747|9878385|FG002|Overall Study|Adverse Event|0
6287050|NCT02347774|9999458|FG000|Study Participation|non-compliance with study drug|0
6287051|NCT02347774|9999459|FG001|Study Participation|non-compliance with study drug|1
6287052|NCT02347774|9999460|FG002|Study Participation|non-compliance with study drug|0
6287053|NCT02347774|9999458|FG000|Study Participation|incarceration|1
6287054|NCT02347774|9999459|FG001|Study Participation|incarceration|0
6287055|NCT02347774|9999460|FG002|Study Participation|incarceration|0
6287056|NCT02347774|9999458|FG000|Study Participation|randomized in error|0
6287057|NCT02347774|9999459|FG001|Study Participation|randomized in error|0
6287058|NCT02347774|9999460|FG002|Study Participation|randomized in error|1
6287059|NCT02347774|9999458|FG000|On Study Treatment|Adverse Event|9
6287060|NCT02347774|9999459|FG001|On Study Treatment|Adverse Event|15
6287061|NCT02347774|9999460|FG002|On Study Treatment|Adverse Event|19
6287062|NCT02347774|9999458|FG000|On Study Treatment|Lack of Efficacy|3
6287063|NCT02347774|9999459|FG001|On Study Treatment|Lack of Efficacy|0
6287064|NCT02347774|9999460|FG002|On Study Treatment|Lack of Efficacy|2
6287065|NCT02347774|9999458|FG000|On Study Treatment|non-complicance with study medication|0
6287066|NCT02347774|9999459|FG001|On Study Treatment|non-complicance with study medication|2
6287067|NCT02347774|9999460|FG002|On Study Treatment|non-complicance with study medication|0
6287068|NCT02347774|9999458|FG000|On Study Treatment|Protocol Violation|0
6287069|NCT02347774|9999459|FG001|On Study Treatment|Protocol Violation|0
6287070|NCT02347774|9999460|FG002|On Study Treatment|Protocol Violation|1
6287071|NCT02347774|9999458|FG000|On Study Treatment|withdrew consent|9
6118132|NCT00875420|9740529|FG003|Overall Study|Withdrawal by Subject|0
6211697|NCT01592747|9878383|FG000|Overall Study|Protocol Violation|4
6211698|NCT01592747|9878384|FG001|Overall Study|Protocol Violation|0
6211699|NCT01592747|9878385|FG002|Overall Study|Protocol Violation|4
6287072|NCT02347774|9999459|FG001|On Study Treatment|withdrew consent|8
6118133|NCT00875420|9740530|FG004|Overall Study|Withdrawal by Subject|0
6118134|NCT00875433|9740542|FG000|Overall Study|Progressive disease|41
6118135|NCT00875433|9740542|FG000|Overall Study|Other Adverse Event|14
6118136|NCT00875433|9740542|FG000|Overall Study|Withdrawal by Subject|2
6118137|NCT00875433|9740542|FG000|Overall Study|Other|3
6118138|NCT00875485|9740548|FG000|Challenge Dose Epoch|Pregnancy|1
6118139|NCT00875485|9740549|FG001|Challenge Dose Epoch|Pregnancy|0
6118140|NCT00875563|9740566|FG000|Overall Study|Death|4
6118141|NCT00875563|9740566|FG000|Overall Study|Withdrawal by Subject|7
6118142|NCT00875563|9740566|FG000|Overall Study|No long-term (3-5 year) consent|6
6118143|NCT00875563|9740566|FG000|Overall Study|Still be eligible for follow-up|7
6118144|NCT00875615|9740579|FG000|Overall Study|Withdrawal by Subject|1
6118145|NCT00875667|9740598|FG000|Overall Study|Adverse Event|29
6118146|NCT00875667|9740599|FG001|Overall Study|Adverse Event|10
6118147|NCT00875667|9740598|FG000|Overall Study|Withdrawal by Subject|17
6118148|NCT00875667|9740599|FG001|Overall Study|Withdrawal by Subject|5
6118149|NCT00875667|9740598|FG000|Overall Study|Death|7
6118150|NCT00875667|9740599|FG001|Overall Study|Death|2
6118151|NCT00875667|9740598|FG000|Overall Study|Protocol Violation|2
6118152|NCT00875667|9740599|FG001|Overall Study|Protocol Violation|0
6118153|NCT00875667|9740598|FG000|Overall Study|Disease Progression|100
6118154|NCT00875667|9740599|FG001|Overall Study|Disease Progression|49
6118155|NCT00875667|9740598|FG000|Overall Study|Miscellaneous|12
6118156|NCT00875667|9740599|FG001|Overall Study|Miscellaneous|6
6118157|NCT00875667|9740598|FG000|Overall Study|Randomized but no Study Drug Given|3
6118158|NCT00875667|9740599|FG001|Overall Study|Randomized but no Study Drug Given|1
6118159|NCT00875706|9740608|FG000|Overall Study|Withdrawal by Subject|1
6118160|NCT00875706|9740609|FG001|Overall Study|Withdrawal by Subject|0
6118161|NCT00875706|9740610|FG002|Overall Study|Withdrawal by Subject|0
6211700|NCT01592747|9878383|FG000|Overall Study|Lack of Efficacy|0
6211701|NCT01592747|9878384|FG001|Overall Study|Lack of Efficacy|1
6211702|NCT01592747|9878385|FG002|Overall Study|Lack of Efficacy|0
6211703|NCT01592747|9878383|FG000|Overall Study|Withdrawal by Subject|2
6211704|NCT01592747|9878384|FG001|Overall Study|Withdrawal by Subject|0
6211705|NCT01592747|9878385|FG002|Overall Study|Withdrawal by Subject|2
6211706|NCT01592747|9878383|FG000|Overall Study|Lost to Follow-up|1
6211707|NCT01592747|9878384|FG001|Overall Study|Lost to Follow-up|0
6211708|NCT01592747|9878385|FG002|Overall Study|Lost to Follow-up|1
6211709|NCT01592747|9878383|FG000|Overall Study|Other Reasons|1
6211710|NCT01592747|9878384|FG001|Overall Study|Other Reasons|1
6211711|NCT01592747|9878385|FG002|Overall Study|Other Reasons|0
6211712|NCT01592760|9878397|FG000|24-hour Follow-Up|Lost to Follow-up|4
6211713|NCT01592760|9878398|FG001|24-hour Follow-Up|Lost to Follow-up|3
6211714|NCT01592760|9878399|FG002|24-hour Follow-Up|Lost to Follow-up|2
6211715|NCT01592773|9878410|FG000|Overall Study|Study Terminated by Sponsor|582
6211716|NCT01592773|9878410|FG000|Overall Study|Withdrawal by Subject|35
6211717|NCT01592773|9878410|FG000|Overall Study|Lost to Follow-up|19
6211718|NCT01592773|9878410|FG000|Overall Study|Adverse Event|17
6211719|NCT01592773|9878410|FG000|Overall Study|Lack of Efficacy|9
6211720|NCT01592773|9878410|FG000|Overall Study|Protocol Violation|2
6211721|NCT01592773|9878410|FG000|Overall Study|Inclusion/exclusion not meet|1
6211722|NCT01592773|9878410|FG000|Overall Study|Other Reason|1
6211723|NCT01592786|9878414|FG000|Overall Study|Adverse Event|60
6211724|NCT01592786|9878414|FG000|Overall Study|Lack of Efficacy|19
6211725|NCT01592786|9878414|FG000|Overall Study|Protocol Violation|14
6211726|NCT01592786|9878414|FG000|Overall Study|Withdrawal by Subject|23
6211727|NCT01592786|9878414|FG000|Overall Study|Lost to Follow-up|19
6211728|NCT01592786|9878414|FG000|Overall Study|Other|3
6211729|NCT01592864|9878435|FG000|Overall Study|Withdrawal by Subject|0
6211730|NCT01592864|9878436|FG001|Overall Study|Withdrawal by Subject|1
6211731|NCT01593020|9878444|FG000|Overall Study|Adverse Event|1
6211732|NCT01593020|9878445|FG001|Overall Study|Adverse Event|1
6211733|NCT01593020|9878444|FG000|Overall Study|Death|0
6211734|NCT01593020|9878445|FG001|Overall Study|Death|1
6211735|NCT01593020|9878444|FG000|Overall Study|Ineligible|1
6211736|NCT01593020|9878445|FG001|Overall Study|Ineligible|0
6211737|NCT01593696|9878477|FG000|Dose Escalation|Progressive Disease|2
6211738|NCT01593696|9878478|FG001|Dose Escalation|Progressive Disease|0
6211739|NCT01593696|9878479|FG002|Dose Escalation|Progressive Disease|0
6211740|NCT01593696|9878480|FG003|Dose Escalation|Progressive Disease|0
6211741|NCT01593696|9878477|FG000|Dose Expansion|Fungal infection|0
6211742|NCT01593696|9878478|FG001|Dose Expansion|Fungal infection|0
6211743|NCT01593696|9878479|FG002|Dose Expansion|Fungal infection|1
6211744|NCT01593696|9878480|FG003|Dose Expansion|Fungal infection|0
6211745|NCT01593787|9878513|FG000|Overall Study|Adverse Event|1
6211746|NCT01593787|9878514|FG001|Overall Study|Adverse Event|0
6211747|NCT01593787|9878515|FG002|Overall Study|Adverse Event|0
6211748|NCT01593917|9878525|FG000|Overall Study|Death|67
6211749|NCT01593917|9878525|FG000|Overall Study|Valve-in-valve Transcatheter Aortic Valve Implantation (TAVI) or Surgical Explant|60
6118162|NCT00875797|9740620|FG000|Overall Study|Protocol Violation|6
6118163|NCT00875797|9740621|FG001|Overall Study|Protocol Violation|3
6211750|NCT01593917|9878525|FG000|Overall Study|Withdrawal by Subject|23
6211751|NCT01593917|9878525|FG000|Overall Study|Lost to Follow-up|12
6211752|NCT01593917|9878525|FG000|Overall Study|Protocol Violation|5
6118164|NCT00875810|9740630|FG000|Overall Study|Withdrawal by Subject|1
6118165|NCT00875810|9740630|FG000|Overall Study|Physician Decision|3
6118166|NCT00875810|9740630|FG000|Overall Study|Lost to Follow-up|39
6118167|NCT00875810|9740630|FG000|Overall Study|Patient enroled but not implanted|2
6118168|NCT00875810|9740630|FG000|Overall Study|Device explanted|1
6118169|NCT00875979|9740645|FG000|Dose Escalation Phase - 3.0 mg/kg|Disease Progression|1
6118170|NCT00875979|9740646|FG001|Dose Escalation Phase - 3.0 mg/kg|Disease Progression|0
6118171|NCT00875979|9740645|FG000|Dose Escalation Phase - 3.0 mg/kg|Physician Decision|1
6118172|NCT00875979|9740646|FG001|Dose Escalation Phase - 3.0 mg/kg|Physician Decision|0
6118173|NCT00875979|9740645|FG000|Dose Escalation Phase - 3.0 mg/kg|Patient/Legal Guardian Decision|1
6118174|NCT00875979|9740646|FG001|Dose Escalation Phase - 3.0 mg/kg|Patient/Legal Guardian Decision|0
6118175|NCT00875979|9740645|FG000|Dose Escalation Phase - 3.6 mg/kg|Disease Progression|0
6118176|NCT00875979|9740646|FG001|Dose Escalation Phase - 3.6 mg/kg|Disease Progression|6
6118177|NCT00875979|9740645|FG000|Dose Expansion Phase - 3.6 mg/kg|Disease Progression|0
6118178|NCT00875979|9740646|FG001|Dose Expansion Phase - 3.6 mg/kg|Disease Progression|37
6118179|NCT00875979|9740645|FG000|Dose Expansion Phase - 3.6 mg/kg|Physician Decision|0
6118180|NCT00875979|9740646|FG001|Dose Expansion Phase - 3.6 mg/kg|Physician Decision|3
6118181|NCT00875979|9740645|FG000|Dose Expansion Phase - 3.6 mg/kg|Patient/legal Guardian Decision|0
6118182|NCT00875979|9740646|FG001|Dose Expansion Phase - 3.6 mg/kg|Patient/legal Guardian Decision|3
6118183|NCT00875979|9740645|FG000|Dose Expansion Phase - 3.6 mg/kg|Started Non-protocol Anti-Cancer Therapy|0
6118184|NCT00875979|9740646|FG001|Dose Expansion Phase - 3.6 mg/kg|Started Non-protocol Anti-Cancer Therapy|3
6118185|NCT00875979|9740645|FG000|Dose Expansion Phase - 3.6 mg/kg|Death|0
6118186|NCT00875979|9740646|FG001|Dose Expansion Phase - 3.6 mg/kg|Death|1
6118187|NCT00876018|9740655|FG000|Overall Study|Lost to Follow-up|0
6118188|NCT00876018|9740656|FG001|Overall Study|Lost to Follow-up|1
6118189|NCT00876018|9740657|FG002|Overall Study|Lost to Follow-up|1
6118190|NCT00876018|9740655|FG000|Overall Study|Withdrew Consent due to Adverse Event|5
6118191|NCT00876018|9740656|FG001|Overall Study|Withdrew Consent due to Adverse Event|4
6118192|NCT00876018|9740657|FG002|Overall Study|Withdrew Consent due to Adverse Event|2
6118193|NCT00876187|9740672|FG000|Overall Study|Adverse Event|14
6118194|NCT00876187|9740673|FG001|Overall Study|Adverse Event|12
6118195|NCT00876187|9740674|FG002|Overall Study|Adverse Event|19
6118196|NCT00876187|9740675|FG003|Overall Study|Adverse Event|29
6118197|NCT00876187|9740676|FG004|Overall Study|Adverse Event|10
6118198|NCT00876187|9740672|FG000|Overall Study|Lack of Efficacy|59
6118199|NCT00876187|9740673|FG001|Overall Study|Lack of Efficacy|34
6118200|NCT00876187|9740674|FG002|Overall Study|Lack of Efficacy|45
6118201|NCT00876187|9740675|FG003|Overall Study|Lack of Efficacy|34
6118202|NCT00876187|9740676|FG004|Overall Study|Lack of Efficacy|59
6118203|NCT00876187|9740672|FG000|Overall Study|Lost to Follow-up|9
6118204|NCT00876187|9740673|FG001|Overall Study|Lost to Follow-up|10
6118205|NCT00876187|9740674|FG002|Overall Study|Lost to Follow-up|8
6118206|NCT00876187|9740675|FG003|Overall Study|Lost to Follow-up|8
6118207|NCT00876187|9740676|FG004|Overall Study|Lost to Follow-up|11
6118208|NCT00876187|9740672|FG000|Overall Study|Protocol Violation|6
6118209|NCT00876187|9740673|FG001|Overall Study|Protocol Violation|7
6118210|NCT00876187|9740674|FG002|Overall Study|Protocol Violation|7
6118211|NCT00876187|9740675|FG003|Overall Study|Protocol Violation|6
6118212|NCT00876187|9740676|FG004|Overall Study|Protocol Violation|3
6118213|NCT00876187|9740672|FG000|Overall Study|Withdrawal by Subject|16
6118214|NCT00876187|9740673|FG001|Overall Study|Withdrawal by Subject|26
6118215|NCT00876187|9740674|FG002|Overall Study|Withdrawal by Subject|32
6118216|NCT00876187|9740675|FG003|Overall Study|Withdrawal by Subject|38
6118217|NCT00876187|9740676|FG004|Overall Study|Withdrawal by Subject|37
6118218|NCT00876187|9740672|FG000|Overall Study|Entered extension study|101
6118219|NCT00876187|9740673|FG001|Overall Study|Entered extension study|120
6118220|NCT00876187|9740674|FG002|Overall Study|Entered extension study|156
6118221|NCT00876187|9740675|FG003|Overall Study|Entered extension study|151
6118222|NCT00876187|9740676|FG004|Overall Study|Entered extension study|144
6118223|NCT00876187|9740672|FG000|Overall Study|Randomized but not treated|3
6118224|NCT00876187|9740673|FG001|Overall Study|Randomized but not treated|1
6118225|NCT00876187|9740674|FG002|Overall Study|Randomized but not treated|3
6118226|NCT00876187|9740675|FG003|Overall Study|Randomized but not treated|2
6118227|NCT00876187|9740676|FG004|Overall Study|Randomized but not treated|3
6118228|NCT00876187|9740672|FG000|Overall Study|Other|2
6118229|NCT00876187|9740673|FG001|Overall Study|Other|5
6118230|NCT00876187|9740674|FG002|Overall Study|Other|9
6118231|NCT00876187|9740675|FG003|Overall Study|Other|7
6211753|NCT01593917|9878525|FG000|Overall Study|Physician Decision|3
6211754|NCT01594125|9878534|FG000|Overall Study|Withdrawal by Subject|1
6211755|NCT01594125|9878535|FG001|Overall Study|Withdrawal by Subject|0
6211756|NCT01594125|9878536|FG002|Overall Study|Withdrawal by Subject|0
6211757|NCT01594125|9878537|FG003|Overall Study|Withdrawal by Subject|1
6211758|NCT01594125|9878538|FG004|Overall Study|Withdrawal by Subject|0
6211759|NCT01594125|9878534|FG000|Overall Study|Progressive Disease|3
6211760|NCT01594125|9878535|FG001|Overall Study|Progressive Disease|12
6211761|NCT01594125|9878536|FG002|Overall Study|Progressive Disease|3
6211762|NCT01594125|9878537|FG003|Overall Study|Progressive Disease|3
6211763|NCT01594125|9878538|FG004|Overall Study|Progressive Disease|7
6211764|NCT01594281|9878553|FG000|Interventional Core Phase|Protocol Deviation|1
6211765|NCT01594281|9878554|FG001|Interventional Core Phase|Protocol Deviation|0
6118232|NCT00876187|9740676|FG004|Overall Study|Other|4
6118233|NCT00876265|9740700|FG000|Overall Study|Miscellaneous reasons|4
6118234|NCT00876265|9740700|FG000|Overall Study|Lost to Follow-up|6
6118235|NCT00876265|9740700|FG000|Overall Study|Withdrawal by Subject|2
6118236|NCT00876343|9740709|FG000|Overall Study|Adverse Event|7
6118237|NCT00876343|9740710|FG001|Overall Study|Adverse Event|8
6118238|NCT00876343|9740711|FG002|Overall Study|Adverse Event|2
6118239|NCT00876343|9740709|FG000|Overall Study|Withdrawal by Subject|4
6118240|NCT00876343|9740710|FG001|Overall Study|Withdrawal by Subject|4
6118241|NCT00876343|9740711|FG002|Overall Study|Withdrawal by Subject|3
6118242|NCT00876343|9740709|FG000|Overall Study|Lack of Efficacy|0
6118243|NCT00876343|9740710|FG001|Overall Study|Lack of Efficacy|0
6118244|NCT00876343|9740711|FG002|Overall Study|Lack of Efficacy|1
6118245|NCT00876343|9740709|FG000|Overall Study|Protocol Violation|4
6118246|NCT00876343|9740710|FG001|Overall Study|Protocol Violation|1
6118247|NCT00876343|9740711|FG002|Overall Study|Protocol Violation|1
6118248|NCT00876343|9740709|FG000|Overall Study|Physician Decision|0
6118249|NCT00876343|9740710|FG001|Overall Study|Physician Decision|1
6118250|NCT00876343|9740711|FG002|Overall Study|Physician Decision|1
6118251|NCT00876343|9740709|FG000|Overall Study|Diabetic glucose level or HbA1C>=6.5%|0
6118252|NCT00876343|9740710|FG001|Overall Study|Diabetic glucose level or HbA1C>=6.5%|1
6118253|NCT00876343|9740711|FG002|Overall Study|Diabetic glucose level or HbA1C>=6.5%|1
6118254|NCT00876343|9740709|FG000|Overall Study|Change of residence or other commitments|2
6118255|NCT00876343|9740710|FG001|Overall Study|Change of residence or other commitments|2
6211766|NCT01594281|9878555|FG002|Interventional Core Phase|Protocol Deviation|0
6211767|NCT01594281|9878553|FG000|Interventional Core Phase|Subject Withdrew Consent|0
6211768|NCT01594281|9878554|FG001|Interventional Core Phase|Subject Withdrew Consent|1
6211769|NCT01594281|9878555|FG002|Interventional Core Phase|Subject Withdrew Consent|1
6211770|NCT01594281|9878553|FG000|Interventional Core Phase|Death|1
6211771|NCT01594281|9878554|FG001|Interventional Core Phase|Death|1
6211772|NCT01594281|9878555|FG002|Interventional Core Phase|Death|2
6211773|NCT01594281|9878553|FG000|Interventional Core Phase|Lost to Follow-up|1
6211774|NCT01594281|9878554|FG001|Interventional Core Phase|Lost to Follow-up|4
6211775|NCT01594281|9878555|FG002|Interventional Core Phase|Lost to Follow-up|1
6211776|NCT01594281|9878553|FG000|Interventional Core Phase|Adverse Event|4
6211777|NCT01594281|9878554|FG001|Interventional Core Phase|Adverse Event|4
6211778|NCT01594281|9878555|FG002|Interventional Core Phase|Adverse Event|4
6211779|NCT01594281|9878553|FG000|Non-Interventional Follow Up Phase|Lost to Follow-up|2
6211780|NCT01594281|9878554|FG001|Non-Interventional Follow Up Phase|Lost to Follow-up|2
6287073|NCT02347774|9999460|FG002|On Study Treatment|withdrew consent|12
6287074|NCT02347774|9999458|FG000|On Study Treatment|Lost to Follow-up|2
6287075|NCT02347774|9999459|FG001|On Study Treatment|Lost to Follow-up|6
6287076|NCT02347774|9999460|FG002|On Study Treatment|Lost to Follow-up|1
6287077|NCT02347774|9999458|FG000|On Study Treatment|Met Prolonged QT criteria|1
6287078|NCT02347774|9999459|FG001|On Study Treatment|Met Prolonged QT criteria|0
6287079|NCT02347774|9999460|FG002|On Study Treatment|Met Prolonged QT criteria|0
6287080|NCT02347774|9999458|FG000|On Study Treatment|ranomized in error|0
6287081|NCT02347774|9999459|FG001|On Study Treatment|ranomized in error|0
6287082|NCT02347774|9999460|FG002|On Study Treatment|ranomized in error|1
6287083|NCT02347787|9999470|FG000|6 Month Follow-Up|Lost to Follow-up|63
6287084|NCT02347787|9999471|FG001|6 Month Follow-Up|Lost to Follow-up|47
6287085|NCT02347787|9999470|FG000|6 Month Follow-Up|Withdrawal by Subject|3
6287086|NCT02347787|9999471|FG001|6 Month Follow-Up|Withdrawal by Subject|9
6287087|NCT02347787|9999470|FG000|9 Month Follow-Up|Lost to Follow-up|52
6287088|NCT02347787|9999471|FG001|9 Month Follow-Up|Lost to Follow-up|59
6287089|NCT02347787|9999470|FG000|9 Month Follow-Up|Withdrawal by Subject|9
6287090|NCT02347787|9999471|FG001|9 Month Follow-Up|Withdrawal by Subject|12
6287091|NCT02347813|9999484|FG000|First Intervention, 24 Weeks|Withdrawal by Subject|1
6287092|NCT02347813|9999485|FG001|First Intervention, 24 Weeks|Withdrawal by Subject|1
6287093|NCT02347813|9999484|FG000|First Intervention, 24 Weeks|Adverse Event|1
6287094|NCT02347813|9999485|FG001|First Intervention, 24 Weeks|Adverse Event|1
6287095|NCT02348008|9999493|FG000|Overall Study|Adverse Event|2
6287096|NCT02348008|9999494|FG001|Overall Study|Adverse Event|3
6287097|NCT02348008|9999495|FG002|Overall Study|Adverse Event|3
6287098|NCT02348008|9999493|FG000|Overall Study|Disease Progression|1
6287099|NCT02348008|9999494|FG001|Overall Study|Disease Progression|5
6287100|NCT02348008|9999495|FG002|Overall Study|Disease Progression|16
6287101|NCT02348008|9999493|FG000|Overall Study|Withdrawal by Subject|0
6118256|NCT00876343|9740711|FG002|Overall Study|Change of residence or other commitments|3
6118257|NCT00876395|9740721|FG000|Overall Study|Untreated|8
6118258|NCT00876395|9740722|FG001|Overall Study|Untreated|1
6118259|NCT00876395|9740721|FG000|Overall Study|Adverse Event|63
6118260|NCT00876395|9740722|FG001|Overall Study|Adverse Event|11
6287102|NCT02348008|9999494|FG001|Overall Study|Withdrawal by Subject|1
6287103|NCT02348008|9999495|FG002|Overall Study|Withdrawal by Subject|0
6287104|NCT02348008|9999493|FG000|Overall Study|Symptomatic Deterioration|0
6287105|NCT02348008|9999494|FG001|Overall Study|Symptomatic Deterioration|1
6287106|NCT02348008|9999495|FG002|Overall Study|Symptomatic Deterioration|0
6287107|NCT02348489|9999523|FG000|Overall Study|Death|336
6287108|NCT02348489|9999524|FG001|Overall Study|Death|335
6118261|NCT00876395|9740721|FG000|Overall Study|Abnormal test procedure result(s)|1
6118262|NCT00876395|9740722|FG001|Overall Study|Abnormal test procedure result(s)|0
6118263|NCT00876395|9740721|FG000|Overall Study|Disease progression|259
6118264|NCT00876395|9740722|FG001|Overall Study|Disease progression|162
6118265|NCT00876395|9740721|FG000|Overall Study|New cancer therapy|25
6118266|NCT00876395|9740722|FG001|Overall Study|New cancer therapy|7
6118267|NCT00876395|9740721|FG000|Overall Study|Protocol Violation|5
6118268|NCT00876395|9740722|FG001|Overall Study|Protocol Violation|2
6118269|NCT00876395|9740721|FG000|Overall Study|Withdrawal by Subject|66
6118270|NCT00876395|9740722|FG001|Overall Study|Withdrawal by Subject|33
6211781|NCT01594281|9878555|FG002|Non-Interventional Follow Up Phase|Lost to Follow-up|0
6211782|NCT01594281|9878553|FG000|Non-Interventional Follow Up Phase|Administrative Problems|0
6211783|NCT01594281|9878554|FG001|Non-Interventional Follow Up Phase|Administrative Problems|0
6211784|NCT01594281|9878555|FG002|Non-Interventional Follow Up Phase|Administrative Problems|1
6211785|NCT01594281|9878553|FG000|Non-Interventional Follow Up Phase|Subject Withdrew Consent|1
6211786|NCT01594281|9878554|FG001|Non-Interventional Follow Up Phase|Subject Withdrew Consent|0
6211787|NCT01594281|9878555|FG002|Non-Interventional Follow Up Phase|Subject Withdrew Consent|1
6211788|NCT01594333|9878577|FG000|Overall Study|Death|96
6287109|NCT02348489|9999523|FG000|Overall Study|Withdrawal by Subject|14
6287110|NCT02348489|9999524|FG001|Overall Study|Withdrawal by Subject|27
6287111|NCT02348489|9999523|FG000|Overall Study|Lost to Follow-up|3
6287112|NCT02348489|9999524|FG001|Overall Study|Lost to Follow-up|5
6287113|NCT02348723|9999597|FG000|Overall Study|No ablation|21
6287114|NCT02348723|9999598|FG001|Overall Study|No ablation|20
6287115|NCT02348723|9999597|FG000|Overall Study|Non-compliant with Protocol|1
6287116|NCT02348723|9999598|FG001|Overall Study|Non-compliant with Protocol|0
6287117|NCT02348723|9999597|FG000|Overall Study|Lost to Follow-up|1
6287118|NCT02348723|9999598|FG001|Overall Study|Lost to Follow-up|1
6287119|NCT02348723|9999597|FG000|Overall Study|Consent withdrawn|1
6287120|NCT02348723|9999598|FG001|Overall Study|Consent withdrawn|3
6287121|NCT02348723|9999597|FG000|Overall Study|Reason other than specified|1
6287122|NCT02348723|9999598|FG001|Overall Study|Reason other than specified|1
6287123|NCT02348723|9999597|FG000|Overall Study|Adverse Event|3
6287124|NCT02348723|9999598|FG001|Overall Study|Adverse Event|1
6287125|NCT02348840|9999617|FG000|Overall Study|Withdrawal by Subject|2
6287126|NCT02348840|9999618|FG001|Overall Study|Withdrawal by Subject|1
6287127|NCT02348840|9999619|FG002|Overall Study|Withdrawal by Subject|0
6287128|NCT02348840|9999620|FG003|Overall Study|Withdrawal by Subject|0
6287129|NCT02349048|9999669|FG000|Overall Study|Withdrawal by Subject|4
6287130|NCT02349048|9999670|FG001|Overall Study|Withdrawal by Subject|0
6287131|NCT02349048|9999669|FG000|Overall Study|Lost to Follow-up|1
6287132|NCT02349048|9999670|FG001|Overall Study|Lost to Follow-up|0
6287133|NCT02349061|9999678|FG000|Main Study: PCP (Up to Week 24)|Adverse Event|4
6287134|NCT02349061|9999679|FG001|Main Study: PCP (Up to Week 24)|Adverse Event|3
6287135|NCT02349061|9999680|FG002|Main Study: PCP (Up to Week 24)|Adverse Event|0
6287136|NCT02349061|9999678|FG000|Main Study: PCP (Up to Week 24)|Lack of Efficacy|1
6287137|NCT02349061|9999679|FG001|Main Study: PCP (Up to Week 24)|Lack of Efficacy|0
6287138|NCT02349061|9999680|FG002|Main Study: PCP (Up to Week 24)|Lack of Efficacy|0
6287139|NCT02349061|9999678|FG000|Main Study: PCP (Up to Week 24)|Physician Decision|1
6287140|NCT02349061|9999679|FG001|Main Study: PCP (Up to Week 24)|Physician Decision|0
6287141|NCT02349061|9999680|FG002|Main Study: PCP (Up to Week 24)|Physician Decision|0
5980799|NCT02366728|9569453|FG000|Overall Study|Adverse Event|1
5980800|NCT02366728|9569454|FG001|Overall Study|Adverse Event|0
5980801|NCT02366728|9569455|FG002|Overall Study|Adverse Event|0
5980802|NCT02366728|9569453|FG000|Overall Study|Screen Failure|2
5980803|NCT02366728|9569454|FG001|Overall Study|Screen Failure|1
5980804|NCT02366728|9569455|FG002|Overall Study|Screen Failure|0
5980805|NCT02366728|9569453|FG000|Overall Study|Only yielded 2 vaccines|1
5980806|NCT02366728|9569454|FG001|Overall Study|Only yielded 2 vaccines|0
5980807|NCT02366728|9569455|FG002|Overall Study|Only yielded 2 vaccines|0
5980808|NCT02236572|9569463|FG000|Overall Study|Withdrawal by Subject|1
5980809|NCT02236572|9569463|FG000|Overall Study|Protocol Violation|1
5980810|NCT02236572|9569463|FG000|Overall Study|Lost to Follow-up|1
6063268|NCT00505752|9664625|FG003|Overall Study|Adverse Event|0
6211789|NCT01594333|9878578|FG001|Overall Study|Death|83
6211790|NCT01594333|9878577|FG000|Overall Study|Lost to Follow-up|5
6211791|NCT01594333|9878578|FG001|Overall Study|Lost to Follow-up|5
6211792|NCT01594333|9878577|FG000|Overall Study|Withdrawal by Subject|60
6211793|NCT01594333|9878578|FG001|Overall Study|Withdrawal by Subject|63
6287142|NCT02349061|9999678|FG000|Main Study: PCP (Up to Week 24)|Other|1
6287143|NCT02349061|9999679|FG001|Main Study: PCP (Up to Week 24)|Other|1
6287144|NCT02349061|9999680|FG002|Main Study: PCP (Up to Week 24)|Other|0
6287145|NCT02349061|9999678|FG000|Main Study: PCP (Up to Week 24)|Withdrawal by Subject|2
6063269|NCT00505752|9664622|FG000|Overall Study|Lost to Follow-up|1
6063270|NCT00505752|9664623|FG001|Overall Study|Lost to Follow-up|0
6063271|NCT00505752|9664624|FG002|Overall Study|Lost to Follow-up|0
6063272|NCT00505752|9664625|FG003|Overall Study|Lost to Follow-up|0
6063273|NCT00505752|9664622|FG000|Overall Study|Lack of ovarian response|1
6063274|NCT00505752|9664623|FG001|Overall Study|Lack of ovarian response|3
6063275|NCT00505752|9664624|FG002|Overall Study|Lack of ovarian response|0
6063276|NCT00505752|9664625|FG003|Overall Study|Lack of ovarian response|0
6063277|NCT00505752|9664622|FG000|Overall Study|Ovarian hyperstimulation syndrome risk|1
6118271|NCT00876395|9740721|FG000|Overall Study|Lost to Follow-up|2
6118272|NCT00876395|9740722|FG001|Overall Study|Lost to Follow-up|0
6118273|NCT00876395|9740721|FG000|Overall Study|Administrative problems|39
6118274|NCT00876395|9740722|FG001|Overall Study|Administrative problems|23
6118275|NCT00876395|9740721|FG000|Overall Study|Death|12
6211794|NCT01594411|9878597|FG000|Overall Study|Lost to Follow-up|2
6211795|NCT01594476|9878610|FG000|Overall Study|Protocol Violation|1
6211796|NCT01594476|9878611|FG001|Overall Study|Protocol Violation|3
6211797|NCT01594749|9878675|FG000|Overall Study|Adverse Event|2
6211798|NCT01594749|9878676|FG001|Overall Study|Adverse Event|1
6211799|NCT01594749|9878675|FG000|Overall Study|Withdrawal by Subject|2
6211800|NCT01594749|9878676|FG001|Overall Study|Withdrawal by Subject|2
6211801|NCT01594749|9878675|FG000|Overall Study|Protocol Violation|2
6211802|NCT01594749|9878676|FG001|Overall Study|Protocol Violation|0
6211803|NCT01594749|9878675|FG000|Overall Study|Physician Decision|1
6211804|NCT01594749|9878676|FG001|Overall Study|Physician Decision|1
6211805|NCT01594749|9878675|FG000|Overall Study|Non-compliance with Protocol|0
6211806|NCT01594749|9878676|FG001|Overall Study|Non-compliance with Protocol|1
6211807|NCT01594749|9878675|FG000|Overall Study|Lost to Follow-up|1
6211808|NCT01594749|9878676|FG001|Overall Study|Lost to Follow-up|0
6211809|NCT01594749|9878675|FG000|Overall Study|Death|9
6211810|NCT01594749|9878676|FG001|Overall Study|Death|3
6287146|NCT02349061|9999679|FG001|Main Study: PCP (Up to Week 24)|Withdrawal by Subject|0
6287147|NCT02349061|9999680|FG002|Main Study: PCP (Up to Week 24)|Withdrawal by Subject|0
6287148|NCT02349061|9999678|FG000|Main Study: Week 24 to 56|Adverse Event|0
6287149|NCT02349061|9999679|FG001|Main Study: Week 24 to 56|Adverse Event|2
6287150|NCT02349061|9999680|FG002|Main Study: Week 24 to 56|Adverse Event|1
6287151|NCT02349061|9999678|FG000|Main Study: Week 24 to 56|Lack of Efficacy|0
6287152|NCT02349061|9999679|FG001|Main Study: Week 24 to 56|Lack of Efficacy|1
6287153|NCT02349061|9999680|FG002|Main Study: Week 24 to 56|Lack of Efficacy|0
6287154|NCT02349061|9999678|FG000|Main Study: Week 24 to 56|Withdrawal by Subject|0
6287155|NCT02349061|9999679|FG001|Main Study: Week 24 to 56|Withdrawal by Subject|0
6287156|NCT02349061|9999680|FG002|Main Study: Week 24 to 56|Withdrawal by Subject|1
6287157|NCT02349061|9999678|FG000|Main Study: Week 24 to 56|Physician Decision|0
6287158|NCT02349061|9999679|FG001|Main Study: Week 24 to 56|Physician Decision|0
6287159|NCT02349061|9999680|FG002|Main Study: Week 24 to 56|Physician Decision|1
5980811|NCT02083354|9569467|FG000|Overall Study|Withdrawal by Subject|9
5980812|NCT02083354|9569467|FG000|Overall Study|Lost to Follow-up|1
5980813|NCT02083354|9569467|FG000|Overall Study|Adverse Event|3
5980814|NCT02083354|9569467|FG000|Overall Study|Disease progression|46
5980815|NCT02083354|9569467|FG000|Overall Study|Study closed/terminated|5
5980816|NCT01446016|9569501|FG000|Overall Study|Lost to Follow-up|3
5980817|NCT01446016|9569501|FG000|Overall Study|Withdrawal by Subject|1
5980818|NCT01446016|9569501|FG000|Overall Study|Toxicity|3
5980819|NCT01434602|9569523|FG000|Phase I Dose Escalation|Participant was underdosed (i.e., was taking incorrect dose at home)/Not evaluable|0
5980820|NCT01434602|9569524|FG001|Phase I Dose Escalation|Participant was underdosed (i.e., was taking incorrect dose at home)/Not evaluable|1
5980821|NCT01434602|9569525|FG002|Phase I Dose Escalation|Participant was underdosed (i.e., was taking incorrect dose at home)/Not evaluable|0
5980822|NCT01434602|9569526|FG003|Phase I Dose Escalation|Participant was underdosed (i.e., was taking incorrect dose at home)/Not evaluable|0
5980823|NCT01434602|9569527|FG004|Phase I Dose Escalation|Participant was underdosed (i.e., was taking incorrect dose at home)/Not evaluable|0
5980824|NCT01434602|9569523|FG000|Phase II Recommended Phase 2 Dose|Active progression before start of treatment|0
5980825|NCT01434602|9569524|FG001|Phase II Recommended Phase 2 Dose|Active progression before start of treatment|0
5980826|NCT01434602|9569525|FG002|Phase II Recommended Phase 2 Dose|Active progression before start of treatment|0
5980827|NCT01434602|9569526|FG003|Phase II Recommended Phase 2 Dose|Active progression before start of treatment|1
5980828|NCT01434602|9569527|FG004|Phase II Recommended Phase 2 Dose|Active progression before start of treatment|0
5980829|NCT01434602|9569523|FG000|Phase II Recommended Phase 2 Dose|Bilateral large pulmonary embolisms in the right and left main pulmonary arteries|0
5980830|NCT01434602|9569524|FG001|Phase II Recommended Phase 2 Dose|Bilateral large pulmonary embolisms in the right and left main pulmonary arteries|0
5980831|NCT01434602|9569525|FG002|Phase II Recommended Phase 2 Dose|Bilateral large pulmonary embolisms in the right and left main pulmonary arteries|0
5980832|NCT01434602|9569526|FG003|Phase II Recommended Phase 2 Dose|Bilateral large pulmonary embolisms in the right and left main pulmonary arteries|1
5980833|NCT01434602|9569527|FG004|Phase II Recommended Phase 2 Dose|Bilateral large pulmonary embolisms in the right and left main pulmonary arteries|0
5980834|NCT01434602|9569523|FG000|Phase II Recommended Phase 2 Dose|Started new therapy|0
5980835|NCT01434602|9569524|FG001|Phase II Recommended Phase 2 Dose|Started new therapy|0
5980836|NCT01434602|9569525|FG002|Phase II Recommended Phase 2 Dose|Started new therapy|0
5980837|NCT01434602|9569526|FG003|Phase II Recommended Phase 2 Dose|Started new therapy|1
5980838|NCT01434602|9569527|FG004|Phase II Recommended Phase 2 Dose|Started new therapy|0
5980839|NCT01434602|9569523|FG000|Phase II Recommended Phase 2 Dose|Decline in patient condition/health/ADL's|0
5980840|NCT01434602|9569524|FG001|Phase II Recommended Phase 2 Dose|Decline in patient condition/health/ADL's|0
6118276|NCT00876395|9740722|FG001|Overall Study|Death|0
6118277|NCT00876447|9740735|FG000|Overall Study|Other miscellaneous reasons|3
6211811|NCT01594749|9878675|FG000|Overall Study|Not Treated|4
6211812|NCT01594749|9878676|FG001|Overall Study|Not Treated|10
6118278|NCT00876447|9740736|FG001|Overall Study|Other miscellaneous reasons|8
6118279|NCT00876447|9740735|FG000|Overall Study|Site closure|19
6118280|NCT00876447|9740736|FG001|Overall Study|Site closure|14
6118281|NCT00876447|9740735|FG000|Overall Study|Protocol Violation|9
6118282|NCT00876447|9740736|FG001|Overall Study|Protocol Violation|3
6118283|NCT00876447|9740735|FG000|Overall Study|Personal reasons|30
6118284|NCT00876447|9740736|FG001|Overall Study|Personal reasons|28
6118285|NCT00876447|9740735|FG000|Overall Study|Lost to Follow-up|6
6118286|NCT00876447|9740736|FG001|Overall Study|Lost to Follow-up|15
6118287|NCT00876447|9740735|FG000|Overall Study|Pregnancy|4
6118288|NCT00876447|9740736|FG001|Overall Study|Pregnancy|2
6118289|NCT00876447|9740735|FG000|Overall Study|Lack of Efficacy|5
6118290|NCT00876447|9740736|FG001|Overall Study|Lack of Efficacy|3
6118291|NCT00876447|9740735|FG000|Overall Study|Adverse Event|4
6118292|NCT00876447|9740736|FG001|Overall Study|Adverse Event|8
6118293|NCT00876460|9740774|FG000|Combination Therapy Phase|Progressive disease|2
6118294|NCT00876460|9740775|FG001|Combination Therapy Phase|Progressive disease|3
6118295|NCT00876460|9740776|FG002|Combination Therapy Phase|Progressive disease|3
6118296|NCT00876460|9740777|FG003|Combination Therapy Phase|Progressive disease|3
6118297|NCT00876460|9740778|FG004|Combination Therapy Phase|Progressive disease|3
6118298|NCT00876460|9740779|FG005|Combination Therapy Phase|Progressive disease|1
6118299|NCT00876460|9740780|FG006|Combination Therapy Phase|Progressive disease|1
6118300|NCT00876460|9740781|FG007|Combination Therapy Phase|Progressive disease|1
6211813|NCT01594749|9878675|FG000|Overall Study|Lost Source Documentation|1
6211814|NCT01594749|9878676|FG001|Overall Study|Lost Source Documentation|0
6211815|NCT01594762|9878684|FG000|Overall Study|Withdrawal by Subject|1
6118301|NCT00876460|9740774|FG000|Combination Therapy Phase|Dose limiting toxicity|0
6118302|NCT00876460|9740775|FG001|Combination Therapy Phase|Dose limiting toxicity|1
6118303|NCT00876460|9740776|FG002|Combination Therapy Phase|Dose limiting toxicity|0
6118304|NCT00876460|9740777|FG003|Combination Therapy Phase|Dose limiting toxicity|1
6118305|NCT00876460|9740778|FG004|Combination Therapy Phase|Dose limiting toxicity|1
6118306|NCT00876460|9740779|FG005|Combination Therapy Phase|Dose limiting toxicity|2
6118307|NCT00876460|9740780|FG006|Combination Therapy Phase|Dose limiting toxicity|2
6118308|NCT00876460|9740781|FG007|Combination Therapy Phase|Dose limiting toxicity|1
6118309|NCT00876460|9740774|FG000|Combination Therapy Phase|Adverse Event|0
6118310|NCT00876460|9740775|FG001|Combination Therapy Phase|Adverse Event|2
6118311|NCT00876460|9740776|FG002|Combination Therapy Phase|Adverse Event|0
6118312|NCT00876460|9740777|FG003|Combination Therapy Phase|Adverse Event|2
6118313|NCT00876460|9740778|FG004|Combination Therapy Phase|Adverse Event|2
6118314|NCT00876460|9740779|FG005|Combination Therapy Phase|Adverse Event|0
6118315|NCT00876460|9740780|FG006|Combination Therapy Phase|Adverse Event|3
6118316|NCT00876460|9740781|FG007|Combination Therapy Phase|Adverse Event|2
6118317|NCT00876460|9740774|FG000|Combination Therapy Phase|Withdrawal by Subject|1
6118318|NCT00876460|9740775|FG001|Combination Therapy Phase|Withdrawal by Subject|1
6118319|NCT00876460|9740776|FG002|Combination Therapy Phase|Withdrawal by Subject|0
6118320|NCT00876460|9740777|FG003|Combination Therapy Phase|Withdrawal by Subject|0
6118321|NCT00876460|9740778|FG004|Combination Therapy Phase|Withdrawal by Subject|1
6118322|NCT00876460|9740779|FG005|Combination Therapy Phase|Withdrawal by Subject|0
6118323|NCT00876460|9740780|FG006|Combination Therapy Phase|Withdrawal by Subject|0
6118324|NCT00876460|9740781|FG007|Combination Therapy Phase|Withdrawal by Subject|0
6118325|NCT00876460|9740774|FG000|Combination Therapy Phase|Other reason not defined above|0
6118326|NCT00876460|9740775|FG001|Combination Therapy Phase|Other reason not defined above|0
6118327|NCT00876460|9740776|FG002|Combination Therapy Phase|Other reason not defined above|0
6118328|NCT00876460|9740777|FG003|Combination Therapy Phase|Other reason not defined above|0
6118329|NCT00876460|9740778|FG004|Combination Therapy Phase|Other reason not defined above|0
6118330|NCT00876460|9740779|FG005|Combination Therapy Phase|Other reason not defined above|0
6118331|NCT00876460|9740780|FG006|Combination Therapy Phase|Other reason not defined above|1
6118332|NCT00876460|9740781|FG007|Combination Therapy Phase|Other reason not defined above|2
6118333|NCT00876460|9740774|FG000|Combination Therapy Phase|Not treated|0
6118334|NCT00876460|9740775|FG001|Combination Therapy Phase|Not treated|0
6118335|NCT00876460|9740776|FG002|Combination Therapy Phase|Not treated|0
6118336|NCT00876460|9740777|FG003|Combination Therapy Phase|Not treated|0
6118337|NCT00876460|9740778|FG004|Combination Therapy Phase|Not treated|0
6118338|NCT00876460|9740779|FG005|Combination Therapy Phase|Not treated|0
6118339|NCT00876460|9740780|FG006|Combination Therapy Phase|Not treated|1
6118340|NCT00876460|9740781|FG007|Combination Therapy Phase|Not treated|0
6118341|NCT00876460|9740774|FG000|Mono Therapy Phase|Progressive disease|0
6118342|NCT00876460|9740775|FG001|Mono Therapy Phase|Progressive disease|0
6118343|NCT00876460|9740776|FG002|Mono Therapy Phase|Progressive disease|0
6118344|NCT00876460|9740777|FG003|Mono Therapy Phase|Progressive disease|0
6118345|NCT00876460|9740778|FG004|Mono Therapy Phase|Progressive disease|2
6118346|NCT00876460|9740779|FG005|Mono Therapy Phase|Progressive disease|0
6118347|NCT00876460|9740780|FG006|Mono Therapy Phase|Progressive disease|1
6118348|NCT00876460|9740781|FG007|Mono Therapy Phase|Progressive disease|3
6118349|NCT00876460|9740774|FG000|Mono Therapy Phase|Withdrawal by Subject|0
6118350|NCT00876460|9740775|FG001|Mono Therapy Phase|Withdrawal by Subject|1
6118351|NCT00876460|9740776|FG002|Mono Therapy Phase|Withdrawal by Subject|0
6118352|NCT00876460|9740777|FG003|Mono Therapy Phase|Withdrawal by Subject|0
6118353|NCT00876460|9740778|FG004|Mono Therapy Phase|Withdrawal by Subject|0
6118354|NCT00876460|9740779|FG005|Mono Therapy Phase|Withdrawal by Subject|0
6118355|NCT00876460|9740780|FG006|Mono Therapy Phase|Withdrawal by Subject|0
6118356|NCT00876460|9740781|FG007|Mono Therapy Phase|Withdrawal by Subject|0
6118357|NCT00876460|9740774|FG000|Mono Therapy Phase|Adverse Event|0
6118358|NCT00876460|9740775|FG001|Mono Therapy Phase|Adverse Event|0
6118359|NCT00876460|9740776|FG002|Mono Therapy Phase|Adverse Event|0
6118360|NCT00876460|9740777|FG003|Mono Therapy Phase|Adverse Event|1
6118361|NCT00876460|9740778|FG004|Mono Therapy Phase|Adverse Event|0
6118362|NCT00876460|9740779|FG005|Mono Therapy Phase|Adverse Event|0
6118363|NCT00876460|9740780|FG006|Mono Therapy Phase|Adverse Event|0
6118364|NCT00876460|9740781|FG007|Mono Therapy Phase|Adverse Event|0
6118365|NCT00876694|9740813|FG000|Overall Study|Adverse Event|10
6118366|NCT00876694|9740814|FG001|Overall Study|Adverse Event|7
6118367|NCT00876694|9740813|FG000|Overall Study|Subject withdrew consent|6
6118368|NCT00876694|9740814|FG001|Overall Study|Subject withdrew consent|4
6118369|NCT00876694|9740813|FG000|Overall Study|Unsatisfactory therapeutic effect|2
6118370|NCT00876694|9740814|FG001|Overall Study|Unsatisfactory therapeutic effect|0
6118371|NCT00876694|9740813|FG000|Overall Study|Abnormal test procedure result(s)|1
6118372|NCT00876694|9740814|FG001|Overall Study|Abnormal test procedure result(s)|0
6118373|NCT00876694|9740813|FG000|Overall Study|Administrative problems|1
6118374|NCT00876694|9740814|FG001|Overall Study|Administrative problems|1
6118375|NCT00876694|9740813|FG000|Overall Study|Death|1
6118376|NCT00876694|9740814|FG001|Overall Study|Death|0
6118377|NCT00876733|9740824|FG000|Overall Study|Adverse Event|34
6118378|NCT00876733|9740825|FG001|Overall Study|Adverse Event|20
6118379|NCT00876733|9740826|FG002|Overall Study|Adverse Event|10
6118380|NCT00876733|9740827|FG003|Overall Study|Adverse Event|3
6211816|NCT01594762|9878685|FG001|Overall Study|Withdrawal by Subject|0
6211817|NCT01594762|9878684|FG000|Overall Study|Lost to Follow-up|10
6211818|NCT01594762|9878685|FG001|Overall Study|Lost to Follow-up|10
6211819|NCT01594827|9878693|FG000|Overall Study|Adverse Event|1
6211820|NCT01594827|9878694|FG001|Overall Study|Adverse Event|0
6211821|NCT01594827|9878693|FG000|Overall Study|Physician Decision|3
6211822|NCT01594827|9878694|FG001|Overall Study|Physician Decision|0
6211823|NCT01594853|9878704|FG000|Overall Study|Withdrawal by Subject|1
6211824|NCT01594853|9878705|FG001|Overall Study|Withdrawal by Subject|1
6211825|NCT01594853|9878704|FG000|Overall Study|Lost to Follow-up|1
6211826|NCT01594853|9878705|FG001|Overall Study|Lost to Follow-up|1
6211827|NCT01594853|9878704|FG000|Overall Study|noncompliance with exercise|0
6211828|NCT01594853|9878705|FG001|Overall Study|noncompliance with exercise|1
6211829|NCT01594931|9878714|FG000|Overall Study|Adverse Event|3
6211830|NCT01594931|9878715|FG001|Overall Study|Adverse Event|1
6211831|NCT01594931|9878716|FG002|Overall Study|Adverse Event|1
6211832|NCT01594931|9878714|FG000|Overall Study|Withdrawal by Subject|2
6211833|NCT01594931|9878715|FG001|Overall Study|Withdrawal by Subject|1
6211834|NCT01594931|9878716|FG002|Overall Study|Withdrawal by Subject|1
6211835|NCT01594931|9878714|FG000|Overall Study|Lack of Efficacy|7
6211836|NCT01594931|9878715|FG001|Overall Study|Lack of Efficacy|2
6211837|NCT01594931|9878716|FG002|Overall Study|Lack of Efficacy|2
6211838|NCT01594931|9878714|FG000|Overall Study|Lost to Follow-up|4
6211839|NCT01594931|9878715|FG001|Overall Study|Lost to Follow-up|3
6211840|NCT01594931|9878716|FG002|Overall Study|Lost to Follow-up|3
6211841|NCT01594931|9878714|FG000|Overall Study|Protocol Violation|2
6211842|NCT01594931|9878715|FG001|Overall Study|Protocol Violation|1
6211843|NCT01594931|9878716|FG002|Overall Study|Protocol Violation|0
6211844|NCT01594931|9878714|FG000|Overall Study|No defiined|11
6211845|NCT01594931|9878715|FG001|Overall Study|No defiined|4
6211846|NCT01594931|9878716|FG002|Overall Study|No defiined|7
6211847|NCT01594970|9878727|FG000|Overall Study|Non-Adverse Event Related|4
6211848|NCT01594970|9878728|FG001|Overall Study|Non-Adverse Event Related|5
6211849|NCT01594970|9878729|FG002|Overall Study|Non-Adverse Event Related|6
6211850|NCT01594970|9878727|FG000|Overall Study|Adverse Event|17
6211851|NCT01594970|9878728|FG001|Overall Study|Adverse Event|23
6211852|NCT01594970|9878729|FG002|Overall Study|Adverse Event|23
6211853|NCT01594970|9878727|FG000|Overall Study|Lost to Follow-up|54
6211854|NCT01594970|9878728|FG001|Overall Study|Lost to Follow-up|54
6211855|NCT01594970|9878729|FG002|Overall Study|Lost to Follow-up|37
6211856|NCT01595438|9878757|FG000|Overall Study|Lost to Follow-up|20
6211857|NCT01595438|9878758|FG001|Overall Study|Lost to Follow-up|20
6211858|NCT01595438|9878757|FG000|Overall Study|Withdrawal by Subject|12
6211859|NCT01595438|9878758|FG001|Overall Study|Withdrawal by Subject|12
6211860|NCT01595438|9878757|FG000|Overall Study|Other Eligibility criteria|11
6211861|NCT01595438|9878758|FG001|Overall Study|Other Eligibility criteria|9
6211862|NCT01595529|9878793|FG000|Overall Study|Adverse Event|2
6211863|NCT01595529|9878794|FG001|Overall Study|Adverse Event|0
6211864|NCT01595529|9878793|FG000|Overall Study|Subject Non-Compliant|2
6211865|NCT01595529|9878794|FG001|Overall Study|Subject Non-Compliant|0
6211866|NCT01595529|9878793|FG000|Overall Study|Lost to Follow-up|8
6211867|NCT01595529|9878794|FG001|Overall Study|Lost to Follow-up|14
6211868|NCT01595529|9878793|FG000|Overall Study|Protocol Violation|1
6211869|NCT01595529|9878794|FG001|Overall Study|Protocol Violation|2
6211870|NCT01595529|9878793|FG000|Overall Study|Physician Decision|1
6211871|NCT01595529|9878794|FG001|Overall Study|Physician Decision|0
6211872|NCT01595529|9878793|FG000|Overall Study|Consent Withdrawn/Voluntary Withdrawal|3
6211873|NCT01595529|9878794|FG001|Overall Study|Consent Withdrawn/Voluntary Withdrawal|3
6118381|NCT00876733|9740824|FG000|Overall Study|Lack of Efficacy|17
6118382|NCT00876733|9740825|FG001|Overall Study|Lack of Efficacy|9
6118383|NCT00876733|9740826|FG002|Overall Study|Lack of Efficacy|10
6118384|NCT00876733|9740827|FG003|Overall Study|Lack of Efficacy|1
6118385|NCT00876733|9740824|FG000|Overall Study|Lost to Follow-up|26
6118386|NCT00876733|9740825|FG001|Overall Study|Lost to Follow-up|10
6118387|NCT00876733|9740826|FG002|Overall Study|Lost to Follow-up|3
6118388|NCT00876733|9740827|FG003|Overall Study|Lost to Follow-up|2
6118389|NCT00876733|9740824|FG000|Overall Study|Data not available|14
6118390|NCT00876733|9740825|FG001|Overall Study|Data not available|3
6118391|NCT00876733|9740826|FG002|Overall Study|Data not available|7
6118392|NCT00876733|9740827|FG003|Overall Study|Data not available|1
6118393|NCT00876928|9740852|FG000|Overall Study|Lost to Follow-up|2
6118394|NCT00876928|9740853|FG001|Overall Study|Lost to Follow-up|5
6118395|NCT00876928|9740852|FG000|Overall Study|Hypokalemia-affects insulin secretion|1
6118396|NCT00876928|9740853|FG001|Overall Study|Hypokalemia-affects insulin secretion|0
6118397|NCT00877006|9740884|FG000|Treatment Period|Death|2
6118398|NCT00877006|9740885|FG001|Treatment Period|Death|1
6118399|NCT00877006|9740884|FG000|Treatment Period|Adverse Event|10
6118400|NCT00877006|9740885|FG001|Treatment Period|Adverse Event|3
6118401|NCT00877006|9740884|FG000|Treatment Period|Withdrawal by Subject|2
6118402|NCT00877006|9740885|FG001|Treatment Period|Withdrawal by Subject|3
6118403|NCT00877006|9740884|FG000|Treatment Period|Protocol Violation|1
6118404|NCT00877006|9740885|FG001|Treatment Period|Protocol Violation|0
6118405|NCT00877006|9740884|FG000|Treatment Period|Lost to Follow-up|0
6118406|NCT00877006|9740885|FG001|Treatment Period|Lost to Follow-up|1
6118407|NCT00877006|9740884|FG000|Treatment Period|Disease Progression|1
6118408|NCT00877006|9740885|FG001|Treatment Period|Disease Progression|2
6118409|NCT00877006|9740884|FG000|Treatment Period|Started New Treatment Regimen|2
6118410|NCT00877006|9740885|FG001|Treatment Period|Started New Treatment Regimen|5
6118411|NCT00877006|9740884|FG000|Treatment Period|Other|4
6118412|NCT00877006|9740885|FG001|Treatment Period|Other|4
6118413|NCT00877006|9740884|FG000|Treatment Period|Randomized but Not Treated|3
6118414|NCT00877006|9740885|FG001|Treatment Period|Randomized but Not Treated|8
6118415|NCT00877006|9740884|FG000|Long-Term Follow-up Period|Withdrawal by Subject|12
6118416|NCT00877006|9740885|FG001|Long-Term Follow-up Period|Withdrawal by Subject|19
6118417|NCT00877006|9740884|FG000|Long-Term Follow-up Period|Lost to Follow-up|8
6211874|NCT01595529|9878793|FG000|Overall Study|Administrative Decision|1
6211875|NCT01595529|9878794|FG001|Overall Study|Administrative Decision|0
6211876|NCT01595529|9878793|FG000|Overall Study|Entry Failure/Screening Failure|6
6211877|NCT01595529|9878794|FG001|Overall Study|Entry Failure/Screening Failure|1
6211878|NCT01595646|9878803|FG000|Overall Study|Withdrawal by Subject|1
6211879|NCT01595646|9878804|FG001|Overall Study|Withdrawal by Subject|0
6211880|NCT01595646|9878805|FG002|Overall Study|Withdrawal by Subject|0
6211881|NCT01596062|9878846|FG000|Overall Study|Adverse Event|1
6211882|NCT01596062|9878847|FG001|Overall Study|Adverse Event|0
6211883|NCT01596062|9878848|FG002|Overall Study|Adverse Event|2
6211884|NCT01596062|9878846|FG000|Overall Study|Lack of Efficacy|0
6211885|NCT01596062|9878847|FG001|Overall Study|Lack of Efficacy|0
6211886|NCT01596062|9878848|FG002|Overall Study|Lack of Efficacy|1
6211887|NCT01596127|9878860|FG000|Overall Study|Patient Ineligible|1
6211888|NCT01596335|9878886|FG000|Overall Study|exacerbation of primary disease|5
6211889|NCT01596335|9878887|FG001|Overall Study|exacerbation of primary disease|9
6211890|NCT01596504|9878896|FG000|Overall Study|Participant's Private Reason|0
6211891|NCT01596504|9878897|FG001|Overall Study|Participant's Private Reason|1
6211892|NCT01596504|9878898|FG002|Overall Study|Participant's Private Reason|0
6211893|NCT01596504|9878896|FG000|Overall Study|Adverse Event|1
6211894|NCT01596504|9878897|FG001|Overall Study|Adverse Event|2
6211895|NCT01596504|9878898|FG002|Overall Study|Adverse Event|1
6211896|NCT01596504|9878896|FG000|Overall Study|Withdrawal by Subject|1
6211897|NCT01596504|9878897|FG001|Overall Study|Withdrawal by Subject|0
6211898|NCT01596504|9878898|FG002|Overall Study|Withdrawal by Subject|0
6211899|NCT01596582|9878909|FG000|Overall Study|Deemed ineligible after study visit|3
6211900|NCT01596582|9878910|FG001|Overall Study|Deemed ineligible after study visit|6
6211901|NCT01596582|9878909|FG000|Overall Study|Missing all outcome data|1
6211902|NCT01596582|9878910|FG001|Overall Study|Missing all outcome data|1
6211903|NCT01596972|9878981|FG000|Overall Study|Physician Decision|1
6211904|NCT01596972|9878982|FG001|Overall Study|Physician Decision|9
6211905|NCT01596972|9878981|FG000|Overall Study|Lost to Follow-up|0
6211906|NCT01596972|9878982|FG001|Overall Study|Lost to Follow-up|4
6211907|NCT01596972|9878981|FG000|Overall Study|Withdrawal by Subject|0
6211908|NCT01596972|9878982|FG001|Overall Study|Withdrawal by Subject|1
6211909|NCT01597050|9878990|FG000|Overall Study|Withdrawal by Subject|1
6211910|NCT01597050|9878991|FG001|Overall Study|Withdrawal by Subject|0
6211911|NCT01597193|9879024|FG000|Stage 1: Dose Escalation (141 Days)|Disease progression|7
6211912|NCT01597193|9879025|FG001|Stage 1: Dose Escalation (141 Days)|Disease progression|8
6211913|NCT01597193|9879026|FG002|Stage 1: Dose Escalation (141 Days)|Disease progression|0
6211914|NCT01597193|9879027|FG003|Stage 1: Dose Escalation (141 Days)|Disease progression|0
6211915|NCT01597193|9879028|FG004|Stage 1: Dose Escalation (141 Days)|Disease progression|0
6211916|NCT01597193|9879029|FG005|Stage 1: Dose Escalation (141 Days)|Disease progression|0
6211917|NCT01597193|9879030|FG006|Stage 1: Dose Escalation (141 Days)|Disease progression|0
6118418|NCT00877006|9740885|FG001|Long-Term Follow-up Period|Lost to Follow-up|9
6118419|NCT00877006|9740884|FG000|Long-Term Follow-up Period|Death|26
6118420|NCT00877006|9740885|FG001|Long-Term Follow-up Period|Death|18
6118421|NCT00877006|9740884|FG000|Long-Term Follow-up Period|Other|7
6118422|NCT00877006|9740885|FG001|Long-Term Follow-up Period|Other|9
6118423|NCT00877032|9740900|FG000|Overall Study|Did not meet entrance criteria|0
6118424|NCT00877032|9740901|FG001|Overall Study|Did not meet entrance criteria|0
6118425|NCT00877032|9740902|FG002|Overall Study|Did not meet entrance criteria|0
6118426|NCT00877032|9740903|FG003|Overall Study|Did not meet entrance criteria|1
6118427|NCT00877032|9740904|FG004|Overall Study|Did not meet entrance criteria|0
6118428|NCT00877032|9740905|FG005|Overall Study|Did not meet entrance criteria|0
6118429|NCT00877032|9740906|FG006|Overall Study|Did not meet entrance criteria|2
6118430|NCT00877383|9740941|FG000|Overall Study|Adverse Event|13
6118431|NCT00877383|9740942|FG001|Overall Study|Adverse Event|14
6118432|NCT00877383|9740941|FG000|Overall Study|Lost to Follow-up|5
6118433|NCT00877383|9740942|FG001|Overall Study|Lost to Follow-up|3
6118434|NCT00877383|9740941|FG000|Overall Study|Subject withdrew consent|3
6118435|NCT00877383|9740942|FG001|Overall Study|Subject withdrew consent|12
6118436|NCT00877383|9740941|FG000|Overall Study|Subject no longer requires study drug|2
6118437|NCT00877383|9740942|FG001|Overall Study|Subject no longer requires study drug|0
6118438|NCT00877383|9740941|FG000|Overall Study|Administrative problems|2
6118439|NCT00877383|9740942|FG001|Overall Study|Administrative problems|0
6118440|NCT00877383|9740941|FG000|Overall Study|Protocol deviation|2
6118441|NCT00877383|9740942|FG001|Overall Study|Protocol deviation|6
6118442|NCT00877383|9740941|FG000|Overall Study|Unsatisfactory therapeutic effect|1
6118443|NCT00877383|9740942|FG001|Overall Study|Unsatisfactory therapeutic effect|0
6118444|NCT00877383|9740941|FG000|Overall Study|Death|1
6118445|NCT00877383|9740942|FG001|Overall Study|Death|2
6118446|NCT00877487|9740977|FG000|Open-label Treatment Phase|Adverse Event|1
6118447|NCT00877487|9740978|FG001|Open-label Treatment Phase|Adverse Event|0
6118448|NCT00877487|9740977|FG000|Open-label Treatment Phase|Protocol Violation|3
6118449|NCT00877487|9740978|FG001|Open-label Treatment Phase|Protocol Violation|0
6118450|NCT00877487|9740977|FG000|Open-label Treatment Phase|Withdrawal by Subject|1
6118451|NCT00877487|9740978|FG001|Open-label Treatment Phase|Withdrawal by Subject|0
6118452|NCT00877487|9740977|FG000|Open-label Treatment Phase|Lost to Follow-up|1
6118453|NCT00877487|9740978|FG001|Open-label Treatment Phase|Lost to Follow-up|0
6118454|NCT00877487|9740977|FG000|Open-label Treatment Phase|Out of country for business|1
6118455|NCT00877487|9740978|FG001|Open-label Treatment Phase|Out of country for business|0
6118456|NCT00877487|9740977|FG000|Double-blind Randomized Withdrawal Phase|Relapse criteria met|5
6118457|NCT00877487|9740978|FG001|Double-blind Randomized Withdrawal Phase|Relapse criteria met|45
6118458|NCT00877487|9740977|FG000|Double-blind Randomized Withdrawal Phase|Adverse Event|0
6118459|NCT00877487|9740978|FG001|Double-blind Randomized Withdrawal Phase|Adverse Event|1
6118460|NCT00877487|9740977|FG000|Double-blind Randomized Withdrawal Phase|Protocol Violation|0
6118461|NCT00877487|9740978|FG001|Double-blind Randomized Withdrawal Phase|Protocol Violation|1
6118462|NCT00877487|9740977|FG000|Double-blind Randomized Withdrawal Phase|Moved out of state|1
6118463|NCT00877487|9740978|FG001|Double-blind Randomized Withdrawal Phase|Moved out of state|0
6118464|NCT00877773|9740993|FG000|Overall Study|Disease Progression|44
6118465|NCT00877799|9741002|FG000|Cohort 1: 24 Hours After Surgery (Day 1)|Adverse Event|2
6118466|NCT00877799|9741003|FG001|Cohort 1: 24 Hours After Surgery (Day 1)|Adverse Event|1
6118467|NCT00877799|9741004|FG002|Cohort 1: 24 Hours After Surgery (Day 1)|Adverse Event|1
6118468|NCT00877799|9741005|FG003|Cohort 1: 24 Hours After Surgery (Day 1)|Adverse Event|0
6118469|NCT00877799|9741006|FG004|Cohort 1: 24 Hours After Surgery (Day 1)|Adverse Event|0
6118470|NCT00877799|9741002|FG000|Cohort 1: 24 Hours After Surgery (Day 1)|Lost to Follow-up|1
6118471|NCT00877799|9741003|FG001|Cohort 1: 24 Hours After Surgery (Day 1)|Lost to Follow-up|1
6118472|NCT00877799|9741004|FG002|Cohort 1: 24 Hours After Surgery (Day 1)|Lost to Follow-up|2
6118473|NCT00877799|9741005|FG003|Cohort 1: 24 Hours After Surgery (Day 1)|Lost to Follow-up|0
6118474|NCT00877799|9741006|FG004|Cohort 1: 24 Hours After Surgery (Day 1)|Lost to Follow-up|0
6118475|NCT00877799|9741002|FG000|Cohort 1: 24 Hours After Surgery (Day 1)|Withdrawal by Subject|0
6118476|NCT00877799|9741003|FG001|Cohort 1: 24 Hours After Surgery (Day 1)|Withdrawal by Subject|3
6118477|NCT00877799|9741004|FG002|Cohort 1: 24 Hours After Surgery (Day 1)|Withdrawal by Subject|0
6118478|NCT00877799|9741005|FG003|Cohort 1: 24 Hours After Surgery (Day 1)|Withdrawal by Subject|0
6118479|NCT00877799|9741006|FG004|Cohort 1: 24 Hours After Surgery (Day 1)|Withdrawal by Subject|0
6118480|NCT00877799|9741002|FG000|Cohort 2: Immediately Post-op (Day 0)|Protocol Violation|0
6118481|NCT00877799|9741003|FG001|Cohort 2: Immediately Post-op (Day 0)|Protocol Violation|0
6118482|NCT00877799|9741004|FG002|Cohort 2: Immediately Post-op (Day 0)|Protocol Violation|0
6118483|NCT00877799|9741005|FG003|Cohort 2: Immediately Post-op (Day 0)|Protocol Violation|1
6118484|NCT00877799|9741006|FG004|Cohort 2: Immediately Post-op (Day 0)|Protocol Violation|0
6211918|NCT01597193|9879024|FG000|Stage 2: Dose Expansion (1067 Days)|Adverse Event|0
6211919|NCT01597193|9879025|FG001|Stage 2: Dose Expansion (1067 Days)|Adverse Event|0
6211920|NCT01597193|9879026|FG002|Stage 2: Dose Expansion (1067 Days)|Adverse Event|0
6118485|NCT00877799|9741002|FG000|Cohort 2: Immediately Post-op (Day 0)|Lost to Follow-up|0
6118486|NCT00877799|9741003|FG001|Cohort 2: Immediately Post-op (Day 0)|Lost to Follow-up|0
6118487|NCT00877799|9741004|FG002|Cohort 2: Immediately Post-op (Day 0)|Lost to Follow-up|0
6118488|NCT00877799|9741005|FG003|Cohort 2: Immediately Post-op (Day 0)|Lost to Follow-up|1
6118489|NCT00877799|9741006|FG004|Cohort 2: Immediately Post-op (Day 0)|Lost to Follow-up|1
6118490|NCT00877890|9741028|FG000|Overall Study|Adverse Event|6
6118491|NCT00877890|9741029|FG001|Overall Study|Adverse Event|6
6118492|NCT00877890|9741028|FG000|Overall Study|Lost to Follow-up|5
6118493|NCT00877890|9741029|FG001|Overall Study|Lost to Follow-up|5
6211921|NCT01597193|9879027|FG003|Stage 2: Dose Expansion (1067 Days)|Adverse Event|1
6211922|NCT01597193|9879028|FG004|Stage 2: Dose Expansion (1067 Days)|Adverse Event|2
6211923|NCT01597193|9879029|FG005|Stage 2: Dose Expansion (1067 Days)|Adverse Event|3
6211924|NCT01597193|9879030|FG006|Stage 2: Dose Expansion (1067 Days)|Adverse Event|0
6211925|NCT01597193|9879024|FG000|Stage 2: Dose Expansion (1067 Days)|Disease progression|0
6211926|NCT01597193|9879025|FG001|Stage 2: Dose Expansion (1067 Days)|Disease progression|0
6211927|NCT01597193|9879026|FG002|Stage 2: Dose Expansion (1067 Days)|Disease progression|14
6211928|NCT01597193|9879027|FG003|Stage 2: Dose Expansion (1067 Days)|Disease progression|18
6211929|NCT01597193|9879028|FG004|Stage 2: Dose Expansion (1067 Days)|Disease progression|14
6211930|NCT01597193|9879029|FG005|Stage 2: Dose Expansion (1067 Days)|Disease progression|18
6211931|NCT01597193|9879030|FG006|Stage 2: Dose Expansion (1067 Days)|Disease progression|11
6211932|NCT01597193|9879024|FG000|Stage 2: Dose Expansion (1067 Days)|Other|0
6211933|NCT01597193|9879025|FG001|Stage 2: Dose Expansion (1067 Days)|Other|0
6211934|NCT01597193|9879026|FG002|Stage 2: Dose Expansion (1067 Days)|Other|0
6211935|NCT01597193|9879027|FG003|Stage 2: Dose Expansion (1067 Days)|Other|0
6211936|NCT01597193|9879028|FG004|Stage 2: Dose Expansion (1067 Days)|Other|0
6211937|NCT01597193|9879029|FG005|Stage 2: Dose Expansion (1067 Days)|Other|1
6211938|NCT01597193|9879030|FG006|Stage 2: Dose Expansion (1067 Days)|Other|0
6211939|NCT01597193|9879024|FG000|Stage 2: Dose Expansion (1067 Days)|Withdrawal by Subject|0
6211940|NCT01597193|9879025|FG001|Stage 2: Dose Expansion (1067 Days)|Withdrawal by Subject|0
6211941|NCT01597193|9879026|FG002|Stage 2: Dose Expansion (1067 Days)|Withdrawal by Subject|0
6211942|NCT01597193|9879027|FG003|Stage 2: Dose Expansion (1067 Days)|Withdrawal by Subject|1
6211943|NCT01597193|9879028|FG004|Stage 2: Dose Expansion (1067 Days)|Withdrawal by Subject|0
6211944|NCT01597193|9879029|FG005|Stage 2: Dose Expansion (1067 Days)|Withdrawal by Subject|1
6211945|NCT01597193|9879030|FG006|Stage 2: Dose Expansion (1067 Days)|Withdrawal by Subject|0
6211946|NCT01597245|9879055|FG000|Induction Period (Week 0 - Week 12)|Adverse Event|1
6211947|NCT01597245|9879056|FG001|Induction Period (Week 0 - Week 12)|Adverse Event|5
6211948|NCT01597245|9879057|FG002|Induction Period (Week 0 - Week 12)|Adverse Event|5
6211949|NCT01597245|9879058|FG003|Induction Period (Week 0 - Week 12)|Adverse Event|4
6211950|NCT01597245|9879059|FG004|Induction Period (Week 0 - Week 12)|Adverse Event|0
6211951|NCT01597245|9879060|FG005|Induction Period (Week 0 - Week 12)|Adverse Event|0
6211952|NCT01597245|9879061|FG006|Induction Period (Week 0 - Week 12)|Adverse Event|0
6211953|NCT01597245|9879062|FG007|Induction Period (Week 0 - Week 12)|Adverse Event|0
6211954|NCT01597245|9879063|FG008|Induction Period (Week 0 - Week 12)|Adverse Event|0
6211955|NCT01597245|9879064|FG009|Induction Period (Week 0 - Week 12)|Adverse Event|0
6211956|NCT01597245|9879065|FG010|Induction Period (Week 0 - Week 12)|Adverse Event|0
6211957|NCT01597245|9879066|FG011|Induction Period (Week 0 - Week 12)|Adverse Event|0
6211958|NCT01597245|9879067|FG012|Induction Period (Week 0 - Week 12)|Adverse Event|0
6211959|NCT01597245|9879068|FG013|Induction Period (Week 0 - Week 12)|Adverse Event|0
6211960|NCT01597245|9879069|FG014|Induction Period (Week 0 - Week 12)|Adverse Event|0
6211961|NCT01597245|9879070|FG015|Induction Period (Week 0 - Week 12)|Adverse Event|0
6211962|NCT01597245|9879071|FG016|Induction Period (Week 0 - Week 12)|Adverse Event|0
6211963|NCT01597245|9879072|FG017|Induction Period (Week 0 - Week 12)|Adverse Event|0
6211964|NCT01597245|9879073|FG018|Induction Period (Week 0 - Week 12)|Adverse Event|0
6211965|NCT01597245|9879074|FG019|Induction Period (Week 0 - Week 12)|Adverse Event|0
6211966|NCT01597245|9879075|FG020|Induction Period (Week 0 - Week 12)|Adverse Event|0
6211967|NCT01597245|9879055|FG000|Induction Period (Week 0 - Week 12)|Withdrawal by Subject|2
6211968|NCT01597245|9879056|FG001|Induction Period (Week 0 - Week 12)|Withdrawal by Subject|8
6211969|NCT01597245|9879057|FG002|Induction Period (Week 0 - Week 12)|Withdrawal by Subject|6
6211970|NCT01597245|9879058|FG003|Induction Period (Week 0 - Week 12)|Withdrawal by Subject|2
6211971|NCT01597245|9879059|FG004|Induction Period (Week 0 - Week 12)|Withdrawal by Subject|0
6211972|NCT01597245|9879060|FG005|Induction Period (Week 0 - Week 12)|Withdrawal by Subject|0
6211973|NCT01597245|9879061|FG006|Induction Period (Week 0 - Week 12)|Withdrawal by Subject|0
6211974|NCT01597245|9879062|FG007|Induction Period (Week 0 - Week 12)|Withdrawal by Subject|0
6211975|NCT01597245|9879063|FG008|Induction Period (Week 0 - Week 12)|Withdrawal by Subject|0
6211976|NCT01597245|9879064|FG009|Induction Period (Week 0 - Week 12)|Withdrawal by Subject|0
6211977|NCT01597245|9879065|FG010|Induction Period (Week 0 - Week 12)|Withdrawal by Subject|0
6211978|NCT01597245|9879066|FG011|Induction Period (Week 0 - Week 12)|Withdrawal by Subject|0
6211979|NCT01597245|9879067|FG012|Induction Period (Week 0 - Week 12)|Withdrawal by Subject|0
6211980|NCT01597245|9879068|FG013|Induction Period (Week 0 - Week 12)|Withdrawal by Subject|0
6211981|NCT01597245|9879069|FG014|Induction Period (Week 0 - Week 12)|Withdrawal by Subject|0
6211982|NCT01597245|9879070|FG015|Induction Period (Week 0 - Week 12)|Withdrawal by Subject|0
6211983|NCT01597245|9879071|FG016|Induction Period (Week 0 - Week 12)|Withdrawal by Subject|0
6211984|NCT01597245|9879072|FG017|Induction Period (Week 0 - Week 12)|Withdrawal by Subject|0
6211985|NCT01597245|9879073|FG018|Induction Period (Week 0 - Week 12)|Withdrawal by Subject|0
6211986|NCT01597245|9879074|FG019|Induction Period (Week 0 - Week 12)|Withdrawal by Subject|0
6211987|NCT01597245|9879075|FG020|Induction Period (Week 0 - Week 12)|Withdrawal by Subject|0
6118494|NCT00877890|9741028|FG000|Overall Study|Protocol Violation|0
6118495|NCT00877890|9741029|FG001|Overall Study|Protocol Violation|1
6118496|NCT00877890|9741028|FG000|Overall Study|Withdrawal of Consent|6
6118497|NCT00877890|9741029|FG001|Overall Study|Withdrawal of Consent|12
6118498|NCT00877890|9741028|FG000|Overall Study|Investigator Decision|0
6118499|NCT00877890|9741029|FG001|Overall Study|Investigator Decision|2
6118500|NCT00877890|9741028|FG000|Overall Study|Loss of Glucose Control|3
6118501|NCT00877890|9741029|FG001|Overall Study|Loss of Glucose Control|4
6118502|NCT00877929|9741041|FG000|Overall Study|Adverse Event|11
6118503|NCT00877929|9741042|FG001|Overall Study|Adverse Event|20
6118504|NCT00877929|9741041|FG000|Overall Study|Protocol Violation|3
6118505|NCT00877929|9741042|FG001|Overall Study|Protocol Violation|3
6118506|NCT00877929|9741041|FG000|Overall Study|Lost to Follow-up|0
6118507|NCT00877929|9741042|FG001|Overall Study|Lost to Follow-up|1
6118508|NCT00877929|9741041|FG000|Overall Study|Withdrawal by Subject|4
6118509|NCT00877929|9741042|FG001|Overall Study|Withdrawal by Subject|4
6118510|NCT00877929|9741041|FG000|Overall Study|Lack of Efficacy|0
6118511|NCT00877929|9741042|FG001|Overall Study|Lack of Efficacy|1
6118512|NCT00877929|9741041|FG000|Overall Study|Other reason (not specified)|2
6118513|NCT00877929|9741042|FG001|Overall Study|Other reason (not specified)|6
6118514|NCT00878072|9741052|FG000|Overall Study|Withdrew consent|2
6118515|NCT00878189|9741063|FG000|Overall Study|Death|0
6118516|NCT00878189|9741064|FG001|Overall Study|Death|1
6118517|NCT00878189|9741065|FG002|Overall Study|Death|0
6118518|NCT00878189|9741066|FG003|Overall Study|Death|1
6118519|NCT00878189|9741067|FG004|Overall Study|Death|0
6118520|NCT00878189|9741068|FG005|Overall Study|Death|0
6211988|NCT01597245|9879055|FG000|Induction Period (Week 0 - Week 12)|Protocol Violation|2
6211989|NCT01597245|9879056|FG001|Induction Period (Week 0 - Week 12)|Protocol Violation|4
6211990|NCT01597245|9879057|FG002|Induction Period (Week 0 - Week 12)|Protocol Violation|5
6211991|NCT01597245|9879058|FG003|Induction Period (Week 0 - Week 12)|Protocol Violation|2
6211992|NCT01597245|9879059|FG004|Induction Period (Week 0 - Week 12)|Protocol Violation|0
6211993|NCT01597245|9879060|FG005|Induction Period (Week 0 - Week 12)|Protocol Violation|0
6211994|NCT01597245|9879061|FG006|Induction Period (Week 0 - Week 12)|Protocol Violation|0
6211995|NCT01597245|9879062|FG007|Induction Period (Week 0 - Week 12)|Protocol Violation|0
6287160|NCT02349061|9999678|FG000|Study Extension (Week 56 to Week 120)|Adverse Event|0
6287161|NCT02349061|9999679|FG001|Study Extension (Week 56 to Week 120)|Adverse Event|3
6287162|NCT02349061|9999680|FG002|Study Extension (Week 56 to Week 120)|Adverse Event|0
6287163|NCT02349061|9999678|FG000|Study Extension (Week 56 to Week 120)|Lack of Efficacy|0
6287164|NCT02349061|9999679|FG001|Study Extension (Week 56 to Week 120)|Lack of Efficacy|0
6287165|NCT02349061|9999680|FG002|Study Extension (Week 56 to Week 120)|Lack of Efficacy|1
6287166|NCT02349061|9999678|FG000|Study Extension (Week 56 to Week 120)|Withdrawal by Subject|0
6287167|NCT02349061|9999679|FG001|Study Extension (Week 56 to Week 120)|Withdrawal by Subject|2
6287168|NCT02349061|9999680|FG002|Study Extension (Week 56 to Week 120)|Withdrawal by Subject|1
6287169|NCT02349061|9999678|FG000|Study Extension (Week 56 to Week 120)|Physician Decision|0
6287170|NCT02349061|9999679|FG001|Study Extension (Week 56 to Week 120)|Physician Decision|0
6287171|NCT02349061|9999680|FG002|Study Extension (Week 56 to Week 120)|Physician Decision|1
6287172|NCT02349295|9999706|FG000|Double Blind Treatment (Week 0-24)|Adverse Event|7
6287173|NCT02349295|9999707|FG001|Double Blind Treatment (Week 0-24)|Adverse Event|5
6287174|NCT02349295|9999708|FG002|Double Blind Treatment (Week 0-24)|Adverse Event|5
6287175|NCT02349295|9999709|FG003|Double Blind Treatment (Week 0-24)|Adverse Event|0
6287176|NCT02349295|9999710|FG004|Double Blind Treatment (Week 0-24)|Adverse Event|0
6287177|NCT02349295|9999711|FG005|Double Blind Treatment (Week 0-24)|Adverse Event|0
6287178|NCT02349295|9999712|FG006|Double Blind Treatment (Week 0-24)|Adverse Event|0
6287179|NCT02349295|9999713|FG007|Double Blind Treatment (Week 0-24)|Adverse Event|0
6287180|NCT02349295|9999714|FG008|Double Blind Treatment (Week 0-24)|Adverse Event|0
6118521|NCT00878189|9741069|FG006|Overall Study|Death|0
6118522|NCT00878189|9741070|FG007|Overall Study|Death|0
6118523|NCT00878189|9741071|FG008|Overall Study|Death|1
6118524|NCT00878189|9741063|FG000|Overall Study|Participant Refused to Follow-up|0
6118525|NCT00878189|9741064|FG001|Overall Study|Participant Refused to Follow-up|0
6118526|NCT00878189|9741065|FG002|Overall Study|Participant Refused to Follow-up|0
6118527|NCT00878189|9741066|FG003|Overall Study|Participant Refused to Follow-up|0
6118528|NCT00878189|9741067|FG004|Overall Study|Participant Refused to Follow-up|0
6211996|NCT01597245|9879063|FG008|Induction Period (Week 0 - Week 12)|Protocol Violation|0
6211997|NCT01597245|9879064|FG009|Induction Period (Week 0 - Week 12)|Protocol Violation|0
6211998|NCT01597245|9879065|FG010|Induction Period (Week 0 - Week 12)|Protocol Violation|0
6211999|NCT01597245|9879066|FG011|Induction Period (Week 0 - Week 12)|Protocol Violation|0
6212000|NCT01597245|9879067|FG012|Induction Period (Week 0 - Week 12)|Protocol Violation|0
6212001|NCT01597245|9879068|FG013|Induction Period (Week 0 - Week 12)|Protocol Violation|0
6212002|NCT01597245|9879069|FG014|Induction Period (Week 0 - Week 12)|Protocol Violation|0
6212003|NCT01597245|9879070|FG015|Induction Period (Week 0 - Week 12)|Protocol Violation|0
6212004|NCT01597245|9879071|FG016|Induction Period (Week 0 - Week 12)|Protocol Violation|0
6212005|NCT01597245|9879072|FG017|Induction Period (Week 0 - Week 12)|Protocol Violation|0
6212006|NCT01597245|9879073|FG018|Induction Period (Week 0 - Week 12)|Protocol Violation|0
6212007|NCT01597245|9879074|FG019|Induction Period (Week 0 - Week 12)|Protocol Violation|0
6118529|NCT00878189|9741068|FG005|Overall Study|Participant Refused to Follow-up|4
6118530|NCT00878189|9741069|FG006|Overall Study|Participant Refused to Follow-up|0
6118531|NCT00878189|9741070|FG007|Overall Study|Participant Refused to Follow-up|0
6118532|NCT00878189|9741071|FG008|Overall Study|Participant Refused to Follow-up|0
6118533|NCT00878189|9741063|FG000|Overall Study|Other|3
6118534|NCT00878189|9741064|FG001|Overall Study|Other|2
6118535|NCT00878189|9741065|FG002|Overall Study|Other|4
6118536|NCT00878189|9741066|FG003|Overall Study|Other|7
6118537|NCT00878189|9741067|FG004|Overall Study|Other|4
6118538|NCT00878189|9741068|FG005|Overall Study|Other|18
6118539|NCT00878189|9741069|FG006|Overall Study|Other|15
6118540|NCT00878189|9741070|FG007|Overall Study|Other|3
6118541|NCT00878189|9741071|FG008|Overall Study|Other|4
6118542|NCT00878189|9741063|FG000|Overall Study|Lost to Follow-up|0
6118543|NCT00878189|9741064|FG001|Overall Study|Lost to Follow-up|0
6118544|NCT00878189|9741065|FG002|Overall Study|Lost to Follow-up|0
6118545|NCT00878189|9741066|FG003|Overall Study|Lost to Follow-up|0
6118546|NCT00878189|9741067|FG004|Overall Study|Lost to Follow-up|0
6118547|NCT00878189|9741068|FG005|Overall Study|Lost to Follow-up|1
6118548|NCT00878189|9741069|FG006|Overall Study|Lost to Follow-up|1
6118549|NCT00878189|9741070|FG007|Overall Study|Lost to Follow-up|0
6118550|NCT00878189|9741071|FG008|Overall Study|Lost to Follow-up|0
6118551|NCT00878189|9741063|FG000|Overall Study|Objection Progression or Relapse|0
6118552|NCT00878189|9741064|FG001|Overall Study|Objection Progression or Relapse|0
6212008|NCT01597245|9879075|FG020|Induction Period (Week 0 - Week 12)|Protocol Violation|0
6212009|NCT01597245|9879055|FG000|Induction Period (Week 0 - Week 12)|Lost to Follow-up|1
6212010|NCT01597245|9879056|FG001|Induction Period (Week 0 - Week 12)|Lost to Follow-up|5
6212011|NCT01597245|9879057|FG002|Induction Period (Week 0 - Week 12)|Lost to Follow-up|2
6212012|NCT01597245|9879058|FG003|Induction Period (Week 0 - Week 12)|Lost to Follow-up|0
6212013|NCT01597245|9879059|FG004|Induction Period (Week 0 - Week 12)|Lost to Follow-up|0
6212014|NCT01597245|9879060|FG005|Induction Period (Week 0 - Week 12)|Lost to Follow-up|0
6212015|NCT01597245|9879061|FG006|Induction Period (Week 0 - Week 12)|Lost to Follow-up|0
6212016|NCT01597245|9879062|FG007|Induction Period (Week 0 - Week 12)|Lost to Follow-up|0
6212017|NCT01597245|9879063|FG008|Induction Period (Week 0 - Week 12)|Lost to Follow-up|0
6212018|NCT01597245|9879064|FG009|Induction Period (Week 0 - Week 12)|Lost to Follow-up|0
6212019|NCT01597245|9879065|FG010|Induction Period (Week 0 - Week 12)|Lost to Follow-up|0
6212020|NCT01597245|9879066|FG011|Induction Period (Week 0 - Week 12)|Lost to Follow-up|0
6212021|NCT01597245|9879067|FG012|Induction Period (Week 0 - Week 12)|Lost to Follow-up|0
6212022|NCT01597245|9879068|FG013|Induction Period (Week 0 - Week 12)|Lost to Follow-up|0
6212023|NCT01597245|9879069|FG014|Induction Period (Week 0 - Week 12)|Lost to Follow-up|0
6212024|NCT01597245|9879070|FG015|Induction Period (Week 0 - Week 12)|Lost to Follow-up|0
6212025|NCT01597245|9879071|FG016|Induction Period (Week 0 - Week 12)|Lost to Follow-up|0
6212026|NCT01597245|9879072|FG017|Induction Period (Week 0 - Week 12)|Lost to Follow-up|0
6212027|NCT01597245|9879073|FG018|Induction Period (Week 0 - Week 12)|Lost to Follow-up|0
6212028|NCT01597245|9879074|FG019|Induction Period (Week 0 - Week 12)|Lost to Follow-up|0
6212029|NCT01597245|9879075|FG020|Induction Period (Week 0 - Week 12)|Lost to Follow-up|0
6212030|NCT01597245|9879055|FG000|Induction Period (Week 0 - Week 12)|Physician Decision|1
6212031|NCT01597245|9879056|FG001|Induction Period (Week 0 - Week 12)|Physician Decision|0
6212032|NCT01597245|9879057|FG002|Induction Period (Week 0 - Week 12)|Physician Decision|0
6212033|NCT01597245|9879058|FG003|Induction Period (Week 0 - Week 12)|Physician Decision|1
6212034|NCT01597245|9879059|FG004|Induction Period (Week 0 - Week 12)|Physician Decision|0
6212035|NCT01597245|9879060|FG005|Induction Period (Week 0 - Week 12)|Physician Decision|0
6212036|NCT01597245|9879061|FG006|Induction Period (Week 0 - Week 12)|Physician Decision|0
6212037|NCT01597245|9879062|FG007|Induction Period (Week 0 - Week 12)|Physician Decision|0
6212038|NCT01597245|9879063|FG008|Induction Period (Week 0 - Week 12)|Physician Decision|0
6212039|NCT01597245|9879064|FG009|Induction Period (Week 0 - Week 12)|Physician Decision|0
6212040|NCT01597245|9879065|FG010|Induction Period (Week 0 - Week 12)|Physician Decision|0
6212041|NCT01597245|9879066|FG011|Induction Period (Week 0 - Week 12)|Physician Decision|0
6212042|NCT01597245|9879067|FG012|Induction Period (Week 0 - Week 12)|Physician Decision|0
6212043|NCT01597245|9879068|FG013|Induction Period (Week 0 - Week 12)|Physician Decision|0
6212044|NCT01597245|9879069|FG014|Induction Period (Week 0 - Week 12)|Physician Decision|0
6212045|NCT01597245|9879070|FG015|Induction Period (Week 0 - Week 12)|Physician Decision|0
6212046|NCT01597245|9879071|FG016|Induction Period (Week 0 - Week 12)|Physician Decision|0
6287181|NCT02349295|9999715|FG009|Double Blind Treatment (Week 0-24)|Adverse Event|0
6287182|NCT02349295|9999716|FG010|Double Blind Treatment (Week 0-24)|Adverse Event|0
6287183|NCT02349295|9999717|FG011|Double Blind Treatment (Week 0-24)|Adverse Event|0
6287184|NCT02349295|9999718|FG012|Double Blind Treatment (Week 0-24)|Adverse Event|0
6287185|NCT02349295|9999719|FG013|Double Blind Treatment (Week 0-24)|Adverse Event|0
6287186|NCT02349295|9999706|FG000|Double Blind Treatment (Week 0-24)|Lack of Efficacy|4
6118553|NCT00878189|9741065|FG002|Overall Study|Objection Progression or Relapse|0
6118554|NCT00878189|9741066|FG003|Overall Study|Objection Progression or Relapse|0
6118555|NCT00878189|9741067|FG004|Overall Study|Objection Progression or Relapse|0
6118556|NCT00878189|9741068|FG005|Overall Study|Objection Progression or Relapse|0
6118557|NCT00878189|9741069|FG006|Overall Study|Objection Progression or Relapse|0
6118558|NCT00878189|9741070|FG007|Overall Study|Objection Progression or Relapse|0
6118559|NCT00878189|9741071|FG008|Overall Study|Objection Progression or Relapse|3
6118560|NCT00878215|9741109|FG000|Overall Study|Determined to be ineligible|0
6118561|NCT00878215|9741110|FG001|Overall Study|Determined to be ineligible|10
6118562|NCT00878215|9741111|FG002|Overall Study|Determined to be ineligible|0
6118563|NCT00878215|9741112|FG003|Overall Study|Determined to be ineligible|0
6212047|NCT01597245|9879072|FG017|Induction Period (Week 0 - Week 12)|Physician Decision|0
6212048|NCT01597245|9879073|FG018|Induction Period (Week 0 - Week 12)|Physician Decision|0
6212049|NCT01597245|9879074|FG019|Induction Period (Week 0 - Week 12)|Physician Decision|0
6212050|NCT01597245|9879075|FG020|Induction Period (Week 0 - Week 12)|Physician Decision|0
6212051|NCT01597245|9879055|FG000|Induction Period (Week 0 - Week 12)|Lack of Efficacy|3
6212052|NCT01597245|9879056|FG001|Induction Period (Week 0 - Week 12)|Lack of Efficacy|3
6212053|NCT01597245|9879057|FG002|Induction Period (Week 0 - Week 12)|Lack of Efficacy|1
6212054|NCT01597245|9879058|FG003|Induction Period (Week 0 - Week 12)|Lack of Efficacy|0
6212055|NCT01597245|9879059|FG004|Induction Period (Week 0 - Week 12)|Lack of Efficacy|0
6212056|NCT01597245|9879060|FG005|Induction Period (Week 0 - Week 12)|Lack of Efficacy|0
6212057|NCT01597245|9879061|FG006|Induction Period (Week 0 - Week 12)|Lack of Efficacy|0
6212058|NCT01597245|9879062|FG007|Induction Period (Week 0 - Week 12)|Lack of Efficacy|0
6212059|NCT01597245|9879063|FG008|Induction Period (Week 0 - Week 12)|Lack of Efficacy|0
6212060|NCT01597245|9879064|FG009|Induction Period (Week 0 - Week 12)|Lack of Efficacy|0
6212061|NCT01597245|9879065|FG010|Induction Period (Week 0 - Week 12)|Lack of Efficacy|0
6212062|NCT01597245|9879066|FG011|Induction Period (Week 0 - Week 12)|Lack of Efficacy|0
6212063|NCT01597245|9879067|FG012|Induction Period (Week 0 - Week 12)|Lack of Efficacy|0
6212064|NCT01597245|9879068|FG013|Induction Period (Week 0 - Week 12)|Lack of Efficacy|0
6212065|NCT01597245|9879069|FG014|Induction Period (Week 0 - Week 12)|Lack of Efficacy|0
6212066|NCT01597245|9879070|FG015|Induction Period (Week 0 - Week 12)|Lack of Efficacy|0
6212067|NCT01597245|9879071|FG016|Induction Period (Week 0 - Week 12)|Lack of Efficacy|0
6212068|NCT01597245|9879072|FG017|Induction Period (Week 0 - Week 12)|Lack of Efficacy|0
6212069|NCT01597245|9879073|FG018|Induction Period (Week 0 - Week 12)|Lack of Efficacy|0
6212070|NCT01597245|9879074|FG019|Induction Period (Week 0 - Week 12)|Lack of Efficacy|0
6212071|NCT01597245|9879075|FG020|Induction Period (Week 0 - Week 12)|Lack of Efficacy|0
6212072|NCT01597245|9879055|FG000|Maintenance Period (Week 12 to Week 60)|On study treatment|0
6212073|NCT01597245|9879056|FG001|Maintenance Period (Week 12 to Week 60)|On study treatment|0
6212074|NCT01597245|9879057|FG002|Maintenance Period (Week 12 to Week 60)|On study treatment|0
6212075|NCT01597245|9879058|FG003|Maintenance Period (Week 12 to Week 60)|On study treatment|0
6212076|NCT01597245|9879059|FG004|Maintenance Period (Week 12 to Week 60)|On study treatment|0
6212077|NCT01597245|9879060|FG005|Maintenance Period (Week 12 to Week 60)|On study treatment|1
6212078|NCT01597245|9879061|FG006|Maintenance Period (Week 12 to Week 60)|On study treatment|1
6212079|NCT01597245|9879062|FG007|Maintenance Period (Week 12 to Week 60)|On study treatment|0
6212080|NCT01597245|9879063|FG008|Maintenance Period (Week 12 to Week 60)|On study treatment|0
6212081|NCT01597245|9879064|FG009|Maintenance Period (Week 12 to Week 60)|On study treatment|0
6212082|NCT01597245|9879065|FG010|Maintenance Period (Week 12 to Week 60)|On study treatment|0
6212083|NCT01597245|9879066|FG011|Maintenance Period (Week 12 to Week 60)|On study treatment|0
6212084|NCT01597245|9879067|FG012|Maintenance Period (Week 12 to Week 60)|On study treatment|0
6212085|NCT01597245|9879068|FG013|Maintenance Period (Week 12 to Week 60)|On study treatment|0
6212086|NCT01597245|9879069|FG014|Maintenance Period (Week 12 to Week 60)|On study treatment|0
6212087|NCT01597245|9879070|FG015|Maintenance Period (Week 12 to Week 60)|On study treatment|0
6212088|NCT01597245|9879071|FG016|Maintenance Period (Week 12 to Week 60)|On study treatment|0
6212089|NCT01597245|9879072|FG017|Maintenance Period (Week 12 to Week 60)|On study treatment|0
6212090|NCT01597245|9879073|FG018|Maintenance Period (Week 12 to Week 60)|On study treatment|0
6212091|NCT01597245|9879074|FG019|Maintenance Period (Week 12 to Week 60)|On study treatment|0
6212092|NCT01597245|9879075|FG020|Maintenance Period (Week 12 to Week 60)|On study treatment|0
6212093|NCT01597245|9879055|FG000|Maintenance Period (Week 12 to Week 60)|Relapsed|0
6212094|NCT01597245|9879056|FG001|Maintenance Period (Week 12 to Week 60)|Relapsed|0
6212095|NCT01597245|9879057|FG002|Maintenance Period (Week 12 to Week 60)|Relapsed|0
6212096|NCT01597245|9879058|FG003|Maintenance Period (Week 12 to Week 60)|Relapsed|0
6212097|NCT01597245|9879059|FG004|Maintenance Period (Week 12 to Week 60)|Relapsed|150
6212098|NCT01597245|9879060|FG005|Maintenance Period (Week 12 to Week 60)|Relapsed|22
6212099|NCT01597245|9879061|FG006|Maintenance Period (Week 12 to Week 60)|Relapsed|80
6212100|NCT01597245|9879062|FG007|Maintenance Period (Week 12 to Week 60)|Relapsed|2
6212101|NCT01597245|9879063|FG008|Maintenance Period (Week 12 to Week 60)|Relapsed|0
6212102|NCT01597245|9879064|FG009|Maintenance Period (Week 12 to Week 60)|Relapsed|114
6212103|NCT01597245|9879065|FG010|Maintenance Period (Week 12 to Week 60)|Relapsed|0
6212104|NCT01597245|9879066|FG011|Maintenance Period (Week 12 to Week 60)|Relapsed|0
6212105|NCT01597245|9879067|FG012|Maintenance Period (Week 12 to Week 60)|Relapsed|0
6212106|NCT01597245|9879068|FG013|Maintenance Period (Week 12 to Week 60)|Relapsed|0
6212107|NCT01597245|9879069|FG014|Maintenance Period (Week 12 to Week 60)|Relapsed|0
6212108|NCT01597245|9879070|FG015|Maintenance Period (Week 12 to Week 60)|Relapsed|0
6212109|NCT01597245|9879071|FG016|Maintenance Period (Week 12 to Week 60)|Relapsed|0
6212110|NCT01597245|9879072|FG017|Maintenance Period (Week 12 to Week 60)|Relapsed|0
6212111|NCT01597245|9879073|FG018|Maintenance Period (Week 12 to Week 60)|Relapsed|0
6118564|NCT00878501|9741143|FG000|Overall Study|Adverse Event|11
6118565|NCT00878501|9741144|FG001|Overall Study|Adverse Event|3
6118566|NCT00878501|9741145|FG002|Overall Study|Adverse Event|3
6118567|NCT00878501|9741143|FG000|Overall Study|Lack of Efficacy|2
6118568|NCT00878501|9741144|FG001|Overall Study|Lack of Efficacy|1
6118569|NCT00878501|9741145|FG002|Overall Study|Lack of Efficacy|0
6118570|NCT00878501|9741143|FG000|Overall Study|Withdrawal by Subject|2
6118571|NCT00878501|9741144|FG001|Overall Study|Withdrawal by Subject|1
6118572|NCT00878501|9741145|FG002|Overall Study|Withdrawal by Subject|2
6118573|NCT00878501|9741143|FG000|Overall Study|Protocol Violation|0
6118574|NCT00878501|9741144|FG001|Overall Study|Protocol Violation|0
6118575|NCT00878501|9741145|FG002|Overall Study|Protocol Violation|1
6118576|NCT00878501|9741143|FG000|Overall Study|Incorrect enrolment|1
6118577|NCT00878501|9741144|FG001|Overall Study|Incorrect enrolment|2
6118578|NCT00878501|9741145|FG002|Overall Study|Incorrect enrolment|0
6118579|NCT00878501|9741143|FG000|Overall Study|Intake of prohibited concom. medication|0
6118580|NCT00878501|9741144|FG001|Overall Study|Intake of prohibited concom. medication|0
6118581|NCT00878501|9741145|FG002|Overall Study|Intake of prohibited concom. medication|1
6118582|NCT00878501|9741143|FG000|Overall Study|Mis-randomisation of patient|1
6118583|NCT00878501|9741144|FG001|Overall Study|Mis-randomisation of patient|0
6118584|NCT00878501|9741145|FG002|Overall Study|Mis-randomisation of patient|0
6118585|NCT00878501|9741143|FG000|Overall Study|Administrative|0
6118586|NCT00878501|9741144|FG001|Overall Study|Administrative|0
6118587|NCT00878501|9741145|FG002|Overall Study|Administrative|1
6118588|NCT00878553|9741157|FG000|Sleep Study|Withdrawal by Subject|2
6118589|NCT00878553|9741158|FG001|Sleep Study|Withdrawal by Subject|0
6118590|NCT00878553|9741159|FG002|Sleep Study|Withdrawal by Subject|0
6118591|NCT00878553|9741160|FG003|Sleep Study|Withdrawal by Subject|0
6118592|NCT00878553|9741161|FG004|Sleep Study|Withdrawal by Subject|0
6118593|NCT00878553|9741157|FG000|Sleep Study|Lost to Follow-up|1
6118594|NCT00878553|9741158|FG001|Sleep Study|Lost to Follow-up|0
6118595|NCT00878553|9741159|FG002|Sleep Study|Lost to Follow-up|0
6118596|NCT00878553|9741160|FG003|Sleep Study|Lost to Follow-up|0
6118597|NCT00878553|9741161|FG004|Sleep Study|Lost to Follow-up|0
6118598|NCT00878553|9741157|FG000|Sleep Study|car accident|1
6118599|NCT00878553|9741158|FG001|Sleep Study|car accident|0
6118600|NCT00878553|9741159|FG002|Sleep Study|car accident|0
6118601|NCT00878553|9741160|FG003|Sleep Study|car accident|0
6118602|NCT00878553|9741161|FG004|Sleep Study|car accident|0
6118603|NCT00878553|9741157|FG000|Sleep Study|family emergency|1
6118604|NCT00878553|9741158|FG001|Sleep Study|family emergency|0
6118605|NCT00878553|9741159|FG002|Sleep Study|family emergency|0
6118606|NCT00878553|9741160|FG003|Sleep Study|family emergency|0
6118607|NCT00878553|9741161|FG004|Sleep Study|family emergency|0
6118608|NCT00878553|9741157|FG000|PK Study|Withdrawal by Subject|0
6118609|NCT00878553|9741158|FG001|PK Study|Withdrawal by Subject|0
6212112|NCT01597245|9879074|FG019|Maintenance Period (Week 12 to Week 60)|Relapsed|0
6212113|NCT01597245|9879075|FG020|Maintenance Period (Week 12 to Week 60)|Relapsed|0
6212114|NCT01597245|9879055|FG000|Maintenance Period (Week 12 to Week 60)|Lack of Efficacy|0
6212115|NCT01597245|9879056|FG001|Maintenance Period (Week 12 to Week 60)|Lack of Efficacy|0
6212116|NCT01597245|9879057|FG002|Maintenance Period (Week 12 to Week 60)|Lack of Efficacy|0
6212117|NCT01597245|9879058|FG003|Maintenance Period (Week 12 to Week 60)|Lack of Efficacy|0
6212118|NCT01597245|9879059|FG004|Maintenance Period (Week 12 to Week 60)|Lack of Efficacy|0
6212119|NCT01597245|9879060|FG005|Maintenance Period (Week 12 to Week 60)|Lack of Efficacy|1
6212120|NCT01597245|9879061|FG006|Maintenance Period (Week 12 to Week 60)|Lack of Efficacy|0
6212121|NCT01597245|9879062|FG007|Maintenance Period (Week 12 to Week 60)|Lack of Efficacy|0
6212122|NCT01597245|9879063|FG008|Maintenance Period (Week 12 to Week 60)|Lack of Efficacy|3
6212123|NCT01597245|9879064|FG009|Maintenance Period (Week 12 to Week 60)|Lack of Efficacy|0
6212124|NCT01597245|9879065|FG010|Maintenance Period (Week 12 to Week 60)|Lack of Efficacy|2
6212125|NCT01597245|9879066|FG011|Maintenance Period (Week 12 to Week 60)|Lack of Efficacy|10
6212126|NCT01597245|9879067|FG012|Maintenance Period (Week 12 to Week 60)|Lack of Efficacy|4
6212127|NCT01597245|9879068|FG013|Maintenance Period (Week 12 to Week 60)|Lack of Efficacy|0
6212128|NCT01597245|9879069|FG014|Maintenance Period (Week 12 to Week 60)|Lack of Efficacy|0
6212129|NCT01597245|9879070|FG015|Maintenance Period (Week 12 to Week 60)|Lack of Efficacy|0
6212130|NCT01597245|9879071|FG016|Maintenance Period (Week 12 to Week 60)|Lack of Efficacy|0
6212131|NCT01597245|9879072|FG017|Maintenance Period (Week 12 to Week 60)|Lack of Efficacy|0
6212132|NCT01597245|9879073|FG018|Maintenance Period (Week 12 to Week 60)|Lack of Efficacy|0
6212133|NCT01597245|9879074|FG019|Maintenance Period (Week 12 to Week 60)|Lack of Efficacy|0
6212134|NCT01597245|9879075|FG020|Maintenance Period (Week 12 to Week 60)|Lack of Efficacy|0
6212135|NCT01597245|9879055|FG000|Maintenance Period (Week 12 to Week 60)|Adverse Event|0
6212136|NCT01597245|9879056|FG001|Maintenance Period (Week 12 to Week 60)|Adverse Event|0
6212137|NCT01597245|9879057|FG002|Maintenance Period (Week 12 to Week 60)|Adverse Event|0
6212138|NCT01597245|9879058|FG003|Maintenance Period (Week 12 to Week 60)|Adverse Event|0
6212139|NCT01597245|9879059|FG004|Maintenance Period (Week 12 to Week 60)|Adverse Event|4
6212140|NCT01597245|9879060|FG005|Maintenance Period (Week 12 to Week 60)|Adverse Event|6
6212141|NCT01597245|9879061|FG006|Maintenance Period (Week 12 to Week 60)|Adverse Event|6
6212142|NCT01597245|9879062|FG007|Maintenance Period (Week 12 to Week 60)|Adverse Event|1
6118610|NCT00878553|9741159|FG002|PK Study|Withdrawal by Subject|0
6118611|NCT00878553|9741160|FG003|PK Study|Withdrawal by Subject|1
6118612|NCT00878553|9741161|FG004|PK Study|Withdrawal by Subject|0
6118613|NCT00878709|9741189|FG000|Overall Study|Withdrawal by Subject|197
6118614|NCT00878709|9741190|FG001|Overall Study|Withdrawal by Subject|120
6118615|NCT00878709|9741189|FG000|Overall Study|Lost to Follow-up|35
6118616|NCT00878709|9741190|FG001|Overall Study|Lost to Follow-up|33
6118617|NCT00878709|9741189|FG000|Overall Study|Other Reasons|93
6118618|NCT00878709|9741190|FG001|Overall Study|Other Reasons|84
6118619|NCT00878722|9741205|FG000|Overall Study|Progressive disease|3
6118620|NCT00878722|9741206|FG001|Overall Study|Progressive disease|3
6118621|NCT00878722|9741207|FG002|Overall Study|Progressive disease|3
6118622|NCT00878722|9741208|FG003|Overall Study|Progressive disease|7
6118623|NCT00878722|9741209|FG004|Overall Study|Progressive disease|7
6118624|NCT00878722|9741210|FG005|Overall Study|Progressive disease|1
6118625|NCT00878722|9741211|FG006|Overall Study|Progressive disease|4
6118626|NCT00878722|9741212|FG007|Overall Study|Progressive disease|3
6118627|NCT00878722|9741205|FG000|Overall Study|Death|0
6118628|NCT00878722|9741206|FG001|Overall Study|Death|0
6118629|NCT00878722|9741207|FG002|Overall Study|Death|0
6118630|NCT00878722|9741208|FG003|Overall Study|Death|1
6118631|NCT00878722|9741209|FG004|Overall Study|Death|0
6118632|NCT00878722|9741210|FG005|Overall Study|Death|1
6118633|NCT00878722|9741211|FG006|Overall Study|Death|0
6118634|NCT00878722|9741212|FG007|Overall Study|Death|2
6118635|NCT00878722|9741205|FG000|Overall Study|Adverse Event|0
6118636|NCT00878722|9741206|FG001|Overall Study|Adverse Event|0
6118637|NCT00878722|9741207|FG002|Overall Study|Adverse Event|0
6118638|NCT00878722|9741208|FG003|Overall Study|Adverse Event|0
6118639|NCT00878722|9741209|FG004|Overall Study|Adverse Event|0
6118640|NCT00878722|9741210|FG005|Overall Study|Adverse Event|0
6118641|NCT00878722|9741211|FG006|Overall Study|Adverse Event|2
6118642|NCT00878722|9741212|FG007|Overall Study|Adverse Event|0
6118643|NCT00878722|9741205|FG000|Overall Study|Withdrawal by Subject|0
6118644|NCT00878722|9741206|FG001|Overall Study|Withdrawal by Subject|0
6118645|NCT00878722|9741207|FG002|Overall Study|Withdrawal by Subject|0
6118646|NCT00878722|9741208|FG003|Overall Study|Withdrawal by Subject|0
6118647|NCT00878722|9741209|FG004|Overall Study|Withdrawal by Subject|0
6118648|NCT00878722|9741210|FG005|Overall Study|Withdrawal by Subject|0
6118649|NCT00878722|9741211|FG006|Overall Study|Withdrawal by Subject|0
6118650|NCT00878722|9741212|FG007|Overall Study|Withdrawal by Subject|2
6118651|NCT00878722|9741205|FG000|Overall Study|Relapse|0
6118652|NCT00878722|9741206|FG001|Overall Study|Relapse|0
6118653|NCT00878722|9741207|FG002|Overall Study|Relapse|0
6118654|NCT00878722|9741208|FG003|Overall Study|Relapse|1
6118655|NCT00878722|9741209|FG004|Overall Study|Relapse|0
6118656|NCT00878722|9741210|FG005|Overall Study|Relapse|0
6118657|NCT00878722|9741211|FG006|Overall Study|Relapse|0
6118658|NCT00878722|9741212|FG007|Overall Study|Relapse|0
6118659|NCT00878800|9741238|FG000|Overall Study|Adverse Event|0
6118660|NCT00878800|9741239|FG001|Overall Study|Adverse Event|0
6212143|NCT01597245|9879063|FG008|Maintenance Period (Week 12 to Week 60)|Adverse Event|8
6212144|NCT01597245|9879064|FG009|Maintenance Period (Week 12 to Week 60)|Adverse Event|2
6212145|NCT01597245|9879065|FG010|Maintenance Period (Week 12 to Week 60)|Adverse Event|8
6212146|NCT01597245|9879066|FG011|Maintenance Period (Week 12 to Week 60)|Adverse Event|1
6212147|NCT01597245|9879067|FG012|Maintenance Period (Week 12 to Week 60)|Adverse Event|2
6212148|NCT01597245|9879068|FG013|Maintenance Period (Week 12 to Week 60)|Adverse Event|0
6212149|NCT01597245|9879069|FG014|Maintenance Period (Week 12 to Week 60)|Adverse Event|0
6212150|NCT01597245|9879070|FG015|Maintenance Period (Week 12 to Week 60)|Adverse Event|0
6212151|NCT01597245|9879071|FG016|Maintenance Period (Week 12 to Week 60)|Adverse Event|0
6212152|NCT01597245|9879072|FG017|Maintenance Period (Week 12 to Week 60)|Adverse Event|0
6212153|NCT01597245|9879073|FG018|Maintenance Period (Week 12 to Week 60)|Adverse Event|0
6212154|NCT01597245|9879074|FG019|Maintenance Period (Week 12 to Week 60)|Adverse Event|0
6212155|NCT01597245|9879075|FG020|Maintenance Period (Week 12 to Week 60)|Adverse Event|0
6212156|NCT01597245|9879055|FG000|Maintenance Period (Week 12 to Week 60)|Withdrawal by Subject|0
6212157|NCT01597245|9879056|FG001|Maintenance Period (Week 12 to Week 60)|Withdrawal by Subject|0
6212158|NCT01597245|9879057|FG002|Maintenance Period (Week 12 to Week 60)|Withdrawal by Subject|0
6212159|NCT01597245|9879058|FG003|Maintenance Period (Week 12 to Week 60)|Withdrawal by Subject|0
6212160|NCT01597245|9879059|FG004|Maintenance Period (Week 12 to Week 60)|Withdrawal by Subject|3
6212161|NCT01597245|9879060|FG005|Maintenance Period (Week 12 to Week 60)|Withdrawal by Subject|3
6212162|NCT01597245|9879061|FG006|Maintenance Period (Week 12 to Week 60)|Withdrawal by Subject|1
6212163|NCT01597245|9879062|FG007|Maintenance Period (Week 12 to Week 60)|Withdrawal by Subject|0
6212164|NCT01597245|9879063|FG008|Maintenance Period (Week 12 to Week 60)|Withdrawal by Subject|4
6212165|NCT01597245|9879064|FG009|Maintenance Period (Week 12 to Week 60)|Withdrawal by Subject|1
6212166|NCT01597245|9879065|FG010|Maintenance Period (Week 12 to Week 60)|Withdrawal by Subject|6
6118661|NCT00878800|9741240|FG002|Overall Study|Adverse Event|2
6118662|NCT00878800|9741241|FG003|Overall Study|Adverse Event|0
6118663|NCT00878800|9741242|FG004|Overall Study|Adverse Event|1
6118664|NCT00878800|9741238|FG000|Overall Study|Progressive disease|1
6118665|NCT00878800|9741239|FG001|Overall Study|Progressive disease|5
6118666|NCT00878800|9741240|FG002|Overall Study|Progressive disease|6
6118667|NCT00878800|9741241|FG003|Overall Study|Progressive disease|5
6118668|NCT00878800|9741242|FG004|Overall Study|Progressive disease|13
6118669|NCT00878800|9741238|FG000|Overall Study|Withdrew consent|1
6118670|NCT00878800|9741239|FG001|Overall Study|Withdrew consent|1
6118671|NCT00878800|9741240|FG002|Overall Study|Withdrew consent|0
6118672|NCT00878800|9741241|FG003|Overall Study|Withdrew consent|1
6118673|NCT00878800|9741242|FG004|Overall Study|Withdrew consent|1
6118674|NCT00878800|9741238|FG000|Overall Study|Death|0
6118675|NCT00878800|9741239|FG001|Overall Study|Death|0
6118676|NCT00878800|9741240|FG002|Overall Study|Death|1
6118677|NCT00878800|9741241|FG003|Overall Study|Death|0
6118678|NCT00878800|9741242|FG004|Overall Study|Death|0
6118679|NCT00878800|9741238|FG000|Overall Study|Other|1
6118680|NCT00878800|9741239|FG001|Overall Study|Other|1
6118681|NCT00878800|9741240|FG002|Overall Study|Other|0
6118682|NCT00878800|9741241|FG003|Overall Study|Other|0
6118683|NCT00878800|9741242|FG004|Overall Study|Other|1
6118684|NCT00878995|9741279|FG000|Baseline Study - Midpoint Study|Withdrawal by Subject|0
6118685|NCT00878995|9741280|FG001|Baseline Study - Midpoint Study|Withdrawal by Subject|2
6118686|NCT00879229|9741313|FG000|Overall Study|Study terminated by Sponsor|13
6118687|NCT00879229|9741314|FG001|Overall Study|Study terminated by Sponsor|12
6118688|NCT00879229|9741313|FG000|Overall Study|Death|4
6118689|NCT00879229|9741314|FG001|Overall Study|Death|2
6118690|NCT00879229|9741313|FG000|Overall Study|Adverse Event|2
6118691|NCT00879229|9741314|FG001|Overall Study|Adverse Event|0
6118692|NCT00879229|9741313|FG000|Overall Study|Withdrawal by Subject|1
6118693|NCT00879229|9741314|FG001|Overall Study|Withdrawal by Subject|0
6118694|NCT00879229|9741313|FG000|Overall Study|Clinical status did not improve|1
6118695|NCT00879229|9741314|FG001|Overall Study|Clinical status did not improve|0
6118696|NCT00879229|9741313|FG000|Overall Study|Other|1
6118697|NCT00879229|9741314|FG001|Overall Study|Other|0
6118698|NCT00879333|9741331|FG000|Overall Study|Adverse Event|94
6118699|NCT00879333|9741332|FG001|Overall Study|Adverse Event|34
6118700|NCT00879333|9741331|FG000|Overall Study|Abnormal Laboratory Value|1
6118701|NCT00879333|9741332|FG001|Overall Study|Abnormal Laboratory Value|0
6118702|NCT00879333|9741331|FG000|Overall Study|Withdrawal by Subject|20
6118703|NCT00879333|9741332|FG001|Overall Study|Withdrawal by Subject|7
6118704|NCT00879333|9741331|FG000|Overall Study|Lost to Follow-up|2
6118705|NCT00879333|9741332|FG001|Overall Study|Lost to Follow-up|1
6118706|NCT00879333|9741331|FG000|Overall Study|Administrative Problems|2
6118707|NCT00879333|9741332|FG001|Overall Study|Administrative Problems|0
6118708|NCT00879333|9741331|FG000|Overall Study|Death|16
6118709|NCT00879333|9741332|FG001|Overall Study|Death|5
6118710|NCT00879333|9741331|FG000|Overall Study|Disease Progression|292
6118711|NCT00879333|9741332|FG001|Overall Study|Disease Progression|169
6118712|NCT00879333|9741331|FG000|Overall Study|Protocol Violation|1
6118713|NCT00879333|9741332|FG001|Overall Study|Protocol Violation|1
6118714|NCT00879398|9741345|FG000|Overall Study|Visit Stop|399
6118715|NCT00879398|9741345|FG000|Overall Study|Lack of Efficacy|64
6118716|NCT00879398|9741345|FG000|Overall Study|Adverse Event|41
6118717|NCT00879398|9741345|FG000|Overall Study|Other Reasons|171
6118718|NCT00879411|9741349|FG000|Overall Study|lost to follow-up (non-AE)|162
6118719|NCT00879437|9741353|FG000|Overall Study|Protocol Violation|0
6118720|NCT00879437|9741354|FG001|Overall Study|Protocol Violation|1
6118721|NCT00879437|9741353|FG000|Overall Study|Death|1
6118722|NCT00879437|9741354|FG001|Overall Study|Death|0
6118723|NCT00879645|9741366|FG000|Overall Study|Adverse Event|1
6287187|NCT02349295|9999707|FG001|Double Blind Treatment (Week 0-24)|Lack of Efficacy|2
6287188|NCT02349295|9999708|FG002|Double Blind Treatment (Week 0-24)|Lack of Efficacy|9
6287189|NCT02349295|9999709|FG003|Double Blind Treatment (Week 0-24)|Lack of Efficacy|0
6287190|NCT02349295|9999710|FG004|Double Blind Treatment (Week 0-24)|Lack of Efficacy|0
6287191|NCT02349295|9999711|FG005|Double Blind Treatment (Week 0-24)|Lack of Efficacy|0
6287192|NCT02349295|9999712|FG006|Double Blind Treatment (Week 0-24)|Lack of Efficacy|0
6287193|NCT02349295|9999713|FG007|Double Blind Treatment (Week 0-24)|Lack of Efficacy|0
6287194|NCT02349295|9999714|FG008|Double Blind Treatment (Week 0-24)|Lack of Efficacy|0
6287195|NCT02349295|9999715|FG009|Double Blind Treatment (Week 0-24)|Lack of Efficacy|0
6287196|NCT02349295|9999716|FG010|Double Blind Treatment (Week 0-24)|Lack of Efficacy|0
6287197|NCT02349295|9999717|FG011|Double Blind Treatment (Week 0-24)|Lack of Efficacy|0
6287198|NCT02349295|9999718|FG012|Double Blind Treatment (Week 0-24)|Lack of Efficacy|0
6287199|NCT02349295|9999719|FG013|Double Blind Treatment (Week 0-24)|Lack of Efficacy|0
6287200|NCT02349295|9999706|FG000|Double Blind Treatment (Week 0-24)|Withdrawal by Subject|2
6118724|NCT00879645|9741367|FG001|Overall Study|Adverse Event|0
6118725|NCT00879645|9741368|FG002|Overall Study|Adverse Event|0
6118726|NCT00879645|9741369|FG003|Overall Study|Adverse Event|0
6118727|NCT00879658|9741386|FG000|Overall Study|Abnormal laboratory value(s)|3
6118728|NCT00879658|9741387|FG001|Overall Study|Abnormal laboratory value(s)|0
6118729|NCT00879658|9741388|FG002|Overall Study|Abnormal laboratory value(s)|0
6118730|NCT00879658|9741389|FG003|Overall Study|Abnormal laboratory value(s)|1
6118731|NCT00879658|9741390|FG004|Overall Study|Abnormal laboratory value(s)|0
6118732|NCT00879658|9741391|FG005|Overall Study|Abnormal laboratory value(s)|0
6118733|NCT00879658|9741392|FG006|Overall Study|Abnormal laboratory value(s)|0
6118734|NCT00879658|9741386|FG000|Overall Study|Administrative problems|2
6118735|NCT00879658|9741387|FG001|Overall Study|Administrative problems|1
6118736|NCT00879658|9741388|FG002|Overall Study|Administrative problems|0
6118737|NCT00879658|9741389|FG003|Overall Study|Administrative problems|1
6118738|NCT00879658|9741390|FG004|Overall Study|Administrative problems|0
6118739|NCT00879658|9741391|FG005|Overall Study|Administrative problems|0
6118740|NCT00879658|9741392|FG006|Overall Study|Administrative problems|0
6118741|NCT00879658|9741386|FG000|Overall Study|Adverse Event|6
6118742|NCT00879658|9741387|FG001|Overall Study|Adverse Event|4
6118743|NCT00879658|9741388|FG002|Overall Study|Adverse Event|3
6118744|NCT00879658|9741389|FG003|Overall Study|Adverse Event|1
6118745|NCT00879658|9741390|FG004|Overall Study|Adverse Event|2
6118746|NCT00879658|9741391|FG005|Overall Study|Adverse Event|0
6118747|NCT00879658|9741392|FG006|Overall Study|Adverse Event|0
6118748|NCT00879658|9741386|FG000|Overall Study|Protocol Violation|1
6118749|NCT00879658|9741387|FG001|Overall Study|Protocol Violation|0
6118750|NCT00879658|9741388|FG002|Overall Study|Protocol Violation|0
6118751|NCT00879658|9741389|FG003|Overall Study|Protocol Violation|0
6118752|NCT00879658|9741390|FG004|Overall Study|Protocol Violation|0
6118753|NCT00879658|9741391|FG005|Overall Study|Protocol Violation|0
6118754|NCT00879658|9741392|FG006|Overall Study|Protocol Violation|0
6212167|NCT01597245|9879066|FG011|Maintenance Period (Week 12 to Week 60)|Withdrawal by Subject|5
6212168|NCT01597245|9879067|FG012|Maintenance Period (Week 12 to Week 60)|Withdrawal by Subject|4
6212169|NCT01597245|9879068|FG013|Maintenance Period (Week 12 to Week 60)|Withdrawal by Subject|0
6212170|NCT01597245|9879069|FG014|Maintenance Period (Week 12 to Week 60)|Withdrawal by Subject|0
6212171|NCT01597245|9879070|FG015|Maintenance Period (Week 12 to Week 60)|Withdrawal by Subject|0
6212172|NCT01597245|9879071|FG016|Maintenance Period (Week 12 to Week 60)|Withdrawal by Subject|0
6212173|NCT01597245|9879072|FG017|Maintenance Period (Week 12 to Week 60)|Withdrawal by Subject|0
6212174|NCT01597245|9879073|FG018|Maintenance Period (Week 12 to Week 60)|Withdrawal by Subject|0
6212175|NCT01597245|9879074|FG019|Maintenance Period (Week 12 to Week 60)|Withdrawal by Subject|0
6212176|NCT01597245|9879075|FG020|Maintenance Period (Week 12 to Week 60)|Withdrawal by Subject|0
6212177|NCT01597245|9879055|FG000|Maintenance Period (Week 12 to Week 60)|Protocol Violation|0
6212178|NCT01597245|9879056|FG001|Maintenance Period (Week 12 to Week 60)|Protocol Violation|0
6212179|NCT01597245|9879057|FG002|Maintenance Period (Week 12 to Week 60)|Protocol Violation|0
6212180|NCT01597245|9879058|FG003|Maintenance Period (Week 12 to Week 60)|Protocol Violation|0
6212181|NCT01597245|9879059|FG004|Maintenance Period (Week 12 to Week 60)|Protocol Violation|1
6287201|NCT02349295|9999707|FG001|Double Blind Treatment (Week 0-24)|Withdrawal by Subject|2
6287202|NCT02349295|9999708|FG002|Double Blind Treatment (Week 0-24)|Withdrawal by Subject|7
6287203|NCT02349295|9999709|FG003|Double Blind Treatment (Week 0-24)|Withdrawal by Subject|0
6287204|NCT02349295|9999710|FG004|Double Blind Treatment (Week 0-24)|Withdrawal by Subject|0
6287205|NCT02349295|9999711|FG005|Double Blind Treatment (Week 0-24)|Withdrawal by Subject|0
6287206|NCT02349295|9999712|FG006|Double Blind Treatment (Week 0-24)|Withdrawal by Subject|0
6287207|NCT02349295|9999713|FG007|Double Blind Treatment (Week 0-24)|Withdrawal by Subject|0
6287208|NCT02349295|9999714|FG008|Double Blind Treatment (Week 0-24)|Withdrawal by Subject|0
6287209|NCT02349295|9999715|FG009|Double Blind Treatment (Week 0-24)|Withdrawal by Subject|0
6287210|NCT02349295|9999716|FG010|Double Blind Treatment (Week 0-24)|Withdrawal by Subject|0
6287211|NCT02349295|9999717|FG011|Double Blind Treatment (Week 0-24)|Withdrawal by Subject|0
6287212|NCT02349295|9999718|FG012|Double Blind Treatment (Week 0-24)|Withdrawal by Subject|0
6287213|NCT02349295|9999719|FG013|Double Blind Treatment (Week 0-24)|Withdrawal by Subject|0
6287214|NCT02349295|9999706|FG000|Double Blind Treatment (Week 0-24)|Lost to Follow-up|1
6287215|NCT02349295|9999707|FG001|Double Blind Treatment (Week 0-24)|Lost to Follow-up|1
6287216|NCT02349295|9999708|FG002|Double Blind Treatment (Week 0-24)|Lost to Follow-up|2
6287217|NCT02349295|9999709|FG003|Double Blind Treatment (Week 0-24)|Lost to Follow-up|0
6287218|NCT02349295|9999710|FG004|Double Blind Treatment (Week 0-24)|Lost to Follow-up|0
6287219|NCT02349295|9999711|FG005|Double Blind Treatment (Week 0-24)|Lost to Follow-up|0
6287220|NCT02349295|9999712|FG006|Double Blind Treatment (Week 0-24)|Lost to Follow-up|0
6287221|NCT02349295|9999713|FG007|Double Blind Treatment (Week 0-24)|Lost to Follow-up|0
6287222|NCT02349295|9999714|FG008|Double Blind Treatment (Week 0-24)|Lost to Follow-up|0
6287223|NCT02349295|9999715|FG009|Double Blind Treatment (Week 0-24)|Lost to Follow-up|0
6287224|NCT02349295|9999716|FG010|Double Blind Treatment (Week 0-24)|Lost to Follow-up|0
6287225|NCT02349295|9999717|FG011|Double Blind Treatment (Week 0-24)|Lost to Follow-up|0
6287226|NCT02349295|9999718|FG012|Double Blind Treatment (Week 0-24)|Lost to Follow-up|0
6287227|NCT02349295|9999719|FG013|Double Blind Treatment (Week 0-24)|Lost to Follow-up|0
6287228|NCT02349295|9999706|FG000|Double Blind Treatment (Week 0-24)|Failure To Meet Randomization|0
6287229|NCT02349295|9999707|FG001|Double Blind Treatment (Week 0-24)|Failure To Meet Randomization|1
6287230|NCT02349295|9999708|FG002|Double Blind Treatment (Week 0-24)|Failure To Meet Randomization|1
6287231|NCT02349295|9999709|FG003|Double Blind Treatment (Week 0-24)|Failure To Meet Randomization|0
6287232|NCT02349295|9999710|FG004|Double Blind Treatment (Week 0-24)|Failure To Meet Randomization|0
6287233|NCT02349295|9999711|FG005|Double Blind Treatment (Week 0-24)|Failure To Meet Randomization|0
6287234|NCT02349295|9999712|FG006|Double Blind Treatment (Week 0-24)|Failure To Meet Randomization|0
6287235|NCT02349295|9999713|FG007|Double Blind Treatment (Week 0-24)|Failure To Meet Randomization|0
6287236|NCT02349295|9999714|FG008|Double Blind Treatment (Week 0-24)|Failure To Meet Randomization|0
6287237|NCT02349295|9999715|FG009|Double Blind Treatment (Week 0-24)|Failure To Meet Randomization|0
6118755|NCT00879658|9741386|FG000|Overall Study|Withdrawal by Subject|3
6118756|NCT00879658|9741387|FG001|Overall Study|Withdrawal by Subject|0
6118757|NCT00879658|9741388|FG002|Overall Study|Withdrawal by Subject|2
6118758|NCT00879658|9741389|FG003|Overall Study|Withdrawal by Subject|0
6118759|NCT00879658|9741390|FG004|Overall Study|Withdrawal by Subject|0
6118760|NCT00879658|9741391|FG005|Overall Study|Withdrawal by Subject|1
6118761|NCT00879658|9741392|FG006|Overall Study|Withdrawal by Subject|0
6118762|NCT00879658|9741386|FG000|Overall Study|Lack of Efficacy|0
6118763|NCT00879658|9741387|FG001|Overall Study|Lack of Efficacy|0
6118764|NCT00879658|9741388|FG002|Overall Study|Lack of Efficacy|2
6118765|NCT00879658|9741389|FG003|Overall Study|Lack of Efficacy|0
6118766|NCT00879658|9741390|FG004|Overall Study|Lack of Efficacy|0
6118767|NCT00879658|9741391|FG005|Overall Study|Lack of Efficacy|0
6118768|NCT00879658|9741392|FG006|Overall Study|Lack of Efficacy|0
6118769|NCT00879658|9741386|FG000|Overall Study|misrandomized (never received study med)|0
6118770|NCT00879658|9741387|FG001|Overall Study|misrandomized (never received study med)|0
6118771|NCT00879658|9741388|FG002|Overall Study|misrandomized (never received study med)|0
6118772|NCT00879658|9741389|FG003|Overall Study|misrandomized (never received study med)|1
6118773|NCT00879658|9741390|FG004|Overall Study|misrandomized (never received study med)|0
6212182|NCT01597245|9879060|FG005|Maintenance Period (Week 12 to Week 60)|Protocol Violation|0
6212183|NCT01597245|9879061|FG006|Maintenance Period (Week 12 to Week 60)|Protocol Violation|0
6212184|NCT01597245|9879062|FG007|Maintenance Period (Week 12 to Week 60)|Protocol Violation|0
6212185|NCT01597245|9879063|FG008|Maintenance Period (Week 12 to Week 60)|Protocol Violation|3
6212186|NCT01597245|9879064|FG009|Maintenance Period (Week 12 to Week 60)|Protocol Violation|1
6212187|NCT01597245|9879065|FG010|Maintenance Period (Week 12 to Week 60)|Protocol Violation|2
6212188|NCT01597245|9879066|FG011|Maintenance Period (Week 12 to Week 60)|Protocol Violation|0
6212189|NCT01597245|9879067|FG012|Maintenance Period (Week 12 to Week 60)|Protocol Violation|1
6212190|NCT01597245|9879068|FG013|Maintenance Period (Week 12 to Week 60)|Protocol Violation|0
6212191|NCT01597245|9879069|FG014|Maintenance Period (Week 12 to Week 60)|Protocol Violation|0
6212192|NCT01597245|9879070|FG015|Maintenance Period (Week 12 to Week 60)|Protocol Violation|0
6212193|NCT01597245|9879071|FG016|Maintenance Period (Week 12 to Week 60)|Protocol Violation|0
6212194|NCT01597245|9879072|FG017|Maintenance Period (Week 12 to Week 60)|Protocol Violation|0
6212195|NCT01597245|9879073|FG018|Maintenance Period (Week 12 to Week 60)|Protocol Violation|0
6212196|NCT01597245|9879074|FG019|Maintenance Period (Week 12 to Week 60)|Protocol Violation|0
6212197|NCT01597245|9879075|FG020|Maintenance Period (Week 12 to Week 60)|Protocol Violation|0
6212198|NCT01597245|9879055|FG000|Maintenance Period (Week 12 to Week 60)|Lost to Follow-up|0
6212199|NCT01597245|9879056|FG001|Maintenance Period (Week 12 to Week 60)|Lost to Follow-up|0
6212200|NCT01597245|9879057|FG002|Maintenance Period (Week 12 to Week 60)|Lost to Follow-up|0
6212201|NCT01597245|9879058|FG003|Maintenance Period (Week 12 to Week 60)|Lost to Follow-up|0
6212202|NCT01597245|9879059|FG004|Maintenance Period (Week 12 to Week 60)|Lost to Follow-up|3
6212203|NCT01597245|9879060|FG005|Maintenance Period (Week 12 to Week 60)|Lost to Follow-up|4
6212204|NCT01597245|9879061|FG006|Maintenance Period (Week 12 to Week 60)|Lost to Follow-up|1
6212205|NCT01597245|9879062|FG007|Maintenance Period (Week 12 to Week 60)|Lost to Follow-up|0
6212206|NCT01597245|9879063|FG008|Maintenance Period (Week 12 to Week 60)|Lost to Follow-up|1
6212207|NCT01597245|9879064|FG009|Maintenance Period (Week 12 to Week 60)|Lost to Follow-up|2
6212208|NCT01597245|9879065|FG010|Maintenance Period (Week 12 to Week 60)|Lost to Follow-up|2
6212209|NCT01597245|9879066|FG011|Maintenance Period (Week 12 to Week 60)|Lost to Follow-up|2
6212210|NCT01597245|9879067|FG012|Maintenance Period (Week 12 to Week 60)|Lost to Follow-up|1
6212211|NCT01597245|9879068|FG013|Maintenance Period (Week 12 to Week 60)|Lost to Follow-up|0
6212212|NCT01597245|9879069|FG014|Maintenance Period (Week 12 to Week 60)|Lost to Follow-up|0
6212213|NCT01597245|9879070|FG015|Maintenance Period (Week 12 to Week 60)|Lost to Follow-up|0
6212214|NCT01597245|9879071|FG016|Maintenance Period (Week 12 to Week 60)|Lost to Follow-up|0
6212215|NCT01597245|9879072|FG017|Maintenance Period (Week 12 to Week 60)|Lost to Follow-up|0
6212216|NCT01597245|9879073|FG018|Maintenance Period (Week 12 to Week 60)|Lost to Follow-up|0
6212217|NCT01597245|9879074|FG019|Maintenance Period (Week 12 to Week 60)|Lost to Follow-up|0
6212218|NCT01597245|9879075|FG020|Maintenance Period (Week 12 to Week 60)|Lost to Follow-up|0
6212219|NCT01597245|9879055|FG000|Maintenance Period (Week 12 to Week 60)|Physician Decision|0
6212220|NCT01597245|9879056|FG001|Maintenance Period (Week 12 to Week 60)|Physician Decision|0
6118774|NCT00879658|9741391|FG005|Overall Study|misrandomized (never received study med)|0
6118775|NCT00879658|9741392|FG006|Overall Study|misrandomized (never received study med)|0
6118776|NCT00879684|9741414|FG000|Stage 1: Dose Escalation|Adverse Event|1
6118777|NCT00879684|9741415|FG001|Stage 1: Dose Escalation|Adverse Event|0
6118778|NCT00879684|9741416|FG002|Stage 1: Dose Escalation|Adverse Event|0
6118779|NCT00879684|9741417|FG003|Stage 1: Dose Escalation|Adverse Event|0
6118780|NCT00879684|9741418|FG004|Stage 1: Dose Escalation|Adverse Event|0
6118781|NCT00879684|9741419|FG005|Stage 1: Dose Escalation|Adverse Event|0
6118782|NCT00879684|9741420|FG006|Stage 1: Dose Escalation|Adverse Event|0
6118783|NCT00879684|9741414|FG000|Stage 1: Dose Escalation|Progressive Disease|2
6118784|NCT00879684|9741415|FG001|Stage 1: Dose Escalation|Progressive Disease|3
6118785|NCT00879684|9741416|FG002|Stage 1: Dose Escalation|Progressive Disease|0
6118786|NCT00879684|9741417|FG003|Stage 1: Dose Escalation|Progressive Disease|4
6118787|NCT00879684|9741418|FG004|Stage 1: Dose Escalation|Progressive Disease|3
6118788|NCT00879684|9741419|FG005|Stage 1: Dose Escalation|Progressive Disease|3
6118789|NCT00879684|9741420|FG006|Stage 1: Dose Escalation|Progressive Disease|0
6118790|NCT00879684|9741414|FG000|Stage 1: Dose Escalation|Investigator declined participation|0
6118791|NCT00879684|9741415|FG001|Stage 1: Dose Escalation|Investigator declined participation|0
6118792|NCT00879684|9741416|FG002|Stage 1: Dose Escalation|Investigator declined participation|2
6118793|NCT00879684|9741417|FG003|Stage 1: Dose Escalation|Investigator declined participation|2
6118794|NCT00879684|9741418|FG004|Stage 1: Dose Escalation|Investigator declined participation|0
6118795|NCT00879684|9741419|FG005|Stage 1: Dose Escalation|Investigator declined participation|0
6118796|NCT00879684|9741420|FG006|Stage 1: Dose Escalation|Investigator declined participation|0
6118797|NCT00879684|9741414|FG000|Stage 1: Dose Escalation|Death|0
6118798|NCT00879684|9741415|FG001|Stage 1: Dose Escalation|Death|0
6118799|NCT00879684|9741416|FG002|Stage 1: Dose Escalation|Death|1
6118800|NCT00879684|9741417|FG003|Stage 1: Dose Escalation|Death|0
6118801|NCT00879684|9741418|FG004|Stage 1: Dose Escalation|Death|0
6118802|NCT00879684|9741419|FG005|Stage 1: Dose Escalation|Death|0
6118803|NCT00879684|9741420|FG006|Stage 1: Dose Escalation|Death|0
6118804|NCT00879684|9741414|FG000|Stage 2: Expanded Cohort|Lost to Follow-up|0
6118805|NCT00879684|9741415|FG001|Stage 2: Expanded Cohort|Lost to Follow-up|0
6118806|NCT00879684|9741416|FG002|Stage 2: Expanded Cohort|Lost to Follow-up|0
6118807|NCT00879684|9741417|FG003|Stage 2: Expanded Cohort|Lost to Follow-up|0
6118808|NCT00879684|9741418|FG004|Stage 2: Expanded Cohort|Lost to Follow-up|0
6118809|NCT00879684|9741419|FG005|Stage 2: Expanded Cohort|Lost to Follow-up|0
6118810|NCT00879684|9741420|FG006|Stage 2: Expanded Cohort|Lost to Follow-up|1
6118811|NCT00879684|9741414|FG000|Stage 2: Expanded Cohort|Progressive Disease|0
6118812|NCT00879684|9741415|FG001|Stage 2: Expanded Cohort|Progressive Disease|0
6118813|NCT00879684|9741416|FG002|Stage 2: Expanded Cohort|Progressive Disease|0
6118814|NCT00879684|9741417|FG003|Stage 2: Expanded Cohort|Progressive Disease|0
6118815|NCT00879684|9741418|FG004|Stage 2: Expanded Cohort|Progressive Disease|0
6118816|NCT00879684|9741419|FG005|Stage 2: Expanded Cohort|Progressive Disease|0
6118817|NCT00879684|9741420|FG006|Stage 2: Expanded Cohort|Progressive Disease|11
6118818|NCT00879684|9741414|FG000|Stage 2: Expanded Cohort|Investigator declined participation|0
6118819|NCT00879684|9741415|FG001|Stage 2: Expanded Cohort|Investigator declined participation|0
6118820|NCT00879684|9741416|FG002|Stage 2: Expanded Cohort|Investigator declined participation|0
6118821|NCT00879684|9741417|FG003|Stage 2: Expanded Cohort|Investigator declined participation|0
6118822|NCT00879684|9741418|FG004|Stage 2: Expanded Cohort|Investigator declined participation|0
6118823|NCT00879684|9741419|FG005|Stage 2: Expanded Cohort|Investigator declined participation|0
6118824|NCT00879684|9741420|FG006|Stage 2: Expanded Cohort|Investigator declined participation|1
6118825|NCT00879697|9741441|FG000|Overall Study|Physician Decision|2
6118826|NCT00879697|9741442|FG001|Overall Study|Physician Decision|2
6118827|NCT00879710|9741450|FG000|Phase 1 - 6 Weeks|Lost to Follow-up|2
6118828|NCT00879710|9741451|FG001|Phase 1 - 6 Weeks|Lost to Follow-up|3
6118829|NCT00879710|9741452|FG002|Phase 1 - 6 Weeks|Lost to Follow-up|1
6118830|NCT00879710|9741453|FG003|Phase 1 - 6 Weeks|Lost to Follow-up|4
6118831|NCT00879710|9741450|FG000|Phase 1 - 6 Weeks|Adverse Event|0
6118832|NCT00879710|9741451|FG001|Phase 1 - 6 Weeks|Adverse Event|0
6118833|NCT00879710|9741452|FG002|Phase 1 - 6 Weeks|Adverse Event|1
6118834|NCT00879710|9741453|FG003|Phase 1 - 6 Weeks|Adverse Event|0
6118835|NCT00879775|9741463|FG000|Overall Study|Lost to Follow-up|2
6118836|NCT00879775|9741464|FG001|Overall Study|Lost to Follow-up|1
6118837|NCT00879814|9741474|FG000|Overall Study|Adverse Event|0
6118838|NCT00879814|9741475|FG001|Overall Study|Adverse Event|1
6118839|NCT00879814|9741476|FG002|Overall Study|Adverse Event|0
6118840|NCT00879814|9741477|FG003|Overall Study|Adverse Event|0
6118841|NCT00879814|9741474|FG000|Overall Study|Lost to Follow-up|1
6118842|NCT00879814|9741475|FG001|Overall Study|Lost to Follow-up|0
6118843|NCT00879814|9741476|FG002|Overall Study|Lost to Follow-up|0
6118844|NCT00879814|9741477|FG003|Overall Study|Lost to Follow-up|2
6118845|NCT00879814|9741474|FG000|Overall Study|Participant Failed to Return|0
6118846|NCT00879814|9741475|FG001|Overall Study|Participant Failed to Return|0
6118847|NCT00879814|9741476|FG002|Overall Study|Participant Failed to Return|0
6118848|NCT00879814|9741477|FG003|Overall Study|Participant Failed to Return|1
6118849|NCT00879814|9741474|FG000|Overall Study|Withdrawal by Subject|3
6118850|NCT00879814|9741475|FG001|Overall Study|Withdrawal by Subject|1
6118851|NCT00879814|9741476|FG002|Overall Study|Withdrawal by Subject|1
6118852|NCT00879814|9741477|FG003|Overall Study|Withdrawal by Subject|2
6118853|NCT00879814|9741474|FG000|Overall Study|Physician Decision|0
6118854|NCT00879814|9741475|FG001|Overall Study|Physician Decision|0
6118855|NCT00879814|9741476|FG002|Overall Study|Physician Decision|1
6118856|NCT00879814|9741477|FG003|Overall Study|Physician Decision|0
6118857|NCT00879814|9741474|FG000|Overall Study|Other|0
6118858|NCT00879814|9741475|FG001|Overall Study|Other|0
6118859|NCT00879814|9741476|FG002|Overall Study|Other|1
6212221|NCT01597245|9879057|FG002|Maintenance Period (Week 12 to Week 60)|Physician Decision|0
6212222|NCT01597245|9879058|FG003|Maintenance Period (Week 12 to Week 60)|Physician Decision|0
6212223|NCT01597245|9879059|FG004|Maintenance Period (Week 12 to Week 60)|Physician Decision|0
6212224|NCT01597245|9879060|FG005|Maintenance Period (Week 12 to Week 60)|Physician Decision|1
6212225|NCT01597245|9879061|FG006|Maintenance Period (Week 12 to Week 60)|Physician Decision|0
6118860|NCT00879814|9741477|FG003|Overall Study|Other|0
6212226|NCT01597245|9879062|FG007|Maintenance Period (Week 12 to Week 60)|Physician Decision|0
6212227|NCT01597245|9879063|FG008|Maintenance Period (Week 12 to Week 60)|Physician Decision|1
6212228|NCT01597245|9879064|FG009|Maintenance Period (Week 12 to Week 60)|Physician Decision|1
6212229|NCT01597245|9879065|FG010|Maintenance Period (Week 12 to Week 60)|Physician Decision|1
6212230|NCT01597245|9879066|FG011|Maintenance Period (Week 12 to Week 60)|Physician Decision|1
6212231|NCT01597245|9879067|FG012|Maintenance Period (Week 12 to Week 60)|Physician Decision|0
6212232|NCT01597245|9879068|FG013|Maintenance Period (Week 12 to Week 60)|Physician Decision|0
6212233|NCT01597245|9879069|FG014|Maintenance Period (Week 12 to Week 60)|Physician Decision|0
6212234|NCT01597245|9879070|FG015|Maintenance Period (Week 12 to Week 60)|Physician Decision|0
6212235|NCT01597245|9879071|FG016|Maintenance Period (Week 12 to Week 60)|Physician Decision|0
6212236|NCT01597245|9879072|FG017|Maintenance Period (Week 12 to Week 60)|Physician Decision|0
6212237|NCT01597245|9879073|FG018|Maintenance Period (Week 12 to Week 60)|Physician Decision|0
6212238|NCT01597245|9879074|FG019|Maintenance Period (Week 12 to Week 60)|Physician Decision|0
6287238|NCT02349295|9999716|FG010|Double Blind Treatment (Week 0-24)|Failure To Meet Randomization|0
6287239|NCT02349295|9999717|FG011|Double Blind Treatment (Week 0-24)|Failure To Meet Randomization|0
6287240|NCT02349295|9999718|FG012|Double Blind Treatment (Week 0-24)|Failure To Meet Randomization|0
6287241|NCT02349295|9999719|FG013|Double Blind Treatment (Week 0-24)|Failure To Meet Randomization|0
6287242|NCT02349295|9999706|FG000|IR (Week 16-24)|Lack of Efficacy|0
6287243|NCT02349295|9999707|FG001|IR (Week 16-24)|Lack of Efficacy|0
6287244|NCT02349295|9999708|FG002|IR (Week 16-24)|Lack of Efficacy|0
6287245|NCT02349295|9999709|FG003|IR (Week 16-24)|Lack of Efficacy|1
6287246|NCT02349295|9999710|FG004|IR (Week 16-24)|Lack of Efficacy|0
6287247|NCT02349295|9999711|FG005|IR (Week 16-24)|Lack of Efficacy|0
6287248|NCT02349295|9999712|FG006|IR (Week 16-24)|Lack of Efficacy|0
6287249|NCT02349295|9999713|FG007|IR (Week 16-24)|Lack of Efficacy|0
6287250|NCT02349295|9999714|FG008|IR (Week 16-24)|Lack of Efficacy|0
6287251|NCT02349295|9999715|FG009|IR (Week 16-24)|Lack of Efficacy|0
6287252|NCT02349295|9999716|FG010|IR (Week 16-24)|Lack of Efficacy|0
6287253|NCT02349295|9999717|FG011|IR (Week 16-24)|Lack of Efficacy|0
6287254|NCT02349295|9999718|FG012|IR (Week 16-24)|Lack of Efficacy|0
6287255|NCT02349295|9999719|FG013|IR (Week 16-24)|Lack of Efficacy|0
6287256|NCT02349295|9999706|FG000|Long-Term Extension Period (Week 24-156)|Lack of Efficacy|0
6287257|NCT02349295|9999707|FG001|Long-Term Extension Period (Week 24-156)|Lack of Efficacy|0
6287258|NCT02349295|9999708|FG002|Long-Term Extension Period (Week 24-156)|Lack of Efficacy|0
6287259|NCT02349295|9999709|FG003|Long-Term Extension Period (Week 24-156)|Lack of Efficacy|0
6287260|NCT02349295|9999710|FG004|Long-Term Extension Period (Week 24-156)|Lack of Efficacy|0
6287261|NCT02349295|9999711|FG005|Long-Term Extension Period (Week 24-156)|Lack of Efficacy|0
6287262|NCT02349295|9999712|FG006|Long-Term Extension Period (Week 24-156)|Lack of Efficacy|0
6287263|NCT02349295|9999713|FG007|Long-Term Extension Period (Week 24-156)|Lack of Efficacy|32
6287264|NCT02349295|9999714|FG008|Long-Term Extension Period (Week 24-156)|Lack of Efficacy|25
6287265|NCT02349295|9999715|FG009|Long-Term Extension Period (Week 24-156)|Lack of Efficacy|19
6287266|NCT02349295|9999716|FG010|Long-Term Extension Period (Week 24-156)|Lack of Efficacy|18
6287267|NCT02349295|9999717|FG011|Long-Term Extension Period (Week 24-156)|Lack of Efficacy|0
6287268|NCT02349295|9999718|FG012|Long-Term Extension Period (Week 24-156)|Lack of Efficacy|0
6287269|NCT02349295|9999719|FG013|Long-Term Extension Period (Week 24-156)|Lack of Efficacy|0
6287270|NCT02349295|9999706|FG000|Long-Term Extension Period (Week 24-156)|Adverse Event|0
6287271|NCT02349295|9999707|FG001|Long-Term Extension Period (Week 24-156)|Adverse Event|0
6287272|NCT02349295|9999708|FG002|Long-Term Extension Period (Week 24-156)|Adverse Event|0
5980841|NCT01434602|9569525|FG002|Phase II Recommended Phase 2 Dose|Decline in patient condition/health/ADL's|0
5980842|NCT01434602|9569526|FG003|Phase II Recommended Phase 2 Dose|Decline in patient condition/health/ADL's|1
5980843|NCT01434602|9569527|FG004|Phase II Recommended Phase 2 Dose|Decline in patient condition/health/ADL's|0
5980844|NCT01434602|9569523|FG000|Phase II Recommended Phase 2 Dose|Transfer of care|0
6118861|NCT00879879|9741487|FG000|Overall Study|Death|1
6118862|NCT00879879|9741487|FG000|Overall Study|Withdrawal by Subject|1
6118863|NCT00879879|9741487|FG000|Overall Study|Physician Decision|1
6118864|NCT00879970|9741496|FG000|Period 1 TZD Randomization|Refused to Attend Final Visit|3
6118865|NCT00879970|9741497|FG001|Period 1 TZD Randomization|Refused to Attend Final Visit|3
6118866|NCT00879970|9741498|FG002|Period 1 TZD Randomization|Refused to Attend Final Visit|4
6118867|NCT00879970|9741499|FG003|Period 1 TZD Randomization|Refused to Attend Final Visit|0
6118868|NCT00879970|9741500|FG004|Period 1 TZD Randomization|Refused to Attend Final Visit|0
6118869|NCT00879970|9741496|FG000|Period 1 TZD Randomization|Lost to Follow-up|1
6118870|NCT00879970|9741497|FG001|Period 1 TZD Randomization|Lost to Follow-up|0
6118871|NCT00879970|9741498|FG002|Period 1 TZD Randomization|Lost to Follow-up|1
6118872|NCT00879970|9741499|FG003|Period 1 TZD Randomization|Lost to Follow-up|0
6118873|NCT00879970|9741500|FG004|Period 1 TZD Randomization|Lost to Follow-up|0
5980845|NCT01434602|9569524|FG001|Phase II Recommended Phase 2 Dose|Transfer of care|0
5980846|NCT01434602|9569525|FG002|Phase II Recommended Phase 2 Dose|Transfer of care|0
5980847|NCT01434602|9569526|FG003|Phase II Recommended Phase 2 Dose|Transfer of care|1
5980848|NCT01434602|9569527|FG004|Phase II Recommended Phase 2 Dose|Transfer of care|0
5980849|NCT01434602|9569523|FG000|Phase II Recommended Phase 2 Dose|Withdrawal by Subject|0
5980850|NCT01434602|9569524|FG001|Phase II Recommended Phase 2 Dose|Withdrawal by Subject|0
6118874|NCT00879970|9741496|FG000|Period 1 TZD Randomization|Death|2
6118875|NCT00879970|9741497|FG001|Period 1 TZD Randomization|Death|1
6118876|NCT00879970|9741498|FG002|Period 1 TZD Randomization|Death|0
6118877|NCT00879970|9741499|FG003|Period 1 TZD Randomization|Death|0
6118878|NCT00879970|9741500|FG004|Period 1 TZD Randomization|Death|0
6118879|NCT00879970|9741496|FG000|Period 1 TZD Randomization|Final or Study Hold Visits Not Completed|2
6118880|NCT00879970|9741497|FG001|Period 1 TZD Randomization|Final or Study Hold Visits Not Completed|0
6118881|NCT00879970|9741498|FG002|Period 1 TZD Randomization|Final or Study Hold Visits Not Completed|1
6118882|NCT00879970|9741499|FG003|Period 1 TZD Randomization|Final or Study Hold Visits Not Completed|0
6118883|NCT00879970|9741500|FG004|Period 1 TZD Randomization|Final or Study Hold Visits Not Completed|0
6118884|NCT00879970|9741496|FG000|Period 2 Vitamin D Randomization|Refused to Attend Final Visit|0
6118885|NCT00879970|9741497|FG001|Period 2 Vitamin D Randomization|Refused to Attend Final Visit|0
6118886|NCT00879970|9741498|FG002|Period 2 Vitamin D Randomization|Refused to Attend Final Visit|0
6118887|NCT00879970|9741499|FG003|Period 2 Vitamin D Randomization|Refused to Attend Final Visit|2
6118888|NCT00879970|9741500|FG004|Period 2 Vitamin D Randomization|Refused to Attend Final Visit|6
6118889|NCT00879970|9741496|FG000|Period 2 Vitamin D Randomization|Lost to Follow-up|0
6118890|NCT00879970|9741497|FG001|Period 2 Vitamin D Randomization|Lost to Follow-up|0
6118891|NCT00879970|9741498|FG002|Period 2 Vitamin D Randomization|Lost to Follow-up|0
6118892|NCT00879970|9741499|FG003|Period 2 Vitamin D Randomization|Lost to Follow-up|0
6118893|NCT00879970|9741500|FG004|Period 2 Vitamin D Randomization|Lost to Follow-up|1
6118894|NCT00879970|9741496|FG000|Period 2 Vitamin D Randomization|Death|0
6118895|NCT00879970|9741497|FG001|Period 2 Vitamin D Randomization|Death|0
6118896|NCT00879970|9741498|FG002|Period 2 Vitamin D Randomization|Death|0
6118897|NCT00879970|9741499|FG003|Period 2 Vitamin D Randomization|Death|2
6118898|NCT00879970|9741500|FG004|Period 2 Vitamin D Randomization|Death|0
6118899|NCT00879996|9741520|FG000|Overall Study|Lost to Follow-up|7
6118900|NCT00879996|9741521|FG001|Overall Study|Lost to Follow-up|6
6118901|NCT00879996|9741520|FG000|Overall Study|non-compliance|6
6118902|NCT00879996|9741521|FG001|Overall Study|non-compliance|4
6118903|NCT00879996|9741520|FG000|Overall Study|Physician Decision|1
6118904|NCT00879996|9741521|FG001|Overall Study|Physician Decision|2
6118905|NCT00879996|9741520|FG000|Overall Study|psychiatric problem|0
6118906|NCT00879996|9741521|FG001|Overall Study|psychiatric problem|1
6118907|NCT00879996|9741520|FG000|Overall Study|put on parole|1
6118908|NCT00879996|9741521|FG001|Overall Study|put on parole|0
6118909|NCT00880009|9741529|FG000|Overall Study|Study terminated by sponsor|14
6118910|NCT00880009|9741529|FG000|Overall Study|Withdrawal by Subject|1
6118911|NCT00880009|9741529|FG000|Overall Study|Protocol Violation|1
6118912|NCT00880048|9741550|FG000|Overall Study|Adverse Event|2
6118913|NCT00880048|9741551|FG001|Overall Study|Adverse Event|3
6118914|NCT00880048|9741552|FG002|Overall Study|Adverse Event|5
6118915|NCT00880048|9741550|FG000|Overall Study|Lack of Efficacy|1
6118916|NCT00880048|9741551|FG001|Overall Study|Lack of Efficacy|2
6118917|NCT00880048|9741552|FG002|Overall Study|Lack of Efficacy|2
6118918|NCT00880048|9741550|FG000|Overall Study|Protocol Violation|4
6118919|NCT00880048|9741551|FG001|Overall Study|Protocol Violation|6
6118920|NCT00880048|9741552|FG002|Overall Study|Protocol Violation|5
6118921|NCT00880048|9741550|FG000|Overall Study|Lost to Follow-up|6
6118922|NCT00880048|9741551|FG001|Overall Study|Lost to Follow-up|6
6118923|NCT00880048|9741552|FG002|Overall Study|Lost to Follow-up|5
6118924|NCT00880048|9741550|FG000|Overall Study|Physician Decision|1
6118925|NCT00880048|9741551|FG001|Overall Study|Physician Decision|1
6118926|NCT00880048|9741552|FG002|Overall Study|Physician Decision|7
6118927|NCT00880048|9741550|FG000|Overall Study|Withdrawal by Subject|5
6118928|NCT00880048|9741551|FG001|Overall Study|Withdrawal by Subject|8
6118929|NCT00880048|9741552|FG002|Overall Study|Withdrawal by Subject|5
6118930|NCT00880048|9741550|FG000|Overall Study|Study closed/terminated|9
6118931|NCT00880048|9741551|FG001|Overall Study|Study closed/terminated|7
6118932|NCT00880048|9741552|FG002|Overall Study|Study closed/terminated|6
6118933|NCT00880087|9741562|FG000|Overall Study|Lost to Follow-up|0
6118934|NCT00880087|9741563|FG001|Overall Study|Lost to Follow-up|2
6118935|NCT00880100|9741569|FG000|Baseline Phase-Usual Pancreatic Enzymes|Protocol Violation|1
6118936|NCT00880100|9741569|FG000|Treatment Phase With Ultrase® MT12|Adverse Event|1
6118937|NCT00880100|9741569|FG000|Treatment Phase With Ultrase® MT12|Protocol Violation|2
6118938|NCT00880165|9741575|FG000|Overall Study|Withdrawal by Subject|27
6118939|NCT00880165|9741576|FG001|Overall Study|Withdrawal by Subject|23
6118940|NCT00880165|9741575|FG000|Overall Study|Not diagnosed with OSA|14
6118941|NCT00880165|9741576|FG001|Overall Study|Not diagnosed with OSA|8
6118942|NCT00880165|9741575|FG000|Overall Study|Required BIPAP or oxygen treatment|12
6118943|NCT00880165|9741576|FG001|Overall Study|Required BIPAP or oxygen treatment|4
6118944|NCT00880165|9741575|FG000|Overall Study|Lost to follow|9
6118945|NCT00880165|9741576|FG001|Overall Study|Lost to follow|15
6118946|NCT00880191|9741584|FG000|Overall Study|Refused further treatment|4
6212239|NCT01597245|9879075|FG020|Maintenance Period (Week 12 to Week 60)|Physician Decision|0
6212240|NCT01597245|9879055|FG000|Maintenance Period (Week 12 to Week 60)|Sponsor Decision|0
6212241|NCT01597245|9879056|FG001|Maintenance Period (Week 12 to Week 60)|Sponsor Decision|0
6212242|NCT01597245|9879057|FG002|Maintenance Period (Week 12 to Week 60)|Sponsor Decision|0
6212243|NCT01597245|9879058|FG003|Maintenance Period (Week 12 to Week 60)|Sponsor Decision|0
6118947|NCT00880191|9741585|FG001|Overall Study|Refused further treatment|1
6118948|NCT00880191|9741584|FG000|Overall Study|Adverse Event|8
6118949|NCT00880191|9741585|FG001|Overall Study|Adverse Event|6
6212244|NCT01597245|9879059|FG004|Maintenance Period (Week 12 to Week 60)|Sponsor Decision|0
6212245|NCT01597245|9879060|FG005|Maintenance Period (Week 12 to Week 60)|Sponsor Decision|0
6212246|NCT01597245|9879061|FG006|Maintenance Period (Week 12 to Week 60)|Sponsor Decision|0
6212247|NCT01597245|9879062|FG007|Maintenance Period (Week 12 to Week 60)|Sponsor Decision|0
6212248|NCT01597245|9879063|FG008|Maintenance Period (Week 12 to Week 60)|Sponsor Decision|0
6212249|NCT01597245|9879064|FG009|Maintenance Period (Week 12 to Week 60)|Sponsor Decision|0
6212250|NCT01597245|9879065|FG010|Maintenance Period (Week 12 to Week 60)|Sponsor Decision|1
6212251|NCT01597245|9879066|FG011|Maintenance Period (Week 12 to Week 60)|Sponsor Decision|0
6212252|NCT01597245|9879067|FG012|Maintenance Period (Week 12 to Week 60)|Sponsor Decision|0
6212253|NCT01597245|9879068|FG013|Maintenance Period (Week 12 to Week 60)|Sponsor Decision|0
6212254|NCT01597245|9879069|FG014|Maintenance Period (Week 12 to Week 60)|Sponsor Decision|0
6212255|NCT01597245|9879070|FG015|Maintenance Period (Week 12 to Week 60)|Sponsor Decision|0
6212256|NCT01597245|9879071|FG016|Maintenance Period (Week 12 to Week 60)|Sponsor Decision|0
6212257|NCT01597245|9879072|FG017|Maintenance Period (Week 12 to Week 60)|Sponsor Decision|0
6212258|NCT01597245|9879073|FG018|Maintenance Period (Week 12 to Week 60)|Sponsor Decision|0
6212259|NCT01597245|9879074|FG019|Maintenance Period (Week 12 to Week 60)|Sponsor Decision|0
6212260|NCT01597245|9879075|FG020|Maintenance Period (Week 12 to Week 60)|Sponsor Decision|0
6212261|NCT01597245|9879055|FG000|Long Term Extension (Week 60 - Week 264)|Adverse Event|0
6212262|NCT01597245|9879056|FG001|Long Term Extension (Week 60 - Week 264)|Adverse Event|0
6212263|NCT01597245|9879057|FG002|Long Term Extension (Week 60 - Week 264)|Adverse Event|0
6212264|NCT01597245|9879058|FG003|Long Term Extension (Week 60 - Week 264)|Adverse Event|0
6212265|NCT01597245|9879059|FG004|Long Term Extension (Week 60 - Week 264)|Adverse Event|0
6212266|NCT01597245|9879060|FG005|Long Term Extension (Week 60 - Week 264)|Adverse Event|0
6212267|NCT01597245|9879061|FG006|Long Term Extension (Week 60 - Week 264)|Adverse Event|0
6212268|NCT01597245|9879062|FG007|Long Term Extension (Week 60 - Week 264)|Adverse Event|0
6212269|NCT01597245|9879063|FG008|Long Term Extension (Week 60 - Week 264)|Adverse Event|0
6212270|NCT01597245|9879064|FG009|Long Term Extension (Week 60 - Week 264)|Adverse Event|0
6212271|NCT01597245|9879065|FG010|Long Term Extension (Week 60 - Week 264)|Adverse Event|0
6212272|NCT01597245|9879066|FG011|Long Term Extension (Week 60 - Week 264)|Adverse Event|0
6212273|NCT01597245|9879067|FG012|Long Term Extension (Week 60 - Week 264)|Adverse Event|0
6212274|NCT01597245|9879068|FG013|Long Term Extension (Week 60 - Week 264)|Adverse Event|1
6118950|NCT00880191|9741584|FG000|Overall Study|Hospitalization/efficacy|1
6118951|NCT00880191|9741585|FG001|Overall Study|Hospitalization/efficacy|1
6118952|NCT00880256|9741595|FG000|Overall Study|Lost to Follow-up|28
6118953|NCT00880269|9741601|FG000|Overall Study|Protocol Violation|1
6118954|NCT00880269|9741602|FG001|Overall Study|Protocol Violation|0
6118955|NCT00880269|9741601|FG000|Overall Study|Disease Progression|13
6118956|NCT00880269|9741602|FG001|Overall Study|Disease Progression|11
6118957|NCT00880269|9741601|FG000|Overall Study|New Cancer Therapy|1
6118958|NCT00880269|9741602|FG001|Overall Study|New Cancer Therapy|0
6118959|NCT00880269|9741601|FG000|Overall Study|Death|4
6118960|NCT00880269|9741602|FG001|Overall Study|Death|2
6118961|NCT00880269|9741601|FG000|Overall Study|Lost to Follow-up|0
6118962|NCT00880269|9741602|FG001|Overall Study|Lost to Follow-up|1
6118963|NCT00880269|9741601|FG000|Overall Study|Withdrawal by Subject|3
6118964|NCT00880269|9741602|FG001|Overall Study|Withdrawal by Subject|4
6118965|NCT00880269|9741601|FG000|Overall Study|Adverse Event|10
6118966|NCT00880269|9741602|FG001|Overall Study|Adverse Event|9
6118967|NCT00880334|9741610|FG000|Randomized Phase|Physician Decision|1
6118968|NCT00880334|9741611|FG001|Randomized Phase|Physician Decision|0
6118969|NCT00880334|9741610|FG000|Randomized Phase|Withdrawal by Subject|2
6118970|NCT00880334|9741611|FG001|Randomized Phase|Withdrawal by Subject|1
6118971|NCT00880334|9741610|FG000|Randomized Phase|Inadequate Labs|1
6118972|NCT00880334|9741611|FG001|Randomized Phase|Inadequate Labs|1
6118973|NCT00880334|9741610|FG000|Randomized Phase|Brain Metastasis|0
6118974|NCT00880334|9741611|FG001|Randomized Phase|Brain Metastasis|1
6118975|NCT00880334|9741610|FG000|Randomized Phase|Crossover Participants|0
6118976|NCT00880334|9741611|FG001|Randomized Phase|Crossover Participants|37
6118977|NCT00880399|9741629|FG000|Overall Study|Adverse Event|4
6118978|NCT00880399|9741630|FG001|Overall Study|Adverse Event|6
6118979|NCT00880399|9741631|FG002|Overall Study|Adverse Event|5
6118980|NCT00880399|9741629|FG000|Overall Study|Lack of Efficacy|1
6118981|NCT00880399|9741630|FG001|Overall Study|Lack of Efficacy|4
6118982|NCT00880399|9741631|FG002|Overall Study|Lack of Efficacy|2
6118983|NCT00880399|9741629|FG000|Overall Study|Protocol Violation|4
6118984|NCT00880399|9741630|FG001|Overall Study|Protocol Violation|4
6118985|NCT00880399|9741631|FG002|Overall Study|Protocol Violation|6
6118986|NCT00880399|9741629|FG000|Overall Study|Study closed/terminated|3
6118987|NCT00880399|9741630|FG001|Overall Study|Study closed/terminated|7
6118988|NCT00880399|9741631|FG002|Overall Study|Study closed/terminated|4
6118989|NCT00880399|9741629|FG000|Overall Study|Lost to Follow-up|8
6118990|NCT00880399|9741630|FG001|Overall Study|Lost to Follow-up|5
6118991|NCT00880399|9741631|FG002|Overall Study|Lost to Follow-up|3
6118992|NCT00880399|9741629|FG000|Overall Study|Physician Decision|5
6118993|NCT00880399|9741630|FG001|Overall Study|Physician Decision|0
6118994|NCT00880399|9741631|FG002|Overall Study|Physician Decision|3
6118995|NCT00880399|9741629|FG000|Overall Study|Withdrawal by Subject|6
6118996|NCT00880399|9741630|FG001|Overall Study|Withdrawal by Subject|3
6118997|NCT00880399|9741631|FG002|Overall Study|Withdrawal by Subject|3
6118998|NCT00880555|9741653|FG000|Overall Study|Physician Decision|0
6118999|NCT00880555|9741654|FG001|Overall Study|Physician Decision|8
6119000|NCT00880555|9741655|FG002|Overall Study|Physician Decision|0
6119001|NCT00880555|9741656|FG003|Overall Study|Physician Decision|2
6119002|NCT00880555|9741657|FG004|Overall Study|Physician Decision|1
6119003|NCT00880555|9741658|FG005|Overall Study|Physician Decision|0
6119004|NCT00880555|9741653|FG000|Overall Study|Withdrawal by Subject|1
6119005|NCT00880555|9741654|FG001|Overall Study|Withdrawal by Subject|1
6119006|NCT00880555|9741655|FG002|Overall Study|Withdrawal by Subject|0
6119007|NCT00880555|9741656|FG003|Overall Study|Withdrawal by Subject|0
6119008|NCT00880555|9741657|FG004|Overall Study|Withdrawal by Subject|0
6119009|NCT00880555|9741658|FG005|Overall Study|Withdrawal by Subject|0
6119010|NCT00880555|9741653|FG000|Overall Study|Lack of resources (hired rater)|9
6119011|NCT00880555|9741654|FG001|Overall Study|Lack of resources (hired rater)|7
6119012|NCT00880555|9741655|FG002|Overall Study|Lack of resources (hired rater)|5
6119013|NCT00880555|9741656|FG003|Overall Study|Lack of resources (hired rater)|0
6119014|NCT00880555|9741657|FG004|Overall Study|Lack of resources (hired rater)|0
6119015|NCT00880555|9741658|FG005|Overall Study|Lack of resources (hired rater)|0
6119016|NCT00880555|9741653|FG000|Overall Study|Death|0
6119017|NCT00880555|9741654|FG001|Overall Study|Death|0
6119018|NCT00880555|9741655|FG002|Overall Study|Death|0
6119019|NCT00880555|9741656|FG003|Overall Study|Death|0
6119020|NCT00880555|9741657|FG004|Overall Study|Death|0
6119021|NCT00880555|9741658|FG005|Overall Study|Death|1
6119022|NCT00880555|9741653|FG000|Overall Study|Lost to Follow-up|0
6119023|NCT00880555|9741654|FG001|Overall Study|Lost to Follow-up|1
6119024|NCT00880555|9741655|FG002|Overall Study|Lost to Follow-up|0
6119025|NCT00880555|9741656|FG003|Overall Study|Lost to Follow-up|0
6119026|NCT00880555|9741657|FG004|Overall Study|Lost to Follow-up|0
6119027|NCT00880555|9741658|FG005|Overall Study|Lost to Follow-up|0
6119028|NCT00880568|9741678|FG000|Overall Study|Disease progression|3
6119029|NCT00880568|9741679|FG001|Overall Study|Disease progression|3
6119030|NCT00880568|9741680|FG002|Overall Study|Disease progression|3
6119031|NCT00880568|9741681|FG003|Overall Study|Disease progression|1
6119032|NCT00880568|9741682|FG004|Overall Study|Disease progression|3
6119033|NCT00880568|9741683|FG005|Overall Study|Disease progression|3
6119034|NCT00880568|9741684|FG006|Overall Study|Disease progression|5
6119035|NCT00880568|9741685|FG007|Overall Study|Disease progression|0
6119036|NCT00880568|9741686|FG008|Overall Study|Disease progression|3
6119037|NCT00880568|9741678|FG000|Overall Study|Adverse Event|0
6119038|NCT00880568|9741679|FG001|Overall Study|Adverse Event|0
6119039|NCT00880568|9741680|FG002|Overall Study|Adverse Event|0
6119040|NCT00880568|9741681|FG003|Overall Study|Adverse Event|0
6119041|NCT00880568|9741682|FG004|Overall Study|Adverse Event|0
6119042|NCT00880568|9741683|FG005|Overall Study|Adverse Event|0
6119043|NCT00880568|9741684|FG006|Overall Study|Adverse Event|1
6119044|NCT00880568|9741685|FG007|Overall Study|Adverse Event|1
6119045|NCT00880568|9741686|FG008|Overall Study|Adverse Event|0
6212275|NCT01597245|9879069|FG014|Long Term Extension (Week 60 - Week 264)|Adverse Event|69
6212276|NCT01597245|9879070|FG015|Long Term Extension (Week 60 - Week 264)|Adverse Event|70
6212277|NCT01597245|9879071|FG016|Long Term Extension (Week 60 - Week 264)|Adverse Event|0
6212278|NCT01597245|9879072|FG017|Long Term Extension (Week 60 - Week 264)|Adverse Event|0
6212279|NCT01597245|9879073|FG018|Long Term Extension (Week 60 - Week 264)|Adverse Event|0
6212280|NCT01597245|9879074|FG019|Long Term Extension (Week 60 - Week 264)|Adverse Event|0
6212281|NCT01597245|9879075|FG020|Long Term Extension (Week 60 - Week 264)|Adverse Event|0
6212282|NCT01597245|9879055|FG000|Long Term Extension (Week 60 - Week 264)|Withdrawal by Subject|0
6212283|NCT01597245|9879056|FG001|Long Term Extension (Week 60 - Week 264)|Withdrawal by Subject|0
6212284|NCT01597245|9879057|FG002|Long Term Extension (Week 60 - Week 264)|Withdrawal by Subject|0
6212285|NCT01597245|9879058|FG003|Long Term Extension (Week 60 - Week 264)|Withdrawal by Subject|0
6212286|NCT01597245|9879059|FG004|Long Term Extension (Week 60 - Week 264)|Withdrawal by Subject|0
6212287|NCT01597245|9879060|FG005|Long Term Extension (Week 60 - Week 264)|Withdrawal by Subject|0
6212288|NCT01597245|9879061|FG006|Long Term Extension (Week 60 - Week 264)|Withdrawal by Subject|0
6212289|NCT01597245|9879062|FG007|Long Term Extension (Week 60 - Week 264)|Withdrawal by Subject|0
6212290|NCT01597245|9879063|FG008|Long Term Extension (Week 60 - Week 264)|Withdrawal by Subject|0
6119046|NCT00880568|9741678|FG000|Overall Study|Withdrawal by Subject|0
6119047|NCT00880568|9741679|FG001|Overall Study|Withdrawal by Subject|0
6119048|NCT00880568|9741680|FG002|Overall Study|Withdrawal by Subject|0
6119049|NCT00880568|9741681|FG003|Overall Study|Withdrawal by Subject|0
6119050|NCT00880568|9741682|FG004|Overall Study|Withdrawal by Subject|0
6119051|NCT00880568|9741683|FG005|Overall Study|Withdrawal by Subject|0
6119052|NCT00880568|9741684|FG006|Overall Study|Withdrawal by Subject|0
6119053|NCT00880568|9741685|FG007|Overall Study|Withdrawal by Subject|1
6119054|NCT00880568|9741686|FG008|Overall Study|Withdrawal by Subject|0
6119055|NCT00880607|9741717|FG000|Overall Study|Physician Decision|2
6119056|NCT00880607|9741718|FG001|Overall Study|Physician Decision|2
6119057|NCT00880607|9741717|FG000|Overall Study|Protocol Violation|2
6119058|NCT00880607|9741718|FG001|Overall Study|Protocol Violation|1
6119059|NCT00880607|9741717|FG000|Overall Study|surgery did not extend past L1 level|3
6119060|NCT00880607|9741718|FG001|Overall Study|surgery did not extend past L1 level|0
6119061|NCT00880620|9741730|FG000|Overall Study|Adverse Event|4
6119062|NCT00880620|9741731|FG001|Overall Study|Adverse Event|5
6119063|NCT00880620|9741732|FG002|Overall Study|Adverse Event|15
6119064|NCT00880620|9741733|FG003|Overall Study|Adverse Event|15
6119065|NCT00880620|9741730|FG000|Overall Study|Death|0
6119066|NCT00880620|9741731|FG001|Overall Study|Death|0
6119067|NCT00880620|9741732|FG002|Overall Study|Death|1
6119068|NCT00880620|9741733|FG003|Overall Study|Death|0
6119069|NCT00880620|9741730|FG000|Overall Study|Lack of Efficacy|12
6119070|NCT00880620|9741731|FG001|Overall Study|Lack of Efficacy|4
6119071|NCT00880620|9741732|FG002|Overall Study|Lack of Efficacy|0
6119072|NCT00880620|9741733|FG003|Overall Study|Lack of Efficacy|1
6119073|NCT00880620|9741730|FG000|Overall Study|Lost to Follow-up|0
6119074|NCT00880620|9741731|FG001|Overall Study|Lost to Follow-up|1
6119075|NCT00880620|9741732|FG002|Overall Study|Lost to Follow-up|1
6119076|NCT00880620|9741733|FG003|Overall Study|Lost to Follow-up|0
6119077|NCT00880620|9741730|FG000|Overall Study|Protocol Violation|0
6119078|NCT00880620|9741731|FG001|Overall Study|Protocol Violation|1
6119079|NCT00880620|9741732|FG002|Overall Study|Protocol Violation|0
6119080|NCT00880620|9741733|FG003|Overall Study|Protocol Violation|2
6119081|NCT00880620|9741730|FG000|Overall Study|Withdrawal by Subject|4
6212291|NCT01597245|9879064|FG009|Long Term Extension (Week 60 - Week 264)|Withdrawal by Subject|0
6212292|NCT01597245|9879065|FG010|Long Term Extension (Week 60 - Week 264)|Withdrawal by Subject|0
6212293|NCT01597245|9879066|FG011|Long Term Extension (Week 60 - Week 264)|Withdrawal by Subject|0
6212294|NCT01597245|9879067|FG012|Long Term Extension (Week 60 - Week 264)|Withdrawal by Subject|0
6212295|NCT01597245|9879068|FG013|Long Term Extension (Week 60 - Week 264)|Withdrawal by Subject|1
6212296|NCT01597245|9879069|FG014|Long Term Extension (Week 60 - Week 264)|Withdrawal by Subject|62
6212297|NCT01597245|9879070|FG015|Long Term Extension (Week 60 - Week 264)|Withdrawal by Subject|63
6212298|NCT01597245|9879071|FG016|Long Term Extension (Week 60 - Week 264)|Withdrawal by Subject|0
6212299|NCT01597245|9879072|FG017|Long Term Extension (Week 60 - Week 264)|Withdrawal by Subject|0
6212300|NCT01597245|9879073|FG018|Long Term Extension (Week 60 - Week 264)|Withdrawal by Subject|0
6212301|NCT01597245|9879074|FG019|Long Term Extension (Week 60 - Week 264)|Withdrawal by Subject|0
6212302|NCT01597245|9879075|FG020|Long Term Extension (Week 60 - Week 264)|Withdrawal by Subject|0
6212303|NCT01597245|9879055|FG000|Long Term Extension (Week 60 - Week 264)|Lost to Follow-up|0
6212304|NCT01597245|9879056|FG001|Long Term Extension (Week 60 - Week 264)|Lost to Follow-up|0
6212305|NCT01597245|9879057|FG002|Long Term Extension (Week 60 - Week 264)|Lost to Follow-up|0
6212306|NCT01597245|9879058|FG003|Long Term Extension (Week 60 - Week 264)|Lost to Follow-up|0
6212307|NCT01597245|9879059|FG004|Long Term Extension (Week 60 - Week 264)|Lost to Follow-up|0
6212308|NCT01597245|9879060|FG005|Long Term Extension (Week 60 - Week 264)|Lost to Follow-up|0
6212309|NCT01597245|9879061|FG006|Long Term Extension (Week 60 - Week 264)|Lost to Follow-up|0
6212310|NCT01597245|9879062|FG007|Long Term Extension (Week 60 - Week 264)|Lost to Follow-up|0
6212311|NCT01597245|9879063|FG008|Long Term Extension (Week 60 - Week 264)|Lost to Follow-up|0
6212312|NCT01597245|9879064|FG009|Long Term Extension (Week 60 - Week 264)|Lost to Follow-up|0
6212313|NCT01597245|9879065|FG010|Long Term Extension (Week 60 - Week 264)|Lost to Follow-up|0
6212314|NCT01597245|9879066|FG011|Long Term Extension (Week 60 - Week 264)|Lost to Follow-up|0
6212315|NCT01597245|9879067|FG012|Long Term Extension (Week 60 - Week 264)|Lost to Follow-up|0
6212316|NCT01597245|9879068|FG013|Long Term Extension (Week 60 - Week 264)|Lost to Follow-up|0
6212317|NCT01597245|9879069|FG014|Long Term Extension (Week 60 - Week 264)|Lost to Follow-up|38
6212318|NCT01597245|9879070|FG015|Long Term Extension (Week 60 - Week 264)|Lost to Follow-up|38
6212319|NCT01597245|9879071|FG016|Long Term Extension (Week 60 - Week 264)|Lost to Follow-up|0
6212320|NCT01597245|9879072|FG017|Long Term Extension (Week 60 - Week 264)|Lost to Follow-up|0
6212321|NCT01597245|9879073|FG018|Long Term Extension (Week 60 - Week 264)|Lost to Follow-up|0
6212322|NCT01597245|9879074|FG019|Long Term Extension (Week 60 - Week 264)|Lost to Follow-up|0
6212323|NCT01597245|9879075|FG020|Long Term Extension (Week 60 - Week 264)|Lost to Follow-up|0
6212324|NCT01597245|9879055|FG000|Long Term Extension (Week 60 - Week 264)|Lack of Efficacy|0
6212325|NCT01597245|9879056|FG001|Long Term Extension (Week 60 - Week 264)|Lack of Efficacy|0
6212326|NCT01597245|9879057|FG002|Long Term Extension (Week 60 - Week 264)|Lack of Efficacy|0
6212327|NCT01597245|9879058|FG003|Long Term Extension (Week 60 - Week 264)|Lack of Efficacy|0
6212328|NCT01597245|9879059|FG004|Long Term Extension (Week 60 - Week 264)|Lack of Efficacy|0
6212329|NCT01597245|9879060|FG005|Long Term Extension (Week 60 - Week 264)|Lack of Efficacy|0
6212330|NCT01597245|9879061|FG006|Long Term Extension (Week 60 - Week 264)|Lack of Efficacy|0
6212331|NCT01597245|9879062|FG007|Long Term Extension (Week 60 - Week 264)|Lack of Efficacy|0
6287273|NCT02349295|9999709|FG003|Long-Term Extension Period (Week 24-156)|Adverse Event|0
6287274|NCT02349295|9999710|FG004|Long-Term Extension Period (Week 24-156)|Adverse Event|0
6287275|NCT02349295|9999711|FG005|Long-Term Extension Period (Week 24-156)|Adverse Event|0
6287276|NCT02349295|9999712|FG006|Long-Term Extension Period (Week 24-156)|Adverse Event|0
6119082|NCT00880620|9741731|FG001|Overall Study|Withdrawal by Subject|3
6119083|NCT00880620|9741732|FG002|Overall Study|Withdrawal by Subject|1
6119084|NCT00880620|9741733|FG003|Overall Study|Withdrawal by Subject|3
6119085|NCT00880620|9741730|FG000|Overall Study|Noncompliance|0
6119086|NCT00880620|9741731|FG001|Overall Study|Noncompliance|0
6119087|NCT00880620|9741732|FG002|Overall Study|Noncompliance|1
6119088|NCT00880620|9741733|FG003|Overall Study|Noncompliance|1
6119089|NCT00880620|9741730|FG000|Overall Study|Other|1
6119090|NCT00880620|9741731|FG001|Overall Study|Other|1
6119091|NCT00880620|9741732|FG002|Overall Study|Other|2
6119092|NCT00880620|9741733|FG003|Overall Study|Other|2
6119093|NCT00880685|9741747|FG000|Memantine 10mg|Lost to Follow-up|2
6119094|NCT00880685|9741747|FG000|Memantine 20mg|Withdrawal by Subject|1
6119095|NCT00880698|9741758|FG000|Overall Study|Death|0
6119096|NCT00880698|9741759|FG001|Overall Study|Death|0
6119097|NCT00880698|9741760|FG002|Overall Study|Death|1
6119098|NCT00880698|9741761|FG003|Overall Study|Death|2
6119099|NCT00880698|9741758|FG000|Overall Study|Lost to Follow-up|1
6119100|NCT00880698|9741759|FG001|Overall Study|Lost to Follow-up|3
6119101|NCT00880698|9741760|FG002|Overall Study|Lost to Follow-up|0
6119102|NCT00880698|9741761|FG003|Overall Study|Lost to Follow-up|1
6119103|NCT00880750|9741775|FG000|First Intervention|Adverse Event|1
6119104|NCT00880750|9741776|FG001|First Intervention|Adverse Event|0
6119105|NCT00880750|9741775|FG000|First Intervention|Unable to collect urine|4
6119106|NCT00880750|9741776|FG001|First Intervention|Unable to collect urine|0
6119107|NCT00880750|9741775|FG000|First Intervention|Non-compliance with meals|0
6119108|NCT00880750|9741776|FG001|First Intervention|Non-compliance with meals|1
6119109|NCT00880750|9741775|FG000|First Intervention|Withdrawal by Subject|2
6119110|NCT00880750|9741776|FG001|First Intervention|Withdrawal by Subject|0
6119111|NCT00880750|9741775|FG000|First Intervention|Lost to Follow-up|2
6119112|NCT00880750|9741776|FG001|First Intervention|Lost to Follow-up|0
6212332|NCT01597245|9879063|FG008|Long Term Extension (Week 60 - Week 264)|Lack of Efficacy|0
6212333|NCT01597245|9879064|FG009|Long Term Extension (Week 60 - Week 264)|Lack of Efficacy|0
6212334|NCT01597245|9879065|FG010|Long Term Extension (Week 60 - Week 264)|Lack of Efficacy|0
6212335|NCT01597245|9879066|FG011|Long Term Extension (Week 60 - Week 264)|Lack of Efficacy|0
6212336|NCT01597245|9879067|FG012|Long Term Extension (Week 60 - Week 264)|Lack of Efficacy|0
6212337|NCT01597245|9879068|FG013|Long Term Extension (Week 60 - Week 264)|Lack of Efficacy|0
6212338|NCT01597245|9879069|FG014|Long Term Extension (Week 60 - Week 264)|Lack of Efficacy|26
6212339|NCT01597245|9879070|FG015|Long Term Extension (Week 60 - Week 264)|Lack of Efficacy|26
6212340|NCT01597245|9879071|FG016|Long Term Extension (Week 60 - Week 264)|Lack of Efficacy|0
6212341|NCT01597245|9879072|FG017|Long Term Extension (Week 60 - Week 264)|Lack of Efficacy|0
6212342|NCT01597245|9879073|FG018|Long Term Extension (Week 60 - Week 264)|Lack of Efficacy|0
6212343|NCT01597245|9879074|FG019|Long Term Extension (Week 60 - Week 264)|Lack of Efficacy|0
6212344|NCT01597245|9879075|FG020|Long Term Extension (Week 60 - Week 264)|Lack of Efficacy|0
6212345|NCT01597245|9879055|FG000|Long Term Extension (Week 60 - Week 264)|Physician Decision|0
6212346|NCT01597245|9879056|FG001|Long Term Extension (Week 60 - Week 264)|Physician Decision|0
6212347|NCT01597245|9879057|FG002|Long Term Extension (Week 60 - Week 264)|Physician Decision|0
6212348|NCT01597245|9879058|FG003|Long Term Extension (Week 60 - Week 264)|Physician Decision|0
6212349|NCT01597245|9879059|FG004|Long Term Extension (Week 60 - Week 264)|Physician Decision|0
6212350|NCT01597245|9879060|FG005|Long Term Extension (Week 60 - Week 264)|Physician Decision|0
6212351|NCT01597245|9879061|FG006|Long Term Extension (Week 60 - Week 264)|Physician Decision|0
6212352|NCT01597245|9879062|FG007|Long Term Extension (Week 60 - Week 264)|Physician Decision|0
6212353|NCT01597245|9879063|FG008|Long Term Extension (Week 60 - Week 264)|Physician Decision|0
6212354|NCT01597245|9879064|FG009|Long Term Extension (Week 60 - Week 264)|Physician Decision|0
6212355|NCT01597245|9879065|FG010|Long Term Extension (Week 60 - Week 264)|Physician Decision|0
6212356|NCT01597245|9879066|FG011|Long Term Extension (Week 60 - Week 264)|Physician Decision|0
6212357|NCT01597245|9879067|FG012|Long Term Extension (Week 60 - Week 264)|Physician Decision|0
6212358|NCT01597245|9879068|FG013|Long Term Extension (Week 60 - Week 264)|Physician Decision|1
6212359|NCT01597245|9879069|FG014|Long Term Extension (Week 60 - Week 264)|Physician Decision|11
6212360|NCT01597245|9879070|FG015|Long Term Extension (Week 60 - Week 264)|Physician Decision|12
6212361|NCT01597245|9879071|FG016|Long Term Extension (Week 60 - Week 264)|Physician Decision|0
6212362|NCT01597245|9879072|FG017|Long Term Extension (Week 60 - Week 264)|Physician Decision|0
6212363|NCT01597245|9879073|FG018|Long Term Extension (Week 60 - Week 264)|Physician Decision|0
6212364|NCT01597245|9879074|FG019|Long Term Extension (Week 60 - Week 264)|Physician Decision|0
6212365|NCT01597245|9879075|FG020|Long Term Extension (Week 60 - Week 264)|Physician Decision|0
6212366|NCT01597245|9879055|FG000|Long Term Extension (Week 60 - Week 264)|Death|0
6212367|NCT01597245|9879056|FG001|Long Term Extension (Week 60 - Week 264)|Death|0
6212368|NCT01597245|9879057|FG002|Long Term Extension (Week 60 - Week 264)|Death|0
6212369|NCT01597245|9879058|FG003|Long Term Extension (Week 60 - Week 264)|Death|0
6212370|NCT01597245|9879059|FG004|Long Term Extension (Week 60 - Week 264)|Death|0
6212371|NCT01597245|9879060|FG005|Long Term Extension (Week 60 - Week 264)|Death|0
6212372|NCT01597245|9879061|FG006|Long Term Extension (Week 60 - Week 264)|Death|0
6212373|NCT01597245|9879062|FG007|Long Term Extension (Week 60 - Week 264)|Death|0
6212374|NCT01597245|9879063|FG008|Long Term Extension (Week 60 - Week 264)|Death|0
6212375|NCT01597245|9879064|FG009|Long Term Extension (Week 60 - Week 264)|Death|0
6212376|NCT01597245|9879065|FG010|Long Term Extension (Week 60 - Week 264)|Death|0
6212377|NCT01597245|9879066|FG011|Long Term Extension (Week 60 - Week 264)|Death|0
6119113|NCT00880750|9741775|FG000|Second Intervention|Withdrawal by Subject|2
6119114|NCT00880750|9741776|FG001|Second Intervention|Withdrawal by Subject|2
6119115|NCT00880750|9741775|FG000|Second Intervention|Protocol Violation|1
6119116|NCT00880750|9741776|FG001|Second Intervention|Protocol Violation|0
6119117|NCT00880750|9741775|FG000|Second Intervention|Unable to collect urine|1
6119118|NCT00880750|9741776|FG001|Second Intervention|Unable to collect urine|0
6119119|NCT00880763|9741786|FG000|Extension Period (Part 2)|Adverse Event|0
6119120|NCT00880763|9741787|FG001|Extension Period (Part 2)|Adverse Event|0
6119121|NCT00880763|9741788|FG002|Extension Period (Part 2)|Adverse Event|1
6119122|NCT00880763|9741789|FG003|Extension Period (Part 2)|Adverse Event|1
6119123|NCT00880763|9741786|FG000|Extension Period (Part 2)|Withdrawal by Subject|0
6119124|NCT00880763|9741787|FG001|Extension Period (Part 2)|Withdrawal by Subject|2
6119125|NCT00880763|9741788|FG002|Extension Period (Part 2)|Withdrawal by Subject|1
6119126|NCT00880763|9741789|FG003|Extension Period (Part 2)|Withdrawal by Subject|1
6119127|NCT00880763|9741786|FG000|Extension Period (Part 2)|Physician Decision|0
6119128|NCT00880763|9741787|FG001|Extension Period (Part 2)|Physician Decision|1
6119129|NCT00880763|9741788|FG002|Extension Period (Part 2)|Physician Decision|1
6119130|NCT00880763|9741789|FG003|Extension Period (Part 2)|Physician Decision|0
6119131|NCT00880763|9741786|FG000|Extension Period (Part 2)|Lack of Efficacy|0
6119132|NCT00880763|9741787|FG001|Extension Period (Part 2)|Lack of Efficacy|0
6119133|NCT00880763|9741788|FG002|Extension Period (Part 2)|Lack of Efficacy|0
6119134|NCT00880763|9741789|FG003|Extension Period (Part 2)|Lack of Efficacy|1
6119135|NCT00880906|9741801|FG000|Overall Study|Lost to Follow-up|0
6119136|NCT00880906|9741802|FG001|Overall Study|Lost to Follow-up|1
6119137|NCT00880906|9741801|FG000|Overall Study|Did not meet criteria following patholog|12
6119138|NCT00880906|9741802|FG001|Overall Study|Did not meet criteria following patholog|6
6119139|NCT00881335|9741839|FG000|Overall Study|Lost to Follow-up|3
6119140|NCT00881335|9741840|FG001|Overall Study|Lost to Follow-up|2
6119141|NCT00881361|9741848|FG000|Overall Study|Terminated prior to surgery|27
6119142|NCT00881361|9741849|FG001|Overall Study|Terminated prior to surgery|7
6119143|NCT00881361|9741850|FG002|Overall Study|Terminated prior to surgery|0
6119144|NCT00881361|9741848|FG000|Overall Study|Ineligible|17
6119145|NCT00881361|9741849|FG001|Overall Study|Ineligible|2
6119146|NCT00881361|9741850|FG002|Overall Study|Ineligible|2
6119147|NCT00881504|9741868|FG000|Overall Study|Withdrawal by Subject|1
6119148|NCT00881530|9741878|FG000|Overall Study|Adverse Event|5
6119149|NCT00881530|9741879|FG001|Overall Study|Adverse Event|1
6119150|NCT00881530|9741880|FG002|Overall Study|Adverse Event|1
6119151|NCT00881530|9741881|FG003|Overall Study|Adverse Event|4
6119152|NCT00881530|9741882|FG004|Overall Study|Adverse Event|10
6119153|NCT00881530|9741883|FG005|Overall Study|Adverse Event|2
6119154|NCT00881530|9741878|FG000|Overall Study|Lack of Efficacy|1
6119155|NCT00881530|9741879|FG001|Overall Study|Lack of Efficacy|0
6119156|NCT00881530|9741880|FG002|Overall Study|Lack of Efficacy|0
6119157|NCT00881530|9741881|FG003|Overall Study|Lack of Efficacy|0
6119158|NCT00881530|9741882|FG004|Overall Study|Lack of Efficacy|1
6119159|NCT00881530|9741883|FG005|Overall Study|Lack of Efficacy|1
6119160|NCT00881530|9741878|FG000|Overall Study|Not compliant with the protocol|0
6119161|NCT00881530|9741879|FG001|Overall Study|Not compliant with the protocol|0
6119162|NCT00881530|9741880|FG002|Overall Study|Not compliant with the protocol|0
6119163|NCT00881530|9741881|FG003|Overall Study|Not compliant with the protocol|0
6119164|NCT00881530|9741882|FG004|Overall Study|Not compliant with the protocol|2
6119165|NCT00881530|9741883|FG005|Overall Study|Not compliant with the protocol|0
6119166|NCT00881530|9741878|FG000|Overall Study|Lost to Follow-up|0
6119167|NCT00881530|9741879|FG001|Overall Study|Lost to Follow-up|1
6119168|NCT00881530|9741880|FG002|Overall Study|Lost to Follow-up|1
6119169|NCT00881530|9741881|FG003|Overall Study|Lost to Follow-up|3
6119170|NCT00881530|9741882|FG004|Overall Study|Lost to Follow-up|1
6119171|NCT00881530|9741883|FG005|Overall Study|Lost to Follow-up|0
6119172|NCT00881530|9741878|FG000|Overall Study|Refused to continue medication|7
6119173|NCT00881530|9741879|FG001|Overall Study|Refused to continue medication|2
6212378|NCT01597245|9879067|FG012|Long Term Extension (Week 60 - Week 264)|Death|0
6212379|NCT01597245|9879068|FG013|Long Term Extension (Week 60 - Week 264)|Death|0
6212380|NCT01597245|9879069|FG014|Long Term Extension (Week 60 - Week 264)|Death|8
6212381|NCT01597245|9879070|FG015|Long Term Extension (Week 60 - Week 264)|Death|8
6212382|NCT01597245|9879071|FG016|Long Term Extension (Week 60 - Week 264)|Death|0
6212383|NCT01597245|9879072|FG017|Long Term Extension (Week 60 - Week 264)|Death|0
6212384|NCT01597245|9879073|FG018|Long Term Extension (Week 60 - Week 264)|Death|0
6212385|NCT01597245|9879074|FG019|Long Term Extension (Week 60 - Week 264)|Death|0
6212386|NCT01597245|9879075|FG020|Long Term Extension (Week 60 - Week 264)|Death|0
6212387|NCT01597245|9879055|FG000|Long Term Extension (Week 60 - Week 264)|Protocol Violation|0
6212388|NCT01597245|9879056|FG001|Long Term Extension (Week 60 - Week 264)|Protocol Violation|0
6212389|NCT01597245|9879057|FG002|Long Term Extension (Week 60 - Week 264)|Protocol Violation|0
6212390|NCT01597245|9879058|FG003|Long Term Extension (Week 60 - Week 264)|Protocol Violation|0
6212391|NCT01597245|9879059|FG004|Long Term Extension (Week 60 - Week 264)|Protocol Violation|0
6119174|NCT00881530|9741880|FG002|Overall Study|Refused to continue medication|1
6119175|NCT00881530|9741881|FG003|Overall Study|Refused to continue medication|2
6119176|NCT00881530|9741882|FG004|Overall Study|Refused to continue medication|0
6119177|NCT00881530|9741883|FG005|Overall Study|Refused to continue medication|0
6212392|NCT01597245|9879060|FG005|Long Term Extension (Week 60 - Week 264)|Protocol Violation|0
6119178|NCT00881530|9741878|FG000|Overall Study|Other reason not defined above|1
6119179|NCT00881530|9741879|FG001|Overall Study|Other reason not defined above|1
6119180|NCT00881530|9741880|FG002|Overall Study|Other reason not defined above|2
6119181|NCT00881530|9741881|FG003|Overall Study|Other reason not defined above|0
6119182|NCT00881530|9741882|FG004|Overall Study|Other reason not defined above|0
6119183|NCT00881530|9741883|FG005|Overall Study|Other reason not defined above|2
6119184|NCT00881569|9741899|FG000|Overall Study|Disease progression|1
6119185|NCT00881569|9741900|FG001|Overall Study|Disease progression|1
6119186|NCT00881621|9741906|FG000|Overall Study|Physician Decision|34
6119187|NCT00881712|9741922|FG000|Overall Study|Death|1
6119188|NCT00881712|9741923|FG001|Overall Study|Death|0
6119189|NCT00881712|9741924|FG002|Overall Study|Death|0
6119190|NCT00881712|9741922|FG000|Overall Study|Withdrawal by Subject|1
6119191|NCT00881712|9741923|FG001|Overall Study|Withdrawal by Subject|0
6119192|NCT00881712|9741924|FG002|Overall Study|Withdrawal by Subject|0
6119193|NCT00881751|9741934|FG000|Overall Study|Physician Decision|0
6119194|NCT00881751|9741935|FG001|Overall Study|Physician Decision|1
6119195|NCT00881751|9741934|FG000|Overall Study|Adverse Event|0
6119196|NCT00881751|9741935|FG001|Overall Study|Adverse Event|2
6119197|NCT00881751|9741934|FG000|Overall Study|Withdrawal by Subject|0
6119198|NCT00881751|9741935|FG001|Overall Study|Withdrawal by Subject|2
6119199|NCT00881868|9741943|FG000|Overall Study|Adverse Event|0
6119200|NCT00881868|9741944|FG001|Overall Study|Adverse Event|1
6119201|NCT00881868|9741943|FG000|Overall Study|Lost to Follow-up|2
6119202|NCT00881868|9741944|FG001|Overall Study|Lost to Follow-up|1
6119203|NCT00881868|9741943|FG000|Overall Study|Physician Decision|4
6119204|NCT00881868|9741944|FG001|Overall Study|Physician Decision|0
6119205|NCT00881868|9741943|FG000|Overall Study|Protocol Violation|2
6119206|NCT00881868|9741944|FG001|Overall Study|Protocol Violation|0
6119207|NCT00881894|9741952|FG000|Overall Study|Consent withdrawn|0
6119208|NCT00881894|9741953|FG001|Overall Study|Consent withdrawn|1
6119209|NCT00881894|9741952|FG000|Overall Study|Other reasons for premature termination|1
6119210|NCT00881894|9741953|FG001|Overall Study|Other reasons for premature termination|2
6119211|NCT00881959|9741961|FG000|Overall Study|Lost to Follow-up|2
6119212|NCT00881959|9741962|FG001|Overall Study|Lost to Follow-up|4
6119213|NCT00882115|9741972|FG000|Overall Study|Withdrawal by Subject|3
6119214|NCT00882115|9741972|FG000|Overall Study|did not respond to DEP challe|6
6119215|NCT00882362|9741983|FG000|Overall Study|Adverse Event|13
6119216|NCT00882362|9741984|FG001|Overall Study|Adverse Event|10
6119217|NCT00882362|9741983|FG000|Overall Study|Withdrawal by Subject|13
6119218|NCT00882362|9741984|FG001|Overall Study|Withdrawal by Subject|10
6119219|NCT00882362|9741983|FG000|Overall Study|Lack of Efficacy|3
6119220|NCT00882362|9741984|FG001|Overall Study|Lack of Efficacy|0
6119221|NCT00882362|9741983|FG000|Overall Study|Protocol Violation|7
6119222|NCT00882362|9741984|FG001|Overall Study|Protocol Violation|2
6119223|NCT00882362|9741983|FG000|Overall Study|Pregnancy|1
6119224|NCT00882362|9741984|FG001|Overall Study|Pregnancy|0
6119225|NCT00882362|9741983|FG000|Overall Study|Physician Decision|5
6119226|NCT00882362|9741984|FG001|Overall Study|Physician Decision|1
6119227|NCT00882362|9741983|FG000|Overall Study|Diabetic glucose level or HbA1C>=6.5%|2
6119228|NCT00882362|9741984|FG001|Overall Study|Diabetic glucose level or HbA1C>=6.5%|0
6119229|NCT00882362|9741983|FG000|Overall Study|change of residence or other commitments|5
6119230|NCT00882362|9741984|FG001|Overall Study|change of residence or other commitments|0
6119231|NCT00882518|9741992|FG000|Overall Study|Adverse Event|9
6119232|NCT00882518|9741993|FG001|Overall Study|Adverse Event|18
6119233|NCT00882518|9741992|FG000|Overall Study|Withdrawal by Subject|9
6119234|NCT00882518|9741993|FG001|Overall Study|Withdrawal by Subject|13
6119235|NCT00882518|9741992|FG000|Overall Study|Lack of Efficacy|12
6119236|NCT00882518|9741993|FG001|Overall Study|Lack of Efficacy|9
6119237|NCT00882518|9741992|FG000|Overall Study|Severe non-compliance to protocol|3
6119238|NCT00882518|9741993|FG001|Overall Study|Severe non-compliance to protocol|1
6119239|NCT00882518|9741992|FG000|Overall Study|Incorrect enrolment|4
6119240|NCT00882518|9741993|FG001|Overall Study|Incorrect enrolment|2
6119241|NCT00882518|9741992|FG000|Overall Study|Central lab closure for National day|1
6119242|NCT00882518|9741993|FG001|Overall Study|Central lab closure for National day|0
6119243|NCT00882518|9741992|FG000|Overall Study|Allocating random number by mistake|0
6212393|NCT01597245|9879061|FG006|Long Term Extension (Week 60 - Week 264)|Protocol Violation|0
6212394|NCT01597245|9879062|FG007|Long Term Extension (Week 60 - Week 264)|Protocol Violation|0
6212395|NCT01597245|9879063|FG008|Long Term Extension (Week 60 - Week 264)|Protocol Violation|0
6212396|NCT01597245|9879064|FG009|Long Term Extension (Week 60 - Week 264)|Protocol Violation|0
6212397|NCT01597245|9879065|FG010|Long Term Extension (Week 60 - Week 264)|Protocol Violation|0
6212398|NCT01597245|9879066|FG011|Long Term Extension (Week 60 - Week 264)|Protocol Violation|0
6212399|NCT01597245|9879067|FG012|Long Term Extension (Week 60 - Week 264)|Protocol Violation|0
6212400|NCT01597245|9879068|FG013|Long Term Extension (Week 60 - Week 264)|Protocol Violation|0
6119244|NCT00882518|9741993|FG001|Overall Study|Allocating random number by mistake|1
6119245|NCT00882557|9742001|FG000|Overall Study|Withdrawal by Subject|1
6119246|NCT00882557|9742002|FG001|Overall Study|Withdrawal by Subject|0
6119247|NCT00882557|9742001|FG000|Overall Study|Trouble with Vein Access|1
6119248|NCT00882557|9742002|FG001|Overall Study|Trouble with Vein Access|0
6119249|NCT00882557|9742001|FG000|Overall Study|Randomized Not Treated|0
6119250|NCT00882557|9742002|FG001|Overall Study|Randomized Not Treated|1
6119251|NCT00882583|9742010|FG000|Overall Study|Physician Decision|1
6119252|NCT00882583|9742011|FG001|Overall Study|Physician Decision|0
6119253|NCT00882583|9742010|FG000|Overall Study|Adverse Event|0
6119254|NCT00882583|9742011|FG001|Overall Study|Adverse Event|1
6119255|NCT00882713|9742046|FG000|Overall Study|Adverse Event|2
6119256|NCT00882713|9742046|FG000|Overall Study|Death|3
6119257|NCT00882713|9742046|FG000|Overall Study|Administrative reasons|4
6119258|NCT00882713|9742046|FG000|Overall Study|refused treatment/withdrew consent|4
6119259|NCT00882713|9742046|FG000|Overall Study|Blood transfusion|2
6119260|NCT00882713|9742046|FG000|Overall Study|Insufficient therapeutic response|3
6119261|NCT00882713|9742046|FG000|Overall Study|Failure to return|2
6119262|NCT00882713|9742046|FG000|Overall Study|Other - Reasons|2
6119263|NCT00882908|9742060|FG000|Overall Study|Adverse Event|0
6119264|NCT00882908|9742061|FG001|Overall Study|Adverse Event|0
6119265|NCT00882908|9742062|FG002|Overall Study|Adverse Event|1
6119266|NCT00882908|9742063|FG003|Overall Study|Adverse Event|0
6119267|NCT00882908|9742064|FG004|Overall Study|Adverse Event|1
6119268|NCT00882908|9742060|FG000|Overall Study|Lost to Follow-up|3
6119269|NCT00882908|9742061|FG001|Overall Study|Lost to Follow-up|5
6119270|NCT00882908|9742062|FG002|Overall Study|Lost to Follow-up|3
6119271|NCT00882908|9742063|FG003|Overall Study|Lost to Follow-up|1
6119272|NCT00882908|9742064|FG004|Overall Study|Lost to Follow-up|2
6119273|NCT00882908|9742060|FG000|Overall Study|Protocol Violation|0
6212401|NCT01597245|9879069|FG014|Long Term Extension (Week 60 - Week 264)|Protocol Violation|6
6212402|NCT01597245|9879070|FG015|Long Term Extension (Week 60 - Week 264)|Protocol Violation|6
6212403|NCT01597245|9879071|FG016|Long Term Extension (Week 60 - Week 264)|Protocol Violation|0
6212404|NCT01597245|9879072|FG017|Long Term Extension (Week 60 - Week 264)|Protocol Violation|0
6212405|NCT01597245|9879073|FG018|Long Term Extension (Week 60 - Week 264)|Protocol Violation|0
6212406|NCT01597245|9879074|FG019|Long Term Extension (Week 60 - Week 264)|Protocol Violation|0
6212407|NCT01597245|9879075|FG020|Long Term Extension (Week 60 - Week 264)|Protocol Violation|0
6212408|NCT01597245|9879055|FG000|Long Term Extension (Week 60 - Week 264)|Clinical Relapse|0
6212409|NCT01597245|9879056|FG001|Long Term Extension (Week 60 - Week 264)|Clinical Relapse|0
6212410|NCT01597245|9879057|FG002|Long Term Extension (Week 60 - Week 264)|Clinical Relapse|0
6212411|NCT01597245|9879058|FG003|Long Term Extension (Week 60 - Week 264)|Clinical Relapse|0
6212412|NCT01597245|9879059|FG004|Long Term Extension (Week 60 - Week 264)|Clinical Relapse|0
6212413|NCT01597245|9879060|FG005|Long Term Extension (Week 60 - Week 264)|Clinical Relapse|0
6212414|NCT01597245|9879061|FG006|Long Term Extension (Week 60 - Week 264)|Clinical Relapse|0
6212415|NCT01597245|9879062|FG007|Long Term Extension (Week 60 - Week 264)|Clinical Relapse|0
6212416|NCT01597245|9879063|FG008|Long Term Extension (Week 60 - Week 264)|Clinical Relapse|0
6212417|NCT01597245|9879064|FG009|Long Term Extension (Week 60 - Week 264)|Clinical Relapse|0
6212418|NCT01597245|9879065|FG010|Long Term Extension (Week 60 - Week 264)|Clinical Relapse|0
6212419|NCT01597245|9879066|FG011|Long Term Extension (Week 60 - Week 264)|Clinical Relapse|0
6212420|NCT01597245|9879067|FG012|Long Term Extension (Week 60 - Week 264)|Clinical Relapse|0
6212421|NCT01597245|9879068|FG013|Long Term Extension (Week 60 - Week 264)|Clinical Relapse|0
6212422|NCT01597245|9879069|FG014|Long Term Extension (Week 60 - Week 264)|Clinical Relapse|4
6212423|NCT01597245|9879070|FG015|Long Term Extension (Week 60 - Week 264)|Clinical Relapse|4
6212424|NCT01597245|9879071|FG016|Long Term Extension (Week 60 - Week 264)|Clinical Relapse|0
6212425|NCT01597245|9879072|FG017|Long Term Extension (Week 60 - Week 264)|Clinical Relapse|0
6212426|NCT01597245|9879073|FG018|Long Term Extension (Week 60 - Week 264)|Clinical Relapse|0
6212427|NCT01597245|9879074|FG019|Long Term Extension (Week 60 - Week 264)|Clinical Relapse|0
6212428|NCT01597245|9879075|FG020|Long Term Extension (Week 60 - Week 264)|Clinical Relapse|0
6212429|NCT01597245|9879055|FG000|Long Term Extension (Week 60 - Week 264)|Sponsor Decision|0
6212430|NCT01597245|9879056|FG001|Long Term Extension (Week 60 - Week 264)|Sponsor Decision|0
6212431|NCT01597245|9879057|FG002|Long Term Extension (Week 60 - Week 264)|Sponsor Decision|0
6212432|NCT01597245|9879058|FG003|Long Term Extension (Week 60 - Week 264)|Sponsor Decision|0
6212433|NCT01597245|9879059|FG004|Long Term Extension (Week 60 - Week 264)|Sponsor Decision|0
6212434|NCT01597245|9879060|FG005|Long Term Extension (Week 60 - Week 264)|Sponsor Decision|0
6212435|NCT01597245|9879061|FG006|Long Term Extension (Week 60 - Week 264)|Sponsor Decision|0
6212436|NCT01597245|9879062|FG007|Long Term Extension (Week 60 - Week 264)|Sponsor Decision|0
6212437|NCT01597245|9879063|FG008|Long Term Extension (Week 60 - Week 264)|Sponsor Decision|0
6212438|NCT01597245|9879064|FG009|Long Term Extension (Week 60 - Week 264)|Sponsor Decision|0
6212439|NCT01597245|9879065|FG010|Long Term Extension (Week 60 - Week 264)|Sponsor Decision|0
6212440|NCT01597245|9879066|FG011|Long Term Extension (Week 60 - Week 264)|Sponsor Decision|0
6212441|NCT01597245|9879067|FG012|Long Term Extension (Week 60 - Week 264)|Sponsor Decision|0
6212442|NCT01597245|9879068|FG013|Long Term Extension (Week 60 - Week 264)|Sponsor Decision|0
6212443|NCT01597245|9879069|FG014|Long Term Extension (Week 60 - Week 264)|Sponsor Decision|1
6212444|NCT01597245|9879070|FG015|Long Term Extension (Week 60 - Week 264)|Sponsor Decision|1
6212445|NCT01597245|9879071|FG016|Long Term Extension (Week 60 - Week 264)|Sponsor Decision|0
6212446|NCT01597245|9879072|FG017|Long Term Extension (Week 60 - Week 264)|Sponsor Decision|0
6212447|NCT01597245|9879073|FG018|Long Term Extension (Week 60 - Week 264)|Sponsor Decision|0
6212448|NCT01597245|9879074|FG019|Long Term Extension (Week 60 - Week 264)|Sponsor Decision|0
6212449|NCT01597245|9879075|FG020|Long Term Extension (Week 60 - Week 264)|Sponsor Decision|0
6119274|NCT00882908|9742061|FG001|Overall Study|Protocol Violation|1
6119275|NCT00882908|9742062|FG002|Overall Study|Protocol Violation|0
6119276|NCT00882908|9742063|FG003|Overall Study|Protocol Violation|0
6119277|NCT00882908|9742064|FG004|Overall Study|Protocol Violation|0
6119278|NCT00882908|9742060|FG000|Overall Study|Withdrawal by Subject|0
6212450|NCT01597245|9879055|FG000|Long Term Extension (Week 60 - Week 264)|Switched from PBO to Ixe|0
6212451|NCT01597245|9879056|FG001|Long Term Extension (Week 60 - Week 264)|Switched from PBO to Ixe|0
6212452|NCT01597245|9879057|FG002|Long Term Extension (Week 60 - Week 264)|Switched from PBO to Ixe|0
6212453|NCT01597245|9879058|FG003|Long Term Extension (Week 60 - Week 264)|Switched from PBO to Ixe|0
6212454|NCT01597245|9879059|FG004|Long Term Extension (Week 60 - Week 264)|Switched from PBO to Ixe|0
6212455|NCT01597245|9879060|FG005|Long Term Extension (Week 60 - Week 264)|Switched from PBO to Ixe|0
6212456|NCT01597245|9879061|FG006|Long Term Extension (Week 60 - Week 264)|Switched from PBO to Ixe|0
6212457|NCT01597245|9879062|FG007|Long Term Extension (Week 60 - Week 264)|Switched from PBO to Ixe|0
6212458|NCT01597245|9879063|FG008|Long Term Extension (Week 60 - Week 264)|Switched from PBO to Ixe|0
6212459|NCT01597245|9879064|FG009|Long Term Extension (Week 60 - Week 264)|Switched from PBO to Ixe|0
6212460|NCT01597245|9879065|FG010|Long Term Extension (Week 60 - Week 264)|Switched from PBO to Ixe|0
6212461|NCT01597245|9879066|FG011|Long Term Extension (Week 60 - Week 264)|Switched from PBO to Ixe|0
6212462|NCT01597245|9879067|FG012|Long Term Extension (Week 60 - Week 264)|Switched from PBO to Ixe|0
6212463|NCT01597245|9879068|FG013|Long Term Extension (Week 60 - Week 264)|Switched from PBO to Ixe|23
6212464|NCT01597245|9879069|FG014|Long Term Extension (Week 60 - Week 264)|Switched from PBO to Ixe|0
6212465|NCT01597245|9879070|FG015|Long Term Extension (Week 60 - Week 264)|Switched from PBO to Ixe|0
6212466|NCT01597245|9879071|FG016|Long Term Extension (Week 60 - Week 264)|Switched from PBO to Ixe|0
6212467|NCT01597245|9879072|FG017|Long Term Extension (Week 60 - Week 264)|Switched from PBO to Ixe|0
6212468|NCT01597245|9879073|FG018|Long Term Extension (Week 60 - Week 264)|Switched from PBO to Ixe|0
6212469|NCT01597245|9879074|FG019|Long Term Extension (Week 60 - Week 264)|Switched from PBO to Ixe|0
6212470|NCT01597245|9879075|FG020|Long Term Extension (Week 60 - Week 264)|Switched from PBO to Ixe|0
6212471|NCT01597245|9879055|FG000|Post Treatment Follow-Up (12 - 24 Weeks)|Adverse Event|0
6212472|NCT01597245|9879056|FG001|Post Treatment Follow-Up (12 - 24 Weeks)|Adverse Event|0
6212473|NCT01597245|9879057|FG002|Post Treatment Follow-Up (12 - 24 Weeks)|Adverse Event|0
6212474|NCT01597245|9879058|FG003|Post Treatment Follow-Up (12 - 24 Weeks)|Adverse Event|0
6212475|NCT01597245|9879059|FG004|Post Treatment Follow-Up (12 - 24 Weeks)|Adverse Event|0
6212476|NCT01597245|9879060|FG005|Post Treatment Follow-Up (12 - 24 Weeks)|Adverse Event|0
6212477|NCT01597245|9879061|FG006|Post Treatment Follow-Up (12 - 24 Weeks)|Adverse Event|0
6212478|NCT01597245|9879062|FG007|Post Treatment Follow-Up (12 - 24 Weeks)|Adverse Event|0
6212479|NCT01597245|9879063|FG008|Post Treatment Follow-Up (12 - 24 Weeks)|Adverse Event|0
6212480|NCT01597245|9879064|FG009|Post Treatment Follow-Up (12 - 24 Weeks)|Adverse Event|0
6212481|NCT01597245|9879065|FG010|Post Treatment Follow-Up (12 - 24 Weeks)|Adverse Event|0
6212482|NCT01597245|9879066|FG011|Post Treatment Follow-Up (12 - 24 Weeks)|Adverse Event|0
6212483|NCT01597245|9879067|FG012|Post Treatment Follow-Up (12 - 24 Weeks)|Adverse Event|0
6212484|NCT01597245|9879068|FG013|Post Treatment Follow-Up (12 - 24 Weeks)|Adverse Event|0
6212485|NCT01597245|9879069|FG014|Post Treatment Follow-Up (12 - 24 Weeks)|Adverse Event|0
6212486|NCT01597245|9879070|FG015|Post Treatment Follow-Up (12 - 24 Weeks)|Adverse Event|0
6212487|NCT01597245|9879071|FG016|Post Treatment Follow-Up (12 - 24 Weeks)|Adverse Event|9
6212488|NCT01597245|9879072|FG017|Post Treatment Follow-Up (12 - 24 Weeks)|Adverse Event|5
6212489|NCT01597245|9879073|FG018|Post Treatment Follow-Up (12 - 24 Weeks)|Adverse Event|8
6212490|NCT01597245|9879074|FG019|Post Treatment Follow-Up (12 - 24 Weeks)|Adverse Event|63
6212491|NCT01597245|9879075|FG020|Post Treatment Follow-Up (12 - 24 Weeks)|Adverse Event|13
6212492|NCT01597245|9879055|FG000|Post Treatment Follow-Up (12 - 24 Weeks)|Withdrawal by Subject|0
6212493|NCT01597245|9879056|FG001|Post Treatment Follow-Up (12 - 24 Weeks)|Withdrawal by Subject|0
6212494|NCT01597245|9879057|FG002|Post Treatment Follow-Up (12 - 24 Weeks)|Withdrawal by Subject|0
6212495|NCT01597245|9879058|FG003|Post Treatment Follow-Up (12 - 24 Weeks)|Withdrawal by Subject|0
6212496|NCT01597245|9879059|FG004|Post Treatment Follow-Up (12 - 24 Weeks)|Withdrawal by Subject|0
6212497|NCT01597245|9879060|FG005|Post Treatment Follow-Up (12 - 24 Weeks)|Withdrawal by Subject|0
6212498|NCT01597245|9879061|FG006|Post Treatment Follow-Up (12 - 24 Weeks)|Withdrawal by Subject|0
6212499|NCT01597245|9879062|FG007|Post Treatment Follow-Up (12 - 24 Weeks)|Withdrawal by Subject|0
6212500|NCT01597245|9879063|FG008|Post Treatment Follow-Up (12 - 24 Weeks)|Withdrawal by Subject|0
6212501|NCT01597245|9879064|FG009|Post Treatment Follow-Up (12 - 24 Weeks)|Withdrawal by Subject|0
6212502|NCT01597245|9879065|FG010|Post Treatment Follow-Up (12 - 24 Weeks)|Withdrawal by Subject|0
6212503|NCT01597245|9879066|FG011|Post Treatment Follow-Up (12 - 24 Weeks)|Withdrawal by Subject|0
6212504|NCT01597245|9879067|FG012|Post Treatment Follow-Up (12 - 24 Weeks)|Withdrawal by Subject|0
6212505|NCT01597245|9879068|FG013|Post Treatment Follow-Up (12 - 24 Weeks)|Withdrawal by Subject|0
6212506|NCT01597245|9879069|FG014|Post Treatment Follow-Up (12 - 24 Weeks)|Withdrawal by Subject|0
6212507|NCT01597245|9879070|FG015|Post Treatment Follow-Up (12 - 24 Weeks)|Withdrawal by Subject|0
6212508|NCT01597245|9879071|FG016|Post Treatment Follow-Up (12 - 24 Weeks)|Withdrawal by Subject|0
6212509|NCT01597245|9879072|FG017|Post Treatment Follow-Up (12 - 24 Weeks)|Withdrawal by Subject|1
6212510|NCT01597245|9879073|FG018|Post Treatment Follow-Up (12 - 24 Weeks)|Withdrawal by Subject|1
6212511|NCT01597245|9879074|FG019|Post Treatment Follow-Up (12 - 24 Weeks)|Withdrawal by Subject|41
6119279|NCT00882908|9742061|FG001|Overall Study|Withdrawal by Subject|0
6119280|NCT00882908|9742062|FG002|Overall Study|Withdrawal by Subject|3
6119281|NCT00882908|9742063|FG003|Overall Study|Withdrawal by Subject|5
6119282|NCT00882908|9742064|FG004|Overall Study|Withdrawal by Subject|2
6119283|NCT00882908|9742060|FG000|Overall Study|Subject reached a virologic endpoint|0
6119284|NCT00882908|9742061|FG001|Overall Study|Subject reached a virologic endpoint|0
6119285|NCT00882908|9742062|FG002|Overall Study|Subject reached a virologic endpoint|0
6119286|NCT00882908|9742063|FG003|Overall Study|Subject reached a virologic endpoint|0
6119287|NCT00882908|9742064|FG004|Overall Study|Subject reached a virologic endpoint|1
6119288|NCT00882908|9742060|FG000|Overall Study|Study terminated in error|0
6119289|NCT00882908|9742061|FG001|Overall Study|Study terminated in error|0
6119290|NCT00882908|9742062|FG002|Overall Study|Study terminated in error|0
6119291|NCT00882908|9742063|FG003|Overall Study|Study terminated in error|1
6119292|NCT00882908|9742064|FG004|Overall Study|Study terminated in error|0
6119293|NCT00882921|9742077|FG000|Overall Study|Death|2
6119294|NCT00882921|9742077|FG000|Overall Study|Other|3
6119295|NCT00882921|9742077|FG000|Overall Study|Lost to Follow-up|2
6119296|NCT00882921|9742077|FG000|Overall Study|Termination By Investigator|3
6119297|NCT00882921|9742077|FG000|Overall Study|Withdrawal Of Consent|1
6119298|NCT00882999|9742089|FG000|Overall Study|Adverse Event|0
6119299|NCT00882999|9742090|FG001|Overall Study|Adverse Event|0
6119300|NCT00882999|9742091|FG002|Overall Study|Adverse Event|0
6119301|NCT00882999|9742092|FG003|Overall Study|Adverse Event|0
6119302|NCT00882999|9742093|FG004|Overall Study|Adverse Event|1
6119303|NCT00882999|9742094|FG005|Overall Study|Adverse Event|0
6119304|NCT00882999|9742095|FG006|Overall Study|Adverse Event|0
6119305|NCT00882999|9742089|FG000|Overall Study|Death|0
6119306|NCT00882999|9742090|FG001|Overall Study|Death|1
6119307|NCT00882999|9742091|FG002|Overall Study|Death|0
6119308|NCT00882999|9742092|FG003|Overall Study|Death|0
6119309|NCT00882999|9742093|FG004|Overall Study|Death|0
6119310|NCT00882999|9742094|FG005|Overall Study|Death|0
6119311|NCT00882999|9742095|FG006|Overall Study|Death|0
6119312|NCT00882999|9742089|FG000|Overall Study|Withdrawal by Subject|7
6119313|NCT00882999|9742090|FG001|Overall Study|Withdrawal by Subject|6
6119314|NCT00882999|9742091|FG002|Overall Study|Withdrawal by Subject|3
6119315|NCT00882999|9742092|FG003|Overall Study|Withdrawal by Subject|3
6119316|NCT00882999|9742093|FG004|Overall Study|Withdrawal by Subject|6
6119317|NCT00882999|9742094|FG005|Overall Study|Withdrawal by Subject|5
6119318|NCT00882999|9742095|FG006|Overall Study|Withdrawal by Subject|5
6119319|NCT00882999|9742089|FG000|Overall Study|Lost to Follow-up|0
6119320|NCT00882999|9742090|FG001|Overall Study|Lost to Follow-up|1
6119321|NCT00882999|9742091|FG002|Overall Study|Lost to Follow-up|1
6119322|NCT00882999|9742092|FG003|Overall Study|Lost to Follow-up|2
6119323|NCT00882999|9742093|FG004|Overall Study|Lost to Follow-up|1
6119324|NCT00882999|9742094|FG005|Overall Study|Lost to Follow-up|1
6119325|NCT00882999|9742095|FG006|Overall Study|Lost to Follow-up|2
6119326|NCT00882999|9742089|FG000|Overall Study|Physician Decision|1
6119327|NCT00882999|9742090|FG001|Overall Study|Physician Decision|0
6119328|NCT00882999|9742091|FG002|Overall Study|Physician Decision|0
6119329|NCT00882999|9742092|FG003|Overall Study|Physician Decision|0
6119330|NCT00882999|9742093|FG004|Overall Study|Physician Decision|0
6119331|NCT00882999|9742094|FG005|Overall Study|Physician Decision|1
6119332|NCT00882999|9742095|FG006|Overall Study|Physician Decision|1
6119333|NCT00883051|9742123|FG000|Overall Study|Lost to Follow-up|0
6119334|NCT00883051|9742124|FG001|Overall Study|Lost to Follow-up|0
6119335|NCT00883051|9742125|FG002|Overall Study|Lost to Follow-up|0
6119336|NCT00883051|9742126|FG003|Overall Study|Lost to Follow-up|0
6119337|NCT00883051|9742127|FG004|Overall Study|Lost to Follow-up|1
6119338|NCT00883051|9742123|FG000|Overall Study|Did not use study medication|24
6119339|NCT00883051|9742124|FG001|Overall Study|Did not use study medication|22
6119340|NCT00883051|9742125|FG002|Overall Study|Did not use study medication|29
6119341|NCT00883051|9742126|FG003|Overall Study|Did not use study medication|29
6119342|NCT00883051|9742127|FG004|Overall Study|Did not use study medication|17
6119343|NCT00883090|9742139|FG000|Overall Study|Sponsor's decision|1
6119344|NCT00883090|9742139|FG000|Overall Study|Withdrawal by Subject|1
6119345|NCT00883116|9742154|FG000|Overall Study|Adverse event unrelated to study drug|5
6119346|NCT00883116|9742155|FG001|Overall Study|Adverse event unrelated to study drug|10
6119347|NCT00883116|9742154|FG000|Overall Study|Death|6
6119348|NCT00883116|9742155|FG001|Overall Study|Death|2
6119349|NCT00883116|9742154|FG000|Overall Study|Disease progression|130
6119350|NCT00883116|9742155|FG001|Overall Study|Disease progression|128
6119351|NCT00883116|9742154|FG000|Overall Study|Lost to Follow-up|0
6119352|NCT00883116|9742155|FG001|Overall Study|Lost to Follow-up|1
6119353|NCT00883116|9742154|FG000|Overall Study|Maximum clinical benefit|13
6119354|NCT00883116|9742155|FG001|Overall Study|Maximum clinical benefit|46
6119355|NCT00883116|9742154|FG000|Overall Study|Not identified|3
6119356|NCT00883116|9742155|FG001|Overall Study|Not identified|6
6119357|NCT00883116|9742154|FG000|Overall Study|Study drug toxicity|36
6119358|NCT00883116|9742155|FG001|Overall Study|Study drug toxicity|16
6119359|NCT00883116|9742154|FG000|Overall Study|Withdrawal by Subject|14
6119360|NCT00883116|9742155|FG001|Overall Study|Withdrawal by Subject|8
6119361|NCT00883116|9742154|FG000|Overall Study|No longer meets study criteria|2
6119362|NCT00883116|9742155|FG001|Overall Study|No longer meets study criteria|2
6119363|NCT00883129|9742165|FG000|Overall Study|Adverse Event|7
6119364|NCT00883129|9742166|FG001|Overall Study|Adverse Event|15
6119365|NCT00883129|9742165|FG000|Overall Study|Withdrawal by Subject|8
6119366|NCT00883129|9742166|FG001|Overall Study|Withdrawal by Subject|9
6212512|NCT01597245|9879075|FG020|Post Treatment Follow-Up (12 - 24 Weeks)|Withdrawal by Subject|13
6212513|NCT01597245|9879055|FG000|Post Treatment Follow-Up (12 - 24 Weeks)|Lack of Efficacy|0
6212514|NCT01597245|9879056|FG001|Post Treatment Follow-Up (12 - 24 Weeks)|Lack of Efficacy|0
6212515|NCT01597245|9879057|FG002|Post Treatment Follow-Up (12 - 24 Weeks)|Lack of Efficacy|0
6212516|NCT01597245|9879058|FG003|Post Treatment Follow-Up (12 - 24 Weeks)|Lack of Efficacy|0
6212517|NCT01597245|9879059|FG004|Post Treatment Follow-Up (12 - 24 Weeks)|Lack of Efficacy|0
6212518|NCT01597245|9879060|FG005|Post Treatment Follow-Up (12 - 24 Weeks)|Lack of Efficacy|0
6212519|NCT01597245|9879061|FG006|Post Treatment Follow-Up (12 - 24 Weeks)|Lack of Efficacy|0
6212520|NCT01597245|9879062|FG007|Post Treatment Follow-Up (12 - 24 Weeks)|Lack of Efficacy|0
6212521|NCT01597245|9879063|FG008|Post Treatment Follow-Up (12 - 24 Weeks)|Lack of Efficacy|0
6212522|NCT01597245|9879064|FG009|Post Treatment Follow-Up (12 - 24 Weeks)|Lack of Efficacy|0
6212523|NCT01597245|9879065|FG010|Post Treatment Follow-Up (12 - 24 Weeks)|Lack of Efficacy|0
6212524|NCT01597245|9879066|FG011|Post Treatment Follow-Up (12 - 24 Weeks)|Lack of Efficacy|0
6212525|NCT01597245|9879067|FG012|Post Treatment Follow-Up (12 - 24 Weeks)|Lack of Efficacy|0
6212526|NCT01597245|9879068|FG013|Post Treatment Follow-Up (12 - 24 Weeks)|Lack of Efficacy|0
6212527|NCT01597245|9879069|FG014|Post Treatment Follow-Up (12 - 24 Weeks)|Lack of Efficacy|0
6119367|NCT00883129|9742165|FG000|Overall Study|Non-compliance|3
6119368|NCT00883129|9742166|FG001|Overall Study|Non-compliance|6
6119369|NCT00883129|9742165|FG000|Overall Study|Lost to Follow-up|1
6119370|NCT00883129|9742166|FG001|Overall Study|Lost to Follow-up|2
6119371|NCT00883129|9742165|FG000|Overall Study|Death|1
6119372|NCT00883129|9742166|FG001|Overall Study|Death|2
6119373|NCT00883129|9742165|FG000|Overall Study|Defined Treatment Failure|0
6119374|NCT00883129|9742166|FG001|Overall Study|Defined Treatment Failure|2
6119375|NCT00883181|9742189|FG000|Overall Study|Hematological Adverse Event|26
6119376|NCT00883181|9742189|FG000|Overall Study|Non-hematological Adverse Event|55
6119377|NCT00883181|9742189|FG000|Overall Study|Disease Progression|94
6119378|NCT00883181|9742189|FG000|Overall Study|Administrative Reason|24
6119379|NCT00883181|9742189|FG000|Overall Study|Withdrawal by Subject|4
6212528|NCT01597245|9879070|FG015|Post Treatment Follow-Up (12 - 24 Weeks)|Lack of Efficacy|0
6212529|NCT01597245|9879071|FG016|Post Treatment Follow-Up (12 - 24 Weeks)|Lack of Efficacy|2
6212530|NCT01597245|9879072|FG017|Post Treatment Follow-Up (12 - 24 Weeks)|Lack of Efficacy|0
6212531|NCT01597245|9879073|FG018|Post Treatment Follow-Up (12 - 24 Weeks)|Lack of Efficacy|0
6212532|NCT01597245|9879074|FG019|Post Treatment Follow-Up (12 - 24 Weeks)|Lack of Efficacy|29
6212533|NCT01597245|9879075|FG020|Post Treatment Follow-Up (12 - 24 Weeks)|Lack of Efficacy|3
6212534|NCT01597245|9879055|FG000|Post Treatment Follow-Up (12 - 24 Weeks)|Lost to Follow-up|0
6212535|NCT01597245|9879056|FG001|Post Treatment Follow-Up (12 - 24 Weeks)|Lost to Follow-up|0
6212536|NCT01597245|9879057|FG002|Post Treatment Follow-Up (12 - 24 Weeks)|Lost to Follow-up|0
6212537|NCT01597245|9879058|FG003|Post Treatment Follow-Up (12 - 24 Weeks)|Lost to Follow-up|0
6212538|NCT01597245|9879059|FG004|Post Treatment Follow-Up (12 - 24 Weeks)|Lost to Follow-up|0
6212539|NCT01597245|9879060|FG005|Post Treatment Follow-Up (12 - 24 Weeks)|Lost to Follow-up|0
6212540|NCT01597245|9879061|FG006|Post Treatment Follow-Up (12 - 24 Weeks)|Lost to Follow-up|0
6212541|NCT01597245|9879062|FG007|Post Treatment Follow-Up (12 - 24 Weeks)|Lost to Follow-up|0
6212542|NCT01597245|9879063|FG008|Post Treatment Follow-Up (12 - 24 Weeks)|Lost to Follow-up|0
6212543|NCT01597245|9879064|FG009|Post Treatment Follow-Up (12 - 24 Weeks)|Lost to Follow-up|0
6212544|NCT01597245|9879065|FG010|Post Treatment Follow-Up (12 - 24 Weeks)|Lost to Follow-up|0
6212545|NCT01597245|9879066|FG011|Post Treatment Follow-Up (12 - 24 Weeks)|Lost to Follow-up|0
6212546|NCT01597245|9879067|FG012|Post Treatment Follow-Up (12 - 24 Weeks)|Lost to Follow-up|0
6212547|NCT01597245|9879068|FG013|Post Treatment Follow-Up (12 - 24 Weeks)|Lost to Follow-up|0
6212548|NCT01597245|9879069|FG014|Post Treatment Follow-Up (12 - 24 Weeks)|Lost to Follow-up|0
6212549|NCT01597245|9879070|FG015|Post Treatment Follow-Up (12 - 24 Weeks)|Lost to Follow-up|0
6212550|NCT01597245|9879071|FG016|Post Treatment Follow-Up (12 - 24 Weeks)|Lost to Follow-up|0
6212551|NCT01597245|9879072|FG017|Post Treatment Follow-Up (12 - 24 Weeks)|Lost to Follow-up|0
6212552|NCT01597245|9879073|FG018|Post Treatment Follow-Up (12 - 24 Weeks)|Lost to Follow-up|1
6212553|NCT01597245|9879074|FG019|Post Treatment Follow-Up (12 - 24 Weeks)|Lost to Follow-up|14
6212554|NCT01597245|9879075|FG020|Post Treatment Follow-Up (12 - 24 Weeks)|Lost to Follow-up|4
6212555|NCT01597245|9879055|FG000|Post Treatment Follow-Up (12 - 24 Weeks)|Physician Decision|0
6212556|NCT01597245|9879056|FG001|Post Treatment Follow-Up (12 - 24 Weeks)|Physician Decision|0
6212557|NCT01597245|9879057|FG002|Post Treatment Follow-Up (12 - 24 Weeks)|Physician Decision|0
6212558|NCT01597245|9879058|FG003|Post Treatment Follow-Up (12 - 24 Weeks)|Physician Decision|0
6212559|NCT01597245|9879059|FG004|Post Treatment Follow-Up (12 - 24 Weeks)|Physician Decision|0
6119380|NCT00883181|9742189|FG000|Overall Study|Death|31
6119381|NCT00883181|9742189|FG000|Overall Study|Other|38
6119382|NCT00883181|9742189|FG000|Overall Study|Protocol Deviation|3
6119383|NCT00883181|9742189|FG000|Overall Study|Noncompliance|3
6119384|NCT00883337|9742236|FG000|Core Treatment Period|Adverse Event|9
6119385|NCT00883337|9742237|FG001|Core Treatment Period|Adverse Event|12
6119386|NCT00883337|9742238|FG002|Core Treatment Period|Adverse Event|22
6119387|NCT00883337|9742236|FG000|Core Treatment Period|Lack of Efficacy|7
6119388|NCT00883337|9742237|FG001|Core Treatment Period|Lack of Efficacy|4
6119389|NCT00883337|9742238|FG002|Core Treatment Period|Lack of Efficacy|2
6119390|NCT00883337|9742236|FG000|Core Treatment Period|Lost to Follow-up|1
6119391|NCT00883337|9742237|FG001|Core Treatment Period|Lost to Follow-up|1
6119392|NCT00883337|9742238|FG002|Core Treatment Period|Lost to Follow-up|0
6119393|NCT00883337|9742236|FG000|Core Treatment Period|Withdrawal by Subject|2
6119394|NCT00883337|9742237|FG001|Core Treatment Period|Withdrawal by Subject|2
6119395|NCT00883337|9742238|FG002|Core Treatment Period|Withdrawal by Subject|6
6119396|NCT00883337|9742236|FG000|Core Treatment Period|Wish to be pregnant|1
6119397|NCT00883337|9742237|FG001|Core Treatment Period|Wish to be pregnant|2
6119398|NCT00883337|9742238|FG002|Core Treatment Period|Wish to be pregnant|1
6212560|NCT01597245|9879060|FG005|Post Treatment Follow-Up (12 - 24 Weeks)|Physician Decision|0
6212561|NCT01597245|9879061|FG006|Post Treatment Follow-Up (12 - 24 Weeks)|Physician Decision|0
6212562|NCT01597245|9879062|FG007|Post Treatment Follow-Up (12 - 24 Weeks)|Physician Decision|0
6212563|NCT01597245|9879063|FG008|Post Treatment Follow-Up (12 - 24 Weeks)|Physician Decision|0
6212564|NCT01597245|9879064|FG009|Post Treatment Follow-Up (12 - 24 Weeks)|Physician Decision|0
6212565|NCT01597245|9879065|FG010|Post Treatment Follow-Up (12 - 24 Weeks)|Physician Decision|0
6212566|NCT01597245|9879066|FG011|Post Treatment Follow-Up (12 - 24 Weeks)|Physician Decision|0
6212567|NCT01597245|9879067|FG012|Post Treatment Follow-Up (12 - 24 Weeks)|Physician Decision|0
6212568|NCT01597245|9879068|FG013|Post Treatment Follow-Up (12 - 24 Weeks)|Physician Decision|0
6212569|NCT01597245|9879069|FG014|Post Treatment Follow-Up (12 - 24 Weeks)|Physician Decision|0
6212570|NCT01597245|9879070|FG015|Post Treatment Follow-Up (12 - 24 Weeks)|Physician Decision|0
6212571|NCT01597245|9879071|FG016|Post Treatment Follow-Up (12 - 24 Weeks)|Physician Decision|1
6212572|NCT01597245|9879072|FG017|Post Treatment Follow-Up (12 - 24 Weeks)|Physician Decision|0
6212573|NCT01597245|9879073|FG018|Post Treatment Follow-Up (12 - 24 Weeks)|Physician Decision|0
6212574|NCT01597245|9879074|FG019|Post Treatment Follow-Up (12 - 24 Weeks)|Physician Decision|9
6212575|NCT01597245|9879075|FG020|Post Treatment Follow-Up (12 - 24 Weeks)|Physician Decision|1
6212576|NCT01597245|9879055|FG000|Post Treatment Follow-Up (12 - 24 Weeks)|Protocol Violation|0
6212577|NCT01597245|9879056|FG001|Post Treatment Follow-Up (12 - 24 Weeks)|Protocol Violation|0
6212578|NCT01597245|9879057|FG002|Post Treatment Follow-Up (12 - 24 Weeks)|Protocol Violation|0
6212579|NCT01597245|9879058|FG003|Post Treatment Follow-Up (12 - 24 Weeks)|Protocol Violation|0
6212580|NCT01597245|9879059|FG004|Post Treatment Follow-Up (12 - 24 Weeks)|Protocol Violation|0
6212581|NCT01597245|9879060|FG005|Post Treatment Follow-Up (12 - 24 Weeks)|Protocol Violation|0
6212582|NCT01597245|9879061|FG006|Post Treatment Follow-Up (12 - 24 Weeks)|Protocol Violation|0
6212583|NCT01597245|9879062|FG007|Post Treatment Follow-Up (12 - 24 Weeks)|Protocol Violation|0
6212584|NCT01597245|9879063|FG008|Post Treatment Follow-Up (12 - 24 Weeks)|Protocol Violation|0
6212585|NCT01597245|9879064|FG009|Post Treatment Follow-Up (12 - 24 Weeks)|Protocol Violation|0
6212586|NCT01597245|9879065|FG010|Post Treatment Follow-Up (12 - 24 Weeks)|Protocol Violation|0
6212587|NCT01597245|9879066|FG011|Post Treatment Follow-Up (12 - 24 Weeks)|Protocol Violation|0
6212588|NCT01597245|9879067|FG012|Post Treatment Follow-Up (12 - 24 Weeks)|Protocol Violation|0
6212589|NCT01597245|9879068|FG013|Post Treatment Follow-Up (12 - 24 Weeks)|Protocol Violation|0
6212590|NCT01597245|9879069|FG014|Post Treatment Follow-Up (12 - 24 Weeks)|Protocol Violation|0
6212591|NCT01597245|9879070|FG015|Post Treatment Follow-Up (12 - 24 Weeks)|Protocol Violation|0
6212592|NCT01597245|9879071|FG016|Post Treatment Follow-Up (12 - 24 Weeks)|Protocol Violation|1
6212593|NCT01597245|9879072|FG017|Post Treatment Follow-Up (12 - 24 Weeks)|Protocol Violation|0
6212594|NCT01597245|9879073|FG018|Post Treatment Follow-Up (12 - 24 Weeks)|Protocol Violation|0
6212595|NCT01597245|9879074|FG019|Post Treatment Follow-Up (12 - 24 Weeks)|Protocol Violation|6
6212596|NCT01597245|9879075|FG020|Post Treatment Follow-Up (12 - 24 Weeks)|Protocol Violation|2
6212597|NCT01597245|9879055|FG000|Post Treatment Follow-Up (12 - 24 Weeks)|Entry Criteria Not Met|0
6212598|NCT01597245|9879056|FG001|Post Treatment Follow-Up (12 - 24 Weeks)|Entry Criteria Not Met|0
6212599|NCT01597245|9879057|FG002|Post Treatment Follow-Up (12 - 24 Weeks)|Entry Criteria Not Met|0
6212600|NCT01597245|9879058|FG003|Post Treatment Follow-Up (12 - 24 Weeks)|Entry Criteria Not Met|0
6212601|NCT01597245|9879059|FG004|Post Treatment Follow-Up (12 - 24 Weeks)|Entry Criteria Not Met|0
6212602|NCT01597245|9879060|FG005|Post Treatment Follow-Up (12 - 24 Weeks)|Entry Criteria Not Met|0
6212603|NCT01597245|9879061|FG006|Post Treatment Follow-Up (12 - 24 Weeks)|Entry Criteria Not Met|0
6212604|NCT01597245|9879062|FG007|Post Treatment Follow-Up (12 - 24 Weeks)|Entry Criteria Not Met|0
6212605|NCT01597245|9879063|FG008|Post Treatment Follow-Up (12 - 24 Weeks)|Entry Criteria Not Met|0
6212606|NCT01597245|9879064|FG009|Post Treatment Follow-Up (12 - 24 Weeks)|Entry Criteria Not Met|0
6212607|NCT01597245|9879065|FG010|Post Treatment Follow-Up (12 - 24 Weeks)|Entry Criteria Not Met|0
6212608|NCT01597245|9879066|FG011|Post Treatment Follow-Up (12 - 24 Weeks)|Entry Criteria Not Met|0
6212609|NCT01597245|9879067|FG012|Post Treatment Follow-Up (12 - 24 Weeks)|Entry Criteria Not Met|0
6212610|NCT01597245|9879068|FG013|Post Treatment Follow-Up (12 - 24 Weeks)|Entry Criteria Not Met|0
6212611|NCT01597245|9879069|FG014|Post Treatment Follow-Up (12 - 24 Weeks)|Entry Criteria Not Met|0
6287277|NCT02349295|9999713|FG007|Long-Term Extension Period (Week 24-156)|Adverse Event|9
6287278|NCT02349295|9999714|FG008|Long-Term Extension Period (Week 24-156)|Adverse Event|9
6287279|NCT02349295|9999715|FG009|Long-Term Extension Period (Week 24-156)|Adverse Event|2
6119399|NCT00883337|9742236|FG000|Core Treatment Period|Poor compliance to protocol|0
6119400|NCT00883337|9742237|FG001|Core Treatment Period|Poor compliance to protocol|0
6119401|NCT00883337|9742238|FG002|Core Treatment Period|Poor compliance to protocol|1
6119402|NCT00883337|9742236|FG000|Core Treatment Period|Other than above|0
6119403|NCT00883337|9742237|FG001|Core Treatment Period|Other than above|1
6119404|NCT00883337|9742238|FG002|Core Treatment Period|Other than above|1
6119405|NCT00883337|9742236|FG000|Extension Treatment Period|Adverse Event|8
6119406|NCT00883337|9742237|FG001|Extension Treatment Period|Adverse Event|5
6119407|NCT00883337|9742238|FG002|Extension Treatment Period|Adverse Event|5
6119408|NCT00883337|9742236|FG000|Extension Treatment Period|Lack of Efficacy|8
6212612|NCT01597245|9879070|FG015|Post Treatment Follow-Up (12 - 24 Weeks)|Entry Criteria Not Met|0
6212613|NCT01597245|9879071|FG016|Post Treatment Follow-Up (12 - 24 Weeks)|Entry Criteria Not Met|2
6212614|NCT01597245|9879072|FG017|Post Treatment Follow-Up (12 - 24 Weeks)|Entry Criteria Not Met|0
6212615|NCT01597245|9879073|FG018|Post Treatment Follow-Up (12 - 24 Weeks)|Entry Criteria Not Met|0
6212616|NCT01597245|9879074|FG019|Post Treatment Follow-Up (12 - 24 Weeks)|Entry Criteria Not Met|3
6212617|NCT01597245|9879075|FG020|Post Treatment Follow-Up (12 - 24 Weeks)|Entry Criteria Not Met|0
6212618|NCT01597245|9879055|FG000|Post Treatment Follow-Up (12 - 24 Weeks)|Sponsor Decision|0
6212619|NCT01597245|9879056|FG001|Post Treatment Follow-Up (12 - 24 Weeks)|Sponsor Decision|0
6212620|NCT01597245|9879057|FG002|Post Treatment Follow-Up (12 - 24 Weeks)|Sponsor Decision|0
6212621|NCT01597245|9879058|FG003|Post Treatment Follow-Up (12 - 24 Weeks)|Sponsor Decision|0
6212622|NCT01597245|9879059|FG004|Post Treatment Follow-Up (12 - 24 Weeks)|Sponsor Decision|0
6212623|NCT01597245|9879060|FG005|Post Treatment Follow-Up (12 - 24 Weeks)|Sponsor Decision|0
6212624|NCT01597245|9879061|FG006|Post Treatment Follow-Up (12 - 24 Weeks)|Sponsor Decision|0
6212625|NCT01597245|9879062|FG007|Post Treatment Follow-Up (12 - 24 Weeks)|Sponsor Decision|0
6212626|NCT01597245|9879063|FG008|Post Treatment Follow-Up (12 - 24 Weeks)|Sponsor Decision|0
6212627|NCT01597245|9879064|FG009|Post Treatment Follow-Up (12 - 24 Weeks)|Sponsor Decision|0
6212628|NCT01597245|9879065|FG010|Post Treatment Follow-Up (12 - 24 Weeks)|Sponsor Decision|0
6212629|NCT01597245|9879066|FG011|Post Treatment Follow-Up (12 - 24 Weeks)|Sponsor Decision|0
6212630|NCT01597245|9879067|FG012|Post Treatment Follow-Up (12 - 24 Weeks)|Sponsor Decision|0
6212631|NCT01597245|9879068|FG013|Post Treatment Follow-Up (12 - 24 Weeks)|Sponsor Decision|0
6212632|NCT01597245|9879069|FG014|Post Treatment Follow-Up (12 - 24 Weeks)|Sponsor Decision|0
6212633|NCT01597245|9879070|FG015|Post Treatment Follow-Up (12 - 24 Weeks)|Sponsor Decision|0
6212634|NCT01597245|9879071|FG016|Post Treatment Follow-Up (12 - 24 Weeks)|Sponsor Decision|1
6212635|NCT01597245|9879072|FG017|Post Treatment Follow-Up (12 - 24 Weeks)|Sponsor Decision|0
6212636|NCT01597245|9879073|FG018|Post Treatment Follow-Up (12 - 24 Weeks)|Sponsor Decision|0
6212637|NCT01597245|9879074|FG019|Post Treatment Follow-Up (12 - 24 Weeks)|Sponsor Decision|1
6212638|NCT01597245|9879075|FG020|Post Treatment Follow-Up (12 - 24 Weeks)|Sponsor Decision|0
6212639|NCT01597245|9879055|FG000|Post Treatment Follow-Up (12 - 24 Weeks)|Clinical Relapse|0
6212640|NCT01597245|9879056|FG001|Post Treatment Follow-Up (12 - 24 Weeks)|Clinical Relapse|0
6212641|NCT01597245|9879057|FG002|Post Treatment Follow-Up (12 - 24 Weeks)|Clinical Relapse|0
6212642|NCT01597245|9879058|FG003|Post Treatment Follow-Up (12 - 24 Weeks)|Clinical Relapse|0
6212643|NCT01597245|9879059|FG004|Post Treatment Follow-Up (12 - 24 Weeks)|Clinical Relapse|0
6212644|NCT01597245|9879060|FG005|Post Treatment Follow-Up (12 - 24 Weeks)|Clinical Relapse|0
6212645|NCT01597245|9879061|FG006|Post Treatment Follow-Up (12 - 24 Weeks)|Clinical Relapse|0
6212646|NCT01597245|9879062|FG007|Post Treatment Follow-Up (12 - 24 Weeks)|Clinical Relapse|0
6212647|NCT01597245|9879063|FG008|Post Treatment Follow-Up (12 - 24 Weeks)|Clinical Relapse|0
6212648|NCT01597245|9879064|FG009|Post Treatment Follow-Up (12 - 24 Weeks)|Clinical Relapse|0
6212649|NCT01597245|9879065|FG010|Post Treatment Follow-Up (12 - 24 Weeks)|Clinical Relapse|0
6212650|NCT01597245|9879066|FG011|Post Treatment Follow-Up (12 - 24 Weeks)|Clinical Relapse|0
6212651|NCT01597245|9879067|FG012|Post Treatment Follow-Up (12 - 24 Weeks)|Clinical Relapse|0
6212652|NCT01597245|9879068|FG013|Post Treatment Follow-Up (12 - 24 Weeks)|Clinical Relapse|0
6212653|NCT01597245|9879069|FG014|Post Treatment Follow-Up (12 - 24 Weeks)|Clinical Relapse|0
6212654|NCT01597245|9879070|FG015|Post Treatment Follow-Up (12 - 24 Weeks)|Clinical Relapse|0
6212655|NCT01597245|9879071|FG016|Post Treatment Follow-Up (12 - 24 Weeks)|Clinical Relapse|0
6212656|NCT01597245|9879072|FG017|Post Treatment Follow-Up (12 - 24 Weeks)|Clinical Relapse|0
6212657|NCT01597245|9879073|FG018|Post Treatment Follow-Up (12 - 24 Weeks)|Clinical Relapse|0
6212658|NCT01597245|9879074|FG019|Post Treatment Follow-Up (12 - 24 Weeks)|Clinical Relapse|1
6212659|NCT01597245|9879075|FG020|Post Treatment Follow-Up (12 - 24 Weeks)|Clinical Relapse|0
6212660|NCT01597258|9879108|FG000|Overall Study|No Drug Administration|1
6212661|NCT01597375|9879112|FG000|First Intervention (4 Weeks)|Uncontrolled Asthma|1
6212662|NCT01597375|9879113|FG001|First Intervention (4 Weeks)|Uncontrolled Asthma|0
6212663|NCT01597375|9879112|FG000|First Intervention (4 Weeks)|Needed surgery|1
6212664|NCT01597375|9879113|FG001|First Intervention (4 Weeks)|Needed surgery|0
6212665|NCT01597375|9879112|FG000|First Intervention (4 Weeks)|Lost to Follow-up|0
6212666|NCT01597375|9879113|FG001|First Intervention (4 Weeks)|Lost to Follow-up|1
6287280|NCT02349295|9999716|FG010|Long-Term Extension Period (Week 24-156)|Adverse Event|2
6287281|NCT02349295|9999717|FG011|Long-Term Extension Period (Week 24-156)|Adverse Event|0
6287282|NCT02349295|9999718|FG012|Long-Term Extension Period (Week 24-156)|Adverse Event|0
6287283|NCT02349295|9999719|FG013|Long-Term Extension Period (Week 24-156)|Adverse Event|0
6287284|NCT02349295|9999706|FG000|Long-Term Extension Period (Week 24-156)|Unknown/Missing|0
6287285|NCT02349295|9999707|FG001|Long-Term Extension Period (Week 24-156)|Unknown/Missing|0
6119409|NCT00883337|9742237|FG001|Extension Treatment Period|Lack of Efficacy|8
6119410|NCT00883337|9742238|FG002|Extension Treatment Period|Lack of Efficacy|8
6119411|NCT00883337|9742236|FG000|Extension Treatment Period|Poor compliance to protocol|1
6119412|NCT00883337|9742237|FG001|Extension Treatment Period|Poor compliance to protocol|1
6119413|NCT00883337|9742238|FG002|Extension Treatment Period|Poor compliance to protocol|1
6119414|NCT00883337|9742236|FG000|Extension Treatment Period|Lost to Follow-up|1
6212667|NCT01597375|9879112|FG000|Washout (2 Weeks)|Adverse Event|1
6212668|NCT01597375|9879113|FG001|Washout (2 Weeks)|Adverse Event|0
6212669|NCT01597375|9879112|FG000|Second Intervention|Failed to react at both Aspirin|1
6212670|NCT01597375|9879113|FG001|Second Intervention|Failed to react at both Aspirin|1
6212671|NCT01597479|9879133|FG000|Overall Study|Protocol Violation|1
6212672|NCT01597479|9879134|FG001|Overall Study|Protocol Violation|0
6212673|NCT01597479|9879133|FG000|Overall Study|Lost to Follow-up|1
6212674|NCT01597479|9879134|FG001|Overall Study|Lost to Follow-up|0
6212675|NCT01597492|9879143|FG000|Overall Study|Withdrawal by Subject|1
6212676|NCT01597492|9879144|FG001|Overall Study|Withdrawal by Subject|2
6212677|NCT01597492|9879143|FG000|Overall Study|Adverse Event|3
6212678|NCT01597492|9879144|FG001|Overall Study|Adverse Event|0
6212679|NCT01597492|9879143|FG000|Overall Study|Lost to Follow-up|0
6212680|NCT01597492|9879144|FG001|Overall Study|Lost to Follow-up|2
6212681|NCT01597492|9879143|FG000|Overall Study|Other Reason|2
6212682|NCT01597492|9879144|FG001|Overall Study|Other Reason|0
6212683|NCT01597505|9879152|FG000|Overall Study|Physician Decision|5
6212684|NCT01597505|9879153|FG001|Overall Study|Physician Decision|0
6212685|NCT01597505|9879152|FG000|Overall Study|Adverse Event|19
6212686|NCT01597505|9879153|FG001|Overall Study|Adverse Event|7
6212687|NCT01597505|9879152|FG000|Overall Study|Lost to Follow-up|4
6212688|NCT01597505|9879153|FG001|Overall Study|Lost to Follow-up|2
6212689|NCT01597505|9879152|FG000|Overall Study|Withdrawal by Subject|10
6212690|NCT01597505|9879153|FG001|Overall Study|Withdrawal by Subject|18
6212691|NCT01597505|9879152|FG000|Overall Study|Other|5
6212692|NCT01597505|9879153|FG001|Overall Study|Other|6
6212693|NCT01597505|9879152|FG000|Overall Study|Missing|1
6212694|NCT01597505|9879153|FG001|Overall Study|Missing|0
6212695|NCT01597557|9879162|FG000|Overall Study|Did not undergo cardioversion procedure|4
6212696|NCT01597557|9879163|FG001|Overall Study|Did not undergo cardioversion procedure|3
6212697|NCT01597596|9879171|FG000|Overall Study|Study terminated by sponsor|1
6212698|NCT01597596|9879172|FG001|Overall Study|Study terminated by sponsor|0
6212699|NCT01597596|9879171|FG000|Overall Study|Physician Decision|0
6212700|NCT01597596|9879172|FG001|Overall Study|Physician Decision|1
6212701|NCT01597622|9879178|FG000|Overall Study|Adverse Event|7
6212702|NCT01597622|9879178|FG000|Overall Study|Lack of Efficacy|3
6212703|NCT01597622|9879178|FG000|Overall Study|Protocol Violation|1
6212704|NCT01597622|9879178|FG000|Overall Study|Lost to Follow-up|1
6212705|NCT01597622|9879178|FG000|Overall Study|Investigator Discretion|5
6212706|NCT01597622|9879178|FG000|Overall Study|Withdrawal by Subject|20
6212707|NCT01597622|9879178|FG000|Overall Study|Death|1
6212708|NCT01597635|9879185|FG000|Part A|Adverse Event|3
6212709|NCT01597635|9879186|FG001|Part A|Adverse Event|0
6119415|NCT00883337|9742237|FG001|Extension Treatment Period|Lost to Follow-up|0
6119416|NCT00883337|9742238|FG002|Extension Treatment Period|Lost to Follow-up|0
6119417|NCT00883337|9742236|FG000|Extension Treatment Period|Other than above|10
6119418|NCT00883337|9742237|FG001|Extension Treatment Period|Other than above|9
6119419|NCT00883337|9742238|FG002|Extension Treatment Period|Other than above|5
6119420|NCT00883493|9742262|FG000|Overall Study|Adverse Event|11
6119421|NCT00883493|9742263|FG001|Overall Study|Adverse Event|12
6119422|NCT00883493|9742262|FG000|Overall Study|Lack of Efficacy|4
6119423|NCT00883493|9742263|FG001|Overall Study|Lack of Efficacy|3
6119424|NCT00883493|9742262|FG000|Overall Study|Lost to Follow-up|7
6119425|NCT00883493|9742263|FG001|Overall Study|Lost to Follow-up|6
6119426|NCT00883493|9742262|FG000|Overall Study|Withdrawal by Subject|11
6119427|NCT00883493|9742263|FG001|Overall Study|Withdrawal by Subject|20
6119428|NCT00883493|9742262|FG000|Overall Study|Eligibility Criteria not fullfilled|6
6119429|NCT00883493|9742263|FG001|Overall Study|Eligibility Criteria not fullfilled|6
6119430|NCT00883493|9742262|FG000|Overall Study|Study specific disc. criteria|2
6119431|NCT00883493|9742263|FG001|Overall Study|Study specific disc. criteria|0
6119432|NCT00883493|9742262|FG000|Overall Study|Other|5
6119433|NCT00883493|9742263|FG001|Overall Study|Other|3
6119434|NCT00883558|9742269|FG000|Titration Period (Weeks 0 to 4)|Withdrawal by Subject|2
6119435|NCT00883558|9742270|FG001|Titration Period (Weeks 0 to 4)|Withdrawal by Subject|0
6119436|NCT00883558|9742271|FG002|Titration Period (Weeks 0 to 4)|Withdrawal by Subject|0
6119437|NCT00883558|9742269|FG000|First Treatment Cycle (Weeks 4 to 16)|Adverse Event|0
6119438|NCT00883558|9742270|FG001|First Treatment Cycle (Weeks 4 to 16)|Adverse Event|1
6119439|NCT00883558|9742271|FG002|First Treatment Cycle (Weeks 4 to 16)|Adverse Event|0
6119440|NCT00883558|9742269|FG000|First Treatment Cycle (Weeks 4 to 16)|Withdrawal by Subject|0
6119441|NCT00883558|9742270|FG001|First Treatment Cycle (Weeks 4 to 16)|Withdrawal by Subject|1
6119442|NCT00883558|9742271|FG002|First Treatment Cycle (Weeks 4 to 16)|Withdrawal by Subject|1
6119443|NCT00883558|9742269|FG000|First Treatment Cycle (Weeks 4 to 16)|Protocol Violation|0
6119444|NCT00883558|9742270|FG001|First Treatment Cycle (Weeks 4 to 16)|Protocol Violation|1
6212710|NCT01597635|9879187|FG002|Part A|Adverse Event|0
6119445|NCT00883558|9742271|FG002|First Treatment Cycle (Weeks 4 to 16)|Protocol Violation|0
6119446|NCT00883558|9742269|FG000|Second Treatment Cycle (Weeks 16 to 28)|Withdrawal by Subject|0
6119447|NCT00883558|9742270|FG001|Second Treatment Cycle (Weeks 16 to 28)|Withdrawal by Subject|0
6119448|NCT00883558|9742271|FG002|Second Treatment Cycle (Weeks 16 to 28)|Withdrawal by Subject|1
6212711|NCT01597635|9879185|FG000|Part B|Adverse Event|0
6212712|NCT01597635|9879186|FG001|Part B|Adverse Event|0
6212713|NCT01597635|9879187|FG002|Part B|Adverse Event|1
6212714|NCT01597635|9879185|FG000|Part B|Protocol Violation|0
6212715|NCT01597635|9879186|FG001|Part B|Protocol Violation|1
6212716|NCT01597635|9879187|FG002|Part B|Protocol Violation|0
6212717|NCT01597635|9879185|FG000|Part B|Protocol-defined stopping criteria|0
6212718|NCT01597635|9879186|FG001|Part B|Protocol-defined stopping criteria|4
6212719|NCT01597635|9879187|FG002|Part B|Protocol-defined stopping criteria|3
6212720|NCT01597635|9879185|FG000|Part B|Withdrawal by Subject|0
6212721|NCT01597635|9879186|FG001|Part B|Withdrawal by Subject|1
6212722|NCT01597635|9879187|FG002|Part B|Withdrawal by Subject|0
6212723|NCT01597791|9879227|FG000|Overall Study|Physician Decision|2
6212724|NCT01597791|9879228|FG001|Overall Study|Physician Decision|1
6212725|NCT01597791|9879227|FG000|Overall Study|Cesarean Section|6
6212726|NCT01597791|9879228|FG001|Overall Study|Cesarean Section|7
6212727|NCT01597791|9879227|FG000|Overall Study|Subject withdrawal|0
6212728|NCT01597791|9879228|FG001|Overall Study|Subject withdrawal|1
6212729|NCT01597791|9879227|FG000|Overall Study|Protocol Violation|0
6212730|NCT01597791|9879228|FG001|Overall Study|Protocol Violation|1
6212731|NCT01597908|9879263|FG000|Randomized Phase|Death|217
6212732|NCT01597908|9879264|FG001|Randomized Phase|Death|238
6212733|NCT01597908|9879265|FG002|Randomized Phase|Death|0
6212734|NCT01597908|9879263|FG000|Randomized Phase|Sponsor Decision|93
6212735|NCT01597908|9879264|FG001|Randomized Phase|Sponsor Decision|39
6212736|NCT01597908|9879265|FG002|Randomized Phase|Sponsor Decision|0
6212737|NCT01597908|9879263|FG000|Randomized Phase|Lost to Follow-up|9
6212738|NCT01597908|9879264|FG001|Randomized Phase|Lost to Follow-up|16
6212739|NCT01597908|9879265|FG002|Randomized Phase|Lost to Follow-up|0
6212740|NCT01597908|9879263|FG000|Randomized Phase|Physician Decision|6
6212741|NCT01597908|9879264|FG001|Randomized Phase|Physician Decision|3
6212742|NCT01597908|9879265|FG002|Randomized Phase|Physician Decision|0
6212743|NCT01597908|9879263|FG000|Randomized Phase|Withdrawal by Subject|26
6212744|NCT01597908|9879264|FG001|Randomized Phase|Withdrawal by Subject|22
6212745|NCT01597908|9879265|FG002|Randomized Phase|Withdrawal by Subject|0
6212746|NCT01597908|9879263|FG000|Randomized Phase|Crossover to Dabrafenib&Trametinib|0
6212747|NCT01597908|9879264|FG001|Randomized Phase|Crossover to Dabrafenib&Trametinib|34
6212748|NCT01597908|9879265|FG002|Randomized Phase|Crossover to Dabrafenib&Trametinib|0
6287286|NCT02349295|9999708|FG002|Long-Term Extension Period (Week 24-156)|Unknown/Missing|0
6287287|NCT02349295|9999709|FG003|Long-Term Extension Period (Week 24-156)|Unknown/Missing|0
6287288|NCT02349295|9999710|FG004|Long-Term Extension Period (Week 24-156)|Unknown/Missing|0
6287289|NCT02349295|9999711|FG005|Long-Term Extension Period (Week 24-156)|Unknown/Missing|0
6287290|NCT02349295|9999712|FG006|Long-Term Extension Period (Week 24-156)|Unknown/Missing|0
6287291|NCT02349295|9999713|FG007|Long-Term Extension Period (Week 24-156)|Unknown/Missing|2
6287292|NCT02349295|9999714|FG008|Long-Term Extension Period (Week 24-156)|Unknown/Missing|0
6287293|NCT02349295|9999715|FG009|Long-Term Extension Period (Week 24-156)|Unknown/Missing|3
6287294|NCT02349295|9999716|FG010|Long-Term Extension Period (Week 24-156)|Unknown/Missing|0
6287295|NCT02349295|9999717|FG011|Long-Term Extension Period (Week 24-156)|Unknown/Missing|0
6287296|NCT02349295|9999718|FG012|Long-Term Extension Period (Week 24-156)|Unknown/Missing|0
6287297|NCT02349295|9999719|FG013|Long-Term Extension Period (Week 24-156)|Unknown/Missing|0
6287298|NCT02349295|9999706|FG000|Long-Term Extension Period (Week 24-156)|Death|0
6212749|NCT01597908|9879263|FG000|Crossover Phase|Death|0
6212750|NCT01597908|9879264|FG001|Crossover Phase|Death|0
6212751|NCT01597908|9879265|FG002|Crossover Phase|Death|11
6212752|NCT01597908|9879263|FG000|Crossover Phase|Withdrawal by Subject|0
6212753|NCT01597908|9879264|FG001|Crossover Phase|Withdrawal by Subject|0
6212754|NCT01597908|9879265|FG002|Crossover Phase|Withdrawal by Subject|3
6212755|NCT01597908|9879263|FG000|Crossover Phase|Sponsor Decision|0
6212756|NCT01597908|9879264|FG001|Crossover Phase|Sponsor Decision|0
6212757|NCT01597908|9879265|FG002|Crossover Phase|Sponsor Decision|20
6212758|NCT01597973|9879276|FG000|Overall Study|Found ineligible before study medication started|4
6212759|NCT01597973|9879277|FG001|Overall Study|Found ineligible before study medication started|2
6212760|NCT01597973|9879276|FG000|Overall Study|Eligible pathogen not confirmed|14
6212761|NCT01597973|9879277|FG001|Overall Study|Eligible pathogen not confirmed|15
6212762|NCT01597973|9879276|FG000|Overall Study|LAR not authorized to consent|0
6212763|NCT01597973|9879277|FG001|Overall Study|LAR not authorized to consent|1
6212764|NCT01597973|9879276|FG000|Overall Study|Ineligible due to early seizures|1
6212765|NCT01597973|9879277|FG001|Overall Study|Ineligible due to early seizures|0
6287299|NCT02349295|9999707|FG001|Long-Term Extension Period (Week 24-156)|Death|0
6212766|NCT01597973|9879276|FG000|Overall Study|Ineligible due to non-target infection|1
6212767|NCT01597973|9879277|FG001|Overall Study|Ineligible due to non-target infection|1
6212768|NCT01598090|9879299|FG000|Treatment Period|Poor/non-compliance|0
6212769|NCT01598090|9879300|FG001|Treatment Period|Poor/non-compliance|2
6212770|NCT01598090|9879301|FG002|Treatment Period|Poor/non-compliance|0
6212771|NCT01598090|9879299|FG000|Treatment Period|No longer meet study criteria|0
6119449|NCT00883688|9742281|FG000|Overall Study|Ineligible|2
6119450|NCT00883740|9742285|FG000|First Intervention|Lost to Follow-up|1
6119451|NCT00883740|9742286|FG001|First Intervention|Lost to Follow-up|0
6119452|NCT00883740|9742285|FG000|First Intervention|No longer willing to participate|2
6119453|NCT00883740|9742286|FG001|First Intervention|No longer willing to participate|0
6119454|NCT00883740|9742285|FG000|First Intervention|Protocol Violation|3
6119455|NCT00883740|9742286|FG001|First Intervention|Protocol Violation|6
6119456|NCT00883740|9742285|FG000|First Intervention|Adverse Event|1
6119457|NCT00883740|9742286|FG001|First Intervention|Adverse Event|2
6119458|NCT00883740|9742285|FG000|Second Intervention|Protocol Violation|1
6119459|NCT00883740|9742286|FG001|Second Intervention|Protocol Violation|0
6119460|NCT00883740|9742285|FG000|Second Intervention|No longer willing to participate|0
6119461|NCT00883740|9742286|FG001|Second Intervention|No longer willing to participate|1
6119462|NCT00883753|9742292|FG000|Overall Study|Adverse Event|37
6119463|NCT00883753|9742292|FG000|Overall Study|Death|2
6119464|NCT00883753|9742292|FG000|Overall Study|Insufficient therapeutic response|16
6119465|NCT00883753|9742292|FG000|Overall Study|Lost to Follow-up|4
6119466|NCT00883753|9742292|FG000|Overall Study|Violation of selection criteria at entry|7
6119467|NCT00883753|9742292|FG000|Overall Study|Protocol Violation|2
6119468|NCT00883753|9742292|FG000|Overall Study|Refused treatment|4
6119469|NCT00883753|9742292|FG000|Overall Study|Withdrew consent|10
6119470|NCT00883753|9742292|FG000|Overall Study|Investigator's decision|17
6119471|NCT00883753|9742292|FG000|Overall Study|Administrative/Other|8
6119472|NCT00883779|9742301|FG000|Primary Study Treatment Phase|Did not receive allocated intervention|4
6119473|NCT00883779|9742302|FG001|Primary Study Treatment Phase|Did not receive allocated intervention|4
6119474|NCT00883779|9742301|FG000|Primary Study Treatment Phase|Disease progression|75
6119475|NCT00883779|9742302|FG001|Primary Study Treatment Phase|Disease progression|59
6119476|NCT00883779|9742301|FG000|Primary Study Treatment Phase|Adverse Event|16
6119477|NCT00883779|9742302|FG001|Primary Study Treatment Phase|Adverse Event|16
6119478|NCT00883779|9742301|FG000|Primary Study Treatment Phase|Death|2
6119479|NCT00883779|9742302|FG001|Primary Study Treatment Phase|Death|3
6119480|NCT00883779|9742301|FG000|Primary Study Treatment Phase|Refused Treatment|5
6119481|NCT00883779|9742302|FG001|Primary Study Treatment Phase|Refused Treatment|4
6119482|NCT00883779|9742301|FG000|Primary Study Treatment Phase|Other|3
6119483|NCT00883779|9742302|FG001|Primary Study Treatment Phase|Other|0
6119484|NCT00883779|9742301|FG000|Post-Study Treatment Phase|Adverse Event|2
6119485|NCT00883779|9742302|FG001|Post-Study Treatment Phase|Adverse Event|3
6119486|NCT00883779|9742301|FG000|Post-Study Treatment Phase|Death|1
6119487|NCT00883779|9742302|FG001|Post-Study Treatment Phase|Death|3
6119488|NCT00883779|9742301|FG000|Post-Study Treatment Phase|Protocol Violation|0
6119489|NCT00883779|9742302|FG001|Post-Study Treatment Phase|Protocol Violation|1
6119490|NCT00883779|9742301|FG000|Post-Study Treatment Phase|Refused Treatment|3
6119491|NCT00883779|9742302|FG001|Post-Study Treatment Phase|Refused Treatment|0
6119492|NCT00883779|9742301|FG000|Post-Study Treatment Phase|Disease progression|103
6119493|NCT00883779|9742302|FG001|Post-Study Treatment Phase|Disease progression|122
6119494|NCT00883779|9742301|FG000|Post-Study Treatment Phase|Other|3
6119495|NCT00883779|9742302|FG001|Post-Study Treatment Phase|Other|0
6119496|NCT00883779|9742301|FG000|Post-Study Treatment Phase|Ongoing in the study|0
6119497|NCT00883779|9742302|FG001|Post-Study Treatment Phase|Ongoing in the study|6
6119498|NCT00883779|9742301|FG000|Off-study Phase|Death|185
6119499|NCT00883779|9742302|FG001|Off-study Phase|Death|174
6119500|NCT00883779|9742301|FG000|Off-study Phase|Refused treatment|1
6119501|NCT00883779|9742302|FG001|Off-study Phase|Refused treatment|1
6119502|NCT00883779|9742301|FG000|Off-study Phase|Failure to return|5
6119503|NCT00883779|9742302|FG001|Off-study Phase|Failure to return|6
6119504|NCT00883779|9742301|FG000|Off-study Phase|Other|18
6119505|NCT00883779|9742302|FG001|Off-study Phase|Other|21
6119506|NCT00884039|9742310|FG000|Overall Study|Withdrawal by Subject|0
6119507|NCT00884039|9742311|FG001|Overall Study|Withdrawal by Subject|1
6119508|NCT00884039|9742310|FG000|Overall Study|Lack of Efficacy|2
6119509|NCT00884039|9742311|FG001|Overall Study|Lack of Efficacy|0
6119510|NCT00884117|9742333|FG000|Overall Study|Adverse Event|2
6119511|NCT00884117|9742333|FG000|Overall Study|Withdrawal by Subject|89
6119512|NCT00884117|9742333|FG000|Overall Study|Death|3
6119513|NCT00884117|9742333|FG000|Overall Study|Lost to Follow-up|143
6119514|NCT00884117|9742333|FG000|Overall Study|Other|12
6119515|NCT00884221|9742352|FG000|Overall Study|Withdrawal by Subject|0
6119516|NCT00884221|9742353|FG001|Overall Study|Withdrawal by Subject|3
6119517|NCT00884221|9742352|FG000|Overall Study|Adverse Event|6
6119518|NCT00884221|9742353|FG001|Overall Study|Adverse Event|3
6119519|NCT00884221|9742352|FG000|Overall Study|Protocol Violation|16
6119520|NCT00884221|9742353|FG001|Overall Study|Protocol Violation|13
6119521|NCT00884221|9742352|FG000|Overall Study|Cancellation of Cycle and Other Reason|12
6119522|NCT00884221|9742353|FG001|Overall Study|Cancellation of Cycle and Other Reason|13
6212772|NCT01598090|9879300|FG001|Treatment Period|No longer meet study criteria|1
6212773|NCT01598090|9879301|FG002|Treatment Period|No longer meet study criteria|0
6119523|NCT00884273|9742363|FG000|Overall Study|Adverse Event|0
6119524|NCT00884273|9742364|FG001|Overall Study|Adverse Event|2
6119525|NCT00884273|9742363|FG000|Overall Study|Protocol Violation|1
6119526|NCT00884273|9742364|FG001|Overall Study|Protocol Violation|3
6119527|NCT00884273|9742363|FG000|Overall Study|Practical reasons|1
6119528|NCT00884273|9742364|FG001|Overall Study|Practical reasons|0
6119529|NCT00884286|9742372|FG000|Overall Study|Progressive disease|21
6119530|NCT00884286|9742373|FG001|Overall Study|Progressive disease|28
6119531|NCT00884286|9742372|FG000|Overall Study|Toxicity|4
6119532|NCT00884286|9742373|FG001|Overall Study|Toxicity|1
6119533|NCT00884286|9742372|FG000|Overall Study|Death|2
6119534|NCT00884286|9742373|FG001|Overall Study|Death|2
6119535|NCT00884286|9742372|FG000|Overall Study|Physician Decision|1
6119536|NCT00884286|9742373|FG001|Overall Study|Physician Decision|0
6119537|NCT00884286|9742372|FG000|Overall Study|Septic shock|1
6119538|NCT00884286|9742373|FG001|Overall Study|Septic shock|0
6119539|NCT00884286|9742372|FG000|Overall Study|Thrombus in right auricle|1
6119540|NCT00884286|9742373|FG001|Overall Study|Thrombus in right auricle|0
6119541|NCT00884286|9742372|FG000|Overall Study|Not treated|2
6119542|NCT00884286|9742373|FG001|Overall Study|Not treated|1
6119543|NCT00884286|9742372|FG000|Overall Study|Comprised lung carcinoma|0
6119544|NCT00884286|9742373|FG001|Overall Study|Comprised lung carcinoma|1
6119545|NCT00884312|9742382|FG000|Overall Study|Non-fatal Progressive Disease|0
6119546|NCT00884312|9742383|FG001|Overall Study|Non-fatal Progressive Disease|8
6119547|NCT00884312|9742382|FG000|Overall Study|Fatal Progressive Disease|0
6119548|NCT00884312|9742383|FG001|Overall Study|Fatal Progressive Disease|1
6119549|NCT00884312|9742382|FG000|Overall Study|Non-fatal Adverse Event|1
6119550|NCT00884312|9742383|FG001|Overall Study|Non-fatal Adverse Event|0
6119551|NCT00884312|9742382|FG000|Overall Study|Fatal Adverse Event|1
6119552|NCT00884312|9742383|FG001|Overall Study|Fatal Adverse Event|4
6119553|NCT00884312|9742382|FG000|Overall Study|Withdrawal by Subject|0
6119554|NCT00884312|9742383|FG001|Overall Study|Withdrawal by Subject|6
6119555|NCT00884312|9742382|FG000|Overall Study|Physician Decision|0
6119556|NCT00884312|9742383|FG001|Overall Study|Physician Decision|1
6119557|NCT00884312|9742382|FG000|Overall Study|Other|0
6119558|NCT00884312|9742383|FG001|Overall Study|Other|4
6119559|NCT00884312|9742382|FG000|Overall Study|Did Not Receive Study Drug|0
6119560|NCT00884312|9742383|FG001|Overall Study|Did Not Receive Study Drug|1
6119561|NCT00884325|9742391|FG000|Overall Study|Lost to Follow-up|1
6119562|NCT00884325|9742392|FG001|Overall Study|Lost to Follow-up|2
6119563|NCT00884325|9742391|FG000|Overall Study|Lack of Efficacy|0
6119564|NCT00884325|9742392|FG001|Overall Study|Lack of Efficacy|1
6119565|NCT00884325|9742391|FG000|Overall Study|Withdrawal by Subject|1
6119566|NCT00884325|9742392|FG001|Overall Study|Withdrawal by Subject|1
6119567|NCT00884325|9742391|FG000|Overall Study|Not provided|1
6212774|NCT01598090|9879299|FG000|Treatment Period|Lack of Efficacy|5
6212775|NCT01598090|9879300|FG001|Treatment Period|Lack of Efficacy|14
6212776|NCT01598090|9879301|FG002|Treatment Period|Lack of Efficacy|6
6212777|NCT01598090|9879299|FG000|Treatment Period|Adverse Event|2
6212778|NCT01598090|9879300|FG001|Treatment Period|Adverse Event|33
6212779|NCT01598090|9879301|FG002|Treatment Period|Adverse Event|17
6212780|NCT01598090|9879299|FG000|Treatment Period|Other reasons|0
6212781|NCT01598090|9879300|FG001|Treatment Period|Other reasons|4
6212782|NCT01598090|9879301|FG002|Treatment Period|Other reasons|1
6212783|NCT01598090|9879299|FG000|Treatment Period|Withdrawal by Subject|3
6212784|NCT01598090|9879300|FG001|Treatment Period|Withdrawal by Subject|13
6212785|NCT01598090|9879301|FG002|Treatment Period|Withdrawal by Subject|10
6212786|NCT01598090|9879299|FG000|Treatment Period|Lost to Follow-up|1
6212787|NCT01598090|9879300|FG001|Treatment Period|Lost to Follow-up|5
6212788|NCT01598090|9879301|FG002|Treatment Period|Lost to Follow-up|1
6212789|NCT01598090|9879299|FG000|Follow-up Period|Death|0
6212790|NCT01598090|9879300|FG001|Follow-up Period|Death|1
6212791|NCT01598090|9879301|FG002|Follow-up Period|Death|0
6212792|NCT01598090|9879299|FG000|Follow-up Period|No longer required per protocol|1
6212793|NCT01598090|9879300|FG001|Follow-up Period|No longer required per protocol|3
6212794|NCT01598090|9879301|FG002|Follow-up Period|No longer required per protocol|2
6212795|NCT01598090|9879299|FG000|Follow-up Period|Not reported|0
6212796|NCT01598090|9879300|FG001|Follow-up Period|Not reported|10
6212797|NCT01598090|9879301|FG002|Follow-up Period|Not reported|4
6212798|NCT01598090|9879299|FG000|Follow-up Period|Withdrawal by Subject|0
6212799|NCT01598090|9879300|FG001|Follow-up Period|Withdrawal by Subject|3
6212800|NCT01598090|9879301|FG002|Follow-up Period|Withdrawal by Subject|2
6212801|NCT01598090|9879299|FG000|Follow-up Period|Other reasons|2
6212802|NCT01598090|9879300|FG001|Follow-up Period|Other reasons|8
6212803|NCT01598090|9879301|FG002|Follow-up Period|Other reasons|8
6212804|NCT01598090|9879299|FG000|Follow-up Period|Lost to Follow-up|2
6212805|NCT01598090|9879300|FG001|Follow-up Period|Lost to Follow-up|10
6212806|NCT01598090|9879301|FG002|Follow-up Period|Lost to Follow-up|12
6212807|NCT01598129|9879312|FG000|Overall Study|Disease progression|6
6212808|NCT01598129|9879312|FG000|Overall Study|Deterioration of WHO status to WHO 4|2
6212809|NCT01598129|9879312|FG000|Overall Study|Withdrawal by Subject|1
6212810|NCT01598298|9879341|FG000|Overall Study|Not eligible|5
6212811|NCT01598298|9879342|FG001|Overall Study|Not eligible|5
6212812|NCT01598298|9879341|FG000|Overall Study|Adverse Event|21
6212813|NCT01598298|9879342|FG001|Overall Study|Adverse Event|19
6212814|NCT01598298|9879341|FG000|Overall Study|Progression/relapse|0
6212815|NCT01598298|9879342|FG001|Overall Study|Progression/relapse|2
6119568|NCT00884325|9742392|FG001|Overall Study|Not provided|0
6212816|NCT01598298|9879341|FG000|Overall Study|Withdrawal by Subject|10
6212817|NCT01598298|9879342|FG001|Overall Study|Withdrawal by Subject|15
6119569|NCT00884377|9742400|FG000|Overall Study|Withdrawal by Subject|1
6119570|NCT00884377|9742401|FG001|Overall Study|Withdrawal by Subject|0
6119571|NCT00884377|9742400|FG000|Overall Study|Could not confirm diagnosis|1
6119572|NCT00884377|9742401|FG001|Overall Study|Could not confirm diagnosis|0
6119573|NCT00884377|9742400|FG000|Overall Study|Physician Decision|0
6119574|NCT00884377|9742401|FG001|Overall Study|Physician Decision|1
6119575|NCT00884390|9742415|FG000|Overall Study|Adverse Event|0
6119576|NCT00884390|9742416|FG001|Overall Study|Adverse Event|1
6119577|NCT00884390|9742415|FG000|Overall Study|Lost to Follow-up|0
6119578|NCT00884390|9742416|FG001|Overall Study|Lost to Follow-up|1
6119579|NCT00884390|9742415|FG000|Overall Study|Physician Decision|2
6119580|NCT00884390|9742416|FG001|Overall Study|Physician Decision|1
6119581|NCT00884390|9742415|FG000|Overall Study|Protocol Violation|4
6119582|NCT00884390|9742416|FG001|Overall Study|Protocol Violation|1
6119583|NCT00884390|9742415|FG000|Overall Study|Withdrawal by Subject|4
6119584|NCT00884390|9742416|FG001|Overall Study|Withdrawal by Subject|1
6119585|NCT00884390|9742415|FG000|Overall Study|Discontinuation of Study by Sponsor|2
6119586|NCT00884390|9742416|FG001|Overall Study|Discontinuation of Study by Sponsor|2
6119587|NCT00884390|9742415|FG000|Overall Study|Other|11
6119588|NCT00884390|9742416|FG001|Overall Study|Other|1
6119589|NCT00884650|9742451|FG000|Overall Study|Did not return complete pain diaries|7
6119590|NCT00884650|9742452|FG001|Overall Study|Did not return complete pain diaries|7
6119591|NCT00884650|9742451|FG000|Overall Study|Admitted Post-Op|1
6119592|NCT00884650|9742452|FG001|Overall Study|Admitted Post-Op|0
6119593|NCT00884650|9742451|FG000|Overall Study|Femoral Stress Fracture|1
6119594|NCT00884650|9742452|FG001|Overall Study|Femoral Stress Fracture|0
6119595|NCT00884650|9742451|FG000|Overall Study|Pain Pump Complication|0
6119596|NCT00884650|9742452|FG001|Overall Study|Pain Pump Complication|1
6119597|NCT00884741|9742462|FG000|Step 1 Registration: Tissue Screening|Protocol Violation|157
6119598|NCT00884741|9742463|FG001|Step 1 Registration: Tissue Screening|Protocol Violation|0
6119599|NCT00884741|9742464|FG002|Step 1 Registration: Tissue Screening|Protocol Violation|0
6119600|NCT00884741|9742465|FG003|Step 1 Registration: Tissue Screening|Protocol Violation|0
6119601|NCT00884741|9742462|FG000|Step 1 Registration: Tissue Screening|Death|3
6119602|NCT00884741|9742463|FG001|Step 1 Registration: Tissue Screening|Death|0
6212818|NCT01598298|9879341|FG000|Overall Study|Other reason (not protocol specified)|4
6212819|NCT01598298|9879342|FG001|Overall Study|Other reason (not protocol specified)|0
6212820|NCT01598311|9879350|FG000|Overall Study|Physician Decision|4
6212821|NCT01598311|9879351|FG001|Overall Study|Physician Decision|5
6212822|NCT01598311|9879350|FG000|Overall Study|Adverse Event|9
6212823|NCT01598311|9879351|FG001|Overall Study|Adverse Event|13
6212824|NCT01598311|9879350|FG000|Overall Study|Lost to Follow-up|7
6212825|NCT01598311|9879351|FG001|Overall Study|Lost to Follow-up|12
6212826|NCT01598311|9879350|FG000|Overall Study|Withdrawal by Subject|9
6212827|NCT01598311|9879351|FG001|Overall Study|Withdrawal by Subject|13
6212828|NCT01598311|9879350|FG000|Overall Study|No reason provided.|0
6212829|NCT01598311|9879351|FG001|Overall Study|No reason provided.|5
6212830|NCT01598311|9879350|FG000|Overall Study|Randomized but never treated|8
6212831|NCT01598311|9879351|FG001|Overall Study|Randomized but never treated|5
6212832|NCT01598311|9879350|FG000|Overall Study|Treated but no confirmed CDAD|9
6212833|NCT01598311|9879351|FG001|Overall Study|Treated but no confirmed CDAD|8
6212834|NCT01598311|9879350|FG000|Overall Study|Assigned to CB but received vancomycin|1
6212835|NCT01598311|9879351|FG001|Overall Study|Assigned to CB but received vancomycin|0
6212836|NCT01598506|9879366|FG000|Overall Study|Withdrawal by Subject|2
6212837|NCT01598532|9879371|FG000|Overall Study|Lost to Follow-up|3
6212838|NCT01598532|9879371|FG000|Overall Study|Did not meet inclusion criteria|8
6212839|NCT01598610|9879382|FG000|Overall Study|Adverse Event|1
6212840|NCT01598662|9879388|FG000|Overall Study|Lost to Follow-up|10
6212841|NCT01598662|9879389|FG001|Overall Study|Lost to Follow-up|17
6212842|NCT01598662|9879388|FG000|Overall Study|Physician Decision|1
6212843|NCT01598662|9879389|FG001|Overall Study|Physician Decision|2
6212844|NCT01598662|9879388|FG000|Overall Study|IUD expelled before month 6|0
6212845|NCT01598662|9879389|FG001|Overall Study|IUD expelled before month 6|2
6212846|NCT01598753|9879418|FG000|Overall Study|Adverse Event|1
6212847|NCT01598753|9879419|FG001|Overall Study|Adverse Event|9
6212848|NCT01598753|9879420|FG002|Overall Study|Adverse Event|1
6212849|NCT01598753|9879421|FG003|Overall Study|Adverse Event|7
6212850|NCT01598753|9879418|FG000|Overall Study|Lost to Follow-up|4
6212851|NCT01598753|9879419|FG001|Overall Study|Lost to Follow-up|3
6212852|NCT01598753|9879420|FG002|Overall Study|Lost to Follow-up|7
6212853|NCT01598753|9879421|FG003|Overall Study|Lost to Follow-up|5
6212854|NCT01598753|9879418|FG000|Overall Study|Physician Decision|0
6212855|NCT01598753|9879419|FG001|Overall Study|Physician Decision|1
6212856|NCT01598753|9879420|FG002|Overall Study|Physician Decision|0
6212857|NCT01598753|9879421|FG003|Overall Study|Physician Decision|2
6212858|NCT01598753|9879418|FG000|Overall Study|Withdrawal by Subject|7
6212859|NCT01598753|9879419|FG001|Overall Study|Withdrawal by Subject|2
6212860|NCT01598753|9879420|FG002|Overall Study|Withdrawal by Subject|0
6212861|NCT01598753|9879421|FG003|Overall Study|Withdrawal by Subject|1
6212862|NCT01598896|9879446|FG000|Overall Study|Withdrawal by Subject|0
6212863|NCT01598896|9879447|FG001|Overall Study|Withdrawal by Subject|1
6212864|NCT01598896|9879446|FG000|Overall Study|Lack of Efficacy|0
6212865|NCT01598896|9879447|FG001|Overall Study|Lack of Efficacy|1
6119603|NCT00884741|9742464|FG002|Step 1 Registration: Tissue Screening|Death|0
6119604|NCT00884741|9742465|FG003|Step 1 Registration: Tissue Screening|Death|0
6119605|NCT00884741|9742462|FG000|Step 1 Registration: Tissue Screening|Physician Decision|3
6119606|NCT00884741|9742463|FG001|Step 1 Registration: Tissue Screening|Physician Decision|0
6119607|NCT00884741|9742464|FG002|Step 1 Registration: Tissue Screening|Physician Decision|0
6119608|NCT00884741|9742465|FG003|Step 1 Registration: Tissue Screening|Physician Decision|0
6119609|NCT00884741|9742462|FG000|Step 1 Registration: Tissue Screening|Insufficient tissue|105
6119610|NCT00884741|9742463|FG001|Step 1 Registration: Tissue Screening|Insufficient tissue|0
6119611|NCT00884741|9742464|FG002|Step 1 Registration: Tissue Screening|Insufficient tissue|0
6119612|NCT00884741|9742465|FG003|Step 1 Registration: Tissue Screening|Insufficient tissue|0
6119613|NCT00884741|9742462|FG000|Step 1 Registration: Tissue Screening|Disease progression|12
6119614|NCT00884741|9742463|FG001|Step 1 Registration: Tissue Screening|Disease progression|0
6119615|NCT00884741|9742464|FG002|Step 1 Registration: Tissue Screening|Disease progression|0
6119616|NCT00884741|9742465|FG003|Step 1 Registration: Tissue Screening|Disease progression|0
6119617|NCT00884741|9742462|FG000|Step 1 Registration: Tissue Screening|Patient refusal|32
6119618|NCT00884741|9742463|FG001|Step 1 Registration: Tissue Screening|Patient refusal|0
6119619|NCT00884741|9742464|FG002|Step 1 Registration: Tissue Screening|Patient refusal|0
6119620|NCT00884741|9742465|FG003|Step 1 Registration: Tissue Screening|Patient refusal|0
6119621|NCT00884741|9742462|FG000|Step 2 Registration: Tissue Analysis|Protocol Violation|0
6119622|NCT00884741|9742463|FG001|Step 2 Registration: Tissue Analysis|Protocol Violation|15
6119623|NCT00884741|9742464|FG002|Step 2 Registration: Tissue Analysis|Protocol Violation|0
6119624|NCT00884741|9742465|FG003|Step 2 Registration: Tissue Analysis|Protocol Violation|0
6119625|NCT00884741|9742462|FG000|Step 2 Registration: Tissue Analysis|Death|0
6119626|NCT00884741|9742463|FG001|Step 2 Registration: Tissue Analysis|Death|1
6119627|NCT00884741|9742464|FG002|Step 2 Registration: Tissue Analysis|Death|0
6119628|NCT00884741|9742465|FG003|Step 2 Registration: Tissue Analysis|Death|0
6119629|NCT00884741|9742462|FG000|Step 2 Registration: Tissue Analysis|Adverse Event|0
6119630|NCT00884741|9742463|FG001|Step 2 Registration: Tissue Analysis|Adverse Event|2
6119631|NCT00884741|9742464|FG002|Step 2 Registration: Tissue Analysis|Adverse Event|0
6119632|NCT00884741|9742465|FG003|Step 2 Registration: Tissue Analysis|Adverse Event|0
6119633|NCT00884741|9742462|FG000|Step 2 Registration: Tissue Analysis|Patient refusal|0
6119634|NCT00884741|9742463|FG001|Step 2 Registration: Tissue Analysis|Patient refusal|7
6119635|NCT00884741|9742464|FG002|Step 2 Registration: Tissue Analysis|Patient refusal|0
6119636|NCT00884741|9742465|FG003|Step 2 Registration: Tissue Analysis|Patient refusal|0
6119637|NCT00884741|9742462|FG000|Step 2 Registration: Tissue Analysis|Disease Progression|0
6119638|NCT00884741|9742463|FG001|Step 2 Registration: Tissue Analysis|Disease Progression|4
6119639|NCT00884741|9742464|FG002|Step 2 Registration: Tissue Analysis|Disease Progression|0
6119640|NCT00884741|9742465|FG003|Step 2 Registration: Tissue Analysis|Disease Progression|0
6119641|NCT00884741|9742462|FG000|Randomization|Protocol Violation|0
6119642|NCT00884741|9742463|FG001|Randomization|Protocol Violation|0
6119643|NCT00884741|9742464|FG002|Randomization|Protocol Violation|8
6119644|NCT00884741|9742465|FG003|Randomization|Protocol Violation|8
6119645|NCT00884793|9742481|FG000|Overall Study|Withdrawal by Subject|1
6119646|NCT00884832|9742491|FG000|Overall Study|Withdrawal by Subject|0
6119647|NCT00884832|9742492|FG001|Overall Study|Withdrawal by Subject|1
6119648|NCT00884949|9742511|FG000|Weeks 1-12: 0.1 mg/kg/Week|Adverse Event|1
6119649|NCT00884949|9742511|FG000|Weeks 1-12: 0.1 mg/kg/Week|Withdrawal by Subject|1
6119650|NCT00885105|9742544|FG000|Overall Study|Withdrawal by Subject|0
6119651|NCT00885105|9742545|FG001|Overall Study|Withdrawal by Subject|8
6119652|NCT00885105|9742544|FG000|Overall Study|Adverse Event|1
6119653|NCT00885105|9742545|FG001|Overall Study|Adverse Event|0
6119654|NCT00885105|9742544|FG000|Overall Study|Protocol Violation|0
6119655|NCT00885105|9742545|FG001|Overall Study|Protocol Violation|2
6119656|NCT00885118|9742556|FG000|Overall Study|Adverse Event|1
6119657|NCT00885118|9742557|FG001|Overall Study|Adverse Event|0
6119658|NCT00885118|9742558|FG002|Overall Study|Adverse Event|0
6119659|NCT00885118|9742559|FG003|Overall Study|Adverse Event|0
6119660|NCT00885118|9742560|FG004|Overall Study|Adverse Event|0
6119661|NCT00885118|9742556|FG000|Overall Study|Withdrawal by Subject|0
6119662|NCT00885118|9742557|FG001|Overall Study|Withdrawal by Subject|0
6119663|NCT00885118|9742558|FG002|Overall Study|Withdrawal by Subject|0
6119664|NCT00885118|9742559|FG003|Overall Study|Withdrawal by Subject|0
6119665|NCT00885118|9742560|FG004|Overall Study|Withdrawal by Subject|1
6119666|NCT00885118|9742556|FG000|Overall Study|Other reason not defined above|0
6119667|NCT00885118|9742557|FG001|Overall Study|Other reason not defined above|0
6119668|NCT00885118|9742558|FG002|Overall Study|Other reason not defined above|1
6119669|NCT00885118|9742559|FG003|Overall Study|Other reason not defined above|0
6119670|NCT00885118|9742560|FG004|Overall Study|Other reason not defined above|0
6119671|NCT00885170|9742578|FG000|Overall Study|Adverse Event|12
6119672|NCT00885170|9742579|FG001|Overall Study|Adverse Event|4
6119673|NCT00885170|9742578|FG000|Overall Study|Excessive bone loss|6
6119674|NCT00885170|9742579|FG001|Overall Study|Excessive bone loss|3
6119675|NCT00885170|9742578|FG000|Overall Study|Lost to Follow-up|2
6119676|NCT00885170|9742579|FG001|Overall Study|Lost to Follow-up|1
6119677|NCT00885170|9742578|FG000|Overall Study|Physician Decision|2
6119678|NCT00885170|9742579|FG001|Overall Study|Physician Decision|1
6119679|NCT00885170|9742578|FG000|Overall Study|Protocol Violation|3
6119680|NCT00885170|9742579|FG001|Overall Study|Protocol Violation|1
6119681|NCT00885170|9742578|FG000|Overall Study|Withdrawal by Subject|13
6119682|NCT00885170|9742579|FG001|Overall Study|Withdrawal by Subject|13
6119683|NCT00885352|9742587|FG000|Overall Study|Adverse Event|2
6119684|NCT00885352|9742588|FG001|Overall Study|Adverse Event|3
6119685|NCT00885352|9742587|FG000|Overall Study|Lost to Follow-up|2
6119686|NCT00885352|9742588|FG001|Overall Study|Lost to Follow-up|2
6119687|NCT00885352|9742587|FG000|Overall Study|Physician Decision|0
6119688|NCT00885352|9742588|FG001|Overall Study|Physician Decision|3
6119689|NCT00885352|9742587|FG000|Overall Study|Protocol Violation|0
6119690|NCT00885352|9742588|FG001|Overall Study|Protocol Violation|2
6119691|NCT00885352|9742587|FG000|Overall Study|Withdrawal by Subject|1
6119692|NCT00885352|9742588|FG001|Overall Study|Withdrawal by Subject|5
6119693|NCT00885352|9742587|FG000|Overall Study|Contradiction to study medication|0
6119694|NCT00885352|9742588|FG001|Overall Study|Contradiction to study medication|2
6119695|NCT00885352|9742587|FG000|Overall Study|Excluded medication|2
6119696|NCT00885352|9742588|FG001|Overall Study|Excluded medication|2
6119697|NCT00885352|9742587|FG000|Overall Study|Lab abnormalities|1
6119698|NCT00885352|9742588|FG001|Overall Study|Lab abnormalities|1
6119699|NCT00885365|9742596|FG000|4 Weeks ON Treatment|Adverse Event|2
6119700|NCT00885365|9742597|FG001|4 Weeks ON Treatment|Adverse Event|4
6119701|NCT00885365|9742596|FG000|4 Weeks ON Treatment|Protocol Violation|1
6119702|NCT00885365|9742597|FG001|4 Weeks ON Treatment|Protocol Violation|2
6119703|NCT00885365|9742596|FG000|4 Weeks ON Treatment|Withdrawal by Subject|1
6119704|NCT00885365|9742597|FG001|4 Weeks ON Treatment|Withdrawal by Subject|0
6119705|NCT00885378|9742605|FG000|Overall Study|Lack of Efficacy|2
6119706|NCT00885378|9742606|FG001|Overall Study|Lack of Efficacy|2
6119707|NCT00885378|9742605|FG000|Overall Study|Withdrawal by Subject|1
6119708|NCT00885378|9742606|FG001|Overall Study|Withdrawal by Subject|2
6212866|NCT01598987|9879462|FG000|Baseline to Month 12|Administrative problems|2
6212867|NCT01598987|9879462|FG000|Baseline to Month 12|Withdrawal by Subject|4
6212868|NCT01598987|9879462|FG000|Baseline to 24 Month|Withdrawal by Subject|5
6212869|NCT01598987|9879462|FG000|Baseline to 24 Month|Administrative problems|2
6212870|NCT01598987|9879462|FG000|Baseline to 24 Month|Lost to Follow-up|1
6212871|NCT01599104|9879476|FG000|Overall Study|Withdrawal by Subject|1
6212872|NCT01599104|9879477|FG001|Overall Study|Withdrawal by Subject|1
6212873|NCT01599104|9879478|FG002|Overall Study|Withdrawal by Subject|2
6212874|NCT01599104|9879476|FG000|Overall Study|Technical Problems|1
6212875|NCT01599104|9879477|FG001|Overall Study|Technical Problems|0
6212876|NCT01599104|9879478|FG002|Overall Study|Technical Problems|0
6212877|NCT01599104|9879476|FG000|Overall Study|Physician Decision|3
6212878|NCT01599104|9879477|FG001|Overall Study|Physician Decision|2
6212879|NCT01599104|9879478|FG002|Overall Study|Physician Decision|2
6212880|NCT01599104|9879476|FG000|Overall Study|Non-compliance with study treatment|0
6212881|NCT01599104|9879477|FG001|Overall Study|Non-compliance with study treatment|1
6212882|NCT01599104|9879478|FG002|Overall Study|Non-compliance with study treatment|0
6212883|NCT01599104|9879476|FG000|Overall Study|Lack of Efficacy|4
6212884|NCT01599104|9879477|FG001|Overall Study|Lack of Efficacy|4
6212885|NCT01599104|9879478|FG002|Overall Study|Lack of Efficacy|10
6212886|NCT01599104|9879476|FG000|Overall Study|Adverse Event|7
6119709|NCT00885378|9742605|FG000|Overall Study|Lost to Follow-up|1
6119710|NCT00885378|9742606|FG001|Overall Study|Lost to Follow-up|2
6119711|NCT00885378|9742605|FG000|Overall Study|Poor/Noncompliance|2
6119712|NCT00885378|9742606|FG001|Overall Study|Poor/Noncompliance|2
6119713|NCT00885378|9742605|FG000|Overall Study|Protocol Violation|2
6119714|NCT00885378|9742606|FG001|Overall Study|Protocol Violation|0
6119715|NCT00885482|9742612|FG000|Overall Study|Pregnancy|1
6119716|NCT00885482|9742612|FG000|Overall Study|Lack of Efficacy|1
6119717|NCT00885482|9742612|FG000|Overall Study|Death|1
6119718|NCT00885482|9742612|FG000|Overall Study|low Therapeutic drug monitoring (TDM)|1
6119719|NCT00885534|9742616|FG000|Overall Study|Patient deemed ineligible|1
6119720|NCT00885677|9742630|FG000|Overall Study|Death|40
6119721|NCT00885677|9742631|FG001|Overall Study|Death|34
6119722|NCT00885677|9742630|FG000|Overall Study|Lost to Follow-up|15
6119723|NCT00885677|9742631|FG001|Overall Study|Lost to Follow-up|13
6119724|NCT00885677|9742630|FG000|Overall Study|Protocol Violation|54
6119725|NCT00885677|9742631|FG001|Overall Study|Protocol Violation|54
6119726|NCT00885677|9742630|FG000|Overall Study|premature study closure|41
6119727|NCT00885677|9742631|FG001|Overall Study|premature study closure|44
6119728|NCT00885677|9742630|FG000|Overall Study|device/lead revision or replacement|7
6119729|NCT00885677|9742631|FG001|Overall Study|device/lead revision or replacement|6
6119730|NCT00885677|9742630|FG000|Overall Study|Heart transplantation|1
6119731|NCT00885677|9742631|FG001|Overall Study|Heart transplantation|0
6119732|NCT00885677|9742630|FG000|Overall Study|Inclusion/exclusion not met|25
6119733|NCT00885677|9742631|FG001|Overall Study|Inclusion/exclusion not met|27
6119734|NCT00885703|9742644|FG000|Overall Study|Death|9
6119735|NCT00885703|9742645|FG001|Overall Study|Death|7
6119736|NCT00885703|9742646|FG002|Overall Study|Death|8
6119737|NCT00885703|9742647|FG003|Overall Study|Death|7
6212887|NCT01599104|9879477|FG001|Overall Study|Adverse Event|6
6119738|NCT00885703|9742648|FG004|Overall Study|Death|7
6119739|NCT00885703|9742649|FG005|Overall Study|Death|8
6119740|NCT00885703|9742650|FG006|Overall Study|Death|4
6119741|NCT00885703|9742644|FG000|Overall Study|Lost to Follow-up|0
6119742|NCT00885703|9742645|FG001|Overall Study|Lost to Follow-up|0
6119743|NCT00885703|9742646|FG002|Overall Study|Lost to Follow-up|1
6119744|NCT00885703|9742647|FG003|Overall Study|Lost to Follow-up|0
6119745|NCT00885703|9742648|FG004|Overall Study|Lost to Follow-up|0
6119746|NCT00885703|9742649|FG005|Overall Study|Lost to Follow-up|1
6119747|NCT00885703|9742650|FG006|Overall Study|Lost to Follow-up|0
6119748|NCT00885703|9742644|FG000|Overall Study|Withdrawal by Subject|0
6119749|NCT00885703|9742645|FG001|Overall Study|Withdrawal by Subject|0
6212888|NCT01599104|9879478|FG002|Overall Study|Adverse Event|12
6212889|NCT01599234|9879488|FG000|Overall Study|Adverse Event|9
6212890|NCT01599234|9879489|FG001|Overall Study|Adverse Event|5
6212891|NCT01599234|9879488|FG000|Overall Study|Withdrawal by Subject|2
6212892|NCT01599234|9879489|FG001|Overall Study|Withdrawal by Subject|1
6212893|NCT01599234|9879488|FG000|Overall Study|Lost to Follow-up|1
6212894|NCT01599234|9879489|FG001|Overall Study|Lost to Follow-up|2
6212895|NCT01599234|9879488|FG000|Overall Study|Lack of Efficacy|2
6212896|NCT01599234|9879489|FG001|Overall Study|Lack of Efficacy|4
6212897|NCT01599234|9879488|FG000|Overall Study|Unable to operate spray|1
6212898|NCT01599234|9879489|FG001|Overall Study|Unable to operate spray|0
6212899|NCT01599234|9879488|FG000|Overall Study|Sponsor request as creatinine levels <50|0
6212900|NCT01599234|9879489|FG001|Overall Study|Sponsor request as creatinine levels <50|1
6212901|NCT01599234|9879488|FG000|Overall Study|Death|1
6212902|NCT01599234|9879489|FG001|Overall Study|Death|0
6212903|NCT01599234|9879488|FG000|Overall Study|Patient would not stop driving|1
6212904|NCT01599234|9879489|FG001|Overall Study|Patient would not stop driving|0
6212905|NCT01599234|9879488|FG000|Overall Study|Contra-indication discovered|0
6212906|NCT01599234|9879489|FG001|Overall Study|Contra-indication discovered|1
6212907|NCT01599234|9879488|FG000|Overall Study|Pregnancy|0
6212908|NCT01599234|9879489|FG001|Overall Study|Pregnancy|1
6212909|NCT01599325|9879504|FG000|Primary Parent Phase|Adverse Event|5
6212910|NCT01599325|9879504|FG000|Primary Parent Phase|Disease Progression|7
6212911|NCT01599325|9879504|FG000|Primary Parent Phase|Withdrawal by Subject|20
6212912|NCT01599325|9879504|FG000|Primary Parent Phase|Death|13
6287300|NCT02349295|9999708|FG002|Long-Term Extension Period (Week 24-156)|Death|0
6287301|NCT02349295|9999709|FG003|Long-Term Extension Period (Week 24-156)|Death|0
6287302|NCT02349295|9999710|FG004|Long-Term Extension Period (Week 24-156)|Death|0
6287303|NCT02349295|9999711|FG005|Long-Term Extension Period (Week 24-156)|Death|0
6287304|NCT02349295|9999712|FG006|Long-Term Extension Period (Week 24-156)|Death|0
6287305|NCT02349295|9999713|FG007|Long-Term Extension Period (Week 24-156)|Death|1
6287306|NCT02349295|9999714|FG008|Long-Term Extension Period (Week 24-156)|Death|1
6287307|NCT02349295|9999715|FG009|Long-Term Extension Period (Week 24-156)|Death|1
6287308|NCT02349295|9999716|FG010|Long-Term Extension Period (Week 24-156)|Death|0
6287309|NCT02349295|9999717|FG011|Long-Term Extension Period (Week 24-156)|Death|0
6287310|NCT02349295|9999718|FG012|Long-Term Extension Period (Week 24-156)|Death|0
6287311|NCT02349295|9999719|FG013|Long-Term Extension Period (Week 24-156)|Death|0
6287312|NCT02349295|9999706|FG000|Long-Term Extension Period (Week 24-156)|Withdrawal by Subject|0
6287313|NCT02349295|9999707|FG001|Long-Term Extension Period (Week 24-156)|Withdrawal by Subject|0
6287314|NCT02349295|9999708|FG002|Long-Term Extension Period (Week 24-156)|Withdrawal by Subject|0
6287315|NCT02349295|9999709|FG003|Long-Term Extension Period (Week 24-156)|Withdrawal by Subject|0
6287316|NCT02349295|9999710|FG004|Long-Term Extension Period (Week 24-156)|Withdrawal by Subject|0
6287317|NCT02349295|9999711|FG005|Long-Term Extension Period (Week 24-156)|Withdrawal by Subject|0
6287318|NCT02349295|9999712|FG006|Long-Term Extension Period (Week 24-156)|Withdrawal by Subject|0
6287319|NCT02349295|9999713|FG007|Long-Term Extension Period (Week 24-156)|Withdrawal by Subject|4
6287320|NCT02349295|9999714|FG008|Long-Term Extension Period (Week 24-156)|Withdrawal by Subject|2
6287321|NCT02349295|9999715|FG009|Long-Term Extension Period (Week 24-156)|Withdrawal by Subject|1
6287322|NCT02349295|9999716|FG010|Long-Term Extension Period (Week 24-156)|Withdrawal by Subject|3
6287323|NCT02349295|9999717|FG011|Long-Term Extension Period (Week 24-156)|Withdrawal by Subject|0
6287324|NCT02349295|9999718|FG012|Long-Term Extension Period (Week 24-156)|Withdrawal by Subject|0
6287325|NCT02349295|9999719|FG013|Long-Term Extension Period (Week 24-156)|Withdrawal by Subject|0
6287326|NCT02349295|9999706|FG000|Long-Term Extension Period (Week 24-156)|Lost to Follow-up|0
6287327|NCT02349295|9999707|FG001|Long-Term Extension Period (Week 24-156)|Lost to Follow-up|0
6287328|NCT02349295|9999708|FG002|Long-Term Extension Period (Week 24-156)|Lost to Follow-up|0
6287329|NCT02349295|9999709|FG003|Long-Term Extension Period (Week 24-156)|Lost to Follow-up|0
6287330|NCT02349295|9999710|FG004|Long-Term Extension Period (Week 24-156)|Lost to Follow-up|0
6287331|NCT02349295|9999711|FG005|Long-Term Extension Period (Week 24-156)|Lost to Follow-up|0
6287332|NCT02349295|9999712|FG006|Long-Term Extension Period (Week 24-156)|Lost to Follow-up|0
6287333|NCT02349295|9999713|FG007|Long-Term Extension Period (Week 24-156)|Lost to Follow-up|2
6287334|NCT02349295|9999714|FG008|Long-Term Extension Period (Week 24-156)|Lost to Follow-up|2
6287335|NCT02349295|9999715|FG009|Long-Term Extension Period (Week 24-156)|Lost to Follow-up|0
6287336|NCT02349295|9999716|FG010|Long-Term Extension Period (Week 24-156)|Lost to Follow-up|0
6287337|NCT02349295|9999717|FG011|Long-Term Extension Period (Week 24-156)|Lost to Follow-up|0
6287338|NCT02349295|9999718|FG012|Long-Term Extension Period (Week 24-156)|Lost to Follow-up|0
6287339|NCT02349295|9999719|FG013|Long-Term Extension Period (Week 24-156)|Lost to Follow-up|0
6287340|NCT02349295|9999706|FG000|Long-Term Extension Period (Week 24-156)|Physician Decision|0
6119750|NCT00885703|9742646|FG002|Overall Study|Withdrawal by Subject|0
6119751|NCT00885703|9742647|FG003|Overall Study|Withdrawal by Subject|1
6119752|NCT00885703|9742648|FG004|Overall Study|Withdrawal by Subject|3
6119753|NCT00885703|9742649|FG005|Overall Study|Withdrawal by Subject|1
6119754|NCT00885703|9742650|FG006|Overall Study|Withdrawal by Subject|1
6119755|NCT00885703|9742644|FG000|Overall Study|Ineligible (no CM)|1
6119756|NCT00885703|9742645|FG001|Overall Study|Ineligible (no CM)|3
6119757|NCT00885703|9742646|FG002|Overall Study|Ineligible (no CM)|2
6119758|NCT00885703|9742647|FG003|Overall Study|Ineligible (no CM)|1
6119759|NCT00885703|9742648|FG004|Overall Study|Ineligible (no CM)|2
6119760|NCT00885703|9742649|FG005|Overall Study|Ineligible (no CM)|3
6119761|NCT00885703|9742650|FG006|Overall Study|Ineligible (no CM)|1
6119762|NCT00885755|9742677|FG000|Part I: Trastuzumab+Taxane|Adverse Event|1
6119763|NCT00885755|9742678|FG001|Part I: Trastuzumab+Taxane|Adverse Event|0
6119764|NCT00885755|9742679|FG002|Part I: Trastuzumab+Taxane|Adverse Event|0
6119765|NCT00885755|9742677|FG000|Part I: Trastuzumab+Taxane|Unknown Reason|16
6119766|NCT00885755|9742678|FG001|Part I: Trastuzumab+Taxane|Unknown Reason|0
6119767|NCT00885755|9742679|FG002|Part I: Trastuzumab+Taxane|Unknown Reason|0
6119768|NCT00885755|9742677|FG000|Part I: Trastuzumab+Taxane|Sufficient Response Achieved|1
6119769|NCT00885755|9742678|FG001|Part I: Trastuzumab+Taxane|Sufficient Response Achieved|0
6119770|NCT00885755|9742679|FG002|Part I: Trastuzumab+Taxane|Sufficient Response Achieved|0
6119771|NCT00885755|9742677|FG000|Part I: Trastuzumab+Taxane|Death|0
6119772|NCT00885755|9742678|FG001|Part I: Trastuzumab+Taxane|Death|0
6119773|NCT00885755|9742679|FG002|Part I: Trastuzumab+Taxane|Death|1
6119774|NCT00885755|9742677|FG000|Part II: Trastuzumab + Capecitabine.|Unknown Reason|5
6119775|NCT00885755|9742678|FG001|Part II: Trastuzumab + Capecitabine.|Unknown Reason|0
6119776|NCT00885755|9742679|FG002|Part II: Trastuzumab + Capecitabine.|Unknown Reason|0
6119777|NCT00885846|9742694|FG000|Overall Study|Withdrawal by Subject|2
6119778|NCT00885846|9742695|FG001|Overall Study|Withdrawal by Subject|5
6119779|NCT00885846|9742696|FG002|Overall Study|Withdrawal by Subject|2
6119780|NCT00886015|9742706|FG000|Overall Study|Death|0
6119781|NCT00886015|9742707|FG001|Overall Study|Death|2
6119782|NCT00886119|9742713|FG000|Period 1|Did not meet inclusion criteria|1
6119783|NCT00886119|9742714|FG001|Period 1|Did not meet inclusion criteria|0
6119784|NCT00886288|9742750|FG000|Overall Study|no respect of the 12 weeks period|657
6119785|NCT00886288|9742751|FG001|Overall Study|no respect of the 12 weeks period|227
6119786|NCT00886288|9742750|FG000|Overall Study|Lost to Follow-up|86
6119787|NCT00886288|9742751|FG001|Overall Study|Lost to Follow-up|0
6119788|NCT00886340|9742761|FG000|Overall Study|Withdrawal by Subject|0
6119789|NCT00886340|9742762|FG001|Overall Study|Withdrawal by Subject|7
6119790|NCT00886379|9742773|FG000|Overall Study|Transferred Schools|0
6119791|NCT00886379|9742774|FG001|Overall Study|Transferred Schools|0
6119792|NCT00886379|9742775|FG002|Overall Study|Transferred Schools|2
6119793|NCT00886379|9742776|FG003|Overall Study|Transferred Schools|1
6212913|NCT01599325|9879504|FG000|Primary Parent Phase|Protocol Violation|1
6212914|NCT01599325|9879504|FG000|Primary Parent Phase|Lack of Therapeutic Effect|9
6212915|NCT01599325|9879504|FG000|Primary Parent Phase|Other|2
6212916|NCT01599325|9879504|FG000|Extension Phase|Study Closure|1
6212917|NCT01599325|9879504|FG000|Extension Phase|Stopped to Receive Stem Cell Transplant|1
6212918|NCT01599325|9879504|FG000|Extension Phase|Lack of Therapeutic Effect|4
6212919|NCT01599325|9879504|FG000|Extension Phase|Disease Progression|1
6212920|NCT01599325|9879504|FG000|Extension Phase|Withdrawal by Subject|8
6212921|NCT01599585|9879511|FG000|Overall Study|Withdrawal by Subject|16
6212922|NCT01599585|9879512|FG001|Overall Study|Withdrawal by Subject|9
6212923|NCT01599585|9879511|FG000|Overall Study|Lost to Follow-up|3
6212924|NCT01599585|9879512|FG001|Overall Study|Lost to Follow-up|5
6212925|NCT01599585|9879511|FG000|Overall Study|randomized did not start treatment|3
6212926|NCT01599585|9879512|FG001|Overall Study|randomized did not start treatment|3
6212927|NCT01599637|9879521|FG000|Overall Study|administrative problems|0
6212928|NCT01599637|9879522|FG001|Overall Study|administrative problems|2
6212929|NCT01599637|9879523|FG002|Overall Study|administrative problems|0
6212930|NCT01599637|9879521|FG000|Overall Study|Adverse Event|1
6212931|NCT01599637|9879522|FG001|Overall Study|Adverse Event|0
6212932|NCT01599637|9879523|FG002|Overall Study|Adverse Event|0
6212933|NCT01599650|9879536|FG000|Overall Study|Administrative issue|1
6212934|NCT01599650|9879537|FG001|Overall Study|Administrative issue|0
6212935|NCT01599650|9879538|FG002|Overall Study|Administrative issue|1
6212936|NCT01599650|9879536|FG000|Overall Study|Physician Decision|2
6212937|NCT01599650|9879537|FG001|Overall Study|Physician Decision|0
6212938|NCT01599650|9879538|FG002|Overall Study|Physician Decision|7
6212939|NCT01599650|9879536|FG000|Overall Study|Protocol Violation|0
6212940|NCT01599650|9879537|FG001|Overall Study|Protocol Violation|3
6212941|NCT01599650|9879538|FG002|Overall Study|Protocol Violation|0
6212942|NCT01599650|9879536|FG000|Overall Study|Death|2
6212943|NCT01599650|9879537|FG001|Overall Study|Death|1
6212944|NCT01599650|9879538|FG002|Overall Study|Death|2
6212945|NCT01599650|9879536|FG000|Overall Study|Lost to Follow-up|3
6212946|NCT01599650|9879537|FG001|Overall Study|Lost to Follow-up|3
6212947|NCT01599650|9879538|FG002|Overall Study|Lost to Follow-up|3
6212948|NCT01599650|9879536|FG000|Overall Study|Withdrawal by Subject|11
6119794|NCT00886379|9742777|FG004|Overall Study|Transferred Schools|1
6119795|NCT00886379|9742773|FG000|Overall Study|Final blood draw not obtained|3
6212949|NCT01599650|9879537|FG001|Overall Study|Withdrawal by Subject|11
6212950|NCT01599650|9879538|FG002|Overall Study|Withdrawal by Subject|10
6119796|NCT00886379|9742774|FG001|Overall Study|Final blood draw not obtained|3
6119797|NCT00886379|9742775|FG002|Overall Study|Final blood draw not obtained|4
6119798|NCT00886379|9742776|FG003|Overall Study|Final blood draw not obtained|2
6119799|NCT00886379|9742777|FG004|Overall Study|Final blood draw not obtained|2
6119800|NCT00886483|9742791|FG000|Overall Study|Lost to Follow-up|0
6119801|NCT00886483|9742792|FG001|Overall Study|Lost to Follow-up|1
6119802|NCT00886483|9742791|FG000|Overall Study|Pursue medications|1
6119803|NCT00886483|9742792|FG001|Overall Study|Pursue medications|2
6119804|NCT00886483|9742791|FG000|Overall Study|Distance to center, poor grades|1
6119805|NCT00886483|9742792|FG001|Overall Study|Distance to center, poor grades|0
6119806|NCT00886587|9742808|FG000|Overall Study|Adverse Event|2
6119807|NCT00886587|9742809|FG001|Overall Study|Adverse Event|1
6119808|NCT00886587|9742808|FG000|Overall Study|Protocol Violation|2
6119809|NCT00886587|9742809|FG001|Overall Study|Protocol Violation|0
6119810|NCT00886587|9742808|FG000|Overall Study|Withdrawal by Subject|0
6119811|NCT00886587|9742809|FG001|Overall Study|Withdrawal by Subject|1
6119812|NCT00886613|9742818|FG000|Overall Study|Protocol deviation (Part B)|1
6119813|NCT00886613|9742819|FG001|Overall Study|Protocol deviation (Part B)|0
6119814|NCT00886613|9742820|FG002|Overall Study|Protocol deviation (Part B)|0
6119815|NCT00886613|9742818|FG000|Overall Study|Lost to follow-up (Part B)|1
6119816|NCT00886613|9742819|FG001|Overall Study|Lost to follow-up (Part B)|0
6119817|NCT00886613|9742820|FG002|Overall Study|Lost to follow-up (Part B)|1
6119818|NCT00886613|9742818|FG000|Overall Study|Subject withdrew consent (Part A)|0
6119819|NCT00886613|9742819|FG001|Overall Study|Subject withdrew consent (Part A)|0
6119820|NCT00886613|9742820|FG002|Overall Study|Subject withdrew consent (Part A)|2
6119821|NCT00886639|9742838|FG000|Overall Study|acute exacerbation|14
6119822|NCT00886639|9742838|FG000|Overall Study|non-compliance|2
6119823|NCT00886743|9742853|FG000|Overall Study|Adverse Event|3
6119824|NCT00886743|9742853|FG000|Overall Study|Other|1
6119825|NCT00886769|9742859|FG000|Overall Study|Unsatisfactory therapeutic effect|6
6119826|NCT00886769|9742860|FG001|Overall Study|Unsatisfactory therapeutic effect|37
6119827|NCT00886795|9742866|FG000|Overall Study|Lack of Efficacy|1
6119828|NCT00886821|9742885|FG000|Stage 2|Adverse Event|0
6119829|NCT00886821|9742886|FG001|Stage 2|Adverse Event|0
6119830|NCT00886821|9742887|FG002|Stage 2|Adverse Event|0
6119831|NCT00886821|9742888|FG003|Stage 2|Adverse Event|0
6119832|NCT00886821|9742889|FG004|Stage 2|Adverse Event|0
6119833|NCT00886821|9742890|FG005|Stage 2|Adverse Event|0
6119834|NCT00886821|9742891|FG006|Stage 2|Adverse Event|0
6119835|NCT00886821|9742892|FG007|Stage 2|Adverse Event|0
6212951|NCT01599650|9879536|FG000|Overall Study|Adverse Event|3
6212952|NCT01599650|9879537|FG001|Overall Study|Adverse Event|8
6212953|NCT01599650|9879538|FG002|Overall Study|Adverse Event|4
6212954|NCT01599754|9879550|FG000|Overall Study|Anticancer therapy need not in protocol|5
6212955|NCT01599754|9879551|FG001|Overall Study|Anticancer therapy need not in protocol|2
6212956|NCT01599754|9879550|FG000|Overall Study|Participant noncompliance|4
6212957|NCT01599754|9879551|FG001|Overall Study|Participant noncompliance|4
6212958|NCT01599754|9879550|FG000|Overall Study|Lost to Follow-up|13
6212959|NCT01599754|9879551|FG001|Overall Study|Lost to Follow-up|6
6212960|NCT01599754|9879550|FG000|Overall Study|Death|31
6212961|NCT01599754|9879551|FG001|Overall Study|Death|33
6212962|NCT01599754|9879550|FG000|Overall Study|Adverse Event|3
6212963|NCT01599754|9879551|FG001|Overall Study|Adverse Event|2
6212964|NCT01599754|9879550|FG000|Overall Study|Investigator decision|1
6212965|NCT01599754|9879551|FG001|Overall Study|Investigator decision|3
6212966|NCT01599754|9879550|FG000|Overall Study|Withdrawal by Subject|24
6212967|NCT01599754|9879551|FG001|Overall Study|Withdrawal by Subject|25
6212968|NCT01599754|9879550|FG000|Overall Study|Study terminated by sponsor|282
6212969|NCT01599754|9879551|FG001|Overall Study|Study terminated by sponsor|285
6212970|NCT01599793|9879557|FG000|Overall Study|Adverse Event|2
6212971|NCT01599806|9879563|FG000|Overall Study|Lost to Follow-up|20
6212972|NCT01599806|9879564|FG001|Overall Study|Lost to Follow-up|20
6212973|NCT01599806|9879563|FG000|Overall Study|Withdrawal by Subject|12
6212974|NCT01599806|9879564|FG001|Overall Study|Withdrawal by Subject|12
6212975|NCT01599806|9879563|FG000|Overall Study|Other Eligibility criteria|11
6212976|NCT01599806|9879564|FG001|Overall Study|Other Eligibility criteria|9
6212977|NCT01600014|9879574|FG000|1. Cycle & Observation Period D1 to W52|Withdrawal by Subject|24
6287341|NCT02349295|9999707|FG001|Long-Term Extension Period (Week 24-156)|Physician Decision|0
6287342|NCT02349295|9999708|FG002|Long-Term Extension Period (Week 24-156)|Physician Decision|0
6287343|NCT02349295|9999709|FG003|Long-Term Extension Period (Week 24-156)|Physician Decision|0
6287344|NCT02349295|9999710|FG004|Long-Term Extension Period (Week 24-156)|Physician Decision|0
6287345|NCT02349295|9999711|FG005|Long-Term Extension Period (Week 24-156)|Physician Decision|0
6287346|NCT02349295|9999712|FG006|Long-Term Extension Period (Week 24-156)|Physician Decision|0
6287347|NCT02349295|9999713|FG007|Long-Term Extension Period (Week 24-156)|Physician Decision|2
6119836|NCT00886821|9742893|FG008|Stage 2|Adverse Event|0
6119837|NCT00886821|9742894|FG009|Stage 2|Adverse Event|0
6119838|NCT00886821|9742895|FG010|Stage 2|Adverse Event|0
6119839|NCT00886821|9742896|FG011|Stage 2|Adverse Event|1
6119840|NCT00886821|9742897|FG012|Stage 2|Adverse Event|3
6119841|NCT00886821|9742898|FG013|Stage 2|Adverse Event|0
6119842|NCT00886821|9742885|FG000|Stage 2|Lost to Follow-up|0
6119843|NCT00886821|9742886|FG001|Stage 2|Lost to Follow-up|0
6119844|NCT00886821|9742887|FG002|Stage 2|Lost to Follow-up|0
6119845|NCT00886821|9742888|FG003|Stage 2|Lost to Follow-up|0
6119846|NCT00886821|9742889|FG004|Stage 2|Lost to Follow-up|0
6119847|NCT00886821|9742890|FG005|Stage 2|Lost to Follow-up|0
6119848|NCT00886821|9742891|FG006|Stage 2|Lost to Follow-up|0
6119849|NCT00886821|9742892|FG007|Stage 2|Lost to Follow-up|0
6119850|NCT00886821|9742893|FG008|Stage 2|Lost to Follow-up|0
6119851|NCT00886821|9742894|FG009|Stage 2|Lost to Follow-up|0
6119852|NCT00886821|9742895|FG010|Stage 2|Lost to Follow-up|0
6119853|NCT00886821|9742896|FG011|Stage 2|Lost to Follow-up|0
6212978|NCT01600014|9879575|FG001|1. Cycle & Observation Period D1 to W52|Withdrawal by Subject|0
6212979|NCT01600014|9879574|FG000|1. Cycle & Observation Period D1 to W52|Included in 2nd cycle|203
6212980|NCT01600014|9879575|FG001|1. Cycle & Observation Period D1 to W52|Included in 2nd cycle|0
6212981|NCT01600014|9879574|FG000|1. Cycle & Observation Period D1 to W52|Adverse Event|6
6212982|NCT01600014|9879575|FG001|1. Cycle & Observation Period D1 to W52|Adverse Event|0
6212983|NCT01600014|9879574|FG000|1. Cycle & Observation Period D1 to W52|Other|27
6212984|NCT01600014|9879575|FG001|1. Cycle & Observation Period D1 to W52|Other|0
6212985|NCT01600014|9879574|FG000|1. Cycle & Observation Period D1 to W52|Exclusion Criteria Emerging during Study|14
6212986|NCT01600014|9879575|FG001|1. Cycle & Observation Period D1 to W52|Exclusion Criteria Emerging during Study|0
6212987|NCT01600014|9879574|FG000|1. Cycle & Observation Period D1 to W52|Protocol Violation|6
6212988|NCT01600014|9879575|FG001|1. Cycle & Observation Period D1 to W52|Protocol Violation|0
6212989|NCT01600014|9879574|FG000|1. Cycle & Observation Period D1 to W52|Lost to Follow-up|8
6212990|NCT01600014|9879575|FG001|1. Cycle & Observation Period D1 to W52|Lost to Follow-up|0
6212991|NCT01600014|9879574|FG000|2. Cycle Recalcitrant Subgroup W8 to W52|Death|1
6119854|NCT00886821|9742897|FG012|Stage 2|Lost to Follow-up|2
6119855|NCT00886821|9742898|FG013|Stage 2|Lost to Follow-up|1
6119856|NCT00886834|9742944|FG000|Overall Study|Protocol Violation|0
6119857|NCT00886834|9742945|FG001|Overall Study|Protocol Violation|3
6119858|NCT00886938|9742955|FG000|Overall Study|Adverse Event|1
6119859|NCT00886938|9742955|FG000|Overall Study|Withdrawal by Subject|1
6119860|NCT00887068|9742961|FG000|Overall Study|Withdrawal by Subject|2
6119861|NCT00887068|9742962|FG001|Overall Study|Withdrawal by Subject|0
6119862|NCT00887068|9742961|FG000|Overall Study|Didn't meet eligibility to start cycle 1|4
6119863|NCT00887068|9742962|FG001|Overall Study|Didn't meet eligibility to start cycle 1|0
6119864|NCT00887159|9742971|FG000|Overall Study|Disease progression|6
6119865|NCT00887159|9742972|FG001|Overall Study|Disease progression|39
6119866|NCT00887159|9742973|FG002|Overall Study|Disease progression|33
6119867|NCT00887159|9742971|FG000|Overall Study|Adverse Event|3
6119868|NCT00887159|9742972|FG001|Overall Study|Adverse Event|4
6119869|NCT00887159|9742973|FG002|Overall Study|Adverse Event|17
6119870|NCT00887159|9742971|FG000|Overall Study|Death|2
6119871|NCT00887159|9742972|FG001|Overall Study|Death|2
6119872|NCT00887159|9742973|FG002|Overall Study|Death|0
6119873|NCT00887159|9742971|FG000|Overall Study|Withdrawal by Subject|4
6119874|NCT00887159|9742972|FG001|Overall Study|Withdrawal by Subject|4
6119875|NCT00887159|9742973|FG002|Overall Study|Withdrawal by Subject|2
6119876|NCT00887159|9742971|FG000|Overall Study|Alternative therapy|2
6119877|NCT00887159|9742972|FG001|Overall Study|Alternative therapy|0
6119878|NCT00887159|9742973|FG002|Overall Study|Alternative therapy|0
6119879|NCT00887159|9742971|FG000|Overall Study|Physician Decision|1
6119880|NCT00887159|9742972|FG001|Overall Study|Physician Decision|1
6119881|NCT00887159|9742973|FG002|Overall Study|Physician Decision|0
6119882|NCT00887159|9742971|FG000|Overall Study|Sympomatic deterioration|1
6119883|NCT00887159|9742972|FG001|Overall Study|Sympomatic deterioration|0
6119884|NCT00887159|9742973|FG002|Overall Study|Sympomatic deterioration|0
6119885|NCT00887159|9742971|FG000|Overall Study|Treatment delayed|1
6119886|NCT00887159|9742972|FG001|Overall Study|Treatment delayed|1
6119887|NCT00887159|9742973|FG002|Overall Study|Treatment delayed|0
6119888|NCT00887159|9742971|FG000|Overall Study|Pt had PD but was SD when re-measured|0
6212992|NCT01600014|9879575|FG001|2. Cycle Recalcitrant Subgroup W8 to W52|Death|2
6212993|NCT01600014|9879574|FG000|2. Cycle Recalcitrant Subgroup W8 to W52|Other|1
6212994|NCT01600014|9879575|FG001|2. Cycle Recalcitrant Subgroup W8 to W52|Other|3
6212995|NCT01600014|9879574|FG000|2. Cycle Recalcitrant Subgroup W8 to W52|Withdrawal by Subject|2
6212996|NCT01600014|9879575|FG001|2. Cycle Recalcitrant Subgroup W8 to W52|Withdrawal by Subject|1
6212997|NCT01600014|9879574|FG000|2. Cycle Recalcitrant Subgroup W8 to W52|Lack of Efficacy|1
6212998|NCT01600014|9879575|FG001|2. Cycle Recalcitrant Subgroup W8 to W52|Lack of Efficacy|0
6212999|NCT01600014|9879574|FG000|2. Cycle Recalcitrant Subgroup W8 to W52|Protocol Violation|5
6213000|NCT01600014|9879575|FG001|2. Cycle Recalcitrant Subgroup W8 to W52|Protocol Violation|0
6213001|NCT01600014|9879574|FG000|2. Cycle Recalcitrant Subgroup W8 to W52|Exclusion Criteria Emerging during Study|1
6213002|NCT01600014|9879575|FG001|2. Cycle Recalcitrant Subgroup W8 to W52|Exclusion Criteria Emerging during Study|1
6213003|NCT01600014|9879574|FG000|2. Cycle Recalcitrant Subgroup W8 to W52|Lost to Follow-up|1
6119889|NCT00887159|9742972|FG001|Overall Study|Pt had PD but was SD when re-measured|1
6119890|NCT00887159|9742973|FG002|Overall Study|Pt had PD but was SD when re-measured|0
6119891|NCT00887159|9742971|FG000|Overall Study|Received more tx instead of observation|1
6119892|NCT00887159|9742972|FG001|Overall Study|Received more tx instead of observation|0
6119893|NCT00887159|9742973|FG002|Overall Study|Received more tx instead of observation|0
6119894|NCT00887159|9742971|FG000|Overall Study|Ineligible|5
6119895|NCT00887159|9742972|FG001|Overall Study|Ineligible|1
6119896|NCT00887159|9742973|FG002|Overall Study|Ineligible|0
6119897|NCT00887159|9742971|FG000|Overall Study|Never started assigned therapy|3
6119898|NCT00887159|9742972|FG001|Overall Study|Never started assigned therapy|3
6119899|NCT00887159|9742973|FG002|Overall Study|Never started assigned therapy|4
6119900|NCT00887198|9742985|FG000|Randomized Period|Ongoing|42
6119901|NCT00887198|9742986|FG001|Randomized Period|Ongoing|0
6119902|NCT00887198|9742987|FG002|Randomized Period|Ongoing|0
6119903|NCT00887198|9742985|FG000|Randomized Period|Adverse Event|50
6119904|NCT00887198|9742986|FG001|Randomized Period|Adverse Event|33
6119905|NCT00887198|9742987|FG002|Randomized Period|Adverse Event|0
6119906|NCT00887198|9742985|FG000|Randomized Period|Lost to Follow-up|1
6119907|NCT00887198|9742986|FG001|Randomized Period|Lost to Follow-up|0
6119908|NCT00887198|9742987|FG002|Randomized Period|Lost to Follow-up|0
6119909|NCT00887198|9742985|FG000|Randomized Period|Cross-over to AA (under amendment 3)|0
6119910|NCT00887198|9742986|FG001|Randomized Period|Cross-over to AA (under amendment 3)|51
6119911|NCT00887198|9742987|FG002|Randomized Period|Cross-over to AA (under amendment 3)|0
6119912|NCT00887198|9742985|FG000|Randomized Period|Withdrawal by Subject|41
6119913|NCT00887198|9742986|FG001|Randomized Period|Withdrawal by Subject|56
6119914|NCT00887198|9742987|FG002|Randomized Period|Withdrawal by Subject|0
6119915|NCT00887198|9742985|FG000|Randomized Period|Progressive disease|366
6119916|NCT00887198|9742986|FG001|Randomized Period|Progressive disease|370
6119917|NCT00887198|9742987|FG002|Randomized Period|Progressive disease|0
6119918|NCT00887198|9742985|FG000|Randomized Period|Other|42
6119919|NCT00887198|9742986|FG001|Randomized Period|Other|30
6119920|NCT00887198|9742987|FG002|Randomized Period|Other|0
6119921|NCT00887198|9742985|FG000|Randomized Period|Randomized, Not treated|4
6119922|NCT00887198|9742986|FG001|Randomized Period|Randomized, Not treated|2
6119923|NCT00887198|9742987|FG002|Randomized Period|Randomized, Not treated|0
6119924|NCT00887198|9742985|FG000|Cross Over (Placebo to AA)|Started other prostate cancer treatment|0
6119925|NCT00887198|9742986|FG001|Cross Over (Placebo to AA)|Started other prostate cancer treatment|0
6119926|NCT00887198|9742987|FG002|Cross Over (Placebo to AA)|Started other prostate cancer treatment|8
6119927|NCT00887198|9742985|FG000|Cross Over (Placebo to AA)|Ongoing|0
6119928|NCT00887198|9742986|FG001|Cross Over (Placebo to AA)|Ongoing|0
6119929|NCT00887198|9742987|FG002|Cross Over (Placebo to AA)|Ongoing|35
6119930|NCT00887198|9742985|FG000|Cross Over (Placebo to AA)|Adverse Event|0
6119931|NCT00887198|9742986|FG001|Cross Over (Placebo to AA)|Adverse Event|0
6119932|NCT00887198|9742987|FG002|Cross Over (Placebo to AA)|Adverse Event|9
6119933|NCT00887198|9742985|FG000|Cross Over (Placebo to AA)|Withdrawal by Subject|0
6119934|NCT00887198|9742986|FG001|Cross Over (Placebo to AA)|Withdrawal by Subject|0
6119935|NCT00887198|9742987|FG002|Cross Over (Placebo to AA)|Withdrawal by Subject|2
6119936|NCT00887198|9742985|FG000|Cross Over (Placebo to AA)|Progressive disease|0
6119937|NCT00887198|9742986|FG001|Cross Over (Placebo to AA)|Progressive disease|0
6213004|NCT01600014|9879575|FG001|2. Cycle Recalcitrant Subgroup W8 to W52|Lost to Follow-up|3
6213005|NCT01600014|9879574|FG000|2. Cycl Recurrent Subgroup W26/44 to W52|Adverse Event|1
6213006|NCT01600014|9879575|FG001|2. Cycl Recurrent Subgroup W26/44 to W52|Adverse Event|0
6213007|NCT01600014|9879574|FG000|2. Cycl Recurrent Subgroup W26/44 to W52|Withdrawal by Subject|1
6213008|NCT01600014|9879575|FG001|2. Cycl Recurrent Subgroup W26/44 to W52|Withdrawal by Subject|0
6213009|NCT01600014|9879574|FG000|2. Cycl Recurrent Subgroup W26/44 to W52|Lost to Follow-up|1
6213010|NCT01600014|9879575|FG001|2. Cycl Recurrent Subgroup W26/44 to W52|Lost to Follow-up|0
6213011|NCT01600053|9879593|FG000|Overall Study|Adverse Event|2
6213012|NCT01600053|9879593|FG000|Overall Study|trial will not meet the interim endpoint|9
6213013|NCT01600092|9879599|FG000|Overall Study|Adverse Event|2
6213014|NCT01600092|9879600|FG001|Overall Study|Adverse Event|0
6213015|NCT01600092|9879599|FG000|Overall Study|Lost to Follow-up|4
6213016|NCT01600092|9879600|FG001|Overall Study|Lost to Follow-up|6
6213017|NCT01600092|9879599|FG000|Overall Study|Withdrawal by parent/guardian|8
6213018|NCT01600092|9879600|FG001|Overall Study|Withdrawal by parent/guardian|6
6213019|NCT01600092|9879599|FG000|Overall Study|Physician Decision|1
6213020|NCT01600092|9879600|FG001|Overall Study|Physician Decision|1
6213021|NCT01600092|9879599|FG000|Overall Study|Randomized but not vaccinated|3
6213022|NCT01600092|9879600|FG001|Overall Study|Randomized but not vaccinated|3
6213023|NCT01600105|9879608|FG000|Total Participants|Withdrawal by Subject|1
6213024|NCT01600105|9879609|FG001|Total Participants|Withdrawal by Subject|0
6213025|NCT01600105|9879608|FG000|Total Participants|No images in PACS|10
6213026|NCT01600105|9879609|FG001|Total Participants|No images in PACS|0
6213027|NCT01600105|9879608|FG000|Total Participants|Insufficient image quality|30
6213028|NCT01600105|9879609|FG001|Total Participants|Insufficient image quality|10
6213029|NCT01600105|9879608|FG000|Sub Study I|Insufficient image quality|0
6213030|NCT01600105|9879609|FG001|Sub Study I|Insufficient image quality|10
6213031|NCT01600105|9879608|FG000|Sub Study II|Withdrawal by Subject|1
6213032|NCT01600105|9879609|FG001|Sub Study II|Withdrawal by Subject|0
6213033|NCT01600105|9879608|FG000|Sub Study II|No images in PACS|1
6213034|NCT01600105|9879609|FG001|Sub Study II|No images in PACS|0
6213035|NCT01600105|9879608|FG000|Sub Study II|Insufficient image quality|3
6213036|NCT01600105|9879609|FG001|Sub Study II|Insufficient image quality|0
6213037|NCT01600105|9879608|FG000|Sub Study III|Insufficient image quality|5
6213038|NCT01600105|9879609|FG001|Sub Study III|Insufficient image quality|0
6213039|NCT01600105|9879608|FG000|Sub Study V|Poor Image Quality|2
6119938|NCT00887198|9742987|FG002|Cross Over (Placebo to AA)|Progressive disease|20
6119939|NCT00887198|9742985|FG000|Cross Over (Placebo to AA)|Other|0
6119940|NCT00887198|9742986|FG001|Cross Over (Placebo to AA)|Other|0
6119941|NCT00887198|9742987|FG002|Cross Over (Placebo to AA)|Other|19
6119942|NCT00887224|9742998|FG000|Open-label Response (OLR) Phase|Adverse Event|46
6119943|NCT00887224|9742999|FG001|Open-label Response (OLR) Phase|Adverse Event|0
6119944|NCT00887224|9743000|FG002|Open-label Response (OLR) Phase|Adverse Event|0
6119945|NCT00887224|9742998|FG000|Open-label Response (OLR) Phase|Failed to return|6
6119946|NCT00887224|9742999|FG001|Open-label Response (OLR) Phase|Failed to return|0
6119947|NCT00887224|9743000|FG002|Open-label Response (OLR) Phase|Failed to return|0
6119948|NCT00887224|9742998|FG000|Open-label Response (OLR) Phase|Lack of Efficacy|26
6119949|NCT00887224|9742999|FG001|Open-label Response (OLR) Phase|Lack of Efficacy|0
6119950|NCT00887224|9743000|FG002|Open-label Response (OLR) Phase|Lack of Efficacy|0
6119951|NCT00887224|9742998|FG000|Open-label Response (OLR) Phase|Lost to Follow-up|16
6119952|NCT00887224|9742999|FG001|Open-label Response (OLR) Phase|Lost to Follow-up|0
6213040|NCT01600105|9879609|FG001|Sub Study V|Poor Image Quality|0
6213041|NCT01600326|9879646|FG000|Overall Study|Lost to Follow-up|1
6213042|NCT01600326|9879647|FG001|Overall Study|Lost to Follow-up|1
6213043|NCT01600586|9879674|FG000|Overall Study|Physician Decision|3
6213044|NCT01600586|9879675|FG001|Overall Study|Physician Decision|3
6287348|NCT02349295|9999714|FG008|Long-Term Extension Period (Week 24-156)|Physician Decision|2
6287349|NCT02349295|9999715|FG009|Long-Term Extension Period (Week 24-156)|Physician Decision|0
6287350|NCT02349295|9999716|FG010|Long-Term Extension Period (Week 24-156)|Physician Decision|0
6287351|NCT02349295|9999717|FG011|Long-Term Extension Period (Week 24-156)|Physician Decision|0
6287352|NCT02349295|9999718|FG012|Long-Term Extension Period (Week 24-156)|Physician Decision|0
6287353|NCT02349295|9999719|FG013|Long-Term Extension Period (Week 24-156)|Physician Decision|0
6287354|NCT02349295|9999706|FG000|Follow-Up Period (Up to 12-24 Weeks)|Withdrawal by Subject|0
6287355|NCT02349295|9999707|FG001|Follow-Up Period (Up to 12-24 Weeks)|Withdrawal by Subject|0
6287356|NCT02349295|9999708|FG002|Follow-Up Period (Up to 12-24 Weeks)|Withdrawal by Subject|0
6287357|NCT02349295|9999709|FG003|Follow-Up Period (Up to 12-24 Weeks)|Withdrawal by Subject|0
6287358|NCT02349295|9999710|FG004|Follow-Up Period (Up to 12-24 Weeks)|Withdrawal by Subject|0
6287359|NCT02349295|9999711|FG005|Follow-Up Period (Up to 12-24 Weeks)|Withdrawal by Subject|0
6287360|NCT02349295|9999712|FG006|Follow-Up Period (Up to 12-24 Weeks)|Withdrawal by Subject|0
6287361|NCT02349295|9999713|FG007|Follow-Up Period (Up to 12-24 Weeks)|Withdrawal by Subject|0
6287362|NCT02349295|9999714|FG008|Follow-Up Period (Up to 12-24 Weeks)|Withdrawal by Subject|0
6287363|NCT02349295|9999715|FG009|Follow-Up Period (Up to 12-24 Weeks)|Withdrawal by Subject|0
6287364|NCT02349295|9999716|FG010|Follow-Up Period (Up to 12-24 Weeks)|Withdrawal by Subject|0
6287365|NCT02349295|9999717|FG011|Follow-Up Period (Up to 12-24 Weeks)|Withdrawal by Subject|1
6287366|NCT02349295|9999718|FG012|Follow-Up Period (Up to 12-24 Weeks)|Withdrawal by Subject|5
6287367|NCT02349295|9999719|FG013|Follow-Up Period (Up to 12-24 Weeks)|Withdrawal by Subject|1
6287368|NCT02349295|9999706|FG000|Follow-Up Period (Up to 12-24 Weeks)|Lost to Follow-up|0
6287369|NCT02349295|9999707|FG001|Follow-Up Period (Up to 12-24 Weeks)|Lost to Follow-up|0
6287370|NCT02349295|9999708|FG002|Follow-Up Period (Up to 12-24 Weeks)|Lost to Follow-up|0
6287371|NCT02349295|9999709|FG003|Follow-Up Period (Up to 12-24 Weeks)|Lost to Follow-up|0
6287372|NCT02349295|9999710|FG004|Follow-Up Period (Up to 12-24 Weeks)|Lost to Follow-up|0
6287373|NCT02349295|9999711|FG005|Follow-Up Period (Up to 12-24 Weeks)|Lost to Follow-up|0
6119953|NCT00887224|9743000|FG002|Open-label Response (OLR) Phase|Lost to Follow-up|0
6213045|NCT01600716|9879710|FG000|Overall Study|Other Reasons|3
6287374|NCT02349295|9999712|FG006|Follow-Up Period (Up to 12-24 Weeks)|Lost to Follow-up|0
6287375|NCT02349295|9999713|FG007|Follow-Up Period (Up to 12-24 Weeks)|Lost to Follow-up|0
6287376|NCT02349295|9999714|FG008|Follow-Up Period (Up to 12-24 Weeks)|Lost to Follow-up|0
6287377|NCT02349295|9999715|FG009|Follow-Up Period (Up to 12-24 Weeks)|Lost to Follow-up|0
6287378|NCT02349295|9999716|FG010|Follow-Up Period (Up to 12-24 Weeks)|Lost to Follow-up|0
6287379|NCT02349295|9999717|FG011|Follow-Up Period (Up to 12-24 Weeks)|Lost to Follow-up|1
6287380|NCT02349295|9999718|FG012|Follow-Up Period (Up to 12-24 Weeks)|Lost to Follow-up|2
6287381|NCT02349295|9999719|FG013|Follow-Up Period (Up to 12-24 Weeks)|Lost to Follow-up|0
6287382|NCT02349295|9999706|FG000|Follow-Up Period (Up to 12-24 Weeks)|Adverse Event|0
6287383|NCT02349295|9999707|FG001|Follow-Up Period (Up to 12-24 Weeks)|Adverse Event|0
6287384|NCT02349295|9999708|FG002|Follow-Up Period (Up to 12-24 Weeks)|Adverse Event|0
6287385|NCT02349295|9999709|FG003|Follow-Up Period (Up to 12-24 Weeks)|Adverse Event|0
6287386|NCT02349295|9999710|FG004|Follow-Up Period (Up to 12-24 Weeks)|Adverse Event|0
6287387|NCT02349295|9999711|FG005|Follow-Up Period (Up to 12-24 Weeks)|Adverse Event|0
6287388|NCT02349295|9999712|FG006|Follow-Up Period (Up to 12-24 Weeks)|Adverse Event|0
6213046|NCT01600716|9879711|FG001|Overall Study|Other Reasons|1
6213047|NCT01600716|9879710|FG000|Overall Study|Personal Reasons|0
6213048|NCT01600716|9879711|FG001|Overall Study|Personal Reasons|2
6213049|NCT01600716|9879710|FG000|Overall Study|Lost to Follow-up|0
6213050|NCT01600716|9879711|FG001|Overall Study|Lost to Follow-up|2
6213051|NCT01600716|9879710|FG000|Overall Study|Pregnancy|1
6213052|NCT01600716|9879711|FG001|Overall Study|Pregnancy|0
6213053|NCT01600716|9879710|FG000|Overall Study|Lack of Efficacy|2
6213054|NCT01600716|9879711|FG001|Overall Study|Lack of Efficacy|1
6213055|NCT01600716|9879710|FG000|Overall Study|Adverse Event|1
6213056|NCT01600716|9879711|FG001|Overall Study|Adverse Event|1
6119954|NCT00887224|9742998|FG000|Open-label Response (OLR) Phase|Other|1
6119955|NCT00887224|9742999|FG001|Open-label Response (OLR) Phase|Other|0
6119956|NCT00887224|9743000|FG002|Open-label Response (OLR) Phase|Other|0
6119957|NCT00887224|9742998|FG000|Open-label Response (OLR) Phase|Protocol Violation|12
6119958|NCT00887224|9742999|FG001|Open-label Response (OLR) Phase|Protocol Violation|0
6119959|NCT00887224|9743000|FG002|Open-label Response (OLR) Phase|Protocol Violation|0
6119960|NCT00887224|9742998|FG000|Open-label Response (OLR) Phase|Withdrawal by Subject|15
6119961|NCT00887224|9742999|FG001|Open-label Response (OLR) Phase|Withdrawal by Subject|0
6119962|NCT00887224|9743000|FG002|Open-label Response (OLR) Phase|Withdrawal by Subject|0
6119963|NCT00887224|9742998|FG000|Open-label Stability (OLS) Phase|Adverse Event|22
6119964|NCT00887224|9742999|FG001|Open-label Stability (OLS) Phase|Adverse Event|0
6119965|NCT00887224|9743000|FG002|Open-label Stability (OLS) Phase|Adverse Event|0
6119966|NCT00887224|9742998|FG000|Open-label Stability (OLS) Phase|Failed to return|3
6119967|NCT00887224|9742999|FG001|Open-label Stability (OLS) Phase|Failed to return|0
6119968|NCT00887224|9743000|FG002|Open-label Stability (OLS) Phase|Failed to return|0
6119969|NCT00887224|9742998|FG000|Open-label Stability (OLS) Phase|Lack of Efficacy|16
6119970|NCT00887224|9742999|FG001|Open-label Stability (OLS) Phase|Lack of Efficacy|0
6119971|NCT00887224|9743000|FG002|Open-label Stability (OLS) Phase|Lack of Efficacy|0
6119972|NCT00887224|9742998|FG000|Open-label Stability (OLS) Phase|Lost to Follow-up|9
6119973|NCT00887224|9742999|FG001|Open-label Stability (OLS) Phase|Lost to Follow-up|0
6119974|NCT00887224|9743000|FG002|Open-label Stability (OLS) Phase|Lost to Follow-up|0
6119975|NCT00887224|9742998|FG000|Open-label Stability (OLS) Phase|Other|1
6119976|NCT00887224|9742999|FG001|Open-label Stability (OLS) Phase|Other|0
6119977|NCT00887224|9743000|FG002|Open-label Stability (OLS) Phase|Other|0
6119978|NCT00887224|9742998|FG000|Open-label Stability (OLS) Phase|Protocol Violation|13
6119979|NCT00887224|9742999|FG001|Open-label Stability (OLS) Phase|Protocol Violation|0
6119980|NCT00887224|9743000|FG002|Open-label Stability (OLS) Phase|Protocol Violation|0
6119981|NCT00887224|9742998|FG000|Open-label Stability (OLS) Phase|Withdrawal by Subject|19
6119982|NCT00887224|9742999|FG001|Open-label Stability (OLS) Phase|Withdrawal by Subject|0
6119983|NCT00887224|9743000|FG002|Open-label Stability (OLS) Phase|Withdrawal by Subject|0
6119984|NCT00887224|9742998|FG000|OL Taper Phase / OL Follow Up|Adverse Event|28
6119985|NCT00887224|9742999|FG001|OL Taper Phase / OL Follow Up|Adverse Event|0
6119986|NCT00887224|9743000|FG002|OL Taper Phase / OL Follow Up|Adverse Event|0
6119987|NCT00887224|9742998|FG000|OL Taper Phase / OL Follow Up|Failed to return|17
6119988|NCT00887224|9742999|FG001|OL Taper Phase / OL Follow Up|Failed to return|0
6119989|NCT00887224|9743000|FG002|OL Taper Phase / OL Follow Up|Failed to return|0
6119990|NCT00887224|9742998|FG000|OL Taper Phase / OL Follow Up|Physician Decision|10
6119991|NCT00887224|9742999|FG001|OL Taper Phase / OL Follow Up|Physician Decision|0
6119992|NCT00887224|9743000|FG002|OL Taper Phase / OL Follow Up|Physician Decision|0
6119993|NCT00887224|9742998|FG000|OL Taper Phase / OL Follow Up|Lost to Follow-up|8
6119994|NCT00887224|9742999|FG001|OL Taper Phase / OL Follow Up|Lost to Follow-up|0
6119995|NCT00887224|9743000|FG002|OL Taper Phase / OL Follow Up|Lost to Follow-up|0
6119996|NCT00887224|9742998|FG000|OL Taper Phase / OL Follow Up|Other|30
6119997|NCT00887224|9742999|FG001|OL Taper Phase / OL Follow Up|Other|0
6119998|NCT00887224|9743000|FG002|OL Taper Phase / OL Follow Up|Other|0
6119999|NCT00887224|9742998|FG000|OL Taper Phase / OL Follow Up|Protocol Violation|3
6120000|NCT00887224|9742999|FG001|OL Taper Phase / OL Follow Up|Protocol Violation|0
6120001|NCT00887224|9743000|FG002|OL Taper Phase / OL Follow Up|Protocol Violation|0
6120002|NCT00887224|9742998|FG000|OL Taper Phase / OL Follow Up|Withdrawal by Subject|48
6120003|NCT00887224|9742999|FG001|OL Taper Phase / OL Follow Up|Withdrawal by Subject|0
6120004|NCT00887224|9743000|FG002|OL Taper Phase / OL Follow Up|Withdrawal by Subject|0
6120005|NCT00887224|9742998|FG000|Double-blind (DB) Phase|Adverse Event|0
6120006|NCT00887224|9742999|FG001|Double-blind (DB) Phase|Adverse Event|7
6120007|NCT00887224|9743000|FG002|Double-blind (DB) Phase|Adverse Event|2
6120008|NCT00887224|9742998|FG000|Double-blind (DB) Phase|Failed to return|0
6120009|NCT00887224|9742999|FG001|Double-blind (DB) Phase|Failed to return|2
6120010|NCT00887224|9743000|FG002|Double-blind (DB) Phase|Failed to return|2
6120011|NCT00887224|9742998|FG000|Double-blind (DB) Phase|Lack of Efficacy|0
6120012|NCT00887224|9742999|FG001|Double-blind (DB) Phase|Lack of Efficacy|67
6120013|NCT00887224|9743000|FG002|Double-blind (DB) Phase|Lack of Efficacy|33
6120014|NCT00887224|9742998|FG000|Double-blind (DB) Phase|Lost to Follow-up|0
6120015|NCT00887224|9742999|FG001|Double-blind (DB) Phase|Lost to Follow-up|8
6120016|NCT00887224|9743000|FG002|Double-blind (DB) Phase|Lost to Follow-up|8
6120017|NCT00887224|9742998|FG000|Double-blind (DB) Phase|Other|0
6120018|NCT00887224|9742999|FG001|Double-blind (DB) Phase|Other|2
6120019|NCT00887224|9743000|FG002|Double-blind (DB) Phase|Other|0
6120020|NCT00887224|9742998|FG000|Double-blind (DB) Phase|Protocol Violation|0
6120021|NCT00887224|9742999|FG001|Double-blind (DB) Phase|Protocol Violation|8
6120022|NCT00887224|9743000|FG002|Double-blind (DB) Phase|Protocol Violation|5
6120023|NCT00887224|9742998|FG000|Double-blind (DB) Phase|Withdrawal by Subject|0
6120024|NCT00887224|9742999|FG001|Double-blind (DB) Phase|Withdrawal by Subject|6
6120025|NCT00887224|9743000|FG002|Double-blind (DB) Phase|Withdrawal by Subject|12
6120026|NCT00887224|9742998|FG000|DB Taper Phase / Post Study Follow Up|Adverse Event|0
6120027|NCT00887224|9742999|FG001|DB Taper Phase / Post Study Follow Up|Adverse Event|5
6120028|NCT00887224|9743000|FG002|DB Taper Phase / Post Study Follow Up|Adverse Event|0
6120029|NCT00887224|9742998|FG000|DB Taper Phase / Post Study Follow Up|Failed to return|0
6120030|NCT00887224|9742999|FG001|DB Taper Phase / Post Study Follow Up|Failed to return|5
6120031|NCT00887224|9743000|FG002|DB Taper Phase / Post Study Follow Up|Failed to return|4
6120032|NCT00887224|9742998|FG000|DB Taper Phase / Post Study Follow Up|Physician Decision|0
6120033|NCT00887224|9742999|FG001|DB Taper Phase / Post Study Follow Up|Physician Decision|6
6120034|NCT00887224|9743000|FG002|DB Taper Phase / Post Study Follow Up|Physician Decision|0
6120035|NCT00887224|9742998|FG000|DB Taper Phase / Post Study Follow Up|Lost to Follow-up|0
6120036|NCT00887224|9742999|FG001|DB Taper Phase / Post Study Follow Up|Lost to Follow-up|2
6120037|NCT00887224|9743000|FG002|DB Taper Phase / Post Study Follow Up|Lost to Follow-up|2
6120038|NCT00887224|9742998|FG000|DB Taper Phase / Post Study Follow Up|Other|0
6213057|NCT01600885|9879723|FG000|First Period|Adverse Event|1
6213058|NCT01600885|9879724|FG001|First Period|Adverse Event|1
6213059|NCT01600885|9879723|FG000|First Period|moved out of area|1
6213060|NCT01600885|9879724|FG001|First Period|moved out of area|0
6213061|NCT01601132|9879746|FG000|Overall Study|Patient withdrew consent|1
6213062|NCT01601132|9879746|FG000|Overall Study|Protocol deviation|1
6213063|NCT01601470|9879782|FG000|Period 2 - LCZ696|Physician Decision|1
6213064|NCT01601496|9879788|FG000|Overall Study|Physician Decision|1
6213065|NCT01601496|9879788|FG000|Overall Study|Withdrawal by Subject|1
6213066|NCT01601496|9879788|FG000|Overall Study|Lost to Follow-up|6
6213067|NCT01601496|9879788|FG000|Overall Study|Death|4
6213068|NCT01601496|9879788|FG000|Overall Study|Other: patient refusal to continue|3
6213069|NCT01601535|9879798|FG000|Phase 1|Adverse Event|1
6213070|NCT01601535|9879799|FG001|Phase 1|Adverse Event|0
6213071|NCT01601535|9879800|FG002|Phase 1|Adverse Event|2
6213072|NCT01601535|9879801|FG003|Phase 1|Adverse Event|1
6213073|NCT01601535|9879802|FG004|Phase 1|Adverse Event|0
6213074|NCT01601535|9879803|FG005|Phase 1|Adverse Event|0
6213075|NCT01601535|9879798|FG000|Phase 1|Withdrawal by Subject|2
6213076|NCT01601535|9879799|FG001|Phase 1|Withdrawal by Subject|1
6213077|NCT01601535|9879800|FG002|Phase 1|Withdrawal by Subject|1
6213078|NCT01601535|9879801|FG003|Phase 1|Withdrawal by Subject|2
6213079|NCT01601535|9879802|FG004|Phase 1|Withdrawal by Subject|0
6213080|NCT01601535|9879803|FG005|Phase 1|Withdrawal by Subject|0
6213081|NCT01601535|9879798|FG000|Phase 1|Progressive Disease|2
6213082|NCT01601535|9879799|FG001|Phase 1|Progressive Disease|3
6213083|NCT01601535|9879800|FG002|Phase 1|Progressive Disease|2
6213084|NCT01601535|9879801|FG003|Phase 1|Progressive Disease|1
6213085|NCT01601535|9879802|FG004|Phase 1|Progressive Disease|0
6213086|NCT01601535|9879803|FG005|Phase 1|Progressive Disease|0
6213087|NCT01601535|9879798|FG000|Phase 1|Started Another Treatment|1
6213088|NCT01601535|9879799|FG001|Phase 1|Started Another Treatment|2
6213089|NCT01601535|9879800|FG002|Phase 1|Started Another Treatment|0
6213090|NCT01601535|9879801|FG003|Phase 1|Started Another Treatment|0
6213091|NCT01601535|9879802|FG004|Phase 1|Started Another Treatment|0
6213092|NCT01601535|9879803|FG005|Phase 1|Started Another Treatment|0
6213093|NCT01601535|9879798|FG000|Phase 2|Adverse Event|0
6213094|NCT01601535|9879799|FG001|Phase 2|Adverse Event|0
6213095|NCT01601535|9879800|FG002|Phase 2|Adverse Event|0
6213096|NCT01601535|9879801|FG003|Phase 2|Adverse Event|0
6213097|NCT01601535|9879802|FG004|Phase 2|Adverse Event|5
6213098|NCT01601535|9879803|FG005|Phase 2|Adverse Event|1
6213099|NCT01601535|9879798|FG000|Phase 2|Withdrawal by Subject|0
6213100|NCT01601535|9879799|FG001|Phase 2|Withdrawal by Subject|0
6120039|NCT00887224|9742999|FG001|DB Taper Phase / Post Study Follow Up|Other|11
6120040|NCT00887224|9743000|FG002|DB Taper Phase / Post Study Follow Up|Other|12
6120041|NCT00887224|9742998|FG000|DB Taper Phase / Post Study Follow Up|Protocol Violation|0
6120042|NCT00887224|9742999|FG001|DB Taper Phase / Post Study Follow Up|Protocol Violation|4
6120043|NCT00887224|9743000|FG002|DB Taper Phase / Post Study Follow Up|Protocol Violation|1
6120044|NCT00887224|9742998|FG000|DB Taper Phase / Post Study Follow Up|Withdrawal by Subject|0
6120045|NCT00887224|9742999|FG001|DB Taper Phase / Post Study Follow Up|Withdrawal by Subject|8
6120046|NCT00887224|9743000|FG002|DB Taper Phase / Post Study Follow Up|Withdrawal by Subject|11
6120047|NCT00887289|9743012|FG000|Overall Study|Lack of Efficacy|14
6120048|NCT00887289|9743012|FG000|Overall Study|Adverse Event|27
6120049|NCT00887289|9743012|FG000|Overall Study|Withdrawal by Subject|26
6120050|NCT00887289|9743012|FG000|Overall Study|Lost to Follow-up|8
6120051|NCT00887289|9743012|FG000|Overall Study|Other|20
6120052|NCT00887341|9743018|FG000|Overall Study|Refused treatment|1
6120053|NCT00887341|9743019|FG001|Overall Study|Refused treatment|0
6120054|NCT00887341|9743018|FG000|Overall Study|Withdrawal by Subject|1
6120055|NCT00887341|9743019|FG001|Overall Study|Withdrawal by Subject|1
6120056|NCT00887341|9743018|FG000|Overall Study|Adverse Event|0
6120057|NCT00887341|9743019|FG001|Overall Study|Adverse Event|1
6120058|NCT00887341|9743018|FG000|Overall Study|Lost to Follow-up|0
6120059|NCT00887341|9743019|FG001|Overall Study|Lost to Follow-up|1
6213101|NCT01601535|9879800|FG002|Phase 2|Withdrawal by Subject|0
6120060|NCT00887354|9743027|FG000|Treatment Phase (Week 0 to Week 26)|Death|0
6120061|NCT00887354|9743028|FG001|Treatment Phase (Week 0 to Week 26)|Death|1
6213102|NCT01601535|9879801|FG003|Phase 2|Withdrawal by Subject|0
6213103|NCT01601535|9879802|FG004|Phase 2|Withdrawal by Subject|8
6213104|NCT01601535|9879803|FG005|Phase 2|Withdrawal by Subject|2
6213105|NCT01601535|9879798|FG000|Phase 2|Progressive Disease|0
6213106|NCT01601535|9879799|FG001|Phase 2|Progressive Disease|0
6213107|NCT01601535|9879800|FG002|Phase 2|Progressive Disease|0
6120062|NCT00887354|9743027|FG000|Treatment Phase (Week 0 to Week 26)|Sponsor Decision|1
6120063|NCT00887354|9743028|FG001|Treatment Phase (Week 0 to Week 26)|Sponsor Decision|1
6120064|NCT00887354|9743027|FG000|Treatment Phase (Week 0 to Week 26)|Physician Decision|2
6120065|NCT00887354|9743028|FG001|Treatment Phase (Week 0 to Week 26)|Physician Decision|1
6120066|NCT00887354|9743027|FG000|Treatment Phase (Week 0 to Week 26)|Withdrawal by Subject|14
6120067|NCT00887354|9743028|FG001|Treatment Phase (Week 0 to Week 26)|Withdrawal by Subject|8
6120068|NCT00887354|9743027|FG000|Treatment Phase (Week 0 to Week 26)|Adverse Event|3
6120069|NCT00887354|9743028|FG001|Treatment Phase (Week 0 to Week 26)|Adverse Event|3
6120070|NCT00887354|9743027|FG000|Treatment Phase (Week 0 to Week 26)|Lost to Follow-up|2
6120071|NCT00887354|9743028|FG001|Treatment Phase (Week 0 to Week 26)|Lost to Follow-up|1
6120072|NCT00887354|9743027|FG000|Treatment Phase (Week 0 to Week 26)|Entry Criteria Not Met|3
6120073|NCT00887354|9743028|FG001|Treatment Phase (Week 0 to Week 26)|Entry Criteria Not Met|3
6120074|NCT00887354|9743027|FG000|Treatment Phase (Week 0 to Week 26)|Caregiver Decision|1
6120075|NCT00887354|9743028|FG001|Treatment Phase (Week 0 to Week 26)|Caregiver Decision|2
6120076|NCT00887354|9743027|FG000|Treatment Phase (Week 0 to Week 26)|No efficacy data|20
6120077|NCT00887354|9743028|FG001|Treatment Phase (Week 0 to Week 26)|No efficacy data|25
6120078|NCT00887354|9743027|FG000|Treatment Phase (Week 0 to Week 26)|Not Treated|5
6120079|NCT00887354|9743028|FG001|Treatment Phase (Week 0 to Week 26)|Not Treated|3
6213108|NCT01601535|9879801|FG003|Phase 2|Progressive Disease|0
6213109|NCT01601535|9879802|FG004|Phase 2|Progressive Disease|5
6213110|NCT01601535|9879803|FG005|Phase 2|Progressive Disease|7
6213111|NCT01601535|9879798|FG000|Phase 2|Started Another Treatment|0
6213112|NCT01601535|9879799|FG001|Phase 2|Started Another Treatment|0
6213113|NCT01601535|9879800|FG002|Phase 2|Started Another Treatment|0
6213114|NCT01601535|9879801|FG003|Phase 2|Started Another Treatment|0
6213115|NCT01601535|9879802|FG004|Phase 2|Started Another Treatment|1
6213116|NCT01601535|9879803|FG005|Phase 2|Started Another Treatment|2
6213117|NCT01601626|9879829|FG000|Overall Study|Death|1
6213118|NCT01601626|9879830|FG001|Overall Study|Death|1
6213119|NCT01601626|9879831|FG002|Overall Study|Death|1
6213120|NCT01601626|9879829|FG000|Overall Study|Lost to Follow-up|1
6213121|NCT01601626|9879830|FG001|Overall Study|Lost to Follow-up|2
6213122|NCT01601626|9879831|FG002|Overall Study|Lost to Follow-up|0
6213123|NCT01601626|9879829|FG000|Overall Study|Unable to Get to Clinic|0
6213124|NCT01601626|9879830|FG001|Overall Study|Unable to Get to Clinic|1
6213125|NCT01601626|9879831|FG002|Overall Study|Unable to Get to Clinic|0
6213126|NCT01601626|9879829|FG000|Overall Study|Withdrawal by Subject|0
6213127|NCT01601626|9879830|FG001|Overall Study|Withdrawal by Subject|1
6213128|NCT01601626|9879831|FG002|Overall Study|Withdrawal by Subject|1
6213129|NCT01601626|9879829|FG000|Overall Study|Not Willing to Adhere to Requirements|1
6213130|NCT01601626|9879830|FG001|Overall Study|Not Willing to Adhere to Requirements|0
6213131|NCT01601626|9879831|FG002|Overall Study|Not Willing to Adhere to Requirements|0
6213132|NCT01601652|9879839|FG000|Overall Study|Death|1
6213133|NCT01601704|9879849|FG000|Overall Study|Randomized but not dispensed study med|1
6213134|NCT01601704|9879850|FG001|Overall Study|Randomized but not dispensed study med|4
6213135|NCT01601821|9879862|FG000|Overall Study|Death|2
6213136|NCT01601821|9879863|FG001|Overall Study|Death|5
6213137|NCT01601821|9879862|FG000|Overall Study|Protocol Violation|2
6213138|NCT01601821|9879863|FG001|Overall Study|Protocol Violation|2
6213139|NCT01601821|9879862|FG000|Overall Study|Lost to Follow-up|6
6213140|NCT01601821|9879863|FG001|Overall Study|Lost to Follow-up|14
6213141|NCT01601821|9879862|FG000|Overall Study|Withdrawal by Subject|1
6213142|NCT01601821|9879863|FG001|Overall Study|Withdrawal by Subject|0
6213143|NCT01601821|9879862|FG000|Overall Study|Graft Loss|6
6213144|NCT01601821|9879863|FG001|Overall Study|Graft Loss|6
6213145|NCT01601821|9879862|FG000|Overall Study|Study Events|7
6213146|NCT01601821|9879863|FG001|Overall Study|Study Events|1
6213147|NCT01601821|9879862|FG000|Overall Study|Other|5
6213148|NCT01601821|9879863|FG001|Overall Study|Other|1
6213149|NCT01601847|9879871|FG000|Overall Study|Death|1
6213150|NCT01601847|9879872|FG001|Overall Study|Death|0
6213151|NCT01601847|9879871|FG000|Overall Study|Withdrawal by Subject|11
6213152|NCT01601847|9879872|FG001|Overall Study|Withdrawal by Subject|7
6213153|NCT01601847|9879871|FG000|Overall Study|Lost to Follow-up|1
6213154|NCT01601847|9879872|FG001|Overall Study|Lost to Follow-up|3
6213155|NCT01601873|9879890|FG000|Overall Study|Lost to Follow-up|2
6213156|NCT01601873|9879891|FG001|Overall Study|Lost to Follow-up|3
6213157|NCT01602120|9879916|FG000|Overall Study|Adverse Event|3
6213158|NCT01602120|9879917|FG001|Overall Study|Adverse Event|6
6213159|NCT01602120|9879918|FG002|Overall Study|Adverse Event|0
6213160|NCT01602120|9879919|FG003|Overall Study|Adverse Event|2
6213161|NCT01602120|9879916|FG000|Overall Study|Death|0
6213162|NCT01602120|9879917|FG001|Overall Study|Death|4
6213163|NCT01602120|9879918|FG002|Overall Study|Death|0
6213164|NCT01602120|9879919|FG003|Overall Study|Death|0
6213165|NCT01602120|9879916|FG000|Overall Study|Lost to Follow-up|0
6213166|NCT01602120|9879917|FG001|Overall Study|Lost to Follow-up|1
6213167|NCT01602120|9879918|FG002|Overall Study|Lost to Follow-up|0
6213168|NCT01602120|9879919|FG003|Overall Study|Lost to Follow-up|1
6213169|NCT01602120|9879916|FG000|Overall Study|Protocol Violation|1
6213170|NCT01602120|9879917|FG001|Overall Study|Protocol Violation|1
6213171|NCT01602120|9879918|FG002|Overall Study|Protocol Violation|0
6213172|NCT01602120|9879919|FG003|Overall Study|Protocol Violation|0
6120080|NCT00887354|9743027|FG000|Open Label Phase (Week 26 to Week 78)|Death|0
6120081|NCT00887354|9743028|FG001|Open Label Phase (Week 26 to Week 78)|Death|2
6120082|NCT00887354|9743027|FG000|Open Label Phase (Week 26 to Week 78)|Physician Decision|0
6120083|NCT00887354|9743028|FG001|Open Label Phase (Week 26 to Week 78)|Physician Decision|1
6120084|NCT00887354|9743027|FG000|Open Label Phase (Week 26 to Week 78)|Withdrawal by Subject|1
6120085|NCT00887354|9743028|FG001|Open Label Phase (Week 26 to Week 78)|Withdrawal by Subject|2
6120086|NCT00887354|9743027|FG000|Open Label Phase (Week 26 to Week 78)|Adverse Event|1
6120087|NCT00887354|9743028|FG001|Open Label Phase (Week 26 to Week 78)|Adverse Event|0
6120088|NCT00887354|9743027|FG000|Open Label Phase (Week 26 to Week 78)|Lost to Follow-up|1
6120089|NCT00887354|9743028|FG001|Open Label Phase (Week 26 to Week 78)|Lost to Follow-up|1
6120090|NCT00887432|9743037|FG000|Overall Study|Start Excluded Therapy|3
6120091|NCT00887432|9743038|FG001|Overall Study|Start Excluded Therapy|0
6120092|NCT00887432|9743037|FG000|Overall Study|Did not complete treatment|6
6120093|NCT00887432|9743038|FG001|Overall Study|Did not complete treatment|8
6120094|NCT00887432|9743037|FG000|Overall Study|Protocol Violation|2
6120095|NCT00887432|9743038|FG001|Overall Study|Protocol Violation|3
6120096|NCT00887432|9743037|FG000|Overall Study|Withdrawal by Subject|3
6120097|NCT00887432|9743038|FG001|Overall Study|Withdrawal by Subject|2
6120098|NCT00887432|9743037|FG000|Overall Study|Lost to Follow-up|1
6120099|NCT00887432|9743038|FG001|Overall Study|Lost to Follow-up|0
6120100|NCT00887432|9743037|FG000|Overall Study|No reason provided|0
6120101|NCT00887432|9743038|FG001|Overall Study|No reason provided|1
6120102|NCT00887484|9743064|FG000|Full Face Treatment (Weeks 5 and 8)|Adverse Event|1
6120103|NCT00887484|9743064|FG000|Full Face Treatment (Weeks 5 and 8)|Lost to Follow-up|1
6120104|NCT00887484|9743064|FG000|Full Face Treatment (Weeks 5 and 8)|Pregnancy|1
6120105|NCT00887549|9743082|FG000|Induction Therapy|Adverse Event|8
6120106|NCT00887549|9743082|FG000|Induction Therapy|Physician Decision|1
6120107|NCT00887549|9743082|FG000|Induction Therapy|Progressive Disease|13
6120108|NCT00887549|9743082|FG000|Induction Therapy|Death due to Study Disease|4
6120109|NCT00887549|9743082|FG000|Induction Therapy|Death due to Study Drug Toxicity|1
6120110|NCT00887549|9743082|FG000|Maintenance Therapy|Adverse Event|16
6120111|NCT00887549|9743082|FG000|Maintenance Therapy|Physician Decision|1
6120112|NCT00887549|9743082|FG000|Maintenance Therapy|Progressive Disease|25
6120113|NCT00887549|9743082|FG000|Maintenance Therapy|Death due to adverse event|1
6120114|NCT00887588|9743110|FG000|Core Period|Death|1
6120115|NCT00887588|9743111|FG001|Core Period|Death|1
6120116|NCT00887588|9743110|FG000|Core Period|Lost to Follow-up|3
6120117|NCT00887588|9743111|FG001|Core Period|Lost to Follow-up|1
6120118|NCT00887588|9743110|FG000|Core Period|Withdrawal by Subject|6
6120119|NCT00887588|9743111|FG001|Core Period|Withdrawal by Subject|8
6120120|NCT00887588|9743110|FG000|Core Period|Adverse Event|9
6120121|NCT00887588|9743111|FG001|Core Period|Adverse Event|11
6120122|NCT00887588|9743110|FG000|Extension Period|Adverse Event|4
6120123|NCT00887588|9743111|FG001|Extension Period|Adverse Event|4
6120124|NCT00887588|9743110|FG000|Extension Period|Death|0
6120125|NCT00887588|9743111|FG001|Extension Period|Death|1
6120126|NCT00887588|9743110|FG000|Extension Period|Protocol deviation|1
6120127|NCT00887588|9743111|FG001|Extension Period|Protocol deviation|0
6120128|NCT00887588|9743110|FG000|Extension Period|Lost to Follow-up|1
6120129|NCT00887588|9743111|FG001|Extension Period|Lost to Follow-up|0
6120130|NCT00887679|9743125|FG000|Overall Study|Withdrawal by Subject|1
6120131|NCT00887679|9743125|FG000|Overall Study|Lost to Follow-up|4
6120132|NCT00887679|9743125|FG000|Overall Study|Physician Decision|5
6120133|NCT00887744|9743130|FG000|Overall Study|Adverse Event|3
6213173|NCT01602120|9879916|FG000|Overall Study|Non-compliance|0
6213174|NCT01602120|9879917|FG001|Overall Study|Non-compliance|3
6213175|NCT01602120|9879918|FG002|Overall Study|Non-compliance|0
6213176|NCT01602120|9879919|FG003|Overall Study|Non-compliance|1
6213177|NCT01602120|9879916|FG000|Overall Study|Withdrawal by Subject|8
6213178|NCT01602120|9879917|FG001|Overall Study|Withdrawal by Subject|17
6213179|NCT01602120|9879918|FG002|Overall Study|Withdrawal by Subject|0
6213180|NCT01602120|9879919|FG003|Overall Study|Withdrawal by Subject|3
6213181|NCT01602120|9879916|FG000|Overall Study|Study Terminated by Sponsor|12
6213182|NCT01602120|9879917|FG001|Overall Study|Study Terminated by Sponsor|24
6213183|NCT01602120|9879918|FG002|Overall Study|Study Terminated by Sponsor|17
6213184|NCT01602120|9879919|FG003|Overall Study|Study Terminated by Sponsor|44
6213185|NCT01602120|9879916|FG000|Overall Study|Physician Decision|2
6213186|NCT01602120|9879917|FG001|Overall Study|Physician Decision|3
6213187|NCT01602120|9879918|FG002|Overall Study|Physician Decision|0
6213188|NCT01602120|9879919|FG003|Overall Study|Physician Decision|0
6213189|NCT01602120|9879916|FG000|Overall Study|Unspecified Reason|3
6213190|NCT01602120|9879917|FG001|Overall Study|Unspecified Reason|1
6213191|NCT01602120|9879918|FG002|Overall Study|Unspecified Reason|0
6213192|NCT01602120|9879919|FG003|Overall Study|Unspecified Reason|2
6120134|NCT00887744|9743130|FG000|Overall Study|Death|1
6120135|NCT00887744|9743130|FG000|Overall Study|Lost to Follow-up|3
6120136|NCT00887744|9743130|FG000|Overall Study|Withdrawal by Subject|18
6120137|NCT00887744|9743130|FG000|Overall Study|Various reasons|9
6120138|NCT00887809|9743136|FG000|Overall Study|Patient Not Treated|3
6120139|NCT00887809|9743137|FG001|Overall Study|Patient Not Treated|0
6120140|NCT00887809|9743136|FG000|Overall Study|Death|1
6120141|NCT00887809|9743137|FG001|Overall Study|Death|0
6120142|NCT00887822|9743145|FG000|Overall Study|Insufficient therapeutic response|53
6120143|NCT00887822|9743146|FG001|Overall Study|Insufficient therapeutic response|55
6120144|NCT00887822|9743145|FG000|Overall Study|Adverse Event|14
6120145|NCT00887822|9743146|FG001|Overall Study|Adverse Event|17
6120146|NCT00887822|9743145|FG000|Overall Study|Failure to return|11
6120147|NCT00887822|9743146|FG001|Overall Study|Failure to return|11
6120148|NCT00887822|9743145|FG000|Overall Study|Refused treatment/Did not cooperate|12
6120149|NCT00887822|9743146|FG001|Overall Study|Refused treatment/Did not cooperate|10
6120150|NCT00887822|9743145|FG000|Overall Study|Administrative/Other than specified|5
6120151|NCT00887822|9743146|FG001|Overall Study|Administrative/Other than specified|4
6120152|NCT00887822|9743145|FG000|Overall Study|Death|2
6120153|NCT00887822|9743146|FG001|Overall Study|Death|3
6120154|NCT00887822|9743145|FG000|Overall Study|Protocol Violation|0
6120155|NCT00887822|9743146|FG001|Overall Study|Protocol Violation|1
6120156|NCT00887822|9743145|FG000|Overall Study|Randomized but not treated|0
6120157|NCT00887822|9743146|FG001|Overall Study|Randomized but not treated|1
6120158|NCT00887913|9743152|FG000|Overall Study|Withdrawal by Subject|6
6120159|NCT00887926|9743160|FG000|Overall Study|Withdrawal by Subject|0
6120160|NCT00887926|9743161|FG001|Overall Study|Withdrawal by Subject|1
6213193|NCT01602224|9879953|FG000|Overall Study|Adverse Event|0
6213194|NCT01602224|9879954|FG001|Overall Study|Adverse Event|1
6213195|NCT01602224|9879955|FG002|Overall Study|Adverse Event|0
6213196|NCT01602224|9879953|FG000|Overall Study|Investigator Decison|1
6213197|NCT01602224|9879954|FG001|Overall Study|Investigator Decison|0
6213198|NCT01602224|9879955|FG002|Overall Study|Investigator Decison|0
6213199|NCT01602224|9879953|FG000|Overall Study|Lost to Follow-up|0
6213200|NCT01602224|9879954|FG001|Overall Study|Lost to Follow-up|0
6213201|NCT01602224|9879955|FG002|Overall Study|Lost to Follow-up|1
6213202|NCT01602224|9879953|FG000|Overall Study|Protocol Violation|0
6213203|NCT01602224|9879954|FG001|Overall Study|Protocol Violation|1
6213204|NCT01602224|9879955|FG002|Overall Study|Protocol Violation|0
6213205|NCT01602224|9879953|FG000|Overall Study|Sponsor Decision|2
6213206|NCT01602224|9879954|FG001|Overall Study|Sponsor Decision|3
6213207|NCT01602224|9879955|FG002|Overall Study|Sponsor Decision|2
6213208|NCT01602224|9879953|FG000|Overall Study|Withdrawal by Subject|5
6213209|NCT01602224|9879954|FG001|Overall Study|Withdrawal by Subject|3
6213210|NCT01602224|9879955|FG002|Overall Study|Withdrawal by Subject|3
6213211|NCT01602315|9879972|FG000|Overall Study|Protocol Violation|0
6120161|NCT00887926|9743162|FG002|Overall Study|Withdrawal by Subject|0
6120162|NCT00887926|9743163|FG003|Overall Study|Withdrawal by Subject|0
6120163|NCT00887978|9743181|FG000|Overall Study|Adverse Event|18
6120164|NCT00887978|9743182|FG001|Overall Study|Adverse Event|5
6120165|NCT00887978|9743181|FG000|Overall Study|Clinical Worsening|4
6120166|NCT00887978|9743182|FG001|Overall Study|Clinical Worsening|4
6120167|NCT00887978|9743181|FG000|Overall Study|Death|2
6120168|NCT00887978|9743182|FG001|Overall Study|Death|3
6120169|NCT00887978|9743181|FG000|Overall Study|Withdrawal by Subject|1
6120170|NCT00887978|9743182|FG001|Overall Study|Withdrawal by Subject|2
6120171|NCT00887978|9743181|FG000|Overall Study|Lost to Follow-up|0
6120172|NCT00887978|9743182|FG001|Overall Study|Lost to Follow-up|1
6120173|NCT00888134|9743188|FG000|Treatment With Study Drug|Withdrawal by Subject|1
6120174|NCT00888134|9743188|FG000|Follow-up|being followed for long-term survival|1
6120175|NCT00888173|9743193|FG000|Overall Study|Wrong Primary|1
6120176|NCT00888173|9743193|FG000|Overall Study|Ineligible: required test not done|1
6120177|NCT00888238|9743197|FG000|Washout Period After Period 2|Adverse Event|0
6120178|NCT00888238|9743198|FG001|Washout Period After Period 2|Adverse Event|0
6120179|NCT00888238|9743199|FG002|Washout Period After Period 2|Adverse Event|1
6120180|NCT00888329|9743207|FG000|Overall Study|Physician Decision|6
6120181|NCT00888329|9743208|FG001|Overall Study|Physician Decision|9
6120182|NCT00888381|9743216|FG000|Overall Study|Lost to Follow-up|0
6120183|NCT00888381|9743217|FG001|Overall Study|Lost to Follow-up|1
6120184|NCT00888433|9743225|FG000|Overall Study|Withdrawal by Subject|1
6120185|NCT00888433|9743226|FG001|Overall Study|Withdrawal by Subject|2
6120186|NCT00888433|9743225|FG000|Overall Study|Missed Visit|2
6120187|NCT00888433|9743226|FG001|Overall Study|Missed Visit|1
6120188|NCT00888615|9743245|FG000|Overall Study|No treatment|2
6213212|NCT01602315|9879973|FG001|Overall Study|Protocol Violation|0
6213213|NCT01602315|9879974|FG002|Overall Study|Protocol Violation|0
6213214|NCT01602315|9879975|FG003|Overall Study|Protocol Violation|0
6213215|NCT01602315|9879976|FG004|Overall Study|Protocol Violation|0
6213216|NCT01602315|9879977|FG005|Overall Study|Protocol Violation|1
6213217|NCT01602315|9879978|FG006|Overall Study|Protocol Violation|0
6213218|NCT01602315|9879972|FG000|Overall Study|Physician Decision|2
6213219|NCT01602315|9879973|FG001|Overall Study|Physician Decision|0
6213220|NCT01602315|9879974|FG002|Overall Study|Physician Decision|0
6213221|NCT01602315|9879975|FG003|Overall Study|Physician Decision|0
6213222|NCT01602315|9879976|FG004|Overall Study|Physician Decision|2
6213223|NCT01602315|9879977|FG005|Overall Study|Physician Decision|1
6213224|NCT01602315|9879978|FG006|Overall Study|Physician Decision|1
6213225|NCT01602315|9879972|FG000|Overall Study|Disease progression|6
6213226|NCT01602315|9879973|FG001|Overall Study|Disease progression|3
6213227|NCT01602315|9879974|FG002|Overall Study|Disease progression|10
6213228|NCT01602315|9879975|FG003|Overall Study|Disease progression|1
6213229|NCT01602315|9879976|FG004|Overall Study|Disease progression|41
6213230|NCT01602315|9879977|FG005|Overall Study|Disease progression|12
6213231|NCT01602315|9879978|FG006|Overall Study|Disease progression|15
6120189|NCT00888654|9743253|FG000|Overall Study|Problems swallowing oral meds.|1
6120190|NCT00888654|9743253|FG000|Overall Study|Not enough oral meds before surgery|3
6120191|NCT00888654|9743253|FG000|Overall Study|Surgery aborted|2
6120192|NCT00888654|9743253|FG000|Overall Study|Withdrawal by Subject|1
6120193|NCT00888654|9743253|FG000|Overall Study|Inelig. due to contraindication of med|1
6120194|NCT00888654|9743253|FG000|Overall Study|Change in surg date|1
6120195|NCT00888654|9743253|FG000|Overall Study|Stopped meds due to headaches|1
6120196|NCT00888849|9743259|FG000|Overall Study|Death|4
6120197|NCT00888849|9743260|FG001|Overall Study|Death|7
6120198|NCT00888849|9743259|FG000|Overall Study|Lost to Follow-up|1
6120199|NCT00888849|9743260|FG001|Overall Study|Lost to Follow-up|2
6120200|NCT00888927|9743270|FG000|Overall Study|Adverse Event|0
6120201|NCT00888927|9743271|FG001|Overall Study|Adverse Event|0
6120202|NCT00888927|9743272|FG002|Overall Study|Adverse Event|0
6120203|NCT00888927|9743273|FG003|Overall Study|Adverse Event|1
6120204|NCT00888927|9743270|FG000|Overall Study|Withdrawal of consent|0
6120205|NCT00888927|9743271|FG001|Overall Study|Withdrawal of consent|0
6120206|NCT00888927|9743272|FG002|Overall Study|Withdrawal of consent|0
6120207|NCT00888927|9743273|FG003|Overall Study|Withdrawal of consent|1
6120208|NCT00888940|9743285|FG000|Overall Study|Adverse Event|12
6120209|NCT00888940|9743286|FG001|Overall Study|Adverse Event|3
6120210|NCT00888940|9743285|FG000|Overall Study|Lost to Follow-up|5
6120211|NCT00888940|9743286|FG001|Overall Study|Lost to Follow-up|5
6120212|NCT00888940|9743285|FG000|Overall Study|Randomized Not Treated|11
6120213|NCT00888940|9743286|FG001|Overall Study|Randomized Not Treated|13
6120214|NCT00889005|9743298|FG000|Overall Study|Lost to Follow-up|4
6120215|NCT00889005|9743299|FG001|Overall Study|Lost to Follow-up|2
6120216|NCT00889005|9743298|FG000|Overall Study|Withdrawal by Subject|4
6120217|NCT00889005|9743299|FG001|Overall Study|Withdrawal by Subject|0
6120218|NCT00889252|9743333|FG000|Overall Study|Adverse Event|2
6120219|NCT00889252|9743334|FG001|Overall Study|Adverse Event|4
6120220|NCT00889252|9743333|FG000|Overall Study|Withdrawal by Subject|3
6120221|NCT00889252|9743334|FG001|Overall Study|Withdrawal by Subject|0
6120222|NCT00889252|9743333|FG000|Overall Study|Protocol Violation|2
6120223|NCT00889252|9743334|FG001|Overall Study|Protocol Violation|0
6120224|NCT00889265|9743340|FG000|Overall Study|Adverse Event|1
6120225|NCT00889265|9743340|FG000|Overall Study|Lost to Follow-up|5
6120226|NCT00889265|9743340|FG000|Overall Study|Protocol Violation|1
6120227|NCT00889603|9743362|FG000|Overall Study|Adverse Event|7
6120228|NCT00889603|9743362|FG000|Overall Study|Death|3
6120229|NCT00889603|9743362|FG000|Overall Study|Lost to Follow-up|19
6120230|NCT00889603|9743362|FG000|Overall Study|No longer willing to participant in stud|4
6120231|NCT00889603|9743362|FG000|Overall Study|Other|4
6120232|NCT00889681|9743366|FG000|Overall Study|Not meeting qualification Criteria|2
6120233|NCT00889681|9743366|FG000|Overall Study|Insurance disapproval|1
6120234|NCT00889707|9743372|FG000|Overall Study|Adverse Event|1
6120235|NCT00889707|9743373|FG001|Overall Study|Adverse Event|0
6120236|NCT00889707|9743372|FG000|Overall Study|Withdrawal by Subject|4
6120237|NCT00889707|9743373|FG001|Overall Study|Withdrawal by Subject|3
6120238|NCT00889707|9743372|FG000|Overall Study|Lost to Follow-up|0
6120239|NCT00889707|9743373|FG001|Overall Study|Lost to Follow-up|2
6120240|NCT00889707|9743372|FG000|Overall Study|Lack of Efficacy|2
6120241|NCT00889707|9743373|FG001|Overall Study|Lack of Efficacy|5
6120242|NCT00889720|9743379|FG000|Overall Study|Withdrawal by Subject|4
6120243|NCT00889720|9743379|FG000|Overall Study|Other|4
6120244|NCT00889863|9743387|FG000|Part I: Open Label|Death|1
6120245|NCT00889863|9743388|FG001|Part I: Open Label|Death|0
6120246|NCT00889863|9743387|FG000|Part I: Open Label|Adverse Event|4
6120247|NCT00889863|9743388|FG001|Part I: Open Label|Adverse Event|0
6120248|NCT00889863|9743387|FG000|Part I: Open Label|Unsatisfactory therapeutic effect|72
6120249|NCT00889863|9743388|FG001|Part I: Open Label|Unsatisfactory therapeutic effect|0
6120250|NCT00889863|9743387|FG000|Part II: Randomized Double Blind|Adverse Event|0
6120251|NCT00889863|9743388|FG001|Part II: Randomized Double Blind|Adverse Event|4
6120252|NCT00889863|9743387|FG000|Part II: Randomized Double Blind|Unsatisfactory therapeutic effect|11
6120253|NCT00889863|9743388|FG001|Part II: Randomized Double Blind|Unsatisfactory therapeutic effect|20
6120254|NCT00889863|9743387|FG000|Part II: Randomized Double Blind|Withdrawal by Subject|0
6120255|NCT00889863|9743388|FG001|Part II: Randomized Double Blind|Withdrawal by Subject|1
6120256|NCT00889863|9743387|FG000|Part II: Randomized Double Blind|Protocol deviation|0
6120257|NCT00889863|9743388|FG001|Part II: Randomized Double Blind|Protocol deviation|1
6120258|NCT00890045|9743419|FG000|Overall Study|Death|0
6120259|NCT00890045|9743420|FG001|Overall Study|Death|1
6120260|NCT00890045|9743419|FG000|Overall Study|Did not receive HeRO Graft|0
6120261|NCT00890045|9743420|FG001|Overall Study|Did not receive HeRO Graft|2
6120262|NCT00890045|9743419|FG000|Overall Study|Lost to Follow-up|5
6120263|NCT00890045|9743420|FG001|Overall Study|Lost to Follow-up|7
6120264|NCT00890084|9743426|FG000|Overall Study|Adverse Event|16
6120265|NCT00890084|9743426|FG000|Overall Study|Lost to Follow-up|126
6120266|NCT00890097|9743433|FG000|Overall Study|Adverse Event|21
6120267|NCT00890097|9743434|FG001|Overall Study|Adverse Event|32
6120268|NCT00890097|9743435|FG002|Overall Study|Adverse Event|28
6120269|NCT00890097|9743433|FG000|Overall Study|Decision Unrelated to an Adverse Event|15
6120270|NCT00890097|9743434|FG001|Overall Study|Decision Unrelated to an Adverse Event|12
6120271|NCT00890097|9743435|FG002|Overall Study|Decision Unrelated to an Adverse Event|17
6120272|NCT00890097|9743433|FG000|Overall Study|Withdrew Consent|9
6120273|NCT00890097|9743434|FG001|Overall Study|Withdrew Consent|6
6120274|NCT00890097|9743435|FG002|Overall Study|Withdrew Consent|9
6120275|NCT00890097|9743433|FG000|Overall Study|Lost to Follow-up|5
6120276|NCT00890097|9743434|FG001|Overall Study|Lost to Follow-up|5
6120277|NCT00890097|9743435|FG002|Overall Study|Lost to Follow-up|5
6120278|NCT00890097|9743433|FG000|Overall Study|Noncompliance|0
6120279|NCT00890097|9743434|FG001|Overall Study|Noncompliance|4
6120280|NCT00890097|9743435|FG002|Overall Study|Noncompliance|4
6120281|NCT00890097|9743433|FG000|Overall Study|Sponsor Decision|7
6120282|NCT00890097|9743434|FG001|Overall Study|Sponsor Decision|11
6120283|NCT00890097|9743435|FG002|Overall Study|Sponsor Decision|7
6120284|NCT00890097|9743433|FG000|Overall Study|Did not attend final visit|2
6120285|NCT00890097|9743434|FG001|Overall Study|Did not attend final visit|3
6120286|NCT00890097|9743435|FG002|Overall Study|Did not attend final visit|0
6120287|NCT00890097|9743433|FG000|Overall Study|Subject Decision|3
6120288|NCT00890097|9743434|FG001|Overall Study|Subject Decision|2
6120289|NCT00890097|9743435|FG002|Overall Study|Subject Decision|6
6120290|NCT00890097|9743433|FG000|Overall Study|Randomization Error|2
6120291|NCT00890097|9743434|FG001|Overall Study|Randomization Error|0
6120292|NCT00890097|9743435|FG002|Overall Study|Randomization Error|0
6120293|NCT00890097|9743433|FG000|Overall Study|Failed inclusion criteria|3
6120294|NCT00890097|9743434|FG001|Overall Study|Failed inclusion criteria|4
6120295|NCT00890097|9743435|FG002|Overall Study|Failed inclusion criteria|0
6120296|NCT00890097|9743433|FG000|Overall Study|Transportation|0
6120297|NCT00890097|9743434|FG001|Overall Study|Transportation|2
6120298|NCT00890097|9743435|FG002|Overall Study|Transportation|0
6120299|NCT00890097|9743433|FG000|Overall Study|Subject Moved|0
6120300|NCT00890097|9743434|FG001|Overall Study|Subject Moved|4
6120301|NCT00890097|9743435|FG002|Overall Study|Subject Moved|0
6120302|NCT00890097|9743433|FG000|Overall Study|Protocol Deviation|1
6120303|NCT00890097|9743434|FG001|Overall Study|Protocol Deviation|1
6120304|NCT00890097|9743435|FG002|Overall Study|Protocol Deviation|1
6120305|NCT00890201|9743454|FG000|Overall Study|Protocol Violation|5
6213232|NCT01602315|9879972|FG000|Overall Study|Death|1
6213233|NCT01602315|9879973|FG001|Overall Study|Death|1
6213234|NCT01602315|9879974|FG002|Overall Study|Death|1
6213235|NCT01602315|9879975|FG003|Overall Study|Death|1
6213236|NCT01602315|9879976|FG004|Overall Study|Death|7
6213237|NCT01602315|9879977|FG005|Overall Study|Death|2
6213238|NCT01602315|9879978|FG006|Overall Study|Death|2
6213239|NCT01602315|9879972|FG000|Overall Study|Withdrawal by Subject|2
6213240|NCT01602315|9879973|FG001|Overall Study|Withdrawal by Subject|0
6287389|NCT02349295|9999713|FG007|Follow-Up Period (Up to 12-24 Weeks)|Adverse Event|0
6287390|NCT02349295|9999714|FG008|Follow-Up Period (Up to 12-24 Weeks)|Adverse Event|0
6287391|NCT02349295|9999715|FG009|Follow-Up Period (Up to 12-24 Weeks)|Adverse Event|0
6287392|NCT02349295|9999716|FG010|Follow-Up Period (Up to 12-24 Weeks)|Adverse Event|0
6287393|NCT02349295|9999717|FG011|Follow-Up Period (Up to 12-24 Weeks)|Adverse Event|1
6287394|NCT02349295|9999718|FG012|Follow-Up Period (Up to 12-24 Weeks)|Adverse Event|1
6287395|NCT02349295|9999719|FG013|Follow-Up Period (Up to 12-24 Weeks)|Adverse Event|0
6287396|NCT02349295|9999706|FG000|Follow-Up Period (Up to 12-24 Weeks)|Physician Decision|0
6287397|NCT02349295|9999707|FG001|Follow-Up Period (Up to 12-24 Weeks)|Physician Decision|0
6120306|NCT00890201|9743455|FG001|Overall Study|Protocol Violation|56
6120307|NCT00890552|9743473|FG000|Enrollment and Pre-treatment|Death/ lost to follow up|1
6120308|NCT00890552|9743473|FG000|On-treatment|Early prog disease/ death|10
6120309|NCT00890695|9743496|FG000|Overall Study|Protocol Violation|1
6120310|NCT00890695|9743497|FG001|Overall Study|Protocol Violation|0
6120311|NCT00890825|9743514|FG000|Overall Study|Withdrawal by Subject|1
6120312|NCT00890825|9743515|FG001|Overall Study|Withdrawal by Subject|0
6120313|NCT00890825|9743514|FG000|Overall Study|Alive at data cut off (DCO)|13
6120314|NCT00890825|9743515|FG001|Overall Study|Alive at data cut off (DCO)|14
6120315|NCT00890929|9743525|FG000|Overall Study|Death before treatment|2
6120316|NCT00890929|9743525|FG000|Overall Study|Withdrawal by Subject|3
6120317|NCT00890929|9743525|FG000|Overall Study|Physician Decision|1
6120318|NCT00891020|9743541|FG000|24 Week Treatment Period|Adverse event or intercurrent illness|11
6120319|NCT00891020|9743542|FG001|24 Week Treatment Period|Adverse event or intercurrent illness|32
6120320|NCT00891020|9743543|FG002|24 Week Treatment Period|Adverse event or intercurrent illness|17
6120321|NCT00891020|9743541|FG000|24 Week Treatment Period|Death|0
6120322|NCT00891020|9743542|FG001|24 Week Treatment Period|Death|2
6120323|NCT00891020|9743543|FG002|24 Week Treatment Period|Death|0
6120324|NCT00891020|9743541|FG000|24 Week Treatment Period|Insufficient therapeutic response|6
6120325|NCT00891020|9743542|FG001|24 Week Treatment Period|Insufficient therapeutic response|9
6120326|NCT00891020|9743543|FG002|24 Week Treatment Period|Insufficient therapeutic response|15
6120327|NCT00891020|9743541|FG000|24 Week Treatment Period|Failure to return|4
6120328|NCT00891020|9743542|FG001|24 Week Treatment Period|Failure to return|5
6120329|NCT00891020|9743543|FG002|24 Week Treatment Period|Failure to return|5
6120330|NCT00891020|9743541|FG000|24 Week Treatment Period|Violation of selection criteria at entry|1
6213241|NCT01602315|9879974|FG002|Overall Study|Withdrawal by Subject|2
6213242|NCT01602315|9879975|FG003|Overall Study|Withdrawal by Subject|0
6213243|NCT01602315|9879976|FG004|Overall Study|Withdrawal by Subject|6
6213244|NCT01602315|9879977|FG005|Overall Study|Withdrawal by Subject|0
6120331|NCT00891020|9743542|FG001|24 Week Treatment Period|Violation of selection criteria at entry|0
6120332|NCT00891020|9743543|FG002|24 Week Treatment Period|Violation of selection criteria at entry|2
6120333|NCT00891020|9743541|FG000|24 Week Treatment Period|Other protocol violation|1
6120334|NCT00891020|9743542|FG001|24 Week Treatment Period|Other protocol violation|1
6120335|NCT00891020|9743543|FG002|24 Week Treatment Period|Other protocol violation|2
6120336|NCT00891020|9743541|FG000|24 Week Treatment Period|Refused treatment/did not cooperate|3
6213245|NCT01602315|9879978|FG006|Overall Study|Withdrawal by Subject|1
6213246|NCT01602315|9879972|FG000|Overall Study|Adverse Event|5
6213247|NCT01602315|9879973|FG001|Overall Study|Adverse Event|1
6213248|NCT01602315|9879974|FG002|Overall Study|Adverse Event|5
6213249|NCT01602315|9879975|FG003|Overall Study|Adverse Event|4
6213250|NCT01602315|9879976|FG004|Overall Study|Adverse Event|15
6213251|NCT01602315|9879977|FG005|Overall Study|Adverse Event|3
6213252|NCT01602315|9879978|FG006|Overall Study|Adverse Event|9
6213253|NCT01602315|9879972|FG000|Overall Study|Subject/guardian decision|0
6213254|NCT01602315|9879973|FG001|Overall Study|Subject/guardian decision|0
6213255|NCT01602315|9879974|FG002|Overall Study|Subject/guardian decision|0
6213256|NCT01602315|9879975|FG003|Overall Study|Subject/guardian decision|0
6213257|NCT01602315|9879976|FG004|Overall Study|Subject/guardian decision|0
6213258|NCT01602315|9879977|FG005|Overall Study|Subject/guardian decision|0
6213259|NCT01602315|9879978|FG006|Overall Study|Subject/guardian decision|1
6213260|NCT01602315|9879972|FG000|Overall Study|Cross-over patients to combo treatment|0
6213261|NCT01602315|9879973|FG001|Overall Study|Cross-over patients to combo treatment|0
6213262|NCT01602315|9879974|FG002|Overall Study|Cross-over patients to combo treatment|0
6213263|NCT01602315|9879975|FG003|Overall Study|Cross-over patients to combo treatment|0
6213264|NCT01602315|9879976|FG004|Overall Study|Cross-over patients to combo treatment|0
6213265|NCT01602315|9879977|FG005|Overall Study|Cross-over patients to combo treatment|16
6213266|NCT01602315|9879978|FG006|Overall Study|Cross-over patients to combo treatment|0
6213267|NCT01602341|9880016|FG000|Overall Study|Adverse Event|0
6213268|NCT01602341|9880017|FG001|Overall Study|Adverse Event|1
6213269|NCT01602419|9880027|FG000|Overall Study|Not treated with Wilate|9
6213270|NCT01602419|9880027|FG000|Overall Study|Adverse Drug Reaction|4
6213271|NCT01602419|9880027|FG000|Overall Study|Insurance issues|3
6213272|NCT01602419|9880027|FG000|Overall Study|Changed treatment centre|1
6213273|NCT01602419|9880027|FG000|Overall Study|Treatment centre closed|1
6213274|NCT01602419|9880027|FG000|Overall Study|Withdrawal by Subject|5
6213275|NCT01602419|9880027|FG000|Overall Study|Lost to Follow-up|6
6213276|NCT01602484|9880074|FG000|Overall Study|Airway issues unrelated to study|0
6213277|NCT01602484|9880075|FG001|Overall Study|Airway issues unrelated to study|1
6213278|NCT01602510|9880081|FG000|Open Label Phase|Adverse Event|46
6213279|NCT01602510|9880082|FG001|Open Label Phase|Adverse Event|0
6213280|NCT01602510|9880083|FG002|Open Label Phase|Adverse Event|0
6213281|NCT01602510|9880081|FG000|Open Label Phase|Lack of Efficacy|22
6213282|NCT01602510|9880082|FG001|Open Label Phase|Lack of Efficacy|0
6213283|NCT01602510|9880083|FG002|Open Label Phase|Lack of Efficacy|0
6213284|NCT01602510|9880081|FG000|Open Label Phase|Protocol Violation|15
6213285|NCT01602510|9880082|FG001|Open Label Phase|Protocol Violation|0
6213286|NCT01602510|9880083|FG002|Open Label Phase|Protocol Violation|0
6213287|NCT01602510|9880081|FG000|Open Label Phase|Met protocol-defined stopping criteria|122
6213288|NCT01602510|9880082|FG001|Open Label Phase|Met protocol-defined stopping criteria|0
6213289|NCT01602510|9880083|FG002|Open Label Phase|Met protocol-defined stopping criteria|0
6213290|NCT01602510|9880081|FG000|Open Label Phase|Lost to Follow-up|22
6213291|NCT01602510|9880082|FG001|Open Label Phase|Lost to Follow-up|0
6213292|NCT01602510|9880083|FG002|Open Label Phase|Lost to Follow-up|0
6213293|NCT01602510|9880081|FG000|Open Label Phase|Physician Decision|19
6213294|NCT01602510|9880082|FG001|Open Label Phase|Physician Decision|0
6213295|NCT01602510|9880083|FG002|Open Label Phase|Physician Decision|0
6213296|NCT01602510|9880081|FG000|Open Label Phase|Withdrawal by Subject|57
6213297|NCT01602510|9880082|FG001|Open Label Phase|Withdrawal by Subject|0
6213298|NCT01602510|9880083|FG002|Open Label Phase|Withdrawal by Subject|0
6213299|NCT01602510|9880081|FG000|Randomized Phase|Adverse Event|0
6213300|NCT01602510|9880082|FG001|Randomized Phase|Adverse Event|2
6213301|NCT01602510|9880083|FG002|Randomized Phase|Adverse Event|6
6213302|NCT01602510|9880081|FG000|Randomized Phase|Lack of Efficacy|0
6213303|NCT01602510|9880082|FG001|Randomized Phase|Lack of Efficacy|4
6213304|NCT01602510|9880083|FG002|Randomized Phase|Lack of Efficacy|4
6213305|NCT01602510|9880081|FG000|Randomized Phase|Protocol Violation|0
6213306|NCT01602510|9880082|FG001|Randomized Phase|Protocol Violation|3
6213307|NCT01602510|9880083|FG002|Randomized Phase|Protocol Violation|3
6213308|NCT01602510|9880081|FG000|Randomized Phase|Met protocol-defined stopping criteria|0
6213309|NCT01602510|9880082|FG001|Randomized Phase|Met protocol-defined stopping criteria|58
6213310|NCT01602510|9880083|FG002|Randomized Phase|Met protocol-defined stopping criteria|48
6213311|NCT01602510|9880081|FG000|Randomized Phase|Lost to Follow-up|0
6213312|NCT01602510|9880082|FG001|Randomized Phase|Lost to Follow-up|1
6213313|NCT01602510|9880083|FG002|Randomized Phase|Lost to Follow-up|3
6213314|NCT01602510|9880081|FG000|Randomized Phase|Physician Decision|0
6213315|NCT01602510|9880082|FG001|Randomized Phase|Physician Decision|0
6213316|NCT01602510|9880083|FG002|Randomized Phase|Physician Decision|2
5980851|NCT01434602|9569525|FG002|Phase II Recommended Phase 2 Dose|Withdrawal by Subject|0
6120337|NCT00891020|9743542|FG001|24 Week Treatment Period|Refused treatment/did not cooperate|2
6213317|NCT01602510|9880081|FG000|Randomized Phase|Withdrawal by Subject|0
6213318|NCT01602510|9880082|FG001|Randomized Phase|Withdrawal by Subject|6
6213319|NCT01602510|9880083|FG002|Randomized Phase|Withdrawal by Subject|7
6213320|NCT01602549|9880091|FG000|Overall Study|Protocol Violation|0
6213321|NCT01602549|9880092|FG001|Overall Study|Protocol Violation|1
6213322|NCT01602549|9880091|FG000|Overall Study|Withdrawal by Subject|1
6213323|NCT01602549|9880092|FG001|Overall Study|Withdrawal by Subject|0
6213324|NCT01602562|9880102|FG000|Overall Study|Adverse Event|3
6213325|NCT01602562|9880103|FG001|Overall Study|Adverse Event|1
6213326|NCT01602562|9880102|FG000|Overall Study|Physician Decision|1
6213327|NCT01602562|9880103|FG001|Overall Study|Physician Decision|1
6213328|NCT01602562|9880102|FG000|Overall Study|Withdrawal by Subject|1
6213329|NCT01602562|9880103|FG001|Overall Study|Withdrawal by Subject|1
6213330|NCT01602744|9880161|FG000|Overall Study|Death|17
6213331|NCT01602744|9880162|FG001|Overall Study|Death|15
6213332|NCT01602744|9880161|FG000|Overall Study|Lost to Follow-up|13
6213333|NCT01602744|9880162|FG001|Overall Study|Lost to Follow-up|8
6213334|NCT01602965|9880170|FG000|Overall Study|Lost to Follow-up|4
6213335|NCT01602965|9880171|FG001|Overall Study|Lost to Follow-up|2
6213336|NCT01603082|9880188|FG000|Overall Study|Adverse Event|0
6213337|NCT01603082|9880189|FG001|Overall Study|Adverse Event|1
6213338|NCT01603082|9880188|FG000|Overall Study|Withdrawal by Subject|1
6213339|NCT01603082|9880189|FG001|Overall Study|Withdrawal by Subject|0
6213340|NCT01603082|9880188|FG000|Overall Study|Failed inclusion criterion after dosed|1
6213341|NCT01603082|9880189|FG001|Overall Study|Failed inclusion criterion after dosed|0
6213342|NCT01603277|9880197|FG000|Overall Study|Adverse Event|1
6213343|NCT01603277|9880198|FG001|Overall Study|Adverse Event|2
6213344|NCT01603277|9880197|FG000|Overall Study|Physician Decision|0
6213345|NCT01603277|9880198|FG001|Overall Study|Physician Decision|1
6213346|NCT01603277|9880197|FG000|Overall Study|Protocol Violation|6
6213347|NCT01603277|9880198|FG001|Overall Study|Protocol Violation|10
6213348|NCT01603277|9880197|FG000|Overall Study|Withdrawal by Subject|5
6213349|NCT01603277|9880198|FG001|Overall Study|Withdrawal by Subject|4
6213350|NCT01603277|9880197|FG000|Overall Study|Non-Compliance|2
6213351|NCT01603277|9880198|FG001|Overall Study|Non-Compliance|1
6213352|NCT01603355|9880204|FG000|Overall Study|Lack of Efficacy|2
6213353|NCT01603459|9880229|FG000|Overall Study|Adverse Event|5
6287398|NCT02349295|9999708|FG002|Follow-Up Period (Up to 12-24 Weeks)|Physician Decision|0
6287399|NCT02349295|9999709|FG003|Follow-Up Period (Up to 12-24 Weeks)|Physician Decision|0
6287400|NCT02349295|9999710|FG004|Follow-Up Period (Up to 12-24 Weeks)|Physician Decision|0
6287401|NCT02349295|9999711|FG005|Follow-Up Period (Up to 12-24 Weeks)|Physician Decision|0
6287402|NCT02349295|9999712|FG006|Follow-Up Period (Up to 12-24 Weeks)|Physician Decision|0
6287403|NCT02349295|9999713|FG007|Follow-Up Period (Up to 12-24 Weeks)|Physician Decision|0
6287404|NCT02349295|9999714|FG008|Follow-Up Period (Up to 12-24 Weeks)|Physician Decision|0
6287405|NCT02349295|9999715|FG009|Follow-Up Period (Up to 12-24 Weeks)|Physician Decision|0
6287406|NCT02349295|9999716|FG010|Follow-Up Period (Up to 12-24 Weeks)|Physician Decision|0
6287407|NCT02349295|9999717|FG011|Follow-Up Period (Up to 12-24 Weeks)|Physician Decision|2
6287408|NCT02349295|9999718|FG012|Follow-Up Period (Up to 12-24 Weeks)|Physician Decision|0
6287409|NCT02349295|9999719|FG013|Follow-Up Period (Up to 12-24 Weeks)|Physician Decision|0
6287410|NCT02349295|9999706|FG000|Follow-Up Period (Up to 12-24 Weeks)|Unknown/Missing|0
6287411|NCT02349295|9999707|FG001|Follow-Up Period (Up to 12-24 Weeks)|Unknown/Missing|0
6287412|NCT02349295|9999708|FG002|Follow-Up Period (Up to 12-24 Weeks)|Unknown/Missing|0
6287413|NCT02349295|9999709|FG003|Follow-Up Period (Up to 12-24 Weeks)|Unknown/Missing|0
6287414|NCT02349295|9999710|FG004|Follow-Up Period (Up to 12-24 Weeks)|Unknown/Missing|0
6287415|NCT02349295|9999711|FG005|Follow-Up Period (Up to 12-24 Weeks)|Unknown/Missing|0
6287416|NCT02349295|9999712|FG006|Follow-Up Period (Up to 12-24 Weeks)|Unknown/Missing|0
6213354|NCT01603459|9880229|FG000|Overall Study|Withdrawal by Subject|5
6213355|NCT01603459|9880229|FG000|Overall Study|Lost to Follow-up|3
6213356|NCT01603459|9880229|FG000|Overall Study|Predefined discontinuation criteria|3
6213357|NCT01603459|9880229|FG000|Overall Study|Non-compliance|1
6213358|NCT01603459|9880229|FG000|Overall Study|Administrative reason|1
6213359|NCT01603602|9880254|FG000|Overall Study|Adverse Event|1
6213360|NCT01603602|9880255|FG001|Overall Study|Adverse Event|0
6213361|NCT01603602|9880256|FG002|Overall Study|Adverse Event|0
6213362|NCT01603602|9880254|FG000|Overall Study|Personal Reasons|1
6213363|NCT01603602|9880255|FG001|Overall Study|Personal Reasons|0
6213364|NCT01603602|9880256|FG002|Overall Study|Personal Reasons|1
6213365|NCT01603615|9880264|FG000|Overall Study|Did not Receive Treatment|7
6213366|NCT01603615|9880264|FG000|Overall Study|Lost to Follow-up|9
6213367|NCT01603615|9880264|FG000|Overall Study|Personal Reasons|17
6213368|NCT01603615|9880264|FG000|Overall Study|Other Miscellaneous|1
6213369|NCT01603628|9880271|FG000|Overall Study|Personal Reasons|1
6213370|NCT01603628|9880272|FG001|Overall Study|Personal Reasons|1
6213371|NCT01603628|9880273|FG002|Overall Study|Personal Reasons|2
6213372|NCT01603628|9880271|FG000|Overall Study|Protocol Violation|1
6213373|NCT01603628|9880272|FG001|Overall Study|Protocol Violation|1
6213374|NCT01603628|9880273|FG002|Overall Study|Protocol Violation|0
6213375|NCT01603628|9880271|FG000|Overall Study|Lost to Follow-up|0
6213376|NCT01603628|9880272|FG001|Overall Study|Lost to Follow-up|1
6120338|NCT00891020|9743543|FG002|24 Week Treatment Period|Refused treatment/did not cooperate|1
6120339|NCT00891020|9743541|FG000|24 Week Treatment Period|Withdrew consent|6
6120340|NCT00891020|9743542|FG001|24 Week Treatment Period|Withdrew consent|3
6120341|NCT00891020|9743543|FG002|24 Week Treatment Period|Withdrew consent|15
6120342|NCT00891020|9743541|FG000|24 Week Treatment Period|Administrative/Other|5
6120343|NCT00891020|9743542|FG001|24 Week Treatment Period|Administrative/Other|6
6120344|NCT00891020|9743543|FG002|24 Week Treatment Period|Administrative/Other|1
6120345|NCT00891020|9743541|FG000|Long-term Extension Period|Adverse Event|1
6120346|NCT00891020|9743542|FG001|Long-term Extension Period|Adverse Event|11
6120347|NCT00891020|9743543|FG002|Long-term Extension Period|Adverse Event|10
6120348|NCT00891020|9743541|FG000|Long-term Extension Period|Death|0
6120349|NCT00891020|9743542|FG001|Long-term Extension Period|Death|0
6120350|NCT00891020|9743543|FG002|Long-term Extension Period|Death|1
6120351|NCT00891020|9743541|FG000|Long-term Extension Period|Insufficient therapeutic response|3
6120352|NCT00891020|9743542|FG001|Long-term Extension Period|Insufficient therapeutic response|2
6120353|NCT00891020|9743543|FG002|Long-term Extension Period|Insufficient therapeutic response|2
6120354|NCT00891020|9743541|FG000|Long-term Extension Period|Protocol Violation|0
6120355|NCT00891020|9743542|FG001|Long-term Extension Period|Protocol Violation|1
6120356|NCT00891020|9743543|FG002|Long-term Extension Period|Protocol Violation|1
6120357|NCT00891020|9743541|FG000|Long-term Extension Period|Refused treatment/did not cooperate|1
6120358|NCT00891020|9743542|FG001|Long-term Extension Period|Refused treatment/did not cooperate|6
6120359|NCT00891020|9743543|FG002|Long-term Extension Period|Refused treatment/did not cooperate|4
6120360|NCT00891020|9743541|FG000|Long-term Extension Period|Failure to return|0
6120361|NCT00891020|9743542|FG001|Long-term Extension Period|Failure to return|2
6120362|NCT00891020|9743543|FG002|Long-term Extension Period|Failure to return|3
6120363|NCT00891020|9743541|FG000|Long-term Extension Period|Administrative|1
6120364|NCT00891020|9743542|FG001|Long-term Extension Period|Administrative|2
6120365|NCT00891020|9743543|FG002|Long-term Extension Period|Administrative|2
6120366|NCT00891046|9743558|FG000|Overall Study|Protocol Violation|1
6120367|NCT00891046|9743559|FG001|Overall Study|Protocol Violation|1
6213377|NCT01603628|9880273|FG002|Overall Study|Lost to Follow-up|0
6213378|NCT01603628|9880271|FG000|Overall Study|Other Miscellaneous Reason|1
6213379|NCT01603628|9880272|FG001|Overall Study|Other Miscellaneous Reason|0
6213380|NCT01603628|9880273|FG002|Overall Study|Other Miscellaneous Reason|0
6213381|NCT01603641|9880281|FG000|Overall Study|Did not Receive Treatment|3
6213382|NCT01603641|9880281|FG000|Overall Study|Adverse Event|1
6213383|NCT01603641|9880281|FG000|Overall Study|Lack of Efficacy|1
6213384|NCT01603641|9880281|FG000|Overall Study|Lost to Follow-up|6
6213385|NCT01603641|9880281|FG000|Overall Study|Personal Reasons|18
6213386|NCT01603641|9880281|FG000|Overall Study|Other Miscellaneous Reasons|6
6213387|NCT01603875|9880288|FG000|Overall Study|Preexisting rabies antibody|3
6213388|NCT01603875|9880289|FG001|Overall Study|Preexisting rabies antibody|4
6213389|NCT01603875|9880290|FG002|Overall Study|Preexisting rabies antibody|3
6213390|NCT01603875|9880288|FG000|Overall Study|Lost to Follow-up|4
6213391|NCT01603875|9880289|FG001|Overall Study|Lost to Follow-up|3
6213392|NCT01603875|9880290|FG002|Overall Study|Lost to Follow-up|6
6213393|NCT01603875|9880288|FG000|Overall Study|Protocol Violation|0
6213394|NCT01603875|9880289|FG001|Overall Study|Protocol Violation|1
6213395|NCT01603875|9880290|FG002|Overall Study|Protocol Violation|0
6213396|NCT01604265|9880328|FG000|Overall Study|Adverse Event|1
6213397|NCT01604265|9880329|FG001|Overall Study|Adverse Event|0
6213398|NCT01604265|9880328|FG000|Overall Study|Withdrawal by Subject|1
6213399|NCT01604265|9880329|FG001|Overall Study|Withdrawal by Subject|0
6213400|NCT01604278|9880337|FG000|Overall Study|Lack of Efficacy|0
6213401|NCT01604278|9880338|FG001|Overall Study|Lack of Efficacy|1
6213402|NCT01604278|9880337|FG000|Overall Study|Lost to Follow-up|1
6213403|NCT01604278|9880338|FG001|Overall Study|Lost to Follow-up|0
6213404|NCT01604278|9880337|FG000|Overall Study|Administrative problems|2
6213405|NCT01604278|9880338|FG001|Overall Study|Administrative problems|1
6213406|NCT01604278|9880337|FG000|Overall Study|Withdrawal by Subject|3
6213407|NCT01604278|9880338|FG001|Overall Study|Withdrawal by Subject|3
6213408|NCT01604278|9880337|FG000|Overall Study|Adverse Event|3
6213409|NCT01604278|9880338|FG001|Overall Study|Adverse Event|5
6213410|NCT01604278|9880337|FG000|Overall Study|Protocol Deviation|5
6213411|NCT01604278|9880338|FG001|Overall Study|Protocol Deviation|3
6213412|NCT01604343|9880372|FG000|Prior to W52 Administration(Through W52)|Lost to Follow-up|5
6213413|NCT01604343|9880373|FG001|Prior to W52 Administration(Through W52)|Lost to Follow-up|0
6213414|NCT01604343|9880374|FG002|Prior to W52 Administration(Through W52)|Lost to Follow-up|4
6213415|NCT01604343|9880375|FG003|Prior to W52 Administration(Through W52)|Lost to Follow-up|0
6213416|NCT01604343|9880376|FG004|Prior to W52 Administration(Through W52)|Lost to Follow-up|3
6213417|NCT01604343|9880372|FG000|Prior to W52 Administration(Through W52)|Withdrawal by Subject|19
6213418|NCT01604343|9880373|FG001|Prior to W52 Administration(Through W52)|Withdrawal by Subject|0
6213419|NCT01604343|9880374|FG002|Prior to W52 Administration(Through W52)|Withdrawal by Subject|12
6213420|NCT01604343|9880375|FG003|Prior to W52 Administration(Through W52)|Withdrawal by Subject|0
6213421|NCT01604343|9880376|FG004|Prior to W52 Administration(Through W52)|Withdrawal by Subject|16
6213422|NCT01604343|9880372|FG000|Prior to W52 Administration(Through W52)|Adverse Event|25
6213423|NCT01604343|9880373|FG001|Prior to W52 Administration(Through W52)|Adverse Event|0
6120368|NCT00891046|9743560|FG002|Overall Study|Protocol Violation|0
6120369|NCT00891046|9743561|FG003|Overall Study|Protocol Violation|0
6120370|NCT00891046|9743562|FG004|Overall Study|Protocol Violation|1
6120371|NCT00891046|9743558|FG000|Overall Study|Unsatisfactory therapeutic effect|5
6120372|NCT00891046|9743559|FG001|Overall Study|Unsatisfactory therapeutic effect|2
6120373|NCT00891046|9743560|FG002|Overall Study|Unsatisfactory therapeutic effect|19
6120374|NCT00891046|9743561|FG003|Overall Study|Unsatisfactory therapeutic effect|2
6120375|NCT00891046|9743562|FG004|Overall Study|Unsatisfactory therapeutic effect|20
6120376|NCT00891046|9743558|FG000|Overall Study|Administrative problems|0
6120377|NCT00891046|9743559|FG001|Overall Study|Administrative problems|0
6120378|NCT00891046|9743560|FG002|Overall Study|Administrative problems|0
6120379|NCT00891046|9743561|FG003|Overall Study|Administrative problems|0
6120380|NCT00891046|9743562|FG004|Overall Study|Administrative problems|1
6120381|NCT00891046|9743558|FG000|Overall Study|Participant no longer required drug|0
6120382|NCT00891046|9743559|FG001|Overall Study|Participant no longer required drug|2
6120383|NCT00891046|9743560|FG002|Overall Study|Participant no longer required drug|0
6120384|NCT00891046|9743561|FG003|Overall Study|Participant no longer required drug|0
6120385|NCT00891046|9743562|FG004|Overall Study|Participant no longer required drug|1
6120386|NCT00891046|9743558|FG000|Overall Study|Adverse Event|4
6120387|NCT00891046|9743559|FG001|Overall Study|Adverse Event|3
6120388|NCT00891046|9743560|FG002|Overall Study|Adverse Event|2
6120389|NCT00891046|9743561|FG003|Overall Study|Adverse Event|0
6120390|NCT00891046|9743562|FG004|Overall Study|Adverse Event|14
6120391|NCT00891046|9743558|FG000|Overall Study|Withdrawal by Subject|2
6120392|NCT00891046|9743559|FG001|Overall Study|Withdrawal by Subject|1
6120393|NCT00891046|9743560|FG002|Overall Study|Withdrawal by Subject|2
6120394|NCT00891046|9743561|FG003|Overall Study|Withdrawal by Subject|1
6120395|NCT00891046|9743562|FG004|Overall Study|Withdrawal by Subject|1
6120396|NCT00891046|9743558|FG000|Overall Study|Lost to Follow-up|0
6120397|NCT00891046|9743559|FG001|Overall Study|Lost to Follow-up|0
6120398|NCT00891046|9743560|FG002|Overall Study|Lost to Follow-up|0
6120399|NCT00891046|9743561|FG003|Overall Study|Lost to Follow-up|0
6120400|NCT00891046|9743562|FG004|Overall Study|Lost to Follow-up|1
6120401|NCT00891202|9743614|FG000|PAP (Up To Week 39)|Withdrawal by Subject|1
6120402|NCT00891202|9743615|FG001|PAP (Up To Week 39)|Withdrawal by Subject|0
6120403|NCT00891202|9743616|FG002|PAP (Up To Week 39)|Withdrawal by Subject|0
6120404|NCT00891202|9743617|FG003|PAP (Up To Week 39)|Withdrawal by Subject|0
6120405|NCT00891202|9743614|FG000|LTTP (Post-Week 39 up to Week 312)|Withdrawal by Subject|0
6120406|NCT00891202|9743615|FG001|LTTP (Post-Week 39 up to Week 312)|Withdrawal by Subject|0
6120407|NCT00891202|9743616|FG002|LTTP (Post-Week 39 up to Week 312)|Withdrawal by Subject|4
6120408|NCT00891202|9743617|FG003|LTTP (Post-Week 39 up to Week 312)|Withdrawal by Subject|0
6120409|NCT00891202|9743614|FG000|LTTP (Post-Week 39 up to Week 312)|Pregnancy|0
6120410|NCT00891202|9743615|FG001|LTTP (Post-Week 39 up to Week 312)|Pregnancy|0
6120411|NCT00891202|9743616|FG002|LTTP (Post-Week 39 up to Week 312)|Pregnancy|1
6213424|NCT01604343|9880374|FG002|Prior to W52 Administration(Through W52)|Adverse Event|41
6213425|NCT01604343|9880375|FG003|Prior to W52 Administration(Through W52)|Adverse Event|0
6213426|NCT01604343|9880376|FG004|Prior to W52 Administration(Through W52)|Adverse Event|42
6213427|NCT01604343|9880372|FG000|Prior to W52 Administration(Through W52)|Death|5
6213428|NCT01604343|9880373|FG001|Prior to W52 Administration(Through W52)|Death|0
6213429|NCT01604343|9880374|FG002|Prior to W52 Administration(Through W52)|Death|2
6213430|NCT01604343|9880375|FG003|Prior to W52 Administration(Through W52)|Death|0
6213431|NCT01604343|9880376|FG004|Prior to W52 Administration(Through W52)|Death|4
6213432|NCT01604343|9880372|FG000|Prior to W52 Administration(Through W52)|Lack of Efficacy|24
6213433|NCT01604343|9880373|FG001|Prior to W52 Administration(Through W52)|Lack of Efficacy|0
6213434|NCT01604343|9880374|FG002|Prior to W52 Administration(Through W52)|Lack of Efficacy|5
6213435|NCT01604343|9880375|FG003|Prior to W52 Administration(Through W52)|Lack of Efficacy|0
6213436|NCT01604343|9880376|FG004|Prior to W52 Administration(Through W52)|Lack of Efficacy|14
6287417|NCT02349295|9999713|FG007|Follow-Up Period (Up to 12-24 Weeks)|Unknown/Missing|0
6287418|NCT02349295|9999714|FG008|Follow-Up Period (Up to 12-24 Weeks)|Unknown/Missing|0
6287419|NCT02349295|9999715|FG009|Follow-Up Period (Up to 12-24 Weeks)|Unknown/Missing|0
6287420|NCT02349295|9999716|FG010|Follow-Up Period (Up to 12-24 Weeks)|Unknown/Missing|0
6287421|NCT02349295|9999717|FG011|Follow-Up Period (Up to 12-24 Weeks)|Unknown/Missing|4
6287422|NCT02349295|9999718|FG012|Follow-Up Period (Up to 12-24 Weeks)|Unknown/Missing|0
6287423|NCT02349295|9999719|FG013|Follow-Up Period (Up to 12-24 Weeks)|Unknown/Missing|0
6287424|NCT02349360|9999746|FG000|Overall Study|Withdrawal by Subject|0
6287425|NCT02349360|9999747|FG001|Overall Study|Withdrawal by Subject|1
6287426|NCT02349412|9999755|FG000|Overall Study|Withdrawal by Subject|7
6287427|NCT02349412|9999756|FG001|Overall Study|Withdrawal by Subject|7
6287428|NCT02349425|9999766|FG000|Period 1|Adverse Event|1
6287429|NCT02349425|9999767|FG001|Period 1|Adverse Event|1
6287430|NCT02349425|9999768|FG002|Period 1|Adverse Event|0
6287431|NCT02349425|9999769|FG003|Period 1|Adverse Event|0
6287432|NCT02349425|9999766|FG000|Period 2|Adverse Event|0
6287433|NCT02349425|9999767|FG001|Period 2|Adverse Event|1
6287434|NCT02349425|9999768|FG002|Period 2|Adverse Event|1
6287435|NCT02349425|9999769|FG003|Period 2|Adverse Event|0
6120412|NCT00891202|9743617|FG003|LTTP (Post-Week 39 up to Week 312)|Pregnancy|0
6120413|NCT00891202|9743614|FG000|LTTP (Post-Week 39 up to Week 312)|Transitioned to commercial eliglustat|0
6120414|NCT00891202|9743615|FG001|LTTP (Post-Week 39 up to Week 312)|Transitioned to commercial eliglustat|0
6120415|NCT00891202|9743616|FG002|LTTP (Post-Week 39 up to Week 312)|Transitioned to commercial eliglustat|2
6120416|NCT00891202|9743617|FG003|LTTP (Post-Week 39 up to Week 312)|Transitioned to commercial eliglustat|5
6120417|NCT00891228|9743628|FG000|Overall Study|Adverse Event|0
6120418|NCT00891228|9743629|FG001|Overall Study|Adverse Event|2
6120419|NCT00891228|9743630|FG002|Overall Study|Adverse Event|3
6120420|NCT00891228|9743628|FG000|Overall Study|Withdrawal by Subject|2
6120421|NCT00891228|9743629|FG001|Overall Study|Withdrawal by Subject|4
6120422|NCT00891228|9743630|FG002|Overall Study|Withdrawal by Subject|5
6120423|NCT00891228|9743628|FG000|Overall Study|Protocol Violation|3
6120424|NCT00891228|9743629|FG001|Overall Study|Protocol Violation|1
6120425|NCT00891228|9743630|FG002|Overall Study|Protocol Violation|2
6120426|NCT00891228|9743628|FG000|Overall Study|Physician Decision|2
6120427|NCT00891228|9743629|FG001|Overall Study|Physician Decision|1
6120428|NCT00891228|9743630|FG002|Overall Study|Physician Decision|0
6120429|NCT00891228|9743628|FG000|Overall Study|Lost to Follow-up|4
6120430|NCT00891228|9743629|FG001|Overall Study|Lost to Follow-up|4
6120431|NCT00891228|9743630|FG002|Overall Study|Lost to Follow-up|5
6120432|NCT00891228|9743628|FG000|Overall Study|Pregnancy|0
6120433|NCT00891228|9743629|FG001|Overall Study|Pregnancy|1
6120434|NCT00891228|9743630|FG002|Overall Study|Pregnancy|0
6120435|NCT00891293|9743638|FG000|Overall Study|Adverse Event|2
6120436|NCT00891293|9743638|FG000|Overall Study|Protocol Violation|2
6120437|NCT00891293|9743638|FG000|Overall Study|Laboratory abnormality|4
6120438|NCT00891293|9743638|FG000|Overall Study|Lost to Follow-up|7
6120439|NCT00891293|9743638|FG000|Overall Study|Subject withdrew consent|7
6120440|NCT00891293|9743638|FG000|Overall Study|Sponsor termination|62
6120441|NCT00891371|9743651|FG000|Pre-assignment|Inclusion/exclusion|5
6120442|NCT00891371|9743651|FG000|Pre-assignment|Consent withdrawal|1
6120443|NCT00891371|9743651|FG000|Treatment|Lack of Efficacy|5
6120444|NCT00891371|9743651|FG000|Treatment|Adverse Event|2
6120445|NCT00891371|9743651|FG000|Treatment|Death|1
6120446|NCT00891371|9743651|FG000|Treatment|Lost to Follow-up|1
6120447|NCT00891462|9743667|FG000|Overall Study|Withdrawal by Subject|9
6120448|NCT00891462|9743668|FG001|Overall Study|Withdrawal by Subject|6
6120449|NCT00891462|9743669|FG002|Overall Study|Withdrawal by Subject|7
6120450|NCT00891462|9743667|FG000|Overall Study|Adverse Event|7
6120451|NCT00891462|9743668|FG001|Overall Study|Adverse Event|8
6120452|NCT00891462|9743669|FG002|Overall Study|Adverse Event|7
6120453|NCT00891462|9743667|FG000|Overall Study|Lack of Efficacy|10
6120454|NCT00891462|9743668|FG001|Overall Study|Lack of Efficacy|5
6120455|NCT00891462|9743669|FG002|Overall Study|Lack of Efficacy|1
6120456|NCT00891462|9743667|FG000|Overall Study|COPD exacerbation|7
6120457|NCT00891462|9743668|FG001|Overall Study|COPD exacerbation|4
6120458|NCT00891462|9743669|FG002|Overall Study|COPD exacerbation|1
6120459|NCT00891462|9743667|FG000|Overall Study|Other Reason|2
6120460|NCT00891462|9743668|FG001|Overall Study|Other Reason|5
6120461|NCT00891462|9743669|FG002|Overall Study|Other Reason|3
6120462|NCT00891462|9743667|FG000|Overall Study|Protocol Violation|2
6213437|NCT01604343|9880372|FG000|Prior to W52 Administration(Through W52)|Physician Decision|4
6213438|NCT01604343|9880373|FG001|Prior to W52 Administration(Through W52)|Physician Decision|0
6213439|NCT01604343|9880374|FG002|Prior to W52 Administration(Through W52)|Physician Decision|1
6213440|NCT01604343|9880375|FG003|Prior to W52 Administration(Through W52)|Physician Decision|0
6213441|NCT01604343|9880376|FG004|Prior to W52 Administration(Through W52)|Physician Decision|2
6213442|NCT01604343|9880372|FG000|Prior to W52 Administration(Through W52)|Pregnancy|1
6213443|NCT01604343|9880373|FG001|Prior to W52 Administration(Through W52)|Pregnancy|0
6213444|NCT01604343|9880374|FG002|Prior to W52 Administration(Through W52)|Pregnancy|1
6213445|NCT01604343|9880375|FG003|Prior to W52 Administration(Through W52)|Pregnancy|0
6213446|NCT01604343|9880376|FG004|Prior to W52 Administration(Through W52)|Pregnancy|0
6213447|NCT01604343|9880372|FG000|Prior to W52 Administration(Through W52)|Other|15
6213448|NCT01604343|9880373|FG001|Prior to W52 Administration(Through W52)|Other|0
6213449|NCT01604343|9880374|FG002|Prior to W52 Administration(Through W52)|Other|10
6213450|NCT01604343|9880375|FG003|Prior to W52 Administration(Through W52)|Other|0
6213451|NCT01604343|9880376|FG004|Prior to W52 Administration(Through W52)|Other|6
6213452|NCT01604343|9880372|FG000|Week 52 to Week 104|Lost to Follow-up|0
6213453|NCT01604343|9880373|FG001|Week 52 to Week 104|Lost to Follow-up|2
6213454|NCT01604343|9880374|FG002|Week 52 to Week 104|Lost to Follow-up|4
6213455|NCT01604343|9880375|FG003|Week 52 to Week 104|Lost to Follow-up|2
6213456|NCT01604343|9880376|FG004|Week 52 to Week 104|Lost to Follow-up|1
6213457|NCT01604343|9880372|FG000|Week 52 to Week 104|Withdrawal by Subject|0
6213458|NCT01604343|9880373|FG001|Week 52 to Week 104|Withdrawal by Subject|7
6213459|NCT01604343|9880374|FG002|Week 52 to Week 104|Withdrawal by Subject|12
6120463|NCT00891462|9743668|FG001|Overall Study|Protocol Violation|1
6120464|NCT00891462|9743669|FG002|Overall Study|Protocol Violation|3
6120465|NCT00891462|9743667|FG000|Overall Study|Inclusion/exclusion criteria|0
6120466|NCT00891462|9743668|FG001|Overall Study|Inclusion/exclusion criteria|2
6120467|NCT00891462|9743669|FG002|Overall Study|Inclusion/exclusion criteria|2
6120468|NCT00891462|9743667|FG000|Overall Study|Lost to Follow-up|0
6120469|NCT00891462|9743668|FG001|Overall Study|Lost to Follow-up|2
6120470|NCT00891462|9743669|FG002|Overall Study|Lost to Follow-up|0
6120471|NCT00891527|9743679|FG000|Overall Study|Withdrawal by Subject|2
6120472|NCT00891618|9743684|FG000|Overall Study|Withdrawal by Subject|1
6120473|NCT00891657|9743690|FG000|Overall Study|Withdrawal by Subject|1
6120474|NCT00891657|9743691|FG001|Overall Study|Withdrawal by Subject|1
6120475|NCT00891735|9743701|FG000|Overall Study|Adverse Event|2
6120476|NCT00891735|9743702|FG001|Overall Study|Adverse Event|0
6120477|NCT00891735|9743703|FG002|Overall Study|Adverse Event|2
6120478|NCT00891735|9743704|FG003|Overall Study|Adverse Event|0
6120479|NCT00891735|9743701|FG000|Overall Study|Death|8
6120480|NCT00891735|9743702|FG001|Overall Study|Death|5
6120481|NCT00891735|9743703|FG002|Overall Study|Death|4
6120482|NCT00891735|9743704|FG003|Overall Study|Death|5
6120483|NCT00891735|9743701|FG000|Overall Study|Lost to Follow-up|2
6120484|NCT00891735|9743702|FG001|Overall Study|Lost to Follow-up|2
6120485|NCT00891735|9743703|FG002|Overall Study|Lost to Follow-up|2
6120486|NCT00891735|9743704|FG003|Overall Study|Lost to Follow-up|2
6120487|NCT00891735|9743701|FG000|Overall Study|Physician's decision to withdraw patient|1
6120488|NCT00891735|9743702|FG001|Overall Study|Physician's decision to withdraw patient|0
6120489|NCT00891735|9743703|FG002|Overall Study|Physician's decision to withdraw patient|0
6120490|NCT00891735|9743704|FG003|Overall Study|Physician's decision to withdraw patient|0
6120491|NCT00891735|9743701|FG000|Overall Study|Patient's decision to withdraw|4
6120492|NCT00891735|9743702|FG001|Overall Study|Patient's decision to withdraw|9
6120493|NCT00891735|9743703|FG002|Overall Study|Patient's decision to withdraw|4
6120494|NCT00891735|9743704|FG003|Overall Study|Patient's decision to withdraw|8
6120495|NCT00891774|9743714|FG000|Overall Study|Lost to Follow-up|5
6120496|NCT00891774|9743714|FG000|Overall Study|Illness (Self/Mother)|3
6120497|NCT00891774|9743714|FG000|Overall Study|Withdrawal by Subject|2
6120498|NCT00891774|9743714|FG000|Overall Study|Protocol Violation|4
6120499|NCT00891813|9743718|FG000|Overall Study|Adverse Event|3
6120500|NCT00891813|9743718|FG000|Overall Study|Withdrawal by Subject|1
6120501|NCT00891813|9743718|FG000|Overall Study|Patient Noncompliance|6
6120502|NCT00891813|9743718|FG000|Overall Study|Protocol Violation|2
6120503|NCT00891839|9743722|FG000|Overall Study|Adverse Event|2
6120504|NCT00891839|9743722|FG000|Overall Study|Withdrawal by Subject|2
6213460|NCT01604343|9880375|FG003|Week 52 to Week 104|Withdrawal by Subject|8
6213461|NCT01604343|9880376|FG004|Week 52 to Week 104|Withdrawal by Subject|4
6213462|NCT01604343|9880372|FG000|Week 52 to Week 104|Adverse Event|0
6213463|NCT01604343|9880373|FG001|Week 52 to Week 104|Adverse Event|12
6213464|NCT01604343|9880374|FG002|Week 52 to Week 104|Adverse Event|26
6213465|NCT01604343|9880375|FG003|Week 52 to Week 104|Adverse Event|21
6213466|NCT01604343|9880376|FG004|Week 52 to Week 104|Adverse Event|27
6213467|NCT01604343|9880372|FG000|Week 52 to Week 104|Death|0
6213468|NCT01604343|9880373|FG001|Week 52 to Week 104|Death|4
6287436|NCT02349451|9999818|FG000|Overall Study|Withdrawal by Subject|0
6287437|NCT02349451|9999819|FG001|Overall Study|Withdrawal by Subject|1
6287438|NCT02349451|9999820|FG002|Overall Study|Withdrawal by Subject|2
6287439|NCT02349451|9999821|FG003|Overall Study|Withdrawal by Subject|1
6287440|NCT02349542|9999847|FG000|Overall Study|Withdrawal by Subject|5
6287441|NCT02349633|9999865|FG000|Overall Study|Death|0
6287442|NCT02349633|9999866|FG001|Overall Study|Death|1
6287443|NCT02349633|9999867|FG002|Overall Study|Death|0
6287444|NCT02349633|9999868|FG003|Overall Study|Death|0
6287445|NCT02349633|9999869|FG004|Overall Study|Death|0
6287446|NCT02349633|9999870|FG005|Overall Study|Death|1
6287447|NCT02349633|9999871|FG006|Overall Study|Death|1
6287448|NCT02349633|9999872|FG007|Overall Study|Death|1
6287449|NCT02349633|9999873|FG008|Overall Study|Death|0
6287450|NCT02349633|9999874|FG009|Overall Study|Death|1
6287451|NCT02349633|9999875|FG010|Overall Study|Death|0
6287452|NCT02349633|9999876|FG011|Overall Study|Death|0
6287453|NCT02349633|9999877|FG012|Overall Study|Death|0
6287454|NCT02349633|9999878|FG013|Overall Study|Death|0
6287455|NCT02349633|9999865|FG000|Overall Study|Withdrawal by Subject|0
6287456|NCT02349633|9999866|FG001|Overall Study|Withdrawal by Subject|0
6287457|NCT02349633|9999867|FG002|Overall Study|Withdrawal by Subject|0
6287458|NCT02349633|9999868|FG003|Overall Study|Withdrawal by Subject|1
6287459|NCT02349633|9999869|FG004|Overall Study|Withdrawal by Subject|0
6287460|NCT02349633|9999870|FG005|Overall Study|Withdrawal by Subject|0
6287461|NCT02349633|9999871|FG006|Overall Study|Withdrawal by Subject|0
6287462|NCT02349633|9999872|FG007|Overall Study|Withdrawal by Subject|2
6287463|NCT02349633|9999873|FG008|Overall Study|Withdrawal by Subject|2
6287464|NCT02349633|9999874|FG009|Overall Study|Withdrawal by Subject|1
6287465|NCT02349633|9999875|FG010|Overall Study|Withdrawal by Subject|0
6287466|NCT02349633|9999876|FG011|Overall Study|Withdrawal by Subject|0
6287467|NCT02349633|9999877|FG012|Overall Study|Withdrawal by Subject|0
6287468|NCT02349633|9999878|FG013|Overall Study|Withdrawal by Subject|0
6287469|NCT02349633|9999865|FG000|Overall Study|Withdrawal of informed consent|0
6287470|NCT02349633|9999866|FG001|Overall Study|Withdrawal of informed consent|0
6120505|NCT00891839|9743722|FG000|Overall Study|Disease progression|3
6213469|NCT01604343|9880374|FG002|Week 52 to Week 104|Death|2
6287471|NCT02349633|9999867|FG002|Overall Study|Withdrawal of informed consent|0
6287472|NCT02349633|9999868|FG003|Overall Study|Withdrawal of informed consent|1
6287473|NCT02349633|9999869|FG004|Overall Study|Withdrawal of informed consent|1
6287474|NCT02349633|9999870|FG005|Overall Study|Withdrawal of informed consent|0
6287475|NCT02349633|9999871|FG006|Overall Study|Withdrawal of informed consent|0
6120506|NCT00891930|9743735|FG000|Part 1: Panitumumab +Irinotecan|Death|38
6120507|NCT00891930|9743735|FG000|Part 1: Panitumumab +Irinotecan|Withdrawal by Subject|1
6120508|NCT00891930|9743735|FG000|Part 1: Panitumumab +Irinotecan|Lost to Follow-up|1
6120509|NCT00891930|9743735|FG000|Part 2: Panitumumab + Ganitumab|Death|30
6120510|NCT00891930|9743735|FG000|Part 2: Panitumumab + Ganitumab|Withdrawal by Subject|1
6213470|NCT01604343|9880375|FG003|Week 52 to Week 104|Death|5
6213471|NCT01604343|9880376|FG004|Week 52 to Week 104|Death|0
6213472|NCT01604343|9880372|FG000|Week 52 to Week 104|Lack of Efficacy|0
6213473|NCT01604343|9880373|FG001|Week 52 to Week 104|Lack of Efficacy|6
6213474|NCT01604343|9880374|FG002|Week 52 to Week 104|Lack of Efficacy|11
6213475|NCT01604343|9880375|FG003|Week 52 to Week 104|Lack of Efficacy|2
6213476|NCT01604343|9880376|FG004|Week 52 to Week 104|Lack of Efficacy|3
6213477|NCT01604343|9880372|FG000|Week 52 to Week 104|Physician Decision|0
6213478|NCT01604343|9880373|FG001|Week 52 to Week 104|Physician Decision|1
6213479|NCT01604343|9880374|FG002|Week 52 to Week 104|Physician Decision|0
6213480|NCT01604343|9880375|FG003|Week 52 to Week 104|Physician Decision|0
6213481|NCT01604343|9880376|FG004|Week 52 to Week 104|Physician Decision|2
6213482|NCT01604343|9880372|FG000|Week 52 to Week 104|Pregnancy|0
6213483|NCT01604343|9880373|FG001|Week 52 to Week 104|Pregnancy|0
6213484|NCT01604343|9880374|FG002|Week 52 to Week 104|Pregnancy|1
6213485|NCT01604343|9880375|FG003|Week 52 to Week 104|Pregnancy|2
6213486|NCT01604343|9880376|FG004|Week 52 to Week 104|Pregnancy|1
6213487|NCT01604343|9880372|FG000|Week 52 to Week 104|Other|0
6213488|NCT01604343|9880373|FG001|Week 52 to Week 104|Other|11
6213489|NCT01604343|9880374|FG002|Week 52 to Week 104|Other|11
6213490|NCT01604343|9880375|FG003|Week 52 to Week 104|Other|6
6213491|NCT01604343|9880376|FG004|Week 52 to Week 104|Other|3
6213492|NCT01604343|9880372|FG000|Safety Follow-up Period (Week 104-120)|Lost to Follow-up|3
6213493|NCT01604343|9880373|FG001|Safety Follow-up Period (Week 104-120)|Lost to Follow-up|1
6287476|NCT02349633|9999872|FG007|Overall Study|Withdrawal of informed consent|3
6287477|NCT02349633|9999873|FG008|Overall Study|Withdrawal of informed consent|0
6287478|NCT02349633|9999874|FG009|Overall Study|Withdrawal of informed consent|0
6287479|NCT02349633|9999875|FG010|Overall Study|Withdrawal of informed consent|0
6287480|NCT02349633|9999876|FG011|Overall Study|Withdrawal of informed consent|0
6287481|NCT02349633|9999877|FG012|Overall Study|Withdrawal of informed consent|0
6287482|NCT02349633|9999878|FG013|Overall Study|Withdrawal of informed consent|0
6287483|NCT02349633|9999865|FG000|Overall Study|Transition to compassionate use|0
6287484|NCT02349633|9999866|FG001|Overall Study|Transition to compassionate use|0
6287485|NCT02349633|9999867|FG002|Overall Study|Transition to compassionate use|0
6287486|NCT02349633|9999868|FG003|Overall Study|Transition to compassionate use|0
6287487|NCT02349633|9999869|FG004|Overall Study|Transition to compassionate use|1
6287488|NCT02349633|9999870|FG005|Overall Study|Transition to compassionate use|0
6287489|NCT02349633|9999871|FG006|Overall Study|Transition to compassionate use|0
6287490|NCT02349633|9999872|FG007|Overall Study|Transition to compassionate use|3
6287491|NCT02349633|9999873|FG008|Overall Study|Transition to compassionate use|0
6287492|NCT02349633|9999874|FG009|Overall Study|Transition to compassionate use|1
6287493|NCT02349633|9999875|FG010|Overall Study|Transition to compassionate use|0
6287494|NCT02349633|9999876|FG011|Overall Study|Transition to compassionate use|0
6287495|NCT02349633|9999877|FG012|Overall Study|Transition to compassionate use|0
6287496|NCT02349633|9999878|FG013|Overall Study|Transition to compassionate use|0
6287497|NCT02349633|9999865|FG000|Overall Study|Early termination of survival follow-up|0
6287498|NCT02349633|9999866|FG001|Overall Study|Early termination of survival follow-up|0
6287499|NCT02349633|9999867|FG002|Overall Study|Early termination of survival follow-up|0
6287500|NCT02349633|9999868|FG003|Overall Study|Early termination of survival follow-up|0
6287501|NCT02349633|9999869|FG004|Overall Study|Early termination of survival follow-up|0
6287502|NCT02349633|9999870|FG005|Overall Study|Early termination of survival follow-up|0
6287503|NCT02349633|9999871|FG006|Overall Study|Early termination of survival follow-up|0
6120511|NCT00892008|9743761|FG000|Overall Study|Death|5
6120512|NCT00892008|9743761|FG000|Overall Study|Lack of Efficacy|3
6120513|NCT00892008|9743761|FG000|Overall Study|Lost to Follow-up|142
6120514|NCT00892008|9743761|FG000|Overall Study|Other|378
6120515|NCT00892008|9743761|FG000|Overall Study|Adverse Event|37
6120516|NCT00892047|9743767|FG000|Overall Study|Adverse Event|2
6120517|NCT00892047|9743768|FG001|Overall Study|Adverse Event|2
6120518|NCT00892047|9743767|FG000|Overall Study|subject burden|2
6120519|NCT00892047|9743768|FG001|Overall Study|subject burden|3
6120520|NCT00892047|9743767|FG000|Overall Study|Lack of Efficacy|0
6120521|NCT00892047|9743768|FG001|Overall Study|Lack of Efficacy|2
6120522|NCT00892099|9743779|FG000|Overall Study|Death|1
6120523|NCT00892099|9743780|FG001|Overall Study|Death|0
6120524|NCT00892099|9743781|FG002|Overall Study|Death|1
6120525|NCT00892099|9743779|FG000|Overall Study|Adverse Event|1
6120526|NCT00892099|9743780|FG001|Overall Study|Adverse Event|0
6213494|NCT01604343|9880374|FG002|Safety Follow-up Period (Week 104-120)|Lost to Follow-up|2
6213495|NCT01604343|9880375|FG003|Safety Follow-up Period (Week 104-120)|Lost to Follow-up|1
6213496|NCT01604343|9880376|FG004|Safety Follow-up Period (Week 104-120)|Lost to Follow-up|1
6213497|NCT01604343|9880372|FG000|Safety Follow-up Period (Week 104-120)|Withdrawal by Subject|12
6213498|NCT01604343|9880373|FG001|Safety Follow-up Period (Week 104-120)|Withdrawal by Subject|4
6213499|NCT01604343|9880374|FG002|Safety Follow-up Period (Week 104-120)|Withdrawal by Subject|11
6120527|NCT00892099|9743781|FG002|Overall Study|Adverse Event|0
6120528|NCT00892099|9743779|FG000|Overall Study|replocated|1
6120529|NCT00892099|9743780|FG001|Overall Study|replocated|0
6120530|NCT00892099|9743781|FG002|Overall Study|replocated|2
6120531|NCT00892099|9743779|FG000|Overall Study|Prolonged hospitalization|1
6120532|NCT00892099|9743780|FG001|Overall Study|Prolonged hospitalization|0
6120533|NCT00892099|9743781|FG002|Overall Study|Prolonged hospitalization|1
6120534|NCT00892099|9743779|FG000|Overall Study|no further details|1
6120535|NCT00892099|9743780|FG001|Overall Study|no further details|0
6120536|NCT00892099|9743781|FG002|Overall Study|no further details|1
6120537|NCT00892099|9743779|FG000|Overall Study|kidney function recovered|0
6120538|NCT00892099|9743780|FG001|Overall Study|kidney function recovered|1
6120539|NCT00892099|9743781|FG002|Overall Study|kidney function recovered|0
6120540|NCT00892099|9743779|FG000|Overall Study|investigator decision|0
6120541|NCT00892099|9743780|FG001|Overall Study|investigator decision|0
6120542|NCT00892099|9743781|FG002|Overall Study|investigator decision|1
6120543|NCT00892099|9743779|FG000|Overall Study|Lost to Follow-up|0
6120544|NCT00892099|9743780|FG001|Overall Study|Lost to Follow-up|0
6120545|NCT00892099|9743781|FG002|Overall Study|Lost to Follow-up|1
6120546|NCT00892151|9743789|FG000|Overall Study|Protocol Violation|1
6120547|NCT00892177|9743796|FG000|Phase II|Ineligible|0
6120548|NCT00892177|9743797|FG001|Phase II|Ineligible|0
6120549|NCT00892177|9743798|FG002|Phase II|Ineligible|0
6120550|NCT00892177|9743799|FG003|Phase II|Ineligible|0
6120551|NCT00892177|9743800|FG004|Phase II|Ineligible|1
6120552|NCT00892177|9743801|FG005|Phase II|Ineligible|1
6120553|NCT00892177|9743796|FG000|Phase II|Withdrawal by Subject|0
6120554|NCT00892177|9743797|FG001|Phase II|Withdrawal by Subject|0
6120555|NCT00892177|9743798|FG002|Phase II|Withdrawal by Subject|0
6120556|NCT00892177|9743799|FG003|Phase II|Withdrawal by Subject|0
6120557|NCT00892177|9743800|FG004|Phase II|Withdrawal by Subject|4
6120558|NCT00892177|9743801|FG005|Phase II|Withdrawal by Subject|1
6120559|NCT00892281|9743818|FG000|Overall Study|Adverse Event|65
6120560|NCT00892281|9743819|FG001|Overall Study|Adverse Event|8
6120561|NCT00892281|9743818|FG000|Overall Study|Lost to Follow-up|81
6120562|NCT00892281|9743819|FG001|Overall Study|Lost to Follow-up|8
6120563|NCT00892281|9743818|FG000|Overall Study|Pregnancy|1
6213500|NCT01604343|9880375|FG003|Safety Follow-up Period (Week 104-120)|Withdrawal by Subject|3
6213501|NCT01604343|9880376|FG004|Safety Follow-up Period (Week 104-120)|Withdrawal by Subject|14
6213502|NCT01604343|9880372|FG000|Safety Follow-up Period (Week 104-120)|Other|15
6287504|NCT02349633|9999872|FG007|Overall Study|Early termination of survival follow-up|4
6287505|NCT02349633|9999873|FG008|Overall Study|Early termination of survival follow-up|0
6287506|NCT02349633|9999874|FG009|Overall Study|Early termination of survival follow-up|0
6120564|NCT00892281|9743819|FG001|Overall Study|Pregnancy|0
6120565|NCT00892281|9743818|FG000|Overall Study|Protocol Violation|7
6120566|NCT00892281|9743819|FG001|Overall Study|Protocol Violation|2
6120567|NCT00892281|9743818|FG000|Overall Study|Withdrawal by Subject|86
6120568|NCT00892281|9743819|FG001|Overall Study|Withdrawal by Subject|14
6120569|NCT00892281|9743818|FG000|Overall Study|Subject failed to return for final visit|2
6120570|NCT00892281|9743819|FG001|Overall Study|Subject failed to return for final visit|0
6120571|NCT00892281|9743818|FG000|Overall Study|Subject unable to keep follow-up visits|1
6120572|NCT00892281|9743819|FG001|Overall Study|Subject unable to keep follow-up visits|0
6213503|NCT01604343|9880373|FG001|Safety Follow-up Period (Week 104-120)|Other|2
6213504|NCT01604343|9880374|FG002|Safety Follow-up Period (Week 104-120)|Other|20
6213505|NCT01604343|9880375|FG003|Safety Follow-up Period (Week 104-120)|Other|6
6213506|NCT01604343|9880376|FG004|Safety Follow-up Period (Week 104-120)|Other|14
6213507|NCT01604408|9880388|FG000|Treatment Period 1|Protocol Violation|0
6213508|NCT01604408|9880389|FG001|Treatment Period 1|Protocol Violation|1
6213509|NCT01604408|9880388|FG000|Treatment Period 2|Withdrawal by Subject|1
6213510|NCT01604408|9880389|FG001|Treatment Period 2|Withdrawal by Subject|1
6213511|NCT01604408|9880388|FG000|Treatment Period 2|Protocol Violation|1
6213512|NCT01604408|9880389|FG001|Treatment Period 2|Protocol Violation|0
6213513|NCT01604408|9880388|FG000|Treatment Period 2|Adverse Event|0
6213514|NCT01604408|9880389|FG001|Treatment Period 2|Adverse Event|1
6213515|NCT01604408|9880388|FG000|Treatment Period 3|Protocol Violation|1
6213516|NCT01604408|9880389|FG001|Treatment Period 3|Protocol Violation|1
6213517|NCT01604408|9880388|FG000|Treatment Period 3|Adverse Event|0
6213518|NCT01604408|9880389|FG001|Treatment Period 3|Adverse Event|3
6213519|NCT01604408|9880388|FG000|Treatment Period 3|Withdrawal by Subject|3
6213520|NCT01604408|9880389|FG001|Treatment Period 3|Withdrawal by Subject|1
6213521|NCT01604408|9880388|FG000|Treatment Period 3|Sponsor Decision|1
6213522|NCT01604408|9880389|FG001|Treatment Period 3|Sponsor Decision|0
6213523|NCT01604408|9880388|FG000|Treatment Period 4|Death|1
6213524|NCT01604408|9880389|FG001|Treatment Period 4|Death|0
6213525|NCT01604408|9880388|FG000|Treatment Period 4|Withdrawal by Subject|2
6213526|NCT01604408|9880389|FG001|Treatment Period 4|Withdrawal by Subject|1
6213527|NCT01604408|9880388|FG000|Treatment Period 4|Adverse Event|0
6213528|NCT01604408|9880389|FG001|Treatment Period 4|Adverse Event|1
6213529|NCT01604408|9880388|FG000|Treatment Period 5|Adverse Event|4
6213530|NCT01604408|9880389|FG001|Treatment Period 5|Adverse Event|0
6213531|NCT01604408|9880388|FG000|Treatment Period 6|Lost to Follow-up|0
6120573|NCT00892281|9743818|FG000|Overall Study|Final visit completed 4 weeks late|0
6120574|NCT00892281|9743819|FG001|Overall Study|Final visit completed 4 weeks late|1
6120575|NCT00892281|9743818|FG000|Overall Study|Subject completed day after study closed|1
6120576|NCT00892281|9743819|FG001|Overall Study|Subject completed day after study closed|0
6120577|NCT00892281|9743818|FG000|Overall Study|Family emergency|1
6120578|NCT00892281|9743819|FG001|Overall Study|Family emergency|0
6120579|NCT00892281|9743818|FG000|Overall Study|Last visit not done - death in family|1
6120580|NCT00892281|9743819|FG001|Overall Study|Last visit not done - death in family|0
6120581|NCT00892281|9743818|FG000|Overall Study|Did not meet incl/excl criteria|1
6120582|NCT00892281|9743819|FG001|Overall Study|Did not meet incl/excl criteria|0
6213532|NCT01604408|9880389|FG001|Treatment Period 6|Lost to Follow-up|1
6213533|NCT01604408|9880388|FG000|Treatment Period 6|Adverse Event|2
6213534|NCT01604408|9880389|FG001|Treatment Period 6|Adverse Event|0
6213535|NCT01604408|9880388|FG000|Treatment Period 6|Sponsor decision|0
6213536|NCT01604408|9880389|FG001|Treatment Period 6|Sponsor decision|1
6213537|NCT01604408|9880388|FG000|Observation Period|Adverse Event|1
6213538|NCT01604408|9880389|FG001|Observation Period|Adverse Event|1
6213539|NCT01604408|9880388|FG000|Observation Period|Withdrawal by Subject|0
6213540|NCT01604408|9880389|FG001|Observation Period|Withdrawal by Subject|2
6213541|NCT01604785|9880402|FG000|Overall Study|Repeat Visits Not Included in Analysis|7
6213542|NCT01604785|9880403|FG001|Overall Study|Repeat Visits Not Included in Analysis|1
6213543|NCT01604824|9880413|FG000|Open-label Extension (OLE) Period|Chose not to enter OLE Period|0
6213544|NCT01604824|9880414|FG001|Open-label Extension (OLE) Period|Chose not to enter OLE Period|0
6213545|NCT01604824|9880415|FG002|Open-label Extension (OLE) Period|Chose not to enter OLE Period|0
6213546|NCT01604824|9880416|FG003|Open-label Extension (OLE) Period|Chose not to enter OLE Period|0
6213547|NCT01604824|9880417|FG004|Open-label Extension (OLE) Period|Chose not to enter OLE Period|2
6213548|NCT01604824|9880418|FG005|Open-label Extension (OLE) Period|Chose not to enter OLE Period|0
6213549|NCT01604824|9880413|FG000|Open-label Extension (OLE) Period|Refused to come into office|0
6213550|NCT01604824|9880414|FG001|Open-label Extension (OLE) Period|Refused to come into office|0
6213551|NCT01604824|9880415|FG002|Open-label Extension (OLE) Period|Refused to come into office|0
6213552|NCT01604824|9880416|FG003|Open-label Extension (OLE) Period|Refused to come into office|0
6213553|NCT01604824|9880417|FG004|Open-label Extension (OLE) Period|Refused to come into office|1
6213554|NCT01604824|9880418|FG005|Open-label Extension (OLE) Period|Refused to come into office|0
6213555|NCT01604850|9880432|FG000|Overall Study|Enrolled but never treated|0
6213556|NCT01604850|9880433|FG001|Overall Study|Enrolled but never treated|1
6213557|NCT01604850|9880432|FG000|Overall Study|Efficacy Failure|50
6213558|NCT01604850|9880433|FG001|Overall Study|Efficacy Failure|29
6213559|NCT01604850|9880432|FG000|Overall Study|Lost to Follow-up|1
6213560|NCT01604850|9880433|FG001|Overall Study|Lost to Follow-up|0
6213561|NCT01604850|9880432|FG000|Overall Study|Subject withdrew consent|1
6213562|NCT01604850|9880433|FG001|Overall Study|Subject withdrew consent|0
6213563|NCT01604941|9880441|FG000|Overall Study|Adverse Event|1
6213564|NCT01604941|9880442|FG001|Overall Study|Adverse Event|2
6213565|NCT01604941|9880443|FG002|Overall Study|Adverse Event|0
6213566|NCT01604941|9880444|FG003|Overall Study|Adverse Event|0
6213567|NCT01604941|9880445|FG004|Overall Study|Adverse Event|1
6213568|NCT01604941|9880446|FG005|Overall Study|Adverse Event|5
6213569|NCT01604941|9880441|FG000|Overall Study|Non-compliance|1
6213570|NCT01604941|9880442|FG001|Overall Study|Non-compliance|0
6213571|NCT01604941|9880443|FG002|Overall Study|Non-compliance|0
6213572|NCT01604941|9880444|FG003|Overall Study|Non-compliance|0
6213573|NCT01604941|9880445|FG004|Overall Study|Non-compliance|0
6213574|NCT01604941|9880446|FG005|Overall Study|Non-compliance|0
6213575|NCT01604941|9880441|FG000|Overall Study|Participant Decision|0
6213576|NCT01604941|9880442|FG001|Overall Study|Participant Decision|0
6213577|NCT01604941|9880443|FG002|Overall Study|Participant Decision|0
6213578|NCT01604941|9880444|FG003|Overall Study|Participant Decision|0
6213579|NCT01604941|9880445|FG004|Overall Study|Participant Decision|0
6213580|NCT01604941|9880446|FG005|Overall Study|Participant Decision|2
6213581|NCT01604941|9880441|FG000|Overall Study|Early Study Termination|9
6213582|NCT01604941|9880442|FG001|Overall Study|Early Study Termination|2
6213583|NCT01604941|9880443|FG002|Overall Study|Early Study Termination|3
6213584|NCT01604941|9880444|FG003|Overall Study|Early Study Termination|3
6213585|NCT01604941|9880445|FG004|Overall Study|Early Study Termination|0
6213586|NCT01604941|9880446|FG005|Overall Study|Early Study Termination|0
6213587|NCT01605071|9880458|FG000|Overall Study|Withdrawal by Subject|3
6213588|NCT01605071|9880459|FG001|Overall Study|Withdrawal by Subject|2
6213589|NCT01605097|9880467|FG000|Overall Study|Protocol Violation|1
6213590|NCT01605136|9880474|FG000|Study Period|Withdrawal by Subject|2
6213591|NCT01605136|9880475|FG001|Study Period|Withdrawal by Subject|0
6213592|NCT01605136|9880474|FG000|Study Period|Physician Decision|1
6213593|NCT01605136|9880475|FG001|Study Period|Physician Decision|1
6213594|NCT01605136|9880474|FG000|Study Period|Lost to Follow-up|0
6213595|NCT01605136|9880475|FG001|Study Period|Lost to Follow-up|2
6213596|NCT01605136|9880474|FG000|Safety Follow-Up Period|Withdrawal by Subject|1
6213597|NCT01605136|9880475|FG001|Safety Follow-Up Period|Withdrawal by Subject|2
6213598|NCT01605227|9880483|FG000|Overall Study|Did not receive study treatment|2
6213599|NCT01605227|9880484|FG001|Overall Study|Did not receive study treatment|3
6213600|NCT01605227|9880483|FG000|Overall Study|Adverse Event|228
6120583|NCT00892281|9743818|FG000|Overall Study|Rosacea cleared; subject D/C'd self|1
6120584|NCT00892281|9743819|FG001|Overall Study|Rosacea cleared; subject D/C'd self|0
6120585|NCT00892281|9743818|FG000|Overall Study|Unable to redeem the drug voucher|1
6120586|NCT00892281|9743819|FG001|Overall Study|Unable to redeem the drug voucher|0
6120587|NCT00892281|9743818|FG000|Overall Study|Subject not good candidate for study|1
6120588|NCT00892281|9743819|FG001|Overall Study|Subject not good candidate for study|0
6120589|NCT00892281|9743818|FG000|Overall Study|Subject did not return for any visits|1
6120590|NCT00892281|9743819|FG001|Overall Study|Subject did not return for any visits|0
6120591|NCT00892281|9743818|FG000|Overall Study|Subject missed several visits/lost meds|1
6213601|NCT01605227|9880484|FG001|Overall Study|Adverse Event|42
6213602|NCT01605227|9880483|FG000|Overall Study|Progressive Disease|132
6213603|NCT01605227|9880484|FG001|Overall Study|Progressive Disease|128
6213604|NCT01605227|9880483|FG000|Overall Study|Clinical Deterioration|227
6213605|NCT01605227|9880484|FG001|Overall Study|Clinical Deterioration|133
6213606|NCT01605227|9880483|FG000|Overall Study|Lost to Follow-up|1
6213607|NCT01605227|9880484|FG001|Overall Study|Lost to Follow-up|0
6213608|NCT01605227|9880483|FG000|Overall Study|Protocol Violation|1
6213609|NCT01605227|9880484|FG001|Overall Study|Protocol Violation|0
6213610|NCT01605227|9880483|FG000|Overall Study|Physician Decision|9
6213611|NCT01605227|9880484|FG001|Overall Study|Physician Decision|7
6213612|NCT01605227|9880483|FG000|Overall Study|Withdrawal by Subject|18
6213613|NCT01605227|9880484|FG001|Overall Study|Withdrawal by Subject|14
6213614|NCT01605227|9880483|FG000|Overall Study|Sponsor Decision|2
6213615|NCT01605227|9880484|FG001|Overall Study|Sponsor Decision|0
6213616|NCT01605227|9880483|FG000|Overall Study|Started New Therapy|1
6213617|NCT01605227|9880484|FG001|Overall Study|Started New Therapy|0
6213618|NCT01605227|9880483|FG000|Overall Study|Subject Decision|0
6213619|NCT01605227|9880484|FG001|Overall Study|Subject Decision|1
6213620|NCT01605227|9880483|FG000|Overall Study|Dose Held >6 weeks|0
6213621|NCT01605227|9880484|FG001|Overall Study|Dose Held >6 weeks|1
6213622|NCT01605396|9880501|FG000|Overall Study|Adverse Event|5
6213623|NCT01605396|9880502|FG001|Overall Study|Adverse Event|3
6213624|NCT01605396|9880501|FG000|Overall Study|Lost to Follow-up|1
6213625|NCT01605396|9880502|FG001|Overall Study|Lost to Follow-up|0
6213626|NCT01605396|9880501|FG000|Overall Study|Non-Compliance With Study Drug|1
6213627|NCT01605396|9880502|FG001|Overall Study|Non-Compliance With Study Drug|1
6213628|NCT01605396|9880501|FG000|Overall Study|Physician Decision|2
6213629|NCT01605396|9880502|FG001|Overall Study|Physician Decision|2
6213630|NCT01605396|9880501|FG000|Overall Study|Progressive Disease|23
6213631|NCT01605396|9880502|FG001|Overall Study|Progressive Disease|27
6213632|NCT01605396|9880501|FG000|Overall Study|Withdrawal by Subject|4
6213633|NCT01605396|9880502|FG001|Overall Study|Withdrawal by Subject|2
6213634|NCT01605396|9880501|FG000|Overall Study|Transfer Off Study|4
6213635|NCT01605396|9880502|FG001|Overall Study|Transfer Off Study|5
6213636|NCT01605461|9880526|FG000|Overall Study|Lost to Follow-up|3
6213637|NCT01605461|9880526|FG000|Overall Study|Withdrawal by Subject|1
6213638|NCT01605799|9880559|FG000|Overall Study|Withdrawal by Subject|2
6213639|NCT01605799|9880560|FG001|Overall Study|Withdrawal by Subject|1
6213640|NCT01605825|9880568|FG000|Overall Study|Adverse Event|4
6213641|NCT01605825|9880569|FG001|Overall Study|Adverse Event|2
6213642|NCT01605825|9880568|FG000|Overall Study|Withdrawal by Subject|0
6213643|NCT01605825|9880569|FG001|Overall Study|Withdrawal by Subject|1
6213644|NCT01605825|9880568|FG000|Overall Study|Non-Compliance -Investigational Drug|3
6213645|NCT01605825|9880569|FG001|Overall Study|Non-Compliance -Investigational Drug|0
6213646|NCT01605825|9880568|FG000|Overall Study|Non-Compliance with Protocol|3
6213647|NCT01605825|9880569|FG001|Overall Study|Non-Compliance with Protocol|0
6213648|NCT01605877|9880575|FG000|Overall Study|Withdrawal by Subject|1
6213649|NCT01605916|9880615|FG000|Overall Study|Adverse Event|1
6213650|NCT01605916|9880616|FG001|Overall Study|Adverse Event|0
6213651|NCT01605916|9880617|FG002|Overall Study|Adverse Event|0
6213652|NCT01605916|9880618|FG003|Overall Study|Adverse Event|1
6213653|NCT01605916|9880619|FG004|Overall Study|Adverse Event|0
6213654|NCT01605916|9880615|FG000|Overall Study|Lack of Efficacy|2
6213655|NCT01605916|9880616|FG001|Overall Study|Lack of Efficacy|3
6213656|NCT01605916|9880617|FG002|Overall Study|Lack of Efficacy|3
6213657|NCT01605916|9880618|FG003|Overall Study|Lack of Efficacy|5
6213658|NCT01605916|9880619|FG004|Overall Study|Lack of Efficacy|4
6213659|NCT01605916|9880615|FG000|Overall Study|Withdrawal by Subject|1
6213660|NCT01605916|9880616|FG001|Overall Study|Withdrawal by Subject|1
6213661|NCT01605916|9880617|FG002|Overall Study|Withdrawal by Subject|0
6213662|NCT01605916|9880618|FG003|Overall Study|Withdrawal by Subject|0
6213663|NCT01605916|9880619|FG004|Overall Study|Withdrawal by Subject|2
6213664|NCT01606007|9880644|FG000|Overall Study|Reason 'Other' in the protocol|0
6213665|NCT01606007|9880645|FG001|Overall Study|Reason 'Other' in the protocol|1
6213666|NCT01606007|9880646|FG002|Overall Study|Reason 'Other' in the protocol|1
6213667|NCT01606007|9880644|FG000|Overall Study|Pregnancy|0
6213668|NCT01606007|9880645|FG001|Overall Study|Pregnancy|1
6213669|NCT01606007|9880646|FG002|Overall Study|Pregnancy|1
6213670|NCT01606007|9880644|FG000|Overall Study|Withdrawal by Subject|8
6213671|NCT01606007|9880645|FG001|Overall Study|Withdrawal by Subject|6
6213672|NCT01606007|9880646|FG002|Overall Study|Withdrawal by Subject|1
6213673|NCT01606007|9880644|FG000|Overall Study|Adverse Event|0
6213674|NCT01606007|9880645|FG001|Overall Study|Adverse Event|1
6120592|NCT00892281|9743819|FG001|Overall Study|Subject missed several visits/lost meds|0
6120593|NCT00892281|9743818|FG000|Overall Study|Missed Visit 4 and off meds for 65 days|1
6120594|NCT00892281|9743819|FG001|Overall Study|Missed Visit 4 and off meds for 65 days|1
6120595|NCT00892281|9743818|FG000|Overall Study|Scheduled for knee replacement|0
6120596|NCT00892281|9743819|FG001|Overall Study|Scheduled for knee replacement|1
6213675|NCT01606007|9880646|FG002|Overall Study|Adverse Event|1
6213676|NCT01606007|9880644|FG000|Overall Study|discontinue study treatment|0
6213677|NCT01606007|9880645|FG001|Overall Study|discontinue study treatment|2
6213678|NCT01606007|9880646|FG002|Overall Study|discontinue study treatment|1
6213679|NCT01606007|9880644|FG000|Overall Study|Lost to Follow-up|6
6213680|NCT01606007|9880645|FG001|Overall Study|Lost to Follow-up|8
6213681|NCT01606007|9880646|FG002|Overall Study|Lost to Follow-up|5
6213682|NCT01606007|9880644|FG000|Overall Study|Poor/Non-compliance|1
6213683|NCT01606007|9880645|FG001|Overall Study|Poor/Non-compliance|0
6213684|NCT01606007|9880646|FG002|Overall Study|Poor/Non-compliance|0
6213685|NCT01606137|9880663|FG000|Overall Study|Adverse Event|85
6213686|NCT01606137|9880663|FG000|Overall Study|Withdrawal by Subject|74
6213687|NCT01606137|9880663|FG000|Overall Study|Lack of Efficacy|56
6213688|NCT01606137|9880663|FG000|Overall Study|Lost to Follow-up|15
6213689|NCT01606137|9880663|FG000|Overall Study|Protocol Violation|1
6213690|NCT01606137|9880663|FG000|Overall Study|Patient non-compliance|9
6213691|NCT01606137|9880663|FG000|Overall Study|Death|1
6213692|NCT01606137|9880663|FG000|Overall Study|Decreased/no pain|4
6213693|NCT01606137|9880663|FG000|Overall Study|Issues with driving|4
6213694|NCT01606137|9880663|FG000|Overall Study|multiple sclerosis less stable|1
6213695|NCT01606137|9880663|FG000|Overall Study|Increased bilirubin|1
6213696|NCT01606137|9880663|FG000|Overall Study|Spray causes nausea|1
6213697|NCT01606137|9880663|FG000|Overall Study|Not enough improvement|4
6213698|NCT01606137|9880663|FG000|Overall Study|Wanted to try another treatment|1
6213699|NCT01606137|9880663|FG000|Overall Study|Patient leaving country|1
6213700|NCT01606137|9880663|FG000|Overall Study|Personal reasons|1
6213701|NCT01606137|9880663|FG000|Overall Study|Unable to tolerate study med. taste|1
6213702|NCT01606137|9880663|FG000|Overall Study|Patient moving|1
6213703|NCT01606137|9880663|FG000|Overall Study|Unable to collect consistent data|1
6213704|NCT01606176|9880669|FG000|Overall Study|Adverse Event|2
6213705|NCT01606176|9880670|FG001|Overall Study|Adverse Event|3
6213706|NCT01606176|9880669|FG000|Overall Study|Disease progression|1
6213707|NCT01606176|9880670|FG001|Overall Study|Disease progression|0
6213708|NCT01606176|9880669|FG000|Overall Study|Withdrawal by Subject|1
6213709|NCT01606176|9880670|FG001|Overall Study|Withdrawal by Subject|0
6213710|NCT01606189|9880676|FG000|Second Intenvention (14-20 Days)|Adverse Event|0
6213711|NCT01606189|9880677|FG001|Second Intenvention (14-20 Days)|Adverse Event|0
6213712|NCT01606189|9880678|FG002|Second Intenvention (14-20 Days)|Adverse Event|0
6213713|NCT01606189|9880679|FG003|Second Intenvention (14-20 Days)|Adverse Event|0
6213714|NCT01606189|9880680|FG004|Second Intenvention (14-20 Days)|Adverse Event|0
6213715|NCT01606189|9880681|FG005|Second Intenvention (14-20 Days)|Adverse Event|1
6213716|NCT01606189|9880676|FG000|Third Intenvention (14-20 Days)|Withdrawal by Subject|0
6213717|NCT01606189|9880677|FG001|Third Intenvention (14-20 Days)|Withdrawal by Subject|0
6213718|NCT01606189|9880678|FG002|Third Intenvention (14-20 Days)|Withdrawal by Subject|0
6213719|NCT01606189|9880679|FG003|Third Intenvention (14-20 Days)|Withdrawal by Subject|0
6213720|NCT01606189|9880680|FG004|Third Intenvention (14-20 Days)|Withdrawal by Subject|0
6213721|NCT01606189|9880681|FG005|Third Intenvention (14-20 Days)|Withdrawal by Subject|1
6213722|NCT01606202|9880691|FG000|Overall Study|Adverse Event|5
6213723|NCT01606202|9880692|FG001|Overall Study|Adverse Event|0
6213724|NCT01606202|9880691|FG000|Overall Study|Withdrawal by Subject|2
6213725|NCT01606202|9880692|FG001|Overall Study|Withdrawal by Subject|1
6213726|NCT01606202|9880691|FG000|Overall Study|Personal problems|0
6213727|NCT01606202|9880692|FG001|Overall Study|Personal problems|1
6213728|NCT01606202|9880691|FG000|Overall Study|Problems with administration|0
6213729|NCT01606202|9880692|FG001|Overall Study|Problems with administration|1
6213730|NCT01606228|9880698|FG000|Overall Study|Lost to Follow-up|20
6213731|NCT01606228|9880698|FG000|Overall Study|Withdrawal by Subject|3
6213732|NCT01606228|9880698|FG000|Overall Study|Non-compliant|3
6213733|NCT01606228|9880698|FG000|Overall Study|Lack of Efficacy|2
6213734|NCT01606228|9880698|FG000|Overall Study|Adverse Event|1
6213735|NCT01606254|9880706|FG000|Overall Study|Withdrawal by Subject|1
6213736|NCT01606254|9880707|FG001|Overall Study|Withdrawal by Subject|3
6213737|NCT01606254|9880708|FG002|Overall Study|Withdrawal by Subject|0
6213738|NCT01606254|9880709|FG003|Overall Study|Withdrawal by Subject|2
6213739|NCT01606254|9880706|FG000|Overall Study|Adverse Event|1
6213740|NCT01606254|9880707|FG001|Overall Study|Adverse Event|1
6213741|NCT01606254|9880708|FG002|Overall Study|Adverse Event|0
6213742|NCT01606254|9880709|FG003|Overall Study|Adverse Event|1
6213743|NCT01606306|9880725|FG000|Overall Study|Lack of Efficacy|2
6213744|NCT01606306|9880726|FG001|Overall Study|Lack of Efficacy|1
6213745|NCT01606306|9880727|FG002|Overall Study|Lack of Efficacy|4
6213746|NCT01606306|9880728|FG003|Overall Study|Lack of Efficacy|4
6213747|NCT01606306|9880729|FG004|Overall Study|Lack of Efficacy|1
6213748|NCT01606306|9880730|FG005|Overall Study|Lack of Efficacy|2
6213749|NCT01606306|9880725|FG000|Overall Study|Adverse Event|1
6213750|NCT01606306|9880726|FG001|Overall Study|Adverse Event|0
6213751|NCT01606306|9880727|FG002|Overall Study|Adverse Event|1
6120597|NCT00892281|9743818|FG000|Overall Study|PI complained of inadequate compensation|3
6120598|NCT00892281|9743819|FG001|Overall Study|PI complained of inadequate compensation|0
6120599|NCT00892281|9743818|FG000|Overall Study|Subject lost interest in program|0
6120600|NCT00892281|9743819|FG001|Overall Study|Subject lost interest in program|1
6120601|NCT00892281|9743818|FG000|Overall Study|Bad taste in mouth after taking Oracea®|0
6120602|NCT00892281|9743819|FG001|Overall Study|Bad taste in mouth after taking Oracea®|1
6120603|NCT00892281|9743818|FG000|Overall Study|Death in family|1
6120604|NCT00892281|9743819|FG001|Overall Study|Death in family|0
6120605|NCT00892281|9743818|FG000|Overall Study|Lack of efficacy of study product|2
6120606|NCT00892281|9743819|FG001|Overall Study|Lack of efficacy of study product|0
6120607|NCT00892281|9743818|FG000|Overall Study|Subject not seen by PI at final visit|1
6120608|NCT00892281|9743819|FG001|Overall Study|Subject not seen by PI at final visit|0
6120609|NCT00892281|9743818|FG000|Overall Study|No show Visit 2; prescription not filled|1
6120610|NCT00892281|9743819|FG001|Overall Study|No show Visit 2; prescription not filled|0
6120611|NCT00892281|9743818|FG000|Overall Study|Missed multiple visits|1
6120612|NCT00892281|9743819|FG001|Overall Study|Missed multiple visits|0
6120613|NCT00892281|9743818|FG000|Overall Study|Missed visits rescheduled out of window|1
6120614|NCT00892281|9743819|FG001|Overall Study|Missed visits rescheduled out of window|0
6120615|NCT00892281|9743818|FG000|Overall Study|Non-compliant with visits as scheduled|1
6120616|NCT00892281|9743819|FG001|Overall Study|Non-compliant with visits as scheduled|0
6120617|NCT00892281|9743818|FG000|Overall Study|Subject had history of drug abuse|1
6120618|NCT00892281|9743819|FG001|Overall Study|Subject had history of drug abuse|0
6120619|NCT00892281|9743818|FG000|Overall Study|Rash on hand|1
6120620|NCT00892281|9743819|FG001|Overall Study|Rash on hand|0
6120621|NCT00892281|9743818|FG000|Overall Study|Visit 4 date out of window|1
6120622|NCT00892281|9743819|FG001|Overall Study|Visit 4 date out of window|0
6120623|NCT00892437|9743827|FG000|Randomized Phase|Randomized but not treated|6
6120624|NCT00892437|9743828|FG001|Randomized Phase|Randomized but not treated|0
6120625|NCT00892437|9743827|FG000|Randomized Phase|Adverse Event|2
6120626|NCT00892437|9743828|FG001|Randomized Phase|Adverse Event|2
6120627|NCT00892437|9743827|FG000|Randomized Phase|Lost to Follow-up|1
6120628|NCT00892437|9743828|FG001|Randomized Phase|Lost to Follow-up|3
6120629|NCT00892437|9743827|FG000|Randomized Phase|Investigator's Discretion|1
6120630|NCT00892437|9743828|FG001|Randomized Phase|Investigator's Discretion|0
6120631|NCT00892437|9743827|FG000|Randomized Phase|Withdrew Consent|1
6120632|NCT00892437|9743828|FG001|Randomized Phase|Withdrew Consent|0
6120633|NCT00892437|9743827|FG000|Open-Label Extension Phase|Adverse Event|4
6120634|NCT00892437|9743828|FG001|Open-Label Extension Phase|Adverse Event|2
6120635|NCT00892437|9743827|FG000|Open-Label Extension Phase|Lack of Efficacy|1
6120636|NCT00892437|9743828|FG001|Open-Label Extension Phase|Lack of Efficacy|0
6120637|NCT00892437|9743827|FG000|Open-Label Extension Phase|Lost to Follow-up|3
6120638|NCT00892437|9743828|FG001|Open-Label Extension Phase|Lost to Follow-up|1
6213752|NCT01606306|9880728|FG003|Overall Study|Adverse Event|1
6213753|NCT01606306|9880729|FG004|Overall Study|Adverse Event|2
6213754|NCT01606306|9880730|FG005|Overall Study|Adverse Event|0
6213755|NCT01606306|9880725|FG000|Overall Study|Lost to Follow-up|7
6213756|NCT01606306|9880726|FG001|Overall Study|Lost to Follow-up|4
6213757|NCT01606306|9880727|FG002|Overall Study|Lost to Follow-up|5
6213758|NCT01606306|9880728|FG003|Overall Study|Lost to Follow-up|4
6213759|NCT01606306|9880729|FG004|Overall Study|Lost to Follow-up|3
6213760|NCT01606306|9880730|FG005|Overall Study|Lost to Follow-up|5
6213761|NCT01606306|9880725|FG000|Overall Study|Withdrawal by Subject|4
6213762|NCT01606306|9880726|FG001|Overall Study|Withdrawal by Subject|3
6213763|NCT01606306|9880727|FG002|Overall Study|Withdrawal by Subject|4
6213764|NCT01606306|9880728|FG003|Overall Study|Withdrawal by Subject|4
6213765|NCT01606306|9880729|FG004|Overall Study|Withdrawal by Subject|5
6213766|NCT01606306|9880730|FG005|Overall Study|Withdrawal by Subject|4
6213767|NCT01606306|9880725|FG000|Overall Study|Physician Decision|1
6213768|NCT01606306|9880726|FG001|Overall Study|Physician Decision|2
6120639|NCT00892437|9743827|FG000|Open-Label Extension Phase|Investigator's Discretion|1
6120640|NCT00892437|9743828|FG001|Open-Label Extension Phase|Investigator's Discretion|0
6120641|NCT00892437|9743827|FG000|Open-Label Extension Phase|Withdrew Consent|3
6120642|NCT00892437|9743828|FG001|Open-Label Extension Phase|Withdrew Consent|1
6120643|NCT00892723|9743865|FG000|Overall Study|Lost to Follow-up|1
6120644|NCT00892723|9743866|FG001|Overall Study|Lost to Follow-up|3
6120645|NCT00892723|9743867|FG002|Overall Study|Lost to Follow-up|1
6120646|NCT00892723|9743865|FG000|Overall Study|Withdrawal by Subject|1
6120647|NCT00892723|9743866|FG001|Overall Study|Withdrawal by Subject|1
6120648|NCT00892723|9743867|FG002|Overall Study|Withdrawal by Subject|1
6120649|NCT00892775|9743910|FG000|Overall Study|Protocol Violation|1
6120650|NCT00892775|9743911|FG001|Overall Study|Protocol Violation|0
6120651|NCT00892775|9743910|FG000|Overall Study|Subject difficulties with blood drawing|1
6120652|NCT00892775|9743911|FG001|Overall Study|Subject difficulties with blood drawing|0
6213769|NCT01606306|9880727|FG002|Overall Study|Physician Decision|0
6213770|NCT01606306|9880728|FG003|Overall Study|Physician Decision|0
6120653|NCT00892775|9743910|FG000|Overall Study|Disclaimer/ Withdrawal caused by H1N1|1
6120654|NCT00892775|9743911|FG001|Overall Study|Disclaimer/ Withdrawal caused by H1N1|0
6213771|NCT01606306|9880729|FG004|Overall Study|Physician Decision|0
6120655|NCT00892775|9743910|FG000|Overall Study|Migrated/ moved from study area|1
6120656|NCT00892775|9743911|FG001|Overall Study|Migrated/ moved from study area|0
6120657|NCT00892775|9743910|FG000|Overall Study|Withdrawal by Subject|0
6120658|NCT00892775|9743911|FG001|Overall Study|Withdrawal by Subject|1
6120659|NCT00892775|9743910|FG000|Overall Study|Lost to Follow-up|1
6120660|NCT00892775|9743911|FG001|Overall Study|Lost to Follow-up|0
6120661|NCT00892957|9743919|FG000|Between Postoperative Day 1 and Day 14|Death|0
6120662|NCT00892957|9743920|FG001|Between Postoperative Day 1 and Day 14|Death|2
6120663|NCT00892957|9743919|FG000|Between Postoperative Day 1 and Day 14|Lost to Follow-up|0
6120664|NCT00892957|9743920|FG001|Between Postoperative Day 1 and Day 14|Lost to Follow-up|2
6120665|NCT00893113|9743957|FG000|Overall Study|Lost to Follow-up|4
6120666|NCT00893113|9743958|FG001|Overall Study|Lost to Follow-up|8
6120667|NCT00893113|9743957|FG000|Overall Study|Early Termination|1
6120668|NCT00893113|9743958|FG001|Overall Study|Early Termination|1
6120669|NCT00893113|9743957|FG000|Overall Study|Withdrew Consent|8
6120670|NCT00893113|9743958|FG001|Overall Study|Withdrew Consent|7
6120671|NCT00893464|9743981|FG000|Overall Study|Did not complete therapy/experience PD|0
6120672|NCT00893464|9743982|FG001|Overall Study|Did not complete therapy/experience PD|0
6120673|NCT00893464|9743983|FG002|Overall Study|Did not complete therapy/experience PD|0
6120674|NCT00893464|9743984|FG003|Overall Study|Did not complete therapy/experience PD|0
6120675|NCT00893464|9743985|FG004|Overall Study|Did not complete therapy/experience PD|0
6120676|NCT00893464|9743986|FG005|Overall Study|Did not complete therapy/experience PD|0
6120677|NCT00893464|9743987|FG006|Overall Study|Did not complete therapy/experience PD|2
6120678|NCT00893464|9743988|FG007|Overall Study|Did not complete therapy/experience PD|2
6120679|NCT00893737|9744011|FG000|Overall Study|Adverse Event|4
6120680|NCT00893737|9744011|FG000|Overall Study|Withdrawal by Subject|2
6120681|NCT00893737|9744011|FG000|Overall Study|Lost to Follow-up|6
6120682|NCT00893763|9744017|FG000|Overall Study|extubated|110
6120683|NCT00893763|9744018|FG001|Overall Study|extubated|110
6120684|NCT00893971|9744026|FG000|Overall Study|Physician Decision|3
6120685|NCT00894166|9744059|FG000|Overall Study|Withdrew or Lost to Follow-Up|61
6120686|NCT00894166|9744060|FG001|Overall Study|Withdrew or Lost to Follow-Up|63
6120687|NCT00894166|9744061|FG002|Overall Study|Withdrew or Lost to Follow-Up|62
6287507|NCT02349633|9999875|FG010|Overall Study|Early termination of survival follow-up|0
6120688|NCT00894166|9744062|FG003|Overall Study|Withdrew or Lost to Follow-Up|68
6120689|NCT00894166|9744063|FG004|Overall Study|Withdrew or Lost to Follow-Up|24
6120690|NCT00894166|9744064|FG005|Overall Study|Withdrew or Lost to Follow-Up|16
6120691|NCT00894166|9744065|FG006|Overall Study|Withdrew or Lost to Follow-Up|16
6120692|NCT00894166|9744066|FG007|Overall Study|Withdrew or Lost to Follow-Up|34
6120693|NCT00894166|9744059|FG000|Overall Study|Death|0
6120694|NCT00894166|9744060|FG001|Overall Study|Death|0
6120695|NCT00894166|9744061|FG002|Overall Study|Death|0
6120696|NCT00894166|9744062|FG003|Overall Study|Death|1
6120697|NCT00894166|9744063|FG004|Overall Study|Death|0
6120698|NCT00894166|9744064|FG005|Overall Study|Death|0
6120699|NCT00894166|9744065|FG006|Overall Study|Death|0
6120700|NCT00894166|9744066|FG007|Overall Study|Death|0
6120701|NCT00894322|9744092|FG000|Overall Study|Withdrawal by Subject|1
6120702|NCT00894322|9744093|FG001|Overall Study|Withdrawal by Subject|0
6120703|NCT00894322|9744094|FG002|Overall Study|Withdrawal by Subject|0
6120704|NCT00894361|9744106|FG000|Overall Study|deaths and less than 2 years followup|24
6120705|NCT00894361|9744107|FG001|Overall Study|deaths and less than 2 years followup|64
6120706|NCT00894387|9744117|FG000|Overall Study|Adverse Event|44
6120707|NCT00894387|9744118|FG001|Overall Study|Adverse Event|45
6120708|NCT00894387|9744117|FG000|Overall Study|Abnormal Laboratory values|2
6120709|NCT00894387|9744118|FG001|Overall Study|Abnormal Laboratory values|2
6120710|NCT00894387|9744117|FG000|Overall Study|Unsatisfactory therapeutic effect|0
6120711|NCT00894387|9744118|FG001|Overall Study|Unsatisfactory therapeutic effect|1
6120712|NCT00894387|9744117|FG000|Overall Study|Lost to Follow-up|3
6120713|NCT00894387|9744118|FG001|Overall Study|Lost to Follow-up|5
6120714|NCT00894387|9744117|FG000|Overall Study|Administrative problems|2
6120715|NCT00894387|9744118|FG001|Overall Study|Administrative problems|2
6120716|NCT00894387|9744117|FG000|Overall Study|Death|77
6120717|NCT00894387|9744118|FG001|Overall Study|Death|76
6120718|NCT00894387|9744117|FG000|Overall Study|Protocol Deviation|4
6120719|NCT00894387|9744118|FG001|Overall Study|Protocol Deviation|0
6120720|NCT00894387|9744117|FG000|Overall Study|Patient's request|25
6120721|NCT00894387|9744118|FG001|Overall Study|Patient's request|30
6213772|NCT01606306|9880730|FG005|Overall Study|Physician Decision|0
6213773|NCT01606319|9880738|FG000|Overall Study|Lost to Follow-up|17
6213774|NCT01606319|9880739|FG001|Overall Study|Lost to Follow-up|14
6213775|NCT01606319|9880738|FG000|Overall Study|Withdrawal by Subject|9
6213776|NCT01606319|9880739|FG001|Overall Study|Withdrawal by Subject|12
6213777|NCT01606319|9880738|FG000|Overall Study|Physician Decision|1
6213778|NCT01606319|9880739|FG001|Overall Study|Physician Decision|2
6213779|NCT01606319|9880738|FG000|Overall Study|Lack of Efficacy|6
6213780|NCT01606319|9880739|FG001|Overall Study|Lack of Efficacy|8
6213781|NCT01606319|9880738|FG000|Overall Study|Adverse Event|1
6213782|NCT01606319|9880739|FG001|Overall Study|Adverse Event|4
6213783|NCT01606670|9880745|FG000|Overall Study|Adverse Event|6
6213784|NCT01606670|9880745|FG000|Overall Study|Lack of Efficacy|2
6213785|NCT01606670|9880745|FG000|Overall Study|Lost to Follow-up|3
6120722|NCT00894387|9744117|FG000|Overall Study|Other (Missing)|5
6120723|NCT00894387|9744118|FG001|Overall Study|Other (Missing)|3
6120724|NCT00894387|9744117|FG000|Overall Study|Mis-randomized|13
6120725|NCT00894387|9744118|FG001|Overall Study|Mis-randomized|9
6120726|NCT00894387|9744117|FG000|Overall Study|GCP non-compliance|0
6120727|NCT00894387|9744118|FG001|Overall Study|GCP non-compliance|2
6120728|NCT00894413|9744126|FG000|Overall Study|Physician Decision|0
6120729|NCT00894413|9744127|FG001|Overall Study|Physician Decision|2
6120730|NCT00894413|9744126|FG000|Overall Study|Adverse Event|0
6120731|NCT00894413|9744127|FG001|Overall Study|Adverse Event|2
6120732|NCT00894413|9744126|FG000|Overall Study|Withdrawal by Subject|0
6120733|NCT00894413|9744127|FG001|Overall Study|Withdrawal by Subject|4
6213786|NCT01606670|9880745|FG000|Overall Study|Withdrawal by Subject|3
6213787|NCT01606670|9880745|FG000|Overall Study|Other Reason|2
6213788|NCT01606748|9880764|FG000|Overall Study|Adverse Event|1
6213789|NCT01606748|9880765|FG001|Overall Study|Adverse Event|0
6213790|NCT01606748|9880764|FG000|Overall Study|Progressive Disease|1
6213791|NCT01606748|9880765|FG001|Overall Study|Progressive Disease|0
6213792|NCT01606748|9880764|FG000|Overall Study|Withdrawal by Subject|1
6287508|NCT02349633|9999876|FG011|Overall Study|Early termination of survival follow-up|0
6287509|NCT02349633|9999877|FG012|Overall Study|Early termination of survival follow-up|0
6287510|NCT02349633|9999878|FG013|Overall Study|Early termination of survival follow-up|0
6287511|NCT02349633|9999865|FG000|Overall Study|Termination by sponsor|0
6287512|NCT02349633|9999866|FG001|Overall Study|Termination by sponsor|0
6287513|NCT02349633|9999867|FG002|Overall Study|Termination by sponsor|0
6287514|NCT02349633|9999868|FG003|Overall Study|Termination by sponsor|0
6287515|NCT02349633|9999869|FG004|Overall Study|Termination by sponsor|0
6287516|NCT02349633|9999870|FG005|Overall Study|Termination by sponsor|0
6287517|NCT02349633|9999871|FG006|Overall Study|Termination by sponsor|0
6287518|NCT02349633|9999872|FG007|Overall Study|Termination by sponsor|1
6287519|NCT02349633|9999873|FG008|Overall Study|Termination by sponsor|0
6287520|NCT02349633|9999874|FG009|Overall Study|Termination by sponsor|2
6287521|NCT02349633|9999875|FG010|Overall Study|Termination by sponsor|0
6287522|NCT02349633|9999876|FG011|Overall Study|Termination by sponsor|0
6287523|NCT02349633|9999877|FG012|Overall Study|Termination by sponsor|0
6287524|NCT02349633|9999878|FG013|Overall Study|Termination by sponsor|0
6287525|NCT02349633|9999865|FG000|Overall Study|Other|0
6287526|NCT02349633|9999866|FG001|Overall Study|Other|0
6287527|NCT02349633|9999867|FG002|Overall Study|Other|0
6287528|NCT02349633|9999868|FG003|Overall Study|Other|0
6287529|NCT02349633|9999869|FG004|Overall Study|Other|0
6287530|NCT02349633|9999870|FG005|Overall Study|Other|0
6287531|NCT02349633|9999871|FG006|Overall Study|Other|0
6287532|NCT02349633|9999872|FG007|Overall Study|Other|2
6287533|NCT02349633|9999873|FG008|Overall Study|Other|0
6287534|NCT02349633|9999874|FG009|Overall Study|Other|0
6287535|NCT02349633|9999875|FG010|Overall Study|Other|0
6287536|NCT02349633|9999876|FG011|Overall Study|Other|0
6287537|NCT02349633|9999877|FG012|Overall Study|Other|0
6287538|NCT02349633|9999878|FG013|Overall Study|Other|0
6287539|NCT02349711|9999958|FG000|Overall Study|Withdrawal by Subject|2
6287540|NCT02349711|9999959|FG001|Overall Study|Withdrawal by Subject|1
6287541|NCT02349711|9999958|FG000|Overall Study|Lost to Follow-up|1
6287542|NCT02349711|9999959|FG001|Overall Study|Lost to Follow-up|1
6287543|NCT02349789|9999965|FG000|Overall Study|Withdrawal by Subject|2
6287544|NCT02350127|9999971|FG000|4-Month Assessment|Withdrawal by Subject|10
6287545|NCT02350127|9999972|FG001|4-Month Assessment|Withdrawal by Subject|9
6287546|NCT02350127|9999971|FG000|4-Month Assessment|Death|1
6287547|NCT02350127|9999972|FG001|4-Month Assessment|Death|0
6287548|NCT02350127|9999971|FG000|8-Month Assessment|Death|1
6287549|NCT02350127|9999972|FG001|8-Month Assessment|Death|1
6287550|NCT02350127|9999971|FG000|8-Month Assessment|Withdrawal by Subject|5
6287551|NCT02350127|9999972|FG001|8-Month Assessment|Withdrawal by Subject|8
6287552|NCT02350309|9999985|FG000|Treatment Period 1 (2 Days)|Physician Decision|0
6287553|NCT02350309|9999986|FG001|Treatment Period 1 (2 Days)|Physician Decision|0
6287554|NCT02350309|9999987|FG002|Treatment Period 1 (2 Days)|Physician Decision|1
6287555|NCT02350309|9999988|FG003|Treatment Period 1 (2 Days)|Physician Decision|0
6287556|NCT02350309|9999989|FG004|Treatment Period 1 (2 Days)|Physician Decision|0
6213793|NCT01606748|9880765|FG001|Overall Study|Withdrawal by Subject|0
6213794|NCT01606761|9880786|FG000|Prior to Week 24|Lost to Follow-up|0
6213795|NCT01606761|9880787|FG001|Prior to Week 24|Lost to Follow-up|3
6213796|NCT01606761|9880788|FG002|Prior to Week 24|Lost to Follow-up|2
6213797|NCT01606761|9880789|FG003|Prior to Week 24|Lost to Follow-up|0
6213798|NCT01606761|9880790|FG004|Prior to Week 24|Lost to Follow-up|0
6213799|NCT01606761|9880786|FG000|Prior to Week 24|Withdrawal by Subject|12
6213800|NCT01606761|9880787|FG001|Prior to Week 24|Withdrawal by Subject|10
6213801|NCT01606761|9880788|FG002|Prior to Week 24|Withdrawal by Subject|9
6213802|NCT01606761|9880789|FG003|Prior to Week 24|Withdrawal by Subject|0
6287557|NCT02350309|9999990|FG005|Treatment Period 1 (2 Days)|Physician Decision|0
6287558|NCT02350309|9999985|FG000|Treatment Period 4 (2 Days)|Death in the Family|0
6287559|NCT02350309|9999986|FG001|Treatment Period 4 (2 Days)|Death in the Family|0
6287560|NCT02350309|9999987|FG002|Treatment Period 4 (2 Days)|Death in the Family|0
6287561|NCT02350309|9999988|FG003|Treatment Period 4 (2 Days)|Death in the Family|0
6287562|NCT02350309|9999989|FG004|Treatment Period 4 (2 Days)|Death in the Family|0
6120734|NCT00894543|9744169|FG000|Baseline to Week 4|No diary or lost or withdrew|3
6120735|NCT00894543|9744170|FG001|Baseline to Week 4|No diary or lost or withdrew|2
6120736|NCT00894543|9744169|FG000|Week 4 to Week 8|No diary or lost or withdrew|4
6120737|NCT00894543|9744170|FG001|Week 4 to Week 8|No diary or lost or withdrew|2
6120738|NCT00894647|9744178|FG000|Overall Study|Adverse Event|5
6120739|NCT00894647|9744179|FG001|Overall Study|Adverse Event|4
6120740|NCT00894647|9744178|FG000|Overall Study|Withdrawal by Subject|4
6120741|NCT00894647|9744179|FG001|Overall Study|Withdrawal by Subject|4
6120742|NCT00894647|9744178|FG000|Overall Study|Lost to Follow-up|0
6120743|NCT00894647|9744179|FG001|Overall Study|Lost to Follow-up|2
6120744|NCT00894647|9744178|FG000|Overall Study|Non-compliance with study procedures|0
6120745|NCT00894647|9744179|FG001|Overall Study|Non-compliance with study procedures|2
6120746|NCT00894647|9744178|FG000|Overall Study|Other, not due to AE|1
6120747|NCT00894647|9744179|FG001|Overall Study|Other, not due to AE|2
6120748|NCT00894686|9744185|FG000|Overall Study|Withdrawal by Subject|50
6120749|NCT00894686|9744185|FG000|Overall Study|Physician Decision|1
6120750|NCT00894686|9744185|FG000|Overall Study|Other|5
6120751|NCT00894803|9744209|FG000|Overall Study|Death|20
6120752|NCT00894803|9744210|FG001|Overall Study|Death|4
6120753|NCT00894803|9744209|FG000|Overall Study|Lost to Follow-up|0
6120754|NCT00894803|9744210|FG001|Overall Study|Lost to Follow-up|1
6120755|NCT00894933|9744216|FG000|Overall Study|Lost to Follow-up|2
6120756|NCT00894933|9744216|FG000|Overall Study|Cancelled Procedure|1
6120757|NCT00894933|9744216|FG000|Overall Study|Did not meeting incl/excl criteria|1
6120758|NCT00895011|9744223|FG000|Overall Study|Withdrawal by Subject|14
6120759|NCT00895011|9744224|FG001|Overall Study|Withdrawal by Subject|7
6120760|NCT00895011|9744225|FG002|Overall Study|Withdrawal by Subject|2
6120761|NCT00895011|9744223|FG000|Overall Study|Lost to Follow-up|5
6120762|NCT00895011|9744224|FG001|Overall Study|Lost to Follow-up|4
6120763|NCT00895011|9744225|FG002|Overall Study|Lost to Follow-up|1
6120764|NCT00895011|9744223|FG000|Overall Study|Protocol Violation|3
6120765|NCT00895011|9744224|FG001|Overall Study|Protocol Violation|1
6213803|NCT01606761|9880790|FG004|Prior to Week 24|Withdrawal by Subject|0
6213804|NCT01606761|9880786|FG000|Prior to Week 24|Adverse Event|11
6213805|NCT01606761|9880787|FG001|Prior to Week 24|Adverse Event|18
6213806|NCT01606761|9880788|FG002|Prior to Week 24|Adverse Event|22
6213807|NCT01606761|9880789|FG003|Prior to Week 24|Adverse Event|0
6213808|NCT01606761|9880790|FG004|Prior to Week 24|Adverse Event|0
6213809|NCT01606761|9880786|FG000|Prior to Week 24|Lack of Efficacy|15
6213810|NCT01606761|9880787|FG001|Prior to Week 24|Lack of Efficacy|14
6213811|NCT01606761|9880788|FG002|Prior to Week 24|Lack of Efficacy|8
6213812|NCT01606761|9880789|FG003|Prior to Week 24|Lack of Efficacy|0
6213813|NCT01606761|9880790|FG004|Prior to Week 24|Lack of Efficacy|0
6213814|NCT01606761|9880786|FG000|Prior to Week 24|Physician Decision|0
6213815|NCT01606761|9880787|FG001|Prior to Week 24|Physician Decision|3
6213816|NCT01606761|9880788|FG002|Prior to Week 24|Physician Decision|1
6213817|NCT01606761|9880789|FG003|Prior to Week 24|Physician Decision|0
6213818|NCT01606761|9880790|FG004|Prior to Week 24|Physician Decision|0
6213819|NCT01606761|9880786|FG000|Prior to Week 24|Other|4
6213820|NCT01606761|9880787|FG001|Prior to Week 24|Other|7
6213821|NCT01606761|9880788|FG002|Prior to Week 24|Other|5
6213822|NCT01606761|9880789|FG003|Prior to Week 24|Other|0
6213823|NCT01606761|9880790|FG004|Prior to Week 24|Other|0
6213824|NCT01606761|9880786|FG000|Week 24 to Week 52|Lost to Follow-up|0
6213825|NCT01606761|9880787|FG001|Week 24 to Week 52|Lost to Follow-up|1
6213826|NCT01606761|9880788|FG002|Week 24 to Week 52|Lost to Follow-up|1
6213827|NCT01606761|9880789|FG003|Week 24 to Week 52|Lost to Follow-up|1
6213828|NCT01606761|9880790|FG004|Week 24 to Week 52|Lost to Follow-up|0
6213829|NCT01606761|9880786|FG000|Week 24 to Week 52|Withdrawal by Subject|0
6213830|NCT01606761|9880787|FG001|Week 24 to Week 52|Withdrawal by Subject|6
6213831|NCT01606761|9880788|FG002|Week 24 to Week 52|Withdrawal by Subject|3
6213832|NCT01606761|9880789|FG003|Week 24 to Week 52|Withdrawal by Subject|0
6287563|NCT02350309|9999990|FG005|Treatment Period 4 (2 Days)|Death in the Family|1
6287564|NCT02350478|10000007|FG000|Overall Study|Lost to Follow-up|5
6287565|NCT02350478|10000008|FG001|Overall Study|Lost to Follow-up|1
6287566|NCT02351167|10000124|FG000|Overall Study|Withdrawal by Subject|19
6287567|NCT02351167|10000125|FG001|Overall Study|Withdrawal by Subject|18
6287568|NCT02351167|10000126|FG002|Overall Study|Withdrawal by Subject|21
6287569|NCT02351349|10000154|FG000|Overall Study|Withdrawal by Subject|2
6287570|NCT02351349|10000155|FG001|Overall Study|Withdrawal by Subject|3
6287571|NCT02351817|10000191|FG000|Period 1|Adverse Event|1
6287572|NCT02351817|10000192|FG001|Period 1|Adverse Event|2
6287573|NCT02351817|10000191|FG000|Period 1|Lack of Efficacy|0
6287574|NCT02351817|10000192|FG001|Period 1|Lack of Efficacy|1
6287575|NCT02351817|10000191|FG000|Period 2|Adverse Event|0
6287576|NCT02351817|10000192|FG001|Period 2|Adverse Event|2
6287577|NCT02351817|10000191|FG000|Period 2|Protocol Violation|1
6287578|NCT02351817|10000192|FG001|Period 2|Protocol Violation|0
6287579|NCT02351934|10000201|FG000|Allocation|POD weight<pre-op weight|3
6287580|NCT02351934|10000202|FG001|Allocation|POD weight<pre-op weight|0
6287581|NCT02351934|10000201|FG000|Allocation|Hypotension preventing administration|2
6120766|NCT00895011|9744225|FG002|Overall Study|Protocol Violation|3
6120767|NCT00895011|9744223|FG000|Overall Study|Adverse Event|1
6213833|NCT01606761|9880790|FG004|Week 24 to Week 52|Withdrawal by Subject|0
6213834|NCT01606761|9880786|FG000|Week 24 to Week 52|Adverse Event|0
6213835|NCT01606761|9880787|FG001|Week 24 to Week 52|Adverse Event|11
6213836|NCT01606761|9880788|FG002|Week 24 to Week 52|Adverse Event|14
6213837|NCT01606761|9880789|FG003|Week 24 to Week 52|Adverse Event|3
6213838|NCT01606761|9880790|FG004|Week 24 to Week 52|Adverse Event|15
6213839|NCT01606761|9880786|FG000|Week 24 to Week 52|Death|0
6213840|NCT01606761|9880787|FG001|Week 24 to Week 52|Death|0
6213841|NCT01606761|9880788|FG002|Week 24 to Week 52|Death|2
6213842|NCT01606761|9880789|FG003|Week 24 to Week 52|Death|1
6213843|NCT01606761|9880790|FG004|Week 24 to Week 52|Death|0
6213844|NCT01606761|9880786|FG000|Week 24 to Week 52|Lack of Efficacy|0
6213845|NCT01606761|9880787|FG001|Week 24 to Week 52|Lack of Efficacy|13
6213846|NCT01606761|9880788|FG002|Week 24 to Week 52|Lack of Efficacy|7
6213847|NCT01606761|9880789|FG003|Week 24 to Week 52|Lack of Efficacy|10
6213848|NCT01606761|9880790|FG004|Week 24 to Week 52|Lack of Efficacy|3
6213849|NCT01606761|9880786|FG000|Week 24 to Week 52|Physician Decision|0
6213850|NCT01606761|9880787|FG001|Week 24 to Week 52|Physician Decision|1
6213851|NCT01606761|9880788|FG002|Week 24 to Week 52|Physician Decision|1
6213852|NCT01606761|9880789|FG003|Week 24 to Week 52|Physician Decision|0
6213853|NCT01606761|9880790|FG004|Week 24 to Week 52|Physician Decision|0
6213854|NCT01606761|9880786|FG000|Week 24 to Week 52|Other|0
6213855|NCT01606761|9880787|FG001|Week 24 to Week 52|Other|1
6213856|NCT01606761|9880788|FG002|Week 24 to Week 52|Other|5
6213857|NCT01606761|9880789|FG003|Week 24 to Week 52|Other|2
6213858|NCT01606761|9880790|FG004|Week 24 to Week 52|Other|2
6213859|NCT01606761|9880786|FG000|Safety Follow-up Period (Week 52-68)|Lost to Follow-up|0
6213860|NCT01606761|9880787|FG001|Safety Follow-up Period (Week 52-68)|Lost to Follow-up|1
6213861|NCT01606761|9880788|FG002|Safety Follow-up Period (Week 52-68)|Lost to Follow-up|2
6213862|NCT01606761|9880789|FG003|Safety Follow-up Period (Week 52-68)|Lost to Follow-up|0
6213863|NCT01606761|9880790|FG004|Safety Follow-up Period (Week 52-68)|Lost to Follow-up|1
6213864|NCT01606761|9880786|FG000|Safety Follow-up Period (Week 52-68)|Withdrawal by Subject|4
6213865|NCT01606761|9880787|FG001|Safety Follow-up Period (Week 52-68)|Withdrawal by Subject|6
6213866|NCT01606761|9880788|FG002|Safety Follow-up Period (Week 52-68)|Withdrawal by Subject|6
6213867|NCT01606761|9880789|FG003|Safety Follow-up Period (Week 52-68)|Withdrawal by Subject|1
6213868|NCT01606761|9880790|FG004|Safety Follow-up Period (Week 52-68)|Withdrawal by Subject|3
6213869|NCT01606761|9880786|FG000|Safety Follow-up Period (Week 52-68)|Death|0
6213870|NCT01606761|9880787|FG001|Safety Follow-up Period (Week 52-68)|Death|0
6213871|NCT01606761|9880788|FG002|Safety Follow-up Period (Week 52-68)|Death|0
6213872|NCT01606761|9880789|FG003|Safety Follow-up Period (Week 52-68)|Death|0
6213873|NCT01606761|9880790|FG004|Safety Follow-up Period (Week 52-68)|Death|1
6213874|NCT01606761|9880786|FG000|Safety Follow-up Period (Week 52-68)|Other|0
6213875|NCT01606761|9880787|FG001|Safety Follow-up Period (Week 52-68)|Other|3
6213876|NCT01606761|9880788|FG002|Safety Follow-up Period (Week 52-68)|Other|9
6213877|NCT01606761|9880789|FG003|Safety Follow-up Period (Week 52-68)|Other|1
6213878|NCT01606761|9880790|FG004|Safety Follow-up Period (Week 52-68)|Other|3
6213879|NCT01606787|9880807|FG000|Overall Study|Withdrawal by Subject|4
6213880|NCT01606787|9880808|FG001|Overall Study|Withdrawal by Subject|5
6213881|NCT01606787|9880807|FG000|Overall Study|Surgery canceled|0
6213882|NCT01606787|9880808|FG001|Overall Study|Surgery canceled|2
6213883|NCT01606800|9880816|FG000|Overall Study|Adverse Event|3
6213884|NCT01606800|9880817|FG001|Overall Study|Adverse Event|1
6213885|NCT01606800|9880816|FG000|Overall Study|Participant withdrew consent|0
6213886|NCT01606800|9880817|FG001|Overall Study|Participant withdrew consent|1
6213887|NCT01606800|9880816|FG000|Overall Study|Missing completion status|2
6213888|NCT01606800|9880817|FG001|Overall Study|Missing completion status|0
6213889|NCT01607073|9880832|FG000|Overall Study|Adverse Event|1
6287582|NCT02351934|10000202|FG001|Allocation|Hypotension preventing administration|0
6287583|NCT02351934|10000201|FG000|Allocation|Acute Kidney Injury on Post Op Day 1|1
6287584|NCT02351934|10000202|FG001|Allocation|Acute Kidney Injury on Post Op Day 1|0
6287585|NCT02351934|10000201|FG000|Follow-Up|POD weight<pre-op weight|3
6287586|NCT02351934|10000202|FG001|Follow-Up|POD weight<pre-op weight|0
6287587|NCT02351934|10000201|FG000|Follow-Up|Acute Kidney Injury|1
6063278|NCT00505752|9664623|FG001|Overall Study|Ovarian hyperstimulation syndrome risk|1
6063279|NCT00505752|9664624|FG002|Overall Study|Ovarian hyperstimulation syndrome risk|3
6063280|NCT00505752|9664625|FG003|Overall Study|Ovarian hyperstimulation syndrome risk|1
6063281|NCT00505752|9664622|FG000|Overall Study|No oocytes retrieved|0
6063282|NCT00505752|9664623|FG001|Overall Study|No oocytes retrieved|2
6063283|NCT00505752|9664624|FG002|Overall Study|No oocytes retrieved|0
6063284|NCT00505752|9664625|FG003|Overall Study|No oocytes retrieved|1
6063285|NCT00505752|9664622|FG000|Overall Study|No Fertilization|1
6063286|NCT00505752|9664623|FG001|Overall Study|No Fertilization|1
6063287|NCT00505752|9664624|FG002|Overall Study|No Fertilization|2
6063288|NCT00505752|9664625|FG003|Overall Study|No Fertilization|1
6063289|NCT00505752|9664622|FG000|Overall Study|All embryos/blastocysts discarded|0
6063290|NCT00505752|9664623|FG001|Overall Study|All embryos/blastocysts discarded|0
6063291|NCT00505752|9664624|FG002|Overall Study|All embryos/blastocysts discarded|1
6063292|NCT00505752|9664625|FG003|Overall Study|All embryos/blastocysts discarded|1
6063293|NCT00505752|9664622|FG000|Overall Study|Other|1
6063294|NCT00505752|9664623|FG001|Overall Study|Other|2
6063295|NCT00505752|9664624|FG002|Overall Study|Other|1
6063296|NCT00505752|9664625|FG003|Overall Study|Other|2
6120768|NCT00895011|9744224|FG001|Overall Study|Adverse Event|2
6120769|NCT00895011|9744225|FG002|Overall Study|Adverse Event|2
6120770|NCT00895011|9744223|FG000|Overall Study|schedule conflict|1
6120771|NCT00895011|9744224|FG001|Overall Study|schedule conflict|0
6120772|NCT00895011|9744225|FG002|Overall Study|schedule conflict|0
6120773|NCT00895037|9744237|FG000|Overall Study|Death|0
6120774|NCT00895037|9744238|FG001|Overall Study|Death|2
6120775|NCT00895037|9744239|FG002|Overall Study|Death|1
6120776|NCT00895154|9744249|FG000|Overall Study|Lost to Follow-up|1
6120777|NCT00895154|9744250|FG001|Overall Study|Lost to Follow-up|1
6120778|NCT00895154|9744249|FG000|Overall Study|Withdrawal by Subject|0
6120779|NCT00895154|9744250|FG001|Overall Study|Withdrawal by Subject|1
6213890|NCT01607346|9880875|FG000|Overall Study|Adverse Event|3
6213891|NCT01607398|9880881|FG000|Overall Study|Adverse Event|0
6213892|NCT01607398|9880882|FG001|Overall Study|Adverse Event|2
6213893|NCT01607398|9880881|FG000|Overall Study|Severe COPD|2
6213894|NCT01607398|9880882|FG001|Overall Study|Severe COPD|0
6213895|NCT01607476|9880938|FG000|Overall Study|Withdrawal by Subject|1
6213896|NCT01607476|9880939|FG001|Overall Study|Withdrawal by Subject|0
6213897|NCT01607476|9880940|FG002|Overall Study|Withdrawal by Subject|1
6213898|NCT01607476|9880938|FG000|Overall Study|Lost to Follow-up|0
6213899|NCT01607476|9880939|FG001|Overall Study|Lost to Follow-up|0
6213900|NCT01607476|9880940|FG002|Overall Study|Lost to Follow-up|2
6213901|NCT01607554|9880948|FG000|Overall Study|Disease progression|2
6213902|NCT01607593|9880952|FG000|Overall Study|Adverse Event|15
6213903|NCT01607593|9880952|FG000|Overall Study|Lack of Efficacy|16
6213904|NCT01607593|9880952|FG000|Overall Study|Lost to Follow-up|25
6213905|NCT01607593|9880952|FG000|Overall Study|Continuation|33
6213906|NCT01607593|9880952|FG000|Overall Study|Other|4
6213907|NCT01607892|9880994|FG000|Overall Study|Need of treatment not allowed per protocol|0
6213908|NCT01607892|9880995|FG001|Overall Study|Need of treatment not allowed per protocol|0
6213909|NCT01607892|9880996|FG002|Overall Study|Need of treatment not allowed per protocol|0
6213910|NCT01607892|9880997|FG003|Overall Study|Need of treatment not allowed per protocol|1
6213911|NCT01607892|9880998|FG004|Overall Study|Need of treatment not allowed per protocol|0
6213912|NCT01607892|9880994|FG000|Overall Study|Death|4
6213913|NCT01607892|9880995|FG001|Overall Study|Death|2
6213914|NCT01607892|9880996|FG002|Overall Study|Death|8
6213915|NCT01607892|9880997|FG003|Overall Study|Death|10
6213916|NCT01607892|9880998|FG004|Overall Study|Death|3
6213917|NCT01607892|9880994|FG000|Overall Study|Investigator discretion|2
6213918|NCT01607892|9880995|FG001|Overall Study|Investigator discretion|4
6213919|NCT01607892|9880996|FG002|Overall Study|Investigator discretion|4
6213920|NCT01607892|9880997|FG003|Overall Study|Investigator discretion|8
6213921|NCT01607892|9880998|FG004|Overall Study|Investigator discretion|0
6213922|NCT01607892|9880994|FG000|Overall Study|Other treatments became available|1
6213923|NCT01607892|9880995|FG001|Overall Study|Other treatments became available|1
6213924|NCT01607892|9880996|FG002|Overall Study|Other treatments became available|0
6213925|NCT01607892|9880997|FG003|Overall Study|Other treatments became available|0
6213926|NCT01607892|9880998|FG004|Overall Study|Other treatments became available|2
6213927|NCT01607892|9880994|FG000|Overall Study|Intercurrent illness|1
6213928|NCT01607892|9880995|FG001|Overall Study|Intercurrent illness|0
6213929|NCT01607892|9880996|FG002|Overall Study|Intercurrent illness|0
6213930|NCT01607892|9880997|FG003|Overall Study|Intercurrent illness|3
6213931|NCT01607892|9880998|FG004|Overall Study|Intercurrent illness|0
6213932|NCT01607892|9880994|FG000|Overall Study|Non-Compliance with study procedures|0
6213933|NCT01607892|9880995|FG001|Overall Study|Non-Compliance with study procedures|0
6213934|NCT01607892|9880996|FG002|Overall Study|Non-Compliance with study procedures|1
6213935|NCT01607892|9880997|FG003|Overall Study|Non-Compliance with study procedures|0
6213936|NCT01607892|9880998|FG004|Overall Study|Non-Compliance with study procedures|0
6213937|NCT01607892|9880994|FG000|Overall Study|Consent withdrawn by participant|9
6213938|NCT01607892|9880995|FG001|Overall Study|Consent withdrawn by participant|4
6213939|NCT01607892|9880996|FG002|Overall Study|Consent withdrawn by participant|24
6213940|NCT01607892|9880997|FG003|Overall Study|Consent withdrawn by participant|14
6213941|NCT01607892|9880998|FG004|Overall Study|Consent withdrawn by participant|4
6213942|NCT01607892|9880994|FG000|Overall Study|Disease progression|38
6213943|NCT01607892|9880995|FG001|Overall Study|Disease progression|13
6213944|NCT01607892|9880996|FG002|Overall Study|Disease progression|37
6213945|NCT01607892|9880997|FG003|Overall Study|Disease progression|57
6213946|NCT01607892|9880998|FG004|Overall Study|Disease progression|9
6213947|NCT01607892|9880994|FG000|Overall Study|Incidence or severity of Adverse events|3
6213948|NCT01607892|9880995|FG001|Overall Study|Incidence or severity of Adverse events|3
6213949|NCT01607892|9880996|FG002|Overall Study|Incidence or severity of Adverse events|7
6213950|NCT01607892|9880997|FG003|Overall Study|Incidence or severity of Adverse events|2
6213951|NCT01607892|9880998|FG004|Overall Study|Incidence or severity of Adverse events|6
6213952|NCT01607905|9881031|FG000|Overall Study|Withdrawal by participant|7
6213953|NCT01607905|9881032|FG001|Overall Study|Withdrawal by participant|2
6213954|NCT01607905|9881033|FG002|Overall Study|Withdrawal by participant|4
6213955|NCT01607905|9881034|FG003|Overall Study|Withdrawal by participant|6
6213956|NCT01607905|9881035|FG004|Overall Study|Withdrawal by participant|0
6213957|NCT01607905|9881036|FG005|Overall Study|Withdrawal by participant|4
6213958|NCT01607905|9881037|FG006|Overall Study|Withdrawal by participant|12
6120780|NCT00895245|9744297|FG000|Overall Study|Lack of Efficacy|6
6120781|NCT00895310|9744301|FG000|Overall Study|Withdrawal by Subject|1
6120782|NCT00895414|9744305|FG000|First Intervention (14 Days)|Withdrawal by Subject|1
6120783|NCT00895414|9744306|FG001|First Intervention (14 Days)|Withdrawal by Subject|0
6120784|NCT00895414|9744305|FG000|First Intervention (14 Days)|Physician Decision|0
6120785|NCT00895414|9744306|FG001|First Intervention (14 Days)|Physician Decision|1
6120786|NCT00895453|9744315|FG000|Overall Study|Lost to Follow-up|25
6120787|NCT00895453|9744316|FG001|Overall Study|Lost to Follow-up|25
6120788|NCT00895453|9744317|FG002|Overall Study|Lost to Follow-up|23
6120789|NCT00895583|9744336|FG000|Overall Study|Adverse Event|28
6120790|NCT00895583|9744337|FG001|Overall Study|Adverse Event|4
6120791|NCT00895583|9744336|FG000|Overall Study|Death|2
6120792|NCT00895583|9744337|FG001|Overall Study|Death|1
6120793|NCT00895583|9744336|FG000|Overall Study|Physician Decision|3
6120794|NCT00895583|9744337|FG001|Overall Study|Physician Decision|1
6120795|NCT00895583|9744336|FG000|Overall Study|Lost to Follow-up|1
6213959|NCT01607905|9881031|FG000|Overall Study|Incidence or severity of AEs|5
6213960|NCT01607905|9881032|FG001|Overall Study|Incidence or severity of AEs|1
6213961|NCT01607905|9881033|FG002|Overall Study|Incidence or severity of AEs|1
6213962|NCT01607905|9881034|FG003|Overall Study|Incidence or severity of AEs|3
6213963|NCT01607905|9881035|FG004|Overall Study|Incidence or severity of AEs|0
6213964|NCT01607905|9881036|FG005|Overall Study|Incidence or severity of AEs|2
6213965|NCT01607905|9881037|FG006|Overall Study|Incidence or severity of AEs|8
6213966|NCT01607905|9881031|FG000|Overall Study|Disease progression|44
6213967|NCT01607905|9881032|FG001|Overall Study|Disease progression|16
6213968|NCT01607905|9881033|FG002|Overall Study|Disease progression|15
6213969|NCT01607905|9881034|FG003|Overall Study|Disease progression|11
6213970|NCT01607905|9881035|FG004|Overall Study|Disease progression|6
6213971|NCT01607905|9881036|FG005|Overall Study|Disease progression|7
6213972|NCT01607905|9881037|FG006|Overall Study|Disease progression|21
6213973|NCT01607905|9881031|FG000|Overall Study|Non-compliance with study procedures|0
6213974|NCT01607905|9881032|FG001|Overall Study|Non-compliance with study procedures|0
6213975|NCT01607905|9881033|FG002|Overall Study|Non-compliance with study procedures|0
6213976|NCT01607905|9881034|FG003|Overall Study|Non-compliance with study procedures|0
6213977|NCT01607905|9881035|FG004|Overall Study|Non-compliance with study procedures|0
6213978|NCT01607905|9881036|FG005|Overall Study|Non-compliance with study procedures|0
6213979|NCT01607905|9881037|FG006|Overall Study|Non-compliance with study procedures|1
6213980|NCT01607905|9881031|FG000|Overall Study|Death|1
6213981|NCT01607905|9881032|FG001|Overall Study|Death|1
6213982|NCT01607905|9881033|FG002|Overall Study|Death|1
6213983|NCT01607905|9881034|FG003|Overall Study|Death|1
6213984|NCT01607905|9881035|FG004|Overall Study|Death|0
6213985|NCT01607905|9881036|FG005|Overall Study|Death|0
6213986|NCT01607905|9881037|FG006|Overall Study|Death|3
6213987|NCT01607905|9881031|FG000|Overall Study|Other treatments become available|1
6213988|NCT01607905|9881032|FG001|Overall Study|Other treatments become available|0
6213989|NCT01607905|9881033|FG002|Overall Study|Other treatments become available|0
6213990|NCT01607905|9881034|FG003|Overall Study|Other treatments become available|0
6213991|NCT01607905|9881035|FG004|Overall Study|Other treatments become available|0
6213992|NCT01607905|9881036|FG005|Overall Study|Other treatments become available|0
6213993|NCT01607905|9881037|FG006|Overall Study|Other treatments become available|1
6213994|NCT01607905|9881031|FG000|Overall Study|Investigator discretion|0
6213995|NCT01607905|9881032|FG001|Overall Study|Investigator discretion|0
6213996|NCT01607905|9881033|FG002|Overall Study|Investigator discretion|0
6213997|NCT01607905|9881034|FG003|Overall Study|Investigator discretion|0
6213998|NCT01607905|9881035|FG004|Overall Study|Investigator discretion|0
6213999|NCT01607905|9881036|FG005|Overall Study|Investigator discretion|1
6214000|NCT01607905|9881037|FG006|Overall Study|Investigator discretion|0
6214001|NCT01607905|9881031|FG000|Overall Study|Other|1
6214002|NCT01607905|9881032|FG001|Overall Study|Other|0
6214003|NCT01607905|9881033|FG002|Overall Study|Other|0
6214004|NCT01607905|9881034|FG003|Overall Study|Other|0
6214005|NCT01607905|9881035|FG004|Overall Study|Other|0
6214006|NCT01607905|9881036|FG005|Overall Study|Other|0
6214007|NCT01607905|9881037|FG006|Overall Study|Other|1
6287588|NCT02351934|10000202|FG001|Follow-Up|Acute Kidney Injury|0
6287589|NCT02351934|10000201|FG000|Follow-Up|Early dismissal|3
6287590|NCT02351934|10000202|FG001|Follow-Up|Early dismissal|0
6287591|NCT02351934|10000201|FG000|Follow-Up|Hypotension|3
6287592|NCT02351934|10000202|FG001|Follow-Up|Hypotension|0
6287593|NCT02351934|10000201|FG000|Follow-Up|No documentation|2
6287594|NCT02351934|10000202|FG001|Follow-Up|No documentation|0
6287595|NCT02351934|10000201|FG000|Follow-Up|1 ERAS Component Noncompliant|0
6287596|NCT02351934|10000202|FG001|Follow-Up|1 ERAS Component Noncompliant|6
6287597|NCT02351934|10000201|FG000|Follow-Up|2 ERAS Components Noncompliant|0
6287598|NCT02351934|10000202|FG001|Follow-Up|2 ERAS Components Noncompliant|4
6287599|NCT02351960|10000210|FG000|Overall Study|Pretreatment Event/Adverse Event|6
6120796|NCT00895583|9744337|FG001|Overall Study|Lost to Follow-up|3
6120797|NCT00895583|9744336|FG000|Overall Study|Protocol Violation|1
6120798|NCT00895583|9744337|FG001|Overall Study|Protocol Violation|0
6214008|NCT01607905|9881031|FG000|Overall Study|Randomized but not treated|1
6287600|NCT02351960|10000211|FG001|Overall Study|Pretreatment Event/Adverse Event|3
6287601|NCT02351960|10000210|FG000|Overall Study|Voluntary Withdrawal|5
6120799|NCT00895583|9744336|FG000|Overall Study|Withdrawal by Subject|4
6120800|NCT00895583|9744337|FG001|Overall Study|Withdrawal by Subject|2
6120801|NCT00895583|9744336|FG000|Overall Study|Lack of Efficacy|5
6120802|NCT00895583|9744337|FG001|Overall Study|Lack of Efficacy|0
6120803|NCT00895583|9744336|FG000|Overall Study|Other|0
6120804|NCT00895583|9744337|FG001|Overall Study|Other|1
6120805|NCT00895622|9744346|FG000|Overall Study|Protocol Violation|5
6120806|NCT00895622|9744347|FG001|Overall Study|Protocol Violation|4
6120807|NCT00895622|9744348|FG002|Overall Study|Protocol Violation|4
6120808|NCT00895661|9744364|FG000|Overall Study|Death|1
6120809|NCT00895661|9744364|FG000|Overall Study|reason unknown|2
6120810|NCT00895843|9744406|FG000|Overall Study|Protocol Violation|12
6120811|NCT00895843|9744407|FG001|Overall Study|Protocol Violation|12
6120812|NCT00895895|9744418|FG000|Period 1|Adverse Event|7
6120813|NCT00895895|9744419|FG001|Period 1|Adverse Event|6
6120814|NCT00895895|9744420|FG002|Period 1|Adverse Event|4
6120815|NCT00895895|9744421|FG003|Period 1|Adverse Event|6
6120816|NCT00895895|9744422|FG004|Period 1|Adverse Event|7
6120817|NCT00895895|9744418|FG000|Period 1|Death|0
6120818|NCT00895895|9744419|FG001|Period 1|Death|0
6120819|NCT00895895|9744420|FG002|Period 1|Death|0
6120820|NCT00895895|9744421|FG003|Period 1|Death|0
6120821|NCT00895895|9744422|FG004|Period 1|Death|1
6214009|NCT01607905|9881032|FG001|Overall Study|Randomized but not treated|0
6214010|NCT01607905|9881033|FG002|Overall Study|Randomized but not treated|0
6214011|NCT01607905|9881034|FG003|Overall Study|Randomized but not treated|0
6214012|NCT01607905|9881035|FG004|Overall Study|Randomized but not treated|1
6214013|NCT01607905|9881036|FG005|Overall Study|Randomized but not treated|1
6214014|NCT01607905|9881037|FG006|Overall Study|Randomized but not treated|0
6214015|NCT01607957|9881097|FG000|Overall Study|Not treated|1
6214016|NCT01607957|9881098|FG001|Overall Study|Not treated|1
6214017|NCT01607957|9881097|FG000|Overall Study|Death|367
6214018|NCT01607957|9881098|FG001|Overall Study|Death|211
6214019|NCT01607957|9881097|FG000|Overall Study|Lost to Follow-up|3
6214020|NCT01607957|9881098|FG001|Overall Study|Lost to Follow-up|3
6214021|NCT01607957|9881097|FG000|Overall Study|Participant refusal|1
6214022|NCT01607957|9881098|FG001|Overall Study|Participant refusal|0
6214023|NCT01608087|9881117|FG000|Overall Study|Lost to Follow-up|0
6214024|NCT01608087|9881118|FG001|Overall Study|Lost to Follow-up|1
6214025|NCT01608087|9881119|FG002|Overall Study|Lost to Follow-up|0
6214026|NCT01608087|9881117|FG000|Overall Study|Other Reason|0
6214027|NCT01608087|9881118|FG001|Overall Study|Other Reason|1
6214028|NCT01608087|9881119|FG002|Overall Study|Other Reason|0
6214029|NCT01608308|9881165|FG000|Overall Study|pretreatment medical and billing reasons|0
6214030|NCT01608308|9881166|FG001|Overall Study|pretreatment medical and billing reasons|2
6214031|NCT01608321|9881174|FG000|Overall Study|Withdrawal by Subject|1
6214032|NCT01608321|9881175|FG001|Overall Study|Withdrawal by Subject|0
6214033|NCT01608724|9881198|FG000|Overall Study|Withdrawal by Subject|131
6214034|NCT01608724|9881198|FG000|Overall Study|Lost to Follow-up|41
6214035|NCT01608724|9881198|FG000|Overall Study|Study-specific discontinuation criteria|32
6214036|NCT01608724|9881198|FG000|Overall Study|Adverse Event|29
6214037|NCT01608724|9881198|FG000|Overall Study|Protocol Violation|6
6214038|NCT01608724|9881198|FG000|Overall Study|bood sugar too high, etc.|3
6214039|NCT01608724|9881198|FG000|Overall Study|Safety reasons|1
6214040|NCT01609010|9881229|FG000|Overall Study|Stable disease (SD)|22
6214041|NCT01609010|9881230|FG001|Overall Study|Stable disease (SD)|16
6214042|NCT01609010|9881229|FG000|Overall Study|Progressive disease (PD)|8
6214043|NCT01609010|9881230|FG001|Overall Study|Progressive disease (PD)|10
6214044|NCT01609010|9881229|FG000|Overall Study|Adverse Event|3
6214045|NCT01609010|9881230|FG001|Overall Study|Adverse Event|6
6214046|NCT01609010|9881229|FG000|Overall Study|Withdrawal by Subject|2
6214047|NCT01609010|9881230|FG001|Overall Study|Withdrawal by Subject|2
6214048|NCT01609010|9881229|FG000|Overall Study|Other|2
6214049|NCT01609010|9881230|FG001|Overall Study|Other|0
6214050|NCT01609010|9881229|FG000|Overall Study|Other malignancy|1
6214051|NCT01609010|9881230|FG001|Overall Study|Other malignancy|0
6214052|NCT01609010|9881229|FG000|Overall Study|Pathology review|2
6214053|NCT01609010|9881230|FG001|Overall Study|Pathology review|1
6214054|NCT01609010|9881229|FG000|Overall Study|Protocol Violation|1
6214055|NCT01609010|9881230|FG001|Overall Study|Protocol Violation|1
6214056|NCT01609010|9881229|FG000|Overall Study|New cancer|1
6214057|NCT01609010|9881230|FG001|Overall Study|New cancer|0
6214058|NCT01609010|9881229|FG000|Overall Study|Lost to Follow-up|1
6214059|NCT01609010|9881230|FG001|Overall Study|Lost to Follow-up|1
6214060|NCT01609023|9881236|FG000|Overall Study|Lack of Efficacy|3
6214061|NCT01609023|9881236|FG000|Overall Study|Withdrawal by Subject|4
6214062|NCT01609023|9881236|FG000|Overall Study|Lost to Follow-up|8
6214063|NCT01609023|9881236|FG000|Overall Study|Toxicity|3
6214064|NCT01609023|9881236|FG000|Overall Study|Disease progression|10
6214065|NCT01609023|9881236|FG000|Overall Study|Physician Decision|2
6214066|NCT01609023|9881236|FG000|Overall Study|Death|2
6214067|NCT01609023|9881236|FG000|Overall Study|Personal reasons|1
6214068|NCT01609062|9881242|FG000|Extension Phase|Terminated by Sponsor|14
6214069|NCT01609062|9881243|FG001|Extension Phase|Terminated by Sponsor|9
6214070|NCT01609062|9881242|FG000|Extension Phase|Discontinued drug and then was pregnant|1
6214071|NCT01609062|9881243|FG001|Extension Phase|Discontinued drug and then was pregnant|0
6120822|NCT00895895|9744418|FG000|Period 1|discontinued by sponsor|2
6120823|NCT00895895|9744419|FG001|Period 1|discontinued by sponsor|1
6120824|NCT00895895|9744420|FG002|Period 1|discontinued by sponsor|2
6120825|NCT00895895|9744421|FG003|Period 1|discontinued by sponsor|1
6120826|NCT00895895|9744422|FG004|Period 1|discontinued by sponsor|1
6120827|NCT00895895|9744418|FG000|Period 1|failed to return|0
6120828|NCT00895895|9744419|FG001|Period 1|failed to return|0
6120829|NCT00895895|9744420|FG002|Period 1|failed to return|1
6120830|NCT00895895|9744421|FG003|Period 1|failed to return|0
6120831|NCT00895895|9744422|FG004|Period 1|failed to return|1
6120832|NCT00895895|9744418|FG000|Period 1|investigator request|0
6120833|NCT00895895|9744419|FG001|Period 1|investigator request|1
6120834|NCT00895895|9744420|FG002|Period 1|investigator request|0
6120835|NCT00895895|9744421|FG003|Period 1|investigator request|0
6120836|NCT00895895|9744422|FG004|Period 1|investigator request|0
6120837|NCT00895895|9744418|FG000|Period 1|Lost to Follow-up|2
6120838|NCT00895895|9744419|FG001|Period 1|Lost to Follow-up|1
6120839|NCT00895895|9744420|FG002|Period 1|Lost to Follow-up|3
6120840|NCT00895895|9744421|FG003|Period 1|Lost to Follow-up|2
6120841|NCT00895895|9744422|FG004|Period 1|Lost to Follow-up|3
6120842|NCT00895895|9744418|FG000|Period 1|Other|1
6120843|NCT00895895|9744419|FG001|Period 1|Other|2
6120844|NCT00895895|9744420|FG002|Period 1|Other|1
6214072|NCT01609062|9881242|FG000|Extension Phase|Anticipated surgery & transition to EAP|0
6214073|NCT01609062|9881243|FG001|Extension Phase|Anticipated surgery & transition to EAP|1
6214074|NCT01609218|9881250|FG000|Period 1|Adverse Event|3
6214075|NCT01609218|9881251|FG001|Period 1|Adverse Event|5
6214076|NCT01609218|9881250|FG000|Period 1|Sponsor Decision|0
6214077|NCT01609218|9881251|FG001|Period 1|Sponsor Decision|1
6214078|NCT01609218|9881250|FG000|Period 2|Adverse Event|1
6214079|NCT01609218|9881251|FG001|Period 2|Adverse Event|0
6214080|NCT01609257|9881259|FG000|Overall Study|Lost to Follow-up|2
6214081|NCT01609257|9881260|FG001|Overall Study|Lost to Follow-up|1
6214082|NCT01609257|9881259|FG000|Overall Study|Voluntary Withdrawal by Subject|0
6214083|NCT01609257|9881260|FG001|Overall Study|Voluntary Withdrawal by Subject|1
6214084|NCT01609257|9881259|FG000|Overall Study|Non-compliance/Protocol deviation|4
6214085|NCT01609257|9881260|FG001|Overall Study|Non-compliance/Protocol deviation|6
6214086|NCT01609296|9881269|FG000|Overall Study|Death|253
6214087|NCT01609296|9881269|FG000|Overall Study|Withdrawal by Subject|151
6214088|NCT01609296|9881269|FG000|Overall Study|Lost to Follow-up|21
6214089|NCT01609296|9881269|FG000|Overall Study|Exit reason other than withdrawal, death or lost to follow up|35
6214090|NCT01609296|9881269|FG000|Overall Study|missed visit but known to be alive|28
6214091|NCT01609478|9881289|FG000|Overall Study|Adverse Event|3
6214092|NCT01609478|9881290|FG001|Overall Study|Adverse Event|1
6214093|NCT01609478|9881291|FG002|Overall Study|Adverse Event|5
6214094|NCT01609478|9881289|FG000|Overall Study|Protocol Deviation|0
6214095|NCT01609478|9881290|FG001|Overall Study|Protocol Deviation|1
6214096|NCT01609478|9881291|FG002|Overall Study|Protocol Deviation|1
6214097|NCT01609478|9881289|FG000|Overall Study|Non-Compliance with study treatment|1
6214098|NCT01609478|9881290|FG001|Overall Study|Non-Compliance with study treatment|0
6214099|NCT01609478|9881291|FG002|Overall Study|Non-Compliance with study treatment|0
6214100|NCT01609478|9881289|FG000|Overall Study|Physician Decision|1
6214101|NCT01609478|9881290|FG001|Overall Study|Physician Decision|0
6214102|NCT01609478|9881291|FG002|Overall Study|Physician Decision|1
6214103|NCT01609478|9881289|FG000|Overall Study|Withdrawal by Subject|2
6214104|NCT01609478|9881290|FG001|Overall Study|Withdrawal by Subject|0
6214105|NCT01609478|9881291|FG002|Overall Study|Withdrawal by Subject|2
6214106|NCT01609543|9881299|FG000|Overall Study|Disease Progression|28
6214107|NCT01609543|9881299|FG000|Overall Study|Adverse Event|5
6214108|NCT01609543|9881299|FG000|Overall Study|Withdrawal by Subject|1
6214109|NCT01609543|9881299|FG000|Overall Study|Protocol Violation|1
6214110|NCT01609543|9881299|FG000|Overall Study|Death|7
6287602|NCT02351960|10000211|FG001|Overall Study|Voluntary Withdrawal|4
6287603|NCT02351960|10000210|FG000|Overall Study|Significant Protocol Deviation|0
6287604|NCT02351960|10000211|FG001|Overall Study|Significant Protocol Deviation|5
6287605|NCT02352493|10000254|FG000|Overall Study|Pregnancy|0
6120845|NCT00895895|9744421|FG003|Period 1|Other|1
6287606|NCT02352493|10000255|FG001|Overall Study|Pregnancy|0
6287607|NCT02352493|10000256|FG002|Overall Study|Pregnancy|0
6287608|NCT02352493|10000257|FG003|Overall Study|Pregnancy|0
6287609|NCT02352493|10000258|FG004|Overall Study|Pregnancy|0
6287610|NCT02352493|10000259|FG005|Overall Study|Pregnancy|0
6287611|NCT02352493|10000260|FG006|Overall Study|Pregnancy|1
6287612|NCT02352493|10000261|FG007|Overall Study|Pregnancy|0
6287613|NCT02352493|10000262|FG008|Overall Study|Pregnancy|1
6287614|NCT02352493|10000263|FG009|Overall Study|Pregnancy|0
6287615|NCT02352493|10000264|FG010|Overall Study|Pregnancy|0
6287616|NCT02352493|10000265|FG011|Overall Study|Pregnancy|0
6287617|NCT02352493|10000266|FG012|Overall Study|Pregnancy|0
6287618|NCT02352493|10000267|FG013|Overall Study|Pregnancy|0
6287619|NCT02352493|10000268|FG014|Overall Study|Pregnancy|0
6287620|NCT02352493|10000269|FG015|Overall Study|Pregnancy|0
6120846|NCT00895895|9744422|FG004|Period 1|Other|1
6120847|NCT00895895|9744418|FG000|Period 1|Protocol Violation|0
6287621|NCT02352493|10000270|FG016|Overall Study|Pregnancy|0
6287622|NCT02352493|10000271|FG017|Overall Study|Pregnancy|0
6287623|NCT02352493|10000254|FG000|Overall Study|Withdrawal by Subject|0
6287624|NCT02352493|10000255|FG001|Overall Study|Withdrawal by Subject|0
6120848|NCT00895895|9744419|FG001|Period 1|Protocol Violation|1
6120849|NCT00895895|9744420|FG002|Period 1|Protocol Violation|0
6120850|NCT00895895|9744421|FG003|Period 1|Protocol Violation|0
6120851|NCT00895895|9744422|FG004|Period 1|Protocol Violation|0
6120852|NCT00895895|9744418|FG000|Period 1|Withdrawal by Subject|6
6120853|NCT00895895|9744419|FG001|Period 1|Withdrawal by Subject|6
6120854|NCT00895895|9744420|FG002|Period 1|Withdrawal by Subject|8
6120855|NCT00895895|9744421|FG003|Period 1|Withdrawal by Subject|2
6120856|NCT00895895|9744422|FG004|Period 1|Withdrawal by Subject|4
6120857|NCT00895895|9744418|FG000|Period 1|unsatisfactory response-efficacy|2
6120858|NCT00895895|9744419|FG001|Period 1|unsatisfactory response-efficacy|0
6120859|NCT00895895|9744420|FG002|Period 1|unsatisfactory response-efficacy|0
6120860|NCT00895895|9744421|FG003|Period 1|unsatisfactory response-efficacy|0
6120861|NCT00895895|9744422|FG004|Period 1|unsatisfactory response-efficacy|0
6120862|NCT00895895|9744418|FG000|Period 1|randomized and not treated|1
6120863|NCT00895895|9744419|FG001|Period 1|randomized and not treated|3
6120864|NCT00895895|9744420|FG002|Period 1|randomized and not treated|1
6120865|NCT00895895|9744421|FG003|Period 1|randomized and not treated|1
6120866|NCT00895895|9744422|FG004|Period 1|randomized and not treated|2
6120867|NCT00895895|9744418|FG000|After Period 1, Prior to Period 2|Adverse Event|0
6120868|NCT00895895|9744419|FG001|After Period 1, Prior to Period 2|Adverse Event|0
6120869|NCT00895895|9744420|FG002|After Period 1, Prior to Period 2|Adverse Event|1
6120870|NCT00895895|9744421|FG003|After Period 1, Prior to Period 2|Adverse Event|0
6120871|NCT00895895|9744422|FG004|After Period 1, Prior to Period 2|Adverse Event|0
6120872|NCT00895895|9744418|FG000|After Period 1, Prior to Period 2|Other|0
6120873|NCT00895895|9744419|FG001|After Period 1, Prior to Period 2|Other|0
6120874|NCT00895895|9744420|FG002|After Period 1, Prior to Period 2|Other|1
6120875|NCT00895895|9744421|FG003|After Period 1, Prior to Period 2|Other|0
6120876|NCT00895895|9744422|FG004|After Period 1, Prior to Period 2|Other|0
6120877|NCT00895895|9744418|FG000|After Period 1, Prior to Period 2|Protocol Violation|0
6120878|NCT00895895|9744419|FG001|After Period 1, Prior to Period 2|Protocol Violation|0
6120879|NCT00895895|9744420|FG002|After Period 1, Prior to Period 2|Protocol Violation|0
6120880|NCT00895895|9744421|FG003|After Period 1, Prior to Period 2|Protocol Violation|0
6214111|NCT01609556|9881320|FG000|Dose Escalation: Maximum 101.3 Weeks|Adverse Event|0
6214112|NCT01609556|9881321|FG001|Dose Escalation: Maximum 101.3 Weeks|Adverse Event|0
6214113|NCT01609556|9881322|FG002|Dose Escalation: Maximum 101.3 Weeks|Adverse Event|0
6214114|NCT01609556|9881323|FG003|Dose Escalation: Maximum 101.3 Weeks|Adverse Event|0
6214115|NCT01609556|9881324|FG004|Dose Escalation: Maximum 101.3 Weeks|Adverse Event|1
6214116|NCT01609556|9881325|FG005|Dose Escalation: Maximum 101.3 Weeks|Adverse Event|0
6214117|NCT01609556|9881326|FG006|Dose Escalation: Maximum 101.3 Weeks|Adverse Event|0
6214118|NCT01609556|9881327|FG007|Dose Escalation: Maximum 101.3 Weeks|Adverse Event|1
6214119|NCT01609556|9881328|FG008|Dose Escalation: Maximum 101.3 Weeks|Adverse Event|1
6214120|NCT01609556|9881329|FG009|Dose Escalation: Maximum 101.3 Weeks|Adverse Event|0
6214121|NCT01609556|9881330|FG010|Dose Escalation: Maximum 101.3 Weeks|Adverse Event|1
6214122|NCT01609556|9881331|FG011|Dose Escalation: Maximum 101.3 Weeks|Adverse Event|1
6214123|NCT01609556|9881332|FG012|Dose Escalation: Maximum 101.3 Weeks|Adverse Event|0
6214124|NCT01609556|9881333|FG013|Dose Escalation: Maximum 101.3 Weeks|Adverse Event|0
6214125|NCT01609556|9881334|FG014|Dose Escalation: Maximum 101.3 Weeks|Adverse Event|0
6214126|NCT01609556|9881335|FG015|Dose Escalation: Maximum 101.3 Weeks|Adverse Event|0
6214127|NCT01609556|9881320|FG000|Dose Escalation: Maximum 101.3 Weeks|Disease Progression|0
6287625|NCT02352493|10000256|FG002|Overall Study|Withdrawal by Subject|0
6287626|NCT02352493|10000257|FG003|Overall Study|Withdrawal by Subject|0
6287627|NCT02352493|10000258|FG004|Overall Study|Withdrawal by Subject|0
6287628|NCT02352493|10000259|FG005|Overall Study|Withdrawal by Subject|0
6287629|NCT02352493|10000260|FG006|Overall Study|Withdrawal by Subject|0
6287630|NCT02352493|10000261|FG007|Overall Study|Withdrawal by Subject|0
6287631|NCT02352493|10000262|FG008|Overall Study|Withdrawal by Subject|1
6287632|NCT02352493|10000263|FG009|Overall Study|Withdrawal by Subject|0
6287633|NCT02352493|10000264|FG010|Overall Study|Withdrawal by Subject|0
6287634|NCT02352493|10000265|FG011|Overall Study|Withdrawal by Subject|0
6287635|NCT02352493|10000266|FG012|Overall Study|Withdrawal by Subject|0
6287636|NCT02352493|10000267|FG013|Overall Study|Withdrawal by Subject|0
6287637|NCT02352493|10000268|FG014|Overall Study|Withdrawal by Subject|1
6287638|NCT02352493|10000269|FG015|Overall Study|Withdrawal by Subject|0
6287639|NCT02352493|10000270|FG016|Overall Study|Withdrawal by Subject|0
6287640|NCT02352493|10000271|FG017|Overall Study|Withdrawal by Subject|0
6120881|NCT00895895|9744422|FG004|After Period 1, Prior to Period 2|Protocol Violation|1
6120882|NCT00895895|9744418|FG000|After Period 1, Prior to Period 2|Withdrawal by Subject|0
6120883|NCT00895895|9744419|FG001|After Period 1, Prior to Period 2|Withdrawal by Subject|0
6120884|NCT00895895|9744420|FG002|After Period 1, Prior to Period 2|Withdrawal by Subject|0
6120885|NCT00895895|9744421|FG003|After Period 1, Prior to Period 2|Withdrawal by Subject|0
6120886|NCT00895895|9744422|FG004|After Period 1, Prior to Period 2|Withdrawal by Subject|1
6120887|NCT00895895|9744418|FG000|Period 2|Adverse Event|3
6120888|NCT00895895|9744419|FG001|Period 2|Adverse Event|3
6120889|NCT00895895|9744420|FG002|Period 2|Adverse Event|5
6120890|NCT00895895|9744421|FG003|Period 2|Adverse Event|2
6287641|NCT02352493|10000254|FG000|Overall Study|Lost to Follow-up|0
6287642|NCT02352493|10000255|FG001|Overall Study|Lost to Follow-up|0
6287643|NCT02352493|10000256|FG002|Overall Study|Lost to Follow-up|0
6120891|NCT00895895|9744422|FG004|Period 2|Adverse Event|5
6120892|NCT00895895|9744418|FG000|Period 2|Death|0
6120893|NCT00895895|9744419|FG001|Period 2|Death|0
6120894|NCT00895895|9744420|FG002|Period 2|Death|1
6120895|NCT00895895|9744421|FG003|Period 2|Death|0
6120896|NCT00895895|9744422|FG004|Period 2|Death|0
6120897|NCT00895895|9744418|FG000|Period 2|discontinued by sponsor|44
6120898|NCT00895895|9744419|FG001|Period 2|discontinued by sponsor|44
6120899|NCT00895895|9744420|FG002|Period 2|discontinued by sponsor|38
6120900|NCT00895895|9744421|FG003|Period 2|discontinued by sponsor|46
6120901|NCT00895895|9744422|FG004|Period 2|discontinued by sponsor|37
6120902|NCT00895895|9744418|FG000|Period 2|failed to return|2
6120903|NCT00895895|9744419|FG001|Period 2|failed to return|0
6120904|NCT00895895|9744420|FG002|Period 2|failed to return|0
6120905|NCT00895895|9744421|FG003|Period 2|failed to return|0
6120906|NCT00895895|9744422|FG004|Period 2|failed to return|0
6120907|NCT00895895|9744418|FG000|Period 2|investigator request|2
6120908|NCT00895895|9744419|FG001|Period 2|investigator request|0
6120909|NCT00895895|9744420|FG002|Period 2|investigator request|0
6120910|NCT00895895|9744421|FG003|Period 2|investigator request|0
6120911|NCT00895895|9744422|FG004|Period 2|investigator request|0
6120912|NCT00895895|9744418|FG000|Period 2|Lost to Follow-up|1
6120913|NCT00895895|9744419|FG001|Period 2|Lost to Follow-up|2
6120914|NCT00895895|9744420|FG002|Period 2|Lost to Follow-up|1
6120915|NCT00895895|9744421|FG003|Period 2|Lost to Follow-up|1
6120916|NCT00895895|9744422|FG004|Period 2|Lost to Follow-up|0
6120917|NCT00895895|9744418|FG000|Period 2|Other|1
6214128|NCT01609556|9881321|FG001|Dose Escalation: Maximum 101.3 Weeks|Disease Progression|1
6214129|NCT01609556|9881322|FG002|Dose Escalation: Maximum 101.3 Weeks|Disease Progression|1
6214130|NCT01609556|9881323|FG003|Dose Escalation: Maximum 101.3 Weeks|Disease Progression|1
6214131|NCT01609556|9881324|FG004|Dose Escalation: Maximum 101.3 Weeks|Disease Progression|8
6214132|NCT01609556|9881325|FG005|Dose Escalation: Maximum 101.3 Weeks|Disease Progression|13
6214133|NCT01609556|9881326|FG006|Dose Escalation: Maximum 101.3 Weeks|Disease Progression|5
6214134|NCT01609556|9881327|FG007|Dose Escalation: Maximum 101.3 Weeks|Disease Progression|4
6214135|NCT01609556|9881328|FG008|Dose Escalation: Maximum 101.3 Weeks|Disease Progression|3
6214136|NCT01609556|9881329|FG009|Dose Escalation: Maximum 101.3 Weeks|Disease Progression|3
6214137|NCT01609556|9881330|FG010|Dose Escalation: Maximum 101.3 Weeks|Disease Progression|6
6214138|NCT01609556|9881331|FG011|Dose Escalation: Maximum 101.3 Weeks|Disease Progression|3
6214139|NCT01609556|9881332|FG012|Dose Escalation: Maximum 101.3 Weeks|Disease Progression|0
6214140|NCT01609556|9881333|FG013|Dose Escalation: Maximum 101.3 Weeks|Disease Progression|0
6214141|NCT01609556|9881334|FG014|Dose Escalation: Maximum 101.3 Weeks|Disease Progression|0
6214142|NCT01609556|9881335|FG015|Dose Escalation: Maximum 101.3 Weeks|Disease Progression|0
6214143|NCT01609556|9881320|FG000|Dose Escalation: Maximum 101.3 Weeks|Clinical Progression|0
6214144|NCT01609556|9881321|FG001|Dose Escalation: Maximum 101.3 Weeks|Clinical Progression|0
6214145|NCT01609556|9881322|FG002|Dose Escalation: Maximum 101.3 Weeks|Clinical Progression|0
6214146|NCT01609556|9881323|FG003|Dose Escalation: Maximum 101.3 Weeks|Clinical Progression|0
6214147|NCT01609556|9881324|FG004|Dose Escalation: Maximum 101.3 Weeks|Clinical Progression|0
6214148|NCT01609556|9881325|FG005|Dose Escalation: Maximum 101.3 Weeks|Clinical Progression|2
6214149|NCT01609556|9881326|FG006|Dose Escalation: Maximum 101.3 Weeks|Clinical Progression|2
6214150|NCT01609556|9881327|FG007|Dose Escalation: Maximum 101.3 Weeks|Clinical Progression|0
6214151|NCT01609556|9881328|FG008|Dose Escalation: Maximum 101.3 Weeks|Clinical Progression|0
6214152|NCT01609556|9881329|FG009|Dose Escalation: Maximum 101.3 Weeks|Clinical Progression|1
6214153|NCT01609556|9881330|FG010|Dose Escalation: Maximum 101.3 Weeks|Clinical Progression|1
6214154|NCT01609556|9881331|FG011|Dose Escalation: Maximum 101.3 Weeks|Clinical Progression|2
6214155|NCT01609556|9881332|FG012|Dose Escalation: Maximum 101.3 Weeks|Clinical Progression|0
6214156|NCT01609556|9881333|FG013|Dose Escalation: Maximum 101.3 Weeks|Clinical Progression|0
6214157|NCT01609556|9881334|FG014|Dose Escalation: Maximum 101.3 Weeks|Clinical Progression|0
6214158|NCT01609556|9881335|FG015|Dose Escalation: Maximum 101.3 Weeks|Clinical Progression|0
6214159|NCT01609556|9881320|FG000|Dose Escalation: Maximum 101.3 Weeks|Began New Anticancer Therapy|0
6214160|NCT01609556|9881321|FG001|Dose Escalation: Maximum 101.3 Weeks|Began New Anticancer Therapy|0
6214161|NCT01609556|9881322|FG002|Dose Escalation: Maximum 101.3 Weeks|Began New Anticancer Therapy|0
6214162|NCT01609556|9881323|FG003|Dose Escalation: Maximum 101.3 Weeks|Began New Anticancer Therapy|0
6214163|NCT01609556|9881324|FG004|Dose Escalation: Maximum 101.3 Weeks|Began New Anticancer Therapy|0
6214164|NCT01609556|9881325|FG005|Dose Escalation: Maximum 101.3 Weeks|Began New Anticancer Therapy|1
6214165|NCT01609556|9881326|FG006|Dose Escalation: Maximum 101.3 Weeks|Began New Anticancer Therapy|0
6214166|NCT01609556|9881327|FG007|Dose Escalation: Maximum 101.3 Weeks|Began New Anticancer Therapy|0
6214167|NCT01609556|9881328|FG008|Dose Escalation: Maximum 101.3 Weeks|Began New Anticancer Therapy|0
6214168|NCT01609556|9881329|FG009|Dose Escalation: Maximum 101.3 Weeks|Began New Anticancer Therapy|0
6214169|NCT01609556|9881330|FG010|Dose Escalation: Maximum 101.3 Weeks|Began New Anticancer Therapy|0
6214170|NCT01609556|9881331|FG011|Dose Escalation: Maximum 101.3 Weeks|Began New Anticancer Therapy|1
6214171|NCT01609556|9881332|FG012|Dose Escalation: Maximum 101.3 Weeks|Began New Anticancer Therapy|0
6214172|NCT01609556|9881333|FG013|Dose Escalation: Maximum 101.3 Weeks|Began New Anticancer Therapy|0
6214173|NCT01609556|9881334|FG014|Dose Escalation: Maximum 101.3 Weeks|Began New Anticancer Therapy|0
6120918|NCT00895895|9744419|FG001|Period 2|Other|1
6120919|NCT00895895|9744420|FG002|Period 2|Other|3
6120920|NCT00895895|9744421|FG003|Period 2|Other|1
6120921|NCT00895895|9744422|FG004|Period 2|Other|1
6120922|NCT00895895|9744418|FG000|Period 2|Protocol Violation|1
6120923|NCT00895895|9744419|FG001|Period 2|Protocol Violation|0
6120924|NCT00895895|9744420|FG002|Period 2|Protocol Violation|1
6120925|NCT00895895|9744421|FG003|Period 2|Protocol Violation|1
6120926|NCT00895895|9744422|FG004|Period 2|Protocol Violation|1
6120927|NCT00895895|9744418|FG000|Period 2|Withdrawal by Subject|0
6120928|NCT00895895|9744419|FG001|Period 2|Withdrawal by Subject|2
6120929|NCT00895895|9744420|FG002|Period 2|Withdrawal by Subject|0
6120930|NCT00895895|9744421|FG003|Period 2|Withdrawal by Subject|3
6120931|NCT00895895|9744422|FG004|Period 2|Withdrawal by Subject|5
6214174|NCT01609556|9881335|FG015|Dose Escalation: Maximum 101.3 Weeks|Began New Anticancer Therapy|0
6214175|NCT01609556|9881320|FG000|Dose Escalation: Maximum 101.3 Weeks|Withdrawal by Subject|0
6214176|NCT01609556|9881321|FG001|Dose Escalation: Maximum 101.3 Weeks|Withdrawal by Subject|0
6214177|NCT01609556|9881322|FG002|Dose Escalation: Maximum 101.3 Weeks|Withdrawal by Subject|0
6214178|NCT01609556|9881323|FG003|Dose Escalation: Maximum 101.3 Weeks|Withdrawal by Subject|0
6214179|NCT01609556|9881324|FG004|Dose Escalation: Maximum 101.3 Weeks|Withdrawal by Subject|0
6214180|NCT01609556|9881325|FG005|Dose Escalation: Maximum 101.3 Weeks|Withdrawal by Subject|1
6214181|NCT01609556|9881326|FG006|Dose Escalation: Maximum 101.3 Weeks|Withdrawal by Subject|0
6214182|NCT01609556|9881327|FG007|Dose Escalation: Maximum 101.3 Weeks|Withdrawal by Subject|0
6214183|NCT01609556|9881328|FG008|Dose Escalation: Maximum 101.3 Weeks|Withdrawal by Subject|0
6214184|NCT01609556|9881329|FG009|Dose Escalation: Maximum 101.3 Weeks|Withdrawal by Subject|0
6214185|NCT01609556|9881330|FG010|Dose Escalation: Maximum 101.3 Weeks|Withdrawal by Subject|0
6214186|NCT01609556|9881331|FG011|Dose Escalation: Maximum 101.3 Weeks|Withdrawal by Subject|0
6214187|NCT01609556|9881332|FG012|Dose Escalation: Maximum 101.3 Weeks|Withdrawal by Subject|0
6214188|NCT01609556|9881333|FG013|Dose Escalation: Maximum 101.3 Weeks|Withdrawal by Subject|0
6214189|NCT01609556|9881334|FG014|Dose Escalation: Maximum 101.3 Weeks|Withdrawal by Subject|0
6214190|NCT01609556|9881335|FG015|Dose Escalation: Maximum 101.3 Weeks|Withdrawal by Subject|0
6287644|NCT02352493|10000257|FG003|Overall Study|Lost to Follow-up|0
6287645|NCT02352493|10000258|FG004|Overall Study|Lost to Follow-up|0
6287646|NCT02352493|10000259|FG005|Overall Study|Lost to Follow-up|0
6287647|NCT02352493|10000260|FG006|Overall Study|Lost to Follow-up|0
6287648|NCT02352493|10000261|FG007|Overall Study|Lost to Follow-up|0
6287649|NCT02352493|10000262|FG008|Overall Study|Lost to Follow-up|0
6287650|NCT02352493|10000263|FG009|Overall Study|Lost to Follow-up|1
6287651|NCT02352493|10000264|FG010|Overall Study|Lost to Follow-up|0
6287652|NCT02352493|10000265|FG011|Overall Study|Lost to Follow-up|0
6287653|NCT02352493|10000266|FG012|Overall Study|Lost to Follow-up|1
6287654|NCT02352493|10000267|FG013|Overall Study|Lost to Follow-up|2
6287655|NCT02352493|10000268|FG014|Overall Study|Lost to Follow-up|0
6287656|NCT02352493|10000269|FG015|Overall Study|Lost to Follow-up|0
5980852|NCT01434602|9569526|FG003|Phase II Recommended Phase 2 Dose|Withdrawal by Subject|0
5980853|NCT01434602|9569527|FG004|Phase II Recommended Phase 2 Dose|Withdrawal by Subject|1
5980854|NCT01434602|9569523|FG000|Phase II Recommended Phase 2 Dose|Physician Decision|0
5980855|NCT01434602|9569524|FG001|Phase II Recommended Phase 2 Dose|Physician Decision|0
6063297|NCT00505765|9664638|FG000|Overall Study|Withdrawal by Subject|1
6120932|NCT00895895|9744418|FG000|Period 2|unsatisfactory response-efficacy|2
6120933|NCT00895895|9744419|FG001|Period 2|unsatisfactory response-efficacy|1
6120934|NCT00895895|9744420|FG002|Period 2|unsatisfactory response-efficacy|0
6120935|NCT00895895|9744421|FG003|Period 2|unsatisfactory response-efficacy|0
6120936|NCT00895895|9744422|FG004|Period 2|unsatisfactory response-efficacy|0
6120937|NCT00895947|9744467|FG000|Overall Study|Adverse Event|3
6120938|NCT00895947|9744468|FG001|Overall Study|Adverse Event|4
6120939|NCT00895947|9744467|FG000|Overall Study|Lost to Follow-up|3
6120940|NCT00895947|9744468|FG001|Overall Study|Lost to Follow-up|4
6120941|NCT00895947|9744467|FG000|Overall Study|Protocol Violation|4
6120942|NCT00895947|9744468|FG001|Overall Study|Protocol Violation|2
6120943|NCT00895947|9744467|FG000|Overall Study|Withdrawal by Subject|2
6120944|NCT00895947|9744468|FG001|Overall Study|Withdrawal by Subject|0
6120945|NCT00896051|9744494|FG000|Overall Study|Adverse Event|2
6120946|NCT00896051|9744495|FG001|Overall Study|Adverse Event|1
6120947|NCT00896051|9744494|FG000|Overall Study|Lost to Follow-up|3
6287657|NCT02352493|10000270|FG016|Overall Study|Lost to Follow-up|0
6287658|NCT02352493|10000271|FG017|Overall Study|Lost to Follow-up|0
6063298|NCT00505765|9664639|FG001|Overall Study|Withdrawal by Subject|0
6063299|NCT00505765|9664640|FG002|Overall Study|Withdrawal by Subject|0
6063300|NCT00505765|9664638|FG000|Overall Study|Adverse Event|1
6063301|NCT00505765|9664639|FG001|Overall Study|Adverse Event|2
6063302|NCT00505765|9664640|FG002|Overall Study|Adverse Event|0
6063303|NCT00505765|9664638|FG000|Overall Study|Noncompliance|0
6063304|NCT00505765|9664639|FG001|Overall Study|Noncompliance|1
6063305|NCT00505765|9664640|FG002|Overall Study|Noncompliance|3
6063306|NCT00505778|9664650|FG000|Overall Study|Adverse Event|2
6063307|NCT00505778|9664651|FG001|Overall Study|Adverse Event|7
6063308|NCT00505778|9664650|FG000|Overall Study|Physician Decision|8
6063309|NCT00505778|9664651|FG001|Overall Study|Physician Decision|14
6063310|NCT00505778|9664650|FG000|Overall Study|Lost to Follow-up|17
6063311|NCT00505778|9664651|FG001|Overall Study|Lost to Follow-up|23
6063312|NCT00505778|9664650|FG000|Overall Study|Unable to Meet Protocol Criteria|4
6063313|NCT00505778|9664651|FG001|Overall Study|Unable to Meet Protocol Criteria|1
6120948|NCT00896051|9744495|FG001|Overall Study|Lost to Follow-up|2
6120949|NCT00896051|9744494|FG000|Overall Study|Withdrawal by Subject|3
6120950|NCT00896051|9744495|FG001|Overall Study|Withdrawal by Subject|2
6120951|NCT00896051|9744494|FG000|Overall Study|Subject noncompliant|1
6120952|NCT00896051|9744495|FG001|Overall Study|Subject noncompliant|3
6120953|NCT00896051|9744494|FG000|Overall Study|Other|1
6120954|NCT00896051|9744495|FG001|Overall Study|Other|1
6120955|NCT00896168|9744521|FG000|Overall Study|Adverse Event|4
6120956|NCT00896168|9744522|FG001|Overall Study|Adverse Event|7
6120957|NCT00896168|9744521|FG000|Overall Study|Treatment failure|8
6120958|NCT00896168|9744522|FG001|Overall Study|Treatment failure|10
6120959|NCT00896168|9744521|FG000|Overall Study|Lost to Follow-up|1
6120960|NCT00896168|9744522|FG001|Overall Study|Lost to Follow-up|1
6120961|NCT00896168|9744521|FG000|Overall Study|Other|1
6120962|NCT00896168|9744522|FG001|Overall Study|Other|1
6120963|NCT00896233|9744532|FG000|Overall Study|Claustrophobia during MRI|1
6120964|NCT00896337|9744546|FG000|Overall Study|Death|7
6120965|NCT00896337|9744546|FG000|Overall Study|Withdrawal by Subject|7
6120966|NCT00896337|9744546|FG000|Overall Study|Lost to Follow-up|11
6214191|NCT01609556|9881320|FG000|Dose Escalation: Maximum 101.3 Weeks|Investigator Decision|0
6214192|NCT01609556|9881321|FG001|Dose Escalation: Maximum 101.3 Weeks|Investigator Decision|0
6214193|NCT01609556|9881322|FG002|Dose Escalation: Maximum 101.3 Weeks|Investigator Decision|0
6214194|NCT01609556|9881323|FG003|Dose Escalation: Maximum 101.3 Weeks|Investigator Decision|0
6214195|NCT01609556|9881324|FG004|Dose Escalation: Maximum 101.3 Weeks|Investigator Decision|0
6214196|NCT01609556|9881325|FG005|Dose Escalation: Maximum 101.3 Weeks|Investigator Decision|0
6214197|NCT01609556|9881326|FG006|Dose Escalation: Maximum 101.3 Weeks|Investigator Decision|0
6214198|NCT01609556|9881327|FG007|Dose Escalation: Maximum 101.3 Weeks|Investigator Decision|0
6214199|NCT01609556|9881328|FG008|Dose Escalation: Maximum 101.3 Weeks|Investigator Decision|1
6214200|NCT01609556|9881329|FG009|Dose Escalation: Maximum 101.3 Weeks|Investigator Decision|0
6214201|NCT01609556|9881330|FG010|Dose Escalation: Maximum 101.3 Weeks|Investigator Decision|0
6214202|NCT01609556|9881331|FG011|Dose Escalation: Maximum 101.3 Weeks|Investigator Decision|0
6214203|NCT01609556|9881332|FG012|Dose Escalation: Maximum 101.3 Weeks|Investigator Decision|0
6214204|NCT01609556|9881333|FG013|Dose Escalation: Maximum 101.3 Weeks|Investigator Decision|0
6214205|NCT01609556|9881334|FG014|Dose Escalation: Maximum 101.3 Weeks|Investigator Decision|0
6214206|NCT01609556|9881335|FG015|Dose Escalation: Maximum 101.3 Weeks|Investigator Decision|0
6214207|NCT01609556|9881320|FG000|Dose Escalation: Maximum 101.3 Weeks|Death|2
6214208|NCT01609556|9881321|FG001|Dose Escalation: Maximum 101.3 Weeks|Death|0
6214209|NCT01609556|9881322|FG002|Dose Escalation: Maximum 101.3 Weeks|Death|0
6214210|NCT01609556|9881323|FG003|Dose Escalation: Maximum 101.3 Weeks|Death|0
6214211|NCT01609556|9881324|FG004|Dose Escalation: Maximum 101.3 Weeks|Death|0
6214212|NCT01609556|9881325|FG005|Dose Escalation: Maximum 101.3 Weeks|Death|1
6214213|NCT01609556|9881326|FG006|Dose Escalation: Maximum 101.3 Weeks|Death|0
6214214|NCT01609556|9881327|FG007|Dose Escalation: Maximum 101.3 Weeks|Death|0
6214215|NCT01609556|9881328|FG008|Dose Escalation: Maximum 101.3 Weeks|Death|0
6214216|NCT01609556|9881329|FG009|Dose Escalation: Maximum 101.3 Weeks|Death|0
6214217|NCT01609556|9881330|FG010|Dose Escalation: Maximum 101.3 Weeks|Death|1
6214218|NCT01609556|9881331|FG011|Dose Escalation: Maximum 101.3 Weeks|Death|0
6214219|NCT01609556|9881332|FG012|Dose Escalation: Maximum 101.3 Weeks|Death|0
6214220|NCT01609556|9881333|FG013|Dose Escalation: Maximum 101.3 Weeks|Death|0
6214221|NCT01609556|9881334|FG014|Dose Escalation: Maximum 101.3 Weeks|Death|0
6214222|NCT01609556|9881335|FG015|Dose Escalation: Maximum 101.3 Weeks|Death|0
6214223|NCT01609556|9881320|FG000|Dose Expansion: Maximum 124 Weeks|Adverse Event|0
6214224|NCT01609556|9881321|FG001|Dose Expansion: Maximum 124 Weeks|Adverse Event|0
6214225|NCT01609556|9881322|FG002|Dose Expansion: Maximum 124 Weeks|Adverse Event|0
6214226|NCT01609556|9881323|FG003|Dose Expansion: Maximum 124 Weeks|Adverse Event|0
6214227|NCT01609556|9881324|FG004|Dose Expansion: Maximum 124 Weeks|Adverse Event|0
6214228|NCT01609556|9881325|FG005|Dose Expansion: Maximum 124 Weeks|Adverse Event|0
6214229|NCT01609556|9881326|FG006|Dose Expansion: Maximum 124 Weeks|Adverse Event|0
6214230|NCT01609556|9881327|FG007|Dose Expansion: Maximum 124 Weeks|Adverse Event|0
6214231|NCT01609556|9881328|FG008|Dose Expansion: Maximum 124 Weeks|Adverse Event|0
6214232|NCT01609556|9881329|FG009|Dose Expansion: Maximum 124 Weeks|Adverse Event|0
6214233|NCT01609556|9881330|FG010|Dose Expansion: Maximum 124 Weeks|Adverse Event|0
6214234|NCT01609556|9881331|FG011|Dose Expansion: Maximum 124 Weeks|Adverse Event|0
6214235|NCT01609556|9881332|FG012|Dose Expansion: Maximum 124 Weeks|Adverse Event|4
6214236|NCT01609556|9881333|FG013|Dose Expansion: Maximum 124 Weeks|Adverse Event|2
6214237|NCT01609556|9881334|FG014|Dose Expansion: Maximum 124 Weeks|Adverse Event|2
6214238|NCT01609556|9881335|FG015|Dose Expansion: Maximum 124 Weeks|Adverse Event|2
6214239|NCT01609556|9881320|FG000|Dose Expansion: Maximum 124 Weeks|Disease Progression|0
6214240|NCT01609556|9881321|FG001|Dose Expansion: Maximum 124 Weeks|Disease Progression|0
6214241|NCT01609556|9881322|FG002|Dose Expansion: Maximum 124 Weeks|Disease Progression|0
6214242|NCT01609556|9881323|FG003|Dose Expansion: Maximum 124 Weeks|Disease Progression|0
6120967|NCT00896363|9744558|FG000|Overall Study|Adverse Event|3
6120968|NCT00896363|9744559|FG001|Overall Study|Adverse Event|4
6120969|NCT00896363|9744560|FG002|Overall Study|Adverse Event|2
6120970|NCT00896363|9744558|FG000|Overall Study|Lack of Efficacy|0
6120971|NCT00896363|9744559|FG001|Overall Study|Lack of Efficacy|2
6120972|NCT00896363|9744560|FG002|Overall Study|Lack of Efficacy|1
6120973|NCT00896363|9744558|FG000|Overall Study|Withdrawal by Subject|3
6120974|NCT00896363|9744559|FG001|Overall Study|Withdrawal by Subject|5
6120975|NCT00896363|9744560|FG002|Overall Study|Withdrawal by Subject|5
6120976|NCT00896454|9744579|FG000|Overall Study|Death|10
6120977|NCT00896454|9744579|FG000|Overall Study|Adverse Event|8
6120978|NCT00896454|9744579|FG000|Overall Study|Disease Progression|5
6120979|NCT00896454|9744579|FG000|Overall Study|Other|4
6120980|NCT00896454|9744579|FG000|Overall Study|Requirement for alternative therapy|3
6120981|NCT00896454|9744579|FG000|Overall Study|Ongoing in study|2
6120982|NCT00896454|9744579|FG000|Overall Study|Withdrawal by Subject|1
6120983|NCT00896480|9744583|FG000|Overall Study|Disease progression/recurrence|21
6120984|NCT00896532|9744598|FG000|Months 1-24: Romosozumab Treatment Phase|Protocol Deviation|0
6120985|NCT00896532|9744599|FG001|Months 1-24: Romosozumab Treatment Phase|Protocol Deviation|0
6120986|NCT00896532|9744600|FG002|Months 1-24: Romosozumab Treatment Phase|Protocol Deviation|0
6120987|NCT00896532|9744601|FG003|Months 1-24: Romosozumab Treatment Phase|Protocol Deviation|1
6120988|NCT00896532|9744602|FG004|Months 1-24: Romosozumab Treatment Phase|Protocol Deviation|0
6120989|NCT00896532|9744603|FG005|Months 1-24: Romosozumab Treatment Phase|Protocol Deviation|1
6120990|NCT00896532|9744604|FG006|Months 1-24: Romosozumab Treatment Phase|Protocol Deviation|0
6120991|NCT00896532|9744605|FG007|Months 1-24: Romosozumab Treatment Phase|Protocol Deviation|0
6120992|NCT00896532|9744606|FG008|Months 1-24: Romosozumab Treatment Phase|Protocol Deviation|0
6120993|NCT00896532|9744607|FG009|Months 1-24: Romosozumab Treatment Phase|Protocol Deviation|0
6120994|NCT00896532|9744608|FG010|Months 1-24: Romosozumab Treatment Phase|Protocol Deviation|0
6120995|NCT00896532|9744609|FG011|Months 1-24: Romosozumab Treatment Phase|Protocol Deviation|0
6120996|NCT00896532|9744610|FG012|Months 1-24: Romosozumab Treatment Phase|Protocol Deviation|0
6120997|NCT00896532|9744611|FG013|Months 1-24: Romosozumab Treatment Phase|Protocol Deviation|0
6120998|NCT00896532|9744612|FG014|Months 1-24: Romosozumab Treatment Phase|Protocol Deviation|0
6120999|NCT00896532|9744613|FG015|Months 1-24: Romosozumab Treatment Phase|Protocol Deviation|0
6121000|NCT00896532|9744614|FG016|Months 1-24: Romosozumab Treatment Phase|Protocol Deviation|0
6121001|NCT00896532|9744615|FG017|Months 1-24: Romosozumab Treatment Phase|Protocol Deviation|0
6121002|NCT00896532|9744616|FG018|Months 1-24: Romosozumab Treatment Phase|Protocol Deviation|0
6121003|NCT00896532|9744617|FG019|Months 1-24: Romosozumab Treatment Phase|Protocol Deviation|0
6121004|NCT00896532|9744618|FG020|Months 1-24: Romosozumab Treatment Phase|Protocol Deviation|0
6121005|NCT00896532|9744619|FG021|Months 1-24: Romosozumab Treatment Phase|Protocol Deviation|0
6121006|NCT00896532|9744620|FG022|Months 1-24: Romosozumab Treatment Phase|Protocol Deviation|0
6121007|NCT00896532|9744598|FG000|Months 1-24: Romosozumab Treatment Phase|Adverse Event|1
6121008|NCT00896532|9744599|FG001|Months 1-24: Romosozumab Treatment Phase|Adverse Event|2
6121009|NCT00896532|9744600|FG002|Months 1-24: Romosozumab Treatment Phase|Adverse Event|1
6121010|NCT00896532|9744601|FG003|Months 1-24: Romosozumab Treatment Phase|Adverse Event|2
6121011|NCT00896532|9744602|FG004|Months 1-24: Romosozumab Treatment Phase|Adverse Event|1
6121012|NCT00896532|9744603|FG005|Months 1-24: Romosozumab Treatment Phase|Adverse Event|1
6121013|NCT00896532|9744604|FG006|Months 1-24: Romosozumab Treatment Phase|Adverse Event|1
6121014|NCT00896532|9744605|FG007|Months 1-24: Romosozumab Treatment Phase|Adverse Event|0
6121015|NCT00896532|9744606|FG008|Months 1-24: Romosozumab Treatment Phase|Adverse Event|0
6121016|NCT00896532|9744607|FG009|Months 1-24: Romosozumab Treatment Phase|Adverse Event|0
6121017|NCT00896532|9744608|FG010|Months 1-24: Romosozumab Treatment Phase|Adverse Event|0
6121018|NCT00896532|9744609|FG011|Months 1-24: Romosozumab Treatment Phase|Adverse Event|0
6121019|NCT00896532|9744610|FG012|Months 1-24: Romosozumab Treatment Phase|Adverse Event|0
6121020|NCT00896532|9744611|FG013|Months 1-24: Romosozumab Treatment Phase|Adverse Event|0
6121021|NCT00896532|9744612|FG014|Months 1-24: Romosozumab Treatment Phase|Adverse Event|0
6121022|NCT00896532|9744613|FG015|Months 1-24: Romosozumab Treatment Phase|Adverse Event|0
6121023|NCT00896532|9744614|FG016|Months 1-24: Romosozumab Treatment Phase|Adverse Event|0
6121024|NCT00896532|9744615|FG017|Months 1-24: Romosozumab Treatment Phase|Adverse Event|0
6121025|NCT00896532|9744616|FG018|Months 1-24: Romosozumab Treatment Phase|Adverse Event|0
6121026|NCT00896532|9744617|FG019|Months 1-24: Romosozumab Treatment Phase|Adverse Event|0
6121027|NCT00896532|9744618|FG020|Months 1-24: Romosozumab Treatment Phase|Adverse Event|0
6121028|NCT00896532|9744619|FG021|Months 1-24: Romosozumab Treatment Phase|Adverse Event|0
6121029|NCT00896532|9744620|FG022|Months 1-24: Romosozumab Treatment Phase|Adverse Event|0
6121030|NCT00896532|9744598|FG000|Months 1-24: Romosozumab Treatment Phase|Withdrawal by Subject|4
6121031|NCT00896532|9744599|FG001|Months 1-24: Romosozumab Treatment Phase|Withdrawal by Subject|3
6121032|NCT00896532|9744600|FG002|Months 1-24: Romosozumab Treatment Phase|Withdrawal by Subject|4
6121033|NCT00896532|9744601|FG003|Months 1-24: Romosozumab Treatment Phase|Withdrawal by Subject|6
6121034|NCT00896532|9744602|FG004|Months 1-24: Romosozumab Treatment Phase|Withdrawal by Subject|5
6121035|NCT00896532|9744603|FG005|Months 1-24: Romosozumab Treatment Phase|Withdrawal by Subject|6
6121036|NCT00896532|9744604|FG006|Months 1-24: Romosozumab Treatment Phase|Withdrawal by Subject|4
6121037|NCT00896532|9744605|FG007|Months 1-24: Romosozumab Treatment Phase|Withdrawal by Subject|4
6121038|NCT00896532|9744606|FG008|Months 1-24: Romosozumab Treatment Phase|Withdrawal by Subject|0
6287659|NCT02352779|10000329|FG000|Overall Study|Personal Issues|1
6287660|NCT02352779|10000330|FG001|Overall Study|Personal Issues|1
6121039|NCT00896532|9744607|FG009|Months 1-24: Romosozumab Treatment Phase|Withdrawal by Subject|0
6121040|NCT00896532|9744608|FG010|Months 1-24: Romosozumab Treatment Phase|Withdrawal by Subject|0
6121041|NCT00896532|9744609|FG011|Months 1-24: Romosozumab Treatment Phase|Withdrawal by Subject|0
6121042|NCT00896532|9744610|FG012|Months 1-24: Romosozumab Treatment Phase|Withdrawal by Subject|0
6121043|NCT00896532|9744611|FG013|Months 1-24: Romosozumab Treatment Phase|Withdrawal by Subject|0
6121044|NCT00896532|9744612|FG014|Months 1-24: Romosozumab Treatment Phase|Withdrawal by Subject|0
6121045|NCT00896532|9744613|FG015|Months 1-24: Romosozumab Treatment Phase|Withdrawal by Subject|0
6121046|NCT00896532|9744614|FG016|Months 1-24: Romosozumab Treatment Phase|Withdrawal by Subject|0
6214243|NCT01609556|9881324|FG004|Dose Expansion: Maximum 124 Weeks|Disease Progression|0
6214244|NCT01609556|9881325|FG005|Dose Expansion: Maximum 124 Weeks|Disease Progression|0
6214245|NCT01609556|9881326|FG006|Dose Expansion: Maximum 124 Weeks|Disease Progression|0
6214246|NCT01609556|9881327|FG007|Dose Expansion: Maximum 124 Weeks|Disease Progression|0
6214247|NCT01609556|9881328|FG008|Dose Expansion: Maximum 124 Weeks|Disease Progression|0
6214248|NCT01609556|9881329|FG009|Dose Expansion: Maximum 124 Weeks|Disease Progression|0
6214249|NCT01609556|9881330|FG010|Dose Expansion: Maximum 124 Weeks|Disease Progression|0
6214250|NCT01609556|9881331|FG011|Dose Expansion: Maximum 124 Weeks|Disease Progression|0
6214251|NCT01609556|9881332|FG012|Dose Expansion: Maximum 124 Weeks|Disease Progression|32
6214252|NCT01609556|9881333|FG013|Dose Expansion: Maximum 124 Weeks|Disease Progression|13
6214253|NCT01609556|9881334|FG014|Dose Expansion: Maximum 124 Weeks|Disease Progression|20
6287661|NCT02352779|10000331|FG002|Overall Study|Personal Issues|0
6287662|NCT02352779|10000329|FG000|Overall Study|Too Many Forms|2
6287663|NCT02352779|10000330|FG001|Overall Study|Too Many Forms|0
6287664|NCT02352779|10000331|FG002|Overall Study|Too Many Forms|0
6121047|NCT00896532|9744615|FG017|Months 1-24: Romosozumab Treatment Phase|Withdrawal by Subject|0
6121048|NCT00896532|9744616|FG018|Months 1-24: Romosozumab Treatment Phase|Withdrawal by Subject|0
6121049|NCT00896532|9744617|FG019|Months 1-24: Romosozumab Treatment Phase|Withdrawal by Subject|0
6121050|NCT00896532|9744618|FG020|Months 1-24: Romosozumab Treatment Phase|Withdrawal by Subject|0
6121051|NCT00896532|9744619|FG021|Months 1-24: Romosozumab Treatment Phase|Withdrawal by Subject|0
6121052|NCT00896532|9744620|FG022|Months 1-24: Romosozumab Treatment Phase|Withdrawal by Subject|0
6121053|NCT00896532|9744598|FG000|Months 1-24: Romosozumab Treatment Phase|Lost to Follow-up|0
6121054|NCT00896532|9744599|FG001|Months 1-24: Romosozumab Treatment Phase|Lost to Follow-up|0
6121055|NCT00896532|9744600|FG002|Months 1-24: Romosozumab Treatment Phase|Lost to Follow-up|2
6121056|NCT00896532|9744601|FG003|Months 1-24: Romosozumab Treatment Phase|Lost to Follow-up|0
6121057|NCT00896532|9744602|FG004|Months 1-24: Romosozumab Treatment Phase|Lost to Follow-up|1
6121058|NCT00896532|9744603|FG005|Months 1-24: Romosozumab Treatment Phase|Lost to Follow-up|0
6121059|NCT00896532|9744604|FG006|Months 1-24: Romosozumab Treatment Phase|Lost to Follow-up|0
6121060|NCT00896532|9744605|FG007|Months 1-24: Romosozumab Treatment Phase|Lost to Follow-up|0
6121061|NCT00896532|9744606|FG008|Months 1-24: Romosozumab Treatment Phase|Lost to Follow-up|0
6121062|NCT00896532|9744607|FG009|Months 1-24: Romosozumab Treatment Phase|Lost to Follow-up|0
6121063|NCT00896532|9744608|FG010|Months 1-24: Romosozumab Treatment Phase|Lost to Follow-up|0
6121064|NCT00896532|9744609|FG011|Months 1-24: Romosozumab Treatment Phase|Lost to Follow-up|0
6121065|NCT00896532|9744610|FG012|Months 1-24: Romosozumab Treatment Phase|Lost to Follow-up|0
6121066|NCT00896532|9744611|FG013|Months 1-24: Romosozumab Treatment Phase|Lost to Follow-up|0
6121067|NCT00896532|9744612|FG014|Months 1-24: Romosozumab Treatment Phase|Lost to Follow-up|0
6121068|NCT00896532|9744613|FG015|Months 1-24: Romosozumab Treatment Phase|Lost to Follow-up|0
6121069|NCT00896532|9744614|FG016|Months 1-24: Romosozumab Treatment Phase|Lost to Follow-up|0
6121070|NCT00896532|9744615|FG017|Months 1-24: Romosozumab Treatment Phase|Lost to Follow-up|0
6121071|NCT00896532|9744616|FG018|Months 1-24: Romosozumab Treatment Phase|Lost to Follow-up|0
6121072|NCT00896532|9744617|FG019|Months 1-24: Romosozumab Treatment Phase|Lost to Follow-up|0
6121073|NCT00896532|9744618|FG020|Months 1-24: Romosozumab Treatment Phase|Lost to Follow-up|0
6121074|NCT00896532|9744619|FG021|Months 1-24: Romosozumab Treatment Phase|Lost to Follow-up|0
6121075|NCT00896532|9744620|FG022|Months 1-24: Romosozumab Treatment Phase|Lost to Follow-up|0
6121076|NCT00896532|9744598|FG000|Months 1-24: Romosozumab Treatment Phase|Death|1
6121077|NCT00896532|9744599|FG001|Months 1-24: Romosozumab Treatment Phase|Death|0
6121078|NCT00896532|9744600|FG002|Months 1-24: Romosozumab Treatment Phase|Death|0
6121079|NCT00896532|9744601|FG003|Months 1-24: Romosozumab Treatment Phase|Death|1
6121080|NCT00896532|9744602|FG004|Months 1-24: Romosozumab Treatment Phase|Death|0
6121081|NCT00896532|9744603|FG005|Months 1-24: Romosozumab Treatment Phase|Death|0
6121082|NCT00896532|9744604|FG006|Months 1-24: Romosozumab Treatment Phase|Death|0
6287665|NCT02352779|10000329|FG000|Overall Study|Feeling Overwhelmed|1
6287666|NCT02352779|10000330|FG001|Overall Study|Feeling Overwhelmed|0
6287667|NCT02352779|10000331|FG002|Overall Study|Feeling Overwhelmed|0
6287668|NCT02352779|10000329|FG000|Overall Study|Disliked Intervention|1
6287669|NCT02352779|10000330|FG001|Overall Study|Disliked Intervention|0
6287670|NCT02352779|10000331|FG002|Overall Study|Disliked Intervention|0
6287671|NCT02352779|10000329|FG000|Overall Study|Changed Mind|1
6287672|NCT02352779|10000330|FG001|Overall Study|Changed Mind|0
6287673|NCT02352779|10000331|FG002|Overall Study|Changed Mind|0
6121083|NCT00896532|9744605|FG007|Months 1-24: Romosozumab Treatment Phase|Death|0
6121084|NCT00896532|9744606|FG008|Months 1-24: Romosozumab Treatment Phase|Death|0
6121085|NCT00896532|9744607|FG009|Months 1-24: Romosozumab Treatment Phase|Death|0
6121086|NCT00896532|9744608|FG010|Months 1-24: Romosozumab Treatment Phase|Death|0
6121087|NCT00896532|9744609|FG011|Months 1-24: Romosozumab Treatment Phase|Death|0
6121088|NCT00896532|9744610|FG012|Months 1-24: Romosozumab Treatment Phase|Death|0
6121089|NCT00896532|9744611|FG013|Months 1-24: Romosozumab Treatment Phase|Death|0
6121090|NCT00896532|9744612|FG014|Months 1-24: Romosozumab Treatment Phase|Death|0
6121091|NCT00896532|9744613|FG015|Months 1-24: Romosozumab Treatment Phase|Death|0
6121092|NCT00896532|9744614|FG016|Months 1-24: Romosozumab Treatment Phase|Death|0
6121093|NCT00896532|9744615|FG017|Months 1-24: Romosozumab Treatment Phase|Death|0
6121094|NCT00896532|9744616|FG018|Months 1-24: Romosozumab Treatment Phase|Death|0
6121095|NCT00896532|9744617|FG019|Months 1-24: Romosozumab Treatment Phase|Death|0
6121096|NCT00896532|9744618|FG020|Months 1-24: Romosozumab Treatment Phase|Death|0
6121097|NCT00896532|9744619|FG021|Months 1-24: Romosozumab Treatment Phase|Death|0
6121098|NCT00896532|9744620|FG022|Months 1-24: Romosozumab Treatment Phase|Death|0
6121099|NCT00896532|9744598|FG000|Months 1-24: Romosozumab Treatment Phase|Administrative Decision|0
6121100|NCT00896532|9744599|FG001|Months 1-24: Romosozumab Treatment Phase|Administrative Decision|0
6121101|NCT00896532|9744600|FG002|Months 1-24: Romosozumab Treatment Phase|Administrative Decision|1
6121102|NCT00896532|9744601|FG003|Months 1-24: Romosozumab Treatment Phase|Administrative Decision|0
6121103|NCT00896532|9744602|FG004|Months 1-24: Romosozumab Treatment Phase|Administrative Decision|0
6121104|NCT00896532|9744603|FG005|Months 1-24: Romosozumab Treatment Phase|Administrative Decision|0
6121105|NCT00896532|9744604|FG006|Months 1-24: Romosozumab Treatment Phase|Administrative Decision|0
6121106|NCT00896532|9744605|FG007|Months 1-24: Romosozumab Treatment Phase|Administrative Decision|0
6121107|NCT00896532|9744606|FG008|Months 1-24: Romosozumab Treatment Phase|Administrative Decision|0
6121108|NCT00896532|9744607|FG009|Months 1-24: Romosozumab Treatment Phase|Administrative Decision|0
6121109|NCT00896532|9744608|FG010|Months 1-24: Romosozumab Treatment Phase|Administrative Decision|0
6121110|NCT00896532|9744609|FG011|Months 1-24: Romosozumab Treatment Phase|Administrative Decision|0
6121111|NCT00896532|9744610|FG012|Months 1-24: Romosozumab Treatment Phase|Administrative Decision|0
6121112|NCT00896532|9744611|FG013|Months 1-24: Romosozumab Treatment Phase|Administrative Decision|0
6121113|NCT00896532|9744612|FG014|Months 1-24: Romosozumab Treatment Phase|Administrative Decision|0
6121114|NCT00896532|9744613|FG015|Months 1-24: Romosozumab Treatment Phase|Administrative Decision|0
6121115|NCT00896532|9744614|FG016|Months 1-24: Romosozumab Treatment Phase|Administrative Decision|0
6121116|NCT00896532|9744615|FG017|Months 1-24: Romosozumab Treatment Phase|Administrative Decision|0
6121117|NCT00896532|9744616|FG018|Months 1-24: Romosozumab Treatment Phase|Administrative Decision|0
6121118|NCT00896532|9744617|FG019|Months 1-24: Romosozumab Treatment Phase|Administrative Decision|0
6121119|NCT00896532|9744618|FG020|Months 1-24: Romosozumab Treatment Phase|Administrative Decision|0
6121120|NCT00896532|9744619|FG021|Months 1-24: Romosozumab Treatment Phase|Administrative Decision|0
6121121|NCT00896532|9744620|FG022|Months 1-24: Romosozumab Treatment Phase|Administrative Decision|0
6121122|NCT00896532|9744598|FG000|Months 1-24: Romosozumab Treatment Phase|Noncompliance|0
6121123|NCT00896532|9744599|FG001|Months 1-24: Romosozumab Treatment Phase|Noncompliance|0
6121124|NCT00896532|9744600|FG002|Months 1-24: Romosozumab Treatment Phase|Noncompliance|1
6121125|NCT00896532|9744601|FG003|Months 1-24: Romosozumab Treatment Phase|Noncompliance|0
6121126|NCT00896532|9744602|FG004|Months 1-24: Romosozumab Treatment Phase|Noncompliance|0
6121127|NCT00896532|9744603|FG005|Months 1-24: Romosozumab Treatment Phase|Noncompliance|0
6121128|NCT00896532|9744604|FG006|Months 1-24: Romosozumab Treatment Phase|Noncompliance|0
6121129|NCT00896532|9744605|FG007|Months 1-24: Romosozumab Treatment Phase|Noncompliance|0
6121130|NCT00896532|9744606|FG008|Months 1-24: Romosozumab Treatment Phase|Noncompliance|0
6121131|NCT00896532|9744607|FG009|Months 1-24: Romosozumab Treatment Phase|Noncompliance|0
6121132|NCT00896532|9744608|FG010|Months 1-24: Romosozumab Treatment Phase|Noncompliance|0
6121133|NCT00896532|9744609|FG011|Months 1-24: Romosozumab Treatment Phase|Noncompliance|0
6121134|NCT00896532|9744610|FG012|Months 1-24: Romosozumab Treatment Phase|Noncompliance|0
6121135|NCT00896532|9744611|FG013|Months 1-24: Romosozumab Treatment Phase|Noncompliance|0
6121136|NCT00896532|9744612|FG014|Months 1-24: Romosozumab Treatment Phase|Noncompliance|0
6121137|NCT00896532|9744613|FG015|Months 1-24: Romosozumab Treatment Phase|Noncompliance|0
6121138|NCT00896532|9744614|FG016|Months 1-24: Romosozumab Treatment Phase|Noncompliance|0
6121139|NCT00896532|9744615|FG017|Months 1-24: Romosozumab Treatment Phase|Noncompliance|0
6121140|NCT00896532|9744616|FG018|Months 1-24: Romosozumab Treatment Phase|Noncompliance|0
6121141|NCT00896532|9744617|FG019|Months 1-24: Romosozumab Treatment Phase|Noncompliance|0
6121142|NCT00896532|9744618|FG020|Months 1-24: Romosozumab Treatment Phase|Noncompliance|0
6121143|NCT00896532|9744619|FG021|Months 1-24: Romosozumab Treatment Phase|Noncompliance|0
6121144|NCT00896532|9744620|FG022|Months 1-24: Romosozumab Treatment Phase|Noncompliance|0
6121145|NCT00896532|9744598|FG000|Months 1-24: Romosozumab Treatment Phase|On-study But No Month 24 Visit|0
6121146|NCT00896532|9744599|FG001|Months 1-24: Romosozumab Treatment Phase|On-study But No Month 24 Visit|0
6121147|NCT00896532|9744600|FG002|Months 1-24: Romosozumab Treatment Phase|On-study But No Month 24 Visit|0
6121148|NCT00896532|9744601|FG003|Months 1-24: Romosozumab Treatment Phase|On-study But No Month 24 Visit|1
6121149|NCT00896532|9744602|FG004|Months 1-24: Romosozumab Treatment Phase|On-study But No Month 24 Visit|0
6121150|NCT00896532|9744603|FG005|Months 1-24: Romosozumab Treatment Phase|On-study But No Month 24 Visit|0
6121151|NCT00896532|9744604|FG006|Months 1-24: Romosozumab Treatment Phase|On-study But No Month 24 Visit|0
6121152|NCT00896532|9744605|FG007|Months 1-24: Romosozumab Treatment Phase|On-study But No Month 24 Visit|0
6121153|NCT00896532|9744606|FG008|Months 1-24: Romosozumab Treatment Phase|On-study But No Month 24 Visit|0
6121154|NCT00896532|9744607|FG009|Months 1-24: Romosozumab Treatment Phase|On-study But No Month 24 Visit|0
6121155|NCT00896532|9744608|FG010|Months 1-24: Romosozumab Treatment Phase|On-study But No Month 24 Visit|0
6121156|NCT00896532|9744609|FG011|Months 1-24: Romosozumab Treatment Phase|On-study But No Month 24 Visit|0
6121157|NCT00896532|9744610|FG012|Months 1-24: Romosozumab Treatment Phase|On-study But No Month 24 Visit|0
6121158|NCT00896532|9744611|FG013|Months 1-24: Romosozumab Treatment Phase|On-study But No Month 24 Visit|0
6121159|NCT00896532|9744612|FG014|Months 1-24: Romosozumab Treatment Phase|On-study But No Month 24 Visit|0
6121160|NCT00896532|9744613|FG015|Months 1-24: Romosozumab Treatment Phase|On-study But No Month 24 Visit|0
6214254|NCT01609556|9881335|FG015|Dose Expansion: Maximum 124 Weeks|Disease Progression|27
6214255|NCT01609556|9881320|FG000|Dose Expansion: Maximum 124 Weeks|Clinical Progression|0
6214256|NCT01609556|9881321|FG001|Dose Expansion: Maximum 124 Weeks|Clinical Progression|0
6214257|NCT01609556|9881322|FG002|Dose Expansion: Maximum 124 Weeks|Clinical Progression|0
6214258|NCT01609556|9881323|FG003|Dose Expansion: Maximum 124 Weeks|Clinical Progression|0
6214259|NCT01609556|9881324|FG004|Dose Expansion: Maximum 124 Weeks|Clinical Progression|0
6214260|NCT01609556|9881325|FG005|Dose Expansion: Maximum 124 Weeks|Clinical Progression|0
6214261|NCT01609556|9881326|FG006|Dose Expansion: Maximum 124 Weeks|Clinical Progression|0
6214262|NCT01609556|9881327|FG007|Dose Expansion: Maximum 124 Weeks|Clinical Progression|0
6214263|NCT01609556|9881328|FG008|Dose Expansion: Maximum 124 Weeks|Clinical Progression|0
6214264|NCT01609556|9881329|FG009|Dose Expansion: Maximum 124 Weeks|Clinical Progression|0
6214265|NCT01609556|9881330|FG010|Dose Expansion: Maximum 124 Weeks|Clinical Progression|0
6214266|NCT01609556|9881331|FG011|Dose Expansion: Maximum 124 Weeks|Clinical Progression|0
6214267|NCT01609556|9881332|FG012|Dose Expansion: Maximum 124 Weeks|Clinical Progression|3
6214268|NCT01609556|9881333|FG013|Dose Expansion: Maximum 124 Weeks|Clinical Progression|3
6214269|NCT01609556|9881334|FG014|Dose Expansion: Maximum 124 Weeks|Clinical Progression|3
6214270|NCT01609556|9881335|FG015|Dose Expansion: Maximum 124 Weeks|Clinical Progression|2
6214271|NCT01609556|9881320|FG000|Dose Expansion: Maximum 124 Weeks|Began New Anticancer Therapy|0
6214272|NCT01609556|9881321|FG001|Dose Expansion: Maximum 124 Weeks|Began New Anticancer Therapy|0
6214273|NCT01609556|9881322|FG002|Dose Expansion: Maximum 124 Weeks|Began New Anticancer Therapy|0
6214274|NCT01609556|9881323|FG003|Dose Expansion: Maximum 124 Weeks|Began New Anticancer Therapy|0
6214275|NCT01609556|9881324|FG004|Dose Expansion: Maximum 124 Weeks|Began New Anticancer Therapy|0
6214276|NCT01609556|9881325|FG005|Dose Expansion: Maximum 124 Weeks|Began New Anticancer Therapy|0
6214277|NCT01609556|9881326|FG006|Dose Expansion: Maximum 124 Weeks|Began New Anticancer Therapy|0
6214278|NCT01609556|9881327|FG007|Dose Expansion: Maximum 124 Weeks|Began New Anticancer Therapy|0
6214279|NCT01609556|9881328|FG008|Dose Expansion: Maximum 124 Weeks|Began New Anticancer Therapy|0
6214280|NCT01609556|9881329|FG009|Dose Expansion: Maximum 124 Weeks|Began New Anticancer Therapy|0
6214281|NCT01609556|9881330|FG010|Dose Expansion: Maximum 124 Weeks|Began New Anticancer Therapy|0
6214282|NCT01609556|9881331|FG011|Dose Expansion: Maximum 124 Weeks|Began New Anticancer Therapy|0
6214283|NCT01609556|9881332|FG012|Dose Expansion: Maximum 124 Weeks|Began New Anticancer Therapy|1
6214284|NCT01609556|9881333|FG013|Dose Expansion: Maximum 124 Weeks|Began New Anticancer Therapy|0
6214285|NCT01609556|9881334|FG014|Dose Expansion: Maximum 124 Weeks|Began New Anticancer Therapy|0
6214286|NCT01609556|9881335|FG015|Dose Expansion: Maximum 124 Weeks|Began New Anticancer Therapy|0
6214287|NCT01609556|9881320|FG000|Dose Expansion: Maximum 124 Weeks|Withdrawal by Subject|0
6214288|NCT01609556|9881321|FG001|Dose Expansion: Maximum 124 Weeks|Withdrawal by Subject|0
6214289|NCT01609556|9881322|FG002|Dose Expansion: Maximum 124 Weeks|Withdrawal by Subject|0
6214290|NCT01609556|9881323|FG003|Dose Expansion: Maximum 124 Weeks|Withdrawal by Subject|0
6214291|NCT01609556|9881324|FG004|Dose Expansion: Maximum 124 Weeks|Withdrawal by Subject|0
6214292|NCT01609556|9881325|FG005|Dose Expansion: Maximum 124 Weeks|Withdrawal by Subject|0
6214293|NCT01609556|9881326|FG006|Dose Expansion: Maximum 124 Weeks|Withdrawal by Subject|0
6214294|NCT01609556|9881327|FG007|Dose Expansion: Maximum 124 Weeks|Withdrawal by Subject|0
6214295|NCT01609556|9881328|FG008|Dose Expansion: Maximum 124 Weeks|Withdrawal by Subject|0
6214296|NCT01609556|9881329|FG009|Dose Expansion: Maximum 124 Weeks|Withdrawal by Subject|0
6214297|NCT01609556|9881330|FG010|Dose Expansion: Maximum 124 Weeks|Withdrawal by Subject|0
6214298|NCT01609556|9881331|FG011|Dose Expansion: Maximum 124 Weeks|Withdrawal by Subject|0
6214299|NCT01609556|9881332|FG012|Dose Expansion: Maximum 124 Weeks|Withdrawal by Subject|1
6214300|NCT01609556|9881333|FG013|Dose Expansion: Maximum 124 Weeks|Withdrawal by Subject|4
6214301|NCT01609556|9881334|FG014|Dose Expansion: Maximum 124 Weeks|Withdrawal by Subject|2
6214302|NCT01609556|9881335|FG015|Dose Expansion: Maximum 124 Weeks|Withdrawal by Subject|5
6214303|NCT01609556|9881320|FG000|Dose Expansion: Maximum 124 Weeks|Investigator Decision|0
6214304|NCT01609556|9881321|FG001|Dose Expansion: Maximum 124 Weeks|Investigator Decision|0
6214305|NCT01609556|9881322|FG002|Dose Expansion: Maximum 124 Weeks|Investigator Decision|0
6214306|NCT01609556|9881323|FG003|Dose Expansion: Maximum 124 Weeks|Investigator Decision|0
6214307|NCT01609556|9881324|FG004|Dose Expansion: Maximum 124 Weeks|Investigator Decision|0
6214308|NCT01609556|9881325|FG005|Dose Expansion: Maximum 124 Weeks|Investigator Decision|0
6214309|NCT01609556|9881326|FG006|Dose Expansion: Maximum 124 Weeks|Investigator Decision|0
6214310|NCT01609556|9881327|FG007|Dose Expansion: Maximum 124 Weeks|Investigator Decision|0
6214311|NCT01609556|9881328|FG008|Dose Expansion: Maximum 124 Weeks|Investigator Decision|0
6214312|NCT01609556|9881329|FG009|Dose Expansion: Maximum 124 Weeks|Investigator Decision|0
6121161|NCT00896532|9744614|FG016|Months 1-24: Romosozumab Treatment Phase|On-study But No Month 24 Visit|0
6121162|NCT00896532|9744615|FG017|Months 1-24: Romosozumab Treatment Phase|On-study But No Month 24 Visit|0
6121163|NCT00896532|9744616|FG018|Months 1-24: Romosozumab Treatment Phase|On-study But No Month 24 Visit|0
6121164|NCT00896532|9744617|FG019|Months 1-24: Romosozumab Treatment Phase|On-study But No Month 24 Visit|0
6121165|NCT00896532|9744618|FG020|Months 1-24: Romosozumab Treatment Phase|On-study But No Month 24 Visit|0
6121166|NCT00896532|9744619|FG021|Months 1-24: Romosozumab Treatment Phase|On-study But No Month 24 Visit|0
6121167|NCT00896532|9744620|FG022|Months 1-24: Romosozumab Treatment Phase|On-study But No Month 24 Visit|0
6121168|NCT00896532|9744598|FG000|Months 1-24: Romosozumab Treatment Phase|Other|0
6121169|NCT00896532|9744599|FG001|Months 1-24: Romosozumab Treatment Phase|Other|1
6121170|NCT00896532|9744600|FG002|Months 1-24: Romosozumab Treatment Phase|Other|0
6287674|NCT02352779|10000329|FG000|Overall Study|Study Related Symptoms|1
6287675|NCT02352779|10000330|FG001|Overall Study|Study Related Symptoms|0
6287676|NCT02352779|10000331|FG002|Overall Study|Study Related Symptoms|0
6287677|NCT02352779|10000329|FG000|Overall Study|Absence of Symptoms|1
6287678|NCT02352779|10000330|FG001|Overall Study|Absence of Symptoms|0
6287679|NCT02352779|10000331|FG002|Overall Study|Absence of Symptoms|0
6287680|NCT02352779|10000329|FG000|Overall Study|Other Medical Reason|0
6287681|NCT02352779|10000330|FG001|Overall Study|Other Medical Reason|0
6287682|NCT02352779|10000331|FG002|Overall Study|Other Medical Reason|1
6287683|NCT02352779|10000329|FG000|Overall Study|No Reason|0
6287684|NCT02352779|10000330|FG001|Overall Study|No Reason|0
6287685|NCT02352779|10000331|FG002|Overall Study|No Reason|1
6287686|NCT02353169|10000389|FG000|Overall Study|QTc > 450 msec|1
6287687|NCT02353169|10000390|FG001|Overall Study|QTc > 450 msec|1
6287688|NCT02353169|10000391|FG002|Overall Study|QTc > 450 msec|1
6287689|NCT02353169|10000392|FG003|Overall Study|QTc > 450 msec|1
6287690|NCT02353169|10000389|FG000|Overall Study|OR team declined|2
6287691|NCT02353169|10000390|FG001|Overall Study|OR team declined|0
6287692|NCT02353169|10000391|FG002|Overall Study|OR team declined|0
6214313|NCT01609556|9881330|FG010|Dose Expansion: Maximum 124 Weeks|Investigator Decision|0
6214314|NCT01609556|9881331|FG011|Dose Expansion: Maximum 124 Weeks|Investigator Decision|0
6214315|NCT01609556|9881332|FG012|Dose Expansion: Maximum 124 Weeks|Investigator Decision|0
6214316|NCT01609556|9881333|FG013|Dose Expansion: Maximum 124 Weeks|Investigator Decision|0
6214317|NCT01609556|9881334|FG014|Dose Expansion: Maximum 124 Weeks|Investigator Decision|0
6214318|NCT01609556|9881335|FG015|Dose Expansion: Maximum 124 Weeks|Investigator Decision|1
6214319|NCT01609556|9881320|FG000|Dose Expansion: Maximum 124 Weeks|Death|0
6214320|NCT01609556|9881321|FG001|Dose Expansion: Maximum 124 Weeks|Death|0
6214321|NCT01609556|9881322|FG002|Dose Expansion: Maximum 124 Weeks|Death|0
6214322|NCT01609556|9881323|FG003|Dose Expansion: Maximum 124 Weeks|Death|0
6214323|NCT01609556|9881324|FG004|Dose Expansion: Maximum 124 Weeks|Death|0
6214324|NCT01609556|9881325|FG005|Dose Expansion: Maximum 124 Weeks|Death|0
6214325|NCT01609556|9881326|FG006|Dose Expansion: Maximum 124 Weeks|Death|0
6214326|NCT01609556|9881327|FG007|Dose Expansion: Maximum 124 Weeks|Death|0
6214327|NCT01609556|9881328|FG008|Dose Expansion: Maximum 124 Weeks|Death|0
6214328|NCT01609556|9881329|FG009|Dose Expansion: Maximum 124 Weeks|Death|0
6214329|NCT01609556|9881330|FG010|Dose Expansion: Maximum 124 Weeks|Death|0
6214330|NCT01609556|9881331|FG011|Dose Expansion: Maximum 124 Weeks|Death|0
6214331|NCT01609556|9881332|FG012|Dose Expansion: Maximum 124 Weeks|Death|4
6214332|NCT01609556|9881333|FG013|Dose Expansion: Maximum 124 Weeks|Death|2
6214333|NCT01609556|9881334|FG014|Dose Expansion: Maximum 124 Weeks|Death|0
6214334|NCT01609556|9881335|FG015|Dose Expansion: Maximum 124 Weeks|Death|3
6214335|NCT01609556|9881320|FG000|Dose Expansion: Maximum 124 Weeks|Other Than Specified|0
6214336|NCT01609556|9881321|FG001|Dose Expansion: Maximum 124 Weeks|Other Than Specified|0
6214337|NCT01609556|9881322|FG002|Dose Expansion: Maximum 124 Weeks|Other Than Specified|0
6214338|NCT01609556|9881323|FG003|Dose Expansion: Maximum 124 Weeks|Other Than Specified|0
6214339|NCT01609556|9881324|FG004|Dose Expansion: Maximum 124 Weeks|Other Than Specified|0
6214340|NCT01609556|9881325|FG005|Dose Expansion: Maximum 124 Weeks|Other Than Specified|0
6214341|NCT01609556|9881326|FG006|Dose Expansion: Maximum 124 Weeks|Other Than Specified|0
6214342|NCT01609556|9881327|FG007|Dose Expansion: Maximum 124 Weeks|Other Than Specified|0
6214343|NCT01609556|9881328|FG008|Dose Expansion: Maximum 124 Weeks|Other Than Specified|0
6214344|NCT01609556|9881329|FG009|Dose Expansion: Maximum 124 Weeks|Other Than Specified|0
6214345|NCT01609556|9881330|FG010|Dose Expansion: Maximum 124 Weeks|Other Than Specified|0
6214346|NCT01609556|9881331|FG011|Dose Expansion: Maximum 124 Weeks|Other Than Specified|0
6214347|NCT01609556|9881332|FG012|Dose Expansion: Maximum 124 Weeks|Other Than Specified|1
6214348|NCT01609556|9881333|FG013|Dose Expansion: Maximum 124 Weeks|Other Than Specified|0
6214349|NCT01609556|9881334|FG014|Dose Expansion: Maximum 124 Weeks|Other Than Specified|0
6214350|NCT01609556|9881335|FG015|Dose Expansion: Maximum 124 Weeks|Other Than Specified|0
6214351|NCT01609582|9881378|FG000|Overall Study|Adverse Event|20
6287693|NCT02353169|10000392|FG003|Overall Study|OR team declined|0
6287694|NCT02353169|10000389|FG000|Overall Study|Inhalational induction|0
6287695|NCT02353169|10000390|FG001|Overall Study|Inhalational induction|2
6287696|NCT02353169|10000391|FG002|Overall Study|Inhalational induction|0
6121171|NCT00896532|9744601|FG003|Months 1-24: Romosozumab Treatment Phase|Other|1
6287697|NCT02353169|10000392|FG003|Overall Study|Inhalational induction|0
6287698|NCT02353169|10000389|FG000|Overall Study|ECG data error|0
6287699|NCT02353169|10000390|FG001|Overall Study|ECG data error|3
6121172|NCT00896532|9744602|FG004|Months 1-24: Romosozumab Treatment Phase|Other|1
6121173|NCT00896532|9744603|FG005|Months 1-24: Romosozumab Treatment Phase|Other|0
6121174|NCT00896532|9744604|FG006|Months 1-24: Romosozumab Treatment Phase|Other|0
6121175|NCT00896532|9744605|FG007|Months 1-24: Romosozumab Treatment Phase|Other|0
6121176|NCT00896532|9744606|FG008|Months 1-24: Romosozumab Treatment Phase|Other|0
6121177|NCT00896532|9744607|FG009|Months 1-24: Romosozumab Treatment Phase|Other|0
6121178|NCT00896532|9744608|FG010|Months 1-24: Romosozumab Treatment Phase|Other|0
6121179|NCT00896532|9744609|FG011|Months 1-24: Romosozumab Treatment Phase|Other|0
6121180|NCT00896532|9744610|FG012|Months 1-24: Romosozumab Treatment Phase|Other|0
6121181|NCT00896532|9744611|FG013|Months 1-24: Romosozumab Treatment Phase|Other|0
6121182|NCT00896532|9744612|FG014|Months 1-24: Romosozumab Treatment Phase|Other|0
6121183|NCT00896532|9744613|FG015|Months 1-24: Romosozumab Treatment Phase|Other|0
6121184|NCT00896532|9744614|FG016|Months 1-24: Romosozumab Treatment Phase|Other|0
6121185|NCT00896532|9744615|FG017|Months 1-24: Romosozumab Treatment Phase|Other|0
6121186|NCT00896532|9744616|FG018|Months 1-24: Romosozumab Treatment Phase|Other|0
6121187|NCT00896532|9744617|FG019|Months 1-24: Romosozumab Treatment Phase|Other|0
6121188|NCT00896532|9744618|FG020|Months 1-24: Romosozumab Treatment Phase|Other|0
6121189|NCT00896532|9744619|FG021|Months 1-24: Romosozumab Treatment Phase|Other|0
6121190|NCT00896532|9744620|FG022|Months 1-24: Romosozumab Treatment Phase|Other|0
6121191|NCT00896532|9744598|FG000|Months 24-36: Denosumab Extension Phase|Protocol Deviation|0
6121192|NCT00896532|9744599|FG001|Months 24-36: Denosumab Extension Phase|Protocol Deviation|0
6121193|NCT00896532|9744600|FG002|Months 24-36: Denosumab Extension Phase|Protocol Deviation|0
6121194|NCT00896532|9744601|FG003|Months 24-36: Denosumab Extension Phase|Protocol Deviation|0
6121195|NCT00896532|9744602|FG004|Months 24-36: Denosumab Extension Phase|Protocol Deviation|0
6121196|NCT00896532|9744603|FG005|Months 24-36: Denosumab Extension Phase|Protocol Deviation|0
6121197|NCT00896532|9744604|FG006|Months 24-36: Denosumab Extension Phase|Protocol Deviation|0
6121198|NCT00896532|9744605|FG007|Months 24-36: Denosumab Extension Phase|Protocol Deviation|0
6121199|NCT00896532|9744606|FG008|Months 24-36: Denosumab Extension Phase|Protocol Deviation|1
6121200|NCT00896532|9744607|FG009|Months 24-36: Denosumab Extension Phase|Protocol Deviation|0
6121201|NCT00896532|9744608|FG010|Months 24-36: Denosumab Extension Phase|Protocol Deviation|0
6121202|NCT00896532|9744609|FG011|Months 24-36: Denosumab Extension Phase|Protocol Deviation|0
6121203|NCT00896532|9744610|FG012|Months 24-36: Denosumab Extension Phase|Protocol Deviation|0
6121204|NCT00896532|9744611|FG013|Months 24-36: Denosumab Extension Phase|Protocol Deviation|0
6121205|NCT00896532|9744612|FG014|Months 24-36: Denosumab Extension Phase|Protocol Deviation|0
6121206|NCT00896532|9744613|FG015|Months 24-36: Denosumab Extension Phase|Protocol Deviation|0
6121207|NCT00896532|9744614|FG016|Months 24-36: Denosumab Extension Phase|Protocol Deviation|0
6121208|NCT00896532|9744615|FG017|Months 24-36: Denosumab Extension Phase|Protocol Deviation|0
6121209|NCT00896532|9744616|FG018|Months 24-36: Denosumab Extension Phase|Protocol Deviation|0
6121210|NCT00896532|9744617|FG019|Months 24-36: Denosumab Extension Phase|Protocol Deviation|0
6121211|NCT00896532|9744618|FG020|Months 24-36: Denosumab Extension Phase|Protocol Deviation|0
6121212|NCT00896532|9744619|FG021|Months 24-36: Denosumab Extension Phase|Protocol Deviation|0
6121213|NCT00896532|9744620|FG022|Months 24-36: Denosumab Extension Phase|Protocol Deviation|0
6121214|NCT00896532|9744598|FG000|Months 24-36: Denosumab Extension Phase|Noncompliance|0
6121215|NCT00896532|9744599|FG001|Months 24-36: Denosumab Extension Phase|Noncompliance|0
6121216|NCT00896532|9744600|FG002|Months 24-36: Denosumab Extension Phase|Noncompliance|0
6121217|NCT00896532|9744601|FG003|Months 24-36: Denosumab Extension Phase|Noncompliance|0
6121218|NCT00896532|9744602|FG004|Months 24-36: Denosumab Extension Phase|Noncompliance|0
6121219|NCT00896532|9744603|FG005|Months 24-36: Denosumab Extension Phase|Noncompliance|0
6121220|NCT00896532|9744604|FG006|Months 24-36: Denosumab Extension Phase|Noncompliance|0
6121221|NCT00896532|9744605|FG007|Months 24-36: Denosumab Extension Phase|Noncompliance|0
6121222|NCT00896532|9744606|FG008|Months 24-36: Denosumab Extension Phase|Noncompliance|0
6121223|NCT00896532|9744607|FG009|Months 24-36: Denosumab Extension Phase|Noncompliance|0
6121224|NCT00896532|9744608|FG010|Months 24-36: Denosumab Extension Phase|Noncompliance|0
6121225|NCT00896532|9744609|FG011|Months 24-36: Denosumab Extension Phase|Noncompliance|0
6121226|NCT00896532|9744610|FG012|Months 24-36: Denosumab Extension Phase|Noncompliance|1
6121227|NCT00896532|9744611|FG013|Months 24-36: Denosumab Extension Phase|Noncompliance|0
6121228|NCT00896532|9744612|FG014|Months 24-36: Denosumab Extension Phase|Noncompliance|0
6121229|NCT00896532|9744613|FG015|Months 24-36: Denosumab Extension Phase|Noncompliance|0
6121230|NCT00896532|9744614|FG016|Months 24-36: Denosumab Extension Phase|Noncompliance|0
6121231|NCT00896532|9744615|FG017|Months 24-36: Denosumab Extension Phase|Noncompliance|0
6121232|NCT00896532|9744616|FG018|Months 24-36: Denosumab Extension Phase|Noncompliance|0
6121233|NCT00896532|9744617|FG019|Months 24-36: Denosumab Extension Phase|Noncompliance|0
6121234|NCT00896532|9744618|FG020|Months 24-36: Denosumab Extension Phase|Noncompliance|0
6121235|NCT00896532|9744619|FG021|Months 24-36: Denosumab Extension Phase|Noncompliance|0
6121236|NCT00896532|9744620|FG022|Months 24-36: Denosumab Extension Phase|Noncompliance|0
6287700|NCT02353169|10000391|FG002|Overall Study|ECG data error|2
6287701|NCT02353169|10000392|FG003|Overall Study|ECG data error|2
6287702|NCT02353169|10000389|FG000|Overall Study|Pre-op medication|0
6287703|NCT02353169|10000390|FG001|Overall Study|Pre-op medication|0
6287704|NCT02353169|10000391|FG002|Overall Study|Pre-op medication|1
6121237|NCT00896532|9744598|FG000|Months 24-36: Denosumab Extension Phase|Adverse Event|0
6121238|NCT00896532|9744599|FG001|Months 24-36: Denosumab Extension Phase|Adverse Event|0
6121239|NCT00896532|9744600|FG002|Months 24-36: Denosumab Extension Phase|Adverse Event|0
6121240|NCT00896532|9744601|FG003|Months 24-36: Denosumab Extension Phase|Adverse Event|0
6121241|NCT00896532|9744602|FG004|Months 24-36: Denosumab Extension Phase|Adverse Event|0
6121242|NCT00896532|9744603|FG005|Months 24-36: Denosumab Extension Phase|Adverse Event|0
6121243|NCT00896532|9744604|FG006|Months 24-36: Denosumab Extension Phase|Adverse Event|0
6214352|NCT01609582|9881379|FG001|Overall Study|Adverse Event|18
6214353|NCT01609582|9881378|FG000|Overall Study|Lost to Follow-up|10
6214354|NCT01609582|9881379|FG001|Overall Study|Lost to Follow-up|10
6214355|NCT01609582|9881378|FG000|Overall Study|Withdrawal by Subject|21
6214356|NCT01609582|9881379|FG001|Overall Study|Withdrawal by Subject|15
6214357|NCT01609582|9881378|FG000|Overall Study|Study Terminated by Sponsor|1543
6214358|NCT01609582|9881379|FG001|Overall Study|Study Terminated by Sponsor|1548
6214359|NCT01609582|9881378|FG000|Overall Study|Other|9
6214360|NCT01609582|9881379|FG001|Overall Study|Other|10
6214361|NCT01609582|9881378|FG000|Overall Study|Randomized, but not treated|0
6214362|NCT01609582|9881379|FG001|Overall Study|Randomized, but not treated|3
6214363|NCT01609933|9881385|FG000|Overall Study|Adverse Event|1
6214364|NCT01609933|9881385|FG000|Overall Study|Withdrawal by Subject|3
6214365|NCT01610037|9881403|FG000|All Patients|Adverse Event|27
6214366|NCT01610037|9881404|FG001|All Patients|Adverse Event|22
6214367|NCT01610037|9881405|FG002|All Patients|Adverse Event|26
6214368|NCT01610037|9881403|FG000|All Patients|Withdrawal by Subject|12
6214369|NCT01610037|9881404|FG001|All Patients|Withdrawal by Subject|10
6214370|NCT01610037|9881405|FG002|All Patients|Withdrawal by Subject|20
6214371|NCT01610037|9881403|FG000|All Patients|Unsatisfactory therapeutic effect|9
6214372|NCT01610037|9881404|FG001|All Patients|Unsatisfactory therapeutic effect|8
6214373|NCT01610037|9881405|FG002|All Patients|Unsatisfactory therapeutic effect|27
6214374|NCT01610037|9881403|FG000|All Patients|Death|4
6214375|NCT01610037|9881404|FG001|All Patients|Death|2
6214376|NCT01610037|9881405|FG002|All Patients|Death|1
6214377|NCT01610037|9881403|FG000|All Patients|Protocol deviation|4
6214378|NCT01610037|9881404|FG001|All Patients|Protocol deviation|3
6214379|NCT01610037|9881405|FG002|All Patients|Protocol deviation|3
6214380|NCT01610037|9881403|FG000|All Patients|Abnormal laboratory value|1
6214381|NCT01610037|9881404|FG001|All Patients|Abnormal laboratory value|1
6214382|NCT01610037|9881405|FG002|All Patients|Abnormal laboratory value|0
6214383|NCT01610037|9881403|FG000|All Patients|Administrative problems|1
6214384|NCT01610037|9881404|FG001|All Patients|Administrative problems|4
6214385|NCT01610037|9881405|FG002|All Patients|Administrative problems|4
6214386|NCT01610037|9881403|FG000|All Patients|Lost to Follow-up|1
6214387|NCT01610037|9881404|FG001|All Patients|Lost to Follow-up|0
6214388|NCT01610037|9881405|FG002|All Patients|Lost to Follow-up|0
6214389|NCT01610037|9881403|FG000|All Patients|Abnormal test procedure result(s)|0
6214390|NCT01610037|9881404|FG001|All Patients|Abnormal test procedure result(s)|1
6214391|NCT01610037|9881405|FG002|All Patients|Abnormal test procedure result(s)|3
6214392|NCT01610037|9881403|FG000|Treatment and Follow up Period|Subject withdrew consent|13
6214393|NCT01610037|9881404|FG001|Treatment and Follow up Period|Subject withdrew consent|14
6214394|NCT01610037|9881405|FG002|Treatment and Follow up Period|Subject withdrew consent|16
6214395|NCT01610037|9881403|FG000|Treatment and Follow up Period|Death|10
6214396|NCT01610037|9881404|FG001|Treatment and Follow up Period|Death|5
6214397|NCT01610037|9881405|FG002|Treatment and Follow up Period|Death|4
6214398|NCT01610037|9881403|FG000|Treatment and Follow up Period|Administrative problems|1
6214399|NCT01610037|9881404|FG001|Treatment and Follow up Period|Administrative problems|3
6214400|NCT01610037|9881405|FG002|Treatment and Follow up Period|Administrative problems|2
6214401|NCT01610037|9881403|FG000|Treatment and Follow up Period|Lost to Follow-up|1
6214402|NCT01610037|9881404|FG001|Treatment and Follow up Period|Lost to Follow-up|6
6214403|NCT01610037|9881405|FG002|Treatment and Follow up Period|Lost to Follow-up|4
6214404|NCT01610063|9881415|FG000|Overall Study|Lost to Follow-up|42
6214405|NCT01610063|9881416|FG001|Overall Study|Lost to Follow-up|20
6214406|NCT01610076|9881424|FG000|Overall Study|Technical issue with video|0
6214407|NCT01610076|9881425|FG001|Overall Study|Technical issue with video|1
6214408|NCT01610076|9881424|FG000|Overall Study|Lost to Follow-up|3
6214409|NCT01610076|9881425|FG001|Overall Study|Lost to Follow-up|4
6214410|NCT01610167|9881441|FG000|Overall Study|Scheduling conflict.|0
6214411|NCT01610167|9881442|FG001|Overall Study|Scheduling conflict.|0
6214412|NCT01610167|9881443|FG002|Overall Study|Scheduling conflict.|2
6214413|NCT01610206|9881453|FG000|Overall Study|Adverse Event|10
6121244|NCT00896532|9744605|FG007|Months 24-36: Denosumab Extension Phase|Adverse Event|0
6121245|NCT00896532|9744606|FG008|Months 24-36: Denosumab Extension Phase|Adverse Event|0
6121246|NCT00896532|9744607|FG009|Months 24-36: Denosumab Extension Phase|Adverse Event|0
6121247|NCT00896532|9744608|FG010|Months 24-36: Denosumab Extension Phase|Adverse Event|1
6214414|NCT01610206|9881454|FG001|Overall Study|Adverse Event|30
6214415|NCT01610271|9881462|FG000|Overall Study|Surgery not complete|0
6214416|NCT01610271|9881463|FG001|Overall Study|Surgery not complete|1
6214417|NCT01610271|9881462|FG000|Overall Study|Prosthesis not implanted|2
6214418|NCT01610271|9881463|FG001|Overall Study|Prosthesis not implanted|3
6214419|NCT01610284|9881473|FG000|Randomization Phase|Adverse Event|1
6214420|NCT01610284|9881474|FG001|Randomization Phase|Adverse Event|0
6121248|NCT00896532|9744609|FG011|Months 24-36: Denosumab Extension Phase|Adverse Event|0
6121249|NCT00896532|9744610|FG012|Months 24-36: Denosumab Extension Phase|Adverse Event|1
6121250|NCT00896532|9744611|FG013|Months 24-36: Denosumab Extension Phase|Adverse Event|0
6121251|NCT00896532|9744612|FG014|Months 24-36: Denosumab Extension Phase|Adverse Event|0
6214421|NCT01610284|9881473|FG000|Randomization Phase|Physician Decision|1
6214422|NCT01610284|9881474|FG001|Randomization Phase|Physician Decision|1
6214423|NCT01610284|9881473|FG000|Randomization Phase|Death|0
6214424|NCT01610284|9881474|FG001|Randomization Phase|Death|1
6214425|NCT01610284|9881473|FG000|Treatment Phase|Adverse Event|80
6214426|NCT01610284|9881474|FG001|Treatment Phase|Adverse Event|12
6214427|NCT01610284|9881473|FG000|Treatment Phase|Lost to Follow-up|1
6214428|NCT01610284|9881474|FG001|Treatment Phase|Lost to Follow-up|0
6214429|NCT01610284|9881473|FG000|Treatment Phase|Non-compliance with Study Treatment|8
6214430|NCT01610284|9881474|FG001|Treatment Phase|Non-compliance with Study Treatment|1
6214431|NCT01610284|9881473|FG000|Treatment Phase|Physician Decision|27
6214432|NCT01610284|9881474|FG001|Treatment Phase|Physician Decision|24
6214433|NCT01610284|9881473|FG000|Treatment Phase|Progressive Disease|377
6214434|NCT01610284|9881474|FG001|Treatment Phase|Progressive Disease|486
6214435|NCT01610284|9881473|FG000|Treatment Phase|Protocol Deviation|2
6214436|NCT01610284|9881474|FG001|Treatment Phase|Protocol Deviation|3
6214437|NCT01610284|9881473|FG000|Treatment Phase|Study terminated by Sponsor|18
6214438|NCT01610284|9881474|FG001|Treatment Phase|Study terminated by Sponsor|15
6214439|NCT01610284|9881473|FG000|Treatment Phase|Subject/Guardian Decision|55
6214440|NCT01610284|9881474|FG001|Treatment Phase|Subject/Guardian Decision|23
6214441|NCT01610284|9881473|FG000|Treatment Phase|Death|6
6214442|NCT01610284|9881474|FG001|Treatment Phase|Death|5
6214443|NCT01610284|9881473|FG000|Post-Treatment Efficacy Follow-Up Phase|Adverse Event|2
6214444|NCT01610284|9881474|FG001|Post-Treatment Efficacy Follow-Up Phase|Adverse Event|0
6287705|NCT02353169|10000392|FG003|Overall Study|Pre-op medication|0
6287706|NCT02353442|10000425|FG000|Overall Study|Withdrawal by Subject|3
6287707|NCT02353442|10000426|FG001|Overall Study|Withdrawal by Subject|4
6287708|NCT02353871|10000462|FG000|Overall Study|Protocol deviation|0
6287709|NCT02353871|10000463|FG001|Overall Study|Protocol deviation|1
6287710|NCT02353871|10000462|FG000|Overall Study|Consent withdrawn|1
6287711|NCT02353871|10000463|FG001|Overall Study|Consent withdrawn|8
6287712|NCT02353871|10000462|FG000|Overall Study|Lost to Follow-up|2
6287713|NCT02353871|10000463|FG001|Overall Study|Lost to Follow-up|0
6287714|NCT02354222|10000489|FG000|Overall Study|Adverse Event|0
6287715|NCT02354222|10000490|FG001|Overall Study|Adverse Event|3
6063314|NCT00505778|9664650|FG000|Overall Study|Protocol Violation|7
6063315|NCT00505778|9664651|FG001|Overall Study|Protocol Violation|9
6063316|NCT00505778|9664650|FG000|Overall Study|Withdrawal by Subject|29
6063317|NCT00505778|9664651|FG001|Overall Study|Withdrawal by Subject|14
6063318|NCT00505778|9664650|FG000|Overall Study|Relapse|65
6063319|NCT00505778|9664651|FG001|Overall Study|Relapse|65
6063320|NCT00505778|9664650|FG000|Overall Study|Took No Study Drug|2
6063321|NCT00505778|9664651|FG001|Overall Study|Took No Study Drug|2
6063322|NCT00505921|9664666|FG000|Overall Study|Ineligible|1
6063323|NCT00505921|9664666|FG000|Overall Study|Failed to Mobilize|8
6063324|NCT00505934|9664670|FG000|Overall Study|Adverse Event|1
6063325|NCT00505934|9664670|FG000|Overall Study|Other: Unable to obtain IV & PK samples|1
6063326|NCT00505934|9664670|FG000|Overall Study|Other: IV dose needed to be changed|1
6063327|NCT00506077|9664689|FG000|Treatment Period 1|Adverse Event|2
6063328|NCT00506077|9664690|FG001|Treatment Period 1|Adverse Event|1
6063329|NCT00506077|9664689|FG000|Treatment Period 1|Lost to Follow-up|0
6063330|NCT00506077|9664690|FG001|Treatment Period 1|Lost to Follow-up|2
6063331|NCT00506077|9664689|FG000|Treatment Period 1|Withdrawal by Subject|2
6063332|NCT00506077|9664690|FG001|Treatment Period 1|Withdrawal by Subject|0
6063333|NCT00506077|9664689|FG000|Treatment Period 2|Adverse Event|0
6063334|NCT00506077|9664690|FG001|Treatment Period 2|Adverse Event|1
6063335|NCT00506077|9664689|FG000|Treatment Period 2|Withdrawal by Subject|1
6063336|NCT00506077|9664690|FG001|Treatment Period 2|Withdrawal by Subject|0
6063337|NCT00506129|9664696|FG000|Overall Study|Disease Progression/Relapse|15
6063338|NCT00506129|9664696|FG000|Overall Study|Death|7
6063339|NCT00506142|9664702|FG000|Overall Study|Adverse Event|8
6063340|NCT00506142|9664703|FG001|Overall Study|Adverse Event|7
6063341|NCT00506142|9664702|FG000|Overall Study|Lack of Efficacy|21
6063342|NCT00506142|9664703|FG001|Overall Study|Lack of Efficacy|7
6063343|NCT00506142|9664702|FG000|Overall Study|Withdrawal by Subject|4
6063344|NCT00506142|9664703|FG001|Overall Study|Withdrawal by Subject|5
6063345|NCT00506142|9664702|FG000|Overall Study|Physician Decision|1
6063346|NCT00506142|9664703|FG001|Overall Study|Physician Decision|0
6063347|NCT00506142|9664702|FG000|Overall Study|New health condition|1
6063348|NCT00506142|9664703|FG001|Overall Study|New health condition|0
6063349|NCT00506285|9664715|FG000|3 Week Screening Phase|Withdrawal by Subject|17
6063350|NCT00506285|9664716|FG001|3 Week Screening Phase|Withdrawal by Subject|10
6063351|NCT00506285|9664715|FG000|Double Blind Cross-Over Phase|Withdrawal by Subject|4
6063352|NCT00506285|9664716|FG001|Double Blind Cross-Over Phase|Withdrawal by Subject|3
6063353|NCT00506285|9664715|FG000|Double Blind Cross-Over Phase|Lost to Follow-up|5
6063354|NCT00506285|9664716|FG001|Double Blind Cross-Over Phase|Lost to Follow-up|2
6063355|NCT00506285|9664715|FG000|6-month Open Label Phase|Lost to Follow-up|1
6063356|NCT00506285|9664716|FG001|6-month Open Label Phase|Lost to Follow-up|7
6063357|NCT00506285|9664715|FG000|6-month Open Label Phase|Withdrawal by Subject|9
6063358|NCT00506285|9664716|FG001|6-month Open Label Phase|Withdrawal by Subject|5
6063359|NCT00506350|9664733|FG000|Overall Study|Serious Adverse Event|1
6063360|NCT00506350|9664734|FG001|Overall Study|Serious Adverse Event|0
6063361|NCT00506350|9664735|FG002|Overall Study|Serious Adverse Event|0
6063362|NCT00506350|9664736|FG003|Overall Study|Serious Adverse Event|0
6063363|NCT00506350|9664737|FG004|Overall Study|Serious Adverse Event|0
6063364|NCT00506350|9664738|FG005|Overall Study|Serious Adverse Event|0
6063365|NCT00506350|9664739|FG006|Overall Study|Serious Adverse Event|0
6063366|NCT00506350|9664740|FG007|Overall Study|Serious Adverse Event|0
6063367|NCT00506350|9664741|FG008|Overall Study|Serious Adverse Event|0
6063368|NCT00506350|9664733|FG000|Overall Study|Adverse Event|0
6063369|NCT00506350|9664734|FG001|Overall Study|Adverse Event|0
6063370|NCT00506350|9664735|FG002|Overall Study|Adverse Event|0
6063371|NCT00506350|9664736|FG003|Overall Study|Adverse Event|0
6063372|NCT00506350|9664737|FG004|Overall Study|Adverse Event|0
6063373|NCT00506350|9664738|FG005|Overall Study|Adverse Event|0
6063374|NCT00506350|9664739|FG006|Overall Study|Adverse Event|0
6063375|NCT00506350|9664740|FG007|Overall Study|Adverse Event|1
6063376|NCT00506350|9664741|FG008|Overall Study|Adverse Event|1
6063377|NCT00506350|9664733|FG000|Overall Study|Protocol Violation|0
6063378|NCT00506350|9664734|FG001|Overall Study|Protocol Violation|0
6063379|NCT00506350|9664735|FG002|Overall Study|Protocol Violation|1
6063380|NCT00506350|9664736|FG003|Overall Study|Protocol Violation|0
6063381|NCT00506350|9664737|FG004|Overall Study|Protocol Violation|0
6063382|NCT00506350|9664738|FG005|Overall Study|Protocol Violation|0
6063383|NCT00506350|9664739|FG006|Overall Study|Protocol Violation|1
6063384|NCT00506350|9664740|FG007|Overall Study|Protocol Violation|0
6063385|NCT00506350|9664741|FG008|Overall Study|Protocol Violation|0
6063386|NCT00506350|9664733|FG000|Overall Study|Withdrawal by Subject|0
6063387|NCT00506350|9664734|FG001|Overall Study|Withdrawal by Subject|1
6063388|NCT00506350|9664735|FG002|Overall Study|Withdrawal by Subject|1
6063389|NCT00506350|9664736|FG003|Overall Study|Withdrawal by Subject|1
6063390|NCT00506350|9664737|FG004|Overall Study|Withdrawal by Subject|4
6063391|NCT00506350|9664738|FG005|Overall Study|Withdrawal by Subject|1
6063392|NCT00506350|9664739|FG006|Overall Study|Withdrawal by Subject|1
6063393|NCT00506350|9664740|FG007|Overall Study|Withdrawal by Subject|2
6063394|NCT00506350|9664741|FG008|Overall Study|Withdrawal by Subject|0
6063395|NCT00506350|9664733|FG000|Overall Study|Lost to Follow-up|1
6063396|NCT00506350|9664734|FG001|Overall Study|Lost to Follow-up|1
6063397|NCT00506350|9664735|FG002|Overall Study|Lost to Follow-up|1
6063398|NCT00506350|9664736|FG003|Overall Study|Lost to Follow-up|1
6063399|NCT00506350|9664737|FG004|Overall Study|Lost to Follow-up|2
6063400|NCT00506350|9664738|FG005|Overall Study|Lost to Follow-up|1
6063401|NCT00506350|9664739|FG006|Overall Study|Lost to Follow-up|0
6063402|NCT00506350|9664740|FG007|Overall Study|Lost to Follow-up|0
6063403|NCT00506350|9664741|FG008|Overall Study|Lost to Follow-up|2
6063404|NCT00506350|9664733|FG000|Overall Study|Medical Reason|0
6063405|NCT00506350|9664734|FG001|Overall Study|Medical Reason|0
6063406|NCT00506350|9664735|FG002|Overall Study|Medical Reason|0
6063407|NCT00506350|9664736|FG003|Overall Study|Medical Reason|0
6063408|NCT00506350|9664737|FG004|Overall Study|Medical Reason|1
6063409|NCT00506350|9664738|FG005|Overall Study|Medical Reason|0
6063410|NCT00506350|9664739|FG006|Overall Study|Medical Reason|0
6063411|NCT00506350|9664740|FG007|Overall Study|Medical Reason|0
6063412|NCT00506350|9664741|FG008|Overall Study|Medical Reason|0
6063413|NCT00506350|9664733|FG000|Overall Study|Other|1
6063414|NCT00506350|9664734|FG001|Overall Study|Other|1
6063415|NCT00506350|9664735|FG002|Overall Study|Other|3
6063416|NCT00506350|9664736|FG003|Overall Study|Other|0
6063417|NCT00506350|9664737|FG004|Overall Study|Other|3
6063418|NCT00506350|9664738|FG005|Overall Study|Other|0
6063419|NCT00506350|9664739|FG006|Overall Study|Other|0
6063420|NCT00506350|9664740|FG007|Overall Study|Other|2
6063421|NCT00506350|9664741|FG008|Overall Study|Other|2
6063422|NCT00506389|9664771|FG000|In-treatment Period|Other|3
6063423|NCT00506389|9664772|FG001|In-treatment Period|Other|3
6063424|NCT00506389|9664773|FG002|In-treatment Period|Other|4
6063425|NCT00506389|9664771|FG000|In-treatment Period|Lost to Follow-up|0
6063426|NCT00506389|9664772|FG001|In-treatment Period|Lost to Follow-up|0
6063427|NCT00506389|9664773|FG002|In-treatment Period|Lost to Follow-up|1
6063428|NCT00506389|9664771|FG000|In-treatment Period|Lack of compliance|1
6063429|NCT00506389|9664772|FG001|In-treatment Period|Lack of compliance|0
6063430|NCT00506389|9664773|FG002|In-treatment Period|Lack of compliance|0
6063431|NCT00506389|9664771|FG000|In-treatment Period|Reasons not related to trial|4
6063432|NCT00506389|9664772|FG001|In-treatment Period|Reasons not related to trial|1
6063433|NCT00506389|9664773|FG002|In-treatment Period|Reasons not related to trial|0
6063434|NCT00506389|9664771|FG000|In-treatment Period|Withdrawal by Subject|3
6063435|NCT00506389|9664772|FG001|In-treatment Period|Withdrawal by Subject|3
6063436|NCT00506389|9664773|FG002|In-treatment Period|Withdrawal by Subject|4
6063437|NCT00506389|9664771|FG000|In-treatment Period|Lack of Efficacy|0
6063438|NCT00506389|9664772|FG001|In-treatment Period|Lack of Efficacy|2
6121252|NCT00896532|9744613|FG015|Months 24-36: Denosumab Extension Phase|Adverse Event|0
6121253|NCT00896532|9744614|FG016|Months 24-36: Denosumab Extension Phase|Adverse Event|0
6121254|NCT00896532|9744615|FG017|Months 24-36: Denosumab Extension Phase|Adverse Event|0
6121255|NCT00896532|9744616|FG018|Months 24-36: Denosumab Extension Phase|Adverse Event|0
6121256|NCT00896532|9744617|FG019|Months 24-36: Denosumab Extension Phase|Adverse Event|0
6121257|NCT00896532|9744618|FG020|Months 24-36: Denosumab Extension Phase|Adverse Event|0
6121258|NCT00896532|9744619|FG021|Months 24-36: Denosumab Extension Phase|Adverse Event|0
6121259|NCT00896532|9744620|FG022|Months 24-36: Denosumab Extension Phase|Adverse Event|0
6121260|NCT00896532|9744598|FG000|Months 24-36: Denosumab Extension Phase|Withdrawal by Subject|0
6121261|NCT00896532|9744599|FG001|Months 24-36: Denosumab Extension Phase|Withdrawal by Subject|0
6121262|NCT00896532|9744600|FG002|Months 24-36: Denosumab Extension Phase|Withdrawal by Subject|0
6121263|NCT00896532|9744601|FG003|Months 24-36: Denosumab Extension Phase|Withdrawal by Subject|0
6121264|NCT00896532|9744602|FG004|Months 24-36: Denosumab Extension Phase|Withdrawal by Subject|0
6121265|NCT00896532|9744603|FG005|Months 24-36: Denosumab Extension Phase|Withdrawal by Subject|0
6121266|NCT00896532|9744604|FG006|Months 24-36: Denosumab Extension Phase|Withdrawal by Subject|0
6121267|NCT00896532|9744605|FG007|Months 24-36: Denosumab Extension Phase|Withdrawal by Subject|0
6121268|NCT00896532|9744606|FG008|Months 24-36: Denosumab Extension Phase|Withdrawal by Subject|0
6121269|NCT00896532|9744607|FG009|Months 24-36: Denosumab Extension Phase|Withdrawal by Subject|0
6121270|NCT00896532|9744608|FG010|Months 24-36: Denosumab Extension Phase|Withdrawal by Subject|0
6121271|NCT00896532|9744609|FG011|Months 24-36: Denosumab Extension Phase|Withdrawal by Subject|0
6214445|NCT01610284|9881473|FG000|Post-Treatment Efficacy Follow-Up Phase|Physician Decision|10
6214446|NCT01610284|9881474|FG001|Post-Treatment Efficacy Follow-Up Phase|Physician Decision|3
6214447|NCT01610284|9881473|FG000|Post-Treatment Efficacy Follow-Up Phase|Progressive Disease|24
6214448|NCT01610284|9881474|FG001|Post-Treatment Efficacy Follow-Up Phase|Progressive Disease|8
6214449|NCT01610284|9881473|FG000|Post-Treatment Efficacy Follow-Up Phase|Subject/Guardian Decision|11
6214450|NCT01610284|9881474|FG001|Post-Treatment Efficacy Follow-Up Phase|Subject/Guardian Decision|1
6214451|NCT01610284|9881473|FG000|Post-Treatment Efficacy Follow-Up Phase|Death|4
6214452|NCT01610284|9881474|FG001|Post-Treatment Efficacy Follow-Up Phase|Death|4
6214453|NCT01610284|9881473|FG000|Post-Treatment Efficacy Follow-Up Phase|New therapy for study indication|38
6214454|NCT01610284|9881474|FG001|Post-Treatment Efficacy Follow-Up Phase|New therapy for study indication|13
6214455|NCT01610297|9881480|FG000|Overall Study|Lost to Follow-up|1
6214456|NCT01610336|9881495|FG000|Overall Study|Progressive Disease|4
6214457|NCT01610336|9881496|FG001|Overall Study|Progressive Disease|6
6214458|NCT01610336|9881497|FG002|Overall Study|Progressive Disease|6
6214459|NCT01610336|9881498|FG003|Overall Study|Progressive Disease|5
6214460|NCT01610336|9881499|FG004|Overall Study|Progressive Disease|3
6214461|NCT01610336|9881500|FG005|Overall Study|Progressive Disease|10
6214462|NCT01610336|9881501|FG006|Overall Study|Progressive Disease|1
6214463|NCT01610336|9881502|FG007|Overall Study|Progressive Disease|6
6214464|NCT01610336|9881503|FG008|Overall Study|Progressive Disease|6
6214465|NCT01610336|9881504|FG009|Overall Study|Progressive Disease|40
6214466|NCT01610336|9881505|FG010|Overall Study|Progressive Disease|36
6214467|NCT01610336|9881495|FG000|Overall Study|Adverse Event|0
6214468|NCT01610336|9881496|FG001|Overall Study|Adverse Event|0
6214469|NCT01610336|9881497|FG002|Overall Study|Adverse Event|0
6214470|NCT01610336|9881498|FG003|Overall Study|Adverse Event|1
6214471|NCT01610336|9881499|FG004|Overall Study|Adverse Event|1
6214472|NCT01610336|9881500|FG005|Overall Study|Adverse Event|1
6214473|NCT01610336|9881501|FG006|Overall Study|Adverse Event|0
6214474|NCT01610336|9881502|FG007|Overall Study|Adverse Event|0
6214475|NCT01610336|9881503|FG008|Overall Study|Adverse Event|2
6214476|NCT01610336|9881504|FG009|Overall Study|Adverse Event|8
6214477|NCT01610336|9881505|FG010|Overall Study|Adverse Event|6
6214478|NCT01610336|9881495|FG000|Overall Study|Subject/Guardian decision|1
6214479|NCT01610336|9881496|FG001|Overall Study|Subject/Guardian decision|1
6214480|NCT01610336|9881497|FG002|Overall Study|Subject/Guardian decision|0
6214481|NCT01610336|9881498|FG003|Overall Study|Subject/Guardian decision|1
6121272|NCT00896532|9744610|FG012|Months 24-36: Denosumab Extension Phase|Withdrawal by Subject|1
6121273|NCT00896532|9744611|FG013|Months 24-36: Denosumab Extension Phase|Withdrawal by Subject|1
6121274|NCT00896532|9744612|FG014|Months 24-36: Denosumab Extension Phase|Withdrawal by Subject|0
6121275|NCT00896532|9744613|FG015|Months 24-36: Denosumab Extension Phase|Withdrawal by Subject|0
6121276|NCT00896532|9744614|FG016|Months 24-36: Denosumab Extension Phase|Withdrawal by Subject|0
6121277|NCT00896532|9744615|FG017|Months 24-36: Denosumab Extension Phase|Withdrawal by Subject|0
6121278|NCT00896532|9744616|FG018|Months 24-36: Denosumab Extension Phase|Withdrawal by Subject|0
6121279|NCT00896532|9744617|FG019|Months 24-36: Denosumab Extension Phase|Withdrawal by Subject|0
6121280|NCT00896532|9744618|FG020|Months 24-36: Denosumab Extension Phase|Withdrawal by Subject|0
6121281|NCT00896532|9744619|FG021|Months 24-36: Denosumab Extension Phase|Withdrawal by Subject|0
6121282|NCT00896532|9744620|FG022|Months 24-36: Denosumab Extension Phase|Withdrawal by Subject|0
6214482|NCT01610336|9881499|FG004|Overall Study|Subject/Guardian decision|0
6214483|NCT01610336|9881500|FG005|Overall Study|Subject/Guardian decision|0
6214484|NCT01610336|9881501|FG006|Overall Study|Subject/Guardian decision|0
6214485|NCT01610336|9881502|FG007|Overall Study|Subject/Guardian decision|1
6214486|NCT01610336|9881503|FG008|Overall Study|Subject/Guardian decision|0
6121283|NCT00896532|9744598|FG000|Months 24-36: Denosumab Extension Phase|Other|0
6121284|NCT00896532|9744599|FG001|Months 24-36: Denosumab Extension Phase|Other|0
6121285|NCT00896532|9744600|FG002|Months 24-36: Denosumab Extension Phase|Other|0
6121286|NCT00896532|9744601|FG003|Months 24-36: Denosumab Extension Phase|Other|0
6121287|NCT00896532|9744602|FG004|Months 24-36: Denosumab Extension Phase|Other|0
6121288|NCT00896532|9744603|FG005|Months 24-36: Denosumab Extension Phase|Other|0
6121289|NCT00896532|9744604|FG006|Months 24-36: Denosumab Extension Phase|Other|0
6121290|NCT00896532|9744605|FG007|Months 24-36: Denosumab Extension Phase|Other|0
6121291|NCT00896532|9744606|FG008|Months 24-36: Denosumab Extension Phase|Other|0
6121292|NCT00896532|9744607|FG009|Months 24-36: Denosumab Extension Phase|Other|0
6121293|NCT00896532|9744608|FG010|Months 24-36: Denosumab Extension Phase|Other|1
6121294|NCT00896532|9744609|FG011|Months 24-36: Denosumab Extension Phase|Other|2
6121295|NCT00896532|9744610|FG012|Months 24-36: Denosumab Extension Phase|Other|2
6121296|NCT00896532|9744611|FG013|Months 24-36: Denosumab Extension Phase|Other|1
6121297|NCT00896532|9744612|FG014|Months 24-36: Denosumab Extension Phase|Other|0
6121298|NCT00896532|9744613|FG015|Months 24-36: Denosumab Extension Phase|Other|0
6121299|NCT00896532|9744614|FG016|Months 24-36: Denosumab Extension Phase|Other|0
6121300|NCT00896532|9744615|FG017|Months 24-36: Denosumab Extension Phase|Other|0
6121301|NCT00896532|9744616|FG018|Months 24-36: Denosumab Extension Phase|Other|0
6121302|NCT00896532|9744617|FG019|Months 24-36: Denosumab Extension Phase|Other|0
6121303|NCT00896532|9744618|FG020|Months 24-36: Denosumab Extension Phase|Other|0
6121304|NCT00896532|9744619|FG021|Months 24-36: Denosumab Extension Phase|Other|0
6121305|NCT00896532|9744620|FG022|Months 24-36: Denosumab Extension Phase|Other|0
6121306|NCT00896532|9744598|FG000|Months 36-48: Romosozumab Retreatment|Adverse Event|0
6121307|NCT00896532|9744599|FG001|Months 36-48: Romosozumab Retreatment|Adverse Event|0
6121308|NCT00896532|9744600|FG002|Months 36-48: Romosozumab Retreatment|Adverse Event|0
6121309|NCT00896532|9744601|FG003|Months 36-48: Romosozumab Retreatment|Adverse Event|0
6121310|NCT00896532|9744602|FG004|Months 36-48: Romosozumab Retreatment|Adverse Event|0
6121311|NCT00896532|9744603|FG005|Months 36-48: Romosozumab Retreatment|Adverse Event|0
6121312|NCT00896532|9744604|FG006|Months 36-48: Romosozumab Retreatment|Adverse Event|0
6121313|NCT00896532|9744605|FG007|Months 36-48: Romosozumab Retreatment|Adverse Event|0
6121314|NCT00896532|9744606|FG008|Months 36-48: Romosozumab Retreatment|Adverse Event|0
6121315|NCT00896532|9744607|FG009|Months 36-48: Romosozumab Retreatment|Adverse Event|0
6214487|NCT01610336|9881504|FG009|Overall Study|Subject/Guardian decision|2
6214488|NCT01610336|9881505|FG010|Overall Study|Subject/Guardian decision|2
6214489|NCT01610336|9881495|FG000|Overall Study|Death|0
6214490|NCT01610336|9881496|FG001|Overall Study|Death|0
6214491|NCT01610336|9881497|FG002|Overall Study|Death|0
6214492|NCT01610336|9881498|FG003|Overall Study|Death|0
6214493|NCT01610336|9881499|FG004|Overall Study|Death|0
6214494|NCT01610336|9881500|FG005|Overall Study|Death|1
6214495|NCT01610336|9881501|FG006|Overall Study|Death|3
6214496|NCT01610336|9881502|FG007|Overall Study|Death|0
6214497|NCT01610336|9881503|FG008|Overall Study|Death|0
6214498|NCT01610336|9881504|FG009|Overall Study|Death|1
6214499|NCT01610336|9881505|FG010|Overall Study|Death|2
6214500|NCT01610336|9881495|FG000|Overall Study|Non-Compliance with study treatment|0
6214501|NCT01610336|9881496|FG001|Overall Study|Non-Compliance with study treatment|0
6214502|NCT01610336|9881497|FG002|Overall Study|Non-Compliance with study treatment|0
6214503|NCT01610336|9881498|FG003|Overall Study|Non-Compliance with study treatment|0
6214504|NCT01610336|9881499|FG004|Overall Study|Non-Compliance with study treatment|0
6214505|NCT01610336|9881500|FG005|Overall Study|Non-Compliance with study treatment|0
6214506|NCT01610336|9881501|FG006|Overall Study|Non-Compliance with study treatment|0
6287716|NCT02354222|10000489|FG000|Overall Study|Physician Decision|1
6287717|NCT02354222|10000490|FG001|Overall Study|Physician Decision|1
6287718|NCT02354222|10000489|FG000|Overall Study|Pregnancy|1
6287719|NCT02354222|10000490|FG001|Overall Study|Pregnancy|0
6287720|NCT02354222|10000489|FG000|Overall Study|Withdrawal by Subject|2
6287721|NCT02354222|10000490|FG001|Overall Study|Withdrawal by Subject|3
6287722|NCT02354222|10000489|FG000|Overall Study|Conflict with the stopping criteria|0
6287723|NCT02354222|10000490|FG001|Overall Study|Conflict with the stopping criteria|4
6287724|NCT02354235|10000498|FG000|Overall Study|Adverse Event|2
6287725|NCT02354235|10000499|FG001|Overall Study|Adverse Event|2
6287726|NCT02354235|10000498|FG000|Overall Study|Physician Decision|0
6287727|NCT02354235|10000499|FG001|Overall Study|Physician Decision|1
6287728|NCT02354235|10000498|FG000|Overall Study|Withdrawal by Subject|1
6287729|NCT02354235|10000499|FG001|Overall Study|Withdrawal by Subject|3
6287730|NCT02354235|10000498|FG000|Overall Study|Conflict with the stopping criteria|0
6287731|NCT02354235|10000499|FG001|Overall Study|Conflict with the stopping criteria|1
6287732|NCT02354417|10000532|FG000|Overall Study|Physician Decision|1
6287733|NCT02354508|10000557|FG000|Period 1: Core Phase|Adverse Event|1
6287734|NCT02354508|10000558|FG001|Period 1: Core Phase|Adverse Event|1
6287735|NCT02354508|10000559|FG002|Period 1: Core Phase|Adverse Event|2
6287736|NCT02354508|10000557|FG000|Period 1: Core Phase|Unsatisfactory therapeutic effect|1
6287737|NCT02354508|10000558|FG001|Period 1: Core Phase|Unsatisfactory therapeutic effect|0
6214507|NCT01610336|9881502|FG007|Overall Study|Non-Compliance with study treatment|0
6214508|NCT01610336|9881503|FG008|Overall Study|Non-Compliance with study treatment|0
6287738|NCT02354508|10000559|FG002|Period 1: Core Phase|Unsatisfactory therapeutic effect|2
6121316|NCT00896532|9744608|FG010|Months 36-48: Romosozumab Retreatment|Adverse Event|0
6121317|NCT00896532|9744609|FG011|Months 36-48: Romosozumab Retreatment|Adverse Event|0
6121318|NCT00896532|9744610|FG012|Months 36-48: Romosozumab Retreatment|Adverse Event|0
6121319|NCT00896532|9744611|FG013|Months 36-48: Romosozumab Retreatment|Adverse Event|0
6121320|NCT00896532|9744612|FG014|Months 36-48: Romosozumab Retreatment|Adverse Event|0
6121321|NCT00896532|9744613|FG015|Months 36-48: Romosozumab Retreatment|Adverse Event|1
6121322|NCT00896532|9744614|FG016|Months 36-48: Romosozumab Retreatment|Adverse Event|3
6121323|NCT00896532|9744615|FG017|Months 36-48: Romosozumab Retreatment|Adverse Event|0
6214509|NCT01610336|9881504|FG009|Overall Study|Non-Compliance with study treatment|1
6214510|NCT01610336|9881505|FG010|Overall Study|Non-Compliance with study treatment|0
6214511|NCT01610336|9881495|FG000|Overall Study|Physician Decision|0
6214512|NCT01610336|9881496|FG001|Overall Study|Physician Decision|0
6214513|NCT01610336|9881497|FG002|Overall Study|Physician Decision|0
6214514|NCT01610336|9881498|FG003|Overall Study|Physician Decision|0
6214515|NCT01610336|9881499|FG004|Overall Study|Physician Decision|0
6214516|NCT01610336|9881500|FG005|Overall Study|Physician Decision|0
6214517|NCT01610336|9881501|FG006|Overall Study|Physician Decision|1
6214518|NCT01610336|9881502|FG007|Overall Study|Physician Decision|0
6214519|NCT01610336|9881503|FG008|Overall Study|Physician Decision|0
6214520|NCT01610336|9881504|FG009|Overall Study|Physician Decision|0
6214521|NCT01610336|9881505|FG010|Overall Study|Physician Decision|0
6214522|NCT01610336|9881495|FG000|Overall Study|Protocol Deviation|0
6214523|NCT01610336|9881496|FG001|Overall Study|Protocol Deviation|0
6214524|NCT01610336|9881497|FG002|Overall Study|Protocol Deviation|0
6214525|NCT01610336|9881498|FG003|Overall Study|Protocol Deviation|0
6214526|NCT01610336|9881499|FG004|Overall Study|Protocol Deviation|0
6214527|NCT01610336|9881500|FG005|Overall Study|Protocol Deviation|0
6214528|NCT01610336|9881501|FG006|Overall Study|Protocol Deviation|0
6214529|NCT01610336|9881502|FG007|Overall Study|Protocol Deviation|0
6214530|NCT01610336|9881503|FG008|Overall Study|Protocol Deviation|0
6214531|NCT01610336|9881504|FG009|Overall Study|Protocol Deviation|1
6214532|NCT01610336|9881505|FG010|Overall Study|Protocol Deviation|0
6214533|NCT01610336|9881495|FG000|Overall Study|Transfer to another trial|0
6214534|NCT01610336|9881496|FG001|Overall Study|Transfer to another trial|0
6214535|NCT01610336|9881497|FG002|Overall Study|Transfer to another trial|0
6214536|NCT01610336|9881498|FG003|Overall Study|Transfer to another trial|0
6214537|NCT01610336|9881499|FG004|Overall Study|Transfer to another trial|0
6214538|NCT01610336|9881500|FG005|Overall Study|Transfer to another trial|0
6214539|NCT01610336|9881501|FG006|Overall Study|Transfer to another trial|0
6214540|NCT01610336|9881502|FG007|Overall Study|Transfer to another trial|0
6214541|NCT01610336|9881503|FG008|Overall Study|Transfer to another trial|0
6214542|NCT01610336|9881504|FG009|Overall Study|Transfer to another trial|0
6214543|NCT01610336|9881505|FG010|Overall Study|Transfer to another trial|1
6214544|NCT01610414|9881535|FG000|Study Start - Month 13|Serious Adverse Event|65
6214545|NCT01610414|9881536|FG001|Study Start - Month 13|Serious Adverse Event|67
6214546|NCT01610414|9881535|FG000|Study Start - Month 13|Adverse Event|14
6214547|NCT01610414|9881536|FG001|Study Start - Month 13|Adverse Event|14
6214548|NCT01610414|9881535|FG000|Study Start - Month 13|Protocol Violation|3
6214549|NCT01610414|9881536|FG001|Study Start - Month 13|Protocol Violation|1
6214550|NCT01610414|9881535|FG000|Study Start - Month 13|Withdrawal by Subject|23
6214551|NCT01610414|9881536|FG001|Study Start - Month 13|Withdrawal by Subject|30
6214552|NCT01610414|9881535|FG000|Study Start - Month 13|Migrated/moved from study area|2
6214553|NCT01610414|9881536|FG001|Study Start - Month 13|Migrated/moved from study area|4
6214554|NCT01610414|9881535|FG000|Study Start - Month 13|Lost to Follow-up|4
6214555|NCT01610414|9881536|FG001|Study Start - Month 13|Lost to Follow-up|6
6214556|NCT01610414|9881535|FG000|Study Start - Month 13|Suspected HZ episode|1
6121324|NCT00896532|9744616|FG018|Months 36-48: Romosozumab Retreatment|Adverse Event|0
6121325|NCT00896532|9744617|FG019|Months 36-48: Romosozumab Retreatment|Adverse Event|0
6121326|NCT00896532|9744618|FG020|Months 36-48: Romosozumab Retreatment|Adverse Event|0
6121327|NCT00896532|9744619|FG021|Months 36-48: Romosozumab Retreatment|Adverse Event|0
6121328|NCT00896532|9744620|FG022|Months 36-48: Romosozumab Retreatment|Adverse Event|0
6121329|NCT00896532|9744598|FG000|Months 36-48: Romosozumab Retreatment|Withdrawal by Subject|0
6121330|NCT00896532|9744599|FG001|Months 36-48: Romosozumab Retreatment|Withdrawal by Subject|0
6121331|NCT00896532|9744600|FG002|Months 36-48: Romosozumab Retreatment|Withdrawal by Subject|0
6121332|NCT00896532|9744601|FG003|Months 36-48: Romosozumab Retreatment|Withdrawal by Subject|0
6121333|NCT00896532|9744602|FG004|Months 36-48: Romosozumab Retreatment|Withdrawal by Subject|0
6121334|NCT00896532|9744603|FG005|Months 36-48: Romosozumab Retreatment|Withdrawal by Subject|0
6121335|NCT00896532|9744604|FG006|Months 36-48: Romosozumab Retreatment|Withdrawal by Subject|0
6121336|NCT00896532|9744605|FG007|Months 36-48: Romosozumab Retreatment|Withdrawal by Subject|0
6121337|NCT00896532|9744606|FG008|Months 36-48: Romosozumab Retreatment|Withdrawal by Subject|0
6121338|NCT00896532|9744607|FG009|Months 36-48: Romosozumab Retreatment|Withdrawal by Subject|0
6214557|NCT01610414|9881536|FG001|Study Start - Month 13|Suspected HZ episode|3
6214558|NCT01610414|9881535|FG000|Study Start - Month 13|Other reasons for withdrawal|3
5980856|NCT01434602|9569525|FG002|Phase II Recommended Phase 2 Dose|Physician Decision|0
6214559|NCT01610414|9881536|FG001|Study Start - Month 13|Other reasons for withdrawal|4
6214560|NCT01610414|9881535|FG000|Month 13 - Month 25|Serious Adverse Event|35
6214561|NCT01610414|9881536|FG001|Month 13 - Month 25|Serious Adverse Event|38
6121339|NCT00896532|9744608|FG010|Months 36-48: Romosozumab Retreatment|Withdrawal by Subject|0
6121340|NCT00896532|9744609|FG011|Months 36-48: Romosozumab Retreatment|Withdrawal by Subject|0
6121341|NCT00896532|9744610|FG012|Months 36-48: Romosozumab Retreatment|Withdrawal by Subject|0
6121342|NCT00896532|9744611|FG013|Months 36-48: Romosozumab Retreatment|Withdrawal by Subject|0
6121343|NCT00896532|9744612|FG014|Months 36-48: Romosozumab Retreatment|Withdrawal by Subject|0
6121344|NCT00896532|9744613|FG015|Months 36-48: Romosozumab Retreatment|Withdrawal by Subject|1
6121345|NCT00896532|9744614|FG016|Months 36-48: Romosozumab Retreatment|Withdrawal by Subject|2
6121346|NCT00896532|9744615|FG017|Months 36-48: Romosozumab Retreatment|Withdrawal by Subject|2
6121347|NCT00896532|9744616|FG018|Months 36-48: Romosozumab Retreatment|Withdrawal by Subject|0
6121348|NCT00896532|9744617|FG019|Months 36-48: Romosozumab Retreatment|Withdrawal by Subject|0
6121349|NCT00896532|9744618|FG020|Months 36-48: Romosozumab Retreatment|Withdrawal by Subject|0
6121350|NCT00896532|9744619|FG021|Months 36-48: Romosozumab Retreatment|Withdrawal by Subject|0
6121351|NCT00896532|9744620|FG022|Months 36-48: Romosozumab Retreatment|Withdrawal by Subject|0
6121352|NCT00896532|9744598|FG000|Months 36-48: Romosozumab Retreatment|Lost to Follow-up|0
6214562|NCT01610414|9881535|FG000|Month 13 - Month 25|Adverse Event|8
6214563|NCT01610414|9881536|FG001|Month 13 - Month 25|Adverse Event|4
6214564|NCT01610414|9881535|FG000|Month 13 - Month 25|Withdrawal by Subject|7
6287739|NCT02354508|10000557|FG000|Period 1: Core Phase|Withdrawal by Subject|0
6287740|NCT02354508|10000558|FG001|Period 1: Core Phase|Withdrawal by Subject|1
6287741|NCT02354508|10000559|FG002|Period 1: Core Phase|Withdrawal by Subject|2
6287742|NCT02354508|10000557|FG000|Period 2: Extension Phase|Unsatisfactory therapeutic effect|1
6287743|NCT02354508|10000558|FG001|Period 2: Extension Phase|Unsatisfactory therapeutic effect|3
6287744|NCT02354508|10000559|FG002|Period 2: Extension Phase|Unsatisfactory therapeutic effect|2
6287745|NCT02354508|10000557|FG000|Period 2: Extension Phase|Withdrawal by Subject|0
6287746|NCT02354508|10000558|FG001|Period 2: Extension Phase|Withdrawal by Subject|1
6287747|NCT02354508|10000559|FG002|Period 2: Extension Phase|Withdrawal by Subject|0
6287748|NCT02354508|10000557|FG000|Period 2: Extension Phase|Physician Decision|5
6287749|NCT02354508|10000558|FG001|Period 2: Extension Phase|Physician Decision|0
6287750|NCT02354508|10000559|FG002|Period 2: Extension Phase|Physician Decision|1
6287751|NCT02354508|10000557|FG000|Period 3: Post-treatment Follow up Phase|Unsatisfactory therapeutic effect|1
6287752|NCT02354508|10000558|FG001|Period 3: Post-treatment Follow up Phase|Unsatisfactory therapeutic effect|2
6287753|NCT02354508|10000559|FG002|Period 3: Post-treatment Follow up Phase|Unsatisfactory therapeutic effect|2
6287754|NCT02354508|10000557|FG000|Period 3: Post-treatment Follow up Phase|Withdrawal by Subject|0
6287755|NCT02354508|10000558|FG001|Period 3: Post-treatment Follow up Phase|Withdrawal by Subject|1
6287756|NCT02354508|10000559|FG002|Period 3: Post-treatment Follow up Phase|Withdrawal by Subject|0
6287757|NCT02354508|10000557|FG000|Period 3: Post-treatment Follow up Phase|Physician Decision|3
6287758|NCT02354508|10000558|FG001|Period 3: Post-treatment Follow up Phase|Physician Decision|0
6287759|NCT02354508|10000559|FG002|Period 3: Post-treatment Follow up Phase|Physician Decision|1
6287760|NCT02354586|10000625|FG000|Overall Study|Death|168
6287761|NCT02354586|10000625|FG000|Overall Study|Withdrawal by Subject|51
6287762|NCT02354586|10000625|FG000|Overall Study|Lost to Follow-up|6
6287763|NCT02354586|10000625|FG000|Overall Study|Disease progression|116
6287764|NCT02354599|10000635|FG000|Overall Study|Pretreatment Event/Adverse Event|0
6287765|NCT02354599|10000636|FG001|Overall Study|Pretreatment Event/Adverse Event|0
6287766|NCT02354599|10000637|FG002|Overall Study|Pretreatment Event/Adverse Event|0
6287767|NCT02354599|10000638|FG003|Overall Study|Pretreatment Event/Adverse Event|0
6287768|NCT02354599|10000639|FG004|Overall Study|Pretreatment Event/Adverse Event|0
6287769|NCT02354599|10000640|FG005|Overall Study|Pretreatment Event/Adverse Event|1
6287770|NCT02354599|10000635|FG000|Overall Study|Withdrawal by Subject|1
6287771|NCT02354599|10000636|FG001|Overall Study|Withdrawal by Subject|1
6287772|NCT02354599|10000637|FG002|Overall Study|Withdrawal by Subject|0
6287773|NCT02354599|10000638|FG003|Overall Study|Withdrawal by Subject|0
6287774|NCT02354599|10000639|FG004|Overall Study|Withdrawal by Subject|0
6287775|NCT02354599|10000640|FG005|Overall Study|Withdrawal by Subject|0
6287776|NCT02354690|10000660|FG000|Overall Study|Physician Decision|1
6287777|NCT02354976|10000703|FG000|Overall Study|Other - reason not specified|1
6287778|NCT02354976|10000704|FG001|Overall Study|Other - reason not specified|0
6287779|NCT02354976|10000705|FG002|Overall Study|Other - reason not specified|1
6287780|NCT02354976|10000703|FG000|Overall Study|Study-specifc withdrawal criteria|0
6287781|NCT02354976|10000704|FG001|Overall Study|Study-specifc withdrawal criteria|1
6287782|NCT02354976|10000705|FG002|Overall Study|Study-specifc withdrawal criteria|0
6287783|NCT02354976|10000703|FG000|Overall Study|Adverse Event|1
6287784|NCT02354976|10000704|FG001|Overall Study|Adverse Event|0
6287785|NCT02354976|10000705|FG002|Overall Study|Adverse Event|2
6287786|NCT02355028|10000715|FG000|Overall Study|Adverse Event|2
6287787|NCT02355028|10000716|FG001|Overall Study|Adverse Event|0
6287788|NCT02355028|10000715|FG000|Overall Study|Withdrawal by Subject|1
6214565|NCT01610414|9881536|FG001|Month 13 - Month 25|Withdrawal by Subject|8
6214566|NCT01610414|9881535|FG000|Month 13 - Month 25|Migrated/moved from study area|4
6214567|NCT01610414|9881536|FG001|Month 13 - Month 25|Migrated/moved from study area|2
6214568|NCT01610414|9881535|FG000|Month 13 - Month 25|Protocol Violation|0
6214569|NCT01610414|9881536|FG001|Month 13 - Month 25|Protocol Violation|2
6214570|NCT01610414|9881535|FG000|Month 13 - Month 25|Lost to Follow-up|5
6121353|NCT00896532|9744599|FG001|Months 36-48: Romosozumab Retreatment|Lost to Follow-up|0
6121354|NCT00896532|9744600|FG002|Months 36-48: Romosozumab Retreatment|Lost to Follow-up|0
6121355|NCT00896532|9744601|FG003|Months 36-48: Romosozumab Retreatment|Lost to Follow-up|0
6121356|NCT00896532|9744602|FG004|Months 36-48: Romosozumab Retreatment|Lost to Follow-up|0
6121357|NCT00896532|9744603|FG005|Months 36-48: Romosozumab Retreatment|Lost to Follow-up|0
6121358|NCT00896532|9744604|FG006|Months 36-48: Romosozumab Retreatment|Lost to Follow-up|0
6121359|NCT00896532|9744605|FG007|Months 36-48: Romosozumab Retreatment|Lost to Follow-up|0
6121360|NCT00896532|9744606|FG008|Months 36-48: Romosozumab Retreatment|Lost to Follow-up|0
6121361|NCT00896532|9744607|FG009|Months 36-48: Romosozumab Retreatment|Lost to Follow-up|0
6121362|NCT00896532|9744608|FG010|Months 36-48: Romosozumab Retreatment|Lost to Follow-up|0
6121363|NCT00896532|9744609|FG011|Months 36-48: Romosozumab Retreatment|Lost to Follow-up|0
6121364|NCT00896532|9744610|FG012|Months 36-48: Romosozumab Retreatment|Lost to Follow-up|0
6121365|NCT00896532|9744611|FG013|Months 36-48: Romosozumab Retreatment|Lost to Follow-up|0
6121366|NCT00896532|9744612|FG014|Months 36-48: Romosozumab Retreatment|Lost to Follow-up|0
6121367|NCT00896532|9744613|FG015|Months 36-48: Romosozumab Retreatment|Lost to Follow-up|0
6121368|NCT00896532|9744614|FG016|Months 36-48: Romosozumab Retreatment|Lost to Follow-up|1
6121369|NCT00896532|9744615|FG017|Months 36-48: Romosozumab Retreatment|Lost to Follow-up|0
6121370|NCT00896532|9744616|FG018|Months 36-48: Romosozumab Retreatment|Lost to Follow-up|0
6121371|NCT00896532|9744617|FG019|Months 36-48: Romosozumab Retreatment|Lost to Follow-up|0
6121372|NCT00896532|9744618|FG020|Months 36-48: Romosozumab Retreatment|Lost to Follow-up|0
6121373|NCT00896532|9744619|FG021|Months 36-48: Romosozumab Retreatment|Lost to Follow-up|0
6121374|NCT00896532|9744620|FG022|Months 36-48: Romosozumab Retreatment|Lost to Follow-up|0
6121375|NCT00896532|9744598|FG000|Months 36-48: Romosozumab Retreatment|Other|0
6121376|NCT00896532|9744599|FG001|Months 36-48: Romosozumab Retreatment|Other|0
6121377|NCT00896532|9744600|FG002|Months 36-48: Romosozumab Retreatment|Other|0
6121378|NCT00896532|9744601|FG003|Months 36-48: Romosozumab Retreatment|Other|0
6121379|NCT00896532|9744602|FG004|Months 36-48: Romosozumab Retreatment|Other|0
6121380|NCT00896532|9744603|FG005|Months 36-48: Romosozumab Retreatment|Other|0
6121381|NCT00896532|9744604|FG006|Months 36-48: Romosozumab Retreatment|Other|0
6121382|NCT00896532|9744605|FG007|Months 36-48: Romosozumab Retreatment|Other|0
6121383|NCT00896532|9744606|FG008|Months 36-48: Romosozumab Retreatment|Other|0
6121384|NCT00896532|9744607|FG009|Months 36-48: Romosozumab Retreatment|Other|0
6121385|NCT00896532|9744608|FG010|Months 36-48: Romosozumab Retreatment|Other|0
6121386|NCT00896532|9744609|FG011|Months 36-48: Romosozumab Retreatment|Other|0
6121387|NCT00896532|9744610|FG012|Months 36-48: Romosozumab Retreatment|Other|0
6121388|NCT00896532|9744611|FG013|Months 36-48: Romosozumab Retreatment|Other|0
6121389|NCT00896532|9744612|FG014|Months 36-48: Romosozumab Retreatment|Other|0
6121390|NCT00896532|9744613|FG015|Months 36-48: Romosozumab Retreatment|Other|0
6121391|NCT00896532|9744614|FG016|Months 36-48: Romosozumab Retreatment|Other|0
6121392|NCT00896532|9744615|FG017|Months 36-48: Romosozumab Retreatment|Other|1
6121393|NCT00896532|9744616|FG018|Months 36-48: Romosozumab Retreatment|Other|0
6121394|NCT00896532|9744617|FG019|Months 36-48: Romosozumab Retreatment|Other|0
6121395|NCT00896532|9744618|FG020|Months 36-48: Romosozumab Retreatment|Other|0
6121396|NCT00896532|9744619|FG021|Months 36-48: Romosozumab Retreatment|Other|0
6121397|NCT00896532|9744620|FG022|Months 36-48: Romosozumab Retreatment|Other|0
6121398|NCT00896532|9744598|FG000|Months 36-48: Romosozumab Retreatment|Continuing the re-treatment phase|0
6121399|NCT00896532|9744599|FG001|Months 36-48: Romosozumab Retreatment|Continuing the re-treatment phase|0
6121400|NCT00896532|9744600|FG002|Months 36-48: Romosozumab Retreatment|Continuing the re-treatment phase|0
6121401|NCT00896532|9744601|FG003|Months 36-48: Romosozumab Retreatment|Continuing the re-treatment phase|0
6214571|NCT01610414|9881536|FG001|Month 13 - Month 25|Lost to Follow-up|9
6214572|NCT01610414|9881535|FG000|Month 13 - Month 25|Other reasons for withdrawal|6
6214573|NCT01610414|9881536|FG001|Month 13 - Month 25|Other reasons for withdrawal|7
6214574|NCT01610414|9881535|FG000|After Month 25|Study end not reached|48
6214575|NCT01610414|9881536|FG001|After Month 25|Study end not reached|53
6214576|NCT01610492|9881552|FG000|Overall Study|Adverse Event|1
6214577|NCT01610492|9881552|FG000|Overall Study|Lack of Efficacy|3
6214578|NCT01610492|9881552|FG000|Overall Study|Other: Reached stopping criteria|1
6214579|NCT01610492|9881552|FG000|Overall Study|Other:Treatment stopped due to remission|1
6214580|NCT01610557|9881560|FG000|36-Week Randomized Crossover Phase|Withdrawal by Subject|0
6214581|NCT01610557|9881561|FG001|36-Week Randomized Crossover Phase|Withdrawal by Subject|1
6214582|NCT01610557|9881562|FG002|36-Week Randomized Crossover Phase|Withdrawal by Subject|0
6214583|NCT01610557|9881563|FG003|36-Week Randomized Crossover Phase|Withdrawal by Subject|0
6214584|NCT01610557|9881564|FG004|36-Week Randomized Crossover Phase|Withdrawal by Subject|0
6214585|NCT01610557|9881560|FG000|Post-36-Week Extension Phase|Withdrawal by Subject|0
6214586|NCT01610557|9881561|FG001|Post-36-Week Extension Phase|Withdrawal by Subject|0
6214587|NCT01610557|9881562|FG002|Post-36-Week Extension Phase|Withdrawal by Subject|0
6214588|NCT01610557|9881563|FG003|Post-36-Week Extension Phase|Withdrawal by Subject|0
6214589|NCT01610557|9881564|FG004|Post-36-Week Extension Phase|Withdrawal by Subject|3
6214590|NCT01610596|9881600|FG000|Overall Study|Lost to Follow-up|0
6214591|NCT01610596|9881601|FG001|Overall Study|Lost to Follow-up|1
6214592|NCT01610687|9881607|FG000|Overall Study|Lack of Efficacy|26
6214593|NCT01610687|9881607|FG000|Overall Study|Adverse Event|18
6121402|NCT00896532|9744602|FG004|Months 36-48: Romosozumab Retreatment|Continuing the re-treatment phase|0
6121403|NCT00896532|9744603|FG005|Months 36-48: Romosozumab Retreatment|Continuing the re-treatment phase|0
6121404|NCT00896532|9744604|FG006|Months 36-48: Romosozumab Retreatment|Continuing the re-treatment phase|0
6121405|NCT00896532|9744605|FG007|Months 36-48: Romosozumab Retreatment|Continuing the re-treatment phase|0
6121406|NCT00896532|9744606|FG008|Months 36-48: Romosozumab Retreatment|Continuing the re-treatment phase|0
6121407|NCT00896532|9744607|FG009|Months 36-48: Romosozumab Retreatment|Continuing the re-treatment phase|0
6121408|NCT00896532|9744608|FG010|Months 36-48: Romosozumab Retreatment|Continuing the re-treatment phase|0
6121409|NCT00896532|9744609|FG011|Months 36-48: Romosozumab Retreatment|Continuing the re-treatment phase|0
6121410|NCT00896532|9744610|FG012|Months 36-48: Romosozumab Retreatment|Continuing the re-treatment phase|0
6121411|NCT00896532|9744611|FG013|Months 36-48: Romosozumab Retreatment|Continuing the re-treatment phase|0
6121412|NCT00896532|9744612|FG014|Months 36-48: Romosozumab Retreatment|Continuing the re-treatment phase|0
6121413|NCT00896532|9744613|FG015|Months 36-48: Romosozumab Retreatment|Continuing the re-treatment phase|0
6121414|NCT00896532|9744614|FG016|Months 36-48: Romosozumab Retreatment|Continuing the re-treatment phase|1
6121415|NCT00896532|9744615|FG017|Months 36-48: Romosozumab Retreatment|Continuing the re-treatment phase|0
6121416|NCT00896532|9744616|FG018|Months 36-48: Romosozumab Retreatment|Continuing the re-treatment phase|0
6121417|NCT00896532|9744617|FG019|Months 36-48: Romosozumab Retreatment|Continuing the re-treatment phase|0
6121418|NCT00896532|9744618|FG020|Months 36-48: Romosozumab Retreatment|Continuing the re-treatment phase|0
6214594|NCT01610687|9881607|FG000|Overall Study|Moved out of area|6
6214595|NCT01610687|9881607|FG000|Overall Study|Withdrawal by Subject|7
6214596|NCT01610687|9881607|FG000|Overall Study|Lost to Follow-up|4
6214597|NCT01610687|9881607|FG000|Overall Study|Symptom control without study medication|2
6214598|NCT01610687|9881607|FG000|Overall Study|Unable to make journey|1
6214599|NCT01610687|9881607|FG000|Overall Study|Death|1
6214600|NCT01610687|9881607|FG000|Overall Study|Cannabis affecting job|1
6214601|NCT01610687|9881607|FG000|Overall Study|Felt more alter without study medication|1
6214602|NCT01610700|9881613|FG000|Overall Study|Adverse Event|3
6214603|NCT01610700|9881614|FG001|Overall Study|Adverse Event|1
6214604|NCT01610700|9881613|FG000|Overall Study|Withdrawal by Subject|0
6214605|NCT01610700|9881614|FG001|Overall Study|Withdrawal by Subject|1
6214606|NCT01610700|9881613|FG000|Overall Study|subject took one dose of street cannabis|0
6214607|NCT01610700|9881614|FG001|Overall Study|subject took one dose of street cannabis|1
6214608|NCT01610713|9881623|FG000|Overall Study|Adverse Event|3
6287789|NCT02355028|10000716|FG001|Overall Study|Withdrawal by Subject|1
6287790|NCT02355028|10000715|FG000|Overall Study|Deemed ineligible after randomization|8
6287791|NCT02355028|10000716|FG001|Overall Study|Deemed ineligible after randomization|4
6287792|NCT02355665|10000771|FG000|Overall Study|Adverse Event|16
6287793|NCT02355665|10000772|FG001|Overall Study|Adverse Event|24
6287794|NCT02355665|10000771|FG000|Overall Study|Protocol Violation|2
6214609|NCT01610713|9881624|FG001|Overall Study|Adverse Event|0
6214610|NCT01610713|9881623|FG000|Overall Study|Lack of Efficacy|1
6214611|NCT01610713|9881624|FG001|Overall Study|Lack of Efficacy|0
6214612|NCT01610713|9881623|FG000|Overall Study|low mood and poor motivation|1
6214613|NCT01610713|9881624|FG001|Overall Study|low mood and poor motivation|0
6214614|NCT01610713|9881623|FG000|Overall Study|adv. to use original dose/amitriptyline|1
6214615|NCT01610713|9881624|FG001|Overall Study|adv. to use original dose/amitriptyline|0
6214616|NCT01610713|9881623|FG000|Overall Study|Lost to Follow-up|0
6214617|NCT01610713|9881624|FG001|Overall Study|Lost to Follow-up|1
6214618|NCT01610752|9881633|FG000|Overall Study|Miscarriage/Pregnancy loss|0
6214619|NCT01610752|9881634|FG001|Overall Study|Miscarriage/Pregnancy loss|0
6214620|NCT01610752|9881635|FG002|Overall Study|Miscarriage/Pregnancy loss|4
6214621|NCT01610791|9881643|FG000|Overall Study|Lost to Follow-up|7
6214622|NCT01610791|9881643|FG000|Overall Study|Adverse Event|6
6214623|NCT01610791|9881643|FG000|Overall Study|Physician Decision|1
6214624|NCT01610791|9881643|FG000|Overall Study|Adverse event and Investigator decision|1
6214625|NCT01610791|9881643|FG000|Overall Study|Death|1
6287795|NCT02355665|10000772|FG001|Overall Study|Protocol Violation|0
6287796|NCT02355665|10000771|FG000|Overall Study|Withdrawal by Subject|90
6287797|NCT02355665|10000772|FG001|Overall Study|Withdrawal by Subject|100
6287798|NCT02355665|10000771|FG000|Overall Study|Lost to Follow-up|131
6287799|NCT02355665|10000772|FG001|Overall Study|Lost to Follow-up|103
6287800|NCT02355665|10000771|FG000|Overall Study|Death|4
6287801|NCT02355665|10000772|FG001|Overall Study|Death|2
6287802|NCT02355665|10000771|FG000|Overall Study|Compliance, PI decision, move, eligible|6
6287803|NCT02355665|10000772|FG001|Overall Study|Compliance, PI decision, move, eligible|3
6287804|NCT02355691|10000780|FG000|Overall Study|Loss of Research Personnel|7
6287805|NCT02355691|10000781|FG001|Overall Study|Loss of Research Personnel|9
6287806|NCT02355743|10000787|FG000|Overall Study|Withdrawal by Subject|1
6287807|NCT02355743|10000787|FG000|Overall Study|Lost to Follow-up|1
6287808|NCT02356211|10000842|FG000|Overall Study|Withdrawal by Subject|2
6287809|NCT02356211|10000843|FG001|Overall Study|Withdrawal by Subject|2
6287810|NCT02356211|10000842|FG000|Overall Study|ineligible|1
6287811|NCT02356211|10000843|FG001|Overall Study|ineligible|8
6287812|NCT02356562|10000859|FG000|Overall Study|Withdrawal by Subject|0
6287813|NCT02356562|10000860|FG001|Overall Study|Withdrawal by Subject|1
6287814|NCT02356562|10000859|FG000|Overall Study|Re-entered treatment in a previous study|1
6287815|NCT02356562|10000860|FG001|Overall Study|Re-entered treatment in a previous study|0
6121419|NCT00896532|9744619|FG021|Months 36-48: Romosozumab Retreatment|Continuing the re-treatment phase|0
6121420|NCT00896532|9744620|FG022|Months 36-48: Romosozumab Retreatment|Continuing the re-treatment phase|0
6121421|NCT00896532|9744598|FG000|Months 48-72: Follow-on Phase|Death|0
6121422|NCT00896532|9744599|FG001|Months 48-72: Follow-on Phase|Death|0
6121423|NCT00896532|9744600|FG002|Months 48-72: Follow-on Phase|Death|0
6121424|NCT00896532|9744601|FG003|Months 48-72: Follow-on Phase|Death|0
6121425|NCT00896532|9744602|FG004|Months 48-72: Follow-on Phase|Death|0
6121426|NCT00896532|9744603|FG005|Months 48-72: Follow-on Phase|Death|0
6121427|NCT00896532|9744604|FG006|Months 48-72: Follow-on Phase|Death|0
6121428|NCT00896532|9744605|FG007|Months 48-72: Follow-on Phase|Death|0
6121429|NCT00896532|9744606|FG008|Months 48-72: Follow-on Phase|Death|0
6121430|NCT00896532|9744607|FG009|Months 48-72: Follow-on Phase|Death|0
6121431|NCT00896532|9744608|FG010|Months 48-72: Follow-on Phase|Death|0
6121432|NCT00896532|9744609|FG011|Months 48-72: Follow-on Phase|Death|0
6121433|NCT00896532|9744610|FG012|Months 48-72: Follow-on Phase|Death|0
6121434|NCT00896532|9744611|FG013|Months 48-72: Follow-on Phase|Death|0
6214626|NCT01610791|9881643|FG000|Overall Study|Not determined|5
6214627|NCT01611090|9881649|FG000|Randomized Period|Lost to Follow-up|8
6287816|NCT02356562|10000859|FG000|Overall Study|site closure|1
6287817|NCT02356562|10000860|FG001|Overall Study|site closure|0
6287818|NCT02356588|10000869|FG000|Overall Study|Lack of Efficacy|4
6287819|NCT02356588|10000870|FG001|Overall Study|Lack of Efficacy|10
6214628|NCT01611090|9881650|FG001|Randomized Period|Lost to Follow-up|3
6214629|NCT01611090|9881651|FG002|Randomized Period|Lost to Follow-up|0
6214630|NCT01611090|9881649|FG000|Randomized Period|Withdrawal by Subject|22
6214631|NCT01611090|9881650|FG001|Randomized Period|Withdrawal by Subject|26
6214632|NCT01611090|9881651|FG002|Randomized Period|Withdrawal by Subject|0
6214633|NCT01611090|9881649|FG000|Cross Over (Placebo to Ibrutinib)|Lost to Follow-up|0
6214634|NCT01611090|9881650|FG001|Cross Over (Placebo to Ibrutinib)|Lost to Follow-up|0
6214635|NCT01611090|9881651|FG002|Cross Over (Placebo to Ibrutinib)|Lost to Follow-up|4
6214636|NCT01611090|9881649|FG000|Cross Over (Placebo to Ibrutinib)|Withdrawal by Subject|0
6214637|NCT01611090|9881650|FG001|Cross Over (Placebo to Ibrutinib)|Withdrawal by Subject|0
6214638|NCT01611090|9881651|FG002|Cross Over (Placebo to Ibrutinib)|Withdrawal by Subject|1
6214639|NCT01611155|9881660|FG000|Overall Study|Adverse Event|1
6214640|NCT01611155|9881661|FG001|Overall Study|Adverse Event|1
6214641|NCT01611155|9881660|FG000|Overall Study|Refused further treatment|6
6214642|NCT01611155|9881661|FG001|Overall Study|Refused further treatment|4
6214643|NCT01611155|9881660|FG000|Overall Study|Disease progression|1
6214644|NCT01611155|9881661|FG001|Overall Study|Disease progression|0
6214645|NCT01611155|9881660|FG000|Overall Study|Withdrawal by Subject|1
6214646|NCT01611155|9881661|FG001|Overall Study|Withdrawal by Subject|0
6214647|NCT01611155|9881660|FG000|Overall Study|Alternative treatment|0
6214648|NCT01611155|9881661|FG001|Overall Study|Alternative treatment|1
6214649|NCT01611155|9881660|FG000|Overall Study|Ineligible patient|0
6214650|NCT01611155|9881661|FG001|Overall Study|Ineligible patient|1
6214651|NCT01611194|9881669|FG000|Overall Study|Lost to Follow-up|0
6214652|NCT01611194|9881670|FG001|Overall Study|Lost to Follow-up|1
6214653|NCT01611194|9881669|FG000|Overall Study|Withdrawal by Subject|0
6214654|NCT01611194|9881670|FG001|Overall Study|Withdrawal by Subject|1
6214655|NCT01611194|9881669|FG000|Overall Study|drug use|0
6214656|NCT01611194|9881670|FG001|Overall Study|drug use|1
6214657|NCT01611259|9881676|FG000|Overall Study|Physician Decision|1
6214658|NCT01611259|9881676|FG000|Overall Study|Lack of Efficacy|2
6214659|NCT01611259|9881676|FG000|Overall Study|Adverse Event|4
6214660|NCT01611259|9881676|FG000|Overall Study|Withdrawal by Subject|7
6214661|NCT01611298|9881680|FG000|Overall Study|Relapsed|2
6214662|NCT01611454|9881686|FG000|Overall Study|Lack of Efficacy|18
6214663|NCT01611454|9881687|FG001|Overall Study|Lack of Efficacy|10
6214664|NCT01611558|9881697|FG000|Induction Phase|Study drug toxicity|15
6214665|NCT01611558|9881697|FG000|Induction Phase|Disease progression|18
6214666|NCT01611558|9881697|FG000|Induction Phase|Heart arrest,urosepsis,respiratory fail|1
6214667|NCT01611558|9881697|FG000|Induction Phase|Adverse event unrelated to study drug|3
6214668|NCT01611558|9881697|FG000|Induction Phase|Death|1
6214669|NCT01611558|9881697|FG000|Maintenance Phase|Withdrawal by Subject|1
6214670|NCT01611558|9881697|FG000|Maintenance Phase|Elevated Uric acid|1
6214671|NCT01611792|9881725|FG000|Initial Period: Time 0|unable to schedule 10 consecutive appts|12
6214672|NCT01611792|9881726|FG001|Initial Period: Time 0|unable to schedule 10 consecutive appts|9
6214673|NCT01611792|9881725|FG000|Followup: at 6 Months|Lost to Follow-up|6
6214674|NCT01611792|9881726|FG001|Followup: at 6 Months|Lost to Follow-up|13
6214675|NCT01611857|9881735|FG000|Overall Study|Withdrawal by Subject|0
6214676|NCT01611857|9881736|FG001|Overall Study|Withdrawal by Subject|2
6214677|NCT01611935|9881746|FG000|Overall Study|Family Declined Participation|1
6214678|NCT01611935|9881747|FG001|Overall Study|Family Declined Participation|0
6214679|NCT01611974|9881765|FG000|Overall Study|Death|10
6214680|NCT01611974|9881766|FG001|Overall Study|Death|12
6214681|NCT01611974|9881767|FG002|Overall Study|Death|10
6214682|NCT01611974|9881765|FG000|Overall Study|Lost to Follow-up|0
6214683|NCT01611974|9881766|FG001|Overall Study|Lost to Follow-up|1
6214684|NCT01611974|9881767|FG002|Overall Study|Lost to Follow-up|0
6214685|NCT01611974|9881765|FG000|Overall Study|Physician Decision|5
6214686|NCT01611974|9881766|FG001|Overall Study|Physician Decision|1
6121435|NCT00896532|9744612|FG014|Months 48-72: Follow-on Phase|Death|0
6121436|NCT00896532|9744613|FG015|Months 48-72: Follow-on Phase|Death|0
6121437|NCT00896532|9744614|FG016|Months 48-72: Follow-on Phase|Death|0
6121438|NCT00896532|9744615|FG017|Months 48-72: Follow-on Phase|Death|0
6121439|NCT00896532|9744616|FG018|Months 48-72: Follow-on Phase|Death|1
6121440|NCT00896532|9744617|FG019|Months 48-72: Follow-on Phase|Death|0
6121441|NCT00896532|9744618|FG020|Months 48-72: Follow-on Phase|Death|0
6121442|NCT00896532|9744619|FG021|Months 48-72: Follow-on Phase|Death|0
6121443|NCT00896532|9744620|FG022|Months 48-72: Follow-on Phase|Death|0
6121444|NCT00896532|9744598|FG000|Months 48-72: Follow-on Phase|Ineligibility Determined|0
6121445|NCT00896532|9744599|FG001|Months 48-72: Follow-on Phase|Ineligibility Determined|0
6121446|NCT00896532|9744600|FG002|Months 48-72: Follow-on Phase|Ineligibility Determined|0
6121447|NCT00896532|9744601|FG003|Months 48-72: Follow-on Phase|Ineligibility Determined|0
6121448|NCT00896532|9744602|FG004|Months 48-72: Follow-on Phase|Ineligibility Determined|0
6121449|NCT00896532|9744603|FG005|Months 48-72: Follow-on Phase|Ineligibility Determined|0
6121450|NCT00896532|9744604|FG006|Months 48-72: Follow-on Phase|Ineligibility Determined|0
6121451|NCT00896532|9744605|FG007|Months 48-72: Follow-on Phase|Ineligibility Determined|0
6121452|NCT00896532|9744606|FG008|Months 48-72: Follow-on Phase|Ineligibility Determined|0
6121453|NCT00896532|9744607|FG009|Months 48-72: Follow-on Phase|Ineligibility Determined|0
6121454|NCT00896532|9744608|FG010|Months 48-72: Follow-on Phase|Ineligibility Determined|0
6121455|NCT00896532|9744609|FG011|Months 48-72: Follow-on Phase|Ineligibility Determined|0
6121456|NCT00896532|9744610|FG012|Months 48-72: Follow-on Phase|Ineligibility Determined|0
6121457|NCT00896532|9744611|FG013|Months 48-72: Follow-on Phase|Ineligibility Determined|0
6121458|NCT00896532|9744612|FG014|Months 48-72: Follow-on Phase|Ineligibility Determined|0
6121459|NCT00896532|9744613|FG015|Months 48-72: Follow-on Phase|Ineligibility Determined|0
6121460|NCT00896532|9744614|FG016|Months 48-72: Follow-on Phase|Ineligibility Determined|0
6121461|NCT00896532|9744615|FG017|Months 48-72: Follow-on Phase|Ineligibility Determined|0
6121462|NCT00896532|9744616|FG018|Months 48-72: Follow-on Phase|Ineligibility Determined|0
6121463|NCT00896532|9744617|FG019|Months 48-72: Follow-on Phase|Ineligibility Determined|0
6121464|NCT00896532|9744618|FG020|Months 48-72: Follow-on Phase|Ineligibility Determined|0
6121465|NCT00896532|9744619|FG021|Months 48-72: Follow-on Phase|Ineligibility Determined|1
6121466|NCT00896532|9744620|FG022|Months 48-72: Follow-on Phase|Ineligibility Determined|0
6121467|NCT00896532|9744598|FG000|Months 48-72: Follow-on Phase|Withdrawal by Subject|0
6121468|NCT00896532|9744599|FG001|Months 48-72: Follow-on Phase|Withdrawal by Subject|0
6121469|NCT00896532|9744600|FG002|Months 48-72: Follow-on Phase|Withdrawal by Subject|0
6121470|NCT00896532|9744601|FG003|Months 48-72: Follow-on Phase|Withdrawal by Subject|0
6121471|NCT00896532|9744602|FG004|Months 48-72: Follow-on Phase|Withdrawal by Subject|0
6121472|NCT00896532|9744603|FG005|Months 48-72: Follow-on Phase|Withdrawal by Subject|0
6121473|NCT00896532|9744604|FG006|Months 48-72: Follow-on Phase|Withdrawal by Subject|0
6121474|NCT00896532|9744605|FG007|Months 48-72: Follow-on Phase|Withdrawal by Subject|0
6121475|NCT00896532|9744606|FG008|Months 48-72: Follow-on Phase|Withdrawal by Subject|0
6121476|NCT00896532|9744607|FG009|Months 48-72: Follow-on Phase|Withdrawal by Subject|0
6121477|NCT00896532|9744608|FG010|Months 48-72: Follow-on Phase|Withdrawal by Subject|0
6121478|NCT00896532|9744609|FG011|Months 48-72: Follow-on Phase|Withdrawal by Subject|0
6121479|NCT00896532|9744610|FG012|Months 48-72: Follow-on Phase|Withdrawal by Subject|0
6214687|NCT01611974|9881767|FG002|Overall Study|Physician Decision|2
6214688|NCT01611974|9881765|FG000|Overall Study|Withdrawal by Subject|0
6214689|NCT01611974|9881766|FG001|Overall Study|Withdrawal by Subject|1
6214690|NCT01611974|9881767|FG002|Overall Study|Withdrawal by Subject|4
6214691|NCT01612000|9881779|FG000|Overall Study|Lost to Follow-up|6
6214692|NCT01612000|9881780|FG001|Overall Study|Lost to Follow-up|4
6214693|NCT01612000|9881781|FG002|Overall Study|Lost to Follow-up|4
6214694|NCT01612000|9881782|FG003|Overall Study|Lost to Follow-up|8
6214695|NCT01612000|9881779|FG000|Overall Study|Physician Decision|0
6214696|NCT01612000|9881780|FG001|Overall Study|Physician Decision|0
6121480|NCT00896532|9744611|FG013|Months 48-72: Follow-on Phase|Withdrawal by Subject|0
6214697|NCT01612000|9881781|FG002|Overall Study|Physician Decision|1
6214698|NCT01612000|9881782|FG003|Overall Study|Physician Decision|0
6214699|NCT01612000|9881779|FG000|Overall Study|Withdrawal by Subject|3
6214700|NCT01612000|9881780|FG001|Overall Study|Withdrawal by Subject|1
6214701|NCT01612000|9881781|FG002|Overall Study|Withdrawal by Subject|2
6214702|NCT01612000|9881782|FG003|Overall Study|Withdrawal by Subject|2
6214703|NCT01612156|9881794|FG000|Overall Study|Protocol Violation|2
6214704|NCT01612156|9881795|FG001|Overall Study|Protocol Violation|0
6214705|NCT01612676|9881827|FG000|Overall Study|Adverse Event|2
6214706|NCT01612676|9881828|FG001|Overall Study|Adverse Event|3
6214707|NCT01612676|9881829|FG002|Overall Study|Adverse Event|1
6214708|NCT01612676|9881830|FG003|Overall Study|Adverse Event|3
6214709|NCT01612676|9881827|FG000|Overall Study|Protocol Violation|0
6214710|NCT01612676|9881828|FG001|Overall Study|Protocol Violation|1
6214711|NCT01612676|9881829|FG002|Overall Study|Protocol Violation|0
6214712|NCT01612676|9881830|FG003|Overall Study|Protocol Violation|0
6214713|NCT01612702|9881844|FG000|Overall Study|Protocol Violation|11
6214714|NCT01612702|9881845|FG001|Overall Study|Protocol Violation|11
6214715|NCT01612780|9881876|FG000|Overall Study|Treatment not completed|1
6214716|NCT01612780|9881876|FG000|Overall Study|Withdrawal by Subject|5
6214717|NCT01612858|9881891|FG000|Overall Study|Withdrawal by Subject|5
6121481|NCT00896532|9744612|FG014|Months 48-72: Follow-on Phase|Withdrawal by Subject|0
6121482|NCT00896532|9744613|FG015|Months 48-72: Follow-on Phase|Withdrawal by Subject|0
6121483|NCT00896532|9744614|FG016|Months 48-72: Follow-on Phase|Withdrawal by Subject|0
6121484|NCT00896532|9744615|FG017|Months 48-72: Follow-on Phase|Withdrawal by Subject|0
6121485|NCT00896532|9744616|FG018|Months 48-72: Follow-on Phase|Withdrawal by Subject|0
6121486|NCT00896532|9744617|FG019|Months 48-72: Follow-on Phase|Withdrawal by Subject|0
6121487|NCT00896532|9744618|FG020|Months 48-72: Follow-on Phase|Withdrawal by Subject|0
6121488|NCT00896532|9744619|FG021|Months 48-72: Follow-on Phase|Withdrawal by Subject|1
6121489|NCT00896532|9744620|FG022|Months 48-72: Follow-on Phase|Withdrawal by Subject|0
6121490|NCT00896649|9744667|FG000|Overall Study|Physician Decision|1
6121491|NCT00896649|9744667|FG000|Overall Study|Pregnancy|1
6121492|NCT00896649|9744667|FG000|Overall Study|missing documentation|1
6121493|NCT00896649|9744667|FG000|Overall Study|technical difficulties|2
6121494|NCT00897390|9744681|FG000|Overall Study|Adverse Event|2
6121495|NCT00897390|9744681|FG000|Overall Study|No Longer Met Study Criteria|1
6121496|NCT00897390|9744681|FG000|Overall Study|Personal Reasons|1
6121497|NCT00897390|9744681|FG000|Overall Study|Did not Return for the Clinic Visit|2
6121498|NCT00897715|9744708|FG000|Overall Study|Lost to Follow-up|0
6121499|NCT00897715|9744709|FG001|Overall Study|Lost to Follow-up|1
6121500|NCT00897715|9744708|FG000|Overall Study|Physician Decision|1
6121501|NCT00897715|9744709|FG001|Overall Study|Physician Decision|0
6121502|NCT00897715|9744708|FG000|Overall Study|increased risk of infection|1
6121503|NCT00897715|9744709|FG001|Overall Study|increased risk of infection|0
6121504|NCT00898443|9744725|FG000|Overall Study|Withdrawal by Subject|1
6121505|NCT00898443|9744726|FG001|Overall Study|Withdrawal by Subject|0
6121506|NCT00898807|9744740|FG000|Overall Study|Withdrawal by Subject|5
6121507|NCT00898807|9744741|FG001|Overall Study|Withdrawal by Subject|3
6121508|NCT00898807|9744740|FG000|Overall Study|Family pressure to discontinue|2
6121509|NCT00898807|9744741|FG001|Overall Study|Family pressure to discontinue|2
6121510|NCT00898807|9744740|FG000|Overall Study|Lost to Follow-up|1
6121511|NCT00898807|9744741|FG001|Overall Study|Lost to Follow-up|3
6121512|NCT00898807|9744740|FG000|Overall Study|Death|0
6121513|NCT00898807|9744741|FG001|Overall Study|Death|1
6121514|NCT00899353|9744760|FG000|Overall Study|Adverse Event|2
6121515|NCT00899353|9744760|FG000|Overall Study|Lost to Follow-up|1
6121516|NCT00899353|9744760|FG000|Overall Study|Withdrawal by Subject|2
6121517|NCT00899392|9744783|FG000|Overall Study|Subject didn't finish/partial pilot data|21
6121518|NCT00899392|9744784|FG001|Overall Study|Subject didn't finish/partial pilot data|24
6121519|NCT00899431|9744793|FG000|Overall Study|Physician Decision|1
6121520|NCT00899431|9744794|FG001|Overall Study|Physician Decision|0
6121521|NCT00899431|9744795|FG002|Overall Study|Physician Decision|0
6121522|NCT00899548|9744824|FG000|Overall Study|Physician Decision|3
6121523|NCT00899678|9744848|FG000|Induction Period (Weeks 0 to 6)|Adverse Event|6
6121524|NCT00899678|9744849|FG001|Induction Period (Weeks 0 to 6)|Adverse Event|0
6121525|NCT00899678|9744850|FG002|Induction Period (Weeks 0 to 6)|Adverse Event|0
6121526|NCT00899678|9744848|FG000|Induction Period (Weeks 0 to 6)|Lack of Efficacy|17
6121527|NCT00899678|9744849|FG001|Induction Period (Weeks 0 to 6)|Lack of Efficacy|0
6121528|NCT00899678|9744850|FG002|Induction Period (Weeks 0 to 6)|Lack of Efficacy|0
6121529|NCT00899678|9744848|FG000|Induction Period (Weeks 0 to 6)|Protocol Violation|1
6121530|NCT00899678|9744849|FG001|Induction Period (Weeks 0 to 6)|Protocol Violation|0
6121531|NCT00899678|9744850|FG002|Induction Period (Weeks 0 to 6)|Protocol Violation|0
6121532|NCT00899678|9744848|FG000|Induction Period (Weeks 0 to 6)|Other reason|1
6121533|NCT00899678|9744849|FG001|Induction Period (Weeks 0 to 6)|Other reason|0
6121534|NCT00899678|9744850|FG002|Induction Period (Weeks 0 to 6)|Other reason|0
6121535|NCT00899678|9744848|FG000|Maintenance Period (Weeks 8 to 62)|Adverse Event|0
6121536|NCT00899678|9744849|FG001|Maintenance Period (Weeks 8 to 62)|Adverse Event|10
6121537|NCT00899678|9744850|FG002|Maintenance Period (Weeks 8 to 62)|Adverse Event|5
6121538|NCT00899678|9744848|FG000|Maintenance Period (Weeks 8 to 62)|Lack of Efficacy|0
6121539|NCT00899678|9744849|FG001|Maintenance Period (Weeks 8 to 62)|Lack of Efficacy|11
6121540|NCT00899678|9744850|FG002|Maintenance Period (Weeks 8 to 62)|Lack of Efficacy|18
6121541|NCT00899678|9744848|FG000|Maintenance Period (Weeks 8 to 62)|Protocol Violation|0
6121542|NCT00899678|9744849|FG001|Maintenance Period (Weeks 8 to 62)|Protocol Violation|1
6121543|NCT00899678|9744850|FG002|Maintenance Period (Weeks 8 to 62)|Protocol Violation|1
6121544|NCT00899678|9744848|FG000|Maintenance Period (Weeks 8 to 62)|Withdrawal by Subject|0
6121545|NCT00899678|9744849|FG001|Maintenance Period (Weeks 8 to 62)|Withdrawal by Subject|1
6121546|NCT00899678|9744850|FG002|Maintenance Period (Weeks 8 to 62)|Withdrawal by Subject|2
6121547|NCT00899678|9744848|FG000|Maintenance Period (Weeks 8 to 62)|Other reason|0
6121548|NCT00899678|9744849|FG001|Maintenance Period (Weeks 8 to 62)|Other reason|2
6121549|NCT00899678|9744850|FG002|Maintenance Period (Weeks 8 to 62)|Other reason|2
6214718|NCT01612858|9881892|FG001|Overall Study|Withdrawal by Subject|1
6214719|NCT01613027|9881916|FG000|Overall Study|Lost to Follow-up|5
6214720|NCT01613027|9881916|FG000|Overall Study|Switched Physician|1
6214721|NCT01613027|9881916|FG000|Overall Study|Lack of Efficacy|1
6214722|NCT01613027|9881916|FG000|Overall Study|Patient's Decision Due to Adverse Event|1
6214723|NCT01613131|9881922|FG000|Overall Study|Withdrawal by Subject|3
6121550|NCT00899847|9744873|FG000|Overall Study|Lack of suitable allogeneic donor|2
6121551|NCT00900029|9744884|FG000|Overall Study|Lost to Follow-up|0
6121552|NCT00900029|9744885|FG001|Overall Study|Lost to Follow-up|2
6121553|NCT00900029|9744886|FG002|Overall Study|Lost to Follow-up|1
6121554|NCT00900029|9744887|FG003|Overall Study|Lost to Follow-up|4
6121555|NCT00900029|9744888|FG004|Overall Study|Lost to Follow-up|4
6121556|NCT00900029|9744884|FG000|Overall Study|Withdrawal by Subject|2
6121557|NCT00900029|9744885|FG001|Overall Study|Withdrawal by Subject|2
6121558|NCT00900029|9744886|FG002|Overall Study|Withdrawal by Subject|1
6121559|NCT00900029|9744887|FG003|Overall Study|Withdrawal by Subject|1
6121560|NCT00900029|9744888|FG004|Overall Study|Withdrawal by Subject|1
6121561|NCT00900029|9744884|FG000|Overall Study|Adverse Event|0
6121562|NCT00900029|9744885|FG001|Overall Study|Adverse Event|0
6121563|NCT00900029|9744886|FG002|Overall Study|Adverse Event|1
6121564|NCT00900029|9744887|FG003|Overall Study|Adverse Event|1
6121565|NCT00900029|9744888|FG004|Overall Study|Adverse Event|1
6121566|NCT00900029|9744884|FG000|Overall Study|Death|1
6121567|NCT00900029|9744885|FG001|Overall Study|Death|0
6121568|NCT00900029|9744886|FG002|Overall Study|Death|0
6121569|NCT00900029|9744887|FG003|Overall Study|Death|1
6121570|NCT00900029|9744888|FG004|Overall Study|Death|0
6121571|NCT00900146|9744905|FG000|Dose Finding: Period II (4 Months)|Withdrawal by Subject|2
6121572|NCT00900146|9744906|FG001|Dose Finding: Period II (4 Months)|Withdrawal by Subject|2
6214724|NCT01613131|9881923|FG001|Overall Study|Withdrawal by Subject|5
6214725|NCT01613222|9881929|FG000|Overall Study|Physician Decision|1
6214726|NCT01613222|9881929|FG000|Overall Study|Unable to place arterial line|1
6214727|NCT01613222|9881929|FG000|Overall Study|Reused disposable sensors|10
6214728|NCT01613248|9881948|FG000|Overall Study|Adverse Event|0
6214729|NCT01613248|9881949|FG001|Overall Study|Adverse Event|0
6214730|NCT01613248|9881950|FG002|Overall Study|Adverse Event|0
6214731|NCT01613248|9881951|FG003|Overall Study|Adverse Event|1
6214732|NCT01613248|9881952|FG004|Overall Study|Adverse Event|0
6214733|NCT01613248|9881953|FG005|Overall Study|Adverse Event|0
6214734|NCT01613248|9881948|FG000|Overall Study|Withdrawal by Subject|3
6214735|NCT01613248|9881949|FG001|Overall Study|Withdrawal by Subject|2
6214736|NCT01613248|9881950|FG002|Overall Study|Withdrawal by Subject|2
6214737|NCT01613248|9881951|FG003|Overall Study|Withdrawal by Subject|5
6214738|NCT01613248|9881952|FG004|Overall Study|Withdrawal by Subject|0
6214739|NCT01613248|9881953|FG005|Overall Study|Withdrawal by Subject|1
6214740|NCT01613248|9881948|FG000|Overall Study|Lost to Follow-up|5
6214741|NCT01613248|9881949|FG001|Overall Study|Lost to Follow-up|7
6214742|NCT01613248|9881950|FG002|Overall Study|Lost to Follow-up|4
6214743|NCT01613248|9881951|FG003|Overall Study|Lost to Follow-up|8
6214744|NCT01613248|9881952|FG004|Overall Study|Lost to Follow-up|4
6214745|NCT01613248|9881953|FG005|Overall Study|Lost to Follow-up|2
6214746|NCT01613248|9881948|FG000|Overall Study|Study Terminated by Sponsor|4
6214747|NCT01613248|9881949|FG001|Overall Study|Study Terminated by Sponsor|6
6214748|NCT01613248|9881950|FG002|Overall Study|Study Terminated by Sponsor|8
6214749|NCT01613248|9881951|FG003|Overall Study|Study Terminated by Sponsor|8
6214750|NCT01613248|9881952|FG004|Overall Study|Study Terminated by Sponsor|9
6214751|NCT01613248|9881953|FG005|Overall Study|Study Terminated by Sponsor|11
6214752|NCT01613248|9881948|FG000|Overall Study|Physician Decision|8
6214753|NCT01613248|9881949|FG001|Overall Study|Physician Decision|8
6214754|NCT01613248|9881950|FG002|Overall Study|Physician Decision|9
6214755|NCT01613248|9881951|FG003|Overall Study|Physician Decision|4
6214756|NCT01613248|9881952|FG004|Overall Study|Physician Decision|7
6214757|NCT01613248|9881953|FG005|Overall Study|Physician Decision|6
6214758|NCT01613248|9881948|FG000|Overall Study|Lack of Qualifying Event|9
6214759|NCT01613248|9881949|FG001|Overall Study|Lack of Qualifying Event|11
6214760|NCT01613248|9881950|FG002|Overall Study|Lack of Qualifying Event|10
6214761|NCT01613248|9881951|FG003|Overall Study|Lack of Qualifying Event|11
6214762|NCT01613248|9881952|FG004|Overall Study|Lack of Qualifying Event|15
6214763|NCT01613248|9881953|FG005|Overall Study|Lack of Qualifying Event|18
6214764|NCT01613248|9881948|FG000|Overall Study|Pregnancy|0
6214765|NCT01613248|9881949|FG001|Overall Study|Pregnancy|0
6214766|NCT01613248|9881950|FG002|Overall Study|Pregnancy|0
6214767|NCT01613248|9881951|FG003|Overall Study|Pregnancy|1
6214768|NCT01613248|9881952|FG004|Overall Study|Pregnancy|0
6214769|NCT01613248|9881953|FG005|Overall Study|Pregnancy|0
6214770|NCT01613326|9881986|FG000|Overall Study|Adverse Event|7
6214771|NCT01613326|9881987|FG001|Overall Study|Adverse Event|5
6214772|NCT01613326|9881986|FG000|Overall Study|Withdrawal by Subject|3
6214773|NCT01613326|9881987|FG001|Overall Study|Withdrawal by Subject|4
6214774|NCT01613326|9881986|FG000|Overall Study|Abnormal test procedure result(s)|2
6121573|NCT00900146|9744907|FG002|Dose Finding: Period II (4 Months)|Withdrawal by Subject|5
6121574|NCT00900146|9744908|FG003|Dose Finding: Period II (4 Months)|Withdrawal by Subject|1
6121575|NCT00900146|9744909|FG004|Dose Finding: Period II (4 Months)|Withdrawal by Subject|9
6214775|NCT01613326|9881987|FG001|Overall Study|Abnormal test procedure result(s)|0
6214776|NCT01613326|9881986|FG000|Overall Study|inability to use device|1
6214777|NCT01613326|9881987|FG001|Overall Study|inability to use device|0
6214778|NCT01613326|9881986|FG000|Overall Study|Lack of Efficacy|0
6214779|NCT01613326|9881987|FG001|Overall Study|Lack of Efficacy|1
6214780|NCT01613326|9881986|FG000|Overall Study|Lost to Follow-up|0
6214781|NCT01613326|9881987|FG001|Overall Study|Lost to Follow-up|1
6214782|NCT01613326|9881986|FG000|Overall Study|Administrative|0
6214783|NCT01613326|9881987|FG001|Overall Study|Administrative|2
6214784|NCT01613326|9881986|FG000|Overall Study|Protocol Violation|0
6121576|NCT00900146|9744905|FG000|Dose Finding: Period II (4 Months)|Lost to Follow-up|2
6121577|NCT00900146|9744906|FG001|Dose Finding: Period II (4 Months)|Lost to Follow-up|0
6121578|NCT00900146|9744907|FG002|Dose Finding: Period II (4 Months)|Lost to Follow-up|0
6121579|NCT00900146|9744908|FG003|Dose Finding: Period II (4 Months)|Lost to Follow-up|1
6121580|NCT00900146|9744909|FG004|Dose Finding: Period II (4 Months)|Lost to Follow-up|3
6121581|NCT00900146|9744905|FG000|Dose Finding: Period II (4 Months)|Administrative problems|1
6121582|NCT00900146|9744906|FG001|Dose Finding: Period II (4 Months)|Administrative problems|0
6121583|NCT00900146|9744907|FG002|Dose Finding: Period II (4 Months)|Administrative problems|0
6121584|NCT00900146|9744908|FG003|Dose Finding: Period II (4 Months)|Administrative problems|0
6121585|NCT00900146|9744909|FG004|Dose Finding: Period II (4 Months)|Administrative problems|0
6121586|NCT00900146|9744905|FG000|Intermediate: Period III|Withdrawal by Subject|0
6121587|NCT00900146|9744906|FG001|Intermediate: Period III|Withdrawal by Subject|1
6121588|NCT00900146|9744907|FG002|Intermediate: Period III|Withdrawal by Subject|0
6214785|NCT01613326|9881987|FG001|Overall Study|Protocol Violation|1
6214786|NCT01613378|9882001|FG000|Overall Study|Lack of Efficacy|13
6214787|NCT01613378|9882001|FG000|Overall Study|Adverse Event|11
6214788|NCT01613378|9882001|FG000|Overall Study|Withdrawal by Subject|8
6214789|NCT01613378|9882001|FG000|Overall Study|Death|2
6214790|NCT01613378|9882001|FG000|Overall Study|Lost to Follow-up|1
6214791|NCT01613378|9882001|FG000|Overall Study|Other Reason|4
6214792|NCT01613417|9882007|FG000|Washout (no Second Injection/MRI)|Withdrawal by Subject|13
6214793|NCT01613417|9882008|FG001|Washout (no Second Injection/MRI)|Withdrawal by Subject|7
6214794|NCT01613599|9882024|FG000|Overall Study|Death|9
6214795|NCT01613599|9882024|FG000|Overall Study|Lost to Follow-up|5
6214796|NCT01613599|9882024|FG000|Overall Study|Withdrawal by Subject|8
6214797|NCT01613599|9882024|FG000|Overall Study|Reason not specified|3
6287820|NCT02356588|10000869|FG000|Overall Study|Adverse Event|0
6287821|NCT02356588|10000870|FG001|Overall Study|Adverse Event|2
6287822|NCT02356588|10000869|FG000|Overall Study|Withdrawal by Subject|1
6287823|NCT02356588|10000870|FG001|Overall Study|Withdrawal by Subject|0
6287824|NCT02356588|10000869|FG000|Overall Study|Protocol Violation|0
6287825|NCT02356588|10000870|FG001|Overall Study|Protocol Violation|1
6287826|NCT02356783|10000887|FG000|Overall Study|Lost to Follow-up|1
6287827|NCT02356783|10000888|FG001|Overall Study|Lost to Follow-up|3
6287828|NCT02356887|10000894|FG000|Overall Study|poor compliance|2
6287829|NCT02357134|10000921|FG000|Overall Study|Lost to Follow-up|1
6287830|NCT02357134|10000922|FG001|Overall Study|Lost to Follow-up|0
6287831|NCT02357134|10000923|FG002|Overall Study|Lost to Follow-up|0
6287832|NCT02357134|10000924|FG003|Overall Study|Lost to Follow-up|0
6287833|NCT02357147|10000936|FG000|Combination Treatment Phase|Progressive Disease (Radiographic test)|3
6287834|NCT02357147|10000937|FG001|Combination Treatment Phase|Progressive Disease (Radiographic test)|3
6287835|NCT02357147|10000936|FG000|Combination Treatment Phase|Progressive Disease(Clinical assessment)|0
6287836|NCT02357147|10000937|FG001|Combination Treatment Phase|Progressive Disease(Clinical assessment)|1
6287837|NCT02357147|10000936|FG000|Combination Treatment Phase|Investigator Discretion|1
6287838|NCT02357147|10000937|FG001|Combination Treatment Phase|Investigator Discretion|1
6287839|NCT02357147|10000936|FG000|Combination Treatment Phase|Withdrawal by Subject|4
6287840|NCT02357147|10000937|FG001|Combination Treatment Phase|Withdrawal by Subject|2
6287841|NCT02357147|10000936|FG000|Combination Treatment Phase|Test Article Held (Greater than 21 Days)|4
6287842|NCT02357147|10000937|FG001|Combination Treatment Phase|Test Article Held (Greater than 21 Days)|1
6287843|NCT02357147|10000936|FG000|Combination Treatment Phase|Adverse Event|12
6287844|NCT02357147|10000937|FG001|Combination Treatment Phase|Adverse Event|4
6287845|NCT02357147|10000936|FG000|Combination Treatment Phase|Death|1
6287846|NCT02357147|10000937|FG001|Combination Treatment Phase|Death|1
6287847|NCT02357147|10000936|FG000|Combination Treatment Phase|Sponsor Decision|0
6287848|NCT02357147|10000937|FG001|Combination Treatment Phase|Sponsor Decision|12
6287849|NCT02357147|10000936|FG000|Combination Treatment Phase|Other|1
6287850|NCT02357147|10000937|FG001|Combination Treatment Phase|Other|0
6287851|NCT02357147|10000936|FG000|Combination Treatment Phase|Not treated|0
6287852|NCT02357147|10000937|FG001|Combination Treatment Phase|Not treated|2
6287853|NCT02357147|10000936|FG000|Maintenance Treatment Phase|Progressive Disease (Radiographic test)|15
6287854|NCT02357147|10000937|FG001|Maintenance Treatment Phase|Progressive Disease (Radiographic test)|10
6287855|NCT02357147|10000936|FG000|Maintenance Treatment Phase|Withdrawal by Subject|0
6287856|NCT02357147|10000937|FG001|Maintenance Treatment Phase|Withdrawal by Subject|1
6287857|NCT02357147|10000936|FG000|Maintenance Treatment Phase|Test Article Held (Greater than 21 Days)|10
6287858|NCT02357147|10000937|FG001|Maintenance Treatment Phase|Test Article Held (Greater than 21 Days)|0
6287859|NCT02357147|10000936|FG000|Maintenance Treatment Phase|Adverse Event|0
6287860|NCT02357147|10000937|FG001|Maintenance Treatment Phase|Adverse Event|3
6287861|NCT02357147|10000936|FG000|Maintenance Treatment Phase|Sponsor Decision|0
6287862|NCT02357147|10000937|FG001|Maintenance Treatment Phase|Sponsor Decision|15
6287863|NCT02357147|10000936|FG000|Maintenance Treatment Phase|Not Treated|1
6287864|NCT02357147|10000937|FG001|Maintenance Treatment Phase|Not Treated|0
6287865|NCT02357342|10000975|FG000|First 6 Months|Death|2
6287866|NCT02357342|10000976|FG001|First 6 Months|Death|0
6287867|NCT02357368|10000986|FG000|Overall Study|Lost to Follow-up|0
6287868|NCT02357368|10000987|FG001|Overall Study|Lost to Follow-up|0
6287869|NCT02357368|10000988|FG002|Overall Study|Lost to Follow-up|0
6287870|NCT02357368|10000989|FG003|Overall Study|Lost to Follow-up|1
6121589|NCT00900146|9744908|FG003|Intermediate: Period III|Withdrawal by Subject|0
6121590|NCT00900146|9744909|FG004|Intermediate: Period III|Withdrawal by Subject|3
6121591|NCT00900146|9744905|FG000|Intermediate: Period III|Lost to Follow-up|2
6121592|NCT00900146|9744906|FG001|Intermediate: Period III|Lost to Follow-up|0
6121593|NCT00900146|9744907|FG002|Intermediate: Period III|Lost to Follow-up|0
6121594|NCT00900146|9744908|FG003|Intermediate: Period III|Lost to Follow-up|0
6121595|NCT00900146|9744909|FG004|Intermediate: Period III|Lost to Follow-up|1
6121596|NCT00900146|9744905|FG000|Intermediate: Period III|Administrative problems|85
6121597|NCT00900146|9744906|FG001|Intermediate: Period III|Administrative problems|92
6121598|NCT00900146|9744907|FG002|Intermediate: Period III|Administrative problems|84
6121599|NCT00900146|9744908|FG003|Intermediate: Period III|Administrative problems|90
6121600|NCT00900146|9744909|FG004|Intermediate: Period III|Administrative problems|163
6121601|NCT00900159|9744923|FG000|Second Intervention|disempanelled for inappropriate behavior|1
6121602|NCT00900159|9744924|FG001|Second Intervention|disempanelled for inappropriate behavior|0
6121603|NCT00900562|9744941|FG000|Overall Study|Progressive disease|9
6121604|NCT00900562|9744942|FG001|Overall Study|Progressive disease|5
6121605|NCT00900562|9744941|FG000|Overall Study|Toxicity|1
6121606|NCT00900562|9744942|FG001|Overall Study|Toxicity|0
6121607|NCT00900562|9744941|FG000|Overall Study|Death|1
6121608|NCT00900562|9744942|FG001|Overall Study|Death|1
6121609|NCT00900562|9744941|FG000|Overall Study|Withdrawal by Subject|0
6121610|NCT00900562|9744942|FG001|Overall Study|Withdrawal by Subject|1
6121611|NCT00900562|9744941|FG000|Overall Study|Unrelated adverse event|1
6121612|NCT00900562|9744942|FG001|Overall Study|Unrelated adverse event|0
6121613|NCT00900601|9744949|FG000|Overall Study|Physician Decision|1
6121614|NCT00900627|9744959|FG000|Overall Study|Condition under investigation worsened|4
6121615|NCT00900627|9744960|FG001|Overall Study|Condition under investigation worsened|0
6121616|NCT00900627|9744961|FG002|Overall Study|Condition under investigation worsened|5
6121617|NCT00900627|9744962|FG003|Overall Study|Condition under investigation worsened|3
6121618|NCT00900627|9744963|FG004|Overall Study|Condition under investigation worsened|0
6121619|NCT00900627|9744964|FG005|Overall Study|Condition under investigation worsened|0
6121620|NCT00900627|9744959|FG000|Overall Study|Withdrawal by Subject|1
6121621|NCT00900627|9744960|FG001|Overall Study|Withdrawal by Subject|0
6121622|NCT00900627|9744961|FG002|Overall Study|Withdrawal by Subject|1
6121623|NCT00900627|9744962|FG003|Overall Study|Withdrawal by Subject|0
6121624|NCT00900627|9744963|FG004|Overall Study|Withdrawal by Subject|1
6121625|NCT00900627|9744964|FG005|Overall Study|Withdrawal by Subject|2
6121626|NCT00900627|9744959|FG000|Overall Study|Adverse Event|1
6121627|NCT00900627|9744960|FG001|Overall Study|Adverse Event|2
6121628|NCT00900627|9744961|FG002|Overall Study|Adverse Event|0
6121629|NCT00900627|9744962|FG003|Overall Study|Adverse Event|3
6121630|NCT00900627|9744963|FG004|Overall Study|Adverse Event|0
6121631|NCT00900627|9744964|FG005|Overall Study|Adverse Event|0
6121632|NCT00900627|9744959|FG000|Overall Study|Death|0
6121633|NCT00900627|9744960|FG001|Overall Study|Death|0
6121634|NCT00900627|9744961|FG002|Overall Study|Death|0
6121635|NCT00900627|9744962|FG003|Overall Study|Death|0
6121636|NCT00900627|9744963|FG004|Overall Study|Death|28
6121637|NCT00900627|9744964|FG005|Overall Study|Death|24
6121638|NCT00900731|9744989|FG000|Overall Study|Adverse Event|31
6121639|NCT00900731|9744990|FG001|Overall Study|Adverse Event|27
6121640|NCT00900731|9744989|FG000|Overall Study|Withdrawal by Subject|8
6121641|NCT00900731|9744990|FG001|Overall Study|Withdrawal by Subject|7
6121642|NCT00900731|9744989|FG000|Overall Study|Protocol Deviation|8
6121643|NCT00900731|9744990|FG001|Overall Study|Protocol Deviation|11
6121644|NCT00900731|9744989|FG000|Overall Study|Administrative Problems|5
6121645|NCT00900731|9744990|FG001|Overall Study|Administrative Problems|4
6121646|NCT00900731|9744989|FG000|Overall Study|Abnormal Test Procedure Result(s)|3
6121647|NCT00900731|9744990|FG001|Overall Study|Abnormal Test Procedure Result(s)|0
6121648|NCT00900731|9744989|FG000|Overall Study|Abnormal Laboratory Value(s)|2
6121649|NCT00900731|9744990|FG001|Overall Study|Abnormal Laboratory Value(s)|4
6121650|NCT00900731|9744989|FG000|Overall Study|Lost to Follow-up|2
6121651|NCT00900731|9744990|FG001|Overall Study|Lost to Follow-up|3
6121652|NCT00900731|9744989|FG000|Overall Study|Lack of Efficacy|1
6121653|NCT00900731|9744990|FG001|Overall Study|Lack of Efficacy|3
6121654|NCT00900731|9744989|FG000|Overall Study|Death|0
6121655|NCT00900731|9744990|FG001|Overall Study|Death|2
6121656|NCT00900757|9744996|FG000|Overall Study|screen failure|19
6121657|NCT00900796|9745000|FG000|Phase 1|Lacked sufficient information|4
6121658|NCT00900796|9745000|FG000|Phase 1|Missing information at Week 16|7
6121659|NCT00900796|9745000|FG000|Between Phase 1 and Phase 2|Responded to therapy- ineligible for Ph2|110
6121660|NCT00900796|9745000|FG000|Phase 2|Lost to Follow-up|5
6121661|NCT00901186|9745021|FG000|Overall Study|Lack of Efficacy|0
6121662|NCT00901186|9745022|FG001|Overall Study|Lack of Efficacy|1
6121663|NCT00901186|9745021|FG000|Overall Study|Abnormal laboratory values|0
6121664|NCT00901186|9745022|FG001|Overall Study|Abnormal laboratory values|1
6121665|NCT00901186|9745021|FG000|Overall Study|Lost to Follow-up|2
6121666|NCT00901186|9745022|FG001|Overall Study|Lost to Follow-up|0
6121667|NCT00901186|9745021|FG000|Overall Study|Adverse Event|2
6121668|NCT00901186|9745022|FG001|Overall Study|Adverse Event|4
6121669|NCT00901186|9745021|FG000|Overall Study|Administration problems|0
6121670|NCT00901186|9745022|FG001|Overall Study|Administration problems|1
6121671|NCT00901186|9745021|FG000|Overall Study|Protocol deviations|5
6121672|NCT00901186|9745022|FG001|Overall Study|Protocol deviations|4
6121673|NCT00901342|9745045|FG000|Overall Study|Adverse Event|1
6121674|NCT00901342|9745045|FG000|Overall Study|Death|4
6121675|NCT00901342|9745045|FG000|Overall Study|Disease progression|1
6121676|NCT00901342|9745045|FG000|Overall Study|Withdrawal by Subject|9
6121677|NCT00901394|9745052|FG000|Overall Study|Physician Decision|1
6214798|NCT01613716|9882028|FG000|Overall Study|screen failures|3
6214799|NCT01613716|9882028|FG000|Overall Study|Lost to Follow-up|4
6214800|NCT01614093|9882037|FG000|Overall Study|Withdrawal by Subject|1
6214801|NCT01614249|9882048|FG000|Overall Study|Lost to Follow-up|11
6214802|NCT01614249|9882049|FG001|Overall Study|Lost to Follow-up|23
6214803|NCT01614457|9882066|FG000|Overall Study|Non-Compliance|1
6214804|NCT01614457|9882067|FG001|Overall Study|Non-Compliance|0
6214805|NCT01614457|9882066|FG000|Overall Study|Pregnancy (Self or Partner)|1
6214806|NCT01614457|9882067|FG001|Overall Study|Pregnancy (Self or Partner)|0
6214807|NCT01614470|9882075|FG000|Part 1: Treatment Period 1 (8 Weeks)|Lost to Follow-up|1
6214808|NCT01614470|9882076|FG001|Part 1: Treatment Period 1 (8 Weeks)|Lost to Follow-up|0
6214809|NCT01614470|9882077|FG002|Part 1: Treatment Period 1 (8 Weeks)|Lost to Follow-up|0
6214810|NCT01614470|9882075|FG000|Part 1: Treatment Period 1 (8 Weeks)|Need to extend washout period|1
6214811|NCT01614470|9882076|FG001|Part 1: Treatment Period 1 (8 Weeks)|Need to extend washout period|1
6214812|NCT01614470|9882077|FG002|Part 1: Treatment Period 1 (8 Weeks)|Need to extend washout period|0
6214813|NCT01614600|9882099|FG000|Overall Study|Unacceptable fit|1
6214814|NCT01614600|9882099|FG000|Overall Study|Discomfort|1
6214815|NCT01614600|9882099|FG000|Overall Study|Unable to remove lens at the end of day|1
6214816|NCT01614600|9882099|FG000|Overall Study|Protocol deviation|1
6214817|NCT01614769|9882117|FG000|Period 1|Discontinued due to Hypoglycemia|0
6214818|NCT01614769|9882118|FG001|Period 1|Discontinued due to Hypoglycemia|0
6214819|NCT01614769|9882119|FG002|Period 1|Discontinued due to Hypoglycemia|0
6214820|NCT01614769|9882120|FG003|Period 1|Discontinued due to Hypoglycemia|1
6214821|NCT01614769|9882121|FG004|Period 1|Discontinued due to Hypoglycemia|0
6214822|NCT01614769|9882122|FG005|Period 1|Discontinued due to Hypoglycemia|1
6214823|NCT01614769|9882117|FG000|Period 1|Protocol Violation|0
6214824|NCT01614769|9882118|FG001|Period 1|Protocol Violation|0
6214825|NCT01614769|9882119|FG002|Period 1|Protocol Violation|0
6214826|NCT01614769|9882120|FG003|Period 1|Protocol Violation|1
6214827|NCT01614769|9882121|FG004|Period 1|Protocol Violation|0
6121678|NCT00901394|9745053|FG001|Overall Study|Physician Decision|1
6121679|NCT00901394|9745054|FG002|Overall Study|Physician Decision|2
6121680|NCT00901459|9745062|FG000|Overall Study|Withdrawal by Subject|6
6121681|NCT00901485|9745073|FG000|Overall Study|Lack of Efficacy|0
6121682|NCT00901485|9745074|FG001|Overall Study|Lack of Efficacy|2
6121683|NCT00901485|9745073|FG000|Overall Study|Withdrawal by Subject|1
6121684|NCT00901485|9745074|FG001|Overall Study|Withdrawal by Subject|2
6121685|NCT00901576|9745086|FG000|Second Intervention|Withdrawal by Subject|0
6121686|NCT00901576|9745087|FG001|Second Intervention|Withdrawal by Subject|0
6121687|NCT00901576|9745088|FG002|Second Intervention|Withdrawal by Subject|0
6121688|NCT00901576|9745089|FG003|Second Intervention|Withdrawal by Subject|1
6121689|NCT00901576|9745090|FG004|Second Intervention|Withdrawal by Subject|0
6121690|NCT00901576|9745091|FG005|Second Intervention|Withdrawal by Subject|1
6121691|NCT00901576|9745086|FG000|Second Intervention|Physician Decision|1
6121692|NCT00901576|9745087|FG001|Second Intervention|Physician Decision|0
6214828|NCT01614769|9882122|FG005|Period 1|Protocol Violation|0
6287871|NCT02357368|10000986|FG000|Overall Study|Pregnancy|3
6287872|NCT02357368|10000987|FG001|Overall Study|Pregnancy|2
6287873|NCT02357368|10000988|FG002|Overall Study|Pregnancy|0
6287874|NCT02357368|10000989|FG003|Overall Study|Pregnancy|0
6287875|NCT02357368|10000986|FG000|Overall Study|Withdrawal by Subject|3
6287876|NCT02357368|10000987|FG001|Overall Study|Withdrawal by Subject|1
6287877|NCT02357368|10000988|FG002|Overall Study|Withdrawal by Subject|1
6287878|NCT02357368|10000989|FG003|Overall Study|Withdrawal by Subject|2
6287879|NCT02357420|10001012|FG000|Overall Study|Adverse Event|3
6287880|NCT02357420|10001013|FG001|Overall Study|Adverse Event|3
6287881|NCT02357420|10001014|FG002|Overall Study|Adverse Event|8
6287882|NCT02357420|10001015|FG003|Overall Study|Adverse Event|9
6287883|NCT02357420|10001012|FG000|Overall Study|Investigator Decision|1
6287884|NCT02357420|10001013|FG001|Overall Study|Investigator Decision|0
6287885|NCT02357420|10001014|FG002|Overall Study|Investigator Decision|0
6287886|NCT02357420|10001015|FG003|Overall Study|Investigator Decision|0
6287887|NCT02357420|10001012|FG000|Overall Study|Prohibited Medication|1
6287888|NCT02357420|10001013|FG001|Overall Study|Prohibited Medication|1
6287889|NCT02357420|10001014|FG002|Overall Study|Prohibited Medication|0
6287890|NCT02357420|10001015|FG003|Overall Study|Prohibited Medication|0
5980857|NCT01434602|9569526|FG003|Phase II Recommended Phase 2 Dose|Physician Decision|1
6121693|NCT00901576|9745088|FG002|Second Intervention|Physician Decision|0
6121694|NCT00901576|9745089|FG003|Second Intervention|Physician Decision|0
6214829|NCT01614769|9882117|FG000|Period 1|Withdrawal by Subject|1
6214830|NCT01614769|9882118|FG001|Period 1|Withdrawal by Subject|0
6214831|NCT01614769|9882119|FG002|Period 1|Withdrawal by Subject|0
6214832|NCT01614769|9882120|FG003|Period 1|Withdrawal by Subject|0
6214833|NCT01614769|9882121|FG004|Period 1|Withdrawal by Subject|0
6287891|NCT02357420|10001012|FG000|Overall Study|Protocol Non-compliance|0
6287892|NCT02357420|10001013|FG001|Overall Study|Protocol Non-compliance|0
6121695|NCT00901576|9745090|FG004|Second Intervention|Physician Decision|0
6121696|NCT00901576|9745091|FG005|Second Intervention|Physician Decision|0
6121697|NCT00901628|9745101|FG000|Overall Study|disconnection of catheter|4
6121698|NCT00901628|9745102|FG001|Overall Study|disconnection of catheter|8
6121699|NCT00901628|9745101|FG000|Overall Study|disconnection of drain|0
6121700|NCT00901628|9745102|FG001|Overall Study|disconnection of drain|1
6121701|NCT00901628|9745101|FG000|Overall Study|peroneal nerve palsy|0
6121702|NCT00901628|9745102|FG001|Overall Study|peroneal nerve palsy|1
6121703|NCT00901901|9745110|FG000|Treatment Period|Adverse Event|120
6121704|NCT00901901|9745111|FG001|Treatment Period|Adverse Event|128
6121705|NCT00901901|9745110|FG000|Treatment Period|Withdrawal by Subject|26
6121706|NCT00901901|9745111|FG001|Treatment Period|Withdrawal by Subject|24
6121707|NCT00901901|9745110|FG000|Treatment Period|Physician Decision|2
6121708|NCT00901901|9745111|FG001|Treatment Period|Physician Decision|2
6121709|NCT00901901|9745110|FG000|Treatment Period|Lost to Follow-up|3
6121710|NCT00901901|9745111|FG001|Treatment Period|Lost to Follow-up|5
6121711|NCT00901901|9745110|FG000|Treatment Period|Noncompliance with study medication|4
6121712|NCT00901901|9745111|FG001|Treatment Period|Noncompliance with study medication|1
6121713|NCT00901901|9745110|FG000|Treatment Period|Missing|1
6121714|NCT00901901|9745111|FG001|Treatment Period|Missing|0
6121715|NCT00901901|9745110|FG000|Treatment Period|Never treated|0
6121716|NCT00901901|9745111|FG001|Treatment Period|Never treated|3
6121717|NCT00901901|9745110|FG000|Treatment Period|Protocol driven decision point|0
6121718|NCT00901901|9745111|FG001|Treatment Period|Protocol driven decision point|2
6121719|NCT00901901|9745110|FG000|Treatment Period|Study terminated by sponsor|2
6214834|NCT01614769|9882122|FG005|Period 1|Withdrawal by Subject|0
6214835|NCT01614769|9882117|FG000|Period 3|Withdrawal by Subject|0
6214836|NCT01614769|9882118|FG001|Period 3|Withdrawal by Subject|0
6214837|NCT01614769|9882119|FG002|Period 3|Withdrawal by Subject|1
6214838|NCT01614769|9882120|FG003|Period 3|Withdrawal by Subject|0
6214839|NCT01614769|9882121|FG004|Period 3|Withdrawal by Subject|0
6214840|NCT01614769|9882122|FG005|Period 3|Withdrawal by Subject|0
6214841|NCT01614795|9882134|FG000|Overall Study|Adverse Event|0
6214842|NCT01614795|9882135|FG001|Overall Study|Adverse Event|0
6214843|NCT01614795|9882136|FG002|Overall Study|Adverse Event|1
6214844|NCT01614795|9882137|FG003|Overall Study|Adverse Event|1
6214845|NCT01614795|9882134|FG000|Overall Study|Lack of Efficacy|10
6214846|NCT01614795|9882135|FG001|Overall Study|Lack of Efficacy|10
6214847|NCT01614795|9882136|FG002|Overall Study|Lack of Efficacy|9
6214848|NCT01614795|9882137|FG003|Overall Study|Lack of Efficacy|8
6214849|NCT01614795|9882134|FG000|Overall Study|Physician Decision|1
6214850|NCT01614795|9882135|FG001|Overall Study|Physician Decision|0
6214851|NCT01614795|9882136|FG002|Overall Study|Physician Decision|1
6214852|NCT01614795|9882137|FG003|Overall Study|Physician Decision|1
6214853|NCT01614795|9882134|FG000|Overall Study|Withdrawal by Subject|0
6214854|NCT01614795|9882135|FG001|Overall Study|Withdrawal by Subject|1
6214855|NCT01614795|9882136|FG002|Overall Study|Withdrawal by Subject|0
6214856|NCT01614795|9882137|FG003|Overall Study|Withdrawal by Subject|2
6214857|NCT01614795|9882134|FG000|Overall Study|Ineligible|0
6214858|NCT01614795|9882135|FG001|Overall Study|Ineligible|1
6214859|NCT01614795|9882136|FG002|Overall Study|Ineligible|0
6214860|NCT01614795|9882137|FG003|Overall Study|Ineligible|0
6214861|NCT01614886|9882168|FG000|Overall Study|Adverse Event|15
6214862|NCT01614886|9882169|FG001|Overall Study|Adverse Event|20
6214863|NCT01614886|9882168|FG000|Overall Study|Withdrawal by Subject|4
6214864|NCT01614886|9882169|FG001|Overall Study|Withdrawal by Subject|4
6214865|NCT01614886|9882168|FG000|Overall Study|Death|1
6214866|NCT01614886|9882169|FG001|Overall Study|Death|0
6214867|NCT01614886|9882168|FG000|Overall Study|Protocol deviation|0
6214868|NCT01614886|9882169|FG001|Overall Study|Protocol deviation|2
6214869|NCT01614925|9882177|FG000|Overall Study|Withdrawal by Subject|1
6214870|NCT01614925|9882178|FG001|Overall Study|Withdrawal by Subject|0
6214871|NCT01614925|9882177|FG000|Overall Study|Protocol Violation|3
6214872|NCT01614925|9882178|FG001|Overall Study|Protocol Violation|2
6214873|NCT01615198|9882195|FG000|Overall Study|Withdrawal by Subject|5
6214874|NCT01615198|9882196|FG001|Overall Study|Withdrawal by Subject|5
6214875|NCT01615198|9882195|FG000|Overall Study|Protocol deviation|1
6214876|NCT01615198|9882196|FG001|Overall Study|Protocol deviation|1
6214877|NCT01615198|9882195|FG000|Overall Study|Physician Decision|5
6214878|NCT01615198|9882196|FG001|Overall Study|Physician Decision|1
6214879|NCT01615198|9882195|FG000|Overall Study|Lost to Follow-up|1
6214880|NCT01615198|9882196|FG001|Overall Study|Lost to Follow-up|1
6214881|NCT01615198|9882195|FG000|Overall Study|Lack of Efficacy|1
6214882|NCT01615198|9882196|FG001|Overall Study|Lack of Efficacy|6
6214883|NCT01615198|9882195|FG000|Overall Study|Adverse Event|11
6214884|NCT01615198|9882196|FG001|Overall Study|Adverse Event|5
6214885|NCT01615263|9882204|FG000|Overall Study|Post-randomization exclusion|0
6214886|NCT01615263|9882205|FG001|Overall Study|Post-randomization exclusion|2
6214887|NCT01615328|9882213|FG000|Overall Study|Lost to Follow-up|3
6121720|NCT00901901|9745111|FG001|Treatment Period|Study terminated by sponsor|0
6121721|NCT00901901|9745110|FG000|Treatment Period|Protocol Violation|5
6121722|NCT00901901|9745111|FG001|Treatment Period|Protocol Violation|9
6214888|NCT01615328|9882214|FG001|Overall Study|Lost to Follow-up|5
6214889|NCT01615822|9882258|FG000|Period 1|Withdrawal by Subject|0
6214890|NCT01615822|9882259|FG001|Period 1|Withdrawal by Subject|1
6121723|NCT00901901|9745110|FG000|Treatment Period|Switch to commercial drug|1
6121724|NCT00901901|9745111|FG001|Treatment Period|Switch to commercial drug|1
6121725|NCT00901901|9745110|FG000|Treatment Period|Transfer to treatment continuation study|5
6121726|NCT00901901|9745111|FG001|Treatment Period|Transfer to treatment continuation study|2
6121727|NCT00901901|9745110|FG000|Follow-up Period|Death|181
6121728|NCT00901901|9745111|FG001|Follow-up Period|Death|208
6121729|NCT00901901|9745110|FG000|Follow-up Period|Protocol driven decision point|47
6121730|NCT00901901|9745111|FG001|Follow-up Period|Protocol driven decision point|36
6121731|NCT00901901|9745110|FG000|Follow-up Period|Withdrawal by Subject|6
6121732|NCT00901901|9745111|FG001|Follow-up Period|Withdrawal by Subject|9
6121733|NCT00901901|9745110|FG000|Follow-up Period|Lost to Follow-up|12
6121734|NCT00901901|9745111|FG001|Follow-up Period|Lost to Follow-up|8
6121735|NCT00901901|9745110|FG000|Follow-up Period|Missing|94
6121736|NCT00901901|9745111|FG001|Follow-up Period|Missing|80
6121737|NCT00901927|9745119|FG000|Overall Study|Lack of Efficacy|1
6121738|NCT00901927|9745119|FG000|Overall Study|Protocol Violation|3
6121739|NCT00901927|9745119|FG000|Overall Study|Withdrawal by Subject|2
6121740|NCT00902174|9745158|FG000|Overall Study|Adverse Event|27
6121741|NCT00902174|9745159|FG001|Overall Study|Adverse Event|7
6121742|NCT00902174|9745158|FG000|Overall Study|Lack of Efficacy|1
6121743|NCT00902174|9745159|FG001|Overall Study|Lack of Efficacy|5
6121744|NCT00902174|9745158|FG000|Overall Study|Death|2
6121745|NCT00902174|9745159|FG001|Overall Study|Death|2
6121746|NCT00902174|9745158|FG000|Overall Study|Withdrawal by Subject|2
6121747|NCT00902174|9745159|FG001|Overall Study|Withdrawal by Subject|1
6121748|NCT00902174|9745158|FG000|Overall Study|Abnormal labs|1
6121749|NCT00902174|9745159|FG001|Overall Study|Abnormal labs|1
6121750|NCT00902174|9745158|FG000|Overall Study|Protocol Violation|1
6121751|NCT00902174|9745159|FG001|Overall Study|Protocol Violation|1
6121752|NCT00902174|9745158|FG000|Overall Study|Administration problem|0
6121753|NCT00902174|9745159|FG001|Overall Study|Administration problem|1
6121754|NCT00902265|9745172|FG000|Overall Study|Lost to Follow-up Prior to First Visit|1
6121755|NCT00902265|9745172|FG000|Overall Study|Adverse Event|2
6121756|NCT00902265|9745172|FG000|Overall Study|Lack of Efficacy|2
6121757|NCT00902265|9745172|FG000|Overall Study|Protocol Violation|1
6121758|NCT00902278|9745181|FG000|Overall Study|Physician Decision|1
6121759|NCT00902278|9745182|FG001|Overall Study|Physician Decision|0
6121760|NCT00902278|9745183|FG002|Overall Study|Physician Decision|2
6121761|NCT00902278|9745184|FG003|Overall Study|Physician Decision|0
6121762|NCT00902278|9745185|FG004|Overall Study|Physician Decision|1
6121763|NCT00902278|9745181|FG000|Overall Study|Lost to Follow-up|3
6121764|NCT00902278|9745182|FG001|Overall Study|Lost to Follow-up|2
6121765|NCT00902278|9745183|FG002|Overall Study|Lost to Follow-up|3
6121766|NCT00902278|9745184|FG003|Overall Study|Lost to Follow-up|0
6121767|NCT00902278|9745185|FG004|Overall Study|Lost to Follow-up|1
6121768|NCT00902304|9745200|FG000|Overall Study|Adverse Event|4
6121769|NCT00902304|9745201|FG001|Overall Study|Adverse Event|10
6121770|NCT00902304|9745202|FG002|Overall Study|Adverse Event|25
6121771|NCT00902304|9745200|FG000|Overall Study|Investigator discretion|3
6121772|NCT00902304|9745201|FG001|Overall Study|Investigator discretion|5
6121773|NCT00902304|9745202|FG002|Overall Study|Investigator discretion|13
6121774|NCT00902304|9745200|FG000|Overall Study|Lost to Follow-up|7
6214891|NCT01615822|9882260|FG002|Period 1|Withdrawal by Subject|0
6214892|NCT01615822|9882258|FG000|Period 1|Adverse Event|1
6214893|NCT01615822|9882259|FG001|Period 1|Adverse Event|1
6214894|NCT01615822|9882260|FG002|Period 1|Adverse Event|0
6214895|NCT01615822|9882258|FG000|Period 2|Lost to Follow-up|0
6214896|NCT01615822|9882259|FG001|Period 2|Lost to Follow-up|1
6214897|NCT01615822|9882260|FG002|Period 2|Lost to Follow-up|2
6214898|NCT01615939|9882273|FG000|Overall Study|Lost to Follow-up|5
6214899|NCT01615939|9882274|FG001|Overall Study|Lost to Follow-up|0
6214900|NCT01616173|9882301|FG000|Overall Study|Lost to Follow-up|0
6214901|NCT01616173|9882302|FG001|Overall Study|Lost to Follow-up|2
6214902|NCT01616173|9882303|FG002|Overall Study|Lost to Follow-up|0
6214903|NCT01616459|9882315|FG000|Overall Study|Adverse Event|1
6214904|NCT01616459|9882316|FG001|Overall Study|Adverse Event|1
6214905|NCT01616459|9882317|FG002|Overall Study|Adverse Event|2
6214906|NCT01616459|9882318|FG003|Overall Study|Adverse Event|0
6214907|NCT01616459|9882315|FG000|Overall Study|Lost to Follow-up|1
6121775|NCT00902304|9745201|FG001|Overall Study|Lost to Follow-up|7
6121776|NCT00902304|9745202|FG002|Overall Study|Lost to Follow-up|7
6121777|NCT00902304|9745200|FG000|Overall Study|Protocol Violation|9
6121778|NCT00902304|9745201|FG001|Overall Study|Protocol Violation|18
6121779|NCT00902304|9745202|FG002|Overall Study|Protocol Violation|20
6121780|NCT00902304|9745200|FG000|Overall Study|Withdrawal by Subject|32
6121781|NCT00902304|9745201|FG001|Overall Study|Withdrawal by Subject|22
6121782|NCT00902304|9745202|FG002|Overall Study|Withdrawal by Subject|43
6121783|NCT00902304|9745200|FG000|Overall Study|includes pregnancy|3
6121784|NCT00902304|9745201|FG001|Overall Study|includes pregnancy|9
6121785|NCT00902304|9745202|FG002|Overall Study|includes pregnancy|2
6121786|NCT00902330|9745213|FG000|Overall Study|Too overwhelmed by treatment|2
6121787|NCT00902330|9745214|FG001|Overall Study|Too overwhelmed by treatment|5
6214908|NCT01616459|9882316|FG001|Overall Study|Lost to Follow-up|11
6121788|NCT00902330|9745213|FG000|Overall Study|Adverse Event|1
6121789|NCT00902330|9745214|FG001|Overall Study|Adverse Event|0
6214909|NCT01616459|9882317|FG002|Overall Study|Lost to Follow-up|3
6121790|NCT00902330|9745213|FG000|Overall Study|No post baseline data|1
6121791|NCT00902330|9745214|FG001|Overall Study|No post baseline data|0
6121792|NCT00902486|9745227|FG000|Treatment Period (Weeks 0 Through 12)|Adverse Event|1
6121793|NCT00902486|9745228|FG001|Treatment Period (Weeks 0 Through 12)|Adverse Event|0
6121794|NCT00902486|9745229|FG002|Treatment Period (Weeks 0 Through 12)|Adverse Event|0
6121795|NCT00902486|9745230|FG003|Treatment Period (Weeks 0 Through 12)|Adverse Event|1
6121796|NCT00902486|9745231|FG004|Treatment Period (Weeks 0 Through 12)|Adverse Event|1
6121797|NCT00902486|9745232|FG005|Treatment Period (Weeks 0 Through 12)|Adverse Event|2
6121798|NCT00902486|9745227|FG000|Treatment Period (Weeks 0 Through 12)|Consent Withdrawn|1
6121799|NCT00902486|9745228|FG001|Treatment Period (Weeks 0 Through 12)|Consent Withdrawn|0
6121800|NCT00902486|9745229|FG002|Treatment Period (Weeks 0 Through 12)|Consent Withdrawn|0
6121801|NCT00902486|9745230|FG003|Treatment Period (Weeks 0 Through 12)|Consent Withdrawn|0
6121802|NCT00902486|9745231|FG004|Treatment Period (Weeks 0 Through 12)|Consent Withdrawn|0
6121803|NCT00902486|9745232|FG005|Treatment Period (Weeks 0 Through 12)|Consent Withdrawn|2
6121804|NCT00902486|9745227|FG000|Treatment Period (Weeks 0 Through 12)|Protocol Deviation|0
6121805|NCT00902486|9745228|FG001|Treatment Period (Weeks 0 Through 12)|Protocol Deviation|0
6121806|NCT00902486|9745229|FG002|Treatment Period (Weeks 0 Through 12)|Protocol Deviation|0
6121807|NCT00902486|9745230|FG003|Treatment Period (Weeks 0 Through 12)|Protocol Deviation|0
6121808|NCT00902486|9745231|FG004|Treatment Period (Weeks 0 Through 12)|Protocol Deviation|1
6121809|NCT00902486|9745232|FG005|Treatment Period (Weeks 0 Through 12)|Protocol Deviation|1
6121810|NCT00902486|9745227|FG000|Treatment Period (Weeks 0 Through 12)|Lost to Follow-up|0
6214910|NCT01616459|9882318|FG003|Overall Study|Lost to Follow-up|2
6214911|NCT01616459|9882315|FG000|Overall Study|Protocol Violation|0
6214912|NCT01616459|9882316|FG001|Overall Study|Protocol Violation|0
6214913|NCT01616459|9882317|FG002|Overall Study|Protocol Violation|0
6214914|NCT01616459|9882318|FG003|Overall Study|Protocol Violation|2
6214915|NCT01616459|9882315|FG000|Overall Study|Withdrawal by Subject|2
6214916|NCT01616459|9882316|FG001|Overall Study|Withdrawal by Subject|4
6214917|NCT01616459|9882317|FG002|Overall Study|Withdrawal by Subject|4
6214918|NCT01616459|9882318|FG003|Overall Study|Withdrawal by Subject|4
6214919|NCT01616459|9882315|FG000|Overall Study|Other reason|0
6214920|NCT01616459|9882316|FG001|Overall Study|Other reason|1
6214921|NCT01616459|9882317|FG002|Overall Study|Other reason|1
6214922|NCT01616459|9882318|FG003|Overall Study|Other reason|0
6214923|NCT01616563|9882333|FG000|Overall Study|Lost to Follow-up|40
6214924|NCT01616654|9882355|FG000|Overall Study|Lack of Efficacy|1
6214925|NCT01616654|9882356|FG001|Overall Study|Lack of Efficacy|0
6214926|NCT01616654|9882357|FG002|Overall Study|Lack of Efficacy|0
6214927|NCT01616654|9882358|FG003|Overall Study|Lack of Efficacy|0
6214928|NCT01616654|9882359|FG004|Overall Study|Lack of Efficacy|1
6214929|NCT01616654|9882355|FG000|Overall Study|Adverse Event|0
6214930|NCT01616654|9882356|FG001|Overall Study|Adverse Event|1
6214931|NCT01616654|9882357|FG002|Overall Study|Adverse Event|2
6214932|NCT01616654|9882358|FG003|Overall Study|Adverse Event|1
6214933|NCT01616654|9882359|FG004|Overall Study|Adverse Event|0
6214934|NCT01616654|9882355|FG000|Overall Study|Withdrawal by Subject|2
6214935|NCT01616654|9882356|FG001|Overall Study|Withdrawal by Subject|2
6214936|NCT01616654|9882357|FG002|Overall Study|Withdrawal by Subject|3
6214937|NCT01616654|9882358|FG003|Overall Study|Withdrawal by Subject|1
6214938|NCT01616654|9882359|FG004|Overall Study|Withdrawal by Subject|5
6214939|NCT01616654|9882355|FG000|Overall Study|Protocol Violation|0
6214940|NCT01616654|9882356|FG001|Overall Study|Protocol Violation|5
6214941|NCT01616654|9882357|FG002|Overall Study|Protocol Violation|2
6214942|NCT01616654|9882358|FG003|Overall Study|Protocol Violation|4
6214943|NCT01616654|9882359|FG004|Overall Study|Protocol Violation|4
6214944|NCT01616654|9882355|FG000|Overall Study|Lost to Follow-up|1
6214945|NCT01616654|9882356|FG001|Overall Study|Lost to Follow-up|0
6214946|NCT01616654|9882357|FG002|Overall Study|Lost to Follow-up|3
6214947|NCT01616654|9882358|FG003|Overall Study|Lost to Follow-up|2
6214948|NCT01616654|9882359|FG004|Overall Study|Lost to Follow-up|1
6214949|NCT01616654|9882355|FG000|Overall Study|Pregnancy|1
6214950|NCT01616654|9882356|FG001|Overall Study|Pregnancy|0
6214951|NCT01616654|9882357|FG002|Overall Study|Pregnancy|0
6214952|NCT01616654|9882358|FG003|Overall Study|Pregnancy|0
6214953|NCT01616654|9882359|FG004|Overall Study|Pregnancy|1
6214954|NCT01616693|9882376|FG000|Evaluated for Safety|Physician Decision|1
6214955|NCT01616693|9882377|FG001|Evaluated for Safety|Physician Decision|0
6214956|NCT01616693|9882378|FG002|Evaluated for Safety|Physician Decision|1
6214957|NCT01616693|9882379|FG003|Evaluated for Safety|Physician Decision|0
6214958|NCT01616693|9882376|FG000|Received Both Vaccines|Adverse Event|2
6214959|NCT01616693|9882377|FG001|Received Both Vaccines|Adverse Event|0
6214960|NCT01616693|9882378|FG002|Received Both Vaccines|Adverse Event|0
6214961|NCT01616693|9882379|FG003|Received Both Vaccines|Adverse Event|0
6214962|NCT01616693|9882376|FG000|Received Both Vaccines|Withdrawal by Subject|7
6214963|NCT01616693|9882377|FG001|Received Both Vaccines|Withdrawal by Subject|7
6214964|NCT01616693|9882378|FG002|Received Both Vaccines|Withdrawal by Subject|8
6214965|NCT01616693|9882379|FG003|Received Both Vaccines|Withdrawal by Subject|15
6214966|NCT01616693|9882376|FG000|Received Both Vaccines|Lost to Follow-up|4
6214967|NCT01616693|9882377|FG001|Received Both Vaccines|Lost to Follow-up|3
6214968|NCT01616693|9882378|FG002|Received Both Vaccines|Lost to Follow-up|4
6214969|NCT01616693|9882379|FG003|Received Both Vaccines|Lost to Follow-up|4
6121811|NCT00902486|9745228|FG001|Treatment Period (Weeks 0 Through 12)|Lost to Follow-up|0
6121812|NCT00902486|9745229|FG002|Treatment Period (Weeks 0 Through 12)|Lost to Follow-up|0
6121813|NCT00902486|9745230|FG003|Treatment Period (Weeks 0 Through 12)|Lost to Follow-up|1
6121814|NCT00902486|9745231|FG004|Treatment Period (Weeks 0 Through 12)|Lost to Follow-up|0
6121815|NCT00902486|9745232|FG005|Treatment Period (Weeks 0 Through 12)|Lost to Follow-up|0
6121816|NCT00902486|9745227|FG000|Treatment Period (Weeks 0 Through 12)|corrected QT (QTc) exclusion criteria|0
6121817|NCT00902486|9745228|FG001|Treatment Period (Weeks 0 Through 12)|corrected QT (QTc) exclusion criteria|0
6121818|NCT00902486|9745229|FG002|Treatment Period (Weeks 0 Through 12)|corrected QT (QTc) exclusion criteria|0
6121819|NCT00902486|9745230|FG003|Treatment Period (Weeks 0 Through 12)|corrected QT (QTc) exclusion criteria|1
6121820|NCT00902486|9745231|FG004|Treatment Period (Weeks 0 Through 12)|corrected QT (QTc) exclusion criteria|0
6121821|NCT00902486|9745232|FG005|Treatment Period (Weeks 0 Through 12)|corrected QT (QTc) exclusion criteria|0
6121822|NCT00902486|9745227|FG000|Extension Period (Weeks 12 Through 24)|Adverse Event|0
6121823|NCT00902486|9745228|FG001|Extension Period (Weeks 12 Through 24)|Adverse Event|0
6121824|NCT00902486|9745229|FG002|Extension Period (Weeks 12 Through 24)|Adverse Event|0
6121825|NCT00902486|9745230|FG003|Extension Period (Weeks 12 Through 24)|Adverse Event|0
6121826|NCT00902486|9745231|FG004|Extension Period (Weeks 12 Through 24)|Adverse Event|1
6214970|NCT01616693|9882376|FG000|Blood Analyzed for Immunogenicity|Protocol Violation|4
6214971|NCT01616693|9882377|FG001|Blood Analyzed for Immunogenicity|Protocol Violation|2
6214972|NCT01616693|9882378|FG002|Blood Analyzed for Immunogenicity|Protocol Violation|6
6214973|NCT01616693|9882379|FG003|Blood Analyzed for Immunogenicity|Protocol Violation|1
6214974|NCT01616771|9882393|FG000|Smaller Sized GVL for 5 Sec|lack of GVL size|4
6214975|NCT01616953|9882404|FG000|Overall Study|Lost to Follow-up|1
6214976|NCT01616953|9882405|FG001|Overall Study|Lost to Follow-up|0
6214977|NCT01616953|9882404|FG000|Overall Study|lack of bone and soft tissue|1
6214978|NCT01616953|9882405|FG001|Overall Study|lack of bone and soft tissue|0
6214979|NCT01617005|9882411|FG000|Overall Study|Pregnancy|1
6214980|NCT01617005|9882411|FG000|Overall Study|Lack of motivation for treatment|1
6214981|NCT01617070|9882415|FG000|BH4 and LNAA (4 Weeks)|started medication interfere with study|1
6214982|NCT01617434|9882454|FG000|Overall Study|Adverse Event|12
6214983|NCT01617434|9882455|FG001|Overall Study|Adverse Event|3
6214984|NCT01617434|9882454|FG000|Overall Study|Protocol Violation|8
6214985|NCT01617434|9882455|FG001|Overall Study|Protocol Violation|7
6214986|NCT01617434|9882454|FG000|Overall Study|Withdrawal Criteria|12
6214987|NCT01617434|9882455|FG001|Overall Study|Withdrawal Criteria|37
6214988|NCT01617434|9882454|FG000|Overall Study|Unclassified|3
6214989|NCT01617434|9882455|FG001|Overall Study|Unclassified|4
6214990|NCT01617447|9882463|FG000|Overall Study|Adverse Event|0
6214991|NCT01617447|9882464|FG001|Overall Study|Adverse Event|1
6214992|NCT01617447|9882463|FG000|Overall Study|Physician Decision|0
6214993|NCT01617447|9882464|FG001|Overall Study|Physician Decision|2
6214994|NCT01617460|9882470|FG000|Overall Study|Adverse Event|10
6214995|NCT01617460|9882470|FG000|Overall Study|Physician Decision|16
6214996|NCT01617460|9882470|FG000|Overall Study|Protocol Violation|5
6214997|NCT01617460|9882470|FG000|Overall Study|Withdrawal by Subject|9
6214998|NCT01617629|9882497|FG000|Overall Study|Death|2
6214999|NCT01617629|9882497|FG000|Overall Study|Investigator's Clinical Judgement|1
6215000|NCT01617629|9882497|FG000|Overall Study|Reason Not Specified|1
6215001|NCT01617629|9882497|FG000|Overall Study|Participant Withdrew Consent|2
6215002|NCT01617655|9882503|FG000|Overall Study|Adverse Event|2
6215003|NCT01617655|9882504|FG001|Overall Study|Adverse Event|3
6215004|NCT01617655|9882503|FG000|Overall Study|Poor compliance to protocol|1
6215005|NCT01617655|9882504|FG001|Overall Study|Poor compliance to protocol|4
6215006|NCT01617655|9882503|FG000|Overall Study|Participants moved|0
6215007|NCT01617655|9882504|FG001|Overall Study|Participants moved|4
6215008|NCT01617655|9882503|FG000|Overall Study|Consent withdrawn by participant|1
6215009|NCT01617655|9882504|FG001|Overall Study|Consent withdrawn by participant|1
6215010|NCT01617655|9882503|FG000|Overall Study|Last visit outside protocol visit window|1
6215011|NCT01617655|9882504|FG001|Overall Study|Last visit outside protocol visit window|10
6215012|NCT01617655|9882503|FG000|Overall Study|Site closure|3
6215013|NCT01617655|9882504|FG001|Overall Study|Site closure|5
6215014|NCT01617655|9882503|FG000|Overall Study|Other than specified above|1
6215015|NCT01617655|9882504|FG001|Overall Study|Other than specified above|2
6215016|NCT01617668|9882514|FG000|Overall Study|Adverse Event|7
6215017|NCT01617668|9882515|FG001|Overall Study|Adverse Event|0
6215018|NCT01617668|9882516|FG002|Overall Study|Adverse Event|12
6215019|NCT01617668|9882517|FG003|Overall Study|Adverse Event|5
6215020|NCT01617668|9882514|FG000|Overall Study|Physician Decision|1
6215021|NCT01617668|9882515|FG001|Overall Study|Physician Decision|2
6215022|NCT01617668|9882516|FG002|Overall Study|Physician Decision|3
6215023|NCT01617668|9882517|FG003|Overall Study|Physician Decision|0
6215024|NCT01617668|9882514|FG000|Overall Study|Progressive Disease|4
6215025|NCT01617668|9882515|FG001|Overall Study|Progressive Disease|4
6215026|NCT01617668|9882516|FG002|Overall Study|Progressive Disease|6
6215027|NCT01617668|9882517|FG003|Overall Study|Progressive Disease|9
6215028|NCT01617668|9882514|FG000|Overall Study|Subject/guardian decision|1
6215029|NCT01617668|9882515|FG001|Overall Study|Subject/guardian decision|3
6215030|NCT01617668|9882516|FG002|Overall Study|Subject/guardian decision|2
6215031|NCT01617668|9882517|FG003|Overall Study|Subject/guardian decision|1
6121827|NCT00902486|9745232|FG005|Extension Period (Weeks 12 Through 24)|Adverse Event|2
6121828|NCT00902486|9745227|FG000|Extension Period (Weeks 12 Through 24)|Consent Withdrawn|0
6121829|NCT00902486|9745228|FG001|Extension Period (Weeks 12 Through 24)|Consent Withdrawn|0
6121830|NCT00902486|9745229|FG002|Extension Period (Weeks 12 Through 24)|Consent Withdrawn|1
6121831|NCT00902486|9745230|FG003|Extension Period (Weeks 12 Through 24)|Consent Withdrawn|1
6121832|NCT00902486|9745231|FG004|Extension Period (Weeks 12 Through 24)|Consent Withdrawn|0
6121833|NCT00902486|9745232|FG005|Extension Period (Weeks 12 Through 24)|Consent Withdrawn|0
6121834|NCT00902486|9745227|FG000|Extension Period (Weeks 12 Through 24)|Protocol Deviation|0
6121835|NCT00902486|9745228|FG001|Extension Period (Weeks 12 Through 24)|Protocol Deviation|0
6121836|NCT00902486|9745229|FG002|Extension Period (Weeks 12 Through 24)|Protocol Deviation|0
6121837|NCT00902486|9745230|FG003|Extension Period (Weeks 12 Through 24)|Protocol Deviation|0
6121838|NCT00902486|9745231|FG004|Extension Period (Weeks 12 Through 24)|Protocol Deviation|0
6121839|NCT00902486|9745232|FG005|Extension Period (Weeks 12 Through 24)|Protocol Deviation|1
6121840|NCT00902486|9745227|FG000|Extension Period (Weeks 12 Through 24)|Disease Progression|0
6121841|NCT00902486|9745228|FG001|Extension Period (Weeks 12 Through 24)|Disease Progression|0
6121842|NCT00902486|9745229|FG002|Extension Period (Weeks 12 Through 24)|Disease Progression|0
6121843|NCT00902486|9745230|FG003|Extension Period (Weeks 12 Through 24)|Disease Progression|1
6121844|NCT00902486|9745231|FG004|Extension Period (Weeks 12 Through 24)|Disease Progression|0
6121845|NCT00902486|9745232|FG005|Extension Period (Weeks 12 Through 24)|Disease Progression|0
6121846|NCT00902486|9745227|FG000|Extension Period (Weeks 12 Through 24)|Lost to Follow-up|0
6121847|NCT00902486|9745228|FG001|Extension Period (Weeks 12 Through 24)|Lost to Follow-up|0
6121848|NCT00902486|9745229|FG002|Extension Period (Weeks 12 Through 24)|Lost to Follow-up|1
6215032|NCT01617681|9882535|FG000|Period 1 Double Blind|Adverse Event|2
6215033|NCT01617681|9882536|FG001|Period 1 Double Blind|Adverse Event|0
6215034|NCT01617681|9882537|FG002|Period 1 Double Blind|Adverse Event|0
6215035|NCT01617681|9882538|FG003|Period 1 Double Blind|Adverse Event|2
6215036|NCT01617681|9882539|FG004|Period 1 Double Blind|Adverse Event|0
6215037|NCT01617681|9882535|FG000|Period 1 Double Blind|Withdrawal by Subject|1
6215038|NCT01617681|9882536|FG001|Period 1 Double Blind|Withdrawal by Subject|1
6215039|NCT01617681|9882537|FG002|Period 1 Double Blind|Withdrawal by Subject|1
6215040|NCT01617681|9882538|FG003|Period 1 Double Blind|Withdrawal by Subject|0
6215041|NCT01617681|9882539|FG004|Period 1 Double Blind|Withdrawal by Subject|0
6215042|NCT01617681|9882535|FG000|Period 2 Open Label|Adverse Event|0
6215043|NCT01617681|9882536|FG001|Period 2 Open Label|Adverse Event|0
6215044|NCT01617681|9882537|FG002|Period 2 Open Label|Adverse Event|0
6215045|NCT01617681|9882538|FG003|Period 2 Open Label|Adverse Event|0
6215046|NCT01617681|9882539|FG004|Period 2 Open Label|Adverse Event|3
6215047|NCT01617681|9882535|FG000|Period 2 Open Label|Withdrawal by Subject|0
6215048|NCT01617681|9882536|FG001|Period 2 Open Label|Withdrawal by Subject|0
6215049|NCT01617681|9882537|FG002|Period 2 Open Label|Withdrawal by Subject|0
6215050|NCT01617681|9882538|FG003|Period 2 Open Label|Withdrawal by Subject|0
6215051|NCT01617681|9882539|FG004|Period 2 Open Label|Withdrawal by Subject|3
6215052|NCT01617967|9882554|FG000|Overall Study|Protocol Violation|0
6215053|NCT01617967|9882555|FG001|Overall Study|Protocol Violation|0
6215054|NCT01617967|9882556|FG002|Overall Study|Protocol Violation|0
6215055|NCT01617967|9882557|FG003|Overall Study|Protocol Violation|1
6215056|NCT01617967|9882558|FG004|Overall Study|Protocol Violation|0
6215057|NCT01617967|9882559|FG005|Overall Study|Protocol Violation|0
6215058|NCT01617967|9882554|FG000|Overall Study|Withdrawal by Subject|0
6215059|NCT01617967|9882555|FG001|Overall Study|Withdrawal by Subject|0
6121849|NCT00902486|9745230|FG003|Extension Period (Weeks 12 Through 24)|Lost to Follow-up|0
6121850|NCT00902486|9745231|FG004|Extension Period (Weeks 12 Through 24)|Lost to Follow-up|0
6121851|NCT00902486|9745232|FG005|Extension Period (Weeks 12 Through 24)|Lost to Follow-up|0
6121852|NCT00902486|9745227|FG000|Follow-up (After Week 24)|Lost to Follow-up|0
6121853|NCT00902486|9745228|FG001|Follow-up (After Week 24)|Lost to Follow-up|0
6121854|NCT00902486|9745229|FG002|Follow-up (After Week 24)|Lost to Follow-up|0
6121855|NCT00902486|9745230|FG003|Follow-up (After Week 24)|Lost to Follow-up|1
6121856|NCT00902486|9745231|FG004|Follow-up (After Week 24)|Lost to Follow-up|0
6121857|NCT00902486|9745232|FG005|Follow-up (After Week 24)|Lost to Follow-up|0
6121858|NCT00902538|9745265|FG000|1-Single-blind, Run-in, Single-Treatment|Adverse Event|49
6121859|NCT00902538|9745266|FG001|1-Single-blind, Run-in, Single-Treatment|Adverse Event|0
6121860|NCT00902538|9745267|FG002|1-Single-blind, Run-in, Single-Treatment|Adverse Event|0
6121861|NCT00902538|9745268|FG003|1-Single-blind, Run-in, Single-Treatment|Adverse Event|0
6121862|NCT00902538|9745269|FG004|1-Single-blind, Run-in, Single-Treatment|Adverse Event|0
6121863|NCT00902538|9745270|FG005|1-Single-blind, Run-in, Single-Treatment|Adverse Event|0
6215060|NCT01617967|9882556|FG002|Overall Study|Withdrawal by Subject|0
6215061|NCT01617967|9882557|FG003|Overall Study|Withdrawal by Subject|0
6215062|NCT01617967|9882558|FG004|Overall Study|Withdrawal by Subject|0
6215063|NCT01617967|9882559|FG005|Overall Study|Withdrawal by Subject|1
6287893|NCT02357420|10001014|FG002|Overall Study|Protocol Non-compliance|0
6287894|NCT02357420|10001015|FG003|Overall Study|Protocol Non-compliance|1
6287895|NCT02357420|10001012|FG000|Overall Study|Withdrawn Consent|4
6287896|NCT02357420|10001013|FG001|Overall Study|Withdrawn Consent|8
6287897|NCT02357420|10001014|FG002|Overall Study|Withdrawn Consent|6
6287898|NCT02357420|10001015|FG003|Overall Study|Withdrawn Consent|6
6287899|NCT02357420|10001012|FG000|Overall Study|Lost to Follow-up|3
6121864|NCT00902538|9745265|FG000|1-Single-blind, Run-in, Single-Treatment|Withdrawal by Subject|30
6121865|NCT00902538|9745266|FG001|1-Single-blind, Run-in, Single-Treatment|Withdrawal by Subject|0
6121866|NCT00902538|9745267|FG002|1-Single-blind, Run-in, Single-Treatment|Withdrawal by Subject|0
6121867|NCT00902538|9745268|FG003|1-Single-blind, Run-in, Single-Treatment|Withdrawal by Subject|0
6121868|NCT00902538|9745269|FG004|1-Single-blind, Run-in, Single-Treatment|Withdrawal by Subject|0
6121869|NCT00902538|9745270|FG005|1-Single-blind, Run-in, Single-Treatment|Withdrawal by Subject|0
6121870|NCT00902538|9745265|FG000|1-Single-blind, Run-in, Single-Treatment|Protocol Violation|22
6121871|NCT00902538|9745266|FG001|1-Single-blind, Run-in, Single-Treatment|Protocol Violation|0
6121872|NCT00902538|9745267|FG002|1-Single-blind, Run-in, Single-Treatment|Protocol Violation|0
6121873|NCT00902538|9745268|FG003|1-Single-blind, Run-in, Single-Treatment|Protocol Violation|0
6121874|NCT00902538|9745269|FG004|1-Single-blind, Run-in, Single-Treatment|Protocol Violation|0
6121875|NCT00902538|9745270|FG005|1-Single-blind, Run-in, Single-Treatment|Protocol Violation|0
6121876|NCT00902538|9745265|FG000|1-Single-blind, Run-in, Single-Treatment|Other Reason|13
6121877|NCT00902538|9745266|FG001|1-Single-blind, Run-in, Single-Treatment|Other Reason|0
6121878|NCT00902538|9745267|FG002|1-Single-blind, Run-in, Single-Treatment|Other Reason|0
6121879|NCT00902538|9745268|FG003|1-Single-blind, Run-in, Single-Treatment|Other Reason|0
6121880|NCT00902538|9745269|FG004|1-Single-blind, Run-in, Single-Treatment|Other Reason|0
6121881|NCT00902538|9745270|FG005|1-Single-blind, Run-in, Single-Treatment|Other Reason|0
6121882|NCT00902538|9745265|FG000|1-Single-blind, Run-in, Single-Treatment|Lost to Follow-up|4
6121883|NCT00902538|9745266|FG001|1-Single-blind, Run-in, Single-Treatment|Lost to Follow-up|0
6121884|NCT00902538|9745267|FG002|1-Single-blind, Run-in, Single-Treatment|Lost to Follow-up|0
6121885|NCT00902538|9745268|FG003|1-Single-blind, Run-in, Single-Treatment|Lost to Follow-up|0
6121886|NCT00902538|9745269|FG004|1-Single-blind, Run-in, Single-Treatment|Lost to Follow-up|0
6121887|NCT00902538|9745270|FG005|1-Single-blind, Run-in, Single-Treatment|Lost to Follow-up|0
6121888|NCT00902538|9745265|FG000|2-Randomized Double-blind 3 Treatments|Adverse Event|4
6121889|NCT00902538|9745266|FG001|2-Randomized Double-blind 3 Treatments|Adverse Event|2
6121890|NCT00902538|9745267|FG002|2-Randomized Double-blind 3 Treatments|Adverse Event|3
6121891|NCT00902538|9745268|FG003|2-Randomized Double-blind 3 Treatments|Adverse Event|0
6121892|NCT00902538|9745269|FG004|2-Randomized Double-blind 3 Treatments|Adverse Event|0
6121893|NCT00902538|9745270|FG005|2-Randomized Double-blind 3 Treatments|Adverse Event|0
6121894|NCT00902538|9745265|FG000|2-Randomized Double-blind 3 Treatments|Withdrawal by Subject|1
6121895|NCT00902538|9745266|FG001|2-Randomized Double-blind 3 Treatments|Withdrawal by Subject|2
6121896|NCT00902538|9745267|FG002|2-Randomized Double-blind 3 Treatments|Withdrawal by Subject|1
6121897|NCT00902538|9745268|FG003|2-Randomized Double-blind 3 Treatments|Withdrawal by Subject|0
6215064|NCT01617967|9882554|FG000|Overall Study|Dosing Suspended by Sponsor|1
6215065|NCT01617967|9882555|FG001|Overall Study|Dosing Suspended by Sponsor|0
6215066|NCT01617967|9882556|FG002|Overall Study|Dosing Suspended by Sponsor|0
6215067|NCT01617967|9882557|FG003|Overall Study|Dosing Suspended by Sponsor|0
6215068|NCT01617967|9882558|FG004|Overall Study|Dosing Suspended by Sponsor|0
6215069|NCT01617967|9882559|FG005|Overall Study|Dosing Suspended by Sponsor|0
6215070|NCT01618019|9882576|FG000|Overall Study|Withdrawal by Subject|14
6215071|NCT01618019|9882577|FG001|Overall Study|Withdrawal by Subject|14
6215072|NCT01618162|9882585|FG000|Overall Study|Protocol Violation|13
6215073|NCT01618162|9882586|FG001|Overall Study|Protocol Violation|10
6215074|NCT01618162|9882585|FG000|Overall Study|Adverse Event|9
6215075|NCT01618162|9882586|FG001|Overall Study|Adverse Event|2
6215076|NCT01618162|9882585|FG000|Overall Study|Withdrawal Criteria|2
6215077|NCT01618162|9882586|FG001|Overall Study|Withdrawal Criteria|10
6215078|NCT01618162|9882585|FG000|Overall Study|Unclassified|14
6215079|NCT01618162|9882586|FG001|Overall Study|Unclassified|13
6215080|NCT01618214|9882594|FG000|Overall Study|Adverse Event|3
6215081|NCT01618214|9882595|FG001|Overall Study|Adverse Event|1
6215082|NCT01618214|9882594|FG000|Overall Study|Lack of Efficacy|1
6215083|NCT01618214|9882595|FG001|Overall Study|Lack of Efficacy|1
6215084|NCT01618214|9882594|FG000|Overall Study|Protocol Violation|1
6215085|NCT01618214|9882595|FG001|Overall Study|Protocol Violation|4
6215086|NCT01618214|9882594|FG000|Overall Study|Withdrawal Criteria|1
6215087|NCT01618214|9882595|FG001|Overall Study|Withdrawal Criteria|2
6215088|NCT01618214|9882594|FG000|Overall Study|Unclassified|4
6215089|NCT01618214|9882595|FG001|Overall Study|Unclassified|5
6215090|NCT01618266|9882614|FG000|Overall Study|Lost to Follow-up|9
6215091|NCT01618266|9882614|FG000|Overall Study|Treatment satisfaction|10
6215092|NCT01618266|9882614|FG000|Overall Study|Other reasons|11
6215093|NCT01618266|9882614|FG000|Overall Study|Lack of Efficacy|23
6215094|NCT01618266|9882614|FG000|Overall Study|Protocol Violation|43
6215095|NCT01618305|9882620|FG000|Overall Study|Death|0
6215096|NCT01618305|9882621|FG001|Overall Study|Death|1
6215097|NCT01618305|9882620|FG000|Overall Study|Lost to Follow-up|11
6215098|NCT01618305|9882621|FG001|Overall Study|Lost to Follow-up|7
6215099|NCT01618305|9882620|FG000|Overall Study|Protocol Violation|1
6215100|NCT01618305|9882621|FG001|Overall Study|Protocol Violation|0
6215101|NCT01618305|9882620|FG000|Overall Study|Withdrawal by Subject|3
6215102|NCT01618305|9882621|FG001|Overall Study|Withdrawal by Subject|2
6215103|NCT01618669|9882646|FG000|Overall Study|Lost to Follow-up|1
6215104|NCT01618669|9882647|FG001|Overall Study|Lost to Follow-up|1
6215105|NCT01618669|9882646|FG000|Overall Study|Randomized but Never Received Study Drug|3
6121898|NCT00902538|9745269|FG004|2-Randomized Double-blind 3 Treatments|Withdrawal by Subject|0
6121899|NCT00902538|9745270|FG005|2-Randomized Double-blind 3 Treatments|Withdrawal by Subject|0
6121900|NCT00902538|9745265|FG000|2-Randomized Double-blind 3 Treatments|Lost to Follow-up|1
6121901|NCT00902538|9745266|FG001|2-Randomized Double-blind 3 Treatments|Lost to Follow-up|0
6121902|NCT00902538|9745267|FG002|2-Randomized Double-blind 3 Treatments|Lost to Follow-up|2
6121903|NCT00902538|9745268|FG003|2-Randomized Double-blind 3 Treatments|Lost to Follow-up|0
6121904|NCT00902538|9745269|FG004|2-Randomized Double-blind 3 Treatments|Lost to Follow-up|0
6121905|NCT00902538|9745270|FG005|2-Randomized Double-blind 3 Treatments|Lost to Follow-up|0
6121906|NCT00902538|9745265|FG000|2-Randomized Double-blind 3 Treatments|Other|2
6121907|NCT00902538|9745266|FG001|2-Randomized Double-blind 3 Treatments|Other|1
6121908|NCT00902538|9745267|FG002|2-Randomized Double-blind 3 Treatments|Other|0
6121909|NCT00902538|9745268|FG003|2-Randomized Double-blind 3 Treatments|Other|0
6121910|NCT00902538|9745269|FG004|2-Randomized Double-blind 3 Treatments|Other|0
6121911|NCT00902538|9745270|FG005|2-Randomized Double-blind 3 Treatments|Other|0
6121912|NCT00902538|9745265|FG000|2-Randomized Double-blind 3 Treatments|Protocol Violation|1
6121913|NCT00902538|9745266|FG001|2-Randomized Double-blind 3 Treatments|Protocol Violation|1
6121914|NCT00902538|9745267|FG002|2-Randomized Double-blind 3 Treatments|Protocol Violation|2
6121915|NCT00902538|9745268|FG003|2-Randomized Double-blind 3 Treatments|Protocol Violation|0
6121916|NCT00902538|9745269|FG004|2-Randomized Double-blind 3 Treatments|Protocol Violation|0
6121917|NCT00902538|9745270|FG005|2-Randomized Double-blind 3 Treatments|Protocol Violation|0
6121918|NCT00902538|9745265|FG000|3-Single-blind, Single Treatment|Adverse Event|0
6287900|NCT02357420|10001013|FG001|Overall Study|Lost to Follow-up|0
6287901|NCT02357420|10001014|FG002|Overall Study|Lost to Follow-up|2
6121919|NCT00902538|9745266|FG001|3-Single-blind, Single Treatment|Adverse Event|5
6121920|NCT00902538|9745267|FG002|3-Single-blind, Single Treatment|Adverse Event|0
6121921|NCT00902538|9745268|FG003|3-Single-blind, Single Treatment|Adverse Event|0
6121922|NCT00902538|9745269|FG004|3-Single-blind, Single Treatment|Adverse Event|0
6121923|NCT00902538|9745270|FG005|3-Single-blind, Single Treatment|Adverse Event|0
6121924|NCT00902538|9745265|FG000|3-Single-blind, Single Treatment|Protocol Violation|0
6121925|NCT00902538|9745266|FG001|3-Single-blind, Single Treatment|Protocol Violation|5
6121926|NCT00902538|9745267|FG002|3-Single-blind, Single Treatment|Protocol Violation|0
6121927|NCT00902538|9745268|FG003|3-Single-blind, Single Treatment|Protocol Violation|0
6121928|NCT00902538|9745269|FG004|3-Single-blind, Single Treatment|Protocol Violation|0
6121929|NCT00902538|9745270|FG005|3-Single-blind, Single Treatment|Protocol Violation|0
6121930|NCT00902538|9745265|FG000|3-Single-blind, Single Treatment|Withdrawal by Subject|0
6121931|NCT00902538|9745266|FG001|3-Single-blind, Single Treatment|Withdrawal by Subject|4
6121932|NCT00902538|9745267|FG002|3-Single-blind, Single Treatment|Withdrawal by Subject|0
6121933|NCT00902538|9745268|FG003|3-Single-blind, Single Treatment|Withdrawal by Subject|0
6121934|NCT00902538|9745269|FG004|3-Single-blind, Single Treatment|Withdrawal by Subject|0
6121935|NCT00902538|9745270|FG005|3-Single-blind, Single Treatment|Withdrawal by Subject|0
6121936|NCT00902538|9745265|FG000|3-Single-blind, Single Treatment|Lost to Follow-up|0
6121937|NCT00902538|9745266|FG001|3-Single-blind, Single Treatment|Lost to Follow-up|1
6121938|NCT00902538|9745267|FG002|3-Single-blind, Single Treatment|Lost to Follow-up|0
6121939|NCT00902538|9745268|FG003|3-Single-blind, Single Treatment|Lost to Follow-up|0
6121940|NCT00902538|9745269|FG004|3-Single-blind, Single Treatment|Lost to Follow-up|0
6121941|NCT00902538|9745270|FG005|3-Single-blind, Single Treatment|Lost to Follow-up|0
6121942|NCT00902538|9745265|FG000|4-Randomized Double-blind 2 Treatments|Adverse Event|0
6121943|NCT00902538|9745266|FG001|4-Randomized Double-blind 2 Treatments|Adverse Event|0
6121944|NCT00902538|9745267|FG002|4-Randomized Double-blind 2 Treatments|Adverse Event|0
6121945|NCT00902538|9745268|FG003|4-Randomized Double-blind 2 Treatments|Adverse Event|3
6121946|NCT00902538|9745269|FG004|4-Randomized Double-blind 2 Treatments|Adverse Event|1
6121947|NCT00902538|9745270|FG005|4-Randomized Double-blind 2 Treatments|Adverse Event|1
6215106|NCT01618669|9882647|FG001|Overall Study|Randomized but Never Received Study Drug|2
6215107|NCT01618669|9882646|FG000|Overall Study|Adverse Event|16
6215108|NCT01618669|9882647|FG001|Overall Study|Adverse Event|7
6215109|NCT01618669|9882646|FG000|Overall Study|Protocol Violation|5
6215110|NCT01618669|9882647|FG001|Overall Study|Protocol Violation|3
6215111|NCT01618669|9882646|FG000|Overall Study|Withdrawal by Subject|9
6215112|NCT01618669|9882647|FG001|Overall Study|Withdrawal by Subject|9
6215113|NCT01618669|9882646|FG000|Overall Study|Miscellaneous Reason|0
6215114|NCT01618669|9882647|FG001|Overall Study|Miscellaneous Reason|1
6215115|NCT01618695|9882669|FG000|Core Phase|Adverse Event|4
6215116|NCT01618695|9882670|FG001|Core Phase|Adverse Event|5
6215117|NCT01618695|9882671|FG002|Core Phase|Adverse Event|15
6215118|NCT01618695|9882672|FG003|Core Phase|Adverse Event|20
6215119|NCT01618695|9882669|FG000|Core Phase|Lost to Follow-up|0
5980858|NCT01434602|9569527|FG004|Phase II Recommended Phase 2 Dose|Physician Decision|1
6121948|NCT00902538|9745265|FG000|4-Randomized Double-blind 2 Treatments|Withdrawal by Subject|0
6121949|NCT00902538|9745266|FG001|4-Randomized Double-blind 2 Treatments|Withdrawal by Subject|0
6121950|NCT00902538|9745267|FG002|4-Randomized Double-blind 2 Treatments|Withdrawal by Subject|0
6121951|NCT00902538|9745268|FG003|4-Randomized Double-blind 2 Treatments|Withdrawal by Subject|3
6121952|NCT00902538|9745269|FG004|4-Randomized Double-blind 2 Treatments|Withdrawal by Subject|1
6215120|NCT01618695|9882670|FG001|Core Phase|Lost to Follow-up|0
6121953|NCT00902538|9745270|FG005|4-Randomized Double-blind 2 Treatments|Withdrawal by Subject|0
6121954|NCT00902538|9745265|FG000|4-Randomized Double-blind 2 Treatments|Protocol Violation|0
6121955|NCT00902538|9745266|FG001|4-Randomized Double-blind 2 Treatments|Protocol Violation|0
6121956|NCT00902538|9745267|FG002|4-Randomized Double-blind 2 Treatments|Protocol Violation|0
6121957|NCT00902538|9745268|FG003|4-Randomized Double-blind 2 Treatments|Protocol Violation|3
6121958|NCT00902538|9745269|FG004|4-Randomized Double-blind 2 Treatments|Protocol Violation|0
6121959|NCT00902538|9745270|FG005|4-Randomized Double-blind 2 Treatments|Protocol Violation|0
6121960|NCT00902564|9745282|FG000|Overall Study|Withdrawal by Subject|2
6121961|NCT00902577|9745286|FG000|Overall Study|Withdrawal by Subject|6
6121962|NCT00902577|9745286|FG000|Overall Study|FMISO production failure|2
6121963|NCT00902746|9745309|FG000|Overall Study|Protocol Violation|7
6121964|NCT00902746|9745309|FG000|Overall Study|Withdrawal by Subject|16
6121965|NCT00902746|9745309|FG000|Overall Study|Adverse Event|8
6121966|NCT00902746|9745309|FG000|Overall Study|Lost to Follow-up|3
6121967|NCT00902746|9745309|FG000|Overall Study|Physician Decision|2
6121968|NCT00902850|9745315|FG000|Overall Study|Physician Decision|2
6121969|NCT00902850|9745316|FG001|Overall Study|Physician Decision|2
6121970|NCT00903032|9745324|FG000|Overall Study|Withdrawal by Subject|5
6121971|NCT00903032|9745325|FG001|Overall Study|Withdrawal by Subject|3
6121972|NCT00903032|9745324|FG000|Overall Study|Lost to Follow-up|2
6121973|NCT00903032|9745325|FG001|Overall Study|Lost to Follow-up|2
6121974|NCT00903175|9745337|FG000|Period 1 - First Line|Adverse Event|36
6121975|NCT00903175|9745338|FG001|Period 1 - First Line|Adverse Event|50
6121976|NCT00903175|9745337|FG000|Period 1 - First Line|Abnormal lab value(s)|0
6121977|NCT00903175|9745338|FG001|Period 1 - First Line|Abnormal lab value(s)|1
6121978|NCT00903175|9745337|FG000|Period 1 - First Line|Abnormal test procedure result(s)|1
6121979|NCT00903175|9745338|FG001|Period 1 - First Line|Abnormal test procedure result(s)|0
6121980|NCT00903175|9745337|FG000|Period 1 - First Line|Protocol Violation|3
6121981|NCT00903175|9745338|FG001|Period 1 - First Line|Protocol Violation|3
6121982|NCT00903175|9745337|FG000|Period 1 - First Line|Withdrawal by Subject|8
6121983|NCT00903175|9745338|FG001|Period 1 - First Line|Withdrawal by Subject|12
6121984|NCT00903175|9745337|FG000|Period 1 - First Line|Administrative problems|12
6121985|NCT00903175|9745338|FG001|Period 1 - First Line|Administrative problems|13
6121986|NCT00903175|9745337|FG000|Period 1 - First Line|Death|17
6121987|NCT00903175|9745338|FG001|Period 1 - First Line|Death|10
6121988|NCT00903175|9745337|FG000|Period 2 - Second Line|Missing|1
6121989|NCT00903175|9745338|FG001|Period 2 - Second Line|Missing|0
6121990|NCT00903175|9745337|FG000|Period 2 - Second Line|Adverse Event|16
6121991|NCT00903175|9745338|FG001|Period 2 - Second Line|Adverse Event|20
6121992|NCT00903175|9745337|FG000|Period 2 - Second Line|Withdrawal by Subject|7
6121993|NCT00903175|9745338|FG001|Period 2 - Second Line|Withdrawal by Subject|5
6121994|NCT00903175|9745337|FG000|Period 2 - Second Line|Lost to Follow-up|1
6121995|NCT00903175|9745338|FG001|Period 2 - Second Line|Lost to Follow-up|0
6121996|NCT00903175|9745337|FG000|Period 2 - Second Line|Administrative problems|19
6121997|NCT00903175|9745338|FG001|Period 2 - Second Line|Administrative problems|9
6121998|NCT00903175|9745337|FG000|Period 2 - Second Line|Death|5
6121999|NCT00903175|9745338|FG001|Period 2 - Second Line|Death|2
6122000|NCT00903201|9745347|FG000|Overall Study|Adverse Event|1
6122001|NCT00903201|9745348|FG001|Overall Study|Adverse Event|4
6122002|NCT00903201|9745349|FG002|Overall Study|Adverse Event|0
6122003|NCT00903201|9745347|FG000|Overall Study|Protocol Violation|2
6122004|NCT00903201|9745348|FG001|Overall Study|Protocol Violation|1
6122005|NCT00903201|9745349|FG002|Overall Study|Protocol Violation|0
6122006|NCT00903201|9745347|FG000|Overall Study|Lost to Follow-up|0
6122007|NCT00903201|9745348|FG001|Overall Study|Lost to Follow-up|1
6122008|NCT00903201|9745349|FG002|Overall Study|Lost to Follow-up|0
6122009|NCT00903201|9745347|FG000|Overall Study|Physician Decision|1
6122010|NCT00903201|9745348|FG001|Overall Study|Physician Decision|0
6122011|NCT00903201|9745349|FG002|Overall Study|Physician Decision|1
6122012|NCT00903201|9745347|FG000|Overall Study|Withdrawal by Subject|1
6122013|NCT00903201|9745348|FG001|Overall Study|Withdrawal by Subject|0
6122014|NCT00903201|9745349|FG002|Overall Study|Withdrawal by Subject|1
6122015|NCT00903331|9745361|FG000|Overall Study|Death|4
6122016|NCT00903331|9745362|FG001|Overall Study|Death|8
6122017|NCT00903331|9745361|FG000|Overall Study|Withdrawal of consent|1
6122018|NCT00903331|9745362|FG001|Overall Study|Withdrawal of consent|8
6122019|NCT00903331|9745361|FG000|Overall Study|Lung transplant|0
6122020|NCT00903331|9745362|FG001|Overall Study|Lung transplant|2
6122021|NCT00903344|9745370|FG000|Overall Study|Pregnancy|2
6122022|NCT00903344|9745371|FG001|Overall Study|Pregnancy|3
6122023|NCT00903344|9745370|FG000|Overall Study|Lost to Follow-up|3
6122024|NCT00903344|9745371|FG001|Overall Study|Lost to Follow-up|0
6122025|NCT00903357|9745377|FG000|First Intervention|Withdrawal by Subject|5
6122026|NCT00903357|9745378|FG001|First Intervention|Withdrawal by Subject|3
6122027|NCT00903357|9745377|FG000|First Intervention|Flu|0
6122028|NCT00903357|9745378|FG001|First Intervention|Flu|1
6122029|NCT00903357|9745377|FG000|Wash Out Period of 2 Weeks|Flu|0
5980859|NCT01434602|9569523|FG000|Phase II Recommended Phase 2 Dose|Switched to alternative treatment|0
5980860|NCT01434602|9569524|FG001|Phase II Recommended Phase 2 Dose|Switched to alternative treatment|0
5980861|NCT01434602|9569525|FG002|Phase II Recommended Phase 2 Dose|Switched to alternative treatment|0
6122030|NCT00903357|9745378|FG001|Wash Out Period of 2 Weeks|Flu|1
6122031|NCT00903357|9745377|FG000|Second Intervention|Lost to Follow-up|1
6122032|NCT00903357|9745378|FG001|Second Intervention|Lost to Follow-up|0
6122033|NCT00903370|9745390|FG000|Overall Study|Death|13
6122034|NCT00903370|9745391|FG001|Overall Study|Death|10
6122035|NCT00903370|9745390|FG000|Overall Study|Withdrawal by Subject|9
6122036|NCT00903370|9745391|FG001|Overall Study|Withdrawal by Subject|6
6122037|NCT00903370|9745390|FG000|Overall Study|Lost to Follow-up|6
6122038|NCT00903370|9745391|FG001|Overall Study|Lost to Follow-up|8
6215121|NCT01618695|9882671|FG002|Core Phase|Lost to Follow-up|1
6215122|NCT01618695|9882672|FG003|Core Phase|Lost to Follow-up|0
6215123|NCT01618695|9882669|FG000|Core Phase|Withdrawal by Subject|16
6215124|NCT01618695|9882670|FG001|Core Phase|Withdrawal by Subject|11
6215125|NCT01618695|9882671|FG002|Core Phase|Withdrawal by Subject|9
6215126|NCT01618695|9882672|FG003|Core Phase|Withdrawal by Subject|13
6215127|NCT01618695|9882669|FG000|Core Phase|Pregnancy|2
6215128|NCT01618695|9882670|FG001|Core Phase|Pregnancy|0
6215129|NCT01618695|9882671|FG002|Core Phase|Pregnancy|0
6215130|NCT01618695|9882672|FG003|Core Phase|Pregnancy|0
6215131|NCT01618695|9882669|FG000|Core Phase|Lack of Efficacy|1
6215132|NCT01618695|9882670|FG001|Core Phase|Lack of Efficacy|2
6215133|NCT01618695|9882671|FG002|Core Phase|Lack of Efficacy|1
6215134|NCT01618695|9882672|FG003|Core Phase|Lack of Efficacy|1
6215135|NCT01618695|9882669|FG000|Core Phase|Other than specified|1
6287902|NCT02357420|10001015|FG003|Overall Study|Lost to Follow-up|3
6287903|NCT02357459|10001028|FG000|Overall Study|Adverse Event|0
6287904|NCT02357459|10001029|FG001|Overall Study|Adverse Event|1
6287905|NCT02357459|10001030|FG002|Overall Study|Adverse Event|1
6287906|NCT02357459|10001028|FG000|Overall Study|Withdrawal by Subject|5
6287907|NCT02357459|10001029|FG001|Overall Study|Withdrawal by Subject|3
6287908|NCT02357459|10001030|FG002|Overall Study|Withdrawal by Subject|3
6287909|NCT02357459|10001028|FG000|Overall Study|Physician Decision|0
6287910|NCT02357459|10001029|FG001|Overall Study|Physician Decision|2
6287911|NCT02357459|10001030|FG002|Overall Study|Physician Decision|0
6287912|NCT02357459|10001028|FG000|Overall Study|Protocol Violation|1
6287913|NCT02357459|10001029|FG001|Overall Study|Protocol Violation|1
6287914|NCT02357459|10001030|FG002|Overall Study|Protocol Violation|0
6287915|NCT02357459|10001028|FG000|Overall Study|Lost to Follow-up|1
6287916|NCT02357459|10001029|FG001|Overall Study|Lost to Follow-up|3
6287917|NCT02357459|10001030|FG002|Overall Study|Lost to Follow-up|0
6287918|NCT02357459|10001028|FG000|Overall Study|Lack of Efficacy|7
6287919|NCT02357459|10001029|FG001|Overall Study|Lack of Efficacy|4
6287920|NCT02357459|10001030|FG002|Overall Study|Lack of Efficacy|4
6287921|NCT02357459|10001028|FG000|Overall Study|Patient Relocated|2
6287922|NCT02357459|10001029|FG001|Overall Study|Patient Relocated|0
6287923|NCT02357459|10001030|FG002|Overall Study|Patient Relocated|0
6287924|NCT02357459|10001028|FG000|Overall Study|Instruction from PCP|1
6287925|NCT02357459|10001029|FG001|Overall Study|Instruction from PCP|0
6287926|NCT02357459|10001030|FG002|Overall Study|Instruction from PCP|0
6287927|NCT02357459|10001028|FG000|Overall Study|Incarceration|0
6287928|NCT02357459|10001029|FG001|Overall Study|Incarceration|0
6287929|NCT02357459|10001030|FG002|Overall Study|Incarceration|1
6287930|NCT02357459|10001028|FG000|Overall Study|Pre-planned Knee surgery|0
6287931|NCT02357459|10001029|FG001|Overall Study|Pre-planned Knee surgery|0
6287932|NCT02357459|10001030|FG002|Overall Study|Pre-planned Knee surgery|2
6287933|NCT02357459|10001028|FG000|Overall Study|Job Commitments|0
6287934|NCT02357459|10001029|FG001|Overall Study|Job Commitments|0
6287935|NCT02357459|10001030|FG002|Overall Study|Job Commitments|1
5980862|NCT01434602|9569526|FG003|Phase II Recommended Phase 2 Dose|Switched to alternative treatment|1
5980863|NCT01434602|9569527|FG004|Phase II Recommended Phase 2 Dose|Switched to alternative treatment|0
6215136|NCT01618695|9882670|FG001|Core Phase|Other than specified|2
6215137|NCT01618695|9882671|FG002|Core Phase|Other than specified|2
6215138|NCT01618695|9882672|FG003|Core Phase|Other than specified|2
6215139|NCT01618695|9882669|FG000|Core Phase|Not treated|1
6122039|NCT00903383|9745401|FG000|Overall Study|Adverse Event|1
6122040|NCT00903383|9745402|FG001|Overall Study|Adverse Event|2
6122041|NCT00903383|9745403|FG002|Overall Study|Adverse Event|3
6122042|NCT00903383|9745404|FG003|Overall Study|Adverse Event|1
6122043|NCT00903383|9745401|FG000|Overall Study|Physician Decision|1
6122044|NCT00903383|9745402|FG001|Overall Study|Physician Decision|2
6122045|NCT00903383|9745403|FG002|Overall Study|Physician Decision|0
6122046|NCT00903383|9745404|FG003|Overall Study|Physician Decision|0
6122047|NCT00903383|9745401|FG000|Overall Study|Lost to Follow-up|0
6122048|NCT00903383|9745402|FG001|Overall Study|Lost to Follow-up|0
6122049|NCT00903383|9745403|FG002|Overall Study|Lost to Follow-up|0
6122050|NCT00903383|9745404|FG003|Overall Study|Lost to Follow-up|1
6122051|NCT00903383|9745401|FG000|Overall Study|Decision of Sponsor|1
6122052|NCT00903383|9745402|FG001|Overall Study|Decision of Sponsor|0
6122053|NCT00903383|9745403|FG002|Overall Study|Decision of Sponsor|0
6122054|NCT00903383|9745404|FG003|Overall Study|Decision of Sponsor|0
6122055|NCT00903383|9745401|FG000|Overall Study|Withdrawal by Subject|4
6122056|NCT00903383|9745402|FG001|Overall Study|Withdrawal by Subject|1
6122057|NCT00903383|9745403|FG002|Overall Study|Withdrawal by Subject|0
6122058|NCT00903383|9745404|FG003|Overall Study|Withdrawal by Subject|2
6122059|NCT00903383|9745401|FG000|Overall Study|Patient Decision - Lack of Efficacy|0
6122060|NCT00903383|9745402|FG001|Overall Study|Patient Decision - Lack of Efficacy|1
6122061|NCT00903383|9745403|FG002|Overall Study|Patient Decision - Lack of Efficacy|0
6122062|NCT00903383|9745404|FG003|Overall Study|Patient Decision - Lack of Efficacy|0
6122063|NCT00903383|9745401|FG000|Overall Study|Patient Decision|0
6122064|NCT00903383|9745402|FG001|Overall Study|Patient Decision|0
6122065|NCT00903383|9745403|FG002|Overall Study|Patient Decision|0
6122066|NCT00903383|9745404|FG003|Overall Study|Patient Decision|1
6122067|NCT00903409|9745416|FG000|Overall Study|Adverse Event|11
6122068|NCT00903409|9745417|FG001|Overall Study|Adverse Event|9
6122069|NCT00903409|9745416|FG000|Overall Study|Non-compliance with Protocol|1
6122070|NCT00903409|9745417|FG001|Overall Study|Non-compliance with Protocol|1
6122071|NCT00903409|9745416|FG000|Overall Study|Laboratory Abnormality|2
6122072|NCT00903409|9745417|FG001|Overall Study|Laboratory Abnormality|0
6122073|NCT00903409|9745416|FG000|Overall Study|Withdrawal by Subject|8
6215140|NCT01618695|9882670|FG001|Core Phase|Not treated|0
6215141|NCT01618695|9882671|FG002|Core Phase|Not treated|2
6215142|NCT01618695|9882672|FG003|Core Phase|Not treated|0
6215143|NCT01618695|9882669|FG000|Extension Phase|Lack of Efficacy|17
6215144|NCT01618695|9882670|FG001|Extension Phase|Lack of Efficacy|33
6215145|NCT01618695|9882671|FG002|Extension Phase|Lack of Efficacy|26
6215146|NCT01618695|9882672|FG003|Extension Phase|Lack of Efficacy|24
6215147|NCT01618695|9882669|FG000|Extension Phase|Pregnancy|2
6215148|NCT01618695|9882670|FG001|Extension Phase|Pregnancy|0
6215149|NCT01618695|9882671|FG002|Extension Phase|Pregnancy|1
6215150|NCT01618695|9882672|FG003|Extension Phase|Pregnancy|1
6215151|NCT01618695|9882669|FG000|Extension Phase|Withdrawal by Subject|43
6215152|NCT01618695|9882670|FG001|Extension Phase|Withdrawal by Subject|48
6215153|NCT01618695|9882671|FG002|Extension Phase|Withdrawal by Subject|42
6215154|NCT01618695|9882672|FG003|Extension Phase|Withdrawal by Subject|33
6215155|NCT01618695|9882669|FG000|Extension Phase|Adverse Event|18
6215156|NCT01618695|9882670|FG001|Extension Phase|Adverse Event|16
6215157|NCT01618695|9882671|FG002|Extension Phase|Adverse Event|9
6215158|NCT01618695|9882672|FG003|Extension Phase|Adverse Event|20
6215159|NCT01618695|9882669|FG000|Extension Phase|Lost to Follow-up|2
6215160|NCT01618695|9882670|FG001|Extension Phase|Lost to Follow-up|1
6215161|NCT01618695|9882671|FG002|Extension Phase|Lost to Follow-up|1
6215162|NCT01618695|9882672|FG003|Extension Phase|Lost to Follow-up|1
6215163|NCT01618695|9882669|FG000|Extension Phase|Other than specified|13
6215164|NCT01618695|9882670|FG001|Extension Phase|Other than specified|18
6215165|NCT01618695|9882671|FG002|Extension Phase|Other than specified|13
6215166|NCT01618695|9882672|FG003|Extension Phase|Other than specified|18
6215167|NCT01618708|9882685|FG000|Overall Study|Adverse Event|10
6122074|NCT00903409|9745417|FG001|Overall Study|Withdrawal by Subject|8
6122075|NCT00903409|9745416|FG000|Overall Study|Other|2
6122076|NCT00903409|9745417|FG001|Overall Study|Other|3
6122077|NCT00903409|9745416|FG000|Overall Study|Lost to Follow-up|2
6122078|NCT00903409|9745417|FG001|Overall Study|Lost to Follow-up|6
6122079|NCT00903617|9745436|FG000|Overall Study|Adverse Event|0
6122080|NCT00903617|9745437|FG001|Overall Study|Adverse Event|1
6122081|NCT00903617|9745438|FG002|Overall Study|Adverse Event|1
6122082|NCT00903617|9745439|FG003|Overall Study|Adverse Event|0
6122083|NCT00903617|9745436|FG000|Overall Study|Protocol-defined stopping criteria|0
6122084|NCT00903617|9745437|FG001|Overall Study|Protocol-defined stopping criteria|2
6122085|NCT00903617|9745438|FG002|Overall Study|Protocol-defined stopping criteria|0
6122086|NCT00903617|9745439|FG003|Overall Study|Protocol-defined stopping criteria|0
6122087|NCT00903617|9745436|FG000|Overall Study|Lost to Follow-up|2
6122088|NCT00903617|9745437|FG001|Overall Study|Lost to Follow-up|0
6122089|NCT00903617|9745438|FG002|Overall Study|Lost to Follow-up|1
6122090|NCT00903617|9745439|FG003|Overall Study|Lost to Follow-up|1
6215168|NCT01618708|9882686|FG001|Overall Study|Adverse Event|10
6215169|NCT01618708|9882685|FG000|Overall Study|Lost to Follow-up|3
6215170|NCT01618708|9882686|FG001|Overall Study|Lost to Follow-up|3
6215171|NCT01618708|9882685|FG000|Overall Study|Withdrawal by Subject|17
6215172|NCT01618708|9882686|FG001|Overall Study|Withdrawal by Subject|22
6215173|NCT01618708|9882685|FG000|Overall Study|Lack of Efficacy|8
6122091|NCT00903617|9745436|FG000|Overall Study|Withdrawal by Subject|1
6122092|NCT00903617|9745437|FG001|Overall Study|Withdrawal by Subject|2
6122093|NCT00903617|9745438|FG002|Overall Study|Withdrawal by Subject|3
6122094|NCT00903617|9745439|FG003|Overall Study|Withdrawal by Subject|0
6122095|NCT00903630|9745453|FG000|Phase 2|Adverse Event|0
6122096|NCT00903630|9745454|FG001|Phase 2|Adverse Event|0
6122097|NCT00903630|9745455|FG002|Phase 2|Adverse Event|1
6122098|NCT00903682|9745467|FG000|Overall Study|Adverse Event|6
6122099|NCT00903682|9745468|FG001|Overall Study|Adverse Event|13
6122100|NCT00903682|9745467|FG000|Overall Study|Lost to Follow-up|1
6122101|NCT00903682|9745468|FG001|Overall Study|Lost to Follow-up|0
6122102|NCT00903682|9745467|FG000|Overall Study|Withdrawal by Subject|5
6122103|NCT00903682|9745468|FG001|Overall Study|Withdrawal by Subject|0
6122104|NCT00903682|9745467|FG000|Overall Study|Pregnancy|0
6122105|NCT00903682|9745468|FG001|Overall Study|Pregnancy|1
6122106|NCT00903682|9745467|FG000|Overall Study|Subject Reached A Virologic Endpoint|1
6122107|NCT00903682|9745468|FG001|Overall Study|Subject Reached A Virologic Endpoint|1
6122108|NCT00903682|9745467|FG000|Overall Study|Subject Non-Compliant|1
6122109|NCT00903682|9745468|FG001|Overall Study|Subject Non-Compliant|0
6122110|NCT00903682|9745467|FG000|Overall Study|Patient Couldn't Come For The Visit Due|1
6122111|NCT00903682|9745468|FG001|Overall Study|Patient Couldn't Come For The Visit Due|0
6122112|NCT00903682|9745467|FG000|Overall Study|For Resistent Profile (Excl Crit 2 Met)|1
6122113|NCT00903682|9745468|FG001|Overall Study|For Resistent Profile (Excl Crit 2 Met)|0
6122114|NCT00903695|9745476|FG000|Overall Study|medical exclusion after 1st testing|1
6122115|NCT00903695|9745477|FG001|Overall Study|medical exclusion after 1st testing|0
6122116|NCT00903695|9745476|FG000|Overall Study|lung cancer|1
6122117|NCT00903695|9745477|FG001|Overall Study|lung cancer|0
6122118|NCT00903760|9745487|FG000|Overall Study|Disease Progression/Death|8
6122119|NCT00903760|9745488|FG001|Overall Study|Disease Progression/Death|6
6122120|NCT00903760|9745487|FG000|Overall Study|Stem Cell Transplant|8
6122121|NCT00903760|9745488|FG001|Overall Study|Stem Cell Transplant|4
6122122|NCT00903760|9745487|FG000|Overall Study|Physician Decision|1
6122123|NCT00903760|9745488|FG001|Overall Study|Physician Decision|2
6122124|NCT00903760|9745487|FG000|Overall Study|Death|0
6122125|NCT00903760|9745488|FG001|Overall Study|Death|1
6122126|NCT00903760|9745487|FG000|Overall Study|Lost to Follow-up|1
6122127|NCT00903760|9745488|FG001|Overall Study|Lost to Follow-up|0
6122128|NCT00903760|9745487|FG000|Overall Study|Withdrawal by Subject|1
6122129|NCT00903760|9745488|FG001|Overall Study|Withdrawal by Subject|2
6122130|NCT00903760|9745487|FG000|Overall Study|Off treatment for long period|0
6122131|NCT00903760|9745488|FG001|Overall Study|Off treatment for long period|1
6122132|NCT00903786|9745494|FG000|Overall Study|Physician Decision|6
6122133|NCT00903786|9745494|FG000|Overall Study|Lack of Efficacy|5
6122134|NCT00903786|9745494|FG000|Overall Study|Reason other than lack of efficacy|4
6122135|NCT00903877|9745499|FG000|Overall Study|Did not meet study criteria|33
6122136|NCT00903877|9745499|FG000|Overall Study|Withdrawal by Subject|3
6122137|NCT00903877|9745499|FG000|Overall Study|Adverse Event|2
6122138|NCT00903877|9745499|FG000|Overall Study|Lost to Follow-up|1
6122139|NCT00903877|9745499|FG000|Overall Study|Participation put on hold|4
6122140|NCT00903929|9745503|FG000|Overall Study|Withdrawal by Subject|0
6122141|NCT00903929|9745504|FG001|Overall Study|Withdrawal by Subject|0
6122142|NCT00903929|9745505|FG002|Overall Study|Withdrawal by Subject|1
6122143|NCT00903929|9745506|FG003|Overall Study|Withdrawal by Subject|2
6122144|NCT00903929|9745503|FG000|Overall Study|Adverse Event|0
6122145|NCT00903929|9745504|FG001|Overall Study|Adverse Event|0
6215174|NCT01618708|9882686|FG001|Overall Study|Lack of Efficacy|8
6215175|NCT01618708|9882685|FG000|Overall Study|Technical problems|2
6215176|NCT01618708|9882686|FG001|Overall Study|Technical problems|0
6287936|NCT02357576|10001048|FG000|Treatment Period|Withdrawal by Subject|0
6287937|NCT02357576|10001049|FG001|Treatment Period|Withdrawal by Subject|1
6287938|NCT02357576|10001048|FG000|Treatment Period|Physician Decision|0
6287939|NCT02357576|10001049|FG001|Treatment Period|Physician Decision|1
6287940|NCT02357576|10001048|FG000|Neurodevelopmental Outcome Follow Up|Scheduling error|1
6287941|NCT02357576|10001049|FG001|Neurodevelopmental Outcome Follow Up|Scheduling error|1
6122146|NCT00903929|9745505|FG002|Overall Study|Adverse Event|0
6122147|NCT00903929|9745506|FG003|Overall Study|Adverse Event|1
6122148|NCT00903968|9745513|FG000|Overall Study|Adverse Event|0
6122149|NCT00903968|9745514|FG001|Overall Study|Adverse Event|0
6122150|NCT00903968|9745515|FG002|Overall Study|Adverse Event|0
6122151|NCT00903968|9745516|FG003|Overall Study|Adverse Event|0
6122152|NCT00903968|9745517|FG004|Overall Study|Adverse Event|0
6122153|NCT00903968|9745518|FG005|Overall Study|Adverse Event|0
6122154|NCT00903968|9745519|FG006|Overall Study|Adverse Event|1
6122155|NCT00903968|9745520|FG007|Overall Study|Adverse Event|8
6122156|NCT00903968|9745513|FG000|Overall Study|DLT|0
6122157|NCT00903968|9745514|FG001|Overall Study|DLT|0
6122158|NCT00903968|9745515|FG002|Overall Study|DLT|0
6215177|NCT01618708|9882685|FG000|Overall Study|Other than specified above|1
6215178|NCT01618708|9882686|FG001|Overall Study|Other than specified above|1
6215179|NCT01618708|9882685|FG000|Overall Study|Randomized but not treated|3
6215180|NCT01618708|9882686|FG001|Overall Study|Randomized but not treated|2
6215181|NCT01618838|9882693|FG000|Overall Study|slow accrual, trial closed prematurely.|4
6215182|NCT01618864|9882698|FG000|Overall Study|Withdrawal by Subject|2
6215183|NCT01618864|9882698|FG000|Overall Study|Lost to Follow-up|2
6122159|NCT00903968|9745516|FG003|Overall Study|DLT|0
6122160|NCT00903968|9745517|FG004|Overall Study|DLT|0
6122161|NCT00903968|9745518|FG005|Overall Study|DLT|0
6122162|NCT00903968|9745519|FG006|Overall Study|DLT|2
6122163|NCT00903968|9745520|FG007|Overall Study|DLT|0
6122164|NCT00903968|9745513|FG000|Overall Study|Withdrawal by Subject|1
6122165|NCT00903968|9745514|FG001|Overall Study|Withdrawal by Subject|0
6122166|NCT00903968|9745515|FG002|Overall Study|Withdrawal by Subject|1
6122167|NCT00903968|9745516|FG003|Overall Study|Withdrawal by Subject|0
6122168|NCT00903968|9745517|FG004|Overall Study|Withdrawal by Subject|1
6122169|NCT00903968|9745518|FG005|Overall Study|Withdrawal by Subject|1
6122170|NCT00903968|9745519|FG006|Overall Study|Withdrawal by Subject|0
6122171|NCT00903968|9745520|FG007|Overall Study|Withdrawal by Subject|4
6122172|NCT00903968|9745513|FG000|Overall Study|Non-Compliance|0
6122173|NCT00903968|9745514|FG001|Overall Study|Non-Compliance|0
6122174|NCT00903968|9745515|FG002|Overall Study|Non-Compliance|0
6122175|NCT00903968|9745516|FG003|Overall Study|Non-Compliance|0
6122176|NCT00903968|9745517|FG004|Overall Study|Non-Compliance|0
6122177|NCT00903968|9745518|FG005|Overall Study|Non-Compliance|1
6122178|NCT00903968|9745519|FG006|Overall Study|Non-Compliance|0
6122179|NCT00903968|9745520|FG007|Overall Study|Non-Compliance|0
6122180|NCT00903968|9745513|FG000|Overall Study|Physician Decision|0
6122181|NCT00903968|9745514|FG001|Overall Study|Physician Decision|0
6122182|NCT00903968|9745515|FG002|Overall Study|Physician Decision|0
6122183|NCT00903968|9745516|FG003|Overall Study|Physician Decision|0
6122184|NCT00903968|9745517|FG004|Overall Study|Physician Decision|0
6122185|NCT00903968|9745518|FG005|Overall Study|Physician Decision|1
6215184|NCT01618916|9882713|FG000|Overall Study|Adverse Event|1
6215185|NCT01618916|9882714|FG001|Overall Study|Adverse Event|0
6215186|NCT01618916|9882715|FG002|Overall Study|Adverse Event|0
6215187|NCT01618916|9882716|FG003|Overall Study|Adverse Event|0
6215188|NCT01618916|9882717|FG004|Overall Study|Adverse Event|0
6215189|NCT01618916|9882718|FG005|Overall Study|Adverse Event|0
6215190|NCT01618916|9882713|FG000|Overall Study|Withdrawal by Subject|0
6215191|NCT01618916|9882714|FG001|Overall Study|Withdrawal by Subject|1
6215192|NCT01618916|9882715|FG002|Overall Study|Withdrawal by Subject|1
6215193|NCT01618916|9882716|FG003|Overall Study|Withdrawal by Subject|0
6215194|NCT01618916|9882717|FG004|Overall Study|Withdrawal by Subject|1
6215195|NCT01618916|9882718|FG005|Overall Study|Withdrawal by Subject|0
6215196|NCT01618916|9882713|FG000|Overall Study|Lost to Follow-up|1
6215197|NCT01618916|9882714|FG001|Overall Study|Lost to Follow-up|0
6215198|NCT01618916|9882715|FG002|Overall Study|Lost to Follow-up|0
6215199|NCT01618916|9882716|FG003|Overall Study|Lost to Follow-up|2
6215200|NCT01618916|9882717|FG004|Overall Study|Lost to Follow-up|0
6215201|NCT01618916|9882718|FG005|Overall Study|Lost to Follow-up|0
6215202|NCT01618968|9882761|FG000|Overall Study|Adverse Event|1
6215203|NCT01618968|9882762|FG001|Overall Study|Adverse Event|0
6215204|NCT01618968|9882763|FG002|Overall Study|Adverse Event|0
6215205|NCT01618968|9882764|FG003|Overall Study|Adverse Event|0
6215206|NCT01618968|9882761|FG000|Overall Study|Death|0
6215207|NCT01618968|9882762|FG001|Overall Study|Death|0
6215208|NCT01618968|9882763|FG002|Overall Study|Death|0
6215209|NCT01618968|9882764|FG003|Overall Study|Death|1
6215210|NCT01619059|9882775|FG000|Short-Term (ST) Treatment Period|Adverse Event|1
6215211|NCT01619059|9882776|FG001|Short-Term (ST) Treatment Period|Adverse Event|0
6215212|NCT01619059|9882775|FG000|Short-Term (ST) Treatment Period|Withdrawal by Subject|2
6215213|NCT01619059|9882776|FG001|Short-Term (ST) Treatment Period|Withdrawal by Subject|5
6215214|NCT01619059|9882775|FG000|Short-Term (ST) Treatment Period|Lost to Follow-up|2
6215215|NCT01619059|9882776|FG001|Short-Term (ST) Treatment Period|Lost to Follow-up|4
6215216|NCT01619059|9882775|FG000|Short-Term (ST) Treatment Period|Non-compliance, not Met Study Criteria|1
6215217|NCT01619059|9882776|FG001|Short-Term (ST) Treatment Period|Non-compliance, not Met Study Criteria|2
6287942|NCT02357576|10001048|FG000|Neurodevelopmental Outcome Follow Up|Became ineligible during follow-up|1
6287943|NCT02357576|10001049|FG001|Neurodevelopmental Outcome Follow Up|Became ineligible during follow-up|0
6287944|NCT02357576|10001048|FG000|Neurodevelopmental Outcome Follow Up|Lost to Follow-up|1
6287945|NCT02357576|10001049|FG001|Neurodevelopmental Outcome Follow Up|Lost to Follow-up|4
6287946|NCT02357576|10001048|FG000|Neurodevelopmental Outcome Follow Up|Withdrawal by Subject|2
6287947|NCT02357576|10001049|FG001|Neurodevelopmental Outcome Follow Up|Withdrawal by Subject|0
6287948|NCT02357901|10001086|FG000|Run-In Period (Days -14 to Day -1)|Run-In failures|161
6287949|NCT02357901|10001087|FG001|Run-In Period (Days -14 to Day -1)|Run-In failures|0
6287950|NCT02357901|10001088|FG002|Run-In Period (Days -14 to Day -1)|Run-In failures|0
6287951|NCT02357901|10001089|FG003|Run-In Period (Days -14 to Day -1)|Run-In failures|0
6287952|NCT02357901|10001086|FG000|Treatment Period (Day 1 to Week 24)|Lost to Follow-up|0
6122186|NCT00903968|9745519|FG006|Overall Study|Physician Decision|0
6122187|NCT00903968|9745520|FG007|Overall Study|Physician Decision|0
6122188|NCT00903968|9745513|FG000|Overall Study|Progressive Disease|2
6122189|NCT00903968|9745514|FG001|Overall Study|Progressive Disease|3
6122190|NCT00903968|9745515|FG002|Overall Study|Progressive Disease|2
6122191|NCT00903968|9745516|FG003|Overall Study|Progressive Disease|3
6122192|NCT00903968|9745517|FG004|Overall Study|Progressive Disease|3
6215218|NCT01619059|9882775|FG000|Long-Term (LT) Treatment Period|Lack of Efficacy|0
6215219|NCT01619059|9882776|FG001|Long-Term (LT) Treatment Period|Lack of Efficacy|1
6215220|NCT01619059|9882775|FG000|Long-Term (LT) Treatment Period|Adverse Event|2
6122193|NCT00903968|9745518|FG005|Overall Study|Progressive Disease|3
6122194|NCT00903968|9745519|FG006|Overall Study|Progressive Disease|0
6122195|NCT00903968|9745520|FG007|Overall Study|Progressive Disease|18
6122196|NCT00903968|9745513|FG000|Overall Study|Lack of Efficacy|0
6122197|NCT00903968|9745514|FG001|Overall Study|Lack of Efficacy|0
6122198|NCT00903968|9745515|FG002|Overall Study|Lack of Efficacy|0
6122199|NCT00903968|9745516|FG003|Overall Study|Lack of Efficacy|0
6122200|NCT00903968|9745517|FG004|Overall Study|Lack of Efficacy|0
6122201|NCT00903968|9745518|FG005|Overall Study|Lack of Efficacy|0
6122202|NCT00903968|9745519|FG006|Overall Study|Lack of Efficacy|0
6122203|NCT00903968|9745520|FG007|Overall Study|Lack of Efficacy|3
6122204|NCT00904033|9745556|FG000|Overall Study|Withdrawal by Subject|1
6122205|NCT00904033|9745557|FG001|Overall Study|Withdrawal by Subject|1
6122206|NCT00904033|9745558|FG002|Overall Study|Withdrawal by Subject|0
6122207|NCT00904033|9745559|FG003|Overall Study|Withdrawal by Subject|0
6122208|NCT00904033|9745556|FG000|Overall Study|Physician Decision|0
6122209|NCT00904033|9745557|FG001|Overall Study|Physician Decision|0
6122210|NCT00904033|9745558|FG002|Overall Study|Physician Decision|1
6122211|NCT00904033|9745559|FG003|Overall Study|Physician Decision|0
6122212|NCT00904033|9745556|FG000|Overall Study|Unable to obtain final blood draw|0
6122213|NCT00904033|9745557|FG001|Overall Study|Unable to obtain final blood draw|0
6122214|NCT00904033|9745558|FG002|Overall Study|Unable to obtain final blood draw|0
6122215|NCT00904033|9745559|FG003|Overall Study|Unable to obtain final blood draw|2
6122216|NCT00904150|9745572|FG000|Saliva Samples (DNA)|saliva samples not suitable for assay|3
6122217|NCT00904150|9745573|FG001|Saliva Samples (DNA)|saliva samples not suitable for assay|0
6122218|NCT00904150|9745572|FG000|Saliva Samples (DNA)|Australian samples of different genotype|0
6122219|NCT00904150|9745573|FG001|Saliva Samples (DNA)|Australian samples of different genotype|145
6122220|NCT00904215|9745579|FG000|Overall Study|Adverse Event|25
6122221|NCT00904215|9745579|FG000|Overall Study|Protocol Violation|10
6122222|NCT00904215|9745579|FG000|Overall Study|Lost to Follow-up|63
6122223|NCT00904215|9745579|FG000|Overall Study|Withdrawal by Subject|9
6122224|NCT00904215|9745579|FG000|Overall Study|Other|28
6122225|NCT00904371|9745587|FG000|Overall Study|Adverse Event|2
6122226|NCT00904371|9745587|FG000|Overall Study|Lost to Follow-up|4
6122227|NCT00904371|9745587|FG000|Overall Study|Discontinued at target blood pressure|2
6122228|NCT00904371|9745587|FG000|Overall Study|Continued with Tritace|1
6122229|NCT00904670|9745607|FG000|Open Label Phase|Withdrawal by Subject|2
6122230|NCT00904670|9745608|FG001|Open Label Phase|Withdrawal by Subject|0
6122231|NCT00904670|9745607|FG000|Open Label Phase|Adverse Event|2
6122232|NCT00904670|9745608|FG001|Open Label Phase|Adverse Event|0
6122233|NCT00904670|9745607|FG000|Open Label Phase|Lack of Efficacy|1
6122234|NCT00904670|9745608|FG001|Open Label Phase|Lack of Efficacy|0
6122235|NCT00904670|9745607|FG000|Open Label Phase|Lost to Follow-up|1
6122236|NCT00904670|9745608|FG001|Open Label Phase|Lost to Follow-up|0
6122237|NCT00904722|9745616|FG000|Overall Study|Physician Decision|1
6122238|NCT00904748|9745620|FG000|Overall Study|Withdrawal by Subject|1
6122239|NCT00904748|9745621|FG001|Overall Study|Withdrawal by Subject|1
6122240|NCT00904748|9745622|FG002|Overall Study|Withdrawal by Subject|1
6122241|NCT00904748|9745623|FG003|Overall Study|Withdrawal by Subject|2
6122242|NCT00904748|9745624|FG004|Overall Study|Withdrawal by Subject|0
6122243|NCT00904748|9745625|FG005|Overall Study|Withdrawal by Subject|0
6122244|NCT00904748|9745620|FG000|Overall Study|Adverse Event|0
6122245|NCT00904748|9745621|FG001|Overall Study|Adverse Event|0
6122246|NCT00904748|9745622|FG002|Overall Study|Adverse Event|0
6122247|NCT00904748|9745623|FG003|Overall Study|Adverse Event|0
6122248|NCT00904748|9745624|FG004|Overall Study|Adverse Event|1
6122249|NCT00904748|9745625|FG005|Overall Study|Adverse Event|0
6122250|NCT00904839|9745672|FG000|Overall Study|Adverse Event|0
6122251|NCT00904839|9745673|FG001|Overall Study|Adverse Event|5
6122252|NCT00904839|9745674|FG002|Overall Study|Adverse Event|4
6122253|NCT00904839|9745672|FG000|Overall Study|Protocol Violation|0
6122254|NCT00904839|9745673|FG001|Overall Study|Protocol Violation|1
6122255|NCT00904839|9745674|FG002|Overall Study|Protocol Violation|1
6122256|NCT00904839|9745672|FG000|Overall Study|Lost to Follow-up|0
6122257|NCT00904839|9745673|FG001|Overall Study|Lost to Follow-up|1
6122258|NCT00904839|9745674|FG002|Overall Study|Lost to Follow-up|2
6122259|NCT00904839|9745672|FG000|Overall Study|Withdrawal by Subject|0
6122260|NCT00904839|9745673|FG001|Overall Study|Withdrawal by Subject|2
6122261|NCT00904839|9745674|FG002|Overall Study|Withdrawal by Subject|0
6122262|NCT00904839|9745672|FG000|Overall Study|Not treated|1
6122263|NCT00904839|9745673|FG001|Overall Study|Not treated|0
6122264|NCT00904839|9745674|FG002|Overall Study|Not treated|1
6122265|NCT00904839|9745672|FG000|Overall Study|Other than above|0
6122266|NCT00904839|9745673|FG001|Overall Study|Other than above|9
6122267|NCT00904839|9745674|FG002|Overall Study|Other than above|7
6122268|NCT00904917|9745689|FG000|Overall Study|Lost to Follow-up|2
6122269|NCT00904917|9745690|FG001|Overall Study|Lost to Follow-up|2
6122270|NCT00904917|9745691|FG002|Overall Study|Lost to Follow-up|2
6122271|NCT00904917|9745692|FG003|Overall Study|Lost to Follow-up|2
6122272|NCT00904969|9745705|FG000|Overall Study|Lost to Follow-up|4
6122273|NCT00904969|9745705|FG000|Overall Study|Withdrawal by Subject|3
6122274|NCT00904969|9745705|FG000|Overall Study|Additional Treatments|11
6122275|NCT00904969|9745705|FG000|Overall Study|Case Aborted; Subject Exited|1
6122276|NCT00904982|9745728|FG000|Overall Study|Withdrawal by Subject|2
6122277|NCT00904982|9745729|FG001|Overall Study|Withdrawal by Subject|0
6122278|NCT00904982|9745730|FG002|Overall Study|Withdrawal by Subject|0
6122279|NCT00904982|9745731|FG003|Overall Study|Withdrawal by Subject|0
6122280|NCT00905021|9745750|FG000|Overall Study|Adverse Event|2
6122281|NCT00905034|9745755|FG000|Overall Study|Withdrawal by Subject|1
6122282|NCT00905255|9745778|FG000|Overall Study|Adverse Event|7
6122283|NCT00905255|9745779|FG001|Overall Study|Adverse Event|5
6122284|NCT00905255|9745778|FG000|Overall Study|Withdrawal by Subject|5
6122285|NCT00905255|9745779|FG001|Overall Study|Withdrawal by Subject|4
6122286|NCT00905255|9745778|FG000|Overall Study|Familial and Personal Reasons|1
6122287|NCT00905255|9745779|FG001|Overall Study|Familial and Personal Reasons|0
6122288|NCT00905307|9745809|FG000|Overall Study|Switched to Open Label Rescue|7
6122289|NCT00905307|9745810|FG001|Overall Study|Switched to Open Label Rescue|17
6122290|NCT00905307|9745811|FG002|Overall Study|Switched to Open Label Rescue|11
6122291|NCT00905307|9745812|FG003|Overall Study|Switched to Open Label Rescue|11
6122292|NCT00905307|9745813|FG004|Overall Study|Switched to Open Label Rescue|4
6122293|NCT00905307|9745814|FG005|Overall Study|Switched to Open Label Rescue|15
6122294|NCT00905307|9745809|FG000|Overall Study|Lost to Follow-up|0
6122295|NCT00905307|9745810|FG001|Overall Study|Lost to Follow-up|0
6122296|NCT00905307|9745811|FG002|Overall Study|Lost to Follow-up|0
6122297|NCT00905307|9745812|FG003|Overall Study|Lost to Follow-up|0
6122298|NCT00905307|9745813|FG004|Overall Study|Lost to Follow-up|1
6122299|NCT00905307|9745814|FG005|Overall Study|Lost to Follow-up|1
6122300|NCT00905307|9745809|FG000|Overall Study|Adverse Event|3
6122301|NCT00905307|9745810|FG001|Overall Study|Adverse Event|4
6122302|NCT00905307|9745811|FG002|Overall Study|Adverse Event|5
6122303|NCT00905307|9745812|FG003|Overall Study|Adverse Event|11
6122304|NCT00905307|9745813|FG004|Overall Study|Adverse Event|3
6122305|NCT00905307|9745814|FG005|Overall Study|Adverse Event|5
6122306|NCT00905307|9745809|FG000|Overall Study|Withdrawal by Subject|5
6122307|NCT00905307|9745810|FG001|Overall Study|Withdrawal by Subject|13
6122308|NCT00905307|9745811|FG002|Overall Study|Withdrawal by Subject|15
6122309|NCT00905307|9745812|FG003|Overall Study|Withdrawal by Subject|11
6122310|NCT00905307|9745813|FG004|Overall Study|Withdrawal by Subject|4
6122311|NCT00905307|9745814|FG005|Overall Study|Withdrawal by Subject|13
6122312|NCT00905307|9745809|FG000|Overall Study|Protocol Violation|1
6122313|NCT00905307|9745810|FG001|Overall Study|Protocol Violation|0
6122314|NCT00905307|9745811|FG002|Overall Study|Protocol Violation|1
6122315|NCT00905307|9745812|FG003|Overall Study|Protocol Violation|0
6122316|NCT00905307|9745813|FG004|Overall Study|Protocol Violation|0
6122317|NCT00905307|9745814|FG005|Overall Study|Protocol Violation|0
6122318|NCT00905307|9745809|FG000|Overall Study|Lack of Efficacy|6
6122319|NCT00905307|9745810|FG001|Overall Study|Lack of Efficacy|3
6122320|NCT00905307|9745811|FG002|Overall Study|Lack of Efficacy|5
6122321|NCT00905307|9745812|FG003|Overall Study|Lack of Efficacy|4
6122322|NCT00905307|9745813|FG004|Overall Study|Lack of Efficacy|4
6122323|NCT00905307|9745814|FG005|Overall Study|Lack of Efficacy|8
6122324|NCT00905359|9745843|FG000|Overall Study|Lost to Follow-up|17
6122325|NCT00905359|9745844|FG001|Overall Study|Lost to Follow-up|10
6122326|NCT00905359|9745843|FG000|Overall Study|Death|2
6122327|NCT00905359|9745844|FG001|Overall Study|Death|0
6122328|NCT00905359|9745843|FG000|Overall Study|Withdrawal consent|5
6215221|NCT01619059|9882776|FG001|Long-Term (LT) Treatment Period|Adverse Event|3
6215222|NCT01619059|9882775|FG000|Long-Term (LT) Treatment Period|Withdrawal by Subject|3
6215223|NCT01619059|9882776|FG001|Long-Term (LT) Treatment Period|Withdrawal by Subject|2
6215224|NCT01619059|9882775|FG000|Long-Term (LT) Treatment Period|Death|1
6215225|NCT01619059|9882776|FG001|Long-Term (LT) Treatment Period|Death|0
6215226|NCT01619059|9882775|FG000|Long-Term (LT) Treatment Period|Lost to Follow-up|2
6215227|NCT01619059|9882776|FG001|Long-Term (LT) Treatment Period|Lost to Follow-up|2
6215228|NCT01619059|9882775|FG000|Long-Term (LT) Treatment Period|Not Met Study Criteria|0
6215229|NCT01619059|9882776|FG001|Long-Term (LT) Treatment Period|Not Met Study Criteria|1
6215230|NCT01619410|9882784|FG000|Overall Study|Lost to Follow-up|7
6215231|NCT01619410|9882785|FG001|Overall Study|Lost to Follow-up|4
6215232|NCT01619423|9882795|FG000|Part 1 (Dose Escalation)|High basal Mn|0
6215233|NCT01619423|9882796|FG001|Part 1 (Dose Escalation)|High basal Mn|2
6122329|NCT00905359|9745844|FG001|Overall Study|Withdrawal consent|6
6122330|NCT00905424|9745852|FG000|Overall Study|Lost to Follow-up|3
6122331|NCT00905424|9745853|FG001|Overall Study|Lost to Follow-up|3
6122332|NCT00905424|9745852|FG000|Overall Study|Withdrawal by Subject|1
6122333|NCT00905424|9745853|FG001|Overall Study|Withdrawal by Subject|2
6122334|NCT00905424|9745852|FG000|Overall Study|Adverse Event|4
6122335|NCT00905424|9745853|FG001|Overall Study|Adverse Event|2
6122336|NCT00905424|9745852|FG000|Overall Study|Non-compliance with study medication|2
6122337|NCT00905424|9745853|FG001|Overall Study|Non-compliance with study medication|0
6122338|NCT00905424|9745852|FG000|Overall Study|Sponsor decision|1
6122339|NCT00905424|9745853|FG001|Overall Study|Sponsor decision|0
6122340|NCT00905424|9745852|FG000|Overall Study|Positive urine drug screen|0
6122341|NCT00905424|9745853|FG001|Overall Study|Positive urine drug screen|1
6122342|NCT00905424|9745852|FG000|Overall Study|Non-adherence to visit schedule|0
6215234|NCT01619423|9882797|FG002|Part 1 (Dose Escalation)|High basal Mn|0
6122343|NCT00905424|9745853|FG001|Overall Study|Non-adherence to visit schedule|1
6122344|NCT00905437|9745863|FG000|Overall Study|Adverse Event|3
6122345|NCT00905437|9745864|FG001|Overall Study|Adverse Event|2
6122346|NCT00905437|9745863|FG000|Overall Study|Lost to Follow-up|0
6122347|NCT00905437|9745864|FG001|Overall Study|Lost to Follow-up|1
6122348|NCT00905437|9745863|FG000|Overall Study|Withdrawal by Subject|0
6122349|NCT00905437|9745864|FG001|Overall Study|Withdrawal by Subject|1
6122350|NCT00905437|9745863|FG000|Overall Study|Other|5
6122351|NCT00905437|9745864|FG001|Overall Study|Other|6
6122352|NCT00905489|9745903|FG000|Pharmaco-kinetic (PK) Phase|Protocol Violation|2
6215235|NCT01619423|9882798|FG003|Part 1 (Dose Escalation)|High basal Mn|0
6122353|NCT00905489|9745903|FG000|Pharmaco-kinetic (PK) Phase|Other reason not defined above|3
6122354|NCT00905489|9745903|FG000|Optional Extension Phase (OEP)|Adverse Event|1
6122355|NCT00905632|9745950|FG000|Overall Study|Adverse Event|0
6122356|NCT00905632|9745951|FG001|Overall Study|Adverse Event|0
6122357|NCT00905632|9745952|FG002|Overall Study|Adverse Event|0
6122358|NCT00905632|9745953|FG003|Overall Study|Adverse Event|0
6122359|NCT00905632|9745954|FG004|Overall Study|Adverse Event|0
6122360|NCT00905632|9745955|FG005|Overall Study|Adverse Event|1
6122361|NCT00905632|9745956|FG006|Overall Study|Adverse Event|4
6122362|NCT00905840|9745992|FG000|Overall Study|Lost to Follow-up|11
6122363|NCT00905840|9745992|FG000|Overall Study|Death|3
6122364|NCT00905840|9745992|FG000|Overall Study|Withdrawal by Subject|1
6122365|NCT00905840|9745992|FG000|Overall Study|Adverse Event|1
6122366|NCT00906087|9746008|FG000|Initial Washout|Withdrawal by Subject|1
6122367|NCT00906087|9746008|FG000|Initial Washout|Physician Decision|1
6122368|NCT00906204|9746035|FG000|Primary Endpoint (Early Safety)|Physician Decision|1
6122369|NCT00906204|9746036|FG001|Primary Endpoint (Early Safety)|Physician Decision|0
6122370|NCT00906204|9746035|FG000|Primary Endpoint (Early Safety)|Untransplantable donor kidney|0
6122371|NCT00906204|9746036|FG001|Primary Endpoint (Early Safety)|Untransplantable donor kidney|1
6122372|NCT00906204|9746035|FG000|Primary Endpoint (Early Safety)|Withdrawal by Subject|1
6122373|NCT00906204|9746036|FG001|Primary Endpoint (Early Safety)|Withdrawal by Subject|0
6122374|NCT00906204|9746035|FG000|Secondary Endpoints (Long-term Safety)|Adverse Event|2
6122375|NCT00906204|9746036|FG001|Secondary Endpoints (Long-term Safety)|Adverse Event|2
6122376|NCT00906204|9746035|FG000|Secondary Endpoints (Long-term Safety)|Death|0
6122377|NCT00906204|9746036|FG001|Secondary Endpoints (Long-term Safety)|Death|1
6122378|NCT00906282|9746046|FG000|Preoperative Chemotherapy|Withdrawal by Subject|2
6122379|NCT00906282|9746046|FG000|Preoperative Chemotherapy|Not surgical candidates, off study|10
6122380|NCT00906282|9746046|FG000|Preoperative Chemotherapy|Progressive disease|6
6122381|NCT00906282|9746046|FG000|Preoperative Chemotherapy|Toxicity|1
6122382|NCT00906347|9746053|FG000|Received Study Drug|8 cm prior to initiation of study drug|18
6122383|NCT00906347|9746054|FG001|Received Study Drug|8 cm prior to initiation of study drug|30
6122384|NCT00906347|9746053|FG000|Received Study Drug|Nonreassuring fetal heart rate|13
6122385|NCT00906347|9746054|FG001|Received Study Drug|Nonreassuring fetal heart rate|1
6122386|NCT00906347|9746053|FG000|Received Study Drug|Refused study drug|1
6122387|NCT00906347|9746054|FG001|Received Study Drug|Refused study drug|0
6122388|NCT00906347|9746053|FG000|Received Study Drug|Uterine tachysystole or hypertonus|8
6122389|NCT00906347|9746054|FG001|Received Study Drug|Uterine tachysystole or hypertonus|0
6122390|NCT00906373|9746062|FG000|Overall Study|Withdrawal by Subject|0
6122391|NCT00906373|9746063|FG001|Overall Study|Withdrawal by Subject|5
6122392|NCT00906373|9746062|FG000|Overall Study|Other|0
6122393|NCT00906373|9746063|FG001|Overall Study|Other|1
6122394|NCT00906373|9746062|FG000|Overall Study|Still on treatment at cutoff date|0
6122395|NCT00906373|9746063|FG001|Overall Study|Still on treatment at cutoff date|2
6122396|NCT00906399|9746073|FG000|Year 1|Randomized But Not Treated|0
6122397|NCT00906399|9746074|FG001|Year 1|Randomized But Not Treated|1
6122398|NCT00906399|9746075|FG002|Year 1|Randomized But Not Treated|3
6122399|NCT00906399|9746076|FG003|Year 1|Randomized But Not Treated|0
6122400|NCT00906399|9746077|FG004|Year 1|Randomized But Not Treated|0
6122401|NCT00906399|9746078|FG005|Year 1|Randomized But Not Treated|0
6122402|NCT00906399|9746079|FG006|Year 1|Randomized But Not Treated|0
6122403|NCT00906399|9746073|FG000|Year 1|Adverse Event|4
6122404|NCT00906399|9746074|FG001|Year 1|Adverse Event|22
6122405|NCT00906399|9746075|FG002|Year 1|Adverse Event|24
6122406|NCT00906399|9746076|FG003|Year 1|Adverse Event|0
6122407|NCT00906399|9746077|FG004|Year 1|Adverse Event|0
6122408|NCT00906399|9746078|FG005|Year 1|Adverse Event|0
6122409|NCT00906399|9746079|FG006|Year 1|Adverse Event|0
6122410|NCT00906399|9746073|FG000|Year 1|Lost to Follow-up|4
6122411|NCT00906399|9746074|FG001|Year 1|Lost to Follow-up|4
6122412|NCT00906399|9746075|FG002|Year 1|Lost to Follow-up|2
6122413|NCT00906399|9746076|FG003|Year 1|Lost to Follow-up|0
6122414|NCT00906399|9746077|FG004|Year 1|Lost to Follow-up|0
6122415|NCT00906399|9746078|FG005|Year 1|Lost to Follow-up|0
6122416|NCT00906399|9746079|FG006|Year 1|Lost to Follow-up|0
6122417|NCT00906399|9746073|FG000|Year 1|Withdrawal by Subject|30
6122418|NCT00906399|9746074|FG001|Year 1|Withdrawal by Subject|32
6122419|NCT00906399|9746075|FG002|Year 1|Withdrawal by Subject|36
6122420|NCT00906399|9746076|FG003|Year 1|Withdrawal by Subject|0
6122421|NCT00906399|9746077|FG004|Year 1|Withdrawal by Subject|0
6122422|NCT00906399|9746078|FG005|Year 1|Withdrawal by Subject|0
6122423|NCT00906399|9746079|FG006|Year 1|Withdrawal by Subject|0
6122424|NCT00906399|9746073|FG000|Year 1|Physician Decision|0
6122425|NCT00906399|9746074|FG001|Year 1|Physician Decision|1
6215236|NCT01619579|9882811|FG000|Overall Study|Withdrawal by Subject|0
6122426|NCT00906399|9746075|FG002|Year 1|Physician Decision|3
6122427|NCT00906399|9746076|FG003|Year 1|Physician Decision|0
6122428|NCT00906399|9746077|FG004|Year 1|Physician Decision|0
6122429|NCT00906399|9746078|FG005|Year 1|Physician Decision|0
6122430|NCT00906399|9746079|FG006|Year 1|Physician Decision|0
6122431|NCT00906399|9746073|FG000|Year 1|Death|2
6122432|NCT00906399|9746074|FG001|Year 1|Death|1
6122433|NCT00906399|9746075|FG002|Year 1|Death|1
6122434|NCT00906399|9746076|FG003|Year 1|Death|0
6122435|NCT00906399|9746077|FG004|Year 1|Death|0
6122436|NCT00906399|9746078|FG005|Year 1|Death|0
6122437|NCT00906399|9746079|FG006|Year 1|Death|0
6122438|NCT00906399|9746073|FG000|Year 1|Other|4
6122439|NCT00906399|9746074|FG001|Year 1|Other|2
6122440|NCT00906399|9746075|FG002|Year 1|Other|7
6215237|NCT01619579|9882812|FG001|Overall Study|Withdrawal by Subject|3
6215238|NCT01619787|9882824|FG000|Overall Study|Lost to Follow-up|5
6215239|NCT01619852|9882850|FG000|24 Hour Assessment|Withdrawal by Subject|1
6215240|NCT01619852|9882851|FG001|24 Hour Assessment|Withdrawal by Subject|1
6215241|NCT01619852|9882850|FG000|3 Month Follow up|Lost to Follow-up|31
6215242|NCT01619852|9882851|FG001|3 Month Follow up|Lost to Follow-up|34
6215243|NCT01619865|9882858|FG000|Overall Study|Adverse Event|1
6215244|NCT01619865|9882858|FG000|Overall Study|Death|2
6215245|NCT01619865|9882858|FG000|Overall Study|subject not able to comply|1
6215246|NCT01619878|9882863|FG000|6 Week Follow-up Phase|Adverse Event|1
6215247|NCT01619878|9882863|FG000|Follow-up at 12 Months of Age|Lost to Follow-up|1
6215248|NCT01619878|9882863|FG000|Follow-up at 12 Months of Age|Death|2
6215249|NCT01620060|9882893|FG000|Overall Study|Adverse Event|9
6215250|NCT01620060|9882893|FG000|Overall Study|Protocol Violation|1
6215251|NCT01620060|9882893|FG000|Overall Study|Withdrawal by Subject|1
6215252|NCT01620060|9882893|FG000|Overall Study|Did not comply with Study Produre|1
6215253|NCT01620060|9882893|FG000|Overall Study|Family emergency|1
6215254|NCT01620060|9882893|FG000|Overall Study|Per Sponsor Decision|2
6215255|NCT01620086|9882899|FG000|Overall Study|Withdrawal by Subject|3
6215256|NCT01620086|9882900|FG001|Overall Study|Withdrawal by Subject|3
6215257|NCT01620086|9882901|FG002|Overall Study|Withdrawal by Subject|0
6215258|NCT01620086|9882899|FG000|Overall Study|failed study criteria|1
6215259|NCT01620086|9882900|FG001|Overall Study|failed study criteria|4
6215260|NCT01620086|9882901|FG002|Overall Study|failed study criteria|0
6215261|NCT01620086|9882899|FG000|Overall Study|Physician Decision|1
6215262|NCT01620086|9882900|FG001|Overall Study|Physician Decision|0
6215263|NCT01620086|9882901|FG002|Overall Study|Physician Decision|0
6215264|NCT01620138|9882912|FG000|Overall Study|Withdrawal by Subject|3
6215265|NCT01620138|9882913|FG001|Overall Study|Withdrawal by Subject|0
6215266|NCT01620138|9882912|FG000|Overall Study|Lack of Efficacy|1
6215267|NCT01620138|9882913|FG001|Overall Study|Lack of Efficacy|0
6215268|NCT01620138|9882912|FG000|Overall Study|Adverse Event|2
6215269|NCT01620138|9882913|FG001|Overall Study|Adverse Event|0
6215270|NCT01620177|9882919|FG000|Overall Study|Failure at Screening Visit|43
6215271|NCT01620177|9882919|FG000|Overall Study|Withdrawal by Subject|26
6215272|NCT01620177|9882919|FG000|Overall Study|Lost to Follow-up|7
6215273|NCT01620177|9882919|FG000|Overall Study|Physician Decision|2
6215274|NCT01620177|9882919|FG000|Overall Study|Randomized, Not Active due to Scheduling|1
6215275|NCT01620255|9882974|FG000|Overall Study|Withdrawal by Subject|4
6215276|NCT01620255|9882975|FG001|Overall Study|Withdrawal by Subject|1
6215277|NCT01620255|9882976|FG002|Overall Study|Withdrawal by Subject|1
6215278|NCT01620255|9882977|FG003|Overall Study|Withdrawal by Subject|2
6215279|NCT01620255|9882978|FG004|Overall Study|Withdrawal by Subject|4
6215280|NCT01620255|9882974|FG000|Overall Study|Participant underwent fecal transplant|0
6287953|NCT02357901|10001087|FG001|Treatment Period (Day 1 to Week 24)|Lost to Follow-up|26
6287954|NCT02357901|10001088|FG002|Treatment Period (Day 1 to Week 24)|Lost to Follow-up|23
6287955|NCT02357901|10001089|FG003|Treatment Period (Day 1 to Week 24)|Lost to Follow-up|12
6287956|NCT02357901|10001086|FG000|Treatment Period (Day 1 to Week 24)|Withdrawal by Subject|0
6215281|NCT01620255|9882975|FG001|Overall Study|Participant underwent fecal transplant|0
6215282|NCT01620255|9882976|FG002|Overall Study|Participant underwent fecal transplant|1
6215283|NCT01620255|9882977|FG003|Overall Study|Participant underwent fecal transplant|0
6215284|NCT01620255|9882978|FG004|Overall Study|Participant underwent fecal transplant|0
6215285|NCT01620255|9882974|FG000|Overall Study|Non-compliance|0
6215286|NCT01620255|9882975|FG001|Overall Study|Non-compliance|1
6215287|NCT01620255|9882976|FG002|Overall Study|Non-compliance|0
6215288|NCT01620255|9882977|FG003|Overall Study|Non-compliance|0
6215289|NCT01620255|9882978|FG004|Overall Study|Non-compliance|0
6215290|NCT01620255|9882974|FG000|Overall Study|Adverse Event|0
6215291|NCT01620255|9882975|FG001|Overall Study|Adverse Event|4
6215292|NCT01620255|9882976|FG002|Overall Study|Adverse Event|0
6215293|NCT01620255|9882977|FG003|Overall Study|Adverse Event|1
6215294|NCT01620255|9882978|FG004|Overall Study|Adverse Event|1
6215295|NCT01620255|9882974|FG000|Overall Study|Withdrawn at discretion of investigator|0
6215296|NCT01620255|9882975|FG001|Overall Study|Withdrawn at discretion of investigator|0
6215297|NCT01620255|9882976|FG002|Overall Study|Withdrawn at discretion of investigator|0
6122441|NCT00906399|9746076|FG003|Year 1|Other|0
6122442|NCT00906399|9746077|FG004|Year 1|Other|0
6122443|NCT00906399|9746078|FG005|Year 1|Other|0
6215298|NCT01620255|9882977|FG003|Overall Study|Withdrawn at discretion of investigator|0
6122444|NCT00906399|9746079|FG006|Year 1|Other|0
6122445|NCT00906399|9746073|FG000|Year 2|Adverse Event|0
6122446|NCT00906399|9746074|FG001|Year 2|Adverse Event|0
6122447|NCT00906399|9746075|FG002|Year 2|Adverse Event|0
6122448|NCT00906399|9746076|FG003|Year 2|Adverse Event|9
6122449|NCT00906399|9746077|FG004|Year 2|Adverse Event|8
6122450|NCT00906399|9746078|FG005|Year 2|Adverse Event|11
6122451|NCT00906399|9746079|FG006|Year 2|Adverse Event|6
6122452|NCT00906399|9746073|FG000|Year 2|Lost to Follow-up|0
6122453|NCT00906399|9746074|FG001|Year 2|Lost to Follow-up|0
6122454|NCT00906399|9746075|FG002|Year 2|Lost to Follow-up|0
6122455|NCT00906399|9746076|FG003|Year 2|Lost to Follow-up|1
6122456|NCT00906399|9746077|FG004|Year 2|Lost to Follow-up|4
6122457|NCT00906399|9746078|FG005|Year 2|Lost to Follow-up|2
6122458|NCT00906399|9746079|FG006|Year 2|Lost to Follow-up|4
6122459|NCT00906399|9746073|FG000|Year 2|Withdrawal by Subject|0
6122460|NCT00906399|9746074|FG001|Year 2|Withdrawal by Subject|0
6122461|NCT00906399|9746075|FG002|Year 2|Withdrawal by Subject|0
6122462|NCT00906399|9746076|FG003|Year 2|Withdrawal by Subject|17
6122463|NCT00906399|9746077|FG004|Year 2|Withdrawal by Subject|18
6122464|NCT00906399|9746078|FG005|Year 2|Withdrawal by Subject|27
6122465|NCT00906399|9746079|FG006|Year 2|Withdrawal by Subject|13
6122466|NCT00906399|9746073|FG000|Year 2|Physician Decision|0
6122467|NCT00906399|9746074|FG001|Year 2|Physician Decision|0
6122468|NCT00906399|9746075|FG002|Year 2|Physician Decision|0
6122469|NCT00906399|9746076|FG003|Year 2|Physician Decision|0
6122470|NCT00906399|9746077|FG004|Year 2|Physician Decision|2
6122471|NCT00906399|9746078|FG005|Year 2|Physician Decision|6
6122472|NCT00906399|9746079|FG006|Year 2|Physician Decision|3
6215299|NCT01620255|9882978|FG004|Overall Study|Withdrawn at discretion of investigator|1
6215300|NCT01620489|9882992|FG000|Overall Study|Adverse Event|17
6215301|NCT01620489|9882993|FG001|Overall Study|Adverse Event|4
6215302|NCT01620489|9882992|FG000|Overall Study|Protocol Violation|0
6215303|NCT01620489|9882993|FG001|Overall Study|Protocol Violation|3
6215304|NCT01620489|9882992|FG000|Overall Study|Withdrawal Criteria|17
6215305|NCT01620489|9882993|FG001|Overall Study|Withdrawal Criteria|25
6215306|NCT01620489|9882992|FG000|Overall Study|Unclassified|1
6215307|NCT01620489|9882993|FG001|Overall Study|Unclassified|2
6215308|NCT01620528|9883002|FG000|Treatment Period|Did Not Receive Study Drug|0
6215309|NCT01620528|9883003|FG001|Treatment Period|Did Not Receive Study Drug|0
6215310|NCT01620528|9883004|FG002|Treatment Period|Did Not Receive Study Drug|1
6215311|NCT01620528|9883002|FG000|Treatment Period|Withdrawal by Subject|35
6215312|NCT01620528|9883003|FG001|Treatment Period|Withdrawal by Subject|21
6215313|NCT01620528|9883004|FG002|Treatment Period|Withdrawal by Subject|16
6215314|NCT01620528|9883002|FG000|Treatment Period|Adverse Event|17
6215315|NCT01620528|9883003|FG001|Treatment Period|Adverse Event|13
6215316|NCT01620528|9883004|FG002|Treatment Period|Adverse Event|21
6215317|NCT01620528|9883002|FG000|Treatment Period|Lost to Follow-up|16
6215318|NCT01620528|9883003|FG001|Treatment Period|Lost to Follow-up|8
6215319|NCT01620528|9883004|FG002|Treatment Period|Lost to Follow-up|14
6215320|NCT01620528|9883002|FG000|Treatment Period|Other|9
6215321|NCT01620528|9883003|FG001|Treatment Period|Other|5
6215322|NCT01620528|9883004|FG002|Treatment Period|Other|7
6215323|NCT01620528|9883002|FG000|Treatment Period|Subject Noncompliant|11
6215324|NCT01620528|9883003|FG001|Treatment Period|Subject Noncompliant|2
6215325|NCT01620528|9883004|FG002|Treatment Period|Subject Noncompliant|2
6215326|NCT01620528|9883002|FG000|Treatment Period|Pregnancy|7
6215327|NCT01620528|9883003|FG001|Treatment Period|Pregnancy|2
6215328|NCT01620528|9883004|FG002|Treatment Period|Pregnancy|2
6215329|NCT01620528|9883002|FG000|Treatment Period|Surgery/Invasive Intervention|5
6215330|NCT01620528|9883003|FG001|Treatment Period|Surgery/Invasive Intervention|1
6215331|NCT01620528|9883004|FG002|Treatment Period|Surgery/Invasive Intervention|3
6215332|NCT01620528|9883002|FG000|Treatment Period|Exclusionary Medication Received|0
6215333|NCT01620528|9883003|FG001|Treatment Period|Exclusionary Medication Received|1
6215334|NCT01620528|9883004|FG002|Treatment Period|Exclusionary Medication Received|0
6215335|NCT01620528|9883002|FG000|Post-Treatment Follow-Up Period|Withdrawal by Subject|3
6215336|NCT01620528|9883003|FG001|Post-Treatment Follow-Up Period|Withdrawal by Subject|7
6215337|NCT01620528|9883004|FG002|Post-Treatment Follow-Up Period|Withdrawal by Subject|3
6215338|NCT01620528|9883002|FG000|Post-Treatment Follow-Up Period|Lost to Follow-up|3
6215339|NCT01620528|9883003|FG001|Post-Treatment Follow-Up Period|Lost to Follow-up|2
6215340|NCT01620528|9883004|FG002|Post-Treatment Follow-Up Period|Lost to Follow-up|4
6215341|NCT01620528|9883002|FG000|Post-Treatment Follow-Up Period|Exclusionary Medication Received|0
6215342|NCT01620528|9883003|FG001|Post-Treatment Follow-Up Period|Exclusionary Medication Received|1
6215343|NCT01620528|9883004|FG002|Post-Treatment Follow-Up Period|Exclusionary Medication Received|1
6215344|NCT01620528|9883002|FG000|Post-Treatment Follow-Up Period|Surgery/Invasive Intervention|8
6215345|NCT01620528|9883003|FG001|Post-Treatment Follow-Up Period|Surgery/Invasive Intervention|3
6215346|NCT01620528|9883004|FG002|Post-Treatment Follow-Up Period|Surgery/Invasive Intervention|4
6215347|NCT01620528|9883002|FG000|Post-Treatment Follow-Up Period|Other|6
6215348|NCT01620528|9883003|FG001|Post-Treatment Follow-Up Period|Other|4
6215349|NCT01620528|9883004|FG002|Post-Treatment Follow-Up Period|Other|2
6215350|NCT01620762|9883036|FG000|Overall Study|Protocol Violation|1
6215351|NCT01620762|9883037|FG001|Overall Study|Protocol Violation|1
6122473|NCT00906399|9746073|FG000|Year 2|Death|0
6122474|NCT00906399|9746074|FG001|Year 2|Death|0
6122475|NCT00906399|9746075|FG002|Year 2|Death|0
6122476|NCT00906399|9746076|FG003|Year 2|Death|1
6122477|NCT00906399|9746077|FG004|Year 2|Death|0
6122478|NCT00906399|9746078|FG005|Year 2|Death|0
6122479|NCT00906399|9746079|FG006|Year 2|Death|3
6122480|NCT00906399|9746073|FG000|Year 2|Other|0
6122481|NCT00906399|9746074|FG001|Year 2|Other|0
6122482|NCT00906399|9746075|FG002|Year 2|Other|0
6122483|NCT00906399|9746076|FG003|Year 2|Other|2
6122484|NCT00906399|9746077|FG004|Year 2|Other|3
6122485|NCT00906399|9746078|FG005|Year 2|Other|1
6122486|NCT00906399|9746079|FG006|Year 2|Other|0
6122487|NCT00906698|9746110|FG000|Overall Study|Dose-limiting toxicity (DLT)|0
6122488|NCT00906698|9746111|FG001|Overall Study|Dose-limiting toxicity (DLT)|6
6122489|NCT00906698|9746112|FG002|Overall Study|Dose-limiting toxicity (DLT)|0
6122490|NCT00906698|9746113|FG003|Overall Study|Dose-limiting toxicity (DLT)|0
6122491|NCT00906698|9746114|FG004|Overall Study|Dose-limiting toxicity (DLT)|1
6122492|NCT00906698|9746115|FG005|Overall Study|Dose-limiting toxicity (DLT)|0
6122493|NCT00906698|9746110|FG000|Overall Study|Adverse Event|0
6122494|NCT00906698|9746111|FG001|Overall Study|Adverse Event|0
6122495|NCT00906698|9746112|FG002|Overall Study|Adverse Event|2
6122496|NCT00906698|9746113|FG003|Overall Study|Adverse Event|0
6122497|NCT00906698|9746114|FG004|Overall Study|Adverse Event|4
6122498|NCT00906698|9746115|FG005|Overall Study|Adverse Event|1
6122499|NCT00906698|9746110|FG000|Overall Study|Disease progression|3
6122500|NCT00906698|9746111|FG001|Overall Study|Disease progression|12
6122501|NCT00906698|9746112|FG002|Overall Study|Disease progression|4
6122502|NCT00906698|9746113|FG003|Overall Study|Disease progression|4
6122503|NCT00906698|9746114|FG004|Overall Study|Disease progression|12
6122504|NCT00906698|9746115|FG005|Overall Study|Disease progression|4
6122505|NCT00906698|9746110|FG000|Overall Study|Withdrawal by Subject|0
6122506|NCT00906698|9746111|FG001|Overall Study|Withdrawal by Subject|0
6122507|NCT00906698|9746112|FG002|Overall Study|Withdrawal by Subject|0
6122508|NCT00906698|9746113|FG003|Overall Study|Withdrawal by Subject|0
6122509|NCT00906698|9746114|FG004|Overall Study|Withdrawal by Subject|1
6122510|NCT00906698|9746115|FG005|Overall Study|Withdrawal by Subject|0
6122511|NCT00906698|9746110|FG000|Overall Study|incl. non compliance, lost to follow-up|0
6122512|NCT00906698|9746111|FG001|Overall Study|incl. non compliance, lost to follow-up|1
6122513|NCT00906698|9746112|FG002|Overall Study|incl. non compliance, lost to follow-up|0
6122514|NCT00906698|9746113|FG003|Overall Study|incl. non compliance, lost to follow-up|0
6122515|NCT00906698|9746114|FG004|Overall Study|incl. non compliance, lost to follow-up|0
6122516|NCT00906698|9746115|FG005|Overall Study|incl. non compliance, lost to follow-up|0
6122517|NCT00906945|9746167|FG000|Overall Study|Found to be not eligible|0
6122518|NCT00906945|9746168|FG001|Overall Study|Found to be not eligible|0
6122519|NCT00906945|9746169|FG002|Overall Study|Found to be not eligible|0
6122520|NCT00906945|9746170|FG003|Overall Study|Found to be not eligible|1
6122521|NCT00906945|9746171|FG004|Overall Study|Found to be not eligible|1
6122522|NCT00906945|9746172|FG005|Overall Study|Found to be not eligible|1
6122523|NCT00906945|9746167|FG000|Overall Study|Physician Decision|0
6122524|NCT00906945|9746168|FG001|Overall Study|Physician Decision|0
6122525|NCT00906945|9746169|FG002|Overall Study|Physician Decision|0
6122526|NCT00906945|9746170|FG003|Overall Study|Physician Decision|0
6122527|NCT00906945|9746171|FG004|Overall Study|Physician Decision|0
6122528|NCT00906945|9746172|FG005|Overall Study|Physician Decision|1
6122529|NCT00906971|9746199|FG000|Overall Study|Withdrawal by Subject|8
6122530|NCT00906971|9746200|FG001|Overall Study|Withdrawal by Subject|2
6122531|NCT00906971|9746199|FG000|Overall Study|Lost to Follow-up|0
6122532|NCT00906971|9746200|FG001|Overall Study|Lost to Follow-up|1
6122533|NCT00907153|9746221|FG000|Overall Study|Lost to Follow-up|1
6122534|NCT00907153|9746222|FG001|Overall Study|Lost to Follow-up|1
6122535|NCT00907153|9746221|FG000|Overall Study|Withdrawal by Subject|1
6122536|NCT00907153|9746222|FG001|Overall Study|Withdrawal by Subject|3
6215352|NCT01620762|9883038|FG002|Overall Study|Protocol Violation|1
6215353|NCT01620762|9883036|FG000|Overall Study|Adverse Event|9
6215354|NCT01620762|9883037|FG001|Overall Study|Adverse Event|5
6215355|NCT01620762|9883038|FG002|Overall Study|Adverse Event|2
6215356|NCT01620762|9883036|FG000|Overall Study|Withdrawal by Subject|23
6215357|NCT01620762|9883037|FG001|Overall Study|Withdrawal by Subject|26
6215358|NCT01620762|9883038|FG002|Overall Study|Withdrawal by Subject|27
6215359|NCT01620762|9883036|FG000|Overall Study|Lost to Follow-up|11
6122537|NCT00907257|9746230|FG000|Overall Study|Adverse Event|0
6122538|NCT00907257|9746231|FG001|Overall Study|Adverse Event|4
6122539|NCT00907257|9746230|FG000|Overall Study|Protocol Violation|1
6122540|NCT00907257|9746231|FG001|Overall Study|Protocol Violation|2
6122541|NCT00907257|9746230|FG000|Overall Study|Lost to Follow-up|3
6122542|NCT00907257|9746231|FG001|Overall Study|Lost to Follow-up|3
6122543|NCT00907257|9746230|FG000|Overall Study|Withdrawal by Subject|1
6122544|NCT00907257|9746231|FG001|Overall Study|Withdrawal by Subject|2
6122545|NCT00907257|9746230|FG000|Overall Study|Per IRB-Subject became vulnerable|1
6215360|NCT01620762|9883037|FG001|Overall Study|Lost to Follow-up|17
6122546|NCT00907257|9746231|FG001|Overall Study|Per IRB-Subject became vulnerable|0
6122547|NCT00907257|9746230|FG000|Overall Study|Moved|1
6122548|NCT00907257|9746231|FG001|Overall Study|Moved|0
6122549|NCT00907257|9746230|FG000|Overall Study|Personal Reasons|6
6122550|NCT00907257|9746231|FG001|Overall Study|Personal Reasons|1
6122551|NCT00907296|9746247|FG000|Overall Study|Ineligibility Determined|1
6122552|NCT00907296|9746248|FG001|Overall Study|Ineligibility Determined|0
6122553|NCT00907296|9746249|FG002|Overall Study|Ineligibility Determined|0
6122554|NCT00907296|9746250|FG003|Overall Study|Ineligibility Determined|1
6122555|NCT00907296|9746251|FG004|Overall Study|Ineligibility Determined|0
6122556|NCT00907296|9746252|FG005|Overall Study|Ineligibility Determined|0
6122557|NCT00907296|9746253|FG006|Overall Study|Ineligibility Determined|0
6122558|NCT00907296|9746254|FG007|Overall Study|Ineligibility Determined|1
6122559|NCT00907296|9746255|FG008|Overall Study|Ineligibility Determined|0
6122560|NCT00907296|9746256|FG009|Overall Study|Ineligibility Determined|0
6122561|NCT00907296|9746247|FG000|Overall Study|Protocol Deviation|0
6122562|NCT00907296|9746248|FG001|Overall Study|Protocol Deviation|1
6122563|NCT00907296|9746249|FG002|Overall Study|Protocol Deviation|0
6122564|NCT00907296|9746250|FG003|Overall Study|Protocol Deviation|0
6122565|NCT00907296|9746251|FG004|Overall Study|Protocol Deviation|0
6122566|NCT00907296|9746252|FG005|Overall Study|Protocol Deviation|0
6122567|NCT00907296|9746253|FG006|Overall Study|Protocol Deviation|0
6122568|NCT00907296|9746254|FG007|Overall Study|Protocol Deviation|0
6122569|NCT00907296|9746255|FG008|Overall Study|Protocol Deviation|0
6122570|NCT00907296|9746256|FG009|Overall Study|Protocol Deviation|0
6122571|NCT00907296|9746247|FG000|Overall Study|Noncompliance|1
6122572|NCT00907296|9746248|FG001|Overall Study|Noncompliance|1
6122573|NCT00907296|9746249|FG002|Overall Study|Noncompliance|1
6122574|NCT00907296|9746250|FG003|Overall Study|Noncompliance|0
6122575|NCT00907296|9746251|FG004|Overall Study|Noncompliance|0
6122576|NCT00907296|9746252|FG005|Overall Study|Noncompliance|1
6122577|NCT00907296|9746253|FG006|Overall Study|Noncompliance|0
6122578|NCT00907296|9746254|FG007|Overall Study|Noncompliance|2
6122579|NCT00907296|9746255|FG008|Overall Study|Noncompliance|0
6122580|NCT00907296|9746256|FG009|Overall Study|Noncompliance|0
6122581|NCT00907296|9746247|FG000|Overall Study|Adverse Event|2
6122582|NCT00907296|9746248|FG001|Overall Study|Adverse Event|0
6122583|NCT00907296|9746249|FG002|Overall Study|Adverse Event|0
6122584|NCT00907296|9746250|FG003|Overall Study|Adverse Event|0
6215361|NCT01620762|9883038|FG002|Overall Study|Lost to Follow-up|10
6215362|NCT01620762|9883036|FG000|Overall Study|Protocol deviation|1
6215363|NCT01620762|9883037|FG001|Overall Study|Protocol deviation|1
6215364|NCT01620762|9883038|FG002|Overall Study|Protocol deviation|6
6215365|NCT01620762|9883036|FG000|Overall Study|Subject deterioration|0
6215366|NCT01620762|9883037|FG001|Overall Study|Subject deterioration|1
6215367|NCT01620762|9883038|FG002|Overall Study|Subject deterioration|1
6215368|NCT01620762|9883036|FG000|Overall Study|Non-specified|3
6215369|NCT01620762|9883037|FG001|Overall Study|Non-specified|6
6215370|NCT01620762|9883038|FG002|Overall Study|Non-specified|5
6215371|NCT01620762|9883036|FG000|Overall Study|Use of prohibted therapies|0
6215372|NCT01620762|9883037|FG001|Overall Study|Use of prohibted therapies|1
6215373|NCT01620762|9883038|FG002|Overall Study|Use of prohibted therapies|1
6122585|NCT00907296|9746251|FG004|Overall Study|Adverse Event|0
6122586|NCT00907296|9746252|FG005|Overall Study|Adverse Event|0
6122587|NCT00907296|9746253|FG006|Overall Study|Adverse Event|1
6122588|NCT00907296|9746254|FG007|Overall Study|Adverse Event|0
6122589|NCT00907296|9746255|FG008|Overall Study|Adverse Event|0
6122590|NCT00907296|9746256|FG009|Overall Study|Adverse Event|1
6122591|NCT00907296|9746247|FG000|Overall Study|Withdrawal by Subject|7
6122592|NCT00907296|9746248|FG001|Overall Study|Withdrawal by Subject|2
6122593|NCT00907296|9746249|FG002|Overall Study|Withdrawal by Subject|1
6122594|NCT00907296|9746250|FG003|Overall Study|Withdrawal by Subject|1
6122595|NCT00907296|9746251|FG004|Overall Study|Withdrawal by Subject|1
6122596|NCT00907296|9746252|FG005|Overall Study|Withdrawal by Subject|5
6122597|NCT00907296|9746253|FG006|Overall Study|Withdrawal by Subject|3
6122598|NCT00907296|9746254|FG007|Overall Study|Withdrawal by Subject|2
6122599|NCT00907296|9746255|FG008|Overall Study|Withdrawal by Subject|4
6122600|NCT00907296|9746256|FG009|Overall Study|Withdrawal by Subject|2
6122601|NCT00907296|9746247|FG000|Overall Study|Lost to Follow-up|9
6122602|NCT00907296|9746248|FG001|Overall Study|Lost to Follow-up|1
6122603|NCT00907296|9746249|FG002|Overall Study|Lost to Follow-up|0
6122604|NCT00907296|9746250|FG003|Overall Study|Lost to Follow-up|2
6122605|NCT00907296|9746251|FG004|Overall Study|Lost to Follow-up|0
6122606|NCT00907296|9746252|FG005|Overall Study|Lost to Follow-up|3
6215374|NCT01620983|9883049|FG000|Overall Study|Lost to Follow-up|8
6122607|NCT00907296|9746253|FG006|Overall Study|Lost to Follow-up|2
6122608|NCT00907296|9746254|FG007|Overall Study|Lost to Follow-up|2
6122609|NCT00907296|9746255|FG008|Overall Study|Lost to Follow-up|0
6122610|NCT00907296|9746256|FG009|Overall Study|Lost to Follow-up|4
6122611|NCT00907335|9746280|FG000|Overall Study|Withdrawal by Subject|2
6122612|NCT00907335|9746281|FG001|Overall Study|Withdrawal by Subject|0
6122613|NCT00907335|9746280|FG000|Overall Study|Adverse Event|4
6122614|NCT00907335|9746281|FG001|Overall Study|Adverse Event|1
6122615|NCT00907335|9746280|FG000|Overall Study|Lost to Follow-up|2
6122616|NCT00907335|9746281|FG001|Overall Study|Lost to Follow-up|0
6122617|NCT00907374|9746289|FG000|Overall Study|Noncompliant w/study protocol at <3 mos|2
6122618|NCT00907374|9746290|FG001|Overall Study|Noncompliant w/study protocol at <3 mos|2
6122619|NCT00907478|9746311|FG000|Overall Study|Ineligibility determined|0
6122620|NCT00907478|9746312|FG001|Overall Study|Ineligibility determined|0
6122621|NCT00907478|9746313|FG002|Overall Study|Ineligibility determined|1
6122622|NCT00907478|9746311|FG000|Overall Study|Noncompliance|0
6122623|NCT00907478|9746312|FG001|Overall Study|Noncompliance|0
6122624|NCT00907478|9746313|FG002|Overall Study|Noncompliance|1
6122625|NCT00907478|9746311|FG000|Overall Study|Adverse Event|3
6122626|NCT00907478|9746312|FG001|Overall Study|Adverse Event|1
6122627|NCT00907478|9746313|FG002|Overall Study|Adverse Event|2
6122628|NCT00907478|9746311|FG000|Overall Study|Withdrawal by Subject|8
6122629|NCT00907478|9746312|FG001|Overall Study|Withdrawal by Subject|9
6122630|NCT00907478|9746313|FG002|Overall Study|Withdrawal by Subject|6
6122631|NCT00907478|9746311|FG000|Overall Study|Requirement for alternative therapy|1
6122632|NCT00907478|9746312|FG001|Overall Study|Requirement for alternative therapy|2
6122633|NCT00907478|9746313|FG002|Overall Study|Requirement for alternative therapy|3
6122634|NCT00907478|9746311|FG000|Overall Study|Physician Decision|2
6122635|NCT00907478|9746312|FG001|Overall Study|Physician Decision|0
6122636|NCT00907478|9746313|FG002|Overall Study|Physician Decision|3
6122637|NCT00907478|9746311|FG000|Overall Study|Death|4
6122638|NCT00907478|9746312|FG001|Overall Study|Death|2
6122639|NCT00907478|9746313|FG002|Overall Study|Death|1
6122640|NCT00907478|9746311|FG000|Overall Study|Protocol-specified criteria|5
6122641|NCT00907478|9746312|FG001|Overall Study|Protocol-specified criteria|2
6122642|NCT00907478|9746313|FG002|Overall Study|Protocol-specified criteria|3
6122643|NCT00907478|9746311|FG000|Overall Study|Pregnancy|0
6122644|NCT00907478|9746312|FG001|Overall Study|Pregnancy|1
6122645|NCT00907478|9746313|FG002|Overall Study|Pregnancy|1
6122646|NCT00907478|9746311|FG000|Overall Study|Lost to Follow-up|1
6122647|NCT00907478|9746312|FG001|Overall Study|Lost to Follow-up|0
6122648|NCT00907478|9746313|FG002|Overall Study|Lost to Follow-up|0
6122649|NCT00907478|9746311|FG000|Overall Study|Other|3
6122650|NCT00907478|9746312|FG001|Overall Study|Other|0
6122651|NCT00907478|9746313|FG002|Overall Study|Other|1
6122652|NCT00907517|9746328|FG000|Overall Study|Progressive Disease|3
6122653|NCT00907517|9746329|FG001|Overall Study|Progressive Disease|3
6122654|NCT00907517|9746330|FG002|Overall Study|Progressive Disease|4
6122655|NCT00907517|9746331|FG003|Overall Study|Progressive Disease|4
6122656|NCT00907517|9746332|FG004|Overall Study|Progressive Disease|4
6122657|NCT00907517|9746328|FG000|Overall Study|Symptomatic Deterioration|0
6122658|NCT00907517|9746329|FG001|Overall Study|Symptomatic Deterioration|0
6122659|NCT00907517|9746330|FG002|Overall Study|Symptomatic Deterioration|0
6122660|NCT00907517|9746331|FG003|Overall Study|Symptomatic Deterioration|0
6122661|NCT00907517|9746332|FG004|Overall Study|Symptomatic Deterioration|1
6122662|NCT00907621|9746346|FG000|Overall Study|Lost to Follow-up|6
6122663|NCT00907621|9746347|FG001|Overall Study|Lost to Follow-up|3
6122664|NCT00907621|9746346|FG000|Overall Study|intercurrent febrile illness|1
6215375|NCT01620983|9883050|FG001|Overall Study|Lost to Follow-up|4
6215376|NCT01620983|9883051|FG002|Overall Study|Lost to Follow-up|9
6215377|NCT01620983|9883049|FG000|Overall Study|Withdrawal by Subject|6
6215378|NCT01620983|9883050|FG001|Overall Study|Withdrawal by Subject|8
6215379|NCT01620983|9883051|FG002|Overall Study|Withdrawal by Subject|1
6215380|NCT01620983|9883049|FG000|Overall Study|Death|2
6215381|NCT01620983|9883050|FG001|Overall Study|Death|0
6215382|NCT01620983|9883051|FG002|Overall Study|Death|0
6215383|NCT01620983|9883049|FG000|Overall Study|Physician Decision|3
6215384|NCT01620983|9883050|FG001|Overall Study|Physician Decision|10
6215385|NCT01620983|9883051|FG002|Overall Study|Physician Decision|5
6287957|NCT02357901|10001087|FG001|Treatment Period (Day 1 to Week 24)|Withdrawal by Subject|20
6287958|NCT02357901|10001088|FG002|Treatment Period (Day 1 to Week 24)|Withdrawal by Subject|21
6287959|NCT02357901|10001089|FG003|Treatment Period (Day 1 to Week 24)|Withdrawal by Subject|18
6287960|NCT02357901|10001086|FG000|Treatment Period (Day 1 to Week 24)|Lack of Efficacy|0
6287961|NCT02357901|10001087|FG001|Treatment Period (Day 1 to Week 24)|Lack of Efficacy|3
6287962|NCT02357901|10001088|FG002|Treatment Period (Day 1 to Week 24)|Lack of Efficacy|5
6287963|NCT02357901|10001089|FG003|Treatment Period (Day 1 to Week 24)|Lack of Efficacy|18
6287964|NCT02357901|10001086|FG000|Treatment Period (Day 1 to Week 24)|Adverse Event|0
6287965|NCT02357901|10001087|FG001|Treatment Period (Day 1 to Week 24)|Adverse Event|6
6287966|NCT02357901|10001088|FG002|Treatment Period (Day 1 to Week 24)|Adverse Event|10
6287967|NCT02357901|10001089|FG003|Treatment Period (Day 1 to Week 24)|Adverse Event|2
6287968|NCT02357901|10001086|FG000|Treatment Period (Day 1 to Week 24)|Protocol Violation|0
6287969|NCT02357901|10001087|FG001|Treatment Period (Day 1 to Week 24)|Protocol Violation|2
6287970|NCT02357901|10001088|FG002|Treatment Period (Day 1 to Week 24)|Protocol Violation|5
6287971|NCT02357901|10001089|FG003|Treatment Period (Day 1 to Week 24)|Protocol Violation|0
6287972|NCT02357901|10001086|FG000|Treatment Period (Day 1 to Week 24)|Withdrawal symptoms|0
6287973|NCT02357901|10001087|FG001|Treatment Period (Day 1 to Week 24)|Withdrawal symptoms|1
6287974|NCT02357901|10001088|FG002|Treatment Period (Day 1 to Week 24)|Withdrawal symptoms|1
6287975|NCT02357901|10001089|FG003|Treatment Period (Day 1 to Week 24)|Withdrawal symptoms|3
6287976|NCT02357901|10001086|FG000|Treatment Period (Day 1 to Week 24)|Non-compliance with study drug|0
6287977|NCT02357901|10001087|FG001|Treatment Period (Day 1 to Week 24)|Non-compliance with study drug|2
6287978|NCT02357901|10001088|FG002|Treatment Period (Day 1 to Week 24)|Non-compliance with study drug|0
6287979|NCT02357901|10001089|FG003|Treatment Period (Day 1 to Week 24)|Non-compliance with study drug|2
6287980|NCT02357901|10001086|FG000|Treatment Period (Day 1 to Week 24)|Subject withdrawn by investigator|0
6287981|NCT02357901|10001087|FG001|Treatment Period (Day 1 to Week 24)|Subject withdrawn by investigator|1
6122665|NCT00907621|9746347|FG001|Overall Study|intercurrent febrile illness|1
6122666|NCT00907738|9746358|FG000|Overall Study|Adverse Event|2
6122667|NCT00907738|9746359|FG001|Overall Study|Adverse Event|0
6122668|NCT00907738|9746360|FG002|Overall Study|Adverse Event|1
6122669|NCT00907738|9746361|FG003|Overall Study|Adverse Event|0
6122670|NCT00907738|9746362|FG004|Overall Study|Adverse Event|0
6122671|NCT00907738|9746358|FG000|Overall Study|not specified or withdrew consent|3
6122672|NCT00907738|9746359|FG001|Overall Study|not specified or withdrew consent|0
6122673|NCT00907738|9746360|FG002|Overall Study|not specified or withdrew consent|0
6122674|NCT00907738|9746361|FG003|Overall Study|not specified or withdrew consent|0
6122675|NCT00907738|9746362|FG004|Overall Study|not specified or withdrew consent|0
6122676|NCT00907738|9746358|FG000|Overall Study|Disease progression|8
6122677|NCT00907738|9746359|FG001|Overall Study|Disease progression|1
6122678|NCT00907738|9746360|FG002|Overall Study|Disease progression|6
6122679|NCT00907738|9746361|FG003|Overall Study|Disease progression|4
6122680|NCT00907738|9746362|FG004|Overall Study|Disease progression|2
6122681|NCT00907777|9746380|FG000|Overall Study|Withdrawal by Subject|0
6122682|NCT00907777|9746381|FG001|Overall Study|Withdrawal by Subject|1
6122683|NCT00907803|9746390|FG000|Overall Study|Withdrawal of consent - long commute|1
6122684|NCT00907803|9746391|FG001|Overall Study|Withdrawal of consent - long commute|0
6122685|NCT00907803|9746392|FG002|Overall Study|Withdrawal of consent - long commute|0
6215386|NCT01621126|9883074|FG000|Overall Study|Physician Decision|6
6215387|NCT01621178|9883081|FG000|Overall Study|Adverse Event|5
6215388|NCT01621178|9883082|FG001|Overall Study|Adverse Event|2
6215389|NCT01621178|9883083|FG002|Overall Study|Adverse Event|8
6215390|NCT01621178|9883081|FG000|Overall Study|Death|6
6215391|NCT01621178|9883082|FG001|Overall Study|Death|7
6215392|NCT01621178|9883083|FG002|Overall Study|Death|2
6215393|NCT01621178|9883081|FG000|Overall Study|Lost to Follow-up|1
6215394|NCT01621178|9883082|FG001|Overall Study|Lost to Follow-up|2
6215395|NCT01621178|9883083|FG002|Overall Study|Lost to Follow-up|1
6215396|NCT01621178|9883081|FG000|Overall Study|Withdrawal by Subject|14
6215397|NCT01621178|9883082|FG001|Overall Study|Withdrawal by Subject|17
6215398|NCT01621178|9883083|FG002|Overall Study|Withdrawal by Subject|18
6215399|NCT01621178|9883081|FG000|Overall Study|Physician Decision|5
6215400|NCT01621178|9883082|FG001|Overall Study|Physician Decision|2
6215401|NCT01621178|9883083|FG002|Overall Study|Physician Decision|7
6215402|NCT01621191|9883095|FG000|Overall Study|Adverse Event|9
6215403|NCT01621191|9883095|FG000|Overall Study|Withdrawal by Subject|8
6215404|NCT01621191|9883095|FG000|Overall Study|Lack of Efficacy|6
6215405|NCT01621191|9883095|FG000|Overall Study|Lost to Follow-up|1
6215406|NCT01621191|9883095|FG000|Overall Study|Site Removed From Study|1
6215407|NCT01621490|9883125|FG000|Overall Study|Participant completed treatment|4
6215408|NCT01621490|9883126|FG001|Overall Study|Participant completed treatment|4
6215409|NCT01621490|9883127|FG002|Overall Study|Participant completed treatment|1
6215410|NCT01621490|9883128|FG003|Overall Study|Participant completed treatment|0
6215411|NCT01621490|9883129|FG004|Overall Study|Participant completed treatment|0
6122686|NCT00907803|9746390|FG000|Overall Study|Adverse Event|2
6122687|NCT00907803|9746391|FG001|Overall Study|Adverse Event|0
6122688|NCT00907803|9746392|FG002|Overall Study|Adverse Event|0
6122689|NCT00907803|9746390|FG000|Overall Study|Withdrawal by Subject|0
6122690|NCT00907803|9746391|FG001|Overall Study|Withdrawal by Subject|1
6122691|NCT00907803|9746392|FG002|Overall Study|Withdrawal by Subject|0
6122692|NCT00907803|9746390|FG000|Overall Study|Lost to Follow-up|0
6122693|NCT00907803|9746391|FG001|Overall Study|Lost to Follow-up|1
6122694|NCT00907803|9746392|FG002|Overall Study|Lost to Follow-up|0
6122695|NCT00907803|9746390|FG000|Overall Study|Protocol Violation|0
6122696|NCT00907803|9746391|FG001|Overall Study|Protocol Violation|1
6122697|NCT00907803|9746392|FG002|Overall Study|Protocol Violation|0
6122698|NCT00907881|9746400|FG000|Overall Study|Lost to Follow-up|59
6122699|NCT00907881|9746400|FG000|Overall Study|Noncompliance|5
6122700|NCT00907881|9746400|FG000|Overall Study|Withdrawal by Subject|5
6122701|NCT00907881|9746400|FG000|Overall Study|Protocol Violation|1
6122702|NCT00907881|9746400|FG000|Overall Study|Missing discontinuation information|15
6122703|NCT00908011|9746406|FG000|Overall Study|Withdrawal by Subject|2
6122704|NCT00908011|9746407|FG001|Overall Study|Withdrawal by Subject|2
6122705|NCT00908037|9746420|FG000|Part 2 (7 Week Randomized Period)|Protocol Violation|0
6122706|NCT00908037|9746421|FG001|Part 2 (7 Week Randomized Period)|Protocol Violation|0
6122707|NCT00908037|9746422|FG002|Part 2 (7 Week Randomized Period)|Protocol Violation|0
6122708|NCT00908037|9746423|FG003|Part 2 (7 Week Randomized Period)|Protocol Violation|0
6122709|NCT00908037|9746424|FG004|Part 2 (7 Week Randomized Period)|Protocol Violation|1
6122710|NCT00908037|9746425|FG005|Part 2 (7 Week Randomized Period)|Protocol Violation|0
6122711|NCT00908037|9746426|FG006|Part 2 (7 Week Randomized Period)|Protocol Violation|3
6122712|NCT00908037|9746427|FG007|Part 2 (7 Week Randomized Period)|Protocol Violation|0
6122713|NCT00908037|9746428|FG008|Part 2 (7 Week Randomized Period)|Protocol Violation|1
6122714|NCT00908037|9746429|FG009|Part 2 (7 Week Randomized Period)|Protocol Violation|0
6122715|NCT00908037|9746430|FG010|Part 2 (7 Week Randomized Period)|Protocol Violation|0
6122716|NCT00908037|9746431|FG011|Part 2 (7 Week Randomized Period)|Protocol Violation|0
6122717|NCT00908037|9746420|FG000|Part 2 (7 Week Randomized Period)|Lost to Follow-up|0
6215412|NCT01621490|9883130|FG005|Overall Study|Participant completed treatment|0
6215413|NCT01621490|9883131|FG006|Overall Study|Participant completed treatment|0
6122718|NCT00908037|9746421|FG001|Part 2 (7 Week Randomized Period)|Lost to Follow-up|0
6122719|NCT00908037|9746422|FG002|Part 2 (7 Week Randomized Period)|Lost to Follow-up|0
6122720|NCT00908037|9746423|FG003|Part 2 (7 Week Randomized Period)|Lost to Follow-up|0
6215414|NCT01621490|9883132|FG007|Overall Study|Participant completed treatment|1
6215415|NCT01621490|9883133|FG008|Overall Study|Participant completed treatment|0
6215416|NCT01621490|9883125|FG000|Overall Study|Patient could not travel|1
6215417|NCT01621490|9883126|FG001|Overall Study|Patient could not travel|0
6215418|NCT01621490|9883127|FG002|Overall Study|Patient could not travel|0
6215419|NCT01621490|9883128|FG003|Overall Study|Patient could not travel|0
6215420|NCT01621490|9883129|FG004|Overall Study|Patient could not travel|0
6215421|NCT01621490|9883130|FG005|Overall Study|Patient could not travel|0
6215422|NCT01621490|9883131|FG006|Overall Study|Patient could not travel|0
6215423|NCT01621490|9883132|FG007|Overall Study|Patient could not travel|0
6215424|NCT01621490|9883133|FG008|Overall Study|Patient could not travel|0
6215425|NCT01621490|9883125|FG000|Overall Study|Subject no longer meets study criteria|0
6215426|NCT01621490|9883126|FG001|Overall Study|Subject no longer meets study criteria|0
6215427|NCT01621490|9883127|FG002|Overall Study|Subject no longer meets study criteria|0
6215428|NCT01621490|9883128|FG003|Overall Study|Subject no longer meets study criteria|0
6215429|NCT01621490|9883129|FG004|Overall Study|Subject no longer meets study criteria|1
6215430|NCT01621490|9883130|FG005|Overall Study|Subject no longer meets study criteria|0
6215431|NCT01621490|9883131|FG006|Overall Study|Subject no longer meets study criteria|0
6215432|NCT01621490|9883132|FG007|Overall Study|Subject no longer meets study criteria|0
6215433|NCT01621490|9883133|FG008|Overall Study|Subject no longer meets study criteria|0
6215434|NCT01621490|9883125|FG000|Overall Study|Maximum clinical benefit|3
6215435|NCT01621490|9883126|FG001|Overall Study|Maximum clinical benefit|2
6215436|NCT01621490|9883127|FG002|Overall Study|Maximum clinical benefit|0
6215437|NCT01621490|9883128|FG003|Overall Study|Maximum clinical benefit|0
6215438|NCT01621490|9883129|FG004|Overall Study|Maximum clinical benefit|0
6215439|NCT01621490|9883130|FG005|Overall Study|Maximum clinical benefit|0
6215440|NCT01621490|9883131|FG006|Overall Study|Maximum clinical benefit|1
6215441|NCT01621490|9883132|FG007|Overall Study|Maximum clinical benefit|2
6215442|NCT01621490|9883133|FG008|Overall Study|Maximum clinical benefit|0
6215443|NCT01621490|9883125|FG000|Overall Study|Withdrawal by Subject|1
6215444|NCT01621490|9883126|FG001|Overall Study|Withdrawal by Subject|0
6215445|NCT01621490|9883127|FG002|Overall Study|Withdrawal by Subject|0
6215446|NCT01621490|9883128|FG003|Overall Study|Withdrawal by Subject|0
6215447|NCT01621490|9883129|FG004|Overall Study|Withdrawal by Subject|0
6215448|NCT01621490|9883130|FG005|Overall Study|Withdrawal by Subject|3
6215449|NCT01621490|9883131|FG006|Overall Study|Withdrawal by Subject|0
6215450|NCT01621490|9883132|FG007|Overall Study|Withdrawal by Subject|0
6215451|NCT01621490|9883133|FG008|Overall Study|Withdrawal by Subject|0
6215452|NCT01621490|9883125|FG000|Overall Study|Subject request to discontinue study|1
6215453|NCT01621490|9883126|FG001|Overall Study|Subject request to discontinue study|3
6215454|NCT01621490|9883127|FG002|Overall Study|Subject request to discontinue study|1
6215455|NCT01621490|9883128|FG003|Overall Study|Subject request to discontinue study|1
6215456|NCT01621490|9883129|FG004|Overall Study|Subject request to discontinue study|0
6215457|NCT01621490|9883130|FG005|Overall Study|Subject request to discontinue study|2
6215458|NCT01621490|9883131|FG006|Overall Study|Subject request to discontinue study|1
6215459|NCT01621490|9883132|FG007|Overall Study|Subject request to discontinue study|0
6215460|NCT01621490|9883133|FG008|Overall Study|Subject request to discontinue study|1
6215461|NCT01621490|9883125|FG000|Overall Study|Adverse event unrelated to study drug|2
6215462|NCT01621490|9883126|FG001|Overall Study|Adverse event unrelated to study drug|1
6215463|NCT01621490|9883127|FG002|Overall Study|Adverse event unrelated to study drug|0
6215464|NCT01621490|9883128|FG003|Overall Study|Adverse event unrelated to study drug|0
6215465|NCT01621490|9883129|FG004|Overall Study|Adverse event unrelated to study drug|0
6215466|NCT01621490|9883130|FG005|Overall Study|Adverse event unrelated to study drug|0
6215467|NCT01621490|9883131|FG006|Overall Study|Adverse event unrelated to study drug|0
6215468|NCT01621490|9883132|FG007|Overall Study|Adverse event unrelated to study drug|2
6215469|NCT01621490|9883133|FG008|Overall Study|Adverse event unrelated to study drug|1
6215470|NCT01621490|9883125|FG000|Overall Study|Disease progression|27
6215471|NCT01621490|9883126|FG001|Overall Study|Disease progression|28
6215472|NCT01621490|9883127|FG002|Overall Study|Disease progression|1
6215473|NCT01621490|9883128|FG003|Overall Study|Disease progression|5
6215474|NCT01621490|9883129|FG004|Overall Study|Disease progression|3
6215475|NCT01621490|9883130|FG005|Overall Study|Disease progression|8
6215476|NCT01621490|9883131|FG006|Overall Study|Disease progression|7
6215477|NCT01621490|9883132|FG007|Overall Study|Disease progression|0
6215478|NCT01621490|9883133|FG008|Overall Study|Disease progression|4
6215479|NCT01621490|9883125|FG000|Overall Study|Study drug toxicity|1
6215480|NCT01621490|9883126|FG001|Overall Study|Study drug toxicity|4
6215481|NCT01621490|9883127|FG002|Overall Study|Study drug toxicity|5
6215482|NCT01621490|9883128|FG003|Overall Study|Study drug toxicity|3
6215483|NCT01621490|9883129|FG004|Overall Study|Study drug toxicity|1
6287982|NCT02357901|10001088|FG002|Treatment Period (Day 1 to Week 24)|Subject withdrawn by investigator|0
6215484|NCT01621490|9883130|FG005|Overall Study|Study drug toxicity|10
6215485|NCT01621490|9883131|FG006|Overall Study|Study drug toxicity|1
6215486|NCT01621490|9883132|FG007|Overall Study|Study drug toxicity|4
6122721|NCT00908037|9746424|FG004|Part 2 (7 Week Randomized Period)|Lost to Follow-up|2
6122722|NCT00908037|9746425|FG005|Part 2 (7 Week Randomized Period)|Lost to Follow-up|0
6122723|NCT00908037|9746426|FG006|Part 2 (7 Week Randomized Period)|Lost to Follow-up|0
6122724|NCT00908037|9746427|FG007|Part 2 (7 Week Randomized Period)|Lost to Follow-up|0
6122725|NCT00908037|9746428|FG008|Part 2 (7 Week Randomized Period)|Lost to Follow-up|4
6122726|NCT00908037|9746429|FG009|Part 2 (7 Week Randomized Period)|Lost to Follow-up|0
6122727|NCT00908037|9746430|FG010|Part 2 (7 Week Randomized Period)|Lost to Follow-up|0
6122728|NCT00908037|9746431|FG011|Part 2 (7 Week Randomized Period)|Lost to Follow-up|0
6122729|NCT00908037|9746420|FG000|Part 2 (7 Week Randomized Period)|Withdrawal by parent/ guardian|0
6122730|NCT00908037|9746421|FG001|Part 2 (7 Week Randomized Period)|Withdrawal by parent/ guardian|0
6122731|NCT00908037|9746422|FG002|Part 2 (7 Week Randomized Period)|Withdrawal by parent/ guardian|0
6122732|NCT00908037|9746423|FG003|Part 2 (7 Week Randomized Period)|Withdrawal by parent/ guardian|1
6122733|NCT00908037|9746424|FG004|Part 2 (7 Week Randomized Period)|Withdrawal by parent/ guardian|0
6122734|NCT00908037|9746425|FG005|Part 2 (7 Week Randomized Period)|Withdrawal by parent/ guardian|0
6122735|NCT00908037|9746426|FG006|Part 2 (7 Week Randomized Period)|Withdrawal by parent/ guardian|1
6122736|NCT00908037|9746427|FG007|Part 2 (7 Week Randomized Period)|Withdrawal by parent/ guardian|0
6122737|NCT00908037|9746428|FG008|Part 2 (7 Week Randomized Period)|Withdrawal by parent/ guardian|0
6122738|NCT00908037|9746429|FG009|Part 2 (7 Week Randomized Period)|Withdrawal by parent/ guardian|0
6122739|NCT00908037|9746430|FG010|Part 2 (7 Week Randomized Period)|Withdrawal by parent/ guardian|0
6122740|NCT00908037|9746431|FG011|Part 2 (7 Week Randomized Period)|Withdrawal by parent/ guardian|0
6122741|NCT00908037|9746420|FG000|Part 2/3(Eltrombopag Open-Label Period)|Lack of Efficacy|0
6122742|NCT00908037|9746421|FG001|Part 2/3(Eltrombopag Open-Label Period)|Lack of Efficacy|0
6122743|NCT00908037|9746422|FG002|Part 2/3(Eltrombopag Open-Label Period)|Lack of Efficacy|0
6122744|NCT00908037|9746423|FG003|Part 2/3(Eltrombopag Open-Label Period)|Lack of Efficacy|0
6122745|NCT00908037|9746424|FG004|Part 2/3(Eltrombopag Open-Label Period)|Lack of Efficacy|0
6122746|NCT00908037|9746425|FG005|Part 2/3(Eltrombopag Open-Label Period)|Lack of Efficacy|0
6122747|NCT00908037|9746426|FG006|Part 2/3(Eltrombopag Open-Label Period)|Lack of Efficacy|0
6122748|NCT00908037|9746427|FG007|Part 2/3(Eltrombopag Open-Label Period)|Lack of Efficacy|0
6122749|NCT00908037|9746428|FG008|Part 2/3(Eltrombopag Open-Label Period)|Lack of Efficacy|0
6122750|NCT00908037|9746429|FG009|Part 2/3(Eltrombopag Open-Label Period)|Lack of Efficacy|0
6122751|NCT00908037|9746430|FG010|Part 2/3(Eltrombopag Open-Label Period)|Lack of Efficacy|0
6122752|NCT00908037|9746431|FG011|Part 2/3(Eltrombopag Open-Label Period)|Lack of Efficacy|1
6122753|NCT00908037|9746420|FG000|Part 2/3(Eltrombopag Open-Label Period)|Lost to Follow-up|0
6122754|NCT00908037|9746421|FG001|Part 2/3(Eltrombopag Open-Label Period)|Lost to Follow-up|0
6122755|NCT00908037|9746422|FG002|Part 2/3(Eltrombopag Open-Label Period)|Lost to Follow-up|0
6122756|NCT00908037|9746423|FG003|Part 2/3(Eltrombopag Open-Label Period)|Lost to Follow-up|0
6122757|NCT00908037|9746424|FG004|Part 2/3(Eltrombopag Open-Label Period)|Lost to Follow-up|0
6122758|NCT00908037|9746425|FG005|Part 2/3(Eltrombopag Open-Label Period)|Lost to Follow-up|0
6122759|NCT00908037|9746426|FG006|Part 2/3(Eltrombopag Open-Label Period)|Lost to Follow-up|0
6122760|NCT00908037|9746427|FG007|Part 2/3(Eltrombopag Open-Label Period)|Lost to Follow-up|0
6122761|NCT00908037|9746428|FG008|Part 2/3(Eltrombopag Open-Label Period)|Lost to Follow-up|0
6122762|NCT00908037|9746429|FG009|Part 2/3(Eltrombopag Open-Label Period)|Lost to Follow-up|1
6122763|NCT00908037|9746430|FG010|Part 2/3(Eltrombopag Open-Label Period)|Lost to Follow-up|0
6122764|NCT00908037|9746431|FG011|Part 2/3(Eltrombopag Open-Label Period)|Lost to Follow-up|2
6122765|NCT00908037|9746420|FG000|Part 2/3(Eltrombopag Open-Label Period)|Withdrawal by parent/guardian|0
6122766|NCT00908037|9746421|FG001|Part 2/3(Eltrombopag Open-Label Period)|Withdrawal by parent/guardian|0
6122767|NCT00908037|9746422|FG002|Part 2/3(Eltrombopag Open-Label Period)|Withdrawal by parent/guardian|0
6122768|NCT00908037|9746423|FG003|Part 2/3(Eltrombopag Open-Label Period)|Withdrawal by parent/guardian|0
6122769|NCT00908037|9746424|FG004|Part 2/3(Eltrombopag Open-Label Period)|Withdrawal by parent/guardian|0
6122770|NCT00908037|9746425|FG005|Part 2/3(Eltrombopag Open-Label Period)|Withdrawal by parent/guardian|0
6122771|NCT00908037|9746426|FG006|Part 2/3(Eltrombopag Open-Label Period)|Withdrawal by parent/guardian|0
6122772|NCT00908037|9746427|FG007|Part 2/3(Eltrombopag Open-Label Period)|Withdrawal by parent/guardian|0
6122773|NCT00908037|9746428|FG008|Part 2/3(Eltrombopag Open-Label Period)|Withdrawal by parent/guardian|0
6122774|NCT00908037|9746429|FG009|Part 2/3(Eltrombopag Open-Label Period)|Withdrawal by parent/guardian|1
6122775|NCT00908037|9746430|FG010|Part 2/3(Eltrombopag Open-Label Period)|Withdrawal by parent/guardian|0
6122776|NCT00908037|9746431|FG011|Part 2/3(Eltrombopag Open-Label Period)|Withdrawal by parent/guardian|0
6122777|NCT00908037|9746420|FG000|Part 2/3(Eltrombopag Open-Label Period)|Adverse Event|0
6122778|NCT00908037|9746421|FG001|Part 2/3(Eltrombopag Open-Label Period)|Adverse Event|0
6122779|NCT00908037|9746422|FG002|Part 2/3(Eltrombopag Open-Label Period)|Adverse Event|0
6215487|NCT01621490|9883133|FG008|Overall Study|Study drug toxicity|1
6215488|NCT01621490|9883125|FG000|Overall Study|Death|0
6215489|NCT01621490|9883126|FG001|Overall Study|Death|0
6215490|NCT01621490|9883127|FG002|Overall Study|Death|0
6215491|NCT01621490|9883128|FG003|Overall Study|Death|0
6287983|NCT02357901|10001089|FG003|Treatment Period (Day 1 to Week 24)|Subject withdrawn by investigator|3
6287984|NCT02357901|10001086|FG000|Treatment Period (Day 1 to Week 24)|Physician Decision|0
6215492|NCT01621490|9883129|FG004|Overall Study|Death|0
6215493|NCT01621490|9883130|FG005|Overall Study|Death|0
6215494|NCT01621490|9883131|FG006|Overall Study|Death|0
6122780|NCT00908037|9746423|FG003|Part 2/3(Eltrombopag Open-Label Period)|Adverse Event|0
6122781|NCT00908037|9746424|FG004|Part 2/3(Eltrombopag Open-Label Period)|Adverse Event|0
6122782|NCT00908037|9746425|FG005|Part 2/3(Eltrombopag Open-Label Period)|Adverse Event|0
6122783|NCT00908037|9746426|FG006|Part 2/3(Eltrombopag Open-Label Period)|Adverse Event|0
6122784|NCT00908037|9746427|FG007|Part 2/3(Eltrombopag Open-Label Period)|Adverse Event|0
6122785|NCT00908037|9746428|FG008|Part 2/3(Eltrombopag Open-Label Period)|Adverse Event|0
6215495|NCT01621490|9883132|FG007|Overall Study|Death|1
6215496|NCT01621490|9883133|FG008|Overall Study|Death|0
6215497|NCT01621490|9883125|FG000|Overall Study|Grade 4 Lipase elevation|1
6215498|NCT01621490|9883126|FG001|Overall Study|Grade 4 Lipase elevation|0
6215499|NCT01621490|9883127|FG002|Overall Study|Grade 4 Lipase elevation|0
6215500|NCT01621490|9883128|FG003|Overall Study|Grade 4 Lipase elevation|0
6215501|NCT01621490|9883129|FG004|Overall Study|Grade 4 Lipase elevation|0
6215502|NCT01621490|9883130|FG005|Overall Study|Grade 4 Lipase elevation|0
6215503|NCT01621490|9883131|FG006|Overall Study|Grade 4 Lipase elevation|0
6215504|NCT01621490|9883132|FG007|Overall Study|Grade 4 Lipase elevation|0
6215505|NCT01621490|9883133|FG008|Overall Study|Grade 4 Lipase elevation|0
6215506|NCT01621490|9883125|FG000|Overall Study|BMS informed of patient status|0
6215507|NCT01621490|9883126|FG001|Overall Study|BMS informed of patient status|0
6215508|NCT01621490|9883127|FG002|Overall Study|BMS informed of patient status|1
6215509|NCT01621490|9883128|FG003|Overall Study|BMS informed of patient status|0
6215510|NCT01621490|9883129|FG004|Overall Study|BMS informed of patient status|0
6287985|NCT02357901|10001087|FG001|Treatment Period (Day 1 to Week 24)|Physician Decision|0
6287986|NCT02357901|10001088|FG002|Treatment Period (Day 1 to Week 24)|Physician Decision|1
6287987|NCT02357901|10001089|FG003|Treatment Period (Day 1 to Week 24)|Physician Decision|1
6287988|NCT02357901|10001086|FG000|Treatment Period (Day 1 to Week 24)|site closed by sponsor, incarceration...|0
6287989|NCT02357901|10001087|FG001|Treatment Period (Day 1 to Week 24)|site closed by sponsor, incarceration...|17
6287990|NCT02357901|10001088|FG002|Treatment Period (Day 1 to Week 24)|site closed by sponsor, incarceration...|6
6287991|NCT02357901|10001089|FG003|Treatment Period (Day 1 to Week 24)|site closed by sponsor, incarceration...|7
6287992|NCT02357940|10001099|FG000|Overall Study|Adverse Event|0
6287993|NCT02357940|10001100|FG001|Overall Study|Adverse Event|1
6287994|NCT02357940|10001099|FG000|Overall Study|Investigator's judgement|0
6287995|NCT02357940|10001100|FG001|Overall Study|Investigator's judgement|1
6287996|NCT02357979|10001108|FG000|Overall Study|Lost to Follow-up|5
6287997|NCT02357979|10001109|FG001|Overall Study|Lost to Follow-up|5
6287998|NCT02358044|10001117|FG000|Overall Study|Adverse Event|0
6287999|NCT02358044|10001118|FG001|Overall Study|Adverse Event|1
6288000|NCT02358044|10001117|FG000|Overall Study|Lost to Follow-up|2
6288001|NCT02358044|10001118|FG001|Overall Study|Lost to Follow-up|1
6288002|NCT02358044|10001117|FG000|Overall Study|Physician Decision|0
6288003|NCT02358044|10001118|FG001|Overall Study|Physician Decision|1
6288004|NCT02358044|10001117|FG000|Overall Study|Withdrawal by Subject|0
6288005|NCT02358044|10001118|FG001|Overall Study|Withdrawal by Subject|4
6288006|NCT02358343|10001138|FG000|Screening Intervention|Death|0
6288007|NCT02358343|10001139|FG001|Screening Intervention|Death|2
6288008|NCT02358343|10001140|FG002|Screening Intervention|Death|0
6288009|NCT02358343|10001141|FG003|Screening Intervention|Death|0
6288010|NCT02358343|10001142|FG004|Screening Intervention|Death|0
6288011|NCT02358343|10001138|FG000|Screening Intervention|Withdrawal by Subject|1
6063439|NCT00506389|9664773|FG002|In-treatment Period|Lack of Efficacy|0
6063440|NCT00506389|9664771|FG000|In-treatment Period|Adverse Event|11
6122786|NCT00908037|9746429|FG009|Part 2/3(Eltrombopag Open-Label Period)|Adverse Event|0
6122787|NCT00908037|9746430|FG010|Part 2/3(Eltrombopag Open-Label Period)|Adverse Event|2
6122788|NCT00908037|9746431|FG011|Part 2/3(Eltrombopag Open-Label Period)|Adverse Event|0
6122789|NCT00908037|9746420|FG000|Part 2/3(Eltrombopag Open-Label Period)|Physician Decision|0
6122790|NCT00908037|9746421|FG001|Part 2/3(Eltrombopag Open-Label Period)|Physician Decision|0
6122791|NCT00908037|9746422|FG002|Part 2/3(Eltrombopag Open-Label Period)|Physician Decision|0
6122792|NCT00908037|9746423|FG003|Part 2/3(Eltrombopag Open-Label Period)|Physician Decision|0
6122793|NCT00908037|9746424|FG004|Part 2/3(Eltrombopag Open-Label Period)|Physician Decision|0
6122794|NCT00908037|9746425|FG005|Part 2/3(Eltrombopag Open-Label Period)|Physician Decision|0
6122795|NCT00908037|9746426|FG006|Part 2/3(Eltrombopag Open-Label Period)|Physician Decision|0
6122796|NCT00908037|9746427|FG007|Part 2/3(Eltrombopag Open-Label Period)|Physician Decision|0
6122797|NCT00908037|9746428|FG008|Part 2/3(Eltrombopag Open-Label Period)|Physician Decision|0
6122798|NCT00908037|9746429|FG009|Part 2/3(Eltrombopag Open-Label Period)|Physician Decision|1
6122799|NCT00908037|9746430|FG010|Part 2/3(Eltrombopag Open-Label Period)|Physician Decision|0
6122800|NCT00908037|9746431|FG011|Part 2/3(Eltrombopag Open-Label Period)|Physician Decision|0
6122801|NCT00908037|9746420|FG000|Part 2/3(Eltrombopag Open-Label Period)|Randomized but did not receive treatment|0
6215511|NCT01621490|9883130|FG005|Overall Study|BMS informed of patient status|0
6215512|NCT01621490|9883131|FG006|Overall Study|BMS informed of patient status|0
6215513|NCT01621490|9883132|FG007|Overall Study|BMS informed of patient status|0
6215514|NCT01621490|9883133|FG008|Overall Study|BMS informed of patient status|0
6288012|NCT02358343|10001139|FG001|Screening Intervention|Withdrawal by Subject|0
6288013|NCT02358343|10001140|FG002|Screening Intervention|Withdrawal by Subject|0
6288014|NCT02358343|10001141|FG003|Screening Intervention|Withdrawal by Subject|0
6063441|NCT00506389|9664772|FG001|In-treatment Period|Adverse Event|5
6122802|NCT00908037|9746421|FG001|Part 2/3(Eltrombopag Open-Label Period)|Randomized but did not receive treatment|0
6122803|NCT00908037|9746422|FG002|Part 2/3(Eltrombopag Open-Label Period)|Randomized but did not receive treatment|0
6122804|NCT00908037|9746423|FG003|Part 2/3(Eltrombopag Open-Label Period)|Randomized but did not receive treatment|0
6122805|NCT00908037|9746424|FG004|Part 2/3(Eltrombopag Open-Label Period)|Randomized but did not receive treatment|0
6122806|NCT00908037|9746425|FG005|Part 2/3(Eltrombopag Open-Label Period)|Randomized but did not receive treatment|0
6122807|NCT00908037|9746426|FG006|Part 2/3(Eltrombopag Open-Label Period)|Randomized but did not receive treatment|0
6122808|NCT00908037|9746427|FG007|Part 2/3(Eltrombopag Open-Label Period)|Randomized but did not receive treatment|0
6122809|NCT00908037|9746428|FG008|Part 2/3(Eltrombopag Open-Label Period)|Randomized but did not receive treatment|0
6122810|NCT00908037|9746429|FG009|Part 2/3(Eltrombopag Open-Label Period)|Randomized but did not receive treatment|0
6122811|NCT00908037|9746430|FG010|Part 2/3(Eltrombopag Open-Label Period)|Randomized but did not receive treatment|2
6122812|NCT00908037|9746431|FG011|Part 2/3(Eltrombopag Open-Label Period)|Randomized but did not receive treatment|0
6122813|NCT00908076|9746485|FG000|Overall Study|Lack of Efficacy|1
6122814|NCT00908076|9746486|FG001|Overall Study|Lack of Efficacy|1
6122815|NCT00908115|9746492|FG000|Overall Study|Other|14
6122816|NCT00908141|9746498|FG000|Overall Study|Withdrawal by Subject|0
6122817|NCT00908141|9746499|FG001|Overall Study|Withdrawal by Subject|1
6122818|NCT00908232|9746505|FG000|Cycle 1 to 4|Death|5
6122819|NCT00908232|9746506|FG001|Cycle 1 to 4|Death|0
6122820|NCT00908232|9746507|FG002|Cycle 1 to 4|Death|0
6122821|NCT00908232|9746508|FG003|Cycle 1 to 4|Death|0
6122822|NCT00908232|9746505|FG000|Cycle 1 to 4|Withdrawal by Subject|4
6122823|NCT00908232|9746506|FG001|Cycle 1 to 4|Withdrawal by Subject|0
6122824|NCT00908232|9746507|FG002|Cycle 1 to 4|Withdrawal by Subject|0
6122825|NCT00908232|9746508|FG003|Cycle 1 to 4|Withdrawal by Subject|0
6122826|NCT00908232|9746505|FG000|Cycle 1 to 4|Progressive Disease|6
6122827|NCT00908232|9746506|FG001|Cycle 1 to 4|Progressive Disease|0
6122828|NCT00908232|9746507|FG002|Cycle 1 to 4|Progressive Disease|0
6122829|NCT00908232|9746508|FG003|Cycle 1 to 4|Progressive Disease|0
6122830|NCT00908232|9746505|FG000|Cycle 1 to 4|Adverse Event|12
6122831|NCT00908232|9746506|FG001|Cycle 1 to 4|Adverse Event|0
6122832|NCT00908232|9746507|FG002|Cycle 1 to 4|Adverse Event|0
6122833|NCT00908232|9746508|FG003|Cycle 1 to 4|Adverse Event|0
6122834|NCT00908232|9746505|FG000|Cycle 1 to 4|Other|1
6122835|NCT00908232|9746506|FG001|Cycle 1 to 4|Other|0
6122836|NCT00908232|9746507|FG002|Cycle 1 to 4|Other|0
6122837|NCT00908232|9746508|FG003|Cycle 1 to 4|Other|0
6122838|NCT00908232|9746505|FG000|Randomization (Cycle 5) to Cycle 8|Complete Response/Partial Response|1
6122839|NCT00908232|9746506|FG001|Randomization (Cycle 5) to Cycle 8|Complete Response/Partial Response|0
6122840|NCT00908232|9746507|FG002|Randomization (Cycle 5) to Cycle 8|Complete Response/Partial Response|0
6122841|NCT00908232|9746508|FG003|Randomization (Cycle 5) to Cycle 8|Complete Response/Partial Response|0
6122842|NCT00908232|9746505|FG000|Randomization (Cycle 5) to Cycle 8|Progressive Disease|5
6122843|NCT00908232|9746506|FG001|Randomization (Cycle 5) to Cycle 8|Progressive Disease|0
6122844|NCT00908232|9746507|FG002|Randomization (Cycle 5) to Cycle 8|Progressive Disease|0
6215515|NCT01621490|9883125|FG000|Overall Study|Investigator decision|0
6215516|NCT01621490|9883126|FG001|Overall Study|Investigator decision|0
6215517|NCT01621490|9883127|FG002|Overall Study|Investigator decision|1
6215518|NCT01621490|9883128|FG003|Overall Study|Investigator decision|0
6215519|NCT01621490|9883129|FG004|Overall Study|Investigator decision|1
6215520|NCT01621490|9883130|FG005|Overall Study|Investigator decision|0
6215521|NCT01621490|9883131|FG006|Overall Study|Investigator decision|1
6215522|NCT01621490|9883132|FG007|Overall Study|Investigator decision|0
6215523|NCT01621490|9883133|FG008|Overall Study|Investigator decision|0
6288015|NCT02358343|10001142|FG004|Screening Intervention|Withdrawal by Subject|0
6122845|NCT00908232|9746508|FG003|Randomization (Cycle 5) to Cycle 8|Progressive Disease|0
6122846|NCT00908232|9746505|FG000|Randomization (Cycle 5) to Cycle 8|Death|2
6122847|NCT00908232|9746506|FG001|Randomization (Cycle 5) to Cycle 8|Death|0
6122848|NCT00908232|9746507|FG002|Randomization (Cycle 5) to Cycle 8|Death|0
6288016|NCT02358343|10001138|FG000|Screening Intervention|Determined Ineligible|5
6288017|NCT02358343|10001139|FG001|Screening Intervention|Determined Ineligible|6
6288018|NCT02358343|10001140|FG002|Screening Intervention|Determined Ineligible|0
6288019|NCT02358343|10001141|FG003|Screening Intervention|Determined Ineligible|0
6288020|NCT02358343|10001142|FG004|Screening Intervention|Determined Ineligible|0
6288021|NCT02358343|10001138|FG000|Comparative Efficacy Trial / Observation|Death|0
6288022|NCT02358343|10001139|FG001|Comparative Efficacy Trial / Observation|Death|0
5980864|NCT01434602|9569523|FG000|Phase II Recommended Phase 2 Dose|Refused further treatment|0
6122849|NCT00908232|9746508|FG003|Randomization (Cycle 5) to Cycle 8|Death|0
6122850|NCT00908232|9746505|FG000|Randomization (Cycle 5) to Cycle 8|Withdrawal by Subject|4
6122851|NCT00908232|9746506|FG001|Randomization (Cycle 5) to Cycle 8|Withdrawal by Subject|0
6122852|NCT00908232|9746507|FG002|Randomization (Cycle 5) to Cycle 8|Withdrawal by Subject|1
6122853|NCT00908232|9746508|FG003|Randomization (Cycle 5) to Cycle 8|Withdrawal by Subject|0
6288023|NCT02358343|10001140|FG002|Comparative Efficacy Trial / Observation|Death|2
6288024|NCT02358343|10001141|FG003|Comparative Efficacy Trial / Observation|Death|0
6288025|NCT02358343|10001142|FG004|Comparative Efficacy Trial / Observation|Death|0
6288026|NCT02358343|10001138|FG000|Comparative Efficacy Trial / Observation|Withdrawal by Subject|0
6122854|NCT00908232|9746505|FG000|Randomization (Cycle 5) to Cycle 8|Adverse Event|17
6122855|NCT00908232|9746506|FG001|Randomization (Cycle 5) to Cycle 8|Adverse Event|2
6122856|NCT00908232|9746507|FG002|Randomization (Cycle 5) to Cycle 8|Adverse Event|0
6122857|NCT00908232|9746508|FG003|Randomization (Cycle 5) to Cycle 8|Adverse Event|0
6122858|NCT00908232|9746505|FG000|Randomization (Cycle 5) to Cycle 8|Physician Decision|2
6122859|NCT00908232|9746506|FG001|Randomization (Cycle 5) to Cycle 8|Physician Decision|0
6122860|NCT00908232|9746507|FG002|Randomization (Cycle 5) to Cycle 8|Physician Decision|0
6122861|NCT00908232|9746508|FG003|Randomization (Cycle 5) to Cycle 8|Physician Decision|0
6122862|NCT00908232|9746505|FG000|Randomization (Cycle 5) to Cycle 8|Other|3
6122863|NCT00908232|9746506|FG001|Randomization (Cycle 5) to Cycle 8|Other|1
6122864|NCT00908232|9746507|FG002|Randomization (Cycle 5) to Cycle 8|Other|0
6122865|NCT00908232|9746508|FG003|Randomization (Cycle 5) to Cycle 8|Other|0
6122866|NCT00908232|9746505|FG000|Randomization (Cycle 5) to Cycle 8|Protocol Violation|1
6122867|NCT00908232|9746506|FG001|Randomization (Cycle 5) to Cycle 8|Protocol Violation|0
6122868|NCT00908232|9746507|FG002|Randomization (Cycle 5) to Cycle 8|Protocol Violation|0
6122869|NCT00908232|9746508|FG003|Randomization (Cycle 5) to Cycle 8|Protocol Violation|0
6122870|NCT00908310|9746514|FG000|Overall Study|Death|37
6122871|NCT00908310|9746514|FG000|Overall Study|Withdrawal by Subject|7
6122872|NCT00908310|9746514|FG000|Overall Study|Lost to Follow-up|7
6122873|NCT00908310|9746514|FG000|Overall Study|Screening failure|5
6122874|NCT00908310|9746514|FG000|Overall Study|Other reasons|4
6122875|NCT00908349|9746518|FG000|Overall Study|Adverse Event|10
6122876|NCT00908349|9746518|FG000|Overall Study|Withdrawal by Subject|9
6122877|NCT00908349|9746518|FG000|Overall Study|Physician Decision|5
6122878|NCT00908349|9746518|FG000|Overall Study|Lost to Follow-up|5
6122879|NCT00908349|9746518|FG000|Overall Study|Various|6
6122880|NCT00908375|9746524|FG000|Overall Study|Withdrawal by Subject|2
6122881|NCT00908375|9746525|FG001|Overall Study|Withdrawal by Subject|4
6122882|NCT00908375|9746524|FG000|Overall Study|Lost to Follow-up|8
6122883|NCT00908375|9746525|FG001|Overall Study|Lost to Follow-up|6
6122884|NCT00908544|9746546|FG000|Overall Study|Withdrawal by Subject|2
6122885|NCT00908544|9746547|FG001|Overall Study|Withdrawal by Subject|4
6122886|NCT00908544|9746546|FG000|Overall Study|Lack of Efficacy|0
6122887|NCT00908544|9746547|FG001|Overall Study|Lack of Efficacy|1
6122888|NCT00908544|9746546|FG000|Overall Study|Pregnancy|1
6122889|NCT00908544|9746547|FG001|Overall Study|Pregnancy|0
6122890|NCT00908544|9746546|FG000|Overall Study|Relocation abroad|1
6122891|NCT00908544|9746547|FG001|Overall Study|Relocation abroad|1
6122892|NCT00908544|9746546|FG000|Overall Study|Unable to visit sutdy center|1
6122893|NCT00908544|9746547|FG001|Overall Study|Unable to visit sutdy center|0
6122894|NCT00908583|9746553|FG000|Phase 1|Withdrawal by Subject|1
6122895|NCT00908583|9746553|FG000|Phase 1|Adverse Event|4
6122896|NCT00908583|9746553|FG000|Phase 2|Physician Decision|1
6122897|NCT00908583|9746553|FG000|Phase 2|Adverse Event|1
6122898|NCT00908583|9746553|FG000|Phase 3|Adverse Event|2
6122899|NCT00908583|9746553|FG000|Phase 4|Adverse Event|1
6122900|NCT00908583|9746553|FG000|Phase 4|Physician Decision|1
6122901|NCT00908583|9746553|FG000|Phase 5|Adverse Event|3
6122902|NCT00908596|9746575|FG000|Overall Study|Other reasons|46
6122903|NCT00908596|9746576|FG001|Overall Study|Other reasons|6
6215524|NCT01621490|9883125|FG000|Overall Study|Documented disease progression|0
6215525|NCT01621490|9883126|FG001|Overall Study|Documented disease progression|0
6215526|NCT01621490|9883127|FG002|Overall Study|Documented disease progression|1
6215527|NCT01621490|9883128|FG003|Overall Study|Documented disease progression|0
6215528|NCT01621490|9883129|FG004|Overall Study|Documented disease progression|0
6215529|NCT01621490|9883130|FG005|Overall Study|Documented disease progression|0
6215530|NCT01621490|9883131|FG006|Overall Study|Documented disease progression|0
6215531|NCT01621490|9883132|FG007|Overall Study|Documented disease progression|0
6215532|NCT01621490|9883133|FG008|Overall Study|Documented disease progression|0
6215533|NCT01621490|9883125|FG000|Overall Study|Patient reached treatment 2 yr limit|0
6215534|NCT01621490|9883126|FG001|Overall Study|Patient reached treatment 2 yr limit|1
6215535|NCT01621490|9883127|FG002|Overall Study|Patient reached treatment 2 yr limit|0
6215536|NCT01621490|9883128|FG003|Overall Study|Patient reached treatment 2 yr limit|0
6215537|NCT01621490|9883129|FG004|Overall Study|Patient reached treatment 2 yr limit|0
6215538|NCT01621490|9883130|FG005|Overall Study|Patient reached treatment 2 yr limit|0
6215539|NCT01621490|9883131|FG006|Overall Study|Patient reached treatment 2 yr limit|0
6215540|NCT01621490|9883132|FG007|Overall Study|Patient reached treatment 2 yr limit|0
6215541|NCT01621490|9883133|FG008|Overall Study|Patient reached treatment 2 yr limit|0
6215542|NCT01621490|9883125|FG000|Overall Study|Clinical deterioration|0
6215543|NCT01621490|9883126|FG001|Overall Study|Clinical deterioration|1
6215544|NCT01621490|9883127|FG002|Overall Study|Clinical deterioration|0
6215545|NCT01621490|9883128|FG003|Overall Study|Clinical deterioration|0
6122904|NCT00908596|9746577|FG002|Overall Study|Other reasons|2
6215546|NCT01621490|9883129|FG004|Overall Study|Clinical deterioration|0
6122905|NCT00908596|9746578|FG003|Overall Study|Other reasons|0
6122906|NCT00908596|9746575|FG000|Overall Study|Lost to Follow-up|0
6122907|NCT00908596|9746576|FG001|Overall Study|Lost to Follow-up|1
6122908|NCT00908596|9746577|FG002|Overall Study|Lost to Follow-up|12
6122909|NCT00908596|9746578|FG003|Overall Study|Lost to Follow-up|4
6122910|NCT00908596|9746575|FG000|Overall Study|Death|0
6122911|NCT00908596|9746576|FG001|Overall Study|Death|5
6122912|NCT00908596|9746577|FG002|Overall Study|Death|57
6122913|NCT00908596|9746578|FG003|Overall Study|Death|32
6122914|NCT00908596|9746575|FG000|Overall Study|Protocol Violation|1
6122915|NCT00908596|9746576|FG001|Overall Study|Protocol Violation|0
6122916|NCT00908596|9746577|FG002|Overall Study|Protocol Violation|0
6122917|NCT00908596|9746578|FG003|Overall Study|Protocol Violation|0
6122918|NCT00908596|9746575|FG000|Overall Study|Withdrawal by Subject|0
6122919|NCT00908596|9746576|FG001|Overall Study|Withdrawal by Subject|1
6122920|NCT00908596|9746577|FG002|Overall Study|Withdrawal by Subject|3
6122921|NCT00908596|9746578|FG003|Overall Study|Withdrawal by Subject|1
6122922|NCT00908895|9746621|FG000|Overall Study|Lost to Follow-up|1
6122923|NCT00908895|9746622|FG001|Overall Study|Lost to Follow-up|3
6122924|NCT00908895|9746621|FG000|Overall Study|algodystrophy|2
6122925|NCT00908895|9746622|FG001|Overall Study|algodystrophy|2
6122926|NCT00908895|9746621|FG000|Overall Study|Adverse Event|1
6122927|NCT00908895|9746622|FG001|Overall Study|Adverse Event|1
6215547|NCT01621490|9883130|FG005|Overall Study|Clinical deterioration|0
6215548|NCT01621490|9883131|FG006|Overall Study|Clinical deterioration|0
6215549|NCT01621490|9883132|FG007|Overall Study|Clinical deterioration|0
6215550|NCT01621490|9883133|FG008|Overall Study|Clinical deterioration|0
6215551|NCT01621490|9883125|FG000|Overall Study|Complete response|0
6215552|NCT01621490|9883126|FG001|Overall Study|Complete response|0
6215553|NCT01621490|9883127|FG002|Overall Study|Complete response|0
6215554|NCT01621490|9883128|FG003|Overall Study|Complete response|0
6215555|NCT01621490|9883129|FG004|Overall Study|Complete response|0
6215556|NCT01621490|9883130|FG005|Overall Study|Complete response|0
6215557|NCT01621490|9883131|FG006|Overall Study|Complete response|0
6215558|NCT01621490|9883132|FG007|Overall Study|Complete response|0
6215559|NCT01621490|9883133|FG008|Overall Study|Complete response|1
6215560|NCT01621490|9883125|FG000|Overall Study|Patient delayed due to toxicity|0
6215561|NCT01621490|9883126|FG001|Overall Study|Patient delayed due to toxicity|0
6215562|NCT01621490|9883127|FG002|Overall Study|Patient delayed due to toxicity|0
6215563|NCT01621490|9883128|FG003|Overall Study|Patient delayed due to toxicity|0
6215564|NCT01621490|9883129|FG004|Overall Study|Patient delayed due to toxicity|0
6215565|NCT01621490|9883130|FG005|Overall Study|Patient delayed due to toxicity|1
6215566|NCT01621490|9883131|FG006|Overall Study|Patient delayed due to toxicity|0
6215567|NCT01621490|9883132|FG007|Overall Study|Patient delayed due to toxicity|0
6215568|NCT01621490|9883133|FG008|Overall Study|Patient delayed due to toxicity|0
6215569|NCT01621542|9883252|FG000|Overall Study|Adverse Event|0
6215570|NCT01621542|9883253|FG001|Overall Study|Adverse Event|0
6215571|NCT01621542|9883254|FG002|Overall Study|Adverse Event|1
6215572|NCT01621542|9883255|FG003|Overall Study|Adverse Event|3
6215573|NCT01621542|9883256|FG004|Overall Study|Adverse Event|0
6215574|NCT01621542|9883257|FG005|Overall Study|Adverse Event|0
6215575|NCT01621542|9883252|FG000|Overall Study|Death|0
6215576|NCT01621542|9883253|FG001|Overall Study|Death|1
6215577|NCT01621542|9883254|FG002|Overall Study|Death|0
6215578|NCT01621542|9883255|FG003|Overall Study|Death|0
6215579|NCT01621542|9883256|FG004|Overall Study|Death|0
6215580|NCT01621542|9883257|FG005|Overall Study|Death|0
6215581|NCT01621542|9883252|FG000|Overall Study|Physician Decision|1
6215582|NCT01621542|9883253|FG001|Overall Study|Physician Decision|0
6215583|NCT01621542|9883254|FG002|Overall Study|Physician Decision|1
6215584|NCT01621542|9883255|FG003|Overall Study|Physician Decision|13
6215585|NCT01621542|9883256|FG004|Overall Study|Physician Decision|3
6215586|NCT01621542|9883257|FG005|Overall Study|Physician Decision|1
6215587|NCT01621542|9883252|FG000|Overall Study|Withdrawal by Subject|2
6215588|NCT01621542|9883253|FG001|Overall Study|Withdrawal by Subject|0
6215589|NCT01621542|9883254|FG002|Overall Study|Withdrawal by Subject|1
6215590|NCT01621542|9883255|FG003|Overall Study|Withdrawal by Subject|3
6215591|NCT01621542|9883256|FG004|Overall Study|Withdrawal by Subject|3
6215592|NCT01621542|9883257|FG005|Overall Study|Withdrawal by Subject|3
6215593|NCT01621542|9883252|FG000|Overall Study|progression/treatment failure|2
6215594|NCT01621542|9883253|FG001|Overall Study|progression/treatment failure|4
6215595|NCT01621542|9883254|FG002|Overall Study|progression/treatment failure|3
6215596|NCT01621542|9883255|FG003|Overall Study|progression/treatment failure|7
6215597|NCT01621542|9883256|FG004|Overall Study|progression/treatment failure|3
6215598|NCT01621542|9883257|FG005|Overall Study|progression/treatment failure|5
6215599|NCT01621542|9883252|FG000|Overall Study|Protocol Violation|0
6215600|NCT01621542|9883253|FG001|Overall Study|Protocol Violation|0
6215601|NCT01621542|9883254|FG002|Overall Study|Protocol Violation|0
6215602|NCT01621542|9883255|FG003|Overall Study|Protocol Violation|1
6215603|NCT01621542|9883256|FG004|Overall Study|Protocol Violation|0
6215604|NCT01621542|9883257|FG005|Overall Study|Protocol Violation|0
6215605|NCT01621542|9883252|FG000|Overall Study|study stopped by sponsor|0
6215606|NCT01621542|9883253|FG001|Overall Study|study stopped by sponsor|0
6215607|NCT01621542|9883254|FG002|Overall Study|study stopped by sponsor|0
6215608|NCT01621542|9883255|FG003|Overall Study|study stopped by sponsor|1
6215609|NCT01621542|9883256|FG004|Overall Study|study stopped by sponsor|0
6215610|NCT01621542|9883257|FG005|Overall Study|study stopped by sponsor|0
6215611|NCT01621802|9883316|FG000|Overall Study|Protocol Violation|0
6215612|NCT01621802|9883317|FG001|Overall Study|Protocol Violation|0
6215613|NCT01621802|9883318|FG002|Overall Study|Protocol Violation|0
6215614|NCT01621802|9883319|FG003|Overall Study|Protocol Violation|0
6122928|NCT00908960|9746640|FG000|Overall Study|Presence VTE dx or Absent VTE eval|1
6122929|NCT00908960|9746641|FG001|Overall Study|Presence VTE dx or Absent VTE eval|1
6122930|NCT00908960|9746642|FG002|Overall Study|Presence VTE dx or Absent VTE eval|2
6122931|NCT00909038|9746650|FG000|Overall Study|Protocol Violation|187
6122932|NCT00909038|9746650|FG000|Overall Study|Non-evaluable Subjects|230
6122933|NCT00909090|9746660|FG000|Overall Study|Lost to Follow-up|17
6122934|NCT00909090|9746661|FG001|Overall Study|Lost to Follow-up|17
6122935|NCT00909181|9746689|FG000|Overall Study|Lost to Follow-up|39
6122936|NCT00909181|9746690|FG001|Overall Study|Lost to Follow-up|18
6122937|NCT00909181|9746691|FG002|Overall Study|Lost to Follow-up|33
6122938|NCT00909363|9746722|FG000|Overall Study|Withdrawal by Subject|1
6122939|NCT00909363|9746723|FG001|Overall Study|Withdrawal by Subject|0
6122940|NCT00909363|9746724|FG002|Overall Study|Withdrawal by Subject|0
6122941|NCT00909363|9746722|FG000|Overall Study|Lack of Efficacy|1
6122942|NCT00909363|9746723|FG001|Overall Study|Lack of Efficacy|0
6122943|NCT00909363|9746724|FG002|Overall Study|Lack of Efficacy|0
6122944|NCT00909428|9746738|FG000|Overall Study|Lost to Follow-up|13
6122945|NCT00909428|9746739|FG001|Overall Study|Lost to Follow-up|10
6122946|NCT00909428|9746740|FG002|Overall Study|Lost to Follow-up|9
6122947|NCT00909480|9746749|FG000|Overall Study|Adverse Event|5
6122948|NCT00909480|9746750|FG001|Overall Study|Adverse Event|3
6122949|NCT00909480|9746749|FG000|Overall Study|Protocol Violation|6
6122950|NCT00909480|9746750|FG001|Overall Study|Protocol Violation|8
6122951|NCT00909480|9746749|FG000|Overall Study|Withdrawal criteria|9
6122952|NCT00909480|9746750|FG001|Overall Study|Withdrawal criteria|11
6122953|NCT00909480|9746749|FG000|Overall Study|Unclassified|18
6122954|NCT00909480|9746750|FG001|Overall Study|Unclassified|19
6122955|NCT00909532|9746758|FG000|Overall Study|Adverse Event|4
6122956|NCT00909532|9746759|FG001|Overall Study|Adverse Event|1
6122957|NCT00909532|9746758|FG000|Overall Study|Pregnancy|0
6122958|NCT00909532|9746759|FG001|Overall Study|Pregnancy|1
6122959|NCT00909532|9746758|FG000|Overall Study|Prohibited Medication|2
6122960|NCT00909532|9746759|FG001|Overall Study|Prohibited Medication|1
6122961|NCT00909532|9746758|FG000|Overall Study|Withdrawal of Consent|1
6122962|NCT00909532|9746759|FG001|Overall Study|Withdrawal of Consent|1
6122963|NCT00909532|9746758|FG000|Overall Study|Noncompliance with Study Requirements|0
6122964|NCT00909532|9746759|FG001|Overall Study|Noncompliance with Study Requirements|2
6122965|NCT00909532|9746758|FG000|Overall Study|Physician Decision|1
6122966|NCT00909532|9746759|FG001|Overall Study|Physician Decision|0
6122967|NCT00909532|9746758|FG000|Overall Study|Wrong Genotype|1
6122968|NCT00909532|9746759|FG001|Overall Study|Wrong Genotype|0
6122969|NCT00909532|9746758|FG000|Overall Study|Increased Lab Draws, Difficult Lab Stick|1
6122970|NCT00909532|9746759|FG001|Overall Study|Increased Lab Draws, Difficult Lab Stick|0
6215615|NCT01621802|9883320|FG004|Overall Study|Protocol Violation|0
6215616|NCT01621802|9883321|FG005|Overall Study|Protocol Violation|1
6215617|NCT01621802|9883316|FG000|Overall Study|Withdrawal by Subject|8
6215618|NCT01621802|9883317|FG001|Overall Study|Withdrawal by Subject|4
6215619|NCT01621802|9883318|FG002|Overall Study|Withdrawal by Subject|4
6215620|NCT01621802|9883319|FG003|Overall Study|Withdrawal by Subject|2
6215621|NCT01621802|9883320|FG004|Overall Study|Withdrawal by Subject|2
6215622|NCT01621802|9883321|FG005|Overall Study|Withdrawal by Subject|0
6215623|NCT01621802|9883316|FG000|Overall Study|Migrated/moved from study area|0
6215624|NCT01621802|9883317|FG001|Overall Study|Migrated/moved from study area|0
6215625|NCT01621802|9883318|FG002|Overall Study|Migrated/moved from study area|2
6215626|NCT01621802|9883319|FG003|Overall Study|Migrated/moved from study area|0
6215627|NCT01621802|9883320|FG004|Overall Study|Migrated/moved from study area|1
6215628|NCT01621802|9883321|FG005|Overall Study|Migrated/moved from study area|0
6122971|NCT00909727|9746786|FG000|Overall Study|Adverse Event|1
6215629|NCT01621802|9883316|FG000|Overall Study|Others|3
6215630|NCT01621802|9883317|FG001|Overall Study|Others|3
6215631|NCT01621802|9883318|FG002|Overall Study|Others|3
6215632|NCT01621802|9883319|FG003|Overall Study|Others|2
6215633|NCT01621802|9883320|FG004|Overall Study|Others|1
6215634|NCT01621802|9883321|FG005|Overall Study|Others|0
6215635|NCT01621802|9883316|FG000|Overall Study|Lost to Follow-up|36
6215636|NCT01621802|9883317|FG001|Overall Study|Lost to Follow-up|16
6215637|NCT01621802|9883318|FG002|Overall Study|Lost to Follow-up|24
6215638|NCT01621802|9883319|FG003|Overall Study|Lost to Follow-up|7
6215639|NCT01621802|9883320|FG004|Overall Study|Lost to Follow-up|31
6215640|NCT01621802|9883321|FG005|Overall Study|Lost to Follow-up|11
6215641|NCT01621880|9883340|FG000|Overall Study|Adverse Event|5
6215642|NCT01621880|9883341|FG001|Overall Study|Adverse Event|1
6215643|NCT01621880|9883340|FG000|Overall Study|Withdrawal by Subject|5
6215644|NCT01621880|9883341|FG001|Overall Study|Withdrawal by Subject|4
6215645|NCT01622231|9883359|FG000|Overall Study|Physician Decision|1
6215646|NCT01622231|9883359|FG000|Overall Study|Withdrawal by Subject|1
6215647|NCT01622348|9883385|FG000|Overall Study|Withdrawal by Subject|1
6215648|NCT01622348|9883386|FG001|Overall Study|Withdrawal by Subject|0
5980865|NCT01434602|9569524|FG001|Phase II Recommended Phase 2 Dose|Refused further treatment|0
6215649|NCT01622348|9883387|FG002|Overall Study|Withdrawal by Subject|1
6215650|NCT01622569|9883408|FG000|Double-Blind Treatment Phase (Wks 1-16)|Adverse Event|4
6215651|NCT01622569|9883409|FG001|Double-Blind Treatment Phase (Wks 1-16)|Adverse Event|2
6215652|NCT01622569|9883410|FG002|Double-Blind Treatment Phase (Wks 1-16)|Adverse Event|3
6122972|NCT00909727|9746787|FG001|Overall Study|Adverse Event|0
6122973|NCT00909727|9746786|FG000|Overall Study|Wrong Genotype|1
6122974|NCT00909727|9746787|FG001|Overall Study|Wrong Genotype|0
6122975|NCT00909727|9746786|FG000|Overall Study|Withdrawal of Consent|1
6122976|NCT00909727|9746787|FG001|Overall Study|Withdrawal of Consent|0
6122977|NCT00909727|9746786|FG000|Overall Study|Prohibited Medication|1
6122978|NCT00909727|9746787|FG001|Overall Study|Prohibited Medication|0
6122979|NCT00909779|9746795|FG000|Overall Study|Adverse Event|53
6122980|NCT00909779|9746796|FG001|Overall Study|Adverse Event|55
6122981|NCT00909779|9746795|FG000|Overall Study|Lack of Efficacy|7
6215653|NCT01622569|9883411|FG003|Double-Blind Treatment Phase (Wks 1-16)|Adverse Event|1
6215654|NCT01622569|9883408|FG000|Double-Blind Treatment Phase (Wks 1-16)|Lost to Follow-up|0
6215655|NCT01622569|9883409|FG001|Double-Blind Treatment Phase (Wks 1-16)|Lost to Follow-up|0
6215656|NCT01622569|9883410|FG002|Double-Blind Treatment Phase (Wks 1-16)|Lost to Follow-up|1
6215657|NCT01622569|9883411|FG003|Double-Blind Treatment Phase (Wks 1-16)|Lost to Follow-up|0
6215658|NCT01622569|9883408|FG000|Double-Blind Treatment Phase (Wks 1-16)|Lack of Efficacy|6
6215659|NCT01622569|9883409|FG001|Double-Blind Treatment Phase (Wks 1-16)|Lack of Efficacy|0
6215660|NCT01622569|9883410|FG002|Double-Blind Treatment Phase (Wks 1-16)|Lack of Efficacy|3
6215661|NCT01622569|9883411|FG003|Double-Blind Treatment Phase (Wks 1-16)|Lack of Efficacy|2
6215662|NCT01622569|9883408|FG000|Double-Blind Treatment Phase (Wks 1-16)|Protocol Violation|0
6215663|NCT01622569|9883409|FG001|Double-Blind Treatment Phase (Wks 1-16)|Protocol Violation|2
6215664|NCT01622569|9883410|FG002|Double-Blind Treatment Phase (Wks 1-16)|Protocol Violation|0
6215665|NCT01622569|9883411|FG003|Double-Blind Treatment Phase (Wks 1-16)|Protocol Violation|1
6215666|NCT01622569|9883408|FG000|Double-Blind Treatment Phase (Wks 1-16)|Withdrawal by Subject|2
6215667|NCT01622569|9883409|FG001|Double-Blind Treatment Phase (Wks 1-16)|Withdrawal by Subject|2
6215668|NCT01622569|9883410|FG002|Double-Blind Treatment Phase (Wks 1-16)|Withdrawal by Subject|2
6215669|NCT01622569|9883411|FG003|Double-Blind Treatment Phase (Wks 1-16)|Withdrawal by Subject|0
6215670|NCT01622569|9883408|FG000|Open-Label Extension Phase (Wks 17-24)|Adverse Event|0
6215671|NCT01622569|9883409|FG001|Open-Label Extension Phase (Wks 17-24)|Adverse Event|2
6215672|NCT01622569|9883410|FG002|Open-Label Extension Phase (Wks 17-24)|Adverse Event|1
6215673|NCT01622569|9883411|FG003|Open-Label Extension Phase (Wks 17-24)|Adverse Event|0
6215674|NCT01622569|9883408|FG000|Open-Label Extension Phase (Wks 17-24)|Lack of Efficacy|1
6215675|NCT01622569|9883409|FG001|Open-Label Extension Phase (Wks 17-24)|Lack of Efficacy|0
6215676|NCT01622569|9883410|FG002|Open-Label Extension Phase (Wks 17-24)|Lack of Efficacy|2
6215677|NCT01622569|9883411|FG003|Open-Label Extension Phase (Wks 17-24)|Lack of Efficacy|1
6215678|NCT01622569|9883408|FG000|Open-Label Extension Phase (Wks 17-24)|Withdrawal by Subject|0
6215679|NCT01622569|9883409|FG001|Open-Label Extension Phase (Wks 17-24)|Withdrawal by Subject|0
6215680|NCT01622569|9883410|FG002|Open-Label Extension Phase (Wks 17-24)|Withdrawal by Subject|0
6215681|NCT01622569|9883411|FG003|Open-Label Extension Phase (Wks 17-24)|Withdrawal by Subject|1
6215682|NCT01622660|9883431|FG000|Overall Study|Adverse Event|1
6215683|NCT01622673|9883441|FG000|Treatment Period 1|Withdrawal by Subject|0
6215684|NCT01622673|9883442|FG001|Treatment Period 1|Withdrawal by Subject|0
6215685|NCT01622673|9883443|FG002|Treatment Period 1|Withdrawal by Subject|0
6215686|NCT01622673|9883444|FG003|Treatment Period 1|Withdrawal by Subject|1
6215687|NCT01622673|9883445|FG004|Treatment Period 1|Withdrawal by Subject|0
6215688|NCT01622673|9883446|FG005|Treatment Period 1|Withdrawal by Subject|0
6215689|NCT01622673|9883441|FG000|Treatment Period 1|Protocol Violation|0
6215690|NCT01622673|9883442|FG001|Treatment Period 1|Protocol Violation|1
6215691|NCT01622673|9883443|FG002|Treatment Period 1|Protocol Violation|0
6215692|NCT01622673|9883444|FG003|Treatment Period 1|Protocol Violation|0
6215693|NCT01622673|9883445|FG004|Treatment Period 1|Protocol Violation|0
6215694|NCT01622673|9883446|FG005|Treatment Period 1|Protocol Violation|0
6215695|NCT01622673|9883441|FG000|Treatment Period 2|Withdrawal by Subject|0
6215696|NCT01622673|9883442|FG001|Treatment Period 2|Withdrawal by Subject|0
6215697|NCT01622673|9883443|FG002|Treatment Period 2|Withdrawal by Subject|0
6215698|NCT01622673|9883444|FG003|Treatment Period 2|Withdrawal by Subject|1
6215699|NCT01622673|9883445|FG004|Treatment Period 2|Withdrawal by Subject|0
6215700|NCT01622673|9883446|FG005|Treatment Period 2|Withdrawal by Subject|0
6215701|NCT01622673|9883441|FG000|Treatment Period 3|Protocol Violation|0
6215702|NCT01622673|9883442|FG001|Treatment Period 3|Protocol Violation|1
6215703|NCT01622673|9883443|FG002|Treatment Period 3|Protocol Violation|0
6215704|NCT01622673|9883444|FG003|Treatment Period 3|Protocol Violation|0
6215705|NCT01622673|9883445|FG004|Treatment Period 3|Protocol Violation|0
6215706|NCT01622673|9883446|FG005|Treatment Period 3|Protocol Violation|0
6215707|NCT01623050|9883480|FG000|Overall Study|Lost to Follow-up|9
6215708|NCT01623115|9883486|FG000|Overall Study|Randomized but not treated|0
6215709|NCT01623115|9883487|FG001|Overall Study|Randomized but not treated|1
6215710|NCT01623115|9883486|FG000|Overall Study|Physician Decision|1
6215711|NCT01623115|9883487|FG001|Overall Study|Physician Decision|0
6215712|NCT01623115|9883486|FG000|Overall Study|Participants moved|1
6215713|NCT01623115|9883487|FG001|Overall Study|Participants moved|5
6215714|NCT01623115|9883486|FG000|Overall Study|Adverse Event|10
6215715|NCT01623115|9883487|FG001|Overall Study|Adverse Event|13
6215716|NCT01623115|9883486|FG000|Overall Study|Poor compliance to protocol|4
6122982|NCT00909779|9746796|FG001|Overall Study|Lack of Efficacy|4
6122983|NCT00909779|9746795|FG000|Overall Study|Lost to Follow-up|19
6122984|NCT00909779|9746796|FG001|Overall Study|Lost to Follow-up|15
6122985|NCT00909779|9746795|FG000|Overall Study|Physician Decision|8
6215717|NCT01623115|9883487|FG001|Overall Study|Poor compliance to protocol|10
6215718|NCT01623115|9883486|FG000|Overall Study|Consent withdrawn by participant|2
6215719|NCT01623115|9883487|FG001|Overall Study|Consent withdrawn by participant|6
6215720|NCT01623115|9883486|FG000|Overall Study|Related to study drug administration|0
6215721|NCT01623115|9883487|FG001|Overall Study|Related to study drug administration|2
6215722|NCT01623115|9883486|FG000|Overall Study|Last visit outside protocol visit window|14
6215723|NCT01623115|9883487|FG001|Overall Study|Last visit outside protocol visit window|26
6215724|NCT01623115|9883486|FG000|Overall Study|Site closure|1
6215725|NCT01623115|9883487|FG001|Overall Study|Site closure|7
6215726|NCT01623115|9883486|FG000|Overall Study|Death|0
6215727|NCT01623115|9883487|FG001|Overall Study|Death|4
6215728|NCT01623115|9883486|FG000|Overall Study|Other than specified above|0
6215729|NCT01623115|9883487|FG001|Overall Study|Other than specified above|3
6215730|NCT01623154|9883493|FG000|Overall Study|Did not drink Pranactin Citric|4
6215731|NCT01623271|9883499|FG000|Overall Study|Withdrawal by Subject|2
6215732|NCT01623310|9883503|FG000|Overall Study|Adverse Event|21
6215733|NCT01623310|9883503|FG000|Overall Study|Lost to Follow-up|18
6215734|NCT01623310|9883503|FG000|Overall Study|Lack of Efficacy|6
6215735|NCT01623310|9883503|FG000|Overall Study|Protocol Violation|6
6215736|NCT01623310|9883503|FG000|Overall Study|Withdrawal by Subject|25
6215737|NCT01623310|9883503|FG000|Overall Study|Became potentially child-bearing|1
6215738|NCT01623310|9883503|FG000|Overall Study|Diagnoses of bilateral cateracts|1
6215739|NCT01623310|9883503|FG000|Overall Study|Investigators Discretion-Noncompliant|1
6215740|NCT01623531|9883526|FG000|Overall Study|Death|1
6215741|NCT01623531|9883527|FG001|Overall Study|Death|0
6215742|NCT01623531|9883526|FG000|Overall Study|Protocol Violation|2
6215743|NCT01623531|9883527|FG001|Overall Study|Protocol Violation|1
6215744|NCT01623531|9883526|FG000|Overall Study|Missing data at primary outcome time poi|1
6215745|NCT01623531|9883527|FG001|Overall Study|Missing data at primary outcome time poi|1
6215746|NCT01623596|9883538|FG000|Overall Study|Abnormal laboratory values|2
6215747|NCT01623596|9883539|FG001|Overall Study|Abnormal laboratory values|0
6215748|NCT01623596|9883538|FG000|Overall Study|Administrative problems|9
6215749|NCT01623596|9883539|FG001|Overall Study|Administrative problems|13
6215750|NCT01623596|9883538|FG000|Overall Study|Adverse Event|20
6215751|NCT01623596|9883539|FG001|Overall Study|Adverse Event|29
6215752|NCT01623596|9883538|FG000|Overall Study|Death|0
6215753|NCT01623596|9883539|FG001|Overall Study|Death|2
6215754|NCT01623596|9883538|FG000|Overall Study|Lost to Follow-up|12
6215755|NCT01623596|9883539|FG001|Overall Study|Lost to Follow-up|16
6215756|NCT01623596|9883538|FG000|Overall Study|Withdrawal by Subject|13
6215757|NCT01623596|9883539|FG001|Overall Study|Withdrawal by Subject|31
6215758|NCT01623596|9883538|FG000|Overall Study|Patient no longer requires study drug|1
6215759|NCT01623596|9883539|FG001|Overall Study|Patient no longer requires study drug|0
6215760|NCT01623596|9883538|FG000|Overall Study|Protocol Violation|0
6215761|NCT01623596|9883539|FG001|Overall Study|Protocol Violation|6
6215762|NCT01623596|9883538|FG000|Overall Study|Lack of Efficacy|5
6215763|NCT01623596|9883539|FG001|Overall Study|Lack of Efficacy|3
6215764|NCT01623752|9883560|FG000|Phase 1 (78 Weeks)|No Data|249
6215765|NCT01623752|9883561|FG001|Phase 1 (78 Weeks)|No Data|66
6215766|NCT01623752|9883562|FG002|Phase 1 (78 Weeks)|No Data|2
6215767|NCT01623752|9883560|FG000|Phase 1 (78 Weeks)|Other|33
6215768|NCT01623752|9883561|FG001|Phase 1 (78 Weeks)|Other|20
6215769|NCT01623752|9883562|FG002|Phase 1 (78 Weeks)|Other|0
6215770|NCT01623752|9883560|FG000|Phase 1 (78 Weeks)|Adverse Event|122
6215771|NCT01623752|9883561|FG001|Phase 1 (78 Weeks)|Adverse Event|39
6215772|NCT01623752|9883562|FG002|Phase 1 (78 Weeks)|Adverse Event|0
6215773|NCT01623752|9883560|FG000|Phase 1 (78 Weeks)|Lack of Efficacy|227
6215774|NCT01623752|9883561|FG001|Phase 1 (78 Weeks)|Lack of Efficacy|82
6215775|NCT01623752|9883562|FG002|Phase 1 (78 Weeks)|Lack of Efficacy|0
6215776|NCT01623752|9883560|FG000|Phase 2 (78 Weeks)|Lack of Efficacy|14
6215777|NCT01623752|9883561|FG001|Phase 2 (78 Weeks)|Lack of Efficacy|2
6215778|NCT01623752|9883562|FG002|Phase 2 (78 Weeks)|Lack of Efficacy|0
6215779|NCT01623752|9883560|FG000|Phase 2 (78 Weeks)|Other|5
6215780|NCT01623752|9883561|FG001|Phase 2 (78 Weeks)|Other|1
6215781|NCT01623752|9883562|FG002|Phase 2 (78 Weeks)|Other|0
6215782|NCT01623752|9883560|FG000|Phase 2 (78 Weeks)|No Data|43
6215783|NCT01623752|9883561|FG001|Phase 2 (78 Weeks)|No Data|11
6215784|NCT01623752|9883562|FG002|Phase 2 (78 Weeks)|No Data|0
6215785|NCT01623752|9883560|FG000|Phase 2 (78 Weeks)|Adverse Event|4
6215786|NCT01623752|9883561|FG001|Phase 2 (78 Weeks)|Adverse Event|4
6215787|NCT01623752|9883562|FG002|Phase 2 (78 Weeks)|Adverse Event|0
6215788|NCT01623830|9883573|FG000|Overall Study|Withdrawal by Subject|6
6215789|NCT01623830|9883574|FG001|Overall Study|Withdrawal by Subject|7
6215790|NCT01623830|9883573|FG000|Overall Study|Exclusion from Study|1
6215791|NCT01623830|9883574|FG001|Overall Study|Exclusion from Study|2
6215792|NCT01624090|9883588|FG000|Overall Study|DLT, taken off therapy|0
6215793|NCT01624090|9883589|FG001|Overall Study|DLT, taken off therapy|1
6215794|NCT01624090|9883590|FG002|Overall Study|DLT, taken off therapy|0
6215795|NCT01624090|9883591|FG003|Overall Study|DLT, taken off therapy|0
6215796|NCT01624090|9883588|FG000|Overall Study|Withdrew prior to treatment|0
6215797|NCT01624090|9883589|FG001|Overall Study|Withdrew prior to treatment|1
6122986|NCT00909779|9746796|FG001|Overall Study|Physician Decision|2
6122987|NCT00909779|9746795|FG000|Overall Study|Protocol Violation|2
6122988|NCT00909779|9746796|FG001|Overall Study|Protocol Violation|5
6122989|NCT00909779|9746795|FG000|Overall Study|Withdrawal by Subject|116
6122990|NCT00909779|9746796|FG001|Overall Study|Withdrawal by Subject|80
6122991|NCT00909779|9746795|FG000|Overall Study|Site Ceasing Operation|2
6215798|NCT01624090|9883590|FG002|Overall Study|Withdrew prior to treatment|0
6215799|NCT01624090|9883591|FG003|Overall Study|Withdrew prior to treatment|0
6215800|NCT01624090|9883588|FG000|Overall Study|Died on study|0
6215801|NCT01624090|9883589|FG001|Overall Study|Died on study|0
6215802|NCT01624090|9883590|FG002|Overall Study|Died on study|2
6215803|NCT01624090|9883591|FG003|Overall Study|Died on study|0
6215804|NCT01624090|9883588|FG000|Overall Study|Did not complete 1 crse of therapy|0
6215805|NCT01624090|9883589|FG001|Overall Study|Did not complete 1 crse of therapy|0
6215806|NCT01624090|9883590|FG002|Overall Study|Did not complete 1 crse of therapy|2
6215807|NCT01624090|9883591|FG003|Overall Study|Did not complete 1 crse of therapy|0
6215808|NCT01624090|9883588|FG000|Overall Study|Dose escalated|0
6215809|NCT01624090|9883589|FG001|Overall Study|Dose escalated|0
6215810|NCT01624090|9883590|FG002|Overall Study|Dose escalated|3
6215811|NCT01624090|9883591|FG003|Overall Study|Dose escalated|0
6215812|NCT01624142|9883603|FG000|Overall Study|Withdrawal by Subject|14
6215813|NCT01624142|9883604|FG001|Overall Study|Withdrawal by Subject|4
6215814|NCT01624142|9883603|FG000|Overall Study|Death|3
6215815|NCT01624142|9883604|FG001|Overall Study|Death|6
6215816|NCT01624142|9883603|FG000|Overall Study|Study Closure|12
6215817|NCT01624142|9883604|FG001|Overall Study|Study Closure|6
6215818|NCT01624142|9883603|FG000|Overall Study|Lost to Follow-up|2
6215819|NCT01624142|9883604|FG001|Overall Study|Lost to Follow-up|0
6215820|NCT01624142|9883603|FG000|Overall Study|Other|1
6215821|NCT01624142|9883604|FG001|Overall Study|Other|0
6215822|NCT01624194|9883626|FG000|Overall Study|Lost to Follow-up|1
6215823|NCT01624194|9883627|FG001|Overall Study|Lost to Follow-up|0
6215824|NCT01624194|9883626|FG000|Overall Study|Withdrawal by Subject|1
6215825|NCT01624194|9883627|FG001|Overall Study|Withdrawal by Subject|0
6215826|NCT01624233|9883634|FG000|Period 2 - Induction|Adverse Event|1
6215827|NCT01624233|9883634|FG000|Period 3 - Maintenance|Adverse Event|2
6215828|NCT01624233|9883634|FG000|Period 3 - Maintenance|Lack of Efficacy|1
6215829|NCT01624233|9883634|FG000|Period 3 - Maintenance|Physician Decision|2
6215830|NCT01624233|9883634|FG000|Period 3 - Maintenance|Withdrawal by Subject|2
6215831|NCT01624233|9883634|FG000|Period 4 - Drug Free Period|Relapsed|61
6215832|NCT01624233|9883634|FG000|Period 5 - Retreatment Period|Adverse Event|5
6215833|NCT01624233|9883634|FG000|Period 5 - Retreatment Period|Lack of Efficacy|1
6215834|NCT01624233|9883634|FG000|Period 5 - Retreatment Period|Physician Decision|1
6215835|NCT01624233|9883634|FG000|Period 5 - Retreatment Period|Withdrawal by Subject|3
6215836|NCT01624233|9883634|FG000|Period 6: Follow-up|Adverse Event|3
6215837|NCT01624233|9883634|FG000|Period 6: Follow-up|Lack of Efficacy|2
6215838|NCT01624233|9883634|FG000|Period 6: Follow-up|Physician Decision|1
6215839|NCT01624233|9883634|FG000|Period 6: Follow-up|Withdrawal by Subject|3
6215840|NCT01624259|9883644|FG000|Overall Study|Adverse Event|18
6215841|NCT01624259|9883645|FG001|Overall Study|Adverse Event|18
6215842|NCT01624259|9883644|FG000|Overall Study|Protocol Violation|1
6215843|NCT01624259|9883645|FG001|Overall Study|Protocol Violation|2
6215844|NCT01624259|9883644|FG000|Overall Study|Withdrawal by Subject|5
6215845|NCT01624259|9883645|FG001|Overall Study|Withdrawal by Subject|7
6215846|NCT01624259|9883644|FG000|Overall Study|Physician Decision|1
6215847|NCT01624259|9883645|FG001|Overall Study|Physician Decision|1
6215848|NCT01624259|9883644|FG000|Overall Study|Lost to Follow-up|2
6215849|NCT01624259|9883645|FG001|Overall Study|Lost to Follow-up|3
6215850|NCT01624259|9883644|FG000|Overall Study|Abnormal laboratory measure|3
6215851|NCT01624259|9883645|FG001|Overall Study|Abnormal laboratory measure|0
6215852|NCT01624467|9883677|FG000|Overall Study|Withdrawal by Subject|2
6215853|NCT01624467|9883677|FG000|Overall Study|Lost to Follow-up|1
6215854|NCT01624467|9883677|FG000|Overall Study|Adverse Event|7
6288027|NCT02358343|10001139|FG001|Comparative Efficacy Trial / Observation|Withdrawal by Subject|0
6215855|NCT01624467|9883677|FG000|Overall Study|Progressive Disease|19
6215856|NCT01624467|9883677|FG000|Overall Study|Per Sponsor Requirement|1
6215857|NCT01624467|9883677|FG000|Overall Study|Subject Withdrew from Treatment|1
6215858|NCT01624506|9883685|FG000|Overall Study|Lost to Follow-up|29
6215859|NCT01624506|9883686|FG001|Overall Study|Lost to Follow-up|15
6215860|NCT01624506|9883685|FG000|Overall Study|Withdrawal by Subject|9
6215861|NCT01624506|9883686|FG001|Overall Study|Withdrawal by Subject|2
6215862|NCT01624506|9883685|FG000|Overall Study|Death|1
6215863|NCT01624506|9883686|FG001|Overall Study|Death|0
6288028|NCT02358343|10001140|FG002|Comparative Efficacy Trial / Observation|Withdrawal by Subject|2
6288029|NCT02358343|10001141|FG003|Comparative Efficacy Trial / Observation|Withdrawal by Subject|2
6288030|NCT02358343|10001142|FG004|Comparative Efficacy Trial / Observation|Withdrawal by Subject|2
6122992|NCT00909779|9746796|FG001|Overall Study|Site Ceasing Operation|2
6215864|NCT01624506|9883685|FG000|Overall Study|LINX explants|23
6215865|NCT01624506|9883686|FG001|Overall Study|LINX explants|0
6215866|NCT01624506|9883685|FG000|Overall Study|Adverse Event|3
6215867|NCT01624506|9883686|FG001|Overall Study|Adverse Event|0
6215868|NCT01624662|9883696|FG000|Double-Blind Treatment Phase (Wks 1-16)|Adverse Event|2
6215869|NCT01624662|9883697|FG001|Double-Blind Treatment Phase (Wks 1-16)|Adverse Event|1
6122993|NCT00909779|9746795|FG000|Overall Study|Medical Monitor Decision|1
6122994|NCT00909779|9746796|FG001|Overall Study|Medical Monitor Decision|0
6122995|NCT00909779|9746795|FG000|Overall Study|Noncompliance|1
6122996|NCT00909779|9746796|FG001|Overall Study|Noncompliance|1
6122997|NCT00909779|9746795|FG000|Overall Study|Randomized in error|1
6122998|NCT00909779|9746796|FG001|Overall Study|Randomized in error|1
6122999|NCT00909792|9746804|FG000|Period 1|Did not meet inclusion criteria|0
6123000|NCT00909792|9746805|FG001|Period 1|Did not meet inclusion criteria|1
6123001|NCT00909792|9746804|FG000|Period 2|Biomicroscopy|1
6123002|NCT00909792|9746805|FG001|Period 2|Biomicroscopy|0
6123003|NCT00909792|9746804|FG000|Period 2|Lost to Follow-up|0
6123004|NCT00909792|9746805|FG001|Period 2|Lost to Follow-up|1
6123005|NCT00909844|9746811|FG000|Overall Study|Adverse Event|1
6123006|NCT00909844|9746811|FG000|Overall Study|Withdrawal by Subject|1
6123007|NCT00909844|9746811|FG000|Overall Study|Lost to Follow-up|2
6123008|NCT00909857|9746818|FG000|Overall Study|Withdrawal by Subject|6
6123009|NCT00909857|9746819|FG001|Overall Study|Withdrawal by Subject|10
6123010|NCT00909857|9746818|FG000|Overall Study|Adverse Event|5
6123011|NCT00909857|9746819|FG001|Overall Study|Adverse Event|5
6123012|NCT00909857|9746818|FG000|Overall Study|Lost to Follow-up|2
6123013|NCT00909857|9746819|FG001|Overall Study|Lost to Follow-up|5
6123014|NCT00909857|9746818|FG000|Overall Study|Protocol Violation|2
6123015|NCT00909857|9746819|FG001|Overall Study|Protocol Violation|1
6123016|NCT00909857|9746818|FG000|Overall Study|Pregnancy|1
6123017|NCT00909857|9746819|FG001|Overall Study|Pregnancy|0
6123018|NCT00909857|9746818|FG000|Overall Study|Other|1
6123019|NCT00909857|9746819|FG001|Overall Study|Other|0
6123020|NCT00909857|9746818|FG000|Overall Study|Did not receive study medication|19
6123021|NCT00909857|9746819|FG001|Overall Study|Did not receive study medication|24
6123022|NCT00909870|9746827|FG000|Overall Study|Adverse Event|13
6123023|NCT00909870|9746828|FG001|Overall Study|Adverse Event|7
6123024|NCT00909870|9746827|FG000|Overall Study|Protocol Violation|1
6123025|NCT00909870|9746828|FG001|Overall Study|Protocol Violation|2
6123026|NCT00909870|9746827|FG000|Overall Study|Withdrawal by Subject|5
6123027|NCT00909870|9746828|FG001|Overall Study|Withdrawal by Subject|8
6123028|NCT00909870|9746827|FG000|Overall Study|Lost to Follow-up|3
6123029|NCT00909870|9746828|FG001|Overall Study|Lost to Follow-up|3
6123030|NCT00909870|9746827|FG000|Overall Study|Physician Decision|0
6123031|NCT00909870|9746828|FG001|Overall Study|Physician Decision|2
6123032|NCT00909870|9746827|FG000|Overall Study|Other|1
6123033|NCT00909870|9746828|FG001|Overall Study|Other|5
6123034|NCT00910000|9746841|FG000|Overall Study|Adverse Event|0
6123035|NCT00910000|9746842|FG001|Overall Study|Adverse Event|3
6123036|NCT00910000|9746843|FG002|Overall Study|Adverse Event|2
6123037|NCT00910000|9746844|FG003|Overall Study|Adverse Event|2
6123038|NCT00910000|9746845|FG004|Overall Study|Adverse Event|0
6123039|NCT00910000|9746846|FG005|Overall Study|Adverse Event|1
6123040|NCT00910000|9746841|FG000|Overall Study|Withdrawal by Subject|0
6123041|NCT00910000|9746842|FG001|Overall Study|Withdrawal by Subject|0
6123042|NCT00910000|9746843|FG002|Overall Study|Withdrawal by Subject|1
6123043|NCT00910000|9746844|FG003|Overall Study|Withdrawal by Subject|0
6123044|NCT00910000|9746845|FG004|Overall Study|Withdrawal by Subject|1
6123045|NCT00910000|9746846|FG005|Overall Study|Withdrawal by Subject|0
6123046|NCT00910039|9746856|FG000|Overall Study|Physician Decision|1
6123047|NCT00910091|9746863|FG000|Pre-assignment|Withdrawal by Subject|0
6123048|NCT00910091|9746864|FG001|Pre-assignment|Withdrawal by Subject|2
6123049|NCT00910091|9746863|FG000|Treatment and Survival|Withdrawal by Subject|3
6123050|NCT00910091|9746864|FG001|Treatment and Survival|Withdrawal by Subject|4
6123051|NCT00910091|9746863|FG000|Treatment and Survival|Adverse Event|1
6123052|NCT00910091|9746864|FG001|Treatment and Survival|Adverse Event|0
6123053|NCT00910247|9746884|FG000|Overall Study|Adverse Event|15
6123054|NCT00910247|9746884|FG000|Overall Study|Death|2
6123055|NCT00910247|9746884|FG000|Overall Study|Lost to Follow-up|10
6123056|NCT00910247|9746884|FG000|Overall Study|Physician Decision|3
6123057|NCT00910247|9746884|FG000|Overall Study|Protocol Violation|10
6123058|NCT00910247|9746884|FG000|Overall Study|Withdrawal by Subject|25
6123059|NCT00910247|9746884|FG000|Overall Study|Not collected|4
6123060|NCT00910273|9746890|FG000|Overall Study|Lack of Efficacy|6
6123061|NCT00910273|9746891|FG001|Overall Study|Lack of Efficacy|9
6123062|NCT00910273|9746890|FG000|Overall Study|Adverse Event|1
6123063|NCT00910273|9746891|FG001|Overall Study|Adverse Event|1
6123064|NCT00910273|9746890|FG000|Overall Study|Withdrawal by Subject|1
6123065|NCT00910273|9746891|FG001|Overall Study|Withdrawal by Subject|0
6123066|NCT00910273|9746890|FG000|Overall Study|Discontinuation of study by sponsor|8
6123067|NCT00910273|9746891|FG001|Overall Study|Discontinuation of study by sponsor|2
6123068|NCT00910273|9746890|FG000|Overall Study|Protocol Violation|1
6123069|NCT00910273|9746891|FG001|Overall Study|Protocol Violation|0
6123070|NCT00910273|9746890|FG000|Overall Study|Lost to Follow-up|1
6123071|NCT00910273|9746891|FG001|Overall Study|Lost to Follow-up|1
6123072|NCT00910299|9746899|FG000|Overall Study|Withdrawal by Subject|16
6123073|NCT00910299|9746900|FG001|Overall Study|Withdrawal by Subject|13
6123074|NCT00910299|9746899|FG000|Overall Study|Sponsor Decision|58
6123075|NCT00910299|9746900|FG001|Overall Study|Sponsor Decision|60
6123076|NCT00910299|9746899|FG000|Overall Study|Didn't receive any study drug|2
6123077|NCT00910299|9746900|FG001|Overall Study|Didn't receive any study drug|1
6123078|NCT00910429|9746908|FG000|Overall Study|Death|18
6123079|NCT00910429|9746909|FG001|Overall Study|Death|12
6123080|NCT00910429|9746908|FG000|Overall Study|Withdrawal by Subject|3
6123081|NCT00910429|9746909|FG001|Overall Study|Withdrawal by Subject|2
6123082|NCT00910429|9746908|FG000|Overall Study|Protocol Violation|1
6123083|NCT00910429|9746909|FG001|Overall Study|Protocol Violation|0
6123084|NCT00910429|9746908|FG000|Overall Study|Lost to Follow-up|2
6123085|NCT00910429|9746909|FG001|Overall Study|Lost to Follow-up|1
6123086|NCT00910429|9746908|FG000|Overall Study|Adverse Event|10
6123087|NCT00910429|9746909|FG001|Overall Study|Adverse Event|5
6123088|NCT00910429|9746908|FG000|Overall Study|Drug non-compliance|1
6215870|NCT01624662|9883698|FG002|Double-Blind Treatment Phase (Wks 1-16)|Adverse Event|1
6215871|NCT01624662|9883699|FG003|Double-Blind Treatment Phase (Wks 1-16)|Adverse Event|0
6215872|NCT01624662|9883696|FG000|Double-Blind Treatment Phase (Wks 1-16)|Lack of Efficacy|5
6215873|NCT01624662|9883697|FG001|Double-Blind Treatment Phase (Wks 1-16)|Lack of Efficacy|1
6215874|NCT01624662|9883698|FG002|Double-Blind Treatment Phase (Wks 1-16)|Lack of Efficacy|0
6215875|NCT01624662|9883699|FG003|Double-Blind Treatment Phase (Wks 1-16)|Lack of Efficacy|0
6215876|NCT01624662|9883696|FG000|Double-Blind Treatment Phase (Wks 1-16)|Protocol Violation|0
6215877|NCT01624662|9883697|FG001|Double-Blind Treatment Phase (Wks 1-16)|Protocol Violation|1
6215878|NCT01624662|9883698|FG002|Double-Blind Treatment Phase (Wks 1-16)|Protocol Violation|0
6215879|NCT01624662|9883699|FG003|Double-Blind Treatment Phase (Wks 1-16)|Protocol Violation|0
6215880|NCT01624662|9883696|FG000|Double-Blind Treatment Phase (Wks 1-16)|Withdrawal by Subject|3
6215881|NCT01624662|9883697|FG001|Double-Blind Treatment Phase (Wks 1-16)|Withdrawal by Subject|0
6215882|NCT01624662|9883698|FG002|Double-Blind Treatment Phase (Wks 1-16)|Withdrawal by Subject|3
6215883|NCT01624662|9883699|FG003|Double-Blind Treatment Phase (Wks 1-16)|Withdrawal by Subject|0
6215884|NCT01624662|9883696|FG000|Open-Label Extension Phase (Wks 17-24)|Adverse Event|1
6215885|NCT01624662|9883697|FG001|Open-Label Extension Phase (Wks 17-24)|Adverse Event|1
6215886|NCT01624662|9883698|FG002|Open-Label Extension Phase (Wks 17-24)|Adverse Event|0
6215887|NCT01624662|9883699|FG003|Open-Label Extension Phase (Wks 17-24)|Adverse Event|1
5980866|NCT01434602|9569525|FG002|Phase II Recommended Phase 2 Dose|Refused further treatment|0
5980867|NCT01434602|9569526|FG003|Phase II Recommended Phase 2 Dose|Refused further treatment|2
5980868|NCT01434602|9569527|FG004|Phase II Recommended Phase 2 Dose|Refused further treatment|0
5980869|NCT01411332|9569548|FG000|Overall Study|Lost to Follow-up|1
5980870|NCT01411332|9569549|FG001|Overall Study|Lost to Follow-up|0
5980871|NCT01411332|9569548|FG000|Overall Study|Protocol Violation|1
5980872|NCT01411332|9569549|FG001|Overall Study|Protocol Violation|1
5980873|NCT01411332|9569548|FG000|Overall Study|Withdrawal by Subject|0
5980874|NCT01411332|9569549|FG001|Overall Study|Withdrawal by Subject|1
5980875|NCT01399918|9569555|FG000|Overall Study|Not eligible and not enrolled in the study|2
5980876|NCT01147653|9569565|FG000|Year 2|Withdrawal by Subject|2
5980877|NCT01147653|9569566|FG001|Year 2|Withdrawal by Subject|3
6215888|NCT01624662|9883696|FG000|Open-Label Extension Phase (Wks 17-24)|Withdrawal by Subject|0
6215889|NCT01624662|9883697|FG001|Open-Label Extension Phase (Wks 17-24)|Withdrawal by Subject|1
6215890|NCT01624662|9883698|FG002|Open-Label Extension Phase (Wks 17-24)|Withdrawal by Subject|0
6215891|NCT01624662|9883699|FG003|Open-Label Extension Phase (Wks 17-24)|Withdrawal by Subject|0
6215892|NCT01624662|9883696|FG000|Open-Label Extension Phase (Wks 17-24)|Lack of Efficacy|0
6215893|NCT01624662|9883697|FG001|Open-Label Extension Phase (Wks 17-24)|Lack of Efficacy|0
6215894|NCT01624662|9883698|FG002|Open-Label Extension Phase (Wks 17-24)|Lack of Efficacy|1
6215895|NCT01624662|9883699|FG003|Open-Label Extension Phase (Wks 17-24)|Lack of Efficacy|0
6215896|NCT01624870|9883720|FG000|Overall Study|Death|19
6215897|NCT01624870|9883720|FG000|Overall Study|Withdrawal by Subject|1
6215898|NCT01624870|9883720|FG000|Overall Study|CoreValve not implanted|6
6215899|NCT01624870|9883720|FG000|Overall Study|Lost to follow up|1
6215900|NCT01624974|9883751|FG000|Period III of Treatment (4 Weeks)|Lack of Efficacy|0
6215901|NCT01624974|9883752|FG001|Period III of Treatment (4 Weeks)|Lack of Efficacy|2
6215902|NCT01624974|9883751|FG000|Period III of Treatment (4 Weeks)|Non-Compliance with Protocol|1
6215903|NCT01624974|9883752|FG001|Period III of Treatment (4 Weeks)|Non-Compliance with Protocol|2
6215904|NCT01624974|9883751|FG000|Period III of Treatment (4 Weeks)|Physician Decision|5
6215905|NCT01624974|9883752|FG001|Period III of Treatment (4 Weeks)|Physician Decision|3
6215906|NCT01624974|9883751|FG000|Period III of Treatment (4 Weeks)|Protocol Violation|1
6215907|NCT01624974|9883752|FG001|Period III of Treatment (4 Weeks)|Protocol Violation|0
6215908|NCT01624974|9883751|FG000|Period III of Treatment (4 Weeks)|Adverse Event|0
6215909|NCT01624974|9883752|FG001|Period III of Treatment (4 Weeks)|Adverse Event|1
6215910|NCT01624974|9883751|FG000|Period IV Washout (4 Weeks)|Lack of Efficacy|1
6215911|NCT01624974|9883752|FG001|Period IV Washout (4 Weeks)|Lack of Efficacy|1
6215912|NCT01624974|9883751|FG000|Period IV Washout (4 Weeks)|Withdrawal by Subject|0
6215913|NCT01624974|9883752|FG001|Period IV Washout (4 Weeks)|Withdrawal by Subject|1
6215914|NCT01624974|9883751|FG000|Period IV Washout (4 Weeks)|Adverse Event|2
6215915|NCT01624974|9883752|FG001|Period IV Washout (4 Weeks)|Adverse Event|0
6215916|NCT01624974|9883751|FG000|Period IV Washout (4 Weeks)|Non-Compliance with Study Drug|0
5980878|NCT01078454|9569586|FG000|Overall Study|Adverse Event|1
5980879|NCT01078454|9569587|FG001|Overall Study|Adverse Event|1
5980880|NCT01078454|9569586|FG000|Overall Study|Death|0
5980881|NCT01078454|9569587|FG001|Overall Study|Death|1
5980882|NCT00687596|9569595|FG000|Overall Study|Adverse Event (AE)|10
5980883|NCT00687596|9569596|FG001|Overall Study|Adverse Event (AE)|3
6123089|NCT00910429|9746909|FG001|Overall Study|Drug non-compliance|0
6123090|NCT00910429|9746908|FG000|Overall Study|Lack of Efficacy|4
6123091|NCT00910429|9746909|FG001|Overall Study|Lack of Efficacy|1
6123092|NCT00910624|9746937|FG000|Treatment Phase|Adverse Event|2
6123093|NCT00910624|9746938|FG001|Treatment Phase|Adverse Event|6
6123094|NCT00910624|9746939|FG002|Treatment Phase|Adverse Event|6
6123095|NCT00910624|9746940|FG003|Treatment Phase|Adverse Event|0
6123096|NCT00910624|9746937|FG000|Treatment Phase|Treatment Failure|23
6123097|NCT00910624|9746938|FG001|Treatment Phase|Treatment Failure|10
6123098|NCT00910624|9746939|FG002|Treatment Phase|Treatment Failure|0
6123099|NCT00910624|9746940|FG003|Treatment Phase|Treatment Failure|0
6123100|NCT00910624|9746937|FG000|Treatment Phase|Lost to Follow-up|0
6123101|NCT00910624|9746938|FG001|Treatment Phase|Lost to Follow-up|0
6123102|NCT00910624|9746939|FG002|Treatment Phase|Lost to Follow-up|1
6123103|NCT00910624|9746940|FG003|Treatment Phase|Lost to Follow-up|0
6123104|NCT00910624|9746937|FG000|Treatment Phase|Reasons Unrelated To Assigned Treatment|3
6123105|NCT00910624|9746938|FG001|Treatment Phase|Reasons Unrelated To Assigned Treatment|3
6123106|NCT00910624|9746939|FG002|Treatment Phase|Reasons Unrelated To Assigned Treatment|1
6123107|NCT00910624|9746940|FG003|Treatment Phase|Reasons Unrelated To Assigned Treatment|0
6123108|NCT00910624|9746937|FG000|Treatment Phase|Withdrawal by Subject|2
6123109|NCT00910624|9746938|FG001|Treatment Phase|Withdrawal by Subject|1
6123110|NCT00910624|9746939|FG002|Treatment Phase|Withdrawal by Subject|0
6123111|NCT00910624|9746940|FG003|Treatment Phase|Withdrawal by Subject|0
6123112|NCT00910624|9746937|FG000|Treatment Phase|Non-Compliance With Protocol|0
6123113|NCT00910624|9746938|FG001|Treatment Phase|Non-Compliance With Protocol|1
6123114|NCT00910624|9746939|FG002|Treatment Phase|Non-Compliance With Protocol|1
6123115|NCT00910624|9746940|FG003|Treatment Phase|Non-Compliance With Protocol|0
6123116|NCT00910624|9746937|FG000|Follow-Up Phase|Adverse Event|0
6123117|NCT00910624|9746938|FG001|Follow-Up Phase|Adverse Event|0
6123118|NCT00910624|9746939|FG002|Follow-Up Phase|Adverse Event|1
6123119|NCT00910624|9746940|FG003|Follow-Up Phase|Adverse Event|0
6123120|NCT00910624|9746937|FG000|Follow-Up Phase|Lost to Follow-up|3
6123121|NCT00910624|9746938|FG001|Follow-Up Phase|Lost to Follow-up|1
6123122|NCT00910624|9746939|FG002|Follow-Up Phase|Lost to Follow-up|2
6123123|NCT00910624|9746940|FG003|Follow-Up Phase|Lost to Follow-up|0
6215917|NCT01624974|9883752|FG001|Period IV Washout (4 Weeks)|Non-Compliance with Study Drug|1
6215918|NCT01624974|9883751|FG000|Period V of Treatment (4 Weeks)|Lack of Efficacy|1
6215919|NCT01624974|9883752|FG001|Period V of Treatment (4 Weeks)|Lack of Efficacy|0
6215920|NCT01624974|9883751|FG000|Period V of Treatment (4 Weeks)|Physician Decision|3
6215921|NCT01624974|9883752|FG001|Period V of Treatment (4 Weeks)|Physician Decision|0
6215922|NCT01624974|9883751|FG000|Period V of Treatment (4 Weeks)|Adverse Event|1
6215923|NCT01624974|9883752|FG001|Period V of Treatment (4 Weeks)|Adverse Event|0
6215924|NCT01625000|9883764|FG000|Overall Study|Physician Decision|15
6215925|NCT01625000|9883765|FG001|Overall Study|Physician Decision|7
6215926|NCT01625000|9883766|FG002|Overall Study|Physician Decision|7
6215927|NCT01625000|9883767|FG003|Overall Study|Physician Decision|2
6123124|NCT00910624|9746937|FG000|Follow-Up Phase|Reasons Unrelated To Assigned Treatment|1
6123125|NCT00910624|9746938|FG001|Follow-Up Phase|Reasons Unrelated To Assigned Treatment|2
6123126|NCT00910624|9746939|FG002|Follow-Up Phase|Reasons Unrelated To Assigned Treatment|0
6123127|NCT00910624|9746940|FG003|Follow-Up Phase|Reasons Unrelated To Assigned Treatment|0
6123128|NCT00910624|9746937|FG000|Follow-Up Phase|Withdrawal by Subject|1
6123129|NCT00910624|9746938|FG001|Follow-Up Phase|Withdrawal by Subject|0
6123130|NCT00910624|9746939|FG002|Follow-Up Phase|Withdrawal by Subject|0
6123131|NCT00910624|9746940|FG003|Follow-Up Phase|Withdrawal by Subject|0
6123132|NCT00910624|9746937|FG000|Follow-Up Phase|Withdrew Due To Retreatment Opportunity|1
6123133|NCT00910624|9746938|FG001|Follow-Up Phase|Withdrew Due To Retreatment Opportunity|0
6123134|NCT00910624|9746939|FG002|Follow-Up Phase|Withdrew Due To Retreatment Opportunity|0
6123135|NCT00910624|9746940|FG003|Follow-Up Phase|Withdrew Due To Retreatment Opportunity|0
6123136|NCT00910624|9746937|FG000|Follow-Up Phase|Administrative|0
6123137|NCT00910624|9746938|FG001|Follow-Up Phase|Administrative|1
6123138|NCT00910624|9746939|FG002|Follow-Up Phase|Administrative|1
6123139|NCT00910624|9746940|FG003|Follow-Up Phase|Administrative|0
6123140|NCT00910663|9746950|FG000|Period 1|Withdrawal by Subject|0
6123141|NCT00910663|9746951|FG001|Period 1|Withdrawal by Subject|1
6123142|NCT00910689|9746961|FG000|Month 1: Optimal Acute Therapy Run in|No Post OAT Run-in data|2
6123143|NCT00910689|9746962|FG001|Month 1: Optimal Acute Therapy Run in|No Post OAT Run-in data|1
6123144|NCT00910689|9746963|FG002|Month 1: Optimal Acute Therapy Run in|No Post OAT Run-in data|5
6123145|NCT00910689|9746964|FG003|Month 1: Optimal Acute Therapy Run in|No Post OAT Run-in data|10
6123146|NCT00910689|9746961|FG000|Month 2- 4: Treatment Period|Lost to Follow-up|3
6123147|NCT00910689|9746962|FG001|Month 2- 4: Treatment Period|Lost to Follow-up|4
6123148|NCT00910689|9746963|FG002|Month 2- 4: Treatment Period|Lost to Follow-up|1
6123149|NCT00910689|9746964|FG003|Month 2- 4: Treatment Period|Lost to Follow-up|3
6123150|NCT00910689|9746961|FG000|Month 2- 4: Treatment Period|Adverse Event|2
6123151|NCT00910689|9746962|FG001|Month 2- 4: Treatment Period|Adverse Event|3
6123152|NCT00910689|9746963|FG002|Month 2- 4: Treatment Period|Adverse Event|2
6123153|NCT00910689|9746964|FG003|Month 2- 4: Treatment Period|Adverse Event|0
6123154|NCT00910689|9746961|FG000|Month 2- 4: Treatment Period|Time Demands|1
6123155|NCT00910689|9746962|FG001|Month 2- 4: Treatment Period|Time Demands|0
6123156|NCT00910689|9746963|FG002|Month 2- 4: Treatment Period|Time Demands|4
6123157|NCT00910689|9746964|FG003|Month 2- 4: Treatment Period|Time Demands|8
6123158|NCT00910689|9746961|FG000|Month 2- 4: Treatment Period|Lack of Efficacy|2
6123159|NCT00910689|9746962|FG001|Month 2- 4: Treatment Period|Lack of Efficacy|1
6123160|NCT00910689|9746963|FG002|Month 2- 4: Treatment Period|Lack of Efficacy|0
6123161|NCT00910689|9746964|FG003|Month 2- 4: Treatment Period|Lack of Efficacy|0
6123162|NCT00910689|9746961|FG000|Month 2- 4: Treatment Period|Perceived Improvement|0
6123163|NCT00910689|9746962|FG001|Month 2- 4: Treatment Period|Perceived Improvement|0
6123164|NCT00910689|9746963|FG002|Month 2- 4: Treatment Period|Perceived Improvement|1
6123165|NCT00910689|9746964|FG003|Month 2- 4: Treatment Period|Perceived Improvement|0
6123166|NCT00910689|9746961|FG000|Month 2- 4: Treatment Period|Pregnancy|0
6123167|NCT00910689|9746962|FG001|Month 2- 4: Treatment Period|Pregnancy|2
6123168|NCT00910689|9746963|FG002|Month 2- 4: Treatment Period|Pregnancy|0
6123169|NCT00910689|9746964|FG003|Month 2- 4: Treatment Period|Pregnancy|0
6123170|NCT00910689|9746961|FG000|Month 2- 4: Treatment Period|Protocol Violation|1
6123171|NCT00910689|9746962|FG001|Month 2- 4: Treatment Period|Protocol Violation|0
6123172|NCT00910689|9746963|FG002|Month 2- 4: Treatment Period|Protocol Violation|0
6123173|NCT00910689|9746964|FG003|Month 2- 4: Treatment Period|Protocol Violation|0
6123174|NCT00910689|9746961|FG000|Months 5 - 10: Evaluation Period I|Lost to Follow-up|2
6123175|NCT00910689|9746962|FG001|Months 5 - 10: Evaluation Period I|Lost to Follow-up|5
6123176|NCT00910689|9746963|FG002|Months 5 - 10: Evaluation Period I|Lost to Follow-up|1
6123177|NCT00910689|9746964|FG003|Months 5 - 10: Evaluation Period I|Lost to Follow-up|1
6123178|NCT00910689|9746961|FG000|Months 5 - 10: Evaluation Period I|Adverse Event|1
6123179|NCT00910689|9746962|FG001|Months 5 - 10: Evaluation Period I|Adverse Event|0
6123180|NCT00910689|9746963|FG002|Months 5 - 10: Evaluation Period I|Adverse Event|2
6123181|NCT00910689|9746964|FG003|Months 5 - 10: Evaluation Period I|Adverse Event|4
6123182|NCT00910689|9746961|FG000|Months 5 - 10: Evaluation Period I|Lack of Efficacy|0
6123183|NCT00910689|9746962|FG001|Months 5 - 10: Evaluation Period I|Lack of Efficacy|1
6123184|NCT00910689|9746963|FG002|Months 5 - 10: Evaluation Period I|Lack of Efficacy|1
6123185|NCT00910689|9746964|FG003|Months 5 - 10: Evaluation Period I|Lack of Efficacy|1
6123186|NCT00910689|9746961|FG000|Months 5 - 10: Evaluation Period I|Protocol Violation|1
6123187|NCT00910689|9746962|FG001|Months 5 - 10: Evaluation Period I|Protocol Violation|1
6123188|NCT00910689|9746963|FG002|Months 5 - 10: Evaluation Period I|Protocol Violation|0
6123189|NCT00910689|9746964|FG003|Months 5 - 10: Evaluation Period I|Protocol Violation|0
6123190|NCT00910689|9746961|FG000|Months 5 - 10: Evaluation Period I|Pregnancy|0
6123191|NCT00910689|9746962|FG001|Months 5 - 10: Evaluation Period I|Pregnancy|0
6123192|NCT00910689|9746963|FG002|Months 5 - 10: Evaluation Period I|Pregnancy|2
6123193|NCT00910689|9746964|FG003|Months 5 - 10: Evaluation Period I|Pregnancy|0
6123194|NCT00910689|9746961|FG000|Months 5 - 10: Evaluation Period I|Time Demands|0
6123195|NCT00910689|9746962|FG001|Months 5 - 10: Evaluation Period I|Time Demands|0
6123196|NCT00910689|9746963|FG002|Months 5 - 10: Evaluation Period I|Time Demands|1
6123197|NCT00910689|9746964|FG003|Months 5 - 10: Evaluation Period I|Time Demands|1
6123198|NCT00910689|9746961|FG000|Months 11- 16: Evaluation Period II|Lost to Follow-up|3
6123199|NCT00910689|9746962|FG001|Months 11- 16: Evaluation Period II|Lost to Follow-up|0
6123200|NCT00910689|9746963|FG002|Months 11- 16: Evaluation Period II|Lost to Follow-up|1
6123201|NCT00910689|9746964|FG003|Months 11- 16: Evaluation Period II|Lost to Follow-up|2
6123202|NCT00910689|9746961|FG000|Months 11- 16: Evaluation Period II|Adverse Event|2
6123203|NCT00910689|9746962|FG001|Months 11- 16: Evaluation Period II|Adverse Event|4
6123204|NCT00910689|9746963|FG002|Months 11- 16: Evaluation Period II|Adverse Event|2
6123205|NCT00910689|9746964|FG003|Months 11- 16: Evaluation Period II|Adverse Event|2
6123206|NCT00910689|9746961|FG000|Months 11- 16: Evaluation Period II|Pregnancy|1
6123207|NCT00910689|9746962|FG001|Months 11- 16: Evaluation Period II|Pregnancy|0
6123208|NCT00910689|9746963|FG002|Months 11- 16: Evaluation Period II|Pregnancy|0
6123209|NCT00910689|9746964|FG003|Months 11- 16: Evaluation Period II|Pregnancy|0
6123210|NCT00910689|9746961|FG000|Months 11- 16: Evaluation Period II|Lack of Efficacy|2
6123211|NCT00910689|9746962|FG001|Months 11- 16: Evaluation Period II|Lack of Efficacy|3
6123212|NCT00910689|9746963|FG002|Months 11- 16: Evaluation Period II|Lack of Efficacy|3
6123213|NCT00910689|9746964|FG003|Months 11- 16: Evaluation Period II|Lack of Efficacy|1
6123214|NCT00910689|9746961|FG000|Months 11- 16: Evaluation Period II|Time Demands|2
6123215|NCT00910689|9746962|FG001|Months 11- 16: Evaluation Period II|Time Demands|1
6123216|NCT00910689|9746963|FG002|Months 11- 16: Evaluation Period II|Time Demands|0
6123217|NCT00910689|9746964|FG003|Months 11- 16: Evaluation Period II|Time Demands|0
6123218|NCT00910689|9746961|FG000|Months 11- 16: Evaluation Period II|Perceived Improvement|0
6123219|NCT00910689|9746962|FG001|Months 11- 16: Evaluation Period II|Perceived Improvement|0
6123220|NCT00910689|9746963|FG002|Months 11- 16: Evaluation Period II|Perceived Improvement|0
6123221|NCT00910689|9746964|FG003|Months 11- 16: Evaluation Period II|Perceived Improvement|1
6123222|NCT00910689|9746961|FG000|Months 11- 16: Evaluation Period II|Physician Decision|0
6123223|NCT00910689|9746962|FG001|Months 11- 16: Evaluation Period II|Physician Decision|2
6123224|NCT00910689|9746963|FG002|Months 11- 16: Evaluation Period II|Physician Decision|1
6123225|NCT00910689|9746964|FG003|Months 11- 16: Evaluation Period II|Physician Decision|0
6123226|NCT00910715|9746977|FG000|Overall Study|Lost to Follow-up|22
6123227|NCT00910715|9746978|FG001|Overall Study|Lost to Follow-up|26
6123228|NCT00910715|9746979|FG002|Overall Study|Lost to Follow-up|0
6123229|NCT00910728|9746998|FG000|Overall Study|Lack of Efficacy|2
6123230|NCT00910728|9746999|FG001|Overall Study|Lack of Efficacy|3
6123231|NCT00910728|9747000|FG002|Overall Study|Lack of Efficacy|1
6123232|NCT00910728|9747001|FG003|Overall Study|Lack of Efficacy|2
6123233|NCT00910728|9747002|FG004|Overall Study|Lack of Efficacy|1
6123234|NCT00910728|9747003|FG005|Overall Study|Lack of Efficacy|0
6123235|NCT00910728|9747004|FG006|Overall Study|Lack of Efficacy|2
6123236|NCT00910728|9747005|FG007|Overall Study|Lack of Efficacy|2
6123237|NCT00910728|9747006|FG008|Overall Study|Lack of Efficacy|2
6123238|NCT00910728|9746998|FG000|Overall Study|Withdrawal by Subject|0
6123239|NCT00910728|9746999|FG001|Overall Study|Withdrawal by Subject|0
6123240|NCT00910728|9747000|FG002|Overall Study|Withdrawal by Subject|0
6123241|NCT00910728|9747001|FG003|Overall Study|Withdrawal by Subject|0
6123242|NCT00910728|9747002|FG004|Overall Study|Withdrawal by Subject|3
6123243|NCT00910728|9747003|FG005|Overall Study|Withdrawal by Subject|1
6123244|NCT00910728|9747004|FG006|Overall Study|Withdrawal by Subject|2
6123245|NCT00910728|9747005|FG007|Overall Study|Withdrawal by Subject|0
6123246|NCT00910728|9747006|FG008|Overall Study|Withdrawal by Subject|0
6123247|NCT00910728|9746998|FG000|Overall Study|(not specified)|2
6123248|NCT00910728|9746999|FG001|Overall Study|(not specified)|0
6215928|NCT01625000|9883768|FG004|Overall Study|Physician Decision|15
6215929|NCT01625000|9883764|FG000|Overall Study|Protocol Violation|3
6215930|NCT01625000|9883765|FG001|Overall Study|Protocol Violation|10
6215931|NCT01625000|9883766|FG002|Overall Study|Protocol Violation|4
6215932|NCT01625000|9883767|FG003|Overall Study|Protocol Violation|1
6215933|NCT01625000|9883768|FG004|Overall Study|Protocol Violation|2
6215934|NCT01625000|9883764|FG000|Overall Study|Withdrawal by Subject|19
6215935|NCT01625000|9883765|FG001|Overall Study|Withdrawal by Subject|16
6215936|NCT01625000|9883766|FG002|Overall Study|Withdrawal by Subject|11
6215937|NCT01625000|9883767|FG003|Overall Study|Withdrawal by Subject|9
6215938|NCT01625000|9883768|FG004|Overall Study|Withdrawal by Subject|17
6215939|NCT01625000|9883764|FG000|Overall Study|Adverse Event (including Death)|15
6215940|NCT01625000|9883765|FG001|Overall Study|Adverse Event (including Death)|19
6215941|NCT01625000|9883766|FG002|Overall Study|Adverse Event (including Death)|11
6215942|NCT01625000|9883767|FG003|Overall Study|Adverse Event (including Death)|7
6215943|NCT01625000|9883768|FG004|Overall Study|Adverse Event (including Death)|21
6215944|NCT01625091|9883787|FG000|Intervention|Death|1
6215945|NCT01625091|9883788|FG001|Intervention|Death|1
6215946|NCT01625091|9883787|FG000|Intervention|Withdrawal by Subject|4
6215947|NCT01625091|9883788|FG001|Intervention|Withdrawal by Subject|1
6215948|NCT01625091|9883787|FG000|Intervention|Adverse Event|0
6215949|NCT01625091|9883788|FG001|Intervention|Adverse Event|2
6215950|NCT01625091|9883787|FG000|Intervention|Lost to Follow-up|4
6215951|NCT01625091|9883788|FG001|Intervention|Lost to Follow-up|4
6215952|NCT01625091|9883787|FG000|Intervention|Study termination|2
6215953|NCT01625091|9883788|FG001|Intervention|Study termination|3
6215954|NCT01625091|9883787|FG000|Post-intervention|Death|0
6215955|NCT01625091|9883788|FG001|Post-intervention|Death|1
6215956|NCT01625091|9883787|FG000|Post-intervention|Lost to Follow-up|2
6215957|NCT01625091|9883788|FG001|Post-intervention|Lost to Follow-up|0
6215958|NCT01625091|9883787|FG000|Post-intervention|Study termination|2
6215959|NCT01625091|9883788|FG001|Post-intervention|Study termination|1
6215960|NCT01625182|9883809|FG000|Overall Study|Administrative problems|1
6215961|NCT01625182|9883810|FG001|Overall Study|Administrative problems|0
6215962|NCT01625182|9883809|FG000|Overall Study|Protocol deviation|0
6215963|NCT01625182|9883810|FG001|Overall Study|Protocol deviation|2
6215964|NCT01625182|9883809|FG000|Overall Study|Adverse Event|2
6215965|NCT01625182|9883810|FG001|Overall Study|Adverse Event|0
6288031|NCT02358343|10001138|FG000|Comparative Efficacy Trial / Observation|Administrative Withdrawal|0
6288032|NCT02358343|10001139|FG001|Comparative Efficacy Trial / Observation|Administrative Withdrawal|0
6288033|NCT02358343|10001140|FG002|Comparative Efficacy Trial / Observation|Administrative Withdrawal|1
6288034|NCT02358343|10001141|FG003|Comparative Efficacy Trial / Observation|Administrative Withdrawal|0
6288035|NCT02358343|10001142|FG004|Comparative Efficacy Trial / Observation|Administrative Withdrawal|0
6288036|NCT02358369|10001156|FG000|Pre-Randomization Washout Period|Not Qualified for Randomization|35
6288037|NCT02358369|10001157|FG001|Pre-Randomization Washout Period|Not Qualified for Randomization|0
6288038|NCT02358369|10001158|FG002|Pre-Randomization Washout Period|Not Qualified for Randomization|0
6288039|NCT02358369|10001159|FG003|Pre-Randomization Washout Period|Not Qualified for Randomization|0
6288040|NCT02358369|10001160|FG004|Pre-Randomization Washout Period|Not Qualified for Randomization|0
6288041|NCT02358369|10001156|FG000|Treatment Period A/B|Adverse Event|0
6288042|NCT02358369|10001157|FG001|Treatment Period A/B|Adverse Event|0
6288043|NCT02358369|10001158|FG002|Treatment Period A/B|Adverse Event|1
6288044|NCT02358369|10001159|FG003|Treatment Period A/B|Adverse Event|2
6288045|NCT02358369|10001160|FG004|Treatment Period A/B|Adverse Event|0
6288046|NCT02358369|10001156|FG000|Treatment Period A/B|Death|0
6288047|NCT02358369|10001157|FG001|Treatment Period A/B|Death|0
6288048|NCT02358369|10001158|FG002|Treatment Period A/B|Death|1
6288049|NCT02358369|10001159|FG003|Treatment Period A/B|Death|0
6288050|NCT02358369|10001160|FG004|Treatment Period A/B|Death|0
6288051|NCT02358369|10001156|FG000|Treatment Period A/B|Withdrawal by Subject|0
6288052|NCT02358369|10001157|FG001|Treatment Period A/B|Withdrawal by Subject|2
6215966|NCT01625182|9883809|FG000|Overall Study|Withdrawal by Subject|5
6215967|NCT01625182|9883810|FG001|Overall Study|Withdrawal by Subject|1
6123249|NCT00910728|9747000|FG002|Overall Study|(not specified)|1
6123250|NCT00910728|9747001|FG003|Overall Study|(not specified)|0
6123251|NCT00910728|9747002|FG004|Overall Study|(not specified)|1
6123252|NCT00910728|9747003|FG005|Overall Study|(not specified)|0
6123253|NCT00910728|9747004|FG006|Overall Study|(not specified)|0
6123254|NCT00910728|9747005|FG007|Overall Study|(not specified)|0
6123255|NCT00910728|9747006|FG008|Overall Study|(not specified)|0
6123256|NCT00910728|9746998|FG000|Overall Study|Adverse Event|2
6123257|NCT00910728|9746999|FG001|Overall Study|Adverse Event|0
6123258|NCT00910728|9747000|FG002|Overall Study|Adverse Event|1
6123259|NCT00910728|9747001|FG003|Overall Study|Adverse Event|1
6123260|NCT00910728|9747002|FG004|Overall Study|Adverse Event|0
6123261|NCT00910728|9747003|FG005|Overall Study|Adverse Event|0
6123262|NCT00910728|9747004|FG006|Overall Study|Adverse Event|2
6123263|NCT00910728|9747005|FG007|Overall Study|Adverse Event|1
6123264|NCT00910728|9747006|FG008|Overall Study|Adverse Event|1
6123265|NCT00910858|9747038|FG000|Pharmacokinetic Phase|Adverse Event|1
6123266|NCT00910858|9747039|FG001|Pharmacokinetic Phase|Adverse Event|0
6123267|NCT00910858|9747040|FG002|Pharmacokinetic Phase|Adverse Event|0
6123268|NCT00910858|9747038|FG000|Monotherapy Phase|Adverse Event|3
6123269|NCT00910858|9747039|FG001|Monotherapy Phase|Adverse Event|2
6123270|NCT00910858|9747040|FG002|Monotherapy Phase|Adverse Event|0
6123271|NCT00910858|9747038|FG000|Monotherapy Phase|Lack of therapeutic effect|9
6123272|NCT00910858|9747039|FG001|Monotherapy Phase|Lack of therapeutic effect|6
6123273|NCT00910858|9747040|FG002|Monotherapy Phase|Lack of therapeutic effect|4
6215968|NCT01625182|9883809|FG000|Overall Study|Lack of Efficacy|12
6215969|NCT01625182|9883810|FG001|Overall Study|Lack of Efficacy|8
6215970|NCT01625338|9883824|FG000|Overall Study|Enrolled but not Treated|0
6215971|NCT01625338|9883825|FG001|Overall Study|Enrolled but not Treated|0
6215972|NCT01625338|9883826|FG002|Overall Study|Enrolled but not Treated|1
6215973|NCT01625338|9883824|FG000|Overall Study|Efficacy Failure|27
6215974|NCT01625338|9883825|FG001|Overall Study|Efficacy Failure|39
6215975|NCT01625338|9883826|FG002|Overall Study|Efficacy Failure|31
6215976|NCT01625338|9883824|FG000|Overall Study|Lost to Follow-up|3
6215977|NCT01625338|9883825|FG001|Overall Study|Lost to Follow-up|3
6215978|NCT01625338|9883826|FG002|Overall Study|Lost to Follow-up|2
6215979|NCT01625338|9883824|FG000|Overall Study|Investigator Decision|0
6215980|NCT01625338|9883825|FG001|Overall Study|Investigator Decision|2
6215981|NCT01625338|9883826|FG002|Overall Study|Investigator Decision|1
6215982|NCT01625338|9883824|FG000|Overall Study|Subject Withdrew Consent|1
6215983|NCT01625338|9883825|FG001|Overall Study|Subject Withdrew Consent|0
6215984|NCT01625338|9883826|FG002|Overall Study|Subject Withdrew Consent|2
6215985|NCT01625338|9883824|FG000|Overall Study|Adverse Event|1
6215986|NCT01625338|9883825|FG001|Overall Study|Adverse Event|0
6215987|NCT01625338|9883826|FG002|Overall Study|Adverse Event|1
6215988|NCT01625338|9883824|FG000|Overall Study|Study Discontinued by Sponsor|0
6215989|NCT01625338|9883825|FG001|Overall Study|Study Discontinued by Sponsor|0
6215990|NCT01625338|9883826|FG002|Overall Study|Study Discontinued by Sponsor|1
6215991|NCT01625377|9883836|FG000|Overall Study|Death|1
6215992|NCT01625377|9883837|FG001|Overall Study|Death|1
6215993|NCT01625377|9883836|FG000|Overall Study|Administrative Problem|1
6215994|NCT01625377|9883837|FG001|Overall Study|Administrative Problem|1
6215995|NCT01625377|9883836|FG000|Overall Study|Protocol Violation|0
6215996|NCT01625377|9883837|FG001|Overall Study|Protocol Violation|3
6215997|NCT01625377|9883836|FG000|Overall Study|Adverse Event|3
6215998|NCT01625377|9883837|FG001|Overall Study|Adverse Event|16
6215999|NCT01625377|9883836|FG000|Overall Study|Graft loss|1
6216000|NCT01625377|9883837|FG001|Overall Study|Graft loss|0
6216001|NCT01625377|9883836|FG000|Overall Study|Unsatisfactory therapeutic effect|0
6216002|NCT01625377|9883837|FG001|Overall Study|Unsatisfactory therapeutic effect|1
6216003|NCT01625377|9883836|FG000|Overall Study|Abnormal laboratory values|1
6216004|NCT01625377|9883837|FG001|Overall Study|Abnormal laboratory values|0
6216005|NCT01625689|9883869|FG000|Overall Study|Migration|2
6216006|NCT01625689|9883870|FG001|Overall Study|Migration|1
6216007|NCT01625845|9883878|FG000|Overall Study|Adverse Event|1
6216008|NCT01625845|9883879|FG001|Overall Study|Adverse Event|2
6288053|NCT02358369|10001158|FG002|Treatment Period A/B|Withdrawal by Subject|0
6288054|NCT02358369|10001159|FG003|Treatment Period A/B|Withdrawal by Subject|2
6288055|NCT02358369|10001160|FG004|Treatment Period A/B|Withdrawal by Subject|0
6288056|NCT02358369|10001156|FG000|Treatment Period C|Adverse Event|0
6288057|NCT02358369|10001157|FG001|Treatment Period C|Adverse Event|0
6288058|NCT02358369|10001158|FG002|Treatment Period C|Adverse Event|0
6288059|NCT02358369|10001159|FG003|Treatment Period C|Adverse Event|0
6123274|NCT00910858|9747038|FG000|Monotherapy Phase|Withdrawal by Subject|1
6288060|NCT02358369|10001160|FG004|Treatment Period C|Adverse Event|7
6288061|NCT02358473|10001170|FG000|Overall Study|Disease Progession|6
6288062|NCT02358473|10001170|FG000|Overall Study|Adverse Event|3
6123275|NCT00910858|9747039|FG001|Monotherapy Phase|Withdrawal by Subject|3
6216009|NCT01625845|9883878|FG000|Overall Study|Lost to Follow-up|2
6288063|NCT02358473|10001170|FG000|Overall Study|Withdrawal by Subject|2
6288064|NCT02358473|10001170|FG000|Overall Study|Physician Decision|2
6123276|NCT00910858|9747040|FG002|Monotherapy Phase|Withdrawal by Subject|1
6123277|NCT00910858|9747038|FG000|Monotherapy Phase|Protocol Violation|1
6123278|NCT00910858|9747039|FG001|Monotherapy Phase|Protocol Violation|0
6288065|NCT02358668|10001186|FG000|Overall Study|Adverse Event|2
6123279|NCT00910858|9747040|FG002|Monotherapy Phase|Protocol Violation|0
6123280|NCT00910858|9747038|FG000|Monotherapy Phase|Other|3
6123281|NCT00910858|9747039|FG001|Monotherapy Phase|Other|4
6123282|NCT00910858|9747040|FG002|Monotherapy Phase|Other|2
6123283|NCT00910858|9747038|FG000|Combined Treatment Phase|Lack of therapeutic effect|8
6123284|NCT00910858|9747039|FG001|Combined Treatment Phase|Lack of therapeutic effect|6
6123285|NCT00910858|9747040|FG002|Combined Treatment Phase|Lack of therapeutic effect|3
6123286|NCT00910858|9747038|FG000|Combined Treatment Phase|Withdrawal by Subject|0
6123287|NCT00910858|9747039|FG001|Combined Treatment Phase|Withdrawal by Subject|2
6123288|NCT00910858|9747040|FG002|Combined Treatment Phase|Withdrawal by Subject|0
6123289|NCT00910858|9747038|FG000|Combined Treatment Phase|Protocol Violation|1
6123290|NCT00910858|9747039|FG001|Combined Treatment Phase|Protocol Violation|0
6123291|NCT00910858|9747040|FG002|Combined Treatment Phase|Protocol Violation|0
6123292|NCT00910858|9747038|FG000|Combined Treatment Phase|Other|0
6123293|NCT00910858|9747039|FG001|Combined Treatment Phase|Other|2
6123294|NCT00910858|9747040|FG002|Combined Treatment Phase|Other|1
6123295|NCT00910871|9747056|FG000|Overall Study|Adverse Event|5
6123296|NCT00910871|9747056|FG000|Overall Study|Death|12
6123297|NCT00910871|9747056|FG000|Overall Study|Lost to Follow-up|8
6123298|NCT00910871|9747056|FG000|Overall Study|Protocol Violation|11
6123299|NCT00910871|9747056|FG000|Overall Study|Withdrawal by Subject|12
6123300|NCT00910871|9747056|FG000|Overall Study|Subject didn't meet eligibility criteria|5
6123301|NCT00910871|9747056|FG000|Overall Study|Undefined|1
6123302|NCT00910910|9747062|FG000|Overall Study|Adverse Event|63
6123303|NCT00910910|9747063|FG001|Overall Study|Adverse Event|35
6123304|NCT00910910|9747062|FG000|Overall Study|PD without histologic change|27
6123305|NCT00910910|9747063|FG001|Overall Study|PD without histologic change|23
6123306|NCT00910910|9747062|FG000|Overall Study|PD with histologic change|0
6216010|NCT01625845|9883879|FG001|Overall Study|Lost to Follow-up|1
6216011|NCT01625845|9883878|FG000|Overall Study|Withdrawal by Subject|2
6216012|NCT01625845|9883879|FG001|Overall Study|Withdrawal by Subject|0
6216013|NCT01625897|9883887|FG000|Overall Study|Adverse Event|27
6216014|NCT01625897|9883888|FG001|Overall Study|Adverse Event|10
6216015|NCT01625897|9883887|FG000|Overall Study|Physician Decision|0
6216016|NCT01625897|9883888|FG001|Overall Study|Physician Decision|1
6216017|NCT01625897|9883887|FG000|Overall Study|Withdrawal by Subject|25
6216018|NCT01625897|9883888|FG001|Overall Study|Withdrawal by Subject|3
6216019|NCT01625910|9883896|FG000|Overall Study|Lost to Follow-up|3
6216020|NCT01625910|9883897|FG001|Overall Study|Lost to Follow-up|4
6216021|NCT01625988|9883912|FG000|Overall Study|Lost to Follow-up|5
6216022|NCT01625988|9883913|FG001|Overall Study|Lost to Follow-up|6
6216023|NCT01625988|9883912|FG000|Overall Study|Withdrawal by Subject|8
6216024|NCT01625988|9883913|FG001|Overall Study|Withdrawal by Subject|3
6216025|NCT01625988|9883912|FG000|Overall Study|Adverse Event|0
6216026|NCT01625988|9883913|FG001|Overall Study|Adverse Event|1
6216027|NCT01625988|9883912|FG000|Overall Study|Lack of Efficacy|0
6216028|NCT01625988|9883913|FG001|Overall Study|Lack of Efficacy|1
6216029|NCT01625988|9883912|FG000|Overall Study|Randomized Inappropriately|1
6216030|NCT01625988|9883913|FG001|Overall Study|Randomized Inappropriately|0
6216031|NCT01625988|9883912|FG000|Overall Study|Protocol Violation|0
6216032|NCT01625988|9883913|FG001|Overall Study|Protocol Violation|2
6216033|NCT01626118|9883930|FG000|Overall Study|Lack of Efficacy|1
6216034|NCT01626118|9883931|FG001|Overall Study|Lack of Efficacy|0
6216035|NCT01626118|9883932|FG002|Overall Study|Lack of Efficacy|1
6216036|NCT01626118|9883933|FG003|Overall Study|Lack of Efficacy|3
6216037|NCT01626118|9883930|FG000|Overall Study|Lost to Follow-up|1
6123307|NCT00910910|9747063|FG001|Overall Study|PD with histologic change|2
6123308|NCT00910910|9747062|FG000|Overall Study|Withdrawal by Subject|7
6123309|NCT00910910|9747063|FG001|Overall Study|Withdrawal by Subject|5
6123310|NCT00910910|9747062|FG000|Overall Study|Lost to Follow-up|2
6123311|NCT00910910|9747063|FG001|Overall Study|Lost to Follow-up|2
6123312|NCT00910910|9747062|FG000|Overall Study|Death|9
6123313|NCT00910910|9747063|FG001|Overall Study|Death|3
6123314|NCT00910910|9747062|FG000|Overall Study|Protocol Violation|2
6123315|NCT00910910|9747063|FG001|Overall Study|Protocol Violation|2
6123316|NCT00910910|9747062|FG000|Overall Study|Completed 13 cycles of treatment|0
6123317|NCT00910910|9747063|FG001|Overall Study|Completed 13 cycles of treatment|118
6123318|NCT00910910|9747062|FG000|Overall Study|Other|114
6123319|NCT00910910|9747063|FG001|Overall Study|Other|32
6123320|NCT00910910|9747062|FG000|Overall Study|Untreated before cycle 1|1
6123321|NCT00910910|9747063|FG001|Overall Study|Untreated before cycle 1|2
6123322|NCT00910962|9747072|FG000|Overall Study|Adverse Event|5
6123323|NCT00910962|9747073|FG001|Overall Study|Adverse Event|20
6123324|NCT00910962|9747074|FG002|Overall Study|Adverse Event|17
6123325|NCT00910962|9747072|FG000|Overall Study|Protocol Violation|1
6123326|NCT00910962|9747073|FG001|Overall Study|Protocol Violation|3
6123327|NCT00910962|9747074|FG002|Overall Study|Protocol Violation|3
6123328|NCT00910962|9747072|FG000|Overall Study|Lost to Follow-up|0
6123329|NCT00910962|9747073|FG001|Overall Study|Lost to Follow-up|3
6216038|NCT01626118|9883931|FG001|Overall Study|Lost to Follow-up|0
6216039|NCT01626118|9883932|FG002|Overall Study|Lost to Follow-up|0
6216040|NCT01626118|9883933|FG003|Overall Study|Lost to Follow-up|0
6216041|NCT01626118|9883930|FG000|Overall Study|Adverse Event|0
6123330|NCT00910962|9747074|FG002|Overall Study|Lost to Follow-up|1
6123331|NCT00910962|9747072|FG000|Overall Study|Physician Decision|0
6123332|NCT00910962|9747073|FG001|Overall Study|Physician Decision|6
6123333|NCT00910962|9747074|FG002|Overall Study|Physician Decision|6
6123334|NCT00910962|9747072|FG000|Overall Study|Withdrawal by Subject|25
6123335|NCT00910962|9747073|FG001|Overall Study|Withdrawal by Subject|32
6123336|NCT00910962|9747074|FG002|Overall Study|Withdrawal by Subject|32
6123337|NCT00910962|9747072|FG000|Overall Study|Reached defined stopping criteria|12
6123338|NCT00910962|9747073|FG001|Overall Study|Reached defined stopping criteria|14
6123339|NCT00910962|9747074|FG002|Overall Study|Reached defined stopping criteria|17
6123340|NCT00910988|9747088|FG000|Overall Study|Lost to Follow-up|2
6123341|NCT00910988|9747089|FG001|Overall Study|Lost to Follow-up|4
6123342|NCT00910988|9747090|FG002|Overall Study|Lost to Follow-up|3
6123343|NCT00910988|9747091|FG003|Overall Study|Lost to Follow-up|0
6123344|NCT00911144|9747119|FG000|Overall Study|Withdrawal by Subject|16
6123345|NCT00911144|9747120|FG001|Overall Study|Withdrawal by Subject|5
6123346|NCT00911157|9747128|FG000|Overall Study|Adverse Event|4
6123347|NCT00911157|9747129|FG001|Overall Study|Adverse Event|1
6123348|NCT00911157|9747128|FG000|Overall Study|Withdrawal by Subject|1
6123349|NCT00911157|9747129|FG001|Overall Study|Withdrawal by Subject|1
6123350|NCT00911157|9747128|FG000|Overall Study|Need for prohibited drug (heparin)|1
6123351|NCT00911157|9747129|FG001|Overall Study|Need for prohibited drug (heparin)|0
6123352|NCT00911157|9747128|FG000|Overall Study|Need to treat for lung cancer|1
6123353|NCT00911157|9747129|FG001|Overall Study|Need to treat for lung cancer|0
6123354|NCT00911170|9747137|FG000|Treatment Period|Randomized in error|1
6123355|NCT00911170|9747138|FG001|Treatment Period|Randomized in error|1
6123356|NCT00911170|9747137|FG000|Treatment Period|Ineligibility determined|1
6123357|NCT00911170|9747138|FG001|Treatment Period|Ineligibility determined|3
6123358|NCT00911170|9747137|FG000|Treatment Period|Protocol deviation|1
6123359|NCT00911170|9747138|FG001|Treatment Period|Protocol deviation|2
6123360|NCT00911170|9747137|FG000|Treatment Period|Adverse Event|9
6123361|NCT00911170|9747138|FG001|Treatment Period|Adverse Event|10
6123362|NCT00911170|9747137|FG000|Treatment Period|Withdrawal by Subject|4
6123363|NCT00911170|9747138|FG001|Treatment Period|Withdrawal by Subject|4
6123364|NCT00911170|9747137|FG000|Treatment Period|Disease progression|0
6123365|NCT00911170|9747138|FG001|Treatment Period|Disease progression|2
6123366|NCT00911170|9747137|FG000|Treatment Period|Physician Decision|5
6123367|NCT00911170|9747138|FG001|Treatment Period|Physician Decision|5
6216042|NCT01626118|9883931|FG001|Overall Study|Adverse Event|1
6216043|NCT01626118|9883932|FG002|Overall Study|Adverse Event|1
6216044|NCT01626118|9883933|FG003|Overall Study|Adverse Event|0
6216045|NCT01626118|9883930|FG000|Overall Study|Investigator Decision|0
6216046|NCT01626118|9883931|FG001|Overall Study|Investigator Decision|1
6216047|NCT01626118|9883932|FG002|Overall Study|Investigator Decision|0
6216048|NCT01626118|9883933|FG003|Overall Study|Investigator Decision|0
6216049|NCT01626352|9883943|FG000|Overall Study|Disease Progression|3
6216050|NCT01626352|9883943|FG000|Overall Study|Intercurrent Illness|2
6216051|NCT01626352|9883943|FG000|Overall Study|Death|2
6216052|NCT01626352|9883943|FG000|Overall Study|Withdrawal by Subject|1
6216053|NCT01626352|9883943|FG000|Overall Study|Non-Compliance|1
6216054|NCT01626352|9883943|FG000|Overall Study|Never Treated|1
6216055|NCT01626391|9883952|FG000|Overall Study|Physician Decision|1
6216056|NCT01626391|9883953|FG001|Overall Study|Physician Decision|0
6216057|NCT01626391|9883952|FG000|Overall Study|Withdrawal by Subject|1
6216058|NCT01626391|9883953|FG001|Overall Study|Withdrawal by Subject|0
6216059|NCT01626456|9883961|FG000|Overall Study|Withdrawal by Subject|21
6216060|NCT01626456|9883962|FG001|Overall Study|Withdrawal by Subject|46
6216061|NCT01626456|9883961|FG000|Overall Study|Adverse Event|2
6216062|NCT01626456|9883962|FG001|Overall Study|Adverse Event|27
6216063|NCT01626456|9883961|FG000|Overall Study|Lost to Follow-up|2
6216064|NCT01626456|9883962|FG001|Overall Study|Lost to Follow-up|27
6216065|NCT01626456|9883961|FG000|Overall Study|Lack of Efficacy|6
6216066|NCT01626456|9883962|FG001|Overall Study|Lack of Efficacy|7
6216067|NCT01626456|9883961|FG000|Overall Study|Physician Decision|1
6216068|NCT01626456|9883962|FG001|Overall Study|Physician Decision|4
6216069|NCT01626456|9883961|FG000|Overall Study|Protocol Violation|1
6216070|NCT01626456|9883962|FG001|Overall Study|Protocol Violation|1
6216071|NCT01626456|9883961|FG000|Overall Study|Site Closure|2
6216072|NCT01626456|9883962|FG001|Overall Study|Site Closure|3
6216073|NCT01626456|9883961|FG000|Overall Study|Incarceration|0
6123368|NCT00911170|9747137|FG000|Treatment Period|Lost to Follow-up|0
6123369|NCT00911170|9747138|FG001|Treatment Period|Lost to Follow-up|1
6123370|NCT00911170|9747137|FG000|Treatment Period|Death|6
6123371|NCT00911170|9747138|FG001|Treatment Period|Death|9
6123372|NCT00911170|9747137|FG000|Long Term Follow-Up|Continuing in study|274
6123373|NCT00911170|9747138|FG001|Long Term Follow-Up|Continuing in study|269
6216074|NCT01626456|9883962|FG001|Overall Study|Incarceration|2
6216075|NCT01626495|9883977|FG000|Overall Study|Adverse Event|3
6216076|NCT01626495|9883977|FG000|Overall Study|Disease progression|27
6216077|NCT01626495|9883977|FG000|Overall Study|Withdrawal by Subject|1
6216078|NCT01626495|9883977|FG000|Overall Study|Administrative problem|1
6216079|NCT01626495|9883977|FG000|Overall Study|Death|2
6123374|NCT00911170|9747137|FG000|Long Term Follow-Up|Withdrawal by Subject|20
6123375|NCT00911170|9747138|FG001|Long Term Follow-Up|Withdrawal by Subject|21
6123376|NCT00911170|9747137|FG000|Long Term Follow-Up|Physician Decision|5
6216080|NCT01626495|9883977|FG000|Overall Study|Physician Decision|1
6123377|NCT00911170|9747138|FG001|Long Term Follow-Up|Physician Decision|4
6123378|NCT00911170|9747137|FG000|Long Term Follow-Up|Lost to Follow-up|8
6123379|NCT00911170|9747138|FG001|Long Term Follow-Up|Lost to Follow-up|7
6123380|NCT00911170|9747137|FG000|Long Term Follow-Up|Death|116
6123381|NCT00911170|9747138|FG001|Long Term Follow-Up|Death|121
6123382|NCT00911300|9747146|FG000|Overall Study|Primary Endpoint Component Occurred|1
6123383|NCT00911300|9747147|FG001|Overall Study|Primary Endpoint Component Occurred|2
6123384|NCT00911300|9747146|FG000|Overall Study|Death|1
6123385|NCT00911300|9747147|FG001|Overall Study|Death|0
6123386|NCT00911300|9747146|FG000|Overall Study|Thrombus Persistant in Second TEE|3
6123387|NCT00911300|9747147|FG001|Overall Study|Thrombus Persistant in Second TEE|7
6123388|NCT00911300|9747146|FG000|Overall Study|Adverse Event|14
6123389|NCT00911300|9747147|FG001|Overall Study|Adverse Event|6
6123390|NCT00911300|9747146|FG000|Overall Study|Protocol Violation|3
6123391|NCT00911300|9747147|FG001|Overall Study|Protocol Violation|2
6123392|NCT00911300|9747146|FG000|Overall Study|Consent Withdrawn|4
6123393|NCT00911300|9747147|FG001|Overall Study|Consent Withdrawn|12
6123394|NCT00911300|9747146|FG000|Overall Study|Coronary Angiography Performed|1
6123395|NCT00911300|9747147|FG001|Overall Study|Coronary Angiography Performed|0
6123396|NCT00911300|9747146|FG000|Overall Study|Atrial Fibrillation (AF) Recurrence|3
6123397|NCT00911300|9747147|FG001|Overall Study|Atrial Fibrillation (AF) Recurrence|3
6123398|NCT00911300|9747146|FG000|Overall Study|Received Commercial Treatment|1
6123399|NCT00911300|9747147|FG001|Overall Study|Received Commercial Treatment|0
6123400|NCT00911300|9747146|FG000|Overall Study|Recurrent Tachyarrhythmia|1
6123401|NCT00911300|9747147|FG001|Overall Study|Recurrent Tachyarrhythmia|1
6123402|NCT00911300|9747146|FG000|Overall Study|Recurrent Tachy-Arrhythmia Absoluta|1
6123403|NCT00911300|9747147|FG001|Overall Study|Recurrent Tachy-Arrhythmia Absoluta|1
6123404|NCT00911300|9747146|FG000|Overall Study|Nurse Unavailable in Participant's City|1
6123405|NCT00911300|9747147|FG001|Overall Study|Nurse Unavailable in Participant's City|0
6123406|NCT00911300|9747146|FG000|Overall Study|CV Unsuccessful; Phenprocoumon Received|1
6123407|NCT00911300|9747147|FG001|Overall Study|CV Unsuccessful; Phenprocoumon Received|0
6123408|NCT00911300|9747146|FG000|Overall Study|Participant Could Not Stay in Hospital|0
6123409|NCT00911300|9747147|FG001|Overall Study|Participant Could Not Stay in Hospital|1
6123410|NCT00911300|9747146|FG000|Overall Study|Investigator's Decision; New AF Episode|0
6123411|NCT00911300|9747147|FG001|Overall Study|Investigator's Decision; New AF Episode|1
6123412|NCT00911300|9747146|FG000|Overall Study|International Normalized Ratio Too High|0
6123413|NCT00911300|9747147|FG001|Overall Study|International Normalized Ratio Too High|1
6123414|NCT00911300|9747146|FG000|Overall Study|Participant Refused Hospital Consulation|0
6123415|NCT00911300|9747147|FG001|Overall Study|Participant Refused Hospital Consulation|1
6123416|NCT00911300|9747146|FG000|Overall Study|Underlying Disease (Myocarditis)|0
6123417|NCT00911300|9747147|FG001|Overall Study|Underlying Disease (Myocarditis)|1
6123418|NCT00911300|9747146|FG000|Overall Study|Physician Decision|0
6216081|NCT01626495|9883977|FG000|Overall Study|New cancer therapy|16
6216082|NCT01626495|9883977|FG000|Overall Study|Manufacturing failure|1
6216083|NCT01626690|9883994|FG000|Overall Study|Protocol Violation|1
6216084|NCT01626690|9883995|FG001|Overall Study|Protocol Violation|0
6216085|NCT01626690|9883994|FG000|Overall Study|Adverse Event|1
6216086|NCT01626690|9883995|FG001|Overall Study|Adverse Event|0
6216087|NCT01626859|9884016|FG000|Overall Study|Adverse Event|1
6216088|NCT01626859|9884017|FG001|Overall Study|Adverse Event|3
6216089|NCT01626859|9884018|FG002|Overall Study|Adverse Event|2
6216090|NCT01626859|9884016|FG000|Overall Study|Physician Decision|0
6216091|NCT01626859|9884017|FG001|Overall Study|Physician Decision|1
6216092|NCT01626859|9884018|FG002|Overall Study|Physician Decision|0
6216093|NCT01626859|9884016|FG000|Overall Study|Withdrawal by Subject|1
6216094|NCT01626859|9884017|FG001|Overall Study|Withdrawal by Subject|4
6216095|NCT01626859|9884018|FG002|Overall Study|Withdrawal by Subject|2
6216096|NCT01626872|9884029|FG000|Overall Study|Physician Decision|13
6216097|NCT01626872|9884030|FG001|Overall Study|Physician Decision|9
6216098|NCT01626872|9884031|FG002|Overall Study|Physician Decision|6
6216099|NCT01626872|9884029|FG000|Overall Study|Withdrawal by Subject|19
6216100|NCT01626872|9884030|FG001|Overall Study|Withdrawal by Subject|27
6216101|NCT01626872|9884031|FG002|Overall Study|Withdrawal by Subject|8
6216102|NCT01626872|9884029|FG000|Overall Study|Adverse Event (including Death)|20
6216103|NCT01626872|9884030|FG001|Overall Study|Adverse Event (including Death)|28
6216104|NCT01626872|9884031|FG002|Overall Study|Adverse Event (including Death)|8
6216105|NCT01626872|9884029|FG000|Overall Study|Protocol Violation (including Pregnancy)|0
6216106|NCT01626872|9884030|FG001|Overall Study|Protocol Violation (including Pregnancy)|2
6216107|NCT01626872|9884031|FG002|Overall Study|Protocol Violation (including Pregnancy)|2
6216108|NCT01626885|9884039|FG000|Overall Study|Adverse Event|8
6216109|NCT01626885|9884039|FG000|Overall Study|Withdrawal by Subject|4
6216110|NCT01626989|9884043|FG000|Screening Period|Screen Failure|15
6216111|NCT01626989|9884044|FG001|Screening Period|Screen Failure|0
6216112|NCT01626989|9884045|FG002|Screening Period|Screen Failure|0
6216113|NCT01626989|9884043|FG000|Screening Period|Withdrawal by Subject|2
6216114|NCT01626989|9884044|FG001|Screening Period|Withdrawal by Subject|0
6216115|NCT01626989|9884045|FG002|Screening Period|Withdrawal by Subject|0
6216116|NCT01627067|9884091|FG000|Overall Study|Screen Failure|1
6216117|NCT01627249|9884100|FG000|Overall Study|Death|3
6216118|NCT01627249|9884101|FG001|Overall Study|Death|5
6123419|NCT00911300|9747147|FG001|Overall Study|Physician Decision|1
6123420|NCT00911300|9747146|FG000|Overall Study|Treatment Stopped by Mistake|0
6216119|NCT01627249|9884102|FG002|Overall Study|Death|3
6216120|NCT01627249|9884100|FG000|Overall Study|Withdrawal by Subject|12
6216121|NCT01627249|9884101|FG001|Overall Study|Withdrawal by Subject|6
6216122|NCT01627249|9884102|FG002|Overall Study|Withdrawal by Subject|9
6216123|NCT01627249|9884100|FG000|Overall Study|Missed Visit|1
6216124|NCT01627249|9884101|FG001|Overall Study|Missed Visit|1
6216125|NCT01627249|9884102|FG002|Overall Study|Missed Visit|0
6216126|NCT01627327|9884131|FG000|Overall Study|Adverse Event|6
6216127|NCT01627327|9884132|FG001|Overall Study|Adverse Event|12
6216128|NCT01627327|9884131|FG000|Overall Study|Lack of Efficacy-No Sub-Reason|0
6216129|NCT01627327|9884132|FG001|Overall Study|Lack of Efficacy-No Sub-Reason|2
6216130|NCT01627327|9884131|FG000|Overall Study|Lack of Efficacy-Sub-Reason Exacerbation|4
6216131|NCT01627327|9884132|FG001|Overall Study|Lack of Efficacy-Sub-Reason Exacerbation|9
6216132|NCT01627327|9884131|FG000|Overall Study|Protocol Violation|4
6216133|NCT01627327|9884132|FG001|Overall Study|Protocol Violation|10
6216134|NCT01627327|9884131|FG000|Overall Study|Lost to Follow-up|1
6216135|NCT01627327|9884132|FG001|Overall Study|Lost to Follow-up|3
6216136|NCT01627327|9884131|FG000|Overall Study|Physician Decision|1
6216137|NCT01627327|9884132|FG001|Overall Study|Physician Decision|0
6216138|NCT01627327|9884131|FG000|Overall Study|Withdrawal by Subject|3
6216139|NCT01627327|9884132|FG001|Overall Study|Withdrawal by Subject|3
6216140|NCT01627340|9884140|FG000|Overall Study|Adverse Event|1
6216141|NCT01627340|9884141|FG001|Overall Study|Adverse Event|0
6216142|NCT01627340|9884140|FG000|Overall Study|Lost to Follow-up|8
6216143|NCT01627340|9884141|FG001|Overall Study|Lost to Follow-up|4
6216144|NCT01627340|9884140|FG000|Overall Study|Pregnancy|1
6216145|NCT01627340|9884141|FG001|Overall Study|Pregnancy|0
6216146|NCT01627340|9884140|FG000|Overall Study|Withdrawal by Subject|2
6216147|NCT01627340|9884141|FG001|Overall Study|Withdrawal by Subject|0
6216148|NCT01627574|9884151|FG000|Overall Study|Withdrawal by Subject|8
6216149|NCT01627574|9884152|FG001|Overall Study|Withdrawal by Subject|5
6216150|NCT01627574|9884151|FG000|Overall Study|Lost to Follow-up|13
6216151|NCT01627574|9884152|FG001|Overall Study|Lost to Follow-up|13
6216152|NCT01627691|9884158|FG000|Overall Study|Death|11
6216153|NCT01627691|9884158|FG000|Overall Study|Lost to Follow-up|3
6216154|NCT01627691|9884158|FG000|Overall Study|Withdrawal by Subject|1
6216155|NCT01627691|9884158|FG000|Overall Study|Missed the visit|3
6216156|NCT01627782|9884166|FG000|Overall Study|Adverse Event|1
6216157|NCT01627782|9884167|FG001|Overall Study|Adverse Event|2
6216158|NCT01627782|9884168|FG002|Overall Study|Adverse Event|0
6216159|NCT01627782|9884169|FG003|Overall Study|Adverse Event|1
6216160|NCT01627782|9884166|FG000|Overall Study|Lack of Efficacy|11
6216161|NCT01627782|9884167|FG001|Overall Study|Lack of Efficacy|1
6216162|NCT01627782|9884168|FG002|Overall Study|Lack of Efficacy|15
6216163|NCT01627782|9884169|FG003|Overall Study|Lack of Efficacy|2
6216164|NCT01627782|9884166|FG000|Overall Study|Protocol Violation|1
6216165|NCT01627782|9884167|FG001|Overall Study|Protocol Violation|0
6216166|NCT01627782|9884168|FG002|Overall Study|Protocol Violation|0
6216167|NCT01627782|9884169|FG003|Overall Study|Protocol Violation|0
6216168|NCT01627782|9884166|FG000|Overall Study|Withdrawal by Subject|2
6216169|NCT01627782|9884167|FG001|Overall Study|Withdrawal by Subject|1
6216170|NCT01627782|9884168|FG002|Overall Study|Withdrawal by Subject|0
6216171|NCT01627782|9884169|FG003|Overall Study|Withdrawal by Subject|0
6216172|NCT01627782|9884166|FG000|Overall Study|Other|0
6216173|NCT01627782|9884167|FG001|Overall Study|Other|2
6216174|NCT01627782|9884168|FG002|Overall Study|Other|0
6216175|NCT01627782|9884169|FG003|Overall Study|Other|3
6288066|NCT02358668|10001187|FG001|Overall Study|Adverse Event|0
6288067|NCT02358668|10001188|FG002|Overall Study|Adverse Event|0
6288068|NCT02358668|10001186|FG000|Overall Study|Withdrawal by Subject|0
6288069|NCT02358668|10001187|FG001|Overall Study|Withdrawal by Subject|1
6288070|NCT02358668|10001188|FG002|Overall Study|Withdrawal by Subject|0
6288071|NCT02358863|10001196|FG000|Overall Study|Physician Decision|3
6288072|NCT02359045|10001234|FG000|Overall Study|Eligibility criteria not fulfilled|3
6123421|NCT00911300|9747147|FG001|Overall Study|Treatment Stopped by Mistake|1
6123422|NCT00911300|9747146|FG000|Overall Study|Randomized; No Study Medication Received|0
6123423|NCT00911300|9747147|FG001|Overall Study|Randomized; No Study Medication Received|2
6123424|NCT00911508|9747164|FG000|Overall Study|Lost to Follow-up|27
6123425|NCT00911508|9747165|FG001|Overall Study|Lost to Follow-up|18
6123426|NCT00911508|9747164|FG000|Overall Study|Withdrawal by Subject|79
6123427|NCT00911508|9747165|FG001|Overall Study|Withdrawal by Subject|112
6123428|NCT00911534|9747173|FG000|Overall Study|Adverse Event|4
6123429|NCT00911534|9747174|FG001|Overall Study|Adverse Event|4
6123430|NCT00911534|9747173|FG000|Overall Study|Lost to Follow-up|2
6123431|NCT00911534|9747174|FG001|Overall Study|Lost to Follow-up|4
6123432|NCT00911534|9747173|FG000|Overall Study|Withdrawal by Subject|2
6123433|NCT00911534|9747174|FG001|Overall Study|Withdrawal by Subject|1
6123434|NCT00911534|9747173|FG000|Overall Study|Lack of Efficacy|4
6216176|NCT01627782|9884166|FG000|Overall Study|Randomized But Not Treated|1
6288073|NCT02359045|10001235|FG001|Overall Study|Eligibility criteria not fulfilled|1
6123435|NCT00911534|9747174|FG001|Overall Study|Lack of Efficacy|1
6216177|NCT01627782|9884167|FG001|Overall Study|Randomized But Not Treated|0
6216178|NCT01627782|9884168|FG002|Overall Study|Randomized But Not Treated|0
6123436|NCT00911534|9747173|FG000|Overall Study|Withdrawal of consent|1
6123437|NCT00911534|9747174|FG001|Overall Study|Withdrawal of consent|4
6123438|NCT00911534|9747173|FG000|Overall Study|Other|2
6123439|NCT00911534|9747174|FG001|Overall Study|Other|2
6123440|NCT00911625|9747196|FG000|Overall Study|Lost to Follow-up|7
6123441|NCT00911625|9747197|FG001|Overall Study|Lost to Follow-up|0
6123442|NCT00911768|9747214|FG000|Overall Study|Protocol Violation|5
6123443|NCT00911768|9747215|FG001|Overall Study|Protocol Violation|4
6216179|NCT01627782|9884169|FG003|Overall Study|Randomized But Not Treated|0
6216180|NCT01627860|9884183|FG000|Overall Study|Adverse Event|9
6216181|NCT01627860|9884184|FG001|Overall Study|Adverse Event|4
6216182|NCT01627860|9884183|FG000|Overall Study|Withdrawal by Subject|2
6216183|NCT01627860|9884184|FG001|Overall Study|Withdrawal by Subject|1
6216184|NCT01627860|9884183|FG000|Overall Study|Seizure frequency doubled|0
6216185|NCT01627860|9884184|FG001|Overall Study|Seizure frequency doubled|1
6216186|NCT01627860|9884183|FG000|Overall Study|Protocol Violation|1
6216187|NCT01627860|9884184|FG001|Overall Study|Protocol Violation|0
6216188|NCT01628107|9884222|FG000|Overall Study|Withdrawal by Subject|17
6216189|NCT01628107|9884222|FG000|Overall Study|Lost to Follow-up|4
6216190|NCT01628107|9884222|FG000|Overall Study|Adverse Event|33
6216191|NCT01628107|9884222|FG000|Overall Study|Physician Decision|2
6216192|NCT01628107|9884222|FG000|Overall Study|Not met Inclusion/Exclusion Criteria|1
6216193|NCT01628107|9884222|FG000|Overall Study|Non-compliant with Study Procedures|10
6216194|NCT01628107|9884222|FG000|Overall Study|Not Treated|8
6216195|NCT01628107|9884222|FG000|Overall Study|Sponsor Decision|11
6216196|NCT01628107|9884222|FG000|Overall Study|Missed Study Drug More than 2 Weeks|7
6216197|NCT01628107|9884222|FG000|Overall Study|Relocated|8
6216198|NCT01628107|9884222|FG000|Overall Study|Kidney Transplant|9
6216199|NCT01628107|9884222|FG000|Overall Study|Use of Standard of Care|9
6216200|NCT01628120|9884226|FG000|Overall Study|Withdrawal by Subject|7
6216201|NCT01628120|9884226|FG000|Overall Study|Adverse Event|12
6216202|NCT01628120|9884226|FG000|Overall Study|Lost to Follow-up|1
6216203|NCT01628120|9884226|FG000|Overall Study|Not met Inclusion/Exclusion Criteria|2
6216204|NCT01628120|9884226|FG000|Overall Study|Non-compliant with Study Procedures|1
6216205|NCT01628120|9884226|FG000|Overall Study|Not Treated|3
6216206|NCT01628120|9884226|FG000|Overall Study|Sponsor Decision|5
6216207|NCT01628120|9884226|FG000|Overall Study|Switched Dialysis Method|2
6216208|NCT01628120|9884226|FG000|Overall Study|Missed Study Drug More than 2 Weeks|3
6216209|NCT01628120|9884226|FG000|Overall Study|Moved or Relocated|5
6216210|NCT01628120|9884226|FG000|Overall Study|Kidney Transplant|2
6216211|NCT01628120|9884226|FG000|Overall Study|Use of Standard of Care|1
6216212|NCT01628198|9884234|FG000|Overall Study|Lost to Follow-up|7
6216213|NCT01628198|9884234|FG000|Overall Study|Withdrawal by Subject|10
6216214|NCT01628198|9884234|FG000|Overall Study|Screen failure|1
6288074|NCT02359045|10001234|FG000|Overall Study|Lost to Follow-up|1
6288075|NCT02359045|10001235|FG001|Overall Study|Lost to Follow-up|1
6288076|NCT02359045|10001234|FG000|Overall Study|Adverse Event|0
6288077|NCT02359045|10001235|FG001|Overall Study|Adverse Event|1
6288078|NCT02359435|10001285|FG000|Overall Study|Lost to Follow-up|4
6288079|NCT02359435|10001286|FG001|Overall Study|Lost to Follow-up|4
6288080|NCT02359552|10001294|FG000|Overall Study|Lost to Follow-up|3
6288081|NCT02359552|10001295|FG001|Overall Study|Lost to Follow-up|4
6288082|NCT02359851|10001301|FG000|Overall Study|Death|1
6288083|NCT02359851|10001301|FG000|Overall Study|Disease progression|1
6288084|NCT02359877|10001309|FG000|Overall Study|Withdrawal by Subject|1
6288085|NCT02359877|10001310|FG001|Overall Study|Withdrawal by Subject|0
6288086|NCT02359877|10001311|FG002|Overall Study|Withdrawal by Subject|0
6288087|NCT02359877|10001312|FG003|Overall Study|Withdrawal by Subject|2
6288088|NCT02359877|10001309|FG000|Overall Study|Adverse Event|0
6288089|NCT02359877|10001310|FG001|Overall Study|Adverse Event|0
6288090|NCT02359877|10001311|FG002|Overall Study|Adverse Event|0
6288091|NCT02359877|10001312|FG003|Overall Study|Adverse Event|1
6288092|NCT02359890|10001340|FG000|Overall Study|Not meeting eligibility|4
6288093|NCT02359890|10001340|FG000|Overall Study|Never treated with study catheter|6
6288094|NCT02359903|10001346|FG000|Overall Study|Adverse Event|0
6288095|NCT02359903|10001347|FG001|Overall Study|Adverse Event|2
6288096|NCT02360098|10001413|FG000|Overall Study|Physician Decision|7
6288097|NCT02360228|10001446|FG000|Overall Study|Withdrawal by Subject|1
6288098|NCT02360228|10001447|FG001|Overall Study|Withdrawal by Subject|0
6288099|NCT02360228|10001448|FG002|Overall Study|Withdrawal by Subject|0
6288100|NCT02360228|10001446|FG000|Overall Study|Self-discontinued medication|0
6288101|NCT02360228|10001447|FG001|Overall Study|Self-discontinued medication|1
6288102|NCT02360228|10001448|FG002|Overall Study|Self-discontinued medication|0
6288103|NCT02360228|10001446|FG000|Overall Study|Unstable symptoms during screening|0
6288104|NCT02360228|10001447|FG001|Overall Study|Unstable symptoms during screening|0
6288105|NCT02360228|10001448|FG002|Overall Study|Unstable symptoms during screening|1
6288106|NCT02360280|10001458|FG000|Overall Study|Withdrawal by Subject|2
6288107|NCT02360280|10001459|FG001|Overall Study|Withdrawal by Subject|0
6288108|NCT02360280|10001458|FG000|Overall Study|Adverse Event|0
6288109|NCT02360280|10001459|FG001|Overall Study|Adverse Event|1
6288110|NCT02360280|10001458|FG000|Overall Study|Lost to Follow-up|1
6288111|NCT02360280|10001459|FG001|Overall Study|Lost to Follow-up|0
6288112|NCT02360293|10001467|FG000|Overall Study|Lost to Follow-up|73
6288113|NCT02360293|10001468|FG001|Overall Study|Lost to Follow-up|95
6123444|NCT00911768|9747214|FG000|Overall Study|Withdrawal by Subject|1
6123445|NCT00911768|9747215|FG001|Overall Study|Withdrawal by Subject|0
6123446|NCT00911807|9747224|FG000|Overall Study|Adverse Event|2
6123447|NCT00911807|9747225|FG001|Overall Study|Adverse Event|1
6123448|NCT00911807|9747226|FG002|Overall Study|Adverse Event|5
6123449|NCT00911807|9747224|FG000|Overall Study|Death|0
6123450|NCT00911807|9747225|FG001|Overall Study|Death|0
6123451|NCT00911807|9747226|FG002|Overall Study|Death|1
6123452|NCT00911807|9747224|FG000|Overall Study|Protocol Violation|6
6216215|NCT01628367|9884249|FG000|Overall Study|Adverse Event|1
6216216|NCT01628367|9884250|FG001|Overall Study|Adverse Event|0
6216217|NCT01628393|9884259|FG000|Placebo-controlled Treatment Period|Lost to Follow-up|1
6216218|NCT01628393|9884260|FG001|Placebo-controlled Treatment Period|Lost to Follow-up|0
6216219|NCT01628393|9884261|FG002|Placebo-controlled Treatment Period|Lost to Follow-up|0
6216220|NCT01628393|9884262|FG003|Placebo-controlled Treatment Period|Lost to Follow-up|0
6216221|NCT01628393|9884263|FG004|Placebo-controlled Treatment Period|Lost to Follow-up|0
6216222|NCT01628393|9884259|FG000|Placebo-controlled Treatment Period|Protocol Violation|0
6216223|NCT01628393|9884260|FG001|Placebo-controlled Treatment Period|Protocol Violation|1
6216224|NCT01628393|9884261|FG002|Placebo-controlled Treatment Period|Protocol Violation|0
6216225|NCT01628393|9884262|FG003|Placebo-controlled Treatment Period|Protocol Violation|0
6216226|NCT01628393|9884263|FG004|Placebo-controlled Treatment Period|Protocol Violation|0
6216227|NCT01628393|9884259|FG000|Placebo-controlled Treatment Period|Withdrawal by Subject|2
6216228|NCT01628393|9884260|FG001|Placebo-controlled Treatment Period|Withdrawal by Subject|1
6216229|NCT01628393|9884261|FG002|Placebo-controlled Treatment Period|Withdrawal by Subject|1
6216230|NCT01628393|9884262|FG003|Placebo-controlled Treatment Period|Withdrawal by Subject|0
6216231|NCT01628393|9884263|FG004|Placebo-controlled Treatment Period|Withdrawal by Subject|0
6216232|NCT01628393|9884259|FG000|Blinded Active Extension Period|Adverse Event|0
6216233|NCT01628393|9884260|FG001|Blinded Active Extension Period|Adverse Event|1
6216234|NCT01628393|9884261|FG002|Blinded Active Extension Period|Adverse Event|0
6216235|NCT01628393|9884262|FG003|Blinded Active Extension Period|Adverse Event|2
6216236|NCT01628393|9884263|FG004|Blinded Active Extension Period|Adverse Event|2
6216237|NCT01628393|9884259|FG000|Blinded Active Extension Period|Lack of Efficacy|0
6216238|NCT01628393|9884260|FG001|Blinded Active Extension Period|Lack of Efficacy|0
6216239|NCT01628393|9884261|FG002|Blinded Active Extension Period|Lack of Efficacy|2
6216240|NCT01628393|9884262|FG003|Blinded Active Extension Period|Lack of Efficacy|0
6216241|NCT01628393|9884263|FG004|Blinded Active Extension Period|Lack of Efficacy|2
6216242|NCT01628393|9884259|FG000|Blinded Active Extension Period|Physician Decision|0
6216243|NCT01628393|9884260|FG001|Blinded Active Extension Period|Physician Decision|3
6216244|NCT01628393|9884261|FG002|Blinded Active Extension Period|Physician Decision|0
6216245|NCT01628393|9884262|FG003|Blinded Active Extension Period|Physician Decision|1
6216246|NCT01628393|9884263|FG004|Blinded Active Extension Period|Physician Decision|0
6216247|NCT01628393|9884259|FG000|Blinded Active Extension Period|Protocol Violation|0
6216248|NCT01628393|9884260|FG001|Blinded Active Extension Period|Protocol Violation|0
6216249|NCT01628393|9884261|FG002|Blinded Active Extension Period|Protocol Violation|2
6216250|NCT01628393|9884262|FG003|Blinded Active Extension Period|Protocol Violation|1
6216251|NCT01628393|9884263|FG004|Blinded Active Extension Period|Protocol Violation|0
6216252|NCT01628393|9884259|FG000|Blinded Active Extension Period|Withdrawal by Subject|0
6216253|NCT01628393|9884260|FG001|Blinded Active Extension Period|Withdrawal by Subject|6
6216254|NCT01628393|9884261|FG002|Blinded Active Extension Period|Withdrawal by Subject|2
6216255|NCT01628393|9884262|FG003|Blinded Active Extension Period|Withdrawal by Subject|0
6216256|NCT01628393|9884263|FG004|Blinded Active Extension Period|Withdrawal by Subject|2
6216257|NCT01628510|9884279|FG000|Overall Study|Withdrawal by Subject|0
6216258|NCT01628510|9884280|FG001|Overall Study|Withdrawal by Subject|4
6216259|NCT01628510|9884279|FG000|Overall Study|Death|3
6216260|NCT01628510|9884280|FG001|Overall Study|Death|1
6216261|NCT01628549|9884297|FG000|Overall Study|Adverse Event|1
6216262|NCT01628549|9884298|FG001|Overall Study|Adverse Event|1
6216263|NCT01628549|9884299|FG002|Overall Study|Adverse Event|0
6216264|NCT01628549|9884300|FG003|Overall Study|Adverse Event|4
6216265|NCT01628549|9884297|FG000|Overall Study|Lost to Follow-up|3
6216266|NCT01628549|9884298|FG001|Overall Study|Lost to Follow-up|4
6216267|NCT01628549|9884299|FG002|Overall Study|Lost to Follow-up|3
6216268|NCT01628549|9884300|FG003|Overall Study|Lost to Follow-up|3
6216269|NCT01628549|9884297|FG000|Overall Study|Withdrawal by Subject|3
6216270|NCT01628549|9884298|FG001|Overall Study|Withdrawal by Subject|4
6216271|NCT01628549|9884299|FG002|Overall Study|Withdrawal by Subject|4
6216272|NCT01628549|9884300|FG003|Overall Study|Withdrawal by Subject|1
6216273|NCT01628549|9884297|FG000|Overall Study|Protocol Violation|2
6216274|NCT01628549|9884298|FG001|Overall Study|Protocol Violation|1
6216275|NCT01628549|9884299|FG002|Overall Study|Protocol Violation|1
6216276|NCT01628549|9884300|FG003|Overall Study|Protocol Violation|0
6216277|NCT01628549|9884297|FG000|Overall Study|withdrawn for noncompliance|0
6216278|NCT01628549|9884298|FG001|Overall Study|withdrawn for noncompliance|2
6216279|NCT01628549|9884299|FG002|Overall Study|withdrawn for noncompliance|1
6123453|NCT00911807|9747225|FG001|Overall Study|Protocol Violation|4
6123454|NCT00911807|9747226|FG002|Overall Study|Protocol Violation|9
6123455|NCT00911807|9747224|FG000|Overall Study|Withdrawal by Subject|8
6123456|NCT00911807|9747225|FG001|Overall Study|Withdrawal by Subject|10
6123457|NCT00911807|9747226|FG002|Overall Study|Withdrawal by Subject|7
6123458|NCT00911807|9747224|FG000|Overall Study|Organizational reasons|1
6123459|NCT00911807|9747225|FG001|Overall Study|Organizational reasons|3
6123460|NCT00911807|9747226|FG002|Overall Study|Organizational reasons|1
6123461|NCT00911820|9747236|FG000|Overall Study|RECIST progression|12
6123462|NCT00911820|9747237|FG001|Overall Study|RECIST progression|8
6216280|NCT01628549|9884300|FG003|Overall Study|withdrawn for noncompliance|0
6216281|NCT01628549|9884297|FG000|Overall Study|abnormal laboratory test results|0
6216282|NCT01628549|9884298|FG001|Overall Study|abnormal laboratory test results|0
6216283|NCT01628549|9884299|FG002|Overall Study|abnormal laboratory test results|1
6216284|NCT01628549|9884300|FG003|Overall Study|abnormal laboratory test results|0
6216285|NCT01628549|9884297|FG000|Overall Study|positive pregnancy test|0
6216286|NCT01628549|9884298|FG001|Overall Study|positive pregnancy test|0
6216287|NCT01628549|9884299|FG002|Overall Study|positive pregnancy test|0
6216288|NCT01628549|9884300|FG003|Overall Study|positive pregnancy test|1
6216289|NCT01628692|9884328|FG000|Overall Study|Lack of Efficacy|4
6216290|NCT01628692|9884329|FG001|Overall Study|Lack of Efficacy|4
6216291|NCT01628692|9884330|FG002|Overall Study|Lack of Efficacy|5
6216292|NCT01628692|9884331|FG003|Overall Study|Lack of Efficacy|1
6216293|NCT01628692|9884332|FG004|Overall Study|Lack of Efficacy|4
6216294|NCT01628692|9884333|FG005|Overall Study|Lack of Efficacy|7
6216295|NCT01628692|9884328|FG000|Overall Study|Adverse Event|2
6216296|NCT01628692|9884329|FG001|Overall Study|Adverse Event|0
6216297|NCT01628692|9884330|FG002|Overall Study|Adverse Event|2
6216298|NCT01628692|9884331|FG003|Overall Study|Adverse Event|0
6216299|NCT01628692|9884332|FG004|Overall Study|Adverse Event|0
6216300|NCT01628692|9884333|FG005|Overall Study|Adverse Event|0
6216301|NCT01628692|9884328|FG000|Overall Study|Withdrawal by Subject|0
6216302|NCT01628692|9884329|FG001|Overall Study|Withdrawal by Subject|1
6216303|NCT01628692|9884330|FG002|Overall Study|Withdrawal by Subject|1
6216304|NCT01628692|9884331|FG003|Overall Study|Withdrawal by Subject|0
6216305|NCT01628692|9884332|FG004|Overall Study|Withdrawal by Subject|0
6216306|NCT01628692|9884333|FG005|Overall Study|Withdrawal by Subject|0
6216307|NCT01628692|9884328|FG000|Overall Study|Death|0
6216308|NCT01628692|9884329|FG001|Overall Study|Death|1
6216309|NCT01628692|9884330|FG002|Overall Study|Death|0
6216310|NCT01628692|9884331|FG003|Overall Study|Death|0
6216311|NCT01628692|9884332|FG004|Overall Study|Death|0
6216312|NCT01628692|9884333|FG005|Overall Study|Death|0
6216313|NCT01628692|9884328|FG000|Overall Study|Poor compliance/noncompliance|1
6216314|NCT01628692|9884329|FG001|Overall Study|Poor compliance/noncompliance|0
6216315|NCT01628692|9884330|FG002|Overall Study|Poor compliance/noncompliance|0
6216316|NCT01628692|9884331|FG003|Overall Study|Poor compliance/noncompliance|0
6216317|NCT01628692|9884332|FG004|Overall Study|Poor compliance/noncompliance|0
6216318|NCT01628692|9884333|FG005|Overall Study|Poor compliance/noncompliance|0
6216319|NCT01628692|9884328|FG000|Overall Study|Administrative reason by sponsor|0
6216320|NCT01628692|9884329|FG001|Overall Study|Administrative reason by sponsor|0
6216321|NCT01628692|9884330|FG002|Overall Study|Administrative reason by sponsor|0
6216322|NCT01628692|9884331|FG003|Overall Study|Administrative reason by sponsor|0
6216323|NCT01628692|9884332|FG004|Overall Study|Administrative reason by sponsor|0
6216324|NCT01628692|9884333|FG005|Overall Study|Administrative reason by sponsor|1
6216325|NCT01628692|9884328|FG000|Overall Study|Completed 12 Week only|0
6216326|NCT01628692|9884329|FG001|Overall Study|Completed 12 Week only|0
6216327|NCT01628692|9884330|FG002|Overall Study|Completed 12 Week only|0
6216328|NCT01628692|9884331|FG003|Overall Study|Completed 12 Week only|0
6216329|NCT01628692|9884332|FG004|Overall Study|Completed 12 Week only|0
6216330|NCT01628692|9884333|FG005|Overall Study|Completed 12 Week only|1
6216331|NCT01628848|9884361|FG000|Overall Study|Adverse Event|9
6216332|NCT01628848|9884362|FG001|Overall Study|Adverse Event|7
6216333|NCT01628848|9884361|FG000|Overall Study|Lack of Efficacy|0
6216334|NCT01628848|9884362|FG001|Overall Study|Lack of Efficacy|4
6216335|NCT01628848|9884361|FG000|Overall Study|Withdrawal by Subject|0
6216336|NCT01628848|9884362|FG001|Overall Study|Withdrawal by Subject|2
6216337|NCT01628848|9884361|FG000|Overall Study|Physician Decision|3
6216338|NCT01628848|9884362|FG001|Overall Study|Physician Decision|1
6216339|NCT01628874|9884370|FG000|Overall Study|Physician Decision|1
6216340|NCT01628874|9884371|FG001|Overall Study|Physician Decision|1
6216341|NCT01628874|9884370|FG000|Overall Study|Age >4 months|4
6216342|NCT01628874|9884371|FG001|Overall Study|Age >4 months|2
6216343|NCT01628913|9884379|FG000|Overall Study|Adverse Event|12
6216344|NCT01628913|9884380|FG001|Overall Study|Adverse Event|5
6216345|NCT01628913|9884379|FG000|Overall Study|Disease Progression|11
6216346|NCT01628913|9884380|FG001|Overall Study|Disease Progression|14
6216347|NCT01628913|9884379|FG000|Overall Study|Protocol Violation|1
6216348|NCT01628913|9884380|FG001|Overall Study|Protocol Violation|0
6216349|NCT01628913|9884379|FG000|Overall Study|Death|1
6216350|NCT01628913|9884380|FG001|Overall Study|Death|0
6216351|NCT01628913|9884379|FG000|Overall Study|study terminated by Sponsor|4
6288114|NCT02360293|10001467|FG000|Overall Study|Withdrawal by Subject|2
6123463|NCT00911820|9747236|FG000|Overall Study|Adverse Event|8
6216352|NCT01628913|9884380|FG001|Overall Study|study terminated by Sponsor|9
6216353|NCT01628913|9884379|FG000|Overall Study|Withdrawal by Subject|1
6123464|NCT00911820|9747237|FG001|Overall Study|Adverse Event|8
6123465|NCT00911820|9747236|FG000|Overall Study|Clinical Progression|7
6123466|NCT00911820|9747237|FG001|Overall Study|Clinical Progression|5
6123467|NCT00911820|9747236|FG000|Overall Study|Physician Decision|5
6123468|NCT00911820|9747237|FG001|Overall Study|Physician Decision|9
6123469|NCT00911820|9747236|FG000|Overall Study|Decline in Performance Status|4
6123470|NCT00911820|9747237|FG001|Overall Study|Decline in Performance Status|2
6123471|NCT00911820|9747236|FG000|Overall Study|Withdrawal by Subject|3
6123472|NCT00911820|9747237|FG001|Overall Study|Withdrawal by Subject|4
6123473|NCT00911820|9747236|FG000|Overall Study|Death|1
6123474|NCT00911820|9747237|FG001|Overall Study|Death|2
6123475|NCT00911820|9747236|FG000|Overall Study|Pursue surgery|1
6123476|NCT00911820|9747237|FG001|Overall Study|Pursue surgery|1
6123477|NCT00911820|9747236|FG000|Overall Study|Pursue Radiation|1
6123478|NCT00911820|9747237|FG001|Overall Study|Pursue Radiation|0
6123479|NCT00911820|9747236|FG000|Overall Study|Still on Therapy|2
6123480|NCT00911820|9747237|FG001|Overall Study|Still on Therapy|2
6123481|NCT00911820|9747236|FG000|Overall Study|Pathology Not Confirmed|1
6123482|NCT00911820|9747237|FG001|Overall Study|Pathology Not Confirmed|0
6123483|NCT00911820|9747236|FG000|Overall Study|Withdraw before Receive Treatment|0
6123484|NCT00911820|9747237|FG001|Overall Study|Withdraw before Receive Treatment|2
6123485|NCT00911859|9747246|FG000|Treatment Period|Adverse Event|3
6123486|NCT00911859|9747247|FG001|Treatment Period|Adverse Event|3
6123487|NCT00911859|9747248|FG002|Treatment Period|Adverse Event|7
6123488|NCT00911859|9747246|FG000|Treatment Period|Death|1
6123489|NCT00911859|9747247|FG001|Treatment Period|Death|3
6123490|NCT00911859|9747248|FG002|Treatment Period|Death|5
6123491|NCT00911859|9747246|FG000|Treatment Period|Lack of Efficacy|1
6123492|NCT00911859|9747247|FG001|Treatment Period|Lack of Efficacy|7
6123493|NCT00911859|9747248|FG002|Treatment Period|Lack of Efficacy|5
6123494|NCT00911859|9747246|FG000|Treatment Period|Physician Decision|3
6123495|NCT00911859|9747247|FG001|Treatment Period|Physician Decision|3
6123496|NCT00911859|9747248|FG002|Treatment Period|Physician Decision|3
6123497|NCT00911859|9747246|FG000|Treatment Period|Withdrawal by Subject|0
6123498|NCT00911859|9747247|FG001|Treatment Period|Withdrawal by Subject|4
6123499|NCT00911859|9747248|FG002|Treatment Period|Withdrawal by Subject|5
6123500|NCT00911859|9747246|FG000|Treatment Period|Did not receive study treatment|0
6123501|NCT00911859|9747247|FG001|Treatment Period|Did not receive study treatment|1
6123502|NCT00911859|9747248|FG002|Treatment Period|Did not receive study treatment|0
6123503|NCT00911859|9747246|FG000|Maintainance Period|Lack of Efficacy|0
6123504|NCT00911859|9747247|FG001|Maintainance Period|Lack of Efficacy|0
6123505|NCT00911859|9747248|FG002|Maintainance Period|Lack of Efficacy|9
6123506|NCT00911859|9747246|FG000|Maintainance Period|Physician Decision|0
6123507|NCT00911859|9747247|FG001|Maintainance Period|Physician Decision|0
6123508|NCT00911859|9747248|FG002|Maintainance Period|Physician Decision|9
6123509|NCT00911859|9747246|FG000|Maintainance Period|Withdrawal by Subject|0
6123510|NCT00911859|9747247|FG001|Maintainance Period|Withdrawal by Subject|0
6123511|NCT00911859|9747248|FG002|Maintainance Period|Withdrawal by Subject|3
6123512|NCT00911859|9747246|FG000|Follow-up Period|Death|5
6123513|NCT00911859|9747247|FG001|Follow-up Period|Death|8
6123514|NCT00911859|9747248|FG002|Follow-up Period|Death|10
6123515|NCT00911859|9747246|FG000|Follow-up Period|Lost to Follow-up|1
6123516|NCT00911859|9747247|FG001|Follow-up Period|Lost to Follow-up|1
6123517|NCT00911859|9747248|FG002|Follow-up Period|Lost to Follow-up|0
6123518|NCT00911859|9747246|FG000|Follow-up Period|Withdrawal by Subject|0
6123519|NCT00911859|9747247|FG001|Follow-up Period|Withdrawal by Subject|4
6123520|NCT00911859|9747248|FG002|Follow-up Period|Withdrawal by Subject|4
6123521|NCT00911859|9747246|FG000|Follow-up Period|Study terminated by sponsor|5
6123522|NCT00911859|9747247|FG001|Follow-up Period|Study terminated by sponsor|33
6123523|NCT00911859|9747248|FG002|Follow-up Period|Study terminated by sponsor|27
6123524|NCT00911937|9747262|FG000|Overall Study|Death|1
6123525|NCT00911937|9747263|FG001|Overall Study|Death|0
6123526|NCT00911937|9747262|FG000|Overall Study|Lost to Follow-up|8
6123527|NCT00911937|9747263|FG001|Overall Study|Lost to Follow-up|5
6123528|NCT00911937|9747262|FG000|Overall Study|Withdrawal by Subject|10
6123529|NCT00911937|9747263|FG001|Overall Study|Withdrawal by Subject|7
6123530|NCT00911937|9747262|FG000|Overall Study|Withdrawn due to pregnancy|1
6123531|NCT00911937|9747263|FG001|Overall Study|Withdrawn due to pregnancy|0
6216354|NCT01628913|9884380|FG001|Overall Study|Withdrawal by Subject|0
6123532|NCT00911937|9747262|FG000|Overall Study|Adverse Event|11
6123533|NCT00911937|9747263|FG001|Overall Study|Adverse Event|25
6123534|NCT00911937|9747262|FG000|Overall Study|Lack of Efficacy|11
6123535|NCT00911937|9747263|FG001|Overall Study|Lack of Efficacy|6
6123536|NCT00911937|9747262|FG000|Overall Study|Did not meet inclusion criteria|9
6123537|NCT00911937|9747263|FG001|Overall Study|Did not meet inclusion criteria|11
6123538|NCT00911937|9747262|FG000|Overall Study|Protocol Violation|14
6123539|NCT00911937|9747263|FG001|Overall Study|Protocol Violation|23
6123540|NCT00911937|9747262|FG000|Overall Study|Randomized but not treated|13
6123541|NCT00911937|9747263|FG001|Overall Study|Randomized but not treated|13
6123542|NCT00911937|9747262|FG000|Overall Study|Other|9
6123543|NCT00911937|9747263|FG001|Overall Study|Other|5
6123544|NCT00911989|9747269|FG000|Overall Study|Adverse Event|1
6123545|NCT00912015|9747282|FG000|Overall Study|Lack of Efficacy|1
6123546|NCT00912015|9747283|FG001|Overall Study|Lack of Efficacy|0
6123547|NCT00912015|9747284|FG002|Overall Study|Lack of Efficacy|0
6123548|NCT00912015|9747285|FG003|Overall Study|Lack of Efficacy|0
6123549|NCT00912015|9747282|FG000|Overall Study|Withdrawal by Subject|8
6123550|NCT00912015|9747283|FG001|Overall Study|Withdrawal by Subject|8
6123551|NCT00912015|9747284|FG002|Overall Study|Withdrawal by Subject|3
6123552|NCT00912015|9747285|FG003|Overall Study|Withdrawal by Subject|0
6123553|NCT00912015|9747282|FG000|Overall Study|Protocol Violation|1
6123554|NCT00912015|9747283|FG001|Overall Study|Protocol Violation|0
6123555|NCT00912015|9747284|FG002|Overall Study|Protocol Violation|0
6216355|NCT01628913|9884379|FG000|Overall Study|Physician Decision|1
6216356|NCT01628913|9884380|FG001|Overall Study|Physician Decision|3
6216357|NCT01628926|9884389|FG000|Overall Study|Adverse Event|13
6216358|NCT01628926|9884390|FG001|Overall Study|Adverse Event|11
6216359|NCT01628926|9884391|FG002|Overall Study|Adverse Event|9
6216360|NCT01628926|9884389|FG000|Overall Study|Lack of Efficacy|2
6216361|NCT01628926|9884390|FG001|Overall Study|Lack of Efficacy|1
6216362|NCT01628926|9884391|FG002|Overall Study|Lack of Efficacy|5
6216363|NCT01628926|9884389|FG000|Overall Study|Withdrawal by Subject|6
6216364|NCT01628926|9884390|FG001|Overall Study|Withdrawal by Subject|4
6216365|NCT01628926|9884391|FG002|Overall Study|Withdrawal by Subject|2
6216366|NCT01628926|9884389|FG000|Overall Study|Protocol Violation|0
6216367|NCT01628926|9884390|FG001|Overall Study|Protocol Violation|1
6216368|NCT01628926|9884391|FG002|Overall Study|Protocol Violation|0
6216369|NCT01628926|9884389|FG000|Overall Study|Discontinuation criteria|3
6216370|NCT01628926|9884390|FG001|Overall Study|Discontinuation criteria|4
6216371|NCT01628926|9884391|FG002|Overall Study|Discontinuation criteria|0
6216372|NCT01628926|9884389|FG000|Overall Study|Physician Decision|2
6216373|NCT01628926|9884390|FG001|Overall Study|Physician Decision|2
6216374|NCT01628926|9884391|FG002|Overall Study|Physician Decision|1
6216375|NCT01628965|9884400|FG000|Overall Study|Adverse Event|30
6216376|NCT01628965|9884400|FG000|Overall Study|Lack of Efficacy|7
6216377|NCT01628965|9884400|FG000|Overall Study|Withdrawal by Subject|3
6216378|NCT01628965|9884400|FG000|Overall Study|Lost to Follow-up|1
6216379|NCT01628965|9884400|FG000|Overall Study|Discontinuation criteria|8
6216380|NCT01629381|9884420|FG000|Overall Study|Withdrawal by Subject|2
6216381|NCT01629381|9884421|FG001|Overall Study|Withdrawal by Subject|5
6216382|NCT01629563|9884433|FG000|Overall Study|Adverse Event|16
6216383|NCT01629563|9884434|FG001|Overall Study|Adverse Event|16
6216384|NCT01629563|9884433|FG000|Overall Study|Death|2
6216385|NCT01629563|9884434|FG001|Overall Study|Death|0
6216386|NCT01629563|9884433|FG000|Overall Study|Lack of Efficacy|2
6216387|NCT01629563|9884434|FG001|Overall Study|Lack of Efficacy|3
6216388|NCT01629563|9884433|FG000|Overall Study|Lost to Follow-up|1
6216389|NCT01629563|9884434|FG001|Overall Study|Lost to Follow-up|0
6216390|NCT01629563|9884433|FG000|Overall Study|Pregnancy|1
6216391|NCT01629563|9884434|FG001|Overall Study|Pregnancy|2
6216392|NCT01629563|9884433|FG000|Overall Study|Protocol Violation|0
6216393|NCT01629563|9884434|FG001|Overall Study|Protocol Violation|1
6216394|NCT01629563|9884433|FG000|Overall Study|Withdrawal by Subject|27
6216395|NCT01629563|9884434|FG001|Overall Study|Withdrawal by Subject|20
6216396|NCT01629563|9884433|FG000|Overall Study|surgery|0
6216397|NCT01629563|9884434|FG001|Overall Study|surgery|3
6216398|NCT01629563|9884433|FG000|Overall Study|Lack of return of menses|12
6216399|NCT01629563|9884434|FG001|Overall Study|Lack of return of menses|7
6216400|NCT01629563|9884433|FG000|Overall Study|Protocol Violation|0
6216401|NCT01629563|9884434|FG001|Overall Study|Protocol Violation|1
6216402|NCT01629589|9884442|FG000|Overall Study|Protocol Violation|4
6216403|NCT01629589|9884443|FG001|Overall Study|Protocol Violation|2
6216404|NCT01629589|9884442|FG000|Overall Study|Lost to Follow-up|2
6216405|NCT01629589|9884443|FG001|Overall Study|Lost to Follow-up|1
6216406|NCT01629589|9884442|FG000|Overall Study|Withdrawal by Subject|2
6216407|NCT01629589|9884443|FG001|Overall Study|Withdrawal by Subject|3
6216408|NCT01629589|9884442|FG000|Overall Study|Did not receive study vaccine|0
6216409|NCT01629589|9884443|FG001|Overall Study|Did not receive study vaccine|1
6216410|NCT01629667|9884456|FG000|Overall Study|Lost to Follow-up|0
6123556|NCT00912015|9747285|FG003|Overall Study|Protocol Violation|1
6123557|NCT00912015|9747282|FG000|Overall Study|Adverse Event|6
6123558|NCT00912015|9747283|FG001|Overall Study|Adverse Event|0
6123559|NCT00912015|9747284|FG002|Overall Study|Adverse Event|0
6123560|NCT00912015|9747285|FG003|Overall Study|Adverse Event|1
6123561|NCT00912028|9747298|FG000|Overall Study|Lost to Follow-up|2
6123562|NCT00912028|9747299|FG001|Overall Study|Lost to Follow-up|3
6216411|NCT01629667|9884457|FG001|Overall Study|Lost to Follow-up|1
6216412|NCT01629667|9884458|FG002|Overall Study|Lost to Follow-up|1
6216413|NCT01629667|9884456|FG000|Overall Study|Withdrawal by Subject|31
6216414|NCT01629667|9884457|FG001|Overall Study|Withdrawal by Subject|20
6216415|NCT01629667|9884458|FG002|Overall Study|Withdrawal by Subject|28
6216416|NCT01629667|9884456|FG000|Overall Study|Death|1
6123563|NCT00912028|9747300|FG002|Overall Study|Lost to Follow-up|0
6123564|NCT00912028|9747301|FG003|Overall Study|Lost to Follow-up|1
6216417|NCT01629667|9884457|FG001|Overall Study|Death|5
6123565|NCT00912028|9747302|FG004|Overall Study|Lost to Follow-up|3
6123566|NCT00912028|9747298|FG000|Overall Study|Withdrawal by Subject|3
6216418|NCT01629667|9884458|FG002|Overall Study|Death|3
6216419|NCT01629667|9884456|FG000|Overall Study|Randomized, not treated|2
6216420|NCT01629667|9884457|FG001|Overall Study|Randomized, not treated|1
6123567|NCT00912028|9747299|FG001|Overall Study|Withdrawal by Subject|0
6123568|NCT00912028|9747300|FG002|Overall Study|Withdrawal by Subject|0
6123569|NCT00912028|9747301|FG003|Overall Study|Withdrawal by Subject|0
6123570|NCT00912028|9747302|FG004|Overall Study|Withdrawal by Subject|0
6123571|NCT00912093|9747317|FG000|The Controlled Phase|Death|0
6123572|NCT00912093|9747318|FG001|The Controlled Phase|Death|1
6123573|NCT00912093|9747319|FG002|The Controlled Phase|Death|0
6123574|NCT00912093|9747320|FG003|The Controlled Phase|Death|0
6123575|NCT00912093|9747321|FG004|The Controlled Phase|Death|0
6123576|NCT00912093|9747317|FG000|The Controlled Phase|Medical Condition|0
6123577|NCT00912093|9747318|FG001|The Controlled Phase|Medical Condition|1
6123578|NCT00912093|9747319|FG002|The Controlled Phase|Medical Condition|0
6123579|NCT00912093|9747320|FG003|The Controlled Phase|Medical Condition|0
6123580|NCT00912093|9747321|FG004|The Controlled Phase|Medical Condition|0
6123581|NCT00912093|9747317|FG000|The Controlled Phase|Lost to Follow-up|0
6123582|NCT00912093|9747318|FG001|The Controlled Phase|Lost to Follow-up|0
6123583|NCT00912093|9747319|FG002|The Controlled Phase|Lost to Follow-up|0
6123584|NCT00912093|9747320|FG003|The Controlled Phase|Lost to Follow-up|0
6123585|NCT00912093|9747321|FG004|The Controlled Phase|Lost to Follow-up|1
6123586|NCT00912197|9747331|FG000|Overall Study|Withdrawal by Subject|3
6123587|NCT00912197|9747332|FG001|Overall Study|Withdrawal by Subject|3
6123588|NCT00912288|9747342|FG000|Overall Study|Death|0
6123589|NCT00912288|9747343|FG001|Overall Study|Death|1
6123590|NCT00912288|9747342|FG000|Overall Study|Adverse Event|1
6123591|NCT00912288|9747343|FG001|Overall Study|Adverse Event|1
6123592|NCT00912288|9747342|FG000|Overall Study|Lost to Follow-up|1
6123593|NCT00912288|9747343|FG001|Overall Study|Lost to Follow-up|0
6123594|NCT00912288|9747342|FG000|Overall Study|Protocol Violation|1
6123595|NCT00912288|9747343|FG001|Overall Study|Protocol Violation|0
6123596|NCT00912288|9747342|FG000|Overall Study|Withdrawal by Subject|3
6123597|NCT00912288|9747343|FG001|Overall Study|Withdrawal by Subject|3
6123598|NCT00912288|9747342|FG000|Overall Study|Study terminated by sponsor|34
6123599|NCT00912288|9747343|FG001|Overall Study|Study terminated by sponsor|35
6123600|NCT00912288|9747342|FG000|Overall Study|Other|1
6123601|NCT00912288|9747343|FG001|Overall Study|Other|0
6123602|NCT00912340|9747365|FG000|Overall Study|Adverse Event|2
6123603|NCT00912340|9747366|FG001|Overall Study|Adverse Event|4
6123604|NCT00912340|9747367|FG002|Overall Study|Adverse Event|0
6123605|NCT00912340|9747365|FG000|Overall Study|Protocol revised to remove arm|0
6123606|NCT00912340|9747366|FG001|Overall Study|Protocol revised to remove arm|0
6123607|NCT00912340|9747367|FG002|Overall Study|Protocol revised to remove arm|4
6123608|NCT00912405|9747375|FG000|Overall Study|Lost to Follow-up|5
6123609|NCT00912509|9747381|FG000|Overall Study|Lost to Follow-up|1
6123610|NCT00912509|9747382|FG001|Overall Study|Lost to Follow-up|0
6123611|NCT00912509|9747381|FG000|Overall Study|Lack of Efficacy|4
6216421|NCT01629667|9884458|FG002|Overall Study|Randomized, not treated|0
6216422|NCT01629667|9884456|FG000|Overall Study|Ongoing AE worsening right heart failure|0
6216423|NCT01629667|9884457|FG001|Overall Study|Ongoing AE worsening right heart failure|1
6216424|NCT01629667|9884458|FG002|Overall Study|Ongoing AE worsening right heart failure|0
6216425|NCT01629667|9884456|FG000|Overall Study|Requiring lung transplant|2
6216426|NCT01629667|9884457|FG001|Overall Study|Requiring lung transplant|1
6216427|NCT01629667|9884458|FG002|Overall Study|Requiring lung transplant|3
6216428|NCT01629667|9884456|FG000|Overall Study|Early tretmt termntd, cmpltd safety f-up|9
6216429|NCT01629667|9884457|FG001|Overall Study|Early tretmt termntd, cmpltd safety f-up|11
6216430|NCT01629667|9884458|FG002|Overall Study|Early tretmt termntd, cmpltd safety f-up|8
6216431|NCT01629667|9884456|FG000|Overall Study|Started other medicine|1
6216432|NCT01629667|9884457|FG001|Overall Study|Started other medicine|0
6216433|NCT01629667|9884458|FG002|Overall Study|Started other medicine|1
6216434|NCT01629667|9884456|FG000|Overall Study|Site error in safety follow-up|0
6216435|NCT01629667|9884457|FG001|Overall Study|Site error in safety follow-up|0
6216436|NCT01629667|9884458|FG002|Overall Study|Site error in safety follow-up|1
6216437|NCT01629667|9884456|FG000|Overall Study|Enrolled in another clinical study|0
6216438|NCT01629667|9884457|FG001|Overall Study|Enrolled in another clinical study|1
6216439|NCT01629667|9884458|FG002|Overall Study|Enrolled in another clinical study|0
6216440|NCT01629667|9884456|FG000|Overall Study|Code break|1
6216441|NCT01629667|9884457|FG001|Overall Study|Code break|0
6216442|NCT01629667|9884458|FG002|Overall Study|Code break|0
6216443|NCT01629693|9884470|FG000|Overall Study|Lost to Follow-up|2
6216444|NCT01629693|9884471|FG001|Overall Study|Lost to Follow-up|4
6216445|NCT01629693|9884470|FG000|Overall Study|Withdrawal by Subject|2
6216446|NCT01629693|9884471|FG001|Overall Study|Withdrawal by Subject|2
6216447|NCT01629693|9884470|FG000|Overall Study|Adverse Event|1
6123612|NCT00912509|9747382|FG001|Overall Study|Lack of Efficacy|3
6123613|NCT00912743|9747391|FG000|Overall Study|Adverse Event|3
6123614|NCT00912743|9747392|FG001|Overall Study|Adverse Event|1
6123615|NCT00912743|9747391|FG000|Overall Study|Lack of Efficacy|9
6123616|NCT00912743|9747392|FG001|Overall Study|Lack of Efficacy|18
6123617|NCT00912743|9747391|FG000|Overall Study|Toxicity|0
6123618|NCT00912743|9747392|FG001|Overall Study|Toxicity|1
6123619|NCT00912743|9747391|FG000|Overall Study|End of treatment form was not collected|1
6123620|NCT00912743|9747392|FG001|Overall Study|End of treatment form was not collected|0
6123621|NCT00912782|9747400|FG000|Overall Study|Death|2
6123622|NCT00912782|9747401|FG001|Overall Study|Death|1
6123623|NCT00912782|9747400|FG000|Overall Study|Lost to Follow-up|0
6123624|NCT00912782|9747401|FG001|Overall Study|Lost to Follow-up|1
6123625|NCT00912782|9747400|FG000|Overall Study|Did not receive vascular access type|1
6123626|NCT00912782|9747401|FG001|Overall Study|Did not receive vascular access type|2
6123627|NCT00912782|9747400|FG000|Overall Study|Relocated before study completion|0
6123628|NCT00912782|9747401|FG001|Overall Study|Relocated before study completion|1
6123629|NCT00912808|9747418|FG000|First Intervention (6 Weeks)|Adverse Event|2
6123630|NCT00912808|9747419|FG001|First Intervention (6 Weeks)|Adverse Event|1
6123631|NCT00912808|9747418|FG000|Washout|Withdrawal by Subject|0
6123632|NCT00912808|9747419|FG001|Washout|Withdrawal by Subject|1
6123633|NCT00912808|9747418|FG000|Second Intervention (6 Weeks)|Adverse Event|0
6123634|NCT00912808|9747419|FG001|Second Intervention (6 Weeks)|Adverse Event|1
6123635|NCT00912808|9747418|FG000|Second Intervention (6 Weeks)|Withdrawal by Subject|1
6123636|NCT00912808|9747419|FG001|Second Intervention (6 Weeks)|Withdrawal by Subject|0
6123637|NCT00912912|9747439|FG000|Overall Study|Withdrawal by Subject|1
6123638|NCT00912912|9747439|FG000|Overall Study|Disease Progression|3
6123639|NCT00912964|9747455|FG000|Overall Study|Eligibility criterion not met|1
6123640|NCT00912964|9747456|FG001|Overall Study|Eligibility criterion not met|1
6123641|NCT00912964|9747457|FG002|Overall Study|Eligibility criterion not met|0
6123642|NCT00912964|9747455|FG000|Overall Study|Adverse Event|15
6123643|NCT00912964|9747456|FG001|Overall Study|Adverse Event|18
6123644|NCT00912964|9747457|FG002|Overall Study|Adverse Event|12
6123645|NCT00912964|9747455|FG000|Overall Study|Lack of Efficacy|11
6123646|NCT00912964|9747456|FG001|Overall Study|Lack of Efficacy|4
6123647|NCT00912964|9747457|FG002|Overall Study|Lack of Efficacy|3
6123648|NCT00912964|9747455|FG000|Overall Study|Withdrawal by Subject|20
6123649|NCT00912964|9747456|FG001|Overall Study|Withdrawal by Subject|12
6123650|NCT00912964|9747457|FG002|Overall Study|Withdrawal by Subject|18
6123651|NCT00912964|9747455|FG000|Overall Study|Lost to Follow-up|4
6123652|NCT00912964|9747456|FG001|Overall Study|Lost to Follow-up|3
6123653|NCT00912964|9747457|FG002|Overall Study|Lost to Follow-up|3
6123654|NCT00912964|9747455|FG000|Overall Study|Protocol Violation|5
6123655|NCT00912964|9747456|FG001|Overall Study|Protocol Violation|3
6123656|NCT00912964|9747457|FG002|Overall Study|Protocol Violation|8
6123657|NCT00912964|9747455|FG000|Overall Study|Taking exclusionary medications|7
6123658|NCT00912964|9747456|FG001|Overall Study|Taking exclusionary medications|4
6123659|NCT00912964|9747457|FG002|Overall Study|Taking exclusionary medications|8
6123660|NCT00912964|9747455|FG000|Overall Study|Medical History|1
6216448|NCT01629693|9884471|FG001|Overall Study|Adverse Event|0
6216449|NCT01629693|9884470|FG000|Overall Study|Investigator decision|0
6216450|NCT01629693|9884471|FG001|Overall Study|Investigator decision|1
6216451|NCT01629693|9884470|FG000|Overall Study|Poor comfort of study lenses|0
6216452|NCT01629693|9884471|FG001|Overall Study|Poor comfort of study lenses|2
6216453|NCT01629693|9884470|FG000|Overall Study|Subject decision unrelated to AE|0
6216454|NCT01629693|9884471|FG001|Overall Study|Subject decision unrelated to AE|1
6216455|NCT01629706|9884477|FG000|Phase 1 PureVision|Screen Failure|4
6288115|NCT02360293|10001468|FG001|Overall Study|Withdrawal by Subject|1
6288116|NCT02360293|10001467|FG000|Overall Study|Excluded|1
6288117|NCT02360293|10001468|FG001|Overall Study|Excluded|0
6288118|NCT02360397|10001496|FG000|Overall Study|Incomplete screening|3
6288119|NCT02360397|10001496|FG000|Overall Study|Adverse Event|1
6288120|NCT02360475|10001505|FG000|Overall Study|Lost to Follow-up|4
6288121|NCT02360475|10001506|FG001|Overall Study|Lost to Follow-up|12
6288122|NCT02360475|10001507|FG002|Overall Study|Lost to Follow-up|6
6288123|NCT02360475|10001508|FG003|Overall Study|Lost to Follow-up|4
6288124|NCT02360475|10001505|FG000|Overall Study|Withdrawal by Subject|0
6288125|NCT02360475|10001506|FG001|Overall Study|Withdrawal by Subject|1
6288126|NCT02360475|10001507|FG002|Overall Study|Withdrawal by Subject|2
6288127|NCT02360475|10001508|FG003|Overall Study|Withdrawal by Subject|0
6288128|NCT02360475|10001505|FG000|Overall Study|Migrated/moved from study area|0
6288129|NCT02360475|10001506|FG001|Overall Study|Migrated/moved from study area|0
6288130|NCT02360475|10001507|FG002|Overall Study|Migrated/moved from study area|0
6288131|NCT02360475|10001508|FG003|Overall Study|Migrated/moved from study area|1
6288132|NCT02360605|10001529|FG000|Overall Study|Withdrawal by Subject|4
6288133|NCT02360605|10001530|FG001|Overall Study|Withdrawal by Subject|9
6123661|NCT00912964|9747456|FG001|Overall Study|Medical History|0
6123662|NCT00912964|9747457|FG002|Overall Study|Medical History|0
6123663|NCT00912964|9747455|FG000|Overall Study|Non-compliance with study procedures|2
6123664|NCT00912964|9747456|FG001|Overall Study|Non-compliance with study procedures|0
6123665|NCT00912964|9747457|FG002|Overall Study|Non-compliance with study procedures|0
6288134|NCT02360605|10001529|FG000|Overall Study|Lost to Follow-up|7
6123666|NCT00912964|9747455|FG000|Overall Study|Violation of exclusion criterion|0
6123667|NCT00912964|9747456|FG001|Overall Study|Violation of exclusion criterion|0
6123668|NCT00912964|9747457|FG002|Overall Study|Violation of exclusion criterion|2
6123669|NCT00912964|9747455|FG000|Overall Study|Randomized but never received study drug|0
6123670|NCT00912964|9747456|FG001|Overall Study|Randomized but never received study drug|1
6123671|NCT00912964|9747457|FG002|Overall Study|Randomized but never received study drug|0
6123672|NCT00913380|9747516|FG000|Clinical Outcomes|Lost to Follow-up|6
6216456|NCT01629706|9884477|FG000|Phase 1 PureVision|Slit Lamp Finding prior to Dispense|1
6288135|NCT02360605|10001530|FG001|Overall Study|Lost to Follow-up|8
6123673|NCT00913380|9747517|FG001|Clinical Outcomes|Lost to Follow-up|6
6123674|NCT00913458|9747523|FG000|Phase 1|Non-Responder|54
6123675|NCT00913458|9747524|FG001|Phase 1|Non-Responder|0
6123676|NCT00913458|9747525|FG002|Phase 1|Non-Responder|0
6123677|NCT00913458|9747526|FG003|Phase 1|Non-Responder|0
6123678|NCT00913458|9747527|FG004|Phase 1|Non-Responder|0
6123679|NCT00913458|9747528|FG005|Phase 1|Non-Responder|0
6123680|NCT00913458|9747529|FG006|Phase 1|Non-Responder|0
6123681|NCT00913458|9747523|FG000|Phase 1|Subject Request|17
6123682|NCT00913458|9747524|FG001|Phase 1|Subject Request|0
6123683|NCT00913458|9747525|FG002|Phase 1|Subject Request|0
6123684|NCT00913458|9747526|FG003|Phase 1|Subject Request|0
6123685|NCT00913458|9747527|FG004|Phase 1|Subject Request|0
6123686|NCT00913458|9747528|FG005|Phase 1|Subject Request|0
6123687|NCT00913458|9747529|FG006|Phase 1|Subject Request|0
6123688|NCT00913458|9747523|FG000|Phase 1|Adverse Event|20
6123689|NCT00913458|9747524|FG001|Phase 1|Adverse Event|0
6123690|NCT00913458|9747525|FG002|Phase 1|Adverse Event|0
6123691|NCT00913458|9747526|FG003|Phase 1|Adverse Event|0
6123692|NCT00913458|9747527|FG004|Phase 1|Adverse Event|0
6123693|NCT00913458|9747528|FG005|Phase 1|Adverse Event|0
6123694|NCT00913458|9747529|FG006|Phase 1|Adverse Event|0
6123695|NCT00913458|9747523|FG000|Phase 1|Lost to Follow-up|2
6123696|NCT00913458|9747524|FG001|Phase 1|Lost to Follow-up|0
6123697|NCT00913458|9747525|FG002|Phase 1|Lost to Follow-up|0
6123698|NCT00913458|9747526|FG003|Phase 1|Lost to Follow-up|0
6123699|NCT00913458|9747527|FG004|Phase 1|Lost to Follow-up|0
6123700|NCT00913458|9747528|FG005|Phase 1|Lost to Follow-up|0
6123701|NCT00913458|9747529|FG006|Phase 1|Lost to Follow-up|0
6123702|NCT00913458|9747523|FG000|Phase 1|Protocol Violation|10
6123703|NCT00913458|9747524|FG001|Phase 1|Protocol Violation|0
6123704|NCT00913458|9747525|FG002|Phase 1|Protocol Violation|0
6123705|NCT00913458|9747526|FG003|Phase 1|Protocol Violation|0
6123706|NCT00913458|9747527|FG004|Phase 1|Protocol Violation|0
6123707|NCT00913458|9747528|FG005|Phase 1|Protocol Violation|0
6216457|NCT01629706|9884477|FG000|Phase 1 PureVision|Inconvenience prior to Dispense|1
6216458|NCT01629706|9884477|FG000|Phase 1 PureVision|No Solution-Induced Corneal Staining|3
6216459|NCT01629706|9884477|FG000|Phase 2 Habitual|Screen Failure|6
6216460|NCT01629706|9884477|FG000|Phase 2 Habitual|Slit Lamp Finding prior to Dispense|1
6216461|NCT01629706|9884477|FG000|Phase 2 Habitual|Relocation prior to Dispense|1
6216462|NCT01629706|9884477|FG000|Phase 2 Habitual|Lost to Follow Up prior to Dispense|1
6216463|NCT01629706|9884477|FG000|Phase 2 Habitual|Lost to Follow Up after Dispense|1
6216464|NCT01629823|9884511|FG000|Trial Period|Missed visit|11
6216465|NCT01629823|9884512|FG001|Trial Period|Missed visit|9
6216466|NCT01629823|9884513|FG002|Trial Period|Missed visit|8
6216467|NCT01629823|9884511|FG000|Trial Period|Pre-diluent FEV₁ predicted <70%|1
6216468|NCT01629823|9884512|FG001|Trial Period|Pre-diluent FEV₁ predicted <70%|1
6216469|NCT01629823|9884513|FG002|Trial Period|Pre-diluent FEV₁ predicted <70%|1
6216470|NCT01629823|9884511|FG000|Trial Period|Pregnancy|1
6216471|NCT01629823|9884512|FG001|Trial Period|Pregnancy|0
6216472|NCT01629823|9884513|FG002|Trial Period|Pregnancy|0
6216473|NCT01629823|9884511|FG000|Trial Period|Adverse Event|0
6216474|NCT01629823|9884512|FG001|Trial Period|Adverse Event|1
6216475|NCT01629823|9884513|FG002|Trial Period|Adverse Event|0
6216476|NCT01629823|9884511|FG000|Trial Period|Out-of-window visit|0
6216477|NCT01629823|9884512|FG001|Trial Period|Out-of-window visit|2
6216478|NCT01629823|9884513|FG002|Trial Period|Out-of-window visit|0
6216479|NCT01629823|9884511|FG000|Trial Period|Failed to hold medication|0
6216480|NCT01629823|9884512|FG001|Trial Period|Failed to hold medication|0
6216481|NCT01629823|9884513|FG002|Trial Period|Failed to hold medication|1
6216482|NCT01629823|9884511|FG000|Washout Period|Safety|2
6216483|NCT01629823|9884512|FG001|Washout Period|Safety|5
6288136|NCT02360605|10001529|FG000|Overall Study|Death|0
6288137|NCT02360605|10001530|FG001|Overall Study|Death|1
6288138|NCT02360995|10001561|FG000|Overall Study|Lost to Follow-up|2
6288139|NCT02360995|10001562|FG001|Overall Study|Lost to Follow-up|0
6288140|NCT02360995|10001563|FG002|Overall Study|Lost to Follow-up|2
6288141|NCT02360995|10001561|FG000|Overall Study|Withdrawal by Subject|0
6288142|NCT02360995|10001562|FG001|Overall Study|Withdrawal by Subject|1
6288143|NCT02360995|10001563|FG002|Overall Study|Withdrawal by Subject|0
6288144|NCT02361216|10001573|FG000|3 Day Treatment and 8 Week Follow/up|Lack of Efficacy|0
6288145|NCT02361216|10001574|FG001|3 Day Treatment and 8 Week Follow/up|Lack of Efficacy|1
6288146|NCT02361216|10001573|FG000|3 Day Treatment and 8 Week Follow/up|Adverse Event|1
6288147|NCT02361216|10001574|FG001|3 Day Treatment and 8 Week Follow/up|Adverse Event|2
6123708|NCT00913458|9747529|FG006|Phase 1|Protocol Violation|0
6123709|NCT00913458|9747523|FG000|Phase 1|Sponsor|2
6123710|NCT00913458|9747524|FG001|Phase 1|Sponsor|0
6123711|NCT00913458|9747525|FG002|Phase 1|Sponsor|0
6123712|NCT00913458|9747526|FG003|Phase 1|Sponsor|0
6123713|NCT00913458|9747527|FG004|Phase 1|Sponsor|0
6123714|NCT00913458|9747528|FG005|Phase 1|Sponsor|0
6123715|NCT00913458|9747529|FG006|Phase 1|Sponsor|0
6123716|NCT00913458|9747523|FG000|Phase 1|Unsatisfactory Response per Investigator|7
6123717|NCT00913458|9747524|FG001|Phase 1|Unsatisfactory Response per Investigator|0
6123718|NCT00913458|9747525|FG002|Phase 1|Unsatisfactory Response per Investigator|0
6123719|NCT00913458|9747526|FG003|Phase 1|Unsatisfactory Response per Investigator|0
6216484|NCT01629823|9884513|FG002|Washout Period|Safety|0
6216485|NCT01629823|9884511|FG000|Washout Period|Pregnancy|1
6123720|NCT00913458|9747527|FG004|Phase 1|Unsatisfactory Response per Investigator|0
6123721|NCT00913458|9747528|FG005|Phase 1|Unsatisfactory Response per Investigator|0
6123722|NCT00913458|9747529|FG006|Phase 1|Unsatisfactory Response per Investigator|0
6123723|NCT00913458|9747523|FG000|Phase 2|Non-Responder|0
6123724|NCT00913458|9747524|FG001|Phase 2|Non-Responder|5
6123725|NCT00913458|9747525|FG002|Phase 2|Non-Responder|7
6123726|NCT00913458|9747526|FG003|Phase 2|Non-Responder|12
6123727|NCT00913458|9747527|FG004|Phase 2|Non-Responder|0
6123728|NCT00913458|9747528|FG005|Phase 2|Non-Responder|0
6123729|NCT00913458|9747529|FG006|Phase 2|Non-Responder|0
6123730|NCT00913458|9747523|FG000|Phase 2|Subject Request|0
6123731|NCT00913458|9747524|FG001|Phase 2|Subject Request|0
6123732|NCT00913458|9747525|FG002|Phase 2|Subject Request|1
6123733|NCT00913458|9747526|FG003|Phase 2|Subject Request|2
6123734|NCT00913458|9747527|FG004|Phase 2|Subject Request|0
6123735|NCT00913458|9747528|FG005|Phase 2|Subject Request|0
6123736|NCT00913458|9747529|FG006|Phase 2|Subject Request|0
6123737|NCT00913458|9747523|FG000|Phase 2|Adverse Event|0
6123738|NCT00913458|9747524|FG001|Phase 2|Adverse Event|3
6123739|NCT00913458|9747525|FG002|Phase 2|Adverse Event|0
6123740|NCT00913458|9747526|FG003|Phase 2|Adverse Event|1
6123741|NCT00913458|9747527|FG004|Phase 2|Adverse Event|0
6123742|NCT00913458|9747528|FG005|Phase 2|Adverse Event|0
6123743|NCT00913458|9747529|FG006|Phase 2|Adverse Event|0
6123744|NCT00913458|9747523|FG000|Phase 2|Lost to Follow-up|0
6123745|NCT00913458|9747524|FG001|Phase 2|Lost to Follow-up|0
6123746|NCT00913458|9747525|FG002|Phase 2|Lost to Follow-up|0
6123747|NCT00913458|9747526|FG003|Phase 2|Lost to Follow-up|1
6123748|NCT00913458|9747527|FG004|Phase 2|Lost to Follow-up|0
6123749|NCT00913458|9747528|FG005|Phase 2|Lost to Follow-up|0
6123750|NCT00913458|9747529|FG006|Phase 2|Lost to Follow-up|0
6123751|NCT00913458|9747523|FG000|Phase 2|Protocol Violation|0
6123752|NCT00913458|9747524|FG001|Phase 2|Protocol Violation|2
6216486|NCT01629823|9884512|FG001|Washout Period|Pregnancy|0
6216487|NCT01629823|9884513|FG002|Washout Period|Pregnancy|0
6216488|NCT01629823|9884511|FG000|Washout Period|Protocol Violation|0
6216489|NCT01629823|9884512|FG001|Washout Period|Protocol Violation|1
6216490|NCT01629823|9884513|FG002|Washout Period|Protocol Violation|0
6216491|NCT01629953|9884532|FG000|Overall Study|Death|3
6216492|NCT01629953|9884533|FG001|Overall Study|Death|1
6216493|NCT01629953|9884532|FG000|Overall Study|Lost to Follow-up|10
6216494|NCT01629953|9884533|FG001|Overall Study|Lost to Follow-up|14
6216495|NCT01629966|9884542|FG000|Overall Study|Pregnancy|0
6216496|NCT01629966|9884543|FG001|Overall Study|Pregnancy|1
6216497|NCT01629966|9884544|FG002|Overall Study|Pregnancy|0
6216498|NCT01629966|9884542|FG000|Overall Study|Lost to Follow-up|10
6216499|NCT01629966|9884543|FG001|Overall Study|Lost to Follow-up|13
6216500|NCT01629966|9884544|FG002|Overall Study|Lost to Follow-up|9
6216501|NCT01629966|9884542|FG000|Overall Study|Withdrawal by Subject|8
6216502|NCT01629966|9884543|FG001|Overall Study|Withdrawal by Subject|9
6216503|NCT01629966|9884544|FG002|Overall Study|Withdrawal by Subject|16
6216504|NCT01629966|9884542|FG000|Overall Study|Protocol Violation|7
6216505|NCT01629966|9884543|FG001|Overall Study|Protocol Violation|9
6216506|NCT01629966|9884544|FG002|Overall Study|Protocol Violation|7
6216507|NCT01629966|9884542|FG000|Overall Study|Lack of Efficacy|5
6216508|NCT01629966|9884543|FG001|Overall Study|Lack of Efficacy|2
6216509|NCT01629966|9884544|FG002|Overall Study|Lack of Efficacy|4
6216510|NCT01629966|9884542|FG000|Overall Study|Adverse Event|11
6216511|NCT01629966|9884543|FG001|Overall Study|Adverse Event|18
6216512|NCT01629966|9884544|FG002|Overall Study|Adverse Event|30
6216513|NCT01630135|9884573|FG000|Overall Study|Protocol-defined Stopping Criteria Met|0
6216514|NCT01630135|9884574|FG001|Overall Study|Protocol-defined Stopping Criteria Met|2
6216515|NCT01630616|9884595|FG000|Overall Study|Adverse Event|0
6216516|NCT01630616|9884596|FG001|Overall Study|Adverse Event|0
6216517|NCT01630616|9884597|FG002|Overall Study|Adverse Event|0
6216518|NCT01630616|9884598|FG003|Overall Study|Adverse Event|1
6216519|NCT01630616|9884599|FG004|Overall Study|Adverse Event|0
6216520|NCT01630616|9884600|FG005|Overall Study|Adverse Event|0
6216521|NCT01630616|9884595|FG000|Overall Study|Withdrawal by Subject|0
6216522|NCT01630616|9884596|FG001|Overall Study|Withdrawal by Subject|0
6216523|NCT01630616|9884597|FG002|Overall Study|Withdrawal by Subject|0
6216524|NCT01630616|9884598|FG003|Overall Study|Withdrawal by Subject|2
6216525|NCT01630616|9884599|FG004|Overall Study|Withdrawal by Subject|0
6216526|NCT01630616|9884600|FG005|Overall Study|Withdrawal by Subject|0
6216527|NCT01630811|9884626|FG000|Second Intervention (8 Weeks)|Withdrawal by Subject|1
6216528|NCT01630811|9884627|FG001|Second Intervention (8 Weeks)|Withdrawal by Subject|0
6216529|NCT01630889|9884635|FG000|Overall Study|Death|2
6216530|NCT01630889|9884635|FG000|Overall Study|Withdrawal by Subject|1
6216531|NCT01630889|9884635|FG000|Overall Study|Other than Specified|2
6123753|NCT00913458|9747525|FG002|Phase 2|Protocol Violation|0
6123754|NCT00913458|9747526|FG003|Phase 2|Protocol Violation|0
6123755|NCT00913458|9747527|FG004|Phase 2|Protocol Violation|0
6123756|NCT00913458|9747528|FG005|Phase 2|Protocol Violation|0
6123757|NCT00913458|9747529|FG006|Phase 2|Protocol Violation|0
6123758|NCT00913458|9747523|FG000|Phase 2|Unsatisfactory Response per Investigator|0
6123759|NCT00913458|9747524|FG001|Phase 2|Unsatisfactory Response per Investigator|0
6216532|NCT01630889|9884635|FG000|Overall Study|Lost to Follow-up|4
6216533|NCT01630889|9884635|FG000|Overall Study|Other|1
6216534|NCT01631188|9884666|FG000|Overall Study|Physician Decision|75
6123760|NCT00913458|9747525|FG002|Phase 2|Unsatisfactory Response per Investigator|11
6123761|NCT00913458|9747526|FG003|Phase 2|Unsatisfactory Response per Investigator|17
6123762|NCT00913458|9747527|FG004|Phase 2|Unsatisfactory Response per Investigator|0
6123763|NCT00913458|9747528|FG005|Phase 2|Unsatisfactory Response per Investigator|0
6123764|NCT00913458|9747529|FG006|Phase 2|Unsatisfactory Response per Investigator|0
6123765|NCT00913458|9747523|FG000|Phase 3|Adverse Event|0
6123766|NCT00913458|9747524|FG001|Phase 3|Adverse Event|0
6123767|NCT00913458|9747525|FG002|Phase 3|Adverse Event|0
6123768|NCT00913458|9747526|FG003|Phase 3|Adverse Event|0
6123769|NCT00913458|9747527|FG004|Phase 3|Adverse Event|5
6123770|NCT00913458|9747528|FG005|Phase 3|Adverse Event|4
6123771|NCT00913458|9747529|FG006|Phase 3|Adverse Event|1
6123772|NCT00913458|9747523|FG000|Phase 3|Lost to Follow-up|0
6216535|NCT01631214|9884672|FG000|Overall Study|Withdrawal by Subject|276
6216536|NCT01631214|9884673|FG001|Overall Study|Withdrawal by Subject|290
6216537|NCT01631214|9884672|FG000|Overall Study|Death|113
6216538|NCT01631214|9884673|FG001|Overall Study|Death|106
6216539|NCT01631214|9884672|FG000|Overall Study|Lost to Follow-up|54
6216540|NCT01631214|9884673|FG001|Overall Study|Lost to Follow-up|40
6216541|NCT01631214|9884672|FG000|Overall Study|Adverse Event|45
6216542|NCT01631214|9884673|FG001|Overall Study|Adverse Event|45
6216543|NCT01631214|9884672|FG000|Overall Study|Other|22
6216544|NCT01631214|9884673|FG001|Overall Study|Other|19
6216545|NCT01631214|9884672|FG000|Overall Study|Noncompliance|16
6216546|NCT01631214|9884673|FG001|Overall Study|Noncompliance|15
6216547|NCT01631214|9884672|FG000|Overall Study|Requirement for Alternative Therapy|8
6216548|NCT01631214|9884673|FG001|Overall Study|Requirement for Alternative Therapy|3
6216549|NCT01631214|9884672|FG000|Overall Study|Protocol Deviation|4
6216550|NCT01631214|9884673|FG001|Overall Study|Protocol Deviation|3
6216551|NCT01631214|9884672|FG000|Overall Study|Ineligibility determined|5
6216552|NCT01631214|9884673|FG001|Overall Study|Ineligibility determined|2
6216553|NCT01631214|9884672|FG000|Overall Study|Administrative Decision|1
6216554|NCT01631214|9884673|FG001|Overall Study|Administrative Decision|0
6216555|NCT01631227|9884683|FG000|Overall Study|withdrawn consent|27
6216556|NCT01631227|9884684|FG001|Overall Study|withdrawn consent|21
6216557|NCT01631227|9884683|FG000|Overall Study|Adverse Event|1
6123773|NCT00913458|9747524|FG001|Phase 3|Lost to Follow-up|0
6123774|NCT00913458|9747525|FG002|Phase 3|Lost to Follow-up|0
6123775|NCT00913458|9747526|FG003|Phase 3|Lost to Follow-up|0
6123776|NCT00913458|9747527|FG004|Phase 3|Lost to Follow-up|2
6123777|NCT00913458|9747528|FG005|Phase 3|Lost to Follow-up|0
6123778|NCT00913458|9747529|FG006|Phase 3|Lost to Follow-up|0
6123779|NCT00913458|9747523|FG000|Phase 3|Non-Responder|0
6123780|NCT00913458|9747524|FG001|Phase 3|Non-Responder|0
6123781|NCT00913458|9747525|FG002|Phase 3|Non-Responder|0
6123782|NCT00913458|9747526|FG003|Phase 3|Non-Responder|0
6123783|NCT00913458|9747527|FG004|Phase 3|Non-Responder|0
6123784|NCT00913458|9747528|FG005|Phase 3|Non-Responder|1
6123785|NCT00913458|9747529|FG006|Phase 3|Non-Responder|3
6123786|NCT00913458|9747523|FG000|Phase 3|Withdrawal by Subject|0
6123787|NCT00913458|9747524|FG001|Phase 3|Withdrawal by Subject|0
6123788|NCT00913458|9747525|FG002|Phase 3|Withdrawal by Subject|0
6123789|NCT00913458|9747526|FG003|Phase 3|Withdrawal by Subject|0
6123790|NCT00913458|9747527|FG004|Phase 3|Withdrawal by Subject|1
6123791|NCT00913458|9747528|FG005|Phase 3|Withdrawal by Subject|2
6123792|NCT00913458|9747529|FG006|Phase 3|Withdrawal by Subject|0
6123793|NCT00913458|9747523|FG000|Phase 3|Unsatisfactory Response per Investigator|0
6123794|NCT00913458|9747524|FG001|Phase 3|Unsatisfactory Response per Investigator|0
6123795|NCT00913458|9747525|FG002|Phase 3|Unsatisfactory Response per Investigator|0
6123796|NCT00913458|9747526|FG003|Phase 3|Unsatisfactory Response per Investigator|0
6123797|NCT00913458|9747527|FG004|Phase 3|Unsatisfactory Response per Investigator|14
6123798|NCT00913458|9747528|FG005|Phase 3|Unsatisfactory Response per Investigator|11
6123799|NCT00913458|9747529|FG006|Phase 3|Unsatisfactory Response per Investigator|4
6123800|NCT00913523|9747558|FG000|Overall Study|Withdrawal by Subject|3
6123801|NCT00913523|9747559|FG001|Overall Study|Withdrawal by Subject|2
6123802|NCT00913523|9747560|FG002|Overall Study|Withdrawal by Subject|2
6123803|NCT00913523|9747558|FG000|Overall Study|Lost to Follow-up|1
6123804|NCT00913523|9747559|FG001|Overall Study|Lost to Follow-up|1
6123805|NCT00913523|9747560|FG002|Overall Study|Lost to Follow-up|1
6123806|NCT00913523|9747558|FG000|Overall Study|Adverse Event|1
6123807|NCT00913523|9747559|FG001|Overall Study|Adverse Event|0
6123808|NCT00913523|9747560|FG002|Overall Study|Adverse Event|0
6123809|NCT00913523|9747558|FG000|Overall Study|Protocol Violation|5
6123810|NCT00913523|9747559|FG001|Overall Study|Protocol Violation|8
6123811|NCT00913523|9747560|FG002|Overall Study|Protocol Violation|8
6123812|NCT00913523|9747558|FG000|Overall Study|Pregnancy|1
6123813|NCT00913523|9747559|FG001|Overall Study|Pregnancy|3
6123814|NCT00913523|9747560|FG002|Overall Study|Pregnancy|0
6123815|NCT00913523|9747558|FG000|Overall Study|Inadequate Number of Tampons Used|7
6216558|NCT01631227|9884684|FG001|Overall Study|Adverse Event|0
6123816|NCT00913523|9747559|FG001|Overall Study|Inadequate Number of Tampons Used|2
6123817|NCT00913523|9747560|FG002|Overall Study|Inadequate Number of Tampons Used|3
6123818|NCT00913744|9747587|FG000|Overall Study|Adverse Event|2
6123819|NCT00913744|9747588|FG001|Overall Study|Adverse Event|0
6123820|NCT00913744|9747587|FG000|Overall Study|Withdrawal by Subject|2
6216559|NCT01631227|9884683|FG000|Overall Study|administrative|2
6216560|NCT01631227|9884684|FG001|Overall Study|administrative|1
6123821|NCT00913744|9747588|FG001|Overall Study|Withdrawal by Subject|1
6123822|NCT00913744|9747587|FG000|Overall Study|Death|1
6123823|NCT00913744|9747588|FG001|Overall Study|Death|0
6123824|NCT00913770|9747597|FG000|Overall Study|Unable to contact|24
6123825|NCT00913770|9747598|FG001|Overall Study|Unable to contact|19
6123826|NCT00913770|9747599|FG002|Overall Study|Unable to contact|13
6123827|NCT00913770|9747597|FG000|Overall Study|Refused|11
6123828|NCT00913770|9747598|FG001|Overall Study|Refused|10
6123829|NCT00913770|9747599|FG002|Overall Study|Refused|8
6123830|NCT00913835|9747609|FG000|Olara+Lip Dox and Lip Dox Monotherapy|Withdrawal by Subject|2
6123831|NCT00913835|9747610|FG001|Olara+Lip Dox and Lip Dox Monotherapy|Withdrawal by Subject|3
6123832|NCT00913835|9747609|FG000|Olara+Lip Dox and Lip Dox Monotherapy|Lost to Follow-up|1
6123833|NCT00913835|9747610|FG001|Olara+Lip Dox and Lip Dox Monotherapy|Lost to Follow-up|0
6123834|NCT00913835|9747609|FG000|Olara+Lip Dox and Lip Dox Monotherapy|Other|4
6123835|NCT00913835|9747610|FG001|Olara+Lip Dox and Lip Dox Monotherapy|Other|3
6123836|NCT00913835|9747609|FG000|Olara+Lip Dox and Lip Dox Monotherapy|Off Study Treatment/Alive|1
6123837|NCT00913835|9747610|FG001|Olara+Lip Dox and Lip Dox Monotherapy|Off Study Treatment/Alive|1
6123838|NCT00913835|9747609|FG000|Lip Dox: Olaratumab Monotherapy|Other|0
6123839|NCT00913835|9747610|FG001|Lip Dox: Olaratumab Monotherapy|Other|3
6123840|NCT00913978|9747629|FG000|Overall Study|Surgeon choice|1
6123841|NCT00913978|9747630|FG001|Overall Study|Surgeon choice|3
6123842|NCT00914316|9747667|FG000|Phase 1|Physician Decision|4
6123843|NCT00914316|9747668|FG001|Phase 1|Physician Decision|0
6123844|NCT00914316|9747669|FG002|Phase 1|Physician Decision|1
6123845|NCT00914316|9747670|FG003|Phase 1|Physician Decision|2
6123846|NCT00914316|9747667|FG000|Phase 1|Withdrawal by Subject|0
6123847|NCT00914316|9747668|FG001|Phase 1|Withdrawal by Subject|2
6123848|NCT00914316|9747669|FG002|Phase 1|Withdrawal by Subject|4
6123849|NCT00914316|9747670|FG003|Phase 1|Withdrawal by Subject|0
6123850|NCT00914316|9747667|FG000|Phase 1|Adverse Event|1
6123851|NCT00914316|9747668|FG001|Phase 1|Adverse Event|0
6123852|NCT00914316|9747669|FG002|Phase 1|Adverse Event|0
6123853|NCT00914316|9747670|FG003|Phase 1|Adverse Event|0
6123854|NCT00914316|9747667|FG000|Phase 2|Withdrawal by Subject|1
6123855|NCT00914316|9747668|FG001|Phase 2|Withdrawal by Subject|0
6123856|NCT00914316|9747669|FG002|Phase 2|Withdrawal by Subject|1
6123857|NCT00914316|9747670|FG003|Phase 2|Withdrawal by Subject|0
6123858|NCT00914459|9747682|FG000|Overall Study|Protocol Violation|0
6123859|NCT00914459|9747683|FG001|Overall Study|Protocol Violation|1
6216561|NCT01631435|9884695|FG000|Overall Study|Adverse Event|2
6216562|NCT01631435|9884695|FG000|Overall Study|Withdrawal by Subject|2
6216563|NCT01631435|9884695|FG000|Overall Study|incomplete study procedure|5
6216564|NCT01631474|9884705|FG000|Overall Study|Lost to Follow-up|8
6216565|NCT01631474|9884706|FG001|Overall Study|Lost to Follow-up|5
6216566|NCT01631474|9884707|FG002|Overall Study|Lost to Follow-up|7
6216567|NCT01631474|9884708|FG003|Overall Study|Lost to Follow-up|5
6216568|NCT01631474|9884709|FG004|Overall Study|Lost to Follow-up|5
6288148|NCT02361216|10001573|FG000|3 Day Treatment and 8 Week Follow/up|Unacceptable Local Skin Reaction (LSR)|1
6288149|NCT02361216|10001574|FG001|3 Day Treatment and 8 Week Follow/up|Unacceptable Local Skin Reaction (LSR)|0
6288150|NCT02361216|10001573|FG000|3 Day Treatment and 8 Week Follow/up|Withdrawal by Subject|6
6288151|NCT02361216|10001574|FG001|3 Day Treatment and 8 Week Follow/up|Withdrawal by Subject|11
6288152|NCT02361216|10001573|FG000|3 Day Treatment and 8 Week Follow/up|Trial site closed|3
6288153|NCT02361216|10001574|FG001|3 Day Treatment and 8 Week Follow/up|Trial site closed|3
6288154|NCT02361216|10001573|FG000|3 Day Treatment and 8 Week Follow/up|Lost to Follow-up|0
6288155|NCT02361216|10001574|FG001|3 Day Treatment and 8 Week Follow/up|Lost to Follow-up|2
6288156|NCT02361307|10001585|FG000|Overall Study|Unstable medical condition.|0
6288157|NCT02361307|10001586|FG001|Overall Study|Unstable medical condition.|1
6288158|NCT02361762|10001612|FG000|Overall Study|Withdrawal by Subject|0
6288159|NCT02361762|10001613|FG001|Overall Study|Withdrawal by Subject|1
6288160|NCT02361762|10001612|FG000|Overall Study|Lost to Follow-up|0
6288161|NCT02361762|10001613|FG001|Overall Study|Lost to Follow-up|1
6288162|NCT02362269|10001634|FG000|Overall Study|Moved|1
6288163|NCT02362269|10001635|FG001|Overall Study|Moved|0
6288164|NCT02362269|10001634|FG000|Overall Study|Lost to Follow-up|0
6288165|NCT02362269|10001635|FG001|Overall Study|Lost to Follow-up|6
6288166|NCT02362282|10001643|FG000|Overall Study|Withdrawal by Subject|1
6288167|NCT02362282|10001644|FG001|Overall Study|Withdrawal by Subject|0
6288168|NCT02362360|10001659|FG000|Period 1|Lack of Efficacy|1
6288169|NCT02362360|10001660|FG001|Period 1|Lack of Efficacy|0
6288170|NCT02362360|10001659|FG000|Period 1|Withdrawal by Subject|2
6288171|NCT02362360|10001660|FG001|Period 1|Withdrawal by Subject|1
6288172|NCT02362412|10001670|FG000|Treatment Period III|Lost to Follow-up|0
6288173|NCT02362412|10001671|FG001|Treatment Period III|Lost to Follow-up|1
6288174|NCT02362425|10001687|FG000|Phase 1 (up to 6 Months)|Withdrawal by Subject|2
6288175|NCT02362425|10001688|FG001|Phase 1 (up to 6 Months)|Withdrawal by Subject|0
6288176|NCT02362425|10001689|FG002|Phase 1 (up to 6 Months)|Withdrawal by Subject|0
6288177|NCT02362425|10001690|FG003|Phase 1 (up to 6 Months)|Withdrawal by Subject|0
6123860|NCT00914459|9747682|FG000|Overall Study|Parent/Legal guardian request|1
6288178|NCT02362425|10001687|FG000|Phase 1 (up to 6 Months)|Medicinal contraindication|1
6123861|NCT00914459|9747683|FG001|Overall Study|Parent/Legal guardian request|0
6216569|NCT01631474|9884705|FG000|Overall Study|Withdrawal by Subject|4
6216570|NCT01631474|9884706|FG001|Overall Study|Withdrawal by Subject|4
6123862|NCT00914589|9747698|FG000|Overall Study|Adverse Event|1
6123863|NCT00914589|9747699|FG001|Overall Study|Adverse Event|0
6123864|NCT00914589|9747700|FG002|Overall Study|Adverse Event|1
6123865|NCT00914589|9747698|FG000|Overall Study|Protocol Violation|8
6123866|NCT00914589|9747699|FG001|Overall Study|Protocol Violation|6
6123867|NCT00914589|9747700|FG002|Overall Study|Protocol Violation|3
6123868|NCT00914589|9747698|FG000|Overall Study|unclassified|16
6123869|NCT00914589|9747699|FG001|Overall Study|unclassified|9
6123870|NCT00914589|9747700|FG002|Overall Study|unclassified|7
6123871|NCT00914589|9747698|FG000|Overall Study|Death|0
6123872|NCT00914589|9747699|FG001|Overall Study|Death|1
6123873|NCT00914589|9747700|FG002|Overall Study|Death|1
6123874|NCT00914628|9747710|FG000|Overall Study|Death|35
6123875|NCT00914628|9747711|FG001|Overall Study|Death|17
6123876|NCT00914628|9747710|FG000|Overall Study|Medical decision|4
6123877|NCT00914628|9747711|FG001|Overall Study|Medical decision|0
6123878|NCT00914628|9747710|FG000|Overall Study|Protocol Violation|1
6123879|NCT00914628|9747711|FG001|Overall Study|Protocol Violation|0
6123880|NCT00914628|9747710|FG000|Overall Study|Lack of Efficacy|1
6123881|NCT00914628|9747711|FG001|Overall Study|Lack of Efficacy|0
6123882|NCT00914628|9747710|FG000|Overall Study|non-randomized|1
6123883|NCT00914628|9747711|FG001|Overall Study|non-randomized|0
6123884|NCT00914628|9747710|FG000|Overall Study|Relapse|1
6123885|NCT00914628|9747711|FG001|Overall Study|Relapse|2
6123886|NCT00914628|9747710|FG000|Overall Study|Study terminated by Sponsor|14
6123887|NCT00914628|9747711|FG001|Overall Study|Study terminated by Sponsor|8
6123888|NCT00914628|9747710|FG000|Overall Study|Patients who did not receive a single dose|7
6123889|NCT00914628|9747711|FG001|Overall Study|Patients who did not receive a single dose|1
6123890|NCT00914732|9747724|FG000|Overall Study|Lost to Follow-up|6
6123891|NCT00914732|9747725|FG001|Overall Study|Lost to Follow-up|7
6216571|NCT01631474|9884707|FG002|Overall Study|Withdrawal by Subject|2
6216572|NCT01631474|9884708|FG003|Overall Study|Withdrawal by Subject|6
6216573|NCT01631474|9884709|FG004|Overall Study|Withdrawal by Subject|5
6216574|NCT01631474|9884705|FG000|Overall Study|Lack of Efficacy|2
6216575|NCT01631474|9884706|FG001|Overall Study|Lack of Efficacy|2
6216576|NCT01631474|9884707|FG002|Overall Study|Lack of Efficacy|0
6216577|NCT01631474|9884708|FG003|Overall Study|Lack of Efficacy|0
6216578|NCT01631474|9884709|FG004|Overall Study|Lack of Efficacy|2
6216579|NCT01631474|9884705|FG000|Overall Study|Noncompliance with Study Drug|0
6216580|NCT01631474|9884706|FG001|Overall Study|Noncompliance with Study Drug|0
6216581|NCT01631474|9884707|FG002|Overall Study|Noncompliance with Study Drug|0
6216582|NCT01631474|9884708|FG003|Overall Study|Noncompliance with Study Drug|0
6216583|NCT01631474|9884709|FG004|Overall Study|Noncompliance with Study Drug|1
6216584|NCT01631474|9884705|FG000|Overall Study|Adverse Event|0
6216585|NCT01631474|9884706|FG001|Overall Study|Adverse Event|1
6216586|NCT01631474|9884707|FG002|Overall Study|Adverse Event|0
6216587|NCT01631474|9884708|FG003|Overall Study|Adverse Event|0
6216588|NCT01631474|9884709|FG004|Overall Study|Adverse Event|0
6216589|NCT01631747|9884777|FG000|Randomization Through End of Pregnancy|Lost to Follow-up|1
6216590|NCT01631747|9884778|FG001|Randomization Through End of Pregnancy|Lost to Follow-up|0
6123892|NCT00914732|9747726|FG002|Overall Study|Lost to Follow-up|9
6123893|NCT00914732|9747724|FG000|Overall Study|Withdrawal by Subject|3
6123894|NCT00914732|9747725|FG001|Overall Study|Withdrawal by Subject|0
6123895|NCT00914732|9747726|FG002|Overall Study|Withdrawal by Subject|2
6123896|NCT00914732|9747724|FG000|Overall Study|Adverse Event|1
6123897|NCT00914732|9747725|FG001|Overall Study|Adverse Event|0
6123898|NCT00914732|9747726|FG002|Overall Study|Adverse Event|0
6123899|NCT00914810|9747737|FG000|Overall Study|Withdrawal by Subject|1
6123900|NCT00914810|9747738|FG001|Overall Study|Withdrawal by Subject|0
6123901|NCT00914810|9747737|FG000|Overall Study|Relocated out of state|1
6123902|NCT00914810|9747738|FG001|Overall Study|Relocated out of state|0
6123903|NCT00914810|9747737|FG000|Overall Study|Hospitalized and unable to follow up.|0
6123904|NCT00914810|9747738|FG001|Overall Study|Hospitalized and unable to follow up.|1
6123905|NCT00914849|9747746|FG000|Overall Study|Withdrawal by Subject|1
6123906|NCT00914849|9747747|FG001|Overall Study|Withdrawal by Subject|0
6123907|NCT00914849|9747746|FG000|Overall Study|Not eligible|0
6123908|NCT00914849|9747747|FG001|Overall Study|Not eligible|1
6123909|NCT00914927|9747781|FG000|Overall Study|Adverse Event|0
6123910|NCT00914927|9747782|FG001|Overall Study|Adverse Event|0
6123911|NCT00914927|9747783|FG002|Overall Study|Adverse Event|0
6123912|NCT00914927|9747784|FG003|Overall Study|Adverse Event|0
6216591|NCT01631747|9884777|FG000|Live Birth|Pregnancy Termination|1
6216592|NCT01631747|9884778|FG001|Live Birth|Pregnancy Termination|0
6216593|NCT01631747|9884777|FG000|Live Birth|MIscarriage|2
6216594|NCT01631747|9884778|FG001|Live Birth|MIscarriage|0
6216595|NCT01631747|9884777|FG000|Live Birth|Stillbirth|1
6123913|NCT00914927|9747785|FG004|Overall Study|Adverse Event|1
6216596|NCT01631747|9884778|FG001|Live Birth|Stillbirth|1
6216597|NCT01631747|9884777|FG000|One Year Infant Outcomes|Patient Refused|13
6123914|NCT00914927|9747786|FG005|Overall Study|Adverse Event|0
6123915|NCT00914927|9747787|FG006|Overall Study|Adverse Event|0
6123916|NCT00914927|9747781|FG000|Overall Study|Withdrawal by Subject|0
6123917|NCT00914927|9747782|FG001|Overall Study|Withdrawal by Subject|1
6123918|NCT00914927|9747783|FG002|Overall Study|Withdrawal by Subject|0
6123919|NCT00914927|9747784|FG003|Overall Study|Withdrawal by Subject|1
6123920|NCT00914927|9747785|FG004|Overall Study|Withdrawal by Subject|0
6123921|NCT00914927|9747786|FG005|Overall Study|Withdrawal by Subject|0
6123922|NCT00914927|9747787|FG006|Overall Study|Withdrawal by Subject|0
6123923|NCT00914927|9747781|FG000|Overall Study|Lost to Follow-up|0
6123924|NCT00914927|9747782|FG001|Overall Study|Lost to Follow-up|0
6123925|NCT00914927|9747783|FG002|Overall Study|Lost to Follow-up|0
6123926|NCT00914927|9747784|FG003|Overall Study|Lost to Follow-up|1
6123927|NCT00914927|9747785|FG004|Overall Study|Lost to Follow-up|0
6123928|NCT00914927|9747786|FG005|Overall Study|Lost to Follow-up|0
6123929|NCT00914927|9747787|FG006|Overall Study|Lost to Follow-up|0
6123930|NCT00914927|9747781|FG000|Overall Study|Administrative/Other|2
6123931|NCT00914927|9747782|FG001|Overall Study|Administrative/Other|1
6123932|NCT00914927|9747783|FG002|Overall Study|Administrative/Other|0
6123933|NCT00914927|9747784|FG003|Overall Study|Administrative/Other|0
6123934|NCT00914927|9747785|FG004|Overall Study|Administrative/Other|1
6123935|NCT00914927|9747786|FG005|Overall Study|Administrative/Other|0
6123936|NCT00914927|9747787|FG006|Overall Study|Administrative/Other|0
6123937|NCT00914940|9747812|FG000|D0 to D100 Post-transplant|Death|2
6123938|NCT00914940|9747812|FG000|D101 to 2 Years Post-transplant|Death|8
6123939|NCT00914940|9747812|FG000|2 Years to 5 Years Post-transplant|Death|3
6216598|NCT01631747|9884778|FG001|One Year Infant Outcomes|Patient Refused|9
6216599|NCT01631812|9884785|FG000|Overall Study|Adverse Event|25
6216600|NCT01631812|9884785|FG000|Overall Study|Lack of Efficacy|5
6216601|NCT01631812|9884785|FG000|Overall Study|Withdrawal by Subject|4
6216602|NCT01631812|9884785|FG000|Overall Study|Physician Decision|3
6216603|NCT01631825|9884789|FG000|Overall Study|Adverse Event|42
6216604|NCT01631825|9884789|FG000|Overall Study|Lack of Efficacy|7
6216605|NCT01631825|9884789|FG000|Overall Study|Withdrawal by Subject|9
6216606|NCT01631825|9884789|FG000|Overall Study|Protocol Violation|4
6216607|NCT01631825|9884789|FG000|Overall Study|Discontinuation criteria|1
6216608|NCT01631825|9884789|FG000|Overall Study|Physician Decision|2
6216609|NCT01631864|9884795|FG000|Overall Study|Withdrawal by Subject|0
6216610|NCT01631864|9884796|FG001|Overall Study|Withdrawal by Subject|1
6216611|NCT01631864|9884795|FG000|Overall Study|Adverse Event|2
6216612|NCT01631864|9884796|FG001|Overall Study|Adverse Event|3
6216613|NCT01632150|9884811|FG000|Overall Study|Disease progression|27
6216614|NCT01632150|9884811|FG000|Overall Study|Study drug toxicity|1
6216615|NCT01632150|9884811|FG000|Overall Study|Unrelated adverse event|7
6216616|NCT01632150|9884811|FG000|Overall Study|Withdrawal by Subject|2
6216617|NCT01632150|9884811|FG000|Overall Study|Patient underwent autologous transplant|1
6216618|NCT01632150|9884811|FG000|Overall Study|Moved to compassionate program|2
6216619|NCT01632241|9884838|FG000|Double-blinded (Up to Week 52)|Site Closed|3
6216620|NCT01632241|9884839|FG001|Double-blinded (Up to Week 52)|Site Closed|5
6216621|NCT01632241|9884838|FG000|Double-blinded (Up to Week 52)|Protocol Violation|2
6216622|NCT01632241|9884839|FG001|Double-blinded (Up to Week 52)|Protocol Violation|6
6216623|NCT01632241|9884838|FG000|Double-blinded (Up to Week 52)|Lost to Follow-up|1
6216624|NCT01632241|9884839|FG001|Double-blinded (Up to Week 52)|Lost to Follow-up|8
6216625|NCT01632241|9884838|FG000|Double-blinded (Up to Week 52)|Physician Decision|9
6216626|NCT01632241|9884839|FG001|Double-blinded (Up to Week 52)|Physician Decision|12
6216627|NCT01632241|9884838|FG000|Double-blinded (Up to Week 52)|Lack of Efficacy|9
6216628|NCT01632241|9884839|FG001|Double-blinded (Up to Week 52)|Lack of Efficacy|15
6216629|NCT01632241|9884838|FG000|Double-blinded (Up to Week 52)|Withdrawal by Subject|10
6216630|NCT01632241|9884839|FG001|Double-blinded (Up to Week 52)|Withdrawal by Subject|14
6216631|NCT01632241|9884838|FG000|Double-blinded (Up to Week 52)|Adverse Event|10
6216632|NCT01632241|9884839|FG001|Double-blinded (Up to Week 52)|Adverse Event|19
6216633|NCT01632241|9884838|FG000|Open-label (Week 52 to Week 76)|Withdrawal by Subject|5
6216634|NCT01632241|9884839|FG001|Open-label (Week 52 to Week 76)|Withdrawal by Subject|2
6216635|NCT01632241|9884838|FG000|Open-label (Week 52 to Week 76)|Physician Decision|1
6216636|NCT01632241|9884839|FG001|Open-label (Week 52 to Week 76)|Physician Decision|4
6216637|NCT01632241|9884838|FG000|Open-label (Week 52 to Week 76)|Lost to Follow-up|1
6216638|NCT01632241|9884839|FG001|Open-label (Week 52 to Week 76)|Lost to Follow-up|4
6216639|NCT01632241|9884838|FG000|Open-label (Week 52 to Week 76)|Site Closed|2
6216640|NCT01632241|9884839|FG001|Open-label (Week 52 to Week 76)|Site Closed|8
6216641|NCT01632241|9884838|FG000|Open-label (Week 52 to Week 76)|Protocol Violation|0
6216642|NCT01632241|9884839|FG001|Open-label (Week 52 to Week 76)|Protocol Violation|2
6216643|NCT01632241|9884838|FG000|Open-label (Week 52 to Week 76)|Lack of Efficacy|0
6216644|NCT01632241|9884839|FG001|Open-label (Week 52 to Week 76)|Lack of Efficacy|2
6216645|NCT01632241|9884838|FG000|Open-label (Week 52 to Week 76)|Adverse Event|1
6216646|NCT01632241|9884839|FG001|Open-label (Week 52 to Week 76)|Adverse Event|0
6216647|NCT01632280|9884857|FG000|Overall Study|Withdrawal by Subject|1
6216648|NCT01632280|9884858|FG001|Overall Study|Withdrawal by Subject|0
6216649|NCT01632306|9884866|FG000|Overall Study|Protocol Violation|1
6216650|NCT01632306|9884867|FG001|Overall Study|Protocol Violation|0
6216651|NCT01632306|9884868|FG002|Overall Study|Protocol Violation|0
6216652|NCT01632345|9884879|FG000|Treatment: Part I|Adverse Event|1
6216653|NCT01632345|9884880|FG001|Treatment: Part I|Adverse Event|4
6216654|NCT01632345|9884881|FG002|Treatment: Part I|Adverse Event|2
6123940|NCT00914966|9747816|FG000|Step 1: 1500 Units|Withdrawal by Subject|1
6123941|NCT00914966|9747816|FG000|Step 1: 1500 Units|Physician Decision|1
6123942|NCT00914966|9747816|FG000|Step 2: 2000 Units|Withdrawal by Subject|1
6123943|NCT00915005|9747827|FG000|Overall Study|Withdrawal by Subject|4
6123944|NCT00915005|9747828|FG001|Overall Study|Withdrawal by Subject|4
6123945|NCT00915005|9747827|FG000|Overall Study|Patient preferred protons therapy|6
6123946|NCT00915005|9747828|FG001|Overall Study|Patient preferred protons therapy|0
6123947|NCT00915005|9747827|FG000|Overall Study|Insurance denial|3
6123948|NCT00915005|9747828|FG001|Overall Study|Insurance denial|15
6123949|NCT00915018|9747836|FG000|Overall Study|Death|75
6123950|NCT00915018|9747837|FG001|Overall Study|Death|70
6123951|NCT00915018|9747836|FG000|Overall Study|Lost to Follow-up|10
6123952|NCT00915018|9747837|FG001|Overall Study|Lost to Follow-up|5
6123953|NCT00915018|9747836|FG000|Overall Study|Withdrawal by Subject|38
6123954|NCT00915018|9747837|FG001|Overall Study|Withdrawal by Subject|27
6123955|NCT00915018|9747836|FG000|Overall Study|By Sponsor due to Protocol Amendment|92
6123956|NCT00915018|9747837|FG001|Overall Study|By Sponsor due to Protocol Amendment|105
6123957|NCT00915278|9747862|FG000|Overall Study|Death|1
6123958|NCT00915278|9747863|FG001|Overall Study|Death|0
6123959|NCT00915278|9747864|FG002|Overall Study|Death|0
6123960|NCT00915278|9747865|FG003|Overall Study|Death|0
6123961|NCT00915278|9747866|FG004|Overall Study|Death|0
6123962|NCT00915278|9747867|FG005|Overall Study|Death|0
6123963|NCT00915278|9747862|FG000|Overall Study|Lost to Follow-up|0
6123964|NCT00915278|9747863|FG001|Overall Study|Lost to Follow-up|1
6123965|NCT00915278|9747864|FG002|Overall Study|Lost to Follow-up|0
6123966|NCT00915278|9747865|FG003|Overall Study|Lost to Follow-up|0
6123967|NCT00915278|9747866|FG004|Overall Study|Lost to Follow-up|0
6123968|NCT00915278|9747867|FG005|Overall Study|Lost to Follow-up|0
6123969|NCT00915278|9747862|FG000|Overall Study|Withdrawal by Subject|0
6123970|NCT00915278|9747863|FG001|Overall Study|Withdrawal by Subject|1
6123971|NCT00915278|9747864|FG002|Overall Study|Withdrawal by Subject|0
6123972|NCT00915278|9747865|FG003|Overall Study|Withdrawal by Subject|0
6123973|NCT00915278|9747866|FG004|Overall Study|Withdrawal by Subject|1
6123974|NCT00915278|9747867|FG005|Overall Study|Withdrawal by Subject|4
6123975|NCT00915278|9747862|FG000|Overall Study|Adverse Event|4
6123976|NCT00915278|9747863|FG001|Overall Study|Adverse Event|1
6216655|NCT01632345|9884882|FG003|Treatment: Part I|Adverse Event|1
6216656|NCT01632345|9884883|FG004|Treatment: Part I|Adverse Event|3
6216657|NCT01632345|9884884|FG005|Treatment: Part I|Adverse Event|0
6216658|NCT01632345|9884885|FG006|Treatment: Part I|Adverse Event|0
6216659|NCT01632345|9884879|FG000|Treatment: Part I|Lack of Efficacy|0
6216660|NCT01632345|9884880|FG001|Treatment: Part I|Lack of Efficacy|1
6216661|NCT01632345|9884881|FG002|Treatment: Part I|Lack of Efficacy|0
6216662|NCT01632345|9884882|FG003|Treatment: Part I|Lack of Efficacy|1
6216663|NCT01632345|9884883|FG004|Treatment: Part I|Lack of Efficacy|1
6216664|NCT01632345|9884884|FG005|Treatment: Part I|Lack of Efficacy|0
6216665|NCT01632345|9884885|FG006|Treatment: Part I|Lack of Efficacy|0
6216666|NCT01632345|9884879|FG000|Treatment: Part I|Lost to Follow-up|3
6216667|NCT01632345|9884880|FG001|Treatment: Part I|Lost to Follow-up|2
6123977|NCT00915278|9747864|FG002|Overall Study|Adverse Event|0
6123978|NCT00915278|9747865|FG003|Overall Study|Adverse Event|0
6123979|NCT00915278|9747866|FG004|Overall Study|Adverse Event|0
6123980|NCT00915278|9747867|FG005|Overall Study|Adverse Event|0
6123981|NCT00915278|9747862|FG000|Overall Study|Progressive disease/clinical progression|0
6123982|NCT00915278|9747863|FG001|Overall Study|Progressive disease/clinical progression|0
6123983|NCT00915278|9747864|FG002|Overall Study|Progressive disease/clinical progression|0
6123984|NCT00915278|9747865|FG003|Overall Study|Progressive disease/clinical progression|3
6123985|NCT00915278|9747866|FG004|Overall Study|Progressive disease/clinical progression|1
6123986|NCT00915278|9747867|FG005|Overall Study|Progressive disease/clinical progression|2
6123987|NCT00915278|9747862|FG000|Overall Study|Infusion related AEs|0
6123988|NCT00915278|9747863|FG001|Overall Study|Infusion related AEs|0
6123989|NCT00915278|9747864|FG002|Overall Study|Infusion related AEs|0
6123990|NCT00915278|9747865|FG003|Overall Study|Infusion related AEs|0
6123991|NCT00915278|9747866|FG004|Overall Study|Infusion related AEs|0
6123992|NCT00915278|9747867|FG005|Overall Study|Infusion related AEs|2
6123993|NCT00915278|9747862|FG000|Overall Study|Admission to hospice|0
6123994|NCT00915278|9747863|FG001|Overall Study|Admission to hospice|0
6123995|NCT00915278|9747864|FG002|Overall Study|Admission to hospice|1
6123996|NCT00915278|9747865|FG003|Overall Study|Admission to hospice|0
6123997|NCT00915278|9747866|FG004|Overall Study|Admission to hospice|0
6123998|NCT00915278|9747867|FG005|Overall Study|Admission to hospice|0
6123999|NCT00915343|9747881|FG000|Part B - Open Label Period|Treatment switch|0
6124000|NCT00915343|9747882|FG001|Part B - Open Label Period|Treatment switch|0
6124001|NCT00915343|9747883|FG002|Part B - Open Label Period|Treatment switch|1
6124002|NCT00915343|9747881|FG000|Part B - Open Label Period|Did not attend the last visit|0
6124003|NCT00915343|9747882|FG001|Part B - Open Label Period|Did not attend the last visit|0
6124004|NCT00915343|9747883|FG002|Part B - Open Label Period|Did not attend the last visit|1
6124005|NCT00915356|9747900|FG000|Overall Study|Withdrawal by Subject|1
6124006|NCT00915356|9747901|FG001|Overall Study|Withdrawal by Subject|0
6216668|NCT01632345|9884881|FG002|Treatment: Part I|Lost to Follow-up|1
6216669|NCT01632345|9884882|FG003|Treatment: Part I|Lost to Follow-up|3
6216670|NCT01632345|9884883|FG004|Treatment: Part I|Lost to Follow-up|4
6124007|NCT00915356|9747902|FG002|Overall Study|Withdrawal by Subject|0
6124008|NCT00915356|9747903|FG003|Overall Study|Withdrawal by Subject|0
6124009|NCT00915356|9747904|FG004|Overall Study|Withdrawal by Subject|0
6124010|NCT00915473|9747918|FG000|Screening|Withdrawal by Subject|1
6124011|NCT00915473|9747919|FG001|Screening|Withdrawal by Subject|0
6124012|NCT00915473|9747918|FG000|4-week Follow Up|Lost to Follow-up|1
6124013|NCT00915473|9747919|FG001|4-week Follow Up|Lost to Follow-up|5
6124014|NCT00915525|9747936|FG000|Overall Study|Protocol Violation|9
6124015|NCT00915525|9747937|FG001|Overall Study|Protocol Violation|4
6124016|NCT00915525|9747936|FG000|Overall Study|Withdrawal by Subject|59
6124017|NCT00915525|9747937|FG001|Overall Study|Withdrawal by Subject|21
6124018|NCT00915525|9747936|FG000|Overall Study|Lost to Follow-up|27
6124019|NCT00915525|9747937|FG001|Overall Study|Lost to Follow-up|16
6124020|NCT00915525|9747936|FG000|Overall Study|Pregnancy|2
6124021|NCT00915525|9747937|FG001|Overall Study|Pregnancy|0
6124022|NCT00915525|9747936|FG000|Overall Study|Lack of Efficacy|15
6124023|NCT00915525|9747937|FG001|Overall Study|Lack of Efficacy|32
6124024|NCT00915525|9747936|FG000|Overall Study|Adverse Event|29
6124025|NCT00915525|9747937|FG001|Overall Study|Adverse Event|13
6124026|NCT00915525|9747936|FG000|Overall Study|Missing|12
6124027|NCT00915525|9747937|FG001|Overall Study|Missing|1
6124028|NCT00915525|9747936|FG000|Overall Study|Other Reason|35
6124029|NCT00915525|9747937|FG001|Overall Study|Other Reason|12
6124030|NCT00915525|9747936|FG000|Overall Study|Site Closed|27
6124031|NCT00915525|9747937|FG001|Overall Study|Site Closed|9
6124032|NCT00915525|9747936|FG000|Overall Study|Retreat Request >Wk 144 (exclusionary)|4
6124033|NCT00915525|9747937|FG001|Overall Study|Retreat Request >Wk 144 (exclusionary)|5
6124034|NCT00915525|9747936|FG000|Overall Study|Study Burden|28
6124035|NCT00915525|9747937|FG001|Overall Study|Study Burden|12
6124036|NCT00915525|9747936|FG000|Overall Study|Non-Compliance|3
6124037|NCT00915525|9747937|FG001|Overall Study|Non-Compliance|1
6124038|NCT00915525|9747936|FG000|Overall Study|Patient Moved|15
6124039|NCT00915525|9747937|FG001|Overall Study|Patient Moved|9
6124040|NCT00915551|9747976|FG000|Overall Study|Withdrawal by Subject|0
6124041|NCT00915551|9747977|FG001|Overall Study|Withdrawal by Subject|1
6124042|NCT00915772|9748023|FG000|Overall Study|Adverse Event|12
6124043|NCT00915772|9748024|FG001|Overall Study|Adverse Event|13
6124044|NCT00915772|9748025|FG002|Overall Study|Adverse Event|11
6124045|NCT00915772|9748023|FG000|Overall Study|Protocol Violation|4
6124046|NCT00915772|9748024|FG001|Overall Study|Protocol Violation|1
6124047|NCT00915772|9748025|FG002|Overall Study|Protocol Violation|2
6124048|NCT00915772|9748023|FG000|Overall Study|Lost to Follow-up|1
6124049|NCT00915772|9748024|FG001|Overall Study|Lost to Follow-up|2
6124050|NCT00915772|9748025|FG002|Overall Study|Lost to Follow-up|2
6124051|NCT00915772|9748023|FG000|Overall Study|Lack of Efficacy|9
6124052|NCT00915772|9748024|FG001|Overall Study|Lack of Efficacy|15
6124053|NCT00915772|9748025|FG002|Overall Study|Lack of Efficacy|3
6124054|NCT00915772|9748023|FG000|Overall Study|Refused to continue trial medication|6
6124055|NCT00915772|9748024|FG001|Overall Study|Refused to continue trial medication|8
6124056|NCT00915772|9748025|FG002|Overall Study|Refused to continue trial medication|4
6124057|NCT00915772|9748023|FG000|Overall Study|Any other reason|4
6124058|NCT00915772|9748024|FG001|Overall Study|Any other reason|7
6124059|NCT00915772|9748025|FG002|Overall Study|Any other reason|7
6124060|NCT00915876|9748063|FG000|Overall Study|Adverse Event|0
6124061|NCT00915876|9748064|FG001|Overall Study|Adverse Event|1
6124062|NCT00916006|9748115|FG000|Overall Study|Adverse Event|1
6124063|NCT00916006|9748116|FG001|Overall Study|Adverse Event|1
6124064|NCT00916006|9748115|FG000|Overall Study|Withdrawal by Subject|2
6124065|NCT00916006|9748116|FG001|Overall Study|Withdrawal by Subject|5
6124066|NCT00916006|9748115|FG000|Overall Study|Protocol Violation|0
6124067|NCT00916006|9748116|FG001|Overall Study|Protocol Violation|1
6124068|NCT00916058|9748136|FG000|Phase 1|Screen Failure|0
6124069|NCT00916058|9748137|FG001|Phase 1|Screen Failure|0
6124070|NCT00916058|9748138|FG002|Phase 1|Screen Failure|0
6124071|NCT00916058|9748139|FG003|Phase 1|Screen Failure|0
6124072|NCT00916058|9748140|FG004|Phase 1|Screen Failure|0
6124073|NCT00916058|9748141|FG005|Phase 1|Screen Failure|1
6124074|NCT00916058|9748142|FG006|Phase 1|Screen Failure|0
6124075|NCT00916058|9748136|FG000|Phase 2|Screen Failure|0
6124076|NCT00916058|9748137|FG001|Phase 2|Screen Failure|0
6124077|NCT00916058|9748138|FG002|Phase 2|Screen Failure|0
6124078|NCT00916058|9748139|FG003|Phase 2|Screen Failure|0
6124079|NCT00916058|9748140|FG004|Phase 2|Screen Failure|0
6124080|NCT00916058|9748141|FG005|Phase 2|Screen Failure|0
6124081|NCT00916058|9748142|FG006|Phase 2|Screen Failure|3
6124082|NCT00916149|9748172|FG000|Overall Study|Lost to Follow-up|3
6124083|NCT00916149|9748173|FG001|Overall Study|Lost to Follow-up|2
6124084|NCT00916149|9748174|FG002|Overall Study|Lost to Follow-up|0
6124085|NCT00916149|9748172|FG000|Overall Study|Unable to place scalp EEG leads|1
6124086|NCT00916149|9748173|FG001|Overall Study|Unable to place scalp EEG leads|0
6124087|NCT00916149|9748174|FG002|Overall Study|Unable to place scalp EEG leads|0
6124088|NCT00916279|9748181|FG000|Overall Study|Death|2
6124089|NCT00916279|9748181|FG000|Overall Study|Lost to Follow-up|2
6124090|NCT00916305|9748190|FG000|Overall Study|Lost to Follow-up|21
6124091|NCT00916305|9748191|FG001|Overall Study|Lost to Follow-up|27
6124092|NCT00916305|9748190|FG000|Overall Study|Withdrawal by Subject|0
6124093|NCT00916305|9748191|FG001|Overall Study|Withdrawal by Subject|1
6124094|NCT00916344|9748197|FG000|Overall Study|Death|2
6124095|NCT00916344|9748197|FG000|Overall Study|ICD upgrade|1
6124096|NCT00916344|9748197|FG000|Overall Study|Drop-out|5
6124097|NCT00916357|9748201|FG000|Period 1|Withdrawal by Subject|1
6124098|NCT00916357|9748202|FG001|Period 1|Withdrawal by Subject|0
6124099|NCT00916357|9748203|FG002|Period 1|Withdrawal by Subject|0
6124100|NCT00916357|9748204|FG003|Period 1|Withdrawal by Subject|0
6124101|NCT00916357|9748205|FG004|Period 1|Withdrawal by Subject|0
6124102|NCT00916357|9748206|FG005|Period 1|Withdrawal by Subject|0
6124103|NCT00916357|9748201|FG000|Period 2|Weight loss > 3 kilograms (kg)|0
6124104|NCT00916357|9748202|FG001|Period 2|Weight loss > 3 kilograms (kg)|0
6124105|NCT00916357|9748203|FG002|Period 2|Weight loss > 3 kilograms (kg)|0
6124106|NCT00916357|9748204|FG003|Period 2|Weight loss > 3 kilograms (kg)|1
6124107|NCT00916357|9748205|FG004|Period 2|Weight loss > 3 kilograms (kg)|0
6124108|NCT00916357|9748206|FG005|Period 2|Weight loss > 3 kilograms (kg)|0
6124109|NCT00916370|9748217|FG000|Overall Study|Death|3
6124110|NCT00916370|9748218|FG001|Overall Study|Death|1
6124111|NCT00916370|9748217|FG000|Overall Study|Withdrawal by Subject|2
6124112|NCT00916370|9748218|FG001|Overall Study|Withdrawal by Subject|0
6124113|NCT00916370|9748217|FG000|Overall Study|Physician Decision|0
6124114|NCT00916370|9748218|FG001|Overall Study|Physician Decision|1
6124115|NCT00916383|9748225|FG000|Overall Study|Adverse Event|1
6124116|NCT00916383|9748225|FG000|Overall Study|Death|1
6124117|NCT00916383|9748225|FG000|Overall Study|Protocol Violation|1
6124118|NCT00916578|9748242|FG000|Overall Study|Physician Decision|2
6124119|NCT00916578|9748242|FG000|Overall Study|Withdrawal by Subject|3
6124120|NCT00916578|9748242|FG000|Overall Study|Insurance Denial|2
6124121|NCT00916617|9748250|FG000|Overall Study|Adverse Event|3
6124122|NCT00916617|9748251|FG001|Overall Study|Adverse Event|2
6124123|NCT00916617|9748252|FG002|Overall Study|Adverse Event|6
6124124|NCT00916617|9748253|FG003|Overall Study|Adverse Event|3
6124125|NCT00916617|9748250|FG000|Overall Study|Withdrawal by Subject|3
6124126|NCT00916617|9748251|FG001|Overall Study|Withdrawal by Subject|2
6216671|NCT01632345|9884884|FG005|Treatment: Part I|Lost to Follow-up|0
6216672|NCT01632345|9884885|FG006|Treatment: Part I|Lost to Follow-up|0
6216673|NCT01632345|9884879|FG000|Treatment: Part I|Non-Compliance with Study Drug|3
6216674|NCT01632345|9884880|FG001|Treatment: Part I|Non-Compliance with Study Drug|2
6216675|NCT01632345|9884881|FG002|Treatment: Part I|Non-Compliance with Study Drug|2
6216676|NCT01632345|9884882|FG003|Treatment: Part I|Non-Compliance with Study Drug|1
6216677|NCT01632345|9884883|FG004|Treatment: Part I|Non-Compliance with Study Drug|0
6216678|NCT01632345|9884884|FG005|Treatment: Part I|Non-Compliance with Study Drug|0
6216679|NCT01632345|9884885|FG006|Treatment: Part I|Non-Compliance with Study Drug|0
6216680|NCT01632345|9884879|FG000|Treatment: Part I|Physician Decision|2
6216681|NCT01632345|9884880|FG001|Treatment: Part I|Physician Decision|1
6216682|NCT01632345|9884881|FG002|Treatment: Part I|Physician Decision|0
6216683|NCT01632345|9884882|FG003|Treatment: Part I|Physician Decision|0
6216684|NCT01632345|9884883|FG004|Treatment: Part I|Physician Decision|1
6216685|NCT01632345|9884884|FG005|Treatment: Part I|Physician Decision|0
6216686|NCT01632345|9884885|FG006|Treatment: Part I|Physician Decision|0
6216687|NCT01632345|9884879|FG000|Treatment: Part I|Pregnancy|0
6216688|NCT01632345|9884880|FG001|Treatment: Part I|Pregnancy|1
6216689|NCT01632345|9884881|FG002|Treatment: Part I|Pregnancy|0
6216690|NCT01632345|9884882|FG003|Treatment: Part I|Pregnancy|0
6216691|NCT01632345|9884883|FG004|Treatment: Part I|Pregnancy|0
6216692|NCT01632345|9884884|FG005|Treatment: Part I|Pregnancy|0
6216693|NCT01632345|9884885|FG006|Treatment: Part I|Pregnancy|0
6216694|NCT01632345|9884879|FG000|Treatment: Part I|Protocol Deviation|0
6216695|NCT01632345|9884880|FG001|Treatment: Part I|Protocol Deviation|0
6216696|NCT01632345|9884881|FG002|Treatment: Part I|Protocol Deviation|1
6216697|NCT01632345|9884882|FG003|Treatment: Part I|Protocol Deviation|1
6216698|NCT01632345|9884883|FG004|Treatment: Part I|Protocol Deviation|0
6216699|NCT01632345|9884884|FG005|Treatment: Part I|Protocol Deviation|0
6216700|NCT01632345|9884885|FG006|Treatment: Part I|Protocol Deviation|0
6216701|NCT01632345|9884879|FG000|Treatment: Part I|Withdrawal by Subject|3
6216702|NCT01632345|9884880|FG001|Treatment: Part I|Withdrawal by Subject|4
6216703|NCT01632345|9884881|FG002|Treatment: Part I|Withdrawal by Subject|4
6216704|NCT01632345|9884882|FG003|Treatment: Part I|Withdrawal by Subject|1
6216705|NCT01632345|9884883|FG004|Treatment: Part I|Withdrawal by Subject|4
6216706|NCT01632345|9884884|FG005|Treatment: Part I|Withdrawal by Subject|0
6216707|NCT01632345|9884885|FG006|Treatment: Part I|Withdrawal by Subject|0
6216708|NCT01632345|9884879|FG000|Treatment: Part II|Adverse Event|0
6216709|NCT01632345|9884880|FG001|Treatment: Part II|Adverse Event|0
6216710|NCT01632345|9884881|FG002|Treatment: Part II|Adverse Event|0
6216711|NCT01632345|9884882|FG003|Treatment: Part II|Adverse Event|0
6216712|NCT01632345|9884883|FG004|Treatment: Part II|Adverse Event|0
6216713|NCT01632345|9884884|FG005|Treatment: Part II|Adverse Event|3
6124127|NCT00916617|9748252|FG002|Overall Study|Withdrawal by Subject|0
6124128|NCT00916617|9748253|FG003|Overall Study|Withdrawal by Subject|1
6124129|NCT00916617|9748250|FG000|Overall Study|Caregiver Request|3
6124130|NCT00916617|9748251|FG001|Overall Study|Caregiver Request|2
6124131|NCT00916617|9748252|FG002|Overall Study|Caregiver Request|1
6124132|NCT00916617|9748253|FG003|Overall Study|Caregiver Request|0
6124133|NCT00916617|9748250|FG000|Overall Study|Physician Decision|1
6124134|NCT00916617|9748251|FG001|Overall Study|Physician Decision|1
6124135|NCT00916617|9748252|FG002|Overall Study|Physician Decision|0
6124136|NCT00916617|9748253|FG003|Overall Study|Physician Decision|0
6124137|NCT00916617|9748250|FG000|Overall Study|Discontinuation of Study by Sponsor|8
6124138|NCT00916617|9748251|FG001|Overall Study|Discontinuation of Study by Sponsor|13
6124139|NCT00916617|9748252|FG002|Overall Study|Discontinuation of Study by Sponsor|3
6124140|NCT00916617|9748253|FG003|Overall Study|Discontinuation of Study by Sponsor|1
6124141|NCT00916617|9748250|FG000|Overall Study|Lost to Follow-up|2
6124142|NCT00916617|9748251|FG001|Overall Study|Lost to Follow-up|1
6124143|NCT00916617|9748252|FG002|Overall Study|Lost to Follow-up|0
6124144|NCT00916617|9748253|FG003|Overall Study|Lost to Follow-up|0
6124145|NCT00916617|9748250|FG000|Overall Study|Lack of Efficacy|1
6124146|NCT00916617|9748251|FG001|Overall Study|Lack of Efficacy|0
6124147|NCT00916617|9748252|FG002|Overall Study|Lack of Efficacy|0
6124148|NCT00916617|9748253|FG003|Overall Study|Lack of Efficacy|0
6124149|NCT00916617|9748250|FG000|Overall Study|Other|2
6124150|NCT00916617|9748251|FG001|Overall Study|Other|0
6124151|NCT00916617|9748252|FG002|Overall Study|Other|0
6124152|NCT00916617|9748253|FG003|Overall Study|Other|2
6124153|NCT00916721|9748269|FG000|Overall Study|Lost to Follow-up|0
6124154|NCT00916721|9748270|FG001|Overall Study|Lost to Follow-up|1
6124155|NCT00916721|9748269|FG000|Overall Study|Adverse Event|6
6124156|NCT00916721|9748270|FG001|Overall Study|Adverse Event|3
6124157|NCT00916721|9748269|FG000|Overall Study|Withdrawal by Subject|2
6124158|NCT00916721|9748270|FG001|Overall Study|Withdrawal by Subject|2
6124159|NCT00916721|9748269|FG000|Overall Study|Protocol Violation|2
6124160|NCT00916721|9748270|FG001|Overall Study|Protocol Violation|4
6124161|NCT00916929|9748278|FG000|Overall Study|Lost to Follow-up|1
6124162|NCT00916929|9748279|FG001|Overall Study|Lost to Follow-up|3
6124163|NCT00916929|9748278|FG000|Overall Study|Death|5
6124164|NCT00916929|9748279|FG001|Overall Study|Death|10
6124165|NCT00916929|9748278|FG000|Overall Study|Withdrawal by Subject|1
6124166|NCT00916929|9748279|FG001|Overall Study|Withdrawal by Subject|5
6216714|NCT01632345|9884885|FG006|Treatment: Part II|Adverse Event|8
6216715|NCT01632345|9884879|FG000|Treatment: Part II|Lost to Follow-up|0
6216716|NCT01632345|9884880|FG001|Treatment: Part II|Lost to Follow-up|0
6216717|NCT01632345|9884881|FG002|Treatment: Part II|Lost to Follow-up|0
6216718|NCT01632345|9884882|FG003|Treatment: Part II|Lost to Follow-up|0
6216719|NCT01632345|9884883|FG004|Treatment: Part II|Lost to Follow-up|0
6216720|NCT01632345|9884884|FG005|Treatment: Part II|Lost to Follow-up|3
6216721|NCT01632345|9884885|FG006|Treatment: Part II|Lost to Follow-up|1
6216722|NCT01632345|9884879|FG000|Treatment: Part II|Non-Compliance with Study Drug|0
6216723|NCT01632345|9884880|FG001|Treatment: Part II|Non-Compliance with Study Drug|0
6216724|NCT01632345|9884881|FG002|Treatment: Part II|Non-Compliance with Study Drug|0
6216725|NCT01632345|9884882|FG003|Treatment: Part II|Non-Compliance with Study Drug|0
6216726|NCT01632345|9884883|FG004|Treatment: Part II|Non-Compliance with Study Drug|0
6216727|NCT01632345|9884884|FG005|Treatment: Part II|Non-Compliance with Study Drug|3
6216728|NCT01632345|9884885|FG006|Treatment: Part II|Non-Compliance with Study Drug|0
6216729|NCT01632345|9884879|FG000|Treatment: Part II|Withdrawal by Subject|0
6216730|NCT01632345|9884880|FG001|Treatment: Part II|Withdrawal by Subject|0
6216731|NCT01632345|9884881|FG002|Treatment: Part II|Withdrawal by Subject|0
6216732|NCT01632345|9884882|FG003|Treatment: Part II|Withdrawal by Subject|0
6216733|NCT01632345|9884883|FG004|Treatment: Part II|Withdrawal by Subject|0
6216734|NCT01632345|9884884|FG005|Treatment: Part II|Withdrawal by Subject|2
6216735|NCT01632345|9884885|FG006|Treatment: Part II|Withdrawal by Subject|2
6216736|NCT01632566|9884909|FG000|Overall Study|Withdrawal by Subject|0
6216737|NCT01632566|9884910|FG001|Overall Study|Withdrawal by Subject|1
6216738|NCT01632566|9884911|FG002|Overall Study|Withdrawal by Subject|0
6216739|NCT01632566|9884912|FG003|Overall Study|Withdrawal by Subject|0
6216740|NCT01632566|9884913|FG004|Overall Study|Withdrawal by Subject|0
6216741|NCT01632566|9884909|FG000|Overall Study|Sponsor Decision|0
6216742|NCT01632566|9884910|FG001|Overall Study|Sponsor Decision|2
6216743|NCT01632566|9884911|FG002|Overall Study|Sponsor Decision|9
6216744|NCT01632566|9884912|FG003|Overall Study|Sponsor Decision|2
6216745|NCT01632566|9884913|FG004|Overall Study|Sponsor Decision|2
6216746|NCT01632579|9884929|FG000|Washout Period|Adverse Event|1
6216747|NCT01632579|9884930|FG001|Washout Period|Adverse Event|0
6216748|NCT01632579|9884931|FG002|Washout Period|Adverse Event|0
6216749|NCT01632579|9884932|FG003|Washout Period|Adverse Event|0
6216750|NCT01632579|9884933|FG004|Washout Period|Adverse Event|0
6216751|NCT01632579|9884934|FG005|Washout Period|Adverse Event|0
6216752|NCT01632579|9884935|FG006|Washout Period|Adverse Event|0
6216753|NCT01632579|9884936|FG007|Washout Period|Adverse Event|0
6216754|NCT01632579|9884937|FG008|Washout Period|Adverse Event|0
6216755|NCT01632579|9884929|FG000|Period 2 (Second Intervention)|Adverse Event|1
6216756|NCT01632579|9884930|FG001|Period 2 (Second Intervention)|Adverse Event|0
6216757|NCT01632579|9884931|FG002|Period 2 (Second Intervention)|Adverse Event|0
6124167|NCT00916929|9748278|FG000|Overall Study|Left ventricular epicardial lead|1
6124168|NCT00916929|9748279|FG001|Overall Study|Left ventricular epicardial lead|2
6124169|NCT00916929|9748278|FG000|Overall Study|Transferred to hospice care|1
6216758|NCT01632579|9884932|FG003|Period 2 (Second Intervention)|Adverse Event|0
6216759|NCT01632579|9884933|FG004|Period 2 (Second Intervention)|Adverse Event|0
6216760|NCT01632579|9884934|FG005|Period 2 (Second Intervention)|Adverse Event|0
6216761|NCT01632579|9884935|FG006|Period 2 (Second Intervention)|Adverse Event|0
6216762|NCT01632579|9884936|FG007|Period 2 (Second Intervention)|Adverse Event|0
6124170|NCT00916929|9748279|FG001|Overall Study|Transferred to hospice care|1
6124171|NCT00916929|9748278|FG000|Overall Study|System explant|1
6124172|NCT00916929|9748279|FG001|Overall Study|System explant|0
6124173|NCT00916929|9748278|FG000|Overall Study|Moved to another state|0
6124174|NCT00916929|9748279|FG001|Overall Study|Moved to another state|1
6124175|NCT00916929|9748278|FG000|Overall Study|Device unable to process impedance data|0
6124176|NCT00916929|9748279|FG001|Overall Study|Device unable to process impedance data|7
6124177|NCT00917124|9748289|FG000|Overall Study|Protocol Violation|4
6124178|NCT00917124|9748290|FG001|Overall Study|Protocol Violation|6
6124179|NCT00917150|9748300|FG000|Overall Study|Adverse Event|12
6124180|NCT00917150|9748301|FG001|Overall Study|Adverse Event|7
6124181|NCT00917150|9748302|FG002|Overall Study|Adverse Event|12
6124182|NCT00917150|9748303|FG003|Overall Study|Adverse Event|11
6124183|NCT00917150|9748300|FG000|Overall Study|Death|1
6124184|NCT00917150|9748301|FG001|Overall Study|Death|4
6124185|NCT00917150|9748302|FG002|Overall Study|Death|3
6124186|NCT00917150|9748303|FG003|Overall Study|Death|2
6124187|NCT00917150|9748300|FG000|Overall Study|Lost to Follow-up|1
6124188|NCT00917150|9748301|FG001|Overall Study|Lost to Follow-up|0
6124189|NCT00917150|9748302|FG002|Overall Study|Lost to Follow-up|4
6124190|NCT00917150|9748303|FG003|Overall Study|Lost to Follow-up|2
6124191|NCT00917150|9748300|FG000|Overall Study|Physician Decision|0
6124192|NCT00917150|9748301|FG001|Overall Study|Physician Decision|2
6124193|NCT00917150|9748302|FG002|Overall Study|Physician Decision|0
6124194|NCT00917150|9748303|FG003|Overall Study|Physician Decision|1
6124195|NCT00917150|9748300|FG000|Overall Study|Protocol Violation|5
6124196|NCT00917150|9748301|FG001|Overall Study|Protocol Violation|5
6124197|NCT00917150|9748302|FG002|Overall Study|Protocol Violation|3
6124198|NCT00917150|9748303|FG003|Overall Study|Protocol Violation|5
6124199|NCT00917150|9748300|FG000|Overall Study|Withdrawal by Subject|15
6124200|NCT00917150|9748301|FG001|Overall Study|Withdrawal by Subject|16
6124201|NCT00917150|9748302|FG002|Overall Study|Withdrawal by Subject|18
6124202|NCT00917150|9748303|FG003|Overall Study|Withdrawal by Subject|11
6124203|NCT00917150|9748300|FG000|Overall Study|Other than specified|3
6124204|NCT00917150|9748301|FG001|Overall Study|Other than specified|3
6124205|NCT00917150|9748302|FG002|Overall Study|Other than specified|2
6124206|NCT00917150|9748303|FG003|Overall Study|Other than specified|2
6124207|NCT00917267|9748315|FG000|Overall Study|Adverse Event|15
6124208|NCT00917267|9748316|FG001|Overall Study|Adverse Event|36
6124209|NCT00917267|9748315|FG000|Overall Study|Physician Decision|2
6124210|NCT00917267|9748316|FG001|Overall Study|Physician Decision|4
6124211|NCT00917267|9748315|FG000|Overall Study|Protocol Violation|9
6124212|NCT00917267|9748316|FG001|Overall Study|Protocol Violation|18
6124213|NCT00917267|9748315|FG000|Overall Study|Withdrawal by Subject|5
6124214|NCT00917267|9748316|FG001|Overall Study|Withdrawal by Subject|12
6124215|NCT00917267|9748315|FG000|Overall Study|Lost to follow up|0
6124216|NCT00917267|9748316|FG001|Overall Study|Lost to follow up|2
6124217|NCT00917267|9748315|FG000|Overall Study|Entry Criteria Not Met|1
6124218|NCT00917267|9748316|FG001|Overall Study|Entry Criteria Not Met|0
6124219|NCT00917267|9748315|FG000|Overall Study|Sponsor Decision|5
6124220|NCT00917267|9748316|FG001|Overall Study|Sponsor Decision|5
6124221|NCT00917267|9748315|FG000|Overall Study|Lack of Efficacy-Loss of Glucose Control|2
6124222|NCT00917267|9748316|FG001|Overall Study|Lack of Efficacy-Loss of Glucose Control|2
6124223|NCT00917384|9748328|FG000|Overall Study|Lost to Follow-up|4
6124224|NCT00917384|9748329|FG001|Overall Study|Lost to Follow-up|2
6124225|NCT00917384|9748328|FG000|Overall Study|Withdrawal by Subject|10
6124226|NCT00917384|9748329|FG001|Overall Study|Withdrawal by Subject|2
6124227|NCT00917462|9748335|FG000|Overall Study|Clinical Deterioration|1
6124228|NCT00917501|9748341|FG000|Overall Study|Lost to Follow-up|4
6124229|NCT00917501|9748342|FG001|Overall Study|Lost to Follow-up|1
6124230|NCT00917501|9748341|FG000|Overall Study|Withdrawal by Subject|3
6124231|NCT00917501|9748342|FG001|Overall Study|Withdrawal by Subject|1
6124232|NCT00917501|9748341|FG000|Overall Study|Lack of Efficacy|1
6124233|NCT00917501|9748342|FG001|Overall Study|Lack of Efficacy|2
6124234|NCT00917501|9748341|FG000|Overall Study|trouble swollowing capsules|0
6288179|NCT02362425|10001688|FG001|Phase 1 (up to 6 Months)|Medicinal contraindication|0
6124235|NCT00917501|9748342|FG001|Overall Study|trouble swollowing capsules|1
6124236|NCT00917553|9748350|FG000|Overall Study|Lost to Follow-up|2
6124237|NCT00917553|9748351|FG001|Overall Study|Lost to Follow-up|1
6124238|NCT00917579|9748357|FG000|Washout >= 2 Weeks|Adverse Event|1
6124239|NCT00917579|9748358|FG001|Washout >= 2 Weeks|Adverse Event|0
6124240|NCT00917579|9748357|FG000|Washout >= 2 Weeks|Withdrawal by Subject|1
6124241|NCT00917579|9748358|FG001|Washout >= 2 Weeks|Withdrawal by Subject|0
6124242|NCT00917644|9748364|FG000|Period: Washout Period of > = 2 Weeks|Protocol Violation|1
6124243|NCT00917644|9748365|FG001|Period: Washout Period of > = 2 Weeks|Protocol Violation|0
6124244|NCT00917644|9748364|FG000|Period: Washout Period of > = 2 Weeks|Withdrawal by Subject|1
6124245|NCT00917644|9748365|FG001|Period: Washout Period of > = 2 Weeks|Withdrawal by Subject|0
6124246|NCT00917644|9748364|FG000|Period 2: Second Intervention|family emergency|1
6124247|NCT00917644|9748365|FG001|Period 2: Second Intervention|family emergency|0
6124248|NCT00917852|9748380|FG000|Overall Study|Death|6
6124249|NCT00918138|9748410|FG000|Overall Study|Subject withdrew consent|1
6124250|NCT00918138|9748411|FG001|Overall Study|Subject withdrew consent|1
6124251|NCT00918138|9748410|FG000|Overall Study|Death|1
6124252|NCT00918138|9748411|FG001|Overall Study|Death|0
6124253|NCT00918203|9748419|FG000|Treatment With or Without Olaratumab|Lost to Follow-up|1
6124254|NCT00918203|9748420|FG001|Treatment With or Without Olaratumab|Lost to Follow-up|1
6124255|NCT00918203|9748421|FG002|Treatment With or Without Olaratumab|Lost to Follow-up|0
6124256|NCT00918203|9748419|FG000|Treatment With or Without Olaratumab|Withdrawal by Subject|2
6124257|NCT00918203|9748420|FG001|Treatment With or Without Olaratumab|Withdrawal by Subject|8
6124258|NCT00918203|9748421|FG002|Treatment With or Without Olaratumab|Withdrawal by Subject|0
6124259|NCT00918203|9748419|FG000|Treatment With or Without Olaratumab|Other Therapy Started|2
6124260|NCT00918203|9748420|FG001|Treatment With or Without Olaratumab|Other Therapy Started|1
6124261|NCT00918203|9748421|FG002|Treatment With or Without Olaratumab|Other Therapy Started|0
6124262|NCT00918203|9748419|FG000|Treatment With or Without Olaratumab|Never Treated/Death|1
6124263|NCT00918203|9748420|FG001|Treatment With or Without Olaratumab|Never Treated/Death|0
6124264|NCT00918203|9748421|FG002|Treatment With or Without Olaratumab|Never Treated/Death|0
6124265|NCT00918255|9748440|FG000|Overall Study|Adverse Event|1
6124266|NCT00918255|9748441|FG001|Overall Study|Adverse Event|0
6124267|NCT00918255|9748442|FG002|Overall Study|Adverse Event|0
6124268|NCT00918255|9748440|FG000|Overall Study|Withdrawal by Subject|1
6124269|NCT00918255|9748441|FG001|Overall Study|Withdrawal by Subject|0
6124270|NCT00918255|9748442|FG002|Overall Study|Withdrawal by Subject|2
6124271|NCT00918255|9748440|FG000|Overall Study|Lack of Efficacy|1
6124272|NCT00918255|9748441|FG001|Overall Study|Lack of Efficacy|0
6124273|NCT00918255|9748442|FG002|Overall Study|Lack of Efficacy|0
6124274|NCT00918255|9748440|FG000|Overall Study|Lost to Follow-up|1
6124275|NCT00918255|9748441|FG001|Overall Study|Lost to Follow-up|0
6124276|NCT00918255|9748442|FG002|Overall Study|Lost to Follow-up|2
6124277|NCT00918255|9748440|FG000|Overall Study|Exceeded allowed number of interventions|0
6124278|NCT00918255|9748441|FG001|Overall Study|Exceeded allowed number of interventions|0
6124279|NCT00918255|9748442|FG002|Overall Study|Exceeded allowed number of interventions|1
6124280|NCT00918255|9748440|FG000|Overall Study|Non-compliance|1
6124281|NCT00918255|9748441|FG001|Overall Study|Non-compliance|0
6124282|NCT00918255|9748442|FG002|Overall Study|Non-compliance|0
6124283|NCT00918255|9748440|FG000|Overall Study|Investigator discretion|1
6124284|NCT00918255|9748441|FG001|Overall Study|Investigator discretion|0
6124285|NCT00918255|9748442|FG002|Overall Study|Investigator discretion|0
6216763|NCT01632579|9884937|FG008|Period 2 (Second Intervention)|Adverse Event|0
6216764|NCT01632800|9884994|FG000|Overall Study|Subject did not fit in apparatus|1
6216765|NCT01632891|9885000|FG000|Overall Study|Lost to Follow-up|0
6216766|NCT01632891|9885001|FG001|Overall Study|Lost to Follow-up|1
6216767|NCT01632891|9885000|FG000|Overall Study|Withdrawal by Subject|1
6216768|NCT01632891|9885001|FG001|Overall Study|Withdrawal by Subject|0
6216769|NCT01632904|9885013|FG000|Overall Study|Adverse Event|4
6216770|NCT01632904|9885014|FG001|Overall Study|Adverse Event|1
6216771|NCT01632904|9885013|FG000|Overall Study|Physician Decision|0
6216772|NCT01632904|9885014|FG001|Overall Study|Physician Decision|1
6216773|NCT01632904|9885013|FG000|Overall Study|Subject decision|3
6216774|NCT01632904|9885014|FG001|Overall Study|Subject decision|2
6216775|NCT01632904|9885013|FG000|Overall Study|Disease Progression|0
6216776|NCT01632904|9885014|FG001|Overall Study|Disease Progression|1
6216777|NCT01632904|9885013|FG000|Overall Study|Reason for discontinuation not available|0
6216778|NCT01632904|9885014|FG001|Overall Study|Reason for discontinuation not available|1
6216779|NCT01633060|9885028|FG000|Randomization Phase|Protocol deviation|1
6216780|NCT01633060|9885029|FG001|Randomization Phase|Protocol deviation|2
6216781|NCT01633060|9885028|FG000|Randomization Phase|Technical problem|0
6216782|NCT01633060|9885029|FG001|Randomization Phase|Technical problem|1
6216783|NCT01633060|9885028|FG000|Treatment Phase|Adverse Event|24
6216784|NCT01633060|9885029|FG001|Treatment Phase|Adverse Event|3
6216785|NCT01633060|9885028|FG000|Treatment Phase|Lost to Follow-up|1
6216786|NCT01633060|9885029|FG001|Treatment Phase|Lost to Follow-up|0
6216787|NCT01633060|9885028|FG000|Treatment Phase|Physician Decision|16
6216788|NCT01633060|9885029|FG001|Treatment Phase|Physician Decision|7
6216789|NCT01633060|9885028|FG000|Treatment Phase|Progressive Disease|210
6216790|NCT01633060|9885029|FG001|Treatment Phase|Progressive Disease|120
6216791|NCT01633060|9885028|FG000|Treatment Phase|Protocol Deviation|1
6216792|NCT01633060|9885029|FG001|Treatment Phase|Protocol Deviation|0
6216793|NCT01633060|9885028|FG000|Treatment Phase|Study Terminated by sponsor|7
6216794|NCT01633060|9885029|FG001|Treatment Phase|Study Terminated by sponsor|3
6216795|NCT01633060|9885028|FG000|Treatment Phase|Subject/guardian decision|25
6216796|NCT01633060|9885029|FG001|Treatment Phase|Subject/guardian decision|4
6216797|NCT01633060|9885028|FG000|Treatment Phase|Death|4
6216798|NCT01633060|9885029|FG001|Treatment Phase|Death|3
6216799|NCT01633060|9885028|FG000|Post-Treatment Efficacy Follow-Up Phase|Adverse Event|2
6216800|NCT01633060|9885029|FG001|Post-Treatment Efficacy Follow-Up Phase|Adverse Event|0
6216801|NCT01633060|9885028|FG000|Post-Treatment Efficacy Follow-Up Phase|Physician Decision|1
6216802|NCT01633060|9885029|FG001|Post-Treatment Efficacy Follow-Up Phase|Physician Decision|0
6216803|NCT01633060|9885028|FG000|Post-Treatment Efficacy Follow-Up Phase|Progressive Disease|10
6216804|NCT01633060|9885029|FG001|Post-Treatment Efficacy Follow-Up Phase|Progressive Disease|1
6216805|NCT01633060|9885028|FG000|Post-Treatment Efficacy Follow-Up Phase|Study terminated by sponsor|1
6216806|NCT01633060|9885029|FG001|Post-Treatment Efficacy Follow-Up Phase|Study terminated by sponsor|0
6216807|NCT01633060|9885028|FG000|Post-Treatment Efficacy Follow-Up Phase|Subject/Guardian Decision|1
6216808|NCT01633060|9885029|FG001|Post-Treatment Efficacy Follow-Up Phase|Subject/Guardian Decision|1
6124286|NCT00918281|9748450|FG000|Overall Study|Physician Decision|29
6124287|NCT00918333|9748459|FG000|Overall Study|Drug not taken per protocol|1
6124288|NCT00918333|9748460|FG001|Overall Study|Drug not taken per protocol|0
6124289|NCT00918333|9748459|FG000|Overall Study|Inadequate amount of drugs provided|1
6124290|NCT00918333|9748460|FG001|Overall Study|Inadequate amount of drugs provided|4
6124291|NCT00918333|9748459|FG000|Overall Study|Ineligible|1
6124292|NCT00918333|9748460|FG001|Overall Study|Ineligible|0
6124293|NCT00918333|9748459|FG000|Overall Study|Withdrawal by Subject|0
6124294|NCT00918333|9748460|FG001|Overall Study|Withdrawal by Subject|1
6124295|NCT00918346|9748469|FG000|First Treatment Period (4 Weeks)|Lack of Efficacy|0
6124296|NCT00918346|9748470|FG001|First Treatment Period (4 Weeks)|Lack of Efficacy|1
6216809|NCT01633060|9885028|FG000|Post-Treatment Efficacy Follow-Up Phase|Death|1
6216810|NCT01633060|9885029|FG001|Post-Treatment Efficacy Follow-Up Phase|Death|0
6216811|NCT01633112|9885039|FG000|Overall Study|Lack of Efficacy|1
6216812|NCT01633112|9885040|FG001|Overall Study|Lack of Efficacy|6
6216813|NCT01633112|9885041|FG002|Overall Study|Lack of Efficacy|13
6216814|NCT01633112|9885039|FG000|Overall Study|Abnormal laboratory value(s)|3
6216815|NCT01633112|9885040|FG001|Overall Study|Abnormal laboratory value(s)|1
6216816|NCT01633112|9885041|FG002|Overall Study|Abnormal laboratory value(s)|0
6216817|NCT01633112|9885039|FG000|Overall Study|Abnormal test procedure result(s)|0
6216818|NCT01633112|9885040|FG001|Overall Study|Abnormal test procedure result(s)|1
6216819|NCT01633112|9885041|FG002|Overall Study|Abnormal test procedure result(s)|0
6216820|NCT01633112|9885039|FG000|Overall Study|Administrative problems|1
6216821|NCT01633112|9885040|FG001|Overall Study|Administrative problems|2
6216822|NCT01633112|9885041|FG002|Overall Study|Administrative problems|5
6216823|NCT01633112|9885039|FG000|Overall Study|Adverse Event|16
6216824|NCT01633112|9885040|FG001|Overall Study|Adverse Event|18
6216825|NCT01633112|9885041|FG002|Overall Study|Adverse Event|20
6216826|NCT01633112|9885039|FG000|Overall Study|Lost to Follow-up|7
6216827|NCT01633112|9885040|FG001|Overall Study|Lost to Follow-up|19
6216828|NCT01633112|9885041|FG002|Overall Study|Lost to Follow-up|6
6216829|NCT01633112|9885039|FG000|Overall Study|Protocol Violation|4
6216830|NCT01633112|9885040|FG001|Overall Study|Protocol Violation|0
6216831|NCT01633112|9885041|FG002|Overall Study|Protocol Violation|2
6216832|NCT01633112|9885039|FG000|Overall Study|Subject no longer requires study drug|0
6216833|NCT01633112|9885040|FG001|Overall Study|Subject no longer requires study drug|0
6216834|NCT01633112|9885041|FG002|Overall Study|Subject no longer requires study drug|1
6216835|NCT01633112|9885039|FG000|Overall Study|Withdrawal by Subject|20
6216836|NCT01633112|9885040|FG001|Overall Study|Withdrawal by Subject|12
6216837|NCT01633112|9885041|FG002|Overall Study|Withdrawal by Subject|41
6216838|NCT01633112|9885039|FG000|Overall Study|missing Study Completion CRF|1
6216839|NCT01633112|9885040|FG001|Overall Study|missing Study Completion CRF|1
6216840|NCT01633112|9885041|FG002|Overall Study|missing Study Completion CRF|4
6216841|NCT01633788|9885072|FG000|Overall Study|Adverse Event|1
6216842|NCT01633788|9885073|FG001|Overall Study|Adverse Event|3
6216843|NCT01633788|9885074|FG002|Overall Study|Adverse Event|3
6216844|NCT01633788|9885075|FG003|Overall Study|Adverse Event|3
6216845|NCT01633788|9885072|FG000|Overall Study|Lost to Follow-up|2
6216846|NCT01633788|9885073|FG001|Overall Study|Lost to Follow-up|2
6216847|NCT01633788|9885074|FG002|Overall Study|Lost to Follow-up|2
6216848|NCT01633788|9885075|FG003|Overall Study|Lost to Follow-up|0
6216849|NCT01633788|9885072|FG000|Overall Study|Personal Reasons|3
6216850|NCT01633788|9885073|FG001|Overall Study|Personal Reasons|1
6216851|NCT01633788|9885074|FG002|Overall Study|Personal Reasons|1
6216852|NCT01633788|9885075|FG003|Overall Study|Personal Reasons|3
6216853|NCT01633788|9885072|FG000|Overall Study|Protocol Violation|1
6216854|NCT01633788|9885073|FG001|Overall Study|Protocol Violation|0
6216855|NCT01633788|9885074|FG002|Overall Study|Protocol Violation|1
6216856|NCT01633788|9885075|FG003|Overall Study|Protocol Violation|0
6216857|NCT01633788|9885072|FG000|Overall Study|Other Reasons|0
6216858|NCT01633788|9885073|FG001|Overall Study|Other Reasons|2
6216859|NCT01633788|9885074|FG002|Overall Study|Other Reasons|3
6216860|NCT01633788|9885075|FG003|Overall Study|Other Reasons|7
6216861|NCT01633944|9885115|FG000|Open-label Titration Phase|Adverse Event|109
6288180|NCT02362425|10001689|FG002|Phase 1 (up to 6 Months)|Medicinal contraindication|0
6216862|NCT01633944|9885116|FG001|Open-label Titration Phase|Adverse Event|0
6216863|NCT01633944|9885117|FG002|Open-label Titration Phase|Adverse Event|0
6216864|NCT01633944|9885115|FG000|Open-label Titration Phase|Lack of Efficacy|33
6216865|NCT01633944|9885116|FG001|Open-label Titration Phase|Lack of Efficacy|0
6216866|NCT01633944|9885117|FG002|Open-label Titration Phase|Lack of Efficacy|0
6216867|NCT01633944|9885115|FG000|Open-label Titration Phase|Withdrawal by Subject|34
6216868|NCT01633944|9885116|FG001|Open-label Titration Phase|Withdrawal by Subject|0
6216869|NCT01633944|9885117|FG002|Open-label Titration Phase|Withdrawal by Subject|0
6216870|NCT01633944|9885115|FG000|Open-label Titration Phase|Protocol Violation|24
6124297|NCT00918385|9748481|FG000|Monotherapy|Adverse Event|1
6216871|NCT01633944|9885116|FG001|Open-label Titration Phase|Protocol Violation|0
6216872|NCT01633944|9885117|FG002|Open-label Titration Phase|Protocol Violation|0
6216873|NCT01633944|9885115|FG000|Open-label Titration Phase|Lost to Follow-up|22
6216874|NCT01633944|9885116|FG001|Open-label Titration Phase|Lost to Follow-up|0
6216875|NCT01633944|9885117|FG002|Open-label Titration Phase|Lost to Follow-up|0
6216876|NCT01633944|9885115|FG000|Open-label Titration Phase|Other|68
6124298|NCT00918385|9748482|FG001|Monotherapy|Adverse Event|6
6124299|NCT00918385|9748481|FG000|Monotherapy|Complicating illness|1
6124300|NCT00918385|9748482|FG001|Monotherapy|Complicating illness|0
6124301|NCT00918385|9748481|FG000|Combination Nilutamide and Dasatinib|Adverse Event|1
6124302|NCT00918385|9748482|FG001|Combination Nilutamide and Dasatinib|Adverse Event|1
6124303|NCT00918385|9748481|FG000|Combination Nilutamide and Dasatinib|Withdrawal by Subject|2
6124304|NCT00918385|9748482|FG001|Combination Nilutamide and Dasatinib|Withdrawal by Subject|0
6124305|NCT00918385|9748481|FG000|Combination Nilutamide and Dasatinib|Complicating illness|1
6124306|NCT00918385|9748482|FG001|Combination Nilutamide and Dasatinib|Complicating illness|0
6124307|NCT00918385|9748481|FG000|Combination Nilutamide and Dasatinib|Withdrawal by Subject|2
6124308|NCT00918385|9748482|FG001|Combination Nilutamide and Dasatinib|Withdrawal by Subject|7
6124309|NCT00918567|9748492|FG000|Overall Study|Lack of Efficacy|3
6124310|NCT00918567|9748493|FG001|Overall Study|Lack of Efficacy|1
6124311|NCT00918567|9748492|FG000|Overall Study|Withdrawal by Subject|1
6124312|NCT00918567|9748493|FG001|Overall Study|Withdrawal by Subject|1
6124313|NCT00918567|9748492|FG000|Overall Study|Adverse Event|1
6124314|NCT00918567|9748493|FG001|Overall Study|Adverse Event|0
6124315|NCT00918580|9748499|FG000|Up to 6-month Follow-up(FU)|Adverse Event|1
6124316|NCT00918580|9748499|FG000|Up to 6-month Follow-up(FU)|Lost to Follow-up|5
6124317|NCT00918580|9748499|FG000|Up to 6-month Follow-up(FU)|Withdrawal by Subject|2
6124318|NCT00918580|9748499|FG000|Up to 6-month Follow-up(FU)|Parent/Legal Guardian Request|2
6124319|NCT00918580|9748499|FG000|Up to 6-month Follow-up(FU)|Failed to Return|1
5980884|NCT00687596|9569595|FG000|Overall Study|Radiological Disease Progression|6
5980885|NCT00687596|9569596|FG001|Overall Study|Radiological Disease Progression|2
6216877|NCT01633944|9885116|FG001|Open-label Titration Phase|Other|0
6216878|NCT01633944|9885117|FG002|Open-label Titration Phase|Other|0
6288181|NCT02362425|10001690|FG003|Phase 1 (up to 6 Months)|Medicinal contraindication|0
6288182|NCT02362425|10001687|FG000|Phase 1 (up to 6 Months)|Screening failure|1
6288183|NCT02362425|10001688|FG001|Phase 1 (up to 6 Months)|Screening failure|0
6288184|NCT02362425|10001689|FG002|Phase 1 (up to 6 Months)|Screening failure|0
6288185|NCT02362425|10001690|FG003|Phase 1 (up to 6 Months)|Screening failure|0
6288186|NCT02362425|10001687|FG000|Phase 1 (up to 6 Months)|Confirmatory genetic testing negative|3
6288187|NCT02362425|10001688|FG001|Phase 1 (up to 6 Months)|Confirmatory genetic testing negative|0
6288188|NCT02362425|10001689|FG002|Phase 1 (up to 6 Months)|Confirmatory genetic testing negative|0
6288189|NCT02362425|10001690|FG003|Phase 1 (up to 6 Months)|Confirmatory genetic testing negative|0
6288190|NCT02362425|10001687|FG000|Phase 1 (up to 6 Months)|Study closure|9
6288191|NCT02362425|10001688|FG001|Phase 1 (up to 6 Months)|Study closure|0
5980886|NCT00687596|9569595|FG000|Overall Study|Clinical Disease Progression|1
5980887|NCT00687596|9569596|FG001|Overall Study|Clinical Disease Progression|3
5980888|NCT00687596|9569595|FG000|Overall Study|Investigator Discretion|3
5980889|NCT00687596|9569596|FG001|Overall Study|Investigator Discretion|1
6124320|NCT00918580|9748499|FG000|After 6-month FU to 1-year FU|Did Not Continue After 6-Month FU|58
6124321|NCT00918580|9748499|FG000|After 6-month FU to 1-year FU|Failed to Return|2
6124322|NCT00918684|9748510|FG000|Two Week Drug Washout and Placebo Phase|Placebo Reponder|16
6124323|NCT00918684|9748510|FG000|Treatment Phase|Lack of Efficacy|6
6124324|NCT00918684|9748510|FG000|Treatment Phase|Lost to Follow-up|2
6124325|NCT00918684|9748510|FG000|Treatment Phase|Physician Decision|8
6124326|NCT00918684|9748510|FG000|Treatment Phase|Protocol Violation|1
6124327|NCT00918684|9748510|FG000|Treatment Phase|Withdrawal by Subject|8
6124328|NCT00918736|9748520|FG000|Overall Study|Withdrawal by Subject|4
6216879|NCT01633944|9885115|FG000|Double-blind Treatment Phase|Adverse Event|0
6216880|NCT01633944|9885116|FG001|Double-blind Treatment Phase|Adverse Event|13
6216881|NCT01633944|9885117|FG002|Double-blind Treatment Phase|Adverse Event|7
6216882|NCT01633944|9885115|FG000|Double-blind Treatment Phase|Lack of Efficacy|0
6216883|NCT01633944|9885116|FG001|Double-blind Treatment Phase|Lack of Efficacy|8
6216884|NCT01633944|9885117|FG002|Double-blind Treatment Phase|Lack of Efficacy|23
6216885|NCT01633944|9885115|FG000|Double-blind Treatment Phase|Withdrawal by Subject|0
6216886|NCT01633944|9885116|FG001|Double-blind Treatment Phase|Withdrawal by Subject|11
5980890|NCT00687596|9569595|FG000|Overall Study|Sponsor Terminated Study|6
5980891|NCT00687596|9569596|FG001|Overall Study|Sponsor Terminated Study|17
5980892|NCT00458536|9569602|FG000|Overall Study|Disease progression prior to treatment|7
5980893|NCT00458536|9569602|FG000|Overall Study|Unable to make vaccine|3
5980894|NCT00458536|9569602|FG000|Overall Study|No measurable disease after surgery|2
5980895|NCT00458536|9569602|FG000|Overall Study|Did not have renal cell carcinoma|2
5980896|NCT00458536|9569602|FG000|Overall Study|Patient did not have surgery|1
5980897|NCT00458536|9569602|FG000|Overall Study|Ineligible due to toxicity|1
5980898|NCT00458536|9569602|FG000|Overall Study|Withdrawal by Subject|1
5980899|NCT00458536|9569602|FG000|Overall Study|Progressive disease during treatment|2
6124329|NCT00918749|9748527|FG000|Overall Study|Adverse Event|1
6124330|NCT00918749|9748528|FG001|Overall Study|Adverse Event|0
6124331|NCT00918749|9748529|FG002|Overall Study|Adverse Event|1
6124332|NCT00918749|9748527|FG000|Overall Study|Lost to Follow-up|0
6124333|NCT00918749|9748528|FG001|Overall Study|Lost to Follow-up|0
6124334|NCT00918749|9748529|FG002|Overall Study|Lost to Follow-up|1
6124335|NCT00918749|9748527|FG000|Overall Study|Withdrawal by Subject|5
6124336|NCT00918749|9748528|FG001|Overall Study|Withdrawal by Subject|3
6124337|NCT00918749|9748529|FG002|Overall Study|Withdrawal by Subject|5
6124338|NCT00918749|9748527|FG000|Overall Study|No Study Medication Taken|1
6124339|NCT00918749|9748528|FG001|Overall Study|No Study Medication Taken|0
6124340|NCT00918749|9748529|FG002|Overall Study|No Study Medication Taken|0
6124341|NCT00918879|9748548|FG000|Overall Study|Withdrawal by Subject|4
6124342|NCT00918879|9748549|FG001|Overall Study|Withdrawal by Subject|4
6124343|NCT00918879|9748548|FG000|Overall Study|Lost to Follow-up|1
6124344|NCT00918879|9748549|FG001|Overall Study|Lost to Follow-up|1
6124345|NCT00918879|9748548|FG000|Overall Study|Severe non-compliance to protocol|1
6124346|NCT00918879|9748549|FG001|Overall Study|Severe non-compliance to protocol|1
6124347|NCT00918957|9748561|FG000|Overall Study|Adverse Event|2
6124348|NCT00918957|9748562|FG001|Overall Study|Adverse Event|0
6124349|NCT00918957|9748561|FG000|Overall Study|Withdrawal by Subject|1
6124350|NCT00918957|9748562|FG001|Overall Study|Withdrawal by Subject|0
6124351|NCT00919061|9748572|FG000|Overall Study|Adverse Event|1
6124352|NCT00919061|9748572|FG000|Overall Study|Withdrawal by Subject|1
6124353|NCT00919633|9748627|FG000|Overall Study|Adverse Event|1
6124354|NCT00919633|9748628|FG001|Overall Study|Adverse Event|9
6124355|NCT00919633|9748629|FG002|Overall Study|Adverse Event|12
6124356|NCT00919633|9748630|FG003|Overall Study|Adverse Event|10
6124357|NCT00919633|9748627|FG000|Overall Study|Death|0
6124358|NCT00919633|9748628|FG001|Overall Study|Death|0
6124359|NCT00919633|9748629|FG002|Overall Study|Death|2
6124360|NCT00919633|9748630|FG003|Overall Study|Death|0
6124361|NCT00919633|9748627|FG000|Overall Study|Lack of Efficacy|17
6124362|NCT00919633|9748628|FG001|Overall Study|Lack of Efficacy|3
6124363|NCT00919633|9748629|FG002|Overall Study|Lack of Efficacy|2
6124364|NCT00919633|9748630|FG003|Overall Study|Lack of Efficacy|3
6124365|NCT00919633|9748627|FG000|Overall Study|Withdrawal by Subject|1
6124366|NCT00919633|9748628|FG001|Overall Study|Withdrawal by Subject|2
6124367|NCT00919633|9748629|FG002|Overall Study|Withdrawal by Subject|4
6124368|NCT00919633|9748630|FG003|Overall Study|Withdrawal by Subject|3
6124369|NCT00919633|9748627|FG000|Overall Study|Lost to Follow-up|3
6124370|NCT00919633|9748628|FG001|Overall Study|Lost to Follow-up|1
6124371|NCT00919633|9748629|FG002|Overall Study|Lost to Follow-up|0
6124372|NCT00919633|9748630|FG003|Overall Study|Lost to Follow-up|2
6124373|NCT00919633|9748627|FG000|Overall Study|Withdraw consent post transition to SOC|0
6124374|NCT00919633|9748628|FG001|Overall Study|Withdraw consent post transition to SOC|0
6124375|NCT00919633|9748629|FG002|Overall Study|Withdraw consent post transition to SOC|1
6124376|NCT00919633|9748630|FG003|Overall Study|Withdraw consent post transition to SOC|1
6124377|NCT00919633|9748627|FG000|Overall Study|Protocol Violation|0
6124378|NCT00919633|9748628|FG001|Overall Study|Protocol Violation|0
6124379|NCT00919633|9748629|FG002|Overall Study|Protocol Violation|0
6124380|NCT00919633|9748630|FG003|Overall Study|Protocol Violation|1
6124381|NCT00919633|9748627|FG000|Overall Study|Physician Decision|0
6124382|NCT00919633|9748628|FG001|Overall Study|Physician Decision|0
6124383|NCT00919633|9748629|FG002|Overall Study|Physician Decision|0
6124384|NCT00919633|9748630|FG003|Overall Study|Physician Decision|1
6124385|NCT00919633|9748627|FG000|Overall Study|Request of withdrawal w/o future contact|0
6124386|NCT00919633|9748628|FG001|Overall Study|Request of withdrawal w/o future contact|0
6124387|NCT00919633|9748629|FG002|Overall Study|Request of withdrawal w/o future contact|1
6124388|NCT00919633|9748630|FG003|Overall Study|Request of withdrawal w/o future contact|0
6124389|NCT00919633|9748627|FG000|Overall Study|Viral rebound outside protocol timepoint|0
6124390|NCT00919633|9748628|FG001|Overall Study|Viral rebound outside protocol timepoint|0
6124391|NCT00919633|9748629|FG002|Overall Study|Viral rebound outside protocol timepoint|1
6124392|NCT00919633|9748630|FG003|Overall Study|Viral rebound outside protocol timepoint|0
6124393|NCT00919711|9748642|FG000|Overall Study|Withdrawal by Subject|15
6124394|NCT00919711|9748643|FG001|Overall Study|Withdrawal by Subject|7
6124395|NCT00919711|9748642|FG000|Overall Study|Adverse Event|13
6124396|NCT00919711|9748643|FG001|Overall Study|Adverse Event|3
6124397|NCT00919711|9748642|FG000|Overall Study|Other|1
6124398|NCT00919711|9748643|FG001|Overall Study|Other|2
6124399|NCT00919711|9748642|FG000|Overall Study|Administrative Decision|0
6124400|NCT00919711|9748643|FG001|Overall Study|Administrative Decision|1
6124401|NCT00919711|9748642|FG000|Overall Study|Lost to Follow-up|2
6124402|NCT00919711|9748643|FG001|Overall Study|Lost to Follow-up|0
6124403|NCT00919711|9748642|FG000|Overall Study|Death|1
6124404|NCT00919711|9748643|FG001|Overall Study|Death|0
6124405|NCT00919711|9748642|FG000|Overall Study|Noncompliance|1
6124406|NCT00919711|9748643|FG001|Overall Study|Noncompliance|0
6124407|NCT00919854|9748674|FG000|Overall Study|Adverse Event|1
6124408|NCT00919867|9748684|FG000|First Intervention|Withdrawal by Subject|0
6124409|NCT00919867|9748685|FG001|First Intervention|Withdrawal by Subject|0
6124410|NCT00919867|9748686|FG002|First Intervention|Withdrawal by Subject|1
6124411|NCT00919867|9748687|FG003|First Intervention|Withdrawal by Subject|0
6124412|NCT00919867|9748688|FG004|First Intervention|Withdrawal by Subject|0
6124413|NCT00919867|9748689|FG005|First Intervention|Withdrawal by Subject|0
6124414|NCT00919867|9748684|FG000|First Intervention|Physician Decision|0
6124415|NCT00919867|9748685|FG001|First Intervention|Physician Decision|0
6124416|NCT00919867|9748686|FG002|First Intervention|Physician Decision|0
6124417|NCT00919867|9748687|FG003|First Intervention|Physician Decision|0
6124418|NCT00919867|9748688|FG004|First Intervention|Physician Decision|0
6124419|NCT00919867|9748689|FG005|First Intervention|Physician Decision|1
6124420|NCT00920140|9748719|FG000|Phase 1 (Dose Escalation)|Adverse Event|3
6124421|NCT00920140|9748720|FG001|Phase 1 (Dose Escalation)|Adverse Event|3
6216887|NCT01633944|9885117|FG002|Double-blind Treatment Phase|Withdrawal by Subject|8
6216888|NCT01633944|9885115|FG000|Double-blind Treatment Phase|Protocol Violation|0
6216889|NCT01633944|9885116|FG001|Double-blind Treatment Phase|Protocol Violation|7
6216890|NCT01633944|9885117|FG002|Double-blind Treatment Phase|Protocol Violation|10
6216891|NCT01633944|9885115|FG000|Double-blind Treatment Phase|Lost to Follow-up|0
6216892|NCT01633944|9885116|FG001|Double-blind Treatment Phase|Lost to Follow-up|4
6216893|NCT01633944|9885117|FG002|Double-blind Treatment Phase|Lost to Follow-up|9
6216894|NCT01633944|9885115|FG000|Double-blind Treatment Phase|Withdrawal due to opioid withdrawal|0
6216895|NCT01633944|9885116|FG001|Double-blind Treatment Phase|Withdrawal due to opioid withdrawal|3
6216896|NCT01633944|9885117|FG002|Double-blind Treatment Phase|Withdrawal due to opioid withdrawal|1
6216897|NCT01633944|9885115|FG000|Double-blind Treatment Phase|Not exposed to DB study medication|0
6216898|NCT01633944|9885116|FG001|Double-blind Treatment Phase|Not exposed to DB study medication|1
6216899|NCT01633944|9885117|FG002|Double-blind Treatment Phase|Not exposed to DB study medication|0
6216900|NCT01633944|9885115|FG000|Double-blind Treatment Phase|Other|0
6216901|NCT01633944|9885116|FG001|Double-blind Treatment Phase|Other|7
6216902|NCT01633944|9885117|FG002|Double-blind Treatment Phase|Other|0
6216903|NCT01634100|9885125|FG000|Overall Study|Withdrawal by Subject|1
6216904|NCT01634100|9885126|FG001|Overall Study|Withdrawal by Subject|0
6216905|NCT01634100|9885127|FG002|Overall Study|Withdrawal by Subject|1
6216906|NCT01634100|9885128|FG003|Overall Study|Withdrawal by Subject|0
6216907|NCT01634100|9885129|FG004|Overall Study|Withdrawal by Subject|0
6216908|NCT01634100|9885130|FG005|Overall Study|Withdrawal by Subject|0
6216909|NCT01634113|9885141|FG000|Overall Study|Not treated|0
6216910|NCT01634113|9885142|FG001|Overall Study|Not treated|0
6216911|NCT01634113|9885143|FG002|Overall Study|Not treated|1
6216912|NCT01634139|9885154|FG000|Overall Study|Non compliant with protocol|1
6216913|NCT01634139|9885155|FG001|Overall Study|Non compliant with protocol|0
6216914|NCT01634139|9885156|FG002|Overall Study|Non compliant with protocol|0
6216915|NCT01634139|9885154|FG000|Overall Study|Consent withdrawn not due to AE|4
6216916|NCT01634139|9885155|FG001|Overall Study|Consent withdrawn not due to AE|3
6216917|NCT01634139|9885156|FG002|Overall Study|Consent withdrawn not due to AE|2
6216918|NCT01634139|9885154|FG000|Overall Study|Other|4
5980900|NCT00112840|9569609|FG000|Overall Study|Physician Decision|1
5980901|NCT00112840|9569610|FG001|Overall Study|Physician Decision|0
5980902|NCT00112840|9569611|FG002|Overall Study|Physician Decision|0
5980903|NCT00112840|9569609|FG000|Overall Study|Withdrawal by Subject|1
5980904|NCT00112840|9569610|FG001|Overall Study|Withdrawal by Subject|0
5980905|NCT00112840|9569611|FG002|Overall Study|Withdrawal by Subject|1
5980906|NCT00112840|9569609|FG000|Overall Study|Protocol Violation|0
5980907|NCT00112840|9569610|FG001|Overall Study|Protocol Violation|0
5980908|NCT00112840|9569611|FG002|Overall Study|Protocol Violation|5
6063442|NCT00506389|9664773|FG002|In-treatment Period|Adverse Event|2
6063443|NCT00506389|9664771|FG000|In-treatment Period|Randomized but not treated|4
6063444|NCT00506389|9664772|FG001|In-treatment Period|Randomized but not treated|1
6063445|NCT00506389|9664773|FG002|In-treatment Period|Randomized but not treated|1
6063446|NCT00506415|9664784|FG000|Initial Open Label (Maximum 48 Weeks)|Adverse Event|272
6063447|NCT00506415|9664785|FG001|Initial Open Label (Maximum 48 Weeks)|Adverse Event|0
6124422|NCT00920140|9748721|FG002|Phase 1 (Dose Escalation)|Adverse Event|0
6216919|NCT01634139|9885155|FG001|Overall Study|Other|0
6216920|NCT01634139|9885156|FG002|Overall Study|Other|3
6216921|NCT01634139|9885154|FG000|Overall Study|Lost to Follow-up|0
6216922|NCT01634139|9885155|FG001|Overall Study|Lost to Follow-up|2
6216923|NCT01634139|9885156|FG002|Overall Study|Lost to Follow-up|0
6216924|NCT01634139|9885154|FG000|Overall Study|Not treated|1
6216925|NCT01634139|9885155|FG001|Overall Study|Not treated|1
6216926|NCT01634139|9885156|FG002|Overall Study|Not treated|0
6216927|NCT01634152|9885167|FG000|Overall Study|Adverse Event|2
6216928|NCT01634152|9885168|FG001|Overall Study|Adverse Event|0
6216929|NCT01634152|9885169|FG002|Overall Study|Adverse Event|2
6216930|NCT01634152|9885167|FG000|Overall Study|Consent withdrawn not due to AE|1
6216931|NCT01634152|9885168|FG001|Overall Study|Consent withdrawn not due to AE|0
6216932|NCT01634152|9885169|FG002|Overall Study|Consent withdrawn not due to AE|1
6216933|NCT01634152|9885167|FG000|Overall Study|Not treated|0
6216934|NCT01634152|9885168|FG001|Overall Study|Not treated|1
6216935|NCT01634152|9885169|FG002|Overall Study|Not treated|0
6216936|NCT01634152|9885167|FG000|Overall Study|Other reason not defined above|1
6216937|NCT01634152|9885168|FG001|Overall Study|Other reason not defined above|0
6216938|NCT01634152|9885169|FG002|Overall Study|Other reason not defined above|1
6216939|NCT01634165|9885177|FG000|Period 2|Adverse Event|0
6216940|NCT01634165|9885178|FG001|Period 2|Adverse Event|1
6124423|NCT00920140|9748722|FG003|Phase 1 (Dose Escalation)|Adverse Event|0
6124424|NCT00920140|9748723|FG004|Phase 1 (Dose Escalation)|Adverse Event|0
6124425|NCT00920140|9748719|FG000|Phase 1 (Dose Escalation)|Lack of Efficacy|2
6124426|NCT00920140|9748720|FG001|Phase 1 (Dose Escalation)|Lack of Efficacy|4
6124427|NCT00920140|9748721|FG002|Phase 1 (Dose Escalation)|Lack of Efficacy|0
6216941|NCT01634165|9885179|FG002|Period 2|Adverse Event|0
6216942|NCT01634165|9885180|FG003|Period 2|Adverse Event|0
6216943|NCT01634178|9885190|FG000|Treatment Period 1|Adverse Event|0
6216944|NCT01634178|9885191|FG001|Treatment Period 1|Adverse Event|1
6216945|NCT01634178|9885190|FG000|Treatment Period 2|Adverse Event|1
6124428|NCT00920140|9748722|FG003|Phase 1 (Dose Escalation)|Lack of Efficacy|0
6124429|NCT00920140|9748723|FG004|Phase 1 (Dose Escalation)|Lack of Efficacy|0
6124430|NCT00920140|9748719|FG000|Phase 1 (Dose Escalation)|Withdrawal by Subject|0
6124431|NCT00920140|9748720|FG001|Phase 1 (Dose Escalation)|Withdrawal by Subject|2
6124432|NCT00920140|9748721|FG002|Phase 1 (Dose Escalation)|Withdrawal by Subject|0
6124433|NCT00920140|9748722|FG003|Phase 1 (Dose Escalation)|Withdrawal by Subject|0
6124434|NCT00920140|9748723|FG004|Phase 1 (Dose Escalation)|Withdrawal by Subject|0
6124435|NCT00920140|9748719|FG000|Phase 2|Adverse Event|0
6124436|NCT00920140|9748720|FG001|Phase 2|Adverse Event|0
6124437|NCT00920140|9748721|FG002|Phase 2|Adverse Event|14
6124438|NCT00920140|9748722|FG003|Phase 2|Adverse Event|2
6124439|NCT00920140|9748723|FG004|Phase 2|Adverse Event|3
6124440|NCT00920140|9748719|FG000|Phase 2|Lack of Efficacy|0
6124441|NCT00920140|9748720|FG001|Phase 2|Lack of Efficacy|0
6124442|NCT00920140|9748721|FG002|Phase 2|Lack of Efficacy|29
6124443|NCT00920140|9748722|FG003|Phase 2|Lack of Efficacy|14
6124444|NCT00920140|9748723|FG004|Phase 2|Lack of Efficacy|5
6124445|NCT00920140|9748719|FG000|Phase 2|Lost to Follow-up|0
6124446|NCT00920140|9748720|FG001|Phase 2|Lost to Follow-up|0
6124447|NCT00920140|9748721|FG002|Phase 2|Lost to Follow-up|0
6124448|NCT00920140|9748722|FG003|Phase 2|Lost to Follow-up|1
6124449|NCT00920140|9748723|FG004|Phase 2|Lost to Follow-up|0
6124450|NCT00920140|9748719|FG000|Phase 2|Physician Decision|0
6124451|NCT00920140|9748720|FG001|Phase 2|Physician Decision|0
6124452|NCT00920140|9748721|FG002|Phase 2|Physician Decision|3
6124453|NCT00920140|9748722|FG003|Phase 2|Physician Decision|3
6216946|NCT01634178|9885191|FG001|Treatment Period 2|Adverse Event|0
6216947|NCT01634243|9885222|FG000|Overall Study|Adverse Event|5
6216948|NCT01634243|9885223|FG001|Overall Study|Adverse Event|5
6216949|NCT01634243|9885222|FG000|Overall Study|Lack of Efficacy|1
6216950|NCT01634243|9885223|FG001|Overall Study|Lack of Efficacy|0
6216951|NCT01634360|9885250|FG000|Overall Study|Adverse Event|10
6216952|NCT01634360|9885251|FG001|Overall Study|Adverse Event|34
6216953|NCT01634360|9885250|FG000|Overall Study|subject withdrew consent|13
6216954|NCT01634360|9885251|FG001|Overall Study|subject withdrew consent|23
6216955|NCT01634360|9885250|FG000|Overall Study|Protocol Violation|1
6216956|NCT01634360|9885251|FG001|Overall Study|Protocol Violation|1
5980909|NCT04207749|9569640|FG000|Overall Study|Lost to Follow-up|0
5980910|NCT04207749|9569641|FG001|Overall Study|Lost to Follow-up|2
6216957|NCT01634360|9885250|FG000|Overall Study|Lack of Efficacy|4
6216958|NCT01634360|9885251|FG001|Overall Study|Lack of Efficacy|14
6216959|NCT01634360|9885250|FG000|Overall Study|Other|3
6216960|NCT01634360|9885251|FG001|Overall Study|Other|20
6216961|NCT01634360|9885250|FG000|Overall Study|Study termination by sponsor|18
6216962|NCT01634360|9885251|FG001|Overall Study|Study termination by sponsor|44
6216963|NCT01634555|9885257|FG000|Overall Study|Adverse Event|3
6216964|NCT01634555|9885257|FG000|Overall Study|Physician Decision|1
6216965|NCT01634659|9885273|FG000|Period 2 - Second 8 Days of Wear|Adverse Event|2
6216966|NCT01634659|9885274|FG001|Period 2 - Second 8 Days of Wear|Adverse Event|0
6216967|NCT01634659|9885273|FG000|Period 2 - Second 8 Days of Wear|Physician Decision|1
6216968|NCT01634659|9885274|FG001|Period 2 - Second 8 Days of Wear|Physician Decision|0
6216969|NCT01634854|9885282|FG000|Overall Study|Cesarean delivery|2
6216970|NCT01634854|9885283|FG001|Overall Study|Cesarean delivery|7
6288192|NCT02362425|10001689|FG002|Phase 1 (up to 6 Months)|Study closure|0
6288193|NCT02362425|10001690|FG003|Phase 1 (up to 6 Months)|Study closure|0
6288194|NCT02362425|10001687|FG000|Phase 2 (up to 6 Months, Randomized)|Adverse Event|0
6288195|NCT02362425|10001688|FG001|Phase 2 (up to 6 Months, Randomized)|Adverse Event|0
6288196|NCT02362425|10001689|FG002|Phase 2 (up to 6 Months, Randomized)|Adverse Event|0
6288197|NCT02362425|10001690|FG003|Phase 2 (up to 6 Months, Randomized)|Adverse Event|2
5980911|NCT04207749|9569640|FG000|Overall Study|Protocol Violation|0
5980912|NCT04207749|9569641|FG001|Overall Study|Protocol Violation|1
6288198|NCT02362425|10001687|FG000|Phase 2 (up to 6 Months, Randomized)|Withdrawal by Subject|0
6288199|NCT02362425|10001688|FG001|Phase 2 (up to 6 Months, Randomized)|Withdrawal by Subject|0
6288200|NCT02362425|10001689|FG002|Phase 2 (up to 6 Months, Randomized)|Withdrawal by Subject|0
6288201|NCT02362425|10001690|FG003|Phase 2 (up to 6 Months, Randomized)|Withdrawal by Subject|1
6288202|NCT02362425|10001687|FG000|Phase 2 (up to 6 Months, Randomized)|Discontinued study drug due to procedure|0
6288203|NCT02362425|10001688|FG001|Phase 2 (up to 6 Months, Randomized)|Discontinued study drug due to procedure|0
6288204|NCT02362425|10001689|FG002|Phase 2 (up to 6 Months, Randomized)|Discontinued study drug due to procedure|1
6288205|NCT02362425|10001690|FG003|Phase 2 (up to 6 Months, Randomized)|Discontinued study drug due to procedure|0
6288206|NCT02362646|10001712|FG000|Overall Study|Death|15
6288207|NCT02362646|10001713|FG001|Overall Study|Death|8
6288208|NCT02362646|10001712|FG000|Overall Study|Withdrawal by Subject|2
6288209|NCT02362646|10001713|FG001|Overall Study|Withdrawal by Subject|2
6124454|NCT00920140|9748723|FG004|Phase 2|Physician Decision|2
6124455|NCT00920140|9748719|FG000|Phase 2|Withdrawal by Subject|0
6124456|NCT00920140|9748720|FG001|Phase 2|Withdrawal by Subject|0
6124457|NCT00920140|9748721|FG002|Phase 2|Withdrawal by Subject|4
6124458|NCT00920140|9748722|FG003|Phase 2|Withdrawal by Subject|2
6124459|NCT00920140|9748723|FG004|Phase 2|Withdrawal by Subject|1
6124460|NCT00920218|9748740|FG000|Overall Study|Serious Adverse Event|2
6124461|NCT00920218|9748741|FG001|Overall Study|Serious Adverse Event|0
6124462|NCT00920218|9748742|FG002|Overall Study|Serious Adverse Event|2
6124463|NCT00920218|9748743|FG003|Overall Study|Serious Adverse Event|1
6124464|NCT00920218|9748740|FG000|Overall Study|Withdrawal by Subject|0
6124465|NCT00920218|9748741|FG001|Overall Study|Withdrawal by Subject|3
6124466|NCT00920218|9748742|FG002|Overall Study|Withdrawal by Subject|2
6124467|NCT00920218|9748743|FG003|Overall Study|Withdrawal by Subject|0
6124468|NCT00920218|9748740|FG000|Overall Study|Migrated/moved from study area|0
6124469|NCT00920218|9748741|FG001|Overall Study|Migrated/moved from study area|0
6124470|NCT00920218|9748742|FG002|Overall Study|Migrated/moved from study area|1
6124471|NCT00920218|9748743|FG003|Overall Study|Migrated/moved from study area|0
6124472|NCT00920218|9748740|FG000|Overall Study|Lost to Follow-up|0
6124473|NCT00920218|9748741|FG001|Overall Study|Lost to Follow-up|1
6124474|NCT00920218|9748742|FG002|Overall Study|Lost to Follow-up|0
6124475|NCT00920218|9748743|FG003|Overall Study|Lost to Follow-up|3
6124476|NCT00920218|9748740|FG000|Overall Study|Transplant failed/malignancy recurrence|0
6124477|NCT00920218|9748741|FG001|Overall Study|Transplant failed/malignancy recurrence|1
6124478|NCT00920218|9748742|FG002|Overall Study|Transplant failed/malignancy recurrence|2
6124479|NCT00920218|9748743|FG003|Overall Study|Transplant failed/malignancy recurrence|3
6124480|NCT00920218|9748740|FG000|Overall Study|Other|0
6124481|NCT00920218|9748741|FG001|Overall Study|Other|0
6124482|NCT00920218|9748742|FG002|Overall Study|Other|1
6124483|NCT00920218|9748743|FG003|Overall Study|Other|0
6216971|NCT01635153|9885320|FG000|Overall Study|Lost to Follow-up|40
6216972|NCT01635153|9885321|FG001|Overall Study|Lost to Follow-up|43
6216973|NCT01635218|9885330|FG000|Overall Study|Lost to Follow-up|3
6216974|NCT01635218|9885331|FG001|Overall Study|Lost to Follow-up|7
6216975|NCT01635218|9885332|FG002|Overall Study|Lost to Follow-up|6
6216976|NCT01635283|9885353|FG000|Overall Study|Tumor Progression|3
6216977|NCT01635283|9885353|FG000|Overall Study|Lost to Follow-up|1
6216978|NCT01635764|9885378|FG000|Overall Study|Adverse Event|46
6216979|NCT01635764|9885378|FG000|Overall Study|Lack of Efficacy|76
6216980|NCT01635764|9885378|FG000|Overall Study|Exceed Protocol-specified Interventions|2
6216981|NCT01635764|9885378|FG000|Overall Study|Protocol Deviation|1
6216982|NCT01635764|9885378|FG000|Overall Study|Withdrew Consent|67
6216983|NCT01635764|9885378|FG000|Overall Study|Lost to Follow-up|53
6216984|NCT01635764|9885378|FG000|Overall Study|Other|28
6216985|NCT01635855|9885389|FG000|Overall Study|Withdrawal by Subject|4
6216986|NCT01635920|9885399|FG000|Overall Study|Adverse Event|1
6216987|NCT01635920|9885400|FG001|Overall Study|Adverse Event|0
6216988|NCT01635920|9885399|FG000|Overall Study|Lost to Follow-up|0
6216989|NCT01635920|9885400|FG001|Overall Study|Lost to Follow-up|1
6216990|NCT01635920|9885399|FG000|Overall Study|Subject decision|2
6216991|NCT01635920|9885400|FG001|Overall Study|Subject decision|0
6216992|NCT01635933|9885409|FG000|Overall Study|Adverse Event|1
6216993|NCT01635933|9885410|FG001|Overall Study|Adverse Event|0
6216994|NCT01635933|9885409|FG000|Overall Study|Lost to Follow-up|0
6216995|NCT01635933|9885410|FG001|Overall Study|Lost to Follow-up|5
6216996|NCT01635933|9885409|FG000|Overall Study|Subject decision|1
6216997|NCT01635933|9885410|FG001|Overall Study|Subject decision|1
6216998|NCT01635933|9885409|FG000|Overall Study|Noncompliance|0
6216999|NCT01635933|9885410|FG001|Overall Study|Noncompliance|1
6217000|NCT01635933|9885409|FG000|Overall Study|No longer had transportation|0
6217001|NCT01635933|9885410|FG001|Overall Study|No longer had transportation|1
6217002|NCT01635998|9885418|FG000|Overall Study|Death|1
6217003|NCT01635998|9885419|FG001|Overall Study|Death|1
6217004|NCT01635998|9885418|FG000|Overall Study|Lost to Follow-up|2
6217005|NCT01635998|9885419|FG001|Overall Study|Lost to Follow-up|1
6217006|NCT01635998|9885418|FG000|Overall Study|Withdrawal by Subject|1
6217007|NCT01635998|9885419|FG001|Overall Study|Withdrawal by Subject|5
6217008|NCT01636076|9885436|FG000|Overall Study|Terminated by sponsor|1
6217009|NCT01636076|9885437|FG001|Overall Study|Terminated by sponsor|1
6217010|NCT01636076|9885436|FG000|Overall Study|Lack of Efficacy|0
6217011|NCT01636076|9885437|FG001|Overall Study|Lack of Efficacy|1
6217012|NCT01636076|9885436|FG000|Overall Study|Lost to Follow-up|1
6217013|NCT01636076|9885437|FG001|Overall Study|Lost to Follow-up|0
6217014|NCT01636076|9885436|FG000|Overall Study|Physician Decision|1
6217015|NCT01636076|9885437|FG001|Overall Study|Physician Decision|1
6217016|NCT01636076|9885436|FG000|Overall Study|Non-compliance with study treatment|1
6217017|NCT01636076|9885437|FG001|Overall Study|Non-compliance with study treatment|1
6217018|NCT01636076|9885436|FG000|Overall Study|Adverse Event|6
6217019|NCT01636076|9885437|FG001|Overall Study|Adverse Event|11
6217020|NCT01636076|9885436|FG000|Overall Study|Withdrawal by Subject|7
6217021|NCT01636076|9885437|FG001|Overall Study|Withdrawal by Subject|10
6217022|NCT01636362|9885488|FG000|Overall Study|Physician Decision|6
6217023|NCT01636362|9885488|FG000|Overall Study|Subject healed, not returning|1
6217024|NCT01636362|9885488|FG000|Overall Study|Withdrawal by Subject|1
6217025|NCT01636687|9885521|FG000|Induction Period|Withdrawal by Subject|1
6217026|NCT01636687|9885522|FG001|Induction Period|Withdrawal by Subject|0
6217027|NCT01636687|9885523|FG002|Induction Period|Withdrawal by Subject|0
6217028|NCT01636687|9885524|FG003|Induction Period|Withdrawal by Subject|0
6217029|NCT01636687|9885525|FG004|Induction Period|Withdrawal by Subject|0
6217030|NCT01636687|9885521|FG000|Induction Period|Adverse Event|1
6217031|NCT01636687|9885522|FG001|Induction Period|Adverse Event|0
6217032|NCT01636687|9885523|FG002|Induction Period|Adverse Event|0
6217033|NCT01636687|9885524|FG003|Induction Period|Adverse Event|0
6124484|NCT00920426|9748780|FG000|ITZ111451|Adverse Event|1
6124485|NCT00920426|9748781|FG001|ITZ111451|Adverse Event|0
6124486|NCT00920426|9748782|FG002|ITZ111451|Adverse Event|0
6124487|NCT00920426|9748783|FG003|ITZ111451|Adverse Event|0
6124488|NCT00920556|9748799|FG000|Overall Study|Adverse Event|16
6124489|NCT00920556|9748799|FG000|Overall Study|Physician Decision|7
6124490|NCT00920556|9748799|FG000|Overall Study|Withdrawal by Subject|1
6124491|NCT00920686|9748837|FG000|Overall Study|Lost to Follow-up|2
6124492|NCT00920686|9748838|FG001|Overall Study|Lost to Follow-up|3
6124493|NCT00920686|9748839|FG002|Overall Study|Lost to Follow-up|1
6124494|NCT00920686|9748837|FG000|Overall Study|Study drug dosing criteria not met|17
6124495|NCT00920686|9748838|FG001|Overall Study|Study drug dosing criteria not met|19
6124496|NCT00920686|9748839|FG002|Overall Study|Study drug dosing criteria not met|12
6124497|NCT00920699|9748854|FG000|Overall Study|Withdrawal by Subject|2
6124498|NCT00920699|9748855|FG001|Overall Study|Withdrawal by Subject|0
6124499|NCT00920699|9748856|FG002|Overall Study|Withdrawal by Subject|2
6124500|NCT00920699|9748854|FG000|Overall Study|no longer met eligibility|0
6124501|NCT00920699|9748855|FG001|Overall Study|no longer met eligibility|1
6124502|NCT00920699|9748856|FG002|Overall Study|no longer met eligibility|0
6124503|NCT00920699|9748854|FG000|Overall Study|Lost to Follow-up|0
6124504|NCT00920699|9748855|FG001|Overall Study|Lost to Follow-up|0
6124505|NCT00920699|9748856|FG002|Overall Study|Lost to Follow-up|2
6124506|NCT00920790|9748864|FG000|Overall Study|aggravation of general condition|14
6124507|NCT00920829|9748872|FG000|Allocation|No post randomization data|3
6124508|NCT00920829|9748873|FG001|Allocation|No post randomization data|1
6124509|NCT00920829|9748874|FG002|Allocation|No post randomization data|0
6124510|NCT00920829|9748875|FG003|Allocation|No post randomization data|2
6124511|NCT00920829|9748872|FG000|Available for Analysis|Withdrawal by Subject|6
6124512|NCT00920829|9748873|FG001|Available for Analysis|Withdrawal by Subject|6
6124513|NCT00920829|9748874|FG002|Available for Analysis|Withdrawal by Subject|6
6124514|NCT00920829|9748875|FG003|Available for Analysis|Withdrawal by Subject|10
6124515|NCT00920829|9748872|FG000|Available for Analysis|Required Medical Treatment|0
6124516|NCT00920829|9748873|FG001|Available for Analysis|Required Medical Treatment|1
6124517|NCT00920829|9748874|FG002|Available for Analysis|Required Medical Treatment|2
6124518|NCT00920829|9748875|FG003|Available for Analysis|Required Medical Treatment|0
6124519|NCT00920829|9748872|FG000|Available for Analysis|Adverse Event|1
6124520|NCT00920829|9748873|FG001|Available for Analysis|Adverse Event|2
6124521|NCT00920829|9748874|FG002|Available for Analysis|Adverse Event|1
6217034|NCT01636687|9885525|FG004|Induction Period|Adverse Event|1
6217035|NCT01636687|9885521|FG000|Induction Period|Lack of Efficacy|0
6217036|NCT01636687|9885522|FG001|Induction Period|Lack of Efficacy|0
6217037|NCT01636687|9885523|FG002|Induction Period|Lack of Efficacy|0
6217038|NCT01636687|9885524|FG003|Induction Period|Lack of Efficacy|0
6217039|NCT01636687|9885525|FG004|Induction Period|Lack of Efficacy|1
6217040|NCT01636687|9885521|FG000|Induction Period|Physician Decision|1
6217041|NCT01636687|9885522|FG001|Induction Period|Physician Decision|0
6217042|NCT01636687|9885523|FG002|Induction Period|Physician Decision|0
6217043|NCT01636687|9885524|FG003|Induction Period|Physician Decision|0
6217044|NCT01636687|9885525|FG004|Induction Period|Physician Decision|0
6217045|NCT01636687|9885521|FG000|Maintenance Period|Withdrawal by Subject|2
6217046|NCT01636687|9885522|FG001|Maintenance Period|Withdrawal by Subject|0
6217047|NCT01636687|9885523|FG002|Maintenance Period|Withdrawal by Subject|2
6217048|NCT01636687|9885524|FG003|Maintenance Period|Withdrawal by Subject|0
6217049|NCT01636687|9885525|FG004|Maintenance Period|Withdrawal by Subject|0
6217050|NCT01636687|9885521|FG000|Maintenance Period|Adverse Event|1
6217051|NCT01636687|9885522|FG001|Maintenance Period|Adverse Event|0
6217052|NCT01636687|9885523|FG002|Maintenance Period|Adverse Event|0
6217053|NCT01636687|9885524|FG003|Maintenance Period|Adverse Event|0
6217054|NCT01636687|9885525|FG004|Maintenance Period|Adverse Event|0
6217055|NCT01636687|9885521|FG000|Maintenance Period|Lack of Efficacy|4
6217056|NCT01636687|9885522|FG001|Maintenance Period|Lack of Efficacy|1
6217057|NCT01636687|9885523|FG002|Maintenance Period|Lack of Efficacy|0
6217058|NCT01636687|9885524|FG003|Maintenance Period|Lack of Efficacy|0
6217059|NCT01636687|9885525|FG004|Maintenance Period|Lack of Efficacy|0
6217060|NCT01636687|9885521|FG000|Maintenance Period|Lost to Follow-up|1
6217061|NCT01636687|9885522|FG001|Maintenance Period|Lost to Follow-up|1
6217062|NCT01636687|9885523|FG002|Maintenance Period|Lost to Follow-up|0
6217063|NCT01636687|9885524|FG003|Maintenance Period|Lost to Follow-up|0
6217064|NCT01636687|9885525|FG004|Maintenance Period|Lost to Follow-up|1
6217065|NCT01636687|9885521|FG000|Maintenance Period|Physician Decision|0
6124522|NCT00920829|9748875|FG003|Available for Analysis|Adverse Event|0
6124523|NCT00920829|9748872|FG000|Available for Analysis|Death|1
6124524|NCT00920829|9748873|FG001|Available for Analysis|Death|0
6124525|NCT00920829|9748874|FG002|Available for Analysis|Death|0
6124526|NCT00920829|9748875|FG003|Available for Analysis|Death|0
6124527|NCT00920829|9748872|FG000|Available for Analysis|Protocol Violation|0
6124528|NCT00920829|9748873|FG001|Available for Analysis|Protocol Violation|0
6124529|NCT00920829|9748874|FG002|Available for Analysis|Protocol Violation|1
6124530|NCT00920829|9748875|FG003|Available for Analysis|Protocol Violation|0
6124531|NCT00920829|9748872|FG000|Available for Analysis|Required more treatment|0
6124532|NCT00920829|9748873|FG001|Available for Analysis|Required more treatment|2
6217066|NCT01636687|9885522|FG001|Maintenance Period|Physician Decision|0
6124533|NCT00920829|9748874|FG002|Available for Analysis|Required more treatment|0
6124534|NCT00920829|9748875|FG003|Available for Analysis|Required more treatment|1
6124535|NCT00920855|9748888|FG000|Overall Study|Adverse Event|1
6124536|NCT00920855|9748889|FG001|Overall Study|Adverse Event|1
6124537|NCT00920855|9748890|FG002|Overall Study|Adverse Event|4
6124538|NCT00920855|9748888|FG000|Overall Study|Withdrawal by Subject|2
6124539|NCT00920855|9748889|FG001|Overall Study|Withdrawal by Subject|1
6124540|NCT00920855|9748890|FG002|Overall Study|Withdrawal by Subject|6
6124541|NCT00920855|9748888|FG000|Overall Study|Disease progression|2
6124542|NCT00920855|9748889|FG001|Overall Study|Disease progression|1
6124543|NCT00920855|9748890|FG002|Overall Study|Disease progression|10
6124544|NCT00920855|9748888|FG000|Overall Study|Noncompliance to study medication|0
6124545|NCT00920855|9748889|FG001|Overall Study|Noncompliance to study medication|0
6124546|NCT00920855|9748890|FG002|Overall Study|Noncompliance to study medication|1
6124547|NCT00920855|9748888|FG000|Overall Study|Response plateau; started maintenance|0
6124548|NCT00920855|9748889|FG001|Overall Study|Response plateau; started maintenance|0
6124549|NCT00920855|9748890|FG002|Overall Study|Response plateau; started maintenance|1
6124550|NCT00920907|9748901|FG000|Induction Period|Adverse Event|0
6124551|NCT00920907|9748902|FG001|Induction Period|Adverse Event|2
6124552|NCT00920907|9748901|FG000|Induction Period|Death|1
6124553|NCT00920907|9748902|FG001|Induction Period|Death|1
6124554|NCT00920907|9748901|FG000|Induction Period|Disease Progression|12
6124555|NCT00920907|9748902|FG001|Induction Period|Disease Progression|11
6124556|NCT00920907|9748901|FG000|Induction Period|Study Drug Toxicity|8
6124557|NCT00920907|9748902|FG001|Induction Period|Study Drug Toxicity|6
6124558|NCT00920907|9748901|FG000|Induction Period|No longer meets study criteria|0
6124559|NCT00920907|9748902|FG001|Induction Period|No longer meets study criteria|1
6124560|NCT00920907|9748901|FG000|Induction Period|Withdrawal by Subject|1
6124561|NCT00920907|9748902|FG001|Induction Period|Withdrawal by Subject|1
6124562|NCT00920907|9748901|FG000|Maintenance Period|Disease Progression|3
6124563|NCT00920907|9748902|FG001|Maintenance Period|Disease Progression|7
6124564|NCT00920907|9748901|FG000|Maintenance Period|Administrative (study closure)|7
6124565|NCT00920907|9748902|FG001|Maintenance Period|Administrative (study closure)|2
6124566|NCT00920907|9748901|FG000|Maintenance Period|Study Drug Toxicity|0
6124567|NCT00920907|9748902|FG001|Maintenance Period|Study Drug Toxicity|2
6124568|NCT00920907|9748901|FG000|Maintenance Period|Death|1
6124569|NCT00920907|9748902|FG001|Maintenance Period|Death|1
6124570|NCT00920907|9748901|FG000|Maintenance Period|Withdrawal by Subject|1
6124571|NCT00920907|9748902|FG001|Maintenance Period|Withdrawal by Subject|0
6124572|NCT00920907|9748901|FG000|Maintenance Period|Adverse Event|0
6124573|NCT00920907|9748902|FG001|Maintenance Period|Adverse Event|1
6124574|NCT00921024|9748912|FG000|Overall Study|Lost to Follow-up|2
6124575|NCT00921024|9748913|FG001|Overall Study|Lost to Follow-up|0
6124576|NCT00921024|9748912|FG000|Overall Study|Received concomittant therapy|2
6124577|NCT00921024|9748913|FG001|Overall Study|Received concomittant therapy|0
6217067|NCT01636687|9885523|FG002|Maintenance Period|Physician Decision|0
6217068|NCT01636687|9885524|FG003|Maintenance Period|Physician Decision|0
6217069|NCT01636687|9885525|FG004|Maintenance Period|Physician Decision|1
6217070|NCT01636687|9885521|FG000|Extension Period|technical problems|0
6217071|NCT01636687|9885522|FG001|Extension Period|technical problems|1
6217072|NCT01636687|9885523|FG002|Extension Period|technical problems|2
6217073|NCT01636687|9885524|FG003|Extension Period|technical problems|1
6217074|NCT01636687|9885525|FG004|Extension Period|technical problems|0
6217075|NCT01636687|9885521|FG000|Extension Period|Adverse Event|4
6217076|NCT01636687|9885522|FG001|Extension Period|Adverse Event|3
6217077|NCT01636687|9885523|FG002|Extension Period|Adverse Event|2
6217078|NCT01636687|9885524|FG003|Extension Period|Adverse Event|1
6217079|NCT01636687|9885525|FG004|Extension Period|Adverse Event|0
6217080|NCT01636687|9885521|FG000|Extension Period|Lack of Efficacy|7
6217081|NCT01636687|9885522|FG001|Extension Period|Lack of Efficacy|0
6217082|NCT01636687|9885523|FG002|Extension Period|Lack of Efficacy|2
6217083|NCT01636687|9885524|FG003|Extension Period|Lack of Efficacy|1
6217084|NCT01636687|9885525|FG004|Extension Period|Lack of Efficacy|0
6217085|NCT01636687|9885521|FG000|Extension Period|Lost to Follow-up|1
6217086|NCT01636687|9885522|FG001|Extension Period|Lost to Follow-up|0
6217087|NCT01636687|9885523|FG002|Extension Period|Lost to Follow-up|1
6217088|NCT01636687|9885524|FG003|Extension Period|Lost to Follow-up|0
6217089|NCT01636687|9885525|FG004|Extension Period|Lost to Follow-up|0
6217090|NCT01636687|9885521|FG000|Extension Period|Physician Decision|1
6217091|NCT01636687|9885522|FG001|Extension Period|Physician Decision|0
6217092|NCT01636687|9885523|FG002|Extension Period|Physician Decision|0
6217093|NCT01636687|9885524|FG003|Extension Period|Physician Decision|1
6217094|NCT01636687|9885525|FG004|Extension Period|Physician Decision|0
6124578|NCT00921024|9748912|FG000|Overall Study|Withdrawal by Subject|0
6124579|NCT00921024|9748913|FG001|Overall Study|Withdrawal by Subject|3
6124580|NCT00921557|9748951|FG000|Weeks 0-48 (on Study Treatment)|Baseline lumbar spine > -1.5|2
6124581|NCT00921557|9748952|FG001|Weeks 0-48 (on Study Treatment)|Baseline lumbar spine > -1.5|0
6124582|NCT00921557|9748953|FG002|Weeks 0-48 (on Study Treatment)|Baseline lumbar spine > -1.5|0
6124583|NCT00921557|9748951|FG000|Weeks 48-96 (on Study Treatment)|Site Closure|0
6124584|NCT00921557|9748952|FG001|Weeks 48-96 (on Study Treatment)|Site Closure|1
6124585|NCT00921557|9748953|FG002|Weeks 48-96 (on Study Treatment)|Site Closure|0
6124586|NCT00921557|9748951|FG000|Weeks 48-96 (on Study Treatment)|Became a ward of the state|0
6124587|NCT00921557|9748952|FG001|Weeks 48-96 (on Study Treatment)|Became a ward of the state|0
6124588|NCT00921557|9748953|FG002|Weeks 48-96 (on Study Treatment)|Became a ward of the state|1
6124589|NCT00921557|9748951|FG000|Weeks 96-144 (Off Study Treatment)|Site closure|1
6124590|NCT00921557|9748952|FG001|Weeks 96-144 (Off Study Treatment)|Site closure|0
6124591|NCT00921557|9748953|FG002|Weeks 96-144 (Off Study Treatment)|Site closure|0
6124592|NCT00921557|9748951|FG000|Weeks 96-144 (Off Study Treatment)|Not able to attend clinic|2
6124593|NCT00921557|9748952|FG001|Weeks 96-144 (Off Study Treatment)|Not able to attend clinic|1
6124594|NCT00921557|9748953|FG002|Weeks 96-144 (Off Study Treatment)|Not able to attend clinic|1
6124595|NCT00922116|9749010|FG000|Overall Study|Adverse Event|4
6124596|NCT00922116|9749010|FG000|Overall Study|Death|1
6124597|NCT00922116|9749010|FG000|Overall Study|Lost to Follow-up|1
6124598|NCT00922116|9749010|FG000|Overall Study|Withdrawal by Subject|4
6124599|NCT00922116|9749010|FG000|Overall Study|Other|5
6124600|NCT00922207|9749021|FG000|Overall Study|Adverse Event/Intercurrent Illness|3
6124601|NCT00922207|9749022|FG001|Overall Study|Adverse Event/Intercurrent Illness|0
6124602|NCT00922207|9749023|FG002|Overall Study|Adverse Event/Intercurrent Illness|0
6124603|NCT00922207|9749021|FG000|Overall Study|Insufficient Therapeutic Response|0
6124604|NCT00922207|9749022|FG001|Overall Study|Insufficient Therapeutic Response|0
6124605|NCT00922207|9749023|FG002|Overall Study|Insufficient Therapeutic Response|1
6124606|NCT00922207|9749021|FG000|Overall Study|Violation of Selection Criteria at Entry|0
6124607|NCT00922207|9749022|FG001|Overall Study|Violation of Selection Criteria at Entry|1
6124608|NCT00922207|9749023|FG002|Overall Study|Violation of Selection Criteria at Entry|0
6124609|NCT00922207|9749021|FG000|Overall Study|Refused Treatment/Did Not Cooperate|1
6124610|NCT00922207|9749022|FG001|Overall Study|Refused Treatment/Did Not Cooperate|0
6124611|NCT00922207|9749023|FG002|Overall Study|Refused Treatment/Did Not Cooperate|0
6124612|NCT00922207|9749021|FG000|Overall Study|Withdrew Consent|2
6124613|NCT00922207|9749022|FG001|Overall Study|Withdrew Consent|5
6124614|NCT00922207|9749023|FG002|Overall Study|Withdrew Consent|2
6124615|NCT00922207|9749021|FG000|Overall Study|Abnormality of Laboratory Test|0
6124616|NCT00922207|9749022|FG001|Overall Study|Abnormality of Laboratory Test|1
6124617|NCT00922207|9749023|FG002|Overall Study|Abnormality of Laboratory Test|1
6124618|NCT00922272|9749036|FG000|Open-label Phase|Adverse Event|5
6124619|NCT00922272|9749037|FG001|Open-label Phase|Adverse Event|0
6124620|NCT00922272|9749036|FG000|Open-label Phase|Protocol Violation|1
6124621|NCT00922272|9749037|FG001|Open-label Phase|Protocol Violation|0
6124622|NCT00922272|9749036|FG000|Open-label Phase|Withdrawal by Subject|11
6124623|NCT00922272|9749037|FG001|Open-label Phase|Withdrawal by Subject|0
6124624|NCT00922272|9749036|FG000|Open-label Phase|Failure to meet randomization criteria|1
6124625|NCT00922272|9749037|FG001|Open-label Phase|Failure to meet randomization criteria|0
6124626|NCT00922272|9749036|FG000|Open-label Phase|Withdrawal criteria met|5
6124627|NCT00922272|9749037|FG001|Open-label Phase|Withdrawal criteria met|0
6124628|NCT00922272|9749036|FG000|Double-blind Phase|Adverse Event|1
6124629|NCT00922272|9749037|FG001|Double-blind Phase|Adverse Event|1
6124630|NCT00922272|9749036|FG000|Double-blind Phase|Withdrawal by Subject|1
6124631|NCT00922272|9749037|FG001|Double-blind Phase|Withdrawal by Subject|1
6124632|NCT00922272|9749036|FG000|Double-blind Phase|Lost to Follow-up|2
6124633|NCT00922272|9749037|FG001|Double-blind Phase|Lost to Follow-up|1
6124634|NCT00922272|9749036|FG000|Double-blind Phase|Withdrawal criteria met|1
6124635|NCT00922272|9749037|FG001|Double-blind Phase|Withdrawal criteria met|1
6124636|NCT00922272|9749036|FG000|Double-blind Phase|Noncompliance|1
6124637|NCT00922272|9749037|FG001|Double-blind Phase|Noncompliance|1
6124638|NCT00922272|9749036|FG000|Double-blind Phase|Positive urine drug screen|1
6124639|NCT00922272|9749037|FG001|Double-blind Phase|Positive urine drug screen|1
6124640|NCT00922428|9749045|FG000|Overall Study|retrospective/extremely implausible data|2
6124641|NCT00922428|9749045|FG000|Overall Study|no medication use or questionable use|13
6124642|NCT00922441|9749058|FG000|Overall Study|Protocol Violation|0
6124643|NCT00922441|9749059|FG001|Overall Study|Protocol Violation|0
6124644|NCT00922441|9749060|FG002|Overall Study|Protocol Violation|2
6124645|NCT00922441|9749058|FG000|Overall Study|Withdrawal by Subject|0
6124646|NCT00922441|9749059|FG001|Overall Study|Withdrawal by Subject|0
6124647|NCT00922441|9749060|FG002|Overall Study|Withdrawal by Subject|1
6124648|NCT00922480|9749070|FG000|Main Study|Protocol Violation|3
6124649|NCT00922480|9749071|FG001|Main Study|Protocol Violation|6
6124650|NCT00922480|9749070|FG000|Main Study|Adverse Event|6
6124651|NCT00922480|9749071|FG001|Main Study|Adverse Event|7
6124652|NCT00922480|9749070|FG000|Main Study|Lack of Efficacy|3
6124653|NCT00922480|9749071|FG001|Main Study|Lack of Efficacy|0
6217095|NCT01636687|9885521|FG000|Extension Period|study terminated by sponsor|33
6217096|NCT01636687|9885522|FG001|Extension Period|study terminated by sponsor|50
6217097|NCT01636687|9885523|FG002|Extension Period|study terminated by sponsor|17
6217098|NCT01636687|9885524|FG003|Extension Period|study terminated by sponsor|23
6217099|NCT01636687|9885525|FG004|Extension Period|study terminated by sponsor|0
6217100|NCT01636687|9885521|FG000|Extension Period|Withdrawal by Subject|1
6217101|NCT01636687|9885522|FG001|Extension Period|Withdrawal by Subject|0
6288210|NCT02362646|10001712|FG000|Overall Study|received transplant|21
6124654|NCT00922480|9749070|FG000|Main Study|Withdrawal by Subject|20
6124655|NCT00922480|9749071|FG001|Main Study|Withdrawal by Subject|15
6217102|NCT01636687|9885523|FG002|Extension Period|Withdrawal by Subject|1
6124656|NCT00922480|9749070|FG000|Main Study|Lost to Follow-up|5
6124657|NCT00922480|9749071|FG001|Main Study|Lost to Follow-up|0
6124658|NCT00922480|9749070|FG000|Main Study|Physician Decision|0
6124659|NCT00922480|9749071|FG001|Main Study|Physician Decision|1
6124660|NCT00922480|9749070|FG000|Extension Study|Protocol Violation|3
6124661|NCT00922480|9749071|FG001|Extension Study|Protocol Violation|0
6124662|NCT00922480|9749070|FG000|Extension Study|Adverse Event|1
6124663|NCT00922480|9749071|FG001|Extension Study|Adverse Event|1
6124664|NCT00922480|9749070|FG000|Extension Study|Withdrawal by Subject|1
6124665|NCT00922480|9749071|FG001|Extension Study|Withdrawal by Subject|1
6124666|NCT00922480|9749070|FG000|Extension Study|Others|0
6124667|NCT00922480|9749071|FG001|Extension Study|Others|1
6124668|NCT00922623|9749079|FG000|Overall Study|Other|4
6124669|NCT00922623|9749079|FG000|Overall Study|Lost to Follow-up|1
6124670|NCT00922636|9749090|FG000|Overall Study|Adverse Event|3
6124671|NCT00922636|9749091|FG001|Overall Study|Adverse Event|3
6124672|NCT00922636|9749092|FG002|Overall Study|Adverse Event|2
6124673|NCT00922636|9749093|FG003|Overall Study|Adverse Event|3
6124674|NCT00922636|9749094|FG004|Overall Study|Adverse Event|2
6124675|NCT00922636|9749090|FG000|Overall Study|Lack of Efficacy|1
6124676|NCT00922636|9749091|FG001|Overall Study|Lack of Efficacy|7
6124677|NCT00922636|9749092|FG002|Overall Study|Lack of Efficacy|3
6124678|NCT00922636|9749093|FG003|Overall Study|Lack of Efficacy|2
6124679|NCT00922636|9749094|FG004|Overall Study|Lack of Efficacy|4
6124680|NCT00922636|9749090|FG000|Overall Study|Sponsor Decision|0
6124681|NCT00922636|9749091|FG001|Overall Study|Sponsor Decision|0
6124682|NCT00922636|9749092|FG002|Overall Study|Sponsor Decision|2
6124683|NCT00922636|9749093|FG003|Overall Study|Sponsor Decision|0
6124684|NCT00922636|9749094|FG004|Overall Study|Sponsor Decision|0
6124685|NCT00922636|9749090|FG000|Overall Study|Withdrawal by Subject|0
6124686|NCT00922636|9749091|FG001|Overall Study|Withdrawal by Subject|0
6124687|NCT00922636|9749092|FG002|Overall Study|Withdrawal by Subject|5
6124688|NCT00922636|9749093|FG003|Overall Study|Withdrawal by Subject|2
6124689|NCT00922636|9749094|FG004|Overall Study|Withdrawal by Subject|4
6124690|NCT00922636|9749090|FG000|Overall Study|Protocol Violation|0
6124691|NCT00922636|9749091|FG001|Overall Study|Protocol Violation|0
6124692|NCT00922636|9749092|FG002|Overall Study|Protocol Violation|2
6124693|NCT00922636|9749093|FG003|Overall Study|Protocol Violation|2
6124694|NCT00922636|9749094|FG004|Overall Study|Protocol Violation|0
6124695|NCT00922636|9749090|FG000|Overall Study|Entry Criteria Not Met|0
6124696|NCT00922636|9749091|FG001|Overall Study|Entry Criteria Not Met|0
6124697|NCT00922636|9749092|FG002|Overall Study|Entry Criteria Not Met|1
6124698|NCT00922636|9749093|FG003|Overall Study|Entry Criteria Not Met|1
6124699|NCT00922636|9749094|FG004|Overall Study|Entry Criteria Not Met|0
6124700|NCT00922636|9749090|FG000|Overall Study|Parent/Caregiver Decision|2
6124701|NCT00922636|9749091|FG001|Overall Study|Parent/Caregiver Decision|4
6124702|NCT00922636|9749092|FG002|Overall Study|Parent/Caregiver Decision|3
6124703|NCT00922636|9749093|FG003|Overall Study|Parent/Caregiver Decision|5
6124704|NCT00922636|9749094|FG004|Overall Study|Parent/Caregiver Decision|2
6124705|NCT00922636|9749090|FG000|Overall Study|Lost to Follow-up|1
6124706|NCT00922636|9749091|FG001|Overall Study|Lost to Follow-up|2
6124707|NCT00922636|9749092|FG002|Overall Study|Lost to Follow-up|2
6217103|NCT01636687|9885524|FG003|Extension Period|Withdrawal by Subject|1
6217104|NCT01636687|9885525|FG004|Extension Period|Withdrawal by Subject|0
6217105|NCT01636687|9885521|FG000|Follow-up Period|Withdrawal by Subject|1
6217106|NCT01636687|9885522|FG001|Follow-up Period|Withdrawal by Subject|0
6217107|NCT01636687|9885523|FG002|Follow-up Period|Withdrawal by Subject|0
6217108|NCT01636687|9885524|FG003|Follow-up Period|Withdrawal by Subject|0
6217109|NCT01636687|9885525|FG004|Follow-up Period|Withdrawal by Subject|1
6217110|NCT01636713|9885546|FG000|Overall Study|Adverse Event|16
6217111|NCT01636713|9885547|FG001|Overall Study|Adverse Event|16
6217112|NCT01636713|9885548|FG002|Overall Study|Adverse Event|7
6217113|NCT01636713|9885546|FG000|Overall Study|Lack of Efficacy|6
6217114|NCT01636713|9885547|FG001|Overall Study|Lack of Efficacy|6
6217115|NCT01636713|9885548|FG002|Overall Study|Lack of Efficacy|2
6217116|NCT01636713|9885546|FG000|Overall Study|Protocol Violation|3
6217117|NCT01636713|9885547|FG001|Overall Study|Protocol Violation|0
6217118|NCT01636713|9885548|FG002|Overall Study|Protocol Violation|1
6217119|NCT01636713|9885546|FG000|Overall Study|Lost to Follow-up|0
6217120|NCT01636713|9885547|FG001|Overall Study|Lost to Follow-up|0
6217121|NCT01636713|9885548|FG002|Overall Study|Lost to Follow-up|1
6217122|NCT01636713|9885546|FG000|Overall Study|Withdrawal by Subject|5
6217123|NCT01636713|9885547|FG001|Overall Study|Withdrawal by Subject|4
6217124|NCT01636713|9885548|FG002|Overall Study|Withdrawal by Subject|8
6217125|NCT01636713|9885546|FG000|Overall Study|Met Protocol-defined Stopping Criteria|2
6217126|NCT01636713|9885547|FG001|Overall Study|Met Protocol-defined Stopping Criteria|2
6217127|NCT01636713|9885548|FG002|Overall Study|Met Protocol-defined Stopping Criteria|4
6217128|NCT01636778|9885560|FG000|Pre-Antiviral Treatment Period (Part 1)|Protocol Violation|3
6288211|NCT02362646|10001713|FG001|Overall Study|received transplant|14
6124708|NCT00922636|9749093|FG003|Overall Study|Lost to Follow-up|2
6124709|NCT00922636|9749094|FG004|Overall Study|Lost to Follow-up|4
6124710|NCT00922766|9749115|FG000|Overall Study|Death|3
6124711|NCT00922766|9749115|FG000|Overall Study|Withdrawal by Subject|2
6124712|NCT00922766|9749115|FG000|Overall Study|Other|1
6124713|NCT00922766|9749115|FG000|Overall Study|Adverse Event|1
6124714|NCT00922779|9749119|FG000|Overall Study|Adverse Event|67
6124715|NCT00922779|9749119|FG000|Overall Study|Pregnancy|7
6124716|NCT00922779|9749119|FG000|Overall Study|Withdrawal by Subject|308
6124717|NCT00922779|9749119|FG000|Overall Study|Lost to Follow-up|44
6124718|NCT00922779|9749119|FG000|Overall Study|Other|27
6124719|NCT00922779|9749119|FG000|Overall Study|Missing|1874
6124720|NCT00922935|9749130|FG000|Overall Study|Protocol Violation|0
6124721|NCT00922935|9749131|FG001|Overall Study|Protocol Violation|3
6124722|NCT00922935|9749132|FG002|Overall Study|Protocol Violation|0
6124723|NCT00922935|9749130|FG000|Overall Study|Physician Decision|1
6124724|NCT00922935|9749131|FG001|Overall Study|Physician Decision|1
6124725|NCT00922935|9749132|FG002|Overall Study|Physician Decision|0
6124726|NCT00922935|9749130|FG000|Overall Study|Lost to Follow-up|0
6124727|NCT00922935|9749131|FG001|Overall Study|Lost to Follow-up|1
6124728|NCT00922935|9749132|FG002|Overall Study|Lost to Follow-up|0
6124729|NCT00922974|9749143|FG000|Phase II Component|Protocol Violation|2
6124730|NCT00922974|9749144|FG001|Phase II Component|Protocol Violation|0
6124731|NCT00922974|9749143|FG000|Phase II Component|Not evaluable for treatment review|5
6124732|NCT00922974|9749144|FG001|Phase II Component|Not evaluable for treatment review|0
6124733|NCT00922974|9749143|FG000|Phase III Component|Protocol Violation|8
6124734|NCT00922974|9749144|FG001|Phase III Component|Protocol Violation|6
6124735|NCT00922987|9749152|FG000|Overall Study|Insufficient clinical response|1
6124736|NCT00922987|9749152|FG000|Overall Study|Protocol Violation|2
6124737|NCT00922987|9749152|FG000|Overall Study|Adverse Event|1
6124738|NCT00923078|9749159|FG000|First Intervention (Weeks 1-4)|Withdrawal by Subject|1
6124739|NCT00923078|9749160|FG001|First Intervention (Weeks 1-4)|Withdrawal by Subject|1
6124740|NCT00923078|9749161|FG002|First Intervention (Weeks 1-4)|Withdrawal by Subject|0
6124741|NCT00923078|9749159|FG000|First Intervention (Weeks 1-4)|No intervention per protocol|0
6124742|NCT00923078|9749160|FG001|First Intervention (Weeks 1-4)|No intervention per protocol|0
6124743|NCT00923078|9749161|FG002|First Intervention (Weeks 1-4)|No intervention per protocol|20
6124744|NCT00923091|9749176|FG000|PeriodI-II (Randomized, Double-Blind)|Adverse Event|11
6124745|NCT00923091|9749177|FG001|PeriodI-II (Randomized, Double-Blind)|Adverse Event|3
6124746|NCT00923091|9749178|FG002|PeriodI-II (Randomized, Double-Blind)|Adverse Event|7
6124747|NCT00923091|9749179|FG003|PeriodI-II (Randomized, Double-Blind)|Adverse Event|13
6124748|NCT00923091|9749180|FG004|PeriodI-II (Randomized, Double-Blind)|Adverse Event|10
6124749|NCT00923091|9749181|FG005|PeriodI-II (Randomized, Double-Blind)|Adverse Event|5
6124750|NCT00923091|9749182|FG006|PeriodI-II (Randomized, Double-Blind)|Adverse Event|9
6217129|NCT01636778|9885561|FG001|Pre-Antiviral Treatment Period (Part 1)|Protocol Violation|0
6217130|NCT01636778|9885562|FG002|Pre-Antiviral Treatment Period (Part 1)|Protocol Violation|0
6217131|NCT01636778|9885560|FG000|Pre-Antiviral Treatment Period (Part 1)|Protocol-Defined Stopping Criteria|1
6217132|NCT01636778|9885561|FG001|Pre-Antiviral Treatment Period (Part 1)|Protocol-Defined Stopping Criteria|0
6217133|NCT01636778|9885562|FG002|Pre-Antiviral Treatment Period (Part 1)|Protocol-Defined Stopping Criteria|0
6217134|NCT01636778|9885560|FG000|Antiviral Treatment Period (Part 2)|Adverse Event|0
6217135|NCT01636778|9885561|FG001|Antiviral Treatment Period (Part 2)|Adverse Event|7
6217136|NCT01636778|9885562|FG002|Antiviral Treatment Period (Part 2)|Adverse Event|0
6217137|NCT01636778|9885560|FG000|Antiviral Treatment Period (Part 2)|Protocol Violation|0
6217138|NCT01636778|9885561|FG001|Antiviral Treatment Period (Part 2)|Protocol Violation|1
6217139|NCT01636778|9885562|FG002|Antiviral Treatment Period (Part 2)|Protocol Violation|0
6217140|NCT01636778|9885560|FG000|Antiviral Treatment Period (Part 2)|Physician Decision|0
6217141|NCT01636778|9885561|FG001|Antiviral Treatment Period (Part 2)|Physician Decision|2
6217142|NCT01636778|9885562|FG002|Antiviral Treatment Period (Part 2)|Physician Decision|0
6217143|NCT01636778|9885560|FG000|Follow-up Period After Part 2|Other|0
6217144|NCT01636778|9885561|FG001|Follow-up Period After Part 2|Other|0
6217145|NCT01636778|9885562|FG002|Follow-up Period After Part 2|Other|1
6217146|NCT01636778|9885560|FG000|Follow-up Period After Part 2|Not entered FU period after withdrawal|0
6217147|NCT01636778|9885561|FG001|Follow-up Period After Part 2|Not entered FU period after withdrawal|0
6217148|NCT01636778|9885562|FG002|Follow-up Period After Part 2|Not entered FU period after withdrawal|1
6217149|NCT01636778|9885560|FG000|Follow-up Period After Part 2|Withdrawal by Subject|0
6217150|NCT01636778|9885561|FG001|Follow-up Period After Part 2|Withdrawal by Subject|0
6217151|NCT01636778|9885562|FG002|Follow-up Period After Part 2|Withdrawal by Subject|2
6217152|NCT01636934|9885576|FG000|Overall Study|Withdrawal by Subject|3
6217153|NCT01636934|9885577|FG001|Overall Study|Withdrawal by Subject|2
6217154|NCT01636934|9885576|FG000|Overall Study|Chemo cancel|1
6217155|NCT01636934|9885577|FG001|Overall Study|Chemo cancel|0
6217156|NCT01636934|9885576|FG000|Overall Study|Too ill to continue|1
6217157|NCT01636934|9885577|FG001|Overall Study|Too ill to continue|0
6217158|NCT01636934|9885576|FG000|Overall Study|Never started study medication|1
6217159|NCT01636934|9885577|FG001|Overall Study|Never started study medication|1
6217160|NCT01636947|9885585|FG000|Overall Study|Not Treated|2
6217161|NCT01636947|9885586|FG001|Overall Study|Not Treated|2
6217162|NCT01636947|9885585|FG000|Overall Study|Lost to Follow-up|4
6217163|NCT01636947|9885586|FG001|Overall Study|Lost to Follow-up|0
6217164|NCT01636947|9885585|FG000|Overall Study|Protocol Violation|1
6217165|NCT01636947|9885586|FG001|Overall Study|Protocol Violation|1
6217166|NCT01636947|9885585|FG000|Overall Study|Withdrawal by Subject|3
6217167|NCT01636947|9885586|FG001|Overall Study|Withdrawal by Subject|3
6124751|NCT00923091|9749183|FG007|PeriodI-II (Randomized, Double-Blind)|Adverse Event|17
6124752|NCT00923091|9749184|FG008|PeriodI-II (Randomized, Double-Blind)|Adverse Event|0
6124753|NCT00923091|9749185|FG009|PeriodI-II (Randomized, Double-Blind)|Adverse Event|0
6124754|NCT00923091|9749186|FG010|PeriodI-II (Randomized, Double-Blind)|Adverse Event|0
6124755|NCT00923091|9749187|FG011|PeriodI-II (Randomized, Double-Blind)|Adverse Event|0
6124756|NCT00923091|9749188|FG012|PeriodI-II (Randomized, Double-Blind)|Adverse Event|0
6124757|NCT00923091|9749176|FG000|PeriodI-II (Randomized, Double-Blind)|Withdrawal by Subject|4
6124758|NCT00923091|9749177|FG001|PeriodI-II (Randomized, Double-Blind)|Withdrawal by Subject|6
6124759|NCT00923091|9749178|FG002|PeriodI-II (Randomized, Double-Blind)|Withdrawal by Subject|5
6124760|NCT00923091|9749179|FG003|PeriodI-II (Randomized, Double-Blind)|Withdrawal by Subject|8
6124761|NCT00923091|9749180|FG004|PeriodI-II (Randomized, Double-Blind)|Withdrawal by Subject|7
6124762|NCT00923091|9749181|FG005|PeriodI-II (Randomized, Double-Blind)|Withdrawal by Subject|6
6124763|NCT00923091|9749182|FG006|PeriodI-II (Randomized, Double-Blind)|Withdrawal by Subject|5
6124764|NCT00923091|9749183|FG007|PeriodI-II (Randomized, Double-Blind)|Withdrawal by Subject|5
6124765|NCT00923091|9749184|FG008|PeriodI-II (Randomized, Double-Blind)|Withdrawal by Subject|0
6124766|NCT00923091|9749185|FG009|PeriodI-II (Randomized, Double-Blind)|Withdrawal by Subject|0
6124767|NCT00923091|9749186|FG010|PeriodI-II (Randomized, Double-Blind)|Withdrawal by Subject|0
6124768|NCT00923091|9749187|FG011|PeriodI-II (Randomized, Double-Blind)|Withdrawal by Subject|0
6124769|NCT00923091|9749188|FG012|PeriodI-II (Randomized, Double-Blind)|Withdrawal by Subject|0
6124770|NCT00923091|9749176|FG000|PeriodI-II (Randomized, Double-Blind)|Protocol Violation|1
6124771|NCT00923091|9749177|FG001|PeriodI-II (Randomized, Double-Blind)|Protocol Violation|1
6124772|NCT00923091|9749178|FG002|PeriodI-II (Randomized, Double-Blind)|Protocol Violation|1
6124773|NCT00923091|9749179|FG003|PeriodI-II (Randomized, Double-Blind)|Protocol Violation|5
6124774|NCT00923091|9749180|FG004|PeriodI-II (Randomized, Double-Blind)|Protocol Violation|4
6124775|NCT00923091|9749181|FG005|PeriodI-II (Randomized, Double-Blind)|Protocol Violation|2
6124776|NCT00923091|9749182|FG006|PeriodI-II (Randomized, Double-Blind)|Protocol Violation|4
6124777|NCT00923091|9749183|FG007|PeriodI-II (Randomized, Double-Blind)|Protocol Violation|3
6124778|NCT00923091|9749184|FG008|PeriodI-II (Randomized, Double-Blind)|Protocol Violation|0
6124779|NCT00923091|9749185|FG009|PeriodI-II (Randomized, Double-Blind)|Protocol Violation|0
6217168|NCT01636947|9885585|FG000|Overall Study|Adverse Event|1
6124780|NCT00923091|9749186|FG010|PeriodI-II (Randomized, Double-Blind)|Protocol Violation|0
6124781|NCT00923091|9749187|FG011|PeriodI-II (Randomized, Double-Blind)|Protocol Violation|0
6124782|NCT00923091|9749188|FG012|PeriodI-II (Randomized, Double-Blind)|Protocol Violation|0
6124783|NCT00923091|9749176|FG000|PeriodI-II (Randomized, Double-Blind)|Lost to Follow-up|0
6124784|NCT00923091|9749177|FG001|PeriodI-II (Randomized, Double-Blind)|Lost to Follow-up|0
6124785|NCT00923091|9749178|FG002|PeriodI-II (Randomized, Double-Blind)|Lost to Follow-up|0
6217169|NCT01636947|9885586|FG001|Overall Study|Adverse Event|1
6217170|NCT01636947|9885585|FG000|Overall Study|Did Not Meet Eligibility Criteria|1
6217171|NCT01636947|9885586|FG001|Overall Study|Did Not Meet Eligibility Criteria|4
6217172|NCT01636960|9885592|FG000|Induction Phase|Adverse Event|2
6217173|NCT01636960|9885592|FG000|Maintenance Phase|Continued drug after regulatory approval|3
6217174|NCT01636960|9885592|FG000|Maintenance Phase|Adverse Event|3
6217175|NCT01636960|9885592|FG000|Maintenance Phase|Progressive disease|1
6217176|NCT01636986|9885598|FG000|Overall Study|Withdrawal by Subject|0
6217177|NCT01636986|9885599|FG001|Overall Study|Withdrawal by Subject|1
6217178|NCT01636986|9885598|FG000|Overall Study|Corneal Staining|0
6217179|NCT01636986|9885599|FG001|Overall Study|Corneal Staining|1
6217180|NCT01637077|9885607|FG000|Overall Study|Cancel|1
6217181|NCT01637077|9885608|FG001|Overall Study|Cancel|1
6217182|NCT01637077|9885607|FG000|Overall Study|Withdrawal by Subject|1
6217183|NCT01637077|9885608|FG001|Overall Study|Withdrawal by Subject|0
6217184|NCT01637077|9885607|FG000|Overall Study|No cycle 1 questionnaire data|2
6217185|NCT01637077|9885608|FG001|Overall Study|No cycle 1 questionnaire data|0
6217186|NCT01637142|9885618|FG000|Washout Period (at Least 3 Days)|Physician Decision|1
6217187|NCT01637272|9885628|FG000|Overall Study|Adverse Event|6
6217188|NCT01637272|9885628|FG000|Overall Study|Unsatisfactory therapeutic effect|2
6217189|NCT01637272|9885628|FG000|Overall Study|Withdrawal by Subject|3
6217190|NCT01637272|9885628|FG000|Overall Study|Lost to Follow-up|2
6217191|NCT01637272|9885628|FG000|Overall Study|completed core, did not enter ext. phase|4
6217192|NCT01637272|9885628|FG000|Overall Study|Administrative problems|1
6217193|NCT01637272|9885628|FG000|Overall Study|Protocol Violation|2
6217194|NCT01637402|9885647|FG000|Standard Dose Regimen|Lack of Efficacy|2
6217195|NCT01637402|9885648|FG001|Standard Dose Regimen|Lack of Efficacy|0
6217196|NCT01637402|9885647|FG000|Standard Dose Regimen|Adverse Event|1
6217197|NCT01637402|9885648|FG001|Standard Dose Regimen|Adverse Event|0
6217198|NCT01637402|9885647|FG000|Week 12 Evaluation|Lack of Efficacy|6
6217199|NCT01637402|9885648|FG001|Week 12 Evaluation|Lack of Efficacy|0
6217200|NCT01637402|9885647|FG000|Treatment Regiments Post Week 12|Not evaluable for response after 12wks|0
6217201|NCT01637402|9885648|FG001|Treatment Regiments Post Week 12|Not evaluable for response after 12wks|4
6217202|NCT01637402|9885647|FG000|Treatment Regiments Post Week 12|Withdrawal by Subject|4
6217203|NCT01637402|9885648|FG001|Treatment Regiments Post Week 12|Withdrawal by Subject|0
6217204|NCT01637402|9885647|FG000|Treatment Regiments Post Week 12|Progression after escalation arm closed|5
6288212|NCT02362724|10001736|FG000|Overall Study|Withdrawal by Subject|3
6124786|NCT00923091|9749179|FG003|PeriodI-II (Randomized, Double-Blind)|Lost to Follow-up|0
6124787|NCT00923091|9749180|FG004|PeriodI-II (Randomized, Double-Blind)|Lost to Follow-up|0
6124788|NCT00923091|9749181|FG005|PeriodI-II (Randomized, Double-Blind)|Lost to Follow-up|1
6124789|NCT00923091|9749182|FG006|PeriodI-II (Randomized, Double-Blind)|Lost to Follow-up|0
6124790|NCT00923091|9749183|FG007|PeriodI-II (Randomized, Double-Blind)|Lost to Follow-up|0
6124791|NCT00923091|9749184|FG008|PeriodI-II (Randomized, Double-Blind)|Lost to Follow-up|0
6124792|NCT00923091|9749185|FG009|PeriodI-II (Randomized, Double-Blind)|Lost to Follow-up|0
6124793|NCT00923091|9749186|FG010|PeriodI-II (Randomized, Double-Blind)|Lost to Follow-up|0
6124794|NCT00923091|9749187|FG011|PeriodI-II (Randomized, Double-Blind)|Lost to Follow-up|0
6124795|NCT00923091|9749188|FG012|PeriodI-II (Randomized, Double-Blind)|Lost to Follow-up|0
6124796|NCT00923091|9749176|FG000|PeriodI-II (Randomized, Double-Blind)|Other Reason|0
6124797|NCT00923091|9749177|FG001|PeriodI-II (Randomized, Double-Blind)|Other Reason|1
6124798|NCT00923091|9749178|FG002|PeriodI-II (Randomized, Double-Blind)|Other Reason|0
6124799|NCT00923091|9749179|FG003|PeriodI-II (Randomized, Double-Blind)|Other Reason|1
6124800|NCT00923091|9749180|FG004|PeriodI-II (Randomized, Double-Blind)|Other Reason|0
6124801|NCT00923091|9749181|FG005|PeriodI-II (Randomized, Double-Blind)|Other Reason|1
6124802|NCT00923091|9749182|FG006|PeriodI-II (Randomized, Double-Blind)|Other Reason|0
6124803|NCT00923091|9749183|FG007|PeriodI-II (Randomized, Double-Blind)|Other Reason|0
6124804|NCT00923091|9749184|FG008|PeriodI-II (Randomized, Double-Blind)|Other Reason|0
6124805|NCT00923091|9749185|FG009|PeriodI-II (Randomized, Double-Blind)|Other Reason|0
6124806|NCT00923091|9749186|FG010|PeriodI-II (Randomized, Double-Blind)|Other Reason|0
6124807|NCT00923091|9749187|FG011|PeriodI-II (Randomized, Double-Blind)|Other Reason|0
6124808|NCT00923091|9749188|FG012|PeriodI-II (Randomized, Double-Blind)|Other Reason|0
6124809|NCT00923091|9749176|FG000|Period III (Single-Blind)|Adverse Event|5
6124810|NCT00923091|9749177|FG001|Period III (Single-Blind)|Adverse Event|0
6124811|NCT00923091|9749178|FG002|Period III (Single-Blind)|Adverse Event|0
6124812|NCT00923091|9749179|FG003|Period III (Single-Blind)|Adverse Event|0
6124813|NCT00923091|9749180|FG004|Period III (Single-Blind)|Adverse Event|0
6124814|NCT00923091|9749181|FG005|Period III (Single-Blind)|Adverse Event|0
6217205|NCT01637402|9885648|FG001|Treatment Regiments Post Week 12|Progression after escalation arm closed|0
6217206|NCT01637584|9885675|FG000|Overall Study|Withdrawal by Subject|1
6217207|NCT01637584|9885676|FG001|Overall Study|Withdrawal by Subject|3
6217208|NCT01637623|9885686|FG000|Overall Study|Lost to Follow-up|0
6217209|NCT01637623|9885687|FG001|Overall Study|Lost to Follow-up|0
6217210|NCT01637623|9885688|FG002|Overall Study|Lost to Follow-up|2
6217211|NCT01637623|9885686|FG000|Overall Study|Physician Decision|1
6217212|NCT01637623|9885687|FG001|Overall Study|Physician Decision|0
6217213|NCT01637623|9885688|FG002|Overall Study|Physician Decision|1
6217214|NCT01637922|9885702|FG000|Overall Study|Adverse Event|0
6217215|NCT01637922|9885703|FG001|Overall Study|Adverse Event|1
6217216|NCT01637922|9885702|FG000|Overall Study|Protocol Violation|0
6217217|NCT01637922|9885703|FG001|Overall Study|Protocol Violation|1
6217218|NCT01637922|9885702|FG000|Overall Study|Withdrawal by Subject|0
6217219|NCT01637922|9885703|FG001|Overall Study|Withdrawal by Subject|3
6217220|NCT01637922|9885702|FG000|Overall Study|Lost to Follow-up|2
6217221|NCT01637922|9885703|FG001|Overall Study|Lost to Follow-up|0
6217222|NCT01637961|9885719|FG000|Overall Study|Ineligible: wrong primary|1
6217223|NCT01637961|9885719|FG000|Overall Study|Ineligible: inadequate pathology|1
6217224|NCT01638000|9885731|FG000|Overall Study|Randomized but Never Received Drug|7
6217225|NCT01638000|9885732|FG001|Overall Study|Randomized but Never Received Drug|10
6217226|NCT01638000|9885731|FG000|Overall Study|Adverse Event|14
6217227|NCT01638000|9885732|FG001|Overall Study|Adverse Event|16
6217228|NCT01638000|9885731|FG000|Overall Study|Lack of Efficacy|5
6217229|NCT01638000|9885732|FG001|Overall Study|Lack of Efficacy|6
6217230|NCT01638000|9885731|FG000|Overall Study|Protocol Violation|11
6217231|NCT01638000|9885732|FG001|Overall Study|Protocol Violation|13
6217232|NCT01638000|9885731|FG000|Overall Study|Withdrawal by Subject|21
6217233|NCT01638000|9885732|FG001|Overall Study|Withdrawal by Subject|24
6217234|NCT01638000|9885731|FG000|Overall Study|Miscellaneous|2
6217235|NCT01638000|9885732|FG001|Overall Study|Miscellaneous|2
6217236|NCT01638013|9885741|FG000|Overall Study|Adverse Event|36
6217237|NCT01638013|9885742|FG001|Overall Study|Adverse Event|29
6217238|NCT01638013|9885743|FG002|Overall Study|Adverse Event|48
6217239|NCT01638013|9885741|FG000|Overall Study|Lack of Efficacy|39
6217240|NCT01638013|9885742|FG001|Overall Study|Lack of Efficacy|11
6124815|NCT00923091|9749182|FG006|Period III (Single-Blind)|Adverse Event|0
6217241|NCT01638013|9885743|FG002|Overall Study|Lack of Efficacy|14
6217242|NCT01638013|9885741|FG000|Overall Study|Protocol Violation|10
6217243|NCT01638013|9885742|FG001|Overall Study|Protocol Violation|7
6217244|NCT01638013|9885743|FG002|Overall Study|Protocol Violation|11
6217245|NCT01638013|9885741|FG000|Overall Study|Met discontinuation criteria|4
6217246|NCT01638013|9885742|FG001|Overall Study|Met discontinuation criteria|0
6217247|NCT01638013|9885743|FG002|Overall Study|Met discontinuation criteria|7
6217248|NCT01638013|9885741|FG000|Overall Study|Subject Lost to Follow up|1
6217249|NCT01638013|9885742|FG001|Overall Study|Subject Lost to Follow up|0
6217250|NCT01638013|9885743|FG002|Overall Study|Subject Lost to Follow up|1
6217251|NCT01638013|9885741|FG000|Overall Study|Miscellaneous|25
6217252|NCT01638013|9885742|FG001|Overall Study|Miscellaneous|19
6217253|NCT01638013|9885743|FG002|Overall Study|Miscellaneous|23
6124816|NCT00923091|9749183|FG007|Period III (Single-Blind)|Adverse Event|0
6124817|NCT00923091|9749184|FG008|Period III (Single-Blind)|Adverse Event|0
6124818|NCT00923091|9749185|FG009|Period III (Single-Blind)|Adverse Event|0
6124819|NCT00923091|9749186|FG010|Period III (Single-Blind)|Adverse Event|0
6124820|NCT00923091|9749187|FG011|Period III (Single-Blind)|Adverse Event|0
6124821|NCT00923091|9749188|FG012|Period III (Single-Blind)|Adverse Event|0
6124822|NCT00923091|9749176|FG000|Period III (Single-Blind)|Withdrawal by Subject|10
6124823|NCT00923091|9749177|FG001|Period III (Single-Blind)|Withdrawal by Subject|0
6124824|NCT00923091|9749178|FG002|Period III (Single-Blind)|Withdrawal by Subject|0
6124825|NCT00923091|9749179|FG003|Period III (Single-Blind)|Withdrawal by Subject|0
6124826|NCT00923091|9749180|FG004|Period III (Single-Blind)|Withdrawal by Subject|0
6124827|NCT00923091|9749181|FG005|Period III (Single-Blind)|Withdrawal by Subject|0
6124828|NCT00923091|9749182|FG006|Period III (Single-Blind)|Withdrawal by Subject|0
6124829|NCT00923091|9749183|FG007|Period III (Single-Blind)|Withdrawal by Subject|0
6124830|NCT00923091|9749184|FG008|Period III (Single-Blind)|Withdrawal by Subject|0
6124831|NCT00923091|9749185|FG009|Period III (Single-Blind)|Withdrawal by Subject|0
6124832|NCT00923091|9749186|FG010|Period III (Single-Blind)|Withdrawal by Subject|0
6124833|NCT00923091|9749187|FG011|Period III (Single-Blind)|Withdrawal by Subject|0
6124834|NCT00923091|9749188|FG012|Period III (Single-Blind)|Withdrawal by Subject|0
6124835|NCT00923091|9749176|FG000|Period III (Single-Blind)|Protocol Violation|3
6124836|NCT00923091|9749177|FG001|Period III (Single-Blind)|Protocol Violation|0
6124837|NCT00923091|9749178|FG002|Period III (Single-Blind)|Protocol Violation|0
6124838|NCT00923091|9749179|FG003|Period III (Single-Blind)|Protocol Violation|0
6124839|NCT00923091|9749180|FG004|Period III (Single-Blind)|Protocol Violation|0
6124840|NCT00923091|9749181|FG005|Period III (Single-Blind)|Protocol Violation|0
6124841|NCT00923091|9749182|FG006|Period III (Single-Blind)|Protocol Violation|0
6124842|NCT00923091|9749183|FG007|Period III (Single-Blind)|Protocol Violation|0
6124843|NCT00923091|9749184|FG008|Period III (Single-Blind)|Protocol Violation|0
6124844|NCT00923091|9749185|FG009|Period III (Single-Blind)|Protocol Violation|0
6124845|NCT00923091|9749186|FG010|Period III (Single-Blind)|Protocol Violation|0
6124846|NCT00923091|9749187|FG011|Period III (Single-Blind)|Protocol Violation|0
6124847|NCT00923091|9749188|FG012|Period III (Single-Blind)|Protocol Violation|0
6124848|NCT00923091|9749176|FG000|Period III (Single-Blind)|Lost to Follow-up|2
6124849|NCT00923091|9749177|FG001|Period III (Single-Blind)|Lost to Follow-up|0
6124850|NCT00923091|9749178|FG002|Period III (Single-Blind)|Lost to Follow-up|0
6124851|NCT00923091|9749179|FG003|Period III (Single-Blind)|Lost to Follow-up|0
6124852|NCT00923091|9749180|FG004|Period III (Single-Blind)|Lost to Follow-up|0
6124853|NCT00923091|9749181|FG005|Period III (Single-Blind)|Lost to Follow-up|0
6124854|NCT00923091|9749182|FG006|Period III (Single-Blind)|Lost to Follow-up|0
6124855|NCT00923091|9749183|FG007|Period III (Single-Blind)|Lost to Follow-up|0
6124856|NCT00923091|9749184|FG008|Period III (Single-Blind)|Lost to Follow-up|0
6124857|NCT00923091|9749185|FG009|Period III (Single-Blind)|Lost to Follow-up|0
6124858|NCT00923091|9749186|FG010|Period III (Single-Blind)|Lost to Follow-up|0
6124859|NCT00923091|9749187|FG011|Period III (Single-Blind)|Lost to Follow-up|0
6124860|NCT00923091|9749188|FG012|Period III (Single-Blind)|Lost to Follow-up|0
6124861|NCT00923091|9749176|FG000|Period IV (Double-Blind)|Adverse Event|2
6124862|NCT00923091|9749177|FG001|Period IV (Double-Blind)|Adverse Event|0
6124863|NCT00923091|9749178|FG002|Period IV (Double-Blind)|Adverse Event|0
6124864|NCT00923091|9749179|FG003|Period IV (Double-Blind)|Adverse Event|0
6124865|NCT00923091|9749180|FG004|Period IV (Double-Blind)|Adverse Event|0
6124866|NCT00923091|9749181|FG005|Period IV (Double-Blind)|Adverse Event|0
6124867|NCT00923091|9749182|FG006|Period IV (Double-Blind)|Adverse Event|0
6124868|NCT00923091|9749183|FG007|Period IV (Double-Blind)|Adverse Event|0
6124869|NCT00923091|9749184|FG008|Period IV (Double-Blind)|Adverse Event|0
6124870|NCT00923091|9749185|FG009|Period IV (Double-Blind)|Adverse Event|0
6124871|NCT00923091|9749186|FG010|Period IV (Double-Blind)|Adverse Event|0
6124872|NCT00923091|9749187|FG011|Period IV (Double-Blind)|Adverse Event|0
6124873|NCT00923091|9749188|FG012|Period IV (Double-Blind)|Adverse Event|0
6124874|NCT00923091|9749176|FG000|Period IV (Double-Blind)|Withdrawal by Subject|0
6124875|NCT00923091|9749177|FG001|Period IV (Double-Blind)|Withdrawal by Subject|1
6124876|NCT00923091|9749178|FG002|Period IV (Double-Blind)|Withdrawal by Subject|0
6124877|NCT00923091|9749179|FG003|Period IV (Double-Blind)|Withdrawal by Subject|0
6124878|NCT00923091|9749180|FG004|Period IV (Double-Blind)|Withdrawal by Subject|0
6217254|NCT01638013|9885741|FG000|Overall Study|Withdrawal of Consent|16
6217255|NCT01638013|9885742|FG001|Overall Study|Withdrawal of Consent|12
6124879|NCT00923091|9749181|FG005|Period IV (Double-Blind)|Withdrawal by Subject|0
6124880|NCT00923091|9749182|FG006|Period IV (Double-Blind)|Withdrawal by Subject|0
6124881|NCT00923091|9749183|FG007|Period IV (Double-Blind)|Withdrawal by Subject|0
6124882|NCT00923091|9749184|FG008|Period IV (Double-Blind)|Withdrawal by Subject|0
6124883|NCT00923091|9749185|FG009|Period IV (Double-Blind)|Withdrawal by Subject|0
6124884|NCT00923091|9749186|FG010|Period IV (Double-Blind)|Withdrawal by Subject|0
6124885|NCT00923091|9749187|FG011|Period IV (Double-Blind)|Withdrawal by Subject|0
6217256|NCT01638013|9885743|FG002|Overall Study|Withdrawal of Consent|16
6124886|NCT00923091|9749188|FG012|Period IV (Double-Blind)|Withdrawal by Subject|0
6124887|NCT00923091|9749176|FG000|Period IV (Double-Blind)|Protocol Violation|0
6217257|NCT01638013|9885741|FG000|Overall Study|Not met inclusion or exclusion criteria|0
6124888|NCT00923091|9749177|FG001|Period IV (Double-Blind)|Protocol Violation|1
6124889|NCT00923091|9749178|FG002|Period IV (Double-Blind)|Protocol Violation|0
6124890|NCT00923091|9749179|FG003|Period IV (Double-Blind)|Protocol Violation|0
6124891|NCT00923091|9749180|FG004|Period IV (Double-Blind)|Protocol Violation|0
6124892|NCT00923091|9749181|FG005|Period IV (Double-Blind)|Protocol Violation|0
6124893|NCT00923091|9749182|FG006|Period IV (Double-Blind)|Protocol Violation|0
6124894|NCT00923091|9749183|FG007|Period IV (Double-Blind)|Protocol Violation|0
6124895|NCT00923091|9749184|FG008|Period IV (Double-Blind)|Protocol Violation|0
6124896|NCT00923091|9749185|FG009|Period IV (Double-Blind)|Protocol Violation|0
6124897|NCT00923091|9749186|FG010|Period IV (Double-Blind)|Protocol Violation|0
6124898|NCT00923091|9749187|FG011|Period IV (Double-Blind)|Protocol Violation|0
6124899|NCT00923091|9749188|FG012|Period IV (Double-Blind)|Protocol Violation|0
6124900|NCT00923091|9749176|FG000|Period V (Double -Blind)|Withdrawal by Subject|0
6124901|NCT00923091|9749177|FG001|Period V (Double -Blind)|Withdrawal by Subject|0
6124902|NCT00923091|9749178|FG002|Period V (Double -Blind)|Withdrawal by Subject|0
6124903|NCT00923091|9749179|FG003|Period V (Double -Blind)|Withdrawal by Subject|0
6124904|NCT00923091|9749180|FG004|Period V (Double -Blind)|Withdrawal by Subject|0
6124905|NCT00923091|9749181|FG005|Period V (Double -Blind)|Withdrawal by Subject|0
6124906|NCT00923091|9749182|FG006|Period V (Double -Blind)|Withdrawal by Subject|0
6124907|NCT00923091|9749183|FG007|Period V (Double -Blind)|Withdrawal by Subject|0
6124908|NCT00923091|9749184|FG008|Period V (Double -Blind)|Withdrawal by Subject|1
6124909|NCT00923091|9749185|FG009|Period V (Double -Blind)|Withdrawal by Subject|0
6124910|NCT00923091|9749186|FG010|Period V (Double -Blind)|Withdrawal by Subject|0
6124911|NCT00923091|9749187|FG011|Period V (Double -Blind)|Withdrawal by Subject|0
6124912|NCT00923091|9749188|FG012|Period V (Double -Blind)|Withdrawal by Subject|1
6124913|NCT00923091|9749176|FG000|Period V (Double -Blind)|Protocol Violation|0
6124914|NCT00923091|9749177|FG001|Period V (Double -Blind)|Protocol Violation|0
6124915|NCT00923091|9749178|FG002|Period V (Double -Blind)|Protocol Violation|0
6124916|NCT00923091|9749179|FG003|Period V (Double -Blind)|Protocol Violation|0
6124917|NCT00923091|9749180|FG004|Period V (Double -Blind)|Protocol Violation|0
6124918|NCT00923091|9749181|FG005|Period V (Double -Blind)|Protocol Violation|0
6217258|NCT01638013|9885742|FG001|Overall Study|Not met inclusion or exclusion criteria|0
6217259|NCT01638013|9885743|FG002|Overall Study|Not met inclusion or exclusion criteria|1
6217260|NCT01638390|9885773|FG000|Overall Study|screening failures|21
6217261|NCT01638429|9885794|FG000|Overall Study|Withdrawal by Subject|1
6217262|NCT01638546|9885814|FG000|Overall Study|Adverse Event|1
6217263|NCT01638546|9885815|FG001|Overall Study|Adverse Event|3
6217264|NCT01638559|9885823|FG000|Overall Study|Lost to Follow-up|1
6217265|NCT01638559|9885823|FG000|Overall Study|Withdrawal by Subject|1
6217266|NCT01638559|9885823|FG000|Overall Study|Subject declined to travel for biopsy|1
6217267|NCT01638819|9885840|FG000|Overall Study|Lost to Follow-up|1
6217268|NCT01638819|9885841|FG001|Overall Study|Lost to Follow-up|0
6217269|NCT01639001|9885848|FG000|Overall Study|Refused further follow-up|9
6217270|NCT01639001|9885849|FG001|Overall Study|Refused further follow-up|12
6217271|NCT01639001|9885848|FG000|Overall Study|Lost to Follow-up|3
6217272|NCT01639001|9885849|FG001|Overall Study|Lost to Follow-up|0
6217273|NCT01639001|9885848|FG000|Overall Study|Death|62
6217274|NCT01639001|9885849|FG001|Overall Study|Death|61
6217275|NCT01639001|9885848|FG000|Overall Study|Randomized but not treated|0
6217276|NCT01639001|9885849|FG001|Overall Study|Randomized but not treated|2
6217277|NCT01639001|9885848|FG000|Overall Study|Long-term follow-up participants who did not respond to the contact from their study sites.|1
6217278|NCT01639001|9885849|FG001|Overall Study|Long-term follow-up participants who did not respond to the contact from their study sites.|2
6217279|NCT01639040|9885859|FG000|Overall Study|Adverse Event|1
6217280|NCT01639040|9885860|FG001|Overall Study|Adverse Event|0
6217281|NCT01639144|9885871|FG000|Overall Study|Withdrawal by Subject|4
6217282|NCT01639144|9885872|FG001|Overall Study|Withdrawal by Subject|2
6217283|NCT01639144|9885871|FG000|Overall Study|Physician Decision|2
6217284|NCT01639144|9885872|FG001|Overall Study|Physician Decision|0
6217285|NCT01639144|9885871|FG000|Overall Study|Met postoperative exclusion criteria|4
6217286|NCT01639144|9885872|FG001|Overall Study|Met postoperative exclusion criteria|3
6217287|NCT01639339|9885893|FG000|Double-blind Period (Up to Week 104)|Withdrawal by Subject|26
6217288|NCT01639339|9885894|FG001|Double-blind Period (Up to Week 104)|Withdrawal by Subject|19
6217289|NCT01639339|9885893|FG000|Double-blind Period (Up to Week 104)|Physician Decision|11
6217290|NCT01639339|9885894|FG001|Double-blind Period (Up to Week 104)|Physician Decision|5
6217291|NCT01639339|9885893|FG000|Double-blind Period (Up to Week 104)|Lost to Follow-up|5
6217292|NCT01639339|9885894|FG001|Double-blind Period (Up to Week 104)|Lost to Follow-up|4
6217293|NCT01639339|9885893|FG000|Double-blind Period (Up to Week 104)|Protocol Violation|0
6217294|NCT01639339|9885894|FG001|Double-blind Period (Up to Week 104)|Protocol Violation|2
6217295|NCT01639339|9885893|FG000|Double-blind Period (Up to Week 104)|Lack of Efficacy|2
6217296|NCT01639339|9885894|FG001|Double-blind Period (Up to Week 104)|Lack of Efficacy|1
6124919|NCT00923091|9749182|FG006|Period V (Double -Blind)|Protocol Violation|0
6124920|NCT00923091|9749183|FG007|Period V (Double -Blind)|Protocol Violation|0
6124921|NCT00923091|9749184|FG008|Period V (Double -Blind)|Protocol Violation|0
6124922|NCT00923091|9749185|FG009|Period V (Double -Blind)|Protocol Violation|0
6124923|NCT00923091|9749186|FG010|Period V (Double -Blind)|Protocol Violation|0
6124924|NCT00923091|9749187|FG011|Period V (Double -Blind)|Protocol Violation|0
6124925|NCT00923091|9749188|FG012|Period V (Double -Blind)|Protocol Violation|1
6124926|NCT00923091|9749176|FG000|Period V (Double -Blind)|Lost to Follow-up|0
6124927|NCT00923091|9749177|FG001|Period V (Double -Blind)|Lost to Follow-up|0
6124928|NCT00923091|9749178|FG002|Period V (Double -Blind)|Lost to Follow-up|0
6124929|NCT00923091|9749179|FG003|Period V (Double -Blind)|Lost to Follow-up|0
6124930|NCT00923091|9749180|FG004|Period V (Double -Blind)|Lost to Follow-up|0
6217297|NCT01639339|9885893|FG000|Double-blind Period (Up to Week 104)|Adverse Event|10
6217298|NCT01639339|9885894|FG001|Double-blind Period (Up to Week 104)|Adverse Event|7
6217299|NCT01639339|9885893|FG000|Open-label Period (Up to Week 28)|Withdrawal by Subject|0
6217300|NCT01639339|9885894|FG001|Open-label Period (Up to Week 28)|Withdrawal by Subject|2
6217301|NCT01639339|9885893|FG000|Open-label Period (Up to Week 28)|Lost to Follow-up|0
6217302|NCT01639339|9885894|FG001|Open-label Period (Up to Week 28)|Lost to Follow-up|1
6217303|NCT01639339|9885893|FG000|Open-label Period (Up to Week 28)|Protocol Violation|0
6217304|NCT01639339|9885894|FG001|Open-label Period (Up to Week 28)|Protocol Violation|1
6217305|NCT01639339|9885893|FG000|Open-label Period (Up to Week 28)|Adverse Event|1
6217306|NCT01639339|9885894|FG001|Open-label Period (Up to Week 28)|Adverse Event|4
6217307|NCT01639469|9885919|FG000|Overall Study|Death|4
6217308|NCT01639469|9885920|FG001|Overall Study|Death|2
6217309|NCT01639469|9885919|FG000|Overall Study|Lost to Follow-up|1
6217310|NCT01639469|9885920|FG001|Overall Study|Lost to Follow-up|1
6217311|NCT01639495|9885926|FG000|Overall Study|Lost to Follow-up|6
6217312|NCT01639495|9885926|FG000|Overall Study|Consented but didn't have study catheter|4
6217313|NCT01639495|9885926|FG000|Overall Study|Not meeting inclusion/exclusion criteria|4
6217314|NCT01639495|9885926|FG000|Overall Study|No radiofrequency energy applied|2
6217315|NCT01639560|9885932|FG000|Overall Study|Withdrawal by Subject|9
6217316|NCT01639560|9885933|FG001|Overall Study|Withdrawal by Subject|14
6217317|NCT01639560|9885932|FG000|Overall Study|Lack of Efficacy|1
6217318|NCT01639560|9885933|FG001|Overall Study|Lack of Efficacy|2
6288213|NCT02362724|10001737|FG001|Overall Study|Withdrawal by Subject|1
6288214|NCT02362724|10001736|FG000|Overall Study|Adverse Event|3
6288215|NCT02362724|10001737|FG001|Overall Study|Adverse Event|0
6288216|NCT02362789|10001745|FG000|Run-in Phase (Week 0 to 16)|Death unrelated to study treatment|1
6288217|NCT02362789|10001746|FG001|Run-in Phase (Week 0 to 16)|Death unrelated to study treatment|0
6288218|NCT02362789|10001747|FG002|Run-in Phase (Week 0 to 16)|Death unrelated to study treatment|0
6288219|NCT02362789|10001745|FG000|Run-in Phase (Week 0 to 16)|Adverse Event|1
6288220|NCT02362789|10001746|FG001|Run-in Phase (Week 0 to 16)|Adverse Event|0
6288221|NCT02362789|10001747|FG002|Run-in Phase (Week 0 to 16)|Adverse Event|0
6288222|NCT02362789|10001745|FG000|Randomized Withdrawal (Wk 16 to 32)|Lack of Efficacy|0
6288223|NCT02362789|10001746|FG001|Randomized Withdrawal (Wk 16 to 32)|Lack of Efficacy|2
6288224|NCT02362789|10001747|FG002|Randomized Withdrawal (Wk 16 to 32)|Lack of Efficacy|6
6288225|NCT02362789|10001745|FG000|Randomized Withdrawal (Wk 16 to 32)|Withdrawal by Subject|0
6288226|NCT02362789|10001746|FG001|Randomized Withdrawal (Wk 16 to 32)|Withdrawal by Subject|1
6288227|NCT02362789|10001747|FG002|Randomized Withdrawal (Wk 16 to 32)|Withdrawal by Subject|4
6288228|NCT02362789|10001745|FG000|Randomized Withdrawal (Wk 16 to 32)|Subject/guardian decision|0
6288229|NCT02362789|10001746|FG001|Randomized Withdrawal (Wk 16 to 32)|Subject/guardian decision|1
6288230|NCT02362789|10001747|FG002|Randomized Withdrawal (Wk 16 to 32)|Subject/guardian decision|2
6288231|NCT02363283|10001763|FG000|Overall Study|Withdrawal by Subject|1
6288232|NCT02363283|10001763|FG000|Overall Study|Not eligible due to transaminitis|1
6288233|NCT02363322|10001769|FG000|Overall Study|Lost to Follow-up|1
6288234|NCT02363322|10001770|FG001|Overall Study|Lost to Follow-up|0
6288235|NCT02363439|10001776|FG000|Overall Study|Lack of Efficacy|4
6288236|NCT02363478|10001780|FG000|Overall Study|Lost to Follow-up|4
6217319|NCT01639560|9885932|FG000|Overall Study|Lost to Follow-up|9
6217320|NCT01639560|9885933|FG001|Overall Study|Lost to Follow-up|11
6217321|NCT01639560|9885932|FG000|Overall Study|Adverse Event|0
6217322|NCT01639560|9885933|FG001|Overall Study|Adverse Event|2
6217323|NCT01639703|9885962|FG000|Overall Study|Withdrawal by Subject|5
6217324|NCT01639703|9885962|FG000|Overall Study|Other reason|7
6217325|NCT01639729|9885978|FG000|Overall Study|Withdrawal by Subject|1
6217326|NCT01639729|9885979|FG001|Overall Study|Withdrawal by Subject|0
6217327|NCT01639729|9885980|FG002|Overall Study|Withdrawal by Subject|1
6217328|NCT01639729|9885981|FG003|Overall Study|Withdrawal by Subject|1
6217329|NCT01639729|9885982|FG004|Overall Study|Withdrawal by Subject|0
6217330|NCT01639729|9885983|FG005|Overall Study|Withdrawal by Subject|0
6217331|NCT01639742|9885993|FG000|Overall Study|Study Ongoing|17
6217332|NCT01639742|9885993|FG000|Overall Study|Lost to Follow-up|1
6217333|NCT01639755|9885997|FG000|Overall Study|Study Ongoing|15
6217334|NCT01639755|9885997|FG000|Overall Study|Patient had device explantation|4
6217335|NCT01639833|9886003|FG000|Overall Study|Death|4
6217336|NCT01639833|9886004|FG001|Overall Study|Death|2
6217337|NCT01639833|9886003|FG000|Overall Study|Withdrawal by Subject|2
6217338|NCT01639833|9886004|FG001|Overall Study|Withdrawal by Subject|2
6217339|NCT01640054|9886019|FG000|Overall Study|Study-specific disc criteria|1
6217340|NCT01640054|9886019|FG000|Overall Study|Lack of Efficacy|3
6217341|NCT01640054|9886019|FG000|Overall Study|Adverse Event|2
6217342|NCT01640184|9886031|FG000|Overall Study|Death|1
6217343|NCT01640184|9886032|FG001|Overall Study|Death|0
6217344|NCT01640184|9886033|FG002|Overall Study|Death|0
6124931|NCT00923091|9749181|FG005|Period V (Double -Blind)|Lost to Follow-up|0
6124932|NCT00923091|9749182|FG006|Period V (Double -Blind)|Lost to Follow-up|0
6124933|NCT00923091|9749183|FG007|Period V (Double -Blind)|Lost to Follow-up|0
6124934|NCT00923091|9749184|FG008|Period V (Double -Blind)|Lost to Follow-up|0
6124935|NCT00923091|9749185|FG009|Period V (Double -Blind)|Lost to Follow-up|0
6124936|NCT00923091|9749186|FG010|Period V (Double -Blind)|Lost to Follow-up|1
6124937|NCT00923091|9749187|FG011|Period V (Double -Blind)|Lost to Follow-up|0
6124938|NCT00923091|9749188|FG012|Period V (Double -Blind)|Lost to Follow-up|0
6124939|NCT00923091|9749176|FG000|Period VI (Open-Label)|Adverse Event|17
6124940|NCT00923091|9749177|FG001|Period VI (Open-Label)|Adverse Event|0
6124941|NCT00923091|9749178|FG002|Period VI (Open-Label)|Adverse Event|4
6288237|NCT02363478|10001780|FG000|Overall Study|Adverse Event|4
6288238|NCT02363686|10001794|FG000|Overall Study|Withdrawal by Subject|22
6288239|NCT02363686|10001794|FG000|Overall Study|incomplete FEES examinations|13
6288240|NCT02363738|10001800|FG000|Overall Study|Adverse Event|5
6288241|NCT02363738|10001801|FG001|Overall Study|Adverse Event|2
6288242|NCT02363738|10001800|FG000|Overall Study|Lack of Efficacy|1
6288243|NCT02363738|10001801|FG001|Overall Study|Lack of Efficacy|2
6288244|NCT02363738|10001800|FG000|Overall Study|Lost to Follow-up|2
6288245|NCT02363738|10001801|FG001|Overall Study|Lost to Follow-up|1
6288246|NCT02363946|10001843|FG000|Overall Study|Lost to Follow-up|0
6124942|NCT00923091|9749179|FG003|Period VI (Open-Label)|Adverse Event|1
6124943|NCT00923091|9749180|FG004|Period VI (Open-Label)|Adverse Event|1
6124944|NCT00923091|9749181|FG005|Period VI (Open-Label)|Adverse Event|0
6124945|NCT00923091|9749182|FG006|Period VI (Open-Label)|Adverse Event|0
6124946|NCT00923091|9749183|FG007|Period VI (Open-Label)|Adverse Event|0
6124947|NCT00923091|9749184|FG008|Period VI (Open-Label)|Adverse Event|0
6124948|NCT00923091|9749185|FG009|Period VI (Open-Label)|Adverse Event|0
6124949|NCT00923091|9749186|FG010|Period VI (Open-Label)|Adverse Event|0
6124950|NCT00923091|9749187|FG011|Period VI (Open-Label)|Adverse Event|0
6124951|NCT00923091|9749188|FG012|Period VI (Open-Label)|Adverse Event|0
6124952|NCT00923091|9749176|FG000|Period VI (Open-Label)|Withdrawal by Subject|15
6124953|NCT00923091|9749177|FG001|Period VI (Open-Label)|Withdrawal by Subject|7
6124954|NCT00923091|9749178|FG002|Period VI (Open-Label)|Withdrawal by Subject|5
6124955|NCT00923091|9749179|FG003|Period VI (Open-Label)|Withdrawal by Subject|0
6124956|NCT00923091|9749180|FG004|Period VI (Open-Label)|Withdrawal by Subject|1
6124957|NCT00923091|9749181|FG005|Period VI (Open-Label)|Withdrawal by Subject|0
6124958|NCT00923091|9749182|FG006|Period VI (Open-Label)|Withdrawal by Subject|0
6124959|NCT00923091|9749183|FG007|Period VI (Open-Label)|Withdrawal by Subject|0
6124960|NCT00923091|9749184|FG008|Period VI (Open-Label)|Withdrawal by Subject|0
6124961|NCT00923091|9749185|FG009|Period VI (Open-Label)|Withdrawal by Subject|0
6124962|NCT00923091|9749186|FG010|Period VI (Open-Label)|Withdrawal by Subject|0
6124963|NCT00923091|9749187|FG011|Period VI (Open-Label)|Withdrawal by Subject|0
6124964|NCT00923091|9749188|FG012|Period VI (Open-Label)|Withdrawal by Subject|0
6124965|NCT00923091|9749176|FG000|Period VI (Open-Label)|Protocol Violation|6
6124966|NCT00923091|9749177|FG001|Period VI (Open-Label)|Protocol Violation|1
6124967|NCT00923091|9749178|FG002|Period VI (Open-Label)|Protocol Violation|3
6124968|NCT00923091|9749179|FG003|Period VI (Open-Label)|Protocol Violation|1
6217345|NCT01640184|9886031|FG000|Overall Study|Lost to Follow-up|4
6217346|NCT01640184|9886032|FG001|Overall Study|Lost to Follow-up|1
6217347|NCT01640184|9886033|FG002|Overall Study|Lost to Follow-up|0
6217348|NCT01640184|9886031|FG000|Overall Study|Physician Decision|3
6217349|NCT01640184|9886032|FG001|Overall Study|Physician Decision|0
6217350|NCT01640184|9886033|FG002|Overall Study|Physician Decision|0
6217351|NCT01640184|9886031|FG000|Overall Study|Withdrawal by Subject|0
6217352|NCT01640184|9886032|FG001|Overall Study|Withdrawal by Subject|1
6217353|NCT01640184|9886033|FG002|Overall Study|Withdrawal by Subject|1
6217354|NCT01640184|9886031|FG000|Overall Study|Protocol Violation|0
6217355|NCT01640184|9886032|FG001|Overall Study|Protocol Violation|0
6217356|NCT01640184|9886033|FG002|Overall Study|Protocol Violation|1
6217357|NCT01640249|9886060|FG000|Period 1|Withdrawal by Subject|1
6217358|NCT01640249|9886061|FG001|Period 1|Withdrawal by Subject|0
6217359|NCT01640249|9886062|FG002|Period 1|Withdrawal by Subject|0
6217360|NCT01640249|9886063|FG003|Period 1|Withdrawal by Subject|0
6217361|NCT01640249|9886064|FG004|Period 1|Withdrawal by Subject|0
6217362|NCT01640249|9886065|FG005|Period 1|Withdrawal by Subject|1
6217363|NCT01640249|9886066|FG006|Period 1|Withdrawal by Subject|0
6217364|NCT01640288|9886087|FG000|Overall Study|Equipment Failure or Poor Image Quality|4
6217365|NCT01640288|9886088|FG001|Overall Study|Equipment Failure or Poor Image Quality|5
6124969|NCT00923091|9749180|FG004|Period VI (Open-Label)|Protocol Violation|4
6124970|NCT00923091|9749181|FG005|Period VI (Open-Label)|Protocol Violation|0
6124971|NCT00923091|9749182|FG006|Period VI (Open-Label)|Protocol Violation|0
6124972|NCT00923091|9749183|FG007|Period VI (Open-Label)|Protocol Violation|0
6124973|NCT00923091|9749184|FG008|Period VI (Open-Label)|Protocol Violation|0
6124974|NCT00923091|9749185|FG009|Period VI (Open-Label)|Protocol Violation|0
6124975|NCT00923091|9749186|FG010|Period VI (Open-Label)|Protocol Violation|0
6217366|NCT01640288|9886087|FG000|Overall Study|Screen Failure|20
6217367|NCT01640288|9886088|FG001|Overall Study|Screen Failure|18
6217368|NCT01640288|9886087|FG000|Overall Study|Withdrawn by PI|5
6217369|NCT01640288|9886088|FG001|Overall Study|Withdrawn by PI|0
6288247|NCT02363946|10001844|FG001|Overall Study|Lost to Follow-up|0
6124976|NCT00923091|9749187|FG011|Period VI (Open-Label)|Protocol Violation|0
6124977|NCT00923091|9749188|FG012|Period VI (Open-Label)|Protocol Violation|0
6124978|NCT00923091|9749176|FG000|Period VI (Open-Label)|Lost to Follow-up|1
6124979|NCT00923091|9749177|FG001|Period VI (Open-Label)|Lost to Follow-up|0
6124980|NCT00923091|9749178|FG002|Period VI (Open-Label)|Lost to Follow-up|1
6124981|NCT00923091|9749179|FG003|Period VI (Open-Label)|Lost to Follow-up|0
6124982|NCT00923091|9749180|FG004|Period VI (Open-Label)|Lost to Follow-up|0
6124983|NCT00923091|9749181|FG005|Period VI (Open-Label)|Lost to Follow-up|0
6124984|NCT00923091|9749182|FG006|Period VI (Open-Label)|Lost to Follow-up|0
6124985|NCT00923091|9749183|FG007|Period VI (Open-Label)|Lost to Follow-up|0
6124986|NCT00923091|9749184|FG008|Period VI (Open-Label)|Lost to Follow-up|0
6124987|NCT00923091|9749185|FG009|Period VI (Open-Label)|Lost to Follow-up|0
6124988|NCT00923091|9749186|FG010|Period VI (Open-Label)|Lost to Follow-up|0
6124989|NCT00923091|9749187|FG011|Period VI (Open-Label)|Lost to Follow-up|0
6124990|NCT00923091|9749188|FG012|Period VI (Open-Label)|Lost to Follow-up|0
6124991|NCT00923091|9749176|FG000|Period VI (Open-Label)|Other Reason|0
6124992|NCT00923091|9749177|FG001|Period VI (Open-Label)|Other Reason|0
6124993|NCT00923091|9749178|FG002|Period VI (Open-Label)|Other Reason|0
6124994|NCT00923091|9749179|FG003|Period VI (Open-Label)|Other Reason|1
6124995|NCT00923091|9749180|FG004|Period VI (Open-Label)|Other Reason|1
6124996|NCT00923091|9749181|FG005|Period VI (Open-Label)|Other Reason|0
6124997|NCT00923091|9749182|FG006|Period VI (Open-Label)|Other Reason|0
6124998|NCT00923091|9749183|FG007|Period VI (Open-Label)|Other Reason|0
6124999|NCT00923091|9749184|FG008|Period VI (Open-Label)|Other Reason|0
6125000|NCT00923091|9749185|FG009|Period VI (Open-Label)|Other Reason|0
6125001|NCT00923091|9749186|FG010|Period VI (Open-Label)|Other Reason|0
6125002|NCT00923091|9749187|FG011|Period VI (Open-Label)|Other Reason|0
6125003|NCT00923091|9749188|FG012|Period VI (Open-Label)|Other Reason|0
6125004|NCT00923130|9749222|FG000|Overall Study|Stopped treatment due to progression|17
6125005|NCT00923130|9749222|FG000|Overall Study|Death|1
6125006|NCT00923130|9749222|FG000|Overall Study|Discontinued treatment due to toxicities|3
6125007|NCT00923130|9749222|FG000|Overall Study|Switched to alternative treatment|2
6125008|NCT00923130|9749222|FG000|Overall Study|Refused further treatment|2
6125009|NCT00923156|9749229|FG000|Overall Study|Adverse Event|0
6125010|NCT00923156|9749230|FG001|Overall Study|Adverse Event|2
6125011|NCT00923156|9749231|FG002|Overall Study|Adverse Event|1
6125012|NCT00923156|9749229|FG000|Overall Study|Abnormal laboratory values|0
6125013|NCT00923156|9749230|FG001|Overall Study|Abnormal laboratory values|0
6125014|NCT00923156|9749231|FG002|Overall Study|Abnormal laboratory values|1
6125015|NCT00923156|9749229|FG000|Overall Study|Withdrawal by Subject|0
6125016|NCT00923156|9749230|FG001|Overall Study|Withdrawal by Subject|1
6125017|NCT00923156|9749231|FG002|Overall Study|Withdrawal by Subject|0
6125018|NCT00923156|9749229|FG000|Overall Study|Death|0
6125019|NCT00923156|9749230|FG001|Overall Study|Death|1
6125020|NCT00923156|9749231|FG002|Overall Study|Death|0
6125021|NCT00923156|9749229|FG000|Overall Study|Lack of Efficacy|0
6217370|NCT01640288|9886087|FG000|Overall Study|Withdrawal by Subject|1
6217371|NCT01640288|9886088|FG001|Overall Study|Withdrawal by Subject|0
6217372|NCT01640314|9886097|FG000|Overall Study|Protocol Violation|0
6217373|NCT01640314|9886098|FG001|Overall Study|Protocol Violation|1
6217374|NCT01640353|9886122|FG000|Overall Study|Withdrew prior to treatment|10
6217375|NCT01640353|9886122|FG000|Overall Study|Withdrawn from analysis at term site|12
6217376|NCT01640353|9886122|FG000|Overall Study|Withdrawal by Subject|5
6217377|NCT01640353|9886122|FG000|Overall Study|Death|2
6217378|NCT01640353|9886122|FG000|Overall Study|Early site termination|3
6217379|NCT01640353|9886122|FG000|Overall Study|Lost to Follow-up|12
6217380|NCT01640353|9886122|FG000|Overall Study|Physician Decision|1
6217381|NCT01640366|9886126|FG000|Overall Study|Withdrawal by Subject|1
6217382|NCT01640366|9886126|FG000|Overall Study|Protocol Violation|16
6217383|NCT01640366|9886126|FG000|Overall Study|Lost to Follow-up|5
6125022|NCT00923156|9749230|FG001|Overall Study|Lack of Efficacy|0
6125023|NCT00923156|9749231|FG002|Overall Study|Lack of Efficacy|1
6125024|NCT00923195|9749241|FG000|Overall Study|Death|0
6125025|NCT00923195|9749242|FG001|Overall Study|Death|1
6125026|NCT00923260|9749250|FG000|Overall Study|Lost to Follow-up|1
6125027|NCT00923260|9749251|FG001|Overall Study|Lost to Follow-up|1
6125028|NCT00923273|9749262|FG000|Phase II Treatment Period|NE-brain mets/met disease prior enrollmt|0
6125029|NCT00923273|9749263|FG001|Phase II Treatment Period|NE-brain mets/met disease prior enrollmt|0
6125030|NCT00923273|9749264|FG002|Phase II Treatment Period|NE-brain mets/met disease prior enrollmt|0
6125031|NCT00923273|9749265|FG003|Phase II Treatment Period|NE-brain mets/met disease prior enrollmt|1
6125032|NCT00923273|9749266|FG004|Phase II Treatment Period|NE-brain mets/met disease prior enrollmt|0
6125033|NCT00923273|9749262|FG000|Phase II Treatment Period|NE-not complete 2Cy trmt/no imaging done|0
6125034|NCT00923273|9749263|FG001|Phase II Treatment Period|NE-not complete 2Cy trmt/no imaging done|0
6125035|NCT00923273|9749264|FG002|Phase II Treatment Period|NE-not complete 2Cy trmt/no imaging done|0
6125036|NCT00923273|9749265|FG003|Phase II Treatment Period|NE-not complete 2Cy trmt/no imaging done|6
6125037|NCT00923273|9749266|FG004|Phase II Treatment Period|NE-not complete 2Cy trmt/no imaging done|0
6125038|NCT00923351|9749286|FG000|Overall Study|no apheresis/adequate tumor sample|0
6125039|NCT00923351|9749287|FG001|Overall Study|no apheresis/adequate tumor sample|0
6217384|NCT01640808|9886148|FG000|Overall Study|Unable to continue dynamic CT|14
6125040|NCT00923351|9749288|FG002|Overall Study|no apheresis/adequate tumor sample|12
6217385|NCT01640808|9886149|FG001|Overall Study|Unable to continue dynamic CT|4
6217386|NCT01640808|9886148|FG000|Overall Study|Withdrawal by Subject|12
6217387|NCT01640808|9886149|FG001|Overall Study|Withdrawal by Subject|4
6217388|NCT01640808|9886148|FG000|Overall Study|Lost to Follow-up|4
6217389|NCT01640808|9886149|FG001|Overall Study|Lost to Follow-up|0
6217390|NCT01640808|9886148|FG000|Overall Study|Start an antiviral therapy using IFN|3
6125041|NCT00923364|9749294|FG000|Overall Study|Death|3
6125042|NCT00923364|9749295|FG001|Overall Study|Death|0
6125043|NCT00923364|9749294|FG000|Overall Study|Did not go to transplant|1
6125044|NCT00923364|9749295|FG001|Overall Study|Did not go to transplant|0
6125045|NCT00923559|9749306|FG000|Overall Study|Lost to Follow-up|2
6125046|NCT00923559|9749307|FG001|Overall Study|Lost to Follow-up|3
6125047|NCT00923845|9749326|FG000|Induction Therapy|Poor performance status|0
6125048|NCT00923845|9749327|FG001|Induction Therapy|Poor performance status|2
6125049|NCT00923936|9749344|FG000|Overall Study|progressive disease on study|2
6125050|NCT00923936|9749345|FG001|Overall Study|progressive disease on study|1
6125051|NCT00923936|9749344|FG000|Overall Study|Adverse Event|2
6125052|NCT00923936|9749345|FG001|Overall Study|Adverse Event|1
6125053|NCT00923936|9749344|FG000|Overall Study|Lost to follow up|2
6125054|NCT00923936|9749345|FG001|Overall Study|Lost to follow up|0
6125055|NCT00923936|9749344|FG000|Overall Study|Continuing in follow up period|2
6125056|NCT00923936|9749345|FG001|Overall Study|Continuing in follow up period|1
6125057|NCT00923975|9749357|FG000|Overall Study|Did not meet inclusion criteria|1
6125058|NCT00924287|9749404|FG000|Overall Study|Death|1
6125059|NCT00924313|9749408|FG000|Overall Study|not imaged due to failed tracer imaging|1
6125060|NCT00924404|9749422|FG000|Overall Study|Lost to Follow-up|6
6125061|NCT00924404|9749423|FG001|Overall Study|Lost to Follow-up|4
6125062|NCT00924443|9749429|FG000|Overall Study|Physician Decision|2
6125063|NCT00924443|9749429|FG000|Overall Study|Protocol Violation|1
6125064|NCT00924469|9749435|FG000|Overall Study|Adverse Event|2
6125065|NCT00924469|9749436|FG001|Overall Study|Adverse Event|0
6125066|NCT00924469|9749435|FG000|Overall Study|Withdrawal by Subject|0
6125067|NCT00924469|9749436|FG001|Overall Study|Withdrawal by Subject|1
6125068|NCT00924469|9749435|FG000|Overall Study|Lost to Follow-up|0
6125069|NCT00924469|9749436|FG001|Overall Study|Lost to Follow-up|1
6125070|NCT00924508|9749447|FG000|Overall Study|Withdrawal by Subject|3
6125071|NCT00924560|9749457|FG000|Overall Study|Did Not Meet Protocol Requirements|4
6125072|NCT00924560|9749458|FG001|Overall Study|Did Not Meet Protocol Requirements|2
6125073|NCT00924560|9749459|FG002|Overall Study|Did Not Meet Protocol Requirements|1
6125074|NCT00924560|9749457|FG000|Overall Study|Non Compliance with the Protocol|20
6125075|NCT00924560|9749458|FG001|Overall Study|Non Compliance with the Protocol|15
6125076|NCT00924560|9749459|FG002|Overall Study|Non Compliance with the Protocol|4
6125077|NCT00924560|9749457|FG000|Overall Study|Physician Decision|2
6125078|NCT00924560|9749458|FG001|Overall Study|Physician Decision|3
6125079|NCT00924560|9749459|FG002|Overall Study|Physician Decision|4
6125080|NCT00924560|9749457|FG000|Overall Study|Withdrawal by Subject|50
6125081|NCT00924560|9749458|FG001|Overall Study|Withdrawal by Subject|44
6125082|NCT00924560|9749459|FG002|Overall Study|Withdrawal by Subject|18
6125083|NCT00924560|9749457|FG000|Overall Study|Adverse Event|39
6125084|NCT00924560|9749458|FG001|Overall Study|Adverse Event|33
6125085|NCT00924560|9749459|FG002|Overall Study|Adverse Event|0
6125086|NCT00924560|9749457|FG000|Overall Study|Pregnancy|5
6125087|NCT00924560|9749458|FG001|Overall Study|Pregnancy|7
6125088|NCT00924560|9749459|FG002|Overall Study|Pregnancy|1
6125089|NCT00924560|9749457|FG000|Overall Study|Lost to Follow-up|78
6125090|NCT00924560|9749458|FG001|Overall Study|Lost to Follow-up|94
6125091|NCT00924560|9749459|FG002|Overall Study|Lost to Follow-up|45
6125092|NCT00924560|9749457|FG000|Overall Study|Miscellaneous Reasons|13
6125093|NCT00924560|9749458|FG001|Overall Study|Miscellaneous Reasons|10
6125094|NCT00924560|9749459|FG002|Overall Study|Miscellaneous Reasons|10
6125095|NCT00924638|9749486|FG000|Overall Study|Death|3
6125096|NCT00924638|9749487|FG001|Overall Study|Death|2
6125097|NCT00924638|9749486|FG000|Overall Study|Lost to Follow-up|1
6125098|NCT00924638|9749487|FG001|Overall Study|Lost to Follow-up|1
6125099|NCT00924638|9749486|FG000|Overall Study|Withdrawal by Subject|5
6125100|NCT00924638|9749487|FG001|Overall Study|Withdrawal by Subject|7
6125101|NCT00924638|9749486|FG000|Overall Study|Physician Decision|3
6125102|NCT00924638|9749487|FG001|Overall Study|Physician Decision|3
6125103|NCT00924651|9749495|FG000|Overall Study|Chemo started too soon|2
6125104|NCT00924651|9749496|FG001|Overall Study|Chemo started too soon|3
6125105|NCT00924651|9749495|FG000|Overall Study|No Reason|3
6125106|NCT00924651|9749496|FG001|Overall Study|No Reason|7
6125107|NCT00924651|9749495|FG000|Overall Study|Overwhelmed|6
6125108|NCT00924651|9749496|FG001|Overall Study|Overwhelmed|6
6125109|NCT00924651|9749495|FG000|Overall Study|Noncompliant|1
6125110|NCT00924651|9749496|FG001|Overall Study|Noncompliant|4
6125111|NCT00924651|9749495|FG000|Overall Study|Medical|1
6125112|NCT00924651|9749496|FG001|Overall Study|Medical|3
6125113|NCT00924651|9749495|FG000|Overall Study|Changed Mind|10
6125114|NCT00924651|9749496|FG001|Overall Study|Changed Mind|1
6125115|NCT00924651|9749495|FG000|Overall Study|Incomplete Form|2
6125116|NCT00924651|9749496|FG001|Overall Study|Incomplete Form|1
6125117|NCT00924664|9749504|FG000|Overall Study|Adverse Event|23
6217391|NCT01640808|9886149|FG001|Overall Study|Start an antiviral therapy using IFN|0
6125118|NCT00924664|9749505|FG001|Overall Study|Adverse Event|39
6125119|NCT00924664|9749504|FG000|Overall Study|Lack of Efficacy|10
6125120|NCT00924664|9749505|FG001|Overall Study|Lack of Efficacy|15
6125121|NCT00924664|9749504|FG000|Overall Study|Lost to Follow-up|10
6125122|NCT00924664|9749505|FG001|Overall Study|Lost to Follow-up|12
6125123|NCT00924664|9749504|FG000|Overall Study|Withdrawal by Subject|47
6125124|NCT00924664|9749505|FG001|Overall Study|Withdrawal by Subject|71
6288248|NCT02363946|10001845|FG002|Overall Study|Lost to Follow-up|0
6288249|NCT02363946|10001846|FG003|Overall Study|Lost to Follow-up|0
6288250|NCT02363946|10001847|FG004|Overall Study|Lost to Follow-up|0
6125125|NCT00924664|9749504|FG000|Overall Study|Protocol Violation|2
6125126|NCT00924664|9749505|FG001|Overall Study|Protocol Violation|5
6125127|NCT00924664|9749504|FG000|Overall Study|Pregnancy|1
6125128|NCT00924664|9749505|FG001|Overall Study|Pregnancy|1
6125129|NCT00924664|9749504|FG000|Overall Study|Death|0
6125130|NCT00924664|9749505|FG001|Overall Study|Death|2
6125131|NCT00924664|9749504|FG000|Overall Study|Study terminated by sponsor|199
6125132|NCT00924664|9749505|FG001|Overall Study|Study terminated by sponsor|330
6125133|NCT00924664|9749504|FG000|Overall Study|Other|29
6125134|NCT00924664|9749505|FG001|Overall Study|Other|52
6125135|NCT00924664|9749504|FG000|Overall Study|Randomized but not Treated|1
6125136|NCT00924664|9749505|FG001|Overall Study|Randomized but not Treated|0
6125137|NCT00924703|9749511|FG000|Overall Study|Withdrawal by Subject|11
6125138|NCT00924703|9749511|FG000|Overall Study|Physician Decision|5
6125139|NCT00924703|9749511|FG000|Overall Study|Lost to Follow-up|3
6125140|NCT00924703|9749511|FG000|Overall Study|Adverse Event|2
6125141|NCT00924703|9749511|FG000|Overall Study|Withdrawal by Sponsor|1
6125142|NCT00924729|9749517|FG000|Overall Study|insufficient volume for analysis|1
6125143|NCT00924729|9749518|FG001|Overall Study|insufficient volume for analysis|0
6125144|NCT00924729|9749517|FG000|Overall Study|Protocol Violation|1
6125145|NCT00924729|9749518|FG001|Overall Study|Protocol Violation|0
6125146|NCT00924781|9749530|FG000|Overall Study|Study terminated by sponsor|12
6125147|NCT00924781|9749531|FG001|Overall Study|Study terminated by sponsor|10
6125148|NCT00924820|9749547|FG000|Overall Study|Death|2
6125149|NCT00924820|9749547|FG000|Overall Study|Ineligible, Screen Failure|5
6125150|NCT00924898|9749562|FG000|Overall Study|Withdrawal by Subject|2
6125151|NCT00924950|9749571|FG000|Overall Study|Lost to Follow-up|2
6125152|NCT00925002|9749581|FG000|Overall Study|Other|1
6125153|NCT00925002|9749582|FG001|Overall Study|Other|4
6125154|NCT00925002|9749583|FG002|Overall Study|Other|0
6125155|NCT00925002|9749581|FG000|Overall Study|Death|1
6125156|NCT00925002|9749582|FG001|Overall Study|Death|1
6125157|NCT00925002|9749583|FG002|Overall Study|Death|5
6125158|NCT00925002|9749581|FG000|Overall Study|Adverse Event|3
6125159|NCT00925002|9749582|FG001|Overall Study|Adverse Event|1
6125160|NCT00925002|9749583|FG002|Overall Study|Adverse Event|2
6125161|NCT00925002|9749581|FG000|Overall Study|Participant withdrew consent|1
6125162|NCT00925002|9749582|FG001|Overall Study|Participant withdrew consent|3
6125163|NCT00925002|9749583|FG002|Overall Study|Participant withdrew consent|3
6125164|NCT00925015|9749595|FG000|Overall Study|Adverse Event|1
6125165|NCT00925015|9749596|FG001|Overall Study|Adverse Event|2
6125166|NCT00925015|9749597|FG002|Overall Study|Adverse Event|1
6125167|NCT00925015|9749595|FG000|Overall Study|Physician Decision|0
6125168|NCT00925015|9749596|FG001|Overall Study|Physician Decision|1
6125169|NCT00925015|9749597|FG002|Overall Study|Physician Decision|0
6125170|NCT00925015|9749595|FG000|Overall Study|Progressive Disease|7
6125171|NCT00925015|9749596|FG001|Overall Study|Progressive Disease|3
6125172|NCT00925015|9749597|FG002|Overall Study|Progressive Disease|4
6125173|NCT00925015|9749595|FG000|Overall Study|Withdrawal by Subject|0
6125174|NCT00925015|9749596|FG001|Overall Study|Withdrawal by Subject|0
6125175|NCT00925015|9749597|FG002|Overall Study|Withdrawal by Subject|1
6125176|NCT00925132|9749635|FG000|Overall Study|Withdrawal by Subject|2
6125177|NCT00925132|9749636|FG001|Overall Study|Withdrawal by Subject|0
6125178|NCT00925132|9749637|FG002|Overall Study|Withdrawal by Subject|0
6125179|NCT00925132|9749638|FG003|Overall Study|Withdrawal by Subject|0
6217392|NCT01640808|9886148|FG000|Overall Study|Administration of anticancer drugs|2
6217393|NCT01640808|9886149|FG001|Overall Study|Administration of anticancer drugs|1
6217394|NCT01640808|9886148|FG000|Overall Study|Physician Decision|19
6217395|NCT01640808|9886149|FG001|Overall Study|Physician Decision|5
6217396|NCT01640808|9886148|FG000|Overall Study|Randomized but not treated|4
6217397|NCT01640808|9886149|FG001|Overall Study|Randomized but not treated|2
6217398|NCT01640873|9886172|FG000|Overall Study|Protocol Violation|2
6217399|NCT01640873|9886173|FG001|Overall Study|Protocol Violation|1
6217400|NCT01640925|9886181|FG000|Overall Study|Withdrawal by Subject|1
6217401|NCT01640925|9886182|FG001|Overall Study|Withdrawal by Subject|0
6217402|NCT01640925|9886181|FG000|Overall Study|Previously enrolled in this trial|13
6217403|NCT01640925|9886182|FG001|Overall Study|Previously enrolled in this trial|11
6125180|NCT00925132|9749639|FG004|Overall Study|Withdrawal by Subject|1
6125181|NCT00925132|9749635|FG000|Overall Study|Removed due to disease progression|0
6125182|NCT00925132|9749636|FG001|Overall Study|Removed due to disease progression|0
6125183|NCT00925132|9749637|FG002|Overall Study|Removed due to disease progression|0
6125184|NCT00925132|9749638|FG003|Overall Study|Removed due to disease progression|0
6125185|NCT00925132|9749639|FG004|Overall Study|Removed due to disease progression|4
6217404|NCT01640951|9886196|FG000|Overall Study|Adverse Event|8
6288251|NCT02363946|10001848|FG005|Overall Study|Lost to Follow-up|0
6125186|NCT00925288|9749647|FG000|Overall Study|Lost to Follow-up|9
6125187|NCT00925288|9749648|FG001|Overall Study|Lost to Follow-up|7
6125188|NCT00925301|9749658|FG000|6-Month Double-blind (Stage 1)|Withdrawal by Subject|0
6125189|NCT00925301|9749659|FG001|6-Month Double-blind (Stage 1)|Withdrawal by Subject|2
6125190|NCT00925301|9749660|FG002|6-Month Double-blind (Stage 1)|Withdrawal by Subject|0
6125191|NCT00925301|9749661|FG003|6-Month Double-blind (Stage 1)|Withdrawal by Subject|0
6125192|NCT00925301|9749658|FG000|6-Month Double-blind (Stage 1)|Pregnancy|0
6125193|NCT00925301|9749659|FG001|6-Month Double-blind (Stage 1)|Pregnancy|1
6125194|NCT00925301|9749660|FG002|6-Month Double-blind (Stage 1)|Pregnancy|0
6125195|NCT00925301|9749661|FG003|6-Month Double-blind (Stage 1)|Pregnancy|0
6125196|NCT00925301|9749658|FG000|6-Month Open-label (Stage 2)|Withdrawal by Subject|0
6125197|NCT00925301|9749659|FG001|6-Month Open-label (Stage 2)|Withdrawal by Subject|0
6125198|NCT00925301|9749660|FG002|6-Month Open-label (Stage 2)|Withdrawal by Subject|1
6125199|NCT00925301|9749661|FG003|6-Month Open-label (Stage 2)|Withdrawal by Subject|0
6125200|NCT00925301|9749658|FG000|6-Month Open-label (Stage 2)|Adverse Event|0
6125201|NCT00925301|9749659|FG001|6-Month Open-label (Stage 2)|Adverse Event|0
6125202|NCT00925301|9749660|FG002|6-Month Open-label (Stage 2)|Adverse Event|2
6125203|NCT00925301|9749661|FG003|6-Month Open-label (Stage 2)|Adverse Event|0
6125204|NCT00925301|9749658|FG000|12-Month Open-label Extension (Optional)|Withdrawal by Subject|0
6125205|NCT00925301|9749659|FG001|12-Month Open-label Extension (Optional)|Withdrawal by Subject|0
6125206|NCT00925301|9749660|FG002|12-Month Open-label Extension (Optional)|Withdrawal by Subject|0
6125207|NCT00925301|9749661|FG003|12-Month Open-label Extension (Optional)|Withdrawal by Subject|1
6125208|NCT00925301|9749658|FG000|12-Month Open-label Extension (Optional)|Pregnancy|0
6125209|NCT00925301|9749659|FG001|12-Month Open-label Extension (Optional)|Pregnancy|0
6125210|NCT00925301|9749660|FG002|12-Month Open-label Extension (Optional)|Pregnancy|0
6125211|NCT00925301|9749661|FG003|12-Month Open-label Extension (Optional)|Pregnancy|1
6288252|NCT02363946|10001849|FG006|Overall Study|Lost to Follow-up|0
6288253|NCT02363946|10001850|FG007|Overall Study|Lost to Follow-up|1
6288254|NCT02363946|10001851|FG008|Overall Study|Lost to Follow-up|0
6288255|NCT02363946|10001852|FG009|Overall Study|Lost to Follow-up|0
6288256|NCT02363946|10001853|FG010|Overall Study|Lost to Follow-up|0
6288257|NCT02363946|10001854|FG011|Overall Study|Lost to Follow-up|0
6288258|NCT02363946|10001855|FG012|Overall Study|Lost to Follow-up|0
6288259|NCT02363959|10001885|FG000|Overall Study|Medical instability|1
6288260|NCT02363959|10001886|FG001|Overall Study|Medical instability|0
6288261|NCT02364037|10001898|FG000|Overall Study|Withdrawal by Subject|7
6288262|NCT02364037|10001899|FG001|Overall Study|Withdrawal by Subject|4
6288263|NCT02364037|10001898|FG000|Overall Study|Lost to Follow-up|37
6288264|NCT02364037|10001899|FG001|Overall Study|Lost to Follow-up|49
6125212|NCT00925301|9749658|FG000|12-Month Open-label Extension (Optional)|Lost to Follow-up|0
6125213|NCT00925301|9749659|FG001|12-Month Open-label Extension (Optional)|Lost to Follow-up|0
6125214|NCT00925301|9749660|FG002|12-Month Open-label Extension (Optional)|Lost to Follow-up|0
6125215|NCT00925301|9749661|FG003|12-Month Open-label Extension (Optional)|Lost to Follow-up|1
6125216|NCT00925353|9749672|FG000|Overall Study|Failed preliminary EKG or lab criteria.|3
6125217|NCT00925522|9749676|FG000|Overall Study|study closed -- business decision|20
6125218|NCT00925587|9749682|FG000|Overall Study|Protocol Specified Criteria|6
6125219|NCT00925587|9749683|FG001|Overall Study|Protocol Specified Criteria|6
6125220|NCT00925587|9749682|FG000|Overall Study|Physician Decision|4
6125221|NCT00925587|9749683|FG001|Overall Study|Physician Decision|1
6125222|NCT00925587|9749682|FG000|Overall Study|Protocol Violation|6
6125223|NCT00925587|9749683|FG001|Overall Study|Protocol Violation|4
6125224|NCT00925587|9749682|FG000|Overall Study|Withdrawal by Subject|9
6125225|NCT00925587|9749683|FG001|Overall Study|Withdrawal by Subject|6
6125226|NCT00925587|9749682|FG000|Overall Study|Death|5
6125227|NCT00925587|9749683|FG001|Overall Study|Death|5
6125228|NCT00925587|9749682|FG000|Overall Study|Adverse Event|6
6125229|NCT00925587|9749683|FG001|Overall Study|Adverse Event|2
6125230|NCT00925587|9749682|FG000|Overall Study|Lost to Follow-up|0
6125231|NCT00925587|9749683|FG001|Overall Study|Lost to Follow-up|1
6125232|NCT00925600|9749691|FG000|Overall Study|Withdrawal by Subject|16
6125233|NCT00925600|9749692|FG001|Overall Study|Withdrawal by Subject|14
6125234|NCT00925600|9749691|FG000|Overall Study|Death|4
6125235|NCT00925600|9749692|FG001|Overall Study|Death|3
6125236|NCT00925600|9749691|FG000|Overall Study|Lost to Follow-up|2
6125237|NCT00925600|9749692|FG001|Overall Study|Lost to Follow-up|2
6125238|NCT00925600|9749691|FG000|Overall Study|Disease Progression|1
6125239|NCT00925600|9749692|FG001|Overall Study|Disease Progression|3
6125240|NCT00925600|9749691|FG000|Overall Study|Administrative Decision|1
6125241|NCT00925600|9749692|FG001|Overall Study|Administrative Decision|1
6125242|NCT00925600|9749691|FG000|Overall Study|Noncompliance|2
6125243|NCT00925600|9749692|FG001|Overall Study|Noncompliance|0
6125244|NCT00925600|9749691|FG000|Overall Study|Ineligibility Determined|2
6125245|NCT00925600|9749692|FG001|Overall Study|Ineligibility Determined|0
6125246|NCT00925600|9749691|FG000|Overall Study|Protocol Deviation|0
6125247|NCT00925600|9749692|FG001|Overall Study|Protocol Deviation|1
6125248|NCT00925600|9749691|FG000|Overall Study|Requirement for Alternative Therapy|0
6288265|NCT02364180|10001909|FG000|Overall Study|Screen Fail|1
6288266|NCT02364336|10001925|FG000|Overall Study|Adverse Event|0
6288267|NCT02364336|10001926|FG001|Overall Study|Adverse Event|1
6288268|NCT02364388|10001933|FG000|Overall Study|Protocol Violation|1
6125249|NCT00925600|9749692|FG001|Overall Study|Requirement for Alternative Therapy|1
6125250|NCT00925600|9749691|FG000|Overall Study|Other|3
6125251|NCT00925600|9749692|FG001|Overall Study|Other|1
6125252|NCT00925600|9749691|FG000|Overall Study|Adverse Event|1
6125253|NCT00925600|9749692|FG001|Overall Study|Adverse Event|2
6125254|NCT00925704|9749708|FG000|First Intervention|Withdrew consent|0
6125255|NCT00925704|9749709|FG001|First Intervention|Withdrew consent|0
6125256|NCT00925704|9749710|FG002|First Intervention|Withdrew consent|0
6125257|NCT00925704|9749711|FG003|First Intervention|Withdrew consent|1
6125258|NCT00925704|9749712|FG004|First Intervention|Withdrew consent|1
6125259|NCT00925704|9749713|FG005|First Intervention|Withdrew consent|0
6125260|NCT00925704|9749708|FG000|Second Intervention|Withdrawal by Subject|1
6125261|NCT00925704|9749709|FG001|Second Intervention|Withdrawal by Subject|0
6125262|NCT00925704|9749710|FG002|Second Intervention|Withdrawal by Subject|0
6125263|NCT00925704|9749711|FG003|Second Intervention|Withdrawal by Subject|0
6125264|NCT00925704|9749712|FG004|Second Intervention|Withdrawal by Subject|1
6125265|NCT00925704|9749713|FG005|Second Intervention|Withdrawal by Subject|0
6125266|NCT00925704|9749708|FG000|Third Intervention|Withdrew consent|0
6125267|NCT00925704|9749709|FG001|Third Intervention|Withdrew consent|0
6125268|NCT00925704|9749710|FG002|Third Intervention|Withdrew consent|0
6217405|NCT01640951|9886197|FG001|Overall Study|Adverse Event|3
6217406|NCT01640951|9886198|FG002|Overall Study|Adverse Event|10
6217407|NCT01640951|9886199|FG003|Overall Study|Adverse Event|6
6125269|NCT00925704|9749711|FG003|Third Intervention|Withdrew consent|0
6125270|NCT00925704|9749712|FG004|Third Intervention|Withdrew consent|0
6125271|NCT00925704|9749713|FG005|Third Intervention|Withdrew consent|1
6125272|NCT00925769|9749728|FG000|Overall Study|Major toxicity|1
6125273|NCT00925769|9749729|FG001|Overall Study|Major toxicity|0
6125274|NCT00925769|9749730|FG002|Overall Study|Major toxicity|1
6125275|NCT00925769|9749731|FG003|Overall Study|Major toxicity|1
6125276|NCT00925769|9749732|FG004|Overall Study|Major toxicity|0
6125277|NCT00925769|9749733|FG005|Overall Study|Major toxicity|0
6125278|NCT00925769|9749728|FG000|Overall Study|Disease progression|4
6125279|NCT00925769|9749729|FG001|Overall Study|Disease progression|5
6125280|NCT00925769|9749730|FG002|Overall Study|Disease progression|3
6125281|NCT00925769|9749731|FG003|Overall Study|Disease progression|4
6125282|NCT00925769|9749732|FG004|Overall Study|Disease progression|2
6125283|NCT00925769|9749733|FG005|Overall Study|Disease progression|3
6125284|NCT00925769|9749728|FG000|Overall Study|Death|0
6125285|NCT00925769|9749729|FG001|Overall Study|Death|0
6125286|NCT00925769|9749730|FG002|Overall Study|Death|1
6125287|NCT00925769|9749731|FG003|Overall Study|Death|0
6125288|NCT00925769|9749732|FG004|Overall Study|Death|0
6125289|NCT00925769|9749733|FG005|Overall Study|Death|0
6125290|NCT00925769|9749728|FG000|Overall Study|Physician Decision|1
6125291|NCT00925769|9749729|FG001|Overall Study|Physician Decision|0
6125292|NCT00925769|9749730|FG002|Overall Study|Physician Decision|0
6125293|NCT00925769|9749731|FG003|Overall Study|Physician Decision|0
6125294|NCT00925769|9749732|FG004|Overall Study|Physician Decision|0
6125295|NCT00925769|9749733|FG005|Overall Study|Physician Decision|0
6125296|NCT00925769|9749728|FG000|Overall Study|Missing documentation|0
6125297|NCT00925769|9749729|FG001|Overall Study|Missing documentation|1
6125298|NCT00925769|9749730|FG002|Overall Study|Missing documentation|0
6125299|NCT00925769|9749731|FG003|Overall Study|Missing documentation|0
6125300|NCT00925769|9749732|FG004|Overall Study|Missing documentation|0
6125301|NCT00925769|9749733|FG005|Overall Study|Missing documentation|0
6125302|NCT00925769|9749728|FG000|Overall Study|End of study visit not done|0
6125303|NCT00925769|9749729|FG001|Overall Study|End of study visit not done|0
6125304|NCT00925769|9749730|FG002|Overall Study|End of study visit not done|1
6125305|NCT00925769|9749731|FG003|Overall Study|End of study visit not done|0
6125306|NCT00925769|9749732|FG004|Overall Study|End of study visit not done|0
6125307|NCT00925769|9749733|FG005|Overall Study|End of study visit not done|0
6125308|NCT00925769|9749728|FG000|Overall Study|Participant is unable to swallow drug|0
6217408|NCT01640951|9886200|FG004|Overall Study|Adverse Event|1
6125309|NCT00925769|9749729|FG001|Overall Study|Participant is unable to swallow drug|0
6125310|NCT00925769|9749730|FG002|Overall Study|Participant is unable to swallow drug|0
6125311|NCT00925769|9749731|FG003|Overall Study|Participant is unable to swallow drug|1
6125312|NCT00925769|9749732|FG004|Overall Study|Participant is unable to swallow drug|0
6217409|NCT01640951|9886201|FG005|Overall Study|Adverse Event|11
6217410|NCT01640951|9886202|FG006|Overall Study|Adverse Event|1
6217411|NCT01640951|9886203|FG007|Overall Study|Adverse Event|3
6217412|NCT01640951|9886196|FG000|Overall Study|Lack of Efficacy|20
6217413|NCT01640951|9886197|FG001|Overall Study|Lack of Efficacy|1
6217414|NCT01640951|9886198|FG002|Overall Study|Lack of Efficacy|7
6217415|NCT01640951|9886199|FG003|Overall Study|Lack of Efficacy|14
6217416|NCT01640951|9886200|FG004|Overall Study|Lack of Efficacy|0
6217417|NCT01640951|9886201|FG005|Overall Study|Lack of Efficacy|6
6217418|NCT01640951|9886202|FG006|Overall Study|Lack of Efficacy|5
6217419|NCT01640951|9886203|FG007|Overall Study|Lack of Efficacy|6
6217420|NCT01640951|9886196|FG000|Overall Study|Lost to Follow-up|1
6217421|NCT01640951|9886197|FG001|Overall Study|Lost to Follow-up|0
6217422|NCT01640951|9886198|FG002|Overall Study|Lost to Follow-up|6
6288269|NCT02364388|10001933|FG000|Overall Study|Technical Failure|3
6217423|NCT01640951|9886199|FG003|Overall Study|Lost to Follow-up|2
6125313|NCT00925769|9749733|FG005|Overall Study|Participant is unable to swallow drug|0
6125314|NCT00925769|9749728|FG000|Overall Study|Adverse Event|0
6125315|NCT00925769|9749729|FG001|Overall Study|Adverse Event|0
6125316|NCT00925769|9749730|FG002|Overall Study|Adverse Event|0
6125317|NCT00925769|9749731|FG003|Overall Study|Adverse Event|0
6125318|NCT00925769|9749732|FG004|Overall Study|Adverse Event|1
6125319|NCT00925769|9749733|FG005|Overall Study|Adverse Event|0
6125320|NCT00925899|9749759|FG000|Part 1|Death|1
6125321|NCT00925899|9749760|FG001|Part 1|Death|2
6125322|NCT00925899|9749759|FG000|Part 1|Withdrawal by Subject|10
6125323|NCT00925899|9749760|FG001|Part 1|Withdrawal by Subject|9
6217424|NCT01640951|9886200|FG004|Overall Study|Lost to Follow-up|2
6217425|NCT01640951|9886201|FG005|Overall Study|Lost to Follow-up|3
6217426|NCT01640951|9886202|FG006|Overall Study|Lost to Follow-up|1
6217427|NCT01640951|9886203|FG007|Overall Study|Lost to Follow-up|1
6217428|NCT01640951|9886196|FG000|Overall Study|Non-compliance with study treatment|0
6217429|NCT01640951|9886197|FG001|Overall Study|Non-compliance with study treatment|0
6217430|NCT01640951|9886198|FG002|Overall Study|Non-compliance with study treatment|1
6217431|NCT01640951|9886199|FG003|Overall Study|Non-compliance with study treatment|1
6217432|NCT01640951|9886200|FG004|Overall Study|Non-compliance with study treatment|1
6217433|NCT01640951|9886201|FG005|Overall Study|Non-compliance with study treatment|4
6217434|NCT01640951|9886202|FG006|Overall Study|Non-compliance with study treatment|1
6217435|NCT01640951|9886203|FG007|Overall Study|Non-compliance with study treatment|0
6217436|NCT01640951|9886196|FG000|Overall Study|Physician Decision|2
6217437|NCT01640951|9886197|FG001|Overall Study|Physician Decision|5
6217438|NCT01640951|9886198|FG002|Overall Study|Physician Decision|2
6217439|NCT01640951|9886199|FG003|Overall Study|Physician Decision|2
6217440|NCT01640951|9886200|FG004|Overall Study|Physician Decision|2
6217441|NCT01640951|9886201|FG005|Overall Study|Physician Decision|3
6217442|NCT01640951|9886202|FG006|Overall Study|Physician Decision|3
6217443|NCT01640951|9886203|FG007|Overall Study|Physician Decision|0
6217444|NCT01640951|9886196|FG000|Overall Study|Pregnancy|3
6217445|NCT01640951|9886197|FG001|Overall Study|Pregnancy|0
6217446|NCT01640951|9886198|FG002|Overall Study|Pregnancy|0
6217447|NCT01640951|9886199|FG003|Overall Study|Pregnancy|4
6217448|NCT01640951|9886200|FG004|Overall Study|Pregnancy|0
6217449|NCT01640951|9886201|FG005|Overall Study|Pregnancy|0
6217450|NCT01640951|9886202|FG006|Overall Study|Pregnancy|2
6217451|NCT01640951|9886203|FG007|Overall Study|Pregnancy|0
6217452|NCT01640951|9886196|FG000|Overall Study|Protocol Deviation|0
6217453|NCT01640951|9886197|FG001|Overall Study|Protocol Deviation|1
6217454|NCT01640951|9886198|FG002|Overall Study|Protocol Deviation|2
6217455|NCT01640951|9886199|FG003|Overall Study|Protocol Deviation|1
6217456|NCT01640951|9886200|FG004|Overall Study|Protocol Deviation|0
6217457|NCT01640951|9886201|FG005|Overall Study|Protocol Deviation|1
6217458|NCT01640951|9886202|FG006|Overall Study|Protocol Deviation|0
6217459|NCT01640951|9886203|FG007|Overall Study|Protocol Deviation|0
6217460|NCT01640951|9886196|FG000|Overall Study|Subject/Guardian decision|12
6217461|NCT01640951|9886197|FG001|Overall Study|Subject/Guardian decision|4
6217462|NCT01640951|9886198|FG002|Overall Study|Subject/Guardian decision|13
6217463|NCT01640951|9886199|FG003|Overall Study|Subject/Guardian decision|15
6217464|NCT01640951|9886200|FG004|Overall Study|Subject/Guardian decision|7
6217465|NCT01640951|9886201|FG005|Overall Study|Subject/Guardian decision|19
6217466|NCT01640951|9886202|FG006|Overall Study|Subject/Guardian decision|5
6217467|NCT01640951|9886203|FG007|Overall Study|Subject/Guardian decision|4
6217468|NCT01640951|9886196|FG000|Overall Study|Death|0
6217469|NCT01640951|9886197|FG001|Overall Study|Death|1
6217470|NCT01640951|9886198|FG002|Overall Study|Death|1
6217471|NCT01640951|9886199|FG003|Overall Study|Death|0
6217472|NCT01640951|9886200|FG004|Overall Study|Death|0
6217473|NCT01640951|9886201|FG005|Overall Study|Death|0
6217474|NCT01640951|9886202|FG006|Overall Study|Death|0
6217475|NCT01640951|9886203|FG007|Overall Study|Death|2
6217476|NCT01640964|9886226|FG000|Overall Study|Lost to Follow-up|0
6217477|NCT01640964|9886227|FG001|Overall Study|Lost to Follow-up|0
6217478|NCT01640964|9886228|FG002|Overall Study|Lost to Follow-up|1
6217479|NCT01640964|9886226|FG000|Overall Study|Protocol Deviation|1
6217480|NCT01640964|9886227|FG001|Overall Study|Protocol Deviation|1
6217481|NCT01640964|9886228|FG002|Overall Study|Protocol Deviation|2
6217482|NCT01641081|9886246|FG000|Period 1|Sponsor request (potential unblinding)|0
6217483|NCT01641081|9886247|FG001|Period 1|Sponsor request (potential unblinding)|0
6288270|NCT02364388|10001933|FG000|Overall Study|No OA/US data|2
6288271|NCT02364388|10001933|FG000|Overall Study|No Biopsy|2
6288272|NCT02364947|10001977|FG000|Overall Study|Withdrawal by Subject|10
6288273|NCT02364947|10001978|FG001|Overall Study|Withdrawal by Subject|8
6217484|NCT01641081|9886248|FG002|Period 1|Sponsor request (potential unblinding)|0
6217485|NCT01641081|9886249|FG003|Period 1|Sponsor request (potential unblinding)|0
6217486|NCT01641081|9886250|FG004|Period 1|Sponsor request (potential unblinding)|0
6217487|NCT01641081|9886251|FG005|Period 1|Sponsor request (potential unblinding)|0
6217488|NCT01641081|9886252|FG006|Period 1|Sponsor request (potential unblinding)|1
6217489|NCT01641081|9886253|FG007|Period 1|Sponsor request (potential unblinding)|0
6217490|NCT01641081|9886254|FG008|Period 1|Sponsor request (potential unblinding)|0
6217491|NCT01641081|9886255|FG009|Period 1|Sponsor request (potential unblinding)|0
6217492|NCT01641081|9886246|FG000|Period 1|Protocol Violation|0
6217493|NCT01641081|9886247|FG001|Period 1|Protocol Violation|0
6217494|NCT01641081|9886248|FG002|Period 1|Protocol Violation|0
6125324|NCT00925990|9749782|FG000|Overall Study|Adverse Event|1
6125325|NCT00925990|9749783|FG001|Overall Study|Adverse Event|3
6125326|NCT00925990|9749782|FG000|Overall Study|Withdrawal by Subject|2
6125327|NCT00925990|9749783|FG001|Overall Study|Withdrawal by Subject|2
6125328|NCT00925990|9749782|FG000|Overall Study|Lost to Follow-up|1
6125329|NCT00925990|9749783|FG001|Overall Study|Lost to Follow-up|3
6125330|NCT00925990|9749782|FG000|Overall Study|Physician Decision|1
6125331|NCT00925990|9749783|FG001|Overall Study|Physician Decision|1
6125332|NCT00925990|9749782|FG000|Overall Study|moved out of state, missed medication|0
6125333|NCT00925990|9749783|FG001|Overall Study|moved out of state, missed medication|2
6125334|NCT00926003|9749792|FG000|Post-Training Evaluation|Withdrawal by Subject|1
6125335|NCT00926003|9749793|FG001|Post-Training Evaluation|Withdrawal by Subject|0
6125336|NCT00926003|9749794|FG002|Post-Training Evaluation|Withdrawal by Subject|0
6217495|NCT01641081|9886249|FG003|Period 1|Protocol Violation|0
6217496|NCT01641081|9886250|FG004|Period 1|Protocol Violation|1
6217497|NCT01641081|9886251|FG005|Period 1|Protocol Violation|0
6217498|NCT01641081|9886252|FG006|Period 1|Protocol Violation|0
6217499|NCT01641081|9886253|FG007|Period 1|Protocol Violation|1
6217500|NCT01641081|9886254|FG008|Period 1|Protocol Violation|0
6217501|NCT01641081|9886255|FG009|Period 1|Protocol Violation|0
6217502|NCT01641081|9886246|FG000|Period 1|Adverse Event|1
6217503|NCT01641081|9886247|FG001|Period 1|Adverse Event|0
6217504|NCT01641081|9886248|FG002|Period 1|Adverse Event|0
6217505|NCT01641081|9886249|FG003|Period 1|Adverse Event|0
6217506|NCT01641081|9886250|FG004|Period 1|Adverse Event|0
6217507|NCT01641081|9886251|FG005|Period 1|Adverse Event|0
6217508|NCT01641081|9886252|FG006|Period 1|Adverse Event|0
6217509|NCT01641081|9886253|FG007|Period 1|Adverse Event|2
6217510|NCT01641081|9886254|FG008|Period 1|Adverse Event|0
6217511|NCT01641081|9886255|FG009|Period 1|Adverse Event|0
6217512|NCT01641081|9886246|FG000|Period 2|Adverse Event|0
6217513|NCT01641081|9886247|FG001|Period 2|Adverse Event|0
6217514|NCT01641081|9886248|FG002|Period 2|Adverse Event|0
6217515|NCT01641081|9886249|FG003|Period 2|Adverse Event|0
6217516|NCT01641081|9886250|FG004|Period 2|Adverse Event|0
6217517|NCT01641081|9886251|FG005|Period 2|Adverse Event|1
6217518|NCT01641081|9886252|FG006|Period 2|Adverse Event|0
6217519|NCT01641081|9886253|FG007|Period 2|Adverse Event|0
6217520|NCT01641081|9886254|FG008|Period 2|Adverse Event|0
6217521|NCT01641081|9886255|FG009|Period 2|Adverse Event|0
6217522|NCT01641081|9886246|FG000|Period 2|Withdrawal by Subject|0
6217523|NCT01641081|9886247|FG001|Period 2|Withdrawal by Subject|0
6217524|NCT01641081|9886248|FG002|Period 2|Withdrawal by Subject|0
6217525|NCT01641081|9886249|FG003|Period 2|Withdrawal by Subject|1
6217526|NCT01641081|9886250|FG004|Period 2|Withdrawal by Subject|0
6217527|NCT01641081|9886251|FG005|Period 2|Withdrawal by Subject|0
6217528|NCT01641081|9886252|FG006|Period 2|Withdrawal by Subject|2
6217529|NCT01641081|9886253|FG007|Period 2|Withdrawal by Subject|0
6217530|NCT01641081|9886254|FG008|Period 2|Withdrawal by Subject|0
6217531|NCT01641081|9886255|FG009|Period 2|Withdrawal by Subject|0
6217532|NCT01641081|9886246|FG000|Period 2|Protocol Violation|1
6217533|NCT01641081|9886247|FG001|Period 2|Protocol Violation|0
6217534|NCT01641081|9886248|FG002|Period 2|Protocol Violation|0
6217535|NCT01641081|9886249|FG003|Period 2|Protocol Violation|0
6217536|NCT01641081|9886250|FG004|Period 2|Protocol Violation|0
6217537|NCT01641081|9886251|FG005|Period 2|Protocol Violation|0
6217538|NCT01641081|9886252|FG006|Period 2|Protocol Violation|0
6217539|NCT01641081|9886253|FG007|Period 2|Protocol Violation|0
6217540|NCT01641081|9886254|FG008|Period 2|Protocol Violation|0
6217541|NCT01641081|9886255|FG009|Period 2|Protocol Violation|0
6217542|NCT01641081|9886246|FG000|Period 3|Adverse Event|0
6217543|NCT01641081|9886247|FG001|Period 3|Adverse Event|0
6217544|NCT01641081|9886248|FG002|Period 3|Adverse Event|1
6217545|NCT01641081|9886249|FG003|Period 3|Adverse Event|0
6217546|NCT01641081|9886250|FG004|Period 3|Adverse Event|0
6217547|NCT01641081|9886251|FG005|Period 3|Adverse Event|0
6217548|NCT01641081|9886252|FG006|Period 3|Adverse Event|0
6217549|NCT01641081|9886253|FG007|Period 3|Adverse Event|0
6217550|NCT01641081|9886254|FG008|Period 3|Adverse Event|0
6217551|NCT01641081|9886255|FG009|Period 3|Adverse Event|0
6217552|NCT01641081|9886246|FG000|Period 3|Withdrawal by Subject|0
6217553|NCT01641081|9886247|FG001|Period 3|Withdrawal by Subject|0
6217554|NCT01641081|9886248|FG002|Period 3|Withdrawal by Subject|0
6217555|NCT01641081|9886249|FG003|Period 3|Withdrawal by Subject|0
6217556|NCT01641081|9886250|FG004|Period 3|Withdrawal by Subject|0
6217557|NCT01641081|9886251|FG005|Period 3|Withdrawal by Subject|0
6217558|NCT01641081|9886252|FG006|Period 3|Withdrawal by Subject|0
6217559|NCT01641081|9886253|FG007|Period 3|Withdrawal by Subject|0
6217560|NCT01641081|9886254|FG008|Period 3|Withdrawal by Subject|1
6217561|NCT01641081|9886255|FG009|Period 3|Withdrawal by Subject|0
6217562|NCT01641081|9886246|FG000|Period 4|Adverse Event|0
6217563|NCT01641081|9886247|FG001|Period 4|Adverse Event|1
6125337|NCT00926003|9749792|FG000|Post-Training 3-month Follow-up|Lost to Follow-up|1
6217564|NCT01641081|9886248|FG002|Period 4|Adverse Event|0
6217565|NCT01641081|9886249|FG003|Period 4|Adverse Event|1
6217566|NCT01641081|9886250|FG004|Period 4|Adverse Event|0
6217567|NCT01641081|9886251|FG005|Period 4|Adverse Event|0
6217568|NCT01641081|9886252|FG006|Period 4|Adverse Event|0
6217569|NCT01641081|9886253|FG007|Period 4|Adverse Event|0
6217570|NCT01641081|9886254|FG008|Period 4|Adverse Event|0
6125338|NCT00926003|9749793|FG001|Post-Training 3-month Follow-up|Lost to Follow-up|0
6125339|NCT00926003|9749794|FG002|Post-Training 3-month Follow-up|Lost to Follow-up|0
6125340|NCT00926029|9749805|FG000|Overall Study|Lost to Follow-up|2
6125341|NCT00926029|9749806|FG001|Overall Study|Lost to Follow-up|1
6125342|NCT00926029|9749807|FG002|Overall Study|Lost to Follow-up|1
6217571|NCT01641081|9886255|FG009|Period 4|Adverse Event|0
6217572|NCT01641081|9886246|FG000|Period 5|Adverse Event|0
6217573|NCT01641081|9886247|FG001|Period 5|Adverse Event|0
6217574|NCT01641081|9886248|FG002|Period 5|Adverse Event|2
6217575|NCT01641081|9886249|FG003|Period 5|Adverse Event|0
6217576|NCT01641081|9886250|FG004|Period 5|Adverse Event|0
6217577|NCT01641081|9886251|FG005|Period 5|Adverse Event|0
6217578|NCT01641081|9886252|FG006|Period 5|Adverse Event|0
6217579|NCT01641081|9886253|FG007|Period 5|Adverse Event|0
6217580|NCT01641081|9886254|FG008|Period 5|Adverse Event|0
6217581|NCT01641081|9886255|FG009|Period 5|Adverse Event|0
6217582|NCT01641133|9886277|FG000|Overall Study|Protocol Violation|0
6217583|NCT01641133|9886278|FG001|Overall Study|Protocol Violation|1
6217584|NCT01641133|9886279|FG002|Overall Study|Protocol Violation|1
6288274|NCT02364947|10001979|FG002|Overall Study|Withdrawal by Subject|9
6288275|NCT02364947|10001977|FG000|Overall Study|Adverse Event|45
6288276|NCT02364947|10001978|FG001|Overall Study|Adverse Event|33
6288277|NCT02364947|10001979|FG002|Overall Study|Adverse Event|11
6288278|NCT02364947|10001977|FG000|Overall Study|Protocol Violation|1
6288279|NCT02364947|10001978|FG001|Overall Study|Protocol Violation|1
6288280|NCT02364947|10001979|FG002|Overall Study|Protocol Violation|1
6288281|NCT02364947|10001977|FG000|Overall Study|Physician Decision|3
6288282|NCT02364947|10001978|FG001|Overall Study|Physician Decision|2
6288283|NCT02364947|10001979|FG002|Overall Study|Physician Decision|5
6288284|NCT02364947|10001977|FG000|Overall Study|Death|0
6288285|NCT02364947|10001978|FG001|Overall Study|Death|1
6288286|NCT02364947|10001979|FG002|Overall Study|Death|0
6288287|NCT02364999|10001989|FG000|Overall Study|Death|136
6288288|NCT02364999|10001990|FG001|Overall Study|Death|138
6288289|NCT02364999|10001989|FG000|Overall Study|Lost to Follow-up|10
6288290|NCT02364999|10001990|FG001|Overall Study|Lost to Follow-up|15
6288291|NCT02364999|10001989|FG000|Overall Study|Protocol Violation|3
6288292|NCT02364999|10001990|FG001|Overall Study|Protocol Violation|2
6288293|NCT02364999|10001989|FG000|Overall Study|Withdrawal by Subject|14
6288294|NCT02364999|10001990|FG001|Overall Study|Withdrawal by Subject|14
6288295|NCT02364999|10001989|FG000|Overall Study|Other|0
6288296|NCT02364999|10001990|FG001|Overall Study|Other|1
6288297|NCT02364999|10001989|FG000|Overall Study|Randomized but did not receive treatment|2
6288298|NCT02364999|10001990|FG001|Overall Study|Randomized but did not receive treatment|3
6288299|NCT02365064|10001999|FG000|Overall Study|Patients met baseline exclusion requirem|2
6288300|NCT02365064|10002000|FG001|Overall Study|Patients met baseline exclusion requirem|15
6288301|NCT02365064|10001999|FG000|Overall Study|Withdrawal by Subject|6
6288302|NCT02365064|10002000|FG001|Overall Study|Withdrawal by Subject|9
6288303|NCT02365064|10001999|FG000|Overall Study|Treatment intolerance|2
6288304|NCT02365064|10002000|FG001|Overall Study|Treatment intolerance|4
6288305|NCT02365285|10002010|FG000|Overall Study|Physician Decision|0
6288306|NCT02365285|10002011|FG001|Overall Study|Physician Decision|1
6288307|NCT02365285|10002012|FG002|Overall Study|Physician Decision|1
6288308|NCT02365285|10002013|FG003|Overall Study|Physician Decision|0
6288309|NCT02365285|10002010|FG000|Overall Study|Adverse Event|0
6288310|NCT02365285|10002011|FG001|Overall Study|Adverse Event|0
6288311|NCT02365285|10002012|FG002|Overall Study|Adverse Event|0
6288312|NCT02365285|10002013|FG003|Overall Study|Adverse Event|2
6288313|NCT02365298|10002025|FG000|Period 2|incorrect Rx dispensed|1
6288314|NCT02365298|10002026|FG001|Period 2|incorrect Rx dispensed|0
6288315|NCT02365298|10002025|FG000|Period 2|Discontinued at request of Sponsor|1
6288316|NCT02365298|10002026|FG001|Period 2|Discontinued at request of Sponsor|0
6288317|NCT02365298|10002025|FG000|Period 2|Test Article longer available|0
6288318|NCT02365298|10002026|FG001|Period 2|Test Article longer available|1
6288319|NCT02365298|10002025|FG000|Period 2|Protocol Violation|0
6125343|NCT00926211|9749834|FG000|Overall Study|Lost to Follow-up|1
6125344|NCT00926237|9749839|FG000|Overall Study|Withdrawal by Subject|2
6125345|NCT00926237|9749840|FG001|Overall Study|Withdrawal by Subject|1
6125346|NCT00926289|9749862|FG000|Overall Study|Adverse Event|9
6125347|NCT00926289|9749863|FG001|Overall Study|Adverse Event|11
6125348|NCT00926289|9749862|FG000|Overall Study|Protocol Violation|8
6125349|NCT00926289|9749863|FG001|Overall Study|Protocol Violation|12
6125350|NCT00926289|9749862|FG000|Overall Study|Lost to Follow-up|3
6125351|NCT00926289|9749863|FG001|Overall Study|Lost to Follow-up|6
6125352|NCT00926289|9749862|FG000|Overall Study|Withdrawal by Subject|4
6125353|NCT00926289|9749863|FG001|Overall Study|Withdrawal by Subject|4
6125354|NCT00926289|9749862|FG000|Overall Study|Other|1
6125355|NCT00926289|9749863|FG001|Overall Study|Other|3
6125356|NCT00926328|9749871|FG000|Overall Study|Lost to Follow-up|12
6125357|NCT00926328|9749872|FG001|Overall Study|Lost to Follow-up|14
6125358|NCT00926367|9749880|FG000|Overall Study|Withdrawal by Subject|0
6125359|NCT00926367|9749881|FG001|Overall Study|Withdrawal by Subject|1
6125360|NCT00926367|9749880|FG000|Overall Study|Lost to Follow-up|1
6125361|NCT00926367|9749881|FG001|Overall Study|Lost to Follow-up|0
6217585|NCT01641133|9886277|FG000|Overall Study|Migrated/moved from study area|5
6217586|NCT01641133|9886278|FG001|Overall Study|Migrated/moved from study area|3
6125362|NCT00926367|9749880|FG000|Overall Study|Skin Irritation|1
6125363|NCT00926367|9749881|FG001|Overall Study|Skin Irritation|2
6125364|NCT00926393|9749904|FG000|Overall Study|Withdrawal by Subject|1
6125365|NCT00926393|9749905|FG001|Overall Study|Withdrawal by Subject|2
6125366|NCT00926393|9749904|FG000|Overall Study|Adverse Event|1
6125367|NCT00926393|9749905|FG001|Overall Study|Adverse Event|1
6125368|NCT00926536|9749922|FG000|Overall Study|Physician Decision|1
6125369|NCT00926536|9749923|FG001|Overall Study|Physician Decision|2
6125370|NCT00926783|9749940|FG000|Overall Study|Incomplete CFAE Procedures|3
6125371|NCT00926783|9749941|FG001|Overall Study|Incomplete CFAE Procedures|3
6125372|NCT00926796|9749949|FG000|Overall Study|Did not receive randomized treatment|4
6125373|NCT00926796|9749950|FG001|Overall Study|Did not receive randomized treatment|7
6125374|NCT00926796|9749949|FG000|Overall Study|Ineligible, negative for gonorrhea|57
6125375|NCT00926796|9749950|FG001|Overall Study|Ineligible, negative for gonorrhea|60
6125376|NCT00926796|9749949|FG000|Overall Study|Ineligible, but positive for gonorrhea|1
6125377|NCT00926796|9749950|FG001|Overall Study|Ineligible, but positive for gonorrhea|1
6125378|NCT00926796|9749949|FG000|Overall Study|Adverse Event|7
6125379|NCT00926796|9749950|FG001|Overall Study|Adverse Event|14
6125380|NCT00926796|9749949|FG000|Overall Study|Lost to Follow-up|22
6125381|NCT00926796|9749950|FG001|Overall Study|Lost to Follow-up|13
6125382|NCT00926796|9749949|FG000|Overall Study|Protocol Violation|15
6125383|NCT00926796|9749950|FG001|Overall Study|Protocol Violation|11
6125384|NCT00926796|9749949|FG000|Overall Study|Withdrawal by Subject|1
6125385|NCT00926796|9749950|FG001|Overall Study|Withdrawal by Subject|0
6125386|NCT00927069|9749992|FG000|Week 0 to Week 12|Worsening of psoriasis|1
6125387|NCT00927069|9749993|FG001|Week 0 to Week 12|Worsening of psoriasis|1
6125388|NCT00927069|9749994|FG002|Week 0 to Week 12|Worsening of psoriasis|0
6125389|NCT00927069|9749995|FG003|Week 0 to Week 12|Worsening of psoriasis|0
6125390|NCT00927069|9749992|FG000|Week 12 to Week 24|Lack of Efficacy|0
6125391|NCT00927069|9749993|FG001|Week 12 to Week 24|Lack of Efficacy|0
6125392|NCT00927069|9749994|FG002|Week 12 to Week 24|Lack of Efficacy|2
6125393|NCT00927069|9749995|FG003|Week 12 to Week 24|Lack of Efficacy|3
6125394|NCT00927069|9749992|FG000|Week 12 to Week 24|Lost to Follow-up|0
6125395|NCT00927069|9749993|FG001|Week 12 to Week 24|Lost to Follow-up|0
6125396|NCT00927069|9749994|FG002|Week 12 to Week 24|Lost to Follow-up|1
6125397|NCT00927069|9749995|FG003|Week 12 to Week 24|Lost to Follow-up|0
6125398|NCT00927069|9749992|FG000|Week 12 to Week 24|Withdrawal by Subject|1
6125399|NCT00927069|9749993|FG001|Week 12 to Week 24|Withdrawal by Subject|0
6125400|NCT00927069|9749994|FG002|Week 12 to Week 24|Withdrawal by Subject|0
6125401|NCT00927069|9749995|FG003|Week 12 to Week 24|Withdrawal by Subject|0
6125402|NCT00927069|9749992|FG000|Week 12 to Week 24|Had a vaccination, removed from study|1
6125403|NCT00927069|9749993|FG001|Week 12 to Week 24|Had a vaccination, removed from study|0
6125404|NCT00927069|9749994|FG002|Week 12 to Week 24|Had a vaccination, removed from study|0
6125405|NCT00927069|9749995|FG003|Week 12 to Week 24|Had a vaccination, removed from study|0
6125406|NCT00927082|9750009|FG000|Overall Study|Lost to Follow-up|9
6125407|NCT00927082|9750010|FG001|Overall Study|Lost to Follow-up|8
6125408|NCT00927082|9750011|FG002|Overall Study|Lost to Follow-up|12
6125409|NCT00927082|9750012|FG003|Overall Study|Lost to Follow-up|16
6125410|NCT00927082|9750009|FG000|Overall Study|Withdrawal by Subject|3
6125411|NCT00927082|9750010|FG001|Overall Study|Withdrawal by Subject|2
6125412|NCT00927082|9750011|FG002|Overall Study|Withdrawal by Subject|7
6125413|NCT00927082|9750012|FG003|Overall Study|Withdrawal by Subject|2
6125414|NCT00927082|9750009|FG000|Overall Study|Death|0
6125415|NCT00927082|9750010|FG001|Overall Study|Death|0
6125416|NCT00927082|9750011|FG002|Overall Study|Death|1
6125417|NCT00927082|9750012|FG003|Overall Study|Death|0
6217587|NCT01641133|9886279|FG002|Overall Study|Migrated/moved from study area|1
6217588|NCT01641133|9886277|FG000|Overall Study|Adverse Event|0
6217589|NCT01641133|9886278|FG001|Overall Study|Adverse Event|0
6217590|NCT01641133|9886279|FG002|Overall Study|Adverse Event|1
6217591|NCT01641133|9886277|FG000|Overall Study|Withdrawal by Subject|5
6217592|NCT01641133|9886278|FG001|Overall Study|Withdrawal by Subject|3
6217593|NCT01641133|9886279|FG002|Overall Study|Withdrawal by Subject|3
6125418|NCT00927082|9750009|FG000|Overall Study|Screen fail,Participant migrated,Unknown|0
6125419|NCT00927082|9750010|FG001|Overall Study|Screen fail,Participant migrated,Unknown|0
6125420|NCT00927082|9750011|FG002|Overall Study|Screen fail,Participant migrated,Unknown|2
6125421|NCT00927082|9750012|FG003|Overall Study|Screen fail,Participant migrated,Unknown|1
6125422|NCT00927095|9750029|FG000|Overall Study|Adverse Event|3
6125423|NCT00927095|9750030|FG001|Overall Study|Adverse Event|1
6125424|NCT00927095|9750031|FG002|Overall Study|Adverse Event|0
6125425|NCT00927095|9750029|FG000|Overall Study|Withdrawal by Subject|2
6125426|NCT00927095|9750030|FG001|Overall Study|Withdrawal by Subject|1
6125427|NCT00927095|9750031|FG002|Overall Study|Withdrawal by Subject|1
6125428|NCT00927095|9750029|FG000|Overall Study|Physician Decision|1
6125429|NCT00927095|9750030|FG001|Overall Study|Physician Decision|2
6125430|NCT00927095|9750031|FG002|Overall Study|Physician Decision|1
6125431|NCT00927186|9750050|FG000|12 Months Primary Study|Adverse Event|5
6125432|NCT00927186|9750051|FG001|12 Months Primary Study|Adverse Event|2
6125433|NCT00927186|9750050|FG000|12 Months Primary Study|Lost to Follow-up|1
6125434|NCT00927186|9750051|FG001|12 Months Primary Study|Lost to Follow-up|0
6125435|NCT00927186|9750050|FG000|12 Months Primary Study|Protocol Violation|0
6125436|NCT00927186|9750051|FG001|12 Months Primary Study|Protocol Violation|1
6125437|NCT00927186|9750050|FG000|12 Months Primary Study|Withdrawal by Subject|1
6125438|NCT00927186|9750051|FG001|12 Months Primary Study|Withdrawal by Subject|1
6125439|NCT00927251|9750060|FG000|Overall Study|Patients not implanted with 4296 lead|8
6125440|NCT00927355|9750077|FG000|Overall Study|Adverse Event|1
6125441|NCT00927355|9750078|FG001|Overall Study|Adverse Event|1
6125442|NCT00927368|9750099|FG000|Overall Study|enrollment in another study|1
6125443|NCT00927368|9750100|FG001|Overall Study|enrollment in another study|1
6125444|NCT00927368|9750101|FG002|Overall Study|enrollment in another study|2
6125445|NCT00927368|9750099|FG000|Overall Study|Lost to Follow-up|4
6125446|NCT00927368|9750100|FG001|Overall Study|Lost to Follow-up|0
6125447|NCT00927368|9750101|FG002|Overall Study|Lost to Follow-up|0
6125448|NCT00927368|9750099|FG000|Overall Study|equipment failure|1
6125449|NCT00927368|9750100|FG001|Overall Study|equipment failure|0
6125450|NCT00927368|9750101|FG002|Overall Study|equipment failure|0
6125451|NCT00927368|9750099|FG000|Overall Study|ineligible post randomization|0
6125452|NCT00927368|9750100|FG001|Overall Study|ineligible post randomization|3
6125453|NCT00927368|9750101|FG002|Overall Study|ineligible post randomization|1
6125454|NCT00927368|9750099|FG000|Overall Study|cancellation of surgery|0
6125455|NCT00927368|9750100|FG001|Overall Study|cancellation of surgery|1
6125456|NCT00927368|9750101|FG002|Overall Study|cancellation of surgery|2
6125457|NCT00927394|9750111|FG000|Overall Study|Adverse Event|14
6125458|NCT00927394|9750112|FG001|Overall Study|Adverse Event|9
6125459|NCT00927394|9750111|FG000|Overall Study|Unsatisfactory therapeutic effect|17
6125460|NCT00927394|9750112|FG001|Overall Study|Unsatisfactory therapeutic effect|23
6125461|NCT00927394|9750111|FG000|Overall Study|Withdrawal by Subject|20
6125462|NCT00927394|9750112|FG001|Overall Study|Withdrawal by Subject|24
6125463|NCT00927394|9750111|FG000|Overall Study|Lost to Follow-up|8
6125464|NCT00927394|9750112|FG001|Overall Study|Lost to Follow-up|14
6125465|NCT00927394|9750111|FG000|Overall Study|Administrative Problem|1
6125466|NCT00927394|9750112|FG001|Overall Study|Administrative Problem|0
6125467|NCT00927394|9750111|FG000|Overall Study|Death|1
6125468|NCT00927394|9750112|FG001|Overall Study|Death|1
6125469|NCT00927394|9750111|FG000|Overall Study|Protocol deviation|16
6125470|NCT00927394|9750112|FG001|Overall Study|Protocol deviation|13
6125471|NCT00927394|9750111|FG000|Overall Study|Randomized in error|0
6125472|NCT00927394|9750112|FG001|Overall Study|Randomized in error|1
6125473|NCT00927472|9750121|FG000|Overall Study|Withdrawal by Subject|10
6125474|NCT00927472|9750122|FG001|Overall Study|Withdrawal by Subject|11
6125475|NCT00927472|9750121|FG000|Overall Study|Lost to Follow-up|1
6217594|NCT01641133|9886277|FG000|Overall Study|Lost to Follow-up|0
6217595|NCT01641133|9886278|FG001|Overall Study|Lost to Follow-up|2
6217596|NCT01641133|9886279|FG002|Overall Study|Lost to Follow-up|2
6217597|NCT01641159|9886289|FG000|Overall Study|Lost to Follow-up|2
6217598|NCT01641159|9886290|FG001|Overall Study|Lost to Follow-up|1
6288320|NCT02365298|10002026|FG001|Period 2|Protocol Violation|1
6288321|NCT02365480|10002034|FG000|Overall Study|Withdrawal by Subject|2
6125476|NCT00927472|9750122|FG001|Overall Study|Lost to Follow-up|6
6125477|NCT00927472|9750121|FG000|Overall Study|Protocol Violation|0
6125478|NCT00927472|9750122|FG001|Overall Study|Protocol Violation|1
6125479|NCT00927472|9750121|FG000|Overall Study|Post treatment Assessment out of window|0
6125480|NCT00927472|9750122|FG001|Overall Study|Post treatment Assessment out of window|4
6125481|NCT00927485|9750130|FG000|Overall Study|Adverse Event|4
6125482|NCT00927485|9750131|FG001|Overall Study|Adverse Event|2
6125483|NCT00927485|9750130|FG000|Overall Study|noncompliance, prophylactic surgery, inc|2
6125484|NCT00927485|9750131|FG001|Overall Study|noncompliance, prophylactic surgery, inc|2
6125485|NCT00927563|9750137|FG000|Overall Study|Lost to Follow-up|1
6125486|NCT00927563|9750137|FG000|Overall Study|Withdrawal by Subject|1
6125487|NCT00927589|9750149|FG000|Overall Study|Death|1
6125488|NCT00927589|9750149|FG000|Overall Study|Physician Decision|1
6125489|NCT00927589|9750149|FG000|Overall Study|Withdrawal by Subject|3
6125490|NCT00927589|9750149|FG000|Overall Study|Adverse Event|2
6125491|NCT00927589|9750149|FG000|Overall Study|Disease Progression|8
6125492|NCT00927589|9750149|FG000|Overall Study|Non-compliance|1
6125493|NCT00927758|9750153|FG000|Treatment Cycle 1 (Day 1 - Day 7)|Withdrawal by Subject|0
6125494|NCT00927758|9750154|FG001|Treatment Cycle 1 (Day 1 - Day 7)|Withdrawal by Subject|0
6125495|NCT00927758|9750155|FG002|Treatment Cycle 1 (Day 1 - Day 7)|Withdrawal by Subject|0
6125496|NCT00927758|9750156|FG003|Treatment Cycle 1 (Day 1 - Day 7)|Withdrawal by Subject|1
6288322|NCT02365480|10002035|FG001|Overall Study|Withdrawal by Subject|0
6125497|NCT00927758|9750157|FG004|Treatment Cycle 1 (Day 1 - Day 7)|Withdrawal by Subject|0
6125498|NCT00927758|9750158|FG005|Treatment Cycle 1 (Day 1 - Day 7)|Withdrawal by Subject|1
6125499|NCT00927758|9750153|FG000|Treatment Cycle 2 (Day 1 - Day 7)|Did not meet eNO criteria|0
6125500|NCT00927758|9750154|FG001|Treatment Cycle 2 (Day 1 - Day 7)|Did not meet eNO criteria|0
6125501|NCT00927758|9750155|FG002|Treatment Cycle 2 (Day 1 - Day 7)|Did not meet eNO criteria|1
6125502|NCT00927758|9750156|FG003|Treatment Cycle 2 (Day 1 - Day 7)|Did not meet eNO criteria|1
6125503|NCT00927758|9750157|FG004|Treatment Cycle 2 (Day 1 - Day 7)|Did not meet eNO criteria|0
6125504|NCT00927758|9750158|FG005|Treatment Cycle 2 (Day 1 - Day 7)|Did not meet eNO criteria|1
6125505|NCT00927784|9750168|FG000|Overall Study|Death|1
6125506|NCT00927784|9750169|FG001|Overall Study|Death|0
6125507|NCT00927784|9750168|FG000|Overall Study|Withdrawal by Subject|1
6125508|NCT00927784|9750169|FG001|Overall Study|Withdrawal by Subject|0
6125509|NCT00927810|9750179|FG000|Overall Study|Withdrawal by Subject|0
6125510|NCT00927810|9750180|FG001|Overall Study|Withdrawal by Subject|3
6125511|NCT00927810|9750181|FG002|Overall Study|Withdrawal by Subject|0
6125512|NCT00927810|9750182|FG003|Overall Study|Withdrawal by Subject|1
6125513|NCT00927810|9750179|FG000|Overall Study|Lost to Follow-up|0
6125514|NCT00927810|9750180|FG001|Overall Study|Lost to Follow-up|2
6125515|NCT00927810|9750181|FG002|Overall Study|Lost to Follow-up|1
6125516|NCT00927810|9750182|FG003|Overall Study|Lost to Follow-up|1
6125517|NCT00927810|9750179|FG000|Overall Study|Death|0
6125518|NCT00927810|9750180|FG001|Overall Study|Death|2
6125519|NCT00927810|9750181|FG002|Overall Study|Death|0
6125520|NCT00927810|9750182|FG003|Overall Study|Death|0
6125521|NCT00927810|9750179|FG000|Overall Study|Abnormal laboratory value(s)|0
6125522|NCT00927810|9750180|FG001|Overall Study|Abnormal laboratory value(s)|1
6125523|NCT00927810|9750181|FG002|Overall Study|Abnormal laboratory value(s)|0
6125524|NCT00927810|9750182|FG003|Overall Study|Abnormal laboratory value(s)|0
6125525|NCT00927823|9750200|FG000|Continuous Dosing Period|Death|0
6125526|NCT00927823|9750201|FG001|Continuous Dosing Period|Death|0
6125527|NCT00927823|9750202|FG002|Continuous Dosing Period|Death|6
6125528|NCT00927823|9750203|FG003|Continuous Dosing Period|Death|0
6125529|NCT00927823|9750200|FG000|Continuous Dosing Period|Lost to Follow-up|1
6125530|NCT00927823|9750201|FG001|Continuous Dosing Period|Lost to Follow-up|1
6125531|NCT00927823|9750202|FG002|Continuous Dosing Period|Lost to Follow-up|9
6125532|NCT00927823|9750203|FG003|Continuous Dosing Period|Lost to Follow-up|0
6125533|NCT00927823|9750200|FG000|Continuous Dosing Period|Withdrawal by Subject|1
6125534|NCT00927823|9750201|FG001|Continuous Dosing Period|Withdrawal by Subject|0
6125535|NCT00927823|9750202|FG002|Continuous Dosing Period|Withdrawal by Subject|2
6125536|NCT00927823|9750203|FG003|Continuous Dosing Period|Withdrawal by Subject|2
6125537|NCT00927823|9750200|FG000|Continuous Dosing Period|Other|1
6125538|NCT00927823|9750201|FG001|Continuous Dosing Period|Other|2
6125539|NCT00927823|9750202|FG002|Continuous Dosing Period|Other|9
6125540|NCT00927823|9750203|FG003|Continuous Dosing Period|Other|3
6125541|NCT00927862|9750235|FG000|Overall Study|Missing data needed for endpt analyses|27
6125542|NCT00927862|9750236|FG001|Overall Study|Missing data needed for endpt analyses|45
6125543|NCT00927901|9750255|FG000|Treatment Period 1|Subject withdrew consent|0
6125544|NCT00927901|9750256|FG001|Treatment Period 1|Subject withdrew consent|0
6125545|NCT00927901|9750257|FG002|Treatment Period 1|Subject withdrew consent|1
6125546|NCT00927901|9750258|FG003|Treatment Period 1|Subject withdrew consent|0
6125547|NCT00927901|9750255|FG000|Treatment Period 4|Adverse Event|0
6125548|NCT00927901|9750256|FG001|Treatment Period 4|Adverse Event|0
6125549|NCT00927901|9750257|FG002|Treatment Period 4|Adverse Event|0
6125550|NCT00927901|9750258|FG003|Treatment Period 4|Adverse Event|1
6125551|NCT00927901|9750255|FG000|Treatment Period 4|Subject withdrew consent|0
6125552|NCT00927901|9750256|FG001|Treatment Period 4|Subject withdrew consent|0
6125553|NCT00927901|9750257|FG002|Treatment Period 4|Subject withdrew consent|1
6125554|NCT00927901|9750258|FG003|Treatment Period 4|Subject withdrew consent|0
6125555|NCT00927927|9750286|FG000|Overall Study|Withdrawal by Subject|0
6125556|NCT00927927|9750287|FG001|Overall Study|Withdrawal by Subject|0
6125557|NCT00927927|9750288|FG002|Overall Study|Withdrawal by Subject|0
6125558|NCT00927927|9750289|FG003|Overall Study|Withdrawal by Subject|0
6125559|NCT00927927|9750290|FG004|Overall Study|Withdrawal by Subject|0
6125560|NCT00927927|9750291|FG005|Overall Study|Withdrawal by Subject|0
6217599|NCT01641159|9886289|FG000|Overall Study|Withdrawal by Subject|0
6217600|NCT01641159|9886290|FG001|Overall Study|Withdrawal by Subject|1
6217601|NCT01641198|9886299|FG000|After 12 Months of Function|Lost to Follow-up|3
6217602|NCT01641198|9886300|FG001|After 12 Months of Function|Lost to Follow-up|2
6288323|NCT02365506|10002044|FG000|Overall Study|Investigator's Discretion|0
6288324|NCT02365506|10002045|FG001|Overall Study|Investigator's Discretion|0
6288325|NCT02365506|10002046|FG002|Overall Study|Investigator's Discretion|1
6288326|NCT02365519|10002056|FG000|Randomized and Treated|Adverse Event|0
6288327|NCT02365519|10002057|FG001|Randomized and Treated|Adverse Event|1
6125561|NCT00927927|9750292|FG006|Overall Study|Withdrawal by Subject|0
6125562|NCT00927927|9750293|FG007|Overall Study|Withdrawal by Subject|2
6125563|NCT00927927|9750294|FG008|Overall Study|Withdrawal by Subject|0
6125564|NCT00927927|9750295|FG009|Overall Study|Withdrawal by Subject|0
6125565|NCT00927927|9750296|FG010|Overall Study|Withdrawal by Subject|0
6125566|NCT00927927|9750297|FG011|Overall Study|Withdrawal by Subject|2
6125567|NCT00927927|9750298|FG012|Overall Study|Withdrawal by Subject|0
6125568|NCT00927927|9750299|FG013|Overall Study|Withdrawal by Subject|0
6125569|NCT00927927|9750300|FG014|Overall Study|Withdrawal by Subject|0
6217603|NCT01641198|9886301|FG002|After 12 Months of Function|Lost to Follow-up|2
6217604|NCT01641198|9886299|FG000|After 12 Months of Function|Protocol Violation|1
6217605|NCT01641198|9886300|FG001|After 12 Months of Function|Protocol Violation|0
6217606|NCT01641198|9886301|FG002|After 12 Months of Function|Protocol Violation|0
6217607|NCT01641198|9886299|FG000|After 12 Months of Function|Adverse Event|0
6217608|NCT01641198|9886300|FG001|After 12 Months of Function|Adverse Event|1
6217609|NCT01641198|9886301|FG002|After 12 Months of Function|Adverse Event|0
6217610|NCT01641198|9886299|FG000|After 24 Months of Function|Lost to Follow-up|4
6217611|NCT01641198|9886300|FG001|After 24 Months of Function|Lost to Follow-up|9
6125570|NCT00927940|9750332|FG000|Overall Study|Death|1
6125571|NCT00928018|9750343|FG000|Overall Study|Withdrawal by Subject|1
6125572|NCT00928018|9750344|FG001|Overall Study|Withdrawal by Subject|0
6125573|NCT00928057|9750356|FG000|Overall Study|Adverse Event|1
6125574|NCT00928057|9750357|FG001|Overall Study|Adverse Event|2
6125575|NCT00928057|9750356|FG000|Overall Study|Withdrawal by Subject|1
6125576|NCT00928057|9750357|FG001|Overall Study|Withdrawal by Subject|0
6125577|NCT00928057|9750356|FG000|Overall Study|Lost to Follow-up|0
6125578|NCT00928057|9750357|FG001|Overall Study|Lost to Follow-up|1
6125579|NCT00928057|9750356|FG000|Overall Study|Protocol Violation|0
6125580|NCT00928057|9750357|FG001|Overall Study|Protocol Violation|1
6125581|NCT00928070|9750375|FG000|Overall Study|Lost to Follow-up|1
6125582|NCT00928070|9750376|FG001|Overall Study|Lost to Follow-up|2
6125583|NCT00928070|9750375|FG000|Overall Study|Withdrawal by Subject|10
6125584|NCT00928070|9750376|FG001|Overall Study|Withdrawal by Subject|3
6125585|NCT00928070|9750375|FG000|Overall Study|Adverse Event|14
6125586|NCT00928070|9750376|FG001|Overall Study|Adverse Event|26
6125587|NCT00928070|9750375|FG000|Overall Study|Lack of Efficacy|9
6125588|NCT00928070|9750376|FG001|Overall Study|Lack of Efficacy|5
6125589|NCT00928070|9750375|FG000|Overall Study|Did not meet entrance criteria|16
6125590|NCT00928070|9750376|FG001|Overall Study|Did not meet entrance criteria|9
6125591|NCT00928070|9750375|FG000|Overall Study|Protocol Violation|6
6125592|NCT00928070|9750376|FG001|Overall Study|Protocol Violation|5
6125593|NCT00928070|9750375|FG000|Overall Study|Randomized but not treated|2
6125594|NCT00928070|9750376|FG001|Overall Study|Randomized but not treated|2
6125595|NCT00928070|9750375|FG000|Overall Study|Other|5
6125596|NCT00928070|9750376|FG001|Overall Study|Other|5
6125597|NCT00928135|9750444|FG000|Overall Study|Withdrawal by Subject|1
6125598|NCT00928135|9750445|FG001|Overall Study|Withdrawal by Subject|0
6125599|NCT00928187|9750458|FG000|Overall Study|Death|1
6125600|NCT00928187|9750459|FG001|Overall Study|Death|2
6125601|NCT00928187|9750460|FG002|Overall Study|Death|3
6125602|NCT00928187|9750458|FG000|Overall Study|Lost to Follow-up|1
6125603|NCT00928187|9750459|FG001|Overall Study|Lost to Follow-up|2
6125604|NCT00928187|9750460|FG002|Overall Study|Lost to Follow-up|1
6125605|NCT00928187|9750458|FG000|Overall Study|Withdrawal by Subject|0
6125606|NCT00928187|9750459|FG001|Overall Study|Withdrawal by Subject|1
6125607|NCT00928187|9750460|FG002|Overall Study|Withdrawal by Subject|1
6125608|NCT00928187|9750458|FG000|Overall Study|Protocol Violation|0
6125609|NCT00928187|9750459|FG001|Overall Study|Protocol Violation|1
6217612|NCT01641198|9886301|FG002|After 24 Months of Function|Lost to Follow-up|6
6217613|NCT01641198|9886299|FG000|At 15-20 Years of Function|Lost to Follow-up|5
6217614|NCT01641198|9886300|FG001|At 15-20 Years of Function|Lost to Follow-up|1
6217615|NCT01641198|9886301|FG002|At 15-20 Years of Function|Lost to Follow-up|1
6217616|NCT01641198|9886299|FG000|At 15-20 Years of Function|Death|1
6217617|NCT01641198|9886300|FG001|At 15-20 Years of Function|Death|0
6217618|NCT01641198|9886301|FG002|At 15-20 Years of Function|Death|1
6217619|NCT01641237|9886310|FG000|Period II|Withdrawal by Subject|1
6217620|NCT01641237|9886311|FG001|Period II|Withdrawal by Subject|0
6217621|NCT01641237|9886312|FG002|Period II|Withdrawal by Subject|0
6217622|NCT01641237|9886313|FG003|Period II|Withdrawal by Subject|0
6217623|NCT01641237|9886310|FG000|Period III|Lost to Follow-up|1
6217624|NCT01641237|9886311|FG001|Period III|Lost to Follow-up|0
6217625|NCT01641237|9886312|FG002|Period III|Lost to Follow-up|0
6217626|NCT01641237|9886313|FG003|Period III|Lost to Follow-up|0
6288328|NCT02365519|10002058|FG002|Randomized and Treated|Adverse Event|0
6288329|NCT02365519|10002056|FG000|Randomized and Treated|Withdrawal by Subject|0
6288330|NCT02365519|10002057|FG001|Randomized and Treated|Withdrawal by Subject|1
6288331|NCT02365519|10002058|FG002|Randomized and Treated|Withdrawal by Subject|1
6288332|NCT02365558|10002067|FG000|Period 1 (Day 1 Through Day 7)|Adverse Event|1
6288333|NCT02365558|10002068|FG001|Period 1 (Day 1 Through Day 7)|Adverse Event|0
6288334|NCT02365558|10002067|FG000|Period 2 (Day 8 Through Day 20)|Withdrawal by Subject|0
6125610|NCT00928187|9750460|FG002|Overall Study|Protocol Violation|0
6125611|NCT00928252|9750472|FG000|Overall Study|Physician Decision|3
6125612|NCT00928408|9750495|FG000|Overall Study|Other|2
6125613|NCT00928408|9750495|FG000|Overall Study|Withdrawal by Subject|4
6125614|NCT00928408|9750495|FG000|Overall Study|Death|5
6125615|NCT00928408|9750495|FG000|Overall Study|Lost to Follow-up|12
6125616|NCT00928434|9750506|FG000|Overall Study|Adverse Event|14
6125617|NCT00928434|9750507|FG001|Overall Study|Adverse Event|5
6125618|NCT00928434|9750508|FG002|Overall Study|Adverse Event|18
6125619|NCT00928434|9750506|FG000|Overall Study|Protocol Violation|5
6125620|NCT00928434|9750507|FG001|Overall Study|Protocol Violation|0
6125621|NCT00928434|9750508|FG002|Overall Study|Protocol Violation|8
6125622|NCT00928434|9750506|FG000|Overall Study|Physician Decision|2
6125623|NCT00928434|9750507|FG001|Overall Study|Physician Decision|0
6288335|NCT02365558|10002068|FG001|Period 2 (Day 8 Through Day 20)|Withdrawal by Subject|1
6288336|NCT02365584|10002079|FG000|Overall Study|Adverse Event|2
6288337|NCT02365584|10002080|FG001|Overall Study|Adverse Event|2
6125624|NCT00928434|9750508|FG002|Overall Study|Physician Decision|3
6125625|NCT00928434|9750506|FG000|Overall Study|Lost to Follow-up|1
6288338|NCT02365584|10002079|FG000|Overall Study|Withdrawal by Subject|1
6125626|NCT00928434|9750507|FG001|Overall Study|Lost to Follow-up|0
6125627|NCT00928434|9750508|FG002|Overall Study|Lost to Follow-up|3
6125628|NCT00928434|9750506|FG000|Overall Study|Withdrawal by Subject|5
6125629|NCT00928434|9750507|FG001|Overall Study|Withdrawal by Subject|3
6125630|NCT00928434|9750508|FG002|Overall Study|Withdrawal by Subject|2
6125631|NCT00928434|9750506|FG000|Overall Study|PSA failure (>2 ng/mL) at Visit 8|10
6125632|NCT00928434|9750507|FG001|Overall Study|PSA failure (>2 ng/mL) at Visit 8|4
6125633|NCT00928434|9750508|FG002|Overall Study|PSA failure (>2 ng/mL) at Visit 8|7
6125634|NCT00928434|9750506|FG000|Overall Study|PSA failure (>2 ng/mL) on other visit|2
6125635|NCT00928434|9750507|FG001|Overall Study|PSA failure (>2 ng/mL) on other visit|1
6125636|NCT00928434|9750508|FG002|Overall Study|PSA failure (>2 ng/mL) on other visit|1
6125637|NCT00928434|9750506|FG000|Overall Study|Other (not meeting above criteria)|5
6125638|NCT00928434|9750507|FG001|Overall Study|Other (not meeting above criteria)|1
6125639|NCT00928434|9750508|FG002|Overall Study|Other (not meeting above criteria)|2
6125640|NCT00928486|9750524|FG000|Overall Study|Adverse Event|2
6125641|NCT00928486|9750524|FG000|Overall Study|Disease Progression|7
6125642|NCT00928486|9750524|FG000|Overall Study|Withdrawal by Subject|1
6125643|NCT00928512|9750533|FG000|Overall Study|Adverse Event|4
6125644|NCT00928512|9750534|FG001|Overall Study|Adverse Event|3
6125645|NCT00928512|9750535|FG002|Overall Study|Adverse Event|2
6217627|NCT01641367|9886329|FG000|Cohorts|Death|18
6217628|NCT01641367|9886330|FG001|Cohorts|Death|1
6217629|NCT01641367|9886331|FG002|Cohorts|Death|2
6217630|NCT01641367|9886332|FG003|Cohorts|Death|0
6217631|NCT01641367|9886333|FG004|Cohorts|Death|1
6217632|NCT01641367|9886334|FG005|Cohorts|Death|1
6217633|NCT01641367|9886335|FG006|Cohorts|Death|0
6217634|NCT01641367|9886336|FG007|Cohorts|Death|0
6217635|NCT01641367|9886329|FG000|Cohorts|Lost to Follow-up|16
6217636|NCT01641367|9886330|FG001|Cohorts|Lost to Follow-up|0
6217637|NCT01641367|9886331|FG002|Cohorts|Lost to Follow-up|2
6217638|NCT01641367|9886332|FG003|Cohorts|Lost to Follow-up|0
6217639|NCT01641367|9886333|FG004|Cohorts|Lost to Follow-up|2
6217640|NCT01641367|9886334|FG005|Cohorts|Lost to Follow-up|0
6217641|NCT01641367|9886335|FG006|Cohorts|Lost to Follow-up|0
6217642|NCT01641367|9886336|FG007|Cohorts|Lost to Follow-up|0
6217643|NCT01641367|9886329|FG000|Randomized Adherence Intervention|Death|0
6217644|NCT01641367|9886330|FG001|Randomized Adherence Intervention|Death|0
6217645|NCT01641367|9886331|FG002|Randomized Adherence Intervention|Death|0
6217646|NCT01641367|9886332|FG003|Randomized Adherence Intervention|Death|0
6217647|NCT01641367|9886333|FG004|Randomized Adherence Intervention|Death|0
6217648|NCT01641367|9886334|FG005|Randomized Adherence Intervention|Death|0
6217649|NCT01641367|9886335|FG006|Randomized Adherence Intervention|Death|11
6217650|NCT01641367|9886336|FG007|Randomized Adherence Intervention|Death|12
6217651|NCT01641367|9886329|FG000|Randomized Adherence Intervention|Lost to Follow-up|0
6217652|NCT01641367|9886330|FG001|Randomized Adherence Intervention|Lost to Follow-up|0
6217653|NCT01641367|9886331|FG002|Randomized Adherence Intervention|Lost to Follow-up|0
6217654|NCT01641367|9886332|FG003|Randomized Adherence Intervention|Lost to Follow-up|0
6217655|NCT01641367|9886333|FG004|Randomized Adherence Intervention|Lost to Follow-up|0
6217656|NCT01641367|9886334|FG005|Randomized Adherence Intervention|Lost to Follow-up|0
6217657|NCT01641367|9886335|FG006|Randomized Adherence Intervention|Lost to Follow-up|8
6288339|NCT02365584|10002080|FG001|Overall Study|Withdrawal by Subject|0
6288340|NCT02365584|10002079|FG000|Overall Study|Disease Progression|9
6288341|NCT02365584|10002080|FG001|Overall Study|Disease Progression|12
6217658|NCT01641367|9886336|FG007|Randomized Adherence Intervention|Lost to Follow-up|12
6217659|NCT01641471|9886380|FG000|Overall Study|Withdrawal by Subject|19
6217660|NCT01641471|9886381|FG001|Overall Study|Withdrawal by Subject|19
6217661|NCT01641471|9886380|FG000|Overall Study|Lost to Follow-up|2
6217662|NCT01641471|9886381|FG001|Overall Study|Lost to Follow-up|4
6217663|NCT01641471|9886380|FG000|Overall Study|Protocol Violation|2
6217664|NCT01641471|9886381|FG001|Overall Study|Protocol Violation|4
6217665|NCT01641640|9886387|FG000|Overall Study|Enrolled but not treated|1
6217666|NCT01641640|9886387|FG000|Overall Study|Efficacy failure|29
6217667|NCT01641640|9886387|FG000|Overall Study|Lost to Follow-up|3
6125646|NCT00928512|9750536|FG003|Overall Study|Adverse Event|8
6217668|NCT01641640|9886387|FG000|Overall Study|Withdrawal by Subject|2
6217669|NCT01641640|9886387|FG000|Overall Study|Adverse Event|1
6125647|NCT00928512|9750537|FG004|Overall Study|Adverse Event|6
6125648|NCT00928512|9750533|FG000|Overall Study|Lack of Efficacy|2
6125649|NCT00928512|9750534|FG001|Overall Study|Lack of Efficacy|0
6125650|NCT00928512|9750535|FG002|Overall Study|Lack of Efficacy|4
6125651|NCT00928512|9750536|FG003|Overall Study|Lack of Efficacy|7
6125652|NCT00928512|9750537|FG004|Overall Study|Lack of Efficacy|3
6125653|NCT00928512|9750533|FG000|Overall Study|Protocol Violation|0
6125654|NCT00928512|9750534|FG001|Overall Study|Protocol Violation|1
6125655|NCT00928512|9750535|FG002|Overall Study|Protocol Violation|0
6125656|NCT00928512|9750536|FG003|Overall Study|Protocol Violation|1
6125657|NCT00928512|9750537|FG004|Overall Study|Protocol Violation|3
6125658|NCT00928512|9750533|FG000|Overall Study|Withdrawal by Subject|3
6125659|NCT00928512|9750534|FG001|Overall Study|Withdrawal by Subject|0
6125660|NCT00928512|9750535|FG002|Overall Study|Withdrawal by Subject|3
6125661|NCT00928512|9750536|FG003|Overall Study|Withdrawal by Subject|4
6125662|NCT00928512|9750537|FG004|Overall Study|Withdrawal by Subject|0
6125663|NCT00928512|9750533|FG000|Overall Study|Lost to Follow-up|1
6125664|NCT00928512|9750534|FG001|Overall Study|Lost to Follow-up|1
6125665|NCT00928512|9750535|FG002|Overall Study|Lost to Follow-up|2
6125666|NCT00928512|9750536|FG003|Overall Study|Lost to Follow-up|1
6125667|NCT00928512|9750537|FG004|Overall Study|Lost to Follow-up|3
6125668|NCT00928512|9750533|FG000|Overall Study|Administrative Problems|0
6125669|NCT00928512|9750534|FG001|Overall Study|Administrative Problems|1
6217670|NCT01641692|9886403|FG000|Treatment Period 1|Adverse Event|1
6217671|NCT01641692|9886404|FG001|Treatment Period 1|Adverse Event|0
6217672|NCT01641692|9886405|FG002|Treatment Period 1|Adverse Event|0
6217673|NCT01641692|9886406|FG003|Treatment Period 1|Adverse Event|0
6217674|NCT01641692|9886407|FG004|Treatment Period 1|Adverse Event|0
6217675|NCT01641692|9886408|FG005|Treatment Period 1|Adverse Event|0
6217676|NCT01641692|9886409|FG006|Treatment Period 1|Adverse Event|0
6217677|NCT01641692|9886410|FG007|Treatment Period 1|Adverse Event|0
6217678|NCT01641692|9886403|FG000|Treatment Period 1|Lack of Efficacy|0
6217679|NCT01641692|9886404|FG001|Treatment Period 1|Lack of Efficacy|0
6217680|NCT01641692|9886405|FG002|Treatment Period 1|Lack of Efficacy|0
6217681|NCT01641692|9886406|FG003|Treatment Period 1|Lack of Efficacy|0
6217682|NCT01641692|9886407|FG004|Treatment Period 1|Lack of Efficacy|0
6217683|NCT01641692|9886408|FG005|Treatment Period 1|Lack of Efficacy|0
6217684|NCT01641692|9886409|FG006|Treatment Period 1|Lack of Efficacy|0
6217685|NCT01641692|9886410|FG007|Treatment Period 1|Lack of Efficacy|1
6217686|NCT01641692|9886403|FG000|Treatment Period 1|Protocol Violation|1
6217687|NCT01641692|9886404|FG001|Treatment Period 1|Protocol Violation|0
6217688|NCT01641692|9886405|FG002|Treatment Period 1|Protocol Violation|0
6288342|NCT02365636|10002089|FG000|Overall Study|Adverse Event|3
6288343|NCT02365636|10002090|FG001|Overall Study|Adverse Event|3
6288344|NCT02365636|10002091|FG002|Overall Study|Adverse Event|2
6288345|NCT02365636|10002089|FG000|Overall Study|Protocol Violation|1
6288346|NCT02365636|10002090|FG001|Overall Study|Protocol Violation|4
6288347|NCT02365636|10002091|FG002|Overall Study|Protocol Violation|0
6288348|NCT02365636|10002089|FG000|Overall Study|Lost to Follow-up|0
6288349|NCT02365636|10002090|FG001|Overall Study|Lost to Follow-up|0
6288350|NCT02365636|10002091|FG002|Overall Study|Lost to Follow-up|1
6288351|NCT02365636|10002089|FG000|Overall Study|Other|2
6288352|NCT02365636|10002090|FG001|Overall Study|Other|0
6288353|NCT02365636|10002091|FG002|Overall Study|Other|0
6288354|NCT02366091|10002125|FG000|Overall Study|Withdrawal by Subject|3
6288355|NCT02366091|10002126|FG001|Overall Study|Withdrawal by Subject|7
6288356|NCT02366091|10002127|FG002|Overall Study|Withdrawal by Subject|3
6288357|NCT02366091|10002128|FG003|Overall Study|Withdrawal by Subject|1
6288358|NCT02366130|10002138|FG000|Overall Study|Withdrawal by Subject|3
6288359|NCT02366130|10002138|FG000|Overall Study|Ineligible|6
6288360|NCT02366143|10002145|FG000|Overall Study|Death|307
6288361|NCT02366143|10002146|FG001|Overall Study|Death|278
6288362|NCT02366143|10002147|FG002|Overall Study|Death|280
6288363|NCT02366143|10002145|FG000|Overall Study|Lost to Follow-up|2
6288364|NCT02366143|10002146|FG001|Overall Study|Lost to Follow-up|4
6288365|NCT02366143|10002147|FG002|Overall Study|Lost to Follow-up|2
6288366|NCT02366143|10002145|FG000|Overall Study|Physician Decision|1
6288367|NCT02366143|10002146|FG001|Overall Study|Physician Decision|2
6288368|NCT02366143|10002147|FG002|Overall Study|Physician Decision|1
6288369|NCT02366143|10002145|FG000|Overall Study|Protocol Violation|0
6288370|NCT02366143|10002146|FG001|Overall Study|Protocol Violation|0
6288371|NCT02366143|10002147|FG002|Overall Study|Protocol Violation|2
6288372|NCT02366143|10002145|FG000|Overall Study|Withdrawal by Subject|16
6288373|NCT02366143|10002146|FG001|Overall Study|Withdrawal by Subject|17
6288374|NCT02366143|10002147|FG002|Overall Study|Withdrawal by Subject|22
6288375|NCT02366143|10002145|FG000|Overall Study|Sponsor request to withdraw/discontinue patient|0
6288376|NCT02366143|10002146|FG001|Overall Study|Sponsor request to withdraw/discontinue patient|6
6288377|NCT02366143|10002147|FG002|Overall Study|Sponsor request to withdraw/discontinue patient|0
6125670|NCT00928512|9750535|FG002|Overall Study|Administrative Problems|0
6125671|NCT00928512|9750536|FG003|Overall Study|Administrative Problems|0
6125672|NCT00928512|9750537|FG004|Overall Study|Administrative Problems|0
6217689|NCT01641692|9886406|FG003|Treatment Period 1|Protocol Violation|0
6288378|NCT02366143|10002145|FG000|Overall Study|Increased Microscopic RBCS on Urinalysis|0
6288379|NCT02366143|10002146|FG001|Overall Study|Increased Microscopic RBCS on Urinalysis|1
6125673|NCT00928564|9750555|FG000|Overall Study|Lost to Follow-up|6
6125674|NCT00928564|9750556|FG001|Overall Study|Lost to Follow-up|0
6217690|NCT01641692|9886407|FG004|Treatment Period 1|Protocol Violation|2
6217691|NCT01641692|9886408|FG005|Treatment Period 1|Protocol Violation|0
6217692|NCT01641692|9886409|FG006|Treatment Period 1|Protocol Violation|0
6217693|NCT01641692|9886410|FG007|Treatment Period 1|Protocol Violation|0
6217694|NCT01641692|9886403|FG000|Treatment Period 1|Protocol-defined Stopping Criteria|0
6217695|NCT01641692|9886404|FG001|Treatment Period 1|Protocol-defined Stopping Criteria|0
6217696|NCT01641692|9886405|FG002|Treatment Period 1|Protocol-defined Stopping Criteria|0
6217697|NCT01641692|9886406|FG003|Treatment Period 1|Protocol-defined Stopping Criteria|0
6217698|NCT01641692|9886407|FG004|Treatment Period 1|Protocol-defined Stopping Criteria|1
6217699|NCT01641692|9886408|FG005|Treatment Period 1|Protocol-defined Stopping Criteria|0
6217700|NCT01641692|9886409|FG006|Treatment Period 1|Protocol-defined Stopping Criteria|0
6217701|NCT01641692|9886410|FG007|Treatment Period 1|Protocol-defined Stopping Criteria|1
6217702|NCT01641692|9886403|FG000|Treatment Period 1|Lost to Follow-up|0
6217703|NCT01641692|9886404|FG001|Treatment Period 1|Lost to Follow-up|0
6217704|NCT01641692|9886405|FG002|Treatment Period 1|Lost to Follow-up|1
6217705|NCT01641692|9886406|FG003|Treatment Period 1|Lost to Follow-up|0
6217706|NCT01641692|9886407|FG004|Treatment Period 1|Lost to Follow-up|0
6217707|NCT01641692|9886408|FG005|Treatment Period 1|Lost to Follow-up|0
6217708|NCT01641692|9886409|FG006|Treatment Period 1|Lost to Follow-up|0
6217709|NCT01641692|9886410|FG007|Treatment Period 1|Lost to Follow-up|0
6217710|NCT01641692|9886403|FG000|Treatment Period 1|Physician Decision|0
6217711|NCT01641692|9886404|FG001|Treatment Period 1|Physician Decision|0
6217712|NCT01641692|9886405|FG002|Treatment Period 1|Physician Decision|0
6217713|NCT01641692|9886406|FG003|Treatment Period 1|Physician Decision|0
6217714|NCT01641692|9886407|FG004|Treatment Period 1|Physician Decision|1
6217715|NCT01641692|9886408|FG005|Treatment Period 1|Physician Decision|0
6217716|NCT01641692|9886409|FG006|Treatment Period 1|Physician Decision|0
6217717|NCT01641692|9886410|FG007|Treatment Period 1|Physician Decision|0
6217718|NCT01641692|9886403|FG000|Treatment Period 1|Withdrawal by Subject|0
6217719|NCT01641692|9886404|FG001|Treatment Period 1|Withdrawal by Subject|0
6217720|NCT01641692|9886405|FG002|Treatment Period 1|Withdrawal by Subject|0
6217721|NCT01641692|9886406|FG003|Treatment Period 1|Withdrawal by Subject|0
6217722|NCT01641692|9886407|FG004|Treatment Period 1|Withdrawal by Subject|0
6217723|NCT01641692|9886408|FG005|Treatment Period 1|Withdrawal by Subject|2
6217724|NCT01641692|9886409|FG006|Treatment Period 1|Withdrawal by Subject|0
6217725|NCT01641692|9886410|FG007|Treatment Period 1|Withdrawal by Subject|1
6217726|NCT01641692|9886403|FG000|Washout Period 1 (12-14 Days)|Adverse Event|2
6217727|NCT01641692|9886404|FG001|Washout Period 1 (12-14 Days)|Adverse Event|0
6217728|NCT01641692|9886405|FG002|Washout Period 1 (12-14 Days)|Adverse Event|0
6217729|NCT01641692|9886406|FG003|Washout Period 1 (12-14 Days)|Adverse Event|0
6217730|NCT01641692|9886407|FG004|Washout Period 1 (12-14 Days)|Adverse Event|0
6217731|NCT01641692|9886408|FG005|Washout Period 1 (12-14 Days)|Adverse Event|0
6217732|NCT01641692|9886409|FG006|Washout Period 1 (12-14 Days)|Adverse Event|0
6217733|NCT01641692|9886410|FG007|Washout Period 1 (12-14 Days)|Adverse Event|0
6217734|NCT01641692|9886403|FG000|Washout Period 1 (12-14 Days)|Protocol Violation|0
6217735|NCT01641692|9886404|FG001|Washout Period 1 (12-14 Days)|Protocol Violation|0
6217736|NCT01641692|9886405|FG002|Washout Period 1 (12-14 Days)|Protocol Violation|0
6288380|NCT02366143|10002147|FG002|Overall Study|Increased Microscopic RBCS on Urinalysis|0
6288381|NCT02366143|10002145|FG000|Overall Study|Randomization Error|1
6288382|NCT02366143|10002146|FG001|Overall Study|Randomization Error|0
6288383|NCT02366143|10002147|FG002|Overall Study|Randomization Error|0
6288384|NCT02366143|10002145|FG000|Overall Study|PI Move and Site Closure|1
6288385|NCT02366143|10002146|FG001|Overall Study|PI Move and Site Closure|0
6288386|NCT02366143|10002147|FG002|Overall Study|PI Move and Site Closure|1
6288387|NCT02366143|10002145|FG000|Overall Study|Study Terminated By Sponsor|0
6288388|NCT02366143|10002146|FG001|Overall Study|Study Terminated By Sponsor|0
6288389|NCT02366143|10002147|FG002|Overall Study|Study Terminated By Sponsor|2
6288390|NCT02366143|10002145|FG000|Overall Study|Sponsor request to withdraw/discontinue patient in survival follow up|70
6288391|NCT02366143|10002146|FG001|Overall Study|Sponsor request to withdraw/discontinue patient in survival follow up|57
6288392|NCT02366143|10002147|FG002|Overall Study|Sponsor request to withdraw/discontinue patient in survival follow up|52
6288393|NCT02366143|10002145|FG000|Overall Study|Patient moved to roll-over study|1
6288394|NCT02366143|10002146|FG001|Overall Study|Patient moved to roll-over study|19
6288395|NCT02366143|10002147|FG002|Overall Study|Patient moved to roll-over study|28
6288396|NCT02366143|10002145|FG000|Overall Study|Patient moved to commercial stock|0
6288397|NCT02366143|10002146|FG001|Overall Study|Patient moved to commercial stock|0
6288398|NCT02366143|10002147|FG002|Overall Study|Patient moved to commercial stock|1
6288399|NCT02366143|10002145|FG000|Overall Study|Patient stopped treatment due to disease progression;didn't enter follow up due to study termination|0
6288400|NCT02366143|10002146|FG001|Overall Study|Patient stopped treatment due to disease progression;didn't enter follow up due to study termination|0
6288401|NCT02366143|10002147|FG002|Overall Study|Patient stopped treatment due to disease progression;didn't enter follow up due to study termination|1
6288402|NCT02366143|10002145|FG000|Overall Study|Patient rolling over to patient assistance program|0
6288403|NCT02366143|10002146|FG001|Overall Study|Patient rolling over to patient assistance program|0
6125675|NCT00928668|9750569|FG000|Overall Study|Adverse Event|1
6125676|NCT00928668|9750570|FG001|Overall Study|Adverse Event|0
6125677|NCT00928668|9750571|FG002|Overall Study|Adverse Event|0
6125678|NCT00928668|9750572|FG003|Overall Study|Adverse Event|0
6125679|NCT00928668|9750573|FG004|Overall Study|Adverse Event|0
6125680|NCT00928668|9750569|FG000|Overall Study|Protocol Violation|0
6125681|NCT00928668|9750570|FG001|Overall Study|Protocol Violation|0
6125682|NCT00928668|9750571|FG002|Overall Study|Protocol Violation|0
6125683|NCT00928668|9750572|FG003|Overall Study|Protocol Violation|0
6125684|NCT00928668|9750573|FG004|Overall Study|Protocol Violation|1
6125685|NCT00928668|9750569|FG000|Overall Study|Withdrawal by Subject|0
6125686|NCT00928668|9750570|FG001|Overall Study|Withdrawal by Subject|1
6125687|NCT00928668|9750571|FG002|Overall Study|Withdrawal by Subject|1
6125688|NCT00928668|9750572|FG003|Overall Study|Withdrawal by Subject|0
6125689|NCT00928668|9750573|FG004|Overall Study|Withdrawal by Subject|0
6125690|NCT00928668|9750569|FG000|Overall Study|Other reasons not listed above|0
6217737|NCT01641692|9886406|FG003|Washout Period 1 (12-14 Days)|Protocol Violation|0
6217738|NCT01641692|9886407|FG004|Washout Period 1 (12-14 Days)|Protocol Violation|0
6217739|NCT01641692|9886408|FG005|Washout Period 1 (12-14 Days)|Protocol Violation|0
6217740|NCT01641692|9886409|FG006|Washout Period 1 (12-14 Days)|Protocol Violation|1
6217741|NCT01641692|9886410|FG007|Washout Period 1 (12-14 Days)|Protocol Violation|0
6217742|NCT01641692|9886403|FG000|Washout Period 1 (12-14 Days)|Protocol-defined Stopping Criteria|1
6217743|NCT01641692|9886404|FG001|Washout Period 1 (12-14 Days)|Protocol-defined Stopping Criteria|0
6217744|NCT01641692|9886405|FG002|Washout Period 1 (12-14 Days)|Protocol-defined Stopping Criteria|3
6217745|NCT01641692|9886406|FG003|Washout Period 1 (12-14 Days)|Protocol-defined Stopping Criteria|1
6217746|NCT01641692|9886407|FG004|Washout Period 1 (12-14 Days)|Protocol-defined Stopping Criteria|3
6217747|NCT01641692|9886408|FG005|Washout Period 1 (12-14 Days)|Protocol-defined Stopping Criteria|0
6217748|NCT01641692|9886409|FG006|Washout Period 1 (12-14 Days)|Protocol-defined Stopping Criteria|0
6217749|NCT01641692|9886410|FG007|Washout Period 1 (12-14 Days)|Protocol-defined Stopping Criteria|1
6217750|NCT01641692|9886403|FG000|Washout Period 1 (12-14 Days)|Withdrawal by Subject|1
6217751|NCT01641692|9886404|FG001|Washout Period 1 (12-14 Days)|Withdrawal by Subject|1
6217752|NCT01641692|9886405|FG002|Washout Period 1 (12-14 Days)|Withdrawal by Subject|0
6217753|NCT01641692|9886406|FG003|Washout Period 1 (12-14 Days)|Withdrawal by Subject|1
6217754|NCT01641692|9886407|FG004|Washout Period 1 (12-14 Days)|Withdrawal by Subject|1
6217755|NCT01641692|9886408|FG005|Washout Period 1 (12-14 Days)|Withdrawal by Subject|0
6217756|NCT01641692|9886409|FG006|Washout Period 1 (12-14 Days)|Withdrawal by Subject|1
6217757|NCT01641692|9886410|FG007|Washout Period 1 (12-14 Days)|Withdrawal by Subject|0
6217758|NCT01641692|9886403|FG000|Treatment Period 2|Lack of Efficacy|1
6217759|NCT01641692|9886404|FG001|Treatment Period 2|Lack of Efficacy|0
6217760|NCT01641692|9886405|FG002|Treatment Period 2|Lack of Efficacy|0
6217761|NCT01641692|9886406|FG003|Treatment Period 2|Lack of Efficacy|0
6217762|NCT01641692|9886407|FG004|Treatment Period 2|Lack of Efficacy|0
6217763|NCT01641692|9886408|FG005|Treatment Period 2|Lack of Efficacy|0
6288404|NCT02366143|10002147|FG002|Overall Study|Patient rolling over to patient assistance program|1
6288405|NCT02366143|10002145|FG000|Overall Study|Patient continue same treatment via Post Trial Access Progarm (PTAP)|0
6288406|NCT02366143|10002146|FG001|Overall Study|Patient continue same treatment via Post Trial Access Progarm (PTAP)|0
6288407|NCT02366143|10002147|FG002|Overall Study|Patient continue same treatment via Post Trial Access Progarm (PTAP)|1
6288408|NCT02366143|10002145|FG000|Overall Study|Requester's instructions|1
6288409|NCT02366143|10002146|FG001|Overall Study|Requester's instructions|1
5980913|NCT04207749|9569640|FG000|Overall Study|Withdrawal by Subject|3
5980914|NCT04207749|9569641|FG001|Overall Study|Withdrawal by Subject|0
5980915|NCT04207749|9569640|FG000|Overall Study|Unable to attend study visits due to COVID-19 pandemic|1
5980916|NCT04207749|9569641|FG001|Overall Study|Unable to attend study visits due to COVID-19 pandemic|4
6063448|NCT00506415|9664786|FG002|Initial Open Label (Maximum 48 Weeks)|Adverse Event|0
6217764|NCT01641692|9886409|FG006|Treatment Period 2|Lack of Efficacy|0
6217765|NCT01641692|9886410|FG007|Treatment Period 2|Lack of Efficacy|0
6217766|NCT01641692|9886403|FG000|Treatment Period 2|Protocol-defined Stopping Criteria|1
6217767|NCT01641692|9886404|FG001|Treatment Period 2|Protocol-defined Stopping Criteria|0
6217768|NCT01641692|9886405|FG002|Treatment Period 2|Protocol-defined Stopping Criteria|0
6217769|NCT01641692|9886406|FG003|Treatment Period 2|Protocol-defined Stopping Criteria|0
6217770|NCT01641692|9886407|FG004|Treatment Period 2|Protocol-defined Stopping Criteria|0
6217771|NCT01641692|9886408|FG005|Treatment Period 2|Protocol-defined Stopping Criteria|0
6217772|NCT01641692|9886409|FG006|Treatment Period 2|Protocol-defined Stopping Criteria|0
6217773|NCT01641692|9886410|FG007|Treatment Period 2|Protocol-defined Stopping Criteria|0
6217774|NCT01641692|9886403|FG000|Treatment Period 2|Lost to Follow-up|0
6217775|NCT01641692|9886404|FG001|Treatment Period 2|Lost to Follow-up|0
6217776|NCT01641692|9886405|FG002|Treatment Period 2|Lost to Follow-up|0
6217777|NCT01641692|9886406|FG003|Treatment Period 2|Lost to Follow-up|0
6217778|NCT01641692|9886407|FG004|Treatment Period 2|Lost to Follow-up|0
6217779|NCT01641692|9886408|FG005|Treatment Period 2|Lost to Follow-up|1
6217780|NCT01641692|9886409|FG006|Treatment Period 2|Lost to Follow-up|0
6217781|NCT01641692|9886410|FG007|Treatment Period 2|Lost to Follow-up|0
6217782|NCT01641692|9886403|FG000|Treatment Period 2|Withdrawal by Subject|1
6217783|NCT01641692|9886404|FG001|Treatment Period 2|Withdrawal by Subject|0
6063449|NCT00506415|9664787|FG003|Initial Open Label (Maximum 48 Weeks)|Adverse Event|0
6125691|NCT00928668|9750570|FG001|Overall Study|Other reasons not listed above|0
6125692|NCT00928668|9750571|FG002|Overall Study|Other reasons not listed above|0
6125693|NCT00928668|9750572|FG003|Overall Study|Other reasons not listed above|1
6125694|NCT00928668|9750573|FG004|Overall Study|Other reasons not listed above|0
6125695|NCT00928707|9750599|FG000|Overall Study|Protocol Violation|1
6125696|NCT00928707|9750600|FG001|Overall Study|Protocol Violation|0
6125697|NCT00928746|9750622|FG000|Overall Study|Adverse Event|2
6125698|NCT00928746|9750622|FG000|Overall Study|Protocol Violation|1
6125699|NCT00928746|9750622|FG000|Overall Study|Withdrawal by Subject|1
6125700|NCT00928746|9750622|FG000|Overall Study|Other|2
6125701|NCT00928889|9750643|FG000|Overall Study|Lost to Follow-up|3
6125702|NCT00928889|9750644|FG001|Overall Study|Lost to Follow-up|1
6125703|NCT00928889|9750643|FG000|Overall Study|Protocol Violation|0
6125704|NCT00928889|9750644|FG001|Overall Study|Protocol Violation|1
6125705|NCT00928889|9750643|FG000|Overall Study|Adverse Event|1
6125706|NCT00928889|9750644|FG001|Overall Study|Adverse Event|0
6125707|NCT00928889|9750643|FG000|Overall Study|Other|1
6125708|NCT00928889|9750644|FG001|Overall Study|Other|0
6125709|NCT00929110|9750667|FG000|Overall Study|Adverse Event|40
6125710|NCT00929110|9750668|FG001|Overall Study|Adverse Event|29
6125711|NCT00929110|9750669|FG002|Overall Study|Adverse Event|18
6125712|NCT00929110|9750667|FG000|Overall Study|Subject withdrew consent|40
6125713|NCT00929110|9750668|FG001|Overall Study|Subject withdrew consent|23
6125714|NCT00929110|9750669|FG002|Overall Study|Subject withdrew consent|26
6125715|NCT00929110|9750667|FG000|Overall Study|Unsatisfactory therapeutic effect|20
6125716|NCT00929110|9750668|FG001|Overall Study|Unsatisfactory therapeutic effect|9
6125717|NCT00929110|9750669|FG002|Overall Study|Unsatisfactory therapeutic effect|6
6217784|NCT01641692|9886405|FG002|Treatment Period 2|Withdrawal by Subject|0
6217785|NCT01641692|9886406|FG003|Treatment Period 2|Withdrawal by Subject|0
6217786|NCT01641692|9886407|FG004|Treatment Period 2|Withdrawal by Subject|0
6217787|NCT01641692|9886408|FG005|Treatment Period 2|Withdrawal by Subject|1
6217788|NCT01641692|9886409|FG006|Treatment Period 2|Withdrawal by Subject|0
6217789|NCT01641692|9886410|FG007|Treatment Period 2|Withdrawal by Subject|1
6217790|NCT01641692|9886403|FG000|Washout Period 2 (12-14 Days)|Protocol-defined Stopping Criteria|0
6217791|NCT01641692|9886404|FG001|Washout Period 2 (12-14 Days)|Protocol-defined Stopping Criteria|0
6217792|NCT01641692|9886405|FG002|Washout Period 2 (12-14 Days)|Protocol-defined Stopping Criteria|0
6217793|NCT01641692|9886406|FG003|Washout Period 2 (12-14 Days)|Protocol-defined Stopping Criteria|0
6217794|NCT01641692|9886407|FG004|Washout Period 2 (12-14 Days)|Protocol-defined Stopping Criteria|3
6217795|NCT01641692|9886408|FG005|Washout Period 2 (12-14 Days)|Protocol-defined Stopping Criteria|0
6217796|NCT01641692|9886409|FG006|Washout Period 2 (12-14 Days)|Protocol-defined Stopping Criteria|1
6217797|NCT01641692|9886410|FG007|Washout Period 2 (12-14 Days)|Protocol-defined Stopping Criteria|0
6217798|NCT01641692|9886403|FG000|Washout Period 2 (12-14 Days)|Withdrawal by Subject|0
6217799|NCT01641692|9886404|FG001|Washout Period 2 (12-14 Days)|Withdrawal by Subject|0
6217800|NCT01641692|9886405|FG002|Washout Period 2 (12-14 Days)|Withdrawal by Subject|1
6217801|NCT01641692|9886406|FG003|Washout Period 2 (12-14 Days)|Withdrawal by Subject|0
6217802|NCT01641692|9886407|FG004|Washout Period 2 (12-14 Days)|Withdrawal by Subject|0
6217803|NCT01641692|9886408|FG005|Washout Period 2 (12-14 Days)|Withdrawal by Subject|1
6217804|NCT01641692|9886409|FG006|Washout Period 2 (12-14 Days)|Withdrawal by Subject|0
6217805|NCT01641692|9886410|FG007|Washout Period 2 (12-14 Days)|Withdrawal by Subject|1
6217806|NCT01641692|9886403|FG000|Treatment Period 3|Adverse Event|0
6217807|NCT01641692|9886404|FG001|Treatment Period 3|Adverse Event|0
6217808|NCT01641692|9886405|FG002|Treatment Period 3|Adverse Event|0
6217809|NCT01641692|9886406|FG003|Treatment Period 3|Adverse Event|0
6217810|NCT01641692|9886407|FG004|Treatment Period 3|Adverse Event|0
6217811|NCT01641692|9886408|FG005|Treatment Period 3|Adverse Event|0
6217812|NCT01641692|9886409|FG006|Treatment Period 3|Adverse Event|1
6217813|NCT01641692|9886410|FG007|Treatment Period 3|Adverse Event|0
6217814|NCT01641692|9886403|FG000|Treatment Period 3|Protocol Violation|0
6217815|NCT01641692|9886404|FG001|Treatment Period 3|Protocol Violation|0
6217816|NCT01641692|9886405|FG002|Treatment Period 3|Protocol Violation|1
6217817|NCT01641692|9886406|FG003|Treatment Period 3|Protocol Violation|0
6217818|NCT01641692|9886407|FG004|Treatment Period 3|Protocol Violation|0
6217819|NCT01641692|9886408|FG005|Treatment Period 3|Protocol Violation|0
6288410|NCT02366143|10002147|FG002|Overall Study|Requester's instructions|1
6288411|NCT02366143|10002145|FG000|Overall Study|Uneligible|0
6288412|NCT02366143|10002146|FG001|Overall Study|Uneligible|1
6288413|NCT02366143|10002147|FG002|Overall Study|Uneligible|0
6288414|NCT02366143|10002145|FG000|Overall Study|Post Trial Migration|0
6288415|NCT02366143|10002146|FG001|Overall Study|Post Trial Migration|1
6288416|NCT02366143|10002147|FG002|Overall Study|Post Trial Migration|0
6288417|NCT02366143|10002145|FG000|Overall Study|Patient moving onto PTAP commercial stock|0
6288418|NCT02366143|10002146|FG001|Overall Study|Patient moving onto PTAP commercial stock|1
6288419|NCT02366143|10002147|FG002|Overall Study|Patient moving onto PTAP commercial stock|0
6288420|NCT02366143|10002145|FG000|Overall Study|Patient switched to PTAP|0
6288421|NCT02366143|10002146|FG001|Overall Study|Patient switched to PTAP|1
6217820|NCT01641692|9886409|FG006|Treatment Period 3|Protocol Violation|0
6288422|NCT02366143|10002147|FG002|Overall Study|Patient switched to PTAP|0
6125718|NCT00929110|9750667|FG000|Overall Study|Lost to Follow-up|7
6125719|NCT00929110|9750668|FG001|Overall Study|Lost to Follow-up|7
6125720|NCT00929110|9750669|FG002|Overall Study|Lost to Follow-up|3
6125721|NCT00929110|9750667|FG000|Overall Study|Protocol deviation|5
6125722|NCT00929110|9750668|FG001|Overall Study|Protocol deviation|2
6125723|NCT00929110|9750669|FG002|Overall Study|Protocol deviation|4
6125724|NCT00929110|9750667|FG000|Overall Study|Administrative problems|4
6125725|NCT00929110|9750668|FG001|Overall Study|Administrative problems|1
6125726|NCT00929110|9750669|FG002|Overall Study|Administrative problems|2
6125727|NCT00929110|9750667|FG000|Overall Study|Death|2
6125728|NCT00929110|9750668|FG001|Overall Study|Death|2
6125729|NCT00929110|9750669|FG002|Overall Study|Death|2
6125730|NCT00929110|9750667|FG000|Overall Study|Abnormal laboratory value(s)|0
6125731|NCT00929110|9750668|FG001|Overall Study|Abnormal laboratory value(s)|1
6125732|NCT00929110|9750669|FG002|Overall Study|Abnormal laboratory value(s)|0
6125733|NCT00929110|9750667|FG000|Overall Study|Abnormal test procedure result(s)|0
6125734|NCT00929110|9750668|FG001|Overall Study|Abnormal test procedure result(s)|1
6125735|NCT00929110|9750669|FG002|Overall Study|Abnormal test procedure result(s)|1
6125736|NCT00929110|9750667|FG000|Overall Study|Patient inability to use the device|0
6125737|NCT00929110|9750668|FG001|Overall Study|Patient inability to use the device|1
6125738|NCT00929110|9750669|FG002|Overall Study|Patient inability to use the device|0
6125739|NCT00929162|9750679|FG000|Overall Study|Adverse Event|8
6125740|NCT00929162|9750680|FG001|Overall Study|Adverse Event|5
6125741|NCT00929162|9750679|FG000|Overall Study|Withdrawal by Subject|3
6125742|NCT00929162|9750680|FG001|Overall Study|Withdrawal by Subject|1
6125743|NCT00929162|9750679|FG000|Overall Study|Protocol Violation|32
6125744|NCT00929162|9750680|FG001|Overall Study|Protocol Violation|30
6125745|NCT00929162|9750679|FG000|Overall Study|Other termination reason|5
6125746|NCT00929162|9750680|FG001|Overall Study|Other termination reason|6
6125747|NCT00929201|9750686|FG000|Period 1|Withdrawal by Subject|0
6217821|NCT01641692|9886410|FG007|Treatment Period 3|Protocol Violation|0
6217822|NCT01641692|9886403|FG000|Treatment Period 3|Protocol-defined Stopping Criteria|0
6217823|NCT01641692|9886404|FG001|Treatment Period 3|Protocol-defined Stopping Criteria|0
6217824|NCT01641692|9886405|FG002|Treatment Period 3|Protocol-defined Stopping Criteria|0
6217825|NCT01641692|9886406|FG003|Treatment Period 3|Protocol-defined Stopping Criteria|0
6217826|NCT01641692|9886407|FG004|Treatment Period 3|Protocol-defined Stopping Criteria|0
6217827|NCT01641692|9886408|FG005|Treatment Period 3|Protocol-defined Stopping Criteria|0
6217828|NCT01641692|9886409|FG006|Treatment Period 3|Protocol-defined Stopping Criteria|1
6125748|NCT00929201|9750687|FG001|Period 1|Withdrawal by Subject|1
6125749|NCT00929240|9750694|FG000|Initial Treatment Phase|Adverse Event|31
6125750|NCT00929240|9750695|FG001|Initial Treatment Phase|Adverse Event|0
6125751|NCT00929240|9750696|FG002|Initial Treatment Phase|Adverse Event|0
6125752|NCT00929240|9750694|FG000|Initial Treatment Phase|Disease progression|41
6125753|NCT00929240|9750695|FG001|Initial Treatment Phase|Disease progression|0
6125754|NCT00929240|9750696|FG002|Initial Treatment Phase|Disease progression|0
6125755|NCT00929240|9750694|FG000|Initial Treatment Phase|Withdrawal by Subject|13
6125756|NCT00929240|9750695|FG001|Initial Treatment Phase|Withdrawal by Subject|0
6125757|NCT00929240|9750696|FG002|Initial Treatment Phase|Withdrawal by Subject|0
6125758|NCT00929240|9750694|FG000|Initial Treatment Phase|Protocol Violation|5
6125759|NCT00929240|9750695|FG001|Initial Treatment Phase|Protocol Violation|0
6125760|NCT00929240|9750696|FG002|Initial Treatment Phase|Protocol Violation|0
6125761|NCT00929240|9750694|FG000|Initial Treatment Phase|Death|2
6125762|NCT00929240|9750695|FG001|Initial Treatment Phase|Death|0
6125763|NCT00929240|9750696|FG002|Initial Treatment Phase|Death|0
6125764|NCT00929240|9750694|FG000|Initial Treatment Phase|Health authority/Study termination|3
6125765|NCT00929240|9750695|FG001|Initial Treatment Phase|Health authority/Study termination|0
6125766|NCT00929240|9750696|FG002|Initial Treatment Phase|Health authority/Study termination|0
6125767|NCT00929240|9750694|FG000|Initial Treatment Phase|Physician Decision|4
6125768|NCT00929240|9750695|FG001|Initial Treatment Phase|Physician Decision|0
6125769|NCT00929240|9750696|FG002|Initial Treatment Phase|Physician Decision|0
6125770|NCT00929240|9750694|FG000|Maintenance Phase|Disease progression|0
6125771|NCT00929240|9750695|FG001|Maintenance Phase|Disease progression|73
6125772|NCT00929240|9750696|FG002|Maintenance Phase|Disease progression|60
6125773|NCT00929240|9750694|FG000|Maintenance Phase|Adverse Event|0
6125774|NCT00929240|9750695|FG001|Maintenance Phase|Adverse Event|9
6125775|NCT00929240|9750696|FG002|Maintenance Phase|Adverse Event|12
6125776|NCT00929240|9750694|FG000|Maintenance Phase|Withdrawal by Subject|0
6125777|NCT00929240|9750695|FG001|Maintenance Phase|Withdrawal by Subject|2
6125778|NCT00929240|9750696|FG002|Maintenance Phase|Withdrawal by Subject|6
6125779|NCT00929240|9750694|FG000|Maintenance Phase|Protocol Violation|0
6125780|NCT00929240|9750695|FG001|Maintenance Phase|Protocol Violation|1
6125781|NCT00929240|9750696|FG002|Maintenance Phase|Protocol Violation|0
6125782|NCT00929240|9750694|FG000|Maintenance Phase|Health authority/Study termination|0
6125783|NCT00929240|9750695|FG001|Maintenance Phase|Health authority/Study termination|1
6125784|NCT00929240|9750696|FG002|Maintenance Phase|Health authority/Study termination|2
6125785|NCT00929240|9750694|FG000|Maintenance Phase|Physician Decision|0
6125786|NCT00929240|9750695|FG001|Maintenance Phase|Physician Decision|2
6125787|NCT00929240|9750696|FG002|Maintenance Phase|Physician Decision|1
6125788|NCT00929240|9750694|FG000|Maintenance Phase|Change of treatment|0
6125789|NCT00929240|9750695|FG001|Maintenance Phase|Change of treatment|4
6125790|NCT00929240|9750696|FG002|Maintenance Phase|Change of treatment|0
6125791|NCT00929240|9750694|FG000|Maintenance Phase|Treatment ongoing at study closure|0
6125792|NCT00929240|9750695|FG001|Maintenance Phase|Treatment ongoing at study closure|0
6125793|NCT00929240|9750696|FG002|Maintenance Phase|Treatment ongoing at study closure|10
6125794|NCT00929240|9750694|FG000|Maintenance Phase|Participant not treated|0
6125795|NCT00929240|9750695|FG001|Maintenance Phase|Participant not treated|2
6125796|NCT00929240|9750696|FG002|Maintenance Phase|Participant not treated|0
6125797|NCT00929526|9750761|FG000|Overall Study|Withdrawal by Subject|1
6125798|NCT00929526|9750762|FG001|Overall Study|Withdrawal by Subject|11
6125799|NCT00929526|9750761|FG000|Overall Study|Lost to Follow-up|8
6125800|NCT00929526|9750762|FG001|Overall Study|Lost to Follow-up|12
6125801|NCT00929526|9750761|FG000|Overall Study|Other|8
6125802|NCT00929526|9750762|FG001|Overall Study|Other|6
6125803|NCT00929643|9750777|FG000|Overall Study|Protocol Violation|2
6125804|NCT00929656|9750783|FG000|Overall Study|Lost to Follow-up|0
6125805|NCT00929656|9750784|FG001|Overall Study|Lost to Follow-up|1
6125806|NCT00929669|9750790|FG000|Overall Study|elevated glucose levels|1
6125807|NCT00929695|9750796|FG000|Overall Study|Death|2
6125808|NCT00929695|9750797|FG001|Overall Study|Death|1
6125809|NCT00929695|9750796|FG000|Overall Study|Withdrawal by Subject|0
6125810|NCT00929695|9750797|FG001|Overall Study|Withdrawal by Subject|2
6125811|NCT00929695|9750796|FG000|Overall Study|discharge home|4
6125812|NCT00929695|9750797|FG001|Overall Study|discharge home|3
6125813|NCT00929695|9750796|FG000|Overall Study|incorrect stratification|2
6125814|NCT00929695|9750797|FG001|Overall Study|incorrect stratification|0
6125815|NCT00929708|9750813|FG000|Overall Study|Protocol Violation|2
6125816|NCT00929708|9750814|FG001|Overall Study|Protocol Violation|1
6125817|NCT00929708|9750815|FG002|Overall Study|Protocol Violation|1
6125818|NCT00929708|9750816|FG003|Overall Study|Protocol Violation|1
6125819|NCT00929708|9750817|FG004|Overall Study|Protocol Violation|1
6125820|NCT00929708|9750813|FG000|Overall Study|Withdrawal by Subject|2
6125821|NCT00929708|9750814|FG001|Overall Study|Withdrawal by Subject|0
6125822|NCT00929708|9750815|FG002|Overall Study|Withdrawal by Subject|0
6125823|NCT00929708|9750816|FG003|Overall Study|Withdrawal by Subject|2
6125824|NCT00929708|9750817|FG004|Overall Study|Withdrawal by Subject|1
6125825|NCT00929708|9750813|FG000|Overall Study|Adverse Event|0
6125826|NCT00929708|9750814|FG001|Overall Study|Adverse Event|0
6125827|NCT00929708|9750815|FG002|Overall Study|Adverse Event|0
6125828|NCT00929708|9750816|FG003|Overall Study|Adverse Event|0
6125829|NCT00929708|9750817|FG004|Overall Study|Adverse Event|3
6125830|NCT00929708|9750813|FG000|Overall Study|Physician Decision|0
6125831|NCT00929708|9750814|FG001|Overall Study|Physician Decision|2
6125832|NCT00929708|9750815|FG002|Overall Study|Physician Decision|2
6125833|NCT00929708|9750816|FG003|Overall Study|Physician Decision|2
6125834|NCT00929708|9750817|FG004|Overall Study|Physician Decision|1
6125835|NCT00929708|9750813|FG000|Overall Study|Lost to Follow-up|0
6125836|NCT00929708|9750814|FG001|Overall Study|Lost to Follow-up|0
6125837|NCT00929708|9750815|FG002|Overall Study|Lost to Follow-up|0
6125838|NCT00929708|9750816|FG003|Overall Study|Lost to Follow-up|1
6125839|NCT00929708|9750817|FG004|Overall Study|Lost to Follow-up|0
6125840|NCT00929734|9750831|FG000|Overall Study|Lost to Follow-up|2
6125841|NCT00929734|9750832|FG001|Overall Study|Lost to Follow-up|1
6125842|NCT00929734|9750831|FG000|Overall Study|Withdrawal by Subject|0
6125843|NCT00929734|9750832|FG001|Overall Study|Withdrawal by Subject|2
6125844|NCT00929864|9750867|FG000|Overall Study|Death|1
6125845|NCT00929864|9750868|FG001|Overall Study|Death|1
6125846|NCT00929864|9750867|FG000|Overall Study|Adverse Event|11
6125847|NCT00929864|9750868|FG001|Overall Study|Adverse Event|30
6125848|NCT00929864|9750867|FG000|Overall Study|Lack of Efficacy|19
6125849|NCT00929864|9750868|FG001|Overall Study|Lack of Efficacy|16
6125850|NCT00929864|9750867|FG000|Overall Study|Lost to Follow-up|7
6125851|NCT00929864|9750868|FG001|Overall Study|Lost to Follow-up|12
6125852|NCT00929864|9750867|FG000|Overall Study|Withdrawal by Subject|20
6125853|NCT00929864|9750868|FG001|Overall Study|Withdrawal by Subject|9
6125854|NCT00929864|9750867|FG000|Overall Study|No longer met criteria|2
6125855|NCT00929864|9750868|FG001|Overall Study|No longer met criteria|1
6125856|NCT00929864|9750867|FG000|Overall Study|Poor or non-compliance|3
6125857|NCT00929864|9750868|FG001|Overall Study|Poor or non-compliance|3
6125858|NCT00929864|9750867|FG000|Overall Study|Pregnancy|0
6125859|NCT00929864|9750868|FG001|Overall Study|Pregnancy|3
6125860|NCT00929864|9750867|FG000|Overall Study|Administrative reason by Sponsor|1
6125861|NCT00929864|9750868|FG001|Overall Study|Administrative reason by Sponsor|1
6125862|NCT00929864|9750867|FG000|Overall Study|Non-specified|2
6125863|NCT00929864|9750868|FG001|Overall Study|Non-specified|7
6125864|NCT00929994|9750878|FG000|Overall Study|Withdrawal by Subject|1
6125865|NCT00929994|9750878|FG000|Overall Study|medical issue unrelated to intervention|4
6125866|NCT00929994|9750878|FG000|Overall Study|employment|1
6125867|NCT00930046|9750887|FG000|Overall Study|Wound catheter malfunctioned|1
6125868|NCT00930046|9750888|FG001|Overall Study|Wound catheter malfunctioned|2
6125869|NCT00930059|9750896|FG000|Overall Study|Death|1
6125870|NCT00930059|9750897|FG001|Overall Study|Death|0
6125871|NCT00930059|9750896|FG000|Overall Study|Did not meet entrance criteria|1
6125872|NCT00930059|9750897|FG001|Overall Study|Did not meet entrance criteria|1
6125873|NCT00930059|9750896|FG000|Overall Study|Withdrawal by Subject|3
6125874|NCT00930059|9750897|FG001|Overall Study|Withdrawal by Subject|4
6125875|NCT00930059|9750896|FG000|Overall Study|Other|1
6125876|NCT00930059|9750897|FG001|Overall Study|Other|0
6125877|NCT00930059|9750896|FG000|Overall Study|1 site terminated by sponsor|1
6125878|NCT00930059|9750897|FG001|Overall Study|1 site terminated by sponsor|1
6125879|NCT00930059|9750896|FG000|Overall Study|Adverse Event|1
6125880|NCT00930059|9750897|FG001|Overall Study|Adverse Event|6
6125881|NCT00930176|9750903|FG000|Overall Study|Death|1
6217829|NCT01641692|9886410|FG007|Treatment Period 3|Protocol-defined Stopping Criteria|0
6217830|NCT01641692|9886403|FG000|Treatment Period 3|Lost to Follow-up|0
6217831|NCT01641692|9886404|FG001|Treatment Period 3|Lost to Follow-up|1
6217832|NCT01641692|9886405|FG002|Treatment Period 3|Lost to Follow-up|0
6217833|NCT01641692|9886406|FG003|Treatment Period 3|Lost to Follow-up|0
6217834|NCT01641692|9886407|FG004|Treatment Period 3|Lost to Follow-up|0
6217835|NCT01641692|9886408|FG005|Treatment Period 3|Lost to Follow-up|0
6217836|NCT01641692|9886409|FG006|Treatment Period 3|Lost to Follow-up|0
6217837|NCT01641692|9886410|FG007|Treatment Period 3|Lost to Follow-up|0
6217838|NCT01641692|9886403|FG000|Washout Period 3 or Follow-up|Protocol Violation|0
6217839|NCT01641692|9886404|FG001|Washout Period 3 or Follow-up|Protocol Violation|0
6217840|NCT01641692|9886405|FG002|Washout Period 3 or Follow-up|Protocol Violation|0
6217841|NCT01641692|9886406|FG003|Washout Period 3 or Follow-up|Protocol Violation|0
6217842|NCT01641692|9886407|FG004|Washout Period 3 or Follow-up|Protocol Violation|0
6217843|NCT01641692|9886408|FG005|Washout Period 3 or Follow-up|Protocol Violation|1
6217844|NCT01641692|9886409|FG006|Washout Period 3 or Follow-up|Protocol Violation|0
6217845|NCT01641692|9886410|FG007|Washout Period 3 or Follow-up|Protocol Violation|0
6217846|NCT01641692|9886403|FG000|Washout Period 3 or Follow-up|Protocol-defined Stopping Criteria|1
6217847|NCT01641692|9886404|FG001|Washout Period 3 or Follow-up|Protocol-defined Stopping Criteria|0
6217848|NCT01641692|9886405|FG002|Washout Period 3 or Follow-up|Protocol-defined Stopping Criteria|1
6217849|NCT01641692|9886406|FG003|Washout Period 3 or Follow-up|Protocol-defined Stopping Criteria|1
6217850|NCT01641692|9886407|FG004|Washout Period 3 or Follow-up|Protocol-defined Stopping Criteria|0
6217851|NCT01641692|9886408|FG005|Washout Period 3 or Follow-up|Protocol-defined Stopping Criteria|1
6217852|NCT01641692|9886409|FG006|Washout Period 3 or Follow-up|Protocol-defined Stopping Criteria|1
6217853|NCT01641692|9886410|FG007|Washout Period 3 or Follow-up|Protocol-defined Stopping Criteria|0
6217854|NCT01641809|9886433|FG000|Induction Phase (Day 1 to Week 24)|Withdrawal by Subject|1
6217855|NCT01641809|9886434|FG001|Induction Phase (Day 1 to Week 24)|Withdrawal by Subject|1
6217856|NCT01641809|9886435|FG002|Induction Phase (Day 1 to Week 24)|Withdrawal by Subject|0
6217857|NCT01641809|9886436|FG003|Induction Phase (Day 1 to Week 24)|Withdrawal by Subject|1
6217858|NCT01641809|9886433|FG000|Induction Phase (Day 1 to Week 24)|Physician Decision|0
6217859|NCT01641809|9886434|FG001|Induction Phase (Day 1 to Week 24)|Physician Decision|1
6217860|NCT01641809|9886435|FG002|Induction Phase (Day 1 to Week 24)|Physician Decision|0
6217861|NCT01641809|9886436|FG003|Induction Phase (Day 1 to Week 24)|Physician Decision|1
6217862|NCT01641809|9886433|FG000|Induction Phase (Day 1 to Week 24)|Lost to Follow-up|1
6217863|NCT01641809|9886434|FG001|Induction Phase (Day 1 to Week 24)|Lost to Follow-up|2
6217864|NCT01641809|9886435|FG002|Induction Phase (Day 1 to Week 24)|Lost to Follow-up|0
6217865|NCT01641809|9886436|FG003|Induction Phase (Day 1 to Week 24)|Lost to Follow-up|3
6217866|NCT01641809|9886433|FG000|Induction Phase (Day 1 to Week 24)|Protocol Violation|2
6217867|NCT01641809|9886434|FG001|Induction Phase (Day 1 to Week 24)|Protocol Violation|1
6217868|NCT01641809|9886435|FG002|Induction Phase (Day 1 to Week 24)|Protocol Violation|1
6217869|NCT01641809|9886436|FG003|Induction Phase (Day 1 to Week 24)|Protocol Violation|0
6217870|NCT01641809|9886433|FG000|Induction Phase (Day 1 to Week 24)|Lack of Efficacy|4
6217871|NCT01641809|9886434|FG001|Induction Phase (Day 1 to Week 24)|Lack of Efficacy|1
6217872|NCT01641809|9886435|FG002|Induction Phase (Day 1 to Week 24)|Lack of Efficacy|2
6217873|NCT01641809|9886436|FG003|Induction Phase (Day 1 to Week 24)|Lack of Efficacy|3
6217874|NCT01641809|9886433|FG000|Induction Phase (Day 1 to Week 24)|Adverse Event|0
6217875|NCT01641809|9886434|FG001|Induction Phase (Day 1 to Week 24)|Adverse Event|1
6217876|NCT01641809|9886435|FG002|Induction Phase (Day 1 to Week 24)|Adverse Event|3
6217877|NCT01641809|9886436|FG003|Induction Phase (Day 1 to Week 24)|Adverse Event|7
6217878|NCT01641809|9886433|FG000|Maintenance Phase (Week 24 to Week 96)|Withdrawal by Subject|2
6217879|NCT01641809|9886434|FG001|Maintenance Phase (Week 24 to Week 96)|Withdrawal by Subject|3
6217880|NCT01641809|9886435|FG002|Maintenance Phase (Week 24 to Week 96)|Withdrawal by Subject|1
6217881|NCT01641809|9886436|FG003|Maintenance Phase (Week 24 to Week 96)|Withdrawal by Subject|0
6217882|NCT01641809|9886433|FG000|Maintenance Phase (Week 24 to Week 96)|Physician Decision|0
6217883|NCT01641809|9886434|FG001|Maintenance Phase (Week 24 to Week 96)|Physician Decision|1
6217884|NCT01641809|9886435|FG002|Maintenance Phase (Week 24 to Week 96)|Physician Decision|0
6217885|NCT01641809|9886436|FG003|Maintenance Phase (Week 24 to Week 96)|Physician Decision|0
6217886|NCT01641809|9886433|FG000|Maintenance Phase (Week 24 to Week 96)|Lost to Follow-up|2
6217887|NCT01641809|9886434|FG001|Maintenance Phase (Week 24 to Week 96)|Lost to Follow-up|0
6217888|NCT01641809|9886435|FG002|Maintenance Phase (Week 24 to Week 96)|Lost to Follow-up|1
6217889|NCT01641809|9886436|FG003|Maintenance Phase (Week 24 to Week 96)|Lost to Follow-up|2
6217890|NCT01641809|9886433|FG000|Maintenance Phase (Week 24 to Week 96)|Lack of Efficacy|1
6217891|NCT01641809|9886434|FG001|Maintenance Phase (Week 24 to Week 96)|Lack of Efficacy|1
6217892|NCT01641809|9886435|FG002|Maintenance Phase (Week 24 to Week 96)|Lack of Efficacy|0
6217893|NCT01641809|9886436|FG003|Maintenance Phase (Week 24 to Week 96)|Lack of Efficacy|2
6217894|NCT01641809|9886433|FG000|Maintenance Phase (Week 24 to Week 96)|Adverse Event|1
6125882|NCT00930553|9750916|FG000|Overall Study|Adverse Event|1
6125883|NCT00930553|9750916|FG000|Overall Study|Lack of Efficacy|7
6125884|NCT00930553|9750916|FG000|Overall Study|Physician Decision|39
6125885|NCT00930553|9750916|FG000|Overall Study|Protocol Violation|1
6125886|NCT00930553|9750916|FG000|Overall Study|Pregnancy|1
6125887|NCT00930553|9750916|FG000|Overall Study|Withdrawal by Subject|88
6125888|NCT00930553|9750916|FG000|Overall Study|Lost to Follow-up|25
6125889|NCT00930553|9750916|FG000|Overall Study|Death|9
6125890|NCT00930553|9750916|FG000|Overall Study|Study terminated by sponsor|24
6125891|NCT00930553|9750916|FG000|Overall Study|Other than specified above|28
6125892|NCT00930644|9750938|FG000|Overall Study|Withdrawal by Subject|4
6125893|NCT00930644|9750938|FG000|Overall Study|Physician Decision|2
6125894|NCT00930644|9750938|FG000|Overall Study|Death|1
6125895|NCT00930644|9750938|FG000|Overall Study|Adverse Event|16
6125896|NCT00930761|9750947|FG000|Overall Study|3 newborns died; 1 mother quit the study|4
6125897|NCT00930761|9750948|FG001|Overall Study|3 newborns died; 1 mother quit the study|0
6125898|NCT00930761|9750947|FG000|Overall Study|less than 3 music therapy sessions|0
6125899|NCT00930761|9750948|FG001|Overall Study|less than 3 music therapy sessions|3
6125900|NCT00930774|9750958|FG000|Overall Study|Withdrawal by Subject|1
6125901|NCT00930774|9750959|FG001|Overall Study|Withdrawal by Subject|9
6125902|NCT00930774|9750960|FG002|Overall Study|Withdrawal by Subject|2
6125903|NCT00930774|9750961|FG003|Overall Study|Withdrawal by Subject|0
6125904|NCT00930813|9750974|FG000|Overall Study|Death|4
6125905|NCT00930813|9750975|FG001|Overall Study|Death|5
6125906|NCT00930813|9750974|FG000|Overall Study|Withdrawal by Subject|2
6125907|NCT00930813|9750975|FG001|Overall Study|Withdrawal by Subject|5
6125908|NCT00930813|9750974|FG000|Overall Study|Lost to Follow-up|2
6125909|NCT00930813|9750975|FG001|Overall Study|Lost to Follow-up|4
6125910|NCT00930930|9750985|FG000|Overall Study|Death|1
6125911|NCT00930930|9750986|FG001|Overall Study|Death|0
6125912|NCT00930930|9750985|FG000|Overall Study|Physician Decision|1
6125913|NCT00930930|9750986|FG001|Overall Study|Physician Decision|0
6125914|NCT00930930|9750985|FG000|Overall Study|Adverse Event|13
6125915|NCT00930930|9750986|FG001|Overall Study|Adverse Event|3
6125916|NCT00930930|9750985|FG000|Overall Study|Withdrawal by Subject|3
6125917|NCT00930930|9750986|FG001|Overall Study|Withdrawal by Subject|1
6125918|NCT00930930|9750985|FG000|Overall Study|Disease progression|2
6125919|NCT00930930|9750986|FG001|Overall Study|Disease progression|3
6125920|NCT00930930|9750985|FG000|Overall Study|excessive lapse btw txs, not eligible|0
6125921|NCT00930930|9750986|FG001|Overall Study|excessive lapse btw txs, not eligible|1
6125922|NCT00930930|9750985|FG000|Overall Study|patients not compliant|1
6125923|NCT00930930|9750986|FG001|Overall Study|patients not compliant|1
6125924|NCT00930969|9750992|FG000|Overall Study|Death|5
6125925|NCT00930969|9750992|FG000|Overall Study|Lost to Follow-up|1
6125926|NCT00930969|9750992|FG000|Overall Study|Physician Decision|13
6125927|NCT00930969|9750992|FG000|Overall Study|Withdrawal by Subject|19
6125928|NCT00930982|9750998|FG000|Overall Study|Adverse Event|19
6125929|NCT00930982|9750999|FG001|Overall Study|Adverse Event|23
6125930|NCT00930982|9750998|FG000|Overall Study|Protocol Violation|1
6125931|NCT00930982|9750999|FG001|Overall Study|Protocol Violation|5
6125932|NCT00930982|9750998|FG000|Overall Study|Withdrawal by Subject|1
6125933|NCT00930982|9750999|FG001|Overall Study|Withdrawal by Subject|1
6125934|NCT00931268|9751016|FG000|Overall Study|Lost to Follow-up|6
6217895|NCT01641809|9886434|FG001|Maintenance Phase (Week 24 to Week 96)|Adverse Event|0
6217896|NCT01641809|9886435|FG002|Maintenance Phase (Week 24 to Week 96)|Adverse Event|1
6217897|NCT01641809|9886436|FG003|Maintenance Phase (Week 24 to Week 96)|Adverse Event|2
6217898|NCT01641809|9886433|FG000|Open-label (Week 96 to Week 324)|Withdrawal by Subject|2
6217899|NCT01641809|9886434|FG001|Open-label (Week 96 to Week 324)|Withdrawal by Subject|3
6217900|NCT01641809|9886435|FG002|Open-label (Week 96 to Week 324)|Withdrawal by Subject|1
6217901|NCT01641809|9886436|FG003|Open-label (Week 96 to Week 324)|Withdrawal by Subject|0
6217902|NCT01641809|9886433|FG000|Open-label (Week 96 to Week 324)|Physician Decision|0
6217903|NCT01641809|9886434|FG001|Open-label (Week 96 to Week 324)|Physician Decision|1
6217904|NCT01641809|9886435|FG002|Open-label (Week 96 to Week 324)|Physician Decision|1
6217905|NCT01641809|9886436|FG003|Open-label (Week 96 to Week 324)|Physician Decision|0
6217906|NCT01641809|9886433|FG000|Open-label (Week 96 to Week 324)|Lost to Follow-up|5
6217907|NCT01641809|9886434|FG001|Open-label (Week 96 to Week 324)|Lost to Follow-up|4
6288423|NCT02366143|10002145|FG000|Overall Study|Patient moved to commercial atezolizumab use|0
6288424|NCT02366143|10002146|FG001|Overall Study|Patient moved to commercial atezolizumab use|11
6217908|NCT01641809|9886435|FG002|Open-label (Week 96 to Week 324)|Lost to Follow-up|5
6217909|NCT01641809|9886436|FG003|Open-label (Week 96 to Week 324)|Lost to Follow-up|0
6217910|NCT01641809|9886433|FG000|Open-label (Week 96 to Week 324)|Site closed|1
6217911|NCT01641809|9886434|FG001|Open-label (Week 96 to Week 324)|Site closed|0
6217912|NCT01641809|9886435|FG002|Open-label (Week 96 to Week 324)|Site closed|0
6217913|NCT01641809|9886436|FG003|Open-label (Week 96 to Week 324)|Site closed|0
6217914|NCT01641809|9886433|FG000|Open-label (Week 96 to Week 324)|Protocol Violation|1
6125935|NCT00931307|9751020|FG000|Overall Study|Lack of Efficacy|12
6125936|NCT00931307|9751020|FG000|Overall Study|Biomicroscopy|1
6125937|NCT00931385|9751033|FG000|Overall Study|Adverse Event|2
6125938|NCT00931385|9751034|FG001|Overall Study|Adverse Event|1
6125939|NCT00931385|9751035|FG002|Overall Study|Adverse Event|0
6125940|NCT00931385|9751036|FG003|Overall Study|Adverse Event|3
6125941|NCT00931385|9751033|FG000|Overall Study|Protocol Violation|0
6125942|NCT00931385|9751034|FG001|Overall Study|Protocol Violation|0
6125943|NCT00931385|9751035|FG002|Overall Study|Protocol Violation|1
6125944|NCT00931385|9751036|FG003|Overall Study|Protocol Violation|0
6125945|NCT00931385|9751033|FG000|Overall Study|Withdrawal by Subject|0
6125946|NCT00931385|9751034|FG001|Overall Study|Withdrawal by Subject|1
6125947|NCT00931385|9751035|FG002|Overall Study|Withdrawal by Subject|0
6125948|NCT00931385|9751036|FG003|Overall Study|Withdrawal by Subject|1
6125949|NCT00931385|9751033|FG000|Overall Study|Lost to Follow-up|0
6125950|NCT00931385|9751034|FG001|Overall Study|Lost to Follow-up|0
6125951|NCT00931385|9751035|FG002|Overall Study|Lost to Follow-up|0
6125952|NCT00931385|9751036|FG003|Overall Study|Lost to Follow-up|1
6125953|NCT00931411|9751052|FG000|First Intervention - 42 Days|Adverse Event|2
6125954|NCT00931411|9751053|FG001|First Intervention - 42 Days|Adverse Event|3
6125955|NCT00931411|9751052|FG000|First Intervention - 42 Days|Lost to Follow-up|2
6125956|NCT00931411|9751053|FG001|First Intervention - 42 Days|Lost to Follow-up|0
6125957|NCT00931411|9751052|FG000|After Crossover - 14 Days (up to Day 56)|Adverse Event|0
6125958|NCT00931411|9751053|FG001|After Crossover - 14 Days (up to Day 56)|Adverse Event|1
6125959|NCT00931463|9751065|FG000|Overall Study|Death|8
6125960|NCT00931463|9751066|FG001|Overall Study|Death|4
6125961|NCT00931463|9751065|FG000|Overall Study|Withdrawal by Subject|5
6125962|NCT00931463|9751066|FG001|Overall Study|Withdrawal by Subject|0
6125963|NCT00931463|9751065|FG000|Overall Study|Lost to Follow-up|4
6125964|NCT00931463|9751066|FG001|Overall Study|Lost to Follow-up|1
6125965|NCT00931515|9751094|FG000|Overall Study|Lost to Follow-up|2
6125966|NCT00931515|9751095|FG001|Overall Study|Lost to Follow-up|5
6125967|NCT00931528|9751103|FG000|Overall Study|Protocol Violation|9
6125968|NCT00931528|9751104|FG001|Overall Study|Protocol Violation|12
6125969|NCT00931528|9751103|FG000|Overall Study|Withdrawal by Subject|4
6125970|NCT00931528|9751104|FG001|Overall Study|Withdrawal by Subject|12
6125971|NCT00931528|9751103|FG000|Overall Study|Lost to Follow-up|6
6125972|NCT00931528|9751104|FG001|Overall Study|Lost to Follow-up|13
6125973|NCT00931528|9751103|FG000|Overall Study|Assessment outside of Time Frame|22
6125974|NCT00931528|9751104|FG001|Overall Study|Assessment outside of Time Frame|23
6125975|NCT00931632|9751113|FG000|Overall Study|Withdrawal by Subject|2
6125976|NCT00931632|9751114|FG001|Overall Study|Withdrawal by Subject|3
6125977|NCT00931632|9751113|FG000|Overall Study|Adverse Event|19
6125978|NCT00931632|9751114|FG001|Overall Study|Adverse Event|15
6125979|NCT00931710|9751122|FG000|Overall Study|Adverse Event|16
6125980|NCT00931710|9751123|FG001|Overall Study|Adverse Event|10
6125981|NCT00931710|9751122|FG000|Overall Study|Abnormal test procedure results|2
6125982|NCT00931710|9751123|FG001|Overall Study|Abnormal test procedure results|0
6125983|NCT00931710|9751122|FG000|Overall Study|Unsatisfactory therapeutic effects|5
6125984|NCT00931710|9751123|FG001|Overall Study|Unsatisfactory therapeutic effects|12
6125985|NCT00931710|9751122|FG000|Overall Study|Patient withdrew consent|4
6125986|NCT00931710|9751123|FG001|Overall Study|Patient withdrew consent|9
6125987|NCT00931710|9751122|FG000|Overall Study|Lost to Follow-up|6
6125988|NCT00931710|9751123|FG001|Overall Study|Lost to Follow-up|5
6125989|NCT00931710|9751122|FG000|Overall Study|Protocol deviation|1
6125990|NCT00931710|9751123|FG001|Overall Study|Protocol deviation|2
6125991|NCT00931723|9751131|FG000|Overall Study|Withdrawal by Subject|11
6125992|NCT00931723|9751132|FG001|Overall Study|Withdrawal by Subject|13
6125993|NCT00931723|9751131|FG000|Overall Study|Adverse Event|6
6125994|NCT00931723|9751132|FG001|Overall Study|Adverse Event|13
6125995|NCT00931723|9751131|FG000|Overall Study|Lithium found in blood|0
6125996|NCT00931723|9751132|FG001|Overall Study|Lithium found in blood|1
6125997|NCT00931723|9751131|FG000|Overall Study|Condition under investigation worsened|1
6125998|NCT00931723|9751132|FG001|Overall Study|Condition under investigation worsened|2
6125999|NCT00931723|9751131|FG000|Overall Study|Lost to Follow-up|1
6126000|NCT00931723|9751132|FG001|Overall Study|Lost to Follow-up|2
6126001|NCT00931723|9751131|FG000|Overall Study|Study-specific discontinuation criteria|1
6126002|NCT00931723|9751132|FG001|Overall Study|Study-specific discontinuation criteria|1
6126003|NCT00931723|9751131|FG000|Overall Study|Severe non-compliance to protocol|2
6126004|NCT00931723|9751132|FG001|Overall Study|Severe non-compliance to protocol|0
6126005|NCT00931723|9751131|FG000|Overall Study|Safety reasons|0
6126006|NCT00931723|9751132|FG001|Overall Study|Safety reasons|1
6126007|NCT00931723|9751131|FG000|Overall Study|Took prohibited concomitant medication|0
6126008|NCT00931723|9751132|FG001|Overall Study|Took prohibited concomitant medication|1
6126009|NCT00931723|9751131|FG000|Overall Study|Lack or insufficient theraputic response|2
6126010|NCT00931723|9751132|FG001|Overall Study|Lack or insufficient theraputic response|5
6126011|NCT00931723|9751131|FG000|Overall Study|Sponsor decision|1
6126012|NCT00931723|9751132|FG001|Overall Study|Sponsor decision|0
6126013|NCT00931723|9751131|FG000|Overall Study|Late hospital discharge|1
6126014|NCT00931723|9751132|FG001|Overall Study|Late hospital discharge|0
6126015|NCT00931762|9751138|FG000|Overall Study|Abnormal Laboratory Value (s)|2
6126016|NCT00931762|9751138|FG000|Overall Study|Administrative Problems|5
6126017|NCT00931762|9751138|FG000|Overall Study|Death|1
6126018|NCT00931762|9751138|FG000|Overall Study|Disease Progression|3
6126019|NCT00931762|9751138|FG000|Overall Study|Adverse Event (s)|11
6126020|NCT00931762|9751138|FG000|Overall Study|Subject withdrew consent|13
6126021|NCT00931801|9751145|FG000|Overall Study|Adverse Event|0
6217915|NCT01641809|9886434|FG001|Open-label (Week 96 to Week 324)|Protocol Violation|1
6217916|NCT01641809|9886435|FG002|Open-label (Week 96 to Week 324)|Protocol Violation|0
6217917|NCT01641809|9886436|FG003|Open-label (Week 96 to Week 324)|Protocol Violation|0
6217918|NCT01641809|9886433|FG000|Open-label (Week 96 to Week 324)|Lack of Efficacy|4
6217919|NCT01641809|9886434|FG001|Open-label (Week 96 to Week 324)|Lack of Efficacy|1
6217920|NCT01641809|9886435|FG002|Open-label (Week 96 to Week 324)|Lack of Efficacy|0
6217921|NCT01641809|9886436|FG003|Open-label (Week 96 to Week 324)|Lack of Efficacy|0
6217922|NCT01641809|9886433|FG000|Open-label (Week 96 to Week 324)|Adverse Event|3
6217923|NCT01641809|9886434|FG001|Open-label (Week 96 to Week 324)|Adverse Event|2
6217924|NCT01641809|9886435|FG002|Open-label (Week 96 to Week 324)|Adverse Event|1
6217925|NCT01641809|9886436|FG003|Open-label (Week 96 to Week 324)|Adverse Event|0
6217926|NCT01641822|9886456|FG000|Run-in Phase|Noncompliance with study drug|1
6217927|NCT01641822|9886457|FG001|Run-in Phase|Noncompliance with study drug|0
6217928|NCT01641822|9886458|FG002|Run-in Phase|Noncompliance with study drug|0
6217929|NCT01641822|9886456|FG000|Run-in Phase|Adverse Event|3
6217930|NCT01641822|9886457|FG001|Run-in Phase|Adverse Event|0
6217931|NCT01641822|9886458|FG002|Run-in Phase|Adverse Event|0
6217932|NCT01641822|9886456|FG000|Run-in Phase|Withdrew consent|1
6217933|NCT01641822|9886457|FG001|Run-in Phase|Withdrew consent|0
6217934|NCT01641822|9886458|FG002|Run-in Phase|Withdrew consent|0
6217935|NCT01641822|9886456|FG000|Run-in Phase|Protocol-specified criteria for withdraw|9
6217936|NCT01641822|9886457|FG001|Run-in Phase|Protocol-specified criteria for withdraw|0
6217937|NCT01641822|9886458|FG002|Run-in Phase|Protocol-specified criteria for withdraw|0
6217938|NCT01641822|9886456|FG000|Comparative Phase|Noncompliance with study drug|0
6217939|NCT01641822|9886457|FG001|Comparative Phase|Noncompliance with study drug|1
6217940|NCT01641822|9886458|FG002|Comparative Phase|Noncompliance with study drug|0
6217941|NCT01641822|9886456|FG000|Comparative Phase|Investigator's discretion|0
6217942|NCT01641822|9886457|FG001|Comparative Phase|Investigator's discretion|0
6217943|NCT01641822|9886458|FG002|Comparative Phase|Investigator's discretion|1
6217944|NCT01641822|9886456|FG000|Comparative Phase|Pregnancy|0
6217945|NCT01641822|9886457|FG001|Comparative Phase|Pregnancy|0
6217946|NCT01641822|9886458|FG002|Comparative Phase|Pregnancy|1
6217947|NCT01641822|9886456|FG000|Comparative Phase|Adverse event, serious fatal|0
6217948|NCT01641822|9886457|FG001|Comparative Phase|Adverse event, serious fatal|1
6217949|NCT01641822|9886458|FG002|Comparative Phase|Adverse event, serious fatal|0
6217950|NCT01641822|9886456|FG000|Comparative Phase|Withdrew consent|0
6217951|NCT01641822|9886457|FG001|Comparative Phase|Withdrew consent|3
6217952|NCT01641822|9886458|FG002|Comparative Phase|Withdrew consent|7
6217953|NCT01641822|9886456|FG000|Comparative Phase|Protocol-specified criteria for withdraw|0
6217954|NCT01641822|9886457|FG001|Comparative Phase|Protocol-specified criteria for withdraw|1
6217955|NCT01641822|9886458|FG002|Comparative Phase|Protocol-specified criteria for withdraw|1
6217956|NCT01641861|9886471|FG000|Overall Study|Lost to Follow-up|21
6217957|NCT01641861|9886472|FG001|Overall Study|Lost to Follow-up|16
6217958|NCT01641861|9886471|FG000|Overall Study|Lost the tooth due to normal exfoliation|14
6217959|NCT01641861|9886472|FG001|Overall Study|Lost the tooth due to normal exfoliation|8
6217960|NCT01641861|9886471|FG000|Overall Study|Died due to drowning|0
6217961|NCT01641861|9886472|FG001|Overall Study|Died due to drowning|1
6217962|NCT01641900|9886480|FG000|Overall Study|Withdrawal by Subject|2
6217963|NCT01641900|9886481|FG001|Overall Study|Withdrawal by Subject|2
6217964|NCT01641926|9886493|FG000|Overall Study|Adverse Event|5
6217965|NCT01641926|9886494|FG001|Overall Study|Adverse Event|2
6217966|NCT01641926|9886495|FG002|Overall Study|Adverse Event|3
6217967|NCT01641926|9886496|FG003|Overall Study|Adverse Event|1
6217968|NCT01641926|9886493|FG000|Overall Study|Lost to Follow-up|2
6217969|NCT01641926|9886494|FG001|Overall Study|Lost to Follow-up|2
6217970|NCT01641926|9886495|FG002|Overall Study|Lost to Follow-up|1
6217971|NCT01641926|9886496|FG003|Overall Study|Lost to Follow-up|0
6217972|NCT01641926|9886493|FG000|Overall Study|Physician Decision|6
6217973|NCT01641926|9886494|FG001|Overall Study|Physician Decision|5
6217974|NCT01641926|9886495|FG002|Overall Study|Physician Decision|0
6217975|NCT01641926|9886496|FG003|Overall Study|Physician Decision|1
6217976|NCT01641926|9886493|FG000|Overall Study|Protocol Violation|1
6217977|NCT01641926|9886494|FG001|Overall Study|Protocol Violation|0
6217978|NCT01641926|9886495|FG002|Overall Study|Protocol Violation|0
6217979|NCT01641926|9886496|FG003|Overall Study|Protocol Violation|1
6217980|NCT01641926|9886493|FG000|Overall Study|Withdrawal by Subject|13
6217981|NCT01641926|9886494|FG001|Overall Study|Withdrawal by Subject|5
6217982|NCT01641926|9886495|FG002|Overall Study|Withdrawal by Subject|6
6217983|NCT01641926|9886496|FG003|Overall Study|Withdrawal by Subject|1
6217984|NCT01641926|9886493|FG000|Overall Study|Not Treated|1
6217985|NCT01641926|9886494|FG001|Overall Study|Not Treated|1
6217986|NCT01641926|9886495|FG002|Overall Study|Not Treated|1
6217987|NCT01641926|9886496|FG003|Overall Study|Not Treated|0
6217988|NCT01641939|9886509|FG000|Overall Study|Death|90
6217989|NCT01641939|9886510|FG001|Overall Study|Death|187
6217990|NCT01641939|9886511|FG002|Overall Study|Death|61
6217991|NCT01641939|9886509|FG000|Overall Study|Lost to Follow-up|3
6217992|NCT01641939|9886510|FG001|Overall Study|Lost to Follow-up|2
6217993|NCT01641939|9886511|FG002|Overall Study|Lost to Follow-up|1
6217994|NCT01641939|9886509|FG000|Overall Study|Withdrawal by Subject|14
6126022|NCT00931801|9751146|FG001|Overall Study|Adverse Event|0
6217995|NCT01641939|9886510|FG001|Overall Study|Withdrawal by Subject|11
6217996|NCT01641939|9886511|FG002|Overall Study|Withdrawal by Subject|5
6217997|NCT01641939|9886509|FG000|Overall Study|Study Terminated by Sponsor|10
6217998|NCT01641939|9886510|FG001|Overall Study|Study Terminated by Sponsor|28
6217999|NCT01641939|9886511|FG002|Overall Study|Study Terminated by Sponsor|3
6218000|NCT01641952|9886521|FG000|Overall Study|Lost to Follow-up|28
6218001|NCT01641952|9886521|FG000|Overall Study|Adverse Event|6
6218002|NCT01641991|9886537|FG000|Overall Study|Physician Decision|0
6218003|NCT01641991|9886538|FG001|Overall Study|Physician Decision|1
6218004|NCT01641991|9886539|FG002|Overall Study|Physician Decision|7
6218005|NCT01641991|9886540|FG003|Overall Study|Physician Decision|5
6218006|NCT01641991|9886537|FG000|Overall Study|Withdrawal by Subject|4
6218007|NCT01641991|9886538|FG001|Overall Study|Withdrawal by Subject|2
6218008|NCT01641991|9886539|FG002|Overall Study|Withdrawal by Subject|1
6218009|NCT01641991|9886540|FG003|Overall Study|Withdrawal by Subject|5
6218010|NCT01641991|9886537|FG000|Overall Study|Adverse Event|2
6218011|NCT01641991|9886538|FG001|Overall Study|Adverse Event|1
6218012|NCT01641991|9886539|FG002|Overall Study|Adverse Event|2
6218013|NCT01641991|9886540|FG003|Overall Study|Adverse Event|1
6218014|NCT01641991|9886537|FG000|Overall Study|Lost to Follow-up|0
6218015|NCT01641991|9886538|FG001|Overall Study|Lost to Follow-up|2
6218016|NCT01641991|9886539|FG002|Overall Study|Lost to Follow-up|3
6218017|NCT01641991|9886540|FG003|Overall Study|Lost to Follow-up|1
6218018|NCT01641991|9886537|FG000|Overall Study|Protocol Violation|1
6218019|NCT01641991|9886538|FG001|Overall Study|Protocol Violation|1
6218020|NCT01641991|9886539|FG002|Overall Study|Protocol Violation|3
6218021|NCT01641991|9886540|FG003|Overall Study|Protocol Violation|0
6218022|NCT01641991|9886537|FG000|Overall Study|Pregnancy|0
6218023|NCT01641991|9886538|FG001|Overall Study|Pregnancy|0
6218024|NCT01641991|9886539|FG002|Overall Study|Pregnancy|1
6218025|NCT01641991|9886540|FG003|Overall Study|Pregnancy|0
6218026|NCT01641991|9886537|FG000|Overall Study|no longer eligible|2
6218027|NCT01641991|9886538|FG001|Overall Study|no longer eligible|1
6218028|NCT01641991|9886539|FG002|Overall Study|no longer eligible|0
6218029|NCT01641991|9886540|FG003|Overall Study|no longer eligible|4
6288425|NCT02366143|10002147|FG002|Overall Study|Patient moved to commercial atezolizumab use|7
6288426|NCT02366195|10002159|FG000|Overall Study|Protocol-specified criteria|3
6288427|NCT02366195|10002159|FG000|Overall Study|Withdrawal by Subject|9
6288428|NCT02366195|10002159|FG000|Overall Study|Lost to Follow-up|1
6288429|NCT02366195|10002159|FG000|Overall Study|Death|41
6288430|NCT02366312|10002165|FG000|Overall Study|Lost to Follow-up|0
6288431|NCT02366312|10002166|FG001|Overall Study|Lost to Follow-up|1
6288432|NCT02366468|10002196|FG000|Overall Study|Adverse Event|2
6288433|NCT02366468|10002197|FG001|Overall Study|Adverse Event|0
6288434|NCT02366468|10002196|FG000|Overall Study|Withdrawal by Subject|1
6288435|NCT02366468|10002197|FG001|Overall Study|Withdrawal by Subject|5
6288436|NCT02366468|10002196|FG000|Overall Study|Lost to Follow-up|2
6288437|NCT02366468|10002197|FG001|Overall Study|Lost to Follow-up|0
6288438|NCT02366468|10002196|FG000|Overall Study|Death|1
6288439|NCT02366468|10002197|FG001|Overall Study|Death|2
6288440|NCT02366468|10002196|FG000|Overall Study|Other|0
6288441|NCT02366468|10002197|FG001|Overall Study|Other|2
6288442|NCT02366637|10002213|FG000|First Intervention Period|Adverse Event|0
6288443|NCT02366637|10002214|FG001|First Intervention Period|Adverse Event|1
6288444|NCT02366637|10002213|FG000|First Intervention Period|Study Terminated by Sponsor|6
6288445|NCT02366637|10002214|FG001|First Intervention Period|Study Terminated by Sponsor|4
6288446|NCT02366637|10002213|FG000|Second Intervention Period|Study Terminated by Sponsor|1
6288447|NCT02366637|10002214|FG001|Second Intervention Period|Study Terminated by Sponsor|1
6288448|NCT02366689|10002232|FG000|Overall Study|Withdrawal by Subject|1
6288449|NCT02366689|10002233|FG001|Overall Study|Withdrawal by Subject|0
6288450|NCT02366689|10002234|FG002|Overall Study|Withdrawal by Subject|1
6288451|NCT02366689|10002232|FG000|Overall Study|Lost to Follow-up|3
6288452|NCT02366689|10002233|FG001|Overall Study|Lost to Follow-up|2
6288453|NCT02366689|10002234|FG002|Overall Study|Lost to Follow-up|0
6126023|NCT00931801|9751147|FG002|Overall Study|Adverse Event|1
6126024|NCT00931801|9751145|FG000|Overall Study|Lost to Follow-up|0
6126025|NCT00931801|9751146|FG001|Overall Study|Lost to Follow-up|1
6126026|NCT00931801|9751147|FG002|Overall Study|Lost to Follow-up|0
6126027|NCT00931801|9751145|FG000|Overall Study|Withdrawal by Subject|1
6126028|NCT00931801|9751146|FG001|Overall Study|Withdrawal by Subject|0
6218030|NCT01642212|9886584|FG000|Single-blind Baseline|Did Not Meet Eligibility Criteria|26
6218031|NCT01642212|9886585|FG001|Single-blind Baseline|Did Not Meet Eligibility Criteria|0
6218032|NCT01642212|9886586|FG002|Single-blind Baseline|Did Not Meet Eligibility Criteria|0
6218033|NCT01642212|9886587|FG003|Single-blind Baseline|Did Not Meet Eligibility Criteria|0
6218034|NCT01642212|9886588|FG004|Single-blind Baseline|Did Not Meet Eligibility Criteria|0
6218035|NCT01642212|9886584|FG000|Double-blind Treatment|Other|0
6218036|NCT01642212|9886585|FG001|Double-blind Treatment|Other|2
6218037|NCT01642212|9886586|FG002|Double-blind Treatment|Other|1
6218038|NCT01642212|9886587|FG003|Double-blind Treatment|Other|0
6218039|NCT01642212|9886588|FG004|Double-blind Treatment|Other|0
6288454|NCT02366689|10002232|FG000|Overall Study|Pregnancy|0
6288455|NCT02366689|10002233|FG001|Overall Study|Pregnancy|1
6126029|NCT00931801|9751147|FG002|Overall Study|Withdrawal by Subject|0
6126030|NCT00931801|9751145|FG000|Overall Study|Confirmed Virologic Failure|0
6126031|NCT00931801|9751146|FG001|Overall Study|Confirmed Virologic Failure|0
6126032|NCT00931801|9751147|FG002|Overall Study|Confirmed Virologic Failure|3
6126033|NCT00931892|9751171|FG000|Completed Endoscopies|Patient did not complete third endoscopy due to discomfort|0
6126034|NCT00931892|9751172|FG001|Completed Endoscopies|Patient did not complete third endoscopy due to discomfort|1
6126035|NCT00931918|9751220|FG000|Overall Study|Adverse Event|4
6126036|NCT00931918|9751221|FG001|Overall Study|Adverse Event|6
6126037|NCT00931918|9751220|FG000|Overall Study|Progressive Disease|2
6218040|NCT01642212|9886584|FG000|Double-blind Treatment|Non-compliance|0
6218041|NCT01642212|9886585|FG001|Double-blind Treatment|Non-compliance|1
6218042|NCT01642212|9886586|FG002|Double-blind Treatment|Non-compliance|0
6218043|NCT01642212|9886587|FG003|Double-blind Treatment|Non-compliance|0
6218044|NCT01642212|9886588|FG004|Double-blind Treatment|Non-compliance|0
6218045|NCT01642212|9886584|FG000|Double-blind Treatment|Adverse Event|0
6218046|NCT01642212|9886585|FG001|Double-blind Treatment|Adverse Event|0
6218047|NCT01642212|9886586|FG002|Double-blind Treatment|Adverse Event|1
6218048|NCT01642212|9886587|FG003|Double-blind Treatment|Adverse Event|0
6218049|NCT01642212|9886588|FG004|Double-blind Treatment|Adverse Event|0
6218050|NCT01642212|9886584|FG000|Open-label Extension|Adverse Event|0
6218051|NCT01642212|9886585|FG001|Open-label Extension|Adverse Event|0
6218052|NCT01642212|9886586|FG002|Open-label Extension|Adverse Event|0
6218053|NCT01642212|9886587|FG003|Open-label Extension|Adverse Event|3
6218054|NCT01642212|9886588|FG004|Open-label Extension|Adverse Event|0
6218055|NCT01642212|9886584|FG000|Open-label Extension|Sponsor Decision|0
6218056|NCT01642212|9886585|FG001|Open-label Extension|Sponsor Decision|0
6218057|NCT01642212|9886586|FG002|Open-label Extension|Sponsor Decision|0
6218058|NCT01642212|9886587|FG003|Open-label Extension|Sponsor Decision|7
6218059|NCT01642212|9886588|FG004|Open-label Extension|Sponsor Decision|4
6218060|NCT01642212|9886584|FG000|Open-label Extension|Consent Withdrawn|0
6218061|NCT01642212|9886585|FG001|Open-label Extension|Consent Withdrawn|0
6218062|NCT01642212|9886586|FG002|Open-label Extension|Consent Withdrawn|0
6218063|NCT01642212|9886587|FG003|Open-label Extension|Consent Withdrawn|0
6218064|NCT01642212|9886588|FG004|Open-label Extension|Consent Withdrawn|2
6218065|NCT01642212|9886584|FG000|Open-label Extension|Lost to Follow-up|0
6218066|NCT01642212|9886585|FG001|Open-label Extension|Lost to Follow-up|0
6218067|NCT01642212|9886586|FG002|Open-label Extension|Lost to Follow-up|0
6218068|NCT01642212|9886587|FG003|Open-label Extension|Lost to Follow-up|0
6218069|NCT01642212|9886588|FG004|Open-label Extension|Lost to Follow-up|1
6218070|NCT01642212|9886584|FG000|Open-label Extension|Other|0
6218071|NCT01642212|9886585|FG001|Open-label Extension|Other|0
6218072|NCT01642212|9886586|FG002|Open-label Extension|Other|0
6218073|NCT01642212|9886587|FG003|Open-label Extension|Other|0
6218074|NCT01642212|9886588|FG004|Open-label Extension|Other|1
6218075|NCT01642251|9886606|FG000|Overall Study|Progressive disease|0
6218076|NCT01642251|9886607|FG001|Overall Study|Progressive disease|0
6218077|NCT01642251|9886608|FG002|Overall Study|Progressive disease|3
6218078|NCT01642251|9886609|FG003|Overall Study|Progressive disease|3
6218079|NCT01642251|9886606|FG000|Overall Study|Adverse Event|0
6218080|NCT01642251|9886607|FG001|Overall Study|Adverse Event|0
6218081|NCT01642251|9886608|FG002|Overall Study|Adverse Event|5
6218082|NCT01642251|9886609|FG003|Overall Study|Adverse Event|4
6218083|NCT01642251|9886606|FG000|Overall Study|Death|0
6218084|NCT01642251|9886607|FG001|Overall Study|Death|0
6218085|NCT01642251|9886608|FG002|Overall Study|Death|1
6218086|NCT01642251|9886609|FG003|Overall Study|Death|3
6218087|NCT01642251|9886606|FG000|Overall Study|Withdrawal by Subject|0
6218088|NCT01642251|9886607|FG001|Overall Study|Withdrawal by Subject|0
6218089|NCT01642251|9886608|FG002|Overall Study|Withdrawal by Subject|1
6218090|NCT01642251|9886609|FG003|Overall Study|Withdrawal by Subject|3
6218091|NCT01642251|9886606|FG000|Overall Study|Alternative therapy|0
6218092|NCT01642251|9886607|FG001|Overall Study|Alternative therapy|0
6218093|NCT01642251|9886608|FG002|Overall Study|Alternative therapy|0
6218094|NCT01642251|9886609|FG003|Overall Study|Alternative therapy|2
6218095|NCT01642251|9886606|FG000|Overall Study|Other complicating disease|0
6218096|NCT01642251|9886607|FG001|Overall Study|Other complicating disease|0
6218097|NCT01642251|9886608|FG002|Overall Study|Other complicating disease|1
6218098|NCT01642251|9886609|FG003|Overall Study|Other complicating disease|0
6218099|NCT01642251|9886606|FG000|Overall Study|Ineligible/never start protocol therapy|0
6218100|NCT01642251|9886607|FG001|Overall Study|Ineligible/never start protocol therapy|0
6218101|NCT01642251|9886608|FG002|Overall Study|Ineligible/never start protocol therapy|11
6218102|NCT01642251|9886609|FG003|Overall Study|Ineligible/never start protocol therapy|8
6218103|NCT01642277|9886620|FG000|Overall Study|Adverse Event|10
6218104|NCT01642277|9886621|FG001|Overall Study|Adverse Event|0
6218105|NCT01642277|9886620|FG000|Overall Study|Physician Decision|2
6218106|NCT01642277|9886621|FG001|Overall Study|Physician Decision|0
6218107|NCT01642277|9886620|FG000|Overall Study|Protocol Violation|1
6218108|NCT01642277|9886621|FG001|Overall Study|Protocol Violation|0
6218109|NCT01642277|9886620|FG000|Overall Study|Withdrawal by Subject|11
6218110|NCT01642277|9886621|FG001|Overall Study|Withdrawal by Subject|0
6218111|NCT01642407|9886628|FG000|Part 1 (Screening Till Week 16)|Insufficient clinical response|3
6218112|NCT01642407|9886628|FG000|Part 2(Week17 to Maximum of 119.6 Weeks)|Coil Embolization|1
6126038|NCT00931918|9751221|FG001|Overall Study|Progressive Disease|1
6126039|NCT00931918|9751220|FG000|Overall Study|Symptomatic Deterioration|1
6126040|NCT00931918|9751221|FG001|Overall Study|Symptomatic Deterioration|0
6126041|NCT00931918|9751220|FG000|Overall Study|Withdrawal by Patient|3
6126042|NCT00931918|9751221|FG001|Overall Study|Withdrawal by Patient|4
6126043|NCT00931918|9751220|FG000|Overall Study|Other Reason not Specified|4
6126044|NCT00931918|9751221|FG001|Overall Study|Other Reason not Specified|4
6126045|NCT00931918|9751220|FG000|Overall Study|Did not receive study drug|3
6126046|NCT00931918|9751221|FG001|Overall Study|Did not receive study drug|2
6126047|NCT00931944|9751227|FG000|Overall Study|Adverse Event|4
6126048|NCT00931944|9751227|FG000|Overall Study|W/D Consent (due to ALS progression))|19
6126049|NCT00931944|9751227|FG000|Overall Study|Withdrawal Consent (due to other)|2
6126050|NCT00931944|9751227|FG000|Overall Study|Death|28
6126051|NCT00931944|9751227|FG000|Overall Study|Other|2
6126052|NCT00932113|9751255|FG000|Overall Study|Lost to Follow-up|1
6126053|NCT00932113|9751256|FG001|Overall Study|Lost to Follow-up|0
6126054|NCT00932126|9751262|FG000|Overall Study|Adverse Event|0
6126055|NCT00932126|9751263|FG001|Overall Study|Adverse Event|0
6126056|NCT00932126|9751264|FG002|Overall Study|Adverse Event|0
6126057|NCT00932126|9751265|FG003|Overall Study|Adverse Event|0
6126058|NCT00932126|9751266|FG004|Overall Study|Adverse Event|0
6126059|NCT00932126|9751267|FG005|Overall Study|Adverse Event|0
6126060|NCT00932126|9751268|FG006|Overall Study|Adverse Event|1
6126061|NCT00932126|9751269|FG007|Overall Study|Adverse Event|2
6126062|NCT00932126|9751262|FG000|Overall Study|Protocol Violation|0
6126063|NCT00932126|9751263|FG001|Overall Study|Protocol Violation|0
6126064|NCT00932126|9751264|FG002|Overall Study|Protocol Violation|0
6126065|NCT00932126|9751265|FG003|Overall Study|Protocol Violation|0
6126066|NCT00932126|9751266|FG004|Overall Study|Protocol Violation|1
6126067|NCT00932126|9751267|FG005|Overall Study|Protocol Violation|0
6126068|NCT00932126|9751268|FG006|Overall Study|Protocol Violation|0
6126069|NCT00932126|9751269|FG007|Overall Study|Protocol Violation|0
6126070|NCT00932126|9751262|FG000|Overall Study|Withdrawal by Subject|0
6126071|NCT00932126|9751263|FG001|Overall Study|Withdrawal by Subject|0
6126072|NCT00932126|9751264|FG002|Overall Study|Withdrawal by Subject|1
6126073|NCT00932126|9751265|FG003|Overall Study|Withdrawal by Subject|0
6126074|NCT00932126|9751266|FG004|Overall Study|Withdrawal by Subject|0
6126075|NCT00932126|9751267|FG005|Overall Study|Withdrawal by Subject|0
6126076|NCT00932126|9751268|FG006|Overall Study|Withdrawal by Subject|0
6126077|NCT00932126|9751269|FG007|Overall Study|Withdrawal by Subject|1
6126078|NCT00932126|9751262|FG000|Overall Study|Objective progression or relapse|3
6126079|NCT00932126|9751263|FG001|Overall Study|Objective progression or relapse|3
6126080|NCT00932126|9751264|FG002|Overall Study|Objective progression or relapse|2
6126081|NCT00932126|9751265|FG003|Overall Study|Objective progression or relapse|3
6126082|NCT00932126|9751266|FG004|Overall Study|Objective progression or relapse|3
6126083|NCT00932126|9751267|FG005|Overall Study|Objective progression or relapse|3
6126084|NCT00932126|9751268|FG006|Overall Study|Objective progression or relapse|3
6126085|NCT00932126|9751269|FG007|Overall Study|Objective progression or relapse|5
6126086|NCT00932126|9751262|FG000|Overall Study|Other|0
6126087|NCT00932126|9751263|FG001|Overall Study|Other|0
6126088|NCT00932126|9751264|FG002|Overall Study|Other|0
6126089|NCT00932126|9751265|FG003|Overall Study|Other|0
6126090|NCT00932126|9751266|FG004|Overall Study|Other|1
6126091|NCT00932126|9751267|FG005|Overall Study|Other|0
6126092|NCT00932126|9751268|FG006|Overall Study|Other|1
6126093|NCT00932126|9751269|FG007|Overall Study|Other|2
6126094|NCT00932165|9751289|FG000|Overall Study|Lost to Follow-up|1
6126095|NCT00932360|9751312|FG000|Washout (One Week)|Withdrawal by Subject|0
6126096|NCT00932360|9751313|FG001|Washout (One Week)|Withdrawal by Subject|0
6126097|NCT00932360|9751314|FG002|Washout (One Week)|Withdrawal by Subject|0
6126098|NCT00932360|9751315|FG003|Washout (One Week)|Withdrawal by Subject|0
6126099|NCT00932360|9751316|FG004|Washout (One Week)|Withdrawal by Subject|2
6126100|NCT00932360|9751317|FG005|Washout (One Week)|Withdrawal by Subject|0
6126101|NCT00932373|9751342|FG000|Overall Study|Progressive disease|3
6126102|NCT00932373|9751343|FG001|Overall Study|Progressive disease|1
6126103|NCT00932373|9751344|FG002|Overall Study|Progressive disease|0
6126104|NCT00932373|9751345|FG003|Overall Study|Progressive disease|0
6126105|NCT00932373|9751346|FG004|Overall Study|Progressive disease|10
6126106|NCT00932373|9751347|FG005|Overall Study|Progressive disease|1
6126107|NCT00932373|9751348|FG006|Overall Study|Progressive disease|0
6126108|NCT00932373|9751349|FG007|Overall Study|Progressive disease|2
6126109|NCT00932373|9751350|FG008|Overall Study|Progressive disease|1
6126110|NCT00932373|9751351|FG009|Overall Study|Progressive disease|9
6126111|NCT00932373|9751352|FG010|Overall Study|Progressive disease|2
6126112|NCT00932373|9751342|FG000|Overall Study|Adverse Event|0
6126113|NCT00932373|9751343|FG001|Overall Study|Adverse Event|0
6126114|NCT00932373|9751344|FG002|Overall Study|Adverse Event|0
6126115|NCT00932373|9751345|FG003|Overall Study|Adverse Event|0
6126116|NCT00932373|9751346|FG004|Overall Study|Adverse Event|2
6126117|NCT00932373|9751347|FG005|Overall Study|Adverse Event|1
6126118|NCT00932373|9751348|FG006|Overall Study|Adverse Event|0
6126119|NCT00932373|9751349|FG007|Overall Study|Adverse Event|1
6126120|NCT00932373|9751350|FG008|Overall Study|Adverse Event|0
6126121|NCT00932373|9751351|FG009|Overall Study|Adverse Event|2
6126122|NCT00932373|9751352|FG010|Overall Study|Adverse Event|1
6126123|NCT00932373|9751342|FG000|Overall Study|Physician Decision|0
6126124|NCT00932373|9751343|FG001|Overall Study|Physician Decision|0
6126125|NCT00932373|9751344|FG002|Overall Study|Physician Decision|1
6126126|NCT00932373|9751345|FG003|Overall Study|Physician Decision|0
6126127|NCT00932373|9751346|FG004|Overall Study|Physician Decision|2
6126128|NCT00932373|9751347|FG005|Overall Study|Physician Decision|0
6126129|NCT00932373|9751348|FG006|Overall Study|Physician Decision|0
6126130|NCT00932373|9751349|FG007|Overall Study|Physician Decision|0
6126131|NCT00932373|9751350|FG008|Overall Study|Physician Decision|0
6126132|NCT00932373|9751351|FG009|Overall Study|Physician Decision|1
6126133|NCT00932373|9751352|FG010|Overall Study|Physician Decision|0
6218113|NCT01642407|9886628|FG000|Part 2(Week17 to Maximum of 119.6 Weeks)|Change of treatment plan|1
6218114|NCT01642589|9886659|FG000|Overall Study|Withdrawal by Subject|1
6218115|NCT01642589|9886660|FG001|Overall Study|Withdrawal by Subject|1
6218116|NCT01642602|9886666|FG000|Overall Study|Adverse Event|2
6218117|NCT01642615|9886670|FG000|Open Label Maintenance Phase|Pretreatment Event/Adverse Event|1
6218118|NCT01642615|9886671|FG001|Open Label Maintenance Phase|Pretreatment Event/Adverse Event|0
6218119|NCT01642615|9886672|FG002|Open Label Maintenance Phase|Pretreatment Event/Adverse Event|0
6218120|NCT01642615|9886670|FG000|Open Label Maintenance Phase|Major Protocol Deviation|1
6218121|NCT01642615|9886671|FG001|Open Label Maintenance Phase|Major Protocol Deviation|0
6218122|NCT01642615|9886672|FG002|Open Label Maintenance Phase|Major Protocol Deviation|0
6218123|NCT01642615|9886670|FG000|Open Label Maintenance Phase|Lost to Follow-up|1
6218124|NCT01642615|9886671|FG001|Open Label Maintenance Phase|Lost to Follow-up|0
6218125|NCT01642615|9886672|FG002|Open Label Maintenance Phase|Lost to Follow-up|0
6218126|NCT01642615|9886670|FG000|Open Label Maintenance Phase|Voluntary Withdrawal|1
6218127|NCT01642615|9886671|FG001|Open Label Maintenance Phase|Voluntary Withdrawal|0
6218128|NCT01642615|9886672|FG002|Open Label Maintenance Phase|Voluntary Withdrawal|0
6218129|NCT01642615|9886670|FG000|Open Label Maintenance Phase|Did not receive treatment|1
6218130|NCT01642615|9886671|FG001|Open Label Maintenance Phase|Did not receive treatment|0
6218131|NCT01642615|9886672|FG002|Open Label Maintenance Phase|Did not receive treatment|0
6218132|NCT01642615|9886670|FG000|Double Blind Maintenance Phase|Lack of Efficacy|0
6218133|NCT01642615|9886671|FG001|Double Blind Maintenance Phase|Lack of Efficacy|1
6218134|NCT01642615|9886672|FG002|Double Blind Maintenance Phase|Lack of Efficacy|3
6218135|NCT01642615|9886670|FG000|Double Blind Maintenance Phase|Voluntary Withdrawal|0
6218136|NCT01642615|9886671|FG001|Double Blind Maintenance Phase|Voluntary Withdrawal|5
6218137|NCT01642615|9886672|FG002|Double Blind Maintenance Phase|Voluntary Withdrawal|2
6218138|NCT01642615|9886670|FG000|Double Blind Maintenance Phase|Pretreatment Event/Adverse Event|0
6218139|NCT01642615|9886671|FG001|Double Blind Maintenance Phase|Pretreatment Event/Adverse Event|1
6218140|NCT01642615|9886672|FG002|Double Blind Maintenance Phase|Pretreatment Event/Adverse Event|0
6218141|NCT01642615|9886670|FG000|Double Blind Maintenance Phase|Requires Treatment with Another Drug|0
6218142|NCT01642615|9886671|FG001|Double Blind Maintenance Phase|Requires Treatment with Another Drug|0
6218143|NCT01642615|9886672|FG002|Double Blind Maintenance Phase|Requires Treatment with Another Drug|1
6218144|NCT01642914|9886683|FG000|Overall Study|Adverse Event|11
6218145|NCT01642914|9886684|FG001|Overall Study|Adverse Event|7
6218146|NCT01642914|9886685|FG002|Overall Study|Adverse Event|15
6218147|NCT01642914|9886683|FG000|Overall Study|Lack of Efficacy|9
6218148|NCT01642914|9886684|FG001|Overall Study|Lack of Efficacy|4
6218149|NCT01642914|9886685|FG002|Overall Study|Lack of Efficacy|2
6218150|NCT01642914|9886683|FG000|Overall Study|Protocol Violation|15
6218151|NCT01642914|9886684|FG001|Overall Study|Protocol Violation|13
6218152|NCT01642914|9886685|FG002|Overall Study|Protocol Violation|6
6218153|NCT01642914|9886683|FG000|Overall Study|Withdrawal by Subject|5
6288456|NCT02366689|10002234|FG002|Overall Study|Pregnancy|1
6288457|NCT02366767|10002244|FG000|Overall Study|left for home after 1 day at camp|1
6288458|NCT02366767|10002245|FG001|Overall Study|left for home after 1 day at camp|0
6288459|NCT02366910|10002269|FG000|Overall Study|Withdrawal by Subject|2
6288460|NCT02366910|10002269|FG000|Overall Study|Screen Failure|3
6288461|NCT02366923|10002275|FG000|Overall Study|Withdrawal by Subject|1
6288462|NCT02366923|10002275|FG000|Overall Study|Positive Slit Lamp Findings|2
6288463|NCT02366923|10002275|FG000|Overall Study|High Astigmatism|3
6288464|NCT02366936|10002280|FG000|Overall Study|Withdrawal by Subject|2
6288465|NCT02366936|10002280|FG000|Overall Study|Lost to Follow-up|4
6288466|NCT02366936|10002280|FG000|Overall Study|Physician Decision|2
6288467|NCT02367131|10002317|FG000|Overall Study|Adverse Event|64
6288468|NCT02367131|10002317|FG000|Overall Study|No visit since the first visit|4
6288469|NCT02367131|10002317|FG000|Overall Study|Request by patient|54
6288470|NCT02367131|10002317|FG000|Overall Study|Improvement/remission|2
6288471|NCT02367131|10002317|FG000|Overall Study|No change/progressive disease|78
6288472|NCT02367131|10002317|FG000|Overall Study|Other than stated above|20
6288473|NCT02367352|10002321|FG000|Overall Study|Progressive disease|7
6288474|NCT02367352|10002322|FG001|Overall Study|Progressive disease|0
6288475|NCT02367352|10002323|FG002|Overall Study|Progressive disease|0
6288476|NCT02367352|10002321|FG000|Overall Study|Participant Received Alternative Therapy|1
6288477|NCT02367352|10002322|FG001|Overall Study|Participant Received Alternative Therapy|0
6288478|NCT02367352|10002323|FG002|Overall Study|Participant Received Alternative Therapy|0
6288479|NCT02367352|10002321|FG000|Overall Study|Adverse Event|1
6288480|NCT02367352|10002322|FG001|Overall Study|Adverse Event|0
6288481|NCT02367352|10002323|FG002|Overall Study|Adverse Event|0
6288482|NCT02367521|10002344|FG000|Overall Study|severe headache after intervention|2
6126134|NCT00932373|9751342|FG000|Overall Study|Dose limiting toxicity|0
6126135|NCT00932373|9751343|FG001|Overall Study|Dose limiting toxicity|0
6126136|NCT00932373|9751344|FG002|Overall Study|Dose limiting toxicity|0
6126137|NCT00932373|9751345|FG003|Overall Study|Dose limiting toxicity|0
6126138|NCT00932373|9751346|FG004|Overall Study|Dose limiting toxicity|0
6126139|NCT00932373|9751347|FG005|Overall Study|Dose limiting toxicity|1
6126140|NCT00932373|9751348|FG006|Overall Study|Dose limiting toxicity|0
6126141|NCT00932373|9751349|FG007|Overall Study|Dose limiting toxicity|0
6126142|NCT00932373|9751350|FG008|Overall Study|Dose limiting toxicity|0
6126143|NCT00932373|9751351|FG009|Overall Study|Dose limiting toxicity|0
6126144|NCT00932373|9751352|FG010|Overall Study|Dose limiting toxicity|0
6126145|NCT00932373|9751342|FG000|Overall Study|Withdrawal by Subject|0
6126146|NCT00932373|9751343|FG001|Overall Study|Withdrawal by Subject|0
6126147|NCT00932373|9751344|FG002|Overall Study|Withdrawal by Subject|0
6218154|NCT01642914|9886684|FG001|Overall Study|Withdrawal by Subject|5
6218155|NCT01642914|9886685|FG002|Overall Study|Withdrawal by Subject|10
6218156|NCT01642914|9886683|FG000|Overall Study|Lost to Follow-up|5
6218157|NCT01642914|9886684|FG001|Overall Study|Lost to Follow-up|3
6218158|NCT01642914|9886685|FG002|Overall Study|Lost to Follow-up|7
6218159|NCT01642914|9886683|FG000|Overall Study|Other Reason|1
6218160|NCT01642914|9886684|FG001|Overall Study|Other Reason|0
6218161|NCT01642914|9886685|FG002|Overall Study|Other Reason|0
6218162|NCT01643044|9886697|FG000|Overall Study|Lost to Follow-up|1
6218163|NCT01643044|9886698|FG001|Overall Study|Lost to Follow-up|1
6218164|NCT01643044|9886697|FG000|Overall Study|Miscarried baby|2
6218165|NCT01643044|9886698|FG001|Overall Study|Miscarried baby|2
6218166|NCT01643044|9886697|FG000|Overall Study|Delivered outside of hospital|1
6218167|NCT01643044|9886698|FG001|Overall Study|Delivered outside of hospital|2
6218168|NCT01643408|9886722|FG000|Overall Study|Adverse Event|12
6218169|NCT01643408|9886722|FG000|Overall Study|Other|2
6218170|NCT01643473|9886728|FG000|Overall Study|Lost to Follow-up|1
6218171|NCT01643473|9886729|FG001|Overall Study|Lost to Follow-up|0
6218172|NCT01643668|9886744|FG000|Overall Study|Death|1
6218173|NCT01643772|9886764|FG000|Overall Study|Protocol Violation|0
6218174|NCT01643772|9886765|FG001|Overall Study|Protocol Violation|0
6218175|NCT01643772|9886766|FG002|Overall Study|Protocol Violation|0
6218176|NCT01643772|9886767|FG003|Overall Study|Protocol Violation|1
6218177|NCT01643772|9886764|FG000|Overall Study|Adverse Event|0
6218178|NCT01643772|9886765|FG001|Overall Study|Adverse Event|0
6218179|NCT01643772|9886766|FG002|Overall Study|Adverse Event|0
6218180|NCT01643772|9886767|FG003|Overall Study|Adverse Event|1
6218181|NCT01643798|9886779|FG000|Pretreatment 1 and Stimulation|Withdrawal by Subject|1
6218182|NCT01643798|9886780|FG001|Pretreatment 1 and Stimulation|Withdrawal by Subject|0
6218183|NCT01643850|9886800|FG000|Overall Study|Withdrawal by Subject|0
6218184|NCT01643850|9886801|FG001|Overall Study|Withdrawal by Subject|0
6218185|NCT01643850|9886802|FG002|Overall Study|Withdrawal by Subject|0
6218186|NCT01643850|9886803|FG003|Overall Study|Withdrawal by Subject|0
6218187|NCT01643850|9886804|FG004|Overall Study|Withdrawal by Subject|1
6218188|NCT01643850|9886805|FG005|Overall Study|Withdrawal by Subject|0
6218189|NCT01643850|9886806|FG006|Overall Study|Withdrawal by Subject|0
6218190|NCT01643850|9886807|FG007|Overall Study|Withdrawal by Subject|0
6218191|NCT01643850|9886808|FG008|Overall Study|Withdrawal by Subject|0
6218192|NCT01643850|9886800|FG000|Overall Study|Lost to Follow-up|0
6218193|NCT01643850|9886801|FG001|Overall Study|Lost to Follow-up|0
6218194|NCT01643850|9886802|FG002|Overall Study|Lost to Follow-up|0
6218195|NCT01643850|9886803|FG003|Overall Study|Lost to Follow-up|0
6218196|NCT01643850|9886804|FG004|Overall Study|Lost to Follow-up|0
6218197|NCT01643850|9886805|FG005|Overall Study|Lost to Follow-up|0
6218198|NCT01643850|9886806|FG006|Overall Study|Lost to Follow-up|1
6218199|NCT01643850|9886807|FG007|Overall Study|Lost to Follow-up|0
6218200|NCT01643850|9886808|FG008|Overall Study|Lost to Follow-up|1
6218201|NCT01643850|9886800|FG000|Overall Study|Adverse Event|0
6218202|NCT01643850|9886801|FG001|Overall Study|Adverse Event|0
6218203|NCT01643850|9886802|FG002|Overall Study|Adverse Event|0
6218204|NCT01643850|9886803|FG003|Overall Study|Adverse Event|0
6218205|NCT01643850|9886804|FG004|Overall Study|Adverse Event|1
6218206|NCT01643850|9886805|FG005|Overall Study|Adverse Event|0
6218207|NCT01643850|9886806|FG006|Overall Study|Adverse Event|0
6218208|NCT01643850|9886807|FG007|Overall Study|Adverse Event|0
6218209|NCT01643850|9886808|FG008|Overall Study|Adverse Event|0
6218210|NCT01643850|9886800|FG000|Overall Study|Administrative Problems|0
6218211|NCT01643850|9886801|FG001|Overall Study|Administrative Problems|0
6218212|NCT01643850|9886802|FG002|Overall Study|Administrative Problems|1
6218213|NCT01643850|9886803|FG003|Overall Study|Administrative Problems|0
6218214|NCT01643850|9886804|FG004|Overall Study|Administrative Problems|1
6218215|NCT01643850|9886805|FG005|Overall Study|Administrative Problems|0
6218216|NCT01643850|9886806|FG006|Overall Study|Administrative Problems|0
6218217|NCT01643850|9886807|FG007|Overall Study|Administrative Problems|0
6218218|NCT01643850|9886808|FG008|Overall Study|Administrative Problems|0
6218219|NCT01643928|9886888|FG000|Overall Study|Lost to Follow-up|1
6218220|NCT01643928|9886889|FG001|Overall Study|Lost to Follow-up|0
6218221|NCT01643928|9886890|FG002|Overall Study|Lost to Follow-up|2
6218222|NCT01643928|9886891|FG003|Overall Study|Lost to Follow-up|0
6218223|NCT01643928|9886892|FG004|Overall Study|Lost to Follow-up|0
6218224|NCT01643928|9886888|FG000|Overall Study|Withdrawal by Subject|2
6126148|NCT00932373|9751345|FG003|Overall Study|Withdrawal by Subject|0
6126149|NCT00932373|9751346|FG004|Overall Study|Withdrawal by Subject|0
6126150|NCT00932373|9751347|FG005|Overall Study|Withdrawal by Subject|0
6126151|NCT00932373|9751348|FG006|Overall Study|Withdrawal by Subject|0
6126152|NCT00932373|9751349|FG007|Overall Study|Withdrawal by Subject|0
6126153|NCT00932373|9751350|FG008|Overall Study|Withdrawal by Subject|1
6126154|NCT00932373|9751351|FG009|Overall Study|Withdrawal by Subject|0
6126155|NCT00932373|9751352|FG010|Overall Study|Withdrawal by Subject|0
6126156|NCT00932373|9751342|FG000|Overall Study|Clinical progression|0
6126157|NCT00932373|9751343|FG001|Overall Study|Clinical progression|0
6126158|NCT00932373|9751344|FG002|Overall Study|Clinical progression|0
6126159|NCT00932373|9751345|FG003|Overall Study|Clinical progression|0
6126160|NCT00932373|9751346|FG004|Overall Study|Clinical progression|0
6126161|NCT00932373|9751347|FG005|Overall Study|Clinical progression|0
6126162|NCT00932373|9751348|FG006|Overall Study|Clinical progression|1
6126163|NCT00932373|9751349|FG007|Overall Study|Clinical progression|0
6126164|NCT00932373|9751350|FG008|Overall Study|Clinical progression|0
6126165|NCT00932373|9751351|FG009|Overall Study|Clinical progression|0
6126166|NCT00932373|9751352|FG010|Overall Study|Clinical progression|0
6126167|NCT00932373|9751342|FG000|Overall Study|Lack of Efficacy|0
6126168|NCT00932373|9751343|FG001|Overall Study|Lack of Efficacy|0
6126169|NCT00932373|9751344|FG002|Overall Study|Lack of Efficacy|0
6126170|NCT00932373|9751345|FG003|Overall Study|Lack of Efficacy|0
6126171|NCT00932373|9751346|FG004|Overall Study|Lack of Efficacy|0
6126172|NCT00932373|9751347|FG005|Overall Study|Lack of Efficacy|0
6126173|NCT00932373|9751348|FG006|Overall Study|Lack of Efficacy|0
6126174|NCT00932373|9751349|FG007|Overall Study|Lack of Efficacy|0
6126175|NCT00932373|9751350|FG008|Overall Study|Lack of Efficacy|0
6126176|NCT00932373|9751351|FG009|Overall Study|Lack of Efficacy|1
6126177|NCT00932373|9751352|FG010|Overall Study|Lack of Efficacy|0
6126178|NCT00932425|9751395|FG000|Overall Study|Lost to Follow-up|0
6126179|NCT00932425|9751396|FG001|Overall Study|Lost to Follow-up|1
6126180|NCT00932425|9751395|FG000|Overall Study|Withdrawal by Subject|0
6126181|NCT00932425|9751396|FG001|Overall Study|Withdrawal by Subject|1
6126182|NCT00932451|9751413|FG000|Overall Study|Withdrawal by Subject|69
6126183|NCT00932451|9751413|FG000|Overall Study|Lost to Follow-up|22
6126184|NCT00932451|9751413|FG000|Overall Study|Death|726
6126185|NCT00932451|9751413|FG000|Overall Study|Other reasons|5
6126186|NCT00932646|9751445|FG000|Overall Study|Adverse Event|2
6126187|NCT00932646|9751446|FG001|Overall Study|Adverse Event|1
6126188|NCT00932646|9751447|FG002|Overall Study|Adverse Event|1
6218225|NCT01643928|9886889|FG001|Overall Study|Withdrawal by Subject|0
6218226|NCT01643928|9886890|FG002|Overall Study|Withdrawal by Subject|0
6218227|NCT01643928|9886891|FG003|Overall Study|Withdrawal by Subject|1
6218228|NCT01643928|9886892|FG004|Overall Study|Withdrawal by Subject|0
6218229|NCT01643928|9886888|FG000|Overall Study|Pregnancy|0
6218230|NCT01643928|9886889|FG001|Overall Study|Pregnancy|0
6218231|NCT01643928|9886890|FG002|Overall Study|Pregnancy|0
6218232|NCT01643928|9886891|FG003|Overall Study|Pregnancy|1
6218233|NCT01643928|9886892|FG004|Overall Study|Pregnancy|0
6218234|NCT01643928|9886888|FG000|Overall Study|Other|5
6218235|NCT01643928|9886889|FG001|Overall Study|Other|1
6218236|NCT01643928|9886890|FG002|Overall Study|Other|1
6218237|NCT01643928|9886891|FG003|Overall Study|Other|0
6218238|NCT01643928|9886892|FG004|Overall Study|Other|0
6218239|NCT01643928|9886888|FG000|Overall Study|Adverse Event|2
6218240|NCT01643928|9886889|FG001|Overall Study|Adverse Event|1
6218241|NCT01643928|9886890|FG002|Overall Study|Adverse Event|0
6218242|NCT01643928|9886891|FG003|Overall Study|Adverse Event|1
6218243|NCT01643928|9886892|FG004|Overall Study|Adverse Event|2
6218244|NCT01644149|9886940|FG000|Overall Study|Withdrawal by Subject|1
6218245|NCT01644149|9886941|FG001|Overall Study|Withdrawal by Subject|0
6218246|NCT01644149|9886940|FG000|Overall Study|Lost to Follow-up|3
6218247|NCT01644149|9886941|FG001|Overall Study|Lost to Follow-up|1
6218248|NCT01644175|9886950|FG000|Overall Study|Randomized But Not Treated|0
6218249|NCT01644175|9886951|FG001|Overall Study|Randomized But Not Treated|2
6288483|NCT02367521|10002345|FG001|Overall Study|severe headache after intervention|0
6288484|NCT02367521|10002344|FG000|Overall Study|unable to find transportation|2
6288485|NCT02367521|10002345|FG001|Overall Study|unable to find transportation|0
6288486|NCT02367716|10002360|FG000|Overall Study|Patient did not meet inclusion criteria|1
6288487|NCT02367729|10002367|FG000|Overall Study|Organic disorder diagnosed|2
6288488|NCT02367729|10002368|FG001|Overall Study|Organic disorder diagnosed|1
6288489|NCT02367729|10002367|FG000|Overall Study|Adverse Event|1
6288490|NCT02367729|10002368|FG001|Overall Study|Adverse Event|2
6126189|NCT00932646|9751448|FG003|Overall Study|Adverse Event|1
6218250|NCT01644175|9886950|FG000|Overall Study|Adverse Event|8
6288491|NCT02367729|10002367|FG000|Overall Study|Withdrawal by Subject|0
6288492|NCT02367729|10002368|FG001|Overall Study|Withdrawal by Subject|5
6288493|NCT02367781|10002377|FG000|Overall Study|Withdrawal by Subject|20
6288494|NCT02367781|10002378|FG001|Overall Study|Withdrawal by Subject|13
6288495|NCT02367781|10002377|FG000|Overall Study|Protocol Violation|0
6218251|NCT01644175|9886951|FG001|Overall Study|Adverse Event|13
6126190|NCT00932646|9751445|FG000|Overall Study|Lost to Follow-up|2
6126191|NCT00932646|9751446|FG001|Overall Study|Lost to Follow-up|1
6126192|NCT00932646|9751447|FG002|Overall Study|Lost to Follow-up|0
6126193|NCT00932646|9751448|FG003|Overall Study|Lost to Follow-up|0
6126194|NCT00932646|9751445|FG000|Overall Study|Withdrawal by Subject|1
6126195|NCT00932646|9751446|FG001|Overall Study|Withdrawal by Subject|1
6126196|NCT00932646|9751447|FG002|Overall Study|Withdrawal by Subject|3
6126197|NCT00932646|9751448|FG003|Overall Study|Withdrawal by Subject|0
6126198|NCT00932698|9751477|FG000|Part 1 (Dose Escalation)|Progressive Disease|3
6126199|NCT00932698|9751478|FG001|Part 1 (Dose Escalation)|Progressive Disease|2
6126200|NCT00932698|9751479|FG002|Part 1 (Dose Escalation)|Progressive Disease|2
6126201|NCT00932698|9751480|FG003|Part 1 (Dose Escalation)|Progressive Disease|2
6126202|NCT00932698|9751481|FG004|Part 1 (Dose Escalation)|Progressive Disease|3
6126203|NCT00932698|9751482|FG005|Part 1 (Dose Escalation)|Progressive Disease|5
6126204|NCT00932698|9751483|FG006|Part 1 (Dose Escalation)|Progressive Disease|2
6126205|NCT00932698|9751484|FG007|Part 1 (Dose Escalation)|Progressive Disease|0
6126206|NCT00932698|9751485|FG008|Part 1 (Dose Escalation)|Progressive Disease|0
6126207|NCT00932698|9751486|FG009|Part 1 (Dose Escalation)|Progressive Disease|0
6126208|NCT00932698|9751487|FG010|Part 1 (Dose Escalation)|Progressive Disease|0
6126209|NCT00932698|9751477|FG000|Part 1 (Dose Escalation)|Withdrawal by Participant|0
6126210|NCT00932698|9751478|FG001|Part 1 (Dose Escalation)|Withdrawal by Participant|1
6218252|NCT01644175|9886950|FG000|Overall Study|Death|1
6218253|NCT01644175|9886951|FG001|Overall Study|Death|2
6218254|NCT01644175|9886950|FG000|Overall Study|Poor compliance to protocol|9
6218255|NCT01644175|9886951|FG001|Overall Study|Poor compliance to protocol|10
6218256|NCT01644175|9886950|FG000|Overall Study|Physician Decision|1
6218257|NCT01644175|9886951|FG001|Overall Study|Physician Decision|2
6218258|NCT01644175|9886950|FG000|Overall Study|Participant Moved|1
6218259|NCT01644175|9886951|FG001|Overall Study|Participant Moved|2
6218260|NCT01644175|9886950|FG000|Overall Study|Consent withdrawn by participant|3
6218261|NCT01644175|9886951|FG001|Overall Study|Consent withdrawn by participant|4
6218262|NCT01644175|9886950|FG000|Overall Study|Related to Autoinjector Administration|2
6218263|NCT01644175|9886951|FG001|Overall Study|Related to Autoinjector Administration|1
6218264|NCT01644175|9886950|FG000|Overall Study|Last visit outside protocol visit window|4
6218265|NCT01644175|9886951|FG001|Overall Study|Last visit outside protocol visit window|11
6218266|NCT01644175|9886950|FG000|Overall Study|Selection criteria finally not met|0
6218267|NCT01644175|9886951|FG001|Overall Study|Selection criteria finally not met|1
6218268|NCT01644175|9886950|FG000|Overall Study|Site closure|2
6218269|NCT01644175|9886951|FG001|Overall Study|Site closure|2
6218270|NCT01644175|9886950|FG000|Overall Study|Lost to Follow-up|1
6218271|NCT01644175|9886951|FG001|Overall Study|Lost to Follow-up|0
6218272|NCT01644175|9886950|FG000|Overall Study|Other than specified above|0
6218273|NCT01644175|9886951|FG001|Overall Study|Other than specified above|3
6218274|NCT01644188|9886959|FG000|Overall Study|Adverse Event|44
6218275|NCT01644188|9886960|FG001|Overall Study|Adverse Event|20
6218276|NCT01644188|9886959|FG000|Overall Study|Poor compliance to protocol|26
6218277|NCT01644188|9886960|FG001|Overall Study|Poor compliance to protocol|14
6218278|NCT01644188|9886959|FG000|Overall Study|Physician Decision|1
6218279|NCT01644188|9886960|FG001|Overall Study|Physician Decision|3
6218280|NCT01644188|9886959|FG000|Overall Study|Participant moved|7
6218281|NCT01644188|9886960|FG001|Overall Study|Participant moved|2
6218282|NCT01644188|9886959|FG000|Overall Study|Related to auto-injector administration|2
6218283|NCT01644188|9886960|FG001|Overall Study|Related to auto-injector administration|2
6218284|NCT01644188|9886959|FG000|Overall Study|Consent withdrawn by participant|14
6218285|NCT01644188|9886960|FG001|Overall Study|Consent withdrawn by participant|7
6218286|NCT01644188|9886959|FG000|Overall Study|Selection criteria finally not met|2
6218287|NCT01644188|9886960|FG001|Overall Study|Selection criteria finally not met|0
6218288|NCT01644188|9886959|FG000|Overall Study|Lost to Follow-up|1
6218289|NCT01644188|9886960|FG001|Overall Study|Lost to Follow-up|0
6218290|NCT01644188|9886959|FG000|Overall Study|Death|4
6218291|NCT01644188|9886960|FG001|Overall Study|Death|3
6218292|NCT01644188|9886959|FG000|Overall Study|Last visit outside protocol visit window|14
6218293|NCT01644188|9886960|FG001|Overall Study|Last visit outside protocol visit window|16
6218294|NCT01644188|9886959|FG000|Overall Study|Site closure|1
6218295|NCT01644188|9886960|FG001|Overall Study|Site closure|1
6218296|NCT01644188|9886959|FG000|Overall Study|Other than specified above|6
6218297|NCT01644188|9886960|FG001|Overall Study|Other than specified above|7
6218298|NCT01644474|9886999|FG000|Overall Study|Poor compliance to protocol|1
6218299|NCT01644474|9887000|FG001|Overall Study|Poor compliance to protocol|0
6218300|NCT01644474|9886999|FG000|Overall Study|Consent withdrawn by participant|0
6218301|NCT01644474|9887000|FG001|Overall Study|Consent withdrawn by participant|1
6218302|NCT01644474|9886999|FG000|Overall Study|Participant moved|0
6218303|NCT01644474|9887000|FG001|Overall Study|Participant moved|1
6218304|NCT01644474|9886999|FG000|Overall Study|Adverse Event|4
6218305|NCT01644474|9887000|FG001|Overall Study|Adverse Event|5
6218306|NCT01644474|9886999|FG000|Overall Study|Site scheduling error|1
6218307|NCT01644474|9887000|FG001|Overall Study|Site scheduling error|1
6218308|NCT01644474|9886999|FG000|Overall Study|Protocol Violation|1
6218309|NCT01644474|9887000|FG001|Overall Study|Protocol Violation|0
6218310|NCT01644500|9887009|FG000|Overall Study|Adverse Event|6
6218311|NCT01644500|9887010|FG001|Overall Study|Adverse Event|1
6218312|NCT01644500|9887011|FG002|Overall Study|Adverse Event|2
6218313|NCT01644500|9887009|FG000|Overall Study|Death|0
6218314|NCT01644500|9887010|FG001|Overall Study|Death|1
6126211|NCT00932698|9751479|FG002|Part 1 (Dose Escalation)|Withdrawal by Participant|0
6126212|NCT00932698|9751480|FG003|Part 1 (Dose Escalation)|Withdrawal by Participant|1
6126213|NCT00932698|9751481|FG004|Part 1 (Dose Escalation)|Withdrawal by Participant|0
6126214|NCT00932698|9751482|FG005|Part 1 (Dose Escalation)|Withdrawal by Participant|1
6126215|NCT00932698|9751483|FG006|Part 1 (Dose Escalation)|Withdrawal by Participant|1
6126216|NCT00932698|9751484|FG007|Part 1 (Dose Escalation)|Withdrawal by Participant|0
6126217|NCT00932698|9751485|FG008|Part 1 (Dose Escalation)|Withdrawal by Participant|0
6126218|NCT00932698|9751486|FG009|Part 1 (Dose Escalation)|Withdrawal by Participant|0
6126219|NCT00932698|9751487|FG010|Part 1 (Dose Escalation)|Withdrawal by Participant|0
6126220|NCT00932698|9751477|FG000|Part 1 (Dose Escalation)|Adverse Event|0
6126221|NCT00932698|9751478|FG001|Part 1 (Dose Escalation)|Adverse Event|0
6126222|NCT00932698|9751479|FG002|Part 1 (Dose Escalation)|Adverse Event|0
6126223|NCT00932698|9751480|FG003|Part 1 (Dose Escalation)|Adverse Event|0
6126224|NCT00932698|9751481|FG004|Part 1 (Dose Escalation)|Adverse Event|0
6126225|NCT00932698|9751482|FG005|Part 1 (Dose Escalation)|Adverse Event|1
6126226|NCT00932698|9751483|FG006|Part 1 (Dose Escalation)|Adverse Event|0
6126227|NCT00932698|9751484|FG007|Part 1 (Dose Escalation)|Adverse Event|0
6126228|NCT00932698|9751485|FG008|Part 1 (Dose Escalation)|Adverse Event|0
6126229|NCT00932698|9751486|FG009|Part 1 (Dose Escalation)|Adverse Event|0
6126230|NCT00932698|9751487|FG010|Part 1 (Dose Escalation)|Adverse Event|0
6126231|NCT00932698|9751477|FG000|Part 1 (Dose Escalation)|Other|0
6126232|NCT00932698|9751478|FG001|Part 1 (Dose Escalation)|Other|0
6126233|NCT00932698|9751479|FG002|Part 1 (Dose Escalation)|Other|1
6126234|NCT00932698|9751480|FG003|Part 1 (Dose Escalation)|Other|0
6126235|NCT00932698|9751481|FG004|Part 1 (Dose Escalation)|Other|0
6126236|NCT00932698|9751482|FG005|Part 1 (Dose Escalation)|Other|0
6126237|NCT00932698|9751483|FG006|Part 1 (Dose Escalation)|Other|1
6126238|NCT00932698|9751484|FG007|Part 1 (Dose Escalation)|Other|0
6126239|NCT00932698|9751485|FG008|Part 1 (Dose Escalation)|Other|0
6126240|NCT00932698|9751486|FG009|Part 1 (Dose Escalation)|Other|0
6126241|NCT00932698|9751487|FG010|Part 1 (Dose Escalation)|Other|0
6126242|NCT00932698|9751477|FG000|Part 2 (Dose Expansion)|Progressive Disease|0
6126243|NCT00932698|9751478|FG001|Part 2 (Dose Expansion)|Progressive Disease|0
6126244|NCT00932698|9751479|FG002|Part 2 (Dose Expansion)|Progressive Disease|0
6126245|NCT00932698|9751480|FG003|Part 2 (Dose Expansion)|Progressive Disease|0
6126246|NCT00932698|9751481|FG004|Part 2 (Dose Expansion)|Progressive Disease|0
6126247|NCT00932698|9751482|FG005|Part 2 (Dose Expansion)|Progressive Disease|0
6126248|NCT00932698|9751483|FG006|Part 2 (Dose Expansion)|Progressive Disease|0
6126249|NCT00932698|9751484|FG007|Part 2 (Dose Expansion)|Progressive Disease|14
6126250|NCT00932698|9751485|FG008|Part 2 (Dose Expansion)|Progressive Disease|8
6126251|NCT00932698|9751486|FG009|Part 2 (Dose Expansion)|Progressive Disease|3
6126252|NCT00932698|9751487|FG010|Part 2 (Dose Expansion)|Progressive Disease|2
6126253|NCT00932698|9751477|FG000|Part 2 (Dose Expansion)|Withdrawal by Subject|0
6126254|NCT00932698|9751478|FG001|Part 2 (Dose Expansion)|Withdrawal by Subject|0
6126255|NCT00932698|9751479|FG002|Part 2 (Dose Expansion)|Withdrawal by Subject|0
6126256|NCT00932698|9751480|FG003|Part 2 (Dose Expansion)|Withdrawal by Subject|0
6126257|NCT00932698|9751481|FG004|Part 2 (Dose Expansion)|Withdrawal by Subject|0
6126258|NCT00932698|9751482|FG005|Part 2 (Dose Expansion)|Withdrawal by Subject|0
6126259|NCT00932698|9751483|FG006|Part 2 (Dose Expansion)|Withdrawal by Subject|0
6126260|NCT00932698|9751484|FG007|Part 2 (Dose Expansion)|Withdrawal by Subject|1
6126261|NCT00932698|9751485|FG008|Part 2 (Dose Expansion)|Withdrawal by Subject|3
6126262|NCT00932698|9751486|FG009|Part 2 (Dose Expansion)|Withdrawal by Subject|2
6126263|NCT00932698|9751487|FG010|Part 2 (Dose Expansion)|Withdrawal by Subject|0
6126264|NCT00932698|9751477|FG000|Part 2 (Dose Expansion)|Adverse Event|0
6126265|NCT00932698|9751478|FG001|Part 2 (Dose Expansion)|Adverse Event|0
6126266|NCT00932698|9751479|FG002|Part 2 (Dose Expansion)|Adverse Event|0
6126267|NCT00932698|9751480|FG003|Part 2 (Dose Expansion)|Adverse Event|0
6126268|NCT00932698|9751481|FG004|Part 2 (Dose Expansion)|Adverse Event|0
6126269|NCT00932698|9751482|FG005|Part 2 (Dose Expansion)|Adverse Event|0
6126270|NCT00932698|9751483|FG006|Part 2 (Dose Expansion)|Adverse Event|0
6126271|NCT00932698|9751484|FG007|Part 2 (Dose Expansion)|Adverse Event|5
6126272|NCT00932698|9751485|FG008|Part 2 (Dose Expansion)|Adverse Event|1
6126273|NCT00932698|9751486|FG009|Part 2 (Dose Expansion)|Adverse Event|1
6126274|NCT00932698|9751487|FG010|Part 2 (Dose Expansion)|Adverse Event|0
6126275|NCT00932893|9751519|FG000|Overall Study|Death|115
6126276|NCT00932893|9751520|FG001|Overall Study|Death|24
6126277|NCT00932893|9751519|FG000|Overall Study|Lost to Follow-up|8
6126278|NCT00932893|9751520|FG001|Overall Study|Lost to Follow-up|0
6126279|NCT00932893|9751519|FG000|Overall Study|Withdrawal by Subject|5
6288496|NCT02367781|10002378|FG001|Overall Study|Protocol Violation|1
6126280|NCT00932893|9751520|FG001|Overall Study|Withdrawal by Subject|2
6126281|NCT00932893|9751519|FG000|Overall Study|Other|5
6126282|NCT00932893|9751520|FG001|Overall Study|Other|144
6126283|NCT00933166|9751527|FG000|Overall Study|Lost to Follow-up|4
6126284|NCT00933166|9751527|FG000|Overall Study|Lack of Efficacy|9
6126285|NCT00933166|9751527|FG000|Overall Study|Unavailable|4
6126286|NCT00933166|9751527|FG000|Overall Study|Withdrawal by Subject|1
6126287|NCT00933244|9751534|FG000|Overall Study|Withdrawal by Subject|5
6126288|NCT00933244|9751535|FG001|Overall Study|Withdrawal by Subject|1
6126289|NCT00933244|9751536|FG002|Overall Study|Withdrawal by Subject|3
6126290|NCT00933270|9751544|FG000|Overall Study|Withdrawal by Subject|26
6126291|NCT00933270|9751544|FG000|Overall Study|Insufficient Follow-up|10
6126292|NCT00933270|9751544|FG000|Overall Study|Lost to Follow-up|14
6126293|NCT00933270|9751544|FG000|Overall Study|Adverse Event|1
6126294|NCT00933270|9751544|FG000|Overall Study|Missed Visit|2
6126295|NCT00933270|9751544|FG000|Overall Study|Death|24
6126296|NCT00933270|9751544|FG000|Overall Study|Moved or would not return|10
6126297|NCT00933335|9751551|FG000|Overall Study|Lost to Follow-up|1
6126298|NCT00933335|9751552|FG001|Overall Study|Lost to Follow-up|3
6126299|NCT00933335|9751551|FG000|Overall Study|Withdrawal by Subject|0
6126300|NCT00933335|9751552|FG001|Overall Study|Withdrawal by Subject|1
6126301|NCT00933335|9751551|FG000|Overall Study|Progressive Disease|0
6126302|NCT00933335|9751552|FG001|Overall Study|Progressive Disease|11
6126303|NCT00933335|9751551|FG000|Overall Study|Didn't Meet Criteria for TST/I 131 TST|0
6218315|NCT01644500|9887011|FG002|Overall Study|Death|0
6218316|NCT01644500|9887009|FG000|Overall Study|Lost to Follow-up|3
6218317|NCT01644500|9887010|FG001|Overall Study|Lost to Follow-up|8
6218318|NCT01644500|9887011|FG002|Overall Study|Lost to Follow-up|0
6218319|NCT01644500|9887009|FG000|Overall Study|Protocol Violation|1
6218320|NCT01644500|9887010|FG001|Overall Study|Protocol Violation|1
6218321|NCT01644500|9887011|FG002|Overall Study|Protocol Violation|0
6288497|NCT02367781|10002377|FG000|Overall Study|Physician Decision|7
6288498|NCT02367781|10002378|FG001|Overall Study|Physician Decision|0
6288499|NCT02367781|10002377|FG000|Overall Study|Randomized in Error|5
6288500|NCT02367781|10002378|FG001|Overall Study|Randomized in Error|4
6288501|NCT02367781|10002377|FG000|Overall Study|Non-Compliance|1
6288502|NCT02367781|10002378|FG001|Overall Study|Non-Compliance|0
6288503|NCT02367781|10002377|FG000|Overall Study|Lost to Follow-up|1
6288504|NCT02367781|10002378|FG001|Overall Study|Lost to Follow-up|2
6288505|NCT02367781|10002377|FG000|Overall Study|Death|330
6288506|NCT02367781|10002378|FG001|Overall Study|Death|176
6288507|NCT02367781|10002377|FG000|Overall Study|Patient Moving to Roll-Over Study|17
6288508|NCT02367781|10002378|FG001|Overall Study|Patient Moving to Roll-Over Study|5
6288509|NCT02367781|10002377|FG000|Overall Study|Prolonged Hospitalization|1
6288510|NCT02367781|10002378|FG001|Overall Study|Prolonged Hospitalization|0
6288511|NCT02367781|10002377|FG000|Overall Study|Death Prior First Dose|1
6288512|NCT02367781|10002378|FG001|Overall Study|Death Prior First Dose|0
6288513|NCT02367781|10002377|FG000|Overall Study|Administrative-Change Facility|1
6288514|NCT02367781|10002378|FG001|Overall Study|Administrative-Change Facility|0
6288515|NCT02367781|10002377|FG000|Overall Study|Request From Sponsor to Withdraw Patient in Survival Follow-Up|78
6288516|NCT02367781|10002378|FG001|Overall Study|Request From Sponsor to Withdraw Patient in Survival Follow-Up|29
6288517|NCT02367781|10002377|FG000|Overall Study|Patient Moved to Commercial Atezolizumab Use|14
6288518|NCT02367781|10002378|FG001|Overall Study|Patient Moved to Commercial Atezolizumab Use|9
6288519|NCT02367781|10002377|FG000|Overall Study|Study Terminated by Sponsor|3
6288520|NCT02367781|10002378|FG001|Overall Study|Study Terminated by Sponsor|1
6288521|NCT02367781|10002377|FG000|Overall Study|Patient Admitted to Hospital & Couldn't be Dosed for Randomization|1
6288522|NCT02367781|10002378|FG001|Overall Study|Patient Admitted to Hospital & Couldn't be Dosed for Randomization|0
6288523|NCT02367781|10002377|FG000|Overall Study|Sponsor Decision|2
6288524|NCT02367781|10002378|FG001|Overall Study|Sponsor Decision|0
6288525|NCT02367781|10002377|FG000|Overall Study|3 Year Treatment Completed, Immunotherapy Paused, Continuing Follow-Up Planned|1
6288526|NCT02367781|10002378|FG001|Overall Study|3 Year Treatment Completed, Immunotherapy Paused, Continuing Follow-Up Planned|0
6288527|NCT02367833|10002403|FG000|Overall Study|Withdrawal by Subject|1
6288528|NCT02367833|10002404|FG001|Overall Study|Withdrawal by Subject|1
6288529|NCT02367833|10002405|FG002|Overall Study|Withdrawal by Subject|0
6288530|NCT02367885|10002462|FG000|Overall Study|Lost to Follow-up|1
6288531|NCT02367885|10002463|FG001|Overall Study|Lost to Follow-up|0
6288532|NCT02367885|10002464|FG002|Overall Study|Lost to Follow-up|0
6288533|NCT02367885|10002462|FG000|Overall Study|Withdrawal by Subject|1
6288534|NCT02367885|10002463|FG001|Overall Study|Withdrawal by Subject|0
6288535|NCT02367885|10002464|FG002|Overall Study|Withdrawal by Subject|0
6288536|NCT02367911|10002477|FG000|Overall Study|Withdrawal by Subject|3
6288537|NCT02367911|10002478|FG001|Overall Study|Withdrawal by Subject|2
6288538|NCT02367911|10002477|FG000|Overall Study|Lost to Follow-up|2
6288539|NCT02367911|10002478|FG001|Overall Study|Lost to Follow-up|2
6288540|NCT02368210|10002495|FG000|Overall Study|Withdrawal by Subject|1
6288541|NCT02368210|10002496|FG001|Overall Study|Withdrawal by Subject|0
6288542|NCT02368210|10002495|FG000|Overall Study|Adverse Event|0
6288543|NCT02368210|10002496|FG001|Overall Study|Adverse Event|1
6288544|NCT02368314|10002504|FG000|Overall Study|Withdrawal by Subject|2
6288545|NCT02368314|10002505|FG001|Overall Study|Withdrawal by Subject|1
6288546|NCT02368314|10002504|FG000|Overall Study|Adverse Event|1
6288547|NCT02368314|10002505|FG001|Overall Study|Adverse Event|2
6288548|NCT02368691|10002530|FG000|Overall Study|Death|13
6288549|NCT02368691|10002530|FG000|Overall Study|Lack of Efficacy|15
6288550|NCT02368691|10002530|FG000|Overall Study|Physician Decision|4
6126304|NCT00933335|9751552|FG001|Overall Study|Didn't Meet Criteria for TST/I 131 TST|1
6126305|NCT00933335|9751551|FG000|Overall Study|Co-morbid Illness|1
6126306|NCT00933335|9751552|FG001|Overall Study|Co-morbid Illness|0
6126307|NCT00933543|9751575|FG000|Overall Study|Adverse Event|2
6218322|NCT01644500|9887009|FG000|Overall Study|Withdrawal by Subject|11
6218323|NCT01644500|9887010|FG001|Overall Study|Withdrawal by Subject|12
6126308|NCT00933543|9751576|FG001|Overall Study|Adverse Event|1
6126309|NCT00933543|9751575|FG000|Overall Study|Lost to Follow-up|0
6126310|NCT00933543|9751576|FG001|Overall Study|Lost to Follow-up|1
6126311|NCT00933543|9751575|FG000|Overall Study|Withdrawal by Subject|0
6126312|NCT00933543|9751576|FG001|Overall Study|Withdrawal by Subject|1
6126313|NCT00933543|9751575|FG000|Overall Study|Lack of Efficacy|0
6126314|NCT00933543|9751576|FG001|Overall Study|Lack of Efficacy|3
6126315|NCT00933543|9751575|FG000|Overall Study|Other|1
6126316|NCT00933543|9751576|FG001|Overall Study|Other|1
6126317|NCT00933608|9751584|FG000|Overall Study|Adverse Event|4
6126318|NCT00933608|9751585|FG001|Overall Study|Adverse Event|2
6126319|NCT00933608|9751584|FG000|Overall Study|Physician Decision|1
6126320|NCT00933608|9751585|FG001|Overall Study|Physician Decision|0
6126321|NCT00933686|9751593|FG000|Overall Study|Protocol Violation|0
6126322|NCT00933686|9751594|FG001|Overall Study|Protocol Violation|1
6126323|NCT00933686|9751593|FG000|Overall Study|Lost to Follow-up|2
6126324|NCT00933686|9751594|FG001|Overall Study|Lost to Follow-up|2
6126325|NCT00933686|9751593|FG000|Overall Study|Withdrawal by Subject|6
6126326|NCT00933686|9751594|FG001|Overall Study|Withdrawal by Subject|5
6126327|NCT00933686|9751593|FG000|Overall Study|Adverse Event|1
6126328|NCT00933686|9751594|FG001|Overall Study|Adverse Event|1
6126329|NCT00933686|9751593|FG000|Overall Study|Physician Decision|1
6126330|NCT00933686|9751594|FG001|Overall Study|Physician Decision|0
6126331|NCT00933686|9751593|FG000|Overall Study|Failure to show up at endpoint visits|0
6126332|NCT00933686|9751594|FG001|Overall Study|Failure to show up at endpoint visits|2
6126333|NCT00933933|9751605|FG000|General Population From 16 to 89 Years|Did not meet criteria for analysis|0
6126334|NCT00933933|9751606|FG001|General Population From 16 to 89 Years|Did not meet criteria for analysis|20
6218324|NCT01644500|9887011|FG002|Overall Study|Withdrawal by Subject|12
6218325|NCT01644500|9887009|FG000|Overall Study|Physician Decision|1
6218326|NCT01644500|9887010|FG001|Overall Study|Physician Decision|1
6218327|NCT01644500|9887011|FG002|Overall Study|Physician Decision|1
6218328|NCT01644565|9887019|FG000|Overall Study|Undisclosed Medical History|1
6218329|NCT01644565|9887020|FG001|Overall Study|Undisclosed Medical History|0
6218330|NCT01644565|9887021|FG002|Overall Study|Undisclosed Medical History|0
6218331|NCT01644565|9887022|FG003|Overall Study|Undisclosed Medical History|0
6218332|NCT01644565|9887023|FG004|Overall Study|Undisclosed Medical History|0
6218333|NCT01644565|9887024|FG005|Overall Study|Undisclosed Medical History|0
6218334|NCT01644565|9887025|FG006|Overall Study|Undisclosed Medical History|0
6218335|NCT01644565|9887026|FG007|Overall Study|Undisclosed Medical History|0
6218336|NCT01644565|9887027|FG008|Overall Study|Undisclosed Medical History|0
6218337|NCT01644565|9887019|FG000|Overall Study|Lost to Follow-up|0
6218338|NCT01644565|9887020|FG001|Overall Study|Lost to Follow-up|0
6218339|NCT01644565|9887021|FG002|Overall Study|Lost to Follow-up|0
6218340|NCT01644565|9887022|FG003|Overall Study|Lost to Follow-up|1
6218341|NCT01644565|9887023|FG004|Overall Study|Lost to Follow-up|0
6218342|NCT01644565|9887024|FG005|Overall Study|Lost to Follow-up|0
6218343|NCT01644565|9887025|FG006|Overall Study|Lost to Follow-up|0
6218344|NCT01644565|9887026|FG007|Overall Study|Lost to Follow-up|2
6218345|NCT01644565|9887027|FG008|Overall Study|Lost to Follow-up|0
6218346|NCT01644565|9887019|FG000|Overall Study|Family emergency|0
6218347|NCT01644565|9887020|FG001|Overall Study|Family emergency|0
6218348|NCT01644565|9887021|FG002|Overall Study|Family emergency|0
6218349|NCT01644565|9887022|FG003|Overall Study|Family emergency|0
6218350|NCT01644565|9887023|FG004|Overall Study|Family emergency|1
6218351|NCT01644565|9887024|FG005|Overall Study|Family emergency|0
6218352|NCT01644565|9887025|FG006|Overall Study|Family emergency|0
6218353|NCT01644565|9887026|FG007|Overall Study|Family emergency|0
6218354|NCT01644565|9887027|FG008|Overall Study|Family emergency|0
6218355|NCT01644565|9887019|FG000|Overall Study|Relocation|0
6218356|NCT01644565|9887020|FG001|Overall Study|Relocation|0
6218357|NCT01644565|9887021|FG002|Overall Study|Relocation|0
6218358|NCT01644565|9887022|FG003|Overall Study|Relocation|0
6218359|NCT01644565|9887023|FG004|Overall Study|Relocation|0
6218360|NCT01644565|9887024|FG005|Overall Study|Relocation|0
6218361|NCT01644565|9887025|FG006|Overall Study|Relocation|0
6218362|NCT01644565|9887026|FG007|Overall Study|Relocation|0
6218363|NCT01644565|9887027|FG008|Overall Study|Relocation|1
6218364|NCT01644617|9887050|FG000|Overall Study|Withdrawal by Subject|3
6218365|NCT01644617|9887051|FG001|Overall Study|Withdrawal by Subject|4
6218366|NCT01644617|9887052|FG002|Overall Study|Withdrawal by Subject|1
6218367|NCT01644617|9887050|FG000|Overall Study|Lost to Follow-up|0
6218368|NCT01644617|9887051|FG001|Overall Study|Lost to Follow-up|1
6218369|NCT01644617|9887052|FG002|Overall Study|Lost to Follow-up|0
6218370|NCT01644617|9887050|FG000|Overall Study|Adverse Event|3
6218371|NCT01644617|9887051|FG001|Overall Study|Adverse Event|0
6218372|NCT01644617|9887052|FG002|Overall Study|Adverse Event|6
6218373|NCT01644643|9887064|FG000|Overall Study|Death|1
6218374|NCT01644643|9887065|FG001|Overall Study|Death|0
6218375|NCT01644643|9887066|FG002|Overall Study|Death|3
6218376|NCT01644643|9887067|FG003|Overall Study|Death|3
6218377|NCT01644643|9887064|FG000|Overall Study|Lost to Follow-up|0
6218378|NCT01644643|9887065|FG001|Overall Study|Lost to Follow-up|0
6218379|NCT01644643|9887066|FG002|Overall Study|Lost to Follow-up|0
6218380|NCT01644643|9887067|FG003|Overall Study|Lost to Follow-up|4
6218381|NCT01644643|9887064|FG000|Overall Study|Withdrawal by Subject|1
6218382|NCT01644643|9887065|FG001|Overall Study|Withdrawal by Subject|0
6126335|NCT00933933|9751607|FG002|General Population From 16 to 89 Years|Did not meet criteria for analysis|0
6126336|NCT00933933|9751605|FG000|Pregnant Females Between 16-44 Years|Specimens classified incorrectly|0
6288551|NCT02369159|10002545|FG000|Overall Study|Adverse Event|0
6288552|NCT02369159|10002546|FG001|Overall Study|Adverse Event|1
6288553|NCT02369159|10002545|FG000|Overall Study|Lost to Follow-up|1
6288554|NCT02369159|10002546|FG001|Overall Study|Lost to Follow-up|1
6288555|NCT02369159|10002545|FG000|Overall Study|Withdrawal by Subject|7
6288556|NCT02369159|10002546|FG001|Overall Study|Withdrawal by Subject|0
6288557|NCT02369341|10002596|FG000|Overall Study|Migrated/moved from study area|1
6288558|NCT02369341|10002597|FG001|Overall Study|Migrated/moved from study area|0
6126337|NCT00933933|9751606|FG001|Pregnant Females Between 16-44 Years|Specimens classified incorrectly|2
6126338|NCT00933933|9751607|FG002|Pregnant Females Between 16-44 Years|Specimens classified incorrectly|0
6126339|NCT00934050|9751637|FG000|Enrolled Prior to 15 Dec 2009|Adverse Event|1
6126340|NCT00934050|9751638|FG001|Enrolled Prior to 15 Dec 2009|Adverse Event|0
6126341|NCT00934050|9751639|FG002|Enrolled Prior to 15 Dec 2009|Adverse Event|0
6126342|NCT00934050|9751640|FG003|Enrolled Prior to 15 Dec 2009|Adverse Event|1
6126343|NCT00934050|9751641|FG004|Enrolled Prior to 15 Dec 2009|Adverse Event|0
6126344|NCT00934050|9751642|FG005|Enrolled Prior to 15 Dec 2009|Adverse Event|0
6126345|NCT00934050|9751637|FG000|Enrolled Prior to 15 Dec 2009|Sponsor Decision|11
6126346|NCT00934050|9751638|FG001|Enrolled Prior to 15 Dec 2009|Sponsor Decision|12
6126347|NCT00934050|9751639|FG002|Enrolled Prior to 15 Dec 2009|Sponsor Decision|11
6126348|NCT00934050|9751640|FG003|Enrolled Prior to 15 Dec 2009|Sponsor Decision|13
6126349|NCT00934050|9751641|FG004|Enrolled Prior to 15 Dec 2009|Sponsor Decision|0
6126350|NCT00934050|9751642|FG005|Enrolled Prior to 15 Dec 2009|Sponsor Decision|0
6126351|NCT00934050|9751637|FG000|Enrolled Prior to 15 Dec 2009|Withdrawal by Subject|0
6126352|NCT00934050|9751638|FG001|Enrolled Prior to 15 Dec 2009|Withdrawal by Subject|0
6126353|NCT00934050|9751639|FG002|Enrolled Prior to 15 Dec 2009|Withdrawal by Subject|1
6126354|NCT00934050|9751640|FG003|Enrolled Prior to 15 Dec 2009|Withdrawal by Subject|0
6126355|NCT00934050|9751641|FG004|Enrolled Prior to 15 Dec 2009|Withdrawal by Subject|0
6126356|NCT00934050|9751642|FG005|Enrolled Prior to 15 Dec 2009|Withdrawal by Subject|0
6126357|NCT00934050|9751637|FG000|Enrolled After 15 Dec 2009|Adverse Event|0
6126358|NCT00934050|9751638|FG001|Enrolled After 15 Dec 2009|Adverse Event|0
6126359|NCT00934050|9751639|FG002|Enrolled After 15 Dec 2009|Adverse Event|0
6126360|NCT00934050|9751640|FG003|Enrolled After 15 Dec 2009|Adverse Event|0
6126361|NCT00934050|9751641|FG004|Enrolled After 15 Dec 2009|Adverse Event|3
6126362|NCT00934050|9751642|FG005|Enrolled After 15 Dec 2009|Adverse Event|0
6126363|NCT00934050|9751637|FG000|Enrolled After 15 Dec 2009|Death|0
6126364|NCT00934050|9751638|FG001|Enrolled After 15 Dec 2009|Death|0
6126365|NCT00934050|9751639|FG002|Enrolled After 15 Dec 2009|Death|0
6126366|NCT00934050|9751640|FG003|Enrolled After 15 Dec 2009|Death|0
6126367|NCT00934050|9751641|FG004|Enrolled After 15 Dec 2009|Death|0
6126368|NCT00934050|9751642|FG005|Enrolled After 15 Dec 2009|Death|1
6126369|NCT00934050|9751637|FG000|Enrolled After 15 Dec 2009|Lost to Follow-up|0
6126370|NCT00934050|9751638|FG001|Enrolled After 15 Dec 2009|Lost to Follow-up|0
6126371|NCT00934050|9751639|FG002|Enrolled After 15 Dec 2009|Lost to Follow-up|0
6126372|NCT00934050|9751640|FG003|Enrolled After 15 Dec 2009|Lost to Follow-up|0
6218383|NCT01644643|9887066|FG002|Overall Study|Withdrawal by Subject|2
6218384|NCT01644643|9887067|FG003|Overall Study|Withdrawal by Subject|1
6218385|NCT01644643|9887064|FG000|Overall Study|Other Eligibility criteria|0
6218386|NCT01644643|9887065|FG001|Overall Study|Other Eligibility criteria|0
6218387|NCT01644643|9887066|FG002|Overall Study|Other Eligibility criteria|0
6218388|NCT01644643|9887067|FG003|Overall Study|Other Eligibility criteria|2
6218389|NCT01644734|9887087|FG000|Overall Study|Adverse Event|4
6218390|NCT01644734|9887087|FG000|Overall Study|Lost to Follow-up|17
6218391|NCT01644734|9887087|FG000|Overall Study|Reasons other than stated above|7
6218392|NCT01644734|9887087|FG000|Overall Study|Missing documentation|238
6218393|NCT01644890|9887093|FG000|Overall Study|Adverse Event|7
6218394|NCT01644890|9887094|FG001|Overall Study|Adverse Event|20
6218395|NCT01644890|9887093|FG000|Overall Study|Death|1
6218396|NCT01644890|9887094|FG001|Overall Study|Death|3
6218397|NCT01644890|9887093|FG000|Overall Study|Physician Decision|3
6218398|NCT01644890|9887094|FG001|Overall Study|Physician Decision|9
6218399|NCT01644890|9887093|FG000|Overall Study|Protocol Violation|6
6218400|NCT01644890|9887094|FG001|Overall Study|Protocol Violation|7
6218401|NCT01644890|9887093|FG000|Overall Study|Withdrawal by Subject|19
6218402|NCT01644890|9887094|FG001|Overall Study|Withdrawal by Subject|27
6218403|NCT01644890|9887093|FG000|Overall Study|Progression Disease|160
6218404|NCT01644890|9887094|FG001|Overall Study|Progression Disease|131
6218405|NCT01644890|9887093|FG000|Overall Study|Clinical Progression|6
6218406|NCT01644890|9887094|FG001|Overall Study|Clinical Progression|6
6218407|NCT01644890|9887093|FG000|Overall Study|> 28 days since last dose of study drug|6
6218408|NCT01644890|9887094|FG001|Overall Study|> 28 days since last dose of study drug|3
6218409|NCT01644890|9887093|FG000|Overall Study|Other|8
6218410|NCT01644890|9887094|FG001|Overall Study|Other|9
6218411|NCT01645111|9887118|FG000|Overall Study|Did not require Clevidipine|15
6218412|NCT01645176|9887122|FG000|Overall Study|Lack of Efficacy|4
6218413|NCT01645176|9887122|FG000|Overall Study|did not complete final MRI|1
6288559|NCT02369510|10002614|FG000|Overall Study|Spilled Medication|1
6218414|NCT01645280|9887131|FG000|Overall Study|Death|0
6126373|NCT00934050|9751641|FG004|Enrolled After 15 Dec 2009|Lost to Follow-up|0
6126374|NCT00934050|9751642|FG005|Enrolled After 15 Dec 2009|Lost to Follow-up|1
6126375|NCT00934050|9751637|FG000|Enrolled After 15 Dec 2009|Withdrawal by Subject|0
6126376|NCT00934050|9751638|FG001|Enrolled After 15 Dec 2009|Withdrawal by Subject|0
6126377|NCT00934050|9751639|FG002|Enrolled After 15 Dec 2009|Withdrawal by Subject|0
6126378|NCT00934050|9751640|FG003|Enrolled After 15 Dec 2009|Withdrawal by Subject|0
6126379|NCT00934050|9751641|FG004|Enrolled After 15 Dec 2009|Withdrawal by Subject|4
6126380|NCT00934050|9751642|FG005|Enrolled After 15 Dec 2009|Withdrawal by Subject|2
6126381|NCT00934089|9751654|FG000|First Intervention Period (14 Days)|Withdrawal by Subject|1
6126382|NCT00934089|9751655|FG001|First Intervention Period (14 Days)|Withdrawal by Subject|0
6126383|NCT00934089|9751654|FG000|First Intervention Period (14 Days)|Randomized, but not treated|1
6126384|NCT00934089|9751655|FG001|First Intervention Period (14 Days)|Randomized, but not treated|0
6126385|NCT00934102|9751661|FG000|Period 1, One Night of Wear|Personal Reasons|1
6126386|NCT00934102|9751662|FG001|Period 1, One Night of Wear|Personal Reasons|0
6126387|NCT00934102|9751663|FG002|Period 1, One Night of Wear|Personal Reasons|0
6126388|NCT00934128|9751673|FG000|First Intervention (2 Hours)|Withdrawal by Subject|0
6126389|NCT00934128|9751674|FG001|First Intervention (2 Hours)|Withdrawal by Subject|1
6126390|NCT00934128|9751673|FG000|First Intervention (2 Hours)|Adverse Event|4
6126391|NCT00934128|9751674|FG001|First Intervention (2 Hours)|Adverse Event|1
6218415|NCT01645280|9887132|FG001|Overall Study|Death|1
6218416|NCT01645280|9887133|FG002|Overall Study|Death|0
6218417|NCT01645280|9887134|FG003|Overall Study|Death|0
6218418|NCT01645280|9887135|FG004|Overall Study|Death|0
6218419|NCT01645280|9887131|FG000|Overall Study|Withdrawal by Subject|4
6218420|NCT01645280|9887132|FG001|Overall Study|Withdrawal by Subject|0
6218421|NCT01645280|9887133|FG002|Overall Study|Withdrawal by Subject|2
6218422|NCT01645280|9887134|FG003|Overall Study|Withdrawal by Subject|4
6218423|NCT01645280|9887135|FG004|Overall Study|Withdrawal by Subject|5
6218424|NCT01645280|9887131|FG000|Overall Study|Lost to Follow-up|0
6218425|NCT01645280|9887132|FG001|Overall Study|Lost to Follow-up|0
6218426|NCT01645280|9887133|FG002|Overall Study|Lost to Follow-up|0
6218427|NCT01645280|9887134|FG003|Overall Study|Lost to Follow-up|2
6218428|NCT01645280|9887135|FG004|Overall Study|Lost to Follow-up|1
6218429|NCT01645280|9887131|FG000|Overall Study|Other|1
6218430|NCT01645280|9887132|FG001|Overall Study|Other|1
6218431|NCT01645280|9887133|FG002|Overall Study|Other|2
6218432|NCT01645280|9887134|FG003|Overall Study|Other|0
6218433|NCT01645280|9887135|FG004|Overall Study|Other|0
6218434|NCT01645280|9887131|FG000|Overall Study|Treatment not completed/Completed f/u|1
6218435|NCT01645280|9887132|FG001|Overall Study|Treatment not completed/Completed f/u|1
6218436|NCT01645280|9887133|FG002|Overall Study|Treatment not completed/Completed f/u|2
6218437|NCT01645280|9887134|FG003|Overall Study|Treatment not completed/Completed f/u|0
6218438|NCT01645280|9887135|FG004|Overall Study|Treatment not completed/Completed f/u|2
6218439|NCT01645735|9887163|FG000|Overall Study|Physician Decision|2
6218440|NCT01645735|9887164|FG001|Overall Study|Physician Decision|0
6218441|NCT01645735|9887163|FG000|Overall Study|Withdrawal by Subject|1
6218442|NCT01645735|9887164|FG001|Overall Study|Withdrawal by Subject|0
6218443|NCT01645735|9887163|FG000|Overall Study|Protocol Violation|1
6218444|NCT01645735|9887164|FG001|Overall Study|Protocol Violation|0
6218445|NCT01645735|9887163|FG000|Overall Study|Adverse Event|0
6218446|NCT01645735|9887164|FG001|Overall Study|Adverse Event|1
6218447|NCT01645930|9887171|FG000|Overall Study|Participants Ongoing on Study Treatment|22
6218448|NCT01645930|9887171|FG000|Overall Study|Progressive Disease|12
6218449|NCT01645930|9887171|FG000|Overall Study|Adverse Event|4
6218450|NCT01645930|9887171|FG000|Overall Study|Unsatisfactory Therapeutic Response|2
6218451|NCT01645930|9887171|FG000|Overall Study|Withdrawal by Participant|2
6218452|NCT01645930|9887171|FG000|Overall Study|Reason not Defined|1
6218453|NCT01646021|9887177|FG000|Overall Study|Death|77
6218454|NCT01646021|9887178|FG001|Overall Study|Death|83
6218455|NCT01646021|9887177|FG000|Overall Study|Study Terminated by Sponsor|50
6218456|NCT01646021|9887178|FG001|Overall Study|Study Terminated by Sponsor|41
6218457|NCT01646021|9887177|FG000|Overall Study|Lost to Follow-up|2
6218458|NCT01646021|9887178|FG001|Overall Study|Lost to Follow-up|2
6218459|NCT01646021|9887177|FG000|Overall Study|Withdrawal by Subject|10
6218460|NCT01646021|9887178|FG001|Overall Study|Withdrawal by Subject|15
6218461|NCT01646073|9887186|FG000|Period A (12 Weeks)|Adverse Event|0
6218462|NCT01646073|9887187|FG001|Period A (12 Weeks)|Adverse Event|2
6218463|NCT01646073|9887186|FG000|Period A (12 Weeks)|Withdrawal by Subject|1
6218464|NCT01646073|9887187|FG001|Period A (12 Weeks)|Withdrawal by Subject|1
6218465|NCT01646073|9887186|FG000|Period A (12 Weeks)|Lack of Efficacy|1
6218466|NCT01646073|9887187|FG001|Period A (12 Weeks)|Lack of Efficacy|0
6218467|NCT01646073|9887186|FG000|Period A (12 Weeks)|Protocol Violation|0
6218468|NCT01646073|9887187|FG001|Period A (12 Weeks)|Protocol Violation|1
6218469|NCT01646073|9887186|FG000|Period A (12 Weeks)|Other|0
6218470|NCT01646073|9887187|FG001|Period A (12 Weeks)|Other|1
6218471|NCT01646073|9887186|FG000|Period B (12 Weeks)|Adverse Event|0
6218472|NCT01646073|9887187|FG001|Period B (12 Weeks)|Adverse Event|7
6218473|NCT01646073|9887186|FG000|Period B (12 Weeks)|Withdrawal by Subject|1
6218474|NCT01646073|9887187|FG001|Period B (12 Weeks)|Withdrawal by Subject|5
6218475|NCT01646073|9887186|FG000|Period B (12 Weeks)|Lost to Follow-up|0
6218476|NCT01646073|9887187|FG001|Period B (12 Weeks)|Lost to Follow-up|1
6218477|NCT01646125|9887198|FG000|Overall Study|Untreated|2
6126392|NCT00934128|9751673|FG000|First Intervention (2 Hours)|Treatment Delivery Order Switched|1
6126393|NCT00934128|9751674|FG001|First Intervention (2 Hours)|Treatment Delivery Order Switched|0
6126394|NCT00934128|9751673|FG000|Washout Period (1 Hour)|Patient preference|1
6126395|NCT00934128|9751674|FG001|Washout Period (1 Hour)|Patient preference|3
6126396|NCT00934128|9751673|FG000|Washout Period (1 Hour)|Pain|1
6126397|NCT00934128|9751674|FG001|Washout Period (1 Hour)|Pain|0
6126398|NCT00934128|9751673|FG000|Washout Period (1 Hour)|Too tired|1
6126399|NCT00934128|9751674|FG001|Washout Period (1 Hour)|Too tired|0
6126400|NCT00934128|9751673|FG000|Washout Period (1 Hour)|Dyspnea too low to continue|4
6126401|NCT00934128|9751674|FG001|Washout Period (1 Hour)|Dyspnea too low to continue|2
6126402|NCT00934128|9751673|FG000|Second Intervention (2 Hours)|Claustrophobia/anxiety|0
6126403|NCT00934128|9751674|FG001|Second Intervention (2 Hours)|Claustrophobia/anxiety|3
6126404|NCT00934362|9751701|FG000|Overall Study|Adverse Event|1
6126405|NCT00934362|9751702|FG001|Overall Study|Adverse Event|0
6126406|NCT00934440|9751717|FG000|Overall Study|Lost to Follow-up|1
6126407|NCT00934544|9751724|FG000|Primary Endpoint Analysis (Interim)|Adverse Event|12
6126408|NCT00934544|9751725|FG001|Primary Endpoint Analysis (Interim)|Adverse Event|4
6126409|NCT00934544|9751726|FG002|Primary Endpoint Analysis (Interim)|Adverse Event|0
6126410|NCT00934544|9751724|FG000|Primary Endpoint Analysis (Interim)|Withdrawal by Subject|2
6126411|NCT00934544|9751725|FG001|Primary Endpoint Analysis (Interim)|Withdrawal by Subject|9
6126412|NCT00934544|9751726|FG002|Primary Endpoint Analysis (Interim)|Withdrawal by Subject|0
6126413|NCT00934544|9751724|FG000|Primary Endpoint Analysis (Interim)|Protocol Violation|2
6126414|NCT00934544|9751725|FG001|Primary Endpoint Analysis (Interim)|Protocol Violation|0
6126415|NCT00934544|9751726|FG002|Primary Endpoint Analysis (Interim)|Protocol Violation|0
6126416|NCT00934544|9751724|FG000|Primary Endpoint Analysis (Interim)|Disease Progression|1
6126417|NCT00934544|9751725|FG001|Primary Endpoint Analysis (Interim)|Disease Progression|3
6126418|NCT00934544|9751726|FG002|Primary Endpoint Analysis (Interim)|Disease Progression|0
6126419|NCT00934544|9751724|FG000|Primary Endpoint Analysis (Interim)|Non-compliance with study Medication|2
6126420|NCT00934544|9751725|FG001|Primary Endpoint Analysis (Interim)|Non-compliance with study Medication|0
6126421|NCT00934544|9751726|FG002|Primary Endpoint Analysis (Interim)|Non-compliance with study Medication|0
6126422|NCT00934544|9751724|FG000|Primary Endpoint Analysis (Interim)|Non-compliance with study procedures|0
6126423|NCT00934544|9751725|FG001|Primary Endpoint Analysis (Interim)|Non-compliance with study procedures|1
6126424|NCT00934544|9751726|FG002|Primary Endpoint Analysis (Interim)|Non-compliance with study procedures|0
6126425|NCT00934544|9751724|FG000|Primary Endpoint Analysis (Interim)|Other reasons|7
6126426|NCT00934544|9751725|FG001|Primary Endpoint Analysis (Interim)|Other reasons|7
6126427|NCT00934544|9751726|FG002|Primary Endpoint Analysis (Interim)|Other reasons|0
6126428|NCT00934544|9751724|FG000|Primary Endpoint Analysis (Interim)|Entered extension phase|29
6126429|NCT00934544|9751725|FG001|Primary Endpoint Analysis (Interim)|Entered extension phase|18
6126430|NCT00934544|9751726|FG002|Primary Endpoint Analysis (Interim)|Entered extension phase|0
6126431|NCT00934544|9751724|FG000|Overall Disposition at 5 Year Follow-up|Including stem cell transplantation|16
6126432|NCT00934544|9751725|FG001|Overall Disposition at 5 Year Follow-up|Including stem cell transplantation|9
6126433|NCT00934544|9751726|FG002|Overall Disposition at 5 Year Follow-up|Including stem cell transplantation|6
6126434|NCT00934544|9751724|FG000|Overall Disposition at 5 Year Follow-up|Adverse Event|35
6126435|NCT00934544|9751725|FG001|Overall Disposition at 5 Year Follow-up|Adverse Event|5
6126436|NCT00934544|9751726|FG002|Overall Disposition at 5 Year Follow-up|Adverse Event|10
6126437|NCT00934544|9751724|FG000|Overall Disposition at 5 Year Follow-up|Withdrawal by Subject|10
6126438|NCT00934544|9751725|FG001|Overall Disposition at 5 Year Follow-up|Withdrawal by Subject|9
6126439|NCT00934544|9751726|FG002|Overall Disposition at 5 Year Follow-up|Withdrawal by Subject|0
6126440|NCT00934544|9751724|FG000|Overall Disposition at 5 Year Follow-up|Protocol Violation|2
6126441|NCT00934544|9751725|FG001|Overall Disposition at 5 Year Follow-up|Protocol Violation|0
6126442|NCT00934544|9751726|FG002|Overall Disposition at 5 Year Follow-up|Protocol Violation|5
6126443|NCT00934544|9751724|FG000|Overall Disposition at 5 Year Follow-up|Disease progression|32
6126444|NCT00934544|9751725|FG001|Overall Disposition at 5 Year Follow-up|Disease progression|4
6126445|NCT00934544|9751726|FG002|Overall Disposition at 5 Year Follow-up|Disease progression|7
6126446|NCT00934544|9751724|FG000|Overall Disposition at 5 Year Follow-up|Noncompliance with study medication|4
6126447|NCT00934544|9751725|FG001|Overall Disposition at 5 Year Follow-up|Noncompliance with study medication|0
6126448|NCT00934544|9751726|FG002|Overall Disposition at 5 Year Follow-up|Noncompliance with study medication|1
6126449|NCT00934544|9751724|FG000|Overall Disposition at 5 Year Follow-up|Noncompliance with study procedures|0
6126450|NCT00934544|9751725|FG001|Overall Disposition at 5 Year Follow-up|Noncompliance with study procedures|1
6126451|NCT00934544|9751726|FG002|Overall Disposition at 5 Year Follow-up|Noncompliance with study procedures|0
6126452|NCT00934544|9751724|FG000|Overall Disposition at 5 Year Follow-up|Lack of Efficacy|8
6126453|NCT00934544|9751725|FG001|Overall Disposition at 5 Year Follow-up|Lack of Efficacy|0
6126454|NCT00934544|9751726|FG002|Overall Disposition at 5 Year Follow-up|Lack of Efficacy|5
6126455|NCT00934622|9751756|FG000|Overall Study|Lost to Follow-up|7
6126456|NCT00934622|9751756|FG000|Overall Study|2nd Intraoperative exclusion criteria|1
6126457|NCT00934648|9751797|FG000|Overall Study|Failure to return|8
6126458|NCT00934648|9751797|FG000|Overall Study|Withdrawal by Subject|1
6126459|NCT00934661|9751803|FG000|Overall Study|Failure of Combined/Spinal Epidural|1
6126460|NCT00934661|9751804|FG001|Overall Study|Failure of Combined/Spinal Epidural|0
6126461|NCT00934843|9751812|FG000|Overall Study|Protocol Violation|0
6126462|NCT00934843|9751813|FG001|Overall Study|Protocol Violation|1
6126463|NCT00934856|9751825|FG000|Feasibility Part|Progressive disease|4
6126464|NCT00934856|9751826|FG001|Feasibility Part|Progressive disease|4
6126465|NCT00934856|9751827|FG002|Feasibility Part|Progressive disease|2
6126466|NCT00934856|9751828|FG003|Feasibility Part|Progressive disease|3
6126467|NCT00934856|9751829|FG004|Feasibility Part|Progressive disease|0
6126468|NCT00934856|9751830|FG005|Feasibility Part|Progressive disease|0
6126469|NCT00934856|9751825|FG000|Feasibility Part|Physician Decision|0
6126470|NCT00934856|9751826|FG001|Feasibility Part|Physician Decision|0
6126471|NCT00934856|9751827|FG002|Feasibility Part|Physician Decision|1
6126472|NCT00934856|9751828|FG003|Feasibility Part|Physician Decision|0
6126473|NCT00934856|9751829|FG004|Feasibility Part|Physician Decision|0
6126474|NCT00934856|9751830|FG005|Feasibility Part|Physician Decision|0
6126475|NCT00934856|9751825|FG000|Feasibility Part|Adverse Event|1
6126476|NCT00934856|9751826|FG001|Feasibility Part|Adverse Event|1
6126477|NCT00934856|9751827|FG002|Feasibility Part|Adverse Event|0
6126478|NCT00934856|9751828|FG003|Feasibility Part|Adverse Event|1
6126479|NCT00934856|9751829|FG004|Feasibility Part|Adverse Event|0
6126480|NCT00934856|9751830|FG005|Feasibility Part|Adverse Event|2
6126481|NCT00934856|9751825|FG000|Feasibility Part|Withdrawal by Subject|0
6126482|NCT00934856|9751826|FG001|Feasibility Part|Withdrawal by Subject|0
6126483|NCT00934856|9751827|FG002|Feasibility Part|Withdrawal by Subject|0
6126484|NCT00934856|9751828|FG003|Feasibility Part|Withdrawal by Subject|1
6218478|NCT01646125|9887199|FG001|Overall Study|Untreated|5
6218479|NCT01646125|9887198|FG000|Overall Study|Adverse Event|2
6218480|NCT01646125|9887199|FG001|Overall Study|Adverse Event|1
6218481|NCT01646125|9887198|FG000|Overall Study|Death|1
6218482|NCT01646125|9887199|FG001|Overall Study|Death|1
6218483|NCT01646125|9887198|FG000|Overall Study|Physician Decision|1
6288560|NCT02369510|10002615|FG001|Overall Study|Spilled Medication|2
6126485|NCT00934856|9751829|FG004|Feasibility Part|Withdrawal by Subject|0
6126486|NCT00934856|9751830|FG005|Feasibility Part|Withdrawal by Subject|1
6126487|NCT00934856|9751825|FG000|Extension Part|Adverse Event|0
6126488|NCT00934856|9751826|FG001|Extension Part|Adverse Event|0
6126489|NCT00934856|9751827|FG002|Extension Part|Adverse Event|0
6126490|NCT00934856|9751828|FG003|Extension Part|Adverse Event|1
6126491|NCT00934856|9751829|FG004|Extension Part|Adverse Event|4
6126492|NCT00934856|9751830|FG005|Extension Part|Adverse Event|4
6126493|NCT00934856|9751825|FG000|Extension Part|Progressive disease|0
6126494|NCT00934856|9751826|FG001|Extension Part|Progressive disease|0
6126495|NCT00934856|9751827|FG002|Extension Part|Progressive disease|0
6126496|NCT00934856|9751828|FG003|Extension Part|Progressive disease|1
6126497|NCT00934856|9751829|FG004|Extension Part|Progressive disease|0
6126498|NCT00934856|9751830|FG005|Extension Part|Progressive disease|0
6126499|NCT00934856|9751825|FG000|Extension Part|Non-compliance with drug|0
6126500|NCT00934856|9751826|FG001|Extension Part|Non-compliance with drug|0
6126501|NCT00934856|9751827|FG002|Extension Part|Non-compliance with drug|0
6126502|NCT00934856|9751828|FG003|Extension Part|Non-compliance with drug|0
6126503|NCT00934856|9751829|FG004|Extension Part|Non-compliance with drug|0
6126504|NCT00934856|9751830|FG005|Extension Part|Non-compliance with drug|1
6126505|NCT00934947|9751876|FG000|Overall Study|Adverse Event|0
6126506|NCT00934947|9751877|FG001|Overall Study|Adverse Event|2
6126507|NCT00935012|9751885|FG000|Overall Study|Death|19
6126508|NCT00935012|9751885|FG000|Overall Study|Withdrawal by Subject|3
6126509|NCT00935012|9751885|FG000|Overall Study|Other|5
6126510|NCT00935012|9751885|FG000|Overall Study|Adverse Event|2
6126511|NCT00935220|9751898|FG000|Overall Study|Adverse Event|1
6126512|NCT00935220|9751898|FG000|Overall Study|Other reason (not specified)|1
6126513|NCT00935259|9751902|FG000|Period 1|Administrative (scheduling conflict)|1
6126514|NCT00935259|9751903|FG001|Period 1|Administrative (scheduling conflict)|1
6126515|NCT00935272|9751913|FG000|Overall Study|Lost to Follow-up|10
6126516|NCT00935272|9751914|FG001|Overall Study|Lost to Follow-up|3
6126517|NCT00935272|9751913|FG000|Overall Study|Withdrawal by Subject|8
6126518|NCT00935272|9751914|FG001|Overall Study|Withdrawal by Subject|2
6126519|NCT00935272|9751913|FG000|Overall Study|Physician Decision|1
6218484|NCT01646125|9887199|FG001|Overall Study|Physician Decision|3
6218485|NCT01646125|9887198|FG000|Overall Study|Progressive disease|22
6218486|NCT01646125|9887199|FG001|Overall Study|Progressive disease|16
6218487|NCT01646125|9887198|FG000|Overall Study|Study terminated by sponsor|2
6218488|NCT01646125|9887199|FG001|Overall Study|Study terminated by sponsor|1
6218489|NCT01646125|9887198|FG000|Overall Study|Subject/Guardian decision|1
6218490|NCT01646125|9887199|FG001|Overall Study|Subject/Guardian decision|1
6218491|NCT01646138|9887211|FG000|Overall Study|Lost to Follow-up|0
6218492|NCT01646138|9887212|FG001|Overall Study|Lost to Follow-up|0
6218493|NCT01646138|9887213|FG002|Overall Study|Lost to Follow-up|0
6218494|NCT01646138|9887214|FG003|Overall Study|Lost to Follow-up|0
6218495|NCT01646138|9887215|FG004|Overall Study|Lost to Follow-up|2
6218496|NCT01646177|9887235|FG000|Blinded Induction Dosing (Week 0-12)|Adverse Event|2
6218497|NCT01646177|9887236|FG001|Blinded Induction Dosing (Week 0-12)|Adverse Event|4
6126520|NCT00935272|9751914|FG001|Overall Study|Physician Decision|0
6126521|NCT00935272|9751913|FG000|Overall Study|Protocol Violation|0
6126522|NCT00935272|9751914|FG001|Overall Study|Protocol Violation|1
6126523|NCT00935493|9751947|FG000|Overall Study|Lost to Follow-up|1
6126524|NCT00935493|9751948|FG001|Overall Study|Lost to Follow-up|1
6218498|NCT01646177|9887237|FG002|Blinded Induction Dosing (Week 0-12)|Adverse Event|9
6218499|NCT01646177|9887238|FG003|Blinded Induction Dosing (Week 0-12)|Adverse Event|8
6218500|NCT01646177|9887239|FG004|Blinded Induction Dosing (Week 0-12)|Adverse Event|0
6288561|NCT02369510|10002616|FG002|Overall Study|Spilled Medication|1
6288562|NCT02369510|10002614|FG000|Overall Study|Epidural Activation|1
6288563|NCT02369510|10002615|FG001|Overall Study|Epidural Activation|1
6288564|NCT02369510|10002616|FG002|Overall Study|Epidural Activation|5
6288565|NCT02369848|10002654|FG000|Overall Study|Death|1
6288566|NCT02369848|10002654|FG000|Overall Study|Withdrawal by Subject|2
6288567|NCT02369848|10002654|FG000|Overall Study|Lost to Follow-up|1
6288568|NCT02369874|10002661|FG000|Overall Study|Lost to Follow-up|2
6288569|NCT02369874|10002662|FG001|Overall Study|Lost to Follow-up|2
6288570|NCT02369874|10002663|FG002|Overall Study|Lost to Follow-up|2
6288571|NCT02369874|10002661|FG000|Overall Study|Withdrawal by Subject|7
6288572|NCT02369874|10002662|FG001|Overall Study|Withdrawal by Subject|9
6288573|NCT02369874|10002663|FG002|Overall Study|Withdrawal by Subject|27
6288574|NCT02369874|10002661|FG000|Overall Study|Miscellaneous|1
6288575|NCT02369874|10002662|FG001|Overall Study|Miscellaneous|1
6288576|NCT02369874|10002663|FG002|Overall Study|Miscellaneous|0
6288577|NCT02369874|10002661|FG000|Overall Study|On Treatment/Off Study|34
6288578|NCT02369874|10002662|FG001|Overall Study|On Treatment/Off Study|45
6288579|NCT02369874|10002663|FG002|Overall Study|On Treatment/Off Study|32
6288580|NCT02370043|10002689|FG000|Overall Study|Withdrawal by Subject|0
6288581|NCT02370043|10002690|FG001|Overall Study|Withdrawal by Subject|0
6288582|NCT02370043|10002691|FG002|Overall Study|Withdrawal by Subject|0
6288583|NCT02370043|10002692|FG003|Overall Study|Withdrawal by Subject|0
6288584|NCT02370043|10002693|FG004|Overall Study|Withdrawal by Subject|1
6288585|NCT02370043|10002694|FG005|Overall Study|Withdrawal by Subject|1
6288586|NCT02370095|10002733|FG000|Overall Study|Withdrawal by Subject|0
6288587|NCT02370095|10002734|FG001|Overall Study|Withdrawal by Subject|1
6288588|NCT02370121|10002742|FG000|Overall Study|Lost to Follow-up|1
6288589|NCT02370121|10002743|FG001|Overall Study|Lost to Follow-up|1
6288590|NCT02370160|10002749|FG000|Overall Study|Death|3
6288591|NCT02370160|10002750|FG001|Overall Study|Death|4
6288592|NCT02370160|10002751|FG002|Overall Study|Death|1
6288593|NCT02370238|10002766|FG000|Overall Study|Death|42
6288594|NCT02370238|10002767|FG001|Overall Study|Death|35
6288595|NCT02370238|10002766|FG000|Overall Study|Lost to Follow-up|1
6288596|NCT02370238|10002767|FG001|Overall Study|Lost to Follow-up|3
6288597|NCT02370238|10002766|FG000|Overall Study|Withdrawal by Subject|2
6288598|NCT02370238|10002767|FG001|Overall Study|Withdrawal by Subject|6
6288599|NCT02370238|10002766|FG000|Overall Study|Other|2
6288600|NCT02370238|10002767|FG001|Overall Study|Other|1
6288601|NCT02370251|10002777|FG000|Overall Study|Received less than 8 days of Omegaven|7
6288602|NCT02370251|10002777|FG000|Overall Study|Death|4
6288603|NCT02370368|10002783|FG000|Overall Study|Adverse Event|1
6288604|NCT02370368|10002784|FG001|Overall Study|Adverse Event|2
6288605|NCT02370368|10002783|FG000|Overall Study|Withdrawal by Subject|5
6288606|NCT02370368|10002784|FG001|Overall Study|Withdrawal by Subject|4
6288607|NCT02370394|10002792|FG000|Overall Study|Lost to Follow-up|2
6126525|NCT00935493|9751949|FG002|Overall Study|Lost to Follow-up|1
6126526|NCT00935493|9751947|FG000|Overall Study|Treatment Discontinued|0
6126527|NCT00935493|9751948|FG001|Overall Study|Treatment Discontinued|1
6126528|NCT00935493|9751949|FG002|Overall Study|Treatment Discontinued|0
6218501|NCT01646177|9887240|FG005|Blinded Induction Dosing (Week 0-12)|Adverse Event|0
6218502|NCT01646177|9887241|FG006|Blinded Induction Dosing (Week 0-12)|Adverse Event|0
6218503|NCT01646177|9887242|FG007|Blinded Induction Dosing (Week 0-12)|Adverse Event|0
6218504|NCT01646177|9887243|FG008|Blinded Induction Dosing (Week 0-12)|Adverse Event|0
6218505|NCT01646177|9887244|FG009|Blinded Induction Dosing (Week 0-12)|Adverse Event|0
6218506|NCT01646177|9887245|FG010|Blinded Induction Dosing (Week 0-12)|Adverse Event|0
6218507|NCT01646177|9887246|FG011|Blinded Induction Dosing (Week 0-12)|Adverse Event|0
6218508|NCT01646177|9887235|FG000|Blinded Induction Dosing (Week 0-12)|Protocol Violation|1
6218509|NCT01646177|9887236|FG001|Blinded Induction Dosing (Week 0-12)|Protocol Violation|3
6218510|NCT01646177|9887237|FG002|Blinded Induction Dosing (Week 0-12)|Protocol Violation|8
6218511|NCT01646177|9887238|FG003|Blinded Induction Dosing (Week 0-12)|Protocol Violation|7
6218512|NCT01646177|9887239|FG004|Blinded Induction Dosing (Week 0-12)|Protocol Violation|0
6218513|NCT01646177|9887240|FG005|Blinded Induction Dosing (Week 0-12)|Protocol Violation|0
6218514|NCT01646177|9887241|FG006|Blinded Induction Dosing (Week 0-12)|Protocol Violation|0
6218515|NCT01646177|9887242|FG007|Blinded Induction Dosing (Week 0-12)|Protocol Violation|0
6218516|NCT01646177|9887243|FG008|Blinded Induction Dosing (Week 0-12)|Protocol Violation|0
6218517|NCT01646177|9887244|FG009|Blinded Induction Dosing (Week 0-12)|Protocol Violation|0
6218518|NCT01646177|9887245|FG010|Blinded Induction Dosing (Week 0-12)|Protocol Violation|0
6218519|NCT01646177|9887246|FG011|Blinded Induction Dosing (Week 0-12)|Protocol Violation|0
6218520|NCT01646177|9887235|FG000|Blinded Induction Dosing (Week 0-12)|Withdrawal by Subject|3
6218521|NCT01646177|9887236|FG001|Blinded Induction Dosing (Week 0-12)|Withdrawal by Subject|2
6218522|NCT01646177|9887237|FG002|Blinded Induction Dosing (Week 0-12)|Withdrawal by Subject|4
6218523|NCT01646177|9887238|FG003|Blinded Induction Dosing (Week 0-12)|Withdrawal by Subject|4
6126529|NCT00935532|9751959|FG000|Overall Study|Adverse Event|11
6126530|NCT00935532|9751960|FG001|Overall Study|Adverse Event|6
6126531|NCT00935532|9751959|FG000|Overall Study|Death|1
6126532|NCT00935532|9751960|FG001|Overall Study|Death|0
6126533|NCT00935532|9751959|FG000|Overall Study|Lost to Follow-up|1
6126534|NCT00935532|9751960|FG001|Overall Study|Lost to Follow-up|0
6126535|NCT00935532|9751959|FG000|Overall Study|Physician Decision|1
6126536|NCT00935532|9751960|FG001|Overall Study|Physician Decision|2
6126537|NCT00935532|9751959|FG000|Overall Study|Protocol Violation|2
6126538|NCT00935532|9751960|FG001|Overall Study|Protocol Violation|1
6126539|NCT00935532|9751959|FG000|Overall Study|Subject Decision|2
6126540|NCT00935532|9751960|FG001|Overall Study|Subject Decision|1
6126541|NCT00935532|9751959|FG000|Overall Study|Sponsor Decision|0
6126542|NCT00935532|9751960|FG001|Overall Study|Sponsor Decision|1
6126543|NCT00935532|9751959|FG000|Overall Study|Loss Glucose Control|4
6126544|NCT00935532|9751960|FG001|Overall Study|Loss Glucose Control|0
6126545|NCT00935584|9751968|FG000|Overall Study|Withdrawal by Subject|9
6126546|NCT00935584|9751969|FG001|Overall Study|Withdrawal by Subject|0
6126547|NCT00935584|9751968|FG000|Overall Study|Death|3
6126548|NCT00935584|9751969|FG001|Overall Study|Death|0
6126549|NCT00935584|9751968|FG000|Overall Study|Lost to Follow-up|8
6126550|NCT00935584|9751969|FG001|Overall Study|Lost to Follow-up|0
6126551|NCT00935584|9751968|FG000|Overall Study|No show|9
6126552|NCT00935584|9751969|FG001|Overall Study|No show|0
6126553|NCT00935584|9751968|FG000|Overall Study|Relocated|3
6126554|NCT00935584|9751969|FG001|Overall Study|Relocated|0
6126555|NCT00935584|9751968|FG000|Overall Study|Patient changed provider|3
6126556|NCT00935584|9751969|FG001|Overall Study|Patient changed provider|0
6126557|NCT00935584|9751968|FG000|Overall Study|Provider dropped out of study|14
6126558|NCT00935584|9751969|FG001|Overall Study|Provider dropped out of study|4
6126559|NCT00935701|9751973|FG000|Overall Study|Failure to Transition to Acupuncture|1
6126560|NCT00935818|9752004|FG000|Overall Study|Withdrawal by Subject|45
6126561|NCT00935818|9752005|FG001|Overall Study|Withdrawal by Subject|50
6126562|NCT00935818|9752004|FG000|Overall Study|Lost to Follow-up|40
6126563|NCT00935818|9752005|FG001|Overall Study|Lost to Follow-up|42
6126564|NCT00935818|9752004|FG000|Overall Study|Adverse Event|6
6126565|NCT00935818|9752005|FG001|Overall Study|Adverse Event|7
6126566|NCT00935818|9752004|FG000|Overall Study|Physician Decision|0
6126567|NCT00935818|9752005|FG001|Overall Study|Physician Decision|1
6126568|NCT00935883|9752022|FG000|Treatment Period|Physician Decision|1
6126569|NCT00935883|9752023|FG001|Treatment Period|Physician Decision|0
6126570|NCT00935883|9752022|FG000|Treatment Period|Withdrawal by Subject|0
6126571|NCT00935883|9752023|FG001|Treatment Period|Withdrawal by Subject|2
6126572|NCT00936065|9752032|FG000|Overall Study|Adverse Event|1
6126573|NCT00936065|9752033|FG001|Overall Study|Adverse Event|0
6126574|NCT00936065|9752034|FG002|Overall Study|Adverse Event|1
6126575|NCT00936065|9752032|FG000|Overall Study|Lack of Efficacy|1
6126576|NCT00936065|9752033|FG001|Overall Study|Lack of Efficacy|0
6126577|NCT00936065|9752034|FG002|Overall Study|Lack of Efficacy|1
6126578|NCT00936065|9752032|FG000|Overall Study|Lost to Follow-up|1
6126579|NCT00936065|9752033|FG001|Overall Study|Lost to Follow-up|0
6126580|NCT00936065|9752034|FG002|Overall Study|Lost to Follow-up|0
6126581|NCT00936065|9752032|FG000|Overall Study|Protocol Violation|1
6126582|NCT00936065|9752033|FG001|Overall Study|Protocol Violation|2
6126583|NCT00936065|9752034|FG002|Overall Study|Protocol Violation|1
6126584|NCT00936065|9752032|FG000|Overall Study|Withdrawal by Subject|0
6126585|NCT00936065|9752033|FG001|Overall Study|Withdrawal by Subject|2
6126586|NCT00936065|9752034|FG002|Overall Study|Withdrawal by Subject|4
6126587|NCT00936117|9752042|FG000|Overall Study|Adverse Event|7
6126588|NCT00936117|9752042|FG000|Overall Study|Unable to continue oral medication|3
6126589|NCT00936208|9752049|FG000|Overall Study|Protocol Violation|37
6218524|NCT01646177|9887239|FG004|Blinded Induction Dosing (Week 0-12)|Withdrawal by Subject|0
6218525|NCT01646177|9887240|FG005|Blinded Induction Dosing (Week 0-12)|Withdrawal by Subject|0
6218526|NCT01646177|9887241|FG006|Blinded Induction Dosing (Week 0-12)|Withdrawal by Subject|0
6218527|NCT01646177|9887242|FG007|Blinded Induction Dosing (Week 0-12)|Withdrawal by Subject|0
6218528|NCT01646177|9887243|FG008|Blinded Induction Dosing (Week 0-12)|Withdrawal by Subject|0
6218529|NCT01646177|9887244|FG009|Blinded Induction Dosing (Week 0-12)|Withdrawal by Subject|0
6218530|NCT01646177|9887245|FG010|Blinded Induction Dosing (Week 0-12)|Withdrawal by Subject|0
6218531|NCT01646177|9887246|FG011|Blinded Induction Dosing (Week 0-12)|Withdrawal by Subject|0
6218532|NCT01646177|9887235|FG000|Blinded Induction Dosing (Week 0-12)|Physician Decision|1
6218533|NCT01646177|9887236|FG001|Blinded Induction Dosing (Week 0-12)|Physician Decision|2
6218534|NCT01646177|9887237|FG002|Blinded Induction Dosing (Week 0-12)|Physician Decision|1
6218535|NCT01646177|9887238|FG003|Blinded Induction Dosing (Week 0-12)|Physician Decision|2
6218536|NCT01646177|9887239|FG004|Blinded Induction Dosing (Week 0-12)|Physician Decision|0
6218537|NCT01646177|9887240|FG005|Blinded Induction Dosing (Week 0-12)|Physician Decision|0
6218538|NCT01646177|9887241|FG006|Blinded Induction Dosing (Week 0-12)|Physician Decision|0
6126590|NCT00936208|9752050|FG001|Overall Study|Protocol Violation|22
6126591|NCT00936221|9752058|FG000|Overall Study|Withdrawal by Subject|1
6126592|NCT00936221|9752059|FG001|Overall Study|Withdrawal by Subject|1
6218539|NCT01646177|9887242|FG007|Blinded Induction Dosing (Week 0-12)|Physician Decision|0
6218540|NCT01646177|9887243|FG008|Blinded Induction Dosing (Week 0-12)|Physician Decision|0
6126593|NCT00936611|9752122|FG000|Overall Study|Progressive Disease|3
6126594|NCT00936611|9752122|FG000|Overall Study|New Systemic Therapy|22
6126595|NCT00936611|9752122|FG000|Overall Study|Lost to Follow-up|1
6126596|NCT00936611|9752122|FG000|Overall Study|Withdrawal by Subject|2
6126597|NCT00936611|9752122|FG000|Overall Study|Still on Follow-up|1
6126598|NCT00936611|9752122|FG000|Overall Study|Still on Active Therapy|7
6126599|NCT00936611|9752122|FG000|Overall Study|Ineligible for Study Drug|3
6126600|NCT00936702|9752135|FG000|Overall Study|Disease progression|34
6126601|NCT00936702|9752135|FG000|Overall Study|Adverse Event|8
6126602|NCT00936702|9752135|FG000|Overall Study|Withdrawal by Subject|2
6126603|NCT00936702|9752135|FG000|Overall Study|Alternative Treatment|1
6126604|NCT00936702|9752135|FG000|Overall Study|Other|1
6126605|NCT00936715|9752139|FG000|Overall Study|Investigators Discretion|1
6126606|NCT00936715|9752139|FG000|Overall Study|Protocol Violation|1
6126607|NCT00936715|9752139|FG000|Overall Study|Safety or Tolerability Reasons|4
6126608|NCT00936858|9752147|FG000|Overall Study|Death|3
6126609|NCT00936858|9752147|FG000|Overall Study|Progression|29
6126610|NCT00936858|9752147|FG000|Overall Study|Withdrawal by Subject|5
6126611|NCT00936858|9752147|FG000|Overall Study|Adverse Event|1
6126612|NCT00936858|9752147|FG000|Overall Study|Physician Decision|7
6126613|NCT00936858|9752147|FG000|Overall Study|Still on protocol treatment/ No documentation to say off protocol treatment|4
6218541|NCT01646177|9887244|FG009|Blinded Induction Dosing (Week 0-12)|Physician Decision|0
6218542|NCT01646177|9887245|FG010|Blinded Induction Dosing (Week 0-12)|Physician Decision|0
6218543|NCT01646177|9887246|FG011|Blinded Induction Dosing (Week 0-12)|Physician Decision|0
6218544|NCT01646177|9887235|FG000|Blinded Induction Dosing (Week 0-12)|Lack of Efficacy|0
6218545|NCT01646177|9887236|FG001|Blinded Induction Dosing (Week 0-12)|Lack of Efficacy|0
6218546|NCT01646177|9887237|FG002|Blinded Induction Dosing (Week 0-12)|Lack of Efficacy|2
6218547|NCT01646177|9887238|FG003|Blinded Induction Dosing (Week 0-12)|Lack of Efficacy|1
6126614|NCT00936858|9752147|FG000|Overall Study|Lost to Follow-up|1
6126615|NCT00936884|9752154|FG000|Double-blind|Withdrawal by Subject|6
6126616|NCT00936884|9752155|FG001|Double-blind|Withdrawal by Subject|4
6126617|NCT00936884|9752156|FG002|Double-blind|Withdrawal by Subject|0
6126618|NCT00936884|9752154|FG000|Double-blind|Death|2
6126619|NCT00936884|9752155|FG001|Double-blind|Death|1
6126620|NCT00936884|9752156|FG002|Double-blind|Death|0
6126621|NCT00936884|9752154|FG000|Double-blind|Lack of Efficacy|1
6126622|NCT00936884|9752155|FG001|Double-blind|Lack of Efficacy|1
6126623|NCT00936884|9752156|FG002|Double-blind|Lack of Efficacy|0
6126624|NCT00936884|9752154|FG000|Double-blind|Adverse Event|1
6126625|NCT00936884|9752155|FG001|Double-blind|Adverse Event|0
6126626|NCT00936884|9752156|FG002|Double-blind|Adverse Event|0
6126627|NCT00936884|9752154|FG000|Double-blind|Physician Decision|1
6126628|NCT00936884|9752155|FG001|Double-blind|Physician Decision|0
6126629|NCT00936884|9752156|FG002|Double-blind|Physician Decision|0
6126630|NCT00936884|9752154|FG000|Double-blind|No post baseline diary entry|1
6126631|NCT00936884|9752155|FG001|Double-blind|No post baseline diary entry|0
6126632|NCT00936884|9752156|FG002|Double-blind|No post baseline diary entry|0
6126633|NCT00936884|9752154|FG000|Double-blind|Did not receive study drug|0
6126634|NCT00936884|9752155|FG001|Double-blind|Did not receive study drug|1
6126635|NCT00936884|9752156|FG002|Double-blind|Did not receive study drug|0
6126636|NCT00936897|9752165|FG000|Overall Study|Withdrawal by Subject|9
6126637|NCT00936897|9752166|FG001|Overall Study|Withdrawal by Subject|19
6126638|NCT00936897|9752165|FG000|Overall Study|Adverse Event|4
6126639|NCT00936897|9752166|FG001|Overall Study|Adverse Event|13
6126640|NCT00936897|9752165|FG000|Overall Study|Other|3
6126641|NCT00936897|9752166|FG001|Overall Study|Other|9
6126642|NCT00936897|9752165|FG000|Overall Study|Lost to Follow-up|1
6126643|NCT00936897|9752166|FG001|Overall Study|Lost to Follow-up|10
6126644|NCT00936897|9752165|FG000|Overall Study|Administrative Decision|1
6126645|NCT00936897|9752166|FG001|Overall Study|Administrative Decision|2
6126646|NCT00936897|9752165|FG000|Overall Study|Protocol Violation|1
6126647|NCT00936897|9752166|FG001|Overall Study|Protocol Violation|1
6126648|NCT00936897|9752165|FG000|Overall Study|Ineligibility Determined|0
6126649|NCT00936897|9752166|FG001|Overall Study|Ineligibility Determined|3
6126650|NCT00936897|9752165|FG000|Overall Study|Noncompliance|0
6126651|NCT00936897|9752166|FG001|Overall Study|Noncompliance|2
6126652|NCT00936897|9752165|FG000|Overall Study|Death|0
6126653|NCT00936897|9752166|FG001|Overall Study|Death|1
6126654|NCT00936910|9752172|FG000|Overall Study|Lack of Efficacy|3
6126655|NCT00936975|9752177|FG000|Overall Study|Withdrawal by Subject|1
6126656|NCT00936975|9752177|FG000|Overall Study|Disease progression|3
6126657|NCT00936975|9752177|FG000|Overall Study|Post-Tx scan uninterpretable|2
6126658|NCT00937040|9752184|FG000|Overall Study|Adverse Event|5
6126659|NCT00937040|9752185|FG001|Overall Study|Adverse Event|8
6126660|NCT00937040|9752184|FG000|Overall Study|Lost to Follow-up|12
6126661|NCT00937040|9752185|FG001|Overall Study|Lost to Follow-up|12
6126662|NCT00937040|9752184|FG000|Overall Study|Protocol Violation|3
6126663|NCT00937040|9752185|FG001|Overall Study|Protocol Violation|0
6126664|NCT00937040|9752184|FG000|Overall Study|Withdrawal by Subject|13
6126665|NCT00937040|9752185|FG001|Overall Study|Withdrawal by Subject|7
6126666|NCT00937040|9752184|FG000|Overall Study|NONCOMPLIANCE WITH STUDY DRUG|3
6126667|NCT00937040|9752185|FG001|Overall Study|NONCOMPLIANCE WITH STUDY DRUG|2
6126668|NCT00937040|9752184|FG000|Overall Study|POST ENROLL EXCLUSIONARY LAB(S)/ECG FIND|5
6126669|NCT00937040|9752185|FG001|Overall Study|POST ENROLL EXCLUSIONARY LAB(S)/ECG FIND|8
6126670|NCT00937157|9752216|FG000|Overall Study|Pregnancy|1
6126671|NCT00937157|9752216|FG000|Overall Study|Lost to Follow-up|3
6126672|NCT00937326|9752234|FG000|Overall Study|Adverse Event|0
6126673|NCT00937326|9752235|FG001|Overall Study|Adverse Event|3
6126674|NCT00937326|9752236|FG002|Overall Study|Adverse Event|1
6126675|NCT00937326|9752237|FG003|Overall Study|Adverse Event|1
6126676|NCT00937326|9752238|FG004|Overall Study|Adverse Event|2
6126677|NCT00937326|9752234|FG000|Overall Study|Death|0
6126678|NCT00937326|9752235|FG001|Overall Study|Death|0
6126679|NCT00937326|9752236|FG002|Overall Study|Death|1
6126680|NCT00937326|9752237|FG003|Overall Study|Death|0
6126681|NCT00937326|9752238|FG004|Overall Study|Death|0
6126682|NCT00937326|9752234|FG000|Overall Study|Withdrawal by Subject|3
6126683|NCT00937326|9752235|FG001|Overall Study|Withdrawal by Subject|4
6126684|NCT00937326|9752236|FG002|Overall Study|Withdrawal by Subject|1
6126685|NCT00937326|9752237|FG003|Overall Study|Withdrawal by Subject|4
6126686|NCT00937326|9752238|FG004|Overall Study|Withdrawal by Subject|3
6126687|NCT00937326|9752234|FG000|Overall Study|Chest X-ray showed a suspicious shadow|0
6126688|NCT00937326|9752235|FG001|Overall Study|Chest X-ray showed a suspicious shadow|0
6126689|NCT00937326|9752236|FG002|Overall Study|Chest X-ray showed a suspicious shadow|1
6126690|NCT00937326|9752237|FG003|Overall Study|Chest X-ray showed a suspicious shadow|0
6126691|NCT00937326|9752238|FG004|Overall Study|Chest X-ray showed a suspicious shadow|0
6126692|NCT00937391|9752266|FG000|Stage 2|Withdrawal by Subject|1
6126693|NCT00937404|9752283|FG000|Overall Study|Protocol Violation|1
6126694|NCT00937404|9752283|FG000|Overall Study|Withdrawal by Subject|1
6126695|NCT00937495|9752287|FG000|Overall Study|Protocol Violation|2
6126696|NCT00937521|9752299|FG000|Overall Study - Prior to Booster Dose|Adverse Event|0
6126697|NCT00937521|9752300|FG001|Overall Study - Prior to Booster Dose|Adverse Event|0
6126698|NCT00937521|9752301|FG002|Overall Study - Prior to Booster Dose|Adverse Event|2
6126699|NCT00937521|9752302|FG003|Overall Study - Prior to Booster Dose|Adverse Event|0
6126700|NCT00937521|9752303|FG004|Overall Study - Prior to Booster Dose|Adverse Event|0
6126701|NCT00937521|9752304|FG005|Overall Study - Prior to Booster Dose|Adverse Event|0
6126702|NCT00937521|9752305|FG006|Overall Study - Prior to Booster Dose|Adverse Event|1
6126703|NCT00937521|9752306|FG007|Overall Study - Prior to Booster Dose|Adverse Event|0
6126704|NCT00937521|9752299|FG000|Overall Study - Prior to Booster Dose|Withdrawal by Subject|2
6126705|NCT00937521|9752300|FG001|Overall Study - Prior to Booster Dose|Withdrawal by Subject|1
6126706|NCT00937521|9752301|FG002|Overall Study - Prior to Booster Dose|Withdrawal by Subject|3
6126707|NCT00937521|9752302|FG003|Overall Study - Prior to Booster Dose|Withdrawal by Subject|0
6126708|NCT00937521|9752303|FG004|Overall Study - Prior to Booster Dose|Withdrawal by Subject|1
6126709|NCT00937521|9752304|FG005|Overall Study - Prior to Booster Dose|Withdrawal by Subject|0
6126710|NCT00937521|9752305|FG006|Overall Study - Prior to Booster Dose|Withdrawal by Subject|2
6218548|NCT01646177|9887239|FG004|Blinded Induction Dosing (Week 0-12)|Lack of Efficacy|0
6218549|NCT01646177|9887240|FG005|Blinded Induction Dosing (Week 0-12)|Lack of Efficacy|0
6218550|NCT01646177|9887241|FG006|Blinded Induction Dosing (Week 0-12)|Lack of Efficacy|0
6218551|NCT01646177|9887242|FG007|Blinded Induction Dosing (Week 0-12)|Lack of Efficacy|0
6218552|NCT01646177|9887243|FG008|Blinded Induction Dosing (Week 0-12)|Lack of Efficacy|0
6218553|NCT01646177|9887244|FG009|Blinded Induction Dosing (Week 0-12)|Lack of Efficacy|0
6218554|NCT01646177|9887245|FG010|Blinded Induction Dosing (Week 0-12)|Lack of Efficacy|0
6218555|NCT01646177|9887246|FG011|Blinded Induction Dosing (Week 0-12)|Lack of Efficacy|0
6218556|NCT01646177|9887235|FG000|Blinded Induction Dosing (Week 0-12)|Lost to Follow-up|3
6218557|NCT01646177|9887236|FG001|Blinded Induction Dosing (Week 0-12)|Lost to Follow-up|2
6218558|NCT01646177|9887237|FG002|Blinded Induction Dosing (Week 0-12)|Lost to Follow-up|2
6218559|NCT01646177|9887238|FG003|Blinded Induction Dosing (Week 0-12)|Lost to Follow-up|0
6218560|NCT01646177|9887239|FG004|Blinded Induction Dosing (Week 0-12)|Lost to Follow-up|0
6218561|NCT01646177|9887240|FG005|Blinded Induction Dosing (Week 0-12)|Lost to Follow-up|0
6218562|NCT01646177|9887241|FG006|Blinded Induction Dosing (Week 0-12)|Lost to Follow-up|0
6218563|NCT01646177|9887242|FG007|Blinded Induction Dosing (Week 0-12)|Lost to Follow-up|0
6218564|NCT01646177|9887243|FG008|Blinded Induction Dosing (Week 0-12)|Lost to Follow-up|0
6218565|NCT01646177|9887244|FG009|Blinded Induction Dosing (Week 0-12)|Lost to Follow-up|0
6218566|NCT01646177|9887245|FG010|Blinded Induction Dosing (Week 0-12)|Lost to Follow-up|0
6218567|NCT01646177|9887246|FG011|Blinded Induction Dosing (Week 0-12)|Lost to Follow-up|0
6218568|NCT01646177|9887235|FG000|Long-Term Extension Period (Week 12-264)|Adverse Event|0
6218569|NCT01646177|9887236|FG001|Long-Term Extension Period (Week 12-264)|Adverse Event|0
6218570|NCT01646177|9887237|FG002|Long-Term Extension Period (Week 12-264)|Adverse Event|0
6218571|NCT01646177|9887238|FG003|Long-Term Extension Period (Week 12-264)|Adverse Event|0
6218572|NCT01646177|9887239|FG004|Long-Term Extension Period (Week 12-264)|Adverse Event|16
6218573|NCT01646177|9887240|FG005|Long-Term Extension Period (Week 12-264)|Adverse Event|34
6126711|NCT00937521|9752306|FG007|Overall Study - Prior to Booster Dose|Withdrawal by Subject|1
6126712|NCT00937521|9752299|FG000|Overall Study - Prior to Booster Dose|Lost to Follow-up|0
6126713|NCT00937521|9752300|FG001|Overall Study - Prior to Booster Dose|Lost to Follow-up|0
6126714|NCT00937521|9752301|FG002|Overall Study - Prior to Booster Dose|Lost to Follow-up|1
6126715|NCT00937521|9752302|FG003|Overall Study - Prior to Booster Dose|Lost to Follow-up|1
6126716|NCT00937521|9752303|FG004|Overall Study - Prior to Booster Dose|Lost to Follow-up|0
6126717|NCT00937521|9752304|FG005|Overall Study - Prior to Booster Dose|Lost to Follow-up|0
6126718|NCT00937521|9752305|FG006|Overall Study - Prior to Booster Dose|Lost to Follow-up|0
6126719|NCT00937521|9752306|FG007|Overall Study - Prior to Booster Dose|Lost to Follow-up|0
6126720|NCT00937521|9752299|FG000|Overall Study - Prior to Booster Dose|Inappropriate enrollment|0
6126721|NCT00937521|9752300|FG001|Overall Study - Prior to Booster Dose|Inappropriate enrollment|4
6126722|NCT00937521|9752301|FG002|Overall Study - Prior to Booster Dose|Inappropriate enrollment|0
6126723|NCT00937521|9752302|FG003|Overall Study - Prior to Booster Dose|Inappropriate enrollment|0
6126724|NCT00937521|9752303|FG004|Overall Study - Prior to Booster Dose|Inappropriate enrollment|2
6126725|NCT00937521|9752304|FG005|Overall Study - Prior to Booster Dose|Inappropriate enrollment|1
6126726|NCT00937521|9752305|FG006|Overall Study - Prior to Booster Dose|Inappropriate enrollment|1
6126727|NCT00937521|9752306|FG007|Overall Study - Prior to Booster Dose|Inappropriate enrollment|0
6126728|NCT00937521|9752299|FG000|Overall Study - Prior to Booster Dose|Protocol Deviation|1
6126729|NCT00937521|9752300|FG001|Overall Study - Prior to Booster Dose|Protocol Deviation|0
6126730|NCT00937521|9752301|FG002|Overall Study - Prior to Booster Dose|Protocol Deviation|0
6126731|NCT00937521|9752302|FG003|Overall Study - Prior to Booster Dose|Protocol Deviation|0
6126732|NCT00937521|9752303|FG004|Overall Study - Prior to Booster Dose|Protocol Deviation|0
6126733|NCT00937521|9752304|FG005|Overall Study - Prior to Booster Dose|Protocol Deviation|0
6126734|NCT00937521|9752305|FG006|Overall Study - Prior to Booster Dose|Protocol Deviation|1
6126735|NCT00937521|9752306|FG007|Overall Study - Prior to Booster Dose|Protocol Deviation|0
6126736|NCT00937521|9752299|FG000|Booster Phase|Adverse Event|0
6126737|NCT00937521|9752300|FG001|Booster Phase|Adverse Event|0
6126738|NCT00937521|9752301|FG002|Booster Phase|Adverse Event|0
6126739|NCT00937521|9752302|FG003|Booster Phase|Adverse Event|0
6126740|NCT00937521|9752303|FG004|Booster Phase|Adverse Event|0
6126741|NCT00937521|9752304|FG005|Booster Phase|Adverse Event|0
6126742|NCT00937521|9752305|FG006|Booster Phase|Adverse Event|1
6218574|NCT01646177|9887241|FG006|Long-Term Extension Period (Week 12-264)|Adverse Event|43
6218575|NCT01646177|9887242|FG007|Long-Term Extension Period (Week 12-264)|Adverse Event|30
6218576|NCT01646177|9887243|FG008|Long-Term Extension Period (Week 12-264)|Adverse Event|0
6218577|NCT01646177|9887244|FG009|Long-Term Extension Period (Week 12-264)|Adverse Event|0
6288608|NCT02370394|10002793|FG001|Overall Study|Lost to Follow-up|1
6126743|NCT00937521|9752306|FG007|Booster Phase|Adverse Event|0
6126744|NCT00937521|9752299|FG000|Booster Phase|Withdrawal by Subject|1
6126745|NCT00937521|9752300|FG001|Booster Phase|Withdrawal by Subject|0
6126746|NCT00937521|9752301|FG002|Booster Phase|Withdrawal by Subject|0
6126747|NCT00937521|9752302|FG003|Booster Phase|Withdrawal by Subject|1
6126748|NCT00937521|9752303|FG004|Booster Phase|Withdrawal by Subject|0
6126749|NCT00937521|9752304|FG005|Booster Phase|Withdrawal by Subject|0
6126750|NCT00937521|9752305|FG006|Booster Phase|Withdrawal by Subject|0
6126751|NCT00937521|9752306|FG007|Booster Phase|Withdrawal by Subject|2
6126752|NCT00937521|9752299|FG000|Booster Phase|Lost to Follow-up|2
6126753|NCT00937521|9752300|FG001|Booster Phase|Lost to Follow-up|2
6126754|NCT00937521|9752301|FG002|Booster Phase|Lost to Follow-up|4
6126755|NCT00937521|9752302|FG003|Booster Phase|Lost to Follow-up|2
6126756|NCT00937521|9752303|FG004|Booster Phase|Lost to Follow-up|4
6126757|NCT00937521|9752304|FG005|Booster Phase|Lost to Follow-up|4
6126758|NCT00937521|9752305|FG006|Booster Phase|Lost to Follow-up|3
6218578|NCT01646177|9887245|FG010|Long-Term Extension Period (Week 12-264)|Adverse Event|0
6218579|NCT01646177|9887246|FG011|Long-Term Extension Period (Week 12-264)|Adverse Event|0
6218580|NCT01646177|9887235|FG000|Long-Term Extension Period (Week 12-264)|Withdrawal by Subject|0
6218581|NCT01646177|9887236|FG001|Long-Term Extension Period (Week 12-264)|Withdrawal by Subject|0
6218582|NCT01646177|9887237|FG002|Long-Term Extension Period (Week 12-264)|Withdrawal by Subject|0
6218583|NCT01646177|9887238|FG003|Long-Term Extension Period (Week 12-264)|Withdrawal by Subject|0
6218584|NCT01646177|9887239|FG004|Long-Term Extension Period (Week 12-264)|Withdrawal by Subject|11
6218585|NCT01646177|9887240|FG005|Long-Term Extension Period (Week 12-264)|Withdrawal by Subject|30
6218586|NCT01646177|9887241|FG006|Long-Term Extension Period (Week 12-264)|Withdrawal by Subject|29
6218587|NCT01646177|9887242|FG007|Long-Term Extension Period (Week 12-264)|Withdrawal by Subject|27
6218588|NCT01646177|9887243|FG008|Long-Term Extension Period (Week 12-264)|Withdrawal by Subject|0
6218589|NCT01646177|9887244|FG009|Long-Term Extension Period (Week 12-264)|Withdrawal by Subject|0
6218590|NCT01646177|9887245|FG010|Long-Term Extension Period (Week 12-264)|Withdrawal by Subject|0
6218591|NCT01646177|9887246|FG011|Long-Term Extension Period (Week 12-264)|Withdrawal by Subject|0
6218592|NCT01646177|9887235|FG000|Long-Term Extension Period (Week 12-264)|Lost to Follow-up|0
6218593|NCT01646177|9887236|FG001|Long-Term Extension Period (Week 12-264)|Lost to Follow-up|0
6218594|NCT01646177|9887237|FG002|Long-Term Extension Period (Week 12-264)|Lost to Follow-up|0
6218595|NCT01646177|9887238|FG003|Long-Term Extension Period (Week 12-264)|Lost to Follow-up|0
6218596|NCT01646177|9887239|FG004|Long-Term Extension Period (Week 12-264)|Lost to Follow-up|6
6218597|NCT01646177|9887240|FG005|Long-Term Extension Period (Week 12-264)|Lost to Follow-up|17
6218598|NCT01646177|9887241|FG006|Long-Term Extension Period (Week 12-264)|Lost to Follow-up|23
6218599|NCT01646177|9887242|FG007|Long-Term Extension Period (Week 12-264)|Lost to Follow-up|18
6126759|NCT00937521|9752306|FG007|Booster Phase|Lost to Follow-up|0
6126760|NCT00937521|9752299|FG000|Booster Phase|Administrative Reason|0
6126761|NCT00937521|9752300|FG001|Booster Phase|Administrative Reason|0
6126762|NCT00937521|9752301|FG002|Booster Phase|Administrative Reason|1
6126763|NCT00937521|9752302|FG003|Booster Phase|Administrative Reason|0
6126764|NCT00937521|9752303|FG004|Booster Phase|Administrative Reason|1
6126765|NCT00937521|9752304|FG005|Booster Phase|Administrative Reason|1
6126766|NCT00937521|9752305|FG006|Booster Phase|Administrative Reason|0
6126767|NCT00937521|9752306|FG007|Booster Phase|Administrative Reason|0
6126768|NCT00937521|9752299|FG000|Booster Phase|Protocol Deviation|0
6126769|NCT00937521|9752300|FG001|Booster Phase|Protocol Deviation|0
6126770|NCT00937521|9752301|FG002|Booster Phase|Protocol Deviation|0
6126771|NCT00937521|9752302|FG003|Booster Phase|Protocol Deviation|0
6126772|NCT00937521|9752303|FG004|Booster Phase|Protocol Deviation|0
6126773|NCT00937521|9752304|FG005|Booster Phase|Protocol Deviation|0
6126774|NCT00937521|9752305|FG006|Booster Phase|Protocol Deviation|1
6126775|NCT00937521|9752306|FG007|Booster Phase|Protocol Deviation|0
6126776|NCT00937547|9752342|FG000|Overall Study|misdiagnosis|1
6126777|NCT00937547|9752343|FG001|Overall Study|misdiagnosis|6
6126778|NCT00937547|9752344|FG002|Overall Study|misdiagnosis|7
6126779|NCT00937560|9752352|FG000|Initial Treatment|Death|6
6126780|NCT00937560|9752352|FG000|Initial Treatment|Withdraw consent|3
6126781|NCT00937560|9752352|FG000|Initial Treatment|Adverse Event|1
6126782|NCT00937560|9752352|FG000|Initial Treatment|Lost to Follow-up|1
6126783|NCT00937560|9752352|FG000|Initial Treatment|No end of study page|10
6126784|NCT00937560|9752352|FG000|Maintenance Treatment|Death|12
6126785|NCT00937560|9752352|FG000|Maintenance Treatment|Withdraw consent|5
6126786|NCT00937560|9752352|FG000|Maintenance Treatment|According to protocol|1
6126787|NCT00937768|9752358|FG000|Overall Study|Refused Further Treatment|3
6218600|NCT01646177|9887243|FG008|Long-Term Extension Period (Week 12-264)|Lost to Follow-up|0
6218601|NCT01646177|9887244|FG009|Long-Term Extension Period (Week 12-264)|Lost to Follow-up|0
6288609|NCT02370394|10002792|FG000|Overall Study|Withdrawal by Subject|0
6126788|NCT00937768|9752359|FG001|Overall Study|Refused Further Treatment|2
6126789|NCT00937768|9752358|FG000|Overall Study|Disease Progression|1
6126790|NCT00937768|9752359|FG001|Overall Study|Disease Progression|1
6126791|NCT00937768|9752358|FG000|Overall Study|Alternate Treatment|0
6126792|NCT00937768|9752359|FG001|Overall Study|Alternate Treatment|1
6126793|NCT00937768|9752358|FG000|Overall Study|No Further Funding|4
6126794|NCT00937768|9752359|FG001|Overall Study|No Further Funding|4
6126795|NCT00937833|9752371|FG000|Overall Study|Protocol Violation|1
6126796|NCT00937833|9752372|FG001|Overall Study|Protocol Violation|2
6126797|NCT00937833|9752371|FG000|Overall Study|Procedure delayed; enrollment closed|0
6126798|NCT00937833|9752372|FG001|Overall Study|Procedure delayed; enrollment closed|1
6126799|NCT00937833|9752371|FG000|Overall Study|Lost to Follow-up|10
6126800|NCT00937833|9752372|FG001|Overall Study|Lost to Follow-up|8
6126801|NCT00937833|9752371|FG000|Overall Study|Withdrawal by Subject|4
6126802|NCT00937833|9752372|FG001|Overall Study|Withdrawal by Subject|6
6126803|NCT00937950|9752387|FG000|Overall Study|Withdrawal by Subject|23
6126804|NCT00937950|9752387|FG000|Overall Study|Migrated/moved from study area|27
6126805|NCT00937950|9752387|FG000|Overall Study|Lost to Follow-up|144
6218602|NCT01646177|9887245|FG010|Long-Term Extension Period (Week 12-264)|Lost to Follow-up|0
6218603|NCT01646177|9887246|FG011|Long-Term Extension Period (Week 12-264)|Lost to Follow-up|0
6218604|NCT01646177|9887235|FG000|Long-Term Extension Period (Week 12-264)|Lack of Efficacy|0
6218605|NCT01646177|9887236|FG001|Long-Term Extension Period (Week 12-264)|Lack of Efficacy|0
6218606|NCT01646177|9887237|FG002|Long-Term Extension Period (Week 12-264)|Lack of Efficacy|0
6218607|NCT01646177|9887238|FG003|Long-Term Extension Period (Week 12-264)|Lack of Efficacy|0
6218608|NCT01646177|9887239|FG004|Long-Term Extension Period (Week 12-264)|Lack of Efficacy|6
6218609|NCT01646177|9887240|FG005|Long-Term Extension Period (Week 12-264)|Lack of Efficacy|14
6218610|NCT01646177|9887241|FG006|Long-Term Extension Period (Week 12-264)|Lack of Efficacy|10
6218611|NCT01646177|9887242|FG007|Long-Term Extension Period (Week 12-264)|Lack of Efficacy|11
6218612|NCT01646177|9887243|FG008|Long-Term Extension Period (Week 12-264)|Lack of Efficacy|0
6218613|NCT01646177|9887244|FG009|Long-Term Extension Period (Week 12-264)|Lack of Efficacy|0
6218614|NCT01646177|9887245|FG010|Long-Term Extension Period (Week 12-264)|Lack of Efficacy|0
6218615|NCT01646177|9887246|FG011|Long-Term Extension Period (Week 12-264)|Lack of Efficacy|0
6218616|NCT01646177|9887235|FG000|Long-Term Extension Period (Week 12-264)|Physician Decision|0
6218617|NCT01646177|9887236|FG001|Long-Term Extension Period (Week 12-264)|Physician Decision|0
6218618|NCT01646177|9887237|FG002|Long-Term Extension Period (Week 12-264)|Physician Decision|0
6218619|NCT01646177|9887238|FG003|Long-Term Extension Period (Week 12-264)|Physician Decision|0
6218620|NCT01646177|9887239|FG004|Long-Term Extension Period (Week 12-264)|Physician Decision|3
6218621|NCT01646177|9887240|FG005|Long-Term Extension Period (Week 12-264)|Physician Decision|5
6218622|NCT01646177|9887241|FG006|Long-Term Extension Period (Week 12-264)|Physician Decision|5
6218623|NCT01646177|9887242|FG007|Long-Term Extension Period (Week 12-264)|Physician Decision|5
6218624|NCT01646177|9887243|FG008|Long-Term Extension Period (Week 12-264)|Physician Decision|0
6218625|NCT01646177|9887244|FG009|Long-Term Extension Period (Week 12-264)|Physician Decision|0
6288610|NCT02370394|10002793|FG001|Overall Study|Withdrawal by Subject|1
6288611|NCT02370420|10002815|FG000|Overall Study|Physician Decision|3
6126806|NCT00937950|9752387|FG000|Overall Study|Missing confirmed|4
6126807|NCT00937950|9752387|FG000|Overall Study|Other|18
6126808|NCT00938015|9752391|FG000|Overall Study|Death|2
6126809|NCT00938015|9752391|FG000|Overall Study|Lost to Follow-up|32
6126810|NCT00938015|9752391|FG000|Overall Study|Adverse Event|32
6126811|NCT00938015|9752391|FG000|Overall Study|Non-responder|52
6126812|NCT00938015|9752391|FG000|Overall Study|Reason not related to Etanercept|29
6126813|NCT00938041|9752395|FG000|Overall Study|Lost to Follow-up|6
6126814|NCT00938041|9752395|FG000|Overall Study|Received Alternative Therapy|1
6126815|NCT00938041|9752395|FG000|Overall Study|Progressive Disease|5
6126816|NCT00938041|9752395|FG000|Overall Study|Death|12
6126817|NCT00938041|9752395|FG000|Overall Study|Adrenal Insufficiency|3
6126818|NCT00938327|9752416|FG000|Overall Study|Adverse Event|2
6126819|NCT00938327|9752416|FG000|Overall Study|Protocol Violation|1
6126820|NCT00938327|9752416|FG000|Overall Study|Withdrawal by Subject|4
6126821|NCT00938327|9752416|FG000|Overall Study|Lost to Follow-up|37
6126822|NCT00938327|9752416|FG000|Overall Study|2nd dose received outside of the study|7
6126823|NCT00938327|9752416|FG000|Overall Study|Vaccine not received as out of stock|9
6126824|NCT00938340|9752420|FG000|Overall Study|Withdrawal by Subject|3
6126825|NCT00938340|9752420|FG000|Overall Study|Protocol Violation|1
6126826|NCT00938340|9752420|FG000|Overall Study|Adverse Event|1
6126827|NCT00938366|9752468|FG000|Overall Study|Withdrawal by Subject|1
6126828|NCT00938366|9752469|FG001|Overall Study|Withdrawal by Subject|0
6126829|NCT00938392|9752477|FG000|Overall Study|Adverse Event|0
6126830|NCT00938392|9752478|FG001|Overall Study|Adverse Event|1
6126831|NCT00938392|9752477|FG000|Overall Study|Withdrawal by Subject|0
6126832|NCT00938392|9752478|FG001|Overall Study|Withdrawal by Subject|1
6126833|NCT00938392|9752477|FG000|Overall Study|Lost to Follow-up|2
6126834|NCT00938392|9752478|FG001|Overall Study|Lost to Follow-up|2
6126835|NCT00938431|9752487|FG000|Overall Study|Adverse Event|5
6126836|NCT00938431|9752488|FG001|Overall Study|Adverse Event|8
6126837|NCT00938431|9752489|FG002|Overall Study|Adverse Event|6
6126838|NCT00938431|9752487|FG000|Overall Study|Lack of Efficacy|0
6126839|NCT00938431|9752488|FG001|Overall Study|Lack of Efficacy|1
6126840|NCT00938431|9752489|FG002|Overall Study|Lack of Efficacy|0
6126841|NCT00938431|9752487|FG000|Overall Study|Did not up titrate to 12 mg kg/day|1
6126842|NCT00938431|9752488|FG001|Overall Study|Did not up titrate to 12 mg kg/day|0
6126843|NCT00938431|9752489|FG002|Overall Study|Did not up titrate to 12 mg kg/day|0
6126844|NCT00938431|9752487|FG000|Overall Study|Dosing compliance issue|0
6126845|NCT00938431|9752488|FG001|Overall Study|Dosing compliance issue|0
6126846|NCT00938431|9752489|FG002|Overall Study|Dosing compliance issue|1
6126847|NCT00938431|9752487|FG000|Overall Study|Reached maximum dose early|0
6218626|NCT01646177|9887245|FG010|Long-Term Extension Period (Week 12-264)|Physician Decision|0
6218627|NCT01646177|9887246|FG011|Long-Term Extension Period (Week 12-264)|Physician Decision|0
6218628|NCT01646177|9887235|FG000|Long-Term Extension Period (Week 12-264)|Protocol Violation|0
6218629|NCT01646177|9887236|FG001|Long-Term Extension Period (Week 12-264)|Protocol Violation|0
6218630|NCT01646177|9887237|FG002|Long-Term Extension Period (Week 12-264)|Protocol Violation|0
6218631|NCT01646177|9887238|FG003|Long-Term Extension Period (Week 12-264)|Protocol Violation|0
6218632|NCT01646177|9887239|FG004|Long-Term Extension Period (Week 12-264)|Protocol Violation|1
6218633|NCT01646177|9887240|FG005|Long-Term Extension Period (Week 12-264)|Protocol Violation|4
6218634|NCT01646177|9887241|FG006|Long-Term Extension Period (Week 12-264)|Protocol Violation|0
6218635|NCT01646177|9887242|FG007|Long-Term Extension Period (Week 12-264)|Protocol Violation|5
6218636|NCT01646177|9887243|FG008|Long-Term Extension Period (Week 12-264)|Protocol Violation|0
6218637|NCT01646177|9887244|FG009|Long-Term Extension Period (Week 12-264)|Protocol Violation|0
6218638|NCT01646177|9887245|FG010|Long-Term Extension Period (Week 12-264)|Protocol Violation|0
6218639|NCT01646177|9887246|FG011|Long-Term Extension Period (Week 12-264)|Protocol Violation|0
6218640|NCT01646177|9887235|FG000|Long-Term Extension Period (Week 12-264)|Sponsor Decision|0
6218641|NCT01646177|9887236|FG001|Long-Term Extension Period (Week 12-264)|Sponsor Decision|0
6218642|NCT01646177|9887237|FG002|Long-Term Extension Period (Week 12-264)|Sponsor Decision|0
6218643|NCT01646177|9887238|FG003|Long-Term Extension Period (Week 12-264)|Sponsor Decision|0
6288612|NCT02370420|10002816|FG001|Overall Study|Physician Decision|3
6288613|NCT02370420|10002815|FG000|Overall Study|Lost to Follow-up|11
6288614|NCT02370420|10002816|FG001|Overall Study|Lost to Follow-up|9
6288615|NCT02370498|10002824|FG000|Overall Study|Adverse Event|10
6288616|NCT02370498|10002825|FG001|Overall Study|Adverse Event|8
6288617|NCT02370498|10002824|FG000|Overall Study|Death|222
6288618|NCT02370498|10002825|FG001|Overall Study|Death|242
6288619|NCT02370498|10002824|FG000|Overall Study|Lost to Follow-up|1
6288620|NCT02370498|10002825|FG001|Overall Study|Lost to Follow-up|0
6288621|NCT02370498|10002824|FG000|Overall Study|Protocol Violation|1
6288622|NCT02370498|10002825|FG001|Overall Study|Protocol Violation|2
6288623|NCT02370498|10002824|FG000|Overall Study|Withdrawal by Subject|6
6288624|NCT02370498|10002825|FG001|Overall Study|Withdrawal by Subject|11
6288625|NCT02370498|10002824|FG000|Overall Study|Ongoing In Trial|56
6288626|NCT02370498|10002825|FG001|Overall Study|Ongoing In Trial|33
6288627|NCT02370511|10002834|FG000|Overall Study|Death|10
6126848|NCT00938431|9752488|FG001|Overall Study|Reached maximum dose early|0
6126849|NCT00938431|9752489|FG002|Overall Study|Reached maximum dose early|1
6126850|NCT00938470|9752507|FG000|Overall Study|Disease Progression|3
6126851|NCT00938470|9752508|FG001|Overall Study|Disease Progression|0
6126852|NCT00938470|9752507|FG000|Overall Study|Alternate Treatment|1
6288628|NCT02370511|10002835|FG001|Overall Study|Death|7
6126853|NCT00938470|9752508|FG001|Overall Study|Alternate Treatment|0
6126854|NCT00938470|9752507|FG000|Overall Study|Death|3
6126855|NCT00938470|9752508|FG001|Overall Study|Death|2
6126856|NCT00938470|9752507|FG000|Overall Study|Other Reason|0
6126857|NCT00938470|9752508|FG001|Overall Study|Other Reason|1
6126858|NCT00938639|9752525|FG000|Overall Study|Moved away from study area|0
6126859|NCT00938639|9752526|FG001|Overall Study|Moved away from study area|1
6126860|NCT00938639|9752525|FG000|Overall Study|Lost to Follow-up|1
6126861|NCT00938639|9752526|FG001|Overall Study|Lost to Follow-up|2
6126862|NCT00938639|9752525|FG000|Overall Study|Family issues|1
6126863|NCT00938639|9752526|FG001|Overall Study|Family issues|1
6126864|NCT00938639|9752525|FG000|Overall Study|Participant noncompliance|1
6126865|NCT00938639|9752526|FG001|Overall Study|Participant noncompliance|0
6126866|NCT00938717|9752547|FG000|Overall Study|Adverse Event|10
6126867|NCT00938717|9752548|FG001|Overall Study|Adverse Event|41
6126868|NCT00938717|9752547|FG000|Overall Study|Protocol Violation|11
6126869|NCT00938717|9752548|FG001|Overall Study|Protocol Violation|8
6126870|NCT00938717|9752547|FG000|Overall Study|Withdrawal by Subject|26
6126871|NCT00938717|9752548|FG001|Overall Study|Withdrawal by Subject|24
6126872|NCT00938717|9752547|FG000|Overall Study|Lost to Follow-up|13
6126873|NCT00938717|9752548|FG001|Overall Study|Lost to Follow-up|18
6126874|NCT00938717|9752547|FG000|Overall Study|Lack of Efficacy|33
6126875|NCT00938717|9752548|FG001|Overall Study|Lack of Efficacy|15
6126876|NCT00938717|9752547|FG000|Overall Study|Other reason|5
6126877|NCT00938717|9752548|FG001|Overall Study|Other reason|2
6126878|NCT00938860|9752565|FG000|Overall Study|Adverse Event|2
6126879|NCT00938860|9752566|FG001|Overall Study|Adverse Event|1
6126880|NCT00938860|9752565|FG000|Overall Study|Abnormal laboratory values|2
6126881|NCT00938860|9752566|FG001|Overall Study|Abnormal laboratory values|2
6126882|NCT00938860|9752565|FG000|Overall Study|Withdrawal by Subject|11
6126883|NCT00938860|9752566|FG001|Overall Study|Withdrawal by Subject|8
6126884|NCT00938860|9752565|FG000|Overall Study|Lost to Follow-up|4
6126885|NCT00938860|9752566|FG001|Overall Study|Lost to Follow-up|4
6126886|NCT00938860|9752565|FG000|Overall Study|Administration problems|2
6126887|NCT00938860|9752566|FG001|Overall Study|Administration problems|0
6126888|NCT00938860|9752565|FG000|Overall Study|Death|1
6126889|NCT00938860|9752566|FG001|Overall Study|Death|1
6126890|NCT00938860|9752565|FG000|Overall Study|Protocol Violation|3
6126891|NCT00938860|9752566|FG001|Overall Study|Protocol Violation|1
6126892|NCT00938886|9752574|FG000|Overall Study|Death|0
6126893|NCT00938886|9752575|FG001|Overall Study|Death|1
6126894|NCT00938886|9752574|FG000|Overall Study|Withdrawal by Subject|4
6126895|NCT00938886|9752575|FG001|Overall Study|Withdrawal by Subject|7
6126896|NCT00938886|9752574|FG000|Overall Study|Lost to Follow-up|3
6126897|NCT00938886|9752575|FG001|Overall Study|Lost to Follow-up|2
6126898|NCT00938964|9752583|FG000|Overall Study|Death|3
6126899|NCT00938964|9752584|FG001|Overall Study|Death|3
6126900|NCT00938964|9752583|FG000|Overall Study|Lost to Follow-up|2
6126901|NCT00938964|9752584|FG001|Overall Study|Lost to Follow-up|3
6126902|NCT00938964|9752583|FG000|Overall Study|Withdrawal by Subject|22
6126903|NCT00938964|9752584|FG001|Overall Study|Withdrawal by Subject|18
6126904|NCT00938964|9752583|FG000|Overall Study|Found to Meet Exclusion Criteria|3
6126905|NCT00938964|9752584|FG001|Overall Study|Found to Meet Exclusion Criteria|4
6126906|NCT00939003|9752592|FG000|Double-blind Treatment Period|Adverse Event|1
6126907|NCT00939003|9752593|FG001|Double-blind Treatment Period|Adverse Event|1
6126908|NCT00939003|9752592|FG000|Double-blind Treatment Period|Lack of Efficacy|0
6126909|NCT00939003|9752593|FG001|Double-blind Treatment Period|Lack of Efficacy|1
6126910|NCT00939003|9752592|FG000|Double-blind Treatment Period|Pregnancy|0
6218644|NCT01646177|9887239|FG004|Long-Term Extension Period (Week 12-264)|Sponsor Decision|3
6218645|NCT01646177|9887240|FG005|Long-Term Extension Period (Week 12-264)|Sponsor Decision|2
6218646|NCT01646177|9887241|FG006|Long-Term Extension Period (Week 12-264)|Sponsor Decision|2
6218647|NCT01646177|9887242|FG007|Long-Term Extension Period (Week 12-264)|Sponsor Decision|2
6218648|NCT01646177|9887243|FG008|Long-Term Extension Period (Week 12-264)|Sponsor Decision|0
6218649|NCT01646177|9887244|FG009|Long-Term Extension Period (Week 12-264)|Sponsor Decision|0
6218650|NCT01646177|9887245|FG010|Long-Term Extension Period (Week 12-264)|Sponsor Decision|0
6218651|NCT01646177|9887246|FG011|Long-Term Extension Period (Week 12-264)|Sponsor Decision|0
6218652|NCT01646177|9887235|FG000|Long-Term Extension Period (Week 12-264)|Death|0
6218653|NCT01646177|9887236|FG001|Long-Term Extension Period (Week 12-264)|Death|0
6218654|NCT01646177|9887237|FG002|Long-Term Extension Period (Week 12-264)|Death|0
6218655|NCT01646177|9887238|FG003|Long-Term Extension Period (Week 12-264)|Death|0
6218656|NCT01646177|9887239|FG004|Long-Term Extension Period (Week 12-264)|Death|1
6218657|NCT01646177|9887240|FG005|Long-Term Extension Period (Week 12-264)|Death|3
6218658|NCT01646177|9887241|FG006|Long-Term Extension Period (Week 12-264)|Death|1
6218659|NCT01646177|9887242|FG007|Long-Term Extension Period (Week 12-264)|Death|3
6218660|NCT01646177|9887243|FG008|Long-Term Extension Period (Week 12-264)|Death|0
6218661|NCT01646177|9887244|FG009|Long-Term Extension Period (Week 12-264)|Death|0
6218662|NCT01646177|9887245|FG010|Long-Term Extension Period (Week 12-264)|Death|0
6218663|NCT01646177|9887246|FG011|Long-Term Extension Period (Week 12-264)|Death|0
6218664|NCT01646177|9887235|FG000|Long-Term Extension Period (Week 12-264)|Clinical Relapse|0
6218665|NCT01646177|9887236|FG001|Long-Term Extension Period (Week 12-264)|Clinical Relapse|0
6126911|NCT00939003|9752593|FG001|Double-blind Treatment Period|Pregnancy|1
6126912|NCT00939003|9752592|FG000|Double-blind Treatment Period|MRI Not Diagnostic|1
6126913|NCT00939003|9752593|FG001|Double-blind Treatment Period|MRI Not Diagnostic|1
6126914|NCT00939003|9752592|FG000|Open-label Treatment Period|Adverse Event|4
6126915|NCT00939003|9752593|FG001|Open-label Treatment Period|Adverse Event|8
6126916|NCT00939003|9752592|FG000|Open-label Treatment Period|Withdrawal by Subject|14
6126917|NCT00939003|9752593|FG001|Open-label Treatment Period|Withdrawal by Subject|7
6126918|NCT00939003|9752592|FG000|Open-label Treatment Period|Lack of Efficacy|6
6126919|NCT00939003|9752593|FG001|Open-label Treatment Period|Lack of Efficacy|9
6126920|NCT00939003|9752592|FG000|Open-label Treatment Period|Pregnancy|1
6218666|NCT01646177|9887237|FG002|Long-Term Extension Period (Week 12-264)|Clinical Relapse|0
6218667|NCT01646177|9887238|FG003|Long-Term Extension Period (Week 12-264)|Clinical Relapse|0
6218668|NCT01646177|9887239|FG004|Long-Term Extension Period (Week 12-264)|Clinical Relapse|1
6218669|NCT01646177|9887240|FG005|Long-Term Extension Period (Week 12-264)|Clinical Relapse|1
6218670|NCT01646177|9887241|FG006|Long-Term Extension Period (Week 12-264)|Clinical Relapse|1
6218671|NCT01646177|9887242|FG007|Long-Term Extension Period (Week 12-264)|Clinical Relapse|4
6218672|NCT01646177|9887243|FG008|Long-Term Extension Period (Week 12-264)|Clinical Relapse|0
6218673|NCT01646177|9887244|FG009|Long-Term Extension Period (Week 12-264)|Clinical Relapse|0
6288629|NCT02370511|10002836|FG002|Overall Study|Death|1
6288630|NCT02370511|10002834|FG000|Overall Study|Withdrawal by Subject|2
6126921|NCT00939003|9752593|FG001|Open-label Treatment Period|Pregnancy|1
6126922|NCT00939003|9752592|FG000|Open-label Treatment Period|Exclusion Criteria|1
6126923|NCT00939003|9752593|FG001|Open-label Treatment Period|Exclusion Criteria|0
6126924|NCT00939003|9752592|FG000|Open-label Treatment Period|Site Closure|3
6126925|NCT00939003|9752593|FG001|Open-label Treatment Period|Site Closure|4
6126926|NCT00939029|9752604|FG000|Overall Study|Withdrawal by Subject|3
6126927|NCT00939029|9752605|FG001|Overall Study|Withdrawal by Subject|7
6126928|NCT00939029|9752604|FG000|Overall Study|Lost to Follow-up|3
6126929|NCT00939029|9752605|FG001|Overall Study|Lost to Follow-up|4
6126930|NCT00939029|9752604|FG000|Overall Study|Adverse Event|0
6126931|NCT00939029|9752605|FG001|Overall Study|Adverse Event|1
6126932|NCT00939055|9752613|FG000|Overall Study|Discontinuation prior to procedure|4
6126933|NCT00939055|9752614|FG001|Overall Study|Discontinuation prior to procedure|0
6126934|NCT00939094|9752623|FG000|Overall Study|Adverse Event|9
6126935|NCT00939094|9752624|FG001|Overall Study|Adverse Event|0
6126936|NCT00939094|9752623|FG000|Overall Study|Withdrawal by Subject|1
6126937|NCT00939094|9752624|FG001|Overall Study|Withdrawal by Subject|6
6126938|NCT00939094|9752623|FG000|Overall Study|Lost to Follow-up|1
6126939|NCT00939094|9752624|FG001|Overall Study|Lost to Follow-up|1
6126940|NCT00939094|9752623|FG000|Overall Study|Eligibility criteria not fulfilled|2
6126941|NCT00939094|9752624|FG001|Overall Study|Eligibility criteria not fulfilled|0
6126942|NCT00939094|9752623|FG000|Overall Study|Severe non-compliance to protocol|0
6126943|NCT00939094|9752624|FG001|Overall Study|Severe non-compliance to protocol|1
6126944|NCT00939094|9752623|FG000|Overall Study|Study stopped by sponsor|0
6126945|NCT00939094|9752624|FG001|Overall Study|Study stopped by sponsor|2
6126946|NCT00939094|9752623|FG000|Overall Study|Abnormal ECG findings|1
6126947|NCT00939094|9752624|FG001|Overall Study|Abnormal ECG findings|0
6126948|NCT00939107|9752632|FG000|Overall Study|Lost to Follow-up|14
6126949|NCT00939107|9752633|FG001|Overall Study|Lost to Follow-up|12
6126950|NCT00939185|9752652|FG000|Overall Study|Adverse Event|3
6126951|NCT00939185|9752652|FG000|Overall Study|Lack of Efficacy|1
6126952|NCT00939185|9752652|FG000|Overall Study|Lost to Follow-up|6
6126953|NCT00939185|9752652|FG000|Overall Study|Other|3
6126954|NCT00939185|9752652|FG000|Overall Study|Withdrawal by Subject|2
6126955|NCT00939185|9752652|FG000|Overall Study|Randomized But Did Not Receive Treatment|10
6126956|NCT00939341|9752673|FG000|Overall Study|Adverse Event|15
6126957|NCT00939341|9752673|FG000|Overall Study|Pregnancy|1
6126958|NCT00939341|9752673|FG000|Overall Study|Lost to Follow-up|23
6126959|NCT00939341|9752673|FG000|Overall Study|Withdrawal by Subject|13
6126960|NCT00939341|9752673|FG000|Overall Study|Protocol Violation|6
6126961|NCT00939341|9752673|FG000|Overall Study|Incorrect enrolment|8
6126962|NCT00939393|9752686|FG000|Overall Study|Withdrawal by Subject|1
6126963|NCT00939393|9752687|FG001|Overall Study|Withdrawal by Subject|0
6126964|NCT00939393|9752686|FG000|Overall Study|Lost to Follow-up|3
6126965|NCT00939393|9752687|FG001|Overall Study|Lost to Follow-up|0
6126966|NCT00939484|9752702|FG000|Overall Study|Progression/Relapse|8
6126967|NCT00939484|9752703|FG001|Overall Study|Progression/Relapse|20
6126968|NCT00939484|9752704|FG002|Overall Study|Progression/Relapse|3
6126969|NCT00939510|9752714|FG000|Overall Study|Withdrawal by Subject|1
6126970|NCT00939523|9752718|FG000|Overall Study|Lack of Efficacy|1
6126971|NCT00939523|9752718|FG000|Overall Study|Physician Decision|2
6126972|NCT00939627|9752740|FG000|Overall Study|Disease Progression|16
6126973|NCT00939627|9752741|FG001|Overall Study|Disease Progression|12
6126974|NCT00939627|9752742|FG002|Overall Study|Disease Progression|0
6126975|NCT00939627|9752740|FG000|Overall Study|Adverse Event|6
6126976|NCT00939627|9752741|FG001|Overall Study|Adverse Event|7
6126977|NCT00939627|9752742|FG002|Overall Study|Adverse Event|0
5980917|NCT04167345|9569655|FG000|Overall Study|Other|1
6126978|NCT00939627|9752740|FG000|Overall Study|Death|0
6126979|NCT00939627|9752741|FG001|Overall Study|Death|2
6126980|NCT00939627|9752742|FG002|Overall Study|Death|0
6126981|NCT00939627|9752740|FG000|Overall Study|Withdrawal by Subject|2
6126982|NCT00939627|9752741|FG001|Overall Study|Withdrawal by Subject|4
6126983|NCT00939627|9752742|FG002|Overall Study|Withdrawal by Subject|0
6218674|NCT01646177|9887245|FG010|Long-Term Extension Period (Week 12-264)|Clinical Relapse|0
6288631|NCT02370511|10002835|FG001|Overall Study|Withdrawal by Subject|0
6288632|NCT02370511|10002836|FG002|Overall Study|Withdrawal by Subject|0
6288633|NCT02370511|10002834|FG000|Overall Study|Lost to Follow-up|0
6288634|NCT02370511|10002835|FG001|Overall Study|Lost to Follow-up|4
6288635|NCT02370511|10002836|FG002|Overall Study|Lost to Follow-up|0
6288636|NCT02370537|10002847|FG000|Part A (Open-label Recruitment)|Withdrawal by Subject|0
6288637|NCT02370537|10002848|FG001|Part A (Open-label Recruitment)|Withdrawal by Subject|1
6288638|NCT02370537|10002849|FG002|Part A (Open-label Recruitment)|Withdrawal by Subject|0
6288639|NCT02370537|10002847|FG000|Part A (Open-label Recruitment)|Adverse Event|0
6288640|NCT02370537|10002848|FG001|Part A (Open-label Recruitment)|Adverse Event|0
6288641|NCT02370537|10002849|FG002|Part A (Open-label Recruitment)|Adverse Event|1
6288642|NCT02370537|10002847|FG000|Part B|Not randomised to receive treatment|1
6288643|NCT02370537|10002848|FG001|Part B|Not randomised to receive treatment|2
6288644|NCT02370537|10002849|FG002|Part B|Not randomised to receive treatment|259
6288645|NCT02370537|10002847|FG000|Part B|Withdrawal by Subject|0
6288646|NCT02370537|10002848|FG001|Part B|Withdrawal by Subject|1
6288647|NCT02370537|10002849|FG002|Part B|Withdrawal by Subject|0
6288648|NCT02370602|10002872|FG000|Overall Study|Pretreatment Event/Adverse Event|1
6288649|NCT02370602|10002873|FG001|Overall Study|Pretreatment Event/Adverse Event|0
6288650|NCT02370602|10002874|FG002|Overall Study|Pretreatment Event/Adverse Event|0
6288651|NCT02370602|10002875|FG003|Overall Study|Pretreatment Event/Adverse Event|0
6288652|NCT02370602|10002876|FG004|Overall Study|Pretreatment Event/Adverse Event|0
6288653|NCT02370602|10002877|FG005|Overall Study|Pretreatment Event/Adverse Event|0
6288654|NCT02370615|10002896|FG000|Overall Study|Adverse Event|1
6288655|NCT02370615|10002897|FG001|Overall Study|Adverse Event|0
5980918|NCT04167345|9569656|FG001|Overall Study|Other|1
5980919|NCT04167345|9569657|FG002|Overall Study|Other|0
5980920|NCT04167345|9569658|FG003|Overall Study|Other|0
5980921|NCT04167345|9569659|FG004|Overall Study|Other|0
5980922|NCT04042077|9569677|FG000|Overall Study|Adverse Event|0
5980923|NCT04042077|9569678|FG001|Overall Study|Adverse Event|1
5980924|NCT04042077|9569677|FG000|Overall Study|Death|2
6126984|NCT00939627|9752740|FG000|Overall Study|Other complicating disease|1
6126985|NCT00939627|9752741|FG001|Overall Study|Other complicating disease|1
6126986|NCT00939627|9752742|FG002|Overall Study|Other complicating disease|0
6126987|NCT00939627|9752740|FG000|Overall Study|Not compliant|2
6126988|NCT00939627|9752741|FG001|Overall Study|Not compliant|0
6126989|NCT00939627|9752742|FG002|Overall Study|Not compliant|0
6126990|NCT00939627|9752740|FG000|Overall Study|No off-tx reason given|0
6126991|NCT00939627|9752741|FG001|Overall Study|No off-tx reason given|2
6126992|NCT00939627|9752742|FG002|Overall Study|No off-tx reason given|0
6126993|NCT00939640|9752748|FG000|Overall Study|Physician Decision|1
6126994|NCT00939692|9752764|FG000|Period 1 - First Intervention - 5 Days|Withdrawal by Subject|1
6218675|NCT01646177|9887246|FG011|Long-Term Extension Period (Week 12-264)|Clinical Relapse|0
6218676|NCT01646177|9887235|FG000|Long-Term Extension Period (Week 12-264)|Parent/Caregiver Decision|0
6218677|NCT01646177|9887236|FG001|Long-Term Extension Period (Week 12-264)|Parent/Caregiver Decision|0
6218678|NCT01646177|9887237|FG002|Long-Term Extension Period (Week 12-264)|Parent/Caregiver Decision|0
6218679|NCT01646177|9887238|FG003|Long-Term Extension Period (Week 12-264)|Parent/Caregiver Decision|0
6218680|NCT01646177|9887239|FG004|Long-Term Extension Period (Week 12-264)|Parent/Caregiver Decision|0
6218681|NCT01646177|9887240|FG005|Long-Term Extension Period (Week 12-264)|Parent/Caregiver Decision|0
6218682|NCT01646177|9887241|FG006|Long-Term Extension Period (Week 12-264)|Parent/Caregiver Decision|0
6218683|NCT01646177|9887242|FG007|Long-Term Extension Period (Week 12-264)|Parent/Caregiver Decision|1
6218684|NCT01646177|9887243|FG008|Long-Term Extension Period (Week 12-264)|Parent/Caregiver Decision|0
6218685|NCT01646177|9887244|FG009|Long-Term Extension Period (Week 12-264)|Parent/Caregiver Decision|0
6218686|NCT01646177|9887245|FG010|Long-Term Extension Period (Week 12-264)|Parent/Caregiver Decision|0
6218687|NCT01646177|9887246|FG011|Long-Term Extension Period (Week 12-264)|Parent/Caregiver Decision|0
6218688|NCT01646177|9887235|FG000|Long-Term Extension Period (Week 12-264)|Missing Disposition Form|0
6218689|NCT01646177|9887236|FG001|Long-Term Extension Period (Week 12-264)|Missing Disposition Form|0
6218690|NCT01646177|9887237|FG002|Long-Term Extension Period (Week 12-264)|Missing Disposition Form|0
6218691|NCT01646177|9887238|FG003|Long-Term Extension Period (Week 12-264)|Missing Disposition Form|0
6218692|NCT01646177|9887239|FG004|Long-Term Extension Period (Week 12-264)|Missing Disposition Form|0
6218693|NCT01646177|9887240|FG005|Long-Term Extension Period (Week 12-264)|Missing Disposition Form|3
6218694|NCT01646177|9887241|FG006|Long-Term Extension Period (Week 12-264)|Missing Disposition Form|2
6218695|NCT01646177|9887242|FG007|Long-Term Extension Period (Week 12-264)|Missing Disposition Form|1
6218696|NCT01646177|9887243|FG008|Long-Term Extension Period (Week 12-264)|Missing Disposition Form|0
6218697|NCT01646177|9887244|FG009|Long-Term Extension Period (Week 12-264)|Missing Disposition Form|0
6218698|NCT01646177|9887245|FG010|Long-Term Extension Period (Week 12-264)|Missing Disposition Form|0
6218699|NCT01646177|9887246|FG011|Long-Term Extension Period (Week 12-264)|Missing Disposition Form|0
6218700|NCT01646177|9887235|FG000|Follow-Up Period (Minimum of 12 Weeks)|Adverse Event|0
6218701|NCT01646177|9887236|FG001|Follow-Up Period (Minimum of 12 Weeks)|Adverse Event|0
6218702|NCT01646177|9887237|FG002|Follow-Up Period (Minimum of 12 Weeks)|Adverse Event|0
6126995|NCT00939692|9752765|FG001|Period 1 - First Intervention - 5 Days|Withdrawal by Subject|0
6126996|NCT00939692|9752764|FG000|Period 2 - Second Intervent - 5 Days|Protocol Violation|0
6126997|NCT00939692|9752765|FG001|Period 2 - Second Intervent - 5 Days|Protocol Violation|1
6126998|NCT00939770|9752795|FG000|Overall Study|Adverse Event|1
6126999|NCT00939770|9752796|FG001|Overall Study|Adverse Event|1
6127000|NCT00939770|9752797|FG002|Overall Study|Adverse Event|0
6127001|NCT00939770|9752798|FG003|Overall Study|Adverse Event|0
6127002|NCT00939770|9752799|FG004|Overall Study|Adverse Event|6
6127003|NCT00939770|9752800|FG005|Overall Study|Adverse Event|2
6127004|NCT00939770|9752801|FG006|Overall Study|Adverse Event|1
6127005|NCT00939770|9752802|FG007|Overall Study|Adverse Event|1
6127006|NCT00939770|9752795|FG000|Overall Study|Lack of Efficacy|4
6127007|NCT00939770|9752796|FG001|Overall Study|Lack of Efficacy|6
6127008|NCT00939770|9752797|FG002|Overall Study|Lack of Efficacy|13
6127009|NCT00939770|9752798|FG003|Overall Study|Lack of Efficacy|9
6127010|NCT00939770|9752799|FG004|Overall Study|Lack of Efficacy|16
6127011|NCT00939770|9752800|FG005|Overall Study|Lack of Efficacy|8
6127012|NCT00939770|9752801|FG006|Overall Study|Lack of Efficacy|11
6127013|NCT00939770|9752802|FG007|Overall Study|Lack of Efficacy|1
6127014|NCT00939770|9752795|FG000|Overall Study|Lost to Follow-up|0
6127015|NCT00939770|9752796|FG001|Overall Study|Lost to Follow-up|0
6127016|NCT00939770|9752797|FG002|Overall Study|Lost to Follow-up|0
6127017|NCT00939770|9752798|FG003|Overall Study|Lost to Follow-up|0
6127018|NCT00939770|9752799|FG004|Overall Study|Lost to Follow-up|1
6127019|NCT00939770|9752800|FG005|Overall Study|Lost to Follow-up|0
6127020|NCT00939770|9752801|FG006|Overall Study|Lost to Follow-up|0
6127021|NCT00939770|9752802|FG007|Overall Study|Lost to Follow-up|0
6127022|NCT00939770|9752795|FG000|Overall Study|Physician Decision|0
6127023|NCT00939770|9752796|FG001|Overall Study|Physician Decision|0
6127024|NCT00939770|9752797|FG002|Overall Study|Physician Decision|2
6127025|NCT00939770|9752798|FG003|Overall Study|Physician Decision|0
6127026|NCT00939770|9752799|FG004|Overall Study|Physician Decision|7
6127027|NCT00939770|9752800|FG005|Overall Study|Physician Decision|1
6127028|NCT00939770|9752801|FG006|Overall Study|Physician Decision|0
6127029|NCT00939770|9752802|FG007|Overall Study|Physician Decision|6
6127030|NCT00939770|9752795|FG000|Overall Study|Protocol Violation|0
6127031|NCT00939770|9752796|FG001|Overall Study|Protocol Violation|0
6127032|NCT00939770|9752797|FG002|Overall Study|Protocol Violation|0
6218703|NCT01646177|9887238|FG003|Follow-Up Period (Minimum of 12 Weeks)|Adverse Event|0
6218704|NCT01646177|9887239|FG004|Follow-Up Period (Minimum of 12 Weeks)|Adverse Event|0
6218705|NCT01646177|9887240|FG005|Follow-Up Period (Minimum of 12 Weeks)|Adverse Event|0
6218706|NCT01646177|9887241|FG006|Follow-Up Period (Minimum of 12 Weeks)|Adverse Event|0
6218707|NCT01646177|9887242|FG007|Follow-Up Period (Minimum of 12 Weeks)|Adverse Event|0
6218708|NCT01646177|9887243|FG008|Follow-Up Period (Minimum of 12 Weeks)|Adverse Event|13
6218709|NCT01646177|9887244|FG009|Follow-Up Period (Minimum of 12 Weeks)|Adverse Event|28
6218710|NCT01646177|9887245|FG010|Follow-Up Period (Minimum of 12 Weeks)|Adverse Event|34
6218711|NCT01646177|9887246|FG011|Follow-Up Period (Minimum of 12 Weeks)|Adverse Event|30
6218712|NCT01646177|9887235|FG000|Follow-Up Period (Minimum of 12 Weeks)|Withdrawal by Subject|0
6218713|NCT01646177|9887236|FG001|Follow-Up Period (Minimum of 12 Weeks)|Withdrawal by Subject|0
6218714|NCT01646177|9887237|FG002|Follow-Up Period (Minimum of 12 Weeks)|Withdrawal by Subject|0
6218715|NCT01646177|9887238|FG003|Follow-Up Period (Minimum of 12 Weeks)|Withdrawal by Subject|0
6218716|NCT01646177|9887239|FG004|Follow-Up Period (Minimum of 12 Weeks)|Withdrawal by Subject|0
6218717|NCT01646177|9887240|FG005|Follow-Up Period (Minimum of 12 Weeks)|Withdrawal by Subject|0
6218718|NCT01646177|9887241|FG006|Follow-Up Period (Minimum of 12 Weeks)|Withdrawal by Subject|0
6218719|NCT01646177|9887242|FG007|Follow-Up Period (Minimum of 12 Weeks)|Withdrawal by Subject|0
6218720|NCT01646177|9887243|FG008|Follow-Up Period (Minimum of 12 Weeks)|Withdrawal by Subject|7
6218721|NCT01646177|9887244|FG009|Follow-Up Period (Minimum of 12 Weeks)|Withdrawal by Subject|21
6218722|NCT01646177|9887245|FG010|Follow-Up Period (Minimum of 12 Weeks)|Withdrawal by Subject|19
6218723|NCT01646177|9887246|FG011|Follow-Up Period (Minimum of 12 Weeks)|Withdrawal by Subject|19
6218724|NCT01646177|9887235|FG000|Follow-Up Period (Minimum of 12 Weeks)|Lost to Follow-up|0
6218725|NCT01646177|9887236|FG001|Follow-Up Period (Minimum of 12 Weeks)|Lost to Follow-up|0
6218726|NCT01646177|9887237|FG002|Follow-Up Period (Minimum of 12 Weeks)|Lost to Follow-up|0
6218727|NCT01646177|9887238|FG003|Follow-Up Period (Minimum of 12 Weeks)|Lost to Follow-up|0
6218728|NCT01646177|9887239|FG004|Follow-Up Period (Minimum of 12 Weeks)|Lost to Follow-up|0
6218729|NCT01646177|9887240|FG005|Follow-Up Period (Minimum of 12 Weeks)|Lost to Follow-up|0
6218730|NCT01646177|9887241|FG006|Follow-Up Period (Minimum of 12 Weeks)|Lost to Follow-up|0
6218731|NCT01646177|9887242|FG007|Follow-Up Period (Minimum of 12 Weeks)|Lost to Follow-up|0
6218732|NCT01646177|9887243|FG008|Follow-Up Period (Minimum of 12 Weeks)|Lost to Follow-up|4
6127033|NCT00939770|9752798|FG003|Overall Study|Protocol Violation|0
6127034|NCT00939770|9752799|FG004|Overall Study|Protocol Violation|1
6127035|NCT00939770|9752800|FG005|Overall Study|Protocol Violation|0
6127036|NCT00939770|9752801|FG006|Overall Study|Protocol Violation|0
6127037|NCT00939770|9752802|FG007|Overall Study|Protocol Violation|0
6127038|NCT00939770|9752795|FG000|Overall Study|Withdrawal by Subject|0
6127039|NCT00939770|9752796|FG001|Overall Study|Withdrawal by Subject|1
6127040|NCT00939770|9752797|FG002|Overall Study|Withdrawal by Subject|5
6127041|NCT00939770|9752798|FG003|Overall Study|Withdrawal by Subject|2
6127042|NCT00939770|9752799|FG004|Overall Study|Withdrawal by Subject|6
6127043|NCT00939770|9752800|FG005|Overall Study|Withdrawal by Subject|0
6127044|NCT00939770|9752801|FG006|Overall Study|Withdrawal by Subject|2
6127045|NCT00939770|9752802|FG007|Overall Study|Withdrawal by Subject|2
6127046|NCT00939783|9752833|FG000|Overall Study|Death|6
6127047|NCT00939783|9752833|FG000|Overall Study|Adverse Event|39
6127048|NCT00939783|9752833|FG000|Overall Study|Study Terminated by Sponsor|498
6127049|NCT00939783|9752833|FG000|Overall Study|Withdrawal by Subject|78
6127050|NCT00939783|9752833|FG000|Overall Study|Other|16
6127051|NCT00939783|9752833|FG000|Overall Study|Lost to Follow-up|8
6127052|NCT00939783|9752833|FG000|Overall Study|Protocol Violation|3
6127053|NCT00939783|9752833|FG000|Overall Study|Enrolled but not treated|1
6127054|NCT00939809|9752841|FG000|Overall Study|Adverse Event|2
6127055|NCT00939809|9752841|FG000|Overall Study|Death|1
6127056|NCT00939822|9752847|FG000|Overall Study|Lost to Follow-up|1
6127057|NCT00939822|9752848|FG001|Overall Study|Lost to Follow-up|0
6127058|NCT00939822|9752847|FG000|Overall Study|withdrew from study due to busy schedule|1
6127059|NCT00939822|9752848|FG001|Overall Study|withdrew from study due to busy schedule|1
6127060|NCT00939822|9752847|FG000|Overall Study|Mental health issues|0
6127061|NCT00939822|9752848|FG001|Overall Study|Mental health issues|2
6127062|NCT00940017|9752880|FG000|Overall Study|did not meet entrance criteria|3
6127063|NCT00940017|9752880|FG000|Overall Study|Adverse Event|1
6127064|NCT00940108|9752888|FG000|Overall Study|Adverse Event|2
6127065|NCT00940108|9752889|FG001|Overall Study|Adverse Event|4
6127066|NCT00940108|9752890|FG002|Overall Study|Adverse Event|0
6127067|NCT00940108|9752891|FG003|Overall Study|Adverse Event|2
6127068|NCT00940108|9752888|FG000|Overall Study|Withdrew Consent|2
6127069|NCT00940108|9752889|FG001|Overall Study|Withdrew Consent|1
6127070|NCT00940108|9752890|FG002|Overall Study|Withdrew Consent|0
6127071|NCT00940108|9752891|FG003|Overall Study|Withdrew Consent|1
6127072|NCT00940108|9752888|FG000|Overall Study|Dose 2 contraindicated|1
6127073|NCT00940108|9752889|FG001|Overall Study|Dose 2 contraindicated|1
6127074|NCT00940108|9752890|FG002|Overall Study|Dose 2 contraindicated|0
6127075|NCT00940108|9752891|FG003|Overall Study|Dose 2 contraindicated|1
6127076|NCT00940108|9752888|FG000|Overall Study|Declined further vaccination|0
6127077|NCT00940108|9752889|FG001|Overall Study|Declined further vaccination|1
6127078|NCT00940108|9752890|FG002|Overall Study|Declined further vaccination|3
6127079|NCT00940108|9752891|FG003|Overall Study|Declined further vaccination|0
6127080|NCT00940108|9752888|FG000|Overall Study|Refused - pyrexia after Dose 1|0
6127081|NCT00940108|9752889|FG001|Overall Study|Refused - pyrexia after Dose 1|1
6127082|NCT00940108|9752890|FG002|Overall Study|Refused - pyrexia after Dose 1|0
6127083|NCT00940108|9752891|FG003|Overall Study|Refused - pyrexia after Dose 1|0
6127084|NCT00940108|9752888|FG000|Overall Study|Viral illness after Dose 1|0
6127085|NCT00940108|9752889|FG001|Overall Study|Viral illness after Dose 1|1
6127086|NCT00940108|9752890|FG002|Overall Study|Viral illness after Dose 1|0
6127087|NCT00940108|9752891|FG003|Overall Study|Viral illness after Dose 1|0
6127088|NCT00940108|9752888|FG000|Overall Study|Diagnosed with H1N1|0
6127089|NCT00940108|9752889|FG001|Overall Study|Diagnosed with H1N1|0
6127090|NCT00940108|9752890|FG002|Overall Study|Diagnosed with H1N1|0
6127091|NCT00940108|9752891|FG003|Overall Study|Diagnosed with H1N1|1
6127092|NCT00940316|9752921|FG000|Reached First Response at 8 Weeks|Adverse Event|2
6218733|NCT01646177|9887244|FG009|Follow-Up Period (Minimum of 12 Weeks)|Lost to Follow-up|8
6218734|NCT01646177|9887245|FG010|Follow-Up Period (Minimum of 12 Weeks)|Lost to Follow-up|9
6218735|NCT01646177|9887246|FG011|Follow-Up Period (Minimum of 12 Weeks)|Lost to Follow-up|9
6218736|NCT01646177|9887235|FG000|Follow-Up Period (Minimum of 12 Weeks)|Lack of Efficacy|0
6218737|NCT01646177|9887236|FG001|Follow-Up Period (Minimum of 12 Weeks)|Lack of Efficacy|0
6218738|NCT01646177|9887237|FG002|Follow-Up Period (Minimum of 12 Weeks)|Lack of Efficacy|0
6218739|NCT01646177|9887238|FG003|Follow-Up Period (Minimum of 12 Weeks)|Lack of Efficacy|0
6218740|NCT01646177|9887239|FG004|Follow-Up Period (Minimum of 12 Weeks)|Lack of Efficacy|0
6218741|NCT01646177|9887240|FG005|Follow-Up Period (Minimum of 12 Weeks)|Lack of Efficacy|0
6218742|NCT01646177|9887241|FG006|Follow-Up Period (Minimum of 12 Weeks)|Lack of Efficacy|0
6218743|NCT01646177|9887242|FG007|Follow-Up Period (Minimum of 12 Weeks)|Lack of Efficacy|0
6218744|NCT01646177|9887243|FG008|Follow-Up Period (Minimum of 12 Weeks)|Lack of Efficacy|4
6218745|NCT01646177|9887244|FG009|Follow-Up Period (Minimum of 12 Weeks)|Lack of Efficacy|9
6218746|NCT01646177|9887245|FG010|Follow-Up Period (Minimum of 12 Weeks)|Lack of Efficacy|8
6218747|NCT01646177|9887246|FG011|Follow-Up Period (Minimum of 12 Weeks)|Lack of Efficacy|9
6218748|NCT01646177|9887235|FG000|Follow-Up Period (Minimum of 12 Weeks)|Protocol Violation|0
6218749|NCT01646177|9887236|FG001|Follow-Up Period (Minimum of 12 Weeks)|Protocol Violation|0
6218750|NCT01646177|9887237|FG002|Follow-Up Period (Minimum of 12 Weeks)|Protocol Violation|0
6127093|NCT00940316|9752922|FG001|Reached First Response at 8 Weeks|Adverse Event|1
6127094|NCT00940316|9752923|FG002|Reached First Response at 8 Weeks|Adverse Event|0
6127095|NCT00940316|9752921|FG000|Reached First Response at 8 Weeks|Progressive disease|1
6127096|NCT00940316|9752922|FG001|Reached First Response at 8 Weeks|Progressive disease|3
6127097|NCT00940316|9752923|FG002|Reached First Response at 8 Weeks|Progressive disease|0
6127098|NCT00940316|9752921|FG000|Moved on to be Treated Cycle 5|Adverse Event|2
6127099|NCT00940316|9752922|FG001|Moved on to be Treated Cycle 5|Adverse Event|0
6127100|NCT00940316|9752923|FG002|Moved on to be Treated Cycle 5|Adverse Event|0
6127101|NCT00940316|9752921|FG000|Treated After Cycle 5|Adverse Event|0
6127102|NCT00940316|9752922|FG001|Treated After Cycle 5|Adverse Event|0
6127103|NCT00940316|9752923|FG002|Treated After Cycle 5|Adverse Event|1
6127104|NCT00940316|9752921|FG000|Treated After Cycle 5|Progressive disease|0
6127105|NCT00940316|9752922|FG001|Treated After Cycle 5|Progressive disease|1
6127106|NCT00940316|9752923|FG002|Treated After Cycle 5|Progressive disease|0
6127107|NCT00940342|9752942|FG000|Overall Study|Adverse Event|0
6127108|NCT00940342|9752943|FG001|Overall Study|Adverse Event|2
6127109|NCT00940342|9752944|FG002|Overall Study|Adverse Event|1
6127110|NCT00940485|9752965|FG000|Overall Study|HBeAb positive at Baseline|3
6127111|NCT00940485|9752966|FG001|Overall Study|HBeAb positive at Baseline|2
6127112|NCT00940485|9752965|FG000|Overall Study|Lost to Follow-up|2
6127113|NCT00940485|9752966|FG001|Overall Study|Lost to Follow-up|3
6127114|NCT00940485|9752965|FG000|Overall Study|Adverse Event|8
6127115|NCT00940485|9752966|FG001|Overall Study|Adverse Event|0
6127116|NCT00940485|9752965|FG000|Overall Study|Withdrawal by Subject|1
6127117|NCT00940485|9752966|FG001|Overall Study|Withdrawal by Subject|1
6127118|NCT00940485|9752965|FG000|Overall Study|Others|1
6127119|NCT00940485|9752966|FG001|Overall Study|Others|1
6127120|NCT00940602|9753001|FG000|Overall Study|Administrative problems|1
6127121|NCT00940602|9753002|FG001|Overall Study|Administrative problems|1
6127122|NCT00940602|9753001|FG000|Overall Study|Patient/guardian decision|13
6218751|NCT01646177|9887238|FG003|Follow-Up Period (Minimum of 12 Weeks)|Protocol Violation|0
6218752|NCT01646177|9887239|FG004|Follow-Up Period (Minimum of 12 Weeks)|Protocol Violation|0
6218753|NCT01646177|9887240|FG005|Follow-Up Period (Minimum of 12 Weeks)|Protocol Violation|0
6218754|NCT01646177|9887241|FG006|Follow-Up Period (Minimum of 12 Weeks)|Protocol Violation|0
6218755|NCT01646177|9887242|FG007|Follow-Up Period (Minimum of 12 Weeks)|Protocol Violation|0
6218756|NCT01646177|9887243|FG008|Follow-Up Period (Minimum of 12 Weeks)|Protocol Violation|1
6218757|NCT01646177|9887244|FG009|Follow-Up Period (Minimum of 12 Weeks)|Protocol Violation|6
6218758|NCT01646177|9887245|FG010|Follow-Up Period (Minimum of 12 Weeks)|Protocol Violation|4
6218759|NCT01646177|9887246|FG011|Follow-Up Period (Minimum of 12 Weeks)|Protocol Violation|7
6218760|NCT01646177|9887235|FG000|Follow-Up Period (Minimum of 12 Weeks)|Physician Decision|0
6218761|NCT01646177|9887236|FG001|Follow-Up Period (Minimum of 12 Weeks)|Physician Decision|0
6218762|NCT01646177|9887237|FG002|Follow-Up Period (Minimum of 12 Weeks)|Physician Decision|0
6218763|NCT01646177|9887238|FG003|Follow-Up Period (Minimum of 12 Weeks)|Physician Decision|0
6218764|NCT01646177|9887239|FG004|Follow-Up Period (Minimum of 12 Weeks)|Physician Decision|0
6218765|NCT01646177|9887240|FG005|Follow-Up Period (Minimum of 12 Weeks)|Physician Decision|0
6218766|NCT01646177|9887241|FG006|Follow-Up Period (Minimum of 12 Weeks)|Physician Decision|0
6127123|NCT00940602|9753002|FG001|Overall Study|Patient/guardian decision|28
6127124|NCT00940602|9753001|FG000|Overall Study|Physician Decision|8
6127125|NCT00940602|9753002|FG001|Overall Study|Physician Decision|5
6127126|NCT00940602|9753001|FG000|Overall Study|Pregnancy|1
6127127|NCT00940602|9753002|FG001|Overall Study|Pregnancy|0
6127128|NCT00940602|9753001|FG000|Overall Study|Protocol Deviation (untreated)|1
6127129|NCT00940602|9753002|FG001|Overall Study|Protocol Deviation (untreated)|0
6127130|NCT00940602|9753001|FG000|Overall Study|Disease progression|8
6127131|NCT00940602|9753002|FG001|Overall Study|Disease progression|2
6127132|NCT00940602|9753001|FG000|Overall Study|Death|38
6127133|NCT00940602|9753002|FG001|Overall Study|Death|19
6127134|NCT00940602|9753001|FG000|Overall Study|Lost to Follow-up|3
6127135|NCT00940602|9753002|FG001|Overall Study|Lost to Follow-up|1
6127136|NCT00940602|9753001|FG000|Overall Study|Patient withdrew consent|26
6127137|NCT00940602|9753002|FG001|Overall Study|Patient withdrew consent|13
6127138|NCT00940602|9753001|FG000|Overall Study|Adverse Event|7
6127139|NCT00940602|9753002|FG001|Overall Study|Adverse Event|2
6127140|NCT00940602|9753001|FG000|Overall Study|Study terminated by Sponsor = trial was to continue for 3 years from date the last patient enrolled|43
6127141|NCT00940602|9753002|FG001|Overall Study|Study terminated by Sponsor = trial was to continue for 3 years from date the last patient enrolled|5
6127142|NCT00940823|9753015|FG000|Overall Study|Death|8
6127143|NCT00940823|9753016|FG001|Overall Study|Death|12
6127144|NCT00940823|9753015|FG000|Overall Study|Lost to Follow-up|27
6127145|NCT00940823|9753016|FG001|Overall Study|Lost to Follow-up|20
6127146|NCT00940875|9753026|FG000|Treatment Phase|Adverse Event|9
6127147|NCT00940875|9753027|FG001|Treatment Phase|Adverse Event|3
6127148|NCT00940875|9753026|FG000|Treatment Phase|Death|3
6127149|NCT00940875|9753027|FG001|Treatment Phase|Death|5
6127150|NCT00940875|9753026|FG000|Treatment Phase|Lack of Efficacy|1
6127151|NCT00940875|9753027|FG001|Treatment Phase|Lack of Efficacy|0
6127152|NCT00940875|9753026|FG000|Treatment Phase|Withdrawal by Subject|3
6127153|NCT00940875|9753027|FG001|Treatment Phase|Withdrawal by Subject|0
6127154|NCT00940875|9753026|FG000|Treatment Phase|Disease progression|9
6127155|NCT00940875|9753027|FG001|Treatment Phase|Disease progression|11
6127156|NCT00940875|9753026|FG000|Treatment Phase|Physician Decision|1
6127157|NCT00940875|9753027|FG001|Treatment Phase|Physician Decision|0
6127158|NCT00940875|9753026|FG000|Post-Study Treatment|Death|0
6127159|NCT00940875|9753027|FG001|Post-Study Treatment|Death|1
6218767|NCT01646177|9887242|FG007|Follow-Up Period (Minimum of 12 Weeks)|Physician Decision|0
6127160|NCT00940875|9753026|FG000|Post-Study Treatment|Disease Progression|0
6127161|NCT00940875|9753027|FG001|Post-Study Treatment|Disease Progression|2
6127162|NCT00940888|9753034|FG000|Overall Study|Unsuccessful Implant|4
6127163|NCT00940888|9753034|FG000|Overall Study|Death|461
6127164|NCT00940888|9753034|FG000|Overall Study|Withdrawn - Non-Death|364
6127165|NCT00940888|9753034|FG000|Overall Study|Lost to Follow-up|6
6127166|NCT00940992|9753056|FG000|Overall Study|Adverse Event|2
6127167|NCT00940992|9753057|FG001|Overall Study|Adverse Event|0
6127168|NCT00940992|9753058|FG002|Overall Study|Adverse Event|1
6127169|NCT00940992|9753056|FG000|Overall Study|subject request|2
6127170|NCT00940992|9753057|FG001|Overall Study|subject request|1
6127171|NCT00940992|9753058|FG002|Overall Study|subject request|0
6127172|NCT00940992|9753056|FG000|Overall Study|Lost to Follow-up|0
6127173|NCT00940992|9753057|FG001|Overall Study|Lost to Follow-up|1
6127174|NCT00940992|9753058|FG002|Overall Study|Lost to Follow-up|1
6218768|NCT01646177|9887243|FG008|Follow-Up Period (Minimum of 12 Weeks)|Physician Decision|1
6218769|NCT01646177|9887244|FG009|Follow-Up Period (Minimum of 12 Weeks)|Physician Decision|2
6218770|NCT01646177|9887245|FG010|Follow-Up Period (Minimum of 12 Weeks)|Physician Decision|2
6218771|NCT01646177|9887246|FG011|Follow-Up Period (Minimum of 12 Weeks)|Physician Decision|3
6218772|NCT01646177|9887235|FG000|Follow-Up Period (Minimum of 12 Weeks)|Clinical Relapse|0
6218773|NCT01646177|9887236|FG001|Follow-Up Period (Minimum of 12 Weeks)|Clinical Relapse|0
6218774|NCT01646177|9887237|FG002|Follow-Up Period (Minimum of 12 Weeks)|Clinical Relapse|0
6218775|NCT01646177|9887238|FG003|Follow-Up Period (Minimum of 12 Weeks)|Clinical Relapse|0
6218776|NCT01646177|9887239|FG004|Follow-Up Period (Minimum of 12 Weeks)|Clinical Relapse|0
6218777|NCT01646177|9887240|FG005|Follow-Up Period (Minimum of 12 Weeks)|Clinical Relapse|0
6218778|NCT01646177|9887241|FG006|Follow-Up Period (Minimum of 12 Weeks)|Clinical Relapse|0
6218779|NCT01646177|9887242|FG007|Follow-Up Period (Minimum of 12 Weeks)|Clinical Relapse|0
6218780|NCT01646177|9887243|FG008|Follow-Up Period (Minimum of 12 Weeks)|Clinical Relapse|0
6218781|NCT01646177|9887244|FG009|Follow-Up Period (Minimum of 12 Weeks)|Clinical Relapse|1
6218782|NCT01646177|9887245|FG010|Follow-Up Period (Minimum of 12 Weeks)|Clinical Relapse|1
6218783|NCT01646177|9887246|FG011|Follow-Up Period (Minimum of 12 Weeks)|Clinical Relapse|3
6218784|NCT01646177|9887235|FG000|Follow-Up Period (Minimum of 12 Weeks)|Sponsor Decision|0
6218785|NCT01646177|9887236|FG001|Follow-Up Period (Minimum of 12 Weeks)|Sponsor Decision|0
6218786|NCT01646177|9887237|FG002|Follow-Up Period (Minimum of 12 Weeks)|Sponsor Decision|0
6218787|NCT01646177|9887238|FG003|Follow-Up Period (Minimum of 12 Weeks)|Sponsor Decision|0
6218788|NCT01646177|9887239|FG004|Follow-Up Period (Minimum of 12 Weeks)|Sponsor Decision|0
6218789|NCT01646177|9887240|FG005|Follow-Up Period (Minimum of 12 Weeks)|Sponsor Decision|0
6218790|NCT01646177|9887241|FG006|Follow-Up Period (Minimum of 12 Weeks)|Sponsor Decision|0
6218791|NCT01646177|9887242|FG007|Follow-Up Period (Minimum of 12 Weeks)|Sponsor Decision|0
6218792|NCT01646177|9887243|FG008|Follow-Up Period (Minimum of 12 Weeks)|Sponsor Decision|0
6218793|NCT01646177|9887244|FG009|Follow-Up Period (Minimum of 12 Weeks)|Sponsor Decision|1
6218794|NCT01646177|9887245|FG010|Follow-Up Period (Minimum of 12 Weeks)|Sponsor Decision|1
6218795|NCT01646177|9887246|FG011|Follow-Up Period (Minimum of 12 Weeks)|Sponsor Decision|1
6218796|NCT01646177|9887235|FG000|Follow-Up Period (Minimum of 12 Weeks)|Death|0
6218797|NCT01646177|9887236|FG001|Follow-Up Period (Minimum of 12 Weeks)|Death|0
6218798|NCT01646177|9887237|FG002|Follow-Up Period (Minimum of 12 Weeks)|Death|0
6218799|NCT01646177|9887238|FG003|Follow-Up Period (Minimum of 12 Weeks)|Death|0
6218800|NCT01646177|9887239|FG004|Follow-Up Period (Minimum of 12 Weeks)|Death|0
6218801|NCT01646177|9887240|FG005|Follow-Up Period (Minimum of 12 Weeks)|Death|0
6218802|NCT01646177|9887241|FG006|Follow-Up Period (Minimum of 12 Weeks)|Death|0
6218803|NCT01646177|9887242|FG007|Follow-Up Period (Minimum of 12 Weeks)|Death|0
6218804|NCT01646177|9887243|FG008|Follow-Up Period (Minimum of 12 Weeks)|Death|1
6218805|NCT01646177|9887244|FG009|Follow-Up Period (Minimum of 12 Weeks)|Death|0
6218806|NCT01646177|9887245|FG010|Follow-Up Period (Minimum of 12 Weeks)|Death|1
6218807|NCT01646177|9887246|FG011|Follow-Up Period (Minimum of 12 Weeks)|Death|1
6218808|NCT01646177|9887235|FG000|Follow-Up Period (Minimum of 12 Weeks)|Entry Criteria Not Met|0
6218809|NCT01646177|9887236|FG001|Follow-Up Period (Minimum of 12 Weeks)|Entry Criteria Not Met|0
6218810|NCT01646177|9887237|FG002|Follow-Up Period (Minimum of 12 Weeks)|Entry Criteria Not Met|0
6218811|NCT01646177|9887238|FG003|Follow-Up Period (Minimum of 12 Weeks)|Entry Criteria Not Met|0
6218812|NCT01646177|9887239|FG004|Follow-Up Period (Minimum of 12 Weeks)|Entry Criteria Not Met|0
6218813|NCT01646177|9887240|FG005|Follow-Up Period (Minimum of 12 Weeks)|Entry Criteria Not Met|0
6218814|NCT01646177|9887241|FG006|Follow-Up Period (Minimum of 12 Weeks)|Entry Criteria Not Met|0
6218815|NCT01646177|9887242|FG007|Follow-Up Period (Minimum of 12 Weeks)|Entry Criteria Not Met|0
6218816|NCT01646177|9887243|FG008|Follow-Up Period (Minimum of 12 Weeks)|Entry Criteria Not Met|0
6218817|NCT01646177|9887244|FG009|Follow-Up Period (Minimum of 12 Weeks)|Entry Criteria Not Met|0
6218818|NCT01646177|9887245|FG010|Follow-Up Period (Minimum of 12 Weeks)|Entry Criteria Not Met|1
6218819|NCT01646177|9887246|FG011|Follow-Up Period (Minimum of 12 Weeks)|Entry Criteria Not Met|1
6218820|NCT01646203|9887269|FG000|Overall Study|Adverse Event|2
6218821|NCT01646203|9887270|FG001|Overall Study|Adverse Event|0
6218822|NCT01646203|9887271|FG002|Overall Study|Adverse Event|1
6218823|NCT01646203|9887269|FG000|Overall Study|Withdrawal by Subject|0
6218824|NCT01646203|9887270|FG001|Overall Study|Withdrawal by Subject|1
6218825|NCT01646203|9887271|FG002|Overall Study|Withdrawal by Subject|0
6218826|NCT01646203|9887269|FG000|Overall Study|Physician's Decision|0
6218827|NCT01646203|9887270|FG001|Overall Study|Physician's Decision|1
6218828|NCT01646203|9887271|FG002|Overall Study|Physician's Decision|0
6218829|NCT01646216|9887286|FG000|Overall Study|Baseline step length difference (<5cm)|10
6218830|NCT01646216|9887287|FG001|Overall Study|Baseline step length difference (<5cm)|10
6218831|NCT01646216|9887286|FG000|Overall Study|Did not complete training|0
6127175|NCT00941031|9753081|FG000|Induction Period|Lack of Efficacy|2
6127176|NCT00941031|9753082|FG001|Induction Period|Lack of Efficacy|1
6127177|NCT00941031|9753083|FG002|Induction Period|Lack of Efficacy|0
6127178|NCT00941031|9753084|FG003|Induction Period|Lack of Efficacy|5
6127179|NCT00941031|9753085|FG004|Induction Period|Lack of Efficacy|0
6218832|NCT01646216|9887287|FG001|Overall Study|Did not complete training|2
6218833|NCT01646216|9887286|FG000|Overall Study|Investigator decision|1
6218834|NCT01646216|9887287|FG001|Overall Study|Investigator decision|1
6218835|NCT01646255|9887299|FG000|Overall Study|Adverse Event|7
6218836|NCT01646255|9887300|FG001|Overall Study|Adverse Event|8
6218837|NCT01646255|9887299|FG000|Overall Study|Lack of Efficacy|2
6218838|NCT01646255|9887300|FG001|Overall Study|Lack of Efficacy|0
6218839|NCT01646255|9887299|FG000|Overall Study|Withdrawal by Subject|10
6218840|NCT01646255|9887300|FG001|Overall Study|Withdrawal by Subject|6
6218841|NCT01646255|9887299|FG000|Overall Study|Compliance is not well|1
6218842|NCT01646255|9887300|FG001|Overall Study|Compliance is not well|0
6218843|NCT01646255|9887299|FG000|Overall Study|Inclusion Criteria Deviation|1
6218844|NCT01646255|9887300|FG001|Overall Study|Inclusion Criteria Deviation|0
6218845|NCT01646268|9887309|FG000|Overall Study|Adverse Event|6
6218846|NCT01646268|9887310|FG001|Overall Study|Adverse Event|7
6218847|NCT01646268|9887309|FG000|Overall Study|Lack of Efficacy|1
6218848|NCT01646268|9887310|FG001|Overall Study|Lack of Efficacy|3
6218849|NCT01646268|9887309|FG000|Overall Study|Protocol Violation|0
6218850|NCT01646268|9887310|FG001|Overall Study|Protocol Violation|1
6218851|NCT01646268|9887309|FG000|Overall Study|Withdrawal by Subject|2
6218852|NCT01646268|9887310|FG001|Overall Study|Withdrawal by Subject|5
6218853|NCT01646268|9887309|FG000|Overall Study|Other|2
6218854|NCT01646268|9887310|FG001|Overall Study|Other|0
6218855|NCT01646320|9887318|FG000|Short-term Period (Day 1 to Week 24)|Adverse Event|3
6218856|NCT01646320|9887319|FG001|Short-term Period (Day 1 to Week 24)|Adverse Event|0
6218857|NCT01646320|9887318|FG000|Short-term Period (Day 1 to Week 24)|No longer meets study criteria|0
6218858|NCT01646320|9887319|FG001|Short-term Period (Day 1 to Week 24)|No longer meets study criteria|1
6218859|NCT01646320|9887318|FG000|Short-term Period (Day 1 to Week 24)|Not reported|2
6218860|NCT01646320|9887319|FG001|Short-term Period (Day 1 to Week 24)|Not reported|2
6218861|NCT01646320|9887318|FG000|Short-term Period (Day 1 to Week 24)|Other|1
6218862|NCT01646320|9887319|FG001|Short-term Period (Day 1 to Week 24)|Other|0
6218863|NCT01646320|9887318|FG000|Short-term Period (Day 1 to Week 24)|Lost to Follow-up|4
6218864|NCT01646320|9887319|FG001|Short-term Period (Day 1 to Week 24)|Lost to Follow-up|4
6218865|NCT01646320|9887318|FG000|Short-term Period (Day 1 to Week 24)|Withdrawal by Subject|2
6218866|NCT01646320|9887319|FG001|Short-term Period (Day 1 to Week 24)|Withdrawal by Subject|0
6218867|NCT01646320|9887318|FG000|Long-term Period (Weeks 24 to 52)|Subject no longer meets study criteria|2
6218868|NCT01646320|9887319|FG001|Long-term Period (Weeks 24 to 52)|Subject no longer meets study criteria|0
6218869|NCT01646320|9887318|FG000|Long-term Period (Weeks 24 to 52)|Withdrawal by Subject|0
6218870|NCT01646320|9887319|FG001|Long-term Period (Weeks 24 to 52)|Withdrawal by Subject|2
6218871|NCT01646320|9887318|FG000|Long-term Period (Weeks 24 to 52)|Adverse Event|4
6218872|NCT01646320|9887319|FG001|Long-term Period (Weeks 24 to 52)|Adverse Event|2
6218873|NCT01646320|9887318|FG000|Long-term Period (Weeks 24 to 52)|Lack of Efficacy|0
6218874|NCT01646320|9887319|FG001|Long-term Period (Weeks 24 to 52)|Lack of Efficacy|1
6218875|NCT01646320|9887318|FG000|Long-term Period (Weeks 24 to 52)|Lost to Follow-up|0
6218876|NCT01646320|9887319|FG001|Long-term Period (Weeks 24 to 52)|Lost to Follow-up|2
6218877|NCT01646385|9887331|FG000|Overall Study|Death|202
6218878|NCT01646385|9887332|FG001|Overall Study|Death|222
6218879|NCT01646385|9887331|FG000|Overall Study|Switched to alternate biologic|636
6218880|NCT01646385|9887332|FG001|Overall Study|Switched to alternate biologic|649
6218881|NCT01646398|9887340|FG000|Overall Study|Withdrawal by Subject|1
6218882|NCT01646398|9887341|FG001|Overall Study|Withdrawal by Subject|0
6218883|NCT01646645|9887347|FG000|Overall Study|No Treated|1
6218884|NCT01646645|9887347|FG000|Overall Study|Inevaluable Donor|29
6218885|NCT01646827|9887372|FG000|Overall Study|Lost to Follow-up|0
6218886|NCT01646827|9887373|FG001|Overall Study|Lost to Follow-up|3
6218887|NCT01646827|9887372|FG000|Overall Study|Physician Decision|1
6218888|NCT01646827|9887373|FG001|Overall Study|Physician Decision|2
6218889|NCT01646827|9887372|FG000|Overall Study|Withdrawal by Subject|1
6218890|NCT01646827|9887373|FG001|Overall Study|Withdrawal by Subject|0
6218891|NCT01647282|9887392|FG000|Overall Study|Physician Decision|7
6218892|NCT01647282|9887393|FG001|Overall Study|Physician Decision|5
6218893|NCT01647516|9887415|FG000|Induction Period (IP)|Physician Decision|2
6218894|NCT01647516|9887416|FG001|Induction Period (IP)|Physician Decision|0
6218895|NCT01647516|9887417|FG002|Induction Period (IP)|Physician Decision|0
6218896|NCT01647516|9887418|FG003|Induction Period (IP)|Physician Decision|0
6218897|NCT01647516|9887419|FG004|Induction Period (IP)|Physician Decision|0
6218898|NCT01647516|9887420|FG005|Induction Period (IP)|Physician Decision|0
6218899|NCT01647516|9887415|FG000|Induction Period (IP)|Adverse Event|1
6218900|NCT01647516|9887416|FG001|Induction Period (IP)|Adverse Event|2
6218901|NCT01647516|9887417|FG002|Induction Period (IP)|Adverse Event|0
6218902|NCT01647516|9887418|FG003|Induction Period (IP)|Adverse Event|0
6218903|NCT01647516|9887419|FG004|Induction Period (IP)|Adverse Event|0
6218904|NCT01647516|9887420|FG005|Induction Period (IP)|Adverse Event|0
6218905|NCT01647516|9887415|FG000|Induction Period (IP)|Withdrawal by Subject|1
6127180|NCT00941031|9753086|FG005|Induction Period|Lack of Efficacy|0
6127181|NCT00941031|9753087|FG006|Induction Period|Lack of Efficacy|0
6127182|NCT00941031|9753081|FG000|Induction Period|Withdrawal by Subject|1
6127183|NCT00941031|9753082|FG001|Induction Period|Withdrawal by Subject|2
6127184|NCT00941031|9753083|FG002|Induction Period|Withdrawal by Subject|2
6127185|NCT00941031|9753084|FG003|Induction Period|Withdrawal by Subject|2
6127186|NCT00941031|9753085|FG004|Induction Period|Withdrawal by Subject|0
6127187|NCT00941031|9753086|FG005|Induction Period|Withdrawal by Subject|0
6127188|NCT00941031|9753087|FG006|Induction Period|Withdrawal by Subject|0
6127189|NCT00941031|9753081|FG000|Induction Period|Adminstative Problems|1
6127190|NCT00941031|9753082|FG001|Induction Period|Adminstative Problems|1
6127191|NCT00941031|9753083|FG002|Induction Period|Adminstative Problems|1
6127192|NCT00941031|9753084|FG003|Induction Period|Adminstative Problems|0
6127193|NCT00941031|9753085|FG004|Induction Period|Adminstative Problems|0
6127194|NCT00941031|9753086|FG005|Induction Period|Adminstative Problems|0
6127195|NCT00941031|9753087|FG006|Induction Period|Adminstative Problems|0
6127196|NCT00941031|9753081|FG000|Induction Period|Adverse Event|1
6127197|NCT00941031|9753082|FG001|Induction Period|Adverse Event|0
6127198|NCT00941031|9753083|FG002|Induction Period|Adverse Event|3
6127199|NCT00941031|9753084|FG003|Induction Period|Adverse Event|2
6127200|NCT00941031|9753085|FG004|Induction Period|Adverse Event|0
6127201|NCT00941031|9753086|FG005|Induction Period|Adverse Event|0
6127202|NCT00941031|9753087|FG006|Induction Period|Adverse Event|0
6127203|NCT00941031|9753081|FG000|Maintenance Period|Withdrawal by Subject|0
6127204|NCT00941031|9753082|FG001|Maintenance Period|Withdrawal by Subject|0
6127205|NCT00941031|9753083|FG002|Maintenance Period|Withdrawal by Subject|0
6127206|NCT00941031|9753084|FG003|Maintenance Period|Withdrawal by Subject|0
6127207|NCT00941031|9753085|FG004|Maintenance Period|Withdrawal by Subject|6
6127208|NCT00941031|9753086|FG005|Maintenance Period|Withdrawal by Subject|2
6127209|NCT00941031|9753087|FG006|Maintenance Period|Withdrawal by Subject|13
6127210|NCT00941031|9753081|FG000|Maintenance Period|Administrative Problems|0
6127211|NCT00941031|9753082|FG001|Maintenance Period|Administrative Problems|0
6127212|NCT00941031|9753083|FG002|Maintenance Period|Administrative Problems|0
6127213|NCT00941031|9753084|FG003|Maintenance Period|Administrative Problems|0
6127214|NCT00941031|9753085|FG004|Maintenance Period|Administrative Problems|1
6127215|NCT00941031|9753086|FG005|Maintenance Period|Administrative Problems|0
6218906|NCT01647516|9887416|FG001|Induction Period (IP)|Withdrawal by Subject|0
6218907|NCT01647516|9887417|FG002|Induction Period (IP)|Withdrawal by Subject|3
6218908|NCT01647516|9887418|FG003|Induction Period (IP)|Withdrawal by Subject|0
6218909|NCT01647516|9887419|FG004|Induction Period (IP)|Withdrawal by Subject|0
6218910|NCT01647516|9887420|FG005|Induction Period (IP)|Withdrawal by Subject|0
6218911|NCT01647516|9887415|FG000|Induction Period (IP)|Participant Choice|0
6218912|NCT01647516|9887416|FG001|Induction Period (IP)|Participant Choice|0
6218913|NCT01647516|9887417|FG002|Induction Period (IP)|Participant Choice|1
6288656|NCT02370641|10002912|FG000|Overall Study|dropped study|4
6288657|NCT02370641|10002913|FG001|Overall Study|dropped study|2
6288658|NCT02370667|10002922|FG000|Overall Study|Lost to Follow-up|0
6288659|NCT02370667|10002923|FG001|Overall Study|Lost to Follow-up|1
6288660|NCT02370667|10002924|FG002|Overall Study|Lost to Follow-up|0
6288661|NCT02370784|10002944|FG000|Overall Study|Patient started prohibited medication|0
6288662|NCT02370784|10002945|FG001|Overall Study|Patient started prohibited medication|1
6288663|NCT02370914|10002964|FG000|Overall Study|Protocol Violation|2
6288664|NCT02371616|10003013|FG000|Overall Study|Protocol Violation|2
6288665|NCT02371616|10003014|FG001|Overall Study|Protocol Violation|1
6288666|NCT02371616|10003013|FG000|Overall Study|Adverse Event|0
6288667|NCT02371616|10003014|FG001|Overall Study|Adverse Event|1
6288668|NCT02371616|10003013|FG000|Overall Study|Withdrawal of Consent|1
6288669|NCT02371616|10003014|FG001|Overall Study|Withdrawal of Consent|0
6288670|NCT02371616|10003013|FG000|Overall Study|Other (Not specified)|1
6288671|NCT02371616|10003014|FG001|Overall Study|Other (Not specified)|5
6288672|NCT02371629|10003022|FG000|Overall Study|Patient decision|14
6288673|NCT02371629|10003023|FG001|Overall Study|Patient decision|10
6288674|NCT02371629|10003022|FG000|Overall Study|Adverse Event|8
6288675|NCT02371629|10003023|FG001|Overall Study|Adverse Event|8
6288676|NCT02371629|10003022|FG000|Overall Study|Physician Decision|2
6288677|NCT02371629|10003023|FG001|Overall Study|Physician Decision|3
6288678|NCT02371629|10003022|FG000|Overall Study|Death|1
6288679|NCT02371629|10003023|FG001|Overall Study|Death|1
6288680|NCT02371629|10003022|FG000|Overall Study|Noncompliance with study treatment|1
6288681|NCT02371629|10003023|FG001|Overall Study|Noncompliance with study treatment|0
6288682|NCT02371629|10003022|FG000|Overall Study|Lack of Efficacy|0
6288683|NCT02371629|10003023|FG001|Overall Study|Lack of Efficacy|2
6288684|NCT02371629|10003022|FG000|Overall Study|Protocol deviation|0
6127216|NCT00941031|9753087|FG006|Maintenance Period|Administrative Problems|1
6127217|NCT00941031|9753081|FG000|Maintenance Period|Protocol Violation|0
6127218|NCT00941031|9753082|FG001|Maintenance Period|Protocol Violation|0
6127219|NCT00941031|9753083|FG002|Maintenance Period|Protocol Violation|0
6127220|NCT00941031|9753084|FG003|Maintenance Period|Protocol Violation|0
6127221|NCT00941031|9753085|FG004|Maintenance Period|Protocol Violation|0
6218914|NCT01647516|9887418|FG003|Induction Period (IP)|Participant Choice|0
6288685|NCT02371629|10003023|FG001|Overall Study|Protocol deviation|1
6288686|NCT02371746|10003045|FG000|Overall Study|Consent withdrawn|0
6127222|NCT00941031|9753086|FG005|Maintenance Period|Protocol Violation|0
6127223|NCT00941031|9753087|FG006|Maintenance Period|Protocol Violation|1
6127224|NCT00941031|9753081|FG000|Maintenance Period|Adverse Event|0
6127225|NCT00941031|9753082|FG001|Maintenance Period|Adverse Event|0
6127226|NCT00941031|9753083|FG002|Maintenance Period|Adverse Event|0
6127227|NCT00941031|9753084|FG003|Maintenance Period|Adverse Event|0
6127228|NCT00941031|9753085|FG004|Maintenance Period|Adverse Event|0
6127229|NCT00941031|9753086|FG005|Maintenance Period|Adverse Event|2
6127230|NCT00941031|9753087|FG006|Maintenance Period|Adverse Event|8
6127231|NCT00941031|9753081|FG000|Maintenance Period|Lost to Follow-up|0
6127232|NCT00941031|9753082|FG001|Maintenance Period|Lost to Follow-up|0
6127233|NCT00941031|9753083|FG002|Maintenance Period|Lost to Follow-up|0
6127234|NCT00941031|9753084|FG003|Maintenance Period|Lost to Follow-up|0
6127235|NCT00941031|9753085|FG004|Maintenance Period|Lost to Follow-up|2
6127236|NCT00941031|9753086|FG005|Maintenance Period|Lost to Follow-up|2
6127237|NCT00941031|9753087|FG006|Maintenance Period|Lost to Follow-up|7
6127238|NCT00941031|9753081|FG000|Maintenance Period|Lack of Efficacy|0
6127239|NCT00941031|9753082|FG001|Maintenance Period|Lack of Efficacy|0
6127240|NCT00941031|9753083|FG002|Maintenance Period|Lack of Efficacy|0
6127241|NCT00941031|9753084|FG003|Maintenance Period|Lack of Efficacy|0
6127242|NCT00941031|9753085|FG004|Maintenance Period|Lack of Efficacy|0
6127243|NCT00941031|9753086|FG005|Maintenance Period|Lack of Efficacy|0
6127244|NCT00941031|9753087|FG006|Maintenance Period|Lack of Efficacy|13
6127245|NCT00941070|9753106|FG000|Overall Study|Patient non-compliant|1
6127246|NCT00941304|9753117|FG000|Overall Study|Lost to Follow-up|1
6127247|NCT00941304|9753118|FG001|Overall Study|Lost to Follow-up|0
6127248|NCT00941304|9753119|FG002|Overall Study|Lost to Follow-up|0
6127249|NCT00941304|9753120|FG003|Overall Study|Lost to Follow-up|0
6127250|NCT00941304|9753121|FG004|Overall Study|Lost to Follow-up|0
6127251|NCT00941330|9753135|FG000|Overall Study|Other|1
6127252|NCT00941330|9753136|FG001|Overall Study|Other|0
6127253|NCT00941330|9753135|FG000|Overall Study|Physician Decision|0
6127254|NCT00941330|9753136|FG001|Overall Study|Physician Decision|2
6127255|NCT00941603|9753148|FG000|Overall Study|Adverse Event|10
6127256|NCT00941603|9753149|FG001|Overall Study|Adverse Event|15
6127257|NCT00941603|9753150|FG002|Overall Study|Adverse Event|5
6127258|NCT00941603|9753151|FG003|Overall Study|Adverse Event|1
6127259|NCT00941603|9753152|FG004|Overall Study|Adverse Event|4
6127260|NCT00941603|9753153|FG005|Overall Study|Adverse Event|0
6127261|NCT00941603|9753148|FG000|Overall Study|Lost to Follow-up|0
6127262|NCT00941603|9753149|FG001|Overall Study|Lost to Follow-up|0
6127263|NCT00941603|9753150|FG002|Overall Study|Lost to Follow-up|0
6127264|NCT00941603|9753151|FG003|Overall Study|Lost to Follow-up|1
6127265|NCT00941603|9753152|FG004|Overall Study|Lost to Follow-up|0
6127266|NCT00941603|9753153|FG005|Overall Study|Lost to Follow-up|2
6127267|NCT00941603|9753148|FG000|Overall Study|Withdrawal by Subject|0
6127268|NCT00941603|9753149|FG001|Overall Study|Withdrawal by Subject|0
6127269|NCT00941603|9753150|FG002|Overall Study|Withdrawal by Subject|0
6127270|NCT00941603|9753151|FG003|Overall Study|Withdrawal by Subject|2
6127271|NCT00941603|9753152|FG004|Overall Study|Withdrawal by Subject|0
6127272|NCT00941603|9753153|FG005|Overall Study|Withdrawal by Subject|1
6127273|NCT00941603|9753148|FG000|Overall Study|Protocol Violation|0
6127274|NCT00941603|9753149|FG001|Overall Study|Protocol Violation|1
6127275|NCT00941603|9753150|FG002|Overall Study|Protocol Violation|0
6127276|NCT00941603|9753151|FG003|Overall Study|Protocol Violation|0
6127277|NCT00941603|9753152|FG004|Overall Study|Protocol Violation|0
6127278|NCT00941603|9753153|FG005|Overall Study|Protocol Violation|0
6127279|NCT00941603|9753148|FG000|Overall Study|Did not meet protocol eligibility|1
6127280|NCT00941603|9753149|FG001|Overall Study|Did not meet protocol eligibility|0
6127281|NCT00941603|9753150|FG002|Overall Study|Did not meet protocol eligibility|0
6127282|NCT00941603|9753151|FG003|Overall Study|Did not meet protocol eligibility|0
6127283|NCT00941603|9753152|FG004|Overall Study|Did not meet protocol eligibility|0
6127284|NCT00941603|9753153|FG005|Overall Study|Did not meet protocol eligibility|0
6127285|NCT00941655|9753169|FG000|Overall Study|received some chemo, 4 and 9 cycles|1
6127286|NCT00941655|9753170|FG001|Overall Study|received some chemo, 4 and 9 cycles|0
6127287|NCT00941655|9753169|FG000|Overall Study|not meet criteria for chemo foll surgery|4
6127288|NCT00941655|9753170|FG001|Overall Study|not meet criteria for chemo foll surgery|0
6127289|NCT00941655|9753169|FG000|Overall Study|progressed while on chemo|0
6127290|NCT00941655|9753170|FG001|Overall Study|progressed while on chemo|2
6127291|NCT00941655|9753169|FG000|Overall Study|refused further treatment|0
6127292|NCT00941655|9753170|FG001|Overall Study|refused further treatment|1
6127293|NCT00941655|9753169|FG000|Overall Study|withdrew consent|0
6127294|NCT00941655|9753170|FG001|Overall Study|withdrew consent|1
6127295|NCT00941655|9753169|FG000|Overall Study|non-compliant|0
6127296|NCT00941655|9753170|FG001|Overall Study|non-compliant|1
6127297|NCT00941720|9753199|FG000|Overall Study|Withdrawal by Subject|1
6127298|NCT00941720|9753199|FG000|Overall Study|Insurance denied participation|11
6127299|NCT00941720|9753199|FG000|Overall Study|ineligible|2
6127300|NCT00941733|9753205|FG000|Overall Study|Death|24
6127301|NCT00941733|9753206|FG001|Overall Study|Death|10
6127302|NCT00941733|9753205|FG000|Overall Study|Withdrawal by Subject|14
6127303|NCT00941733|9753206|FG001|Overall Study|Withdrawal by Subject|6
6127304|NCT00941733|9753205|FG000|Overall Study|Adverse Event|20
6127305|NCT00941733|9753206|FG001|Overall Study|Adverse Event|4
6127306|NCT00941733|9753205|FG000|Overall Study|Lost to Follow-up|1
6127307|NCT00941733|9753206|FG001|Overall Study|Lost to Follow-up|2
6127308|NCT00941733|9753205|FG000|Overall Study|Protocol Violation|15
6127309|NCT00941733|9753206|FG001|Overall Study|Protocol Violation|6
6127310|NCT00941798|9753214|FG000|Overall Study|Withdrawal by Subject|72
6127311|NCT00941798|9753215|FG001|Overall Study|Withdrawal by Subject|74
6218915|NCT01647516|9887419|FG004|Induction Period (IP)|Participant Choice|0
6218916|NCT01647516|9887420|FG005|Induction Period (IP)|Participant Choice|0
6218917|NCT01647516|9887415|FG000|Induction Period (IP)|Lack of Efficacy|1
6218918|NCT01647516|9887416|FG001|Induction Period (IP)|Lack of Efficacy|0
6218919|NCT01647516|9887417|FG002|Induction Period (IP)|Lack of Efficacy|0
6218920|NCT01647516|9887418|FG003|Induction Period (IP)|Lack of Efficacy|0
6218921|NCT01647516|9887419|FG004|Induction Period (IP)|Lack of Efficacy|0
6218922|NCT01647516|9887420|FG005|Induction Period (IP)|Lack of Efficacy|0
6218923|NCT01647516|9887415|FG000|Induction Period (IP)|No study drug received|1
6218924|NCT01647516|9887416|FG001|Induction Period (IP)|No study drug received|1
6218925|NCT01647516|9887417|FG002|Induction Period (IP)|No study drug received|0
6218926|NCT01647516|9887418|FG003|Induction Period (IP)|No study drug received|0
6218927|NCT01647516|9887419|FG004|Induction Period (IP)|No study drug received|0
6218928|NCT01647516|9887420|FG005|Induction Period (IP)|No study drug received|0
6218929|NCT01647516|9887415|FG000|Maintenance Period (MP)|Adverse Event|2
6218930|NCT01647516|9887416|FG001|Maintenance Period (MP)|Adverse Event|1
6218931|NCT01647516|9887417|FG002|Maintenance Period (MP)|Adverse Event|0
6218932|NCT01647516|9887418|FG003|Maintenance Period (MP)|Adverse Event|0
6218933|NCT01647516|9887419|FG004|Maintenance Period (MP)|Adverse Event|0
6218934|NCT01647516|9887420|FG005|Maintenance Period (MP)|Adverse Event|0
6218935|NCT01647516|9887415|FG000|Maintenance Period (MP)|Non-compliance|1
6218936|NCT01647516|9887416|FG001|Maintenance Period (MP)|Non-compliance|0
6218937|NCT01647516|9887417|FG002|Maintenance Period (MP)|Non-compliance|0
6218938|NCT01647516|9887418|FG003|Maintenance Period (MP)|Non-compliance|0
6218939|NCT01647516|9887419|FG004|Maintenance Period (MP)|Non-compliance|0
6218940|NCT01647516|9887420|FG005|Maintenance Period (MP)|Non-compliance|0
6218941|NCT01647516|9887415|FG000|Maintenance Period (MP)|Withdrawal by Subject|0
6218942|NCT01647516|9887416|FG001|Maintenance Period (MP)|Withdrawal by Subject|1
6218943|NCT01647516|9887417|FG002|Maintenance Period (MP)|Withdrawal by Subject|1
6218944|NCT01647516|9887418|FG003|Maintenance Period (MP)|Withdrawal by Subject|0
6218945|NCT01647516|9887419|FG004|Maintenance Period (MP)|Withdrawal by Subject|0
6218946|NCT01647516|9887420|FG005|Maintenance Period (MP)|Withdrawal by Subject|0
6218947|NCT01647516|9887415|FG000|Maintenance Period (MP)|Lack of Efficacy|1
6218948|NCT01647516|9887416|FG001|Maintenance Period (MP)|Lack of Efficacy|4
6218949|NCT01647516|9887417|FG002|Maintenance Period (MP)|Lack of Efficacy|1
6218950|NCT01647516|9887418|FG003|Maintenance Period (MP)|Lack of Efficacy|0
6218951|NCT01647516|9887419|FG004|Maintenance Period (MP)|Lack of Efficacy|0
6218952|NCT01647516|9887420|FG005|Maintenance Period (MP)|Lack of Efficacy|0
6218953|NCT01647516|9887415|FG000|Open-Label Period|Adverse Event|0
6218954|NCT01647516|9887416|FG001|Open-Label Period|Adverse Event|0
6218955|NCT01647516|9887417|FG002|Open-Label Period|Adverse Event|0
6218956|NCT01647516|9887418|FG003|Open-Label Period|Adverse Event|5
6218957|NCT01647516|9887419|FG004|Open-Label Period|Adverse Event|6
6218958|NCT01647516|9887420|FG005|Open-Label Period|Adverse Event|3
6218959|NCT01647516|9887415|FG000|Open-Label Period|Pregnancy|0
6218960|NCT01647516|9887416|FG001|Open-Label Period|Pregnancy|0
6218961|NCT01647516|9887417|FG002|Open-Label Period|Pregnancy|0
6218962|NCT01647516|9887418|FG003|Open-Label Period|Pregnancy|0
6218963|NCT01647516|9887419|FG004|Open-Label Period|Pregnancy|0
6218964|NCT01647516|9887420|FG005|Open-Label Period|Pregnancy|1
6218965|NCT01647516|9887415|FG000|Open-Label Period|Non-compliance|0
6218966|NCT01647516|9887416|FG001|Open-Label Period|Non-compliance|0
6218967|NCT01647516|9887417|FG002|Open-Label Period|Non-compliance|0
6218968|NCT01647516|9887418|FG003|Open-Label Period|Non-compliance|1
6218969|NCT01647516|9887419|FG004|Open-Label Period|Non-compliance|0
6218970|NCT01647516|9887420|FG005|Open-Label Period|Non-compliance|1
6218971|NCT01647516|9887415|FG000|Open-Label Period|Physician Decision|0
6218972|NCT01647516|9887416|FG001|Open-Label Period|Physician Decision|0
6218973|NCT01647516|9887417|FG002|Open-Label Period|Physician Decision|0
6218974|NCT01647516|9887418|FG003|Open-Label Period|Physician Decision|1
6218975|NCT01647516|9887419|FG004|Open-Label Period|Physician Decision|1
6218976|NCT01647516|9887420|FG005|Open-Label Period|Physician Decision|0
6218977|NCT01647516|9887415|FG000|Open-Label Period|Withdrawal by Subject|0
6218978|NCT01647516|9887416|FG001|Open-Label Period|Withdrawal by Subject|0
6218979|NCT01647516|9887417|FG002|Open-Label Period|Withdrawal by Subject|0
6218980|NCT01647516|9887418|FG003|Open-Label Period|Withdrawal by Subject|9
6218981|NCT01647516|9887419|FG004|Open-Label Period|Withdrawal by Subject|11
6218982|NCT01647516|9887420|FG005|Open-Label Period|Withdrawal by Subject|6
6218983|NCT01647516|9887415|FG000|Open-Label Period|Lost to Follow-up|0
6218984|NCT01647516|9887416|FG001|Open-Label Period|Lost to Follow-up|0
6218985|NCT01647516|9887417|FG002|Open-Label Period|Lost to Follow-up|0
6218986|NCT01647516|9887418|FG003|Open-Label Period|Lost to Follow-up|1
6218987|NCT01647516|9887419|FG004|Open-Label Period|Lost to Follow-up|0
6218988|NCT01647516|9887420|FG005|Open-Label Period|Lost to Follow-up|1
6218989|NCT01647516|9887415|FG000|Open-Label Period|Sponsor Termination; moved to 3102 study|0
6127312|NCT00941798|9753214|FG000|Overall Study|Adverse Event|43
6127313|NCT00941798|9753215|FG001|Overall Study|Adverse Event|23
6127314|NCT00941798|9753214|FG000|Overall Study|Lost to Follow-up|29
6127315|NCT00941798|9753215|FG001|Overall Study|Lost to Follow-up|23
6127316|NCT00941798|9753214|FG000|Overall Study|Protocol Violation|17
6127317|NCT00941798|9753215|FG001|Overall Study|Protocol Violation|20
6127318|NCT00941798|9753214|FG000|Overall Study|Administrative problems|13
6127319|NCT00941798|9753215|FG001|Overall Study|Administrative problems|23
6127320|NCT00941798|9753214|FG000|Overall Study|Lack of Efficacy|10
6127321|NCT00941798|9753215|FG001|Overall Study|Lack of Efficacy|17
6127322|NCT00941798|9753214|FG000|Overall Study|Patient's inability to use device|6
6127323|NCT00941798|9753215|FG001|Overall Study|Patient's inability to use device|1
6127324|NCT00941798|9753214|FG000|Overall Study|Abnormal test procedure results|3
6127325|NCT00941798|9753215|FG001|Overall Study|Abnormal test procedure results|1
6127326|NCT00941798|9753214|FG000|Overall Study|Abnormal laboratory values|1
6127327|NCT00941798|9753215|FG001|Overall Study|Abnormal laboratory values|2
6127328|NCT00941798|9753214|FG000|Overall Study|Death|0
6127329|NCT00941798|9753215|FG001|Overall Study|Death|1
6127330|NCT00941863|9753226|FG000|Until Primary Completion Date (PCD)|Adverse Event|1
6127331|NCT00941863|9753227|FG001|Until Primary Completion Date (PCD)|Adverse Event|2
6127332|NCT00941863|9753228|FG002|Until Primary Completion Date (PCD)|Adverse Event|2
6127333|NCT00941863|9753229|FG003|Until Primary Completion Date (PCD)|Adverse Event|1
6127334|NCT00941863|9753230|FG004|Until Primary Completion Date (PCD)|Adverse Event|5
6127335|NCT00941863|9753226|FG000|Until Primary Completion Date (PCD)|Physician Decision|0
6127336|NCT00941863|9753227|FG001|Until Primary Completion Date (PCD)|Physician Decision|0
6127337|NCT00941863|9753228|FG002|Until Primary Completion Date (PCD)|Physician Decision|0
6127338|NCT00941863|9753229|FG003|Until Primary Completion Date (PCD)|Physician Decision|0
6127339|NCT00941863|9753230|FG004|Until Primary Completion Date (PCD)|Physician Decision|1
6127340|NCT00941863|9753226|FG000|Until Primary Completion Date (PCD)|Withdrawal by Subject|0
6127341|NCT00941863|9753227|FG001|Until Primary Completion Date (PCD)|Withdrawal by Subject|0
6127342|NCT00941863|9753228|FG002|Until Primary Completion Date (PCD)|Withdrawal by Subject|1
6127343|NCT00941863|9753229|FG003|Until Primary Completion Date (PCD)|Withdrawal by Subject|0
6127344|NCT00941863|9753230|FG004|Until Primary Completion Date (PCD)|Withdrawal by Subject|8
6127345|NCT00941863|9753226|FG000|Until Primary Completion Date (PCD)|Death|0
6127346|NCT00941863|9753227|FG001|Until Primary Completion Date (PCD)|Death|0
6127347|NCT00941863|9753228|FG002|Until Primary Completion Date (PCD)|Death|1
6127348|NCT00941863|9753229|FG003|Until Primary Completion Date (PCD)|Death|2
6127349|NCT00941863|9753230|FG004|Until Primary Completion Date (PCD)|Death|7
6127350|NCT00941863|9753226|FG000|Until Primary Completion Date (PCD)|Disease progression|6
6127351|NCT00941863|9753227|FG001|Until Primary Completion Date (PCD)|Disease progression|1
6127352|NCT00941863|9753228|FG002|Until Primary Completion Date (PCD)|Disease progression|8
6218990|NCT01647516|9887416|FG001|Open-Label Period|Sponsor Termination; moved to 3102 study|0
6218991|NCT01647516|9887417|FG002|Open-Label Period|Sponsor Termination; moved to 3102 study|0
6218992|NCT01647516|9887418|FG003|Open-Label Period|Sponsor Termination; moved to 3102 study|18
6218993|NCT01647516|9887419|FG004|Open-Label Period|Sponsor Termination; moved to 3102 study|13
6218994|NCT01647516|9887420|FG005|Open-Label Period|Sponsor Termination; moved to 3102 study|23
6218995|NCT01647516|9887415|FG000|Open-Label Period|Lack of Efficacy|0
6218996|NCT01647516|9887416|FG001|Open-Label Period|Lack of Efficacy|0
6218997|NCT01647516|9887417|FG002|Open-Label Period|Lack of Efficacy|0
6218998|NCT01647516|9887418|FG003|Open-Label Period|Lack of Efficacy|7
6288687|NCT02371746|10003046|FG001|Overall Study|Consent withdrawn|0
6288688|NCT02371746|10003047|FG002|Overall Study|Consent withdrawn|0
6288689|NCT02371746|10003048|FG003|Overall Study|Consent withdrawn|0
6127353|NCT00941863|9753229|FG003|Until Primary Completion Date (PCD)|Disease progression|14
6127354|NCT00941863|9753230|FG004|Until Primary Completion Date (PCD)|Disease progression|73
6127355|NCT00941863|9753226|FG000|Continued After PCD|Withdrawal by Subject|0
6127356|NCT00941863|9753227|FG001|Continued After PCD|Withdrawal by Subject|0
6127357|NCT00941863|9753228|FG002|Continued After PCD|Withdrawal by Subject|0
6127358|NCT00941863|9753229|FG003|Continued After PCD|Withdrawal by Subject|0
6127359|NCT00941863|9753230|FG004|Continued After PCD|Withdrawal by Subject|1
6127360|NCT00941863|9753226|FG000|Continued After PCD|Disease progression, recurrence, relapse|0
6127361|NCT00941863|9753227|FG001|Continued After PCD|Disease progression, recurrence, relapse|0
6127362|NCT00941863|9753228|FG002|Continued After PCD|Disease progression, recurrence, relapse|0
6127363|NCT00941863|9753229|FG003|Continued After PCD|Disease progression, recurrence, relapse|0
6127364|NCT00941863|9753230|FG004|Continued After PCD|Disease progression, recurrence, relapse|18
6127365|NCT00942084|9753260|FG000|Overall Study|Death|2
6127366|NCT00942162|9753271|FG000|Overall Study|Death|45
6127367|NCT00942162|9753272|FG001|Overall Study|Death|35
6127368|NCT00942162|9753273|FG002|Overall Study|Death|0
6127369|NCT00942162|9753271|FG000|Overall Study|Withdrawal by Subject|7
6127370|NCT00942162|9753272|FG001|Overall Study|Withdrawal by Subject|2
6127371|NCT00942162|9753273|FG002|Overall Study|Withdrawal by Subject|0
6127372|NCT00942162|9753271|FG000|Overall Study|Lost to Follow-up|4
6127373|NCT00942162|9753272|FG001|Overall Study|Lost to Follow-up|0
6127374|NCT00942162|9753273|FG002|Overall Study|Lost to Follow-up|0
6127375|NCT00942162|9753271|FG000|Overall Study|Other|14
6127376|NCT00942162|9753272|FG001|Overall Study|Other|13
6127377|NCT00942162|9753273|FG002|Overall Study|Other|2
6218999|NCT01647516|9887419|FG004|Open-Label Period|Lack of Efficacy|9
6127378|NCT00942175|9753287|FG000|Overall Study|Adverse Event|2
6127379|NCT00942175|9753288|FG001|Overall Study|Adverse Event|1
6127380|NCT00942175|9753289|FG002|Overall Study|Adverse Event|0
6127381|NCT00942175|9753290|FG003|Overall Study|Adverse Event|0
6127382|NCT00942175|9753287|FG000|Overall Study|Protocol Violation|0
6127383|NCT00942175|9753288|FG001|Overall Study|Protocol Violation|1
6127384|NCT00942175|9753289|FG002|Overall Study|Protocol Violation|2
6127385|NCT00942175|9753290|FG003|Overall Study|Protocol Violation|0
6127386|NCT00942175|9753287|FG000|Overall Study|Pregnancy|0
6127387|NCT00942175|9753288|FG001|Overall Study|Pregnancy|0
6127388|NCT00942175|9753289|FG002|Overall Study|Pregnancy|0
6127389|NCT00942175|9753290|FG003|Overall Study|Pregnancy|1
6127390|NCT00942175|9753287|FG000|Overall Study|Elevated Alanine Amino Transferase|0
6127391|NCT00942175|9753288|FG001|Overall Study|Elevated Alanine Amino Transferase|0
6127392|NCT00942175|9753289|FG002|Overall Study|Elevated Alanine Amino Transferase|0
6127393|NCT00942175|9753290|FG003|Overall Study|Elevated Alanine Amino Transferase|1
6127394|NCT00942175|9753287|FG000|Overall Study|Low Platelet Count|0
6219000|NCT01647516|9887420|FG005|Open-Label Period|Lack of Efficacy|10
6219001|NCT01647516|9887415|FG000|Open-Label Period|Participant Choice to Stop Study Drug|0
6219002|NCT01647516|9887416|FG001|Open-Label Period|Participant Choice to Stop Study Drug|0
6219003|NCT01647516|9887417|FG002|Open-Label Period|Participant Choice to Stop Study Drug|0
6219004|NCT01647516|9887418|FG003|Open-Label Period|Participant Choice to Stop Study Drug|7
6219005|NCT01647516|9887419|FG004|Open-Label Period|Participant Choice to Stop Study Drug|9
6219006|NCT01647516|9887420|FG005|Open-Label Period|Participant Choice to Stop Study Drug|10
6219007|NCT01647516|9887415|FG000|Open-Label Period|No completion / discontinuation visit|0
6219008|NCT01647516|9887416|FG001|Open-Label Period|No completion / discontinuation visit|0
6219009|NCT01647516|9887417|FG002|Open-Label Period|No completion / discontinuation visit|0
6219010|NCT01647516|9887418|FG003|Open-Label Period|No completion / discontinuation visit|0
6219011|NCT01647516|9887419|FG004|Open-Label Period|No completion / discontinuation visit|2
6219012|NCT01647516|9887420|FG005|Open-Label Period|No completion / discontinuation visit|1
6288690|NCT02371746|10003049|FG004|Overall Study|Consent withdrawn|0
6288691|NCT02371746|10003050|FG005|Overall Study|Consent withdrawn|0
6288692|NCT02371746|10003051|FG006|Overall Study|Consent withdrawn|1
6288693|NCT02371759|10003075|FG000|Overall Study|Protocol Violation|3
6288694|NCT02371759|10003076|FG001|Overall Study|Protocol Violation|1
6288695|NCT02371759|10003077|FG002|Overall Study|Protocol Violation|1
6288696|NCT02371759|10003078|FG003|Overall Study|Protocol Violation|0
6288697|NCT02371759|10003079|FG004|Overall Study|Protocol Violation|3
6288698|NCT02371759|10003080|FG005|Overall Study|Protocol Violation|1
6288699|NCT02371759|10003081|FG006|Overall Study|Protocol Violation|0
6288700|NCT02371759|10003082|FG007|Overall Study|Protocol Violation|3
6288701|NCT02371759|10003075|FG000|Overall Study|Withdrawal by Subject|0
6288702|NCT02371759|10003076|FG001|Overall Study|Withdrawal by Subject|0
6288703|NCT02371759|10003077|FG002|Overall Study|Withdrawal by Subject|0
6288704|NCT02371759|10003078|FG003|Overall Study|Withdrawal by Subject|0
6288705|NCT02371759|10003079|FG004|Overall Study|Withdrawal by Subject|0
6288706|NCT02371759|10003080|FG005|Overall Study|Withdrawal by Subject|0
6288707|NCT02371759|10003081|FG006|Overall Study|Withdrawal by Subject|0
6288708|NCT02371759|10003082|FG007|Overall Study|Withdrawal by Subject|1
6288709|NCT02371980|10003129|FG000|Open-label Period|Pretreatment Event/Adverse Event|63
6288710|NCT02371980|10003130|FG001|Open-label Period|Pretreatment Event/Adverse Event|0
6288711|NCT02371980|10003131|FG002|Open-label Period|Pretreatment Event/Adverse Event|0
6288712|NCT02371980|10003132|FG003|Open-label Period|Pretreatment Event/Adverse Event|0
6288713|NCT02371980|10003133|FG004|Open-label Period|Pretreatment Event/Adverse Event|0
6288714|NCT02371980|10003129|FG000|Open-label Period|Significant Protocol Deviation|19
6288715|NCT02371980|10003130|FG001|Open-label Period|Significant Protocol Deviation|0
6288716|NCT02371980|10003131|FG002|Open-label Period|Significant Protocol Deviation|0
6288717|NCT02371980|10003132|FG003|Open-label Period|Significant Protocol Deviation|0
6288718|NCT02371980|10003133|FG004|Open-label Period|Significant Protocol Deviation|0
6288719|NCT02371980|10003129|FG000|Open-label Period|Noncompliance with Study Drug|10
6288720|NCT02371980|10003130|FG001|Open-label Period|Noncompliance with Study Drug|0
6288721|NCT02371980|10003131|FG002|Open-label Period|Noncompliance with Study Drug|0
6288722|NCT02371980|10003132|FG003|Open-label Period|Noncompliance with Study Drug|0
6288723|NCT02371980|10003133|FG004|Open-label Period|Noncompliance with Study Drug|0
6288724|NCT02371980|10003129|FG000|Open-label Period|Lost to Follow-up|55
6288725|NCT02371980|10003130|FG001|Open-label Period|Lost to Follow-up|0
6288726|NCT02371980|10003131|FG002|Open-label Period|Lost to Follow-up|0
6288727|NCT02371980|10003132|FG003|Open-label Period|Lost to Follow-up|0
6288728|NCT02371980|10003133|FG004|Open-label Period|Lost to Follow-up|0
6288729|NCT02371980|10003129|FG000|Open-label Period|Voluntary Withdrawal|91
6127395|NCT00942175|9753288|FG001|Overall Study|Low Platelet Count|2
6127396|NCT00942175|9753289|FG002|Overall Study|Low Platelet Count|0
6288730|NCT02371980|10003130|FG001|Open-label Period|Voluntary Withdrawal|0
6288731|NCT02371980|10003131|FG002|Open-label Period|Voluntary Withdrawal|0
6288732|NCT02371980|10003132|FG003|Open-label Period|Voluntary Withdrawal|0
6288733|NCT02371980|10003133|FG004|Open-label Period|Voluntary Withdrawal|0
6288734|NCT02371980|10003129|FG000|Open-label Period|Pregnancy|1
6288735|NCT02371980|10003130|FG001|Open-label Period|Pregnancy|0
6288736|NCT02371980|10003131|FG002|Open-label Period|Pregnancy|0
6127397|NCT00942175|9753290|FG003|Overall Study|Low Platelet Count|0
6127398|NCT00942188|9753312|FG000|Overall Study|Adverse Event|0
6127399|NCT00942188|9753313|FG001|Overall Study|Adverse Event|3
6127400|NCT00942188|9753314|FG002|Overall Study|Adverse Event|2
6127401|NCT00942188|9753315|FG003|Overall Study|Adverse Event|0
6127402|NCT00942188|9753312|FG000|Overall Study|Lack of Efficacy|0
6219013|NCT01647542|9887438|FG000|Overall Study|Major Protocol Deviation|1
6219014|NCT01647542|9887439|FG001|Overall Study|Major Protocol Deviation|0
6219015|NCT01647542|9887440|FG002|Overall Study|Major Protocol Deviation|0
6219016|NCT01647542|9887438|FG000|Overall Study|Adverse Event|4
6219017|NCT01647542|9887439|FG001|Overall Study|Adverse Event|5
6219018|NCT01647542|9887440|FG002|Overall Study|Adverse Event|4
6219019|NCT01647542|9887438|FG000|Overall Study|Lost to Follow-up|0
6219020|NCT01647542|9887439|FG001|Overall Study|Lost to Follow-up|2
6219021|NCT01647542|9887440|FG002|Overall Study|Lost to Follow-up|2
6219022|NCT01647542|9887438|FG000|Overall Study|Withdrawal by Subject|6
6288737|NCT02371980|10003132|FG003|Open-label Period|Pregnancy|0
6127403|NCT00942188|9753313|FG001|Overall Study|Lack of Efficacy|0
6127404|NCT00942188|9753314|FG002|Overall Study|Lack of Efficacy|0
6127405|NCT00942188|9753315|FG003|Overall Study|Lack of Efficacy|1
6127406|NCT00942188|9753312|FG000|Overall Study|Protocol Violation|1
6127407|NCT00942188|9753313|FG001|Overall Study|Protocol Violation|1
6127408|NCT00942188|9753314|FG002|Overall Study|Protocol Violation|0
6127409|NCT00942188|9753315|FG003|Overall Study|Protocol Violation|0
6127410|NCT00942188|9753312|FG000|Overall Study|Lost to Follow-up|2
6127411|NCT00942188|9753313|FG001|Overall Study|Lost to Follow-up|1
6127412|NCT00942188|9753314|FG002|Overall Study|Lost to Follow-up|2
6127413|NCT00942188|9753315|FG003|Overall Study|Lost to Follow-up|0
6127414|NCT00942188|9753312|FG000|Overall Study|Withdrawal by Subject|1
6127415|NCT00942188|9753313|FG001|Overall Study|Withdrawal by Subject|3
6127416|NCT00942188|9753314|FG002|Overall Study|Withdrawal by Subject|4
6127417|NCT00942188|9753315|FG003|Overall Study|Withdrawal by Subject|2
6127418|NCT00942188|9753312|FG000|Overall Study|Physician Decision|0
6127419|NCT00942188|9753313|FG001|Overall Study|Physician Decision|0
6127420|NCT00942188|9753314|FG002|Overall Study|Physician Decision|1
6127421|NCT00942188|9753315|FG003|Overall Study|Physician Decision|0
6127422|NCT00942188|9753312|FG000|Overall Study|Sponsor Decision|0
6127423|NCT00942188|9753313|FG001|Overall Study|Sponsor Decision|2
6127424|NCT00942188|9753314|FG002|Overall Study|Sponsor Decision|0
6127425|NCT00942188|9753315|FG003|Overall Study|Sponsor Decision|1
6127426|NCT00942266|9753327|FG000|Overall Study|Withdrawal by Subject|1
6127427|NCT00942266|9753328|FG001|Overall Study|Withdrawal by Subject|0
6127428|NCT00942266|9753327|FG000|Overall Study|Adverse Event|2
6127429|NCT00942266|9753328|FG001|Overall Study|Adverse Event|1
6127430|NCT00942266|9753327|FG000|Overall Study|Disease Progression|38
6127431|NCT00942266|9753328|FG001|Overall Study|Disease Progression|11
6127432|NCT00942266|9753327|FG000|Overall Study|Failure to thrive and pt withdrawal|0
6127433|NCT00942266|9753328|FG001|Overall Study|Failure to thrive and pt withdrawal|1
6127434|NCT00942266|9753327|FG000|Overall Study|Intercurrent illness|0
6127435|NCT00942266|9753328|FG001|Overall Study|Intercurrent illness|1
6127436|NCT00942266|9753327|FG000|Overall Study|Physician Decision|2
6127437|NCT00942266|9753328|FG001|Overall Study|Physician Decision|0
6127438|NCT00942266|9753327|FG000|Overall Study|medical deterioration (pneumonia)|0
6127439|NCT00942266|9753328|FG001|Overall Study|medical deterioration (pneumonia)|1
6127440|NCT00942357|9753377|FG000|Overall Study|Ineligible|37
6127441|NCT00942357|9753378|FG001|Overall Study|Ineligible|40
6127442|NCT00942422|9753384|FG000|Overall Study|Withdrawal by Subject|1
6127443|NCT00942422|9753384|FG000|Overall Study|Death|1
6127444|NCT00942422|9753384|FG000|Overall Study|Progressive diease|1
6127445|NCT00942604|9753429|FG000|Overall Study|Protocol Violation|1
6127446|NCT00942604|9753430|FG001|Overall Study|Protocol Violation|1
6127447|NCT00942604|9753429|FG000|Overall Study|Adverse Event|0
6127448|NCT00942604|9753430|FG001|Overall Study|Adverse Event|1
6127449|NCT00942604|9753429|FG000|Overall Study|Withdrawal by Subject|0
6127450|NCT00942604|9753430|FG001|Overall Study|Withdrawal by Subject|1
6127451|NCT00942604|9753429|FG000|Overall Study|Patient relocation|1
6127452|NCT00942604|9753430|FG001|Overall Study|Patient relocation|1
6127453|NCT00942708|9753436|FG000|Overall Study|Withdrawal by Subject|1
6127454|NCT00942734|9753441|FG000|Overall Study|Adverse Event|2
6127455|NCT00942734|9753441|FG000|Overall Study|Protocol Violation|3
6127456|NCT00942734|9753441|FG000|Overall Study|Disease Progression|2
6127457|NCT00942734|9753441|FG000|Overall Study|Physician Decision|1
6127458|NCT00942968|9753488|FG000|Overall Study|Adverse Event|60
6127459|NCT00942968|9753488|FG000|Overall Study|Death|76
6127460|NCT00942968|9753488|FG000|Overall Study|Protocol Violation|9
6127461|NCT00942968|9753488|FG000|Overall Study|Lost to Follow-up|4
6127462|NCT00942968|9753488|FG000|Overall Study|Withdrawal by Subject|44
6127463|NCT00942968|9753488|FG000|Overall Study|Sponsor request|5
6127464|NCT00942968|9753488|FG000|Overall Study|Physician Decision|11
6127465|NCT00942968|9753488|FG000|Overall Study|Progression of disease|12
6127466|NCT00942968|9753488|FG000|Overall Study|Inferior vena cava filter placement|4
6127467|NCT00942968|9753488|FG000|Overall Study|Pulmonary embolism (PE)|1
6219023|NCT01647542|9887439|FG001|Overall Study|Withdrawal by Subject|4
6219024|NCT01647542|9887440|FG002|Overall Study|Withdrawal by Subject|0
6288738|NCT02371980|10003133|FG004|Open-label Period|Pregnancy|0
6219025|NCT01647542|9887438|FG000|Overall Study|Study Termination|64
6127468|NCT00942968|9753488|FG000|Overall Study|Participant required pancreatic biopsy|1
6127469|NCT00942968|9753488|FG000|Overall Study|Deep vein thrombosis (DVT)|2
6127470|NCT00942994|9753494|FG000|Overall Study|Adverse Event|7
6127471|NCT00942994|9753495|FG001|Overall Study|Adverse Event|4
6127472|NCT00942994|9753494|FG000|Overall Study|Abnormal laboratory value(s)|1
6127473|NCT00942994|9753495|FG001|Overall Study|Abnormal laboratory value(s)|0
6127474|NCT00942994|9753494|FG000|Overall Study|Unsatisfactory therapeutic effect|1
6127475|NCT00942994|9753495|FG001|Overall Study|Unsatisfactory therapeutic effect|1
6127476|NCT00942994|9753494|FG000|Overall Study|Patient withdrew consent|5
6127477|NCT00942994|9753495|FG001|Overall Study|Patient withdrew consent|8
6127478|NCT00942994|9753494|FG000|Overall Study|Lost to Follow-up|1
6127479|NCT00942994|9753495|FG001|Overall Study|Lost to Follow-up|4
6127480|NCT00942994|9753494|FG000|Overall Study|Protocol deviation|1
6127481|NCT00942994|9753495|FG001|Overall Study|Protocol deviation|2
6127482|NCT00943072|9753503|FG000|Overall Study|Adverse Event|0
6127483|NCT00943072|9753504|FG001|Overall Study|Adverse Event|3
6288739|NCT02371980|10003129|FG000|Open-label Period|Lack of Efficacy|116
6288740|NCT02371980|10003130|FG001|Open-label Period|Lack of Efficacy|0
6288741|NCT02371980|10003131|FG002|Open-label Period|Lack of Efficacy|0
6127484|NCT00943072|9753503|FG000|Overall Study|Death|0
6127485|NCT00943072|9753504|FG001|Overall Study|Death|2
6127486|NCT00943072|9753503|FG000|Overall Study|Withdrawal by Subject|3
6219026|NCT01647542|9887439|FG001|Overall Study|Study Termination|61
6219027|NCT01647542|9887440|FG002|Overall Study|Study Termination|65
6219028|NCT01647542|9887438|FG000|Overall Study|Lack of Efficacy|1
6219029|NCT01647542|9887439|FG001|Overall Study|Lack of Efficacy|1
6219030|NCT01647542|9887440|FG002|Overall Study|Lack of Efficacy|0
6219031|NCT01647542|9887438|FG000|Overall Study|Death|0
6219032|NCT01647542|9887439|FG001|Overall Study|Death|0
6219033|NCT01647542|9887440|FG002|Overall Study|Death|1
6219034|NCT01647711|9887462|FG000|Overall Study|Progressive disease|6
6219035|NCT01647711|9887463|FG001|Overall Study|Progressive disease|2
6219036|NCT01647711|9887464|FG002|Overall Study|Progressive disease|6
6219037|NCT01647711|9887465|FG003|Overall Study|Progressive disease|8
6219038|NCT01647711|9887466|FG004|Overall Study|Progressive disease|2
6219039|NCT01647711|9887462|FG000|Overall Study|Other adverse event|0
6219040|NCT01647711|9887463|FG001|Overall Study|Other adverse event|0
6219041|NCT01647711|9887464|FG002|Overall Study|Other adverse event|2
6219042|NCT01647711|9887465|FG003|Overall Study|Other adverse event|0
6219043|NCT01647711|9887466|FG004|Overall Study|Other adverse event|2
6219044|NCT01647711|9887462|FG000|Overall Study|Protocol Violation|0
6219045|NCT01647711|9887463|FG001|Overall Study|Protocol Violation|0
6219046|NCT01647711|9887464|FG002|Overall Study|Protocol Violation|0
6219047|NCT01647711|9887465|FG003|Overall Study|Protocol Violation|0
6219048|NCT01647711|9887466|FG004|Overall Study|Protocol Violation|1
6219049|NCT01647711|9887462|FG000|Overall Study|Refused to continue taking medication|0
6219050|NCT01647711|9887463|FG001|Overall Study|Refused to continue taking medication|0
6219051|NCT01647711|9887464|FG002|Overall Study|Refused to continue taking medication|0
6219052|NCT01647711|9887465|FG003|Overall Study|Refused to continue taking medication|2
6219053|NCT01647711|9887466|FG004|Overall Study|Refused to continue taking medication|1
6219054|NCT01647711|9887462|FG000|Overall Study|Other reason not defined|0
6219055|NCT01647711|9887463|FG001|Overall Study|Other reason not defined|1
6219056|NCT01647711|9887464|FG002|Overall Study|Other reason not defined|1
6219057|NCT01647711|9887465|FG003|Overall Study|Other reason not defined|1
6219058|NCT01647711|9887466|FG004|Overall Study|Other reason not defined|0
6219059|NCT01647958|9887508|FG000|Initial Study|Lost to Follow-up|2
6219060|NCT01647958|9887509|FG001|Initial Study|Lost to Follow-up|3
6219061|NCT01647958|9887508|FG000|Continuation Phase|treatment received during Overall Study|39
6219062|NCT01647958|9887509|FG001|Continuation Phase|treatment received during Overall Study|0
6219063|NCT01647958|9887508|FG000|Extended Follow-up Phase|Lost to Follow-up|8
6219064|NCT01647958|9887509|FG001|Extended Follow-up Phase|Lost to Follow-up|0
6219065|NCT01648101|9887527|FG000|Titration Phase (4 Weeks)|Protocol Violation|2
6219066|NCT01648101|9887528|FG001|Titration Phase (4 Weeks)|Protocol Violation|1
6219067|NCT01648101|9887529|FG002|Titration Phase (4 Weeks)|Protocol Violation|2
6219068|NCT01648101|9887527|FG000|Titration Phase (4 Weeks)|Adverse Event|0
6219069|NCT01648101|9887528|FG001|Titration Phase (4 Weeks)|Adverse Event|2
6219070|NCT01648101|9887529|FG002|Titration Phase (4 Weeks)|Adverse Event|3
6219071|NCT01648101|9887527|FG000|Titration Phase (4 Weeks)|Reached Protocol Defined Criteria|0
6219072|NCT01648101|9887528|FG001|Titration Phase (4 Weeks)|Reached Protocol Defined Criteria|0
6219073|NCT01648101|9887529|FG002|Titration Phase (4 Weeks)|Reached Protocol Defined Criteria|1
6219074|NCT01648101|9887527|FG000|Maintenance Phase (12 Weeks)|Withdrew Consent|1
6219075|NCT01648101|9887528|FG001|Maintenance Phase (12 Weeks)|Withdrew Consent|0
6219076|NCT01648101|9887529|FG002|Maintenance Phase (12 Weeks)|Withdrew Consent|1
6219077|NCT01648101|9887527|FG000|Maintenance Phase (12 Weeks)|Lack of Efficacy|1
6219078|NCT01648101|9887528|FG001|Maintenance Phase (12 Weeks)|Lack of Efficacy|0
6219079|NCT01648101|9887529|FG002|Maintenance Phase (12 Weeks)|Lack of Efficacy|1
6127487|NCT00943072|9753504|FG001|Overall Study|Withdrawal by Subject|1
6219080|NCT01648101|9887527|FG000|Maintenance Phase (12 Weeks)|Adverse Event|1
6219081|NCT01648101|9887528|FG001|Maintenance Phase (12 Weeks)|Adverse Event|3
6219082|NCT01648101|9887529|FG002|Maintenance Phase (12 Weeks)|Adverse Event|4
6219083|NCT01648101|9887527|FG000|Transition Phase (4 Weeks)|Adverse Event|4
6127488|NCT00943072|9753503|FG000|Overall Study|Protocol Violation|0
6127489|NCT00943072|9753504|FG001|Overall Study|Protocol Violation|1
6127490|NCT00943072|9753503|FG000|Overall Study|Lost to Follow-up|1
6127491|NCT00943072|9753504|FG001|Overall Study|Lost to Follow-up|2
6127492|NCT00943072|9753503|FG000|Overall Study|Lack of Efficacy|0
6127493|NCT00943072|9753504|FG001|Overall Study|Lack of Efficacy|4
6127494|NCT00943072|9753503|FG000|Overall Study|Other|1
6127495|NCT00943072|9753504|FG001|Overall Study|Other|1
6127496|NCT00943111|9753523|FG000|52-Weeks Primary Analysis Period|Adverse Event|2
6127497|NCT00943111|9753524|FG001|52-Weeks Primary Analysis Period|Adverse Event|1
6127498|NCT00943111|9753525|FG002|52-Weeks Primary Analysis Period|Adverse Event|0
6127499|NCT00943111|9753523|FG000|52-Weeks Primary Analysis Period|Non-Compliance with Study Drug|0
6127500|NCT00943111|9753524|FG001|52-Weeks Primary Analysis Period|Non-Compliance with Study Drug|1
6127501|NCT00943111|9753525|FG002|52-Weeks Primary Analysis Period|Non-Compliance with Study Drug|0
6127502|NCT00943111|9753523|FG000|5 Years Long-term Treatment Period|Transition to commercial eliglustat|0
6127503|NCT00943111|9753524|FG001|5 Years Long-term Treatment Period|Transition to commercial eliglustat|0
6127504|NCT00943111|9753525|FG002|5 Years Long-term Treatment Period|Transition to commercial eliglustat|51
6127505|NCT00943111|9753523|FG000|5 Years Long-term Treatment Period|Adverse Event|0
6127506|NCT00943111|9753524|FG001|5 Years Long-term Treatment Period|Adverse Event|0
6127507|NCT00943111|9753525|FG002|5 Years Long-term Treatment Period|Adverse Event|9
6127508|NCT00943111|9753523|FG000|5 Years Long-term Treatment Period|Withdrawal by Subject|0
6127509|NCT00943111|9753524|FG001|5 Years Long-term Treatment Period|Withdrawal by Subject|0
6127510|NCT00943111|9753525|FG002|5 Years Long-term Treatment Period|Withdrawal by Subject|8
6127511|NCT00943111|9753523|FG000|5 Years Long-term Treatment Period|Pregnancy|0
6127512|NCT00943111|9753524|FG001|5 Years Long-term Treatment Period|Pregnancy|0
6127513|NCT00943111|9753525|FG002|5 Years Long-term Treatment Period|Pregnancy|4
6127514|NCT00943111|9753523|FG000|5 Years Long-term Treatment Period|Lost to Follow-up|0
6127515|NCT00943111|9753524|FG001|5 Years Long-term Treatment Period|Lost to Follow-up|0
6127516|NCT00943111|9753525|FG002|5 Years Long-term Treatment Period|Lost to Follow-up|1
6127517|NCT00943111|9753523|FG000|5 Years Long-term Treatment Period|Other than specified above|0
6127518|NCT00943111|9753524|FG001|5 Years Long-term Treatment Period|Other than specified above|0
6127519|NCT00943111|9753525|FG002|5 Years Long-term Treatment Period|Other than specified above|2
6127520|NCT00943124|9753532|FG000|Period 1|Withdrawal by Subject|1
6127521|NCT00943124|9753533|FG001|Period 1|Withdrawal by Subject|1
6127522|NCT00943124|9753532|FG000|Period 1|Did Not Follow Study Procedures|1
6127523|NCT00943124|9753533|FG001|Period 1|Did Not Follow Study Procedures|0
6127524|NCT00943124|9753532|FG000|Period 1|Personal Reasons|0
6127525|NCT00943124|9753533|FG001|Period 1|Personal Reasons|1
6127526|NCT00943306|9753570|FG000|Overall Study|Physician Decision|1
6127527|NCT00943306|9753570|FG000|Overall Study|Death|1
6127528|NCT00943306|9753570|FG000|Overall Study|Sponsor decision due to non-compliance|1
6127529|NCT00943319|9753574|FG000|Overall Study|Death|1
6127530|NCT00943384|9753578|FG000|Overall Study|Dispositioned prior to treatment|23
6127531|NCT00943384|9753578|FG000|Overall Study|Treated off protocol-protocol violation|5
6127532|NCT00943384|9753578|FG000|Overall Study|Lost to Follow-up|16
6127533|NCT00943384|9753578|FG000|Overall Study|Withdrawal by Subject|5
6127534|NCT00943579|9753602|FG000|Overall Study|Adverse Event|4
6127535|NCT00943579|9753603|FG001|Overall Study|Adverse Event|3
6127536|NCT00943579|9753602|FG000|Overall Study|Lack of Efficacy|2
6127537|NCT00943579|9753603|FG001|Overall Study|Lack of Efficacy|2
6127538|NCT00943592|9753612|FG000|Overall Study|Death|3
6127539|NCT00943670|9753625|FG000|Single-agent Trastuzumab Emtansine|Physician Decision|2
6219084|NCT01648101|9887528|FG001|Transition Phase (4 Weeks)|Adverse Event|3
6219085|NCT01648101|9887529|FG002|Transition Phase (4 Weeks)|Adverse Event|2
6219086|NCT01648101|9887527|FG000|Transition Phase (4 Weeks)|Lack of Efficacy|0
6219087|NCT01648101|9887528|FG001|Transition Phase (4 Weeks)|Lack of Efficacy|2
6219088|NCT01648101|9887529|FG002|Transition Phase (4 Weeks)|Lack of Efficacy|0
6219089|NCT01648101|9887527|FG000|Transition Phase (4 Weeks)|Withdrawal by Subject|0
6219090|NCT01648101|9887528|FG001|Transition Phase (4 Weeks)|Withdrawal by Subject|0
6219091|NCT01648101|9887529|FG002|Transition Phase (4 Weeks)|Withdrawal by Subject|2
6219092|NCT01648101|9887527|FG000|Transition Phase (4 Weeks)|Study Terminated|1
6219093|NCT01648101|9887528|FG001|Transition Phase (4 Weeks)|Study Terminated|0
6219094|NCT01648101|9887529|FG002|Transition Phase (4 Weeks)|Study Terminated|0
6219095|NCT01648101|9887527|FG000|Taper/Follow-up Phase (4 Weeks)|Lack of Efficacy|0
6219096|NCT01648101|9887528|FG001|Taper/Follow-up Phase (4 Weeks)|Lack of Efficacy|1
6288742|NCT02371980|10003132|FG003|Open-label Period|Lack of Efficacy|0
6288743|NCT02371980|10003133|FG004|Open-label Period|Lack of Efficacy|0
6288744|NCT02371980|10003129|FG000|Open-label Period|Did not Meet Randomization Criteria|162
6288745|NCT02371980|10003130|FG001|Open-label Period|Did not Meet Randomization Criteria|0
6288746|NCT02371980|10003131|FG002|Open-label Period|Did not Meet Randomization Criteria|0
6288747|NCT02371980|10003132|FG003|Open-label Period|Did not Meet Randomization Criteria|0
6288748|NCT02371980|10003133|FG004|Open-label Period|Did not Meet Randomization Criteria|0
6288749|NCT02371980|10003129|FG000|Open-label Period|Reason not Specified|9
6288750|NCT02371980|10003130|FG001|Open-label Period|Reason not Specified|0
6288751|NCT02371980|10003131|FG002|Open-label Period|Reason not Specified|0
6288752|NCT02371980|10003132|FG003|Open-label Period|Reason not Specified|0
6219097|NCT01648101|9887529|FG002|Taper/Follow-up Phase (4 Weeks)|Lack of Efficacy|0
6127540|NCT00943670|9753625|FG000|Single-agent Trastuzumab Emtansine|Withdrawal by Subject|3
6127541|NCT00943670|9753625|FG000|Single-agent Trastuzumab Emtansine|Systemic progression|15
6127542|NCT00943670|9753625|FG000|Single-agent Trastuzumab Emtansine|Adverse Event|2
6127543|NCT00943670|9753625|FG000|Single-agent Trastuzumab Emtansine|Early progressive disease|20
6127544|NCT00943670|9753625|FG000|Trastuzumab Emtansine + Pertuzumab|Physician Decision|1
6127545|NCT00943670|9753625|FG000|Trastuzumab Emtansine + Pertuzumab|Withdrawal by Subject|4
6127546|NCT00943670|9753625|FG000|Trastuzumab Emtansine + Pertuzumab|Systemic progression|6
6127547|NCT00943670|9753625|FG000|Trastuzumab Emtansine + Pertuzumab|Progression of brain metastases|2
6127548|NCT00943670|9753625|FG000|Trastuzumab Emtansine + Pertuzumab|Adverse Event|5
6127549|NCT00943735|9753640|FG000|Overall Study|Adverse Event|12
6127550|NCT00943735|9753640|FG000|Overall Study|Withdrawal by Subject|8
6127551|NCT00943735|9753640|FG000|Overall Study|Death|1
6127552|NCT00943735|9753640|FG000|Overall Study|Other|8
6127553|NCT00943735|9753640|FG000|Overall Study|Other|3
6127554|NCT00943761|9753646|FG000|Overall Study|Lost to Follow-up|2
6127555|NCT00943761|9753647|FG001|Overall Study|Lost to Follow-up|0
6127556|NCT00943761|9753646|FG000|Overall Study|Withdrawal by Subject|2
6127557|NCT00943761|9753647|FG001|Overall Study|Withdrawal by Subject|1
6127558|NCT00943787|9753653|FG000|Overall Study|Physician Decision|4
6127559|NCT00943787|9753653|FG000|Overall Study|Withdrawal by Subject|3
6127560|NCT00943826|9753663|FG000|Concurrent Phase|Adverse Event|50
6127561|NCT00943826|9753664|FG001|Concurrent Phase|Adverse Event|27
6127562|NCT00943826|9753663|FG000|Concurrent Phase|Withdrew consent|3
6127563|NCT00943826|9753664|FG001|Concurrent Phase|Withdrew consent|7
6127564|NCT00943826|9753663|FG000|Concurrent Phase|Refused treatment/Did not cooperate|5
6127565|NCT00943826|9753664|FG001|Concurrent Phase|Refused treatment/Did not cooperate|7
6127566|NCT00943826|9753663|FG000|Concurrent Phase|Administrative reasons|2
6127567|NCT00943826|9753664|FG001|Concurrent Phase|Administrative reasons|1
6127568|NCT00943826|9753663|FG000|Concurrent Phase|Protocol Violation|1
6127569|NCT00943826|9753664|FG001|Concurrent Phase|Protocol Violation|0
6127570|NCT00943826|9753663|FG000|Maintenance Phase|Adverse Event|31
6127571|NCT00943826|9753664|FG001|Maintenance Phase|Adverse Event|30
6127572|NCT00943826|9753663|FG000|Maintenance Phase|Withdrew consent|2
6127573|NCT00943826|9753664|FG001|Maintenance Phase|Withdrew consent|4
6127574|NCT00943826|9753663|FG000|Maintenance Phase|Refused treatment/Did not cooperate|6
6127575|NCT00943826|9753664|FG001|Maintenance Phase|Refused treatment/Did not cooperate|3
6127576|NCT00943826|9753663|FG000|Maintenance Phase|Administrative reasons|4
6127577|NCT00943826|9753664|FG001|Maintenance Phase|Administrative reasons|1
6127578|NCT00943826|9753663|FG000|Maintenance Phase|Failure to return|0
6127579|NCT00943826|9753664|FG001|Maintenance Phase|Failure to return|1
6127580|NCT00943826|9753663|FG000|Monotherapy Phase|Adverse Event|42
6127581|NCT00943826|9753664|FG001|Monotherapy Phase|Adverse Event|5
6127582|NCT00943826|9753663|FG000|Monotherapy Phase|Administrative reasons|11
6127583|NCT00943826|9753664|FG001|Monotherapy Phase|Administrative reasons|5
6127584|NCT00943826|9753663|FG000|Monotherapy Phase|Refused treatment/ Did not cooperate|8
6127585|NCT00943826|9753664|FG001|Monotherapy Phase|Refused treatment/ Did not cooperate|2
6127586|NCT00943826|9753663|FG000|Monotherapy Phase|Withdrew Consent|2
6127587|NCT00943826|9753664|FG001|Monotherapy Phase|Withdrew Consent|3
6127588|NCT00943826|9753663|FG000|Monotherapy Phase|Failure to return|2
6127589|NCT00943826|9753664|FG001|Monotherapy Phase|Failure to return|1
6127590|NCT00943826|9753663|FG000|After Primary Overall Survival Analysis|Adverse Event|11
6127591|NCT00943826|9753664|FG001|After Primary Overall Survival Analysis|Adverse Event|0
6127592|NCT00943826|9753663|FG000|After Primary Overall Survival Analysis|Administrative reasons|10
6127593|NCT00943826|9753664|FG001|After Primary Overall Survival Analysis|Administrative reasons|16
6219098|NCT01648140|9887545|FG000|Overall Study|Physician Decision|1
6219099|NCT01648140|9887546|FG001|Overall Study|Physician Decision|0
6219100|NCT01648140|9887547|FG002|Overall Study|Physician Decision|0
6219101|NCT01648140|9887548|FG003|Overall Study|Physician Decision|0
6219102|NCT01648140|9887545|FG000|Overall Study|Lack of Efficacy|4
6219103|NCT01648140|9887546|FG001|Overall Study|Lack of Efficacy|7
6219104|NCT01648140|9887547|FG002|Overall Study|Lack of Efficacy|1
6219105|NCT01648140|9887548|FG003|Overall Study|Lack of Efficacy|0
6219106|NCT01648140|9887545|FG000|Overall Study|Adverse Event|3
6219107|NCT01648140|9887546|FG001|Overall Study|Adverse Event|1
6288753|NCT02371980|10003133|FG004|Open-label Period|Reason not Specified|0
6288754|NCT02371980|10003129|FG000|Double-blind Period|Pretreatment Event/Adverse Event|0
6288755|NCT02371980|10003130|FG001|Double-blind Period|Pretreatment Event/Adverse Event|4
6288756|NCT02371980|10003131|FG002|Double-blind Period|Pretreatment Event/Adverse Event|3
6288757|NCT02371980|10003132|FG003|Double-blind Period|Pretreatment Event/Adverse Event|2
6288758|NCT02371980|10003133|FG004|Double-blind Period|Pretreatment Event/Adverse Event|9
6288759|NCT02371980|10003129|FG000|Double-blind Period|Significant Protocol Deviation|0
6288760|NCT02371980|10003130|FG001|Double-blind Period|Significant Protocol Deviation|2
6288761|NCT02371980|10003131|FG002|Double-blind Period|Significant Protocol Deviation|7
6288762|NCT02371980|10003132|FG003|Double-blind Period|Significant Protocol Deviation|3
6288763|NCT02371980|10003133|FG004|Double-blind Period|Significant Protocol Deviation|3
6288764|NCT02371980|10003129|FG000|Double-blind Period|Noncompliance with Study Drug|0
6288765|NCT02371980|10003130|FG001|Double-blind Period|Noncompliance with Study Drug|1
6288766|NCT02371980|10003131|FG002|Double-blind Period|Noncompliance with Study Drug|2
6127594|NCT00943826|9753663|FG000|After Primary Overall Survival Analysis|Progression of Disease|2
6127595|NCT00943826|9753664|FG001|After Primary Overall Survival Analysis|Progression of Disease|4
6127596|NCT00943826|9753663|FG000|After Primary Overall Survival Analysis|Withdrew Consent|4
6127597|NCT00943826|9753664|FG001|After Primary Overall Survival Analysis|Withdrew Consent|0
6127598|NCT00943917|9753707|FG000|Stage I|Adverse Event|1
6127599|NCT00943917|9753708|FG001|Stage I|Adverse Event|2
6127600|NCT00943917|9753709|FG002|Stage I|Adverse Event|2
6127601|NCT00943917|9753710|FG003|Stage I|Adverse Event|0
6127602|NCT00943917|9753711|FG004|Stage I|Adverse Event|0
6127603|NCT00943917|9753712|FG005|Stage I|Adverse Event|0
6127604|NCT00943917|9753713|FG006|Stage I|Adverse Event|0
6127605|NCT00943917|9753714|FG007|Stage I|Adverse Event|0
6219108|NCT01648140|9887547|FG002|Overall Study|Adverse Event|2
6219109|NCT01648140|9887548|FG003|Overall Study|Adverse Event|0
6219110|NCT01648140|9887545|FG000|Overall Study|Withdrawal by Subject|2
6127606|NCT00943917|9753715|FG008|Stage I|Adverse Event|0
6127607|NCT00943917|9753716|FG009|Stage I|Adverse Event|0
6127608|NCT00943917|9753717|FG010|Stage I|Adverse Event|0
6127609|NCT00943917|9753718|FG011|Stage I|Adverse Event|0
6127610|NCT00943917|9753719|FG012|Stage I|Adverse Event|0
6127611|NCT00943917|9753720|FG013|Stage I|Adverse Event|0
6127612|NCT00943917|9753721|FG014|Stage I|Adverse Event|0
6127613|NCT00943917|9753707|FG000|Stage I|Lost to Follow-up|0
6127614|NCT00943917|9753708|FG001|Stage I|Lost to Follow-up|0
6127615|NCT00943917|9753709|FG002|Stage I|Lost to Follow-up|1
6127616|NCT00943917|9753710|FG003|Stage I|Lost to Follow-up|0
6127617|NCT00943917|9753711|FG004|Stage I|Lost to Follow-up|0
6127618|NCT00943917|9753712|FG005|Stage I|Lost to Follow-up|0
6127619|NCT00943917|9753713|FG006|Stage I|Lost to Follow-up|0
6127620|NCT00943917|9753714|FG007|Stage I|Lost to Follow-up|0
6127621|NCT00943917|9753715|FG008|Stage I|Lost to Follow-up|0
6127622|NCT00943917|9753716|FG009|Stage I|Lost to Follow-up|0
6127623|NCT00943917|9753717|FG010|Stage I|Lost to Follow-up|0
6127624|NCT00943917|9753718|FG011|Stage I|Lost to Follow-up|0
6127625|NCT00943917|9753719|FG012|Stage I|Lost to Follow-up|0
6127626|NCT00943917|9753720|FG013|Stage I|Lost to Follow-up|0
6127627|NCT00943917|9753721|FG014|Stage I|Lost to Follow-up|0
6127628|NCT00943917|9753707|FG000|Stage I|hyperglycemia|0
6127629|NCT00943917|9753708|FG001|Stage I|hyperglycemia|0
6127630|NCT00943917|9753709|FG002|Stage I|hyperglycemia|1
6127631|NCT00943917|9753710|FG003|Stage I|hyperglycemia|0
6219111|NCT01648140|9887546|FG001|Overall Study|Withdrawal by Subject|3
6219112|NCT01648140|9887547|FG002|Overall Study|Withdrawal by Subject|3
6219113|NCT01648140|9887548|FG003|Overall Study|Withdrawal by Subject|2
6219114|NCT01648140|9887545|FG000|Overall Study|Lost to Follow-up|2
6219115|NCT01648140|9887546|FG001|Overall Study|Lost to Follow-up|1
6219116|NCT01648140|9887547|FG002|Overall Study|Lost to Follow-up|2
6219117|NCT01648140|9887548|FG003|Overall Study|Lost to Follow-up|0
6219118|NCT01648166|9887569|FG000|Overall Study|inadequate toenail samples|53
6219119|NCT01648166|9887570|FG001|Overall Study|inadequate toenail samples|100
6288767|NCT02371980|10003132|FG003|Double-blind Period|Noncompliance with Study Drug|2
6288768|NCT02371980|10003133|FG004|Double-blind Period|Noncompliance with Study Drug|3
6288769|NCT02371980|10003129|FG000|Double-blind Period|Lost to Follow-up|0
6288770|NCT02371980|10003130|FG001|Double-blind Period|Lost to Follow-up|8
6288771|NCT02371980|10003131|FG002|Double-blind Period|Lost to Follow-up|8
6288772|NCT02371980|10003132|FG003|Double-blind Period|Lost to Follow-up|6
6288773|NCT02371980|10003133|FG004|Double-blind Period|Lost to Follow-up|5
6288774|NCT02371980|10003129|FG000|Double-blind Period|Voluntary Withdrawal|0
6288775|NCT02371980|10003130|FG001|Double-blind Period|Voluntary Withdrawal|12
6288776|NCT02371980|10003131|FG002|Double-blind Period|Voluntary Withdrawal|8
6288777|NCT02371980|10003132|FG003|Double-blind Period|Voluntary Withdrawal|9
6288778|NCT02371980|10003133|FG004|Double-blind Period|Voluntary Withdrawal|11
6288779|NCT02371980|10003129|FG000|Double-blind Period|Relapse|0
6288780|NCT02371980|10003130|FG001|Double-blind Period|Relapse|50
6288781|NCT02371980|10003131|FG002|Double-blind Period|Relapse|25
6288782|NCT02371980|10003132|FG003|Double-blind Period|Relapse|25
6288783|NCT02371980|10003133|FG004|Double-blind Period|Relapse|26
6288784|NCT02371980|10003129|FG000|Double-blind Period|Reason not Specified|0
6288785|NCT02371980|10003130|FG001|Double-blind Period|Reason not Specified|3
6288786|NCT02371980|10003131|FG002|Double-blind Period|Reason not Specified|3
6288787|NCT02371980|10003132|FG003|Double-blind Period|Reason not Specified|2
6288788|NCT02371980|10003133|FG004|Double-blind Period|Reason not Specified|1
6288789|NCT02371980|10003129|FG000|Double-blind Period|Missing|0
6288790|NCT02371980|10003130|FG001|Double-blind Period|Missing|1
6288791|NCT02371980|10003131|FG002|Double-blind Period|Missing|0
6288792|NCT02371980|10003132|FG003|Double-blind Period|Missing|0
6288793|NCT02371980|10003133|FG004|Double-blind Period|Missing|0
6288794|NCT02372006|10003147|FG000|Overall Study|Progressive disease|8
6288795|NCT02372006|10003148|FG001|Overall Study|Progressive disease|7
6288796|NCT02372006|10003149|FG002|Overall Study|Progressive disease|34
6288797|NCT02372006|10003147|FG000|Overall Study|Dose limiting toxicity|0
6127632|NCT00943917|9753711|FG004|Stage I|hyperglycemia|0
6127633|NCT00943917|9753712|FG005|Stage I|hyperglycemia|0
6127634|NCT00943917|9753713|FG006|Stage I|hyperglycemia|0
6127635|NCT00943917|9753714|FG007|Stage I|hyperglycemia|0
6127636|NCT00943917|9753715|FG008|Stage I|hyperglycemia|0
6127637|NCT00943917|9753716|FG009|Stage I|hyperglycemia|0
6288798|NCT02372006|10003148|FG001|Overall Study|Dose limiting toxicity|1
6127638|NCT00943917|9753717|FG010|Stage I|hyperglycemia|0
6127639|NCT00943917|9753718|FG011|Stage I|hyperglycemia|0
6127640|NCT00943917|9753719|FG012|Stage I|hyperglycemia|0
6127641|NCT00943917|9753720|FG013|Stage I|hyperglycemia|0
6127642|NCT00943917|9753721|FG014|Stage I|hyperglycemia|0
6127643|NCT00943917|9753707|FG000|Stage I|A1C elevation|1
6127644|NCT00943917|9753708|FG001|Stage I|A1C elevation|0
6127645|NCT00943917|9753709|FG002|Stage I|A1C elevation|0
6127646|NCT00943917|9753710|FG003|Stage I|A1C elevation|0
6127647|NCT00943917|9753711|FG004|Stage I|A1C elevation|0
6127648|NCT00943917|9753712|FG005|Stage I|A1C elevation|0
6127649|NCT00943917|9753713|FG006|Stage I|A1C elevation|0
6127650|NCT00943917|9753714|FG007|Stage I|A1C elevation|0
6127651|NCT00943917|9753715|FG008|Stage I|A1C elevation|0
6127652|NCT00943917|9753716|FG009|Stage I|A1C elevation|0
6127653|NCT00943917|9753717|FG010|Stage I|A1C elevation|0
6127654|NCT00943917|9753718|FG011|Stage I|A1C elevation|0
6127655|NCT00943917|9753719|FG012|Stage I|A1C elevation|0
6127656|NCT00943917|9753720|FG013|Stage I|A1C elevation|0
6127657|NCT00943917|9753721|FG014|Stage I|A1C elevation|0
6127658|NCT00943917|9753707|FG000|Stage I|Withdrawal by Subject|2
6127659|NCT00943917|9753708|FG001|Stage I|Withdrawal by Subject|1
6127660|NCT00943917|9753709|FG002|Stage I|Withdrawal by Subject|2
6127661|NCT00943917|9753710|FG003|Stage I|Withdrawal by Subject|0
6127662|NCT00943917|9753711|FG004|Stage I|Withdrawal by Subject|0
6127663|NCT00943917|9753712|FG005|Stage I|Withdrawal by Subject|0
6127664|NCT00943917|9753713|FG006|Stage I|Withdrawal by Subject|0
6127665|NCT00943917|9753714|FG007|Stage I|Withdrawal by Subject|0
6127666|NCT00943917|9753715|FG008|Stage I|Withdrawal by Subject|0
6127667|NCT00943917|9753716|FG009|Stage I|Withdrawal by Subject|0
6127668|NCT00943917|9753717|FG010|Stage I|Withdrawal by Subject|0
6127669|NCT00943917|9753718|FG011|Stage I|Withdrawal by Subject|0
6127670|NCT00943917|9753719|FG012|Stage I|Withdrawal by Subject|0
6127671|NCT00943917|9753720|FG013|Stage I|Withdrawal by Subject|0
6127672|NCT00943917|9753721|FG014|Stage I|Withdrawal by Subject|0
6127673|NCT00943917|9753707|FG000|Stage II|Adverse Event|0
6127674|NCT00943917|9753708|FG001|Stage II|Adverse Event|0
6127675|NCT00943917|9753709|FG002|Stage II|Adverse Event|0
6127676|NCT00943917|9753710|FG003|Stage II|Adverse Event|0
6127677|NCT00943917|9753711|FG004|Stage II|Adverse Event|0
6127678|NCT00943917|9753712|FG005|Stage II|Adverse Event|1
6127679|NCT00943917|9753713|FG006|Stage II|Adverse Event|3
6127680|NCT00943917|9753714|FG007|Stage II|Adverse Event|0
6127681|NCT00943917|9753715|FG008|Stage II|Adverse Event|1
6127682|NCT00943917|9753716|FG009|Stage II|Adverse Event|0
6127683|NCT00943917|9753717|FG010|Stage II|Adverse Event|0
6127684|NCT00943917|9753718|FG011|Stage II|Adverse Event|0
6127685|NCT00943917|9753719|FG012|Stage II|Adverse Event|0
6127686|NCT00943917|9753720|FG013|Stage II|Adverse Event|0
6127687|NCT00943917|9753721|FG014|Stage II|Adverse Event|0
6127688|NCT00943917|9753707|FG000|Stage II|Withdrawal by Subject|0
6127689|NCT00943917|9753708|FG001|Stage II|Withdrawal by Subject|0
6127690|NCT00943917|9753709|FG002|Stage II|Withdrawal by Subject|0
6127691|NCT00943917|9753710|FG003|Stage II|Withdrawal by Subject|0
6127692|NCT00943917|9753711|FG004|Stage II|Withdrawal by Subject|0
6127693|NCT00943917|9753712|FG005|Stage II|Withdrawal by Subject|1
6127694|NCT00943917|9753713|FG006|Stage II|Withdrawal by Subject|0
6127695|NCT00943917|9753714|FG007|Stage II|Withdrawal by Subject|0
6127696|NCT00943917|9753715|FG008|Stage II|Withdrawal by Subject|0
6127697|NCT00943917|9753716|FG009|Stage II|Withdrawal by Subject|0
6127698|NCT00943917|9753717|FG010|Stage II|Withdrawal by Subject|0
6127699|NCT00943917|9753718|FG011|Stage II|Withdrawal by Subject|0
6127700|NCT00943917|9753719|FG012|Stage II|Withdrawal by Subject|0
6127701|NCT00943917|9753720|FG013|Stage II|Withdrawal by Subject|0
6127702|NCT00943917|9753721|FG014|Stage II|Withdrawal by Subject|0
6127703|NCT00943917|9753707|FG000|Stage II|Pregnancy|0
6127704|NCT00943917|9753708|FG001|Stage II|Pregnancy|0
6127705|NCT00943917|9753709|FG002|Stage II|Pregnancy|0
6127706|NCT00943917|9753710|FG003|Stage II|Pregnancy|0
6127707|NCT00943917|9753711|FG004|Stage II|Pregnancy|0
6127708|NCT00943917|9753712|FG005|Stage II|Pregnancy|1
6127709|NCT00943917|9753713|FG006|Stage II|Pregnancy|0
6127710|NCT00943917|9753714|FG007|Stage II|Pregnancy|0
6127711|NCT00943917|9753715|FG008|Stage II|Pregnancy|0
6127712|NCT00943917|9753716|FG009|Stage II|Pregnancy|0
6127713|NCT00943917|9753717|FG010|Stage II|Pregnancy|0
6127714|NCT00943917|9753718|FG011|Stage II|Pregnancy|0
6127715|NCT00943917|9753719|FG012|Stage II|Pregnancy|0
6127716|NCT00943917|9753720|FG013|Stage II|Pregnancy|0
6127717|NCT00943917|9753721|FG014|Stage II|Pregnancy|0
6127718|NCT00943917|9753707|FG000|Stage II Continuation|Adverse Event|0
6127719|NCT00943917|9753708|FG001|Stage II Continuation|Adverse Event|0
6127720|NCT00943917|9753709|FG002|Stage II Continuation|Adverse Event|0
6127721|NCT00943917|9753710|FG003|Stage II Continuation|Adverse Event|0
6127722|NCT00943917|9753711|FG004|Stage II Continuation|Adverse Event|0
6127723|NCT00943917|9753712|FG005|Stage II Continuation|Adverse Event|0
6127724|NCT00943917|9753713|FG006|Stage II Continuation|Adverse Event|0
6127725|NCT00943917|9753714|FG007|Stage II Continuation|Adverse Event|0
6127726|NCT00943917|9753715|FG008|Stage II Continuation|Adverse Event|0
6127727|NCT00943917|9753716|FG009|Stage II Continuation|Adverse Event|0
6127728|NCT00943917|9753717|FG010|Stage II Continuation|Adverse Event|0
6127729|NCT00943917|9753718|FG011|Stage II Continuation|Adverse Event|1
6127730|NCT00943917|9753719|FG012|Stage II Continuation|Adverse Event|2
6127731|NCT00943917|9753720|FG013|Stage II Continuation|Adverse Event|1
6127732|NCT00943917|9753721|FG014|Stage II Continuation|Adverse Event|1
6127733|NCT00943917|9753707|FG000|Stage II Continuation|Withdrawal by Subject|0
6127734|NCT00943917|9753708|FG001|Stage II Continuation|Withdrawal by Subject|0
6127735|NCT00943917|9753709|FG002|Stage II Continuation|Withdrawal by Subject|0
6127736|NCT00943917|9753710|FG003|Stage II Continuation|Withdrawal by Subject|0
6127737|NCT00943917|9753711|FG004|Stage II Continuation|Withdrawal by Subject|0
6127738|NCT00943917|9753712|FG005|Stage II Continuation|Withdrawal by Subject|0
6127739|NCT00943917|9753713|FG006|Stage II Continuation|Withdrawal by Subject|0
6127740|NCT00943917|9753714|FG007|Stage II Continuation|Withdrawal by Subject|0
6127741|NCT00943917|9753715|FG008|Stage II Continuation|Withdrawal by Subject|0
6219120|NCT01648283|9887576|FG000|Overall Study|Withdrawal by Subject|14
6219121|NCT01648348|9887618|FG000|Overall Study|Cancel|1
6219122|NCT01648348|9887619|FG001|Overall Study|Cancel|0
6219123|NCT01648348|9887620|FG002|Overall Study|Cancel|0
6219124|NCT01648348|9887621|FG003|Overall Study|Cancel|0
6219125|NCT01648348|9887622|FG004|Overall Study|Cancel|3
6219126|NCT01648348|9887623|FG005|Overall Study|Cancel|6
6219127|NCT01648348|9887618|FG000|Overall Study|Replaced for MTD analysis|1
6219128|NCT01648348|9887619|FG001|Overall Study|Replaced for MTD analysis|0
6219129|NCT01648348|9887620|FG002|Overall Study|Replaced for MTD analysis|1
6219130|NCT01648348|9887621|FG003|Overall Study|Replaced for MTD analysis|0
6219131|NCT01648348|9887622|FG004|Overall Study|Replaced for MTD analysis|0
6219132|NCT01648348|9887623|FG005|Overall Study|Replaced for MTD analysis|0
6219133|NCT01648582|9887656|FG000|Overall Study|Adverse Event|6
6219134|NCT01648582|9887657|FG001|Overall Study|Adverse Event|11
6219135|NCT01648582|9887658|FG002|Overall Study|Adverse Event|2
6219136|NCT01648582|9887656|FG000|Overall Study|Lost to Follow-up|9
6219137|NCT01648582|9887657|FG001|Overall Study|Lost to Follow-up|6
6219138|NCT01648582|9887658|FG002|Overall Study|Lost to Follow-up|8
6219139|NCT01648582|9887656|FG000|Overall Study|Protocol Violation|1
6219140|NCT01648582|9887657|FG001|Overall Study|Protocol Violation|2
6219141|NCT01648582|9887658|FG002|Overall Study|Protocol Violation|1
6219142|NCT01648582|9887656|FG000|Overall Study|Withdrawal by Subject|15
6219143|NCT01648582|9887657|FG001|Overall Study|Withdrawal by Subject|17
6288799|NCT02372006|10003149|FG002|Overall Study|Dose limiting toxicity|0
6288800|NCT02372006|10003147|FG000|Overall Study|Adverse Event|0
6288801|NCT02372006|10003148|FG001|Overall Study|Adverse Event|0
6288802|NCT02372006|10003149|FG002|Overall Study|Adverse Event|3
6288803|NCT02372006|10003147|FG000|Overall Study|Withdrawal by Subject|0
6288804|NCT02372006|10003148|FG001|Overall Study|Withdrawal by Subject|1
6288805|NCT02372006|10003149|FG002|Overall Study|Withdrawal by Subject|1
6288806|NCT02372006|10003147|FG000|Overall Study|Other reason for not completing|0
6288807|NCT02372006|10003148|FG001|Overall Study|Other reason for not completing|0
6288808|NCT02372006|10003149|FG002|Overall Study|Other reason for not completing|1
6288809|NCT02372058|10003158|FG000|Overall Study|Withdrawal by Subject|3
6288810|NCT02372071|10003164|FG000|Overall Study|Protocol Violation|18
6288811|NCT02372136|10003180|FG000|Overall Study|Death|3
6288812|NCT02372136|10003181|FG001|Overall Study|Death|1
6288813|NCT02372253|10003191|FG000|Overall Study|Non Compliance|2
6288814|NCT02372253|10003192|FG001|Overall Study|Non Compliance|0
6219144|NCT01648582|9887658|FG002|Overall Study|Withdrawal by Subject|17
6127742|NCT00943917|9753716|FG009|Stage II Continuation|Withdrawal by Subject|0
6127743|NCT00943917|9753717|FG010|Stage II Continuation|Withdrawal by Subject|0
6127744|NCT00943917|9753718|FG011|Stage II Continuation|Withdrawal by Subject|0
6127745|NCT00943917|9753719|FG012|Stage II Continuation|Withdrawal by Subject|0
6127746|NCT00943917|9753720|FG013|Stage II Continuation|Withdrawal by Subject|1
6127747|NCT00943917|9753721|FG014|Stage II Continuation|Withdrawal by Subject|3
6127748|NCT00943917|9753707|FG000|Stage II Continuation|Protocol Violation|0
6127749|NCT00943917|9753708|FG001|Stage II Continuation|Protocol Violation|0
6127750|NCT00943917|9753709|FG002|Stage II Continuation|Protocol Violation|0
6127751|NCT00943917|9753710|FG003|Stage II Continuation|Protocol Violation|0
6127752|NCT00943917|9753711|FG004|Stage II Continuation|Protocol Violation|0
6127753|NCT00943917|9753712|FG005|Stage II Continuation|Protocol Violation|0
6127754|NCT00943917|9753713|FG006|Stage II Continuation|Protocol Violation|0
6127755|NCT00943917|9753714|FG007|Stage II Continuation|Protocol Violation|0
6127756|NCT00943917|9753715|FG008|Stage II Continuation|Protocol Violation|0
6127757|NCT00943917|9753716|FG009|Stage II Continuation|Protocol Violation|1
6127758|NCT00943917|9753717|FG010|Stage II Continuation|Protocol Violation|0
6127759|NCT00943917|9753718|FG011|Stage II Continuation|Protocol Violation|1
6127760|NCT00943917|9753719|FG012|Stage II Continuation|Protocol Violation|0
6127761|NCT00943917|9753720|FG013|Stage II Continuation|Protocol Violation|0
6127762|NCT00943917|9753721|FG014|Stage II Continuation|Protocol Violation|0
6127763|NCT00943917|9753707|FG000|Stage II Continuation|hypoglycemia|0
6127764|NCT00943917|9753708|FG001|Stage II Continuation|hypoglycemia|0
6127765|NCT00943917|9753709|FG002|Stage II Continuation|hypoglycemia|0
6127766|NCT00943917|9753710|FG003|Stage II Continuation|hypoglycemia|0
6127767|NCT00943917|9753711|FG004|Stage II Continuation|hypoglycemia|0
6127768|NCT00943917|9753712|FG005|Stage II Continuation|hypoglycemia|0
6127769|NCT00943917|9753713|FG006|Stage II Continuation|hypoglycemia|0
6127770|NCT00943917|9753714|FG007|Stage II Continuation|hypoglycemia|0
6127771|NCT00943917|9753715|FG008|Stage II Continuation|hypoglycemia|0
6127772|NCT00943917|9753716|FG009|Stage II Continuation|hypoglycemia|0
6127773|NCT00943917|9753717|FG010|Stage II Continuation|hypoglycemia|0
6127774|NCT00943917|9753718|FG011|Stage II Continuation|hypoglycemia|0
6127775|NCT00943917|9753719|FG012|Stage II Continuation|hypoglycemia|1
6127776|NCT00943917|9753720|FG013|Stage II Continuation|hypoglycemia|0
6127777|NCT00943917|9753721|FG014|Stage II Continuation|hypoglycemia|0
6127778|NCT00943917|9753707|FG000|Stage II Continuation|A1C elevation|0
6127779|NCT00943917|9753708|FG001|Stage II Continuation|A1C elevation|0
6127780|NCT00943917|9753709|FG002|Stage II Continuation|A1C elevation|0
6127781|NCT00943917|9753710|FG003|Stage II Continuation|A1C elevation|0
6127782|NCT00943917|9753711|FG004|Stage II Continuation|A1C elevation|0
6127783|NCT00943917|9753712|FG005|Stage II Continuation|A1C elevation|0
6127784|NCT00943917|9753713|FG006|Stage II Continuation|A1C elevation|0
6127785|NCT00943917|9753714|FG007|Stage II Continuation|A1C elevation|0
6127786|NCT00943917|9753715|FG008|Stage II Continuation|A1C elevation|0
6127787|NCT00943917|9753716|FG009|Stage II Continuation|A1C elevation|0
6127788|NCT00943917|9753717|FG010|Stage II Continuation|A1C elevation|0
6127789|NCT00943917|9753718|FG011|Stage II Continuation|A1C elevation|0
6127790|NCT00943917|9753719|FG012|Stage II Continuation|A1C elevation|0
6127791|NCT00943917|9753720|FG013|Stage II Continuation|A1C elevation|1
6127792|NCT00943917|9753721|FG014|Stage II Continuation|A1C elevation|0
6127793|NCT00944034|9753787|FG000|Overall Study|Inappropriate enrollment|0
6127794|NCT00944034|9753788|FG001|Overall Study|Inappropriate enrollment|1
6127795|NCT00944034|9753789|FG002|Overall Study|Inappropriate enrollment|0
6127796|NCT00944034|9753790|FG003|Overall Study|Inappropriate enrollment|1
6127797|NCT00944034|9753791|FG004|Overall Study|Inappropriate enrollment|2
6127798|NCT00944034|9753792|FG005|Overall Study|Inappropriate enrollment|1
6127799|NCT00944034|9753793|FG006|Overall Study|Inappropriate enrollment|0
6127800|NCT00944034|9753794|FG007|Overall Study|Inappropriate enrollment|0
6127801|NCT00944034|9753795|FG008|Overall Study|Inappropriate enrollment|1
6127802|NCT00944034|9753796|FG009|Overall Study|Inappropriate enrollment|1
6127803|NCT00944034|9753797|FG010|Overall Study|Inappropriate enrollment|0
6127804|NCT00944034|9753798|FG011|Overall Study|Inappropriate enrollment|0
6127805|NCT00944034|9753787|FG000|Overall Study|Withdrawal by Subject|3
6127806|NCT00944034|9753788|FG001|Overall Study|Withdrawal by Subject|2
6127807|NCT00944034|9753789|FG002|Overall Study|Withdrawal by Subject|6
6127808|NCT00944034|9753790|FG003|Overall Study|Withdrawal by Subject|2
6127809|NCT00944034|9753791|FG004|Overall Study|Withdrawal by Subject|5
6127810|NCT00944034|9753792|FG005|Overall Study|Withdrawal by Subject|8
6127811|NCT00944034|9753793|FG006|Overall Study|Withdrawal by Subject|2
6127812|NCT00944034|9753794|FG007|Overall Study|Withdrawal by Subject|2
6127813|NCT00944034|9753795|FG008|Overall Study|Withdrawal by Subject|3
6127814|NCT00944034|9753796|FG009|Overall Study|Withdrawal by Subject|4
6127815|NCT00944034|9753797|FG010|Overall Study|Withdrawal by Subject|0
6219145|NCT01648582|9887656|FG000|Overall Study|Physician Decision|0
6127816|NCT00944034|9753798|FG011|Overall Study|Withdrawal by Subject|4
6127817|NCT00944034|9753787|FG000|Overall Study|Lost to Follow-up|0
6127818|NCT00944034|9753788|FG001|Overall Study|Lost to Follow-up|4
6127819|NCT00944034|9753789|FG002|Overall Study|Lost to Follow-up|2
6127820|NCT00944034|9753790|FG003|Overall Study|Lost to Follow-up|0
6127821|NCT00944034|9753791|FG004|Overall Study|Lost to Follow-up|5
6127822|NCT00944034|9753792|FG005|Overall Study|Lost to Follow-up|7
6127823|NCT00944034|9753793|FG006|Overall Study|Lost to Follow-up|0
6127824|NCT00944034|9753794|FG007|Overall Study|Lost to Follow-up|1
6127825|NCT00944034|9753795|FG008|Overall Study|Lost to Follow-up|5
6127826|NCT00944034|9753796|FG009|Overall Study|Lost to Follow-up|1
6127827|NCT00944034|9753797|FG010|Overall Study|Lost to Follow-up|1
6127828|NCT00944034|9753798|FG011|Overall Study|Lost to Follow-up|0
6127829|NCT00944034|9753787|FG000|Overall Study|Death|0
6127830|NCT00944034|9753788|FG001|Overall Study|Death|0
6127831|NCT00944034|9753789|FG002|Overall Study|Death|1
6127832|NCT00944034|9753790|FG003|Overall Study|Death|0
6127833|NCT00944034|9753791|FG004|Overall Study|Death|0
6127834|NCT00944034|9753792|FG005|Overall Study|Death|0
6127835|NCT00944034|9753793|FG006|Overall Study|Death|0
6288815|NCT02372383|10003212|FG000|First Intervention (1 Day)|Unable to collect blood|0
6288816|NCT02372383|10003213|FG001|First Intervention (1 Day)|Unable to collect blood|1
6288817|NCT02372383|10003214|FG002|First Intervention (1 Day)|Unable to collect blood|0
6288818|NCT02372396|10003226|FG000|Overall Study|Lost to Follow-up|7
6288819|NCT02372396|10003227|FG001|Overall Study|Lost to Follow-up|9
6288820|NCT02372799|10003252|FG000|Treatment Period|Adverse Event|3
6127836|NCT00944034|9753794|FG007|Overall Study|Death|0
6127837|NCT00944034|9753795|FG008|Overall Study|Death|0
6127838|NCT00944034|9753796|FG009|Overall Study|Death|0
6127839|NCT00944034|9753797|FG010|Overall Study|Death|0
6127840|NCT00944034|9753798|FG011|Overall Study|Death|0
6127841|NCT00944034|9753787|FG000|Overall Study|Protocol Violation|2
6127842|NCT00944034|9753788|FG001|Overall Study|Protocol Violation|0
6127843|NCT00944034|9753789|FG002|Overall Study|Protocol Violation|0
6127844|NCT00944034|9753790|FG003|Overall Study|Protocol Violation|1
6127845|NCT00944034|9753791|FG004|Overall Study|Protocol Violation|2
6127846|NCT00944034|9753792|FG005|Overall Study|Protocol Violation|3
6127847|NCT00944034|9753793|FG006|Overall Study|Protocol Violation|0
6127848|NCT00944034|9753794|FG007|Overall Study|Protocol Violation|1
6127849|NCT00944034|9753795|FG008|Overall Study|Protocol Violation|1
6127850|NCT00944034|9753796|FG009|Overall Study|Protocol Violation|4
6127851|NCT00944034|9753797|FG010|Overall Study|Protocol Violation|0
6127852|NCT00944034|9753798|FG011|Overall Study|Protocol Violation|0
6127853|NCT00944034|9753787|FG000|Overall Study|Unable to classify|0
6127854|NCT00944034|9753788|FG001|Overall Study|Unable to classify|0
6127855|NCT00944034|9753789|FG002|Overall Study|Unable to classify|0
6127856|NCT00944034|9753790|FG003|Overall Study|Unable to classify|0
6127857|NCT00944034|9753791|FG004|Overall Study|Unable to classify|0
6127858|NCT00944034|9753792|FG005|Overall Study|Unable to classify|1
6219146|NCT01648582|9887657|FG001|Overall Study|Physician Decision|1
6219147|NCT01648582|9887658|FG002|Overall Study|Physician Decision|3
6219148|NCT01648582|9887656|FG000|Overall Study|Death|1
6219149|NCT01648582|9887657|FG001|Overall Study|Death|0
6219150|NCT01648582|9887658|FG002|Overall Study|Death|0
6219151|NCT01648582|9887656|FG000|Overall Study|Sponsor Decision|0
6219152|NCT01648582|9887657|FG001|Overall Study|Sponsor Decision|1
6219153|NCT01648582|9887658|FG002|Overall Study|Sponsor Decision|1
6219154|NCT01648699|9887669|FG000|Overall Study|Death|1
6219155|NCT01648699|9887669|FG000|Overall Study|Lost to Follow-up|2
6219156|NCT01648699|9887669|FG000|Overall Study|Unspecified/unable to complete 4 visits|2
6219157|NCT01648764|9887696|FG000|Overall Study|Progressive Disease|0
6219158|NCT01648764|9887697|FG001|Overall Study|Progressive Disease|1
6219159|NCT01648764|9887698|FG002|Overall Study|Progressive Disease|0
6288821|NCT02372799|10003253|FG001|Treatment Period|Adverse Event|10
6288822|NCT02372799|10003254|FG002|Treatment Period|Adverse Event|6
6288823|NCT02372799|10003252|FG000|Treatment Period|Insufficient therapeutic response|2
6288824|NCT02372799|10003253|FG001|Treatment Period|Insufficient therapeutic response|2
6288825|NCT02372799|10003254|FG002|Treatment Period|Insufficient therapeutic response|0
6288826|NCT02372799|10003252|FG000|Treatment Period|Withdrawal by Subject|10
6288827|NCT02372799|10003253|FG001|Treatment Period|Withdrawal by Subject|10
6288828|NCT02372799|10003254|FG002|Treatment Period|Withdrawal by Subject|2
6288829|NCT02372799|10003252|FG000|Treatment Period|Lost to Follow-up|11
6288830|NCT02372799|10003253|FG001|Treatment Period|Lost to Follow-up|5
6288831|NCT02372799|10003254|FG002|Treatment Period|Lost to Follow-up|3
6288832|NCT02372799|10003252|FG000|Treatment Period|Protocol Violation|3
6288833|NCT02372799|10003253|FG001|Treatment Period|Protocol Violation|0
6288834|NCT02372799|10003254|FG002|Treatment Period|Protocol Violation|0
6288835|NCT02372799|10003252|FG000|Treatment Period|Non-compliance with study drug|4
6288836|NCT02372799|10003253|FG001|Treatment Period|Non-compliance with study drug|4
6288837|NCT02372799|10003254|FG002|Treatment Period|Non-compliance with study drug|4
6288838|NCT02372799|10003252|FG000|Treatment Period|Miscellaneous Reasons|1
6288839|NCT02372799|10003253|FG001|Treatment Period|Miscellaneous Reasons|1
6127859|NCT00944034|9753793|FG006|Overall Study|Unable to classify|1
6127860|NCT00944034|9753794|FG007|Overall Study|Unable to classify|1
6127861|NCT00944034|9753795|FG008|Overall Study|Unable to classify|0
6127862|NCT00944034|9753796|FG009|Overall Study|Unable to classify|0
6127863|NCT00944034|9753797|FG010|Overall Study|Unable to classify|0
6127864|NCT00944034|9753798|FG011|Overall Study|Unable to classify|0
6288840|NCT02372799|10003254|FG002|Treatment Period|Miscellaneous Reasons|0
6127865|NCT00944034|9753787|FG000|Overall Study|Administrative reason|0
6127866|NCT00944034|9753788|FG001|Overall Study|Administrative reason|0
6219160|NCT01648764|9887699|FG003|Overall Study|Progressive Disease|0
6127867|NCT00944034|9753789|FG002|Overall Study|Administrative reason|0
6127868|NCT00944034|9753790|FG003|Overall Study|Administrative reason|0
6127869|NCT00944034|9753791|FG004|Overall Study|Administrative reason|0
6127870|NCT00944034|9753792|FG005|Overall Study|Administrative reason|0
6127871|NCT00944034|9753793|FG006|Overall Study|Administrative reason|1
6127872|NCT00944034|9753794|FG007|Overall Study|Administrative reason|0
6127873|NCT00944034|9753795|FG008|Overall Study|Administrative reason|0
6127874|NCT00944034|9753796|FG009|Overall Study|Administrative reason|0
6127875|NCT00944034|9753797|FG010|Overall Study|Administrative reason|0
6127876|NCT00944034|9753798|FG011|Overall Study|Administrative reason|0
6127877|NCT00944125|9753854|FG000|3 to 6 Months|Withdrawal by Subject|0
6127878|NCT00944125|9753855|FG001|3 to 6 Months|Withdrawal by Subject|2
6127879|NCT00944125|9753854|FG000|6 Months to Study Completion|Withdrawal by Subject|0
6127880|NCT00944125|9753855|FG001|6 Months to Study Completion|Withdrawal by Subject|2
6127881|NCT00944645|9753877|FG000|Period 2|Adverse Event|1
6127882|NCT00944645|9753878|FG001|Period 2|Adverse Event|0
6127883|NCT00944645|9753877|FG000|Period 2|Lost to Follow-up|0
6127884|NCT00944645|9753878|FG001|Period 2|Lost to Follow-up|3
6127885|NCT00944645|9753877|FG000|Period 2|Withdrawal by Subject|7
6127886|NCT00944645|9753878|FG001|Period 2|Withdrawal by Subject|6
6127887|NCT00944658|9753886|FG000|Treatment 12 Weeks|Adverse Event|0
6127888|NCT00944658|9753887|FG001|Treatment 12 Weeks|Adverse Event|2
6127889|NCT00944697|9753914|FG000|Overall Study|Withdrawal by Subject|1
6127890|NCT00944697|9753915|FG001|Overall Study|Withdrawal by Subject|1
6127891|NCT00944697|9753914|FG000|Overall Study|Adverse Event|0
6127892|NCT00944697|9753915|FG001|Overall Study|Adverse Event|3
6127893|NCT00944697|9753914|FG000|Overall Study|Administrative|1
6127894|NCT00944697|9753915|FG001|Overall Study|Administrative|1
6127895|NCT00945191|9753966|FG000|Overall Study|Did not achieve a complete response|18
6127896|NCT00945191|9753966|FG000|Overall Study|Participant relocated to another state|1
6127897|NCT00945191|9753966|FG000|Overall Study|Disease progression|3
6127898|NCT00945191|9753966|FG000|Overall Study|Serious adverse event or adverse event|1
6127899|NCT00945191|9753966|FG000|Overall Study|Investigator's discretion|1
6127900|NCT00945243|9753970|FG000|Overall Study|Study Terminated: Subjects Dispositioned|3
6127901|NCT00945321|9754021|FG000|Period 1|Adverse Event|0
6127902|NCT00945321|9754022|FG001|Period 1|Adverse Event|0
6127903|NCT00945321|9754023|FG002|Period 1|Adverse Event|0
6127904|NCT00945321|9754024|FG003|Period 1|Adverse Event|0
6127905|NCT00945321|9754025|FG004|Period 1|Adverse Event|1
6127906|NCT00945321|9754026|FG005|Period 1|Adverse Event|0
6127907|NCT00945321|9754021|FG000|Period 4|Lost to Follow-up|0
6127908|NCT00945321|9754022|FG001|Period 4|Lost to Follow-up|0
6127909|NCT00945321|9754023|FG002|Period 4|Lost to Follow-up|0
6127910|NCT00945321|9754024|FG003|Period 4|Lost to Follow-up|0
6127911|NCT00945321|9754025|FG004|Period 4|Lost to Follow-up|0
6127912|NCT00945321|9754026|FG005|Period 4|Lost to Follow-up|1
6127913|NCT00945477|9754053|FG000|Overall Study|Adverse Event|3
6127914|NCT00945477|9754053|FG000|Overall Study|Lack of Efficacy|2
6127915|NCT00945477|9754053|FG000|Overall Study|Withdrawal by Subject|1
6127916|NCT00945555|9754058|FG000|Overall Study|Referred to another hospital|5
6127917|NCT00945555|9754058|FG000|Overall Study|Worsening condition, intensive care unit|1
6127918|NCT00945555|9754058|FG000|Overall Study|Withdrawal by Subject|2
6127919|NCT00945555|9754058|FG000|Overall Study|Participant continued treatment at home|1
6127920|NCT00945555|9754058|FG000|Overall Study|Death|18
6127921|NCT00945555|9754058|FG000|Overall Study|Other|1
6127922|NCT00945659|9754076|FG000|Overall Study|Lost to Follow-up|7
6127923|NCT00945659|9754077|FG001|Overall Study|Lost to Follow-up|20
6127924|NCT00945659|9754078|FG002|Overall Study|Lost to Follow-up|17
6127925|NCT00945815|9754105|FG000|Overall Study|Death|3
6127926|NCT00945815|9754105|FG000|Overall Study|Not protocol specified|1
6127927|NCT00945815|9754105|FG000|Overall Study|Ineligible|3
6127928|NCT00945815|9754105|FG000|Overall Study|Did not begin protocol therapy|1
6127929|NCT00945893|9754120|FG000|Overall Study|Lost to Follow-up|2
6127930|NCT00945893|9754121|FG001|Overall Study|Lost to Follow-up|8
6127931|NCT00945893|9754120|FG000|Overall Study|Withdrawal of consent|1
6127932|NCT00945893|9754121|FG001|Overall Study|Withdrawal of consent|2
6127933|NCT00945906|9754131|FG000|Overall Study|Withdrawal by Subject|1
6127934|NCT00945906|9754131|FG000|Overall Study|Did not want to return for last visit|2
6127935|NCT00945906|9754131|FG000|Overall Study|Unable to return for last visit|2
6127936|NCT00945906|9754131|FG000|Overall Study|Moved to another country|2
6127937|NCT00945945|9754137|FG000|Overall Study|Adverse Event|15
6127938|NCT00945945|9754138|FG001|Overall Study|Adverse Event|35
6127939|NCT00945945|9754137|FG000|Overall Study|Withdrawal by Subject|7
6127940|NCT00945945|9754138|FG001|Overall Study|Withdrawal by Subject|10
6127941|NCT00945945|9754137|FG000|Overall Study|Lost to Follow-up|4
6127942|NCT00945945|9754138|FG001|Overall Study|Lost to Follow-up|5
6127943|NCT00945945|9754137|FG000|Overall Study|Lack of Efficacy|6
6127944|NCT00945945|9754138|FG001|Overall Study|Lack of Efficacy|2
6127945|NCT00945945|9754137|FG000|Overall Study|Protocol Violation|4
6127946|NCT00945945|9754138|FG001|Overall Study|Protocol Violation|2
6127947|NCT00945945|9754137|FG000|Overall Study|Entry Criteria Not Met|0
6127948|NCT00945945|9754138|FG001|Overall Study|Entry Criteria Not Met|1
6127949|NCT00946088|9754155|FG000|Overall Study|Withdrawal by Subject|0
6127950|NCT00946088|9754156|FG001|Overall Study|Withdrawal by Subject|1
6219161|NCT01648764|9887700|FG004|Overall Study|Progressive Disease|0
6288841|NCT02372799|10003252|FG000|Down-taper Period|Lost to Follow-up|1
6127951|NCT00946101|9754166|FG000|Overall Study|Lost to Follow-up|2
6127952|NCT00946101|9754167|FG001|Overall Study|Lost to Follow-up|1
6127953|NCT00946101|9754166|FG000|Overall Study|Withdrawal of consent|2
6127954|NCT00946101|9754167|FG001|Overall Study|Withdrawal of consent|0
6127955|NCT00946101|9754166|FG000|Overall Study|Physician Decision|0
6127956|NCT00946101|9754167|FG001|Overall Study|Physician Decision|1
6127957|NCT00946114|9754179|FG000|Overall Study|Death|5
6127958|NCT00946114|9754180|FG001|Overall Study|Death|2
6127959|NCT00946114|9754179|FG000|Overall Study|Other|1
6127960|NCT00946114|9754180|FG001|Overall Study|Other|0
6127961|NCT00946114|9754179|FG000|Overall Study|Withdrawal by Subject|2
6127962|NCT00946114|9754180|FG001|Overall Study|Withdrawal by Subject|0
6127963|NCT00946153|9754191|FG000|Phase 2|Adverse Event|0
6127964|NCT00946153|9754192|FG001|Phase 2|Adverse Event|0
6219162|NCT01648764|9887701|FG005|Overall Study|Progressive Disease|1
6219163|NCT01648764|9887702|FG006|Overall Study|Progressive Disease|1
6219164|NCT01648764|9887703|FG007|Overall Study|Progressive Disease|0
6219165|NCT01648764|9887704|FG008|Overall Study|Progressive Disease|0
6219166|NCT01648764|9887705|FG009|Overall Study|Progressive Disease|2
6219167|NCT01648764|9887706|FG010|Overall Study|Progressive Disease|0
6219168|NCT01648764|9887707|FG011|Overall Study|Progressive Disease|1
6219169|NCT01648764|9887708|FG012|Overall Study|Progressive Disease|2
6219170|NCT01648764|9887709|FG013|Overall Study|Progressive Disease|1
6219171|NCT01648764|9887696|FG000|Overall Study|Adverse Event|0
6219172|NCT01648764|9887697|FG001|Overall Study|Adverse Event|0
6219173|NCT01648764|9887698|FG002|Overall Study|Adverse Event|0
6219174|NCT01648764|9887699|FG003|Overall Study|Adverse Event|0
6219175|NCT01648764|9887700|FG004|Overall Study|Adverse Event|0
6219176|NCT01648764|9887701|FG005|Overall Study|Adverse Event|1
6219177|NCT01648764|9887702|FG006|Overall Study|Adverse Event|0
6219178|NCT01648764|9887703|FG007|Overall Study|Adverse Event|0
6219179|NCT01648764|9887704|FG008|Overall Study|Adverse Event|0
6219180|NCT01648764|9887705|FG009|Overall Study|Adverse Event|1
6219181|NCT01648764|9887706|FG010|Overall Study|Adverse Event|0
6219182|NCT01648764|9887707|FG011|Overall Study|Adverse Event|3
6219183|NCT01648764|9887708|FG012|Overall Study|Adverse Event|1
6219184|NCT01648764|9887709|FG013|Overall Study|Adverse Event|1
6219185|NCT01648764|9887696|FG000|Overall Study|Death|0
6219186|NCT01648764|9887697|FG001|Overall Study|Death|0
6219187|NCT01648764|9887698|FG002|Overall Study|Death|0
6219188|NCT01648764|9887699|FG003|Overall Study|Death|0
6219189|NCT01648764|9887700|FG004|Overall Study|Death|0
6219190|NCT01648764|9887701|FG005|Overall Study|Death|0
6219191|NCT01648764|9887702|FG006|Overall Study|Death|1
6219192|NCT01648764|9887703|FG007|Overall Study|Death|0
6219193|NCT01648764|9887704|FG008|Overall Study|Death|0
6219194|NCT01648764|9887705|FG009|Overall Study|Death|0
6219195|NCT01648764|9887706|FG010|Overall Study|Death|0
6219196|NCT01648764|9887707|FG011|Overall Study|Death|0
6219197|NCT01648764|9887708|FG012|Overall Study|Death|0
6219198|NCT01648764|9887709|FG013|Overall Study|Death|1
6219199|NCT01648764|9887696|FG000|Overall Study|Withdrawal by Subject|0
6219200|NCT01648764|9887697|FG001|Overall Study|Withdrawal by Subject|0
6219201|NCT01648764|9887698|FG002|Overall Study|Withdrawal by Subject|0
6219202|NCT01648764|9887699|FG003|Overall Study|Withdrawal by Subject|0
6219203|NCT01648764|9887700|FG004|Overall Study|Withdrawal by Subject|0
6219204|NCT01648764|9887701|FG005|Overall Study|Withdrawal by Subject|0
6219205|NCT01648764|9887702|FG006|Overall Study|Withdrawal by Subject|2
6219206|NCT01648764|9887703|FG007|Overall Study|Withdrawal by Subject|0
6219207|NCT01648764|9887704|FG008|Overall Study|Withdrawal by Subject|0
6219208|NCT01648764|9887705|FG009|Overall Study|Withdrawal by Subject|0
6219209|NCT01648764|9887706|FG010|Overall Study|Withdrawal by Subject|0
6219210|NCT01648764|9887707|FG011|Overall Study|Withdrawal by Subject|0
6219211|NCT01648764|9887708|FG012|Overall Study|Withdrawal by Subject|1
6219212|NCT01648764|9887709|FG013|Overall Study|Withdrawal by Subject|0
6219213|NCT01648764|9887696|FG000|Overall Study|Investigator Decision|0
6219214|NCT01648764|9887697|FG001|Overall Study|Investigator Decision|0
6219215|NCT01648764|9887698|FG002|Overall Study|Investigator Decision|0
6219216|NCT01648764|9887699|FG003|Overall Study|Investigator Decision|0
6219217|NCT01648764|9887700|FG004|Overall Study|Investigator Decision|0
6219218|NCT01648764|9887701|FG005|Overall Study|Investigator Decision|0
6219219|NCT01648764|9887702|FG006|Overall Study|Investigator Decision|1
6219220|NCT01648764|9887703|FG007|Overall Study|Investigator Decision|0
6219221|NCT01648764|9887704|FG008|Overall Study|Investigator Decision|0
6219222|NCT01648764|9887705|FG009|Overall Study|Investigator Decision|0
6288842|NCT02372799|10003253|FG001|Down-taper Period|Lost to Follow-up|2
6219223|NCT01648764|9887706|FG010|Overall Study|Investigator Decision|0
6219224|NCT01648764|9887707|FG011|Overall Study|Investigator Decision|1
6219225|NCT01648764|9887708|FG012|Overall Study|Investigator Decision|0
6219226|NCT01648764|9887709|FG013|Overall Study|Investigator Decision|0
6219227|NCT01648790|9887743|FG000|Treatment 3|Withdrawal by Subject|0
6219228|NCT01648790|9887744|FG001|Treatment 3|Withdrawal by Subject|0
6219229|NCT01648790|9887745|FG002|Treatment 3|Withdrawal by Subject|0
6219230|NCT01648790|9887746|FG003|Treatment 3|Withdrawal by Subject|1
6127965|NCT00946153|9754193|FG002|Phase 2|Adverse Event|0
6127966|NCT00946153|9754194|FG003|Phase 2|Adverse Event|0
6127967|NCT00946153|9754195|FG004|Phase 2|Adverse Event|6
6127968|NCT00946153|9754191|FG000|Phase 2|Need more reduction of dose|0
6127969|NCT00946153|9754192|FG001|Phase 2|Need more reduction of dose|0
6127970|NCT00946153|9754193|FG002|Phase 2|Need more reduction of dose|0
6127971|NCT00946153|9754194|FG003|Phase 2|Need more reduction of dose|0
6127972|NCT00946153|9754195|FG004|Phase 2|Need more reduction of dose|2
6127973|NCT00946153|9754191|FG000|Phase 2|Physician Decision|0
6127974|NCT00946153|9754192|FG001|Phase 2|Physician Decision|0
6127975|NCT00946153|9754193|FG002|Phase 2|Physician Decision|0
6127976|NCT00946153|9754194|FG003|Phase 2|Physician Decision|0
6127977|NCT00946153|9754195|FG004|Phase 2|Physician Decision|1
6127978|NCT00946153|9754191|FG000|Phase 2|14 days washout for recovery due to AE|0
6127979|NCT00946153|9754192|FG001|Phase 2|14 days washout for recovery due to AE|0
6127980|NCT00946153|9754193|FG002|Phase 2|14 days washout for recovery due to AE|0
6127981|NCT00946153|9754194|FG003|Phase 2|14 days washout for recovery due to AE|0
6127982|NCT00946153|9754195|FG004|Phase 2|14 days washout for recovery due to AE|4
6127983|NCT00946192|9754215|FG000|Overall Study|Lost to Follow-up|6
6127984|NCT00946192|9754216|FG001|Overall Study|Lost to Follow-up|11
6127985|NCT00946192|9754217|FG002|Overall Study|Lost to Follow-up|9
6127986|NCT00946192|9754215|FG000|Overall Study|Withdrawal by Subject|10
6127987|NCT00946192|9754216|FG001|Overall Study|Withdrawal by Subject|7
6127988|NCT00946192|9754217|FG002|Overall Study|Withdrawal by Subject|3
6127989|NCT00946192|9754215|FG000|Overall Study|Did not start medication|2
6127990|NCT00946192|9754216|FG001|Overall Study|Did not start medication|0
6127991|NCT00946192|9754217|FG002|Overall Study|Did not start medication|0
6219231|NCT01648790|9887747|FG004|Treatment 3|Withdrawal by Subject|0
6219232|NCT01649232|9887773|FG000|Overall Study|Physician Decision|2
6219233|NCT01649232|9887774|FG001|Overall Study|Physician Decision|0
6219234|NCT01649271|9887788|FG000|Overall Study|Progressive disease|4
6219235|NCT01649271|9887789|FG001|Overall Study|Progressive disease|5
6219236|NCT01649271|9887788|FG000|Overall Study|Other Adverse Event|0
6219237|NCT01649271|9887789|FG001|Overall Study|Other Adverse Event|2
6219238|NCT01649271|9887788|FG000|Overall Study|Withdrawal by Subject|1
6219239|NCT01649271|9887789|FG001|Overall Study|Withdrawal by Subject|0
6219240|NCT01649271|9887788|FG000|Overall Study|Other than stated above|1
6219241|NCT01649271|9887789|FG001|Overall Study|Other than stated above|0
6219242|NCT01649297|9887801|FG000|Overall Study|Adverse Event|5
6219243|NCT01649297|9887802|FG001|Overall Study|Adverse Event|5
6219244|NCT01649297|9887803|FG002|Overall Study|Adverse Event|4
6219245|NCT01649297|9887804|FG003|Overall Study|Adverse Event|13
6219246|NCT01649297|9887805|FG004|Overall Study|Adverse Event|1
6219247|NCT01649297|9887801|FG000|Overall Study|Lack of Efficacy|0
6219248|NCT01649297|9887802|FG001|Overall Study|Lack of Efficacy|0
6219249|NCT01649297|9887803|FG002|Overall Study|Lack of Efficacy|0
6219250|NCT01649297|9887804|FG003|Overall Study|Lack of Efficacy|0
6219251|NCT01649297|9887805|FG004|Overall Study|Lack of Efficacy|1
6219252|NCT01649297|9887801|FG000|Overall Study|Non compliant with Protocol|1
6219253|NCT01649297|9887802|FG001|Overall Study|Non compliant with Protocol|0
6219254|NCT01649297|9887803|FG002|Overall Study|Non compliant with Protocol|3
6219255|NCT01649297|9887804|FG003|Overall Study|Non compliant with Protocol|2
6219256|NCT01649297|9887805|FG004|Overall Study|Non compliant with Protocol|1
6219257|NCT01649297|9887801|FG000|Overall Study|Lost to Follow-up|1
6219258|NCT01649297|9887802|FG001|Overall Study|Lost to Follow-up|1
6219259|NCT01649297|9887803|FG002|Overall Study|Lost to Follow-up|4
6219260|NCT01649297|9887804|FG003|Overall Study|Lost to Follow-up|3
6219261|NCT01649297|9887805|FG004|Overall Study|Lost to Follow-up|0
6219262|NCT01649297|9887801|FG000|Overall Study|Patient withdrawal (not due to AE)|3
6219263|NCT01649297|9887802|FG001|Overall Study|Patient withdrawal (not due to AE)|6
6219264|NCT01649297|9887803|FG002|Overall Study|Patient withdrawal (not due to AE)|4
6219265|NCT01649297|9887804|FG003|Overall Study|Patient withdrawal (not due to AE)|1
6219266|NCT01649297|9887805|FG004|Overall Study|Patient withdrawal (not due to AE)|1
6219267|NCT01649297|9887801|FG000|Overall Study|For other reason|4
6219268|NCT01649297|9887802|FG001|Overall Study|For other reason|1
6219269|NCT01649297|9887803|FG002|Overall Study|For other reason|2
6219270|NCT01649297|9887804|FG003|Overall Study|For other reason|0
6219271|NCT01649297|9887805|FG004|Overall Study|For other reason|0
6219272|NCT01649375|9887829|FG000|Up to Week 16|Adverse Event|2
6219273|NCT01649375|9887830|FG001|Up to Week 16|Adverse Event|5
6219274|NCT01649375|9887831|FG002|Up to Week 16|Adverse Event|4
6219275|NCT01649375|9887832|FG003|Up to Week 16|Adverse Event|0
6219276|NCT01649375|9887833|FG004|Up to Week 16|Adverse Event|0
6219277|NCT01649375|9887829|FG000|Up to Week 16|Lack of Efficacy|0
6219278|NCT01649375|9887830|FG001|Up to Week 16|Lack of Efficacy|0
6219279|NCT01649375|9887831|FG002|Up to Week 16|Lack of Efficacy|1
6219280|NCT01649375|9887832|FG003|Up to Week 16|Lack of Efficacy|0
6219281|NCT01649375|9887833|FG004|Up to Week 16|Lack of Efficacy|0
6219282|NCT01649375|9887829|FG000|Up to Week 16|Physician Decision|0
6219283|NCT01649375|9887830|FG001|Up to Week 16|Physician Decision|0
6219284|NCT01649375|9887831|FG002|Up to Week 16|Physician Decision|1
6219285|NCT01649375|9887832|FG003|Up to Week 16|Physician Decision|0
6219286|NCT01649375|9887833|FG004|Up to Week 16|Physician Decision|0
6219287|NCT01649375|9887829|FG000|Up to Week 16|Withdrawal by Subject|2
6127992|NCT00946296|9754240|FG000|Overall Study|Physician Decision|3
6127993|NCT00946296|9754241|FG001|Overall Study|Physician Decision|0
6127994|NCT00946309|9754249|FG000|Overall Study|Protocol Violation|1
6127995|NCT00946309|9754250|FG001|Overall Study|Protocol Violation|0
6127996|NCT00946309|9754249|FG000|Overall Study|Lost to Follow-up|0
6127997|NCT00946309|9754250|FG001|Overall Study|Lost to Follow-up|1
6127998|NCT00946309|9754249|FG000|Overall Study|Procedure cancelled/discontinued|0
6127999|NCT00946309|9754250|FG001|Overall Study|Procedure cancelled/discontinued|3
6128000|NCT00946322|9754257|FG000|Pre-treatment|participant failure to follow up|1
6128001|NCT00946322|9754257|FG000|Post-treatment|participant failure to follow up|2
6128002|NCT00946530|9754283|FG000|Overall Study|Withdrawal by Subject|0
6128003|NCT00946530|9754284|FG001|Overall Study|Withdrawal by Subject|3
6128004|NCT00946530|9754285|FG002|Overall Study|Withdrawal by Subject|0
6128005|NCT00946530|9754286|FG003|Overall Study|Withdrawal by Subject|3
6128006|NCT00946530|9754283|FG000|Overall Study|Physician Decision|1
6128007|NCT00946530|9754284|FG001|Overall Study|Physician Decision|1
6128008|NCT00946530|9754285|FG002|Overall Study|Physician Decision|1
6128009|NCT00946530|9754286|FG003|Overall Study|Physician Decision|1
6128010|NCT00946647|9754305|FG000|Phase 1 Part|Adverse Event|2
6128011|NCT00946647|9754306|FG001|Phase 1 Part|Adverse Event|5
6128012|NCT00946647|9754307|FG002|Phase 1 Part|Adverse Event|3
6128013|NCT00946647|9754308|FG003|Phase 1 Part|Adverse Event|0
6128014|NCT00946647|9754309|FG004|Phase 1 Part|Adverse Event|0
6219288|NCT01649375|9887830|FG001|Up to Week 16|Withdrawal by Subject|1
6219289|NCT01649375|9887831|FG002|Up to Week 16|Withdrawal by Subject|2
6219290|NCT01649375|9887832|FG003|Up to Week 16|Withdrawal by Subject|0
6219291|NCT01649375|9887833|FG004|Up to Week 16|Withdrawal by Subject|0
6219292|NCT01649375|9887829|FG000|Up to Week 16|Death|1
6219293|NCT01649375|9887830|FG001|Up to Week 16|Death|0
6219294|NCT01649375|9887831|FG002|Up to Week 16|Death|0
6219295|NCT01649375|9887832|FG003|Up to Week 16|Death|0
6219296|NCT01649375|9887833|FG004|Up to Week 16|Death|0
6219297|NCT01649375|9887829|FG000|Week 16 up to Week 260|Lack of Efficacy|7
6219298|NCT01649375|9887830|FG001|Week 16 up to Week 260|Lack of Efficacy|4
6219299|NCT01649375|9887831|FG002|Week 16 up to Week 260|Lack of Efficacy|0
6219300|NCT01649375|9887832|FG003|Week 16 up to Week 260|Lack of Efficacy|4
6219301|NCT01649375|9887833|FG004|Week 16 up to Week 260|Lack of Efficacy|2
6219302|NCT01649375|9887829|FG000|Week 16 up to Week 260|Non-compliance|0
6219303|NCT01649375|9887830|FG001|Week 16 up to Week 260|Non-compliance|1
6219304|NCT01649375|9887831|FG002|Week 16 up to Week 260|Non-compliance|0
6219305|NCT01649375|9887832|FG003|Week 16 up to Week 260|Non-compliance|1
6219306|NCT01649375|9887833|FG004|Week 16 up to Week 260|Non-compliance|0
6219307|NCT01649375|9887829|FG000|Week 16 up to Week 260|Physician Decision|0
6219308|NCT01649375|9887830|FG001|Week 16 up to Week 260|Physician Decision|2
6219309|NCT01649375|9887831|FG002|Week 16 up to Week 260|Physician Decision|0
6219310|NCT01649375|9887832|FG003|Week 16 up to Week 260|Physician Decision|0
6219311|NCT01649375|9887833|FG004|Week 16 up to Week 260|Physician Decision|0
6219312|NCT01649375|9887829|FG000|Week 16 up to Week 260|Technical issues|0
6219313|NCT01649375|9887830|FG001|Week 16 up to Week 260|Technical issues|1
6219314|NCT01649375|9887831|FG002|Week 16 up to Week 260|Technical issues|0
6219315|NCT01649375|9887832|FG003|Week 16 up to Week 260|Technical issues|1
6219316|NCT01649375|9887833|FG004|Week 16 up to Week 260|Technical issues|0
6219317|NCT01649375|9887829|FG000|Week 16 up to Week 260|Withdrawal by Subject|7
6219318|NCT01649375|9887830|FG001|Week 16 up to Week 260|Withdrawal by Subject|2
6219319|NCT01649375|9887831|FG002|Week 16 up to Week 260|Withdrawal by Subject|0
6219320|NCT01649375|9887832|FG003|Week 16 up to Week 260|Withdrawal by Subject|3
6219321|NCT01649375|9887833|FG004|Week 16 up to Week 260|Withdrawal by Subject|1
6219322|NCT01649375|9887829|FG000|Week 16 up to Week 260|Death|1
6219323|NCT01649375|9887830|FG001|Week 16 up to Week 260|Death|1
6219324|NCT01649375|9887831|FG002|Week 16 up to Week 260|Death|0
6219325|NCT01649375|9887832|FG003|Week 16 up to Week 260|Death|0
6219326|NCT01649375|9887833|FG004|Week 16 up to Week 260|Death|0
6219327|NCT01649375|9887829|FG000|Week 16 up to Week 260|Adverse Event|5
6288843|NCT02372799|10003254|FG002|Down-taper Period|Lost to Follow-up|2
6288844|NCT02373098|10003264|FG000|Overall Study|Lost to Follow-up|1
6288845|NCT02373098|10003265|FG001|Overall Study|Lost to Follow-up|0
6288846|NCT02373098|10003264|FG000|Overall Study|Protocol Violation|3
6288847|NCT02373098|10003265|FG001|Overall Study|Protocol Violation|0
6288848|NCT02373098|10003264|FG000|Overall Study|Withdrawal by Subject|5
6128015|NCT00946647|9754305|FG000|Phase 1 Part|Disease progression|3
6128016|NCT00946647|9754306|FG001|Phase 1 Part|Disease progression|6
6128017|NCT00946647|9754307|FG002|Phase 1 Part|Disease progression|1
6128018|NCT00946647|9754308|FG003|Phase 1 Part|Disease progression|0
6128019|NCT00946647|9754309|FG004|Phase 1 Part|Disease progression|0
6128020|NCT00946647|9754305|FG000|Phase 1 Part|Withdrawal by Subject|1
6219328|NCT01649375|9887830|FG001|Week 16 up to Week 260|Adverse Event|2
6219329|NCT01649375|9887831|FG002|Week 16 up to Week 260|Adverse Event|0
6219330|NCT01649375|9887832|FG003|Week 16 up to Week 260|Adverse Event|3
6219331|NCT01649375|9887833|FG004|Week 16 up to Week 260|Adverse Event|2
6219332|NCT01649427|9887843|FG000|Overall Study|Adverse Event|1
6219333|NCT01649427|9887844|FG001|Overall Study|Adverse Event|1
6219334|NCT01649427|9887843|FG000|Overall Study|Withdrawal by Subject|8
6219335|NCT01649427|9887844|FG001|Overall Study|Withdrawal by Subject|7
6219336|NCT01649427|9887843|FG000|Overall Study|Lost to Follow-up|0
6128021|NCT00946647|9754306|FG001|Phase 1 Part|Withdrawal by Subject|4
6128022|NCT00946647|9754307|FG002|Phase 1 Part|Withdrawal by Subject|3
6128023|NCT00946647|9754308|FG003|Phase 1 Part|Withdrawal by Subject|0
6128024|NCT00946647|9754309|FG004|Phase 1 Part|Withdrawal by Subject|0
6128025|NCT00946647|9754305|FG000|Phase 1 Part|Abnormal values|0
6128026|NCT00946647|9754306|FG001|Phase 1 Part|Abnormal values|2
6128027|NCT00946647|9754307|FG002|Phase 1 Part|Abnormal values|0
6128028|NCT00946647|9754308|FG003|Phase 1 Part|Abnormal values|0
6128029|NCT00946647|9754309|FG004|Phase 1 Part|Abnormal values|0
6128030|NCT00946647|9754305|FG000|Phase 1 Part|Reason missing|0
6128031|NCT00946647|9754306|FG001|Phase 1 Part|Reason missing|1
6128032|NCT00946647|9754307|FG002|Phase 1 Part|Reason missing|0
6128033|NCT00946647|9754308|FG003|Phase 1 Part|Reason missing|0
6128034|NCT00946647|9754309|FG004|Phase 1 Part|Reason missing|0
6128035|NCT00946647|9754305|FG000|Phase ll Part|Untreated|0
6128036|NCT00946647|9754306|FG001|Phase ll Part|Untreated|0
6128037|NCT00946647|9754307|FG002|Phase ll Part|Untreated|0
6128038|NCT00946647|9754308|FG003|Phase ll Part|Untreated|0
6128039|NCT00946647|9754309|FG004|Phase ll Part|Untreated|2
6128040|NCT00946647|9754305|FG000|Phase ll Part|Adverse Event|0
6128041|NCT00946647|9754306|FG001|Phase ll Part|Adverse Event|0
6128042|NCT00946647|9754307|FG002|Phase ll Part|Adverse Event|0
6128043|NCT00946647|9754308|FG003|Phase ll Part|Adverse Event|10
6128044|NCT00946647|9754309|FG004|Phase ll Part|Adverse Event|6
6128045|NCT00946647|9754305|FG000|Phase ll Part|Withdrawal by Subject|0
6128046|NCT00946647|9754306|FG001|Phase ll Part|Withdrawal by Subject|0
6128047|NCT00946647|9754307|FG002|Phase ll Part|Withdrawal by Subject|0
6128048|NCT00946647|9754308|FG003|Phase ll Part|Withdrawal by Subject|8
6128049|NCT00946647|9754309|FG004|Phase ll Part|Withdrawal by Subject|6
6128050|NCT00946647|9754305|FG000|Phase ll Part|Administrative problems|0
6128051|NCT00946647|9754306|FG001|Phase ll Part|Administrative problems|0
6128052|NCT00946647|9754307|FG002|Phase ll Part|Administrative problems|0
6128053|NCT00946647|9754308|FG003|Phase ll Part|Administrative problems|3
6128054|NCT00946647|9754309|FG004|Phase ll Part|Administrative problems|8
6128055|NCT00946647|9754305|FG000|Phase ll Part|Death|0
6128056|NCT00946647|9754306|FG001|Phase ll Part|Death|0
6128057|NCT00946647|9754307|FG002|Phase ll Part|Death|0
6128058|NCT00946647|9754308|FG003|Phase ll Part|Death|7
6128059|NCT00946647|9754309|FG004|Phase ll Part|Death|4
6128060|NCT00946647|9754305|FG000|Phase ll Part|Disease progression|0
6128061|NCT00946647|9754306|FG001|Phase ll Part|Disease progression|0
6128062|NCT00946647|9754307|FG002|Phase ll Part|Disease progression|0
6128063|NCT00946647|9754308|FG003|Phase ll Part|Disease progression|6
6128064|NCT00946647|9754309|FG004|Phase ll Part|Disease progression|14
6128065|NCT00946647|9754305|FG000|Phase ll Part|Protocol Violation|0
6128066|NCT00946647|9754306|FG001|Phase ll Part|Protocol Violation|0
6219337|NCT01649427|9887844|FG001|Overall Study|Lost to Follow-up|1
6219338|NCT01649427|9887843|FG000|Overall Study|Graft loss|0
6219339|NCT01649427|9887844|FG001|Overall Study|Graft loss|1
6219340|NCT01649427|9887843|FG000|Overall Study|Surgical problems during nephrectomy|2
6219341|NCT01649427|9887844|FG001|Overall Study|Surgical problems during nephrectomy|2
6219342|NCT01649557|9887853|FG000|Overall Study|Lost to Follow-up|5
6219343|NCT01649557|9887854|FG001|Overall Study|Lost to Follow-up|0
6219344|NCT01649557|9887855|FG002|Overall Study|Lost to Follow-up|3
6219345|NCT01649557|9887853|FG000|Overall Study|Adverse Event|7
6219346|NCT01649557|9887854|FG001|Overall Study|Adverse Event|5
6219347|NCT01649557|9887855|FG002|Overall Study|Adverse Event|1
6219348|NCT01649557|9887853|FG000|Overall Study|Met withdrawal criteria|4
6219349|NCT01649557|9887854|FG001|Overall Study|Met withdrawal criteria|0
6219350|NCT01649557|9887855|FG002|Overall Study|Met withdrawal criteria|0
6219351|NCT01649557|9887853|FG000|Overall Study|Physician Decision|8
6219352|NCT01649557|9887854|FG001|Overall Study|Physician Decision|2
6219353|NCT01649557|9887855|FG002|Overall Study|Physician Decision|1
6219354|NCT01649557|9887853|FG000|Overall Study|Withdrawal by Subject|15
6219355|NCT01649557|9887854|FG001|Overall Study|Withdrawal by Subject|5
6219356|NCT01649557|9887855|FG002|Overall Study|Withdrawal by Subject|4
6288849|NCT02373098|10003265|FG001|Overall Study|Withdrawal by Subject|0
6288850|NCT02373098|10003264|FG000|Overall Study|Adverse Event|3
6288851|NCT02373098|10003265|FG001|Overall Study|Adverse Event|0
6288852|NCT02373202|10003295|FG000|Overall Study|Adverse Event|2
6288853|NCT02373202|10003296|FG001|Overall Study|Adverse Event|5
6288854|NCT02373202|10003297|FG002|Overall Study|Adverse Event|2
6288855|NCT02373202|10003298|FG003|Overall Study|Adverse Event|1
6128067|NCT00946647|9754307|FG002|Phase ll Part|Protocol Violation|0
6128068|NCT00946647|9754308|FG003|Phase ll Part|Protocol Violation|4
6288856|NCT02373202|10003295|FG000|Overall Study|Lack of Efficacy|0
6288857|NCT02373202|10003296|FG001|Overall Study|Lack of Efficacy|0
6288858|NCT02373202|10003297|FG002|Overall Study|Lack of Efficacy|1
6288859|NCT02373202|10003298|FG003|Overall Study|Lack of Efficacy|0
6288860|NCT02373202|10003295|FG000|Overall Study|Other|0
6288861|NCT02373202|10003296|FG001|Overall Study|Other|1
6128069|NCT00946647|9754309|FG004|Phase ll Part|Protocol Violation|2
6219357|NCT01649557|9887853|FG000|Overall Study|Protocol deviation|0
6219358|NCT01649557|9887854|FG001|Overall Study|Protocol deviation|2
6219359|NCT01649557|9887855|FG002|Overall Study|Protocol deviation|0
6219360|NCT01649557|9887853|FG000|Overall Study|Lack of Efficacy|5
6288862|NCT02373202|10003297|FG002|Overall Study|Other|0
5980925|NCT04042077|9569678|FG001|Overall Study|Death|1
5980926|NCT04042077|9569677|FG000|Overall Study|Physician Decision|2
6128070|NCT00946647|9754305|FG000|Phase ll Part|Subj cond no longer required study drug|0
6128071|NCT00946647|9754306|FG001|Phase ll Part|Subj cond no longer required study drug|0
6128072|NCT00946647|9754307|FG002|Phase ll Part|Subj cond no longer required study drug|0
6128073|NCT00946647|9754308|FG003|Phase ll Part|Subj cond no longer required study drug|2
6128074|NCT00946647|9754309|FG004|Phase ll Part|Subj cond no longer required study drug|0
6128075|NCT00946712|9754324|FG000|Overall Study|Adverse Event|118
6128076|NCT00946712|9754325|FG001|Overall Study|Adverse Event|124
6128077|NCT00946712|9754324|FG000|Overall Study|Disease progression|308
6128078|NCT00946712|9754325|FG001|Overall Study|Disease progression|404
6128079|NCT00946712|9754324|FG000|Overall Study|Death|21
6128080|NCT00946712|9754325|FG001|Overall Study|Death|22
6128081|NCT00946712|9754324|FG000|Overall Study|No treatment given|25
6128082|NCT00946712|9754325|FG001|Overall Study|No treatment given|29
6128083|NCT00946712|9754324|FG000|Overall Study|Other reasons|61
6128084|NCT00946712|9754325|FG001|Overall Study|Other reasons|73
6128085|NCT00946712|9754324|FG000|Overall Study|On Treatment|0
6128086|NCT00946712|9754325|FG001|Overall Study|On Treatment|4
6128087|NCT00946712|9754324|FG000|Overall Study|Ineligible|14
6128088|NCT00946712|9754325|FG001|Overall Study|Ineligible|6
6128089|NCT00946881|9754332|FG000|First Treatment|Withdrawal by Subject|1
6128090|NCT00946881|9754332|FG000|First Treatment|Patient relocated to another state|1
6128091|NCT00946881|9754332|FG000|Retreatment|Withdrawal by Subject|1
6128092|NCT00946920|9754359|FG000|Overall Study|Withdrawal by Subject|28
6128093|NCT00946920|9754360|FG001|Overall Study|Withdrawal by Subject|15
6128094|NCT00946920|9754359|FG000|Overall Study|Lost to Follow-up|2
6128095|NCT00946920|9754360|FG001|Overall Study|Lost to Follow-up|2
6128096|NCT00946920|9754359|FG000|Overall Study|Physician Decision|5
6128097|NCT00946920|9754360|FG001|Overall Study|Physician Decision|2
6128098|NCT00946920|9754359|FG000|Overall Study|Adverse Event|41
6128099|NCT00946920|9754360|FG001|Overall Study|Adverse Event|14
6128100|NCT00946920|9754359|FG000|Overall Study|Protocol Violation|16
6128101|NCT00946920|9754360|FG001|Overall Study|Protocol Violation|8
6128102|NCT00946920|9754359|FG000|Overall Study|Miscellaneous reasons|18
6128103|NCT00946920|9754360|FG001|Overall Study|Miscellaneous reasons|3
6128104|NCT00946998|9754368|FG000|Overall Study|Exited prior to first outcome assessment|5
6128105|NCT00946998|9754369|FG001|Overall Study|Exited prior to first outcome assessment|3
6128106|NCT00947115|9754378|FG000|Overall Study|Missed reporting interval|3
6128107|NCT00947115|9754379|FG001|Overall Study|Missed reporting interval|4
6128108|NCT00947115|9754380|FG002|Overall Study|Missed reporting interval|2
6128109|NCT00947115|9754378|FG000|Overall Study|Physician Decision|0
6128110|NCT00947115|9754379|FG001|Overall Study|Physician Decision|2
6128111|NCT00947115|9754380|FG002|Overall Study|Physician Decision|0
6128112|NCT00947115|9754378|FG000|Overall Study|Death|0
6128113|NCT00947115|9754379|FG001|Overall Study|Death|1
6128114|NCT00947115|9754380|FG002|Overall Study|Death|1
6128115|NCT00947115|9754378|FG000|Overall Study|Migrated from study area|2
6128116|NCT00947115|9754379|FG001|Overall Study|Migrated from study area|0
6128117|NCT00947115|9754380|FG002|Overall Study|Migrated from study area|0
6128118|NCT00947115|9754378|FG000|Overall Study|Withdrawal by Subject|1
6128119|NCT00947115|9754379|FG001|Overall Study|Withdrawal by Subject|3
6128120|NCT00947115|9754380|FG002|Overall Study|Withdrawal by Subject|4
6128121|NCT00947115|9754378|FG000|Overall Study|Lost to Follow-up|11
6219361|NCT01649557|9887854|FG001|Overall Study|Lack of Efficacy|0
6219362|NCT01649557|9887855|FG002|Overall Study|Lack of Efficacy|0
6219363|NCT01649765|9887883|FG000|Overall Study|Adverse Event|5
6219364|NCT01649765|9887884|FG001|Overall Study|Adverse Event|3
6219365|NCT01649765|9887883|FG000|Overall Study|Lack of Efficacy|1
6219366|NCT01649765|9887884|FG001|Overall Study|Lack of Efficacy|1
6219367|NCT01649765|9887883|FG000|Overall Study|Physician Decision|0
6219368|NCT01649765|9887884|FG001|Overall Study|Physician Decision|3
6219369|NCT01649765|9887883|FG000|Overall Study|Protocol Violation|1
6219370|NCT01649765|9887884|FG001|Overall Study|Protocol Violation|0
6219371|NCT01649765|9887883|FG000|Overall Study|Withdrawal by Subject|2
6219372|NCT01649765|9887884|FG001|Overall Study|Withdrawal by Subject|1
6219373|NCT01649791|9887891|FG000|Overall Study|Disease Progression|2
6219374|NCT01649791|9887891|FG000|Overall Study|Adverse Event|1
6219375|NCT01649804|9887895|FG000|Overall Study|Administrative/Other|8
6219376|NCT01649856|9887901|FG000|Overall Study|Withdrawal by Subject|14
6219377|NCT01649856|9887902|FG001|Overall Study|Withdrawal by Subject|14
6128122|NCT00947115|9754379|FG001|Overall Study|Lost to Follow-up|12
6128123|NCT00947115|9754380|FG002|Overall Study|Lost to Follow-up|8
6128124|NCT00947154|9754388|FG000|Overall Study|Lost to Follow-up|1
6128125|NCT00947193|9754397|FG000|Overall Study|Lost to Follow-up|1
6128126|NCT00947193|9754398|FG001|Overall Study|Lost to Follow-up|0
6128127|NCT00947193|9754397|FG000|Overall Study|Withdrawal by Subject|1
6128128|NCT00947193|9754398|FG001|Overall Study|Withdrawal by Subject|0
6128129|NCT00947193|9754397|FG000|Overall Study|Factor VIII >1%|1
6128130|NCT00947193|9754398|FG001|Overall Study|Factor VIII >1%|0
6219378|NCT01649856|9887901|FG000|Overall Study|Protocol Violation|4
6219379|NCT01649856|9887902|FG001|Overall Study|Protocol Violation|4
6219380|NCT01649856|9887901|FG000|Overall Study|Treatment Failure|1
6219381|NCT01649856|9887902|FG001|Overall Study|Treatment Failure|1
6219382|NCT01649856|9887901|FG000|Overall Study|Death|69
6128131|NCT00947349|9754455|FG000|Triple Treatment Combination Period|Adverse Event|0
6128132|NCT00947349|9754456|FG001|Triple Treatment Combination Period|Adverse Event|1
6128133|NCT00947349|9754457|FG002|Triple Treatment Combination Period|Adverse Event|0
6128134|NCT00947349|9754458|FG003|Triple Treatment Combination Period|Adverse Event|0
6128135|NCT00947349|9754455|FG000|Overall Study Standard of Care|Lack of Efficacy|0
6128136|NCT00947349|9754456|FG001|Overall Study Standard of Care|Lack of Efficacy|0
6128137|NCT00947349|9754457|FG002|Overall Study Standard of Care|Lack of Efficacy|1
6128138|NCT00947349|9754458|FG003|Overall Study Standard of Care|Lack of Efficacy|1
6128139|NCT00947349|9754455|FG000|Overall Study Standard of Care|Withdrawal by Subject|0
6128140|NCT00947349|9754456|FG001|Overall Study Standard of Care|Withdrawal by Subject|0
6219383|NCT01649856|9887902|FG001|Overall Study|Death|34
6219384|NCT01649856|9887901|FG000|Overall Study|Stable or Progressed Disease|5
6219385|NCT01649856|9887902|FG001|Overall Study|Stable or Progressed Disease|3
6219386|NCT01649856|9887901|FG000|Overall Study|Lost to Follow-up|20
6219387|NCT01649856|9887902|FG001|Overall Study|Lost to Follow-up|16
6219388|NCT01649856|9887901|FG000|Overall Study|Lack of Compliance|6
6219389|NCT01649856|9887902|FG001|Overall Study|Lack of Compliance|1
6219390|NCT01649856|9887901|FG000|Overall Study|Other|20
6219391|NCT01649856|9887902|FG001|Overall Study|Other|5
6219392|NCT01649869|9887910|FG000|Overall Study|Family member illness|1
6219393|NCT01649869|9887911|FG001|Overall Study|Family member illness|0
6219394|NCT01649869|9887910|FG000|Overall Study|Required treatment outside protocol|1
6219395|NCT01649869|9887911|FG001|Overall Study|Required treatment outside protocol|0
6219396|NCT01649869|9887910|FG000|Overall Study|Severe hearing loss borderline eligible|0
6219397|NCT01649869|9887911|FG001|Overall Study|Severe hearing loss borderline eligible|1
6219398|NCT01650194|9887929|FG000|Overall Study|Progressive Disease (PD)|35
6219399|NCT01650194|9887929|FG000|Overall Study|Withdrawal by Subject|2
6219400|NCT01650194|9887929|FG000|Overall Study|Miscellaneous|10
6219401|NCT01650246|9887934|FG000|Overall Study|Adverse Event|23
6219402|NCT01650246|9887934|FG000|Overall Study|Protocol Violation|5
6219403|NCT01650246|9887934|FG000|Overall Study|Sponsor terminated study|53
6219404|NCT01650246|9887934|FG000|Overall Study|Lost to Follow-up|5
6219405|NCT01650246|9887934|FG000|Overall Study|Withdrawal by Subject|26
6219406|NCT01650246|9887934|FG000|Overall Study|Death|1
6128141|NCT00947349|9754457|FG002|Overall Study Standard of Care|Withdrawal by Subject|1
6128142|NCT00947349|9754458|FG003|Overall Study Standard of Care|Withdrawal by Subject|0
6128143|NCT00947349|9754455|FG000|Overall Study Standard of Care|Other|0
6128144|NCT00947349|9754456|FG001|Overall Study Standard of Care|Other|0
6128145|NCT00947349|9754457|FG002|Overall Study Standard of Care|Other|0
6128146|NCT00947349|9754458|FG003|Overall Study Standard of Care|Other|1
6128147|NCT00947427|9754488|FG000|Overall Study|Withdrawal by Subject|1
6128148|NCT00947427|9754489|FG001|Overall Study|Withdrawal by Subject|3
6128149|NCT00947427|9754488|FG000|Overall Study|Protocol Violation|0
6128150|NCT00947427|9754489|FG001|Overall Study|Protocol Violation|1
6128151|NCT00947531|9754506|FG000|Overall Study|Withdrawal by Subject|10
6128152|NCT00947531|9754507|FG001|Overall Study|Withdrawal by Subject|7
6128153|NCT00947531|9754506|FG000|Overall Study|Administrative Reason|0
6219407|NCT01650246|9887934|FG000|Overall Study|Lack of Efficacy|30
6219408|NCT01650259|9887940|FG000|Overall Study|Improvement|105
6219409|NCT01650259|9887941|FG001|Overall Study|Improvement|0
6219410|NCT01650259|9887940|FG000|Overall Study|Adverse Event|127
6219411|NCT01650259|9887941|FG001|Overall Study|Adverse Event|0
6219412|NCT01650259|9887940|FG000|Overall Study|Lack of Efficacy|143
6219413|NCT01650259|9887941|FG001|Overall Study|Lack of Efficacy|0
6219414|NCT01650259|9887940|FG000|Overall Study|Lost to Follow-up|435
6219415|NCT01650259|9887941|FG001|Overall Study|Lost to Follow-up|0
6219416|NCT01650259|9887940|FG000|Overall Study|Patients had no visit after entry|70
6219417|NCT01650259|9887941|FG001|Overall Study|Patients had no visit after entry|0
6219418|NCT01650259|9887940|FG000|Overall Study|CRF not collected|98
6219419|NCT01650259|9887941|FG001|Overall Study|CRF not collected|82
6219420|NCT01650259|9887940|FG000|Overall Study|Not treated|1
6219421|NCT01650259|9887941|FG001|Overall Study|Not treated|7
6219422|NCT01650259|9887940|FG000|Overall Study|Other than listed|64
6219423|NCT01650259|9887941|FG001|Overall Study|Other than listed|146
6219424|NCT01650519|9887991|FG000|Overall Study|Withdrawal by Subject|1
6219425|NCT01650519|9887992|FG001|Overall Study|Withdrawal by Subject|0
6219426|NCT01650558|9888012|FG000|Overall Study|Migration out of study area|61
6219427|NCT01650558|9888013|FG001|Overall Study|Migration out of study area|71
6219428|NCT01650558|9888014|FG002|Overall Study|Migration out of study area|56
6219429|NCT01650558|9888012|FG000|Overall Study|Lost to Follow-up|10
6128154|NCT00947531|9754507|FG001|Overall Study|Administrative Reason|1
6128155|NCT00947531|9754506|FG000|Overall Study|Adverse Event|2
6128156|NCT00947531|9754507|FG001|Overall Study|Adverse Event|2
6128157|NCT00947531|9754506|FG000|Overall Study|Lack of Efficacy|1
6128158|NCT00947531|9754507|FG001|Overall Study|Lack of Efficacy|0
6128159|NCT00947531|9754506|FG000|Overall Study|Other|1
6128160|NCT00947531|9754507|FG001|Overall Study|Other|1
6128161|NCT00947544|9754513|FG000|Safety-Extension Period (12 Months)|Withdrawal by Subject|1
6128162|NCT00947544|9754514|FG001|Safety-Extension Period (12 Months)|Withdrawal by Subject|0
6128163|NCT00947856|9754553|FG000|Treatment Period|Progressive Disease|33
6128164|NCT00947856|9754554|FG001|Treatment Period|Progressive Disease|12
6219430|NCT01650558|9888013|FG001|Overall Study|Lost to Follow-up|13
6128165|NCT00947856|9754553|FG000|Treatment Period|Adverse Event|15
6128166|NCT00947856|9754554|FG001|Treatment Period|Adverse Event|9
6128167|NCT00947856|9754553|FG000|Treatment Period|Physician Decision|14
6128168|NCT00947856|9754554|FG001|Treatment Period|Physician Decision|6
6128169|NCT00947856|9754553|FG000|Treatment Period|Study Stopped by Sponsor|4
6128170|NCT00947856|9754554|FG001|Treatment Period|Study Stopped by Sponsor|4
6128171|NCT00947856|9754553|FG000|Treatment Period|Withdrawal by Subject|12
6128172|NCT00947856|9754554|FG001|Treatment Period|Withdrawal by Subject|1
6128173|NCT00947856|9754553|FG000|Follow-up Period|Study Stopped by Sponsor|40
6128174|NCT00947856|9754554|FG001|Follow-up Period|Study Stopped by Sponsor|20
6128175|NCT00947856|9754553|FG000|Follow-up Period|Re-enrolled for Retreatment|2
6128176|NCT00947856|9754554|FG001|Follow-up Period|Re-enrolled for Retreatment|3
6128177|NCT00947856|9754553|FG000|Follow-up Period|Lost to Follow-up|7
6128178|NCT00947856|9754554|FG001|Follow-up Period|Lost to Follow-up|0
6128179|NCT00947856|9754553|FG000|Follow-up Period|Patient unavailable for site visits|1
6128180|NCT00947856|9754554|FG001|Follow-up Period|Patient unavailable for site visits|0
6128181|NCT00947856|9754553|FG000|Follow-up Period|Withdrawal by Subject|1
6128182|NCT00947856|9754554|FG001|Follow-up Period|Withdrawal by Subject|0
6128183|NCT00947882|9754573|FG000|Overall Study|Adverse Event|0
6128184|NCT00947882|9754574|FG001|Overall Study|Adverse Event|1
6128185|NCT00947882|9754575|FG002|Overall Study|Adverse Event|4
6128186|NCT00947882|9754576|FG003|Overall Study|Adverse Event|4
6128187|NCT00947882|9754573|FG000|Overall Study|Withdrawal by Subject|2
6128188|NCT00947882|9754574|FG001|Overall Study|Withdrawal by Subject|0
6128189|NCT00947882|9754575|FG002|Overall Study|Withdrawal by Subject|8
6128190|NCT00947882|9754576|FG003|Overall Study|Withdrawal by Subject|2
6219431|NCT01650558|9888014|FG002|Overall Study|Lost to Follow-up|6
6219432|NCT01650558|9888012|FG000|Overall Study|Death|10
6219433|NCT01650558|9888013|FG001|Overall Study|Death|6
6219434|NCT01650558|9888014|FG002|Overall Study|Death|8
6219435|NCT01650558|9888012|FG000|Overall Study|Withdrawal by Subject|1
6219436|NCT01650558|9888013|FG001|Overall Study|Withdrawal by Subject|1
6219437|NCT01650558|9888014|FG002|Overall Study|Withdrawal by Subject|3
6219438|NCT01650558|9888012|FG000|Overall Study|Non-compliant participant|1
6219439|NCT01650558|9888013|FG001|Overall Study|Non-compliant participant|0
6219440|NCT01650558|9888014|FG002|Overall Study|Non-compliant participant|2
6219441|NCT01650558|9888012|FG000|Overall Study|Physician Decision|0
6219442|NCT01650558|9888013|FG001|Overall Study|Physician Decision|1
6219443|NCT01650558|9888014|FG002|Overall Study|Physician Decision|0
6219444|NCT01650636|9888032|FG000|Washout up to 5 Months|Withdrawal by Subject|4
6219445|NCT01650636|9888033|FG001|Washout up to 5 Months|Withdrawal by Subject|8
6219446|NCT01650636|9888032|FG000|Washout up to 5 Months|Physician Decision|2
6219447|NCT01650636|9888033|FG001|Washout up to 5 Months|Physician Decision|2
6219448|NCT01650636|9888032|FG000|Washout up to 5 Months|Death|1
6219449|NCT01650636|9888033|FG001|Washout up to 5 Months|Death|0
6219450|NCT01650636|9888032|FG000|Washout up to 5 Months|Lost to Follow-up|2
6219451|NCT01650636|9888033|FG001|Washout up to 5 Months|Lost to Follow-up|8
6219452|NCT01650636|9888032|FG000|Washout up to 9 Months|Withdrawal by Subject|4
6219453|NCT01650636|9888033|FG001|Washout up to 9 Months|Withdrawal by Subject|2
6219454|NCT01650636|9888032|FG000|Washout up to 9 Months|Lost to Follow-up|2
6219455|NCT01650636|9888033|FG001|Washout up to 9 Months|Lost to Follow-up|1
6219456|NCT01650779|9888039|FG000|Overall Study|Withdrawal by Subject|1
6219457|NCT01650805|9888045|FG000|Overall Study|Withdrawal by Subject|1
6219458|NCT01650805|9888046|FG001|Overall Study|Withdrawal by Subject|0
5980927|NCT04042077|9569678|FG001|Overall Study|Physician Decision|0
6128191|NCT00947882|9754573|FG000|Overall Study|Protocol Violation|0
6128192|NCT00947882|9754574|FG001|Overall Study|Protocol Violation|0
6128193|NCT00947882|9754575|FG002|Overall Study|Protocol Violation|1
6128194|NCT00947882|9754576|FG003|Overall Study|Protocol Violation|0
6128195|NCT00947882|9754573|FG000|Overall Study|Lost to Follow-up|0
6128196|NCT00947882|9754574|FG001|Overall Study|Lost to Follow-up|2
6128197|NCT00947882|9754575|FG002|Overall Study|Lost to Follow-up|1
6128198|NCT00947882|9754576|FG003|Overall Study|Lost to Follow-up|0
6128199|NCT00947882|9754573|FG000|Overall Study|Other/Unknown|10
6128200|NCT00947882|9754574|FG001|Overall Study|Other/Unknown|13
6128201|NCT00947882|9754575|FG002|Overall Study|Other/Unknown|3
6128202|NCT00947882|9754576|FG003|Overall Study|Other/Unknown|6
6128203|NCT00947882|9754573|FG000|Overall Study|Trial Terminated by Sponsor|62
6128204|NCT00947882|9754574|FG001|Overall Study|Trial Terminated by Sponsor|61
6128205|NCT00947882|9754575|FG002|Overall Study|Trial Terminated by Sponsor|62
6128206|NCT00947882|9754576|FG003|Overall Study|Trial Terminated by Sponsor|70
6128207|NCT00948025|9754589|FG000|Phase 1 (Pilot Phase)|Adverse Event|1
6128208|NCT00948025|9754590|FG001|Phase 1 (Pilot Phase)|Adverse Event|1
6128209|NCT00948025|9754589|FG000|Phase 1 (Pilot Phase)|Lost to Follow-up|7
6128210|NCT00948025|9754590|FG001|Phase 1 (Pilot Phase)|Lost to Follow-up|1
6219459|NCT01650831|9888052|FG000|Overall Study|Screen failure|1
6219460|NCT01651000|9888071|FG000|Overall Study|Adverse Event|2
6219461|NCT01651000|9888072|FG001|Overall Study|Adverse Event|8
6219462|NCT01651000|9888071|FG000|Overall Study|Lost to Follow-up|3
6219463|NCT01651000|9888072|FG001|Overall Study|Lost to Follow-up|2
6219464|NCT01651000|9888071|FG000|Overall Study|Protocol Violation|0
6219465|NCT01651000|9888072|FG001|Overall Study|Protocol Violation|3
6128211|NCT00948025|9754589|FG000|Phase 1 (Pilot Phase)|Withdrawal by Subject|1
6128212|NCT00948025|9754590|FG001|Phase 1 (Pilot Phase)|Withdrawal by Subject|1
6128213|NCT00948064|9754600|FG000|Phase I|No treatment received|1
6128214|NCT00948064|9754601|FG001|Phase I|No treatment received|0
6128215|NCT00948064|9754602|FG002|Phase I|No treatment received|0
6128216|NCT00948064|9754600|FG000|Phase II|Physician Decision|0
6128217|NCT00948064|9754601|FG001|Phase II|Physician Decision|0
6128218|NCT00948064|9754602|FG002|Phase II|Physician Decision|1
6128219|NCT00948064|9754600|FG000|Phase II|Withdrawal by Subject|0
6128220|NCT00948064|9754601|FG001|Phase II|Withdrawal by Subject|1
6128221|NCT00948064|9754602|FG002|Phase II|Withdrawal by Subject|0
6128222|NCT00948155|9754626|FG000|First Intervention 21 Days|Lost to Follow-up|2
6128223|NCT00948155|9754627|FG001|First Intervention 21 Days|Lost to Follow-up|2
6128224|NCT00948155|9754626|FG000|Washout 14 Days|Lost to Follow-up|1
6128225|NCT00948155|9754627|FG001|Washout 14 Days|Lost to Follow-up|2
6128226|NCT00948246|9754635|FG000|Overall Study|Lost to Follow-up|11
6128227|NCT00948246|9754635|FG000|Overall Study|Adverse Event|11
6128228|NCT00948246|9754635|FG000|Overall Study|Death|1
6128229|NCT00948246|9754635|FG000|Overall Study|Withdrawal by Subject|1
6128230|NCT00948389|9754653|FG000|Overall Study|Disease Progression/Relapse/Death|3
6128231|NCT00948389|9754654|FG001|Overall Study|Disease Progression/Relapse/Death|3
6128232|NCT00948389|9754655|FG002|Overall Study|Disease Progression/Relapse/Death|7
6128233|NCT00948389|9754656|FG003|Overall Study|Disease Progression/Relapse/Death|8
6128234|NCT00948389|9754657|FG004|Overall Study|Disease Progression/Relapse/Death|1
6128235|NCT00948389|9754653|FG000|Overall Study|Thrombocytopenia, Grade 4|2
6128236|NCT00948389|9754654|FG001|Overall Study|Thrombocytopenia, Grade 4|0
6128237|NCT00948389|9754655|FG002|Overall Study|Thrombocytopenia, Grade 4|0
6128238|NCT00948389|9754656|FG003|Overall Study|Thrombocytopenia, Grade 4|1
6128239|NCT00948389|9754657|FG004|Overall Study|Thrombocytopenia, Grade 4|0
6128240|NCT00948389|9754653|FG000|Overall Study|Both Progression and Toxicity|1
6128241|NCT00948389|9754654|FG001|Overall Study|Both Progression and Toxicity|0
6128242|NCT00948389|9754655|FG002|Overall Study|Both Progression and Toxicity|0
6128243|NCT00948389|9754656|FG003|Overall Study|Both Progression and Toxicity|0
6128244|NCT00948389|9754657|FG004|Overall Study|Both Progression and Toxicity|0
6128245|NCT00948428|9754674|FG000|Overall Study|Withdrawal by Subject|6
6128246|NCT00948428|9754675|FG001|Overall Study|Withdrawal by Subject|12
6128247|NCT00948428|9754676|FG002|Overall Study|Withdrawal by Subject|7
6128248|NCT00948428|9754674|FG000|Overall Study|Adverse Event|6
6128249|NCT00948428|9754675|FG001|Overall Study|Adverse Event|3
6128250|NCT00948428|9754676|FG002|Overall Study|Adverse Event|0
6128251|NCT00948428|9754674|FG000|Overall Study|Lost to Follow-up|2
6128252|NCT00948428|9754675|FG001|Overall Study|Lost to Follow-up|1
6128253|NCT00948428|9754676|FG002|Overall Study|Lost to Follow-up|1
6128254|NCT00948428|9754674|FG000|Overall Study|Death|2
6128255|NCT00948428|9754675|FG001|Overall Study|Death|0
6128256|NCT00948428|9754676|FG002|Overall Study|Death|0
6128257|NCT00948428|9754674|FG000|Overall Study|Intercurrent Illness|1
6128258|NCT00948428|9754675|FG001|Overall Study|Intercurrent Illness|0
6128259|NCT00948428|9754676|FG002|Overall Study|Intercurrent Illness|0
6128260|NCT00948428|9754674|FG000|Overall Study|Non-compliance|1
6219466|NCT01651000|9888071|FG000|Overall Study|Withdrawal by Subject|2
6219467|NCT01651000|9888072|FG001|Overall Study|Withdrawal by Subject|10
6219468|NCT01651000|9888071|FG000|Overall Study|Subject noncompliance|0
6219469|NCT01651000|9888072|FG001|Overall Study|Subject noncompliance|3
6219470|NCT01651000|9888071|FG000|Overall Study|Lack of Efficacy|1
6219471|NCT01651000|9888072|FG001|Overall Study|Lack of Efficacy|1
6219472|NCT01651000|9888071|FG000|Overall Study|Physician Decision|1
6219473|NCT01651000|9888072|FG001|Overall Study|Physician Decision|0
6219474|NCT01651000|9888071|FG000|Overall Study|Administrative reason|1
6219475|NCT01651000|9888072|FG001|Overall Study|Administrative reason|0
6219476|NCT01651000|9888071|FG000|Overall Study|Serum Ca >/= 11.0 mg/dL, repeat confirm|0
6219477|NCT01651000|9888072|FG001|Overall Study|Serum Ca >/= 11.0 mg/dL, repeat confirm|1
6219478|NCT01651039|9888078|FG000|Overall Study|Non-evaluables|5
6219479|NCT01651039|9888078|FG000|Overall Study|Physician Decision|2
6219480|NCT01651039|9888078|FG000|Overall Study|Withdrawal by Subject|1
6219481|NCT01651039|9888078|FG000|Overall Study|Progressive Disease|22
6219482|NCT01651052|9888082|FG000|Overall Study|Death|21
6219483|NCT01651052|9888082|FG000|Overall Study|Explant|1
6219484|NCT01651052|9888082|FG000|Overall Study|Withdrawal by Subject|1
6288863|NCT02373202|10003298|FG003|Overall Study|Other|0
6288864|NCT02373813|10003320|FG000|Run-In Period|Other, Not Specified|5
6288865|NCT02373813|10003321|FG001|Run-In Period|Other, Not Specified|0
6288866|NCT02373813|10003322|FG002|Run-In Period|Other, Not Specified|0
6288867|NCT02373813|10003323|FG003|Run-In Period|Other, Not Specified|0
6288868|NCT02373813|10003320|FG000|Run-In Period|Withdrawal by Subject|16
6288869|NCT02373813|10003321|FG001|Run-In Period|Withdrawal by Subject|0
6288870|NCT02373813|10003322|FG002|Run-In Period|Withdrawal by Subject|0
6128261|NCT00948428|9754675|FG001|Overall Study|Non-compliance|2
6128262|NCT00948428|9754676|FG002|Overall Study|Non-compliance|0
6288871|NCT02373813|10003323|FG003|Run-In Period|Withdrawal by Subject|0
6128263|NCT00948441|9754686|FG000|Overall Study|no longer meet inclusion criteria|1
6219485|NCT01651052|9888082|FG000|Overall Study|Lost to Follow-up|3
6219486|NCT01651117|9888098|FG000|Overall Study|Death|2
6219487|NCT01651117|9888099|FG001|Overall Study|Death|3
6219488|NCT01651117|9888100|FG002|Overall Study|Death|2
6128264|NCT00948441|9754687|FG001|Overall Study|no longer meet inclusion criteria|4
6128265|NCT00948506|9754697|FG000|Overall Study|Withdrawal by Subject|3
6128266|NCT00948506|9754698|FG001|Overall Study|Withdrawal by Subject|1
6128267|NCT00948675|9754718|FG000|Overall Study|Lost to Follow-up|1
6128268|NCT00948675|9754719|FG001|Overall Study|Lost to Follow-up|0
6128269|NCT00948688|9754725|FG000|Period 1: 200 mg Vorinostat|Adverse Event|1
6128270|NCT00948688|9754726|FG001|Period 1: 200 mg Vorinostat|Adverse Event|0
6128271|NCT00948688|9754725|FG000|Period 1: 200 mg Vorinostat|Protocol Violation|1
6128272|NCT00948688|9754726|FG001|Period 1: 200 mg Vorinostat|Protocol Violation|0
6128273|NCT00948688|9754725|FG000|Period 2: 100 mg Vorinostat|Adverse Event|0
6128274|NCT00948688|9754726|FG001|Period 2: 100 mg Vorinostat|Adverse Event|1
6128275|NCT00948766|9754735|FG000|Core Study|Adverse Event|73
6128276|NCT00948766|9754736|FG001|Core Study|Adverse Event|51
6128277|NCT00948766|9754735|FG000|Core Study|Unsatisfactory Therapeutic Effect|13
6128278|NCT00948766|9754736|FG001|Core Study|Unsatisfactory Therapeutic Effect|14
6128279|NCT00948766|9754735|FG000|Core Study|Patient Withdrew Consent|27
6128280|NCT00948766|9754736|FG001|Core Study|Patient Withdrew Consent|46
6128281|NCT00948766|9754735|FG000|Core Study|Lost to Follow-up|3
6128282|NCT00948766|9754736|FG001|Core Study|Lost to Follow-up|2
6128283|NCT00948766|9754735|FG000|Core Study|Administrative Problems|2
6128284|NCT00948766|9754736|FG001|Core Study|Administrative Problems|2
6128285|NCT00948766|9754735|FG000|Core Study|Death|1
6128286|NCT00948766|9754736|FG001|Core Study|Death|1
6128287|NCT00948766|9754735|FG000|Core Study|Protocol Deviation|8
6128288|NCT00948766|9754736|FG001|Core Study|Protocol Deviation|10
6128289|NCT00948766|9754735|FG000|Extension Study|Adverse Event|43
6128290|NCT00948766|9754736|FG001|Extension Study|Adverse Event|0
6128291|NCT00948766|9754735|FG000|Extension Study|Unsatisfactory Therapeutic Effect|2
6128292|NCT00948766|9754736|FG001|Extension Study|Unsatisfactory Therapeutic Effect|0
6128293|NCT00948766|9754735|FG000|Extension Study|Study Drug No Longer Required|1
6128294|NCT00948766|9754736|FG001|Extension Study|Study Drug No Longer Required|0
6128295|NCT00948766|9754735|FG000|Extension Study|Patient Withdrew Consent|32
6128296|NCT00948766|9754736|FG001|Extension Study|Patient Withdrew Consent|0
6128297|NCT00948766|9754735|FG000|Extension Study|Lost to Follow-up|8
6128298|NCT00948766|9754736|FG001|Extension Study|Lost to Follow-up|0
6128299|NCT00948766|9754735|FG000|Extension Study|Administrative Problems|1
6128300|NCT00948766|9754736|FG001|Extension Study|Administrative Problems|0
6128301|NCT00948766|9754735|FG000|Extension Study|Death|4
6128302|NCT00948766|9754736|FG001|Extension Study|Death|0
6128303|NCT00948818|9754751|FG000|Overall Study|Adverse Event|10
6128304|NCT00948818|9754752|FG001|Overall Study|Adverse Event|32
6128305|NCT00948818|9754751|FG000|Overall Study|Protocol Violation|9
6128306|NCT00948818|9754752|FG001|Overall Study|Protocol Violation|10
6128307|NCT00948818|9754751|FG000|Overall Study|Withdrawal by Subject|25
6128308|NCT00948818|9754752|FG001|Overall Study|Withdrawal by Subject|25
6128309|NCT00948818|9754751|FG000|Overall Study|Lost to Follow-up|10
6128310|NCT00948818|9754752|FG001|Overall Study|Lost to Follow-up|17
6128311|NCT00948818|9754751|FG000|Overall Study|Lack of Efficacy|4
6128312|NCT00948818|9754752|FG001|Overall Study|Lack of Efficacy|5
6128313|NCT00948818|9754751|FG000|Overall Study|Other Reason|4
6128314|NCT00948818|9754752|FG001|Overall Study|Other Reason|5
6128315|NCT00948857|9754763|FG000|Overall Study|Lost to Follow-up|1
6128316|NCT00948857|9754764|FG001|Overall Study|Lost to Follow-up|0
6128317|NCT00948896|9754778|FG000|Randomization to 24 Months of Age|Death|1
6128318|NCT00948896|9754779|FG001|Randomization to 24 Months of Age|Death|0
6128319|NCT00948896|9754780|FG002|Randomization to 24 Months of Age|Death|0
6128320|NCT00948896|9754781|FG003|Randomization to 24 Months of Age|Death|0
6128321|NCT00948896|9754782|FG004|Randomization to 24 Months of Age|Death|2
6128322|NCT00948896|9754783|FG005|Randomization to 24 Months of Age|Death|1
6128323|NCT00948896|9754784|FG006|Randomization to 24 Months of Age|Death|2
6128324|NCT00948896|9754785|FG007|Randomization to 24 Months of Age|Death|1
6128325|NCT00948896|9754778|FG000|Randomization to 24 Months of Age|Withdrawal by Subject|3
6128326|NCT00948896|9754779|FG001|Randomization to 24 Months of Age|Withdrawal by Subject|5
6128327|NCT00948896|9754780|FG002|Randomization to 24 Months of Age|Withdrawal by Subject|4
6128328|NCT00948896|9754781|FG003|Randomization to 24 Months of Age|Withdrawal by Subject|4
6128329|NCT00948896|9754782|FG004|Randomization to 24 Months of Age|Withdrawal by Subject|0
6128330|NCT00948896|9754783|FG005|Randomization to 24 Months of Age|Withdrawal by Subject|1
6128331|NCT00948896|9754784|FG006|Randomization to 24 Months of Age|Withdrawal by Subject|0
6128332|NCT00948896|9754785|FG007|Randomization to 24 Months of Age|Withdrawal by Subject|0
6128333|NCT00948896|9754778|FG000|Randomization to 24 Months of Age|Lost to Follow-up|4
6128334|NCT00948896|9754779|FG001|Randomization to 24 Months of Age|Lost to Follow-up|4
6219489|NCT01651117|9888101|FG003|Overall Study|Death|2
6219490|NCT01651208|9888137|FG000|Overall Study|Lost to Follow-up|14
6219491|NCT01651208|9888138|FG001|Overall Study|Lost to Follow-up|16
6128335|NCT00948896|9754780|FG002|Randomization to 24 Months of Age|Lost to Follow-up|2
6128336|NCT00948896|9754781|FG003|Randomization to 24 Months of Age|Lost to Follow-up|5
6128337|NCT00948896|9754782|FG004|Randomization to 24 Months of Age|Lost to Follow-up|0
6128338|NCT00948896|9754783|FG005|Randomization to 24 Months of Age|Lost to Follow-up|0
6128339|NCT00948896|9754784|FG006|Randomization to 24 Months of Age|Lost to Follow-up|1
6128340|NCT00948896|9754785|FG007|Randomization to 24 Months of Age|Lost to Follow-up|0
6219492|NCT01651260|9888145|FG000|Overall Study|unable to apply product|3
6128341|NCT00948896|9754778|FG000|Randomization to 24 Months of Age|Protocol Violation|0
6128342|NCT00948896|9754779|FG001|Randomization to 24 Months of Age|Protocol Violation|1
6128343|NCT00948896|9754780|FG002|Randomization to 24 Months of Age|Protocol Violation|0
6128344|NCT00948896|9754781|FG003|Randomization to 24 Months of Age|Protocol Violation|1
6128345|NCT00948896|9754782|FG004|Randomization to 24 Months of Age|Protocol Violation|0
6128346|NCT00948896|9754783|FG005|Randomization to 24 Months of Age|Protocol Violation|0
6128347|NCT00948896|9754784|FG006|Randomization to 24 Months of Age|Protocol Violation|1
6128348|NCT00948896|9754785|FG007|Randomization to 24 Months of Age|Protocol Violation|1
6128349|NCT00948896|9754778|FG000|Randomization to 24 Months of Age|Moved out of Study Area|0
6128350|NCT00948896|9754779|FG001|Randomization to 24 Months of Age|Moved out of Study Area|3
6128351|NCT00948896|9754780|FG002|Randomization to 24 Months of Age|Moved out of Study Area|3
6128352|NCT00948896|9754781|FG003|Randomization to 24 Months of Age|Moved out of Study Area|1
6128353|NCT00948896|9754782|FG004|Randomization to 24 Months of Age|Moved out of Study Area|0
6128354|NCT00948896|9754783|FG005|Randomization to 24 Months of Age|Moved out of Study Area|2
6128355|NCT00948896|9754784|FG006|Randomization to 24 Months of Age|Moved out of Study Area|0
6128356|NCT00948896|9754785|FG007|Randomization to 24 Months of Age|Moved out of Study Area|0
6128357|NCT00948896|9754778|FG000|24 Months of Age to 36 Months of Age|Death|0
6128358|NCT00948896|9754779|FG001|24 Months of Age to 36 Months of Age|Death|2
6128359|NCT00948896|9754780|FG002|24 Months of Age to 36 Months of Age|Death|2
6128360|NCT00948896|9754781|FG003|24 Months of Age to 36 Months of Age|Death|0
6128361|NCT00948896|9754782|FG004|24 Months of Age to 36 Months of Age|Death|0
6128362|NCT00948896|9754783|FG005|24 Months of Age to 36 Months of Age|Death|1
6128363|NCT00948896|9754784|FG006|24 Months of Age to 36 Months of Age|Death|0
6128364|NCT00948896|9754785|FG007|24 Months of Age to 36 Months of Age|Death|0
6128365|NCT00948896|9754778|FG000|24 Months of Age to 36 Months of Age|Withdrawal by Subject|1
6128366|NCT00948896|9754779|FG001|24 Months of Age to 36 Months of Age|Withdrawal by Subject|0
6128367|NCT00948896|9754780|FG002|24 Months of Age to 36 Months of Age|Withdrawal by Subject|1
6219493|NCT01651780|9888181|FG000|Overall Study|Physician decision: No 30-day visit|2
6219494|NCT01651780|9888182|FG001|Overall Study|Physician decision: No 30-day visit|1
6219495|NCT01651780|9888181|FG000|Overall Study|Reason Not Specified: No 30-day visit|2
6288872|NCT02373813|10003320|FG000|Run-In Period|Decision by Sponsor|11
6288873|NCT02373813|10003321|FG001|Run-In Period|Decision by Sponsor|0
6288874|NCT02373813|10003322|FG002|Run-In Period|Decision by Sponsor|0
6288875|NCT02373813|10003323|FG003|Run-In Period|Decision by Sponsor|0
6288876|NCT02373813|10003320|FG000|Run-In Period|Protocol Violation|75
6288877|NCT02373813|10003321|FG001|Run-In Period|Protocol Violation|0
6288878|NCT02373813|10003322|FG002|Run-In Period|Protocol Violation|0
6288879|NCT02373813|10003323|FG003|Run-In Period|Protocol Violation|0
6288880|NCT02373813|10003320|FG000|Run-In Period|Lost to Follow-up|2
6288881|NCT02373813|10003321|FG001|Run-In Period|Lost to Follow-up|0
6288882|NCT02373813|10003322|FG002|Run-In Period|Lost to Follow-up|0
6288883|NCT02373813|10003323|FG003|Run-In Period|Lost to Follow-up|0
6288884|NCT02373813|10003320|FG000|Run-In Period|Adverse Event|3
6288885|NCT02373813|10003321|FG001|Run-In Period|Adverse Event|0
6288886|NCT02373813|10003322|FG002|Run-In Period|Adverse Event|0
6288887|NCT02373813|10003323|FG003|Run-In Period|Adverse Event|0
6288888|NCT02373813|10003320|FG000|Run-In Period|Noncompliance|1
6288889|NCT02373813|10003321|FG001|Run-In Period|Noncompliance|0
6288890|NCT02373813|10003322|FG002|Run-In Period|Noncompliance|0
6288891|NCT02373813|10003323|FG003|Run-In Period|Noncompliance|0
6288892|NCT02373813|10003320|FG000|Run-In Period|Ineligibility Determined|3
6288893|NCT02373813|10003321|FG001|Run-In Period|Ineligibility Determined|0
6288894|NCT02373813|10003322|FG002|Run-In Period|Ineligibility Determined|0
6288895|NCT02373813|10003323|FG003|Run-In Period|Ineligibility Determined|0
6128368|NCT00948896|9754781|FG003|24 Months of Age to 36 Months of Age|Withdrawal by Subject|1
6128369|NCT00948896|9754782|FG004|24 Months of Age to 36 Months of Age|Withdrawal by Subject|0
6128370|NCT00948896|9754783|FG005|24 Months of Age to 36 Months of Age|Withdrawal by Subject|0
6128371|NCT00948896|9754784|FG006|24 Months of Age to 36 Months of Age|Withdrawal by Subject|0
6128372|NCT00948896|9754785|FG007|24 Months of Age to 36 Months of Age|Withdrawal by Subject|0
6128373|NCT00948896|9754778|FG000|24 Months of Age to 36 Months of Age|Lost to Follow-up|2
6128374|NCT00948896|9754779|FG001|24 Months of Age to 36 Months of Age|Lost to Follow-up|0
6128375|NCT00948896|9754780|FG002|24 Months of Age to 36 Months of Age|Lost to Follow-up|1
6128376|NCT00948896|9754781|FG003|24 Months of Age to 36 Months of Age|Lost to Follow-up|0
6128377|NCT00948896|9754782|FG004|24 Months of Age to 36 Months of Age|Lost to Follow-up|1
6128378|NCT00948896|9754783|FG005|24 Months of Age to 36 Months of Age|Lost to Follow-up|0
6219496|NCT01651780|9888182|FG001|Overall Study|Reason Not Specified: No 30-day visit|2
6219497|NCT01651780|9888181|FG000|Overall Study|Withdrawal by Subject|2
6219498|NCT01651780|9888182|FG001|Overall Study|Withdrawal by Subject|0
6219499|NCT01651780|9888181|FG000|Overall Study|Inclusion/Exclusion Criteria Not Met|3
6219500|NCT01651780|9888182|FG001|Overall Study|Inclusion/Exclusion Criteria Not Met|0
6219501|NCT01651780|9888181|FG000|Overall Study|Lost to Follow-up|1
6288896|NCT02373813|10003320|FG000|Double-Blind Treatment Period|Decision by Sponsor|0
6288897|NCT02373813|10003321|FG001|Double-Blind Treatment Period|Decision by Sponsor|1
6288898|NCT02373813|10003322|FG002|Double-Blind Treatment Period|Decision by Sponsor|2
6288899|NCT02373813|10003323|FG003|Double-Blind Treatment Period|Decision by Sponsor|0
6128379|NCT00948896|9754784|FG006|24 Months of Age to 36 Months of Age|Lost to Follow-up|0
6128380|NCT00948896|9754785|FG007|24 Months of Age to 36 Months of Age|Lost to Follow-up|0
6128381|NCT00948896|9754778|FG000|24 Months of Age to 36 Months of Age|Protocol Violation|0
6128382|NCT00948896|9754779|FG001|24 Months of Age to 36 Months of Age|Protocol Violation|0
6128383|NCT00948896|9754780|FG002|24 Months of Age to 36 Months of Age|Protocol Violation|1
6128384|NCT00948896|9754781|FG003|24 Months of Age to 36 Months of Age|Protocol Violation|0
6128385|NCT00948896|9754782|FG004|24 Months of Age to 36 Months of Age|Protocol Violation|0
6128386|NCT00948896|9754783|FG005|24 Months of Age to 36 Months of Age|Protocol Violation|1
6128387|NCT00948896|9754784|FG006|24 Months of Age to 36 Months of Age|Protocol Violation|0
6128388|NCT00948896|9754785|FG007|24 Months of Age to 36 Months of Age|Protocol Violation|0
6128389|NCT00948896|9754778|FG000|24 Months of Age to 36 Months of Age|Moved out of Study Area|0
6128390|NCT00948896|9754779|FG001|24 Months of Age to 36 Months of Age|Moved out of Study Area|0
6128391|NCT00948896|9754780|FG002|24 Months of Age to 36 Months of Age|Moved out of Study Area|0
6128392|NCT00948896|9754781|FG003|24 Months of Age to 36 Months of Age|Moved out of Study Area|1
6128393|NCT00948896|9754782|FG004|24 Months of Age to 36 Months of Age|Moved out of Study Area|0
6128394|NCT00948896|9754783|FG005|24 Months of Age to 36 Months of Age|Moved out of Study Area|0
6128395|NCT00948896|9754784|FG006|24 Months of Age to 36 Months of Age|Moved out of Study Area|0
6128396|NCT00948896|9754785|FG007|24 Months of Age to 36 Months of Age|Moved out of Study Area|0
6128397|NCT00948922|9754810|FG000|Overall Study|Did not start study treatment|2
6128398|NCT00948922|9754811|FG001|Overall Study|Did not start study treatment|5
6128399|NCT00948922|9754812|FG002|Overall Study|Did not start study treatment|0
6128400|NCT00948922|9754810|FG000|Overall Study|Withdrawal by Subject|0
6128401|NCT00948922|9754811|FG001|Overall Study|Withdrawal by Subject|2
6128402|NCT00948922|9754812|FG002|Overall Study|Withdrawal by Subject|1
6128403|NCT00948922|9754810|FG000|Overall Study|Death|3
6128404|NCT00948922|9754811|FG001|Overall Study|Death|0
6128405|NCT00948922|9754812|FG002|Overall Study|Death|0
6128406|NCT00948922|9754810|FG000|Overall Study|Disease progression|0
6128407|NCT00948922|9754811|FG001|Overall Study|Disease progression|1
6128408|NCT00948922|9754812|FG002|Overall Study|Disease progression|0
6128409|NCT00948922|9754810|FG000|Overall Study|Insurance issues|1
6128410|NCT00948922|9754811|FG001|Overall Study|Insurance issues|0
6128411|NCT00948922|9754812|FG002|Overall Study|Insurance issues|0
6128412|NCT00948922|9754810|FG000|Overall Study|Transplant eligibility issues|2
6128413|NCT00948922|9754811|FG001|Overall Study|Transplant eligibility issues|3
6128414|NCT00948922|9754812|FG002|Overall Study|Transplant eligibility issues|0
6128415|NCT00948922|9754810|FG000|Overall Study|Not evaluable at time of analysis|0
6128416|NCT00948922|9754811|FG001|Overall Study|Not evaluable at time of analysis|3
6128417|NCT00948922|9754812|FG002|Overall Study|Not evaluable at time of analysis|0
6128418|NCT00948974|9754830|FG000|Overall Study|Lost to Follow-up|23
6128419|NCT00948974|9754831|FG001|Overall Study|Lost to Follow-up|20
6128420|NCT00949117|9754848|FG000|Overall Study|Lack of Efficacy|2
6128421|NCT00949117|9754849|FG001|Overall Study|Lack of Efficacy|3
6128422|NCT00949117|9754848|FG000|Overall Study|Protocol Violation|1
6128423|NCT00949117|9754849|FG001|Overall Study|Protocol Violation|1
6128424|NCT00949117|9754848|FG000|Overall Study|Adverse Event|0
6219502|NCT01651780|9888182|FG001|Overall Study|Lost to Follow-up|2
6219503|NCT01651780|9888181|FG000|Overall Study|Physician decision: Day 30 visit <23 day|1
6219504|NCT01651780|9888182|FG001|Overall Study|Physician decision: Day 30 visit <23 day|5
6219505|NCT01651936|9888233|FG000|Base Study|Adverse Event|3
6219506|NCT01651936|9888234|FG001|Base Study|Adverse Event|0
6219507|NCT01651936|9888235|FG002|Base Study|Adverse Event|0
6219508|NCT01651936|9888233|FG000|Base Study|Withdrawal by Subject|1
6219509|NCT01651936|9888234|FG001|Base Study|Withdrawal by Subject|1
6219510|NCT01651936|9888235|FG002|Base Study|Withdrawal by Subject|0
6219511|NCT01651936|9888233|FG000|Base Study|Early Escape|2
6219512|NCT01651936|9888234|FG001|Base Study|Early Escape|8
6219513|NCT01651936|9888235|FG002|Base Study|Early Escape|0
6219514|NCT01651936|9888233|FG000|Base Study|Study terminated by sponsor|21
6219515|NCT01651936|9888234|FG001|Base Study|Study terminated by sponsor|16
6219516|NCT01651936|9888235|FG002|Base Study|Study terminated by sponsor|0
6219517|NCT01651936|9888233|FG000|Extension Study|Lack of Efficacy|0
6219518|NCT01651936|9888234|FG001|Extension Study|Lack of Efficacy|0
6219519|NCT01651936|9888235|FG002|Extension Study|Lack of Efficacy|1
6219520|NCT01651936|9888233|FG000|Extension Study|Study terminated by sponsor|0
6219521|NCT01651936|9888234|FG001|Extension Study|Study terminated by sponsor|0
6219522|NCT01651936|9888235|FG002|Extension Study|Study terminated by sponsor|13
6219523|NCT01651949|9888245|FG000|Overall Study|Unknown status|4
6219524|NCT01651949|9888246|FG001|Overall Study|Unknown status|4
6219525|NCT01651949|9888247|FG002|Overall Study|Unknown status|0
6219526|NCT01651949|9888245|FG000|Overall Study|Lost to Follow-up|30
6219527|NCT01651949|9888246|FG001|Overall Study|Lost to Follow-up|56
6219528|NCT01651949|9888247|FG002|Overall Study|Lost to Follow-up|20
6219529|NCT01651949|9888245|FG000|Overall Study|Protocol Violation|0
6219530|NCT01651949|9888246|FG001|Overall Study|Protocol Violation|2
6219531|NCT01651949|9888247|FG002|Overall Study|Protocol Violation|1
6219532|NCT01651949|9888245|FG000|Overall Study|Physician Decision|0
6219533|NCT01651949|9888246|FG001|Overall Study|Physician Decision|2
6219534|NCT01651949|9888247|FG002|Overall Study|Physician Decision|0
6219535|NCT01651949|9888245|FG000|Overall Study|Adverse Event|0
6128425|NCT00949117|9754849|FG001|Overall Study|Adverse Event|1
6128426|NCT00949325|9754861|FG000|Overall Study|Adverse Event|0
6128427|NCT00949325|9754862|FG001|Overall Study|Adverse Event|2
6128428|NCT00949325|9754863|FG002|Overall Study|Adverse Event|0
6128429|NCT00949533|9754881|FG000|Overall Study|Lost to Follow-up|0
6128430|NCT00949533|9754882|FG001|Overall Study|Lost to Follow-up|1
6128431|NCT00949650|9754890|FG000|Overall Study|Progressive disease|188
6128432|NCT00949650|9754891|FG001|Overall Study|Progressive disease|19
6128433|NCT00949650|9754890|FG000|Overall Study|Completed 6 courses of chemotherapy|0
6128434|NCT00949650|9754891|FG001|Overall Study|Completed 6 courses of chemotherapy|60
6128435|NCT00949650|9754890|FG000|Overall Study|Other Adverse Event (AE)|28
6128436|NCT00949650|9754891|FG001|Overall Study|Other Adverse Event (AE)|17
6128437|NCT00949650|9754890|FG000|Overall Study|Protocol Violation|1
6128438|NCT00949650|9754891|FG001|Overall Study|Protocol Violation|4
6128439|NCT00949650|9754890|FG000|Overall Study|Refusal to continue medication|7
6128440|NCT00949650|9754891|FG001|Overall Study|Refusal to continue medication|11
6128441|NCT00949650|9754890|FG000|Overall Study|Not treated|1
6128442|NCT00949650|9754891|FG001|Overall Study|Not treated|4
6128443|NCT00949650|9754890|FG000|Overall Study|Other not specified above|5
6128444|NCT00949650|9754891|FG001|Overall Study|Other not specified above|0
6128445|NCT00949702|9754901|FG000|Overall Study|Death|40
6128446|NCT00949702|9754901|FG000|Overall Study|Disease progression|7
6128447|NCT00949702|9754901|FG000|Overall Study|Withdrawal of consent|1
6128448|NCT00949715|9754907|FG000|Overall Study|Physician Decision|1
6128449|NCT00949715|9754908|FG001|Overall Study|Physician Decision|0
6128450|NCT00949715|9754907|FG000|Overall Study|Lost to Follow-up|1
6128451|NCT00949715|9754908|FG001|Overall Study|Lost to Follow-up|0
6128452|NCT00949715|9754907|FG000|Overall Study|Missing 24 month LVEF measurement|2
6128453|NCT00949715|9754908|FG001|Overall Study|Missing 24 month LVEF measurement|0
6128454|NCT00949884|9754916|FG000|Overall Study|Adverse Event|14
6128455|NCT00949884|9754917|FG001|Overall Study|Adverse Event|3
6128456|NCT00949884|9754918|FG002|Overall Study|Adverse Event|12
6128457|NCT00949884|9754916|FG000|Overall Study|Did not meet inclusion/exclusion|2
6128458|NCT00949884|9754917|FG001|Overall Study|Did not meet inclusion/exclusion|1
6128459|NCT00949884|9754918|FG002|Overall Study|Did not meet inclusion/exclusion|3
6128460|NCT00949884|9754916|FG000|Overall Study|Lost to Follow-up|7
6128461|NCT00949884|9754917|FG001|Overall Study|Lost to Follow-up|5
6128462|NCT00949884|9754918|FG002|Overall Study|Lost to Follow-up|5
6128463|NCT00949884|9754916|FG000|Overall Study|Physician Decision|5
6128464|NCT00949884|9754917|FG001|Overall Study|Physician Decision|0
6128465|NCT00949884|9754918|FG002|Overall Study|Physician Decision|6
6128466|NCT00949884|9754916|FG000|Overall Study|Treatment non-compliance|5
6128467|NCT00949884|9754917|FG001|Overall Study|Treatment non-compliance|0
6128468|NCT00949884|9754918|FG002|Overall Study|Treatment non-compliance|8
6128469|NCT00949884|9754916|FG000|Overall Study|Withdrawal by Subject|13
6128470|NCT00949884|9754917|FG001|Overall Study|Withdrawal by Subject|4
6128471|NCT00949884|9754918|FG002|Overall Study|Withdrawal by Subject|16
6128472|NCT00949884|9754916|FG000|Overall Study|Lack of Efficacy|4
6128473|NCT00949884|9754917|FG001|Overall Study|Lack of Efficacy|2
6128474|NCT00949884|9754918|FG002|Overall Study|Lack of Efficacy|7
6128475|NCT00949884|9754916|FG000|Overall Study|Study terminated by sponsor|0
6128476|NCT00949884|9754917|FG001|Overall Study|Study terminated by sponsor|0
6128477|NCT00949884|9754918|FG002|Overall Study|Study terminated by sponsor|1
6128478|NCT00949910|9754927|FG000|Overall Study|Progressive Disease|3750
6128479|NCT00949910|9754927|FG000|Overall Study|Symptomatic Deterioration|1088
6128480|NCT00949910|9754927|FG000|Overall Study|Lost to Follow-up|100
6128481|NCT00949910|9754927|FG000|Overall Study|Study Drug-Related Adverse Event|315
6128482|NCT00949910|9754927|FG000|Overall Study|Participant Refusal|390
6128483|NCT00949910|9754927|FG000|Overall Study|Death Due to Malignant Disease|456
6128484|NCT00949910|9754927|FG000|Overall Study|Death Due to Progression/Deterioration|4
6128485|NCT00949910|9754927|FG000|Overall Study|Death Due to Adverse Event|115
6128486|NCT00949910|9754927|FG000|Overall Study|Death Due to Toxicity|3
6128487|NCT00949910|9754927|FG000|Overall Study|Death from Unknown Cause|5
6128488|NCT00949910|9754927|FG000|Overall Study|Unspecified Progression/Deterioration|13
6128489|NCT00949910|9754927|FG000|Overall Study|Switched to Compassionate/Other Use|174
6128490|NCT00949910|9754927|FG000|Overall Study|Switched to Commercial Treatment|4
6128491|NCT00949910|9754927|FG000|Overall Study|Violation of Eligibility|23
6128492|NCT00949910|9754927|FG000|Overall Study|Logistical Reasons|13
6128493|NCT00949910|9754927|FG000|Overall Study|Non-Compliance|10
6128494|NCT00949910|9754927|FG000|Overall Study|Prolonged Dosing Interruption|4
6128495|NCT00949910|9754927|FG000|Overall Study|Adverse Event|83
6128496|NCT00949910|9754927|FG000|Overall Study|Serious Adverse Event|6
6128497|NCT00949910|9754927|FG000|Overall Study|Physician/Participant Decision|7
6128498|NCT00949910|9754927|FG000|Overall Study|Other|4
6128499|NCT00949910|9754927|FG000|Overall Study|No Data|9
6128500|NCT00949975|9754935|FG000|Overall Study|Voluntary discontinuation|6
6128501|NCT00949975|9754936|FG001|Overall Study|Voluntary discontinuation|5
6128502|NCT00949975|9754937|FG002|Overall Study|Voluntary discontinuation|3
6128503|NCT00949975|9754938|FG003|Overall Study|Voluntary discontinuation|6
6128504|NCT00949975|9754935|FG000|Overall Study|Adverse Event|11
6128505|NCT00949975|9754936|FG001|Overall Study|Adverse Event|11
6128506|NCT00949975|9754937|FG002|Overall Study|Adverse Event|10
6128507|NCT00949975|9754938|FG003|Overall Study|Adverse Event|10
6128508|NCT00949975|9754935|FG000|Overall Study|Safety reason|0
6128509|NCT00949975|9754936|FG001|Overall Study|Safety reason|1
6128510|NCT00949975|9754937|FG002|Overall Study|Safety reason|0
6128511|NCT00949975|9754938|FG003|Overall Study|Safety reason|0
6219536|NCT01651949|9888246|FG001|Overall Study|Adverse Event|2
6219537|NCT01651949|9888247|FG002|Overall Study|Adverse Event|1
6219538|NCT01651949|9888245|FG000|Overall Study|Screen failure|2
6219539|NCT01651949|9888246|FG001|Overall Study|Screen failure|2
6219540|NCT01651949|9888247|FG002|Overall Study|Screen failure|0
6219541|NCT01651949|9888245|FG000|Overall Study|Withdrawal by Subject|17
6219542|NCT01651949|9888246|FG001|Overall Study|Withdrawal by Subject|18
6219543|NCT01651949|9888247|FG002|Overall Study|Withdrawal by Subject|9
6219544|NCT01652287|9888276|FG000|Overall Study|Withdrawal by Subject|2
6219545|NCT01652287|9888277|FG001|Overall Study|Withdrawal by Subject|0
6219546|NCT01652469|9888285|FG000|Overall Study|Withdrawal by Subject|1
6219547|NCT01652469|9888286|FG001|Overall Study|Withdrawal by Subject|4
6219548|NCT01652469|9888285|FG000|Overall Study|Lost to Follow-up|0
6219549|NCT01652469|9888286|FG001|Overall Study|Lost to Follow-up|2
6219550|NCT01652573|9888305|FG000|Overall Study|Adverse Event|0
6219551|NCT01652573|9888306|FG001|Overall Study|Adverse Event|1
6219552|NCT01652664|9888314|FG000|Overall Study|Treatment Failure|5
6219553|NCT01652664|9888315|FG001|Overall Study|Treatment Failure|1
6219554|NCT01652664|9888314|FG000|Overall Study|Inadequate IOP control|1
6219555|NCT01652664|9888315|FG001|Overall Study|Inadequate IOP control|0
6219556|NCT01652690|9888324|FG000|Overall Study|Withdrawal by Subject|16
6219557|NCT01652690|9888325|FG001|Overall Study|Withdrawal by Subject|4
6219558|NCT01652690|9888324|FG000|Overall Study|Other|8
6219559|NCT01652690|9888325|FG001|Overall Study|Other|9
6219560|NCT01652690|9888324|FG000|Overall Study|Lost to Follow-up|6
6219561|NCT01652690|9888325|FG001|Overall Study|Lost to Follow-up|6
6219562|NCT01652690|9888324|FG000|Overall Study|Death|5
6219563|NCT01652690|9888325|FG001|Overall Study|Death|2
6219564|NCT01652703|9888337|FG000|Overall Study|Withdrawal by Subject|0
6219565|NCT01652703|9888338|FG001|Overall Study|Withdrawal by Subject|1
6219566|NCT01652703|9888339|FG002|Overall Study|Withdrawal by Subject|3
6219567|NCT01652703|9888340|FG003|Overall Study|Withdrawal by Subject|1
6219568|NCT01652703|9888341|FG004|Overall Study|Withdrawal by Subject|0
6219569|NCT01652703|9888342|FG005|Overall Study|Withdrawal by Subject|1
6219570|NCT01652703|9888337|FG000|Overall Study|Other|0
6219571|NCT01652703|9888338|FG001|Overall Study|Other|0
6219572|NCT01652703|9888339|FG002|Overall Study|Other|0
6219573|NCT01652703|9888340|FG003|Overall Study|Other|1
6219574|NCT01652703|9888341|FG004|Overall Study|Other|1
6219575|NCT01652703|9888342|FG005|Overall Study|Other|1
6219576|NCT01652716|9888358|FG000|Overall Study|Loss of glucose control|1
6219577|NCT01652716|9888359|FG001|Overall Study|Loss of glucose control|0
6219578|NCT01652716|9888358|FG000|Overall Study|Administrative|0
6219579|NCT01652716|9888359|FG001|Overall Study|Administrative|2
6219580|NCT01652716|9888358|FG000|Overall Study|Investigator decision|1
6219581|NCT01652716|9888359|FG001|Overall Study|Investigator decision|4
6219582|NCT01652716|9888358|FG000|Overall Study|Lost to Follow-up|12
6219583|NCT01652716|9888359|FG001|Overall Study|Lost to Follow-up|11
6219584|NCT01652716|9888358|FG000|Overall Study|Protocol Violation|2
6219585|NCT01652716|9888359|FG001|Overall Study|Protocol Violation|1
6219586|NCT01652716|9888358|FG000|Overall Study|Adverse Event|7
6219587|NCT01652716|9888359|FG001|Overall Study|Adverse Event|10
6219588|NCT01652716|9888358|FG000|Overall Study|Withdrawal by Subject|33
6219589|NCT01652716|9888359|FG001|Overall Study|Withdrawal by Subject|18
6219590|NCT01652729|9888368|FG000|Overall Study|Withdrawal by Subject|14
6219591|NCT01652729|9888369|FG001|Overall Study|Withdrawal by Subject|7
6219592|NCT01652729|9888370|FG002|Overall Study|Withdrawal by Subject|7
6219593|NCT01652729|9888368|FG000|Overall Study|Adverse Event|4
6219594|NCT01652729|9888369|FG001|Overall Study|Adverse Event|0
6219595|NCT01652729|9888370|FG002|Overall Study|Adverse Event|3
6219596|NCT01652729|9888368|FG000|Overall Study|Physician Decision|1
6219597|NCT01652729|9888369|FG001|Overall Study|Physician Decision|0
6219598|NCT01652729|9888370|FG002|Overall Study|Physician Decision|1
6219599|NCT01652729|9888368|FG000|Overall Study|Protocol Violation|1
6219600|NCT01652729|9888369|FG001|Overall Study|Protocol Violation|0
6219601|NCT01652729|9888370|FG002|Overall Study|Protocol Violation|0
6219602|NCT01652729|9888368|FG000|Overall Study|Lost to Follow-up|6
6219603|NCT01652729|9888369|FG001|Overall Study|Lost to Follow-up|6
6219604|NCT01652729|9888370|FG002|Overall Study|Lost to Follow-up|3
6219605|NCT01652729|9888368|FG000|Overall Study|Administrative|1
6219606|NCT01652729|9888369|FG001|Overall Study|Administrative|0
6219607|NCT01652729|9888370|FG002|Overall Study|Administrative|0
6219608|NCT01652872|9888380|FG000|Overall Study|Death|36
6219609|NCT01652872|9888381|FG001|Overall Study|Death|39
6128512|NCT00949975|9754935|FG000|Overall Study|Study-specific criteria|0
6128513|NCT00949975|9754936|FG001|Overall Study|Study-specific criteria|1
6219610|NCT01652872|9888380|FG000|Overall Study|Lost to Follow-up|28
6219611|NCT01652872|9888381|FG001|Overall Study|Lost to Follow-up|23
6219612|NCT01652872|9888380|FG000|Overall Study|Decision by sponsor|5
6219613|NCT01652872|9888381|FG001|Overall Study|Decision by sponsor|7
6219614|NCT01652872|9888380|FG000|Overall Study|Withdrawal by Subject|76
6219615|NCT01652872|9888381|FG001|Overall Study|Withdrawal by Subject|84
6219616|NCT01652885|9888387|FG000|Overall Study|Adverse Event|1
6128514|NCT00949975|9754937|FG002|Overall Study|Study-specific criteria|1
6128515|NCT00949975|9754938|FG003|Overall Study|Study-specific criteria|0
6128516|NCT00949975|9754935|FG000|Overall Study|Incorrect enrolment|5
6128517|NCT00949975|9754936|FG001|Overall Study|Incorrect enrolment|10
6128518|NCT00949975|9754937|FG002|Overall Study|Incorrect enrolment|4
6128519|NCT00949975|9754938|FG003|Overall Study|Incorrect enrolment|7
6128520|NCT00949975|9754935|FG000|Overall Study|Severe non-compliance|3
6128521|NCT00949975|9754936|FG001|Overall Study|Severe non-compliance|1
6128522|NCT00949975|9754937|FG002|Overall Study|Severe non-compliance|0
6128523|NCT00949975|9754938|FG003|Overall Study|Severe non-compliance|2
6128524|NCT00949975|9754935|FG000|Overall Study|Lost to Follow-up|1
6128525|NCT00949975|9754936|FG001|Overall Study|Lost to Follow-up|0
6128526|NCT00949975|9754937|FG002|Overall Study|Lost to Follow-up|1
6128527|NCT00949975|9754938|FG003|Overall Study|Lost to Follow-up|3
6128528|NCT00949975|9754935|FG000|Overall Study|Other|1
6128529|NCT00949975|9754936|FG001|Overall Study|Other|0
6128530|NCT00949975|9754937|FG002|Overall Study|Other|0
6128531|NCT00949975|9754938|FG003|Overall Study|Other|0
6128532|NCT00950170|9754948|FG000|Overall Study|Parent/Legal Guardian Request|1
6128533|NCT00950170|9754948|FG000|Overall Study|Adverse Event|2
6128534|NCT00950170|9754948|FG000|Overall Study|Discontinuation of Study by Sponsor|1
6128535|NCT00950248|9754981|FG000|Year 1: Baseline|Withdrawal by Subject|6
6128536|NCT00950248|9754982|FG001|Year 1: Baseline|Withdrawal by Subject|0
6128537|NCT00950248|9754983|FG002|Year 1: Baseline|Withdrawal by Subject|0
6128538|NCT00950248|9754981|FG000|Year 1: Baseline|worsening of symptoms|2
6128539|NCT00950248|9754982|FG001|Year 1: Baseline|worsening of symptoms|0
6128540|NCT00950248|9754983|FG002|Year 1: Baseline|worsening of symptoms|0
6128541|NCT00950248|9754981|FG000|Year 2&3 Treatment Randomization|worsening of symptoms|0
6128542|NCT00950248|9754982|FG001|Year 2&3 Treatment Randomization|worsening of symptoms|2
6128543|NCT00950248|9754983|FG002|Year 2&3 Treatment Randomization|worsening of symptoms|4
6128544|NCT00950248|9754981|FG000|Year 2&3 Treatment Randomization|Withdrawal by Subject|0
6128545|NCT00950248|9754982|FG001|Year 2&3 Treatment Randomization|Withdrawal by Subject|3
6128546|NCT00950248|9754983|FG002|Year 2&3 Treatment Randomization|Withdrawal by Subject|0
6128547|NCT00950248|9754981|FG000|Year 2&3 Treatment Randomization|Death|0
6128548|NCT00950248|9754982|FG001|Year 2&3 Treatment Randomization|Death|0
6128549|NCT00950248|9754983|FG002|Year 2&3 Treatment Randomization|Death|1
6128550|NCT00950248|9754981|FG000|Year 2&3 Treatment Randomization|MRI contraindication|0
6128551|NCT00950248|9754982|FG001|Year 2&3 Treatment Randomization|MRI contraindication|1
6128552|NCT00950248|9754983|FG002|Year 2&3 Treatment Randomization|MRI contraindication|0
6128553|NCT00950300|9754992|FG000|Neoadjuvant/Adjuvant Treatment Periods|Adverse Event or Intercurrent Illness|6
6128554|NCT00950300|9754993|FG001|Neoadjuvant/Adjuvant Treatment Periods|Adverse Event or Intercurrent Illness|15
6128555|NCT00950300|9754992|FG000|Neoadjuvant/Adjuvant Treatment Periods|Death|1
6128556|NCT00950300|9754993|FG001|Neoadjuvant/Adjuvant Treatment Periods|Death|3
6128557|NCT00950300|9754992|FG000|Neoadjuvant/Adjuvant Treatment Periods|Insufficient Therapeutic Response|3
6128558|NCT00950300|9754993|FG001|Neoadjuvant/Adjuvant Treatment Periods|Insufficient Therapeutic Response|0
6128559|NCT00950300|9754992|FG000|Neoadjuvant/Adjuvant Treatment Periods|Violation of Selection Criteria|2
6128560|NCT00950300|9754993|FG001|Neoadjuvant/Adjuvant Treatment Periods|Violation of Selection Criteria|1
6128561|NCT00950300|9754992|FG000|Neoadjuvant/Adjuvant Treatment Periods|Protocol Violation|1
6128562|NCT00950300|9754993|FG001|Neoadjuvant/Adjuvant Treatment Periods|Protocol Violation|0
6128563|NCT00950300|9754992|FG000|Neoadjuvant/Adjuvant Treatment Periods|Participant Refusal/Withdrawal|4
6128564|NCT00950300|9754993|FG001|Neoadjuvant/Adjuvant Treatment Periods|Participant Refusal/Withdrawal|5
6128565|NCT00950300|9754992|FG000|Neoadjuvant/Adjuvant Treatment Periods|Lost to Follow-up|2
6128566|NCT00950300|9754993|FG001|Neoadjuvant/Adjuvant Treatment Periods|Lost to Follow-up|1
6128567|NCT00950300|9754992|FG000|Neoadjuvant/Adjuvant Treatment Periods|Progression of Disease|12
6128568|NCT00950300|9754993|FG001|Neoadjuvant/Adjuvant Treatment Periods|Progression of Disease|11
6128569|NCT00950300|9754992|FG000|Neoadjuvant/Adjuvant Treatment Periods|Recurrence of Disease|10
6128570|NCT00950300|9754993|FG001|Neoadjuvant/Adjuvant Treatment Periods|Recurrence of Disease|5
6128571|NCT00950300|9754992|FG000|Neoadjuvant/Adjuvant Treatment Periods|Other|1
6128572|NCT00950300|9754993|FG001|Neoadjuvant/Adjuvant Treatment Periods|Other|1
6128573|NCT00950300|9754992|FG000|TFFU Period|Adverse Event or Intercurrent Illness|3
6128574|NCT00950300|9754993|FG001|TFFU Period|Adverse Event or Intercurrent Illness|4
6128575|NCT00950300|9754992|FG000|TFFU Period|Death|4
6128576|NCT00950300|9754993|FG001|TFFU Period|Death|1
6128577|NCT00950300|9754992|FG000|TFFU Period|Refused Treatment|10
6128578|NCT00950300|9754993|FG001|TFFU Period|Refused Treatment|11
6128579|NCT00950300|9754992|FG000|TFFU Period|Failure to Return|16
6128580|NCT00950300|9754993|FG001|TFFU Period|Failure to Return|16
6128581|NCT00950300|9754992|FG000|TFFU Period|Recurrence of Disease|63
6128582|NCT00950300|9754993|FG001|TFFU Period|Recurrence of Disease|72
6128583|NCT00950300|9754992|FG000|TFFU Period|Other|4
6128584|NCT00950300|9754993|FG001|TFFU Period|Other|3
6128585|NCT00950300|9754992|FG000|SFU Period|Death|44
6128586|NCT00950300|9754993|FG001|SFU Period|Death|42
6128587|NCT00950300|9754992|FG000|SFU Period|Lost to Follow-up|30
6128588|NCT00950300|9754993|FG001|SFU Period|Lost to Follow-up|28
6128589|NCT00950300|9754992|FG000|SFU Period|Withdrawal by Subject|4
6128590|NCT00950300|9754993|FG001|SFU Period|Withdrawal by Subject|8
6128591|NCT00950599|9755026|FG000|Double-Blind Treatment Period|Administrative reason by sponsor|0
6128592|NCT00950599|9755027|FG001|Double-Blind Treatment Period|Administrative reason by sponsor|0
6128593|NCT00950599|9755028|FG002|Double-Blind Treatment Period|Administrative reason by sponsor|0
6128594|NCT00950599|9755029|FG003|Double-Blind Treatment Period|Administrative reason by sponsor|1
6128595|NCT00950599|9755030|FG004|Double-Blind Treatment Period|Administrative reason by sponsor|0
6128596|NCT00950599|9755031|FG005|Double-Blind Treatment Period|Administrative reason by sponsor|0
6219617|NCT01653132|9888416|FG000|First Intervention|Protocol Violation|1
6219618|NCT01653132|9888417|FG001|First Intervention|Protocol Violation|0
6219619|NCT01653158|9888427|FG000|Overall Study|Death|0
6219620|NCT01653158|9888428|FG001|Overall Study|Death|0
6219621|NCT01653158|9888429|FG002|Overall Study|Death|0
6219622|NCT01653158|9888430|FG003|Overall Study|Death|1
6219623|NCT01653158|9888431|FG004|Overall Study|Death|0
6219624|NCT01653158|9888432|FG005|Overall Study|Death|0
6219625|NCT01653158|9888433|FG006|Overall Study|Death|0
6219626|NCT01653158|9888434|FG007|Overall Study|Death|2
6288900|NCT02373813|10003320|FG000|Double-Blind Treatment Period|Protocol Violation|0
6288901|NCT02373813|10003321|FG001|Double-Blind Treatment Period|Protocol Violation|2
6288902|NCT02373813|10003322|FG002|Double-Blind Treatment Period|Protocol Violation|0
6288903|NCT02373813|10003323|FG003|Double-Blind Treatment Period|Protocol Violation|0
6128597|NCT00950599|9755032|FG006|Double-Blind Treatment Period|Administrative reason by sponsor|0
6219627|NCT01653158|9888427|FG000|Overall Study|Adverse Event|0
6288904|NCT02373813|10003320|FG000|Double-Blind Treatment Period|Lost to Follow-up|0
6288905|NCT02373813|10003321|FG001|Double-Blind Treatment Period|Lost to Follow-up|0
6288906|NCT02373813|10003322|FG002|Double-Blind Treatment Period|Lost to Follow-up|1
6288907|NCT02373813|10003323|FG003|Double-Blind Treatment Period|Lost to Follow-up|1
6288908|NCT02373813|10003320|FG000|Double-Blind Treatment Period|Withdrawal by Subject|0
6288909|NCT02373813|10003321|FG001|Double-Blind Treatment Period|Withdrawal by Subject|10
6288910|NCT02373813|10003322|FG002|Double-Blind Treatment Period|Withdrawal by Subject|6
6288911|NCT02373813|10003323|FG003|Double-Blind Treatment Period|Withdrawal by Subject|3
6288912|NCT02374099|10003353|FG000|Overall Study|Adverse Event|1
6288913|NCT02374099|10003354|FG001|Overall Study|Adverse Event|0
6288914|NCT02374099|10003353|FG000|Overall Study|Progressive Disease|35
6288915|NCT02374099|10003354|FG001|Overall Study|Progressive Disease|40
6288916|NCT02374099|10003353|FG000|Overall Study|Withdrawal by Subject|5
6288917|NCT02374099|10003354|FG001|Overall Study|Withdrawal by Subject|1
6288918|NCT02374099|10003353|FG000|Overall Study|Miscellaneous|2
6288919|NCT02374099|10003354|FG001|Overall Study|Miscellaneous|3
6288920|NCT02374099|10003353|FG000|Overall Study|Randomized, but not treated|2
6288921|NCT02374099|10003354|FG001|Overall Study|Randomized, but not treated|1
6288922|NCT02374099|10003353|FG000|Overall Study|Study Terminated by Sponsor|3
6288923|NCT02374099|10003354|FG001|Overall Study|Study Terminated by Sponsor|4
6288924|NCT02374255|10003387|FG000|Overall Study|Withdrawal by Subject|2
6288925|NCT02374255|10003388|FG001|Overall Study|Withdrawal by Subject|0
6288926|NCT02374255|10003389|FG002|Overall Study|Withdrawal by Subject|0
6288927|NCT02374255|10003390|FG003|Overall Study|Withdrawal by Subject|0
6288928|NCT02374307|10003408|FG000|3-months Follow-up|Lost to Follow-up|1
6288929|NCT02374307|10003409|FG001|3-months Follow-up|Lost to Follow-up|2
6288930|NCT02374307|10003408|FG000|3-months Follow-up|Withdrawal by Subject|1
6288931|NCT02374307|10003409|FG001|3-months Follow-up|Withdrawal by Subject|4
6288932|NCT02374307|10003408|FG000|3-months Follow-up|Death|1
6288933|NCT02374307|10003409|FG001|3-months Follow-up|Death|2
6288934|NCT02374307|10003408|FG000|3-months Follow-up|Missed first follow-up|5
6288935|NCT02374307|10003409|FG001|3-months Follow-up|Missed first follow-up|1
6288936|NCT02374307|10003408|FG000|6-months Follow-up|Lost to Follow-up|1
6288937|NCT02374307|10003409|FG001|6-months Follow-up|Lost to Follow-up|2
6288938|NCT02374307|10003408|FG000|6-months Follow-up|Death|2
6288939|NCT02374307|10003409|FG001|6-months Follow-up|Death|1
6288940|NCT02374307|10003408|FG000|6-months Follow-up|Withdrawal by Subject|0
6288941|NCT02374307|10003409|FG001|6-months Follow-up|Withdrawal by Subject|3
6288942|NCT02374346|10003415|FG000|Overall Study|operated or discharged during weekend|48
6288943|NCT02374463|10003441|FG000|Overall Study|Withdrawal by Subject|3
6288944|NCT02374463|10003442|FG001|Overall Study|Withdrawal by Subject|3
6288945|NCT02374593|10003451|FG000|Overall Study|non-compliant|2
6288946|NCT02374593|10003452|FG001|Overall Study|non-compliant|0
6288947|NCT02374671|10003465|FG000|Observation (Deferred Implantation)|Withdrawal by Subject|0
6288948|NCT02374671|10003466|FG001|Observation (Deferred Implantation)|Withdrawal by Subject|0
6288949|NCT02374671|10003467|FG002|Observation (Deferred Implantation)|Withdrawal by Subject|4
6288950|NCT02374671|10003465|FG000|Observation (Deferred Implantation)|Adverse Event|0
6288951|NCT02374671|10003466|FG001|Observation (Deferred Implantation)|Adverse Event|0
6288952|NCT02374671|10003467|FG002|Observation (Deferred Implantation)|Adverse Event|1
6288953|NCT02374671|10003465|FG000|Implantation- Nonrandomized & Randomized|Lost to Follow-up|17
6288954|NCT02374671|10003466|FG001|Implantation- Nonrandomized & Randomized|Lost to Follow-up|1
6288955|NCT02374671|10003467|FG002|Implantation- Nonrandomized & Randomized|Lost to Follow-up|2
6288956|NCT02374671|10003465|FG000|Implantation- Nonrandomized & Randomized|Adverse Event|7
6288957|NCT02374671|10003466|FG001|Implantation- Nonrandomized & Randomized|Adverse Event|0
6288958|NCT02374671|10003467|FG002|Implantation- Nonrandomized & Randomized|Adverse Event|1
6288959|NCT02374671|10003465|FG000|Implantation- Nonrandomized & Randomized|Withdrawal by Subject|1
6288960|NCT02374671|10003466|FG001|Implantation- Nonrandomized & Randomized|Withdrawal by Subject|0
6128598|NCT00950599|9755033|FG007|Double-Blind Treatment Period|Administrative reason by sponsor|0
6128599|NCT00950599|9755034|FG008|Double-Blind Treatment Period|Administrative reason by sponsor|0
6128600|NCT00950599|9755035|FG009|Double-Blind Treatment Period|Administrative reason by sponsor|0
6128601|NCT00950599|9755026|FG000|Double-Blind Treatment Period|Adverse Event|0
6128602|NCT00950599|9755027|FG001|Double-Blind Treatment Period|Adverse Event|1
6128603|NCT00950599|9755028|FG002|Double-Blind Treatment Period|Adverse Event|1
6128604|NCT00950599|9755029|FG003|Double-Blind Treatment Period|Adverse Event|1
6128605|NCT00950599|9755030|FG004|Double-Blind Treatment Period|Adverse Event|1
6128606|NCT00950599|9755031|FG005|Double-Blind Treatment Period|Adverse Event|1
6128607|NCT00950599|9755032|FG006|Double-Blind Treatment Period|Adverse Event|0
6128608|NCT00950599|9755033|FG007|Double-Blind Treatment Period|Adverse Event|0
6128609|NCT00950599|9755034|FG008|Double-Blind Treatment Period|Adverse Event|0
6128610|NCT00950599|9755035|FG009|Double-Blind Treatment Period|Adverse Event|0
6219628|NCT01653158|9888428|FG001|Overall Study|Adverse Event|0
6219629|NCT01653158|9888429|FG002|Overall Study|Adverse Event|0
6219630|NCT01653158|9888430|FG003|Overall Study|Adverse Event|1
6219631|NCT01653158|9888431|FG004|Overall Study|Adverse Event|0
6219632|NCT01653158|9888432|FG005|Overall Study|Adverse Event|0
6219633|NCT01653158|9888433|FG006|Overall Study|Adverse Event|0
6219634|NCT01653158|9888434|FG007|Overall Study|Adverse Event|3
6219635|NCT01653158|9888427|FG000|Overall Study|Other|0
6219636|NCT01653158|9888428|FG001|Overall Study|Other|0
6219637|NCT01653158|9888429|FG002|Overall Study|Other|0
6219638|NCT01653158|9888430|FG003|Overall Study|Other|0
6219639|NCT01653158|9888431|FG004|Overall Study|Other|0
6219640|NCT01653158|9888432|FG005|Overall Study|Other|0
6219641|NCT01653158|9888433|FG006|Overall Study|Other|0
6219642|NCT01653158|9888434|FG007|Overall Study|Other|1
6219643|NCT01653158|9888427|FG000|Overall Study|Progressive disease|0
6219644|NCT01653158|9888428|FG001|Overall Study|Progressive disease|0
6219645|NCT01653158|9888429|FG002|Overall Study|Progressive disease|0
6219646|NCT01653158|9888430|FG003|Overall Study|Progressive disease|0
6219647|NCT01653158|9888431|FG004|Overall Study|Progressive disease|1
6219648|NCT01653158|9888432|FG005|Overall Study|Progressive disease|1
6219649|NCT01653158|9888433|FG006|Overall Study|Progressive disease|2
6219650|NCT01653158|9888434|FG007|Overall Study|Progressive disease|9
6219651|NCT01653158|9888427|FG000|Overall Study|Withdrawal by Subject|1
6219652|NCT01653158|9888428|FG001|Overall Study|Withdrawal by Subject|0
6219653|NCT01653158|9888429|FG002|Overall Study|Withdrawal by Subject|0
6219654|NCT01653158|9888430|FG003|Overall Study|Withdrawal by Subject|0
6219655|NCT01653158|9888431|FG004|Overall Study|Withdrawal by Subject|0
6219656|NCT01653158|9888432|FG005|Overall Study|Withdrawal by Subject|0
6219657|NCT01653158|9888433|FG006|Overall Study|Withdrawal by Subject|0
6219658|NCT01653158|9888434|FG007|Overall Study|Withdrawal by Subject|0
6219659|NCT01653262|9888461|FG000|Overall Study|Lack of Efficacy|1
6219660|NCT01653262|9888461|FG000|Overall Study|SAE, non-fatal|1
6219661|NCT01653262|9888461|FG000|Overall Study|AE, non-serious non-fatal|1
6219662|NCT01653327|9888476|FG000|Overall Study|Withdrawal by Subject|1
6219663|NCT01653704|9888517|FG000|Overall Study|Technical failure during recording|1
6219664|NCT01653704|9888518|FG001|Overall Study|Technical failure during recording|1
6219665|NCT01653704|9888517|FG000|Overall Study|Performance not reflective of training|1
6288961|NCT02374671|10003467|FG002|Implantation- Nonrandomized & Randomized|Withdrawal by Subject|0
6128611|NCT00950599|9755026|FG000|Double-Blind Treatment Period|Lack of Efficacy|2
6128612|NCT00950599|9755027|FG001|Double-Blind Treatment Period|Lack of Efficacy|5
6128613|NCT00950599|9755028|FG002|Double-Blind Treatment Period|Lack of Efficacy|5
6128614|NCT00950599|9755029|FG003|Double-Blind Treatment Period|Lack of Efficacy|7
6128615|NCT00950599|9755030|FG004|Double-Blind Treatment Period|Lack of Efficacy|3
6128616|NCT00950599|9755031|FG005|Double-Blind Treatment Period|Lack of Efficacy|6
6128617|NCT00950599|9755032|FG006|Double-Blind Treatment Period|Lack of Efficacy|0
6128618|NCT00950599|9755033|FG007|Double-Blind Treatment Period|Lack of Efficacy|1
6128619|NCT00950599|9755034|FG008|Double-Blind Treatment Period|Lack of Efficacy|0
6128620|NCT00950599|9755035|FG009|Double-Blind Treatment Period|Lack of Efficacy|0
6128621|NCT00950599|9755026|FG000|Double-Blind Treatment Period|Lost to Follow-up|0
6128622|NCT00950599|9755027|FG001|Double-Blind Treatment Period|Lost to Follow-up|0
6128623|NCT00950599|9755028|FG002|Double-Blind Treatment Period|Lost to Follow-up|0
6128624|NCT00950599|9755029|FG003|Double-Blind Treatment Period|Lost to Follow-up|1
6128625|NCT00950599|9755030|FG004|Double-Blind Treatment Period|Lost to Follow-up|1
6128626|NCT00950599|9755031|FG005|Double-Blind Treatment Period|Lost to Follow-up|2
6128627|NCT00950599|9755032|FG006|Double-Blind Treatment Period|Lost to Follow-up|0
6128628|NCT00950599|9755033|FG007|Double-Blind Treatment Period|Lost to Follow-up|1
6219666|NCT01653704|9888518|FG001|Overall Study|Performance not reflective of training|0
6219667|NCT01653743|9888526|FG000|Overall Study|Withdrawal by Subject|1
6219668|NCT01653743|9888527|FG001|Overall Study|Withdrawal by Subject|0
6219669|NCT01653743|9888526|FG000|Overall Study|Investigator discretion|3
6219670|NCT01653743|9888527|FG001|Overall Study|Investigator discretion|0
6219671|NCT01653782|9888536|FG000|Overall Study|Withdrawal by Subject|9
6219672|NCT01653782|9888537|FG001|Overall Study|Withdrawal by Subject|15
6219673|NCT01653782|9888538|FG002|Overall Study|Withdrawal by Subject|4
6219674|NCT01653782|9888536|FG000|Overall Study|Lost to Follow-up|7
6219675|NCT01653782|9888537|FG001|Overall Study|Lost to Follow-up|3
6128629|NCT00950599|9755034|FG008|Double-Blind Treatment Period|Lost to Follow-up|0
6128630|NCT00950599|9755035|FG009|Double-Blind Treatment Period|Lost to Follow-up|0
6128631|NCT00950599|9755026|FG000|Double-Blind Treatment Period|Poor/Noncompliance|1
6128632|NCT00950599|9755027|FG001|Double-Blind Treatment Period|Poor/Noncompliance|1
6128633|NCT00950599|9755028|FG002|Double-Blind Treatment Period|Poor/Noncompliance|0
6128634|NCT00950599|9755029|FG003|Double-Blind Treatment Period|Poor/Noncompliance|0
6128635|NCT00950599|9755030|FG004|Double-Blind Treatment Period|Poor/Noncompliance|0
6128636|NCT00950599|9755031|FG005|Double-Blind Treatment Period|Poor/Noncompliance|0
6219676|NCT01653782|9888538|FG002|Overall Study|Lost to Follow-up|2
6219677|NCT01653847|9888548|FG000|Overall Study|Withdrawal by Subject|1
6219678|NCT01653847|9888549|FG001|Overall Study|Withdrawal by Subject|0
6219679|NCT01653912|9888557|FG000|Phase 1-Cohort 1.5: GSK2110183 75 mg|Clinical Progression|0
6219680|NCT01653912|9888558|FG001|Phase 1-Cohort 1.5: GSK2110183 75 mg|Clinical Progression|1
6219681|NCT01653912|9888559|FG002|Phase 1-Cohort 1.5: GSK2110183 75 mg|Clinical Progression|0
6219682|NCT01653912|9888560|FG003|Phase 1-Cohort 1.5: GSK2110183 75 mg|Clinical Progression|0
6219683|NCT01653912|9888561|FG004|Phase 1-Cohort 1.5: GSK2110183 75 mg|Clinical Progression|0
6219684|NCT01653912|9888562|FG005|Phase 1-Cohort 1.5: GSK2110183 75 mg|Clinical Progression|0
6219685|NCT01653912|9888557|FG000|Phase 1-Cohort 2: GSK2110183 100 mg|Adverse Event|0
6219686|NCT01653912|9888558|FG001|Phase 1-Cohort 2: GSK2110183 100 mg|Adverse Event|0
6219687|NCT01653912|9888559|FG002|Phase 1-Cohort 2: GSK2110183 100 mg|Adverse Event|2
6219688|NCT01653912|9888560|FG003|Phase 1-Cohort 2: GSK2110183 100 mg|Adverse Event|0
6219689|NCT01653912|9888561|FG004|Phase 1-Cohort 2: GSK2110183 100 mg|Adverse Event|0
6219690|NCT01653912|9888562|FG005|Phase 1-Cohort 2: GSK2110183 100 mg|Adverse Event|0
6219691|NCT01653912|9888557|FG000|Phase 1-Cohort 3: GSK2110183 125 mg|Clinical Progression|0
6219692|NCT01653912|9888558|FG001|Phase 1-Cohort 3: GSK2110183 125 mg|Clinical Progression|0
6219693|NCT01653912|9888559|FG002|Phase 1-Cohort 3: GSK2110183 125 mg|Clinical Progression|0
6219694|NCT01653912|9888560|FG003|Phase 1-Cohort 3: GSK2110183 125 mg|Clinical Progression|1
6219695|NCT01653912|9888561|FG004|Phase 1-Cohort 3: GSK2110183 125 mg|Clinical Progression|0
6219696|NCT01653912|9888562|FG005|Phase 1-Cohort 3: GSK2110183 125 mg|Clinical Progression|0
6219697|NCT01653912|9888557|FG000|Phase 1-Cohort 3: GSK2110183 125 mg|Withdrawal by Subject|0
6219698|NCT01653912|9888558|FG001|Phase 1-Cohort 3: GSK2110183 125 mg|Withdrawal by Subject|0
6219699|NCT01653912|9888559|FG002|Phase 1-Cohort 3: GSK2110183 125 mg|Withdrawal by Subject|0
6219700|NCT01653912|9888560|FG003|Phase 1-Cohort 3: GSK2110183 125 mg|Withdrawal by Subject|1
6219701|NCT01653912|9888561|FG004|Phase 1-Cohort 3: GSK2110183 125 mg|Withdrawal by Subject|0
6219702|NCT01653912|9888562|FG005|Phase 1-Cohort 3: GSK2110183 125 mg|Withdrawal by Subject|0
6219703|NCT01653912|9888557|FG000|Phase 2: GSK2110183 125 mg|Adverse Event|0
6219704|NCT01653912|9888558|FG001|Phase 2: GSK2110183 125 mg|Adverse Event|0
6219705|NCT01653912|9888559|FG002|Phase 2: GSK2110183 125 mg|Adverse Event|0
6219706|NCT01653912|9888560|FG003|Phase 2: GSK2110183 125 mg|Adverse Event|0
6219707|NCT01653912|9888561|FG004|Phase 2: GSK2110183 125 mg|Adverse Event|0
6219708|NCT01653912|9888562|FG005|Phase 2: GSK2110183 125 mg|Adverse Event|1
6219709|NCT01653912|9888557|FG000|Phase 2: GSK2110183 125 mg|Clinical Progression|0
6219710|NCT01653912|9888558|FG001|Phase 2: GSK2110183 125 mg|Clinical Progression|0
6219711|NCT01653912|9888559|FG002|Phase 2: GSK2110183 125 mg|Clinical Progression|0
6219712|NCT01653912|9888560|FG003|Phase 2: GSK2110183 125 mg|Clinical Progression|0
6219713|NCT01653912|9888561|FG004|Phase 2: GSK2110183 125 mg|Clinical Progression|0
6219714|NCT01653912|9888562|FG005|Phase 2: GSK2110183 125 mg|Clinical Progression|6
6219715|NCT01653912|9888557|FG000|Phase 2: GSK2110183 125 mg|Withdrawal by Subject|0
6219716|NCT01653912|9888558|FG001|Phase 2: GSK2110183 125 mg|Withdrawal by Subject|0
6219717|NCT01653912|9888559|FG002|Phase 2: GSK2110183 125 mg|Withdrawal by Subject|0
6219718|NCT01653912|9888560|FG003|Phase 2: GSK2110183 125 mg|Withdrawal by Subject|0
6219719|NCT01653912|9888561|FG004|Phase 2: GSK2110183 125 mg|Withdrawal by Subject|0
6219720|NCT01653912|9888562|FG005|Phase 2: GSK2110183 125 mg|Withdrawal by Subject|1
6219721|NCT01654224|9888587|FG000|Overall Study|Lost to Follow-up|2
6219722|NCT01654224|9888588|FG001|Overall Study|Lost to Follow-up|2
6219723|NCT01654224|9888587|FG000|Overall Study|Did not receive allocation|1
6219724|NCT01654224|9888588|FG001|Overall Study|Did not receive allocation|8
6219725|NCT01654224|9888587|FG000|Overall Study|Insufficient blood sample|3
6219726|NCT01654224|9888588|FG001|Overall Study|Insufficient blood sample|2
6219727|NCT01654250|9888596|FG000|Overall Study|Lost to Follow-up|1
6219728|NCT01654250|9888597|FG001|Overall Study|Lost to Follow-up|0
6219729|NCT01654276|9888626|FG000|Overall Study|Lack of Efficacy|1
6219730|NCT01654276|9888626|FG000|Overall Study|Lost to Follow-up|4
6219731|NCT01654276|9888626|FG000|Overall Study|Withdrawal by Subject|1
6219732|NCT01654289|9888633|FG000|Overall Study|Withdrawal by Subject|10
6219733|NCT01654289|9888634|FG001|Overall Study|Withdrawal by Subject|8
6219734|NCT01654289|9888635|FG002|Overall Study|Withdrawal by Subject|5
6219735|NCT01654289|9888633|FG000|Overall Study|Withdrew from intervention only|17
6219736|NCT01654289|9888634|FG001|Overall Study|Withdrew from intervention only|20
6219737|NCT01654289|9888635|FG002|Overall Study|Withdrew from intervention only|0
6219738|NCT01654302|9888645|FG000|Second Intervention (Day 7)|Lost to Follow-up|1
6219739|NCT01654302|9888646|FG001|Second Intervention (Day 7)|Lost to Follow-up|1
6219740|NCT01654380|9888654|FG000|Part B, Period 1|Physician Decision|0
6219741|NCT01654380|9888655|FG001|Part B, Period 1|Physician Decision|0
6219742|NCT01654380|9888656|FG002|Part B, Period 1|Physician Decision|1
6219743|NCT01654380|9888657|FG003|Part B, Period 1|Physician Decision|0
6128637|NCT00950599|9755032|FG006|Double-Blind Treatment Period|Poor/Noncompliance|0
6128638|NCT00950599|9755033|FG007|Double-Blind Treatment Period|Poor/Noncompliance|1
6128639|NCT00950599|9755034|FG008|Double-Blind Treatment Period|Poor/Noncompliance|0
6128640|NCT00950599|9755035|FG009|Double-Blind Treatment Period|Poor/Noncompliance|0
6128641|NCT00950599|9755026|FG000|Double-Blind Treatment Period|Subject no longer meets study criteria|0
6128642|NCT00950599|9755027|FG001|Double-Blind Treatment Period|Subject no longer meets study criteria|0
6219744|NCT01654523|9888683|FG000|Overall Study|Withdrawal by Subject|1
6219745|NCT01654536|9888689|FG000|Overall Study|Lost to Follow-up|5
6219746|NCT01654536|9888690|FG001|Overall Study|Lost to Follow-up|5
6219747|NCT01654536|9888689|FG000|Overall Study|Physician Decision|12
6219748|NCT01654536|9888690|FG001|Overall Study|Physician Decision|8
6219749|NCT01654536|9888689|FG000|Overall Study|Withdrawal by Subject|27
6219750|NCT01654536|9888690|FG001|Overall Study|Withdrawal by Subject|25
6219751|NCT01654549|9888699|FG000|Overall Study|H.pylori eradication not successful|0
6219752|NCT01654549|9888700|FG001|Overall Study|H.pylori eradication not successful|1
6219753|NCT01654601|9888712|FG000|1st Administration|Withdrawal by Subject|2
6219754|NCT01654601|9888713|FG001|1st Administration|Withdrawal by Subject|0
6219755|NCT01654601|9888712|FG000|1st Administration|Protocol Violation|0
6219756|NCT01654601|9888713|FG001|1st Administration|Protocol Violation|2
6219757|NCT01654601|9888712|FG000|2nd Administration|Adverse Event|1
6219758|NCT01654601|9888713|FG001|2nd Administration|Adverse Event|0
6219759|NCT01654601|9888712|FG000|2nd Administration|Protocol Violation|0
6219760|NCT01654601|9888713|FG001|2nd Administration|Protocol Violation|1
6219761|NCT01654666|9888722|FG000|Overall Study|Protocol Violation|7
6219762|NCT01654666|9888723|FG001|Overall Study|Protocol Violation|4
6219763|NCT01654666|9888724|FG002|Overall Study|Protocol Violation|8
6219764|NCT01654666|9888722|FG000|Overall Study|Lost to Follow-up|4
6219765|NCT01654666|9888723|FG001|Overall Study|Lost to Follow-up|5
6219766|NCT01654666|9888724|FG002|Overall Study|Lost to Follow-up|5
6219767|NCT01654666|9888722|FG000|Overall Study|Withdrawal by Subject|4
6219768|NCT01654666|9888723|FG001|Overall Study|Withdrawal by Subject|4
6219769|NCT01654666|9888724|FG002|Overall Study|Withdrawal by Subject|1
6219770|NCT01655069|9888768|FG000|Overall Study|Physician Decision|0
6219771|NCT01655069|9888769|FG001|Overall Study|Physician Decision|0
6219772|NCT01655069|9888770|FG002|Overall Study|Physician Decision|0
6219773|NCT01655069|9888771|FG003|Overall Study|Physician Decision|1
6219774|NCT01655069|9888768|FG000|Overall Study|Adverse Event|6
6219775|NCT01655069|9888769|FG001|Overall Study|Adverse Event|7
6219776|NCT01655069|9888770|FG002|Overall Study|Adverse Event|2
6219777|NCT01655069|9888771|FG003|Overall Study|Adverse Event|3
6219778|NCT01655069|9888768|FG000|Overall Study|Lack of Efficacy|0
6219779|NCT01655069|9888769|FG001|Overall Study|Lack of Efficacy|1
6219780|NCT01655069|9888770|FG002|Overall Study|Lack of Efficacy|0
6219781|NCT01655069|9888771|FG003|Overall Study|Lack of Efficacy|0
6219782|NCT01655069|9888768|FG000|Overall Study|No Treatment Needed|0
6219783|NCT01655069|9888769|FG001|Overall Study|No Treatment Needed|1
6219784|NCT01655069|9888770|FG002|Overall Study|No Treatment Needed|0
6219785|NCT01655069|9888771|FG003|Overall Study|No Treatment Needed|0
6219786|NCT01655069|9888768|FG000|Overall Study|Withdrawal by Subject|2
6219787|NCT01655069|9888769|FG001|Overall Study|Withdrawal by Subject|3
6219788|NCT01655069|9888770|FG002|Overall Study|Withdrawal by Subject|0
6219789|NCT01655069|9888771|FG003|Overall Study|Withdrawal by Subject|0
6219790|NCT01655381|9888793|FG000|Overall Study|Investigator Decision|1
6219791|NCT01655381|9888793|FG000|Overall Study|Moved to Another City|1
6219792|NCT01655381|9888793|FG000|Overall Study|Insufficient Treatment Response|1
6219793|NCT01655498|9888798|FG000|Overall Study|Unrelated health issue|2
6219794|NCT01655498|9888798|FG000|Overall Study|Protocol Violation|2
6219795|NCT01655498|9888798|FG000|Overall Study|Withdrawal by Subject|1
6219796|NCT01655693|9888817|FG000|Overall Study|Progression of Disease|92
6219797|NCT01655693|9888818|FG001|Overall Study|Progression of Disease|76
6219798|NCT01655693|9888819|FG002|Overall Study|Progression of Disease|58
6219799|NCT01655693|9888817|FG000|Overall Study|Death|8
6219800|NCT01655693|9888818|FG001|Overall Study|Death|9
6219801|NCT01655693|9888819|FG002|Overall Study|Death|12
6219802|NCT01655693|9888817|FG000|Overall Study|Serious Adverse Event|3
6219803|NCT01655693|9888818|FG001|Overall Study|Serious Adverse Event|15
6219804|NCT01655693|9888819|FG002|Overall Study|Serious Adverse Event|11
6219805|NCT01655693|9888817|FG000|Overall Study|Withdrawal by Subject|3
6219806|NCT01655693|9888818|FG001|Overall Study|Withdrawal by Subject|2
6219807|NCT01655693|9888819|FG002|Overall Study|Withdrawal by Subject|20
6219808|NCT01655693|9888817|FG000|Overall Study|Adverse Event|3
6219809|NCT01655693|9888818|FG001|Overall Study|Adverse Event|11
6219810|NCT01655693|9888819|FG002|Overall Study|Adverse Event|3
6219811|NCT01655693|9888817|FG000|Overall Study|Aggravation of Liver Dysfunction|5
6219812|NCT01655693|9888818|FG001|Overall Study|Aggravation of Liver Dysfunction|4
6219813|NCT01655693|9888819|FG002|Overall Study|Aggravation of Liver Dysfunction|0
6219814|NCT01655693|9888817|FG000|Overall Study|Non-Compliance|0
6219815|NCT01655693|9888818|FG001|Overall Study|Non-Compliance|0
6219816|NCT01655693|9888819|FG002|Overall Study|Non-Compliance|7
6219817|NCT01655693|9888817|FG000|Overall Study|No Respect of Criteria for Continuing Treatment|1
6219818|NCT01655693|9888818|FG001|Overall Study|No Respect of Criteria for Continuing Treatment|3
6288962|NCT02374918|10003477|FG000|Overall Study|Protocol Violation|2
6128643|NCT00950599|9755028|FG002|Double-Blind Treatment Period|Subject no longer meets study criteria|0
6128644|NCT00950599|9755029|FG003|Double-Blind Treatment Period|Subject no longer meets study criteria|0
6128645|NCT00950599|9755030|FG004|Double-Blind Treatment Period|Subject no longer meets study criteria|1
6128646|NCT00950599|9755031|FG005|Double-Blind Treatment Period|Subject no longer meets study criteria|1
6128647|NCT00950599|9755032|FG006|Double-Blind Treatment Period|Subject no longer meets study criteria|0
6128648|NCT00950599|9755033|FG007|Double-Blind Treatment Period|Subject no longer meets study criteria|0
6128649|NCT00950599|9755034|FG008|Double-Blind Treatment Period|Subject no longer meets study criteria|0
6128650|NCT00950599|9755035|FG009|Double-Blind Treatment Period|Subject no longer meets study criteria|0
6128651|NCT00950599|9755026|FG000|Double-Blind Treatment Period|Subject Withdrew consent|4
6128652|NCT00950599|9755027|FG001|Double-Blind Treatment Period|Subject Withdrew consent|3
6128653|NCT00950599|9755028|FG002|Double-Blind Treatment Period|Subject Withdrew consent|3
6128654|NCT00950599|9755029|FG003|Double-Blind Treatment Period|Subject Withdrew consent|1
6128655|NCT00950599|9755030|FG004|Double-Blind Treatment Period|Subject Withdrew consent|1
6128656|NCT00950599|9755031|FG005|Double-Blind Treatment Period|Subject Withdrew consent|2
6128657|NCT00950599|9755032|FG006|Double-Blind Treatment Period|Subject Withdrew consent|0
6128658|NCT00950599|9755033|FG007|Double-Blind Treatment Period|Subject Withdrew consent|3
6128659|NCT00950599|9755034|FG008|Double-Blind Treatment Period|Subject Withdrew consent|0
6128660|NCT00950599|9755035|FG009|Double-Blind Treatment Period|Subject Withdrew consent|0
6128661|NCT00950599|9755026|FG000|Follow-Up Period|Adverse Event|0
6128662|NCT00950599|9755027|FG001|Follow-Up Period|Adverse Event|0
6128663|NCT00950599|9755028|FG002|Follow-Up Period|Adverse Event|0
6128664|NCT00950599|9755029|FG003|Follow-Up Period|Adverse Event|0
6128665|NCT00950599|9755030|FG004|Follow-Up Period|Adverse Event|0
6128666|NCT00950599|9755031|FG005|Follow-Up Period|Adverse Event|0
6128667|NCT00950599|9755032|FG006|Follow-Up Period|Adverse Event|0
6128668|NCT00950599|9755033|FG007|Follow-Up Period|Adverse Event|0
6128669|NCT00950599|9755034|FG008|Follow-Up Period|Adverse Event|1
6128670|NCT00950599|9755035|FG009|Follow-Up Period|Adverse Event|0
6128671|NCT00950599|9755026|FG000|Follow-Up Period|Lack of Efficacy|0
6128672|NCT00950599|9755027|FG001|Follow-Up Period|Lack of Efficacy|0
6128673|NCT00950599|9755028|FG002|Follow-Up Period|Lack of Efficacy|0
6128674|NCT00950599|9755029|FG003|Follow-Up Period|Lack of Efficacy|0
6128675|NCT00950599|9755030|FG004|Follow-Up Period|Lack of Efficacy|0
6128676|NCT00950599|9755031|FG005|Follow-Up Period|Lack of Efficacy|0
6128677|NCT00950599|9755032|FG006|Follow-Up Period|Lack of Efficacy|0
6128678|NCT00950599|9755033|FG007|Follow-Up Period|Lack of Efficacy|0
6128679|NCT00950599|9755034|FG008|Follow-Up Period|Lack of Efficacy|3
6128680|NCT00950599|9755035|FG009|Follow-Up Period|Lack of Efficacy|0
6128681|NCT00950599|9755026|FG000|Follow-Up Period|Lost to Follow-up|0
6128682|NCT00950599|9755027|FG001|Follow-Up Period|Lost to Follow-up|0
6128683|NCT00950599|9755028|FG002|Follow-Up Period|Lost to Follow-up|0
6128684|NCT00950599|9755029|FG003|Follow-Up Period|Lost to Follow-up|0
6128685|NCT00950599|9755030|FG004|Follow-Up Period|Lost to Follow-up|0
6128686|NCT00950599|9755031|FG005|Follow-Up Period|Lost to Follow-up|0
6219819|NCT01655693|9888819|FG002|Overall Study|No Respect of Criteria for Continuing Treatment|0
6219820|NCT01655693|9888817|FG000|Overall Study|Protocol Violation|1
6219821|NCT01655693|9888818|FG001|Overall Study|Protocol Violation|0
6219822|NCT01655693|9888819|FG002|Overall Study|Protocol Violation|3
6219823|NCT01655693|9888817|FG000|Overall Study|Lost to Follow-up|1
6219824|NCT01655693|9888818|FG001|Overall Study|Lost to Follow-up|0
6219825|NCT01655693|9888819|FG002|Overall Study|Lost to Follow-up|1
6219826|NCT01655693|9888817|FG000|Overall Study|Screening Failure|1
6219827|NCT01655693|9888818|FG001|Overall Study|Screening Failure|0
6219828|NCT01655693|9888819|FG002|Overall Study|Screening Failure|0
6219829|NCT01655693|9888817|FG000|Overall Study|Other|8
6219830|NCT01655693|9888818|FG001|Overall Study|Other|6
6219831|NCT01655693|9888819|FG002|Overall Study|Other|15
6219832|NCT01655823|9888846|FG000|Overall Study|Lost to Follow-up|0
6219833|NCT01655823|9888847|FG001|Overall Study|Lost to Follow-up|1
6219834|NCT01655823|9888848|FG002|Overall Study|Lost to Follow-up|0
6219835|NCT01655823|9888849|FG003|Overall Study|Lost to Follow-up|0
6219836|NCT01655823|9888850|FG004|Overall Study|Lost to Follow-up|1
6219837|NCT01655823|9888846|FG000|Overall Study|Withdrawal by Subject|0
6219838|NCT01655823|9888847|FG001|Overall Study|Withdrawal by Subject|1
6219839|NCT01655823|9888848|FG002|Overall Study|Withdrawal by Subject|0
6219840|NCT01655823|9888849|FG003|Overall Study|Withdrawal by Subject|1
6219841|NCT01655823|9888850|FG004|Overall Study|Withdrawal by Subject|0
6219842|NCT01655901|9888862|FG000|Third Intervention (Hour 3)|Lost to Follow-up|1
6219843|NCT01655901|9888863|FG001|Third Intervention (Hour 3)|Lost to Follow-up|1
6219844|NCT01655901|9888864|FG002|Third Intervention (Hour 3)|Lost to Follow-up|1
6219845|NCT01655901|9888865|FG003|Third Intervention (Hour 3)|Lost to Follow-up|0
6219846|NCT01655901|9888866|FG004|Third Intervention (Hour 3)|Lost to Follow-up|1
6219847|NCT01655901|9888867|FG005|Third Intervention (Hour 3)|Lost to Follow-up|0
6128687|NCT00950599|9755032|FG006|Follow-Up Period|Lost to Follow-up|0
6128688|NCT00950599|9755033|FG007|Follow-Up Period|Lost to Follow-up|0
6128689|NCT00950599|9755034|FG008|Follow-Up Period|Lost to Follow-up|5
6128690|NCT00950599|9755035|FG009|Follow-Up Period|Lost to Follow-up|1
6219848|NCT01656161|9888880|FG000|Overall Study|Death|3
6219849|NCT01656161|9888880|FG000|Overall Study|Adverse Event|2
6128691|NCT00950599|9755026|FG000|Follow-Up Period|Physician Decision|0
6128692|NCT00950599|9755027|FG001|Follow-Up Period|Physician Decision|0
6128693|NCT00950599|9755028|FG002|Follow-Up Period|Physician Decision|0
6128694|NCT00950599|9755029|FG003|Follow-Up Period|Physician Decision|0
6128695|NCT00950599|9755030|FG004|Follow-Up Period|Physician Decision|0
6128696|NCT00950599|9755031|FG005|Follow-Up Period|Physician Decision|0
6128697|NCT00950599|9755032|FG006|Follow-Up Period|Physician Decision|0
6128698|NCT00950599|9755033|FG007|Follow-Up Period|Physician Decision|0
6128699|NCT00950599|9755034|FG008|Follow-Up Period|Physician Decision|1
6128700|NCT00950599|9755035|FG009|Follow-Up Period|Physician Decision|0
6128701|NCT00950599|9755026|FG000|Follow-Up Period|Poor/Noncompliance|0
6128702|NCT00950599|9755027|FG001|Follow-Up Period|Poor/Noncompliance|0
6128703|NCT00950599|9755028|FG002|Follow-Up Period|Poor/Noncompliance|0
6219850|NCT01656161|9888880|FG000|Overall Study|Protocol Violation|1
6219851|NCT01656161|9888880|FG000|Overall Study|Withdrawal by Subject|1
6219852|NCT01656200|9888896|FG000|Overall Study|Withdrawal by Subject|1
6219853|NCT01656304|9888906|FG000|Overall Study|Ineligible, uncontrolled hypertension|1
6219854|NCT01656395|9888916|FG000|Overall Study|Adverse Event|1
6219855|NCT01656395|9888917|FG001|Overall Study|Adverse Event|14
6219856|NCT01656395|9888918|FG002|Overall Study|Adverse Event|5
6219857|NCT01656395|9888919|FG003|Overall Study|Adverse Event|4
6219858|NCT01656395|9888920|FG004|Overall Study|Adverse Event|5
6219859|NCT01656395|9888921|FG005|Overall Study|Adverse Event|7
6219860|NCT01656395|9888922|FG006|Overall Study|Adverse Event|0
6219861|NCT01656395|9888923|FG007|Overall Study|Adverse Event|0
6219862|NCT01656395|9888916|FG000|Overall Study|Lack of Efficacy|1
6219863|NCT01656395|9888917|FG001|Overall Study|Lack of Efficacy|8
6219864|NCT01656395|9888918|FG002|Overall Study|Lack of Efficacy|6
6219865|NCT01656395|9888919|FG003|Overall Study|Lack of Efficacy|1
6219866|NCT01656395|9888920|FG004|Overall Study|Lack of Efficacy|1
6219867|NCT01656395|9888921|FG005|Overall Study|Lack of Efficacy|6
6219868|NCT01656395|9888922|FG006|Overall Study|Lack of Efficacy|0
6219869|NCT01656395|9888923|FG007|Overall Study|Lack of Efficacy|0
6219870|NCT01656395|9888916|FG000|Overall Study|Lost to Follow-up|1
6219871|NCT01656395|9888917|FG001|Overall Study|Lost to Follow-up|0
6219872|NCT01656395|9888918|FG002|Overall Study|Lost to Follow-up|0
6219873|NCT01656395|9888919|FG003|Overall Study|Lost to Follow-up|0
6219874|NCT01656395|9888920|FG004|Overall Study|Lost to Follow-up|0
6219875|NCT01656395|9888921|FG005|Overall Study|Lost to Follow-up|0
6219876|NCT01656395|9888922|FG006|Overall Study|Lost to Follow-up|0
6219877|NCT01656395|9888923|FG007|Overall Study|Lost to Follow-up|0
6288963|NCT02374918|10003478|FG001|Overall Study|Protocol Violation|0
6288964|NCT02374918|10003479|FG002|Overall Study|Protocol Violation|2
6288965|NCT02374918|10003480|FG003|Overall Study|Protocol Violation|1
6288966|NCT02374918|10003477|FG000|Overall Study|Withdrawal by Subject|1
6288967|NCT02374918|10003478|FG001|Overall Study|Withdrawal by Subject|1
6288968|NCT02374918|10003479|FG002|Overall Study|Withdrawal by Subject|1
6288969|NCT02374918|10003480|FG003|Overall Study|Withdrawal by Subject|0
6288970|NCT02374918|10003477|FG000|Overall Study|Lack of Efficacy|0
6288971|NCT02374918|10003478|FG001|Overall Study|Lack of Efficacy|0
6288972|NCT02374918|10003479|FG002|Overall Study|Lack of Efficacy|1
6288973|NCT02374918|10003480|FG003|Overall Study|Lack of Efficacy|1
6288974|NCT02374957|10003490|FG000|Overall Study|Patient did not complete forms correctly|1
6288975|NCT02374957|10003491|FG001|Overall Study|Patient did not complete forms correctly|0
6288976|NCT02375347|10003497|FG000|Overall Study|Protocol Violation|1
6288977|NCT02375373|10003501|FG000|Overall Study|Withdrawal by Subject|11
6288978|NCT02375698|10003507|FG000|Overall Study|Withdrawal by Subject|0
6288979|NCT02375698|10003508|FG001|Overall Study|Withdrawal by Subject|2
6288980|NCT02375698|10003507|FG000|Overall Study|Physician Decision|2
6288981|NCT02375698|10003508|FG001|Overall Study|Physician Decision|0
6288982|NCT02375724|10003516|FG000|Overall Study|Lack of Efficacy|1
6288983|NCT02375724|10003517|FG001|Overall Study|Lack of Efficacy|1
6288984|NCT02375724|10003516|FG000|Overall Study|Withdrawal by Subject|1
6288985|NCT02375724|10003517|FG001|Overall Study|Withdrawal by Subject|1
6128704|NCT00950599|9755029|FG003|Follow-Up Period|Poor/Noncompliance|0
6128705|NCT00950599|9755030|FG004|Follow-Up Period|Poor/Noncompliance|0
6128706|NCT00950599|9755031|FG005|Follow-Up Period|Poor/Noncompliance|0
6128707|NCT00950599|9755032|FG006|Follow-Up Period|Poor/Noncompliance|0
6128708|NCT00950599|9755033|FG007|Follow-Up Period|Poor/Noncompliance|0
6128709|NCT00950599|9755034|FG008|Follow-Up Period|Poor/Noncompliance|1
6128710|NCT00950599|9755035|FG009|Follow-Up Period|Poor/Noncompliance|0
6128711|NCT00950599|9755026|FG000|Follow-Up Period|Subject withdrew Consent|0
6128712|NCT00950599|9755027|FG001|Follow-Up Period|Subject withdrew Consent|0
6288986|NCT02375724|10003516|FG000|Overall Study|Lost to Follow-up|1
6288987|NCT02375724|10003517|FG001|Overall Study|Lost to Follow-up|0
6288988|NCT02375724|10003516|FG000|Overall Study|Protocol Violation|1
6288989|NCT02375724|10003517|FG001|Overall Study|Protocol Violation|0
6288990|NCT02375724|10003516|FG000|Overall Study|Adverse Event|2
6288991|NCT02375724|10003517|FG001|Overall Study|Adverse Event|4
6288992|NCT02375971|10003526|FG000|Treatment (Day 1 - Baseline)|Subj/Guardian Decision|0
6128713|NCT00950599|9755028|FG002|Follow-Up Period|Subject withdrew Consent|0
6128714|NCT00950599|9755029|FG003|Follow-Up Period|Subject withdrew Consent|0
6128715|NCT00950599|9755030|FG004|Follow-Up Period|Subject withdrew Consent|0
6219878|NCT01656395|9888916|FG000|Overall Study|Non-Compliance with Study Drug|1
6128716|NCT00950599|9755031|FG005|Follow-Up Period|Subject withdrew Consent|0
6128717|NCT00950599|9755032|FG006|Follow-Up Period|Subject withdrew Consent|0
6128718|NCT00950599|9755033|FG007|Follow-Up Period|Subject withdrew Consent|0
6128719|NCT00950599|9755034|FG008|Follow-Up Period|Subject withdrew Consent|2
6128720|NCT00950599|9755035|FG009|Follow-Up Period|Subject withdrew Consent|1
6128721|NCT00950651|9755069|FG000|Overall Study|Adverse Event|17
6128722|NCT00950651|9755070|FG001|Overall Study|Adverse Event|20
6128723|NCT00950651|9755069|FG000|Overall Study|Death|1
6128724|NCT00950651|9755070|FG001|Overall Study|Death|0
6128725|NCT00950651|9755069|FG000|Overall Study|Lack of Efficacy|2
6128726|NCT00950651|9755070|FG001|Overall Study|Lack of Efficacy|2
6128727|NCT00950651|9755069|FG000|Overall Study|Protocol Violation|3
6128728|NCT00950651|9755070|FG001|Overall Study|Protocol Violation|4
6128729|NCT00950651|9755069|FG000|Overall Study|Withdrawal by Subject|8
6128730|NCT00950651|9755070|FG001|Overall Study|Withdrawal by Subject|9
6128731|NCT00950664|9755078|FG000|First Intervention|Lost to Follow-up|1
6128732|NCT00950664|9755079|FG001|First Intervention|Lost to Follow-up|3
6128733|NCT00950664|9755078|FG000|First Intervention|Withdrawal by Subject|2
6128734|NCT00950664|9755079|FG001|First Intervention|Withdrawal by Subject|2
6128735|NCT00950742|9755091|FG000|Overall Study|Other Adverse Event|1
6128736|NCT00950742|9755092|FG001|Overall Study|Other Adverse Event|0
6128737|NCT00950742|9755091|FG000|Overall Study|Withdrawal by Subject|3
6128738|NCT00950742|9755092|FG001|Overall Study|Withdrawal by Subject|0
6128739|NCT00950742|9755091|FG000|Overall Study|Progressive Disease|6
6128740|NCT00950742|9755092|FG001|Overall Study|Progressive Disease|2
6128741|NCT00950742|9755091|FG000|Overall Study|Dose limiting toxicity|6
6128742|NCT00950742|9755092|FG001|Overall Study|Dose limiting toxicity|0
6128743|NCT00950755|9755102|FG000|Dosimetric and Therapeutic Treatment|Lost to Follow-up|3
6219879|NCT01656395|9888917|FG001|Overall Study|Non-Compliance with Study Drug|1
6219880|NCT01656395|9888918|FG002|Overall Study|Non-Compliance with Study Drug|0
6219881|NCT01656395|9888919|FG003|Overall Study|Non-Compliance with Study Drug|0
6219882|NCT01656395|9888920|FG004|Overall Study|Non-Compliance with Study Drug|1
6219883|NCT01656395|9888921|FG005|Overall Study|Non-Compliance with Study Drug|1
6219884|NCT01656395|9888922|FG006|Overall Study|Non-Compliance with Study Drug|0
6219885|NCT01656395|9888923|FG007|Overall Study|Non-Compliance with Study Drug|0
6219886|NCT01656395|9888916|FG000|Overall Study|Other|0
6219887|NCT01656395|9888917|FG001|Overall Study|Other|0
6219888|NCT01656395|9888918|FG002|Overall Study|Other|1
6219889|NCT01656395|9888919|FG003|Overall Study|Other|0
6219890|NCT01656395|9888920|FG004|Overall Study|Other|0
6219891|NCT01656395|9888921|FG005|Overall Study|Other|1
6219892|NCT01656395|9888922|FG006|Overall Study|Other|0
6219893|NCT01656395|9888923|FG007|Overall Study|Other|0
6219894|NCT01656395|9888916|FG000|Overall Study|Physician Decision|2
6219895|NCT01656395|9888917|FG001|Overall Study|Physician Decision|3
6219896|NCT01656395|9888918|FG002|Overall Study|Physician Decision|3
6219897|NCT01656395|9888919|FG003|Overall Study|Physician Decision|2
6219898|NCT01656395|9888920|FG004|Overall Study|Physician Decision|3
6219899|NCT01656395|9888921|FG005|Overall Study|Physician Decision|3
6219900|NCT01656395|9888922|FG006|Overall Study|Physician Decision|0
6219901|NCT01656395|9888923|FG007|Overall Study|Physician Decision|0
6219902|NCT01656395|9888916|FG000|Overall Study|Pregnancy|0
6219903|NCT01656395|9888917|FG001|Overall Study|Pregnancy|0
6219904|NCT01656395|9888918|FG002|Overall Study|Pregnancy|1
6219905|NCT01656395|9888919|FG003|Overall Study|Pregnancy|0
6219906|NCT01656395|9888920|FG004|Overall Study|Pregnancy|0
6219907|NCT01656395|9888921|FG005|Overall Study|Pregnancy|0
6219908|NCT01656395|9888922|FG006|Overall Study|Pregnancy|0
6219909|NCT01656395|9888923|FG007|Overall Study|Pregnancy|0
6219910|NCT01656395|9888916|FG000|Overall Study|Progressive Disease|0
6219911|NCT01656395|9888917|FG001|Overall Study|Progressive Disease|0
6219912|NCT01656395|9888918|FG002|Overall Study|Progressive Disease|0
6219913|NCT01656395|9888919|FG003|Overall Study|Progressive Disease|0
6219914|NCT01656395|9888920|FG004|Overall Study|Progressive Disease|0
6219915|NCT01656395|9888921|FG005|Overall Study|Progressive Disease|1
6219916|NCT01656395|9888922|FG006|Overall Study|Progressive Disease|0
6219917|NCT01656395|9888923|FG007|Overall Study|Progressive Disease|0
6219918|NCT01656395|9888916|FG000|Overall Study|Protocol Violation|6
6219919|NCT01656395|9888917|FG001|Overall Study|Protocol Violation|6
6219920|NCT01656395|9888918|FG002|Overall Study|Protocol Violation|9
6128744|NCT00950755|9755102|FG000|Dosimetric and Therapeutic Treatment|Received Alternative Therapy|1
6128745|NCT00950755|9755102|FG000|Dosimetric and Therapeutic Treatment|Progressive Disease|27
6128746|NCT00950755|9755102|FG000|Dosimetric and Therapeutic Treatment|Death|1
6219921|NCT01656395|9888919|FG003|Overall Study|Protocol Violation|2
6128747|NCT00950755|9755102|FG000|Dosimetric and Therapeutic Treatment|Stroke; Difficult to Attend Study Visits|1
6128748|NCT00950755|9755102|FG000|Dosimetric and Therapeutic Treatment|Participant Moved; Unable to Follow Up|1
6128749|NCT00950755|9755102|FG000|Dosimetric and Therapeutic Treatment|Rolled Over to Study BEX104528|6
6128750|NCT00950755|9755102|FG000|Dosimetric and Therapeutic Treatment|Investigator Discretion|1
6128751|NCT00950755|9755102|FG000|Long-Term Follow-Up|Lost to Follow-up|1
6128752|NCT00950755|9755102|FG000|Long-Term Follow-Up|Death|8
6219922|NCT01656395|9888920|FG004|Overall Study|Protocol Violation|4
6219923|NCT01656395|9888921|FG005|Overall Study|Protocol Violation|10
6219924|NCT01656395|9888922|FG006|Overall Study|Protocol Violation|0
6219925|NCT01656395|9888923|FG007|Overall Study|Protocol Violation|0
6128753|NCT00950807|9755106|FG000|Treatment Period 1|Lack of Efficacy|1
6128754|NCT00950807|9755107|FG001|Treatment Period 1|Lack of Efficacy|0
6128755|NCT00950807|9755108|FG002|Treatment Period 1|Lack of Efficacy|0
6128756|NCT00950807|9755109|FG003|Treatment Period 1|Lack of Efficacy|0
6128757|NCT00950807|9755110|FG004|Treatment Period 1|Lack of Efficacy|0
6128758|NCT00950807|9755111|FG005|Treatment Period 1|Lack of Efficacy|1
6128759|NCT00950807|9755112|FG006|Treatment Period 1|Lack of Efficacy|0
6128760|NCT00950807|9755113|FG007|Treatment Period 1|Lack of Efficacy|0
6128761|NCT00950807|9755114|FG008|Treatment Period 1|Lack of Efficacy|0
6128762|NCT00950807|9755115|FG009|Treatment Period 1|Lack of Efficacy|0
6128763|NCT00950807|9755106|FG000|Treatment Period 1|Protocol Violation|1
6128764|NCT00950807|9755107|FG001|Treatment Period 1|Protocol Violation|0
6128765|NCT00950807|9755108|FG002|Treatment Period 1|Protocol Violation|0
6128766|NCT00950807|9755109|FG003|Treatment Period 1|Protocol Violation|0
6128767|NCT00950807|9755110|FG004|Treatment Period 1|Protocol Violation|0
6128768|NCT00950807|9755111|FG005|Treatment Period 1|Protocol Violation|0
6128769|NCT00950807|9755112|FG006|Treatment Period 1|Protocol Violation|0
6128770|NCT00950807|9755113|FG007|Treatment Period 1|Protocol Violation|0
6128771|NCT00950807|9755114|FG008|Treatment Period 1|Protocol Violation|0
6128772|NCT00950807|9755115|FG009|Treatment Period 1|Protocol Violation|0
6128773|NCT00950807|9755106|FG000|Treatment Period 1|Lost to Follow-up|0
6128774|NCT00950807|9755107|FG001|Treatment Period 1|Lost to Follow-up|0
6128775|NCT00950807|9755108|FG002|Treatment Period 1|Lost to Follow-up|1
6128776|NCT00950807|9755109|FG003|Treatment Period 1|Lost to Follow-up|0
6128777|NCT00950807|9755110|FG004|Treatment Period 1|Lost to Follow-up|0
6128778|NCT00950807|9755111|FG005|Treatment Period 1|Lost to Follow-up|0
6128779|NCT00950807|9755112|FG006|Treatment Period 1|Lost to Follow-up|0
6128780|NCT00950807|9755113|FG007|Treatment Period 1|Lost to Follow-up|0
6128781|NCT00950807|9755114|FG008|Treatment Period 1|Lost to Follow-up|0
6128782|NCT00950807|9755115|FG009|Treatment Period 1|Lost to Follow-up|0
6128783|NCT00950807|9755106|FG000|Treatment Period 1|Withdrawal by Subject|1
6128784|NCT00950807|9755107|FG001|Treatment Period 1|Withdrawal by Subject|0
6128785|NCT00950807|9755108|FG002|Treatment Period 1|Withdrawal by Subject|0
6128786|NCT00950807|9755109|FG003|Treatment Period 1|Withdrawal by Subject|0
6128787|NCT00950807|9755110|FG004|Treatment Period 1|Withdrawal by Subject|1
6128788|NCT00950807|9755111|FG005|Treatment Period 1|Withdrawal by Subject|0
6128789|NCT00950807|9755112|FG006|Treatment Period 1|Withdrawal by Subject|0
6128790|NCT00950807|9755113|FG007|Treatment Period 1|Withdrawal by Subject|0
6128791|NCT00950807|9755114|FG008|Treatment Period 1|Withdrawal by Subject|1
6128792|NCT00950807|9755115|FG009|Treatment Period 1|Withdrawal by Subject|0
6128793|NCT00950807|9755106|FG000|Treatment Period 1|Adverse Event|0
6128794|NCT00950807|9755107|FG001|Treatment Period 1|Adverse Event|0
6128795|NCT00950807|9755108|FG002|Treatment Period 1|Adverse Event|0
6128796|NCT00950807|9755109|FG003|Treatment Period 1|Adverse Event|0
6128797|NCT00950807|9755110|FG004|Treatment Period 1|Adverse Event|0
6128798|NCT00950807|9755111|FG005|Treatment Period 1|Adverse Event|1
6128799|NCT00950807|9755112|FG006|Treatment Period 1|Adverse Event|0
6128800|NCT00950807|9755113|FG007|Treatment Period 1|Adverse Event|0
6128801|NCT00950807|9755114|FG008|Treatment Period 1|Adverse Event|0
6128802|NCT00950807|9755115|FG009|Treatment Period 1|Adverse Event|0
6128803|NCT00950807|9755106|FG000|Washout Period 1|Lack of Efficacy|0
6128804|NCT00950807|9755107|FG001|Washout Period 1|Lack of Efficacy|0
6128805|NCT00950807|9755108|FG002|Washout Period 1|Lack of Efficacy|0
6128806|NCT00950807|9755109|FG003|Washout Period 1|Lack of Efficacy|0
6128807|NCT00950807|9755110|FG004|Washout Period 1|Lack of Efficacy|0
6128808|NCT00950807|9755111|FG005|Washout Period 1|Lack of Efficacy|0
6128809|NCT00950807|9755112|FG006|Washout Period 1|Lack of Efficacy|1
6128810|NCT00950807|9755113|FG007|Washout Period 1|Lack of Efficacy|0
6128811|NCT00950807|9755114|FG008|Washout Period 1|Lack of Efficacy|0
6128812|NCT00950807|9755115|FG009|Washout Period 1|Lack of Efficacy|0
6128813|NCT00950807|9755106|FG000|Washout Period 1|Withdrawal by Subject|0
6128814|NCT00950807|9755107|FG001|Washout Period 1|Withdrawal by Subject|0
6128815|NCT00950807|9755108|FG002|Washout Period 1|Withdrawal by Subject|0
6128816|NCT00950807|9755109|FG003|Washout Period 1|Withdrawal by Subject|0
6128817|NCT00950807|9755110|FG004|Washout Period 1|Withdrawal by Subject|0
6128818|NCT00950807|9755111|FG005|Washout Period 1|Withdrawal by Subject|0
6128819|NCT00950807|9755112|FG006|Washout Period 1|Withdrawal by Subject|0
6128820|NCT00950807|9755113|FG007|Washout Period 1|Withdrawal by Subject|0
6128821|NCT00950807|9755114|FG008|Washout Period 1|Withdrawal by Subject|1
6128822|NCT00950807|9755115|FG009|Washout Period 1|Withdrawal by Subject|0
6128823|NCT00950807|9755106|FG000|Washout Period 1|Protocol-defined Stopping Criteria|3
6128824|NCT00950807|9755107|FG001|Washout Period 1|Protocol-defined Stopping Criteria|0
6128825|NCT00950807|9755108|FG002|Washout Period 1|Protocol-defined Stopping Criteria|0
6128826|NCT00950807|9755109|FG003|Washout Period 1|Protocol-defined Stopping Criteria|0
6128827|NCT00950807|9755110|FG004|Washout Period 1|Protocol-defined Stopping Criteria|0
6128828|NCT00950807|9755111|FG005|Washout Period 1|Protocol-defined Stopping Criteria|0
6128829|NCT00950807|9755112|FG006|Washout Period 1|Protocol-defined Stopping Criteria|1
6128830|NCT00950807|9755113|FG007|Washout Period 1|Protocol-defined Stopping Criteria|1
6128831|NCT00950807|9755114|FG008|Washout Period 1|Protocol-defined Stopping Criteria|0
6128832|NCT00950807|9755115|FG009|Washout Period 1|Protocol-defined Stopping Criteria|0
6128833|NCT00950807|9755106|FG000|Washout Period 1|Adverse Event|2
6128834|NCT00950807|9755107|FG001|Washout Period 1|Adverse Event|0
6128835|NCT00950807|9755108|FG002|Washout Period 1|Adverse Event|0
6128836|NCT00950807|9755109|FG003|Washout Period 1|Adverse Event|1
6128837|NCT00950807|9755110|FG004|Washout Period 1|Adverse Event|1
6128838|NCT00950807|9755111|FG005|Washout Period 1|Adverse Event|0
6128839|NCT00950807|9755112|FG006|Washout Period 1|Adverse Event|0
6128840|NCT00950807|9755113|FG007|Washout Period 1|Adverse Event|0
6128841|NCT00950807|9755114|FG008|Washout Period 1|Adverse Event|0
6128842|NCT00950807|9755115|FG009|Washout Period 1|Adverse Event|0
6128843|NCT00950807|9755106|FG000|Treatment Period 2|Lack of Efficacy|1
6219926|NCT01656395|9888916|FG000|Overall Study|Screen Failure|2
6219927|NCT01656395|9888917|FG001|Overall Study|Screen Failure|1
6219928|NCT01656395|9888918|FG002|Overall Study|Screen Failure|7
6219929|NCT01656395|9888919|FG003|Overall Study|Screen Failure|1
6219930|NCT01656395|9888920|FG004|Overall Study|Screen Failure|0
6219931|NCT01656395|9888921|FG005|Overall Study|Screen Failure|8
6219932|NCT01656395|9888922|FG006|Overall Study|Screen Failure|0
6219933|NCT01656395|9888923|FG007|Overall Study|Screen Failure|0
6219934|NCT01656395|9888916|FG000|Overall Study|Withdrawal by Subject|3
6219935|NCT01656395|9888917|FG001|Overall Study|Withdrawal by Subject|1
6219936|NCT01656395|9888918|FG002|Overall Study|Withdrawal by Subject|4
6219937|NCT01656395|9888919|FG003|Overall Study|Withdrawal by Subject|2
6219938|NCT01656395|9888920|FG004|Overall Study|Withdrawal by Subject|0
6219939|NCT01656395|9888921|FG005|Overall Study|Withdrawal by Subject|3
6219940|NCT01656395|9888922|FG006|Overall Study|Withdrawal by Subject|0
6219941|NCT01656395|9888923|FG007|Overall Study|Withdrawal by Subject|0
6219942|NCT01656408|9888947|FG000|Overall Study|Adverse Event|0
6219943|NCT01656408|9888948|FG001|Overall Study|Adverse Event|0
6219944|NCT01656408|9888949|FG002|Overall Study|Adverse Event|1
6219945|NCT01656408|9888950|FG003|Overall Study|Adverse Event|0
6219946|NCT01656408|9888951|FG004|Overall Study|Adverse Event|0
6219947|NCT01656408|9888952|FG005|Overall Study|Adverse Event|1
6219948|NCT01656408|9888953|FG006|Overall Study|Adverse Event|1
6219949|NCT01656408|9888954|FG007|Overall Study|Adverse Event|0
6219950|NCT01656408|9888955|FG008|Overall Study|Adverse Event|1
6219951|NCT01656408|9888956|FG009|Overall Study|Adverse Event|0
6219952|NCT01656408|9888947|FG000|Overall Study|Physician Decision|1
6219953|NCT01656408|9888948|FG001|Overall Study|Physician Decision|0
6219954|NCT01656408|9888949|FG002|Overall Study|Physician Decision|1
6219955|NCT01656408|9888950|FG003|Overall Study|Physician Decision|0
6219956|NCT01656408|9888951|FG004|Overall Study|Physician Decision|1
6219957|NCT01656408|9888952|FG005|Overall Study|Physician Decision|1
6219958|NCT01656408|9888953|FG006|Overall Study|Physician Decision|0
6219959|NCT01656408|9888954|FG007|Overall Study|Physician Decision|1
6219960|NCT01656408|9888955|FG008|Overall Study|Physician Decision|1
6219961|NCT01656408|9888956|FG009|Overall Study|Physician Decision|3
6219962|NCT01656733|9889034|FG000|Overall Study|No permission to collect birth outcomes|0
6128844|NCT00950807|9755107|FG001|Treatment Period 2|Lack of Efficacy|0
6128845|NCT00950807|9755108|FG002|Treatment Period 2|Lack of Efficacy|0
6128846|NCT00950807|9755109|FG003|Treatment Period 2|Lack of Efficacy|0
6128847|NCT00950807|9755110|FG004|Treatment Period 2|Lack of Efficacy|0
6128848|NCT00950807|9755111|FG005|Treatment Period 2|Lack of Efficacy|0
6128849|NCT00950807|9755112|FG006|Treatment Period 2|Lack of Efficacy|0
6128850|NCT00950807|9755113|FG007|Treatment Period 2|Lack of Efficacy|0
6128851|NCT00950807|9755114|FG008|Treatment Period 2|Lack of Efficacy|0
6128852|NCT00950807|9755115|FG009|Treatment Period 2|Lack of Efficacy|0
6128853|NCT00950807|9755106|FG000|Treatment Period 2|Withdrawal by Subject|0
6128854|NCT00950807|9755107|FG001|Treatment Period 2|Withdrawal by Subject|0
6128855|NCT00950807|9755108|FG002|Treatment Period 2|Withdrawal by Subject|0
6128856|NCT00950807|9755109|FG003|Treatment Period 2|Withdrawal by Subject|0
6128857|NCT00950807|9755110|FG004|Treatment Period 2|Withdrawal by Subject|0
6128858|NCT00950807|9755111|FG005|Treatment Period 2|Withdrawal by Subject|0
6128859|NCT00950807|9755112|FG006|Treatment Period 2|Withdrawal by Subject|1
6128860|NCT00950807|9755113|FG007|Treatment Period 2|Withdrawal by Subject|2
6219963|NCT01656733|9889035|FG001|Overall Study|No permission to collect birth outcomes|1
6219964|NCT01656733|9889034|FG000|Overall Study|Delivery at another hospital|0
6219965|NCT01656733|9889035|FG001|Overall Study|Delivery at another hospital|2
6219966|NCT01656733|9889034|FG000|Overall Study|Spontaneous abortion|0
6219967|NCT01656733|9889035|FG001|Overall Study|Spontaneous abortion|1
6219968|NCT01656759|9889043|FG000|Overall Study|Protocol Violation|2
6219969|NCT01656759|9889044|FG001|Overall Study|Protocol Violation|3
6219970|NCT01656850|9889061|FG000|First Intervention (3 Months)|Withdrawal by Subject|3
6219971|NCT01656850|9889062|FG001|First Intervention (3 Months)|Withdrawal by Subject|4
6128861|NCT00950807|9755114|FG008|Treatment Period 2|Withdrawal by Subject|0
6128862|NCT00950807|9755115|FG009|Treatment Period 2|Withdrawal by Subject|0
6128863|NCT00950807|9755106|FG000|Treatment Period 2|Protocol-defined Stopping Criteria|1
6128864|NCT00950807|9755107|FG001|Treatment Period 2|Protocol-defined Stopping Criteria|0
6128865|NCT00950807|9755108|FG002|Treatment Period 2|Protocol-defined Stopping Criteria|0
6128866|NCT00950807|9755109|FG003|Treatment Period 2|Protocol-defined Stopping Criteria|0
6128867|NCT00950807|9755110|FG004|Treatment Period 2|Protocol-defined Stopping Criteria|0
6219972|NCT01656889|9889074|FG000|Treatment Period, 12 Weeks|Adverse Event|10
6219973|NCT01656889|9889075|FG001|Treatment Period, 12 Weeks|Adverse Event|4
6219974|NCT01656889|9889074|FG000|Treatment Period, 12 Weeks|Death|0
6128868|NCT00950807|9755111|FG005|Treatment Period 2|Protocol-defined Stopping Criteria|0
6128869|NCT00950807|9755112|FG006|Treatment Period 2|Protocol-defined Stopping Criteria|0
6219975|NCT01656889|9889075|FG001|Treatment Period, 12 Weeks|Death|1
6219976|NCT01656889|9889074|FG000|Treatment Period, 12 Weeks|Lost to Follow-up|1
6219977|NCT01656889|9889075|FG001|Treatment Period, 12 Weeks|Lost to Follow-up|1
6219978|NCT01656889|9889074|FG000|Treatment Period, 12 Weeks|Withdrawal by Subject|1
6219979|NCT01656889|9889075|FG001|Treatment Period, 12 Weeks|Withdrawal by Subject|2
6219980|NCT01656889|9889074|FG000|Treatment Period, 12 Weeks|Protocol Violation|0
6219981|NCT01656889|9889075|FG001|Treatment Period, 12 Weeks|Protocol Violation|1
6219982|NCT01656889|9889074|FG000|Treatment Period, 12 Weeks|Moved out of the area|0
6219983|NCT01656889|9889075|FG001|Treatment Period, 12 Weeks|Moved out of the area|2
6219984|NCT01656889|9889074|FG000|Post Treatment Follow-Up, 3 Months|Death|1
6219985|NCT01656889|9889075|FG001|Post Treatment Follow-Up, 3 Months|Death|5
6219986|NCT01656889|9889074|FG000|Post Treatment Follow-Up, 3 Months|Lost to Follow-up|1
6219987|NCT01656889|9889075|FG001|Post Treatment Follow-Up, 3 Months|Lost to Follow-up|2
6219988|NCT01656889|9889074|FG000|Post Treatment Follow-Up, 3 Months|Withdrawal by Subject|2
6219989|NCT01656889|9889075|FG001|Post Treatment Follow-Up, 3 Months|Withdrawal by Subject|1
6219990|NCT01656889|9889074|FG000|Post Treatment Follow-Up, 3 Months|Site Closure|0
6219991|NCT01656889|9889075|FG001|Post Treatment Follow-Up, 3 Months|Site Closure|1
6219992|NCT01656967|9889083|FG000|Overall Study|faulty monitor|1
6219993|NCT01656967|9889084|FG001|Overall Study|faulty monitor|0
6219994|NCT01656967|9889083|FG000|Overall Study|unsuccessful ETT insertion|3
6219995|NCT01656967|9889084|FG001|Overall Study|unsuccessful ETT insertion|2
6219996|NCT01657019|9889094|FG000|Overall Study|Withdrawal by Subject|65
6219997|NCT01657019|9889094|FG000|Overall Study|Adverse Event|55
6219998|NCT01657019|9889094|FG000|Overall Study|Lost to Follow-up|48
6219999|NCT01657019|9889094|FG000|Overall Study|Protocol Violation|6
6220000|NCT01657019|9889094|FG000|Overall Study|Lack of Efficacy|3
6220001|NCT01657019|9889094|FG000|Overall Study|Other|58
6220002|NCT01657032|9889100|FG000|Overall Study|Lost to Follow-up|0
6220003|NCT01657032|9889101|FG001|Overall Study|Lost to Follow-up|7
6220004|NCT01657162|9889109|FG000|Overall Study|Adverse Event|26
6220005|NCT01657162|9889110|FG001|Overall Study|Adverse Event|36
6220006|NCT01657162|9889109|FG000|Overall Study|Withdrawal by Subject|13
6220007|NCT01657162|9889110|FG001|Overall Study|Withdrawal by Subject|13
6220008|NCT01657162|9889109|FG000|Overall Study|Continuing Significant Deterioration|9
6220009|NCT01657162|9889110|FG001|Overall Study|Continuing Significant Deterioration|3
6220010|NCT01657162|9889109|FG000|Overall Study|Refusal of Treatment|4
6220011|NCT01657162|9889110|FG001|Overall Study|Refusal of Treatment|6
6220012|NCT01657162|9889109|FG000|Overall Study|Lost to Follow-up|3
6220013|NCT01657162|9889110|FG001|Overall Study|Lost to Follow-up|4
6220014|NCT01657162|9889109|FG000|Overall Study|Death|2
6220015|NCT01657162|9889110|FG001|Overall Study|Death|3
6220016|NCT01657162|9889109|FG000|Overall Study|Inability to Complete Study Procedures|1
6220017|NCT01657162|9889110|FG001|Overall Study|Inability to Complete Study Procedures|7
6220018|NCT01657162|9889109|FG000|Overall Study|Protocol Violation|1
6220019|NCT01657162|9889110|FG001|Overall Study|Protocol Violation|0
6220020|NCT01657162|9889109|FG000|Overall Study|Hypersensitivity to Alendronate|0
6220021|NCT01657162|9889110|FG001|Overall Study|Hypersensitivity to Alendronate|1
6220022|NCT01657162|9889109|FG000|Overall Study|Other than Specified|0
6220023|NCT01657162|9889110|FG001|Overall Study|Other than Specified|2
6220024|NCT01657253|9889118|FG000|Overall Study|Lost to Follow-up|6
6220025|NCT01657253|9889119|FG001|Overall Study|Lost to Follow-up|5
6220026|NCT01657253|9889118|FG000|Overall Study|Withdrawal by Subject|11
6220027|NCT01657253|9889119|FG001|Overall Study|Withdrawal by Subject|12
6220028|NCT01657253|9889118|FG000|Overall Study|Adverse Event|0
6220029|NCT01657253|9889119|FG001|Overall Study|Adverse Event|1
6220030|NCT01657266|9889127|FG000|Overall Study|Lost to Follow-up|2
6220031|NCT01657266|9889128|FG001|Overall Study|Lost to Follow-up|2
6220032|NCT01657266|9889127|FG000|Overall Study|Adverse Event|2
6220033|NCT01657266|9889128|FG001|Overall Study|Adverse Event|3
6220034|NCT01657292|9889134|FG000|Overall Study|Adverse Event|6
6220035|NCT01657292|9889134|FG000|Overall Study|Withdrawal by Subject|2
6220036|NCT01657292|9889134|FG000|Overall Study|Violation of eligibility criteria|1
6220037|NCT01657292|9889134|FG000|Overall Study|Change of therapy|1
6220038|NCT01657305|9889141|FG000|Overall Study|Lack of Wound Closure at Day 28|15
6220039|NCT01657305|9889141|FG000|Overall Study|Withdrawal by Subject|4
6220040|NCT01657305|9889141|FG000|Overall Study|Adverse Event|1
6220041|NCT01657305|9889141|FG000|Overall Study|Lost to Follow-up|1
6220042|NCT01657305|9889141|FG000|Overall Study|Did not Adhere to Protocol/Procedures|4
6220043|NCT01657370|9889203|FG000|Overall Study|Withdrawal by Subject|0
6220044|NCT01657370|9889204|FG001|Overall Study|Withdrawal by Subject|0
6220045|NCT01657370|9889205|FG002|Overall Study|Withdrawal by Subject|1
6220046|NCT01657370|9889206|FG003|Overall Study|Withdrawal by Subject|0
6220047|NCT01657370|9889207|FG004|Overall Study|Withdrawal by Subject|0
6220048|NCT01657370|9889208|FG005|Overall Study|Withdrawal by Subject|1
6220049|NCT01657370|9889203|FG000|Overall Study|Physician Decision|2
6220050|NCT01657370|9889204|FG001|Overall Study|Physician Decision|3
6220051|NCT01657370|9889205|FG002|Overall Study|Physician Decision|1
6220052|NCT01657370|9889206|FG003|Overall Study|Physician Decision|2
6220053|NCT01657370|9889207|FG004|Overall Study|Physician Decision|5
6128870|NCT00950807|9755113|FG007|Treatment Period 2|Protocol-defined Stopping Criteria|0
6128871|NCT00950807|9755114|FG008|Treatment Period 2|Protocol-defined Stopping Criteria|0
6128872|NCT00950807|9755115|FG009|Treatment Period 2|Protocol-defined Stopping Criteria|0
6128873|NCT00950807|9755106|FG000|Treatment Period 2|Adverse Event|0
6128874|NCT00950807|9755107|FG001|Treatment Period 2|Adverse Event|1
6128875|NCT00950807|9755108|FG002|Treatment Period 2|Adverse Event|0
6128876|NCT00950807|9755109|FG003|Treatment Period 2|Adverse Event|1
6128877|NCT00950807|9755110|FG004|Treatment Period 2|Adverse Event|0
6128878|NCT00950807|9755111|FG005|Treatment Period 2|Adverse Event|1
6128879|NCT00950807|9755112|FG006|Treatment Period 2|Adverse Event|0
6128880|NCT00950807|9755113|FG007|Treatment Period 2|Adverse Event|1
6128881|NCT00950807|9755114|FG008|Treatment Period 2|Adverse Event|0
6128882|NCT00950807|9755115|FG009|Treatment Period 2|Adverse Event|0
6128883|NCT00950807|9755106|FG000|Washout Period 2|Lack of Efficacy|1
6128884|NCT00950807|9755107|FG001|Washout Period 2|Lack of Efficacy|0
6128885|NCT00950807|9755108|FG002|Washout Period 2|Lack of Efficacy|0
6128886|NCT00950807|9755109|FG003|Washout Period 2|Lack of Efficacy|0
6128887|NCT00950807|9755110|FG004|Washout Period 2|Lack of Efficacy|0
6128888|NCT00950807|9755111|FG005|Washout Period 2|Lack of Efficacy|0
6128889|NCT00950807|9755112|FG006|Washout Period 2|Lack of Efficacy|0
6128890|NCT00950807|9755113|FG007|Washout Period 2|Lack of Efficacy|0
6128891|NCT00950807|9755114|FG008|Washout Period 2|Lack of Efficacy|0
6128892|NCT00950807|9755115|FG009|Washout Period 2|Lack of Efficacy|0
6128893|NCT00950807|9755106|FG000|Washout Period 2|Protocol-defined Stopping Criteria|0
6128894|NCT00950807|9755107|FG001|Washout Period 2|Protocol-defined Stopping Criteria|1
6220054|NCT01657370|9889208|FG005|Overall Study|Physician Decision|0
6220055|NCT01657370|9889203|FG000|Overall Study|Lack of Qualifying Event|1
6220056|NCT01657370|9889204|FG001|Overall Study|Lack of Qualifying Event|0
6220057|NCT01657370|9889205|FG002|Overall Study|Lack of Qualifying Event|3
6220058|NCT01657370|9889206|FG003|Overall Study|Lack of Qualifying Event|2
6220059|NCT01657370|9889207|FG004|Overall Study|Lack of Qualifying Event|1
6220060|NCT01657370|9889208|FG005|Overall Study|Lack of Qualifying Event|2
6220061|NCT01657370|9889203|FG000|Overall Study|Adverse Event|0
6220062|NCT01657370|9889204|FG001|Overall Study|Adverse Event|0
6220063|NCT01657370|9889205|FG002|Overall Study|Adverse Event|0
6220064|NCT01657370|9889206|FG003|Overall Study|Adverse Event|0
6220065|NCT01657370|9889207|FG004|Overall Study|Adverse Event|1
6220066|NCT01657370|9889208|FG005|Overall Study|Adverse Event|0
6220067|NCT01657370|9889203|FG000|Overall Study|Protocol Violation|1
6220068|NCT01657370|9889204|FG001|Overall Study|Protocol Violation|1
6220069|NCT01657370|9889205|FG002|Overall Study|Protocol Violation|1
6220070|NCT01657370|9889206|FG003|Overall Study|Protocol Violation|1
6220071|NCT01657370|9889207|FG004|Overall Study|Protocol Violation|0
6220072|NCT01657370|9889208|FG005|Overall Study|Protocol Violation|0
6220073|NCT01657370|9889203|FG000|Overall Study|Lost to Follow-up|2
6220074|NCT01657370|9889204|FG001|Overall Study|Lost to Follow-up|0
6220075|NCT01657370|9889205|FG002|Overall Study|Lost to Follow-up|1
6220076|NCT01657370|9889206|FG003|Overall Study|Lost to Follow-up|0
6220077|NCT01657370|9889207|FG004|Overall Study|Lost to Follow-up|0
6220078|NCT01657370|9889208|FG005|Overall Study|Lost to Follow-up|1
6220079|NCT01657461|9889229|FG000|Overall Study|Death|9
6220080|NCT01657461|9889230|FG001|Overall Study|Death|12
6220081|NCT01657461|9889229|FG000|Overall Study|Lost to Follow-up|0
6220082|NCT01657461|9889230|FG001|Overall Study|Lost to Follow-up|3
6220083|NCT01657461|9889229|FG000|Overall Study|Physician Decision|0
6220084|NCT01657461|9889230|FG001|Overall Study|Physician Decision|2
6220085|NCT01657461|9889229|FG000|Overall Study|Withdrawal by Subject|1
6220086|NCT01657461|9889230|FG001|Overall Study|Withdrawal by Subject|3
6220087|NCT01657760|9889242|FG000|Overall Study|Withdrawal by Subject|0
6220088|NCT01657760|9889243|FG001|Overall Study|Withdrawal by Subject|0
6220089|NCT01657760|9889244|FG002|Overall Study|Withdrawal by Subject|0
6220090|NCT01657760|9889245|FG003|Overall Study|Withdrawal by Subject|1
6220091|NCT01657760|9889242|FG000|Overall Study|Physician Decision|1
6220092|NCT01657760|9889243|FG001|Overall Study|Physician Decision|1
6220093|NCT01657760|9889244|FG002|Overall Study|Physician Decision|1
6220094|NCT01657760|9889245|FG003|Overall Study|Physician Decision|2
6220095|NCT01657799|9889260|FG000|Overall Study|Adverse Event Related to progression|6
6220096|NCT01657799|9889261|FG001|Overall Study|Adverse Event Related to progression|8
6220097|NCT01657799|9889262|FG002|Overall Study|Adverse Event Related to progression|12
6220098|NCT01657799|9889260|FG000|Overall Study|Adverse Event Not Related to Progression|5
6220099|NCT01657799|9889261|FG001|Overall Study|Adverse Event Not Related to Progression|4
6220100|NCT01657799|9889262|FG002|Overall Study|Adverse Event Not Related to Progression|4
6288993|NCT02375971|10003527|FG001|Treatment (Day 1 - Baseline)|Subj/Guardian Decision|0
6288994|NCT02375971|10003528|FG002|Treatment (Day 1 - Baseline)|Subj/Guardian Decision|2
6288995|NCT02375971|10003526|FG000|Treatment (Day 1 - Baseline)|Physician Decision|1
6128895|NCT00950807|9755108|FG002|Washout Period 2|Protocol-defined Stopping Criteria|0
6128896|NCT00950807|9755109|FG003|Washout Period 2|Protocol-defined Stopping Criteria|0
6220101|NCT01657799|9889260|FG000|Overall Study|Withdrawal by Subject|13
6128897|NCT00950807|9755110|FG004|Washout Period 2|Protocol-defined Stopping Criteria|1
6220102|NCT01657799|9889261|FG001|Overall Study|Withdrawal by Subject|10
6220103|NCT01657799|9889262|FG002|Overall Study|Withdrawal by Subject|10
6220104|NCT01657799|9889260|FG000|Overall Study|Lost to Follow-up|1
6128898|NCT00950807|9755111|FG005|Washout Period 2|Protocol-defined Stopping Criteria|0
6128899|NCT00950807|9755112|FG006|Washout Period 2|Protocol-defined Stopping Criteria|1
6128900|NCT00950807|9755113|FG007|Washout Period 2|Protocol-defined Stopping Criteria|1
6128901|NCT00950807|9755114|FG008|Washout Period 2|Protocol-defined Stopping Criteria|0
6128902|NCT00950807|9755115|FG009|Washout Period 2|Protocol-defined Stopping Criteria|0
6128903|NCT00950807|9755106|FG000|Washout Period 2|Adverse Event|3
6128904|NCT00950807|9755107|FG001|Washout Period 2|Adverse Event|0
6128905|NCT00950807|9755108|FG002|Washout Period 2|Adverse Event|0
6128906|NCT00950807|9755109|FG003|Washout Period 2|Adverse Event|1
6128907|NCT00950807|9755110|FG004|Washout Period 2|Adverse Event|0
6128908|NCT00950807|9755111|FG005|Washout Period 2|Adverse Event|0
6128909|NCT00950807|9755112|FG006|Washout Period 2|Adverse Event|0
6128910|NCT00950807|9755113|FG007|Washout Period 2|Adverse Event|0
6128911|NCT00950807|9755114|FG008|Washout Period 2|Adverse Event|0
6128912|NCT00950807|9755115|FG009|Washout Period 2|Adverse Event|0
6128913|NCT00950807|9755106|FG000|Treatment Period 3|Withdrawal by Subject|0
6128914|NCT00950807|9755107|FG001|Treatment Period 3|Withdrawal by Subject|0
6128915|NCT00950807|9755108|FG002|Treatment Period 3|Withdrawal by Subject|0
6128916|NCT00950807|9755109|FG003|Treatment Period 3|Withdrawal by Subject|0
6128917|NCT00950807|9755110|FG004|Treatment Period 3|Withdrawal by Subject|0
6128918|NCT00950807|9755111|FG005|Treatment Period 3|Withdrawal by Subject|0
6128919|NCT00950807|9755112|FG006|Treatment Period 3|Withdrawal by Subject|0
6128920|NCT00950807|9755113|FG007|Treatment Period 3|Withdrawal by Subject|0
6128921|NCT00950807|9755114|FG008|Treatment Period 3|Withdrawal by Subject|0
6220105|NCT01657799|9889261|FG001|Overall Study|Lost to Follow-up|0
6220106|NCT01657799|9889262|FG002|Overall Study|Lost to Follow-up|1
6220107|NCT01657799|9889260|FG000|Overall Study|Disease Progression|2
6220108|NCT01657799|9889261|FG001|Overall Study|Disease Progression|4
6220109|NCT01657799|9889262|FG002|Overall Study|Disease Progression|4
6220110|NCT01657799|9889260|FG000|Overall Study|Progressive Disease Clinical|7
6220111|NCT01657799|9889261|FG001|Overall Study|Progressive Disease Clinical|4
6220112|NCT01657799|9889262|FG002|Overall Study|Progressive Disease Clinical|7
6220113|NCT01657799|9889260|FG000|Overall Study|Radiographic & Clinical Progression|16
6220114|NCT01657799|9889261|FG001|Overall Study|Radiographic & Clinical Progression|11
6220115|NCT01657799|9889262|FG002|Overall Study|Radiographic & Clinical Progression|15
6220116|NCT01657799|9889260|FG000|Overall Study|Other|52
6220117|NCT01657799|9889261|FG001|Overall Study|Other|62
6220118|NCT01657799|9889262|FG002|Overall Study|Other|49
6220119|NCT01657877|9889270|FG000|Overall Study|Withdrawal by Subject|4
6220120|NCT01657877|9889270|FG000|Overall Study|Protocol Violation|6
6220121|NCT01657877|9889270|FG000|Overall Study|Adverse Event|2
6220122|NCT01657877|9889270|FG000|Overall Study|Other Reason|2
6220123|NCT01657903|9889287|FG000|Overall Study|Lost to Follow-up|1
6220124|NCT01657903|9889287|FG000|Overall Study|Withdrawal by Subject|1
6220125|NCT01658020|9889300|FG000|Overall Study|Adverse Event|3
6220126|NCT01658020|9889301|FG001|Overall Study|Adverse Event|3
6220127|NCT01658020|9889300|FG000|Overall Study|Lost to Follow-up|1
6220128|NCT01658020|9889301|FG001|Overall Study|Lost to Follow-up|0
6220129|NCT01658020|9889300|FG000|Overall Study|Withdrawal by Subject|4
6220130|NCT01658020|9889301|FG001|Overall Study|Withdrawal by Subject|5
6220131|NCT01658020|9889300|FG000|Overall Study|Protocol Violation|0
6220132|NCT01658020|9889301|FG001|Overall Study|Protocol Violation|1
6220133|NCT01658072|9889317|FG000|Overall Study|Protocol Violation|4
6220134|NCT01658072|9889318|FG001|Overall Study|Protocol Violation|2
6220135|NCT01658150|9889324|FG000|Overall Study|Withdrawal by Subject|1
6220136|NCT01658436|9889338|FG000|Overall Study|Adverse Event|6
6220137|NCT01658436|9889339|FG001|Overall Study|Adverse Event|5
6220138|NCT01658436|9889338|FG000|Overall Study|Physician Decision|1
6220139|NCT01658436|9889339|FG001|Overall Study|Physician Decision|0
6220140|NCT01658436|9889338|FG000|Overall Study|Progressive disease|12
6220141|NCT01658436|9889339|FG001|Overall Study|Progressive disease|4
6220142|NCT01658436|9889338|FG000|Overall Study|Study terminated by sponsor|0
6220143|NCT01658436|9889339|FG001|Overall Study|Study terminated by sponsor|1
6220144|NCT01658436|9889338|FG000|Overall Study|Subject/guardian decision|0
6220145|NCT01658436|9889339|FG001|Overall Study|Subject/guardian decision|1
6220146|NCT01658436|9889338|FG000|Overall Study|Death|1
6220147|NCT01658436|9889339|FG001|Overall Study|Death|0
6220148|NCT01658514|9889348|FG000|Overall Study|Protocol Violation|1
6220149|NCT01658514|9889349|FG001|Overall Study|Protocol Violation|0
6220150|NCT01658514|9889350|FG002|Overall Study|Protocol Violation|2
6220151|NCT01658579|9889361|FG000|Treatment Period A|Other|0
6220152|NCT01658579|9889362|FG001|Treatment Period A|Other|0
6288996|NCT02375971|10003527|FG001|Treatment (Day 1 - Baseline)|Physician Decision|1
6288997|NCT02375971|10003528|FG002|Treatment (Day 1 - Baseline)|Physician Decision|1
6288998|NCT02375971|10003526|FG000|Treatment (Day 1 - Baseline)|Lost to Follow-up|0
6288999|NCT02375971|10003527|FG001|Treatment (Day 1 - Baseline)|Lost to Follow-up|0
6289000|NCT02375971|10003528|FG002|Treatment (Day 1 - Baseline)|Lost to Follow-up|1
6289001|NCT02375971|10003526|FG000|Treatment (Day 1 - Baseline)|Adverse Event|0
6289002|NCT02375971|10003527|FG001|Treatment (Day 1 - Baseline)|Adverse Event|0
6220153|NCT01658579|9889363|FG002|Treatment Period A|Other|1
6220154|NCT01658579|9889364|FG003|Treatment Period A|Other|1
6220155|NCT01658579|9889361|FG000|Treatment Period A|Adverse Event|1
6220156|NCT01658579|9889362|FG001|Treatment Period A|Adverse Event|0
6220157|NCT01658579|9889363|FG002|Treatment Period A|Adverse Event|0
6128922|NCT00950807|9755115|FG009|Treatment Period 3|Withdrawal by Subject|1
6128923|NCT00950807|9755106|FG000|Treatment Period 3|Protocol-defined Stopping Criteria|1
6128924|NCT00950807|9755107|FG001|Treatment Period 3|Protocol-defined Stopping Criteria|0
6128925|NCT00950807|9755108|FG002|Treatment Period 3|Protocol-defined Stopping Criteria|0
6128926|NCT00950807|9755109|FG003|Treatment Period 3|Protocol-defined Stopping Criteria|0
6128927|NCT00950807|9755110|FG004|Treatment Period 3|Protocol-defined Stopping Criteria|0
6128928|NCT00950807|9755111|FG005|Treatment Period 3|Protocol-defined Stopping Criteria|0
6128929|NCT00950807|9755112|FG006|Treatment Period 3|Protocol-defined Stopping Criteria|0
6128930|NCT00950807|9755113|FG007|Treatment Period 3|Protocol-defined Stopping Criteria|1
6128931|NCT00950807|9755114|FG008|Treatment Period 3|Protocol-defined Stopping Criteria|0
6128932|NCT00950807|9755115|FG009|Treatment Period 3|Protocol-defined Stopping Criteria|0
6128933|NCT00950807|9755106|FG000|Treatment Period 3|Adverse Event|0
6128934|NCT00950807|9755107|FG001|Treatment Period 3|Adverse Event|0
6128935|NCT00950807|9755108|FG002|Treatment Period 3|Adverse Event|0
6128936|NCT00950807|9755109|FG003|Treatment Period 3|Adverse Event|0
6128937|NCT00950807|9755110|FG004|Treatment Period 3|Adverse Event|0
6128938|NCT00950807|9755111|FG005|Treatment Period 3|Adverse Event|0
6128939|NCT00950807|9755112|FG006|Treatment Period 3|Adverse Event|1
6128940|NCT00950807|9755113|FG007|Treatment Period 3|Adverse Event|0
6128941|NCT00950807|9755114|FG008|Treatment Period 3|Adverse Event|0
6128942|NCT00950807|9755115|FG009|Treatment Period 3|Adverse Event|0
6128943|NCT00950859|9755154|FG000|Overall Study|Adverse Event|3
6128944|NCT00950859|9755155|FG001|Overall Study|Adverse Event|3
6128945|NCT00950859|9755154|FG000|Overall Study|Insufficient Viral Load Response|12
6128946|NCT00950859|9755155|FG001|Overall Study|Insufficient Viral Load Response|3
6128947|NCT00950859|9755154|FG000|Overall Study|Protocol Violation|1
6128948|NCT00950859|9755155|FG001|Overall Study|Protocol Violation|1
6128949|NCT00950859|9755154|FG000|Overall Study|Lost to Follow-up|0
6128950|NCT00950859|9755155|FG001|Overall Study|Lost to Follow-up|3
6128951|NCT00950872|9755161|FG000|Overall Study|Withdrawal by Subject|1
6128952|NCT00950872|9755161|FG000|Overall Study|Did not have surgery|2
6128953|NCT00950911|9755167|FG000|Overall Study|Adverse Event|0
6128954|NCT00950911|9755168|FG001|Overall Study|Adverse Event|2
6128955|NCT00950911|9755167|FG000|Overall Study|Death|4
6128956|NCT00950911|9755168|FG001|Overall Study|Death|6
6128957|NCT00950911|9755167|FG000|Overall Study|Disease progression|2
6128958|NCT00950911|9755168|FG001|Overall Study|Disease progression|2
6128959|NCT00950911|9755167|FG000|Overall Study|Consent withdrawn|1
6128960|NCT00950911|9755168|FG001|Overall Study|Consent withdrawn|3
6128961|NCT00950911|9755167|FG000|Overall Study|Administrative decision|3
6128962|NCT00950911|9755168|FG001|Overall Study|Administrative decision|1
6128963|NCT00950911|9755167|FG000|Overall Study|Ineligibility determined|1
6128964|NCT00950911|9755168|FG001|Overall Study|Ineligibility determined|0
6220158|NCT01658579|9889364|FG003|Treatment Period A|Adverse Event|0
6220159|NCT01658579|9889361|FG000|Treatment Period B|Other|0
6220160|NCT01658579|9889362|FG001|Treatment Period B|Other|0
6220161|NCT01658579|9889363|FG002|Treatment Period B|Other|0
6220162|NCT01658579|9889364|FG003|Treatment Period B|Other|1
6220163|NCT01658735|9889382|FG000|Overall Study|Lack of Efficacy|1
6220164|NCT01658735|9889383|FG001|Overall Study|Lack of Efficacy|0
6220165|NCT01658735|9889384|FG002|Overall Study|Lack of Efficacy|1
6220166|NCT01658735|9889382|FG000|Overall Study|Lost to Follow-up|1
6220167|NCT01658735|9889383|FG001|Overall Study|Lost to Follow-up|1
6220168|NCT01658735|9889384|FG002|Overall Study|Lost to Follow-up|0
6220169|NCT01658735|9889382|FG000|Overall Study|Protocol Violation|0
6220170|NCT01658735|9889383|FG001|Overall Study|Protocol Violation|1
6220171|NCT01658735|9889384|FG002|Overall Study|Protocol Violation|0
6220172|NCT01658735|9889382|FG000|Overall Study|Withdrawal by Subject|3
6220173|NCT01658735|9889383|FG001|Overall Study|Withdrawal by Subject|5
6220174|NCT01658735|9889384|FG002|Overall Study|Withdrawal by Subject|3
6220175|NCT01658904|9889399|FG000|Overall Study|Principal Investigator discretion|2
6220176|NCT01658904|9889400|FG001|Overall Study|Principal Investigator discretion|0
6220177|NCT01658904|9889401|FG002|Overall Study|Principal Investigator discretion|0
6220178|NCT01658943|9889414|FG000|Overall Study|Adverse Event|6
6220179|NCT01658943|9889415|FG001|Overall Study|Adverse Event|13
6220180|NCT01658943|9889414|FG000|Overall Study|Withdrawal by Subject|9
6289003|NCT02375971|10003528|FG002|Treatment (Day 1 - Baseline)|Adverse Event|1
6289004|NCT02375971|10003526|FG000|Follow-Up Phase (up to Day 169)|Adverse Event|1
6289005|NCT02375971|10003527|FG001|Follow-Up Phase (up to Day 169)|Adverse Event|0
6289006|NCT02375971|10003528|FG002|Follow-Up Phase (up to Day 169)|Adverse Event|0
6289007|NCT02375971|10003526|FG000|Follow-Up Phase (up to Day 169)|Subject/Guardian Decision|1
6289008|NCT02375971|10003527|FG001|Follow-Up Phase (up to Day 169)|Subject/Guardian Decision|0
6289009|NCT02375971|10003528|FG002|Follow-Up Phase (up to Day 169)|Subject/Guardian Decision|1
5980928|NCT04042077|9569677|FG000|Overall Study|Withdrawal by Subject|3
6128965|NCT00950911|9755167|FG000|Overall Study|Noncompliance|1
6220181|NCT01658943|9889415|FG001|Overall Study|Withdrawal by Subject|2
6220182|NCT01658943|9889414|FG000|Overall Study|Progression/Relapse|39
6220183|NCT01658943|9889415|FG001|Overall Study|Progression/Relapse|40
6220184|NCT01658943|9889414|FG000|Overall Study|Death|4
6220185|NCT01658943|9889415|FG001|Overall Study|Death|2
6220186|NCT01658943|9889414|FG000|Overall Study|not protocol specified|4
6220187|NCT01658943|9889415|FG001|Overall Study|not protocol specified|1
6128966|NCT00950911|9755168|FG001|Overall Study|Noncompliance|0
6128967|NCT00950911|9755167|FG000|Overall Study|Poor performance status|0
6128968|NCT00950911|9755168|FG001|Overall Study|Poor performance status|1
6128969|NCT00950950|9755176|FG000|Overall Study|Adverse Event|1
6128970|NCT00950950|9755177|FG001|Overall Study|Adverse Event|0
6128971|NCT00950950|9755176|FG000|Overall Study|Withdrawal by Subject|0
6128972|NCT00950950|9755177|FG001|Overall Study|Withdrawal by Subject|1
6220188|NCT01658943|9889414|FG000|Overall Study|Not eligible|7
6220189|NCT01658943|9889415|FG001|Overall Study|Not eligible|9
6220190|NCT01658943|9889414|FG000|Overall Study|Withdrew prior to beginning protocol Tx|1
6220191|NCT01658943|9889415|FG001|Overall Study|Withdrew prior to beginning protocol Tx|0
6220192|NCT01659021|9889432|FG000|Main Study|Adverse Event|2
6220193|NCT01659021|9889433|FG001|Main Study|Adverse Event|3
6220194|NCT01659021|9889432|FG000|Main Study|Lost to Follow-up|1
6220195|NCT01659021|9889433|FG001|Main Study|Lost to Follow-up|0
6220196|NCT01659021|9889432|FG000|Main Study|Unknown Reasons|2
6220197|NCT01659021|9889433|FG001|Main Study|Unknown Reasons|1
6220198|NCT01659021|9889432|FG000|Main Study|Physician Decision|34
6220199|NCT01659021|9889433|FG001|Main Study|Physician Decision|16
6220200|NCT01659021|9889432|FG000|Main Study|Withdrawal by Subject|19
6220201|NCT01659021|9889433|FG001|Main Study|Withdrawal by Subject|16
6220202|NCT01659021|9889432|FG000|Main Study|Study Terminated by Sponsor|16
6220203|NCT01659021|9889433|FG001|Main Study|Study Terminated by Sponsor|1
6220204|NCT01659021|9889432|FG000|Long-Term Follow Up|Lost to Follow-up|3
6220205|NCT01659021|9889433|FG001|Long-Term Follow Up|Lost to Follow-up|3
6220206|NCT01659021|9889432|FG000|Long-Term Follow Up|Withdrawal by Subject|2
6220207|NCT01659021|9889433|FG001|Long-Term Follow Up|Withdrawal by Subject|1
6220208|NCT01659125|9889443|FG000|Overall Study|Withdrawal by Subject|2
6220209|NCT01659125|9889443|FG000|Overall Study|Lost to Follow-up|7
6220210|NCT01659125|9889443|FG000|Overall Study|Technical Problem|1
6220211|NCT01659125|9889443|FG000|Overall Study|Time Constraints|2
6220212|NCT01659125|9889443|FG000|Overall Study|Failed to Start Treatment|2
6220213|NCT01659255|9889464|FG000|Overall Study|Adverse Event|0
6220214|NCT01659255|9889465|FG001|Overall Study|Adverse Event|0
6220215|NCT01659255|9889466|FG002|Overall Study|Adverse Event|0
6220216|NCT01659255|9889467|FG003|Overall Study|Adverse Event|0
6220217|NCT01659255|9889468|FG004|Overall Study|Adverse Event|0
6220218|NCT01659255|9889469|FG005|Overall Study|Adverse Event|1
6220219|NCT01659255|9889470|FG006|Overall Study|Adverse Event|1
6220220|NCT01659255|9889471|FG007|Overall Study|Adverse Event|0
6220221|NCT01659255|9889472|FG008|Overall Study|Adverse Event|0
6220222|NCT01659255|9889473|FG009|Overall Study|Adverse Event|1
6220223|NCT01659255|9889474|FG010|Overall Study|Adverse Event|0
6220224|NCT01659255|9889475|FG011|Overall Study|Adverse Event|1
6220225|NCT01659255|9889476|FG012|Overall Study|Adverse Event|0
6220226|NCT01659255|9889477|FG013|Overall Study|Adverse Event|2
6220227|NCT01659255|9889478|FG014|Overall Study|Adverse Event|0
6220228|NCT01659255|9889479|FG015|Overall Study|Adverse Event|1
6220229|NCT01659255|9889480|FG016|Overall Study|Adverse Event|0
6220230|NCT01659255|9889464|FG000|Overall Study|Death|0
6220231|NCT01659255|9889465|FG001|Overall Study|Death|1
6220232|NCT01659255|9889466|FG002|Overall Study|Death|0
6220233|NCT01659255|9889467|FG003|Overall Study|Death|0
6220234|NCT01659255|9889468|FG004|Overall Study|Death|0
6220235|NCT01659255|9889469|FG005|Overall Study|Death|0
6220236|NCT01659255|9889470|FG006|Overall Study|Death|0
6220237|NCT01659255|9889471|FG007|Overall Study|Death|1
6220238|NCT01659255|9889472|FG008|Overall Study|Death|1
6220239|NCT01659255|9889473|FG009|Overall Study|Death|0
6220240|NCT01659255|9889474|FG010|Overall Study|Death|0
6220241|NCT01659255|9889475|FG011|Overall Study|Death|0
6220242|NCT01659255|9889476|FG012|Overall Study|Death|1
6220243|NCT01659255|9889477|FG013|Overall Study|Death|1
6220244|NCT01659255|9889478|FG014|Overall Study|Death|2
6220245|NCT01659255|9889479|FG015|Overall Study|Death|1
6220246|NCT01659255|9889480|FG016|Overall Study|Death|0
6220247|NCT01659255|9889464|FG000|Overall Study|Progressive Disease|2
6220248|NCT01659255|9889465|FG001|Overall Study|Progressive Disease|0
6220249|NCT01659255|9889466|FG002|Overall Study|Progressive Disease|0
6220250|NCT01659255|9889467|FG003|Overall Study|Progressive Disease|0
6220251|NCT01659255|9889468|FG004|Overall Study|Progressive Disease|0
6220252|NCT01659255|9889469|FG005|Overall Study|Progressive Disease|0
6220253|NCT01659255|9889470|FG006|Overall Study|Progressive Disease|0
6220254|NCT01659255|9889471|FG007|Overall Study|Progressive Disease|1
6220255|NCT01659255|9889472|FG008|Overall Study|Progressive Disease|0
6220256|NCT01659255|9889473|FG009|Overall Study|Progressive Disease|2
6220257|NCT01659255|9889474|FG010|Overall Study|Progressive Disease|2
6220258|NCT01659255|9889475|FG011|Overall Study|Progressive Disease|3
6220259|NCT01659255|9889476|FG012|Overall Study|Progressive Disease|5
6220260|NCT01659255|9889477|FG013|Overall Study|Progressive Disease|13
6220261|NCT01659255|9889478|FG014|Overall Study|Progressive Disease|6
6220262|NCT01659255|9889479|FG015|Overall Study|Progressive Disease|2
6220263|NCT01659255|9889480|FG016|Overall Study|Progressive Disease|3
6220264|NCT01659255|9889464|FG000|Overall Study|Withdrew Consent|0
6220265|NCT01659255|9889465|FG001|Overall Study|Withdrew Consent|0
6220266|NCT01659255|9889466|FG002|Overall Study|Withdrew Consent|0
6220267|NCT01659255|9889467|FG003|Overall Study|Withdrew Consent|0
6220268|NCT01659255|9889468|FG004|Overall Study|Withdrew Consent|0
6128973|NCT00950963|9755186|FG000|Overall Study|Lost to Follow-up|29
6128974|NCT00950963|9755187|FG001|Overall Study|Lost to Follow-up|24
6128975|NCT00951015|9755197|FG000|Randomization Phase 96 Week|Adverse Event|1
6128976|NCT00951015|9755198|FG001|Randomization Phase 96 Week|Adverse Event|1
6128977|NCT00951015|9755199|FG002|Randomization Phase 96 Week|Adverse Event|2
6128978|NCT00951015|9755200|FG003|Randomization Phase 96 Week|Adverse Event|5
6128979|NCT00951015|9755201|FG004|Randomization Phase 96 Week|Adverse Event|0
6128980|NCT00951015|9755197|FG000|Randomization Phase 96 Week|Lack of Efficacy|1
6128981|NCT00951015|9755198|FG001|Randomization Phase 96 Week|Lack of Efficacy|1
6128982|NCT00951015|9755199|FG002|Randomization Phase 96 Week|Lack of Efficacy|0
6128983|NCT00951015|9755200|FG003|Randomization Phase 96 Week|Lack of Efficacy|0
6128984|NCT00951015|9755201|FG004|Randomization Phase 96 Week|Lack of Efficacy|0
6128985|NCT00951015|9755197|FG000|Randomization Phase 96 Week|Protocol Violation|1
6128986|NCT00951015|9755198|FG001|Randomization Phase 96 Week|Protocol Violation|1
6128987|NCT00951015|9755199|FG002|Randomization Phase 96 Week|Protocol Violation|1
6128988|NCT00951015|9755200|FG003|Randomization Phase 96 Week|Protocol Violation|0
6220269|NCT01659255|9889469|FG005|Overall Study|Withdrew Consent|0
6220270|NCT01659255|9889470|FG006|Overall Study|Withdrew Consent|0
6220271|NCT01659255|9889471|FG007|Overall Study|Withdrew Consent|0
6220272|NCT01659255|9889472|FG008|Overall Study|Withdrew Consent|0
6220273|NCT01659255|9889473|FG009|Overall Study|Withdrew Consent|0
6220274|NCT01659255|9889474|FG010|Overall Study|Withdrew Consent|1
6220275|NCT01659255|9889475|FG011|Overall Study|Withdrew Consent|0
6220276|NCT01659255|9889476|FG012|Overall Study|Withdrew Consent|0
6220277|NCT01659255|9889477|FG013|Overall Study|Withdrew Consent|1
6220278|NCT01659255|9889478|FG014|Overall Study|Withdrew Consent|0
6220279|NCT01659255|9889479|FG015|Overall Study|Withdrew Consent|0
6220280|NCT01659255|9889480|FG016|Overall Study|Withdrew Consent|0
6220281|NCT01659255|9889464|FG000|Overall Study|Investigator Decision|0
6220282|NCT01659255|9889465|FG001|Overall Study|Investigator Decision|0
6220283|NCT01659255|9889466|FG002|Overall Study|Investigator Decision|0
5980929|NCT04042077|9569678|FG001|Overall Study|Withdrawal by Subject|2
5980930|NCT04042077|9569677|FG000|Overall Study|Lack of Efficacy|0
5980931|NCT04042077|9569678|FG001|Overall Study|Lack of Efficacy|1
5980932|NCT04001803|9569690|FG000|Overall Study|Ongoing at the time of analysis|103
5980933|NCT04001803|9569690|FG000|Overall Study|Adverse Event|2
5980934|NCT04001803|9569690|FG000|Overall Study|Protocol Violation|2
5980935|NCT04001803|9569690|FG000|Overall Study|Lost to Follow-up|2
5980936|NCT04001803|9569690|FG000|Overall Study|Physician Decision|1
5980937|NCT04001803|9569690|FG000|Overall Study|Withdrawal by Subject|4
5980938|NCT03925324|9569706|FG000|Overall Study|Death|1
5980939|NCT03925324|9569707|FG001|Overall Study|Death|1
5980940|NCT03875092|9569715|FG000|Overall Study|Adverse Event|2
5980941|NCT03875092|9569716|FG001|Overall Study|Adverse Event|5
5980942|NCT03875092|9569715|FG000|Overall Study|Death|28
5980943|NCT03875092|9569716|FG001|Overall Study|Death|41
6128989|NCT00951015|9755201|FG004|Randomization Phase 96 Week|Protocol Violation|0
6220284|NCT01659255|9889467|FG003|Overall Study|Investigator Decision|0
6220285|NCT01659255|9889468|FG004|Overall Study|Investigator Decision|0
6220286|NCT01659255|9889469|FG005|Overall Study|Investigator Decision|0
6220287|NCT01659255|9889470|FG006|Overall Study|Investigator Decision|0
6220288|NCT01659255|9889471|FG007|Overall Study|Investigator Decision|0
6220289|NCT01659255|9889472|FG008|Overall Study|Investigator Decision|0
6220290|NCT01659255|9889473|FG009|Overall Study|Investigator Decision|0
6220291|NCT01659255|9889474|FG010|Overall Study|Investigator Decision|0
6220292|NCT01659255|9889475|FG011|Overall Study|Investigator Decision|0
6220293|NCT01659255|9889476|FG012|Overall Study|Investigator Decision|1
6220294|NCT01659255|9889477|FG013|Overall Study|Investigator Decision|1
6220295|NCT01659255|9889478|FG014|Overall Study|Investigator Decision|0
6128990|NCT00951015|9755197|FG000|Randomization Phase 96 Week|Protocol-Defined Stopping Criteria|0
6128991|NCT00951015|9755198|FG001|Randomization Phase 96 Week|Protocol-Defined Stopping Criteria|0
6128992|NCT00951015|9755199|FG002|Randomization Phase 96 Week|Protocol-Defined Stopping Criteria|0
6128993|NCT00951015|9755200|FG003|Randomization Phase 96 Week|Protocol-Defined Stopping Criteria|1
6128994|NCT00951015|9755201|FG004|Randomization Phase 96 Week|Protocol-Defined Stopping Criteria|0
6128995|NCT00951015|9755197|FG000|Randomization Phase 96 Week|Lost to Follow-up|0
6128996|NCT00951015|9755198|FG001|Randomization Phase 96 Week|Lost to Follow-up|3
6128997|NCT00951015|9755199|FG002|Randomization Phase 96 Week|Lost to Follow-up|1
6128998|NCT00951015|9755200|FG003|Randomization Phase 96 Week|Lost to Follow-up|2
6128999|NCT00951015|9755201|FG004|Randomization Phase 96 Week|Lost to Follow-up|0
6129000|NCT00951015|9755197|FG000|Randomization Phase 96 Week|Withdrawal by Subject|2
6129001|NCT00951015|9755198|FG001|Randomization Phase 96 Week|Withdrawal by Subject|1
6129002|NCT00951015|9755199|FG002|Randomization Phase 96 Week|Withdrawal by Subject|1
6129003|NCT00951015|9755200|FG003|Randomization Phase 96 Week|Withdrawal by Subject|2
6129004|NCT00951015|9755201|FG004|Randomization Phase 96 Week|Withdrawal by Subject|0
6220296|NCT01659255|9889479|FG015|Overall Study|Investigator Decision|0
6220297|NCT01659255|9889480|FG016|Overall Study|Investigator Decision|0
6220298|NCT01659255|9889464|FG000|Overall Study|Sponsor's Decision|0
6220299|NCT01659255|9889465|FG001|Overall Study|Sponsor's Decision|0
6220300|NCT01659255|9889466|FG002|Overall Study|Sponsor's Decision|0
6220301|NCT01659255|9889467|FG003|Overall Study|Sponsor's Decision|0
6220302|NCT01659255|9889468|FG004|Overall Study|Sponsor's Decision|0
6129005|NCT00951015|9755197|FG000|Open-label Phase|Adverse Event|0
6129006|NCT00951015|9755198|FG001|Open-label Phase|Adverse Event|0
6129007|NCT00951015|9755199|FG002|Open-label Phase|Adverse Event|0
6129008|NCT00951015|9755200|FG003|Open-label Phase|Adverse Event|0
6129009|NCT00951015|9755201|FG004|Open-label Phase|Adverse Event|3
6129010|NCT00951015|9755197|FG000|Open-label Phase|Lack of Efficacy|0
6129011|NCT00951015|9755198|FG001|Open-label Phase|Lack of Efficacy|0
6129012|NCT00951015|9755199|FG002|Open-label Phase|Lack of Efficacy|0
6129013|NCT00951015|9755200|FG003|Open-label Phase|Lack of Efficacy|0
6129014|NCT00951015|9755201|FG004|Open-label Phase|Lack of Efficacy|1
6129015|NCT00951015|9755197|FG000|Open-label Phase|Protocol Violation|0
6129016|NCT00951015|9755198|FG001|Open-label Phase|Protocol Violation|0
6129017|NCT00951015|9755199|FG002|Open-label Phase|Protocol Violation|0
6129018|NCT00951015|9755200|FG003|Open-label Phase|Protocol Violation|0
6129019|NCT00951015|9755201|FG004|Open-label Phase|Protocol Violation|12
6129020|NCT00951015|9755197|FG000|Open-label Phase|Lost to Follow-up|0
6129021|NCT00951015|9755198|FG001|Open-label Phase|Lost to Follow-up|0
6129022|NCT00951015|9755199|FG002|Open-label Phase|Lost to Follow-up|0
6129023|NCT00951015|9755200|FG003|Open-label Phase|Lost to Follow-up|0
6129024|NCT00951015|9755201|FG004|Open-label Phase|Lost to Follow-up|12
6129025|NCT00951015|9755197|FG000|Open-label Phase|Withdrawal by Subject|0
6129026|NCT00951015|9755198|FG001|Open-label Phase|Withdrawal by Subject|0
6129027|NCT00951015|9755199|FG002|Open-label Phase|Withdrawal by Subject|0
6129028|NCT00951015|9755200|FG003|Open-label Phase|Withdrawal by Subject|0
6129029|NCT00951015|9755201|FG004|Open-label Phase|Withdrawal by Subject|14
6129030|NCT00951015|9755197|FG000|Open-label Phase|Physician Decision|0
6129031|NCT00951015|9755198|FG001|Open-label Phase|Physician Decision|0
6129032|NCT00951015|9755199|FG002|Open-label Phase|Physician Decision|0
6129033|NCT00951015|9755200|FG003|Open-label Phase|Physician Decision|0
6129034|NCT00951015|9755201|FG004|Open-label Phase|Physician Decision|8
6129035|NCT00951041|9755226|FG000|Overall Study|Withdrawal by Subject|1
6129036|NCT00951041|9755227|FG001|Overall Study|Withdrawal by Subject|1
6129037|NCT00951041|9755226|FG000|Overall Study|Lost to Follow-up|1
6129038|NCT00951041|9755227|FG001|Overall Study|Lost to Follow-up|0
6129039|NCT00951041|9755226|FG000|Overall Study|Other|3
6129040|NCT00951041|9755227|FG001|Overall Study|Other|0
6129041|NCT00951080|9755236|FG000|Overall Study|Adverse Event|3
6129042|NCT00951080|9755237|FG001|Overall Study|Adverse Event|3
6129043|NCT00951080|9755236|FG000|Overall Study|Lost to Follow-up|0
6129044|NCT00951080|9755237|FG001|Overall Study|Lost to Follow-up|1
6129045|NCT00951080|9755236|FG000|Overall Study|Physician Decision|4
6129046|NCT00951080|9755237|FG001|Overall Study|Physician Decision|1
6129047|NCT00951080|9755236|FG000|Overall Study|Other|19
6129048|NCT00951080|9755237|FG001|Overall Study|Other|22
6129049|NCT00951171|9755251|FG000|Overall Study|Adverse Event|2
6129050|NCT00951171|9755252|FG001|Overall Study|Adverse Event|0
6129051|NCT00951275|9755258|FG000|Overall Study|Administrative Reason|1
6129052|NCT00951275|9755258|FG000|Overall Study|Adverse Event|7
6129053|NCT00951275|9755258|FG000|Overall Study|Withdrawal by Subject|4
6129054|NCT00951275|9755258|FG000|Overall Study|Protocol Violation|1
6129055|NCT00951379|9755264|FG000|Overall Study|Adverse Event|4
6129056|NCT00951379|9755265|FG001|Overall Study|Adverse Event|1
6129057|NCT00951379|9755264|FG000|Overall Study|Withdrawal by Subject|1
6129058|NCT00951379|9755265|FG001|Overall Study|Withdrawal by Subject|0
6129059|NCT00951379|9755264|FG000|Overall Study|Noncompliance|1
6129060|NCT00951379|9755265|FG001|Overall Study|Noncompliance|0
6129061|NCT00951379|9755264|FG000|Overall Study|Disease Progression|0
6129062|NCT00951379|9755265|FG001|Overall Study|Disease Progression|1
6129063|NCT00951483|9755281|FG000|Overall Study|Physician Decision|4
6129064|NCT00951483|9755282|FG001|Overall Study|Physician Decision|0
6129065|NCT00951483|9755281|FG000|Overall Study|Withdrawal by Subject|15
6129066|NCT00951483|9755282|FG001|Overall Study|Withdrawal by Subject|0
6129067|NCT00951496|9755293|FG000|Overall Study|Did not initiate study treatment|10
6129068|NCT00951496|9755294|FG001|Overall Study|Did not initiate study treatment|8
6129069|NCT00951496|9755295|FG002|Overall Study|Did not initiate study treatment|13
6129070|NCT00951509|9755306|FG000|Overall Study|Withdrawal by Subject|2
6129071|NCT00951665|9755328|FG000|Phase 1b|Adverse Event|2
6129072|NCT00951665|9755329|FG001|Phase 1b|Adverse Event|1
6129073|NCT00951665|9755330|FG002|Phase 1b|Adverse Event|0
6129074|NCT00951665|9755331|FG003|Phase 1b|Adverse Event|1
6129075|NCT00951665|9755332|FG004|Phase 1b|Adverse Event|0
6129076|NCT00951665|9755333|FG005|Phase 1b|Adverse Event|0
6129077|NCT00951665|9755328|FG000|Phase 1b|Death|1
6129078|NCT00951665|9755329|FG001|Phase 1b|Death|0
6129079|NCT00951665|9755330|FG002|Phase 1b|Death|2
6129080|NCT00951665|9755331|FG003|Phase 1b|Death|0
6129081|NCT00951665|9755332|FG004|Phase 1b|Death|0
6129082|NCT00951665|9755333|FG005|Phase 1b|Death|0
6129083|NCT00951665|9755328|FG000|Phase 1b|Physician Decision|4
6129084|NCT00951665|9755329|FG001|Phase 1b|Physician Decision|0
6220303|NCT01659255|9889469|FG005|Overall Study|Sponsor's Decision|0
6220304|NCT01659255|9889470|FG006|Overall Study|Sponsor's Decision|1
6220305|NCT01659255|9889471|FG007|Overall Study|Sponsor's Decision|0
6129085|NCT00951665|9755330|FG002|Phase 1b|Physician Decision|1
6129086|NCT00951665|9755331|FG003|Phase 1b|Physician Decision|0
6129087|NCT00951665|9755332|FG004|Phase 1b|Physician Decision|0
6220306|NCT01659255|9889472|FG008|Overall Study|Sponsor's Decision|0
6129088|NCT00951665|9755333|FG005|Phase 1b|Physician Decision|0
6129089|NCT00951665|9755328|FG000|Phase 1b|Withdrawal by Subject|0
6129090|NCT00951665|9755329|FG001|Phase 1b|Withdrawal by Subject|1
6129091|NCT00951665|9755330|FG002|Phase 1b|Withdrawal by Subject|0
6129092|NCT00951665|9755331|FG003|Phase 1b|Withdrawal by Subject|0
6129093|NCT00951665|9755332|FG004|Phase 1b|Withdrawal by Subject|0
6129094|NCT00951665|9755333|FG005|Phase 1b|Withdrawal by Subject|0
6129095|NCT00951665|9755328|FG000|Phase 1b|Disease Progression|13
6129096|NCT00951665|9755329|FG001|Phase 1b|Disease Progression|2
6129097|NCT00951665|9755330|FG002|Phase 1b|Disease Progression|14
6129098|NCT00951665|9755331|FG003|Phase 1b|Disease Progression|0
6129099|NCT00951665|9755332|FG004|Phase 1b|Disease Progression|0
6129100|NCT00951665|9755333|FG005|Phase 1b|Disease Progression|0
6129101|NCT00951665|9755328|FG000|Phase 1b|Protocol Violation|2
6129102|NCT00951665|9755329|FG001|Phase 1b|Protocol Violation|0
6129103|NCT00951665|9755330|FG002|Phase 1b|Protocol Violation|0
6129104|NCT00951665|9755331|FG003|Phase 1b|Protocol Violation|0
6129105|NCT00951665|9755332|FG004|Phase 1b|Protocol Violation|0
6129106|NCT00951665|9755333|FG005|Phase 1b|Protocol Violation|0
6129107|NCT00951665|9755328|FG000|Phase 2a|Adverse Event|0
6129108|NCT00951665|9755329|FG001|Phase 2a|Adverse Event|0
6129109|NCT00951665|9755330|FG002|Phase 2a|Adverse Event|0
6129110|NCT00951665|9755331|FG003|Phase 2a|Adverse Event|0
6129111|NCT00951665|9755332|FG004|Phase 2a|Adverse Event|2
6129112|NCT00951665|9755333|FG005|Phase 2a|Adverse Event|0
6129113|NCT00951665|9755328|FG000|Phase 2a|Death|0
6129114|NCT00951665|9755329|FG001|Phase 2a|Death|0
6129115|NCT00951665|9755330|FG002|Phase 2a|Death|0
6129116|NCT00951665|9755331|FG003|Phase 2a|Death|0
6129117|NCT00951665|9755332|FG004|Phase 2a|Death|1
6129118|NCT00951665|9755333|FG005|Phase 2a|Death|1
6129119|NCT00951665|9755328|FG000|Phase 2a|Lost to Follow-up|0
6129120|NCT00951665|9755329|FG001|Phase 2a|Lost to Follow-up|0
6129121|NCT00951665|9755330|FG002|Phase 2a|Lost to Follow-up|0
6129122|NCT00951665|9755331|FG003|Phase 2a|Lost to Follow-up|0
6129123|NCT00951665|9755332|FG004|Phase 2a|Lost to Follow-up|1
6129124|NCT00951665|9755333|FG005|Phase 2a|Lost to Follow-up|0
6129125|NCT00951665|9755328|FG000|Phase 2a|Physician Decision|0
6129126|NCT00951665|9755329|FG001|Phase 2a|Physician Decision|0
6129127|NCT00951665|9755330|FG002|Phase 2a|Physician Decision|0
6129128|NCT00951665|9755331|FG003|Phase 2a|Physician Decision|0
6129129|NCT00951665|9755332|FG004|Phase 2a|Physician Decision|0
6129130|NCT00951665|9755333|FG005|Phase 2a|Physician Decision|1
6129131|NCT00951665|9755328|FG000|Phase 2a|Withdrawal by Subject|0
6129132|NCT00951665|9755329|FG001|Phase 2a|Withdrawal by Subject|0
6129133|NCT00951665|9755330|FG002|Phase 2a|Withdrawal by Subject|0
6220307|NCT01659255|9889473|FG009|Overall Study|Sponsor's Decision|0
6220308|NCT01659255|9889474|FG010|Overall Study|Sponsor's Decision|0
6220309|NCT01659255|9889475|FG011|Overall Study|Sponsor's Decision|0
6220310|NCT01659255|9889476|FG012|Overall Study|Sponsor's Decision|0
6220311|NCT01659255|9889477|FG013|Overall Study|Sponsor's Decision|0
6220312|NCT01659255|9889478|FG014|Overall Study|Sponsor's Decision|0
6220313|NCT01659255|9889479|FG015|Overall Study|Sponsor's Decision|0
6220314|NCT01659255|9889480|FG016|Overall Study|Sponsor's Decision|0
6220315|NCT01659255|9889464|FG000|Overall Study|Completed Treatment Per Protocol at the Time|0
6220316|NCT01659255|9889465|FG001|Overall Study|Completed Treatment Per Protocol at the Time|0
6220317|NCT01659255|9889466|FG002|Overall Study|Completed Treatment Per Protocol at the Time|0
6220318|NCT01659255|9889467|FG003|Overall Study|Completed Treatment Per Protocol at the Time|0
6129134|NCT00951665|9755331|FG003|Phase 2a|Withdrawal by Subject|0
6129135|NCT00951665|9755332|FG004|Phase 2a|Withdrawal by Subject|2
6129136|NCT00951665|9755333|FG005|Phase 2a|Withdrawal by Subject|0
6129137|NCT00951665|9755328|FG000|Phase 2a|Disease Progression|0
6129138|NCT00951665|9755329|FG001|Phase 2a|Disease Progression|0
6129139|NCT00951665|9755330|FG002|Phase 2a|Disease Progression|0
6129140|NCT00951665|9755331|FG003|Phase 2a|Disease Progression|0
6129141|NCT00951665|9755332|FG004|Phase 2a|Disease Progression|6
6129142|NCT00951665|9755333|FG005|Phase 2a|Disease Progression|5
6129143|NCT00951912|9755396|FG000|Overall Study|Lack of Efficacy|1
6220319|NCT01659255|9889468|FG004|Overall Study|Completed Treatment Per Protocol at the Time|0
6289010|NCT02375971|10003526|FG000|Follow-Up Phase (up to Day 169)|Death|4
6129144|NCT00951912|9755397|FG001|Overall Study|Lack of Efficacy|0
6129145|NCT00951912|9755398|FG002|Overall Study|Lack of Efficacy|0
6129146|NCT00951912|9755396|FG000|Overall Study|Adverse Event|0
6129147|NCT00951912|9755397|FG001|Overall Study|Adverse Event|1
6129148|NCT00951912|9755398|FG002|Overall Study|Adverse Event|1
6129149|NCT00951912|9755396|FG000|Overall Study|Lost to Follow-up|2
6129150|NCT00951912|9755397|FG001|Overall Study|Lost to Follow-up|2
6129151|NCT00951912|9755398|FG002|Overall Study|Lost to Follow-up|0
6129152|NCT00951912|9755396|FG000|Overall Study|Physician Decision|1
6129153|NCT00951912|9755397|FG001|Overall Study|Physician Decision|0
6129154|NCT00951912|9755398|FG002|Overall Study|Physician Decision|1
6129155|NCT00951912|9755396|FG000|Overall Study|Withdrawal by Subject|1
6129156|NCT00951912|9755397|FG001|Overall Study|Withdrawal by Subject|1
6129157|NCT00951912|9755398|FG002|Overall Study|Withdrawal by Subject|0
6129158|NCT00951912|9755396|FG000|Overall Study|Other:Depression|1
6129159|NCT00951912|9755397|FG001|Overall Study|Other:Depression|0
6129160|NCT00951912|9755398|FG002|Overall Study|Other:Depression|0
6129161|NCT00951912|9755396|FG000|Overall Study|Other: Colon cancer|1
6129162|NCT00951912|9755397|FG001|Overall Study|Other: Colon cancer|0
6129163|NCT00951912|9755398|FG002|Overall Study|Other: Colon cancer|0
6129164|NCT00951912|9755396|FG000|Overall Study|Other: Stroke|0
6129165|NCT00951912|9755397|FG001|Overall Study|Other: Stroke|1
6129166|NCT00951912|9755398|FG002|Overall Study|Other: Stroke|0
6129167|NCT00952068|9755406|FG000|Overall Study|Adverse Event|3
6129168|NCT00952068|9755406|FG000|Overall Study|Withdrawal by Subject|4
6220320|NCT01659255|9889469|FG005|Overall Study|Completed Treatment Per Protocol at the Time|0
6220321|NCT01659255|9889470|FG006|Overall Study|Completed Treatment Per Protocol at the Time|0
6220322|NCT01659255|9889471|FG007|Overall Study|Completed Treatment Per Protocol at the Time|0
6220323|NCT01659255|9889472|FG008|Overall Study|Completed Treatment Per Protocol at the Time|0
6220324|NCT01659255|9889473|FG009|Overall Study|Completed Treatment Per Protocol at the Time|0
6220325|NCT01659255|9889474|FG010|Overall Study|Completed Treatment Per Protocol at the Time|0
6220326|NCT01659255|9889475|FG011|Overall Study|Completed Treatment Per Protocol at the Time|0
6220327|NCT01659255|9889476|FG012|Overall Study|Completed Treatment Per Protocol at the Time|0
6220328|NCT01659255|9889477|FG013|Overall Study|Completed Treatment Per Protocol at the Time|0
6220329|NCT01659255|9889478|FG014|Overall Study|Completed Treatment Per Protocol at the Time|0
6220330|NCT01659255|9889479|FG015|Overall Study|Completed Treatment Per Protocol at the Time|1
6220331|NCT01659255|9889480|FG016|Overall Study|Completed Treatment Per Protocol at the Time|0
6220332|NCT01659255|9889464|FG000|Overall Study|Participant Went on to Have an Allograft|0
6220333|NCT01659255|9889465|FG001|Overall Study|Participant Went on to Have an Allograft|0
6220334|NCT01659255|9889466|FG002|Overall Study|Participant Went on to Have an Allograft|0
6220335|NCT01659255|9889467|FG003|Overall Study|Participant Went on to Have an Allograft|0
6220336|NCT01659255|9889468|FG004|Overall Study|Participant Went on to Have an Allograft|0
6220337|NCT01659255|9889469|FG005|Overall Study|Participant Went on to Have an Allograft|0
6220338|NCT01659255|9889470|FG006|Overall Study|Participant Went on to Have an Allograft|0
6220339|NCT01659255|9889471|FG007|Overall Study|Participant Went on to Have an Allograft|0
6220340|NCT01659255|9889472|FG008|Overall Study|Participant Went on to Have an Allograft|0
6220341|NCT01659255|9889473|FG009|Overall Study|Participant Went on to Have an Allograft|0
6220342|NCT01659255|9889474|FG010|Overall Study|Participant Went on to Have an Allograft|0
6220343|NCT01659255|9889475|FG011|Overall Study|Participant Went on to Have an Allograft|0
6220344|NCT01659255|9889476|FG012|Overall Study|Participant Went on to Have an Allograft|1
6220345|NCT01659255|9889477|FG013|Overall Study|Participant Went on to Have an Allograft|0
6220346|NCT01659255|9889478|FG014|Overall Study|Participant Went on to Have an Allograft|0
6220347|NCT01659255|9889479|FG015|Overall Study|Participant Went on to Have an Allograft|0
6220348|NCT01659255|9889480|FG016|Overall Study|Participant Went on to Have an Allograft|0
6220349|NCT01659320|9889527|FG000|Overall Study|Withdrawal by Subject|2
6220350|NCT01659320|9889527|FG000|Overall Study|Physician Decision|1
6220351|NCT01659567|9889531|FG000|Overall Study|Lack of Efficacy|22
6220352|NCT01659567|9889531|FG000|Overall Study|Switched to Pegferon|6
6220353|NCT01659567|9889531|FG000|Overall Study|Adverse Event|12
6220354|NCT01659567|9889531|FG000|Overall Study|Good result at early stage of treatment|5
6220355|NCT01659567|9889531|FG000|Overall Study|Withdrawal by Subject|64
6220356|NCT01659567|9889531|FG000|Overall Study|Progression of the main disease|1
6220357|NCT01659567|9889531|FG000|Overall Study|Other|13
6220358|NCT01659736|9889537|FG000|Treatment Period|Adverse Event|1
6220359|NCT01659736|9889538|FG001|Treatment Period|Adverse Event|1
6220360|NCT01659736|9889537|FG000|Treatment Period|Protocol Violation|3
6220361|NCT01659736|9889538|FG001|Treatment Period|Protocol Violation|1
6220362|NCT01659736|9889537|FG000|Treatment Period|Withdrawal by Subject|1
6220363|NCT01659736|9889538|FG001|Treatment Period|Withdrawal by Subject|0
6220364|NCT01659736|9889537|FG000|3-month Follow-up|Lost to Follow-up|0
6220365|NCT01659736|9889538|FG001|3-month Follow-up|Lost to Follow-up|1
6220366|NCT01659853|9889546|FG000|Washout , 3 to 7 Days|Adverse Event|1
6220367|NCT01659853|9889547|FG001|Washout , 3 to 7 Days|Adverse Event|0
6220368|NCT01659853|9889546|FG000|Washout , 3 to 7 Days|Protocol Violation|1
6220369|NCT01659853|9889547|FG001|Washout , 3 to 7 Days|Protocol Violation|0
6220370|NCT01659996|9889567|FG000|Overall Study|Protocol Violation|3
6220371|NCT01659996|9889568|FG001|Overall Study|Protocol Violation|3
6220372|NCT01659996|9889569|FG002|Overall Study|Protocol Violation|3
6220373|NCT01659996|9889567|FG000|Overall Study|Lost to Follow-up|1
6220374|NCT01659996|9889568|FG001|Overall Study|Lost to Follow-up|3
6220375|NCT01659996|9889569|FG002|Overall Study|Lost to Follow-up|2
6220376|NCT01659996|9889567|FG000|Overall Study|Adverse Event|0
6220377|NCT01659996|9889568|FG001|Overall Study|Adverse Event|0
6220378|NCT01659996|9889569|FG002|Overall Study|Adverse Event|1
6220379|NCT01659996|9889567|FG000|Overall Study|Withdrawal by Subject|4
6220380|NCT01659996|9889568|FG001|Overall Study|Withdrawal by Subject|1
6220381|NCT01659996|9889569|FG002|Overall Study|Withdrawal by Subject|5
6220382|NCT01660022|9889585|FG000|First Sequence (7 Days)|Withdrawal by Subject|0
6220383|NCT01660022|9889586|FG001|First Sequence (7 Days)|Withdrawal by Subject|1
6220384|NCT01660022|9889587|FG002|First Sequence (7 Days)|Withdrawal by Subject|0
6220385|NCT01660022|9889588|FG003|First Sequence (7 Days)|Withdrawal by Subject|1
6220386|NCT01660022|9889589|FG004|First Sequence (7 Days)|Withdrawal by Subject|0
6220387|NCT01660022|9889590|FG005|First Sequence (7 Days)|Withdrawal by Subject|0
6220388|NCT01660022|9889585|FG000|First Sequence (7 Days)|Adverse Event|0
6129169|NCT00952276|9755450|FG000|Overall Study|Withdrawal by Subject|1
6129170|NCT00952276|9755451|FG001|Overall Study|Withdrawal by Subject|0
6129171|NCT00952276|9755452|FG002|Overall Study|Withdrawal by Subject|0
6129172|NCT00952276|9755453|FG003|Overall Study|Withdrawal by Subject|1
6129173|NCT00952276|9755454|FG004|Overall Study|Withdrawal by Subject|0
6129174|NCT00952289|9755468|FG000|All Participants|Death|9
6129175|NCT00952289|9755469|FG001|All Participants|Death|9
6129176|NCT00952289|9755468|FG000|All Participants|Adverse Event|8
6129177|NCT00952289|9755469|FG001|All Participants|Adverse Event|8
6129178|NCT00952289|9755468|FG000|All Participants|Disease progression|3
6129179|NCT00952289|9755469|FG001|All Participants|Disease progression|12
6129180|NCT00952289|9755468|FG000|All Participants|Withdrawal by Subject|1
6129181|NCT00952289|9755469|FG001|All Participants|Withdrawal by Subject|10
6129182|NCT00952289|9755468|FG000|All Participants|Data lost during site relocation|0
6129183|NCT00952289|9755469|FG001|All Participants|Data lost during site relocation|1
6129184|NCT00952289|9755468|FG000|Patients Who Crossed Over to Ruxolitinib|Adverse Event|0
6129185|NCT00952289|9755469|FG001|Patients Who Crossed Over to Ruxolitinib|Adverse Event|19
6129186|NCT00952289|9755468|FG000|Patients Who Crossed Over to Ruxolitinib|Disease progression|0
6129187|NCT00952289|9755469|FG001|Patients Who Crossed Over to Ruxolitinib|Disease progression|15
6129188|NCT00952289|9755468|FG000|Patients Who Crossed Over to Ruxolitinib|Withdrawal by Subject|0
6129189|NCT00952289|9755469|FG001|Patients Who Crossed Over to Ruxolitinib|Withdrawal by Subject|11
6129190|NCT00952289|9755468|FG000|Patients Who Crossed Over to Ruxolitinib|Non-compliance to study medication|0
6129191|NCT00952289|9755469|FG001|Patients Who Crossed Over to Ruxolitinib|Non-compliance to study medication|2
6129192|NCT00952289|9755468|FG000|Patients Who Crossed Over to Ruxolitinib|Other Unspecified|0
6129193|NCT00952289|9755469|FG001|Patients Who Crossed Over to Ruxolitinib|Other Unspecified|7
6129194|NCT00952341|9755493|FG000|Cycle 1|Adverse Event|4
6129195|NCT00952341|9755494|FG001|Cycle 1|Adverse Event|1
6129196|NCT00952341|9755493|FG000|Cycle 1|Withdrawal by Subject|3
6129197|NCT00952341|9755494|FG001|Cycle 1|Withdrawal by Subject|8
6129198|NCT00952341|9755493|FG000|Cycle 1|Protocol Violation|2
6129199|NCT00952341|9755494|FG001|Cycle 1|Protocol Violation|1
6129200|NCT00952341|9755493|FG000|Cycle 1|Lost to Follow-up|11
6129201|NCT00952341|9755494|FG001|Cycle 1|Lost to Follow-up|2
6129202|NCT00952341|9755493|FG000|Cycle 1|Physician Decision|0
6129203|NCT00952341|9755494|FG001|Cycle 1|Physician Decision|1
6129204|NCT00952341|9755493|FG000|Cycle 2|Withdrawal by Subject|1
6129205|NCT00952341|9755494|FG001|Cycle 2|Withdrawal by Subject|1
6129206|NCT00952341|9755493|FG000|Cycle 2|Protocol Violation|1
6129207|NCT00952341|9755494|FG001|Cycle 2|Protocol Violation|0
6129208|NCT00952341|9755493|FG000|Cycle 2|Lost to Follow-up|6
6129209|NCT00952341|9755494|FG001|Cycle 2|Lost to Follow-up|9
6129210|NCT00952341|9755493|FG000|Cycle 2|Physician Decision|1
6129211|NCT00952341|9755494|FG001|Cycle 2|Physician Decision|1
6129212|NCT00952341|9755493|FG000|Cycle 2|Progressive Disease|0
6129213|NCT00952341|9755494|FG001|Cycle 2|Progressive Disease|1
6129214|NCT00952367|9755500|FG000|Overall Study|Withdrawal by Subject|2
6129215|NCT00952367|9755500|FG000|Overall Study|Noncoordination|1
6129216|NCT00952367|9755500|FG000|Overall Study|Protocol Violation|3
6129217|NCT00952380|9755509|FG000|Overall Study|Other|0
6129218|NCT00952380|9755510|FG001|Overall Study|Other|0
6129219|NCT00952380|9755511|FG002|Overall Study|Other|0
6129220|NCT00952380|9755512|FG003|Overall Study|Other|0
6129221|NCT00952380|9755513|FG004|Overall Study|Other|1
6129222|NCT00952380|9755509|FG000|Overall Study|Withdrawal by Subject|0
6129223|NCT00952380|9755510|FG001|Overall Study|Withdrawal by Subject|0
6129224|NCT00952380|9755511|FG002|Overall Study|Withdrawal by Subject|1
6129225|NCT00952380|9755512|FG003|Overall Study|Withdrawal by Subject|0
6129226|NCT00952380|9755513|FG004|Overall Study|Withdrawal by Subject|2
6220389|NCT01660022|9889586|FG001|First Sequence (7 Days)|Adverse Event|0
6220390|NCT01660022|9889587|FG002|First Sequence (7 Days)|Adverse Event|0
6220391|NCT01660022|9889588|FG003|First Sequence (7 Days)|Adverse Event|0
6220392|NCT01660022|9889589|FG004|First Sequence (7 Days)|Adverse Event|1
6220393|NCT01660022|9889590|FG005|First Sequence (7 Days)|Adverse Event|3
6220394|NCT01660022|9889585|FG000|First Sequence (7 Days)|Protocol Violation|0
6220395|NCT01660022|9889586|FG001|First Sequence (7 Days)|Protocol Violation|0
6220396|NCT01660022|9889587|FG002|First Sequence (7 Days)|Protocol Violation|0
6220397|NCT01660022|9889588|FG003|First Sequence (7 Days)|Protocol Violation|0
6220398|NCT01660022|9889589|FG004|First Sequence (7 Days)|Protocol Violation|0
6220399|NCT01660022|9889590|FG005|First Sequence (7 Days)|Protocol Violation|1
6220400|NCT01660256|9889682|FG000|Overall Study|Adverse Event|4
6220401|NCT01660256|9889683|FG001|Overall Study|Adverse Event|0
6220402|NCT01660256|9889684|FG002|Overall Study|Adverse Event|2
6220403|NCT01660256|9889682|FG000|Overall Study|Withdrawal by Subject|1
6220404|NCT01660256|9889683|FG001|Overall Study|Withdrawal by Subject|0
6220405|NCT01660256|9889684|FG002|Overall Study|Withdrawal by Subject|2
6220406|NCT01660334|9889696|FG000|Overall Study|Lost to Follow-up|1
6220407|NCT01660412|9889700|FG000|Overall Study|Protocol Violation|0
6220408|NCT01660412|9889701|FG001|Overall Study|Protocol Violation|3
6220409|NCT01660711|9889721|FG000|Overall Study|Adverse Event|7
5980944|NCT03875092|9569715|FG000|Overall Study|Ongoing in Study|35
6129227|NCT00952380|9755509|FG000|Overall Study|Adverse Event|0
6220410|NCT01660711|9889721|FG000|Overall Study|Withdrawal by Subject|1
6129228|NCT00952380|9755510|FG001|Overall Study|Adverse Event|1
6129229|NCT00952380|9755511|FG002|Overall Study|Adverse Event|0
6129230|NCT00952380|9755512|FG003|Overall Study|Adverse Event|0
6129231|NCT00952380|9755513|FG004|Overall Study|Adverse Event|3
6129232|NCT00952380|9755509|FG000|Overall Study|Physician Decision|0
6129233|NCT00952380|9755510|FG001|Overall Study|Physician Decision|0
6129234|NCT00952380|9755511|FG002|Overall Study|Physician Decision|1
6129235|NCT00952380|9755512|FG003|Overall Study|Physician Decision|2
6129236|NCT00952380|9755513|FG004|Overall Study|Physician Decision|0
6129237|NCT00952380|9755509|FG000|Overall Study|Non-compliant to protocol|0
6129238|NCT00952380|9755510|FG001|Overall Study|Non-compliant to protocol|0
6129239|NCT00952380|9755511|FG002|Overall Study|Non-compliant to protocol|0
6129240|NCT00952380|9755512|FG003|Overall Study|Non-compliant to protocol|1
6129241|NCT00952380|9755513|FG004|Overall Study|Non-compliant to protocol|0
6129242|NCT00952419|9755537|FG000|Overall Study|Adverse Event|2
6129243|NCT00952419|9755538|FG001|Overall Study|Adverse Event|0
6129244|NCT00952419|9755539|FG002|Overall Study|Adverse Event|0
6129245|NCT00952419|9755537|FG000|Overall Study|Protocol Violation|3
6129246|NCT00952419|9755538|FG001|Overall Study|Protocol Violation|7
6129247|NCT00952419|9755539|FG002|Overall Study|Protocol Violation|0
6129248|NCT00952419|9755537|FG000|Overall Study|Withdrawal by Subject|1
6129249|NCT00952419|9755538|FG001|Overall Study|Withdrawal by Subject|3
6129250|NCT00952419|9755539|FG002|Overall Study|Withdrawal by Subject|0
6129251|NCT00952484|9755550|FG000|Overall Study|Withdrawal by Subject|0
6129252|NCT00952484|9755551|FG001|Overall Study|Withdrawal by Subject|1
6129253|NCT00952484|9755552|FG002|Overall Study|Withdrawal by Subject|0
6129254|NCT00952523|9755561|FG000|Overall Study|Withdrawal by Subject|7
6129255|NCT00952588|9755569|FG000|Overall Study|Death|28
6129256|NCT00952588|9755570|FG001|Overall Study|Death|13
6129257|NCT00952588|9755569|FG000|Overall Study|Withdrawal by Subject|2
6129258|NCT00952588|9755570|FG001|Overall Study|Withdrawal by Subject|5
6129259|NCT00952588|9755569|FG000|Overall Study|Adverse Event|2
6129260|NCT00952588|9755570|FG001|Overall Study|Adverse Event|3
6129261|NCT00952588|9755569|FG000|Overall Study|Lost to Follow-up|2
6129262|NCT00952588|9755570|FG001|Overall Study|Lost to Follow-up|0
6129263|NCT00952588|9755569|FG000|Overall Study|Physician Decision|0
6129264|NCT00952588|9755570|FG001|Overall Study|Physician Decision|1
6129265|NCT00952588|9755569|FG000|Overall Study|Lack of Efficacy|2
6129266|NCT00952588|9755570|FG001|Overall Study|Lack of Efficacy|2
6129267|NCT00952614|9755576|FG000|Overall Study|Death|3
6129268|NCT00952614|9755576|FG000|Overall Study|Lost to Follow-up|3
6129269|NCT00952614|9755576|FG000|Overall Study|other reason|1
6129270|NCT00952705|9755591|FG000|Overall Study|Lost to Follow-up|24
6129271|NCT00952705|9755592|FG001|Overall Study|Lost to Follow-up|8
6129272|NCT00952705|9755593|FG002|Overall Study|Lost to Follow-up|9
6129273|NCT00952705|9755591|FG000|Overall Study|Withdrawal by Subject|2
6129274|NCT00952705|9755592|FG001|Overall Study|Withdrawal by Subject|1
6129275|NCT00952705|9755593|FG002|Overall Study|Withdrawal by Subject|1
6129276|NCT00952705|9755591|FG000|Overall Study|Death|2
6129277|NCT00952705|9755592|FG001|Overall Study|Death|0
6129278|NCT00952705|9755593|FG002|Overall Study|Death|0
6129279|NCT00952705|9755591|FG000|Overall Study|Incarcerated post dose|5
6129280|NCT00952705|9755592|FG001|Overall Study|Incarcerated post dose|0
6129281|NCT00952705|9755593|FG002|Overall Study|Incarcerated post dose|0
6129282|NCT00952705|9755591|FG000|Overall Study|Exclusion criteria not met pre dose|0
6129283|NCT00952705|9755592|FG001|Overall Study|Exclusion criteria not met pre dose|1
6129284|NCT00952705|9755593|FG002|Overall Study|Exclusion criteria not met pre dose|0
6220411|NCT01660763|9889731|FG000|Overall Study|Lack of Efficacy|45
6220412|NCT01660763|9889732|FG001|Overall Study|Lack of Efficacy|50
6220413|NCT01660763|9889731|FG000|Overall Study|Adverse Event|22
6220414|NCT01660763|9889732|FG001|Overall Study|Adverse Event|7
6220415|NCT01660763|9889731|FG000|Overall Study|Protocol Violation|1
6220416|NCT01660763|9889732|FG001|Overall Study|Protocol Violation|0
6220417|NCT01660763|9889731|FG000|Overall Study|Withdrawal by Subject|4
6220418|NCT01660763|9889732|FG001|Overall Study|Withdrawal by Subject|0
6220419|NCT01660763|9889731|FG000|Overall Study|Patient ready for early discharge|28
6220420|NCT01660763|9889732|FG001|Overall Study|Patient ready for early discharge|4
6220421|NCT01660906|9889765|FG000|Overall Study|Discontinued due to study drug toxicity|3
6220422|NCT01661062|9889769|FG000|Overall Study|Completed Treatment Off Study|3
6220423|NCT01661062|9889769|FG000|Overall Study|Withdrawal by Subject|2
6220424|NCT01661140|9889781|FG000|Open-Label Period|Adverse Event|44
6220425|NCT01661140|9889782|FG001|Open-Label Period|Adverse Event|0
6220426|NCT01661140|9889783|FG002|Open-Label Period|Adverse Event|0
6220427|NCT01661140|9889781|FG000|Open-Label Period|Protocol Violation|3
6220428|NCT01661140|9889782|FG001|Open-Label Period|Protocol Violation|0
6220429|NCT01661140|9889783|FG002|Open-Label Period|Protocol Violation|0
6220430|NCT01661140|9889781|FG000|Open-Label Period|Withdrawal by Subject|5
6129285|NCT00952731|9755618|FG000|Overall Study|Drug supply expired|1
6129286|NCT00952731|9755619|FG001|Overall Study|Drug supply expired|0
6129287|NCT00952822|9755625|FG000|1st Pharmacokinetic Evaluation|Lost to Follow-up|0
6129288|NCT00952822|9755626|FG001|1st Pharmacokinetic Evaluation|Lost to Follow-up|1
6220431|NCT01661140|9889782|FG001|Open-Label Period|Withdrawal by Subject|0
6220432|NCT01661140|9889783|FG002|Open-Label Period|Withdrawal by Subject|0
6220433|NCT01661140|9889781|FG000|Open-Label Period|Investigator Decision|3
6129289|NCT00952822|9755627|FG002|1st Pharmacokinetic Evaluation|Lost to Follow-up|0
6129290|NCT00952822|9755628|FG003|1st Pharmacokinetic Evaluation|Lost to Follow-up|0
6129291|NCT00952822|9755625|FG000|2nd Pharmacokinetic Evaluation|Withdrawal by Subject|0
6129292|NCT00952822|9755626|FG001|2nd Pharmacokinetic Evaluation|Withdrawal by Subject|0
6129293|NCT00952822|9755627|FG002|2nd Pharmacokinetic Evaluation|Withdrawal by Subject|1
6129294|NCT00952822|9755628|FG003|2nd Pharmacokinetic Evaluation|Withdrawal by Subject|0
6129295|NCT00952848|9755639|FG000|Overall Study|Withdrawal by Subject|4
6129296|NCT00953017|9755647|FG000|Overall Study|DId not show up for colonoscopy|4
6129297|NCT00953017|9755648|FG001|Overall Study|DId not show up for colonoscopy|4
6129298|NCT00953017|9755649|FG002|Overall Study|DId not show up for colonoscopy|5
6129299|NCT00953017|9755650|FG003|Overall Study|DId not show up for colonoscopy|4
6129300|NCT00953017|9755647|FG000|Overall Study|Incomplete data|1
6129301|NCT00953017|9755648|FG001|Overall Study|Incomplete data|1
6129302|NCT00953017|9755649|FG002|Overall Study|Incomplete data|0
6129303|NCT00953017|9755650|FG003|Overall Study|Incomplete data|0
6129304|NCT00953017|9755647|FG000|Overall Study|Procedure incomplete due to pain/looping|0
6129305|NCT00953017|9755648|FG001|Overall Study|Procedure incomplete due to pain/looping|1
6129306|NCT00953017|9755649|FG002|Overall Study|Procedure incomplete due to pain/looping|0
6129307|NCT00953017|9755650|FG003|Overall Study|Procedure incomplete due to pain/looping|1
6129308|NCT00953017|9755647|FG000|Overall Study|Brown stool prior to procedure|0
6129309|NCT00953017|9755648|FG001|Overall Study|Brown stool prior to procedure|0
6220434|NCT01661140|9889782|FG001|Open-Label Period|Investigator Decision|0
6220435|NCT01661140|9889783|FG002|Open-Label Period|Investigator Decision|0
6220436|NCT01661140|9889781|FG000|Open-Label Period|Death|1
6220437|NCT01661140|9889782|FG001|Open-Label Period|Death|0
6220438|NCT01661140|9889783|FG002|Open-Label Period|Death|0
6220439|NCT01661140|9889781|FG000|Open-Label Period|Administrative/Other|1
6220440|NCT01661140|9889782|FG001|Open-Label Period|Administrative/Other|0
6220441|NCT01661140|9889783|FG002|Open-Label Period|Administrative/Other|0
6220442|NCT01661140|9889781|FG000|Open-Label Period|Sponsor termination|16
6220443|NCT01661140|9889782|FG001|Open-Label Period|Sponsor termination|0
6220444|NCT01661140|9889783|FG002|Open-Label Period|Sponsor termination|0
6220445|NCT01661140|9889781|FG000|Open-Label Period|Did not meet EULAR criteria|1
6220446|NCT01661140|9889782|FG001|Open-Label Period|Did not meet EULAR criteria|0
6220447|NCT01661140|9889783|FG002|Open-Label Period|Did not meet EULAR criteria|0
6220448|NCT01661140|9889781|FG000|Open-Label Period|Lost to Follow-up|2
6220449|NCT01661140|9889782|FG001|Open-Label Period|Lost to Follow-up|0
6220450|NCT01661140|9889783|FG002|Open-Label Period|Lost to Follow-up|0
6220451|NCT01661140|9889781|FG000|Double-Blind Period|Refused Treatment|0
6220452|NCT01661140|9889782|FG001|Double-Blind Period|Refused Treatment|0
6220453|NCT01661140|9889783|FG002|Double-Blind Period|Refused Treatment|1
6220454|NCT01661140|9889781|FG000|Double-Blind Period|Adverse Event|0
6220455|NCT01661140|9889782|FG001|Double-Blind Period|Adverse Event|16
6220456|NCT01661140|9889783|FG002|Double-Blind Period|Adverse Event|18
6220457|NCT01661140|9889781|FG000|Double-Blind Period|Protocol Violation|0
6220458|NCT01661140|9889782|FG001|Double-Blind Period|Protocol Violation|2
6220459|NCT01661140|9889783|FG002|Double-Blind Period|Protocol Violation|3
6220460|NCT01661140|9889781|FG000|Double-Blind Period|Withdrawal by Subject|0
6220461|NCT01661140|9889782|FG001|Double-Blind Period|Withdrawal by Subject|1
6220462|NCT01661140|9889783|FG002|Double-Blind Period|Withdrawal by Subject|3
6220463|NCT01661140|9889781|FG000|Double-Blind Period|Investigator's Decision|0
6220464|NCT01661140|9889782|FG001|Double-Blind Period|Investigator's Decision|1
6220465|NCT01661140|9889783|FG002|Double-Blind Period|Investigator's Decision|2
6220466|NCT01661140|9889781|FG000|Double-Blind Period|Sponsor Termination|0
6220467|NCT01661140|9889782|FG001|Double-Blind Period|Sponsor Termination|14
6220468|NCT01661140|9889783|FG002|Double-Blind Period|Sponsor Termination|17
6220469|NCT01661140|9889781|FG000|Double-Blind Period|Administrative/Other|0
6220470|NCT01661140|9889782|FG001|Double-Blind Period|Administrative/Other|7
6220471|NCT01661140|9889783|FG002|Double-Blind Period|Administrative/Other|6
6220472|NCT01661179|9889791|FG000|Overall Study|Death|1
6220473|NCT01661179|9889791|FG000|Overall Study|Withdrawal by Subject|1
6220474|NCT01661179|9889791|FG000|Overall Study|Other Eligibility criteria|4
6220475|NCT01661205|9889795|FG000|Overall Study|Physician Decision|2
6220476|NCT01661595|9889817|FG000|Phase 1: Week 0-4|Adverse Event|1
6129310|NCT00953017|9755649|FG002|Overall Study|Brown stool prior to procedure|1
6129311|NCT00953017|9755650|FG003|Overall Study|Brown stool prior to procedure|0
6220477|NCT01661595|9889818|FG001|Phase 1: Week 0-4|Adverse Event|0
5980945|NCT03875092|9569716|FG001|Overall Study|Ongoing in Study|14
6129312|NCT00953043|9755662|FG000|Overall Study|Withdrawal by Subject|4
6129313|NCT00953043|9755663|FG001|Overall Study|Withdrawal by Subject|0
6220478|NCT01661595|9889819|FG002|Phase 1: Week 0-4|Adverse Event|0
6220479|NCT01661595|9889820|FG003|Phase 1: Week 0-4|Adverse Event|0
6220480|NCT01661595|9889817|FG000|Phase 2: Week 5-8.|Protocol Violation|0
6220481|NCT01661595|9889818|FG001|Phase 2: Week 5-8.|Protocol Violation|0
6220482|NCT01661595|9889819|FG002|Phase 2: Week 5-8.|Protocol Violation|1
6220483|NCT01661595|9889820|FG003|Phase 2: Week 5-8.|Protocol Violation|0
6289011|NCT02375971|10003527|FG001|Follow-Up Phase (up to Day 169)|Death|4
6289012|NCT02375971|10003528|FG002|Follow-Up Phase (up to Day 169)|Death|4
6289013|NCT02375971|10003526|FG000|Follow-Up Phase (up to Day 169)|Withdrawal of Consent|1
6289014|NCT02375971|10003527|FG001|Follow-Up Phase (up to Day 169)|Withdrawal of Consent|1
6129314|NCT00953043|9755662|FG000|Overall Study|Physician Decision|0
6129315|NCT00953043|9755663|FG001|Overall Study|Physician Decision|2
6129316|NCT00953056|9755675|FG000|Overall Study|Withdrew Consent|0
6129317|NCT00953056|9755676|FG001|Overall Study|Withdrew Consent|0
6129318|NCT00953056|9755677|FG002|Overall Study|Withdrew Consent|0
6129319|NCT00953056|9755678|FG003|Overall Study|Withdrew Consent|0
6129320|NCT00953056|9755679|FG004|Overall Study|Withdrew Consent|2
6129321|NCT00953056|9755680|FG005|Overall Study|Withdrew Consent|3
6129322|NCT00953056|9755675|FG000|Overall Study|Serious Adverse Event|0
6129323|NCT00953056|9755676|FG001|Overall Study|Serious Adverse Event|0
6129324|NCT00953056|9755677|FG002|Overall Study|Serious Adverse Event|0
6129325|NCT00953056|9755678|FG003|Overall Study|Serious Adverse Event|0
6129326|NCT00953056|9755679|FG004|Overall Study|Serious Adverse Event|0
6129327|NCT00953056|9755680|FG005|Overall Study|Serious Adverse Event|1
6129328|NCT00953147|9755712|FG000|Overall Study|Adverse Event|8
6129329|NCT00953147|9755713|FG001|Overall Study|Adverse Event|16
6129330|NCT00953147|9755714|FG002|Overall Study|Adverse Event|6
6129331|NCT00953147|9755712|FG000|Overall Study|Protocol Violation|2
6129332|NCT00953147|9755713|FG001|Overall Study|Protocol Violation|8
6129333|NCT00953147|9755714|FG002|Overall Study|Protocol Violation|4
6129334|NCT00953147|9755712|FG000|Overall Study|Withdrawal by Subject|13
6129335|NCT00953147|9755713|FG001|Overall Study|Withdrawal by Subject|15
6129336|NCT00953147|9755714|FG002|Overall Study|Withdrawal by Subject|12
6129337|NCT00953147|9755712|FG000|Overall Study|Lost to Follow-up|8
6129338|NCT00953147|9755713|FG001|Overall Study|Lost to Follow-up|9
6129339|NCT00953147|9755714|FG002|Overall Study|Lost to Follow-up|4
6129340|NCT00953147|9755712|FG000|Overall Study|Physician Decision|2
6129341|NCT00953147|9755713|FG001|Overall Study|Physician Decision|7
6129342|NCT00953147|9755714|FG002|Overall Study|Physician Decision|3
6129343|NCT00953147|9755712|FG000|Overall Study|Other|4
6129344|NCT00953147|9755713|FG001|Overall Study|Other|11
6129345|NCT00953147|9755714|FG002|Overall Study|Other|13
6129346|NCT00953160|9755722|FG000|Overall Study|Lost to Follow-up|23
6129347|NCT00953160|9755722|FG000|Overall Study|Withdrawal by Subject|4
6129348|NCT00953225|9755764|FG000|Overall Study|Withdrawal by Subject|2
6129349|NCT00953225|9755765|FG001|Overall Study|Withdrawal by Subject|0
6129350|NCT00953407|9755783|FG000|Overall Study|Failed inclusion criteria|1
6220484|NCT01661686|9889848|FG000|Overall Study|Lost to Follow-up|2
6220485|NCT01661686|9889849|FG001|Overall Study|Lost to Follow-up|1
6220486|NCT01661686|9889848|FG000|Overall Study|did not receive allocated intervention|0
6220487|NCT01661686|9889849|FG001|Overall Study|did not receive allocated intervention|1
6220488|NCT01661790|9889897|FG000|Overall Study|Lost to Follow-up|0
6220489|NCT01661790|9889898|FG001|Overall Study|Lost to Follow-up|2
6220490|NCT01661881|9889904|FG000|Overall Study|Disease Progression|1
6220491|NCT01661933|9889908|FG000|Low-dose Gluten Challenge|Physician Decision|2
6220492|NCT01661933|9889908|FG000|High-dose Gluten Challenge|Withdrawal by Subject|2
6220493|NCT01661972|9889925|FG000|Overall Study|Adverse Event|1
6220494|NCT01661972|9889926|FG001|Overall Study|Adverse Event|2
6220495|NCT01661972|9889925|FG000|Overall Study|Death during Treatment period|1
6220496|NCT01661972|9889926|FG001|Overall Study|Death during Treatment period|1
6220497|NCT01661972|9889925|FG000|Overall Study|Withdrawal by Subject|0
6220498|NCT01661972|9889926|FG001|Overall Study|Withdrawal by Subject|1
6220499|NCT01662024|9889934|FG000|Overall Study|Pregnancy|2
6220500|NCT01662024|9889934|FG000|Overall Study|Withdrawal by Subject|3
6220501|NCT01662063|9889943|FG000|Overall Study|Adverse Event or Intercurrent Illness|1
6220502|NCT01662063|9889944|FG001|Overall Study|Adverse Event or Intercurrent Illness|12
6220503|NCT01662063|9889945|FG002|Overall Study|Adverse Event or Intercurrent Illness|0
6289015|NCT02375971|10003528|FG002|Follow-Up Phase (up to Day 169)|Withdrawal of Consent|0
6289016|NCT02376166|10003549|FG000|Overall Study|Adverse Event|1
6289017|NCT02376166|10003549|FG000|Overall Study|Discontinued metformin early|2
6289018|NCT02376790|10003613|FG000|Overall Study|Withdrawal by Subject|43
6289019|NCT02376790|10003614|FG001|Overall Study|Withdrawal by Subject|36
6289020|NCT02376790|10003615|FG002|Overall Study|Withdrawal by Subject|37
6289021|NCT02376790|10003613|FG000|Overall Study|Decision by Sponsor|2
6289022|NCT02376790|10003614|FG001|Overall Study|Decision by Sponsor|1
6289023|NCT02376790|10003615|FG002|Overall Study|Decision by Sponsor|4
6289024|NCT02376790|10003613|FG000|Overall Study|Lost to Follow-up|15
6289025|NCT02376790|10003614|FG001|Overall Study|Lost to Follow-up|10
6289026|NCT02376790|10003615|FG002|Overall Study|Lost to Follow-up|12
6289027|NCT02377063|10003627|FG000|Overall Study|Non-compliance|5
6289028|NCT02377349|10003633|FG000|Overall Study|Serious Adverse Event|1
6289029|NCT02377349|10003634|FG001|Overall Study|Serious Adverse Event|0
6129351|NCT00953407|9755784|FG001|Overall Study|Failed inclusion criteria|1
6129352|NCT00953407|9755785|FG002|Overall Study|Failed inclusion criteria|1
6129353|NCT00953407|9755786|FG003|Overall Study|Failed inclusion criteria|1
6129354|NCT00953407|9755787|FG004|Overall Study|Failed inclusion criteria|1
6129355|NCT00953407|9755783|FG000|Overall Study|Lost to Follow-up|0
6129356|NCT00953407|9755784|FG001|Overall Study|Lost to Follow-up|0
6129357|NCT00953407|9755785|FG002|Overall Study|Lost to Follow-up|0
6129358|NCT00953407|9755786|FG003|Overall Study|Lost to Follow-up|1
6129359|NCT00953407|9755787|FG004|Overall Study|Lost to Follow-up|0
6129360|NCT00953524|9755803|FG000|Overall Study|Adverse Event|2
6289030|NCT02377349|10003633|FG000|Overall Study|Protocol Violation|3
6289031|NCT02377349|10003634|FG001|Overall Study|Protocol Violation|2
6129361|NCT00953524|9755804|FG001|Overall Study|Adverse Event|0
6129362|NCT00953524|9755805|FG002|Overall Study|Adverse Event|1
6129363|NCT00953524|9755806|FG003|Overall Study|Adverse Event|2
6129364|NCT00953524|9755803|FG000|Overall Study|Protocol Violation|18
6129365|NCT00953524|9755804|FG001|Overall Study|Protocol Violation|10
6129366|NCT00953524|9755805|FG002|Overall Study|Protocol Violation|11
6129367|NCT00953524|9755806|FG003|Overall Study|Protocol Violation|6
6129368|NCT00953524|9755803|FG000|Overall Study|Lost to Follow-up|0
6129369|NCT00953524|9755804|FG001|Overall Study|Lost to Follow-up|1
6129370|NCT00953524|9755805|FG002|Overall Study|Lost to Follow-up|1
6129371|NCT00953524|9755806|FG003|Overall Study|Lost to Follow-up|0
6129372|NCT00953524|9755803|FG000|Overall Study|Withdrawal by Subject|2
6129373|NCT00953524|9755804|FG001|Overall Study|Withdrawal by Subject|4
6129374|NCT00953524|9755805|FG002|Overall Study|Withdrawal by Subject|1
6129375|NCT00953524|9755806|FG003|Overall Study|Withdrawal by Subject|0
6129376|NCT00953576|9755818|FG000|Overall Study|Adverse Event|0
6129377|NCT00953576|9755819|FG001|Overall Study|Adverse Event|1
6129378|NCT00953576|9755818|FG000|Overall Study|Ineligible after Consent|2
6129379|NCT00953576|9755819|FG001|Overall Study|Ineligible after Consent|0
6129380|NCT00953667|9755841|FG000|Overall Study|Lost to Follow-up|11
6129381|NCT00953667|9755841|FG000|Overall Study|Physician Decision|35
6129382|NCT00953667|9755841|FG000|Overall Study|Withdrawal by Subject|63
6129383|NCT00953667|9755841|FG000|Overall Study|Adverse Event|10
6129384|NCT00953667|9755841|FG000|Overall Study|poor venous access,unable to draw blood|4
6129385|NCT00953706|9755847|FG000|Part A (16-Week Double-Blind Treatment)|Adverse Event|2
6129386|NCT00953706|9755848|FG001|Part A (16-Week Double-Blind Treatment)|Adverse Event|3
6129387|NCT00953706|9755849|FG002|Part A (16-Week Double-Blind Treatment)|Adverse Event|0
6129388|NCT00953706|9755850|FG003|Part A (16-Week Double-Blind Treatment)|Adverse Event|0
6129389|NCT00953706|9755847|FG000|Part A (16-Week Double-Blind Treatment)|Lost to Follow-up|0
6129390|NCT00953706|9755848|FG001|Part A (16-Week Double-Blind Treatment)|Lost to Follow-up|1
6129391|NCT00953706|9755849|FG002|Part A (16-Week Double-Blind Treatment)|Lost to Follow-up|0
6129392|NCT00953706|9755850|FG003|Part A (16-Week Double-Blind Treatment)|Lost to Follow-up|0
6129393|NCT00953706|9755847|FG000|Part A (16-Week Double-Blind Treatment)|Noncompliance with Study Requirements|0
6129394|NCT00953706|9755848|FG001|Part A (16-Week Double-Blind Treatment)|Noncompliance with Study Requirements|2
6220504|NCT01662063|9889943|FG000|Overall Study|Lack of Efficacy|1
6220505|NCT01662063|9889944|FG001|Overall Study|Lack of Efficacy|6
6220506|NCT01662063|9889945|FG002|Overall Study|Lack of Efficacy|0
6220507|NCT01662063|9889943|FG000|Overall Study|Lost to Follow-up|0
6220508|NCT01662063|9889944|FG001|Overall Study|Lost to Follow-up|4
6220509|NCT01662063|9889945|FG002|Overall Study|Lost to Follow-up|0
6220510|NCT01662063|9889943|FG000|Overall Study|Protocol Violation|1
6220511|NCT01662063|9889944|FG001|Overall Study|Protocol Violation|0
6220512|NCT01662063|9889945|FG002|Overall Study|Protocol Violation|0
6220513|NCT01662063|9889943|FG000|Overall Study|Withdrawal by Subject|2
6220514|NCT01662063|9889944|FG001|Overall Study|Withdrawal by Subject|4
6220515|NCT01662063|9889945|FG002|Overall Study|Withdrawal by Subject|1
6220516|NCT01662063|9889943|FG000|Overall Study|Physician Decision|0
6220517|NCT01662063|9889944|FG001|Overall Study|Physician Decision|2
6220518|NCT01662063|9889945|FG002|Overall Study|Physician Decision|0
6220519|NCT01662063|9889943|FG000|Overall Study|Other|0
6220520|NCT01662063|9889944|FG001|Overall Study|Other|1
6289032|NCT02377349|10003633|FG000|Overall Study|Withdrawal by Subject|5
6289033|NCT02377349|10003634|FG001|Overall Study|Withdrawal by Subject|3
6289034|NCT02377349|10003633|FG000|Overall Study|Lost to follow-up (partial vaccination)|1
6289035|NCT02377349|10003634|FG001|Overall Study|Lost to follow-up (partial vaccination)|0
6289036|NCT02377349|10003633|FG000|Overall Study|Lost to follow-up (complete vaccination)|6
6289037|NCT02377349|10003634|FG001|Overall Study|Lost to follow-up (complete vaccination)|5
6289038|NCT02377349|10003633|FG000|Overall Study|Other|0
6289039|NCT02377349|10003634|FG001|Overall Study|Other|1
6289040|NCT02377362|10003662|FG000|Part A Second Treatment|Protocol Violation|0
6289041|NCT02377362|10003663|FG001|Part A Second Treatment|Protocol Violation|0
6289042|NCT02377362|10003664|FG002|Part A Second Treatment|Protocol Violation|0
6289043|NCT02377362|10003665|FG003|Part A Second Treatment|Protocol Violation|0
6289044|NCT02377362|10003666|FG004|Part A Second Treatment|Protocol Violation|1
6289045|NCT02377362|10003667|FG005|Part A Second Treatment|Protocol Violation|0
6289046|NCT02377362|10003668|FG006|Part A Second Treatment|Protocol Violation|0
6289047|NCT02377362|10003669|FG007|Part A Second Treatment|Protocol Violation|0
6289048|NCT02377362|10003670|FG008|Part A Second Treatment|Protocol Violation|0
6289049|NCT02377362|10003671|FG009|Part A Second Treatment|Protocol Violation|0
6289050|NCT02377362|10003672|FG010|Part A Second Treatment|Protocol Violation|0
6129395|NCT00953706|9755849|FG002|Part A (16-Week Double-Blind Treatment)|Noncompliance with Study Requirements|0
6129396|NCT00953706|9755850|FG003|Part A (16-Week Double-Blind Treatment)|Noncompliance with Study Requirements|0
6220521|NCT01662063|9889945|FG002|Overall Study|Other|0
6220522|NCT01662310|9889975|FG000|Run-In or Stabilization Phase|Adverse Event|11
6289051|NCT02377362|10003673|FG011|Part A Second Treatment|Protocol Violation|0
6289052|NCT02377362|10003674|FG012|Part A Second Treatment|Protocol Violation|0
6289053|NCT02377362|10003662|FG000|Part A Third Treatment|Highest dose level 1200 not used|0
6289054|NCT02377362|10003663|FG001|Part A Third Treatment|Highest dose level 1200 not used|0
6289055|NCT02377362|10003664|FG002|Part A Third Treatment|Highest dose level 1200 not used|0
6129397|NCT00953706|9755847|FG000|Part A (16-Week Double-Blind Treatment)|Required Prohibited Medication|0
6129398|NCT00953706|9755848|FG001|Part A (16-Week Double-Blind Treatment)|Required Prohibited Medication|1
6129399|NCT00953706|9755849|FG002|Part A (16-Week Double-Blind Treatment)|Required Prohibited Medication|0
6129400|NCT00953706|9755850|FG003|Part A (16-Week Double-Blind Treatment)|Required Prohibited Medication|0
6129401|NCT00953706|9755847|FG000|Part A (16-Week Double-Blind Treatment)|Sponsor Decision|0
6129402|NCT00953706|9755848|FG001|Part A (16-Week Double-Blind Treatment)|Sponsor Decision|1
6129403|NCT00953706|9755849|FG002|Part A (16-Week Double-Blind Treatment)|Sponsor Decision|0
6129404|NCT00953706|9755850|FG003|Part A (16-Week Double-Blind Treatment)|Sponsor Decision|0
6129405|NCT00953706|9755847|FG000|Part B (96-Week Open-Label Extension)|Adverse Event|0
6129406|NCT00953706|9755848|FG001|Part B (96-Week Open-Label Extension)|Adverse Event|0
6129407|NCT00953706|9755849|FG002|Part B (96-Week Open-Label Extension)|Adverse Event|0
6129408|NCT00953706|9755850|FG003|Part B (96-Week Open-Label Extension)|Adverse Event|2
6129409|NCT00953706|9755847|FG000|Part B (96-Week Open-Label Extension)|Noncompliance with Study Requirements|0
6129410|NCT00953706|9755848|FG001|Part B (96-Week Open-Label Extension)|Noncompliance with Study Requirements|0
6129411|NCT00953706|9755849|FG002|Part B (96-Week Open-Label Extension)|Noncompliance with Study Requirements|0
6129412|NCT00953706|9755850|FG003|Part B (96-Week Open-Label Extension)|Noncompliance with Study Requirements|1
6129413|NCT00953706|9755847|FG000|Part B (96-Week Open-Label Extension)|Required Prohibited Medication|0
6129414|NCT00953706|9755848|FG001|Part B (96-Week Open-Label Extension)|Required Prohibited Medication|0
6129415|NCT00953706|9755849|FG002|Part B (96-Week Open-Label Extension)|Required Prohibited Medication|0
6129416|NCT00953706|9755850|FG003|Part B (96-Week Open-Label Extension)|Required Prohibited Medication|1
6129417|NCT00953706|9755847|FG000|Part B (96-Week Open-Label Extension)|Study Termination by Sponsor|0
6220523|NCT01662310|9889976|FG001|Run-In or Stabilization Phase|Adverse Event|0
6220524|NCT01662310|9889977|FG002|Run-In or Stabilization Phase|Adverse Event|0
6220525|NCT01662310|9889978|FG003|Run-In or Stabilization Phase|Adverse Event|0
6220526|NCT01662310|9889979|FG004|Run-In or Stabilization Phase|Adverse Event|0
6220527|NCT01662310|9889975|FG000|Run-In or Stabilization Phase|Lack of Efficacy|9
6220528|NCT01662310|9889976|FG001|Run-In or Stabilization Phase|Lack of Efficacy|0
6220529|NCT01662310|9889977|FG002|Run-In or Stabilization Phase|Lack of Efficacy|0
6220530|NCT01662310|9889978|FG003|Run-In or Stabilization Phase|Lack of Efficacy|0
6220531|NCT01662310|9889979|FG004|Run-In or Stabilization Phase|Lack of Efficacy|0
6220532|NCT01662310|9889975|FG000|Run-In or Stabilization Phase|Lost to Follow-up|4
6220533|NCT01662310|9889976|FG001|Run-In or Stabilization Phase|Lost to Follow-up|0
6220534|NCT01662310|9889977|FG002|Run-In or Stabilization Phase|Lost to Follow-up|0
6220535|NCT01662310|9889978|FG003|Run-In or Stabilization Phase|Lost to Follow-up|0
6220536|NCT01662310|9889979|FG004|Run-In or Stabilization Phase|Lost to Follow-up|0
6220537|NCT01662310|9889975|FG000|Run-In or Stabilization Phase|Protocol Violation|15
6220538|NCT01662310|9889976|FG001|Run-In or Stabilization Phase|Protocol Violation|0
6220539|NCT01662310|9889977|FG002|Run-In or Stabilization Phase|Protocol Violation|0
6220540|NCT01662310|9889978|FG003|Run-In or Stabilization Phase|Protocol Violation|0
6220541|NCT01662310|9889979|FG004|Run-In or Stabilization Phase|Protocol Violation|0
6220542|NCT01662310|9889975|FG000|Run-In or Stabilization Phase|Withdrawal by Subject|25
6220543|NCT01662310|9889976|FG001|Run-In or Stabilization Phase|Withdrawal by Subject|0
6220544|NCT01662310|9889977|FG002|Run-In or Stabilization Phase|Withdrawal by Subject|0
6220545|NCT01662310|9889978|FG003|Run-In or Stabilization Phase|Withdrawal by Subject|0
6220546|NCT01662310|9889979|FG004|Run-In or Stabilization Phase|Withdrawal by Subject|0
6220547|NCT01662310|9889975|FG000|Run-In or Stabilization Phase|Other|1
6220548|NCT01662310|9889976|FG001|Run-In or Stabilization Phase|Other|0
6220549|NCT01662310|9889977|FG002|Run-In or Stabilization Phase|Other|0
6220550|NCT01662310|9889978|FG003|Run-In or Stabilization Phase|Other|0
6220551|NCT01662310|9889979|FG004|Run-In or Stabilization Phase|Other|0
6220552|NCT01662310|9889975|FG000|Double-Blind Phase|Adverse Event|0
6220553|NCT01662310|9889976|FG001|Double-Blind Phase|Adverse Event|0
6220554|NCT01662310|9889977|FG002|Double-Blind Phase|Adverse Event|1
6220555|NCT01662310|9889978|FG003|Double-Blind Phase|Adverse Event|0
6220556|NCT01662310|9889979|FG004|Double-Blind Phase|Adverse Event|0
6220557|NCT01662310|9889975|FG000|Double-Blind Phase|Lost to Follow-up|0
6220558|NCT01662310|9889976|FG001|Double-Blind Phase|Lost to Follow-up|3
6220559|NCT01662310|9889977|FG002|Double-Blind Phase|Lost to Follow-up|0
6220560|NCT01662310|9889978|FG003|Double-Blind Phase|Lost to Follow-up|0
6220561|NCT01662310|9889979|FG004|Double-Blind Phase|Lost to Follow-up|0
6220562|NCT01662310|9889975|FG000|Double-Blind Phase|Pregnancy|0
6220563|NCT01662310|9889976|FG001|Double-Blind Phase|Pregnancy|2
6220564|NCT01662310|9889977|FG002|Double-Blind Phase|Pregnancy|0
6220565|NCT01662310|9889978|FG003|Double-Blind Phase|Pregnancy|0
6220566|NCT01662310|9889979|FG004|Double-Blind Phase|Pregnancy|0
6220567|NCT01662310|9889975|FG000|Double-Blind Phase|Withdrawal by Subject|0
6220568|NCT01662310|9889976|FG001|Double-Blind Phase|Withdrawal by Subject|9
6220569|NCT01662310|9889977|FG002|Double-Blind Phase|Withdrawal by Subject|3
6220570|NCT01662310|9889978|FG003|Double-Blind Phase|Withdrawal by Subject|0
6220571|NCT01662310|9889979|FG004|Double-Blind Phase|Withdrawal by Subject|0
6220572|NCT01662310|9889975|FG000|Double-Blind Phase|Other|0
6220573|NCT01662310|9889976|FG001|Double-Blind Phase|Other|0
6220574|NCT01662310|9889977|FG002|Double-Blind Phase|Other|1
6220575|NCT01662310|9889978|FG003|Double-Blind Phase|Other|0
6129418|NCT00953706|9755848|FG001|Part B (96-Week Open-Label Extension)|Study Termination by Sponsor|0
6129419|NCT00953706|9755849|FG002|Part B (96-Week Open-Label Extension)|Study Termination by Sponsor|4
6129420|NCT00953706|9755850|FG003|Part B (96-Week Open-Label Extension)|Study Termination by Sponsor|25
6220576|NCT01662310|9889979|FG004|Double-Blind Phase|Other|0
6220577|NCT01662310|9889975|FG000|Double-Blind Phase|Randomized but not treated|0
6220578|NCT01662310|9889976|FG001|Double-Blind Phase|Randomized but not treated|1
6220579|NCT01662310|9889977|FG002|Double-Blind Phase|Randomized but not treated|0
6220580|NCT01662310|9889978|FG003|Double-Blind Phase|Randomized but not treated|0
6220581|NCT01662310|9889979|FG004|Double-Blind Phase|Randomized but not treated|0
6220582|NCT01662310|9889975|FG000|Open-Label Extension Phase|Adverse Event|0
6220583|NCT01662310|9889976|FG001|Open-Label Extension Phase|Adverse Event|0
6220584|NCT01662310|9889977|FG002|Open-Label Extension Phase|Adverse Event|0
6220585|NCT01662310|9889978|FG003|Open-Label Extension Phase|Adverse Event|3
6220586|NCT01662310|9889979|FG004|Open-Label Extension Phase|Adverse Event|0
6220587|NCT01662310|9889975|FG000|Open-Label Extension Phase|Death|0
6220588|NCT01662310|9889976|FG001|Open-Label Extension Phase|Death|0
6220589|NCT01662310|9889977|FG002|Open-Label Extension Phase|Death|0
6220590|NCT01662310|9889978|FG003|Open-Label Extension Phase|Death|1
6220591|NCT01662310|9889979|FG004|Open-Label Extension Phase|Death|0
6220592|NCT01662310|9889975|FG000|Open-Label Extension Phase|Lack of Efficacy|0
6220593|NCT01662310|9889976|FG001|Open-Label Extension Phase|Lack of Efficacy|0
6220594|NCT01662310|9889977|FG002|Open-Label Extension Phase|Lack of Efficacy|0
6220595|NCT01662310|9889978|FG003|Open-Label Extension Phase|Lack of Efficacy|2
6220596|NCT01662310|9889979|FG004|Open-Label Extension Phase|Lack of Efficacy|2
6220597|NCT01662310|9889975|FG000|Open-Label Extension Phase|Lost to Follow-up|0
6220598|NCT01662310|9889976|FG001|Open-Label Extension Phase|Lost to Follow-up|0
6220599|NCT01662310|9889977|FG002|Open-Label Extension Phase|Lost to Follow-up|0
6220600|NCT01662310|9889978|FG003|Open-Label Extension Phase|Lost to Follow-up|2
6220601|NCT01662310|9889979|FG004|Open-Label Extension Phase|Lost to Follow-up|1
6220602|NCT01662310|9889975|FG000|Open-Label Extension Phase|Pregnancy|0
6220603|NCT01662310|9889976|FG001|Open-Label Extension Phase|Pregnancy|0
6220604|NCT01662310|9889977|FG002|Open-Label Extension Phase|Pregnancy|0
6220605|NCT01662310|9889978|FG003|Open-Label Extension Phase|Pregnancy|1
6220606|NCT01662310|9889979|FG004|Open-Label Extension Phase|Pregnancy|0
6220607|NCT01662310|9889975|FG000|Open-Label Extension Phase|Withdrawal by Subject|0
6220608|NCT01662310|9889976|FG001|Open-Label Extension Phase|Withdrawal by Subject|0
6220609|NCT01662310|9889977|FG002|Open-Label Extension Phase|Withdrawal by Subject|0
6220610|NCT01662310|9889978|FG003|Open-Label Extension Phase|Withdrawal by Subject|2
6220611|NCT01662310|9889979|FG004|Open-Label Extension Phase|Withdrawal by Subject|7
6220612|NCT01662336|9889991|FG000|Overall Study|Adverse Event|1
6220613|NCT01662336|9889991|FG000|Overall Study|No longer on LPV/r|30
6220614|NCT01662336|9889991|FG000|Overall Study|Other|29
6220615|NCT01662336|9889991|FG000|Overall Study|Withdrawal by Subject|6
6220616|NCT01662362|9890000|FG000|Overall Study|Lost to Follow-up|38
6220617|NCT01662440|9890009|FG000|Overall Study|Adverse Event|1
6220618|NCT01662440|9890010|FG001|Overall Study|Adverse Event|0
6220619|NCT01662440|9890011|FG002|Overall Study|Adverse Event|0
6220620|NCT01662440|9890012|FG003|Overall Study|Adverse Event|1
6220621|NCT01662440|9890009|FG000|Overall Study|Death|0
6220622|NCT01662440|9890010|FG001|Overall Study|Death|1
6220623|NCT01662440|9890011|FG002|Overall Study|Death|0
6220624|NCT01662440|9890012|FG003|Overall Study|Death|0
6220625|NCT01662440|9890009|FG000|Overall Study|Lost to Follow-up|2
6220626|NCT01662440|9890010|FG001|Overall Study|Lost to Follow-up|2
6220627|NCT01662440|9890011|FG002|Overall Study|Lost to Follow-up|4
6220628|NCT01662440|9890012|FG003|Overall Study|Lost to Follow-up|1
6220629|NCT01662440|9890009|FG000|Overall Study|Subject moved to another country.|0
6220630|NCT01662440|9890010|FG001|Overall Study|Subject moved to another country.|1
6220631|NCT01662440|9890011|FG002|Overall Study|Subject moved to another country.|0
6220632|NCT01662440|9890012|FG003|Overall Study|Subject moved to another country.|0
6220633|NCT01662440|9890009|FG000|Overall Study|Protocol Violation|1
6220634|NCT01662440|9890010|FG001|Overall Study|Protocol Violation|0
6220635|NCT01662440|9890011|FG002|Overall Study|Protocol Violation|0
6220636|NCT01662440|9890012|FG003|Overall Study|Protocol Violation|0
6220637|NCT01662440|9890009|FG000|Overall Study|Withdrawal by Subject|5
6220638|NCT01662440|9890010|FG001|Overall Study|Withdrawal by Subject|2
6220639|NCT01662440|9890011|FG002|Overall Study|Withdrawal by Subject|2
6220640|NCT01662440|9890012|FG003|Overall Study|Withdrawal by Subject|2
6220641|NCT01662492|9890035|FG000|Overall Study|Other miscellaneous reasons.|1
6220642|NCT01662492|9890036|FG001|Overall Study|Other miscellaneous reasons.|0
6220643|NCT01662492|9890037|FG002|Overall Study|Other miscellaneous reasons.|1
6220644|NCT01662492|9890035|FG000|Overall Study|Withdrawal by Subject|0
6220645|NCT01662492|9890036|FG001|Overall Study|Withdrawal by Subject|0
6220646|NCT01662492|9890037|FG002|Overall Study|Withdrawal by Subject|1
6220647|NCT01662492|9890035|FG000|Overall Study|Protocol Violation|1
6220648|NCT01662492|9890036|FG001|Overall Study|Protocol Violation|0
6220649|NCT01662492|9890037|FG002|Overall Study|Protocol Violation|0
6220650|NCT01662492|9890035|FG000|Overall Study|Lost to Follow-up|0
6220651|NCT01662492|9890036|FG001|Overall Study|Lost to Follow-up|0
6220652|NCT01662492|9890037|FG002|Overall Study|Lost to Follow-up|2
5980946|NCT03740009|9569726|FG000|Overall Study|Physician Decision|9
6129421|NCT00953706|9755847|FG000|Part B (96-Week Open-Label Extension)|Withdrawal by Subject|0
6129422|NCT00953706|9755848|FG001|Part B (96-Week Open-Label Extension)|Withdrawal by Subject|0
6129423|NCT00953706|9755849|FG002|Part B (96-Week Open-Label Extension)|Withdrawal by Subject|1
6129424|NCT00953706|9755850|FG003|Part B (96-Week Open-Label Extension)|Withdrawal by Subject|2
6129425|NCT00953706|9755847|FG000|Part B (96-Week Open-Label Extension)|Other|0
6129426|NCT00953706|9755848|FG001|Part B (96-Week Open-Label Extension)|Other|0
6129427|NCT00953706|9755849|FG002|Part B (96-Week Open-Label Extension)|Other|0
6129428|NCT00953706|9755850|FG003|Part B (96-Week Open-Label Extension)|Other|2
6129429|NCT00953745|9755871|FG000|Phase 1: 8 Weeks Escitalopram + Placebo|Pregnancy|1
6129430|NCT00953745|9755872|FG001|Phase 1: 8 Weeks Escitalopram + Placebo|Pregnancy|0
6129431|NCT00953745|9755871|FG000|Phase 1: 8 Weeks Escitalopram + Placebo|Withdrawal by Subject|2
6129432|NCT00953745|9755872|FG001|Phase 1: 8 Weeks Escitalopram + Placebo|Withdrawal by Subject|0
6129433|NCT00953745|9755871|FG000|Phase 1: 8 Weeks Escitalopram + Placebo|Lost to Follow-up|3
6129434|NCT00953745|9755872|FG001|Phase 1: 8 Weeks Escitalopram + Placebo|Lost to Follow-up|0
6129435|NCT00953745|9755871|FG000|Phase 1: 8 Weeks Escitalopram + Placebo|Adverse Event|1
6129436|NCT00953745|9755872|FG001|Phase 1: 8 Weeks Escitalopram + Placebo|Adverse Event|0
6129437|NCT00953745|9755871|FG000|Phase 1: 8 Weeks Escitalopram + Placebo|Screen failures|6
6129438|NCT00953745|9755872|FG001|Phase 1: 8 Weeks Escitalopram + Placebo|Screen failures|0
6129439|NCT00953745|9755871|FG000|Phase 2: 2 Weeks Escitalopram + Placebo|Pregnancy|1
6129440|NCT00953745|9755872|FG001|Phase 2: 2 Weeks Escitalopram + Placebo|Pregnancy|0
6129441|NCT00953927|9755909|FG000|Overall Study|Lost to Follow-up|61
6129442|NCT00953927|9755910|FG001|Overall Study|Lost to Follow-up|65
6129443|NCT00953927|9755909|FG000|Overall Study|Withdrawal by Subject|36
6129444|NCT00953927|9755910|FG001|Overall Study|Withdrawal by Subject|25
6129445|NCT00953927|9755909|FG000|Overall Study|Death|7
6129446|NCT00953927|9755910|FG001|Overall Study|Death|4
6129447|NCT00953927|9755909|FG000|Overall Study|Other study discontinuation|1
6129448|NCT00953927|9755910|FG001|Overall Study|Other study discontinuation|1
6129449|NCT00954122|9755920|FG000|Overall Study|Withdrawal by Subject|5
6129450|NCT00954122|9755920|FG000|Overall Study|Adverse Event|1
6129451|NCT00954122|9755920|FG000|Overall Study|Safety Reason|1
6129452|NCT00954174|9755929|FG000|Overall Study|Adverse Event|28
6129453|NCT00954174|9755930|FG001|Overall Study|Adverse Event|23
6129454|NCT00954174|9755931|FG002|Overall Study|Adverse Event|4
6129455|NCT00954174|9755932|FG003|Overall Study|Adverse Event|9
6129456|NCT00954174|9755929|FG000|Overall Study|Death|4
6129457|NCT00954174|9755930|FG001|Overall Study|Death|2
6129458|NCT00954174|9755931|FG002|Overall Study|Death|0
6129459|NCT00954174|9755932|FG003|Overall Study|Death|0
6129460|NCT00954174|9755929|FG000|Overall Study|Lack of Efficacy|32
6129461|NCT00954174|9755930|FG001|Overall Study|Lack of Efficacy|22
6129462|NCT00954174|9755931|FG002|Overall Study|Lack of Efficacy|8
6129463|NCT00954174|9755932|FG003|Overall Study|Lack of Efficacy|6
6129464|NCT00954174|9755929|FG000|Overall Study|Withdrawal by Subject|14
6129465|NCT00954174|9755930|FG001|Overall Study|Withdrawal by Subject|10
6129466|NCT00954174|9755931|FG002|Overall Study|Withdrawal by Subject|4
6129467|NCT00954174|9755932|FG003|Overall Study|Withdrawal by Subject|3
6129468|NCT00954174|9755929|FG000|Overall Study|Medical Reason|4
6129469|NCT00954174|9755930|FG001|Overall Study|Medical Reason|2
6129470|NCT00954174|9755931|FG002|Overall Study|Medical Reason|1
6129471|NCT00954174|9755932|FG003|Overall Study|Medical Reason|0
6129472|NCT00954174|9755929|FG000|Overall Study|Ineligible|40
6129473|NCT00954174|9755930|FG001|Overall Study|Ineligible|47
6129474|NCT00954174|9755931|FG002|Overall Study|Ineligible|7
6129475|NCT00954174|9755932|FG003|Overall Study|Ineligible|4
6129476|NCT00954174|9755929|FG000|Overall Study|Never Treated|4
6129477|NCT00954174|9755930|FG001|Overall Study|Never Treated|17
6129478|NCT00954174|9755931|FG002|Overall Study|Never Treated|0
6129479|NCT00954174|9755932|FG003|Overall Study|Never Treated|3
6129480|NCT00954421|9755954|FG000|Screening|screen failures|3
6129481|NCT00954421|9755954|FG000|6 Months of DBS|Withdrawal by Subject|1
6129482|NCT00954421|9755954|FG000|VIM=ON VO=OFF at 6 Months|Withdrawal by Subject|1
6129483|NCT00954447|9755962|FG000|Overall Study|Adverse Event|33
6129484|NCT00954447|9755963|FG001|Overall Study|Adverse Event|25
6129485|NCT00954447|9755962|FG000|Overall Study|Lack of Efficacy|17
6129486|NCT00954447|9755963|FG001|Overall Study|Lack of Efficacy|3
6129487|NCT00954447|9755962|FG000|Overall Study|Protocol Violation|5
6129488|NCT00954447|9755963|FG001|Overall Study|Protocol Violation|7
6129489|NCT00954447|9755962|FG000|Overall Study|Lost to Follow-up|8
6129490|NCT00954447|9755963|FG001|Overall Study|Lost to Follow-up|14
6129491|NCT00954447|9755962|FG000|Overall Study|Withdrawal by Subject|26
6129492|NCT00954447|9755963|FG001|Overall Study|Withdrawal by Subject|21
6129493|NCT00954447|9755962|FG000|Overall Study|Other|21
6129494|NCT00954447|9755963|FG001|Overall Study|Other|18
6129495|NCT00954512|9755975|FG000|Overall Study|Withdrawal by Subject|0
6220653|NCT01662492|9890035|FG000|Overall Study|Lack of Efficacy|1
5980947|NCT03740009|9569726|FG000|Overall Study|Lost to Follow-up|1
6129496|NCT00954512|9755976|FG001|Overall Study|Withdrawal by Subject|0
6129497|NCT00954512|9755977|FG002|Overall Study|Withdrawal by Subject|0
6129498|NCT00954512|9755978|FG003|Overall Study|Withdrawal by Subject|0
6129499|NCT00954512|9755979|FG004|Overall Study|Withdrawal by Subject|0
6129500|NCT00954512|9755980|FG005|Overall Study|Withdrawal by Subject|1
6129501|NCT00954512|9755975|FG000|Overall Study|Adverse Event|0
6129502|NCT00954512|9755976|FG001|Overall Study|Adverse Event|0
6129503|NCT00954512|9755977|FG002|Overall Study|Adverse Event|0
6129504|NCT00954512|9755978|FG003|Overall Study|Adverse Event|0
6129505|NCT00954512|9755979|FG004|Overall Study|Adverse Event|1
6129506|NCT00954512|9755980|FG005|Overall Study|Adverse Event|2
6129507|NCT00954512|9755975|FG000|Overall Study|Physician Decision|0
6129508|NCT00954512|9755976|FG001|Overall Study|Physician Decision|1
6129509|NCT00954512|9755977|FG002|Overall Study|Physician Decision|0
6129510|NCT00954512|9755978|FG003|Overall Study|Physician Decision|1
6129511|NCT00954512|9755979|FG004|Overall Study|Physician Decision|0
6129512|NCT00954512|9755980|FG005|Overall Study|Physician Decision|0
6129513|NCT00954512|9755975|FG000|Overall Study|Symptomatic Deterioration|0
6129514|NCT00954512|9755976|FG001|Overall Study|Symptomatic Deterioration|1
6129515|NCT00954512|9755977|FG002|Overall Study|Symptomatic Deterioration|0
6129516|NCT00954512|9755978|FG003|Overall Study|Symptomatic Deterioration|0
6129517|NCT00954512|9755979|FG004|Overall Study|Symptomatic Deterioration|2
6129518|NCT00954512|9755980|FG005|Overall Study|Symptomatic Deterioration|0
6129519|NCT00954512|9755975|FG000|Overall Study|Progression of Disease|2
6129520|NCT00954512|9755976|FG001|Overall Study|Progression of Disease|1
6129521|NCT00954512|9755977|FG002|Overall Study|Progression of Disease|0
6129522|NCT00954512|9755978|FG003|Overall Study|Progression of Disease|1
6129523|NCT00954512|9755979|FG004|Overall Study|Progression of Disease|1
6129524|NCT00954512|9755980|FG005|Overall Study|Progression of Disease|1
6220654|NCT01662492|9890036|FG001|Overall Study|Lack of Efficacy|1
6220655|NCT01662492|9890037|FG002|Overall Study|Lack of Efficacy|2
6220656|NCT01662505|9890048|FG000|Overall Study|Progressive disease|6
6220657|NCT01662505|9890049|FG001|Overall Study|Progressive disease|1
6220658|NCT01662505|9890050|FG002|Overall Study|Progressive disease|5
6220659|NCT01662505|9890048|FG000|Overall Study|Refused cont. medication|0
6220660|NCT01662505|9890049|FG001|Overall Study|Refused cont. medication|0
6220661|NCT01662505|9890050|FG002|Overall Study|Refused cont. medication|1
6220662|NCT01662505|9890048|FG000|Overall Study|Not specified above|1
6220663|NCT01662505|9890049|FG001|Overall Study|Not specified above|3
6220664|NCT01662505|9890050|FG002|Overall Study|Not specified above|2
6220665|NCT01662635|9890080|FG000|Overall Study|scarce samples for evaluation|30
6220666|NCT01662648|9890088|FG000|Overall Study|Death|1
6220667|NCT01662648|9890089|FG001|Overall Study|Death|3
6220668|NCT01662648|9890088|FG000|Overall Study|Adverse Event|40
6220669|NCT01662648|9890089|FG001|Overall Study|Adverse Event|37
6220670|NCT01662648|9890088|FG000|Overall Study|Lack of Efficacy|17
6220671|NCT01662648|9890089|FG001|Overall Study|Lack of Efficacy|16
6220672|NCT01662648|9890088|FG000|Overall Study|Participant ineligible to continue trial|1
6220673|NCT01662648|9890089|FG001|Overall Study|Participant ineligible to continue trial|1
6220674|NCT01662648|9890088|FG000|Overall Study|Lost to Follow-up|24
6220675|NCT01662648|9890089|FG001|Overall Study|Lost to Follow-up|36
6220676|NCT01662648|9890088|FG000|Overall Study|Withdrawal by Subject|36
6220677|NCT01662648|9890089|FG001|Overall Study|Withdrawal by Subject|53
6220678|NCT01662648|9890088|FG000|Overall Study|Participant non-compliant|16
6220679|NCT01662648|9890089|FG001|Overall Study|Participant non-compliant|20
6220680|NCT01662648|9890088|FG000|Overall Study|Other|8
6220681|NCT01662648|9890089|FG001|Overall Study|Other|11
6220682|NCT01662648|9890088|FG000|Overall Study|Adverse event and lack of efficacy (LOE)|3
6220683|NCT01662648|9890089|FG001|Overall Study|Adverse event and lack of efficacy (LOE)|0
6220684|NCT01662648|9890088|FG000|Overall Study|LOE and other reason unspecified|1
6220685|NCT01662648|9890089|FG001|Overall Study|LOE and other reason unspecified|0
6220686|NCT01662648|9890088|FG000|Overall Study|LOE and Participant non-compliant|0
6220687|NCT01662648|9890089|FG001|Overall Study|LOE and Participant non-compliant|1
6220688|NCT01662895|9890163|FG000|Overall Study|Lost to Follow-up|0
6220689|NCT01662895|9890164|FG001|Overall Study|Lost to Follow-up|1
6220690|NCT01662986|9890198|FG000|Overall Study|Adverse Event|5
6220691|NCT01662986|9890199|FG001|Overall Study|Adverse Event|4
6220692|NCT01662986|9890198|FG000|Overall Study|Protocol Violation|2
6220693|NCT01662986|9890199|FG001|Overall Study|Protocol Violation|3
6220694|NCT01662986|9890198|FG000|Overall Study|Lost to Follow-up|5
6220695|NCT01662986|9890199|FG001|Overall Study|Lost to Follow-up|4
6220696|NCT01662986|9890198|FG000|Overall Study|Withdrawal by Subject|2
6220697|NCT01662986|9890199|FG001|Overall Study|Withdrawal by Subject|2
6220698|NCT01662986|9890198|FG000|Overall Study|Not Treated|1
6220699|NCT01662986|9890199|FG001|Overall Study|Not Treated|0
6220700|NCT01662986|9890198|FG000|Overall Study|Other than stated above|3
6129525|NCT00954538|9755995|FG000|Part III|Withdrawal by Subject|0
6129526|NCT00954538|9755996|FG001|Part III|Withdrawal by Subject|0
6129527|NCT00954538|9755997|FG002|Part III|Withdrawal by Subject|0
6220701|NCT01662986|9890199|FG001|Overall Study|Other than stated above|0
6220702|NCT01662999|9890211|FG000|Period 3|Withdrawal by Subject|0
6220703|NCT01662999|9890212|FG001|Period 3|Withdrawal by Subject|1
6220704|NCT01662999|9890213|FG002|Period 3|Withdrawal by Subject|0
6129528|NCT00954538|9755998|FG003|Part III|Withdrawal by Subject|0
6129529|NCT00954538|9755999|FG004|Part III|Withdrawal by Subject|1
6220705|NCT01662999|9890214|FG003|Period 3|Withdrawal by Subject|0
6220706|NCT01662999|9890215|FG004|Period 3|Withdrawal by Subject|0
6220707|NCT01662999|9890216|FG005|Period 3|Withdrawal by Subject|0
6220708|NCT01663103|9890252|FG000|Overall Study|Withdrawal by Subject|1
6220709|NCT01663103|9890253|FG001|Overall Study|Withdrawal by Subject|2
6129530|NCT00954538|9756000|FG005|Part III|Withdrawal by Subject|0
6129531|NCT00954707|9756013|FG000|Overall Study|Death|34
6129532|NCT00954707|9756013|FG000|Overall Study|Withdrawal by Subject|100
6129533|NCT00954707|9756013|FG000|Overall Study|Lost to Follow-up|33
6129534|NCT00954733|9756017|FG000|Overall Study|blood gas machine did not work|1
6129535|NCT00954941|9756027|FG000|Overall Study|Received treatment at home|1
6220710|NCT01663103|9890252|FG000|Overall Study|Adverse Event|1
6220711|NCT01663103|9890253|FG001|Overall Study|Adverse Event|0
6220712|NCT01663103|9890252|FG000|Overall Study|dog bite|1
6220713|NCT01663103|9890253|FG001|Overall Study|dog bite|0
6220714|NCT01663233|9890265|FG000|Overall Study|Withdrawal by Subject|3
6220715|NCT01663233|9890266|FG001|Overall Study|Withdrawal by Subject|2
6220716|NCT01663233|9890265|FG000|Overall Study|Protocol Deviation|1
6220717|NCT01663233|9890266|FG001|Overall Study|Protocol Deviation|4
6220718|NCT01663233|9890265|FG000|Overall Study|Lost to Follow-up|0
6220719|NCT01663233|9890266|FG001|Overall Study|Lost to Follow-up|1
6220720|NCT01663402|9890288|FG000|Overall Study|Randomized but not treated|19
6220721|NCT01663402|9890289|FG001|Overall Study|Randomized but not treated|11
6220722|NCT01663402|9890288|FG000|Overall Study|Adverse Event|347
6220723|NCT01663402|9890289|FG001|Overall Study|Adverse Event|362
6220724|NCT01663402|9890288|FG000|Overall Study|Two consecutive LDL-C <15 mg/dL|0
6220725|NCT01663402|9890289|FG001|Overall Study|Two consecutive LDL-C <15 mg/dL|730
6220726|NCT01663402|9890288|FG000|Overall Study|Poor compliance to protocol|529
6220727|NCT01663402|9890289|FG001|Overall Study|Poor compliance to protocol|454
6220728|NCT01663402|9890288|FG000|Overall Study|Physician Decision|77
6220729|NCT01663402|9890289|FG001|Overall Study|Physician Decision|62
6220730|NCT01663402|9890288|FG000|Overall Study|Site terminated by sponsor|1
6220731|NCT01663402|9890289|FG001|Overall Study|Site terminated by sponsor|3
6220732|NCT01663402|9890288|FG000|Overall Study|Participant moved|139
6220733|NCT01663402|9890289|FG001|Overall Study|Participant moved|104
6220734|NCT01663402|9890288|FG000|Overall Study|Withdrawal by Subject|118
6220735|NCT01663402|9890289|FG001|Overall Study|Withdrawal by Subject|91
6220736|NCT01663402|9890288|FG000|Overall Study|Related to study drug administration|96
6220737|NCT01663402|9890289|FG001|Overall Study|Related to study drug administration|105
6220738|NCT01663402|9890288|FG000|Overall Study|Lost to Follow-up|17
6220739|NCT01663402|9890289|FG001|Overall Study|Lost to Follow-up|15
6220740|NCT01663402|9890288|FG000|Overall Study|Other than specified above|172
6220741|NCT01663402|9890289|FG001|Overall Study|Other than specified above|147
6220742|NCT01663506|9890295|FG000|Overall Study|Lack of Efficacy|3
6220743|NCT01663506|9890295|FG000|Overall Study|Consent Withdrawal by Subject|1
6220744|NCT01663506|9890295|FG000|Overall Study|Lost to Follow-up|1
6220745|NCT01663506|9890295|FG000|Overall Study|Adverse Event|1
6220746|NCT01663506|9890295|FG000|Overall Study|Switched to Subcutaneous Tocilizumab|2
6220747|NCT01663532|9890301|FG000|Overall Study|Lost to Follow-up|9
6220748|NCT01663532|9890302|FG001|Overall Study|Lost to Follow-up|10
6220749|NCT01663532|9890301|FG000|Overall Study|Adverse Event|7
6220750|NCT01663532|9890302|FG001|Overall Study|Adverse Event|13
6220751|NCT01663532|9890301|FG000|Overall Study|Met Withdrawal Criteria|7
6220752|NCT01663532|9890302|FG001|Overall Study|Met Withdrawal Criteria|6
6220753|NCT01663532|9890301|FG000|Overall Study|Physician Decision|1
6220754|NCT01663532|9890302|FG001|Overall Study|Physician Decision|1
6220755|NCT01663532|9890301|FG000|Overall Study|Withdrawal by Subject|35
6220756|NCT01663532|9890302|FG001|Overall Study|Withdrawal by Subject|17
6220757|NCT01663532|9890301|FG000|Overall Study|Lack of Efficacy|15
6220758|NCT01663532|9890302|FG001|Overall Study|Lack of Efficacy|60
6220759|NCT01663623|9890310|FG000|Overall Study|Adverse Event|3
6220760|NCT01663623|9890311|FG001|Overall Study|Adverse Event|7
6220761|NCT01663623|9890310|FG000|Overall Study|Lack of Efficacy|5
6220762|NCT01663623|9890311|FG001|Overall Study|Lack of Efficacy|6
6220763|NCT01663623|9890310|FG000|Overall Study|Protocol Violation|0
6220764|NCT01663623|9890311|FG001|Overall Study|Protocol Violation|1
6220765|NCT01663623|9890310|FG000|Overall Study|Other-Study closed/terminated|1
6220766|NCT01663623|9890311|FG001|Overall Study|Other-Study closed/terminated|1
6220767|NCT01663623|9890310|FG000|Overall Study|Physician Decision|1
6220768|NCT01663623|9890311|FG001|Overall Study|Physician Decision|4
6220769|NCT01663623|9890310|FG000|Overall Study|Withdrawal by Subject|2
6220770|NCT01663623|9890311|FG001|Overall Study|Withdrawal by Subject|1
6220771|NCT01663636|9890319|FG000|Infant SMS Reminder Feasibility Study|Lost to Follow-up|25
6220772|NCT01663636|9890320|FG001|Infant SMS Reminder Feasibility Study|Lost to Follow-up|31
6220773|NCT01663714|9890326|FG000|Dosimetric and Therapeutic Treatment|Lost to Follow-up|3
6220774|NCT01663714|9890326|FG000|Dosimetric and Therapeutic Treatment|Progressive Disease|11
6220775|NCT01663714|9890326|FG000|Dosimetric and Therapeutic Treatment|Rolled Over to Study BEX104528|16
6220776|NCT01663714|9890326|FG000|Long-Term Follow-Up|Lost to Follow-up|1
6220777|NCT01663714|9890326|FG000|Long-Term Follow-Up|Death|4
6220778|NCT01663714|9890326|FG000|Long-Term Follow-Up|Non-compliance|1
6220779|NCT01663727|9890334|FG000|Overall Study|Death|161
6220780|NCT01663727|9890335|FG001|Overall Study|Death|155
6220781|NCT01663727|9890334|FG000|Overall Study|Lost to Follow-up|10
6220782|NCT01663727|9890335|FG001|Overall Study|Lost to Follow-up|8
6220783|NCT01663727|9890334|FG000|Overall Study|Withdrawal by Subject|18
6220784|NCT01663727|9890335|FG001|Overall Study|Withdrawal by Subject|25
6220785|NCT01663727|9890334|FG000|Overall Study|Study Terminated|51
6220786|NCT01663727|9890335|FG001|Overall Study|Study Terminated|50
6129536|NCT00954941|9756028|FG001|Overall Study|Received treatment at home|0
6129537|NCT00954941|9756027|FG000|Overall Study|Withdrawal by Subject|1
6129538|NCT00954941|9756028|FG001|Overall Study|Withdrawal by Subject|0
6129539|NCT00954941|9756027|FG000|Overall Study|Insurance Denial|2
6129540|NCT00954941|9756028|FG001|Overall Study|Insurance Denial|2
6129541|NCT00954941|9756027|FG000|Overall Study|Physician Decision|2
6129542|NCT00954941|9756028|FG001|Overall Study|Physician Decision|2
6129543|NCT00954941|9756027|FG000|Overall Study|Ineligible|2
6129544|NCT00954941|9756028|FG001|Overall Study|Ineligible|2
6220787|NCT01663727|9890334|FG000|Overall Study|Withdrawal by subject and Adverse Event.|1
6220788|NCT01663727|9890335|FG001|Overall Study|Withdrawal by subject and Adverse Event.|0
6220789|NCT01663727|9890334|FG000|Overall Study|Withdrawal prior to dosing.|1
6220790|NCT01663727|9890335|FG001|Overall Study|Withdrawal prior to dosing.|0
6220791|NCT01663740|9890343|FG000|Overall Study|Lost to Follow-up|1
6220792|NCT01663740|9890344|FG001|Overall Study|Lost to Follow-up|4
6220793|NCT01663740|9890343|FG000|Overall Study|Other|9
6220794|NCT01663740|9890344|FG001|Overall Study|Other|2
6220795|NCT01663740|9890343|FG000|Overall Study|Inclusion/Exclusion not met|1
6220796|NCT01663740|9890344|FG001|Overall Study|Inclusion/Exclusion not met|0
6220797|NCT01663740|9890343|FG000|Overall Study|Death|0
6220798|NCT01663740|9890344|FG001|Overall Study|Death|1
6220799|NCT01663740|9890343|FG000|Overall Study|Withdrawal by Subject|2
6220800|NCT01663740|9890344|FG001|Overall Study|Withdrawal by Subject|1
6220801|NCT01663740|9890343|FG000|Overall Study|No end of study status|3
6220802|NCT01663740|9890344|FG001|Overall Study|No end of study status|0
6220803|NCT01663857|9890363|FG000|Overall Study|Withdrew Consent to Study Participation|0
6220804|NCT01663857|9890364|FG001|Overall Study|Withdrew Consent to Study Participation|1
6220805|NCT01663857|9890365|FG002|Overall Study|Withdrew Consent to Study Participation|7
6220806|NCT01663857|9890366|FG003|Overall Study|Withdrew Consent to Study Participation|3
6220807|NCT01663857|9890363|FG000|Overall Study|Lost to Follow-up|0
6220808|NCT01663857|9890364|FG001|Overall Study|Lost to Follow-up|0
6220809|NCT01663857|9890365|FG002|Overall Study|Lost to Follow-up|3
6220810|NCT01663857|9890366|FG003|Overall Study|Lost to Follow-up|1
6220811|NCT01663896|9890382|FG000|Overall Study|Various reasons|43
6220812|NCT01663987|9890399|FG000|Overall Study|Adverse Event|7
6220813|NCT01663987|9890400|FG001|Overall Study|Adverse Event|2
6220814|NCT01663987|9890399|FG000|Overall Study|Lost to Follow-up|1
6220815|NCT01663987|9890400|FG001|Overall Study|Lost to Follow-up|1
6220816|NCT01663987|9890399|FG000|Overall Study|Withdrawal by Subject|2
6220817|NCT01663987|9890400|FG001|Overall Study|Withdrawal by Subject|3
6220818|NCT01663987|9890399|FG000|Overall Study|Other reason not defined above|3
6220819|NCT01663987|9890400|FG001|Overall Study|Other reason not defined above|0
6220820|NCT01664039|9890408|FG000|Overall Study|Adverse Event|3
6220821|NCT01664039|9890409|FG001|Overall Study|Adverse Event|4
6220822|NCT01664039|9890408|FG000|Overall Study|Lost to Follow-up|1
6220823|NCT01664039|9890409|FG001|Overall Study|Lost to Follow-up|1
6220824|NCT01664039|9890408|FG000|Overall Study|Withdrawal by Subject|1
6129545|NCT00954941|9756027|FG000|Overall Study|Adverse Event|0
6129546|NCT00954941|9756028|FG001|Overall Study|Adverse Event|1
6129547|NCT00955110|9756058|FG000|Qualification Phase|Did not meet eligibility criteria|24
6129548|NCT00955110|9756058|FG000|Treatment Phase|Adverse Event|2
6129549|NCT00955110|9756058|FG000|Treatment Phase|Administrative reasons|2
6129550|NCT00955110|9756058|FG000|Treatment Phase|Non-compliance with study restrictions|1
6129551|NCT00955110|9756058|FG000|Treatment Phase|Withdrawn by physician pre-treatment|1
6129552|NCT00955279|9756114|FG000|Overall Study|Other|0
6129553|NCT00955279|9756115|FG001|Overall Study|Other|0
6129554|NCT00955279|9756116|FG002|Overall Study|Other|3
6129555|NCT00955279|9756114|FG000|Overall Study|Death|1
6129556|NCT00955279|9756115|FG001|Overall Study|Death|1
6129557|NCT00955279|9756116|FG002|Overall Study|Death|1
6129558|NCT00955279|9756114|FG000|Overall Study|Lost to Follow-up|0
6129559|NCT00955279|9756115|FG001|Overall Study|Lost to Follow-up|3
6129560|NCT00955279|9756116|FG002|Overall Study|Lost to Follow-up|1
6129561|NCT00955279|9756114|FG000|Overall Study|Withdrawal by Subject|2
6129562|NCT00955279|9756115|FG001|Overall Study|Withdrawal by Subject|0
6129563|NCT00955279|9756116|FG002|Overall Study|Withdrawal by Subject|3
6129564|NCT00955305|9756126|FG000|Overall Study|Disease progression|39
6129565|NCT00955305|9756127|FG001|Overall Study|Disease progression|41
6129566|NCT00955305|9756126|FG000|Overall Study|Adverse Event|22
6129567|NCT00955305|9756127|FG001|Overall Study|Adverse Event|22
6129568|NCT00955305|9756126|FG000|Overall Study|Death|2
6129569|NCT00955305|9756127|FG001|Overall Study|Death|1
6129570|NCT00955305|9756126|FG000|Overall Study|Withdrawal by Subject|5
6129571|NCT00955305|9756127|FG001|Overall Study|Withdrawal by Subject|4
6220825|NCT01664039|9890409|FG001|Overall Study|Withdrawal by Subject|3
6220826|NCT01664039|9890408|FG000|Overall Study|Noncompliance|1
6129572|NCT00955305|9756126|FG000|Overall Study|Alternative therapy|4
6129573|NCT00955305|9756127|FG001|Overall Study|Alternative therapy|0
6129574|NCT00955305|9756126|FG000|Overall Study|Other complicating disease|2
6129575|NCT00955305|9756127|FG001|Overall Study|Other complicating disease|4
6220827|NCT01664039|9890409|FG001|Overall Study|Noncompliance|1
6220828|NCT01664052|9890417|FG000|Phase 1|No device placement|6
6220829|NCT01664052|9890418|FG001|Phase 1|No device placement|0
6129576|NCT00955305|9756126|FG000|Overall Study|Physician Decision|1
6129577|NCT00955305|9756127|FG001|Overall Study|Physician Decision|0
6129578|NCT00955305|9756126|FG000|Overall Study|Continued presence of residual disease|0
6129579|NCT00955305|9756127|FG001|Overall Study|Continued presence of residual disease|1
6220830|NCT01664052|9890417|FG000|Phase 1|No HSG 1 hr post placement|1
6220831|NCT01664052|9890418|FG001|Phase 1|No HSG 1 hr post placement|0
6220832|NCT01664052|9890417|FG000|Phase 2|No device placement|0
6220833|NCT01664052|9890418|FG001|Phase 2|No device placement|4
6220834|NCT01664078|9890425|FG000|Overall Study|Death|9
6220835|NCT01664078|9890425|FG000|Overall Study|Withdrawal by Subject|4
6220836|NCT01664078|9890425|FG000|Overall Study|Lost to Follow-up|2
6220837|NCT01664078|9890425|FG000|Overall Study|missed 5 year visit|1
6220838|NCT01664078|9890425|FG000|Overall Study|Other|53
6220839|NCT01664091|9890475|FG000|Overall Study|Death|1
6220840|NCT01664091|9890475|FG000|Overall Study|Disease Progression|2
6220841|NCT01664091|9890475|FG000|Overall Study|Lost to Follow-up|2
6220842|NCT01664091|9890475|FG000|Overall Study|Withdrawal by Subject|1
6220843|NCT01664104|9890480|FG000|Overall Study|Adverse Event|6
6220844|NCT01664104|9890480|FG000|Overall Study|Lack of Efficacy|2
6220845|NCT01664104|9890480|FG000|Overall Study|Withdrawal by Subject|1
6220846|NCT01664104|9890480|FG000|Overall Study|Lost to Follow-up|4
6220847|NCT01664104|9890480|FG000|Overall Study|Other|1
6220848|NCT01664104|9890480|FG000|Overall Study|Unknown: Reason Unrelated to TCZ|2
6220849|NCT01664130|9890493|FG000|Overall Study|competing secondary disease|2
6220850|NCT01664247|9890502|FG000|Overall Study|Adverse Event|5
6220851|NCT01664247|9890503|FG001|Overall Study|Adverse Event|3
6220852|NCT01664247|9890502|FG000|Overall Study|Protocol Violation|3
6220853|NCT01664247|9890503|FG001|Overall Study|Protocol Violation|5
6220854|NCT01664247|9890502|FG000|Overall Study|Withdrawal Criteria|1
6220855|NCT01664247|9890503|FG001|Overall Study|Withdrawal Criteria|4
6220856|NCT01664247|9890502|FG000|Overall Study|Unclassified|5
6220857|NCT01664247|9890503|FG001|Overall Study|Unclassified|29
6220858|NCT01664494|9890509|FG000|Overall Study|Withdrawal by Subject|27
6220859|NCT01664494|9890509|FG000|Overall Study|Death|18
6220860|NCT01664494|9890509|FG000|Overall Study|Other|49
6220861|NCT01664494|9890509|FG000|Overall Study|Lost to Follow-up|99
6220862|NCT01664533|9890513|FG000|Overall Study|Death|42
6220863|NCT01664533|9890513|FG000|Overall Study|Lost to Follow-up|3
6220864|NCT01664533|9890513|FG000|Overall Study|Study termination|9
6220865|NCT01664533|9890513|FG000|Overall Study|Protocol Violation|3
6220866|NCT01664624|9890531|FG000|Overall Study|Adverse Event|0
6220867|NCT01664624|9890532|FG001|Overall Study|Adverse Event|1
6220868|NCT01664624|9890533|FG002|Overall Study|Adverse Event|0
6220869|NCT01664624|9890534|FG003|Overall Study|Adverse Event|0
6220870|NCT01664923|9890598|FG000|Period1:Double Blind Phase-29 Months|Death|8
6220871|NCT01664923|9890599|FG001|Period1:Double Blind Phase-29 Months|Death|6
6220872|NCT01664923|9890598|FG000|Period1:Double Blind Phase-29 Months|Lost to Follow-up|0
6220873|NCT01664923|9890599|FG001|Period1:Double Blind Phase-29 Months|Lost to Follow-up|1
6220874|NCT01664923|9890598|FG000|Period1:Double Blind Phase-29 Months|Protocol Violation|2
6220875|NCT01664923|9890599|FG001|Period1:Double Blind Phase-29 Months|Protocol Violation|0
6220876|NCT01664923|9890598|FG000|Period1:Double Blind Phase-29 Months|Withdrawal by Subject|12
6220877|NCT01664923|9890599|FG001|Period1:Double Blind Phase-29 Months|Withdrawal by Subject|8
6220878|NCT01664923|9890598|FG000|Period1:Double Blind Phase-29 Months|Disease Progression|65
6220879|NCT01664923|9890599|FG001|Period1:Double Blind Phase-29 Months|Disease Progression|132
6220880|NCT01664923|9890598|FG000|Period1:Double Blind Phase-29 Months|Adverse Event|14
6220881|NCT01664923|9890599|FG001|Period1:Double Blind Phase-29 Months|Adverse Event|9
6220882|NCT01664923|9890598|FG000|Period1:Double Blind Phase-29 Months|Other|3
6220883|NCT01664923|9890599|FG001|Period1:Double Blind Phase-29 Months|Other|4
6220884|NCT01664923|9890598|FG000|Period1:Double Blind Phase-29 Months|Randomized, But Not treated|1
6220885|NCT01664923|9890599|FG001|Period1:Double Blind Phase-29 Months|Randomized, But Not treated|0
6220886|NCT01664923|9890598|FG000|Period 2: Open-label Phase-36 Months|Death|3
6220887|NCT01664923|9890599|FG001|Period 2: Open-label Phase-36 Months|Death|1
6220888|NCT01664923|9890598|FG000|Period 2: Open-label Phase-36 Months|On Treatment|1
6220889|NCT01664923|9890599|FG001|Period 2: Open-label Phase-36 Months|On Treatment|1
6220890|NCT01664923|9890598|FG000|Period 2: Open-label Phase-36 Months|Disease progression|28
6220891|NCT01664923|9890599|FG001|Period 2: Open-label Phase-36 Months|Disease progression|9
6220892|NCT01664923|9890598|FG000|Period 2: Open-label Phase-36 Months|Other|3
6220893|NCT01664923|9890599|FG001|Period 2: Open-label Phase-36 Months|Other|1
6220894|NCT01664923|9890598|FG000|Period 2: Open-label Phase-36 Months|Adverse Event|4
6220895|NCT01664923|9890599|FG001|Period 2: Open-label Phase-36 Months|Adverse Event|7
6220896|NCT01664923|9890598|FG000|Period 2: Open-label Phase-36 Months|Withdrawal by Subject|2
6220897|NCT01664923|9890599|FG001|Period 2: Open-label Phase-36 Months|Withdrawal by Subject|4
6220898|NCT01664949|9890611|FG000|Overall Study|Adverse Event|11
6220899|NCT01664949|9890612|FG001|Overall Study|Adverse Event|12
6220900|NCT01664949|9890611|FG000|Overall Study|Lack of Efficacy|1
6220901|NCT01664949|9890612|FG001|Overall Study|Lack of Efficacy|1
6220902|NCT01664949|9890611|FG000|Overall Study|Lost to Follow-up|1
6220903|NCT01664949|9890612|FG001|Overall Study|Lost to Follow-up|2
6129580|NCT00955305|9756126|FG000|Overall Study|Functional decline|2
6220904|NCT01664949|9890611|FG000|Overall Study|Personal Reasons|3
6129581|NCT00955305|9756127|FG001|Overall Study|Functional decline|0
6129582|NCT00955305|9756126|FG000|Overall Study|Maximum response achieved|0
6129583|NCT00955305|9756127|FG001|Overall Study|Maximum response achieved|1
6129584|NCT00955305|9756126|FG000|Overall Study|Lost to Follow-up|0
6129585|NCT00955305|9756127|FG001|Overall Study|Lost to Follow-up|1
6129586|NCT00955305|9756126|FG000|Overall Study|No off-treatment reason submitted|1
6220905|NCT01664949|9890612|FG001|Overall Study|Personal Reasons|4
6220906|NCT01664949|9890611|FG000|Overall Study|Protocol Violation|5
6220907|NCT01664949|9890612|FG001|Overall Study|Protocol Violation|5
6220908|NCT01664949|9890611|FG000|Overall Study|Other Miscellaneous Reasons|3
6220909|NCT01664949|9890612|FG001|Overall Study|Other Miscellaneous Reasons|1
6220910|NCT01665430|9890686|FG000|Overall Study|Adverse Event|1
6220911|NCT01665430|9890686|FG000|Overall Study|Withdrawal by Subject|6
6220912|NCT01665430|9890686|FG000|Overall Study|Other Unspecified|2
6220913|NCT01665599|9890699|FG000|Overall Study|Adverse Event|1
6220914|NCT01665599|9890699|FG000|Overall Study|Consent Withdrawn|1
6220915|NCT01665599|9890699|FG000|Overall Study|Investigator/Sponsor decision|1
6220916|NCT01665599|9890699|FG000|Overall Study|Death|1
6220917|NCT01665599|9890699|FG000|Overall Study|Lost to Follow-up|2
6220918|NCT01665599|9890699|FG000|Overall Study|Participant Left for More Than 3 Months|1
6220919|NCT01665599|9890699|FG000|Overall Study|Could Not Continue Due to Time Constrain|1
6220920|NCT01665768|9890703|FG000|Overall Study|Adverse Event|3
6220921|NCT01665768|9890703|FG000|Overall Study|Lack of Efficacy|19
6220922|NCT01665768|9890703|FG000|Overall Study|Withdrawal by Subject|1
6220923|NCT01665807|9890710|FG000|Overall Study|Withdrawal by Subject|2
6220924|NCT01665807|9890711|FG001|Overall Study|Withdrawal by Subject|0
6220925|NCT01665807|9890712|FG002|Overall Study|Withdrawal by Subject|1
6220926|NCT01665911|9890729|FG000|Overall Study|Protocol Violation|4
6220927|NCT01665911|9890729|FG000|Overall Study|Withdrawal by Subject|1
6220928|NCT01665911|9890729|FG000|Overall Study|Adverse Event|1
6220929|NCT01666002|9890749|FG000|Overall Study|Lost to Follow-up|5
6220930|NCT01666002|9890750|FG001|Overall Study|Lost to Follow-up|0
6220931|NCT01666119|9890757|FG000|Overall Study|Adverse Event|6
6220932|NCT01666119|9890757|FG000|Overall Study|Withdrawal by Subject|16
6220933|NCT01666119|9890757|FG000|Overall Study|Lost to Follow-up|7
6220934|NCT01666119|9890757|FG000|Overall Study|non compliance with study medication, pa|18
6220935|NCT01666119|9890757|FG000|Overall Study|Subject experiencing withdrawal symptoms|5
6220936|NCT01666314|9890787|FG000|Overall Study|Adverse Event|3
6220937|NCT01666314|9890788|FG001|Overall Study|Adverse Event|13
6220938|NCT01666314|9890789|FG002|Overall Study|Adverse Event|7
6220939|NCT01666314|9890790|FG003|Overall Study|Adverse Event|7
6220940|NCT01666314|9890787|FG000|Overall Study|Progressive Disease|11
6220941|NCT01666314|9890788|FG001|Overall Study|Progressive Disease|9
6220942|NCT01666314|9890789|FG002|Overall Study|Progressive Disease|19
6220943|NCT01666314|9890790|FG003|Overall Study|Progressive Disease|20
6220944|NCT01666314|9890787|FG000|Overall Study|Symptomatic Deterioration|1
6220945|NCT01666314|9890788|FG001|Overall Study|Symptomatic Deterioration|0
6220946|NCT01666314|9890789|FG002|Overall Study|Symptomatic Deterioration|2
6220947|NCT01666314|9890790|FG003|Overall Study|Symptomatic Deterioration|0
6220948|NCT01666314|9890787|FG000|Overall Study|Unsatisfactory Therapeutic Response|7
6220949|NCT01666314|9890788|FG001|Overall Study|Unsatisfactory Therapeutic Response|2
6220950|NCT01666314|9890789|FG002|Overall Study|Unsatisfactory Therapeutic Response|1
6220951|NCT01666314|9890790|FG003|Overall Study|Unsatisfactory Therapeutic Response|1
6220952|NCT01666314|9890787|FG000|Overall Study|Withdrawal by Subject|1
6220953|NCT01666314|9890788|FG001|Overall Study|Withdrawal by Subject|1
6220954|NCT01666314|9890789|FG002|Overall Study|Withdrawal by Subject|2
6220955|NCT01666314|9890790|FG003|Overall Study|Withdrawal by Subject|3
6220956|NCT01666314|9890787|FG000|Overall Study|Reason not Specified|10
6220957|NCT01666314|9890788|FG001|Overall Study|Reason not Specified|7
6220958|NCT01666314|9890789|FG002|Overall Study|Reason not Specified|5
6220959|NCT01666314|9890790|FG003|Overall Study|Reason not Specified|5
6220960|NCT01666444|9890813|FG000|Overall Study|Did not initiate treatment|2
6220961|NCT01666444|9890814|FG001|Overall Study|Did not initiate treatment|1
6220962|NCT01666652|9890825|FG000|Overall Study|Serious Adverse Event|0
6220963|NCT01666652|9890826|FG001|Overall Study|Serious Adverse Event|0
6220964|NCT01666652|9890827|FG002|Overall Study|Serious Adverse Event|0
6220965|NCT01666652|9890828|FG003|Overall Study|Serious Adverse Event|1
6220966|NCT01666652|9890829|FG004|Overall Study|Serious Adverse Event|0
6220967|NCT01666652|9890825|FG000|Overall Study|Withdrawal by Subject|0
6220968|NCT01666652|9890826|FG001|Overall Study|Withdrawal by Subject|0
6220969|NCT01666652|9890827|FG002|Overall Study|Withdrawal by Subject|0
6220970|NCT01666652|9890828|FG003|Overall Study|Withdrawal by Subject|0
6220971|NCT01666652|9890829|FG004|Overall Study|Withdrawal by Subject|1
6220972|NCT01666652|9890825|FG000|Overall Study|Moved from study area|1
6220973|NCT01666652|9890826|FG001|Overall Study|Moved from study area|0
6220974|NCT01666652|9890827|FG002|Overall Study|Moved from study area|0
6220975|NCT01666652|9890828|FG003|Overall Study|Moved from study area|2
6220976|NCT01666652|9890829|FG004|Overall Study|Moved from study area|0
6220977|NCT01666652|9890825|FG000|Overall Study|Lost to Follow-up|1
6220978|NCT01666652|9890826|FG001|Overall Study|Lost to Follow-up|1
6220979|NCT01666652|9890827|FG002|Overall Study|Lost to Follow-up|1
6129587|NCT00955305|9756127|FG001|Overall Study|No off-treatment reason submitted|0
6129588|NCT00955305|9756126|FG000|Overall Study|Never started protocol treatment|5
6129589|NCT00955305|9756127|FG001|Overall Study|Never started protocol treatment|5
6129590|NCT00955305|9756126|FG000|Overall Study|Ineligible|5
6129591|NCT00955305|9756127|FG001|Overall Study|Ineligible|7
6129592|NCT00955357|9756135|FG000|Titration Phase|Adverse Event|9
6129593|NCT00955357|9756136|FG001|Titration Phase|Adverse Event|46
6129594|NCT00955357|9756135|FG000|Titration Phase|Lack of Efficacy|0
6129595|NCT00955357|9756136|FG001|Titration Phase|Lack of Efficacy|2
6129596|NCT00955357|9756135|FG000|Titration Phase|Protocol Violation|3
6129597|NCT00955357|9756136|FG001|Titration Phase|Protocol Violation|7
6129598|NCT00955357|9756135|FG000|Titration Phase|Lost to Follow-up|1
6129599|NCT00955357|9756136|FG001|Titration Phase|Lost to Follow-up|3
6129600|NCT00955357|9756135|FG000|Titration Phase|Withdrawal by Subject|3
6129601|NCT00955357|9756136|FG001|Titration Phase|Withdrawal by Subject|5
6129602|NCT00955357|9756135|FG000|Titration Phase|Prohibited Antiepileptic Drug change|0
6129603|NCT00955357|9756136|FG001|Titration Phase|Prohibited Antiepileptic Drug change|1
6129604|NCT00955357|9756135|FG000|Titration Phase|Study medication not tolerated|0
6129605|NCT00955357|9756136|FG001|Titration Phase|Study medication not tolerated|1
6129606|NCT00955357|9756135|FG000|Titration Phase|Non compliance to study procedures|0
6129607|NCT00955357|9756136|FG001|Titration Phase|Non compliance to study procedures|1
6129608|NCT00955357|9756135|FG000|Maintenance Phase|Adverse Event|3
6129609|NCT00955357|9756136|FG001|Maintenance Phase|Adverse Event|23
6129610|NCT00955357|9756135|FG000|Maintenance Phase|Lack of Efficacy|0
6129611|NCT00955357|9756136|FG001|Maintenance Phase|Lack of Efficacy|4
6129612|NCT00955357|9756135|FG000|Maintenance Phase|Protocol Violation|2
6129613|NCT00955357|9756136|FG001|Maintenance Phase|Protocol Violation|6
6129614|NCT00955357|9756135|FG000|Maintenance Phase|Lost to Follow-up|2
6129615|NCT00955357|9756136|FG001|Maintenance Phase|Lost to Follow-up|7
6129616|NCT00955357|9756135|FG000|Maintenance Phase|Withdrawal by Subject|4
6129617|NCT00955357|9756136|FG001|Maintenance Phase|Withdrawal by Subject|4
6220980|NCT01666652|9890828|FG003|Overall Study|Lost to Follow-up|1
6220981|NCT01666652|9890829|FG004|Overall Study|Lost to Follow-up|0
6220982|NCT01666730|9890841|FG000|Overall Study|Adverse Event|16
6220983|NCT01666730|9890841|FG000|Overall Study|Death|2
6220984|NCT01666730|9890841|FG000|Overall Study|Physician Decision|5
6220985|NCT01666730|9890841|FG000|Overall Study|Withdrawal by Subject|9
6220986|NCT01666730|9890841|FG000|Overall Study|Disease progression/relapse|18
6220987|NCT01666782|9890847|FG000|Overall Study|Received 2 doses of vaccine|0
6220988|NCT01666782|9890848|FG001|Overall Study|Received 2 doses of vaccine|1
6220989|NCT01666782|9890847|FG000|Overall Study|Enrolled both years; year 1 data used|4
6220990|NCT01666782|9890848|FG001|Overall Study|Enrolled both years; year 1 data used|0
6220991|NCT01666951|9890865|FG000|Overall Study|Not dosed|1
6220992|NCT01666951|9890866|FG001|Overall Study|Not dosed|1
6220993|NCT01667107|9890881|FG000|Overall Study|Adverse Event|4
6220994|NCT01667107|9890882|FG001|Overall Study|Adverse Event|3
6220995|NCT01667107|9890881|FG000|Overall Study|Tolerability issues|0
6220996|NCT01667107|9890882|FG001|Overall Study|Tolerability issues|2
6220997|NCT01667107|9890881|FG000|Overall Study|Protocol Violation|0
6220998|NCT01667107|9890882|FG001|Overall Study|Protocol Violation|1
6220999|NCT01667107|9890881|FG000|Overall Study|Lack of Efficacy|0
6221000|NCT01667107|9890882|FG001|Overall Study|Lack of Efficacy|1
6221001|NCT01667224|9890890|FG000|Overall Study|Withdrawal by Subject|3
6221002|NCT01667224|9890891|FG001|Overall Study|Withdrawal by Subject|1
6221003|NCT01667224|9890890|FG000|Overall Study|Protocol Violation|1
6221004|NCT01667224|9890891|FG001|Overall Study|Protocol Violation|1
6289056|NCT02377362|10003665|FG003|Part A Third Treatment|Highest dose level 1200 not used|4
6289057|NCT02377362|10003666|FG004|Part A Third Treatment|Highest dose level 1200 not used|3
6289058|NCT02377362|10003667|FG005|Part A Third Treatment|Highest dose level 1200 not used|4
6289059|NCT02377362|10003668|FG006|Part A Third Treatment|Highest dose level 1200 not used|0
6289060|NCT02377362|10003669|FG007|Part A Third Treatment|Highest dose level 1200 not used|0
6289061|NCT02377362|10003670|FG008|Part A Third Treatment|Highest dose level 1200 not used|0
6289062|NCT02377362|10003671|FG009|Part A Third Treatment|Highest dose level 1200 not used|0
6289063|NCT02377362|10003672|FG010|Part A Third Treatment|Highest dose level 1200 not used|0
6289064|NCT02377362|10003673|FG011|Part A Third Treatment|Highest dose level 1200 not used|0
6289065|NCT02377362|10003674|FG012|Part A Third Treatment|Highest dose level 1200 not used|0
6289066|NCT02377362|10003662|FG000|Part B Overall|Protocol Violation|0
6289067|NCT02377362|10003663|FG001|Part B Overall|Protocol Violation|0
6289068|NCT02377362|10003664|FG002|Part B Overall|Protocol Violation|0
6289069|NCT02377362|10003665|FG003|Part B Overall|Protocol Violation|0
6289070|NCT02377362|10003666|FG004|Part B Overall|Protocol Violation|0
6289071|NCT02377362|10003667|FG005|Part B Overall|Protocol Violation|0
6289072|NCT02377362|10003668|FG006|Part B Overall|Protocol Violation|0
6289073|NCT02377362|10003669|FG007|Part B Overall|Protocol Violation|0
6289074|NCT02377362|10003670|FG008|Part B Overall|Protocol Violation|0
6289075|NCT02377362|10003671|FG009|Part B Overall|Protocol Violation|1
6289076|NCT02377362|10003672|FG010|Part B Overall|Protocol Violation|0
6289077|NCT02377362|10003673|FG011|Part B Overall|Protocol Violation|0
6129618|NCT00955357|9756135|FG000|Maintenance Phase|Patient moving out of area|0
6289078|NCT02377362|10003674|FG012|Part B Overall|Protocol Violation|0
6289079|NCT02377362|10003662|FG000|Part B Overall|Adverse Event|0
6289080|NCT02377362|10003663|FG001|Part B Overall|Adverse Event|0
6289081|NCT02377362|10003664|FG002|Part B Overall|Adverse Event|0
6129619|NCT00955357|9756136|FG001|Maintenance Phase|Patient moving out of area|1
6129620|NCT00955357|9756135|FG000|Maintenance Phase|Non compliance to study procedures|1
6129621|NCT00955357|9756136|FG001|Maintenance Phase|Non compliance to study procedures|0
6129622|NCT00955409|9756152|FG000|Overall Study|Lack of Efficacy|1
6129623|NCT00955409|9756153|FG001|Overall Study|Lack of Efficacy|0
6129624|NCT00955409|9756154|FG002|Overall Study|Lack of Efficacy|0
6129625|NCT00955409|9756155|FG003|Overall Study|Lack of Efficacy|0
6129626|NCT00955409|9756156|FG004|Overall Study|Lack of Efficacy|0
6129627|NCT00955409|9756157|FG005|Overall Study|Lack of Efficacy|0
6129628|NCT00955409|9756158|FG006|Overall Study|Lack of Efficacy|0
6129629|NCT00955409|9756159|FG007|Overall Study|Lack of Efficacy|0
6129630|NCT00955409|9756160|FG008|Overall Study|Lack of Efficacy|0
6129631|NCT00955409|9756161|FG009|Overall Study|Lack of Efficacy|0
6129632|NCT00955409|9756152|FG000|Overall Study|Withdrawal by Subject|1
6129633|NCT00955409|9756153|FG001|Overall Study|Withdrawal by Subject|0
6129634|NCT00955409|9756154|FG002|Overall Study|Withdrawal by Subject|5
6129635|NCT00955409|9756155|FG003|Overall Study|Withdrawal by Subject|2
6129636|NCT00955409|9756156|FG004|Overall Study|Withdrawal by Subject|0
6129637|NCT00955409|9756157|FG005|Overall Study|Withdrawal by Subject|0
6129638|NCT00955409|9756158|FG006|Overall Study|Withdrawal by Subject|2
6129639|NCT00955409|9756159|FG007|Overall Study|Withdrawal by Subject|0
6129640|NCT00955409|9756160|FG008|Overall Study|Withdrawal by Subject|1
6129641|NCT00955409|9756161|FG009|Overall Study|Withdrawal by Subject|0
6129642|NCT00955409|9756152|FG000|Overall Study|Caregiver Request|2
6129643|NCT00955409|9756153|FG001|Overall Study|Caregiver Request|0
6129644|NCT00955409|9756154|FG002|Overall Study|Caregiver Request|6
6129645|NCT00955409|9756155|FG003|Overall Study|Caregiver Request|5
6129646|NCT00955409|9756156|FG004|Overall Study|Caregiver Request|0
6129647|NCT00955409|9756157|FG005|Overall Study|Caregiver Request|2
6129648|NCT00955409|9756158|FG006|Overall Study|Caregiver Request|3
6129649|NCT00955409|9756159|FG007|Overall Study|Caregiver Request|1
6129650|NCT00955409|9756160|FG008|Overall Study|Caregiver Request|3
6129651|NCT00955409|9756161|FG009|Overall Study|Caregiver Request|0
6129652|NCT00955409|9756152|FG000|Overall Study|Investigator Request|0
6129653|NCT00955409|9756153|FG001|Overall Study|Investigator Request|0
6129654|NCT00955409|9756154|FG002|Overall Study|Investigator Request|1
6129655|NCT00955409|9756155|FG003|Overall Study|Investigator Request|0
6129656|NCT00955409|9756156|FG004|Overall Study|Investigator Request|0
6129657|NCT00955409|9756157|FG005|Overall Study|Investigator Request|0
6129658|NCT00955409|9756158|FG006|Overall Study|Investigator Request|0
6129659|NCT00955409|9756159|FG007|Overall Study|Investigator Request|0
6129660|NCT00955409|9756160|FG008|Overall Study|Investigator Request|0
6129661|NCT00955409|9756161|FG009|Overall Study|Investigator Request|0
6129662|NCT00955409|9756152|FG000|Overall Study|Discontinuation of Study by Sponsor|0
6129663|NCT00955409|9756153|FG001|Overall Study|Discontinuation of Study by Sponsor|0
6129664|NCT00955409|9756154|FG002|Overall Study|Discontinuation of Study by Sponsor|0
6129665|NCT00955409|9756155|FG003|Overall Study|Discontinuation of Study by Sponsor|0
6129666|NCT00955409|9756156|FG004|Overall Study|Discontinuation of Study by Sponsor|0
6129667|NCT00955409|9756157|FG005|Overall Study|Discontinuation of Study by Sponsor|0
6129668|NCT00955409|9756158|FG006|Overall Study|Discontinuation of Study by Sponsor|0
6129669|NCT00955409|9756159|FG007|Overall Study|Discontinuation of Study by Sponsor|1
6129670|NCT00955409|9756160|FG008|Overall Study|Discontinuation of Study by Sponsor|0
6129671|NCT00955409|9756161|FG009|Overall Study|Discontinuation of Study by Sponsor|0
6129672|NCT00955409|9756152|FG000|Overall Study|Lost to Follow-up|0
6129673|NCT00955409|9756153|FG001|Overall Study|Lost to Follow-up|0
6129674|NCT00955409|9756154|FG002|Overall Study|Lost to Follow-up|1
6129675|NCT00955409|9756155|FG003|Overall Study|Lost to Follow-up|0
6221005|NCT01667419|9890985|FG000|Overall Study|Reason Not Specified|1
6221006|NCT01667419|9890986|FG001|Overall Study|Reason Not Specified|0
6221007|NCT01667419|9890987|FG002|Overall Study|Reason Not Specified|0
6221008|NCT01667419|9890988|FG003|Overall Study|Reason Not Specified|0
6221009|NCT01667419|9890985|FG000|Overall Study|Withdrawal by Subject|16
6221010|NCT01667419|9890986|FG001|Overall Study|Withdrawal by Subject|8
6221011|NCT01667419|9890987|FG002|Overall Study|Withdrawal by Subject|9
6221012|NCT01667419|9890988|FG003|Overall Study|Withdrawal by Subject|8
6221013|NCT01667419|9890985|FG000|Overall Study|Non-compliance|0
6221014|NCT01667419|9890986|FG001|Overall Study|Non-compliance|0
6221015|NCT01667419|9890987|FG002|Overall Study|Non-compliance|0
6221016|NCT01667419|9890988|FG003|Overall Study|Non-compliance|1
6221017|NCT01667419|9890985|FG000|Overall Study|Protocol Violation|1
6221018|NCT01667419|9890986|FG001|Overall Study|Protocol Violation|0
6221019|NCT01667419|9890987|FG002|Overall Study|Protocol Violation|0
6221020|NCT01667419|9890988|FG003|Overall Study|Protocol Violation|0
6221021|NCT01667419|9890985|FG000|Overall Study|Lost to Follow-up|7
6221022|NCT01667419|9890986|FG001|Overall Study|Lost to Follow-up|6
6221023|NCT01667419|9890987|FG002|Overall Study|Lost to Follow-up|2
6221024|NCT01667419|9890988|FG003|Overall Study|Lost to Follow-up|4
6221025|NCT01667419|9890985|FG000|Overall Study|Death|18
6129676|NCT00955409|9756156|FG004|Overall Study|Lost to Follow-up|0
6129677|NCT00955409|9756157|FG005|Overall Study|Lost to Follow-up|0
6129678|NCT00955409|9756158|FG006|Overall Study|Lost to Follow-up|1
6129679|NCT00955409|9756159|FG007|Overall Study|Lost to Follow-up|0
6221026|NCT01667419|9890986|FG001|Overall Study|Death|33
6129680|NCT00955409|9756160|FG008|Overall Study|Lost to Follow-up|0
6129681|NCT00955409|9756161|FG009|Overall Study|Lost to Follow-up|0
6129682|NCT00955409|9756152|FG000|Overall Study|Failed to Return|2
6129683|NCT00955409|9756153|FG001|Overall Study|Failed to Return|0
6129684|NCT00955409|9756154|FG002|Overall Study|Failed to Return|0
6129685|NCT00955409|9756155|FG003|Overall Study|Failed to Return|0
6129686|NCT00955409|9756156|FG004|Overall Study|Failed to Return|0
6129687|NCT00955409|9756157|FG005|Overall Study|Failed to Return|0
6129688|NCT00955409|9756158|FG006|Overall Study|Failed to Return|0
6129689|NCT00955409|9756159|FG007|Overall Study|Failed to Return|2
6129690|NCT00955409|9756160|FG008|Overall Study|Failed to Return|0
6129691|NCT00955409|9756161|FG009|Overall Study|Failed to Return|0
6129692|NCT00955409|9756152|FG000|Overall Study|Adverse Event (AE)|2
6129693|NCT00955409|9756153|FG001|Overall Study|Adverse Event (AE)|0
6129694|NCT00955409|9756154|FG002|Overall Study|Adverse Event (AE)|0
6129695|NCT00955409|9756155|FG003|Overall Study|Adverse Event (AE)|0
6129696|NCT00955409|9756156|FG004|Overall Study|Adverse Event (AE)|0
6129697|NCT00955409|9756157|FG005|Overall Study|Adverse Event (AE)|1
6129698|NCT00955409|9756158|FG006|Overall Study|Adverse Event (AE)|2
6129699|NCT00955409|9756159|FG007|Overall Study|Adverse Event (AE)|0
6129700|NCT00955409|9756160|FG008|Overall Study|Adverse Event (AE)|2
6129701|NCT00955409|9756161|FG009|Overall Study|Adverse Event (AE)|0
6129702|NCT00955409|9756152|FG000|Overall Study|Reason not Specified|2
6129703|NCT00955409|9756153|FG001|Overall Study|Reason not Specified|1
6129704|NCT00955409|9756154|FG002|Overall Study|Reason not Specified|13
6129705|NCT00955409|9756155|FG003|Overall Study|Reason not Specified|1
6129706|NCT00955409|9756156|FG004|Overall Study|Reason not Specified|2
6129707|NCT00955409|9756157|FG005|Overall Study|Reason not Specified|0
6129708|NCT00955409|9756158|FG006|Overall Study|Reason not Specified|16
6129709|NCT00955409|9756159|FG007|Overall Study|Reason not Specified|0
6129710|NCT00955409|9756160|FG008|Overall Study|Reason not Specified|8
6129711|NCT00955409|9756161|FG009|Overall Study|Reason not Specified|1
6129712|NCT00955474|9756189|FG000|Overall Study|Physician Decision|7
6129713|NCT00955474|9756190|FG001|Overall Study|Physician Decision|5
6129714|NCT00955617|9756230|FG000|Second MRA (Between Day 1 and Day 51)|Withdrawal by Subject|2
6129715|NCT00955617|9756231|FG001|Second MRA (Between Day 1 and Day 51)|Withdrawal by Subject|1
6129716|NCT00955617|9756230|FG000|Second MRA (Between Day 1 and Day 51)|Lost to Follow-up|0
6129717|NCT00955617|9756231|FG001|Second MRA (Between Day 1 and Day 51)|Lost to Follow-up|1
6129718|NCT00955617|9756230|FG000|Second MRA (Between Day 1 and Day 51)|technical incident|0
6129719|NCT00955617|9756231|FG001|Second MRA (Between Day 1 and Day 51)|technical incident|1
6129720|NCT00955617|9756230|FG000|Second MRA (Between Day 1 and Day 51)|conventional angiography|1
6129721|NCT00955617|9756231|FG001|Second MRA (Between Day 1 and Day 51)|conventional angiography|0
6129722|NCT00955682|9756239|FG000|Booster Period (Month 48- 49)|Lost to Follow-up|1
6129723|NCT00955682|9756240|FG001|Booster Period (Month 48- 49)|Lost to Follow-up|1
6129724|NCT00955708|9756254|FG000|Overall Study|Death|269
6129725|NCT00955708|9756254|FG000|Overall Study|Lost to Follow-up|72
6129726|NCT00955708|9756254|FG000|Overall Study|Physician Decision|36
6129727|NCT00955708|9756254|FG000|Overall Study|Protocol Violation|134
6129728|NCT00955708|9756254|FG000|Overall Study|Registry Conclusion|186
6129729|NCT00955708|9756254|FG000|Overall Study|Product removed from service|94
6221027|NCT01667419|9890987|FG002|Overall Study|Death|25
6221028|NCT01667419|9890988|FG003|Overall Study|Death|26
6221029|NCT01667432|9890999|FG000|Overall Study|Premature Study Termination|26
6221030|NCT01667432|9890999|FG000|Overall Study|Failure to Return|10
6221031|NCT01667432|9890999|FG000|Overall Study|Moved to Another Center|3
6221032|NCT01667432|9890999|FG000|Overall Study|Lost to Follow-up|3
6221033|NCT01667432|9890999|FG000|Overall Study|Refused Treatment/Withdrew Consent|1
6221034|NCT01667432|9890999|FG000|Overall Study|Insufficient Therapeutic Response|4
6221035|NCT01667432|9890999|FG000|Overall Study|Adverse Event|1
6221036|NCT01667432|9890999|FG000|Overall Study|Protocol Deviation|2
6221037|NCT01667432|9890999|FG000|Overall Study|Principal Investigator Decision|1
6221038|NCT01667432|9890999|FG000|Overall Study|Reason Not Specified|2
6221039|NCT01667432|9890999|FG000|Overall Study|Missing Information|4
6221040|NCT01667549|9891020|FG000|Overall Study|Withdrawal by Subject|3
6221041|NCT01667549|9891021|FG001|Overall Study|Withdrawal by Subject|5
6221042|NCT01667549|9891022|FG002|Overall Study|Withdrawal by Subject|7
6221043|NCT01667549|9891023|FG003|Overall Study|Withdrawal by Subject|6
6221044|NCT01667549|9891024|FG004|Overall Study|Withdrawal by Subject|1
6221045|NCT01667562|9891041|FG000|Diagnostic Phase|Started Erlotinib in Treatment Period|30
6221046|NCT01667562|9891042|FG001|Diagnostic Phase|Started Erlotinib in Treatment Period|0
6221047|NCT01667562|9891041|FG000|Erlotinib Phase|Lost to Follow-up|0
6221048|NCT01667562|9891042|FG001|Erlotinib Phase|Lost to Follow-up|1
6221049|NCT01667562|9891041|FG000|Erlotinib Phase|Adverse Event|0
6221050|NCT01667562|9891042|FG001|Erlotinib Phase|Adverse Event|1
6221051|NCT01667562|9891041|FG000|Erlotinib Phase|Switch to Commercial Drug|0
6221052|NCT01667562|9891042|FG001|Erlotinib Phase|Switch to Commercial Drug|1
6221053|NCT01667679|9891049|FG000|Treatment Period 1 (<=12 Weeks)|Failure to Treat Migraine Headache|2
6221054|NCT01667679|9891050|FG001|Treatment Period 1 (<=12 Weeks)|Failure to Treat Migraine Headache|6
6221055|NCT01667679|9891049|FG000|Treatment Period 1 (<=12 Weeks)|Dosed Incorrectly|2
6221056|NCT01667679|9891050|FG001|Treatment Period 1 (<=12 Weeks)|Dosed Incorrectly|0
6221057|NCT01667679|9891049|FG000|Treatment Period 1 (<=12 Weeks)|Lack of Efficacy|2
6129730|NCT00955708|9756254|FG000|Overall Study|Patient Refused to participate further|116
6129731|NCT00955708|9756254|FG000|Overall Study|Closure of study location|60
6129732|NCT00955708|9756254|FG000|Overall Study|Patient changed care provider/moved|91
6129733|NCT00955721|9756260|FG000|Overall Study|Physician Decision|1
6129734|NCT00955721|9756261|FG001|Overall Study|Physician Decision|0
6129735|NCT00955721|9756260|FG000|Overall Study|Death|1
6129736|NCT00955721|9756261|FG001|Overall Study|Death|0
6129737|NCT00955721|9756260|FG000|Overall Study|Withdrawal by Subject|1
6129738|NCT00955721|9756261|FG001|Overall Study|Withdrawal by Subject|0
6129739|NCT00955825|9756279|FG000|Overall Study|Adverse Event|15
6129740|NCT00955825|9756280|FG001|Overall Study|Adverse Event|2
6129741|NCT00955825|9756279|FG000|Overall Study|Withdrawal by Subject|4
6129742|NCT00955825|9756280|FG001|Overall Study|Withdrawal by Subject|6
6129743|NCT00955825|9756279|FG000|Overall Study|Any other reason not above-mentioned|7
6221058|NCT01667679|9891050|FG001|Treatment Period 1 (<=12 Weeks)|Lack of Efficacy|0
6221059|NCT01667679|9891049|FG000|Treatment Period 1 (<=12 Weeks)|Could Not Tolerate Diary|1
6221060|NCT01667679|9891050|FG001|Treatment Period 1 (<=12 Weeks)|Could Not Tolerate Diary|0
6221061|NCT01667679|9891049|FG000|Treatment Period 1 (<=12 Weeks)|Withdrawal by Subject|6
6221062|NCT01667679|9891050|FG001|Treatment Period 1 (<=12 Weeks)|Withdrawal by Subject|13
6221063|NCT01667679|9891049|FG000|Treatment Period 1 (<=12 Weeks)|Adverse Event|3
6221064|NCT01667679|9891050|FG001|Treatment Period 1 (<=12 Weeks)|Adverse Event|3
6221065|NCT01667679|9891049|FG000|Treatment Period 1 (<=12 Weeks)|Lost to Follow-up|0
6221066|NCT01667679|9891050|FG001|Treatment Period 1 (<=12 Weeks)|Lost to Follow-up|2
6221067|NCT01667679|9891049|FG000|Treatment Period 1 (<=12 Weeks)|Protocol Violation|0
6221068|NCT01667679|9891050|FG001|Treatment Period 1 (<=12 Weeks)|Protocol Violation|2
6221069|NCT01667679|9891049|FG000|Treatment Period 1 (<=12 Weeks)|Non-compliance|0
6221070|NCT01667679|9891050|FG001|Treatment Period 1 (<=12 Weeks)|Non-compliance|3
6221071|NCT01667679|9891049|FG000|Treatment Period 1 (<=12 Weeks)|Moved Out of State|0
6221072|NCT01667679|9891050|FG001|Treatment Period 1 (<=12 Weeks)|Moved Out of State|1
6221073|NCT01667679|9891049|FG000|Treatment Period 2 (<=12 Weeks)|Withdrawal by Subject|6
6221074|NCT01667679|9891050|FG001|Treatment Period 2 (<=12 Weeks)|Withdrawal by Subject|4
6221075|NCT01667679|9891049|FG000|Treatment Period 2 (<=12 Weeks)|Non-compliance with Electronic Diary|2
6221076|NCT01667679|9891050|FG001|Treatment Period 2 (<=12 Weeks)|Non-compliance with Electronic Diary|0
6221077|NCT01667679|9891049|FG000|Treatment Period 2 (<=12 Weeks)|Lost to Follow-up|8
6221078|NCT01667679|9891050|FG001|Treatment Period 2 (<=12 Weeks)|Lost to Follow-up|10
6221079|NCT01667679|9891049|FG000|Treatment Period 2 (<=12 Weeks)|Non-compliance|3
6221080|NCT01667679|9891050|FG001|Treatment Period 2 (<=12 Weeks)|Non-compliance|4
6221081|NCT01667679|9891049|FG000|Treatment Period 2 (<=12 Weeks)|Sponsor Decision|1
6221082|NCT01667679|9891050|FG001|Treatment Period 2 (<=12 Weeks)|Sponsor Decision|0
6221083|NCT01667679|9891049|FG000|Treatment Period 2 (<=12 Weeks)|Failure to Treat Migraine Headache|1
6221084|NCT01667679|9891050|FG001|Treatment Period 2 (<=12 Weeks)|Failure to Treat Migraine Headache|0
6221085|NCT01667679|9891049|FG000|Treatment Period 2 (<=12 Weeks)|Adverse Event|1
6221086|NCT01667679|9891050|FG001|Treatment Period 2 (<=12 Weeks)|Adverse Event|0
6221087|NCT01667679|9891049|FG000|Treatment Period 2 (<=12 Weeks)|Significant Improvement in Migraine|0
6221088|NCT01667679|9891050|FG001|Treatment Period 2 (<=12 Weeks)|Significant Improvement in Migraine|1
6221089|NCT01667679|9891049|FG000|Treatment Period 2 (<=12 Weeks)|Partially Dosed|0
6221090|NCT01667679|9891050|FG001|Treatment Period 2 (<=12 Weeks)|Partially Dosed|1
6221091|NCT01667679|9891049|FG000|Treatment Period 2 (<=12 Weeks)|Brought in before 12 Weeks/5 Migraines|0
6221092|NCT01667679|9891050|FG001|Treatment Period 2 (<=12 Weeks)|Brought in before 12 Weeks/5 Migraines|1
6221093|NCT01667679|9891049|FG000|Treatment Period 2 (<=12 Weeks)|Refused Last Day of Visit 4 Procedures|0
6221094|NCT01667679|9891050|FG001|Treatment Period 2 (<=12 Weeks)|Refused Last Day of Visit 4 Procedures|1
6221095|NCT01667731|9891063|FG000|Overall Study|Enrolled but not treated|0
6221096|NCT01667731|9891064|FG001|Overall Study|Enrolled but not treated|0
6221097|NCT01667731|9891065|FG002|Overall Study|Enrolled but not treated|0
6221098|NCT01667731|9891066|FG003|Overall Study|Enrolled but not treated|0
6289082|NCT02377362|10003665|FG003|Part B Overall|Adverse Event|0
6289083|NCT02377362|10003666|FG004|Part B Overall|Adverse Event|0
6289084|NCT02377362|10003667|FG005|Part B Overall|Adverse Event|0
6289085|NCT02377362|10003668|FG006|Part B Overall|Adverse Event|1
6289086|NCT02377362|10003669|FG007|Part B Overall|Adverse Event|1
6289087|NCT02377362|10003670|FG008|Part B Overall|Adverse Event|0
6289088|NCT02377362|10003671|FG009|Part B Overall|Adverse Event|0
6289089|NCT02377362|10003672|FG010|Part B Overall|Adverse Event|0
6289090|NCT02377362|10003673|FG011|Part B Overall|Adverse Event|0
6289091|NCT02377362|10003674|FG012|Part B Overall|Adverse Event|0
6289092|NCT02377362|10003662|FG000|Part B Overall|Withdrawal by Subject|0
6289093|NCT02377362|10003663|FG001|Part B Overall|Withdrawal by Subject|0
6289094|NCT02377362|10003664|FG002|Part B Overall|Withdrawal by Subject|0
6289095|NCT02377362|10003665|FG003|Part B Overall|Withdrawal by Subject|0
6289096|NCT02377362|10003666|FG004|Part B Overall|Withdrawal by Subject|0
6289097|NCT02377362|10003667|FG005|Part B Overall|Withdrawal by Subject|0
6289098|NCT02377362|10003668|FG006|Part B Overall|Withdrawal by Subject|1
6289099|NCT02377362|10003669|FG007|Part B Overall|Withdrawal by Subject|0
6289100|NCT02377362|10003670|FG008|Part B Overall|Withdrawal by Subject|0
6289101|NCT02377362|10003671|FG009|Part B Overall|Withdrawal by Subject|0
6289102|NCT02377362|10003672|FG010|Part B Overall|Withdrawal by Subject|0
6129744|NCT00955825|9756280|FG001|Overall Study|Any other reason not above-mentioned|9
6129745|NCT00955955|9756319|FG000|Overall Study|Lost to Follow-up|2
6129746|NCT00955955|9756320|FG001|Overall Study|Lost to Follow-up|0
6129747|NCT00955955|9756321|FG002|Overall Study|Lost to Follow-up|0
6129748|NCT00955968|9756337|FG000|Overall Study|Death|2
6129749|NCT00955968|9756338|FG001|Overall Study|Death|4
6129750|NCT00955968|9756337|FG000|Overall Study|Withdrawal by Subject|35
6129751|NCT00955968|9756338|FG001|Overall Study|Withdrawal by Subject|31
6129752|NCT00955968|9756337|FG000|Overall Study|Lost to Follow-up|45
6129753|NCT00955968|9756338|FG001|Overall Study|Lost to Follow-up|39
6129754|NCT00955968|9756337|FG000|Overall Study|Site closed|55
6129755|NCT00955968|9756338|FG001|Overall Study|Site closed|52
6129756|NCT00956293|9756372|FG000|Main Period (Pre-randomization)|Not specified (data missing)|0
6129757|NCT00956293|9756373|FG001|Main Period (Pre-randomization)|Not specified (data missing)|0
6129758|NCT00956293|9756374|FG002|Main Period (Pre-randomization)|Not specified (data missing)|1
6129759|NCT00956293|9756372|FG000|Main Period (Pre-randomization)|Death|0
6129760|NCT00956293|9756373|FG001|Main Period (Pre-randomization)|Death|0
6129761|NCT00956293|9756374|FG002|Main Period (Pre-randomization)|Death|1
6129762|NCT00956293|9756372|FG000|Main Period (Pre-randomization)|Protocol Violation|0
6129763|NCT00956293|9756373|FG001|Main Period (Pre-randomization)|Protocol Violation|0
6129764|NCT00956293|9756374|FG002|Main Period (Pre-randomization)|Protocol Violation|1
6129765|NCT00956293|9756372|FG000|Main Period (Pre-randomization)|Abnormal test procedure result|0
6129766|NCT00956293|9756373|FG001|Main Period (Pre-randomization)|Abnormal test procedure result|0
6129767|NCT00956293|9756374|FG002|Main Period (Pre-randomization)|Abnormal test procedure result|2
6129768|NCT00956293|9756372|FG000|Main Period (Pre-randomization)|Administrative problems|0
6129769|NCT00956293|9756373|FG001|Main Period (Pre-randomization)|Administrative problems|0
6129770|NCT00956293|9756374|FG002|Main Period (Pre-randomization)|Administrative problems|6
6129771|NCT00956293|9756372|FG000|Main Period (Pre-randomization)|Graft loss|0
6129772|NCT00956293|9756373|FG001|Main Period (Pre-randomization)|Graft loss|0
6129773|NCT00956293|9756374|FG002|Main Period (Pre-randomization)|Graft loss|7
6129774|NCT00956293|9756372|FG000|Main Period (Pre-randomization)|Withdrawal by Subject|0
6129775|NCT00956293|9756373|FG001|Main Period (Pre-randomization)|Withdrawal by Subject|0
6129776|NCT00956293|9756374|FG002|Main Period (Pre-randomization)|Withdrawal by Subject|12
6129777|NCT00956293|9756372|FG000|Main Period (Pre-randomization)|Lack of Efficacy|0
6129778|NCT00956293|9756373|FG001|Main Period (Pre-randomization)|Lack of Efficacy|0
6129779|NCT00956293|9756374|FG002|Main Period (Pre-randomization)|Lack of Efficacy|20
6129780|NCT00956293|9756372|FG000|Main Period (Pre-randomization)|Adverse Event|0
6221099|NCT01667731|9891067|FG004|Overall Study|Enrolled but not treated|1
6221100|NCT01667731|9891063|FG000|Overall Study|Efficacy Failure|1
6221101|NCT01667731|9891064|FG001|Overall Study|Efficacy Failure|12
6221102|NCT01667731|9891065|FG002|Overall Study|Efficacy Failure|0
6221103|NCT01667731|9891066|FG003|Overall Study|Efficacy Failure|1
6221104|NCT01667731|9891067|FG004|Overall Study|Efficacy Failure|24
6221105|NCT01667731|9891063|FG000|Overall Study|Lost to Follow-up|2
6221106|NCT01667731|9891064|FG001|Overall Study|Lost to Follow-up|3
6221107|NCT01667731|9891065|FG002|Overall Study|Lost to Follow-up|1
6221108|NCT01667731|9891066|FG003|Overall Study|Lost to Follow-up|1
6221109|NCT01667731|9891067|FG004|Overall Study|Lost to Follow-up|2
6221110|NCT01667731|9891063|FG000|Overall Study|Subject Withdrew Consent|2
6221111|NCT01667731|9891064|FG001|Overall Study|Subject Withdrew Consent|0
6221112|NCT01667731|9891065|FG002|Overall Study|Subject Withdrew Consent|1
6221113|NCT01667731|9891066|FG003|Overall Study|Subject Withdrew Consent|0
6221114|NCT01667731|9891067|FG004|Overall Study|Subject Withdrew Consent|1
6221115|NCT01667731|9891063|FG000|Overall Study|Death|0
6221116|NCT01667731|9891064|FG001|Overall Study|Death|1
6221117|NCT01667731|9891065|FG002|Overall Study|Death|0
6221118|NCT01667731|9891066|FG003|Overall Study|Death|0
6221119|NCT01667731|9891067|FG004|Overall Study|Death|0
6221120|NCT01667900|9891107|FG000|Part B|Death|0
6221121|NCT01667900|9891108|FG001|Part B|Death|0
6221122|NCT01667900|9891109|FG002|Part B|Death|0
6221123|NCT01667900|9891110|FG003|Part B|Death|0
6221124|NCT01667900|9891111|FG004|Part B|Death|0
6221125|NCT01667900|9891112|FG005|Part B|Death|0
6221126|NCT01667900|9891113|FG006|Part B|Death|0
6221127|NCT01667900|9891114|FG007|Part B|Death|0
6221128|NCT01667900|9891115|FG008|Part B|Death|0
6221129|NCT01667900|9891116|FG009|Part B|Death|0
6221130|NCT01667900|9891117|FG010|Part B|Death|0
6221131|NCT01667900|9891118|FG011|Part B|Death|0
6221132|NCT01667900|9891119|FG012|Part B|Death|0
6221133|NCT01667900|9891120|FG013|Part B|Death|0
6221134|NCT01667900|9891121|FG014|Part B|Death|0
6221135|NCT01667900|9891122|FG015|Part B|Death|0
6129781|NCT00956293|9756373|FG001|Main Period (Pre-randomization)|Adverse Event|0
6129782|NCT00956293|9756374|FG002|Main Period (Pre-randomization)|Adverse Event|36
6129783|NCT00956293|9756372|FG000|Main Period (Pre-randomization)|Abnormal laboratory value|0
6129784|NCT00956293|9756373|FG001|Main Period (Pre-randomization)|Abnormal laboratory value|0
6221136|NCT01667900|9891123|FG016|Part B|Death|1
6221137|NCT01667900|9891124|FG017|Part B|Death|0
6221138|NCT01667900|9891125|FG018|Part B|Death|0
6221139|NCT01667900|9891126|FG019|Part B|Death|0
6221140|NCT01667926|9891148|FG000|Overall Study|Withdrawal by Subject|1
6221141|NCT01667926|9891149|FG001|Overall Study|Withdrawal by Subject|2
6129785|NCT00956293|9756374|FG002|Main Period (Pre-randomization)|Abnormal laboratory value|44
6129786|NCT00956293|9756372|FG000|Main Period (Randomization)|Abnormal laboratory value|0
6129787|NCT00956293|9756373|FG001|Main Period (Randomization)|Abnormal laboratory value|2
6129788|NCT00956293|9756374|FG002|Main Period (Randomization)|Abnormal laboratory value|0
6129789|NCT00956293|9756372|FG000|Main Period (Randomization)|Lack of Efficacy|1
6129790|NCT00956293|9756373|FG001|Main Period (Randomization)|Lack of Efficacy|10
6129791|NCT00956293|9756374|FG002|Main Period (Randomization)|Lack of Efficacy|0
6129792|NCT00956293|9756372|FG000|Main Period (Randomization)|Adverse Event|0
6221142|NCT01667926|9891150|FG002|Overall Study|Withdrawal by Subject|2
6221143|NCT01667926|9891148|FG000|Overall Study|Physician Decision|0
6221144|NCT01667926|9891149|FG001|Overall Study|Physician Decision|0
6221145|NCT01667926|9891150|FG002|Overall Study|Physician Decision|1
6221146|NCT01667926|9891148|FG000|Overall Study|Time committment|0
6221147|NCT01667926|9891149|FG001|Overall Study|Time committment|0
6221148|NCT01667926|9891150|FG002|Overall Study|Time committment|2
6221149|NCT01667926|9891148|FG000|Overall Study|Inclusion/Exclusion Criteria|0
6221150|NCT01667926|9891149|FG001|Overall Study|Inclusion/Exclusion Criteria|0
6221151|NCT01667926|9891150|FG002|Overall Study|Inclusion/Exclusion Criteria|5
6221152|NCT01667926|9891148|FG000|Overall Study|Lost to Follow-up|1
6221153|NCT01667926|9891149|FG001|Overall Study|Lost to Follow-up|2
6221154|NCT01667926|9891150|FG002|Overall Study|Lost to Follow-up|1
6221155|NCT01667926|9891148|FG000|Overall Study|Side effects|3
6221156|NCT01667926|9891149|FG001|Overall Study|Side effects|0
6221157|NCT01667926|9891150|FG002|Overall Study|Side effects|0
6221158|NCT01668004|9891165|FG000|Overall Study|Adverse Event|7
6221159|NCT01668004|9891165|FG000|Overall Study|Withdrawal by Subject|2
6221160|NCT01668004|9891165|FG000|Overall Study|Lost to Follow-up|5
6221161|NCT01668004|9891165|FG000|Overall Study|Lack of Efficacy|9
6221162|NCT01668004|9891165|FG000|Overall Study|Non-compliance with treatment|2
6221163|NCT01668173|9891213|FG000|Overall Study|Adverse Event|3
6221164|NCT01668173|9891213|FG000|Overall Study|Trial suspension|4
6221165|NCT01668355|9891219|FG000|Overall Study|Death|3
6221166|NCT01668355|9891220|FG001|Overall Study|Death|1
6221167|NCT01668355|9891219|FG000|Overall Study|Withdrawal by Subject|6
6221168|NCT01668355|9891220|FG001|Overall Study|Withdrawal by Subject|1
6221169|NCT01668537|9891229|FG000|Overall Study|Request to Discontinue Prematurely|1
6221170|NCT01668537|9891230|FG001|Overall Study|Request to Discontinue Prematurely|1
6221171|NCT01668537|9891229|FG000|Overall Study|Subject unwilling/unable to comply|5
6221172|NCT01668537|9891230|FG001|Overall Study|Subject unwilling/unable to comply|0
6289103|NCT02377362|10003673|FG011|Part B Overall|Withdrawal by Subject|1
6289104|NCT02377362|10003674|FG012|Part B Overall|Withdrawal by Subject|0
6289105|NCT02377427|10003714|FG000|Part A (Up to Week 20)|Physician Decision|1
6289106|NCT02377427|10003715|FG001|Part A (Up to Week 20)|Physician Decision|0
6289107|NCT02377427|10003716|FG002|Part A (Up to Week 20)|Physician Decision|0
6289108|NCT02377427|10003717|FG003|Part A (Up to Week 20)|Physician Decision|0
6289109|NCT02377427|10003718|FG004|Part A (Up to Week 20)|Physician Decision|0
6289110|NCT02377427|10003714|FG000|Part A (Up to Week 20)|Other: AE of Asthma Exacerbation|1
6289111|NCT02377427|10003715|FG001|Part A (Up to Week 20)|Other: AE of Asthma Exacerbation|0
6289112|NCT02377427|10003716|FG002|Part A (Up to Week 20)|Other: AE of Asthma Exacerbation|0
6289113|NCT02377427|10003717|FG003|Part A (Up to Week 20)|Other: AE of Asthma Exacerbation|0
6289114|NCT02377427|10003718|FG004|Part A (Up to Week 20)|Other: AE of Asthma Exacerbation|0
6289115|NCT02377427|10003714|FG000|Part A (Up to Week 20)|Withdrawal by Subject|2
6289116|NCT02377427|10003715|FG001|Part A (Up to Week 20)|Withdrawal by Subject|0
6289117|NCT02377427|10003716|FG002|Part A (Up to Week 20)|Withdrawal by Subject|0
6289118|NCT02377427|10003717|FG003|Part A (Up to Week 20)|Withdrawal by Subject|0
6289119|NCT02377427|10003718|FG004|Part A (Up to Week 20)|Withdrawal by Subject|0
6289120|NCT02377427|10003714|FG000|Part B (From Week 20 and up to Week 80)|Protocol Violation|0
6289121|NCT02377427|10003715|FG001|Part B (From Week 20 and up to Week 80)|Protocol Violation|0
6289122|NCT02377427|10003716|FG002|Part B (From Week 20 and up to Week 80)|Protocol Violation|1
6289123|NCT02377427|10003717|FG003|Part B (From Week 20 and up to Week 80)|Protocol Violation|0
6289124|NCT02377427|10003718|FG004|Part B (From Week 20 and up to Week 80)|Protocol Violation|0
6289125|NCT02377466|10003733|FG000|Overall Study|Other: Randomized and not treated|0
6289126|NCT02377466|10003734|FG001|Overall Study|Other: Randomized and not treated|2
6289127|NCT02377817|10003777|FG000|Overall Study|Transportation/childcare barriers.|2
6289128|NCT02377817|10003778|FG001|Overall Study|Transportation/childcare barriers.|0
6289129|NCT02377817|10003777|FG000|Overall Study|Unrelated injury prevented lateral sleep|1
6289130|NCT02377817|10003778|FG001|Overall Study|Unrelated injury prevented lateral sleep|0
6289131|NCT02377921|10003788|FG000|Overall Study|Subject non-compliance|1
6289132|NCT02377921|10003789|FG001|Overall Study|Subject non-compliance|1
6289133|NCT02378220|10003835|FG000|Overall Study|Death|6
6129793|NCT00956293|9756373|FG001|Main Period (Randomization)|Adverse Event|15
6221173|NCT01668537|9891229|FG000|Overall Study|Reason Precludes Participation|1
6221174|NCT01668537|9891230|FG001|Overall Study|Reason Precludes Participation|0
6221175|NCT01668537|9891229|FG000|Overall Study|Lost to Follow-up|13
6221176|NCT01668537|9891230|FG001|Overall Study|Lost to Follow-up|6
6289134|NCT02378220|10003836|FG001|Overall Study|Death|1
6289135|NCT02378480|10003858|FG000|Overall Study|Physician Decision|1
6289136|NCT02378480|10003859|FG001|Overall Study|Physician Decision|1
6289137|NCT02378480|10003858|FG000|Overall Study|Death|1
6129794|NCT00956293|9756374|FG002|Main Period (Randomization)|Adverse Event|0
6129795|NCT00956293|9756372|FG000|Follow-up Period|Follow-up period was terminated.|20
6129796|NCT00956293|9756373|FG001|Follow-up Period|Follow-up period was terminated.|32
6129797|NCT00956293|9756374|FG002|Follow-up Period|Follow-up period was terminated.|0
6129798|NCT00956592|9756399|FG000|Overall Study|Protocol Violation|1
6129799|NCT00956592|9756400|FG001|Overall Study|Protocol Violation|3
6129800|NCT00956813|9756439|FG000|Flaxseed and Placebo|Withdrawal by Subject|5
6129801|NCT00956813|9756440|FG001|Flaxseed and Placebo|Withdrawal by Subject|4
6129802|NCT00956813|9756439|FG000|Flaxseed and Placebo|Ineligible|3
6129803|NCT00956813|9756440|FG001|Flaxseed and Placebo|Ineligible|1
6129804|NCT00956839|9756450|FG000|Overall Study|Lost to Follow-up|3
6129805|NCT00956839|9756451|FG001|Overall Study|Lost to Follow-up|0
6129806|NCT00956839|9756452|FG002|Overall Study|Lost to Follow-up|3
6129807|NCT00956943|9756473|FG000|Overall Study|Lost to Follow-up|9
6129808|NCT00956943|9756474|FG001|Overall Study|Lost to Follow-up|10
6129809|NCT00957008|9756484|FG000|Overall Study|Withdrawal by Subject|13
6221177|NCT01668537|9891229|FG000|Overall Study|Other|2
6221178|NCT01668537|9891230|FG001|Overall Study|Other|3
6129810|NCT00957008|9756485|FG001|Overall Study|Withdrawal by Subject|10
6129811|NCT00957008|9756486|FG002|Overall Study|Withdrawal by Subject|12
6129812|NCT00957008|9756487|FG003|Overall Study|Withdrawal by Subject|16
6129813|NCT00957008|9756484|FG000|Overall Study|Lost to Follow-up|3
6129814|NCT00957008|9756485|FG001|Overall Study|Lost to Follow-up|1
6129815|NCT00957008|9756486|FG002|Overall Study|Lost to Follow-up|3
6129816|NCT00957008|9756487|FG003|Overall Study|Lost to Follow-up|4
6129817|NCT00957008|9756484|FG000|Overall Study|Physician Decision|1
6129818|NCT00957008|9756485|FG001|Overall Study|Physician Decision|0
6129819|NCT00957008|9756486|FG002|Overall Study|Physician Decision|1
6129820|NCT00957008|9756487|FG003|Overall Study|Physician Decision|1
6129821|NCT00957008|9756484|FG000|Overall Study|Relocated; Family conflict|4
6129822|NCT00957008|9756485|FG001|Overall Study|Relocated; Family conflict|1
6129823|NCT00957008|9756486|FG002|Overall Study|Relocated; Family conflict|1
6129824|NCT00957008|9756487|FG003|Overall Study|Relocated; Family conflict|3
6129825|NCT00957021|9756501|FG000|Overall Study|Death|5
6129826|NCT00957021|9756501|FG000|Overall Study|Lost to Follow-up|8
6129827|NCT00957021|9756501|FG000|Overall Study|Withdrawal by Subject|34
6129828|NCT00957021|9756501|FG000|Overall Study|No 2 yr ROM data|35
6129829|NCT00957021|9756501|FG000|Overall Study|Revised study component by 2 yr visit|8
6129830|NCT00957021|9756501|FG000|Overall Study|Site Termination by the 2 yr visit|16
6129831|NCT00957021|9756501|FG000|Overall Study|Surgery Cancelled|9
6129832|NCT00957021|9756501|FG000|Overall Study|Termination due to language issue|2
6129833|NCT00957229|9756534|FG000|Study Start|Adverse Event|0
6129834|NCT00957229|9756535|FG001|Study Start|Adverse Event|3
6129835|NCT00957229|9756534|FG000|Study Start|Disease Progression|1
6129836|NCT00957229|9756535|FG001|Study Start|Disease Progression|0
6129837|NCT00957229|9756534|FG000|Reallocated to or Continued Vismodegib|Death|1
6129838|NCT00957229|9756535|FG001|Reallocated to or Continued Vismodegib|Death|1
6129839|NCT00957229|9756534|FG000|Reallocated to or Continued Vismodegib|Adverse Event|2
6129840|NCT00957229|9756535|FG001|Reallocated to or Continued Vismodegib|Adverse Event|1
6129841|NCT00957268|9756557|FG000|Overall Study|Voluntary Withdrawal|0
6129842|NCT00957268|9756558|FG001|Overall Study|Voluntary Withdrawal|0
6129843|NCT00957268|9756559|FG002|Overall Study|Voluntary Withdrawal|1
6129844|NCT00957268|9756560|FG003|Overall Study|Voluntary Withdrawal|0
6129845|NCT00957268|9756561|FG004|Overall Study|Voluntary Withdrawal|0
6221179|NCT01668589|9891240|FG000|Overall Study|Lost to Follow-up|29
6221180|NCT01668589|9891241|FG001|Overall Study|Lost to Follow-up|37
6221181|NCT01668589|9891242|FG002|Overall Study|Lost to Follow-up|15
6221182|NCT01668589|9891243|FG003|Overall Study|Lost to Follow-up|5
6221183|NCT01668589|9891240|FG000|Overall Study|Full Consent/Agreement Withdrawn|54
6221184|NCT01668589|9891241|FG001|Overall Study|Full Consent/Agreement Withdrawn|8
6221185|NCT01668589|9891242|FG002|Overall Study|Full Consent/Agreement Withdrawn|11
6221186|NCT01668589|9891243|FG003|Overall Study|Full Consent/Agreement Withdrawn|4
6221187|NCT01668589|9891240|FG000|Overall Study|Death|12
6221188|NCT01668589|9891241|FG001|Overall Study|Death|3
6221189|NCT01668589|9891242|FG002|Overall Study|Death|2
6221190|NCT01668589|9891243|FG003|Overall Study|Death|11
6221191|NCT01668589|9891240|FG000|Overall Study|Other|44
6221192|NCT01668589|9891241|FG001|Overall Study|Other|10
6221193|NCT01668589|9891242|FG002|Overall Study|Other|7
6221194|NCT01668589|9891243|FG003|Overall Study|Other|15
6221195|NCT01668654|9891281|FG000|Overall Study|Study Closed/Terminated|3
6221196|NCT01668654|9891281|FG000|Overall Study|Withdrawal by Subject|1
6221197|NCT01668667|9891289|FG000|Overall Study|Adverse Event|3
6221198|NCT01668667|9891290|FG001|Overall Study|Adverse Event|6
6221199|NCT01668667|9891291|FG002|Overall Study|Adverse Event|4
6221200|NCT01668667|9891292|FG003|Overall Study|Adverse Event|4
6221201|NCT01668667|9891289|FG000|Overall Study|Lack of Efficacy|3
6221202|NCT01668667|9891290|FG001|Overall Study|Lack of Efficacy|2
6221203|NCT01668667|9891291|FG002|Overall Study|Lack of Efficacy|2
6221204|NCT01668667|9891292|FG003|Overall Study|Lack of Efficacy|3
6221205|NCT01668667|9891289|FG000|Overall Study|Protocol Violation|6
6221206|NCT01668667|9891290|FG001|Overall Study|Protocol Violation|10
6221207|NCT01668667|9891291|FG002|Overall Study|Protocol Violation|12
6221208|NCT01668667|9891292|FG003|Overall Study|Protocol Violation|5
6129846|NCT00957372|9756589|FG000|PART I|Lost to Follow-up|0
6129847|NCT00957372|9756590|FG001|PART I|Lost to Follow-up|0
6129848|NCT00957372|9756591|FG002|PART I|Lost to Follow-up|1
6129849|NCT00957372|9756592|FG003|PART I|Lost to Follow-up|0
6129850|NCT00957372|9756589|FG000|PART II|Withdrawal by Subject|0
6129851|NCT00957372|9756590|FG001|PART II|Withdrawal by Subject|0
6129852|NCT00957372|9756591|FG002|PART II|Withdrawal by Subject|0
6129853|NCT00957372|9756592|FG003|PART II|Withdrawal by Subject|8
6129854|NCT00957372|9756589|FG000|PART II|Physician Decision|0
6129855|NCT00957372|9756590|FG001|PART II|Physician Decision|0
6129856|NCT00957372|9756591|FG002|PART II|Physician Decision|0
6129857|NCT00957372|9756592|FG003|PART II|Physician Decision|1
6129858|NCT00957372|9756589|FG000|PART II|Pregnancy|0
6129859|NCT00957372|9756590|FG001|PART II|Pregnancy|0
6129860|NCT00957372|9756591|FG002|PART II|Pregnancy|0
6129861|NCT00957372|9756592|FG003|PART II|Pregnancy|1
6129862|NCT00957372|9756589|FG000|PART II|Not Know|0
6129863|NCT00957372|9756590|FG001|PART II|Not Know|0
6129864|NCT00957372|9756591|FG002|PART II|Not Know|0
6129865|NCT00957372|9756592|FG003|PART II|Not Know|20
6129866|NCT00957372|9756589|FG000|PART II|Adverse Event|0
6129867|NCT00957372|9756590|FG001|PART II|Adverse Event|0
6129868|NCT00957372|9756591|FG002|PART II|Adverse Event|0
6129869|NCT00957372|9756592|FG003|PART II|Adverse Event|10
6129870|NCT00957372|9756589|FG000|PART II|Patient non-compliance|0
6129871|NCT00957372|9756590|FG001|PART II|Patient non-compliance|0
6129872|NCT00957372|9756591|FG002|PART II|Patient non-compliance|0
6129873|NCT00957372|9756592|FG003|PART II|Patient non-compliance|4
6129874|NCT00957424|9756608|FG000|Overall Study|Lost to Follow-up|19
6129875|NCT00957424|9756608|FG000|Overall Study|Protocol Violation|3
6129876|NCT00957424|9756608|FG000|Overall Study|Withdrawal by Subject|1
6129877|NCT00957528|9756615|FG000|Overall Study|Protocol Violation|0
6129878|NCT00957528|9756616|FG001|Overall Study|Protocol Violation|1
6129879|NCT00957528|9756617|FG002|Overall Study|Protocol Violation|0
6129880|NCT00957528|9756615|FG000|Overall Study|Withdrawal by Subject|0
6129881|NCT00957528|9756616|FG001|Overall Study|Withdrawal by Subject|0
6129882|NCT00957528|9756617|FG002|Overall Study|Withdrawal by Subject|1
6129883|NCT00957580|9756628|FG000|Overall Study|Ongoing at data cut-off|0
6129884|NCT00957580|9756629|FG001|Overall Study|Ongoing at data cut-off|1
6129885|NCT00957580|9756630|FG002|Overall Study|Ongoing at data cut-off|0
6129886|NCT00957580|9756628|FG000|Overall Study|Enrolled but not treated|0
6129887|NCT00957580|9756629|FG001|Overall Study|Enrolled but not treated|1
6221209|NCT01668667|9891289|FG000|Overall Study|Lost to Follow-up|9
6221210|NCT01668667|9891290|FG001|Overall Study|Lost to Follow-up|4
6221211|NCT01668667|9891291|FG002|Overall Study|Lost to Follow-up|7
6221212|NCT01668667|9891292|FG003|Overall Study|Lost to Follow-up|6
6221213|NCT01668667|9891289|FG000|Overall Study|Physician Decision|3
6221214|NCT01668667|9891290|FG001|Overall Study|Physician Decision|0
6221215|NCT01668667|9891291|FG002|Overall Study|Physician Decision|1
6221216|NCT01668667|9891292|FG003|Overall Study|Physician Decision|0
6221217|NCT01668667|9891289|FG000|Overall Study|Withdrawal by Subject|7
6221218|NCT01668667|9891290|FG001|Overall Study|Withdrawal by Subject|4
6221219|NCT01668667|9891291|FG002|Overall Study|Withdrawal by Subject|5
6221220|NCT01668667|9891292|FG003|Overall Study|Withdrawal by Subject|5
6221221|NCT01668797|9891304|FG000|Phase A (Conversion Phase)|Lost to Follow-up|3
6221222|NCT01668797|9891305|FG001|Phase A (Conversion Phase)|Lost to Follow-up|0
6221223|NCT01668797|9891306|FG002|Phase A (Conversion Phase)|Lost to Follow-up|0
6221224|NCT01668797|9891307|FG003|Phase A (Conversion Phase)|Lost to Follow-up|0
6221225|NCT01668797|9891304|FG000|Phase A (Conversion Phase)|Met Withdrawal Criteria|3
6221226|NCT01668797|9891305|FG001|Phase A (Conversion Phase)|Met Withdrawal Criteria|0
6221227|NCT01668797|9891306|FG002|Phase A (Conversion Phase)|Met Withdrawal Criteria|0
6221228|NCT01668797|9891307|FG003|Phase A (Conversion Phase)|Met Withdrawal Criteria|0
6129888|NCT00957580|9756630|FG002|Overall Study|Enrolled but not treated|0
6129889|NCT00957658|9756662|FG000|Overall Study|Death|1
6129890|NCT00957658|9756662|FG000|Overall Study|Lost to Follow-up|4
6129891|NCT00957658|9756662|FG000|Overall Study|Withdrawal by Subject|12
6129892|NCT00957658|9756662|FG000|Overall Study|Revision|1
6129893|NCT00957658|9756662|FG000|Overall Study|Incomplete 2 yr data|28
6129894|NCT00957658|9756662|FG000|Overall Study|Site termination|10
6129895|NCT00957658|9756662|FG000|Overall Study|unwilling/unable to return|2
6129896|NCT00957658|9756662|FG000|Overall Study|surgery cancelled|2
6129897|NCT00957658|9756662|FG000|Overall Study|Protocol Violation|5
6129898|NCT00957723|9756691|FG000|Overall Study|Death|3
6129899|NCT00957723|9756691|FG000|Overall Study|Revision/ Removal of Study Implant|3
6129900|NCT00957723|9756691|FG000|Overall Study|Lost to Follow-up|8
6129901|NCT00957723|9756691|FG000|Overall Study|Withdrawal by Subject|24
6129902|NCT00957723|9756691|FG000|Overall Study|Investigative Site Terminated|61
6129903|NCT00957723|9756691|FG000|Overall Study|Intercurrent Illness|2
6129904|NCT00957723|9756691|FG000|Overall Study|2yr ROM Data Not Evaluable|12
6129905|NCT00957801|9756701|FG000|Overall Study|Withdrawal by Subject|0
6129906|NCT00957801|9756702|FG001|Overall Study|Withdrawal by Subject|0
6221229|NCT01668797|9891304|FG000|Phase A (Conversion Phase)|Physician Decision|2
6129907|NCT00957801|9756703|FG002|Overall Study|Withdrawal by Subject|0
6129908|NCT00957801|9756704|FG003|Overall Study|Withdrawal by Subject|1
6129909|NCT00957853|9756717|FG000|Overall Study|Withdrawal by Subject|1
6129910|NCT00957853|9756718|FG001|Overall Study|Withdrawal by Subject|0
6129911|NCT00957853|9756719|FG002|Overall Study|Withdrawal by Subject|0
6129912|NCT00957905|9756729|FG000|Part B|Not Treated|0
6129913|NCT00957905|9756730|FG001|Part B|Not Treated|1
6129914|NCT00957905|9756729|FG000|Part B|Physician Decision|0
6129915|NCT00957905|9756730|FG001|Part B|Physician Decision|1
6129916|NCT00957905|9756729|FG000|Part B|Death|0
6129917|NCT00957905|9756730|FG001|Part B|Death|1
6129918|NCT00957905|9756729|FG000|Part B|Protocol Violation|0
6129919|NCT00957905|9756730|FG001|Part B|Protocol Violation|1
6129920|NCT00957931|9756736|FG000|Overall Study|Death|4
6129921|NCT00957944|9756742|FG000|First Intervention- 24 Hours|Withdrawal by Subject|0
6129922|NCT00957944|9756743|FG001|First Intervention- 24 Hours|Withdrawal by Subject|1
6129923|NCT00957996|9756751|FG000|Overall Study|Death|4
6129924|NCT00957996|9756752|FG001|Overall Study|Death|10
6129925|NCT00957996|9756751|FG000|Overall Study|Lost to Follow-up|4
6129926|NCT00957996|9756752|FG001|Overall Study|Lost to Follow-up|7
6129927|NCT00957996|9756751|FG000|Overall Study|Withdrawal by Subject|9
6129928|NCT00957996|9756752|FG001|Overall Study|Withdrawal by Subject|2
6129929|NCT00957996|9756751|FG000|Overall Study|Adverse Event|2
6129930|NCT00957996|9756752|FG001|Overall Study|Adverse Event|1
6129931|NCT00957996|9756751|FG000|Overall Study|Physician Decision|1
6129932|NCT00957996|9756752|FG001|Overall Study|Physician Decision|1
6129933|NCT00957996|9756751|FG000|Overall Study|Influenza-related complication|0
6129934|NCT00957996|9756752|FG001|Overall Study|Influenza-related complication|1
6129935|NCT00957996|9756751|FG000|Overall Study|Missing|1
6129936|NCT00957996|9756752|FG001|Overall Study|Missing|0
6129937|NCT00957996|9756751|FG000|Overall Study|Noncompliance; Protocol Deviations|5
6129938|NCT00957996|9756752|FG001|Overall Study|Noncompliance; Protocol Deviations|6
6129939|NCT00958009|9756760|FG000|Overall Study|Adverse Event|1
6129940|NCT00958009|9756760|FG000|Overall Study|Subject found device difficult to use|1
6129941|NCT00958074|9756775|FG000|Overall Study|Withdrawal by Subject|0
6129942|NCT00958074|9756776|FG001|Overall Study|Withdrawal by Subject|1
6221230|NCT01668797|9891305|FG001|Phase A (Conversion Phase)|Physician Decision|0
6221231|NCT01668797|9891306|FG002|Phase A (Conversion Phase)|Physician Decision|0
6221232|NCT01668797|9891307|FG003|Phase A (Conversion Phase)|Physician Decision|0
6221233|NCT01668797|9891304|FG000|Phase A (Conversion Phase)|Withdrawal by Subject|16
6221234|NCT01668797|9891305|FG001|Phase A (Conversion Phase)|Withdrawal by Subject|0
6221235|NCT01668797|9891306|FG002|Phase A (Conversion Phase)|Withdrawal by Subject|0
6221236|NCT01668797|9891307|FG003|Phase A (Conversion Phase)|Withdrawal by Subject|0
6221237|NCT01668797|9891304|FG000|Phase A (Conversion Phase)|Protocol Violation|2
6221238|NCT01668797|9891305|FG001|Phase A (Conversion Phase)|Protocol Violation|0
6221239|NCT01668797|9891306|FG002|Phase A (Conversion Phase)|Protocol Violation|0
6221240|NCT01668797|9891307|FG003|Phase A (Conversion Phase)|Protocol Violation|0
6221241|NCT01668797|9891304|FG000|Phase A (Conversion Phase)|Lack of Efficacy|7
6221242|NCT01668797|9891305|FG001|Phase A (Conversion Phase)|Lack of Efficacy|0
6221243|NCT01668797|9891306|FG002|Phase A (Conversion Phase)|Lack of Efficacy|0
6221244|NCT01668797|9891307|FG003|Phase A (Conversion Phase)|Lack of Efficacy|0
6221245|NCT01668797|9891304|FG000|Phase A (Conversion Phase)|Adverse Event Without Impending Relapse|8
6221246|NCT01668797|9891305|FG001|Phase A (Conversion Phase)|Adverse Event Without Impending Relapse|0
6221247|NCT01668797|9891306|FG002|Phase A (Conversion Phase)|Adverse Event Without Impending Relapse|0
6221248|NCT01668797|9891307|FG003|Phase A (Conversion Phase)|Adverse Event Without Impending Relapse|0
6221249|NCT01668797|9891304|FG000|Phase A (Conversion Phase)|Terminated Study on Interim Analysis|19
6221250|NCT01668797|9891305|FG001|Phase A (Conversion Phase)|Terminated Study on Interim Analysis|0
6221251|NCT01668797|9891306|FG002|Phase A (Conversion Phase)|Terminated Study on Interim Analysis|0
6221252|NCT01668797|9891307|FG003|Phase A (Conversion Phase)|Terminated Study on Interim Analysis|0
6221253|NCT01668797|9891304|FG000|Phase B (Stabilization Phase)|Lost to Follow-up|0
6221254|NCT01668797|9891305|FG001|Phase B (Stabilization Phase)|Lost to Follow-up|16
6221255|NCT01668797|9891306|FG002|Phase B (Stabilization Phase)|Lost to Follow-up|0
6221256|NCT01668797|9891307|FG003|Phase B (Stabilization Phase)|Lost to Follow-up|0
6221257|NCT01668797|9891304|FG000|Phase B (Stabilization Phase)|Met Withdrawal Criteria|0
6221258|NCT01668797|9891305|FG001|Phase B (Stabilization Phase)|Met Withdrawal Criteria|22
6221259|NCT01668797|9891306|FG002|Phase B (Stabilization Phase)|Met Withdrawal Criteria|0
6221260|NCT01668797|9891307|FG003|Phase B (Stabilization Phase)|Met Withdrawal Criteria|0
6221261|NCT01668797|9891304|FG000|Phase B (Stabilization Phase)|Physician Decision|0
6221262|NCT01668797|9891305|FG001|Phase B (Stabilization Phase)|Physician Decision|11
6221263|NCT01668797|9891306|FG002|Phase B (Stabilization Phase)|Physician Decision|0
6221264|NCT01668797|9891307|FG003|Phase B (Stabilization Phase)|Physician Decision|0
6221265|NCT01668797|9891304|FG000|Phase B (Stabilization Phase)|Withdrawal by Subject|0
6221266|NCT01668797|9891305|FG001|Phase B (Stabilization Phase)|Withdrawal by Subject|60
6221267|NCT01668797|9891306|FG002|Phase B (Stabilization Phase)|Withdrawal by Subject|0
6221268|NCT01668797|9891307|FG003|Phase B (Stabilization Phase)|Withdrawal by Subject|0
6221269|NCT01668797|9891304|FG000|Phase B (Stabilization Phase)|Protocol Violation|0
6221270|NCT01668797|9891305|FG001|Phase B (Stabilization Phase)|Protocol Violation|3
6289138|NCT02378480|10003859|FG001|Overall Study|Death|2
6129943|NCT00958126|9756790|FG000|Overall Study|Serious Adverse Event|0
6129944|NCT00958126|9756791|FG001|Overall Study|Serious Adverse Event|2
6129945|NCT00958126|9756792|FG002|Overall Study|Serious Adverse Event|0
6129946|NCT00958126|9756793|FG003|Overall Study|Serious Adverse Event|0
6129947|NCT00958126|9756794|FG004|Overall Study|Serious Adverse Event|0
6129948|NCT00958126|9756795|FG005|Overall Study|Serious Adverse Event|0
6221271|NCT01668797|9891306|FG002|Phase B (Stabilization Phase)|Protocol Violation|0
6221272|NCT01668797|9891307|FG003|Phase B (Stabilization Phase)|Protocol Violation|0
6221273|NCT01668797|9891304|FG000|Phase B (Stabilization Phase)|Lack of Efficacy|0
6221274|NCT01668797|9891305|FG001|Phase B (Stabilization Phase)|Lack of Efficacy|21
6221275|NCT01668797|9891306|FG002|Phase B (Stabilization Phase)|Lack of Efficacy|0
6221276|NCT01668797|9891307|FG003|Phase B (Stabilization Phase)|Lack of Efficacy|0
6221277|NCT01668797|9891304|FG000|Phase B (Stabilization Phase)|Adverse Event Without Impending Relapse|0
6221278|NCT01668797|9891305|FG001|Phase B (Stabilization Phase)|Adverse Event Without Impending Relapse|43
6221279|NCT01668797|9891306|FG002|Phase B (Stabilization Phase)|Adverse Event Without Impending Relapse|0
6221280|NCT01668797|9891307|FG003|Phase B (Stabilization Phase)|Adverse Event Without Impending Relapse|0
6221281|NCT01668797|9891304|FG000|Phase B (Stabilization Phase)|Terminated Study on Interim Analysis|0
6221282|NCT01668797|9891305|FG001|Phase B (Stabilization Phase)|Terminated Study on Interim Analysis|86
6221283|NCT01668797|9891306|FG002|Phase B (Stabilization Phase)|Terminated Study on Interim Analysis|0
6221284|NCT01668797|9891307|FG003|Phase B (Stabilization Phase)|Terminated Study on Interim Analysis|0
6221285|NCT01668797|9891304|FG000|Phase C (Double-Blind Maintenance Phase)|Lost to Follow-up|0
6221286|NCT01668797|9891305|FG001|Phase C (Double-Blind Maintenance Phase)|Lost to Follow-up|0
6221287|NCT01668797|9891306|FG002|Phase C (Double-Blind Maintenance Phase)|Lost to Follow-up|4
6221288|NCT01668797|9891307|FG003|Phase C (Double-Blind Maintenance Phase)|Lost to Follow-up|6
6221289|NCT01668797|9891304|FG000|Phase C (Double-Blind Maintenance Phase)|Met Withdrawal Criteria|0
6221290|NCT01668797|9891305|FG001|Phase C (Double-Blind Maintenance Phase)|Met Withdrawal Criteria|0
6221291|NCT01668797|9891306|FG002|Phase C (Double-Blind Maintenance Phase)|Met Withdrawal Criteria|3
6221292|NCT01668797|9891307|FG003|Phase C (Double-Blind Maintenance Phase)|Met Withdrawal Criteria|3
6221293|NCT01668797|9891304|FG000|Phase C (Double-Blind Maintenance Phase)|Physician Decision|0
6221294|NCT01668797|9891305|FG001|Phase C (Double-Blind Maintenance Phase)|Physician Decision|0
6221295|NCT01668797|9891306|FG002|Phase C (Double-Blind Maintenance Phase)|Physician Decision|5
6221296|NCT01668797|9891307|FG003|Phase C (Double-Blind Maintenance Phase)|Physician Decision|2
6221297|NCT01668797|9891304|FG000|Phase C (Double-Blind Maintenance Phase)|Withdrawal by Subject|0
6221298|NCT01668797|9891305|FG001|Phase C (Double-Blind Maintenance Phase)|Withdrawal by Subject|0
6221299|NCT01668797|9891306|FG002|Phase C (Double-Blind Maintenance Phase)|Withdrawal by Subject|3
6221300|NCT01668797|9891307|FG003|Phase C (Double-Blind Maintenance Phase)|Withdrawal by Subject|5
6221301|NCT01668797|9891304|FG000|Phase C (Double-Blind Maintenance Phase)|Protocol Violation|0
6221302|NCT01668797|9891305|FG001|Phase C (Double-Blind Maintenance Phase)|Protocol Violation|0
6221303|NCT01668797|9891306|FG002|Phase C (Double-Blind Maintenance Phase)|Protocol Violation|2
6221304|NCT01668797|9891307|FG003|Phase C (Double-Blind Maintenance Phase)|Protocol Violation|0
6221305|NCT01668797|9891304|FG000|Phase C (Double-Blind Maintenance Phase)|Lack of Efficacy|0
6221306|NCT01668797|9891305|FG001|Phase C (Double-Blind Maintenance Phase)|Lack of Efficacy|0
6221307|NCT01668797|9891306|FG002|Phase C (Double-Blind Maintenance Phase)|Lack of Efficacy|2
6221308|NCT01668797|9891307|FG003|Phase C (Double-Blind Maintenance Phase)|Lack of Efficacy|10
6221309|NCT01668797|9891304|FG000|Phase C (Double-Blind Maintenance Phase)|Lack of Efficacy without AE|0
6221310|NCT01668797|9891305|FG001|Phase C (Double-Blind Maintenance Phase)|Lack of Efficacy without AE|0
6221311|NCT01668797|9891306|FG002|Phase C (Double-Blind Maintenance Phase)|Lack of Efficacy without AE|11
6221312|NCT01668797|9891307|FG003|Phase C (Double-Blind Maintenance Phase)|Lack of Efficacy without AE|30
6221313|NCT01668797|9891304|FG000|Phase C (Double-Blind Maintenance Phase)|Adverse Event Without Impending Relapse|0
6221314|NCT01668797|9891305|FG001|Phase C (Double-Blind Maintenance Phase)|Adverse Event Without Impending Relapse|0
6221315|NCT01668797|9891306|FG002|Phase C (Double-Blind Maintenance Phase)|Adverse Event Without Impending Relapse|4
6221316|NCT01668797|9891307|FG003|Phase C (Double-Blind Maintenance Phase)|Adverse Event Without Impending Relapse|2
6221317|NCT01668797|9891304|FG000|Phase C (Double-Blind Maintenance Phase)|Terminated Study on Interim Analysis|0
6221318|NCT01668797|9891305|FG001|Phase C (Double-Blind Maintenance Phase)|Terminated Study on Interim Analysis|0
6289139|NCT02378480|10003858|FG000|Overall Study|Randomized, but Not Treated|6
6289140|NCT02378480|10003859|FG001|Overall Study|Randomized, but Not Treated|4
6289141|NCT02378480|10003858|FG000|Overall Study|Adverse Event|0
6221319|NCT01668797|9891306|FG002|Phase C (Double-Blind Maintenance Phase)|Terminated Study on Interim Analysis|49
6221320|NCT01668797|9891307|FG003|Phase C (Double-Blind Maintenance Phase)|Terminated Study on Interim Analysis|38
6221321|NCT01668966|9891337|FG000|Overall Study|Withdrawal by Subject|1
6221322|NCT01668966|9891337|FG000|Overall Study|Death|1
6221323|NCT01668966|9891337|FG000|Overall Study|Not treated|2
6221324|NCT01669122|9891345|FG000|Period I|Lost to Follow-up|1
6221325|NCT01669122|9891345|FG000|Washout Period II|Protocol Violation|2
6221326|NCT01669174|9891358|FG000|Overall Study|Subject withdrew consent|2
6221327|NCT01669174|9891359|FG001|Overall Study|Subject withdrew consent|2
6221328|NCT01669174|9891358|FG000|Overall Study|Lost to Follow-up|1
6221329|NCT01669174|9891359|FG001|Overall Study|Lost to Follow-up|0
6221330|NCT01669174|9891358|FG000|Overall Study|Adverse Event|2
6221331|NCT01669174|9891359|FG001|Overall Study|Adverse Event|2
6129949|NCT00958126|9756796|FG006|Overall Study|Serious Adverse Event|1
6129950|NCT00958126|9756797|FG007|Overall Study|Serious Adverse Event|0
6129951|NCT00958126|9756790|FG000|Overall Study|Withdrawal by Subject|0
6129952|NCT00958126|9756791|FG001|Overall Study|Withdrawal by Subject|2
6129953|NCT00958126|9756792|FG002|Overall Study|Withdrawal by Subject|0
6129954|NCT00958126|9756793|FG003|Overall Study|Withdrawal by Subject|0
6129955|NCT00958126|9756794|FG004|Overall Study|Withdrawal by Subject|0
6129956|NCT00958126|9756795|FG005|Overall Study|Withdrawal by Subject|0
6129957|NCT00958126|9756796|FG006|Overall Study|Withdrawal by Subject|0
6129958|NCT00958126|9756797|FG007|Overall Study|Withdrawal by Subject|0
6129959|NCT00958126|9756790|FG000|Overall Study|Moved away from study area|0
6129960|NCT00958126|9756791|FG001|Overall Study|Moved away from study area|0
6129961|NCT00958126|9756792|FG002|Overall Study|Moved away from study area|1
6129962|NCT00958126|9756793|FG003|Overall Study|Moved away from study area|1
6129963|NCT00958126|9756794|FG004|Overall Study|Moved away from study area|0
6129964|NCT00958126|9756795|FG005|Overall Study|Moved away from study area|0
6129965|NCT00958126|9756796|FG006|Overall Study|Moved away from study area|0
6129966|NCT00958126|9756797|FG007|Overall Study|Moved away from study area|0
6129967|NCT00958126|9756790|FG000|Overall Study|Lost to Follow-up|1
6129968|NCT00958126|9756791|FG001|Overall Study|Lost to Follow-up|5
6129969|NCT00958126|9756792|FG002|Overall Study|Lost to Follow-up|9
6129970|NCT00958126|9756793|FG003|Overall Study|Lost to Follow-up|8
6129971|NCT00958126|9756794|FG004|Overall Study|Lost to Follow-up|0
6129972|NCT00958126|9756795|FG005|Overall Study|Lost to Follow-up|0
6129973|NCT00958126|9756796|FG006|Overall Study|Lost to Follow-up|0
6129974|NCT00958126|9756797|FG007|Overall Study|Lost to Follow-up|0
6129975|NCT00958126|9756790|FG000|Overall Study|Sponsor/Investigator decision|0
6129976|NCT00958126|9756791|FG001|Overall Study|Sponsor/Investigator decision|0
6129977|NCT00958126|9756792|FG002|Overall Study|Sponsor/Investigator decision|0
6129978|NCT00958126|9756793|FG003|Overall Study|Sponsor/Investigator decision|1
6129979|NCT00958126|9756794|FG004|Overall Study|Sponsor/Investigator decision|0
6129980|NCT00958126|9756795|FG005|Overall Study|Sponsor/Investigator decision|0
6129981|NCT00958126|9756796|FG006|Overall Study|Sponsor/Investigator decision|0
6129982|NCT00958126|9756797|FG007|Overall Study|Sponsor/Investigator decision|0
6129983|NCT00958126|9756790|FG000|Overall Study|Other Reason|0
6129984|NCT00958126|9756791|FG001|Overall Study|Other Reason|0
6129985|NCT00958126|9756792|FG002|Overall Study|Other Reason|0
6129986|NCT00958126|9756793|FG003|Overall Study|Other Reason|1
6129987|NCT00958126|9756794|FG004|Overall Study|Other Reason|0
6129988|NCT00958126|9756795|FG005|Overall Study|Other Reason|1
6129989|NCT00958126|9756796|FG006|Overall Study|Other Reason|0
6129990|NCT00958126|9756797|FG007|Overall Study|Other Reason|0
6129991|NCT00958165|9756819|FG000|Overall Study|Lost to Follow-up|5
6129992|NCT00958165|9756819|FG000|Overall Study|Not eligible|9
6129993|NCT00958191|9756823|FG000|Overall Study|Death|4
6129994|NCT00958191|9756823|FG000|Overall Study|Lost to Follow-up|5
6129995|NCT00958191|9756823|FG000|Overall Study|Inadequate 5 yr x-ray quality|10
6129996|NCT00958191|9756823|FG000|Overall Study|Unable/Unwilling to Return/Withdrawal|21
6129997|NCT00958191|9756823|FG000|Overall Study|Revision of study device|4
6129998|NCT00958191|9756823|FG000|Overall Study|Site termination|11
6129999|NCT00958191|9756823|FG000|Overall Study|No 5 yr x-rays|56
6130000|NCT00958217|9756831|FG000|Overall Study|Death|2
6130001|NCT00958217|9756832|FG001|Overall Study|Death|1
6130002|NCT00958217|9756831|FG000|Overall Study|Withdrawal by Subject|4
6130003|NCT00958217|9756832|FG001|Overall Study|Withdrawal by Subject|3
6130004|NCT00958217|9756831|FG000|Overall Study|Lost to Follow-up|17
6130005|NCT00958217|9756832|FG001|Overall Study|Lost to Follow-up|19
6130006|NCT00958217|9756831|FG000|Overall Study|Moved out of area|1
6130007|NCT00958217|9756832|FG001|Overall Study|Moved out of area|1
6130008|NCT00958217|9756831|FG000|Overall Study|Inpatient hospitalization|0
6130009|NCT00958217|9756832|FG001|Overall Study|Inpatient hospitalization|1
6130010|NCT00958243|9756845|FG000|Overall Study|Withdrawal by Subject|0
6130011|NCT00958243|9756846|FG001|Overall Study|Withdrawal by Subject|1
6221332|NCT01669174|9891358|FG000|Overall Study|Administrative problems|1
6221333|NCT01669174|9891359|FG001|Overall Study|Administrative problems|2
6221334|NCT01669343|9891365|FG000|Part A: All Patients|Withdrawal by Subject|7
6221335|NCT01669343|9891365|FG000|Part A: All Patients|Ineligibility discovered after enrollment|2
6221336|NCT01669343|9891365|FG000|Part B: Patients With BMI>=25|Withdrawal by Subject|13
6221337|NCT01669343|9891365|FG000|Part B: Patients With BMI>=25|Recruited during interim analysis|3
6221338|NCT01669343|9891365|FG000|Part B: Patients With BMI>=25|Ineligibility discovered after enrollment|1
6221339|NCT01669421|9891372|FG000|Phase 1: Standard Dose Therapy|Withdrawal by Subject|1
6221340|NCT01669421|9891372|FG000|Phase 1: Standard Dose Therapy|Physician Decision|1
6221341|NCT01669577|9891404|FG000|Overall Study|Death|22
6221342|NCT01669577|9891404|FG000|Overall Study|Lost to Follow-up|78
6221343|NCT01669577|9891404|FG000|Overall Study|Physician Decision|34
6221344|NCT01669629|9891417|FG000|Period 1|protocol deviation|1
6221345|NCT01669629|9891418|FG001|Period 1|protocol deviation|2
6221346|NCT01669798|9891474|FG000|Overall Study|Physician Decision|5
6221347|NCT01669811|9891480|FG000|Overall Study|Investigator decision|0
6221348|NCT01669811|9891481|FG001|Overall Study|Investigator decision|1
6221349|NCT01669811|9891480|FG000|Overall Study|Withdrawal by Subject|1
6221350|NCT01669811|9891481|FG001|Overall Study|Withdrawal by Subject|2
6130012|NCT00958243|9756847|FG002|Overall Study|Withdrawal by Subject|3
6130013|NCT00958243|9756848|FG003|Overall Study|Withdrawal by Subject|1
6130014|NCT00958243|9756849|FG004|Overall Study|Withdrawal by Subject|1
6221351|NCT01669811|9891480|FG000|Overall Study|Adverse Event|2
6221352|NCT01669811|9891481|FG001|Overall Study|Adverse Event|6
6221353|NCT01669811|9891480|FG000|Overall Study|Eligibility Criteria Not Fulfilled|0
6221354|NCT01669811|9891481|FG001|Overall Study|Eligibility Criteria Not Fulfilled|2
6221355|NCT01669902|9891492|FG000|Overall Study|Adverse Event|11
6221356|NCT01669902|9891492|FG000|Overall Study|Lack of Efficacy|10
6221357|NCT01669902|9891492|FG000|Overall Study|Other|8
6221358|NCT01669928|9891498|FG000|First Intervention|Withdrawal by Subject|3
6221359|NCT01669928|9891499|FG001|First Intervention|Withdrawal by Subject|5
6221360|NCT01670019|9891509|FG000|Overall Study|Adverse Event|3
6221361|NCT01670019|9891510|FG001|Overall Study|Adverse Event|0
6221362|NCT01670019|9891509|FG000|Overall Study|Withdrawal by Subject|6
6221363|NCT01670019|9891510|FG001|Overall Study|Withdrawal by Subject|0
6221364|NCT01670045|9891516|FG000|Overall Study|Withdrawal by Subject|3
6221365|NCT01670045|9891516|FG000|Overall Study|Adverse Event|1
6221366|NCT01670045|9891516|FG000|Overall Study|Death|1
6221367|NCT01670045|9891516|FG000|Overall Study|Lost to Follow-up|11
6221368|NCT01670097|9891522|FG000|Overall Study|Started Phase 1 cancer treatment|1
6221369|NCT01670097|9891523|FG001|Overall Study|Started Phase 1 cancer treatment|0
6221370|NCT01670097|9891522|FG000|Overall Study|Study burden|1
6221371|NCT01670097|9891523|FG001|Overall Study|Study burden|0
6221372|NCT01670097|9891522|FG000|Overall Study|COPD exacerbation|0
6221373|NCT01670097|9891523|FG001|Overall Study|COPD exacerbation|1
6221374|NCT01670097|9891522|FG000|Overall Study|Neutropenia|0
6221375|NCT01670097|9891523|FG001|Overall Study|Neutropenia|1
6221376|NCT01670097|9891522|FG000|Overall Study|Clinical deterioration|0
6221377|NCT01670097|9891523|FG001|Overall Study|Clinical deterioration|1
6221378|NCT01670097|9891522|FG000|Overall Study|Disease progression|0
6221379|NCT01670097|9891523|FG001|Overall Study|Disease progression|1
6221380|NCT01670188|9891540|FG000|Overall Study|Death|0
6221381|NCT01670188|9891541|FG001|Overall Study|Death|1
6221382|NCT01670279|9891554|FG000|Overall Study|Adverse Event|0
6289142|NCT02378480|10003859|FG001|Overall Study|Adverse Event|1
6289143|NCT02378480|10003858|FG000|Overall Study|Missed EOT/PTE Visit|1
6289144|NCT02378480|10003859|FG001|Overall Study|Missed EOT/PTE Visit|2
6289145|NCT02378480|10003858|FG000|Overall Study|Withdrawal by Subject|9
6289146|NCT02378480|10003859|FG001|Overall Study|Withdrawal by Subject|4
6289147|NCT02378480|10003858|FG000|Overall Study|Lost to Follow-up|10
6289148|NCT02378480|10003859|FG001|Overall Study|Lost to Follow-up|18
6289149|NCT02378506|10003865|FG000|Overall Study|Lack of Efficacy|3
6289150|NCT02378506|10003865|FG000|Overall Study|Withdrawal by Subject|4
6289151|NCT02378506|10003865|FG000|Overall Study|Protocol Violation|2
6289152|NCT02378506|10003865|FG000|Overall Study|Death|1
6289153|NCT02378506|10003865|FG000|Overall Study|Adverse Event|14
6289154|NCT02378506|10003865|FG000|Overall Study|Randomized But Not Treated|1
6289155|NCT02378662|10003871|FG000|Overall Study|Early Discontinuation|2
6289156|NCT02378662|10003872|FG001|Overall Study|Early Discontinuation|0
6289157|NCT02378883|10003940|FG000|Enrollment|Subject did not meet Inclusion criteria|6
6289158|NCT02378883|10003940|FG000|Enrollment|Attempt to use Apollo was not performed|3
6289159|NCT02378883|10003940|FG000|30 Day Follow-Up|Withdrawal by Subject|1
6289160|NCT02378883|10003940|FG000|30 Day Follow-Up|Physician Decision|2
6289161|NCT02378883|10003940|FG000|30 Day Follow-Up|Missed Visit|2
6289162|NCT02378883|10003940|FG000|30 Day Follow-Up|Death|1
6289163|NCT02378883|10003940|FG000|12 Months Follow-Up|Lost to Follow-up|3
6289164|NCT02378883|10003940|FG000|12 Months Follow-Up|Death|2
6289165|NCT02378935|10003952|FG000|Overall Study|Lack of Efficacy|10
6289166|NCT02378935|10003953|FG001|Overall Study|Lack of Efficacy|0
6289167|NCT02378935|10003954|FG002|Overall Study|Lack of Efficacy|2
6289168|NCT02378935|10003955|FG003|Overall Study|Lack of Efficacy|6
6289169|NCT02378935|10003956|FG004|Overall Study|Lack of Efficacy|0
6289170|NCT02378935|10003957|FG005|Overall Study|Lack of Efficacy|0
6289171|NCT02378935|10003958|FG006|Overall Study|Lack of Efficacy|0
6289172|NCT02378935|10003952|FG000|Overall Study|Death|0
6289173|NCT02378935|10003953|FG001|Overall Study|Death|0
6289174|NCT02378935|10003954|FG002|Overall Study|Death|1
5980948|NCT03738397|9569732|FG000|Overall Study|Adverse Event|3
5980949|NCT03738397|9569733|FG001|Overall Study|Adverse Event|7
5980950|NCT03738397|9569732|FG000|Overall Study|Withdrawal by Subject|8
6221383|NCT01670279|9891555|FG001|Overall Study|Adverse Event|1
6221384|NCT01670279|9891556|FG002|Overall Study|Adverse Event|0
6221385|NCT01670279|9891557|FG003|Overall Study|Adverse Event|0
6221386|NCT01670279|9891554|FG000|Overall Study|Physician Decision|0
6221387|NCT01670279|9891555|FG001|Overall Study|Physician Decision|1
6221388|NCT01670279|9891556|FG002|Overall Study|Physician Decision|0
6221389|NCT01670279|9891557|FG003|Overall Study|Physician Decision|0
6221390|NCT01670279|9891554|FG000|Overall Study|Participant met withdrawal criteria|0
6221391|NCT01670279|9891555|FG001|Overall Study|Participant met withdrawal criteria|0
6221392|NCT01670279|9891556|FG002|Overall Study|Participant met withdrawal criteria|0
6221393|NCT01670279|9891557|FG003|Overall Study|Participant met withdrawal criteria|1
6221394|NCT01670292|9891565|FG000|Overall Study|Lost to Follow-up|14
6221395|NCT01670526|9891588|FG000|Overall Study|Withdrawal by Subject|3
6221396|NCT01670526|9891589|FG001|Overall Study|Withdrawal by Subject|1
6130015|NCT00958243|9756850|FG005|Overall Study|Withdrawal by Subject|5
6130016|NCT00958243|9756845|FG000|Overall Study|Lost to Follow-up|2
6130017|NCT00958243|9756846|FG001|Overall Study|Lost to Follow-up|5
6130018|NCT00958243|9756847|FG002|Overall Study|Lost to Follow-up|11
6130019|NCT00958243|9756848|FG003|Overall Study|Lost to Follow-up|2
6130020|NCT00958243|9756849|FG004|Overall Study|Lost to Follow-up|8
6130021|NCT00958243|9756850|FG005|Overall Study|Lost to Follow-up|5
6130022|NCT00958256|9756870|FG000|Overall Study|Adverse Event|3
6130023|NCT00958360|9756911|FG000|Overall Study|Withdrawal by Subject|3
6130024|NCT00958360|9756912|FG001|Overall Study|Withdrawal by Subject|1
6130025|NCT00958360|9756911|FG000|Overall Study|Death|6
6130026|NCT00958360|9756912|FG001|Overall Study|Death|7
6130027|NCT00958360|9756911|FG000|Overall Study|Physician Decision|2
6130028|NCT00958360|9756912|FG001|Overall Study|Physician Decision|1
6130029|NCT00958360|9756911|FG000|Overall Study|Lost to Follow-up|0
6130030|NCT00958360|9756912|FG001|Overall Study|Lost to Follow-up|1
6130031|NCT00958412|9756918|FG000|Overall Study|Study prematurely terminated|18
6130032|NCT00958438|9756925|FG000|Overall Study|Protocol Violation|3
6130033|NCT00958438|9756926|FG001|Overall Study|Protocol Violation|2
6130034|NCT00958438|9756927|FG002|Overall Study|Protocol Violation|2
6130035|NCT00958438|9756925|FG000|Overall Study|Withdrawal by Subject|4
6130036|NCT00958438|9756926|FG001|Overall Study|Withdrawal by Subject|2
6130037|NCT00958438|9756927|FG002|Overall Study|Withdrawal by Subject|1
6130038|NCT00958438|9756925|FG000|Overall Study|Adverse Event|0
6130039|NCT00958438|9756926|FG001|Overall Study|Adverse Event|3
6130040|NCT00958438|9756927|FG002|Overall Study|Adverse Event|0
6130041|NCT00958438|9756925|FG000|Overall Study|Physician Decision|1
6130042|NCT00958438|9756926|FG001|Overall Study|Physician Decision|0
6130043|NCT00958438|9756927|FG002|Overall Study|Physician Decision|1
6130044|NCT00958438|9756925|FG000|Overall Study|Other than specified above|2
6130045|NCT00958438|9756926|FG001|Overall Study|Other than specified above|3
6130046|NCT00958438|9756927|FG002|Overall Study|Other than specified above|2
6130047|NCT00958568|9756958|FG000|SPII (Wk 0-8, Acute Open-label)|Response Criteria Not Met|80
6130048|NCT00958568|9756959|FG001|SPII (Wk 0-8, Acute Open-label)|Response Criteria Not Met|0
6130049|NCT00958568|9756960|FG002|SPII (Wk 0-8, Acute Open-label)|Response Criteria Not Met|0
6130050|NCT00958568|9756961|FG003|SPII (Wk 0-8, Acute Open-label)|Response Criteria Not Met|0
6130051|NCT00958568|9756958|FG000|SPII (Wk 0-8, Acute Open-label)|Adverse Event|44
6130052|NCT00958568|9756959|FG001|SPII (Wk 0-8, Acute Open-label)|Adverse Event|0
6130053|NCT00958568|9756960|FG002|SPII (Wk 0-8, Acute Open-label)|Adverse Event|0
6130054|NCT00958568|9756961|FG003|SPII (Wk 0-8, Acute Open-label)|Adverse Event|0
6130055|NCT00958568|9756958|FG000|SPII (Wk 0-8, Acute Open-label)|Entry Criteria Not Met|34
6130056|NCT00958568|9756959|FG001|SPII (Wk 0-8, Acute Open-label)|Entry Criteria Not Met|0
6130057|NCT00958568|9756960|FG002|SPII (Wk 0-8, Acute Open-label)|Entry Criteria Not Met|0
6130058|NCT00958568|9756961|FG003|SPII (Wk 0-8, Acute Open-label)|Entry Criteria Not Met|0
6130059|NCT00958568|9756958|FG000|SPII (Wk 0-8, Acute Open-label)|Withdrawal by Subject|39
6130060|NCT00958568|9756959|FG001|SPII (Wk 0-8, Acute Open-label)|Withdrawal by Subject|0
6130061|NCT00958568|9756960|FG002|SPII (Wk 0-8, Acute Open-label)|Withdrawal by Subject|0
6130062|NCT00958568|9756961|FG003|SPII (Wk 0-8, Acute Open-label)|Withdrawal by Subject|0
6130063|NCT00958568|9756958|FG000|SPII (Wk 0-8, Acute Open-label)|Lost to Follow-up|14
6130064|NCT00958568|9756959|FG001|SPII (Wk 0-8, Acute Open-label)|Lost to Follow-up|0
6130065|NCT00958568|9756960|FG002|SPII (Wk 0-8, Acute Open-label)|Lost to Follow-up|0
6130066|NCT00958568|9756961|FG003|SPII (Wk 0-8, Acute Open-label)|Lost to Follow-up|0
6130067|NCT00958568|9756958|FG000|SPII (Wk 0-8, Acute Open-label)|Protocol Violation|13
6130068|NCT00958568|9756959|FG001|SPII (Wk 0-8, Acute Open-label)|Protocol Violation|0
6130069|NCT00958568|9756960|FG002|SPII (Wk 0-8, Acute Open-label)|Protocol Violation|0
6130070|NCT00958568|9756961|FG003|SPII (Wk 0-8, Acute Open-label)|Protocol Violation|0
6130071|NCT00958568|9756958|FG000|SPII (Wk 0-8, Acute Open-label)|Physician Decision|4
6130072|NCT00958568|9756959|FG001|SPII (Wk 0-8, Acute Open-label)|Physician Decision|0
6130073|NCT00958568|9756960|FG002|SPII (Wk 0-8, Acute Open-label)|Physician Decision|0
6130074|NCT00958568|9756961|FG003|SPII (Wk 0-8, Acute Open-label)|Physician Decision|0
6130075|NCT00958568|9756958|FG000|SPII (Wk 0-8, Acute Open-label)|Sponsor Decision|8
6130076|NCT00958568|9756959|FG001|SPII (Wk 0-8, Acute Open-label)|Sponsor Decision|0
6130077|NCT00958568|9756960|FG002|SPII (Wk 0-8, Acute Open-label)|Sponsor Decision|0
6130078|NCT00958568|9756961|FG003|SPII (Wk 0-8, Acute Open-label)|Sponsor Decision|0
6130079|NCT00958568|9756958|FG000|SPII (Wk 0-8, Acute Open-label)|Unknown, Not Otherwise Specified|1
6130080|NCT00958568|9756959|FG001|SPII (Wk 0-8, Acute Open-label)|Unknown, Not Otherwise Specified|0
6130081|NCT00958568|9756960|FG002|SPII (Wk 0-8, Acute Open-label)|Unknown, Not Otherwise Specified|0
6130082|NCT00958568|9756961|FG003|SPII (Wk 0-8, Acute Open-label)|Unknown, Not Otherwise Specified|0
6130083|NCT00958568|9756958|FG000|SPIII (Wk 9-20,Open-label Stabilization)|Stabilization Criteria Not Met|0
6130084|NCT00958568|9756959|FG001|SPIII (Wk 9-20,Open-label Stabilization)|Stabilization Criteria Not Met|62
6130085|NCT00958568|9756960|FG002|SPIII (Wk 9-20,Open-label Stabilization)|Stabilization Criteria Not Met|0
6130086|NCT00958568|9756961|FG003|SPIII (Wk 9-20,Open-label Stabilization)|Stabilization Criteria Not Met|0
6130087|NCT00958568|9756958|FG000|SPIII (Wk 9-20,Open-label Stabilization)|Blinded Randomization Criteria Not Met|0
6130088|NCT00958568|9756959|FG001|SPIII (Wk 9-20,Open-label Stabilization)|Blinded Randomization Criteria Not Met|30
6130089|NCT00958568|9756960|FG002|SPIII (Wk 9-20,Open-label Stabilization)|Blinded Randomization Criteria Not Met|0
6130090|NCT00958568|9756961|FG003|SPIII (Wk 9-20,Open-label Stabilization)|Blinded Randomization Criteria Not Met|0
6130091|NCT00958568|9756958|FG000|SPIII (Wk 9-20,Open-label Stabilization)|Adverse Event|0
6130092|NCT00958568|9756959|FG001|SPIII (Wk 9-20,Open-label Stabilization)|Adverse Event|28
6130093|NCT00958568|9756960|FG002|SPIII (Wk 9-20,Open-label Stabilization)|Adverse Event|0
6130094|NCT00958568|9756961|FG003|SPIII (Wk 9-20,Open-label Stabilization)|Adverse Event|0
6130095|NCT00958568|9756958|FG000|SPIII (Wk 9-20,Open-label Stabilization)|Withdrawal by Subject|0
6130096|NCT00958568|9756959|FG001|SPIII (Wk 9-20,Open-label Stabilization)|Withdrawal by Subject|41
6130097|NCT00958568|9756960|FG002|SPIII (Wk 9-20,Open-label Stabilization)|Withdrawal by Subject|0
6130098|NCT00958568|9756961|FG003|SPIII (Wk 9-20,Open-label Stabilization)|Withdrawal by Subject|0
6130099|NCT00958568|9756958|FG000|SPIII (Wk 9-20,Open-label Stabilization)|Protocol Violation|0
6130100|NCT00958568|9756959|FG001|SPIII (Wk 9-20,Open-label Stabilization)|Protocol Violation|24
6130101|NCT00958568|9756960|FG002|SPIII (Wk 9-20,Open-label Stabilization)|Protocol Violation|0
6130102|NCT00958568|9756961|FG003|SPIII (Wk 9-20,Open-label Stabilization)|Protocol Violation|0
6130103|NCT00958568|9756958|FG000|SPIII (Wk 9-20,Open-label Stabilization)|Lost to Follow-up|0
6130104|NCT00958568|9756959|FG001|SPIII (Wk 9-20,Open-label Stabilization)|Lost to Follow-up|9
6130105|NCT00958568|9756960|FG002|SPIII (Wk 9-20,Open-label Stabilization)|Lost to Follow-up|0
6130106|NCT00958568|9756961|FG003|SPIII (Wk 9-20,Open-label Stabilization)|Lost to Follow-up|0
6130107|NCT00958568|9756958|FG000|SPIII (Wk 9-20,Open-label Stabilization)|Entry Criteria Not Met|0
6130108|NCT00958568|9756959|FG001|SPIII (Wk 9-20,Open-label Stabilization)|Entry Criteria Not Met|6
6130109|NCT00958568|9756960|FG002|SPIII (Wk 9-20,Open-label Stabilization)|Entry Criteria Not Met|0
6130110|NCT00958568|9756961|FG003|SPIII (Wk 9-20,Open-label Stabilization)|Entry Criteria Not Met|0
6130111|NCT00958568|9756958|FG000|SPIII (Wk 9-20,Open-label Stabilization)|Sponsor Decision|0
6130112|NCT00958568|9756959|FG001|SPIII (Wk 9-20,Open-label Stabilization)|Sponsor Decision|5
6130113|NCT00958568|9756960|FG002|SPIII (Wk 9-20,Open-label Stabilization)|Sponsor Decision|0
6130114|NCT00958568|9756961|FG003|SPIII (Wk 9-20,Open-label Stabilization)|Sponsor Decision|0
6130115|NCT00958568|9756958|FG000|SPIII (Wk 9-20,Open-label Stabilization)|Physician Decision|0
6130116|NCT00958568|9756959|FG001|SPIII (Wk 9-20,Open-label Stabilization)|Physician Decision|4
6130117|NCT00958568|9756960|FG002|SPIII (Wk 9-20,Open-label Stabilization)|Physician Decision|0
6130118|NCT00958568|9756961|FG003|SPIII (Wk 9-20,Open-label Stabilization)|Physician Decision|0
6130119|NCT00958568|9756958|FG000|SPIII (Wk 9-20,Open-label Stabilization)|Relapse Criteria Met|0
6130120|NCT00958568|9756959|FG001|SPIII (Wk 9-20,Open-label Stabilization)|Relapse Criteria Met|1
6130121|NCT00958568|9756960|FG002|SPIII (Wk 9-20,Open-label Stabilization)|Relapse Criteria Met|0
6130122|NCT00958568|9756961|FG003|SPIII (Wk 9-20,Open-label Stabilization)|Relapse Criteria Met|0
6130123|NCT00958568|9756958|FG000|SPIII (Wk 9-20,Open-label Stabilization)|Unknown, Not Otherwise Specified|0
6130124|NCT00958568|9756959|FG001|SPIII (Wk 9-20,Open-label Stabilization)|Unknown, Not Otherwise Specified|1
6130125|NCT00958568|9756960|FG002|SPIII (Wk 9-20,Open-label Stabilization)|Unknown, Not Otherwise Specified|0
6130126|NCT00958568|9756961|FG003|SPIII (Wk 9-20,Open-label Stabilization)|Unknown, Not Otherwise Specified|0
6130127|NCT00958568|9756958|FG000|SPIV (Wk 21-47, DB Relapse Prevention)|Relapse Criteria Met|0
6130128|NCT00958568|9756959|FG001|SPIV (Wk 21-47, DB Relapse Prevention)|Relapse Criteria Met|0
6130129|NCT00958568|9756960|FG002|SPIV (Wk 21-47, DB Relapse Prevention)|Relapse Criteria Met|24
6130130|NCT00958568|9756961|FG003|SPIV (Wk 21-47, DB Relapse Prevention)|Relapse Criteria Met|63
6130131|NCT00958568|9756958|FG000|SPIV (Wk 21-47, DB Relapse Prevention)|Adverse Event|0
6130132|NCT00958568|9756959|FG001|SPIV (Wk 21-47, DB Relapse Prevention)|Adverse Event|0
6130133|NCT00958568|9756960|FG002|SPIV (Wk 21-47, DB Relapse Prevention)|Adverse Event|19
6130134|NCT00958568|9756961|FG003|SPIV (Wk 21-47, DB Relapse Prevention)|Adverse Event|10
6130135|NCT00958568|9756958|FG000|SPIV (Wk 21-47, DB Relapse Prevention)|Withdrawal by Subject|0
6130136|NCT00958568|9756959|FG001|SPIV (Wk 21-47, DB Relapse Prevention)|Withdrawal by Subject|0
6130137|NCT00958568|9756960|FG002|SPIV (Wk 21-47, DB Relapse Prevention)|Withdrawal by Subject|16
6130138|NCT00958568|9756961|FG003|SPIV (Wk 21-47, DB Relapse Prevention)|Withdrawal by Subject|15
6130139|NCT00958568|9756958|FG000|SPIV (Wk 21-47, DB Relapse Prevention)|Protocol Violation|0
6130140|NCT00958568|9756959|FG001|SPIV (Wk 21-47, DB Relapse Prevention)|Protocol Violation|0
6130141|NCT00958568|9756960|FG002|SPIV (Wk 21-47, DB Relapse Prevention)|Protocol Violation|11
6130142|NCT00958568|9756961|FG003|SPIV (Wk 21-47, DB Relapse Prevention)|Protocol Violation|5
6130143|NCT00958568|9756958|FG000|SPIV (Wk 21-47, DB Relapse Prevention)|Lost to Follow-up|0
6130144|NCT00958568|9756959|FG001|SPIV (Wk 21-47, DB Relapse Prevention)|Lost to Follow-up|0
6130145|NCT00958568|9756960|FG002|SPIV (Wk 21-47, DB Relapse Prevention)|Lost to Follow-up|3
6130146|NCT00958568|9756961|FG003|SPIV (Wk 21-47, DB Relapse Prevention)|Lost to Follow-up|8
6130147|NCT00958568|9756958|FG000|SPIV (Wk 21-47, DB Relapse Prevention)|Sponsor Decision|0
6130148|NCT00958568|9756959|FG001|SPIV (Wk 21-47, DB Relapse Prevention)|Sponsor Decision|0
6130149|NCT00958568|9756960|FG002|SPIV (Wk 21-47, DB Relapse Prevention)|Sponsor Decision|5
6130150|NCT00958568|9756961|FG003|SPIV (Wk 21-47, DB Relapse Prevention)|Sponsor Decision|4
6130151|NCT00958568|9756958|FG000|SPIV (Wk 21-47, DB Relapse Prevention)|Entry Criteria Not Met|0
6130152|NCT00958568|9756959|FG001|SPIV (Wk 21-47, DB Relapse Prevention)|Entry Criteria Not Met|0
6130153|NCT00958568|9756960|FG002|SPIV (Wk 21-47, DB Relapse Prevention)|Entry Criteria Not Met|2
6130154|NCT00958568|9756961|FG003|SPIV (Wk 21-47, DB Relapse Prevention)|Entry Criteria Not Met|1
6130155|NCT00958568|9756958|FG000|SPIV (Wk 21-47, DB Relapse Prevention)|Death|0
6130156|NCT00958568|9756959|FG001|SPIV (Wk 21-47, DB Relapse Prevention)|Death|0
6130157|NCT00958568|9756960|FG002|SPIV (Wk 21-47, DB Relapse Prevention)|Death|1
6130158|NCT00958568|9756961|FG003|SPIV (Wk 21-47, DB Relapse Prevention)|Death|0
6130159|NCT00958568|9756958|FG000|SPIV (Wk 21-47, DB Relapse Prevention)|Physician Decision|0
6130160|NCT00958568|9756959|FG001|SPIV (Wk 21-47, DB Relapse Prevention)|Physician Decision|0
6130161|NCT00958568|9756960|FG002|SPIV (Wk 21-47, DB Relapse Prevention)|Physician Decision|1
6130162|NCT00958568|9756961|FG003|SPIV (Wk 21-47, DB Relapse Prevention)|Physician Decision|0
6130163|NCT00958711|9756990|FG000|Overall Study|Withdrawal by Subject|0
6130164|NCT00958711|9756991|FG001|Overall Study|Withdrawal by Subject|4
6130165|NCT00958711|9756990|FG000|Overall Study|Physician Decision|5
6130166|NCT00958711|9756991|FG001|Overall Study|Physician Decision|7
6130167|NCT00958711|9756990|FG000|Overall Study|Lost to Follow-up|4
6130168|NCT00958711|9756991|FG001|Overall Study|Lost to Follow-up|1
6130169|NCT00958711|9756990|FG000|Overall Study|Other|2
6130170|NCT00958711|9756991|FG001|Overall Study|Other|5
6130171|NCT00958711|9756990|FG000|Overall Study|Death|1
6130172|NCT00958711|9756991|FG001|Overall Study|Death|2
6130173|NCT00958711|9756990|FG000|Overall Study|Adverse Event|1
6221397|NCT01670526|9891588|FG000|Overall Study|Lost to Follow-up|9
6221398|NCT01670526|9891589|FG001|Overall Study|Lost to Follow-up|5
6221399|NCT01670721|9891595|FG000|Overall Study|Participant's decision|15
6221400|NCT01670721|9891595|FG000|Overall Study|Other than specified above|38
6221401|NCT01671007|9891623|FG000|Overall Study|Other reasons than listed|166
6221402|NCT01671007|9891624|FG001|Overall Study|Other reasons than listed|373
6221403|NCT01671007|9891625|FG002|Overall Study|Other reasons than listed|197
6221404|NCT01671007|9891626|FG003|Overall Study|Other reasons than listed|228
6221405|NCT01671007|9891627|FG004|Overall Study|Other reasons than listed|14
6130174|NCT00958711|9756991|FG001|Overall Study|Adverse Event|2
6130175|NCT00958724|9756997|FG000|Overall Study|Disease Progression|6
6130176|NCT00958776|9757003|FG000|Overall Study|Adverse Event|0
6130177|NCT00958776|9757004|FG001|Overall Study|Adverse Event|1
6130178|NCT00958776|9757003|FG000|Overall Study|Physician Decision|1
6130179|NCT00958776|9757004|FG001|Overall Study|Physician Decision|0
6130180|NCT00958776|9757003|FG000|Overall Study|Lost to Follow-up|2
6130181|NCT00958776|9757004|FG001|Overall Study|Lost to Follow-up|6
6130182|NCT00958776|9757003|FG000|Overall Study|Withdrawal by Subject|7
6130183|NCT00958776|9757004|FG001|Overall Study|Withdrawal by Subject|16
6130184|NCT00958776|9757003|FG000|Overall Study|Protocol Violation|1
6130185|NCT00958776|9757004|FG001|Overall Study|Protocol Violation|1
6130186|NCT00958776|9757003|FG000|Overall Study|Death|2
6130187|NCT00958776|9757004|FG001|Overall Study|Death|1
6130188|NCT00958776|9757003|FG000|Overall Study|Noncompliance; Protocol Deviations|2
6130189|NCT00958776|9757004|FG001|Overall Study|Noncompliance; Protocol Deviations|3
6130190|NCT00958776|9757003|FG000|Overall Study|Missing|1
6130191|NCT00958776|9757004|FG001|Overall Study|Missing|1
6130192|NCT00958789|9757011|FG000|Overall Study|Death|5
6130193|NCT00958789|9757011|FG000|Overall Study|Lost to Follow-up|14
6130194|NCT00958789|9757011|FG000|Overall Study|Withdrawal by Subject|17
6130195|NCT00958789|9757011|FG000|Overall Study|No 2 yr. Knee Society Score data|4
6130196|NCT00958789|9757011|FG000|Overall Study|2 yr. Knee Society Score not calculable|1
6130197|NCT00958789|9757011|FG000|Overall Study|Subject terminated|2
6130198|NCT00958789|9757011|FG000|Overall Study|Revision|7
6130199|NCT00958828|9757020|FG000|Period 1, 1 Week of Wear|Randomization break|0
6130200|NCT00958828|9757021|FG001|Period 1, 1 Week of Wear|Randomization break|1
6130201|NCT00958828|9757020|FG000|Period 2, 1 Week of Wear|Unacceptable lens fit|0
6130202|NCT00958828|9757021|FG001|Period 2, 1 Week of Wear|Unacceptable lens fit|1
6130203|NCT00958841|9757027|FG000|Overall Study|Abnormal laboratory value(s)|1
6130204|NCT00958841|9757027|FG000|Overall Study|Abnormal test procedure result(s)|3
6130205|NCT00958841|9757027|FG000|Overall Study|Administrative problems|1
6130206|NCT00958841|9757027|FG000|Overall Study|Adverse Event|8
6130207|NCT00958841|9757027|FG000|Overall Study|New cancer therapy|5
6130208|NCT00958841|9757027|FG000|Overall Study|Withdrawal by Subject|1
6130209|NCT00958841|9757027|FG000|Overall Study|Unsatisfactory therapeutic effect|22
6130210|NCT00958841|9757027|FG000|Overall Study|Completed M6/did not enter extension|27
6130211|NCT00958841|9757027|FG000|Overall Study|Discontinued prior to M*|28
6130212|NCT00958880|9757043|FG000|Overall Study|Lost to Follow-up|2
6130213|NCT00958880|9757044|FG001|Overall Study|Lost to Follow-up|2
6130214|NCT00959049|9757070|FG000|Overall Study|Adverse Event|1
6130215|NCT00959049|9757071|FG001|Overall Study|Adverse Event|0
6130216|NCT00959049|9757072|FG002|Overall Study|Adverse Event|0
6130217|NCT00959049|9757073|FG003|Overall Study|Adverse Event|0
6221406|NCT01671007|9891628|FG005|Overall Study|Other reasons than listed|71
6221407|NCT01671007|9891629|FG006|Overall Study|Other reasons than listed|17
6130218|NCT00959049|9757074|FG004|Overall Study|Adverse Event|0
6130219|NCT00959049|9757075|FG005|Overall Study|Adverse Event|0
6130220|NCT00959049|9757070|FG000|Overall Study|Lost to Follow-up|17
6130221|NCT00959049|9757071|FG001|Overall Study|Lost to Follow-up|5
6130222|NCT00959049|9757072|FG002|Overall Study|Lost to Follow-up|1
6130223|NCT00959049|9757073|FG003|Overall Study|Lost to Follow-up|10
6130224|NCT00959049|9757074|FG004|Overall Study|Lost to Follow-up|9
6130225|NCT00959049|9757075|FG005|Overall Study|Lost to Follow-up|1
6130226|NCT00959049|9757070|FG000|Overall Study|Contraindicated medication|0
6130227|NCT00959049|9757071|FG001|Overall Study|Contraindicated medication|0
6130228|NCT00959049|9757072|FG002|Overall Study|Contraindicated medication|0
6130229|NCT00959049|9757073|FG003|Overall Study|Contraindicated medication|1
6130230|NCT00959049|9757074|FG004|Overall Study|Contraindicated medication|0
6130231|NCT00959049|9757075|FG005|Overall Study|Contraindicated medication|0
6130232|NCT00959049|9757070|FG000|Overall Study|Withdrawal by Subject|0
6130233|NCT00959049|9757071|FG001|Overall Study|Withdrawal by Subject|2
6130234|NCT00959049|9757072|FG002|Overall Study|Withdrawal by Subject|0
6130235|NCT00959049|9757073|FG003|Overall Study|Withdrawal by Subject|0
6130236|NCT00959049|9757074|FG004|Overall Study|Withdrawal by Subject|0
6130237|NCT00959049|9757075|FG005|Overall Study|Withdrawal by Subject|0
6130238|NCT00959192|9757113|FG000|Overall Study|Adverse Event|1
6130239|NCT00959192|9757114|FG001|Overall Study|Adverse Event|1
6130240|NCT00959192|9757115|FG002|Overall Study|Adverse Event|1
6130241|NCT00959192|9757116|FG003|Overall Study|Adverse Event|0
6130242|NCT00959192|9757113|FG000|Overall Study|Investigator Request|1
6130243|NCT00959192|9757114|FG001|Overall Study|Investigator Request|0
6130244|NCT00959192|9757115|FG002|Overall Study|Investigator Request|0
6130245|NCT00959192|9757116|FG003|Overall Study|Investigator Request|0
6130246|NCT00959192|9757113|FG000|Overall Study|Caregiver Request|0
6130247|NCT00959192|9757114|FG001|Overall Study|Caregiver Request|0
6130248|NCT00959192|9757115|FG002|Overall Study|Caregiver Request|2
6130249|NCT00959192|9757116|FG003|Overall Study|Caregiver Request|1
6130250|NCT00959374|9757127|FG000|Overall Study|Withdrawal by Subject|2
6130251|NCT00959374|9757127|FG000|Overall Study|Lost to Follow-up|14
6130252|NCT00959374|9757127|FG000|Overall Study|Death|1
6130253|NCT00959374|9757127|FG000|Overall Study|Protocol Violation|1
6130254|NCT00959374|9757127|FG000|Overall Study|Implant Removed/Not Replaced|4
6130255|NCT00959374|9757127|FG000|Overall Study|Physician Decision|1
6130256|NCT00959647|9757135|FG000|Overall Study|Adverse Event|2
6130257|NCT00959647|9757135|FG000|Overall Study|Progressive disease|6
6130258|NCT00959647|9757135|FG000|Overall Study|Study terminated by sponsor|4
6130259|NCT00959647|9757135|FG000|Overall Study|Withdrawal by Subject|7
6130260|NCT00959699|9757158|FG000|Treatment Period|Adverse Event|3
6130261|NCT00959699|9757159|FG001|Treatment Period|Adverse Event|13
6130262|NCT00959699|9757158|FG000|Treatment Period|Lack of Efficacy|15
6130263|NCT00959699|9757159|FG001|Treatment Period|Lack of Efficacy|6
6130264|NCT00959699|9757158|FG000|Treatment Period|Lost to Follow-up|0
6130265|NCT00959699|9757159|FG001|Treatment Period|Lost to Follow-up|1
6130266|NCT00959699|9757158|FG000|Treatment Period|Withdrawal by Subject|1
6130267|NCT00959699|9757159|FG001|Treatment Period|Withdrawal by Subject|3
6130268|NCT00959699|9757158|FG000|Treatment Period|Non-Compliance with Protocol|0
6130269|NCT00959699|9757159|FG001|Treatment Period|Non-Compliance with Protocol|1
6130270|NCT00959699|9757158|FG000|Treatment Period|Did not receive treatment|0
6130271|NCT00959699|9757159|FG001|Treatment Period|Did not receive treatment|1
6130272|NCT00959699|9757158|FG000|Treatment Period|Futility/crossover to boceprevir|4
6130273|NCT00959699|9757159|FG001|Treatment Period|Futility/crossover to boceprevir|0
6130274|NCT00959699|9757158|FG000|Follow-up Period|Lost to Follow-up|3
6130275|NCT00959699|9757159|FG001|Follow-up Period|Lost to Follow-up|2
6130276|NCT00959699|9757158|FG000|Follow-up Period|Withdrawal by Subject|3
6130277|NCT00959699|9757159|FG001|Follow-up Period|Withdrawal by Subject|4
6130278|NCT00959751|9757168|FG000|Overall Study|Lost to Follow-up|2
6130279|NCT00959751|9757169|FG001|Overall Study|Lost to Follow-up|3
6130280|NCT00959751|9757168|FG000|Overall Study|Consent Withdrawn|0
6130281|NCT00959751|9757169|FG001|Overall Study|Consent Withdrawn|1
6130282|NCT00959751|9757168|FG000|Overall Study|Non-compliance to Study Procedures|0
6130283|NCT00959751|9757169|FG001|Overall Study|Non-compliance to Study Procedures|1
6130284|NCT00959751|9757168|FG000|Overall Study|No migraine headache without aura|7
6130285|NCT00959751|9757169|FG001|Overall Study|No migraine headache without aura|7
6130286|NCT00959894|9757195|FG000|Overall Study|Lost to Follow-up|10
6130287|NCT00959894|9757195|FG000|Overall Study|Adverse Event|3
6130288|NCT00959894|9757195|FG000|Overall Study|Withdrawal by Subject|1
6130289|NCT00959894|9757195|FG000|Overall Study|Need for contraindicated medication|1
6130290|NCT00959894|9757195|FG000|Overall Study|Subject moved out of town|1
6130291|NCT00959907|9757202|FG000|Overall Study|Protocol Violation|0
6130292|NCT00959907|9757203|FG001|Overall Study|Protocol Violation|1
6130293|NCT00959907|9757202|FG000|Overall Study|Adverse Event|1
6130294|NCT00959907|9757203|FG001|Overall Study|Adverse Event|0
6130295|NCT00959907|9757202|FG000|Overall Study|Withdrawal by Subject|2
6130296|NCT00959907|9757203|FG001|Overall Study|Withdrawal by Subject|0
6130297|NCT00959946|9757228|FG000|Overall Study|Adverse Event|0
6130298|NCT00959946|9757229|FG001|Overall Study|Adverse Event|0
6130299|NCT00959946|9757230|FG002|Overall Study|Adverse Event|2
6130300|NCT00959946|9757231|FG003|Overall Study|Adverse Event|1
6130301|NCT00959946|9757232|FG004|Overall Study|Adverse Event|0
6130302|NCT00959946|9757233|FG005|Overall Study|Adverse Event|1
6130303|NCT00959946|9757234|FG006|Overall Study|Adverse Event|0
6130304|NCT00959946|9757235|FG007|Overall Study|Adverse Event|0
6130305|NCT00959946|9757228|FG000|Overall Study|Death|0
6130306|NCT00959946|9757229|FG001|Overall Study|Death|0
6130307|NCT00959946|9757230|FG002|Overall Study|Death|0
6130308|NCT00959946|9757231|FG003|Overall Study|Death|0
6130309|NCT00959946|9757232|FG004|Overall Study|Death|0
6130310|NCT00959946|9757233|FG005|Overall Study|Death|1
6130311|NCT00959946|9757234|FG006|Overall Study|Death|0
6221408|NCT01671007|9891630|FG007|Overall Study|Other reasons than listed|66
6221409|NCT01671007|9891631|FG008|Overall Study|Other reasons than listed|0
6221410|NCT01671007|9891623|FG000|Overall Study|Withdrawal by Subject|36
6221411|NCT01671007|9891624|FG001|Overall Study|Withdrawal by Subject|59
6289175|NCT02378935|10003955|FG003|Overall Study|Death|0
6289176|NCT02378935|10003956|FG004|Overall Study|Death|0
6289177|NCT02378935|10003957|FG005|Overall Study|Death|0
6289178|NCT02378935|10003958|FG006|Overall Study|Death|0
5980951|NCT03738397|9569733|FG001|Overall Study|Withdrawal by Subject|11
5980952|NCT03738397|9569732|FG000|Overall Study|Lost to Follow-up|8
5980953|NCT03738397|9569733|FG001|Overall Study|Lost to Follow-up|5
5980954|NCT03738397|9569732|FG000|Overall Study|COVID-19 Logistical Restrictions|1
5980955|NCT03738397|9569733|FG001|Overall Study|COVID-19 Logistical Restrictions|1
5980956|NCT03738397|9569732|FG000|Overall Study|Other|4
5980957|NCT03738397|9569733|FG001|Overall Study|Other|6
5980958|NCT03666624|9569741|FG000|Overall Study|participant grieving over recent death of parent|1
5980959|NCT03666624|9569742|FG001|Overall Study|participant grieving over recent death of parent|0
5980960|NCT03649217|9569748|FG000|Overall Study|subject had severe ataxia not initially found|1
5980961|NCT03649217|9569748|FG000|Overall Study|subject had cognitive issues not initially found|1
5980962|NCT03569293|9569767|FG000|Overall Study|Adverse Event|4
5980963|NCT03569293|9569768|FG001|Overall Study|Adverse Event|1
5980964|NCT03569293|9569769|FG002|Overall Study|Adverse Event|5
5980965|NCT03569293|9569770|FG003|Overall Study|Adverse Event|1
5980966|NCT03569293|9569771|FG004|Overall Study|Adverse Event|0
5980967|NCT03569293|9569772|FG005|Overall Study|Adverse Event|0
5980968|NCT03569293|9569767|FG000|Overall Study|Withdrawal by Subject|16
5980969|NCT03569293|9569768|FG001|Overall Study|Withdrawal by Subject|2
5980970|NCT03569293|9569769|FG002|Overall Study|Withdrawal by Subject|4
5980971|NCT03569293|9569770|FG003|Overall Study|Withdrawal by Subject|1
5980972|NCT03569293|9569771|FG004|Overall Study|Withdrawal by Subject|0
5980973|NCT03569293|9569772|FG005|Overall Study|Withdrawal by Subject|0
5980974|NCT03569293|9569767|FG000|Overall Study|Lost to Follow-up|1
5980975|NCT03569293|9569768|FG001|Overall Study|Lost to Follow-up|3
6130312|NCT00959946|9757235|FG007|Overall Study|Death|0
6130313|NCT00959946|9757228|FG000|Overall Study|Disease Progression|2
6130314|NCT00959946|9757229|FG001|Overall Study|Disease Progression|4
6130315|NCT00959946|9757230|FG002|Overall Study|Disease Progression|2
6130316|NCT00959946|9757231|FG003|Overall Study|Disease Progression|4
6130317|NCT00959946|9757232|FG004|Overall Study|Disease Progression|4
6130318|NCT00959946|9757233|FG005|Overall Study|Disease Progression|6
6130319|NCT00959946|9757234|FG006|Overall Study|Disease Progression|2
6130320|NCT00959946|9757235|FG007|Overall Study|Disease Progression|2
6130321|NCT00959946|9757228|FG000|Overall Study|Withdrawal by Subject|0
6130322|NCT00959946|9757229|FG001|Overall Study|Withdrawal by Subject|0
6130323|NCT00959946|9757230|FG002|Overall Study|Withdrawal by Subject|0
6130324|NCT00959946|9757231|FG003|Overall Study|Withdrawal by Subject|0
6130325|NCT00959946|9757232|FG004|Overall Study|Withdrawal by Subject|0
6130326|NCT00959946|9757233|FG005|Overall Study|Withdrawal by Subject|1
6130327|NCT00959946|9757234|FG006|Overall Study|Withdrawal by Subject|0
6130328|NCT00959946|9757235|FG007|Overall Study|Withdrawal by Subject|0
6130329|NCT00960011|9757277|FG000|Overall Study|Death|5
6130330|NCT00960011|9757278|FG001|Overall Study|Death|0
6130331|NCT00960011|9757277|FG000|Overall Study|Lost to Follow-up|6
6130332|NCT00960011|9757278|FG001|Overall Study|Lost to Follow-up|2
6130333|NCT00960063|9757321|FG000|Overall Study|Adverse Event|1
6130334|NCT00960063|9757322|FG001|Overall Study|Adverse Event|0
6130335|NCT00960063|9757323|FG002|Overall Study|Adverse Event|0
6130336|NCT00960063|9757321|FG000|Overall Study|Progression of Disease|0
6130337|NCT00960063|9757322|FG001|Overall Study|Progression of Disease|0
6130338|NCT00960063|9757323|FG002|Overall Study|Progression of Disease|3
6130339|NCT00960076|9757333|FG000|Overall Study|Adverse Event|1
6130340|NCT00960076|9757334|FG001|Overall Study|Adverse Event|7
6130341|NCT00960076|9757333|FG000|Overall Study|No longer met study criteria|1
6130342|NCT00960076|9757334|FG001|Overall Study|No longer met study criteria|5
6130343|NCT00960076|9757333|FG000|Overall Study|Withdrawal by Subject|1
6130344|NCT00960076|9757334|FG001|Overall Study|Withdrawal by Subject|2
6130345|NCT00960076|9757333|FG000|Overall Study|Lost to Follow-up|3
6130346|NCT00960076|9757334|FG001|Overall Study|Lost to Follow-up|3
6130347|NCT00960076|9757333|FG000|Overall Study|Severe non-compliance to protocol|1
6130348|NCT00960076|9757334|FG001|Overall Study|Severe non-compliance to protocol|2
6130349|NCT00960076|9757333|FG000|Overall Study|Hyperglycemia|1
6130350|NCT00960076|9757334|FG001|Overall Study|Hyperglycemia|5
5980976|NCT03569293|9569769|FG002|Overall Study|Lost to Follow-up|1
5980977|NCT03569293|9569770|FG003|Overall Study|Lost to Follow-up|1
5980978|NCT03569293|9569771|FG004|Overall Study|Lost to Follow-up|0
5980979|NCT03569293|9569772|FG005|Overall Study|Lost to Follow-up|0
5980980|NCT03569293|9569767|FG000|Overall Study|Other|8
5980981|NCT03569293|9569768|FG001|Overall Study|Other|2
5980982|NCT03569293|9569769|FG002|Overall Study|Other|1
5980983|NCT03569293|9569770|FG003|Overall Study|Other|1
5980984|NCT03569293|9569771|FG004|Overall Study|Other|0
5980985|NCT03569293|9569772|FG005|Overall Study|Other|0
5980986|NCT03569293|9569767|FG000|Overall Study|Ongoing at Time of Analysis|8
6130351|NCT00960076|9757333|FG000|Overall Study|Did not attend the termination visit|0
6130352|NCT00960076|9757334|FG001|Overall Study|Did not attend the termination visit|1
6130353|NCT00960115|9757342|FG000|Overall Study|Ongoing treatment at data cut-off date|19
6130354|NCT00960115|9757343|FG001|Overall Study|Ongoing treatment at data cut-off date|15
6130355|NCT00960193|9757349|FG000|14 Day Washout Period|Withdrawal by Subject|1
6130356|NCT00960206|9757359|FG000|Overall Study|Death|7
6130357|NCT00960206|9757360|FG001|Overall Study|Death|4
6130358|NCT00960206|9757361|FG002|Overall Study|Death|1
6130359|NCT00960206|9757359|FG000|Overall Study|Unwilling/Unable to return|1
6130360|NCT00960206|9757360|FG001|Overall Study|Unwilling/Unable to return|2
6130361|NCT00960206|9757361|FG002|Overall Study|Unwilling/Unable to return|0
6130362|NCT00960206|9757359|FG000|Overall Study|Lost to Follow-up|8
6130363|NCT00960206|9757360|FG001|Overall Study|Lost to Follow-up|14
6130364|NCT00960206|9757361|FG002|Overall Study|Lost to Follow-up|8
6130365|NCT00960206|9757359|FG000|Overall Study|Withdrawal by Subject|2
6130366|NCT00960206|9757360|FG001|Overall Study|Withdrawal by Subject|4
6130367|NCT00960206|9757361|FG002|Overall Study|Withdrawal by Subject|0
6130368|NCT00960206|9757359|FG000|Overall Study|Revision of study component|2
6130369|NCT00960206|9757360|FG001|Overall Study|Revision of study component|2
6130370|NCT00960206|9757361|FG002|Overall Study|Revision of study component|2
6130371|NCT00960206|9757359|FG000|Overall Study|Missing 10 year data|20
6130372|NCT00960206|9757360|FG001|Overall Study|Missing 10 year data|1
6130373|NCT00960206|9757361|FG002|Overall Study|Missing 10 year data|1
6130374|NCT00960323|9757370|FG000|Atorvastatin Alone|Withdrawal by Subject|1
6130375|NCT00960375|9757380|FG000|Overall Study|Lost to Follow-up|20
6130376|NCT00960375|9757381|FG001|Overall Study|Lost to Follow-up|22
6130377|NCT00960440|9757391|FG000|Overall Study|Death|0
6130378|NCT00960440|9757392|FG001|Overall Study|Death|0
6130379|NCT00960440|9757393|FG002|Overall Study|Death|0
6130380|NCT00960440|9757394|FG003|Overall Study|Death|1
6130381|NCT00960440|9757391|FG000|Overall Study|Adverse Event|12
6130382|NCT00960440|9757392|FG001|Overall Study|Adverse Event|12
6130383|NCT00960440|9757393|FG002|Overall Study|Adverse Event|4
6130384|NCT00960440|9757394|FG003|Overall Study|Adverse Event|4
6130385|NCT00960440|9757391|FG000|Overall Study|Lack of Efficacy|2
6130386|NCT00960440|9757392|FG001|Overall Study|Lack of Efficacy|5
6130387|NCT00960440|9757393|FG002|Overall Study|Lack of Efficacy|3
6130388|NCT00960440|9757394|FG003|Overall Study|Lack of Efficacy|8
6130389|NCT00960440|9757391|FG000|Overall Study|Protocol Violation|2
6130390|NCT00960440|9757392|FG001|Overall Study|Protocol Violation|8
6130391|NCT00960440|9757393|FG002|Overall Study|Protocol Violation|3
6130392|NCT00960440|9757394|FG003|Overall Study|Protocol Violation|4
6130393|NCT00960440|9757391|FG000|Overall Study|Withdrawal by Subject|9
6130394|NCT00960440|9757392|FG001|Overall Study|Withdrawal by Subject|5
6130395|NCT00960440|9757393|FG002|Overall Study|Withdrawal by Subject|2
6130396|NCT00960440|9757394|FG003|Overall Study|Withdrawal by Subject|1
6130397|NCT00960440|9757391|FG000|Overall Study|Other|1
6130398|NCT00960440|9757392|FG001|Overall Study|Other|1
6130399|NCT00960440|9757393|FG002|Overall Study|Other|1
6130400|NCT00960440|9757394|FG003|Overall Study|Other|0
6130401|NCT00960531|9757429|FG000|Overall Study|Lack of Efficacy|1
6289179|NCT02378961|10003978|FG000|Overall Study|Lack of Efficacy|4
6289180|NCT02378961|10003979|FG001|Overall Study|Lack of Efficacy|2
6289181|NCT02378961|10003980|FG002|Overall Study|Lack of Efficacy|0
6289182|NCT02378961|10003981|FG003|Overall Study|Lack of Efficacy|1
6289183|NCT02378961|10003978|FG000|Overall Study|Death|0
6289184|NCT02378961|10003979|FG001|Overall Study|Death|0
6289185|NCT02378961|10003980|FG002|Overall Study|Death|1
6289186|NCT02378961|10003981|FG003|Overall Study|Death|0
6289187|NCT02379052|10003993|FG000|Overall Study|Protocol Violation|0
6289188|NCT02379052|10003994|FG001|Overall Study|Protocol Violation|1
6289189|NCT02379052|10003993|FG000|Overall Study|Adverse Event|0
6289190|NCT02379052|10003994|FG001|Overall Study|Adverse Event|1
6289191|NCT02379052|10003993|FG000|Overall Study|Physician Decision|1
6289192|NCT02379052|10003994|FG001|Overall Study|Physician Decision|1
6289193|NCT02379052|10003993|FG000|Overall Study|Withdrawal by Subject|2
6289194|NCT02379052|10003994|FG001|Overall Study|Withdrawal by Subject|0
6289195|NCT02379052|10003993|FG000|Overall Study|Lost to Follow-up|2
6289196|NCT02379052|10003994|FG001|Overall Study|Lost to Follow-up|1
6289197|NCT02379052|10003993|FG000|Overall Study|Did Not Meet Inc./ Exclusion Criteria|1
6289198|NCT02379052|10003994|FG001|Overall Study|Did Not Meet Inc./ Exclusion Criteria|0
6289199|NCT02379052|10003993|FG000|Overall Study|Subject was Incarcerated|0
6289200|NCT02379052|10003994|FG001|Overall Study|Subject was Incarcerated|1
6289201|NCT02379078|10004002|FG000|Overall Study|Lost to Follow-up|33
6289202|NCT02379078|10004003|FG001|Overall Study|Lost to Follow-up|30
6130402|NCT00960531|9757430|FG001|Overall Study|Lack of Efficacy|0
6130403|NCT00960531|9757431|FG002|Overall Study|Lack of Efficacy|0
6130404|NCT00960531|9757432|FG003|Overall Study|Lack of Efficacy|0
6130405|NCT00960531|9757433|FG004|Overall Study|Lack of Efficacy|0
6130406|NCT00960531|9757434|FG005|Overall Study|Lack of Efficacy|0
6130407|NCT00960531|9757435|FG006|Overall Study|Lack of Efficacy|0
6130408|NCT00960531|9757436|FG007|Overall Study|Lack of Efficacy|0
5980987|NCT03569293|9569768|FG001|Overall Study|Ongoing at Time of Analysis|1
6130409|NCT00960531|9757437|FG008|Overall Study|Lack of Efficacy|0
6130410|NCT00960531|9757438|FG009|Overall Study|Lack of Efficacy|0
6130411|NCT00960531|9757429|FG000|Overall Study|Withdrawal by Subject|1
6289203|NCT02379078|10004002|FG000|Overall Study|Withdrawal by Subject|6
6130412|NCT00960531|9757430|FG001|Overall Study|Withdrawal by Subject|0
6130413|NCT00960531|9757431|FG002|Overall Study|Withdrawal by Subject|5
6130414|NCT00960531|9757432|FG003|Overall Study|Withdrawal by Subject|2
6130415|NCT00960531|9757433|FG004|Overall Study|Withdrawal by Subject|0
6130416|NCT00960531|9757434|FG005|Overall Study|Withdrawal by Subject|0
6130417|NCT00960531|9757435|FG006|Overall Study|Withdrawal by Subject|2
6130418|NCT00960531|9757436|FG007|Overall Study|Withdrawal by Subject|0
6130419|NCT00960531|9757437|FG008|Overall Study|Withdrawal by Subject|1
6130420|NCT00960531|9757438|FG009|Overall Study|Withdrawal by Subject|0
6130421|NCT00960531|9757429|FG000|Overall Study|Caregiver Request|2
6130422|NCT00960531|9757430|FG001|Overall Study|Caregiver Request|0
6130423|NCT00960531|9757431|FG002|Overall Study|Caregiver Request|6
6130424|NCT00960531|9757432|FG003|Overall Study|Caregiver Request|5
6130425|NCT00960531|9757433|FG004|Overall Study|Caregiver Request|0
6130426|NCT00960531|9757434|FG005|Overall Study|Caregiver Request|2
6130427|NCT00960531|9757435|FG006|Overall Study|Caregiver Request|3
6130428|NCT00960531|9757436|FG007|Overall Study|Caregiver Request|1
6130429|NCT00960531|9757437|FG008|Overall Study|Caregiver Request|3
6130430|NCT00960531|9757438|FG009|Overall Study|Caregiver Request|0
6130431|NCT00960531|9757429|FG000|Overall Study|Investigator Request|0
6130432|NCT00960531|9757430|FG001|Overall Study|Investigator Request|0
6130433|NCT00960531|9757431|FG002|Overall Study|Investigator Request|1
6130434|NCT00960531|9757432|FG003|Overall Study|Investigator Request|0
6130435|NCT00960531|9757433|FG004|Overall Study|Investigator Request|0
6130436|NCT00960531|9757434|FG005|Overall Study|Investigator Request|0
6130437|NCT00960531|9757435|FG006|Overall Study|Investigator Request|0
6130438|NCT00960531|9757436|FG007|Overall Study|Investigator Request|0
6130439|NCT00960531|9757437|FG008|Overall Study|Investigator Request|0
6130440|NCT00960531|9757438|FG009|Overall Study|Investigator Request|0
6130441|NCT00960531|9757429|FG000|Overall Study|Discontinuation of Study by Sponsor|0
6130442|NCT00960531|9757430|FG001|Overall Study|Discontinuation of Study by Sponsor|0
6130443|NCT00960531|9757431|FG002|Overall Study|Discontinuation of Study by Sponsor|0
6130444|NCT00960531|9757432|FG003|Overall Study|Discontinuation of Study by Sponsor|0
6130445|NCT00960531|9757433|FG004|Overall Study|Discontinuation of Study by Sponsor|0
6289204|NCT02379078|10004003|FG001|Overall Study|Withdrawal by Subject|5
6289205|NCT02379091|10004013|FG000|Overall Study|Pretreatment Event/Adverse Event|0
6289206|NCT02379091|10004014|FG001|Overall Study|Pretreatment Event/Adverse Event|2
6130446|NCT00960531|9757434|FG005|Overall Study|Discontinuation of Study by Sponsor|0
6130447|NCT00960531|9757435|FG006|Overall Study|Discontinuation of Study by Sponsor|0
6130448|NCT00960531|9757436|FG007|Overall Study|Discontinuation of Study by Sponsor|1
6130449|NCT00960531|9757437|FG008|Overall Study|Discontinuation of Study by Sponsor|0
6130450|NCT00960531|9757438|FG009|Overall Study|Discontinuation of Study by Sponsor|0
6130451|NCT00960531|9757429|FG000|Overall Study|Lost to Follow-up|0
6130452|NCT00960531|9757430|FG001|Overall Study|Lost to Follow-up|0
6130453|NCT00960531|9757431|FG002|Overall Study|Lost to Follow-up|1
6130454|NCT00960531|9757432|FG003|Overall Study|Lost to Follow-up|0
6130455|NCT00960531|9757433|FG004|Overall Study|Lost to Follow-up|0
6130456|NCT00960531|9757434|FG005|Overall Study|Lost to Follow-up|0
6130457|NCT00960531|9757435|FG006|Overall Study|Lost to Follow-up|1
6130458|NCT00960531|9757436|FG007|Overall Study|Lost to Follow-up|0
6130459|NCT00960531|9757437|FG008|Overall Study|Lost to Follow-up|0
6130460|NCT00960531|9757438|FG009|Overall Study|Lost to Follow-up|0
6130461|NCT00960531|9757429|FG000|Overall Study|Failed to Return|2
6130462|NCT00960531|9757430|FG001|Overall Study|Failed to Return|0
6130463|NCT00960531|9757431|FG002|Overall Study|Failed to Return|0
6130464|NCT00960531|9757432|FG003|Overall Study|Failed to Return|0
6130465|NCT00960531|9757433|FG004|Overall Study|Failed to Return|0
6130466|NCT00960531|9757434|FG005|Overall Study|Failed to Return|0
6130467|NCT00960531|9757435|FG006|Overall Study|Failed to Return|0
6130468|NCT00960531|9757436|FG007|Overall Study|Failed to Return|2
6130469|NCT00960531|9757437|FG008|Overall Study|Failed to Return|0
6130470|NCT00960531|9757438|FG009|Overall Study|Failed to Return|0
6130471|NCT00960531|9757429|FG000|Overall Study|Adverse Event (AE)|2
6130472|NCT00960531|9757430|FG001|Overall Study|Adverse Event (AE)|0
6130473|NCT00960531|9757431|FG002|Overall Study|Adverse Event (AE)|0
6130474|NCT00960531|9757432|FG003|Overall Study|Adverse Event (AE)|0
6130475|NCT00960531|9757433|FG004|Overall Study|Adverse Event (AE)|0
6130476|NCT00960531|9757434|FG005|Overall Study|Adverse Event (AE)|1
6130477|NCT00960531|9757435|FG006|Overall Study|Adverse Event (AE)|2
6130478|NCT00960531|9757436|FG007|Overall Study|Adverse Event (AE)|0
6130479|NCT00960531|9757437|FG008|Overall Study|Adverse Event (AE)|2
6130480|NCT00960531|9757438|FG009|Overall Study|Adverse Event (AE)|0
6130481|NCT00960531|9757429|FG000|Overall Study|Reason not Specified|2
6130482|NCT00960531|9757430|FG001|Overall Study|Reason not Specified|1
6130483|NCT00960531|9757431|FG002|Overall Study|Reason not Specified|13
6130484|NCT00960531|9757432|FG003|Overall Study|Reason not Specified|1
6130485|NCT00960531|9757433|FG004|Overall Study|Reason not Specified|2
6130486|NCT00960531|9757434|FG005|Overall Study|Reason not Specified|0
6130487|NCT00960531|9757435|FG006|Overall Study|Reason not Specified|16
6130488|NCT00960531|9757436|FG007|Overall Study|Reason not Specified|0
6130489|NCT00960531|9757437|FG008|Overall Study|Reason not Specified|8
6130490|NCT00960531|9757438|FG009|Overall Study|Reason not Specified|1
6130491|NCT00960570|9757464|FG000|21 Day Washout Period|Adverse Event|1
6130492|NCT00960570|9757464|FG000|21 Day Washout Period|Withdrawal by Subject|1
6130493|NCT00960570|9757464|FG000|1 Day Period Between Dosing|Adverse Event|2
6130494|NCT00960570|9757464|FG000|1 Day Period Between Dosing|Withdrawal by Subject|1
6130495|NCT00960661|9757482|FG000|Basal Insulin Optimization Phase (BIO)|Adverse Event|6
6130496|NCT00960661|9757483|FG001|Basal Insulin Optimization Phase (BIO)|Adverse Event|0
6130497|NCT00960661|9757484|FG002|Basal Insulin Optimization Phase (BIO)|Adverse Event|0
6130498|NCT00960661|9757482|FG000|Basal Insulin Optimization Phase (BIO)|Lost to Follow-up|4
6130499|NCT00960661|9757483|FG001|Basal Insulin Optimization Phase (BIO)|Lost to Follow-up|0
6221412|NCT01671007|9891625|FG002|Overall Study|Withdrawal by Subject|53
6221413|NCT01671007|9891626|FG003|Overall Study|Withdrawal by Subject|58
6221414|NCT01671007|9891627|FG004|Overall Study|Withdrawal by Subject|4
6221415|NCT01671007|9891628|FG005|Overall Study|Withdrawal by Subject|15
6221416|NCT01671007|9891629|FG006|Overall Study|Withdrawal by Subject|1
6221417|NCT01671007|9891630|FG007|Overall Study|Withdrawal by Subject|19
6221418|NCT01671007|9891631|FG008|Overall Study|Withdrawal by Subject|0
6221419|NCT01671007|9891623|FG000|Overall Study|Lost to Follow-up|93
6221420|NCT01671007|9891624|FG001|Overall Study|Lost to Follow-up|142
6221421|NCT01671007|9891625|FG002|Overall Study|Lost to Follow-up|91
6221422|NCT01671007|9891626|FG003|Overall Study|Lost to Follow-up|63
6221423|NCT01671007|9891627|FG004|Overall Study|Lost to Follow-up|7
6221424|NCT01671007|9891628|FG005|Overall Study|Lost to Follow-up|20
6221425|NCT01671007|9891629|FG006|Overall Study|Lost to Follow-up|2
6221426|NCT01671007|9891630|FG007|Overall Study|Lost to Follow-up|28
6221427|NCT01671007|9891631|FG008|Overall Study|Lost to Follow-up|0
6221428|NCT01671007|9891623|FG000|Overall Study|No end of study case report form|3
6221429|NCT01671007|9891624|FG001|Overall Study|No end of study case report form|1
6221430|NCT01671007|9891625|FG002|Overall Study|No end of study case report form|0
6221431|NCT01671007|9891626|FG003|Overall Study|No end of study case report form|2
6221432|NCT01671007|9891627|FG004|Overall Study|No end of study case report form|0
6221433|NCT01671007|9891628|FG005|Overall Study|No end of study case report form|0
6221434|NCT01671007|9891629|FG006|Overall Study|No end of study case report form|0
6221435|NCT01671007|9891630|FG007|Overall Study|No end of study case report form|0
6221436|NCT01671007|9891631|FG008|Overall Study|No end of study case report form|0
6221437|NCT01671007|9891623|FG000|Overall Study|Not eligible|23
6221438|NCT01671007|9891624|FG001|Overall Study|Not eligible|76
6221439|NCT01671007|9891625|FG002|Overall Study|Not eligible|25
6221440|NCT01671007|9891626|FG003|Overall Study|Not eligible|17
6221441|NCT01671007|9891627|FG004|Overall Study|Not eligible|0
6221442|NCT01671007|9891628|FG005|Overall Study|Not eligible|6
6221443|NCT01671007|9891629|FG006|Overall Study|Not eligible|1
6221444|NCT01671007|9891630|FG007|Overall Study|Not eligible|19
6221445|NCT01671007|9891631|FG008|Overall Study|Not eligible|0
6221446|NCT01671059|9891642|FG000|Overall Study|Adverse Event|4
6221447|NCT01671059|9891642|FG000|Overall Study|Lack of Efficacy|1
6221448|NCT01671085|9891649|FG000|Overall Study|Withdrawal by Subject|1
6221449|NCT01671085|9891650|FG001|Overall Study|Withdrawal by Subject|0
6221450|NCT01671111|9891657|FG000|Overall Study|Adverse Event|2
6221451|NCT01671111|9891657|FG000|Overall Study|Lack of Efficacy|1
6221452|NCT01671111|9891657|FG000|Overall Study|Withdrawal by Subject|2
6221453|NCT01671111|9891657|FG000|Overall Study|Physician Decision|1
6221454|NCT01671111|9891657|FG000|Overall Study|Other|24
6221455|NCT01671280|9891665|FG000|Overall Study|Withdrawal by Subject|2
6221456|NCT01671319|9891678|FG000|Overall Study|Withdrawal by Subject|1
6221457|NCT01671332|9891684|FG000|Overall Study|Withdrawal by Subject|1
6221458|NCT01671332|9891685|FG001|Overall Study|Withdrawal by Subject|1
6221459|NCT01671345|9891693|FG000|Overall Study|Lost to Follow-up|10
6221460|NCT01671345|9891694|FG001|Overall Study|Lost to Follow-up|6
6289207|NCT02379091|10004015|FG002|Overall Study|Pretreatment Event/Adverse Event|0
6289208|NCT02379091|10004016|FG003|Overall Study|Pretreatment Event/Adverse Event|1
6289209|NCT02379091|10004013|FG000|Overall Study|Principal Investigator Discretion|0
6289210|NCT02379091|10004014|FG001|Overall Study|Principal Investigator Discretion|1
6289211|NCT02379091|10004015|FG002|Overall Study|Principal Investigator Discretion|0
6289212|NCT02379091|10004016|FG003|Overall Study|Principal Investigator Discretion|0
6289213|NCT02379091|10004013|FG000|Overall Study|Lost to Follow-up|0
6289214|NCT02379091|10004014|FG001|Overall Study|Lost to Follow-up|0
6289215|NCT02379091|10004015|FG002|Overall Study|Lost to Follow-up|0
6289216|NCT02379091|10004016|FG003|Overall Study|Lost to Follow-up|1
6289217|NCT02379091|10004013|FG000|Overall Study|Voluntary Withdrawal|2
6289218|NCT02379091|10004014|FG001|Overall Study|Voluntary Withdrawal|5
6289219|NCT02379091|10004015|FG002|Overall Study|Voluntary Withdrawal|2
6289220|NCT02379091|10004016|FG003|Overall Study|Voluntary Withdrawal|4
6289221|NCT02379091|10004013|FG000|Overall Study|Study Termination|7
6289222|NCT02379091|10004014|FG001|Overall Study|Study Termination|2
6289223|NCT02379091|10004015|FG002|Overall Study|Study Termination|5
6289224|NCT02379091|10004016|FG003|Overall Study|Study Termination|8
6289225|NCT02379091|10004013|FG000|Overall Study|Lack of Efficacy|3
6289226|NCT02379091|10004014|FG001|Overall Study|Lack of Efficacy|0
6289227|NCT02379091|10004015|FG002|Overall Study|Lack of Efficacy|0
6289228|NCT02379091|10004016|FG003|Overall Study|Lack of Efficacy|0
6289229|NCT02379221|10004041|FG000|Overall Study|Lost to Follow-up|1
6289230|NCT02379637|10004080|FG000|Overall Study|Protocol Violation|0
6289231|NCT02379637|10004081|FG001|Overall Study|Protocol Violation|1
6130500|NCT00960661|9757484|FG002|Basal Insulin Optimization Phase (BIO)|Lost to Follow-up|0
6130501|NCT00960661|9757482|FG000|Basal Insulin Optimization Phase (BIO)|Entry criteria not met|331
6130502|NCT00960661|9757483|FG001|Basal Insulin Optimization Phase (BIO)|Entry criteria not met|0
6130503|NCT00960661|9757484|FG002|Basal Insulin Optimization Phase (BIO)|Entry criteria not met|0
6130504|NCT00960661|9757482|FG000|Basal Insulin Optimization Phase (BIO)|Withdrawal by Subject|47
6130505|NCT00960661|9757483|FG001|Basal Insulin Optimization Phase (BIO)|Withdrawal by Subject|0
6130506|NCT00960661|9757484|FG002|Basal Insulin Optimization Phase (BIO)|Withdrawal by Subject|0
6130507|NCT00960661|9757482|FG000|Basal Insulin Optimization Phase (BIO)|Physician Decision|8
6130508|NCT00960661|9757483|FG001|Basal Insulin Optimization Phase (BIO)|Physician Decision|0
6130509|NCT00960661|9757484|FG002|Basal Insulin Optimization Phase (BIO)|Physician Decision|0
6221461|NCT01671345|9891693|FG000|Overall Study|visit with non-participating physician|3
6221462|NCT01671345|9891694|FG001|Overall Study|visit with non-participating physician|3
6221463|NCT01671488|9891712|FG000|Overall Study|Withdrawal by Subject|1
6221464|NCT01671748|9891727|FG000|4 Week run-in Phase|Withdrawal by Subject|1
6221465|NCT01671748|9891728|FG001|4 Week run-in Phase|Withdrawal by Subject|0
6221466|NCT01671748|9891727|FG000|4 Week run-in Phase|Adverse Event|1
6221467|NCT01671748|9891728|FG001|4 Week run-in Phase|Adverse Event|0
6221468|NCT01671748|9891727|FG000|4 Week run-in Phase|Not eligible|9
6221469|NCT01671748|9891728|FG001|4 Week run-in Phase|Not eligible|0
6221470|NCT01672294|9891745|FG000|Overall Study|Withdrawal by Subject|4
6221471|NCT01672294|9891746|FG001|Overall Study|Withdrawal by Subject|4
6221472|NCT01672294|9891747|FG002|Overall Study|Withdrawal by Subject|4
6221473|NCT01672294|9891748|FG003|Overall Study|Withdrawal by Subject|4
6221474|NCT01672294|9891745|FG000|Overall Study|Excluded by study|1
6221475|NCT01672294|9891746|FG001|Overall Study|Excluded by study|1
6221476|NCT01672294|9891747|FG002|Overall Study|Excluded by study|0
6221477|NCT01672294|9891748|FG003|Overall Study|Excluded by study|0
6221478|NCT01672294|9891745|FG000|Overall Study|Lost to Follow-up|1
6221479|NCT01672294|9891746|FG001|Overall Study|Lost to Follow-up|16
6221480|NCT01672294|9891747|FG002|Overall Study|Lost to Follow-up|7
6221481|NCT01672294|9891748|FG003|Overall Study|Lost to Follow-up|9
6221482|NCT01672710|9891769|FG000|Waitlist Assessed After Sauna Regimen|Withdrawal by Subject|0
6221483|NCT01672710|9891770|FG001|Waitlist Assessed After Sauna Regimen|Withdrawal by Subject|1
6221484|NCT01672710|9891769|FG000|3 Month Follow up|Lost to Follow-up|2
6221485|NCT01672710|9891770|FG001|3 Month Follow up|Lost to Follow-up|3
6221486|NCT01672710|9891769|FG000|3 Month Follow up|follow up due after termination date|4
6221487|NCT01672710|9891770|FG001|3 Month Follow up|follow up due after termination date|1
6221488|NCT01672723|9891776|FG000|First Intervention|Adverse Event|3
6221489|NCT01672723|9891777|FG001|First Intervention|Adverse Event|0
6221490|NCT01672736|9891783|FG000|Overall Study|Available drug expired on 31 May 16|3
6221491|NCT01672788|9891787|FG000|Washout Period 2 (7 Days)|Adverse Event|0
6221492|NCT01672788|9891788|FG001|Washout Period 2 (7 Days)|Adverse Event|0
6221493|NCT01672788|9891789|FG002|Washout Period 2 (7 Days)|Adverse Event|0
6221494|NCT01672788|9891790|FG003|Washout Period 2 (7 Days)|Adverse Event|1
6289232|NCT02379637|10004080|FG000|Overall Study|Adverse Event|1
6221495|NCT01672801|9891802|FG000|Overall Study|Screen Failure|0
6221496|NCT01672801|9891803|FG001|Overall Study|Screen Failure|1
6221497|NCT01672853|9891818|FG000|Overall Study|Protocol Specified Criteria for Withdraw|0
6221498|NCT01672853|9891819|FG001|Overall Study|Protocol Specified Criteria for Withdraw|4
6221499|NCT01672853|9891820|FG002|Overall Study|Protocol Specified Criteria for Withdraw|0
6221500|NCT01672853|9891818|FG000|Overall Study|Pregnancy|0
6221501|NCT01672853|9891819|FG001|Overall Study|Pregnancy|1
6221502|NCT01672853|9891820|FG002|Overall Study|Pregnancy|0
6221503|NCT01672853|9891818|FG000|Overall Study|Investigator's Discretion|1
6221504|NCT01672853|9891819|FG001|Overall Study|Investigator's Discretion|0
6221505|NCT01672853|9891820|FG002|Overall Study|Investigator's Discretion|0
6221506|NCT01672853|9891818|FG000|Overall Study|Withdrew Consent|5
6221507|NCT01672853|9891819|FG001|Overall Study|Withdrew Consent|5
6221508|NCT01672853|9891820|FG002|Overall Study|Withdrew Consent|5
6221509|NCT01672853|9891818|FG000|Overall Study|Adverse Event|4
6221510|NCT01672853|9891819|FG001|Overall Study|Adverse Event|6
6221511|NCT01672853|9891820|FG002|Overall Study|Adverse Event|8
6221512|NCT01672853|9891818|FG000|Overall Study|Lost to Follow-up|0
6221513|NCT01672853|9891819|FG001|Overall Study|Lost to Follow-up|1
6221514|NCT01672853|9891820|FG002|Overall Study|Lost to Follow-up|0
6221515|NCT01672853|9891818|FG000|Overall Study|Randomized but Never Treated|0
6221516|NCT01672853|9891819|FG001|Overall Study|Randomized but Never Treated|0
6221517|NCT01672853|9891820|FG002|Overall Study|Randomized but Never Treated|1
6221518|NCT01672866|9891831|FG000|Blinded Phase (up to 240 Weeks)|Study Terminated by Sponsor|40
6221519|NCT01672866|9891832|FG001|Blinded Phase (up to 240 Weeks)|Study Terminated by Sponsor|42
6221520|NCT01672866|9891833|FG002|Blinded Phase (up to 240 Weeks)|Study Terminated by Sponsor|35
6221521|NCT01672866|9891831|FG000|Blinded Phase (up to 240 Weeks)|Withdrew Consent|9
6221522|NCT01672866|9891832|FG001|Blinded Phase (up to 240 Weeks)|Withdrew Consent|8
6221523|NCT01672866|9891833|FG002|Blinded Phase (up to 240 Weeks)|Withdrew Consent|12
6221524|NCT01672866|9891831|FG000|Blinded Phase (up to 240 Weeks)|Lost to Follow-up|3
6221525|NCT01672866|9891832|FG001|Blinded Phase (up to 240 Weeks)|Lost to Follow-up|3
6221526|NCT01672866|9891833|FG002|Blinded Phase (up to 240 Weeks)|Lost to Follow-up|5
6221527|NCT01672866|9891831|FG000|Blinded Phase (up to 240 Weeks)|Adverse Event|3
6130510|NCT00960661|9757482|FG000|Basal Insulin Optimization Phase (BIO)|Sponsor decision|3
6130511|NCT00960661|9757483|FG001|Basal Insulin Optimization Phase (BIO)|Sponsor decision|0
6130512|NCT00960661|9757484|FG002|Basal Insulin Optimization Phase (BIO)|Sponsor decision|0
6130513|NCT00960661|9757482|FG000|Interventional Phase|Adverse Event|0
6130514|NCT00960661|9757483|FG001|Interventional Phase|Adverse Event|17
6130515|NCT00960661|9757484|FG002|Interventional Phase|Adverse Event|8
6130516|NCT00960661|9757482|FG000|Interventional Phase|Death|0
6130517|NCT00960661|9757483|FG001|Interventional Phase|Death|1
6130518|NCT00960661|9757484|FG002|Interventional Phase|Death|0
6130519|NCT00960661|9757482|FG000|Interventional Phase|Lost to Follow-up|0
6130520|NCT00960661|9757483|FG001|Interventional Phase|Lost to Follow-up|0
6130521|NCT00960661|9757484|FG002|Interventional Phase|Lost to Follow-up|2
6130522|NCT00960661|9757482|FG000|Interventional Phase|entry criteria not met|0
6130523|NCT00960661|9757483|FG001|Interventional Phase|entry criteria not met|3
6130524|NCT00960661|9757484|FG002|Interventional Phase|entry criteria not met|0
6130525|NCT00960661|9757482|FG000|Interventional Phase|Protocol Violation|0
6130526|NCT00960661|9757483|FG001|Interventional Phase|Protocol Violation|7
6130527|NCT00960661|9757484|FG002|Interventional Phase|Protocol Violation|2
6130528|NCT00960661|9757482|FG000|Interventional Phase|Withdrawal by Subject|0
6130529|NCT00960661|9757483|FG001|Interventional Phase|Withdrawal by Subject|18
6130530|NCT00960661|9757484|FG002|Interventional Phase|Withdrawal by Subject|29
6130531|NCT00960661|9757482|FG000|Interventional Phase|Physician Decision|0
6130532|NCT00960661|9757483|FG001|Interventional Phase|Physician Decision|3
6130533|NCT00960661|9757484|FG002|Interventional Phase|Physician Decision|5
6130534|NCT00960661|9757482|FG000|Interventional Phase|sponsor decision|0
6130535|NCT00960661|9757483|FG001|Interventional Phase|sponsor decision|1
6130536|NCT00960661|9757484|FG002|Interventional Phase|sponsor decision|0
6130537|NCT00960661|9757482|FG000|Interventional Phase|Lack of Efficacy|0
6130538|NCT00960661|9757483|FG001|Interventional Phase|Lack of Efficacy|2
6130539|NCT00960661|9757484|FG002|Interventional Phase|Lack of Efficacy|0
6130540|NCT00960687|9757490|FG000|Washout Period of 7 Days|Adverse Event|3
6130541|NCT00960687|9757491|FG001|Washout Period of 7 Days|Adverse Event|2
6130542|NCT00960687|9757490|FG000|Washout Period of 7 Days|Withdrawal by Subject|1
6130543|NCT00960687|9757491|FG001|Washout Period of 7 Days|Withdrawal by Subject|1
6130544|NCT00960804|9757509|FG000|Overall Study|Adverse Event|1
6130545|NCT00960804|9757510|FG001|Overall Study|Adverse Event|0
6130546|NCT00960804|9757511|FG002|Overall Study|Adverse Event|0
6130547|NCT00960804|9757509|FG000|Overall Study|Withdrawal by Subject|1
6130548|NCT00960804|9757510|FG001|Overall Study|Withdrawal by Subject|0
6130549|NCT00960804|9757511|FG002|Overall Study|Withdrawal by Subject|0
6130550|NCT00960804|9757509|FG000|Overall Study|Study terminated by the sponsor|5
6130551|NCT00960804|9757510|FG001|Overall Study|Study terminated by the sponsor|4
6130552|NCT00960804|9757511|FG002|Overall Study|Study terminated by the sponsor|10
6130553|NCT00960843|9757521|FG000|Overall Study|Lost to Follow-up|2
6130554|NCT00960843|9757522|FG001|Overall Study|Lost to Follow-up|0
6130555|NCT00960843|9757521|FG000|Overall Study|Protocol Violation|0
6130556|NCT00960843|9757522|FG001|Overall Study|Protocol Violation|4
6130557|NCT00960843|9757521|FG000|Overall Study|Repeated needle dislodgment|0
6130558|NCT00960843|9757522|FG001|Overall Study|Repeated needle dislodgment|1
6130559|NCT00960856|9757528|FG000|Washout Period of 7 Days|Withdrawal by Subject|0
6130560|NCT00960856|9757529|FG001|Washout Period of 7 Days|Withdrawal by Subject|2
6130561|NCT00960856|9757530|FG002|Washout Period of 7 Days|Withdrawal by Subject|0
6130562|NCT00960856|9757531|FG003|Washout Period of 7 Days|Withdrawal by Subject|0
6130563|NCT00960856|9757528|FG000|Washout Period of 7 Days|Adverse Event|0
6130564|NCT00960856|9757529|FG001|Washout Period of 7 Days|Adverse Event|0
6130565|NCT00960856|9757530|FG002|Washout Period of 7 Days|Adverse Event|1
6130566|NCT00960856|9757531|FG003|Washout Period of 7 Days|Adverse Event|0
6130567|NCT00960869|9757543|FG000|Overall Study|Adverse Event|17
6130568|NCT00960869|9757544|FG001|Overall Study|Adverse Event|26
6130569|NCT00960869|9757543|FG000|Overall Study|Withdrawal by Subject|16
6130570|NCT00960869|9757544|FG001|Overall Study|Withdrawal by Subject|14
6130571|NCT00960869|9757543|FG000|Overall Study|Lost to Follow-up|1
6130572|NCT00960869|9757544|FG001|Overall Study|Lost to Follow-up|4
6130573|NCT00960869|9757543|FG000|Overall Study|Misc|19
6130574|NCT00960869|9757544|FG001|Overall Study|Misc|18
6130575|NCT00960934|9757556|FG000|Overall Study|Adverse Event|2
6130576|NCT00960934|9757557|FG001|Overall Study|Adverse Event|3
6130577|NCT00960934|9757558|FG002|Overall Study|Adverse Event|3
6130578|NCT00960934|9757559|FG003|Overall Study|Adverse Event|2
6130579|NCT00960934|9757560|FG004|Overall Study|Adverse Event|4
6130580|NCT00960934|9757561|FG005|Overall Study|Adverse Event|3
6130581|NCT00960934|9757556|FG000|Overall Study|Lack of Efficacy|1
6130582|NCT00960934|9757557|FG001|Overall Study|Lack of Efficacy|0
6130583|NCT00960934|9757558|FG002|Overall Study|Lack of Efficacy|0
6130584|NCT00960934|9757559|FG003|Overall Study|Lack of Efficacy|0
6130585|NCT00960934|9757560|FG004|Overall Study|Lack of Efficacy|0
6130586|NCT00960934|9757561|FG005|Overall Study|Lack of Efficacy|0
6130587|NCT00960934|9757556|FG000|Overall Study|Lost to Follow-up|0
6130588|NCT00960934|9757557|FG001|Overall Study|Lost to Follow-up|1
6130589|NCT00960934|9757558|FG002|Overall Study|Lost to Follow-up|0
6130590|NCT00960934|9757559|FG003|Overall Study|Lost to Follow-up|0
6130591|NCT00960934|9757560|FG004|Overall Study|Lost to Follow-up|0
6130592|NCT00960934|9757561|FG005|Overall Study|Lost to Follow-up|0
6130593|NCT00960934|9757556|FG000|Overall Study|Other|2
6130594|NCT00960934|9757557|FG001|Overall Study|Other|1
6130595|NCT00960934|9757558|FG002|Overall Study|Other|5
6130596|NCT00960934|9757559|FG003|Overall Study|Other|4
6130597|NCT00960934|9757560|FG004|Overall Study|Other|2
6130598|NCT00960934|9757561|FG005|Overall Study|Other|2
6130599|NCT00960934|9757556|FG000|Overall Study|Physician Decision|0
6130600|NCT00960934|9757557|FG001|Overall Study|Physician Decision|1
6130601|NCT00960934|9757558|FG002|Overall Study|Physician Decision|0
6130602|NCT00960934|9757559|FG003|Overall Study|Physician Decision|0
6130603|NCT00960934|9757560|FG004|Overall Study|Physician Decision|0
6130604|NCT00960934|9757561|FG005|Overall Study|Physician Decision|0
6130605|NCT00960934|9757556|FG000|Overall Study|Progressive Disease|1
6130606|NCT00960934|9757557|FG001|Overall Study|Progressive Disease|1
6130607|NCT00960934|9757558|FG002|Overall Study|Progressive Disease|0
6130608|NCT00960934|9757559|FG003|Overall Study|Progressive Disease|0
6130609|NCT00960934|9757560|FG004|Overall Study|Progressive Disease|1
6130610|NCT00960934|9757561|FG005|Overall Study|Progressive Disease|1
6130611|NCT00960934|9757556|FG000|Overall Study|Protocol Violation|3
6130612|NCT00960934|9757557|FG001|Overall Study|Protocol Violation|4
6130613|NCT00960934|9757558|FG002|Overall Study|Protocol Violation|0
6130614|NCT00960934|9757559|FG003|Overall Study|Protocol Violation|3
6130615|NCT00960934|9757560|FG004|Overall Study|Protocol Violation|3
6130616|NCT00960934|9757561|FG005|Overall Study|Protocol Violation|2
6130617|NCT00960934|9757556|FG000|Overall Study|Withdrawal by Subject|5
6130618|NCT00960934|9757557|FG001|Overall Study|Withdrawal by Subject|6
6130619|NCT00960934|9757558|FG002|Overall Study|Withdrawal by Subject|4
6130620|NCT00960934|9757559|FG003|Overall Study|Withdrawal by Subject|5
6130621|NCT00960934|9757560|FG004|Overall Study|Withdrawal by Subject|5
6130622|NCT00960934|9757561|FG005|Overall Study|Withdrawal by Subject|7
6130623|NCT00960934|9757556|FG000|Overall Study|Study Terminated by Sponsor|50
6130624|NCT00960934|9757557|FG001|Overall Study|Study Terminated by Sponsor|46
6130625|NCT00960934|9757558|FG002|Overall Study|Study Terminated by Sponsor|52
6130626|NCT00960934|9757559|FG003|Overall Study|Study Terminated by Sponsor|50
6130627|NCT00960934|9757560|FG004|Overall Study|Study Terminated by Sponsor|49
6130628|NCT00960934|9757561|FG005|Overall Study|Study Terminated by Sponsor|49
6130629|NCT00960986|9757579|FG000|Period 1 (Screening and Washout)|Adverse Event|1
6130630|NCT00960986|9757580|FG001|Period 1 (Screening and Washout)|Adverse Event|2
6130631|NCT00960986|9757581|FG002|Period 1 (Screening and Washout)|Adverse Event|1
6130632|NCT00960986|9757582|FG003|Period 1 (Screening and Washout)|Adverse Event|1
6130633|NCT00960986|9757579|FG000|Period 1 (Screening and Washout)|Lost to Follow-up|0
6130634|NCT00960986|9757580|FG001|Period 1 (Screening and Washout)|Lost to Follow-up|0
6130635|NCT00960986|9757581|FG002|Period 1 (Screening and Washout)|Lost to Follow-up|2
6130636|NCT00960986|9757582|FG003|Period 1 (Screening and Washout)|Lost to Follow-up|1
6130637|NCT00960986|9757579|FG000|Period 1 (Screening and Washout)|Protocol Violation|1
6130638|NCT00960986|9757580|FG001|Period 1 (Screening and Washout)|Protocol Violation|0
6130639|NCT00960986|9757581|FG002|Period 1 (Screening and Washout)|Protocol Violation|0
6130640|NCT00960986|9757582|FG003|Period 1 (Screening and Washout)|Protocol Violation|0
6130641|NCT00960986|9757579|FG000|Period 1 (Screening and Washout)|Withdrawal by Subject|1
6130642|NCT00960986|9757580|FG001|Period 1 (Screening and Washout)|Withdrawal by Subject|2
6130643|NCT00960986|9757581|FG002|Period 1 (Screening and Washout)|Withdrawal by Subject|1
6130644|NCT00960986|9757582|FG003|Period 1 (Screening and Washout)|Withdrawal by Subject|1
6130645|NCT00960986|9757579|FG000|Period 3 (7-week Therapy Period)|Adverse Event|17
6130646|NCT00960986|9757580|FG001|Period 3 (7-week Therapy Period)|Adverse Event|15
6130647|NCT00960986|9757581|FG002|Period 3 (7-week Therapy Period)|Adverse Event|10
6130648|NCT00960986|9757582|FG003|Period 3 (7-week Therapy Period)|Adverse Event|12
6130649|NCT00960986|9757579|FG000|Period 3 (7-week Therapy Period)|Death|0
6130650|NCT00960986|9757580|FG001|Period 3 (7-week Therapy Period)|Death|0
6221528|NCT01672866|9891832|FG001|Blinded Phase (up to 240 Weeks)|Adverse Event|3
6221529|NCT01672866|9891833|FG002|Blinded Phase (up to 240 Weeks)|Adverse Event|3
6221530|NCT01672866|9891831|FG000|Blinded Phase (up to 240 Weeks)|Investigator's Discretion|3
6221531|NCT01672866|9891832|FG001|Blinded Phase (up to 240 Weeks)|Investigator's Discretion|3
6221532|NCT01672866|9891833|FG002|Blinded Phase (up to 240 Weeks)|Investigator's Discretion|2
6221533|NCT01672866|9891831|FG000|Blinded Phase (up to 240 Weeks)|Protocol Violation|2
6221534|NCT01672866|9891832|FG001|Blinded Phase (up to 240 Weeks)|Protocol Violation|0
6221535|NCT01672866|9891833|FG002|Blinded Phase (up to 240 Weeks)|Protocol Violation|0
6221536|NCT01672866|9891831|FG000|Blinded Phase (up to 240 Weeks)|Death|0
6221537|NCT01672866|9891832|FG001|Blinded Phase (up to 240 Weeks)|Death|0
6221538|NCT01672866|9891833|FG002|Blinded Phase (up to 240 Weeks)|Death|1
6221539|NCT01672866|9891831|FG000|Blinded Phase (up to 240 Weeks)|Randomized but Never Treated|3
6221540|NCT01672866|9891832|FG001|Blinded Phase (up to 240 Weeks)|Randomized but Never Treated|0
6221541|NCT01672866|9891833|FG002|Blinded Phase (up to 240 Weeks)|Randomized but Never Treated|0
6221542|NCT01672866|9891831|FG000|Blinded Phase (up to 240 Weeks)|Met protocol-specified reason(s)|11
6221543|NCT01672866|9891832|FG001|Blinded Phase (up to 240 Weeks)|Met protocol-specified reason(s)|15
6289233|NCT02379637|10004081|FG001|Overall Study|Adverse Event|0
6289234|NCT02379637|10004080|FG000|Overall Study|Withdrawal by Subject|1
6289235|NCT02379637|10004081|FG001|Overall Study|Withdrawal by Subject|0
6289236|NCT02379728|10004089|FG000|Overall Study|Lost to Follow-up|1
6130651|NCT00960986|9757581|FG002|Period 3 (7-week Therapy Period)|Death|1
6130652|NCT00960986|9757582|FG003|Period 3 (7-week Therapy Period)|Death|0
6130653|NCT00960986|9757579|FG000|Period 3 (7-week Therapy Period)|Lost to Follow-up|0
6130654|NCT00960986|9757580|FG001|Period 3 (7-week Therapy Period)|Lost to Follow-up|0
6130655|NCT00960986|9757581|FG002|Period 3 (7-week Therapy Period)|Lost to Follow-up|1
6130656|NCT00960986|9757582|FG003|Period 3 (7-week Therapy Period)|Lost to Follow-up|0
6130657|NCT00960986|9757579|FG000|Period 3 (7-week Therapy Period)|Protocol Violation|10
6130658|NCT00960986|9757580|FG001|Period 3 (7-week Therapy Period)|Protocol Violation|4
6130659|NCT00960986|9757581|FG002|Period 3 (7-week Therapy Period)|Protocol Violation|3
6130660|NCT00960986|9757582|FG003|Period 3 (7-week Therapy Period)|Protocol Violation|11
6130661|NCT00960986|9757579|FG000|Period 3 (7-week Therapy Period)|Withdrawal by Subject|2
6130662|NCT00960986|9757580|FG001|Period 3 (7-week Therapy Period)|Withdrawal by Subject|2
6130663|NCT00960986|9757581|FG002|Period 3 (7-week Therapy Period)|Withdrawal by Subject|4
6130664|NCT00960986|9757582|FG003|Period 3 (7-week Therapy Period)|Withdrawal by Subject|2
6130665|NCT00960986|9757579|FG000|Period 3 (7-week Therapy Period)|Lack of Efficacy|1
6130666|NCT00960986|9757580|FG001|Period 3 (7-week Therapy Period)|Lack of Efficacy|2
6130667|NCT00960986|9757581|FG002|Period 3 (7-week Therapy Period)|Lack of Efficacy|1
6130668|NCT00960986|9757582|FG003|Period 3 (7-week Therapy Period)|Lack of Efficacy|0
6130669|NCT00960999|9757594|FG000|Overall Study|Withdrawal by Subject|1
6130670|NCT00960999|9757595|FG001|Overall Study|Withdrawal by Subject|0
6130671|NCT00960999|9757594|FG000|Overall Study|Protocol Violation|5
6130672|NCT00960999|9757595|FG001|Overall Study|Protocol Violation|2
6130673|NCT00960999|9757594|FG000|Overall Study|RT dose constraints not met|2
6130674|NCT00960999|9757595|FG001|Overall Study|RT dose constraints not met|0
6130675|NCT00961116|9757610|FG000|Washout Period of 7 Days|Adverse Event|1
6130676|NCT00961116|9757611|FG001|Washout Period of 7 Days|Adverse Event|1
6130677|NCT00961116|9757610|FG000|Washout Period of 7 Days|Withdrawal by Subject|1
6130678|NCT00961116|9757611|FG001|Washout Period of 7 Days|Withdrawal by Subject|1
6130679|NCT00961116|9757610|FG000|Washout Period of 7 Days|Protocol Violation|0
6130680|NCT00961116|9757611|FG001|Washout Period of 7 Days|Protocol Violation|1
6130681|NCT00961181|9757618|FG000|Overall Study|Death|2
6130682|NCT00961181|9757618|FG000|Overall Study|Withdrawal by Subject|2
6130683|NCT00961181|9757618|FG000|Overall Study|Lost to Follow-up|1
6221544|NCT01672866|9891833|FG002|Blinded Phase (up to 240 Weeks)|Met protocol-specified reason(s)|16
6221545|NCT01672866|9891831|FG000|Open-Label Phase (up to 240 Weeks)|Study Terminated by Sponsor|8
6221546|NCT01672866|9891832|FG001|Open-Label Phase (up to 240 Weeks)|Study Terminated by Sponsor|15
6221547|NCT01672866|9891833|FG002|Open-Label Phase (up to 240 Weeks)|Study Terminated by Sponsor|15
6221548|NCT01672866|9891831|FG000|Open-Label Phase (up to 240 Weeks)|Withdrew Consent|1
6221549|NCT01672866|9891832|FG001|Open-Label Phase (up to 240 Weeks)|Withdrew Consent|0
6221550|NCT01672866|9891833|FG002|Open-Label Phase (up to 240 Weeks)|Withdrew Consent|1
6221551|NCT01672866|9891831|FG000|Open-Label Phase (up to 240 Weeks)|Death|1
6289237|NCT02379728|10004090|FG001|Overall Study|Lost to Follow-up|0
6289238|NCT02379728|10004091|FG002|Overall Study|Lost to Follow-up|3
6289239|NCT02379728|10004092|FG003|Overall Study|Lost to Follow-up|0
6289240|NCT02379728|10004089|FG000|Overall Study|Withdrawal by Subject|5
6289241|NCT02379728|10004090|FG001|Overall Study|Withdrawal by Subject|0
6289242|NCT02379728|10004091|FG002|Overall Study|Withdrawal by Subject|5
6289243|NCT02379728|10004092|FG003|Overall Study|Withdrawal by Subject|3
6289244|NCT02379728|10004089|FG000|Overall Study|Protocol Violation|0
6289245|NCT02379728|10004090|FG001|Overall Study|Protocol Violation|0
6289246|NCT02379728|10004091|FG002|Overall Study|Protocol Violation|2
6289247|NCT02379728|10004092|FG003|Overall Study|Protocol Violation|0
6289248|NCT02379923|10004110|FG000|Overall Study|Death|5
6289249|NCT02380248|10004126|FG000|Overall Study|Lost to Follow-up|11
6289250|NCT02380248|10004126|FG000|Overall Study|Withdrawal by Subject|3
6289251|NCT02380287|10004143|FG000|Overall Study|Adverse Event|0
6289252|NCT02380287|10004144|FG001|Overall Study|Adverse Event|0
6289253|NCT02380287|10004145|FG002|Overall Study|Adverse Event|1
6289254|NCT02380287|10004146|FG003|Overall Study|Adverse Event|0
6289255|NCT02380287|10004147|FG004|Overall Study|Adverse Event|0
6289256|NCT02380287|10004148|FG005|Overall Study|Adverse Event|0
6289257|NCT02380287|10004149|FG006|Overall Study|Adverse Event|0
6289258|NCT02380287|10004150|FG007|Overall Study|Adverse Event|0
6289259|NCT02380677|10004194|FG000|Overall Study|Adverse Event|0
6289260|NCT02380677|10004195|FG001|Overall Study|Adverse Event|0
6289261|NCT02380677|10004196|FG002|Overall Study|Adverse Event|0
6289262|NCT02380677|10004197|FG003|Overall Study|Adverse Event|1
6289263|NCT02380677|10004198|FG004|Overall Study|Adverse Event|1
6289264|NCT02380677|10004199|FG005|Overall Study|Adverse Event|4
6289265|NCT02380677|10004200|FG006|Overall Study|Adverse Event|2
6289266|NCT02380677|10004201|FG007|Overall Study|Adverse Event|2
6130684|NCT00961220|9757622|FG000|Overall Study|Adverse Event|3
6130685|NCT00961220|9757622|FG000|Overall Study|Lack of Efficacy|1
6289267|NCT02380677|10004202|FG008|Overall Study|Adverse Event|2
6289268|NCT02380677|10004203|FG009|Overall Study|Adverse Event|1
6289269|NCT02380677|10004204|FG010|Overall Study|Adverse Event|2
6289270|NCT02380677|10004205|FG011|Overall Study|Adverse Event|1
6289271|NCT02380677|10004194|FG000|Overall Study|Physician Decision|1
6289272|NCT02380677|10004195|FG001|Overall Study|Physician Decision|0
5980988|NCT03569293|9569769|FG002|Overall Study|Ongoing at Time of Analysis|3
5980989|NCT03569293|9569770|FG003|Overall Study|Ongoing at Time of Analysis|0
5980990|NCT03569293|9569771|FG004|Overall Study|Ongoing at Time of Analysis|0
5980991|NCT03569293|9569772|FG005|Overall Study|Ongoing at Time of Analysis|0
6063450|NCT00506415|9664784|FG000|Initial Open Label (Maximum 48 Weeks)|Abnormal laboratory value|1
6063451|NCT00506415|9664785|FG001|Initial Open Label (Maximum 48 Weeks)|Abnormal laboratory value|0
6063452|NCT00506415|9664786|FG002|Initial Open Label (Maximum 48 Weeks)|Abnormal laboratory value|0
6063453|NCT00506415|9664787|FG003|Initial Open Label (Maximum 48 Weeks)|Abnormal laboratory value|0
6063454|NCT00506415|9664784|FG000|Initial Open Label (Maximum 48 Weeks)|Abnormal test procedure results|1
6063455|NCT00506415|9664785|FG001|Initial Open Label (Maximum 48 Weeks)|Abnormal test procedure results|0
6063456|NCT00506415|9664786|FG002|Initial Open Label (Maximum 48 Weeks)|Abnormal test procedure results|0
6063457|NCT00506415|9664787|FG003|Initial Open Label (Maximum 48 Weeks)|Abnormal test procedure results|0
6063458|NCT00506415|9664784|FG000|Initial Open Label (Maximum 48 Weeks)|Unsatisfactory therapeutic effect|58
6063459|NCT00506415|9664785|FG001|Initial Open Label (Maximum 48 Weeks)|Unsatisfactory therapeutic effect|0
6063460|NCT00506415|9664786|FG002|Initial Open Label (Maximum 48 Weeks)|Unsatisfactory therapeutic effect|0
6063461|NCT00506415|9664787|FG003|Initial Open Label (Maximum 48 Weeks)|Unsatisfactory therapeutic effect|0
6063462|NCT00506415|9664784|FG000|Initial Open Label (Maximum 48 Weeks)|Withdrawal by Subject|88
6063463|NCT00506415|9664785|FG001|Initial Open Label (Maximum 48 Weeks)|Withdrawal by Subject|0
6063464|NCT00506415|9664786|FG002|Initial Open Label (Maximum 48 Weeks)|Withdrawal by Subject|0
6063465|NCT00506415|9664787|FG003|Initial Open Label (Maximum 48 Weeks)|Withdrawal by Subject|0
6063466|NCT00506415|9664784|FG000|Initial Open Label (Maximum 48 Weeks)|Lost to Follow-up|22
6063467|NCT00506415|9664785|FG001|Initial Open Label (Maximum 48 Weeks)|Lost to Follow-up|0
6063468|NCT00506415|9664786|FG002|Initial Open Label (Maximum 48 Weeks)|Lost to Follow-up|0
6063469|NCT00506415|9664787|FG003|Initial Open Label (Maximum 48 Weeks)|Lost to Follow-up|0
6063470|NCT00506415|9664784|FG000|Initial Open Label (Maximum 48 Weeks)|Administrative problem|7
6063471|NCT00506415|9664785|FG001|Initial Open Label (Maximum 48 Weeks)|Administrative problem|0
6063472|NCT00506415|9664786|FG002|Initial Open Label (Maximum 48 Weeks)|Administrative problem|0
6063473|NCT00506415|9664787|FG003|Initial Open Label (Maximum 48 Weeks)|Administrative problem|0
6063474|NCT00506415|9664784|FG000|Initial Open Label (Maximum 48 Weeks)|Death|22
6063475|NCT00506415|9664785|FG001|Initial Open Label (Maximum 48 Weeks)|Death|0
6063476|NCT00506415|9664786|FG002|Initial Open Label (Maximum 48 Weeks)|Death|0
6063477|NCT00506415|9664787|FG003|Initial Open Label (Maximum 48 Weeks)|Death|0
6063478|NCT00506415|9664784|FG000|Initial Open Label (Maximum 48 Weeks)|Protocol Violation|28
6063479|NCT00506415|9664785|FG001|Initial Open Label (Maximum 48 Weeks)|Protocol Violation|0
6130686|NCT00961220|9757622|FG000|Overall Study|No IV access for O6BG|1
6130687|NCT00961220|9757622|FG000|Overall Study|O6BG no longer supplied|1
6130688|NCT00961220|9757622|FG000|Overall Study|Complete Response prior to 12 courses|1
6130689|NCT00961259|9757639|FG000|Washout Period of 7 Days|due to concomitant medication used|0
6130690|NCT00961259|9757640|FG001|Washout Period of 7 Days|due to concomitant medication used|1
6130691|NCT00961259|9757641|FG002|Washout Period of 7 Days|due to concomitant medication used|0
6130692|NCT00961298|9757650|FG000|Two Week Placebo Run in|Withdrawal by Subject|1
6130693|NCT00961298|9757650|FG000|12 Weeks Duloxetine Treatment Phase|Withdrawal by Subject|2
6130694|NCT00961298|9757650|FG000|12 Weeks Duloxetine Treatment Phase|Protocol Violation|1
6130695|NCT00961350|9757660|FG000|Overall Study|Adverse Event|18
6130696|NCT00961350|9757661|FG001|Overall Study|Adverse Event|33
6130697|NCT00961350|9757660|FG000|Overall Study|Withdrawal by Subject|10
6130698|NCT00961350|9757661|FG001|Overall Study|Withdrawal by Subject|10
6130699|NCT00961350|9757660|FG000|Overall Study|Lost to Follow-up|3
6130700|NCT00961350|9757661|FG001|Overall Study|Lost to Follow-up|3
6130701|NCT00961350|9757660|FG000|Overall Study|Misc|16
6130702|NCT00961350|9757661|FG001|Overall Study|Misc|21
6130703|NCT00961415|9757678|FG000|Induction Treatment Phase|Withdrawal by Subject|11
6130704|NCT00961415|9757679|FG001|Induction Treatment Phase|Withdrawal by Subject|0
6130705|NCT00961415|9757680|FG002|Induction Treatment Phase|Withdrawal by Subject|0
6130706|NCT00961415|9757678|FG000|Induction Treatment Phase|Death|77
6130707|NCT00961415|9757679|FG001|Induction Treatment Phase|Death|0
6130708|NCT00961415|9757680|FG002|Induction Treatment Phase|Death|0
6130709|NCT00961415|9757678|FG000|Induction Treatment Phase|Protocol Violation|1
6130710|NCT00961415|9757679|FG001|Induction Treatment Phase|Protocol Violation|0
6130711|NCT00961415|9757680|FG002|Induction Treatment Phase|Protocol Violation|0
6130712|NCT00961415|9757678|FG000|Induction Treatment Phase|Physician Decision|2
6130713|NCT00961415|9757679|FG001|Induction Treatment Phase|Physician Decision|0
6130714|NCT00961415|9757680|FG002|Induction Treatment Phase|Physician Decision|0
6130715|NCT00961415|9757678|FG000|Induction Treatment Phase|Didn't meet maintenance phase criteria|27
6130716|NCT00961415|9757679|FG001|Induction Treatment Phase|Didn't meet maintenance phase criteria|0
6130717|NCT00961415|9757680|FG002|Induction Treatment Phase|Didn't meet maintenance phase criteria|0
6130718|NCT00961415|9757678|FG000|Induction Treatment Phase|Other Reason|5
6130719|NCT00961415|9757679|FG001|Induction Treatment Phase|Other Reason|0
6130720|NCT00961415|9757680|FG002|Induction Treatment Phase|Other Reason|0
6130721|NCT00961415|9757678|FG000|Maintenance Treatment Phase|Death|0
6130722|NCT00961415|9757679|FG001|Maintenance Treatment Phase|Death|42
6130723|NCT00961415|9757680|FG002|Maintenance Treatment Phase|Death|34
6130724|NCT00961415|9757678|FG000|Maintenance Treatment Phase|Investigators decision|0
6130725|NCT00961415|9757679|FG001|Maintenance Treatment Phase|Investigators decision|2
6130726|NCT00961415|9757680|FG002|Maintenance Treatment Phase|Investigators decision|0
6130727|NCT00961415|9757678|FG000|Maintenance Treatment Phase|Withdrawal by Subject|0
6130728|NCT00961415|9757679|FG001|Maintenance Treatment Phase|Withdrawal by Subject|3
6130729|NCT00961415|9757680|FG002|Maintenance Treatment Phase|Withdrawal by Subject|8
6130730|NCT00961415|9757678|FG000|Maintenance Treatment Phase|Other reason|0
6130731|NCT00961415|9757679|FG001|Maintenance Treatment Phase|Other reason|1
6130732|NCT00961415|9757680|FG002|Maintenance Treatment Phase|Other reason|3
6130733|NCT00961571|9757707|FG000|Overall Study|Physician Decision|39
6130734|NCT00961636|9757714|FG000|Overall Study|Adverse Event|35
6130735|NCT00961636|9757715|FG001|Overall Study|Adverse Event|54
6130736|NCT00961636|9757716|FG002|Overall Study|Adverse Event|13
6130737|NCT00961636|9757714|FG000|Overall Study|Flushing Symptoms|29
6130738|NCT00961636|9757715|FG001|Overall Study|Flushing Symptoms|46
6130739|NCT00961636|9757716|FG002|Overall Study|Flushing Symptoms|3
6130740|NCT00961636|9757714|FG000|Overall Study|Lost to Follow-up|2
6130741|NCT00961636|9757715|FG001|Overall Study|Lost to Follow-up|3
6130742|NCT00961636|9757716|FG002|Overall Study|Lost to Follow-up|1
6130743|NCT00961636|9757714|FG000|Overall Study|Physician Decision|3
6130744|NCT00961636|9757715|FG001|Overall Study|Physician Decision|1
6130745|NCT00961636|9757716|FG002|Overall Study|Physician Decision|1
6130746|NCT00961636|9757714|FG000|Overall Study|Protocol Violation|9
6130747|NCT00961636|9757715|FG001|Overall Study|Protocol Violation|5
6130748|NCT00961636|9757716|FG002|Overall Study|Protocol Violation|1
6130749|NCT00961636|9757714|FG000|Overall Study|Withdrawal by Subject|29
6130750|NCT00961636|9757715|FG001|Overall Study|Withdrawal by Subject|22
6130751|NCT00961636|9757716|FG002|Overall Study|Withdrawal by Subject|13
6130752|NCT00961649|9757728|FG000|Overall Study|Adverse Event|4
6130753|NCT00961649|9757729|FG001|Overall Study|Adverse Event|0
6130754|NCT00961649|9757730|FG002|Overall Study|Adverse Event|0
6130755|NCT00961649|9757731|FG003|Overall Study|Adverse Event|2
6130756|NCT00961649|9757728|FG000|Overall Study|Inadequate control of IOP|0
6130757|NCT00961649|9757729|FG001|Overall Study|Inadequate control of IOP|0
6130758|NCT00961649|9757730|FG002|Overall Study|Inadequate control of IOP|0
6130759|NCT00961649|9757731|FG003|Overall Study|Inadequate control of IOP|1
6130760|NCT00961649|9757728|FG000|Overall Study|Patient has travel plans during holidays|0
6130761|NCT00961649|9757729|FG001|Overall Study|Patient has travel plans during holidays|0
6130762|NCT00961649|9757730|FG002|Overall Study|Patient has travel plans during holidays|1
6130763|NCT00961649|9757731|FG003|Overall Study|Patient has travel plans during holidays|0
6130764|NCT00961649|9757728|FG000|Overall Study|Patient left to Mexico-family emergency|1
6130765|NCT00961649|9757729|FG001|Overall Study|Patient left to Mexico-family emergency|0
6130766|NCT00961649|9757730|FG002|Overall Study|Patient left to Mexico-family emergency|0
6130767|NCT00961649|9757731|FG003|Overall Study|Patient left to Mexico-family emergency|0
6130768|NCT00961649|9757728|FG000|Overall Study|Study terminated by sponsor|4
6130769|NCT00961649|9757729|FG001|Overall Study|Study terminated by sponsor|4
6130770|NCT00961649|9757730|FG002|Overall Study|Study terminated by sponsor|4
6130771|NCT00961649|9757731|FG003|Overall Study|Study terminated by sponsor|1
6130772|NCT00961896|9757757|FG000|Overall Study|Abnormal laboratory value|0
6130773|NCT00961896|9757758|FG001|Overall Study|Abnormal laboratory value|0
6130774|NCT00961896|9757759|FG002|Overall Study|Abnormal laboratory value|1
6130775|NCT00961961|9757774|FG000|Phase I|Withdrawal by Subject|7
6130776|NCT00961961|9757775|FG001|Phase I|Withdrawal by Subject|0
6130777|NCT00961961|9757776|FG002|Phase I|Withdrawal by Subject|0
6130778|NCT00961961|9757777|FG003|Phase I|Withdrawal by Subject|0
6130779|NCT00961961|9757774|FG000|Phase I|Lost to Follow-up|10
6130780|NCT00961961|9757775|FG001|Phase I|Lost to Follow-up|0
6130781|NCT00961961|9757776|FG002|Phase I|Lost to Follow-up|0
6130782|NCT00961961|9757777|FG003|Phase I|Lost to Follow-up|0
6130783|NCT00961961|9757774|FG000|Phase I|Lack of Efficacy|94
6130784|NCT00961961|9757775|FG001|Phase I|Lack of Efficacy|0
6130785|NCT00961961|9757776|FG002|Phase I|Lack of Efficacy|0
6130786|NCT00961961|9757777|FG003|Phase I|Lack of Efficacy|0
6130787|NCT00961961|9757774|FG000|Phase I|Adverse Event|7
6221552|NCT01672866|9891832|FG001|Open-Label Phase (up to 240 Weeks)|Death|0
6130788|NCT00961961|9757775|FG001|Phase I|Adverse Event|0
6130789|NCT00961961|9757776|FG002|Phase I|Adverse Event|0
6130790|NCT00961961|9757777|FG003|Phase I|Adverse Event|0
6130791|NCT00961961|9757774|FG000|Phase I|Physician Decision|8
6130792|NCT00961961|9757775|FG001|Phase I|Physician Decision|0
6130793|NCT00961961|9757776|FG002|Phase I|Physician Decision|0
6130794|NCT00961961|9757777|FG003|Phase I|Physician Decision|0
6130795|NCT00961961|9757774|FG000|Phase II|Lost to Follow-up|0
6130796|NCT00961961|9757775|FG001|Phase II|Lost to Follow-up|0
6130797|NCT00961961|9757776|FG002|Phase II|Lost to Follow-up|10
6130798|NCT00961961|9757777|FG003|Phase II|Lost to Follow-up|7
6130799|NCT00961961|9757774|FG000|Phase II|Adverse Event|0
6130800|NCT00961961|9757775|FG001|Phase II|Adverse Event|0
6130801|NCT00961961|9757776|FG002|Phase II|Adverse Event|0
6130802|NCT00961961|9757777|FG003|Phase II|Adverse Event|1
6130803|NCT00961961|9757774|FG000|Phase II|Physician Decision|0
6130804|NCT00961961|9757775|FG001|Phase II|Physician Decision|0
6130805|NCT00961961|9757776|FG002|Phase II|Physician Decision|1
6130806|NCT00961961|9757777|FG003|Phase II|Physician Decision|0
6130807|NCT00961961|9757774|FG000|Phase II|Withdrawal by Subject|0
6130808|NCT00961961|9757775|FG001|Phase II|Withdrawal by Subject|0
6130809|NCT00961961|9757776|FG002|Phase II|Withdrawal by Subject|1
6130810|NCT00961961|9757777|FG003|Phase II|Withdrawal by Subject|0
6221553|NCT01672866|9891833|FG002|Open-Label Phase (up to 240 Weeks)|Death|0
6221554|NCT01672866|9891831|FG000|Open-Label Phase (up to 240 Weeks)|Lost to Follow-up|1
6221555|NCT01672866|9891832|FG001|Open-Label Phase (up to 240 Weeks)|Lost to Follow-up|0
6221556|NCT01672866|9891833|FG002|Open-Label Phase (up to 240 Weeks)|Lost to Follow-up|0
6221557|NCT01672879|9891846|FG000|Blinded Phase (Up to 240 Weeks)|Study Terminated by Sponsor|43
6221558|NCT01672879|9891847|FG001|Blinded Phase (Up to 240 Weeks)|Study Terminated by Sponsor|55
6221559|NCT01672879|9891848|FG002|Blinded Phase (Up to 240 Weeks)|Study Terminated by Sponsor|61
6221560|NCT01672879|9891846|FG000|Blinded Phase (Up to 240 Weeks)|Withdrew Consent|14
6221561|NCT01672879|9891847|FG001|Blinded Phase (Up to 240 Weeks)|Withdrew Consent|7
6221562|NCT01672879|9891848|FG002|Blinded Phase (Up to 240 Weeks)|Withdrew Consent|6
6221563|NCT01672879|9891846|FG000|Blinded Phase (Up to 240 Weeks)|Adverse Event|5
6221564|NCT01672879|9891847|FG001|Blinded Phase (Up to 240 Weeks)|Adverse Event|2
6221565|NCT01672879|9891848|FG002|Blinded Phase (Up to 240 Weeks)|Adverse Event|7
6221566|NCT01672879|9891846|FG000|Blinded Phase (Up to 240 Weeks)|Lost to Follow-up|4
6221567|NCT01672879|9891847|FG001|Blinded Phase (Up to 240 Weeks)|Lost to Follow-up|3
6221568|NCT01672879|9891848|FG002|Blinded Phase (Up to 240 Weeks)|Lost to Follow-up|1
6221569|NCT01672879|9891846|FG000|Blinded Phase (Up to 240 Weeks)|Investigator's Discretion|5
6221570|NCT01672879|9891847|FG001|Blinded Phase (Up to 240 Weeks)|Investigator's Discretion|0
6221571|NCT01672879|9891848|FG002|Blinded Phase (Up to 240 Weeks)|Investigator's Discretion|2
6221572|NCT01672879|9891846|FG000|Blinded Phase (Up to 240 Weeks)|Death|0
6221573|NCT01672879|9891847|FG001|Blinded Phase (Up to 240 Weeks)|Death|2
6221574|NCT01672879|9891848|FG002|Blinded Phase (Up to 240 Weeks)|Death|0
6221575|NCT01672879|9891846|FG000|Blinded Phase (Up to 240 Weeks)|Missing|1
6221576|NCT01672879|9891847|FG001|Blinded Phase (Up to 240 Weeks)|Missing|0
6221577|NCT01672879|9891848|FG002|Blinded Phase (Up to 240 Weeks)|Missing|0
6221578|NCT01672879|9891846|FG000|Blinded Phase (Up to 240 Weeks)|Randomized but Never Treated|0
6221579|NCT01672879|9891847|FG001|Blinded Phase (Up to 240 Weeks)|Randomized but Never Treated|0
6221580|NCT01672879|9891848|FG002|Blinded Phase (Up to 240 Weeks)|Randomized but Never Treated|1
6221581|NCT01672879|9891846|FG000|Blinded Phase (Up to 240 Weeks)|Met Protocol-Specified Reason(s)|15
6221582|NCT01672879|9891847|FG001|Blinded Phase (Up to 240 Weeks)|Met Protocol-Specified Reason(s)|17
6221583|NCT01672879|9891848|FG002|Blinded Phase (Up to 240 Weeks)|Met Protocol-Specified Reason(s)|8
6221584|NCT01672879|9891846|FG000|Open-Label Phase (Up to 240 Weeks)|Study Terminated by Sponsor|8
6221585|NCT01672879|9891847|FG001|Open-Label Phase (Up to 240 Weeks)|Study Terminated by Sponsor|16
6221586|NCT01672879|9891848|FG002|Open-Label Phase (Up to 240 Weeks)|Study Terminated by Sponsor|6
6221587|NCT01672879|9891846|FG000|Open-Label Phase (Up to 240 Weeks)|Adverse Event|5
6221588|NCT01672879|9891847|FG001|Open-Label Phase (Up to 240 Weeks)|Adverse Event|1
6221589|NCT01672879|9891848|FG002|Open-Label Phase (Up to 240 Weeks)|Adverse Event|1
6221590|NCT01672879|9891846|FG000|Open-Label Phase (Up to 240 Weeks)|Investigator's Discretion|1
6221591|NCT01672879|9891847|FG001|Open-Label Phase (Up to 240 Weeks)|Investigator's Discretion|0
6221592|NCT01672879|9891848|FG002|Open-Label Phase (Up to 240 Weeks)|Investigator's Discretion|1
6221593|NCT01672879|9891846|FG000|Open-Label Phase (Up to 240 Weeks)|Progressive Disease|1
6221594|NCT01672879|9891847|FG001|Open-Label Phase (Up to 240 Weeks)|Progressive Disease|0
6221595|NCT01672879|9891848|FG002|Open-Label Phase (Up to 240 Weeks)|Progressive Disease|0
6221596|NCT01672892|9891859|FG000|Overall Study|Protocol Violation|7
6221597|NCT01672892|9891860|FG001|Overall Study|Protocol Violation|3
6221598|NCT01672957|9891869|FG000|Overall Study|Protocol Violation|48
6221599|NCT01672957|9891869|FG000|Overall Study|Death|2
6289273|NCT02380677|10004196|FG002|Overall Study|Physician Decision|1
6289274|NCT02380677|10004197|FG003|Overall Study|Physician Decision|1
6289275|NCT02380677|10004198|FG004|Overall Study|Physician Decision|0
6289276|NCT02380677|10004199|FG005|Overall Study|Physician Decision|0
6289277|NCT02380677|10004200|FG006|Overall Study|Physician Decision|0
6289278|NCT02380677|10004201|FG007|Overall Study|Physician Decision|0
6289279|NCT02380677|10004202|FG008|Overall Study|Physician Decision|0
6289280|NCT02380677|10004203|FG009|Overall Study|Physician Decision|0
6289281|NCT02380677|10004204|FG010|Overall Study|Physician Decision|0
6289282|NCT02380677|10004205|FG011|Overall Study|Physician Decision|0
6289283|NCT02380677|10004194|FG000|Overall Study|Lack of Efficacy|0
6289284|NCT02380677|10004195|FG001|Overall Study|Lack of Efficacy|1
6221600|NCT01672957|9891869|FG000|Overall Study|ICF Signed After Transplantation|5
6221601|NCT01672970|9891873|FG000|Overall Study|Lack of Efficacy|12
6221602|NCT01672970|9891873|FG000|Overall Study|Adverse Event|18
6221603|NCT01672970|9891873|FG000|Overall Study|Withdrawal by Subject|2
6221604|NCT01672970|9891873|FG000|Overall Study|Lost to Follow-up|5
6221605|NCT01672970|9891873|FG000|Overall Study|Other|9
6221606|NCT01672970|9891873|FG000|Overall Study|Enrolled but not treated|1
6221607|NCT01673009|9891935|FG000|Overall Study|Physician Decision|5
6221608|NCT01673009|9891935|FG000|Overall Study|Withdrawal by Subject|8
6221609|NCT01673126|9891955|FG000|Overall Study|change of diagnosis|4
6289285|NCT02380677|10004196|FG002|Overall Study|Lack of Efficacy|2
6289286|NCT02380677|10004197|FG003|Overall Study|Lack of Efficacy|0
6289287|NCT02380677|10004198|FG004|Overall Study|Lack of Efficacy|4
6289288|NCT02380677|10004199|FG005|Overall Study|Lack of Efficacy|1
6289289|NCT02380677|10004200|FG006|Overall Study|Lack of Efficacy|1
6289290|NCT02380677|10004201|FG007|Overall Study|Lack of Efficacy|2
6289291|NCT02380677|10004202|FG008|Overall Study|Lack of Efficacy|2
6289292|NCT02380677|10004203|FG009|Overall Study|Lack of Efficacy|0
6289293|NCT02380677|10004204|FG010|Overall Study|Lack of Efficacy|2
6289294|NCT02380677|10004205|FG011|Overall Study|Lack of Efficacy|1
6289295|NCT02380677|10004194|FG000|Overall Study|Withdrawal by Subject|0
6289296|NCT02380677|10004195|FG001|Overall Study|Withdrawal by Subject|0
6289297|NCT02380677|10004196|FG002|Overall Study|Withdrawal by Subject|0
6289298|NCT02380677|10004197|FG003|Overall Study|Withdrawal by Subject|0
6289299|NCT02380677|10004198|FG004|Overall Study|Withdrawal by Subject|0
6289300|NCT02380677|10004199|FG005|Overall Study|Withdrawal by Subject|0
6289301|NCT02380677|10004200|FG006|Overall Study|Withdrawal by Subject|0
6289302|NCT02380677|10004201|FG007|Overall Study|Withdrawal by Subject|0
6289303|NCT02380677|10004202|FG008|Overall Study|Withdrawal by Subject|0
6289304|NCT02380677|10004203|FG009|Overall Study|Withdrawal by Subject|1
6289305|NCT02380677|10004204|FG010|Overall Study|Withdrawal by Subject|0
6289306|NCT02380677|10004205|FG011|Overall Study|Withdrawal by Subject|3
6289307|NCT02380677|10004194|FG000|Overall Study|Other|0
6289308|NCT02380677|10004195|FG001|Overall Study|Other|0
6289309|NCT02380677|10004196|FG002|Overall Study|Other|0
6289310|NCT02380677|10004197|FG003|Overall Study|Other|1
6289311|NCT02380677|10004198|FG004|Overall Study|Other|1
6289312|NCT02380677|10004199|FG005|Overall Study|Other|1
6289313|NCT02380677|10004200|FG006|Overall Study|Other|0
6289314|NCT02380677|10004201|FG007|Overall Study|Other|0
6289315|NCT02380677|10004202|FG008|Overall Study|Other|0
6289316|NCT02380677|10004203|FG009|Overall Study|Other|0
6289317|NCT02380677|10004204|FG010|Overall Study|Other|0
6289318|NCT02380677|10004205|FG011|Overall Study|Other|0
6289319|NCT02380690|10004235|FG000|Overall Study|Lost to Follow-up|14
6289320|NCT02380690|10004236|FG001|Overall Study|Lost to Follow-up|4
6289321|NCT02380690|10004235|FG000|Overall Study|Withdrawal by Subject|20
6289322|NCT02380690|10004236|FG001|Overall Study|Withdrawal by Subject|8
6289323|NCT02380703|10004244|FG000|Overall Study|Withdrawal by Subject|12
6289324|NCT02380703|10004245|FG001|Overall Study|Withdrawal by Subject|9
6289325|NCT02380703|10004244|FG000|Overall Study|Lost to Follow-up|12
6289326|NCT02380703|10004245|FG001|Overall Study|Lost to Follow-up|12
6289327|NCT02380703|10004244|FG000|Overall Study|Caregiver death|1
6289328|NCT02380703|10004245|FG001|Overall Study|Caregiver death|0
6289329|NCT02380703|10004244|FG000|Overall Study|Person with dementia (PWD) death|7
6289330|NCT02380703|10004245|FG001|Overall Study|Person with dementia (PWD) death|8
6289331|NCT02380703|10004244|FG000|Overall Study|Entered Long-term Care|4
6289332|NCT02380703|10004245|FG001|Overall Study|Entered Long-term Care|7
6289333|NCT02380742|10004253|FG000|Overall Study|Withdrawal by Subject|1
6289334|NCT02380742|10004254|FG001|Overall Study|Withdrawal by Subject|0
6289335|NCT02380859|10004262|FG000|Overall Study|Withdrawal by Subject|2
6289336|NCT02380859|10004263|FG001|Overall Study|Withdrawal by Subject|0
6289337|NCT02381795|10004333|FG000|Overall Study|Withdrawal by Subject|1
6289338|NCT02381795|10004333|FG000|Overall Study|Study Terminated|2
6289339|NCT02382016|10004339|FG000|Double-blind (DB) Treatment Period|Physician Decision|3
6289340|NCT02382016|10004340|FG001|Double-blind (DB) Treatment Period|Physician Decision|0
6289341|NCT02382016|10004339|FG000|Double-blind (DB) Treatment Period|Lack of Efficacy|1
6289342|NCT02382016|10004340|FG001|Double-blind (DB) Treatment Period|Lack of Efficacy|0
6289343|NCT02382016|10004339|FG000|Double-blind (DB) Treatment Period|Withdrawal by Subject|0
6289344|NCT02382016|10004340|FG001|Double-blind (DB) Treatment Period|Withdrawal by Subject|1
6289345|NCT02382016|10004339|FG000|Open-label (OL) Treatment Period|Physician Decision|3
6289346|NCT02382016|10004340|FG001|Open-label (OL) Treatment Period|Physician Decision|0
6289347|NCT02382016|10004339|FG000|Open-label (OL) Treatment Period|Withdrawal by Subject|2
6289348|NCT02382016|10004340|FG001|Open-label (OL) Treatment Period|Withdrawal by Subject|0
6289349|NCT02382016|10004339|FG000|Open-label (OL) Treatment Period|Death|4
6289350|NCT02382016|10004340|FG001|Open-label (OL) Treatment Period|Death|0
6289351|NCT02382016|10004339|FG000|OL Extension Period|Physician Decision|3
6289352|NCT02382016|10004340|FG001|OL Extension Period|Physician Decision|0
6289353|NCT02382016|10004339|FG000|OL Extension Period|Death|2
6289354|NCT02382016|10004340|FG001|OL Extension Period|Death|0
6289355|NCT02382016|10004339|FG000|OL Extension Period|Withdrawal by Subject|1
6289356|NCT02382016|10004340|FG001|OL Extension Period|Withdrawal by Subject|0
6289357|NCT02382133|10004348|FG000|Overall Study|Death|22
6289358|NCT02382133|10004348|FG000|Overall Study|transfer out of ICU|4
6289359|NCT02382133|10004348|FG000|Overall Study|Physician Decision|2
6289360|NCT02382133|10004348|FG000|Overall Study|arterial catheter loss|4
6289361|NCT02382133|10004348|FG000|Overall Study|pressure injury both sites|1
6289362|NCT02382276|10004355|FG000|Overall Study|Withdrawal by Subject|4
6289363|NCT02382276|10004356|FG001|Overall Study|Withdrawal by Subject|8
6289364|NCT02382276|10004357|FG002|Overall Study|Withdrawal by Subject|5
6289365|NCT02382276|10004355|FG000|Overall Study|Adverse Event|7
6289366|NCT02382276|10004356|FG001|Overall Study|Adverse Event|2
6289367|NCT02382276|10004357|FG002|Overall Study|Adverse Event|32
6289368|NCT02382276|10004355|FG000|Overall Study|Physician Decision|0
6289369|NCT02382276|10004356|FG001|Overall Study|Physician Decision|0
6289370|NCT02382276|10004357|FG002|Overall Study|Physician Decision|2
6289371|NCT02382640|10004367|FG000|Intervention Period 4 (3 Days)|Laboratory Abnormality|1
6289372|NCT02382640|10004368|FG001|Intervention Period 4 (3 Days)|Laboratory Abnormality|0
6289373|NCT02382640|10004369|FG002|Intervention Period 4 (3 Days)|Laboratory Abnormality|0
6289374|NCT02382640|10004370|FG003|Intervention Period 4 (3 Days)|Laboratory Abnormality|0
6130811|NCT00962013|9757804|FG000|Overall Study|Did not have surgery|1
6130812|NCT00962013|9757804|FG000|Overall Study|Death|8
6130813|NCT00962013|9757804|FG000|Overall Study|Lost to Follow-up|12
6130814|NCT00962013|9757804|FG000|Overall Study|Unable/Unwilling to return|6
6130815|NCT00962013|9757804|FG000|Overall Study|Withdrawal by Subject|8
6130816|NCT00962013|9757804|FG000|Overall Study|Removal of study device|3
6130817|NCT00962013|9757804|FG000|Overall Study|Site Termination|24
6130818|NCT00962013|9757804|FG000|Overall Study|No 5 year evaluation|6
6130819|NCT00962091|9757846|FG000|Overall Study|Withdrawal by Subject|1
6130820|NCT00962091|9757847|FG001|Overall Study|Withdrawal by Subject|2
6130821|NCT00962091|9757848|FG002|Overall Study|Withdrawal by Subject|1
6130822|NCT00962091|9757849|FG003|Overall Study|Withdrawal by Subject|1
6130823|NCT00962091|9757850|FG004|Overall Study|Withdrawal by Subject|0
6130824|NCT00962091|9757851|FG005|Overall Study|Withdrawal by Subject|1
6130825|NCT00962091|9757852|FG006|Overall Study|Withdrawal by Subject|0
6130826|NCT00962091|9757846|FG000|Overall Study|Adverse Event|0
6130827|NCT00962091|9757847|FG001|Overall Study|Adverse Event|0
6221610|NCT01673126|9891956|FG001|Overall Study|change of diagnosis|3
6221611|NCT01673178|9891967|FG000|Overall Study|Lost to Follow-up|0
6221612|NCT01673178|9891968|FG001|Overall Study|Lost to Follow-up|1
6221613|NCT01673178|9891969|FG002|Overall Study|Lost to Follow-up|0
6221614|NCT01673178|9891970|FG003|Overall Study|Lost to Follow-up|0
6221615|NCT01673178|9891971|FG004|Overall Study|Lost to Follow-up|0
6221616|NCT01673178|9891967|FG000|Overall Study|Withdrawal by Subject|0
6221617|NCT01673178|9891968|FG001|Overall Study|Withdrawal by Subject|0
6221618|NCT01673178|9891969|FG002|Overall Study|Withdrawal by Subject|1
6221619|NCT01673178|9891970|FG003|Overall Study|Withdrawal by Subject|4
6221620|NCT01673178|9891971|FG004|Overall Study|Withdrawal by Subject|2
6221621|NCT01673178|9891967|FG000|Overall Study|Protocol Violation|1
6221622|NCT01673178|9891968|FG001|Overall Study|Protocol Violation|1
6221623|NCT01673178|9891969|FG002|Overall Study|Protocol Violation|0
6221624|NCT01673178|9891970|FG003|Overall Study|Protocol Violation|1
6221625|NCT01673178|9891971|FG004|Overall Study|Protocol Violation|0
6221626|NCT01673178|9891967|FG000|Overall Study|Adverse Event|1
6221627|NCT01673178|9891968|FG001|Overall Study|Adverse Event|0
6221628|NCT01673178|9891969|FG002|Overall Study|Adverse Event|0
6221629|NCT01673178|9891970|FG003|Overall Study|Adverse Event|2
6221630|NCT01673178|9891971|FG004|Overall Study|Adverse Event|0
6221631|NCT01673178|9891967|FG000|Overall Study|Other|1
6221632|NCT01673178|9891968|FG001|Overall Study|Other|0
6221633|NCT01673178|9891969|FG002|Overall Study|Other|2
6221634|NCT01673178|9891970|FG003|Overall Study|Other|1
6221635|NCT01673178|9891971|FG004|Overall Study|Other|0
6221636|NCT01673282|9892002|FG000|Overall Study|Adverse Drug Reaction - Vimpat|9
6221637|NCT01673282|9892003|FG001|Overall Study|Adverse Drug Reaction - Vimpat|5
6221638|NCT01673282|9892002|FG000|Overall Study|Lack of Efficacy|9
6221639|NCT01673282|9892003|FG001|Overall Study|Lack of Efficacy|2
6221640|NCT01673282|9892002|FG000|Overall Study|Lost to Follow-up|11
6221641|NCT01673282|9892003|FG001|Overall Study|Lost to Follow-up|10
6221642|NCT01673282|9892002|FG000|Overall Study|Withdrawal by Subject|3
6221643|NCT01673282|9892003|FG001|Overall Study|Withdrawal by Subject|3
6221644|NCT01673282|9892002|FG000|Overall Study|Other|1
6221645|NCT01673282|9892003|FG001|Overall Study|Other|6
6221646|NCT01673347|9892009|FG000|Overall Study|failure of allograft|7
6130828|NCT00962091|9757848|FG002|Overall Study|Adverse Event|0
6130829|NCT00962091|9757849|FG003|Overall Study|Adverse Event|0
6130830|NCT00962091|9757850|FG004|Overall Study|Adverse Event|0
6130831|NCT00962091|9757851|FG005|Overall Study|Adverse Event|0
6130832|NCT00962091|9757852|FG006|Overall Study|Adverse Event|1
6130833|NCT00962104|9757878|FG000|Overall Study|Adverse Event|10
6130834|NCT00962104|9757879|FG001|Overall Study|Adverse Event|3
6130835|NCT00962104|9757878|FG000|Overall Study|Entry Criteria Not Met|1
6130836|NCT00962104|9757879|FG001|Overall Study|Entry Criteria Not Met|2
6130837|NCT00962104|9757878|FG000|Overall Study|Lack of Efficacy|0
6130838|NCT00962104|9757879|FG001|Overall Study|Lack of Efficacy|1
6130839|NCT00962104|9757878|FG000|Overall Study|Lost to Follow-up|10
6130840|NCT00962104|9757879|FG001|Overall Study|Lost to Follow-up|4
6130841|NCT00962104|9757878|FG000|Overall Study|Physician Decision|1
6130842|NCT00962104|9757879|FG001|Overall Study|Physician Decision|0
6130843|NCT00962104|9757878|FG000|Overall Study|Protocol Violation|6
6130844|NCT00962104|9757879|FG001|Overall Study|Protocol Violation|8
6130845|NCT00962104|9757878|FG000|Overall Study|Sponsor Decision|0
6130846|NCT00962104|9757879|FG001|Overall Study|Sponsor Decision|1
6130847|NCT00962104|9757878|FG000|Overall Study|Withdrawal by Subject|10
6130848|NCT00962104|9757879|FG001|Overall Study|Withdrawal by Subject|6
6130849|NCT00962104|9757878|FG000|Overall Study|Other|2
6130850|NCT00962104|9757879|FG001|Overall Study|Other|0
6130851|NCT00962208|9757887|FG000|Overall Study|Could not achieve good vision|9
6130852|NCT00962208|9757888|FG001|Overall Study|Could not achieve good vision|0
6130853|NCT00962208|9757887|FG000|Overall Study|Contraindicated to continue study|5
6130854|NCT00962208|9757888|FG001|Overall Study|Contraindicated to continue study|1
6130855|NCT00962208|9757887|FG000|Overall Study|Lost to Follow-up|0
6130856|NCT00962208|9757888|FG001|Overall Study|Lost to Follow-up|9
6130857|NCT00962247|9757894|FG000|25% Reduction of Sedentary Activity|Protocol Violation|4
6130858|NCT00962247|9757894|FG000|25% Reduction of Sedentary Activity|Withdrawal by Subject|1
6130859|NCT00962390|9757904|FG000|Overall Study|Adverse Event|0
6130860|NCT00962390|9757905|FG001|Overall Study|Adverse Event|0
6130861|NCT00962390|9757906|FG002|Overall Study|Adverse Event|3
6130862|NCT00962390|9757907|FG003|Overall Study|Adverse Event|1
6130863|NCT00962390|9757904|FG000|Overall Study|Lost to Follow-up|2
6130864|NCT00962390|9757905|FG001|Overall Study|Lost to Follow-up|2
6130865|NCT00962390|9757906|FG002|Overall Study|Lost to Follow-up|0
6130866|NCT00962390|9757907|FG003|Overall Study|Lost to Follow-up|0
6130867|NCT00962390|9757904|FG000|Overall Study|Protocol Violation|1
6130868|NCT00962390|9757905|FG001|Overall Study|Protocol Violation|0
6130869|NCT00962390|9757906|FG002|Overall Study|Protocol Violation|0
6130870|NCT00962390|9757907|FG003|Overall Study|Protocol Violation|0
6130871|NCT00962390|9757904|FG000|Overall Study|Withdrawal by Subject|1
6130872|NCT00962390|9757905|FG001|Overall Study|Withdrawal by Subject|1
6130873|NCT00962390|9757906|FG002|Overall Study|Withdrawal by Subject|1
6130874|NCT00962390|9757907|FG003|Overall Study|Withdrawal by Subject|0
6130875|NCT00962585|9757921|FG000|Overall Study|Adverse Event|0
6130876|NCT00962585|9757922|FG001|Overall Study|Adverse Event|2
6130877|NCT00962585|9757923|FG002|Overall Study|Adverse Event|1
6130878|NCT00962585|9757924|FG003|Overall Study|Adverse Event|0
6130879|NCT00962585|9757921|FG000|Overall Study|Lost to Follow-up|3
6130880|NCT00962585|9757922|FG001|Overall Study|Lost to Follow-up|0
6130881|NCT00962585|9757923|FG002|Overall Study|Lost to Follow-up|1
6130882|NCT00962585|9757924|FG003|Overall Study|Lost to Follow-up|0
6130883|NCT00962585|9757921|FG000|Overall Study|Protocol Violation|0
6130884|NCT00962585|9757922|FG001|Overall Study|Protocol Violation|0
6130885|NCT00962585|9757923|FG002|Overall Study|Protocol Violation|1
6130886|NCT00962585|9757924|FG003|Overall Study|Protocol Violation|0
6130887|NCT00962585|9757921|FG000|Overall Study|Withdrawal by Subject|1
6130888|NCT00962585|9757922|FG001|Overall Study|Withdrawal by Subject|0
6130889|NCT00962585|9757923|FG002|Overall Study|Withdrawal by Subject|0
6130890|NCT00962585|9757924|FG003|Overall Study|Withdrawal by Subject|0
6130891|NCT00962585|9757921|FG000|Overall Study|Withdrew Consent|2
6130892|NCT00962585|9757922|FG001|Overall Study|Withdrew Consent|0
6130893|NCT00962585|9757923|FG002|Overall Study|Withdrew Consent|0
6130894|NCT00962585|9757924|FG003|Overall Study|Withdrew Consent|0
6130895|NCT00962650|9757945|FG000|Overall Study|Transgastric DP was not completed|2
6130896|NCT00962741|9757949|FG000|Overall Study|Failed to return|3
6130897|NCT00962741|9757949|FG000|Overall Study|Lost to Follow-up|2
6130898|NCT00962741|9757949|FG000|Overall Study|Withdrawal by Subject|1
6130899|NCT00962741|9757949|FG000|Overall Study|Lack of Efficacy|1
6130900|NCT00962741|9757949|FG000|Overall Study|drug ineffective+prohibited drug taken|1
6130901|NCT00962780|9757968|FG000|Overall Study|Death|0
6130902|NCT00962780|9757969|FG001|Overall Study|Death|1
6130903|NCT00962780|9757968|FG000|Overall Study|Protocol Violation|9
6221647|NCT01673373|9892013|FG000|Overall Study|Death|2
6221648|NCT01673386|9892017|FG000|Overall Study|Study terminated by sponsor|16
6221649|NCT01673386|9892018|FG001|Overall Study|Study terminated by sponsor|22
6221650|NCT01673386|9892017|FG000|Overall Study|Adverse Event|5
6221651|NCT01673386|9892018|FG001|Overall Study|Adverse Event|2
6221652|NCT01673386|9892017|FG000|Overall Study|Progressive disease|4
6221653|NCT01673386|9892018|FG001|Overall Study|Progressive disease|1
6130904|NCT00962780|9757969|FG001|Overall Study|Protocol Violation|4
6130905|NCT00962780|9757968|FG000|Overall Study|Withdrawal by Subject|1
6130906|NCT00962780|9757969|FG001|Overall Study|Withdrawal by Subject|8
6130907|NCT00962780|9757968|FG000|Overall Study|Other|0
6130908|NCT00962780|9757969|FG001|Overall Study|Other|1
6221654|NCT01673386|9892017|FG000|Overall Study|Withdrawal by Subject|0
6130909|NCT00963235|9758041|FG000|Overall Study|Withdrawal by Subject|22
6130910|NCT00963235|9758041|FG000|Overall Study|Lost to Follow-up|14
6130911|NCT00963235|9758041|FG000|Overall Study|Failed to return|9
6130912|NCT00963235|9758041|FG000|Overall Study|Protocol Violation|7
6130913|NCT00963235|9758041|FG000|Overall Study|Adverse Event|5
6130914|NCT00963235|9758041|FG000|Overall Study|Physician Decision|2
6130915|NCT00963235|9758041|FG000|Overall Study|Other|1
6130916|NCT00963547|9758079|FG000|Overall Study|Adverse Event|0
6130917|NCT00963547|9758080|FG001|Overall Study|Adverse Event|1
6130918|NCT00963547|9758081|FG002|Overall Study|Adverse Event|0
6130919|NCT00963547|9758082|FG003|Overall Study|Adverse Event|1
6130920|NCT00963547|9758083|FG004|Overall Study|Adverse Event|0
6130921|NCT00963547|9758084|FG005|Overall Study|Adverse Event|0
6130922|NCT00963547|9758085|FG006|Overall Study|Adverse Event|0
6221655|NCT01673386|9892018|FG001|Overall Study|Withdrawal by Subject|2
6221656|NCT01673490|9892024|FG000|Overall Study|Lost to Follow-up|1
6221657|NCT01673490|9892024|FG000|Overall Study|Adverse Event|3
6221658|NCT01673490|9892024|FG000|Overall Study|Withdrawal by Subject|3
6221659|NCT01673594|9892039|FG000|Overall Study|Adverse Event|3
6221660|NCT01673594|9892040|FG001|Overall Study|Adverse Event|1
6221661|NCT01673594|9892039|FG000|Overall Study|Lost to Follow-up|1
6221662|NCT01673594|9892040|FG001|Overall Study|Lost to Follow-up|0
6221663|NCT01673594|9892039|FG000|Overall Study|Physician Decision|2
6221664|NCT01673594|9892040|FG001|Overall Study|Physician Decision|4
6221665|NCT01673594|9892039|FG000|Overall Study|Withdrawal by Subject|0
6221666|NCT01673594|9892040|FG001|Overall Study|Withdrawal by Subject|1
6221667|NCT01673646|9892049|FG000|Overall Study|Adverse Event|2
6221668|NCT01673646|9892050|FG001|Overall Study|Adverse Event|1
6221669|NCT01673646|9892051|FG002|Overall Study|Adverse Event|1
6221670|NCT01673646|9892049|FG000|Overall Study|Unsatisfactory therapeutic effect|0
6221671|NCT01673646|9892050|FG001|Overall Study|Unsatisfactory therapeutic effect|2
6221672|NCT01673646|9892051|FG002|Overall Study|Unsatisfactory therapeutic effect|0
6221673|NCT01673646|9892049|FG000|Overall Study|Condition no longer requires study drug|0
6221674|NCT01673646|9892050|FG001|Overall Study|Condition no longer requires study drug|1
6221675|NCT01673646|9892051|FG002|Overall Study|Condition no longer requires study drug|0
6221676|NCT01673646|9892049|FG000|Overall Study|Withdrawal by Subject|0
6221677|NCT01673646|9892050|FG001|Overall Study|Withdrawal by Subject|2
6221678|NCT01673646|9892051|FG002|Overall Study|Withdrawal by Subject|2
6221679|NCT01673646|9892049|FG000|Overall Study|Completed Core/did not enter Ext.|2
6221680|NCT01673646|9892050|FG001|Overall Study|Completed Core/did not enter Ext.|1
6221681|NCT01673646|9892051|FG002|Overall Study|Completed Core/did not enter Ext.|1
6221682|NCT01673698|9892065|FG000|Overall Study|Lost to Follow-up|51
6221683|NCT01673698|9892066|FG001|Overall Study|Lost to Follow-up|13
6221684|NCT01673854|9892086|FG000|Ipilimumab Phase (Ipilimumab, 10 mg/kg)|Disease progression|7
6221685|NCT01673854|9892086|FG000|Ipilimumab Phase (Ipilimumab, 10 mg/kg)|Study drug toxicity|6
6221686|NCT01673854|9892086|FG000|Ipilimumab Phase (Ipilimumab, 10 mg/kg)|Administrative Reason by Sponsor|2
6221687|NCT01673854|9892086|FG000|Ipilimumab Phase (Ipilimumab, 10 mg/kg)|Adverse event unrelated to study drug|1
6221688|NCT01673854|9892086|FG000|Ipilimumab Phase (Ipilimumab, 10 mg/kg)|Maximum clinical benefit|1
6221689|NCT01673854|9892086|FG000|Ipilimumab Phase (Ipilimumab, 10 mg/kg)|Death|1
6221690|NCT01673854|9892086|FG000|Ipilimumab Phase (Ipilimumab, 10 mg/kg)|Not identified|2
6221691|NCT01673854|9892086|FG000|Ipilimumab Phase (Ipilimumab, 10 mg/kg)|Not reported|7
6221692|NCT01673854|9892086|FG000|Vem 2 Phase (Vemurafenib Retreatment)|Disease progression|12
6221693|NCT01673854|9892086|FG000|Vem 2 Phase (Vemurafenib Retreatment)|Study drug toxicity|5
6221694|NCT01673854|9892086|FG000|Vem 2 Phase (Vemurafenib Retreatment)|Adverse event unrelated to study drug|1
6221695|NCT01673854|9892086|FG000|Vem 2 Phase (Vemurafenib Retreatment)|Death|1
6221696|NCT01673984|9892104|FG000|Overall Study|Adverse Event|1
6221697|NCT01673984|9892105|FG001|Overall Study|Adverse Event|0
6221698|NCT01673984|9892104|FG000|Overall Study|Study termination|9
6221699|NCT01673984|9892105|FG001|Overall Study|Study termination|6
6221700|NCT01674010|9892111|FG000|Open Treatment Phase 1|Adverse Event|10
6221701|NCT01674010|9892112|FG001|Open Treatment Phase 1|Adverse Event|0
6221702|NCT01674010|9892113|FG002|Open Treatment Phase 1|Adverse Event|0
6221703|NCT01674010|9892111|FG000|Open Treatment Phase 1|Death|1
6221704|NCT01674010|9892112|FG001|Open Treatment Phase 1|Death|0
6221705|NCT01674010|9892113|FG002|Open Treatment Phase 1|Death|0
6221706|NCT01674010|9892111|FG000|Open Treatment Phase 1|Lost to Follow-up|19
6221707|NCT01674010|9892112|FG001|Open Treatment Phase 1|Lost to Follow-up|0
6221708|NCT01674010|9892113|FG002|Open Treatment Phase 1|Lost to Follow-up|0
6221709|NCT01674010|9892111|FG000|Open Treatment Phase 1|Physician Decision|9
6289375|NCT02382796|10004397|FG000|Overall Study|Global deterioration of health status|1
6289376|NCT02382796|10004397|FG000|Overall Study|Objective progression or relapse|3
6289377|NCT02382796|10004397|FG000|Overall Study|Commercial dacomitinib became available|3
6289378|NCT02382939|10004451|FG000|Overall Study|Adverse Event|1
6289379|NCT02382939|10004452|FG001|Overall Study|Adverse Event|1
6289380|NCT02382939|10004451|FG000|Overall Study|Withdrawal by Subject|2
6130923|NCT00963547|9758079|FG000|Overall Study|Physician Decision|1
6221710|NCT01674010|9892112|FG001|Open Treatment Phase 1|Physician Decision|0
6221711|NCT01674010|9892113|FG002|Open Treatment Phase 1|Physician Decision|0
6221712|NCT01674010|9892111|FG000|Open Treatment Phase 1|Protocol Violation|7
6221713|NCT01674010|9892112|FG001|Open Treatment Phase 1|Protocol Violation|0
6130924|NCT00963547|9758080|FG001|Overall Study|Physician Decision|1
6130925|NCT00963547|9758081|FG002|Overall Study|Physician Decision|0
6130926|NCT00963547|9758082|FG003|Overall Study|Physician Decision|0
6130927|NCT00963547|9758083|FG004|Overall Study|Physician Decision|0
6130928|NCT00963547|9758084|FG005|Overall Study|Physician Decision|0
6130929|NCT00963547|9758085|FG006|Overall Study|Physician Decision|0
6130930|NCT00963547|9758079|FG000|Overall Study|Progressive Disease|3
6130931|NCT00963547|9758080|FG001|Overall Study|Progressive Disease|8
6130932|NCT00963547|9758081|FG002|Overall Study|Progressive Disease|9
6130933|NCT00963547|9758082|FG003|Overall Study|Progressive Disease|5
6130934|NCT00963547|9758083|FG004|Overall Study|Progressive Disease|0
6130935|NCT00963547|9758084|FG005|Overall Study|Progressive Disease|0
6130936|NCT00963547|9758085|FG006|Overall Study|Progressive Disease|0
6130937|NCT00963547|9758079|FG000|Overall Study|Withdrawal by Subject|0
6130938|NCT00963547|9758080|FG001|Overall Study|Withdrawal by Subject|0
6130939|NCT00963547|9758081|FG002|Overall Study|Withdrawal by Subject|3
6130940|NCT00963547|9758082|FG003|Overall Study|Withdrawal by Subject|0
6130941|NCT00963547|9758083|FG004|Overall Study|Withdrawal by Subject|0
6130942|NCT00963547|9758084|FG005|Overall Study|Withdrawal by Subject|0
6130943|NCT00963547|9758085|FG006|Overall Study|Withdrawal by Subject|0
6130944|NCT00963547|9758079|FG000|Overall Study|Reason Unknown|0
6130945|NCT00963547|9758080|FG001|Overall Study|Reason Unknown|1
6130946|NCT00963547|9758081|FG002|Overall Study|Reason Unknown|0
6130947|NCT00963547|9758082|FG003|Overall Study|Reason Unknown|0
6130948|NCT00963547|9758083|FG004|Overall Study|Reason Unknown|0
6130949|NCT00963547|9758084|FG005|Overall Study|Reason Unknown|0
6130950|NCT00963547|9758085|FG006|Overall Study|Reason Unknown|0
6130951|NCT00963807|9758129|FG000|Overall Study|Physician Decision|2
6130952|NCT00963807|9758129|FG000|Overall Study|Reaction to study chemotherapy regimen|1
6130953|NCT00963807|9758129|FG000|Overall Study|Disease progression|15
6130954|NCT00963820|9758135|FG000|Dose Escalation Phase|Progressive Disease|3
6130955|NCT00963820|9758136|FG001|Dose Escalation Phase|Progressive Disease|3
6130956|NCT00963820|9758137|FG002|Dose Escalation Phase|Progressive Disease|3
6130957|NCT00963820|9758138|FG003|Dose Escalation Phase|Progressive Disease|3
6130958|NCT00963820|9758139|FG004|Dose Escalation Phase|Progressive Disease|4
6130959|NCT00963820|9758140|FG005|Dose Escalation Phase|Progressive Disease|3
6130960|NCT00963820|9758141|FG006|Dose Escalation Phase|Progressive Disease|3
6130961|NCT00963820|9758142|FG007|Dose Escalation Phase|Progressive Disease|2
6130962|NCT00963820|9758143|FG008|Dose Escalation Phase|Progressive Disease|0
6130963|NCT00963820|9758144|FG009|Dose Escalation Phase|Progressive Disease|0
6130964|NCT00963820|9758145|FG010|Dose Escalation Phase|Progressive Disease|0
6130965|NCT00963820|9758146|FG011|Dose Escalation Phase|Progressive Disease|0
6130966|NCT00963820|9758135|FG000|Dose Escalation Phase|Adverse Event|0
6130967|NCT00963820|9758136|FG001|Dose Escalation Phase|Adverse Event|0
6130968|NCT00963820|9758137|FG002|Dose Escalation Phase|Adverse Event|0
6130969|NCT00963820|9758138|FG003|Dose Escalation Phase|Adverse Event|0
6130970|NCT00963820|9758139|FG004|Dose Escalation Phase|Adverse Event|0
6130971|NCT00963820|9758140|FG005|Dose Escalation Phase|Adverse Event|0
6221714|NCT01674010|9892113|FG002|Open Treatment Phase 1|Protocol Violation|0
6221715|NCT01674010|9892111|FG000|Open Treatment Phase 1|Sponsor Decision|79
6221716|NCT01674010|9892112|FG001|Open Treatment Phase 1|Sponsor Decision|0
6221717|NCT01674010|9892113|FG002|Open Treatment Phase 1|Sponsor Decision|0
6221718|NCT01674010|9892111|FG000|Open Treatment Phase 1|Did not remain in a stable remission|30
6221719|NCT01674010|9892112|FG001|Open Treatment Phase 1|Did not remain in a stable remission|0
6221720|NCT01674010|9892113|FG002|Open Treatment Phase 1|Did not remain in a stable remission|0
6130972|NCT00963820|9758141|FG006|Dose Escalation Phase|Adverse Event|3
6130973|NCT00963820|9758142|FG007|Dose Escalation Phase|Adverse Event|1
6130974|NCT00963820|9758143|FG008|Dose Escalation Phase|Adverse Event|0
6130975|NCT00963820|9758144|FG009|Dose Escalation Phase|Adverse Event|0
6130976|NCT00963820|9758145|FG010|Dose Escalation Phase|Adverse Event|0
6130977|NCT00963820|9758146|FG011|Dose Escalation Phase|Adverse Event|0
6130978|NCT00963820|9758135|FG000|Dose Escalation Phase|Withdrawal by Subject|0
6130979|NCT00963820|9758136|FG001|Dose Escalation Phase|Withdrawal by Subject|0
6130980|NCT00963820|9758137|FG002|Dose Escalation Phase|Withdrawal by Subject|0
6130981|NCT00963820|9758138|FG003|Dose Escalation Phase|Withdrawal by Subject|0
6130982|NCT00963820|9758139|FG004|Dose Escalation Phase|Withdrawal by Subject|0
6130983|NCT00963820|9758140|FG005|Dose Escalation Phase|Withdrawal by Subject|0
6130984|NCT00963820|9758141|FG006|Dose Escalation Phase|Withdrawal by Subject|1
6221721|NCT01674010|9892111|FG000|Open Treatment Phase 1|Withdrawal by Subject|25
6221722|NCT01674010|9892112|FG001|Open Treatment Phase 1|Withdrawal by Subject|0
6221723|NCT01674010|9892113|FG002|Open Treatment Phase 1|Withdrawal by Subject|0
6221724|NCT01674010|9892111|FG000|Randomization Phase 2|Adverse Event|0
6221725|NCT01674010|9892112|FG001|Randomization Phase 2|Adverse Event|1
6221726|NCT01674010|9892113|FG002|Randomization Phase 2|Adverse Event|1
6221727|NCT01674010|9892111|FG000|Randomization Phase 2|Lost to Follow-up|0
6221728|NCT01674010|9892112|FG001|Randomization Phase 2|Lost to Follow-up|1
6221729|NCT01674010|9892113|FG002|Randomization Phase 2|Lost to Follow-up|2
6130985|NCT00963820|9758142|FG007|Dose Escalation Phase|Withdrawal by Subject|2
6130986|NCT00963820|9758143|FG008|Dose Escalation Phase|Withdrawal by Subject|0
6221730|NCT01674010|9892111|FG000|Randomization Phase 2|Mood episode recurrence|0
6221731|NCT01674010|9892112|FG001|Randomization Phase 2|Mood episode recurrence|8
6130987|NCT00963820|9758144|FG009|Dose Escalation Phase|Withdrawal by Subject|0
6130988|NCT00963820|9758145|FG010|Dose Escalation Phase|Withdrawal by Subject|0
6130989|NCT00963820|9758146|FG011|Dose Escalation Phase|Withdrawal by Subject|0
6130990|NCT00963820|9758135|FG000|Dose Escalation Phase|Unsatisfactory Therapeutic Response|0
6130991|NCT00963820|9758136|FG001|Dose Escalation Phase|Unsatisfactory Therapeutic Response|0
6130992|NCT00963820|9758137|FG002|Dose Escalation Phase|Unsatisfactory Therapeutic Response|0
6130993|NCT00963820|9758138|FG003|Dose Escalation Phase|Unsatisfactory Therapeutic Response|0
6130994|NCT00963820|9758139|FG004|Dose Escalation Phase|Unsatisfactory Therapeutic Response|0
6130995|NCT00963820|9758140|FG005|Dose Escalation Phase|Unsatisfactory Therapeutic Response|0
6130996|NCT00963820|9758141|FG006|Dose Escalation Phase|Unsatisfactory Therapeutic Response|1
6130997|NCT00963820|9758142|FG007|Dose Escalation Phase|Unsatisfactory Therapeutic Response|0
6130998|NCT00963820|9758143|FG008|Dose Escalation Phase|Unsatisfactory Therapeutic Response|0
6130999|NCT00963820|9758144|FG009|Dose Escalation Phase|Unsatisfactory Therapeutic Response|0
6131000|NCT00963820|9758145|FG010|Dose Escalation Phase|Unsatisfactory Therapeutic Response|0
6131001|NCT00963820|9758146|FG011|Dose Escalation Phase|Unsatisfactory Therapeutic Response|0
6131002|NCT00963820|9758135|FG000|Expansion Phase|Progressive Disease|0
6131003|NCT00963820|9758136|FG001|Expansion Phase|Progressive Disease|0
6131004|NCT00963820|9758137|FG002|Expansion Phase|Progressive Disease|0
6131005|NCT00963820|9758138|FG003|Expansion Phase|Progressive Disease|0
6131006|NCT00963820|9758139|FG004|Expansion Phase|Progressive Disease|0
6131007|NCT00963820|9758140|FG005|Expansion Phase|Progressive Disease|0
6131008|NCT00963820|9758141|FG006|Expansion Phase|Progressive Disease|0
6131009|NCT00963820|9758142|FG007|Expansion Phase|Progressive Disease|0
6131010|NCT00963820|9758143|FG008|Expansion Phase|Progressive Disease|8
6131011|NCT00963820|9758144|FG009|Expansion Phase|Progressive Disease|6
6131012|NCT00963820|9758145|FG010|Expansion Phase|Progressive Disease|4
6131013|NCT00963820|9758146|FG011|Expansion Phase|Progressive Disease|2
6131014|NCT00963820|9758135|FG000|Expansion Phase|Adverse Event|0
6131015|NCT00963820|9758136|FG001|Expansion Phase|Adverse Event|0
6131016|NCT00963820|9758137|FG002|Expansion Phase|Adverse Event|0
6131017|NCT00963820|9758138|FG003|Expansion Phase|Adverse Event|0
6131018|NCT00963820|9758139|FG004|Expansion Phase|Adverse Event|0
6131019|NCT00963820|9758140|FG005|Expansion Phase|Adverse Event|0
6131020|NCT00963820|9758141|FG006|Expansion Phase|Adverse Event|0
6131021|NCT00963820|9758142|FG007|Expansion Phase|Adverse Event|0
6131022|NCT00963820|9758143|FG008|Expansion Phase|Adverse Event|1
6131023|NCT00963820|9758144|FG009|Expansion Phase|Adverse Event|3
6131024|NCT00963820|9758145|FG010|Expansion Phase|Adverse Event|0
6131025|NCT00963820|9758146|FG011|Expansion Phase|Adverse Event|0
6131026|NCT00963820|9758135|FG000|Expansion Phase|Withdrawal by Subject|0
6131027|NCT00963820|9758136|FG001|Expansion Phase|Withdrawal by Subject|0
6131028|NCT00963820|9758137|FG002|Expansion Phase|Withdrawal by Subject|0
6131029|NCT00963820|9758138|FG003|Expansion Phase|Withdrawal by Subject|0
6131030|NCT00963820|9758139|FG004|Expansion Phase|Withdrawal by Subject|0
6131031|NCT00963820|9758140|FG005|Expansion Phase|Withdrawal by Subject|0
6131032|NCT00963820|9758141|FG006|Expansion Phase|Withdrawal by Subject|0
6131033|NCT00963820|9758142|FG007|Expansion Phase|Withdrawal by Subject|0
6131034|NCT00963820|9758143|FG008|Expansion Phase|Withdrawal by Subject|1
6131035|NCT00963820|9758144|FG009|Expansion Phase|Withdrawal by Subject|0
6131036|NCT00963820|9758145|FG010|Expansion Phase|Withdrawal by Subject|1
6131037|NCT00963820|9758146|FG011|Expansion Phase|Withdrawal by Subject|1
6131038|NCT00963820|9758135|FG000|Expansion Phase|Unsatisfactory Therapeutic Response|0
6131039|NCT00963820|9758136|FG001|Expansion Phase|Unsatisfactory Therapeutic Response|0
6131040|NCT00963820|9758137|FG002|Expansion Phase|Unsatisfactory Therapeutic Response|0
6131041|NCT00963820|9758138|FG003|Expansion Phase|Unsatisfactory Therapeutic Response|0
6131042|NCT00963820|9758139|FG004|Expansion Phase|Unsatisfactory Therapeutic Response|0
6221732|NCT01674010|9892113|FG002|Randomization Phase 2|Mood episode recurrence|2
6221733|NCT01674010|9892111|FG000|Randomization Phase 2|Physician Decision|0
6221734|NCT01674010|9892112|FG001|Randomization Phase 2|Physician Decision|0
6221735|NCT01674010|9892113|FG002|Randomization Phase 2|Physician Decision|2
6221736|NCT01674010|9892111|FG000|Randomization Phase 2|Pregnancy|0
6221737|NCT01674010|9892112|FG001|Randomization Phase 2|Pregnancy|1
6221738|NCT01674010|9892113|FG002|Randomization Phase 2|Pregnancy|1
6221739|NCT01674010|9892111|FG000|Randomization Phase 2|Protocol Violation|0
6221740|NCT01674010|9892112|FG001|Randomization Phase 2|Protocol Violation|1
6221741|NCT01674010|9892113|FG002|Randomization Phase 2|Protocol Violation|1
6221742|NCT01674010|9892111|FG000|Randomization Phase 2|Sponsor Decision|0
6221743|NCT01674010|9892112|FG001|Randomization Phase 2|Sponsor Decision|42
6221744|NCT01674010|9892113|FG002|Randomization Phase 2|Sponsor Decision|45
6221745|NCT01674010|9892111|FG000|Randomization Phase 2|Withdrawal by Subject|0
6131043|NCT00963820|9758140|FG005|Expansion Phase|Unsatisfactory Therapeutic Response|0
6131044|NCT00963820|9758141|FG006|Expansion Phase|Unsatisfactory Therapeutic Response|0
6131045|NCT00963820|9758142|FG007|Expansion Phase|Unsatisfactory Therapeutic Response|0
6131046|NCT00963820|9758143|FG008|Expansion Phase|Unsatisfactory Therapeutic Response|0
6131047|NCT00963820|9758144|FG009|Expansion Phase|Unsatisfactory Therapeutic Response|0
6221746|NCT01674010|9892112|FG001|Randomization Phase 2|Withdrawal by Subject|8
6221747|NCT01674010|9892113|FG002|Randomization Phase 2|Withdrawal by Subject|7
6221748|NCT01674062|9892123|FG000|Overall Study|Insufficient Therapeutic Response|56
6131048|NCT00963820|9758145|FG010|Expansion Phase|Unsatisfactory Therapeutic Response|0
6131049|NCT00963820|9758146|FG011|Expansion Phase|Unsatisfactory Therapeutic Response|1
6131050|NCT00963924|9758182|FG000|Overall Study|Adverse Event|1
6131051|NCT00963924|9758183|FG001|Overall Study|Adverse Event|0
6131052|NCT00963924|9758182|FG000|Overall Study|Withdrawal by Subject|0
6131053|NCT00963924|9758183|FG001|Overall Study|Withdrawal by Subject|1
6131054|NCT00963924|9758182|FG000|Overall Study|Changed antipsychotic|0
6131055|NCT00963924|9758183|FG001|Overall Study|Changed antipsychotic|1
6131056|NCT00963924|9758182|FG000|Overall Study|Lost to Follow-up|0
6131057|NCT00963924|9758183|FG001|Overall Study|Lost to Follow-up|1
6131058|NCT00963937|9758194|FG000|Overall Study|Protocol Violation|1
6131059|NCT00963937|9758195|FG001|Overall Study|Protocol Violation|1
6131060|NCT00963937|9758196|FG002|Overall Study|Protocol Violation|0
6131061|NCT00963937|9758194|FG000|Overall Study|Physician Decision|18
6131062|NCT00963937|9758195|FG001|Overall Study|Physician Decision|10
6131063|NCT00963937|9758196|FG002|Overall Study|Physician Decision|4
6131064|NCT00964028|9758213|FG000|Overall Study|Withdrawal by Subject|0
6131065|NCT00964028|9758214|FG001|Overall Study|Withdrawal by Subject|1
6131066|NCT00964158|9758227|FG000|Overall Study|Lost to Follow-up|0
6131067|NCT00964158|9758228|FG001|Overall Study|Lost to Follow-up|1
6131068|NCT00964158|9758229|FG002|Overall Study|Lost to Follow-up|2
6131069|NCT00964158|9758227|FG000|Overall Study|Withdrawal by Subject|0
6131070|NCT00964158|9758228|FG001|Overall Study|Withdrawal by Subject|0
6131071|NCT00964158|9758229|FG002|Overall Study|Withdrawal by Subject|6
6131072|NCT00964223|9758240|FG000|Full Face Treatment (Weeks 5 and 8)|Lost to Follow-up|1
6131073|NCT00964366|9758256|FG000|Overall Study|Did not qualify at Day 1|1
6131074|NCT00964366|9758257|FG001|Overall Study|Did not qualify at Day 1|0
6131075|NCT00964366|9758256|FG000|Overall Study|Withdrawal by Subject|0
6131076|NCT00964366|9758257|FG001|Overall Study|Withdrawal by Subject|1
6131077|NCT00964392|9758265|FG000|Overall Study|Withdrawal by Subject|4
6131078|NCT00964392|9758266|FG001|Overall Study|Withdrawal by Subject|6
6131079|NCT00964392|9758265|FG000|Overall Study|Lost to Follow-up|4
6131080|NCT00964392|9758266|FG001|Overall Study|Lost to Follow-up|10
6131081|NCT00964392|9758265|FG000|Overall Study|Early Termination, non-study arrhythmia|1
6131082|NCT00964392|9758266|FG001|Overall Study|Early Termination, non-study arrhythmia|6
6131083|NCT00964392|9758265|FG000|Overall Study|Not completed|44
6131084|NCT00964392|9758266|FG001|Overall Study|Not completed|168
6131085|NCT00964678|9758311|FG000|Overall Study|Physician Decision|4
6131086|NCT00964743|9758316|FG000|Overall Study|Neither patient completed 8 weeks of tre|2
6131087|NCT00964782|9758322|FG000|Overall Study|Lost to Follow-up|1
6131088|NCT00964782|9758323|FG001|Overall Study|Lost to Follow-up|0
6131089|NCT00964795|9758331|FG000|Overall Study|Withdrawal by Subject|79
6131090|NCT00964795|9758331|FG000|Overall Study|Adverse Event|12
6131091|NCT00964795|9758331|FG000|Overall Study|Death|14
6131092|NCT00964795|9758331|FG000|Overall Study|Lost to Follow-up|7
6131093|NCT00964795|9758331|FG000|Overall Study|Termination of Study by Sponsor|169
6131094|NCT00964795|9758331|FG000|Overall Study|Unwilling to sign ICF for amendment 4|3
6131095|NCT00964795|9758331|FG000|Overall Study|Other|23
6131096|NCT00964860|9758338|FG000|Overall Study|Withdrawal by Subject|0
6131097|NCT00964860|9758339|FG001|Overall Study|Withdrawal by Subject|1
6131098|NCT00964886|9758349|FG000|Overall Study|Lost to Follow-up|2
6131099|NCT00964886|9758350|FG001|Overall Study|Lost to Follow-up|2
6131100|NCT00964886|9758351|FG002|Overall Study|Lost to Follow-up|6
6131101|NCT00964886|9758352|FG003|Overall Study|Lost to Follow-up|4
6131102|NCT00964886|9758349|FG000|Overall Study|Withdrawal by Subject|6
6131103|NCT00964886|9758350|FG001|Overall Study|Withdrawal by Subject|2
6131104|NCT00964886|9758351|FG002|Overall Study|Withdrawal by Subject|5
6131105|NCT00964886|9758352|FG003|Overall Study|Withdrawal by Subject|3
6131106|NCT00964886|9758349|FG000|Overall Study|Adverse Event|3
6131107|NCT00964886|9758350|FG001|Overall Study|Adverse Event|1
6131108|NCT00964886|9758351|FG002|Overall Study|Adverse Event|5
6131109|NCT00964886|9758352|FG003|Overall Study|Adverse Event|2
6131110|NCT00964886|9758349|FG000|Overall Study|Protocol Violation|0
6131111|NCT00964886|9758350|FG001|Overall Study|Protocol Violation|2
6131112|NCT00964886|9758351|FG002|Overall Study|Protocol Violation|0
6131113|NCT00964886|9758352|FG003|Overall Study|Protocol Violation|0
6131114|NCT00965081|9758368|FG000|Overall Study|Adverse Event|14
6131115|NCT00965081|9758369|FG001|Overall Study|Adverse Event|9
6289381|NCT02382939|10004452|FG001|Overall Study|Withdrawal by Subject|2
6131116|NCT00965081|9758368|FG000|Overall Study|Lack of Efficacy|2
6131117|NCT00965081|9758369|FG001|Overall Study|Lack of Efficacy|5
6131118|NCT00965081|9758368|FG000|Overall Study|Lost to Follow-up|4
6131119|NCT00965081|9758369|FG001|Overall Study|Lost to Follow-up|5
6131120|NCT00965081|9758368|FG000|Overall Study|Physician Decision|2
6131121|NCT00965081|9758369|FG001|Overall Study|Physician Decision|0
6131122|NCT00965081|9758368|FG000|Overall Study|Protocol Violation|2
6131123|NCT00965081|9758369|FG001|Overall Study|Protocol Violation|5
6131124|NCT00965081|9758368|FG000|Overall Study|Sponsor Decision|1
6131125|NCT00965081|9758369|FG001|Overall Study|Sponsor Decision|0
6131126|NCT00965081|9758368|FG000|Overall Study|Withdrawal by Subject|4
6131127|NCT00965081|9758369|FG001|Overall Study|Withdrawal by Subject|7
6289382|NCT02382991|10004461|FG000|Overall Study|Adverse Event|1
6131128|NCT00965081|9758368|FG000|Overall Study|Switched to Rescue Arm|5
6131129|NCT00965081|9758369|FG001|Overall Study|Switched to Rescue Arm|12
6131130|NCT00965094|9758378|FG000|Overall Study|Adverse Event|5
6131131|NCT00965094|9758379|FG001|Overall Study|Adverse Event|0
6131132|NCT00965094|9758378|FG000|Overall Study|Lost to Follow-up|0
6131133|NCT00965094|9758379|FG001|Overall Study|Lost to Follow-up|1
6131134|NCT00965185|9758388|FG000|Overall Study|Lost to Follow-up|2
6131135|NCT00965185|9758389|FG001|Overall Study|Lost to Follow-up|0
6131136|NCT00965185|9758388|FG000|Overall Study|Withdrawal by Subject|0
6131137|NCT00965185|9758389|FG001|Overall Study|Withdrawal by Subject|1
6131138|NCT00965263|9758415|FG000|Overall Study|Physician Decision|2
6131139|NCT00965263|9758416|FG001|Overall Study|Physician Decision|0
6131140|NCT00965263|9758415|FG000|Overall Study|Family emergency|0
6131141|NCT00965263|9758416|FG001|Overall Study|Family emergency|1
6131142|NCT00965263|9758415|FG000|Overall Study|Protocol Violation|0
6131143|NCT00965263|9758416|FG001|Overall Study|Protocol Violation|2
6131144|NCT00965341|9758442|FG000|Overall Study|Withdrew consent|1
6131145|NCT00965341|9758443|FG001|Overall Study|Withdrew consent|5
6131146|NCT00965341|9758442|FG000|Overall Study|Lost to Follow-up|1
6221749|NCT01674062|9892124|FG001|Overall Study|Insufficient Therapeutic Response|26
6221750|NCT01674062|9892123|FG000|Overall Study|Other|8
6221751|NCT01674062|9892124|FG001|Overall Study|Other|1
6221752|NCT01674062|9892123|FG000|Overall Study|Adverse Event|1
6289383|NCT02382991|10004462|FG001|Overall Study|Adverse Event|2
6289384|NCT02382991|10004461|FG000|Overall Study|Lost to Follow-up|1
6289385|NCT02382991|10004462|FG001|Overall Study|Lost to Follow-up|0
6289386|NCT02382991|10004461|FG000|Overall Study|Withdrawal by Subject|0
6289387|NCT02382991|10004462|FG001|Overall Study|Withdrawal by Subject|1
6289388|NCT02383017|10004469|FG000|Overall Study|Injury Sustained Outside Study|1
6289389|NCT02383017|10004470|FG001|Overall Study|Injury Sustained Outside Study|0
6289390|NCT02383017|10004469|FG000|Overall Study|Compliance|3
6289391|NCT02383017|10004470|FG001|Overall Study|Compliance|2
6289392|NCT02383017|10004469|FG000|Overall Study|Found to be Hypogonadal|1
6289393|NCT02383017|10004470|FG001|Overall Study|Found to be Hypogonadal|0
6289394|NCT02383056|10004492|FG000|Overall Study|Adverse Event|1
6289395|NCT02383056|10004493|FG001|Overall Study|Adverse Event|0
6289396|NCT02383056|10004492|FG000|Overall Study|Lost to Follow-up|0
6289397|NCT02383056|10004493|FG001|Overall Study|Lost to Follow-up|2
6289398|NCT02383173|10004501|FG000|Overall Study|Palliative Care Team withdrew|0
6289399|NCT02383173|10004502|FG001|Overall Study|Palliative Care Team withdrew|2
6289400|NCT02383355|10004510|FG000|Overall Study|Adverse Event|2
6289401|NCT02383355|10004511|FG001|Overall Study|Adverse Event|0
6289402|NCT02383472|10004532|FG000|Overall Study|Withdrawal by Subject|1
6289403|NCT02383472|10004533|FG001|Overall Study|Withdrawal by Subject|1
6289404|NCT02383576|10004543|FG000|Overall Study|Death|53
6289405|NCT02383576|10004544|FG001|Overall Study|Death|33
6289406|NCT02383576|10004543|FG000|Overall Study|Lost to Follow-up|7
6289407|NCT02383576|10004544|FG001|Overall Study|Lost to Follow-up|1
6289408|NCT02383576|10004543|FG000|Overall Study|Withdrew Consent|1
6289409|NCT02383576|10004544|FG001|Overall Study|Withdrew Consent|6
6289410|NCT02383576|10004543|FG000|Overall Study|Investigator's Decision|0
6289411|NCT02383576|10004544|FG001|Overall Study|Investigator's Decision|1
6289412|NCT02383576|10004543|FG000|Overall Study|Administrative/Other|2
6289413|NCT02383576|10004544|FG001|Overall Study|Administrative/Other|4
6289414|NCT02383589|10004552|FG000|Treatment Period|Adverse Event|1
6289415|NCT02383589|10004553|FG001|Treatment Period|Adverse Event|3
6289416|NCT02383589|10004552|FG000|Treatment Period|Lost to Follow-up|0
6289417|NCT02383589|10004553|FG001|Treatment Period|Lost to Follow-up|1
6289418|NCT02383589|10004552|FG000|Treatment Period|Withdrawal by Subject|0
6289419|NCT02383589|10004553|FG001|Treatment Period|Withdrawal by Subject|5
6289420|NCT02383589|10004552|FG000|Treatment Period|Non-compliance with study drug|0
6289421|NCT02383589|10004553|FG001|Treatment Period|Non-compliance with study drug|1
6131147|NCT00965341|9758443|FG001|Overall Study|Lost to Follow-up|0
6131148|NCT00965341|9758442|FG000|Overall Study|Transportation issues|4
6131149|NCT00965341|9758443|FG001|Overall Study|Transportation issues|3
6131150|NCT00965419|9758449|FG000|Open Label Treatment for Responders|Adverse Event|33
6131151|NCT00965419|9758449|FG000|Open Label Treatment for Responders|Entry Criteria Not Met|1
6221753|NCT01674062|9892124|FG001|Overall Study|Adverse Event|1
6221754|NCT01674062|9892123|FG000|Overall Study|Death|0
6221755|NCT01674062|9892124|FG001|Overall Study|Death|1
6221756|NCT01674062|9892123|FG000|Overall Study|Programming Error|1
6221757|NCT01674062|9892124|FG001|Overall Study|Programming Error|0
6221758|NCT01674569|9892139|FG000|Overall Study|Adverse Event|0
6221759|NCT01674569|9892140|FG001|Overall Study|Adverse Event|2
6221760|NCT01674569|9892141|FG002|Overall Study|Adverse Event|0
6221761|NCT01674569|9892142|FG003|Overall Study|Adverse Event|1
6221762|NCT01674569|9892143|FG004|Overall Study|Adverse Event|2
6221763|NCT01674569|9892144|FG005|Overall Study|Adverse Event|2
6221764|NCT01674569|9892139|FG000|Overall Study|Protocol Violation|0
6221765|NCT01674569|9892140|FG001|Overall Study|Protocol Violation|1
6221766|NCT01674569|9892141|FG002|Overall Study|Protocol Violation|1
6221767|NCT01674569|9892142|FG003|Overall Study|Protocol Violation|0
6131152|NCT00965419|9758449|FG000|Open Label Treatment for Responders|Protocol Violation|21
6131153|NCT00965419|9758449|FG000|Open Label Treatment for Responders|Withdrawal by Subject|27
6221768|NCT01674569|9892143|FG004|Overall Study|Protocol Violation|0
6221769|NCT01674569|9892144|FG005|Overall Study|Protocol Violation|0
6221770|NCT01674569|9892139|FG000|Overall Study|Withdrawal by Subject|0
6131154|NCT00965419|9758449|FG000|Open Label Treatment for Responders|Physician Decision|6
6131155|NCT00965419|9758449|FG000|Open Label Treatment for Responders|Sponsor Decision|5
6131156|NCT00965419|9758449|FG000|Open Label Treatment for Responders|Parent/Caregiver Decision|41
6131157|NCT00965419|9758449|FG000|Open Label Treatment for Responders|Lack of Efficacy|67
6131158|NCT00965419|9758449|FG000|Open Label Treatment for Responders|Lost to Follow-up|46
6131159|NCT00965419|9758449|FG000|Follow-up Phase|Adverse Event|9
6131160|NCT00965419|9758449|FG000|Follow-up Phase|Protocol Violation|4
6131161|NCT00965419|9758449|FG000|Follow-up Phase|Withdrawal by Subject|8
6131162|NCT00965419|9758449|FG000|Follow-up Phase|Physician Decision|4
6131163|NCT00965419|9758449|FG000|Follow-up Phase|Parent/Caregiver Decision|9
6131164|NCT00965419|9758449|FG000|Follow-up Phase|Lack of Efficacy|28
6131165|NCT00965458|9758456|FG000|Overall Study|Adverse Event|1
6131166|NCT00965458|9758457|FG001|Overall Study|Adverse Event|0
6131167|NCT00965458|9758456|FG000|Overall Study|Lost to Follow-up|1
6131168|NCT00965458|9758457|FG001|Overall Study|Lost to Follow-up|3
6131169|NCT00965458|9758456|FG000|Overall Study|Withdrawal by Subject|0
6131170|NCT00965458|9758457|FG001|Overall Study|Withdrawal by Subject|1
6131171|NCT00965484|9758465|FG000|Overall Study|Protocol Violation|1
6131172|NCT00965484|9758465|FG000|Overall Study|Withdrawal by Subject|1
6131173|NCT00965497|9758469|FG000|Overall Study|Physician Decision|1
6131174|NCT00965523|9758473|FG000|Study 221|Progressive Disease|4
6131175|NCT00965523|9758473|FG000|Study 221|Physician Decision|3
6131176|NCT00965523|9758473|FG000|Study 224|Progressive Disease|5
6131177|NCT00965523|9758473|FG000|Study 224|Physician Decision|1
6131178|NCT00965562|9758480|FG000|Overall Study|Lost to Follow-up|1
6131179|NCT00965562|9758481|FG001|Overall Study|Lost to Follow-up|2
6131180|NCT00965562|9758482|FG002|Overall Study|Lost to Follow-up|3
6131181|NCT00965562|9758480|FG000|Overall Study|Withdrawal by Subject|2
6131182|NCT00965562|9758481|FG001|Overall Study|Withdrawal by Subject|2
6131183|NCT00965562|9758482|FG002|Overall Study|Withdrawal by Subject|0
6131184|NCT00965575|9758493|FG000|Overall Study|subject unwillingness to swallow study c|1
6131185|NCT00965575|9758494|FG001|Overall Study|subject unwillingness to swallow study c|0
6131186|NCT00965718|9758502|FG000|Overall Study|Withdrawal by Subject|4
6131187|NCT00965731|9758508|FG000|Overall Study|Death|0
6131188|NCT00965731|9758509|FG001|Overall Study|Death|4
6131189|NCT00965731|9758508|FG000|Overall Study|Withdrawal by Subject|0
6131190|NCT00965731|9758509|FG001|Overall Study|Withdrawal by Subject|1
6131191|NCT00965731|9758508|FG000|Overall Study|Other|7
6131192|NCT00965731|9758509|FG001|Overall Study|Other|15
6131193|NCT00965848|9758520|FG000|Overall Study|Protocol Violation|3
6131194|NCT00965848|9758521|FG001|Overall Study|Protocol Violation|0
6289422|NCT02383589|10004552|FG000|Safety Follow-up (SFU)|Lost to Follow-up|2
6289423|NCT02383589|10004553|FG001|Safety Follow-up (SFU)|Lost to Follow-up|4
6289424|NCT02383589|10004552|FG000|Safety Follow-up (SFU)|Withdrawal by Subject|5
6289425|NCT02383589|10004553|FG001|Safety Follow-up (SFU)|Withdrawal by Subject|0
6131195|NCT00965848|9758522|FG002|Overall Study|Protocol Violation|1
6131196|NCT00965848|9758520|FG000|Overall Study|Death|11
6131197|NCT00965848|9758521|FG001|Overall Study|Death|1
6131198|NCT00965848|9758522|FG002|Overall Study|Death|5
6131199|NCT00965848|9758520|FG000|Overall Study|Lost to Follow-up|0
6131200|NCT00965848|9758521|FG001|Overall Study|Lost to Follow-up|0
6221771|NCT01674569|9892140|FG001|Overall Study|Withdrawal by Subject|0
6221772|NCT01674569|9892141|FG002|Overall Study|Withdrawal by Subject|1
6221773|NCT01674569|9892142|FG003|Overall Study|Withdrawal by Subject|0
6221774|NCT01674569|9892143|FG004|Overall Study|Withdrawal by Subject|0
6221775|NCT01674569|9892144|FG005|Overall Study|Withdrawal by Subject|0
6221776|NCT01674621|9892153|FG000|Overall Study|Adverse Event|3
6221777|NCT01674621|9892154|FG001|Overall Study|Adverse Event|2
6221778|NCT01674621|9892155|FG002|Overall Study|Adverse Event|5
6221779|NCT01674621|9892156|FG003|Overall Study|Adverse Event|5
6221780|NCT01674621|9892157|FG004|Overall Study|Adverse Event|1
6221781|NCT01674621|9892153|FG000|Overall Study|Inability to Complete Study Procedures|0
6221782|NCT01674621|9892154|FG001|Overall Study|Inability to Complete Study Procedures|0
6221783|NCT01674621|9892155|FG002|Overall Study|Inability to Complete Study Procedures|0
6221784|NCT01674621|9892156|FG003|Overall Study|Inability to Complete Study Procedures|0
6221785|NCT01674621|9892157|FG004|Overall Study|Inability to Complete Study Procedures|2
6221786|NCT01674621|9892153|FG000|Overall Study|Severe Abaloparatide-SC Hypersensitivity|0
6221787|NCT01674621|9892154|FG001|Overall Study|Severe Abaloparatide-SC Hypersensitivity|0
6221788|NCT01674621|9892155|FG002|Overall Study|Severe Abaloparatide-SC Hypersensitivity|0
6221789|NCT01674621|9892156|FG003|Overall Study|Severe Abaloparatide-SC Hypersensitivity|1
6221790|NCT01674621|9892157|FG004|Overall Study|Severe Abaloparatide-SC Hypersensitivity|0
6221791|NCT01674621|9892153|FG000|Overall Study|Withdrawal by Subject|2
6131201|NCT00965848|9758522|FG002|Overall Study|Lost to Follow-up|1
6221792|NCT01674621|9892154|FG001|Overall Study|Withdrawal by Subject|5
6221793|NCT01674621|9892155|FG002|Overall Study|Withdrawal by Subject|2
6221794|NCT01674621|9892156|FG003|Overall Study|Withdrawal by Subject|0
6131202|NCT00965848|9758520|FG000|Overall Study|Withdrawal by Subject|1
6131203|NCT00965848|9758521|FG001|Overall Study|Withdrawal by Subject|0
6131204|NCT00965848|9758522|FG002|Overall Study|Withdrawal by Subject|0
6131205|NCT00965848|9758520|FG000|Overall Study|Indeterminate Clinical Outcome|2
6131206|NCT00965848|9758521|FG001|Overall Study|Indeterminate Clinical Outcome|0
6131207|NCT00965848|9758522|FG002|Overall Study|Indeterminate Clinical Outcome|1
6131208|NCT00965848|9758520|FG000|Overall Study|Not Clinically Evaluable|7
6131209|NCT00965848|9758521|FG001|Overall Study|Not Clinically Evaluable|1
6131210|NCT00965848|9758522|FG002|Overall Study|Not Clinically Evaluable|1
6131211|NCT00965848|9758520|FG000|Overall Study|Other|5
6131212|NCT00965848|9758521|FG001|Overall Study|Other|0
6131213|NCT00965848|9758522|FG002|Overall Study|Other|1
6131214|NCT00966264|9758566|FG000|Overall Study|Lost to Follow-up|4
6131215|NCT00966264|9758567|FG001|Overall Study|Lost to Follow-up|3
6131216|NCT00966277|9758575|FG000|Overall Study|Withdrawal by Subject|3
6131217|NCT00966277|9758576|FG001|Overall Study|Withdrawal by Subject|0
6221795|NCT01674621|9892157|FG004|Overall Study|Withdrawal by Subject|1
6221796|NCT01674621|9892153|FG000|Overall Study|Other than specified|0
6221797|NCT01674621|9892154|FG001|Overall Study|Other than specified|1
6221798|NCT01674621|9892155|FG002|Overall Study|Other than specified|0
6221799|NCT01674621|9892156|FG003|Overall Study|Other than specified|0
6221800|NCT01674621|9892157|FG004|Overall Study|Other than specified|2
6221801|NCT01674634|9892170|FG000|Overall Study|Withdrawal by Subject|3
6221802|NCT01674634|9892170|FG000|Overall Study|Lost to Follow-up|3
6221803|NCT01674647|9892180|FG000|Treatment Period|Death|4
6221804|NCT01674647|9892181|FG001|Treatment Period|Death|1
6221805|NCT01674647|9892180|FG000|Treatment Period|Efficacy outcome reached|0
6221806|NCT01674647|9892181|FG001|Treatment Period|Efficacy outcome reached|1
6221807|NCT01674647|9892180|FG000|Treatment Period|Physician Decision|3
6221808|NCT01674647|9892181|FG001|Treatment Period|Physician Decision|1
6221809|NCT01674647|9892180|FG000|Treatment Period|Adverse Event|60
6221810|NCT01674647|9892181|FG001|Treatment Period|Adverse Event|22
6221811|NCT01674647|9892180|FG000|Treatment Period|Non-compliance with study drug|3
6221812|NCT01674647|9892181|FG001|Treatment Period|Non-compliance with study drug|0
6221813|NCT01674647|9892180|FG000|Treatment Period|Lost to Follow-up|1
6221814|NCT01674647|9892181|FG001|Treatment Period|Lost to Follow-up|1
6221815|NCT01674647|9892180|FG000|Treatment Period|Withdrawal by Subject|19
6221816|NCT01674647|9892181|FG001|Treatment Period|Withdrawal by Subject|16
6221817|NCT01674647|9892180|FG000|Treatment Period|Switching to other therapy|5
6221818|NCT01674647|9892181|FG001|Treatment Period|Switching to other therapy|2
6221819|NCT01674647|9892180|FG000|Treatment Period|Logistical difficulties|5
6221820|NCT01674647|9892181|FG001|Treatment Period|Logistical difficulties|8
6221821|NCT01674647|9892180|FG000|Treatment Period|Treatment failure|0
6221822|NCT01674647|9892181|FG001|Treatment Period|Treatment failure|14
6221823|NCT01674647|9892180|FG000|Treatment Period|Protocol Violation|56
6221824|NCT01674647|9892181|FG001|Treatment Period|Protocol Violation|36
6221825|NCT01674647|9892180|FG000|30-day Safety Follow-up Period|Death|3
6221826|NCT01674647|9892181|FG001|30-day Safety Follow-up Period|Death|2
6221827|NCT01674647|9892180|FG000|30-day Safety Follow-up Period|Non-compliance with study drug|0
6221828|NCT01674647|9892181|FG001|30-day Safety Follow-up Period|Non-compliance with study drug|1
6221829|NCT01674647|9892180|FG000|30-day Safety Follow-up Period|Protocol Violation|39
6221830|NCT01674647|9892181|FG001|30-day Safety Follow-up Period|Protocol Violation|22
6221831|NCT01674647|9892180|FG000|30-day Safety Follow-up Period|Logistical difficulties|1
6221832|NCT01674647|9892181|FG001|30-day Safety Follow-up Period|Logistical difficulties|3
6221833|NCT01674647|9892180|FG000|30-day Safety Follow-up Period|Withdrawal by Subject|7
6221834|NCT01674647|9892181|FG001|30-day Safety Follow-up Period|Withdrawal by Subject|8
6221835|NCT01674647|9892180|FG000|30-day Safety Follow-up Period|Lost to Follow-up|8
6221836|NCT01674647|9892181|FG001|30-day Safety Follow-up Period|Lost to Follow-up|5
6221837|NCT01674712|9892192|FG000|Overall Study|Adverse Event|5
6221838|NCT01674712|9892193|FG001|Overall Study|Adverse Event|6
6221839|NCT01674712|9892194|FG002|Overall Study|Adverse Event|3
6221840|NCT01674712|9892195|FG003|Overall Study|Adverse Event|4
6221841|NCT01674712|9892196|FG004|Overall Study|Adverse Event|6
6221842|NCT01674712|9892192|FG000|Overall Study|Lost to Follow-up|1
6221843|NCT01674712|9892193|FG001|Overall Study|Lost to Follow-up|0
6221844|NCT01674712|9892194|FG002|Overall Study|Lost to Follow-up|0
6221845|NCT01674712|9892195|FG003|Overall Study|Lost to Follow-up|0
6221846|NCT01674712|9892196|FG004|Overall Study|Lost to Follow-up|0
6221847|NCT01674712|9892192|FG000|Overall Study|Protocol Violation|2
6221848|NCT01674712|9892193|FG001|Overall Study|Protocol Violation|0
6221849|NCT01674712|9892194|FG002|Overall Study|Protocol Violation|0
6221850|NCT01674712|9892195|FG003|Overall Study|Protocol Violation|0
6221851|NCT01674712|9892196|FG004|Overall Study|Protocol Violation|0
6221852|NCT01674712|9892192|FG000|Overall Study|Withdrawal by Subject|2
6221853|NCT01674712|9892193|FG001|Overall Study|Withdrawal by Subject|2
6221854|NCT01674712|9892194|FG002|Overall Study|Withdrawal by Subject|5
6221855|NCT01674712|9892195|FG003|Overall Study|Withdrawal by Subject|4
6221856|NCT01674712|9892196|FG004|Overall Study|Withdrawal by Subject|3
6221857|NCT01674712|9892192|FG000|Overall Study|Administrative|0
6221858|NCT01674712|9892193|FG001|Overall Study|Administrative|1
6221859|NCT01674712|9892194|FG002|Overall Study|Administrative|0
6221860|NCT01674712|9892195|FG003|Overall Study|Administrative|0
6221861|NCT01674712|9892196|FG004|Overall Study|Administrative|1
6221862|NCT01674712|9892192|FG000|Overall Study|Lack of Efficacy|0
6221863|NCT01674712|9892193|FG001|Overall Study|Lack of Efficacy|0
6131218|NCT00966277|9758575|FG000|Overall Study|Ineligible|1
6131219|NCT00966277|9758576|FG001|Overall Study|Ineligible|3
6131220|NCT00966277|9758575|FG000|Overall Study|Treatment Plan Changed|0
6131221|NCT00966277|9758576|FG001|Overall Study|Treatment Plan Changed|1
6131222|NCT00966355|9758585|FG000|Overall Study|non-variceal bleeding on endoscopy|68
6131223|NCT00966355|9758586|FG001|Overall Study|non-variceal bleeding on endoscopy|70
6131224|NCT00966355|9758587|FG002|Overall Study|non-variceal bleeding on endoscopy|71
6131225|NCT00966355|9758585|FG000|Overall Study|newly diagnosed advanced HCC|11
6131226|NCT00966355|9758586|FG001|Overall Study|newly diagnosed advanced HCC|12
6131227|NCT00966355|9758587|FG002|Overall Study|newly diagnosed advanced HCC|10
6131228|NCT00966355|9758585|FG000|Overall Study|Lost to Follow-up|5
6131229|NCT00966355|9758586|FG001|Overall Study|Lost to Follow-up|4
6131230|NCT00966355|9758587|FG002|Overall Study|Lost to Follow-up|3
6131231|NCT00966693|9758643|FG000|Overall Study|Adverse Event|0
6131232|NCT00966693|9758644|FG001|Overall Study|Adverse Event|0
6131233|NCT00966693|9758645|FG002|Overall Study|Adverse Event|1
6131234|NCT00966693|9758646|FG003|Overall Study|Adverse Event|2
6131235|NCT00966693|9758643|FG000|Overall Study|Death|0
6131236|NCT00966693|9758644|FG001|Overall Study|Death|0
6131237|NCT00966693|9758645|FG002|Overall Study|Death|1
6131238|NCT00966693|9758646|FG003|Overall Study|Death|0
6131239|NCT00966693|9758643|FG000|Overall Study|Withdrawal by Subject|1
6131240|NCT00966693|9758644|FG001|Overall Study|Withdrawal by Subject|0
6131241|NCT00966693|9758645|FG002|Overall Study|Withdrawal by Subject|0
6131242|NCT00966693|9758646|FG003|Overall Study|Withdrawal by Subject|5
6131243|NCT00966693|9758643|FG000|Overall Study|Disease Progression|0
6131244|NCT00966693|9758644|FG001|Overall Study|Disease Progression|0
6131245|NCT00966693|9758645|FG002|Overall Study|Disease Progression|1
6131246|NCT00966693|9758646|FG003|Overall Study|Disease Progression|16
6131247|NCT00966719|9758658|FG000|Overall Study|Lost to Follow-up|6
6131248|NCT00966719|9758659|FG001|Overall Study|Lost to Follow-up|11
6131249|NCT00966875|9758691|FG000|Part A|Adverse Event|2
6131250|NCT00966875|9758692|FG001|Part A|Adverse Event|1
6131251|NCT00966875|9758693|FG002|Part A|Adverse Event|0
6131252|NCT00966875|9758694|FG003|Part A|Adverse Event|1
6131253|NCT00966875|9758695|FG004|Part A|Adverse Event|0
6131254|NCT00966875|9758696|FG005|Part A|Adverse Event|1
6131255|NCT00966875|9758697|FG006|Part A|Adverse Event|0
6131256|NCT00966875|9758698|FG007|Part A|Adverse Event|3
6131257|NCT00966875|9758699|FG008|Part A|Adverse Event|3
6131258|NCT00966875|9758691|FG000|Part A|Entry Criteria|0
6131259|NCT00966875|9758692|FG001|Part A|Entry Criteria|0
6131260|NCT00966875|9758693|FG002|Part A|Entry Criteria|0
6131261|NCT00966875|9758694|FG003|Part A|Entry Criteria|0
6131262|NCT00966875|9758695|FG004|Part A|Entry Criteria|0
6131263|NCT00966875|9758696|FG005|Part A|Entry Criteria|2
6131264|NCT00966875|9758697|FG006|Part A|Entry Criteria|0
6131265|NCT00966875|9758698|FG007|Part A|Entry Criteria|0
6131266|NCT00966875|9758699|FG008|Part A|Entry Criteria|0
6131267|NCT00966875|9758691|FG000|Part A|Lack of Efficacy|0
6131268|NCT00966875|9758692|FG001|Part A|Lack of Efficacy|1
6131269|NCT00966875|9758693|FG002|Part A|Lack of Efficacy|0
6131270|NCT00966875|9758694|FG003|Part A|Lack of Efficacy|0
6131271|NCT00966875|9758695|FG004|Part A|Lack of Efficacy|0
6131272|NCT00966875|9758696|FG005|Part A|Lack of Efficacy|0
6131273|NCT00966875|9758697|FG006|Part A|Lack of Efficacy|4
6131274|NCT00966875|9758698|FG007|Part A|Lack of Efficacy|0
6131275|NCT00966875|9758699|FG008|Part A|Lack of Efficacy|0
6131276|NCT00966875|9758691|FG000|Part A|Lost to Follow-up|2
6131277|NCT00966875|9758692|FG001|Part A|Lost to Follow-up|0
6131278|NCT00966875|9758693|FG002|Part A|Lost to Follow-up|0
6131279|NCT00966875|9758694|FG003|Part A|Lost to Follow-up|0
6131280|NCT00966875|9758695|FG004|Part A|Lost to Follow-up|0
6131281|NCT00966875|9758696|FG005|Part A|Lost to Follow-up|1
6131282|NCT00966875|9758697|FG006|Part A|Lost to Follow-up|0
6131283|NCT00966875|9758698|FG007|Part A|Lost to Follow-up|0
6131284|NCT00966875|9758699|FG008|Part A|Lost to Follow-up|0
6131285|NCT00966875|9758691|FG000|Part A|Parent/Caregiver Decision|0
6131286|NCT00966875|9758692|FG001|Part A|Parent/Caregiver Decision|0
6131287|NCT00966875|9758693|FG002|Part A|Parent/Caregiver Decision|0
6131288|NCT00966875|9758694|FG003|Part A|Parent/Caregiver Decision|1
6131289|NCT00966875|9758695|FG004|Part A|Parent/Caregiver Decision|0
6131290|NCT00966875|9758696|FG005|Part A|Parent/Caregiver Decision|0
6131291|NCT00966875|9758697|FG006|Part A|Parent/Caregiver Decision|0
6131292|NCT00966875|9758698|FG007|Part A|Parent/Caregiver Decision|0
6131293|NCT00966875|9758699|FG008|Part A|Parent/Caregiver Decision|0
6221864|NCT01674712|9892194|FG002|Overall Study|Lack of Efficacy|1
6131294|NCT00966875|9758691|FG000|Part A|Physician Decision|0
6131295|NCT00966875|9758692|FG001|Part A|Physician Decision|0
6131296|NCT00966875|9758693|FG002|Part A|Physician Decision|0
6131297|NCT00966875|9758694|FG003|Part A|Physician Decision|0
6131298|NCT00966875|9758695|FG004|Part A|Physician Decision|1
6131299|NCT00966875|9758696|FG005|Part A|Physician Decision|0
6131300|NCT00966875|9758697|FG006|Part A|Physician Decision|1
6131301|NCT00966875|9758698|FG007|Part A|Physician Decision|0
6131302|NCT00966875|9758699|FG008|Part A|Physician Decision|2
6131303|NCT00966875|9758691|FG000|Part A|Sponsor Decision|0
6131304|NCT00966875|9758692|FG001|Part A|Sponsor Decision|0
6131305|NCT00966875|9758693|FG002|Part A|Sponsor Decision|1
6131306|NCT00966875|9758694|FG003|Part A|Sponsor Decision|0
6131307|NCT00966875|9758695|FG004|Part A|Sponsor Decision|1
6131308|NCT00966875|9758696|FG005|Part A|Sponsor Decision|0
6131309|NCT00966875|9758697|FG006|Part A|Sponsor Decision|0
6131310|NCT00966875|9758698|FG007|Part A|Sponsor Decision|2
6131311|NCT00966875|9758699|FG008|Part A|Sponsor Decision|1
6131312|NCT00966875|9758691|FG000|Part A|Withdrawal by Subject|2
6131313|NCT00966875|9758692|FG001|Part A|Withdrawal by Subject|2
6131314|NCT00966875|9758693|FG002|Part A|Withdrawal by Subject|1
6131315|NCT00966875|9758694|FG003|Part A|Withdrawal by Subject|1
6131316|NCT00966875|9758695|FG004|Part A|Withdrawal by Subject|3
6131317|NCT00966875|9758696|FG005|Part A|Withdrawal by Subject|0
6131318|NCT00966875|9758697|FG006|Part A|Withdrawal by Subject|5
6131319|NCT00966875|9758698|FG007|Part A|Withdrawal by Subject|1
6131320|NCT00966875|9758699|FG008|Part A|Withdrawal by Subject|1
6131321|NCT00966875|9758691|FG000|Part A|Protocol Violation|0
6131322|NCT00966875|9758692|FG001|Part A|Protocol Violation|0
6131323|NCT00966875|9758693|FG002|Part A|Protocol Violation|0
6131324|NCT00966875|9758694|FG003|Part A|Protocol Violation|0
6131325|NCT00966875|9758695|FG004|Part A|Protocol Violation|0
6131326|NCT00966875|9758696|FG005|Part A|Protocol Violation|0
6131327|NCT00966875|9758697|FG006|Part A|Protocol Violation|2
6131328|NCT00966875|9758698|FG007|Part A|Protocol Violation|1
6131329|NCT00966875|9758699|FG008|Part A|Protocol Violation|1
6131330|NCT00966875|9758691|FG000|Part B|Adverse Event|0
6131331|NCT00966875|9758692|FG001|Part B|Adverse Event|1
6131332|NCT00966875|9758693|FG002|Part B|Adverse Event|1
6131333|NCT00966875|9758694|FG003|Part B|Adverse Event|0
6131334|NCT00966875|9758695|FG004|Part B|Adverse Event|1
6131335|NCT00966875|9758696|FG005|Part B|Adverse Event|0
6131336|NCT00966875|9758697|FG006|Part B|Adverse Event|5
6131337|NCT00966875|9758698|FG007|Part B|Adverse Event|2
6131338|NCT00966875|9758699|FG008|Part B|Adverse Event|2
6131339|NCT00966875|9758691|FG000|Part B|Death|0
6131340|NCT00966875|9758692|FG001|Part B|Death|0
6131341|NCT00966875|9758693|FG002|Part B|Death|1
6131342|NCT00966875|9758694|FG003|Part B|Death|0
6131343|NCT00966875|9758695|FG004|Part B|Death|0
6131344|NCT00966875|9758696|FG005|Part B|Death|0
6131345|NCT00966875|9758697|FG006|Part B|Death|0
6131346|NCT00966875|9758698|FG007|Part B|Death|1
6131347|NCT00966875|9758699|FG008|Part B|Death|0
6131348|NCT00966875|9758691|FG000|Part B|Lack of Efficacy|2
6131349|NCT00966875|9758692|FG001|Part B|Lack of Efficacy|1
6131350|NCT00966875|9758693|FG002|Part B|Lack of Efficacy|1
6131351|NCT00966875|9758694|FG003|Part B|Lack of Efficacy|1
6131352|NCT00966875|9758695|FG004|Part B|Lack of Efficacy|2
6131353|NCT00966875|9758696|FG005|Part B|Lack of Efficacy|3
6131354|NCT00966875|9758697|FG006|Part B|Lack of Efficacy|12
6131355|NCT00966875|9758698|FG007|Part B|Lack of Efficacy|9
6131356|NCT00966875|9758699|FG008|Part B|Lack of Efficacy|6
6131357|NCT00966875|9758691|FG000|Part B|Lost to Follow-up|0
6131358|NCT00966875|9758692|FG001|Part B|Lost to Follow-up|0
6131359|NCT00966875|9758693|FG002|Part B|Lost to Follow-up|0
6131360|NCT00966875|9758694|FG003|Part B|Lost to Follow-up|1
6131361|NCT00966875|9758695|FG004|Part B|Lost to Follow-up|0
6131362|NCT00966875|9758696|FG005|Part B|Lost to Follow-up|0
6131363|NCT00966875|9758697|FG006|Part B|Lost to Follow-up|0
6131364|NCT00966875|9758698|FG007|Part B|Lost to Follow-up|0
6131365|NCT00966875|9758699|FG008|Part B|Lost to Follow-up|1
6131366|NCT00966875|9758691|FG000|Part B|Physician Decision|0
6131367|NCT00966875|9758692|FG001|Part B|Physician Decision|0
6131368|NCT00966875|9758693|FG002|Part B|Physician Decision|1
6131369|NCT00966875|9758694|FG003|Part B|Physician Decision|0
6131370|NCT00966875|9758695|FG004|Part B|Physician Decision|2
6131371|NCT00966875|9758696|FG005|Part B|Physician Decision|1
6131372|NCT00966875|9758697|FG006|Part B|Physician Decision|0
6131373|NCT00966875|9758698|FG007|Part B|Physician Decision|0
6131374|NCT00966875|9758699|FG008|Part B|Physician Decision|2
6131375|NCT00966875|9758691|FG000|Part B|Sponsor Decision|1
6221865|NCT01674712|9892195|FG003|Overall Study|Lack of Efficacy|0
6221866|NCT01674712|9892196|FG004|Overall Study|Lack of Efficacy|1
6221867|NCT01674725|9892210|FG000|Overall Study|Adverse Event|1
6221868|NCT01674725|9892211|FG001|Overall Study|Adverse Event|0
6221869|NCT01674725|9892210|FG000|Overall Study|Did not receive study drug|1
6221870|NCT01674725|9892211|FG001|Overall Study|Did not receive study drug|0
6221871|NCT01674725|9892210|FG000|Overall Study|Withdrawal by Subject|1
6221872|NCT01674725|9892211|FG001|Overall Study|Withdrawal by Subject|0
6221873|NCT01674725|9892210|FG000|Overall Study|Lost to Follow-up|0
6221874|NCT01674725|9892211|FG001|Overall Study|Lost to Follow-up|1
6221875|NCT01675050|9892219|FG000|Period One Treatment|Withdrawal by Subject|1
6221876|NCT01675050|9892220|FG001|Period One Treatment|Withdrawal by Subject|0
6221877|NCT01675128|9892233|FG000|Overall Study|Disease progression on study|1
6221878|NCT01675128|9892234|FG001|Overall Study|Disease progression on study|1
6221879|NCT01675128|9892235|FG002|Overall Study|Disease progression on study|1
6131376|NCT00966875|9758692|FG001|Part B|Sponsor Decision|0
6131377|NCT00966875|9758693|FG002|Part B|Sponsor Decision|0
6131378|NCT00966875|9758694|FG003|Part B|Sponsor Decision|0
6131379|NCT00966875|9758695|FG004|Part B|Sponsor Decision|0
6131380|NCT00966875|9758696|FG005|Part B|Sponsor Decision|1
6131381|NCT00966875|9758697|FG006|Part B|Sponsor Decision|0
6131382|NCT00966875|9758698|FG007|Part B|Sponsor Decision|2
6131383|NCT00966875|9758699|FG008|Part B|Sponsor Decision|1
6131384|NCT00966875|9758691|FG000|Part B|Withdrawal by Subject|2
6131385|NCT00966875|9758692|FG001|Part B|Withdrawal by Subject|1
6131386|NCT00966875|9758693|FG002|Part B|Withdrawal by Subject|2
6131387|NCT00966875|9758694|FG003|Part B|Withdrawal by Subject|1
6221880|NCT01675128|9892233|FG000|Overall Study|Refused further treatment|1
6131388|NCT00966875|9758695|FG004|Part B|Withdrawal by Subject|2
6131389|NCT00966875|9758696|FG005|Part B|Withdrawal by Subject|1
6131390|NCT00966875|9758697|FG006|Part B|Withdrawal by Subject|4
6131391|NCT00966875|9758698|FG007|Part B|Withdrawal by Subject|5
6131392|NCT00966875|9758699|FG008|Part B|Withdrawal by Subject|5
6131393|NCT00966875|9758691|FG000|Part B|Entry Criteria|0
6131394|NCT00966875|9758692|FG001|Part B|Entry Criteria|0
6131395|NCT00966875|9758693|FG002|Part B|Entry Criteria|0
6131396|NCT00966875|9758694|FG003|Part B|Entry Criteria|0
6131397|NCT00966875|9758695|FG004|Part B|Entry Criteria|0
6131398|NCT00966875|9758696|FG005|Part B|Entry Criteria|0
6131399|NCT00966875|9758697|FG006|Part B|Entry Criteria|1
6131400|NCT00966875|9758698|FG007|Part B|Entry Criteria|0
6131401|NCT00966875|9758699|FG008|Part B|Entry Criteria|1
6131402|NCT00966940|9758774|FG000|Period 1, First 6 Weeks|Withdrawal by Subject|2
6131403|NCT00966940|9758775|FG001|Period 1, First 6 Weeks|Withdrawal by Subject|0
6131404|NCT00966940|9758774|FG000|Period 1, First 6 Weeks|Protocol Violation|1
6131405|NCT00966940|9758775|FG001|Period 1, First 6 Weeks|Protocol Violation|0
6131406|NCT00967005|9758783|FG000|Overall Study|Lost to Follow-up|7
6131407|NCT00967005|9758784|FG001|Overall Study|Lost to Follow-up|10
6131408|NCT00967018|9758790|FG000|Overall Study|Adverse Event|2
6131409|NCT00967018|9758790|FG000|Overall Study|Physician Decision|7
6131410|NCT00967018|9758790|FG000|Overall Study|Lost to Follow-up|2
6131411|NCT00967018|9758790|FG000|Overall Study|Withdrawal by Subject|1
6221881|NCT01675128|9892234|FG001|Overall Study|Refused further treatment|0
6221882|NCT01675128|9892235|FG002|Overall Study|Refused further treatment|0
6221883|NCT01675128|9892233|FG000|Overall Study|Pulmonary complication; off study|0
6221884|NCT01675128|9892234|FG001|Overall Study|Pulmonary complication; off study|1
6289426|NCT02383589|10004552|FG000|Safety Follow-up (SFU)|Treated by not accepted treatment|0
6289427|NCT02383589|10004553|FG001|Safety Follow-up (SFU)|Treated by not accepted treatment|1
6289428|NCT02383758|10004576|FG000|Overall Study|Withdrawal by Subject|0
6289429|NCT02383758|10004577|FG001|Overall Study|Withdrawal by Subject|2
6289430|NCT02383862|10004585|FG000|3 Month Follow up|Lost to Follow-up|23
6289431|NCT02383862|10004586|FG001|3 Month Follow up|Lost to Follow-up|21
6289432|NCT02383940|10004601|FG000|Overall Study|Adverse Event|1
6289433|NCT02383940|10004602|FG001|Overall Study|Adverse Event|0
6289434|NCT02383940|10004601|FG000|Overall Study|Lost to Follow-up|2
6289435|NCT02383940|10004602|FG001|Overall Study|Lost to Follow-up|2
6289436|NCT02383940|10004601|FG000|Overall Study|Physician Decision|2
6289437|NCT02383940|10004602|FG001|Overall Study|Physician Decision|0
6289438|NCT02383940|10004601|FG000|Overall Study|Withdrawal by Subject|1
6289439|NCT02383940|10004602|FG001|Overall Study|Withdrawal by Subject|1
6289440|NCT02383940|10004601|FG000|Overall Study|Randomized but not treated|2
6289441|NCT02383940|10004602|FG001|Overall Study|Randomized but not treated|0
6289442|NCT02383940|10004601|FG000|Overall Study|Other than specified above|1
6289443|NCT02383940|10004602|FG001|Overall Study|Other than specified above|0
6289444|NCT02384382|10004647|FG000|Overall Study|Transitioned to study-NCT02960022|5
6289445|NCT02384382|10004647|FG000|Overall Study|Death|1
6289446|NCT02384382|10004647|FG000|Overall Study|Adverse Event|1
6289447|NCT02384382|10004647|FG000|Overall Study|Disease progression|16
6289448|NCT02384395|10004651|FG000|Overall Study|Physician Decision|4
6289449|NCT02384395|10004651|FG000|Overall Study|Withdrawal by Subject|3
6289450|NCT02384395|10004651|FG000|Overall Study|Lost to Follow-up|3
6289451|NCT02384460|10004657|FG000|Overall Study|Protocol Violation|0
6289452|NCT02384460|10004658|FG001|Overall Study|Protocol Violation|1
6289453|NCT02384460|10004657|FG000|Overall Study|Returned to previous therapeutic regimen|0
6289454|NCT02384460|10004658|FG001|Overall Study|Returned to previous therapeutic regimen|1
6289455|NCT02384460|10004657|FG000|Overall Study|Adverse Event|5
6289456|NCT02384460|10004658|FG001|Overall Study|Adverse Event|2
6289457|NCT02384460|10004657|FG000|Overall Study|Withdrawal by Subject|0
6289458|NCT02384460|10004658|FG001|Overall Study|Withdrawal by Subject|3
6289459|NCT02384460|10004657|FG000|Overall Study|Elective medical treatment|1
6289460|NCT02384460|10004658|FG001|Overall Study|Elective medical treatment|0
6289461|NCT02384460|10004657|FG000|Overall Study|Non-compliance|1
6289462|NCT02384460|10004658|FG001|Overall Study|Non-compliance|0
6289463|NCT02384538|10004666|FG000|Overall Study|Adverse Event|1
6131412|NCT00967018|9758790|FG000|Overall Study|Miscellaneous Reasons|9
6131413|NCT00967226|9758800|FG000|Overall Study|Adverse Event|0
6131414|NCT00967226|9758801|FG001|Overall Study|Adverse Event|5
6131415|NCT00967226|9758800|FG000|Overall Study|Protocol Violation|2
6131416|NCT00967226|9758801|FG001|Overall Study|Protocol Violation|0
6131417|NCT00967226|9758800|FG000|Overall Study|Physician Decision|0
6131418|NCT00967226|9758801|FG001|Overall Study|Physician Decision|1
6221885|NCT01675128|9892235|FG002|Overall Study|Pulmonary complication; off study|0
6221886|NCT01675141|9892250|FG000|Overall Study|Lenalidomide outside NIH|3
6221887|NCT01675141|9892250|FG000|Overall Study|Withdrawal by Subject|3
6221888|NCT01675141|9892250|FG000|Overall Study|Physician Decision|4
6221889|NCT01675141|9892250|FG000|Overall Study|No treatment, per protocol|1
6221890|NCT01675154|9892258|FG000|Third Intervention Period (4 Weeks)|Withdrawal by Subject|0
6221891|NCT01675154|9892259|FG001|Third Intervention Period (4 Weeks)|Withdrawal by Subject|1
6221892|NCT01675154|9892260|FG002|Third Intervention Period (4 Weeks)|Withdrawal by Subject|0
6131419|NCT00967330|9758833|FG000|Overall Study|Protocol Violation|3
6131420|NCT00967330|9758834|FG001|Overall Study|Protocol Violation|4
6131421|NCT00967330|9758833|FG000|Overall Study|Regular|10
6131422|NCT00967330|9758834|FG001|Overall Study|Regular|3
6131423|NCT00967330|9758833|FG000|Overall Study|Withdrawal by Subject|6
6131424|NCT00967330|9758834|FG001|Overall Study|Withdrawal by Subject|0
6131425|NCT00967330|9758833|FG000|Overall Study|Lost to Follow-up|1
6131426|NCT00967330|9758834|FG001|Overall Study|Lost to Follow-up|1
6131427|NCT00967330|9758833|FG000|Overall Study|Death|102
6131428|NCT00967330|9758834|FG001|Overall Study|Death|51
6131429|NCT00967330|9758833|FG000|Overall Study|Severe protocol deviation|0
6131430|NCT00967330|9758834|FG001|Overall Study|Severe protocol deviation|1
6131431|NCT00967343|9758840|FG000|Overall Study|Study termination by sponsor|12
6131432|NCT00967343|9758840|FG000|Overall Study|Death|24
6131433|NCT00967343|9758840|FG000|Overall Study|Relapse|1
6131434|NCT00967343|9758840|FG000|Overall Study|Lost to Follow-up|1
6131435|NCT00967499|9758868|FG000|Overall Study|Adverse Event|0
6131436|NCT00967499|9758869|FG001|Overall Study|Adverse Event|1
6131437|NCT00967499|9758868|FG000|Overall Study|Protocol Violation|1
6131438|NCT00967499|9758869|FG001|Overall Study|Protocol Violation|0
6131439|NCT00967499|9758868|FG000|Overall Study|Sponsor Decision|1
6131440|NCT00967499|9758869|FG001|Overall Study|Sponsor Decision|0
6131441|NCT00967499|9758868|FG000|Overall Study|Randomized but not treated|63
6131442|NCT00967499|9758869|FG001|Overall Study|Randomized but not treated|59
6131443|NCT00967616|9758886|FG000|Overall Study|Adverse Event or Serious Adverse Event|2
6131444|NCT00967616|9758887|FG001|Overall Study|Adverse Event or Serious Adverse Event|17
6131445|NCT00967616|9758886|FG000|Overall Study|Death|0
6131446|NCT00967616|9758887|FG001|Overall Study|Death|3
6131447|NCT00967616|9758886|FG000|Overall Study|Withdrawal by Subject|8
6131448|NCT00967616|9758887|FG001|Overall Study|Withdrawal by Subject|4
6131449|NCT00967616|9758886|FG000|Overall Study|Progressive Disease|31
6131450|NCT00967616|9758887|FG001|Overall Study|Progressive Disease|18
6131451|NCT00967616|9758886|FG000|Overall Study|Other|8
6131452|NCT00967616|9758887|FG001|Overall Study|Other|8
6131453|NCT00967616|9758886|FG000|Overall Study|Protocol Violation|1
6131454|NCT00967616|9758887|FG001|Overall Study|Protocol Violation|0
6131455|NCT00967668|9758896|FG000|Overall Study|Withdrawal by Subject|13
6131456|NCT00967668|9758897|FG001|Overall Study|Withdrawal by Subject|8
6131457|NCT00967668|9758898|FG002|Overall Study|Withdrawal by Subject|8
6131458|NCT00967668|9758896|FG000|Overall Study|Death|0
6131459|NCT00967668|9758897|FG001|Overall Study|Death|2
6131460|NCT00967668|9758898|FG002|Overall Study|Death|4
6131461|NCT00967668|9758896|FG000|Overall Study|Removed due to behavior|1
6131462|NCT00967668|9758897|FG001|Overall Study|Removed due to behavior|1
6131463|NCT00967668|9758898|FG002|Overall Study|Removed due to behavior|2
6131464|NCT00967668|9758896|FG000|Overall Study|Refused Year 2|11
6131465|NCT00967668|9758897|FG001|Overall Study|Refused Year 2|6
6131466|NCT00967668|9758898|FG002|Overall Study|Refused Year 2|4
6131467|NCT00967668|9758896|FG000|Overall Study|Lost to follow-up at 12-mo|27
6131468|NCT00967668|9758897|FG001|Overall Study|Lost to follow-up at 12-mo|29
6131469|NCT00967668|9758898|FG002|Overall Study|Lost to follow-up at 12-mo|26
6131470|NCT00967668|9758896|FG000|Overall Study|Lost to Follow-up|15
6131471|NCT00967668|9758897|FG001|Overall Study|Lost to Follow-up|9
6131472|NCT00967668|9758898|FG002|Overall Study|Lost to Follow-up|16
6131473|NCT00967668|9758896|FG000|Overall Study|Refused 12-mo assessment|3
6131474|NCT00967668|9758897|FG001|Overall Study|Refused 12-mo assessment|1
6131475|NCT00967668|9758898|FG002|Overall Study|Refused 12-mo assessment|9
6131476|NCT00967668|9758896|FG000|Overall Study|Pregnancy|1
6131477|NCT00967668|9758897|FG001|Overall Study|Pregnancy|0
6131478|NCT00967668|9758898|FG002|Overall Study|Pregnancy|0
6131479|NCT00967694|9758909|FG000|Overall Study|Withdrawal by Subject|6
6131480|NCT00967798|9758915|FG000|Overall Study|Withdrawal by Subject|5
6131481|NCT00967798|9758916|FG001|Overall Study|Withdrawal by Subject|2
6131482|NCT00967798|9758915|FG000|Overall Study|Lost to Follow-up|4
6131483|NCT00967798|9758916|FG001|Overall Study|Lost to Follow-up|1
6221893|NCT01675154|9892261|FG003|Third Intervention Period (4 Weeks)|Withdrawal by Subject|0
6221894|NCT01675167|9892285|FG000|Open-label Titration Phase|Adverse Event|81
6221895|NCT01675167|9892286|FG001|Open-label Titration Phase|Adverse Event|0
6221896|NCT01675167|9892287|FG002|Open-label Titration Phase|Adverse Event|0
6221897|NCT01675167|9892285|FG000|Open-label Titration Phase|Lack of Efficacy|63
6221898|NCT01675167|9892286|FG001|Open-label Titration Phase|Lack of Efficacy|0
6221899|NCT01675167|9892287|FG002|Open-label Titration Phase|Lack of Efficacy|0
6221900|NCT01675167|9892285|FG000|Open-label Titration Phase|Withdrawal by Subject|46
6221901|NCT01675167|9892286|FG001|Open-label Titration Phase|Withdrawal by Subject|0
6221902|NCT01675167|9892287|FG002|Open-label Titration Phase|Withdrawal by Subject|0
6221903|NCT01675167|9892285|FG000|Open-label Titration Phase|Protocol Violation|43
6221904|NCT01675167|9892286|FG001|Open-label Titration Phase|Protocol Violation|0
6221905|NCT01675167|9892287|FG002|Open-label Titration Phase|Protocol Violation|0
6221906|NCT01675167|9892285|FG000|Open-label Titration Phase|Lost to Follow-up|15
6221907|NCT01675167|9892286|FG001|Open-label Titration Phase|Lost to Follow-up|0
6221908|NCT01675167|9892287|FG002|Open-label Titration Phase|Lost to Follow-up|0
6221909|NCT01675167|9892285|FG000|Open-label Titration Phase|Withdrawal due to opioid withdrawal|1
6221910|NCT01675167|9892286|FG001|Open-label Titration Phase|Withdrawal due to opioid withdrawal|0
6221911|NCT01675167|9892287|FG002|Open-label Titration Phase|Withdrawal due to opioid withdrawal|0
6221912|NCT01675167|9892285|FG000|Open-label Titration Phase|Other|55
6131484|NCT00968253|9758958|FG000|Overall Study|Death|0
6131485|NCT00968253|9758959|FG001|Overall Study|Death|0
6221913|NCT01675167|9892286|FG001|Open-label Titration Phase|Other|0
6221914|NCT01675167|9892287|FG002|Open-label Titration Phase|Other|0
6221915|NCT01675167|9892285|FG000|Double-blind Treatment Phase|Lack of Efficacy|0
6221916|NCT01675167|9892286|FG001|Double-blind Treatment Phase|Lack of Efficacy|19
6221917|NCT01675167|9892287|FG002|Double-blind Treatment Phase|Lack of Efficacy|61
6221918|NCT01675167|9892285|FG000|Double-blind Treatment Phase|Withdrawal by Subject|0
6221919|NCT01675167|9892286|FG001|Double-blind Treatment Phase|Withdrawal by Subject|11
6221920|NCT01675167|9892287|FG002|Double-blind Treatment Phase|Withdrawal by Subject|6
6221921|NCT01675167|9892285|FG000|Double-blind Treatment Phase|Adverse Event|0
6221922|NCT01675167|9892286|FG001|Double-blind Treatment Phase|Adverse Event|5
6221923|NCT01675167|9892287|FG002|Double-blind Treatment Phase|Adverse Event|13
6221924|NCT01675167|9892285|FG000|Double-blind Treatment Phase|Protocol Violation|0
6221925|NCT01675167|9892286|FG001|Double-blind Treatment Phase|Protocol Violation|4
6289464|NCT02384538|10004667|FG001|Overall Study|Adverse Event|4
6289465|NCT02384538|10004666|FG000|Overall Study|Lack of Efficacy|4
6289466|NCT02384538|10004667|FG001|Overall Study|Lack of Efficacy|4
6289467|NCT02384538|10004666|FG000|Overall Study|Withdrew Consent|0
6289468|NCT02384538|10004667|FG001|Overall Study|Withdrew Consent|4
6289469|NCT02384538|10004666|FG000|Overall Study|Other|1
6289470|NCT02384538|10004667|FG001|Overall Study|Other|3
6289471|NCT02384941|10004676|FG000|Overall Study|Adverse Event|11
6289472|NCT02384941|10004677|FG001|Overall Study|Adverse Event|13
6289473|NCT02384941|10004678|FG002|Overall Study|Adverse Event|17
6289474|NCT02384941|10004676|FG000|Overall Study|Lost to Follow-up|3
6289475|NCT02384941|10004677|FG001|Overall Study|Lost to Follow-up|2
6131486|NCT00968253|9758960|FG002|Overall Study|Death|2
6131487|NCT00968253|9758958|FG000|Overall Study|Withdrawal by Subject|0
6131488|NCT00968253|9758959|FG001|Overall Study|Withdrawal by Subject|0
6131489|NCT00968253|9758960|FG002|Overall Study|Withdrawal by Subject|1
6131490|NCT00968253|9758958|FG000|Overall Study|Disease Progression|0
6131491|NCT00968253|9758959|FG001|Overall Study|Disease Progression|3
6131492|NCT00968253|9758960|FG002|Overall Study|Disease Progression|3
6131493|NCT00968253|9758958|FG000|Overall Study|Adverse Event|0
6131494|NCT00968253|9758959|FG001|Overall Study|Adverse Event|0
6131495|NCT00968253|9758960|FG002|Overall Study|Adverse Event|1
6131496|NCT00968526|9758980|FG000|Overall Study|Adverse Event|2
6131497|NCT00968526|9758981|FG001|Overall Study|Adverse Event|0
6131498|NCT00968526|9758980|FG000|Overall Study|Migrated/moved from study area|1
6131499|NCT00968526|9758981|FG001|Overall Study|Migrated/moved from study area|0
6131500|NCT00968539|9758998|FG000|Overall Study|Lost to follow-up (incompl. vaccination)|1
6131501|NCT00968539|9758999|FG001|Overall Study|Lost to follow-up (incompl. vaccination)|0
6131502|NCT00968617|9759006|FG000|Overall Study|Study terminated by sponsor|6
6131503|NCT00968669|9759014|FG000|Overall Study|Lost to Follow-up|5
6131504|NCT00968669|9759015|FG001|Overall Study|Lost to Follow-up|2
6131505|NCT00968669|9759016|FG002|Overall Study|Lost to Follow-up|1
6131506|NCT00968669|9759017|FG003|Overall Study|Lost to Follow-up|4
6131507|NCT00968669|9759014|FG000|Overall Study|Withdrawal by Subject|9
6131508|NCT00968669|9759015|FG001|Overall Study|Withdrawal by Subject|7
6131509|NCT00968669|9759016|FG002|Overall Study|Withdrawal by Subject|5
6131510|NCT00968669|9759017|FG003|Overall Study|Withdrawal by Subject|3
6131511|NCT00968669|9759014|FG000|Overall Study|Pregnancy|0
6131512|NCT00968669|9759015|FG001|Overall Study|Pregnancy|0
6131513|NCT00968669|9759016|FG002|Overall Study|Pregnancy|2
6131514|NCT00968669|9759017|FG003|Overall Study|Pregnancy|0
6131515|NCT00968669|9759014|FG000|Overall Study|AE|1
6131516|NCT00968669|9759015|FG001|Overall Study|AE|0
6131517|NCT00968669|9759016|FG002|Overall Study|AE|0
6131518|NCT00968669|9759017|FG003|Overall Study|AE|0
6131519|NCT00968669|9759014|FG000|Overall Study|AE-TRANSITIONAL CELL TUMOR IN BLADDER|0
6131520|NCT00968669|9759015|FG001|Overall Study|AE-TRANSITIONAL CELL TUMOR IN BLADDER|0
6131521|NCT00968669|9759016|FG002|Overall Study|AE-TRANSITIONAL CELL TUMOR IN BLADDER|0
6131522|NCT00968669|9759017|FG003|Overall Study|AE-TRANSITIONAL CELL TUMOR IN BLADDER|1
6131523|NCT00968669|9759014|FG000|Overall Study|DID NOT MEET EXCLUSION CRITERIA|1
6131524|NCT00968669|9759015|FG001|Overall Study|DID NOT MEET EXCLUSION CRITERIA|0
6131525|NCT00968669|9759016|FG002|Overall Study|DID NOT MEET EXCLUSION CRITERIA|0
6131526|NCT00968669|9759017|FG003|Overall Study|DID NOT MEET EXCLUSION CRITERIA|0
6131527|NCT00968669|9759014|FG000|Overall Study|DUE TO REPEATED ASTHMA EXACERBATIONS|1
6131528|NCT00968669|9759015|FG001|Overall Study|DUE TO REPEATED ASTHMA EXACERBATIONS|0
6131529|NCT00968669|9759016|FG002|Overall Study|DUE TO REPEATED ASTHMA EXACERBATIONS|0
6131530|NCT00968669|9759017|FG003|Overall Study|DUE TO REPEATED ASTHMA EXACERBATIONS|0
6131531|NCT00968669|9759014|FG000|Overall Study|EARLY DISCONTINUED ON 10-DEC-2010|0
6131532|NCT00968669|9759015|FG001|Overall Study|EARLY DISCONTINUED ON 10-DEC-2010|0
6131533|NCT00968669|9759016|FG002|Overall Study|EARLY DISCONTINUED ON 10-DEC-2010|1
6131534|NCT00968669|9759017|FG003|Overall Study|EARLY DISCONTINUED ON 10-DEC-2010|0
6289476|NCT02384941|10004678|FG002|Overall Study|Lost to Follow-up|1
6131535|NCT00968669|9759014|FG000|Overall Study|EARLY WITHDRAWAL|0
6131536|NCT00968669|9759015|FG001|Overall Study|EARLY WITHDRAWAL|1
6131537|NCT00968669|9759016|FG002|Overall Study|EARLY WITHDRAWAL|0
6131538|NCT00968669|9759017|FG003|Overall Study|EARLY WITHDRAWAL|0
6131539|NCT00968669|9759014|FG000|Overall Study|ERROR IN HADS ADMINISTRATION|0
6131540|NCT00968669|9759015|FG001|Overall Study|ERROR IN HADS ADMINISTRATION|0
6131541|NCT00968669|9759016|FG002|Overall Study|ERROR IN HADS ADMINISTRATION|1
6131542|NCT00968669|9759017|FG003|Overall Study|ERROR IN HADS ADMINISTRATION|0
6131543|NCT00968669|9759014|FG000|Overall Study|INEGIBILITY TO PERFORM VISIT|1
6131544|NCT00968669|9759015|FG001|Overall Study|INEGIBILITY TO PERFORM VISIT|0
6131545|NCT00968669|9759016|FG002|Overall Study|INEGIBILITY TO PERFORM VISIT|0
6131546|NCT00968669|9759017|FG003|Overall Study|INEGIBILITY TO PERFORM VISIT|0
6131547|NCT00968669|9759014|FG000|Overall Study|PATIENT RECEIVE ORAL PREDNISONE|0
6131548|NCT00968669|9759015|FG001|Overall Study|PATIENT RECEIVE ORAL PREDNISONE|1
6131549|NCT00968669|9759016|FG002|Overall Study|PATIENT RECEIVE ORAL PREDNISONE|0
6131550|NCT00968669|9759017|FG003|Overall Study|PATIENT RECEIVE ORAL PREDNISONE|0
6131551|NCT00968669|9759014|FG000|Overall Study|PATIENT WAS ENROLLED BY MISTAKE|0
6131552|NCT00968669|9759015|FG001|Overall Study|PATIENT WAS ENROLLED BY MISTAKE|1
6131553|NCT00968669|9759016|FG002|Overall Study|PATIENT WAS ENROLLED BY MISTAKE|0
6131554|NCT00968669|9759017|FG003|Overall Study|PATIENT WAS ENROLLED BY MISTAKE|0
6131555|NCT00968669|9759014|FG000|Overall Study|PATIENT WAS RANDOMIZED BY MISTAKE|0
6131556|NCT00968669|9759015|FG001|Overall Study|PATIENT WAS RANDOMIZED BY MISTAKE|1
6131557|NCT00968669|9759016|FG002|Overall Study|PATIENT WAS RANDOMIZED BY MISTAKE|0
6131558|NCT00968669|9759017|FG003|Overall Study|PATIENT WAS RANDOMIZED BY MISTAKE|0
6131559|NCT00968669|9759014|FG000|Overall Study|PATIENT WILL BE WORKING ABROAD|0
6131560|NCT00968669|9759015|FG001|Overall Study|PATIENT WILL BE WORKING ABROAD|1
6131561|NCT00968669|9759016|FG002|Overall Study|PATIENT WILL BE WORKING ABROAD|0
6131562|NCT00968669|9759017|FG003|Overall Study|PATIENT WILL BE WORKING ABROAD|0
6131563|NCT00968669|9759014|FG000|Overall Study|SPONSOR DECISION|0
6131564|NCT00968669|9759015|FG001|Overall Study|SPONSOR DECISION|1
6131565|NCT00968669|9759016|FG002|Overall Study|SPONSOR DECISION|0
6131566|NCT00968669|9759017|FG003|Overall Study|SPONSOR DECISION|0
6131567|NCT00968669|9759014|FG000|Overall Study|SUBJECT COMPLETED SAFETY FOLLOW-UP|0
6131568|NCT00968669|9759015|FG001|Overall Study|SUBJECT COMPLETED SAFETY FOLLOW-UP|0
6131569|NCT00968669|9759016|FG002|Overall Study|SUBJECT COMPLETED SAFETY FOLLOW-UP|1
6131570|NCT00968669|9759017|FG003|Overall Study|SUBJECT COMPLETED SAFETY FOLLOW-UP|0
6131571|NCT00968669|9759014|FG000|Overall Study|SUBJECT DID NOT MEET ACQ REQUIREMENT|0
6221926|NCT01675167|9892287|FG002|Double-blind Treatment Phase|Protocol Violation|11
6221927|NCT01675167|9892285|FG000|Double-blind Treatment Phase|Lost to Follow-up|0
6221928|NCT01675167|9892286|FG001|Double-blind Treatment Phase|Lost to Follow-up|1
6221929|NCT01675167|9892287|FG002|Double-blind Treatment Phase|Lost to Follow-up|5
6221930|NCT01675167|9892285|FG000|Double-blind Treatment Phase|Withdrawal due to opioid withdrawal|0
6221931|NCT01675167|9892286|FG001|Double-blind Treatment Phase|Withdrawal due to opioid withdrawal|1
6221932|NCT01675167|9892287|FG002|Double-blind Treatment Phase|Withdrawal due to opioid withdrawal|9
6221933|NCT01675167|9892285|FG000|Double-blind Treatment Phase|Other|0
6221934|NCT01675167|9892286|FG001|Double-blind Treatment Phase|Other|7
6221935|NCT01675167|9892287|FG002|Double-blind Treatment Phase|Other|5
6221936|NCT01675427|9892304|FG000|Overall Study|Withdrawal by Subject|7
6221937|NCT01675427|9892304|FG000|Overall Study|Participant Refused Sample Collection|18
6221938|NCT01675427|9892304|FG000|Overall Study|Sample not Collected by Mistake|2
6221939|NCT01675427|9892304|FG000|Overall Study|Lost to Follow-up|5
6131572|NCT00968669|9759015|FG001|Overall Study|SUBJECT DID NOT MEET ACQ REQUIREMENT|1
6131573|NCT00968669|9759016|FG002|Overall Study|SUBJECT DID NOT MEET ACQ REQUIREMENT|0
6131574|NCT00968669|9759017|FG003|Overall Study|SUBJECT DID NOT MEET ACQ REQUIREMENT|0
6131575|NCT00968669|9759014|FG000|Overall Study|SUBJECT INCARCERATED|0
6131576|NCT00968669|9759015|FG001|Overall Study|SUBJECT INCARCERATED|1
6131577|NCT00968669|9759016|FG002|Overall Study|SUBJECT INCARCERATED|0
6131578|NCT00968669|9759017|FG003|Overall Study|SUBJECT INCARCERATED|0
6131579|NCT00968669|9759014|FG000|Overall Study|SUBJECT WAS RANDOMIZED IN ERROR|0
6131580|NCT00968669|9759015|FG001|Overall Study|SUBJECT WAS RANDOMIZED IN ERROR|1
6131581|NCT00968669|9759016|FG002|Overall Study|SUBJECT WAS RANDOMIZED IN ERROR|0
6131582|NCT00968669|9759017|FG003|Overall Study|SUBJECT WAS RANDOMIZED IN ERROR|0
6131583|NCT00968669|9759014|FG000|Overall Study|WITHDRAWN DUE TO PREDNISONE USE|0
6131584|NCT00968669|9759015|FG001|Overall Study|WITHDRAWN DUE TO PREDNISONE USE|0
6131585|NCT00968669|9759016|FG002|Overall Study|WITHDRAWN DUE TO PREDNISONE USE|0
6131586|NCT00968669|9759017|FG003|Overall Study|WITHDRAWN DUE TO PREDNISONE USE|1
6131587|NCT00968708|9759029|FG000|Overall Study|Adverse Event|169
6131588|NCT00968708|9759030|FG001|Overall Study|Adverse Event|150
6131589|NCT00968708|9759029|FG000|Overall Study|Major Protocol Deviation|0
6131590|NCT00968708|9759030|FG001|Overall Study|Major Protocol Deviation|1
6131591|NCT00968708|9759029|FG000|Overall Study|Lost to Follow-up|19
6131592|NCT00968708|9759030|FG001|Overall Study|Lost to Follow-up|11
6131593|NCT00968708|9759029|FG000|Overall Study|Voluntary Withdrawal|104
6131594|NCT00968708|9759030|FG001|Overall Study|Voluntary Withdrawal|101
6131595|NCT00968708|9759029|FG000|Overall Study|Investigator Discretion|0
6131596|NCT00968708|9759030|FG001|Overall Study|Investigator Discretion|1
6131597|NCT00968708|9759029|FG000|Overall Study|Other|26
6131598|NCT00968708|9759030|FG001|Overall Study|Other|34
6131599|NCT00968799|9759036|FG000|Overall Study|Advanced disease, HIPEC not applicable|2
6221940|NCT01675427|9892304|FG000|Overall Study|Other|2
6131600|NCT00968812|9759043|FG000|Overall Study|Adverse Event|30
6131601|NCT00968812|9759044|FG001|Overall Study|Adverse Event|46
6131602|NCT00968812|9759045|FG002|Overall Study|Adverse Event|33
6131603|NCT00968812|9759043|FG000|Overall Study|Death|2
6131604|NCT00968812|9759044|FG001|Overall Study|Death|2
6131605|NCT00968812|9759045|FG002|Overall Study|Death|1
6131606|NCT00968812|9759043|FG000|Overall Study|Lack of Efficacy|9
6131607|NCT00968812|9759044|FG001|Overall Study|Lack of Efficacy|7
6131608|NCT00968812|9759045|FG002|Overall Study|Lack of Efficacy|16
6131609|NCT00968812|9759043|FG000|Overall Study|Lost to Follow-up|17
6131610|NCT00968812|9759044|FG001|Overall Study|Lost to Follow-up|12
6131611|NCT00968812|9759045|FG002|Overall Study|Lost to Follow-up|11
6131612|NCT00968812|9759043|FG000|Overall Study|Physician Decision|8
6131613|NCT00968812|9759044|FG001|Overall Study|Physician Decision|5
6131614|NCT00968812|9759045|FG002|Overall Study|Physician Decision|9
6131615|NCT00968812|9759043|FG000|Overall Study|Protocol Violation|7
6131616|NCT00968812|9759044|FG001|Overall Study|Protocol Violation|4
6131617|NCT00968812|9759045|FG002|Overall Study|Protocol Violation|3
6131618|NCT00968812|9759043|FG000|Overall Study|Withdrawal by Subject|17
6131619|NCT00968812|9759044|FG001|Overall Study|Withdrawal by Subject|23
6131620|NCT00968812|9759045|FG002|Overall Study|Withdrawal by Subject|25
6131621|NCT00968812|9759043|FG000|Overall Study|Creatinine or eGFR withdrawal criteria|9
6131622|NCT00968812|9759044|FG001|Overall Study|Creatinine or eGFR withdrawal criteria|13
6131623|NCT00968812|9759045|FG002|Overall Study|Creatinine or eGFR withdrawal criteria|7
6131624|NCT00968812|9759043|FG000|Overall Study|Noncompliance with study drug|4
6131625|NCT00968812|9759044|FG001|Overall Study|Noncompliance with study drug|1
6131626|NCT00968812|9759045|FG002|Overall Study|Noncompliance with study drug|6
6131627|NCT00968812|9759043|FG000|Overall Study|Unable to take rescue therapy|12
6131628|NCT00968812|9759044|FG001|Overall Study|Unable to take rescue therapy|12
6131629|NCT00968812|9759045|FG002|Overall Study|Unable to take rescue therapy|17
6221941|NCT01675492|9892347|FG000|Overall Study|study completed early - product approval|42
6221942|NCT01675531|9892352|FG000|Overall Study|Adverse Event|9
6221943|NCT01675531|9892352|FG000|Overall Study|Withdrawal by Subject|7
6221944|NCT01675531|9892352|FG000|Overall Study|Lack of Efficacy|1
6221945|NCT01675531|9892352|FG000|Overall Study|Protocol Violation|8
6221946|NCT01675544|9892357|FG000|Overall Study|Withdrawal by Subject|2
6221947|NCT01675596|9892361|FG000|Overall Study|Death|6
6221948|NCT01675596|9892361|FG000|Overall Study|Exit with other reason|1
6221949|NCT01675596|9892361|FG000|Overall Study|Missed Visit|1
6221950|NCT01675622|9892367|FG000|Overall Study|Withdrawal by Subject|2
6221951|NCT01675622|9892368|FG001|Overall Study|Withdrawal by Subject|2
6221952|NCT01675622|9892367|FG000|Overall Study|Adverse Event|12
6221953|NCT01675622|9892368|FG001|Overall Study|Adverse Event|10
6221954|NCT01675622|9892367|FG000|Overall Study|Protocol Violation|4
6221955|NCT01675622|9892368|FG001|Overall Study|Protocol Violation|1
6221956|NCT01675622|9892367|FG000|Overall Study|Lack of Efficacy|2
6221957|NCT01675622|9892368|FG001|Overall Study|Lack of Efficacy|4
6221958|NCT01675622|9892367|FG000|Overall Study|Lost to Follow-up|1
6221959|NCT01675622|9892368|FG001|Overall Study|Lost to Follow-up|3
6221960|NCT01675622|9892367|FG000|Overall Study|Other|5
6221961|NCT01675622|9892368|FG001|Overall Study|Other|4
6221962|NCT01675661|9892390|FG000|Overall Study|Lost to Follow-up|22
6221963|NCT01675661|9892391|FG001|Overall Study|Lost to Follow-up|23
6221964|NCT01675661|9892390|FG000|Overall Study|Practical problems|9
6221965|NCT01675661|9892391|FG001|Overall Study|Practical problems|5
6221966|NCT01675661|9892390|FG000|Overall Study|Moved away|5
6221967|NCT01675661|9892391|FG001|Overall Study|Moved away|6
6221968|NCT01675661|9892390|FG000|Overall Study|Withdrawal by Subject|3
6221969|NCT01675661|9892391|FG001|Overall Study|Withdrawal by Subject|7
6221970|NCT01675661|9892390|FG000|Overall Study|Physician Decision|0
6221971|NCT01675661|9892391|FG001|Overall Study|Physician Decision|2
6221972|NCT01675661|9892390|FG000|Overall Study|Death|0
6221973|NCT01675661|9892391|FG001|Overall Study|Death|1
6221974|NCT01675661|9892390|FG000|Overall Study|Other reason|1
6221975|NCT01675661|9892391|FG001|Overall Study|Other reason|2
6221976|NCT01675765|9892399|FG000|Overall Study|Progressive disease|4
6221977|NCT01675765|9892400|FG001|Overall Study|Progressive disease|4
6221978|NCT01675765|9892399|FG000|Overall Study|Adverse Event|1
6221979|NCT01675765|9892400|FG001|Overall Study|Adverse Event|2
6221980|NCT01675765|9892399|FG000|Overall Study|Withdrawal by Subject|2
6221981|NCT01675765|9892400|FG001|Overall Study|Withdrawal by Subject|0
6221982|NCT01675765|9892399|FG000|Overall Study|Death|1
6221983|NCT01675765|9892400|FG001|Overall Study|Death|0
6221984|NCT01675765|9892399|FG000|Overall Study|Clinical progression|3
6221985|NCT01675765|9892400|FG001|Overall Study|Clinical progression|2
6221986|NCT01675882|9892419|FG000|Overall Study|Adverse Event|0
6221987|NCT01675882|9892420|FG001|Overall Study|Adverse Event|2
6221988|NCT01675882|9892421|FG002|Overall Study|Adverse Event|1
6221989|NCT01675882|9892422|FG003|Overall Study|Adverse Event|0
6221990|NCT01675882|9892419|FG000|Overall Study|Participant unwilling to continue|2
6221991|NCT01675882|9892420|FG001|Overall Study|Participant unwilling to continue|4
6221992|NCT01675882|9892421|FG002|Overall Study|Participant unwilling to continue|2
6131630|NCT00968812|9759043|FG000|Overall Study|Other|25
6131631|NCT00968812|9759044|FG001|Overall Study|Other|37
6131632|NCT00968812|9759045|FG002|Overall Study|Other|40
6131633|NCT00968968|9759076|FG000|Overall Study|Study closed/terminated|10
6131634|NCT00968968|9759077|FG001|Overall Study|Study closed/terminated|10
6131635|NCT00968968|9759076|FG000|Overall Study|Protocol defined stopping criteria|3
6131636|NCT00968968|9759077|FG001|Overall Study|Protocol defined stopping criteria|1
6131637|NCT00968968|9759076|FG000|Overall Study|Withdrawal by Subject|2
6131638|NCT00968968|9759077|FG001|Overall Study|Withdrawal by Subject|0
6131639|NCT00968968|9759076|FG000|Overall Study|Physician Decision|1
6131640|NCT00968968|9759077|FG001|Overall Study|Physician Decision|2
6131641|NCT00968968|9759076|FG000|Overall Study|Lost to Follow-up|0
6131642|NCT00968968|9759077|FG001|Overall Study|Lost to Follow-up|1
6131643|NCT00968981|9759087|FG000|Overall Study|Adverse Event|2
6131644|NCT00968981|9759088|FG001|Overall Study|Adverse Event|0
6131645|NCT00968981|9759089|FG002|Overall Study|Adverse Event|0
6131646|NCT00968981|9759087|FG000|Overall Study|Disease Progression|14
6131647|NCT00968981|9759088|FG001|Overall Study|Disease Progression|16
6131648|NCT00968981|9759089|FG002|Overall Study|Disease Progression|13
6131649|NCT00968981|9759087|FG000|Overall Study|Lost to Follow-up|0
6131650|NCT00968981|9759088|FG001|Overall Study|Lost to Follow-up|0
6131651|NCT00968981|9759089|FG002|Overall Study|Lost to Follow-up|1
6131652|NCT00968981|9759087|FG000|Overall Study|Physician Decision|5
6131653|NCT00968981|9759088|FG001|Overall Study|Physician Decision|3
6131654|NCT00968981|9759089|FG002|Overall Study|Physician Decision|5
6131655|NCT00968981|9759087|FG000|Overall Study|Withdrawal by Subject|1
6131656|NCT00968981|9759088|FG001|Overall Study|Withdrawal by Subject|3
6131657|NCT00968981|9759089|FG002|Overall Study|Withdrawal by Subject|3
6131658|NCT00969124|9759098|FG000|Overall Study|Protocol Violation|2
6131659|NCT00969124|9759098|FG000|Overall Study|Inadequate bowel preparation|15
6131660|NCT00969124|9759098|FG000|Overall Study|Inability to reach cecum|9
6131661|NCT00969124|9759098|FG000|Overall Study|Previously unrecognized disease|3
6131662|NCT00969124|9759098|FG000|Overall Study|Technical error|1
6131663|NCT00969150|9759105|FG000|Overall Study|Adverse Event|4
6131664|NCT00969150|9759106|FG001|Overall Study|Adverse Event|14
6131665|NCT00969150|9759105|FG000|Overall Study|Lack of Efficacy|1
6131666|NCT00969150|9759106|FG001|Overall Study|Lack of Efficacy|1
6131667|NCT00969150|9759105|FG000|Overall Study|Protocol Violation|9
6131668|NCT00969150|9759106|FG001|Overall Study|Protocol Violation|12
6131669|NCT00969150|9759105|FG000|Overall Study|Withdrawal by Subject|13
6131670|NCT00969150|9759106|FG001|Overall Study|Withdrawal by Subject|9
6131671|NCT00969150|9759105|FG000|Overall Study|Lost to Follow-up|5
6131672|NCT00969150|9759106|FG001|Overall Study|Lost to Follow-up|4
6131673|NCT00969150|9759105|FG000|Overall Study|Other reasons|1
6131674|NCT00969150|9759106|FG001|Overall Study|Other reasons|0
6131675|NCT00969228|9759114|FG000|Overall Study|Adverse Event|1
6131676|NCT00969228|9759115|FG001|Overall Study|Adverse Event|0
6131677|NCT00969228|9759114|FG000|Overall Study|Withdrawal by Subject|4
6131678|NCT00969228|9759115|FG001|Overall Study|Withdrawal by Subject|0
6131679|NCT00969228|9759114|FG000|Overall Study|Porcine circovirus detection in vaccine|38
6131680|NCT00969228|9759115|FG001|Overall Study|Porcine circovirus detection in vaccine|14
6131681|NCT00969280|9759123|FG000|Overall Study|Protocol Violation|2
6131682|NCT00969280|9759124|FG001|Overall Study|Protocol Violation|1
6131683|NCT00969280|9759123|FG000|Overall Study|Withdrawal by Subject|0
6131684|NCT00969280|9759124|FG001|Overall Study|Withdrawal by Subject|1
6131685|NCT00969280|9759123|FG000|Overall Study|infection of influenza A(H1N1)|0
6131686|NCT00969280|9759124|FG001|Overall Study|infection of influenza A(H1N1)|1
6131687|NCT00969332|9759130|FG000|Overall Study|Physician Decision|8
6131688|NCT00969332|9759130|FG000|Overall Study|Withdrawal by Subject|3
6131689|NCT00969436|9759138|FG000|Overall Study|Protocol Violation|1
6131690|NCT00969436|9759139|FG001|Overall Study|Protocol Violation|3
6131691|NCT00969436|9759140|FG002|Overall Study|Protocol Violation|0
6131692|NCT00969436|9759138|FG000|Overall Study|Migrated/moved from study area|12
6131693|NCT00969436|9759139|FG001|Overall Study|Migrated/moved from study area|10
6131694|NCT00969436|9759140|FG002|Overall Study|Migrated/moved from study area|2
6131695|NCT00969436|9759138|FG000|Overall Study|Father - serious health problem|0
6131696|NCT00969436|9759139|FG001|Overall Study|Father - serious health problem|0
6131697|NCT00969436|9759140|FG002|Overall Study|Father - serious health problem|1
6131698|NCT00969436|9759138|FG000|Overall Study|Parents personal problem|0
6131699|NCT00969436|9759139|FG001|Overall Study|Parents personal problem|0
6131700|NCT00969436|9759140|FG002|Overall Study|Parents personal problem|1
6131701|NCT00969436|9759138|FG000|Overall Study|Subject eliminated (other vaccine)|1
6131702|NCT00969436|9759139|FG001|Overall Study|Subject eliminated (other vaccine)|0
6131703|NCT00969436|9759140|FG002|Overall Study|Subject eliminated (other vaccine)|0
6131704|NCT00969436|9759138|FG000|Overall Study|Withdrawal by Subject|3
6131705|NCT00969436|9759139|FG001|Overall Study|Withdrawal by Subject|0
6131706|NCT00969436|9759140|FG002|Overall Study|Withdrawal by Subject|2
6131707|NCT00969436|9759138|FG000|Overall Study|Lost to Follow-up|8
6131708|NCT00969436|9759139|FG001|Overall Study|Lost to Follow-up|8
6131709|NCT00969436|9759140|FG002|Overall Study|Lost to Follow-up|5
6131710|NCT00969540|9759154|FG000|Overall Study|Lost to Follow-up|1
6131711|NCT00969540|9759155|FG001|Overall Study|Lost to Follow-up|1
6131712|NCT00969553|9759182|FG000|Overall Study|Progressive disease (PD)|2
6131713|NCT00969553|9759183|FG001|Overall Study|Progressive disease (PD)|2
6131714|NCT00969553|9759184|FG002|Overall Study|Progressive disease (PD)|6
6131715|NCT00969553|9759185|FG003|Overall Study|Progressive disease (PD)|9
6221993|NCT01675882|9892422|FG003|Overall Study|Participant unwilling to continue|1
6221994|NCT01675882|9892419|FG000|Overall Study|Lost to Follow-up|0
6221995|NCT01675882|9892420|FG001|Overall Study|Lost to Follow-up|1
6221996|NCT01675882|9892421|FG002|Overall Study|Lost to Follow-up|0
6221997|NCT01675882|9892422|FG003|Overall Study|Lost to Follow-up|0
6221998|NCT01675882|9892419|FG000|Overall Study|Non-compliance|0
6221999|NCT01675882|9892420|FG001|Overall Study|Non-compliance|0
6222000|NCT01675882|9892421|FG002|Overall Study|Non-compliance|0
6222001|NCT01675882|9892422|FG003|Overall Study|Non-compliance|1
6222002|NCT01676012|9892432|FG000|Overall Study|Adverse Event|2
6222003|NCT01676012|9892432|FG000|Overall Study|incomplete set of videos|1
6222004|NCT01676116|9892438|FG000|Overall Study|Withdrawal criteria|2
6222005|NCT01676116|9892439|FG001|Overall Study|Withdrawal criteria|14
6222006|NCT01676116|9892438|FG000|Overall Study|Adverse Event|1
6222007|NCT01676116|9892439|FG001|Overall Study|Adverse Event|2
6222008|NCT01676116|9892438|FG000|Overall Study|Unclassified|4
6222009|NCT01676116|9892439|FG001|Overall Study|Unclassified|10
6222010|NCT01676116|9892438|FG000|Overall Study|Protocol Violation|9
6222011|NCT01676116|9892439|FG001|Overall Study|Protocol Violation|3
6222012|NCT01676220|9892447|FG000|Overall Study|Randomized But Not Treated|4
6222013|NCT01676220|9892448|FG001|Overall Study|Randomized But Not Treated|1
6222014|NCT01676220|9892447|FG000|Overall Study|Adverse Event|10
6222015|NCT01676220|9892448|FG001|Overall Study|Adverse Event|8
6222016|NCT01676220|9892447|FG000|Overall Study|Lack of Efficacy|2
6222017|NCT01676220|9892448|FG001|Overall Study|Lack of Efficacy|5
6222018|NCT01676220|9892447|FG000|Overall Study|Protocol Violation|11
6222019|NCT01676220|9892448|FG001|Overall Study|Protocol Violation|12
6222020|NCT01676220|9892447|FG000|Overall Study|Received Rescue Therapy|14
6222021|NCT01676220|9892448|FG001|Overall Study|Received Rescue Therapy|22
6222022|NCT01676220|9892447|FG000|Overall Study|Personal Reason|34
6222023|NCT01676220|9892448|FG001|Overall Study|Personal Reason|45
6222024|NCT01676220|9892447|FG000|Overall Study|Lost to Follow-up|11
6222025|NCT01676220|9892448|FG001|Overall Study|Lost to Follow-up|18
6222026|NCT01676220|9892447|FG000|Overall Study|Selection Criterion/Protocol Violation|9
6222027|NCT01676220|9892448|FG001|Overall Study|Selection Criterion/Protocol Violation|9
6222028|NCT01676220|9892447|FG000|Overall Study|Site Closure/Site Withdrawal|1
6222029|NCT01676220|9892448|FG001|Overall Study|Site Closure/Site Withdrawal|4
6222030|NCT01676220|9892447|FG000|Overall Study|Perceived Lack of Efficacy|3
6222031|NCT01676220|9892448|FG001|Overall Study|Perceived Lack of Efficacy|1
6222032|NCT01676220|9892447|FG000|Overall Study|Non Serious Hypoglycemia|2
6222033|NCT01676220|9892448|FG001|Overall Study|Non Serious Hypoglycemia|0
6222034|NCT01676220|9892447|FG000|Overall Study|No More Need of Insulin|1
6222035|NCT01676220|9892448|FG001|Overall Study|No More Need of Insulin|0
6222036|NCT01676727|9892521|FG000|Overall Study|Death|18
6222037|NCT01676727|9892521|FG000|Overall Study|Withdrawal by Subject|6
6222038|NCT01676727|9892521|FG000|Overall Study|Screening failure|5
6222039|NCT01676727|9892521|FG000|Overall Study|Not willing to attend 1-year visit|2
6222040|NCT01676727|9892521|FG000|Overall Study|Valve explanted|1
6222041|NCT01676896|9892538|FG000|Overall Study|Withdrawal by Subject|12
6222042|NCT01676896|9892539|FG001|Overall Study|Withdrawal by Subject|7
6222043|NCT01676896|9892540|FG002|Overall Study|Withdrawal by Subject|19
6222044|NCT01676909|9892550|FG000|Overall Study|Withdrawal by Subject|3
6222045|NCT01676909|9892551|FG001|Overall Study|Withdrawal by Subject|5
6222046|NCT01676909|9892550|FG000|Overall Study|Lost to Follow-up|15
6222047|NCT01676909|9892551|FG001|Overall Study|Lost to Follow-up|9
6222048|NCT01677182|9892562|FG000|Overall Study|Adverse Event|2
6222049|NCT01677182|9892563|FG001|Overall Study|Adverse Event|1
6222050|NCT01677182|9892564|FG002|Overall Study|Adverse Event|8
6222051|NCT01677182|9892562|FG000|Overall Study|Protocol Violation|5
6222052|NCT01677182|9892563|FG001|Overall Study|Protocol Violation|1
6222053|NCT01677182|9892564|FG002|Overall Study|Protocol Violation|4
6222054|NCT01677182|9892562|FG000|Overall Study|Lost to Follow-up|4
6222055|NCT01677182|9892563|FG001|Overall Study|Lost to Follow-up|0
6222056|NCT01677182|9892564|FG002|Overall Study|Lost to Follow-up|3
6222057|NCT01677182|9892562|FG000|Overall Study|Withdrawal by Subject|7
6222058|NCT01677182|9892563|FG001|Overall Study|Withdrawal by Subject|12
6222059|NCT01677182|9892564|FG002|Overall Study|Withdrawal by Subject|10
6222060|NCT01677182|9892562|FG000|Overall Study|Study termination|12
6222061|NCT01677182|9892563|FG001|Overall Study|Study termination|9
6222062|NCT01677182|9892564|FG002|Overall Study|Study termination|11
5980992|NCT03318003|9569857|FG000|Overall Study|Withdrawal by Subject|1
6222063|NCT01677182|9892562|FG000|Overall Study|Lack of Efficacy|3
6222064|NCT01677182|9892563|FG001|Overall Study|Lack of Efficacy|0
6222065|NCT01677182|9892564|FG002|Overall Study|Lack of Efficacy|1
6222066|NCT01677182|9892562|FG000|Overall Study|Other reasons|1
6222067|NCT01677182|9892563|FG001|Overall Study|Other reasons|5
6222068|NCT01677182|9892564|FG002|Overall Study|Other reasons|2
6222069|NCT01677195|9892575|FG000|Overall Study|Lost to Follow-up|14
6222070|NCT01677195|9892576|FG001|Overall Study|Lost to Follow-up|22
6222071|NCT01677195|9892577|FG002|Overall Study|Lost to Follow-up|22
6222072|NCT01677195|9892575|FG000|Overall Study|Withdrawal by Subject|1
6222073|NCT01677195|9892576|FG001|Overall Study|Withdrawal by Subject|0
6222074|NCT01677195|9892577|FG002|Overall Study|Withdrawal by Subject|1
6222075|NCT01677195|9892575|FG000|Overall Study|Adverse Event|6
6131716|NCT00969553|9759186|FG004|Overall Study|Progressive disease (PD)|2
6131717|NCT00969553|9759187|FG005|Overall Study|Progressive disease (PD)|4
6131718|NCT00969553|9759188|FG006|Overall Study|Progressive disease (PD)|2
6131719|NCT00969553|9759189|FG007|Overall Study|Progressive disease (PD)|12
6131720|NCT00969553|9759190|FG008|Overall Study|Progressive disease (PD)|3
6131721|NCT00969553|9759182|FG000|Overall Study|Dose limiting Toxicity (DLT)|0
6131722|NCT00969553|9759183|FG001|Overall Study|Dose limiting Toxicity (DLT)|0
6131723|NCT00969553|9759184|FG002|Overall Study|Dose limiting Toxicity (DLT)|0
6131724|NCT00969553|9759185|FG003|Overall Study|Dose limiting Toxicity (DLT)|0
6131725|NCT00969553|9759186|FG004|Overall Study|Dose limiting Toxicity (DLT)|1
6131726|NCT00969553|9759187|FG005|Overall Study|Dose limiting Toxicity (DLT)|0
6131727|NCT00969553|9759188|FG006|Overall Study|Dose limiting Toxicity (DLT)|0
6131728|NCT00969553|9759189|FG007|Overall Study|Dose limiting Toxicity (DLT)|0
6131729|NCT00969553|9759190|FG008|Overall Study|Dose limiting Toxicity (DLT)|0
6131730|NCT00969553|9759182|FG000|Overall Study|Other Adverse Event|0
6131731|NCT00969553|9759183|FG001|Overall Study|Other Adverse Event|0
6222076|NCT01677195|9892576|FG001|Overall Study|Adverse Event|4
6222077|NCT01677195|9892577|FG002|Overall Study|Adverse Event|1
6222078|NCT01677195|9892575|FG000|Overall Study|Physician Decision|1
6222079|NCT01677195|9892576|FG001|Overall Study|Physician Decision|2
6222080|NCT01677195|9892577|FG002|Overall Study|Physician Decision|2
6222081|NCT01677195|9892575|FG000|Overall Study|Pregnancy|0
6222082|NCT01677195|9892576|FG001|Overall Study|Pregnancy|1
6222083|NCT01677195|9892577|FG002|Overall Study|Pregnancy|0
6222084|NCT01677195|9892575|FG000|Overall Study|Protocol Violation|7
6222085|NCT01677195|9892576|FG001|Overall Study|Protocol Violation|3
6222086|NCT01677195|9892577|FG002|Overall Study|Protocol Violation|4
6222087|NCT01677299|9892595|FG000|Overall Study|Adverse Event|0
6222088|NCT01677299|9892596|FG001|Overall Study|Adverse Event|2
6222089|NCT01677299|9892597|FG002|Overall Study|Adverse Event|1
6222090|NCT01677299|9892598|FG003|Overall Study|Adverse Event|0
6222091|NCT01677299|9892595|FG000|Overall Study|Withdrawal by Subject|0
6222092|NCT01677299|9892596|FG001|Overall Study|Withdrawal by Subject|1
6222093|NCT01677299|9892597|FG002|Overall Study|Withdrawal by Subject|0
6222094|NCT01677299|9892598|FG003|Overall Study|Withdrawal by Subject|1
6222095|NCT01677377|9892624|FG000|Overall Study|Protocol Violation|1
6222096|NCT01677377|9892625|FG001|Overall Study|Protocol Violation|0
6222097|NCT01677377|9892626|FG002|Overall Study|Protocol Violation|0
6222098|NCT01677377|9892624|FG000|Overall Study|Lost to Follow-up|0
6222099|NCT01677377|9892625|FG001|Overall Study|Lost to Follow-up|1
6222100|NCT01677377|9892626|FG002|Overall Study|Lost to Follow-up|1
6222101|NCT01677377|9892624|FG000|Overall Study|Withdrawal by Subject|0
6222102|NCT01677377|9892625|FG001|Overall Study|Withdrawal by Subject|0
6222103|NCT01677377|9892626|FG002|Overall Study|Withdrawal by Subject|3
6222104|NCT01677377|9892624|FG000|Overall Study|Lack of Efficacy|0
6222105|NCT01677377|9892625|FG001|Overall Study|Lack of Efficacy|0
6222106|NCT01677377|9892626|FG002|Overall Study|Lack of Efficacy|1
6222107|NCT01677377|9892624|FG000|Overall Study|Pregnancy|0
6222108|NCT01677377|9892625|FG001|Overall Study|Pregnancy|0
6222109|NCT01677377|9892626|FG002|Overall Study|Pregnancy|1
6222110|NCT01677507|9892634|FG000|Initial Assignment|Adverse Event|0
6222111|NCT01677507|9892635|FG001|Initial Assignment|Adverse Event|1
6222112|NCT01677507|9892634|FG000|Initial Assignment|Protocol Violation|0
6222113|NCT01677507|9892635|FG001|Initial Assignment|Protocol Violation|1
6222114|NCT01677507|9892634|FG000|Second Assigment|Withdrawal by Subject|2
6222115|NCT01677507|9892635|FG001|Second Assigment|Withdrawal by Subject|2
6222116|NCT01677507|9892634|FG000|Second Assigment|Adverse Event|1
6222117|NCT01677507|9892635|FG001|Second Assigment|Adverse Event|3
6222118|NCT01677624|9892643|FG000|Overall Study|Insuf Resp: intra-articular hemorrhage|1
6222119|NCT01677741|9892655|FG000|Overall Study|Death|0
6222120|NCT01677741|9892656|FG001|Overall Study|Death|0
6222121|NCT01677741|9892657|FG002|Overall Study|Death|0
6222122|NCT01677741|9892658|FG003|Overall Study|Death|1
6222123|NCT01677741|9892659|FG004|Overall Study|Death|0
6222124|NCT01677741|9892660|FG005|Overall Study|Death|1
6222125|NCT01677741|9892661|FG006|Overall Study|Death|0
6222126|NCT01677741|9892662|FG007|Overall Study|Death|0
6222127|NCT01677741|9892655|FG000|Overall Study|Withdrawal by Subject|2
6222128|NCT01677741|9892656|FG001|Overall Study|Withdrawal by Subject|7
6222129|NCT01677741|9892657|FG002|Overall Study|Withdrawal by Subject|5
6222130|NCT01677741|9892658|FG003|Overall Study|Withdrawal by Subject|4
6222131|NCT01677741|9892659|FG004|Overall Study|Withdrawal by Subject|11
6222132|NCT01677741|9892660|FG005|Overall Study|Withdrawal by Subject|20
6222133|NCT01677741|9892661|FG006|Overall Study|Withdrawal by Subject|4
6222134|NCT01677741|9892662|FG007|Overall Study|Withdrawal by Subject|2
6222135|NCT01677741|9892655|FG000|Overall Study|Enrolled in a rollover study|0
6222136|NCT01677741|9892656|FG001|Overall Study|Enrolled in a rollover study|3
6222137|NCT01677741|9892657|FG002|Overall Study|Enrolled in a rollover study|2
6222138|NCT01677741|9892658|FG003|Overall Study|Enrolled in a rollover study|1
6222139|NCT01677741|9892659|FG004|Overall Study|Enrolled in a rollover study|6
6222140|NCT01677741|9892660|FG005|Overall Study|Enrolled in a rollover study|6
6222141|NCT01677741|9892661|FG006|Overall Study|Enrolled in a rollover study|7
6222142|NCT01677741|9892662|FG007|Overall Study|Enrolled in a rollover study|0
6222143|NCT01677741|9892655|FG000|Overall Study|Progressive disease|1
6131732|NCT00969553|9759184|FG002|Overall Study|Other Adverse Event|0
6131733|NCT00969553|9759185|FG003|Overall Study|Other Adverse Event|1
6131734|NCT00969553|9759186|FG004|Overall Study|Other Adverse Event|0
6131735|NCT00969553|9759187|FG005|Overall Study|Other Adverse Event|0
6131736|NCT00969553|9759188|FG006|Overall Study|Other Adverse Event|1
6131737|NCT00969553|9759189|FG007|Overall Study|Other Adverse Event|0
6131738|NCT00969553|9759190|FG008|Overall Study|Other Adverse Event|0
6131739|NCT00969553|9759182|FG000|Overall Study|Refused cont. medication|1
6131740|NCT00969553|9759183|FG001|Overall Study|Refused cont. medication|1
6131741|NCT00969553|9759184|FG002|Overall Study|Refused cont. medication|0
6131742|NCT00969553|9759185|FG003|Overall Study|Refused cont. medication|2
6131743|NCT00969553|9759186|FG004|Overall Study|Refused cont. medication|0
6131744|NCT00969553|9759187|FG005|Overall Study|Refused cont. medication|0
6131745|NCT00969553|9759188|FG006|Overall Study|Refused cont. medication|0
6131746|NCT00969553|9759189|FG007|Overall Study|Refused cont. medication|1
6131747|NCT00969553|9759190|FG008|Overall Study|Refused cont. medication|0
6131748|NCT00969553|9759182|FG000|Overall Study|Not specified above|0
6131749|NCT00969553|9759183|FG001|Overall Study|Not specified above|0
6131750|NCT00969553|9759184|FG002|Overall Study|Not specified above|0
6131751|NCT00969553|9759185|FG003|Overall Study|Not specified above|4
6131752|NCT00969553|9759186|FG004|Overall Study|Not specified above|0
6131753|NCT00969553|9759187|FG005|Overall Study|Not specified above|0
6131754|NCT00969553|9759188|FG006|Overall Study|Not specified above|1
6131755|NCT00969553|9759189|FG007|Overall Study|Not specified above|1
6131756|NCT00969553|9759190|FG008|Overall Study|Not specified above|0
6131757|NCT00969618|9759218|FG000|Overall Study|Adverse Event|29
6131758|NCT00969618|9759218|FG000|Overall Study|Entry Criteria Not Met|3
6131759|NCT00969618|9759218|FG000|Overall Study|Lack of Efficacy|2
6131760|NCT00969618|9759218|FG000|Overall Study|Lost to Follow-up|7
6131761|NCT00969618|9759218|FG000|Overall Study|Physician Decision|1
6131762|NCT00969618|9759218|FG000|Overall Study|Protocol Violation|9
6131763|NCT00969618|9759218|FG000|Overall Study|Withdrawal by Subject|27
6131764|NCT00969709|9759226|FG000|Overall Study|Adverse Event|3
6131765|NCT00969709|9759227|FG001|Overall Study|Adverse Event|13
6131766|NCT00969709|9759228|FG002|Overall Study|Adverse Event|26
6131767|NCT00969709|9759229|FG003|Overall Study|Adverse Event|12
6131768|NCT00969709|9759226|FG000|Overall Study|Lack of Efficacy|7
6131769|NCT00969709|9759227|FG001|Overall Study|Lack of Efficacy|4
6131770|NCT00969709|9759228|FG002|Overall Study|Lack of Efficacy|1
6131771|NCT00969709|9759229|FG003|Overall Study|Lack of Efficacy|3
6131772|NCT00969709|9759226|FG000|Overall Study|Protocol Violation|9
6131773|NCT00969709|9759227|FG001|Overall Study|Protocol Violation|5
6131774|NCT00969709|9759228|FG002|Overall Study|Protocol Violation|9
6131775|NCT00969709|9759229|FG003|Overall Study|Protocol Violation|10
6131776|NCT00969709|9759226|FG000|Overall Study|Withdrawal by Subject|9
6131777|NCT00969709|9759227|FG001|Overall Study|Withdrawal by Subject|12
6131778|NCT00969709|9759228|FG002|Overall Study|Withdrawal by Subject|11
6131779|NCT00969709|9759229|FG003|Overall Study|Withdrawal by Subject|23
6131780|NCT00969709|9759226|FG000|Overall Study|Lost to Follow-up|10
6131781|NCT00969709|9759227|FG001|Overall Study|Lost to Follow-up|14
6131782|NCT00969709|9759228|FG002|Overall Study|Lost to Follow-up|8
6131783|NCT00969709|9759229|FG003|Overall Study|Lost to Follow-up|15
6131784|NCT00969709|9759226|FG000|Overall Study|Other reasons|0
6131785|NCT00969709|9759227|FG001|Overall Study|Other reasons|0
6131786|NCT00969709|9759228|FG002|Overall Study|Other reasons|3
6131787|NCT00969709|9759229|FG003|Overall Study|Other reasons|0
6131788|NCT00969761|9759255|FG000|Discont. Before Start of Treat. Cycle 2|Progressive Disease|1
6131789|NCT00969761|9759256|FG001|Discont. Before Start of Treat. Cycle 2|Progressive Disease|0
6131790|NCT00969761|9759257|FG002|Discont. Before Start of Treat. Cycle 2|Progressive Disease|0
6131791|NCT00969761|9759258|FG003|Discont. Before Start of Treat. Cycle 2|Progressive Disease|1
6131792|NCT00969761|9759259|FG004|Discont. Before Start of Treat. Cycle 2|Progressive Disease|0
6131793|NCT00969761|9759260|FG005|Discont. Before Start of Treat. Cycle 2|Progressive Disease|0
6131794|NCT00969761|9759261|FG006|Discont. Before Start of Treat. Cycle 2|Progressive Disease|0
6131795|NCT00969761|9759262|FG007|Discont. Before Start of Treat. Cycle 2|Progressive Disease|0
6131796|NCT00969761|9759263|FG008|Discont. Before Start of Treat. Cycle 2|Progressive Disease|1
6131797|NCT00969761|9759264|FG009|Discont. Before Start of Treat. Cycle 2|Progressive Disease|1
6131798|NCT00969761|9759265|FG010|Discont. Before Start of Treat. Cycle 2|Progressive Disease|0
6131799|NCT00969761|9759266|FG011|Discont. Before Start of Treat. Cycle 2|Progressive Disease|0
6131800|NCT00969761|9759255|FG000|Discont. Before Start of Treat. Cycle 2|Dose Limiting Toxicity (DLT)|0
6131801|NCT00969761|9759256|FG001|Discont. Before Start of Treat. Cycle 2|Dose Limiting Toxicity (DLT)|0
6131802|NCT00969761|9759257|FG002|Discont. Before Start of Treat. Cycle 2|Dose Limiting Toxicity (DLT)|1
6131803|NCT00969761|9759258|FG003|Discont. Before Start of Treat. Cycle 2|Dose Limiting Toxicity (DLT)|0
6131804|NCT00969761|9759259|FG004|Discont. Before Start of Treat. Cycle 2|Dose Limiting Toxicity (DLT)|0
6131805|NCT00969761|9759260|FG005|Discont. Before Start of Treat. Cycle 2|Dose Limiting Toxicity (DLT)|0
6131806|NCT00969761|9759261|FG006|Discont. Before Start of Treat. Cycle 2|Dose Limiting Toxicity (DLT)|0
6131807|NCT00969761|9759262|FG007|Discont. Before Start of Treat. Cycle 2|Dose Limiting Toxicity (DLT)|0
6131808|NCT00969761|9759263|FG008|Discont. Before Start of Treat. Cycle 2|Dose Limiting Toxicity (DLT)|0
6131809|NCT00969761|9759264|FG009|Discont. Before Start of Treat. Cycle 2|Dose Limiting Toxicity (DLT)|0
6131810|NCT00969761|9759265|FG010|Discont. Before Start of Treat. Cycle 2|Dose Limiting Toxicity (DLT)|0
6131811|NCT00969761|9759266|FG011|Discont. Before Start of Treat. Cycle 2|Dose Limiting Toxicity (DLT)|0
6289477|NCT02384941|10004676|FG000|Overall Study|Non-Compliance With Study Drug|2
6289478|NCT02384941|10004677|FG001|Overall Study|Non-Compliance With Study Drug|0
6289479|NCT02384941|10004678|FG002|Overall Study|Non-Compliance With Study Drug|1
6289480|NCT02384941|10004676|FG000|Overall Study|Physician Decision|1
6289481|NCT02384941|10004677|FG001|Overall Study|Physician Decision|1
6131812|NCT00969761|9759255|FG000|Discont. Before Start of Treat. Cycle 2|Other adverse events|0
6131813|NCT00969761|9759256|FG001|Discont. Before Start of Treat. Cycle 2|Other adverse events|0
6131814|NCT00969761|9759257|FG002|Discont. Before Start of Treat. Cycle 2|Other adverse events|1
6131815|NCT00969761|9759258|FG003|Discont. Before Start of Treat. Cycle 2|Other adverse events|0
6131816|NCT00969761|9759259|FG004|Discont. Before Start of Treat. Cycle 2|Other adverse events|0
6131817|NCT00969761|9759260|FG005|Discont. Before Start of Treat. Cycle 2|Other adverse events|0
6131818|NCT00969761|9759261|FG006|Discont. Before Start of Treat. Cycle 2|Other adverse events|0
6131819|NCT00969761|9759262|FG007|Discont. Before Start of Treat. Cycle 2|Other adverse events|0
6131820|NCT00969761|9759263|FG008|Discont. Before Start of Treat. Cycle 2|Other adverse events|0
6131821|NCT00969761|9759264|FG009|Discont. Before Start of Treat. Cycle 2|Other adverse events|0
6131822|NCT00969761|9759265|FG010|Discont. Before Start of Treat. Cycle 2|Other adverse events|0
6131823|NCT00969761|9759266|FG011|Discont. Before Start of Treat. Cycle 2|Other adverse events|0
6131824|NCT00969761|9759255|FG000|Discont. Before Start of Treat. Cycle 2|Withdrawal by Subject|0
6131825|NCT00969761|9759256|FG001|Discont. Before Start of Treat. Cycle 2|Withdrawal by Subject|0
6131826|NCT00969761|9759257|FG002|Discont. Before Start of Treat. Cycle 2|Withdrawal by Subject|0
6131827|NCT00969761|9759258|FG003|Discont. Before Start of Treat. Cycle 2|Withdrawal by Subject|0
6131828|NCT00969761|9759259|FG004|Discont. Before Start of Treat. Cycle 2|Withdrawal by Subject|0
6131829|NCT00969761|9759260|FG005|Discont. Before Start of Treat. Cycle 2|Withdrawal by Subject|0
6131830|NCT00969761|9759261|FG006|Discont. Before Start of Treat. Cycle 2|Withdrawal by Subject|0
6131831|NCT00969761|9759262|FG007|Discont. Before Start of Treat. Cycle 2|Withdrawal by Subject|0
6131832|NCT00969761|9759263|FG008|Discont. Before Start of Treat. Cycle 2|Withdrawal by Subject|1
6131833|NCT00969761|9759264|FG009|Discont. Before Start of Treat. Cycle 2|Withdrawal by Subject|0
6222144|NCT01677741|9892656|FG001|Overall Study|Progressive disease|0
6222145|NCT01677741|9892657|FG002|Overall Study|Progressive disease|1
6222146|NCT01677741|9892658|FG003|Overall Study|Progressive disease|0
6222147|NCT01677741|9892659|FG004|Overall Study|Progressive disease|0
6222148|NCT01677741|9892660|FG005|Overall Study|Progressive disease|1
6222149|NCT01677741|9892661|FG006|Overall Study|Progressive disease|0
6222150|NCT01677741|9892662|FG007|Overall Study|Progressive disease|0
6222151|NCT01677767|9892696|FG000|Overall Study|Adverse Event|1
6222152|NCT01677767|9892696|FG000|Overall Study|Death|4
6222153|NCT01677767|9892696|FG000|Overall Study|Protocol Violation|4
6222154|NCT01677767|9892696|FG000|Overall Study|Withdrawal by Subject|10
6222155|NCT01677767|9892696|FG000|Overall Study|Non-compliance by the participants|3
6222156|NCT01677858|9892707|FG000|Overall Study|Adverse Event|0
6222157|NCT01677858|9892708|FG001|Overall Study|Adverse Event|0
6222158|NCT01677858|9892709|FG002|Overall Study|Adverse Event|2
6222159|NCT01677858|9892710|FG003|Overall Study|Adverse Event|3
6222160|NCT01677858|9892711|FG004|Overall Study|Adverse Event|13
6222161|NCT01677858|9892707|FG000|Overall Study|Death|0
6222162|NCT01677858|9892708|FG001|Overall Study|Death|0
6222163|NCT01677858|9892709|FG002|Overall Study|Death|0
6222164|NCT01677858|9892710|FG003|Overall Study|Death|0
6222165|NCT01677858|9892711|FG004|Overall Study|Death|1
6222166|NCT01677858|9892707|FG000|Overall Study|Physician Decision|1
6222167|NCT01677858|9892708|FG001|Overall Study|Physician Decision|0
6222168|NCT01677858|9892709|FG002|Overall Study|Physician Decision|2
6222169|NCT01677858|9892710|FG003|Overall Study|Physician Decision|0
6222170|NCT01677858|9892711|FG004|Overall Study|Physician Decision|12
6222171|NCT01677858|9892707|FG000|Overall Study|Progressive Disease|2
6222172|NCT01677858|9892708|FG001|Overall Study|Progressive Disease|1
6222173|NCT01677858|9892709|FG002|Overall Study|Progressive Disease|9
6222174|NCT01677858|9892710|FG003|Overall Study|Progressive Disease|3
6222175|NCT01677858|9892711|FG004|Overall Study|Progressive Disease|43
6222176|NCT01677858|9892707|FG000|Overall Study|Withdrawal by Subject|0
6222177|NCT01677858|9892708|FG001|Overall Study|Withdrawal by Subject|1
6222178|NCT01677858|9892709|FG002|Overall Study|Withdrawal by Subject|1
6222179|NCT01677858|9892710|FG003|Overall Study|Withdrawal by Subject|0
6222180|NCT01677858|9892711|FG004|Overall Study|Withdrawal by Subject|15
6222181|NCT01677858|9892707|FG000|Overall Study|Lost to Follow-up|0
6222182|NCT01677858|9892708|FG001|Overall Study|Lost to Follow-up|0
6222183|NCT01677858|9892709|FG002|Overall Study|Lost to Follow-up|0
6222184|NCT01677858|9892710|FG003|Overall Study|Lost to Follow-up|0
6222185|NCT01677858|9892711|FG004|Overall Study|Lost to Follow-up|1
6222186|NCT01677910|9892731|FG000|Double-Blind Treatment Period|Adverse Event|6
6222187|NCT01677910|9892732|FG001|Double-Blind Treatment Period|Adverse Event|2
6222188|NCT01677910|9892733|FG002|Double-Blind Treatment Period|Adverse Event|3
6222189|NCT01677910|9892734|FG003|Double-Blind Treatment Period|Adverse Event|0
6222190|NCT01677910|9892731|FG000|Double-Blind Treatment Period|Physician Decision|0
6222191|NCT01677910|9892732|FG001|Double-Blind Treatment Period|Physician Decision|0
6289482|NCT02384941|10004678|FG002|Overall Study|Physician Decision|0
6131834|NCT00969761|9759265|FG010|Discont. Before Start of Treat. Cycle 2|Withdrawal by Subject|0
6131835|NCT00969761|9759266|FG011|Discont. Before Start of Treat. Cycle 2|Withdrawal by Subject|0
6131836|NCT00969761|9759255|FG000|Treated in and Beyond Treat. Cycle 2|Progressive disease|2
6131837|NCT00969761|9759256|FG001|Treated in and Beyond Treat. Cycle 2|Progressive disease|3
6131838|NCT00969761|9759257|FG002|Treated in and Beyond Treat. Cycle 2|Progressive disease|10
6131839|NCT00969761|9759258|FG003|Treated in and Beyond Treat. Cycle 2|Progressive disease|3
6131840|NCT00969761|9759259|FG004|Treated in and Beyond Treat. Cycle 2|Progressive disease|2
6131841|NCT00969761|9759260|FG005|Treated in and Beyond Treat. Cycle 2|Progressive disease|3
6131842|NCT00969761|9759261|FG006|Treated in and Beyond Treat. Cycle 2|Progressive disease|3
6131843|NCT00969761|9759262|FG007|Treated in and Beyond Treat. Cycle 2|Progressive disease|6
6131844|NCT00969761|9759263|FG008|Treated in and Beyond Treat. Cycle 2|Progressive disease|9
6131845|NCT00969761|9759264|FG009|Treated in and Beyond Treat. Cycle 2|Progressive disease|2
6131846|NCT00969761|9759265|FG010|Treated in and Beyond Treat. Cycle 2|Progressive disease|3
6131847|NCT00969761|9759266|FG011|Treated in and Beyond Treat. Cycle 2|Progressive disease|3
6131848|NCT00969761|9759255|FG000|Treated in and Beyond Treat. Cycle 2|Other adverse events|0
6131849|NCT00969761|9759256|FG001|Treated in and Beyond Treat. Cycle 2|Other adverse events|0
6131850|NCT00969761|9759257|FG002|Treated in and Beyond Treat. Cycle 2|Other adverse events|0
6131851|NCT00969761|9759258|FG003|Treated in and Beyond Treat. Cycle 2|Other adverse events|2
6131852|NCT00969761|9759259|FG004|Treated in and Beyond Treat. Cycle 2|Other adverse events|1
6131853|NCT00969761|9759260|FG005|Treated in and Beyond Treat. Cycle 2|Other adverse events|0
6131854|NCT00969761|9759261|FG006|Treated in and Beyond Treat. Cycle 2|Other adverse events|0
6131855|NCT00969761|9759262|FG007|Treated in and Beyond Treat. Cycle 2|Other adverse events|0
6131856|NCT00969761|9759263|FG008|Treated in and Beyond Treat. Cycle 2|Other adverse events|2
6131857|NCT00969761|9759264|FG009|Treated in and Beyond Treat. Cycle 2|Other adverse events|0
6131858|NCT00969761|9759265|FG010|Treated in and Beyond Treat. Cycle 2|Other adverse events|0
6131859|NCT00969761|9759266|FG011|Treated in and Beyond Treat. Cycle 2|Other adverse events|0
6131860|NCT00970268|9759331|FG000|Overall Study|Withdrawal by Subject|12
6131861|NCT00970268|9759332|FG001|Overall Study|Withdrawal by Subject|19
6222192|NCT01677910|9892733|FG002|Double-Blind Treatment Period|Physician Decision|1
6222193|NCT01677910|9892734|FG003|Double-Blind Treatment Period|Physician Decision|0
6222194|NCT01677910|9892731|FG000|Double-Blind Treatment Period|Withdrawal of consent|1
6222195|NCT01677910|9892732|FG001|Double-Blind Treatment Period|Withdrawal of consent|0
6222196|NCT01677910|9892733|FG002|Double-Blind Treatment Period|Withdrawal of consent|3
6222197|NCT01677910|9892734|FG003|Double-Blind Treatment Period|Withdrawal of consent|0
6222198|NCT01677910|9892731|FG000|Double-Blind Treatment Period|Reason Not Specified|0
6222199|NCT01677910|9892732|FG001|Double-Blind Treatment Period|Reason Not Specified|1
6222200|NCT01677910|9892733|FG002|Double-Blind Treatment Period|Reason Not Specified|0
6222201|NCT01677910|9892734|FG003|Double-Blind Treatment Period|Reason Not Specified|0
6222202|NCT01677910|9892731|FG000|Open-Label Extension Period (OLE)|Physician Decision|0
6222203|NCT01677910|9892732|FG001|Open-Label Extension Period (OLE)|Physician Decision|0
6222204|NCT01677910|9892733|FG002|Open-Label Extension Period (OLE)|Physician Decision|0
6222205|NCT01677910|9892734|FG003|Open-Label Extension Period (OLE)|Physician Decision|4
6222206|NCT01677910|9892731|FG000|Open-Label Extension Period (OLE)|Reason not Specified|0
6222207|NCT01677910|9892732|FG001|Open-Label Extension Period (OLE)|Reason not Specified|0
6222208|NCT01677910|9892733|FG002|Open-Label Extension Period (OLE)|Reason not Specified|0
6222209|NCT01677910|9892734|FG003|Open-Label Extension Period (OLE)|Reason not Specified|2
6222210|NCT01677910|9892731|FG000|Open-Label Extension Period (OLE)|Withdrawal of Consent|0
6222211|NCT01677910|9892732|FG001|Open-Label Extension Period (OLE)|Withdrawal of Consent|0
6222212|NCT01677910|9892733|FG002|Open-Label Extension Period (OLE)|Withdrawal of Consent|0
6222213|NCT01677910|9892734|FG003|Open-Label Extension Period (OLE)|Withdrawal of Consent|9
6222214|NCT01677910|9892731|FG000|Open-Label Extension Period (OLE)|Lack of Efficacy|0
6222215|NCT01677910|9892732|FG001|Open-Label Extension Period (OLE)|Lack of Efficacy|0
6222216|NCT01677910|9892733|FG002|Open-Label Extension Period (OLE)|Lack of Efficacy|0
6222217|NCT01677910|9892734|FG003|Open-Label Extension Period (OLE)|Lack of Efficacy|5
6222218|NCT01677910|9892731|FG000|Open-Label Extension Period (OLE)|Adverse Event|0
6222219|NCT01677910|9892732|FG001|Open-Label Extension Period (OLE)|Adverse Event|0
6222220|NCT01677910|9892733|FG002|Open-Label Extension Period (OLE)|Adverse Event|0
6222221|NCT01677910|9892734|FG003|Open-Label Extension Period (OLE)|Adverse Event|15
6289483|NCT02384941|10004676|FG000|Overall Study|Protocol Violation|3
6289484|NCT02384941|10004677|FG001|Overall Study|Protocol Violation|0
6289485|NCT02384941|10004678|FG002|Overall Study|Protocol Violation|0
6289486|NCT02384941|10004676|FG000|Overall Study|Withdrawal by Subject|26
6289487|NCT02384941|10004677|FG001|Overall Study|Withdrawal by Subject|19
6289488|NCT02384941|10004678|FG002|Overall Study|Withdrawal by Subject|20
6289489|NCT02384941|10004676|FG000|Overall Study|Pregnancy|0
6289490|NCT02384941|10004677|FG001|Overall Study|Pregnancy|0
6289491|NCT02384941|10004678|FG002|Overall Study|Pregnancy|1
6289492|NCT02384941|10004676|FG000|Overall Study|Other than specified above|4
6289493|NCT02384941|10004677|FG001|Overall Study|Other than specified above|0
6289494|NCT02384941|10004678|FG002|Overall Study|Other than specified above|1
6289495|NCT02385084|10004687|FG000|Period 2|Protocol Violation|0
6289496|NCT02385084|10004688|FG001|Period 2|Protocol Violation|0
6289497|NCT02385084|10004689|FG002|Period 2|Protocol Violation|1
6131862|NCT00970268|9759331|FG000|Overall Study|Adverse Event|15
6131863|NCT00970268|9759332|FG001|Overall Study|Adverse Event|12
6131864|NCT00970268|9759331|FG000|Overall Study|Lack of Efficacy|3
6131865|NCT00970268|9759332|FG001|Overall Study|Lack of Efficacy|6
6131866|NCT00970268|9759331|FG000|Overall Study|Protocol Violation|4
6131867|NCT00970268|9759332|FG001|Overall Study|Protocol Violation|7
6131868|NCT00970268|9759331|FG000|Overall Study|Other Reason|3
6131869|NCT00970268|9759332|FG001|Overall Study|Other Reason|1
6131870|NCT00970268|9759331|FG000|Overall Study|COPD Exacerbation|4
6131871|NCT00970268|9759332|FG001|Overall Study|COPD Exacerbation|2
6131872|NCT00970268|9759331|FG000|Overall Study|Lost to Follow-up|1
6222222|NCT01677910|9892731|FG000|Open-Label Extension Period (OLE)|Lost to Follow-up|0
6222223|NCT01677910|9892732|FG001|Open-Label Extension Period (OLE)|Lost to Follow-up|0
6222224|NCT01677910|9892733|FG002|Open-Label Extension Period (OLE)|Lost to Follow-up|0
6222225|NCT01677910|9892734|FG003|Open-Label Extension Period (OLE)|Lost to Follow-up|1
6222226|NCT01677936|9892746|FG000|Overall Study|Lost to Follow-up|4
6222227|NCT01677936|9892747|FG001|Overall Study|Lost to Follow-up|1
6222228|NCT01677936|9892746|FG000|Overall Study|Protocol Violation|3
6222229|NCT01677936|9892747|FG001|Overall Study|Protocol Violation|0
6222230|NCT01677936|9892746|FG000|Overall Study|Adverse Event|1
6222231|NCT01677936|9892747|FG001|Overall Study|Adverse Event|0
6222232|NCT01677936|9892746|FG000|Overall Study|Lost to Follow-up|1
6222233|NCT01677936|9892747|FG001|Overall Study|Lost to Follow-up|0
6222234|NCT01677936|9892746|FG000|Overall Study|Protocol Violation|0
6222235|NCT01677936|9892747|FG001|Overall Study|Protocol Violation|4
6222236|NCT01677988|9892753|FG000|Overall Study|Lack of Efficacy|2
6222237|NCT01678131|9892761|FG000|Overall Study|Adverse Event|0
6222238|NCT01678131|9892762|FG001|Overall Study|Adverse Event|1
6222239|NCT01678131|9892763|FG002|Overall Study|Adverse Event|0
6222240|NCT01678131|9892761|FG000|Overall Study|Withdrawal by Subject|0
6222241|NCT01678131|9892762|FG001|Overall Study|Withdrawal by Subject|0
6222242|NCT01678131|9892763|FG002|Overall Study|Withdrawal by Subject|2
6222243|NCT01678144|9892771|FG000|Stage 1: MAR Classic|Adverse Event|1
6222244|NCT01678209|9892787|FG000|Overall Study|could not scan twice|1
6222245|NCT01678209|9892788|FG001|Overall Study|could not scan twice|1
6222246|NCT01678209|9892789|FG002|Overall Study|could not scan twice|1
6222247|NCT01678209|9892787|FG000|Overall Study|scheduling conflicts|0
6222248|NCT01678209|9892788|FG001|Overall Study|scheduling conflicts|0
6222249|NCT01678209|9892789|FG002|Overall Study|scheduling conflicts|1
6222250|NCT01678209|9892787|FG000|Overall Study|screen fail|16
6222251|NCT01678209|9892788|FG001|Overall Study|screen fail|17
6222252|NCT01678209|9892789|FG002|Overall Study|screen fail|16
6222253|NCT01678313|9892799|FG000|Completed the 3-month Therapy|Lost to Follow-up|3
6222254|NCT01678313|9892800|FG001|Completed the 3-month Therapy|Lost to Follow-up|8
6222255|NCT01678313|9892799|FG000|Completed the 3-month Therapy|Physician Decision|3
6222256|NCT01678313|9892800|FG001|Completed the 3-month Therapy|Physician Decision|4
6222257|NCT01678313|9892799|FG000|PSA >4 ng/dL at 3 Months|PSA≦4|8
6222258|NCT01678313|9892800|FG001|PSA >4 ng/dL at 3 Months|PSA≦4|9
6222259|NCT01678313|9892799|FG000|Prostate Biopsy at 3 Months|Not received prostate biopsy|11
6222260|NCT01678313|9892800|FG001|Prostate Biopsy at 3 Months|Not received prostate biopsy|12
6222261|NCT01678560|9892812|FG000|Overall Study|Physician Decision|4
6222262|NCT01678560|9892813|FG001|Overall Study|Physician Decision|4
6222263|NCT01678560|9892812|FG000|Overall Study|Death|0
6222264|NCT01678560|9892813|FG001|Overall Study|Death|1
6222265|NCT01678560|9892812|FG000|Overall Study|Withdrawal by Subject|0
6222266|NCT01678560|9892813|FG001|Overall Study|Withdrawal by Subject|1
6222267|NCT01678807|9892835|FG000|Overall Study|Adverse Event|4
6222268|NCT01678807|9892836|FG001|Overall Study|Adverse Event|4
6222269|NCT01678807|9892837|FG002|Overall Study|Adverse Event|0
6222270|NCT01678807|9892835|FG000|Overall Study|Withdrawn by Parent/Guardian|0
6222271|NCT01678807|9892836|FG001|Overall Study|Withdrawn by Parent/Guardian|1
6222272|NCT01678807|9892837|FG002|Overall Study|Withdrawn by Parent/Guardian|0
6222273|NCT01678820|9892848|FG000|Overall Study|Study Terminated by Sponsor|45
6222274|NCT01678820|9892849|FG001|Overall Study|Study Terminated by Sponsor|43
6222275|NCT01678820|9892850|FG002|Overall Study|Study Terminated by Sponsor|43
6289498|NCT02385084|10004690|FG003|Period 2|Protocol Violation|0
6289499|NCT02385084|10004691|FG004|Period 2|Protocol Violation|0
6289500|NCT02385084|10004692|FG005|Period 2|Protocol Violation|0
6289501|NCT02385526|10004739|FG000|Overall Study|Withdrawal by Subject|0
6289502|NCT02385526|10004740|FG001|Overall Study|Withdrawal by Subject|2
6289503|NCT02385526|10004741|FG002|Overall Study|Withdrawal by Subject|0
6289504|NCT02385526|10004739|FG000|Overall Study|Lost to Follow-up|0
6289505|NCT02385526|10004740|FG001|Overall Study|Lost to Follow-up|1
6289506|NCT02385526|10004741|FG002|Overall Study|Lost to Follow-up|0
6289507|NCT02385526|10004739|FG000|Overall Study|Physician Decision|1
6289508|NCT02385526|10004740|FG001|Overall Study|Physician Decision|0
6289509|NCT02385526|10004741|FG002|Overall Study|Physician Decision|0
6289510|NCT02385526|10004739|FG000|Overall Study|Protocol Violation|1
6289511|NCT02385526|10004740|FG001|Overall Study|Protocol Violation|0
6289512|NCT02385526|10004741|FG002|Overall Study|Protocol Violation|0
6131873|NCT00970268|9759332|FG001|Overall Study|Lost to Follow-up|2
6131874|NCT00970268|9759331|FG000|Overall Study|Inclusion/Exclusion Criteria|1
6131875|NCT00970268|9759332|FG001|Overall Study|Inclusion/Exclusion Criteria|0
6131876|NCT00970281|9759346|FG000|Overall Study|Lack of Efficacy|1
6131877|NCT00970281|9759347|FG001|Overall Study|Lack of Efficacy|14
6131878|NCT00970281|9759346|FG000|Overall Study|Withdrawal by Subject|0
6131879|NCT00970281|9759347|FG001|Overall Study|Withdrawal by Subject|1
6131880|NCT00970281|9759346|FG000|Overall Study|Physician Decision|1
6131881|NCT00970281|9759347|FG001|Overall Study|Physician Decision|1
6131882|NCT00970294|9759353|FG000|Overall Study|Physician Decision|4
6131883|NCT00970294|9759353|FG000|Overall Study|Withdrawal by Subject|1
6131884|NCT00970307|9759360|FG000|Overall Study|Serious Adverse Event|1
6131885|NCT00970307|9759361|FG001|Overall Study|Serious Adverse Event|0
6131886|NCT00970307|9759362|FG002|Overall Study|Serious Adverse Event|0
6131887|NCT00970307|9759360|FG000|Overall Study|Withdrawal by Subject|2
6131888|NCT00970307|9759361|FG001|Overall Study|Withdrawal by Subject|3
6131889|NCT00970307|9759362|FG002|Overall Study|Withdrawal by Subject|2
6131890|NCT00970359|9759391|FG000|Overall Study|Not Treated|4
6222276|NCT01678820|9892848|FG000|Overall Study|Withdrawal by Subject|2
6222277|NCT01678820|9892849|FG001|Overall Study|Withdrawal by Subject|5
6289513|NCT02385669|10004749|FG000|Overall Study|Adverse Event|2
6289514|NCT02385708|10004755|FG000|Overall Study|Withdrawal by Subject|0
6289515|NCT02385708|10004756|FG001|Overall Study|Withdrawal by Subject|2
6289516|NCT02385708|10004755|FG000|Overall Study|Withdrawn - surgery canceled|2
6289517|NCT02385708|10004756|FG001|Overall Study|Withdrawn - surgery canceled|5
6289518|NCT02385708|10004755|FG000|Overall Study|Investigator decision|5
6289519|NCT02385708|10004756|FG001|Overall Study|Investigator decision|7
6289520|NCT02385708|10004755|FG000|Overall Study|Protocol Violation|1
6289521|NCT02385708|10004756|FG001|Overall Study|Protocol Violation|1
6289522|NCT02385799|10004768|FG000|Overall Study|Lost to Follow-up|1
6289523|NCT02385799|10004769|FG001|Overall Study|Lost to Follow-up|2
6289524|NCT02385799|10004768|FG000|Overall Study|Adverse Event|4
6131891|NCT00970489|9759397|FG000|Overall Study|Death/Withdrew/Criteria Violation|54
6131892|NCT00970489|9759398|FG001|Overall Study|Death/Withdrew/Criteria Violation|41
6131893|NCT00970502|9759404|FG000|Overall Study|Withdrawal by Subject|1
6131894|NCT00970593|9759419|FG000|Overall Study|Adverse Event|1
6131895|NCT00970593|9759420|FG001|Overall Study|Adverse Event|1
6131896|NCT00970593|9759421|FG002|Overall Study|Adverse Event|0
6131897|NCT00970593|9759422|FG003|Overall Study|Adverse Event|0
6131898|NCT00970593|9759423|FG004|Overall Study|Adverse Event|0
6131899|NCT00970593|9759424|FG005|Overall Study|Adverse Event|0
6131900|NCT00970593|9759425|FG006|Overall Study|Adverse Event|0
6131901|NCT00970593|9759419|FG000|Overall Study|Discontinuation of study by sponsor|0
6131902|NCT00970593|9759420|FG001|Overall Study|Discontinuation of study by sponsor|0
6131903|NCT00970593|9759421|FG002|Overall Study|Discontinuation of study by sponsor|5
6131904|NCT00970593|9759422|FG003|Overall Study|Discontinuation of study by sponsor|0
6131905|NCT00970593|9759423|FG004|Overall Study|Discontinuation of study by sponsor|0
6131906|NCT00970593|9759424|FG005|Overall Study|Discontinuation of study by sponsor|0
6131907|NCT00970593|9759425|FG006|Overall Study|Discontinuation of study by sponsor|2
6131908|NCT00970593|9759419|FG000|Overall Study|Withdrawal by Subject|0
6131909|NCT00970593|9759420|FG001|Overall Study|Withdrawal by Subject|0
6131910|NCT00970593|9759421|FG002|Overall Study|Withdrawal by Subject|1
6222278|NCT01678820|9892850|FG002|Overall Study|Withdrawal by Subject|2
6222279|NCT01678820|9892848|FG000|Overall Study|Protocol Specified Criteria|2
6222280|NCT01678820|9892849|FG001|Overall Study|Protocol Specified Criteria|3
6222281|NCT01678820|9892850|FG002|Overall Study|Protocol Specified Criteria|1
6222282|NCT01678820|9892848|FG000|Overall Study|Adverse Event|2
6222283|NCT01678820|9892849|FG001|Overall Study|Adverse Event|2
6222284|NCT01678820|9892850|FG002|Overall Study|Adverse Event|2
6222285|NCT01678820|9892848|FG000|Overall Study|Lost to Follow-up|7
6222286|NCT01678820|9892849|FG001|Overall Study|Lost to Follow-up|2
6222287|NCT01678820|9892850|FG002|Overall Study|Lost to Follow-up|2
6222288|NCT01678820|9892848|FG000|Overall Study|Non-compliance with study drug|0
6222289|NCT01678820|9892849|FG001|Overall Study|Non-compliance with study drug|1
6222290|NCT01678820|9892850|FG002|Overall Study|Non-compliance with study drug|0
6222291|NCT01678820|9892848|FG000|Overall Study|Physician Decision|0
6222292|NCT01678820|9892849|FG001|Overall Study|Physician Decision|0
6222293|NCT01678820|9892850|FG002|Overall Study|Physician Decision|1
6222294|NCT01678820|9892848|FG000|Overall Study|Protocol Violation|4
6222295|NCT01678820|9892849|FG001|Overall Study|Protocol Violation|5
6222296|NCT01678820|9892850|FG002|Overall Study|Protocol Violation|4
6222297|NCT01678820|9892848|FG000|Overall Study|Not treated with double-blind study drug|0
6222298|NCT01678820|9892849|FG001|Overall Study|Not treated with double-blind study drug|2
6222299|NCT01678820|9892850|FG002|Overall Study|Not treated with double-blind study drug|2
6222300|NCT01678898|9892885|FG000|PB-102-F01|Adverse Event|0
6222301|NCT01678898|9892886|FG001|PB-102-F01|Adverse Event|1
6222302|NCT01678898|9892887|FG002|PB-102-F01|Adverse Event|0
6222303|NCT01678898|9892885|FG000|PB-102-F01|Physician Decision|0
6222304|NCT01678898|9892886|FG001|PB-102-F01|Physician Decision|1
6222305|NCT01678898|9892887|FG002|PB-102-F01|Physician Decision|0
6222306|NCT01678911|9892904|FG000|Second Intervention|Lost to Follow-up|2
6222307|NCT01678911|9892905|FG001|Second Intervention|Lost to Follow-up|0
6222308|NCT01678924|9892915|FG000|Overall Study|Adverse Event|1
6222309|NCT01678924|9892916|FG001|Overall Study|Adverse Event|1
6222310|NCT01678924|9892917|FG002|Overall Study|Adverse Event|0
6222311|NCT01678924|9892918|FG003|Overall Study|Adverse Event|1
6131911|NCT00970593|9759422|FG003|Overall Study|Withdrawal by Subject|0
6131912|NCT00970593|9759423|FG004|Overall Study|Withdrawal by Subject|0
6131913|NCT00970593|9759424|FG005|Overall Study|Withdrawal by Subject|0
6131914|NCT00970593|9759425|FG006|Overall Study|Withdrawal by Subject|0
6131915|NCT00970632|9759448|FG000|Overall Study|Adverse Event|2
6131916|NCT00970632|9759449|FG001|Overall Study|Adverse Event|2
6131917|NCT00970632|9759450|FG002|Overall Study|Adverse Event|1
6131918|NCT00970632|9759448|FG000|Overall Study|Lack of Efficacy|3
6131919|NCT00970632|9759449|FG001|Overall Study|Lack of Efficacy|0
6131920|NCT00970632|9759450|FG002|Overall Study|Lack of Efficacy|0
6131921|NCT00970632|9759448|FG000|Overall Study|Lost to Follow-up|3
6131922|NCT00970632|9759449|FG001|Overall Study|Lost to Follow-up|0
6131923|NCT00970632|9759450|FG002|Overall Study|Lost to Follow-up|2
6131924|NCT00970632|9759448|FG000|Overall Study|Protocol Violation|8
6131925|NCT00970632|9759449|FG001|Overall Study|Protocol Violation|5
6131926|NCT00970632|9759450|FG002|Overall Study|Protocol Violation|8
6131927|NCT00970632|9759448|FG000|Overall Study|Withdrawal by Subject|7
6131928|NCT00970632|9759449|FG001|Overall Study|Withdrawal by Subject|6
6131929|NCT00970632|9759450|FG002|Overall Study|Withdrawal by Subject|4
6131930|NCT00970632|9759448|FG000|Overall Study|Entry criteria not met|0
6131931|NCT00970632|9759449|FG001|Overall Study|Entry criteria not met|2
6131932|NCT00970632|9759450|FG002|Overall Study|Entry criteria not met|2
6131933|NCT00970632|9759448|FG000|Overall Study|Sponsor decision|1
6131934|NCT00970632|9759449|FG001|Overall Study|Sponsor decision|0
6131935|NCT00970632|9759450|FG002|Overall Study|Sponsor decision|1
6131936|NCT00970684|9759458|FG000|Overall Study|Lack of Efficacy|5
6131937|NCT00970684|9759458|FG000|Overall Study|Adverse Event|4
6131938|NCT00970684|9759458|FG000|Overall Study|Withdrawal by Subject|1
6131939|NCT00970944|9759482|FG000|Overall Study|Death|1
6131940|NCT00970944|9759483|FG001|Overall Study|Death|0
6131941|NCT00970944|9759482|FG000|Overall Study|Physician Decision|0
6131942|NCT00970944|9759483|FG001|Overall Study|Physician Decision|2
6131943|NCT00971048|9759494|FG000|Overall Study|Protocol Violation|1
6131944|NCT00971048|9759495|FG001|Overall Study|Protocol Violation|2
6131945|NCT00971048|9759496|FG002|Overall Study|Protocol Violation|0
6131946|NCT00971048|9759497|FG003|Overall Study|Protocol Violation|1
6131947|NCT00971048|9759494|FG000|Overall Study|Adverse Event|0
6131948|NCT00971048|9759495|FG001|Overall Study|Adverse Event|0
6131949|NCT00971048|9759496|FG002|Overall Study|Adverse Event|1
6131950|NCT00971048|9759497|FG003|Overall Study|Adverse Event|0
6131951|NCT00971048|9759494|FG000|Overall Study|Physician Decision|0
6131952|NCT00971048|9759495|FG001|Overall Study|Physician Decision|0
6131953|NCT00971048|9759496|FG002|Overall Study|Physician Decision|0
6131954|NCT00971048|9759497|FG003|Overall Study|Physician Decision|1
6131955|NCT00971178|9759512|FG000|Overall Study|Lost to Follow-up|2
6131956|NCT00971178|9759513|FG001|Overall Study|Lost to Follow-up|2
6131957|NCT00971178|9759514|FG002|Overall Study|Lost to Follow-up|2
6131958|NCT00971204|9759522|FG000|Overall Study|Did not meet all criteria-not treated|14
6131959|NCT00971204|9759522|FG000|Overall Study|Lost to Follow-up|10
6131960|NCT00971243|9759531|FG000|Double Blind Period|Adverse Event|2
6131961|NCT00971243|9759532|FG001|Double Blind Period|Adverse Event|3
6131962|NCT00971243|9759533|FG002|Double Blind Period|Adverse Event|2
6131963|NCT00971243|9759534|FG003|Double Blind Period|Adverse Event|2
6131964|NCT00971243|9759535|FG004|Double Blind Period|Adverse Event|3
6131965|NCT00971243|9759531|FG000|Double Blind Period|Lost to Follow-up|0
6131966|NCT00971243|9759532|FG001|Double Blind Period|Lost to Follow-up|1
6131967|NCT00971243|9759533|FG002|Double Blind Period|Lost to Follow-up|1
6131968|NCT00971243|9759534|FG003|Double Blind Period|Lost to Follow-up|0
6131969|NCT00971243|9759535|FG004|Double Blind Period|Lost to Follow-up|1
6131970|NCT00971243|9759531|FG000|Double Blind Period|Physician Decision|10
6131971|NCT00971243|9759532|FG001|Double Blind Period|Physician Decision|6
6131972|NCT00971243|9759533|FG002|Double Blind Period|Physician Decision|7
6131973|NCT00971243|9759534|FG003|Double Blind Period|Physician Decision|6
6131974|NCT00971243|9759535|FG004|Double Blind Period|Physician Decision|7
6131975|NCT00971243|9759531|FG000|Double Blind Period|Protocol Violation|2
6131976|NCT00971243|9759532|FG001|Double Blind Period|Protocol Violation|0
6131977|NCT00971243|9759533|FG002|Double Blind Period|Protocol Violation|3
6131978|NCT00971243|9759534|FG003|Double Blind Period|Protocol Violation|2
6131979|NCT00971243|9759535|FG004|Double Blind Period|Protocol Violation|2
6222312|NCT01678924|9892915|FG000|Overall Study|Lack of Efficacy|7
6222313|NCT01678924|9892916|FG001|Overall Study|Lack of Efficacy|2
6222314|NCT01678924|9892917|FG002|Overall Study|Lack of Efficacy|0
6222315|NCT01678924|9892918|FG003|Overall Study|Lack of Efficacy|5
6222316|NCT01678924|9892915|FG000|Overall Study|Lost to Follow-up|0
6222317|NCT01678924|9892916|FG001|Overall Study|Lost to Follow-up|4
6222318|NCT01678924|9892917|FG002|Overall Study|Lost to Follow-up|0
6222319|NCT01678924|9892918|FG003|Overall Study|Lost to Follow-up|2
6222320|NCT01678924|9892915|FG000|Overall Study|Personal Reasons|2
6222321|NCT01678924|9892916|FG001|Overall Study|Personal Reasons|2
6131980|NCT00971243|9759531|FG000|Double Blind Period|Withdrawal by Subject|4
6131981|NCT00971243|9759532|FG001|Double Blind Period|Withdrawal by Subject|1
6131982|NCT00971243|9759533|FG002|Double Blind Period|Withdrawal by Subject|4
6131983|NCT00971243|9759534|FG003|Double Blind Period|Withdrawal by Subject|4
6131984|NCT00971243|9759535|FG004|Double Blind Period|Withdrawal by Subject|4
6131985|NCT00971243|9759531|FG000|Double Blind Period|Other reasons|1
6131986|NCT00971243|9759532|FG001|Double Blind Period|Other reasons|0
6131987|NCT00971243|9759533|FG002|Double Blind Period|Other reasons|2
6131988|NCT00971243|9759534|FG003|Double Blind Period|Other reasons|0
6131989|NCT00971243|9759535|FG004|Double Blind Period|Other reasons|1
6131990|NCT00971243|9759531|FG000|Open-label Period|Adverse Event|1
6131991|NCT00971243|9759532|FG001|Open-label Period|Adverse Event|0
6131992|NCT00971243|9759533|FG002|Open-label Period|Adverse Event|1
6131993|NCT00971243|9759534|FG003|Open-label Period|Adverse Event|1
6131994|NCT00971243|9759535|FG004|Open-label Period|Adverse Event|0
6131995|NCT00971243|9759531|FG000|Open-label Period|Physician Decision|5
6131996|NCT00971243|9759532|FG001|Open-label Period|Physician Decision|9
6131997|NCT00971243|9759533|FG002|Open-label Period|Physician Decision|3
6222322|NCT01678924|9892917|FG002|Overall Study|Personal Reasons|2
6222323|NCT01678924|9892918|FG003|Overall Study|Personal Reasons|7
6222324|NCT01678924|9892915|FG000|Overall Study|Withdrawal by Subject|0
6222325|NCT01678924|9892916|FG001|Overall Study|Withdrawal by Subject|3
6222326|NCT01678924|9892917|FG002|Overall Study|Withdrawal by Subject|0
6222327|NCT01678924|9892918|FG003|Overall Study|Withdrawal by Subject|2
6222328|NCT01678924|9892915|FG000|Overall Study|Unable to attend scheduled visits|0
6222329|NCT01678924|9892916|FG001|Overall Study|Unable to attend scheduled visits|0
6222330|NCT01678924|9892917|FG002|Overall Study|Unable to attend scheduled visits|0
6222331|NCT01678924|9892918|FG003|Overall Study|Unable to attend scheduled visits|1
6222332|NCT01679002|9892944|FG000|Overall Study|Adverse Event|1
6222333|NCT01679002|9892945|FG001|Overall Study|Adverse Event|1
6222334|NCT01679002|9892946|FG002|Overall Study|Adverse Event|0
6222335|NCT01679236|9892991|FG000|Overall Study|Lost to Follow-up|15
6289525|NCT02385799|10004769|FG001|Overall Study|Adverse Event|2
6289526|NCT02385799|10004768|FG000|Overall Study|Withdrawal by Subject|0
6289527|NCT02385799|10004769|FG001|Overall Study|Withdrawal by Subject|4
6289528|NCT02386098|10004780|FG000|Stage 1 (96 Weeks)|Other: Administrative reason by sponsor|30
6289529|NCT02386098|10004781|FG001|Stage 1 (96 Weeks)|Other: Administrative reason by sponsor|29
6289530|NCT02386098|10004782|FG002|Stage 1 (96 Weeks)|Other: Administrative reason by sponsor|0
6289531|NCT02386098|10004783|FG003|Stage 1 (96 Weeks)|Other: Administrative reason by sponsor|0
6289532|NCT02386098|10004784|FG004|Stage 1 (96 Weeks)|Other: Administrative reason by sponsor|0
6289533|NCT02386098|10004780|FG000|Stage 1 (96 Weeks)|Adverse Event|2
6289534|NCT02386098|10004781|FG001|Stage 1 (96 Weeks)|Adverse Event|1
6289535|NCT02386098|10004782|FG002|Stage 1 (96 Weeks)|Adverse Event|0
6289536|NCT02386098|10004783|FG003|Stage 1 (96 Weeks)|Adverse Event|0
6289537|NCT02386098|10004784|FG004|Stage 1 (96 Weeks)|Adverse Event|0
6289538|NCT02386098|10004780|FG000|Stage 1 (96 Weeks)|Lost to Follow-up|2
6289539|NCT02386098|10004781|FG001|Stage 1 (96 Weeks)|Lost to Follow-up|2
6289540|NCT02386098|10004782|FG002|Stage 1 (96 Weeks)|Lost to Follow-up|0
6289541|NCT02386098|10004783|FG003|Stage 1 (96 Weeks)|Lost to Follow-up|0
6289542|NCT02386098|10004784|FG004|Stage 1 (96 Weeks)|Lost to Follow-up|0
6289543|NCT02386098|10004780|FG000|Stage 1 (96 Weeks)|Other:Protocol defined stopping criteria|0
6289544|NCT02386098|10004781|FG001|Stage 1 (96 Weeks)|Other:Protocol defined stopping criteria|2
6289545|NCT02386098|10004782|FG002|Stage 1 (96 Weeks)|Other:Protocol defined stopping criteria|0
6289546|NCT02386098|10004783|FG003|Stage 1 (96 Weeks)|Other:Protocol defined stopping criteria|0
6289547|NCT02386098|10004784|FG004|Stage 1 (96 Weeks)|Other:Protocol defined stopping criteria|0
6289548|NCT02386098|10004780|FG000|Stage 1 (96 Weeks)|Withdrawal by Subject|3
6289549|NCT02386098|10004781|FG001|Stage 1 (96 Weeks)|Withdrawal by Subject|1
6289550|NCT02386098|10004782|FG002|Stage 1 (96 Weeks)|Withdrawal by Subject|0
6289551|NCT02386098|10004783|FG003|Stage 1 (96 Weeks)|Withdrawal by Subject|0
6289552|NCT02386098|10004784|FG004|Stage 1 (96 Weeks)|Withdrawal by Subject|0
6289553|NCT02386098|10004780|FG000|Stage 1 (96 Weeks)|Other|1
6289554|NCT02386098|10004781|FG001|Stage 1 (96 Weeks)|Other|0
6289555|NCT02386098|10004782|FG002|Stage 1 (96 Weeks)|Other|0
6289556|NCT02386098|10004783|FG003|Stage 1 (96 Weeks)|Other|0
6289557|NCT02386098|10004784|FG004|Stage 1 (96 Weeks)|Other|0
6289558|NCT02386098|10004780|FG000|Stage 1 (96 Weeks)|Other: Breach of good clinical practice|5
6289559|NCT02386098|10004781|FG001|Stage 1 (96 Weeks)|Other: Breach of good clinical practice|8
6289560|NCT02386098|10004782|FG002|Stage 1 (96 Weeks)|Other: Breach of good clinical practice|0
6289561|NCT02386098|10004783|FG003|Stage 1 (96 Weeks)|Other: Breach of good clinical practice|0
6289562|NCT02386098|10004784|FG004|Stage 1 (96 Weeks)|Other: Breach of good clinical practice|0
6289563|NCT02386189|10004798|FG000|Overall Study|Lost to Follow-up|2
6289564|NCT02386189|10004799|FG001|Overall Study|Lost to Follow-up|3
6289565|NCT02386189|10004798|FG000|Overall Study|Withdrawal by Subject|1
6289566|NCT02386189|10004799|FG001|Overall Study|Withdrawal by Subject|0
6289567|NCT02386189|10004798|FG000|Overall Study|Death|1
6289568|NCT02386189|10004799|FG001|Overall Study|Death|0
6289569|NCT02386345|10004814|FG000|Overall Study|Not treated|14
6289570|NCT02386345|10004814|FG000|Overall Study|Lost to Follow-up|1
6289571|NCT02386345|10004814|FG000|Overall Study|Adverse Event|5
6289572|NCT02386345|10004814|FG000|Overall Study|Repeat Procedure|10
6222336|NCT01679236|9892992|FG001|Overall Study|Lost to Follow-up|15
6289573|NCT02386345|10004814|FG000|Overall Study|Did not complete 12-month follow-up|72
6289574|NCT02387164|10004847|FG000|Overall Study|Lost to Follow-up|2
6289575|NCT02387164|10004848|FG001|Overall Study|Lost to Follow-up|0
6131998|NCT00971243|9759534|FG003|Open-label Period|Physician Decision|7
6289576|NCT02387164|10004847|FG000|Overall Study|Diagnosed|1
6289577|NCT02387164|10004848|FG001|Overall Study|Diagnosed|2
6289578|NCT02387216|10004856|FG000|Overall Study|Progressive disease|2
6289579|NCT02387216|10004857|FG001|Overall Study|Progressive disease|0
6289580|NCT02387216|10004856|FG000|Overall Study|Withdrawal by Subject|3
6289581|NCT02387216|10004857|FG001|Overall Study|Withdrawal by Subject|5
6289582|NCT02387216|10004856|FG000|Overall Study|Physician Decision|2
6289583|NCT02387216|10004857|FG001|Overall Study|Physician Decision|0
6289584|NCT02387216|10004856|FG000|Overall Study|Sponsor Decision|28
6289585|NCT02387216|10004857|FG001|Overall Study|Sponsor Decision|12
6289586|NCT02387216|10004856|FG000|Overall Study|Death|60
6289587|NCT02387216|10004857|FG001|Overall Study|Death|23
6289588|NCT02387216|10004856|FG000|Overall Study|Other|5
6289589|NCT02387216|10004857|FG001|Overall Study|Other|4
6289590|NCT02387216|10004856|FG000|Overall Study|Lost to Follow-up|0
6289591|NCT02387216|10004857|FG001|Overall Study|Lost to Follow-up|3
6289592|NCT02387372|10004892|FG000|Overall Study|Not Treated|1
6289593|NCT02387372|10004893|FG001|Overall Study|Not Treated|0
6289594|NCT02387580|10004954|FG000|Overall Study|Withdrawal by Subject|0
6289595|NCT02387580|10004955|FG001|Overall Study|Withdrawal by Subject|0
6289596|NCT02387580|10004956|FG002|Overall Study|Withdrawal by Subject|0
6289597|NCT02387580|10004957|FG003|Overall Study|Withdrawal by Subject|1
6289598|NCT02387580|10004958|FG004|Overall Study|Withdrawal by Subject|0
6289599|NCT02387580|10004959|FG005|Overall Study|Withdrawal by Subject|0
6289600|NCT02387762|10004995|FG000|Overall Study|Withdrawal by Subject|1
6289601|NCT02387762|10004996|FG001|Overall Study|Withdrawal by Subject|0
6289602|NCT02387840|10005036|FG000|Overall Study|Death|0
6289603|NCT02387840|10005037|FG001|Overall Study|Death|0
6289604|NCT02387840|10005038|FG002|Overall Study|Death|0
6289605|NCT02387840|10005039|FG003|Overall Study|Death|0
6289606|NCT02387840|10005040|FG004|Overall Study|Death|0
6289607|NCT02387840|10005041|FG005|Overall Study|Death|1
6289608|NCT02387957|10005068|FG000|Overall Study|The study was discontinued|21
6289609|NCT02387957|10005069|FG001|Overall Study|The study was discontinued|21
6289610|NCT02387957|10005070|FG002|Overall Study|The study was discontinued|20
6289611|NCT02387970|10005080|FG000|Overall Study|Did not complete 1-year follow up|1
6289612|NCT02387970|10005081|FG001|Overall Study|Did not complete 1-year follow up|2
6289613|NCT02387983|10005087|FG000|Overall Study|Adverse Event|4
6289614|NCT02387983|10005087|FG000|Overall Study|Protocol Violation|1
6289615|NCT02387983|10005087|FG000|Overall Study|Withdrawal by Subject|2
6289616|NCT02388074|10005091|FG000|Overall Study|Lost in Transit|2
6289617|NCT02388074|10005091|FG000|Overall Study|Sample Not Returned|1
6289618|NCT02388165|10005097|FG000|Overall Study|Study terminated by sponsor|5
6289619|NCT02388165|10005098|FG001|Overall Study|Study terminated by sponsor|5
6289620|NCT02388165|10005097|FG000|Overall Study|Other|11
6289621|NCT02388165|10005098|FG001|Overall Study|Other|13
6289622|NCT02388165|10005097|FG000|Overall Study|No longer meet eligibility criteria|40
6289623|NCT02388165|10005098|FG001|Overall Study|No longer meet eligibility criteria|43
6289624|NCT02388165|10005097|FG000|Overall Study|Withdrawal of consent|31
6289625|NCT02388165|10005098|FG001|Overall Study|Withdrawal of consent|32
6289626|NCT02388165|10005097|FG000|Overall Study|Lost to Follow-up|19
6289627|NCT02388165|10005098|FG001|Overall Study|Lost to Follow-up|20
6289628|NCT02388165|10005097|FG000|Overall Study|Death|13
6289629|NCT02388165|10005098|FG001|Overall Study|Death|10
6289630|NCT02388165|10005097|FG000|Overall Study|Adverse Event|3
6289631|NCT02388165|10005098|FG001|Overall Study|Adverse Event|5
6289632|NCT02388165|10005097|FG000|Overall Study|Did not meet entrance criteria|5
6289633|NCT02388165|10005098|FG001|Overall Study|Did not meet entrance criteria|2
6289634|NCT02388191|10005106|FG000|Overall Study|Patient did not receive IUD|1
6289635|NCT02388191|10005107|FG001|Overall Study|Patient did not receive IUD|0
6222337|NCT01679301|9892998|FG000|Screening Period|screen failure|3
6222338|NCT01679301|9892999|FG001|Screening Period|screen failure|0
6222339|NCT01679301|9893000|FG002|Screening Period|screen failure|0
6222340|NCT01679405|9893021|FG000|Overall Study|Death|2
6222341|NCT01679405|9893022|FG001|Overall Study|Death|5
6222342|NCT01679613|9893037|FG000|Overall Study|other than stated above|0
6222343|NCT01679613|9893038|FG001|Overall Study|other than stated above|1
6222344|NCT01679613|9893039|FG002|Overall Study|other than stated above|2
6222345|NCT01679613|9893040|FG003|Overall Study|other than stated above|2
6222346|NCT01680016|9893049|FG000|Overall Study|Adverse Event|0
6222347|NCT01680016|9893050|FG001|Overall Study|Adverse Event|0
6222348|NCT01680016|9893051|FG002|Overall Study|Adverse Event|1
6222349|NCT01680016|9893052|FG003|Overall Study|Adverse Event|4
6222350|NCT01680016|9893049|FG000|Overall Study|The Subject went out of The Trial|1
6289636|NCT02388269|10005117|FG000|Overall Study|Adverse Event|2
6289637|NCT02388269|10005118|FG001|Overall Study|Adverse Event|0
6289638|NCT02388269|10005119|FG002|Overall Study|Adverse Event|0
6289639|NCT02388269|10005117|FG000|Overall Study|Withdrawal by Subject|1
6289640|NCT02388269|10005118|FG001|Overall Study|Withdrawal by Subject|2
6222351|NCT01680016|9893050|FG001|Overall Study|The Subject went out of The Trial|0
6222352|NCT01680016|9893051|FG002|Overall Study|The Subject went out of The Trial|3
6289641|NCT02388269|10005119|FG002|Overall Study|Withdrawal by Subject|0
6289642|NCT02388269|10005117|FG000|Overall Study|less than 50% stimulations|1
6289643|NCT02388269|10005118|FG001|Overall Study|less than 50% stimulations|0
6289644|NCT02388269|10005119|FG002|Overall Study|less than 50% stimulations|0
6289645|NCT02388269|10005117|FG000|Overall Study|no diary data|3
6289646|NCT02388269|10005118|FG001|Overall Study|no diary data|0
6289647|NCT02388269|10005119|FG002|Overall Study|no diary data|0
6289648|NCT02388269|10005117|FG000|Overall Study|Protocol Violation|2
6289649|NCT02388269|10005118|FG001|Overall Study|Protocol Violation|0
6289650|NCT02388269|10005119|FG002|Overall Study|Protocol Violation|0
6289651|NCT02388269|10005117|FG000|Overall Study|Screen Failure|0
6289652|NCT02388269|10005118|FG001|Overall Study|Screen Failure|0
6289653|NCT02388269|10005119|FG002|Overall Study|Screen Failure|10
6289654|NCT02388295|10005146|FG000|Dose Escalation Week 1|Adverse Event|1
6289655|NCT02388295|10005147|FG001|Dose Escalation Week 1|Adverse Event|2
6289656|NCT02388295|10005148|FG002|Dose Escalation Week 1|Adverse Event|1
6289657|NCT02388295|10005146|FG000|Dose Escalation Week 1|Determined not eligible|1
6289658|NCT02388295|10005147|FG001|Dose Escalation Week 1|Determined not eligible|1
6289659|NCT02388295|10005148|FG002|Dose Escalation Week 1|Determined not eligible|1
6289660|NCT02388295|10005146|FG000|Dose Escalation Week 2|Protocol Violation|0
6289661|NCT02388295|10005147|FG001|Dose Escalation Week 2|Protocol Violation|1
6289662|NCT02388295|10005148|FG002|Dose Escalation Week 2|Protocol Violation|0
6289663|NCT02388295|10005146|FG000|Dose Escalation Week 2|Determined not eligible|1
6289664|NCT02388295|10005147|FG001|Dose Escalation Week 2|Determined not eligible|1
6289665|NCT02388295|10005148|FG002|Dose Escalation Week 2|Determined not eligible|1
6289666|NCT02388295|10005146|FG000|Treatment Weeks 3 to 12|Adverse Event|1
6289667|NCT02388295|10005147|FG001|Treatment Weeks 3 to 12|Adverse Event|1
6289668|NCT02388295|10005148|FG002|Treatment Weeks 3 to 12|Adverse Event|0
6289669|NCT02388347|10005170|FG000|Overall Study|Withdrawal by Subject|0
6289670|NCT02388347|10005171|FG001|Overall Study|Withdrawal by Subject|0
6289671|NCT02388347|10005172|FG002|Overall Study|Withdrawal by Subject|1
6289672|NCT02388347|10005173|FG003|Overall Study|Withdrawal by Subject|0
6289673|NCT02388347|10005174|FG004|Overall Study|Withdrawal by Subject|0
6289674|NCT02388724|10005226|FG000|Overall Study|Reason not Specified|0
6289675|NCT02388724|10005227|FG001|Overall Study|Reason not Specified|1
6289676|NCT02388724|10005226|FG000|Overall Study|Major Protocol Deviation|3
6289677|NCT02388724|10005227|FG001|Overall Study|Major Protocol Deviation|3
5980993|NCT03318003|9569858|FG001|Overall Study|Withdrawal by Subject|1
5980994|NCT03318003|9569857|FG000|Overall Study|fetal loss|0
5980995|NCT03318003|9569858|FG001|Overall Study|fetal loss|1
5980996|NCT03132753|9569884|FG000|Baseline - 6 Month Follow-Up|Lost to Follow-up|27
5980997|NCT03132753|9569885|FG001|Baseline - 6 Month Follow-Up|Lost to Follow-up|32
5980998|NCT03132753|9569884|FG000|6 Month Follow-Up - 12 Month Follow-Up|Lost to Follow-up|6
5980999|NCT03132753|9569885|FG001|6 Month Follow-Up - 12 Month Follow-Up|Lost to Follow-up|2
5981000|NCT03067077|9569900|FG000|Overall Study|Did not receive surgery|4
5981001|NCT03067077|9569901|FG001|Overall Study|Did not receive surgery|5
5981002|NCT03067077|9569900|FG000|Overall Study|Lost to Follow-up|3
5981003|NCT03067077|9569901|FG001|Overall Study|Lost to Follow-up|2
5981004|NCT03059446|9569907|FG000|Overall Study|Adverse Event|11
5981005|NCT03059446|9569907|FG000|Overall Study|Withdrawal of Consent|16
5981006|NCT03059446|9569907|FG000|Overall Study|Lost to Follow-up|3
5981007|NCT03059446|9569907|FG000|Overall Study|Protocol Violation|1
5981008|NCT03059446|9569907|FG000|Overall Study|Study Terminated by Sponsor|131
5981009|NCT03059446|9569907|FG000|Overall Study|Reason not Specified|5
5981010|NCT03035409|9569911|FG000|Overall Study|Adverse Event|5
5981011|NCT03035409|9569911|FG000|Overall Study|Death|2
5981012|NCT03035409|9569911|FG000|Overall Study|Withdrawal by Subject|2
5981013|NCT03035409|9569911|FG000|Overall Study|Non compliance|4
5981014|NCT03035409|9569911|FG000|Overall Study|Patient was jittery|1
5981015|NCT03035409|9569911|FG000|Overall Study|Did not like Questionnaire|1
5981016|NCT03035409|9569911|FG000|Overall Study|Aspartate Aminotransferase increased|1
5981017|NCT03035409|9569911|FG000|Overall Study|Did not like taking drugs|1
5981018|NCT03011034|9569921|FG000|Overall Study|Adverse Event|1
5981019|NCT03011034|9569922|FG001|Overall Study|Adverse Event|0
5981020|NCT02853331|9569952|FG000|Overall Study|Death|59
5981021|NCT02853331|9569953|FG001|Overall Study|Death|95
5981022|NCT02853331|9569952|FG000|Overall Study|Withdrawal by Subject|5
5981023|NCT02853331|9569953|FG001|Overall Study|Withdrawal by Subject|9
5981024|NCT02853331|9569952|FG000|Overall Study|Ongoing in study|368
5981025|NCT02853331|9569953|FG001|Overall Study|Ongoing in study|325
5981026|NCT02601014|9569983|FG000|Overall Study|Adverse Event|3
5981027|NCT02601014|9569984|FG001|Overall Study|Adverse Event|3
5981028|NCT02601014|9569983|FG000|Overall Study|Death|3
5981029|NCT02601014|9569984|FG001|Overall Study|Death|1
5981030|NCT02601014|9569983|FG000|Overall Study|Disease progression|4
5981031|NCT02601014|9569984|FG001|Overall Study|Disease progression|8
5981032|NCT02579096|9569992|FG000|Phase 1, Weeks 0 - 24|Side effects with study medications|10
5981033|NCT02579096|9569993|FG001|Phase 1, Weeks 0 - 24|Side effects with study medications|6
5981034|NCT02579096|9569992|FG000|Phase 1, Weeks 0 - 24|Physician Decision|2
5981035|NCT02579096|9569993|FG001|Phase 1, Weeks 0 - 24|Physician Decision|1
5981036|NCT02579096|9569992|FG000|Phase 1, Weeks 0 - 24|Withdrawal by Subject|32
5981037|NCT02579096|9569993|FG001|Phase 1, Weeks 0 - 24|Withdrawal by Subject|36
5981038|NCT02579096|9569992|FG000|Phase 1, Weeks 0 - 24|Lost to Follow-up|9
5981039|NCT02579096|9569993|FG001|Phase 1, Weeks 0 - 24|Lost to Follow-up|4
5981040|NCT02579096|9569992|FG000|Phase 1, Weeks 0 - 24|Other reasons|4
5981041|NCT02579096|9569993|FG001|Phase 1, Weeks 0 - 24|Other reasons|3
5981042|NCT02579096|9569992|FG000|Phase 2, Weeks 25 - 48|Death|2
6289678|NCT02388724|10005226|FG000|Overall Study|Pretreatment Event/Adverse Event|3
6289679|NCT02388724|10005227|FG001|Overall Study|Pretreatment Event/Adverse Event|2
6289680|NCT02388724|10005226|FG000|Overall Study|Voluntary Withdrawal|6
6289681|NCT02388724|10005227|FG001|Overall Study|Voluntary Withdrawal|5
6289682|NCT02388724|10005226|FG000|Overall Study|Randomized but not Treated|0
6289683|NCT02388724|10005227|FG001|Overall Study|Randomized but not Treated|2
6289684|NCT02388737|10005236|FG000|Overall Study|Pretreatment Event/Adverse Event|13
6289685|NCT02388737|10005237|FG001|Overall Study|Pretreatment Event/Adverse Event|11
6222353|NCT01680016|9893052|FG003|Overall Study|The Subject went out of The Trial|0
6222354|NCT01680016|9893049|FG000|Overall Study|Protocol Violation|0
6222355|NCT01680016|9893050|FG001|Overall Study|Protocol Violation|1
6222356|NCT01680016|9893051|FG002|Overall Study|Protocol Violation|0
6222357|NCT01680016|9893052|FG003|Overall Study|Protocol Violation|0
6222358|NCT01680016|9893049|FG000|Overall Study|Withdrawal by Subject|5
6222359|NCT01680016|9893050|FG001|Overall Study|Withdrawal by Subject|7
6222360|NCT01680016|9893051|FG002|Overall Study|Withdrawal by Subject|1
6222361|NCT01680016|9893052|FG003|Overall Study|Withdrawal by Subject|1
6222362|NCT01680159|9893078|FG000|Screening Period|Not meet criteria for dose-up period|7
6222363|NCT01680159|9893078|FG000|Increased Dose Period|Adverse Event|6
6222364|NCT01680159|9893078|FG000|Increased Dose Period|Withdrawal by Subject|2
6222365|NCT01680341|9893144|FG000|Overall Study|Adverse Event|3
6222366|NCT01680341|9893145|FG001|Overall Study|Adverse Event|2
6222367|NCT01680341|9893144|FG000|Overall Study|Unclassified|18
6222368|NCT01680341|9893145|FG001|Overall Study|Unclassified|15
6222369|NCT01680458|9893151|FG000|Overall Study|Protocol Violation|3
6222370|NCT01680497|9893155|FG000|Overall Study|Lost to Follow-up|2
6289686|NCT02388737|10005238|FG002|Overall Study|Pretreatment Event/Adverse Event|12
6289687|NCT02388737|10005236|FG000|Overall Study|Major Protocol Deviation|18
6289688|NCT02388737|10005237|FG001|Overall Study|Major Protocol Deviation|25
6289689|NCT02388737|10005238|FG002|Overall Study|Major Protocol Deviation|22
6289690|NCT02388737|10005236|FG000|Overall Study|Lost to Follow-up|5
6289691|NCT02388737|10005237|FG001|Overall Study|Lost to Follow-up|1
6289692|NCT02388737|10005238|FG002|Overall Study|Lost to Follow-up|4
6289693|NCT02388737|10005236|FG000|Overall Study|Voluntary Withdrawal|10
6289694|NCT02388737|10005237|FG001|Overall Study|Voluntary Withdrawal|18
6289695|NCT02388737|10005238|FG002|Overall Study|Voluntary Withdrawal|17
6289696|NCT02388737|10005236|FG000|Overall Study|Lack of Efficacy|3
6289697|NCT02388737|10005237|FG001|Overall Study|Lack of Efficacy|0
6289698|NCT02388737|10005238|FG002|Overall Study|Lack of Efficacy|3
6289699|NCT02388737|10005236|FG000|Overall Study|Reason Not Specified|5
6289700|NCT02388737|10005237|FG001|Overall Study|Reason Not Specified|5
6289701|NCT02388737|10005238|FG002|Overall Study|Reason Not Specified|4
6289702|NCT02388763|10005246|FG000|Habitual, 10 Days of Wear|Withdrawal by Subject|1
6289703|NCT02388763|10005247|FG001|Habitual, 10 Days of Wear|Withdrawal by Subject|1
6289704|NCT02388763|10005246|FG000|Period 1, 10 Days of Wear|Withdrawal by Subject|1
6289705|NCT02388763|10005247|FG001|Period 1, 10 Days of Wear|Withdrawal by Subject|1
6289706|NCT02388932|10005264|FG000|Overall Study|Death|1
6289707|NCT02388997|10005271|FG000|Overall Study|Adverse Event|1
6289708|NCT02388997|10005272|FG001|Overall Study|Adverse Event|2
6289709|NCT02388997|10005271|FG000|Overall Study|Withdrawal by Subject|2
6289710|NCT02388997|10005272|FG001|Overall Study|Withdrawal by Subject|1
6289711|NCT02388997|10005271|FG000|Overall Study|Lung function exclusion criteria|0
6289712|NCT02388997|10005272|FG001|Overall Study|Lung function exclusion criteria|2
6289713|NCT02388997|10005271|FG000|Overall Study|Tested positive for virus during run-in|0
6289714|NCT02388997|10005272|FG001|Overall Study|Tested positive for virus during run-in|1
6289715|NCT02389452|10005305|FG000|Overall Study|Lost to Follow-up|13
6289716|NCT02389452|10005305|FG000|Overall Study|Adverse Event|1
6289717|NCT02389452|10005305|FG000|Overall Study|Withdrawal by Subject|5
6289718|NCT02389452|10005305|FG000|Overall Study|Enrolled but Not Eligible for Study|6
6289719|NCT02389621|10005312|FG000|Treatment Period|Withdrawal by Subject|1
6289720|NCT02389621|10005313|FG001|Treatment Period|Withdrawal by Subject|1
6289721|NCT02389621|10005312|FG000|Posttreatment Period|Adverse Event|3
6289722|NCT02389621|10005313|FG001|Posttreatment Period|Adverse Event|1
6289723|NCT02389621|10005312|FG000|Posttreatment Period|Withdrawal by Subject|3
6289724|NCT02389621|10005313|FG001|Posttreatment Period|Withdrawal by Subject|2
6289725|NCT02389621|10005312|FG000|Posttreatment Period|Lost to Follow-up|1
6131999|NCT00971243|9759535|FG004|Open-label Period|Physician Decision|2
6132000|NCT00971243|9759531|FG000|Open-label Period|Protocol Violation|1
6132001|NCT00971243|9759532|FG001|Open-label Period|Protocol Violation|1
6132002|NCT00971243|9759533|FG002|Open-label Period|Protocol Violation|1
6132003|NCT00971243|9759534|FG003|Open-label Period|Protocol Violation|0
6132004|NCT00971243|9759535|FG004|Open-label Period|Protocol Violation|1
6132005|NCT00971243|9759531|FG000|Open-label Period|Withdrawal by Subject|1
6132006|NCT00971243|9759532|FG001|Open-label Period|Withdrawal by Subject|0
6289726|NCT02389621|10005313|FG001|Posttreatment Period|Lost to Follow-up|1
6289727|NCT02389621|10005312|FG000|Posttreatment Period|Other - Miscellaneous|2
6289728|NCT02389621|10005313|FG001|Posttreatment Period|Other - Miscellaneous|0
6132007|NCT00971243|9759533|FG002|Open-label Period|Withdrawal by Subject|0
6132008|NCT00971243|9759534|FG003|Open-label Period|Withdrawal by Subject|2
6132009|NCT00971243|9759535|FG004|Open-label Period|Withdrawal by Subject|1
6132010|NCT00971243|9759531|FG000|Open-label Period|Other reason|0
6132011|NCT00971243|9759532|FG001|Open-label Period|Other reason|0
6132012|NCT00971243|9759533|FG002|Open-label Period|Other reason|0
6132013|NCT00971243|9759534|FG003|Open-label Period|Other reason|0
6132014|NCT00971243|9759535|FG004|Open-label Period|Other reason|2
6132015|NCT00971321|9759562|FG000|Up to Month 7|Withdrawal by Subject|1
6132016|NCT00971321|9759563|FG001|Up to Month 7|Withdrawal by Subject|0
6132017|NCT00971321|9759562|FG000|Up to Month 7|Migrated/moved from study area|3
5981043|NCT02579096|9569993|FG001|Phase 2, Weeks 25 - 48|Death|4
5981044|NCT02579096|9569992|FG000|Phase 2, Weeks 25 - 48|Side effects with study medications|3
5981045|NCT02579096|9569993|FG001|Phase 2, Weeks 25 - 48|Side effects with study medications|1
5981046|NCT02579096|9569992|FG000|Phase 2, Weeks 25 - 48|Physician Decision|4
5981047|NCT02579096|9569993|FG001|Phase 2, Weeks 25 - 48|Physician Decision|0
5981048|NCT02579096|9569992|FG000|Phase 2, Weeks 25 - 48|Withdrawal by Subject|9
5981049|NCT02579096|9569993|FG001|Phase 2, Weeks 25 - 48|Withdrawal by Subject|12
5981050|NCT02579096|9569992|FG000|Phase 2, Weeks 25 - 48|Lost to Follow-up|4
5981051|NCT02579096|9569993|FG001|Phase 2, Weeks 25 - 48|Lost to Follow-up|9
5981052|NCT02579096|9569992|FG000|Phase 2, Weeks 25 - 48|Other reasons|0
5981053|NCT02579096|9569993|FG001|Phase 2, Weeks 25 - 48|Other reasons|5
5981054|NCT02579096|9569992|FG000|Phase 3, Weeks 49 - 72|Death|3
5981055|NCT02579096|9569993|FG001|Phase 3, Weeks 49 - 72|Death|2
5981056|NCT02579096|9569992|FG000|Phase 3, Weeks 49 - 72|Side effects with study medications|0
6132018|NCT00971321|9759563|FG001|Up to Month 7|Migrated/moved from study area|2
6132019|NCT00971321|9759562|FG000|Up to Month 11-12|Withdrawal by Subject|2
6132020|NCT00971321|9759563|FG001|Up to Month 11-12|Withdrawal by Subject|1
6132021|NCT00971321|9759562|FG000|Up to Month 11-12|Migrated/moved from study area|2
6132022|NCT00971321|9759563|FG001|Up to Month 11-12|Migrated/moved from study area|2
6132023|NCT00971321|9759562|FG000|Up to Month 11-12|Lost to Follow-up|1
6132024|NCT00971321|9759563|FG001|Up to Month 11-12|Lost to Follow-up|0
6222371|NCT01680861|9893222|FG000|Early Post-transplant Period|Protocol Violation|1
6222372|NCT01680861|9893223|FG001|Early Post-transplant Period|Protocol Violation|1
6222373|NCT01680991|9893252|FG000|Overall Study|Adverse Event|1
6222374|NCT01680991|9893253|FG001|Overall Study|Adverse Event|0
6222375|NCT01680991|9893254|FG002|Overall Study|Adverse Event|0
6222376|NCT01680991|9893252|FG000|Overall Study|Death|1
6222377|NCT01680991|9893253|FG001|Overall Study|Death|0
6222378|NCT01680991|9893254|FG002|Overall Study|Death|1
6222379|NCT01680991|9893252|FG000|Overall Study|Protocol Violation|0
6222380|NCT01680991|9893253|FG001|Overall Study|Protocol Violation|1
6222381|NCT01680991|9893254|FG002|Overall Study|Protocol Violation|0
6222382|NCT01680991|9893252|FG000|Overall Study|Withdrawal by Subject|5
6222383|NCT01680991|9893253|FG001|Overall Study|Withdrawal by Subject|1
6222384|NCT01680991|9893254|FG002|Overall Study|Withdrawal by Subject|0
6222385|NCT01680991|9893252|FG000|Overall Study|Progressive disease (PD)|0
6222386|NCT01680991|9893253|FG001|Overall Study|Progressive disease (PD)|10
6222387|NCT01680991|9893254|FG002|Overall Study|Progressive disease (PD)|0
6222388|NCT01680991|9893252|FG000|Overall Study|Physician Decision|0
6222389|NCT01680991|9893253|FG001|Overall Study|Physician Decision|7
6222390|NCT01680991|9893254|FG002|Overall Study|Physician Decision|2
6222391|NCT01680991|9893252|FG000|Overall Study|Bad physical condition|0
6222392|NCT01680991|9893253|FG001|Overall Study|Bad physical condition|0
6222393|NCT01680991|9893254|FG002|Overall Study|Bad physical condition|1
6222394|NCT01680991|9893252|FG000|Overall Study|PD confirmed in other hospital|1
6222395|NCT01680991|9893253|FG001|Overall Study|PD confirmed in other hospital|0
6222396|NCT01680991|9893254|FG002|Overall Study|PD confirmed in other hospital|0
6222397|NCT01681004|9893266|FG000|Primary Endpoint: 6 Months|Withdrawal by Subject|1
6222398|NCT01681004|9893267|FG001|Primary Endpoint: 6 Months|Withdrawal by Subject|2
6222399|NCT01681004|9893266|FG000|Study Completion|Lost to Follow-up|8
6222400|NCT01681004|9893267|FG001|Study Completion|Lost to Follow-up|3
6222401|NCT01681004|9893266|FG000|Study Completion|Physician Decision|1
6222402|NCT01681004|9893267|FG001|Study Completion|Physician Decision|3
6222403|NCT01681004|9893266|FG000|Study Completion|Site Termination|2
6222404|NCT01681004|9893267|FG001|Study Completion|Site Termination|1
6222405|NCT01681004|9893266|FG000|Study Completion|Death|1
6222406|NCT01681004|9893267|FG001|Study Completion|Death|1
6222407|NCT01681069|9893292|FG000|Overall Study|Withdrawal by Subject|4
6222408|NCT01681069|9893293|FG001|Overall Study|Withdrawal by Subject|5
6222409|NCT01681069|9893292|FG000|Overall Study|Protocol Violation|1
6222410|NCT01681069|9893293|FG001|Overall Study|Protocol Violation|1
6222411|NCT01681069|9893292|FG000|Overall Study|Adverse Event|0
6222412|NCT01681069|9893293|FG001|Overall Study|Adverse Event|1
6222413|NCT01681186|9893327|FG000|Washout Period From Second Intervention|Adverse Event|0
6222414|NCT01681186|9893328|FG001|Washout Period From Second Intervention|Adverse Event|0
6222415|NCT01681186|9893329|FG002|Washout Period From Second Intervention|Adverse Event|0
6222416|NCT01681186|9893330|FG003|Washout Period From Second Intervention|Adverse Event|0
6222417|NCT01681186|9893331|FG004|Washout Period From Second Intervention|Adverse Event|0
6222418|NCT01681186|9893332|FG005|Washout Period From Second Intervention|Adverse Event|0
6222419|NCT01681186|9893333|FG006|Washout Period From Second Intervention|Adverse Event|1
6222420|NCT01681186|9893334|FG007|Washout Period From Second Intervention|Adverse Event|0
6222421|NCT01681186|9893327|FG000|Washout Period From Second Intervention|Protocol Violation|0
5981057|NCT02579096|9569993|FG001|Phase 3, Weeks 49 - 72|Side effects with study medications|1
6132025|NCT00971425|9759571|FG000|Overall Study|Adverse Event|1
6132026|NCT00971425|9759572|FG001|Overall Study|Adverse Event|1
6132027|NCT00971425|9759571|FG000|Overall Study|Withdrawal by Subject|0
6132028|NCT00971425|9759572|FG001|Overall Study|Withdrawal by Subject|1
6132029|NCT00971932|9759623|FG000|Overall Study|Withdrawal by Subject|1
6222422|NCT01681186|9893328|FG001|Washout Period From Second Intervention|Protocol Violation|0
6222423|NCT01681186|9893329|FG002|Washout Period From Second Intervention|Protocol Violation|0
6222424|NCT01681186|9893330|FG003|Washout Period From Second Intervention|Protocol Violation|0
6222425|NCT01681186|9893331|FG004|Washout Period From Second Intervention|Protocol Violation|0
6222426|NCT01681186|9893332|FG005|Washout Period From Second Intervention|Protocol Violation|0
6222427|NCT01681186|9893333|FG006|Washout Period From Second Intervention|Protocol Violation|0
6222428|NCT01681186|9893334|FG007|Washout Period From Second Intervention|Protocol Violation|1
6222429|NCT01681186|9893327|FG000|Washout Period From Third Intervention|Lost to Follow-up|0
6222430|NCT01681186|9893328|FG001|Washout Period From Third Intervention|Lost to Follow-up|0
6222431|NCT01681186|9893329|FG002|Washout Period From Third Intervention|Lost to Follow-up|0
6222432|NCT01681186|9893330|FG003|Washout Period From Third Intervention|Lost to Follow-up|0
6222433|NCT01681186|9893331|FG004|Washout Period From Third Intervention|Lost to Follow-up|0
6222434|NCT01681186|9893332|FG005|Washout Period From Third Intervention|Lost to Follow-up|0
6222435|NCT01681186|9893333|FG006|Washout Period From Third Intervention|Lost to Follow-up|1
6222436|NCT01681186|9893334|FG007|Washout Period From Third Intervention|Lost to Follow-up|0
6222437|NCT01681186|9893327|FG000|Fourth Intervention|Protocol Violation|0
6222438|NCT01681186|9893328|FG001|Fourth Intervention|Protocol Violation|0
6289729|NCT02389764|10005338|FG000|Overall Study|Lack of Efficacy|9
6289730|NCT02389816|10005345|FG000|Overall Study|Randomized but Not Treated|1
6289731|NCT02389816|10005346|FG001|Overall Study|Randomized but Not Treated|0
6289732|NCT02389816|10005347|FG002|Overall Study|Randomized but Not Treated|0
6289733|NCT02389816|10005345|FG000|Overall Study|Pretreatment Event or Adverse Event (AE)|4
6289734|NCT02389816|10005346|FG001|Overall Study|Pretreatment Event or Adverse Event (AE)|6
6289735|NCT02389816|10005347|FG002|Overall Study|Pretreatment Event or Adverse Event (AE)|7
6289736|NCT02389816|10005345|FG000|Overall Study|Major Protocol Deviation|1
6289737|NCT02389816|10005346|FG001|Overall Study|Major Protocol Deviation|0
6289738|NCT02389816|10005347|FG002|Overall Study|Major Protocol Deviation|0
6289739|NCT02389816|10005345|FG000|Overall Study|Lost to Follow-up|1
6289740|NCT02389816|10005346|FG001|Overall Study|Lost to Follow-up|0
6289741|NCT02389816|10005347|FG002|Overall Study|Lost to Follow-up|0
6289742|NCT02389816|10005345|FG000|Overall Study|Withdrawal of Consent|6
6289743|NCT02389816|10005346|FG001|Overall Study|Withdrawal of Consent|4
6289744|NCT02389816|10005347|FG002|Overall Study|Withdrawal of Consent|4
6289745|NCT02389816|10005345|FG000|Overall Study|Lack of Efficacy|1
6289746|NCT02389816|10005346|FG001|Overall Study|Lack of Efficacy|0
6289747|NCT02389816|10005347|FG002|Overall Study|Lack of Efficacy|0
6289748|NCT02389816|10005345|FG000|Overall Study|Non Compliance with Study Drug|1
6289749|NCT02389816|10005346|FG001|Overall Study|Non Compliance with Study Drug|1
6289750|NCT02389816|10005347|FG002|Overall Study|Non Compliance with Study Drug|1
6289751|NCT02389816|10005345|FG000|Overall Study|Reason not Specified|0
6289752|NCT02389816|10005346|FG001|Overall Study|Reason not Specified|2
6289753|NCT02389816|10005347|FG002|Overall Study|Reason not Specified|0
6289754|NCT02389829|10005357|FG000|Overall Study|Lost to Follow-up|0
6289755|NCT02389829|10005358|FG001|Overall Study|Lost to Follow-up|1
6289756|NCT02389894|10005396|FG000|Overall Study|Death|4
6289757|NCT02389894|10005397|FG001|Overall Study|Death|5
6289758|NCT02389894|10005398|FG002|Overall Study|Death|3
6289759|NCT02389894|10005396|FG000|Overall Study|Withdrawal by Subject|2
6289760|NCT02389894|10005397|FG001|Overall Study|Withdrawal by Subject|4
6289761|NCT02389894|10005398|FG002|Overall Study|Withdrawal by Subject|5
6289762|NCT02389894|10005396|FG000|Overall Study|Lost to Follow-up|2
6289763|NCT02389894|10005397|FG001|Overall Study|Lost to Follow-up|1
6289764|NCT02389894|10005398|FG002|Overall Study|Lost to Follow-up|1
6289765|NCT02389998|10005417|FG000|Overall Study|car accident|1
6289766|NCT02389998|10005418|FG001|Overall Study|car accident|0
6289767|NCT02390076|10005446|FG000|Overall Study|Lost to Follow-up|2
6289768|NCT02390076|10005447|FG001|Overall Study|Lost to Follow-up|1
6289769|NCT02390076|10005448|FG002|Overall Study|Lost to Follow-up|4
6289770|NCT02390167|10005456|FG000|Overall Study|Lost to Follow-up|1
6132030|NCT00971932|9759623|FG000|Overall Study|Investigator's decision|2
6132031|NCT00971932|9759623|FG000|Overall Study|Ongoing|4
6132032|NCT00971945|9759627|FG000|Overall Study|Progressive Disease|3
6132033|NCT00971945|9759627|FG000|Overall Study|Change in treatment policy|1
6132034|NCT00971945|9759627|FG000|Overall Study|Other reasons|2
6132035|NCT00971997|9759631|FG000|Overall Study|Adverse Event|2
6132036|NCT00971997|9759631|FG000|Overall Study|Death|1
6132037|NCT00971997|9759631|FG000|Overall Study|Protocol Violation|4
6132038|NCT00971997|9759631|FG000|Overall Study|Withdrawal by Subject|5
6222439|NCT01681186|9893329|FG002|Fourth Intervention|Protocol Violation|0
6222440|NCT01681186|9893330|FG003|Fourth Intervention|Protocol Violation|0
6222441|NCT01681186|9893331|FG004|Fourth Intervention|Protocol Violation|0
6222442|NCT01681186|9893332|FG005|Fourth Intervention|Protocol Violation|0
6222443|NCT01681186|9893333|FG006|Fourth Intervention|Protocol Violation|0
6222444|NCT01681186|9893334|FG007|Fourth Intervention|Protocol Violation|1
6222445|NCT01681212|9893364|FG000|Overall Study|No longer met study criteria|5
6222446|NCT01681212|9893364|FG000|Overall Study|Administrative reason by sponsor|1
6222447|NCT01681277|9893373|FG000|Overall Study|Adverse Event|1
6222448|NCT01681277|9893374|FG001|Overall Study|Adverse Event|0
6222449|NCT01681277|9893375|FG002|Overall Study|Adverse Event|0
6222450|NCT01681277|9893376|FG003|Overall Study|Adverse Event|0
6222451|NCT01681277|9893377|FG004|Overall Study|Adverse Event|0
6222452|NCT01681368|9893393|FG000|Overall Study|Refused further treatment|1
6222453|NCT01681368|9893393|FG000|Overall Study|Refused further follow up|1
6222454|NCT01681433|9893399|FG000|Overall Study|Lack of Efficacy|23
6222455|NCT01681433|9893400|FG001|Overall Study|Lack of Efficacy|23
6222456|NCT01681433|9893399|FG000|Overall Study|Withdrawal by Subject|5
6222457|NCT01681433|9893400|FG001|Overall Study|Withdrawal by Subject|5
6222458|NCT01681433|9893399|FG000|Overall Study|Protocol Violation|2
6222459|NCT01681433|9893400|FG001|Overall Study|Protocol Violation|0
6222460|NCT01681433|9893399|FG000|Overall Study|Adverse Event|2
6222461|NCT01681433|9893400|FG001|Overall Study|Adverse Event|4
6222462|NCT01681433|9893399|FG000|Overall Study|Lost to Follow-up|0
6222463|NCT01681433|9893400|FG001|Overall Study|Lost to Follow-up|1
6222464|NCT01681472|9893410|FG000|Overall Study|Adverse Event|0
6222465|NCT01681472|9893411|FG001|Overall Study|Adverse Event|1
6222466|NCT01681472|9893412|FG002|Overall Study|Adverse Event|0
6222467|NCT01681472|9893413|FG003|Overall Study|Adverse Event|0
6222468|NCT01681511|9893434|FG000|Overall Study|No Treatment Received|1
6222469|NCT01681511|9893435|FG001|Overall Study|No Treatment Received|3
6222470|NCT01681511|9893434|FG000|Overall Study|Failed Inclusion/Exclusion|3
6222471|NCT01681511|9893435|FG001|Overall Study|Failed Inclusion/Exclusion|0
6222472|NCT01681511|9893434|FG000|Overall Study|No Baseline Dips Stick & Urine Culture|3
6222473|NCT01681511|9893435|FG001|Overall Study|No Baseline Dips Stick & Urine Culture|6
6222474|NCT01681511|9893434|FG000|Overall Study|No Daily Urine Sample Collected|0
6222475|NCT01681511|9893435|FG001|Overall Study|No Daily Urine Sample Collected|1
6222476|NCT01681511|9893434|FG000|Overall Study|No post-catheter sample collected|11
6222477|NCT01681511|9893435|FG001|Overall Study|No post-catheter sample collected|4
6222478|NCT01681576|9893443|FG000|Period 1|Adverse Event|1
6222479|NCT01681576|9893444|FG001|Period 1|Adverse Event|0
6222480|NCT01681576|9893443|FG000|Period 1|Protocol Deviation|1
6222481|NCT01681576|9893444|FG001|Period 1|Protocol Deviation|0
6222482|NCT01681576|9893443|FG000|Period 2|subject/guardian decision|3
6222483|NCT01681576|9893444|FG001|Period 2|subject/guardian decision|1
6222484|NCT01681576|9893443|FG000|Period 2|Non-compliance with study treatment|1
6222485|NCT01681576|9893444|FG001|Period 2|Non-compliance with study treatment|0
6222486|NCT01681628|9893454|FG000|Time 1 (Entry) to Time 2 One Week Later.|Lost to Follow-up|14
6222487|NCT01681628|9893455|FG001|Time 1 (Entry) to Time 2 One Week Later.|Lost to Follow-up|6
6222488|NCT01681628|9893454|FG000|Time 2 to Time 3 (One Week Later).|Lost to Follow-up|0
6222489|NCT01681628|9893455|FG001|Time 2 to Time 3 (One Week Later).|Lost to Follow-up|15
6222490|NCT01681628|9893454|FG000|19 Months Follow-up|Death|1
6222491|NCT01681628|9893455|FG001|19 Months Follow-up|Death|0
6222492|NCT01681628|9893454|FG000|19 Months Follow-up|Lost to Follow-up|61
6222493|NCT01681628|9893455|FG001|19 Months Follow-up|Lost to Follow-up|43
6222494|NCT01681771|9893466|FG000|Overall Study|Lost to Follow-up|4
6222495|NCT01681771|9893467|FG001|Overall Study|Lost to Follow-up|2
6222496|NCT01681836|9893477|FG000|Second Intervention|Withdrawal by Subject|0
6222497|NCT01681836|9893478|FG001|Second Intervention|Withdrawal by Subject|1
6222498|NCT01681849|9893487|FG000|Overall Study|Protocol Violation|2
6222499|NCT01681849|9893488|FG001|Overall Study|Protocol Violation|0
6222500|NCT01681849|9893489|FG002|Overall Study|Protocol Violation|0
6222501|NCT01681849|9893487|FG000|Overall Study|Withdrawal by Subject|3
6222502|NCT01681849|9893488|FG001|Overall Study|Withdrawal by Subject|5
6222503|NCT01681849|9893489|FG002|Overall Study|Withdrawal by Subject|33
6222504|NCT01681849|9893487|FG000|Overall Study|Lost to Follow-up|3
6222505|NCT01681849|9893488|FG001|Overall Study|Lost to Follow-up|2
6222506|NCT01681849|9893489|FG002|Overall Study|Lost to Follow-up|6
6222507|NCT01681992|9893499|FG000|Overall Study|Adverse Event|3
6222508|NCT01681992|9893500|FG001|Overall Study|Adverse Event|2
6289771|NCT02390219|10005464|FG000|Overall Study|Death|1
6132039|NCT00971997|9759631|FG000|Overall Study|Physician Decision|7
6132040|NCT00972153|9759645|FG000|Overall Study|Equipment malfunction during case|0
6132041|NCT00972153|9759646|FG001|Overall Study|Equipment malfunction during case|1
6132042|NCT00972153|9759647|FG002|Overall Study|Equipment malfunction during case|0
6132043|NCT00972244|9759664|FG000|Overall Study|Incorrect Enrolment|1
6132044|NCT00972244|9759665|FG001|Overall Study|Incorrect Enrolment|0
6222509|NCT01681992|9893501|FG002|Overall Study|Adverse Event|3
6132045|NCT00972244|9759666|FG002|Overall Study|Incorrect Enrolment|0
6132046|NCT00972244|9759667|FG003|Overall Study|Incorrect Enrolment|0
6132047|NCT00972244|9759668|FG004|Overall Study|Incorrect Enrolment|0
6132048|NCT00972244|9759664|FG000|Overall Study|Adverse Event|0
6132049|NCT00972244|9759665|FG001|Overall Study|Adverse Event|1
6132050|NCT00972244|9759666|FG002|Overall Study|Adverse Event|1
6132051|NCT00972244|9759667|FG003|Overall Study|Adverse Event|0
6132052|NCT00972244|9759668|FG004|Overall Study|Adverse Event|0
6132053|NCT00972244|9759664|FG000|Overall Study|Subject No Longer Meets Study Criteria|2
6132054|NCT00972244|9759665|FG001|Overall Study|Subject No Longer Meets Study Criteria|2
6132055|NCT00972244|9759666|FG002|Overall Study|Subject No Longer Meets Study Criteria|0
6132056|NCT00972244|9759667|FG003|Overall Study|Subject No Longer Meets Study Criteria|0
6132057|NCT00972244|9759668|FG004|Overall Study|Subject No Longer Meets Study Criteria|5
6132058|NCT00972244|9759664|FG000|Overall Study|Withdrawal by Subject|1
6132059|NCT00972244|9759665|FG001|Overall Study|Withdrawal by Subject|2
6132060|NCT00972244|9759666|FG002|Overall Study|Withdrawal by Subject|1
6132061|NCT00972244|9759667|FG003|Overall Study|Withdrawal by Subject|0
6132062|NCT00972244|9759668|FG004|Overall Study|Withdrawal by Subject|1
6132063|NCT00972244|9759664|FG000|Overall Study|Safety|0
6132064|NCT00972244|9759665|FG001|Overall Study|Safety|0
6132065|NCT00972244|9759666|FG002|Overall Study|Safety|0
6132066|NCT00972244|9759667|FG003|Overall Study|Safety|0
6132067|NCT00972244|9759668|FG004|Overall Study|Safety|1
6132068|NCT00972244|9759664|FG000|Overall Study|Death|1
6132069|NCT00972244|9759665|FG001|Overall Study|Death|0
6132070|NCT00972244|9759666|FG002|Overall Study|Death|0
6132071|NCT00972244|9759667|FG003|Overall Study|Death|0
6132072|NCT00972244|9759668|FG004|Overall Study|Death|0
6132073|NCT00972244|9759664|FG000|Overall Study|Various|0
6132074|NCT00972244|9759665|FG001|Overall Study|Various|0
6132075|NCT00972244|9759666|FG002|Overall Study|Various|0
6132076|NCT00972244|9759667|FG003|Overall Study|Various|0
6132077|NCT00972244|9759668|FG004|Overall Study|Various|2
6132078|NCT00972283|9759682|FG000|Main: Week 0 to 52 (NN1250-3582)|Adverse Event|31
6132079|NCT00972283|9759683|FG001|Main: Week 0 to 52 (NN1250-3582)|Adverse Event|9
6132080|NCT00972283|9759682|FG000|Main: Week 0 to 52 (NN1250-3582)|Lack of Efficacy|3
6132081|NCT00972283|9759683|FG001|Main: Week 0 to 52 (NN1250-3582)|Lack of Efficacy|0
6132082|NCT00972283|9759682|FG000|Main: Week 0 to 52 (NN1250-3582)|Protocol Violation|23
6132083|NCT00972283|9759683|FG001|Main: Week 0 to 52 (NN1250-3582)|Protocol Violation|12
6132084|NCT00972283|9759682|FG000|Main: Week 0 to 52 (NN1250-3582)|Withdrawal criteria|8
6222510|NCT01681992|9893499|FG000|Overall Study|Lost to Follow-up|36
6222511|NCT01681992|9893500|FG001|Overall Study|Lost to Follow-up|38
6222512|NCT01681992|9893501|FG002|Overall Study|Lost to Follow-up|53
6222513|NCT01681992|9893499|FG000|Overall Study|As Per Sponsor Decision|0
6222514|NCT01681992|9893500|FG001|Overall Study|As Per Sponsor Decision|0
6222515|NCT01681992|9893501|FG002|Overall Study|As Per Sponsor Decision|1
6222516|NCT01681992|9893499|FG000|Overall Study|Protocol Violation|0
6222517|NCT01681992|9893500|FG001|Overall Study|Protocol Violation|0
6222518|NCT01681992|9893501|FG002|Overall Study|Protocol Violation|1
6222519|NCT01681992|9893499|FG000|Overall Study|Withdrawal by Subject|27
6222520|NCT01681992|9893500|FG001|Overall Study|Withdrawal by Subject|30
6222521|NCT01681992|9893501|FG002|Overall Study|Withdrawal by Subject|25
6222522|NCT01682031|9893511|FG000|Overall Study|Withdrawal by Subject|0
6222523|NCT01682031|9893512|FG001|Overall Study|Withdrawal by Subject|1
6222524|NCT01682031|9893511|FG000|Overall Study|Adverse Event|0
6222525|NCT01682031|9893512|FG001|Overall Study|Adverse Event|2
6222526|NCT01682031|9893511|FG000|Overall Study|MRI results indicate increased nodul|0
6222527|NCT01682031|9893512|FG001|Overall Study|MRI results indicate increased nodul|1
6222528|NCT01682031|9893511|FG000|Overall Study|Patient could not swallow tablets|1
6222529|NCT01682031|9893512|FG001|Overall Study|Patient could not swallow tablets|0
6222530|NCT01682031|9893511|FG000|Overall Study|Patient stopped selenium on his own|0
6222531|NCT01682031|9893512|FG001|Overall Study|Patient stopped selenium on his own|1
6222532|NCT01682044|9893518|FG000|Overall Study|Death|1
6222533|NCT01682044|9893518|FG000|Overall Study|Progression|3
6222534|NCT01682083|9893524|FG000|Overall Study|Lost to Follow-up|11
6222535|NCT01682083|9893525|FG001|Overall Study|Lost to Follow-up|18
6222536|NCT01682083|9893524|FG000|Overall Study|Withdrawal by Subject|31
6222537|NCT01682083|9893525|FG001|Overall Study|Withdrawal by Subject|40
6222538|NCT01682083|9893524|FG000|Overall Study|Death|60
6222539|NCT01682083|9893525|FG001|Overall Study|Death|93
6222540|NCT01682083|9893524|FG000|Overall Study|Physician Decision|5
6222541|NCT01682083|9893525|FG001|Overall Study|Physician Decision|4
6222542|NCT01682148|9893548|FG000|Overall Study|Withdrawal by Subject|2
6222543|NCT01682148|9893549|FG001|Overall Study|Withdrawal by Subject|0
6222544|NCT01682148|9893548|FG000|Overall Study|Lost to Follow-up|1
6289772|NCT02390219|10005464|FG000|Overall Study|Physician Decision|1
6289773|NCT02390219|10005464|FG000|Overall Study|Adverse Event|6
6289774|NCT02390219|10005464|FG000|Overall Study|Withdrawal by Subject|1
6132085|NCT00972283|9759683|FG001|Main: Week 0 to 52 (NN1250-3582)|Withdrawal criteria|2
6132086|NCT00972283|9759682|FG000|Main: Week 0 to 52 (NN1250-3582)|Unclassified|72
6222545|NCT01682148|9893549|FG001|Overall Study|Lost to Follow-up|2
6222546|NCT01682148|9893548|FG000|Overall Study|Protocol Violation|1
6222547|NCT01682148|9893549|FG001|Overall Study|Protocol Violation|1
6222548|NCT01682213|9893560|FG000|Overall Study|Withdrawal by Subject|2
6132087|NCT00972283|9759683|FG001|Main: Week 0 to 52 (NN1250-3582)|Unclassified|17
6132088|NCT00972283|9759682|FG000|Extension: Week 53 to 78 (NN1250-3667)|Adverse Event|4
6132089|NCT00972283|9759683|FG001|Extension: Week 53 to 78 (NN1250-3667)|Adverse Event|0
6132090|NCT00972283|9759682|FG000|Extension: Week 53 to 78 (NN1250-3667)|Lack of Efficacy|1
6132091|NCT00972283|9759683|FG001|Extension: Week 53 to 78 (NN1250-3667)|Lack of Efficacy|1
6132092|NCT00972283|9759682|FG000|Extension: Week 53 to 78 (NN1250-3667)|Protocol Violation|5
6132093|NCT00972283|9759683|FG001|Extension: Week 53 to 78 (NN1250-3667)|Protocol Violation|0
6132094|NCT00972283|9759682|FG000|Extension: Week 53 to 78 (NN1250-3667)|Withdrawal criteria|6
6132095|NCT00972283|9759683|FG001|Extension: Week 53 to 78 (NN1250-3667)|Withdrawal criteria|2
6132096|NCT00972283|9759682|FG000|Extension: Week 53 to 78 (NN1250-3667)|Unclassified|11
6132097|NCT00972283|9759683|FG001|Extension: Week 53 to 78 (NN1250-3667)|Unclassified|5
6132098|NCT00972322|9759691|FG000|Overall Study|Adverse Event|2
6132099|NCT00972322|9759692|FG001|Overall Study|Adverse Event|1
6132100|NCT00972322|9759691|FG000|Overall Study|Positive drug screen|0
6132101|NCT00972322|9759692|FG001|Overall Study|Positive drug screen|1
6132102|NCT00972322|9759691|FG000|Overall Study|Lost to Follow-up|0
6132103|NCT00972322|9759692|FG001|Overall Study|Lost to Follow-up|1
6132104|NCT00972322|9759691|FG000|Overall Study|Consistently high glucose values|1
6132105|NCT00972322|9759692|FG001|Overall Study|Consistently high glucose values|0
6132106|NCT00972504|9759724|FG000|Overall Study|Adverse Event|2
6132107|NCT00972504|9759724|FG000|Overall Study|Investigator discretion|1
6132108|NCT00972517|9759734|FG000|Overall Study|Adverse Event|0
6132109|NCT00972517|9759735|FG001|Overall Study|Adverse Event|0
6132110|NCT00972517|9759736|FG002|Overall Study|Adverse Event|0
6222549|NCT01682460|9893565|FG000|Overall Study|Withdrawal by Subject|2
6222550|NCT01682460|9893565|FG000|Overall Study|Did not meet inclusion criteria|2
6222551|NCT01682512|9893572|FG000|Overall Study|Adverse Event|6
6222552|NCT01682512|9893573|FG001|Overall Study|Adverse Event|5
6222553|NCT01682512|9893574|FG002|Overall Study|Adverse Event|2
6222554|NCT01682512|9893572|FG000|Overall Study|Withdrawal by Subject|2
6222555|NCT01682512|9893573|FG001|Overall Study|Withdrawal by Subject|6
6222556|NCT01682512|9893574|FG002|Overall Study|Withdrawal by Subject|3
6222557|NCT01682512|9893572|FG000|Overall Study|Physician Decision|0
6222558|NCT01682512|9893573|FG001|Overall Study|Physician Decision|2
6222559|NCT01682512|9893574|FG002|Overall Study|Physician Decision|0
6222560|NCT01682512|9893572|FG000|Overall Study|Study terminated by sponsor|46
6222561|NCT01682512|9893573|FG001|Overall Study|Study terminated by sponsor|43
6222562|NCT01682512|9893574|FG002|Overall Study|Study terminated by sponsor|0
6222563|NCT01682512|9893572|FG000|Overall Study|Lost to Follow-up|3
6222564|NCT01682512|9893573|FG001|Overall Study|Lost to Follow-up|0
6222565|NCT01682512|9893574|FG002|Overall Study|Lost to Follow-up|2
6222566|NCT01682512|9893572|FG000|Overall Study|Protocol Violation|2
6222567|NCT01682512|9893573|FG001|Overall Study|Protocol Violation|3
6222568|NCT01682512|9893574|FG002|Overall Study|Protocol Violation|2
6222569|NCT01682512|9893572|FG000|Overall Study|Primary lack of efficacy|10
6132111|NCT00972517|9759737|FG003|Overall Study|Adverse Event|1
6132112|NCT00972517|9759738|FG004|Overall Study|Adverse Event|0
6132113|NCT00972517|9759739|FG005|Overall Study|Adverse Event|0
6132114|NCT00972517|9759734|FG000|Overall Study|Withdrawal by Subject|0
6132115|NCT00972517|9759735|FG001|Overall Study|Withdrawal by Subject|1
6132116|NCT00972517|9759736|FG002|Overall Study|Withdrawal by Subject|0
6132117|NCT00972517|9759737|FG003|Overall Study|Withdrawal by Subject|2
6132118|NCT00972517|9759738|FG004|Overall Study|Withdrawal by Subject|1
6132119|NCT00972517|9759739|FG005|Overall Study|Withdrawal by Subject|0
6132120|NCT00972543|9759770|FG000|Overall Study|Adverse Event|1
6132121|NCT00972543|9759771|FG001|Overall Study|Adverse Event|0
6132122|NCT00972543|9759770|FG000|Overall Study|Early study termination by sponsor|4
6132123|NCT00972543|9759771|FG001|Overall Study|Early study termination by sponsor|1
6132124|NCT00972595|9759777|FG000|Period 1|Adverse Event|1
6132125|NCT00972595|9759778|FG001|Period 1|Adverse Event|0
6132126|NCT00972777|9759804|FG000|Overall Study|Adverse Event|3
6132127|NCT00972777|9759805|FG001|Overall Study|Adverse Event|2
6132128|NCT00972777|9759804|FG000|Overall Study|Lost to Follow-up|0
6132129|NCT00972777|9759805|FG001|Overall Study|Lost to Follow-up|4
6132130|NCT00972777|9759804|FG000|Overall Study|Withdrawal by Subject|4
6132131|NCT00972777|9759805|FG001|Overall Study|Withdrawal by Subject|5
6132132|NCT00972777|9759804|FG000|Overall Study|Physician Decision|4
6132133|NCT00972777|9759805|FG001|Overall Study|Physician Decision|0
6132134|NCT00972777|9759804|FG000|Overall Study|Protocol Violation|0
6132135|NCT00972777|9759805|FG001|Overall Study|Protocol Violation|2
6132136|NCT00972777|9759804|FG000|Overall Study|Screening Failure|2
6132137|NCT00972777|9759805|FG001|Overall Study|Screening Failure|1
6132138|NCT00972777|9759804|FG000|Overall Study|Missed visit|1
6132139|NCT00972777|9759805|FG001|Overall Study|Missed visit|0
6132140|NCT00972816|9759819|FG000|Overall Study|Adverse Event|0
6132141|NCT00972816|9759820|FG001|Overall Study|Adverse Event|0
6132142|NCT00972816|9759821|FG002|Overall Study|Adverse Event|1
6222570|NCT01682512|9893573|FG001|Overall Study|Primary lack of efficacy|7
6222571|NCT01682512|9893574|FG002|Overall Study|Primary lack of efficacy|7
6132143|NCT00972816|9759822|FG003|Overall Study|Adverse Event|0
6132144|NCT00972816|9759823|FG004|Overall Study|Adverse Event|0
6132145|NCT00972816|9759824|FG005|Overall Study|Adverse Event|0
6132146|NCT00972816|9759825|FG006|Overall Study|Adverse Event|0
6132147|NCT00972816|9759826|FG007|Overall Study|Adverse Event|0
6132148|NCT00972816|9759819|FG000|Overall Study|Withdrawal by Subject|4
6132149|NCT00972816|9759820|FG001|Overall Study|Withdrawal by Subject|2
6132150|NCT00972816|9759821|FG002|Overall Study|Withdrawal by Subject|1
6132151|NCT00972816|9759822|FG003|Overall Study|Withdrawal by Subject|3
6132152|NCT00972816|9759823|FG004|Overall Study|Withdrawal by Subject|0
6132153|NCT00972816|9759824|FG005|Overall Study|Withdrawal by Subject|1
6132154|NCT00972816|9759825|FG006|Overall Study|Withdrawal by Subject|1
6132155|NCT00972816|9759826|FG007|Overall Study|Withdrawal by Subject|2
6132156|NCT00972816|9759819|FG000|Overall Study|Lost to Follow-up|11
6132157|NCT00972816|9759820|FG001|Overall Study|Lost to Follow-up|9
6132158|NCT00972816|9759821|FG002|Overall Study|Lost to Follow-up|7
6132159|NCT00972816|9759822|FG003|Overall Study|Lost to Follow-up|5
6132160|NCT00972816|9759823|FG004|Overall Study|Lost to Follow-up|11
6132161|NCT00972816|9759824|FG005|Overall Study|Lost to Follow-up|10
6132162|NCT00972816|9759825|FG006|Overall Study|Lost to Follow-up|7
6132163|NCT00972816|9759826|FG007|Overall Study|Lost to Follow-up|7
6222572|NCT01682512|9893572|FG000|Overall Study|Secondary lack of efficacy|1
6222573|NCT01682512|9893573|FG001|Overall Study|Secondary lack of efficacy|1
6222574|NCT01682512|9893574|FG002|Overall Study|Secondary lack of efficacy|0
6222575|NCT01682512|9893572|FG000|Overall Study|Other than stated above|2
6222576|NCT01682512|9893573|FG001|Overall Study|Other than stated above|4
6222577|NCT01682512|9893574|FG002|Overall Study|Other than stated above|2
6222578|NCT01682603|9893597|FG000|Overall Study|Lost to Follow-up|3
6222579|NCT01682681|9893618|FG000|Overall Study|Lack of Efficacy|62
6222580|NCT01682681|9893618|FG000|Overall Study|Withdrawal by Subject|1
6222581|NCT01682681|9893618|FG000|Overall Study|Moved to other hospital|10
6222582|NCT01682681|9893618|FG000|Overall Study|Lost to Follow-up|174
6222583|NCT01682681|9893618|FG000|Overall Study|Adverse Event|46
6222584|NCT01682681|9893618|FG000|Overall Study|tapering of topiramate|5
6222585|NCT01682681|9893618|FG000|Overall Study|Other|21
6222586|NCT01682681|9893618|FG000|Overall Study|Low compliance|13
6222587|NCT01682720|9893626|FG000|Overall Study|Randomized but Not Treated|0
6222588|NCT01682720|9893627|FG001|Overall Study|Randomized but Not Treated|1
6222589|NCT01682720|9893628|FG002|Overall Study|Randomized but Not Treated|1
6222590|NCT01682720|9893629|FG003|Overall Study|Randomized but Not Treated|0
6222591|NCT01682720|9893626|FG000|Overall Study|Terminated by Sponsor|83
6222592|NCT01682720|9893627|FG001|Overall Study|Terminated by Sponsor|0
6222593|NCT01682720|9893628|FG002|Overall Study|Terminated by Sponsor|0
6222594|NCT01682720|9893629|FG003|Overall Study|Terminated by Sponsor|0
6222595|NCT01682720|9893626|FG000|Overall Study|Efficacy Failure|0
6222596|NCT01682720|9893627|FG001|Overall Study|Efficacy Failure|3
6222597|NCT01682720|9893628|FG002|Overall Study|Efficacy Failure|3
6222598|NCT01682720|9893629|FG003|Overall Study|Efficacy Failure|30
6222599|NCT01682720|9893626|FG000|Overall Study|Lost to Follow-up|1
6222600|NCT01682720|9893627|FG001|Overall Study|Lost to Follow-up|1
6222601|NCT01682720|9893628|FG002|Overall Study|Lost to Follow-up|0
6222602|NCT01682720|9893629|FG003|Overall Study|Lost to Follow-up|6
6222603|NCT01682720|9893626|FG000|Overall Study|Subject Withdrew Consent|0
6222604|NCT01682720|9893627|FG001|Overall Study|Subject Withdrew Consent|0
6222605|NCT01682720|9893628|FG002|Overall Study|Subject Withdrew Consent|2
6222606|NCT01682720|9893629|FG003|Overall Study|Subject Withdrew Consent|2
6222607|NCT01682720|9893626|FG000|Overall Study|Adverse Event|1
6222608|NCT01682720|9893627|FG001|Overall Study|Adverse Event|0
6222609|NCT01682720|9893628|FG002|Overall Study|Adverse Event|1
6222610|NCT01682720|9893629|FG003|Overall Study|Adverse Event|1
6222611|NCT01682759|9893641|FG000|Overall Study|Death|2
6222612|NCT01682759|9893642|FG001|Overall Study|Death|1
6222613|NCT01682759|9893641|FG000|Overall Study|Lost to Follow-up|10
6222614|NCT01682759|9893642|FG001|Overall Study|Lost to Follow-up|13
6222615|NCT01682759|9893641|FG000|Overall Study|Physician Decision|1
6222616|NCT01682759|9893642|FG001|Overall Study|Physician Decision|1
6222617|NCT01682759|9893641|FG000|Overall Study|Withdrawal by Subject|56
6289775|NCT02390219|10005464|FG000|Overall Study|Lost to Follow-up|2
6289776|NCT02390219|10005464|FG000|Overall Study|Other|2
6289777|NCT02390557|10005471|FG000|Wave 2|Survey non-respondent|72
6289778|NCT02390557|10005472|FG001|Wave 2|Survey non-respondent|41
6289779|NCT02390557|10005473|FG002|Wave 2|Survey non-respondent|23
6289780|NCT02391038|10005516|FG000|Overall Study|Progressive disease|3
6289781|NCT02391038|10005517|FG001|Overall Study|Progressive disease|3
6289782|NCT02391038|10005518|FG002|Overall Study|Progressive disease|6
6289783|NCT02391116|10005527|FG000|Treatment|Withdrawal by Subject|1
6289784|NCT02391116|10005527|FG000|Treatment|Protocol Violation|1
6222618|NCT01682759|9893642|FG001|Overall Study|Withdrawal by Subject|55
6222619|NCT01682811|9893655|FG000|Part 2 Dose Level 1|Withdrawal by Subject|0
6222620|NCT01682811|9893656|FG001|Part 2 Dose Level 1|Withdrawal by Subject|0
6222621|NCT01682811|9893657|FG002|Part 2 Dose Level 1|Withdrawal by Subject|0
6222622|NCT01682811|9893658|FG003|Part 2 Dose Level 1|Withdrawal by Subject|0
6222623|NCT01682811|9893659|FG004|Part 2 Dose Level 1|Withdrawal by Subject|1
6222624|NCT01682811|9893660|FG005|Part 2 Dose Level 1|Withdrawal by Subject|0
6222625|NCT01682811|9893661|FG006|Part 2 Dose Level 1|Withdrawal by Subject|0
6289785|NCT02391116|10005527|FG000|Treatment|Adverse Event (AE) Without Clinical PD|9
6222626|NCT01682811|9893655|FG000|Part 2 Dose Level 1|Protocol Violation|0
6222627|NCT01682811|9893656|FG001|Part 2 Dose Level 1|Protocol Violation|0
6132164|NCT00972816|9759819|FG000|Overall Study|Inappropriate enrolment|0
6289786|NCT02391116|10005527|FG000|Treatment|AE with Clinical PD|3
6132165|NCT00972816|9759820|FG001|Overall Study|Inappropriate enrolment|0
6132166|NCT00972816|9759821|FG002|Overall Study|Inappropriate enrolment|0
6132167|NCT00972816|9759822|FG003|Overall Study|Inappropriate enrolment|0
6132168|NCT00972816|9759823|FG004|Overall Study|Inappropriate enrolment|0
6132169|NCT00972816|9759824|FG005|Overall Study|Inappropriate enrolment|0
6132170|NCT00972816|9759825|FG006|Overall Study|Inappropriate enrolment|2
6132171|NCT00972816|9759826|FG007|Overall Study|Inappropriate enrolment|0
6132172|NCT00972816|9759819|FG000|Overall Study|Unable to classify|2
6132173|NCT00972816|9759820|FG001|Overall Study|Unable to classify|0
6132174|NCT00972816|9759821|FG002|Overall Study|Unable to classify|0
6132175|NCT00972816|9759822|FG003|Overall Study|Unable to classify|0
6222628|NCT01682811|9893657|FG002|Part 2 Dose Level 1|Protocol Violation|0
6222629|NCT01682811|9893658|FG003|Part 2 Dose Level 1|Protocol Violation|0
6222630|NCT01682811|9893659|FG004|Part 2 Dose Level 1|Protocol Violation|4
6222631|NCT01682811|9893660|FG005|Part 2 Dose Level 1|Protocol Violation|0
6222632|NCT01682811|9893661|FG006|Part 2 Dose Level 1|Protocol Violation|0
6222633|NCT01682811|9893655|FG000|Part 2 Dose Level 1|Lost to Follow-up|0
6222634|NCT01682811|9893656|FG001|Part 2 Dose Level 1|Lost to Follow-up|0
6222635|NCT01682811|9893657|FG002|Part 2 Dose Level 1|Lost to Follow-up|0
6222636|NCT01682811|9893658|FG003|Part 2 Dose Level 1|Lost to Follow-up|0
6222637|NCT01682811|9893659|FG004|Part 2 Dose Level 1|Lost to Follow-up|6
6222638|NCT01682811|9893660|FG005|Part 2 Dose Level 1|Lost to Follow-up|0
6222639|NCT01682811|9893661|FG006|Part 2 Dose Level 1|Lost to Follow-up|0
6222640|NCT01682811|9893655|FG000|Part 2 Dose Level 2|Lost to Follow-up|0
6222641|NCT01682811|9893656|FG001|Part 2 Dose Level 2|Lost to Follow-up|0
6222642|NCT01682811|9893657|FG002|Part 2 Dose Level 2|Lost to Follow-up|0
6222643|NCT01682811|9893658|FG003|Part 2 Dose Level 2|Lost to Follow-up|0
6222644|NCT01682811|9893659|FG004|Part 2 Dose Level 2|Lost to Follow-up|0
6222645|NCT01682811|9893660|FG005|Part 2 Dose Level 2|Lost to Follow-up|3
6222646|NCT01682811|9893661|FG006|Part 2 Dose Level 2|Lost to Follow-up|0
6222647|NCT01682837|9893680|FG000|Baseline|Withdrawal by Subject|5
6222648|NCT01682863|9893693|FG000|Overall Study|Subject/guardian decision|19
6222649|NCT01682863|9893694|FG001|Overall Study|Subject/guardian decision|12
6222650|NCT01682863|9893695|FG002|Overall Study|Subject/guardian decision|10
6222651|NCT01682863|9893693|FG000|Overall Study|Lost to Follow-up|5
6222652|NCT01682863|9893694|FG001|Overall Study|Lost to Follow-up|1
6222653|NCT01682863|9893695|FG002|Overall Study|Lost to Follow-up|6
6222654|NCT01682863|9893693|FG000|Overall Study|Death|1
6222655|NCT01682863|9893694|FG001|Overall Study|Death|3
6222656|NCT01682863|9893695|FG002|Overall Study|Death|4
6222657|NCT01682863|9893693|FG000|Overall Study|Protocol deviation|1
6222658|NCT01682863|9893694|FG001|Overall Study|Protocol deviation|0
6222659|NCT01682863|9893695|FG002|Overall Study|Protocol deviation|1
6222660|NCT01682863|9893693|FG000|Overall Study|Technical problems|1
6222661|NCT01682863|9893694|FG001|Overall Study|Technical problems|0
6222662|NCT01682863|9893695|FG002|Overall Study|Technical problems|0
6222663|NCT01682863|9893693|FG000|Overall Study|Adverse Event|0
6222664|NCT01682863|9893694|FG001|Overall Study|Adverse Event|1
6222665|NCT01682863|9893695|FG002|Overall Study|Adverse Event|2
6222666|NCT01682863|9893693|FG000|Overall Study|Physician Decision|0
6222667|NCT01682863|9893694|FG001|Overall Study|Physician Decision|0
6222668|NCT01682863|9893695|FG002|Overall Study|Physician Decision|1
6222669|NCT01682876|9893707|FG000|Overall Study|Administrative reason|4
6222670|NCT01682876|9893708|FG001|Overall Study|Administrative reason|4
6222671|NCT01682876|9893709|FG002|Overall Study|Administrative reason|0
6222672|NCT01682876|9893710|FG003|Overall Study|Administrative reason|3
6222673|NCT01682876|9893707|FG000|Overall Study|Adverse Event|0
6222674|NCT01682876|9893708|FG001|Overall Study|Adverse Event|0
6222675|NCT01682876|9893709|FG002|Overall Study|Adverse Event|0
6222676|NCT01682876|9893710|FG003|Overall Study|Adverse Event|1
6222677|NCT01682876|9893707|FG000|Overall Study|Lost to Follow-up|11
6222678|NCT01682876|9893708|FG001|Overall Study|Lost to Follow-up|15
6222679|NCT01682876|9893709|FG002|Overall Study|Lost to Follow-up|9
6132176|NCT00972816|9759823|FG004|Overall Study|Unable to classify|1
6132177|NCT00972816|9759824|FG005|Overall Study|Unable to classify|0
6132178|NCT00972816|9759825|FG006|Overall Study|Unable to classify|0
6132179|NCT00972816|9759826|FG007|Overall Study|Unable to classify|0
6132180|NCT00973102|9759850|FG000|Overall Study|Protocol Violation|1
6132181|NCT00973102|9759851|FG001|Overall Study|Protocol Violation|0
6132182|NCT00973102|9759850|FG000|Overall Study|Prisoner|0
6132183|NCT00973102|9759851|FG001|Overall Study|Prisoner|1
6222680|NCT01682876|9893710|FG003|Overall Study|Lost to Follow-up|11
6222681|NCT01682876|9893707|FG000|Overall Study|Protocol Violation|1
6222682|NCT01682876|9893708|FG001|Overall Study|Protocol Violation|1
6222683|NCT01682876|9893709|FG002|Overall Study|Protocol Violation|1
6222684|NCT01682876|9893710|FG003|Overall Study|Protocol Violation|1
6222685|NCT01682876|9893707|FG000|Overall Study|Withdrawal by Subject|4
6289787|NCT02391116|10005527|FG000|Safety Follow-up|Adverse Event|1
6132184|NCT00973349|9759873|FG000|Overall Study|Adverse Event|0
6132185|NCT00973349|9759874|FG001|Overall Study|Adverse Event|0
6132186|NCT00973349|9759875|FG002|Overall Study|Adverse Event|0
6132187|NCT00973349|9759876|FG003|Overall Study|Adverse Event|0
6222686|NCT01682876|9893708|FG001|Overall Study|Withdrawal by Subject|0
6132188|NCT00973349|9759877|FG004|Overall Study|Adverse Event|1
6222687|NCT01682876|9893709|FG002|Overall Study|Withdrawal by Subject|0
6132189|NCT00973349|9759878|FG005|Overall Study|Adverse Event|0
6132190|NCT00973349|9759879|FG006|Overall Study|Adverse Event|0
6132191|NCT00973349|9759880|FG007|Overall Study|Adverse Event|0
6132192|NCT00973349|9759881|FG008|Overall Study|Adverse Event|1
6132193|NCT00973349|9759882|FG009|Overall Study|Adverse Event|0
6132194|NCT00973349|9759883|FG010|Overall Study|Adverse Event|0
6132195|NCT00973349|9759884|FG011|Overall Study|Adverse Event|0
6132196|NCT00973349|9759885|FG012|Overall Study|Adverse Event|0
6222688|NCT01682876|9893710|FG003|Overall Study|Withdrawal by Subject|2
6222689|NCT01682876|9893707|FG000|Overall Study|Other|1
6222690|NCT01682876|9893708|FG001|Overall Study|Other|0
6222691|NCT01682876|9893709|FG002|Overall Study|Other|1
6222692|NCT01682876|9893710|FG003|Overall Study|Other|1
6222693|NCT01683019|9893735|FG000|Overall Study|Withdrawal by Subject|2
6222694|NCT01683019|9893736|FG001|Overall Study|Withdrawal by Subject|1
6222695|NCT01683019|9893737|FG002|Overall Study|Withdrawal by Subject|4
6222696|NCT01683058|9893745|FG000|Overall Study|Lost to Follow-up|9
6222697|NCT01683058|9893745|FG000|Overall Study|Adverse Event|6
6222698|NCT01683058|9893745|FG000|Overall Study|Subject Met Withdrawal Criteria|5
6222699|NCT01683058|9893745|FG000|Overall Study|Withdrawal by Subject|7
6222700|NCT01683058|9893745|FG000|Overall Study|Lack of Efficacy|2
6222701|NCT01683071|9893756|FG000|Part 1|Lack of Efficacy|1
6222702|NCT01683071|9893757|FG001|Part 1|Lack of Efficacy|0
6222703|NCT01683071|9893758|FG002|Part 1|Lack of Efficacy|0
6222704|NCT01683071|9893759|FG003|Part 1|Lack of Efficacy|3
6222705|NCT01683071|9893760|FG004|Part 1|Lack of Efficacy|0
6222706|NCT01683071|9893761|FG005|Part 1|Lack of Efficacy|0
6222707|NCT01683071|9893756|FG000|Part 1|Withdrawal by Subject|1
6222708|NCT01683071|9893757|FG001|Part 1|Withdrawal by Subject|2
6222709|NCT01683071|9893758|FG002|Part 1|Withdrawal by Subject|2
6222710|NCT01683071|9893759|FG003|Part 1|Withdrawal by Subject|1
6222711|NCT01683071|9893760|FG004|Part 1|Withdrawal by Subject|0
6222712|NCT01683071|9893761|FG005|Part 1|Withdrawal by Subject|0
6222713|NCT01683071|9893756|FG000|Part 1|Surgery Cancelled|1
6222714|NCT01683071|9893757|FG001|Part 1|Surgery Cancelled|0
6222715|NCT01683071|9893758|FG002|Part 1|Surgery Cancelled|0
6222716|NCT01683071|9893759|FG003|Part 1|Surgery Cancelled|0
6222717|NCT01683071|9893760|FG004|Part 1|Surgery Cancelled|0
6222718|NCT01683071|9893761|FG005|Part 1|Surgery Cancelled|0
6222719|NCT01683071|9893756|FG000|Part 1|Did not receive study drug|1
6222720|NCT01683071|9893757|FG001|Part 1|Did not receive study drug|0
6222721|NCT01683071|9893758|FG002|Part 1|Did not receive study drug|0
6222722|NCT01683071|9893759|FG003|Part 1|Did not receive study drug|1
6222723|NCT01683071|9893760|FG004|Part 1|Did not receive study drug|0
6222724|NCT01683071|9893761|FG005|Part 1|Did not receive study drug|0
6222725|NCT01683071|9893756|FG000|Part 1|Early termination; met exclusion criteria|0
6222726|NCT01683071|9893757|FG001|Part 1|Early termination; met exclusion criteria|2
6222727|NCT01683071|9893758|FG002|Part 1|Early termination; met exclusion criteria|1
6222728|NCT01683071|9893759|FG003|Part 1|Early termination; met exclusion criteria|0
6222729|NCT01683071|9893760|FG004|Part 1|Early termination; met exclusion criteria|0
6222730|NCT01683071|9893761|FG005|Part 1|Early termination; met exclusion criteria|0
6222731|NCT01683071|9893756|FG000|Part 2|Lack of Efficacy|0
6222732|NCT01683071|9893757|FG001|Part 2|Lack of Efficacy|0
6222733|NCT01683071|9893758|FG002|Part 2|Lack of Efficacy|0
6222734|NCT01683071|9893759|FG003|Part 2|Lack of Efficacy|0
6222735|NCT01683071|9893760|FG004|Part 2|Lack of Efficacy|3
6222736|NCT01683071|9893761|FG005|Part 2|Lack of Efficacy|4
6222737|NCT01683071|9893756|FG000|Part 2|Lost to Follow-up|0
6222738|NCT01683071|9893757|FG001|Part 2|Lost to Follow-up|0
6222739|NCT01683071|9893758|FG002|Part 2|Lost to Follow-up|0
6222740|NCT01683071|9893759|FG003|Part 2|Lost to Follow-up|0
6222741|NCT01683071|9893760|FG004|Part 2|Lost to Follow-up|2
6222742|NCT01683071|9893761|FG005|Part 2|Lost to Follow-up|0
6222743|NCT01683071|9893756|FG000|Part 2|Withdrawal by Subject|0
6222744|NCT01683071|9893757|FG001|Part 2|Withdrawal by Subject|0
6222745|NCT01683071|9893758|FG002|Part 2|Withdrawal by Subject|0
6222746|NCT01683071|9893759|FG003|Part 2|Withdrawal by Subject|0
6222747|NCT01683071|9893760|FG004|Part 2|Withdrawal by Subject|3
6222748|NCT01683071|9893761|FG005|Part 2|Withdrawal by Subject|3
6222749|NCT01683071|9893756|FG000|Part 2|Surgery cancelled|0
6222750|NCT01683071|9893757|FG001|Part 2|Surgery cancelled|0
6222751|NCT01683071|9893758|FG002|Part 2|Surgery cancelled|0
6222752|NCT01683071|9893759|FG003|Part 2|Surgery cancelled|0
6222753|NCT01683071|9893760|FG004|Part 2|Surgery cancelled|4
6222754|NCT01683071|9893761|FG005|Part 2|Surgery cancelled|2
6222755|NCT01683071|9893756|FG000|Part 2|Did not receive study drug|0
6289788|NCT02391116|10005527|FG000|Safety Follow-up|Withdrawal by Subject|4
6222756|NCT01683071|9893757|FG001|Part 2|Did not receive study drug|0
6222757|NCT01683071|9893758|FG002|Part 2|Did not receive study drug|0
6222758|NCT01683071|9893759|FG003|Part 2|Did not receive study drug|0
6222759|NCT01683071|9893760|FG004|Part 2|Did not receive study drug|2
6222760|NCT01683071|9893761|FG005|Part 2|Did not receive study drug|1
6222761|NCT01683071|9893756|FG000|Part 2|Met exclusion criterion|0
6132197|NCT00973349|9759886|FG013|Overall Study|Adverse Event|0
6222762|NCT01683071|9893757|FG001|Part 2|Met exclusion criterion|0
6222763|NCT01683071|9893758|FG002|Part 2|Met exclusion criterion|0
6222764|NCT01683071|9893759|FG003|Part 2|Met exclusion criterion|0
6222765|NCT01683071|9893760|FG004|Part 2|Met exclusion criterion|1
6222766|NCT01683071|9893761|FG005|Part 2|Met exclusion criterion|1
6132198|NCT00973349|9759887|FG014|Overall Study|Adverse Event|1
6132199|NCT00973349|9759888|FG015|Overall Study|Adverse Event|0
6132200|NCT00973349|9759873|FG000|Overall Study|Withdrawal by Subject|1
6132201|NCT00973349|9759874|FG001|Overall Study|Withdrawal by Subject|2
6222767|NCT01683071|9893756|FG000|Part 2|Protocol deviation|0
6222768|NCT01683071|9893757|FG001|Part 2|Protocol deviation|0
6222769|NCT01683071|9893758|FG002|Part 2|Protocol deviation|0
6222770|NCT01683071|9893759|FG003|Part 2|Protocol deviation|0
6222771|NCT01683071|9893760|FG004|Part 2|Protocol deviation|1
6222772|NCT01683071|9893761|FG005|Part 2|Protocol deviation|2
6222773|NCT01683071|9893756|FG000|Part 2|Withdrawal by investigator decision|0
6222774|NCT01683071|9893757|FG001|Part 2|Withdrawal by investigator decision|0
6222775|NCT01683071|9893758|FG002|Part 2|Withdrawal by investigator decision|0
6222776|NCT01683071|9893759|FG003|Part 2|Withdrawal by investigator decision|0
6222777|NCT01683071|9893760|FG004|Part 2|Withdrawal by investigator decision|1
6222778|NCT01683071|9893761|FG005|Part 2|Withdrawal by investigator decision|2
6222779|NCT01683266|9893783|FG000|Overall Study|Adverse Event|5
6222780|NCT01683266|9893784|FG001|Overall Study|Adverse Event|4
6222781|NCT01683266|9893783|FG000|Overall Study|Lack of Efficacy|5
6222782|NCT01683266|9893784|FG001|Overall Study|Lack of Efficacy|2
6222783|NCT01683266|9893783|FG000|Overall Study|Protocol Violation|13
6222784|NCT01683266|9893784|FG001|Overall Study|Protocol Violation|6
6222785|NCT01683266|9893783|FG000|Overall Study|Personal Reason|17
6222786|NCT01683266|9893784|FG001|Overall Study|Personal Reason|25
6222787|NCT01683266|9893783|FG000|Overall Study|Selection Criterion / Protocol Violation|7
6222788|NCT01683266|9893784|FG001|Overall Study|Selection Criterion / Protocol Violation|5
6222789|NCT01683266|9893783|FG000|Overall Study|Lost to Follow-up|5
6222790|NCT01683266|9893784|FG001|Overall Study|Lost to Follow-up|0
6222791|NCT01683266|9893783|FG000|Overall Study|Site Closure / Site Withdrawal|1
6222792|NCT01683266|9893784|FG001|Overall Study|Site Closure / Site Withdrawal|3
6222793|NCT01683266|9893783|FG000|Overall Study|Nonserious Hypoglycemia|0
6222794|NCT01683266|9893784|FG001|Overall Study|Nonserious Hypoglycemia|3
6222795|NCT01683266|9893783|FG000|Overall Study|Perceived Lack of Efficacy|1
6222796|NCT01683266|9893784|FG001|Overall Study|Perceived Lack of Efficacy|1
6222797|NCT01683266|9893783|FG000|Overall Study|Possibly Hypoglycemia|1
6222798|NCT01683266|9893784|FG001|Overall Study|Possibly Hypoglycemia|0
6222799|NCT01683266|9893783|FG000|Overall Study|Serious Adverse Event of Hypoglycemia|0
6222800|NCT01683266|9893784|FG001|Overall Study|Serious Adverse Event of Hypoglycemia|1
6222801|NCT01683383|9893801|FG000|Overall Study|Infant was not transported|1
6222802|NCT01683383|9893802|FG001|Overall Study|Infant was not transported|0
6222803|NCT01683409|9893813|FG000|Treatment Period (Weeks 1-24)|Inappropriately Enrolled|0
6289789|NCT02391116|10005527|FG000|Safety Follow-up|Switching to Other Therapy|4
6289790|NCT02391116|10005527|FG000|Safety Follow-up|No Follow Up|1
6289791|NCT02391116|10005527|FG000|Safety Follow-up|Deterioration of General Conditions|3
6289792|NCT02391116|10005527|FG000|Active Follow-up|Withdrawal by Subject|1
6289793|NCT02391116|10005527|FG000|Active Follow-up|Switching to Other Therapy|2
6289794|NCT02391116|10005527|FG000|Survival Follow-up|Withdrawal by Subject|3
6289795|NCT02391116|10005527|FG000|Survival Follow-up|Switching to Other Therapy|1
6289796|NCT02391311|10005540|FG000|Overall Study|Lost to Follow-up|2
6289797|NCT02391311|10005541|FG001|Overall Study|Lost to Follow-up|1
6289798|NCT02391311|10005540|FG000|Overall Study|deemed ineligible after baseline|1
6289799|NCT02391311|10005541|FG001|Overall Study|deemed ineligible after baseline|1
6289800|NCT02391337|10005549|FG000|6 Months Follow-up|Death|5
6289801|NCT02391337|10005550|FG001|6 Months Follow-up|Death|4
6289802|NCT02391337|10005549|FG000|6 Months Follow-up|Withdrawal by Subject|1
6289803|NCT02391337|10005550|FG001|6 Months Follow-up|Withdrawal by Subject|1
6289804|NCT02391337|10005549|FG000|12 Months Follow-up|Death|2
6289805|NCT02391337|10005550|FG001|12 Months Follow-up|Death|0
6289806|NCT02391337|10005549|FG000|12 Months Follow-up|Withdrawal by Subject|0
6289807|NCT02391337|10005550|FG001|12 Months Follow-up|Withdrawal by Subject|1
6289808|NCT02391337|10005549|FG000|12 Months Follow-up|Lost to Follow-up|0
6289809|NCT02391337|10005550|FG001|12 Months Follow-up|Lost to Follow-up|2
6289810|NCT02391363|10005567|FG000|Overall Study|Lost to Follow-up|5
6289811|NCT02391363|10005568|FG001|Overall Study|Lost to Follow-up|5
6289812|NCT02391363|10005567|FG000|Overall Study|Withdrawal by Subject|6
6289813|NCT02391363|10005568|FG001|Overall Study|Withdrawal by Subject|3
6289814|NCT02391545|10005576|FG000|Overall Study|Death|0
6289815|NCT02391545|10005577|FG001|Overall Study|Death|2
6289816|NCT02391545|10005576|FG000|Overall Study|Lost to Follow-up|0
6289817|NCT02391545|10005577|FG001|Overall Study|Lost to Follow-up|1
6289818|NCT02391545|10005576|FG000|Overall Study|Termination of study by sponsor|20
6289819|NCT02391545|10005577|FG001|Overall Study|Termination of study by sponsor|20
6222804|NCT01683409|9893814|FG001|Treatment Period (Weeks 1-24)|Inappropriately Enrolled|0
6222805|NCT01683409|9893815|FG002|Treatment Period (Weeks 1-24)|Inappropriately Enrolled|1
6222806|NCT01683409|9893816|FG003|Treatment Period (Weeks 1-24)|Inappropriately Enrolled|0
6222807|NCT01683409|9893817|FG004|Treatment Period (Weeks 1-24)|Inappropriately Enrolled|0
6289820|NCT02391545|10005576|FG000|Overall Study|Withdrawal by Subject|0
6289821|NCT02391545|10005577|FG001|Overall Study|Withdrawal by Subject|1
6289822|NCT02391545|10005576|FG000|Overall Study|Other Reasons|6
6289823|NCT02391545|10005577|FG001|Overall Study|Other Reasons|4
6289824|NCT02391584|10005586|FG000|Primary Endpoint (6-weeks)|Lost to Follow-up|1
6289825|NCT02391584|10005587|FG001|Primary Endpoint (6-weeks)|Lost to Follow-up|2
6132202|NCT00973349|9759875|FG002|Overall Study|Withdrawal by Subject|2
6132203|NCT00973349|9759876|FG003|Overall Study|Withdrawal by Subject|3
6132204|NCT00973349|9759877|FG004|Overall Study|Withdrawal by Subject|2
6132205|NCT00973349|9759878|FG005|Overall Study|Withdrawal by Subject|0
6132206|NCT00973349|9759879|FG006|Overall Study|Withdrawal by Subject|2
6132207|NCT00973349|9759880|FG007|Overall Study|Withdrawal by Subject|2
6132208|NCT00973349|9759881|FG008|Overall Study|Withdrawal by Subject|0
6132209|NCT00973349|9759882|FG009|Overall Study|Withdrawal by Subject|2
6132210|NCT00973349|9759883|FG010|Overall Study|Withdrawal by Subject|0
6132211|NCT00973349|9759884|FG011|Overall Study|Withdrawal by Subject|1
6132212|NCT00973349|9759885|FG012|Overall Study|Withdrawal by Subject|0
6132213|NCT00973349|9759886|FG013|Overall Study|Withdrawal by Subject|0
6132214|NCT00973349|9759887|FG014|Overall Study|Withdrawal by Subject|0
6132215|NCT00973349|9759888|FG015|Overall Study|Withdrawal by Subject|0
6132216|NCT00973349|9759873|FG000|Overall Study|Lost to Follow-up|3
6132217|NCT00973349|9759874|FG001|Overall Study|Lost to Follow-up|1
6132218|NCT00973349|9759875|FG002|Overall Study|Lost to Follow-up|2
6132219|NCT00973349|9759876|FG003|Overall Study|Lost to Follow-up|2
6132220|NCT00973349|9759877|FG004|Overall Study|Lost to Follow-up|1
6132221|NCT00973349|9759878|FG005|Overall Study|Lost to Follow-up|3
6132222|NCT00973349|9759879|FG006|Overall Study|Lost to Follow-up|0
6132223|NCT00973349|9759880|FG007|Overall Study|Lost to Follow-up|1
6132224|NCT00973349|9759881|FG008|Overall Study|Lost to Follow-up|2
6132225|NCT00973349|9759882|FG009|Overall Study|Lost to Follow-up|1
6132226|NCT00973349|9759883|FG010|Overall Study|Lost to Follow-up|0
6132227|NCT00973349|9759884|FG011|Overall Study|Lost to Follow-up|1
6132228|NCT00973349|9759885|FG012|Overall Study|Lost to Follow-up|0
6132229|NCT00973349|9759886|FG013|Overall Study|Lost to Follow-up|0
6132230|NCT00973349|9759887|FG014|Overall Study|Lost to Follow-up|0
6132231|NCT00973349|9759888|FG015|Overall Study|Lost to Follow-up|1
6132232|NCT00973349|9759873|FG000|Overall Study|Inappropriate enrolment|0
6132233|NCT00973349|9759874|FG001|Overall Study|Inappropriate enrolment|0
6132234|NCT00973349|9759875|FG002|Overall Study|Inappropriate enrolment|1
6222808|NCT01683409|9893813|FG000|Treatment Period (Weeks 1-24)|Adverse Event|0
6222809|NCT01683409|9893814|FG001|Treatment Period (Weeks 1-24)|Adverse Event|3
6222810|NCT01683409|9893815|FG002|Treatment Period (Weeks 1-24)|Adverse Event|0
6222811|NCT01683409|9893816|FG003|Treatment Period (Weeks 1-24)|Adverse Event|1
6222812|NCT01683409|9893817|FG004|Treatment Period (Weeks 1-24)|Adverse Event|1
6222813|NCT01683409|9893813|FG000|Treatment Period (Weeks 1-24)|Lost to Follow-up|0
6222814|NCT01683409|9893814|FG001|Treatment Period (Weeks 1-24)|Lost to Follow-up|1
6289826|NCT02391584|10005586|FG000|Primary Endpoint (6-weeks)|Missed primary endpoint visit|1
6289827|NCT02391584|10005587|FG001|Primary Endpoint (6-weeks)|Missed primary endpoint visit|0
6289828|NCT02391584|10005586|FG000|3 Month|Lost to Follow-up|1
6289829|NCT02391584|10005587|FG001|3 Month|Lost to Follow-up|0
6289830|NCT02391584|10005586|FG000|6 Month|Withdrawal by Subject|1
6289831|NCT02391584|10005587|FG001|6 Month|Withdrawal by Subject|0
6289832|NCT02391584|10005586|FG000|12 Month (End of Study)|Lost to Follow-up|2
6289833|NCT02391584|10005587|FG001|12 Month (End of Study)|Lost to Follow-up|0
6289834|NCT02391948|10005621|FG000|6-month Assessment|Death|0
6289835|NCT02391948|10005622|FG001|6-month Assessment|Death|0
6289836|NCT02391948|10005623|FG002|6-month Assessment|Death|0
6289837|NCT02391948|10005624|FG003|6-month Assessment|Death|0
6289838|NCT02391948|10005625|FG004|6-month Assessment|Death|1
6289839|NCT02391948|10005621|FG000|6-month Assessment|Withdrawal by Subject|0
6289840|NCT02391948|10005622|FG001|6-month Assessment|Withdrawal by Subject|0
6289841|NCT02391948|10005623|FG002|6-month Assessment|Withdrawal by Subject|1
6289842|NCT02391948|10005624|FG003|6-month Assessment|Withdrawal by Subject|2
6289843|NCT02391948|10005625|FG004|6-month Assessment|Withdrawal by Subject|0
6289844|NCT02391948|10005621|FG000|6-month Assessment|Lost to Follow-up|4
6289845|NCT02391948|10005622|FG001|6-month Assessment|Lost to Follow-up|5
6289846|NCT02391948|10005623|FG002|6-month Assessment|Lost to Follow-up|2
6289847|NCT02391948|10005624|FG003|6-month Assessment|Lost to Follow-up|3
6289848|NCT02391948|10005625|FG004|6-month Assessment|Lost to Follow-up|1
6289849|NCT02391948|10005621|FG000|6-month Assessment|Medical issue/illness|1
6289850|NCT02391948|10005622|FG001|6-month Assessment|Medical issue/illness|1
6289851|NCT02391948|10005623|FG002|6-month Assessment|Medical issue/illness|0
6289852|NCT02391948|10005624|FG003|6-month Assessment|Medical issue/illness|0
6289853|NCT02391948|10005625|FG004|6-month Assessment|Medical issue/illness|0
6289854|NCT02391948|10005621|FG000|6-month Assessment|Not able to schedule visit in timeframe|6
6289855|NCT02391948|10005622|FG001|6-month Assessment|Not able to schedule visit in timeframe|8
6289856|NCT02391948|10005623|FG002|6-month Assessment|Not able to schedule visit in timeframe|4
6289857|NCT02391948|10005624|FG003|6-month Assessment|Not able to schedule visit in timeframe|5
6289858|NCT02391948|10005625|FG004|6-month Assessment|Not able to schedule visit in timeframe|0
6289859|NCT02391948|10005621|FG000|6-month Assessment|In 2-visit study (6-month N/A)|68
6289860|NCT02391948|10005622|FG001|6-month Assessment|In 2-visit study (6-month N/A)|42
6289861|NCT02391948|10005623|FG002|6-month Assessment|In 2-visit study (6-month N/A)|24
6132235|NCT00973349|9759876|FG003|Overall Study|Inappropriate enrolment|0
6132236|NCT00973349|9759877|FG004|Overall Study|Inappropriate enrolment|0
6132237|NCT00973349|9759878|FG005|Overall Study|Inappropriate enrolment|0
6132238|NCT00973349|9759879|FG006|Overall Study|Inappropriate enrolment|0
6132239|NCT00973349|9759880|FG007|Overall Study|Inappropriate enrolment|0
6132240|NCT00973349|9759881|FG008|Overall Study|Inappropriate enrolment|0
6132241|NCT00973349|9759882|FG009|Overall Study|Inappropriate enrolment|2
6132242|NCT00973349|9759883|FG010|Overall Study|Inappropriate enrolment|0
6132243|NCT00973349|9759884|FG011|Overall Study|Inappropriate enrolment|0
6132244|NCT00973349|9759885|FG012|Overall Study|Inappropriate enrolment|1
6132245|NCT00973349|9759886|FG013|Overall Study|Inappropriate enrolment|0
6132246|NCT00973349|9759887|FG014|Overall Study|Inappropriate enrolment|1
6132247|NCT00973349|9759888|FG015|Overall Study|Inappropriate enrolment|1
6132248|NCT00973349|9759873|FG000|Overall Study|Protocol Violation|0
6132249|NCT00973349|9759874|FG001|Overall Study|Protocol Violation|0
6132250|NCT00973349|9759875|FG002|Overall Study|Protocol Violation|0
6132251|NCT00973349|9759876|FG003|Overall Study|Protocol Violation|0
6132252|NCT00973349|9759877|FG004|Overall Study|Protocol Violation|0
6132253|NCT00973349|9759878|FG005|Overall Study|Protocol Violation|0
6132254|NCT00973349|9759879|FG006|Overall Study|Protocol Violation|0
6132255|NCT00973349|9759880|FG007|Overall Study|Protocol Violation|0
6132256|NCT00973349|9759881|FG008|Overall Study|Protocol Violation|1
6132257|NCT00973349|9759882|FG009|Overall Study|Protocol Violation|0
6132258|NCT00973349|9759883|FG010|Overall Study|Protocol Violation|0
6132259|NCT00973349|9759884|FG011|Overall Study|Protocol Violation|0
6132260|NCT00973349|9759885|FG012|Overall Study|Protocol Violation|0
6132261|NCT00973349|9759886|FG013|Overall Study|Protocol Violation|0
6132262|NCT00973349|9759887|FG014|Overall Study|Protocol Violation|0
6132263|NCT00973349|9759888|FG015|Overall Study|Protocol Violation|0
6132264|NCT00973349|9759873|FG000|Overall Study|Unable to classify|0
6132265|NCT00973349|9759874|FG001|Overall Study|Unable to classify|0
6132266|NCT00973349|9759875|FG002|Overall Study|Unable to classify|0
6222815|NCT01683409|9893815|FG002|Treatment Period (Weeks 1-24)|Lost to Follow-up|0
6222816|NCT01683409|9893816|FG003|Treatment Period (Weeks 1-24)|Lost to Follow-up|0
6222817|NCT01683409|9893817|FG004|Treatment Period (Weeks 1-24)|Lost to Follow-up|0
6222818|NCT01683409|9893813|FG000|Treatment Period (Weeks 1-24)|Withdrawal by Subject|0
6222819|NCT01683409|9893814|FG001|Treatment Period (Weeks 1-24)|Withdrawal by Subject|0
6222820|NCT01683409|9893815|FG002|Treatment Period (Weeks 1-24)|Withdrawal by Subject|0
6222821|NCT01683409|9893816|FG003|Treatment Period (Weeks 1-24)|Withdrawal by Subject|1
6222822|NCT01683409|9893817|FG004|Treatment Period (Weeks 1-24)|Withdrawal by Subject|1
6222823|NCT01683409|9893813|FG000|Washout Period 1 (Weeks 25-28)|Lost to Follow-up|0
6222824|NCT01683409|9893814|FG001|Washout Period 1 (Weeks 25-28)|Lost to Follow-up|0
6222825|NCT01683409|9893815|FG002|Washout Period 1 (Weeks 25-28)|Lost to Follow-up|1
6222826|NCT01683409|9893816|FG003|Washout Period 1 (Weeks 25-28)|Lost to Follow-up|0
6222827|NCT01683409|9893817|FG004|Washout Period 1 (Weeks 25-28)|Lost to Follow-up|0
6132267|NCT00973349|9759876|FG003|Overall Study|Unable to classify|0
6132268|NCT00973349|9759877|FG004|Overall Study|Unable to classify|1
6132269|NCT00973349|9759878|FG005|Overall Study|Unable to classify|1
6132270|NCT00973349|9759879|FG006|Overall Study|Unable to classify|0
6132271|NCT00973349|9759880|FG007|Overall Study|Unable to classify|0
6289862|NCT02391948|10005624|FG003|6-month Assessment|In 2-visit study (6-month N/A)|35
6289863|NCT02391948|10005625|FG004|6-month Assessment|In 2-visit study (6-month N/A)|24
6132272|NCT00973349|9759881|FG008|Overall Study|Unable to classify|0
6132273|NCT00973349|9759882|FG009|Overall Study|Unable to classify|1
6132274|NCT00973349|9759883|FG010|Overall Study|Unable to classify|0
6132275|NCT00973349|9759884|FG011|Overall Study|Unable to classify|0
6132276|NCT00973349|9759885|FG012|Overall Study|Unable to classify|0
6132277|NCT00973349|9759886|FG013|Overall Study|Unable to classify|0
6132278|NCT00973349|9759887|FG014|Overall Study|Unable to classify|0
6132279|NCT00973349|9759888|FG015|Overall Study|Unable to classify|0
6132280|NCT00973362|9759916|FG000|Baseline Evaluation|W/D, later determined to be ineligible|25
6132281|NCT00973362|9759917|FG001|Baseline Evaluation|W/D, later determined to be ineligible|0
6132282|NCT00973362|9759916|FG000|Baseline Evaluation|No colposcopy visit|62
6132283|NCT00973362|9759917|FG001|Baseline Evaluation|No colposcopy visit|0
6132284|NCT00973362|9759916|FG000|Baseline Evaluation|Inevaluable|686
6132285|NCT00973362|9759917|FG001|Baseline Evaluation|Inevaluable|223
6132286|NCT00973362|9759916|FG000|3-Year Follow-up|Lost to Follow-up|17
6132287|NCT00973362|9759917|FG001|3-Year Follow-up|Lost to Follow-up|0
6132288|NCT00973479|9759928|FG000|Overall Study|Lost to Follow-up|0
6132289|NCT00973479|9759929|FG001|Overall Study|Lost to Follow-up|3
6132290|NCT00973479|9759928|FG000|Overall Study|Death|2
6132291|NCT00973479|9759929|FG001|Overall Study|Death|2
6132292|NCT00973479|9759928|FG000|Overall Study|Withdrawal by Subject|15
6132293|NCT00973479|9759929|FG001|Overall Study|Withdrawal by Subject|16
6132294|NCT00973479|9759928|FG000|Overall Study|Lack of Efficacy|5
6132295|NCT00973479|9759929|FG001|Overall Study|Lack of Efficacy|7
6132296|NCT00973479|9759928|FG000|Overall Study|Adverse Event|12
6132297|NCT00973479|9759929|FG001|Overall Study|Adverse Event|32
6132298|NCT00973479|9759928|FG000|Overall Study|Protocol Violation|2
6132299|NCT00973479|9759929|FG001|Overall Study|Protocol Violation|2
6132300|NCT00973479|9759928|FG000|Overall Study|Other|1
6132301|NCT00973479|9759929|FG001|Overall Study|Other|7
6132302|NCT00973622|9759939|FG000|Overall Study|did not attend MRI|14
6132303|NCT00973622|9759940|FG001|Overall Study|did not attend MRI|3
6132304|NCT00973622|9759939|FG000|Overall Study|did not pass MRI screen|6
6132305|NCT00973622|9759940|FG001|Overall Study|did not pass MRI screen|0
6132306|NCT00973622|9759939|FG000|Overall Study|did not complete rTMS sessions|11
6132307|NCT00973622|9759940|FG001|Overall Study|did not complete rTMS sessions|2
6132308|NCT00973674|9759948|FG000|Overall Study|Protocol Violation|2
6132309|NCT00973674|9759949|FG001|Overall Study|Protocol Violation|0
6132310|NCT00973700|9759961|FG000|Overall Study|Withdrawal by Subject|2
6132311|NCT00973700|9759962|FG001|Overall Study|Withdrawal by Subject|2
6132312|NCT00973700|9759963|FG002|Overall Study|Withdrawal by Subject|8
6132313|NCT00973700|9759964|FG003|Overall Study|Withdrawal by Subject|4
6132314|NCT00973700|9759965|FG004|Overall Study|Withdrawal by Subject|4
6132315|NCT00973700|9759961|FG000|Overall Study|Lost to Follow-up|5
6132316|NCT00973700|9759962|FG001|Overall Study|Lost to Follow-up|0
6132317|NCT00973700|9759963|FG002|Overall Study|Lost to Follow-up|1
6132318|NCT00973700|9759964|FG003|Overall Study|Lost to Follow-up|8
6132319|NCT00973700|9759965|FG004|Overall Study|Lost to Follow-up|5
6132320|NCT00973700|9759961|FG000|Overall Study|Inappropriate enrolment|0
6132321|NCT00973700|9759962|FG001|Overall Study|Inappropriate enrolment|0
6132322|NCT00973700|9759963|FG002|Overall Study|Inappropriate enrolment|0
6132323|NCT00973700|9759964|FG003|Overall Study|Inappropriate enrolment|4
6132324|NCT00973700|9759965|FG004|Overall Study|Inappropriate enrolment|0
6132325|NCT00973700|9759961|FG000|Overall Study|Unable to Classify|0
6132326|NCT00973700|9759962|FG001|Overall Study|Unable to Classify|0
6132327|NCT00973700|9759963|FG002|Overall Study|Unable to Classify|1
6132328|NCT00973700|9759964|FG003|Overall Study|Unable to Classify|2
6132329|NCT00973700|9759965|FG004|Overall Study|Unable to Classify|1
6132330|NCT00973765|9760002|FG000|Overall Study|Lost to Follow-up|8
6132331|NCT00973765|9760003|FG001|Overall Study|Lost to Follow-up|14
6132332|NCT00973921|9760009|FG000|Overall Study|IVUS results were not available|9
6132333|NCT00973973|9760015|FG000|Double-blind Treatment Phase (Weeks 1-8)|Adverse Event|1
6132334|NCT00973973|9760016|FG001|Double-blind Treatment Phase (Weeks 1-8)|Adverse Event|3
6132335|NCT00973973|9760015|FG000|Double-blind Treatment Phase (Weeks 1-8)|Protocol Deviation|1
6132336|NCT00973973|9760016|FG001|Double-blind Treatment Phase (Weeks 1-8)|Protocol Deviation|0
6132337|NCT00973973|9760015|FG000|Double-blind Treatment Phase (Weeks 1-8)|Withdrawal by Subject|1
6132338|NCT00973973|9760016|FG001|Double-blind Treatment Phase (Weeks 1-8)|Withdrawal by Subject|3
6132339|NCT00973973|9760015|FG000|Double-blind Treatment Phase (Weeks 1-8)|Lack of Efficacy|1
6132340|NCT00973973|9760016|FG001|Double-blind Treatment Phase (Weeks 1-8)|Lack of Efficacy|0
6132341|NCT00973973|9760015|FG000|Double-blind Treatment Phase (Weeks 1-8)|Lost to Follow-up|1
6132342|NCT00973973|9760016|FG001|Double-blind Treatment Phase (Weeks 1-8)|Lost to Follow-up|1
6132343|NCT00973973|9760015|FG000|Double-blind Treatment Phase (Weeks 1-8)|Sponsor/Investigator Decision|1
6132344|NCT00973973|9760016|FG001|Double-blind Treatment Phase (Weeks 1-8)|Sponsor/Investigator Decision|1
6132345|NCT00973973|9760015|FG000|Open-label Treatment Phase (Weeks 8-24)|Adverse Event|1
6222828|NCT01683409|9893813|FG000|Washout Period 1 (Weeks 25-28)|Protocol Violation|1
6222829|NCT01683409|9893814|FG001|Washout Period 1 (Weeks 25-28)|Protocol Violation|0
6222830|NCT01683409|9893815|FG002|Washout Period 1 (Weeks 25-28)|Protocol Violation|0
6222831|NCT01683409|9893816|FG003|Washout Period 1 (Weeks 25-28)|Protocol Violation|1
6222832|NCT01683409|9893817|FG004|Washout Period 1 (Weeks 25-28)|Protocol Violation|0
6222833|NCT01683409|9893813|FG000|Washout Period 1 (Weeks 25-28)|Withdrawal by Subject|1
6222834|NCT01683409|9893814|FG001|Washout Period 1 (Weeks 25-28)|Withdrawal by Subject|0
6222835|NCT01683409|9893815|FG002|Washout Period 1 (Weeks 25-28)|Withdrawal by Subject|0
6222836|NCT01683409|9893816|FG003|Washout Period 1 (Weeks 25-28)|Withdrawal by Subject|0
6222837|NCT01683409|9893817|FG004|Washout Period 1 (Weeks 25-28)|Withdrawal by Subject|1
6222838|NCT01683409|9893813|FG000|Washout Period 1 (Weeks 25-28)|Physician Decision|1
6222839|NCT01683409|9893814|FG001|Washout Period 1 (Weeks 25-28)|Physician Decision|0
6222840|NCT01683409|9893815|FG002|Washout Period 1 (Weeks 25-28)|Physician Decision|0
6222841|NCT01683409|9893816|FG003|Washout Period 1 (Weeks 25-28)|Physician Decision|0
6222842|NCT01683409|9893817|FG004|Washout Period 1 (Weeks 25-28)|Physician Decision|0
6222843|NCT01683409|9893813|FG000|Washout Period 1 (Weeks 25-28)|Adverse Event|0
6222844|NCT01683409|9893814|FG001|Washout Period 1 (Weeks 25-28)|Adverse Event|4
6222845|NCT01683409|9893815|FG002|Washout Period 1 (Weeks 25-28)|Adverse Event|0
6222846|NCT01683409|9893816|FG003|Washout Period 1 (Weeks 25-28)|Adverse Event|1
6222847|NCT01683409|9893817|FG004|Washout Period 1 (Weeks 25-28)|Adverse Event|2
6222848|NCT01683409|9893813|FG000|Washout Period 2 (Weeks 29-32)|Adverse Event|0
6222849|NCT01683409|9893814|FG001|Washout Period 2 (Weeks 29-32)|Adverse Event|0
6222850|NCT01683409|9893815|FG002|Washout Period 2 (Weeks 29-32)|Adverse Event|0
6289864|NCT02391948|10005621|FG000|12-month Assessment|Death|0
6289865|NCT02391948|10005622|FG001|12-month Assessment|Death|0
6289866|NCT02391948|10005623|FG002|12-month Assessment|Death|0
6289867|NCT02391948|10005624|FG003|12-month Assessment|Death|1
6289868|NCT02391948|10005625|FG004|12-month Assessment|Death|0
6289869|NCT02391948|10005621|FG000|12-month Assessment|Withdrawal by Subject|1
6289870|NCT02391948|10005622|FG001|12-month Assessment|Withdrawal by Subject|0
6289871|NCT02391948|10005623|FG002|12-month Assessment|Withdrawal by Subject|0
6289872|NCT02391948|10005624|FG003|12-month Assessment|Withdrawal by Subject|1
6289873|NCT02391948|10005625|FG004|12-month Assessment|Withdrawal by Subject|0
6289874|NCT02391948|10005621|FG000|12-month Assessment|Lost to Follow-up|5
6289875|NCT02391948|10005622|FG001|12-month Assessment|Lost to Follow-up|4
6289876|NCT02391948|10005623|FG002|12-month Assessment|Lost to Follow-up|4
6289877|NCT02391948|10005624|FG003|12-month Assessment|Lost to Follow-up|4
6289878|NCT02391948|10005625|FG004|12-month Assessment|Lost to Follow-up|5
6289879|NCT02391948|10005621|FG000|12-month Assessment|Medical issue/illness|0
6289880|NCT02391948|10005622|FG001|12-month Assessment|Medical issue/illness|1
6132346|NCT00973973|9760016|FG001|Open-label Treatment Phase (Weeks 8-24)|Adverse Event|2
6132347|NCT00973973|9760015|FG000|Open-label Treatment Phase (Weeks 8-24)|Protocol Deviation|1
6132348|NCT00973973|9760016|FG001|Open-label Treatment Phase (Weeks 8-24)|Protocol Deviation|0
6132349|NCT00973973|9760015|FG000|Open-label Treatment Phase (Weeks 8-24)|Noncompliance|1
6132350|NCT00973973|9760016|FG001|Open-label Treatment Phase (Weeks 8-24)|Noncompliance|0
6132351|NCT00973973|9760015|FG000|Open-label Treatment Phase (Weeks 8-24)|Withdrawal by Subject|1
6132352|NCT00973973|9760016|FG001|Open-label Treatment Phase (Weeks 8-24)|Withdrawal by Subject|3
6132353|NCT00973973|9760015|FG000|Open-label Treatment Phase (Weeks 8-24)|Lost to Follow-up|1
6222851|NCT01683409|9893816|FG003|Washout Period 2 (Weeks 29-32)|Adverse Event|0
6222852|NCT01683409|9893817|FG004|Washout Period 2 (Weeks 29-32)|Adverse Event|3
6222853|NCT01683409|9893813|FG000|Washout Period 2 (Weeks 29-32)|Physician Decision|0
6222854|NCT01683409|9893814|FG001|Washout Period 2 (Weeks 29-32)|Physician Decision|0
6222855|NCT01683409|9893815|FG002|Washout Period 2 (Weeks 29-32)|Physician Decision|1
6222856|NCT01683409|9893816|FG003|Washout Period 2 (Weeks 29-32)|Physician Decision|0
6222857|NCT01683409|9893817|FG004|Washout Period 2 (Weeks 29-32)|Physician Decision|0
6222858|NCT01683565|9893858|FG000|Overall Study|Lost to Follow-up|2
6222859|NCT01683565|9893859|FG001|Overall Study|Lost to Follow-up|0
6222860|NCT01683565|9893858|FG000|Overall Study|Discontinued Intervention|1
6222861|NCT01683565|9893859|FG001|Overall Study|Discontinued Intervention|1
6222862|NCT01683604|9893867|FG000|Overall Study|Adverse Event|2
6222863|NCT01683604|9893867|FG000|Overall Study|Lack of Efficacy|1
6222864|NCT01683604|9893867|FG000|Overall Study|Other|2
6222865|NCT01683838|9893891|FG000|Overall Study|Adverse Event|12
6222866|NCT01683838|9893892|FG001|Overall Study|Adverse Event|2
6222867|NCT01683838|9893891|FG000|Overall Study|Protocol Violation|3
6222868|NCT01683838|9893892|FG001|Overall Study|Protocol Violation|1
6222869|NCT01683838|9893891|FG000|Overall Study|Withdrawal by Subject|6
6222870|NCT01683838|9893892|FG001|Overall Study|Withdrawal by Subject|5
6222871|NCT01683838|9893891|FG000|Overall Study|Lost to Follow-up|1
6222872|NCT01683838|9893892|FG001|Overall Study|Lost to Follow-up|1
6222873|NCT01683838|9893891|FG000|Overall Study|Other|4
6222874|NCT01683838|9893892|FG001|Overall Study|Other|3
6222875|NCT01683994|9893903|FG000|Overall Study|Withdrawal by Subject|1
6222876|NCT01683994|9893904|FG001|Overall Study|Withdrawal by Subject|0
6222877|NCT01683994|9893905|FG002|Overall Study|Withdrawal by Subject|0
6222878|NCT01683994|9893906|FG003|Overall Study|Withdrawal by Subject|1
6222879|NCT01683994|9893907|FG004|Overall Study|Withdrawal by Subject|0
6222880|NCT01683994|9893903|FG000|Overall Study|Intercurrent illness|0
6222881|NCT01683994|9893904|FG001|Overall Study|Intercurrent illness|0
6222882|NCT01683994|9893905|FG002|Overall Study|Intercurrent illness|0
6132354|NCT00973973|9760016|FG001|Open-label Treatment Phase (Weeks 8-24)|Lost to Follow-up|0
6132355|NCT00973973|9760015|FG000|Open-label Treatment Phase (Weeks 8-24)|Sponsor/Investigator Decision|1
6132356|NCT00973973|9760016|FG001|Open-label Treatment Phase (Weeks 8-24)|Sponsor/Investigator Decision|0
6132357|NCT00974090|9760035|FG000|Period 1: Double Blind Period|Adverse Event|2
6132358|NCT00974090|9760036|FG001|Period 1: Double Blind Period|Adverse Event|1
6132359|NCT00974090|9760035|FG000|Period 1: Double Blind Period|Physician Decision|1
6132360|NCT00974090|9760036|FG001|Period 1: Double Blind Period|Physician Decision|0
6132361|NCT00974090|9760035|FG000|Period 2: Open-label Period|Adverse Event|4
6132362|NCT00974090|9760036|FG001|Period 2: Open-label Period|Adverse Event|6
6132363|NCT00974090|9760035|FG000|Period 2: Open-label Period|Lack of Efficacy|3
6132364|NCT00974090|9760036|FG001|Period 2: Open-label Period|Lack of Efficacy|1
6132365|NCT00974090|9760035|FG000|Period 2: Open-label Period|Physician Decision|0
6132366|NCT00974090|9760036|FG001|Period 2: Open-label Period|Physician Decision|3
6132367|NCT00974090|9760035|FG000|Period 2: Open-label Period|Withdrawal by Subject|1
6132368|NCT00974090|9760036|FG001|Period 2: Open-label Period|Withdrawal by Subject|0
6132369|NCT00974220|9760055|FG000|Treatment Period 1|Adverse Event|2
6132370|NCT00974220|9760056|FG001|Treatment Period 1|Adverse Event|1
6132371|NCT00974220|9760055|FG000|Treatment Period 1|noncompliant subjects|0
6132372|NCT00974220|9760056|FG001|Treatment Period 1|noncompliant subjects|1
6222883|NCT01683994|9893906|FG003|Overall Study|Intercurrent illness|2
6222884|NCT01683994|9893907|FG004|Overall Study|Intercurrent illness|1
6222885|NCT01684033|9893943|FG000|Period 1, First 30 Days|Adverse Event|1
6222886|NCT01684033|9893944|FG001|Period 1, First 30 Days|Adverse Event|1
6222887|NCT01684033|9893943|FG000|Period 1, First 30 Days|Noncompliance|1
6222888|NCT01684033|9893944|FG001|Period 1, First 30 Days|Noncompliance|0
6222889|NCT01684033|9893943|FG000|Period 1, First 30 Days|Withdrawal by Subject|1
6222890|NCT01684033|9893944|FG001|Period 1, First 30 Days|Withdrawal by Subject|0
6222891|NCT01684033|9893943|FG000|Period 1, First 30 Days|Lost to Follow-up|1
6222892|NCT01684033|9893944|FG001|Period 1, First 30 Days|Lost to Follow-up|0
6222893|NCT01684033|9893943|FG000|Period 2, Second 30 Days|Adverse Event|1
6222894|NCT01684033|9893944|FG001|Period 2, Second 30 Days|Adverse Event|0
6222895|NCT01684046|9893950|FG000|Period 1, First 30 Days|Adverse Event|0
6222896|NCT01684046|9893951|FG001|Period 1, First 30 Days|Adverse Event|2
6222897|NCT01684202|9893961|FG000|Dose-escalation Period|Adverse Event|0
6222898|NCT01684202|9893962|FG001|Dose-escalation Period|Adverse Event|1
6222899|NCT01684202|9893963|FG002|Dose-escalation Period|Adverse Event|0
6222900|NCT01684202|9893964|FG003|Dose-escalation Period|Adverse Event|0
6289881|NCT02391948|10005623|FG002|12-month Assessment|Medical issue/illness|0
6132373|NCT00974233|9760062|FG000|Induction Chemoimmunotherapy|Death|2
6132374|NCT00974233|9760062|FG000|Induction Chemoimmunotherapy|Lack of Efficacy|5
6132375|NCT00974233|9760062|FG000|Induction Chemoimmunotherapy|Adverse Event|7
6132376|NCT00974233|9760062|FG000|Induction Chemoimmunotherapy|Withdrawal by Subject|1
6132377|NCT00974233|9760062|FG000|Maintenance Lenalidomide|Lack of Efficacy|5
6132378|NCT00974233|9760062|FG000|Maintenance Lenalidomide|Adverse Event|8
6132379|NCT00974259|9760081|FG000|Overall Study|Technically inadequate PbtO2 recordings|2
6132380|NCT00974259|9760082|FG001|Overall Study|Technically inadequate PbtO2 recordings|1
6132381|NCT00974311|9760090|FG000|DB Phase (up to 24 Months)|Lost to Follow-up|5
6132382|NCT00974311|9760091|FG001|DB Phase (up to 24 Months)|Lost to Follow-up|2
6132383|NCT00974311|9760090|FG000|DB Phase (up to 24 Months)|Death|561
6132384|NCT00974311|9760091|FG001|DB Phase (up to 24 Months)|Death|298
6132385|NCT00974311|9760090|FG000|DB Phase (up to 24 Months)|Withdrawal by Subject|16
6132386|NCT00974311|9760091|FG001|DB Phase (up to 24 Months)|Withdrawal by Subject|7
6132387|NCT00974311|9760090|FG000|DB Phase (up to 24 Months)|Study Terminated by Sponsor|108
6132388|NCT00974311|9760091|FG001|DB Phase (up to 24 Months)|Study Terminated by Sponsor|42
6132389|NCT00974311|9760090|FG000|DB Phase (up to 24 Months)|Other|1
6132390|NCT00974311|9760091|FG001|DB Phase (up to 24 Months)|Other|0
6132391|NCT00974311|9760090|FG000|OLE Phase (up to 77 Months)|Death|14
6132392|NCT00974311|9760091|FG001|OLE Phase (up to 77 Months)|Death|21
6132393|NCT00974311|9760090|FG000|OLE Phase (up to 77 Months)|Study Terminated by Sponsor|78
6222901|NCT01684202|9893961|FG000|Dose-escalation Period|Withdrawal by Subject|1
6222902|NCT01684202|9893962|FG001|Dose-escalation Period|Withdrawal by Subject|0
6222903|NCT01684202|9893963|FG002|Dose-escalation Period|Withdrawal by Subject|0
6289882|NCT02391948|10005624|FG003|12-month Assessment|Medical issue/illness|1
6289883|NCT02391948|10005625|FG004|12-month Assessment|Medical issue/illness|0
6289884|NCT02391948|10005621|FG000|12-month Assessment|Not able to schedule visit in timeframe|2
6289885|NCT02391948|10005622|FG001|12-month Assessment|Not able to schedule visit in timeframe|4
6289886|NCT02391948|10005623|FG002|12-month Assessment|Not able to schedule visit in timeframe|0
6289887|NCT02391948|10005624|FG003|12-month Assessment|Not able to schedule visit in timeframe|2
6289888|NCT02391948|10005625|FG004|12-month Assessment|Not able to schedule visit in timeframe|1
6289889|NCT02391948|10005621|FG000|18-month Assessment|Death|0
6289890|NCT02391948|10005622|FG001|18-month Assessment|Death|0
6289891|NCT02391948|10005623|FG002|18-month Assessment|Death|0
6289892|NCT02391948|10005624|FG003|18-month Assessment|Death|1
6289893|NCT02391948|10005625|FG004|18-month Assessment|Death|1
6289894|NCT02391948|10005621|FG000|18-month Assessment|Withdrawal by Subject|1
6289895|NCT02391948|10005622|FG001|18-month Assessment|Withdrawal by Subject|0
6289896|NCT02391948|10005623|FG002|18-month Assessment|Withdrawal by Subject|0
6289897|NCT02391948|10005624|FG003|18-month Assessment|Withdrawal by Subject|1
6289898|NCT02391948|10005625|FG004|18-month Assessment|Withdrawal by Subject|0
6289899|NCT02391948|10005621|FG000|18-month Assessment|Lost to Follow-up|2
6289900|NCT02391948|10005622|FG001|18-month Assessment|Lost to Follow-up|6
6289901|NCT02391948|10005623|FG002|18-month Assessment|Lost to Follow-up|2
6289902|NCT02391948|10005624|FG003|18-month Assessment|Lost to Follow-up|2
6289903|NCT02391948|10005625|FG004|18-month Assessment|Lost to Follow-up|3
6289904|NCT02391948|10005621|FG000|18-month Assessment|Not able to schedule visit in timeframe|3
6289905|NCT02391948|10005622|FG001|18-month Assessment|Not able to schedule visit in timeframe|3
6289906|NCT02391948|10005623|FG002|18-month Assessment|Not able to schedule visit in timeframe|2
6289907|NCT02391948|10005624|FG003|18-month Assessment|Not able to schedule visit in timeframe|1
6289908|NCT02391948|10005625|FG004|18-month Assessment|Not able to schedule visit in timeframe|4
6289909|NCT02391948|10005621|FG000|18-month Assessment|In 2-visit study (18- and 24-month N/A)|66
6289910|NCT02391948|10005622|FG001|18-month Assessment|In 2-visit study (18- and 24-month N/A)|41
6289911|NCT02391948|10005623|FG002|18-month Assessment|In 2-visit study (18- and 24-month N/A)|22
6289912|NCT02391948|10005624|FG003|18-month Assessment|In 2-visit study (18- and 24-month N/A)|31
6289913|NCT02391948|10005625|FG004|18-month Assessment|In 2-visit study (18- and 24-month N/A)|22
6289914|NCT02391948|10005621|FG000|24-month Assessment|Death|0
6289915|NCT02391948|10005622|FG001|24-month Assessment|Death|0
6289916|NCT02391948|10005623|FG002|24-month Assessment|Death|0
6289917|NCT02391948|10005624|FG003|24-month Assessment|Death|0
6289918|NCT02391948|10005625|FG004|24-month Assessment|Death|1
6289919|NCT02391948|10005621|FG000|24-month Assessment|Withdrawal by Subject|1
6222904|NCT01684202|9893964|FG003|Dose-escalation Period|Withdrawal by Subject|0
6222905|NCT01684202|9893961|FG000|Maintenance Period|Adverse Event|1
6222906|NCT01684202|9893962|FG001|Maintenance Period|Adverse Event|1
6222907|NCT01684202|9893963|FG002|Maintenance Period|Adverse Event|1
6222908|NCT01684202|9893964|FG003|Maintenance Period|Adverse Event|1
6222909|NCT01684202|9893961|FG000|Maintenance Period|Physician Decision|0
6222910|NCT01684202|9893962|FG001|Maintenance Period|Physician Decision|1
6222911|NCT01684202|9893963|FG002|Maintenance Period|Physician Decision|0
6222912|NCT01684202|9893964|FG003|Maintenance Period|Physician Decision|0
6222913|NCT01684202|9893961|FG000|Maintenance Period|Withdrawal by Subject|0
6222914|NCT01684202|9893962|FG001|Maintenance Period|Withdrawal by Subject|1
6222915|NCT01684202|9893963|FG002|Maintenance Period|Withdrawal by Subject|0
6222916|NCT01684202|9893964|FG003|Maintenance Period|Withdrawal by Subject|0
6289920|NCT02391948|10005622|FG001|24-month Assessment|Withdrawal by Subject|1
6289921|NCT02391948|10005623|FG002|24-month Assessment|Withdrawal by Subject|0
6289922|NCT02391948|10005624|FG003|24-month Assessment|Withdrawal by Subject|0
6132394|NCT00974311|9760091|FG001|OLE Phase (up to 77 Months)|Study Terminated by Sponsor|26
6132395|NCT00974311|9760090|FG000|OLE Phase (up to 77 Months)|Other|15
6132396|NCT00974311|9760091|FG001|OLE Phase (up to 77 Months)|Other|2
6132397|NCT00974311|9760090|FG000|OLE Phase (up to 77 Months)|Withdrawal by Subject|2
6132398|NCT00974311|9760091|FG001|OLE Phase (up to 77 Months)|Withdrawal by Subject|1
6132399|NCT00974675|9760164|FG000|Overall Study|Adverse Event|2
6132400|NCT00974675|9760165|FG001|Overall Study|Adverse Event|1
6132401|NCT00974675|9760166|FG002|Overall Study|Adverse Event|1
6132402|NCT00974675|9760167|FG003|Overall Study|Adverse Event|1
6132403|NCT00974675|9760164|FG000|Overall Study|Physician Decision|0
6132404|NCT00974675|9760165|FG001|Overall Study|Physician Decision|0
6132405|NCT00974675|9760166|FG002|Overall Study|Physician Decision|1
6132406|NCT00974675|9760167|FG003|Overall Study|Physician Decision|0
6132407|NCT00974675|9760164|FG000|Overall Study|Participant on holiday; unable to attend|0
6132408|NCT00974675|9760165|FG001|Overall Study|Participant on holiday; unable to attend|0
6132409|NCT00974675|9760166|FG002|Overall Study|Participant on holiday; unable to attend|0
6132410|NCT00974675|9760167|FG003|Overall Study|Participant on holiday; unable to attend|1
6132411|NCT00974974|9760188|FG000|IR CD-LD Dose Adjustment|Adverse Event|0
6132412|NCT00974974|9760189|FG001|IR CD-LD Dose Adjustment|Adverse Event|3
6132413|NCT00974974|9760188|FG000|IR CD-LD Dose Adjustment|Protocol Violation|0
6132414|NCT00974974|9760189|FG001|IR CD-LD Dose Adjustment|Protocol Violation|1
6132415|NCT00974974|9760188|FG000|IR CD-LD Dose Adjustment|Noncompliance with study drug|0
6132416|NCT00974974|9760189|FG001|IR CD-LD Dose Adjustment|Noncompliance with study drug|1
6132417|NCT00974974|9760188|FG000|IR CD-LD Dose Adjustment|Withdrawal by Subject|0
6132418|NCT00974974|9760189|FG001|IR CD-LD Dose Adjustment|Withdrawal by Subject|7
6132419|NCT00974974|9760188|FG000|IR CD-LD Dose Adjustment|Various|0
6132420|NCT00974974|9760189|FG001|IR CD-LD Dose Adjustment|Various|9
6132421|NCT00974974|9760188|FG000|IPX066 Dose Conversion|Adverse Event|23
6132422|NCT00974974|9760189|FG001|IPX066 Dose Conversion|Adverse Event|0
6289923|NCT02391948|10005625|FG004|24-month Assessment|Withdrawal by Subject|1
6289924|NCT02391948|10005621|FG000|24-month Assessment|Lost to Follow-up|5
6289925|NCT02391948|10005622|FG001|24-month Assessment|Lost to Follow-up|4
6289926|NCT02391948|10005623|FG002|24-month Assessment|Lost to Follow-up|0
6289927|NCT02391948|10005624|FG003|24-month Assessment|Lost to Follow-up|0
6289928|NCT02391948|10005625|FG004|24-month Assessment|Lost to Follow-up|0
6289929|NCT02391948|10005621|FG000|24-month Assessment|Medical issue/illness|0
6289930|NCT02391948|10005622|FG001|24-month Assessment|Medical issue/illness|0
6289931|NCT02391948|10005623|FG002|24-month Assessment|Medical issue/illness|1
6289932|NCT02391948|10005624|FG003|24-month Assessment|Medical issue/illness|0
6289933|NCT02391948|10005625|FG004|24-month Assessment|Medical issue/illness|0
6289934|NCT02391948|10005621|FG000|24-month Assessment|Not able to schedule visit in timeframe|8
6289935|NCT02391948|10005622|FG001|24-month Assessment|Not able to schedule visit in timeframe|5
6289936|NCT02391948|10005623|FG002|24-month Assessment|Not able to schedule visit in timeframe|2
6289937|NCT02391948|10005624|FG003|24-month Assessment|Not able to schedule visit in timeframe|9
6289938|NCT02391948|10005625|FG004|24-month Assessment|Not able to schedule visit in timeframe|8
6289939|NCT02391961|10005642|FG000|First Intervention (4 Weeks)|Adverse Event|2
6289940|NCT02391961|10005643|FG001|First Intervention (4 Weeks)|Adverse Event|0
6289941|NCT02391961|10005642|FG000|Washout (2 Weeks)|Withdrawal by Subject|1
6289942|NCT02391961|10005643|FG001|Washout (2 Weeks)|Withdrawal by Subject|1
6289943|NCT02391961|10005642|FG000|Second Intervention (4 Weeks)|Withdrawal by Subject|1
6289944|NCT02391961|10005643|FG001|Second Intervention (4 Weeks)|Withdrawal by Subject|1
6289945|NCT02392000|10005658|FG000|Overall Study|Greater than mild sleep apnea exclusion|18
6289946|NCT02392000|10005658|FG000|Overall Study|Withdrawal by Subject|1
6289947|NCT02392000|10005658|FG000|Overall Study|Lost to Follow-up|8
6289948|NCT02392104|10005663|FG000|Overall Study|discontinuation of warfarin|3
6289949|NCT02392104|10005663|FG000|Overall Study|bleeding event|1
6289950|NCT02392104|10005663|FG000|Overall Study|transferred care to another doctor|2
6289951|NCT02392104|10005663|FG000|Overall Study|INR goal range changed|1
6289952|NCT02392104|10005663|FG000|Overall Study|admitted to skilled nursing facility|3
6289953|NCT02392104|10005663|FG000|Overall Study|INRs drawn by visiting nurse services|1
6289954|NCT02392195|10005667|FG000|Overall Study|Lost to Follow-up|4
6289955|NCT02392195|10005667|FG000|Overall Study|Withdrawal by Subject|4
6132423|NCT00974974|9760188|FG000|IPX066 Dose Conversion|Death|2
6132424|NCT00974974|9760189|FG001|IPX066 Dose Conversion|Death|0
6132425|NCT00974974|9760188|FG000|IPX066 Dose Conversion|Lack of Efficacy|13
6132426|NCT00974974|9760189|FG001|IPX066 Dose Conversion|Lack of Efficacy|0
6132427|NCT00974974|9760188|FG000|IPX066 Dose Conversion|Withdrawal by Subject|12
6132428|NCT00974974|9760189|FG001|IPX066 Dose Conversion|Withdrawal by Subject|0
6132429|NCT00974974|9760188|FG000|IPX066 Dose Conversion|Various|3
6132430|NCT00974974|9760189|FG001|IPX066 Dose Conversion|Various|0
6132431|NCT00974974|9760188|FG000|IPX066 Dose Conversion|Protocol Violation|4
6132432|NCT00974974|9760189|FG001|IPX066 Dose Conversion|Protocol Violation|0
6132433|NCT00974974|9760188|FG000|Maintenance - Double Blind Treatment|Adverse Event|3
6132434|NCT00974974|9760189|FG001|Maintenance - Double Blind Treatment|Adverse Event|3
6132435|NCT00974974|9760188|FG000|Maintenance - Double Blind Treatment|Protocol Violation|1
6132436|NCT00974974|9760189|FG001|Maintenance - Double Blind Treatment|Protocol Violation|1
6132437|NCT00974974|9760188|FG000|Maintenance - Double Blind Treatment|Noncompliance with study drug|0
6132438|NCT00974974|9760189|FG001|Maintenance - Double Blind Treatment|Noncompliance with study drug|1
6132439|NCT00974974|9760188|FG000|Maintenance - Double Blind Treatment|Lack of Efficacy|2
6132440|NCT00974974|9760189|FG001|Maintenance - Double Blind Treatment|Lack of Efficacy|2
6132441|NCT00974974|9760188|FG000|Maintenance - Double Blind Treatment|Lost to Follow-up|0
6132442|NCT00974974|9760189|FG001|Maintenance - Double Blind Treatment|Lost to Follow-up|1
6132443|NCT00974974|9760188|FG000|Maintenance - Double Blind Treatment|Withdrawal by Subject|5
6132444|NCT00974974|9760189|FG001|Maintenance - Double Blind Treatment|Withdrawal by Subject|2
6132445|NCT00974974|9760188|FG000|Maintenance - Double Blind Treatment|Various|4
6132446|NCT00974974|9760189|FG001|Maintenance - Double Blind Treatment|Various|0
6132447|NCT00975000|9760197|FG000|Overall Study|Other|1
6132448|NCT00975000|9760198|FG001|Overall Study|Other|0
6132449|NCT00975000|9760197|FG000|Overall Study|Adverse Event|1
6132450|NCT00975000|9760198|FG001|Overall Study|Adverse Event|1
6132451|NCT00975000|9760197|FG000|Overall Study|Withdrawal by Subject|2
6132452|NCT00975000|9760198|FG001|Overall Study|Withdrawal by Subject|2
6132453|NCT00975000|9760197|FG000|Overall Study|Lost to Follow-up|0
6132454|NCT00975000|9760198|FG001|Overall Study|Lost to Follow-up|1
6132455|NCT00975000|9760197|FG000|Overall Study|Protocol-specified Criteria|1
6132456|NCT00975000|9760198|FG001|Overall Study|Protocol-specified Criteria|0
6132457|NCT00975000|9760197|FG000|Overall Study|Non-compliance|0
6132458|NCT00975000|9760198|FG001|Overall Study|Non-compliance|1
6132459|NCT00975130|9760204|FG000|Study Part 1|Adverse Event|150
6132460|NCT00975130|9760205|FG001|Study Part 1|Adverse Event|0
6132461|NCT00975130|9760206|FG002|Study Part 1|Adverse Event|0
6132462|NCT00975130|9760204|FG000|Study Part 1|Lost to Follow-up|19
6132463|NCT00975130|9760205|FG001|Study Part 1|Lost to Follow-up|0
6132464|NCT00975130|9760206|FG002|Study Part 1|Lost to Follow-up|0
6132465|NCT00975130|9760204|FG000|Study Part 1|Withdrawal by Subject|61
6132466|NCT00975130|9760205|FG001|Study Part 1|Withdrawal by Subject|0
6132467|NCT00975130|9760206|FG002|Study Part 1|Withdrawal by Subject|0
6132468|NCT00975130|9760204|FG000|Study Part 1|Protocol Violation|13
6132469|NCT00975130|9760205|FG001|Study Part 1|Protocol Violation|0
6132470|NCT00975130|9760206|FG002|Study Part 1|Protocol Violation|0
6132471|NCT00975130|9760204|FG000|Study Part 1|Did Not Meet Protocol Eligibility|9
6132472|NCT00975130|9760205|FG001|Study Part 1|Did Not Meet Protocol Eligibility|0
6132473|NCT00975130|9760206|FG002|Study Part 1|Did Not Meet Protocol Eligibility|0
6132474|NCT00975130|9760204|FG000|Study Part 1|Administrative|4
6132475|NCT00975130|9760205|FG001|Study Part 1|Administrative|0
6132476|NCT00975130|9760206|FG002|Study Part 1|Administrative|0
6132477|NCT00975130|9760204|FG000|Study Part 1|Withdrew Consent|24
6132478|NCT00975130|9760205|FG001|Study Part 1|Withdrew Consent|0
6132479|NCT00975130|9760206|FG002|Study Part 1|Withdrew Consent|0
6132480|NCT00975130|9760204|FG000|Study Part 2|Adverse Event|0
6132481|NCT00975130|9760205|FG001|Study Part 2|Adverse Event|14
6132482|NCT00975130|9760206|FG002|Study Part 2|Adverse Event|7
6132483|NCT00975130|9760204|FG000|Study Part 2|Lost to Follow-up|0
6132484|NCT00975130|9760205|FG001|Study Part 2|Lost to Follow-up|0
6132485|NCT00975130|9760206|FG002|Study Part 2|Lost to Follow-up|1
6132486|NCT00975130|9760204|FG000|Study Part 2|Withdrawal by Subject|0
6132487|NCT00975130|9760205|FG001|Study Part 2|Withdrawal by Subject|13
6132488|NCT00975130|9760206|FG002|Study Part 2|Withdrawal by Subject|5
6132489|NCT00975130|9760204|FG000|Study Part 2|Withdrew Consent|0
6132490|NCT00975130|9760205|FG001|Study Part 2|Withdrew Consent|6
6132491|NCT00975130|9760206|FG002|Study Part 2|Withdrew Consent|2
6132492|NCT00975130|9760204|FG000|Study Part 2|Did Not Meet Protocol Eligibility|0
6132493|NCT00975130|9760205|FG001|Study Part 2|Did Not Meet Protocol Eligibility|4
6132494|NCT00975130|9760206|FG002|Study Part 2|Did Not Meet Protocol Eligibility|1
6132495|NCT00975130|9760204|FG000|Study Part 2|Administrative|0
6132496|NCT00975130|9760205|FG001|Study Part 2|Administrative|1
6132497|NCT00975130|9760206|FG002|Study Part 2|Administrative|0
6132498|NCT00975130|9760204|FG000|Study Part 2|Protocol Violation|0
6132499|NCT00975130|9760205|FG001|Study Part 2|Protocol Violation|0
6132500|NCT00975130|9760206|FG002|Study Part 2|Protocol Violation|1
6132501|NCT00975143|9760221|FG000|Overall Study|Adverse Event|19
6132502|NCT00975143|9760222|FG001|Overall Study|Adverse Event|15
6132503|NCT00975143|9760221|FG000|Overall Study|Withdrawal by Subject|15
6132504|NCT00975143|9760222|FG001|Overall Study|Withdrawal by Subject|15
6132505|NCT00975143|9760221|FG000|Overall Study|Lost to Follow-up|20
6132506|NCT00975143|9760222|FG001|Overall Study|Lost to Follow-up|16
6132507|NCT00975143|9760221|FG000|Overall Study|Non-compliance|5
6132508|NCT00975143|9760222|FG001|Overall Study|Non-compliance|8
6132509|NCT00975143|9760221|FG000|Overall Study|Physician Decision|1
6132510|NCT00975143|9760222|FG001|Overall Study|Physician Decision|2
6132511|NCT00975143|9760221|FG000|Overall Study|Details not available|10
6132512|NCT00975143|9760222|FG001|Overall Study|Details not available|4
6132513|NCT00975156|9760230|FG000|Overall Study|Protocol Violation|0
6132514|NCT00975156|9760231|FG001|Overall Study|Protocol Violation|1
6132515|NCT00975195|9760243|FG000|Overall Study|Adverse Event|108
6132516|NCT00975195|9760244|FG001|Overall Study|Adverse Event|101
6132517|NCT00975195|9760243|FG000|Overall Study|Lack of Efficacy|6
6132518|NCT00975195|9760244|FG001|Overall Study|Lack of Efficacy|6
6132519|NCT00975195|9760243|FG000|Overall Study|Protocol Violation|27
6132520|NCT00975195|9760244|FG001|Overall Study|Protocol Violation|23
6132521|NCT00975195|9760243|FG000|Overall Study|Lost to Follow-up|9
6132522|NCT00975195|9760244|FG001|Overall Study|Lost to Follow-up|7
6132523|NCT00975195|9760243|FG000|Overall Study|Withdrawal by Subject|48
6132524|NCT00975195|9760244|FG001|Overall Study|Withdrawal by Subject|61
6132525|NCT00975195|9760243|FG000|Overall Study|Other reason not defined above|29
6132526|NCT00975195|9760244|FG001|Overall Study|Other reason not defined above|33
6132527|NCT00975195|9760243|FG000|Overall Study|Not treated|1
6132528|NCT00975195|9760244|FG001|Overall Study|Not treated|2
6132529|NCT00975221|9760252|FG000|Titration Phase (Weeks 1-12)|Withdrawal by Subject|2
6132530|NCT00975221|9760253|FG001|Titration Phase (Weeks 1-12)|Withdrawal by Subject|3
6132531|NCT00975221|9760252|FG000|Titration Phase (Weeks 1-12)|Requirement for alternative therapy|1
6132532|NCT00975221|9760253|FG001|Titration Phase (Weeks 1-12)|Requirement for alternative therapy|0
6132533|NCT00975221|9760252|FG000|Titration Phase (Weeks 1-12)|Other|0
6132534|NCT00975221|9760253|FG001|Titration Phase (Weeks 1-12)|Other|1
6132535|NCT00975221|9760252|FG000|Efficacy Assessment Phase (Weeks 13-28)|Lost to Follow-up|0
6132536|NCT00975221|9760253|FG001|Efficacy Assessment Phase (Weeks 13-28)|Lost to Follow-up|1
6132537|NCT00975221|9760252|FG000|Open-label Extension Phase (Weeks 29-52)|Adverse Event|1
6132538|NCT00975221|9760253|FG001|Open-label Extension Phase (Weeks 29-52)|Adverse Event|1
6132539|NCT00975221|9760252|FG000|Open-label Extension Phase (Weeks 29-52)|Withdrawal by Subject|1
6132540|NCT00975221|9760253|FG001|Open-label Extension Phase (Weeks 29-52)|Withdrawal by Subject|0
6132541|NCT00975286|9760263|FG000|Overall Study|Adverse Event|9
6132542|NCT00975286|9760264|FG001|Overall Study|Adverse Event|19
6222917|NCT01684215|9893978|FG000|Phase 1, Part 1|Adverse Event|1
6222918|NCT01684215|9893979|FG001|Phase 1, Part 1|Adverse Event|0
6222919|NCT01684215|9893980|FG002|Phase 1, Part 1|Adverse Event|0
6222920|NCT01684215|9893981|FG003|Phase 1, Part 1|Adverse Event|0
6222921|NCT01684215|9893978|FG000|Phase 1, Part 1|Objective progression or relapse|5
6222922|NCT01684215|9893979|FG001|Phase 1, Part 1|Objective progression or relapse|6
6222923|NCT01684215|9893980|FG002|Phase 1, Part 1|Objective progression or relapse|0
6222924|NCT01684215|9893981|FG003|Phase 1, Part 1|Objective progression or relapse|0
6222925|NCT01684215|9893978|FG000|Phase 1, Part 2|Adverse Event|0
6222926|NCT01684215|9893979|FG001|Phase 1, Part 2|Adverse Event|0
6222927|NCT01684215|9893980|FG002|Phase 1, Part 2|Adverse Event|1
6222928|NCT01684215|9893981|FG003|Phase 1, Part 2|Adverse Event|0
6222929|NCT01684215|9893978|FG000|Phase 1, Part 2|Commercial avaliabity of Palbociclib|0
6222930|NCT01684215|9893979|FG001|Phase 1, Part 2|Commercial avaliabity of Palbociclib|0
6222931|NCT01684215|9893980|FG002|Phase 1, Part 2|Commercial avaliabity of Palbociclib|4
6222932|NCT01684215|9893981|FG003|Phase 1, Part 2|Commercial avaliabity of Palbociclib|0
6222933|NCT01684215|9893978|FG000|Phase 1, Part 2|Withdrawal by Subject|0
6222934|NCT01684215|9893979|FG001|Phase 1, Part 2|Withdrawal by Subject|0
6222935|NCT01684215|9893980|FG002|Phase 1, Part 2|Withdrawal by Subject|1
6222936|NCT01684215|9893981|FG003|Phase 1, Part 2|Withdrawal by Subject|0
6222937|NCT01684215|9893978|FG000|Phase 2|Death|0
6222938|NCT01684215|9893979|FG001|Phase 2|Death|0
6222939|NCT01684215|9893980|FG002|Phase 2|Death|0
6222940|NCT01684215|9893981|FG003|Phase 2|Death|8
6222941|NCT01684215|9893978|FG000|Phase 2|Study terminated by sponsor|0
6222942|NCT01684215|9893979|FG001|Phase 2|Study terminated by sponsor|0
6222943|NCT01684215|9893980|FG002|Phase 2|Study terminated by sponsor|0
6222944|NCT01684215|9893981|FG003|Phase 2|Study terminated by sponsor|30
6222945|NCT01684215|9893978|FG000|Phase 2|Enrolled but not treated|0
6222946|NCT01684215|9893979|FG001|Phase 2|Enrolled but not treated|0
6222947|NCT01684215|9893980|FG002|Phase 2|Enrolled but not treated|0
6222948|NCT01684215|9893981|FG003|Phase 2|Enrolled but not treated|1
6222949|NCT01684215|9893978|FG000|Phase 2|Lost to Follow-up|0
6222950|NCT01684215|9893979|FG001|Phase 2|Lost to Follow-up|0
6222951|NCT01684215|9893980|FG002|Phase 2|Lost to Follow-up|0
6222952|NCT01684215|9893981|FG003|Phase 2|Lost to Follow-up|4
6222953|NCT01684423|9894012|FG000|Overall Study|Withdrawal by Subject|0
6222954|NCT01684423|9894013|FG001|Overall Study|Withdrawal by Subject|0
6222955|NCT01684423|9894014|FG002|Overall Study|Withdrawal by Subject|1
6222956|NCT01684423|9894015|FG003|Overall Study|Withdrawal by Subject|0
6222957|NCT01684423|9894016|FG004|Overall Study|Withdrawal by Subject|0
6222958|NCT01684722|9894056|FG000|Overall Study|Lost to Follow-up|78
6222959|NCT01684722|9894057|FG001|Overall Study|Lost to Follow-up|56
6222960|NCT01684722|9894058|FG002|Overall Study|Lost to Follow-up|75
6222961|NCT01684722|9894059|FG003|Overall Study|Lost to Follow-up|89
6222962|NCT01684722|9894056|FG000|Overall Study|Death|19
6222963|NCT01684722|9894057|FG001|Overall Study|Death|21
6222964|NCT01684722|9894058|FG002|Overall Study|Death|19
6222965|NCT01684722|9894059|FG003|Overall Study|Death|21
6222966|NCT01684878|9894098|FG000|Part 1: Safety Run in Phase|Participants withdrawn consent|1
6222967|NCT01684878|9894099|FG001|Part 1: Safety Run in Phase|Participants withdrawn consent|1
6222968|NCT01684878|9894100|FG002|Part 1: Safety Run in Phase|Participants withdrawn consent|0
6222969|NCT01684878|9894101|FG003|Part 1: Safety Run in Phase|Participants withdrawn consent|0
6222970|NCT01684878|9894098|FG000|Part 1: Safety Run in Phase|Death|15
6222971|NCT01684878|9894099|FG001|Part 1: Safety Run in Phase|Death|20
6289956|NCT02392234|10005682|FG000|Treatment Period 1 (8 Weeks)|Adverse Event|1
6222972|NCT01684878|9894100|FG002|Part 1: Safety Run in Phase|Death|0
6222973|NCT01684878|9894101|FG003|Part 1: Safety Run in Phase|Death|0
6132543|NCT00975286|9760263|FG000|Overall Study|Protocol Violation|1
6132544|NCT00975286|9760264|FG001|Overall Study|Protocol Violation|2
6132545|NCT00975286|9760263|FG000|Overall Study|Withdrawal by Subject|0
6132546|NCT00975286|9760264|FG001|Overall Study|Withdrawal by Subject|2
6132547|NCT00975286|9760263|FG000|Overall Study|Familial and Personal Reasons|2
6132548|NCT00975286|9760264|FG001|Overall Study|Familial and Personal Reasons|2
6132549|NCT00975286|9760263|FG000|Overall Study|Poor Compliance to Protocol|0
6132550|NCT00975286|9760264|FG001|Overall Study|Poor Compliance to Protocol|2
6132551|NCT00975286|9760263|FG000|Overall Study|Sponsor Decision|0
6132552|NCT00975286|9760264|FG001|Overall Study|Sponsor Decision|2
6132553|NCT00975416|9760272|FG000|Overall Study|early discharge from tx|3
6132554|NCT00975416|9760273|FG001|Overall Study|early discharge from tx|5
6132555|NCT00975481|9760280|FG000|Second Intervention Period|Adverse Event|2
6132556|NCT00975481|9760281|FG001|Second Intervention Period|Adverse Event|1
6132557|NCT00975481|9760282|FG002|Second Intervention Period|Adverse Event|0
6132558|NCT00975481|9760283|FG003|Second Intervention Period|Adverse Event|0
6222974|NCT01684878|9894098|FG000|Part 1: Safety Run in Phase|Lost to Follow-up|0
6222975|NCT01684878|9894099|FG001|Part 1: Safety Run in Phase|Lost to Follow-up|2
6222976|NCT01684878|9894100|FG002|Part 1: Safety Run in Phase|Lost to Follow-up|0
6222977|NCT01684878|9894101|FG003|Part 1: Safety Run in Phase|Lost to Follow-up|0
6222978|NCT01684878|9894098|FG000|Part 2: Randomized Phase|Participant withdrew consent|0
6222979|NCT01684878|9894099|FG001|Part 2: Randomized Phase|Participant withdrew consent|0
6222980|NCT01684878|9894100|FG002|Part 2: Randomized Phase|Participant withdrew consent|1
6222981|NCT01684878|9894101|FG003|Part 2: Randomized Phase|Participant withdrew consent|2
6222982|NCT01684878|9894098|FG000|Part 2: Randomized Phase|Lost to Follow-up|0
6222983|NCT01684878|9894099|FG001|Part 2: Randomized Phase|Lost to Follow-up|0
6222984|NCT01684878|9894100|FG002|Part 2: Randomized Phase|Lost to Follow-up|2
6222985|NCT01684878|9894101|FG003|Part 2: Randomized Phase|Lost to Follow-up|0
6222986|NCT01684878|9894098|FG000|Part 2: Randomized Phase|Death|0
6222987|NCT01684878|9894099|FG001|Part 2: Randomized Phase|Death|0
6222988|NCT01684878|9894100|FG002|Part 2: Randomized Phase|Death|62
6222989|NCT01684878|9894101|FG003|Part 2: Randomized Phase|Death|68
6222990|NCT01684878|9894098|FG000|Part 2: Randomized Phase|Alive at data-cut|0
6222991|NCT01684878|9894099|FG001|Part 2: Randomized Phase|Alive at data-cut|0
6222992|NCT01684878|9894100|FG002|Part 2: Randomized Phase|Alive at data-cut|13
6222993|NCT01684878|9894101|FG003|Part 2: Randomized Phase|Alive at data-cut|7
6222994|NCT01684878|9894098|FG000|Part 2: Randomized Phase|Participant noncompliance|0
6222995|NCT01684878|9894099|FG001|Part 2: Randomized Phase|Participant noncompliance|0
6222996|NCT01684878|9894100|FG002|Part 2: Randomized Phase|Participant noncompliance|0
6222997|NCT01684878|9894101|FG003|Part 2: Randomized Phase|Participant noncompliance|1
6222998|NCT01684930|9894130|FG000|Overall Study|Withdrawal by Subject|3
6222999|NCT01684930|9894131|FG001|Overall Study|Withdrawal by Subject|1
6223000|NCT01684943|9894140|FG000|Overall Study|Inadequate Venous Access|3
6223001|NCT01684943|9894141|FG001|Overall Study|Inadequate Venous Access|0
6223002|NCT01684943|9894142|FG002|Overall Study|Inadequate Venous Access|0
6223003|NCT01684943|9894140|FG000|Overall Study|Principal Investigator Determination|1
6223004|NCT01684943|9894141|FG001|Overall Study|Principal Investigator Determination|0
6223005|NCT01684943|9894142|FG002|Overall Study|Principal Investigator Determination|0
6223006|NCT01684943|9894140|FG000|Overall Study|Excluded from Analysis|1
6223007|NCT01684943|9894141|FG001|Overall Study|Excluded from Analysis|1
6223008|NCT01684943|9894142|FG002|Overall Study|Excluded from Analysis|1
6223009|NCT01684943|9894140|FG000|Overall Study|Lost to Follow-up|3
6223010|NCT01684943|9894141|FG001|Overall Study|Lost to Follow-up|0
6223011|NCT01684943|9894142|FG002|Overall Study|Lost to Follow-up|0
6223012|NCT01684943|9894140|FG000|Overall Study|Planning Pregnancy|1
6223013|NCT01684943|9894141|FG001|Overall Study|Planning Pregnancy|0
6223014|NCT01684943|9894142|FG002|Overall Study|Planning Pregnancy|0
6223015|NCT01685047|9894159|FG000|Overall Study|Withdrawal by Subject|20
6223016|NCT01685047|9894159|FG000|Overall Study|Death|26
6223017|NCT01685047|9894159|FG000|Overall Study|Lost to Follow-up|8
6223018|NCT01685047|9894159|FG000|Overall Study|Physician Decision|25
6223019|NCT01685047|9894159|FG000|Overall Study|Adverse Event|5
6223020|NCT01685047|9894159|FG000|Overall Study|patient withdrawn by sponsor|1
6223021|NCT01685060|9894163|FG000|Overall Study|Rollover patients|16
6223022|NCT01685060|9894163|FG000|Overall Study|Adverse Event|12
6223023|NCT01685060|9894163|FG000|Overall Study|Progressive disease|69
6223024|NCT01685060|9894163|FG000|Overall Study|Physician Decision|14
6223025|NCT01685060|9894163|FG000|Overall Study|Subject/guardian decision|20
6223026|NCT01685060|9894163|FG000|Overall Study|Lost to Follow-up|1
6223027|NCT01685060|9894163|FG000|Overall Study|Death|8
6223028|NCT01685073|9894169|FG000|Overall Study|Lost to Follow-up|6
6223029|NCT01685073|9894170|FG001|Overall Study|Lost to Follow-up|8
6223030|NCT01685073|9894169|FG000|Overall Study|Withdrawal by Subject|24
6223031|NCT01685073|9894170|FG001|Overall Study|Withdrawal by Subject|24
6223032|NCT01685138|9894176|FG000|Overall Study|Lost to Follow-up|1
6223033|NCT01685138|9894176|FG000|Overall Study|Protocol Violation|1
6223034|NCT01685138|9894176|FG000|Overall Study|No longer requires treatment|1
6223035|NCT01685138|9894176|FG000|Overall Study|Subject/guardian decision|2
6223036|NCT01685138|9894176|FG000|Overall Study|Physician Decision|6
6223037|NCT01685138|9894176|FG000|Overall Study|Death|10
6132559|NCT00975481|9760284|FG004|Second Intervention Period|Adverse Event|0
6132560|NCT00975481|9760285|FG005|Second Intervention Period|Adverse Event|0
6132561|NCT00975481|9760280|FG000|Second Intervention Period|Withdrawal by Subject|0
6132562|NCT00975481|9760281|FG001|Second Intervention Period|Withdrawal by Subject|0
6132563|NCT00975481|9760282|FG002|Second Intervention Period|Withdrawal by Subject|1
6132564|NCT00975481|9760283|FG003|Second Intervention Period|Withdrawal by Subject|0
6132565|NCT00975481|9760284|FG004|Second Intervention Period|Withdrawal by Subject|0
6132566|NCT00975481|9760285|FG005|Second Intervention Period|Withdrawal by Subject|0
6132567|NCT00975481|9760280|FG000|Fourth Intervention Period|Withdrawal by Subject|0
6132568|NCT00975481|9760281|FG001|Fourth Intervention Period|Withdrawal by Subject|0
6132569|NCT00975481|9760282|FG002|Fourth Intervention Period|Withdrawal by Subject|1
6132570|NCT00975481|9760283|FG003|Fourth Intervention Period|Withdrawal by Subject|1
6132571|NCT00975481|9760284|FG004|Fourth Intervention Period|Withdrawal by Subject|0
6132572|NCT00975481|9760285|FG005|Fourth Intervention Period|Withdrawal by Subject|0
6132573|NCT00975481|9760280|FG000|Fifth Intervention Period|Withdrawal by Subject|0
6132574|NCT00975481|9760281|FG001|Fifth Intervention Period|Withdrawal by Subject|0
6132575|NCT00975481|9760282|FG002|Fifth Intervention Period|Withdrawal by Subject|0
6132576|NCT00975481|9760283|FG003|Fifth Intervention Period|Withdrawal by Subject|0
6132577|NCT00975481|9760284|FG004|Fifth Intervention Period|Withdrawal by Subject|1
6132578|NCT00975481|9760285|FG005|Fifth Intervention Period|Withdrawal by Subject|0
6132579|NCT00975507|9760305|FG000|Overall Study|Adverse Event|1
6132580|NCT00975507|9760306|FG001|Overall Study|Adverse Event|0
6132581|NCT00975507|9760305|FG000|Overall Study|Lost to Follow-up|7
6132582|NCT00975507|9760306|FG001|Overall Study|Lost to Follow-up|1
6132583|NCT00975507|9760305|FG000|Overall Study|Protocol Violation|2
6132584|NCT00975507|9760306|FG001|Overall Study|Protocol Violation|0
6132585|NCT00975507|9760305|FG000|Overall Study|Withdrawal by Subject|10
6132586|NCT00975507|9760306|FG001|Overall Study|Withdrawal by Subject|3
6223038|NCT01685138|9894176|FG000|Overall Study|Adverse Event|18
6223039|NCT01685138|9894176|FG000|Overall Study|Progressive disease|53
6223040|NCT01685203|9894187|FG000|Overall Study|Lost to Follow-up|3
6223041|NCT01685203|9894188|FG001|Overall Study|Lost to Follow-up|3
6223042|NCT01685203|9894189|FG002|Overall Study|Lost to Follow-up|0
6223043|NCT01685203|9894190|FG003|Overall Study|Lost to Follow-up|1
6223044|NCT01685203|9894191|FG004|Overall Study|Lost to Follow-up|0
6223045|NCT01685203|9894192|FG005|Overall Study|Lost to Follow-up|0
6223046|NCT01685203|9894193|FG006|Overall Study|Lost to Follow-up|0
6223047|NCT01685203|9894187|FG000|Overall Study|Adverse Event|0
6223048|NCT01685203|9894188|FG001|Overall Study|Adverse Event|0
6223049|NCT01685203|9894189|FG002|Overall Study|Adverse Event|0
6223050|NCT01685203|9894190|FG003|Overall Study|Adverse Event|0
6223051|NCT01685203|9894191|FG004|Overall Study|Adverse Event|0
6223052|NCT01685203|9894192|FG005|Overall Study|Adverse Event|2
6223053|NCT01685203|9894193|FG006|Overall Study|Adverse Event|0
6223054|NCT01685203|9894187|FG000|Overall Study|Adverse event and withdrew consent|1
6223055|NCT01685203|9894188|FG001|Overall Study|Adverse event and withdrew consent|0
6223056|NCT01685203|9894189|FG002|Overall Study|Adverse event and withdrew consent|0
6223057|NCT01685203|9894190|FG003|Overall Study|Adverse event and withdrew consent|0
6223058|NCT01685203|9894191|FG004|Overall Study|Adverse event and withdrew consent|0
6223059|NCT01685203|9894192|FG005|Overall Study|Adverse event and withdrew consent|0
6223060|NCT01685203|9894193|FG006|Overall Study|Adverse event and withdrew consent|0
6223061|NCT01685203|9894187|FG000|Overall Study|Patient's decision|0
6223062|NCT01685203|9894188|FG001|Overall Study|Patient's decision|0
6223063|NCT01685203|9894189|FG002|Overall Study|Patient's decision|0
6223064|NCT01685203|9894190|FG003|Overall Study|Patient's decision|0
6223065|NCT01685203|9894191|FG004|Overall Study|Patient's decision|0
6223066|NCT01685203|9894192|FG005|Overall Study|Patient's decision|1
6223067|NCT01685203|9894193|FG006|Overall Study|Patient's decision|0
6223068|NCT01685216|9894209|FG000|Overall Study|Did not receive study drug|1
6223069|NCT01685229|9894215|FG000|Overall Study|Subjects missing Study Exit form|3
6223070|NCT01685229|9894216|FG001|Overall Study|Subjects missing Study Exit form|1
6223071|NCT01685229|9894215|FG000|Overall Study|Lost to Follow-up|16
6223072|NCT01685229|9894216|FG001|Overall Study|Lost to Follow-up|10
6223073|NCT01685229|9894215|FG000|Overall Study|Withdrawal by Subject|6
6223074|NCT01685229|9894216|FG001|Overall Study|Withdrawal by Subject|5
6223075|NCT01685229|9894215|FG000|Overall Study|Death|1
6223076|NCT01685229|9894216|FG001|Overall Study|Death|0
6223077|NCT01685372|9894245|FG000|Timepoint 3 (T3): 3rd Blood Draw|Lost to Follow-up|3
6223078|NCT01685372|9894246|FG001|Timepoint 3 (T3): 3rd Blood Draw|Lost to Follow-up|4
6223079|NCT01685437|9894256|FG000|Overall Study|Withdrawal by Subject|22
6223080|NCT01685437|9894256|FG000|Overall Study|Lost to Follow-up|3
6223081|NCT01685437|9894256|FG000|Overall Study|Adverse Event|1
6132587|NCT00975585|9760316|FG000|Overall Study|Adverse Event|0
6132588|NCT00975585|9760317|FG001|Overall Study|Adverse Event|4
6223082|NCT01685437|9894256|FG000|Overall Study|Protocol Violation|4
6223083|NCT01685437|9894256|FG000|Overall Study|Unable to make visits due to work|1
6223084|NCT01685697|9894287|FG000|Overall Study|Protocol Violation|3
6223085|NCT01685697|9894288|FG001|Overall Study|Protocol Violation|3
6223086|NCT01685801|9894298|FG000|Cycle 1 Period 2 (2 Weeks)|Adverse Event|0
6223087|NCT01685801|9894299|FG001|Cycle 1 Period 2 (2 Weeks)|Adverse Event|0
6223088|NCT01685801|9894300|FG002|Cycle 1 Period 2 (2 Weeks)|Adverse Event|0
6132589|NCT00975585|9760316|FG000|Overall Study|Lost to Follow-up|3
6132590|NCT00975585|9760317|FG001|Overall Study|Lost to Follow-up|5
6132591|NCT00975585|9760316|FG000|Overall Study|Withdrawal by Subject|2
6132592|NCT00975585|9760317|FG001|Overall Study|Withdrawal by Subject|1
6132593|NCT00975585|9760316|FG000|Overall Study|Lens issue|2
6132594|NCT00975585|9760317|FG001|Overall Study|Lens issue|2
6132595|NCT00975676|9760361|FG000|Overall Study|Baseline samples only, no sample analyzed or only single sample available|6
6132596|NCT00975676|9760362|FG001|Overall Study|Baseline samples only, no sample analyzed or only single sample available|8
6132597|NCT00975689|9760375|FG000|Overall Study|Adverse Event|0
6132598|NCT00975689|9760376|FG001|Overall Study|Adverse Event|3
6132599|NCT00975689|9760375|FG000|Overall Study|Withdrawal by Subject|1
6132600|NCT00975689|9760376|FG001|Overall Study|Withdrawal by Subject|0
6132601|NCT00975689|9760375|FG000|Overall Study|Physician Decision|1
6223089|NCT01685801|9894301|FG003|Cycle 1 Period 2 (2 Weeks)|Adverse Event|1
6223090|NCT01685801|9894298|FG000|Cycle 2 Period 2 (2 Weeks)|Non-compliance with Study Drug|0
6223091|NCT01685801|9894299|FG001|Cycle 2 Period 2 (2 Weeks)|Non-compliance with Study Drug|1
6223092|NCT01685801|9894300|FG002|Cycle 2 Period 2 (2 Weeks)|Non-compliance with Study Drug|0
6223093|NCT01685801|9894301|FG003|Cycle 2 Period 2 (2 Weeks)|Non-compliance with Study Drug|1
6289957|NCT02392234|10005683|FG001|Treatment Period 1 (8 Weeks)|Adverse Event|0
6289958|NCT02392234|10005684|FG002|Treatment Period 1 (8 Weeks)|Adverse Event|1
6289959|NCT02392234|10005685|FG003|Treatment Period 1 (8 Weeks)|Adverse Event|0
6289960|NCT02392234|10005686|FG004|Treatment Period 1 (8 Weeks)|Adverse Event|1
6289961|NCT02392234|10005687|FG005|Treatment Period 1 (8 Weeks)|Adverse Event|1
6289962|NCT02392234|10005682|FG000|Treatment Period 1 (8 Weeks)|Withdrawal by Subject|0
6289963|NCT02392234|10005683|FG001|Treatment Period 1 (8 Weeks)|Withdrawal by Subject|0
6289964|NCT02392234|10005684|FG002|Treatment Period 1 (8 Weeks)|Withdrawal by Subject|0
6289965|NCT02392234|10005685|FG003|Treatment Period 1 (8 Weeks)|Withdrawal by Subject|0
6289966|NCT02392234|10005686|FG004|Treatment Period 1 (8 Weeks)|Withdrawal by Subject|2
6289967|NCT02392234|10005687|FG005|Treatment Period 1 (8 Weeks)|Withdrawal by Subject|0
6289968|NCT02392234|10005682|FG000|Treatment Period 1 (8 Weeks)|Lost to Follow-up|0
6289969|NCT02392234|10005683|FG001|Treatment Period 1 (8 Weeks)|Lost to Follow-up|0
6289970|NCT02392234|10005684|FG002|Treatment Period 1 (8 Weeks)|Lost to Follow-up|0
6289971|NCT02392234|10005685|FG003|Treatment Period 1 (8 Weeks)|Lost to Follow-up|0
6289972|NCT02392234|10005686|FG004|Treatment Period 1 (8 Weeks)|Lost to Follow-up|0
6289973|NCT02392234|10005687|FG005|Treatment Period 1 (8 Weeks)|Lost to Follow-up|1
6289974|NCT02392234|10005682|FG000|Treatment Period 1 (8 Weeks)|Pregnancy|1
6289975|NCT02392234|10005683|FG001|Treatment Period 1 (8 Weeks)|Pregnancy|0
6289976|NCT02392234|10005684|FG002|Treatment Period 1 (8 Weeks)|Pregnancy|0
6289977|NCT02392234|10005685|FG003|Treatment Period 1 (8 Weeks)|Pregnancy|1
6289978|NCT02392234|10005686|FG004|Treatment Period 1 (8 Weeks)|Pregnancy|0
6289979|NCT02392234|10005687|FG005|Treatment Period 1 (8 Weeks)|Pregnancy|0
6289980|NCT02392234|10005682|FG000|Treatment Period 1 (8 Weeks)|Noncompliance|0
6289981|NCT02392234|10005683|FG001|Treatment Period 1 (8 Weeks)|Noncompliance|0
6289982|NCT02392234|10005684|FG002|Treatment Period 1 (8 Weeks)|Noncompliance|0
6289983|NCT02392234|10005685|FG003|Treatment Period 1 (8 Weeks)|Noncompliance|0
6289984|NCT02392234|10005686|FG004|Treatment Period 1 (8 Weeks)|Noncompliance|0
6289985|NCT02392234|10005687|FG005|Treatment Period 1 (8 Weeks)|Noncompliance|1
6289986|NCT02392234|10005682|FG000|Treatment Period 1 (8 Weeks)|Other|1
6289987|NCT02392234|10005683|FG001|Treatment Period 1 (8 Weeks)|Other|0
6289988|NCT02392234|10005684|FG002|Treatment Period 1 (8 Weeks)|Other|0
6289989|NCT02392234|10005685|FG003|Treatment Period 1 (8 Weeks)|Other|0
6289990|NCT02392234|10005686|FG004|Treatment Period 1 (8 Weeks)|Other|0
6289991|NCT02392234|10005687|FG005|Treatment Period 1 (8 Weeks)|Other|0
6289992|NCT02392234|10005682|FG000|Treatment Period 1 (8 Weeks)|Randomized but not treated|0
6289993|NCT02392234|10005683|FG001|Treatment Period 1 (8 Weeks)|Randomized but not treated|0
6289994|NCT02392234|10005684|FG002|Treatment Period 1 (8 Weeks)|Randomized but not treated|1
5981058|NCT02579096|9569992|FG000|Phase 3, Weeks 49 - 72|Physician Decision|0
5981059|NCT02579096|9569993|FG001|Phase 3, Weeks 49 - 72|Physician Decision|5
5981060|NCT02579096|9569992|FG000|Phase 3, Weeks 49 - 72|Withdrawal by Subject|6
5981061|NCT02579096|9569993|FG001|Phase 3, Weeks 49 - 72|Withdrawal by Subject|4
5981062|NCT02579096|9569992|FG000|Phase 3, Weeks 49 - 72|Lost to Follow-up|10
5981063|NCT02579096|9569993|FG001|Phase 3, Weeks 49 - 72|Lost to Follow-up|5
5981064|NCT02579096|9569992|FG000|Phase 3, Weeks 49 - 72|Participant required to take exclusion medication on a regular basis|0
5981065|NCT02579096|9569993|FG001|Phase 3, Weeks 49 - 72|Participant required to take exclusion medication on a regular basis|1
5981066|NCT02579096|9569992|FG000|Phase 3, Weeks 49 - 72|Other reasons|3
5981067|NCT02579096|9569993|FG001|Phase 3, Weeks 49 - 72|Other reasons|0
6289995|NCT02392234|10005685|FG003|Treatment Period 1 (8 Weeks)|Randomized but not treated|0
6289996|NCT02392234|10005686|FG004|Treatment Period 1 (8 Weeks)|Randomized but not treated|1
6289997|NCT02392234|10005687|FG005|Treatment Period 1 (8 Weeks)|Randomized but not treated|0
6289998|NCT02392234|10005682|FG000|Treatment Period 2 (8 Weeks)|Adverse Event|1
6289999|NCT02392234|10005683|FG001|Treatment Period 2 (8 Weeks)|Adverse Event|0
6290000|NCT02392234|10005684|FG002|Treatment Period 2 (8 Weeks)|Adverse Event|0
6290001|NCT02392234|10005685|FG003|Treatment Period 2 (8 Weeks)|Adverse Event|0
6290002|NCT02392234|10005686|FG004|Treatment Period 2 (8 Weeks)|Adverse Event|0
6290003|NCT02392234|10005687|FG005|Treatment Period 2 (8 Weeks)|Adverse Event|0
6290004|NCT02392247|10005698|FG000|Overall Study|Withdrawal by Subject|1
6132602|NCT00975689|9760376|FG001|Overall Study|Physician Decision|0
6132603|NCT00975715|9760384|FG000|Titration Period|Adverse Event|6
6132604|NCT00975715|9760385|FG001|Titration Period|Adverse Event|0
6132605|NCT00975715|9760384|FG000|Titration Period|Protocol Violation|1
6132606|NCT00975715|9760385|FG001|Titration Period|Protocol Violation|0
6132607|NCT00975715|9760384|FG000|Maintenance Period|Adverse Event|2
6132608|NCT00975715|9760385|FG001|Maintenance Period|Adverse Event|1
6132609|NCT00975780|9760393|FG000|Follow Up|Death|88
6132610|NCT00975780|9760394|FG001|Follow Up|Death|122
6132611|NCT00975780|9760393|FG000|Follow Up|Facility Withdrawal|7
6132612|NCT00975780|9760394|FG001|Follow Up|Facility Withdrawal|23
6132613|NCT00975780|9760393|FG000|Follow Up|Discharged from Facility|7
6132614|NCT00975780|9760394|FG001|Follow Up|Discharged from Facility|12
6132615|NCT00975806|9760403|FG000|Overall Study|Adverse Event|2
6132616|NCT00975806|9760404|FG001|Overall Study|Adverse Event|1
6132617|NCT00975806|9760405|FG002|Overall Study|Adverse Event|2
6132618|NCT00975806|9760403|FG000|Overall Study|Disease Progression|1
6132619|NCT00975806|9760404|FG001|Overall Study|Disease Progression|5
6132620|NCT00975806|9760405|FG002|Overall Study|Disease Progression|1
6132621|NCT00975806|9760403|FG000|Overall Study|Withdrawal by Subject|1
6132622|NCT00975806|9760404|FG001|Overall Study|Withdrawal by Subject|0
6132623|NCT00975806|9760405|FG002|Overall Study|Withdrawal by Subject|0
6132624|NCT00975806|9760403|FG000|Overall Study|Death|0
6132625|NCT00975806|9760404|FG001|Overall Study|Death|1
6132626|NCT00975806|9760405|FG002|Overall Study|Death|0
6132627|NCT00975806|9760403|FG000|Overall Study|Physician decision and disease related|1
6132628|NCT00975806|9760404|FG001|Overall Study|Physician decision and disease related|0
6132629|NCT00975806|9760405|FG002|Overall Study|Physician decision and disease related|1
6132630|NCT00975884|9760417|FG000|Overall Study|Adverse Event|1
6132631|NCT00975884|9760418|FG001|Overall Study|Adverse Event|0
6223094|NCT01685840|9894320|FG000|Overall Study|Death|77
6223095|NCT01685840|9894321|FG001|Overall Study|Death|66
6223096|NCT01685840|9894320|FG000|Overall Study|Lost to Follow-up|27
6223097|NCT01685840|9894321|FG001|Overall Study|Lost to Follow-up|25
6223098|NCT01685840|9894320|FG000|Overall Study|Physician Decision|3
6223099|NCT01685840|9894321|FG001|Overall Study|Physician Decision|7
6223100|NCT01685840|9894320|FG000|Overall Study|Withdrawal by Subject|14
6223101|NCT01685840|9894321|FG001|Overall Study|Withdrawal by Subject|17
6223102|NCT01685840|9894320|FG000|Overall Study|Futility|197
6223103|NCT01685840|9894321|FG001|Overall Study|Futility|200
6223104|NCT01685840|9894320|FG000|Overall Study|Had VAD, Dialysis or Transplant|11
6223105|NCT01685840|9894321|FG001|Overall Study|Had VAD, Dialysis or Transplant|17
6223106|NCT01685983|9894329|FG000|Overall Study|Adverse Event|7
6223107|NCT01685983|9894329|FG000|Overall Study|Death|1
6223108|NCT01685983|9894329|FG000|Overall Study|Withdrawal by Subject|19
6223109|NCT01685983|9894329|FG000|Overall Study|Protocol Violation|2
6223110|NCT01685983|9894329|FG000|Overall Study|Physician Decision|13
6223111|NCT01685983|9894329|FG000|Overall Study|Other|7
6223112|NCT01685983|9894329|FG000|Overall Study|Progressive Disease|32
6223113|NCT01685983|9894329|FG000|Overall Study|Noncompliance with Study Drug|1
6223114|NCT01686152|9894345|FG000|Overall Study|Withdrawal by Subject|11
6223115|NCT01686152|9894346|FG001|Overall Study|Withdrawal by Subject|11
6223116|NCT01686152|9894347|FG002|Overall Study|Withdrawal by Subject|3
6223117|NCT01686152|9894345|FG000|Overall Study|Drug Code Unblinded|0
6223118|NCT01686152|9894346|FG001|Overall Study|Drug Code Unblinded|1
6223119|NCT01686152|9894347|FG002|Overall Study|Drug Code Unblinded|0
6223120|NCT01686152|9894345|FG000|Overall Study|Protocol Violation|6
6223121|NCT01686152|9894346|FG001|Overall Study|Protocol Violation|1
6223122|NCT01686152|9894347|FG002|Overall Study|Protocol Violation|0
6223123|NCT01686152|9894345|FG000|Overall Study|Adverse Event|12
6223124|NCT01686152|9894346|FG001|Overall Study|Adverse Event|11
6223125|NCT01686152|9894347|FG002|Overall Study|Adverse Event|0
6223126|NCT01686152|9894345|FG000|Overall Study|Lack of Efficacy|0
6223127|NCT01686152|9894346|FG001|Overall Study|Lack of Efficacy|0
6223128|NCT01686152|9894347|FG002|Overall Study|Lack of Efficacy|1
6223129|NCT01686152|9894345|FG000|Overall Study|IP Non-compliance|5
6223130|NCT01686152|9894346|FG001|Overall Study|IP Non-compliance|5
6223131|NCT01686152|9894347|FG002|Overall Study|IP Non-compliance|0
6223132|NCT01686152|9894345|FG000|Overall Study|Lost to Follow-up|7
6223133|NCT01686152|9894346|FG001|Overall Study|Lost to Follow-up|6
6223134|NCT01686152|9894347|FG002|Overall Study|Lost to Follow-up|5
6223135|NCT01686373|9894361|FG000|Overall Study|Lost to Follow-up|3
6223136|NCT01686373|9894362|FG001|Overall Study|Lost to Follow-up|0
6223137|NCT01686373|9894361|FG000|Overall Study|Withdrawal by Subject|0
6223138|NCT01686373|9894362|FG001|Overall Study|Withdrawal by Subject|1
6223139|NCT01686373|9894361|FG000|Overall Study|Adverse Event|0
6223140|NCT01686373|9894362|FG001|Overall Study|Adverse Event|1
6223141|NCT01686438|9894371|FG000|Overall Study|Lost to Follow-up|8
6223142|NCT01686438|9894372|FG001|Overall Study|Lost to Follow-up|9
6132632|NCT00975884|9760417|FG000|Overall Study|Lost to Follow-up|5
6132633|NCT00975884|9760418|FG001|Overall Study|Lost to Follow-up|3
6132634|NCT00975884|9760417|FG000|Overall Study|Withdrawal by Subject|9
6132635|NCT00975884|9760418|FG001|Overall Study|Withdrawal by Subject|9
6132636|NCT00975884|9760417|FG000|Overall Study|Other|1
6132637|NCT00975884|9760418|FG001|Overall Study|Other|3
6223143|NCT01686438|9894373|FG002|Overall Study|Lost to Follow-up|10
6223144|NCT01686438|9894371|FG000|Overall Study|Adverse Event|0
6223145|NCT01686438|9894372|FG001|Overall Study|Adverse Event|0
6132638|NCT00975923|9760436|FG000|Overall Study|Withdrawal by Subject|0
6132639|NCT00975923|9760437|FG001|Overall Study|Withdrawal by Subject|1
6132640|NCT00975975|9760444|FG000|Overall Study|Death|6
6132641|NCT00976027|9760450|FG000|Overall Study|Serious Adverse Event|36
6223146|NCT01686438|9894373|FG002|Overall Study|Adverse Event|1
6223147|NCT01686438|9894371|FG000|Overall Study|Protocol Violation|0
6223148|NCT01686438|9894372|FG001|Overall Study|Protocol Violation|0
6223149|NCT01686438|9894373|FG002|Overall Study|Protocol Violation|1
6223150|NCT01686438|9894371|FG000|Overall Study|Withdrawal by Subject|0
6223151|NCT01686438|9894372|FG001|Overall Study|Withdrawal by Subject|0
6223152|NCT01686438|9894373|FG002|Overall Study|Withdrawal by Subject|1
6223153|NCT01686568|9894413|FG000|Main Study|Withdrawal by Subject|1
6223154|NCT01686568|9894414|FG001|Main Study|Withdrawal by Subject|3
6223155|NCT01686568|9894413|FG000|Main Study|Noncompliance with protocol|0
6223156|NCT01686568|9894414|FG001|Main Study|Noncompliance with protocol|1
6223157|NCT01686568|9894413|FG000|Main Study|Liver enzymes above range of exclusion|1
6223158|NCT01686568|9894414|FG001|Main Study|Liver enzymes above range of exclusion|0
6223159|NCT01686568|9894413|FG000|Sub-Study|Not consented for sub-study|2
6223160|NCT01686568|9894414|FG001|Sub-Study|Not consented for sub-study|2
6223161|NCT01686581|9894420|FG000|Overall Study|Side-effects or Health Problems|15
6223162|NCT01686581|9894420|FG000|Overall Study|Lack of Efficacy|90
6223163|NCT01686581|9894420|FG000|Overall Study|Participant Concerned about Risks|6
6223164|NCT01686581|9894420|FG000|Overall Study|Thinks Injections Too Painful|8
6223165|NCT01686581|9894420|FG000|Overall Study|Thinks Injections Take Too Much Time|2
6223166|NCT01686581|9894420|FG000|Overall Study|Trying to get Pregnant or Nursing|2
6223167|NCT01686581|9894420|FG000|Overall Study|Thinks it is Inconvenient|17
6223168|NCT01686581|9894420|FG000|Overall Study|Other Miscellaneous Reasons|36
6223169|NCT01686581|9894420|FG000|Overall Study|Reason Missing|1
6223170|NCT01686633|9894427|FG000|Overall Study|Lack of Efficacy|33
6223171|NCT01686633|9894428|FG001|Overall Study|Lack of Efficacy|13
6223172|NCT01686633|9894429|FG002|Overall Study|Lack of Efficacy|11
6223173|NCT01686633|9894427|FG000|Overall Study|Withdrawal by Subject|8
6223174|NCT01686633|9894428|FG001|Overall Study|Withdrawal by Subject|8
6223175|NCT01686633|9894429|FG002|Overall Study|Withdrawal by Subject|5
6223176|NCT01686633|9894427|FG000|Overall Study|Physician Decision|3
6223177|NCT01686633|9894428|FG001|Overall Study|Physician Decision|4
6223178|NCT01686633|9894429|FG002|Overall Study|Physician Decision|4
6223179|NCT01686633|9894427|FG000|Overall Study|Adverse Event|4
6223180|NCT01686633|9894428|FG001|Overall Study|Adverse Event|3
6223181|NCT01686633|9894429|FG002|Overall Study|Adverse Event|3
6223182|NCT01686633|9894427|FG000|Overall Study|Protocol Violation|2
6223183|NCT01686633|9894428|FG001|Overall Study|Protocol Violation|3
6223184|NCT01686633|9894429|FG002|Overall Study|Protocol Violation|0
6223185|NCT01686633|9894427|FG000|Overall Study|Protocol-defined Stopping Criteria|1
6223186|NCT01686633|9894428|FG001|Overall Study|Protocol-defined Stopping Criteria|0
6223187|NCT01686633|9894429|FG002|Overall Study|Protocol-defined Stopping Criteria|1
6223188|NCT01686633|9894427|FG000|Overall Study|Lost to Follow-up|0
6223189|NCT01686633|9894428|FG001|Overall Study|Lost to Follow-up|1
6223190|NCT01686633|9894429|FG002|Overall Study|Lost to Follow-up|1
6223191|NCT01686828|9894469|FG000|Overall Study|Physician Decision|1
6223192|NCT01686828|9894470|FG001|Overall Study|Physician Decision|0
6223193|NCT01686828|9894471|FG002|Overall Study|Physician Decision|0
6223194|NCT01686828|9894472|FG003|Overall Study|Physician Decision|0
6223195|NCT01686828|9894469|FG000|Overall Study|New Job|0
6223196|NCT01686828|9894470|FG001|Overall Study|New Job|1
6223197|NCT01686828|9894471|FG002|Overall Study|New Job|0
6223198|NCT01686828|9894472|FG003|Overall Study|New Job|0
6223199|NCT01686828|9894469|FG000|Overall Study|Weight Loss|0
6223200|NCT01686828|9894470|FG001|Overall Study|Weight Loss|0
6223201|NCT01686828|9894471|FG002|Overall Study|Weight Loss|1
6223202|NCT01686828|9894472|FG003|Overall Study|Weight Loss|0
6223203|NCT01686932|9894488|FG000|Period 1|Adverse Event|1
6223204|NCT01686932|9894489|FG001|Period 1|Adverse Event|1
6223205|NCT01686958|9894495|FG000|Overall Study|Withdrawal by Subject|1
6132642|NCT00976027|9760451|FG001|Overall Study|Serious Adverse Event|17
6223206|NCT01687101|9894513|FG000|Overall Study|Lost to Follow-up|7
6223207|NCT01687166|9894525|FG000|Overall Study|Attempt subject|2
6223208|NCT01687166|9894526|FG001|Overall Study|Attempt subject|3
6290005|NCT02392247|10005698|FG000|Overall Study|Surgery cancelled; no data|1
6290006|NCT02392403|10005720|FG000|Overall Study|Adverse Event|1
6290007|NCT02392403|10005720|FG000|Overall Study|Death|1
6132643|NCT00976027|9760450|FG000|Overall Study|Adverse Event|0
6132644|NCT00976027|9760451|FG001|Overall Study|Adverse Event|2
6132645|NCT00976027|9760450|FG000|Overall Study|Protocol Violation|60
6132646|NCT00976027|9760451|FG001|Overall Study|Protocol Violation|27
6132647|NCT00976027|9760450|FG000|Overall Study|Lost to Follow-up|208
6132648|NCT00976027|9760451|FG001|Overall Study|Lost to Follow-up|103
6132649|NCT00976027|9760450|FG000|Overall Study|Withdrawal by Subject|107
6132650|NCT00976027|9760451|FG001|Overall Study|Withdrawal by Subject|66
6132651|NCT00976209|9760463|FG000|Treatment Period 1|Protocol Violation|1
6223209|NCT01687166|9894527|FG002|Overall Study|Attempt subject|2
6223210|NCT01687166|9894528|FG003|Overall Study|Attempt subject|0
6132652|NCT00976209|9760464|FG001|Treatment Period 1|Protocol Violation|0
6132653|NCT00976209|9760463|FG000|Treatment Period 1|Lost to Follow-up|2
6223211|NCT01687166|9894525|FG000|Overall Study|Did not meet eligibility criteria|4
6132654|NCT00976209|9760464|FG001|Treatment Period 1|Lost to Follow-up|0
6132655|NCT00976209|9760463|FG000|Treatment Period 1|Other|0
6132656|NCT00976209|9760464|FG001|Treatment Period 1|Other|1
6132657|NCT00976209|9760463|FG000|Wash-out Period|Adverse Event|1
6132658|NCT00976209|9760464|FG001|Wash-out Period|Adverse Event|2
6132659|NCT00976209|9760463|FG000|Wash-out Period|Lost to Follow-up|1
6132660|NCT00976209|9760464|FG001|Wash-out Period|Lost to Follow-up|0
6132661|NCT00976209|9760463|FG000|Wash-out Period|Protocol Violation|1
6132662|NCT00976209|9760464|FG001|Wash-out Period|Protocol Violation|0
6132663|NCT00976209|9760463|FG000|Wash-out Period|Other|1
6132664|NCT00976209|9760464|FG001|Wash-out Period|Other|0
6132665|NCT00976209|9760463|FG000|Treatment Period 2|Withdrawal by Subject|0
6132666|NCT00976209|9760464|FG001|Treatment Period 2|Withdrawal by Subject|1
6132667|NCT00976209|9760463|FG000|Treatment Period 2|Lost to Follow-up|0
6132668|NCT00976209|9760464|FG001|Treatment Period 2|Lost to Follow-up|1
6132669|NCT00976274|9760476|FG000|Overall Study|Lost to Follow-up|5
6132670|NCT00976274|9760477|FG001|Overall Study|Lost to Follow-up|5
6132671|NCT00976274|9760476|FG000|Overall Study|Withdrawal by Subject|1
6132672|NCT00976274|9760477|FG001|Overall Study|Withdrawal by Subject|1
6132673|NCT00976274|9760476|FG000|Overall Study|Physician Decision|1
6132674|NCT00976274|9760477|FG001|Overall Study|Physician Decision|2
6132675|NCT00976391|9760498|FG000|Treatment Period (52 Weeks)|Adverse Event|16
6132676|NCT00976391|9760499|FG001|Treatment Period (52 Weeks)|Adverse Event|2
6132677|NCT00976391|9760498|FG000|Treatment Period (52 Weeks)|Protocol Violation|1
6132678|NCT00976391|9760499|FG001|Treatment Period (52 Weeks)|Protocol Violation|1
6132679|NCT00976391|9760498|FG000|Treatment Period (52 Weeks)|Noncompliance|4
6132680|NCT00976391|9760499|FG001|Treatment Period (52 Weeks)|Noncompliance|4
6132681|NCT00976391|9760498|FG000|Treatment Period (52 Weeks)|Lost to Follow-up|10
6132682|NCT00976391|9760499|FG001|Treatment Period (52 Weeks)|Lost to Follow-up|8
6132683|NCT00976391|9760498|FG000|Treatment Period (52 Weeks)|Withdrawal by Subject|9
6132684|NCT00976391|9760499|FG001|Treatment Period (52 Weeks)|Withdrawal by Subject|19
6132685|NCT00976391|9760498|FG000|Treatment Period (52 Weeks)|Physician Decision|1
6132686|NCT00976391|9760499|FG001|Treatment Period (52 Weeks)|Physician Decision|1
6132687|NCT00976391|9760498|FG000|Treatment Period (52 Weeks)|Termination of Study/Site by GSK|0
6132688|NCT00976391|9760499|FG001|Treatment Period (52 Weeks)|Termination of Study/Site by GSK|4
6132689|NCT00976391|9760498|FG000|Treatment Period (52 Weeks)|Pregnancy|1
6132690|NCT00976391|9760499|FG001|Treatment Period (52 Weeks)|Pregnancy|0
6132691|NCT00976391|9760498|FG000|Follow-up Period (8 Weeks)|Adverse Event|3
6132692|NCT00976391|9760499|FG001|Follow-up Period (8 Weeks)|Adverse Event|1
6132693|NCT00976391|9760498|FG000|Follow-up Period (8 Weeks)|Noncompliance|2
6132694|NCT00976391|9760499|FG001|Follow-up Period (8 Weeks)|Noncompliance|2
6132695|NCT00976391|9760498|FG000|Follow-up Period (8 Weeks)|Lost to Follow-up|14
6132696|NCT00976391|9760499|FG001|Follow-up Period (8 Weeks)|Lost to Follow-up|12
6132697|NCT00976391|9760498|FG000|Follow-up Period (8 Weeks)|Did not Entered Follow-up|6
6132698|NCT00976391|9760499|FG001|Follow-up Period (8 Weeks)|Did not Entered Follow-up|8
6132699|NCT00976391|9760498|FG000|Follow-up Period (8 Weeks)|Withdrawal by Subject|4
6132700|NCT00976391|9760499|FG001|Follow-up Period (8 Weeks)|Withdrawal by Subject|7
6132701|NCT00976391|9760498|FG000|Follow-up Period (8 Weeks)|Termination of Study/Site by GSK|0
6132702|NCT00976391|9760499|FG001|Follow-up Period (8 Weeks)|Termination of Study/Site by GSK|4
6132703|NCT00976456|9760518|FG000|Overall Study|Adverse Event|17
6132704|NCT00976456|9760519|FG001|Overall Study|Adverse Event|22
6132705|NCT00976456|9760518|FG000|Overall Study|Death|7
6132706|NCT00976456|9760519|FG001|Overall Study|Death|9
6132707|NCT00976456|9760518|FG000|Overall Study|Lack of Efficacy|5
6132708|NCT00976456|9760519|FG001|Overall Study|Lack of Efficacy|2
6132709|NCT00976456|9760518|FG000|Overall Study|Withdrawal by Subject|3
6132710|NCT00976456|9760519|FG001|Overall Study|Withdrawal by Subject|1
6132711|NCT00976456|9760518|FG000|Overall Study|screening failure, unknown|11
6132712|NCT00976456|9760519|FG001|Overall Study|screening failure, unknown|4
6132713|NCT00976482|9760525|FG000|Overall Study|Death|208
6132714|NCT00976482|9760525|FG000|Overall Study|Withdrawal by Subject|45
6223212|NCT01687166|9894526|FG001|Overall Study|Did not meet eligibility criteria|6
6223213|NCT01687166|9894527|FG002|Overall Study|Did not meet eligibility criteria|1
6223214|NCT01687166|9894528|FG003|Overall Study|Did not meet eligibility criteria|1
6223215|NCT01687166|9894525|FG000|Overall Study|Adverse Event|2
6223216|NCT01687166|9894526|FG001|Overall Study|Adverse Event|1
6223217|NCT01687166|9894527|FG002|Overall Study|Adverse Event|0
6223218|NCT01687166|9894528|FG003|Overall Study|Adverse Event|0
6223219|NCT01687166|9894525|FG000|Overall Study|Physician Decision|3
6223220|NCT01687166|9894526|FG001|Overall Study|Physician Decision|2
6132715|NCT00976482|9760525|FG000|Overall Study|Center terminated|1
6132716|NCT00976482|9760525|FG000|Overall Study|Protocol Violation|5
6132717|NCT00976495|9760532|FG000|Overall Study|Withdrawal by Subject|0
6132718|NCT00976495|9760533|FG001|Overall Study|Withdrawal by Subject|1
6132719|NCT00976495|9760534|FG002|Overall Study|Withdrawal by Subject|0
6132720|NCT00976508|9760544|FG000|Overall Study|Death|7
6132721|NCT00976508|9760545|FG001|Overall Study|Death|1
6132722|NCT00976508|9760544|FG000|Overall Study|Lost to Follow-up|1
6132723|NCT00976508|9760545|FG001|Overall Study|Lost to Follow-up|0
6132724|NCT00976508|9760544|FG000|Overall Study|Withdrawal by Subject|1
6132725|NCT00976508|9760545|FG001|Overall Study|Withdrawal by Subject|0
6132726|NCT00976508|9760544|FG000|Overall Study|Disease Progression|4
6132727|NCT00976508|9760545|FG001|Overall Study|Disease Progression|4
6132728|NCT00976508|9760544|FG000|Overall Study|Subject Enrolled in Hospice|1
6132729|NCT00976508|9760545|FG001|Overall Study|Subject Enrolled in Hospice|0
6132730|NCT00976508|9760544|FG000|Overall Study|Terminated by the Sponsor|0
6132731|NCT00976508|9760545|FG001|Overall Study|Terminated by the Sponsor|1
6132732|NCT00976560|9760574|FG000|Overall Study|Adverse Event|5
6132733|NCT00976560|9760575|FG001|Overall Study|Adverse Event|5
6132734|NCT00976560|9760574|FG000|Overall Study|Lack of Efficacy|3
6132735|NCT00976560|9760575|FG001|Overall Study|Lack of Efficacy|5
6132736|NCT00976560|9760574|FG000|Overall Study|Protocol Violation|1
6132737|NCT00976560|9760575|FG001|Overall Study|Protocol Violation|0
6132738|NCT00976560|9760574|FG000|Overall Study|Lost to Follow-up|1
6132739|NCT00976560|9760575|FG001|Overall Study|Lost to Follow-up|0
6132740|NCT00976560|9760574|FG000|Overall Study|Physician Decision|2
6132741|NCT00976560|9760575|FG001|Overall Study|Physician Decision|0
6132742|NCT00976560|9760574|FG000|Overall Study|Withdrawal by Subject|2
6132743|NCT00976560|9760575|FG001|Overall Study|Withdrawal by Subject|3
6132744|NCT00976573|9760583|FG000|Overall Study|Ineligible|0
6132745|NCT00976573|9760584|FG001|Overall Study|Ineligible|1
6132746|NCT00976573|9760583|FG000|Overall Study|Cancel prior to receiving treatment|4
6132747|NCT00976573|9760584|FG001|Overall Study|Cancel prior to receiving treatment|2
6132748|NCT00976677|9760610|FG000|Overall Study|Adverse Event|1
6132749|NCT00976677|9760611|FG001|Overall Study|Adverse Event|0
6132750|NCT00976677|9760610|FG000|Overall Study|Withdrawal by Subject|0
6132751|NCT00976677|9760611|FG001|Overall Study|Withdrawal by Subject|2
6132752|NCT00976677|9760610|FG000|Overall Study|Disease progression|1
6132753|NCT00976677|9760611|FG001|Overall Study|Disease progression|1
6132754|NCT00976677|9760610|FG000|Overall Study|Trial unblinded|2
6132755|NCT00976677|9760611|FG001|Overall Study|Trial unblinded|2
6132756|NCT00976677|9760610|FG000|Overall Study|Unknown/Missing|1
6132757|NCT00976677|9760611|FG001|Overall Study|Unknown/Missing|0
6132758|NCT00976703|9760619|FG000|Overall Study|Physician Decision|1
6132759|NCT00976703|9760620|FG001|Overall Study|Physician Decision|1
6132760|NCT00976703|9760619|FG000|Overall Study|ineligible for study|2
6132761|NCT00976703|9760620|FG001|Overall Study|ineligible for study|2
6132762|NCT00976716|9760626|FG000|Overall Study|Adverse Event|1
6132763|NCT00976820|9760635|FG000|Overall Study|Lost to Follow-up|5
6132764|NCT00976820|9760636|FG001|Overall Study|Lost to Follow-up|16
6132765|NCT00976820|9760637|FG002|Overall Study|Lost to Follow-up|2
6132766|NCT00976820|9760638|FG003|Overall Study|Lost to Follow-up|3
6132767|NCT00976820|9760635|FG000|Overall Study|Poor Compliance. Numerous Visits Booked|1
6132768|NCT00976820|9760636|FG001|Overall Study|Poor Compliance. Numerous Visits Booked|0
6132769|NCT00976820|9760637|FG002|Overall Study|Poor Compliance. Numerous Visits Booked|1
6132770|NCT00976820|9760638|FG003|Overall Study|Poor Compliance. Numerous Visits Booked|0
6132771|NCT00976820|9760635|FG000|Overall Study|Withdrawal by Subject|2
6132772|NCT00976820|9760636|FG001|Overall Study|Withdrawal by Subject|4
6132773|NCT00976820|9760637|FG002|Overall Study|Withdrawal by Subject|1
6132774|NCT00976820|9760638|FG003|Overall Study|Withdrawal by Subject|4
6132775|NCT00976898|9760689|FG000|Overall Study|Protocol Violation|1
6132776|NCT00976898|9760689|FG000|Overall Study|Adverse Event|1
6132777|NCT00976898|9760689|FG000|Overall Study|Physician Decision|1
6132778|NCT00976898|9760689|FG000|Overall Study|Liver Transplant|1
6132779|NCT00976898|9760689|FG000|Overall Study|Progressive Disease|1
6132780|NCT00976911|9760695|FG000|Overall Study|Withdrawal by Subject|4
6132781|NCT00976911|9760696|FG001|Overall Study|Withdrawal by Subject|6
6132782|NCT00976911|9760695|FG000|Overall Study|Death|138
6132783|NCT00976911|9760696|FG001|Overall Study|Death|126
6132784|NCT00976911|9760695|FG000|Overall Study|Adverse Event|0
6132785|NCT00976911|9760696|FG001|Overall Study|Adverse Event|1
6132786|NCT00976911|9760695|FG000|Overall Study|Protocol Violation|2
6132787|NCT00976911|9760696|FG001|Overall Study|Protocol Violation|0
6132788|NCT00976911|9760695|FG000|Overall Study|Other|8
6132789|NCT00976911|9760696|FG001|Overall Study|Other|9
6132790|NCT00976911|9760695|FG000|Overall Study|In Follow-Up as of 25 Jan 2013|30
6132791|NCT00976911|9760696|FG001|Overall Study|In Follow-Up as of 25 Jan 2013|37
6132792|NCT00976937|9760704|FG000|Overall Study|Adverse Event|4
6132793|NCT00976937|9760705|FG001|Overall Study|Adverse Event|5
6132794|NCT00976937|9760704|FG000|Overall Study|Lost to Follow-up|2
6132795|NCT00976937|9760705|FG001|Overall Study|Lost to Follow-up|1
6290008|NCT02392403|10005720|FG000|Overall Study|Withdrawal by Subject|1
6132796|NCT00976937|9760704|FG000|Overall Study|Withdrawal by Subject|5
6132797|NCT00976937|9760705|FG001|Overall Study|Withdrawal by Subject|3
6132798|NCT00976937|9760704|FG000|Overall Study|Poor compliance to protocol|3
6132799|NCT00976937|9760705|FG001|Overall Study|Poor compliance to protocol|0
6132800|NCT00976937|9760704|FG000|Overall Study|Personal and Familial Reason|2
6132801|NCT00976937|9760705|FG001|Overall Study|Personal and Familial Reason|2
6132802|NCT00976950|9760711|FG000|Overall Study|Adverse Event|3
6132803|NCT00976950|9760711|FG000|Overall Study|Events with no relationship to Aptivus|3
6132804|NCT00976989|9760718|FG000|Overall Study|Violation of Selection Criteria at Entry|1
6132805|NCT00976989|9760719|FG001|Overall Study|Violation of Selection Criteria at Entry|0
6132806|NCT00976989|9760720|FG002|Overall Study|Violation of Selection Criteria at Entry|1
6132807|NCT00976989|9760718|FG000|Overall Study|Death|5
6132808|NCT00976989|9760719|FG001|Overall Study|Death|7
6132809|NCT00976989|9760720|FG002|Overall Study|Death|10
6132810|NCT00976989|9760718|FG000|Overall Study|Refused Treatment|4
6132811|NCT00976989|9760719|FG001|Overall Study|Refused Treatment|3
6132812|NCT00976989|9760720|FG002|Overall Study|Refused Treatment|5
6132813|NCT00976989|9760718|FG000|Overall Study|Failure to Return|2
6132814|NCT00976989|9760719|FG001|Overall Study|Failure to Return|1
6132815|NCT00976989|9760720|FG002|Overall Study|Failure to Return|0
6132816|NCT00976989|9760718|FG000|Overall Study|Recurrence of Disease|0
6132817|NCT00976989|9760719|FG001|Overall Study|Recurrence of Disease|1
6132818|NCT00976989|9760720|FG002|Overall Study|Recurrence of Disease|0
6132819|NCT00976989|9760718|FG000|Overall Study|Other|1
6132820|NCT00976989|9760719|FG001|Overall Study|Other|0
6132821|NCT00976989|9760720|FG002|Overall Study|Other|1
6132822|NCT00977080|9760732|FG000|Overall Study|Adverse Event|2
6132823|NCT00977080|9760733|FG001|Overall Study|Adverse Event|7
6132824|NCT00977080|9760734|FG002|Overall Study|Adverse Event|7
6132825|NCT00977080|9760735|FG003|Overall Study|Adverse Event|7
6132826|NCT00977080|9760732|FG000|Overall Study|Withdrawal by Subject|1
6132827|NCT00977080|9760733|FG001|Overall Study|Withdrawal by Subject|5
6132828|NCT00977080|9760734|FG002|Overall Study|Withdrawal by Subject|1
6132829|NCT00977080|9760735|FG003|Overall Study|Withdrawal by Subject|5
6132830|NCT00977080|9760732|FG000|Overall Study|Protocol Violation|7
6132831|NCT00977080|9760733|FG001|Overall Study|Protocol Violation|3
6132832|NCT00977080|9760734|FG002|Overall Study|Protocol Violation|4
6132833|NCT00977080|9760735|FG003|Overall Study|Protocol Violation|3
6132834|NCT00977080|9760732|FG000|Overall Study|Noncompliance|0
6132835|NCT00977080|9760733|FG001|Overall Study|Noncompliance|2
6132836|NCT00977080|9760734|FG002|Overall Study|Noncompliance|1
6132837|NCT00977080|9760735|FG003|Overall Study|Noncompliance|0
6132838|NCT00977080|9760732|FG000|Overall Study|Calcium < 7.5 mg/dL on 3 draws|0
6223221|NCT01687166|9894527|FG002|Overall Study|Physician Decision|1
6223222|NCT01687166|9894528|FG003|Overall Study|Physician Decision|0
6223223|NCT01687166|9894525|FG000|Overall Study|Withdrawal by Subject|11
6223224|NCT01687166|9894526|FG001|Overall Study|Withdrawal by Subject|4
6223225|NCT01687166|9894527|FG002|Overall Study|Withdrawal by Subject|3
6223226|NCT01687166|9894528|FG003|Overall Study|Withdrawal by Subject|0
6223227|NCT01687166|9894525|FG000|Overall Study|Lost to Follow-up|2
6223228|NCT01687166|9894526|FG001|Overall Study|Lost to Follow-up|5
6290009|NCT02392481|10005728|FG000|Overall Study|Adverse Event|0
6290010|NCT02392481|10005729|FG001|Overall Study|Adverse Event|0
6290011|NCT02392481|10005730|FG002|Overall Study|Adverse Event|1
6290012|NCT02392481|10005731|FG003|Overall Study|Adverse Event|2
6290013|NCT02392481|10005728|FG000|Overall Study|Withdrawal by Subject|0
6290014|NCT02392481|10005729|FG001|Overall Study|Withdrawal by Subject|0
6290015|NCT02392481|10005730|FG002|Overall Study|Withdrawal by Subject|1
6290016|NCT02392481|10005731|FG003|Overall Study|Withdrawal by Subject|0
6290017|NCT02392507|10005755|FG000|Induction Regimen|Death|3
6290018|NCT02392507|10005755|FG000|Induction Regimen|On Study Treatment at Study Conclusion|1
6290019|NCT02392507|10005755|FG000|Induction Regimen|Physician Decision|1
6290020|NCT02392507|10005755|FG000|Induction Regimen|Withdrawal by Subject|2
6290021|NCT02392507|10005755|FG000|Maintenance Regimen|Death|1
6290022|NCT02392507|10005755|FG000|Maintenance Regimen|On Study Treatment at Study Conclusion|1
6290023|NCT02392559|10005766|FG000|Overall Study|Withdrawal by Subject|0
6290024|NCT02392559|10005767|FG001|Overall Study|Withdrawal by Subject|1
6290025|NCT02392611|10005783|FG000|Overall Study|Adverse Event|0
6290026|NCT02392611|10005784|FG001|Overall Study|Adverse Event|0
6290027|NCT02392611|10005785|FG002|Overall Study|Adverse Event|0
6290028|NCT02392611|10005786|FG003|Overall Study|Adverse Event|1
6290029|NCT02392611|10005787|FG004|Overall Study|Adverse Event|0
6290030|NCT02392611|10005788|FG005|Overall Study|Adverse Event|0
6290031|NCT02392611|10005789|FG006|Overall Study|Adverse Event|0
6290032|NCT02392611|10005790|FG007|Overall Study|Adverse Event|0
6290033|NCT02392611|10005791|FG008|Overall Study|Adverse Event|0
6132839|NCT00977080|9760733|FG001|Overall Study|Calcium < 7.5 mg/dL on 3 draws|0
6132840|NCT00977080|9760734|FG002|Overall Study|Calcium < 7.5 mg/dL on 3 draws|0
6132841|NCT00977080|9760735|FG003|Overall Study|Calcium < 7.5 mg/dL on 3 draws|1
6132842|NCT00977080|9760732|FG000|Overall Study|Required kidney transplantation|1
6132843|NCT00977080|9760733|FG001|Overall Study|Required kidney transplantation|3
6132844|NCT00977080|9760734|FG002|Overall Study|Required kidney transplantation|3
6223229|NCT01687166|9894527|FG002|Overall Study|Lost to Follow-up|1
6223230|NCT01687166|9894528|FG003|Overall Study|Lost to Follow-up|0
6223231|NCT01687166|9894525|FG000|Overall Study|Equipment/Device Availability|0
6223232|NCT01687166|9894526|FG001|Overall Study|Equipment/Device Availability|1
6223233|NCT01687166|9894527|FG002|Overall Study|Equipment/Device Availability|0
6223234|NCT01687166|9894528|FG003|Overall Study|Equipment/Device Availability|0
6223235|NCT01687166|9894525|FG000|Overall Study|Death|1
6223236|NCT01687166|9894526|FG001|Overall Study|Death|1
6223237|NCT01687166|9894527|FG002|Overall Study|Death|0
6223238|NCT01687166|9894528|FG003|Overall Study|Death|0
6223239|NCT01687166|9894525|FG000|Overall Study|Protocol Violation|1
6223240|NCT01687166|9894526|FG001|Overall Study|Protocol Violation|1
6223241|NCT01687166|9894527|FG002|Overall Study|Protocol Violation|1
6223242|NCT01687166|9894528|FG003|Overall Study|Protocol Violation|0
6223243|NCT01687166|9894525|FG000|Overall Study|Subject moved out of state|0
6223244|NCT01687166|9894526|FG001|Overall Study|Subject moved out of state|1
6132845|NCT00977080|9760735|FG003|Overall Study|Required kidney transplantation|1
6132846|NCT00977080|9760732|FG000|Overall Study|Travel for family reasons|1
6132847|NCT00977080|9760733|FG001|Overall Study|Travel for family reasons|0
6132848|NCT00977080|9760734|FG002|Overall Study|Travel for family reasons|0
6132849|NCT00977080|9760735|FG003|Overall Study|Travel for family reasons|0
6132850|NCT00977106|9760747|FG000|Overall Study|Adverse Event|5
6132851|NCT00977106|9760748|FG001|Overall Study|Adverse Event|6
6132852|NCT00977106|9760747|FG000|Overall Study|Withdrawal by Subject|2
6132853|NCT00977106|9760748|FG001|Overall Study|Withdrawal by Subject|2
6132854|NCT00977106|9760747|FG000|Overall Study|Lack of Efficacy|2
6132855|NCT00977106|9760748|FG001|Overall Study|Lack of Efficacy|2
6132856|NCT00977106|9760747|FG000|Overall Study|Protocol Violation|0
6132857|NCT00977106|9760748|FG001|Overall Study|Protocol Violation|1
6132858|NCT00977106|9760747|FG000|Overall Study|Other|1
6132859|NCT00977106|9760748|FG001|Overall Study|Other|0
6132860|NCT00977197|9760778|FG000|Overall Study|Withdrawal by Subject|3
6132861|NCT00977197|9760779|FG001|Overall Study|Withdrawal by Subject|4
6132862|NCT00977197|9760778|FG000|Overall Study|Adverse Event|3
6132863|NCT00977197|9760779|FG001|Overall Study|Adverse Event|1
6132864|NCT00977197|9760778|FG000|Overall Study|Lack of Efficacy|1
6132865|NCT00977197|9760779|FG001|Overall Study|Lack of Efficacy|0
6132866|NCT00977197|9760778|FG000|Overall Study|Lost to Follow-up|1
6132867|NCT00977197|9760779|FG001|Overall Study|Lost to Follow-up|3
6132868|NCT00977197|9760778|FG000|Overall Study|Nonadherence|1
6132869|NCT00977197|9760779|FG001|Overall Study|Nonadherence|1
6132870|NCT00977314|9760787|FG000|Overall Study|Withdrawal by Subject|1
6132871|NCT00977314|9760788|FG001|Overall Study|Withdrawal by Subject|0
6132872|NCT00977314|9760787|FG000|Overall Study|Physician Decision|1
6132873|NCT00977314|9760788|FG001|Overall Study|Physician Decision|0
6132874|NCT00977379|9760796|FG000|Overall Study|Withdrawal by Subject|1
6132875|NCT00977379|9760797|FG001|Overall Study|Withdrawal by Subject|1
6132876|NCT00977379|9760796|FG000|Overall Study|Death|7
6132877|NCT00977379|9760797|FG001|Overall Study|Death|9
6132878|NCT00977379|9760796|FG000|Overall Study|Premature Study Termination|4
6132879|NCT00977379|9760797|FG001|Overall Study|Premature Study Termination|0
6132880|NCT00977379|9760796|FG000|Overall Study|Participant Moving House|0
6132881|NCT00977379|9760797|FG001|Overall Study|Participant Moving House|1
6132882|NCT00977379|9760796|FG000|Overall Study|Randomization Error|0
6132883|NCT00977379|9760797|FG001|Overall Study|Randomization Error|1
6132884|NCT00977431|9760808|FG000|Overall Study|Other than listed|1
6132885|NCT00977431|9760809|FG001|Overall Study|Other than listed|0
6132886|NCT00977431|9760810|FG002|Overall Study|Other than listed|0
6132887|NCT00977431|9760811|FG003|Overall Study|Other than listed|0
6132888|NCT00977431|9760812|FG004|Overall Study|Other than listed|2
6132889|NCT00977431|9760808|FG000|Overall Study|Protocol Violation|0
6132890|NCT00977431|9760809|FG001|Overall Study|Protocol Violation|0
6132891|NCT00977431|9760810|FG002|Overall Study|Protocol Violation|1
6132892|NCT00977431|9760811|FG003|Overall Study|Protocol Violation|0
6132893|NCT00977431|9760812|FG004|Overall Study|Protocol Violation|0
6132894|NCT00977431|9760808|FG000|Overall Study|Adverse Event|3
6132895|NCT00977431|9760809|FG001|Overall Study|Adverse Event|0
6132896|NCT00977431|9760810|FG002|Overall Study|Adverse Event|4
6132897|NCT00977431|9760811|FG003|Overall Study|Adverse Event|0
6132898|NCT00977431|9760812|FG004|Overall Study|Adverse Event|6
6132899|NCT00977431|9760808|FG000|Overall Study|Dose-limiting toxicity (DLT)|1
6132900|NCT00977431|9760809|FG001|Overall Study|Dose-limiting toxicity (DLT)|0
6132901|NCT00977431|9760810|FG002|Overall Study|Dose-limiting toxicity (DLT)|1
6132902|NCT00977431|9760811|FG003|Overall Study|Dose-limiting toxicity (DLT)|0
6132903|NCT00977431|9760812|FG004|Overall Study|Dose-limiting toxicity (DLT)|0
6132904|NCT00977431|9760808|FG000|Overall Study|Progressive disease|2
6132905|NCT00977431|9760809|FG001|Overall Study|Progressive disease|6
6132906|NCT00977431|9760810|FG002|Overall Study|Progressive disease|1
6132907|NCT00977431|9760811|FG003|Overall Study|Progressive disease|3
6132908|NCT00977431|9760812|FG004|Overall Study|Progressive disease|5
6132909|NCT00977470|9760830|FG000|Overall Study|Lack of Efficacy|32
6132910|NCT00977470|9760831|FG001|Overall Study|Lack of Efficacy|30
6132911|NCT00977470|9760830|FG000|Overall Study|Physician Decision|2
6132912|NCT00977470|9760831|FG001|Overall Study|Physician Decision|0
6132913|NCT00977470|9760830|FG000|Overall Study|Adverse Event|1
6132914|NCT00977470|9760831|FG001|Overall Study|Adverse Event|2
6132915|NCT00977470|9760830|FG000|Overall Study|Protocol Violation|1
6132916|NCT00977470|9760831|FG001|Overall Study|Protocol Violation|0
6132917|NCT00977470|9760830|FG000|Overall Study|Withdrawal by Subject|0
6132918|NCT00977470|9760831|FG001|Overall Study|Withdrawal by Subject|2
6132919|NCT00977470|9760830|FG000|Overall Study|Death|0
6132920|NCT00977470|9760831|FG001|Overall Study|Death|2
6132921|NCT00977470|9760830|FG000|Overall Study|clinical decline|0
6132922|NCT00977470|9760831|FG001|Overall Study|clinical decline|1
6132923|NCT00977470|9760830|FG000|Overall Study|prolonged recovery post-surgery|0
6132924|NCT00977470|9760831|FG001|Overall Study|prolonged recovery post-surgery|1
6132925|NCT00977470|9760830|FG000|Overall Study|Still on-study|2
6132926|NCT00977470|9760831|FG001|Overall Study|Still on-study|0
6132927|NCT00977548|9760837|FG000|Overall Study|Ineligible|4
6132928|NCT00977548|9760837|FG000|Overall Study|Adverse Event|8
6132929|NCT00977548|9760837|FG000|Overall Study|Withdrawal by Subject|1
6132930|NCT00977561|9760843|FG000|Overall Study|Death|3
6132931|NCT00977561|9760844|FG001|Overall Study|Death|2
6132932|NCT00977561|9760843|FG000|Overall Study|Study terminated|0
6132933|NCT00977561|9760844|FG001|Overall Study|Study terminated|2
6132934|NCT00977561|9760843|FG000|Overall Study|Other|2
6132935|NCT00977561|9760844|FG001|Overall Study|Other|0
6132936|NCT00977613|9760852|FG000|Overall Study|Lost to Follow-up|16
6132937|NCT00977665|9760858|FG000|Overall Study|Withdrawal by Subject|1
6132938|NCT00977665|9760859|FG001|Overall Study|Withdrawal by Subject|3
6132939|NCT00977665|9760858|FG000|Overall Study|Physician Decision|2
6132940|NCT00977665|9760859|FG001|Overall Study|Physician Decision|1
6132941|NCT00977665|9760858|FG000|Overall Study|Sponsor requested withdrawal|0
6223245|NCT01687166|9894527|FG002|Overall Study|Subject moved out of state|0
6223246|NCT01687166|9894528|FG003|Overall Study|Subject moved out of state|0
6223247|NCT01687166|9894525|FG000|Overall Study|Patient unable to be compliant|1
6223248|NCT01687166|9894526|FG001|Overall Study|Patient unable to be compliant|0
6223249|NCT01687166|9894527|FG002|Overall Study|Patient unable to be compliant|0
6223250|NCT01687166|9894528|FG003|Overall Study|Patient unable to be compliant|0
6223251|NCT01687166|9894525|FG000|Overall Study|Physician choice to use different device|1
6223252|NCT01687166|9894526|FG001|Overall Study|Physician choice to use different device|2
6223253|NCT01687166|9894527|FG002|Overall Study|Physician choice to use different device|4
6223254|NCT01687166|9894528|FG003|Overall Study|Physician choice to use different device|0
6223255|NCT01687166|9894525|FG000|Overall Study|Insurance|0
6223256|NCT01687166|9894526|FG001|Overall Study|Insurance|0
6223257|NCT01687166|9894527|FG002|Overall Study|Insurance|1
6223258|NCT01687166|9894528|FG003|Overall Study|Insurance|1
6223259|NCT01687218|9894549|FG000|Overall Study|Withdrawal by Subject|2
6223260|NCT01687218|9894550|FG001|Overall Study|Withdrawal by Subject|3
6223261|NCT01687218|9894551|FG002|Overall Study|Withdrawal by Subject|0
6223262|NCT01687218|9894552|FG003|Overall Study|Withdrawal by Subject|1
6223263|NCT01687218|9894553|FG004|Overall Study|Withdrawal by Subject|1
6223264|NCT01687218|9894554|FG005|Overall Study|Withdrawal by Subject|0
6223265|NCT01687218|9894549|FG000|Overall Study|Relocated, no follow-up planned|1
6223266|NCT01687218|9894550|FG001|Overall Study|Relocated, no follow-up planned|0
5981068|NCT02538666|9570002|FG000|Overall Study|Disease progression|1
5981069|NCT02538666|9570003|FG001|Overall Study|Disease progression|0
5981070|NCT02538666|9570004|FG002|Overall Study|Disease progression|0
5981071|NCT02538666|9570002|FG000|Overall Study|no longer meets study criteria|1
5981072|NCT02538666|9570003|FG001|Overall Study|no longer meets study criteria|0
6132942|NCT00977665|9760859|FG001|Overall Study|Sponsor requested withdrawal|1
6223267|NCT01687218|9894551|FG002|Overall Study|Relocated, no follow-up planned|1
6223268|NCT01687218|9894552|FG003|Overall Study|Relocated, no follow-up planned|1
6223269|NCT01687218|9894553|FG004|Overall Study|Relocated, no follow-up planned|0
6223270|NCT01687218|9894554|FG005|Overall Study|Relocated, no follow-up planned|0
6223271|NCT01687257|9894581|FG000|Overall Study|Efficacy Failure|6
6223272|NCT01687257|9894582|FG001|Overall Study|Efficacy Failure|0
6223273|NCT01687257|9894583|FG002|Overall Study|Efficacy Failure|5
6223274|NCT01687257|9894581|FG000|Overall Study|Subject Withdrew Consent|1
6223275|NCT01687257|9894582|FG001|Overall Study|Subject Withdrew Consent|1
6223276|NCT01687257|9894583|FG002|Overall Study|Subject Withdrew Consent|1
6223277|NCT01687257|9894581|FG000|Overall Study|Adverse Event|1
6223278|NCT01687257|9894582|FG001|Overall Study|Adverse Event|0
6223279|NCT01687257|9894583|FG002|Overall Study|Adverse Event|0
6223280|NCT01687257|9894581|FG000|Overall Study|Investigator's Discretion|0
6223281|NCT01687257|9894582|FG001|Overall Study|Investigator's Discretion|3
6223282|NCT01687257|9894583|FG002|Overall Study|Investigator's Discretion|0
6223283|NCT01687270|9894597|FG000|Overall Study|Lack of Efficacy|11
6223284|NCT01687270|9894597|FG000|Overall Study|Lost to Follow-up|1
6223285|NCT01687283|9894603|FG000|Overall Study|Adverse Event|11
6223286|NCT01687283|9894604|FG001|Overall Study|Adverse Event|4
6223287|NCT01687283|9894603|FG000|Overall Study|Lack of Efficacy|3
6223288|NCT01687283|9894604|FG001|Overall Study|Lack of Efficacy|1
6223289|NCT01687283|9894603|FG000|Overall Study|Protocol Violation|1
6223290|NCT01687283|9894604|FG001|Overall Study|Protocol Violation|3
6223291|NCT01687283|9894603|FG000|Overall Study|protocol defined stopping criteria|8
6223292|NCT01687283|9894604|FG001|Overall Study|protocol defined stopping criteria|10
6223293|NCT01687283|9894603|FG000|Overall Study|Lost to Follow-up|1
6223294|NCT01687283|9894604|FG001|Overall Study|Lost to Follow-up|1
6223295|NCT01687283|9894603|FG000|Overall Study|Investigator discretion|2
6223296|NCT01687283|9894604|FG001|Overall Study|Investigator discretion|0
6223297|NCT01687283|9894603|FG000|Overall Study|Withdrawal by Subject|9
6223298|NCT01687283|9894604|FG001|Overall Study|Withdrawal by Subject|8
6223299|NCT01687296|9894612|FG000|Overall Study|Lack of Efficacy|1
6223300|NCT01687296|9894613|FG001|Overall Study|Lack of Efficacy|1
6223301|NCT01687296|9894612|FG000|Overall Study|Protocol Violation|0
6223302|NCT01687296|9894613|FG001|Overall Study|Protocol Violation|1
6223303|NCT01687296|9894612|FG000|Overall Study|Withdrawal by Subject|6
6223304|NCT01687296|9894613|FG001|Overall Study|Withdrawal by Subject|3
6223305|NCT01687413|9894643|FG000|Overall Study|Withdrawal by Subject|0
6223306|NCT01687413|9894644|FG001|Overall Study|Withdrawal by Subject|2
6223307|NCT01687413|9894643|FG000|Overall Study|Not eligible|0
6132943|NCT00977665|9760858|FG000|Overall Study|Lost to Follow-up|1
6223308|NCT01687413|9894644|FG001|Overall Study|Not eligible|2
5981073|NCT02538666|9570004|FG002|Overall Study|no longer meets study criteria|0
6132944|NCT00977665|9760859|FG001|Overall Study|Lost to Follow-up|0
6132945|NCT00977665|9760858|FG000|Overall Study|Death|3
6132946|NCT00977665|9760859|FG001|Overall Study|Death|2
6132947|NCT00977665|9760858|FG000|Overall Study|Adverse Event|14
6132948|NCT00977665|9760859|FG001|Overall Study|Adverse Event|7
6132949|NCT00977665|9760858|FG000|Overall Study|Treatment failure|0
6132950|NCT00977665|9760859|FG001|Overall Study|Treatment failure|1
6132951|NCT00977938|9760891|FG000|Treatment (12-30 mo. Post Procedure)|Withdrawal by Subject|132
6132952|NCT00977938|9760892|FG001|Treatment (12-30 mo. Post Procedure)|Withdrawal by Subject|116
6132953|NCT00977938|9760893|FG002|Treatment (12-30 mo. Post Procedure)|Withdrawal by Subject|13
6132954|NCT00977938|9760894|FG003|Treatment (12-30 mo. Post Procedure)|Withdrawal by Subject|20
6132955|NCT00977938|9760891|FG000|Treatment (12-30 mo. Post Procedure)|Lost to Follow-up|88
6132956|NCT00977938|9760892|FG001|Treatment (12-30 mo. Post Procedure)|Lost to Follow-up|91
6132957|NCT00977938|9760893|FG002|Treatment (12-30 mo. Post Procedure)|Lost to Follow-up|30
6132958|NCT00977938|9760894|FG003|Treatment (12-30 mo. Post Procedure)|Lost to Follow-up|37
6132959|NCT00977938|9760891|FG000|Treatment (12-30 mo. Post Procedure)|Other|17
6132960|NCT00977938|9760892|FG001|Treatment (12-30 mo. Post Procedure)|Other|18
6132961|NCT00977938|9760893|FG002|Treatment (12-30 mo. Post Procedure)|Other|3
6132962|NCT00977938|9760894|FG003|Treatment (12-30 mo. Post Procedure)|Other|4
6132963|NCT00977938|9760891|FG000|Observation (30-33 mo. Post Procedure)|Withdrawal by Subject|9
6132964|NCT00977938|9760892|FG001|Observation (30-33 mo. Post Procedure)|Withdrawal by Subject|12
6132965|NCT00977938|9760893|FG002|Observation (30-33 mo. Post Procedure)|Withdrawal by Subject|2
6132966|NCT00977938|9760894|FG003|Observation (30-33 mo. Post Procedure)|Withdrawal by Subject|0
6132967|NCT00977938|9760891|FG000|Observation (30-33 mo. Post Procedure)|Lost to Follow-up|34
6132968|NCT00977938|9760892|FG001|Observation (30-33 mo. Post Procedure)|Lost to Follow-up|42
6132969|NCT00977938|9760893|FG002|Observation (30-33 mo. Post Procedure)|Lost to Follow-up|10
6132970|NCT00977938|9760894|FG003|Observation (30-33 mo. Post Procedure)|Lost to Follow-up|3
6132971|NCT00977938|9760891|FG000|Observation (30-33 mo. Post Procedure)|Other|8
6223309|NCT01687413|9894643|FG000|Overall Study|Patient withdrew before completing all radiotherapy|1
6223310|NCT01687413|9894644|FG001|Overall Study|Patient withdrew before completing all radiotherapy|0
6223311|NCT01687478|9894670|FG000|Overall Study|Adverse Event|3
6223312|NCT01687478|9894671|FG001|Overall Study|Adverse Event|10
6223313|NCT01687478|9894670|FG000|Overall Study|Lost to Follow-up|1
6223314|NCT01687478|9894671|FG001|Overall Study|Lost to Follow-up|3
6223315|NCT01687478|9894670|FG000|Overall Study|Protocol Violation|0
6223316|NCT01687478|9894671|FG001|Overall Study|Protocol Violation|2
6223317|NCT01687478|9894670|FG000|Overall Study|Withdrawal by Subject|21
6223318|NCT01687478|9894671|FG001|Overall Study|Withdrawal by Subject|19
6223319|NCT01687478|9894670|FG000|Overall Study|Physician Decision|1
6223320|NCT01687478|9894671|FG001|Overall Study|Physician Decision|3
6223321|NCT01687478|9894670|FG000|Overall Study|Entry Criteria Not Met|6
6223322|NCT01687478|9894671|FG001|Overall Study|Entry Criteria Not Met|2
6223323|NCT01687595|9894679|FG000|Overall Study|Withdrawal by Subject|8
6223324|NCT01687595|9894680|FG001|Overall Study|Withdrawal by Subject|0
6223325|NCT01687595|9894679|FG000|Overall Study|Lost to Follow-up|3
6223326|NCT01687595|9894680|FG001|Overall Study|Lost to Follow-up|1
6223327|NCT01687595|9894679|FG000|Overall Study|Investigator's decision|1
6223328|NCT01687595|9894680|FG001|Overall Study|Investigator's decision|0
6223329|NCT01687595|9894679|FG000|Overall Study|Sponsor's decision|1
6223330|NCT01687595|9894680|FG001|Overall Study|Sponsor's decision|0
6223331|NCT01687595|9894679|FG000|Overall Study|Noncompliance|1
6223332|NCT01687595|9894680|FG001|Overall Study|Noncompliance|2
6223333|NCT01687595|9894679|FG000|Overall Study|Other than specified|56
6223334|NCT01687595|9894680|FG001|Overall Study|Other than specified|7
6223335|NCT01687673|9894686|FG000|Overall Study|Physician Decision|1
6223336|NCT01687712|9894692|FG000|Cycle 1|Not Biochemically Pregnant|386
6223337|NCT01687712|9894693|FG001|Cycle 1|Not Biochemically Pregnant|348
6223338|NCT01687712|9894692|FG000|Cycle 1|Early Pregnancy Loss|43
6223339|NCT01687712|9894693|FG001|Cycle 1|Early Pregnancy Loss|60
6223340|NCT01687712|9894692|FG000|Cycle 1|Ectopic Pregnancy|5
6223341|NCT01687712|9894693|FG001|Cycle 1|Ectopic Pregnancy|5
6223342|NCT01687712|9894692|FG000|Cycle 1|Heterotropic Pregnancy|1
6223343|NCT01687712|9894693|FG001|Cycle 1|Heterotropic Pregnancy|0
6223344|NCT01687712|9894692|FG000|Cycle 1|Miscarriage/Spontaneous Abortion|9
6223345|NCT01687712|9894693|FG001|Cycle 1|Miscarriage/Spontaneous Abortion|14
6223346|NCT01687712|9894692|FG000|Cycle 1|Abortion|3
6223347|NCT01687712|9894693|FG001|Cycle 1|Abortion|0
6223348|NCT01687712|9894692|FG000|Cycle 1|Intrauterine Fetal Death|0
6223349|NCT01687712|9894693|FG001|Cycle 1|Intrauterine Fetal Death|1
6223350|NCT01687712|9894692|FG000|Cycle 1|Lost to Follow-up|1
6223351|NCT01687712|9894693|FG001|Cycle 1|Lost to Follow-up|1
6223352|NCT01687712|9894692|FG000|Cycle 2|Not Biochemically Pregnant|74
6223353|NCT01687712|9894693|FG001|Cycle 2|Not Biochemically Pregnant|77
6223354|NCT01687712|9894692|FG000|Cycle 2|Early Pregnancy Loss|18
6223355|NCT01687712|9894693|FG001|Cycle 2|Early Pregnancy Loss|16
6223356|NCT01687712|9894692|FG000|Cycle 2|Ectopic Pregnancy|0
6223357|NCT01687712|9894693|FG001|Cycle 2|Ectopic Pregnancy|1
6223358|NCT01687712|9894692|FG000|Cycle 2|Still Birth|1
6223359|NCT01687712|9894693|FG001|Cycle 2|Still Birth|0
6223360|NCT01687712|9894692|FG000|Cycle 2|Miscarriage/Spontaneous Abortion|0
6223361|NCT01687712|9894693|FG001|Cycle 2|Miscarriage/Spontaneous Abortion|1
6132972|NCT00977938|9760892|FG001|Observation (30-33 mo. Post Procedure)|Other|4
6132973|NCT00977938|9760893|FG002|Observation (30-33 mo. Post Procedure)|Other|0
6132974|NCT00977938|9760894|FG003|Observation (30-33 mo. Post Procedure)|Other|0
6132975|NCT00978029|9760909|FG000|Overall Study|Adverse Event|1
6132976|NCT00978029|9760910|FG001|Overall Study|Adverse Event|2
6132977|NCT00978029|9760911|FG002|Overall Study|Adverse Event|5
6132978|NCT00978029|9760909|FG000|Overall Study|Withdrawal by Subject|0
6132979|NCT00978029|9760910|FG001|Overall Study|Withdrawal by Subject|0
6132980|NCT00978029|9760911|FG002|Overall Study|Withdrawal by Subject|1
6132981|NCT00978029|9760909|FG000|Overall Study|Protocol Violation|0
6132982|NCT00978029|9760910|FG001|Overall Study|Protocol Violation|1
6132983|NCT00978029|9760911|FG002|Overall Study|Protocol Violation|0
6132984|NCT00978042|9760921|FG000|Initial Treatment Period|Treated in Error|0
6223362|NCT01687712|9894692|FG000|Cycle 3|Not Biochemically Pregnant|21
6223363|NCT01687712|9894693|FG001|Cycle 3|Not Biochemically Pregnant|22
6223364|NCT01687712|9894692|FG000|Cycle 3|Early Pregnancy Loss|1
6223365|NCT01687712|9894693|FG001|Cycle 3|Early Pregnancy Loss|2
6223366|NCT01687712|9894692|FG000|Cycle 3|Ectopic Pregnancy|1
6223367|NCT01687712|9894693|FG001|Cycle 3|Ectopic Pregnancy|0
6223368|NCT01687712|9894692|FG000|Cycle 3|Miscarriage/Spontaneous Abortion|1
6223369|NCT01687712|9894693|FG001|Cycle 3|Miscarriage/Spontaneous Abortion|0
6223370|NCT01687998|9894719|FG000|Overall Study|Withdrawal by Subject|49
6223371|NCT01687998|9894720|FG001|Overall Study|Withdrawal by Subject|51
6223372|NCT01687998|9894719|FG000|Overall Study|Known to be Alive at Study End|54
6223373|NCT01687998|9894720|FG001|Overall Study|Known to be Alive at Study End|62
6223374|NCT01687998|9894719|FG000|Overall Study|Lost to Follow-up|9
6223375|NCT01687998|9894720|FG001|Overall Study|Lost to Follow-up|7
6223376|NCT01688037|9894729|FG000|Double-Blind Period (Week 0 to 6)|Adverse Event|1
6223377|NCT01688037|9894730|FG001|Double-Blind Period (Week 0 to 6)|Adverse Event|0
6223378|NCT01688037|9894731|FG002|Double-Blind Period (Week 0 to 6)|Adverse Event|1
6223379|NCT01688037|9894729|FG000|Double-Blind Period (Week 0 to 6)|Non-compliance|1
6223380|NCT01688037|9894730|FG001|Double-Blind Period (Week 0 to 6)|Non-compliance|2
6223381|NCT01688037|9894731|FG002|Double-Blind Period (Week 0 to 6)|Non-compliance|3
6223382|NCT01688037|9894729|FG000|Double-Blind Period (Week 0 to 6)|Withdrawal by Subject|4
6223383|NCT01688037|9894730|FG001|Double-Blind Period (Week 0 to 6)|Withdrawal by Subject|0
6223384|NCT01688037|9894731|FG002|Double-Blind Period (Week 0 to 6)|Withdrawal by Subject|1
6223385|NCT01688037|9894729|FG000|Double-Blind Period (Week 0 to 6)|Lost to Follow-up|1
6223386|NCT01688037|9894730|FG001|Double-Blind Period (Week 0 to 6)|Lost to Follow-up|0
6223387|NCT01688037|9894731|FG002|Double-Blind Period (Week 0 to 6)|Lost to Follow-up|1
6223388|NCT01688037|9894729|FG000|Double-Blind Period (Week 0 to 6)|Physician Decision|0
6223389|NCT01688037|9894730|FG001|Double-Blind Period (Week 0 to 6)|Physician Decision|1
6223390|NCT01688037|9894731|FG002|Double-Blind Period (Week 0 to 6)|Physician Decision|0
6223391|NCT01688037|9894729|FG000|Open-Label Period (Week 6 to 12)|Adverse Event|4
6223392|NCT01688037|9894730|FG001|Open-Label Period (Week 6 to 12)|Adverse Event|1
6223393|NCT01688037|9894731|FG002|Open-Label Period (Week 6 to 12)|Adverse Event|1
6223394|NCT01688037|9894729|FG000|Open-Label Period (Week 6 to 12)|Non-compliance|0
6223395|NCT01688037|9894730|FG001|Open-Label Period (Week 6 to 12)|Non-compliance|0
6223396|NCT01688037|9894731|FG002|Open-Label Period (Week 6 to 12)|Non-compliance|2
6223397|NCT01688037|9894729|FG000|Open-Label Period (Week 6 to 12)|Withdrawal by Subject|1
6223398|NCT01688037|9894730|FG001|Open-Label Period (Week 6 to 12)|Withdrawal by Subject|2
6223399|NCT01688037|9894731|FG002|Open-Label Period (Week 6 to 12)|Withdrawal by Subject|0
6223400|NCT01688037|9894729|FG000|Open-Label Period (Week 6 to 12)|Lost to Follow-up|0
6223401|NCT01688037|9894730|FG001|Open-Label Period (Week 6 to 12)|Lost to Follow-up|0
6223402|NCT01688037|9894731|FG002|Open-Label Period (Week 6 to 12)|Lost to Follow-up|1
6223403|NCT01688037|9894729|FG000|Follow-up Period (Week 12 to 16)|Withdrawal by Subject|0
6223404|NCT01688037|9894730|FG001|Follow-up Period (Week 12 to 16)|Withdrawal by Subject|1
6223405|NCT01688037|9894731|FG002|Follow-up Period (Week 12 to 16)|Withdrawal by Subject|0
6223406|NCT01688050|9894743|FG000|Overall Study|Death|7
6223407|NCT01688050|9894743|FG000|Overall Study|Conversion to open repair|1
6223408|NCT01688050|9894743|FG000|Overall Study|Lost to Follow-up|13
6223409|NCT01688050|9894743|FG000|Overall Study|Withdrawal by Subject|10
6223410|NCT01688466|9894783|FG000|Overall Study|Withdrawal by Subject|2
6223411|NCT01688466|9894784|FG001|Overall Study|Withdrawal by Subject|1
6223412|NCT01688466|9894783|FG000|Overall Study|Death|0
6223413|NCT01688466|9894784|FG001|Overall Study|Death|1
6223414|NCT01688466|9894783|FG000|Overall Study|Adverse Event|0
6223415|NCT01688466|9894784|FG001|Overall Study|Adverse Event|4
6223416|NCT01688466|9894783|FG000|Overall Study|Not evaluable|0
6223417|NCT01688466|9894784|FG001|Overall Study|Not evaluable|1
6223418|NCT01688635|9894803|FG000|Washout 1|Withdrawal by Subject|1
6223419|NCT01688635|9894804|FG001|Washout 1|Withdrawal by Subject|0
6223420|NCT01688635|9894803|FG000|Washout 1|Adverse Event|0
6223421|NCT01688635|9894804|FG001|Washout 1|Adverse Event|1
6223422|NCT01688635|9894803|FG000|Washout 1|Physician Decision|0
6223423|NCT01688635|9894804|FG001|Washout 1|Physician Decision|1
6223424|NCT01688635|9894803|FG000|Washout 2|Physician Decision|1
6223425|NCT01688635|9894804|FG001|Washout 2|Physician Decision|0
6223426|NCT01688635|9894803|FG000|Washout 2|Withdrawal by Subject|1
6223427|NCT01688635|9894804|FG001|Washout 2|Withdrawal by Subject|0
6223428|NCT01688635|9894803|FG000|Washout 2|Sponsor Decision|1
6132985|NCT00978042|9760922|FG001|Initial Treatment Period|Treated in Error|3
6132986|NCT00978042|9760921|FG000|Initial Treatment Period|Ineligibility|1
6132987|NCT00978042|9760922|FG001|Initial Treatment Period|Ineligibility|0
6132988|NCT00978042|9760921|FG000|Initial Treatment Period|Lost to Follow-up|21
6132989|NCT00978042|9760922|FG001|Initial Treatment Period|Lost to Follow-up|3
6132990|NCT00978042|9760921|FG000|Initial Treatment Period|Adverse Event|2
6132991|NCT00978042|9760922|FG001|Initial Treatment Period|Adverse Event|0
6132992|NCT00978042|9760921|FG000|Initial Treatment Period|Discontinuation by Investigator/Sponsor|2
6132993|NCT00978042|9760922|FG001|Initial Treatment Period|Discontinuation by Investigator/Sponsor|0
6132994|NCT00978042|9760921|FG000|Initial Treatment Period|Consent withdrawn|22
6132995|NCT00978042|9760922|FG001|Initial Treatment Period|Consent withdrawn|9
6132996|NCT00978042|9760921|FG000|Initial Treatment Period|Other Miscellaneous Reasons|13
6132997|NCT00978042|9760922|FG001|Initial Treatment Period|Other Miscellaneous Reasons|0
6132998|NCT00978068|9760930|FG000|Overall Study|Were Awaiting Initiation of ART|2
6132999|NCT00978068|9760931|FG001|Overall Study|Were Awaiting Initiation of ART|2
6133000|NCT00978068|9760930|FG000|Overall Study|Death|1
6133001|NCT00978068|9760931|FG001|Overall Study|Death|2
6133002|NCT00978068|9760930|FG000|Overall Study|Lost to Follow-up|1
6133003|NCT00978068|9760931|FG001|Overall Study|Lost to Follow-up|2
6133004|NCT00978068|9760930|FG000|Overall Study|Physician Decision|0
6133005|NCT00978068|9760931|FG001|Overall Study|Physician Decision|1
6133006|NCT00978068|9760930|FG000|Overall Study|Unable to Comply with Study|0
6133007|NCT00978068|9760931|FG001|Overall Study|Unable to Comply with Study|2
6133008|NCT00978120|9760945|FG000|Overall Study|Death|0
6133009|NCT00978120|9760946|FG001|Overall Study|Death|0
6133010|NCT00978120|9760947|FG002|Overall Study|Death|0
6133011|NCT00978120|9760948|FG003|Overall Study|Death|1
6133012|NCT00978120|9760945|FG000|Overall Study|Lost to Follow-up|0
6133013|NCT00978120|9760946|FG001|Overall Study|Lost to Follow-up|0
6133014|NCT00978120|9760947|FG002|Overall Study|Lost to Follow-up|3
6133015|NCT00978120|9760948|FG003|Overall Study|Lost to Follow-up|0
6133016|NCT00978120|9760945|FG000|Overall Study|Withdrawal by Subject|2
6133017|NCT00978120|9760946|FG001|Overall Study|Withdrawal by Subject|0
6133018|NCT00978120|9760947|FG002|Overall Study|Withdrawal by Subject|0
6133019|NCT00978120|9760948|FG003|Overall Study|Withdrawal by Subject|0
6133020|NCT00978120|9760945|FG000|Overall Study|Moved out of state|0
6133021|NCT00978120|9760946|FG001|Overall Study|Moved out of state|0
6133022|NCT00978120|9760947|FG002|Overall Study|Moved out of state|0
6133023|NCT00978120|9760948|FG003|Overall Study|Moved out of state|1
6133024|NCT00978250|9760966|FG000|Overall Study|Late determination of ineligibility|0
6133025|NCT00978250|9760967|FG001|Overall Study|Late determination of ineligibility|1
6133026|NCT00978250|9760968|FG002|Overall Study|Late determination of ineligibility|0
6133027|NCT00978250|9760969|FG003|Overall Study|Late determination of ineligibility|1
6133028|NCT00978341|9760981|FG000|Washout Period of 2 Weeks|Adverse Event|1
6133029|NCT00978341|9760982|FG001|Washout Period of 2 Weeks|Adverse Event|0
6133030|NCT00978380|9760989|FG000|Overall Study|Protocol Violation|2
6133031|NCT00978380|9760989|FG000|Overall Study|Withdrawal criteria|9
6133032|NCT00978380|9760989|FG000|Overall Study|Unclassified|8
6133033|NCT00978432|9760997|FG000|Overall Study|Withdrawal by Subject|0
6133034|NCT00978432|9760998|FG001|Overall Study|Withdrawal by Subject|0
6133035|NCT00978432|9760999|FG002|Overall Study|Withdrawal by Subject|1
6133036|NCT00978432|9760997|FG000|Overall Study|Lack of Efficacy|1
6133037|NCT00978432|9760998|FG001|Overall Study|Lack of Efficacy|1
6133038|NCT00978432|9760999|FG002|Overall Study|Lack of Efficacy|3
6133039|NCT00978432|9760997|FG000|Overall Study|Adverse Event|2
6133040|NCT00978432|9760998|FG001|Overall Study|Adverse Event|0
6133041|NCT00978432|9760999|FG002|Overall Study|Adverse Event|1
6133042|NCT00978627|9761022|FG000|Main: Week 0 to 26 (NN5401-3594)|Adverse Event|4
6133043|NCT00978627|9761023|FG001|Main: Week 0 to 26 (NN5401-3594)|Adverse Event|3
6133044|NCT00978627|9761022|FG000|Main: Week 0 to 26 (NN5401-3594)|Lack of Efficacy|2
6133045|NCT00978627|9761023|FG001|Main: Week 0 to 26 (NN5401-3594)|Lack of Efficacy|0
6133046|NCT00978627|9761022|FG000|Main: Week 0 to 26 (NN5401-3594)|Protocol Violation|8
6133047|NCT00978627|9761023|FG001|Main: Week 0 to 26 (NN5401-3594)|Protocol Violation|6
6133048|NCT00978627|9761022|FG000|Main: Week 0 to 26 (NN5401-3594)|Withdrawal criteria|7
6133049|NCT00978627|9761023|FG001|Main: Week 0 to 26 (NN5401-3594)|Withdrawal criteria|5
6133050|NCT00978627|9761022|FG000|Main: Week 0 to 26 (NN5401-3594)|Unclassified|25
6133051|NCT00978627|9761023|FG001|Main: Week 0 to 26 (NN5401-3594)|Unclassified|12
6133052|NCT00978627|9761022|FG000|Extension: Week 27 to 52 (NN5401-3645)|Adverse Event|3
6133053|NCT00978627|9761023|FG001|Extension: Week 27 to 52 (NN5401-3645)|Adverse Event|0
6133054|NCT00978627|9761022|FG000|Extension: Week 27 to 52 (NN5401-3645)|Protocol Violation|4
6133055|NCT00978627|9761023|FG001|Extension: Week 27 to 52 (NN5401-3645)|Protocol Violation|1
6133056|NCT00978627|9761022|FG000|Extension: Week 27 to 52 (NN5401-3645)|Withdrawal criteria|2
6133057|NCT00978627|9761023|FG001|Extension: Week 27 to 52 (NN5401-3645)|Withdrawal criteria|1
6133058|NCT00978627|9761022|FG000|Extension: Week 27 to 52 (NN5401-3645)|Unclassified|12
6133059|NCT00978627|9761023|FG001|Extension: Week 27 to 52 (NN5401-3645)|Unclassified|7
6133060|NCT00978731|9761033|FG000|Overall Study|Death|4
6133061|NCT00978731|9761034|FG001|Overall Study|Death|1
6133062|NCT00978731|9761035|FG002|Overall Study|Death|1
6133063|NCT00978731|9761036|FG003|Overall Study|Death|0
6133064|NCT00978731|9761033|FG000|Overall Study|Lost to Follow-up|0
6133065|NCT00978731|9761034|FG001|Overall Study|Lost to Follow-up|0
6133066|NCT00978731|9761035|FG002|Overall Study|Lost to Follow-up|0
6133067|NCT00978731|9761036|FG003|Overall Study|Lost to Follow-up|1
6133068|NCT00978731|9761033|FG000|Overall Study|Adverse Event|5
6133069|NCT00978731|9761034|FG001|Overall Study|Adverse Event|2
6133070|NCT00978731|9761035|FG002|Overall Study|Adverse Event|0
6133071|NCT00978731|9761036|FG003|Overall Study|Adverse Event|0
6133072|NCT00978731|9761033|FG000|Overall Study|Participant's request|1
6133073|NCT00978731|9761034|FG001|Overall Study|Participant's request|0
6133074|NCT00978731|9761035|FG002|Overall Study|Participant's request|0
6133075|NCT00978731|9761036|FG003|Overall Study|Participant's request|0
6133076|NCT00978731|9761033|FG000|Overall Study|Administrative reason|3
6133077|NCT00978731|9761034|FG001|Overall Study|Administrative reason|3
6133078|NCT00978731|9761035|FG002|Overall Study|Administrative reason|1
6133079|NCT00978731|9761036|FG003|Overall Study|Administrative reason|0
6133080|NCT00978731|9761033|FG000|Overall Study|Deterioration without progression|0
6133081|NCT00978731|9761034|FG001|Overall Study|Deterioration without progression|1
6133082|NCT00978731|9761035|FG002|Overall Study|Deterioration without progression|0
6133083|NCT00978731|9761036|FG003|Overall Study|Deterioration without progression|0
6133084|NCT00978731|9761033|FG000|Overall Study|Disease progression/relapse|5
6133085|NCT00978731|9761034|FG001|Overall Study|Disease progression/relapse|4
6133086|NCT00978731|9761035|FG002|Overall Study|Disease progression/relapse|2
6223429|NCT01688635|9894804|FG001|Washout 2|Sponsor Decision|2
6223430|NCT01688635|9894803|FG000|Washout 3|Withdrawal by Subject|1
6223431|NCT01688635|9894804|FG001|Washout 3|Withdrawal by Subject|0
6223432|NCT01688726|9894813|FG000|Overall Study|Adverse Event|1
6223433|NCT01688726|9894814|FG001|Overall Study|Adverse Event|0
6223434|NCT01688726|9894813|FG000|Overall Study|Relocated abroad|0
6223435|NCT01688726|9894814|FG001|Overall Study|Relocated abroad|1
6223436|NCT01688739|9894834|FG000|Overall Study|Administrative Decision|1
6223437|NCT01688739|9894835|FG001|Overall Study|Administrative Decision|0
6223438|NCT01688739|9894836|FG002|Overall Study|Administrative Decision|0
6223439|NCT01688739|9894837|FG003|Overall Study|Administrative Decision|0
6223440|NCT01688739|9894838|FG004|Overall Study|Administrative Decision|0
6290034|NCT02392611|10005783|FG000|Overall Study|Progressive disease|0
6290035|NCT02392611|10005784|FG001|Overall Study|Progressive disease|0
6290036|NCT02392611|10005785|FG002|Overall Study|Progressive disease|0
6290037|NCT02392611|10005786|FG003|Overall Study|Progressive disease|2
6290038|NCT02392611|10005787|FG004|Overall Study|Progressive disease|1
6290039|NCT02392611|10005788|FG005|Overall Study|Progressive disease|0
6290040|NCT02392611|10005789|FG006|Overall Study|Progressive disease|0
6290041|NCT02392611|10005790|FG007|Overall Study|Progressive disease|0
6290042|NCT02392611|10005791|FG008|Overall Study|Progressive disease|0
6290043|NCT02392611|10005783|FG000|Overall Study|Death|1
6290044|NCT02392611|10005784|FG001|Overall Study|Death|0
6290045|NCT02392611|10005785|FG002|Overall Study|Death|0
6290046|NCT02392611|10005786|FG003|Overall Study|Death|0
6290047|NCT02392611|10005787|FG004|Overall Study|Death|0
6290048|NCT02392611|10005788|FG005|Overall Study|Death|1
6290049|NCT02392611|10005789|FG006|Overall Study|Death|0
6290050|NCT02392611|10005790|FG007|Overall Study|Death|0
6290051|NCT02392611|10005791|FG008|Overall Study|Death|0
6290052|NCT02392611|10005783|FG000|Overall Study|Withdrawal by Subject|0
6290053|NCT02392611|10005784|FG001|Overall Study|Withdrawal by Subject|0
6290054|NCT02392611|10005785|FG002|Overall Study|Withdrawal by Subject|0
6290055|NCT02392611|10005786|FG003|Overall Study|Withdrawal by Subject|1
6290056|NCT02392611|10005787|FG004|Overall Study|Withdrawal by Subject|0
6290057|NCT02392611|10005788|FG005|Overall Study|Withdrawal by Subject|0
6290058|NCT02392611|10005789|FG006|Overall Study|Withdrawal by Subject|0
6290059|NCT02392611|10005790|FG007|Overall Study|Withdrawal by Subject|0
6290060|NCT02392611|10005791|FG008|Overall Study|Withdrawal by Subject|0
6290061|NCT02392611|10005783|FG000|Overall Study|Lost to Follow-up|0
6290062|NCT02392611|10005784|FG001|Overall Study|Lost to Follow-up|0
6290063|NCT02392611|10005785|FG002|Overall Study|Lost to Follow-up|0
6290064|NCT02392611|10005786|FG003|Overall Study|Lost to Follow-up|0
6290065|NCT02392611|10005787|FG004|Overall Study|Lost to Follow-up|0
6290066|NCT02392611|10005788|FG005|Overall Study|Lost to Follow-up|0
6290067|NCT02392611|10005789|FG006|Overall Study|Lost to Follow-up|1
6290068|NCT02392611|10005790|FG007|Overall Study|Lost to Follow-up|0
6290069|NCT02392611|10005791|FG008|Overall Study|Lost to Follow-up|0
6290070|NCT02392611|10005783|FG000|Overall Study|Enrolled, not treated|0
6290071|NCT02392611|10005784|FG001|Overall Study|Enrolled, not treated|0
5981074|NCT02538666|9570002|FG000|Overall Study|Withdrew Consent|0
6133087|NCT00978731|9761036|FG003|Overall Study|Disease progression/relapse|2
6133088|NCT00978731|9761033|FG000|Overall Study|Study closure|3
6133089|NCT00978731|9761034|FG001|Overall Study|Study closure|4
6133090|NCT00978731|9761035|FG002|Overall Study|Study closure|1
6133091|NCT00978731|9761036|FG003|Overall Study|Study closure|1
6133092|NCT00978731|9761033|FG000|Overall Study|No response|1
6290072|NCT02392611|10005785|FG002|Overall Study|Enrolled, not treated|0
6290073|NCT02392611|10005786|FG003|Overall Study|Enrolled, not treated|2
6290074|NCT02392611|10005787|FG004|Overall Study|Enrolled, not treated|0
6290075|NCT02392611|10005788|FG005|Overall Study|Enrolled, not treated|0
6290076|NCT02392611|10005789|FG006|Overall Study|Enrolled, not treated|0
6290077|NCT02392611|10005790|FG007|Overall Study|Enrolled, not treated|0
6133093|NCT00978731|9761034|FG001|Overall Study|No response|0
6133094|NCT00978731|9761035|FG002|Overall Study|No response|0
6133095|NCT00978731|9761036|FG003|Overall Study|No response|0
6133096|NCT00978757|9761052|FG000|Overall Study|Physician Decision|1
6133097|NCT00978757|9761053|FG001|Overall Study|Physician Decision|3
6133098|NCT00979134|9761090|FG000|Overall Study|Disease progression|18
6133099|NCT00979134|9761091|FG001|Overall Study|Disease progression|2
6133100|NCT00979134|9761092|FG002|Overall Study|Disease progression|5
6133101|NCT00979134|9761090|FG000|Overall Study|Adverse Event|0
6133102|NCT00979134|9761091|FG001|Overall Study|Adverse Event|0
6133103|NCT00979134|9761092|FG002|Overall Study|Adverse Event|2
6133104|NCT00979134|9761090|FG000|Overall Study|Withdrawal by Subject|1
6133105|NCT00979134|9761091|FG001|Overall Study|Withdrawal by Subject|1
6133106|NCT00979134|9761092|FG002|Overall Study|Withdrawal by Subject|2
6133107|NCT00979134|9761090|FG000|Overall Study|Lost to Follow-up|2
6133108|NCT00979134|9761091|FG001|Overall Study|Lost to Follow-up|2
6133109|NCT00979134|9761092|FG002|Overall Study|Lost to Follow-up|0
6133110|NCT00979134|9761090|FG000|Overall Study|Death|4
6133111|NCT00979134|9761091|FG001|Overall Study|Death|0
6133112|NCT00979134|9761092|FG002|Overall Study|Death|26
6133113|NCT00979134|9761090|FG000|Overall Study|Other|8
6133114|NCT00979134|9761091|FG001|Overall Study|Other|1
6133115|NCT00979134|9761092|FG002|Overall Study|Other|5
6133116|NCT00979212|9761111|FG000|Overall Study|Protocol Violation|1
6133117|NCT00979212|9761112|FG001|Overall Study|Protocol Violation|8
6133118|NCT00979212|9761111|FG000|Overall Study|No protocol therapy received|1
6133119|NCT00979212|9761112|FG001|Overall Study|No protocol therapy received|0
6133120|NCT00979407|9761129|FG000|Overall Study|Withdrawal by Subject|3
6133121|NCT00979407|9761130|FG001|Overall Study|Withdrawal by Subject|4
6133122|NCT00979407|9761129|FG000|Overall Study|Lost to Follow-up|3
6133123|NCT00979407|9761130|FG001|Overall Study|Lost to Follow-up|3
6133124|NCT00979420|9761142|FG000|Overall Study|Adverse Event|1
6133125|NCT00979420|9761143|FG001|Overall Study|Adverse Event|0
6133126|NCT00979420|9761144|FG002|Overall Study|Adverse Event|0
6133127|NCT00979420|9761145|FG003|Overall Study|Adverse Event|0
6133128|NCT00979420|9761142|FG000|Overall Study|Lack of Efficacy|3
6223441|NCT01688739|9894839|FG005|Overall Study|Administrative Decision|0
6223442|NCT01688739|9894840|FG006|Overall Study|Administrative Decision|0
6223443|NCT01688739|9894841|FG007|Overall Study|Administrative Decision|0
6223444|NCT01688739|9894842|FG008|Overall Study|Administrative Decision|0
6223445|NCT01688739|9894843|FG009|Overall Study|Administrative Decision|0
6223446|NCT01688830|9894894|FG000|Overall Study|Lost to Follow-up|0
6223447|NCT01688830|9894895|FG001|Overall Study|Lost to Follow-up|0
6223448|NCT01688830|9894896|FG002|Overall Study|Lost to Follow-up|0
6223449|NCT01688830|9894897|FG003|Overall Study|Lost to Follow-up|0
6223450|NCT01688830|9894898|FG004|Overall Study|Lost to Follow-up|0
6223451|NCT01688830|9894899|FG005|Overall Study|Lost to Follow-up|0
6223452|NCT01688830|9894900|FG006|Overall Study|Lost to Follow-up|0
6290078|NCT02392611|10005791|FG008|Overall Study|Enrolled, not treated|0
6290079|NCT02392624|10005814|FG000|Overall Study|Withdrawal by Subject|15
6290080|NCT02392624|10005815|FG001|Overall Study|Withdrawal by Subject|12
6290081|NCT02392624|10005816|FG002|Overall Study|Withdrawal by Subject|9
6290082|NCT02392624|10005814|FG000|Overall Study|Adverse Event|4
6290083|NCT02392624|10005815|FG001|Overall Study|Adverse Event|1
6290084|NCT02392624|10005816|FG002|Overall Study|Adverse Event|2
6290085|NCT02392624|10005814|FG000|Overall Study|Pregnancy|1
6290086|NCT02392624|10005815|FG001|Overall Study|Pregnancy|0
6290087|NCT02392624|10005816|FG002|Overall Study|Pregnancy|0
6290088|NCT02392624|10005814|FG000|Overall Study|Protocol Violation|0
6290089|NCT02392624|10005815|FG001|Overall Study|Protocol Violation|0
6290090|NCT02392624|10005816|FG002|Overall Study|Protocol Violation|1
6290091|NCT02392624|10005814|FG000|Overall Study|Sponsor/Investigator Decision|2
6290092|NCT02392624|10005815|FG001|Overall Study|Sponsor/Investigator Decision|1
6290093|NCT02392624|10005816|FG002|Overall Study|Sponsor/Investigator Decision|0
6290094|NCT02392624|10005814|FG000|Overall Study|Other|49
6290095|NCT02392624|10005815|FG001|Overall Study|Other|1
6290096|NCT02392624|10005816|FG002|Overall Study|Other|1
6290097|NCT02393209|10005846|FG000|Overall Study|Study Terminated by Sponsor|1
6290098|NCT02393209|10005847|FG001|Overall Study|Study Terminated by Sponsor|1
6133129|NCT00979420|9761143|FG001|Overall Study|Lack of Efficacy|0
6133130|NCT00979420|9761144|FG002|Overall Study|Lack of Efficacy|1
6133131|NCT00979420|9761145|FG003|Overall Study|Lack of Efficacy|1
6133132|NCT00979420|9761142|FG000|Overall Study|Other reasons not related to Viramune|3
6133133|NCT00979420|9761143|FG001|Overall Study|Other reasons not related to Viramune|0
6133134|NCT00979420|9761144|FG002|Overall Study|Other reasons not related to Viramune|0
6133135|NCT00979420|9761145|FG003|Overall Study|Other reasons not related to Viramune|1
6133136|NCT00979576|9761165|FG000|Combination Treatment Phase|Progressive disease|3
6133137|NCT00979576|9761166|FG001|Combination Treatment Phase|Progressive disease|1
6223453|NCT01688830|9894901|FG007|Overall Study|Lost to Follow-up|0
6223454|NCT01688830|9894902|FG008|Overall Study|Lost to Follow-up|0
6290099|NCT02393209|10005848|FG002|Overall Study|Study Terminated by Sponsor|0
6290100|NCT02393209|10005849|FG003|Overall Study|Study Terminated by Sponsor|0
6290101|NCT02393209|10005846|FG000|Overall Study|Withdrawal by Patient|1
6290102|NCT02393209|10005847|FG001|Overall Study|Withdrawal by Patient|0
6290103|NCT02393209|10005848|FG002|Overall Study|Withdrawal by Patient|0
6133138|NCT00979576|9761167|FG002|Combination Treatment Phase|Progressive disease|5
6133139|NCT00979576|9761165|FG000|Combination Treatment Phase|Dose limiting toxicity|0
6133140|NCT00979576|9761166|FG001|Combination Treatment Phase|Dose limiting toxicity|3
6133141|NCT00979576|9761167|FG002|Combination Treatment Phase|Dose limiting toxicity|2
6133142|NCT00979576|9761165|FG000|Combination Treatment Phase|Adverse Event|0
6133143|NCT00979576|9761166|FG001|Combination Treatment Phase|Adverse Event|2
6133144|NCT00979576|9761167|FG002|Combination Treatment Phase|Adverse Event|2
6133145|NCT00979576|9761165|FG000|Combination Followed by Monotherapy|Progressive Disease|0
6133146|NCT00979576|9761166|FG001|Combination Followed by Monotherapy|Progressive Disease|2
6133147|NCT00979576|9761167|FG002|Combination Followed by Monotherapy|Progressive Disease|1
6223455|NCT01688830|9894903|FG009|Overall Study|Lost to Follow-up|0
6223456|NCT01688830|9894904|FG010|Overall Study|Lost to Follow-up|1
6223457|NCT01688830|9894905|FG011|Overall Study|Lost to Follow-up|0
6223458|NCT01688830|9894906|FG012|Overall Study|Lost to Follow-up|0
6223459|NCT01688830|9894907|FG013|Overall Study|Lost to Follow-up|0
6223460|NCT01688830|9894908|FG014|Overall Study|Lost to Follow-up|0
6223461|NCT01688830|9894909|FG015|Overall Study|Lost to Follow-up|0
6223462|NCT01688830|9894910|FG016|Overall Study|Lost to Follow-up|0
6223463|NCT01688830|9894911|FG017|Overall Study|Lost to Follow-up|0
6223464|NCT01688830|9894912|FG018|Overall Study|Lost to Follow-up|0
6223465|NCT01688830|9894913|FG019|Overall Study|Lost to Follow-up|0
6223466|NCT01688830|9894914|FG020|Overall Study|Lost to Follow-up|0
6223467|NCT01688882|9895019|FG000|Overall Study|Adverse Event|1
6223468|NCT01688882|9895020|FG001|Overall Study|Adverse Event|0
6223469|NCT01688882|9895019|FG000|Overall Study|Unsatisfactory therapeutic effect|1
6223470|NCT01688882|9895020|FG001|Overall Study|Unsatisfactory therapeutic effect|1
6223471|NCT01688882|9895019|FG000|Overall Study|Administrative problems|1
6223472|NCT01688882|9895020|FG001|Overall Study|Administrative problems|0
6223473|NCT01688921|9895036|FG000|Overall Study|Lost to Follow-up|7
6223474|NCT01688921|9895037|FG001|Overall Study|Lost to Follow-up|13
6223475|NCT01688921|9895036|FG000|Overall Study|Physician Decision|6
6223476|NCT01688921|9895037|FG001|Overall Study|Physician Decision|1
6223477|NCT01688921|9895036|FG000|Overall Study|Protocol Violation|0
6223478|NCT01688921|9895037|FG001|Overall Study|Protocol Violation|1
6223479|NCT01688921|9895036|FG000|Overall Study|informed consent|3
6223480|NCT01688921|9895037|FG001|Overall Study|informed consent|0
6223481|NCT01688973|9895046|FG000|Overall Study|Ineligible|2
6223482|NCT01688973|9895047|FG001|Overall Study|Ineligible|3
6223483|NCT01688999|9895057|FG000|Overall Study|Withdrawal by Subject|5
6223484|NCT01688999|9895058|FG001|Overall Study|Withdrawal by Subject|1
6223485|NCT01688999|9895059|FG002|Overall Study|Withdrawal by Subject|1
6223486|NCT01688999|9895057|FG000|Overall Study|Adverse Event|2
6223487|NCT01688999|9895058|FG001|Overall Study|Adverse Event|0
6223488|NCT01688999|9895059|FG002|Overall Study|Adverse Event|2
6223489|NCT01688999|9895057|FG000|Overall Study|Ineligible/Not treated|1
6223490|NCT01688999|9895058|FG001|Overall Study|Ineligible/Not treated|0
6223491|NCT01688999|9895059|FG002|Overall Study|Ineligible/Not treated|0
6223492|NCT01689207|9895082|FG000|Overall Study|Adverse Event|0
6223493|NCT01689207|9895083|FG001|Overall Study|Adverse Event|1
6223494|NCT01689207|9895084|FG002|Overall Study|Adverse Event|0
6223495|NCT01689207|9895085|FG003|Overall Study|Adverse Event|0
6223496|NCT01689207|9895086|FG004|Overall Study|Adverse Event|2
6223497|NCT01689207|9895087|FG005|Overall Study|Adverse Event|1
6223498|NCT01689207|9895088|FG006|Overall Study|Adverse Event|0
6223499|NCT01689207|9895089|FG007|Overall Study|Adverse Event|0
6223500|NCT01689207|9895090|FG008|Overall Study|Adverse Event|1
6223501|NCT01689207|9895091|FG009|Overall Study|Adverse Event|0
6223502|NCT01689207|9895092|FG010|Overall Study|Adverse Event|0
6223503|NCT01689337|9895126|FG000|Overall Study|Study Discontinuation|1
6223504|NCT01689363|9895141|FG000|Overall Study|Protocol Violation|0
6223505|NCT01689363|9895142|FG001|Overall Study|Protocol Violation|1
6223506|NCT01689363|9895143|FG002|Overall Study|Protocol Violation|0
6223507|NCT01689363|9895144|FG003|Overall Study|Protocol Violation|0
6223508|NCT01689363|9895145|FG004|Overall Study|Protocol Violation|0
6223509|NCT01689363|9895146|FG005|Overall Study|Protocol Violation|0
6223510|NCT01689363|9895147|FG006|Overall Study|Protocol Violation|0
6223511|NCT01689363|9895148|FG007|Overall Study|Protocol Violation|0
6223512|NCT01689532|9895170|FG000|Overall Study|Adverse Event|9
6223513|NCT01689532|9895171|FG001|Overall Study|Adverse Event|5
6223514|NCT01689532|9895170|FG000|Overall Study|Lack of Efficacy|2
6223515|NCT01689532|9895171|FG001|Overall Study|Lack of Efficacy|2
6223516|NCT01689532|9895170|FG000|Overall Study|Withdrawal by Subject|1
6223517|NCT01689532|9895171|FG001|Overall Study|Withdrawal by Subject|2
6223518|NCT01689532|9895170|FG000|Overall Study|Physician Decision|2
6223519|NCT01689532|9895171|FG001|Overall Study|Physician Decision|0
6223520|NCT01689649|9895177|FG000|Overall Study|Lack of Efficacy|3
6223521|NCT01689649|9895177|FG000|Overall Study|Non-compliance|11
6223522|NCT01689649|9895177|FG000|Overall Study|Protocol Violation|3
6223523|NCT01689649|9895177|FG000|Overall Study|Lost to Follow-up|5
6223524|NCT01689857|9895201|FG000|Overall Study|Lost to Follow-up|5
6223525|NCT01689857|9895202|FG001|Overall Study|Lost to Follow-up|2
6223526|NCT01690052|9895217|FG000|FIRST INTERVENTION: 4 WEEKS|Lost to Follow-up|1
6223527|NCT01690052|9895218|FG001|FIRST INTERVENTION: 4 WEEKS|Lost to Follow-up|2
6223528|NCT01690130|9895237|FG000|Overall Study|Subject have cancelled visit.|1
6133148|NCT00979602|9761178|FG000|Overall Study|Serious Adverse Event|5
6133149|NCT00979602|9761179|FG001|Overall Study|Serious Adverse Event|3
6133150|NCT00979602|9761178|FG000|Overall Study|Protocol Violation|3
6133151|NCT00979602|9761179|FG001|Overall Study|Protocol Violation|0
6133152|NCT00979602|9761178|FG000|Overall Study|Withdrawal by Subject|31
6133153|NCT00979602|9761179|FG001|Overall Study|Withdrawal by Subject|25
6133154|NCT00979602|9761178|FG000|Overall Study|Lost to Follow-up|100
6133155|NCT00979602|9761179|FG001|Overall Study|Lost to Follow-up|96
6133156|NCT00979602|9761178|FG000|Overall Study|Migrated/moved from study area|3
6133157|NCT00979602|9761179|FG001|Overall Study|Migrated/moved from study area|6
6133158|NCT00979602|9761178|FG000|Overall Study|Others|3
6133159|NCT00979602|9761179|FG001|Overall Study|Others|3
6133160|NCT00979628|9761209|FG000|Overall Study|received regimen < 24 hours|7
6133161|NCT00979628|9761210|FG001|Overall Study|received regimen < 24 hours|6
6133162|NCT00979628|9761211|FG002|Overall Study|received regimen < 24 hours|5
6133163|NCT00979628|9761209|FG000|Overall Study|received steroids|1
6133164|NCT00979628|9761210|FG001|Overall Study|received steroids|1
6133165|NCT00979628|9761211|FG002|Overall Study|received steroids|0
6133166|NCT00979628|9761209|FG000|Overall Study|transferred to ICU|1
6133167|NCT00979628|9761210|FG001|Overall Study|transferred to ICU|2
6133168|NCT00979628|9761211|FG002|Overall Study|transferred to ICU|1
6133169|NCT00979654|9761222|FG000|Overall Study|Lost to Follow-up|1
6133170|NCT00979654|9761222|FG000|Overall Study|Withdrawal by Subject|22
6133171|NCT00979654|9761222|FG000|Overall Study|Death|1
6133172|NCT00979654|9761222|FG000|Overall Study|Lack of Efficacy|6
6133173|NCT00979654|9761222|FG000|Overall Study|Adverse Event|1
6133174|NCT00979654|9761222|FG000|Overall Study|Adverse Event of Diverticulitis|1
6133175|NCT00979654|9761222|FG000|Overall Study|Per Principal Investigator's Discretion|1
6133176|NCT00979654|9761222|FG000|Overall Study|Patient Wanted to Pursue Other Treatment|1
6133177|NCT00979654|9761222|FG000|Overall Study|Serious Adverse Event|1
6290104|NCT02393209|10005849|FG003|Overall Study|Withdrawal by Patient|0
6290105|NCT02393209|10005846|FG000|Overall Study|Death|2
6290106|NCT02393209|10005847|FG001|Overall Study|Death|2
6290107|NCT02393209|10005848|FG002|Overall Study|Death|0
6290108|NCT02393209|10005849|FG003|Overall Study|Death|0
6290109|NCT02393209|10005846|FG000|Overall Study|Death due to Disease Progression|2
6290110|NCT02393209|10005847|FG001|Overall Study|Death due to Disease Progression|2
6290111|NCT02393209|10005848|FG002|Overall Study|Death due to Disease Progression|0
6290112|NCT02393209|10005849|FG003|Overall Study|Death due to Disease Progression|0
6290113|NCT02393209|10005846|FG000|Overall Study|Death from Legionella Infection|0
6290114|NCT02393209|10005847|FG001|Overall Study|Death from Legionella Infection|1
6290115|NCT02393209|10005848|FG002|Overall Study|Death from Legionella Infection|0
6290116|NCT02393209|10005849|FG003|Overall Study|Death from Legionella Infection|0
6290117|NCT02393209|10005846|FG000|Overall Study|Patient Seen by Another Oncologist|0
6290118|NCT02393209|10005847|FG001|Overall Study|Patient Seen by Another Oncologist|1
6290119|NCT02393209|10005848|FG002|Overall Study|Patient Seen by Another Oncologist|0
6290120|NCT02393209|10005849|FG003|Overall Study|Patient Seen by Another Oncologist|0
6290121|NCT02393209|10005846|FG000|Overall Study|Lost to Follow-up|0
6290122|NCT02393209|10005847|FG001|Overall Study|Lost to Follow-up|1
6290123|NCT02393209|10005848|FG002|Overall Study|Lost to Follow-up|0
6290124|NCT02393209|10005849|FG003|Overall Study|Lost to Follow-up|0
6290125|NCT02393547|10005894|FG000|Overall Study|Adverse Event|2
6290126|NCT02393547|10005894|FG000|Overall Study|Withdrawal by Subject|3
6290127|NCT02393547|10005894|FG000|Overall Study|Lost to Follow-up|1
6290128|NCT02393755|10005909|FG000|Overall Study|Withdrawal by Subject|0
6290129|NCT02393755|10005910|FG001|Overall Study|Withdrawal by Subject|3
6290130|NCT02393755|10005909|FG000|Overall Study|Adverse Event|0
6290131|NCT02393755|10005910|FG001|Overall Study|Adverse Event|2
6290132|NCT02393755|10005909|FG000|Overall Study|Physician Decision|0
6290133|NCT02393755|10005910|FG001|Overall Study|Physician Decision|2
6290134|NCT02393950|10005917|FG000|Overall Study|Adverse Event|1
6290135|NCT02393950|10005918|FG001|Overall Study|Adverse Event|0
6290136|NCT02393950|10005917|FG000|Overall Study|Withdrawal by Subject|0
6290137|NCT02393950|10005918|FG001|Overall Study|Withdrawal by Subject|1
6290138|NCT02394275|10005953|FG000|Overall Study|Adverse Event|22
6290139|NCT02394275|10005953|FG000|Overall Study|Lost to Follow-up|7
6290140|NCT02394340|10005958|FG000|Overall Study|Failed drug screen test|1
6290141|NCT02394340|10005958|FG000|Overall Study|Adverse Event|1
6290142|NCT02394561|10005973|FG000|CORE Phase|Adverse Event|7
6290143|NCT02394561|10005974|FG001|CORE Phase|Adverse Event|9
6290144|NCT02394561|10005973|FG000|CORE Phase|Death|0
6290145|NCT02394561|10005974|FG001|CORE Phase|Death|1
6290146|NCT02394561|10005973|FG000|CORE Phase|Pregnancy|1
5981075|NCT02538666|9570003|FG001|Overall Study|Withdrew Consent|1
6133178|NCT00979654|9761222|FG000|Overall Study|Unfavorable Risk-Benefit Analysis|1
6133179|NCT00979953|9761276|FG000|Overall Study|Adverse Event|5
6133180|NCT00979953|9761277|FG001|Overall Study|Adverse Event|2
6133181|NCT00979953|9761278|FG002|Overall Study|Adverse Event|17
6133182|NCT00979953|9761279|FG003|Overall Study|Adverse Event|4
6290147|NCT02394561|10005974|FG001|CORE Phase|Pregnancy|0
6290148|NCT02394561|10005973|FG000|CORE Phase|Lost to Follow-up|1
6290149|NCT02394561|10005974|FG001|CORE Phase|Lost to Follow-up|0
6290150|NCT02394561|10005973|FG000|CORE Phase|Physician Decision|1
6290151|NCT02394561|10005974|FG001|CORE Phase|Physician Decision|1
6290152|NCT02394561|10005973|FG000|CORE Phase|Withdrawal by Subject|2
6133183|NCT00979953|9761276|FG000|Overall Study|Lack of Efficacy|1
6133184|NCT00979953|9761277|FG001|Overall Study|Lack of Efficacy|2
6133185|NCT00979953|9761278|FG002|Overall Study|Lack of Efficacy|0
6133186|NCT00979953|9761279|FG003|Overall Study|Lack of Efficacy|0
6133187|NCT00979953|9761276|FG000|Overall Study|Lost to Follow-up|1
6133188|NCT00979953|9761277|FG001|Overall Study|Lost to Follow-up|1
6133189|NCT00979953|9761278|FG002|Overall Study|Lost to Follow-up|1
6133190|NCT00979953|9761279|FG003|Overall Study|Lost to Follow-up|0
6133191|NCT00979953|9761276|FG000|Overall Study|Withdrawal by Subject|0
6133192|NCT00979953|9761277|FG001|Overall Study|Withdrawal by Subject|0
6133193|NCT00979953|9761278|FG002|Overall Study|Withdrawal by Subject|2
6133194|NCT00979953|9761279|FG003|Overall Study|Withdrawal by Subject|1
6133195|NCT00979953|9761276|FG000|Overall Study|Protocol Violation|1
6133196|NCT00979953|9761277|FG001|Overall Study|Protocol Violation|0
6133197|NCT00979953|9761278|FG002|Overall Study|Protocol Violation|2
6133198|NCT00979953|9761279|FG003|Overall Study|Protocol Violation|2
6133199|NCT00979992|9761289|FG000|Overall Study|Ineligible - inadequate pathology|1
6133200|NCT00979992|9761289|FG000|Overall Study|Ineligible - wrong cell type|2
6133201|NCT00979992|9761289|FG000|Overall Study|Refused - Never Treated|2
6133202|NCT00980005|9761295|FG000|Overall Study|Withdrawal by Subject|6
6133203|NCT00980005|9761296|FG001|Overall Study|Withdrawal by Subject|17
6133204|NCT00980005|9761295|FG000|Overall Study|Lost to Follow-up|37
6133205|NCT00980005|9761296|FG001|Overall Study|Lost to Follow-up|43
6133206|NCT00980005|9761295|FG000|Overall Study|Other|4
6133207|NCT00980005|9761296|FG001|Overall Study|Other|3
6133208|NCT00980018|9761306|FG000|Overall Study|Adverse Event|8
6133209|NCT00980018|9761306|FG000|Overall Study|Patient withdrew consent|3
6133210|NCT00980018|9761306|FG000|Overall Study|Lost to Follow-up|1
6133211|NCT00980044|9761313|FG000|Overall Study|Withdrawal by Subject|5
6133212|NCT00980044|9761314|FG001|Overall Study|Withdrawal by Subject|7
6133213|NCT00980044|9761315|FG002|Overall Study|Withdrawal by Subject|3
6133214|NCT00980044|9761313|FG000|Overall Study|Protocol Violation|0
6133215|NCT00980044|9761314|FG001|Overall Study|Protocol Violation|0
6133216|NCT00980044|9761315|FG002|Overall Study|Protocol Violation|2
6133217|NCT00980057|9761328|FG000|Overall Study|Death|13
6133218|NCT00980057|9761329|FG001|Overall Study|Death|3
6133219|NCT00980057|9761328|FG000|Overall Study|Adverse Event|0
6133220|NCT00980057|9761329|FG001|Overall Study|Adverse Event|1
6133221|NCT00980057|9761328|FG000|Overall Study|Physician Decision|4
6133222|NCT00980057|9761329|FG001|Overall Study|Physician Decision|0
6133223|NCT00980057|9761328|FG000|Overall Study|Lost to Follow-up|1
6133224|NCT00980057|9761329|FG001|Overall Study|Lost to Follow-up|0
6133225|NCT00980057|9761328|FG000|Overall Study|Withdrawal by Subject|1
6133226|NCT00980057|9761329|FG001|Overall Study|Withdrawal by Subject|1
6133227|NCT00980148|9761338|FG000|Overall Study|Discharged from facility|89
6133228|NCT00980148|9761339|FG001|Overall Study|Discharged from facility|96
6133229|NCT00980148|9761338|FG000|Overall Study|Received other antichlamydia treatment|20
6133230|NCT00980148|9761339|FG001|Overall Study|Received other antichlamydia treatment|14
6133231|NCT00980148|9761338|FG000|Overall Study|Negative for chlamydia at enrollment|12
6133232|NCT00980148|9761339|FG001|Overall Study|Negative for chlamydia at enrollment|9
6133233|NCT00980148|9761338|FG000|Overall Study|Various other reasons|8
6133234|NCT00980148|9761339|FG001|Overall Study|Various other reasons|9
6133235|NCT00980174|9761347|FG000|Overall Study|Withdrawal by Subject|1
6133236|NCT00980174|9761348|FG001|Overall Study|Withdrawal by Subject|4
6223529|NCT01690130|9895238|FG001|Overall Study|Subject have cancelled visit.|0
6223530|NCT01690143|9895244|FG000|Overall Study|Withdrawal by Subject|1
6223531|NCT01690520|9895268|FG000|Overall Study|Death|25
6223532|NCT01690520|9895269|FG001|Overall Study|Death|21
6223533|NCT01690520|9895268|FG000|Overall Study|Lost to Follow-up|2
6290153|NCT02394561|10005974|FG001|CORE Phase|Withdrawal by Subject|2
6290154|NCT02394561|10005973|FG000|CORE Phase|Lack of Efficacy|1
6290155|NCT02394561|10005974|FG001|CORE Phase|Lack of Efficacy|6
6133237|NCT00980174|9761347|FG000|Overall Study|Adverse Event|0
6133238|NCT00980174|9761348|FG001|Overall Study|Adverse Event|3
6133239|NCT00980174|9761347|FG000|Overall Study|Ineligibility determined|2
6133240|NCT00980174|9761348|FG001|Overall Study|Ineligibility determined|1
6133241|NCT00980174|9761347|FG000|Overall Study|Death|1
6133242|NCT00980174|9761348|FG001|Overall Study|Death|1
6133243|NCT00980174|9761347|FG000|Overall Study|Other|0
6133244|NCT00980174|9761348|FG001|Overall Study|Other|1
6133245|NCT00980200|9761354|FG000|7-day Treatment Period 1|Withdrawal by Subject|0
6133246|NCT00980200|9761355|FG001|7-day Treatment Period 1|Withdrawal by Subject|1
6133247|NCT00980200|9761356|FG002|7-day Treatment Period 1|Withdrawal by Subject|0
6133248|NCT00980200|9761357|FG003|7-day Treatment Period 1|Withdrawal by Subject|0
6133249|NCT00980200|9761358|FG004|7-day Treatment Period 1|Withdrawal by Subject|0
6133250|NCT00980200|9761354|FG000|7-day Treatment Period 3|Lack of Efficacy|0
6133251|NCT00980200|9761355|FG001|7-day Treatment Period 3|Lack of Efficacy|1
6133252|NCT00980200|9761356|FG002|7-day Treatment Period 3|Lack of Efficacy|0
6133253|NCT00980200|9761357|FG003|7-day Treatment Period 3|Lack of Efficacy|0
6133254|NCT00980200|9761358|FG004|7-day Treatment Period 3|Lack of Efficacy|1
6133255|NCT00980330|9761386|FG000|Overall Study|Adverse Event|0
6133256|NCT00980330|9761387|FG001|Overall Study|Adverse Event|0
6133257|NCT00980330|9761388|FG002|Overall Study|Adverse Event|0
6290156|NCT02394561|10005973|FG000|Extension Phase|Adverse Event|6
6133258|NCT00980330|9761389|FG003|Overall Study|Adverse Event|1
6133259|NCT00980330|9761390|FG004|Overall Study|Adverse Event|0
6133260|NCT00980330|9761391|FG005|Overall Study|Adverse Event|0
6133261|NCT00980330|9761392|FG006|Overall Study|Adverse Event|0
6133262|NCT00980330|9761386|FG000|Overall Study|Lost to Follow-up|1
6133263|NCT00980330|9761387|FG001|Overall Study|Lost to Follow-up|1
6133264|NCT00980330|9761388|FG002|Overall Study|Lost to Follow-up|4
6133265|NCT00980330|9761389|FG003|Overall Study|Lost to Follow-up|2
6133266|NCT00980330|9761390|FG004|Overall Study|Lost to Follow-up|1
6133267|NCT00980330|9761391|FG005|Overall Study|Lost to Follow-up|1
6133268|NCT00980330|9761392|FG006|Overall Study|Lost to Follow-up|2
6133269|NCT00980330|9761386|FG000|Overall Study|Withdrawal by Subject|2
6133270|NCT00980330|9761387|FG001|Overall Study|Withdrawal by Subject|4
6133271|NCT00980330|9761388|FG002|Overall Study|Withdrawal by Subject|4
6133272|NCT00980330|9761389|FG003|Overall Study|Withdrawal by Subject|1
6133273|NCT00980330|9761390|FG004|Overall Study|Withdrawal by Subject|3
6133274|NCT00980330|9761391|FG005|Overall Study|Withdrawal by Subject|2
6133275|NCT00980330|9761392|FG006|Overall Study|Withdrawal by Subject|5
6133276|NCT00980330|9761386|FG000|Overall Study|(not specified)|2
6133277|NCT00980330|9761387|FG001|Overall Study|(not specified)|0
6133278|NCT00980330|9761388|FG002|Overall Study|(not specified)|0
6133279|NCT00980330|9761389|FG003|Overall Study|(not specified)|1
6133280|NCT00980330|9761390|FG004|Overall Study|(not specified)|1
6133281|NCT00980330|9761391|FG005|Overall Study|(not specified)|1
6133282|NCT00980330|9761392|FG006|Overall Study|(not specified)|0
6133283|NCT00980343|9761411|FG000|Overall Study|no tumor at surgery - treatment effect|1
6133284|NCT00980343|9761412|FG001|Overall Study|no tumor at surgery - treatment effect|3
6133285|NCT00980655|9761444|FG000|Overall Study|Adverse Event|13
6133286|NCT00980655|9761445|FG001|Overall Study|Adverse Event|31
6133287|NCT00980655|9761444|FG000|Overall Study|Death|0
6133288|NCT00980655|9761445|FG001|Overall Study|Death|7
6133289|NCT00980655|9761444|FG000|Overall Study|Protocol Violation|2
6133290|NCT00980655|9761445|FG001|Overall Study|Protocol Violation|7
6133291|NCT00980655|9761444|FG000|Overall Study|Withdrawal by Subject|0
6133292|NCT00980655|9761445|FG001|Overall Study|Withdrawal by Subject|4
6133293|NCT00980655|9761444|FG000|Overall Study|Lost to Follow-up|0
6133294|NCT00980655|9761445|FG001|Overall Study|Lost to Follow-up|1
6133295|NCT00980655|9761444|FG000|Overall Study|Parent/legal guardian request|1
6133296|NCT00980655|9761445|FG001|Overall Study|Parent/legal guardian request|0
6133297|NCT00980655|9761444|FG000|Overall Study|Other|0
6133298|NCT00980655|9761445|FG001|Overall Study|Other|1
6133299|NCT00980798|9761498|FG000|Overall Study|Adverse Event|7
6133300|NCT00980798|9761499|FG001|Overall Study|Adverse Event|36
6133301|NCT00980798|9761498|FG000|Overall Study|Lack of Efficacy|16
6133302|NCT00980798|9761499|FG001|Overall Study|Lack of Efficacy|5
6133303|NCT00980798|9761498|FG000|Overall Study|Lost to Follow-up|0
6133304|NCT00980798|9761499|FG001|Overall Study|Lost to Follow-up|1
6133305|NCT00980798|9761498|FG000|Overall Study|Physician Decision|2
6133306|NCT00980798|9761499|FG001|Overall Study|Physician Decision|1
6133307|NCT00980798|9761498|FG000|Overall Study|Withdrawal by Subject|8
6133308|NCT00980798|9761499|FG001|Overall Study|Withdrawal by Subject|11
6133309|NCT00980798|9761498|FG000|Overall Study|Other|0
6133310|NCT00980798|9761499|FG001|Overall Study|Other|1
6133311|NCT00980980|9761508|FG000|Overall Study|Withdrawal by Hospital|0
6133312|NCT00980980|9761509|FG001|Overall Study|Withdrawal by Hospital|1
6133313|NCT00980980|9761510|FG002|Overall Study|Withdrawal by Hospital|0
6133314|NCT00981019|9761521|FG000|Overall Study|Did not respond|65
6133315|NCT00981019|9761521|FG000|Overall Study|Did not match target population|94
6133316|NCT00981019|9761521|FG000|Overall Study|Inadvertent exclusion|239
6133317|NCT00981019|9761521|FG000|Overall Study|Hit the survey after closure|79
6133318|NCT00981084|9761536|FG000|Post Intervention (Data Analysis)|poor effort|1
6133319|NCT00981084|9761537|FG001|Post Intervention (Data Analysis)|poor effort|1
6133320|NCT00981084|9761536|FG000|Post Intervention (Data Analysis)|imbalance in disease subtype|1
6133321|NCT00981084|9761537|FG001|Post Intervention (Data Analysis)|imbalance in disease subtype|0
6133322|NCT00981149|9761547|FG000|Overall Study|Lost to Follow-up|1
6133323|NCT00981149|9761548|FG001|Overall Study|Lost to Follow-up|2
6133324|NCT00981149|9761547|FG000|Overall Study|Withdrawal by Subject|1
6133325|NCT00981149|9761548|FG001|Overall Study|Withdrawal by Subject|1
6133326|NCT00981175|9761557|FG000|Primary Dose Vaccination|Adverse Event|1
6133327|NCT00981175|9761558|FG001|Primary Dose Vaccination|Adverse Event|0
6133328|NCT00981175|9761557|FG000|Primary Dose Vaccination|Protocol Violation|0
6133329|NCT00981175|9761558|FG001|Primary Dose Vaccination|Protocol Violation|1
6133330|NCT00981175|9761557|FG000|Primary Dose Vaccination|Lost to Follow-up|2
6133331|NCT00981175|9761558|FG001|Primary Dose Vaccination|Lost to Follow-up|1
6133332|NCT00981175|9761557|FG000|Booster Dose Vaccination|Lost to Follow-up|2
6133333|NCT00981175|9761558|FG001|Booster Dose Vaccination|Lost to Follow-up|3
6133334|NCT00981292|9761620|FG000|Day 1|Protocol Violation|1
6133335|NCT00981292|9761621|FG001|Day 1|Protocol Violation|0
6133336|NCT00981292|9761622|FG002|Day 1|Protocol Violation|0
6133337|NCT00981292|9761623|FG003|Day 1|Protocol Violation|0
6133338|NCT00981292|9761624|FG004|Day 1|Protocol Violation|0
6133339|NCT00981292|9761625|FG005|Day 1|Protocol Violation|2
6133340|NCT00981292|9761620|FG000|Day 2|Protocol Violation|2
6133341|NCT00981292|9761621|FG001|Day 2|Protocol Violation|0
6133342|NCT00981292|9761622|FG002|Day 2|Protocol Violation|0
6133343|NCT00981292|9761623|FG003|Day 2|Protocol Violation|0
6133344|NCT00981292|9761624|FG004|Day 2|Protocol Violation|0
6133345|NCT00981292|9761625|FG005|Day 2|Protocol Violation|0
6133346|NCT00981292|9761620|FG000|Day 3|Protocol Violation|0
6133347|NCT00981292|9761621|FG001|Day 3|Protocol Violation|0
6133348|NCT00981292|9761622|FG002|Day 3|Protocol Violation|0
6133349|NCT00981292|9761623|FG003|Day 3|Protocol Violation|0
6133350|NCT00981292|9761624|FG004|Day 3|Protocol Violation|0
6133351|NCT00981292|9761625|FG005|Day 3|Protocol Violation|1
6133352|NCT00981409|9761648|FG000|Overall Study|Adverse Event|4
6133353|NCT00981409|9761649|FG001|Overall Study|Adverse Event|0
6133354|NCT00981409|9761648|FG000|Overall Study|Protocol Violation|0
6133355|NCT00981409|9761649|FG001|Overall Study|Protocol Violation|1
6133356|NCT00981409|9761648|FG000|Overall Study|Prostate Cancer Treatment before Trial|2
6133357|NCT00981409|9761649|FG001|Overall Study|Prostate Cancer Treatment before Trial|0
6133358|NCT00981461|9761670|FG000|Overall Study|Lost to Follow-up|5
6133359|NCT00981461|9761671|FG001|Overall Study|Lost to Follow-up|2
6223534|NCT01690520|9895269|FG001|Overall Study|Lost to Follow-up|3
6223535|NCT01690520|9895268|FG000|Overall Study|Withdrawal by Subject|2
6223536|NCT01690520|9895269|FG001|Overall Study|Withdrawal by Subject|0
6223537|NCT01690520|9895268|FG000|Overall Study|Relapse|0
6223538|NCT01690520|9895269|FG001|Overall Study|Relapse|1
6223539|NCT01690520|9895268|FG000|Overall Study|Other|0
6223540|NCT01690520|9895269|FG001|Overall Study|Other|1
6223541|NCT01690520|9895268|FG000|Overall Study|Ongoing Follow-Up at time of Analysis|22
6223542|NCT01690520|9895269|FG001|Overall Study|Ongoing Follow-Up at time of Analysis|21
6223543|NCT01690988|9895304|FG000|Overall Study|Withdrawal by Subject|2
6223544|NCT01690988|9895305|FG001|Overall Study|Withdrawal by Subject|2
6223545|NCT01690988|9895306|FG002|Overall Study|Withdrawal by Subject|3
6223546|NCT01690988|9895304|FG000|Overall Study|Physician Decision|0
6223547|NCT01690988|9895305|FG001|Overall Study|Physician Decision|0
6223548|NCT01690988|9895306|FG002|Overall Study|Physician Decision|1
6223549|NCT01690988|9895304|FG000|Overall Study|Operation Cancelled|1
6223550|NCT01690988|9895305|FG001|Overall Study|Operation Cancelled|1
6223551|NCT01690988|9895306|FG002|Overall Study|Operation Cancelled|0
6223552|NCT01690988|9895304|FG000|Overall Study|Determined ineligible|1
6223553|NCT01690988|9895305|FG001|Overall Study|Determined ineligible|0
6223554|NCT01690988|9895306|FG002|Overall Study|Determined ineligible|0
6223555|NCT01690988|9895304|FG000|Overall Study|Death|1
6223556|NCT01690988|9895305|FG001|Overall Study|Death|1
6223557|NCT01690988|9895306|FG002|Overall Study|Death|1
6223558|NCT01690988|9895304|FG000|Overall Study|Sedated|1
6223559|NCT01690988|9895305|FG001|Overall Study|Sedated|1
6223560|NCT01690988|9895306|FG002|Overall Study|Sedated|2
6223561|NCT01691014|9895321|FG000|Overall Study|Premature Termination|1
6223562|NCT01691014|9895322|FG001|Overall Study|Premature Termination|6
6223563|NCT01691014|9895323|FG002|Overall Study|Premature Termination|0
6223564|NCT01691014|9895324|FG003|Overall Study|Premature Termination|3
6223565|NCT01691014|9895321|FG000|Overall Study|Other|0
6223566|NCT01691014|9895322|FG001|Overall Study|Other|0
6223567|NCT01691014|9895323|FG002|Overall Study|Other|2
6223568|NCT01691014|9895324|FG003|Overall Study|Other|0
6223569|NCT01691014|9895321|FG000|Overall Study|Withdrawal by Subject|0
6223570|NCT01691014|9895322|FG001|Overall Study|Withdrawal by Subject|1
6223571|NCT01691014|9895323|FG002|Overall Study|Withdrawal by Subject|1
6223572|NCT01691014|9895324|FG003|Overall Study|Withdrawal by Subject|1
6223573|NCT01691014|9895321|FG000|Overall Study|Adverse Event|0
6223574|NCT01691014|9895322|FG001|Overall Study|Adverse Event|5
6223575|NCT01691014|9895323|FG002|Overall Study|Adverse Event|1
6223576|NCT01691014|9895324|FG003|Overall Study|Adverse Event|1
6223577|NCT01691014|9895321|FG000|Overall Study|Lack of Efficacy|2
6223578|NCT01691014|9895322|FG001|Overall Study|Lack of Efficacy|3
6223579|NCT01691014|9895323|FG002|Overall Study|Lack of Efficacy|7
6223580|NCT01691014|9895324|FG003|Overall Study|Lack of Efficacy|0
6223581|NCT01691092|9895339|FG000|Overall Study|Lost to Follow-up|10
6223582|NCT01691092|9895339|FG000|Overall Study|Physician Decision|4
6223583|NCT01691092|9895339|FG000|Overall Study|Withdrawal by Subject|3
6223584|NCT01691092|9895339|FG000|Overall Study|non-compliance|3
6223585|NCT01691092|9895339|FG000|Overall Study|used for different study|2
6223586|NCT01691092|9895339|FG000|Overall Study|screen fail|19
6223587|NCT01691105|9895345|FG000|1 Month Follow-up|Lost to Follow-up|41
6223588|NCT01691105|9895346|FG001|1 Month Follow-up|Lost to Follow-up|38
6223589|NCT01691105|9895345|FG000|1 Month Follow-up|Death|2
6223590|NCT01691105|9895346|FG001|1 Month Follow-up|Death|3
6223591|NCT01691105|9895345|FG000|6 Month Follow-up|Lost to Follow-up|39
6223592|NCT01691105|9895346|FG001|6 Month Follow-up|Lost to Follow-up|58
6223593|NCT01691105|9895345|FG000|6 Month Follow-up|Death|13
6223594|NCT01691105|9895346|FG001|6 Month Follow-up|Death|13
6223595|NCT01691105|9895345|FG000|12 Month Follow-up|Lost to Follow-up|50
6223596|NCT01691105|9895346|FG001|12 Month Follow-up|Lost to Follow-up|71
6223597|NCT01691105|9895345|FG000|12 Month Follow-up|Death|22
6223598|NCT01691105|9895346|FG001|12 Month Follow-up|Death|30
6223599|NCT01691105|9895345|FG000|12 Month Biochemical Verification|Death|22
6223600|NCT01691105|9895346|FG001|12 Month Biochemical Verification|Death|30
6223601|NCT01691105|9895345|FG000|12 Month Biochemical Verification|Lost to Follow-up|50
6223602|NCT01691105|9895346|FG001|12 Month Biochemical Verification|Lost to Follow-up|71
6133360|NCT00981526|9761690|FG000|Overall Study|Withdrawal by Subject|0
6133361|NCT00981526|9761691|FG001|Overall Study|Withdrawal by Subject|2
6133362|NCT00981526|9761690|FG000|Overall Study|Physician Decision|4
6133363|NCT00981526|9761691|FG001|Overall Study|Physician Decision|4
6133364|NCT00981578|9761699|FG000|Overall Study|Death|1
6133365|NCT00981578|9761699|FG000|Overall Study|Withdrawal by Subject|2
6133366|NCT00981682|9761729|FG000|Overall Study|Adverse Event|48
6133367|NCT00981682|9761729|FG000|Overall Study|Withdrawal by Subject|52
6133368|NCT00981682|9761729|FG000|Overall Study|Lost to Follow-up|14
6133369|NCT00981682|9761729|FG000|Overall Study|Lack of Efficacy|13
6133370|NCT00981682|9761729|FG000|Overall Study|Protocol Violation|6
6133371|NCT00981682|9761729|FG000|Overall Study|administrative|9
6133372|NCT00981747|9761733|FG000|Losartan|Withdrawal by Subject|1
6133373|NCT00981747|9761733|FG000|Losartan|Death|1
6133374|NCT00981747|9761733|FG000|Placebo Oral Tablet|Withdrawal by Subject|1
6133375|NCT00981799|9761747|FG000|Overall Study|Adverse Event|1
6133376|NCT00981799|9761748|FG001|Overall Study|Adverse Event|1
6133377|NCT00981799|9761749|FG002|Overall Study|Adverse Event|0
6133378|NCT00981799|9761750|FG003|Overall Study|Adverse Event|0
6133379|NCT00982020|9761793|FG000|Overall Study|Adverse Event|19
6133380|NCT00982020|9761794|FG001|Overall Study|Adverse Event|15
6133381|NCT00982020|9761793|FG000|Overall Study|Withdrawal by Subject|11
6133382|NCT00982020|9761794|FG001|Overall Study|Withdrawal by Subject|14
6133383|NCT00982020|9761793|FG000|Overall Study|Lost to Follow-up|5
6133384|NCT00982020|9761794|FG001|Overall Study|Lost to Follow-up|11
6133385|NCT00982020|9761793|FG000|Overall Study|Lack of Efficacy|10
6133386|NCT00982020|9761794|FG001|Overall Study|Lack of Efficacy|4
6133387|NCT00982020|9761793|FG000|Overall Study|Parent/Caregiver Decision|5
6133388|NCT00982020|9761794|FG001|Overall Study|Parent/Caregiver Decision|5
6133389|NCT00982020|9761793|FG000|Overall Study|Treatment Non-compliance|3
6133390|NCT00982020|9761794|FG001|Overall Study|Treatment Non-compliance|6
6133391|NCT00982020|9761793|FG000|Overall Study|Physician Decision|2
6133392|NCT00982020|9761794|FG001|Overall Study|Physician Decision|5
6133393|NCT00982020|9761793|FG000|Overall Study|Entry Criteria Not Met|2
6133394|NCT00982020|9761794|FG001|Overall Study|Entry Criteria Not Met|1
6133395|NCT00982020|9761793|FG000|Overall Study|Protocol Violation|0
6133396|NCT00982020|9761794|FG001|Overall Study|Protocol Violation|2
6133397|NCT00982020|9761793|FG000|Overall Study|Clinical Relapse|0
6133398|NCT00982020|9761794|FG001|Overall Study|Clinical Relapse|1
6133399|NCT00982137|9761827|FG000|Overall Study|Lost to Follow-up|0
6133400|NCT00982137|9761828|FG001|Overall Study|Lost to Follow-up|0
6133401|NCT00982137|9761829|FG002|Overall Study|Lost to Follow-up|0
6133402|NCT00982137|9761830|FG003|Overall Study|Lost to Follow-up|1
6133403|NCT00982137|9761827|FG000|Overall Study|Withdrawal by Subject|0
6133404|NCT00982137|9761828|FG001|Overall Study|Withdrawal by Subject|1
6133405|NCT00982137|9761829|FG002|Overall Study|Withdrawal by Subject|0
6133406|NCT00982137|9761830|FG003|Overall Study|Withdrawal by Subject|0
6133407|NCT00982228|9761868|FG000|Main: Week 0 to 52 (NN1250-3583)|Adverse Event|12
6133408|NCT00982228|9761869|FG001|Main: Week 0 to 52 (NN1250-3583)|Adverse Event|2
6133409|NCT00982228|9761868|FG000|Main: Week 0 to 52 (NN1250-3583)|Lack of Efficacy|2
6133410|NCT00982228|9761869|FG001|Main: Week 0 to 52 (NN1250-3583)|Lack of Efficacy|0
6133411|NCT00982228|9761868|FG000|Main: Week 0 to 52 (NN1250-3583)|Protocol Violation|11
6133412|NCT00982228|9761869|FG001|Main: Week 0 to 52 (NN1250-3583)|Protocol Violation|2
6133413|NCT00982228|9761868|FG000|Main: Week 0 to 52 (NN1250-3583)|Withdrawal criteria|15
6133414|NCT00982228|9761869|FG001|Main: Week 0 to 52 (NN1250-3583)|Withdrawal criteria|3
6133415|NCT00982228|9761868|FG000|Main: Week 0 to 52 (NN1250-3583)|Unclassified|28
6133416|NCT00982228|9761869|FG001|Main: Week 0 to 52 (NN1250-3583)|Unclassified|13
6133417|NCT00982228|9761868|FG000|Extension: Week 53 to 104 (NN1250-3644)|Adverse Event|3
6133418|NCT00982228|9761869|FG001|Extension: Week 53 to 104 (NN1250-3644)|Adverse Event|2
6133419|NCT00982228|9761868|FG000|Extension: Week 53 to 104 (NN1250-3644)|Lack of Efficacy|1
6133420|NCT00982228|9761869|FG001|Extension: Week 53 to 104 (NN1250-3644)|Lack of Efficacy|0
6133421|NCT00982228|9761868|FG000|Extension: Week 53 to 104 (NN1250-3644)|Protocol Violation|1
6133422|NCT00982228|9761869|FG001|Extension: Week 53 to 104 (NN1250-3644)|Protocol Violation|2
6133423|NCT00982228|9761868|FG000|Extension: Week 53 to 104 (NN1250-3644)|Withdrawal criteria|5
6133424|NCT00982228|9761869|FG001|Extension: Week 53 to 104 (NN1250-3644)|Withdrawal criteria|0
6133425|NCT00982228|9761868|FG000|Extension: Week 53 to 104 (NN1250-3644)|Unclassified|11
6133426|NCT00982228|9761869|FG001|Extension: Week 53 to 104 (NN1250-3644)|Unclassified|1
6133427|NCT00982280|9761875|FG000|Observation Period|Not eligible to be dosed|19
6133428|NCT00982280|9761875|FG000|Titration and Optimal Dose Period|Adverse Event|5
6133429|NCT00982280|9761875|FG000|Titration and Optimal Dose Period|Lack of Efficacy|2
6133430|NCT00982280|9761875|FG000|Titration and Optimal Dose Period|Withdrawal by Subject|1
6133431|NCT00982280|9761875|FG000|Maintenance Period|Adverse Event|1
6133432|NCT00982319|9761882|FG000|Overall Study|Surgery date change|1
6133433|NCT00982319|9761883|FG001|Overall Study|Surgery date change|0
6133434|NCT00982319|9761882|FG000|Overall Study|Preop values out of acceptable range|1
6133435|NCT00982319|9761883|FG001|Overall Study|Preop values out of acceptable range|1
6133436|NCT00982319|9761882|FG000|Overall Study|Pregnancy|0
6133437|NCT00982319|9761883|FG001|Overall Study|Pregnancy|1
6133438|NCT00982410|9761907|FG000|3-month Follow-up Assessment|Could not reach to schedule|8
6133439|NCT00982410|9761908|FG001|3-month Follow-up Assessment|Could not reach to schedule|9
6133440|NCT00982410|9761907|FG000|3-month Follow-up Assessment|Scheduled, no-show|1
6133441|NCT00982410|9761908|FG001|3-month Follow-up Assessment|Scheduled, no-show|2
6133442|NCT00982410|9761907|FG000|3-month Follow-up Assessment|Withdrawal by Subject|0
6133443|NCT00982410|9761908|FG001|3-month Follow-up Assessment|Withdrawal by Subject|2
6133444|NCT00982410|9761907|FG000|6-month Follow-up Assessment|Could not reach to schedule|5
6133445|NCT00982410|9761908|FG001|6-month Follow-up Assessment|Could not reach to schedule|7
6133446|NCT00982410|9761907|FG000|6-month Follow-up Assessment|participant no transportation|1
6133447|NCT00982410|9761908|FG001|6-month Follow-up Assessment|participant no transportation|0
6133448|NCT00982410|9761907|FG000|6-month Follow-up Assessment|incarceration|0
6133449|NCT00982410|9761908|FG001|6-month Follow-up Assessment|incarceration|2
6133450|NCT00982410|9761907|FG000|6-month Follow-up Assessment|patent surgery|0
6133451|NCT00982410|9761908|FG001|6-month Follow-up Assessment|patent surgery|1
6133452|NCT00982410|9761907|FG000|6-month Follow-up Assessment|scheduled, no-show|0
6133453|NCT00982410|9761908|FG001|6-month Follow-up Assessment|scheduled, no-show|1
6133454|NCT00982410|9761907|FG000|12-month Follow-up Assessment|Death|0
6133455|NCT00982410|9761908|FG001|12-month Follow-up Assessment|Death|2
6133456|NCT00982410|9761907|FG000|12-month Follow-up Assessment|could not reach to schedule|6
6133457|NCT00982410|9761908|FG001|12-month Follow-up Assessment|could not reach to schedule|5
6133458|NCT00982410|9761907|FG000|12-month Follow-up Assessment|Withdrawal by Subject|0
6133459|NCT00982410|9761908|FG001|12-month Follow-up Assessment|Withdrawal by Subject|1
6133460|NCT00982410|9761907|FG000|12-month Follow-up Assessment|incarceration|2
6133461|NCT00982410|9761908|FG001|12-month Follow-up Assessment|incarceration|1
6133462|NCT00982410|9761907|FG000|12-month Follow-up Assessment|scheduled, no-show|1
6133463|NCT00982410|9761908|FG001|12-month Follow-up Assessment|scheduled, no-show|0
6133464|NCT00982488|9761930|FG000|Overall Study|Administrative reason by sponsor|81
6133465|NCT00982488|9761931|FG001|Overall Study|Administrative reason by sponsor|3
6133466|NCT00982488|9761932|FG002|Overall Study|Administrative reason by sponsor|11
6133467|NCT00982488|9761933|FG003|Overall Study|Administrative reason by sponsor|0
6133468|NCT00982488|9761934|FG004|Overall Study|Administrative reason by sponsor|0
6133469|NCT00982488|9761930|FG000|Overall Study|Adverse event unrelated to study drug|5
6133470|NCT00982488|9761931|FG001|Overall Study|Adverse event unrelated to study drug|1
6133471|NCT00982488|9761932|FG002|Overall Study|Adverse event unrelated to study drug|0
6133472|NCT00982488|9761933|FG003|Overall Study|Adverse event unrelated to study drug|0
6133473|NCT00982488|9761934|FG004|Overall Study|Adverse event unrelated to study drug|0
6133474|NCT00982488|9761930|FG000|Overall Study|Death|11
6133475|NCT00982488|9761931|FG001|Overall Study|Death|0
6133476|NCT00982488|9761932|FG002|Overall Study|Death|2
6133477|NCT00982488|9761933|FG003|Overall Study|Death|0
6133478|NCT00982488|9761934|FG004|Overall Study|Death|0
6133479|NCT00982488|9761930|FG000|Overall Study|Disease progression|30
6133480|NCT00982488|9761931|FG001|Overall Study|Disease progression|5
6133481|NCT00982488|9761932|FG002|Overall Study|Disease progression|10
6133482|NCT00982488|9761933|FG003|Overall Study|Disease progression|1
6133483|NCT00982488|9761934|FG004|Overall Study|Disease progression|1
6133484|NCT00982488|9761930|FG000|Overall Study|Lost to Follow-up|1
6133485|NCT00982488|9761931|FG001|Overall Study|Lost to Follow-up|0
6133486|NCT00982488|9761932|FG002|Overall Study|Lost to Follow-up|0
6133487|NCT00982488|9761933|FG003|Overall Study|Lost to Follow-up|0
6133488|NCT00982488|9761934|FG004|Overall Study|Lost to Follow-up|0
6133489|NCT00982488|9761930|FG000|Overall Study|Maximum clinical benefit|1
6133490|NCT00982488|9761931|FG001|Overall Study|Maximum clinical benefit|1
6133491|NCT00982488|9761932|FG002|Overall Study|Maximum clinical benefit|1
6133492|NCT00982488|9761933|FG003|Overall Study|Maximum clinical benefit|0
6133493|NCT00982488|9761934|FG004|Overall Study|Maximum clinical benefit|0
6133494|NCT00982488|9761930|FG000|Overall Study|Other|15
6133495|NCT00982488|9761931|FG001|Overall Study|Other|1
6223603|NCT01691105|9895345|FG000|12 Month Biochemical Verification|subject did not self-report abstinence|352
6223604|NCT01691105|9895346|FG001|12 Month Biochemical Verification|subject did not self-report abstinence|401
6223605|NCT01691248|9895354|FG000|Overall Study|Protocol Violation|43
6223606|NCT01691248|9895355|FG001|Overall Study|Protocol Violation|27
6223607|NCT01691248|9895354|FG000|Overall Study|Adverse Event|24
6223608|NCT01691248|9895355|FG001|Overall Study|Adverse Event|22
6223609|NCT01691248|9895354|FG000|Overall Study|Withdrawal by Subject|20
6223610|NCT01691248|9895355|FG001|Overall Study|Withdrawal by Subject|18
6223611|NCT01691248|9895354|FG000|Overall Study|Confirmed CDAD|14
6223612|NCT01691248|9895355|FG001|Overall Study|Confirmed CDAD|31
6223613|NCT01691248|9895354|FG000|Overall Study|Lost to Follow-up|2
6223614|NCT01691248|9895355|FG001|Overall Study|Lost to Follow-up|5
6223615|NCT01691248|9895354|FG000|Overall Study|Reason not provided|4
6223616|NCT01691248|9895355|FG001|Overall Study|Reason not provided|4
6223617|NCT01691248|9895354|FG000|Overall Study|Not Treated|4
6223618|NCT01691248|9895355|FG001|Overall Study|Not Treated|7
6223619|NCT01691378|9895408|FG000|Overall Study|Withdrawal by Subject|2
6223620|NCT01691378|9895409|FG001|Overall Study|Withdrawal by Subject|0
6223621|NCT01691378|9895408|FG000|Overall Study|Lost to Follow-up|5
6133496|NCT00982488|9761932|FG002|Overall Study|Other|3
6133497|NCT00982488|9761933|FG003|Overall Study|Other|1
6133498|NCT00982488|9761934|FG004|Overall Study|Other|0
6133499|NCT00982488|9761930|FG000|Overall Study|Poor compliance/noncompliance|0
6223622|NCT01691378|9895409|FG001|Overall Study|Lost to Follow-up|2
6133500|NCT00982488|9761931|FG001|Overall Study|Poor compliance/noncompliance|1
6133501|NCT00982488|9761932|FG002|Overall Study|Poor compliance/noncompliance|0
6133502|NCT00982488|9761933|FG003|Overall Study|Poor compliance/noncompliance|0
6133503|NCT00982488|9761934|FG004|Overall Study|Poor compliance/noncompliance|0
6133504|NCT00982488|9761930|FG000|Overall Study|Stem cell transplant|2
6133505|NCT00982488|9761931|FG001|Overall Study|Stem cell transplant|0
6133506|NCT00982488|9761932|FG002|Overall Study|Stem cell transplant|0
6133507|NCT00982488|9761933|FG003|Overall Study|Stem cell transplant|1
6133508|NCT00982488|9761934|FG004|Overall Study|Stem cell transplant|0
6133509|NCT00982488|9761930|FG000|Overall Study|Study drug toxicity|34
6133510|NCT00982488|9761931|FG001|Overall Study|Study drug toxicity|1
6133511|NCT00982488|9761932|FG002|Overall Study|Study drug toxicity|6
6133512|NCT00982488|9761933|FG003|Overall Study|Study drug toxicity|0
6133513|NCT00982488|9761934|FG004|Overall Study|Study drug toxicity|0
6133514|NCT00982488|9761930|FG000|Overall Study|Withdrawal by Subject|5
6133515|NCT00982488|9761931|FG001|Overall Study|Withdrawal by Subject|1
6133516|NCT00982488|9761932|FG002|Overall Study|Withdrawal by Subject|1
6133517|NCT00982488|9761933|FG003|Overall Study|Withdrawal by Subject|0
6133518|NCT00982488|9761934|FG004|Overall Study|Withdrawal by Subject|0
6133519|NCT00982644|9761966|FG000|Main: Week 0 to 52 (NN1250-3579)|Adverse Event|20
6133520|NCT00982644|9761967|FG001|Main: Week 0 to 52 (NN1250-3579)|Adverse Event|5
6133521|NCT00982644|9761966|FG000|Main: Week 0 to 52 (NN1250-3579)|Lack of Efficacy|7
6133522|NCT00982644|9761967|FG001|Main: Week 0 to 52 (NN1250-3579)|Lack of Efficacy|2
6133523|NCT00982644|9761966|FG000|Main: Week 0 to 52 (NN1250-3579)|Protocol Violation|46
6133524|NCT00982644|9761967|FG001|Main: Week 0 to 52 (NN1250-3579)|Protocol Violation|18
6133525|NCT00982644|9761966|FG000|Main: Week 0 to 52 (NN1250-3579)|Withdrawal criteria|9
6133526|NCT00982644|9761967|FG001|Main: Week 0 to 52 (NN1250-3579)|Withdrawal criteria|5
6133527|NCT00982644|9761966|FG000|Main: Week 0 to 52 (NN1250-3579)|Unclassified|84
6133528|NCT00982644|9761967|FG001|Main: Week 0 to 52 (NN1250-3579)|Unclassified|30
6133529|NCT00982644|9761966|FG000|Extension: Week 53 to 104 (NN1250-3643)|Adverse Event|12
6133530|NCT00982644|9761967|FG001|Extension: Week 53 to 104 (NN1250-3643)|Adverse Event|5
6133531|NCT00982644|9761966|FG000|Extension: Week 53 to 104 (NN1250-3643)|Lack of Efficacy|3
6133532|NCT00982644|9761967|FG001|Extension: Week 53 to 104 (NN1250-3643)|Lack of Efficacy|1
6133533|NCT00982644|9761966|FG000|Extension: Week 53 to 104 (NN1250-3643)|Protocol Violation|2
6133534|NCT00982644|9761967|FG001|Extension: Week 53 to 104 (NN1250-3643)|Protocol Violation|4
6133535|NCT00982644|9761966|FG000|Extension: Week 53 to 104 (NN1250-3643)|Withdrawal criteria|6
6133536|NCT00982644|9761967|FG001|Extension: Week 53 to 104 (NN1250-3643)|Withdrawal criteria|3
6223623|NCT01691430|9895417|FG000|Overall Study|Death|17
6223624|NCT01691430|9895418|FG001|Overall Study|Death|16
6223625|NCT01691430|9895417|FG000|Overall Study|Withdrawal by Subject|5
6223626|NCT01691430|9895418|FG001|Overall Study|Withdrawal by Subject|1
6223627|NCT01691430|9895417|FG000|Overall Study|Lost to Follow-up|0
6223628|NCT01691430|9895418|FG001|Overall Study|Lost to Follow-up|3
6223629|NCT01691482|9895424|FG000|Treatment Period 2|Adverse Event|0
6223630|NCT01691482|9895425|FG001|Treatment Period 2|Adverse Event|1
6290157|NCT02394561|10005974|FG001|Extension Phase|Adverse Event|1
6290158|NCT02394561|10005973|FG000|Extension Phase|Death|0
6290159|NCT02394561|10005974|FG001|Extension Phase|Death|1
6290160|NCT02394561|10005973|FG000|Extension Phase|Protocol Violation|1
6290161|NCT02394561|10005974|FG001|Extension Phase|Protocol Violation|0
6290162|NCT02394561|10005973|FG000|Extension Phase|Lost to Follow-up|1
5981076|NCT02538666|9570004|FG002|Overall Study|Withdrew Consent|1
5981077|NCT02527200|9570017|FG000|Overall Study|Withdrawal by Subject|3
5981078|NCT02527200|9570018|FG001|Overall Study|Withdrawal by Subject|2
5981079|NCT02527200|9570019|FG002|Overall Study|Withdrawal by Subject|1
5981080|NCT02527200|9570020|FG003|Overall Study|Withdrawal by Subject|0
5981081|NCT02527200|9570017|FG000|Overall Study|Unclassified|0
5981082|NCT02527200|9570018|FG001|Overall Study|Unclassified|1
5981083|NCT02527200|9570019|FG002|Overall Study|Unclassified|0
5981084|NCT02527200|9570020|FG003|Overall Study|Unclassified|0
5981085|NCT02527200|9570017|FG000|Overall Study|Lost to Follow-up|0
5981086|NCT02527200|9570018|FG001|Overall Study|Lost to Follow-up|0
5981087|NCT02527200|9570019|FG002|Overall Study|Lost to Follow-up|1
5981088|NCT02527200|9570020|FG003|Overall Study|Lost to Follow-up|0
6063480|NCT00506415|9664786|FG002|Initial Open Label (Maximum 48 Weeks)|Protocol Violation|0
6063481|NCT00506415|9664787|FG003|Initial Open Label (Maximum 48 Weeks)|Protocol Violation|0
6063482|NCT00506415|9664784|FG000|Double Blind (Maximum 48 Weeks )|Adverse Event|0
6063483|NCT00506415|9664785|FG001|Double Blind (Maximum 48 Weeks )|Adverse Event|33
6063484|NCT00506415|9664786|FG002|Double Blind (Maximum 48 Weeks )|Adverse Event|28
6063485|NCT00506415|9664787|FG003|Double Blind (Maximum 48 Weeks )|Adverse Event|0
6063486|NCT00506415|9664784|FG000|Double Blind (Maximum 48 Weeks )|Death|0
6063487|NCT00506415|9664785|FG001|Double Blind (Maximum 48 Weeks )|Death|5
6223631|NCT01691482|9895424|FG000|Treatment Period 2|Protocol Violation|1
6223632|NCT01691482|9895425|FG001|Treatment Period 2|Protocol Violation|1
6223633|NCT01691508|9895434|FG000|Overall Study|Adverse Event|3
6223634|NCT01691508|9895435|FG001|Overall Study|Adverse Event|3
6223635|NCT01691508|9895434|FG000|Overall Study|Withdrawal by Subject|1
6290163|NCT02394561|10005974|FG001|Extension Phase|Lost to Follow-up|0
6290164|NCT02394561|10005973|FG000|Extension Phase|Physician Decision|0
6133537|NCT00982644|9761966|FG000|Extension: Week 53 to 104 (NN1250-3643)|Unclassified|23
6133538|NCT00982644|9761967|FG001|Extension: Week 53 to 104 (NN1250-3643)|Unclassified|7
6133539|NCT00982657|9761977|FG000|Overall Study|Death|1
6133540|NCT00982657|9761978|FG001|Overall Study|Death|0
6133541|NCT00982657|9761979|FG002|Overall Study|Death|1
6133542|NCT00982657|9761980|FG003|Overall Study|Death|1
6133543|NCT00982657|9761977|FG000|Overall Study|Withdrawal by Subject|0
6133544|NCT00982657|9761978|FG001|Overall Study|Withdrawal by Subject|0
6133545|NCT00982657|9761979|FG002|Overall Study|Withdrawal by Subject|1
6133546|NCT00982657|9761980|FG003|Overall Study|Withdrawal by Subject|3
6223636|NCT01691508|9895435|FG001|Overall Study|Withdrawal by Subject|0
6223637|NCT01691521|9895444|FG000|Overall Study|Adverse Event|4
6223638|NCT01691521|9895445|FG001|Overall Study|Adverse Event|0
6223639|NCT01691521|9895446|FG002|Overall Study|Adverse Event|1
6223640|NCT01691521|9895444|FG000|Overall Study|Lack of Efficacy|1
6223641|NCT01691521|9895445|FG001|Overall Study|Lack of Efficacy|1
6223642|NCT01691521|9895446|FG002|Overall Study|Lack of Efficacy|2
6223643|NCT01691521|9895444|FG000|Overall Study|Protocol Violation|0
6223644|NCT01691521|9895445|FG001|Overall Study|Protocol Violation|3
6223645|NCT01691521|9895446|FG002|Overall Study|Protocol Violation|0
6223646|NCT01691521|9895444|FG000|Overall Study|Lost to Follow-up|0
6223647|NCT01691521|9895445|FG001|Overall Study|Lost to Follow-up|2
6223648|NCT01691521|9895446|FG002|Overall Study|Lost to Follow-up|2
6223649|NCT01691521|9895444|FG000|Overall Study|Physician Decision|2
6223650|NCT01691521|9895445|FG001|Overall Study|Physician Decision|1
6223651|NCT01691521|9895446|FG002|Overall Study|Physician Decision|0
6223652|NCT01691521|9895444|FG000|Overall Study|Withdrawal by Subject|5
6223653|NCT01691521|9895445|FG001|Overall Study|Withdrawal by Subject|9
6223654|NCT01691521|9895446|FG002|Overall Study|Withdrawal by Subject|4
6223655|NCT01691612|9895502|FG000|Overall Study|deemed ineligible after 1st visit|6
6223656|NCT01691612|9895502|FG000|Overall Study|Adverse Event|1
6223657|NCT01691768|9895520|FG000|Overall Study|Death|0
6223658|NCT01691768|9895521|FG001|Overall Study|Death|2
6223659|NCT01691768|9895520|FG000|Overall Study|Lost to Follow-up|4
6223660|NCT01691768|9895521|FG001|Overall Study|Lost to Follow-up|3
6223661|NCT01691768|9895520|FG000|Overall Study|Withdrawal by Subject|10
6223662|NCT01691768|9895521|FG001|Overall Study|Withdrawal by Subject|9
6223663|NCT01691768|9895520|FG000|Overall Study|Relocated|0
6223664|NCT01691768|9895521|FG001|Overall Study|Relocated|1
6223665|NCT01691768|9895520|FG000|Overall Study|Investigator decision|1
6223666|NCT01691768|9895521|FG001|Overall Study|Investigator decision|1
6290165|NCT02394561|10005974|FG001|Extension Phase|Physician Decision|2
6290166|NCT02394561|10005973|FG000|Extension Phase|Withdrawal by Subject|0
6290167|NCT02394561|10005974|FG001|Extension Phase|Withdrawal by Subject|5
6290168|NCT02394561|10005973|FG000|Extension Phase|Lack of Efficacy|3
6290169|NCT02394561|10005974|FG001|Extension Phase|Lack of Efficacy|3
6290170|NCT02394600|10005985|FG000|Overall Study|Adverse Event|3
6290171|NCT02394600|10005986|FG001|Overall Study|Adverse Event|0
6290172|NCT02394600|10005985|FG000|Overall Study|Lost to Follow-up|0
6290173|NCT02394600|10005986|FG001|Overall Study|Lost to Follow-up|1
6290174|NCT02394600|10005985|FG000|Overall Study|Withdrawal by Subject|0
6290175|NCT02394600|10005986|FG001|Overall Study|Withdrawal by Subject|1
6290176|NCT02394600|10005985|FG000|Overall Study|Protocol Violation|1
6290177|NCT02394600|10005986|FG001|Overall Study|Protocol Violation|0
6290178|NCT02394730|10005994|FG000|Overall Study|Lost to Follow-up|1
6290179|NCT02394730|10005995|FG001|Overall Study|Lost to Follow-up|0
6290180|NCT02394730|10005994|FG000|Overall Study|Withdrawal by Subject|0
6290181|NCT02394730|10005995|FG001|Overall Study|Withdrawal by Subject|1
6290182|NCT02394756|10006001|FG000|Period 1|Lens Discomfort|0
6290183|NCT02394756|10006002|FG001|Period 1|Lens Discomfort|0
6290184|NCT02394756|10006003|FG002|Period 1|Lens Discomfort|0
6290185|NCT02394756|10006004|FG003|Period 1|Lens Discomfort|0
6290186|NCT02394756|10006005|FG004|Period 1|Lens Discomfort|0
6290187|NCT02394756|10006006|FG005|Period 1|Lens Discomfort|1
6290188|NCT02394756|10006001|FG000|Period 1|Withdrawal by Subject|0
6290189|NCT02394756|10006002|FG001|Period 1|Withdrawal by Subject|1
6290190|NCT02394756|10006003|FG002|Period 1|Withdrawal by Subject|1
6290191|NCT02394756|10006004|FG003|Period 1|Withdrawal by Subject|1
6290192|NCT02394756|10006005|FG004|Period 1|Withdrawal by Subject|0
6290193|NCT02394756|10006006|FG005|Period 1|Withdrawal by Subject|0
6290194|NCT02394756|10006001|FG000|Period 2|Unsatisfactory Visual Response|0
6290195|NCT02394756|10006002|FG001|Period 2|Unsatisfactory Visual Response|0
6290196|NCT02394756|10006003|FG002|Period 2|Unsatisfactory Visual Response|0
6290197|NCT02394756|10006004|FG003|Period 2|Unsatisfactory Visual Response|0
6290198|NCT02394756|10006005|FG004|Period 2|Unsatisfactory Visual Response|1
6290199|NCT02394756|10006006|FG005|Period 2|Unsatisfactory Visual Response|0
6290200|NCT02394808|10006027|FG000|Period 1|Unsatisfactory lens fitting|0
6290201|NCT02394808|10006028|FG001|Period 1|Unsatisfactory lens fitting|1
6133547|NCT00982657|9761977|FG000|Overall Study|Other|0
6133548|NCT00982657|9761978|FG001|Overall Study|Other|0
6290202|NCT02394808|10006027|FG000|Period 2|Lost to Follow-up|1
6290203|NCT02394808|10006028|FG001|Period 2|Lost to Follow-up|0
6290204|NCT02394925|10006040|FG000|Overall Study|Adverse Event|1
6290205|NCT02394925|10006040|FG000|Overall Study|Lens Discomfort|3
6290206|NCT02394925|10006040|FG000|Overall Study|Lens handling difficulities|5
6290207|NCT02394925|10006040|FG000|Overall Study|Lost to Follow-up|9
6290208|NCT02394925|10006040|FG000|Overall Study|Protocol Violation|5
6133549|NCT00982657|9761979|FG002|Overall Study|Other|0
6133550|NCT00982657|9761980|FG003|Overall Study|Other|4
6223667|NCT01691781|9895530|FG000|Overall Study|Withdrawal by Subject|4
6223668|NCT01691781|9895531|FG001|Overall Study|Withdrawal by Subject|3
6223669|NCT01691781|9895530|FG000|Overall Study|Physician Decision|1
6223670|NCT01691781|9895531|FG001|Overall Study|Physician Decision|1
6223671|NCT01691781|9895530|FG000|Overall Study|Protocol Violation|2
6223672|NCT01691781|9895531|FG001|Overall Study|Protocol Violation|2
6223673|NCT01691781|9895530|FG000|Overall Study|Adverse Event|0
6223674|NCT01691781|9895531|FG001|Overall Study|Adverse Event|1
6223675|NCT01691794|9895540|FG000|Overall Study|Poor/Non-Compliance|1
6223676|NCT01691794|9895541|FG001|Overall Study|Poor/Non-Compliance|4
6223677|NCT01691794|9895542|FG002|Overall Study|Poor/Non-Compliance|1
6223678|NCT01691794|9895540|FG000|Overall Study|Death|0
6223679|NCT01691794|9895541|FG001|Overall Study|Death|0
6223680|NCT01691794|9895542|FG002|Overall Study|Death|1
6223681|NCT01691794|9895540|FG000|Overall Study|Lack of Efficacy|0
6223682|NCT01691794|9895541|FG001|Overall Study|Lack of Efficacy|7
6223683|NCT01691794|9895542|FG002|Overall Study|Lack of Efficacy|1
6223684|NCT01691794|9895540|FG000|Overall Study|Participant request to discontinue|0
6223685|NCT01691794|9895541|FG001|Overall Study|Participant request to discontinue|1
6223686|NCT01691794|9895542|FG002|Overall Study|Participant request to discontinue|0
6223687|NCT01691794|9895540|FG000|Overall Study|Adverse Event|0
6223688|NCT01691794|9895541|FG001|Overall Study|Adverse Event|1
6223689|NCT01691794|9895542|FG002|Overall Study|Adverse Event|1
6223690|NCT01691794|9895540|FG000|Overall Study|Completed Only first 24 weeks of study|0
6223691|NCT01691794|9895541|FG001|Overall Study|Completed Only first 24 weeks of study|2
6223692|NCT01691794|9895542|FG002|Overall Study|Completed Only first 24 weeks of study|3
6223693|NCT01691794|9895540|FG000|Overall Study|Did not complete first 24 weeks of study|0
6223694|NCT01691794|9895541|FG001|Overall Study|Did not complete first 24 weeks of study|3
6223695|NCT01691794|9895542|FG002|Overall Study|Did not complete first 24 weeks of study|3
6223696|NCT01691820|9895552|FG000|Overall Study|Consent withdrawal (not due to an AE)|9
6223697|NCT01691820|9895553|FG001|Overall Study|Consent withdrawal (not due to an AE)|15
6223698|NCT01691820|9895552|FG000|Overall Study|Migrated/moved from study area|7
6223699|NCT01691820|9895553|FG001|Overall Study|Migrated/moved from study area|4
6223700|NCT01691820|9895552|FG000|Overall Study|Lost to Follow-up|6
6223701|NCT01691820|9895553|FG001|Overall Study|Lost to Follow-up|17
6223702|NCT01691820|9895552|FG000|Overall Study|Other (unspecified)|4
6223703|NCT01691820|9895553|FG001|Overall Study|Other (unspecified)|1
6223704|NCT01691859|9895576|FG000|Overall Study|Adverse Event|19
6223705|NCT01691859|9895576|FG000|Overall Study|Lack of Efficacy|11
6223706|NCT01691859|9895576|FG000|Overall Study|Protocol Violation|4
6223707|NCT01691859|9895576|FG000|Overall Study|Product commercially available|221
6223708|NCT01691859|9895576|FG000|Overall Study|Study closed/terminated|50
6223709|NCT01691859|9895576|FG000|Overall Study|Lost to Follow-up|5
6223710|NCT01691859|9895576|FG000|Overall Study|Physician Decision|6
6223711|NCT01691859|9895576|FG000|Overall Study|Withdrawal by Subject|31
6223712|NCT01691885|9895580|FG000|Treatment Period 1(7-14 Days)|Adverse Event|1
6223713|NCT01691885|9895581|FG001|Treatment Period 1(7-14 Days)|Adverse Event|1
6223714|NCT01691885|9895580|FG000|Washout Period (7-9 Days)|Adverse Event|0
6223715|NCT01691885|9895581|FG001|Washout Period (7-9 Days)|Adverse Event|1
6223716|NCT01691898|9895593|FG000|Overall Study|Death|34
6223717|NCT01691898|9895594|FG001|Overall Study|Death|32
6223718|NCT01691898|9895595|FG002|Overall Study|Death|6
6223719|NCT01691898|9895596|FG003|Overall Study|Death|3
6223720|NCT01691898|9895597|FG004|Overall Study|Death|8
6223721|NCT01691898|9895598|FG005|Overall Study|Death|31
6223722|NCT01691898|9895593|FG000|Overall Study|Adverse Event|0
6223723|NCT01691898|9895594|FG001|Overall Study|Adverse Event|1
6223724|NCT01691898|9895595|FG002|Overall Study|Adverse Event|0
6223725|NCT01691898|9895596|FG003|Overall Study|Adverse Event|1
6223726|NCT01691898|9895597|FG004|Overall Study|Adverse Event|1
6223727|NCT01691898|9895598|FG005|Overall Study|Adverse Event|0
6223728|NCT01691898|9895593|FG000|Overall Study|Progression of Disease|1
6223729|NCT01691898|9895594|FG001|Overall Study|Progression of Disease|2
6223730|NCT01691898|9895595|FG002|Overall Study|Progression of Disease|1
6223731|NCT01691898|9895596|FG003|Overall Study|Progression of Disease|0
6223732|NCT01691898|9895597|FG004|Overall Study|Progression of Disease|0
6223733|NCT01691898|9895598|FG005|Overall Study|Progression of Disease|1
6223734|NCT01691898|9895593|FG000|Overall Study|Lost to Follow-up|3
6223735|NCT01691898|9895594|FG001|Overall Study|Lost to Follow-up|1
6223736|NCT01691898|9895595|FG002|Overall Study|Lost to Follow-up|0
6223737|NCT01691898|9895596|FG003|Overall Study|Lost to Follow-up|0
6223738|NCT01691898|9895597|FG004|Overall Study|Lost to Follow-up|1
6223739|NCT01691898|9895598|FG005|Overall Study|Lost to Follow-up|0
6223740|NCT01691898|9895593|FG000|Overall Study|Withdrawal by Subject|9
6223741|NCT01691898|9895594|FG001|Overall Study|Withdrawal by Subject|8
6223742|NCT01691898|9895595|FG002|Overall Study|Withdrawal by Subject|2
6223743|NCT01691898|9895596|FG003|Overall Study|Withdrawal by Subject|1
5981089|NCT02511106|9570036|FG000|Overall Study|Lost to Follow-up|1
6223744|NCT01691898|9895597|FG004|Overall Study|Withdrawal by Subject|3
6223745|NCT01691898|9895598|FG005|Overall Study|Withdrawal by Subject|3
6223746|NCT01691898|9895593|FG000|Overall Study|Non-Compliance|0
6223747|NCT01691898|9895594|FG001|Overall Study|Non-Compliance|0
6133551|NCT00982657|9761977|FG000|Overall Study|On going at date of cut-off|0
6133552|NCT00982657|9761978|FG001|Overall Study|On going at date of cut-off|0
6133553|NCT00982657|9761979|FG002|Overall Study|On going at date of cut-off|0
6133554|NCT00982657|9761980|FG003|Overall Study|On going at date of cut-off|1
6133555|NCT00982735|9762000|FG000|Overall Study|Lost to Follow-up|6
6133556|NCT00982735|9762000|FG000|Overall Study|Patient ineligible for trial|224
6133557|NCT00982878|9762058|FG000|Overall Study|Physician Decision|1
6133558|NCT00982930|9762062|FG000|Overall Study|Adverse Event|1
6133559|NCT00982930|9762062|FG000|Overall Study|Withdrawal by Subject|1
6133560|NCT00982930|9762062|FG000|Overall Study|Administrative Problems|2
6133561|NCT00983073|9762066|FG000|Titration and Optimal Dose Period|Adverse Event|19
6133562|NCT00983073|9762066|FG000|Titration and Optimal Dose Period|Withdrawal by Subject|11
6133563|NCT00983073|9762066|FG000|Titration and Optimal Dose Period|Lack of Efficacy|5
6133564|NCT00983073|9762066|FG000|Titration and Optimal Dose Period|Non-Compliance|1
6133565|NCT00983073|9762066|FG000|Titration and Optimal Dose Period|Other reason|4
6133566|NCT00983073|9762066|FG000|Maintenance Period|Adverse Event|5
6133567|NCT00983073|9762066|FG000|Maintenance Period|Withdrawal by Subject|2
6133568|NCT00983073|9762066|FG000|Maintenance Period|Lack of Efficacy|2
6133569|NCT00983073|9762066|FG000|Maintenance Period|Other Reason|7
6133570|NCT00983294|9762094|FG000|14 Day Washout Period|Withdrawal by Subject|2
6133571|NCT00983294|9762094|FG000|Colchicine With Azithromycin|Adverse Event|1
6133572|NCT00983372|9762113|FG000|14 Day Washout Period|Withdrawal by Subject|1
6133573|NCT00983372|9762113|FG000|Diltiazem ER Alone|missed diltiazem dose|2
6133574|NCT00983372|9762113|FG000|Diltiazem ER Alone|Adverse Event|1
6133575|NCT00983385|9762120|FG000|Observation Period|Not eligible to be dosed|20
6133576|NCT00983385|9762120|FG000|Observation Period|Not Evaluable due to Non Compliance|12
6133577|NCT00983476|9762142|FG000|Overall Study|Did not receive intervention|17
6133578|NCT00983476|9762143|FG001|Overall Study|Did not receive intervention|22
6133579|NCT00983476|9762144|FG002|Overall Study|Did not receive intervention|0
6133580|NCT00983515|9762171|FG000|Ritonavir Alone|liver panel out of range|6
6133581|NCT00983515|9762171|FG000|Colchicine With Ritonavir|Lost to Follow-up|1
6133582|NCT00983528|9762178|FG000|Overall Study|Death|4
6133583|NCT00983528|9762178|FG000|Overall Study|Lost to Follow-up|1
6133584|NCT00983528|9762178|FG000|Overall Study|Study Terminated|1
6133585|NCT00983580|9762188|FG000|Overall Study|Cancel Prior to treatment|1
6133586|NCT00983580|9762189|FG001|Overall Study|Cancel Prior to treatment|3
6133587|NCT00983580|9762188|FG000|Overall Study|Protocol Violation|1
6133588|NCT00983580|9762189|FG001|Overall Study|Protocol Violation|1
6133589|NCT00983580|9762188|FG000|Overall Study|Ineligible|3
6133590|NCT00983580|9762189|FG001|Overall Study|Ineligible|0
6133591|NCT00983619|9762208|FG000|Overall Study|Lost to Follow-up|0
6133592|NCT00983619|9762209|FG001|Overall Study|Lost to Follow-up|1
6133593|NCT00983619|9762210|FG002|Overall Study|Lost to Follow-up|0
6133594|NCT00983619|9762211|FG003|Overall Study|Lost to Follow-up|0
6133595|NCT00983619|9762212|FG004|Overall Study|Lost to Follow-up|0
6133596|NCT00983619|9762213|FG005|Overall Study|Lost to Follow-up|2
6133597|NCT00983619|9762214|FG006|Overall Study|Lost to Follow-up|0
6133598|NCT00983619|9762215|FG007|Overall Study|Lost to Follow-up|0
6133599|NCT00983619|9762216|FG008|Overall Study|Lost to Follow-up|0
6133600|NCT00983619|9762217|FG009|Overall Study|Lost to Follow-up|0
6133601|NCT00983619|9762218|FG010|Overall Study|Lost to Follow-up|0
6223748|NCT01691898|9895595|FG002|Overall Study|Non-Compliance|0
6223749|NCT01691898|9895596|FG003|Overall Study|Non-Compliance|0
6223750|NCT01691898|9895597|FG004|Overall Study|Non-Compliance|1
6223751|NCT01691898|9895598|FG005|Overall Study|Non-Compliance|0
6223752|NCT01692119|9895641|FG000|Overall Study|Protocol Violation|3
6223753|NCT01692119|9895642|FG001|Overall Study|Protocol Violation|1
6223754|NCT01692119|9895641|FG000|Overall Study|Intervention: pts. did not present to participating pharmacy|17
6223755|NCT01692119|9895642|FG001|Overall Study|Intervention: pts. did not present to participating pharmacy|0
6223756|NCT01692197|9895648|FG000|Overall Study|Failed Screening|3
6223757|NCT01692275|9895659|FG000|Overall Study|Lost to Follow-up|57
6223758|NCT01692275|9895660|FG001|Overall Study|Lost to Follow-up|48
6223759|NCT01692275|9895659|FG000|Overall Study|Withdrawal by Subject|9
6223760|NCT01692275|9895660|FG001|Overall Study|Withdrawal by Subject|11
6223761|NCT01692301|9895680|FG000|Overall Study|Adverse Event|15
6223762|NCT01692301|9895681|FG001|Overall Study|Adverse Event|12
6223763|NCT01692301|9895680|FG000|Overall Study|Death|1
6223764|NCT01692301|9895681|FG001|Overall Study|Death|2
6223765|NCT01692301|9895680|FG000|Overall Study|Lack of Efficacy|0
6133602|NCT00983619|9762219|FG011|Overall Study|Lost to Follow-up|2
6133603|NCT00983619|9762208|FG000|Overall Study|Withdrawal by Subject|2
6133604|NCT00983619|9762209|FG001|Overall Study|Withdrawal by Subject|1
6133605|NCT00983619|9762210|FG002|Overall Study|Withdrawal by Subject|1
6133606|NCT00983619|9762211|FG003|Overall Study|Withdrawal by Subject|3
6133607|NCT00983619|9762212|FG004|Overall Study|Withdrawal by Subject|1
6133608|NCT00983619|9762213|FG005|Overall Study|Withdrawal by Subject|23
6133609|NCT00983619|9762214|FG006|Overall Study|Withdrawal by Subject|0
6223766|NCT01692301|9895681|FG001|Overall Study|Lack of Efficacy|5
6223767|NCT01692301|9895680|FG000|Overall Study|Non-compliance with study treatment|1
6223768|NCT01692301|9895681|FG001|Overall Study|Non-compliance with study treatment|2
6223769|NCT01692301|9895680|FG000|Overall Study|Protocol deviation|9
6223770|NCT01692301|9895681|FG001|Overall Study|Protocol deviation|2
6133610|NCT00983619|9762215|FG007|Overall Study|Withdrawal by Subject|0
6133611|NCT00983619|9762216|FG008|Overall Study|Withdrawal by Subject|0
6133612|NCT00983619|9762217|FG009|Overall Study|Withdrawal by Subject|0
6133613|NCT00983619|9762218|FG010|Overall Study|Withdrawal by Subject|1
6133614|NCT00983619|9762219|FG011|Overall Study|Withdrawal by Subject|1
6133615|NCT00983619|9762208|FG000|Overall Study|Death|0
6133616|NCT00983619|9762209|FG001|Overall Study|Death|2
6133617|NCT00983619|9762210|FG002|Overall Study|Death|2
6133618|NCT00983619|9762211|FG003|Overall Study|Death|1
6133619|NCT00983619|9762212|FG004|Overall Study|Death|2
6133620|NCT00983619|9762213|FG005|Overall Study|Death|30
6133621|NCT00983619|9762214|FG006|Overall Study|Death|1
6133622|NCT00983619|9762215|FG007|Overall Study|Death|0
6133623|NCT00983619|9762216|FG008|Overall Study|Death|1
6133624|NCT00983619|9762217|FG009|Overall Study|Death|2
6133625|NCT00983619|9762218|FG010|Overall Study|Death|9
6133626|NCT00983619|9762219|FG011|Overall Study|Death|8
6133627|NCT00983619|9762208|FG000|Overall Study|Other|1
6133628|NCT00983619|9762209|FG001|Overall Study|Other|0
6133629|NCT00983619|9762210|FG002|Overall Study|Other|0
6133630|NCT00983619|9762211|FG003|Overall Study|Other|1
6133631|NCT00983619|9762212|FG004|Overall Study|Other|0
6133632|NCT00983619|9762213|FG005|Overall Study|Other|12
6133633|NCT00983619|9762214|FG006|Overall Study|Other|2
6223771|NCT01692301|9895680|FG000|Overall Study|Patient/guardian decision|16
6223772|NCT01692301|9895681|FG001|Overall Study|Patient/guardian decision|15
6223773|NCT01692301|9895680|FG000|Overall Study|Technical problems|0
6223774|NCT01692301|9895681|FG001|Overall Study|Technical problems|1
6223775|NCT01692301|9895680|FG000|Overall Study|Physician Decision|2
6223776|NCT01692301|9895681|FG001|Overall Study|Physician Decision|2
6223777|NCT01692301|9895680|FG000|Overall Study|Lost to Follow-up|1
6223778|NCT01692301|9895681|FG001|Overall Study|Lost to Follow-up|1
6223779|NCT01692626|9895705|FG000|Overall Study|Death|0
6223780|NCT01692626|9895706|FG001|Overall Study|Death|1
6223781|NCT01692626|9895705|FG000|Overall Study|Adverse Event|2
6223782|NCT01692626|9895706|FG001|Overall Study|Adverse Event|3
6223783|NCT01692626|9895705|FG000|Overall Study|Protocol Violation|1
6223784|NCT01692626|9895706|FG001|Overall Study|Protocol Violation|2
6223785|NCT01692626|9895705|FG000|Overall Study|Withdrawal by Subject|1
6223786|NCT01692626|9895706|FG001|Overall Study|Withdrawal by Subject|0
6223787|NCT01692730|9895713|FG000|Overall Study|Lost to Follow-up|225
6223788|NCT01692730|9895714|FG001|Overall Study|Lost to Follow-up|227
6223789|NCT01692782|9895753|FG000|Overall Study|Adverse Event|12
6223790|NCT01692782|9895754|FG001|Overall Study|Adverse Event|32
6223791|NCT01692782|9895755|FG002|Overall Study|Adverse Event|2
6223792|NCT01692782|9895753|FG000|Overall Study|Lack of Efficacy|1
6223793|NCT01692782|9895754|FG001|Overall Study|Lack of Efficacy|2
6223794|NCT01692782|9895755|FG002|Overall Study|Lack of Efficacy|0
6223795|NCT01692782|9895753|FG000|Overall Study|Lost to Follow-up|2
6223796|NCT01692782|9895754|FG001|Overall Study|Lost to Follow-up|7
6223797|NCT01692782|9895755|FG002|Overall Study|Lost to Follow-up|1
6223798|NCT01692782|9895753|FG000|Overall Study|Pregnancy|1
6223799|NCT01692782|9895754|FG001|Overall Study|Pregnancy|0
6223800|NCT01692782|9895755|FG002|Overall Study|Pregnancy|0
6223801|NCT01692782|9895753|FG000|Overall Study|Protocol Violation|1
6223802|NCT01692782|9895754|FG001|Overall Study|Protocol Violation|0
6223803|NCT01692782|9895755|FG002|Overall Study|Protocol Violation|2
6223804|NCT01692782|9895753|FG000|Overall Study|Non-complance with study drug|0
6223805|NCT01692782|9895754|FG001|Overall Study|Non-complance with study drug|4
6223806|NCT01692782|9895755|FG002|Overall Study|Non-complance with study drug|1
6223807|NCT01692782|9895753|FG000|Overall Study|Non-compliant with study visits|0
6223808|NCT01692782|9895754|FG001|Overall Study|Non-compliant with study visits|0
6223809|NCT01692782|9895755|FG002|Overall Study|Non-compliant with study visits|1
6223810|NCT01692782|9895753|FG000|Overall Study|SAE not related to study drug|0
6223811|NCT01692782|9895754|FG001|Overall Study|SAE not related to study drug|1
6223812|NCT01692782|9895755|FG002|Overall Study|SAE not related to study drug|0
6223813|NCT01692782|9895753|FG000|Overall Study|Withdrawal by Subject|3
6223814|NCT01692782|9895754|FG001|Overall Study|Withdrawal by Subject|10
6223815|NCT01692782|9895755|FG002|Overall Study|Withdrawal by Subject|3
6223816|NCT01692938|9895765|FG000|Overall Study|Protocol Deviation|1
6223817|NCT01692938|9895766|FG001|Overall Study|Protocol Deviation|1
6223818|NCT01692938|9895765|FG000|Overall Study|Study completed prior to site completion|3
6223819|NCT01692938|9895766|FG001|Overall Study|Study completed prior to site completion|3
6223820|NCT01693029|9895796|FG000|Overall Study|Withdrawal by Subject|15
6223821|NCT01693029|9895797|FG001|Overall Study|Withdrawal by Subject|22
6223822|NCT01693029|9895796|FG000|Overall Study|Kidney transplantation|7
6223823|NCT01693029|9895797|FG001|Overall Study|Kidney transplantation|7
6223824|NCT01693029|9895796|FG000|Overall Study|Bindinging anti-EPO antibodies|6
6223825|NCT01693029|9895797|FG001|Overall Study|Bindinging anti-EPO antibodies|2
6223826|NCT01693029|9895796|FG000|Overall Study|Protocol Violation|6
6133634|NCT00983619|9762215|FG007|Overall Study|Other|2
6223827|NCT01693029|9895797|FG001|Overall Study|Protocol Violation|7
6223828|NCT01693029|9895796|FG000|Overall Study|Change in dialysis modality|2
6223829|NCT01693029|9895797|FG001|Overall Study|Change in dialysis modality|1
6133635|NCT00983619|9762216|FG008|Overall Study|Other|0
6133636|NCT00983619|9762217|FG009|Overall Study|Other|1
6133637|NCT00983619|9762218|FG010|Overall Study|Other|1
6133638|NCT00983619|9762219|FG011|Overall Study|Other|0
6133639|NCT00983749|9762267|FG000|Follow-up Phase (Hospital DC to 30 Days)|Lost to Follow-up|1
6133640|NCT00983749|9762268|FG001|Follow-up Phase (Hospital DC to 30 Days)|Lost to Follow-up|3
6133641|NCT00983827|9762278|FG000|Overall Study|Withdrawal by Subject|1
6133642|NCT00983853|9762288|FG000|Overall Study|Lost to Follow-up|1
6133643|NCT00983853|9762289|FG001|Overall Study|Lost to Follow-up|1
6133644|NCT00983853|9762290|FG002|Overall Study|Lost to Follow-up|2
6133645|NCT00983853|9762291|FG003|Overall Study|Lost to Follow-up|2
6133646|NCT00983853|9762292|FG004|Overall Study|Lost to Follow-up|2
6133647|NCT00983853|9762293|FG005|Overall Study|Lost to Follow-up|1
6133648|NCT00983853|9762288|FG000|Overall Study|Withdrawal by Subject|0
6133649|NCT00983853|9762289|FG001|Overall Study|Withdrawal by Subject|0
6133650|NCT00983853|9762290|FG002|Overall Study|Withdrawal by Subject|1
6133651|NCT00983853|9762291|FG003|Overall Study|Withdrawal by Subject|0
6133652|NCT00983853|9762292|FG004|Overall Study|Withdrawal by Subject|1
6133653|NCT00983853|9762293|FG005|Overall Study|Withdrawal by Subject|0
6133654|NCT00983853|9762288|FG000|Overall Study|Unable to come to study follow-up visits|0
6133655|NCT00983853|9762289|FG001|Overall Study|Unable to come to study follow-up visits|1
6133656|NCT00983853|9762290|FG002|Overall Study|Unable to come to study follow-up visits|0
6133657|NCT00983853|9762291|FG003|Overall Study|Unable to come to study follow-up visits|0
6133658|NCT00983853|9762292|FG004|Overall Study|Unable to come to study follow-up visits|0
6223830|NCT01693029|9895796|FG000|Overall Study|Physician Decision|0
6223831|NCT01693029|9895797|FG001|Overall Study|Physician Decision|2
6223832|NCT01693029|9895796|FG000|Overall Study|Lost to Follow-up|0
6223833|NCT01693029|9895797|FG001|Overall Study|Lost to Follow-up|1
6223834|NCT01693029|9895796|FG000|Overall Study|Adverse Event|1
6223835|NCT01693029|9895797|FG001|Overall Study|Adverse Event|6
6223836|NCT01693029|9895796|FG000|Overall Study|Death|5
6223837|NCT01693029|9895797|FG001|Overall Study|Death|8
6223838|NCT01693029|9895796|FG000|Overall Study|Non-compliance|2
6223839|NCT01693029|9895797|FG001|Overall Study|Non-compliance|1
6223840|NCT01693068|9895805|FG000|Randomization Period|On-study|2
6223841|NCT01693068|9895806|FG001|Randomization Period|On-study|5
6223842|NCT01693068|9895807|FG002|Randomization Period|On-study|0
6223843|NCT01693068|9895805|FG000|Cross-over (Dacarbazine To Pimasertib)|On-study|0
6223844|NCT01693068|9895806|FG001|Cross-over (Dacarbazine To Pimasertib)|On-study|0
6223845|NCT01693068|9895807|FG002|Cross-over (Dacarbazine To Pimasertib)|On-study|1
6223846|NCT01693120|9895815|FG000|Enrollment|Lost to Follow-up|1
6223847|NCT01693120|9895815|FG000|Enrollment|Withdrawal by Subject|10
6223848|NCT01693120|9895815|FG000|Enrollment|Protocol Violation|46
6223849|NCT01693120|9895815|FG000|Enrollment|Physician Decision|3
6223850|NCT01693120|9895815|FG000|Enrollment|Adverse Event|1
6223851|NCT01693120|9895815|FG000|Enrollment|Study closed|8
6223852|NCT01693120|9895815|FG000|Enrollment|Other|1
6223853|NCT01693120|9895815|FG000|Phased RF Study Procedure and Follow-up|Lost to Follow-up|1
6223854|NCT01693120|9895815|FG000|Phased RF Study Procedure and Follow-up|Withdrawal by Subject|5
6223855|NCT01693120|9895815|FG000|Phased RF Study Procedure and Follow-up|Physician Decision|3
6223856|NCT01693120|9895815|FG000|Phased RF Study Procedure and Follow-up|Protocol Violation|1
6223857|NCT01693120|9895815|FG000|Phased RF Study Procedure and Follow-up|Other reasons|7
6223858|NCT01693185|9895821|FG000|Overall Study|diagnostic procedure after colonoscopy|0
6223859|NCT01693185|9895822|FG001|Overall Study|diagnostic procedure after colonoscopy|6
6223860|NCT01693250|9895830|FG000|Overall Study|Lost to Follow-up|2
6223861|NCT01693250|9895831|FG001|Overall Study|Lost to Follow-up|2
6223862|NCT01693523|9895842|FG000|Overall Study|Adverse Event|2
6223863|NCT01693523|9895843|FG001|Overall Study|Adverse Event|1
6223864|NCT01693523|9895844|FG002|Overall Study|Adverse Event|0
6223865|NCT01693523|9895842|FG000|Overall Study|Death|0
6223866|NCT01693523|9895843|FG001|Overall Study|Death|1
6223867|NCT01693523|9895844|FG002|Overall Study|Death|1
6223868|NCT01693523|9895842|FG000|Overall Study|Lost to Follow-up|0
6223869|NCT01693523|9895843|FG001|Overall Study|Lost to Follow-up|0
6223870|NCT01693523|9895844|FG002|Overall Study|Lost to Follow-up|4
6223871|NCT01693523|9895842|FG000|Overall Study|Physician Decision|0
6223872|NCT01693523|9895843|FG001|Overall Study|Physician Decision|0
6223873|NCT01693523|9895844|FG002|Overall Study|Physician Decision|1
6223874|NCT01693523|9895842|FG000|Overall Study|Withdrawal by Subject|1
6290209|NCT02394925|10006040|FG000|Overall Study|No longer meet eligibility criteria|1
6290210|NCT02394925|10006040|FG000|Overall Study|Unsatisfactory Visual Response|5
6290211|NCT02395042|10006056|FG000|Treatment 1 Period|Adverse Event|1
5981090|NCT02511106|9570037|FG001|Overall Study|Lost to Follow-up|2
6133659|NCT00983853|9762293|FG005|Overall Study|Unable to come to study follow-up visits|0
6133660|NCT00983892|9762311|FG000|Overall Study|Withdrawal by Subject|10
6133661|NCT00983892|9762312|FG001|Overall Study|Withdrawal by Subject|12
6223875|NCT01693523|9895843|FG001|Overall Study|Withdrawal by Subject|2
6223876|NCT01693523|9895844|FG002|Overall Study|Withdrawal by Subject|2
6223877|NCT01693523|9895842|FG000|Overall Study|Lack of compliance study medication|1
6223878|NCT01693523|9895843|FG001|Overall Study|Lack of compliance study medication|2
6223879|NCT01693523|9895844|FG002|Overall Study|Lack of compliance study medication|0
6223880|NCT01693523|9895842|FG000|Overall Study|Chemotherapy was held|1
6223881|NCT01693523|9895843|FG001|Overall Study|Chemotherapy was held|2
6223882|NCT01693523|9895844|FG002|Overall Study|Chemotherapy was held|0
6290212|NCT02395042|10006057|FG001|Treatment 1 Period|Adverse Event|3
6133662|NCT00983905|9762318|FG000|Theophylline Alone|Adverse Event|1
6133663|NCT00983905|9762318|FG000|Colchicine Alone|Adverse Event|2
6133664|NCT00983918|9762329|FG000|Overall Study|conversion to open cholecystectomy|0
6133665|NCT00983918|9762330|FG001|Overall Study|conversion to open cholecystectomy|2
6133666|NCT00983918|9762331|FG002|Overall Study|conversion to open cholecystectomy|2
6133667|NCT00983918|9762332|FG003|Overall Study|conversion to open cholecystectomy|2
6133668|NCT00983931|9762342|FG000|14 Day Washout Period|Physician Decision|1
6133669|NCT00983957|9762348|FG000|Overall Study|Adverse Event|1
6133670|NCT00983957|9762348|FG000|Overall Study|Personal Reasons|1
6223883|NCT01693562|9895874|FG000|Escalation Phase|Withdrawal by Subject|0
6223884|NCT01693562|9895875|FG001|Escalation Phase|Withdrawal by Subject|1
6223885|NCT01693562|9895876|FG002|Escalation Phase|Withdrawal by Subject|0
6223886|NCT01693562|9895877|FG003|Escalation Phase|Withdrawal by Subject|0
6223887|NCT01693562|9895878|FG004|Escalation Phase|Withdrawal by Subject|0
6223888|NCT01693562|9895879|FG005|Escalation Phase|Withdrawal by Subject|2
6223889|NCT01693562|9895880|FG006|Escalation Phase|Withdrawal by Subject|0
6223890|NCT01693562|9895881|FG007|Escalation Phase|Withdrawal by Subject|0
6223891|NCT01693562|9895882|FG008|Escalation Phase|Withdrawal by Subject|0
6223892|NCT01693562|9895883|FG009|Escalation Phase|Withdrawal by Subject|0
6223893|NCT01693562|9895884|FG010|Escalation Phase|Withdrawal by Subject|0
6223894|NCT01693562|9895885|FG011|Escalation Phase|Withdrawal by Subject|0
6223895|NCT01693562|9895886|FG012|Escalation Phase|Withdrawal by Subject|0
6223896|NCT01693562|9895887|FG013|Escalation Phase|Withdrawal by Subject|0
6223897|NCT01693562|9895888|FG014|Escalation Phase|Withdrawal by Subject|0
6223898|NCT01693562|9895889|FG015|Escalation Phase|Withdrawal by Subject|0
6223899|NCT01693562|9895890|FG016|Escalation Phase|Withdrawal by Subject|0
6223900|NCT01693562|9895891|FG017|Escalation Phase|Withdrawal by Subject|0
6223901|NCT01693562|9895892|FG018|Escalation Phase|Withdrawal by Subject|0
6223902|NCT01693562|9895893|FG019|Escalation Phase|Withdrawal by Subject|0
6223903|NCT01693562|9895894|FG020|Escalation Phase|Withdrawal by Subject|0
6223904|NCT01693562|9895895|FG021|Escalation Phase|Withdrawal by Subject|0
6223905|NCT01693562|9895896|FG022|Escalation Phase|Withdrawal by Subject|0
6223906|NCT01693562|9895874|FG000|Escalation Phase|Death|4
6223907|NCT01693562|9895875|FG001|Escalation Phase|Death|2
6223908|NCT01693562|9895876|FG002|Escalation Phase|Death|0
6223909|NCT01693562|9895877|FG003|Escalation Phase|Death|3
6223910|NCT01693562|9895878|FG004|Escalation Phase|Death|6
6223911|NCT01693562|9895879|FG005|Escalation Phase|Death|4
6223912|NCT01693562|9895880|FG006|Escalation Phase|Death|0
6223913|NCT01693562|9895881|FG007|Escalation Phase|Death|0
6223914|NCT01693562|9895882|FG008|Escalation Phase|Death|0
6223915|NCT01693562|9895883|FG009|Escalation Phase|Death|0
6223916|NCT01693562|9895884|FG010|Escalation Phase|Death|0
6223917|NCT01693562|9895885|FG011|Escalation Phase|Death|0
6223918|NCT01693562|9895886|FG012|Escalation Phase|Death|0
6223919|NCT01693562|9895887|FG013|Escalation Phase|Death|0
6223920|NCT01693562|9895888|FG014|Escalation Phase|Death|0
6223921|NCT01693562|9895889|FG015|Escalation Phase|Death|0
6223922|NCT01693562|9895890|FG016|Escalation Phase|Death|0
6223923|NCT01693562|9895891|FG017|Escalation Phase|Death|0
6223924|NCT01693562|9895892|FG018|Escalation Phase|Death|0
6223925|NCT01693562|9895893|FG019|Escalation Phase|Death|0
6223926|NCT01693562|9895894|FG020|Escalation Phase|Death|0
6223927|NCT01693562|9895895|FG021|Escalation Phase|Death|0
6223928|NCT01693562|9895896|FG022|Escalation Phase|Death|0
6223929|NCT01693562|9895874|FG000|Escalation Phase|Lost to Follow-up|0
6223930|NCT01693562|9895875|FG001|Escalation Phase|Lost to Follow-up|1
6223931|NCT01693562|9895876|FG002|Escalation Phase|Lost to Follow-up|1
6223932|NCT01693562|9895877|FG003|Escalation Phase|Lost to Follow-up|0
6223933|NCT01693562|9895878|FG004|Escalation Phase|Lost to Follow-up|0
6223934|NCT01693562|9895879|FG005|Escalation Phase|Lost to Follow-up|0
6223935|NCT01693562|9895880|FG006|Escalation Phase|Lost to Follow-up|0
6223936|NCT01693562|9895881|FG007|Escalation Phase|Lost to Follow-up|0
6223937|NCT01693562|9895882|FG008|Escalation Phase|Lost to Follow-up|0
6223938|NCT01693562|9895883|FG009|Escalation Phase|Lost to Follow-up|0
6223939|NCT01693562|9895884|FG010|Escalation Phase|Lost to Follow-up|0
6223940|NCT01693562|9895885|FG011|Escalation Phase|Lost to Follow-up|0
6223941|NCT01693562|9895886|FG012|Escalation Phase|Lost to Follow-up|0
6223942|NCT01693562|9895887|FG013|Escalation Phase|Lost to Follow-up|0
6223943|NCT01693562|9895888|FG014|Escalation Phase|Lost to Follow-up|0
6223944|NCT01693562|9895889|FG015|Escalation Phase|Lost to Follow-up|0
6223945|NCT01693562|9895890|FG016|Escalation Phase|Lost to Follow-up|0
6223946|NCT01693562|9895891|FG017|Escalation Phase|Lost to Follow-up|0
6223947|NCT01693562|9895892|FG018|Escalation Phase|Lost to Follow-up|0
6223948|NCT01693562|9895893|FG019|Escalation Phase|Lost to Follow-up|0
6223949|NCT01693562|9895894|FG020|Escalation Phase|Lost to Follow-up|0
6223950|NCT01693562|9895895|FG021|Escalation Phase|Lost to Follow-up|0
6223951|NCT01693562|9895896|FG022|Escalation Phase|Lost to Follow-up|0
6223952|NCT01693562|9895874|FG000|Escalation Phase|Other|0
6223953|NCT01693562|9895875|FG001|Escalation Phase|Other|0
6223954|NCT01693562|9895876|FG002|Escalation Phase|Other|2
6223955|NCT01693562|9895877|FG003|Escalation Phase|Other|0
6223956|NCT01693562|9895878|FG004|Escalation Phase|Other|0
6223957|NCT01693562|9895879|FG005|Escalation Phase|Other|1
6223958|NCT01693562|9895880|FG006|Escalation Phase|Other|0
6223959|NCT01693562|9895881|FG007|Escalation Phase|Other|0
6133671|NCT00984009|9762372|FG000|Grapefruit Juice Alone|missed serving of grapefruit juice|1
6223960|NCT01693562|9895882|FG008|Escalation Phase|Other|0
6223961|NCT01693562|9895883|FG009|Escalation Phase|Other|0
6133672|NCT00984022|9762381|FG000|Overall Study|Lost to Follow-up|10
6133673|NCT00984022|9762382|FG001|Overall Study|Lost to Follow-up|14
6133674|NCT00984061|9762388|FG000|Clarithromycin Alone|Protocol Violation|1
6133675|NCT00984126|9762399|FG000|Overall Study|Protocol Violation|0
6133676|NCT00984126|9762400|FG001|Overall Study|Protocol Violation|0
6133677|NCT00984126|9762401|FG002|Overall Study|Protocol Violation|1
6133678|NCT00984126|9762402|FG003|Overall Study|Protocol Violation|2
6133679|NCT00984126|9762399|FG000|Overall Study|Adverse Event|0
6133680|NCT00984126|9762400|FG001|Overall Study|Adverse Event|0
6133681|NCT00984126|9762401|FG002|Overall Study|Adverse Event|0
6133682|NCT00984126|9762402|FG003|Overall Study|Adverse Event|2
6133683|NCT00984126|9762399|FG000|Overall Study|Choose to join Pathfinder trial™ + other|7
6133684|NCT00984126|9762400|FG001|Overall Study|Choose to join Pathfinder trial™ + other|7
6133685|NCT00984126|9762401|FG002|Overall Study|Choose to join Pathfinder trial™ + other|3
6133686|NCT00984126|9762402|FG003|Overall Study|Choose to join Pathfinder trial™ + other|46
6133687|NCT00984126|9762399|FG000|Overall Study|Withdrawal criteria|0
6133688|NCT00984126|9762400|FG001|Overall Study|Withdrawal criteria|1
6133689|NCT00984126|9762401|FG002|Overall Study|Withdrawal criteria|3
6133690|NCT00984126|9762402|FG003|Overall Study|Withdrawal criteria|9
6133691|NCT00984165|9762429|FG000|Overall Study|Death on study|2
6133692|NCT00984165|9762430|FG001|Overall Study|Death on study|0
6133693|NCT00984165|9762431|FG002|Overall Study|Death on study|0
6133694|NCT00984165|9762432|FG003|Overall Study|Death on study|0
6133695|NCT00984165|9762429|FG000|Overall Study|Disease progression on study|5
6133696|NCT00984165|9762430|FG001|Overall Study|Disease progression on study|1
6133697|NCT00984165|9762431|FG002|Overall Study|Disease progression on study|0
6133698|NCT00984165|9762432|FG003|Overall Study|Disease progression on study|0
6133699|NCT00984165|9762429|FG000|Overall Study|Death of recipient|0
6133700|NCT00984165|9762430|FG001|Overall Study|Death of recipient|0
6133701|NCT00984165|9762431|FG002|Overall Study|Death of recipient|0
6133702|NCT00984165|9762432|FG003|Overall Study|Death of recipient|1
6133703|NCT00984165|9762429|FG000|Overall Study|New protocol|0
6133704|NCT00984165|9762430|FG001|Overall Study|New protocol|0
6133705|NCT00984165|9762431|FG002|Overall Study|New protocol|0
6133706|NCT00984165|9762432|FG003|Overall Study|New protocol|1
6133707|NCT00984165|9762429|FG000|Overall Study|P+/donor pair removed from protocol|0
6133708|NCT00984165|9762430|FG001|Overall Study|P+/donor pair removed from protocol|0
6133709|NCT00984165|9762431|FG002|Overall Study|P+/donor pair removed from protocol|0
6133710|NCT00984165|9762432|FG003|Overall Study|P+/donor pair removed from protocol|1
6133711|NCT00984165|9762429|FG000|Overall Study|removed with a pair recipient|0
6133712|NCT00984165|9762430|FG001|Overall Study|removed with a pair recipient|0
6133713|NCT00984165|9762431|FG002|Overall Study|removed with a pair recipient|0
6133714|NCT00984165|9762432|FG003|Overall Study|removed with a pair recipient|1
6133715|NCT00984204|9762443|FG000|Overall Study|Death|1
6133716|NCT00984204|9762443|FG000|Overall Study|Lost to Follow-up|4
6133717|NCT00984204|9762443|FG000|Overall Study|Lack of Efficacy|10
6133718|NCT00984256|9762449|FG000|Overall Study|Withdrawal by Subject|0
6133719|NCT00984256|9762450|FG001|Overall Study|Withdrawal by Subject|1
6133720|NCT00984282|9762467|FG000|Double Blind Treatment|Adverse Event|40
6133721|NCT00984282|9762468|FG001|Double Blind Treatment|Adverse Event|6
6133722|NCT00984282|9762467|FG000|Double Blind Treatment|Progression, recurrence or relapse|25
6133723|NCT00984282|9762468|FG001|Double Blind Treatment|Progression, recurrence or relapse|3
6133724|NCT00984282|9762467|FG000|Double Blind Treatment|Physician Decision|1
6133725|NCT00984282|9762468|FG001|Double Blind Treatment|Physician Decision|2
6133726|NCT00984282|9762467|FG000|Double Blind Treatment|Noncompliance with study medication|3
6133727|NCT00984282|9762468|FG001|Double Blind Treatment|Noncompliance with study medication|0
6133728|NCT00984282|9762467|FG000|Double Blind Treatment|Progression by clinical judgment|2
6133729|NCT00984282|9762468|FG001|Double Blind Treatment|Progression by clinical judgment|0
6133730|NCT00984282|9762467|FG000|Double Blind Treatment|Withdrawal by Subject|13
6133731|NCT00984282|9762468|FG001|Double Blind Treatment|Withdrawal by Subject|18
6133732|NCT00984282|9762467|FG000|Double Blind Treatment|Lost to Follow-up|3
6133733|NCT00984282|9762468|FG001|Double Blind Treatment|Lost to Follow-up|0
6133734|NCT00984282|9762467|FG000|Double Blind Treatment|Death|8
6133735|NCT00984282|9762468|FG001|Double Blind Treatment|Death|4
6133736|NCT00984282|9762467|FG000|Double Blind Treatment|Not treated|0
6223962|NCT01693562|9895884|FG010|Escalation Phase|Other|0
6223963|NCT01693562|9895885|FG011|Escalation Phase|Other|0
6223964|NCT01693562|9895886|FG012|Escalation Phase|Other|0
6223965|NCT01693562|9895887|FG013|Escalation Phase|Other|0
6223966|NCT01693562|9895888|FG014|Escalation Phase|Other|0
6223967|NCT01693562|9895889|FG015|Escalation Phase|Other|0
6223968|NCT01693562|9895890|FG016|Escalation Phase|Other|0
6223969|NCT01693562|9895891|FG017|Escalation Phase|Other|0
6223970|NCT01693562|9895892|FG018|Escalation Phase|Other|0
6223971|NCT01693562|9895893|FG019|Escalation Phase|Other|0
6223972|NCT01693562|9895894|FG020|Escalation Phase|Other|0
6223973|NCT01693562|9895895|FG021|Escalation Phase|Other|0
6223974|NCT01693562|9895896|FG022|Escalation Phase|Other|0
6223975|NCT01693562|9895874|FG000|Exploration Phase|Withdrawal by Subject|0
6223976|NCT01693562|9895875|FG001|Exploration Phase|Withdrawal by Subject|0
6133737|NCT00984282|9762468|FG001|Double Blind Treatment|Not treated|1
6133738|NCT00984282|9762467|FG000|Double Blind Treatment|Switched to commercial drug|6
6133739|NCT00984282|9762468|FG001|Double Blind Treatment|Switched to commercial drug|1
6133740|NCT00984282|9762467|FG000|Double Blind Treatment|protocol driven decision point|1
6133741|NCT00984282|9762468|FG001|Double Blind Treatment|protocol driven decision point|1
6133742|NCT00984282|9762467|FG000|Double Blind Treatment|Radiological and clinical progression|0
6133743|NCT00984282|9762468|FG001|Double Blind Treatment|Radiological and clinical progression|1
6133744|NCT00984282|9762467|FG000|Double Blind Treatment|Transferred to treat. continuation study|2
6133745|NCT00984282|9762468|FG001|Double Blind Treatment|Transferred to treat. continuation study|1
6133746|NCT00984282|9762467|FG000|Open-label Treatment|Adverse Event|20
6133747|NCT00984282|9762468|FG001|Open-label Treatment|Adverse Event|30
6133748|NCT00984282|9762467|FG000|Open-label Treatment|Withdrawal by Subject|6
6133749|NCT00984282|9762468|FG001|Open-label Treatment|Withdrawal by Subject|21
6133750|NCT00984282|9762467|FG000|Open-label Treatment|Death|7
6133751|NCT00984282|9762468|FG001|Open-label Treatment|Death|15
6133752|NCT00984282|9762467|FG000|Open-label Treatment|Progression, recurrence or relapse|40
6133753|NCT00984282|9762468|FG001|Open-label Treatment|Progression, recurrence or relapse|82
6133754|NCT00984282|9762467|FG000|Open-label Treatment|Lost to Follow-up|1
6133755|NCT00984282|9762468|FG001|Open-label Treatment|Lost to Follow-up|1
6133756|NCT00984282|9762467|FG000|Open-label Treatment|Patient convenience|1
6133757|NCT00984282|9762468|FG001|Open-label Treatment|Patient convenience|0
6133758|NCT00984282|9762467|FG000|Open-label Treatment|Non-compliant with study medication|1
6133759|NCT00984282|9762468|FG001|Open-label Treatment|Non-compliant with study medication|0
6133760|NCT00984282|9762467|FG000|Open-label Treatment|Target lesion removed|0
6133761|NCT00984282|9762468|FG001|Open-label Treatment|Target lesion removed|1
6133762|NCT00984282|9762467|FG000|Open-label Treatment|Protocol driven decision point|1
6133763|NCT00984282|9762468|FG001|Open-label Treatment|Protocol driven decision point|1
6133764|NCT00984282|9762467|FG000|Open-label Treatment|Transferred to treat. continuation study|2
6133765|NCT00984282|9762468|FG001|Open-label Treatment|Transferred to treat. continuation study|3
6133766|NCT00984282|9762467|FG000|Open-label Treatment|Switched to commercial drug|6
6133767|NCT00984282|9762468|FG001|Open-label Treatment|Switched to commercial drug|7
6133768|NCT00984282|9762467|FG000|Open-label Treatment|Physician Decision|1
6133769|NCT00984282|9762468|FG001|Open-label Treatment|Physician Decision|0
6133770|NCT00984282|9762467|FG000|Long Term Follow-up|Withdrawal by Subject|8
6133771|NCT00984282|9762468|FG001|Long Term Follow-up|Withdrawal by Subject|14
6133772|NCT00984282|9762467|FG000|Long Term Follow-up|Death|27
6133773|NCT00984282|9762468|FG001|Long Term Follow-up|Death|68
6133774|NCT00984282|9762467|FG000|Long Term Follow-up|Lost to Follow-up|3
6133775|NCT00984282|9762468|FG001|Long Term Follow-up|Lost to Follow-up|6
6133776|NCT00984282|9762467|FG000|Long Term Follow-up|Protocol driven decision point|25
6133777|NCT00984282|9762468|FG001|Long Term Follow-up|Protocol driven decision point|26
6133778|NCT00984282|9762467|FG000|Long Term Follow-up|Transferred to treat. continuation study|2
6133779|NCT00984282|9762468|FG001|Long Term Follow-up|Transferred to treat. continuation study|3
6133780|NCT00984282|9762467|FG000|Long Term Follow-up|Switched to commercial drug|4
6133781|NCT00984282|9762468|FG001|Long Term Follow-up|Switched to commercial drug|2
6133782|NCT00984282|9762467|FG000|Long Term Follow-up|Disease prog., recurrence or relapse|0
6133783|NCT00984282|9762468|FG001|Long Term Follow-up|Disease prog., recurrence or relapse|1
6133784|NCT00984295|9762479|FG000|Overall Study|Lost to Follow-up|31
6133785|NCT00984295|9762480|FG001|Overall Study|Lost to Follow-up|12
6133786|NCT00984295|9762481|FG002|Overall Study|Lost to Follow-up|13
6133787|NCT00984295|9762479|FG000|Overall Study|Protocol Violation|2
6133788|NCT00984295|9762480|FG001|Overall Study|Protocol Violation|1
6133789|NCT00984295|9762481|FG002|Overall Study|Protocol Violation|4
6133790|NCT00984295|9762479|FG000|Overall Study|Withdrawal by Subject|18
6133791|NCT00984295|9762480|FG001|Overall Study|Withdrawal by Subject|9
6133792|NCT00984295|9762481|FG002|Overall Study|Withdrawal by Subject|12
6133793|NCT00984295|9762479|FG000|Overall Study|CAE - discontinued test vaccine|0
6133794|NCT00984295|9762480|FG001|Overall Study|CAE - discontinued test vaccine|1
6133795|NCT00984295|9762481|FG002|Overall Study|CAE - discontinued test vaccine|3
6133796|NCT00984295|9762479|FG000|Overall Study|Missed one or more blood samplings|3
6133797|NCT00984295|9762480|FG001|Overall Study|Missed one or more blood samplings|7
6133798|NCT00984295|9762481|FG002|Overall Study|Missed one or more blood samplings|2
6133799|NCT00984295|9762479|FG000|Overall Study|Incomplete safety follow-up|11
6133800|NCT00984295|9762480|FG001|Overall Study|Incomplete safety follow-up|2
6133801|NCT00984295|9762481|FG002|Overall Study|Incomplete safety follow-up|3
6133802|NCT00984542|9762519|FG000|Overall Study|disease progression|19
6133803|NCT00984542|9762519|FG000|Overall Study|toxicity|7
6133804|NCT00984542|9762519|FG000|Overall Study|Death|7
6133805|NCT00984542|9762519|FG000|Overall Study|complicating disease|3
6133806|NCT00984542|9762519|FG000|Overall Study|Withdrawal by Subject|3
6133807|NCT00984542|9762519|FG000|Overall Study|clinical deterioration|2
6133808|NCT00984568|9762526|FG000|Overall Study|Withdrawal by Subject|1
6133809|NCT00984568|9762527|FG001|Overall Study|Withdrawal by Subject|2
6133810|NCT00984568|9762526|FG000|Overall Study|Lack of Efficacy|2
6133811|NCT00984568|9762527|FG001|Overall Study|Lack of Efficacy|0
6223977|NCT01693562|9895876|FG002|Exploration Phase|Withdrawal by Subject|0
5981091|NCT02511106|9570036|FG000|Overall Study|Withdrawal by Subject|19
6133812|NCT00984568|9762526|FG000|Overall Study|Adverse Event|2
6133813|NCT00984568|9762527|FG001|Overall Study|Adverse Event|0
6133814|NCT00984568|9762526|FG000|Overall Study|Did Not Meet Randomization Criteria|1
6133815|NCT00984568|9762527|FG001|Overall Study|Did Not Meet Randomization Criteria|0
6133816|NCT00984568|9762526|FG000|Overall Study|Lost to Follow-up|0
6133817|NCT00984568|9762527|FG001|Overall Study|Lost to Follow-up|1
6133818|NCT00984568|9762526|FG000|Overall Study|Opportunistic Infection|1
6133819|NCT00984568|9762527|FG001|Overall Study|Opportunistic Infection|0
6133820|NCT00984568|9762526|FG000|Overall Study|Unknown Reason|1
6133821|NCT00984568|9762527|FG001|Overall Study|Unknown Reason|3
6133822|NCT00984594|9762535|FG000|Overall Study|Lost to Follow-up|1
6133823|NCT00984594|9762536|FG001|Overall Study|Lost to Follow-up|0
6133824|NCT00984594|9762535|FG000|Overall Study|Withdrawal by Subject|0
6133825|NCT00984594|9762536|FG001|Overall Study|Withdrawal by Subject|1
6133826|NCT00984620|9762546|FG000|Overall Study|Adverse Event|5
6133827|NCT00984620|9762547|FG001|Overall Study|Adverse Event|5
6133828|NCT00984620|9762546|FG000|Overall Study|Lost to Follow-up|1
6133829|NCT00984620|9762547|FG001|Overall Study|Lost to Follow-up|1
6133830|NCT00984620|9762546|FG000|Overall Study|Withdrawal by Subject|0
6133831|NCT00984620|9762547|FG001|Overall Study|Withdrawal by Subject|2
6133832|NCT00984620|9762546|FG000|Overall Study|reason other than listed above|0
6133833|NCT00984620|9762547|FG001|Overall Study|reason other than listed above|4
6133834|NCT00984659|9762559|FG000|2-week Run-in Period|Adverse Event|8
6223978|NCT01693562|9895877|FG003|Exploration Phase|Withdrawal by Subject|0
6223979|NCT01693562|9895878|FG004|Exploration Phase|Withdrawal by Subject|0
6223980|NCT01693562|9895879|FG005|Exploration Phase|Withdrawal by Subject|0
6223981|NCT01693562|9895880|FG006|Exploration Phase|Withdrawal by Subject|2
6223982|NCT01693562|9895881|FG007|Exploration Phase|Withdrawal by Subject|0
6223983|NCT01693562|9895882|FG008|Exploration Phase|Withdrawal by Subject|0
6223984|NCT01693562|9895883|FG009|Exploration Phase|Withdrawal by Subject|0
6223985|NCT01693562|9895884|FG010|Exploration Phase|Withdrawal by Subject|0
6223986|NCT01693562|9895885|FG011|Exploration Phase|Withdrawal by Subject|0
6223987|NCT01693562|9895886|FG012|Exploration Phase|Withdrawal by Subject|0
6223988|NCT01693562|9895887|FG013|Exploration Phase|Withdrawal by Subject|0
6223989|NCT01693562|9895888|FG014|Exploration Phase|Withdrawal by Subject|0
6223990|NCT01693562|9895889|FG015|Exploration Phase|Withdrawal by Subject|0
6223991|NCT01693562|9895890|FG016|Exploration Phase|Withdrawal by Subject|0
6223992|NCT01693562|9895891|FG017|Exploration Phase|Withdrawal by Subject|0
6223993|NCT01693562|9895892|FG018|Exploration Phase|Withdrawal by Subject|0
6290213|NCT02395042|10006058|FG002|Treatment 1 Period|Adverse Event|1
6290214|NCT02395042|10006056|FG000|Treatment 1 Period|Lack of Efficacy|1
6290215|NCT02395042|10006057|FG001|Treatment 1 Period|Lack of Efficacy|1
6290216|NCT02395042|10006058|FG002|Treatment 1 Period|Lack of Efficacy|0
6290217|NCT02395042|10006056|FG000|Treatment 1 Period|Lost to Follow-up|1
6290218|NCT02395042|10006057|FG001|Treatment 1 Period|Lost to Follow-up|0
6290219|NCT02395042|10006058|FG002|Treatment 1 Period|Lost to Follow-up|0
6290220|NCT02395042|10006056|FG000|Treatment 1 Period|Other Miscellaneous Reasons|0
6290221|NCT02395042|10006057|FG001|Treatment 1 Period|Other Miscellaneous Reasons|2
6290222|NCT02395042|10006058|FG002|Treatment 1 Period|Other Miscellaneous Reasons|1
6290223|NCT02395042|10006056|FG000|Treatment 2 Period|Lack of Efficacy|1
6290224|NCT02395042|10006057|FG001|Treatment 2 Period|Lack of Efficacy|1
6133835|NCT00984659|9762560|FG001|2-week Run-in Period|Adverse Event|0
6133836|NCT00984659|9762561|FG002|2-week Run-in Period|Adverse Event|0
6133837|NCT00984659|9762562|FG003|2-week Run-in Period|Adverse Event|0
6133838|NCT00984659|9762559|FG000|2-week Run-in Period|Protocol Violation|5
6133839|NCT00984659|9762560|FG001|2-week Run-in Period|Protocol Violation|0
6133840|NCT00984659|9762561|FG002|2-week Run-in Period|Protocol Violation|0
6133841|NCT00984659|9762562|FG003|2-week Run-in Period|Protocol Violation|0
6133842|NCT00984659|9762559|FG000|2-week Run-in Period|Study Closed/Terminated|2
6133843|NCT00984659|9762560|FG001|2-week Run-in Period|Study Closed/Terminated|0
6133844|NCT00984659|9762561|FG002|2-week Run-in Period|Study Closed/Terminated|0
6133845|NCT00984659|9762562|FG003|2-week Run-in Period|Study Closed/Terminated|0
6133846|NCT00984659|9762559|FG000|2-week Run-in Period|Lost to Follow-up|3
6133847|NCT00984659|9762560|FG001|2-week Run-in Period|Lost to Follow-up|0
6290225|NCT02395042|10006058|FG002|Treatment 2 Period|Lack of Efficacy|0
6290226|NCT02395055|10006071|FG000|Overall Study|Withdrawal by Subject|7
6290227|NCT02395055|10006072|FG001|Overall Study|Withdrawal by Subject|3
6290228|NCT02395081|10006081|FG000|Overall Study|Withdrawal by Subject|1
6290229|NCT02395081|10006082|FG001|Overall Study|Withdrawal by Subject|1
5981092|NCT02511106|9570037|FG001|Overall Study|Withdrawal by Subject|14
6133848|NCT00984659|9762561|FG002|2-week Run-in Period|Lost to Follow-up|0
6133849|NCT00984659|9762562|FG003|2-week Run-in Period|Lost to Follow-up|0
6133850|NCT00984659|9762559|FG000|2-week Run-in Period|Physician Decision|10
6133851|NCT00984659|9762560|FG001|2-week Run-in Period|Physician Decision|0
6133852|NCT00984659|9762561|FG002|2-week Run-in Period|Physician Decision|0
6223994|NCT01693562|9895893|FG019|Exploration Phase|Withdrawal by Subject|0
6290230|NCT02395081|10006083|FG002|Overall Study|Withdrawal by Subject|0
6290231|NCT02395081|10006081|FG000|Overall Study|Moved where blood couldn't be collected|4
6290232|NCT02395081|10006082|FG001|Overall Study|Moved where blood couldn't be collected|1
6290233|NCT02395081|10006083|FG002|Overall Study|Moved where blood couldn't be collected|3
6290234|NCT02395081|10006081|FG000|Overall Study|Fetal Loss|2
6133853|NCT00984659|9762562|FG003|2-week Run-in Period|Physician Decision|0
6133854|NCT00984659|9762559|FG000|2-week Run-in Period|Withdrawal by Subject|10
6133855|NCT00984659|9762560|FG001|2-week Run-in Period|Withdrawal by Subject|0
6133856|NCT00984659|9762561|FG002|2-week Run-in Period|Withdrawal by Subject|0
6133857|NCT00984659|9762562|FG003|2-week Run-in Period|Withdrawal by Subject|0
6133858|NCT00984659|9762559|FG000|2-week Run-in Period|Did Not Meet Continuation Criteria|14
6133859|NCT00984659|9762560|FG001|2-week Run-in Period|Did Not Meet Continuation Criteria|0
6133860|NCT00984659|9762561|FG002|2-week Run-in Period|Did Not Meet Continuation Criteria|0
6133861|NCT00984659|9762562|FG003|2-week Run-in Period|Did Not Meet Continuation Criteria|0
6133862|NCT00984659|9762559|FG000|6-week Double-blind Treatment Period|Adverse Event|0
6133863|NCT00984659|9762560|FG001|6-week Double-blind Treatment Period|Adverse Event|3
6133864|NCT00984659|9762561|FG002|6-week Double-blind Treatment Period|Adverse Event|3
6133865|NCT00984659|9762562|FG003|6-week Double-blind Treatment Period|Adverse Event|7
6133866|NCT00984659|9762559|FG000|6-week Double-blind Treatment Period|Lack of Efficacy|0
6133867|NCT00984659|9762560|FG001|6-week Double-blind Treatment Period|Lack of Efficacy|2
6223995|NCT01693562|9895894|FG020|Exploration Phase|Withdrawal by Subject|0
6223996|NCT01693562|9895895|FG021|Exploration Phase|Withdrawal by Subject|0
6223997|NCT01693562|9895896|FG022|Exploration Phase|Withdrawal by Subject|0
6223998|NCT01693562|9895874|FG000|Exploration Phase|Death|0
6223999|NCT01693562|9895875|FG001|Exploration Phase|Death|0
6224000|NCT01693562|9895876|FG002|Exploration Phase|Death|0
6224001|NCT01693562|9895877|FG003|Exploration Phase|Death|0
6224002|NCT01693562|9895878|FG004|Exploration Phase|Death|0
6224003|NCT01693562|9895879|FG005|Exploration Phase|Death|0
6224004|NCT01693562|9895880|FG006|Exploration Phase|Death|17
6224005|NCT01693562|9895881|FG007|Exploration Phase|Death|0
6224006|NCT01693562|9895882|FG008|Exploration Phase|Death|0
6224007|NCT01693562|9895883|FG009|Exploration Phase|Death|0
6224008|NCT01693562|9895884|FG010|Exploration Phase|Death|0
6224009|NCT01693562|9895885|FG011|Exploration Phase|Death|0
6224010|NCT01693562|9895886|FG012|Exploration Phase|Death|0
6224011|NCT01693562|9895887|FG013|Exploration Phase|Death|0
6224012|NCT01693562|9895888|FG014|Exploration Phase|Death|0
6224013|NCT01693562|9895889|FG015|Exploration Phase|Death|0
6224014|NCT01693562|9895890|FG016|Exploration Phase|Death|0
6224015|NCT01693562|9895891|FG017|Exploration Phase|Death|0
6224016|NCT01693562|9895892|FG018|Exploration Phase|Death|0
6224017|NCT01693562|9895893|FG019|Exploration Phase|Death|0
6224018|NCT01693562|9895894|FG020|Exploration Phase|Death|0
6224019|NCT01693562|9895895|FG021|Exploration Phase|Death|0
6224020|NCT01693562|9895896|FG022|Exploration Phase|Death|0
6224021|NCT01693562|9895874|FG000|Exploration Phase|Other|0
6224022|NCT01693562|9895875|FG001|Exploration Phase|Other|0
6224023|NCT01693562|9895876|FG002|Exploration Phase|Other|0
6224024|NCT01693562|9895877|FG003|Exploration Phase|Other|0
6224025|NCT01693562|9895878|FG004|Exploration Phase|Other|0
6224026|NCT01693562|9895879|FG005|Exploration Phase|Other|0
6224027|NCT01693562|9895880|FG006|Exploration Phase|Other|2
6224028|NCT01693562|9895881|FG007|Exploration Phase|Other|0
6224029|NCT01693562|9895882|FG008|Exploration Phase|Other|0
6224030|NCT01693562|9895883|FG009|Exploration Phase|Other|0
6224031|NCT01693562|9895884|FG010|Exploration Phase|Other|0
6224032|NCT01693562|9895885|FG011|Exploration Phase|Other|0
6224033|NCT01693562|9895886|FG012|Exploration Phase|Other|0
6224034|NCT01693562|9895887|FG013|Exploration Phase|Other|0
6224035|NCT01693562|9895888|FG014|Exploration Phase|Other|0
6224036|NCT01693562|9895889|FG015|Exploration Phase|Other|0
6224037|NCT01693562|9895890|FG016|Exploration Phase|Other|0
6224038|NCT01693562|9895891|FG017|Exploration Phase|Other|0
6224039|NCT01693562|9895892|FG018|Exploration Phase|Other|0
6224040|NCT01693562|9895893|FG019|Exploration Phase|Other|0
6224041|NCT01693562|9895894|FG020|Exploration Phase|Other|0
6224042|NCT01693562|9895895|FG021|Exploration Phase|Other|0
6224043|NCT01693562|9895896|FG022|Exploration Phase|Other|0
6224044|NCT01693562|9895874|FG000|Expansion Phase|Withdrawal by Subject|0
6224045|NCT01693562|9895875|FG001|Expansion Phase|Withdrawal by Subject|0
6224046|NCT01693562|9895876|FG002|Expansion Phase|Withdrawal by Subject|0
6224047|NCT01693562|9895877|FG003|Expansion Phase|Withdrawal by Subject|0
6224048|NCT01693562|9895878|FG004|Expansion Phase|Withdrawal by Subject|0
6224049|NCT01693562|9895879|FG005|Expansion Phase|Withdrawal by Subject|0
6224050|NCT01693562|9895880|FG006|Expansion Phase|Withdrawal by Subject|0
6224051|NCT01693562|9895881|FG007|Expansion Phase|Withdrawal by Subject|16
6224052|NCT01693562|9895882|FG008|Expansion Phase|Withdrawal by Subject|2
6224053|NCT01693562|9895883|FG009|Expansion Phase|Withdrawal by Subject|54
6224054|NCT01693562|9895884|FG010|Expansion Phase|Withdrawal by Subject|2
6224055|NCT01693562|9895885|FG011|Expansion Phase|Withdrawal by Subject|2
6224056|NCT01693562|9895886|FG012|Expansion Phase|Withdrawal by Subject|3
6224057|NCT01693562|9895887|FG013|Expansion Phase|Withdrawal by Subject|5
6224058|NCT01693562|9895888|FG014|Expansion Phase|Withdrawal by Subject|16
6224059|NCT01693562|9895889|FG015|Expansion Phase|Withdrawal by Subject|7
6224060|NCT01693562|9895890|FG016|Expansion Phase|Withdrawal by Subject|40
6224061|NCT01693562|9895891|FG017|Expansion Phase|Withdrawal by Subject|4
6224062|NCT01693562|9895892|FG018|Expansion Phase|Withdrawal by Subject|8
6224063|NCT01693562|9895893|FG019|Expansion Phase|Withdrawal by Subject|3
6224064|NCT01693562|9895894|FG020|Expansion Phase|Withdrawal by Subject|1
6224065|NCT01693562|9895895|FG021|Expansion Phase|Withdrawal by Subject|8
6133868|NCT00984659|9762561|FG002|6-week Double-blind Treatment Period|Lack of Efficacy|0
6133869|NCT00984659|9762562|FG003|6-week Double-blind Treatment Period|Lack of Efficacy|1
6133870|NCT00984659|9762559|FG000|6-week Double-blind Treatment Period|Protocol Violation|0
6133871|NCT00984659|9762560|FG001|6-week Double-blind Treatment Period|Protocol Violation|0
6133872|NCT00984659|9762561|FG002|6-week Double-blind Treatment Period|Protocol Violation|0
6133873|NCT00984659|9762562|FG003|6-week Double-blind Treatment Period|Protocol Violation|4
6133874|NCT00984659|9762559|FG000|6-week Double-blind Treatment Period|Study Closed/Terminated|0
6133875|NCT00984659|9762560|FG001|6-week Double-blind Treatment Period|Study Closed/Terminated|0
6133876|NCT00984659|9762561|FG002|6-week Double-blind Treatment Period|Study Closed/Terminated|1
6133877|NCT00984659|9762562|FG003|6-week Double-blind Treatment Period|Study Closed/Terminated|0
6133878|NCT00984659|9762559|FG000|6-week Double-blind Treatment Period|Withdrawal by Subject|0
6133879|NCT00984659|9762560|FG001|6-week Double-blind Treatment Period|Withdrawal by Subject|1
6133880|NCT00984659|9762561|FG002|6-week Double-blind Treatment Period|Withdrawal by Subject|7
6133881|NCT00984659|9762562|FG003|6-week Double-blind Treatment Period|Withdrawal by Subject|1
6133882|NCT00984867|9762584|FG000|Overall Study|Adverse Event|3
6133883|NCT00984867|9762585|FG001|Overall Study|Adverse Event|7
6133884|NCT00984867|9762584|FG000|Overall Study|Death|1
6133885|NCT00984867|9762585|FG001|Overall Study|Death|0
6133886|NCT00984867|9762584|FG000|Overall Study|Withdrawal by Subject|13
6133887|NCT00984867|9762585|FG001|Overall Study|Withdrawal by Subject|4
6133888|NCT00984867|9762584|FG000|Overall Study|Lost to Follow-up|3
6133889|NCT00984867|9762585|FG001|Overall Study|Lost to Follow-up|4
6133890|NCT00984867|9762584|FG000|Overall Study|Poor/non-compliance|0
6133891|NCT00984867|9762585|FG001|Overall Study|Poor/non-compliance|1
6133892|NCT00984867|9762584|FG000|Overall Study|Subject no longer meets study criteria|1
6133893|NCT00984867|9762585|FG001|Overall Study|Subject no longer meets study criteria|1
6133894|NCT00984867|9762584|FG000|Overall Study|site closing|1
6133895|NCT00984867|9762585|FG001|Overall Study|site closing|0
6133896|NCT00984867|9762584|FG000|Overall Study|lack of efficacy and subject compliance|1
6224066|NCT01693562|9895896|FG022|Expansion Phase|Withdrawal by Subject|1
6224067|NCT01693562|9895874|FG000|Expansion Phase|Death|0
6224068|NCT01693562|9895875|FG001|Expansion Phase|Death|0
6224069|NCT01693562|9895876|FG002|Expansion Phase|Death|0
6224070|NCT01693562|9895877|FG003|Expansion Phase|Death|0
6224071|NCT01693562|9895878|FG004|Expansion Phase|Death|0
6224072|NCT01693562|9895879|FG005|Expansion Phase|Death|0
6224073|NCT01693562|9895880|FG006|Expansion Phase|Death|0
6224074|NCT01693562|9895881|FG007|Expansion Phase|Death|42
6224075|NCT01693562|9895882|FG008|Expansion Phase|Death|17
6224076|NCT01693562|9895883|FG009|Expansion Phase|Death|208
6224077|NCT01693562|9895884|FG010|Expansion Phase|Death|30
6224078|NCT01693562|9895885|FG011|Expansion Phase|Death|8
6224079|NCT01693562|9895886|FG012|Expansion Phase|Death|19
6224080|NCT01693562|9895887|FG013|Expansion Phase|Death|42
6224081|NCT01693562|9895888|FG014|Expansion Phase|Death|23
6224082|NCT01693562|9895889|FG015|Expansion Phase|Death|23
6224083|NCT01693562|9895890|FG016|Expansion Phase|Death|128
6224084|NCT01693562|9895891|FG017|Expansion Phase|Death|16
6224085|NCT01693562|9895892|FG018|Expansion Phase|Death|36
6224086|NCT01693562|9895893|FG019|Expansion Phase|Death|16
6224087|NCT01693562|9895894|FG020|Expansion Phase|Death|17
6224088|NCT01693562|9895895|FG021|Expansion Phase|Death|35
6224089|NCT01693562|9895896|FG022|Expansion Phase|Death|7
6224090|NCT01693562|9895874|FG000|Expansion Phase|Lost to Follow-up|0
6224091|NCT01693562|9895875|FG001|Expansion Phase|Lost to Follow-up|0
6224092|NCT01693562|9895876|FG002|Expansion Phase|Lost to Follow-up|0
6224093|NCT01693562|9895877|FG003|Expansion Phase|Lost to Follow-up|0
6224094|NCT01693562|9895878|FG004|Expansion Phase|Lost to Follow-up|0
6224095|NCT01693562|9895879|FG005|Expansion Phase|Lost to Follow-up|0
6224096|NCT01693562|9895880|FG006|Expansion Phase|Lost to Follow-up|0
6224097|NCT01693562|9895881|FG007|Expansion Phase|Lost to Follow-up|1
6224098|NCT01693562|9895882|FG008|Expansion Phase|Lost to Follow-up|2
6224099|NCT01693562|9895883|FG009|Expansion Phase|Lost to Follow-up|10
6224100|NCT01693562|9895884|FG010|Expansion Phase|Lost to Follow-up|4
6224101|NCT01693562|9895885|FG011|Expansion Phase|Lost to Follow-up|4
6224102|NCT01693562|9895886|FG012|Expansion Phase|Lost to Follow-up|1
6224103|NCT01693562|9895887|FG013|Expansion Phase|Lost to Follow-up|3
6224104|NCT01693562|9895888|FG014|Expansion Phase|Lost to Follow-up|0
6224105|NCT01693562|9895889|FG015|Expansion Phase|Lost to Follow-up|1
6224106|NCT01693562|9895890|FG016|Expansion Phase|Lost to Follow-up|1
6224107|NCT01693562|9895891|FG017|Expansion Phase|Lost to Follow-up|0
6063488|NCT00506415|9664786|FG002|Double Blind (Maximum 48 Weeks )|Death|3
6063489|NCT00506415|9664787|FG003|Double Blind (Maximum 48 Weeks )|Death|0
6063490|NCT00506415|9664784|FG000|Double Blind (Maximum 48 Weeks )|Unsatisfactory therapeutic effect|0
6063491|NCT00506415|9664785|FG001|Double Blind (Maximum 48 Weeks )|Unsatisfactory therapeutic effect|13
6063492|NCT00506415|9664786|FG002|Double Blind (Maximum 48 Weeks )|Unsatisfactory therapeutic effect|13
6063493|NCT00506415|9664787|FG003|Double Blind (Maximum 48 Weeks )|Unsatisfactory therapeutic effect|0
6063494|NCT00506415|9664784|FG000|Double Blind (Maximum 48 Weeks )|Protocol Violation|0
6063495|NCT00506415|9664785|FG001|Double Blind (Maximum 48 Weeks )|Protocol Violation|5
6063496|NCT00506415|9664786|FG002|Double Blind (Maximum 48 Weeks )|Protocol Violation|3
6063497|NCT00506415|9664787|FG003|Double Blind (Maximum 48 Weeks )|Protocol Violation|0
6133897|NCT00984867|9762585|FG001|Overall Study|lack of efficacy and subject compliance|0
6133898|NCT00985088|9762610|FG000|Overall Study|Serious Adverse Event|1
6133899|NCT00985088|9762611|FG001|Overall Study|Serious Adverse Event|1
6133900|NCT00985088|9762612|FG002|Overall Study|Serious Adverse Event|0
6133901|NCT00985088|9762613|FG003|Overall Study|Serious Adverse Event|0
6133902|NCT00985088|9762614|FG004|Overall Study|Serious Adverse Event|0
6133903|NCT00985088|9762615|FG005|Overall Study|Serious Adverse Event|0
6133904|NCT00985088|9762616|FG006|Overall Study|Serious Adverse Event|0
6133905|NCT00985088|9762617|FG007|Overall Study|Serious Adverse Event|1
6133906|NCT00985088|9762610|FG000|Overall Study|Adverse Event|0
6133907|NCT00985088|9762611|FG001|Overall Study|Adverse Event|0
6133908|NCT00985088|9762612|FG002|Overall Study|Adverse Event|1
6133909|NCT00985088|9762613|FG003|Overall Study|Adverse Event|0
6133910|NCT00985088|9762614|FG004|Overall Study|Adverse Event|0
6133911|NCT00985088|9762615|FG005|Overall Study|Adverse Event|0
6133912|NCT00985088|9762616|FG006|Overall Study|Adverse Event|0
6224108|NCT01693562|9895892|FG018|Expansion Phase|Lost to Follow-up|2
6224109|NCT01693562|9895893|FG019|Expansion Phase|Lost to Follow-up|1
6224110|NCT01693562|9895894|FG020|Expansion Phase|Lost to Follow-up|2
6224111|NCT01693562|9895895|FG021|Expansion Phase|Lost to Follow-up|2
6224112|NCT01693562|9895896|FG022|Expansion Phase|Lost to Follow-up|1
6224113|NCT01693562|9895874|FG000|Expansion Phase|Other|0
6224114|NCT01693562|9895875|FG001|Expansion Phase|Other|0
6224115|NCT01693562|9895876|FG002|Expansion Phase|Other|0
6224116|NCT01693562|9895877|FG003|Expansion Phase|Other|0
6224117|NCT01693562|9895878|FG004|Expansion Phase|Other|0
6224118|NCT01693562|9895879|FG005|Expansion Phase|Other|0
6224119|NCT01693562|9895880|FG006|Expansion Phase|Other|0
6224120|NCT01693562|9895881|FG007|Expansion Phase|Other|3
6224121|NCT01693562|9895882|FG008|Expansion Phase|Other|1
6224122|NCT01693562|9895883|FG009|Expansion Phase|Other|28
6224123|NCT01693562|9895884|FG010|Expansion Phase|Other|4
6224124|NCT01693562|9895885|FG011|Expansion Phase|Other|7
6224125|NCT01693562|9895886|FG012|Expansion Phase|Other|0
6224126|NCT01693562|9895887|FG013|Expansion Phase|Other|1
6224127|NCT01693562|9895888|FG014|Expansion Phase|Other|1
6224128|NCT01693562|9895889|FG015|Expansion Phase|Other|0
6224129|NCT01693562|9895890|FG016|Expansion Phase|Other|28
6224130|NCT01693562|9895891|FG017|Expansion Phase|Other|0
6224131|NCT01693562|9895892|FG018|Expansion Phase|Other|1
6224132|NCT01693562|9895893|FG019|Expansion Phase|Other|0
6224133|NCT01693562|9895894|FG020|Expansion Phase|Other|1
6224134|NCT01693562|9895895|FG021|Expansion Phase|Other|17
6224135|NCT01693562|9895896|FG022|Expansion Phase|Other|1
6224136|NCT01693614|9895982|FG000|Overall Study|Adverse Event|7
6224137|NCT01693614|9895983|FG001|Overall Study|Adverse Event|11
6224138|NCT01693614|9895984|FG002|Overall Study|Adverse Event|5
6224139|NCT01693614|9895982|FG000|Overall Study|Disease progression|11
6224140|NCT01693614|9895983|FG001|Overall Study|Disease progression|8
6224141|NCT01693614|9895984|FG002|Overall Study|Disease progression|7
6224142|NCT01693614|9895982|FG000|Overall Study|Protocol Violation|5
6224143|NCT01693614|9895983|FG001|Overall Study|Protocol Violation|2
6224144|NCT01693614|9895984|FG002|Overall Study|Protocol Violation|1
6224145|NCT01693614|9895982|FG000|Overall Study|Death|1
6224146|NCT01693614|9895983|FG001|Overall Study|Death|0
6224147|NCT01693614|9895984|FG002|Overall Study|Death|0
6224148|NCT01693614|9895982|FG000|Overall Study|Physician Decision|1
6290235|NCT02395081|10006082|FG001|Overall Study|Fetal Loss|3
6290236|NCT02395081|10006083|FG002|Overall Study|Fetal Loss|1
6290237|NCT02395133|10006098|FG000|Overall Study|Adverse Event|4
6290238|NCT02395133|10006099|FG001|Overall Study|Adverse Event|1
6290239|NCT02395133|10006100|FG002|Overall Study|Adverse Event|3
6290240|NCT02395133|10006101|FG003|Overall Study|Adverse Event|0
6290241|NCT02395133|10006098|FG000|Overall Study|Lack of Efficacy|1
6290242|NCT02395133|10006099|FG001|Overall Study|Lack of Efficacy|0
6290243|NCT02395133|10006100|FG002|Overall Study|Lack of Efficacy|1
6290244|NCT02395133|10006101|FG003|Overall Study|Lack of Efficacy|1
6290245|NCT02395133|10006098|FG000|Overall Study|Protocol Violation|1
6290246|NCT02395133|10006099|FG001|Overall Study|Protocol Violation|1
6290247|NCT02395133|10006100|FG002|Overall Study|Protocol Violation|0
6290248|NCT02395133|10006101|FG003|Overall Study|Protocol Violation|3
6290249|NCT02395133|10006098|FG000|Overall Study|Lost to Follow-up|0
6290250|NCT02395133|10006099|FG001|Overall Study|Lost to Follow-up|1
6290251|NCT02395133|10006100|FG002|Overall Study|Lost to Follow-up|1
6290252|NCT02395133|10006101|FG003|Overall Study|Lost to Follow-up|0
6290253|NCT02395133|10006098|FG000|Overall Study|Pregnancy|0
6290254|NCT02395133|10006099|FG001|Overall Study|Pregnancy|0
6290255|NCT02395133|10006100|FG002|Overall Study|Pregnancy|3
6133913|NCT00985088|9762617|FG007|Overall Study|Adverse Event|0
6133914|NCT00985088|9762610|FG000|Overall Study|Withdrawal by Subject|4
6133915|NCT00985088|9762611|FG001|Overall Study|Withdrawal by Subject|0
6133916|NCT00985088|9762612|FG002|Overall Study|Withdrawal by Subject|0
6224149|NCT01693614|9895983|FG001|Overall Study|Physician Decision|1
6224150|NCT01693614|9895984|FG002|Overall Study|Physician Decision|4
6224151|NCT01693614|9895982|FG000|Overall Study|Withdrawal by subject/guardian|0
6290256|NCT02395133|10006101|FG003|Overall Study|Pregnancy|0
6290257|NCT02395133|10006098|FG000|Overall Study|Consent withdrawn with no reason given|1
6290258|NCT02395133|10006099|FG001|Overall Study|Consent withdrawn with no reason given|3
6290259|NCT02395133|10006100|FG002|Overall Study|Consent withdrawn with no reason given|0
6133917|NCT00985088|9762613|FG003|Overall Study|Withdrawal by Subject|1
6133918|NCT00985088|9762614|FG004|Overall Study|Withdrawal by Subject|3
6133919|NCT00985088|9762615|FG005|Overall Study|Withdrawal by Subject|2
6133920|NCT00985088|9762616|FG006|Overall Study|Withdrawal by Subject|1
6133921|NCT00985088|9762617|FG007|Overall Study|Withdrawal by Subject|2
6133922|NCT00985088|9762610|FG000|Overall Study|Migrated/moved from study area|0
6133923|NCT00985088|9762611|FG001|Overall Study|Migrated/moved from study area|0
6133924|NCT00985088|9762612|FG002|Overall Study|Migrated/moved from study area|1
6133925|NCT00985088|9762613|FG003|Overall Study|Migrated/moved from study area|0
6133926|NCT00985088|9762614|FG004|Overall Study|Migrated/moved from study area|0
6133927|NCT00985088|9762615|FG005|Overall Study|Migrated/moved from study area|0
6133928|NCT00985088|9762616|FG006|Overall Study|Migrated/moved from study area|0
6133929|NCT00985088|9762617|FG007|Overall Study|Migrated/moved from study area|1
6133930|NCT00985088|9762610|FG000|Overall Study|Lost to Follow-up|6
6133931|NCT00985088|9762611|FG001|Overall Study|Lost to Follow-up|1
5981093|NCT02511106|9570036|FG000|Overall Study|Ongoing study at data cut-off|309
5981094|NCT02511106|9570037|FG001|Overall Study|Ongoing study at data cut-off|307
5981095|NCT02511106|9570036|FG000|Overall Study|Without specified reason|1
5981096|NCT02511106|9570037|FG001|Overall Study|Without specified reason|0
5981097|NCT02511106|9570036|FG000|Overall Study|Missing|1
5981098|NCT02511106|9570037|FG001|Overall Study|Missing|0
5981099|NCT02253316|9570077|FG000|Consolidation|Progression|4
5981100|NCT02253316|9570078|FG001|Consolidation|Progression|0
5981101|NCT02253316|9570079|FG002|Consolidation|Progression|0
5981102|NCT02253316|9570077|FG000|Consolidation|Non-Compliance|1
5981103|NCT02253316|9570078|FG001|Consolidation|Non-Compliance|0
5981104|NCT02253316|9570079|FG002|Consolidation|Non-Compliance|0
6224152|NCT01693614|9895983|FG001|Overall Study|Withdrawal by subject/guardian|0
6224153|NCT01693614|9895984|FG002|Overall Study|Withdrawal by subject/guardian|2
6224154|NCT01693614|9895982|FG000|Overall Study|Withdrawal by Subject|1
6224155|NCT01693614|9895983|FG001|Overall Study|Withdrawal by Subject|0
6224156|NCT01693614|9895984|FG002|Overall Study|Withdrawal by Subject|5
6224157|NCT01694121|9896020|FG000|Overall Study|Participant used false ID, was withdrawn|1
6224158|NCT01694121|9896021|FG001|Overall Study|Participant used false ID, was withdrawn|0
6224159|NCT01694420|9896045|FG000|Overall Study|Lost to Follow-up|3
6224160|NCT01694433|9896051|FG000|Overall Study|Adverse Event|7
6224161|NCT01694433|9896052|FG001|Overall Study|Adverse Event|0
6224162|NCT01694433|9896051|FG000|Overall Study|Physician Decision|1
6224163|NCT01694433|9896052|FG001|Overall Study|Physician Decision|0
6224164|NCT01694433|9896051|FG000|Overall Study|Withdrawal by Subject|3
6224165|NCT01694433|9896052|FG001|Overall Study|Withdrawal by Subject|4
6224166|NCT01694485|9896063|FG000|Overall Study|Withdrawal by Subject|20
6224167|NCT01694485|9896064|FG001|Overall Study|Withdrawal by Subject|6
6224168|NCT01694485|9896065|FG002|Overall Study|Withdrawal by Subject|7
6224169|NCT01694485|9896066|FG003|Overall Study|Withdrawal by Subject|25
6224170|NCT01694485|9896067|FG004|Overall Study|Withdrawal by Subject|18
6224171|NCT01694485|9896063|FG000|Overall Study|Sponsor Decision|3
6224172|NCT01694485|9896064|FG001|Overall Study|Sponsor Decision|0
6224173|NCT01694485|9896065|FG002|Overall Study|Sponsor Decision|0
6224174|NCT01694485|9896066|FG003|Overall Study|Sponsor Decision|2
6290260|NCT02395133|10006101|FG003|Overall Study|Consent withdrawn with no reason given|2
6290261|NCT02395133|10006098|FG000|Overall Study|Consent withdrawn with personal reason|0
6290262|NCT02395133|10006099|FG001|Overall Study|Consent withdrawn with personal reason|1
6290263|NCT02395133|10006100|FG002|Overall Study|Consent withdrawn with personal reason|0
6290264|NCT02395133|10006101|FG003|Overall Study|Consent withdrawn with personal reason|3
6290265|NCT02395133|10006098|FG000|Overall Study|Sponsor decision|2
6290266|NCT02395133|10006099|FG001|Overall Study|Sponsor decision|0
6290267|NCT02395133|10006100|FG002|Overall Study|Sponsor decision|0
6290268|NCT02395133|10006101|FG003|Overall Study|Sponsor decision|1
6290269|NCT02395133|10006098|FG000|Overall Study|Other than specified above|5
6290270|NCT02395133|10006099|FG001|Overall Study|Other than specified above|2
6290271|NCT02395133|10006100|FG002|Overall Study|Other than specified above|2
6290272|NCT02395133|10006101|FG003|Overall Study|Other than specified above|4
6290273|NCT02395172|10006113|FG000|Overall Study|Participants randomized but not treated|3
6290274|NCT02395172|10006114|FG001|Overall Study|Participants randomized but not treated|31
6290275|NCT02395302|10006128|FG000|Overall Study|Screen Failure|3
6290276|NCT02395302|10006128|FG000|Overall Study|Run In Failure|7
6290277|NCT02395302|10006128|FG000|Overall Study|Withdrawal by Subject|2
6290278|NCT02395302|10006128|FG000|Overall Study|Physician Decision|2
6290279|NCT02395471|10006134|FG000|Overall Study|Lost to Follow-up|2
6290280|NCT02395471|10006135|FG001|Overall Study|Lost to Follow-up|0
6290281|NCT02395471|10006134|FG000|Overall Study|Withdrawal by Subject|2
6290282|NCT02395471|10006135|FG001|Overall Study|Withdrawal by Subject|1
6290283|NCT02395471|10006134|FG000|Overall Study|Physician Decision|1
6133932|NCT00985088|9762612|FG002|Overall Study|Lost to Follow-up|2
6133933|NCT00985088|9762613|FG003|Overall Study|Lost to Follow-up|6
6224175|NCT01694485|9896067|FG004|Overall Study|Sponsor Decision|0
6224176|NCT01694485|9896063|FG000|Overall Study|Lost to Follow-up|9
6224177|NCT01694485|9896064|FG001|Overall Study|Lost to Follow-up|1
6290284|NCT02395471|10006135|FG001|Overall Study|Physician Decision|0
6224178|NCT01694485|9896065|FG002|Overall Study|Lost to Follow-up|6
5981105|NCT02253316|9570077|FG000|Consolidation|Patient Withdrew Logistical Concerns|2
6133934|NCT00985088|9762614|FG004|Overall Study|Lost to Follow-up|6
6133935|NCT00985088|9762615|FG005|Overall Study|Lost to Follow-up|5
6133936|NCT00985088|9762616|FG006|Overall Study|Lost to Follow-up|3
6133937|NCT00985088|9762617|FG007|Overall Study|Lost to Follow-up|2
6133938|NCT00985114|9762647|FG000|Overall Study|Adverse Event|1
6133939|NCT00985114|9762648|FG001|Overall Study|Adverse Event|0
6224179|NCT01694485|9896066|FG003|Overall Study|Lost to Follow-up|10
6224180|NCT01694485|9896067|FG004|Overall Study|Lost to Follow-up|7
6224181|NCT01694485|9896063|FG000|Overall Study|Death|1
6224182|NCT01694485|9896064|FG001|Overall Study|Death|0
6224183|NCT01694485|9896065|FG002|Overall Study|Death|0
6224184|NCT01694485|9896066|FG003|Overall Study|Death|1
6224185|NCT01694485|9896067|FG004|Overall Study|Death|0
6224186|NCT01694706|9896110|FG000|Overall Study|Adverse Event|0
6224187|NCT01694706|9896111|FG001|Overall Study|Adverse Event|1
6224188|NCT01694706|9896112|FG002|Overall Study|Adverse Event|0
6224189|NCT01694706|9896110|FG000|Overall Study|other reason not defined above|1
6224190|NCT01694706|9896111|FG001|Overall Study|other reason not defined above|0
6224191|NCT01694706|9896112|FG002|Overall Study|other reason not defined above|0
6224192|NCT01694771|9896123|FG000|Overall Study|Adverse Event|18
6224193|NCT01694771|9896124|FG001|Overall Study|Adverse Event|16
6224194|NCT01694771|9896123|FG000|Overall Study|Lack of Efficacy|1
6224195|NCT01694771|9896124|FG001|Overall Study|Lack of Efficacy|0
6224196|NCT01694771|9896123|FG000|Overall Study|Non compliance protocol|7
6224197|NCT01694771|9896124|FG001|Overall Study|Non compliance protocol|6
6224198|NCT01694771|9896123|FG000|Overall Study|Lost to Follow-up|2
6224199|NCT01694771|9896124|FG001|Overall Study|Lost to Follow-up|3
6224200|NCT01694771|9896123|FG000|Overall Study|Consent withdrawn|7
6224201|NCT01694771|9896124|FG001|Overall Study|Consent withdrawn|9
6224202|NCT01694771|9896123|FG000|Overall Study|Other reasons|5
6224203|NCT01694771|9896124|FG001|Overall Study|Other reasons|6
6224204|NCT01695135|9896155|FG000|Double-blind Treatment Phase|Progressive disease|50
6224205|NCT01695135|9896156|FG001|Double-blind Treatment Phase|Progressive disease|110
6224206|NCT01695135|9896157|FG002|Double-blind Treatment Phase|Progressive disease|0
6224207|NCT01695135|9896158|FG003|Double-blind Treatment Phase|Progressive disease|0
6290285|NCT02395471|10006134|FG000|Overall Study|Protocol Violation|0
6290286|NCT02395471|10006135|FG001|Overall Study|Protocol Violation|1
6290287|NCT02395471|10006134|FG000|Overall Study|Failure to swollow sponge twice|1
6290288|NCT02395471|10006135|FG001|Overall Study|Failure to swollow sponge twice|0
6290289|NCT02395471|10006134|FG000|Overall Study|Patient did not return for procedure|0
6290290|NCT02395471|10006135|FG001|Overall Study|Patient did not return for procedure|1
6290291|NCT02395471|10006134|FG000|Overall Study|Subject not eligible|1
6290292|NCT02395471|10006135|FG001|Overall Study|Subject not eligible|0
6290293|NCT02395536|10006152|FG000|Overall Study|Lost to Follow-up|4
6290294|NCT02395536|10006153|FG001|Overall Study|Lost to Follow-up|4
6290295|NCT02395536|10006152|FG000|Overall Study|Death|2
6290296|NCT02395536|10006153|FG001|Overall Study|Death|0
6290297|NCT02395536|10006152|FG000|Overall Study|Physician Decision|4
6290298|NCT02395536|10006153|FG001|Overall Study|Physician Decision|6
6290299|NCT02395536|10006152|FG000|Overall Study|Withdrawal by Subject|9
6290300|NCT02395536|10006153|FG001|Overall Study|Withdrawal by Subject|17
6290301|NCT02395536|10006152|FG000|Overall Study|Inclusion/Excusion Criteria Violation|1
6290302|NCT02395536|10006153|FG001|Overall Study|Inclusion/Excusion Criteria Violation|2
6290303|NCT02395536|10006152|FG000|Overall Study|Insurance issue|0
6290304|NCT02395536|10006153|FG001|Overall Study|Insurance issue|1
6290305|NCT02395627|10006162|FG000|Overall Study|Withdrawal by Subject|0
6290306|NCT02395627|10006163|FG001|Overall Study|Withdrawal by Subject|2
6290307|NCT02395627|10006164|FG002|Overall Study|Withdrawal by Subject|0
6290308|NCT02395627|10006162|FG000|Overall Study|Did not receive pembrolizumab|3
6290309|NCT02395627|10006163|FG001|Overall Study|Did not receive pembrolizumab|1
6290310|NCT02395627|10006164|FG002|Overall Study|Did not receive pembrolizumab|0
6290311|NCT02395653|10006174|FG000|Overall Study|Exclusion Criteria Met at Screening|4
6290312|NCT02395653|10006174|FG000|Overall Study|Consent Withdrawn at Screening|1
6290313|NCT02395653|10006174|FG000|Overall Study|SSEC Application But With 0 Dose|1
6290314|NCT02395653|10006174|FG000|Overall Study|Investigator Decision at Screening|1
6290315|NCT02395653|10006174|FG000|Overall Study|Inclusion Criteria Not Met at Screening|3
6290316|NCT02395653|10006174|FG000|Overall Study|Withdrawal by Subject|1
6290317|NCT02395653|10006174|FG000|Overall Study|Lost to Follow-up|1
6290318|NCT02395822|10006186|FG000|Overall Study|Withdrawal by Subject|1
6290319|NCT02395822|10006186|FG000|Overall Study|Death|1
6290320|NCT02396212|10006243|FG000|Overall Study|Adverse Event|1
6290321|NCT02396212|10006243|FG000|Overall Study|Lack of Efficacy|2
6290322|NCT02396316|10006257|FG000|Overall Study|Physician Decision|1
6290323|NCT02396316|10006258|FG001|Overall Study|Physician Decision|0
6290324|NCT02396316|10006257|FG000|Overall Study|Progressive disease|6
6290325|NCT02396316|10006258|FG001|Overall Study|Progressive disease|3
6290326|NCT02396316|10006257|FG000|Overall Study|Protocol Violation|0
6290327|NCT02396316|10006258|FG001|Overall Study|Protocol Violation|1
6290328|NCT02396316|10006257|FG000|Overall Study|Treatment unblinded|0
6290329|NCT02396316|10006258|FG001|Overall Study|Treatment unblinded|1
6290330|NCT02396381|10006270|FG000|Overall Study|Adverse Event|3
6290331|NCT02396381|10006271|FG001|Overall Study|Adverse Event|2
6290332|NCT02396381|10006270|FG000|Overall Study|Withdrawal by Subject|33
6224208|NCT01695135|9896155|FG000|Double-blind Treatment Phase|Withdrawal by Subject|6
6133940|NCT00985114|9762647|FG000|Overall Study|Withdrawal by Subject|0
6133941|NCT00985114|9762648|FG001|Overall Study|Withdrawal by Subject|2
6133942|NCT00985153|9762662|FG000|Overall Study|Lost to Follow-up|16
6133943|NCT00985153|9762663|FG001|Overall Study|Lost to Follow-up|19
6133944|NCT00985153|9762664|FG002|Overall Study|Lost to Follow-up|17
6133945|NCT00985153|9762665|FG003|Overall Study|Lost to Follow-up|20
6224209|NCT01695135|9896156|FG001|Double-blind Treatment Phase|Withdrawal by Subject|14
6224210|NCT01695135|9896157|FG002|Double-blind Treatment Phase|Withdrawal by Subject|0
6224211|NCT01695135|9896158|FG003|Double-blind Treatment Phase|Withdrawal by Subject|0
6224212|NCT01695135|9896155|FG000|Double-blind Treatment Phase|Adverse Event|7
6224213|NCT01695135|9896156|FG001|Double-blind Treatment Phase|Adverse Event|7
6224214|NCT01695135|9896157|FG002|Double-blind Treatment Phase|Adverse Event|0
6224215|NCT01695135|9896158|FG003|Double-blind Treatment Phase|Adverse Event|0
6224216|NCT01695135|9896155|FG000|Double-blind Treatment Phase|Other|1
6224217|NCT01695135|9896156|FG001|Double-blind Treatment Phase|Other|3
6224218|NCT01695135|9896157|FG002|Double-blind Treatment Phase|Other|0
6224219|NCT01695135|9896158|FG003|Double-blind Treatment Phase|Other|0
6224220|NCT01695135|9896155|FG000|Double-blind Treatment Phase|Physician Decision|6
6224221|NCT01695135|9896156|FG001|Double-blind Treatment Phase|Physician Decision|3
6224222|NCT01695135|9896157|FG002|Double-blind Treatment Phase|Physician Decision|0
6133946|NCT00985153|9762662|FG000|Overall Study|Protocol Violation|3
6133947|NCT00985153|9762663|FG001|Overall Study|Protocol Violation|2
6133948|NCT00985153|9762664|FG002|Overall Study|Protocol Violation|4
6133949|NCT00985153|9762665|FG003|Overall Study|Protocol Violation|3
6133950|NCT00985153|9762662|FG000|Overall Study|Withdrawal by Subject|6
6133951|NCT00985153|9762663|FG001|Overall Study|Withdrawal by Subject|11
6133952|NCT00985153|9762664|FG002|Overall Study|Withdrawal by Subject|11
6133953|NCT00985153|9762665|FG003|Overall Study|Withdrawal by Subject|10
6133954|NCT00985153|9762662|FG000|Overall Study|Missed One or More Bleeds|7
6133955|NCT00985153|9762663|FG001|Overall Study|Missed One or More Bleeds|7
6133956|NCT00985153|9762664|FG002|Overall Study|Missed One or More Bleeds|8
6133957|NCT00985153|9762665|FG003|Overall Study|Missed One or More Bleeds|10
6133958|NCT00985153|9762662|FG000|Overall Study|Incomplete Safety Follow-up|3
6133959|NCT00985153|9762663|FG001|Overall Study|Incomplete Safety Follow-up|5
6133960|NCT00985153|9762664|FG002|Overall Study|Incomplete Safety Follow-up|4
6133961|NCT00985153|9762665|FG003|Overall Study|Incomplete Safety Follow-up|4
6224223|NCT01695135|9896158|FG003|Double-blind Treatment Phase|Physician Decision|0
6224224|NCT01695135|9896155|FG000|Double-blind Treatment Phase|Death|1
6224225|NCT01695135|9896156|FG001|Double-blind Treatment Phase|Death|1
6224226|NCT01695135|9896157|FG002|Double-blind Treatment Phase|Death|0
6224227|NCT01695135|9896158|FG003|Double-blind Treatment Phase|Death|0
6224228|NCT01695135|9896155|FG000|Double-blind Treatment Phase|Noncompliance with study drug|0
6224229|NCT01695135|9896156|FG001|Double-blind Treatment Phase|Noncompliance with study drug|1
6224230|NCT01695135|9896157|FG002|Double-blind Treatment Phase|Noncompliance with study drug|0
6224231|NCT01695135|9896158|FG003|Double-blind Treatment Phase|Noncompliance with study drug|0
6224232|NCT01695135|9896155|FG000|Open Label Extension Treatment Phase|Progressive disease|0
6224233|NCT01695135|9896156|FG001|Open Label Extension Treatment Phase|Progressive disease|0
6224234|NCT01695135|9896157|FG002|Open Label Extension Treatment Phase|Progressive disease|13
6224235|NCT01695135|9896158|FG003|Open Label Extension Treatment Phase|Progressive disease|22
6224236|NCT01695135|9896155|FG000|Open Label Extension Treatment Phase|Withdrawal by Subject|0
6224237|NCT01695135|9896156|FG001|Open Label Extension Treatment Phase|Withdrawal by Subject|0
6224238|NCT01695135|9896157|FG002|Open Label Extension Treatment Phase|Withdrawal by Subject|6
6224239|NCT01695135|9896158|FG003|Open Label Extension Treatment Phase|Withdrawal by Subject|16
6224240|NCT01695135|9896155|FG000|Open Label Extension Treatment Phase|Adverse Event|0
6224241|NCT01695135|9896156|FG001|Open Label Extension Treatment Phase|Adverse Event|0
6224242|NCT01695135|9896157|FG002|Open Label Extension Treatment Phase|Adverse Event|11
6224243|NCT01695135|9896158|FG003|Open Label Extension Treatment Phase|Adverse Event|16
6224244|NCT01695135|9896155|FG000|Open Label Extension Treatment Phase|Other|0
6224245|NCT01695135|9896156|FG001|Open Label Extension Treatment Phase|Other|0
6224246|NCT01695135|9896157|FG002|Open Label Extension Treatment Phase|Other|4
6224247|NCT01695135|9896158|FG003|Open Label Extension Treatment Phase|Other|7
6224248|NCT01695135|9896155|FG000|Open Label Extension Treatment Phase|Physician Decision|0
6224249|NCT01695135|9896156|FG001|Open Label Extension Treatment Phase|Physician Decision|0
6224250|NCT01695135|9896157|FG002|Open Label Extension Treatment Phase|Physician Decision|4
6224251|NCT01695135|9896158|FG003|Open Label Extension Treatment Phase|Physician Decision|1
6224252|NCT01695135|9896155|FG000|Open Label Extension Treatment Phase|Death|0
6224253|NCT01695135|9896156|FG001|Open Label Extension Treatment Phase|Death|0
6224254|NCT01695135|9896157|FG002|Open Label Extension Treatment Phase|Death|2
6224255|NCT01695135|9896158|FG003|Open Label Extension Treatment Phase|Death|7
6224256|NCT01695135|9896155|FG000|Open Label Extension Treatment Phase|Noncompliance with study drug|0
6224257|NCT01695135|9896156|FG001|Open Label Extension Treatment Phase|Noncompliance with study drug|0
6133962|NCT00985166|9762678|FG000|Overall Study|Lost to Follow-up|3
6133963|NCT00985166|9762679|FG001|Overall Study|Lost to Follow-up|2
6133964|NCT00985166|9762680|FG002|Overall Study|Lost to Follow-up|2
6133965|NCT00985166|9762678|FG000|Overall Study|Withdrawal by Subject|3
6133966|NCT00985166|9762679|FG001|Overall Study|Withdrawal by Subject|2
6133967|NCT00985166|9762680|FG002|Overall Study|Withdrawal by Subject|0
6133968|NCT00985166|9762678|FG000|Overall Study|Test not done|2
6133969|NCT00985166|9762679|FG001|Overall Study|Test not done|0
6133970|NCT00985166|9762680|FG002|Overall Study|Test not done|4
6133971|NCT00985166|9762678|FG000|Overall Study|Other|1
6133972|NCT00985166|9762679|FG001|Overall Study|Other|0
6133973|NCT00985166|9762680|FG002|Overall Study|Other|1
6133974|NCT00985192|9762690|FG000|Overall Study|Withdrawal by Subject|1
6133975|NCT00985192|9762690|FG000|Overall Study|Disease Progression|1
6133976|NCT00985192|9762690|FG000|Overall Study|Determined to be Ineligible During Trial|2
6290333|NCT02396381|10006271|FG001|Overall Study|Withdrawal by Subject|24
6290334|NCT02396381|10006270|FG000|Overall Study|Lost to Follow-up|49
6290335|NCT02396381|10006271|FG001|Overall Study|Lost to Follow-up|31
6290336|NCT02396381|10006270|FG000|Overall Study|Protocol Violation|1
6290337|NCT02396381|10006271|FG001|Overall Study|Protocol Violation|0
6290338|NCT02396381|10006270|FG000|Overall Study|Site terminated by sponsor|7
6133977|NCT00985231|9762696|FG000|Overall Study|ineligible|1
6133978|NCT00985231|9762697|FG001|Overall Study|ineligible|0
6133979|NCT00985231|9762696|FG000|Overall Study|Protocol Violation|1
6133980|NCT00985231|9762697|FG001|Overall Study|Protocol Violation|0
6133981|NCT00985231|9762696|FG000|Overall Study|Withdrawal by Subject|1
6133982|NCT00985231|9762697|FG001|Overall Study|Withdrawal by Subject|0
6133983|NCT00985231|9762696|FG000|Overall Study|Lost to Follow-up|0
6133984|NCT00985231|9762697|FG001|Overall Study|Lost to Follow-up|1
6133985|NCT00985231|9762696|FG000|Overall Study|Study related symptoms & complaints|0
6133986|NCT00985231|9762697|FG001|Overall Study|Study related symptoms & complaints|2
6224258|NCT01695135|9896157|FG002|Open Label Extension Treatment Phase|Noncompliance with study drug|0
6224259|NCT01695135|9896158|FG003|Open Label Extension Treatment Phase|Noncompliance with study drug|1
6224260|NCT01695239|9896170|FG000|Double-Blind (DB) Treatment Period|Entry Criteria Not Met|1
6224261|NCT01695239|9896171|FG001|Double-Blind (DB) Treatment Period|Entry Criteria Not Met|1
6224262|NCT01695239|9896172|FG002|Double-Blind (DB) Treatment Period|Entry Criteria Not Met|3
6224263|NCT01695239|9896173|FG003|Double-Blind (DB) Treatment Period|Entry Criteria Not Met|4
6224264|NCT01695239|9896174|FG004|Double-Blind (DB) Treatment Period|Entry Criteria Not Met|0
6224265|NCT01695239|9896175|FG005|Double-Blind (DB) Treatment Period|Entry Criteria Not Met|0
6224266|NCT01695239|9896176|FG006|Double-Blind (DB) Treatment Period|Entry Criteria Not Met|0
6224267|NCT01695239|9896177|FG007|Double-Blind (DB) Treatment Period|Entry Criteria Not Met|0
6224268|NCT01695239|9896178|FG008|Double-Blind (DB) Treatment Period|Entry Criteria Not Met|0
6224269|NCT01695239|9896179|FG009|Double-Blind (DB) Treatment Period|Entry Criteria Not Met|0
6224270|NCT01695239|9896180|FG010|Double-Blind (DB) Treatment Period|Entry Criteria Not Met|0
6224271|NCT01695239|9896181|FG011|Double-Blind (DB) Treatment Period|Entry Criteria Not Met|0
6224272|NCT01695239|9896182|FG012|Double-Blind (DB) Treatment Period|Entry Criteria Not Met|0
6224273|NCT01695239|9896183|FG013|Double-Blind (DB) Treatment Period|Entry Criteria Not Met|0
6224274|NCT01695239|9896170|FG000|Double-Blind (DB) Treatment Period|Adverse Event|2
6224275|NCT01695239|9896171|FG001|Double-Blind (DB) Treatment Period|Adverse Event|2
6224276|NCT01695239|9896172|FG002|Double-Blind (DB) Treatment Period|Adverse Event|2
6224277|NCT01695239|9896173|FG003|Double-Blind (DB) Treatment Period|Adverse Event|3
6224278|NCT01695239|9896174|FG004|Double-Blind (DB) Treatment Period|Adverse Event|0
6224279|NCT01695239|9896175|FG005|Double-Blind (DB) Treatment Period|Adverse Event|0
6224280|NCT01695239|9896176|FG006|Double-Blind (DB) Treatment Period|Adverse Event|0
6224281|NCT01695239|9896177|FG007|Double-Blind (DB) Treatment Period|Adverse Event|0
6224282|NCT01695239|9896178|FG008|Double-Blind (DB) Treatment Period|Adverse Event|0
6224283|NCT01695239|9896179|FG009|Double-Blind (DB) Treatment Period|Adverse Event|0
6224284|NCT01695239|9896180|FG010|Double-Blind (DB) Treatment Period|Adverse Event|0
6224285|NCT01695239|9896181|FG011|Double-Blind (DB) Treatment Period|Adverse Event|0
6224286|NCT01695239|9896182|FG012|Double-Blind (DB) Treatment Period|Adverse Event|0
6224287|NCT01695239|9896183|FG013|Double-Blind (DB) Treatment Period|Adverse Event|0
6224288|NCT01695239|9896170|FG000|Double-Blind (DB) Treatment Period|Lack of Efficacy|4
6224289|NCT01695239|9896171|FG001|Double-Blind (DB) Treatment Period|Lack of Efficacy|0
6224290|NCT01695239|9896172|FG002|Double-Blind (DB) Treatment Period|Lack of Efficacy|2
6224291|NCT01695239|9896173|FG003|Double-Blind (DB) Treatment Period|Lack of Efficacy|0
6224292|NCT01695239|9896174|FG004|Double-Blind (DB) Treatment Period|Lack of Efficacy|0
6224293|NCT01695239|9896175|FG005|Double-Blind (DB) Treatment Period|Lack of Efficacy|0
6224294|NCT01695239|9896176|FG006|Double-Blind (DB) Treatment Period|Lack of Efficacy|0
6224295|NCT01695239|9896177|FG007|Double-Blind (DB) Treatment Period|Lack of Efficacy|0
6224296|NCT01695239|9896178|FG008|Double-Blind (DB) Treatment Period|Lack of Efficacy|0
6224297|NCT01695239|9896179|FG009|Double-Blind (DB) Treatment Period|Lack of Efficacy|0
6224298|NCT01695239|9896180|FG010|Double-Blind (DB) Treatment Period|Lack of Efficacy|0
6224299|NCT01695239|9896181|FG011|Double-Blind (DB) Treatment Period|Lack of Efficacy|0
6290339|NCT02396381|10006271|FG001|Overall Study|Site terminated by sponsor|8
6133987|NCT00985426|9762709|FG000|Overall Study|Adverse Event|0
6133988|NCT00985426|9762710|FG001|Overall Study|Adverse Event|1
6133989|NCT00985426|9762709|FG000|Overall Study|Subject Non-Compliance|3
6133990|NCT00985426|9762710|FG001|Overall Study|Subject Non-Compliance|3
6133991|NCT00985426|9762709|FG000|Overall Study|Withdrawal by Subject|12
6133992|NCT00985426|9762710|FG001|Overall Study|Withdrawal by Subject|16
6133993|NCT00985426|9762709|FG000|Overall Study|Lost to Follow-up|8
6133994|NCT00985426|9762710|FG001|Overall Study|Lost to Follow-up|10
6133995|NCT00985426|9762709|FG000|Overall Study|Death|7
6133996|NCT00985426|9762710|FG001|Overall Study|Death|3
6133997|NCT00985426|9762709|FG000|Overall Study|Protocol Violation|2
6133998|NCT00985426|9762710|FG001|Overall Study|Protocol Violation|0
6133999|NCT00985426|9762709|FG000|Overall Study|Lack of seroprotection at protocol-specified timepoints|11
6134000|NCT00985426|9762710|FG001|Overall Study|Lack of seroprotection at protocol-specified timepoints|11
6134001|NCT00985439|9762720|FG000|Overall Study|Adverse Event|0
6134002|NCT00985439|9762721|FG001|Overall Study|Adverse Event|0
6134003|NCT00985439|9762722|FG002|Overall Study|Adverse Event|1
6134004|NCT00985439|9762723|FG003|Overall Study|Adverse Event|0
6134005|NCT00985465|9762735|FG000|Overall Study|Withdrawal by Subject|1
6134006|NCT00985465|9762736|FG001|Overall Study|Withdrawal by Subject|2
6224300|NCT01695239|9896182|FG012|Double-Blind (DB) Treatment Period|Lack of Efficacy|0
6224301|NCT01695239|9896183|FG013|Double-Blind (DB) Treatment Period|Lack of Efficacy|0
6224302|NCT01695239|9896170|FG000|Double-Blind (DB) Treatment Period|Withdrawal by Subject|3
6224303|NCT01695239|9896171|FG001|Double-Blind (DB) Treatment Period|Withdrawal by Subject|1
6224304|NCT01695239|9896172|FG002|Double-Blind (DB) Treatment Period|Withdrawal by Subject|1
6224305|NCT01695239|9896173|FG003|Double-Blind (DB) Treatment Period|Withdrawal by Subject|0
6224306|NCT01695239|9896174|FG004|Double-Blind (DB) Treatment Period|Withdrawal by Subject|0
6224307|NCT01695239|9896175|FG005|Double-Blind (DB) Treatment Period|Withdrawal by Subject|0
6224308|NCT01695239|9896176|FG006|Double-Blind (DB) Treatment Period|Withdrawal by Subject|0
6224309|NCT01695239|9896177|FG007|Double-Blind (DB) Treatment Period|Withdrawal by Subject|0
6290340|NCT02396381|10006270|FG000|Overall Study|Physician Decision|5
6290341|NCT02396381|10006271|FG001|Overall Study|Physician Decision|5
6290342|NCT02396381|10006270|FG000|Overall Study|Pregnancy|2
6290343|NCT02396381|10006271|FG001|Overall Study|Pregnancy|0
6290344|NCT02396381|10006270|FG000|Overall Study|Non-compliance with study procedures|1
6290345|NCT02396381|10006271|FG001|Overall Study|Non-compliance with study procedures|0
6290346|NCT02396381|10006270|FG000|Overall Study|Moved out of town/state|1
6290347|NCT02396381|10006271|FG001|Overall Study|Moved out of town/state|3
6290348|NCT02396381|10006270|FG000|Overall Study|Could not complete visit|1
6290349|NCT02396381|10006271|FG001|Overall Study|Could not complete visit|0
6290350|NCT02396381|10006270|FG000|Overall Study|Possible conflict of interest|1
6290351|NCT02396381|10006271|FG001|Overall Study|Possible conflict of interest|0
6290352|NCT02396381|10006270|FG000|Overall Study|Randomization/Screening Error|3
6290353|NCT02396381|10006271|FG001|Overall Study|Randomization/Screening Error|1
6290354|NCT02396420|10006280|FG000|Overall Study|Death|1
6290355|NCT02396537|10006291|FG000|Overall Study|Protocol Violation|0
6290356|NCT02396537|10006292|FG001|Overall Study|Protocol Violation|1
6290357|NCT02396758|10006315|FG000|Overall Study|Withdrawal by Subject|2
6290358|NCT02396758|10006316|FG001|Overall Study|Withdrawal by Subject|0
6290359|NCT02396758|10006317|FG002|Overall Study|Withdrawal by Subject|0
6290360|NCT02396758|10006318|FG003|Overall Study|Withdrawal by Subject|1
6290361|NCT02396758|10006315|FG000|Overall Study|Lost to Follow-up|8
6290362|NCT02396758|10006316|FG001|Overall Study|Lost to Follow-up|5
6290363|NCT02396758|10006317|FG002|Overall Study|Lost to Follow-up|3
6290364|NCT02396758|10006318|FG003|Overall Study|Lost to Follow-up|3
6290365|NCT02396758|10006315|FG000|Overall Study|Death|1
6290366|NCT02396758|10006316|FG001|Overall Study|Death|1
6290367|NCT02396758|10006317|FG002|Overall Study|Death|0
6134007|NCT00985465|9762735|FG000|Overall Study|Considered to be part of the other group|0
6134008|NCT00985465|9762736|FG001|Overall Study|Considered to be part of the other group|1
6134009|NCT00985491|9762743|FG000|Overall Study|Adverse Event|8
6134010|NCT00985491|9762743|FG000|Overall Study|device migration|7
6134011|NCT00985491|9762743|FG000|Overall Study|Withdrawal by Subject|1
6134012|NCT00985491|9762743|FG000|Overall Study|implant failure|3
6134013|NCT00985504|9762750|FG000|Acute Treatment Period|Adverse Event|3
6134014|NCT00985504|9762751|FG001|Acute Treatment Period|Adverse Event|4
6134015|NCT00985504|9762750|FG000|Acute Treatment Period|Entry Criteria Not Met|1
6134016|NCT00985504|9762751|FG001|Acute Treatment Period|Entry Criteria Not Met|2
6134017|NCT00985504|9762750|FG000|Acute Treatment Period|Protocol Violation|2
6134018|NCT00985504|9762751|FG001|Acute Treatment Period|Protocol Violation|0
6134019|NCT00985504|9762750|FG000|Acute Treatment Period|Sponsor Decision|0
6134020|NCT00985504|9762751|FG001|Acute Treatment Period|Sponsor Decision|1
6134021|NCT00985504|9762750|FG000|Acute Treatment Period|Withdrawal by Subject|9
6134022|NCT00985504|9762751|FG001|Acute Treatment Period|Withdrawal by Subject|5
6134023|NCT00985504|9762750|FG000|Optimization Period|Adverse Event|7
6134024|NCT00985504|9762751|FG001|Optimization Period|Adverse Event|9
6224310|NCT01695239|9896178|FG008|Double-Blind (DB) Treatment Period|Withdrawal by Subject|0
6224311|NCT01695239|9896179|FG009|Double-Blind (DB) Treatment Period|Withdrawal by Subject|0
6290368|NCT02396758|10006318|FG003|Overall Study|Death|1
6290369|NCT02396758|10006315|FG000|Overall Study|Randomized but not treated|1
6290370|NCT02396758|10006316|FG001|Overall Study|Randomized but not treated|0
6290371|NCT02396758|10006317|FG002|Overall Study|Randomized but not treated|1
6290372|NCT02396758|10006318|FG003|Overall Study|Randomized but not treated|0
6134025|NCT00985504|9762750|FG000|Optimization Period|Death|0
6134026|NCT00985504|9762751|FG001|Optimization Period|Death|1
6134027|NCT00985504|9762750|FG000|Optimization Period|Lack of Efficacy|5
6134028|NCT00985504|9762751|FG001|Optimization Period|Lack of Efficacy|3
6134029|NCT00985504|9762750|FG000|Optimization Period|Lost to Follow-up|0
6134030|NCT00985504|9762751|FG001|Optimization Period|Lost to Follow-up|1
6134031|NCT00985504|9762750|FG000|Optimization Period|Physician Decision|1
6134032|NCT00985504|9762751|FG001|Optimization Period|Physician Decision|0
6134033|NCT00985504|9762750|FG000|Optimization Period|Protocol Violation|3
6134034|NCT00985504|9762751|FG001|Optimization Period|Protocol Violation|1
6134035|NCT00985504|9762750|FG000|Optimization Period|Withdrawal by Subject|10
6134036|NCT00985504|9762751|FG001|Optimization Period|Withdrawal by Subject|8
6134037|NCT00985621|9762785|FG000|Overall Study|Adverse Event|2
6134038|NCT00985621|9762786|FG001|Overall Study|Adverse Event|3
6134039|NCT00985621|9762787|FG002|Overall Study|Adverse Event|4
6134040|NCT00985621|9762788|FG003|Overall Study|Adverse Event|16
6134041|NCT00985621|9762785|FG000|Overall Study|Lack of Efficacy|10
6134042|NCT00985621|9762786|FG001|Overall Study|Lack of Efficacy|6
6134043|NCT00985621|9762787|FG002|Overall Study|Lack of Efficacy|5
6134044|NCT00985621|9762788|FG003|Overall Study|Lack of Efficacy|12
6134045|NCT00985621|9762785|FG000|Overall Study|Lost to Follow-up|2
6134046|NCT00985621|9762786|FG001|Overall Study|Lost to Follow-up|3
6134047|NCT00985621|9762787|FG002|Overall Study|Lost to Follow-up|4
6134048|NCT00985621|9762788|FG003|Overall Study|Lost to Follow-up|4
6134049|NCT00985621|9762785|FG000|Overall Study|Study Terminated by Sponsor|89
6134050|NCT00985621|9762786|FG001|Overall Study|Study Terminated by Sponsor|108
6134051|NCT00985621|9762787|FG002|Overall Study|Study Terminated by Sponsor|99
6134052|NCT00985621|9762788|FG003|Overall Study|Study Terminated by Sponsor|92
6134053|NCT00985621|9762785|FG000|Overall Study|Protocol Violation|1
6134054|NCT00985621|9762786|FG001|Overall Study|Protocol Violation|1
6134055|NCT00985621|9762787|FG002|Overall Study|Protocol Violation|1
6134056|NCT00985621|9762788|FG003|Overall Study|Protocol Violation|0
6134057|NCT00985621|9762785|FG000|Overall Study|Withdrawal by Subject|8
6134058|NCT00985621|9762786|FG001|Overall Study|Withdrawal by Subject|10
6134059|NCT00985621|9762787|FG002|Overall Study|Withdrawal by Subject|8
6224312|NCT01695239|9896180|FG010|Double-Blind (DB) Treatment Period|Withdrawal by Subject|0
6224313|NCT01695239|9896181|FG011|Double-Blind (DB) Treatment Period|Withdrawal by Subject|0
6224314|NCT01695239|9896182|FG012|Double-Blind (DB) Treatment Period|Withdrawal by Subject|0
6224315|NCT01695239|9896183|FG013|Double-Blind (DB) Treatment Period|Withdrawal by Subject|0
6224316|NCT01695239|9896170|FG000|Double-Blind (DB) Treatment Period|Sponsor Decision|3
6224317|NCT01695239|9896171|FG001|Double-Blind (DB) Treatment Period|Sponsor Decision|0
6224318|NCT01695239|9896172|FG002|Double-Blind (DB) Treatment Period|Sponsor Decision|1
6224319|NCT01695239|9896173|FG003|Double-Blind (DB) Treatment Period|Sponsor Decision|0
6224320|NCT01695239|9896174|FG004|Double-Blind (DB) Treatment Period|Sponsor Decision|0
6224321|NCT01695239|9896175|FG005|Double-Blind (DB) Treatment Period|Sponsor Decision|0
6224322|NCT01695239|9896176|FG006|Double-Blind (DB) Treatment Period|Sponsor Decision|0
6224323|NCT01695239|9896177|FG007|Double-Blind (DB) Treatment Period|Sponsor Decision|0
6224324|NCT01695239|9896178|FG008|Double-Blind (DB) Treatment Period|Sponsor Decision|0
6224325|NCT01695239|9896179|FG009|Double-Blind (DB) Treatment Period|Sponsor Decision|0
6224326|NCT01695239|9896180|FG010|Double-Blind (DB) Treatment Period|Sponsor Decision|0
6224327|NCT01695239|9896181|FG011|Double-Blind (DB) Treatment Period|Sponsor Decision|0
6224328|NCT01695239|9896182|FG012|Double-Blind (DB) Treatment Period|Sponsor Decision|0
6224329|NCT01695239|9896183|FG013|Double-Blind (DB) Treatment Period|Sponsor Decision|0
6224330|NCT01695239|9896170|FG000|Double-Blind (DB) Treatment Period|Lost to Follow-up|1
6224331|NCT01695239|9896171|FG001|Double-Blind (DB) Treatment Period|Lost to Follow-up|0
6224332|NCT01695239|9896172|FG002|Double-Blind (DB) Treatment Period|Lost to Follow-up|1
6224333|NCT01695239|9896173|FG003|Double-Blind (DB) Treatment Period|Lost to Follow-up|0
6224334|NCT01695239|9896174|FG004|Double-Blind (DB) Treatment Period|Lost to Follow-up|0
6224335|NCT01695239|9896175|FG005|Double-Blind (DB) Treatment Period|Lost to Follow-up|0
6224336|NCT01695239|9896176|FG006|Double-Blind (DB) Treatment Period|Lost to Follow-up|0
6224337|NCT01695239|9896177|FG007|Double-Blind (DB) Treatment Period|Lost to Follow-up|0
6224338|NCT01695239|9896178|FG008|Double-Blind (DB) Treatment Period|Lost to Follow-up|0
6224339|NCT01695239|9896179|FG009|Double-Blind (DB) Treatment Period|Lost to Follow-up|0
6224340|NCT01695239|9896180|FG010|Double-Blind (DB) Treatment Period|Lost to Follow-up|0
6224341|NCT01695239|9896181|FG011|Double-Blind (DB) Treatment Period|Lost to Follow-up|0
6224342|NCT01695239|9896182|FG012|Double-Blind (DB) Treatment Period|Lost to Follow-up|0
6224343|NCT01695239|9896183|FG013|Double-Blind (DB) Treatment Period|Lost to Follow-up|0
6224344|NCT01695239|9896170|FG000|Double-Blind (DB) Treatment Period|Protocol Violation|1
6224345|NCT01695239|9896171|FG001|Double-Blind (DB) Treatment Period|Protocol Violation|0
6224346|NCT01695239|9896172|FG002|Double-Blind (DB) Treatment Period|Protocol Violation|0
6224347|NCT01695239|9896173|FG003|Double-Blind (DB) Treatment Period|Protocol Violation|0
6224348|NCT01695239|9896174|FG004|Double-Blind (DB) Treatment Period|Protocol Violation|0
6224349|NCT01695239|9896175|FG005|Double-Blind (DB) Treatment Period|Protocol Violation|0
6224350|NCT01695239|9896176|FG006|Double-Blind (DB) Treatment Period|Protocol Violation|0
6134060|NCT00985621|9762788|FG003|Overall Study|Withdrawal by Subject|12
6134061|NCT00985621|9762785|FG000|Overall Study|Other|1
6134062|NCT00985621|9762786|FG001|Overall Study|Other|0
6134063|NCT00985621|9762787|FG002|Overall Study|Other|0
6134064|NCT00985621|9762788|FG003|Overall Study|Other|0
6134065|NCT00985621|9762785|FG000|Overall Study|Randomized but not Treated|1
6134066|NCT00985621|9762786|FG001|Overall Study|Randomized but not Treated|0
6134067|NCT00985621|9762787|FG002|Overall Study|Randomized but not Treated|2
6134068|NCT00985621|9762788|FG003|Overall Study|Randomized but not Treated|1
6134069|NCT00985673|9762806|FG000|Overall Study|Lost to Follow-up|6
6134070|NCT00985673|9762807|FG001|Overall Study|Lost to Follow-up|7
6134071|NCT00985673|9762808|FG002|Overall Study|Lost to Follow-up|6
6134072|NCT00985673|9762809|FG003|Overall Study|Lost to Follow-up|10
6134073|NCT00985673|9762810|FG004|Overall Study|Lost to Follow-up|5
6134074|NCT00985673|9762811|FG005|Overall Study|Lost to Follow-up|3
6134075|NCT00985673|9762806|FG000|Overall Study|Withdrawal by Subject|0
6134076|NCT00985673|9762807|FG001|Overall Study|Withdrawal by Subject|4
6134077|NCT00985673|9762808|FG002|Overall Study|Withdrawal by Subject|5
6224351|NCT01695239|9896177|FG007|Double-Blind (DB) Treatment Period|Protocol Violation|0
6224352|NCT01695239|9896178|FG008|Double-Blind (DB) Treatment Period|Protocol Violation|0
6224353|NCT01695239|9896179|FG009|Double-Blind (DB) Treatment Period|Protocol Violation|0
6224354|NCT01695239|9896180|FG010|Double-Blind (DB) Treatment Period|Protocol Violation|0
6224355|NCT01695239|9896181|FG011|Double-Blind (DB) Treatment Period|Protocol Violation|0
6224356|NCT01695239|9896182|FG012|Double-Blind (DB) Treatment Period|Protocol Violation|0
6224357|NCT01695239|9896183|FG013|Double-Blind (DB) Treatment Period|Protocol Violation|0
6224358|NCT01695239|9896170|FG000|Placebo Washout (Week 24 Up To Week 32)|Lack of Efficacy|0
6224359|NCT01695239|9896171|FG001|Placebo Washout (Week 24 Up To Week 32)|Lack of Efficacy|0
6224360|NCT01695239|9896172|FG002|Placebo Washout (Week 24 Up To Week 32)|Lack of Efficacy|0
6224361|NCT01695239|9896173|FG003|Placebo Washout (Week 24 Up To Week 32)|Lack of Efficacy|0
6224362|NCT01695239|9896174|FG004|Placebo Washout (Week 24 Up To Week 32)|Lack of Efficacy|0
6224363|NCT01695239|9896175|FG005|Placebo Washout (Week 24 Up To Week 32)|Lack of Efficacy|0
6224364|NCT01695239|9896176|FG006|Placebo Washout (Week 24 Up To Week 32)|Lack of Efficacy|0
6224365|NCT01695239|9896177|FG007|Placebo Washout (Week 24 Up To Week 32)|Lack of Efficacy|9
6224366|NCT01695239|9896178|FG008|Placebo Washout (Week 24 Up To Week 32)|Lack of Efficacy|0
6224367|NCT01695239|9896179|FG009|Placebo Washout (Week 24 Up To Week 32)|Lack of Efficacy|0
6224368|NCT01695239|9896180|FG010|Placebo Washout (Week 24 Up To Week 32)|Lack of Efficacy|0
6224369|NCT01695239|9896181|FG011|Placebo Washout (Week 24 Up To Week 32)|Lack of Efficacy|0
6224370|NCT01695239|9896182|FG012|Placebo Washout (Week 24 Up To Week 32)|Lack of Efficacy|0
6224371|NCT01695239|9896183|FG013|Placebo Washout (Week 24 Up To Week 32)|Lack of Efficacy|0
6224372|NCT01695239|9896170|FG000|Placebo Washout (Week 24 Up To Week 32)|Adverse Event|0
6224373|NCT01695239|9896171|FG001|Placebo Washout (Week 24 Up To Week 32)|Adverse Event|0
6224374|NCT01695239|9896172|FG002|Placebo Washout (Week 24 Up To Week 32)|Adverse Event|0
6224375|NCT01695239|9896173|FG003|Placebo Washout (Week 24 Up To Week 32)|Adverse Event|0
6224376|NCT01695239|9896174|FG004|Placebo Washout (Week 24 Up To Week 32)|Adverse Event|0
6224377|NCT01695239|9896175|FG005|Placebo Washout (Week 24 Up To Week 32)|Adverse Event|0
6224378|NCT01695239|9896176|FG006|Placebo Washout (Week 24 Up To Week 32)|Adverse Event|0
6224379|NCT01695239|9896177|FG007|Placebo Washout (Week 24 Up To Week 32)|Adverse Event|1
6224380|NCT01695239|9896178|FG008|Placebo Washout (Week 24 Up To Week 32)|Adverse Event|0
6224381|NCT01695239|9896179|FG009|Placebo Washout (Week 24 Up To Week 32)|Adverse Event|0
6224382|NCT01695239|9896180|FG010|Placebo Washout (Week 24 Up To Week 32)|Adverse Event|0
6224383|NCT01695239|9896181|FG011|Placebo Washout (Week 24 Up To Week 32)|Adverse Event|0
6224384|NCT01695239|9896182|FG012|Placebo Washout (Week 24 Up To Week 32)|Adverse Event|0
6224385|NCT01695239|9896183|FG013|Placebo Washout (Week 24 Up To Week 32)|Adverse Event|0
6224386|NCT01695239|9896170|FG000|Placebo Washout (Week 24 Up To Week 32)|Entry Criteria Not Met|0
6224387|NCT01695239|9896171|FG001|Placebo Washout (Week 24 Up To Week 32)|Entry Criteria Not Met|0
6224388|NCT01695239|9896172|FG002|Placebo Washout (Week 24 Up To Week 32)|Entry Criteria Not Met|0
6224389|NCT01695239|9896173|FG003|Placebo Washout (Week 24 Up To Week 32)|Entry Criteria Not Met|0
6224390|NCT01695239|9896174|FG004|Placebo Washout (Week 24 Up To Week 32)|Entry Criteria Not Met|0
6224391|NCT01695239|9896175|FG005|Placebo Washout (Week 24 Up To Week 32)|Entry Criteria Not Met|0
6224392|NCT01695239|9896176|FG006|Placebo Washout (Week 24 Up To Week 32)|Entry Criteria Not Met|0
6224393|NCT01695239|9896177|FG007|Placebo Washout (Week 24 Up To Week 32)|Entry Criteria Not Met|1
6224394|NCT01695239|9896178|FG008|Placebo Washout (Week 24 Up To Week 32)|Entry Criteria Not Met|0
6224395|NCT01695239|9896179|FG009|Placebo Washout (Week 24 Up To Week 32)|Entry Criteria Not Met|0
6224396|NCT01695239|9896180|FG010|Placebo Washout (Week 24 Up To Week 32)|Entry Criteria Not Met|0
6224397|NCT01695239|9896181|FG011|Placebo Washout (Week 24 Up To Week 32)|Entry Criteria Not Met|0
6224398|NCT01695239|9896182|FG012|Placebo Washout (Week 24 Up To Week 32)|Entry Criteria Not Met|0
6224399|NCT01695239|9896183|FG013|Placebo Washout (Week 24 Up To Week 32)|Entry Criteria Not Met|0
6224400|NCT01695239|9896170|FG000|Extension Long-Term Extension Periods|Lack of Efficacy|0
6224401|NCT01695239|9896171|FG001|Extension Long-Term Extension Periods|Lack of Efficacy|0
6224402|NCT01695239|9896172|FG002|Extension Long-Term Extension Periods|Lack of Efficacy|0
6224403|NCT01695239|9896173|FG003|Extension Long-Term Extension Periods|Lack of Efficacy|0
6224404|NCT01695239|9896174|FG004|Extension Long-Term Extension Periods|Lack of Efficacy|0
6224405|NCT01695239|9896175|FG005|Extension Long-Term Extension Periods|Lack of Efficacy|0
6134078|NCT00985673|9762809|FG003|Overall Study|Withdrawal by Subject|2
6134079|NCT00985673|9762810|FG004|Overall Study|Withdrawal by Subject|2
6134080|NCT00985673|9762811|FG005|Overall Study|Withdrawal by Subject|3
6134081|NCT00985673|9762806|FG000|Overall Study|Other|1
6134082|NCT00985673|9762807|FG001|Overall Study|Other|0
6134083|NCT00985673|9762808|FG002|Overall Study|Other|1
6134084|NCT00985673|9762809|FG003|Overall Study|Other|0
6134085|NCT00985673|9762810|FG004|Overall Study|Other|1
6134086|NCT00985673|9762811|FG005|Overall Study|Other|0
6134087|NCT00985686|9762830|FG000|Overall Study|Lost to Follow-up|1
6134088|NCT00985686|9762831|FG001|Overall Study|Lost to Follow-up|1
6134089|NCT00985686|9762832|FG002|Overall Study|Lost to Follow-up|0
6134090|NCT00985686|9762833|FG003|Overall Study|Lost to Follow-up|2
6134091|NCT00985712|9762843|FG000|Overall Study|Adverse Event|0
6134092|NCT00985712|9762844|FG001|Overall Study|Adverse Event|1
6134093|NCT00985712|9762843|FG000|Overall Study|Lost to Follow-up|2
6134094|NCT00985712|9762844|FG001|Overall Study|Lost to Follow-up|2
6134095|NCT00985712|9762843|FG000|Overall Study|Protocol Violation|0
6134096|NCT00985712|9762844|FG001|Overall Study|Protocol Violation|1
6134097|NCT00985712|9762843|FG000|Overall Study|Withdrawal by Subject|4
6134098|NCT00985712|9762844|FG001|Overall Study|Withdrawal by Subject|1
6134099|NCT00985712|9762843|FG000|Overall Study|Sponsor decision|0
6134100|NCT00985712|9762844|FG001|Overall Study|Sponsor decision|2
6134101|NCT00985725|9762852|FG000|Overall Study|Adverse Event|4
6134102|NCT00985725|9762853|FG001|Overall Study|Adverse Event|1
6134103|NCT00985725|9762852|FG000|Overall Study|Protocol Violation|1
6134104|NCT00985725|9762853|FG001|Overall Study|Protocol Violation|3
6134105|NCT00985725|9762852|FG000|Overall Study|Withdrawal by Subject|4
6134106|NCT00985725|9762853|FG001|Overall Study|Withdrawal by Subject|4
6134107|NCT00985725|9762852|FG000|Overall Study|Lost to Follow-up|1
6134108|NCT00985725|9762853|FG001|Overall Study|Lost to Follow-up|1
6134109|NCT00985725|9762852|FG000|Overall Study|Lack of Efficacy|0
6134110|NCT00985725|9762853|FG001|Overall Study|Lack of Efficacy|1
6134111|NCT00985725|9762852|FG000|Overall Study|Non-compliance|1
6134112|NCT00985725|9762853|FG001|Overall Study|Non-compliance|2
6134113|NCT00985725|9762852|FG000|Overall Study|Out-of-window visits|0
6134114|NCT00985725|9762853|FG001|Overall Study|Out-of-window visits|1
6134115|NCT00985751|9762864|FG000|Overall Study|Adverse Event|0
6134116|NCT00985751|9762865|FG001|Overall Study|Adverse Event|0
6134117|NCT00985751|9762866|FG002|Overall Study|Adverse Event|0
6134118|NCT00985751|9762867|FG003|Overall Study|Adverse Event|0
6134119|NCT00985751|9762868|FG004|Overall Study|Adverse Event|1
6134120|NCT00985790|9762885|FG000|Overall Study|Withdrawal by Subject|1
6134121|NCT00985790|9762886|FG001|Overall Study|Withdrawal by Subject|1
6134122|NCT00985790|9762885|FG000|Overall Study|Lost to Follow-up|6
6134123|NCT00985790|9762886|FG001|Overall Study|Lost to Follow-up|7
6134124|NCT00985946|9762906|FG000|Overall Study|Lost to Follow-up|6
6134125|NCT00985946|9762906|FG000|Overall Study|Withdrawal by Subject|1
6134126|NCT00985959|9762913|FG000|Overall Study|Adverse Event|0
6134127|NCT00985959|9762914|FG001|Overall Study|Adverse Event|0
6134128|NCT00985959|9762915|FG002|Overall Study|Adverse Event|19
6134129|NCT00985959|9762913|FG000|Overall Study|Withdrawal by Subject|0
6134130|NCT00985959|9762914|FG001|Overall Study|Withdrawal by Subject|0
6134131|NCT00985959|9762915|FG002|Overall Study|Withdrawal by Subject|8
6134132|NCT00985959|9762913|FG000|Overall Study|Progressive disease|1
6134133|NCT00985959|9762914|FG001|Overall Study|Progressive disease|2
6134134|NCT00985959|9762915|FG002|Overall Study|Progressive disease|8
6134135|NCT00985959|9762913|FG000|Overall Study|Unrecovered toxicity|0
6134136|NCT00985959|9762914|FG001|Overall Study|Unrecovered toxicity|0
6134137|NCT00985959|9762915|FG002|Overall Study|Unrecovered toxicity|7
6134138|NCT00985959|9762913|FG000|Overall Study|Pneumonitis or pulmonary fibrosis|2
6134139|NCT00985959|9762914|FG001|Overall Study|Pneumonitis or pulmonary fibrosis|0
6134140|NCT00985959|9762915|FG002|Overall Study|Pneumonitis or pulmonary fibrosis|2
6134141|NCT00985959|9762913|FG000|Overall Study|Complete response observed over 2 cycles|0
6134142|NCT00985959|9762914|FG001|Overall Study|Complete response observed over 2 cycles|1
6134143|NCT00985959|9762915|FG002|Overall Study|Complete response observed over 2 cycles|4
6134144|NCT00985959|9762913|FG000|Overall Study|Other|0
6134145|NCT00985959|9762914|FG001|Overall Study|Other|0
6224406|NCT01695239|9896176|FG006|Extension Long-Term Extension Periods|Lack of Efficacy|0
6224407|NCT01695239|9896177|FG007|Extension Long-Term Extension Periods|Lack of Efficacy|0
6224408|NCT01695239|9896178|FG008|Extension Long-Term Extension Periods|Lack of Efficacy|37
6224409|NCT01695239|9896179|FG009|Extension Long-Term Extension Periods|Lack of Efficacy|31
6224410|NCT01695239|9896180|FG010|Extension Long-Term Extension Periods|Lack of Efficacy|0
6224411|NCT01695239|9896181|FG011|Extension Long-Term Extension Periods|Lack of Efficacy|0
6224412|NCT01695239|9896182|FG012|Extension Long-Term Extension Periods|Lack of Efficacy|0
6134146|NCT00985959|9762915|FG002|Overall Study|Other|11
6134147|NCT00985985|9762933|FG000|Overall Study|Adverse Event|4
6134148|NCT00985985|9762934|FG001|Overall Study|Adverse Event|2
6134149|NCT00985985|9762935|FG002|Overall Study|Adverse Event|2
6134150|NCT00985985|9762936|FG003|Overall Study|Adverse Event|2
6134151|NCT00985985|9762933|FG000|Overall Study|Lost to Follow-up|4
6134152|NCT00985985|9762934|FG001|Overall Study|Lost to Follow-up|11
6134153|NCT00985985|9762935|FG002|Overall Study|Lost to Follow-up|2
6134154|NCT00985985|9762936|FG003|Overall Study|Lost to Follow-up|3
6134155|NCT00985985|9762933|FG000|Overall Study|Protocol Violation|1
6134156|NCT00985985|9762934|FG001|Overall Study|Protocol Violation|2
6134157|NCT00985985|9762935|FG002|Overall Study|Protocol Violation|0
6134158|NCT00985985|9762936|FG003|Overall Study|Protocol Violation|1
6134159|NCT00985985|9762933|FG000|Overall Study|Lack of Efficacy|5
6134160|NCT00985985|9762934|FG001|Overall Study|Lack of Efficacy|6
6134161|NCT00985985|9762935|FG002|Overall Study|Lack of Efficacy|1
6134162|NCT00985985|9762936|FG003|Overall Study|Lack of Efficacy|3
6134163|NCT00985985|9762933|FG000|Overall Study|Withdrawal by Subject|4
6134164|NCT00985985|9762934|FG001|Overall Study|Withdrawal by Subject|2
6134165|NCT00985985|9762935|FG002|Overall Study|Withdrawal by Subject|2
6134166|NCT00985985|9762936|FG003|Overall Study|Withdrawal by Subject|2
6134167|NCT00985985|9762933|FG000|Overall Study|Other Reason|6
6224413|NCT01695239|9896183|FG013|Extension Long-Term Extension Periods|Lack of Efficacy|0
6224414|NCT01695239|9896170|FG000|Extension Long-Term Extension Periods|Adverse Event|0
6224415|NCT01695239|9896171|FG001|Extension Long-Term Extension Periods|Adverse Event|0
6224416|NCT01695239|9896172|FG002|Extension Long-Term Extension Periods|Adverse Event|0
6224417|NCT01695239|9896173|FG003|Extension Long-Term Extension Periods|Adverse Event|0
6224418|NCT01695239|9896174|FG004|Extension Long-Term Extension Periods|Adverse Event|0
6224419|NCT01695239|9896175|FG005|Extension Long-Term Extension Periods|Adverse Event|0
6224420|NCT01695239|9896176|FG006|Extension Long-Term Extension Periods|Adverse Event|0
6224421|NCT01695239|9896177|FG007|Extension Long-Term Extension Periods|Adverse Event|0
6224422|NCT01695239|9896178|FG008|Extension Long-Term Extension Periods|Adverse Event|15
6224423|NCT01695239|9896179|FG009|Extension Long-Term Extension Periods|Adverse Event|21
6224424|NCT01695239|9896180|FG010|Extension Long-Term Extension Periods|Adverse Event|0
6224425|NCT01695239|9896181|FG011|Extension Long-Term Extension Periods|Adverse Event|0
6224426|NCT01695239|9896182|FG012|Extension Long-Term Extension Periods|Adverse Event|0
6224427|NCT01695239|9896183|FG013|Extension Long-Term Extension Periods|Adverse Event|0
6224428|NCT01695239|9896170|FG000|Extension Long-Term Extension Periods|Withdrawal by Subject|0
6224429|NCT01695239|9896171|FG001|Extension Long-Term Extension Periods|Withdrawal by Subject|0
6224430|NCT01695239|9896172|FG002|Extension Long-Term Extension Periods|Withdrawal by Subject|0
6224431|NCT01695239|9896173|FG003|Extension Long-Term Extension Periods|Withdrawal by Subject|0
6224432|NCT01695239|9896174|FG004|Extension Long-Term Extension Periods|Withdrawal by Subject|0
6224433|NCT01695239|9896175|FG005|Extension Long-Term Extension Periods|Withdrawal by Subject|0
6224434|NCT01695239|9896176|FG006|Extension Long-Term Extension Periods|Withdrawal by Subject|0
6224435|NCT01695239|9896177|FG007|Extension Long-Term Extension Periods|Withdrawal by Subject|0
6224436|NCT01695239|9896178|FG008|Extension Long-Term Extension Periods|Withdrawal by Subject|6
6224437|NCT01695239|9896179|FG009|Extension Long-Term Extension Periods|Withdrawal by Subject|7
6224438|NCT01695239|9896180|FG010|Extension Long-Term Extension Periods|Withdrawal by Subject|0
6224439|NCT01695239|9896181|FG011|Extension Long-Term Extension Periods|Withdrawal by Subject|0
6224440|NCT01695239|9896182|FG012|Extension Long-Term Extension Periods|Withdrawal by Subject|0
6224441|NCT01695239|9896183|FG013|Extension Long-Term Extension Periods|Withdrawal by Subject|0
6224442|NCT01695239|9896170|FG000|Extension Long-Term Extension Periods|Physician Decision|0
6224443|NCT01695239|9896171|FG001|Extension Long-Term Extension Periods|Physician Decision|0
6224444|NCT01695239|9896172|FG002|Extension Long-Term Extension Periods|Physician Decision|0
6224445|NCT01695239|9896173|FG003|Extension Long-Term Extension Periods|Physician Decision|0
6224446|NCT01695239|9896174|FG004|Extension Long-Term Extension Periods|Physician Decision|0
6224447|NCT01695239|9896175|FG005|Extension Long-Term Extension Periods|Physician Decision|0
6224448|NCT01695239|9896176|FG006|Extension Long-Term Extension Periods|Physician Decision|0
6224449|NCT01695239|9896177|FG007|Extension Long-Term Extension Periods|Physician Decision|0
6224450|NCT01695239|9896178|FG008|Extension Long-Term Extension Periods|Physician Decision|3
6224451|NCT01695239|9896179|FG009|Extension Long-Term Extension Periods|Physician Decision|0
6224452|NCT01695239|9896180|FG010|Extension Long-Term Extension Periods|Physician Decision|0
6224453|NCT01695239|9896181|FG011|Extension Long-Term Extension Periods|Physician Decision|0
6224454|NCT01695239|9896182|FG012|Extension Long-Term Extension Periods|Physician Decision|0
6224455|NCT01695239|9896183|FG013|Extension Long-Term Extension Periods|Physician Decision|0
6224456|NCT01695239|9896170|FG000|Extension Long-Term Extension Periods|Lost to Follow-up|0
6224457|NCT01695239|9896171|FG001|Extension Long-Term Extension Periods|Lost to Follow-up|0
6224458|NCT01695239|9896172|FG002|Extension Long-Term Extension Periods|Lost to Follow-up|0
6224459|NCT01695239|9896173|FG003|Extension Long-Term Extension Periods|Lost to Follow-up|0
6224460|NCT01695239|9896174|FG004|Extension Long-Term Extension Periods|Lost to Follow-up|0
6224461|NCT01695239|9896175|FG005|Extension Long-Term Extension Periods|Lost to Follow-up|0
6224462|NCT01695239|9896176|FG006|Extension Long-Term Extension Periods|Lost to Follow-up|0
6224463|NCT01695239|9896177|FG007|Extension Long-Term Extension Periods|Lost to Follow-up|0
6224464|NCT01695239|9896178|FG008|Extension Long-Term Extension Periods|Lost to Follow-up|2
6224465|NCT01695239|9896179|FG009|Extension Long-Term Extension Periods|Lost to Follow-up|1
6224466|NCT01695239|9896180|FG010|Extension Long-Term Extension Periods|Lost to Follow-up|0
6224467|NCT01695239|9896181|FG011|Extension Long-Term Extension Periods|Lost to Follow-up|0
6224468|NCT01695239|9896182|FG012|Extension Long-Term Extension Periods|Lost to Follow-up|0
6224469|NCT01695239|9896183|FG013|Extension Long-Term Extension Periods|Lost to Follow-up|0
6224470|NCT01695239|9896170|FG000|Extension Long-Term Extension Periods|Sponsor Decision|0
6224471|NCT01695239|9896171|FG001|Extension Long-Term Extension Periods|Sponsor Decision|0
6224472|NCT01695239|9896172|FG002|Extension Long-Term Extension Periods|Sponsor Decision|0
6290373|NCT02396849|10006330|FG000|Overall Study|Lost to Follow-up|1
6134168|NCT00985985|9762934|FG001|Overall Study|Other Reason|1
6134169|NCT00985985|9762935|FG002|Overall Study|Other Reason|4
6224473|NCT01695239|9896173|FG003|Extension Long-Term Extension Periods|Sponsor Decision|0
6224474|NCT01695239|9896174|FG004|Extension Long-Term Extension Periods|Sponsor Decision|0
6224475|NCT01695239|9896175|FG005|Extension Long-Term Extension Periods|Sponsor Decision|0
6224476|NCT01695239|9896176|FG006|Extension Long-Term Extension Periods|Sponsor Decision|0
6134170|NCT00985985|9762936|FG003|Overall Study|Other Reason|2
6134171|NCT00986102|9762955|FG000|Overall Study|Lost to Follow-up|0
6134172|NCT00986102|9762956|FG001|Overall Study|Lost to Follow-up|1
6134173|NCT00986102|9762957|FG002|Overall Study|Lost to Follow-up|0
6134174|NCT00986102|9762958|FG003|Overall Study|Lost to Follow-up|1
6134175|NCT00986102|9762955|FG000|Overall Study|Withdrawal by Subject|1
6134176|NCT00986102|9762956|FG001|Overall Study|Withdrawal by Subject|1
6134177|NCT00986102|9762957|FG002|Overall Study|Withdrawal by Subject|0
6134178|NCT00986102|9762958|FG003|Overall Study|Withdrawal by Subject|0
6134179|NCT00986154|9762970|FG000|Overall Study|Death|136
6134180|NCT00986154|9762971|FG001|Overall Study|Death|127
6224477|NCT01695239|9896177|FG007|Extension Long-Term Extension Periods|Sponsor Decision|0
6224478|NCT01695239|9896178|FG008|Extension Long-Term Extension Periods|Sponsor Decision|2
6224479|NCT01695239|9896179|FG009|Extension Long-Term Extension Periods|Sponsor Decision|1
6224480|NCT01695239|9896180|FG010|Extension Long-Term Extension Periods|Sponsor Decision|0
6224481|NCT01695239|9896181|FG011|Extension Long-Term Extension Periods|Sponsor Decision|0
6224482|NCT01695239|9896182|FG012|Extension Long-Term Extension Periods|Sponsor Decision|0
6224483|NCT01695239|9896183|FG013|Extension Long-Term Extension Periods|Sponsor Decision|0
6224484|NCT01695239|9896170|FG000|Extension Long-Term Extension Periods|Death|0
6224485|NCT01695239|9896171|FG001|Extension Long-Term Extension Periods|Death|0
6224486|NCT01695239|9896172|FG002|Extension Long-Term Extension Periods|Death|0
6224487|NCT01695239|9896173|FG003|Extension Long-Term Extension Periods|Death|0
6224488|NCT01695239|9896174|FG004|Extension Long-Term Extension Periods|Death|0
6224489|NCT01695239|9896175|FG005|Extension Long-Term Extension Periods|Death|0
6224490|NCT01695239|9896176|FG006|Extension Long-Term Extension Periods|Death|0
6224491|NCT01695239|9896177|FG007|Extension Long-Term Extension Periods|Death|0
6224492|NCT01695239|9896178|FG008|Extension Long-Term Extension Periods|Death|1
6224493|NCT01695239|9896179|FG009|Extension Long-Term Extension Periods|Death|0
6224494|NCT01695239|9896180|FG010|Extension Long-Term Extension Periods|Death|0
6224495|NCT01695239|9896181|FG011|Extension Long-Term Extension Periods|Death|0
6224496|NCT01695239|9896182|FG012|Extension Long-Term Extension Periods|Death|0
6224497|NCT01695239|9896183|FG013|Extension Long-Term Extension Periods|Death|0
6224498|NCT01695239|9896170|FG000|Post-Treatment Follow-Up Period|Withdrawal by Subject|0
6224499|NCT01695239|9896171|FG001|Post-Treatment Follow-Up Period|Withdrawal by Subject|0
6224500|NCT01695239|9896172|FG002|Post-Treatment Follow-Up Period|Withdrawal by Subject|0
6224501|NCT01695239|9896173|FG003|Post-Treatment Follow-Up Period|Withdrawal by Subject|0
6224502|NCT01695239|9896174|FG004|Post-Treatment Follow-Up Period|Withdrawal by Subject|0
6224503|NCT01695239|9896175|FG005|Post-Treatment Follow-Up Period|Withdrawal by Subject|0
6224504|NCT01695239|9896176|FG006|Post-Treatment Follow-Up Period|Withdrawal by Subject|0
6224505|NCT01695239|9896177|FG007|Post-Treatment Follow-Up Period|Withdrawal by Subject|0
6224506|NCT01695239|9896178|FG008|Post-Treatment Follow-Up Period|Withdrawal by Subject|0
6224507|NCT01695239|9896179|FG009|Post-Treatment Follow-Up Period|Withdrawal by Subject|0
6224508|NCT01695239|9896180|FG010|Post-Treatment Follow-Up Period|Withdrawal by Subject|0
6224509|NCT01695239|9896181|FG011|Post-Treatment Follow-Up Period|Withdrawal by Subject|1
6224510|NCT01695239|9896182|FG012|Post-Treatment Follow-Up Period|Withdrawal by Subject|6
6224511|NCT01695239|9896183|FG013|Post-Treatment Follow-Up Period|Withdrawal by Subject|3
6224512|NCT01695239|9896170|FG000|Post-Treatment Follow-Up Period|Lost to Follow-up|0
6224513|NCT01695239|9896171|FG001|Post-Treatment Follow-Up Period|Lost to Follow-up|0
6224514|NCT01695239|9896172|FG002|Post-Treatment Follow-Up Period|Lost to Follow-up|0
6224515|NCT01695239|9896173|FG003|Post-Treatment Follow-Up Period|Lost to Follow-up|0
6224516|NCT01695239|9896174|FG004|Post-Treatment Follow-Up Period|Lost to Follow-up|0
6224517|NCT01695239|9896175|FG005|Post-Treatment Follow-Up Period|Lost to Follow-up|0
6224518|NCT01695239|9896176|FG006|Post-Treatment Follow-Up Period|Lost to Follow-up|0
6224519|NCT01695239|9896177|FG007|Post-Treatment Follow-Up Period|Lost to Follow-up|0
6224520|NCT01695239|9896178|FG008|Post-Treatment Follow-Up Period|Lost to Follow-up|0
6224521|NCT01695239|9896179|FG009|Post-Treatment Follow-Up Period|Lost to Follow-up|0
6224522|NCT01695239|9896180|FG010|Post-Treatment Follow-Up Period|Lost to Follow-up|0
6224523|NCT01695239|9896181|FG011|Post-Treatment Follow-Up Period|Lost to Follow-up|0
6224524|NCT01695239|9896182|FG012|Post-Treatment Follow-Up Period|Lost to Follow-up|1
6224525|NCT01695239|9896183|FG013|Post-Treatment Follow-Up Period|Lost to Follow-up|1
6224526|NCT01695239|9896170|FG000|Post-Treatment Follow-Up Period|Physician Decision|0
6224527|NCT01695239|9896171|FG001|Post-Treatment Follow-Up Period|Physician Decision|0
6224528|NCT01695239|9896172|FG002|Post-Treatment Follow-Up Period|Physician Decision|0
6224529|NCT01695239|9896173|FG003|Post-Treatment Follow-Up Period|Physician Decision|0
6224530|NCT01695239|9896174|FG004|Post-Treatment Follow-Up Period|Physician Decision|0
6224531|NCT01695239|9896175|FG005|Post-Treatment Follow-Up Period|Physician Decision|0
6224532|NCT01695239|9896176|FG006|Post-Treatment Follow-Up Period|Physician Decision|0
6134181|NCT00986154|9762970|FG000|Overall Study|Lost to Follow-up|7
6134182|NCT00986154|9762971|FG001|Overall Study|Lost to Follow-up|4
6134183|NCT00986154|9762970|FG000|Overall Study|Withdrawal by Subject|32
6134184|NCT00986154|9762971|FG001|Overall Study|Withdrawal by Subject|33
6224533|NCT01695239|9896177|FG007|Post-Treatment Follow-Up Period|Physician Decision|0
6224534|NCT01695239|9896178|FG008|Post-Treatment Follow-Up Period|Physician Decision|0
6224535|NCT01695239|9896179|FG009|Post-Treatment Follow-Up Period|Physician Decision|0
6224536|NCT01695239|9896180|FG010|Post-Treatment Follow-Up Period|Physician Decision|0
6224537|NCT01695239|9896181|FG011|Post-Treatment Follow-Up Period|Physician Decision|0
6224538|NCT01695239|9896182|FG012|Post-Treatment Follow-Up Period|Physician Decision|2
6224539|NCT01695239|9896183|FG013|Post-Treatment Follow-Up Period|Physician Decision|0
6224540|NCT01695239|9896170|FG000|Post-Treatment Follow-Up Period|Protocol Violation|0
6224541|NCT01695239|9896171|FG001|Post-Treatment Follow-Up Period|Protocol Violation|0
6224542|NCT01695239|9896172|FG002|Post-Treatment Follow-Up Period|Protocol Violation|0
6224543|NCT01695239|9896173|FG003|Post-Treatment Follow-Up Period|Protocol Violation|0
6224544|NCT01695239|9896174|FG004|Post-Treatment Follow-Up Period|Protocol Violation|0
6224545|NCT01695239|9896175|FG005|Post-Treatment Follow-Up Period|Protocol Violation|0
6224546|NCT01695239|9896176|FG006|Post-Treatment Follow-Up Period|Protocol Violation|0
6224547|NCT01695239|9896177|FG007|Post-Treatment Follow-Up Period|Protocol Violation|0
6224548|NCT01695239|9896178|FG008|Post-Treatment Follow-Up Period|Protocol Violation|0
6224549|NCT01695239|9896179|FG009|Post-Treatment Follow-Up Period|Protocol Violation|0
6224550|NCT01695239|9896180|FG010|Post-Treatment Follow-Up Period|Protocol Violation|0
6224551|NCT01695239|9896181|FG011|Post-Treatment Follow-Up Period|Protocol Violation|0
6224552|NCT01695239|9896182|FG012|Post-Treatment Follow-Up Period|Protocol Violation|0
6224553|NCT01695239|9896183|FG013|Post-Treatment Follow-Up Period|Protocol Violation|1
6224554|NCT01695746|9896250|FG000|Overall Study|Adverse Event|1
6224555|NCT01695746|9896250|FG000|Overall Study|Non-compliance by the participant|3
6224556|NCT01695746|9896250|FG000|Overall Study|Protocol Violation|5
6224557|NCT01695746|9896250|FG000|Overall Study|Participant not willing to participate|3
6224558|NCT01695772|9896255|FG000|Overall Study|Withdrawal by Subject|18
6224559|NCT01695772|9896255|FG000|Overall Study|Progressive Disease|8
6224560|NCT01695772|9896255|FG000|Overall Study|Investigator Decision|5
6224561|NCT01695772|9896255|FG000|Overall Study|Lost to Follow-up|4
6224562|NCT01695772|9896255|FG000|Overall Study|Protocol Violation|2
6224563|NCT01695772|9896255|FG000|Overall Study|Unspecified Reason|1
6224564|NCT01695954|9896261|FG000|Overall Study|Withdrawal by Subject|4
6224565|NCT01695954|9896262|FG001|Overall Study|Withdrawal by Subject|0
6224566|NCT01695954|9896261|FG000|Overall Study|Adverse Event|0
6224567|NCT01695954|9896262|FG001|Overall Study|Adverse Event|2
6224568|NCT01695993|9896273|FG000|Overall Study|Lost to Follow-up|2
6224569|NCT01695993|9896274|FG001|Overall Study|Lost to Follow-up|1
6224570|NCT01695993|9896275|FG002|Overall Study|Lost to Follow-up|3
6224571|NCT01695993|9896273|FG000|Overall Study|Withdrawal by Subject|2
6224572|NCT01695993|9896274|FG001|Overall Study|Withdrawal by Subject|2
6224573|NCT01695993|9896275|FG002|Overall Study|Withdrawal by Subject|2
6224574|NCT01695993|9896273|FG000|Overall Study|To ill to continue|1
6224575|NCT01695993|9896274|FG001|Overall Study|To ill to continue|2
6224576|NCT01695993|9896275|FG002|Overall Study|To ill to continue|0
6224577|NCT01695993|9896273|FG000|Overall Study|Changed Medical Facility|0
6224578|NCT01695993|9896274|FG001|Overall Study|Changed Medical Facility|0
6224579|NCT01695993|9896275|FG002|Overall Study|Changed Medical Facility|1
6224580|NCT01696032|9896287|FG000|Overall Study|Withdrawal by Subject|0
6224581|NCT01696032|9896288|FG001|Overall Study|Withdrawal by Subject|0
6224582|NCT01696032|9896289|FG002|Overall Study|Withdrawal by Subject|1
6224583|NCT01696032|9896290|FG003|Overall Study|Withdrawal by Subject|2
6224584|NCT01696032|9896287|FG000|Overall Study|Death|14
6224585|NCT01696032|9896288|FG001|Overall Study|Death|4
6224586|NCT01696032|9896289|FG002|Overall Study|Death|43
6224587|NCT01696032|9896290|FG003|Overall Study|Death|18
6224588|NCT01696032|9896287|FG000|Overall Study|Lost to Follow-up|0
6224589|NCT01696032|9896288|FG001|Overall Study|Lost to Follow-up|1
6224590|NCT01696032|9896289|FG002|Overall Study|Lost to Follow-up|0
6224591|NCT01696032|9896290|FG003|Overall Study|Lost to Follow-up|0
6224592|NCT01696032|9896287|FG000|Overall Study|Database lock|0
6224593|NCT01696032|9896288|FG001|Overall Study|Database lock|1
6224594|NCT01696032|9896289|FG002|Overall Study|Database lock|7
6224595|NCT01696032|9896290|FG003|Overall Study|Database lock|2
6224596|NCT01696045|9896306|FG000|Overall Study|Study drug toxicity|1
6224597|NCT01696045|9896307|FG001|Overall Study|Study drug toxicity|5
6224598|NCT01696045|9896306|FG000|Overall Study|Disease progression|2
6224599|NCT01696045|9896307|FG001|Overall Study|Disease progression|2
6224600|NCT01696058|9896315|FG000|Overall Study|Adverse Event|21
6224601|NCT01696058|9896316|FG001|Overall Study|Adverse Event|11
6224602|NCT01696058|9896315|FG000|Overall Study|Lack of Efficacy|2
6224603|NCT01696058|9896316|FG001|Overall Study|Lack of Efficacy|3
6224604|NCT01696058|9896315|FG000|Overall Study|Protocol Violation|9
6224605|NCT01696058|9896316|FG001|Overall Study|Protocol Violation|3
6224606|NCT01696058|9896315|FG000|Overall Study|Lost to Follow-up|2
6224607|NCT01696058|9896316|FG001|Overall Study|Lost to Follow-up|5
6134185|NCT00986154|9762970|FG000|Overall Study|investigator/subject decide not continue|6
6134186|NCT00986154|9762971|FG001|Overall Study|investigator/subject decide not continue|3
6134187|NCT00986154|9762970|FG000|Overall Study|never received study drug|25
6134188|NCT00986154|9762971|FG001|Overall Study|never received study drug|27
6134189|NCT00986180|9762979|FG000|Overall Study|Adverse Event|21
6134190|NCT00986180|9762980|FG001|Overall Study|Adverse Event|23
6134191|NCT00986180|9762979|FG000|Overall Study|Lack of Efficacy|4
6134192|NCT00986180|9762980|FG001|Overall Study|Lack of Efficacy|3
6134193|NCT00986180|9762979|FG000|Overall Study|Lost to Follow-up|5
6134194|NCT00986180|9762980|FG001|Overall Study|Lost to Follow-up|7
6134195|NCT00986180|9762979|FG000|Overall Study|Physician Decision|1
6134196|NCT00986180|9762980|FG001|Overall Study|Physician Decision|3
6134197|NCT00986180|9762979|FG000|Overall Study|Protocol Violation|2
6134198|NCT00986180|9762980|FG001|Overall Study|Protocol Violation|0
6134199|NCT00986180|9762979|FG000|Overall Study|Withdrawal by Subject|1
6134200|NCT00986180|9762980|FG001|Overall Study|Withdrawal by Subject|9
6134201|NCT00986180|9762979|FG000|Overall Study|Miscellanies|10
6134202|NCT00986180|9762980|FG001|Overall Study|Miscellanies|11
6134203|NCT00986232|9762990|FG000|Overall Study|Adverse Event|1
6134204|NCT00986232|9762991|FG001|Overall Study|Adverse Event|2
6134205|NCT00986232|9762992|FG002|Overall Study|Adverse Event|3
6134206|NCT00986232|9762993|FG003|Overall Study|Adverse Event|0
6134207|NCT00986232|9762990|FG000|Overall Study|Lost to Follow-up|19
6134208|NCT00986232|9762991|FG001|Overall Study|Lost to Follow-up|12
6134209|NCT00986232|9762992|FG002|Overall Study|Lost to Follow-up|12
6134210|NCT00986232|9762993|FG003|Overall Study|Lost to Follow-up|7
6134211|NCT00986232|9762990|FG000|Overall Study|Protocol Violation|2
6134212|NCT00986232|9762991|FG001|Overall Study|Protocol Violation|3
6134213|NCT00986232|9762992|FG002|Overall Study|Protocol Violation|0
6134214|NCT00986232|9762993|FG003|Overall Study|Protocol Violation|1
6134215|NCT00986232|9762990|FG000|Overall Study|Withdrawal by Subject|13
6134216|NCT00986232|9762991|FG001|Overall Study|Withdrawal by Subject|16
6134217|NCT00986232|9762992|FG002|Overall Study|Withdrawal by Subject|12
6134218|NCT00986232|9762993|FG003|Overall Study|Withdrawal by Subject|3
6134219|NCT00986232|9762990|FG000|Overall Study|Missed one or more bleeds|13
6134220|NCT00986232|9762991|FG001|Overall Study|Missed one or more bleeds|10
6134221|NCT00986232|9762992|FG002|Overall Study|Missed one or more bleeds|6
6134222|NCT00986232|9762993|FG003|Overall Study|Missed one or more bleeds|7
6134223|NCT00986232|9762990|FG000|Overall Study|Incomplete safety follow-up|3
6134224|NCT00986232|9762991|FG001|Overall Study|Incomplete safety follow-up|7
6134225|NCT00986232|9762992|FG002|Overall Study|Incomplete safety follow-up|2
6134226|NCT00986232|9762993|FG003|Overall Study|Incomplete safety follow-up|2
6134227|NCT00986245|9763009|FG000|First Intervention|Poor compliance|8
6134228|NCT00986245|9763010|FG001|First Intervention|Poor compliance|4
6134229|NCT00986245|9763009|FG000|First Intervention|Lack of Efficacy|1
6134230|NCT00986245|9763010|FG001|First Intervention|Lack of Efficacy|2
6134231|NCT00986245|9763009|FG000|First Intervention|Withdrawal by Subject|0
6134232|NCT00986245|9763010|FG001|First Intervention|Withdrawal by Subject|1
6134233|NCT00986245|9763009|FG000|First Intervention|Protocol Violation|0
6134234|NCT00986245|9763010|FG001|First Intervention|Protocol Violation|1
6134235|NCT00986245|9763009|FG000|First Intervention|Out of indication|1
6134236|NCT00986245|9763010|FG001|First Intervention|Out of indication|0
6134237|NCT00986245|9763009|FG000|Second Intervention|Poor compliance|1
6134238|NCT00986245|9763010|FG001|Second Intervention|Poor compliance|0
6134239|NCT00986245|9763009|FG000|Second Intervention|Lost to Follow-up|1
6134240|NCT00986245|9763010|FG001|Second Intervention|Lost to Follow-up|0
6134241|NCT00986245|9763009|FG000|Second Intervention|Protocol Violation|0
6134242|NCT00986245|9763010|FG001|Second Intervention|Protocol Violation|1
6134243|NCT00986258|9763021|FG000|Observation Period|Not eligible to be dosed|11
6224608|NCT01696058|9896315|FG000|Overall Study|Withdrawal by Subject|4
6224609|NCT01696058|9896316|FG001|Overall Study|Withdrawal by Subject|6
6224610|NCT01696058|9896315|FG000|Overall Study|Other reason prematurely discontinued|5
6224611|NCT01696058|9896316|FG001|Overall Study|Other reason prematurely discontinued|3
6224612|NCT01696071|9896322|FG000|Treatment Period 2: 4 Weeks|Adverse Event|1
6224613|NCT01696071|9896323|FG001|Treatment Period 2: 4 Weeks|Adverse Event|0
6290374|NCT02396849|10006331|FG001|Overall Study|Lost to Follow-up|1
6290375|NCT02396849|10006330|FG000|Overall Study|Did not tolerate intervention|1
6290376|NCT02396849|10006331|FG001|Overall Study|Did not tolerate intervention|1
6290377|NCT02396953|10006342|FG000|Overall Study|Withdrawal by Subject|0
6290378|NCT02396953|10006343|FG001|Overall Study|Withdrawal by Subject|0
6290379|NCT02396953|10006344|FG002|Overall Study|Withdrawal by Subject|1
6290380|NCT02396953|10006342|FG000|Overall Study|Insulin like Growth Factor-1 increased|3
6134244|NCT00986258|9763021|FG000|Titration and Optimal Dose Period|Adverse Event|15
6134245|NCT00986258|9763021|FG000|Titration and Optimal Dose Period|Lack of Efficacy|3
6134246|NCT00986258|9763021|FG000|Titration and Optimal Dose Period|Withdrawal by Subject|3
6134247|NCT00986258|9763021|FG000|Titration and Optimal Dose Period|Non-Compliance|1
6134248|NCT00986258|9763021|FG000|Titration and Optimal Dose Period|Other|1
6134249|NCT00986258|9763021|FG000|Maintenance Period|Adverse Event|5
6134250|NCT00986258|9763021|FG000|Maintenance Period|Lack of Efficacy|2
6134251|NCT00986258|9763021|FG000|Maintenance Period|Withdrawal by Subject|2
6224614|NCT01696188|9896341|FG000|Overall Study|Protocol Violation|1
6290381|NCT02396953|10006343|FG001|Overall Study|Insulin like Growth Factor-1 increased|2
6290382|NCT02396953|10006344|FG002|Overall Study|Insulin like Growth Factor-1 increased|2
6290383|NCT02396953|10006342|FG000|Overall Study|Personal Reasons|1
6134252|NCT00986349|9763035|FG000|Overall Study|Unsuccessful implant procedure|3
6134253|NCT00986349|9763035|FG000|Overall Study|Adverse Event|2
6134254|NCT00986349|9763035|FG000|Overall Study|Physician Decision|1
6134255|NCT00986349|9763035|FG000|Overall Study|device migration|1
6134256|NCT00986362|9763050|FG000|Overall Study|Death|2
6134257|NCT00986362|9763051|FG001|Overall Study|Death|0
6134258|NCT00986362|9763050|FG000|Overall Study|Lost to Follow-up|0
6134259|NCT00986362|9763051|FG001|Overall Study|Lost to Follow-up|1
6134260|NCT00986427|9763071|FG000|Overall Study|Lost to Follow-up|2
6134261|NCT00986427|9763072|FG001|Overall Study|Lost to Follow-up|0
6134262|NCT00986427|9763071|FG000|Overall Study|Lack of Efficacy|1
6134263|NCT00986427|9763072|FG001|Overall Study|Lack of Efficacy|0
6134264|NCT00986427|9763071|FG000|Overall Study|Withdrawal by Subject|1
6134265|NCT00986427|9763072|FG001|Overall Study|Withdrawal by Subject|0
6134266|NCT00986440|9763084|FG000|Overall Study|Progressive disease|27
6134267|NCT00986440|9763085|FG001|Overall Study|Progressive disease|37
6134268|NCT00986440|9763084|FG000|Overall Study|Serious adverse event or adverse event|9
6134269|NCT00986440|9763085|FG001|Overall Study|Serious adverse event or adverse event|2
6134270|NCT00986440|9763084|FG000|Overall Study|Withdrawal by Subject|1
6134271|NCT00986440|9763085|FG001|Overall Study|Withdrawal by Subject|2
6134272|NCT00986440|9763084|FG000|Overall Study|Screen failure (not dosed)|4
6134273|NCT00986440|9763085|FG001|Overall Study|Screen failure (not dosed)|2
6134274|NCT00986479|9763099|FG000|Period 1|Improved mood|1
6134275|NCT00986479|9763100|FG001|Period 1|Improved mood|0
6134276|NCT00986479|9763099|FG000|Period 1|Administrative reasons|1
6134277|NCT00986479|9763100|FG001|Period 1|Administrative reasons|0
6134278|NCT00986570|9763116|FG000|Overall Study|Lost to Follow-up|6
6134279|NCT00986570|9763116|FG000|Overall Study|Potential bias for objective assessment|1
6134280|NCT00986674|9763133|FG000|Overall Study|Lack of Efficacy|28
6134281|NCT00986674|9763134|FG001|Overall Study|Lack of Efficacy|25
6134282|NCT00986674|9763135|FG002|Overall Study|Lack of Efficacy|23
6134283|NCT00986674|9763133|FG000|Overall Study|Adverse Event|4
6224615|NCT01696188|9896342|FG001|Overall Study|Protocol Violation|1
6224616|NCT01696214|9896352|FG000|Overall Study|Lost to Follow-up|1
6224617|NCT01696214|9896353|FG001|Overall Study|Lost to Follow-up|0
6224618|NCT01696214|9896354|FG002|Overall Study|Lost to Follow-up|0
6224619|NCT01696214|9896355|FG003|Overall Study|Lost to Follow-up|0
6224620|NCT01696279|9896373|FG000|Part 1: Single Dose Lanthanum Carbonate|Kidney Transplant|1
6224621|NCT01696279|9896374|FG001|Part 1: Single Dose Lanthanum Carbonate|Kidney Transplant|0
6224622|NCT01696279|9896375|FG002|Part 1: Single Dose Lanthanum Carbonate|Kidney Transplant|0
6224623|NCT01696279|9896376|FG003|Part 1: Single Dose Lanthanum Carbonate|Kidney Transplant|0
6224624|NCT01696279|9896373|FG000|Part 2a: Calcium Carbonate + Lanthanum|Adverse Event|0
6224625|NCT01696279|9896374|FG001|Part 2a: Calcium Carbonate + Lanthanum|Adverse Event|5
6224626|NCT01696279|9896375|FG002|Part 2a: Calcium Carbonate + Lanthanum|Adverse Event|0
6224627|NCT01696279|9896376|FG003|Part 2a: Calcium Carbonate + Lanthanum|Adverse Event|0
6224628|NCT01696279|9896373|FG000|Part 2a: Calcium Carbonate + Lanthanum|Withdrawal by Subject|0
6224629|NCT01696279|9896374|FG001|Part 2a: Calcium Carbonate + Lanthanum|Withdrawal by Subject|1
6224630|NCT01696279|9896375|FG002|Part 2a: Calcium Carbonate + Lanthanum|Withdrawal by Subject|0
6224631|NCT01696279|9896376|FG003|Part 2a: Calcium Carbonate + Lanthanum|Withdrawal by Subject|0
6290384|NCT02396953|10006343|FG001|Overall Study|Personal Reasons|1
6290385|NCT02396953|10006344|FG002|Overall Study|Personal Reasons|0
6290386|NCT02397057|10006361|FG000|Overall Study|Withdrawal by Subject|6
6290387|NCT02397057|10006362|FG001|Overall Study|Withdrawal by Subject|7
6290388|NCT02397057|10006361|FG000|Overall Study|Lost to Follow-up|4
6290389|NCT02397057|10006362|FG001|Overall Study|Lost to Follow-up|3
6290390|NCT02397057|10006361|FG000|Overall Study|Death|1
6134284|NCT00986674|9763134|FG001|Overall Study|Adverse Event|8
6134285|NCT00986674|9763135|FG002|Overall Study|Adverse Event|9
6134286|NCT00986674|9763133|FG000|Overall Study|Death|5
6134287|NCT00986674|9763134|FG001|Overall Study|Death|0
6290391|NCT02397057|10006362|FG001|Overall Study|Death|0
6290392|NCT02397057|10006361|FG000|Overall Study|Adverse Event|0
6290393|NCT02397057|10006362|FG001|Overall Study|Adverse Event|1
6290394|NCT02397057|10006361|FG000|Overall Study|Physician Decision|0
6290395|NCT02397057|10006362|FG001|Overall Study|Physician Decision|1
6290396|NCT02397057|10006361|FG000|Overall Study|Subject did not receive study drug|0
6290397|NCT02397057|10006362|FG001|Overall Study|Subject did not receive study drug|1
6290398|NCT02397096|10006370|FG000|Day 1 to Week 24|Adverse Event|7
6290399|NCT02397096|10006371|FG001|Day 1 to Week 24|Adverse Event|1
6290400|NCT02397096|10006370|FG000|Day 1 to Week 24|Death|1
6290401|NCT02397096|10006371|FG001|Day 1 to Week 24|Death|0
6290402|NCT02397096|10006370|FG000|Day 1 to Week 24|Lack of Efficacy|0
6290403|NCT02397096|10006371|FG001|Day 1 to Week 24|Lack of Efficacy|1
6290404|NCT02397096|10006370|FG000|Day 1 to Week 24|Lost to Follow-up|3
6290405|NCT02397096|10006371|FG001|Day 1 to Week 24|Lost to Follow-up|4
6290406|NCT02397096|10006370|FG000|Day 1 to Week 24|Physician Decision|2
6290407|NCT02397096|10006371|FG001|Day 1 to Week 24|Physician Decision|3
6290408|NCT02397096|10006370|FG000|Day 1 to Week 24|Protocol Violation|1
6134288|NCT00986674|9763135|FG002|Overall Study|Death|4
6134289|NCT00986674|9763133|FG000|Overall Study|Withdrawal by Subject|6
6134290|NCT00986674|9763134|FG001|Overall Study|Withdrawal by Subject|2
6134291|NCT00986674|9763135|FG002|Overall Study|Withdrawal by Subject|1
6134292|NCT00986674|9763133|FG000|Overall Study|alternative therapy|0
6134293|NCT00986674|9763134|FG001|Overall Study|alternative therapy|0
6134294|NCT00986674|9763135|FG002|Overall Study|alternative therapy|1
6134295|NCT00986674|9763133|FG000|Overall Study|not start protocol therapy|4
6134296|NCT00986674|9763134|FG001|Overall Study|not start protocol therapy|3
6134297|NCT00986674|9763135|FG002|Overall Study|not start protocol therapy|1
6134298|NCT00986674|9763133|FG000|Overall Study|unknown/not specify|0
6134299|NCT00986674|9763134|FG001|Overall Study|unknown/not specify|7
6134300|NCT00986674|9763135|FG002|Overall Study|unknown/not specify|9
6134301|NCT00986830|9763143|FG000|Overall Study|Death|1
6134302|NCT00986830|9763143|FG000|Overall Study|Lost to Follow-up|1
6134303|NCT00986830|9763143|FG000|Overall Study|Lack of Efficacy|1
6134304|NCT00986830|9763143|FG000|Overall Study|Unable to access sinus with device|5
6134305|NCT00986921|9763158|FG000|Overall Study|Physician Decision|1
6134306|NCT00986921|9763159|FG001|Overall Study|Physician Decision|0
6134307|NCT00986973|9763168|FG000|Overall Study|Withdrawn by study team|1
6134308|NCT00986986|9763175|FG000|Overall Study|Lost to Follow-up|0
6134309|NCT00986986|9763176|FG001|Overall Study|Lost to Follow-up|1
6134310|NCT00987337|9763186|FG000|Overall Study|Adverse Event|10
6134311|NCT00987337|9763187|FG001|Overall Study|Adverse Event|9
6134312|NCT00987337|9763188|FG002|Overall Study|Adverse Event|8
6134313|NCT00987337|9763186|FG000|Overall Study|Insufficient Virologic Response|10
6134314|NCT00987337|9763187|FG001|Overall Study|Insufficient Virologic Response|7
6134315|NCT00987337|9763188|FG002|Overall Study|Insufficient Virologic Response|12
6134316|NCT00987337|9763186|FG000|Overall Study|Virologic Breakthrough|2
6134317|NCT00987337|9763187|FG001|Overall Study|Virologic Breakthrough|2
6134318|NCT00987337|9763188|FG002|Overall Study|Virologic Breakthrough|8
6134319|NCT00987337|9763186|FG000|Overall Study|Lost to Follow-up|10
6134320|NCT00987337|9763187|FG001|Overall Study|Lost to Follow-up|6
6134321|NCT00987337|9763188|FG002|Overall Study|Lost to Follow-up|2
6134322|NCT00987337|9763186|FG000|Overall Study|Withdrawal by Subject|6
6134323|NCT00987337|9763187|FG001|Overall Study|Withdrawal by Subject|9
6134324|NCT00987337|9763188|FG002|Overall Study|Withdrawal by Subject|9
6134325|NCT00987337|9763186|FG000|Overall Study|Other|0
6134326|NCT00987337|9763187|FG001|Overall Study|Other|2
6134327|NCT00987337|9763188|FG002|Overall Study|Other|5
6134328|NCT00987337|9763186|FG000|Overall Study|Protocol Violation|1
6134329|NCT00987337|9763187|FG001|Overall Study|Protocol Violation|0
6134330|NCT00987337|9763188|FG002|Overall Study|Protocol Violation|2
6134331|NCT00987337|9763186|FG000|Overall Study|Participant Relapsed|18
6134332|NCT00987337|9763187|FG001|Overall Study|Participant Relapsed|20
6134333|NCT00987337|9763188|FG002|Overall Study|Participant Relapsed|5
6134334|NCT00987389|9763200|FG000|Overall Study|Ineligible|0
6134335|NCT00987389|9763201|FG001|Overall Study|Ineligible|3
6224632|NCT01696279|9896373|FG000|Part 2a: Calcium Carbonate + Lanthanum|Protocol Violation|0
6224633|NCT01696279|9896374|FG001|Part 2a: Calcium Carbonate + Lanthanum|Protocol Violation|1
6224634|NCT01696279|9896375|FG002|Part 2a: Calcium Carbonate + Lanthanum|Protocol Violation|0
6224635|NCT01696279|9896376|FG003|Part 2a: Calcium Carbonate + Lanthanum|Protocol Violation|0
6224636|NCT01696279|9896373|FG000|Part 2a: Calcium Carbonate + Lanthanum|Other (Unspecified)|0
6224637|NCT01696279|9896374|FG001|Part 2a: Calcium Carbonate + Lanthanum|Other (Unspecified)|3
6224638|NCT01696279|9896375|FG002|Part 2a: Calcium Carbonate + Lanthanum|Other (Unspecified)|0
6224639|NCT01696279|9896376|FG003|Part 2a: Calcium Carbonate + Lanthanum|Other (Unspecified)|0
6224640|NCT01696279|9896373|FG000|Part 2a: Calcium Carbonate + Lanthanum|Kidney Transplant|0
6224641|NCT01696279|9896374|FG001|Part 2a: Calcium Carbonate + Lanthanum|Kidney Transplant|7
6224642|NCT01696279|9896375|FG002|Part 2a: Calcium Carbonate + Lanthanum|Kidney Transplant|0
6224643|NCT01696279|9896376|FG003|Part 2a: Calcium Carbonate + Lanthanum|Kidney Transplant|0
6224644|NCT01696279|9896373|FG000|Part 2a: Calcium Carbonate + Lanthanum|Non-Compliance with Study Drug|0
6224645|NCT01696279|9896374|FG001|Part 2a: Calcium Carbonate + Lanthanum|Non-Compliance with Study Drug|2
6224646|NCT01696279|9896375|FG002|Part 2a: Calcium Carbonate + Lanthanum|Non-Compliance with Study Drug|0
6224647|NCT01696279|9896376|FG003|Part 2a: Calcium Carbonate + Lanthanum|Non-Compliance with Study Drug|0
6224648|NCT01696279|9896373|FG000|Part 2b: Lanthanum Carbonate (8 Weeks)|Kidney Transplant|0
6224649|NCT01696279|9896374|FG001|Part 2b: Lanthanum Carbonate (8 Weeks)|Kidney Transplant|0
6224650|NCT01696279|9896375|FG002|Part 2b: Lanthanum Carbonate (8 Weeks)|Kidney Transplant|1
6224651|NCT01696279|9896376|FG003|Part 2b: Lanthanum Carbonate (8 Weeks)|Kidney Transplant|0
6224652|NCT01696279|9896373|FG000|Part 3: Lanthanum Carbonate (6 Months)|Kidney transplant|0
6224653|NCT01696279|9896374|FG001|Part 3: Lanthanum Carbonate (6 Months)|Kidney transplant|0
6224654|NCT01696279|9896375|FG002|Part 3: Lanthanum Carbonate (6 Months)|Kidney transplant|0
6224655|NCT01696279|9896376|FG003|Part 3: Lanthanum Carbonate (6 Months)|Kidney transplant|6
6224656|NCT01696279|9896373|FG000|Part 3: Lanthanum Carbonate (6 Months)|Other (Unspecified)|0
6224657|NCT01696279|9896374|FG001|Part 3: Lanthanum Carbonate (6 Months)|Other (Unspecified)|0
6290409|NCT02397096|10006371|FG001|Day 1 to Week 24|Protocol Violation|4
6290410|NCT02397096|10006370|FG000|Day 1 to Week 24|Withdrawal by Subject|6
6290411|NCT02397096|10006371|FG001|Day 1 to Week 24|Withdrawal by Subject|1
6290412|NCT02397096|10006370|FG000|Week 24 to Week 48|Adverse Event|6
6134336|NCT00987389|9763202|FG002|Overall Study|Ineligible|0
6134337|NCT00987389|9763203|FG003|Overall Study|Ineligible|0
6134338|NCT00987389|9763200|FG000|Overall Study|Lost to Follow-up|4
6134339|NCT00987389|9763201|FG001|Overall Study|Lost to Follow-up|1
6134340|NCT00987389|9763202|FG002|Overall Study|Lost to Follow-up|3
6134341|NCT00987389|9763203|FG003|Overall Study|Lost to Follow-up|1
6134342|NCT00987389|9763200|FG000|Overall Study|Withdrawal by Subject|4
6134343|NCT00987389|9763201|FG001|Overall Study|Withdrawal by Subject|3
6134344|NCT00987389|9763202|FG002|Overall Study|Withdrawal by Subject|2
6134345|NCT00987389|9763203|FG003|Overall Study|Withdrawal by Subject|1
6134346|NCT00987389|9763200|FG000|Overall Study|Withdrawn from Treatment|0
6134347|NCT00987389|9763201|FG001|Overall Study|Withdrawn from Treatment|1
6134348|NCT00987389|9763202|FG002|Overall Study|Withdrawn from Treatment|0
6134349|NCT00987389|9763203|FG003|Overall Study|Withdrawn from Treatment|0
6134350|NCT00987389|9763200|FG000|Overall Study|Multiple different reasons|1
6134351|NCT00987389|9763201|FG001|Overall Study|Multiple different reasons|0
6134352|NCT00987389|9763202|FG002|Overall Study|Multiple different reasons|3
6134353|NCT00987389|9763203|FG003|Overall Study|Multiple different reasons|1
6134354|NCT00987402|9763213|FG000|Overall Study|Insufficient data entry|86
6134355|NCT00987402|9763214|FG001|Overall Study|Insufficient data entry|98
6134356|NCT00987467|9763229|FG000|Overall Study|Lost to Follow-up|2
6134357|NCT00987623|9763248|FG000|Overall Study|Lost to Follow-up|2
6134358|NCT00987623|9763249|FG001|Overall Study|Lost to Follow-up|1
6134359|NCT00987623|9763248|FG000|Overall Study|Time/job conflict|2
6134360|NCT00987623|9763249|FG001|Overall Study|Time/job conflict|0
6134361|NCT00987623|9763248|FG000|Overall Study|Discomfort|1
6134362|NCT00987623|9763249|FG001|Overall Study|Discomfort|0
6134363|NCT00987623|9763248|FG000|Overall Study|Biomicroscopy|0
6134364|NCT00987623|9763249|FG001|Overall Study|Biomicroscopy|1
6134365|NCT00987623|9763248|FG000|Overall Study|Influenza|0
6134366|NCT00987623|9763249|FG001|Overall Study|Influenza|1
6134367|NCT00987831|9763267|FG000|Overall Study|Never flared in 12 months|1
6134368|NCT00987831|9763268|FG001|Overall Study|Never flared in 12 months|0
6134369|NCT00987831|9763269|FG002|Overall Study|Never flared in 12 months|0
6134370|NCT00987831|9763267|FG000|Overall Study|Lost to Follow-up|0
6134371|NCT00987831|9763268|FG001|Overall Study|Lost to Follow-up|3
6134372|NCT00987831|9763269|FG002|Overall Study|Lost to Follow-up|0
6134373|NCT00987935|9763287|FG000|Overall Study|Progressive disease|3
6134374|NCT00987935|9763288|FG001|Overall Study|Progressive disease|2
6134375|NCT00987935|9763289|FG002|Overall Study|Progressive disease|3
6134376|NCT00987935|9763290|FG003|Overall Study|Progressive disease|2
6134377|NCT00987935|9763291|FG004|Overall Study|Progressive disease|5
6134378|NCT00987935|9763292|FG005|Overall Study|Progressive disease|3
6134379|NCT00987935|9763293|FG006|Overall Study|Progressive disease|9
6134380|NCT00987935|9763294|FG007|Overall Study|Progressive disease|48
6134381|NCT00987935|9763295|FG008|Overall Study|Progressive disease|23
6134382|NCT00987935|9763287|FG000|Overall Study|Adverse Event|0
6134383|NCT00987935|9763288|FG001|Overall Study|Adverse Event|1
6134384|NCT00987935|9763289|FG002|Overall Study|Adverse Event|0
6134385|NCT00987935|9763290|FG003|Overall Study|Adverse Event|1
6134386|NCT00987935|9763291|FG004|Overall Study|Adverse Event|1
6134387|NCT00987935|9763292|FG005|Overall Study|Adverse Event|0
6134388|NCT00987935|9763293|FG006|Overall Study|Adverse Event|2
6134389|NCT00987935|9763294|FG007|Overall Study|Adverse Event|10
6134390|NCT00987935|9763295|FG008|Overall Study|Adverse Event|6
6134391|NCT00987935|9763287|FG000|Overall Study|Refused to continue taking trial med.|1
6134392|NCT00987935|9763288|FG001|Overall Study|Refused to continue taking trial med.|0
6134393|NCT00987935|9763289|FG002|Overall Study|Refused to continue taking trial med.|0
6134394|NCT00987935|9763290|FG003|Overall Study|Refused to continue taking trial med.|0
6134395|NCT00987935|9763291|FG004|Overall Study|Refused to continue taking trial med.|1
6134396|NCT00987935|9763292|FG005|Overall Study|Refused to continue taking trial med.|0
6134397|NCT00987935|9763293|FG006|Overall Study|Refused to continue taking trial med.|4
6134398|NCT00987935|9763294|FG007|Overall Study|Refused to continue taking trial med.|4
6134399|NCT00987935|9763295|FG008|Overall Study|Refused to continue taking trial med.|2
6134400|NCT00987935|9763287|FG000|Overall Study|Reason other than those specified above|0
6134401|NCT00987935|9763288|FG001|Overall Study|Reason other than those specified above|0
6134402|NCT00987935|9763289|FG002|Overall Study|Reason other than those specified above|0
6134403|NCT00987935|9763290|FG003|Overall Study|Reason other than those specified above|0
6134404|NCT00987935|9763291|FG004|Overall Study|Reason other than those specified above|0
6134405|NCT00987935|9763292|FG005|Overall Study|Reason other than those specified above|0
6134406|NCT00987935|9763293|FG006|Overall Study|Reason other than those specified above|0
6134407|NCT00987935|9763294|FG007|Overall Study|Reason other than those specified above|0
6134408|NCT00987935|9763295|FG008|Overall Study|Reason other than those specified above|1
6134409|NCT00988065|9763362|FG000|Overall Study|Adverse Event|4
6134410|NCT00988065|9763363|FG001|Overall Study|Adverse Event|10
6134411|NCT00988065|9763364|FG002|Overall Study|Adverse Event|2
6134412|NCT00988065|9763362|FG000|Overall Study|Lost to Follow-up|1
6134413|NCT00988065|9763363|FG001|Overall Study|Lost to Follow-up|2
6134414|NCT00988065|9763364|FG002|Overall Study|Lost to Follow-up|2
6134415|NCT00988065|9763362|FG000|Overall Study|Subject withdrew consent|3
6224658|NCT01696279|9896375|FG002|Part 3: Lanthanum Carbonate (6 Months)|Other (Unspecified)|0
6224659|NCT01696279|9896376|FG003|Part 3: Lanthanum Carbonate (6 Months)|Other (Unspecified)|1
6290413|NCT02397096|10006371|FG001|Week 24 to Week 48|Adverse Event|2
6134416|NCT00988065|9763363|FG001|Overall Study|Subject withdrew consent|5
6134417|NCT00988065|9763364|FG002|Overall Study|Subject withdrew consent|2
6134418|NCT00988065|9763362|FG000|Overall Study|Noncompliance with protocol|5
6134419|NCT00988065|9763363|FG001|Overall Study|Noncompliance with protocol|6
6134420|NCT00988065|9763364|FG002|Overall Study|Noncompliance with protocol|9
6134421|NCT00988091|9763374|FG000|Double-blind Period|Withdrawal by Subject|15
6134422|NCT00988091|9763375|FG001|Double-blind Period|Withdrawal by Subject|13
6134423|NCT00988091|9763374|FG000|Double-blind Period|Lost to Follow-up|12
6134424|NCT00988091|9763375|FG001|Double-blind Period|Lost to Follow-up|14
6134425|NCT00988091|9763374|FG000|Double-blind Period|Other|8
6134426|NCT00988091|9763375|FG001|Double-blind Period|Other|8
6134427|NCT00988091|9763374|FG000|Double-blind Period|Adverse Event|6
6134428|NCT00988091|9763375|FG001|Double-blind Period|Adverse Event|9
6134429|NCT00988091|9763374|FG000|Double-blind Period|Use of exclusionary medication|2
6134430|NCT00988091|9763375|FG001|Double-blind Period|Use of exclusionary medication|3
6134431|NCT00988091|9763374|FG000|Open-label Period|Adverse Event|4
6134432|NCT00988091|9763375|FG001|Open-label Period|Adverse Event|7
6134433|NCT00988091|9763374|FG000|Open-label Period|Use of exclusionary medication|1
6134434|NCT00988091|9763375|FG001|Open-label Period|Use of exclusionary medication|1
6134435|NCT00988091|9763374|FG000|Open-label Period|Protocol Violation|1
6134436|NCT00988091|9763375|FG001|Open-label Period|Protocol Violation|1
6134437|NCT00988091|9763374|FG000|Open-label Period|Withdrawal by Subject|10
6134438|NCT00988091|9763375|FG001|Open-label Period|Withdrawal by Subject|16
6134439|NCT00988091|9763374|FG000|Open-label Period|Lost to Follow-up|3
6134440|NCT00988091|9763375|FG001|Open-label Period|Lost to Follow-up|5
6134441|NCT00988091|9763374|FG000|Open-label Period|Other|2
6134442|NCT00988091|9763375|FG001|Open-label Period|Other|3
6134443|NCT00988117|9763382|FG000|4.6 mg/24 Hours From Baseline to Week 4|Adverse Event|1
6134444|NCT00988117|9763382|FG000|9.5 mg/24 Hours From Week 4 to 12|Adverse Event|2
6134445|NCT00988169|9763409|FG000|Overall Study|Withdrawal by Subject|1
6134446|NCT00988208|9763415|FG000|Overall Study|Adverse Event|71
6134447|NCT00988208|9763416|FG001|Overall Study|Adverse Event|122
6134448|NCT00988208|9763415|FG000|Overall Study|Disease Progression|103
6134449|NCT00988208|9763416|FG001|Overall Study|Disease Progression|89
6134450|NCT00988208|9763415|FG000|Overall Study|Withdrawal by Subject|50
6134451|NCT00988208|9763416|FG001|Overall Study|Withdrawal by Subject|57
6134452|NCT00988208|9763415|FG000|Overall Study|Death|9
6134453|NCT00988208|9763416|FG001|Overall Study|Death|15
6134454|NCT00988208|9763415|FG000|Overall Study|Lost to Follow-up|2
6134455|NCT00988208|9763416|FG001|Overall Study|Lost to Follow-up|3
6134456|NCT00988208|9763415|FG000|Overall Study|Protocol Violation|9
6134457|NCT00988208|9763416|FG001|Overall Study|Protocol Violation|2
6134458|NCT00988208|9763415|FG000|Overall Study|Sponsor Decision|102
6134459|NCT00988208|9763416|FG001|Overall Study|Sponsor Decision|78
6134460|NCT00988208|9763415|FG000|Overall Study|Clinical Progression|17
6134461|NCT00988208|9763416|FG001|Overall Study|Clinical Progression|16
6134462|NCT00988208|9763415|FG000|Overall Study|Biochemical Progression|21
6134463|NCT00988208|9763416|FG001|Overall Study|Biochemical Progression|7
6134464|NCT00988208|9763415|FG000|Overall Study|Clinical Deterioration|7
6134465|NCT00988208|9763416|FG001|Overall Study|Clinical Deterioration|14
6134466|NCT00988208|9763415|FG000|Overall Study|Subject Decision/Investigator Discretion|32
6134467|NCT00988208|9763416|FG001|Overall Study|Subject Decision/Investigator Discretion|32
6134468|NCT00988208|9763415|FG000|Overall Study|Other|8
6134469|NCT00988208|9763416|FG001|Overall Study|Other|3
6134470|NCT00988221|9763425|FG000|Part I|Adverse Event|0
6134471|NCT00988221|9763426|FG001|Part I|Adverse Event|1
6134472|NCT00988221|9763427|FG002|Part I|Adverse Event|2
6134473|NCT00988221|9763428|FG003|Part I|Adverse Event|0
6134474|NCT00988221|9763425|FG000|Part I|Insufficient Therapeutic Response|4
6134475|NCT00988221|9763426|FG001|Part I|Insufficient Therapeutic Response|6
6134476|NCT00988221|9763427|FG002|Part I|Insufficient Therapeutic Response|5
6134477|NCT00988221|9763428|FG003|Part I|Insufficient Therapeutic Response|0
6134478|NCT00988221|9763425|FG000|Part I|Refused Treatment|0
6134479|NCT00988221|9763426|FG001|Part I|Refused Treatment|2
6134480|NCT00988221|9763427|FG002|Part I|Refused Treatment|1
6134481|NCT00988221|9763428|FG003|Part I|Refused Treatment|0
6134482|NCT00988221|9763425|FG000|Part I|Lost to Follow-up|0
6134483|NCT00988221|9763426|FG001|Part I|Lost to Follow-up|1
6134484|NCT00988221|9763427|FG002|Part I|Lost to Follow-up|0
6134485|NCT00988221|9763428|FG003|Part I|Lost to Follow-up|0
6134486|NCT00988221|9763425|FG000|Part II|Adverse Event|1
6134487|NCT00988221|9763426|FG001|Part II|Adverse Event|0
6134488|NCT00988221|9763427|FG002|Part II|Adverse Event|0
6134489|NCT00988221|9763428|FG003|Part II|Adverse Event|1
6224660|NCT01696279|9896373|FG000|Part 3: Lanthanum Carbonate (6 Months)|Missing|0
6224661|NCT01696279|9896374|FG001|Part 3: Lanthanum Carbonate (6 Months)|Missing|0
6224662|NCT01696279|9896375|FG002|Part 3: Lanthanum Carbonate (6 Months)|Missing|0
6224663|NCT01696279|9896376|FG003|Part 3: Lanthanum Carbonate (6 Months)|Missing|1
6224664|NCT01696396|9896398|FG000|Overall Study|Withdrawal by Subject|19
6224665|NCT01696396|9896399|FG001|Overall Study|Withdrawal by Subject|5
6290414|NCT02397096|10006370|FG000|Week 24 to Week 48|Lack of Efficacy|5
6134490|NCT00988221|9763425|FG000|Part II|Withdrawal by Subject|0
6134491|NCT00988221|9763426|FG001|Part II|Withdrawal by Subject|0
6134492|NCT00988221|9763427|FG002|Part II|Withdrawal by Subject|2
6134493|NCT00988221|9763428|FG003|Part II|Withdrawal by Subject|2
6134494|NCT00988221|9763425|FG000|Part II|Reason not Specified|0
6134495|NCT00988221|9763426|FG001|Part II|Reason not Specified|0
6134496|NCT00988221|9763427|FG002|Part II|Reason not Specified|1
6224666|NCT01696396|9896400|FG002|Overall Study|Withdrawal by Subject|19
6134497|NCT00988221|9763428|FG003|Part II|Reason not Specified|0
6134498|NCT00988221|9763425|FG000|Part III|Adverse Event|1
6134499|NCT00988221|9763426|FG001|Part III|Adverse Event|0
6134500|NCT00988221|9763427|FG002|Part III|Adverse Event|1
6134501|NCT00988221|9763428|FG003|Part III|Adverse Event|0
6134502|NCT00988221|9763425|FG000|Part III|Insufficient Therapeutic Response|0
6134503|NCT00988221|9763426|FG001|Part III|Insufficient Therapeutic Response|1
6134504|NCT00988221|9763427|FG002|Part III|Insufficient Therapeutic Response|1
6134505|NCT00988221|9763428|FG003|Part III|Insufficient Therapeutic Response|0
6134506|NCT00988221|9763425|FG000|Part III|Refused Treatment|0
6134507|NCT00988221|9763426|FG001|Part III|Refused Treatment|0
6134508|NCT00988221|9763427|FG002|Part III|Refused Treatment|1
6134509|NCT00988221|9763428|FG003|Part III|Refused Treatment|0
6134510|NCT00988351|9763466|FG000|Overall Study|Withdrawal by Subject|8
6134511|NCT00988351|9763467|FG001|Overall Study|Withdrawal by Subject|0
6134512|NCT00988351|9763466|FG000|Overall Study|Lost to Follow-up|6
6134513|NCT00988351|9763467|FG001|Overall Study|Lost to Follow-up|9
6134514|NCT00988351|9763466|FG000|Overall Study|not using CPAP|5
6134515|NCT00988351|9763467|FG001|Overall Study|not using CPAP|3
6134516|NCT00988429|9763476|FG000|Overall Study|Adverse Event|9
6134517|NCT00988429|9763477|FG001|Overall Study|Adverse Event|21
6134518|NCT00988429|9763478|FG002|Overall Study|Adverse Event|45
6134519|NCT00988429|9763476|FG000|Overall Study|Lack of Efficacy|0
6134520|NCT00988429|9763477|FG001|Overall Study|Lack of Efficacy|0
6134521|NCT00988429|9763478|FG002|Overall Study|Lack of Efficacy|1
6224667|NCT01696396|9896401|FG003|Overall Study|Withdrawal by Subject|11
6224668|NCT01696396|9896398|FG000|Overall Study|Decision by Sponsor|3
6224669|NCT01696396|9896399|FG001|Overall Study|Decision by Sponsor|1
6224670|NCT01696396|9896400|FG002|Overall Study|Decision by Sponsor|2
6224671|NCT01696396|9896401|FG003|Overall Study|Decision by Sponsor|2
6224672|NCT01696396|9896398|FG000|Overall Study|Lost to Follow-up|9
6224673|NCT01696396|9896399|FG001|Overall Study|Lost to Follow-up|1
6224674|NCT01696396|9896400|FG002|Overall Study|Lost to Follow-up|4
6224675|NCT01696396|9896401|FG003|Overall Study|Lost to Follow-up|1
6224676|NCT01696396|9896398|FG000|Overall Study|Death|0
6224677|NCT01696396|9896399|FG001|Overall Study|Death|0
6224678|NCT01696396|9896400|FG002|Overall Study|Death|1
6224679|NCT01696396|9896401|FG003|Overall Study|Death|0
6224680|NCT01696643|9896417|FG000|Overall Study|Adverse Event|15
6224681|NCT01696643|9896418|FG001|Overall Study|Adverse Event|7
6224682|NCT01696643|9896417|FG000|Overall Study|Death|1
6224683|NCT01696643|9896418|FG001|Overall Study|Death|2
6224684|NCT01696643|9896417|FG000|Overall Study|Lack of Efficacy|3
6224685|NCT01696643|9896418|FG001|Overall Study|Lack of Efficacy|0
6224686|NCT01696643|9896417|FG000|Overall Study|Lost to Follow-up|67
6224687|NCT01696643|9896418|FG001|Overall Study|Lost to Follow-up|67
6224688|NCT01696643|9896417|FG000|Overall Study|Physician Decision|3
6224689|NCT01696643|9896418|FG001|Overall Study|Physician Decision|2
6224690|NCT01696643|9896417|FG000|Overall Study|Pregnancy|0
6224691|NCT01696643|9896418|FG001|Overall Study|Pregnancy|1
6224692|NCT01696643|9896417|FG000|Overall Study|Protocol Violation|7
6224693|NCT01696643|9896418|FG001|Overall Study|Protocol Violation|7
6224694|NCT01696643|9896417|FG000|Overall Study|Study Terminated by Sponsor|286
6224695|NCT01696643|9896418|FG001|Overall Study|Study Terminated by Sponsor|294
6224696|NCT01696643|9896417|FG000|Overall Study|Withdrawal by Subject|142
6224697|NCT01696643|9896418|FG001|Overall Study|Withdrawal by Subject|149
6224698|NCT01696643|9896417|FG000|Overall Study|Participant on Restricted Bed Rest|1
6224699|NCT01696643|9896418|FG001|Overall Study|Participant on Restricted Bed Rest|0
6224700|NCT01696643|9896417|FG000|Overall Study|Site Error|2
6224701|NCT01696643|9896418|FG001|Overall Study|Site Error|1
6224702|NCT01696643|9896417|FG000|Overall Study|Participant Incarcerated|0
6224703|NCT01696643|9896418|FG001|Overall Study|Participant Incarcerated|1
6224704|NCT01696643|9896417|FG000|Overall Study|Medical Monitor Decision|0
6224705|NCT01696643|9896418|FG001|Overall Study|Medical Monitor Decision|2
6224706|NCT01696643|9896417|FG000|Overall Study|Participant Did Not Receive Study Drug|2
6224707|NCT01696643|9896418|FG001|Overall Study|Participant Did Not Receive Study Drug|2
6224708|NCT01696695|9896424|FG000|Overall Study|Disease progression|373
6134522|NCT00988429|9763476|FG000|Overall Study|Non-Compliance with Study Drug|5
6134523|NCT00988429|9763477|FG001|Overall Study|Non-Compliance with Study Drug|1
6134524|NCT00988429|9763478|FG002|Overall Study|Non-Compliance with Study Drug|3
6134525|NCT00988429|9763476|FG000|Overall Study|Physician Decision|1
6134526|NCT00988429|9763477|FG001|Overall Study|Physician Decision|0
6134527|NCT00988429|9763478|FG002|Overall Study|Physician Decision|3
6134528|NCT00988429|9763476|FG000|Overall Study|Pregnancy|2
6134529|NCT00988429|9763477|FG001|Overall Study|Pregnancy|1
6224709|NCT01696695|9896424|FG000|Overall Study|Death|29
6224710|NCT01696695|9896424|FG000|Overall Study|Adverse Event|74
6224711|NCT01696695|9896424|FG000|Overall Study|Withdrawal by Subject|92
6224712|NCT01696695|9896424|FG000|Overall Study|Lost to Follow-up|48
6224713|NCT01696695|9896424|FG000|Overall Study|Other|74
6224714|NCT01696695|9896424|FG000|Overall Study|Major Protocol Violation|192
6224715|NCT01696773|9896439|FG000|Days 15-27, Washout|Adverse Event|1
6224716|NCT01696773|9896440|FG001|Days 15-27, Washout|Adverse Event|0
6224717|NCT01696877|9896448|FG000|Overall Study|Adverse Event|0
6224718|NCT01696877|9896449|FG001|Overall Study|Adverse Event|1
6224719|NCT01696929|9896457|FG000|Overall Study|Physician Decision|1
6224720|NCT01696942|9896463|FG000|Overall Study|Withdrawal by Subject|1
6134530|NCT00988429|9763478|FG002|Overall Study|Pregnancy|0
6134531|NCT00988429|9763476|FG000|Overall Study|Protocol Violation|4
6134532|NCT00988429|9763477|FG001|Overall Study|Protocol Violation|3
6134533|NCT00988429|9763478|FG002|Overall Study|Protocol Violation|3
6134534|NCT00988429|9763476|FG000|Overall Study|Withdrawal by Subject|7
6224721|NCT01696942|9896464|FG001|Overall Study|Withdrawal by Subject|0
6224722|NCT01696942|9896463|FG000|Overall Study|Protocol Violation|1
6224723|NCT01696942|9896464|FG001|Overall Study|Protocol Violation|2
6224724|NCT01696942|9896463|FG000|Overall Study|screen failure|0
6224725|NCT01696942|9896464|FG001|Overall Study|screen failure|1
6224726|NCT01696955|9896472|FG000|Main Study|Protocol Violation|1
6224727|NCT01696955|9896473|FG001|Main Study|Protocol Violation|0
6224728|NCT01696955|9896472|FG000|Main Study|Withdrawal by Subject|1
6224729|NCT01696955|9896473|FG001|Main Study|Withdrawal by Subject|1
6224730|NCT01696968|9896488|FG000|Overall Study|Cancer Before Rand. (Lung Screening)|0
6224731|NCT01696968|9896489|FG001|Overall Study|Cancer Before Rand. (Lung Screening)|8
6224732|NCT01696968|9896488|FG000|Overall Study|Died Before Randomization|3
6224733|NCT01696968|9896489|FG001|Overall Study|Died Before Randomization|8
6224734|NCT01696968|9896488|FG000|Overall Study|Died Before ASU (Control)|278
6224735|NCT01696968|9896489|FG001|Overall Study|Died Before ASU (Control)|0
6224736|NCT01696968|9896488|FG000|Overall Study|Refused ASU (Control)|920
6224737|NCT01696968|9896489|FG001|Overall Study|Refused ASU (Control)|0
6224738|NCT01696968|9896488|FG000|Overall Study|Refused Screen (Lung Screening)|0
6224739|NCT01696968|9896489|FG001|Overall Study|Refused Screen (Lung Screening)|6796
6224740|NCT01696981|9896498|FG000|Overall Study|Cancer Before Rand. (Colo. Screening)|0
6224741|NCT01696981|9896499|FG001|Overall Study|Cancer Before Rand. (Colo. Screening)|20
6224742|NCT01696981|9896498|FG000|Overall Study|Died Before Randomization|3
6224743|NCT01696981|9896499|FG001|Overall Study|Died Before Randomization|8
6224744|NCT01696981|9896498|FG000|Overall Study|Died Before ASU (Control)|278
6224745|NCT01696981|9896499|FG001|Overall Study|Died Before ASU (Control)|0
6224746|NCT01696981|9896498|FG000|Overall Study|Refused ASU (Control)|920
6134535|NCT00988429|9763477|FG001|Overall Study|Withdrawal by Subject|7
6134536|NCT00988429|9763478|FG002|Overall Study|Withdrawal by Subject|12
6134537|NCT00988429|9763476|FG000|Overall Study|Administrative Reasons|1
6134538|NCT00988429|9763477|FG001|Overall Study|Administrative Reasons|2
6134539|NCT00988429|9763478|FG002|Overall Study|Administrative Reasons|1
6134540|NCT00988429|9763476|FG000|Overall Study|other reasons|8
6224747|NCT01696981|9896499|FG001|Overall Study|Refused ASU (Control)|0
6224748|NCT01696981|9896498|FG000|Overall Study|Refused Screen (Colorectal Screening)|0
6224749|NCT01696981|9896499|FG001|Overall Study|Refused Screen (Colorectal Screening)|10346
6224750|NCT01696994|9896507|FG000|Overall Study|Cancer Before Rand. (Ovarian Screening)|0
6224751|NCT01696994|9896508|FG001|Overall Study|Cancer Before Rand. (Ovarian Screening)|2
6224752|NCT01696994|9896507|FG000|Overall Study|Died Before Randomization|1
6224753|NCT01696994|9896508|FG001|Overall Study|Died Before Randomization|2
6224754|NCT01696994|9896507|FG000|Overall Study|Died Before ASU (Control)|73
6224755|NCT01696994|9896508|FG001|Overall Study|Died Before ASU (Control)|0
6224756|NCT01696994|9896507|FG000|Overall Study|No Ovaries at Baseline|4807
6224757|NCT01696994|9896508|FG001|Overall Study|No Ovaries at Baseline|4851
6134541|NCT00988429|9763477|FG001|Overall Study|other reasons|8
6134542|NCT00988429|9763478|FG002|Overall Study|other reasons|1
6134543|NCT00988442|9763489|FG000|Overall Study|Death|1
6134544|NCT00988442|9763490|FG001|Overall Study|Death|2
6134545|NCT00988442|9763489|FG000|Overall Study|Lost to Follow-up|0
6134546|NCT00988442|9763490|FG001|Overall Study|Lost to Follow-up|1
6134547|NCT00988442|9763489|FG000|Overall Study|Early Study Closure|29
6134548|NCT00988442|9763490|FG001|Overall Study|Early Study Closure|25
6134549|NCT00988533|9763499|FG000|Overall Study|Lost to Follow-up|3
6134550|NCT00988559|9763507|FG000|Overall Study|Withdrawal by Subject|1
6134551|NCT00988559|9763508|FG001|Overall Study|Withdrawal by Subject|1
6134552|NCT00988559|9763509|FG002|Overall Study|Withdrawal by Subject|0
6134553|NCT00988559|9763510|FG003|Overall Study|Withdrawal by Subject|1
6134554|NCT00988559|9763507|FG000|Overall Study|Pregnancy|0
6134555|NCT00988559|9763508|FG001|Overall Study|Pregnancy|1
6134556|NCT00988559|9763509|FG002|Overall Study|Pregnancy|1
6134557|NCT00988559|9763510|FG003|Overall Study|Pregnancy|0
6134558|NCT00988559|9763507|FG000|Overall Study|Lost to Follow-up|0
6134559|NCT00988559|9763508|FG001|Overall Study|Lost to Follow-up|0
6134560|NCT00988559|9763509|FG002|Overall Study|Lost to Follow-up|1
6134561|NCT00988559|9763510|FG003|Overall Study|Lost to Follow-up|0
6134562|NCT00988598|9763522|FG000|Overall Study|Withdrawal by Subject|2
6134563|NCT00988598|9763523|FG001|Overall Study|Withdrawal by Subject|0
6224758|NCT01696994|9896507|FG000|Overall Study|Refused ASU (Control)|311
6224759|NCT01696994|9896508|FG001|Overall Study|Refused ASU (Control)|0
6224760|NCT01696994|9896507|FG000|Overall Study|Refused Screen (Ovarian Screening)|0
6224761|NCT01696994|9896508|FG001|Overall Study|Refused Screen (Ovarian Screening)|3582
6224762|NCT01697319|9896516|FG000|Primary Phase|Withdrawal by Subject|1
6224763|NCT01697319|9896516|FG000|Extension Phase|Terminated by Sponsor|15
6224764|NCT01697345|9896520|FG000|Overall Study|Withdrawal by Subject|1
6224765|NCT01697358|9896541|FG000|Period I: Randomization to 6 Months|Withdrawal by Subject|6
6224766|NCT01697358|9896542|FG001|Period I: Randomization to 6 Months|Withdrawal by Subject|0
6224767|NCT01697358|9896541|FG000|Period I: Randomization to 6 Months|Physician Decision|4
6224768|NCT01697358|9896542|FG001|Period I: Randomization to 6 Months|Physician Decision|0
6134564|NCT00988637|9763531|FG000|Overall Study|Lost to Follow-up|2
6134565|NCT00988637|9763532|FG001|Overall Study|Lost to Follow-up|1
6134566|NCT00988637|9763531|FG000|Overall Study|Withdrawal by Subject|1
6134567|NCT00988637|9763532|FG001|Overall Study|Withdrawal by Subject|1
6134568|NCT00988637|9763531|FG000|Overall Study|non-compliance with study drug|0
6134569|NCT00988637|9763532|FG001|Overall Study|non-compliance with study drug|1
6134570|NCT00988858|9763545|FG000|Overall Study|Adverse Event|7
6134571|NCT00988858|9763545|FG000|Overall Study|Death|1
6134572|NCT00988858|9763545|FG000|Overall Study|Physician Decision|1
6134573|NCT00988858|9763545|FG000|Overall Study|Sponsor Decision|1
6134574|NCT00988884|9763551|FG000|Overall Study|Adverse Event|0
6134575|NCT00988884|9763552|FG001|Overall Study|Adverse Event|1
6134576|NCT00988884|9763551|FG000|Overall Study|Lost to Follow-up|20
6134577|NCT00988884|9763552|FG001|Overall Study|Lost to Follow-up|16
6134578|NCT00988884|9763551|FG000|Overall Study|Protocol Violation|0
6134579|NCT00988884|9763552|FG001|Overall Study|Protocol Violation|1
6134580|NCT00988884|9763551|FG000|Overall Study|Withdrawal by Subject|15
6134581|NCT00988884|9763552|FG001|Overall Study|Withdrawal by Subject|18
6134582|NCT00989092|9763577|FG000|Overall Study|Physician Decision|9
6134583|NCT00989092|9763578|FG001|Overall Study|Physician Decision|6
6134584|NCT00989092|9763577|FG000|Overall Study|Adverse Event|20
6134585|NCT00989092|9763578|FG001|Overall Study|Adverse Event|1
6134586|NCT00989092|9763577|FG000|Overall Study|Chemotherapy initiated|12
6134587|NCT00989092|9763578|FG001|Overall Study|Chemotherapy initiated|4
6134588|NCT00989092|9763577|FG000|Overall Study|Withdrawal by Subject|17
6134589|NCT00989092|9763578|FG001|Overall Study|Withdrawal by Subject|9
6134590|NCT00989092|9763577|FG000|Overall Study|Death|14
6134591|NCT00989092|9763578|FG001|Overall Study|Death|2
6134592|NCT00989092|9763577|FG000|Overall Study|Ineligibility determined|3
6134593|NCT00989092|9763578|FG001|Overall Study|Ineligibility determined|3
6134594|NCT00989092|9763577|FG000|Overall Study|Lost to Follow-up|6
6134595|NCT00989092|9763578|FG001|Overall Study|Lost to Follow-up|2
6224769|NCT01697358|9896541|FG000|Period I: Randomization to 6 Months|Adverse Event|1
6224770|NCT01697358|9896542|FG001|Period I: Randomization to 6 Months|Adverse Event|1
6224771|NCT01697358|9896541|FG000|Period I: Randomization to 6 Months|Lost to Follow-up|2
6224772|NCT01697358|9896542|FG001|Period I: Randomization to 6 Months|Lost to Follow-up|0
6224773|NCT01697358|9896541|FG000|Period II: 6-24M Long-term Follow-up|Physician Decision|3
6224774|NCT01697358|9896542|FG001|Period II: 6-24M Long-term Follow-up|Physician Decision|12
6224775|NCT01697358|9896541|FG000|Period II: 6-24M Long-term Follow-up|Withdrawal by Subject|8
6224776|NCT01697358|9896542|FG001|Period II: 6-24M Long-term Follow-up|Withdrawal by Subject|10
6224777|NCT01697358|9896541|FG000|Period II: 6-24M Long-term Follow-up|Lost to Follow-up|3
6224778|NCT01697358|9896542|FG001|Period II: 6-24M Long-term Follow-up|Lost to Follow-up|3
6224779|NCT01697358|9896541|FG000|Period II: 6-24M Long-term Follow-up|Death|1
6224780|NCT01697358|9896542|FG001|Period II: 6-24M Long-term Follow-up|Death|1
6224781|NCT01697358|9896541|FG000|Period II: 6-24M Long-term Follow-up|Adverse Event|0
6224782|NCT01697358|9896542|FG001|Period II: 6-24M Long-term Follow-up|Adverse Event|3
6224783|NCT01697358|9896541|FG000|Period II: 6-24M Long-term Follow-up|Active subjects at the time of posting|34
6224784|NCT01697358|9896542|FG001|Period II: 6-24M Long-term Follow-up|Active subjects at the time of posting|26
6224785|NCT01697449|9896548|FG000|Overall Study|Disease progression|47
6224786|NCT01697449|9896548|FG000|Overall Study|Adverse Event|7
6224787|NCT01697449|9896548|FG000|Overall Study|Lost to Follow-up|5
6224788|NCT01697449|9896548|FG000|Overall Study|Withdrawal by Subject|2
6224789|NCT01697449|9896548|FG000|Overall Study|Physician Decision|1
6224790|NCT01697449|9896548|FG000|Overall Study|Death|2
6224791|NCT01697449|9896548|FG000|Overall Study|Other|1
6224792|NCT01697449|9896548|FG000|Overall Study|Missing|25
6224793|NCT01697462|9896555|FG000|Overall Study|Disease Progression|1
6224794|NCT01697462|9896555|FG000|Overall Study|Adverse Event|6
6224795|NCT01697462|9896555|FG000|Overall Study|Lost to Follow-up|21
6224796|NCT01697462|9896555|FG000|Overall Study|Withdrawal by Subject|12
6224797|NCT01697462|9896555|FG000|Overall Study|Investigator Decision|21
6224798|NCT01697462|9896555|FG000|Overall Study|Death|1
6224799|NCT01697462|9896555|FG000|Overall Study|Other|10
6224800|NCT01697462|9896555|FG000|Overall Study|Missing|5
6224801|NCT01697501|9896559|FG000|Overall Study|Protocol Violation|2
6224802|NCT01697579|9896577|FG000|Base Study-Cycle 1|Adverse Event|1
6224803|NCT01697579|9896578|FG001|Base Study-Cycle 1|Adverse Event|0
6224804|NCT01697579|9896579|FG002|Base Study-Cycle 1|Adverse Event|0
6224805|NCT01697579|9896580|FG003|Base Study-Cycle 1|Adverse Event|0
6224806|NCT01697579|9896581|FG004|Base Study-Cycle 1|Adverse Event|0
6224807|NCT01697579|9896582|FG005|Base Study-Cycle 1|Adverse Event|0
6224808|NCT01697579|9896583|FG006|Base Study-Cycle 1|Adverse Event|0
6224809|NCT01697579|9896577|FG000|Base Study-Cycle 1|Withdrawal by Parent/Guardian|1
6224810|NCT01697579|9896578|FG001|Base Study-Cycle 1|Withdrawal by Parent/Guardian|0
6224811|NCT01697579|9896579|FG002|Base Study-Cycle 1|Withdrawal by Parent/Guardian|0
6224812|NCT01697579|9896580|FG003|Base Study-Cycle 1|Withdrawal by Parent/Guardian|0
6134596|NCT00989092|9763577|FG000|Overall Study|Other|3
6134597|NCT00989092|9763578|FG001|Overall Study|Other|1
6134598|NCT00989092|9763577|FG000|Overall Study|Protocol deviation|2
6134599|NCT00989092|9763578|FG001|Overall Study|Protocol deviation|0
6134600|NCT00989092|9763577|FG000|Overall Study|Erythropoietin therapy initiated|2
6134601|NCT00989092|9763578|FG001|Overall Study|Erythropoietin therapy initiated|0
6134602|NCT00989092|9763577|FG000|Overall Study|Did not receive study drug|2
6134603|NCT00989092|9763578|FG001|Overall Study|Did not receive study drug|0
6134604|NCT00989196|9763596|FG000|Treatment Period|Lost to Follow-up|1
6134605|NCT00989196|9763597|FG001|Treatment Period|Lost to Follow-up|0
6134606|NCT00989235|9763605|FG000|Overall Study|Death|0
6134607|NCT00989235|9763606|FG001|Overall Study|Death|1
6134608|NCT00989235|9763605|FG000|Overall Study|Adverse Event|0
6134609|NCT00989235|9763606|FG001|Overall Study|Adverse Event|1
6134610|NCT00989235|9763605|FG000|Overall Study|Lack of Efficacy|1
6134611|NCT00989235|9763606|FG001|Overall Study|Lack of Efficacy|0
6134612|NCT00989235|9763605|FG000|Overall Study|Withdrawal of Consent|1
6134613|NCT00989235|9763606|FG001|Overall Study|Withdrawal of Consent|1
6134614|NCT00989235|9763605|FG000|Overall Study|Desire to Become Pregnant|1
6134615|NCT00989235|9763606|FG001|Overall Study|Desire to Become Pregnant|0
6224813|NCT01697579|9896581|FG004|Base Study-Cycle 1|Withdrawal by Parent/Guardian|0
6224814|NCT01697579|9896582|FG005|Base Study-Cycle 1|Withdrawal by Parent/Guardian|0
6224815|NCT01697579|9896583|FG006|Base Study-Cycle 1|Withdrawal by Parent/Guardian|0
6224816|NCT01697579|9896577|FG000|Base Study-Cycle 1|Protocol Violation|0
6224817|NCT01697579|9896578|FG001|Base Study-Cycle 1|Protocol Violation|0
6224818|NCT01697579|9896579|FG002|Base Study-Cycle 1|Protocol Violation|0
6224819|NCT01697579|9896580|FG003|Base Study-Cycle 1|Protocol Violation|0
6224820|NCT01697579|9896581|FG004|Base Study-Cycle 1|Protocol Violation|3
6224821|NCT01697579|9896582|FG005|Base Study-Cycle 1|Protocol Violation|0
6224822|NCT01697579|9896583|FG006|Base Study-Cycle 1|Protocol Violation|0
6224823|NCT01697579|9896577|FG000|Base Study-Cycle 1|Consent Withdrawn by Participant|0
6224824|NCT01697579|9896578|FG001|Base Study-Cycle 1|Consent Withdrawn by Participant|1
6224825|NCT01697579|9896579|FG002|Base Study-Cycle 1|Consent Withdrawn by Participant|0
6224826|NCT01697579|9896580|FG003|Base Study-Cycle 1|Consent Withdrawn by Participant|0
6224827|NCT01697579|9896581|FG004|Base Study-Cycle 1|Consent Withdrawn by Participant|0
6224828|NCT01697579|9896582|FG005|Base Study-Cycle 1|Consent Withdrawn by Participant|0
6224829|NCT01697579|9896583|FG006|Base Study-Cycle 1|Consent Withdrawn by Participant|0
6224830|NCT01697579|9896577|FG000|Base Study-Cycle 1|Technical Problems|0
6224831|NCT01697579|9896578|FG001|Base Study-Cycle 1|Technical Problems|0
6224832|NCT01697579|9896579|FG002|Base Study-Cycle 1|Technical Problems|1
6224833|NCT01697579|9896580|FG003|Base Study-Cycle 1|Technical Problems|1
6224834|NCT01697579|9896581|FG004|Base Study-Cycle 1|Technical Problems|0
6224835|NCT01697579|9896582|FG005|Base Study-Cycle 1|Technical Problems|0
6224836|NCT01697579|9896583|FG006|Base Study-Cycle 1|Technical Problems|0
6224837|NCT01697579|9896577|FG000|Optional Extension-Cycles 2-6|Death|0
6224838|NCT01697579|9896578|FG001|Optional Extension-Cycles 2-6|Death|0
6224839|NCT01697579|9896579|FG002|Optional Extension-Cycles 2-6|Death|0
6224840|NCT01697579|9896580|FG003|Optional Extension-Cycles 2-6|Death|0
6224841|NCT01697579|9896581|FG004|Optional Extension-Cycles 2-6|Death|0
6224842|NCT01697579|9896582|FG005|Optional Extension-Cycles 2-6|Death|0
6224843|NCT01697579|9896583|FG006|Optional Extension-Cycles 2-6|Death|2
6224844|NCT01697579|9896577|FG000|Optional Extension-Cycles 2-6|Withdrawal by Parent/Guardian|0
6224845|NCT01697579|9896578|FG001|Optional Extension-Cycles 2-6|Withdrawal by Parent/Guardian|0
6224846|NCT01697579|9896579|FG002|Optional Extension-Cycles 2-6|Withdrawal by Parent/Guardian|0
6224847|NCT01697579|9896580|FG003|Optional Extension-Cycles 2-6|Withdrawal by Parent/Guardian|0
6224848|NCT01697579|9896581|FG004|Optional Extension-Cycles 2-6|Withdrawal by Parent/Guardian|0
6224849|NCT01697579|9896582|FG005|Optional Extension-Cycles 2-6|Withdrawal by Parent/Guardian|1
6224850|NCT01697579|9896583|FG006|Optional Extension-Cycles 2-6|Withdrawal by Parent/Guardian|5
6224851|NCT01697579|9896577|FG000|Optional Extension-Cycles 2-6|Physician Decision|0
6224852|NCT01697579|9896578|FG001|Optional Extension-Cycles 2-6|Physician Decision|0
6224853|NCT01697579|9896579|FG002|Optional Extension-Cycles 2-6|Physician Decision|0
6224854|NCT01697579|9896580|FG003|Optional Extension-Cycles 2-6|Physician Decision|0
6224855|NCT01697579|9896581|FG004|Optional Extension-Cycles 2-6|Physician Decision|0
6224856|NCT01697579|9896582|FG005|Optional Extension-Cycles 2-6|Physician Decision|7
6224857|NCT01697579|9896583|FG006|Optional Extension-Cycles 2-6|Physician Decision|11
6224858|NCT01697579|9896577|FG000|Optional Extension-Cycles 2-6|Protocol Violation|0
6224859|NCT01697579|9896578|FG001|Optional Extension-Cycles 2-6|Protocol Violation|0
6224860|NCT01697579|9896579|FG002|Optional Extension-Cycles 2-6|Protocol Violation|0
6224861|NCT01697579|9896580|FG003|Optional Extension-Cycles 2-6|Protocol Violation|0
6224862|NCT01697579|9896581|FG004|Optional Extension-Cycles 2-6|Protocol Violation|0
6224863|NCT01697579|9896582|FG005|Optional Extension-Cycles 2-6|Protocol Violation|0
6224864|NCT01697579|9896583|FG006|Optional Extension-Cycles 2-6|Protocol Violation|4
6224865|NCT01697579|9896577|FG000|Optional Extension-Cycles 2-6|Excluded Medication|0
6224866|NCT01697579|9896578|FG001|Optional Extension-Cycles 2-6|Excluded Medication|0
6224867|NCT01697579|9896579|FG002|Optional Extension-Cycles 2-6|Excluded Medication|0
6224868|NCT01697579|9896580|FG003|Optional Extension-Cycles 2-6|Excluded Medication|0
6224869|NCT01697579|9896581|FG004|Optional Extension-Cycles 2-6|Excluded Medication|0
6224870|NCT01697579|9896582|FG005|Optional Extension-Cycles 2-6|Excluded Medication|1
6224871|NCT01697579|9896583|FG006|Optional Extension-Cycles 2-6|Excluded Medication|2
6224872|NCT01697579|9896577|FG000|Optional Extension-Cycles 2-6|Did Not Respond To Chemotherapy Regimen|0
6224873|NCT01697579|9896578|FG001|Optional Extension-Cycles 2-6|Did Not Respond To Chemotherapy Regimen|0
6134616|NCT00989235|9763605|FG000|Overall Study|Randomized by Mistake|0
6134617|NCT00989235|9763606|FG001|Overall Study|Randomized by Mistake|2
6134618|NCT00989235|9763605|FG000|Overall Study|Lost to Follow-up|0
6134619|NCT00989235|9763606|FG001|Overall Study|Lost to Follow-up|1
6134620|NCT00989261|9763617|FG000|Overall Study|Still in follow up|12
6134621|NCT00989261|9763618|FG001|Overall Study|Still in follow up|21
6134622|NCT00989261|9763617|FG000|Overall Study|Withdrawal by Subject|0
6134623|NCT00989261|9763618|FG001|Overall Study|Withdrawal by Subject|1
6134624|NCT00989261|9763617|FG000|Overall Study|Lost to Follow-up|3
6134625|NCT00989261|9763618|FG001|Overall Study|Lost to Follow-up|0
6134626|NCT00989287|9763626|FG000|Overall Study|Adverse Event|1
6134627|NCT00989287|9763627|FG001|Overall Study|Adverse Event|0
6134628|NCT00989287|9763626|FG000|Overall Study|Lost to Follow-up|0
6134629|NCT00989287|9763627|FG001|Overall Study|Lost to Follow-up|1
6134630|NCT00989573|9763649|FG000|Overall Study|Adverse Event|8
6134631|NCT00989573|9763650|FG001|Overall Study|Adverse Event|12
6134632|NCT00989573|9763651|FG002|Overall Study|Adverse Event|4
6134633|NCT00989573|9763649|FG000|Overall Study|Physician Decision|0
6134634|NCT00989573|9763650|FG001|Overall Study|Physician Decision|2
6134635|NCT00989573|9763651|FG002|Overall Study|Physician Decision|0
6134636|NCT00989573|9763649|FG000|Overall Study|Protocol Violation|1
6134637|NCT00989573|9763650|FG001|Overall Study|Protocol Violation|1
6134638|NCT00989573|9763651|FG002|Overall Study|Protocol Violation|1
6134639|NCT00989573|9763649|FG000|Overall Study|Withdrawal by Subject|4
6134640|NCT00989573|9763650|FG001|Overall Study|Withdrawal by Subject|7
6134641|NCT00989573|9763651|FG002|Overall Study|Withdrawal by Subject|3
6134642|NCT00989664|9763675|FG000|Dosimetric and Therapeutic Treatment|Non-compliant or Uncooperative|1
6134643|NCT00989664|9763675|FG000|Dosimetric and Therapeutic Treatment|Condition/Illness; Study Drug Unrelated|2
6134644|NCT00989664|9763675|FG000|Dosimetric and Therapeutic Treatment|Progressive Disease|49
6134645|NCT00989664|9763675|FG000|Dosimetric and Therapeutic Treatment|Death|1
6134646|NCT00989664|9763675|FG000|Dosimetric and Therapeutic Treatment|Enrolled into Study BEX104526|7
6134647|NCT00989664|9763675|FG000|Dosimetric and Therapeutic Treatment|Did Not Receive Study Drug|1
6134648|NCT00989664|9763675|FG000|Long-Term Follow-Up|Death|3
6134649|NCT00989781|9763691|FG000|Ovarian Response to hCG|Lost to Follow-up|3
6134650|NCT00989781|9763692|FG001|Ovarian Response to hCG|Lost to Follow-up|2
6134651|NCT00989833|9763702|FG000|Overall Study|Lost to Follow-up|0
6134652|NCT00989833|9763703|FG001|Overall Study|Lost to Follow-up|1
6134653|NCT00989833|9763704|FG002|Overall Study|Lost to Follow-up|0
6134654|NCT00989833|9763702|FG000|Overall Study|Protocol Violation|1
6134655|NCT00989833|9763703|FG001|Overall Study|Protocol Violation|2
6134656|NCT00989833|9763704|FG002|Overall Study|Protocol Violation|1
6134657|NCT00989833|9763702|FG000|Overall Study|Withdrawal by Subject|0
6134658|NCT00989833|9763703|FG001|Overall Study|Withdrawal by Subject|0
6134659|NCT00989833|9763704|FG002|Overall Study|Withdrawal by Subject|1
6134660|NCT00989833|9763702|FG000|Overall Study|Incorrectly randomized|1
6134661|NCT00989833|9763703|FG001|Overall Study|Incorrectly randomized|0
6134662|NCT00989833|9763704|FG002|Overall Study|Incorrectly randomized|0
6134663|NCT00989950|9763720|FG000|Randomized Phase|Protocol Violation|1
6134664|NCT00989950|9763721|FG001|Randomized Phase|Protocol Violation|0
6134665|NCT00989950|9763722|FG002|Randomized Phase|Protocol Violation|0
6134666|NCT00989950|9763723|FG003|Randomized Phase|Protocol Violation|0
6134667|NCT00989950|9763720|FG000|Randomized Phase|Adverse Event|0
6134668|NCT00989950|9763721|FG001|Randomized Phase|Adverse Event|1
6134669|NCT00989950|9763722|FG002|Randomized Phase|Adverse Event|0
6224874|NCT01697579|9896579|FG002|Optional Extension-Cycles 2-6|Did Not Respond To Chemotherapy Regimen|0
6224875|NCT01697579|9896580|FG003|Optional Extension-Cycles 2-6|Did Not Respond To Chemotherapy Regimen|0
6224876|NCT01697579|9896581|FG004|Optional Extension-Cycles 2-6|Did Not Respond To Chemotherapy Regimen|0
6224877|NCT01697579|9896582|FG005|Optional Extension-Cycles 2-6|Did Not Respond To Chemotherapy Regimen|1
6224878|NCT01697579|9896583|FG006|Optional Extension-Cycles 2-6|Did Not Respond To Chemotherapy Regimen|0
6224879|NCT01697579|9896577|FG000|Optional Extension-Cycles 2-6|Completed Chemotherapy Regimen|0
6224880|NCT01697579|9896578|FG001|Optional Extension-Cycles 2-6|Completed Chemotherapy Regimen|0
6224881|NCT01697579|9896579|FG002|Optional Extension-Cycles 2-6|Completed Chemotherapy Regimen|0
6224882|NCT01697579|9896580|FG003|Optional Extension-Cycles 2-6|Completed Chemotherapy Regimen|0
6224883|NCT01697579|9896581|FG004|Optional Extension-Cycles 2-6|Completed Chemotherapy Regimen|0
6224884|NCT01697579|9896582|FG005|Optional Extension-Cycles 2-6|Completed Chemotherapy Regimen|15
6224885|NCT01697579|9896583|FG006|Optional Extension-Cycles 2-6|Completed Chemotherapy Regimen|24
6224886|NCT01697579|9896577|FG000|Optional Extension-Cycles 2-6|Did Not Meet Cycle Eligibility Criteria|0
6224887|NCT01697579|9896578|FG001|Optional Extension-Cycles 2-6|Did Not Meet Cycle Eligibility Criteria|0
6224888|NCT01697579|9896579|FG002|Optional Extension-Cycles 2-6|Did Not Meet Cycle Eligibility Criteria|0
6224889|NCT01697579|9896580|FG003|Optional Extension-Cycles 2-6|Did Not Meet Cycle Eligibility Criteria|0
6224890|NCT01697579|9896581|FG004|Optional Extension-Cycles 2-6|Did Not Meet Cycle Eligibility Criteria|0
6224891|NCT01697579|9896582|FG005|Optional Extension-Cycles 2-6|Did Not Meet Cycle Eligibility Criteria|4
6224892|NCT01697579|9896583|FG006|Optional Extension-Cycles 2-6|Did Not Meet Cycle Eligibility Criteria|11
6224893|NCT01697579|9896577|FG000|Optional Extension-Cycles 2-6|Consent Withdrawn by Participant|0
6224894|NCT01697579|9896578|FG001|Optional Extension-Cycles 2-6|Consent Withdrawn by Participant|0
6224895|NCT01697579|9896579|FG002|Optional Extension-Cycles 2-6|Consent Withdrawn by Participant|0
6134670|NCT00989950|9763723|FG003|Randomized Phase|Adverse Event|0
6134671|NCT00989963|9763736|FG000|Overall Study|Adverse Event|1
6134672|NCT00989963|9763737|FG001|Overall Study|Adverse Event|1
6134673|NCT00989963|9763738|FG002|Overall Study|Adverse Event|1
6134674|NCT00990093|9763759|FG000|Test Period 1 (1-14 Days)|Adverse Event|1
6134675|NCT00990093|9763760|FG001|Test Period 1 (1-14 Days)|Adverse Event|0
6134676|NCT00990093|9763759|FG000|Test Period 1 (1-14 Days)|Withdrawal by Subject|2
6134677|NCT00990093|9763760|FG001|Test Period 1 (1-14 Days)|Withdrawal by Subject|0
6224896|NCT01697579|9896580|FG003|Optional Extension-Cycles 2-6|Consent Withdrawn by Participant|0
6224897|NCT01697579|9896581|FG004|Optional Extension-Cycles 2-6|Consent Withdrawn by Participant|0
6224898|NCT01697579|9896582|FG005|Optional Extension-Cycles 2-6|Consent Withdrawn by Participant|0
6224899|NCT01697579|9896583|FG006|Optional Extension-Cycles 2-6|Consent Withdrawn by Participant|2
6224900|NCT01697579|9896577|FG000|Optional Extension-Cycles 2-6|Technical Problems|0
6224901|NCT01697579|9896578|FG001|Optional Extension-Cycles 2-6|Technical Problems|0
6224902|NCT01697579|9896579|FG002|Optional Extension-Cycles 2-6|Technical Problems|0
6224903|NCT01697579|9896580|FG003|Optional Extension-Cycles 2-6|Technical Problems|0
6224904|NCT01697579|9896581|FG004|Optional Extension-Cycles 2-6|Technical Problems|0
6224905|NCT01697579|9896582|FG005|Optional Extension-Cycles 2-6|Technical Problems|0
6224906|NCT01697579|9896583|FG006|Optional Extension-Cycles 2-6|Technical Problems|1
6224907|NCT01697579|9896577|FG000|Optional Extension-Cycles 2-6|Participant Moved|0
6224908|NCT01697579|9896578|FG001|Optional Extension-Cycles 2-6|Participant Moved|0
6224909|NCT01697579|9896579|FG002|Optional Extension-Cycles 2-6|Participant Moved|0
6224910|NCT01697579|9896580|FG003|Optional Extension-Cycles 2-6|Participant Moved|0
6224911|NCT01697579|9896581|FG004|Optional Extension-Cycles 2-6|Participant Moved|0
6224912|NCT01697579|9896582|FG005|Optional Extension-Cycles 2-6|Participant Moved|0
6224913|NCT01697579|9896583|FG006|Optional Extension-Cycles 2-6|Participant Moved|2
6224914|NCT01697579|9896577|FG000|Optional Extension-Cycles 2-6|Non-compliance With Protocol|0
6224915|NCT01697579|9896578|FG001|Optional Extension-Cycles 2-6|Non-compliance With Protocol|0
6224916|NCT01697579|9896579|FG002|Optional Extension-Cycles 2-6|Non-compliance With Protocol|0
6224917|NCT01697579|9896580|FG003|Optional Extension-Cycles 2-6|Non-compliance With Protocol|0
6224918|NCT01697579|9896581|FG004|Optional Extension-Cycles 2-6|Non-compliance With Protocol|0
6224919|NCT01697579|9896582|FG005|Optional Extension-Cycles 2-6|Non-compliance With Protocol|6
6224920|NCT01697579|9896583|FG006|Optional Extension-Cycles 2-6|Non-compliance With Protocol|4
6224921|NCT01697579|9896577|FG000|Optional Extension-Cycles 2-6|Lost to Follow-up|0
6224922|NCT01697579|9896578|FG001|Optional Extension-Cycles 2-6|Lost to Follow-up|0
6224923|NCT01697579|9896579|FG002|Optional Extension-Cycles 2-6|Lost to Follow-up|0
6224924|NCT01697579|9896580|FG003|Optional Extension-Cycles 2-6|Lost to Follow-up|0
6224925|NCT01697579|9896581|FG004|Optional Extension-Cycles 2-6|Lost to Follow-up|0
6224926|NCT01697579|9896582|FG005|Optional Extension-Cycles 2-6|Lost to Follow-up|0
6224927|NCT01697579|9896583|FG006|Optional Extension-Cycles 2-6|Lost to Follow-up|1
6224928|NCT01697592|9896621|FG000|Phase A (Up to 24 Weeks)|Lost to Follow-up|1
6224929|NCT01697592|9896622|FG001|Phase A (Up to 24 Weeks)|Lost to Follow-up|0
6224930|NCT01697592|9896623|FG002|Phase A (Up to 24 Weeks)|Lost to Follow-up|0
6224931|NCT01697592|9896624|FG003|Phase A (Up to 24 Weeks)|Lost to Follow-up|0
6224932|NCT01697592|9896625|FG004|Phase A (Up to 24 Weeks)|Lost to Follow-up|0
6224933|NCT01697592|9896626|FG005|Phase A (Up to 24 Weeks)|Lost to Follow-up|0
6224934|NCT01697592|9896627|FG006|Phase A (Up to 24 Weeks)|Lost to Follow-up|0
6224935|NCT01697592|9896628|FG007|Phase A (Up to 24 Weeks)|Lost to Follow-up|0
6224936|NCT01697592|9896629|FG008|Phase A (Up to 24 Weeks)|Lost to Follow-up|0
6224937|NCT01697592|9896630|FG009|Phase A (Up to 24 Weeks)|Lost to Follow-up|0
6224938|NCT01697592|9896621|FG000|Phase A (Up to 24 Weeks)|Physician Decision|0
6224939|NCT01697592|9896622|FG001|Phase A (Up to 24 Weeks)|Physician Decision|0
6224940|NCT01697592|9896623|FG002|Phase A (Up to 24 Weeks)|Physician Decision|0
6224941|NCT01697592|9896624|FG003|Phase A (Up to 24 Weeks)|Physician Decision|0
6224942|NCT01697592|9896625|FG004|Phase A (Up to 24 Weeks)|Physician Decision|0
6224943|NCT01697592|9896626|FG005|Phase A (Up to 24 Weeks)|Physician Decision|1
6224944|NCT01697592|9896627|FG006|Phase A (Up to 24 Weeks)|Physician Decision|0
6224945|NCT01697592|9896628|FG007|Phase A (Up to 24 Weeks)|Physician Decision|0
6224946|NCT01697592|9896629|FG008|Phase A (Up to 24 Weeks)|Physician Decision|0
6224947|NCT01697592|9896630|FG009|Phase A (Up to 24 Weeks)|Physician Decision|0
6224948|NCT01697592|9896621|FG000|Phase A (Up to 24 Weeks)|Protocol Violation|1
6224949|NCT01697592|9896622|FG001|Phase A (Up to 24 Weeks)|Protocol Violation|0
6224950|NCT01697592|9896623|FG002|Phase A (Up to 24 Weeks)|Protocol Violation|0
6224951|NCT01697592|9896624|FG003|Phase A (Up to 24 Weeks)|Protocol Violation|0
6224952|NCT01697592|9896625|FG004|Phase A (Up to 24 Weeks)|Protocol Violation|0
6134678|NCT00990093|9763759|FG000|Test Period 1 (1-14 Days)|Other|1
6134679|NCT00990093|9763760|FG001|Test Period 1 (1-14 Days)|Other|0
6224953|NCT01697592|9896626|FG005|Phase A (Up to 24 Weeks)|Protocol Violation|0
6224954|NCT01697592|9896627|FG006|Phase A (Up to 24 Weeks)|Protocol Violation|0
6224955|NCT01697592|9896628|FG007|Phase A (Up to 24 Weeks)|Protocol Violation|0
6224956|NCT01697592|9896629|FG008|Phase A (Up to 24 Weeks)|Protocol Violation|0
6224957|NCT01697592|9896630|FG009|Phase A (Up to 24 Weeks)|Protocol Violation|0
6224958|NCT01697592|9896621|FG000|Phase A (Up to 24 Weeks)|Withdrawal by Subject|1
6224959|NCT01697592|9896622|FG001|Phase A (Up to 24 Weeks)|Withdrawal by Subject|1
6134680|NCT00990093|9763759|FG000|Test Period 1 (1-14 Days)|Lack of Efficacy|0
6134681|NCT00990093|9763760|FG001|Test Period 1 (1-14 Days)|Lack of Efficacy|2
6134682|NCT00990093|9763759|FG000|Test Period 2 (15-28 Days)|Adverse Event|1
6134683|NCT00990093|9763760|FG001|Test Period 2 (15-28 Days)|Adverse Event|0
6134684|NCT00990093|9763759|FG000|Test Period 2 (15-28 Days)|Lack of Efficacy|1
6134685|NCT00990093|9763760|FG001|Test Period 2 (15-28 Days)|Lack of Efficacy|0
6134686|NCT00990093|9763759|FG000|Test Period 2 (15-28 Days)|Other|0
6134687|NCT00990093|9763760|FG001|Test Period 2 (15-28 Days)|Other|1
6134688|NCT00990106|9763768|FG000|Overall Study|"too busy to continue"|1
6134689|NCT00990106|9763769|FG001|Overall Study|"too busy to continue"|2
6134690|NCT00990106|9763768|FG000|Overall Study|Lost to Follow-up|1
6134691|NCT00990106|9763769|FG001|Overall Study|Lost to Follow-up|3
6134692|NCT00990106|9763768|FG000|Overall Study|Withdrawal by Subject|2
6134693|NCT00990106|9763769|FG001|Overall Study|Withdrawal by Subject|1
6134694|NCT00990106|9763768|FG000|Overall Study|opted for open label prazosin|1
6134695|NCT00990106|9763769|FG001|Overall Study|opted for open label prazosin|1
6134696|NCT00990106|9763768|FG000|Overall Study|relocation/deployment|4
6134697|NCT00990106|9763769|FG001|Overall Study|relocation/deployment|1
6134698|NCT00990106|9763768|FG000|Overall Study|started exclusionary medication|0
6134699|NCT00990106|9763769|FG001|Overall Study|started exclusionary medication|1
6134700|NCT00990106|9763768|FG000|Overall Study|planned major surgery|0
6134701|NCT00990106|9763769|FG001|Overall Study|planned major surgery|1
6134702|NCT00990106|9763768|FG000|Overall Study|scheduling conflicts|0
6134703|NCT00990106|9763769|FG001|Overall Study|scheduling conflicts|2
6134704|NCT00990184|9763775|FG000|Overall Study|Physician Decision|1
6134705|NCT00990249|9763790|FG000|Overall Study|Disease Progression|8
6134706|NCT00990249|9763790|FG000|Overall Study|Non-Compliance|1
6134707|NCT00990249|9763790|FG000|Overall Study|Death|2
6134708|NCT00990249|9763790|FG000|Overall Study|Not treated|2
6224960|NCT01697592|9896623|FG002|Phase A (Up to 24 Weeks)|Withdrawal by Subject|0
6224961|NCT01697592|9896624|FG003|Phase A (Up to 24 Weeks)|Withdrawal by Subject|0
6224962|NCT01697592|9896625|FG004|Phase A (Up to 24 Weeks)|Withdrawal by Subject|0
6224963|NCT01697592|9896626|FG005|Phase A (Up to 24 Weeks)|Withdrawal by Subject|0
6224964|NCT01697592|9896627|FG006|Phase A (Up to 24 Weeks)|Withdrawal by Subject|1
6224965|NCT01697592|9896628|FG007|Phase A (Up to 24 Weeks)|Withdrawal by Subject|0
6224966|NCT01697592|9896629|FG008|Phase A (Up to 24 Weeks)|Withdrawal by Subject|0
6224967|NCT01697592|9896630|FG009|Phase A (Up to 24 Weeks)|Withdrawal by Subject|1
6224968|NCT01697592|9896621|FG000|Phase A (Up to 24 Weeks)|Adverse Event|0
6224969|NCT01697592|9896622|FG001|Phase A (Up to 24 Weeks)|Adverse Event|2
6224970|NCT01697592|9896623|FG002|Phase A (Up to 24 Weeks)|Adverse Event|1
6224971|NCT01697592|9896624|FG003|Phase A (Up to 24 Weeks)|Adverse Event|2
6134709|NCT00990314|9763803|FG000|Overall Study|Death|2
6134710|NCT00990314|9763803|FG000|Overall Study|Adverse Event|2
6134711|NCT00990314|9763803|FG000|Overall Study|Withdrawal by Subject|3
6134712|NCT00990314|9763803|FG000|Overall Study|Non-Compliance|1
6134713|NCT00990314|9763803|FG000|Overall Study|Physician Decision|3
6224972|NCT01697592|9896625|FG004|Phase A (Up to 24 Weeks)|Adverse Event|0
6224973|NCT01697592|9896626|FG005|Phase A (Up to 24 Weeks)|Adverse Event|0
6224974|NCT01697592|9896627|FG006|Phase A (Up to 24 Weeks)|Adverse Event|1
6224975|NCT01697592|9896628|FG007|Phase A (Up to 24 Weeks)|Adverse Event|0
6224976|NCT01697592|9896629|FG008|Phase A (Up to 24 Weeks)|Adverse Event|0
6224977|NCT01697592|9896630|FG009|Phase A (Up to 24 Weeks)|Adverse Event|1
6224978|NCT01697592|9896621|FG000|Phase B (Week 25 to Week 52)|Physician Decision|1
6224979|NCT01697592|9896622|FG001|Phase B (Week 25 to Week 52)|Physician Decision|0
6224980|NCT01697592|9896623|FG002|Phase B (Week 25 to Week 52)|Physician Decision|0
6224981|NCT01697592|9896624|FG003|Phase B (Week 25 to Week 52)|Physician Decision|1
6224982|NCT01697592|9896625|FG004|Phase B (Week 25 to Week 52)|Physician Decision|0
6224983|NCT01697592|9896626|FG005|Phase B (Week 25 to Week 52)|Physician Decision|0
6224984|NCT01697592|9896627|FG006|Phase B (Week 25 to Week 52)|Physician Decision|0
6224985|NCT01697592|9896628|FG007|Phase B (Week 25 to Week 52)|Physician Decision|0
6224986|NCT01697592|9896629|FG008|Phase B (Week 25 to Week 52)|Physician Decision|0
6224987|NCT01697592|9896630|FG009|Phase B (Week 25 to Week 52)|Physician Decision|0
6224988|NCT01697592|9896621|FG000|Phase B (Week 25 to Week 52)|Withdrawal by Subject|2
6224989|NCT01697592|9896622|FG001|Phase B (Week 25 to Week 52)|Withdrawal by Subject|0
6224990|NCT01697592|9896623|FG002|Phase B (Week 25 to Week 52)|Withdrawal by Subject|0
6290415|NCT02397096|10006371|FG001|Week 24 to Week 48|Lack of Efficacy|1
6290416|NCT02397096|10006370|FG000|Week 24 to Week 48|Non-Compliance With Study Drug|0
6290417|NCT02397096|10006371|FG001|Week 24 to Week 48|Non-Compliance With Study Drug|1
6290418|NCT02397096|10006370|FG000|Week 24 to Week 48|Physician Decision|2
6290419|NCT02397096|10006371|FG001|Week 24 to Week 48|Physician Decision|1
6290420|NCT02397096|10006370|FG000|Week 24 to Week 48|Withdrawal by Subject|5
6290421|NCT02397096|10006371|FG001|Week 24 to Week 48|Withdrawal by Subject|2
6290422|NCT02397096|10006370|FG000|Week 24 to Week 48|Lost to Follow-up|2
6290423|NCT02397096|10006371|FG001|Week 24 to Week 48|Lost to Follow-up|0
6290424|NCT02397096|10006370|FG000|Study Extensions|Ongoing|399
6290425|NCT02397096|10006371|FG001|Study Extensions|Ongoing|202
6290426|NCT02397278|10006406|FG000|Overall Study|Withdrawal by Subject|0
6290427|NCT02397278|10006407|FG001|Overall Study|Withdrawal by Subject|2
6224991|NCT01697592|9896624|FG003|Phase B (Week 25 to Week 52)|Withdrawal by Subject|0
6290428|NCT02397278|10006406|FG000|Overall Study|Deemed ineligible following surgery|1
6134714|NCT00990314|9763803|FG000|Overall Study|Lack of Efficacy|1
6134715|NCT00990340|9763809|FG000|First 14-day Treatment|Not Compliant|2
6134716|NCT00990340|9763810|FG001|First 14-day Treatment|Not Compliant|1
6134717|NCT00990340|9763809|FG000|First 14-day Treatment|Lost to Follow-up|2
6134718|NCT00990340|9763810|FG001|First 14-day Treatment|Lost to Follow-up|1
6134719|NCT00990340|9763809|FG000|First 14-day Treatment|Protocol Violation|2
6134720|NCT00990340|9763810|FG001|First 14-day Treatment|Protocol Violation|2
6134721|NCT00990652|9763838|FG000|Pre-surgical Bortezomib|Adverse Event|1
6134722|NCT00990652|9763838|FG000|Post-sugery Bortezomib + Temozolomide|Withdrawal by Subject|1
6134723|NCT00990665|9763843|FG000|Overall Study|Unsuccessful Implant|8
6134724|NCT00990665|9763843|FG000|Overall Study|Death|29
6134725|NCT00990665|9763843|FG000|Overall Study|Heart Transplant|1
6134726|NCT00990665|9763843|FG000|Overall Study|Withdrawal by Subject|6
6134727|NCT00990665|9763843|FG000|Overall Study|Lost to Follow-up|1
6134728|NCT00990665|9763843|FG000|Overall Study|System Explant|3
6134729|NCT00990704|9763851|FG000|Overall Study|Adverse Event|1
6134730|NCT00990704|9763852|FG001|Overall Study|Adverse Event|1
6134731|NCT00990704|9763851|FG000|Overall Study|Physician Decision|0
6134732|NCT00990704|9763852|FG001|Overall Study|Physician Decision|1
6134733|NCT00990821|9763885|FG000|Overall Study|Withdrawal by Subject|0
6134734|NCT00990821|9763886|FG001|Overall Study|Withdrawal by Subject|2
6134735|NCT00990821|9763887|FG002|Overall Study|Withdrawal by Subject|0
6224992|NCT01697592|9896625|FG004|Phase B (Week 25 to Week 52)|Withdrawal by Subject|0
6224993|NCT01697592|9896626|FG005|Phase B (Week 25 to Week 52)|Withdrawal by Subject|1
6224994|NCT01697592|9896627|FG006|Phase B (Week 25 to Week 52)|Withdrawal by Subject|0
6224995|NCT01697592|9896628|FG007|Phase B (Week 25 to Week 52)|Withdrawal by Subject|1
6224996|NCT01697592|9896629|FG008|Phase B (Week 25 to Week 52)|Withdrawal by Subject|0
6224997|NCT01697592|9896630|FG009|Phase B (Week 25 to Week 52)|Withdrawal by Subject|0
6224998|NCT01697592|9896621|FG000|Phase B (Week 25 to Week 52)|Adverse Event|2
6224999|NCT01697592|9896622|FG001|Phase B (Week 25 to Week 52)|Adverse Event|1
6225000|NCT01697592|9896623|FG002|Phase B (Week 25 to Week 52)|Adverse Event|1
6225001|NCT01697592|9896624|FG003|Phase B (Week 25 to Week 52)|Adverse Event|2
6225002|NCT01697592|9896625|FG004|Phase B (Week 25 to Week 52)|Adverse Event|0
6225003|NCT01697592|9896626|FG005|Phase B (Week 25 to Week 52)|Adverse Event|1
6225004|NCT01697592|9896627|FG006|Phase B (Week 25 to Week 52)|Adverse Event|1
6225005|NCT01697592|9896628|FG007|Phase B (Week 25 to Week 52)|Adverse Event|0
6225006|NCT01697592|9896629|FG008|Phase B (Week 25 to Week 52)|Adverse Event|2
6225007|NCT01697592|9896630|FG009|Phase B (Week 25 to Week 52)|Adverse Event|0
6225008|NCT01697696|9896668|FG000|Overall Study|Study terminated by sponsor|0
6225009|NCT01697696|9896669|FG001|Overall Study|Study terminated by sponsor|3
6225010|NCT01697696|9896668|FG000|Overall Study|Protocol deviation|1
6225011|NCT01697696|9896669|FG001|Overall Study|Protocol deviation|0
6225012|NCT01697696|9896668|FG000|Overall Study|Physician Decision|1
6225013|NCT01697696|9896669|FG001|Overall Study|Physician Decision|0
6225014|NCT01697696|9896668|FG000|Overall Study|Death|4
6225015|NCT01697696|9896669|FG001|Overall Study|Death|2
6225016|NCT01697696|9896668|FG000|Overall Study|Lost to Follow-up|10
6225017|NCT01697696|9896669|FG001|Overall Study|Lost to Follow-up|7
6225018|NCT01697696|9896668|FG000|Overall Study|Subject/guardian decision|31
6225019|NCT01697696|9896669|FG001|Overall Study|Subject/guardian decision|35
6225020|NCT01697748|9896686|FG000|Overall Study|ineligible skin incision|1
6225021|NCT01697748|9896687|FG001|Overall Study|ineligible skin incision|2
6225022|NCT01697748|9896686|FG000|Overall Study|ineligible uterine incision|4
6225023|NCT01697748|9896687|FG001|Overall Study|ineligible uterine incision|1
6225024|NCT01697748|9896686|FG000|Overall Study|Lost to Follow-up|53
6225025|NCT01697748|9896687|FG001|Overall Study|Lost to Follow-up|65
6225026|NCT01697956|9896695|FG000|Overall Study|Protocol Violation|1
6225027|NCT01697956|9896696|FG001|Overall Study|Protocol Violation|1
6225028|NCT01697969|9896708|FG000|Overall Study|Did not meet inc/exc criteria|3
6225029|NCT01698008|9896715|FG000|Overall Study|Withdrawal by Subject|1
6225030|NCT01698008|9896716|FG001|Overall Study|Withdrawal by Subject|2
6225031|NCT01698268|9896724|FG000|Overall Study|Physician Decision|2
6134736|NCT00990821|9763888|FG003|Overall Study|Withdrawal by Subject|0
6134737|NCT00990821|9763889|FG004|Overall Study|Withdrawal by Subject|3
6134738|NCT00990821|9763890|FG005|Overall Study|Withdrawal by Subject|3
6225032|NCT01698268|9896725|FG001|Overall Study|Physician Decision|1
6225033|NCT01698320|9896733|FG000|Run-In Period (Week -1 to Day 0)|Inclusion/exclusion criteria|24
6225034|NCT01698320|9896734|FG001|Run-In Period (Week -1 to Day 0)|Inclusion/exclusion criteria|0
6225035|NCT01698320|9896735|FG002|Run-In Period (Week -1 to Day 0)|Inclusion/exclusion criteria|0
6225036|NCT01698320|9896733|FG000|Run-In Period (Week -1 to Day 0)|Withdrawal by Subject|1
6225037|NCT01698320|9896734|FG001|Run-In Period (Week -1 to Day 0)|Withdrawal by Subject|0
6225038|NCT01698320|9896735|FG002|Run-In Period (Week -1 to Day 0)|Withdrawal by Subject|0
6225039|NCT01698320|9896733|FG000|Run-In Period (Week -1 to Day 0)|Lost to Follow-up|1
6134739|NCT00990821|9763891|FG006|Overall Study|Withdrawal by Subject|1
6134740|NCT00990821|9763892|FG007|Overall Study|Withdrawal by Subject|0
6134741|NCT00990821|9763893|FG008|Overall Study|Withdrawal by Subject|0
6134742|NCT00990821|9763894|FG009|Overall Study|Withdrawal by Subject|1
6134743|NCT00990821|9763895|FG010|Overall Study|Withdrawal by Subject|3
6134744|NCT00990821|9763896|FG011|Overall Study|Withdrawal by Subject|5
6134745|NCT00990821|9763897|FG012|Overall Study|Withdrawal by Subject|2
6134746|NCT00990821|9763898|FG013|Overall Study|Withdrawal by Subject|1
6134747|NCT00991276|9763974|FG000|First Intervention Period|Adverse Event|0
6134748|NCT00991276|9763975|FG001|First Intervention Period|Adverse Event|1
6134749|NCT00991276|9763976|FG002|First Intervention Period|Adverse Event|0
6134750|NCT00991276|9763977|FG003|First Intervention Period|Adverse Event|1
6134751|NCT00991276|9763978|FG004|First Intervention Period|Adverse Event|0
6134752|NCT00991276|9763979|FG005|First Intervention Period|Adverse Event|0
6134753|NCT00991276|9763974|FG000|First Intervention Period|Protocol Violation|0
6134754|NCT00991276|9763975|FG001|First Intervention Period|Protocol Violation|0
6134755|NCT00991276|9763976|FG002|First Intervention Period|Protocol Violation|0
6134756|NCT00991276|9763977|FG003|First Intervention Period|Protocol Violation|0
6134757|NCT00991276|9763978|FG004|First Intervention Period|Protocol Violation|2
6134758|NCT00991276|9763979|FG005|First Intervention Period|Protocol Violation|0
6134759|NCT00991276|9763974|FG000|First Intervention Period|Insufficient clinical response|0
6134760|NCT00991276|9763975|FG001|First Intervention Period|Insufficient clinical response|0
6134761|NCT00991276|9763976|FG002|First Intervention Period|Insufficient clinical response|0
6134762|NCT00991276|9763977|FG003|First Intervention Period|Insufficient clinical response|0
6225040|NCT01698320|9896734|FG001|Run-In Period (Week -1 to Day 0)|Lost to Follow-up|0
6225041|NCT01698320|9896735|FG002|Run-In Period (Week -1 to Day 0)|Lost to Follow-up|0
6225042|NCT01698320|9896733|FG000|Run-In Period (Week -1 to Day 0)|Other|1
6225043|NCT01698320|9896734|FG001|Run-In Period (Week -1 to Day 0)|Other|0
6225044|NCT01698320|9896735|FG002|Run-In Period (Week -1 to Day 0)|Other|0
6225045|NCT01698320|9896733|FG000|12-Week Double-Blind Period|Adverse Event|0
6225046|NCT01698320|9896734|FG001|12-Week Double-Blind Period|Adverse Event|1
6225047|NCT01698320|9896735|FG002|12-Week Double-Blind Period|Adverse Event|1
6225048|NCT01698320|9896733|FG000|12-Week Double-Blind Period|Withdrawal by Subject|0
6225049|NCT01698320|9896734|FG001|12-Week Double-Blind Period|Withdrawal by Subject|2
6225050|NCT01698320|9896735|FG002|12-Week Double-Blind Period|Withdrawal by Subject|2
6225051|NCT01698320|9896733|FG000|12-Week Double-Blind Period|Protocol Violation|0
6225052|NCT01698320|9896734|FG001|12-Week Double-Blind Period|Protocol Violation|0
6225053|NCT01698320|9896735|FG002|12-Week Double-Blind Period|Protocol Violation|2
6225054|NCT01698320|9896733|FG000|12-Week Double-Blind Period|Pregnancy|0
6225055|NCT01698320|9896734|FG001|12-Week Double-Blind Period|Pregnancy|1
6225056|NCT01698320|9896735|FG002|12-Week Double-Blind Period|Pregnancy|1
6225057|NCT01698320|9896733|FG000|12-Week Double-Blind Period|Sponsor requested subject withdrawal|0
6225058|NCT01698320|9896734|FG001|12-Week Double-Blind Period|Sponsor requested subject withdrawal|0
6225059|NCT01698320|9896735|FG002|12-Week Double-Blind Period|Sponsor requested subject withdrawal|2
6225060|NCT01698320|9896733|FG000|12-Week Double-Blind Period|Lost to Follow-up|0
6225061|NCT01698320|9896734|FG001|12-Week Double-Blind Period|Lost to Follow-up|0
6225062|NCT01698320|9896735|FG002|12-Week Double-Blind Period|Lost to Follow-up|4
6225063|NCT01698320|9896733|FG000|40-Week Open-Label Period|Adverse Event|0
6225064|NCT01698320|9896734|FG001|40-Week Open-Label Period|Adverse Event|3
6225065|NCT01698320|9896735|FG002|40-Week Open-Label Period|Adverse Event|2
6225066|NCT01698320|9896733|FG000|40-Week Open-Label Period|Withdrawal by Subject|0
6225067|NCT01698320|9896734|FG001|40-Week Open-Label Period|Withdrawal by Subject|11
6225068|NCT01698320|9896735|FG002|40-Week Open-Label Period|Withdrawal by Subject|7
6225069|NCT01698320|9896733|FG000|40-Week Open-Label Period|Pregnancy|0
6225070|NCT01698320|9896734|FG001|40-Week Open-Label Period|Pregnancy|2
6225071|NCT01698320|9896735|FG002|40-Week Open-Label Period|Pregnancy|1
6225072|NCT01698320|9896733|FG000|40-Week Open-Label Period|Sponsor requested subject withdrawal|0
6225073|NCT01698320|9896734|FG001|40-Week Open-Label Period|Sponsor requested subject withdrawal|1
6225074|NCT01698320|9896735|FG002|40-Week Open-Label Period|Sponsor requested subject withdrawal|0
6225075|NCT01698320|9896733|FG000|40-Week Open-Label Period|Lost to Follow-up|0
6225076|NCT01698320|9896734|FG001|40-Week Open-Label Period|Lost to Follow-up|2
6225077|NCT01698320|9896735|FG002|40-Week Open-Label Period|Lost to Follow-up|0
6225078|NCT01698554|9896773|FG000|Overall Study|Adverse Event|2
6225079|NCT01698554|9896774|FG001|Overall Study|Adverse Event|5
6225080|NCT01698554|9896775|FG002|Overall Study|Adverse Event|0
6225081|NCT01698554|9896776|FG003|Overall Study|Adverse Event|1
6225082|NCT01698554|9896773|FG000|Overall Study|Lost to Follow-up|1
6225083|NCT01698554|9896774|FG001|Overall Study|Lost to Follow-up|0
6225084|NCT01698554|9896775|FG002|Overall Study|Lost to Follow-up|0
6225085|NCT01698554|9896776|FG003|Overall Study|Lost to Follow-up|0
6225086|NCT01698554|9896773|FG000|Overall Study|Personal Reasons|0
6225087|NCT01698554|9896774|FG001|Overall Study|Personal Reasons|5
6225088|NCT01698554|9896775|FG002|Overall Study|Personal Reasons|1
6225089|NCT01698554|9896776|FG003|Overall Study|Personal Reasons|1
6225090|NCT01698554|9896773|FG000|Overall Study|Protocol Violation|2
6225091|NCT01698554|9896774|FG001|Overall Study|Protocol Violation|0
6225092|NCT01698554|9896775|FG002|Overall Study|Protocol Violation|1
6225093|NCT01698554|9896776|FG003|Overall Study|Protocol Violation|0
6134763|NCT00991276|9763978|FG004|First Intervention Period|Insufficient clinical response|1
6134764|NCT00991276|9763979|FG005|First Intervention Period|Insufficient clinical response|0
6134765|NCT00991276|9763974|FG000|First Intervention Period|Other|0
6134766|NCT00991276|9763975|FG001|First Intervention Period|Other|0
6134767|NCT00991276|9763976|FG002|First Intervention Period|Other|0
6134768|NCT00991276|9763977|FG003|First Intervention Period|Other|1
6134769|NCT00991276|9763978|FG004|First Intervention Period|Other|1
6134770|NCT00991276|9763979|FG005|First Intervention Period|Other|0
6134771|NCT00991276|9763974|FG000|First Intervention Period|Withdrawal by Subject|0
6134772|NCT00991276|9763975|FG001|First Intervention Period|Withdrawal by Subject|1
6134773|NCT00991276|9763976|FG002|First Intervention Period|Withdrawal by Subject|0
6134774|NCT00991276|9763977|FG003|First Intervention Period|Withdrawal by Subject|1
6134775|NCT00991276|9763978|FG004|First Intervention Period|Withdrawal by Subject|0
6134776|NCT00991276|9763979|FG005|First Intervention Period|Withdrawal by Subject|1
6134777|NCT00991276|9763974|FG000|First Intervention Period|Lost to Follow-up|0
6134778|NCT00991276|9763975|FG001|First Intervention Period|Lost to Follow-up|1
6134779|NCT00991276|9763976|FG002|First Intervention Period|Lost to Follow-up|0
6134780|NCT00991276|9763977|FG003|First Intervention Period|Lost to Follow-up|1
6134781|NCT00991276|9763978|FG004|First Intervention Period|Lost to Follow-up|0
6134782|NCT00991276|9763979|FG005|First Intervention Period|Lost to Follow-up|0
6134783|NCT00991276|9763974|FG000|Second Intervention Period|Adverse Event|0
6134784|NCT00991276|9763975|FG001|Second Intervention Period|Adverse Event|2
6134785|NCT00991276|9763976|FG002|Second Intervention Period|Adverse Event|0
6134786|NCT00991276|9763977|FG003|Second Intervention Period|Adverse Event|1
6225094|NCT01698554|9896773|FG000|Overall Study|Other Miscellaneous Reasons|1
6225095|NCT01698554|9896774|FG001|Overall Study|Other Miscellaneous Reasons|0
6225096|NCT01698554|9896775|FG002|Overall Study|Other Miscellaneous Reasons|0
6225097|NCT01698554|9896776|FG003|Overall Study|Other Miscellaneous Reasons|0
6290429|NCT02397278|10006407|FG001|Overall Study|Deemed ineligible following surgery|1
6290430|NCT02397408|10006422|FG000|Overall Study|Physician Decision|4
6290431|NCT02397408|10006422|FG000|Overall Study|Surgery not completed within protocol timeframe|2
6290432|NCT02397447|10006428|FG000|Overall Study|Lost to Follow-up|2
6290433|NCT02397447|10006429|FG001|Overall Study|Lost to Follow-up|2
6290434|NCT02397460|10006443|FG000|Treatment Period 2|Adverse Event|0
6290435|NCT02397460|10006444|FG001|Treatment Period 2|Adverse Event|0
6290436|NCT02397460|10006445|FG002|Treatment Period 2|Adverse Event|0
6290437|NCT02397460|10006446|FG003|Treatment Period 2|Adverse Event|0
6290438|NCT02397460|10006447|FG004|Treatment Period 2|Adverse Event|0
6290439|NCT02397460|10006448|FG005|Treatment Period 2|Adverse Event|0
6290440|NCT02397460|10006449|FG006|Treatment Period 2|Adverse Event|0
6290441|NCT02397460|10006450|FG007|Treatment Period 2|Adverse Event|1
6290442|NCT02397460|10006443|FG000|Treatment Period 4|Adverse Event|0
6290443|NCT02397460|10006444|FG001|Treatment Period 4|Adverse Event|1
6290444|NCT02397460|10006445|FG002|Treatment Period 4|Adverse Event|0
6290445|NCT02397460|10006446|FG003|Treatment Period 4|Adverse Event|0
6290446|NCT02397460|10006447|FG004|Treatment Period 4|Adverse Event|0
6290447|NCT02397460|10006448|FG005|Treatment Period 4|Adverse Event|0
6290448|NCT02397460|10006449|FG006|Treatment Period 4|Adverse Event|0
6290449|NCT02397460|10006450|FG007|Treatment Period 4|Adverse Event|0
6290450|NCT02397460|10006443|FG000|Treatment Period 4|Physician Decision|0
6290451|NCT02397460|10006444|FG001|Treatment Period 4|Physician Decision|0
6290452|NCT02397460|10006445|FG002|Treatment Period 4|Physician Decision|0
6290453|NCT02397460|10006446|FG003|Treatment Period 4|Physician Decision|0
6290454|NCT02397460|10006447|FG004|Treatment Period 4|Physician Decision|1
6290455|NCT02397460|10006448|FG005|Treatment Period 4|Physician Decision|0
6290456|NCT02397460|10006449|FG006|Treatment Period 4|Physician Decision|0
6290457|NCT02397460|10006450|FG007|Treatment Period 4|Physician Decision|0
6290458|NCT02397473|10006526|FG000|Treatment Phase|Adverse Event|1
6134787|NCT00991276|9763978|FG004|Second Intervention Period|Adverse Event|1
6134788|NCT00991276|9763979|FG005|Second Intervention Period|Adverse Event|0
6134789|NCT00991276|9763974|FG000|Second Intervention Period|Protocol Violation|1
6134790|NCT00991276|9763975|FG001|Second Intervention Period|Protocol Violation|0
6134791|NCT00991276|9763976|FG002|Second Intervention Period|Protocol Violation|0
6134792|NCT00991276|9763977|FG003|Second Intervention Period|Protocol Violation|0
6134793|NCT00991276|9763978|FG004|Second Intervention Period|Protocol Violation|0
6134794|NCT00991276|9763979|FG005|Second Intervention Period|Protocol Violation|0
6134795|NCT00991276|9763974|FG000|Second Intervention Period|Other|0
6134796|NCT00991276|9763975|FG001|Second Intervention Period|Other|0
6134797|NCT00991276|9763976|FG002|Second Intervention Period|Other|0
6134798|NCT00991276|9763977|FG003|Second Intervention Period|Other|1
6134799|NCT00991276|9763978|FG004|Second Intervention Period|Other|0
6134800|NCT00991276|9763979|FG005|Second Intervention Period|Other|1
6290459|NCT02397473|10006527|FG001|Treatment Phase|Adverse Event|2
6290460|NCT02397473|10006526|FG000|Treatment Phase|Lack of Efficacy|8
6290461|NCT02397473|10006527|FG001|Treatment Phase|Lack of Efficacy|1
6290462|NCT02397473|10006526|FG000|Treatment Phase|Lost to Follow-up|1
6290463|NCT02397473|10006527|FG001|Treatment Phase|Lost to Follow-up|0
6290464|NCT02397473|10006526|FG000|Treatment Phase|Withdrawal by Subject|2
6290465|NCT02397473|10006527|FG001|Treatment Phase|Withdrawal by Subject|1
6290466|NCT02397473|10006526|FG000|Treatment Phase|Protocol Violation(did not receive drug)|0
6134801|NCT00991276|9763974|FG000|Third Intervention Period|Protocol Violation|1
6134802|NCT00991276|9763975|FG001|Third Intervention Period|Protocol Violation|0
6134803|NCT00991276|9763976|FG002|Third Intervention Period|Protocol Violation|0
6134804|NCT00991276|9763977|FG003|Third Intervention Period|Protocol Violation|0
6134805|NCT00991276|9763978|FG004|Third Intervention Period|Protocol Violation|0
6290467|NCT02397473|10006527|FG001|Treatment Phase|Protocol Violation(did not receive drug)|3
6134806|NCT00991276|9763979|FG005|Third Intervention Period|Protocol Violation|0
6134807|NCT00991276|9763974|FG000|Third Intervention Period|Other|0
6134808|NCT00991276|9763975|FG001|Third Intervention Period|Other|0
6134809|NCT00991276|9763976|FG002|Third Intervention Period|Other|0
6134810|NCT00991276|9763977|FG003|Third Intervention Period|Other|0
6134811|NCT00991276|9763978|FG004|Third Intervention Period|Other|0
6134812|NCT00991276|9763979|FG005|Third Intervention Period|Other|1
6134813|NCT00991276|9763974|FG000|Third Intervention Period|Adverse Event|0
6134814|NCT00991276|9763975|FG001|Third Intervention Period|Adverse Event|0
6134815|NCT00991276|9763976|FG002|Third Intervention Period|Adverse Event|1
6134816|NCT00991276|9763977|FG003|Third Intervention Period|Adverse Event|0
6134817|NCT00991276|9763978|FG004|Third Intervention Period|Adverse Event|0
6134818|NCT00991276|9763979|FG005|Third Intervention Period|Adverse Event|0
6134819|NCT00991276|9763974|FG000|Third Intervention Period|Withdrawal by Subject|0
6134820|NCT00991276|9763975|FG001|Third Intervention Period|Withdrawal by Subject|0
6134821|NCT00991276|9763976|FG002|Third Intervention Period|Withdrawal by Subject|0
6134822|NCT00991276|9763977|FG003|Third Intervention Period|Withdrawal by Subject|1
6134823|NCT00991276|9763978|FG004|Third Intervention Period|Withdrawal by Subject|0
6134824|NCT00991276|9763979|FG005|Third Intervention Period|Withdrawal by Subject|0
6225098|NCT01698775|9896805|FG000|Phase A|Adverse Event|2
6225099|NCT01698775|9896806|FG001|Phase A|Adverse Event|1
6225100|NCT01698775|9896805|FG000|Phase A|Death|1
6225101|NCT01698775|9896806|FG001|Phase A|Death|1
6225102|NCT01698775|9896805|FG000|Phase A|Lack of Efficacy|1
6225103|NCT01698775|9896806|FG001|Phase A|Lack of Efficacy|0
6225104|NCT01698775|9896805|FG000|Phase A|Lost to Follow-up|1
6225105|NCT01698775|9896806|FG001|Phase A|Lost to Follow-up|2
6225106|NCT01698775|9896805|FG000|Phase A|Protocol Violation|1
6225107|NCT01698775|9896806|FG001|Phase A|Protocol Violation|0
6225108|NCT01698775|9896805|FG000|Phase A|Withdrawal by Subject|3
6225109|NCT01698775|9896806|FG001|Phase A|Withdrawal by Subject|4
6225110|NCT01698775|9896805|FG000|Phase A|Kidney [transplant]|0
6225111|NCT01698775|9896806|FG001|Phase A|Kidney [transplant]|1
6225112|NCT01698775|9896805|FG000|Phase B|Hyperglycemia Discontinuation Criteria|0
6225113|NCT01698775|9896806|FG001|Phase B|Hyperglycemia Discontinuation Criteria|1
6225114|NCT01698775|9896805|FG000|Phase B|Adverse Event|6
6290468|NCT02397473|10006526|FG000|Post Treatment Follow-up Phase|Lack of Efficacy|1
6290469|NCT02397473|10006527|FG001|Post Treatment Follow-up Phase|Lack of Efficacy|1
6290470|NCT02397473|10006526|FG000|Post Treatment Follow-up Phase|Lost to Follow-up|1
6290471|NCT02397473|10006527|FG001|Post Treatment Follow-up Phase|Lost to Follow-up|0
6290472|NCT02397473|10006526|FG000|Post Treatment Follow-up Phase|Protocol Violation|1
6290473|NCT02397473|10006527|FG001|Post Treatment Follow-up Phase|Protocol Violation|0
6290474|NCT02397473|10006526|FG000|Post Treatment Follow-up Phase|Withdrawal by Subject|0
6290475|NCT02397473|10006527|FG001|Post Treatment Follow-up Phase|Withdrawal by Subject|1
6290476|NCT02397655|10006541|FG000|Overall Study|data not completed|1301
6290477|NCT02397694|10006547|FG000|Double-Blinded Phase|Adverse Event|1
6290478|NCT02397694|10006548|FG001|Double-Blinded Phase|Adverse Event|0
5981106|NCT02253316|9570078|FG001|Consolidation|Patient Withdrew Logistical Concerns|0
5981107|NCT02253316|9570079|FG002|Consolidation|Patient Withdrew Logistical Concerns|0
5981108|NCT02253316|9570077|FG000|Consolidation|Secondary Malignancy|2
5981109|NCT02253316|9570078|FG001|Consolidation|Secondary Malignancy|0
5981110|NCT02253316|9570079|FG002|Consolidation|Secondary Malignancy|0
5981111|NCT02253316|9570077|FG000|Consolidation|Adverse Event|7
5981112|NCT02253316|9570078|FG001|Consolidation|Adverse Event|0
5981113|NCT02253316|9570079|FG002|Consolidation|Adverse Event|0
5981114|NCT02253316|9570077|FG000|Maintenance|Patient Withdrew Logistical Concerns|0
5981115|NCT02253316|9570078|FG001|Maintenance|Patient Withdrew Logistical Concerns|6
5981116|NCT02253316|9570079|FG002|Maintenance|Patient Withdrew Logistical Concerns|6
5981117|NCT02253316|9570077|FG000|Maintenance|Physician Decision|0
5981118|NCT02253316|9570078|FG001|Maintenance|Physician Decision|5
5981119|NCT02253316|9570079|FG002|Maintenance|Physician Decision|16
5981120|NCT02253316|9570077|FG000|Maintenance|Non-Compliance|0
5981121|NCT02253316|9570078|FG001|Maintenance|Non-Compliance|1
5981122|NCT02253316|9570079|FG002|Maintenance|Non-Compliance|1
5981123|NCT02253316|9570077|FG000|Maintenance|Secondary Malignancy|0
5981124|NCT02253316|9570078|FG001|Maintenance|Secondary Malignancy|1
5981125|NCT02253316|9570079|FG002|Maintenance|Secondary Malignancy|5
5981126|NCT02253316|9570077|FG000|Maintenance|Adverse Event|0
5981127|NCT02253316|9570078|FG001|Maintenance|Adverse Event|8
6134825|NCT00991289|9763988|FG000|Overall Study|Adverse Event|1
6225115|NCT01698775|9896806|FG001|Phase B|Adverse Event|3
6225116|NCT01698775|9896805|FG000|Phase B|Death|0
6225117|NCT01698775|9896806|FG001|Phase B|Death|1
6225118|NCT01698775|9896805|FG000|Phase B|Lack of Efficacy|0
5981128|NCT02253316|9570079|FG002|Maintenance|Adverse Event|12
5981129|NCT02253316|9570077|FG000|Maintenance|Still receiving active treatment|0
6134826|NCT00991289|9763988|FG000|Overall Study|Physician Decision|2
6134827|NCT00991289|9763988|FG000|Overall Study|Withdrawal by Subject|3
6134828|NCT00991289|9763988|FG000|Overall Study|Lost to Follow-up|4
6134829|NCT00991289|9763988|FG000|Overall Study|Protocol Violation|2
6134830|NCT00991302|9763994|FG000|Overall Study|Death|0
6225119|NCT01698775|9896806|FG001|Phase B|Lack of Efficacy|1
5981130|NCT02253316|9570078|FG001|Maintenance|Still receiving active treatment|25
6225120|NCT01698775|9896805|FG000|Phase B|Lost to Follow-up|0
6225121|NCT01698775|9896806|FG001|Phase B|Lost to Follow-up|1
6134831|NCT00991302|9763995|FG001|Overall Study|Death|1
6134832|NCT00991302|9763994|FG000|Overall Study|Lost to Follow-up|14
6134833|NCT00991302|9763995|FG001|Overall Study|Lost to Follow-up|12
6134834|NCT00991341|9764003|FG000|Overall Study|no surgery w/in 30 days of randomization|11
6134835|NCT00991341|9764004|FG001|Overall Study|no surgery w/in 30 days of randomization|18
6134836|NCT00991341|9764003|FG000|Overall Study|Death|3
6134837|NCT00991341|9764004|FG001|Overall Study|Death|0
6134838|NCT00991341|9764003|FG000|Overall Study|no RBCs received 96hrs after randomized|186
6134839|NCT00991341|9764004|FG001|Overall Study|no RBCs received 96hrs after randomized|155
6134840|NCT00991341|9764003|FG000|Overall Study|Physician Decision|1
6134841|NCT00991341|9764004|FG001|Overall Study|Physician Decision|2
6134842|NCT00991341|9764003|FG000|Overall Study|Withdrawal by Subject|3
6134843|NCT00991341|9764004|FG001|Overall Study|Withdrawal by Subject|4
6134844|NCT00991406|9764010|FG000|Overall Study|One participant did not respond to FES.|1
6134845|NCT00991510|9764029|FG000|Period I (Days 1-14)|Adverse Event|1
6134846|NCT00991510|9764030|FG001|Period I (Days 1-14)|Adverse Event|0
6134847|NCT00991510|9764029|FG000|Period III (Days 29-112)|Adverse Event|1
6134848|NCT00991510|9764030|FG001|Period III (Days 29-112)|Adverse Event|1
6134849|NCT00991939|9764053|FG000|Overall Study|Lost to Follow-up|0
6134850|NCT00991939|9764054|FG001|Overall Study|Lost to Follow-up|1
6134851|NCT00991939|9764053|FG000|Overall Study|Withdrawal by Subject|1
6134852|NCT00991939|9764054|FG001|Overall Study|Withdrawal by Subject|0
6134853|NCT00991939|9764053|FG000|Overall Study|Entire study terminated|4
6134854|NCT00991939|9764054|FG001|Overall Study|Entire study terminated|1
6134855|NCT00991952|9764064|FG000|Overall Study|Adverse Event|0
6134856|NCT00991952|9764065|FG001|Overall Study|Adverse Event|1
6134857|NCT00992017|9764071|FG000|Overall Study|Lost to Follow-up|2
6134858|NCT00992017|9764071|FG000|Overall Study|Withdrawal by Subject|2
6134859|NCT00992017|9764071|FG000|Overall Study|Unable to get to clinic|5
6134860|NCT00992017|9764071|FG000|Overall Study|Not adhere to study requirements|1
6134861|NCT00992056|9764082|FG000|Treatment Period 1 (6 Weeks)|Withdrawal by Subject|1
6134862|NCT00992056|9764083|FG001|Treatment Period 1 (6 Weeks)|Withdrawal by Subject|2
6134863|NCT00992056|9764082|FG000|Washout Period (2 Weeks)|Physician Decision|1
6134864|NCT00992056|9764083|FG001|Washout Period (2 Weeks)|Physician Decision|0
6134865|NCT00992108|9764091|FG000|Overall Study|Lost to Follow-up|0
6134866|NCT00992108|9764092|FG001|Overall Study|Lost to Follow-up|1
6134867|NCT00992186|9764098|FG000|Overall Study|Withdrawal by Subject|2
6134868|NCT00992186|9764098|FG000|Overall Study|Protocol Violation|1
6134869|NCT00992186|9764098|FG000|Overall Study|Physician Decision|1
6134870|NCT00992186|9764098|FG000|Overall Study|Adverse Event|9
6134871|NCT00992186|9764098|FG000|Overall Study|Progressive Disease|30
6134872|NCT00992186|9764098|FG000|Overall Study|Refusal To Receive Study Agent|3
6134873|NCT00992225|9764103|FG000|Overall Study|Entry Criteria Not Met|8
6134874|NCT00992225|9764103|FG000|Overall Study|Adverse Event|2
6134875|NCT00992394|9764151|FG000|Overall Study|Lack of Efficacy|6
6134876|NCT00992394|9764152|FG001|Overall Study|Lack of Efficacy|3
6134877|NCT00992394|9764151|FG000|Overall Study|Adverse Event|4
6134878|NCT00992394|9764152|FG001|Overall Study|Adverse Event|5
6134879|NCT00992394|9764151|FG000|Overall Study|Withdrawal by Subject|8
6134880|NCT00992394|9764152|FG001|Overall Study|Withdrawal by Subject|2
6134881|NCT00992394|9764151|FG000|Overall Study|Physician Decision|1
6225122|NCT01698775|9896805|FG000|Phase B|Physician Decision|1
6225123|NCT01698775|9896806|FG001|Phase B|Physician Decision|1
6225124|NCT01698775|9896805|FG000|Phase B|Protocol Violation|1
6225125|NCT01698775|9896806|FG001|Phase B|Protocol Violation|1
6225126|NCT01698775|9896805|FG000|Phase B|Withdrawal by Subject|6
6225127|NCT01698775|9896806|FG001|Phase B|Withdrawal by Subject|2
6225128|NCT01698801|9896816|FG000|Treatment Phase|Adverse Event|4
6225129|NCT01698801|9896816|FG000|Treatment Phase|Protocol Violation|1
6225130|NCT01698801|9896816|FG000|Treatment Phase|Other|4
6134882|NCT00992394|9764152|FG001|Overall Study|Physician Decision|0
6134883|NCT00992394|9764151|FG000|Overall Study|Protocol Violation|2
6134884|NCT00992394|9764152|FG001|Overall Study|Protocol Violation|4
6134885|NCT00992394|9764151|FG000|Overall Study|Lost to Follow-up|2
6134886|NCT00992394|9764152|FG001|Overall Study|Lost to Follow-up|0
6134887|NCT00992394|9764151|FG000|Overall Study|Other event|1
6134888|NCT00992394|9764152|FG001|Overall Study|Other event|0
6134889|NCT00992407|9764160|FG000|Overall Study|Protocol Violation|2
6134890|NCT00992407|9764161|FG001|Overall Study|Protocol Violation|1
6134891|NCT00992407|9764160|FG000|Overall Study|Lost to Follow-up|3
6225131|NCT01698801|9896816|FG000|Treatment Phase|Withdrawal by Subject|1
6225132|NCT01698801|9896816|FG000|Treatment Phase|Disease progression|1
6134892|NCT00992407|9764161|FG001|Overall Study|Lost to Follow-up|3
6134893|NCT00992407|9764160|FG000|Overall Study|Adverse Event|3
6134894|NCT00992407|9764161|FG001|Overall Study|Adverse Event|2
6134895|NCT00992407|9764160|FG000|Overall Study|protocol Violation & Adverse events|2
6134896|NCT00992407|9764161|FG001|Overall Study|protocol Violation & Adverse events|4
6134897|NCT00992407|9764160|FG000|Overall Study|Other|2
6134898|NCT00992407|9764161|FG001|Overall Study|Other|0
6134899|NCT00992407|9764160|FG000|Overall Study|Loss of follow-up & Adverse events|2
6134900|NCT00992407|9764161|FG001|Overall Study|Loss of follow-up & Adverse events|1
6134901|NCT00992407|9764160|FG000|Overall Study|Study medication not administered|17
6134902|NCT00992407|9764161|FG001|Overall Study|Study medication not administered|13
6225133|NCT01698801|9896816|FG000|Follow Up Phase|Withdrawal by Subject|1
6134903|NCT00992446|9764179|FG000|Overall Study|Disease Progression|1
6134904|NCT00992446|9764179|FG000|Overall Study|Withdrawal by Subject|2
6134905|NCT00992446|9764179|FG000|Overall Study|Maintenance Therapy Screen Fail|5
6134906|NCT00992459|9764185|FG000|Overall Study|Withdrawal by Subject|0
6134907|NCT00992459|9764186|FG001|Overall Study|Withdrawal by Subject|1
6134908|NCT00992459|9764185|FG000|Overall Study|Adverse Event|1
6134909|NCT00992459|9764186|FG001|Overall Study|Adverse Event|0
6134910|NCT00992511|9764196|FG000|Overall Study|Migrated/moved from study area|1
6134911|NCT00992511|9764197|FG001|Overall Study|Migrated/moved from study area|0
6134912|NCT00992511|9764198|FG002|Overall Study|Migrated/moved from study area|1
6134913|NCT00992511|9764199|FG003|Overall Study|Migrated/moved from study area|2
6134914|NCT00992511|9764196|FG000|Overall Study|Lost to Follow-up|1
6134915|NCT00992511|9764197|FG001|Overall Study|Lost to Follow-up|0
6134916|NCT00992511|9764198|FG002|Overall Study|Lost to Follow-up|0
6134917|NCT00992511|9764199|FG003|Overall Study|Lost to Follow-up|2
6134918|NCT00992511|9764196|FG000|Overall Study|Withdrawal by Subject|0
6134919|NCT00992511|9764197|FG001|Overall Study|Withdrawal by Subject|0
6134920|NCT00992511|9764198|FG002|Overall Study|Withdrawal by Subject|1
6134921|NCT00992511|9764199|FG003|Overall Study|Withdrawal by Subject|1
6134922|NCT00992589|9764209|FG000|Open-Label Phase|Adverse Event|4
6134923|NCT00992589|9764210|FG001|Open-Label Phase|Adverse Event|0
6134924|NCT00992589|9764211|FG002|Open-Label Phase|Adverse Event|0
6134925|NCT00992589|9764212|FG003|Open-Label Phase|Adverse Event|0
6134926|NCT00992589|9764209|FG000|Open-Label Phase|Withdrawal by Subject|20
6134927|NCT00992589|9764210|FG001|Open-Label Phase|Withdrawal by Subject|0
6134928|NCT00992589|9764211|FG002|Open-Label Phase|Withdrawal by Subject|0
6134929|NCT00992589|9764212|FG003|Open-Label Phase|Withdrawal by Subject|0
6134930|NCT00992589|9764209|FG000|Open-Label Phase|Lost to Follow-up|1
6134931|NCT00992589|9764210|FG001|Open-Label Phase|Lost to Follow-up|0
6134932|NCT00992589|9764211|FG002|Open-Label Phase|Lost to Follow-up|0
6134933|NCT00992589|9764212|FG003|Open-Label Phase|Lost to Follow-up|0
6134934|NCT00992589|9764209|FG000|Open-Label Phase|Protocol Violation|3
6225134|NCT01698801|9896816|FG000|Follow Up Phase|Death|4
6225135|NCT01698814|9896823|FG000|Overall Study|Adverse Event|0
6225136|NCT01698814|9896824|FG001|Overall Study|Adverse Event|2
6225137|NCT01698814|9896823|FG000|Overall Study|Lost to Follow-up|0
6225138|NCT01698814|9896824|FG001|Overall Study|Lost to Follow-up|1
6225139|NCT01698814|9896823|FG000|Overall Study|Pregnancy|1
6225140|NCT01698814|9896824|FG001|Overall Study|Pregnancy|0
6225141|NCT01698814|9896823|FG000|Overall Study|Randomized in error|1
6225142|NCT01698814|9896824|FG001|Overall Study|Randomized in error|0
6225143|NCT01698879|9896833|FG000|Overall Study|Withdrawal by Subject|1
6225144|NCT01698879|9896834|FG001|Overall Study|Withdrawal by Subject|0
6225145|NCT01698879|9896835|FG002|Overall Study|Withdrawal by Subject|0
6225146|NCT01699022|9896849|FG000|Overall Study|Early discontinuation from the study|3
6225147|NCT01699087|9896854|FG000|Overall Study|Lost to Follow-up|7
6225148|NCT01699087|9896854|FG000|Overall Study|Screen failure (prior to treatment)|15
6225149|NCT01699087|9896854|FG000|Overall Study|Unable to make future visits|2
6225150|NCT01699178|9896861|FG000|Overall Study|Adverse Event|1
6225151|NCT01699178|9896862|FG001|Overall Study|Adverse Event|5
6225152|NCT01699178|9896861|FG000|Overall Study|Lost to Follow-up|1
6225153|NCT01699178|9896862|FG001|Overall Study|Lost to Follow-up|6
6225154|NCT01699178|9896861|FG000|Overall Study|Non-compliance with Study Drug|3
6225155|NCT01699178|9896862|FG001|Overall Study|Non-compliance with Study Drug|1
6225156|NCT01699178|9896861|FG000|Overall Study|Physician Decision|1
6225157|NCT01699178|9896862|FG001|Overall Study|Physician Decision|0
6225158|NCT01699178|9896861|FG000|Overall Study|Withdrawal by Subject|4
6225159|NCT01699178|9896862|FG001|Overall Study|Withdrawal by Subject|12
6225160|NCT01699178|9896861|FG000|Overall Study|Hematocrit >54%|1
6225161|NCT01699178|9896862|FG001|Overall Study|Hematocrit >54%|1
6225162|NCT01699178|9896861|FG000|Overall Study|PSA increase of >1.4 ng/mL|4
6225163|NCT01699178|9896862|FG001|Overall Study|PSA increase of >1.4 ng/mL|3
6225164|NCT01699178|9896861|FG000|Overall Study|ineligible/noncompliant/ subject reason|4
6225165|NCT01699178|9896862|FG001|Overall Study|ineligible/noncompliant/ subject reason|4
6225166|NCT01699503|9896879|FG000|Overall Study|Death|31
6225167|NCT01699503|9896880|FG001|Overall Study|Death|40
6225168|NCT01699503|9896879|FG000|Overall Study|Withdrawal by Subject|65
6225169|NCT01699503|9896880|FG001|Overall Study|Withdrawal by Subject|57
6225170|NCT01699503|9896879|FG000|Overall Study|Lost to Follow-up|121
6225171|NCT01699503|9896880|FG001|Overall Study|Lost to Follow-up|117
6225172|NCT01699503|9896879|FG000|Overall Study|Excluded due to quality|783
6225173|NCT01699503|9896880|FG001|Overall Study|Excluded due to quality|791
6225174|NCT01699685|9896905|FG000|Period 1|Adverse Event|1
6225175|NCT01699685|9896906|FG001|Period 1|Adverse Event|1
6225176|NCT01699685|9896905|FG000|Period 1|Medical or ethical, noncompliance|2
6225177|NCT01699685|9896906|FG001|Period 1|Medical or ethical, noncompliance|0
6225178|NCT01699685|9896905|FG000|Period 1|Other|0
6225179|NCT01699685|9896906|FG001|Period 1|Other|1
6225180|NCT01699685|9896905|FG000|Period 1|Patient request|0
6225181|NCT01699685|9896906|FG001|Period 1|Patient request|1
6225182|NCT01699685|9896905|FG000|Period 2|Lost to Follow-up|1
6225183|NCT01699685|9896906|FG001|Period 2|Lost to Follow-up|0
6225184|NCT01699750|9896924|FG000|Overall Study|Withdrew Consent|0
6225185|NCT01699750|9896925|FG001|Overall Study|Withdrew Consent|1
6134935|NCT00992589|9764210|FG001|Open-Label Phase|Protocol Violation|0
6134936|NCT00992589|9764211|FG002|Open-Label Phase|Protocol Violation|0
6134937|NCT00992589|9764212|FG003|Open-Label Phase|Protocol Violation|0
6134938|NCT00992589|9764209|FG000|Open-Label Phase|Physician Decision|4
6134939|NCT00992589|9764210|FG001|Open-Label Phase|Physician Decision|0
6134940|NCT00992589|9764211|FG002|Open-Label Phase|Physician Decision|0
6134941|NCT00992589|9764212|FG003|Open-Label Phase|Physician Decision|0
6134942|NCT00992589|9764209|FG000|Open-Label Phase|Other|45
6134943|NCT00992589|9764210|FG001|Open-Label Phase|Other|0
6134944|NCT00992589|9764211|FG002|Open-Label Phase|Other|0
6134945|NCT00992589|9764212|FG003|Open-Label Phase|Other|0
6134946|NCT00992589|9764209|FG000|Double-Blind Phase|Adverse Event|0
6134947|NCT00992589|9764210|FG001|Double-Blind Phase|Adverse Event|6
6134948|NCT00992589|9764211|FG002|Double-Blind Phase|Adverse Event|2
6134949|NCT00992589|9764212|FG003|Double-Blind Phase|Adverse Event|3
6134950|NCT00992589|9764209|FG000|Double-Blind Phase|Withdrawal by Subject|0
6134951|NCT00992589|9764210|FG001|Double-Blind Phase|Withdrawal by Subject|6
6134952|NCT00992589|9764211|FG002|Double-Blind Phase|Withdrawal by Subject|5
6134953|NCT00992589|9764212|FG003|Double-Blind Phase|Withdrawal by Subject|2
6134954|NCT00992589|9764209|FG000|Double-Blind Phase|Lost to Follow-up|0
6134955|NCT00992589|9764210|FG001|Double-Blind Phase|Lost to Follow-up|0
6134956|NCT00992589|9764211|FG002|Double-Blind Phase|Lost to Follow-up|0
6134957|NCT00992589|9764212|FG003|Double-Blind Phase|Lost to Follow-up|2
6134958|NCT00992589|9764209|FG000|Double-Blind Phase|Other|0
6134959|NCT00992589|9764210|FG001|Double-Blind Phase|Other|1
6134960|NCT00992589|9764211|FG002|Double-Blind Phase|Other|6
6134961|NCT00992589|9764212|FG003|Double-Blind Phase|Other|3
6134962|NCT00992784|9764250|FG000|Overall Study|Adverse Event|2
6134963|NCT00992784|9764251|FG001|Overall Study|Adverse Event|1
6134964|NCT00992784|9764252|FG002|Overall Study|Adverse Event|0
6134965|NCT00992784|9764250|FG000|Overall Study|Withdrawal by Subject|1
6134966|NCT00992784|9764251|FG001|Overall Study|Withdrawal by Subject|1
6134967|NCT00992784|9764252|FG002|Overall Study|Withdrawal by Subject|1
6134968|NCT00992836|9764260|FG000|Overall Study|Lost to Follow-up|1
6134969|NCT00992836|9764260|FG000|Overall Study|Withdrawal by Subject|2
6134970|NCT00992836|9764260|FG000|Overall Study|Protocol Violation|2
6225186|NCT01699750|9896924|FG000|Overall Study|Other|0
6225187|NCT01699750|9896925|FG001|Overall Study|Other|2
6225188|NCT01699789|9896941|FG000|Overall Study|Withdrawal by Subject|18
6225189|NCT01699789|9896942|FG001|Overall Study|Withdrawal by Subject|23
6225190|NCT01699789|9896941|FG000|Overall Study|Death|1
6225191|NCT01699789|9896942|FG001|Overall Study|Death|2
6225192|NCT01699789|9896941|FG000|Overall Study|Lost to Follow-up|83
6225193|NCT01699789|9896942|FG001|Overall Study|Lost to Follow-up|101
6225194|NCT01699815|9896952|FG000|Overall Study|Protocol Violation|4
6225195|NCT01699815|9896953|FG001|Overall Study|Protocol Violation|7
6225196|NCT01699815|9896952|FG000|Overall Study|record could not be located|1
6225197|NCT01699815|9896953|FG001|Overall Study|record could not be located|0
6225198|NCT01699815|9896952|FG000|Overall Study|Adverse Event|0
6225199|NCT01699815|9896953|FG001|Overall Study|Adverse Event|1
6225200|NCT01699867|9896959|FG000|Overall Study|Screening Failure|3
6225201|NCT01700049|9896967|FG000|Overall Study|Withdrawal by Subject|1
6225202|NCT01700140|9896975|FG000|Overall Study|Use of rescue drugs|3
6225203|NCT01700140|9896976|FG001|Overall Study|Use of rescue drugs|3
6225204|NCT01700140|9896977|FG002|Overall Study|Use of rescue drugs|1
6225205|NCT01700140|9896975|FG000|Overall Study|Discontinuation of radiotherapy|1
6225206|NCT01700140|9896976|FG001|Overall Study|Discontinuation of radiotherapy|0
6225207|NCT01700140|9896977|FG002|Overall Study|Discontinuation of radiotherapy|0
6225208|NCT01700140|9896975|FG000|Overall Study|Use of chemotherapy or surgical therapy|0
6225209|NCT01700140|9896976|FG001|Overall Study|Use of chemotherapy or surgical therapy|1
6225210|NCT01700140|9896977|FG002|Overall Study|Use of chemotherapy or surgical therapy|0
6134971|NCT00992992|9764279|FG000|Overall Study|Lost to Follow-up|3
6134972|NCT00992992|9764279|FG000|Overall Study|Death|16
6134973|NCT00992992|9764279|FG000|Overall Study|GlaxoSmithKline Closed the Study|2
6134974|NCT00992992|9764279|FG000|Overall Study|Sponsor Closed the Study|4
6225211|NCT01700140|9896975|FG000|Overall Study|Aggravation of symptoms|1
6225212|NCT01700140|9896976|FG001|Overall Study|Aggravation of symptoms|0
6225213|NCT01700140|9896977|FG002|Overall Study|Aggravation of symptoms|0
6225214|NCT01700140|9896975|FG000|Overall Study|Adverse Event|0
6225215|NCT01700140|9896976|FG001|Overall Study|Adverse Event|1
6225216|NCT01700140|9896977|FG002|Overall Study|Adverse Event|0
6225217|NCT01700140|9896975|FG000|Overall Study|Inclusion/exclusion criteria deviation|1
6225218|NCT01700140|9896976|FG001|Overall Study|Inclusion/exclusion criteria deviation|4
6225219|NCT01700140|9896977|FG002|Overall Study|Inclusion/exclusion criteria deviation|0
6225220|NCT01700179|9896988|FG000|Overall Study|Physician Decision|2
6225221|NCT01700192|9896994|FG000|Overall Study|Adverse Event|73
6225222|NCT01700192|9896995|FG001|Overall Study|Adverse Event|18
6134975|NCT00993031|9764285|FG000|Overall Study|Death|0
6134976|NCT00993031|9764286|FG001|Overall Study|Death|1
6134977|NCT00993031|9764285|FG000|Overall Study|Physician Decision|0
6134978|NCT00993031|9764286|FG001|Overall Study|Physician Decision|2
6134979|NCT00993031|9764285|FG000|Overall Study|Withdrawal by Subject|3
6134980|NCT00993031|9764286|FG001|Overall Study|Withdrawal by Subject|3
6134981|NCT00993031|9764285|FG000|Overall Study|Lost to Follow-up|19
6134982|NCT00993031|9764286|FG001|Overall Study|Lost to Follow-up|13
6134983|NCT00993044|9764296|FG000|Irinotecan 50 mg|Physician Decision|1
6134984|NCT00993148|9764301|FG000|Overall Study|Lost to Follow-up|2
6134985|NCT00993148|9764301|FG000|Overall Study|never initiated treatment|1
6134986|NCT00993265|9764340|FG000|Overall Study|Adverse Event|1
6134987|NCT00993265|9764341|FG001|Overall Study|Adverse Event|0
6134988|NCT00993265|9764340|FG000|Overall Study|Changed dose of concomitant drug|2
6134989|NCT00993265|9764341|FG001|Overall Study|Changed dose of concomitant drug|0
6134990|NCT00993265|9764340|FG000|Overall Study|Non-compliant with study medication|1
6134991|NCT00993265|9764341|FG001|Overall Study|Non-compliant with study medication|0
6134992|NCT00993291|9764347|FG000|Overall Study|Withdrawal by Subject|1
6134993|NCT00993317|9764353|FG000|Overall Study|Adverse Event|2
6134994|NCT00993317|9764354|FG001|Overall Study|Adverse Event|4
6134995|NCT00993317|9764353|FG000|Overall Study|Lack of Efficacy|18
6134996|NCT00993317|9764354|FG001|Overall Study|Lack of Efficacy|18
6134997|NCT00993317|9764353|FG000|Overall Study|Withdrawal by Subject|0
6290479|NCT02397694|10006547|FG000|Double-Blinded Phase|Non-compliance with study drug|0
6290480|NCT02397694|10006548|FG001|Double-Blinded Phase|Non-compliance with study drug|2
6290481|NCT02397694|10006547|FG000|Double-Blinded Phase|Withdrawal by Subject|1
6290482|NCT02397694|10006548|FG001|Double-Blinded Phase|Withdrawal by Subject|0
6290483|NCT02397694|10006547|FG000|Double-Blinded Phase|Lost to Follow-up|1
6134998|NCT00993317|9764354|FG001|Overall Study|Withdrawal by Subject|2
6225223|NCT01700192|9896994|FG000|Overall Study|Lack of Efficacy|1
6225224|NCT01700192|9896995|FG001|Overall Study|Lack of Efficacy|0
6225225|NCT01700192|9896994|FG000|Overall Study|Lost to Follow-up|42
6225226|NCT01700192|9896995|FG001|Overall Study|Lost to Follow-up|29
6225227|NCT01700192|9896994|FG000|Overall Study|Noncompliance with study drug|0
6225228|NCT01700192|9896995|FG001|Overall Study|Noncompliance with study drug|5
6225229|NCT01700192|9896994|FG000|Overall Study|Physician Decision|2
6225230|NCT01700192|9896995|FG001|Overall Study|Physician Decision|3
6225231|NCT01700192|9896994|FG000|Overall Study|Pregnancy|1
6225232|NCT01700192|9896995|FG001|Overall Study|Pregnancy|4
6225233|NCT01700192|9896994|FG000|Overall Study|Progressive disease|1
6225234|NCT01700192|9896995|FG001|Overall Study|Progressive disease|0
6225235|NCT01700192|9896994|FG000|Overall Study|Protocol Violation|3
6225236|NCT01700192|9896995|FG001|Overall Study|Protocol Violation|4
6225237|NCT01700192|9896994|FG000|Overall Study|Technical problems|0
6225238|NCT01700192|9896995|FG001|Overall Study|Technical problems|1
6225239|NCT01700192|9896994|FG000|Overall Study|Withdrawal by Subject|56
6225240|NCT01700192|9896995|FG001|Overall Study|Withdrawal by Subject|64
6225241|NCT01700192|9896994|FG000|Overall Study|Never received study drug|1
6225242|NCT01700192|9896995|FG001|Overall Study|Never received study drug|0
6225243|NCT01700205|9897003|FG000|Overall Study|Withdrawal by Subject|13
6290484|NCT02397694|10006548|FG001|Double-Blinded Phase|Lost to Follow-up|1
6290485|NCT02397694|10006547|FG000|Open Label Extension Phase|Protocol Violation|1
6290486|NCT02397694|10006548|FG001|Open Label Extension Phase|Protocol Violation|0
6290487|NCT02397694|10006547|FG000|Open Label Extension Phase|Withdrew Consent|3
6290488|NCT02397694|10006548|FG001|Open Label Extension Phase|Withdrew Consent|1
6290489|NCT02397694|10006547|FG000|Open Label Extension Phase|Lost to Follow-up|4
6290490|NCT02397694|10006548|FG001|Open Label Extension Phase|Lost to Follow-up|0
6290491|NCT02397837|10006583|FG000|Overall Study|Withdrawal by Subject|6
6290492|NCT02397837|10006584|FG001|Overall Study|Withdrawal by Subject|5
6290493|NCT02397837|10006583|FG000|Overall Study|Physician Decision|1
6290494|NCT02397837|10006584|FG001|Overall Study|Physician Decision|1
6290495|NCT02397889|10006592|FG000|Overall Study|Physician Decision|1
6290496|NCT02397889|10006593|FG001|Overall Study|Physician Decision|0
6134999|NCT00993317|9764353|FG000|Overall Study|Investigator's opinion|0
6135000|NCT00993317|9764354|FG001|Overall Study|Investigator's opinion|1
6135001|NCT00993317|9764353|FG000|Overall Study|Early study termination at the site|1
6225244|NCT01700205|9897004|FG001|Overall Study|Withdrawal by Subject|13
6135002|NCT00993317|9764354|FG001|Overall Study|Early study termination at the site|0
6135003|NCT00993421|9764367|FG000|Overall Study|Adverse Event|2
6135004|NCT00993421|9764368|FG001|Overall Study|Adverse Event|7
6135005|NCT00993421|9764369|FG002|Overall Study|Adverse Event|6
6135006|NCT00993421|9764370|FG003|Overall Study|Adverse Event|9
6135007|NCT00993421|9764371|FG004|Overall Study|Adverse Event|5
6135008|NCT00993421|9764372|FG005|Overall Study|Adverse Event|7
6135009|NCT00993421|9764373|FG006|Overall Study|Adverse Event|1
6135010|NCT00993421|9764367|FG000|Overall Study|Sponsor Decision|36
6135011|NCT00993421|9764368|FG001|Overall Study|Sponsor Decision|31
6135012|NCT00993421|9764369|FG002|Overall Study|Sponsor Decision|28
6135013|NCT00993421|9764370|FG003|Overall Study|Sponsor Decision|30
6135014|NCT00993421|9764371|FG004|Overall Study|Sponsor Decision|38
6135015|NCT00993421|9764372|FG005|Overall Study|Sponsor Decision|30
6135016|NCT00993421|9764373|FG006|Overall Study|Sponsor Decision|29
6135017|NCT00993421|9764367|FG000|Overall Study|Lost to Follow-up|3
6135018|NCT00993421|9764368|FG001|Overall Study|Lost to Follow-up|5
6135019|NCT00993421|9764369|FG002|Overall Study|Lost to Follow-up|5
6135020|NCT00993421|9764370|FG003|Overall Study|Lost to Follow-up|0
6135021|NCT00993421|9764371|FG004|Overall Study|Lost to Follow-up|0
6135022|NCT00993421|9764372|FG005|Overall Study|Lost to Follow-up|0
6135023|NCT00993421|9764373|FG006|Overall Study|Lost to Follow-up|6
6135024|NCT00993421|9764367|FG000|Overall Study|Withdrawal by Subject|3
6135025|NCT00993421|9764368|FG001|Overall Study|Withdrawal by Subject|2
6135026|NCT00993421|9764369|FG002|Overall Study|Withdrawal by Subject|3
6135027|NCT00993421|9764370|FG003|Overall Study|Withdrawal by Subject|3
6135028|NCT00993421|9764371|FG004|Overall Study|Withdrawal by Subject|3
6135029|NCT00993421|9764372|FG005|Overall Study|Withdrawal by Subject|5
6135030|NCT00993421|9764373|FG006|Overall Study|Withdrawal by Subject|3
6135031|NCT00993421|9764367|FG000|Overall Study|Death|0
6135032|NCT00993421|9764368|FG001|Overall Study|Death|0
6135033|NCT00993421|9764369|FG002|Overall Study|Death|0
6135034|NCT00993421|9764370|FG003|Overall Study|Death|0
6135035|NCT00993421|9764371|FG004|Overall Study|Death|0
6135036|NCT00993421|9764372|FG005|Overall Study|Death|0
6135037|NCT00993421|9764373|FG006|Overall Study|Death|1
6135038|NCT00993421|9764367|FG000|Overall Study|Entry Criteria Exclusion|0
6135039|NCT00993421|9764368|FG001|Overall Study|Entry Criteria Exclusion|0
6135040|NCT00993421|9764369|FG002|Overall Study|Entry Criteria Exclusion|1
6135041|NCT00993421|9764370|FG003|Overall Study|Entry Criteria Exclusion|3
6135042|NCT00993421|9764371|FG004|Overall Study|Entry Criteria Exclusion|0
6135043|NCT00993421|9764372|FG005|Overall Study|Entry Criteria Exclusion|1
6135044|NCT00993421|9764373|FG006|Overall Study|Entry Criteria Exclusion|0
6135045|NCT00993421|9764367|FG000|Overall Study|Physician Decision|0
6135046|NCT00993421|9764368|FG001|Overall Study|Physician Decision|0
6135047|NCT00993421|9764369|FG002|Overall Study|Physician Decision|0
6135048|NCT00993421|9764370|FG003|Overall Study|Physician Decision|0
6135049|NCT00993421|9764371|FG004|Overall Study|Physician Decision|0
6135050|NCT00993421|9764372|FG005|Overall Study|Physician Decision|1
6135051|NCT00993421|9764373|FG006|Overall Study|Physician Decision|1
6135052|NCT00993421|9764367|FG000|Overall Study|Protocol Violation|0
6135053|NCT00993421|9764368|FG001|Overall Study|Protocol Violation|0
6135054|NCT00993421|9764369|FG002|Overall Study|Protocol Violation|0
6135055|NCT00993421|9764370|FG003|Overall Study|Protocol Violation|0
6135056|NCT00993421|9764371|FG004|Overall Study|Protocol Violation|0
6135057|NCT00993421|9764372|FG005|Overall Study|Protocol Violation|2
6135058|NCT00993421|9764373|FG006|Overall Study|Protocol Violation|1
6135059|NCT00993473|9764391|FG000|Overall Study|Adverse Event|0
6135060|NCT00993473|9764392|FG001|Overall Study|Adverse Event|2
6135061|NCT00993473|9764391|FG000|Overall Study|Protocol Violation|1
6135062|NCT00993473|9764392|FG001|Overall Study|Protocol Violation|2
6135063|NCT00993473|9764391|FG000|Overall Study|Lost to Follow-up|1
6135064|NCT00993473|9764392|FG001|Overall Study|Lost to Follow-up|0
6135065|NCT00993473|9764391|FG000|Overall Study|Withdrawal by Subject|1
6135066|NCT00993473|9764392|FG001|Overall Study|Withdrawal by Subject|5
6135067|NCT00993473|9764391|FG000|Overall Study|Technical problem with CGM device|0
6135068|NCT00993473|9764392|FG001|Overall Study|Technical problem with CGM device|1
6135069|NCT00993473|9764391|FG000|Overall Study|Family event|1
6135070|NCT00993473|9764392|FG001|Overall Study|Family event|0
6135071|NCT00993499|9764404|FG000|Run-in Period (8 Days)|Adverse Event|0
6135072|NCT00993499|9764405|FG001|Run-in Period (8 Days)|Adverse Event|1
6135073|NCT00993499|9764406|FG002|Run-in Period (8 Days)|Adverse Event|0
6135074|NCT00993499|9764407|FG003|Run-in Period (8 Days)|Adverse Event|0
6135075|NCT00993499|9764408|FG004|Run-in Period (8 Days)|Adverse Event|0
6135076|NCT00993499|9764409|FG005|Run-in Period (8 Days)|Adverse Event|0
6225245|NCT01700205|9897003|FG000|Overall Study|Protocol Violation|2
6225246|NCT01700205|9897004|FG001|Overall Study|Protocol Violation|2
6135077|NCT00993499|9764404|FG000|Run-in Period (8 Days)|Inclusion/exclusion criteria not met|1
6135078|NCT00993499|9764405|FG001|Run-in Period (8 Days)|Inclusion/exclusion criteria not met|0
6135079|NCT00993499|9764406|FG002|Run-in Period (8 Days)|Inclusion/exclusion criteria not met|0
6135080|NCT00993499|9764407|FG003|Run-in Period (8 Days)|Inclusion/exclusion criteria not met|0
6135081|NCT00993499|9764408|FG004|Run-in Period (8 Days)|Inclusion/exclusion criteria not met|0
6135082|NCT00993499|9764409|FG005|Run-in Period (8 Days)|Inclusion/exclusion criteria not met|0
6135083|NCT00993499|9764404|FG000|Run-in Period (8 Days)|Consent withdrawn|0
6135084|NCT00993499|9764405|FG001|Run-in Period (8 Days)|Consent withdrawn|1
6135085|NCT00993499|9764406|FG002|Run-in Period (8 Days)|Consent withdrawn|0
6135086|NCT00993499|9764407|FG003|Run-in Period (8 Days)|Consent withdrawn|0
6135087|NCT00993499|9764408|FG004|Run-in Period (8 Days)|Consent withdrawn|0
6135088|NCT00993499|9764409|FG005|Run-in Period (8 Days)|Consent withdrawn|0
6135089|NCT00993499|9764404|FG000|Run-in Period (8 Days)|Progressive disease|0
6135090|NCT00993499|9764405|FG001|Run-in Period (8 Days)|Progressive disease|1
6135091|NCT00993499|9764406|FG002|Run-in Period (8 Days)|Progressive disease|1
6225247|NCT01700387|9897020|FG000|Overall Study|Withdrawal by Subject|1
6225248|NCT01700387|9897021|FG001|Overall Study|Withdrawal by Subject|2
6225249|NCT01700387|9897020|FG000|Overall Study|Adverse Event|1
6225250|NCT01700387|9897021|FG001|Overall Study|Adverse Event|1
6225251|NCT01700387|9897020|FG000|Overall Study|Lost to Follow-up|2
6225252|NCT01700387|9897021|FG001|Overall Study|Lost to Follow-up|1
6225253|NCT01700530|9897047|FG000|Overall Study|Withdrawal by Subject|0
6225254|NCT01700530|9897048|FG001|Overall Study|Withdrawal by Subject|3
6225255|NCT01700530|9897049|FG002|Overall Study|Withdrawal by Subject|1
6225256|NCT01700621|9897059|FG000|Analyzed for Immunogenicity|Lost to Follow-up|7
6225257|NCT01700621|9897060|FG001|Analyzed for Immunogenicity|Lost to Follow-up|4
6225258|NCT01700621|9897059|FG000|Analyzed for Immunogenicity|Protocol Violation|5
6225259|NCT01700621|9897060|FG001|Analyzed for Immunogenicity|Protocol Violation|1
6225260|NCT01700621|9897059|FG000|Analyzed for Immunogenicity|Baseline measles measure high|1
6225261|NCT01700621|9897060|FG001|Analyzed for Immunogenicity|Baseline measles measure high|2
6225262|NCT01700829|9897105|FG000|Overall Study|Withdrawal by Subject|1
6225263|NCT01700829|9897106|FG001|Overall Study|Withdrawal by Subject|1
6225264|NCT01700959|9897127|FG000|Overall Study|Adverse Event|0
6225265|NCT01700959|9897128|FG001|Overall Study|Adverse Event|1
6225266|NCT01700959|9897129|FG002|Overall Study|Adverse Event|1
6225267|NCT01700959|9897130|FG003|Overall Study|Adverse Event|2
6225268|NCT01700959|9897131|FG004|Overall Study|Adverse Event|0
6225269|NCT01700959|9897132|FG005|Overall Study|Adverse Event|2
6225270|NCT01700959|9897127|FG000|Overall Study|Withdrawal by Subject|15
6225271|NCT01700959|9897128|FG001|Overall Study|Withdrawal by Subject|9
6225272|NCT01700959|9897129|FG002|Overall Study|Withdrawal by Subject|12
6225273|NCT01700959|9897130|FG003|Overall Study|Withdrawal by Subject|11
6225274|NCT01700959|9897131|FG004|Overall Study|Withdrawal by Subject|8
6225275|NCT01700959|9897132|FG005|Overall Study|Withdrawal by Subject|12
6225276|NCT01700959|9897127|FG000|Overall Study|Ineligible|2
6225277|NCT01700959|9897128|FG001|Overall Study|Ineligible|1
6225278|NCT01700959|9897129|FG002|Overall Study|Ineligible|2
6225279|NCT01700959|9897130|FG003|Overall Study|Ineligible|0
6225280|NCT01700959|9897131|FG004|Overall Study|Ineligible|0
6225281|NCT01700959|9897132|FG005|Overall Study|Ineligible|1
6225282|NCT01700959|9897127|FG000|Overall Study|Noncompliant|9
6225283|NCT01700959|9897128|FG001|Overall Study|Noncompliant|9
6225284|NCT01700959|9897129|FG002|Overall Study|Noncompliant|17
6225285|NCT01700959|9897130|FG003|Overall Study|Noncompliant|18
6225286|NCT01700959|9897131|FG004|Overall Study|Noncompliant|15
6225287|NCT01700959|9897132|FG005|Overall Study|Noncompliant|9
6225288|NCT01700959|9897127|FG000|Overall Study|Side effects|1
6225289|NCT01700959|9897128|FG001|Overall Study|Side effects|4
6225290|NCT01700959|9897129|FG002|Overall Study|Side effects|8
6225291|NCT01700959|9897130|FG003|Overall Study|Side effects|4
6225292|NCT01700959|9897131|FG004|Overall Study|Side effects|4
6225293|NCT01700959|9897132|FG005|Overall Study|Side effects|1
6225294|NCT01700985|9897150|FG000|Overall Study|Incarcerated|0
6225295|NCT01700985|9897151|FG001|Overall Study|Incarcerated|1
6225296|NCT01701063|9897188|FG000|Overall Study|Lost to Follow-up|0
6225297|NCT01701063|9897189|FG001|Overall Study|Lost to Follow-up|1
6225298|NCT01701063|9897190|FG002|Overall Study|Lost to Follow-up|0
6225299|NCT01701063|9897188|FG000|Overall Study|Withdrawal by Subject|0
6225300|NCT01701063|9897189|FG001|Overall Study|Withdrawal by Subject|0
6225301|NCT01701063|9897190|FG002|Overall Study|Withdrawal by Subject|1
6225302|NCT01701063|9897188|FG000|Overall Study|Other|0
6225303|NCT01701063|9897189|FG001|Overall Study|Other|0
6225304|NCT01701063|9897190|FG002|Overall Study|Other|1
6225305|NCT01701193|9897229|FG000|Overall Study|Withdrawal by Subject|2
6225306|NCT01701193|9897230|FG001|Overall Study|Withdrawal by Subject|2
6225307|NCT01701193|9897231|FG002|Overall Study|Withdrawal by Subject|1
6225308|NCT01701193|9897232|FG003|Overall Study|Withdrawal by Subject|2
6225309|NCT01701193|9897229|FG000|Overall Study|Adverse Event|1
6225310|NCT01701193|9897230|FG001|Overall Study|Adverse Event|0
6290497|NCT02397915|10006599|FG000|Period 1|Protocol Violation|0
6225311|NCT01701193|9897231|FG002|Overall Study|Adverse Event|0
6225312|NCT01701193|9897232|FG003|Overall Study|Adverse Event|0
6225313|NCT01701245|9897247|FG000|Overall Study|Protocol Violation|1
6225314|NCT01701245|9897248|FG001|Overall Study|Protocol Violation|3
6225315|NCT01701245|9897247|FG000|Overall Study|Did not complete the open label period|11
6225316|NCT01701245|9897248|FG001|Overall Study|Did not complete the open label period|12
6225317|NCT01701258|9897258|FG000|Assessment and Scheduling|Found to be Ineligible|57
6225318|NCT01701258|9897259|FG001|Assessment and Scheduling|Found to be Ineligible|0
6225319|NCT01701258|9897260|FG002|Assessment and Scheduling|Found to be Ineligible|0
6225320|NCT01701258|9897261|FG003|Assessment and Scheduling|Found to be Ineligible|0
6135092|NCT00993499|9764407|FG003|Run-in Period (8 Days)|Progressive disease|0
6135093|NCT00993499|9764408|FG004|Run-in Period (8 Days)|Progressive disease|0
6225321|NCT01701258|9897262|FG004|Assessment and Scheduling|Found to be Ineligible|0
6225322|NCT01701258|9897263|FG005|Assessment and Scheduling|Found to be Ineligible|0
6225323|NCT01701258|9897264|FG006|Assessment and Scheduling|Found to be Ineligible|0
6225324|NCT01701258|9897265|FG007|Assessment and Scheduling|Found to be Ineligible|0
6225325|NCT01701258|9897266|FG008|Assessment and Scheduling|Found to be Ineligible|0
6225326|NCT01701258|9897267|FG009|Assessment and Scheduling|Found to be Ineligible|0
6225327|NCT01701258|9897268|FG010|Assessment and Scheduling|Found to be Ineligible|0
6225328|NCT01701258|9897269|FG011|Assessment and Scheduling|Found to be Ineligible|0
6225329|NCT01701258|9897270|FG012|Assessment and Scheduling|Found to be Ineligible|0
6225330|NCT01701258|9897258|FG000|Assessment and Scheduling|Lost to Follow-up|10
6225331|NCT01701258|9897259|FG001|Assessment and Scheduling|Lost to Follow-up|0
6225332|NCT01701258|9897260|FG002|Assessment and Scheduling|Lost to Follow-up|0
6225333|NCT01701258|9897261|FG003|Assessment and Scheduling|Lost to Follow-up|0
6225334|NCT01701258|9897262|FG004|Assessment and Scheduling|Lost to Follow-up|0
6225335|NCT01701258|9897263|FG005|Assessment and Scheduling|Lost to Follow-up|0
6225336|NCT01701258|9897264|FG006|Assessment and Scheduling|Lost to Follow-up|0
6225337|NCT01701258|9897265|FG007|Assessment and Scheduling|Lost to Follow-up|0
6225338|NCT01701258|9897266|FG008|Assessment and Scheduling|Lost to Follow-up|0
6225339|NCT01701258|9897267|FG009|Assessment and Scheduling|Lost to Follow-up|0
6225340|NCT01701258|9897268|FG010|Assessment and Scheduling|Lost to Follow-up|0
6225341|NCT01701258|9897269|FG011|Assessment and Scheduling|Lost to Follow-up|0
6225342|NCT01701258|9897270|FG012|Assessment and Scheduling|Lost to Follow-up|0
6225343|NCT01701258|9897258|FG000|Assessment and Scheduling|Withdrawal by Subject|14
6225344|NCT01701258|9897259|FG001|Assessment and Scheduling|Withdrawal by Subject|0
6225345|NCT01701258|9897260|FG002|Assessment and Scheduling|Withdrawal by Subject|0
6225346|NCT01701258|9897261|FG003|Assessment and Scheduling|Withdrawal by Subject|0
6225347|NCT01701258|9897262|FG004|Assessment and Scheduling|Withdrawal by Subject|0
6225348|NCT01701258|9897263|FG005|Assessment and Scheduling|Withdrawal by Subject|0
6225349|NCT01701258|9897264|FG006|Assessment and Scheduling|Withdrawal by Subject|0
6225350|NCT01701258|9897265|FG007|Assessment and Scheduling|Withdrawal by Subject|0
6225351|NCT01701258|9897266|FG008|Assessment and Scheduling|Withdrawal by Subject|0
6225352|NCT01701258|9897267|FG009|Assessment and Scheduling|Withdrawal by Subject|0
6225353|NCT01701258|9897268|FG010|Assessment and Scheduling|Withdrawal by Subject|0
6225354|NCT01701258|9897269|FG011|Assessment and Scheduling|Withdrawal by Subject|0
6225355|NCT01701258|9897270|FG012|Assessment and Scheduling|Withdrawal by Subject|0
6225356|NCT01701258|9897258|FG000|Assessment and Scheduling|Investigator Terminated|2
6225357|NCT01701258|9897259|FG001|Assessment and Scheduling|Investigator Terminated|0
6225358|NCT01701258|9897260|FG002|Assessment and Scheduling|Investigator Terminated|0
6225359|NCT01701258|9897261|FG003|Assessment and Scheduling|Investigator Terminated|0
6225360|NCT01701258|9897262|FG004|Assessment and Scheduling|Investigator Terminated|0
6225361|NCT01701258|9897263|FG005|Assessment and Scheduling|Investigator Terminated|0
6135094|NCT00993499|9764409|FG005|Run-in Period (8 Days)|Progressive disease|0
6135095|NCT00993499|9764404|FG000|Discontinued Before Starting Course 3|Progressive Disease|2
6135096|NCT00993499|9764405|FG001|Discontinued Before Starting Course 3|Progressive Disease|2
6135097|NCT00993499|9764406|FG002|Discontinued Before Starting Course 3|Progressive Disease|0
6135098|NCT00993499|9764407|FG003|Discontinued Before Starting Course 3|Progressive Disease|0
6135099|NCT00993499|9764408|FG004|Discontinued Before Starting Course 3|Progressive Disease|0
6135100|NCT00993499|9764409|FG005|Discontinued Before Starting Course 3|Progressive Disease|0
6135101|NCT00993499|9764404|FG000|Discontinued Before Starting Course 3|Withdrawal by Subject|2
6135102|NCT00993499|9764405|FG001|Discontinued Before Starting Course 3|Withdrawal by Subject|2
6135103|NCT00993499|9764406|FG002|Discontinued Before Starting Course 3|Withdrawal by Subject|0
6135104|NCT00993499|9764407|FG003|Discontinued Before Starting Course 3|Withdrawal by Subject|0
6135105|NCT00993499|9764408|FG004|Discontinued Before Starting Course 3|Withdrawal by Subject|0
6135106|NCT00993499|9764409|FG005|Discontinued Before Starting Course 3|Withdrawal by Subject|0
6135107|NCT00993499|9764404|FG000|Discontinued Before Starting Course 3|Dose Limiting Toxicity (DLT)|0
6135108|NCT00993499|9764405|FG001|Discontinued Before Starting Course 3|Dose Limiting Toxicity (DLT)|0
6135109|NCT00993499|9764406|FG002|Discontinued Before Starting Course 3|Dose Limiting Toxicity (DLT)|1
6135110|NCT00993499|9764407|FG003|Discontinued Before Starting Course 3|Dose Limiting Toxicity (DLT)|1
6135111|NCT00993499|9764408|FG004|Discontinued Before Starting Course 3|Dose Limiting Toxicity (DLT)|0
6135112|NCT00993499|9764409|FG005|Discontinued Before Starting Course 3|Dose Limiting Toxicity (DLT)|0
6135113|NCT00993499|9764404|FG000|Discontinued Before Starting Course 3|Non compliance with the protocol|0
6135114|NCT00993499|9764405|FG001|Discontinued Before Starting Course 3|Non compliance with the protocol|0
6135115|NCT00993499|9764406|FG002|Discontinued Before Starting Course 3|Non compliance with the protocol|2
6135116|NCT00993499|9764407|FG003|Discontinued Before Starting Course 3|Non compliance with the protocol|0
6135117|NCT00993499|9764408|FG004|Discontinued Before Starting Course 3|Non compliance with the protocol|0
6135118|NCT00993499|9764409|FG005|Discontinued Before Starting Course 3|Non compliance with the protocol|0
6135119|NCT00993499|9764404|FG000|Discontinued After Starting Course 3|Withdrawal by Subject|0
6135120|NCT00993499|9764405|FG001|Discontinued After Starting Course 3|Withdrawal by Subject|1
6135121|NCT00993499|9764406|FG002|Discontinued After Starting Course 3|Withdrawal by Subject|0
6135122|NCT00993499|9764407|FG003|Discontinued After Starting Course 3|Withdrawal by Subject|0
6135123|NCT00993499|9764408|FG004|Discontinued After Starting Course 3|Withdrawal by Subject|0
6135124|NCT00993499|9764409|FG005|Discontinued After Starting Course 3|Withdrawal by Subject|0
6135125|NCT00993499|9764404|FG000|Discontinued After Starting Course 3|Progressive Disease|6
6135126|NCT00993499|9764405|FG001|Discontinued After Starting Course 3|Progressive Disease|4
6135127|NCT00993499|9764406|FG002|Discontinued After Starting Course 3|Progressive Disease|3
6135128|NCT00993499|9764407|FG003|Discontinued After Starting Course 3|Progressive Disease|1
6135129|NCT00993499|9764408|FG004|Discontinued After Starting Course 3|Progressive Disease|3
6135130|NCT00993499|9764409|FG005|Discontinued After Starting Course 3|Progressive Disease|3
6135131|NCT00993499|9764404|FG000|Discontinued After Starting Course 3|DLT|1
6135132|NCT00993499|9764405|FG001|Discontinued After Starting Course 3|DLT|0
6135133|NCT00993499|9764406|FG002|Discontinued After Starting Course 3|DLT|2
6135134|NCT00993499|9764407|FG003|Discontinued After Starting Course 3|DLT|1
6135135|NCT00993499|9764408|FG004|Discontinued After Starting Course 3|DLT|0
6135136|NCT00993499|9764409|FG005|Discontinued After Starting Course 3|DLT|0
6135137|NCT00993499|9764404|FG000|Discontinued After Starting Course 3|Other adverse event|1
6135138|NCT00993499|9764405|FG001|Discontinued After Starting Course 3|Other adverse event|0
6135139|NCT00993499|9764406|FG002|Discontinued After Starting Course 3|Other adverse event|1
6135140|NCT00993499|9764407|FG003|Discontinued After Starting Course 3|Other adverse event|0
6135141|NCT00993499|9764408|FG004|Discontinued After Starting Course 3|Other adverse event|0
6135142|NCT00993499|9764409|FG005|Discontinued After Starting Course 3|Other adverse event|0
6135143|NCT00993616|9764423|FG000|Overall Study|No tumor at entry|1
6135144|NCT00993616|9764423|FG000|Overall Study|Never treated|1
6135145|NCT00993668|9764451|FG000|Single-Blind Period|Adverse Event|1
6135146|NCT00993668|9764452|FG001|Single-Blind Period|Adverse Event|1
6135147|NCT00993668|9764451|FG000|Single-Blind Period|Lack of Efficacy|0
6135148|NCT00993668|9764452|FG001|Single-Blind Period|Lack of Efficacy|1
6135149|NCT00993668|9764451|FG000|Single-Blind Period|Lost to Follow-up|3
6135150|NCT00993668|9764452|FG001|Single-Blind Period|Lost to Follow-up|1
6135151|NCT00993668|9764451|FG000|Open-Label Period|Adverse Event|9
6135152|NCT00993668|9764452|FG001|Open-Label Period|Adverse Event|8
6135153|NCT00993668|9764451|FG000|Open-Label Period|Lack of Efficacy|4
6135154|NCT00993668|9764452|FG001|Open-Label Period|Lack of Efficacy|3
6135155|NCT00993668|9764451|FG000|Open-Label Period|Withdrawal by Subject|4
6135156|NCT00993668|9764452|FG001|Open-Label Period|Withdrawal by Subject|3
6135157|NCT00993668|9764451|FG000|Open-Label Period|Lost to Follow-up|6
6135158|NCT00993668|9764452|FG001|Open-Label Period|Lost to Follow-up|1
6135159|NCT00993915|9764485|FG000|Overall Study|Insufficient clinical response|3
6135160|NCT00993915|9764485|FG000|Overall Study|Withdrawal by Subject|2
6135161|NCT00993915|9764485|FG000|Overall Study|Other|1
6135162|NCT00993915|9764485|FG000|Overall Study|Ongoing|3
6135163|NCT00993928|9764491|FG000|Overall Study|Withdrawal by Subject|4
6135164|NCT00993928|9764492|FG001|Overall Study|Withdrawal by Subject|7
6135165|NCT00993928|9764491|FG000|Overall Study|ineligible|1
6135166|NCT00993928|9764492|FG001|Overall Study|ineligible|0
6225362|NCT01701258|9897264|FG006|Assessment and Scheduling|Investigator Terminated|0
6225363|NCT01701258|9897265|FG007|Assessment and Scheduling|Investigator Terminated|0
6225364|NCT01701258|9897266|FG008|Assessment and Scheduling|Investigator Terminated|0
6225365|NCT01701258|9897267|FG009|Assessment and Scheduling|Investigator Terminated|0
6225366|NCT01701258|9897268|FG010|Assessment and Scheduling|Investigator Terminated|0
6225367|NCT01701258|9897269|FG011|Assessment and Scheduling|Investigator Terminated|0
6225368|NCT01701258|9897270|FG012|Assessment and Scheduling|Investigator Terminated|0
6225369|NCT01701362|9897305|FG000|Overall Study|Adverse events not related to study drug|1
6225370|NCT01701362|9897306|FG001|Overall Study|Adverse events not related to study drug|6
6225371|NCT01701362|9897305|FG000|Overall Study|Adverse events related to study drug|12
6225372|NCT01701362|9897306|FG001|Overall Study|Adverse events related to study drug|10
6225373|NCT01701362|9897305|FG000|Overall Study|Protocol Violation|5
6225374|NCT01701362|9897306|FG001|Overall Study|Protocol Violation|3
6225375|NCT01701362|9897305|FG000|Overall Study|No longer willing to participate|8
6225376|NCT01701362|9897306|FG001|Overall Study|No longer willing to participate|14
6225377|NCT01701362|9897305|FG000|Overall Study|Lost to Follow-up|6
6225378|NCT01701362|9897306|FG001|Overall Study|Lost to Follow-up|9
6225379|NCT01701362|9897305|FG000|Overall Study|Insufficient clinical response|6
6225380|NCT01701362|9897306|FG001|Overall Study|Insufficient clinical response|6
6225381|NCT01701362|9897305|FG000|Overall Study|Death|0
6225382|NCT01701362|9897306|FG001|Overall Study|Death|1
6225383|NCT01701362|9897305|FG000|Overall Study|Randomized but not treated|1
6225384|NCT01701362|9897306|FG001|Overall Study|Randomized but not treated|2
6225385|NCT01701362|9897305|FG000|Overall Study|Reasons other than those mentioned above|3
6135167|NCT00993954|9764504|FG000|Overall Study|Protocol Violation|21
6135168|NCT00993954|9764505|FG001|Overall Study|Protocol Violation|2
6135169|NCT00993967|9764511|FG000|Overall Study|Adverse Event|8
6135170|NCT00993967|9764511|FG000|Overall Study|Death|1
6135171|NCT00993967|9764511|FG000|Overall Study|Lost to Follow-up|14
6135172|NCT00993967|9764511|FG000|Overall Study|Withdrawal by Subject|36
6135173|NCT00993967|9764511|FG000|Overall Study|Protocol Violation|2
6135174|NCT00994110|9764517|FG000|Overall Study|Withdrawal by Subject|9
6135175|NCT00994110|9764518|FG001|Overall Study|Withdrawal by Subject|9
6135176|NCT00994110|9764517|FG000|Overall Study|Not Treated|4
6135177|NCT00994110|9764518|FG001|Overall Study|Not Treated|8
6135178|NCT00994110|9764517|FG000|Overall Study|Adverse Event|1
6135179|NCT00994110|9764518|FG001|Overall Study|Adverse Event|0
6135180|NCT00994110|9764517|FG000|Overall Study|Patient not resected|41
6135181|NCT00994110|9764518|FG001|Overall Study|Patient not resected|52
6135182|NCT00994110|9764517|FG000|Overall Study|Pt not eligible|10
6135183|NCT00994110|9764518|FG001|Overall Study|Pt not eligible|5
6135184|NCT00994214|9764559|FG000|ITT (Intention-to-Treat) - Part A|Adverse Event|0
6135185|NCT00994214|9764560|FG001|ITT (Intention-to-Treat) - Part A|Adverse Event|1
6135186|NCT00994214|9764561|FG002|ITT (Intention-to-Treat) - Part A|Adverse Event|0
6135187|NCT00994214|9764562|FG003|ITT (Intention-to-Treat) - Part A|Adverse Event|0
6135188|NCT00994214|9764559|FG000|ITT (Intention-to-Treat) - Part A|Withdrawal by Subject|0
6135189|NCT00994214|9764560|FG001|ITT (Intention-to-Treat) - Part A|Withdrawal by Subject|0
6135190|NCT00994214|9764561|FG002|ITT (Intention-to-Treat) - Part A|Withdrawal by Subject|0
6135191|NCT00994214|9764562|FG003|ITT (Intention-to-Treat) - Part A|Withdrawal by Subject|1
6135192|NCT00994214|9764559|FG000|ITT (Intention-to-Treat) - Part A|Lost to Follow-up|1
6135193|NCT00994214|9764560|FG001|ITT (Intention-to-Treat) - Part A|Lost to Follow-up|0
6135194|NCT00994214|9764561|FG002|ITT (Intention-to-Treat) - Part A|Lost to Follow-up|0
6135195|NCT00994214|9764562|FG003|ITT (Intention-to-Treat) - Part A|Lost to Follow-up|0
6135196|NCT00994214|9764559|FG000|ITT (Intention-to-Treat) - Part A|Withdrawn - Study termination by sponsor|13
6135197|NCT00994214|9764560|FG001|ITT (Intention-to-Treat) - Part A|Withdrawn - Study termination by sponsor|12
6225386|NCT01701362|9897306|FG001|Overall Study|Reasons other than those mentioned above|5
6225387|NCT01701401|9897320|FG000|Overall Study|Randomized But Not Treated|3
6225388|NCT01701401|9897321|FG001|Overall Study|Randomized But Not Treated|1
6225389|NCT01701401|9897322|FG002|Overall Study|Randomized But Not Treated|0
6225390|NCT01701401|9897323|FG003|Overall Study|Randomized But Not Treated|1
6225391|NCT01701401|9897320|FG000|Overall Study|Lost to Follow-up|5
6225392|NCT01701401|9897321|FG001|Overall Study|Lost to Follow-up|5
6225393|NCT01701401|9897322|FG002|Overall Study|Lost to Follow-up|1
6225394|NCT01701401|9897323|FG003|Overall Study|Lost to Follow-up|3
6225395|NCT01701401|9897320|FG000|Overall Study|Withdrew Consent|0
6225396|NCT01701401|9897321|FG001|Overall Study|Withdrew Consent|3
6225397|NCT01701401|9897322|FG002|Overall Study|Withdrew Consent|1
6225398|NCT01701401|9897323|FG003|Overall Study|Withdrew Consent|2
6225399|NCT01701401|9897320|FG000|Overall Study|Lack of Efficacy|1
6225400|NCT01701401|9897321|FG001|Overall Study|Lack of Efficacy|0
6225401|NCT01701401|9897322|FG002|Overall Study|Lack of Efficacy|2
6225402|NCT01701401|9897323|FG003|Overall Study|Lack of Efficacy|0
6225403|NCT01701401|9897320|FG000|Overall Study|Adverse Event|1
6225404|NCT01701401|9897321|FG001|Overall Study|Adverse Event|0
6225405|NCT01701401|9897322|FG002|Overall Study|Adverse Event|0
6225406|NCT01701401|9897323|FG003|Overall Study|Adverse Event|0
6225407|NCT01701401|9897320|FG000|Overall Study|Protocol Violation|0
6225408|NCT01701401|9897321|FG001|Overall Study|Protocol Violation|0
6225409|NCT01701401|9897322|FG002|Overall Study|Protocol Violation|1
6225410|NCT01701401|9897323|FG003|Overall Study|Protocol Violation|0
6225411|NCT01701973|9897370|FG000|Aim 1: First Intervention (1 Day)|Adverse Event|0
6225412|NCT01701973|9897371|FG001|Aim 1: First Intervention (1 Day)|Adverse Event|1
6225413|NCT01701973|9897372|FG002|Aim 1: First Intervention (1 Day)|Adverse Event|0
6225414|NCT01701973|9897373|FG003|Aim 1: First Intervention (1 Day)|Adverse Event|0
6225415|NCT01701973|9897374|FG004|Aim 1: First Intervention (1 Day)|Adverse Event|0
6225416|NCT01701973|9897375|FG005|Aim 1: First Intervention (1 Day)|Adverse Event|0
6225417|NCT01701973|9897376|FG006|Aim 1: First Intervention (1 Day)|Adverse Event|0
6225418|NCT01701973|9897377|FG007|Aim 1: First Intervention (1 Day)|Adverse Event|0
6225419|NCT01702025|9897430|FG000|Overall Study|Equipment failure|1
6225420|NCT01702025|9897431|FG001|Overall Study|Equipment failure|0
6225421|NCT01702025|9897432|FG002|Overall Study|Equipment failure|0
6225422|NCT01702025|9897433|FG003|Overall Study|Equipment failure|0
6225423|NCT01702025|9897430|FG000|Overall Study|Adverse Event|1
6225424|NCT01702025|9897431|FG001|Overall Study|Adverse Event|1
6225425|NCT01702025|9897432|FG002|Overall Study|Adverse Event|1
6225426|NCT01702025|9897433|FG003|Overall Study|Adverse Event|0
6225427|NCT01702246|9897461|FG000|Overall Study|Lost to Follow-up|2
6225428|NCT01702246|9897461|FG000|Overall Study|Withdrawal by Subject|2
6225429|NCT01702246|9897461|FG000|Overall Study|Physician Decision|1
6225430|NCT01702298|9897477|FG000|Overall Study|Withdrawal by Subject|1
6225431|NCT01702311|9897483|FG000|Overall Study|Withdrawal by Subject|3
6225432|NCT01702311|9897484|FG001|Overall Study|Withdrawal by Subject|2
6225433|NCT01702311|9897483|FG000|Overall Study|Discharge less than 24 hours|10
6225434|NCT01702311|9897484|FG001|Overall Study|Discharge less than 24 hours|7
6225435|NCT01702311|9897483|FG000|Overall Study|Physician Decision|3
6290498|NCT02397915|10006600|FG001|Period 1|Protocol Violation|1
6290499|NCT02397915|10006601|FG002|Period 1|Protocol Violation|0
6290500|NCT02397915|10006602|FG003|Period 1|Protocol Violation|0
6290501|NCT02397915|10006599|FG000|Period 1|Physician Decision|1
6290502|NCT02397915|10006600|FG001|Period 1|Physician Decision|0
6290503|NCT02397915|10006601|FG002|Period 1|Physician Decision|0
6290504|NCT02397915|10006602|FG003|Period 1|Physician Decision|0
6135198|NCT00994214|9764561|FG002|ITT (Intention-to-Treat) - Part A|Withdrawn - Study termination by sponsor|13
6135199|NCT00994214|9764562|FG003|ITT (Intention-to-Treat) - Part A|Withdrawn - Study termination by sponsor|14
6135200|NCT00994214|9764559|FG000|ITT (Intention-to-Treat) - Part B|Withdrawal by Subject|0
6135201|NCT00994214|9764560|FG001|ITT (Intention-to-Treat) - Part B|Withdrawal by Subject|0
6135202|NCT00994214|9764561|FG002|ITT (Intention-to-Treat) - Part B|Withdrawal by Subject|0
6135203|NCT00994214|9764562|FG003|ITT (Intention-to-Treat) - Part B|Withdrawal by Subject|1
6135204|NCT00994214|9764559|FG000|ITT (Intention-to-Treat) - Part B|Withdrawn - Study termination by sponsor|4
6135205|NCT00994214|9764560|FG001|ITT (Intention-to-Treat) - Part B|Withdrawn - Study termination by sponsor|3
6135206|NCT00994214|9764561|FG002|ITT (Intention-to-Treat) - Part B|Withdrawn - Study termination by sponsor|2
6135207|NCT00994214|9764562|FG003|ITT (Intention-to-Treat) - Part B|Withdrawn - Study termination by sponsor|2
6135208|NCT00994240|9764592|FG000|Overall Study|Lost to Follow-up|3
6135209|NCT00994240|9764593|FG001|Overall Study|Lost to Follow-up|2
6135210|NCT00994240|9764592|FG000|Overall Study|Withdrawal by Subject|1
6135211|NCT00994240|9764593|FG001|Overall Study|Withdrawal by Subject|0
6135212|NCT00994240|9764592|FG000|Overall Study|study termination|2
6135213|NCT00994240|9764593|FG001|Overall Study|study termination|3
6135214|NCT00994279|9764601|FG000|Overall Study|Withdrawal by Subject|2
6135215|NCT00994279|9764602|FG001|Overall Study|Withdrawal by Subject|2
6135216|NCT00994279|9764601|FG000|Overall Study|Toxicity|1
6135217|NCT00994279|9764602|FG001|Overall Study|Toxicity|0
6135218|NCT00994279|9764601|FG000|Overall Study|Multiple reasons|1
6135219|NCT00994279|9764602|FG001|Overall Study|Multiple reasons|3
6225436|NCT01702311|9897484|FG001|Overall Study|Physician Decision|4
6225437|NCT01702363|9897493|FG000|Overall Study|Adverse Event|14
6225438|NCT01702363|9897493|FG000|Overall Study|Lack of Efficacy|4
6225439|NCT01702363|9897493|FG000|Overall Study|Withdrawal by Subject|2
6225440|NCT01702428|9897502|FG000|Overall Study|Adverse Event|2
6225441|NCT01702428|9897503|FG001|Overall Study|Adverse Event|0
6225442|NCT01702428|9897504|FG002|Overall Study|Adverse Event|0
6225443|NCT01702428|9897505|FG003|Overall Study|Adverse Event|0
6225444|NCT01702428|9897502|FG000|Overall Study|Lost to Follow-up|33
6225445|NCT01702428|9897503|FG001|Overall Study|Lost to Follow-up|41
6225446|NCT01702428|9897504|FG002|Overall Study|Lost to Follow-up|37
6225447|NCT01702428|9897505|FG003|Overall Study|Lost to Follow-up|44
6225448|NCT01702428|9897502|FG000|Overall Study|Parents cannot assist to site|1
6225449|NCT01702428|9897503|FG001|Overall Study|Parents cannot assist to site|0
6225450|NCT01702428|9897504|FG002|Overall Study|Parents cannot assist to site|1
6225451|NCT01702428|9897505|FG003|Overall Study|Parents cannot assist to site|0
6225452|NCT01702428|9897502|FG000|Overall Study|Lost Coverage|0
6225453|NCT01702428|9897503|FG001|Overall Study|Lost Coverage|0
6225454|NCT01702428|9897504|FG002|Overall Study|Lost Coverage|0
6225455|NCT01702428|9897505|FG003|Overall Study|Lost Coverage|1
6225456|NCT01702428|9897502|FG000|Overall Study|Lost Health Plan|3
6225457|NCT01702428|9897503|FG001|Overall Study|Lost Health Plan|5
6225458|NCT01702428|9897504|FG002|Overall Study|Lost Health Plan|0
6225459|NCT01702428|9897505|FG003|Overall Study|Lost Health Plan|2
6225460|NCT01702428|9897502|FG000|Overall Study|Mother transferred care|0
6225461|NCT01702428|9897503|FG001|Overall Study|Mother transferred care|1
6225462|NCT01702428|9897504|FG002|Overall Study|Mother transferred care|0
6225463|NCT01702428|9897505|FG003|Overall Study|Mother transferred care|0
6225464|NCT01702428|9897502|FG000|Overall Study|Parents too busy|1
6225465|NCT01702428|9897503|FG001|Overall Study|Parents too busy|0
6225466|NCT01702428|9897504|FG002|Overall Study|Parents too busy|0
6225467|NCT01702428|9897505|FG003|Overall Study|Parents too busy|0
6225468|NCT01702428|9897502|FG000|Overall Study|Protocol Violation|3
6225469|NCT01702428|9897503|FG001|Overall Study|Protocol Violation|0
6225470|NCT01702428|9897504|FG002|Overall Study|Protocol Violation|1
6225471|NCT01702428|9897505|FG003|Overall Study|Protocol Violation|0
6225472|NCT01702428|9897502|FG000|Overall Study|Withdrawal by Subject|21
6225473|NCT01702428|9897503|FG001|Overall Study|Withdrawal by Subject|23
6225474|NCT01702428|9897504|FG002|Overall Study|Withdrawal by Subject|14
6225475|NCT01702428|9897505|FG003|Overall Study|Withdrawal by Subject|10
6225476|NCT01702454|9897524|FG000|Overall Study|Consent withdrawal|0
6225477|NCT01702454|9897525|FG001|Overall Study|Consent withdrawal|1
6225478|NCT01702454|9897524|FG000|Overall Study|Migrated/moved from study area|0
6225479|NCT01702454|9897525|FG001|Overall Study|Migrated/moved from study area|1
6225480|NCT01702454|9897524|FG000|Overall Study|Lost to Follow-up|3
6225481|NCT01702454|9897525|FG001|Overall Study|Lost to Follow-up|6
6225482|NCT01702519|9897536|FG000|Washout Period|Lost to Follow-up|1
6225483|NCT01702519|9897537|FG001|Washout Period|Lost to Follow-up|0
6225484|NCT01702519|9897536|FG000|Washout Period|Withdrawal by Subject|0
6225485|NCT01702519|9897537|FG001|Washout Period|Withdrawal by Subject|2
6225486|NCT01702532|9897549|FG000|Overall Study|Adverse Event|0
6225487|NCT01702532|9897550|FG001|Overall Study|Adverse Event|1
6225488|NCT01702558|9897562|FG000|Overall Study|Withdrawal by Subject|0
6225489|NCT01702558|9897563|FG001|Overall Study|Withdrawal by Subject|0
6225490|NCT01702558|9897564|FG002|Overall Study|Withdrawal by Subject|0
6225491|NCT01702558|9897565|FG003|Overall Study|Withdrawal by Subject|12
6225492|NCT01702558|9897566|FG004|Overall Study|Withdrawal by Subject|4
6225493|NCT01702558|9897562|FG000|Overall Study|Lost to Follow-up|0
6225494|NCT01702558|9897563|FG001|Overall Study|Lost to Follow-up|0
6135220|NCT00994422|9764623|FG000|Overall Study|Lost to Follow-up|7
6135221|NCT00994422|9764624|FG001|Overall Study|Lost to Follow-up|1
6135222|NCT00994448|9764634|FG000|Overall Study|Adverse Event|1
6135223|NCT00994448|9764635|FG001|Overall Study|Adverse Event|0
6135224|NCT00994448|9764634|FG000|Overall Study|Lost to Follow-up|5
6135225|NCT00994448|9764635|FG001|Overall Study|Lost to Follow-up|1
6135226|NCT00994448|9764634|FG000|Overall Study|Withdrawal by Subject|1
6225495|NCT01702558|9897564|FG002|Overall Study|Lost to Follow-up|0
6225496|NCT01702558|9897565|FG003|Overall Study|Lost to Follow-up|3
6225497|NCT01702558|9897566|FG004|Overall Study|Lost to Follow-up|0
6225498|NCT01702558|9897562|FG000|Overall Study|Death|4
6225499|NCT01702558|9897563|FG001|Overall Study|Death|3
6225500|NCT01702558|9897564|FG002|Overall Study|Death|3
6225501|NCT01702558|9897565|FG003|Overall Study|Death|16
6225502|NCT01702558|9897566|FG004|Overall Study|Death|20
6225503|NCT01702558|9897562|FG000|Overall Study|Safety Follow-Up less than 3 Months|0
6225504|NCT01702558|9897563|FG001|Overall Study|Safety Follow-Up less than 3 Months|0
6225505|NCT01702558|9897564|FG002|Overall Study|Safety Follow-Up less than 3 Months|2
6225506|NCT01702558|9897565|FG003|Overall Study|Safety Follow-Up less than 3 Months|0
6225507|NCT01702558|9897566|FG004|Overall Study|Safety Follow-Up less than 3 Months|0
6225508|NCT01702558|9897562|FG000|Overall Study|Study Terminated by Sponsor|0
6225509|NCT01702558|9897563|FG001|Overall Study|Study Terminated by Sponsor|1
6225510|NCT01702558|9897564|FG002|Overall Study|Study Terminated by Sponsor|0
6225511|NCT01702558|9897565|FG003|Overall Study|Study Terminated by Sponsor|0
6225512|NCT01702558|9897566|FG004|Overall Study|Study Terminated by Sponsor|1
6225513|NCT01702558|9897562|FG000|Overall Study|Other|0
6225514|NCT01702558|9897563|FG001|Overall Study|Other|0
6225515|NCT01702558|9897564|FG002|Overall Study|Other|0
6225516|NCT01702558|9897565|FG003|Overall Study|Other|16
6225517|NCT01702558|9897566|FG004|Overall Study|Other|17
6225518|NCT01702844|9897579|FG000|Overall Study|Adverse Event|9
6225519|NCT01702844|9897579|FG000|Overall Study|Death|1
6225520|NCT01702844|9897579|FG000|Overall Study|Withdrawal by Subject|3
6225521|NCT01702844|9897579|FG000|Overall Study|Physician Decision|6
6225522|NCT01702961|9897583|FG000|Overall Study|Additional treatment|3
6225523|NCT01702961|9897583|FG000|Overall Study|Progressive disease|5
6225524|NCT01702961|9897583|FG000|Overall Study|Relapse|20
6225525|NCT01702961|9897583|FG000|Overall Study|Death|6
6225526|NCT01702961|9897583|FG000|Overall Study|Lost to Follow-up|2
6225527|NCT01702961|9897583|FG000|Overall Study|Ongoing|11
6225528|NCT01702987|9897589|FG000|Overall Study|Withdrawal by Subject|1
6225529|NCT01702987|9897590|FG001|Overall Study|Withdrawal by Subject|0
6225530|NCT01703000|9897596|FG000|Overall Study|Death|1
6225531|NCT01703065|9897613|FG000|Overall Study|Lack of Efficacy|1
6225532|NCT01703065|9897614|FG001|Overall Study|Lack of Efficacy|0
6225533|NCT01703091|9897623|FG000|Overall Study|Adverse Event|5
6225534|NCT01703091|9897624|FG001|Overall Study|Adverse Event|3
6225535|NCT01703091|9897623|FG000|Overall Study|Physician Decision|2
6225536|NCT01703091|9897624|FG001|Overall Study|Physician Decision|1
6225537|NCT01703091|9897623|FG000|Overall Study|Withdrawal by Subject|1
6225538|NCT01703091|9897624|FG001|Overall Study|Withdrawal by Subject|0
6225539|NCT01703091|9897623|FG000|Overall Study|Sponsor Decision|1
6225540|NCT01703091|9897624|FG001|Overall Study|Sponsor Decision|0
6225541|NCT01703117|9897632|FG000|Overall Study|Adverse Event|4
6225542|NCT01703117|9897633|FG001|Overall Study|Adverse Event|3
6225543|NCT01703117|9897632|FG000|Overall Study|Withdrawal by Subject|0
6225544|NCT01703117|9897633|FG001|Overall Study|Withdrawal by Subject|1
6225545|NCT01703208|9897647|FG000|Overall Study|Death|61
6225546|NCT01703208|9897648|FG001|Overall Study|Death|48
6225547|NCT01703208|9897647|FG000|Overall Study|Lack of Efficacy|1
6225548|NCT01703208|9897648|FG001|Overall Study|Lack of Efficacy|2
6225549|NCT01703208|9897647|FG000|Overall Study|Lost to Follow-up|68
6225550|NCT01703208|9897648|FG001|Overall Study|Lost to Follow-up|62
6225551|NCT01703208|9897647|FG000|Overall Study|Non-Compliance with Study Drug|1
6225552|NCT01703208|9897648|FG001|Overall Study|Non-Compliance with Study Drug|0
6225553|NCT01703208|9897647|FG000|Overall Study|Excluded Medication|1
6290505|NCT02398188|10006616|FG000|Overall Study|Adverse Event|2
6290506|NCT02398188|10006617|FG001|Overall Study|Adverse Event|3
6290507|NCT02398188|10006616|FG000|Overall Study|Lost to Follow-up|5
6290508|NCT02398188|10006617|FG001|Overall Study|Lost to Follow-up|0
6290509|NCT02398188|10006616|FG000|Overall Study|Non-compliance|4
6290510|NCT02398188|10006617|FG001|Overall Study|Non-compliance|4
6290511|NCT02398188|10006616|FG000|Overall Study|Protocol Violation|6
6290512|NCT02398188|10006617|FG001|Overall Study|Protocol Violation|10
6290513|NCT02398188|10006616|FG000|Overall Study|Sponsor Decision|2
6225554|NCT01703208|9897648|FG001|Overall Study|Excluded Medication|2
6225555|NCT01703208|9897647|FG000|Overall Study|Site Discontinued Study Participation|23
6225556|NCT01703208|9897648|FG001|Overall Study|Site Discontinued Study Participation|27
6225557|NCT01703208|9897647|FG000|Overall Study|Physician Decision|11
6225558|NCT01703208|9897648|FG001|Overall Study|Physician Decision|13
6225559|NCT01703208|9897647|FG000|Overall Study|Progressive disease|2
6225560|NCT01703208|9897648|FG001|Overall Study|Progressive disease|2
6135227|NCT00994448|9764635|FG001|Overall Study|Withdrawal by Subject|1
6135228|NCT00994448|9764634|FG000|Overall Study|Physician Decision|1
6225561|NCT01703208|9897647|FG000|Overall Study|Protocol Violation|1
6225562|NCT01703208|9897648|FG001|Overall Study|Protocol Violation|1
6290514|NCT02398188|10006617|FG001|Overall Study|Sponsor Decision|1
6135229|NCT00994448|9764635|FG001|Overall Study|Physician Decision|0
6135230|NCT00994461|9764644|FG000|Overall Study|Adverse Event|2
6135231|NCT00994461|9764645|FG001|Overall Study|Adverse Event|1
6135232|NCT00994461|9764646|FG002|Overall Study|Adverse Event|0
6135233|NCT00994643|9764661|FG000|Overall Study|Withdrawal by Subject|1
6135234|NCT00994682|9764667|FG000|Double Bilnd|Withdrawal by Subject|5
6135235|NCT00994682|9764668|FG001|Double Bilnd|Withdrawal by Subject|6
6135236|NCT00994682|9764667|FG000|Double Bilnd|Lost to Follow-up|3
6135237|NCT00994682|9764668|FG001|Double Bilnd|Lost to Follow-up|3
6135238|NCT00994682|9764667|FG000|Double Bilnd|Adverse Event|1
6135239|NCT00994682|9764668|FG001|Double Bilnd|Adverse Event|0
6135240|NCT00994682|9764667|FG000|Pioglitazone Open Label|Withdrawal by Subject|4
6135241|NCT00994682|9764668|FG001|Pioglitazone Open Label|Withdrawal by Subject|4
6135242|NCT00994682|9764667|FG000|Pioglitazone Open Label|Lost to Follow-up|3
6135243|NCT00994682|9764668|FG001|Pioglitazone Open Label|Lost to Follow-up|2
6135244|NCT00994682|9764667|FG000|Pioglitazone Open Label|Physician Decision|6
6135245|NCT00994682|9764668|FG001|Pioglitazone Open Label|Physician Decision|1
6135246|NCT00994890|9764699|FG000|Overall Study|Adverse Event|13
6135247|NCT00994890|9764700|FG001|Overall Study|Adverse Event|9
6135248|NCT00994890|9764701|FG002|Overall Study|Adverse Event|11
6135249|NCT00994890|9764699|FG000|Overall Study|Lack of Efficacy|0
6135250|NCT00994890|9764700|FG001|Overall Study|Lack of Efficacy|0
6135251|NCT00994890|9764701|FG002|Overall Study|Lack of Efficacy|1
6135252|NCT00994890|9764699|FG000|Overall Study|Lost to Follow-up|6
6135253|NCT00994890|9764700|FG001|Overall Study|Lost to Follow-up|1
6135254|NCT00994890|9764701|FG002|Overall Study|Lost to Follow-up|3
6135255|NCT00994890|9764699|FG000|Overall Study|No longer willing to participate|8
6135256|NCT00994890|9764700|FG001|Overall Study|No longer willing to participate|5
6135257|NCT00994890|9764701|FG002|Overall Study|No longer willing to participate|13
6135258|NCT00994890|9764699|FG000|Overall Study|Protocol Violation|2
6225563|NCT01703208|9897647|FG000|Overall Study|Study Terminated by Sponsor|1710
6225564|NCT01703208|9897648|FG001|Overall Study|Study Terminated by Sponsor|1716
6225565|NCT01703208|9897647|FG000|Overall Study|Withdrawal by Subject|205
6225566|NCT01703208|9897648|FG001|Overall Study|Withdrawal by Subject|209
6225567|NCT01703208|9897647|FG000|Overall Study|Adverse Event|14
6225568|NCT01703208|9897648|FG001|Overall Study|Adverse Event|19
6225569|NCT01703208|9897647|FG000|Overall Study|Technical Problems|0
6225570|NCT01703208|9897648|FG001|Overall Study|Technical Problems|1
6225571|NCT01703208|9897647|FG000|Overall Study|Protocol Deviation|2
6225572|NCT01703208|9897648|FG001|Overall Study|Protocol Deviation|0
6225573|NCT01703221|9897657|FG000|Phase A (Up to 24 Weeks)|Adverse Event|2
6225574|NCT01703221|9897658|FG001|Phase A (Up to 24 Weeks)|Adverse Event|4
6225575|NCT01703221|9897659|FG002|Phase A (Up to 24 Weeks)|Adverse Event|0
6225576|NCT01703221|9897657|FG000|Phase A (Up to 24 Weeks)|Lack of Efficacy|2
6225577|NCT01703221|9897658|FG001|Phase A (Up to 24 Weeks)|Lack of Efficacy|0
6225578|NCT01703221|9897659|FG002|Phase A (Up to 24 Weeks)|Lack of Efficacy|1
6225579|NCT01703221|9897657|FG000|Phase A (Up to 24 Weeks)|Physician Decision|1
6225580|NCT01703221|9897658|FG001|Phase A (Up to 24 Weeks)|Physician Decision|0
6225581|NCT01703221|9897659|FG002|Phase A (Up to 24 Weeks)|Physician Decision|0
6225582|NCT01703221|9897657|FG000|Phase A (Up to 24 Weeks)|Withdrawal by Subject|2
6225583|NCT01703221|9897658|FG001|Phase A (Up to 24 Weeks)|Withdrawal by Subject|0
6225584|NCT01703221|9897659|FG002|Phase A (Up to 24 Weeks)|Withdrawal by Subject|1
6225585|NCT01703221|9897657|FG000|Phase A (Up to 24 Weeks)|Protocol Violation|0
6225586|NCT01703221|9897658|FG001|Phase A (Up to 24 Weeks)|Protocol Violation|0
6225587|NCT01703221|9897659|FG002|Phase A (Up to 24 Weeks)|Protocol Violation|1
6225588|NCT01703221|9897657|FG000|Phase B - (Week 25 to 52)|Withdrawal by Subject|2
6225589|NCT01703221|9897658|FG001|Phase B - (Week 25 to 52)|Withdrawal by Subject|1
6225590|NCT01703221|9897659|FG002|Phase B - (Week 25 to 52)|Withdrawal by Subject|0
6225591|NCT01703221|9897657|FG000|Phase B - (Week 25 to 52)|Adverse Event|2
6225592|NCT01703221|9897658|FG001|Phase B - (Week 25 to 52)|Adverse Event|3
6225593|NCT01703221|9897659|FG002|Phase B - (Week 25 to 52)|Adverse Event|2
6225594|NCT01703221|9897657|FG000|Phase B - (Week 25 to 52)|Lack of Efficacy|12
6225595|NCT01703221|9897658|FG001|Phase B - (Week 25 to 52)|Lack of Efficacy|10
6225596|NCT01703221|9897659|FG002|Phase B - (Week 25 to 52)|Lack of Efficacy|3
6225597|NCT01703260|9897676|FG000|Overall Study|Adverse Event|1
6225598|NCT01703260|9897677|FG001|Overall Study|Adverse Event|2
6225599|NCT01703260|9897678|FG002|Overall Study|Adverse Event|2
6135259|NCT00994890|9764700|FG001|Overall Study|Protocol Violation|4
6135260|NCT00994890|9764701|FG002|Overall Study|Protocol Violation|0
6135261|NCT00994890|9764699|FG000|Overall Study|Study terminated by sponsor|199
6135262|NCT00994890|9764700|FG001|Overall Study|Study terminated by sponsor|201
6135263|NCT00994890|9764701|FG002|Overall Study|Study terminated by sponsor|197
6225600|NCT01703260|9897676|FG000|Overall Study|Lost to Follow-up|1
6225601|NCT01703260|9897677|FG001|Overall Study|Lost to Follow-up|0
6225602|NCT01703260|9897678|FG002|Overall Study|Lost to Follow-up|0
6225603|NCT01703260|9897676|FG000|Overall Study|Withdrawal by Subject|0
6225604|NCT01703260|9897677|FG001|Overall Study|Withdrawal by Subject|0
6225605|NCT01703260|9897678|FG002|Overall Study|Withdrawal by Subject|1
6225606|NCT01703260|9897676|FG000|Overall Study|Study Termination|1
6225607|NCT01703260|9897677|FG001|Overall Study|Study Termination|2
6225608|NCT01703260|9897678|FG002|Overall Study|Study Termination|0
6135264|NCT00994890|9764699|FG000|Overall Study|Randomized, but not treated|1
6135265|NCT00994890|9764700|FG001|Overall Study|Randomized, but not treated|0
6135266|NCT00994890|9764701|FG002|Overall Study|Randomized, but not treated|0
6135267|NCT00994890|9764699|FG000|Overall Study|Other|2
6135268|NCT00994890|9764700|FG001|Overall Study|Other|2
6135269|NCT00994890|9764701|FG002|Overall Study|Other|1
6135270|NCT00995007|9764716|FG000|Overall Study|Withdrew consent|1
6135271|NCT00995007|9764717|FG001|Overall Study|Withdrew consent|0
6135272|NCT00995007|9764716|FG000|Overall Study|Refused further treatment|8
6135273|NCT00995007|9764717|FG001|Overall Study|Refused further treatment|2
6135274|NCT00995007|9764716|FG000|Overall Study|Toxicity|8
6135275|NCT00995007|9764717|FG001|Overall Study|Toxicity|0
6135276|NCT00995020|9764734|FG000|Overall Study|margin analysis not performed|2
6135277|NCT00995020|9764735|FG001|Overall Study|margin analysis not performed|5
6135278|NCT00995020|9764734|FG000|Overall Study|specimen fragmentation, thermal damage|1
6135279|NCT00995020|9764735|FG001|Overall Study|specimen fragmentation, thermal damage|2
6135280|NCT00995085|9764752|FG000|Overall Study|Withdrawal by Subject|5
6135281|NCT00995345|9764766|FG000|Overall Study|Withdrawal by Subject|4
6135282|NCT00995345|9764767|FG001|Overall Study|Withdrawal by Subject|2
6135283|NCT00995345|9764768|FG002|Overall Study|Withdrawal by Subject|1
6135284|NCT00995345|9764769|FG003|Overall Study|Withdrawal by Subject|3
6135285|NCT00995345|9764770|FG004|Overall Study|Withdrawal by Subject|1
6135286|NCT00995345|9764766|FG000|Overall Study|Adverse Event|3
6135287|NCT00995345|9764767|FG001|Overall Study|Adverse Event|1
6135288|NCT00995345|9764768|FG002|Overall Study|Adverse Event|2
6135289|NCT00995345|9764769|FG003|Overall Study|Adverse Event|0
6135290|NCT00995345|9764770|FG004|Overall Study|Adverse Event|1
6135291|NCT00995345|9764766|FG000|Overall Study|Lost to Follow-up|2
6135292|NCT00995345|9764767|FG001|Overall Study|Lost to Follow-up|2
6135293|NCT00995345|9764768|FG002|Overall Study|Lost to Follow-up|2
6135294|NCT00995345|9764769|FG003|Overall Study|Lost to Follow-up|1
6135295|NCT00995345|9764770|FG004|Overall Study|Lost to Follow-up|0
6135296|NCT00995345|9764766|FG000|Overall Study|all other reasons combined|2
6135297|NCT00995345|9764767|FG001|Overall Study|all other reasons combined|2
6135298|NCT00995345|9764768|FG002|Overall Study|all other reasons combined|2
6135299|NCT00995345|9764769|FG003|Overall Study|all other reasons combined|1
6135300|NCT00995345|9764770|FG004|Overall Study|all other reasons combined|3
6135301|NCT00995371|9764784|FG000|After ESI Cross-over to Mild, 26 Weeks|Withdrawal by Subject|5
6135302|NCT00995371|9764785|FG001|After ESI Cross-over to Mild, 26 Weeks|Withdrawal by Subject|5
6135303|NCT00995410|9764793|FG000|Overall Study|Adverse Event|51
6135304|NCT00995410|9764793|FG000|Overall Study|Withdrawal by Subject|7
6135305|NCT00995410|9764793|FG000|Overall Study|Lost to Follow-up|2
6135306|NCT00995410|9764793|FG000|Overall Study|Misc|28
6135307|NCT00995436|9764800|FG000|Overall Study|Withdrawal by Subject|2
6135308|NCT00995436|9764801|FG001|Overall Study|Withdrawal by Subject|5
6135309|NCT00995436|9764802|FG002|Overall Study|Withdrawal by Subject|0
6135310|NCT00995488|9764832|FG000|Overall Study|Withdrawal by Subject|1
6135311|NCT00995553|9764871|FG000|Overall Study|Withdrawal by Subject|2
6135312|NCT00995553|9764872|FG001|Overall Study|Withdrawal by Subject|6
6135313|NCT00995566|9764878|FG000|Overall Study|Adverse Event|2
6135314|NCT00995566|9764878|FG000|Overall Study|Early study termination|52
6135315|NCT00995670|9764885|FG000|Overall Study|Failed arterial cannulation|1
6135316|NCT00995670|9764886|FG001|Overall Study|Failed arterial cannulation|0
6135317|NCT00995670|9764887|FG002|Overall Study|Failed arterial cannulation|3
6135318|NCT00995709|9764898|FG000|Overall Study|Adverse Event|4
6135319|NCT00995709|9764899|FG001|Overall Study|Adverse Event|2
6135320|NCT00995709|9764900|FG002|Overall Study|Adverse Event|0
6135321|NCT00995709|9764898|FG000|Overall Study|Lack of Efficacy|0
6135322|NCT00995709|9764899|FG001|Overall Study|Lack of Efficacy|1
6135323|NCT00995709|9764900|FG002|Overall Study|Lack of Efficacy|4
6135324|NCT00995709|9764898|FG000|Overall Study|Withdrawal by Subject|0
6135325|NCT00995709|9764899|FG001|Overall Study|Withdrawal by Subject|4
6225609|NCT01703286|9897686|FG000|Period 1 Including Washout|Withdrawal by Subject|0
6225610|NCT01703286|9897687|FG001|Period 1 Including Washout|Withdrawal by Subject|0
6225611|NCT01703286|9897688|FG002|Period 1 Including Washout|Withdrawal by Subject|0
6225612|NCT01703286|9897689|FG003|Period 1 Including Washout|Withdrawal by Subject|1
6225613|NCT01703286|9897690|FG004|Period 1 Including Washout|Withdrawal by Subject|0
6225614|NCT01703286|9897691|FG005|Period 1 Including Washout|Withdrawal by Subject|1
6225615|NCT01703286|9897686|FG000|Period 2 Including Washout|Adverse Event|0
6225616|NCT01703286|9897687|FG001|Period 2 Including Washout|Adverse Event|0
6290515|NCT02398188|10006616|FG000|Overall Study|Pregnancy|1
6290516|NCT02398188|10006617|FG001|Overall Study|Pregnancy|0
6290517|NCT02398188|10006616|FG000|Overall Study|Withdrawal by Subject|7
6290518|NCT02398188|10006617|FG001|Overall Study|Withdrawal by Subject|16
6290519|NCT02398227|10006625|FG000|Overall Study|Lost to Follow-up|21
6290520|NCT02398227|10006626|FG001|Overall Study|Lost to Follow-up|12
6290521|NCT02398227|10006625|FG000|Overall Study|Withdrawal by Subject|5
6135326|NCT00995709|9764900|FG002|Overall Study|Withdrawal by Subject|1
6135327|NCT00995709|9764898|FG000|Overall Study|Lost to Follow-up|1
6135328|NCT00995709|9764899|FG001|Overall Study|Lost to Follow-up|0
6135329|NCT00995709|9764900|FG002|Overall Study|Lost to Follow-up|0
6290522|NCT02398227|10006626|FG001|Overall Study|Withdrawal by Subject|6
6290523|NCT02398227|10006625|FG000|Overall Study|Removed from treatment and dropped out|1
6135330|NCT00995709|9764898|FG000|Overall Study|Death|0
6135331|NCT00995709|9764899|FG001|Overall Study|Death|1
6135332|NCT00995709|9764900|FG002|Overall Study|Death|0
6135333|NCT00995709|9764898|FG000|Overall Study|Protocol Violation|2
6135334|NCT00995709|9764899|FG001|Overall Study|Protocol Violation|1
6135335|NCT00995709|9764900|FG002|Overall Study|Protocol Violation|0
6135336|NCT00995774|9764923|FG000|Training Period 2|Withdrawal by Subject|2
6135337|NCT00995774|9764924|FG001|Training Period 2|Withdrawal by Subject|0
6135338|NCT00995865|9764933|FG000|Overall Study|Protocol Violation|2
6135339|NCT00995865|9764934|FG001|Overall Study|Protocol Violation|0
6135340|NCT00995865|9764935|FG002|Overall Study|Protocol Violation|0
6135341|NCT00995865|9764933|FG000|Overall Study|Lost to Follow-up|0
6135342|NCT00995865|9764934|FG001|Overall Study|Lost to Follow-up|0
6135343|NCT00995865|9764935|FG002|Overall Study|Lost to Follow-up|1
6135344|NCT00995930|9764966|FG000|Overall Study|Protocol deviation|2
6135345|NCT00995930|9764967|FG001|Overall Study|Protocol deviation|5
6135346|NCT00995930|9764966|FG000|Overall Study|Death|0
6135347|NCT00995930|9764967|FG001|Overall Study|Death|1
6135348|NCT00995930|9764966|FG000|Overall Study|Administrative problems|4
6135349|NCT00995930|9764967|FG001|Overall Study|Administrative problems|2
6135350|NCT00995930|9764966|FG000|Overall Study|Lost to Follow-up|1
6135351|NCT00995930|9764967|FG001|Overall Study|Lost to Follow-up|2
6135352|NCT00995930|9764966|FG000|Overall Study|Withdrawal by Subject|3
6135353|NCT00995930|9764967|FG001|Overall Study|Withdrawal by Subject|4
6135354|NCT00995930|9764966|FG000|Overall Study|Adverse Event|11
6135355|NCT00995930|9764967|FG001|Overall Study|Adverse Event|14
6135356|NCT00996034|9764974|FG000|Overall Study|Lost to Follow-up|2
6135357|NCT00996034|9764974|FG000|Overall Study|withdrawn by PI|1
6135358|NCT00996125|9764980|FG000|Overall Study|Adverse Event|0
6135359|NCT00996125|9764981|FG001|Overall Study|Adverse Event|2
6135360|NCT00996125|9764980|FG000|Overall Study|Lost to Follow-up|1
6135361|NCT00996125|9764981|FG001|Overall Study|Lost to Follow-up|6
6135362|NCT00996125|9764980|FG000|Overall Study|Withdrawal by Subject|4
6135363|NCT00996125|9764981|FG001|Overall Study|Withdrawal by Subject|3
6135364|NCT00996203|9764996|FG000|Overall Study|Adverse Event|3
6135365|NCT00996203|9764996|FG000|Overall Study|Lost to Follow-up|1
6135366|NCT00996203|9764996|FG000|Overall Study|Lack of Efficacy|1
6135367|NCT00996203|9764996|FG000|Overall Study|Protocol Violation|2
6135368|NCT00996216|9765001|FG000|Part 1 (Pre-Antiviral Treatment Phase)|Withdrawal by Subject|1
6135369|NCT00996216|9765001|FG000|Part 2 (Antiviral Treatment Phase)|Lost to Follow-up|3
6135370|NCT00996216|9765001|FG000|Part 2 (Antiviral Treatment Phase)|Withdrawal by Subject|1
6135371|NCT00996281|9765008|FG000|Overall Study|Adverse Event|75
6135372|NCT00996281|9765009|FG001|Overall Study|Adverse Event|37
6135373|NCT00996281|9765008|FG000|Overall Study|Major Protocol Deviation|6
6135374|NCT00996281|9765009|FG001|Overall Study|Major Protocol Deviation|7
6135375|NCT00996281|9765008|FG000|Overall Study|Lost to Follow-up|14
6135376|NCT00996281|9765009|FG001|Overall Study|Lost to Follow-up|16
6135377|NCT00996281|9765008|FG000|Overall Study|Withdrawal by Subject|31
6225617|NCT01703286|9897688|FG002|Period 2 Including Washout|Adverse Event|0
6225618|NCT01703286|9897689|FG003|Period 2 Including Washout|Adverse Event|1
6225619|NCT01703286|9897690|FG004|Period 2 Including Washout|Adverse Event|0
6225620|NCT01703286|9897691|FG005|Period 2 Including Washout|Adverse Event|0
6225621|NCT01703741|9897736|FG000|Overall Study|Withdrawal by Subject|6
6225622|NCT01703741|9897736|FG000|Overall Study|Adverse Event|2
6225623|NCT01703741|9897736|FG000|Overall Study|Physician Decision|2
6225624|NCT01703741|9897736|FG000|Overall Study|Protocol Violation|1
6225625|NCT01703741|9897736|FG000|Overall Study|Lost to Follow-up|3
6225626|NCT01703741|9897736|FG000|Overall Study|Subject did not want to continue|2
6225627|NCT01703741|9897736|FG000|Overall Study|Subject cannot comply with study visits|1
6225628|NCT01703741|9897736|FG000|Overall Study|Subject started testosterone injections|1
6225629|NCT01703819|9897742|FG000|Overall Study|Adverse Event|0
6225630|NCT01703819|9897743|FG001|Overall Study|Adverse Event|1
6225631|NCT01703819|9897742|FG000|Overall Study|Withdrawal by Subject|0
6135378|NCT00996281|9765009|FG001|Overall Study|Withdrawal by Subject|20
6135379|NCT00996281|9765008|FG000|Overall Study|Lack of Efficacy|0
6135380|NCT00996281|9765009|FG001|Overall Study|Lack of Efficacy|2
6135381|NCT00996281|9765008|FG000|Overall Study|Other|5
6135382|NCT00996281|9765009|FG001|Overall Study|Other|7
6135383|NCT00996307|9765019|FG000|Overall Study|Adverse Event|0
6135384|NCT00996307|9765020|FG001|Overall Study|Adverse Event|1
6135385|NCT00996307|9765021|FG002|Overall Study|Adverse Event|0
6135386|NCT00996307|9765022|FG003|Overall Study|Adverse Event|0
6135387|NCT00996307|9765019|FG000|Overall Study|Withdrawal by Subject|3
6135388|NCT00996307|9765020|FG001|Overall Study|Withdrawal by Subject|2
6135389|NCT00996307|9765021|FG002|Overall Study|Withdrawal by Subject|5
6135390|NCT00996307|9765022|FG003|Overall Study|Withdrawal by Subject|5
6135391|NCT00996307|9765019|FG000|Overall Study|Lost to Follow-up|13
6135392|NCT00996307|9765020|FG001|Overall Study|Lost to Follow-up|13
6135393|NCT00996307|9765021|FG002|Overall Study|Lost to Follow-up|7
6135394|NCT00996307|9765022|FG003|Overall Study|Lost to Follow-up|15
6135395|NCT00996307|9765019|FG000|Overall Study|Administrative reason|0
6135396|NCT00996307|9765020|FG001|Overall Study|Administrative reason|1
6135397|NCT00996307|9765021|FG002|Overall Study|Administrative reason|0
6135398|NCT00996307|9765022|FG003|Overall Study|Administrative reason|0
6135399|NCT00996307|9765019|FG000|Overall Study|Unable to classify|4
6135400|NCT00996307|9765020|FG001|Overall Study|Unable to classify|0
6135401|NCT00996307|9765021|FG002|Overall Study|Unable to classify|2
6135402|NCT00996307|9765022|FG003|Overall Study|Unable to classify|1
6135403|NCT00996437|9765074|FG000|Overall Study|Death|1
6135404|NCT00996437|9765075|FG001|Overall Study|Death|0
6135405|NCT00996437|9765074|FG000|Overall Study|Dropped|2
6135406|NCT00996437|9765075|FG001|Overall Study|Dropped|2
6135407|NCT00996437|9765074|FG000|Overall Study|Missed|2
6135408|NCT00996437|9765075|FG001|Overall Study|Missed|5
6135409|NCT00996476|9765086|FG000|Overall Study|Withdrawal by Subject|1
6135410|NCT00996476|9765087|FG001|Overall Study|Withdrawal by Subject|2
6135411|NCT00996476|9765088|FG002|Overall Study|Withdrawal by Subject|1
6135412|NCT00996476|9765089|FG003|Overall Study|Withdrawal by Subject|0
6135413|NCT00996476|9765090|FG004|Overall Study|Withdrawal by Subject|1
6135414|NCT00996476|9765086|FG000|Overall Study|Adverse Event|0
6135415|NCT00996476|9765087|FG001|Overall Study|Adverse Event|1
6135416|NCT00996476|9765088|FG002|Overall Study|Adverse Event|0
6135417|NCT00996476|9765089|FG003|Overall Study|Adverse Event|0
6135418|NCT00996476|9765090|FG004|Overall Study|Adverse Event|1
6135419|NCT00996489|9765107|FG000|Overall Study|Device failure|45
6135420|NCT00996489|9765107|FG000|Overall Study|Discontinued|116
6135421|NCT00996580|9765111|FG000|Overall Study|Adverse Event|466
6135422|NCT00996580|9765111|FG000|Overall Study|Lost to Follow-up|480
6135423|NCT00996580|9765111|FG000|Overall Study|Noncompliance with the protocol|137
6135424|NCT00996580|9765111|FG000|Overall Study|Physician Decision|5
6135425|NCT00996580|9765111|FG000|Overall Study|Pregnancy|68
6135426|NCT00996580|9765111|FG000|Overall Study|Protocol Violation|16
6135427|NCT00996580|9765111|FG000|Overall Study|Sponsor requested participant withdrawal|35
6135428|NCT00996580|9765111|FG000|Overall Study|Withdrawal by Subject|217
6135429|NCT00996580|9765111|FG000|Overall Study|Other|29
6135430|NCT00996593|9765118|FG000|Dosimetric and Therapeutic Treatment|Lost to Follow-up|7
6135431|NCT00996593|9765118|FG000|Dosimetric and Therapeutic Treatment|Withdrawal by Subject|3
6135432|NCT00996593|9765118|FG000|Dosimetric and Therapeutic Treatment|Progressive Disease|22
6135433|NCT00996593|9765118|FG000|Dosimetric and Therapeutic Treatment|Death|1
6135434|NCT00996593|9765118|FG000|Dosimetric and Therapeutic Treatment|Enrolled in BEX104526|6
6135435|NCT00996593|9765118|FG000|Dosimetric and Therapeutic Treatment|Did Not Receive Any Study Drug|3
6135436|NCT00996593|9765118|FG000|Dosimetric and Therapeutic Treatment|Non-compliance|1
6135437|NCT00996593|9765118|FG000|Long-Term Follow-Up|Withdrawal by Subject|2
6135438|NCT00996593|9765118|FG000|Long-Term Follow-Up|Site Closed|1
6135439|NCT00996606|9765122|FG000|Overall Study|Adverse Event or Intercurrent Illness|2
6225632|NCT01703819|9897743|FG001|Overall Study|Withdrawal by Subject|1
6225633|NCT01703832|9897751|FG000|Overall Study|Withdrawal by Subject|1
6225634|NCT01703832|9897752|FG001|Overall Study|Withdrawal by Subject|0
6290524|NCT02398227|10006626|FG001|Overall Study|Removed from treatment and dropped out|0
6290525|NCT02399163|10006645|FG000|Overall Study|Adverse Event|2
6290526|NCT02399163|10006645|FG000|Overall Study|Protocol Deviation|2
6290527|NCT02399163|10006645|FG000|Overall Study|Withdrawal by Participant|5
6290528|NCT02399254|10006661|FG000|Overall Study|Physician Decision|2
6290529|NCT02399475|10006672|FG000|Overall Study|Physician Decision|1
6290530|NCT02399475|10006673|FG001|Overall Study|Physician Decision|0
6290531|NCT02400307|10006699|FG000|Overall Study|Enrolled and Never Dosed|1
6290532|NCT02400307|10006700|FG001|Overall Study|Enrolled and Never Dosed|0
6290533|NCT02400333|10006710|FG000|Overall Study|Withdrawal by Subject|0
6290534|NCT02400333|10006711|FG001|Overall Study|Withdrawal by Subject|1
6290535|NCT02400333|10006712|FG002|Overall Study|Withdrawal by Subject|0
6290536|NCT02400333|10006713|FG003|Overall Study|Withdrawal by Subject|1
6290537|NCT02400333|10006710|FG000|Overall Study|Protocol Violation|1
6290538|NCT02400333|10006711|FG001|Overall Study|Protocol Violation|0
6135440|NCT00996606|9765122|FG000|Overall Study|Insufficient Therapeutic Response|2
6135441|NCT00996606|9765122|FG000|Overall Study|Protocol Violation|1
6135442|NCT00996606|9765122|FG000|Overall Study|Withdrawal by Subject|3
6135443|NCT00996632|9765128|FG000|Overall Study|Physician Decision|0
6225635|NCT01703845|9897760|FG000|Overall Study|Adverse Event|1
6225636|NCT01703845|9897761|FG001|Overall Study|Adverse Event|0
6225637|NCT01703845|9897760|FG000|Overall Study|Protocol Violation|1
6225638|NCT01703845|9897761|FG001|Overall Study|Protocol Violation|0
6225639|NCT01703845|9897760|FG000|Overall Study|other than stated above|1
6225640|NCT01703845|9897761|FG001|Overall Study|other than stated above|0
6225641|NCT01703858|9897772|FG000|Overall Study|Withdrawal by Subject|0
6225642|NCT01703858|9897773|FG001|Overall Study|Withdrawal by Subject|1
6225643|NCT01703858|9897774|FG002|Overall Study|Withdrawal by Subject|0
6225644|NCT01703988|9897791|FG000|Overall Study|Investigator Judgment|0
6225645|NCT01703988|9897792|FG001|Overall Study|Investigator Judgment|0
6225646|NCT01703988|9897793|FG002|Overall Study|Investigator Judgment|0
6225647|NCT01703988|9897794|FG003|Overall Study|Investigator Judgment|1
6225648|NCT01704079|9897807|FG000|Overall Study|Withdrawal by Subject|5
6225649|NCT01704079|9897808|FG001|Overall Study|Withdrawal by Subject|7
6225650|NCT01704079|9897807|FG000|Overall Study|Lost to Follow-up|2
6225651|NCT01704079|9897808|FG001|Overall Study|Lost to Follow-up|5
6290539|NCT02400333|10006712|FG002|Overall Study|Protocol Violation|2
6225652|NCT01704079|9897807|FG000|Overall Study|Adverse Event|4
6225653|NCT01704079|9897808|FG001|Overall Study|Adverse Event|7
6225654|NCT01704079|9897807|FG000|Overall Study|Protocol Violation|1
6135444|NCT00996632|9765129|FG001|Overall Study|Physician Decision|0
6135445|NCT00996658|9765137|FG000|Overall Study|Adverse Event|2
6135446|NCT00996658|9765138|FG001|Overall Study|Adverse Event|5
6135447|NCT00996658|9765137|FG000|Overall Study|Protocol Violation|0
6135448|NCT00996658|9765138|FG001|Overall Study|Protocol Violation|1
6135449|NCT00996658|9765137|FG000|Overall Study|Lost to Follow-up|2
6135450|NCT00996658|9765138|FG001|Overall Study|Lost to Follow-up|5
6135451|NCT00996658|9765137|FG000|Overall Study|Non-compliance issues|3
6135452|NCT00996658|9765138|FG001|Overall Study|Non-compliance issues|3
6135453|NCT00996658|9765137|FG000|Overall Study|Other|9
6135454|NCT00996658|9765138|FG001|Overall Study|Other|7
6135455|NCT00996736|9765146|FG000|Overall Study|Death|1
6135456|NCT00996736|9765147|FG001|Overall Study|Death|1
6135457|NCT00996736|9765146|FG000|Overall Study|Lost to Follow-up|15
6135458|NCT00996736|9765147|FG001|Overall Study|Lost to Follow-up|14
6135459|NCT00996736|9765146|FG000|Overall Study|Visit not within 3-month window|5
6135460|NCT00996736|9765147|FG001|Overall Study|Visit not within 3-month window|3
6135461|NCT00996801|9765168|FG000|Overall Study|Adverse Event|6
6135462|NCT00996801|9765169|FG001|Overall Study|Adverse Event|4
6135463|NCT00996801|9765170|FG002|Overall Study|Adverse Event|12
6135464|NCT00996801|9765171|FG003|Overall Study|Adverse Event|17
6135465|NCT00996801|9765172|FG004|Overall Study|Adverse Event|31
6135466|NCT00996801|9765173|FG005|Overall Study|Adverse Event|3
6135467|NCT00996801|9765168|FG000|Overall Study|Lack of Efficacy|3
6135468|NCT00996801|9765169|FG001|Overall Study|Lack of Efficacy|0
6135469|NCT00996801|9765170|FG002|Overall Study|Lack of Efficacy|1
6135470|NCT00996801|9765171|FG003|Overall Study|Lack of Efficacy|3
6135471|NCT00996801|9765172|FG004|Overall Study|Lack of Efficacy|0
6135472|NCT00996801|9765173|FG005|Overall Study|Lack of Efficacy|1
6135473|NCT00996801|9765168|FG000|Overall Study|Lost to Follow-up|0
6135474|NCT00996801|9765169|FG001|Overall Study|Lost to Follow-up|0
6135475|NCT00996801|9765170|FG002|Overall Study|Lost to Follow-up|0
6135476|NCT00996801|9765171|FG003|Overall Study|Lost to Follow-up|3
6135477|NCT00996801|9765172|FG004|Overall Study|Lost to Follow-up|3
6135478|NCT00996801|9765173|FG005|Overall Study|Lost to Follow-up|2
6135479|NCT00996801|9765168|FG000|Overall Study|Physician Decision|0
6135480|NCT00996801|9765169|FG001|Overall Study|Physician Decision|0
6135481|NCT00996801|9765170|FG002|Overall Study|Physician Decision|0
6135482|NCT00996801|9765171|FG003|Overall Study|Physician Decision|1
6135483|NCT00996801|9765172|FG004|Overall Study|Physician Decision|0
6135484|NCT00996801|9765173|FG005|Overall Study|Physician Decision|0
6135485|NCT00996801|9765168|FG000|Overall Study|Progressive Disease|0
6135486|NCT00996801|9765169|FG001|Overall Study|Progressive Disease|1
6135487|NCT00996801|9765170|FG002|Overall Study|Progressive Disease|0
6135488|NCT00996801|9765171|FG003|Overall Study|Progressive Disease|0
6135489|NCT00996801|9765172|FG004|Overall Study|Progressive Disease|0
6135490|NCT00996801|9765173|FG005|Overall Study|Progressive Disease|0
6135491|NCT00996801|9765168|FG000|Overall Study|Protocol Violation|3
6135492|NCT00996801|9765169|FG001|Overall Study|Protocol Violation|4
6135493|NCT00996801|9765170|FG002|Overall Study|Protocol Violation|1
6135494|NCT00996801|9765171|FG003|Overall Study|Protocol Violation|2
6135495|NCT00996801|9765172|FG004|Overall Study|Protocol Violation|3
6135496|NCT00996801|9765173|FG005|Overall Study|Protocol Violation|4
6135497|NCT00996801|9765168|FG000|Overall Study|Study Terminated by Sponsor|0
6135498|NCT00996801|9765169|FG001|Overall Study|Study Terminated by Sponsor|1
6135499|NCT00996801|9765170|FG002|Overall Study|Study Terminated by Sponsor|0
6135500|NCT00996801|9765171|FG003|Overall Study|Study Terminated by Sponsor|0
6135501|NCT00996801|9765172|FG004|Overall Study|Study Terminated by Sponsor|46
6135502|NCT00996801|9765173|FG005|Overall Study|Study Terminated by Sponsor|0
6135503|NCT00996801|9765168|FG000|Overall Study|Withdrawal by Subject|8
6135504|NCT00996801|9765169|FG001|Overall Study|Withdrawal by Subject|6
6135505|NCT00996801|9765170|FG002|Overall Study|Withdrawal by Subject|9
6135506|NCT00996801|9765171|FG003|Overall Study|Withdrawal by Subject|5
6135507|NCT00996801|9765172|FG004|Overall Study|Withdrawal by Subject|5
6135508|NCT00996801|9765173|FG005|Overall Study|Withdrawal by Subject|9
6135509|NCT00996840|9765194|FG000|Overall Study|Adverse Event|0
6135510|NCT00996840|9765195|FG001|Overall Study|Adverse Event|1
6135511|NCT00996840|9765196|FG002|Overall Study|Adverse Event|0
6135512|NCT00996840|9765197|FG003|Overall Study|Adverse Event|0
6135513|NCT00996840|9765198|FG004|Overall Study|Adverse Event|0
6135514|NCT00996840|9765194|FG000|Overall Study|Physician Decision|0
6135515|NCT00996840|9765195|FG001|Overall Study|Physician Decision|0
6135516|NCT00996840|9765196|FG002|Overall Study|Physician Decision|1
6135517|NCT00996840|9765197|FG003|Overall Study|Physician Decision|1
6135518|NCT00996840|9765198|FG004|Overall Study|Physician Decision|2
6135519|NCT00996840|9765194|FG000|Overall Study|Withdrawal by Subject|1
6135520|NCT00996840|9765195|FG001|Overall Study|Withdrawal by Subject|1
6135521|NCT00996840|9765196|FG002|Overall Study|Withdrawal by Subject|0
6135522|NCT00996840|9765197|FG003|Overall Study|Withdrawal by Subject|0
6135523|NCT00996840|9765198|FG004|Overall Study|Withdrawal by Subject|0
6135524|NCT00996892|9765214|FG000|Dose-Escalation Stage 1|Adverse Event|0
6135525|NCT00996892|9765215|FG001|Dose-Escalation Stage 1|Adverse Event|0
6135526|NCT00996892|9765216|FG002|Dose-Escalation Stage 1|Adverse Event|0
6135527|NCT00996892|9765217|FG003|Dose-Escalation Stage 1|Adverse Event|2
6135528|NCT00996892|9765218|FG004|Dose-Escalation Stage 1|Adverse Event|0
6135529|NCT00996892|9765219|FG005|Dose-Escalation Stage 1|Adverse Event|0
6135530|NCT00996892|9765220|FG006|Dose-Escalation Stage 1|Adverse Event|1
6135531|NCT00996892|9765221|FG007|Dose-Escalation Stage 1|Adverse Event|0
6135532|NCT00996892|9765222|FG008|Dose-Escalation Stage 1|Adverse Event|0
6225655|NCT01704079|9897808|FG001|Overall Study|Protocol Violation|0
6225656|NCT01704079|9897807|FG000|Overall Study|Subject noncompliance|2
6225657|NCT01704079|9897808|FG001|Overall Study|Subject noncompliance|3
6225658|NCT01704079|9897807|FG000|Overall Study|Serum Calcium >/= 11.0 mg/dL, repeat con|0
6225659|NCT01704079|9897808|FG001|Overall Study|Serum Calcium >/= 11.0 mg/dL, repeat con|1
6225660|NCT01704261|9897825|FG000|Overall Study|Withdrawal by Subject|12
6225661|NCT01704261|9897826|FG001|Overall Study|Withdrawal by Subject|15
6225662|NCT01704261|9897825|FG000|Overall Study|Lost to Follow-up|1
6225663|NCT01704261|9897826|FG001|Overall Study|Lost to Follow-up|0
6225664|NCT01704287|9897835|FG000|Initial Treatment Period|Death|139
6225665|NCT01704287|9897836|FG001|Initial Treatment Period|Death|129
6225666|NCT01704287|9897837|FG002|Initial Treatment Period|Death|71
6225667|NCT01704287|9897838|FG003|Initial Treatment Period|Death|0
6225668|NCT01704287|9897839|FG004|Initial Treatment Period|Death|0
6225669|NCT01704287|9897835|FG000|Initial Treatment Period|Withdrawal by Subject|3
6225670|NCT01704287|9897836|FG001|Initial Treatment Period|Withdrawal by Subject|2
6225671|NCT01704287|9897837|FG002|Initial Treatment Period|Withdrawal by Subject|4
6225672|NCT01704287|9897838|FG003|Initial Treatment Period|Withdrawal by Subject|0
6225673|NCT01704287|9897839|FG004|Initial Treatment Period|Withdrawal by Subject|0
6225674|NCT01704287|9897835|FG000|Initial Treatment Period|Lost to Follow-up|5
6225675|NCT01704287|9897836|FG001|Initial Treatment Period|Lost to Follow-up|3
6225676|NCT01704287|9897837|FG002|Initial Treatment Period|Lost to Follow-up|0
6225677|NCT01704287|9897838|FG003|Initial Treatment Period|Lost to Follow-up|0
6225678|NCT01704287|9897839|FG004|Initial Treatment Period|Lost to Follow-up|0
6225679|NCT01704287|9897835|FG000|Initial Treatment Period|Switched to Pembrolizumab|0
6225680|NCT01704287|9897836|FG001|Initial Treatment Period|Switched to Pembrolizumab|0
6225681|NCT01704287|9897837|FG002|Initial Treatment Period|Switched to Pembrolizumab|98
6225682|NCT01704287|9897838|FG003|Initial Treatment Period|Switched to Pembrolizumab|0
6225683|NCT01704287|9897839|FG004|Initial Treatment Period|Switched to Pembrolizumab|0
6225684|NCT01704287|9897835|FG000|Switch to Pembrolizumab Treatment Period|Lost to Follow-up|0
6225685|NCT01704287|9897836|FG001|Switch to Pembrolizumab Treatment Period|Lost to Follow-up|0
6225686|NCT01704287|9897837|FG002|Switch to Pembrolizumab Treatment Period|Lost to Follow-up|0
6225687|NCT01704287|9897838|FG003|Switch to Pembrolizumab Treatment Period|Lost to Follow-up|2
6225688|NCT01704287|9897839|FG004|Switch to Pembrolizumab Treatment Period|Lost to Follow-up|1
6225689|NCT01704287|9897835|FG000|Switch to Pembrolizumab Treatment Period|Death|0
6225690|NCT01704287|9897836|FG001|Switch to Pembrolizumab Treatment Period|Death|0
6225691|NCT01704287|9897837|FG002|Switch to Pembrolizumab Treatment Period|Death|0
6225692|NCT01704287|9897838|FG003|Switch to Pembrolizumab Treatment Period|Death|35
6225693|NCT01704287|9897839|FG004|Switch to Pembrolizumab Treatment Period|Death|37
6225694|NCT01704287|9897835|FG000|Switch to Pembrolizumab Treatment Period|Withdrawal by Subject|0
6225695|NCT01704287|9897836|FG001|Switch to Pembrolizumab Treatment Period|Withdrawal by Subject|0
6225696|NCT01704287|9897837|FG002|Switch to Pembrolizumab Treatment Period|Withdrawal by Subject|0
6225697|NCT01704287|9897838|FG003|Switch to Pembrolizumab Treatment Period|Withdrawal by Subject|1
6225698|NCT01704287|9897839|FG004|Switch to Pembrolizumab Treatment Period|Withdrawal by Subject|0
6225699|NCT01704456|9897860|FG000|Overall Study|Lost to Follow-up|8
6225700|NCT01704456|9897861|FG001|Overall Study|Lost to Follow-up|14
6225701|NCT01704495|9897871|FG000|Subjects Randomized|Other Reason|3
6225702|NCT01704495|9897872|FG001|Subjects Randomized|Other Reason|2
6225703|NCT01704495|9897873|FG002|Subjects Randomized|Other Reason|3
6225704|NCT01704495|9897874|FG003|Subjects Randomized|Other Reason|2
6225705|NCT01704495|9897871|FG000|Subjects Randomized|Discontinuation criteria met|4
6225706|NCT01704495|9897872|FG001|Subjects Randomized|Discontinuation criteria met|2
6225707|NCT01704495|9897873|FG002|Subjects Randomized|Discontinuation criteria met|2
6225708|NCT01704495|9897874|FG003|Subjects Randomized|Discontinuation criteria met|0
6225709|NCT01704495|9897871|FG000|Subjects Randomized|Adverse Event|8
6225710|NCT01704495|9897872|FG001|Subjects Randomized|Adverse Event|2
6225711|NCT01704495|9897873|FG002|Subjects Randomized|Adverse Event|0
6225712|NCT01704495|9897874|FG003|Subjects Randomized|Adverse Event|7
6225713|NCT01704495|9897871|FG000|Subjects Randomized|Withdrawal by Subject|5
6225714|NCT01704495|9897872|FG001|Subjects Randomized|Withdrawal by Subject|5
6225715|NCT01704495|9897873|FG002|Subjects Randomized|Withdrawal by Subject|5
6225716|NCT01704495|9897874|FG003|Subjects Randomized|Withdrawal by Subject|5
6225717|NCT01704495|9897871|FG000|Subjects Randomized|Protocol Violation|1
6225718|NCT01704495|9897872|FG001|Subjects Randomized|Protocol Violation|1
6225719|NCT01704495|9897873|FG002|Subjects Randomized|Protocol Violation|2
6225720|NCT01704495|9897874|FG003|Subjects Randomized|Protocol Violation|0
6225721|NCT01704495|9897871|FG000|Subjects Randomized|Eligibility criteria not fulfilled|1
6290540|NCT02400333|10006713|FG003|Overall Study|Protocol Violation|1
6290541|NCT02400346|10006724|FG000|Overall Study|Adverse Event|24
6290542|NCT02400346|10006724|FG000|Overall Study|Lack of Efficacy|9
6290543|NCT02400346|10006724|FG000|Overall Study|Non-compliance with IMP|1
6290544|NCT02400346|10006724|FG000|Overall Study|Withdrawal by Subject|7
6290545|NCT02400346|10006724|FG000|Overall Study|Administrative or other reason(s)|2
6290546|NCT02400346|10006724|FG000|Overall Study|Lost to Follow-up|1
6135533|NCT00996892|9765223|FG009|Dose-Escalation Stage 1|Adverse Event|0
6135534|NCT00996892|9765224|FG010|Dose-Escalation Stage 1|Adverse Event|0
6135535|NCT00996892|9765225|FG011|Dose-Escalation Stage 1|Adverse Event|0
6135536|NCT00996892|9765226|FG012|Dose-Escalation Stage 1|Adverse Event|0
6135537|NCT00996892|9765227|FG013|Dose-Escalation Stage 1|Adverse Event|0
6135538|NCT00996892|9765228|FG014|Dose-Escalation Stage 1|Adverse Event|0
6135539|NCT00996892|9765229|FG015|Dose-Escalation Stage 1|Adverse Event|0
6135540|NCT00996892|9765230|FG016|Dose-Escalation Stage 1|Adverse Event|0
6135541|NCT00996892|9765231|FG017|Dose-Escalation Stage 1|Adverse Event|0
6135542|NCT00996892|9765232|FG018|Dose-Escalation Stage 1|Adverse Event|0
6135543|NCT00996892|9765233|FG019|Dose-Escalation Stage 1|Adverse Event|0
6135544|NCT00996892|9765214|FG000|Dose-Escalation Stage 1|Death|1
6135545|NCT00996892|9765215|FG001|Dose-Escalation Stage 1|Death|0
6135546|NCT00996892|9765216|FG002|Dose-Escalation Stage 1|Death|0
6135547|NCT00996892|9765217|FG003|Dose-Escalation Stage 1|Death|0
6225722|NCT01704495|9897872|FG001|Subjects Randomized|Eligibility criteria not fulfilled|3
6225723|NCT01704495|9897873|FG002|Subjects Randomized|Eligibility criteria not fulfilled|4
6225724|NCT01704495|9897874|FG003|Subjects Randomized|Eligibility criteria not fulfilled|3
6225725|NCT01704495|9897871|FG000|Optional Safety Extension|Adverse Event|0
6225726|NCT01704495|9897872|FG001|Optional Safety Extension|Adverse Event|4
6225727|NCT01704495|9897873|FG002|Optional Safety Extension|Adverse Event|0
6225728|NCT01704495|9897874|FG003|Optional Safety Extension|Adverse Event|1
6225729|NCT01704495|9897871|FG000|Optional Safety Extension|Other reason|27
6225730|NCT01704495|9897872|FG001|Optional Safety Extension|Other reason|29
6225731|NCT01704495|9897873|FG002|Optional Safety Extension|Other reason|30
6225732|NCT01704495|9897874|FG003|Optional Safety Extension|Other reason|28
6225733|NCT01704495|9897871|FG000|Optional Safety Extension|Withdrawal by Subject|2
6225734|NCT01704495|9897872|FG001|Optional Safety Extension|Withdrawal by Subject|0
6225735|NCT01704495|9897873|FG002|Optional Safety Extension|Withdrawal by Subject|1
6225736|NCT01704495|9897874|FG003|Optional Safety Extension|Withdrawal by Subject|2
6225737|NCT01704599|9897893|FG000|Overall Study|Adverse Event|1
6225738|NCT01704651|9897922|FG000|Overall Study|Pre-op withdrawal by subject|1
6225739|NCT01704651|9897923|FG001|Overall Study|Pre-op withdrawal by subject|1
6225740|NCT01704651|9897922|FG000|Overall Study|Pre-op change in treatment plan|1
6225741|NCT01704651|9897923|FG001|Overall Study|Pre-op change in treatment plan|4
6225742|NCT01704651|9897922|FG000|Overall Study|Nasogastric tube placement in surgery|1
6225743|NCT01704651|9897923|FG001|Overall Study|Nasogastric tube placement in surgery|1
6225744|NCT01704651|9897922|FG000|Overall Study|Post-op did not have laparotomy|2
6225745|NCT01704651|9897923|FG001|Overall Study|Post-op did not have laparotomy|1
6225746|NCT01704755|9897931|FG000|Overall Study|Adverse Event|4
6225747|NCT01704755|9897932|FG001|Overall Study|Adverse Event|1
6225748|NCT01704755|9897931|FG000|Overall Study|Lost to Follow-up|3
6225749|NCT01704755|9897932|FG001|Overall Study|Lost to Follow-up|4
6225750|NCT01704755|9897931|FG000|Overall Study|Withdrew consent|1
6225751|NCT01704755|9897932|FG001|Overall Study|Withdrew consent|1
6225752|NCT01704755|9897931|FG000|Overall Study|Other (not specified)|3
6225753|NCT01704755|9897932|FG001|Overall Study|Other (not specified)|1
6225754|NCT01704755|9897931|FG000|Overall Study|Withdrew consent and personal issues|1
6225755|NCT01704755|9897932|FG001|Overall Study|Withdrew consent and personal issues|0
6290547|NCT02400580|10006740|FG000|Overall Study|Withdrawal by Subject|1
6290548|NCT02400580|10006741|FG001|Overall Study|Withdrawal by Subject|1
6290549|NCT02400580|10006740|FG000|Overall Study|Adverse Event|1
6290550|NCT02400580|10006741|FG001|Overall Study|Adverse Event|0
6290551|NCT02400749|10006758|FG000|Week 0 -16|Withdrawal by Subject|5
6290552|NCT02400749|10006759|FG001|Week 0 -16|Withdrawal by Subject|5
6290553|NCT02400749|10006758|FG000|Week 0 -16|Adverse Event|3
6290554|NCT02400749|10006759|FG001|Week 0 -16|Adverse Event|1
6290555|NCT02400749|10006758|FG000|Week 0 -16|Lost to Follow-up|2
6290556|NCT02400749|10006759|FG001|Week 0 -16|Lost to Follow-up|0
6290557|NCT02400749|10006758|FG000|Week 0 -16|Protocol Violation|1
6290558|NCT02400749|10006759|FG001|Week 0 -16|Protocol Violation|0
5981131|NCT02253316|9570079|FG002|Maintenance|Still receiving active treatment|27
5981132|NCT02224573|9570089|FG000|Treatment Phase|Caregiver Asked to Stop Investigational Medicinal Product (IMP)|0
6135548|NCT00996892|9765218|FG004|Dose-Escalation Stage 1|Death|0
6290559|NCT02400749|10006758|FG000|Week 17 - 32|Withdrawal by Subject|3
6290560|NCT02400749|10006759|FG001|Week 17 - 32|Withdrawal by Subject|2
6290561|NCT02400749|10006758|FG000|Week 17 - 32|Adverse Event|2
6290562|NCT02400749|10006759|FG001|Week 17 - 32|Adverse Event|1
6290563|NCT02400905|10006765|FG000|Overall Study|Death|24
6290564|NCT02400905|10006765|FG000|Overall Study|Lost to Follow-up|18
6290565|NCT02400905|10006765|FG000|Overall Study|Withdrawal by Subject|16
6290566|NCT02400905|10006765|FG000|Overall Study|Physician Decision|4
6290567|NCT02400905|10006765|FG000|Overall Study|Other|1
6290568|NCT02401230|10006800|FG000|Overall Study|Adverse Event|3
6290569|NCT02401230|10006801|FG001|Overall Study|Adverse Event|2
6135549|NCT00996892|9765219|FG005|Dose-Escalation Stage 1|Death|1
6135550|NCT00996892|9765220|FG006|Dose-Escalation Stage 1|Death|0
6290570|NCT02401230|10006802|FG002|Overall Study|Adverse Event|0
6290571|NCT02401230|10006800|FG000|Overall Study|Withdrawal by Subject|2
6290572|NCT02401230|10006801|FG001|Overall Study|Withdrawal by Subject|1
6290573|NCT02401230|10006802|FG002|Overall Study|Withdrawal by Subject|1
6290574|NCT02401230|10006800|FG000|Overall Study|Lost to Follow-up|1
6135551|NCT00996892|9765221|FG007|Dose-Escalation Stage 1|Death|0
6135552|NCT00996892|9765222|FG008|Dose-Escalation Stage 1|Death|0
6135553|NCT00996892|9765223|FG009|Dose-Escalation Stage 1|Death|0
6135554|NCT00996892|9765224|FG010|Dose-Escalation Stage 1|Death|0
6135555|NCT00996892|9765225|FG011|Dose-Escalation Stage 1|Death|0
6135556|NCT00996892|9765226|FG012|Dose-Escalation Stage 1|Death|0
6135557|NCT00996892|9765227|FG013|Dose-Escalation Stage 1|Death|0
6135558|NCT00996892|9765228|FG014|Dose-Escalation Stage 1|Death|0
6135559|NCT00996892|9765229|FG015|Dose-Escalation Stage 1|Death|0
6135560|NCT00996892|9765230|FG016|Dose-Escalation Stage 1|Death|0
6135561|NCT00996892|9765231|FG017|Dose-Escalation Stage 1|Death|0
6135562|NCT00996892|9765232|FG018|Dose-Escalation Stage 1|Death|0
6135563|NCT00996892|9765233|FG019|Dose-Escalation Stage 1|Death|0
6135564|NCT00996892|9765214|FG000|Dose-Escalation Stage 1|Physician Decision|1
6135565|NCT00996892|9765215|FG001|Dose-Escalation Stage 1|Physician Decision|0
6135566|NCT00996892|9765216|FG002|Dose-Escalation Stage 1|Physician Decision|0
6135567|NCT00996892|9765217|FG003|Dose-Escalation Stage 1|Physician Decision|1
6135568|NCT00996892|9765218|FG004|Dose-Escalation Stage 1|Physician Decision|0
6135569|NCT00996892|9765219|FG005|Dose-Escalation Stage 1|Physician Decision|1
6135570|NCT00996892|9765220|FG006|Dose-Escalation Stage 1|Physician Decision|2
6135571|NCT00996892|9765221|FG007|Dose-Escalation Stage 1|Physician Decision|0
6135572|NCT00996892|9765222|FG008|Dose-Escalation Stage 1|Physician Decision|0
6135573|NCT00996892|9765223|FG009|Dose-Escalation Stage 1|Physician Decision|0
6135574|NCT00996892|9765224|FG010|Dose-Escalation Stage 1|Physician Decision|0
6135575|NCT00996892|9765225|FG011|Dose-Escalation Stage 1|Physician Decision|0
6135576|NCT00996892|9765226|FG012|Dose-Escalation Stage 1|Physician Decision|0
6135577|NCT00996892|9765227|FG013|Dose-Escalation Stage 1|Physician Decision|0
6135578|NCT00996892|9765228|FG014|Dose-Escalation Stage 1|Physician Decision|0
6135579|NCT00996892|9765229|FG015|Dose-Escalation Stage 1|Physician Decision|0
6135580|NCT00996892|9765230|FG016|Dose-Escalation Stage 1|Physician Decision|0
6135581|NCT00996892|9765231|FG017|Dose-Escalation Stage 1|Physician Decision|0
6135582|NCT00996892|9765232|FG018|Dose-Escalation Stage 1|Physician Decision|0
6135583|NCT00996892|9765233|FG019|Dose-Escalation Stage 1|Physician Decision|0
6135584|NCT00996892|9765214|FG000|Dose-Escalation Stage 1|Withdrawal by Subject|0
6135585|NCT00996892|9765215|FG001|Dose-Escalation Stage 1|Withdrawal by Subject|1
6135586|NCT00996892|9765216|FG002|Dose-Escalation Stage 1|Withdrawal by Subject|0
6135587|NCT00996892|9765217|FG003|Dose-Escalation Stage 1|Withdrawal by Subject|2
6135588|NCT00996892|9765218|FG004|Dose-Escalation Stage 1|Withdrawal by Subject|1
6135589|NCT00996892|9765219|FG005|Dose-Escalation Stage 1|Withdrawal by Subject|1
6135590|NCT00996892|9765220|FG006|Dose-Escalation Stage 1|Withdrawal by Subject|1
6135591|NCT00996892|9765221|FG007|Dose-Escalation Stage 1|Withdrawal by Subject|0
6135592|NCT00996892|9765222|FG008|Dose-Escalation Stage 1|Withdrawal by Subject|0
6135593|NCT00996892|9765223|FG009|Dose-Escalation Stage 1|Withdrawal by Subject|0
6135594|NCT00996892|9765224|FG010|Dose-Escalation Stage 1|Withdrawal by Subject|0
6135595|NCT00996892|9765225|FG011|Dose-Escalation Stage 1|Withdrawal by Subject|0
6135596|NCT00996892|9765226|FG012|Dose-Escalation Stage 1|Withdrawal by Subject|0
6135597|NCT00996892|9765227|FG013|Dose-Escalation Stage 1|Withdrawal by Subject|0
6135598|NCT00996892|9765228|FG014|Dose-Escalation Stage 1|Withdrawal by Subject|0
6135599|NCT00996892|9765229|FG015|Dose-Escalation Stage 1|Withdrawal by Subject|0
6135600|NCT00996892|9765230|FG016|Dose-Escalation Stage 1|Withdrawal by Subject|0
6135601|NCT00996892|9765231|FG017|Dose-Escalation Stage 1|Withdrawal by Subject|0
6135602|NCT00996892|9765232|FG018|Dose-Escalation Stage 1|Withdrawal by Subject|0
6135603|NCT00996892|9765233|FG019|Dose-Escalation Stage 1|Withdrawal by Subject|0
6135604|NCT00996892|9765214|FG000|Dose-Escalation Stage 1|Disease Progression|2
6135605|NCT00996892|9765215|FG001|Dose-Escalation Stage 1|Disease Progression|2
6135606|NCT00996892|9765216|FG002|Dose-Escalation Stage 1|Disease Progression|3
6135607|NCT00996892|9765217|FG003|Dose-Escalation Stage 1|Disease Progression|4
6135608|NCT00996892|9765218|FG004|Dose-Escalation Stage 1|Disease Progression|10
6135609|NCT00996892|9765219|FG005|Dose-Escalation Stage 1|Disease Progression|7
6135610|NCT00996892|9765220|FG006|Dose-Escalation Stage 1|Disease Progression|0
6135611|NCT00996892|9765221|FG007|Dose-Escalation Stage 1|Disease Progression|0
6135612|NCT00996892|9765222|FG008|Dose-Escalation Stage 1|Disease Progression|0
6135613|NCT00996892|9765223|FG009|Dose-Escalation Stage 1|Disease Progression|0
6225756|NCT01704846|9897963|FG000|Treatment Period 2|Withdrawal by Subject|0
6225757|NCT01704846|9897964|FG001|Treatment Period 2|Withdrawal by Subject|1
6225758|NCT01705080|9897982|FG000|Overall Study|Missed visit|10
6225759|NCT01705080|9897983|FG001|Overall Study|Missed visit|4
6225760|NCT01705080|9897984|FG002|Overall Study|Missed visit|1
6290575|NCT02401230|10006801|FG001|Overall Study|Lost to Follow-up|3
6290576|NCT02401230|10006802|FG002|Overall Study|Lost to Follow-up|3
6290577|NCT02401256|10006814|FG000|Overall Study|Adverse Event|5
6290578|NCT02401256|10006814|FG000|Overall Study|Withdrawal by Subject|12
6290579|NCT02401412|10006822|FG000|Overall Study|Lost to Follow-up|1
6290580|NCT02401412|10006823|FG001|Overall Study|Lost to Follow-up|0
6290581|NCT02401412|10006822|FG000|Overall Study|Discontinued Intervention|15
6290582|NCT02401412|10006823|FG001|Overall Study|Discontinued Intervention|21
6290583|NCT02401412|10006822|FG000|Overall Study|Withdrawal by Subject|4
6290584|NCT02401412|10006823|FG001|Overall Study|Withdrawal by Subject|4
6135614|NCT00996892|9765224|FG010|Dose-Escalation Stage 1|Disease Progression|0
6135615|NCT00996892|9765225|FG011|Dose-Escalation Stage 1|Disease Progression|0
6135616|NCT00996892|9765226|FG012|Dose-Escalation Stage 1|Disease Progression|0
6135617|NCT00996892|9765227|FG013|Dose-Escalation Stage 1|Disease Progression|0
6135618|NCT00996892|9765228|FG014|Dose-Escalation Stage 1|Disease Progression|0
6135619|NCT00996892|9765229|FG015|Dose-Escalation Stage 1|Disease Progression|0
6135620|NCT00996892|9765230|FG016|Dose-Escalation Stage 1|Disease Progression|0
6135621|NCT00996892|9765231|FG017|Dose-Escalation Stage 1|Disease Progression|0
6135622|NCT00996892|9765232|FG018|Dose-Escalation Stage 1|Disease Progression|0
6135623|NCT00996892|9765233|FG019|Dose-Escalation Stage 1|Disease Progression|0
6135624|NCT00996892|9765214|FG000|Dose-Escalation Stage 1A|Adverse Event|0
6135625|NCT00996892|9765215|FG001|Dose-Escalation Stage 1A|Adverse Event|0
6135626|NCT00996892|9765216|FG002|Dose-Escalation Stage 1A|Adverse Event|0
6135627|NCT00996892|9765217|FG003|Dose-Escalation Stage 1A|Adverse Event|0
6135628|NCT00996892|9765218|FG004|Dose-Escalation Stage 1A|Adverse Event|0
6135629|NCT00996892|9765219|FG005|Dose-Escalation Stage 1A|Adverse Event|0
6135630|NCT00996892|9765220|FG006|Dose-Escalation Stage 1A|Adverse Event|0
6135631|NCT00996892|9765221|FG007|Dose-Escalation Stage 1A|Adverse Event|0
6135632|NCT00996892|9765222|FG008|Dose-Escalation Stage 1A|Adverse Event|0
6135633|NCT00996892|9765223|FG009|Dose-Escalation Stage 1A|Adverse Event|0
6135634|NCT00996892|9765224|FG010|Dose-Escalation Stage 1A|Adverse Event|1
6135635|NCT00996892|9765225|FG011|Dose-Escalation Stage 1A|Adverse Event|0
6135636|NCT00996892|9765226|FG012|Dose-Escalation Stage 1A|Adverse Event|0
6135637|NCT00996892|9765227|FG013|Dose-Escalation Stage 1A|Adverse Event|1
6135638|NCT00996892|9765228|FG014|Dose-Escalation Stage 1A|Adverse Event|0
6135639|NCT00996892|9765229|FG015|Dose-Escalation Stage 1A|Adverse Event|0
6135640|NCT00996892|9765230|FG016|Dose-Escalation Stage 1A|Adverse Event|0
6135641|NCT00996892|9765231|FG017|Dose-Escalation Stage 1A|Adverse Event|0
6135642|NCT00996892|9765232|FG018|Dose-Escalation Stage 1A|Adverse Event|0
6135643|NCT00996892|9765233|FG019|Dose-Escalation Stage 1A|Adverse Event|0
6135644|NCT00996892|9765214|FG000|Dose-Escalation Stage 1A|Death|0
6135645|NCT00996892|9765215|FG001|Dose-Escalation Stage 1A|Death|0
6135646|NCT00996892|9765216|FG002|Dose-Escalation Stage 1A|Death|0
6135647|NCT00996892|9765217|FG003|Dose-Escalation Stage 1A|Death|0
6135648|NCT00996892|9765218|FG004|Dose-Escalation Stage 1A|Death|0
6135649|NCT00996892|9765219|FG005|Dose-Escalation Stage 1A|Death|0
6135650|NCT00996892|9765220|FG006|Dose-Escalation Stage 1A|Death|0
6135651|NCT00996892|9765221|FG007|Dose-Escalation Stage 1A|Death|0
6135652|NCT00996892|9765222|FG008|Dose-Escalation Stage 1A|Death|0
6135653|NCT00996892|9765223|FG009|Dose-Escalation Stage 1A|Death|2
6135654|NCT00996892|9765224|FG010|Dose-Escalation Stage 1A|Death|0
6135655|NCT00996892|9765225|FG011|Dose-Escalation Stage 1A|Death|1
6135656|NCT00996892|9765226|FG012|Dose-Escalation Stage 1A|Death|1
6135657|NCT00996892|9765227|FG013|Dose-Escalation Stage 1A|Death|0
6135658|NCT00996892|9765228|FG014|Dose-Escalation Stage 1A|Death|0
6135659|NCT00996892|9765229|FG015|Dose-Escalation Stage 1A|Death|0
6135660|NCT00996892|9765230|FG016|Dose-Escalation Stage 1A|Death|0
6135661|NCT00996892|9765231|FG017|Dose-Escalation Stage 1A|Death|0
6135662|NCT00996892|9765232|FG018|Dose-Escalation Stage 1A|Death|0
6135663|NCT00996892|9765233|FG019|Dose-Escalation Stage 1A|Death|0
6135664|NCT00996892|9765214|FG000|Dose-Escalation Stage 1A|Physician Decision|0
6135665|NCT00996892|9765215|FG001|Dose-Escalation Stage 1A|Physician Decision|0
6135666|NCT00996892|9765216|FG002|Dose-Escalation Stage 1A|Physician Decision|0
6135667|NCT00996892|9765217|FG003|Dose-Escalation Stage 1A|Physician Decision|0
6135668|NCT00996892|9765218|FG004|Dose-Escalation Stage 1A|Physician Decision|0
6135669|NCT00996892|9765219|FG005|Dose-Escalation Stage 1A|Physician Decision|0
6135670|NCT00996892|9765220|FG006|Dose-Escalation Stage 1A|Physician Decision|0
6135671|NCT00996892|9765221|FG007|Dose-Escalation Stage 1A|Physician Decision|1
6135672|NCT00996892|9765222|FG008|Dose-Escalation Stage 1A|Physician Decision|0
6135673|NCT00996892|9765223|FG009|Dose-Escalation Stage 1A|Physician Decision|0
6135674|NCT00996892|9765224|FG010|Dose-Escalation Stage 1A|Physician Decision|0
6135675|NCT00996892|9765225|FG011|Dose-Escalation Stage 1A|Physician Decision|0
6135676|NCT00996892|9765226|FG012|Dose-Escalation Stage 1A|Physician Decision|0
6135677|NCT00996892|9765227|FG013|Dose-Escalation Stage 1A|Physician Decision|0
6135678|NCT00996892|9765228|FG014|Dose-Escalation Stage 1A|Physician Decision|0
6135679|NCT00996892|9765229|FG015|Dose-Escalation Stage 1A|Physician Decision|0
6135680|NCT00996892|9765230|FG016|Dose-Escalation Stage 1A|Physician Decision|0
6135681|NCT00996892|9765231|FG017|Dose-Escalation Stage 1A|Physician Decision|0
6135682|NCT00996892|9765232|FG018|Dose-Escalation Stage 1A|Physician Decision|0
6135683|NCT00996892|9765233|FG019|Dose-Escalation Stage 1A|Physician Decision|0
6135684|NCT00996892|9765214|FG000|Dose-Escalation Stage 1A|Withdrawal by Subject|0
6135685|NCT00996892|9765215|FG001|Dose-Escalation Stage 1A|Withdrawal by Subject|0
6135686|NCT00996892|9765216|FG002|Dose-Escalation Stage 1A|Withdrawal by Subject|0
6135687|NCT00996892|9765217|FG003|Dose-Escalation Stage 1A|Withdrawal by Subject|0
6135688|NCT00996892|9765218|FG004|Dose-Escalation Stage 1A|Withdrawal by Subject|0
6135689|NCT00996892|9765219|FG005|Dose-Escalation Stage 1A|Withdrawal by Subject|0
6135690|NCT00996892|9765220|FG006|Dose-Escalation Stage 1A|Withdrawal by Subject|0
6135691|NCT00996892|9765221|FG007|Dose-Escalation Stage 1A|Withdrawal by Subject|0
6135692|NCT00996892|9765222|FG008|Dose-Escalation Stage 1A|Withdrawal by Subject|0
6135693|NCT00996892|9765223|FG009|Dose-Escalation Stage 1A|Withdrawal by Subject|1
6135694|NCT00996892|9765224|FG010|Dose-Escalation Stage 1A|Withdrawal by Subject|1
6135695|NCT00996892|9765225|FG011|Dose-Escalation Stage 1A|Withdrawal by Subject|1
6135696|NCT00996892|9765226|FG012|Dose-Escalation Stage 1A|Withdrawal by Subject|1
6135697|NCT00996892|9765227|FG013|Dose-Escalation Stage 1A|Withdrawal by Subject|0
6135698|NCT00996892|9765228|FG014|Dose-Escalation Stage 1A|Withdrawal by Subject|0
6135699|NCT00996892|9765229|FG015|Dose-Escalation Stage 1A|Withdrawal by Subject|0
6135700|NCT00996892|9765230|FG016|Dose-Escalation Stage 1A|Withdrawal by Subject|0
6135701|NCT00996892|9765231|FG017|Dose-Escalation Stage 1A|Withdrawal by Subject|0
6135702|NCT00996892|9765232|FG018|Dose-Escalation Stage 1A|Withdrawal by Subject|0
6135703|NCT00996892|9765233|FG019|Dose-Escalation Stage 1A|Withdrawal by Subject|0
6135704|NCT00996892|9765214|FG000|Dose-Escalation Stage 1A|Disease Progression|0
6135705|NCT00996892|9765215|FG001|Dose-Escalation Stage 1A|Disease Progression|0
6135706|NCT00996892|9765216|FG002|Dose-Escalation Stage 1A|Disease Progression|0
6135707|NCT00996892|9765217|FG003|Dose-Escalation Stage 1A|Disease Progression|0
6135708|NCT00996892|9765218|FG004|Dose-Escalation Stage 1A|Disease Progression|0
6225761|NCT01705080|9897982|FG000|Overall Study|Death|4
6225762|NCT01705080|9897983|FG001|Overall Study|Death|4
6225763|NCT01705080|9897984|FG002|Overall Study|Death|6
6225764|NCT01705080|9897982|FG000|Overall Study|Withdrawal by Subject|61
6135709|NCT00996892|9765219|FG005|Dose-Escalation Stage 1A|Disease Progression|0
6135710|NCT00996892|9765220|FG006|Dose-Escalation Stage 1A|Disease Progression|0
6135711|NCT00996892|9765221|FG007|Dose-Escalation Stage 1A|Disease Progression|2
6135712|NCT00996892|9765222|FG008|Dose-Escalation Stage 1A|Disease Progression|3
6135713|NCT00996892|9765223|FG009|Dose-Escalation Stage 1A|Disease Progression|1
6135714|NCT00996892|9765224|FG010|Dose-Escalation Stage 1A|Disease Progression|5
6135715|NCT00996892|9765225|FG011|Dose-Escalation Stage 1A|Disease Progression|7
6135716|NCT00996892|9765226|FG012|Dose-Escalation Stage 1A|Disease Progression|6
6135717|NCT00996892|9765227|FG013|Dose-Escalation Stage 1A|Disease Progression|4
6135718|NCT00996892|9765228|FG014|Dose-Escalation Stage 1A|Disease Progression|0
6135719|NCT00996892|9765229|FG015|Dose-Escalation Stage 1A|Disease Progression|0
6135720|NCT00996892|9765230|FG016|Dose-Escalation Stage 1A|Disease Progression|0
6135721|NCT00996892|9765231|FG017|Dose-Escalation Stage 1A|Disease Progression|0
6135722|NCT00996892|9765232|FG018|Dose-Escalation Stage 1A|Disease Progression|0
6135723|NCT00996892|9765233|FG019|Dose-Escalation Stage 1A|Disease Progression|0
6135724|NCT00996892|9765214|FG000|Dose-Escalation Stage 1B|Physician Decision|0
6135725|NCT00996892|9765215|FG001|Dose-Escalation Stage 1B|Physician Decision|0
6135726|NCT00996892|9765216|FG002|Dose-Escalation Stage 1B|Physician Decision|0
6225765|NCT01705080|9897983|FG001|Overall Study|Withdrawal by Subject|44
6225766|NCT01705080|9897984|FG002|Overall Study|Withdrawal by Subject|9
6225767|NCT01705145|9897992|FG000|Part B|Adverse Event|1
6225768|NCT01705236|9898008|FG000|Overall Study|Lost to Follow-up|1
6225769|NCT01705236|9898008|FG000|Overall Study|Administrative problems|2
6225770|NCT01705236|9898008|FG000|Overall Study|Unsatisfactory therapeutic effect|3
6225771|NCT01705236|9898008|FG000|Overall Study|Protocol Violation|3
6225772|NCT01705236|9898008|FG000|Overall Study|Abnormal test procedure result(s)|4
6290585|NCT02401412|10006822|FG000|Overall Study|Subject withdrawal prior to intervention|0
6290586|NCT02401412|10006823|FG001|Overall Study|Subject withdrawal prior to intervention|1
6290587|NCT02401412|10006822|FG000|Overall Study|Improper Enrollment per In/Ex Criteria|10
6290588|NCT02401412|10006823|FG001|Overall Study|Improper Enrollment per In/Ex Criteria|6
6290589|NCT02401529|10006850|FG000|Overall Study|Lost to Follow-up|2
6290590|NCT02401529|10006851|FG001|Overall Study|Lost to Follow-up|1
6290591|NCT02401529|10006850|FG000|Overall Study|Physician Decision|2
6290592|NCT02401529|10006851|FG001|Overall Study|Physician Decision|6
6290593|NCT02401529|10006850|FG000|Overall Study|Protocol Violation|5
6290594|NCT02401529|10006851|FG001|Overall Study|Protocol Violation|0
6290595|NCT02401672|10006888|FG000|Overall Study|Withdrawal by Subject|1
6290596|NCT02401672|10006889|FG001|Overall Study|Withdrawal by Subject|3
6290597|NCT02401867|10006895|FG000|Specimen Collection|Didn't receive 1 or more tests|10
6290598|NCT02401867|10006895|FG000|Analysis|Cervical assay could not be conducted|9
6290599|NCT02402166|10006930|FG000|Overall Study|Adverse Event|2
6290600|NCT02402166|10006930|FG000|Overall Study|Withdrawal by Subject|2
6290601|NCT02402166|10006930|FG000|Overall Study|Lost to Follow-up|1
6290602|NCT02402218|10006951|FG000|Overall Study|Did not pickup study medication|12
6290603|NCT02402218|10006952|FG001|Overall Study|Did not pickup study medication|9
6290604|NCT02402218|10006953|FG002|Overall Study|Did not pickup study medication|13
6290605|NCT02402218|10006951|FG000|Overall Study|Lack of Efficacy|0
6290606|NCT02402218|10006952|FG001|Overall Study|Lack of Efficacy|1
6290607|NCT02402218|10006953|FG002|Overall Study|Lack of Efficacy|1
6290608|NCT02402218|10006951|FG000|Overall Study|Death|1
6290609|NCT02402218|10006952|FG001|Overall Study|Death|0
6290610|NCT02402218|10006953|FG002|Overall Study|Death|0
6225773|NCT01705236|9898008|FG000|Overall Study|Abnormal laboratory value(s)|4
6225774|NCT01705236|9898008|FG000|Overall Study|Withdrawal by Subject|5
6225775|NCT01705236|9898008|FG000|Overall Study|Adverse Event|5
6225776|NCT01705509|9898025|FG000|Inclusion CPET|Screen Failure|5
6290611|NCT02402218|10006951|FG000|Overall Study|Reinfection|0
6290612|NCT02402218|10006952|FG001|Overall Study|Reinfection|0
6290613|NCT02402218|10006953|FG002|Overall Study|Reinfection|1
6290614|NCT02402218|10006951|FG000|Overall Study|Adverse Event|0
6135727|NCT00996892|9765217|FG003|Dose-Escalation Stage 1B|Physician Decision|0
6135728|NCT00996892|9765218|FG004|Dose-Escalation Stage 1B|Physician Decision|0
6135729|NCT00996892|9765219|FG005|Dose-Escalation Stage 1B|Physician Decision|0
6135730|NCT00996892|9765220|FG006|Dose-Escalation Stage 1B|Physician Decision|0
6135731|NCT00996892|9765221|FG007|Dose-Escalation Stage 1B|Physician Decision|0
6135732|NCT00996892|9765222|FG008|Dose-Escalation Stage 1B|Physician Decision|0
6135733|NCT00996892|9765223|FG009|Dose-Escalation Stage 1B|Physician Decision|0
6135734|NCT00996892|9765224|FG010|Dose-Escalation Stage 1B|Physician Decision|0
6135735|NCT00996892|9765225|FG011|Dose-Escalation Stage 1B|Physician Decision|0
6135736|NCT00996892|9765226|FG012|Dose-Escalation Stage 1B|Physician Decision|0
6135737|NCT00996892|9765227|FG013|Dose-Escalation Stage 1B|Physician Decision|0
6135738|NCT00996892|9765228|FG014|Dose-Escalation Stage 1B|Physician Decision|0
6135739|NCT00996892|9765229|FG015|Dose-Escalation Stage 1B|Physician Decision|0
6135740|NCT00996892|9765230|FG016|Dose-Escalation Stage 1B|Physician Decision|0
6135741|NCT00996892|9765231|FG017|Dose-Escalation Stage 1B|Physician Decision|2
6135742|NCT00996892|9765232|FG018|Dose-Escalation Stage 1B|Physician Decision|0
6135743|NCT00996892|9765233|FG019|Dose-Escalation Stage 1B|Physician Decision|0
6135744|NCT00996892|9765214|FG000|Dose-Escalation Stage 1B|Disease Progression|0
6135745|NCT00996892|9765215|FG001|Dose-Escalation Stage 1B|Disease Progression|0
6135746|NCT00996892|9765216|FG002|Dose-Escalation Stage 1B|Disease Progression|0
6135747|NCT00996892|9765217|FG003|Dose-Escalation Stage 1B|Disease Progression|0
6135748|NCT00996892|9765218|FG004|Dose-Escalation Stage 1B|Disease Progression|0
6135749|NCT00996892|9765219|FG005|Dose-Escalation Stage 1B|Disease Progression|0
6135750|NCT00996892|9765220|FG006|Dose-Escalation Stage 1B|Disease Progression|0
6135751|NCT00996892|9765221|FG007|Dose-Escalation Stage 1B|Disease Progression|0
6135752|NCT00996892|9765222|FG008|Dose-Escalation Stage 1B|Disease Progression|0
6135753|NCT00996892|9765223|FG009|Dose-Escalation Stage 1B|Disease Progression|0
6135754|NCT00996892|9765224|FG010|Dose-Escalation Stage 1B|Disease Progression|0
6135755|NCT00996892|9765225|FG011|Dose-Escalation Stage 1B|Disease Progression|0
6135756|NCT00996892|9765226|FG012|Dose-Escalation Stage 1B|Disease Progression|0
6135757|NCT00996892|9765227|FG013|Dose-Escalation Stage 1B|Disease Progression|0
6135758|NCT00996892|9765228|FG014|Dose-Escalation Stage 1B|Disease Progression|4
6135759|NCT00996892|9765229|FG015|Dose-Escalation Stage 1B|Disease Progression|3
6135760|NCT00996892|9765230|FG016|Dose-Escalation Stage 1B|Disease Progression|3
6135761|NCT00996892|9765231|FG017|Dose-Escalation Stage 1B|Disease Progression|3
6135762|NCT00996892|9765232|FG018|Dose-Escalation Stage 1B|Disease Progression|0
6135763|NCT00996892|9765233|FG019|Dose-Escalation Stage 1B|Disease Progression|0
6135764|NCT00996892|9765214|FG000|Expansion Stage 2|Adverse Event|0
6135765|NCT00996892|9765215|FG001|Expansion Stage 2|Adverse Event|0
6135766|NCT00996892|9765216|FG002|Expansion Stage 2|Adverse Event|0
6135767|NCT00996892|9765217|FG003|Expansion Stage 2|Adverse Event|0
6135768|NCT00996892|9765218|FG004|Expansion Stage 2|Adverse Event|0
6135769|NCT00996892|9765219|FG005|Expansion Stage 2|Adverse Event|0
6135770|NCT00996892|9765220|FG006|Expansion Stage 2|Adverse Event|0
6225777|NCT01705509|9898025|FG000|Inclusion CPET|Withdrawal by Subject|2
6225778|NCT01705509|9898025|FG000|CPET w/ Ranexa|Screen Failure|2
6225779|NCT01705574|9898031|FG000|Double-Blind Phase|Lost to Follow-up|12
6225780|NCT01705574|9898032|FG001|Double-Blind Phase|Lost to Follow-up|16
6225781|NCT01705574|9898033|FG002|Double-Blind Phase|Lost to Follow-up|0
6225782|NCT01705574|9898034|FG003|Double-Blind Phase|Lost to Follow-up|0
6225783|NCT01705574|9898031|FG000|Double-Blind Phase|Adverse Event|3
6225784|NCT01705574|9898032|FG001|Double-Blind Phase|Adverse Event|10
6225785|NCT01705574|9898033|FG002|Double-Blind Phase|Adverse Event|0
6225786|NCT01705574|9898034|FG003|Double-Blind Phase|Adverse Event|0
6225787|NCT01705574|9898031|FG000|Double-Blind Phase|Withdrew Consent|8
6225788|NCT01705574|9898032|FG001|Double-Blind Phase|Withdrew Consent|5
6225789|NCT01705574|9898033|FG002|Double-Blind Phase|Withdrew Consent|0
6225790|NCT01705574|9898034|FG003|Double-Blind Phase|Withdrew Consent|0
6225791|NCT01705574|9898031|FG000|Double-Blind Phase|Non-Compliance with Study Drug|4
6225792|NCT01705574|9898032|FG001|Double-Blind Phase|Non-Compliance with Study Drug|5
6225793|NCT01705574|9898033|FG002|Double-Blind Phase|Non-Compliance with Study Drug|0
6225794|NCT01705574|9898034|FG003|Double-Blind Phase|Non-Compliance with Study Drug|0
6225795|NCT01705574|9898031|FG000|Double-Blind Phase|Pregnancy|1
6225796|NCT01705574|9898032|FG001|Double-Blind Phase|Pregnancy|1
6225797|NCT01705574|9898033|FG002|Double-Blind Phase|Pregnancy|0
6225798|NCT01705574|9898034|FG003|Double-Blind Phase|Pregnancy|0
6225799|NCT01705574|9898031|FG000|Double-Blind Phase|Protocol Violation|1
6225800|NCT01705574|9898032|FG001|Double-Blind Phase|Protocol Violation|0
6135771|NCT00996892|9765221|FG007|Expansion Stage 2|Adverse Event|0
6135772|NCT00996892|9765222|FG008|Expansion Stage 2|Adverse Event|0
6135773|NCT00996892|9765223|FG009|Expansion Stage 2|Adverse Event|0
6135774|NCT00996892|9765224|FG010|Expansion Stage 2|Adverse Event|0
6135775|NCT00996892|9765225|FG011|Expansion Stage 2|Adverse Event|0
6135776|NCT00996892|9765226|FG012|Expansion Stage 2|Adverse Event|0
6135777|NCT00996892|9765227|FG013|Expansion Stage 2|Adverse Event|0
6135778|NCT00996892|9765228|FG014|Expansion Stage 2|Adverse Event|0
6135779|NCT00996892|9765229|FG015|Expansion Stage 2|Adverse Event|0
6135780|NCT00996892|9765230|FG016|Expansion Stage 2|Adverse Event|0
6135781|NCT00996892|9765231|FG017|Expansion Stage 2|Adverse Event|0
6225801|NCT01705574|9898033|FG002|Double-Blind Phase|Protocol Violation|0
6135782|NCT00996892|9765232|FG018|Expansion Stage 2|Adverse Event|3
6225802|NCT01705574|9898034|FG003|Double-Blind Phase|Protocol Violation|0
6225803|NCT01705574|9898031|FG000|Double-Blind Phase|Randomized but Not Treated|4
6225804|NCT01705574|9898032|FG001|Double-Blind Phase|Randomized but Not Treated|4
6225805|NCT01705574|9898033|FG002|Double-Blind Phase|Randomized but Not Treated|0
6225806|NCT01705574|9898034|FG003|Double-Blind Phase|Randomized but Not Treated|0
6225807|NCT01705574|9898031|FG000|Open-Label Extension Phase|Lost to Follow-up|6
6225808|NCT01705574|9898032|FG001|Open-Label Extension Phase|Lost to Follow-up|0
6225809|NCT01705574|9898033|FG002|Open-Label Extension Phase|Lost to Follow-up|2
6225810|NCT01705574|9898034|FG003|Open-Label Extension Phase|Lost to Follow-up|2
6225811|NCT01705574|9898031|FG000|Open-Label Extension Phase|Withdrew Consent|4
6225812|NCT01705574|9898032|FG001|Open-Label Extension Phase|Withdrew Consent|0
6225813|NCT01705574|9898033|FG002|Open-Label Extension Phase|Withdrew Consent|4
6225814|NCT01705574|9898034|FG003|Open-Label Extension Phase|Withdrew Consent|1
6225815|NCT01705574|9898031|FG000|Open-Label Extension Phase|Adverse Event|3
6225816|NCT01705574|9898032|FG001|Open-Label Extension Phase|Adverse Event|0
6225817|NCT01705574|9898033|FG002|Open-Label Extension Phase|Adverse Event|0
6225818|NCT01705574|9898034|FG003|Open-Label Extension Phase|Adverse Event|1
6225819|NCT01705574|9898031|FG000|Open-Label Extension Phase|Death|2
6225820|NCT01705574|9898032|FG001|Open-Label Extension Phase|Death|0
6225821|NCT01705574|9898033|FG002|Open-Label Extension Phase|Death|1
6225822|NCT01705574|9898034|FG003|Open-Label Extension Phase|Death|0
6290615|NCT02402218|10006952|FG001|Overall Study|Adverse Event|2
6290616|NCT02402218|10006953|FG002|Overall Study|Adverse Event|1
6290617|NCT02402218|10006951|FG000|Overall Study|Withdrawal by Subject|1
6290618|NCT02402218|10006952|FG001|Overall Study|Withdrawal by Subject|1
6290619|NCT02402218|10006953|FG002|Overall Study|Withdrawal by Subject|1
6290620|NCT02402322|10006973|FG000|Pretreatment|Withdrawal by Subject|3
6290621|NCT02402322|10006974|FG001|Pretreatment|Withdrawal by Subject|1
6290622|NCT02402322|10006975|FG002|Pretreatment|Withdrawal by Subject|1
6290623|NCT02402322|10006973|FG000|Follow-up|Withdrawal by Subject|6
6290624|NCT02402322|10006974|FG001|Follow-up|Withdrawal by Subject|3
6290625|NCT02402322|10006975|FG002|Follow-up|Withdrawal by Subject|24
6290626|NCT02402907|10007007|FG000|Overall Study|Delivered vaginally|9
6290627|NCT02402907|10007008|FG001|Overall Study|Delivered vaginally|3
6290628|NCT02402907|10007007|FG000|Overall Study|Delivered outside of Sinai|1
6290629|NCT02402907|10007008|FG001|Overall Study|Delivered outside of Sinai|1
6290630|NCT02402907|10007007|FG000|Overall Study|Lost to follow up after C-Section|10
6290631|NCT02402907|10007008|FG001|Overall Study|Lost to follow up after C-Section|23
6290632|NCT02402933|10007014|FG000|Overall Study|Withdrawal by Subject|4
6290633|NCT02402933|10007014|FG000|Overall Study|Discontinued; Site Termination|10
6290634|NCT02403180|10007020|FG000|Pre-Treatment Period|Withdrawal by subject prior to treatment|0
6290635|NCT02403180|10007021|FG001|Pre-Treatment Period|Withdrawal by subject prior to treatment|1
6290636|NCT02403180|10007020|FG000|Period 2 (5 Days)|Withdrawal by Subject|0
6290637|NCT02403180|10007021|FG001|Period 2 (5 Days)|Withdrawal by Subject|1
6290638|NCT02403206|10007029|FG000|Overall Study|Lost to Follow-up|4
6290639|NCT02403206|10007030|FG001|Overall Study|Lost to Follow-up|3
6290640|NCT02403206|10007029|FG000|Overall Study|Physician Decision|2
6290641|NCT02403206|10007030|FG001|Overall Study|Physician Decision|0
6290642|NCT02403206|10007029|FG000|Overall Study|Withdrawal by Subject|3
6290643|NCT02403206|10007030|FG001|Overall Study|Withdrawal by Subject|3
6290644|NCT02403206|10007029|FG000|Overall Study|Reason not given|2
6290645|NCT02403206|10007030|FG001|Overall Study|Reason not given|4
6290646|NCT02403271|10007037|FG000|Period 1|Other varied reasons|1
6290647|NCT02403271|10007038|FG001|Period 1|Other varied reasons|0
6290648|NCT02403271|10007037|FG000|Period 2|Withdrawal by Subject|0
6290649|NCT02403271|10007038|FG001|Period 2|Withdrawal by Subject|14
6290650|NCT02403271|10007037|FG000|Period 2|Death|0
6290651|NCT02403271|10007038|FG001|Period 2|Death|84
6290652|NCT02403271|10007037|FG000|Period 2|Lost to Follow-up|0
6290653|NCT02403271|10007038|FG001|Period 2|Lost to Follow-up|2
6290654|NCT02403271|10007037|FG000|Period 2|Study Terminated by Sponsor|0
6290655|NCT02403271|10007038|FG001|Period 2|Study Terminated by Sponsor|14
6290656|NCT02403271|10007037|FG000|Period 2|Other varied reasons|0
6290657|NCT02403271|10007038|FG001|Period 2|Other varied reasons|10
6290658|NCT02403635|10007059|FG000|Overall Study|Not eligible|9
6290659|NCT02403674|10007081|FG000|Overall Study|Adverse Event|10
6290660|NCT02403674|10007082|FG001|Overall Study|Adverse Event|23
6290661|NCT02403674|10007081|FG000|Overall Study|Death|1
6290662|NCT02403674|10007082|FG001|Overall Study|Death|3
6290663|NCT02403674|10007081|FG000|Overall Study|Lack of Efficacy|18
6290664|NCT02403674|10007082|FG001|Overall Study|Lack of Efficacy|10
6290665|NCT02403674|10007081|FG000|Overall Study|Lost to Follow-up|6
6290666|NCT02403674|10007082|FG001|Overall Study|Lost to Follow-up|7
6290667|NCT02403674|10007081|FG000|Overall Study|Noncompliance with study drug|1
6290668|NCT02403674|10007082|FG001|Overall Study|Noncompliance with study drug|2
6135783|NCT00996892|9765233|FG019|Expansion Stage 2|Adverse Event|0
6290669|NCT02403674|10007081|FG000|Overall Study|Withdrawal by Subject|8
6290670|NCT02403674|10007082|FG001|Overall Study|Withdrawal by Subject|11
6290671|NCT02403674|10007081|FG000|Overall Study|Physician Decision|2
6290672|NCT02403674|10007082|FG001|Overall Study|Physician Decision|2
6290673|NCT02403674|10007081|FG000|Overall Study|Not treated with study drug|4
6290674|NCT02403674|10007082|FG001|Overall Study|Not treated with study drug|2
6135784|NCT00996892|9765214|FG000|Expansion Stage 2|Death|0
6135785|NCT00996892|9765215|FG001|Expansion Stage 2|Death|0
6135786|NCT00996892|9765216|FG002|Expansion Stage 2|Death|0
6135787|NCT00996892|9765217|FG003|Expansion Stage 2|Death|0
6135788|NCT00996892|9765218|FG004|Expansion Stage 2|Death|0
6135789|NCT00996892|9765219|FG005|Expansion Stage 2|Death|0
6135790|NCT00996892|9765220|FG006|Expansion Stage 2|Death|0
6135791|NCT00996892|9765221|FG007|Expansion Stage 2|Death|0
6135792|NCT00996892|9765222|FG008|Expansion Stage 2|Death|0
6135793|NCT00996892|9765223|FG009|Expansion Stage 2|Death|0
6135794|NCT00996892|9765224|FG010|Expansion Stage 2|Death|0
6135795|NCT00996892|9765225|FG011|Expansion Stage 2|Death|0
6135796|NCT00996892|9765226|FG012|Expansion Stage 2|Death|0
6135797|NCT00996892|9765227|FG013|Expansion Stage 2|Death|0
6135798|NCT00996892|9765228|FG014|Expansion Stage 2|Death|0
6135799|NCT00996892|9765229|FG015|Expansion Stage 2|Death|0
6135800|NCT00996892|9765230|FG016|Expansion Stage 2|Death|0
6135801|NCT00996892|9765231|FG017|Expansion Stage 2|Death|0
6135802|NCT00996892|9765232|FG018|Expansion Stage 2|Death|2
6135803|NCT00996892|9765233|FG019|Expansion Stage 2|Death|0
6135804|NCT00996892|9765214|FG000|Expansion Stage 2|Physician Decision|0
6135805|NCT00996892|9765215|FG001|Expansion Stage 2|Physician Decision|0
6135806|NCT00996892|9765216|FG002|Expansion Stage 2|Physician Decision|0
6135807|NCT00996892|9765217|FG003|Expansion Stage 2|Physician Decision|0
6135808|NCT00996892|9765218|FG004|Expansion Stage 2|Physician Decision|0
6135809|NCT00996892|9765219|FG005|Expansion Stage 2|Physician Decision|0
6135810|NCT00996892|9765220|FG006|Expansion Stage 2|Physician Decision|0
6135811|NCT00996892|9765221|FG007|Expansion Stage 2|Physician Decision|0
6135812|NCT00996892|9765222|FG008|Expansion Stage 2|Physician Decision|0
6135813|NCT00996892|9765223|FG009|Expansion Stage 2|Physician Decision|0
6135814|NCT00996892|9765224|FG010|Expansion Stage 2|Physician Decision|0
6135815|NCT00996892|9765225|FG011|Expansion Stage 2|Physician Decision|0
6135816|NCT00996892|9765226|FG012|Expansion Stage 2|Physician Decision|0
6135817|NCT00996892|9765227|FG013|Expansion Stage 2|Physician Decision|0
6135818|NCT00996892|9765228|FG014|Expansion Stage 2|Physician Decision|0
6135819|NCT00996892|9765229|FG015|Expansion Stage 2|Physician Decision|0
6135820|NCT00996892|9765230|FG016|Expansion Stage 2|Physician Decision|0
6135821|NCT00996892|9765231|FG017|Expansion Stage 2|Physician Decision|0
6135822|NCT00996892|9765232|FG018|Expansion Stage 2|Physician Decision|1
6135823|NCT00996892|9765233|FG019|Expansion Stage 2|Physician Decision|0
6225823|NCT01705574|9898031|FG000|Open-Label Extension Phase|Non-Compliance with Study Drug|0
6225824|NCT01705574|9898032|FG001|Open-Label Extension Phase|Non-Compliance with Study Drug|0
6225825|NCT01705574|9898033|FG002|Open-Label Extension Phase|Non-Compliance with Study Drug|1
6225826|NCT01705574|9898034|FG003|Open-Label Extension Phase|Non-Compliance with Study Drug|0
6225827|NCT01705574|9898031|FG000|Open-Label Extension Phase|Physician Decision|0
6225828|NCT01705574|9898032|FG001|Open-Label Extension Phase|Physician Decision|0
6225829|NCT01705574|9898033|FG002|Open-Label Extension Phase|Physician Decision|2
6225830|NCT01705574|9898034|FG003|Open-Label Extension Phase|Physician Decision|0
6225831|NCT01705574|9898031|FG000|Open-Label Extension Phase|Pregnancy|0
6225832|NCT01705574|9898032|FG001|Open-Label Extension Phase|Pregnancy|0
6225833|NCT01705574|9898033|FG002|Open-Label Extension Phase|Pregnancy|1
6225834|NCT01705574|9898034|FG003|Open-Label Extension Phase|Pregnancy|1
6225835|NCT01705587|9898052|FG000|Overall Study|Withdrawal by Subject|0
6225836|NCT01705587|9898053|FG001|Overall Study|Withdrawal by Subject|1
6225837|NCT01705652|9898061|FG000|Overall Study|Adverse Event|1
6225838|NCT01705652|9898062|FG001|Overall Study|Adverse Event|0
6225839|NCT01705652|9898061|FG000|Overall Study|Withdrawal by Subject|1
6225840|NCT01705652|9898062|FG001|Overall Study|Withdrawal by Subject|2
6225841|NCT01705652|9898061|FG000|Overall Study|non-compliance|1
6225842|NCT01705652|9898062|FG001|Overall Study|non-compliance|1
6225843|NCT01705691|9898070|FG000|Overall Study|Death|1
6225844|NCT01705691|9898071|FG001|Overall Study|Death|2
6225845|NCT01705691|9898070|FG000|Overall Study|Withdrawal by Subject|1
6225846|NCT01705691|9898071|FG001|Overall Study|Withdrawal by Subject|2
6225847|NCT01705691|9898070|FG000|Overall Study|Lost to Follow-up|1
6225848|NCT01705691|9898071|FG001|Overall Study|Lost to Follow-up|1
6225849|NCT01705691|9898070|FG000|Overall Study|Other|0
6225850|NCT01705691|9898071|FG001|Overall Study|Other|1
6225851|NCT01705717|9898079|FG000|Overall Study|Adverse Event|2
6225852|NCT01705717|9898080|FG001|Overall Study|Adverse Event|2
6225853|NCT01705717|9898079|FG000|Overall Study|Lack of Efficacy|0
6225854|NCT01705717|9898080|FG001|Overall Study|Lack of Efficacy|1
6225855|NCT01705717|9898079|FG000|Overall Study|Other|0
6225856|NCT01705717|9898080|FG001|Overall Study|Other|2
6135824|NCT00996892|9765214|FG000|Expansion Stage 2|Withdrawal by Subject|0
6135825|NCT00996892|9765215|FG001|Expansion Stage 2|Withdrawal by Subject|0
6225857|NCT01705730|9898085|FG000|Overall Study|Lack of Efficacy|1
6225858|NCT01705730|9898085|FG000|Overall Study|Adverse Event|3
6225859|NCT01705730|9898085|FG000|Overall Study|Lost to Follow-up|1
6225860|NCT01705730|9898085|FG000|Overall Study|Reason not Specified|4
6135826|NCT00996892|9765216|FG002|Expansion Stage 2|Withdrawal by Subject|0
6135827|NCT00996892|9765217|FG003|Expansion Stage 2|Withdrawal by Subject|0
6135828|NCT00996892|9765218|FG004|Expansion Stage 2|Withdrawal by Subject|0
6135829|NCT00996892|9765219|FG005|Expansion Stage 2|Withdrawal by Subject|0
6135830|NCT00996892|9765220|FG006|Expansion Stage 2|Withdrawal by Subject|0
6135831|NCT00996892|9765221|FG007|Expansion Stage 2|Withdrawal by Subject|0
6135832|NCT00996892|9765222|FG008|Expansion Stage 2|Withdrawal by Subject|0
6135833|NCT00996892|9765223|FG009|Expansion Stage 2|Withdrawal by Subject|0
6135834|NCT00996892|9765224|FG010|Expansion Stage 2|Withdrawal by Subject|0
6135835|NCT00996892|9765225|FG011|Expansion Stage 2|Withdrawal by Subject|0
6135836|NCT00996892|9765226|FG012|Expansion Stage 2|Withdrawal by Subject|0
6135837|NCT00996892|9765227|FG013|Expansion Stage 2|Withdrawal by Subject|0
6135838|NCT00996892|9765228|FG014|Expansion Stage 2|Withdrawal by Subject|0
6135839|NCT00996892|9765229|FG015|Expansion Stage 2|Withdrawal by Subject|0
6135840|NCT00996892|9765230|FG016|Expansion Stage 2|Withdrawal by Subject|0
6135841|NCT00996892|9765231|FG017|Expansion Stage 2|Withdrawal by Subject|0
6135842|NCT00996892|9765232|FG018|Expansion Stage 2|Withdrawal by Subject|1
6135843|NCT00996892|9765233|FG019|Expansion Stage 2|Withdrawal by Subject|0
6135844|NCT00996892|9765214|FG000|Expansion Stage 2|Disease Progression|0
6135845|NCT00996892|9765215|FG001|Expansion Stage 2|Disease Progression|0
6135846|NCT00996892|9765216|FG002|Expansion Stage 2|Disease Progression|0
6135847|NCT00996892|9765217|FG003|Expansion Stage 2|Disease Progression|0
6135848|NCT00996892|9765218|FG004|Expansion Stage 2|Disease Progression|0
6135849|NCT00996892|9765219|FG005|Expansion Stage 2|Disease Progression|0
6135850|NCT00996892|9765220|FG006|Expansion Stage 2|Disease Progression|0
6135851|NCT00996892|9765221|FG007|Expansion Stage 2|Disease Progression|0
6135852|NCT00996892|9765222|FG008|Expansion Stage 2|Disease Progression|0
6135853|NCT00996892|9765223|FG009|Expansion Stage 2|Disease Progression|0
6135854|NCT00996892|9765224|FG010|Expansion Stage 2|Disease Progression|0
6135855|NCT00996892|9765225|FG011|Expansion Stage 2|Disease Progression|0
6135856|NCT00996892|9765226|FG012|Expansion Stage 2|Disease Progression|0
6135857|NCT00996892|9765227|FG013|Expansion Stage 2|Disease Progression|0
6135858|NCT00996892|9765228|FG014|Expansion Stage 2|Disease Progression|0
6135859|NCT00996892|9765229|FG015|Expansion Stage 2|Disease Progression|0
6135860|NCT00996892|9765230|FG016|Expansion Stage 2|Disease Progression|0
6135861|NCT00996892|9765231|FG017|Expansion Stage 2|Disease Progression|0
6135862|NCT00996892|9765232|FG018|Expansion Stage 2|Disease Progression|28
6135863|NCT00996892|9765233|FG019|Expansion Stage 2|Disease Progression|0
6135864|NCT00996892|9765214|FG000|Expansion Stage 2A|Adverse Event|0
6135865|NCT00996892|9765215|FG001|Expansion Stage 2A|Adverse Event|0
6135866|NCT00996892|9765216|FG002|Expansion Stage 2A|Adverse Event|0
6135867|NCT00996892|9765217|FG003|Expansion Stage 2A|Adverse Event|0
6135868|NCT00996892|9765218|FG004|Expansion Stage 2A|Adverse Event|0
6135869|NCT00996892|9765219|FG005|Expansion Stage 2A|Adverse Event|0
6135870|NCT00996892|9765220|FG006|Expansion Stage 2A|Adverse Event|0
6135871|NCT00996892|9765221|FG007|Expansion Stage 2A|Adverse Event|0
6135872|NCT00996892|9765222|FG008|Expansion Stage 2A|Adverse Event|0
6135873|NCT00996892|9765223|FG009|Expansion Stage 2A|Adverse Event|0
6135874|NCT00996892|9765224|FG010|Expansion Stage 2A|Adverse Event|0
6135875|NCT00996892|9765225|FG011|Expansion Stage 2A|Adverse Event|0
6135876|NCT00996892|9765226|FG012|Expansion Stage 2A|Adverse Event|0
6135877|NCT00996892|9765227|FG013|Expansion Stage 2A|Adverse Event|0
6135878|NCT00996892|9765228|FG014|Expansion Stage 2A|Adverse Event|0
6135879|NCT00996892|9765229|FG015|Expansion Stage 2A|Adverse Event|0
6135880|NCT00996892|9765230|FG016|Expansion Stage 2A|Adverse Event|0
6135881|NCT00996892|9765231|FG017|Expansion Stage 2A|Adverse Event|0
6135882|NCT00996892|9765232|FG018|Expansion Stage 2A|Adverse Event|0
6135883|NCT00996892|9765233|FG019|Expansion Stage 2A|Adverse Event|8
6135884|NCT00996892|9765214|FG000|Expansion Stage 2A|Physician Decision|0
6135885|NCT00996892|9765215|FG001|Expansion Stage 2A|Physician Decision|0
6135886|NCT00996892|9765216|FG002|Expansion Stage 2A|Physician Decision|0
6135887|NCT00996892|9765217|FG003|Expansion Stage 2A|Physician Decision|0
6135888|NCT00996892|9765218|FG004|Expansion Stage 2A|Physician Decision|0
6135889|NCT00996892|9765219|FG005|Expansion Stage 2A|Physician Decision|0
6135890|NCT00996892|9765220|FG006|Expansion Stage 2A|Physician Decision|0
6135891|NCT00996892|9765221|FG007|Expansion Stage 2A|Physician Decision|0
6135892|NCT00996892|9765222|FG008|Expansion Stage 2A|Physician Decision|0
6135893|NCT00996892|9765223|FG009|Expansion Stage 2A|Physician Decision|0
6135894|NCT00996892|9765224|FG010|Expansion Stage 2A|Physician Decision|0
6135895|NCT00996892|9765225|FG011|Expansion Stage 2A|Physician Decision|0
6135896|NCT00996892|9765226|FG012|Expansion Stage 2A|Physician Decision|0
6135897|NCT00996892|9765227|FG013|Expansion Stage 2A|Physician Decision|0
6135898|NCT00996892|9765228|FG014|Expansion Stage 2A|Physician Decision|0
6135899|NCT00996892|9765229|FG015|Expansion Stage 2A|Physician Decision|0
6135900|NCT00996892|9765230|FG016|Expansion Stage 2A|Physician Decision|0
6135901|NCT00996892|9765231|FG017|Expansion Stage 2A|Physician Decision|0
6135902|NCT00996892|9765232|FG018|Expansion Stage 2A|Physician Decision|0
6135903|NCT00996892|9765233|FG019|Expansion Stage 2A|Physician Decision|2
6135904|NCT00996892|9765214|FG000|Expansion Stage 2A|Withdrawal by Subject|0
6135905|NCT00996892|9765215|FG001|Expansion Stage 2A|Withdrawal by Subject|0
6135906|NCT00996892|9765216|FG002|Expansion Stage 2A|Withdrawal by Subject|0
6135907|NCT00996892|9765217|FG003|Expansion Stage 2A|Withdrawal by Subject|0
6135908|NCT00996892|9765218|FG004|Expansion Stage 2A|Withdrawal by Subject|0
6135909|NCT00996892|9765219|FG005|Expansion Stage 2A|Withdrawal by Subject|0
6135910|NCT00996892|9765220|FG006|Expansion Stage 2A|Withdrawal by Subject|0
6135911|NCT00996892|9765221|FG007|Expansion Stage 2A|Withdrawal by Subject|0
6135912|NCT00996892|9765222|FG008|Expansion Stage 2A|Withdrawal by Subject|0
6135913|NCT00996892|9765223|FG009|Expansion Stage 2A|Withdrawal by Subject|0
6135914|NCT00996892|9765224|FG010|Expansion Stage 2A|Withdrawal by Subject|0
6135915|NCT00996892|9765225|FG011|Expansion Stage 2A|Withdrawal by Subject|0
6135916|NCT00996892|9765226|FG012|Expansion Stage 2A|Withdrawal by Subject|0
6135917|NCT00996892|9765227|FG013|Expansion Stage 2A|Withdrawal by Subject|0
6135918|NCT00996892|9765228|FG014|Expansion Stage 2A|Withdrawal by Subject|0
6135919|NCT00996892|9765229|FG015|Expansion Stage 2A|Withdrawal by Subject|0
6135920|NCT00996892|9765230|FG016|Expansion Stage 2A|Withdrawal by Subject|0
6135921|NCT00996892|9765231|FG017|Expansion Stage 2A|Withdrawal by Subject|0
6135922|NCT00996892|9765232|FG018|Expansion Stage 2A|Withdrawal by Subject|0
6135923|NCT00996892|9765233|FG019|Expansion Stage 2A|Withdrawal by Subject|4
6135924|NCT00996892|9765214|FG000|Expansion Stage 2A|Disease Progression|0
6135925|NCT00996892|9765215|FG001|Expansion Stage 2A|Disease Progression|0
6135926|NCT00996892|9765216|FG002|Expansion Stage 2A|Disease Progression|0
6135927|NCT00996892|9765217|FG003|Expansion Stage 2A|Disease Progression|0
6135928|NCT00996892|9765218|FG004|Expansion Stage 2A|Disease Progression|0
6135929|NCT00996892|9765219|FG005|Expansion Stage 2A|Disease Progression|0
6135930|NCT00996892|9765220|FG006|Expansion Stage 2A|Disease Progression|0
6135931|NCT00996892|9765221|FG007|Expansion Stage 2A|Disease Progression|0
6135932|NCT00996892|9765222|FG008|Expansion Stage 2A|Disease Progression|0
6135933|NCT00996892|9765223|FG009|Expansion Stage 2A|Disease Progression|0
6135934|NCT00996892|9765224|FG010|Expansion Stage 2A|Disease Progression|0
6135935|NCT00996892|9765225|FG011|Expansion Stage 2A|Disease Progression|0
6135936|NCT00996892|9765226|FG012|Expansion Stage 2A|Disease Progression|0
6135937|NCT00996892|9765227|FG013|Expansion Stage 2A|Disease Progression|0
6135938|NCT00996892|9765228|FG014|Expansion Stage 2A|Disease Progression|0
6135939|NCT00996892|9765229|FG015|Expansion Stage 2A|Disease Progression|0
6135940|NCT00996892|9765230|FG016|Expansion Stage 2A|Disease Progression|0
6135941|NCT00996892|9765231|FG017|Expansion Stage 2A|Disease Progression|0
6135942|NCT00996892|9765232|FG018|Expansion Stage 2A|Disease Progression|0
6135943|NCT00996892|9765233|FG019|Expansion Stage 2A|Disease Progression|31
6135944|NCT00996918|9765299|FG000|Overall Study|Lack of Efficacy|1
6135945|NCT00996918|9765300|FG001|Overall Study|Lack of Efficacy|1
6135946|NCT00996918|9765301|FG002|Overall Study|Lack of Efficacy|2
6135947|NCT00996918|9765302|FG003|Overall Study|Lack of Efficacy|2
6135948|NCT00996918|9765303|FG004|Overall Study|Lack of Efficacy|0
6135949|NCT00996918|9765299|FG000|Overall Study|Adverse Event|2
6135950|NCT00996918|9765300|FG001|Overall Study|Adverse Event|5
6135951|NCT00996918|9765301|FG002|Overall Study|Adverse Event|2
6135952|NCT00996918|9765302|FG003|Overall Study|Adverse Event|6
6135953|NCT00996918|9765303|FG004|Overall Study|Adverse Event|0
6135954|NCT00996918|9765299|FG000|Overall Study|Withdrawal by Subject|1
6135955|NCT00996918|9765300|FG001|Overall Study|Withdrawal by Subject|4
6135956|NCT00996918|9765301|FG002|Overall Study|Withdrawal by Subject|3
6135957|NCT00996918|9765302|FG003|Overall Study|Withdrawal by Subject|3
6135958|NCT00996918|9765303|FG004|Overall Study|Withdrawal by Subject|2
6135959|NCT00996918|9765299|FG000|Overall Study|Physician Decision|1
6135960|NCT00996918|9765300|FG001|Overall Study|Physician Decision|0
6135961|NCT00996918|9765301|FG002|Overall Study|Physician Decision|0
6135962|NCT00996918|9765302|FG003|Overall Study|Physician Decision|0
6135963|NCT00996918|9765303|FG004|Overall Study|Physician Decision|0
6135964|NCT00996918|9765299|FG000|Overall Study|Discontinuation of Study by Sponsor|31
6135965|NCT00996918|9765300|FG001|Overall Study|Discontinuation of Study by Sponsor|54
6135966|NCT00996918|9765301|FG002|Overall Study|Discontinuation of Study by Sponsor|30
6135967|NCT00996918|9765302|FG003|Overall Study|Discontinuation of Study by Sponsor|45
6135968|NCT00996918|9765303|FG004|Overall Study|Discontinuation of Study by Sponsor|2
6135969|NCT00996918|9765299|FG000|Overall Study|Loss of Caregiver|0
6225861|NCT01706003|9898100|FG000|Overall Study|Withdrawal by Subject|2
6225862|NCT01706003|9898101|FG001|Overall Study|Withdrawal by Subject|0
6225863|NCT01706003|9898100|FG000|Overall Study|Not scheduled|3
6225864|NCT01706003|9898101|FG001|Overall Study|Not scheduled|0
6225865|NCT01706003|9898100|FG000|Overall Study|Lost to Follow-up|6
6225866|NCT01706003|9898101|FG001|Overall Study|Lost to Follow-up|4
6225867|NCT01706146|9898116|FG000|Overall Study|Withdrawal by Subject|1
6225868|NCT01706146|9898116|FG000|Overall Study|Adverse Event|3
6225869|NCT01706146|9898116|FG000|Overall Study|Developed AF and need for antiplatelets|2
6225870|NCT01706159|9898122|FG000|Overall Study|Withdrawal Criteria|2
6225871|NCT01706159|9898123|FG001|Overall Study|Withdrawal Criteria|1
6225872|NCT01706159|9898122|FG000|Overall Study|Unclassified|6
6225873|NCT01706159|9898123|FG001|Overall Study|Unclassified|1
6225874|NCT01706198|9898131|FG000|Overall Study|Adverse Event|12
6225875|NCT01706198|9898132|FG001|Overall Study|Adverse Event|15
6225876|NCT01706198|9898131|FG000|Overall Study|Protocol Violation|7
6225877|NCT01706198|9898132|FG001|Overall Study|Protocol Violation|5
6225878|NCT01706198|9898131|FG000|Overall Study|Other: Subject reached stopping criteria|11
6135970|NCT00996918|9765300|FG001|Overall Study|Loss of Caregiver|1
6135971|NCT00996918|9765301|FG002|Overall Study|Loss of Caregiver|0
6135972|NCT00996918|9765302|FG003|Overall Study|Loss of Caregiver|0
6135973|NCT00996918|9765303|FG004|Overall Study|Loss of Caregiver|0
6135974|NCT00996918|9765299|FG000|Overall Study|Other|3
6135975|NCT00996918|9765300|FG001|Overall Study|Other|1
6135976|NCT00996918|9765301|FG002|Overall Study|Other|0
6135977|NCT00996918|9765302|FG003|Overall Study|Other|0
6135978|NCT00996918|9765303|FG004|Overall Study|Other|0
6225879|NCT01706198|9898132|FG001|Overall Study|Other: Subject reached stopping criteria|13
6135979|NCT00996944|9765322|FG000|Double-blind Treatment Period|Adverse Event|2
6135980|NCT00996944|9765323|FG001|Double-blind Treatment Period|Adverse Event|1
6135981|NCT00996944|9765322|FG000|Double-blind Treatment Period|Protocol Violation|1
6135982|NCT00996944|9765323|FG001|Double-blind Treatment Period|Protocol Violation|0
6135983|NCT00996944|9765322|FG000|Double-blind Treatment Period|Study Closed/Terminated|6
6135984|NCT00996944|9765323|FG001|Double-blind Treatment Period|Study Closed/Terminated|5
6135985|NCT00996944|9765322|FG000|Double-blind Treatment Period|Withdrawal by Subject|1
6135986|NCT00996944|9765323|FG001|Double-blind Treatment Period|Withdrawal by Subject|1
6135987|NCT00996944|9765322|FG000|Long-term Treatment Period|Study Closed/Terminated|12
6135988|NCT00996944|9765323|FG001|Long-term Treatment Period|Study Closed/Terminated|5
6135989|NCT00996996|9765331|FG000|Overall Study|Progressive Disease|10
6135990|NCT00996996|9765331|FG000|Overall Study|Non-compliance|8
6135991|NCT00996996|9765331|FG000|Overall Study|Lost to Follow-up|9
6135992|NCT00996996|9765331|FG000|Overall Study|Death|5
6135993|NCT00996996|9765331|FG000|Overall Study|Did Not Receive Study Medications|1
6135994|NCT00997035|9765337|FG000|3-week Followup Visit|Lost to Follow-up|9
6135995|NCT00997035|9765338|FG001|3-week Followup Visit|Lost to Follow-up|6
6135996|NCT00997035|9765337|FG000|3-month Follow-up Visit|Lost to Follow-up|12
6135997|NCT00997035|9765338|FG001|3-month Follow-up Visit|Lost to Follow-up|6
6135998|NCT00997126|9765365|FG000|Overall Study|Physician Decision|7
6135999|NCT00997126|9765366|FG001|Overall Study|Physician Decision|11
6136000|NCT00997243|9765391|FG000|Overall Study|Early termination of study by sponsor|7
6136001|NCT00997321|9765397|FG000|Overall Study|did not undergo sedation after enrollmen|0
6136002|NCT00997321|9765398|FG001|Overall Study|did not undergo sedation after enrollmen|3
6136003|NCT00997334|9765410|FG000|Overall Study|still on therapy|12
6136004|NCT00997334|9765410|FG000|Overall Study|Adverse Event|3
6136005|NCT00997334|9765410|FG000|Overall Study|Patient non-compliance|1
6136006|NCT00997334|9765410|FG000|Overall Study|Withdrawal by Subject|3
6136007|NCT00997334|9765410|FG000|Overall Study|Death|2
6136008|NCT00997334|9765410|FG000|Overall Study|Urgent Palliative Care|2
6136009|NCT00997334|9765410|FG000|Overall Study|No lesion amenable|1
6136010|NCT00997334|9765410|FG000|Overall Study|Ineligible|1
6136011|NCT00997373|9765416|FG000|Overall Study|Withdrawal by Subject|5
6136012|NCT00997373|9765417|FG001|Overall Study|Withdrawal by Subject|0
6136013|NCT00997373|9765416|FG000|Overall Study|wrong tumor type|4
6136014|NCT00997373|9765417|FG001|Overall Study|wrong tumor type|0
6136015|NCT00997373|9765416|FG000|Overall Study|could not have hysterectomy|6
6136016|NCT00997373|9765417|FG001|Overall Study|could not have hysterectomy|0
6136017|NCT00997438|9765431|FG000|Overall Study|Blood draw difficulty|2
6136018|NCT00997438|9765432|FG001|Overall Study|Blood draw difficulty|0
6136019|NCT00997438|9765433|FG002|Overall Study|Blood draw difficulty|1
6136020|NCT00997438|9765431|FG000|Overall Study|Withdrawal by Subject|1
6136021|NCT00997438|9765432|FG001|Overall Study|Withdrawal by Subject|1
6136022|NCT00997438|9765433|FG002|Overall Study|Withdrawal by Subject|0
6136023|NCT00997438|9765431|FG000|Overall Study|Exclusion criteria at visit 1|2
6136024|NCT00997438|9765432|FG001|Overall Study|Exclusion criteria at visit 1|2
6136025|NCT00997438|9765433|FG002|Overall Study|Exclusion criteria at visit 1|3
6136026|NCT00997503|9765442|FG000|Overall Study|Death|53
6225880|NCT01706198|9898131|FG000|Overall Study|Lost to Follow-up|97
6225881|NCT01706198|9898132|FG001|Overall Study|Lost to Follow-up|93
6225882|NCT01706198|9898131|FG000|Overall Study|Physician Decision|23
6225883|NCT01706198|9898132|FG001|Overall Study|Physician Decision|37
6225884|NCT01706198|9898131|FG000|Overall Study|Withdrawal by Subject|23
6225885|NCT01706198|9898132|FG001|Overall Study|Withdrawal by Subject|31
6225886|NCT01706250|9898138|FG000|Overall Study|Lost to Follow-up|2
6225887|NCT01706328|9898154|FG000|2-week Run-in Period|Inclusion/Exclusion Criteria Not Met|140
6225888|NCT01706328|9898155|FG001|2-week Run-in Period|Inclusion/Exclusion Criteria Not Met|0
6225889|NCT01706328|9898156|FG002|2-week Run-in Period|Inclusion/Exclusion Criteria Not Met|0
6225890|NCT01706328|9898154|FG000|2-week Run-in Period|Withdrawal by Subject|15
6225891|NCT01706328|9898155|FG001|2-week Run-in Period|Withdrawal by Subject|0
6225892|NCT01706328|9898156|FG002|2-week Run-in Period|Withdrawal by Subject|0
6225893|NCT01706328|9898154|FG000|2-week Run-in Period|Physician Decision|4
6225894|NCT01706328|9898155|FG001|2-week Run-in Period|Physician Decision|0
6225895|NCT01706328|9898156|FG002|2-week Run-in Period|Physician Decision|0
6225896|NCT01706328|9898154|FG000|2-week Run-in Period|Adverse Event|4
6225897|NCT01706328|9898155|FG001|2-week Run-in Period|Adverse Event|0
6225898|NCT01706328|9898156|FG002|2-week Run-in Period|Adverse Event|0
6225899|NCT01706328|9898154|FG000|2-week Run-in Period|Lost to Follow-up|2
6225900|NCT01706328|9898155|FG001|2-week Run-in Period|Lost to Follow-up|0
6225901|NCT01706328|9898156|FG002|2-week Run-in Period|Lost to Follow-up|0
6225902|NCT01706328|9898154|FG000|12-week Double-blind Treatment Period|Adverse Event|0
6136027|NCT00997503|9765442|FG000|Overall Study|Withdrawal by Subject|76
6136028|NCT00997503|9765442|FG000|Overall Study|Lost to Follow-up|33
6136029|NCT00997503|9765442|FG000|Overall Study|Adverse Event|3
6136030|NCT00997503|9765442|FG000|Overall Study|Physician Decision|10
6136031|NCT00997503|9765442|FG000|Overall Study|Missed 12-month follow-up|85
6136032|NCT00997503|9765442|FG000|Overall Study|Other reason|13
6225903|NCT01706328|9898155|FG001|12-week Double-blind Treatment Period|Adverse Event|14
6225904|NCT01706328|9898156|FG002|12-week Double-blind Treatment Period|Adverse Event|16
6136033|NCT00997893|9765500|FG000|Overall Study|Adverse Event|1
6136034|NCT00997893|9765501|FG001|Overall Study|Adverse Event|0
6136035|NCT00997893|9765502|FG002|Overall Study|Adverse Event|0
6136036|NCT00997893|9765500|FG000|Overall Study|Unable to meet study timelines|1
6136037|NCT00997893|9765501|FG001|Overall Study|Unable to meet study timelines|0
6136038|NCT00997893|9765502|FG002|Overall Study|Unable to meet study timelines|0
6225905|NCT01706328|9898154|FG000|12-week Double-blind Treatment Period|Lack of Efficacy|0
6225906|NCT01706328|9898155|FG001|12-week Double-blind Treatment Period|Lack of Efficacy|4
6225907|NCT01706328|9898156|FG002|12-week Double-blind Treatment Period|Lack of Efficacy|4
6225908|NCT01706328|9898154|FG000|12-week Double-blind Treatment Period|Protocol Violation|0
6225909|NCT01706328|9898155|FG001|12-week Double-blind Treatment Period|Protocol Violation|4
6225910|NCT01706328|9898156|FG002|12-week Double-blind Treatment Period|Protocol Violation|2
6225911|NCT01706328|9898154|FG000|12-week Double-blind Treatment Period|Protocol-defined Stopping Criteria Met|0
6225912|NCT01706328|9898155|FG001|12-week Double-blind Treatment Period|Protocol-defined Stopping Criteria Met|11
6225913|NCT01706328|9898156|FG002|12-week Double-blind Treatment Period|Protocol-defined Stopping Criteria Met|9
6225914|NCT01706328|9898154|FG000|12-week Double-blind Treatment Period|Lost to Follow-up|0
6225915|NCT01706328|9898155|FG001|12-week Double-blind Treatment Period|Lost to Follow-up|3
6225916|NCT01706328|9898156|FG002|12-week Double-blind Treatment Period|Lost to Follow-up|1
6225917|NCT01706328|9898154|FG000|12-week Double-blind Treatment Period|Physician Decision|0
6225918|NCT01706328|9898155|FG001|12-week Double-blind Treatment Period|Physician Decision|2
6225919|NCT01706328|9898156|FG002|12-week Double-blind Treatment Period|Physician Decision|2
6225920|NCT01706328|9898154|FG000|12-week Double-blind Treatment Period|Withdrawal by Subject|0
6225921|NCT01706328|9898155|FG001|12-week Double-blind Treatment Period|Withdrawal by Subject|8
6225922|NCT01706328|9898156|FG002|12-week Double-blind Treatment Period|Withdrawal by Subject|11
6225923|NCT01706458|9898164|FG000|Overall Study|Physician Decision|3
6225924|NCT01706458|9898165|FG001|Overall Study|Physician Decision|4
6225925|NCT01706536|9898180|FG000|Overall Study|Withdrawal by Subject|1
6225926|NCT01706536|9898181|FG001|Overall Study|Withdrawal by Subject|0
6225927|NCT01706536|9898182|FG002|Overall Study|Withdrawal by Subject|1
6225928|NCT01706536|9898183|FG003|Overall Study|Withdrawal by Subject|0
6225929|NCT01706536|9898184|FG004|Overall Study|Withdrawal by Subject|0
6225930|NCT01706536|9898180|FG000|Overall Study|Adverse Event|2
6225931|NCT01706536|9898181|FG001|Overall Study|Adverse Event|3
6225932|NCT01706536|9898182|FG002|Overall Study|Adverse Event|4
6225933|NCT01706536|9898183|FG003|Overall Study|Adverse Event|3
6225934|NCT01706536|9898184|FG004|Overall Study|Adverse Event|2
6225935|NCT01706536|9898180|FG000|Overall Study|Lack of Efficacy|1
6225936|NCT01706536|9898181|FG001|Overall Study|Lack of Efficacy|0
6225937|NCT01706536|9898182|FG002|Overall Study|Lack of Efficacy|0
6225938|NCT01706536|9898183|FG003|Overall Study|Lack of Efficacy|1
6225939|NCT01706536|9898184|FG004|Overall Study|Lack of Efficacy|0
6225940|NCT01706536|9898180|FG000|Overall Study|non compliance|0
6225941|NCT01706536|9898181|FG001|Overall Study|non compliance|1
6225942|NCT01706536|9898182|FG002|Overall Study|non compliance|0
6225943|NCT01706536|9898183|FG003|Overall Study|non compliance|0
6225944|NCT01706536|9898184|FG004|Overall Study|non compliance|0
6225945|NCT01706575|9898201|FG000|Overall Study|Participant Withdrew Consent|4
6225946|NCT01706575|9898201|FG000|Overall Study|Lost to Follow-up|2
6225947|NCT01706575|9898201|FG000|Overall Study|Started but not Treated|6
6225948|NCT01706770|9898241|FG000|Overall Study|Lost to Follow-up|1
6225949|NCT01706770|9898242|FG001|Overall Study|Lost to Follow-up|0
6225950|NCT01706770|9898241|FG000|Overall Study|Physician Decision|1
6225951|NCT01706770|9898242|FG001|Overall Study|Physician Decision|0
6225952|NCT01706926|9898256|FG000|Overall Study|Lost to Follow-up|0
6225953|NCT01706926|9898257|FG001|Overall Study|Lost to Follow-up|0
6225954|NCT01706926|9898258|FG002|Overall Study|Lost to Follow-up|1
6225955|NCT01706926|9898259|FG003|Overall Study|Lost to Follow-up|0
6225956|NCT01706926|9898256|FG000|Overall Study|Withdrawal by Subject|2
6225957|NCT01706926|9898257|FG001|Overall Study|Withdrawal by Subject|0
6225958|NCT01706926|9898258|FG002|Overall Study|Withdrawal by Subject|1
6225959|NCT01706926|9898259|FG003|Overall Study|Withdrawal by Subject|2
6225960|NCT01706926|9898256|FG000|Overall Study|Other|4
6225961|NCT01706926|9898257|FG001|Overall Study|Other|4
6225962|NCT01706926|9898258|FG002|Overall Study|Other|4
6225963|NCT01706926|9898259|FG003|Overall Study|Other|3
6225964|NCT01707004|9898296|FG000|Overall Study|Physician Decision|3
6225965|NCT01707030|9898303|FG000|Overall Study|Death|1
6225966|NCT01707030|9898304|FG001|Overall Study|Death|1
6225967|NCT01707030|9898303|FG000|Overall Study|Withdrawal by Subject|2
6225968|NCT01707030|9898304|FG001|Overall Study|Withdrawal by Subject|3
6225969|NCT01707030|9898303|FG000|Overall Study|Lost to Follow-up|8
6225970|NCT01707030|9898304|FG001|Overall Study|Lost to Follow-up|13
6225971|NCT01707147|9898337|FG000|Overall Study|Administered Trajenta prior to contract|5
6225972|NCT01707147|9898337|FG000|Overall Study|Patients who have not taken Trajenta|1
6225973|NCT01707147|9898337|FG000|Overall Study|Follow-up failure|17
6225974|NCT01707147|9898337|FG000|Overall Study|Violated inclusion/exclusion criteria|77
6225975|NCT01707290|9898357|FG000|Overall Study|Adverse event (AE)|1
6225976|NCT01707290|9898358|FG001|Overall Study|Adverse event (AE)|0
6225977|NCT01707290|9898357|FG000|Overall Study|Physician Decision|1
6225978|NCT01707290|9898358|FG001|Overall Study|Physician Decision|0
6136039|NCT00997893|9765500|FG000|Overall Study|Pain/pain meds during Visit 4|0
6136040|NCT00997893|9765501|FG001|Overall Study|Pain/pain meds during Visit 4|1
6136041|NCT00997893|9765502|FG002|Overall Study|Pain/pain meds during Visit 4|0
6136042|NCT00997984|9765518|FG000|Overall Study|Adverse Event|1
6136043|NCT00997984|9765519|FG001|Overall Study|Adverse Event|8
6136044|NCT00997984|9765520|FG002|Overall Study|Adverse Event|8
6136045|NCT00997984|9765518|FG000|Overall Study|Protocol Violation|1
6136046|NCT00997984|9765519|FG001|Overall Study|Protocol Violation|3
6136047|NCT00997984|9765520|FG002|Overall Study|Protocol Violation|0
6136048|NCT00997984|9765518|FG000|Overall Study|Withdrawal by Subject|6
6136049|NCT00997984|9765519|FG001|Overall Study|Withdrawal by Subject|9
6136050|NCT00997984|9765520|FG002|Overall Study|Withdrawal by Subject|5
6136051|NCT00997984|9765518|FG000|Overall Study|Lost to Follow-up|8
6136052|NCT00997984|9765519|FG001|Overall Study|Lost to Follow-up|5
6136053|NCT00997984|9765520|FG002|Overall Study|Lost to Follow-up|4
6136054|NCT00997984|9765518|FG000|Overall Study|Lack of Efficacy|20
6136055|NCT00997984|9765519|FG001|Overall Study|Lack of Efficacy|6
6136056|NCT00997984|9765520|FG002|Overall Study|Lack of Efficacy|3
6136057|NCT00997984|9765518|FG000|Overall Study|Met exclusion criteria|1
6136058|NCT00997984|9765519|FG001|Overall Study|Met exclusion criteria|0
6136059|NCT00997984|9765520|FG002|Overall Study|Met exclusion criteria|0
6136060|NCT00997984|9765518|FG000|Overall Study|non-compliance|0
6136061|NCT00997984|9765519|FG001|Overall Study|non-compliance|2
6136062|NCT00997984|9765520|FG002|Overall Study|non-compliance|3
6136063|NCT00997984|9765518|FG000|Overall Study|Wrong medication dispensed|0
6136064|NCT00997984|9765519|FG001|Overall Study|Wrong medication dispensed|1
6136065|NCT00997984|9765520|FG002|Overall Study|Wrong medication dispensed|0
6136066|NCT00997984|9765518|FG000|Overall Study|Suicidal ideation|0
6136067|NCT00997984|9765519|FG001|Overall Study|Suicidal ideation|0
6136068|NCT00997984|9765520|FG002|Overall Study|Suicidal ideation|1
6136069|NCT00997984|9765518|FG000|Overall Study|Work schedule|0
6136070|NCT00997984|9765519|FG001|Overall Study|Work schedule|0
6136071|NCT00997984|9765520|FG002|Overall Study|Work schedule|2
6136072|NCT00998296|9765563|FG000|Overall Study|Progressive disease|0
6136073|NCT00998296|9765564|FG001|Overall Study|Progressive disease|1
6136074|NCT00998296|9765565|FG002|Overall Study|Progressive disease|0
6136075|NCT00998296|9765566|FG003|Overall Study|Progressive disease|0
6136076|NCT00998296|9765567|FG004|Overall Study|Progressive disease|0
6136077|NCT00998296|9765568|FG005|Overall Study|Progressive disease|0
6136078|NCT00998296|9765569|FG006|Overall Study|Progressive disease|1
6136079|NCT00998296|9765570|FG007|Overall Study|Progressive disease|0
6136080|NCT00998296|9765571|FG008|Overall Study|Progressive disease|0
6136081|NCT00998296|9765572|FG009|Overall Study|Progressive disease|14
6136082|NCT00998296|9765573|FG010|Overall Study|Progressive disease|5
6136083|NCT00998296|9765563|FG000|Overall Study|Dose limiting or dose reducing toxicity|0
6136084|NCT00998296|9765564|FG001|Overall Study|Dose limiting or dose reducing toxicity|0
6136085|NCT00998296|9765565|FG002|Overall Study|Dose limiting or dose reducing toxicity|0
6136086|NCT00998296|9765566|FG003|Overall Study|Dose limiting or dose reducing toxicity|0
6136087|NCT00998296|9765567|FG004|Overall Study|Dose limiting or dose reducing toxicity|1
6136088|NCT00998296|9765568|FG005|Overall Study|Dose limiting or dose reducing toxicity|0
6136089|NCT00998296|9765569|FG006|Overall Study|Dose limiting or dose reducing toxicity|0
6136090|NCT00998296|9765570|FG007|Overall Study|Dose limiting or dose reducing toxicity|2
6136091|NCT00998296|9765571|FG008|Overall Study|Dose limiting or dose reducing toxicity|2
6136092|NCT00998296|9765572|FG009|Overall Study|Dose limiting or dose reducing toxicity|0
6136093|NCT00998296|9765573|FG010|Overall Study|Dose limiting or dose reducing toxicity|0
6136094|NCT00998296|9765563|FG000|Overall Study|Other adverse event|0
6136095|NCT00998296|9765564|FG001|Overall Study|Other adverse event|0
6136096|NCT00998296|9765565|FG002|Overall Study|Other adverse event|0
6136097|NCT00998296|9765566|FG003|Overall Study|Other adverse event|0
6136098|NCT00998296|9765567|FG004|Overall Study|Other adverse event|1
6136099|NCT00998296|9765568|FG005|Overall Study|Other adverse event|0
6136100|NCT00998296|9765569|FG006|Overall Study|Other adverse event|0
6136101|NCT00998296|9765570|FG007|Overall Study|Other adverse event|0
6136102|NCT00998296|9765571|FG008|Overall Study|Other adverse event|0
6225979|NCT01707290|9898357|FG000|Overall Study|Lost to Follow-up|3
6225980|NCT01707290|9898358|FG001|Overall Study|Lost to Follow-up|0
6225981|NCT01707290|9898357|FG000|Overall Study|Withdrawal of Consent (Not Due to AE)|4
6225982|NCT01707290|9898358|FG001|Overall Study|Withdrawal of Consent (Not Due to AE)|0
6225983|NCT01707290|9898357|FG000|Overall Study|Commercial drug available|60
6225984|NCT01707290|9898358|FG001|Overall Study|Commercial drug available|1
6225985|NCT01707290|9898357|FG000|Overall Study|Other unspecified|17
6225986|NCT01707290|9898358|FG001|Overall Study|Other unspecified|0
6225987|NCT01707667|9898408|FG000|Period 1|expulsion of colonic sensor catheter|1
6225988|NCT01707667|9898409|FG001|Period 1|expulsion of colonic sensor catheter|0
6136103|NCT00998296|9765572|FG009|Overall Study|Other adverse event|1
6136104|NCT00998296|9765573|FG010|Overall Study|Other adverse event|2
6136105|NCT00998296|9765563|FG000|Overall Study|Refused to continue taking trial med.|0
6136106|NCT00998296|9765564|FG001|Overall Study|Refused to continue taking trial med.|0
6136107|NCT00998296|9765565|FG002|Overall Study|Refused to continue taking trial med.|0
6136108|NCT00998296|9765566|FG003|Overall Study|Refused to continue taking trial med.|0
6136109|NCT00998296|9765567|FG004|Overall Study|Refused to continue taking trial med.|0
6136110|NCT00998296|9765568|FG005|Overall Study|Refused to continue taking trial med.|0
6136111|NCT00998296|9765569|FG006|Overall Study|Refused to continue taking trial med.|0
6136112|NCT00998296|9765570|FG007|Overall Study|Refused to continue taking trial med.|0
6136113|NCT00998296|9765571|FG008|Overall Study|Refused to continue taking trial med.|0
6136114|NCT00998296|9765572|FG009|Overall Study|Refused to continue taking trial med.|2
6136115|NCT00998296|9765573|FG010|Overall Study|Refused to continue taking trial med.|0
6136116|NCT00998296|9765563|FG000|Overall Study|Reason other than those specified above|0
6136117|NCT00998296|9765564|FG001|Overall Study|Reason other than those specified above|0
6136118|NCT00998296|9765565|FG002|Overall Study|Reason other than those specified above|0
6136119|NCT00998296|9765566|FG003|Overall Study|Reason other than those specified above|0
6136120|NCT00998296|9765567|FG004|Overall Study|Reason other than those specified above|0
6136121|NCT00998296|9765568|FG005|Overall Study|Reason other than those specified above|0
6225989|NCT01707693|9898417|FG000|Overall Study Allocation|Withdrawal by Subject|9
6225990|NCT01707693|9898418|FG001|Overall Study Allocation|Withdrawal by Subject|5
6225991|NCT01707693|9898417|FG000|Overall Study Allocation|Protocol Violation|4
6225992|NCT01707693|9898418|FG001|Overall Study Allocation|Protocol Violation|3
6225993|NCT01707693|9898417|FG000|Time 3 Measures @ 6 Mth|Lost to Follow-up|0
6225994|NCT01707693|9898418|FG001|Time 3 Measures @ 6 Mth|Lost to Follow-up|3
6225995|NCT01707693|9898417|FG000|Time 3 Measures @ 6 Mth|Withdrawal by Subject|0
6136122|NCT00998296|9765569|FG006|Overall Study|Reason other than those specified above|0
6136123|NCT00998296|9765570|FG007|Overall Study|Reason other than those specified above|0
6136124|NCT00998296|9765571|FG008|Overall Study|Reason other than those specified above|0
6136125|NCT00998296|9765572|FG009|Overall Study|Reason other than those specified above|1
6136126|NCT00998296|9765573|FG010|Overall Study|Reason other than those specified above|0
6136127|NCT00998309|9765602|FG000|Overall Study|Protocol Violation|4
6136128|NCT00998335|9765656|FG000|Randomized Period (Months 3 to 6)|Withdrawal by Subject|0
6136129|NCT00998335|9765657|FG001|Randomized Period (Months 3 to 6)|Withdrawal by Subject|2
6136130|NCT00998400|9765682|FG000|Overall Study|Lack of interest/motivation|1
6225996|NCT01707693|9898418|FG001|Time 3 Measures @ 6 Mth|Withdrawal by Subject|2
6225997|NCT01707992|9898428|FG000|Placebo-Controlled Phase (24 Months)|Adverse Event|8
6225998|NCT01707992|9898429|FG001|Placebo-Controlled Phase (24 Months)|Adverse Event|13
6225999|NCT01707992|9898430|FG002|Placebo-Controlled Phase (24 Months)|Adverse Event|9
6226000|NCT01707992|9898431|FG003|Placebo-Controlled Phase (24 Months)|Adverse Event|0
6226001|NCT01707992|9898432|FG004|Placebo-Controlled Phase (24 Months)|Adverse Event|0
6226002|NCT01707992|9898433|FG005|Placebo-Controlled Phase (24 Months)|Adverse Event|0
6226003|NCT01707992|9898428|FG000|Placebo-Controlled Phase (24 Months)|Lack of Efficacy|10
6226004|NCT01707992|9898429|FG001|Placebo-Controlled Phase (24 Months)|Lack of Efficacy|3
6226005|NCT01707992|9898430|FG002|Placebo-Controlled Phase (24 Months)|Lack of Efficacy|2
6226006|NCT01707992|9898431|FG003|Placebo-Controlled Phase (24 Months)|Lack of Efficacy|0
6226007|NCT01707992|9898432|FG004|Placebo-Controlled Phase (24 Months)|Lack of Efficacy|0
6226008|NCT01707992|9898433|FG005|Placebo-Controlled Phase (24 Months)|Lack of Efficacy|0
6226009|NCT01707992|9898428|FG000|Placebo-Controlled Phase (24 Months)|Withdrawal by Subject|88
6226010|NCT01707992|9898429|FG001|Placebo-Controlled Phase (24 Months)|Withdrawal by Subject|68
6226011|NCT01707992|9898430|FG002|Placebo-Controlled Phase (24 Months)|Withdrawal by Subject|154
6226012|NCT01707992|9898431|FG003|Placebo-Controlled Phase (24 Months)|Withdrawal by Subject|0
6226013|NCT01707992|9898432|FG004|Placebo-Controlled Phase (24 Months)|Withdrawal by Subject|0
6226014|NCT01707992|9898433|FG005|Placebo-Controlled Phase (24 Months)|Withdrawal by Subject|0
6226015|NCT01707992|9898428|FG000|Placebo-Controlled Phase (24 Months)|Protocol Violation|1
6226016|NCT01707992|9898429|FG001|Placebo-Controlled Phase (24 Months)|Protocol Violation|0
6226017|NCT01707992|9898430|FG002|Placebo-Controlled Phase (24 Months)|Protocol Violation|0
6226018|NCT01707992|9898431|FG003|Placebo-Controlled Phase (24 Months)|Protocol Violation|0
6226019|NCT01707992|9898432|FG004|Placebo-Controlled Phase (24 Months)|Protocol Violation|0
6226020|NCT01707992|9898433|FG005|Placebo-Controlled Phase (24 Months)|Protocol Violation|0
6226021|NCT01707992|9898428|FG000|Placebo-Controlled Phase (24 Months)|Pregnancy|12
6226022|NCT01707992|9898429|FG001|Placebo-Controlled Phase (24 Months)|Pregnancy|5
6226023|NCT01707992|9898430|FG002|Placebo-Controlled Phase (24 Months)|Pregnancy|9
6226024|NCT01707992|9898431|FG003|Placebo-Controlled Phase (24 Months)|Pregnancy|0
6226025|NCT01707992|9898432|FG004|Placebo-Controlled Phase (24 Months)|Pregnancy|0
6226026|NCT01707992|9898433|FG005|Placebo-Controlled Phase (24 Months)|Pregnancy|0
6226027|NCT01707992|9898428|FG000|Placebo-Controlled Phase (24 Months)|Lost to Follow-up|10
6226028|NCT01707992|9898429|FG001|Placebo-Controlled Phase (24 Months)|Lost to Follow-up|4
6226029|NCT01707992|9898430|FG002|Placebo-Controlled Phase (24 Months)|Lost to Follow-up|9
6226030|NCT01707992|9898431|FG003|Placebo-Controlled Phase (24 Months)|Lost to Follow-up|0
6226031|NCT01707992|9898432|FG004|Placebo-Controlled Phase (24 Months)|Lost to Follow-up|0
6226032|NCT01707992|9898433|FG005|Placebo-Controlled Phase (24 Months)|Lost to Follow-up|0
6226033|NCT01707992|9898428|FG000|Placebo-Controlled Phase (24 Months)|Death|2
6226034|NCT01707992|9898429|FG001|Placebo-Controlled Phase (24 Months)|Death|1
6226035|NCT01707992|9898430|FG002|Placebo-Controlled Phase (24 Months)|Death|1
6226036|NCT01707992|9898431|FG003|Placebo-Controlled Phase (24 Months)|Death|0
6226037|NCT01707992|9898432|FG004|Placebo-Controlled Phase (24 Months)|Death|0
6226038|NCT01707992|9898433|FG005|Placebo-Controlled Phase (24 Months)|Death|0
6136131|NCT00998400|9765683|FG001|Overall Study|Lack of interest/motivation|2
6136132|NCT00998400|9765682|FG000|Overall Study|Logistical problems|1
6136133|NCT00998400|9765683|FG001|Overall Study|Logistical problems|0
6136134|NCT00998764|9765726|FG000|Overall Study|Lack of Efficacy|3
6136135|NCT00998764|9765727|FG001|Overall Study|Lack of Efficacy|6
6136136|NCT00998764|9765726|FG000|Overall Study|Adverse Event|17
6136137|NCT00998764|9765727|FG001|Overall Study|Adverse Event|12
6136138|NCT00998764|9765726|FG000|Overall Study|Withdrawal by Subject|19
6136139|NCT00998764|9765727|FG001|Overall Study|Withdrawal by Subject|25
6136140|NCT00998764|9765726|FG000|Overall Study|Physician Decision|3
6290675|NCT02403674|10007081|FG000|Overall Study|Pregnancy|1
6136141|NCT00998764|9765727|FG001|Overall Study|Physician Decision|3
6136142|NCT00998764|9765726|FG000|Overall Study|Death|3
6136143|NCT00998764|9765727|FG001|Overall Study|Death|1
6136144|NCT00998764|9765726|FG000|Overall Study|Discontinuation of Study by Sponsor|164
6136145|NCT00998764|9765727|FG001|Overall Study|Discontinuation of Study by Sponsor|217
6136146|NCT00998764|9765726|FG000|Overall Study|Protocol Violation|0
6136147|NCT00998764|9765727|FG001|Overall Study|Protocol Violation|1
6136148|NCT00998764|9765726|FG000|Overall Study|Failed to Return|1
6136149|NCT00998764|9765727|FG001|Overall Study|Failed to Return|1
6136150|NCT00998764|9765726|FG000|Overall Study|Lost to Follow-up|1
6226039|NCT01707992|9898428|FG000|Placebo-Controlled Phase (24 Months)|Noncompliance with drug administration|2
6226040|NCT01707992|9898429|FG001|Placebo-Controlled Phase (24 Months)|Noncompliance with drug administration|1
6226041|NCT01707992|9898430|FG002|Placebo-Controlled Phase (24 Months)|Noncompliance with drug administration|6
6226042|NCT01707992|9898431|FG003|Placebo-Controlled Phase (24 Months)|Noncompliance with drug administration|0
6226043|NCT01707992|9898432|FG004|Placebo-Controlled Phase (24 Months)|Noncompliance with drug administration|0
6226044|NCT01707992|9898433|FG005|Placebo-Controlled Phase (24 Months)|Noncompliance with drug administration|0
6226045|NCT01707992|9898428|FG000|Placebo-Controlled Phase (24 Months)|Other than specified|11
6226046|NCT01707992|9898429|FG001|Placebo-Controlled Phase (24 Months)|Other than specified|9
6226047|NCT01707992|9898430|FG002|Placebo-Controlled Phase (24 Months)|Other than specified|10
6136151|NCT00998764|9765727|FG001|Overall Study|Lost to Follow-up|1
6136152|NCT00998764|9765726|FG000|Overall Study|Loss of Caregiver|0
6136153|NCT00998764|9765727|FG001|Overall Study|Loss of Caregiver|3
6136154|NCT00998764|9765726|FG000|Overall Study|Other|4
6136155|NCT00998764|9765727|FG001|Overall Study|Other|4
6136156|NCT00998764|9765726|FG000|Overall Study|Recurrent Episode of vasogenic edema|1
6136157|NCT00998764|9765727|FG001|Overall Study|Recurrent Episode of vasogenic edema|0
6136158|NCT00998790|9765735|FG000|Overall Study|Withdrawal by Subject|21
6136159|NCT00998881|9765745|FG000|Overall Study|Adverse Event|2
6136160|NCT00998881|9765746|FG001|Overall Study|Adverse Event|2
6136161|NCT00998881|9765745|FG000|Overall Study|Lack of Efficacy|1
6136162|NCT00998881|9765746|FG001|Overall Study|Lack of Efficacy|0
6136163|NCT00998881|9765745|FG000|Overall Study|Physician Decision|3
6136164|NCT00998881|9765746|FG001|Overall Study|Physician Decision|0
6226048|NCT01707992|9898431|FG003|Placebo-Controlled Phase (24 Months)|Other than specified|0
6226049|NCT01707992|9898432|FG004|Placebo-Controlled Phase (24 Months)|Other than specified|0
6226050|NCT01707992|9898433|FG005|Placebo-Controlled Phase (24 Months)|Other than specified|0
6226051|NCT01707992|9898428|FG000|Active Treatment Phase (24 Months)|Adverse Event|0
6226052|NCT01707992|9898429|FG001|Active Treatment Phase (24 Months)|Adverse Event|0
6226053|NCT01707992|9898430|FG002|Active Treatment Phase (24 Months)|Adverse Event|0
6226054|NCT01707992|9898431|FG003|Active Treatment Phase (24 Months)|Adverse Event|4
6226055|NCT01707992|9898432|FG004|Active Treatment Phase (24 Months)|Adverse Event|1
6226056|NCT01707992|9898433|FG005|Active Treatment Phase (24 Months)|Adverse Event|0
6226057|NCT01707992|9898428|FG000|Active Treatment Phase (24 Months)|Lack of Efficacy|0
6226058|NCT01707992|9898429|FG001|Active Treatment Phase (24 Months)|Lack of Efficacy|0
6226059|NCT01707992|9898430|FG002|Active Treatment Phase (24 Months)|Lack of Efficacy|0
6226060|NCT01707992|9898431|FG003|Active Treatment Phase (24 Months)|Lack of Efficacy|3
6226061|NCT01707992|9898432|FG004|Active Treatment Phase (24 Months)|Lack of Efficacy|1
6226062|NCT01707992|9898433|FG005|Active Treatment Phase (24 Months)|Lack of Efficacy|2
6226063|NCT01707992|9898428|FG000|Active Treatment Phase (24 Months)|Withdrawal by Subject|0
6226064|NCT01707992|9898429|FG001|Active Treatment Phase (24 Months)|Withdrawal by Subject|0
6226065|NCT01707992|9898430|FG002|Active Treatment Phase (24 Months)|Withdrawal by Subject|0
6226066|NCT01707992|9898431|FG003|Active Treatment Phase (24 Months)|Withdrawal by Subject|58
6226067|NCT01707992|9898432|FG004|Active Treatment Phase (24 Months)|Withdrawal by Subject|220
6226068|NCT01707992|9898433|FG005|Active Treatment Phase (24 Months)|Withdrawal by Subject|32
6226069|NCT01707992|9898428|FG000|Active Treatment Phase (24 Months)|Pregnancy|0
6226070|NCT01707992|9898429|FG001|Active Treatment Phase (24 Months)|Pregnancy|0
6226071|NCT01707992|9898430|FG002|Active Treatment Phase (24 Months)|Pregnancy|0
6226072|NCT01707992|9898431|FG003|Active Treatment Phase (24 Months)|Pregnancy|2
6226073|NCT01707992|9898432|FG004|Active Treatment Phase (24 Months)|Pregnancy|5
6226074|NCT01707992|9898433|FG005|Active Treatment Phase (24 Months)|Pregnancy|2
6226075|NCT01707992|9898428|FG000|Active Treatment Phase (24 Months)|Lost to Follow-up|0
6226076|NCT01707992|9898429|FG001|Active Treatment Phase (24 Months)|Lost to Follow-up|0
6226077|NCT01707992|9898430|FG002|Active Treatment Phase (24 Months)|Lost to Follow-up|0
6226078|NCT01707992|9898431|FG003|Active Treatment Phase (24 Months)|Lost to Follow-up|5
6136165|NCT00998881|9765745|FG000|Overall Study|Withdrawal by Subject|1
6136166|NCT00998881|9765746|FG001|Overall Study|Withdrawal by Subject|0
6136167|NCT00998881|9765745|FG000|Overall Study|Personal matter|1
6136168|NCT00998881|9765746|FG001|Overall Study|Personal matter|0
6136169|NCT00998946|9765752|FG000|Overall Study|Lost to Follow-up|1
6136170|NCT00998946|9765752|FG000|Overall Study|Withdrawal by Subject|1
6136171|NCT00998946|9765752|FG000|Overall Study|Death|2
6136172|NCT00998946|9765752|FG000|Overall Study|Reason Unspecified|3
6136173|NCT00998946|9765752|FG000|Overall Study|Enrolled but not Dosed|2
6136174|NCT00998985|9765770|FG000|Overall Study|Withdrawal by Subject|0
6136175|NCT00998985|9765771|FG001|Overall Study|Withdrawal by Subject|0
6136176|NCT00998985|9765772|FG002|Overall Study|Withdrawal by Subject|0
6136177|NCT00998985|9765773|FG003|Overall Study|Withdrawal by Subject|0
6226079|NCT01707992|9898432|FG004|Active Treatment Phase (24 Months)|Lost to Follow-up|11
6226080|NCT01707992|9898433|FG005|Active Treatment Phase (24 Months)|Lost to Follow-up|1
6226081|NCT01707992|9898428|FG000|Active Treatment Phase (24 Months)|Death|0
6226082|NCT01707992|9898429|FG001|Active Treatment Phase (24 Months)|Death|0
5981133|NCT02224573|9570090|FG001|Treatment Phase|Caregiver Asked to Stop Investigational Medicinal Product (IMP)|1
5981134|NCT02224573|9570089|FG000|Treatment Phase|Started on Other IMP|1
5981135|NCT02224573|9570090|FG001|Treatment Phase|Started on Other IMP|0
5981136|NCT02224573|9570089|FG000|Treatment Phase|Participant Discontinued IMP|0
5981137|NCT02224573|9570090|FG001|Treatment Phase|Participant Discontinued IMP|1
5981138|NCT02224573|9570089|FG000|Treatment Phase|Lack of Efficacy|15
5981139|NCT02224573|9570090|FG001|Treatment Phase|Lack of Efficacy|8
6136178|NCT00998985|9765774|FG004|Overall Study|Withdrawal by Subject|0
6226083|NCT01707992|9898430|FG002|Active Treatment Phase (24 Months)|Death|0
6226084|NCT01707992|9898431|FG003|Active Treatment Phase (24 Months)|Death|2
6226085|NCT01707992|9898432|FG004|Active Treatment Phase (24 Months)|Death|0
6226086|NCT01707992|9898433|FG005|Active Treatment Phase (24 Months)|Death|0
6226087|NCT01707992|9898428|FG000|Active Treatment Phase (24 Months)|Other than specified|0
6226088|NCT01707992|9898429|FG001|Active Treatment Phase (24 Months)|Other than specified|0
6226089|NCT01707992|9898430|FG002|Active Treatment Phase (24 Months)|Other than specified|0
6226090|NCT01707992|9898431|FG003|Active Treatment Phase (24 Months)|Other than specified|1
6226091|NCT01707992|9898432|FG004|Active Treatment Phase (24 Months)|Other than specified|5
5981140|NCT02224573|9570089|FG000|Treatment Phase|Began Commercial Product|1
6226092|NCT01707992|9898433|FG005|Active Treatment Phase (24 Months)|Other than specified|2
6226093|NCT01707992|9898428|FG000|Active Treatment Phase (24 Months)|Noncompliance|0
6226094|NCT01707992|9898429|FG001|Active Treatment Phase (24 Months)|Noncompliance|0
6226095|NCT01707992|9898430|FG002|Active Treatment Phase (24 Months)|Noncompliance|0
6226096|NCT01707992|9898431|FG003|Active Treatment Phase (24 Months)|Noncompliance|0
6226097|NCT01707992|9898432|FG004|Active Treatment Phase (24 Months)|Noncompliance|4
6226098|NCT01707992|9898433|FG005|Active Treatment Phase (24 Months)|Noncompliance|2
6226099|NCT01707992|9898428|FG000|Active Treatment Phase (24 Months)|Study terminated by sponsor|0
6226100|NCT01707992|9898429|FG001|Active Treatment Phase (24 Months)|Study terminated by sponsor|0
6226101|NCT01707992|9898430|FG002|Active Treatment Phase (24 Months)|Study terminated by sponsor|0
6226102|NCT01707992|9898431|FG003|Active Treatment Phase (24 Months)|Study terminated by sponsor|809
6226103|NCT01707992|9898432|FG004|Active Treatment Phase (24 Months)|Study terminated by sponsor|243
6226104|NCT01707992|9898433|FG005|Active Treatment Phase (24 Months)|Study terminated by sponsor|174
6226105|NCT01707992|9898428|FG000|Active Treatment Phase (24 Months)|Participant withdrew per Sponsor request|0
6226106|NCT01707992|9898429|FG001|Active Treatment Phase (24 Months)|Participant withdrew per Sponsor request|0
6226107|NCT01707992|9898430|FG002|Active Treatment Phase (24 Months)|Participant withdrew per Sponsor request|0
6226108|NCT01707992|9898431|FG003|Active Treatment Phase (24 Months)|Participant withdrew per Sponsor request|0
6226109|NCT01707992|9898432|FG004|Active Treatment Phase (24 Months)|Participant withdrew per Sponsor request|4
6226110|NCT01707992|9898433|FG005|Active Treatment Phase (24 Months)|Participant withdrew per Sponsor request|0
6226111|NCT01708161|9898463|FG000|Overall Study|Adverse Event|1
6226112|NCT01708161|9898464|FG001|Overall Study|Adverse Event|3
6226113|NCT01708161|9898465|FG002|Overall Study|Adverse Event|4
6226114|NCT01708161|9898466|FG003|Overall Study|Adverse Event|2
6226115|NCT01708161|9898467|FG004|Overall Study|Adverse Event|3
6226116|NCT01708161|9898468|FG005|Overall Study|Adverse Event|0
6226117|NCT01708161|9898463|FG000|Overall Study|Death|0
6226118|NCT01708161|9898464|FG001|Overall Study|Death|0
6226119|NCT01708161|9898465|FG002|Overall Study|Death|0
6226120|NCT01708161|9898466|FG003|Overall Study|Death|1
6226121|NCT01708161|9898467|FG004|Overall Study|Death|0
6226122|NCT01708161|9898468|FG005|Overall Study|Death|1
6226123|NCT01708161|9898463|FG000|Overall Study|Withdrawal by Subject|0
6226124|NCT01708161|9898464|FG001|Overall Study|Withdrawal by Subject|1
6226125|NCT01708161|9898465|FG002|Overall Study|Withdrawal by Subject|1
6226126|NCT01708161|9898466|FG003|Overall Study|Withdrawal by Subject|0
6226127|NCT01708161|9898467|FG004|Overall Study|Withdrawal by Subject|0
6226128|NCT01708161|9898468|FG005|Overall Study|Withdrawal by Subject|0
6226129|NCT01708161|9898463|FG000|Overall Study|Administrative problems|0
6226130|NCT01708161|9898464|FG001|Overall Study|Administrative problems|1
6226131|NCT01708161|9898465|FG002|Overall Study|Administrative problems|0
6136179|NCT00998985|9765775|FG005|Overall Study|Withdrawal by Subject|0
6136180|NCT00998985|9765776|FG006|Overall Study|Withdrawal by Subject|0
6136181|NCT00998985|9765777|FG007|Overall Study|Withdrawal by Subject|0
6136182|NCT00998985|9765778|FG008|Overall Study|Withdrawal by Subject|1
6136183|NCT00998985|9765779|FG009|Overall Study|Withdrawal by Subject|0
6136184|NCT00998985|9765780|FG010|Overall Study|Withdrawal by Subject|0
6136185|NCT00998985|9765781|FG011|Overall Study|Withdrawal by Subject|0
6136186|NCT00998985|9765782|FG012|Overall Study|Withdrawal by Subject|0
6136187|NCT00998985|9765783|FG013|Overall Study|Withdrawal by Subject|0
6136188|NCT00998985|9765770|FG000|Overall Study|Protocol Violation|0
6136189|NCT00998985|9765771|FG001|Overall Study|Protocol Violation|0
6136190|NCT00998985|9765772|FG002|Overall Study|Protocol Violation|0
6136191|NCT00998985|9765773|FG003|Overall Study|Protocol Violation|0
6136192|NCT00998985|9765774|FG004|Overall Study|Protocol Violation|0
6136193|NCT00998985|9765775|FG005|Overall Study|Protocol Violation|1
6136194|NCT00998985|9765776|FG006|Overall Study|Protocol Violation|0
6136195|NCT00998985|9765777|FG007|Overall Study|Protocol Violation|0
6136196|NCT00998985|9765778|FG008|Overall Study|Protocol Violation|0
6136197|NCT00998985|9765779|FG009|Overall Study|Protocol Violation|0
6136198|NCT00998985|9765780|FG010|Overall Study|Protocol Violation|0
6136199|NCT00998985|9765781|FG011|Overall Study|Protocol Violation|0
6226132|NCT01708161|9898466|FG003|Overall Study|Administrative problems|0
6226133|NCT01708161|9898467|FG004|Overall Study|Administrative problems|0
6226134|NCT01708161|9898468|FG005|Overall Study|Administrative problems|0
6226135|NCT01708161|9898463|FG000|Overall Study|Disease progression|3
6226136|NCT01708161|9898464|FG001|Overall Study|Disease progression|5
6226137|NCT01708161|9898465|FG002|Overall Study|Disease progression|5
6226138|NCT01708161|9898466|FG003|Overall Study|Disease progression|13
6226139|NCT01708161|9898467|FG004|Overall Study|Disease progression|3
6226140|NCT01708161|9898468|FG005|Overall Study|Disease progression|0
6226141|NCT01708174|9898485|FG000|Treatment Period|Withdrawal by Subject|1
6226142|NCT01708174|9898486|FG001|Treatment Period|Withdrawal by Subject|0
6226143|NCT01708174|9898487|FG002|Treatment Period|Withdrawal by Subject|0
6226144|NCT01708174|9898485|FG000|Treatment Period|Progressive disease|0
6226145|NCT01708174|9898486|FG001|Treatment Period|Progressive disease|1
6226146|NCT01708174|9898487|FG002|Treatment Period|Progressive disease|0
6226147|NCT01708174|9898485|FG000|Treatment Period|Death|0
6226148|NCT01708174|9898486|FG001|Treatment Period|Death|0
6226149|NCT01708174|9898487|FG002|Treatment Period|Death|1
6226150|NCT01708174|9898485|FG000|Treatment Period|Adverse Event|0
6226151|NCT01708174|9898486|FG001|Treatment Period|Adverse Event|1
6226152|NCT01708174|9898487|FG002|Treatment Period|Adverse Event|0
6226153|NCT01708187|9898498|FG000|Overall Study|Lost to Follow-up|0
6226154|NCT01708187|9898499|FG001|Overall Study|Lost to Follow-up|1
6226155|NCT01708291|9898536|FG000|Overall Study|fighting|2
5981141|NCT02224573|9570090|FG001|Treatment Phase|Began Commercial Product|0
5981142|NCT02224573|9570089|FG000|Treatment Phase|Lack of Efficacy per Participant/Caregiver|3
5981143|NCT02224573|9570090|FG001|Treatment Phase|Lack of Efficacy per Participant/Caregiver|3
5981144|NCT02224573|9570089|FG000|Treatment Phase|Met Withdrawal Criteria|5
5981145|NCT02224573|9570090|FG001|Treatment Phase|Met Withdrawal Criteria|7
5981146|NCT02224573|9570089|FG000|Treatment Phase|Participant Did Not Return for Visits|0
5981147|NCT02224573|9570090|FG001|Treatment Phase|Participant Did Not Return for Visits|1
5981148|NCT02224573|9570089|FG000|Treatment Phase|Continued Compassionate Use|1
5981149|NCT02224573|9570090|FG001|Treatment Phase|Continued Compassionate Use|0
5981150|NCT02224573|9570089|FG000|Treatment Phase|Lack of Efficiency|2
5981151|NCT02224573|9570090|FG001|Treatment Phase|Lack of Efficiency|1
5981152|NCT02224573|9570089|FG000|Treatment Phase|Participant with Protocol-Excluded Treatment|0
5981153|NCT02224573|9570090|FG001|Treatment Phase|Participant with Protocol-Excluded Treatment|1
5981154|NCT02224573|9570089|FG000|Treatment Phase|Participant Moved|2
5981155|NCT02224573|9570090|FG001|Treatment Phase|Participant Moved|0
5981156|NCT02224573|9570089|FG000|Treatment Phase|Withdrawal by Participant or Parent/Guardian|62
5981157|NCT02224573|9570090|FG001|Treatment Phase|Withdrawal by Participant or Parent/Guardian|48
6136200|NCT00998985|9765782|FG012|Overall Study|Protocol Violation|0
6136201|NCT00998985|9765783|FG013|Overall Study|Protocol Violation|0
6226156|NCT01708291|9898537|FG001|Overall Study|fighting|1
6226157|NCT01708902|9898623|FG000|Overall Study|Adverse Event|3
6226158|NCT01708902|9898624|FG001|Overall Study|Adverse Event|4
6226159|NCT01708902|9898625|FG002|Overall Study|Adverse Event|9
6226160|NCT01708902|9898626|FG003|Overall Study|Adverse Event|2
6226161|NCT01708902|9898627|FG004|Overall Study|Adverse Event|7
6226162|NCT01708902|9898628|FG005|Overall Study|Adverse Event|3
6226163|NCT01708902|9898629|FG006|Overall Study|Adverse Event|5
6226164|NCT01708902|9898623|FG000|Overall Study|Lack of Efficacy|3
6226165|NCT01708902|9898624|FG001|Overall Study|Lack of Efficacy|1
6226166|NCT01708902|9898625|FG002|Overall Study|Lack of Efficacy|0
6226167|NCT01708902|9898626|FG003|Overall Study|Lack of Efficacy|0
6226168|NCT01708902|9898627|FG004|Overall Study|Lack of Efficacy|0
6226169|NCT01708902|9898628|FG005|Overall Study|Lack of Efficacy|1
6226170|NCT01708902|9898629|FG006|Overall Study|Lack of Efficacy|0
6226171|NCT01708902|9898623|FG000|Overall Study|Non compliance with protocol|0
6226172|NCT01708902|9898624|FG001|Overall Study|Non compliance with protocol|2
6226173|NCT01708902|9898625|FG002|Overall Study|Non compliance with protocol|1
6226174|NCT01708902|9898626|FG003|Overall Study|Non compliance with protocol|3
6136202|NCT00999167|9765908|FG000|Part A: Open Label Safety run-in|Met protocol defined stopping rule|4
6136203|NCT00999167|9765909|FG001|Part A: Open Label Safety run-in|Met protocol defined stopping rule|0
6136204|NCT00999167|9765910|FG002|Part A: Open Label Safety run-in|Met protocol defined stopping rule|0
6136205|NCT00999167|9765908|FG000|Part A: Open Label Safety run-in|Adverse Event|3
6136206|NCT00999167|9765909|FG001|Part A: Open Label Safety run-in|Adverse Event|0
6136207|NCT00999167|9765910|FG002|Part A: Open Label Safety run-in|Adverse Event|0
6136208|NCT00999167|9765908|FG000|Part B: Randomized, Placebo Controlled|Met protocol defined stopping rule|0
6136209|NCT00999167|9765909|FG001|Part B: Randomized, Placebo Controlled|Met protocol defined stopping rule|19
6136210|NCT00999167|9765910|FG002|Part B: Randomized, Placebo Controlled|Met protocol defined stopping rule|16
6136211|NCT00999167|9765908|FG000|Part B: Randomized, Placebo Controlled|Withdrawal by Subject|0
6136212|NCT00999167|9765909|FG001|Part B: Randomized, Placebo Controlled|Withdrawal by Subject|7
6136213|NCT00999167|9765910|FG002|Part B: Randomized, Placebo Controlled|Withdrawal by Subject|4
6136214|NCT00999167|9765908|FG000|Part B: Randomized, Placebo Controlled|Adverse Event|0
6136215|NCT00999167|9765909|FG001|Part B: Randomized, Placebo Controlled|Adverse Event|6
6136216|NCT00999167|9765910|FG002|Part B: Randomized, Placebo Controlled|Adverse Event|1
6136217|NCT00999167|9765908|FG000|Part B: Randomized, Placebo Controlled|Noncompliance|0
6136218|NCT00999167|9765909|FG001|Part B: Randomized, Placebo Controlled|Noncompliance|1
6136219|NCT00999167|9765910|FG002|Part B: Randomized, Placebo Controlled|Noncompliance|0
6136220|NCT00999167|9765908|FG000|Part B: Randomized, Placebo Controlled|Physician Decision|0
6136221|NCT00999167|9765909|FG001|Part B: Randomized, Placebo Controlled|Physician Decision|1
6136222|NCT00999167|9765910|FG002|Part B: Randomized, Placebo Controlled|Physician Decision|0
6136223|NCT00999167|9765908|FG000|Part B: Randomized, Placebo Controlled|Physician stopped drug|0
6136224|NCT00999167|9765909|FG001|Part B: Randomized, Placebo Controlled|Physician stopped drug|1
6136225|NCT00999167|9765910|FG002|Part B: Randomized, Placebo Controlled|Physician stopped drug|0
6136226|NCT00999466|9765923|FG000|Main Part|Withdrawal by Subject|0
6136227|NCT00999466|9765924|FG001|Main Part|Withdrawal by Subject|0
6136228|NCT00999466|9765925|FG002|Main Part|Withdrawal by Subject|2
6136229|NCT00999466|9765923|FG000|Main Part|Adverse Event|0
6136230|NCT00999466|9765924|FG001|Main Part|Adverse Event|4
6136231|NCT00999466|9765925|FG002|Main Part|Adverse Event|2
6136232|NCT00999518|9765938|FG000|Overall Study|Adverse Event|1
6136233|NCT00999518|9765939|FG001|Overall Study|Adverse Event|6
6136234|NCT00999518|9765940|FG002|Overall Study|Adverse Event|3
6136235|NCT00999518|9765941|FG003|Overall Study|Adverse Event|1
6136236|NCT00999518|9765942|FG004|Overall Study|Adverse Event|2
6136237|NCT00999518|9765938|FG000|Overall Study|Lack of Efficacy|2
6136238|NCT00999518|9765939|FG001|Overall Study|Lack of Efficacy|0
6136239|NCT00999518|9765940|FG002|Overall Study|Lack of Efficacy|0
6136240|NCT00999518|9765941|FG003|Overall Study|Lack of Efficacy|2
6136241|NCT00999518|9765942|FG004|Overall Study|Lack of Efficacy|2
6136242|NCT00999518|9765938|FG000|Overall Study|Lost to Follow-up|0
6136243|NCT00999518|9765939|FG001|Overall Study|Lost to Follow-up|0
6136244|NCT00999518|9765940|FG002|Overall Study|Lost to Follow-up|0
6136245|NCT00999518|9765941|FG003|Overall Study|Lost to Follow-up|4
6136246|NCT00999518|9765942|FG004|Overall Study|Lost to Follow-up|1
6136247|NCT00999518|9765938|FG000|Overall Study|Did not meet entrance criteria|0
6136248|NCT00999518|9765939|FG001|Overall Study|Did not meet entrance criteria|0
6136249|NCT00999518|9765940|FG002|Overall Study|Did not meet entrance criteria|0
6136250|NCT00999518|9765941|FG003|Overall Study|Did not meet entrance criteria|0
6136251|NCT00999518|9765942|FG004|Overall Study|Did not meet entrance criteria|1
6136252|NCT00999518|9765938|FG000|Overall Study|Study terminated by sponsor|10
6136253|NCT00999518|9765939|FG001|Overall Study|Study terminated by sponsor|6
6136254|NCT00999518|9765940|FG002|Overall Study|Study terminated by sponsor|5
6136255|NCT00999518|9765941|FG003|Overall Study|Study terminated by sponsor|5
6136256|NCT00999518|9765942|FG004|Overall Study|Study terminated by sponsor|9
6136257|NCT00999518|9765938|FG000|Overall Study|Pregnancy|0
6136258|NCT00999518|9765939|FG001|Overall Study|Pregnancy|0
6136259|NCT00999518|9765940|FG002|Overall Study|Pregnancy|1
6136260|NCT00999518|9765941|FG003|Overall Study|Pregnancy|0
6136261|NCT00999518|9765942|FG004|Overall Study|Pregnancy|0
6136262|NCT00999518|9765938|FG000|Overall Study|Protocol Violation|0
6136263|NCT00999518|9765939|FG001|Overall Study|Protocol Violation|1
6136264|NCT00999518|9765940|FG002|Overall Study|Protocol Violation|0
6136265|NCT00999518|9765941|FG003|Overall Study|Protocol Violation|0
6136266|NCT00999518|9765942|FG004|Overall Study|Protocol Violation|2
6136267|NCT00999518|9765938|FG000|Overall Study|Withdrawal by Subject|5
6136268|NCT00999518|9765939|FG001|Overall Study|Withdrawal by Subject|4
6136269|NCT00999518|9765940|FG002|Overall Study|Withdrawal by Subject|10
6136270|NCT00999518|9765941|FG003|Overall Study|Withdrawal by Subject|6
6136271|NCT00999518|9765942|FG004|Overall Study|Withdrawal by Subject|1
6136272|NCT00999518|9765938|FG000|Overall Study|Other|5
6226175|NCT01708902|9898627|FG004|Overall Study|Non compliance with protocol|0
6226176|NCT01708902|9898628|FG005|Overall Study|Non compliance with protocol|0
6226177|NCT01708902|9898629|FG006|Overall Study|Non compliance with protocol|0
6226178|NCT01708902|9898623|FG000|Overall Study|Lost to Follow-up|2
6226179|NCT01708902|9898624|FG001|Overall Study|Lost to Follow-up|1
6226180|NCT01708902|9898625|FG002|Overall Study|Lost to Follow-up|2
6226181|NCT01708902|9898626|FG003|Overall Study|Lost to Follow-up|2
6136273|NCT00999518|9765939|FG001|Overall Study|Other|7
6136274|NCT00999518|9765940|FG002|Overall Study|Other|1
6136275|NCT00999518|9765941|FG003|Overall Study|Other|4
6136276|NCT00999518|9765942|FG004|Overall Study|Other|5
6136277|NCT00999518|9765938|FG000|Overall Study|Randomized but not Treated|1
6136278|NCT00999518|9765939|FG001|Overall Study|Randomized but not Treated|1
6136279|NCT00999518|9765940|FG002|Overall Study|Randomized but not Treated|2
6136280|NCT00999518|9765941|FG003|Overall Study|Randomized but not Treated|0
6136281|NCT00999518|9765942|FG004|Overall Study|Randomized but not Treated|1
6136282|NCT00999544|9765958|FG000|Overall Study|Withdrawal by Subject|1
6136283|NCT00999596|9765991|FG000|Overall Study|Statistical population not required|101
6136284|NCT00999661|9765996|FG000|Overall Study|Lost to Follow-up|59
6136285|NCT00999661|9765996|FG000|Overall Study|Adverse Event|1
6136286|NCT00999661|9765996|FG000|Overall Study|Withdrawal by Subject|1
6136287|NCT00999661|9765996|FG000|Overall Study|Not meeting eligibility criteria|9
6136288|NCT00999687|9766000|FG000|First Intervention|Withdrawal by Subject|1
6136289|NCT00999687|9766000|FG000|Second Intervention|Withdrawal by Subject|2
6136290|NCT00999687|9766000|FG000|Second Intervention|Lack of Efficacy|1
6136291|NCT00999713|9766008|FG000|Overall Study|Physician Decision|2
6136292|NCT00999713|9766009|FG001|Overall Study|Physician Decision|0
6136293|NCT00999804|9766017|FG000|Overall Study|Lack of Efficacy|9
6136294|NCT00999804|9766018|FG001|Overall Study|Lack of Efficacy|2
6136295|NCT00999804|9766017|FG000|Overall Study|Adverse Event|4
6136296|NCT00999804|9766018|FG001|Overall Study|Adverse Event|3
6226182|NCT01708902|9898627|FG004|Overall Study|Lost to Follow-up|0
6226183|NCT01708902|9898628|FG005|Overall Study|Lost to Follow-up|0
6226184|NCT01708902|9898629|FG006|Overall Study|Lost to Follow-up|1
6226185|NCT01708902|9898623|FG000|Overall Study|Refused to continue trial medication|8
6226186|NCT01708902|9898624|FG001|Overall Study|Refused to continue trial medication|0
6226187|NCT01708902|9898625|FG002|Overall Study|Refused to continue trial medication|4
6226188|NCT01708902|9898626|FG003|Overall Study|Refused to continue trial medication|2
6226189|NCT01708902|9898627|FG004|Overall Study|Refused to continue trial medication|8
6226190|NCT01708902|9898628|FG005|Overall Study|Refused to continue trial medication|1
6226191|NCT01708902|9898629|FG006|Overall Study|Refused to continue trial medication|1
6226192|NCT01708902|9898623|FG000|Overall Study|Other Reason|1
6226193|NCT01708902|9898624|FG001|Overall Study|Other Reason|0
6226194|NCT01708902|9898625|FG002|Overall Study|Other Reason|1
6226195|NCT01708902|9898626|FG003|Overall Study|Other Reason|1
6226196|NCT01708902|9898627|FG004|Overall Study|Other Reason|1
6226197|NCT01708902|9898628|FG005|Overall Study|Other Reason|2
6226198|NCT01708902|9898629|FG006|Overall Study|Other Reason|0
6290676|NCT02403674|10007082|FG001|Overall Study|Pregnancy|1
6290677|NCT02403674|10007081|FG000|Overall Study|Protocol Violation|4
6290678|NCT02403674|10007082|FG001|Overall Study|Protocol Violation|2
6290679|NCT02403817|10007099|FG000|Overall Study|Withdrawal by Subject|5
6290680|NCT02403817|10007100|FG001|Overall Study|Withdrawal by Subject|0
6290681|NCT02404025|10007139|FG000|Overall Study|Adverse Event|1
6290682|NCT02404025|10007139|FG000|Overall Study|Lack of Efficacy|3
6290683|NCT02404103|10007145|FG000|Overall Study|Adverse Event|1
6290684|NCT02404103|10007146|FG001|Overall Study|Adverse Event|0
6290685|NCT02404103|10007145|FG000|Overall Study|Lost to Follow-up|3
6290686|NCT02404103|10007146|FG001|Overall Study|Lost to Follow-up|3
6290687|NCT02404220|10007172|FG000|Overall Study|Adverse Event|0
6290688|NCT02404220|10007173|FG001|Overall Study|Adverse Event|0
6290689|NCT02404220|10007174|FG002|Overall Study|Adverse Event|1
6290690|NCT02404220|10007175|FG003|Overall Study|Adverse Event|0
6290691|NCT02404220|10007172|FG000|Overall Study|Death|5
6290692|NCT02404220|10007173|FG001|Overall Study|Death|5
6290693|NCT02404220|10007174|FG002|Overall Study|Death|3
6290694|NCT02404220|10007175|FG003|Overall Study|Death|8
6290695|NCT02404220|10007172|FG000|Overall Study|Progressive Disease|0
6290696|NCT02404220|10007173|FG001|Overall Study|Progressive Disease|0
6290697|NCT02404220|10007174|FG002|Overall Study|Progressive Disease|1
6290698|NCT02404220|10007175|FG003|Overall Study|Progressive Disease|1
6290699|NCT02404220|10007172|FG000|Overall Study|Study Terminated by Sponsor|0
6290700|NCT02404220|10007173|FG001|Overall Study|Study Terminated by Sponsor|0
6290701|NCT02404220|10007174|FG002|Overall Study|Study Terminated by Sponsor|2
6290702|NCT02404220|10007175|FG003|Overall Study|Study Terminated by Sponsor|1
6290703|NCT02404220|10007172|FG000|Overall Study|Withdrawal by Subject|0
6290704|NCT02404220|10007173|FG001|Overall Study|Withdrawal by Subject|1
6290705|NCT02404220|10007174|FG002|Overall Study|Withdrawal by Subject|0
6290706|NCT02404220|10007175|FG003|Overall Study|Withdrawal by Subject|0
6290707|NCT02404220|10007172|FG000|Overall Study|Enrolled but Never Treated|0
6290708|NCT02404220|10007173|FG001|Overall Study|Enrolled but Never Treated|2
6290709|NCT02404220|10007174|FG002|Overall Study|Enrolled but Never Treated|0
6290710|NCT02404220|10007175|FG003|Overall Study|Enrolled but Never Treated|0
6290711|NCT02404311|10007205|FG000|Part A: Month 0-18|Death|2
6290712|NCT02404311|10007206|FG001|Part A: Month 0-18|Death|0
6290713|NCT02404311|10007207|FG002|Part A: Month 0-18|Death|0
6136297|NCT00999804|9766017|FG000|Overall Study|Withdrawal by Subject|4
6136298|NCT00999804|9766018|FG001|Overall Study|Withdrawal by Subject|0
6136299|NCT00999804|9766017|FG000|Overall Study|Death|1
6136300|NCT00999804|9766018|FG001|Overall Study|Death|0
6136301|NCT00999804|9766017|FG000|Overall Study|Ineligible|3
6136302|NCT00999804|9766018|FG001|Overall Study|Ineligible|0
6136303|NCT00999908|9766033|FG000|Treatment Period 1|Subject withdrew consent|2
6136304|NCT00999908|9766034|FG001|Treatment Period 1|Subject withdrew consent|0
6136305|NCT00999908|9766035|FG002|Treatment Period 1|Subject withdrew consent|0
6136306|NCT00999908|9766033|FG000|Treatment Period 2|Protocol Violation|1
6136307|NCT00999908|9766034|FG001|Treatment Period 2|Protocol Violation|0
6136308|NCT00999908|9766035|FG002|Treatment Period 2|Protocol Violation|0
6136309|NCT00999921|9766045|FG000|Overall Study|Lost to Follow-up|10
6136310|NCT00999921|9766046|FG001|Overall Study|Lost to Follow-up|19
6136311|NCT01000025|9766057|FG000|Overall Study|Adverse Event|43
6136312|NCT01000025|9766058|FG001|Overall Study|Adverse Event|2
6136313|NCT01000025|9766057|FG000|Overall Study|Withdrawal by Subject|13
6136314|NCT01000025|9766058|FG001|Overall Study|Withdrawal by Subject|8
6290714|NCT02404311|10007208|FG003|Part A: Month 0-18|Death|0
6290715|NCT02404311|10007209|FG004|Part A: Month 0-18|Death|0
6290716|NCT02404311|10007205|FG000|Part A: Month 0-18|Physician Decision|1
6290717|NCT02404311|10007206|FG001|Part A: Month 0-18|Physician Decision|0
6290718|NCT02404311|10007207|FG002|Part A: Month 0-18|Physician Decision|0
6290719|NCT02404311|10007208|FG003|Part A: Month 0-18|Physician Decision|0
6290720|NCT02404311|10007209|FG004|Part A: Month 0-18|Physician Decision|0
6290721|NCT02404311|10007205|FG000|Part A: Month 0-18|Lost to Follow-up|4
6290722|NCT02404311|10007206|FG001|Part A: Month 0-18|Lost to Follow-up|2
6290723|NCT02404311|10007207|FG002|Part A: Month 0-18|Lost to Follow-up|0
6290724|NCT02404311|10007208|FG003|Part A: Month 0-18|Lost to Follow-up|0
6290725|NCT02404311|10007209|FG004|Part A: Month 0-18|Lost to Follow-up|0
6290726|NCT02404311|10007205|FG000|Part A: Month 0-18|Withdrawal by Subject|6
6290727|NCT02404311|10007206|FG001|Part A: Month 0-18|Withdrawal by Subject|2
6290728|NCT02404311|10007207|FG002|Part A: Month 0-18|Withdrawal by Subject|0
6290729|NCT02404311|10007208|FG003|Part A: Month 0-18|Withdrawal by Subject|0
6290730|NCT02404311|10007209|FG004|Part A: Month 0-18|Withdrawal by Subject|0
6290731|NCT02404311|10007205|FG000|Part A: Month 0-18|HIV Infection|6
6290732|NCT02404311|10007206|FG001|Part A: Month 0-18|HIV Infection|2
6290733|NCT02404311|10007207|FG002|Part A: Month 0-18|HIV Infection|0
6290734|NCT02404311|10007208|FG003|Part A: Month 0-18|HIV Infection|0
6290735|NCT02404311|10007209|FG004|Part A: Month 0-18|HIV Infection|0
6290736|NCT02404311|10007205|FG000|Part A: Month 0-18|Participant unable to adhere|7
6290737|NCT02404311|10007206|FG001|Part A: Month 0-18|Participant unable to adhere|0
6290738|NCT02404311|10007207|FG002|Part A: Month 0-18|Participant unable to adhere|0
6290739|NCT02404311|10007208|FG003|Part A: Month 0-18|Participant unable to adhere|0
6290740|NCT02404311|10007209|FG004|Part A: Month 0-18|Participant unable to adhere|0
6136315|NCT01000025|9766057|FG000|Overall Study|Death|23
6136316|NCT01000025|9766058|FG001|Overall Study|Death|13
6136317|NCT01000025|9766057|FG000|Overall Study|Lack of Efficacy|363
6136318|NCT01000025|9766058|FG001|Overall Study|Lack of Efficacy|208
6136319|NCT01000025|9766057|FG000|Overall Study|Intercurrent Illness|26
6136320|NCT01000025|9766058|FG001|Overall Study|Intercurrent Illness|7
6136321|NCT01000051|9766066|FG000|Overall Study|Withdrawal by Subject|1
6136322|NCT01000051|9766067|FG001|Overall Study|Withdrawal by Subject|1
6136323|NCT01000051|9766066|FG000|Overall Study|Disease Progression|1
6136324|NCT01000051|9766067|FG001|Overall Study|Disease Progression|0
6136325|NCT01000051|9766066|FG000|Overall Study|Serious noncompliance|1
6136326|NCT01000051|9766067|FG001|Overall Study|Serious noncompliance|0
6136327|NCT01000064|9766073|FG000|Overall Study|Withdrawal by Subject|1
6136328|NCT01000064|9766074|FG001|Overall Study|Withdrawal by Subject|1
6136329|NCT01000155|9766083|FG000|Overall Study|Withdrawal by Subject|1
6136330|NCT01000155|9766083|FG000|Overall Study|Adverse Event|1
6290741|NCT02404350|10007225|FG000|Overall Study|Adverse Event|2
6290742|NCT02404350|10007226|FG001|Overall Study|Adverse Event|2
6290743|NCT02404350|10007227|FG002|Overall Study|Adverse Event|3
6290744|NCT02404350|10007228|FG003|Overall Study|Adverse Event|9
6290745|NCT02404350|10007225|FG000|Overall Study|Lack of Efficacy|3
6290746|NCT02404350|10007226|FG001|Overall Study|Lack of Efficacy|1
6290747|NCT02404350|10007227|FG002|Overall Study|Lack of Efficacy|0
6290748|NCT02404350|10007228|FG003|Overall Study|Lack of Efficacy|3
6290749|NCT02404350|10007225|FG000|Overall Study|Lost to Follow-up|2
6290750|NCT02404350|10007226|FG001|Overall Study|Lost to Follow-up|0
6290751|NCT02404350|10007227|FG002|Overall Study|Lost to Follow-up|0
6290752|NCT02404350|10007228|FG003|Overall Study|Lost to Follow-up|1
6290753|NCT02404350|10007225|FG000|Overall Study|Physician Decision|1
6290754|NCT02404350|10007226|FG001|Overall Study|Physician Decision|0
6290755|NCT02404350|10007227|FG002|Overall Study|Physician Decision|0
6290756|NCT02404350|10007228|FG003|Overall Study|Physician Decision|2
6290757|NCT02404350|10007225|FG000|Overall Study|Pregnancy|0
6290758|NCT02404350|10007226|FG001|Overall Study|Pregnancy|0
6290759|NCT02404350|10007227|FG002|Overall Study|Pregnancy|0
6290760|NCT02404350|10007228|FG003|Overall Study|Pregnancy|1
6290761|NCT02404350|10007225|FG000|Overall Study|Withdrawal by Subject|7
6290762|NCT02404350|10007226|FG001|Overall Study|Withdrawal by Subject|3
6290763|NCT02404350|10007227|FG002|Overall Study|Withdrawal by Subject|3
6136331|NCT01000311|9766105|FG000|Overall Study|Adverse Event|2
6290764|NCT02404350|10007228|FG003|Overall Study|Withdrawal by Subject|19
6290765|NCT02404350|10007225|FG000|Overall Study|Due to Non-compliance with treatment|0
6290766|NCT02404350|10007226|FG001|Overall Study|Due to Non-compliance with treatment|0
6290767|NCT02404350|10007227|FG002|Overall Study|Due to Non-compliance with treatment|0
6290768|NCT02404350|10007228|FG003|Overall Study|Due to Non-compliance with treatment|1
6136332|NCT01000311|9766106|FG001|Overall Study|Adverse Event|5
6136333|NCT01000311|9766105|FG000|Overall Study|Withdrawal by Subject|16
6136334|NCT01000311|9766106|FG001|Overall Study|Withdrawal by Subject|24
6136335|NCT01000311|9766105|FG000|Overall Study|Lost to Follow-up|15
6136336|NCT01000311|9766106|FG001|Overall Study|Lost to Follow-up|24
6136337|NCT01000311|9766105|FG000|Overall Study|Protocol Violation|1
6136338|NCT01000311|9766106|FG001|Overall Study|Protocol Violation|2
6136339|NCT01000311|9766105|FG000|Overall Study|Inappropriate enrollment|2
6136340|NCT01000311|9766106|FG001|Overall Study|Inappropriate enrollment|0
6136341|NCT01000311|9766105|FG000|Overall Study|Administrative reason|9
6136342|NCT01000311|9766106|FG001|Overall Study|Administrative reason|15
6136343|NCT01000337|9766119|FG000|Overall Study|Lost to Follow-up|4
6136344|NCT01000337|9766120|FG001|Overall Study|Lost to Follow-up|3
6136345|NCT01000376|9766128|FG000|Cycle 1 Day 1|Adverse Event|1
6136346|NCT01000376|9766129|FG001|Cycle 1 Day 1|Adverse Event|0
6136347|NCT01000376|9766128|FG000|Cycle 1 Day 1|Progressive Disease|1
6136348|NCT01000376|9766129|FG001|Cycle 1 Day 1|Progressive Disease|0
6136349|NCT01000480|9766135|FG000|Induction Phase|Adverse Event|2
6136350|NCT01000480|9766135|FG000|Induction Phase|Lost to Follow-up|1
6136351|NCT01000480|9766135|FG000|Induction Phase|Physician Decision|1
6136352|NCT01000480|9766135|FG000|Induction Phase|Entry Criteria Not Met|3
6136353|NCT01000480|9766135|FG000|Concurrent Therapy Phase|Adverse Event|4
6136354|NCT01000480|9766135|FG000|Concurrent Therapy Phase|Protocol Violation|2
6136355|NCT01000480|9766135|FG000|Concurrent Therapy Phase|Withdrawal by Subject|3
6136356|NCT01000480|9766135|FG000|Concurrent Therapy Phase|Physician Decision|1
6136357|NCT01000493|9766141|FG000|Overall Study|Adverse Event|3
6136358|NCT01000493|9766142|FG001|Overall Study|Adverse Event|6
6136359|NCT01000493|9766141|FG000|Overall Study|Lack of Efficacy|1
6136360|NCT01000493|9766142|FG001|Overall Study|Lack of Efficacy|1
6136361|NCT01000493|9766141|FG000|Overall Study|Protocol Violation|1
6136362|NCT01000493|9766142|FG001|Overall Study|Protocol Violation|8
6136363|NCT01000493|9766141|FG000|Overall Study|Study closed/terminated|25
6136364|NCT01000493|9766142|FG001|Overall Study|Study closed/terminated|23
6136365|NCT01000493|9766141|FG000|Overall Study|Lost to Follow-up|5
6136366|NCT01000493|9766142|FG001|Overall Study|Lost to Follow-up|9
6136367|NCT01000493|9766141|FG000|Overall Study|Physician Decision|1
6136368|NCT01000493|9766142|FG001|Overall Study|Physician Decision|1
6136369|NCT01000493|9766141|FG000|Overall Study|Withdrawal by Subject|3
6136370|NCT01000493|9766142|FG001|Overall Study|Withdrawal by Subject|7
6136371|NCT01000506|9766152|FG000|Overall Study|Adverse Event|6
6290769|NCT02404350|10007225|FG000|Overall Study|Due to Technical problems|0
6290770|NCT02404350|10007226|FG001|Overall Study|Due to Technical problems|0
6290771|NCT02404350|10007227|FG002|Overall Study|Due to Technical problems|0
6290772|NCT02404350|10007228|FG003|Overall Study|Due to Technical problems|1
6290773|NCT02404389|10007244|FG000|Overall Study|Adverse Event|1
6290774|NCT02404389|10007245|FG001|Overall Study|Adverse Event|0
6290775|NCT02404389|10007246|FG002|Overall Study|Adverse Event|1
6290776|NCT02404389|10007247|FG003|Overall Study|Adverse Event|0
6290777|NCT02404389|10007248|FG004|Overall Study|Adverse Event|2
6290778|NCT02404389|10007244|FG000|Overall Study|Subject/guardian decision|1
6290779|NCT02404389|10007245|FG001|Overall Study|Subject/guardian decision|0
6290780|NCT02404389|10007246|FG002|Overall Study|Subject/guardian decision|0
6290781|NCT02404389|10007247|FG003|Overall Study|Subject/guardian decision|1
6290782|NCT02404389|10007248|FG004|Overall Study|Subject/guardian decision|1
6290783|NCT02404441|10007272|FG000|Phase 1 Part|Adverse Event|1
6290784|NCT02404441|10007273|FG001|Phase 1 Part|Adverse Event|0
6290785|NCT02404441|10007274|FG002|Phase 1 Part|Adverse Event|0
6290786|NCT02404441|10007275|FG003|Phase 1 Part|Adverse Event|0
6290787|NCT02404441|10007276|FG004|Phase 1 Part|Adverse Event|0
6290788|NCT02404441|10007277|FG005|Phase 1 Part|Adverse Event|0
6290789|NCT02404441|10007278|FG006|Phase 1 Part|Adverse Event|0
6290790|NCT02404441|10007279|FG007|Phase 1 Part|Adverse Event|0
6290791|NCT02404441|10007280|FG008|Phase 1 Part|Adverse Event|0
6290792|NCT02404441|10007281|FG009|Phase 1 Part|Adverse Event|0
6290793|NCT02404441|10007272|FG000|Phase 1 Part|Physician Decision|0
6290794|NCT02404441|10007273|FG001|Phase 1 Part|Physician Decision|1
6290795|NCT02404441|10007274|FG002|Phase 1 Part|Physician Decision|0
6290796|NCT02404441|10007275|FG003|Phase 1 Part|Physician Decision|0
6290797|NCT02404441|10007276|FG004|Phase 1 Part|Physician Decision|0
6290798|NCT02404441|10007277|FG005|Phase 1 Part|Physician Decision|0
6290799|NCT02404441|10007278|FG006|Phase 1 Part|Physician Decision|0
6290800|NCT02404441|10007279|FG007|Phase 1 Part|Physician Decision|0
6290801|NCT02404441|10007280|FG008|Phase 1 Part|Physician Decision|0
6290802|NCT02404441|10007281|FG009|Phase 1 Part|Physician Decision|0
6290803|NCT02404441|10007272|FG000|Phase 1 Part|Progressive Disease|14
6290804|NCT02404441|10007273|FG001|Phase 1 Part|Progressive Disease|11
6290805|NCT02404441|10007274|FG002|Phase 1 Part|Progressive Disease|7
6290806|NCT02404441|10007275|FG003|Phase 1 Part|Progressive Disease|6
6290807|NCT02404441|10007276|FG004|Phase 1 Part|Progressive Disease|9
5981158|NCT02224573|9570089|FG000|Treatment Phase|Refused Medication|1
6136372|NCT01000506|9766153|FG001|Overall Study|Adverse Event|5
6290808|NCT02404441|10007277|FG005|Phase 1 Part|Progressive Disease|0
6290809|NCT02404441|10007278|FG006|Phase 1 Part|Progressive Disease|0
6290810|NCT02404441|10007279|FG007|Phase 1 Part|Progressive Disease|0
6290811|NCT02404441|10007280|FG008|Phase 1 Part|Progressive Disease|0
6290812|NCT02404441|10007281|FG009|Phase 1 Part|Progressive Disease|0
6136373|NCT01000506|9766154|FG002|Overall Study|Adverse Event|8
6136374|NCT01000506|9766155|FG003|Overall Study|Adverse Event|9
6136375|NCT01000506|9766152|FG000|Overall Study|Lack of Efficacy|8
6136376|NCT01000506|9766153|FG001|Overall Study|Lack of Efficacy|6
6136377|NCT01000506|9766154|FG002|Overall Study|Lack of Efficacy|4
6136378|NCT01000506|9766155|FG003|Overall Study|Lack of Efficacy|4
6136379|NCT01000506|9766152|FG000|Overall Study|Protocol Violation|1
6136380|NCT01000506|9766153|FG001|Overall Study|Protocol Violation|1
6136381|NCT01000506|9766154|FG002|Overall Study|Protocol Violation|0
6136382|NCT01000506|9766155|FG003|Overall Study|Protocol Violation|0
6290813|NCT02404441|10007272|FG000|Phase 1 Part|Subject/Guardian Decision|0
6290814|NCT02404441|10007273|FG001|Phase 1 Part|Subject/Guardian Decision|2
6290815|NCT02404441|10007274|FG002|Phase 1 Part|Subject/Guardian Decision|3
6290816|NCT02404441|10007275|FG003|Phase 1 Part|Subject/Guardian Decision|0
6290817|NCT02404441|10007276|FG004|Phase 1 Part|Subject/Guardian Decision|0
6290818|NCT02404441|10007277|FG005|Phase 1 Part|Subject/Guardian Decision|0
6290819|NCT02404441|10007278|FG006|Phase 1 Part|Subject/Guardian Decision|0
6290820|NCT02404441|10007279|FG007|Phase 1 Part|Subject/Guardian Decision|0
6290821|NCT02404441|10007280|FG008|Phase 1 Part|Subject/Guardian Decision|0
6290822|NCT02404441|10007281|FG009|Phase 1 Part|Subject/Guardian Decision|0
6290823|NCT02404441|10007272|FG000|Phase 1 Part|Death|1
6290824|NCT02404441|10007273|FG001|Phase 1 Part|Death|1
6290825|NCT02404441|10007274|FG002|Phase 1 Part|Death|1
6290826|NCT02404441|10007275|FG003|Phase 1 Part|Death|0
6290827|NCT02404441|10007276|FG004|Phase 1 Part|Death|1
6290828|NCT02404441|10007277|FG005|Phase 1 Part|Death|0
6290829|NCT02404441|10007278|FG006|Phase 1 Part|Death|0
6290830|NCT02404441|10007279|FG007|Phase 1 Part|Death|0
6290831|NCT02404441|10007280|FG008|Phase 1 Part|Death|0
6290832|NCT02404441|10007281|FG009|Phase 1 Part|Death|0
6290833|NCT02404441|10007272|FG000|Phase 2 Part|Adverse Event|0
6290834|NCT02404441|10007273|FG001|Phase 2 Part|Adverse Event|0
6290835|NCT02404441|10007274|FG002|Phase 2 Part|Adverse Event|0
6290836|NCT02404441|10007275|FG003|Phase 2 Part|Adverse Event|0
6290837|NCT02404441|10007276|FG004|Phase 2 Part|Adverse Event|0
6290838|NCT02404441|10007277|FG005|Phase 2 Part|Adverse Event|2
6290839|NCT02404441|10007278|FG006|Phase 2 Part|Adverse Event|3
6290840|NCT02404441|10007279|FG007|Phase 2 Part|Adverse Event|3
6290841|NCT02404441|10007280|FG008|Phase 2 Part|Adverse Event|6
6290842|NCT02404441|10007281|FG009|Phase 2 Part|Adverse Event|1
6290843|NCT02404441|10007272|FG000|Phase 2 Part|Physician Decision|0
6290844|NCT02404441|10007273|FG001|Phase 2 Part|Physician Decision|0
6290845|NCT02404441|10007274|FG002|Phase 2 Part|Physician Decision|0
6290846|NCT02404441|10007275|FG003|Phase 2 Part|Physician Decision|0
6290847|NCT02404441|10007276|FG004|Phase 2 Part|Physician Decision|0
6290848|NCT02404441|10007277|FG005|Phase 2 Part|Physician Decision|7
6290849|NCT02404441|10007278|FG006|Phase 2 Part|Physician Decision|9
6290850|NCT02404441|10007279|FG007|Phase 2 Part|Physician Decision|2
6290851|NCT02404441|10007280|FG008|Phase 2 Part|Physician Decision|1
6290852|NCT02404441|10007281|FG009|Phase 2 Part|Physician Decision|3
6290853|NCT02404441|10007272|FG000|Phase 2 Part|Progressive disease|0
6290854|NCT02404441|10007273|FG001|Phase 2 Part|Progressive disease|0
6290855|NCT02404441|10007274|FG002|Phase 2 Part|Progressive disease|0
6290856|NCT02404441|10007275|FG003|Phase 2 Part|Progressive disease|0
6290857|NCT02404441|10007276|FG004|Phase 2 Part|Progressive disease|0
6290858|NCT02404441|10007277|FG005|Phase 2 Part|Progressive disease|43
6136383|NCT01000506|9766152|FG000|Overall Study|Lost to Follow-up|1
6136384|NCT01000506|9766153|FG001|Overall Study|Lost to Follow-up|1
6136385|NCT01000506|9766154|FG002|Overall Study|Lost to Follow-up|4
6136386|NCT01000506|9766155|FG003|Overall Study|Lost to Follow-up|0
6136387|NCT01000506|9766152|FG000|Overall Study|Physician Decision|1
6136388|NCT01000506|9766153|FG001|Overall Study|Physician Decision|3
6136389|NCT01000506|9766154|FG002|Overall Study|Physician Decision|3
6136390|NCT01000506|9766155|FG003|Overall Study|Physician Decision|3
6136391|NCT01000506|9766152|FG000|Overall Study|Withdrawal by Subject|11
6136392|NCT01000506|9766153|FG001|Overall Study|Withdrawal by Subject|8
6136393|NCT01000506|9766154|FG002|Overall Study|Withdrawal by Subject|2
6136394|NCT01000506|9766155|FG003|Overall Study|Withdrawal by Subject|7
6136395|NCT01000610|9766165|FG000|Overall Study|Adverse Event|1
6136396|NCT01000610|9766165|FG000|Overall Study|Lost to Follow-up|4
6136397|NCT01000610|9766165|FG000|Overall Study|Treatment failure|1
6290859|NCT02404441|10007278|FG006|Phase 2 Part|Progressive disease|32
6290860|NCT02404441|10007279|FG007|Phase 2 Part|Progressive disease|31
6290861|NCT02404441|10007280|FG008|Phase 2 Part|Progressive disease|39
6290862|NCT02404441|10007281|FG009|Phase 2 Part|Progressive disease|27
6290863|NCT02404441|10007272|FG000|Phase 2 Part|Subject/guardian decision|0
6290864|NCT02404441|10007273|FG001|Phase 2 Part|Subject/guardian decision|0
6290865|NCT02404441|10007274|FG002|Phase 2 Part|Subject/guardian decision|0
6290866|NCT02404441|10007275|FG003|Phase 2 Part|Subject/guardian decision|0
6290867|NCT02404441|10007276|FG004|Phase 2 Part|Subject/guardian decision|0
6290868|NCT02404441|10007277|FG005|Phase 2 Part|Subject/guardian decision|3
6290869|NCT02404441|10007278|FG006|Phase 2 Part|Subject/guardian decision|9
6290870|NCT02404441|10007279|FG007|Phase 2 Part|Subject/guardian decision|0
6290871|NCT02404441|10007280|FG008|Phase 2 Part|Subject/guardian decision|3
6290872|NCT02404441|10007281|FG009|Phase 2 Part|Subject/guardian decision|2
6290873|NCT02404441|10007272|FG000|Phase 2 Part|Death|0
6290874|NCT02404441|10007273|FG001|Phase 2 Part|Death|0
6136398|NCT01000636|9766169|FG000|Overall Study|Withdrawal by Subject|1
6290875|NCT02404441|10007274|FG002|Phase 2 Part|Death|0
6290876|NCT02404441|10007275|FG003|Phase 2 Part|Death|0
6290877|NCT02404441|10007276|FG004|Phase 2 Part|Death|0
6290878|NCT02404441|10007277|FG005|Phase 2 Part|Death|4
6290879|NCT02404441|10007278|FG006|Phase 2 Part|Death|8
6290880|NCT02404441|10007279|FG007|Phase 2 Part|Death|4
6290881|NCT02404441|10007280|FG008|Phase 2 Part|Death|10
6290882|NCT02404441|10007281|FG009|Phase 2 Part|Death|9
6290883|NCT02404493|10007327|FG000|Overall Study|Adverse Event|1
6290884|NCT02404493|10007328|FG001|Overall Study|Adverse Event|1
6290885|NCT02404649|10007354|FG000|Overall Study|Adverse Event|1
6290886|NCT02404649|10007355|FG001|Overall Study|Adverse Event|2
6290887|NCT02404805|10007378|FG000|Overall Study|Withdrawal by Subject|1
6290888|NCT02404805|10007379|FG001|Overall Study|Withdrawal by Subject|0
6290889|NCT02404805|10007380|FG002|Overall Study|Withdrawal by Subject|0
6290890|NCT02404805|10007381|FG003|Overall Study|Withdrawal by Subject|0
6290891|NCT02404805|10007382|FG004|Overall Study|Withdrawal by Subject|0
6290892|NCT02404805|10007383|FG005|Overall Study|Withdrawal by Subject|0
6290893|NCT02405091|10007395|FG000|Overall Study|Adverse Event|16
6290894|NCT02405091|10007396|FG001|Overall Study|Adverse Event|10
6290895|NCT02405091|10007397|FG002|Overall Study|Adverse Event|0
6290896|NCT02405091|10007395|FG000|Overall Study|Protocol Violation|1
6290897|NCT02405091|10007396|FG001|Overall Study|Protocol Violation|0
6290898|NCT02405091|10007397|FG002|Overall Study|Protocol Violation|0
6290899|NCT02405091|10007395|FG000|Overall Study|Noncompliance|1
6290900|NCT02405091|10007396|FG001|Overall Study|Noncompliance|6
6290901|NCT02405091|10007397|FG002|Overall Study|Noncompliance|2
6290902|NCT02405091|10007395|FG000|Overall Study|Withdrawal by Subject|4
6290903|NCT02405091|10007396|FG001|Overall Study|Withdrawal by Subject|8
6290904|NCT02405091|10007397|FG002|Overall Study|Withdrawal by Subject|0
6290905|NCT02405091|10007395|FG000|Overall Study|Death|0
6290906|NCT02405091|10007396|FG001|Overall Study|Death|1
6290907|NCT02405091|10007397|FG002|Overall Study|Death|0
6290908|NCT02405091|10007395|FG000|Overall Study|Lost to Follow-up|5
6290909|NCT02405091|10007396|FG001|Overall Study|Lost to Follow-up|6
6290910|NCT02405091|10007397|FG002|Overall Study|Lost to Follow-up|0
6290911|NCT02405091|10007395|FG000|Overall Study|Physician Decision|2
6290912|NCT02405091|10007396|FG001|Overall Study|Physician Decision|2
6290913|NCT02405091|10007397|FG002|Overall Study|Physician Decision|0
6290914|NCT02405442|10007438|FG000|Double-Blind Phase (up to Week 8)|Adverse Event|0
6290915|NCT02405442|10007439|FG001|Double-Blind Phase (up to Week 8)|Adverse Event|2
6290916|NCT02405442|10007440|FG002|Double-Blind Phase (up to Week 8)|Adverse Event|4
6290917|NCT02405442|10007441|FG003|Double-Blind Phase (up to Week 8)|Adverse Event|1
6290918|NCT02405442|10007438|FG000|Double-Blind Phase (up to Week 8)|Withdrew Consent|0
6290919|NCT02405442|10007439|FG001|Double-Blind Phase (up to Week 8)|Withdrew Consent|1
6290920|NCT02405442|10007440|FG002|Double-Blind Phase (up to Week 8)|Withdrew Consent|2
6290921|NCT02405442|10007441|FG003|Double-Blind Phase (up to Week 8)|Withdrew Consent|0
6290922|NCT02405442|10007438|FG000|Double-Blind Phase (up to Week 8)|Study Disease-Related Symptoms|1
6290923|NCT02405442|10007439|FG001|Double-Blind Phase (up to Week 8)|Study Disease-Related Symptoms|1
6290924|NCT02405442|10007440|FG002|Double-Blind Phase (up to Week 8)|Study Disease-Related Symptoms|0
6290925|NCT02405442|10007441|FG003|Double-Blind Phase (up to Week 8)|Study Disease-Related Symptoms|0
6290926|NCT02405442|10007438|FG000|Double-Blind Phase (up to Week 8)|Investigator's Discretion|0
6290927|NCT02405442|10007439|FG001|Double-Blind Phase (up to Week 8)|Investigator's Discretion|1
6290928|NCT02405442|10007440|FG002|Double-Blind Phase (up to Week 8)|Investigator's Discretion|0
6290929|NCT02405442|10007441|FG003|Double-Blind Phase (up to Week 8)|Investigator's Discretion|0
6290930|NCT02405442|10007438|FG000|Open-Label Phase (up to Week 52)|Study Terminated by Sponsor|27
6290931|NCT02405442|10007439|FG001|Open-Label Phase (up to Week 52)|Study Terminated by Sponsor|28
6290932|NCT02405442|10007440|FG002|Open-Label Phase (up to Week 52)|Study Terminated by Sponsor|28
6290933|NCT02405442|10007441|FG003|Open-Label Phase (up to Week 52)|Study Terminated by Sponsor|13
6290934|NCT02405442|10007438|FG000|Open-Label Phase (up to Week 52)|Investigator's Discretion|14
6290935|NCT02405442|10007439|FG001|Open-Label Phase (up to Week 52)|Investigator's Discretion|11
6290936|NCT02405442|10007440|FG002|Open-Label Phase (up to Week 52)|Investigator's Discretion|11
6290937|NCT02405442|10007441|FG003|Open-Label Phase (up to Week 52)|Investigator's Discretion|2
6290938|NCT02405442|10007438|FG000|Open-Label Phase (up to Week 52)|Adverse Event|6
6290939|NCT02405442|10007439|FG001|Open-Label Phase (up to Week 52)|Adverse Event|1
6290940|NCT02405442|10007440|FG002|Open-Label Phase (up to Week 52)|Adverse Event|2
6290941|NCT02405442|10007441|FG003|Open-Label Phase (up to Week 52)|Adverse Event|6
6290942|NCT02405442|10007438|FG000|Open-Label Phase (up to Week 52)|Study Disease-Related Symptoms|0
6290943|NCT02405442|10007439|FG001|Open-Label Phase (up to Week 52)|Study Disease-Related Symptoms|1
6290944|NCT02405442|10007440|FG002|Open-Label Phase (up to Week 52)|Study Disease-Related Symptoms|3
6290945|NCT02405442|10007441|FG003|Open-Label Phase (up to Week 52)|Study Disease-Related Symptoms|2
6290946|NCT02405442|10007438|FG000|Open-Label Phase (up to Week 52)|Withdrew Consent|1
6290947|NCT02405442|10007439|FG001|Open-Label Phase (up to Week 52)|Withdrew Consent|2
6290948|NCT02405442|10007440|FG002|Open-Label Phase (up to Week 52)|Withdrew Consent|1
6290949|NCT02405442|10007441|FG003|Open-Label Phase (up to Week 52)|Withdrew Consent|1
6290950|NCT02405442|10007438|FG000|Open-Label Phase (up to Week 52)|Lack of Efficacy|0
6136399|NCT01000636|9766169|FG000|Overall Study|Adverse Event|1
6136400|NCT01000649|9766177|FG000|Overall Study|Adverse Event|5
6136401|NCT01000649|9766178|FG001|Overall Study|Adverse Event|1
6136402|NCT01000649|9766179|FG002|Overall Study|Adverse Event|2
6136403|NCT01000649|9766180|FG003|Overall Study|Adverse Event|4
6136404|NCT01000649|9766177|FG000|Overall Study|Lost to Follow-up|0
6136405|NCT01000649|9766178|FG001|Overall Study|Lost to Follow-up|2
6136406|NCT01000649|9766179|FG002|Overall Study|Lost to Follow-up|0
6136407|NCT01000649|9766180|FG003|Overall Study|Lost to Follow-up|2
6136408|NCT01000727|9766202|FG000|Overall Study|Lost to Follow-up|41
6136409|NCT01000727|9766203|FG001|Overall Study|Lost to Follow-up|43
6136410|NCT01000727|9766202|FG000|Overall Study|Withdrawal by Subject|111
6136411|NCT01000727|9766203|FG001|Overall Study|Withdrawal by Subject|109
6136412|NCT01000727|9766202|FG000|Overall Study|Study closed/terminated|23
6136413|NCT01000727|9766203|FG001|Overall Study|Study closed/terminated|24
6136414|NCT01000805|9766213|FG000|Overall Study|Adverse Event|21
6136415|NCT01000805|9766214|FG001|Overall Study|Adverse Event|9
6136416|NCT01000805|9766213|FG000|Overall Study|Lack of Efficacy|5
6136417|NCT01000805|9766214|FG001|Overall Study|Lack of Efficacy|16
6136418|NCT01000805|9766213|FG000|Overall Study|Lost to Follow-up|16
6136419|NCT01000805|9766214|FG001|Overall Study|Lost to Follow-up|21
6290951|NCT02405442|10007439|FG001|Open-Label Phase (up to Week 52)|Lack of Efficacy|1
6290952|NCT02405442|10007440|FG002|Open-Label Phase (up to Week 52)|Lack of Efficacy|0
6290953|NCT02405442|10007441|FG003|Open-Label Phase (up to Week 52)|Lack of Efficacy|0
6290954|NCT02405442|10007438|FG000|Open-Label Phase (up to Week 52)|Lost to Follow-up|0
6290955|NCT02405442|10007439|FG001|Open-Label Phase (up to Week 52)|Lost to Follow-up|1
6290956|NCT02405442|10007440|FG002|Open-Label Phase (up to Week 52)|Lost to Follow-up|0
6290957|NCT02405442|10007441|FG003|Open-Label Phase (up to Week 52)|Lost to Follow-up|0
6290958|NCT02405442|10007438|FG000|Extended Treatment Phase(up to Week 208)|Study Terminated by Sponsor|2
6290959|NCT02405442|10007439|FG001|Extended Treatment Phase(up to Week 208)|Study Terminated by Sponsor|1
6290960|NCT02405442|10007440|FG002|Extended Treatment Phase(up to Week 208)|Study Terminated by Sponsor|2
6290961|NCT02405442|10007441|FG003|Extended Treatment Phase(up to Week 208)|Study Terminated by Sponsor|2
6290962|NCT02405442|10007438|FG000|Extended Treatment Phase(up to Week 208)|Investigator's Discretion|0
6290963|NCT02405442|10007439|FG001|Extended Treatment Phase(up to Week 208)|Investigator's Discretion|1
6290964|NCT02405442|10007440|FG002|Extended Treatment Phase(up to Week 208)|Investigator's Discretion|0
6290965|NCT02405442|10007441|FG003|Extended Treatment Phase(up to Week 208)|Investigator's Discretion|0
6290966|NCT02405442|10007438|FG000|Extended Treatment Phase(up to Week 208)|Study Disease-Related Symptoms|1
6290967|NCT02405442|10007439|FG001|Extended Treatment Phase(up to Week 208)|Study Disease-Related Symptoms|0
6290968|NCT02405442|10007440|FG002|Extended Treatment Phase(up to Week 208)|Study Disease-Related Symptoms|0
6290969|NCT02405442|10007441|FG003|Extended Treatment Phase(up to Week 208)|Study Disease-Related Symptoms|0
6290970|NCT02405780|10007459|FG000|Period I|Adverse Event|8
6290971|NCT02405780|10007460|FG001|Period I|Adverse Event|0
6290972|NCT02405780|10007461|FG002|Period I|Adverse Event|3
6290973|NCT02405780|10007462|FG003|Period I|Adverse Event|7
6290974|NCT02405780|10007459|FG000|Period I|Medical reasons|1
6290975|NCT02405780|10007460|FG001|Period I|Medical reasons|1
6290976|NCT02405780|10007461|FG002|Period I|Medical reasons|0
6290977|NCT02405780|10007462|FG003|Period I|Medical reasons|1
6290978|NCT02405780|10007459|FG000|Period I|Screening Failure|1
6290979|NCT02405780|10007460|FG001|Period I|Screening Failure|0
6290980|NCT02405780|10007461|FG002|Period I|Screening Failure|1
6290981|NCT02405780|10007462|FG003|Period I|Screening Failure|0
6290982|NCT02405780|10007459|FG000|Period I|Withdrawal by Subject|9
6290983|NCT02405780|10007460|FG001|Period I|Withdrawal by Subject|1
6290984|NCT02405780|10007461|FG002|Period I|Withdrawal by Subject|3
6290985|NCT02405780|10007462|FG003|Period I|Withdrawal by Subject|4
6290986|NCT02405780|10007459|FG000|Period I|Non-compliance with study procedures|8
6290987|NCT02405780|10007460|FG001|Period I|Non-compliance with study procedures|6
6290988|NCT02405780|10007461|FG002|Period I|Non-compliance with study procedures|8
6290989|NCT02405780|10007462|FG003|Period I|Non-compliance with study procedures|11
6290990|NCT02405780|10007459|FG000|Period II|Adverse Event|3
6290991|NCT02405780|10007460|FG001|Period II|Adverse Event|5
6290992|NCT02405780|10007461|FG002|Period II|Adverse Event|4
6290993|NCT02405780|10007462|FG003|Period II|Adverse Event|11
6290994|NCT02405780|10007459|FG000|Period II|Medical reason|0
6290995|NCT02405780|10007460|FG001|Period II|Medical reason|1
6290996|NCT02405780|10007461|FG002|Period II|Medical reason|0
6290997|NCT02405780|10007462|FG003|Period II|Medical reason|0
6290998|NCT02405780|10007459|FG000|Period II|Pregnancy|0
6290999|NCT02405780|10007460|FG001|Period II|Pregnancy|0
6291000|NCT02405780|10007461|FG002|Period II|Pregnancy|1
6291001|NCT02405780|10007462|FG003|Period II|Pregnancy|0
6291002|NCT02405780|10007459|FG000|Period II|Withdrawal by Subject|7
6291003|NCT02405780|10007460|FG001|Period II|Withdrawal by Subject|4
6291004|NCT02405780|10007461|FG002|Period II|Withdrawal by Subject|0
6291005|NCT02405780|10007462|FG003|Period II|Withdrawal by Subject|3
6291006|NCT02405780|10007459|FG000|Period II|Non-compliance with study procedures|5
6291007|NCT02405780|10007460|FG001|Period II|Non-compliance with study procedures|2
6291008|NCT02405780|10007461|FG002|Period II|Non-compliance with study procedures|7
6291009|NCT02405780|10007462|FG003|Period II|Non-compliance with study procedures|4
6136420|NCT01000805|9766213|FG000|Overall Study|Physician Decision|0
6136421|NCT01000805|9766214|FG001|Overall Study|Physician Decision|1
6136422|NCT01000805|9766213|FG000|Overall Study|Protocol Violation|12
6136423|NCT01000805|9766214|FG001|Overall Study|Protocol Violation|8
6136424|NCT01000805|9766213|FG000|Overall Study|Withdrawal by Subject|16
5981159|NCT02224573|9570090|FG001|Treatment Phase|Refused Medication|1
5981160|NCT02224573|9570089|FG000|Treatment Phase|Adverse Event|26
5981161|NCT02224573|9570090|FG001|Treatment Phase|Adverse Event|38
5981162|NCT02224573|9570089|FG000|Treatment Phase|Placed in Group Home|0
5981163|NCT02224573|9570090|FG001|Treatment Phase|Placed in Group Home|1
5981164|NCT02224573|9570089|FG000|Treatment Phase|Pursued Other Trials|1
5981165|NCT02224573|9570090|FG001|Treatment Phase|Pursued Other Trials|0
5981166|NCT02224573|9570089|FG000|Treatment Phase|Withdrawn by the Investigator|23
5981167|NCT02224573|9570090|FG001|Treatment Phase|Withdrawn by the Investigator|11
6136425|NCT01000805|9766214|FG001|Overall Study|Withdrawal by Subject|6
6136426|NCT01000805|9766213|FG000|Overall Study|Sponsor Decision|0
6136427|NCT01000805|9766214|FG001|Overall Study|Sponsor Decision|1
6136428|NCT01000961|9766230|FG000|First Intervention (3 Weeks)|Withdrawal by Subject|0
6136429|NCT01000961|9766231|FG001|First Intervention (3 Weeks)|Withdrawal by Subject|1
6136430|NCT01000961|9766230|FG000|First Intervention (3 Weeks)|Infection after pre-planned surgery|0
6136431|NCT01000961|9766231|FG001|First Intervention (3 Weeks)|Infection after pre-planned surgery|1
6136432|NCT01000974|9766242|FG000|Primary Vaccination Phase|Withdrawal by Subject|109
6136433|NCT01000974|9766243|FG001|Primary Vaccination Phase|Withdrawal by Subject|17
6136434|NCT01000974|9766244|FG002|Primary Vaccination Phase|Withdrawal by Subject|21
6136435|NCT01000974|9766242|FG000|Primary Vaccination Phase|Lost to Follow-up|171
6136436|NCT01000974|9766243|FG001|Primary Vaccination Phase|Lost to Follow-up|19
6136437|NCT01000974|9766244|FG002|Primary Vaccination Phase|Lost to Follow-up|26
6136438|NCT01000974|9766242|FG000|Primary Vaccination Phase|Protocol Violation|40
6136439|NCT01000974|9766243|FG001|Primary Vaccination Phase|Protocol Violation|3
6136440|NCT01000974|9766244|FG002|Primary Vaccination Phase|Protocol Violation|2
6136441|NCT01000974|9766242|FG000|Primary Vaccination Phase|Adverse Event|14
6136442|NCT01000974|9766243|FG001|Primary Vaccination Phase|Adverse Event|2
6136443|NCT01000974|9766244|FG002|Primary Vaccination Phase|Adverse Event|2
6136444|NCT01000974|9766242|FG000|Primary Vaccination Phase|Other|4
6136445|NCT01000974|9766243|FG001|Primary Vaccination Phase|Other|9
6136446|NCT01000974|9766244|FG002|Primary Vaccination Phase|Other|12
6136447|NCT01000974|9766242|FG000|Booster Vaccination Phase|Protocol Violation|0
6136448|NCT01000974|9766243|FG001|Booster Vaccination Phase|Protocol Violation|0
6136449|NCT01000974|9766244|FG002|Booster Vaccination Phase|Protocol Violation|2
6136450|NCT01000974|9766242|FG000|Booster Vaccination Phase|Withdrawal by Subject|3
6136451|NCT01000974|9766243|FG001|Booster Vaccination Phase|Withdrawal by Subject|1
6136452|NCT01000974|9766244|FG002|Booster Vaccination Phase|Withdrawal by Subject|1
6291010|NCT02405962|10007489|FG000|Overall Study|Lost to Follow-up|1
6291011|NCT02405962|10007490|FG001|Overall Study|Lost to Follow-up|4
6136453|NCT01000974|9766242|FG000|Booster Vaccination Phase|Lost to Follow-up|40
6136454|NCT01000974|9766243|FG001|Booster Vaccination Phase|Lost to Follow-up|5
6136455|NCT01000974|9766244|FG002|Booster Vaccination Phase|Lost to Follow-up|7
6136456|NCT01000974|9766242|FG000|Booster Vaccination Phase|Other|24
6136457|NCT01000974|9766243|FG001|Booster Vaccination Phase|Other|6
6136458|NCT01000974|9766244|FG002|Booster Vaccination Phase|Other|4
6136459|NCT01001104|9766290|FG000|Overall Study|Adverse Event|2
6136460|NCT01001104|9766291|FG001|Overall Study|Adverse Event|1
6136461|NCT01001104|9766292|FG002|Overall Study|Adverse Event|0
6136462|NCT01001104|9766293|FG003|Overall Study|Adverse Event|0
6136463|NCT01001104|9766290|FG000|Overall Study|Lost to Follow-up|0
6136464|NCT01001104|9766291|FG001|Overall Study|Lost to Follow-up|0
6136465|NCT01001104|9766292|FG002|Overall Study|Lost to Follow-up|1
6136466|NCT01001104|9766293|FG003|Overall Study|Lost to Follow-up|0
6136467|NCT01001104|9766290|FG000|Overall Study|Entry Criteria Not Met|0
6136468|NCT01001104|9766291|FG001|Overall Study|Entry Criteria Not Met|0
6136469|NCT01001104|9766292|FG002|Overall Study|Entry Criteria Not Met|0
6136470|NCT01001104|9766293|FG003|Overall Study|Entry Criteria Not Met|1
6136471|NCT01001104|9766290|FG000|Overall Study|Withdrawal by Subject|0
6136472|NCT01001104|9766291|FG001|Overall Study|Withdrawal by Subject|0
6136473|NCT01001104|9766292|FG002|Overall Study|Withdrawal by Subject|0
6136474|NCT01001104|9766293|FG003|Overall Study|Withdrawal by Subject|2
6136475|NCT01001169|9766308|FG000|Overall Study|Withdrawal by Subject|2
6136476|NCT01001169|9766309|FG001|Overall Study|Withdrawal by Subject|1
6136477|NCT01001208|9766342|FG000|Overall Study|Adverse Event|10
6136478|NCT01001208|9766343|FG001|Overall Study|Adverse Event|5
6136479|NCT01001208|9766342|FG000|Overall Study|Lost to Follow-up|5
6136480|NCT01001208|9766343|FG001|Overall Study|Lost to Follow-up|9
6136481|NCT01001208|9766342|FG000|Overall Study|Physician Decision|1
6136482|NCT01001208|9766343|FG001|Overall Study|Physician Decision|0
6136483|NCT01001208|9766342|FG000|Overall Study|Withdrawal by Subject|4
6136484|NCT01001208|9766343|FG001|Overall Study|Withdrawal by Subject|5
6136485|NCT01001208|9766342|FG000|Overall Study|Ineligibility Determined|4
6136486|NCT01001208|9766343|FG001|Overall Study|Ineligibility Determined|2
6136487|NCT01001208|9766342|FG000|Overall Study|Noncompliance|4
6291012|NCT02405962|10007489|FG000|Overall Study|A participant has moved to another place|0
6136488|NCT01001208|9766343|FG001|Overall Study|Noncompliance|7
6136489|NCT01001208|9766342|FG000|Overall Study|Disease Progression|0
6136490|NCT01001208|9766343|FG001|Overall Study|Disease Progression|3
6136491|NCT01001208|9766342|FG000|Overall Study|Other|0
6136492|NCT01001208|9766343|FG001|Overall Study|Other|2
6136493|NCT01001221|9766353|FG000|Overall Study|Adverse Event|1
6136494|NCT01001221|9766354|FG001|Overall Study|Adverse Event|2
6136495|NCT01001221|9766355|FG002|Overall Study|Adverse Event|0
6136496|NCT01001221|9766356|FG003|Overall Study|Adverse Event|2
6136497|NCT01001221|9766357|FG004|Overall Study|Adverse Event|0
6136498|NCT01001221|9766353|FG000|Overall Study|Disease progression|3
6136499|NCT01001221|9766354|FG001|Overall Study|Disease progression|2
6291013|NCT02405962|10007490|FG001|Overall Study|A participant has moved to another place|1
6291014|NCT02406027|10007499|FG000|Double-blind Treatment Phase (Period 1)|Adverse Event|0
6291015|NCT02406027|10007500|FG001|Double-blind Treatment Phase (Period 1)|Adverse Event|2
6291016|NCT02406027|10007501|FG002|Double-blind Treatment Phase (Period 1)|Adverse Event|1
6291017|NCT02406027|10007502|FG003|Double-blind Treatment Phase (Period 1)|Adverse Event|0
6291018|NCT02406027|10007503|FG004|Double-blind Treatment Phase (Period 1)|Adverse Event|0
6291019|NCT02406027|10007504|FG005|Double-blind Treatment Phase (Period 1)|Adverse Event|0
6291020|NCT02406027|10007505|FG006|Double-blind Treatment Phase (Period 1)|Adverse Event|0
6291021|NCT02406027|10007499|FG000|Double-blind Treatment Phase (Period 1)|Physician Decision|3
6291022|NCT02406027|10007500|FG001|Double-blind Treatment Phase (Period 1)|Physician Decision|0
6291023|NCT02406027|10007501|FG002|Double-blind Treatment Phase (Period 1)|Physician Decision|1
6291024|NCT02406027|10007502|FG003|Double-blind Treatment Phase (Period 1)|Physician Decision|0
6291025|NCT02406027|10007503|FG004|Double-blind Treatment Phase (Period 1)|Physician Decision|0
6291026|NCT02406027|10007504|FG005|Double-blind Treatment Phase (Period 1)|Physician Decision|0
6291027|NCT02406027|10007505|FG006|Double-blind Treatment Phase (Period 1)|Physician Decision|0
6291028|NCT02406027|10007499|FG000|Double-blind Treatment Phase (Period 1)|Withdrawal by Subject|2
6291029|NCT02406027|10007500|FG001|Double-blind Treatment Phase (Period 1)|Withdrawal by Subject|1
6291030|NCT02406027|10007501|FG002|Double-blind Treatment Phase (Period 1)|Withdrawal by Subject|1
6291031|NCT02406027|10007502|FG003|Double-blind Treatment Phase (Period 1)|Withdrawal by Subject|0
6291032|NCT02406027|10007503|FG004|Double-blind Treatment Phase (Period 1)|Withdrawal by Subject|0
6291033|NCT02406027|10007504|FG005|Double-blind Treatment Phase (Period 1)|Withdrawal by Subject|0
6291034|NCT02406027|10007505|FG006|Double-blind Treatment Phase (Period 1)|Withdrawal by Subject|0
6291035|NCT02406027|10007499|FG000|Double-blind Treatment Phase (Period 1)|Subject Refused Further Study Treatment|1
6291036|NCT02406027|10007500|FG001|Double-blind Treatment Phase (Period 1)|Subject Refused Further Study Treatment|0
6291037|NCT02406027|10007501|FG002|Double-blind Treatment Phase (Period 1)|Subject Refused Further Study Treatment|1
6291038|NCT02406027|10007502|FG003|Double-blind Treatment Phase (Period 1)|Subject Refused Further Study Treatment|0
6291039|NCT02406027|10007503|FG004|Double-blind Treatment Phase (Period 1)|Subject Refused Further Study Treatment|0
6291040|NCT02406027|10007504|FG005|Double-blind Treatment Phase (Period 1)|Subject Refused Further Study Treatment|0
6291041|NCT02406027|10007505|FG006|Double-blind Treatment Phase (Period 1)|Subject Refused Further Study Treatment|0
6291042|NCT02406027|10007499|FG000|Open-label Phase (Period 2)|Adverse Event|0
6291043|NCT02406027|10007500|FG001|Open-label Phase (Period 2)|Adverse Event|0
6291044|NCT02406027|10007501|FG002|Open-label Phase (Period 2)|Adverse Event|0
6291045|NCT02406027|10007502|FG003|Open-label Phase (Period 2)|Adverse Event|2
6291046|NCT02406027|10007503|FG004|Open-label Phase (Period 2)|Adverse Event|2
6291047|NCT02406027|10007504|FG005|Open-label Phase (Period 2)|Adverse Event|0
6291048|NCT02406027|10007505|FG006|Open-label Phase (Period 2)|Adverse Event|0
6291049|NCT02406027|10007499|FG000|Open-label Phase (Period 2)|Physician Decision|0
6291050|NCT02406027|10007500|FG001|Open-label Phase (Period 2)|Physician Decision|0
6291051|NCT02406027|10007501|FG002|Open-label Phase (Period 2)|Physician Decision|0
6291052|NCT02406027|10007502|FG003|Open-label Phase (Period 2)|Physician Decision|0
6291053|NCT02406027|10007503|FG004|Open-label Phase (Period 2)|Physician Decision|0
6291054|NCT02406027|10007504|FG005|Open-label Phase (Period 2)|Physician Decision|1
6291055|NCT02406027|10007505|FG006|Open-label Phase (Period 2)|Physician Decision|1
6291056|NCT02406027|10007499|FG000|Open-label Phase (Period 2)|Withdrawal by Subject|0
6291057|NCT02406027|10007500|FG001|Open-label Phase (Period 2)|Withdrawal by Subject|0
6291058|NCT02406027|10007501|FG002|Open-label Phase (Period 2)|Withdrawal by Subject|0
6291059|NCT02406027|10007502|FG003|Open-label Phase (Period 2)|Withdrawal by Subject|2
6291060|NCT02406027|10007503|FG004|Open-label Phase (Period 2)|Withdrawal by Subject|4
6291061|NCT02406027|10007504|FG005|Open-label Phase (Period 2)|Withdrawal by Subject|0
6291062|NCT02406027|10007505|FG006|Open-label Phase (Period 2)|Withdrawal by Subject|2
6291063|NCT02406027|10007499|FG000|Open-label Phase (Period 2)|Study Terminated by Sponsor|0
6291064|NCT02406027|10007500|FG001|Open-label Phase (Period 2)|Study Terminated by Sponsor|0
6291065|NCT02406027|10007501|FG002|Open-label Phase (Period 2)|Study Terminated by Sponsor|0
6291066|NCT02406027|10007502|FG003|Open-label Phase (Period 2)|Study Terminated by Sponsor|11
6291067|NCT02406027|10007503|FG004|Open-label Phase (Period 2)|Study Terminated by Sponsor|7
6291068|NCT02406027|10007504|FG005|Open-label Phase (Period 2)|Study Terminated by Sponsor|24
6291069|NCT02406027|10007505|FG006|Open-label Phase (Period 2)|Study Terminated by Sponsor|19
6291070|NCT02406027|10007499|FG000|Open-label Phase (Period 2)|At Spouse Request With PI Agreement|0
6291071|NCT02406027|10007500|FG001|Open-label Phase (Period 2)|At Spouse Request With PI Agreement|0
6291072|NCT02406027|10007501|FG002|Open-label Phase (Period 2)|At Spouse Request With PI Agreement|0
5981168|NCT02224573|9570089|FG000|Treatment Phase|Lost to Follow-up|2
6136500|NCT01001221|9766355|FG002|Overall Study|Disease progression|2
6136501|NCT01001221|9766356|FG003|Overall Study|Disease progression|4
6136502|NCT01001221|9766357|FG004|Overall Study|Disease progression|0
6136503|NCT01001221|9766353|FG000|Overall Study|Other|1
6136504|NCT01001221|9766354|FG001|Overall Study|Other|1
6136505|NCT01001221|9766355|FG002|Overall Study|Other|0
6136506|NCT01001221|9766356|FG003|Overall Study|Other|0
6136507|NCT01001221|9766357|FG004|Overall Study|Other|0
6136508|NCT01001221|9766353|FG000|Overall Study|Not treated; protocol exclusion|0
6136509|NCT01001221|9766354|FG001|Overall Study|Not treated; protocol exclusion|0
6136510|NCT01001221|9766355|FG002|Overall Study|Not treated; protocol exclusion|1
6136511|NCT01001221|9766356|FG003|Overall Study|Not treated; protocol exclusion|0
6136512|NCT01001221|9766357|FG004|Overall Study|Not treated; protocol exclusion|0
6136513|NCT01001299|9766368|FG000|Overall Study|Insufficient Therapeutic Response|20
6136514|NCT01001299|9766368|FG000|Overall Study|Adverse event or Intercurrent Illness|1
6136515|NCT01001299|9766368|FG000|Overall Study|Death|1
6136516|NCT01001299|9766368|FG000|Overall Study|Began Taking Commercially Available Drug|2
6136517|NCT01001299|9766368|FG000|Overall Study|Withdrew Consent|1
6136518|NCT01001325|9766374|FG000|Overall Study|Lost to Follow-up|16
6136519|NCT01001325|9766375|FG001|Overall Study|Lost to Follow-up|10
6136520|NCT01001325|9766374|FG000|Overall Study|Protocol Violation|2
6136521|NCT01001325|9766375|FG001|Overall Study|Protocol Violation|0
6136522|NCT01001377|9766383|FG000|Overall Study|Ineligibility determined|2
6136523|NCT01001377|9766384|FG001|Overall Study|Ineligibility determined|0
6136524|NCT01001377|9766383|FG000|Overall Study|Withdrawal by Subject|19
6136525|NCT01001377|9766384|FG001|Overall Study|Withdrawal by Subject|20
6136526|NCT01001377|9766383|FG000|Overall Study|Lost to Follow-up|14
6136527|NCT01001377|9766384|FG001|Overall Study|Lost to Follow-up|17
6136528|NCT01001377|9766383|FG000|Overall Study|Death|391
6136529|NCT01001377|9766384|FG001|Overall Study|Death|384
6136530|NCT01001429|9766401|FG000|Overall Study|surgery cancelled|0
6136531|NCT01001429|9766402|FG001|Overall Study|surgery cancelled|1
6136532|NCT01001494|9766472|FG000|Overall Study|Adverse Event|8
6136533|NCT01001494|9766473|FG001|Overall Study|Adverse Event|4
6136534|NCT01001494|9766474|FG002|Overall Study|Adverse Event|6
6136535|NCT01001494|9766472|FG000|Overall Study|Protocol Violation|0
6136536|NCT01001494|9766473|FG001|Overall Study|Protocol Violation|1
6136537|NCT01001494|9766474|FG002|Overall Study|Protocol Violation|1
6136538|NCT01001494|9766472|FG000|Overall Study|Lost to Follow-up|2
6136539|NCT01001494|9766473|FG001|Overall Study|Lost to Follow-up|0
6136540|NCT01001494|9766474|FG002|Overall Study|Lost to Follow-up|1
6136541|NCT01001494|9766472|FG000|Overall Study|Withdrawal by Subject|9
6136542|NCT01001494|9766473|FG001|Overall Study|Withdrawal by Subject|7
6136543|NCT01001494|9766474|FG002|Overall Study|Withdrawal by Subject|17
6136544|NCT01001494|9766472|FG000|Overall Study|COPD exacerbation|3
6136545|NCT01001494|9766473|FG001|Overall Study|COPD exacerbation|4
6136546|NCT01001494|9766474|FG002|Overall Study|COPD exacerbation|5
6136547|NCT01001494|9766472|FG000|Overall Study|Lack of Efficacy|2
6136548|NCT01001494|9766473|FG001|Overall Study|Lack of Efficacy|0
6136549|NCT01001494|9766474|FG002|Overall Study|Lack of Efficacy|8
6136550|NCT01001494|9766472|FG000|Overall Study|Other|0
6136551|NCT01001494|9766473|FG001|Overall Study|Other|1
6136552|NCT01001494|9766474|FG002|Overall Study|Other|3
6136553|NCT01001520|9766482|FG000|Medication Period 1|Withdrawal by Subject|2
6136554|NCT01001520|9766483|FG001|Medication Period 1|Withdrawal by Subject|2
6136555|NCT01001520|9766482|FG000|Medication Period 1|Ineligible: Positive Urine Drug Screen|0
6136556|NCT01001520|9766483|FG001|Medication Period 1|Ineligible: Positive Urine Drug Screen|3
6136557|NCT01001520|9766482|FG000|Medication Period 1|Ineligible: fMRI contraindicated metal|0
6136558|NCT01001520|9766483|FG001|Medication Period 1|Ineligible: fMRI contraindicated metal|2
6136559|NCT01001520|9766482|FG000|Medication Period 1|Ineligible: Claustrophobia in fMRI|2
6136560|NCT01001520|9766483|FG001|Medication Period 1|Ineligible: Claustrophobia in fMRI|0
6136561|NCT01001520|9766482|FG000|Washout Period|Withdrawal by Subject|2
6136562|NCT01001520|9766483|FG001|Washout Period|Withdrawal by Subject|1
6136563|NCT01001520|9766482|FG000|Medication Period 2|Withdrawal by Subject|0
6291073|NCT02406027|10007502|FG003|Open-label Phase (Period 2)|At Spouse Request With PI Agreement|0
6291074|NCT02406027|10007503|FG004|Open-label Phase (Period 2)|At Spouse Request With PI Agreement|0
6291075|NCT02406027|10007504|FG005|Open-label Phase (Period 2)|At Spouse Request With PI Agreement|1
6291076|NCT02406027|10007505|FG006|Open-label Phase (Period 2)|At Spouse Request With PI Agreement|0
6291077|NCT02406027|10007499|FG000|Open-label Phase (Period 2)|Subject not Compliant to Study Procedure|0
6291078|NCT02406027|10007500|FG001|Open-label Phase (Period 2)|Subject not Compliant to Study Procedure|0
6291079|NCT02406027|10007501|FG002|Open-label Phase (Period 2)|Subject not Compliant to Study Procedure|0
6291080|NCT02406027|10007502|FG003|Open-label Phase (Period 2)|Subject not Compliant to Study Procedure|0
6136564|NCT01001520|9766483|FG001|Medication Period 2|Withdrawal by Subject|3
6136565|NCT01001572|9766512|FG000|Single-Blind Valsartan 160 mg|Withdrawal by Subject|32
6136566|NCT01001572|9766513|FG001|Single-Blind Valsartan 160 mg|Withdrawal by Subject|0
6136567|NCT01001572|9766514|FG002|Single-Blind Valsartan 160 mg|Withdrawal by Subject|0
6136568|NCT01001572|9766512|FG000|Single-Blind Valsartan 160 mg|Adverse Event|11
6136569|NCT01001572|9766513|FG001|Single-Blind Valsartan 160 mg|Adverse Event|0
6136570|NCT01001572|9766514|FG002|Single-Blind Valsartan 160 mg|Adverse Event|0
6136571|NCT01001572|9766512|FG000|Single-Blind Valsartan 160 mg|Abnormal Test Procedure Result(s)|96
6136572|NCT01001572|9766513|FG001|Single-Blind Valsartan 160 mg|Abnormal Test Procedure Result(s)|0
6136573|NCT01001572|9766514|FG002|Single-Blind Valsartan 160 mg|Abnormal Test Procedure Result(s)|0
6136574|NCT01001572|9766512|FG000|Single-Blind Valsartan 160 mg|Unsatisfactory therapeutic effect|7
6136575|NCT01001572|9766513|FG001|Single-Blind Valsartan 160 mg|Unsatisfactory therapeutic effect|0
6136576|NCT01001572|9766514|FG002|Single-Blind Valsartan 160 mg|Unsatisfactory therapeutic effect|0
6136577|NCT01001572|9766512|FG000|Single-Blind Valsartan 160 mg|Abnormal Laboratory Value|1
6136578|NCT01001572|9766513|FG001|Single-Blind Valsartan 160 mg|Abnormal Laboratory Value|0
6136579|NCT01001572|9766514|FG002|Single-Blind Valsartan 160 mg|Abnormal Laboratory Value|0
6136580|NCT01001572|9766512|FG000|Single-Blind Valsartan 160 mg|Lost to Follow-up|4
6136581|NCT01001572|9766513|FG001|Single-Blind Valsartan 160 mg|Lost to Follow-up|0
6136582|NCT01001572|9766514|FG002|Single-Blind Valsartan 160 mg|Lost to Follow-up|0
6136583|NCT01001572|9766512|FG000|Single-Blind Valsartan 160 mg|Administrative problems|82
6136584|NCT01001572|9766513|FG001|Single-Blind Valsartan 160 mg|Administrative problems|0
6136585|NCT01001572|9766514|FG002|Single-Blind Valsartan 160 mg|Administrative problems|0
6136586|NCT01001572|9766512|FG000|Single-Blind Valsartan 160 mg|Condition no longer requires study drug|45
6136587|NCT01001572|9766513|FG001|Single-Blind Valsartan 160 mg|Condition no longer requires study drug|0
6136588|NCT01001572|9766514|FG002|Single-Blind Valsartan 160 mg|Condition no longer requires study drug|0
6136589|NCT01001572|9766512|FG000|Double-Blind Treatment Phase|Adverse Event|0
6136590|NCT01001572|9766513|FG001|Double-Blind Treatment Phase|Adverse Event|2
6136591|NCT01001572|9766514|FG002|Double-Blind Treatment Phase|Adverse Event|2
6136592|NCT01001572|9766512|FG000|Double-Blind Treatment Phase|Withdrawal by Subject|0
6136593|NCT01001572|9766513|FG001|Double-Blind Treatment Phase|Withdrawal by Subject|8
6136594|NCT01001572|9766514|FG002|Double-Blind Treatment Phase|Withdrawal by Subject|13
6136595|NCT01001572|9766512|FG000|Double-Blind Treatment Phase|Abnormal test procedure result(s)|0
6136596|NCT01001572|9766513|FG001|Double-Blind Treatment Phase|Abnormal test procedure result(s)|0
6136597|NCT01001572|9766514|FG002|Double-Blind Treatment Phase|Abnormal test procedure result(s)|1
6136598|NCT01001572|9766512|FG000|Double-Blind Treatment Phase|Unsatisfactory therapeutic effect|0
6136599|NCT01001572|9766513|FG001|Double-Blind Treatment Phase|Unsatisfactory therapeutic effect|0
6136600|NCT01001572|9766514|FG002|Double-Blind Treatment Phase|Unsatisfactory therapeutic effect|1
6136601|NCT01001572|9766512|FG000|Double-Blind Treatment Phase|Protocol deviation|0
6136602|NCT01001572|9766513|FG001|Double-Blind Treatment Phase|Protocol deviation|0
6136603|NCT01001572|9766514|FG002|Double-Blind Treatment Phase|Protocol deviation|1
6136604|NCT01001572|9766512|FG000|Double-Blind Treatment Phase|Lost to Follow-up|0
6136605|NCT01001572|9766513|FG001|Double-Blind Treatment Phase|Lost to Follow-up|0
6136606|NCT01001572|9766514|FG002|Double-Blind Treatment Phase|Lost to Follow-up|1
6136607|NCT01001598|9766520|FG000|Overall Study|Hematopoietic Stem Cell Transplant|1
6136608|NCT01001598|9766520|FG000|Overall Study|Adverse Event|1
6136609|NCT01001702|9766524|FG000|Overall Study|Lost to Follow-up|7
6136610|NCT01001702|9766524|FG000|Overall Study|Adverse Event|7
6136611|NCT01001702|9766524|FG000|Overall Study|Sponsor Discontinued Study|4
6136612|NCT01001702|9766524|FG000|Overall Study|Subject met Withdrawal Criteria|22
6136613|NCT01001702|9766524|FG000|Overall Study|Investigator withdrew Subject|10
6136614|NCT01001702|9766524|FG000|Overall Study|Withdrawal by Subject|19
6136615|NCT01001702|9766524|FG000|Overall Study|Lack of Efficacy per Investigator|3
6136616|NCT01001767|9766530|FG000|Overall Study|no baseline study performed|1
6136617|NCT01001767|9766531|FG001|Overall Study|no baseline study performed|0
6136618|NCT01001767|9766530|FG000|Overall Study|Protocol Violation|1
6136619|NCT01001767|9766531|FG001|Overall Study|Protocol Violation|0
6136620|NCT01001767|9766530|FG000|Overall Study|Lost to Follow-up|1
6291081|NCT02406027|10007503|FG004|Open-label Phase (Period 2)|Subject not Compliant to Study Procedure|1
6291082|NCT02406027|10007504|FG005|Open-label Phase (Period 2)|Subject not Compliant to Study Procedure|0
6291083|NCT02406027|10007505|FG006|Open-label Phase (Period 2)|Subject not Compliant to Study Procedure|0
6291084|NCT02406248|10007521|FG000|Overall Study|Death|7
6291085|NCT02406248|10007521|FG000|Overall Study|Withdrawal by Subject|2
6291086|NCT02406261|10007527|FG000|Period 1|Lost to Follow-up|2
6291087|NCT02406261|10007528|FG001|Period 1|Lost to Follow-up|0
6291088|NCT02406261|10007527|FG000|Period 1|Adverse Event|1
6291089|NCT02406261|10007528|FG001|Period 1|Adverse Event|0
6291090|NCT02406261|10007527|FG000|Period 2|Physician Decision|0
6291091|NCT02406261|10007528|FG001|Period 2|Physician Decision|1
6291092|NCT02406261|10007527|FG000|Period 2|Protocol Violation|0
6291093|NCT02406261|10007528|FG001|Period 2|Protocol Violation|1
6291094|NCT02406261|10007527|FG000|Period 2|Withdrawal by Subject|0
6291095|NCT02406261|10007528|FG001|Period 2|Withdrawal by Subject|1
6291096|NCT02406586|10007564|FG000|Overall Study|Lost to Follow-up|0
6291097|NCT02406586|10007565|FG001|Overall Study|Lost to Follow-up|4
6291098|NCT02406586|10007566|FG002|Overall Study|Lost to Follow-up|2
6291099|NCT02406586|10007564|FG000|Overall Study|Withdrawal by Subject|1
6291100|NCT02406586|10007565|FG001|Overall Study|Withdrawal by Subject|0
6291101|NCT02406586|10007566|FG002|Overall Study|Withdrawal by Subject|0
6291102|NCT02406612|10007579|FG000|Overall Study|Screening Failure|3
6291103|NCT02406612|10007580|FG001|Overall Study|Screening Failure|0
6291104|NCT02406612|10007579|FG000|Overall Study|Intra-procedural Exclusion|1
6291105|NCT02406612|10007580|FG001|Overall Study|Intra-procedural Exclusion|3
6291106|NCT02406612|10007579|FG000|Overall Study|Guidewire Failure|0
6291107|NCT02406612|10007580|FG001|Overall Study|Guidewire Failure|1
6136621|NCT01001767|9766531|FG001|Overall Study|Lost to Follow-up|0
6136622|NCT01001767|9766530|FG000|Overall Study|Physician Decision|1
6136623|NCT01001767|9766531|FG001|Overall Study|Physician Decision|0
6136624|NCT01001832|9766552|FG000|Short-term Period|Adverse Event|2
6136625|NCT01001832|9766553|FG001|Short-term Period|Adverse Event|3
6136626|NCT01001832|9766552|FG000|Long-term Period|Adverse Event|2
6136627|NCT01001832|9766553|FG001|Long-term Period|Adverse Event|1
6136628|NCT01001832|9766552|FG000|Long-term Period|Withdrawal by Subject|1
6136629|NCT01001832|9766553|FG001|Long-term Period|Withdrawal by Subject|0
6136630|NCT01001832|9766552|FG000|Long-term Period|Lack of Efficacy|0
6136631|NCT01001832|9766553|FG001|Long-term Period|Lack of Efficacy|2
6136632|NCT01001832|9766552|FG000|Long-term Period|Other|1
6136633|NCT01001832|9766553|FG001|Long-term Period|Other|2
6136634|NCT01001832|9766552|FG000|Follow-up Period|Withdrawal by Subject|1
6136635|NCT01001832|9766553|FG001|Follow-up Period|Withdrawal by Subject|0
6136636|NCT01001832|9766552|FG000|Follow-up Period|Follow-up no longer required /protocol|15
6136637|NCT01001832|9766553|FG001|Follow-up Period|Follow-up no longer required /protocol|20
6136638|NCT01001832|9766552|FG000|Follow-up Period|Other|2
6136639|NCT01001832|9766553|FG001|Follow-up Period|Other|1
6136640|NCT01001910|9766562|FG000|Overall Study|Did not meet protocol defined eligibility s7.1.1 for primary outcome|6
6136641|NCT01001988|9766575|FG000|Overall Study|Protocol Violation|84
6136642|NCT01001988|9766575|FG000|Overall Study|Withdrawal by Subject|18
6136643|NCT01001988|9766575|FG000|Overall Study|Lost to Follow-up|15
6136644|NCT01002105|9766581|FG000|Overall Study|Lost to Follow-up|10
6136645|NCT01002105|9766582|FG001|Overall Study|Lost to Follow-up|16
6136646|NCT01002105|9766581|FG000|Overall Study|non compliance|5
6136647|NCT01002105|9766582|FG001|Overall Study|non compliance|3
6136648|NCT01002105|9766581|FG000|Overall Study|condition worsened|4
6136649|NCT01002105|9766582|FG001|Overall Study|condition worsened|2
6136650|NCT01002339|9766607|FG000|Overall Study|Withdrawal by Subject|0
6136651|NCT01002339|9766608|FG001|Overall Study|Withdrawal by Subject|1
6136652|NCT01002339|9766609|FG002|Overall Study|Withdrawal by Subject|0
6136653|NCT01002339|9766607|FG000|Overall Study|Incorrect treatment assignment|0
6136654|NCT01002339|9766608|FG001|Overall Study|Incorrect treatment assignment|0
6136655|NCT01002339|9766609|FG002|Overall Study|Incorrect treatment assignment|1
6136656|NCT01002339|9766607|FG000|Overall Study|Protocol Violation|0
6136657|NCT01002339|9766608|FG001|Overall Study|Protocol Violation|0
6136658|NCT01002339|9766609|FG002|Overall Study|Protocol Violation|2
6136659|NCT01002339|9766607|FG000|Overall Study|Lung cancer detected before transplant|0
6136660|NCT01002339|9766608|FG001|Overall Study|Lung cancer detected before transplant|0
6136661|NCT01002339|9766609|FG002|Overall Study|Lung cancer detected before transplant|1
6136662|NCT01002339|9766607|FG000|Overall Study|Randomized. Not transplanted|0
6291108|NCT02406651|10007586|FG000|Overall Study|30 subjects dosed based on initial screening. 3 subjects were removed because they screened fail.|3
6291109|NCT02406677|10007593|FG000|Overall Study|Death|16
6291110|NCT02406677|10007594|FG001|Overall Study|Death|8
6291111|NCT02406677|10007593|FG000|Overall Study|Discharged without P2Y12|1
6291112|NCT02406677|10007594|FG001|Overall Study|Discharged without P2Y12|3
6291113|NCT02406677|10007593|FG000|Overall Study|Discharged on prasugrel|283
6291114|NCT02406677|10007594|FG001|Overall Study|Discharged on prasugrel|587
6291115|NCT02406677|10007593|FG000|Overall Study|Withdrawal by Subject|1
6291116|NCT02406677|10007594|FG001|Overall Study|Withdrawal by Subject|0
6291117|NCT02406742|10007607|FG000|Overall Study|Progression of Disease|5
6291118|NCT02406742|10007608|FG001|Overall Study|Progression of Disease|1
6291119|NCT02406742|10007609|FG002|Overall Study|Progression of Disease|6
6291120|NCT02406742|10007607|FG000|Overall Study|Adverse Event|3
6291121|NCT02406742|10007608|FG001|Overall Study|Adverse Event|0
6291122|NCT02406742|10007609|FG002|Overall Study|Adverse Event|2
6291123|NCT02406742|10007607|FG000|Overall Study|Death|1
6291124|NCT02406742|10007608|FG001|Overall Study|Death|0
6291125|NCT02406742|10007609|FG002|Overall Study|Death|0
6291126|NCT02406742|10007607|FG000|Overall Study|Lack of Efficacy|0
6291127|NCT02406742|10007608|FG001|Overall Study|Lack of Efficacy|0
6291128|NCT02406742|10007609|FG002|Overall Study|Lack of Efficacy|1
6291129|NCT02406742|10007607|FG000|Overall Study|Withdrawal by Participant|1
6291130|NCT02406742|10007608|FG001|Overall Study|Withdrawal by Participant|2
6291131|NCT02406742|10007609|FG002|Overall Study|Withdrawal by Participant|0
6291132|NCT02406742|10007607|FG000|Overall Study|Physician Decision|1
6291133|NCT02406742|10007608|FG001|Overall Study|Physician Decision|2
6291134|NCT02406742|10007609|FG002|Overall Study|Physician Decision|1
6291135|NCT02406742|10007607|FG000|Overall Study|Transition to other treatment|2
6291136|NCT02406742|10007608|FG001|Overall Study|Transition to other treatment|0
6291137|NCT02406742|10007609|FG002|Overall Study|Transition to other treatment|1
6291138|NCT02406742|10007607|FG000|Overall Study|Other Reasons|1
6291139|NCT02406742|10007608|FG001|Overall Study|Other Reasons|11
6291140|NCT02406742|10007609|FG002|Overall Study|Other Reasons|5
6291141|NCT02407054|10007671|FG000|Overall Study|Adverse Event|1
6291142|NCT02407054|10007672|FG001|Overall Study|Adverse Event|4
6291143|NCT02407054|10007673|FG002|Overall Study|Adverse Event|1
6136663|NCT01002339|9766608|FG001|Overall Study|Randomized. Not transplanted|0
6136664|NCT01002339|9766609|FG002|Overall Study|Randomized. Not transplanted|1
6136665|NCT01002482|9766630|FG000|Overall Study|Withdrawal by Subject|14
6136666|NCT01002482|9766631|FG001|Overall Study|Withdrawal by Subject|21
6136667|NCT01002482|9766630|FG000|Overall Study|Included twice|1
6136668|NCT01002482|9766631|FG001|Overall Study|Included twice|0
6136669|NCT01002547|9766640|FG000|Overall Study|Withdrawal by Subject|4
6136670|NCT01002547|9766641|FG001|Overall Study|Withdrawal by Subject|0
6136671|NCT01002547|9766642|FG002|Overall Study|Withdrawal by Subject|5
6136672|NCT01002547|9766640|FG000|Overall Study|Lost to Follow-up|2
6136673|NCT01002547|9766641|FG001|Overall Study|Lost to Follow-up|1
6136674|NCT01002547|9766642|FG002|Overall Study|Lost to Follow-up|1
6136675|NCT01002547|9766640|FG000|Overall Study|Physician Decision|1
6136676|NCT01002547|9766641|FG001|Overall Study|Physician Decision|0
6136677|NCT01002547|9766642|FG002|Overall Study|Physician Decision|0
6136678|NCT01002547|9766640|FG000|Overall Study|Death|0
6136679|NCT01002547|9766641|FG001|Overall Study|Death|2
6136680|NCT01002547|9766642|FG002|Overall Study|Death|2
6136681|NCT01002547|9766640|FG000|Overall Study|Adverse Event|1
6136682|NCT01002547|9766641|FG001|Overall Study|Adverse Event|0
6136683|NCT01002547|9766642|FG002|Overall Study|Adverse Event|0
6136684|NCT01002573|9766652|FG000|Overall Study|Subject did not receive at least 1 dose|11
6136685|NCT01002573|9766653|FG001|Overall Study|Subject did not receive at least 1 dose|7
6136686|NCT01002742|9766661|FG000|Overall Study|Determined to be ineligible|0
6136687|NCT01002742|9766662|FG001|Overall Study|Determined to be ineligible|1
6136688|NCT01002989|9766672|FG000|Overall Study|exclusion criteria, no consent|5
6136689|NCT01003184|9766721|FG000|Overall Study|Adverse Event|12
6136690|NCT01003184|9766722|FG001|Overall Study|Adverse Event|5
6136691|NCT01003184|9766721|FG000|Overall Study|Lost to Follow-up|1
6291144|NCT02407054|10007671|FG000|Overall Study|Non-compliance with Study|0
6291145|NCT02407054|10007672|FG001|Overall Study|Non-compliance with Study|2
6291146|NCT02407054|10007673|FG002|Overall Study|Non-compliance with Study|1
6291147|NCT02407054|10007671|FG000|Overall Study|Physician Decision|1
6291148|NCT02407054|10007672|FG001|Overall Study|Physician Decision|3
6291149|NCT02407054|10007673|FG002|Overall Study|Physician Decision|3
6291150|NCT02407054|10007671|FG000|Overall Study|Withdrawal by Subject|5
6291151|NCT02407054|10007672|FG001|Overall Study|Withdrawal by Subject|9
6291152|NCT02407054|10007673|FG002|Overall Study|Withdrawal by Subject|2
6291153|NCT02407223|10007694|FG000|Overall Study|Adverse Event|1
6291154|NCT02407223|10007695|FG001|Overall Study|Adverse Event|0
6291155|NCT02407223|10007696|FG002|Overall Study|Adverse Event|1
6291156|NCT02407223|10007694|FG000|Overall Study|Lack of Efficacy|6
6291157|NCT02407223|10007695|FG001|Overall Study|Lack of Efficacy|6
6291158|NCT02407223|10007696|FG002|Overall Study|Lack of Efficacy|4
6291159|NCT02407223|10007694|FG000|Overall Study|Lost to Follow-up|1
6291160|NCT02407223|10007695|FG001|Overall Study|Lost to Follow-up|0
6291161|NCT02407223|10007696|FG002|Overall Study|Lost to Follow-up|2
6291162|NCT02407223|10007694|FG000|Overall Study|Withdrawal by Subject|2
6291163|NCT02407223|10007695|FG001|Overall Study|Withdrawal by Subject|4
6291164|NCT02407223|10007696|FG002|Overall Study|Withdrawal by Subject|4
6291165|NCT02407223|10007694|FG000|Overall Study|Study Terminated by Sponsor|77
6291166|NCT02407223|10007695|FG001|Overall Study|Study Terminated by Sponsor|80
6291167|NCT02407223|10007696|FG002|Overall Study|Study Terminated by Sponsor|86
6291168|NCT02407223|10007694|FG000|Overall Study|Subject Refused Further Study Treatment|0
6291169|NCT02407223|10007695|FG001|Overall Study|Subject Refused Further Study Treatment|1
6291170|NCT02407223|10007696|FG002|Overall Study|Subject Refused Further Study Treatment|0
6291171|NCT02407223|10007694|FG000|Overall Study|Other|29
6291172|NCT02407223|10007695|FG001|Overall Study|Other|27
6291173|NCT02407223|10007696|FG002|Overall Study|Other|25
6136692|NCT01003184|9766722|FG001|Overall Study|Lost to Follow-up|0
6136693|NCT01003184|9766721|FG000|Overall Study|Loss of glucose control|1
6136694|NCT01003184|9766722|FG001|Overall Study|Loss of glucose control|1
6136695|NCT01003184|9766721|FG000|Overall Study|Protocol Violation|3
6136696|NCT01003184|9766722|FG001|Overall Study|Protocol Violation|0
6136697|NCT01003184|9766721|FG000|Overall Study|Withdrawal by Subject|1
6136698|NCT01003184|9766722|FG001|Overall Study|Withdrawal by Subject|6
6136699|NCT01003184|9766721|FG000|Overall Study|Physician Decision|1
6136700|NCT01003184|9766722|FG001|Overall Study|Physician Decision|0
6136701|NCT01003210|9766730|FG000|Overall Study|Lost to Follow-up|1
6136702|NCT01003210|9766731|FG001|Overall Study|Lost to Follow-up|3
6136703|NCT01003249|9766737|FG000|First Intervention (4 Weeks)|Withdrawal by Subject|1
6136704|NCT01003249|9766738|FG001|First Intervention (4 Weeks)|Withdrawal by Subject|1
6136705|NCT01003249|9766737|FG000|First Intervention (4 Weeks)|Non-Serious Event|1
6136706|NCT01003249|9766738|FG001|First Intervention (4 Weeks)|Non-Serious Event|1
6136707|NCT01003249|9766737|FG000|Second Intervention (4 Weeks)|Withdrawal by Subject|0
6136708|NCT01003249|9766738|FG001|Second Intervention (4 Weeks)|Withdrawal by Subject|1
6136709|NCT01003249|9766737|FG000|Second Intervention (4 Weeks)|Adverse Event|1
6136710|NCT01003249|9766738|FG001|Second Intervention (4 Weeks)|Adverse Event|0
6136711|NCT01003639|9766784|FG000|Overall Study|Lost to Follow-up|6
6136712|NCT01003639|9766785|FG001|Overall Study|Lost to Follow-up|9
6136713|NCT01003639|9766784|FG000|Overall Study|Withdrawal by Subject|9
6136714|NCT01003639|9766785|FG001|Overall Study|Withdrawal by Subject|5
6136715|NCT01003639|9766784|FG000|Overall Study|Lack of Efficacy|1
6136716|NCT01003639|9766785|FG001|Overall Study|Lack of Efficacy|6
6136717|NCT01003639|9766784|FG000|Overall Study|Adverse Event|0
6136718|NCT01003639|9766785|FG001|Overall Study|Adverse Event|1
6136719|NCT01003639|9766784|FG000|Overall Study|Protocol Violation|0
6136720|NCT01003639|9766785|FG001|Overall Study|Protocol Violation|1
6136721|NCT01003639|9766784|FG000|Overall Study|Physician Decision|1
6136722|NCT01003639|9766785|FG001|Overall Study|Physician Decision|0
6136723|NCT01003886|9766795|FG000|Overall Study|Lack of Efficacy|5
6136724|NCT01003886|9766795|FG000|Overall Study|Lost to Follow-up|169
6136725|NCT01003886|9766795|FG000|Overall Study|Withdrawal by Subject|39
6136726|NCT01003886|9766795|FG000|Overall Study|Other|14
6136727|NCT01003886|9766795|FG000|Overall Study|Adverse Event|3
6136728|NCT01003899|9766799|FG000|Overall Study|Other Adverse Event|8
6136729|NCT01003899|9766799|FG000|Overall Study|Not entered|4
6136730|NCT01003899|9766799|FG000|Overall Study|Not treated|1
6136731|NCT01003899|9766799|FG000|Overall Study|Progressive disease|34
6136732|NCT01003990|9766810|FG000|Overall Study|Adverse Event|8
6136733|NCT01003990|9766811|FG001|Overall Study|Adverse Event|5
6136734|NCT01003990|9766812|FG002|Overall Study|Adverse Event|11
6136735|NCT01003990|9766810|FG000|Overall Study|Death|0
6136736|NCT01003990|9766811|FG001|Overall Study|Death|8
6136737|NCT01003990|9766812|FG002|Overall Study|Death|1
6136738|NCT01003990|9766810|FG000|Overall Study|Lack of Efficacy|10
6136739|NCT01003990|9766811|FG001|Overall Study|Lack of Efficacy|2
6136740|NCT01003990|9766812|FG002|Overall Study|Lack of Efficacy|3
6136741|NCT01003990|9766810|FG000|Overall Study|Lost to Follow-up|30
6136742|NCT01003990|9766811|FG001|Overall Study|Lost to Follow-up|12
6136743|NCT01003990|9766812|FG002|Overall Study|Lost to Follow-up|7
6136744|NCT01003990|9766810|FG000|Overall Study|Reasons Not Identified|14
6136745|NCT01003990|9766811|FG001|Overall Study|Reasons Not Identified|13
6136746|NCT01003990|9766812|FG002|Overall Study|Reasons Not Identified|8
6136747|NCT01003990|9766810|FG000|Overall Study|Poor/Non-compliance|4
6136748|NCT01003990|9766811|FG001|Overall Study|Poor/Non-compliance|3
6136749|NCT01003990|9766812|FG002|Overall Study|Poor/Non-compliance|2
6136750|NCT01003990|9766810|FG000|Overall Study|Pregnancy|10
6136751|NCT01003990|9766811|FG001|Overall Study|Pregnancy|2
6136752|NCT01003990|9766812|FG002|Overall Study|Pregnancy|4
6136753|NCT01003990|9766810|FG000|Overall Study|No Longer Met Study Criteria|4
6136754|NCT01003990|9766811|FG001|Overall Study|No Longer Met Study Criteria|1
6136755|NCT01003990|9766812|FG002|Overall Study|No Longer Met Study Criteria|0
6136756|NCT01003990|9766810|FG000|Overall Study|Subject Withdrew Consent|12
6136757|NCT01003990|9766811|FG001|Overall Study|Subject Withdrew Consent|5
6136758|NCT01003990|9766812|FG002|Overall Study|Subject Withdrew Consent|7
6136759|NCT01004003|9766829|FG000|Overall Study|Progressive disease|2
6136760|NCT01004003|9766830|FG001|Overall Study|Progressive disease|1
6136761|NCT01004003|9766831|FG002|Overall Study|Progressive disease|1
6136762|NCT01004003|9766832|FG003|Overall Study|Progressive disease|0
6136763|NCT01004003|9766833|FG004|Overall Study|Progressive disease|2
6136764|NCT01004003|9766834|FG005|Overall Study|Progressive disease|1
6136765|NCT01004003|9766835|FG006|Overall Study|Progressive disease|1
6136766|NCT01004003|9766836|FG007|Overall Study|Progressive disease|39
6136767|NCT01004003|9766837|FG008|Overall Study|Progressive disease|22
6136768|NCT01004003|9766829|FG000|Overall Study|Adverse Event|4
6136769|NCT01004003|9766830|FG001|Overall Study|Adverse Event|2
6136770|NCT01004003|9766831|FG002|Overall Study|Adverse Event|3
6136771|NCT01004003|9766832|FG003|Overall Study|Adverse Event|3
6136772|NCT01004003|9766833|FG004|Overall Study|Adverse Event|2
6136773|NCT01004003|9766834|FG005|Overall Study|Adverse Event|2
6136774|NCT01004003|9766835|FG006|Overall Study|Adverse Event|7
6136775|NCT01004003|9766836|FG007|Overall Study|Adverse Event|21
6136776|NCT01004003|9766837|FG008|Overall Study|Adverse Event|6
6136777|NCT01004003|9766829|FG000|Overall Study|Refused to continue taking trial med.|0
6136778|NCT01004003|9766830|FG001|Overall Study|Refused to continue taking trial med.|0
6136779|NCT01004003|9766831|FG002|Overall Study|Refused to continue taking trial med.|0
6136780|NCT01004003|9766832|FG003|Overall Study|Refused to continue taking trial med.|0
6136781|NCT01004003|9766833|FG004|Overall Study|Refused to continue taking trial med.|0
6136782|NCT01004003|9766834|FG005|Overall Study|Refused to continue taking trial med.|0
6136783|NCT01004003|9766835|FG006|Overall Study|Refused to continue taking trial med.|0
6136784|NCT01004003|9766836|FG007|Overall Study|Refused to continue taking trial med.|0
6136785|NCT01004003|9766837|FG008|Overall Study|Refused to continue taking trial med.|2
6136786|NCT01004003|9766829|FG000|Overall Study|Other|0
6136787|NCT01004003|9766830|FG001|Overall Study|Other|0
6136788|NCT01004003|9766831|FG002|Overall Study|Other|0
6136789|NCT01004003|9766832|FG003|Overall Study|Other|0
6136790|NCT01004003|9766833|FG004|Overall Study|Other|0
6136791|NCT01004003|9766834|FG005|Overall Study|Other|1
6136792|NCT01004003|9766835|FG006|Overall Study|Other|0
6136793|NCT01004003|9766836|FG007|Overall Study|Other|0
6136794|NCT01004003|9766837|FG008|Overall Study|Other|0
6136795|NCT01004146|9766908|FG000|Overall Study|Withdrawal by Subject|4
6136796|NCT01004146|9766909|FG001|Overall Study|Withdrawal by Subject|5
6136797|NCT01004159|9766915|FG000|Overall Study|Adverse Event|2
6136798|NCT01004159|9766915|FG000|Overall Study|Disease Progression|18
6136799|NCT01004172|9766919|FG000|Overall Study|Progressive Disease in CNS Only|16
6136800|NCT01004172|9766919|FG000|Overall Study|Progressive Disease in Non-CNS Only|16
6136801|NCT01004172|9766919|FG000|Overall Study|Progressive Disease in CNS and Non-CNS|2
6136802|NCT01004172|9766919|FG000|Overall Study|Adverse Event|1
6136803|NCT01004172|9766919|FG000|Overall Study|Physician Decision|1
6136804|NCT01004172|9766919|FG000|Overall Study|Symptomatic Deterioration|2
6136805|NCT01004185|9766926|FG000|Overall Study|Adverse Event|1
6136806|NCT01004185|9766927|FG001|Overall Study|Adverse Event|1
6136807|NCT01004185|9766926|FG000|Overall Study|Lost to Follow-up|0
6136808|NCT01004185|9766927|FG001|Overall Study|Lost to Follow-up|1
6136809|NCT01004185|9766926|FG000|Overall Study|Lack of Efficacy|2
6136810|NCT01004185|9766927|FG001|Overall Study|Lack of Efficacy|1
6136811|NCT01004185|9766926|FG000|Overall Study|Sponsor Terminated Study|4
6136812|NCT01004185|9766927|FG001|Overall Study|Sponsor Terminated Study|5
6136813|NCT01004185|9766926|FG000|Overall Study|Withdrawal by Subject|2
6136814|NCT01004185|9766927|FG001|Overall Study|Withdrawal by Subject|1
6136815|NCT01004250|9766933|FG000|Induction Therapy Period|Adverse Event|10
6136816|NCT01004250|9766933|FG000|Induction Therapy Period|Entry Criteria Not Met|1
6136817|NCT01004250|9766933|FG000|Induction Therapy Period|Withdrawal by Subject|2
6136818|NCT01004250|9766933|FG000|Induction Therapy Period|Physician Decision|2
6136819|NCT01004250|9766933|FG000|Maintenance Therapy Period|Adverse Event|15
6136820|NCT01004250|9766933|FG000|Maintenance Therapy Period|Lost to Follow-up|1
6136821|NCT01004250|9766933|FG000|Maintenance Therapy Period|Protocol Violation|1
6136822|NCT01004250|9766933|FG000|Maintenance Therapy Period|Withdrawal by Subject|5
6136823|NCT01004250|9766933|FG000|Maintenance Therapy Period|Physician Decision|4
6136824|NCT01004250|9766933|FG000|Follow-Up (FU) Period|Lost to Follow-up|1
6136825|NCT01004406|9766951|FG000|Overall Study|Withdrawal by Subject|2
6136826|NCT01004406|9766952|FG001|Overall Study|Withdrawal by Subject|0
6136827|NCT01004406|9766951|FG000|Overall Study|Lost to Follow-up|1
6136828|NCT01004406|9766952|FG001|Overall Study|Lost to Follow-up|0
6136829|NCT01004432|9766958|FG000|Open-label (OL) Period (Week 0 - 16)|Adverse Event|20
6136830|NCT01004432|9766959|FG001|Open-label (OL) Period (Week 0 - 16)|Adverse Event|0
6136831|NCT01004432|9766960|FG002|Open-label (OL) Period (Week 0 - 16)|Adverse Event|0
6136832|NCT01004432|9766961|FG003|Open-label (OL) Period (Week 0 - 16)|Adverse Event|0
6136833|NCT01004432|9766962|FG004|Open-label (OL) Period (Week 0 - 16)|Adverse Event|0
6136834|NCT01004432|9766958|FG000|Open-label (OL) Period (Week 0 - 16)|Protocol Violation|29
6136835|NCT01004432|9766959|FG001|Open-label (OL) Period (Week 0 - 16)|Protocol Violation|0
6136836|NCT01004432|9766960|FG002|Open-label (OL) Period (Week 0 - 16)|Protocol Violation|0
6136837|NCT01004432|9766961|FG003|Open-label (OL) Period (Week 0 - 16)|Protocol Violation|0
6136838|NCT01004432|9766962|FG004|Open-label (OL) Period (Week 0 - 16)|Protocol Violation|0
6136839|NCT01004432|9766958|FG000|Open-label (OL) Period (Week 0 - 16)|Withdrawal by Subject|17
6136840|NCT01004432|9766959|FG001|Open-label (OL) Period (Week 0 - 16)|Withdrawal by Subject|0
6136841|NCT01004432|9766960|FG002|Open-label (OL) Period (Week 0 - 16)|Withdrawal by Subject|0
6136842|NCT01004432|9766961|FG003|Open-label (OL) Period (Week 0 - 16)|Withdrawal by Subject|0
6136843|NCT01004432|9766962|FG004|Open-label (OL) Period (Week 0 - 16)|Withdrawal by Subject|0
6136844|NCT01004432|9766958|FG000|Open-label (OL) Period (Week 0 - 16)|Lack of Efficacy|15
6136845|NCT01004432|9766959|FG001|Open-label (OL) Period (Week 0 - 16)|Lack of Efficacy|0
6136846|NCT01004432|9766960|FG002|Open-label (OL) Period (Week 0 - 16)|Lack of Efficacy|0
6136847|NCT01004432|9766961|FG003|Open-label (OL) Period (Week 0 - 16)|Lack of Efficacy|0
6136848|NCT01004432|9766962|FG004|Open-label (OL) Period (Week 0 - 16)|Lack of Efficacy|0
6136849|NCT01004432|9766958|FG000|Open-label (OL) Period (Week 0 - 16)|Lost to Follow-up|2
6136850|NCT01004432|9766959|FG001|Open-label (OL) Period (Week 0 - 16)|Lost to Follow-up|0
6136851|NCT01004432|9766960|FG002|Open-label (OL) Period (Week 0 - 16)|Lost to Follow-up|0
6136852|NCT01004432|9766961|FG003|Open-label (OL) Period (Week 0 - 16)|Lost to Follow-up|0
6136853|NCT01004432|9766962|FG004|Open-label (OL) Period (Week 0 - 16)|Lost to Follow-up|0
6136854|NCT01004432|9766958|FG000|OL/Double-Blind (DB) Period (Week 16-52)|Adverse Event|0
6136855|NCT01004432|9766959|FG001|OL/Double-Blind (DB) Period (Week 16-52)|Adverse Event|1
6136856|NCT01004432|9766960|FG002|OL/Double-Blind (DB) Period (Week 16-52)|Adverse Event|5
6136857|NCT01004432|9766961|FG003|OL/Double-Blind (DB) Period (Week 16-52)|Adverse Event|6
6136858|NCT01004432|9766962|FG004|OL/Double-Blind (DB) Period (Week 16-52)|Adverse Event|0
6136859|NCT01004432|9766958|FG000|OL/Double-Blind (DB) Period (Week 16-52)|Protocol Violation|0
6136860|NCT01004432|9766959|FG001|OL/Double-Blind (DB) Period (Week 16-52)|Protocol Violation|3
6136861|NCT01004432|9766960|FG002|OL/Double-Blind (DB) Period (Week 16-52)|Protocol Violation|3
6136862|NCT01004432|9766961|FG003|OL/Double-Blind (DB) Period (Week 16-52)|Protocol Violation|4
6136863|NCT01004432|9766962|FG004|OL/Double-Blind (DB) Period (Week 16-52)|Protocol Violation|0
6136864|NCT01004432|9766958|FG000|OL/Double-Blind (DB) Period (Week 16-52)|Withdrawal by Subject|0
6136865|NCT01004432|9766959|FG001|OL/Double-Blind (DB) Period (Week 16-52)|Withdrawal by Subject|1
6136866|NCT01004432|9766960|FG002|OL/Double-Blind (DB) Period (Week 16-52)|Withdrawal by Subject|4
6136867|NCT01004432|9766961|FG003|OL/Double-Blind (DB) Period (Week 16-52)|Withdrawal by Subject|7
6136868|NCT01004432|9766962|FG004|OL/Double-Blind (DB) Period (Week 16-52)|Withdrawal by Subject|0
6136869|NCT01004432|9766958|FG000|OL/Double-Blind (DB) Period (Week 16-52)|Death|0
6136870|NCT01004432|9766959|FG001|OL/Double-Blind (DB) Period (Week 16-52)|Death|0
6136871|NCT01004432|9766960|FG002|OL/Double-Blind (DB) Period (Week 16-52)|Death|0
6136872|NCT01004432|9766961|FG003|OL/Double-Blind (DB) Period (Week 16-52)|Death|1
6136873|NCT01004432|9766962|FG004|OL/Double-Blind (DB) Period (Week 16-52)|Death|0
6136874|NCT01004432|9766958|FG000|OL/Double-Blind (DB) Period (Week 16-52)|Lack of Efficacy|0
6136875|NCT01004432|9766959|FG001|OL/Double-Blind (DB) Period (Week 16-52)|Lack of Efficacy|2
6136876|NCT01004432|9766960|FG002|OL/Double-Blind (DB) Period (Week 16-52)|Lack of Efficacy|24
6136877|NCT01004432|9766961|FG003|OL/Double-Blind (DB) Period (Week 16-52)|Lack of Efficacy|37
6136878|NCT01004432|9766962|FG004|OL/Double-Blind (DB) Period (Week 16-52)|Lack of Efficacy|0
6136879|NCT01004432|9766958|FG000|OL/Double-Blind (DB) Period (Week 16-52)|Lost to Follow-up|0
6136880|NCT01004432|9766959|FG001|OL/Double-Blind (DB) Period (Week 16-52)|Lost to Follow-up|3
6136881|NCT01004432|9766960|FG002|OL/Double-Blind (DB) Period (Week 16-52)|Lost to Follow-up|1
6136882|NCT01004432|9766961|FG003|OL/Double-Blind (DB) Period (Week 16-52)|Lost to Follow-up|3
6136883|NCT01004432|9766962|FG004|OL/Double-Blind (DB) Period (Week 16-52)|Lost to Follow-up|0
6136884|NCT01004432|9766958|FG000|OL Study Extension (Week 52 - 76)|Adverse Event|0
6136885|NCT01004432|9766959|FG001|OL Study Extension (Week 52 - 76)|Adverse Event|0
6136886|NCT01004432|9766960|FG002|OL Study Extension (Week 52 - 76)|Adverse Event|0
6136887|NCT01004432|9766961|FG003|OL Study Extension (Week 52 - 76)|Adverse Event|0
6291174|NCT02407249|10007706|FG000|Overall Study|Did not complete 12-month follow-up|13
6291175|NCT02407249|10007706|FG000|Overall Study|Not treated|13
6291176|NCT02407457|10007712|FG000|1 Month|Death|3
6291177|NCT02407457|10007713|FG001|1 Month|Death|0
6291178|NCT02407457|10007712|FG000|1 Month|Lost to Follow-up|1
6291179|NCT02407457|10007713|FG001|1 Month|Lost to Follow-up|1
6291180|NCT02407457|10007712|FG000|1 Month|missed visit|2
6291181|NCT02407457|10007713|FG001|1 Month|missed visit|6
6291182|NCT02407457|10007712|FG000|6-Month|Death|2
6291183|NCT02407457|10007713|FG001|6-Month|Death|8
6291184|NCT02407457|10007712|FG000|6-Month|Lost to Follow-up|2
6291185|NCT02407457|10007713|FG001|6-Month|Lost to Follow-up|2
6291186|NCT02407457|10007712|FG000|6-Month|missed visit|15
6291187|NCT02407457|10007713|FG001|6-Month|missed visit|12
6291188|NCT02407457|10007712|FG000|6-Month|Over Due|1
6291189|NCT02407457|10007713|FG001|6-Month|Over Due|2
6291190|NCT02407457|10007712|FG000|6-Month|Open Repair|0
6291191|NCT02407457|10007713|FG001|6-Month|Open Repair|1
6291192|NCT02407457|10007712|FG000|1 Year|Death|6
6291193|NCT02407457|10007713|FG001|1 Year|Death|11
6291194|NCT02407457|10007712|FG000|1 Year|Lost to Follow-up|3
6291195|NCT02407457|10007713|FG001|1 Year|Lost to Follow-up|2
6291196|NCT02407457|10007712|FG000|1 Year|Missed Visit|18
6291197|NCT02407457|10007713|FG001|1 Year|Missed Visit|10
6291198|NCT02407457|10007712|FG000|1 Year|Over Due|6
6291199|NCT02407457|10007713|FG001|1 Year|Over Due|4
6291200|NCT02407457|10007712|FG000|1 Year|Open Repair|0
6291201|NCT02407457|10007713|FG001|1 Year|Open Repair|1
6291202|NCT02407457|10007712|FG000|2-year|Death|14
6291203|NCT02407457|10007713|FG001|2-year|Death|8
6291204|NCT02407457|10007712|FG000|2-year|Lost to Follow-up|6
6291205|NCT02407457|10007713|FG001|2-year|Lost to Follow-up|9
6291206|NCT02407457|10007712|FG000|2-year|Missed Visit|13
6291207|NCT02407457|10007713|FG001|2-year|Missed Visit|11
6291208|NCT02407457|10007712|FG000|2-year|Over Due|1
6291209|NCT02407457|10007713|FG001|2-year|Over Due|5
6291210|NCT02407457|10007712|FG000|2-year|Open Repair|0
6291211|NCT02407457|10007713|FG001|2-year|Open Repair|2
6291212|NCT02407457|10007712|FG000|3-year|Death|11
6291213|NCT02407457|10007713|FG001|3-year|Death|10
6291214|NCT02407457|10007712|FG000|3-year|Lost to Follow-up|6
6291215|NCT02407457|10007713|FG001|3-year|Lost to Follow-up|9
6291216|NCT02407457|10007712|FG000|3-year|Missed Visit|21
6291217|NCT02407457|10007713|FG001|3-year|Missed Visit|16
6291218|NCT02407457|10007712|FG000|3-year|Over Due|4
6291219|NCT02407457|10007713|FG001|3-year|Over Due|3
6291220|NCT02407457|10007712|FG000|4-year|Death|14
6291221|NCT02407457|10007713|FG001|4-year|Death|7
6291222|NCT02407457|10007712|FG000|4-year|Lost to Follow-up|9
6291223|NCT02407457|10007713|FG001|4-year|Lost to Follow-up|12
6291224|NCT02407457|10007712|FG000|4-year|Over Due|10
6291225|NCT02407457|10007713|FG001|4-year|Over Due|5
6291226|NCT02407457|10007712|FG000|4-year|Missed Visit|13
6291227|NCT02407457|10007713|FG001|4-year|Missed Visit|13
6291228|NCT02407457|10007712|FG000|4-year|Pending visit|19
6291229|NCT02407457|10007713|FG001|4-year|Pending visit|14
6291230|NCT02407457|10007712|FG000|4-year|Not Due|16
6291231|NCT02407457|10007713|FG001|4-year|Not Due|10
6291232|NCT02407457|10007712|FG000|5-year|Death|6
6291233|NCT02407457|10007713|FG001|5-year|Death|1
6291234|NCT02407457|10007712|FG000|5-year|Lost to Follow-up|4
6291235|NCT02407457|10007713|FG001|5-year|Lost to Follow-up|4
6291236|NCT02407457|10007712|FG000|5-year|Missed Visit|10
6291237|NCT02407457|10007713|FG001|5-year|Missed Visit|9
6291238|NCT02407457|10007712|FG000|5-year|Pending Visit|18
6291239|NCT02407457|10007713|FG001|5-year|Pending Visit|17
6291240|NCT02407457|10007712|FG000|5-year|Not Due|54
6291241|NCT02407457|10007713|FG001|5-year|Not Due|46
6291242|NCT02407704|10007723|FG000|Overall Study|Lost to Follow-up|0
6291243|NCT02407704|10007724|FG001|Overall Study|Lost to Follow-up|0
6291244|NCT02407704|10007725|FG002|Overall Study|Lost to Follow-up|0
6291245|NCT02407704|10007726|FG003|Overall Study|Lost to Follow-up|2
6291246|NCT02407704|10007723|FG000|Overall Study|Protocol Violation|0
6291247|NCT02407704|10007724|FG001|Overall Study|Protocol Violation|0
6291248|NCT02407704|10007725|FG002|Overall Study|Protocol Violation|0
6291249|NCT02407704|10007726|FG003|Overall Study|Protocol Violation|1
6291250|NCT02407704|10007723|FG000|Overall Study|Withdrawal by Subject|0
6291251|NCT02407704|10007724|FG001|Overall Study|Withdrawal by Subject|0
6291252|NCT02407704|10007725|FG002|Overall Study|Withdrawal by Subject|1
6291253|NCT02407704|10007726|FG003|Overall Study|Withdrawal by Subject|0
6291254|NCT02407990|10007765|FG000|Overall Study|Death|2
6291255|NCT02407990|10007766|FG001|Overall Study|Death|22
6291256|NCT02407990|10007767|FG002|Overall Study|Death|23
6291257|NCT02407990|10007768|FG003|Overall Study|Death|7
6291258|NCT02407990|10007769|FG004|Overall Study|Death|17
6291259|NCT02407990|10007770|FG005|Overall Study|Death|16
6291260|NCT02407990|10007771|FG006|Overall Study|Death|10
6291261|NCT02407990|10007772|FG007|Overall Study|Death|248
6291262|NCT02407990|10007765|FG000|Overall Study|Lost to Follow-up|0
6291263|NCT02407990|10007766|FG001|Overall Study|Lost to Follow-up|1
6291264|NCT02407990|10007767|FG002|Overall Study|Lost to Follow-up|0
6291265|NCT02407990|10007768|FG003|Overall Study|Lost to Follow-up|0
6291266|NCT02407990|10007769|FG004|Overall Study|Lost to Follow-up|0
6291267|NCT02407990|10007770|FG005|Overall Study|Lost to Follow-up|0
6291268|NCT02407990|10007771|FG006|Overall Study|Lost to Follow-up|0
6291269|NCT02407990|10007772|FG007|Overall Study|Lost to Follow-up|17
6291270|NCT02407990|10007765|FG000|Overall Study|Progressive Disease|0
6291271|NCT02407990|10007766|FG001|Overall Study|Progressive Disease|0
6291272|NCT02407990|10007767|FG002|Overall Study|Progressive Disease|0
6291273|NCT02407990|10007768|FG003|Overall Study|Progressive Disease|0
6291274|NCT02407990|10007769|FG004|Overall Study|Progressive Disease|0
6291275|NCT02407990|10007770|FG005|Overall Study|Progressive Disease|0
6291276|NCT02407990|10007771|FG006|Overall Study|Progressive Disease|0
6291277|NCT02407990|10007772|FG007|Overall Study|Progressive Disease|1
6291278|NCT02407990|10007765|FG000|Overall Study|Withdrawal by Subject|0
6291279|NCT02407990|10007766|FG001|Overall Study|Withdrawal by Subject|0
6291280|NCT02407990|10007767|FG002|Overall Study|Withdrawal by Subject|0
6291281|NCT02407990|10007768|FG003|Overall Study|Withdrawal by Subject|0
6291282|NCT02407990|10007769|FG004|Overall Study|Withdrawal by Subject|1
6291283|NCT02407990|10007770|FG005|Overall Study|Withdrawal by Subject|0
6291284|NCT02407990|10007771|FG006|Overall Study|Withdrawal by Subject|0
6291285|NCT02407990|10007772|FG007|Overall Study|Withdrawal by Subject|30
6291286|NCT02407990|10007765|FG000|Overall Study|Study Terminated by Sponsor|1
6291287|NCT02407990|10007766|FG001|Overall Study|Study Terminated by Sponsor|3
6291288|NCT02407990|10007767|FG002|Overall Study|Study Terminated by Sponsor|3
6291289|NCT02407990|10007768|FG003|Overall Study|Study Terminated by Sponsor|0
6291290|NCT02407990|10007769|FG004|Overall Study|Study Terminated by Sponsor|3
6291291|NCT02407990|10007770|FG005|Overall Study|Study Terminated by Sponsor|4
6291292|NCT02407990|10007771|FG006|Overall Study|Study Terminated by Sponsor|3
6291293|NCT02407990|10007772|FG007|Overall Study|Study Terminated by Sponsor|37
6291294|NCT02407990|10007765|FG000|Overall Study|Logistics|0
6291295|NCT02407990|10007766|FG001|Overall Study|Logistics|0
6291296|NCT02407990|10007767|FG002|Overall Study|Logistics|0
6291297|NCT02407990|10007768|FG003|Overall Study|Logistics|0
6291298|NCT02407990|10007769|FG004|Overall Study|Logistics|0
6291299|NCT02407990|10007770|FG005|Overall Study|Logistics|0
6291300|NCT02407990|10007771|FG006|Overall Study|Logistics|0
6291301|NCT02407990|10007772|FG007|Overall Study|Logistics|1
6291302|NCT02407990|10007765|FG000|Overall Study|Rolled into long-term extension study|0
6291303|NCT02407990|10007766|FG001|Overall Study|Rolled into long-term extension study|0
6291304|NCT02407990|10007767|FG002|Overall Study|Rolled into long-term extension study|0
6291305|NCT02407990|10007768|FG003|Overall Study|Rolled into long-term extension study|0
6291306|NCT02407990|10007769|FG004|Overall Study|Rolled into long-term extension study|0
6291307|NCT02407990|10007770|FG005|Overall Study|Rolled into long-term extension study|0
6291308|NCT02407990|10007771|FG006|Overall Study|Rolled into long-term extension study|0
6291309|NCT02407990|10007772|FG007|Overall Study|Rolled into long-term extension study|1
6291310|NCT02408016|10007799|FG000|Overall Study|Death|6
6291311|NCT02408016|10007800|FG001|Overall Study|Death|1
6291312|NCT02408016|10007801|FG002|Overall Study|Death|0
6291313|NCT02408016|10007799|FG000|Overall Study|Physician Decision|0
6291314|NCT02408016|10007800|FG001|Overall Study|Physician Decision|2
6291315|NCT02408016|10007801|FG002|Overall Study|Physician Decision|0
6291316|NCT02408120|10007811|FG000|Overall Study|Withdrawal by Subject|0
6291317|NCT02408120|10007812|FG001|Overall Study|Withdrawal by Subject|1
6291318|NCT02408120|10007811|FG000|Overall Study|Treatment Refusal|1
6291319|NCT02408120|10007812|FG001|Overall Study|Treatment Refusal|0
6291320|NCT02408120|10007811|FG000|Overall Study|Received Steroids|1
6291321|NCT02408120|10007812|FG001|Overall Study|Received Steroids|1
6291322|NCT02408120|10007811|FG000|Overall Study|Discharged same day|1
6291323|NCT02408120|10007812|FG001|Overall Study|Discharged same day|1
6291324|NCT02408120|10007811|FG000|Overall Study|Did not receive insulin|1
6291325|NCT02408120|10007812|FG001|Overall Study|Did not receive insulin|2
6291326|NCT02408484|10007841|FG000|Overall Study|Withdrawal by Subject|3
6291327|NCT02408484|10007841|FG000|Overall Study|Not treated during study period|1
6291328|NCT02408523|10007863|FG000|Overall Study|Adverse Event|4
6291329|NCT02408523|10007864|FG001|Overall Study|Adverse Event|10
6291330|NCT02408523|10007863|FG000|Overall Study|Lack of Efficacy|0
6291331|NCT02408523|10007864|FG001|Overall Study|Lack of Efficacy|1
6291332|NCT02408523|10007863|FG000|Overall Study|Protocol Violation|1
6291333|NCT02408523|10007864|FG001|Overall Study|Protocol Violation|2
6291334|NCT02408523|10007863|FG000|Overall Study|Lost to Follow-up|2
6291335|NCT02408523|10007864|FG001|Overall Study|Lost to Follow-up|3
6291336|NCT02408523|10007863|FG000|Overall Study|Withdrawal by Subject|3
6291337|NCT02408523|10007864|FG001|Overall Study|Withdrawal by Subject|1
6291338|NCT02408523|10007863|FG000|Overall Study|Sponsor request|1
6291339|NCT02408523|10007864|FG001|Overall Study|Sponsor request|0
6291340|NCT02408523|10007863|FG000|Overall Study|Did not satisfy extension conditions|0
6291341|NCT02408523|10007864|FG001|Overall Study|Did not satisfy extension conditions|1
6291342|NCT02409667|10007957|FG000|Treatment Period 1, Baseline to Week 24|Withdrawal of informed consent|6
6291343|NCT02409667|10007958|FG001|Treatment Period 1, Baseline to Week 24|Withdrawal of informed consent|0
6291344|NCT02409667|10007959|FG002|Treatment Period 1, Baseline to Week 24|Withdrawal of informed consent|0
6291345|NCT02409667|10007960|FG003|Treatment Period 1, Baseline to Week 24|Withdrawal of informed consent|0
6291346|NCT02409667|10007961|FG004|Treatment Period 1, Baseline to Week 24|Withdrawal of informed consent|0
6291347|NCT02409667|10007957|FG000|Treatment Period 1, Baseline to Week 24|Withdrawal by Subject|6
6291348|NCT02409667|10007958|FG001|Treatment Period 1, Baseline to Week 24|Withdrawal by Subject|0
6291349|NCT02409667|10007959|FG002|Treatment Period 1, Baseline to Week 24|Withdrawal by Subject|0
6291350|NCT02409667|10007960|FG003|Treatment Period 1, Baseline to Week 24|Withdrawal by Subject|0
6291351|NCT02409667|10007961|FG004|Treatment Period 1, Baseline to Week 24|Withdrawal by Subject|0
6291352|NCT02409667|10007957|FG000|Treatment Period 1, Baseline to Week 24|Protocol deviation|20
6291353|NCT02409667|10007958|FG001|Treatment Period 1, Baseline to Week 24|Protocol deviation|0
6291354|NCT02409667|10007959|FG002|Treatment Period 1, Baseline to Week 24|Protocol deviation|0
6291355|NCT02409667|10007960|FG003|Treatment Period 1, Baseline to Week 24|Protocol deviation|0
6291356|NCT02409667|10007961|FG004|Treatment Period 1, Baseline to Week 24|Protocol deviation|0
6291357|NCT02409667|10007957|FG000|Treatment Period 1, Baseline to Week 24|Pregnancy|1
6291358|NCT02409667|10007958|FG001|Treatment Period 1, Baseline to Week 24|Pregnancy|0
6291359|NCT02409667|10007959|FG002|Treatment Period 1, Baseline to Week 24|Pregnancy|0
6291360|NCT02409667|10007960|FG003|Treatment Period 1, Baseline to Week 24|Pregnancy|0
6291361|NCT02409667|10007961|FG004|Treatment Period 1, Baseline to Week 24|Pregnancy|0
6291362|NCT02409667|10007957|FG000|Treatment Period 1, Baseline to Week 24|Physician Decision|4
6291363|NCT02409667|10007958|FG001|Treatment Period 1, Baseline to Week 24|Physician Decision|0
6291364|NCT02409667|10007959|FG002|Treatment Period 1, Baseline to Week 24|Physician Decision|0
6291365|NCT02409667|10007960|FG003|Treatment Period 1, Baseline to Week 24|Physician Decision|0
6291366|NCT02409667|10007961|FG004|Treatment Period 1, Baseline to Week 24|Physician Decision|0
6291367|NCT02409667|10007957|FG000|Treatment Period 1, Baseline to Week 24|Non-compliance with study treatment|5
6291368|NCT02409667|10007958|FG001|Treatment Period 1, Baseline to Week 24|Non-compliance with study treatment|0
6291369|NCT02409667|10007959|FG002|Treatment Period 1, Baseline to Week 24|Non-compliance with study treatment|0
6291370|NCT02409667|10007960|FG003|Treatment Period 1, Baseline to Week 24|Non-compliance with study treatment|0
6291371|NCT02409667|10007961|FG004|Treatment Period 1, Baseline to Week 24|Non-compliance with study treatment|0
6291372|NCT02409667|10007957|FG000|Treatment Period 1, Baseline to Week 24|Lost to Follow-up|6
6291373|NCT02409667|10007958|FG001|Treatment Period 1, Baseline to Week 24|Lost to Follow-up|0
6291374|NCT02409667|10007959|FG002|Treatment Period 1, Baseline to Week 24|Lost to Follow-up|0
6291375|NCT02409667|10007960|FG003|Treatment Period 1, Baseline to Week 24|Lost to Follow-up|0
6291376|NCT02409667|10007961|FG004|Treatment Period 1, Baseline to Week 24|Lost to Follow-up|0
6291377|NCT02409667|10007957|FG000|Treatment Period 1, Baseline to Week 24|Lack of Efficacy|48
6291378|NCT02409667|10007958|FG001|Treatment Period 1, Baseline to Week 24|Lack of Efficacy|0
6291379|NCT02409667|10007959|FG002|Treatment Period 1, Baseline to Week 24|Lack of Efficacy|0
6291380|NCT02409667|10007960|FG003|Treatment Period 1, Baseline to Week 24|Lack of Efficacy|0
6291381|NCT02409667|10007961|FG004|Treatment Period 1, Baseline to Week 24|Lack of Efficacy|0
6291382|NCT02409667|10007957|FG000|Treatment Period 1, Baseline to Week 24|Adverse Event|25
6291383|NCT02409667|10007958|FG001|Treatment Period 1, Baseline to Week 24|Adverse Event|0
6291384|NCT02409667|10007959|FG002|Treatment Period 1, Baseline to Week 24|Adverse Event|0
6291385|NCT02409667|10007960|FG003|Treatment Period 1, Baseline to Week 24|Adverse Event|0
6291386|NCT02409667|10007961|FG004|Treatment Period 1, Baseline to Week 24|Adverse Event|0
6291387|NCT02409667|10007957|FG000|Treatment Period 2, Week 24 to Week 52)|Lost to Follow-up|0
6291388|NCT02409667|10007958|FG001|Treatment Period 2, Week 24 to Week 52)|Lost to Follow-up|7
6291389|NCT02409667|10007959|FG002|Treatment Period 2, Week 24 to Week 52)|Lost to Follow-up|4
6291390|NCT02409667|10007960|FG003|Treatment Period 2, Week 24 to Week 52)|Lost to Follow-up|3
6291391|NCT02409667|10007961|FG004|Treatment Period 2, Week 24 to Week 52)|Lost to Follow-up|0
6291392|NCT02409667|10007957|FG000|Treatment Period 2, Week 24 to Week 52)|Lack of Efficacy|0
6291393|NCT02409667|10007958|FG001|Treatment Period 2, Week 24 to Week 52)|Lack of Efficacy|0
6291394|NCT02409667|10007959|FG002|Treatment Period 2, Week 24 to Week 52)|Lack of Efficacy|0
6291395|NCT02409667|10007960|FG003|Treatment Period 2, Week 24 to Week 52)|Lack of Efficacy|2
6291396|NCT02409667|10007961|FG004|Treatment Period 2, Week 24 to Week 52)|Lack of Efficacy|0
6291397|NCT02409667|10007957|FG000|Treatment Period 2, Week 24 to Week 52)|Adverse Event|0
6291398|NCT02409667|10007958|FG001|Treatment Period 2, Week 24 to Week 52)|Adverse Event|7
6291399|NCT02409667|10007959|FG002|Treatment Period 2, Week 24 to Week 52)|Adverse Event|4
6291400|NCT02409667|10007960|FG003|Treatment Period 2, Week 24 to Week 52)|Adverse Event|1
6291401|NCT02409667|10007961|FG004|Treatment Period 2, Week 24 to Week 52)|Adverse Event|2
6291402|NCT02409667|10007957|FG000|Treatment Period 2, Week 24 to Week 52)|Withdrawal of informed consent|0
6291403|NCT02409667|10007958|FG001|Treatment Period 2, Week 24 to Week 52)|Withdrawal of informed consent|5
6291404|NCT02409667|10007959|FG002|Treatment Period 2, Week 24 to Week 52)|Withdrawal of informed consent|4
6291405|NCT02409667|10007960|FG003|Treatment Period 2, Week 24 to Week 52)|Withdrawal of informed consent|0
6291406|NCT02409667|10007961|FG004|Treatment Period 2, Week 24 to Week 52)|Withdrawal of informed consent|0
6291407|NCT02409667|10007957|FG000|Treatment Period 2, Week 24 to Week 52)|Withdrawal by Subject|0
6291408|NCT02409667|10007958|FG001|Treatment Period 2, Week 24 to Week 52)|Withdrawal by Subject|4
6291409|NCT02409667|10007959|FG002|Treatment Period 2, Week 24 to Week 52)|Withdrawal by Subject|5
6291410|NCT02409667|10007960|FG003|Treatment Period 2, Week 24 to Week 52)|Withdrawal by Subject|2
6291411|NCT02409667|10007961|FG004|Treatment Period 2, Week 24 to Week 52)|Withdrawal by Subject|0
6291412|NCT02409667|10007957|FG000|Treatment Period 2, Week 24 to Week 52)|Pregnancy|0
6291413|NCT02409667|10007958|FG001|Treatment Period 2, Week 24 to Week 52)|Pregnancy|0
6291414|NCT02409667|10007959|FG002|Treatment Period 2, Week 24 to Week 52)|Pregnancy|1
6291415|NCT02409667|10007960|FG003|Treatment Period 2, Week 24 to Week 52)|Pregnancy|0
6291416|NCT02409667|10007961|FG004|Treatment Period 2, Week 24 to Week 52)|Pregnancy|1
6291417|NCT02409667|10007957|FG000|Treatment Period 2, Week 24 to Week 52)|Protocol deviation|0
6291418|NCT02409667|10007958|FG001|Treatment Period 2, Week 24 to Week 52)|Protocol deviation|0
6291419|NCT02409667|10007959|FG002|Treatment Period 2, Week 24 to Week 52)|Protocol deviation|3
6291420|NCT02409667|10007960|FG003|Treatment Period 2, Week 24 to Week 52)|Protocol deviation|0
6291421|NCT02409667|10007961|FG004|Treatment Period 2, Week 24 to Week 52)|Protocol deviation|0
6291422|NCT02409680|10007974|FG000|Overall Study|Lost to Follow-up|15
6291423|NCT02409680|10007975|FG001|Overall Study|Lost to Follow-up|30
6291424|NCT02409719|10007983|FG000|Overall Study|Lost to Follow-up|3
6291425|NCT02409719|10007984|FG001|Overall Study|Lost to Follow-up|3
6291426|NCT02409732|10007990|FG000|Overall Study|Withdrawal by Subject|4
6291427|NCT02409732|10007990|FG000|Overall Study|Lost to Follow-up|2
6291428|NCT02410200|10008026|FG000|Overall Study|Adverse Event|2
6291429|NCT02410252|10008037|FG000|Overall Study|Withdrawal by Subject|4
6291430|NCT02410252|10008037|FG000|Overall Study|Physician Decision|2
6291431|NCT02410278|10008045|FG000|Run-in Period|Adverse Event|5
6291432|NCT02410278|10008046|FG001|Run-in Period|Adverse Event|0
6291433|NCT02410278|10008047|FG002|Run-in Period|Adverse Event|0
6291434|NCT02410278|10008045|FG000|Run-in Period|GSRS Threshold Not Met|30
6291435|NCT02410278|10008046|FG001|Run-in Period|GSRS Threshold Not Met|0
6291436|NCT02410278|10008047|FG002|Run-in Period|GSRS Threshold Not Met|0
6291437|NCT02410278|10008045|FG000|Run-in Period|Lost to Follow-up|1
6291438|NCT02410278|10008046|FG001|Run-in Period|Lost to Follow-up|0
6291439|NCT02410278|10008047|FG002|Run-in Period|Lost to Follow-up|0
6291440|NCT02410278|10008045|FG000|Run-in Period|Withdrawal by Subject|1
6291441|NCT02410278|10008046|FG001|Run-in Period|Withdrawal by Subject|0
6291442|NCT02410278|10008047|FG002|Run-in Period|Withdrawal by Subject|0
6291443|NCT02410278|10008045|FG000|Run-in Period|Pregnancy|1
6291444|NCT02410278|10008046|FG001|Run-in Period|Pregnancy|0
6291445|NCT02410278|10008047|FG002|Run-in Period|Pregnancy|0
6291446|NCT02410278|10008045|FG000|Study Treatment Period|Adverse Event|0
6291447|NCT02410278|10008046|FG001|Study Treatment Period|Adverse Event|6
6291448|NCT02410278|10008047|FG002|Study Treatment Period|Adverse Event|3
6291449|NCT02410278|10008045|FG000|Study Treatment Period|Physician Decision|0
6291450|NCT02410278|10008046|FG001|Study Treatment Period|Physician Decision|0
6291451|NCT02410278|10008047|FG002|Study Treatment Period|Physician Decision|1
6291452|NCT02410278|10008045|FG000|Study Treatment Period|Withdrawal by Subject|0
6291453|NCT02410278|10008046|FG001|Study Treatment Period|Withdrawal by Subject|1
6291454|NCT02410278|10008047|FG002|Study Treatment Period|Withdrawal by Subject|0
6291455|NCT02410278|10008045|FG000|Study Treatment Period|Other|0
6291456|NCT02410278|10008046|FG001|Study Treatment Period|Other|3
6291457|NCT02410278|10008047|FG002|Study Treatment Period|Other|0
6291458|NCT02410278|10008045|FG000|Study Treatment Period|GSRS Threshold Not Met|0
6291459|NCT02410278|10008046|FG001|Study Treatment Period|GSRS Threshold Not Met|1
6291460|NCT02410278|10008047|FG002|Study Treatment Period|GSRS Threshold Not Met|0
6291461|NCT02410629|10008074|FG000|Overall Study|Family cannot commit to the study|2
6291462|NCT02410629|10008075|FG001|Overall Study|Family cannot commit to the study|1
6291463|NCT02410629|10008074|FG000|Overall Study|Subject returned to work|1
6291464|NCT02410629|10008075|FG001|Overall Study|Subject returned to work|0
6291465|NCT02410629|10008074|FG000|Overall Study|Subject moved back to home country|0
6291466|NCT02410629|10008075|FG001|Overall Study|Subject moved back to home country|1
6291467|NCT02410629|10008074|FG000|Overall Study|Subject underwent heart surgery|0
6291468|NCT02410629|10008075|FG001|Overall Study|Subject underwent heart surgery|1
6291469|NCT02410772|10008090|FG000|Overall Study|Death|3
6291470|NCT02410772|10008091|FG001|Overall Study|Death|4
6291471|NCT02410772|10008092|FG002|Overall Study|Death|8
6291472|NCT02410772|10008090|FG000|Overall Study|Lost to Follow-up|31
6291473|NCT02410772|10008091|FG001|Overall Study|Lost to Follow-up|23
6291474|NCT02410772|10008092|FG002|Overall Study|Lost to Follow-up|22
6291475|NCT02410772|10008090|FG000|Overall Study|Pregnancy|8
6291476|NCT02410772|10008091|FG001|Overall Study|Pregnancy|4
6291477|NCT02410772|10008092|FG002|Overall Study|Pregnancy|5
6291478|NCT02410772|10008090|FG000|Overall Study|Protocol Violation|8
6291479|NCT02410772|10008091|FG001|Overall Study|Protocol Violation|8
6291480|NCT02410772|10008092|FG002|Overall Study|Protocol Violation|4
6291481|NCT02410772|10008090|FG000|Overall Study|Baseline Drug Resistance|49
6291482|NCT02410772|10008091|FG001|Overall Study|Baseline Drug Resistance|40
6291483|NCT02410772|10008092|FG002|Overall Study|Baseline Drug Resistance|51
6291484|NCT02410772|10008090|FG000|Overall Study|No positive Mycobacterium tuberculosis culture|4
6291485|NCT02410772|10008091|FG001|Overall Study|No positive Mycobacterium tuberculosis culture|6
6291486|NCT02410772|10008092|FG002|Overall Study|No positive Mycobacterium tuberculosis culture|3
6291487|NCT02410772|10008090|FG000|Overall Study|Reinfection with a new strain of MTB|0
6291488|NCT02410772|10008091|FG001|Overall Study|Reinfection with a new strain of MTB|1
6291489|NCT02410772|10008092|FG002|Overall Study|Reinfection with a new strain of MTB|0
6291490|NCT02410811|10008109|FG000|Overall Study|Withdrawal by Subject|0
6291491|NCT02410811|10008110|FG001|Overall Study|Withdrawal by Subject|0
6291492|NCT02410811|10008111|FG002|Overall Study|Withdrawal by Subject|1
6291493|NCT02410811|10008112|FG003|Overall Study|Withdrawal by Subject|0
6291494|NCT02410824|10008122|FG000|First Intervention (One Week)|Headache|0
6291495|NCT02410824|10008123|FG001|First Intervention (One Week)|Headache|1
6291496|NCT02410837|10008130|FG000|Overall Study|Death|387
6291497|NCT02410837|10008130|FG000|Overall Study|Lost to Follow-up|50
6291498|NCT02410837|10008130|FG000|Overall Study|Withdrawal by Subject|44
6291499|NCT02410837|10008130|FG000|Overall Study|Physician Decision|6
6291500|NCT02410837|10008130|FG000|Overall Study|Moved to nursing home, cannot communicat|1
6291501|NCT02411084|10008145|FG000|Overall Study|Lack of Efficacy|6
6291502|NCT02411084|10008146|FG001|Overall Study|Lack of Efficacy|3
6291503|NCT02411084|10008145|FG000|Overall Study|Death|5
6291504|NCT02411084|10008146|FG001|Overall Study|Death|4
6291505|NCT02411084|10008145|FG000|Overall Study|Adverse Event|2
6291506|NCT02411084|10008146|FG001|Overall Study|Adverse Event|1
6291507|NCT02411084|10008145|FG000|Overall Study|Other reasons|0
6291508|NCT02411084|10008146|FG001|Overall Study|Other reasons|5
6291509|NCT02411110|10008154|FG000|Treatment Period 1|Adverse Event|4
6291510|NCT02411110|10008155|FG001|Treatment Period 1|Adverse Event|2
6291511|NCT02411110|10008154|FG000|Treatment Period 1|Lost to Follow-up|1
6291512|NCT02411110|10008155|FG001|Treatment Period 1|Lost to Follow-up|0
6291513|NCT02411110|10008154|FG000|Treatment Period 1|Personal Reasons|2
6291514|NCT02411110|10008155|FG001|Treatment Period 1|Personal Reasons|5
6291515|NCT02411110|10008154|FG000|Treatment Period 1|Other Miscellaneous Reasons|2
6291516|NCT02411110|10008155|FG001|Treatment Period 1|Other Miscellaneous Reasons|0
6291517|NCT02411110|10008154|FG000|Treatment Period 2|Adverse Event|1
6291518|NCT02411110|10008155|FG001|Treatment Period 2|Adverse Event|0
6291519|NCT02411110|10008154|FG000|Treatment Period 2|Lost to Follow-up|0
6291520|NCT02411110|10008155|FG001|Treatment Period 2|Lost to Follow-up|2
6291521|NCT02411110|10008154|FG000|Treatment Period 2|Personal Reasons|0
6291522|NCT02411110|10008155|FG001|Treatment Period 2|Personal Reasons|2
6291523|NCT02411201|10008163|FG000|Overall Study|Adverse Event|2
6291524|NCT02411201|10008163|FG000|Overall Study|Withdrawal by Subject|2
6291525|NCT02411201|10008163|FG000|Overall Study|Age group completed|2
6291526|NCT02411292|10008169|FG000|Overall Study|Discharged before 3rd enoxaparin dose|16
6291527|NCT02411292|10008169|FG000|Overall Study|Death|2
6291528|NCT02411292|10008169|FG000|Overall Study|Lost to Follow-up|3
6291529|NCT02411396|10008175|FG000|Overall Study|Lost to Follow-up|31
6291530|NCT02411396|10008175|FG000|Overall Study|Death|10
6291531|NCT02411539|10008199|FG000|Overall Study|Lost to Follow-up|2
6291532|NCT02411539|10008200|FG001|Overall Study|Lost to Follow-up|0
6291533|NCT02411539|10008199|FG000|Overall Study|Confounding medical condition|0
6291534|NCT02411539|10008200|FG001|Overall Study|Confounding medical condition|1
6291535|NCT02411578|10008220|FG000|Crossover Trial Phase|Pregnancy|0
6291536|NCT02411578|10008221|FG001|Crossover Trial Phase|Pregnancy|1
6291537|NCT02411591|10008232|FG000|Overall Study|Adverse Event|0
6291538|NCT02411591|10008233|FG001|Overall Study|Adverse Event|4
6291539|NCT02411591|10008234|FG002|Overall Study|Adverse Event|2
6291540|NCT02411591|10008232|FG000|Overall Study|Withdrawal by Subject|0
6291541|NCT02411591|10008233|FG001|Overall Study|Withdrawal by Subject|3
6291542|NCT02411591|10008234|FG002|Overall Study|Withdrawal by Subject|0
6291543|NCT02411591|10008232|FG000|Overall Study|Physician Decision|0
6291544|NCT02411591|10008233|FG001|Overall Study|Physician Decision|3
6291545|NCT02411591|10008234|FG002|Overall Study|Physician Decision|1
6291546|NCT02411747|10008252|FG000|Overall Study|Withdrawal by Subject|1
6291547|NCT02411747|10008253|FG001|Overall Study|Withdrawal by Subject|0
6291548|NCT02411747|10008252|FG000|Overall Study|Protocol Violation|2
6291549|NCT02411747|10008253|FG001|Overall Study|Protocol Violation|4
6291550|NCT02412111|10008296|FG000|Ivacaftor Run-in Period (4 Weeks)|Did not meet eligibility criteria|1
6291551|NCT02412111|10008297|FG001|Ivacaftor Run-in Period (4 Weeks)|Did not meet eligibility criteria|0
6291552|NCT02412111|10008298|FG002|Ivacaftor Run-in Period (4 Weeks)|Did not meet eligibility criteria|0
6291553|NCT02412111|10008296|FG000|Ivacaftor Run-in Period (4 Weeks)|Participants refused further dosing|2
6291554|NCT02412111|10008297|FG001|Ivacaftor Run-in Period (4 Weeks)|Participants refused further dosing|0
6291555|NCT02412111|10008298|FG002|Ivacaftor Run-in Period (4 Weeks)|Participants refused further dosing|0
6291556|NCT02412111|10008296|FG000|Active Comparator Period (8 Weeks)|Adverse Event|0
6291557|NCT02412111|10008297|FG001|Active Comparator Period (8 Weeks)|Adverse Event|0
6291558|NCT02412111|10008298|FG002|Active Comparator Period (8 Weeks)|Adverse Event|2
6291559|NCT02412111|10008296|FG000|Active Comparator Period (8 Weeks)|Participants refused further dosing|0
6291560|NCT02412111|10008297|FG001|Active Comparator Period (8 Weeks)|Participants refused further dosing|0
6291561|NCT02412111|10008298|FG002|Active Comparator Period (8 Weeks)|Participants refused further dosing|1
6291562|NCT02412111|10008296|FG000|Active Comparator Period (8 Weeks)|Lost to Follow-up|0
6291563|NCT02412111|10008297|FG001|Active Comparator Period (8 Weeks)|Lost to Follow-up|0
6291564|NCT02412111|10008298|FG002|Active Comparator Period (8 Weeks)|Lost to Follow-up|1
6291565|NCT02412111|10008296|FG000|Active Comparator Period (8 Weeks)|Other non-compliance|0
6291566|NCT02412111|10008297|FG001|Active Comparator Period (8 Weeks)|Other non-compliance|1
6291567|NCT02412111|10008298|FG002|Active Comparator Period (8 Weeks)|Other non-compliance|0
6291568|NCT02412111|10008296|FG000|Active Comparator Period (8 Weeks)|Other|0
6291569|NCT02412111|10008297|FG001|Active Comparator Period (8 Weeks)|Other|0
6291570|NCT02412111|10008298|FG002|Active Comparator Period (8 Weeks)|Other|2
6291571|NCT02412306|10008317|FG000|Overall Study|Lost to Follow-up|0
6291572|NCT02412306|10008318|FG001|Overall Study|Lost to Follow-up|1
6291573|NCT02412306|10008319|FG002|Overall Study|Lost to Follow-up|0
6291574|NCT02412306|10008320|FG003|Overall Study|Lost to Follow-up|0
6291575|NCT02412306|10008321|FG004|Overall Study|Lost to Follow-up|0
6291576|NCT02412306|10008317|FG000|Overall Study|Withdrawal by Subject|0
6291577|NCT02412306|10008318|FG001|Overall Study|Withdrawal by Subject|0
6291578|NCT02412306|10008319|FG002|Overall Study|Withdrawal by Subject|1
6291579|NCT02412306|10008320|FG003|Overall Study|Withdrawal by Subject|0
6291580|NCT02412306|10008321|FG004|Overall Study|Withdrawal by Subject|0
6291581|NCT02412306|10008317|FG000|Overall Study|Death|5
6291582|NCT02412306|10008318|FG001|Overall Study|Death|7
6291583|NCT02412306|10008319|FG002|Overall Study|Death|15
6291584|NCT02412306|10008320|FG003|Overall Study|Death|0
6291585|NCT02412306|10008321|FG004|Overall Study|Death|2
6291586|NCT02412371|10008348|FG000|Overall Study|Withdrawal by Subject|0
6291587|NCT02412371|10008349|FG001|Overall Study|Withdrawal by Subject|2
6291588|NCT02412371|10008350|FG002|Overall Study|Withdrawal by Subject|0
6291589|NCT02412371|10008351|FG003|Overall Study|Withdrawal by Subject|1
6291590|NCT02412371|10008352|FG004|Overall Study|Withdrawal by Subject|1
6291591|NCT02412371|10008353|FG005|Overall Study|Withdrawal by Subject|0
6291592|NCT02412371|10008348|FG000|Overall Study|Sponsor Discontinued Study|1
6291593|NCT02412371|10008349|FG001|Overall Study|Sponsor Discontinued Study|4
6291594|NCT02412371|10008350|FG002|Overall Study|Sponsor Discontinued Study|6
6291595|NCT02412371|10008351|FG003|Overall Study|Sponsor Discontinued Study|4
6291596|NCT02412371|10008352|FG004|Overall Study|Sponsor Discontinued Study|5
6291597|NCT02412371|10008353|FG005|Overall Study|Sponsor Discontinued Study|0
6291598|NCT02412371|10008348|FG000|Overall Study|Death|4
6291599|NCT02412371|10008349|FG001|Overall Study|Death|2
6291600|NCT02412371|10008350|FG002|Overall Study|Death|1
6291601|NCT02412371|10008351|FG003|Overall Study|Death|3
6291602|NCT02412371|10008352|FG004|Overall Study|Death|5
6291603|NCT02412371|10008353|FG005|Overall Study|Death|2
6291604|NCT02412371|10008348|FG000|Overall Study|Other|2
6291605|NCT02412371|10008349|FG001|Overall Study|Other|1
6291606|NCT02412371|10008350|FG002|Overall Study|Other|0
6291607|NCT02412371|10008351|FG003|Overall Study|Other|0
6291608|NCT02412371|10008352|FG004|Overall Study|Other|1
6291609|NCT02412371|10008353|FG005|Overall Study|Other|3
6291610|NCT02412436|10008368|FG000|Overall Study|Protocol-mandated Discontinuation|7
6291611|NCT02412436|10008368|FG000|Overall Study|Lost to Follow-up|6
6291612|NCT02412436|10008368|FG000|Overall Study|Unable to get to clinic|3
6291613|NCT02412436|10008368|FG000|Overall Study|Death|1
6291614|NCT02412436|10008368|FG000|Overall Study|Not Willing to Adhere to Requirements|1
6291615|NCT02412488|10008372|FG000|Overall Study|Lost to Follow-up|10
6291616|NCT02412488|10008372|FG000|Overall Study|Withdrawal by Subject|5
6291617|NCT02412488|10008372|FG000|Overall Study|Physician Decision|1
6291618|NCT02412488|10008372|FG000|Overall Study|No Reveal LINQ Insertion Attempt|1
6291619|NCT02412488|10008372|FG000|Overall Study|Reveal LINQ explant|1
6291620|NCT02412631|10008383|FG000|Overall Study|Adverse Event|1
6291621|NCT02412631|10008384|FG001|Overall Study|Adverse Event|2
6291622|NCT02412631|10008383|FG000|Overall Study|Lost to Follow-up|5
6291623|NCT02412631|10008384|FG001|Overall Study|Lost to Follow-up|9
6291624|NCT02412631|10008383|FG000|Overall Study|Withdrawal by Subject|9
6291625|NCT02412631|10008384|FG001|Overall Study|Withdrawal by Subject|3
6291626|NCT02412631|10008383|FG000|Overall Study|Early stop by FDA|5
6291627|NCT02412631|10008384|FG001|Overall Study|Early stop by FDA|2
6291628|NCT02412631|10008383|FG000|Overall Study|Unspecified reason|6
6291629|NCT02412631|10008384|FG001|Overall Study|Unspecified reason|8
6291630|NCT02412657|10008406|FG000|Overall Study|Lost to Follow-up|1
6291631|NCT02412657|10008407|FG001|Overall Study|Lost to Follow-up|0
6291632|NCT02412657|10008408|FG002|Overall Study|Lost to Follow-up|0
6291633|NCT02412657|10008406|FG000|Overall Study|Protocol Violation|0
6291634|NCT02412657|10008407|FG001|Overall Study|Protocol Violation|2
6291635|NCT02412657|10008408|FG002|Overall Study|Protocol Violation|3
6291636|NCT02412722|10008422|FG000|Overall Study|Adverse Event|0
6291637|NCT02412722|10008423|FG001|Overall Study|Adverse Event|2
6291638|NCT02412722|10008424|FG002|Overall Study|Adverse Event|0
6291639|NCT02412722|10008425|FG003|Overall Study|Adverse Event|3
6291640|NCT02412722|10008426|FG004|Overall Study|Adverse Event|0
6291641|NCT02412722|10008427|FG005|Overall Study|Adverse Event|3
6291642|NCT02412722|10008422|FG000|Overall Study|Progressive Disease|6
6291643|NCT02412722|10008423|FG001|Overall Study|Progressive Disease|4
6291644|NCT02412722|10008424|FG002|Overall Study|Progressive Disease|4
6291645|NCT02412722|10008425|FG003|Overall Study|Progressive Disease|9
6291646|NCT02412722|10008426|FG004|Overall Study|Progressive Disease|3
6291647|NCT02412722|10008427|FG005|Overall Study|Progressive Disease|3
6291648|NCT02412722|10008422|FG000|Overall Study|Withdrawal by Subject|2
6291649|NCT02412722|10008423|FG001|Overall Study|Withdrawal by Subject|0
6291650|NCT02412722|10008424|FG002|Overall Study|Withdrawal by Subject|1
6291651|NCT02412722|10008425|FG003|Overall Study|Withdrawal by Subject|2
6291652|NCT02412722|10008426|FG004|Overall Study|Withdrawal by Subject|1
5981169|NCT02224573|9570090|FG001|Treatment Phase|Lost to Follow-up|1
5981170|NCT02224573|9570089|FG000|Taper Phase|Completed Incorrect Number of Taper Days|1
5981171|NCT02224573|9570090|FG001|Taper Phase|Completed Incorrect Number of Taper Days|0
5981172|NCT02224573|9570089|FG000|Taper Phase|Hospitalization/Dose Reduction|1
5981173|NCT02224573|9570090|FG001|Taper Phase|Hospitalization/Dose Reduction|0
5981174|NCT02224573|9570089|FG000|Taper Phase|Withdrawn by participants or parent/guardian|0
5981175|NCT02224573|9570090|FG001|Taper Phase|Withdrawn by participants or parent/guardian|3
5981176|NCT02224573|9570089|FG000|Taper Phase|Adverse Event|1
5981177|NCT02224573|9570090|FG001|Taper Phase|Adverse Event|1
5981178|NCT01991067|9570099|FG000|Overall Study|Lost to Follow-up|6
5981179|NCT01991067|9570100|FG001|Overall Study|Lost to Follow-up|5
5981180|NCT01966471|9570108|FG000|Overall Study|Death|33
5981181|NCT01966471|9570109|FG001|Overall Study|Death|44
5981182|NCT01966471|9570108|FG000|Overall Study|Lost to Follow-up|14
5981183|NCT01966471|9570109|FG001|Overall Study|Lost to Follow-up|16
5981184|NCT01966471|9570108|FG000|Overall Study|Other|3
5981185|NCT01966471|9570109|FG001|Overall Study|Other|5
5981186|NCT01966471|9570108|FG000|Overall Study|Physician Decision|5
5981187|NCT01966471|9570109|FG001|Overall Study|Physician Decision|5
5981188|NCT01966471|9570108|FG000|Overall Study|Withdrawal by Subject|48
5981189|NCT01966471|9570109|FG001|Overall Study|Withdrawal by Subject|43
5981190|NCT01774721|9570130|FG000|Overall Study|Death|76
5981191|NCT01774721|9570131|FG001|Overall Study|Death|91
5981192|NCT01774721|9570130|FG000|Overall Study|Withdrawal by Subject|14
5981193|NCT01774721|9570131|FG001|Overall Study|Withdrawal by Subject|10
5981194|NCT01774721|9570130|FG000|Overall Study|Lost to Follow-up|1
5981195|NCT01774721|9570131|FG001|Overall Study|Lost to Follow-up|1
5981196|NCT01774721|9570130|FG000|Overall Study|Did not meet eligibility criteria|0
5981197|NCT01774721|9570131|FG001|Overall Study|Did not meet eligibility criteria|3
5981198|NCT01774721|9570130|FG000|Overall Study|Ongoing in study|136
5981199|NCT01774721|9570131|FG001|Overall Study|Ongoing in study|120
5981200|NCT01709331|9570148|FG000|Overall Study|Adverse Event|1
5981201|NCT01656434|9570169|FG000|Overall Study|Adverse Event|199
5981202|NCT01656434|9570170|FG001|Overall Study|Adverse Event|63
5981203|NCT01656434|9570169|FG000|Overall Study|Enrollment terminated at trial site|2
5981204|NCT01656434|9570170|FG001|Overall Study|Enrollment terminated at trial site|0
6291653|NCT02412722|10008427|FG005|Overall Study|Withdrawal by Subject|1
6291654|NCT02412722|10008422|FG000|Overall Study|Lost to Follow-up|0
6291655|NCT02412722|10008423|FG001|Overall Study|Lost to Follow-up|0
6291656|NCT02412722|10008424|FG002|Overall Study|Lost to Follow-up|0
6291657|NCT02412722|10008425|FG003|Overall Study|Lost to Follow-up|0
6291658|NCT02412722|10008426|FG004|Overall Study|Lost to Follow-up|1
6291659|NCT02412722|10008427|FG005|Overall Study|Lost to Follow-up|0
6291660|NCT02412722|10008422|FG000|Overall Study|Received drug in run-in and discontinued|0
6291661|NCT02412722|10008423|FG001|Overall Study|Received drug in run-in and discontinued|2
6291662|NCT02412722|10008424|FG002|Overall Study|Received drug in run-in and discontinued|0
6291663|NCT02412722|10008425|FG003|Overall Study|Received drug in run-in and discontinued|0
6291664|NCT02412722|10008426|FG004|Overall Study|Received drug in run-in and discontinued|0
6291665|NCT02412722|10008427|FG005|Overall Study|Received drug in run-in and discontinued|0
6291666|NCT02412722|10008422|FG000|Overall Study|Reason not Specified|3
6291667|NCT02412722|10008423|FG001|Overall Study|Reason not Specified|0
6291668|NCT02412722|10008424|FG002|Overall Study|Reason not Specified|2
5981205|NCT01656434|9570169|FG000|Overall Study|Lost to Follow-up|309
6291669|NCT02412722|10008425|FG003|Overall Study|Reason not Specified|1
6291670|NCT02412722|10008426|FG004|Overall Study|Reason not Specified|2
6291671|NCT02412722|10008427|FG005|Overall Study|Reason not Specified|6
6291672|NCT02412761|10008461|FG000|First Intervention (2 Weeks)|Withdrawal by Subject|0
6291673|NCT02412761|10008462|FG001|First Intervention (2 Weeks)|Withdrawal by Subject|1
6291674|NCT02412761|10008463|FG002|First Intervention (2 Weeks)|Withdrawal by Subject|1
6291675|NCT02412761|10008464|FG003|First Intervention (2 Weeks)|Withdrawal by Subject|0
6291676|NCT02412761|10008465|FG004|First Intervention (2 Weeks)|Withdrawal by Subject|0
6291677|NCT02412761|10008466|FG005|First Intervention (2 Weeks)|Withdrawal by Subject|1
6291678|NCT02412852|10008478|FG000|Overall Study|Withdrawal by Subject|0
6291679|NCT02412852|10008479|FG001|Overall Study|Withdrawal by Subject|1
6291680|NCT02412852|10008480|FG002|Overall Study|Withdrawal by Subject|0
6291681|NCT02412852|10008481|FG003|Overall Study|Withdrawal by Subject|0
6291682|NCT02412852|10008478|FG000|Overall Study|Physician Decision|0
6291683|NCT02412852|10008479|FG001|Overall Study|Physician Decision|0
6291684|NCT02412852|10008480|FG002|Overall Study|Physician Decision|0
6291685|NCT02412852|10008481|FG003|Overall Study|Physician Decision|1
6291686|NCT02412878|10008491|FG000|Overall Study|Withdrawal by Subject|19
6291687|NCT02412878|10008492|FG001|Overall Study|Withdrawal by Subject|10
6291688|NCT02412878|10008491|FG000|Overall Study|Lost to Follow-up|2
6291689|NCT02412878|10008492|FG001|Overall Study|Lost to Follow-up|3
6291690|NCT02413229|10008569|FG000|Overall Study|Adverse Event|0
6291691|NCT02413229|10008570|FG001|Overall Study|Adverse Event|0
6291692|NCT02413229|10008571|FG002|Overall Study|Adverse Event|0
6291693|NCT02413229|10008572|FG003|Overall Study|Adverse Event|1
6291694|NCT02413229|10008573|FG004|Overall Study|Adverse Event|0
6291695|NCT02413229|10008574|FG005|Overall Study|Adverse Event|0
6291696|NCT02413229|10008575|FG006|Overall Study|Adverse Event|0
6291697|NCT02413229|10008576|FG007|Overall Study|Adverse Event|1
6291698|NCT02413229|10008569|FG000|Overall Study|Lost to Follow-up|0
6291699|NCT02413229|10008570|FG001|Overall Study|Lost to Follow-up|0
6291700|NCT02413229|10008571|FG002|Overall Study|Lost to Follow-up|1
6291701|NCT02413229|10008572|FG003|Overall Study|Lost to Follow-up|0
6291702|NCT02413229|10008573|FG004|Overall Study|Lost to Follow-up|2
6291703|NCT02413229|10008574|FG005|Overall Study|Lost to Follow-up|0
6291704|NCT02413229|10008575|FG006|Overall Study|Lost to Follow-up|0
6291705|NCT02413229|10008576|FG007|Overall Study|Lost to Follow-up|0
6291706|NCT02413229|10008569|FG000|Overall Study|Withdrawal by Subject|1
6291707|NCT02413229|10008570|FG001|Overall Study|Withdrawal by Subject|1
6291708|NCT02413229|10008571|FG002|Overall Study|Withdrawal by Subject|0
6291709|NCT02413229|10008572|FG003|Overall Study|Withdrawal by Subject|0
6291710|NCT02413229|10008573|FG004|Overall Study|Withdrawal by Subject|1
6291711|NCT02413229|10008574|FG005|Overall Study|Withdrawal by Subject|0
6291712|NCT02413229|10008575|FG006|Overall Study|Withdrawal by Subject|0
6291713|NCT02413229|10008576|FG007|Overall Study|Withdrawal by Subject|2
6291714|NCT02413229|10008569|FG000|Overall Study|Progressive Disease|0
6291715|NCT02413229|10008570|FG001|Overall Study|Progressive Disease|0
6291716|NCT02413229|10008571|FG002|Overall Study|Progressive Disease|0
6291717|NCT02413229|10008572|FG003|Overall Study|Progressive Disease|0
6291718|NCT02413229|10008573|FG004|Overall Study|Progressive Disease|0
6291719|NCT02413229|10008574|FG005|Overall Study|Progressive Disease|0
6291720|NCT02413229|10008575|FG006|Overall Study|Progressive Disease|0
6291721|NCT02413229|10008576|FG007|Overall Study|Progressive Disease|1
6291722|NCT02413255|10008611|FG000|Overall Study|Voluntary Withdrawal|0
6291723|NCT02413255|10008612|FG001|Overall Study|Voluntary Withdrawal|0
6291724|NCT02413255|10008613|FG002|Overall Study|Voluntary Withdrawal|0
6291725|NCT02413255|10008614|FG003|Overall Study|Voluntary Withdrawal|0
6291726|NCT02413255|10008615|FG004|Overall Study|Voluntary Withdrawal|0
6291727|NCT02413255|10008616|FG005|Overall Study|Voluntary Withdrawal|0
6291728|NCT02413255|10008617|FG006|Overall Study|Voluntary Withdrawal|0
6291729|NCT02413255|10008618|FG007|Overall Study|Voluntary Withdrawal|0
6291730|NCT02413255|10008619|FG008|Overall Study|Voluntary Withdrawal|0
6291731|NCT02413255|10008620|FG009|Overall Study|Voluntary Withdrawal|0
6291732|NCT02413255|10008621|FG010|Overall Study|Voluntary Withdrawal|0
6291733|NCT02413255|10008622|FG011|Overall Study|Voluntary Withdrawal|0
6291734|NCT02413255|10008623|FG012|Overall Study|Voluntary Withdrawal|0
6291735|NCT02413255|10008624|FG013|Overall Study|Voluntary Withdrawal|0
6291736|NCT02413255|10008625|FG014|Overall Study|Voluntary Withdrawal|1
6291737|NCT02413255|10008626|FG015|Overall Study|Voluntary Withdrawal|0
6291738|NCT02413255|10008627|FG016|Overall Study|Voluntary Withdrawal|0
6291739|NCT02413294|10008678|FG000|Overall Study|Withdrawal by Subject|1
6291740|NCT02413333|10008695|FG000|Period 1|Adverse Event|1
6291741|NCT02413333|10008696|FG001|Period 1|Adverse Event|0
6291742|NCT02413333|10008695|FG000|Period 1|Reason Not Specified|0
6291743|NCT02413333|10008696|FG001|Period 1|Reason Not Specified|1
6291744|NCT02413333|10008695|FG000|Period 2|Protocol Deviation|1
6291745|NCT02413333|10008696|FG001|Period 2|Protocol Deviation|0
6291746|NCT02413346|10008704|FG000|Overall Study|Adverse Event|6
6291747|NCT02413346|10008705|FG001|Overall Study|Adverse Event|6
6291748|NCT02413346|10008704|FG000|Overall Study|Withdrawal by Subject|30
6291749|NCT02413346|10008705|FG001|Overall Study|Withdrawal by Subject|40
6291750|NCT02413346|10008704|FG000|Overall Study|Lost to Follow-up|17
6291751|NCT02413346|10008705|FG001|Overall Study|Lost to Follow-up|21
6291752|NCT02413346|10008704|FG000|Overall Study|Protocol Violation|2
6291753|NCT02413346|10008705|FG001|Overall Study|Protocol Violation|0
6291754|NCT02413346|10008704|FG000|Overall Study|Other Miscellaneous Reasons|4
6291755|NCT02413346|10008705|FG001|Overall Study|Other Miscellaneous Reasons|3
6291756|NCT02413372|10008714|FG000|Treatment|Lost to Follow-up|0
6291757|NCT02413372|10008715|FG001|Treatment|Lost to Follow-up|2
6291758|NCT02413372|10008716|FG002|Treatment|Lost to Follow-up|1
6291759|NCT02413372|10008714|FG000|Treatment|Withdrawal by Subject|1
6291760|NCT02413372|10008715|FG001|Treatment|Withdrawal by Subject|0
6291761|NCT02413372|10008716|FG002|Treatment|Withdrawal by Subject|0
6291762|NCT02413372|10008714|FG000|Follow-up|Lost to Follow-up|1
6291763|NCT02413372|10008715|FG001|Follow-up|Lost to Follow-up|1
6291764|NCT02413372|10008716|FG002|Follow-up|Lost to Follow-up|0
6291765|NCT02413372|10008714|FG000|Follow-up|Subject Withdrew Consent|1
6291766|NCT02413372|10008715|FG001|Follow-up|Subject Withdrew Consent|0
6291767|NCT02413372|10008716|FG002|Follow-up|Subject Withdrew Consent|1
6291768|NCT02413372|10008714|FG000|Follow-up|Subject unable to return for visit|0
6291769|NCT02413372|10008715|FG001|Follow-up|Subject unable to return for visit|0
6291770|NCT02413372|10008716|FG002|Follow-up|Subject unable to return for visit|1
6291771|NCT02413398|10008726|FG000|Overall Study|Lost to Follow-up|2
6291772|NCT02413398|10008727|FG001|Overall Study|Lost to Follow-up|4
6291773|NCT02413398|10008726|FG000|Overall Study|Withdrawal by Subject|1
6291774|NCT02413398|10008727|FG001|Overall Study|Withdrawal by Subject|1
6291775|NCT02413398|10008726|FG000|Overall Study|Other Eligibility criteria|1
6291776|NCT02413398|10008727|FG001|Overall Study|Other Eligibility criteria|2
6291777|NCT02413489|10008745|FG000|Overall Study|Death|11
6291778|NCT02413489|10008746|FG001|Overall Study|Death|3
6291779|NCT02413489|10008747|FG002|Overall Study|Death|4
6291780|NCT02413489|10008745|FG000|Overall Study|Withdrawal by Subject|2
6291781|NCT02413489|10008746|FG001|Overall Study|Withdrawal by Subject|0
6291782|NCT02413489|10008747|FG002|Overall Study|Withdrawal by Subject|0
6291783|NCT02413489|10008745|FG000|Overall Study|Study Terminated By Sponsor|2
6291784|NCT02413489|10008746|FG001|Overall Study|Study Terminated By Sponsor|13
6291785|NCT02413489|10008747|FG002|Overall Study|Study Terminated By Sponsor|1
6291786|NCT02413593|10008759|FG000|Overall Study|Lost to Follow-up|3
6291787|NCT02413593|10008759|FG000|Overall Study|Adverse Event|1
6291788|NCT02413996|10008780|FG000|Overall Study|not comfortable with the intervention|9
6291789|NCT02413996|10008781|FG001|Overall Study|not comfortable with the intervention|2
6291790|NCT02414828|10008814|FG000|Overall Study|Lost to Follow-up|0
6291791|NCT02414828|10008815|FG001|Overall Study|Lost to Follow-up|1
6291792|NCT02414828|10008816|FG002|Overall Study|Lost to Follow-up|1
6291793|NCT02414828|10008817|FG003|Overall Study|Lost to Follow-up|2
6291794|NCT02414841|10008830|FG000|Overall Study|Withdrawal by Subject|7
5981206|NCT01656434|9570170|FG001|Overall Study|Lost to Follow-up|76
5981207|NCT01656434|9570169|FG000|Overall Study|Site discontinued study participation|24
5981208|NCT01656434|9570170|FG001|Overall Study|Site discontinued study participation|9
5981209|NCT01656434|9570169|FG000|Overall Study|Screen failure|2
5981210|NCT01656434|9570170|FG001|Overall Study|Screen failure|0
5981211|NCT01656434|9570169|FG000|Overall Study|Protocol Violation|7
5981212|NCT01656434|9570170|FG001|Overall Study|Protocol Violation|0
5981213|NCT01656434|9570169|FG000|Overall Study|Pregnancy wish|18
5981214|NCT01656434|9570170|FG001|Overall Study|Pregnancy wish|6
5981215|NCT01656434|9570169|FG000|Overall Study|Pregnancy|45
5981216|NCT01656434|9570170|FG001|Overall Study|Pregnancy|10
5981217|NCT01656434|9570169|FG000|Overall Study|Physician Decision|7
5981218|NCT01656434|9570170|FG001|Overall Study|Physician Decision|2
5981219|NCT01656434|9570169|FG000|Overall Study|Non-compliance with study drug|48
5981220|NCT01656434|9570170|FG001|Overall Study|Non-compliance with study drug|9
5981221|NCT01656434|9570169|FG000|Overall Study|Study terminated by sponsor|1501
5981222|NCT01656434|9570170|FG001|Overall Study|Study terminated by sponsor|348
5981223|NCT01656434|9570169|FG000|Overall Study|Participant discontinued; drug related|13
5981224|NCT01656434|9570170|FG001|Overall Study|Participant discontinued; drug related|4
5981225|NCT01656434|9570169|FG000|Overall Study|Part. discontinued; unrelated to drug|55
5981226|NCT01656434|9570170|FG001|Overall Study|Part. discontinued; unrelated to drug|10
5981227|NCT01656434|9570169|FG000|Overall Study|Non-compliance with protocol|39
5981228|NCT01656434|9570170|FG001|Overall Study|Non-compliance with protocol|15
5981229|NCT01656434|9570169|FG000|Overall Study|Participant moved|40
5981230|NCT01656434|9570170|FG001|Overall Study|Participant moved|12
5981231|NCT01656434|9570169|FG000|Overall Study|Participant withdrew consent|28
5981232|NCT01656434|9570170|FG001|Overall Study|Participant withdrew consent|9
5981233|NCT01656434|9570169|FG000|Overall Study|Withdrawal by Subject|64
5981234|NCT01656434|9570170|FG001|Overall Study|Withdrawal by Subject|7
5981235|NCT01496118|9570199|FG000|Overall Study|Disease progression|3
5981236|NCT01496118|9570200|FG001|Overall Study|Disease progression|2
5981237|NCT01496118|9570201|FG002|Overall Study|Disease progression|3
5981238|NCT01496118|9570202|FG003|Overall Study|Disease progression|1
6291795|NCT02414841|10008831|FG001|Overall Study|Withdrawal by Subject|5
6291796|NCT02414841|10008830|FG000|Overall Study|Lost to Follow-up|13
5981239|NCT01496118|9570203|FG004|Overall Study|Disease progression|2
5981240|NCT01496118|9570204|FG005|Overall Study|Disease progression|2
5981241|NCT01496118|9570205|FG006|Overall Study|Disease progression|14
5981242|NCT01496118|9570206|FG007|Overall Study|Disease progression|10
5981243|NCT01496118|9570199|FG000|Overall Study|Physician Decision|0
5981244|NCT01496118|9570200|FG001|Overall Study|Physician Decision|0
5981245|NCT01496118|9570201|FG002|Overall Study|Physician Decision|0
6291797|NCT02414841|10008831|FG001|Overall Study|Lost to Follow-up|6
6291798|NCT02414841|10008830|FG000|Overall Study|Death|17
6291799|NCT02414841|10008831|FG001|Overall Study|Death|14
6291800|NCT02414841|10008830|FG000|Overall Study|Received a Kidney Transplant|13
6291801|NCT02414841|10008831|FG001|Overall Study|Received a Kidney Transplant|4
6291802|NCT02414841|10008830|FG000|Overall Study|Randomized But Not Treated|6
6291803|NCT02414841|10008831|FG001|Overall Study|Randomized But Not Treated|4
6291804|NCT02414854|10008843|FG000|Overall Study|Adverse Event|9
6291805|NCT02414854|10008844|FG001|Overall Study|Adverse Event|7
6291806|NCT02414854|10008845|FG002|Overall Study|Adverse Event|1
6291807|NCT02414854|10008846|FG003|Overall Study|Adverse Event|12
6291808|NCT02414854|10008843|FG000|Overall Study|Poor compliance to protocol|1
6291809|NCT02414854|10008844|FG001|Overall Study|Poor compliance to protocol|1
6291810|NCT02414854|10008845|FG002|Overall Study|Poor compliance to protocol|2
6291811|NCT02414854|10008846|FG003|Overall Study|Poor compliance to protocol|2
6291812|NCT02414854|10008843|FG000|Overall Study|Other than specified above|12
6291813|NCT02414854|10008844|FG001|Overall Study|Other than specified above|37
6291814|NCT02414854|10008845|FG002|Overall Study|Other than specified above|17
6291815|NCT02414854|10008846|FG003|Overall Study|Other than specified above|37
6291816|NCT02414932|10008858|FG000|Overall Study|Withdrawal by Subject|2
6291817|NCT02414932|10008859|FG001|Overall Study|Withdrawal by Subject|3
6291818|NCT02414932|10008858|FG000|Overall Study|Adverse Event|1
6291819|NCT02414932|10008859|FG001|Overall Study|Adverse Event|0
6291820|NCT02414958|10008868|FG000|Overall Study|Adverse Event|6
6291821|NCT02414958|10008869|FG001|Overall Study|Adverse Event|6
6291822|NCT02414958|10008870|FG002|Overall Study|Adverse Event|3
6291823|NCT02414958|10008868|FG000|Overall Study|Protocol Violation|10
6291824|NCT02414958|10008869|FG001|Overall Study|Protocol Violation|3
6291825|NCT02414958|10008870|FG002|Overall Study|Protocol Violation|1
6291826|NCT02414958|10008868|FG000|Overall Study|Lost to Follow-up|7
6291827|NCT02414958|10008869|FG001|Overall Study|Lost to Follow-up|4
6291828|NCT02414958|10008870|FG002|Overall Study|Lost to Follow-up|0
6291829|NCT02414958|10008868|FG000|Overall Study|Withdrawal by Subject|5
6291830|NCT02414958|10008869|FG001|Overall Study|Withdrawal by Subject|3
6291831|NCT02414958|10008870|FG002|Overall Study|Withdrawal by Subject|5
6291832|NCT02414958|10008868|FG000|Overall Study|Other than specified|4
6291833|NCT02414958|10008869|FG001|Overall Study|Other than specified|4
6291834|NCT02414958|10008870|FG002|Overall Study|Other than specified|5
6291835|NCT02415127|10008880|FG000|Overall Study|Adverse Event|1
6291836|NCT02415127|10008881|FG001|Overall Study|Adverse Event|0
6291837|NCT02415400|10008900|FG000|Overall Study|Adverse Event|0
6291838|NCT02415400|10008901|FG001|Overall Study|Adverse Event|1
6291839|NCT02415400|10008902|FG002|Overall Study|Adverse Event|1
6291840|NCT02415400|10008903|FG003|Overall Study|Adverse Event|2
6291841|NCT02415400|10008900|FG000|Overall Study|Participant request to stop therapy|4
6291842|NCT02415400|10008901|FG001|Overall Study|Participant request to stop therapy|3
6291843|NCT02415400|10008902|FG002|Overall Study|Participant request to stop therapy|8
6291844|NCT02415400|10008903|FG003|Overall Study|Participant request to stop therapy|6
6291845|NCT02415400|10008900|FG000|Overall Study|Participant withdrew consent|14
6291846|NCT02415400|10008901|FG001|Overall Study|Participant withdrew consent|12
6291847|NCT02415400|10008902|FG002|Overall Study|Participant withdrew consent|30
6291848|NCT02415400|10008903|FG003|Overall Study|Participant withdrew consent|21
6291849|NCT02415400|10008900|FG000|Overall Study|Death|39
6291850|NCT02415400|10008901|FG001|Overall Study|Death|41
6291851|NCT02415400|10008902|FG002|Overall Study|Death|35
6291852|NCT02415400|10008903|FG003|Overall Study|Death|42
6291853|NCT02415400|10008900|FG000|Overall Study|Lost to Follow-up|3
6291854|NCT02415400|10008901|FG001|Overall Study|Lost to Follow-up|3
6291855|NCT02415400|10008902|FG002|Overall Study|Lost to Follow-up|2
6291856|NCT02415400|10008903|FG003|Overall Study|Lost to Follow-up|5
6291857|NCT02415400|10008900|FG000|Overall Study|Poor/Non-Compliance|0
6291858|NCT02415400|10008901|FG001|Overall Study|Poor/Non-Compliance|1
6291859|NCT02415400|10008902|FG002|Overall Study|Poor/Non-Compliance|3
6291860|NCT02415400|10008903|FG003|Overall Study|Poor/Non-Compliance|4
6291861|NCT02415400|10008900|FG000|Overall Study|Participant no longer meets criteria|2
6291862|NCT02415400|10008901|FG001|Overall Study|Participant no longer meets criteria|0
6291863|NCT02415400|10008902|FG002|Overall Study|Participant no longer meets criteria|0
6291864|NCT02415400|10008903|FG003|Overall Study|Participant no longer meets criteria|1
6291865|NCT02415400|10008900|FG000|Overall Study|Participant doesn't answer phone|1
6291866|NCT02415400|10008901|FG001|Overall Study|Participant doesn't answer phone|0
6291867|NCT02415400|10008902|FG002|Overall Study|Participant doesn't answer phone|0
6291868|NCT02415400|10008903|FG003|Overall Study|Participant doesn't answer phone|0
6291869|NCT02415400|10008900|FG000|Overall Study|Participant wanted home visits|1
6291870|NCT02415400|10008901|FG001|Overall Study|Participant wanted home visits|0
6291871|NCT02415400|10008902|FG002|Overall Study|Participant wanted home visits|0
6291872|NCT02415400|10008903|FG003|Overall Study|Participant wanted home visits|0
6291873|NCT02415400|10008900|FG000|Overall Study|Randomized in error|2
6291874|NCT02415400|10008901|FG001|Overall Study|Randomized in error|0
6291875|NCT02415400|10008902|FG002|Overall Study|Randomized in error|0
6291876|NCT02415400|10008903|FG003|Overall Study|Randomized in error|0
6291877|NCT02415400|10008900|FG000|Overall Study|No study drug on site|0
6291878|NCT02415400|10008901|FG001|Overall Study|No study drug on site|1
6291879|NCT02415400|10008902|FG002|Overall Study|No study drug on site|0
6291880|NCT02415400|10008903|FG003|Overall Study|No study drug on site|0
6291881|NCT02415400|10008900|FG000|Overall Study|Stroke and stroke rehabilitation|0
6291882|NCT02415400|10008901|FG001|Overall Study|Stroke and stroke rehabilitation|0
6291883|NCT02415400|10008902|FG002|Overall Study|Stroke and stroke rehabilitation|1
6291884|NCT02415400|10008903|FG003|Overall Study|Stroke and stroke rehabilitation|0
6291885|NCT02415400|10008900|FG000|Overall Study|Coagulation values cannot be set|0
6291886|NCT02415400|10008901|FG001|Overall Study|Coagulation values cannot be set|0
6291887|NCT02415400|10008902|FG002|Overall Study|Coagulation values cannot be set|1
6291888|NCT02415400|10008903|FG003|Overall Study|Coagulation values cannot be set|0
6291889|NCT02415400|10008900|FG000|Overall Study|State regulations prevent participation|0
6291890|NCT02415400|10008901|FG001|Overall Study|State regulations prevent participation|0
6291891|NCT02415400|10008902|FG002|Overall Study|State regulations prevent participation|1
6291892|NCT02415400|10008903|FG003|Overall Study|State regulations prevent participation|0
6291893|NCT02415400|10008900|FG000|Overall Study|Poor treatment monitoring|0
6291894|NCT02415400|10008901|FG001|Overall Study|Poor treatment monitoring|0
6291895|NCT02415400|10008902|FG002|Overall Study|Poor treatment monitoring|1
6291896|NCT02415400|10008903|FG003|Overall Study|Poor treatment monitoring|0
6291897|NCT02415400|10008900|FG000|Overall Study|Participant in jail|0
6291898|NCT02415400|10008901|FG001|Overall Study|Participant in jail|0
6291899|NCT02415400|10008902|FG002|Overall Study|Participant in jail|1
6291900|NCT02415400|10008903|FG003|Overall Study|Participant in jail|0
6291901|NCT02415400|10008900|FG000|Overall Study|Investigator decision|0
6291902|NCT02415400|10008901|FG001|Overall Study|Investigator decision|0
6291903|NCT02415400|10008902|FG002|Overall Study|Investigator decision|1
6291904|NCT02415400|10008903|FG003|Overall Study|Investigator decision|1
6291905|NCT02415400|10008900|FG000|Overall Study|Site closure; participant won't transfer|0
6291906|NCT02415400|10008901|FG001|Overall Study|Site closure; participant won't transfer|0
6291907|NCT02415400|10008902|FG002|Overall Study|Site closure; participant won't transfer|0
6291908|NCT02415400|10008903|FG003|Overall Study|Site closure; participant won't transfer|1
6291909|NCT02415595|10008976|FG000|Overall Study|Administrative reason by sponsor|39
6291910|NCT02415595|10008977|FG001|Overall Study|Administrative reason by sponsor|40
6291911|NCT02415595|10008978|FG002|Overall Study|Administrative reason by sponsor|41
6291912|NCT02415595|10008979|FG003|Overall Study|Administrative reason by sponsor|39
6291913|NCT02415595|10008976|FG000|Overall Study|Adverse Event|1
6291914|NCT02415595|10008977|FG001|Overall Study|Adverse Event|3
6291915|NCT02415595|10008978|FG002|Overall Study|Adverse Event|5
6291916|NCT02415595|10008979|FG003|Overall Study|Adverse Event|10
6291917|NCT02415595|10008976|FG000|Overall Study|Lack of Efficacy|4
6291918|NCT02415595|10008977|FG001|Overall Study|Lack of Efficacy|4
6291919|NCT02415595|10008978|FG002|Overall Study|Lack of Efficacy|0
6291920|NCT02415595|10008979|FG003|Overall Study|Lack of Efficacy|0
6291921|NCT02415595|10008976|FG000|Overall Study|Lost to Follow-up|1
6291922|NCT02415595|10008977|FG001|Overall Study|Lost to Follow-up|3
6291923|NCT02415595|10008978|FG002|Overall Study|Lost to Follow-up|1
6291924|NCT02415595|10008979|FG003|Overall Study|Lost to Follow-up|1
6291925|NCT02415595|10008976|FG000|Overall Study|Poor/Non-compliance|1
6291926|NCT02415595|10008977|FG001|Overall Study|Poor/Non-compliance|0
6291927|NCT02415595|10008978|FG002|Overall Study|Poor/Non-compliance|1
6291928|NCT02415595|10008979|FG003|Overall Study|Poor/Non-compliance|0
6291929|NCT02415595|10008976|FG000|Overall Study|Reached stopping criteria|0
6291930|NCT02415595|10008977|FG001|Overall Study|Reached stopping criteria|1
6291931|NCT02415595|10008978|FG002|Overall Study|Reached stopping criteria|1
6291932|NCT02415595|10008979|FG003|Overall Study|Reached stopping criteria|0
6291933|NCT02415595|10008976|FG000|Overall Study|Withdrawal by Subject|4
6291934|NCT02415595|10008977|FG001|Overall Study|Withdrawal by Subject|0
6291935|NCT02415595|10008978|FG002|Overall Study|Withdrawal by Subject|1
6291936|NCT02415595|10008979|FG003|Overall Study|Withdrawal by Subject|3
6291937|NCT02415595|10008976|FG000|Overall Study|Other|0
6291938|NCT02415595|10008977|FG001|Overall Study|Other|1
6291939|NCT02415595|10008978|FG002|Overall Study|Other|1
6291940|NCT02415595|10008979|FG003|Overall Study|Other|0
6291941|NCT02415959|10009083|FG000|Overall Study|Adverse Event|0
6291942|NCT02415959|10009084|FG001|Overall Study|Adverse Event|1
6291943|NCT02415959|10009085|FG002|Overall Study|Adverse Event|0
6291944|NCT02415959|10009086|FG003|Overall Study|Adverse Event|0
6291945|NCT02415959|10009087|FG004|Overall Study|Adverse Event|0
6291946|NCT02415959|10009083|FG000|Overall Study|Protocol Violation|0
6291947|NCT02415959|10009084|FG001|Overall Study|Protocol Violation|0
6291948|NCT02415959|10009085|FG002|Overall Study|Protocol Violation|0
6291949|NCT02415959|10009086|FG003|Overall Study|Protocol Violation|1
6291950|NCT02415959|10009087|FG004|Overall Study|Protocol Violation|0
6291951|NCT02416180|10009116|FG000|Overall Study|Withdrawal by Subject|1
6291952|NCT02416453|10009140|FG000|Overall Study|Adverse Event|0
6291953|NCT02416453|10009141|FG001|Overall Study|Adverse Event|0
6291954|NCT02416453|10009142|FG002|Overall Study|Adverse Event|0
6291955|NCT02416453|10009143|FG003|Overall Study|Adverse Event|2
6291956|NCT02416453|10009144|FG004|Overall Study|Adverse Event|0
6291957|NCT02416453|10009145|FG005|Overall Study|Adverse Event|1
6291958|NCT02416453|10009146|FG006|Overall Study|Adverse Event|0
6291959|NCT02416453|10009147|FG007|Overall Study|Adverse Event|0
6291960|NCT02416453|10009148|FG008|Overall Study|Adverse Event|0
6291961|NCT02416453|10009149|FG009|Overall Study|Adverse Event|0
6291962|NCT02416453|10009150|FG010|Overall Study|Adverse Event|0
6291963|NCT02416453|10009140|FG000|Overall Study|Lost to Follow-up|1
6291964|NCT02416453|10009141|FG001|Overall Study|Lost to Follow-up|3
6291965|NCT02416453|10009142|FG002|Overall Study|Lost to Follow-up|0
6291966|NCT02416453|10009143|FG003|Overall Study|Lost to Follow-up|8
6291967|NCT02416453|10009144|FG004|Overall Study|Lost to Follow-up|0
6291968|NCT02416453|10009145|FG005|Overall Study|Lost to Follow-up|5
6291969|NCT02416453|10009146|FG006|Overall Study|Lost to Follow-up|1
6291970|NCT02416453|10009147|FG007|Overall Study|Lost to Follow-up|3
6291971|NCT02416453|10009148|FG008|Overall Study|Lost to Follow-up|1
6291972|NCT02416453|10009149|FG009|Overall Study|Lost to Follow-up|0
6291973|NCT02416453|10009150|FG010|Overall Study|Lost to Follow-up|0
6291974|NCT02416453|10009140|FG000|Overall Study|Physician Decision|0
6291975|NCT02416453|10009141|FG001|Overall Study|Physician Decision|0
6291976|NCT02416453|10009142|FG002|Overall Study|Physician Decision|0
6291977|NCT02416453|10009143|FG003|Overall Study|Physician Decision|0
6291978|NCT02416453|10009144|FG004|Overall Study|Physician Decision|0
6291979|NCT02416453|10009145|FG005|Overall Study|Physician Decision|1
6291980|NCT02416453|10009146|FG006|Overall Study|Physician Decision|1
6291981|NCT02416453|10009147|FG007|Overall Study|Physician Decision|1
6291982|NCT02416453|10009148|FG008|Overall Study|Physician Decision|0
6291983|NCT02416453|10009149|FG009|Overall Study|Physician Decision|0
6291984|NCT02416453|10009150|FG010|Overall Study|Physician Decision|0
6291985|NCT02416453|10009140|FG000|Overall Study|Withdrawal by Subject|2
6291986|NCT02416453|10009141|FG001|Overall Study|Withdrawal by Subject|0
6291987|NCT02416453|10009142|FG002|Overall Study|Withdrawal by Subject|0
6291988|NCT02416453|10009143|FG003|Overall Study|Withdrawal by Subject|5
6291989|NCT02416453|10009144|FG004|Overall Study|Withdrawal by Subject|1
6291990|NCT02416453|10009145|FG005|Overall Study|Withdrawal by Subject|8
6291991|NCT02416453|10009146|FG006|Overall Study|Withdrawal by Subject|0
6291992|NCT02416453|10009147|FG007|Overall Study|Withdrawal by Subject|8
6291993|NCT02416453|10009148|FG008|Overall Study|Withdrawal by Subject|4
6291994|NCT02416453|10009149|FG009|Overall Study|Withdrawal by Subject|0
6291995|NCT02416453|10009150|FG010|Overall Study|Withdrawal by Subject|0
6291996|NCT02416453|10009140|FG000|Overall Study|PARTICIPANT UNABLE TO ATTEND ANY FURTHER|0
6291997|NCT02416453|10009141|FG001|Overall Study|PARTICIPANT UNABLE TO ATTEND ANY FURTHER|0
6291998|NCT02416453|10009142|FG002|Overall Study|PARTICIPANT UNABLE TO ATTEND ANY FURTHER|1
6291999|NCT02416453|10009143|FG003|Overall Study|PARTICIPANT UNABLE TO ATTEND ANY FURTHER|0
6292000|NCT02416453|10009144|FG004|Overall Study|PARTICIPANT UNABLE TO ATTEND ANY FURTHER|0
6292001|NCT02416453|10009145|FG005|Overall Study|PARTICIPANT UNABLE TO ATTEND ANY FURTHER|0
6292002|NCT02416453|10009146|FG006|Overall Study|PARTICIPANT UNABLE TO ATTEND ANY FURTHER|0
6292003|NCT02416453|10009147|FG007|Overall Study|PARTICIPANT UNABLE TO ATTEND ANY FURTHER|0
6292004|NCT02416453|10009148|FG008|Overall Study|PARTICIPANT UNABLE TO ATTEND ANY FURTHER|0
6292005|NCT02416453|10009149|FG009|Overall Study|PARTICIPANT UNABLE TO ATTEND ANY FURTHER|0
6292006|NCT02416453|10009150|FG010|Overall Study|PARTICIPANT UNABLE TO ATTEND ANY FURTHER|0
6292007|NCT02416453|10009140|FG000|Overall Study|PARTICIPANT HAS MOVED TO SINGAPORE|0
6292008|NCT02416453|10009141|FG001|Overall Study|PARTICIPANT HAS MOVED TO SINGAPORE|0
6292009|NCT02416453|10009142|FG002|Overall Study|PARTICIPANT HAS MOVED TO SINGAPORE|0
6292010|NCT02416453|10009143|FG003|Overall Study|PARTICIPANT HAS MOVED TO SINGAPORE|0
6292011|NCT02416453|10009144|FG004|Overall Study|PARTICIPANT HAS MOVED TO SINGAPORE|0
6292012|NCT02416453|10009145|FG005|Overall Study|PARTICIPANT HAS MOVED TO SINGAPORE|1
6292013|NCT02416453|10009146|FG006|Overall Study|PARTICIPANT HAS MOVED TO SINGAPORE|0
6292014|NCT02416453|10009147|FG007|Overall Study|PARTICIPANT HAS MOVED TO SINGAPORE|0
6292015|NCT02416453|10009148|FG008|Overall Study|PARTICIPANT HAS MOVED TO SINGAPORE|0
6292016|NCT02416453|10009149|FG009|Overall Study|PARTICIPANT HAS MOVED TO SINGAPORE|0
6292017|NCT02416453|10009150|FG010|Overall Study|PARTICIPANT HAS MOVED TO SINGAPORE|0
6292018|NCT02416791|10009213|FG000|6 Months|Lost to Follow-up|0
6292019|NCT02416791|10009214|FG001|6 Months|Lost to Follow-up|0
6292020|NCT02416791|10009215|FG002|6 Months|Lost to Follow-up|1
6292021|NCT02416908|10009226|FG000|Dose Escalation Phase|Adverse Event|0
5981246|NCT01496118|9570202|FG003|Overall Study|Physician Decision|0
5981247|NCT01496118|9570203|FG004|Overall Study|Physician Decision|1
5981248|NCT01496118|9570204|FG005|Overall Study|Physician Decision|0
5981249|NCT01496118|9570205|FG006|Overall Study|Physician Decision|3
5981250|NCT01496118|9570206|FG007|Overall Study|Physician Decision|6
5981251|NCT01496118|9570199|FG000|Overall Study|Adverse Event|1
5981252|NCT01496118|9570200|FG001|Overall Study|Adverse Event|1
5981253|NCT01496118|9570201|FG002|Overall Study|Adverse Event|0
5981254|NCT01496118|9570202|FG003|Overall Study|Adverse Event|0
5981255|NCT01496118|9570203|FG004|Overall Study|Adverse Event|0
5981256|NCT01496118|9570204|FG005|Overall Study|Adverse Event|0
5981257|NCT01496118|9570205|FG006|Overall Study|Adverse Event|6
5981258|NCT01496118|9570206|FG007|Overall Study|Adverse Event|10
5981259|NCT01496118|9570199|FG000|Overall Study|Conditions requiring other treatment not permitted by protocol|0
5981260|NCT01496118|9570200|FG001|Overall Study|Conditions requiring other treatment not permitted by protocol|0
5981261|NCT01496118|9570201|FG002|Overall Study|Conditions requiring other treatment not permitted by protocol|0
5981262|NCT01496118|9570202|FG003|Overall Study|Conditions requiring other treatment not permitted by protocol|0
5981263|NCT01496118|9570203|FG004|Overall Study|Conditions requiring other treatment not permitted by protocol|0
5981264|NCT01496118|9570204|FG005|Overall Study|Conditions requiring other treatment not permitted by protocol|0
5981265|NCT01496118|9570205|FG006|Overall Study|Conditions requiring other treatment not permitted by protocol|1
5981266|NCT01496118|9570206|FG007|Overall Study|Conditions requiring other treatment not permitted by protocol|0
5981267|NCT01496118|9570199|FG000|Overall Study|Death|0
5981268|NCT01496118|9570200|FG001|Overall Study|Death|0
5981269|NCT01496118|9570201|FG002|Overall Study|Death|0
5981270|NCT01496118|9570202|FG003|Overall Study|Death|0
5981271|NCT01496118|9570203|FG004|Overall Study|Death|0
5981272|NCT01496118|9570204|FG005|Overall Study|Death|0
5981273|NCT01496118|9570205|FG006|Overall Study|Death|1
5981274|NCT01496118|9570206|FG007|Overall Study|Death|1
5981275|NCT01496118|9570199|FG000|Overall Study|Withdrawal by Subject|0
5981276|NCT01496118|9570200|FG001|Overall Study|Withdrawal by Subject|0
5981277|NCT01496118|9570201|FG002|Overall Study|Withdrawal by Subject|0
5981278|NCT01496118|9570202|FG003|Overall Study|Withdrawal by Subject|2
5981279|NCT01496118|9570203|FG004|Overall Study|Withdrawal by Subject|0
5981280|NCT01496118|9570204|FG005|Overall Study|Withdrawal by Subject|1
5981281|NCT01496118|9570205|FG006|Overall Study|Withdrawal by Subject|6
5981282|NCT01496118|9570206|FG007|Overall Study|Withdrawal by Subject|3
5981283|NCT01350934|9570226|FG000|Base Study|Adverse Event|6
5981284|NCT01350934|9570227|FG001|Base Study|Adverse Event|0
5981285|NCT01350934|9570226|FG000|Base Study|Lost to Follow-up|1
5981286|NCT01350934|9570227|FG001|Base Study|Lost to Follow-up|0
5981287|NCT01350934|9570226|FG000|Base Study|Protocol Violation|1
5981288|NCT01350934|9570227|FG001|Base Study|Protocol Violation|1
5981289|NCT01350934|9570226|FG000|Base Study|Withdrawal by Subject|1
5981290|NCT01350934|9570227|FG001|Base Study|Withdrawal by Subject|2
5981291|NCT01350934|9570226|FG000|Base Study|Non-Compliance With Study Drug|2
5981292|NCT01350934|9570227|FG001|Base Study|Non-Compliance With Study Drug|0
5981293|NCT01350934|9570226|FG000|Extension Study|Adverse Event|2
5981294|NCT01350934|9570227|FG001|Extension Study|Adverse Event|1
5981295|NCT01350934|9570226|FG000|Extension Study|Lost to Follow-up|2
5981296|NCT01350934|9570227|FG001|Extension Study|Lost to Follow-up|0
5981297|NCT01350934|9570226|FG000|Extension Study|Protocol Violation|1
5981298|NCT01350934|9570227|FG001|Extension Study|Protocol Violation|1
5981299|NCT01350934|9570226|FG000|Extension Study|Lack of Efficacy|0
5981300|NCT01350934|9570227|FG001|Extension Study|Lack of Efficacy|1
5981301|NCT01350934|9570226|FG000|Extension Study|Withdrawal by Subject|0
5981302|NCT01350934|9570227|FG001|Extension Study|Withdrawal by Subject|1
6292022|NCT02416908|10009227|FG001|Dose Escalation Phase|Adverse Event|0
6292023|NCT02416908|10009228|FG002|Dose Escalation Phase|Adverse Event|3
6292024|NCT02416908|10009229|FG003|Dose Escalation Phase|Adverse Event|0
6292025|NCT02416908|10009226|FG000|Dose Escalation Phase|Withdrawal by Subject|0
6292026|NCT02416908|10009227|FG001|Dose Escalation Phase|Withdrawal by Subject|0
6292027|NCT02416908|10009228|FG002|Dose Escalation Phase|Withdrawal by Subject|1
6292028|NCT02416908|10009229|FG003|Dose Escalation Phase|Withdrawal by Subject|0
6292029|NCT02416934|10009238|FG000|Overall Study|given steroids|1
6292030|NCT02416934|10009239|FG001|Overall Study|given steroids|2
6292031|NCT02416934|10009238|FG000|Overall Study|Lost to Follow-up|0
6292032|NCT02416934|10009239|FG001|Overall Study|Lost to Follow-up|2
6292033|NCT02416934|10009238|FG000|Overall Study|Withdrawal by Subject|1
6292034|NCT02416934|10009239|FG001|Overall Study|Withdrawal by Subject|0
6292035|NCT02416934|10009238|FG000|Overall Study|recruited during continuing renewal proc|0
6292036|NCT02416934|10009239|FG001|Overall Study|recruited during continuing renewal proc|1
6292037|NCT02416934|10009238|FG000|Overall Study|Protocol Violation|0
6292038|NCT02416934|10009239|FG001|Overall Study|Protocol Violation|1
6292039|NCT02416934|10009238|FG000|Overall Study|surgery started late|0
6292040|NCT02416934|10009239|FG001|Overall Study|surgery started late|1
6292041|NCT02416934|10009238|FG000|Overall Study|re-operation|1
6292042|NCT02416934|10009239|FG001|Overall Study|re-operation|0
6292043|NCT02417064|10009267|FG000|Double-blind Induction Phase (4 Weeks)|Adverse Event|1
6292044|NCT02417064|10009268|FG001|Double-blind Induction Phase (4 Weeks)|Adverse Event|7
6292045|NCT02417064|10009269|FG002|Double-blind Induction Phase (4 Weeks)|Adverse Event|2
6292046|NCT02417064|10009267|FG000|Double-blind Induction Phase (4 Weeks)|Lack of Efficacy|1
6292047|NCT02417064|10009268|FG001|Double-blind Induction Phase (4 Weeks)|Lack of Efficacy|1
6292048|NCT02417064|10009269|FG002|Double-blind Induction Phase (4 Weeks)|Lack of Efficacy|0
6292049|NCT02417064|10009267|FG000|Double-blind Induction Phase (4 Weeks)|Lost to Follow-up|0
6292050|NCT02417064|10009268|FG001|Double-blind Induction Phase (4 Weeks)|Lost to Follow-up|1
6292051|NCT02417064|10009269|FG002|Double-blind Induction Phase (4 Weeks)|Lost to Follow-up|0
6292052|NCT02417064|10009267|FG000|Double-blind Induction Phase (4 Weeks)|Protocol Violation|2
6292053|NCT02417064|10009268|FG001|Double-blind Induction Phase (4 Weeks)|Protocol Violation|1
6292054|NCT02417064|10009269|FG002|Double-blind Induction Phase (4 Weeks)|Protocol Violation|1
6292055|NCT02417064|10009267|FG000|Double-blind Induction Phase (4 Weeks)|Withdrawal by Subject|1
6292056|NCT02417064|10009268|FG001|Double-blind Induction Phase (4 Weeks)|Withdrawal by Subject|5
6292057|NCT02417064|10009269|FG002|Double-blind Induction Phase (4 Weeks)|Withdrawal by Subject|1
6292058|NCT02417064|10009267|FG000|Double-blind Induction Phase (4 Weeks)|Other|1
6292059|NCT02417064|10009268|FG001|Double-blind Induction Phase (4 Weeks)|Other|4
6292060|NCT02417064|10009269|FG002|Double-blind Induction Phase (4 Weeks)|Other|2
6292061|NCT02417064|10009267|FG000|Follow-up Phase (24 Weeks)|Lost to Follow-up|0
6292062|NCT02417064|10009268|FG001|Follow-up Phase (24 Weeks)|Lost to Follow-up|2
6292063|NCT02417064|10009269|FG002|Follow-up Phase (24 Weeks)|Lost to Follow-up|1
6292064|NCT02417064|10009267|FG000|Follow-up Phase (24 Weeks)|Protocol Violation|0
6292065|NCT02417064|10009268|FG001|Follow-up Phase (24 Weeks)|Protocol Violation|0
6292066|NCT02417064|10009269|FG002|Follow-up Phase (24 Weeks)|Protocol Violation|1
6292067|NCT02417064|10009267|FG000|Follow-up Phase (24 Weeks)|Withdrawal by Subject|3
6292068|NCT02417064|10009268|FG001|Follow-up Phase (24 Weeks)|Withdrawal by Subject|9
6292069|NCT02417064|10009269|FG002|Follow-up Phase (24 Weeks)|Withdrawal by Subject|2
6292070|NCT02417064|10009267|FG000|Follow-up Phase (24 Weeks)|PI Decision|34
6292071|NCT02417064|10009268|FG001|Follow-up Phase (24 Weeks)|PI Decision|29
6292072|NCT02417064|10009269|FG002|Follow-up Phase (24 Weeks)|PI Decision|44
6292073|NCT02417064|10009267|FG000|Follow-up Phase (24 Weeks)|Other|2
6292074|NCT02417064|10009268|FG001|Follow-up Phase (24 Weeks)|Other|2
6292075|NCT02417064|10009269|FG002|Follow-up Phase (24 Weeks)|Other|3
6292076|NCT02417233|10009290|FG000|Overall Study|Death|4
6292077|NCT02417233|10009291|FG001|Overall Study|Death|10
6292078|NCT02417233|10009292|FG002|Overall Study|Death|14
6292079|NCT02417233|10009290|FG000|Overall Study|Lost to Follow-up|27
6292080|NCT02417233|10009291|FG001|Overall Study|Lost to Follow-up|39
6292081|NCT02417233|10009292|FG002|Overall Study|Lost to Follow-up|34
6292082|NCT02417233|10009290|FG000|Overall Study|Protocol Violation|2
6292083|NCT02417233|10009291|FG001|Overall Study|Protocol Violation|0
6292084|NCT02417233|10009292|FG002|Overall Study|Protocol Violation|2
6292085|NCT02417233|10009290|FG000|Overall Study|Withdrawal by Subject|2
6292086|NCT02417233|10009291|FG001|Overall Study|Withdrawal by Subject|1
6292087|NCT02417233|10009292|FG002|Overall Study|Withdrawal by Subject|8
6292088|NCT02417233|10009290|FG000|Overall Study|Relocation out of study area|1
6292089|NCT02417233|10009291|FG001|Overall Study|Relocation out of study area|0
6292090|NCT02417233|10009292|FG002|Overall Study|Relocation out of study area|1
6292091|NCT02417233|10009290|FG000|Overall Study|Mentally unstable|0
6292092|NCT02417233|10009291|FG001|Overall Study|Mentally unstable|1
6292093|NCT02417233|10009292|FG002|Overall Study|Mentally unstable|0
6292094|NCT02417246|10009303|FG000|Phase 1 Brand Name Metoprolol ER|Lost to Follow-up|1
6292095|NCT02417246|10009304|FG001|Phase 1 Brand Name Metoprolol ER|Lost to Follow-up|1
6292096|NCT02417246|10009303|FG000|Phase 1 Brand Name Metoprolol ER|Physician Decision|1
6292097|NCT02417246|10009304|FG001|Phase 1 Brand Name Metoprolol ER|Physician Decision|0
6292098|NCT02417246|10009303|FG000|Phase 1 Brand Name Metoprolol ER|Withdrawal by Subject|2
6292099|NCT02417246|10009304|FG001|Phase 1 Brand Name Metoprolol ER|Withdrawal by Subject|3
6292100|NCT02417246|10009303|FG000|Phase 2 1st Generic Administered|Physician Decision|1
6292101|NCT02417246|10009304|FG001|Phase 2 1st Generic Administered|Physician Decision|0
6292102|NCT02417441|10009323|FG000|Overall Study|Inconclusive due to missing data|52
6292103|NCT02417441|10009324|FG001|Overall Study|Inconclusive due to missing data|19
6292104|NCT02417753|10009337|FG000|Overall Study|Death|1
6292105|NCT02417935|10009357|FG000|Treatment Period|Adverse Event|12
6292106|NCT02417935|10009358|FG001|Treatment Period|Adverse Event|10
6292107|NCT02417935|10009357|FG000|Treatment Period|Lost to Follow-up|1
6292108|NCT02417935|10009358|FG001|Treatment Period|Lost to Follow-up|0
6292109|NCT02417935|10009357|FG000|Treatment Period|Entry Criteria not met|0
6292110|NCT02417935|10009358|FG001|Treatment Period|Entry Criteria not met|1
6292111|NCT02417935|10009357|FG000|Treatment Period|Protocol Violation|2
6292112|NCT02417935|10009358|FG001|Treatment Period|Protocol Violation|1
6292113|NCT02417935|10009357|FG000|Treatment Period|Withdrawal by Subject|3
6292114|NCT02417935|10009358|FG001|Treatment Period|Withdrawal by Subject|3
6292115|NCT02417935|10009357|FG000|Treatment Period|Physician Decision|3
6292116|NCT02417935|10009358|FG001|Treatment Period|Physician Decision|1
6292117|NCT02417961|10009364|FG000|Overall Study|Adverse Event|1
6292118|NCT02417961|10009364|FG000|Overall Study|Lost to Follow-up|1
6292119|NCT02417961|10009364|FG000|Overall Study|Withdrawal by Subject|2
6292120|NCT02418000|10009373|FG000|Cohort 1: E6201 240 mg/m^2 Weekly|Withdrawal by Subject|2
6292121|NCT02418000|10009374|FG001|Cohort 1: E6201 240 mg/m^2 Weekly|Withdrawal by Subject|0
6292122|NCT02418000|10009375|FG002|Cohort 1: E6201 240 mg/m^2 Weekly|Withdrawal by Subject|0
6292123|NCT02418000|10009376|FG003|Cohort 1: E6201 240 mg/m^2 Weekly|Withdrawal by Subject|0
6292124|NCT02418000|10009377|FG004|Cohort 1: E6201 240 mg/m^2 Weekly|Withdrawal by Subject|0
6292125|NCT02418000|10009373|FG000|Cohort 1: E6201 240 mg/m^2 Weekly|Lack of Efficacy|4
6292126|NCT02418000|10009374|FG001|Cohort 1: E6201 240 mg/m^2 Weekly|Lack of Efficacy|0
6292127|NCT02418000|10009375|FG002|Cohort 1: E6201 240 mg/m^2 Weekly|Lack of Efficacy|0
6292128|NCT02418000|10009376|FG003|Cohort 1: E6201 240 mg/m^2 Weekly|Lack of Efficacy|0
6292129|NCT02418000|10009377|FG004|Cohort 1: E6201 240 mg/m^2 Weekly|Lack of Efficacy|0
6292130|NCT02418000|10009373|FG000|Cohort 1: E6201 240 mg/m^2 Weekly|Prepare for HSCT|1
6292131|NCT02418000|10009374|FG001|Cohort 1: E6201 240 mg/m^2 Weekly|Prepare for HSCT|0
6292132|NCT02418000|10009375|FG002|Cohort 1: E6201 240 mg/m^2 Weekly|Prepare for HSCT|0
6292133|NCT02418000|10009376|FG003|Cohort 1: E6201 240 mg/m^2 Weekly|Prepare for HSCT|0
6292134|NCT02418000|10009377|FG004|Cohort 1: E6201 240 mg/m^2 Weekly|Prepare for HSCT|0
6292135|NCT02418000|10009373|FG000|Cohort 2: E6201 320 mg/m^2 Weekly|Withdrawal by Subject|0
6292136|NCT02418000|10009374|FG001|Cohort 2: E6201 320 mg/m^2 Weekly|Withdrawal by Subject|1
6292137|NCT02418000|10009375|FG002|Cohort 2: E6201 320 mg/m^2 Weekly|Withdrawal by Subject|0
6292138|NCT02418000|10009376|FG003|Cohort 2: E6201 320 mg/m^2 Weekly|Withdrawal by Subject|0
6292139|NCT02418000|10009377|FG004|Cohort 2: E6201 320 mg/m^2 Weekly|Withdrawal by Subject|0
6292140|NCT02418000|10009373|FG000|Cohort 2: E6201 320 mg/m^2 Weekly|Lack of Efficacy|0
6292141|NCT02418000|10009374|FG001|Cohort 2: E6201 320 mg/m^2 Weekly|Lack of Efficacy|9
6292142|NCT02418000|10009375|FG002|Cohort 2: E6201 320 mg/m^2 Weekly|Lack of Efficacy|0
6292143|NCT02418000|10009376|FG003|Cohort 2: E6201 320 mg/m^2 Weekly|Lack of Efficacy|0
6292144|NCT02418000|10009377|FG004|Cohort 2: E6201 320 mg/m^2 Weekly|Lack of Efficacy|0
6292145|NCT02418000|10009373|FG000|Cohort 3: 160 mg/m^2 Twice Weekly|Lack of Efficacy|0
6292146|NCT02418000|10009374|FG001|Cohort 3: 160 mg/m^2 Twice Weekly|Lack of Efficacy|0
6292147|NCT02418000|10009375|FG002|Cohort 3: 160 mg/m^2 Twice Weekly|Lack of Efficacy|3
6292148|NCT02418000|10009376|FG003|Cohort 3: 160 mg/m^2 Twice Weekly|Lack of Efficacy|0
6292149|NCT02418000|10009377|FG004|Cohort 3: 160 mg/m^2 Twice Weekly|Lack of Efficacy|0
6292150|NCT02418000|10009373|FG000|Cohort 4: 240 mg/m^2 Twice Weekly|Lack of Efficacy|0
6292151|NCT02418000|10009374|FG001|Cohort 4: 240 mg/m^2 Twice Weekly|Lack of Efficacy|0
6292152|NCT02418000|10009375|FG002|Cohort 4: 240 mg/m^2 Twice Weekly|Lack of Efficacy|0
6292153|NCT02418000|10009376|FG003|Cohort 4: 240 mg/m^2 Twice Weekly|Lack of Efficacy|3
6292154|NCT02418000|10009377|FG004|Cohort 4: 240 mg/m^2 Twice Weekly|Lack of Efficacy|0
6292155|NCT02418000|10009373|FG000|Cohort 5: 320 mg/m^2 Twice Weekly|Withdrawal by Subject|0
6292156|NCT02418000|10009374|FG001|Cohort 5: 320 mg/m^2 Twice Weekly|Withdrawal by Subject|0
6292157|NCT02418000|10009375|FG002|Cohort 5: 320 mg/m^2 Twice Weekly|Withdrawal by Subject|0
6292158|NCT02418000|10009376|FG003|Cohort 5: 320 mg/m^2 Twice Weekly|Withdrawal by Subject|0
6292159|NCT02418000|10009377|FG004|Cohort 5: 320 mg/m^2 Twice Weekly|Withdrawal by Subject|1
6292160|NCT02418000|10009373|FG000|Cohort 5: 320 mg/m^2 Twice Weekly|Lack of Efficacy|0
6292161|NCT02418000|10009374|FG001|Cohort 5: 320 mg/m^2 Twice Weekly|Lack of Efficacy|0
6292162|NCT02418000|10009375|FG002|Cohort 5: 320 mg/m^2 Twice Weekly|Lack of Efficacy|0
6292163|NCT02418000|10009376|FG003|Cohort 5: 320 mg/m^2 Twice Weekly|Lack of Efficacy|0
6292164|NCT02418000|10009377|FG004|Cohort 5: 320 mg/m^2 Twice Weekly|Lack of Efficacy|3
6292165|NCT02418156|10009410|FG000|Overall Study|Lost to Follow-up|12
6292166|NCT02418156|10009410|FG000|Overall Study|Death|2
6292167|NCT02418156|10009410|FG000|Overall Study|Physician Decision|1
6292168|NCT02418156|10009410|FG000|Overall Study|Withdrawal by Subject|1
6292169|NCT02418156|10009410|FG000|Overall Study|Subject refused to return|1
6292170|NCT02418182|10009416|FG000|Overall Study|Unable to re-consent|18
6292171|NCT02418182|10009417|FG001|Overall Study|Unable to re-consent|15
6292172|NCT02418182|10009416|FG000|Overall Study|Lost to Follow-up|0
6292173|NCT02418182|10009417|FG001|Overall Study|Lost to Follow-up|2
6292174|NCT02418455|10009440|FG000|48-Week Treatment Period|Other- Not Specified|1
6292175|NCT02418455|10009440|FG000|Continuation Period|Sponsor Decision|7
6292176|NCT02418468|10009448|FG000|Overall Study|Adverse Event|1
6292177|NCT02418468|10009449|FG001|Overall Study|Adverse Event|0
6292178|NCT02418468|10009448|FG000|Overall Study|Withdrawal of informed consent|1
6292179|NCT02418468|10009449|FG001|Overall Study|Withdrawal of informed consent|1
6292180|NCT02418585|10009470|FG000|Double Blind (DB) Phase (4 Weeks)|Lost to Follow-up|1
6292181|NCT02418585|10009471|FG001|Double Blind (DB) Phase (4 Weeks)|Lost to Follow-up|1
6292182|NCT02418585|10009470|FG000|Double Blind (DB) Phase (4 Weeks)|Protocol Violation|2
6292183|NCT02418585|10009471|FG001|Double Blind (DB) Phase (4 Weeks)|Protocol Violation|2
6292184|NCT02418585|10009470|FG000|Double Blind (DB) Phase (4 Weeks)|Withdrawal by Subject|4
6292185|NCT02418585|10009471|FG001|Double Blind (DB) Phase (4 Weeks)|Withdrawal by Subject|7
6292186|NCT02418585|10009470|FG000|Double Blind (DB) Phase (4 Weeks)|Lack of Efficacy|2
6292187|NCT02418585|10009471|FG001|Double Blind (DB) Phase (4 Weeks)|Lack of Efficacy|0
6292188|NCT02418585|10009470|FG000|Double Blind (DB) Phase (4 Weeks)|Adverse Event|9
6292189|NCT02418585|10009471|FG001|Double Blind (DB) Phase (4 Weeks)|Adverse Event|1
6292190|NCT02418585|10009470|FG000|Double Blind (DB) Phase (4 Weeks)|Other|0
6292191|NCT02418585|10009471|FG001|Double Blind (DB) Phase (4 Weeks)|Other|1
6292192|NCT02418585|10009470|FG000|Follow-up Phase (24 Weeks)|Lost to Follow-up|3
6292193|NCT02418585|10009471|FG001|Follow-up Phase (24 Weeks)|Lost to Follow-up|3
6292194|NCT02418585|10009470|FG000|Follow-up Phase (24 Weeks)|Withdrawal by Subject|6
6292195|NCT02418585|10009471|FG001|Follow-up Phase (24 Weeks)|Withdrawal by Subject|3
6292196|NCT02418585|10009470|FG000|Follow-up Phase (24 Weeks)|Investigator Decision|6
6292197|NCT02418585|10009471|FG001|Follow-up Phase (24 Weeks)|Investigator Decision|17
6292198|NCT02418585|10009470|FG000|Follow-up Phase (24 Weeks)|Other|3
6292199|NCT02418585|10009471|FG001|Follow-up Phase (24 Weeks)|Other|2
6292200|NCT02418754|10009495|FG000|Period 1 (Day 1 to Week 12)|Adverse Event|0
6292201|NCT02418754|10009496|FG001|Period 1 (Day 1 to Week 12)|Adverse Event|2
6292202|NCT02418754|10009497|FG002|Period 1 (Day 1 to Week 12)|Adverse Event|0
6292203|NCT02418754|10009498|FG003|Period 1 (Day 1 to Week 12)|Adverse Event|0
6292204|NCT02418754|10009499|FG004|Period 1 (Day 1 to Week 12)|Adverse Event|0
6292205|NCT02418754|10009495|FG000|Period 1 (Day 1 to Week 12)|Death|1
6292206|NCT02418754|10009496|FG001|Period 1 (Day 1 to Week 12)|Death|0
6292207|NCT02418754|10009497|FG002|Period 1 (Day 1 to Week 12)|Death|0
6292208|NCT02418754|10009498|FG003|Period 1 (Day 1 to Week 12)|Death|0
6292209|NCT02418754|10009499|FG004|Period 1 (Day 1 to Week 12)|Death|0
6292210|NCT02418754|10009495|FG000|Period 1 (Day 1 to Week 12)|Physician Decision|1
6292211|NCT02418754|10009496|FG001|Period 1 (Day 1 to Week 12)|Physician Decision|0
6292212|NCT02418754|10009497|FG002|Period 1 (Day 1 to Week 12)|Physician Decision|0
6292213|NCT02418754|10009498|FG003|Period 1 (Day 1 to Week 12)|Physician Decision|0
6292214|NCT02418754|10009499|FG004|Period 1 (Day 1 to Week 12)|Physician Decision|0
6292215|NCT02418754|10009495|FG000|Period 1 (Day 1 to Week 12)|Withdrawal by Subject|0
6292216|NCT02418754|10009496|FG001|Period 1 (Day 1 to Week 12)|Withdrawal by Subject|2
6292217|NCT02418754|10009497|FG002|Period 1 (Day 1 to Week 12)|Withdrawal by Subject|1
6292218|NCT02418754|10009498|FG003|Period 1 (Day 1 to Week 12)|Withdrawal by Subject|0
6292219|NCT02418754|10009499|FG004|Period 1 (Day 1 to Week 12)|Withdrawal by Subject|0
6292220|NCT02418754|10009495|FG000|Period 1 (Day 1 to Week 12)|Lost to Follow-up|0
6292221|NCT02418754|10009496|FG001|Period 1 (Day 1 to Week 12)|Lost to Follow-up|0
6292222|NCT02418754|10009497|FG002|Period 1 (Day 1 to Week 12)|Lost to Follow-up|1
6292223|NCT02418754|10009498|FG003|Period 1 (Day 1 to Week 12)|Lost to Follow-up|0
6292224|NCT02418754|10009499|FG004|Period 1 (Day 1 to Week 12)|Lost to Follow-up|0
6292225|NCT02418754|10009495|FG000|Period 2 (Day 1 to Week 52/End of Study)|Adverse Event|3
6292226|NCT02418754|10009496|FG001|Period 2 (Day 1 to Week 52/End of Study)|Adverse Event|7
6292227|NCT02418754|10009497|FG002|Period 2 (Day 1 to Week 52/End of Study)|Adverse Event|6
6292228|NCT02418754|10009498|FG003|Period 2 (Day 1 to Week 52/End of Study)|Adverse Event|2
6292229|NCT02418754|10009499|FG004|Period 2 (Day 1 to Week 52/End of Study)|Adverse Event|2
6292230|NCT02418754|10009495|FG000|Period 2 (Day 1 to Week 52/End of Study)|Death|1
6292231|NCT02418754|10009496|FG001|Period 2 (Day 1 to Week 52/End of Study)|Death|0
6292232|NCT02418754|10009497|FG002|Period 2 (Day 1 to Week 52/End of Study)|Death|0
6292233|NCT02418754|10009498|FG003|Period 2 (Day 1 to Week 52/End of Study)|Death|0
6292234|NCT02418754|10009499|FG004|Period 2 (Day 1 to Week 52/End of Study)|Death|0
6292235|NCT02418754|10009495|FG000|Period 2 (Day 1 to Week 52/End of Study)|Physician Decision|26
6292236|NCT02418754|10009496|FG001|Period 2 (Day 1 to Week 52/End of Study)|Physician Decision|28
6292237|NCT02418754|10009497|FG002|Period 2 (Day 1 to Week 52/End of Study)|Physician Decision|26
6292238|NCT02418754|10009498|FG003|Period 2 (Day 1 to Week 52/End of Study)|Physician Decision|21
6292239|NCT02418754|10009499|FG004|Period 2 (Day 1 to Week 52/End of Study)|Physician Decision|24
6292240|NCT02418754|10009495|FG000|Period 2 (Day 1 to Week 52/End of Study)|Withdrawal by Subject|3
6292241|NCT02418754|10009496|FG001|Period 2 (Day 1 to Week 52/End of Study)|Withdrawal by Subject|4
6292242|NCT02418754|10009497|FG002|Period 2 (Day 1 to Week 52/End of Study)|Withdrawal by Subject|4
6292243|NCT02418754|10009498|FG003|Period 2 (Day 1 to Week 52/End of Study)|Withdrawal by Subject|1
6292244|NCT02418754|10009499|FG004|Period 2 (Day 1 to Week 52/End of Study)|Withdrawal by Subject|0
6292245|NCT02418754|10009495|FG000|Period 2 (Day 1 to Week 52/End of Study)|Lost to Follow-up|0
6292246|NCT02418754|10009496|FG001|Period 2 (Day 1 to Week 52/End of Study)|Lost to Follow-up|2
6292247|NCT02418754|10009497|FG002|Period 2 (Day 1 to Week 52/End of Study)|Lost to Follow-up|1
6292248|NCT02418754|10009498|FG003|Period 2 (Day 1 to Week 52/End of Study)|Lost to Follow-up|2
6292249|NCT02418754|10009499|FG004|Period 2 (Day 1 to Week 52/End of Study)|Lost to Follow-up|1
6292250|NCT02418754|10009495|FG000|Period 2 (Day 1 to Week 52/End of Study)|Other Un-specified|0
6292251|NCT02418754|10009496|FG001|Period 2 (Day 1 to Week 52/End of Study)|Other Un-specified|1
6292252|NCT02418754|10009497|FG002|Period 2 (Day 1 to Week 52/End of Study)|Other Un-specified|0
6292253|NCT02418754|10009498|FG003|Period 2 (Day 1 to Week 52/End of Study)|Other Un-specified|1
6292254|NCT02418754|10009499|FG004|Period 2 (Day 1 to Week 52/End of Study)|Other Un-specified|0
6292255|NCT02418819|10009513|FG000|Overall Study|Adverse Event|0
6292256|NCT02418819|10009514|FG001|Overall Study|Adverse Event|0
6292257|NCT02418819|10009515|FG002|Overall Study|Adverse Event|1
6292258|NCT02418819|10009516|FG003|Overall Study|Adverse Event|0
6292259|NCT02418819|10009513|FG000|Overall Study|Lost to Follow-up|1
6292260|NCT02418819|10009514|FG001|Overall Study|Lost to Follow-up|0
6292261|NCT02418819|10009515|FG002|Overall Study|Lost to Follow-up|0
6292262|NCT02418819|10009516|FG003|Overall Study|Lost to Follow-up|0
6292263|NCT02418819|10009513|FG000|Overall Study|No longer meets eligibility criteria|0
6292264|NCT02418819|10009514|FG001|Overall Study|No longer meets eligibility criteria|0
6292265|NCT02418819|10009515|FG002|Overall Study|No longer meets eligibility criteria|1
6292266|NCT02418819|10009516|FG003|Overall Study|No longer meets eligibility criteria|0
6292267|NCT02418819|10009513|FG000|Overall Study|No longer willing to participate|0
6292268|NCT02418819|10009514|FG001|Overall Study|No longer willing to participate|0
6292269|NCT02418819|10009515|FG002|Overall Study|No longer willing to participate|2
6292270|NCT02418819|10009516|FG003|Overall Study|No longer willing to participate|1
6292271|NCT02418845|10009528|FG000|Overall Study|Lost to Follow-up|7
6292272|NCT02418845|10009529|FG001|Overall Study|Lost to Follow-up|2
6292273|NCT02418845|10009528|FG000|Overall Study|Lack of Efficacy|0
6292274|NCT02418845|10009529|FG001|Overall Study|Lack of Efficacy|3
6292275|NCT02418845|10009528|FG000|Overall Study|Physician Decision|5
6292276|NCT02418845|10009529|FG001|Overall Study|Physician Decision|5
6292277|NCT02418845|10009528|FG000|Overall Study|Protocol Violation|1
6292278|NCT02418845|10009529|FG001|Overall Study|Protocol Violation|0
6292279|NCT02418845|10009528|FG000|Overall Study|Withdrawal by Subject|3
6292280|NCT02418845|10009529|FG001|Overall Study|Withdrawal by Subject|2
6292281|NCT02418910|10009535|FG000|Overall Study|Lost to Follow-up|3
6292282|NCT02418910|10009535|FG000|Overall Study|Withdrawal by Subject|4
6292283|NCT02418949|10009543|FG000|Overall Study|Withdrawal by Subject|1
6292284|NCT02418949|10009544|FG001|Overall Study|Withdrawal by Subject|0
6292285|NCT02418949|10009545|FG002|Overall Study|Withdrawal by Subject|1
6292286|NCT02418949|10009546|FG003|Overall Study|Withdrawal by Subject|1
6292287|NCT02418949|10009543|FG000|Overall Study|Lost to Follow-up|1
6292288|NCT02418949|10009544|FG001|Overall Study|Lost to Follow-up|0
6292289|NCT02418949|10009545|FG002|Overall Study|Lost to Follow-up|1
6292290|NCT02418949|10009546|FG003|Overall Study|Lost to Follow-up|0
6292291|NCT02418949|10009543|FG000|Overall Study|Physician Decision|1
6292292|NCT02418949|10009544|FG001|Overall Study|Physician Decision|1
6292293|NCT02418949|10009545|FG002|Overall Study|Physician Decision|1
6292294|NCT02418949|10009546|FG003|Overall Study|Physician Decision|0
6292295|NCT02419001|10009558|FG000|Period 1- Ceftriaxone Without SYN-004|AE w/ ceftriaxone, not dosed w/ IP|1
6292296|NCT02419001|10009559|FG001|Period 1- Ceftriaxone Without SYN-004|AE w/ ceftriaxone, not dosed w/ IP|0
6292297|NCT02419313|10009565|FG000|First Intervention|Lost to Follow-up|2
6292298|NCT02419313|10009566|FG001|First Intervention|Lost to Follow-up|0
6292299|NCT02419313|10009565|FG000|Second Intervention|Lost to Follow-up|1
6292300|NCT02419313|10009566|FG001|Second Intervention|Lost to Follow-up|0
6292301|NCT02419469|10009572|FG000|Overall Study|Withdrawal by Subject|1
6292302|NCT02419508|10009578|FG000|Overall Study|Adverse Event|9
6292303|NCT02419508|10009579|FG001|Overall Study|Adverse Event|3
6292304|NCT02419508|10009578|FG000|Overall Study|Withdrawal by Subject|1
6292305|NCT02419508|10009579|FG001|Overall Study|Withdrawal by Subject|0
6292306|NCT02419508|10009578|FG000|Overall Study|Other - Reason not specified|0
6292307|NCT02419508|10009579|FG001|Overall Study|Other - Reason not specified|1
6292308|NCT02419573|10009595|FG000|Overall Study|Lost to Follow-up|3
6292309|NCT02419573|10009596|FG001|Overall Study|Lost to Follow-up|0
6292310|NCT02419573|10009595|FG000|Overall Study|Withdrawal by Subject|1
6292311|NCT02419573|10009596|FG001|Overall Study|Withdrawal by Subject|0
6292312|NCT02419612|10009604|FG000|Short-term Treatment Period|Adverse Event|1
6292313|NCT02419612|10009605|FG001|Short-term Treatment Period|Adverse Event|1
6292314|NCT02419612|10009604|FG000|Short-term Treatment Period|Death|0
6292315|NCT02419612|10009605|FG001|Short-term Treatment Period|Death|2
6292316|NCT02419612|10009604|FG000|Short-term Treatment Period|Lost to Follow-up|6
6292317|NCT02419612|10009605|FG001|Short-term Treatment Period|Lost to Follow-up|6
6292318|NCT02419612|10009604|FG000|Short-term Treatment Period|Withdrawal by Subject|9
6292319|NCT02419612|10009605|FG001|Short-term Treatment Period|Withdrawal by Subject|9
6292320|NCT02419612|10009604|FG000|Short-term Treatment Period|Subject Request To Discontinue Treatment|1
6292321|NCT02419612|10009605|FG001|Short-term Treatment Period|Subject Request To Discontinue Treatment|1
6292322|NCT02419612|10009604|FG000|Short-term Treatment Period|Non-compliance with Study Drug|0
6292323|NCT02419612|10009605|FG001|Short-term Treatment Period|Non-compliance with Study Drug|2
6292324|NCT02419612|10009604|FG000|Short-term Treatment Period|Worsening of liver function|0
6292325|NCT02419612|10009605|FG001|Short-term Treatment Period|Worsening of liver function|1
6292326|NCT02419612|10009604|FG000|Short-term Treatment Period|Subject moved out of state|0
6292327|NCT02419612|10009605|FG001|Short-term Treatment Period|Subject moved out of state|1
6292328|NCT02419612|10009604|FG000|Long-term Treatment Period|Non-compliance with Study Drug|1
6292329|NCT02419612|10009605|FG001|Long-term Treatment Period|Non-compliance with Study Drug|1
6292330|NCT02419612|10009604|FG000|Long-term Treatment Period|Lost to Follow-up|6
6292331|NCT02419612|10009605|FG001|Long-term Treatment Period|Lost to Follow-up|4
6292332|NCT02419612|10009604|FG000|Long-term Treatment Period|Lack of Efficacy|1
6292333|NCT02419612|10009605|FG001|Long-term Treatment Period|Lack of Efficacy|1
6292334|NCT02419612|10009604|FG000|Long-term Treatment Period|Death|0
6292335|NCT02419612|10009605|FG001|Long-term Treatment Period|Death|1
6292336|NCT02419612|10009604|FG000|Long-term Treatment Period|Adverse Event|0
6292337|NCT02419612|10009605|FG001|Long-term Treatment Period|Adverse Event|5
6292338|NCT02419612|10009604|FG000|Long-term Treatment Period|Other|4
6292339|NCT02419612|10009605|FG001|Long-term Treatment Period|Other|4
6292340|NCT02419612|10009604|FG000|Long-term Treatment Period|Subject Decision|2
6292341|NCT02419612|10009605|FG001|Long-term Treatment Period|Subject Decision|4
6292342|NCT02419612|10009604|FG000|Long-term Treatment Period|Withdrawal by Subject|8
6292343|NCT02419612|10009605|FG001|Long-term Treatment Period|Withdrawal by Subject|2
6292344|NCT02419755|10009622|FG000|Overall Study|Death|1
6292345|NCT02419755|10009623|FG001|Overall Study|Death|3
6292346|NCT02419755|10009622|FG000|Overall Study|Relapse|0
6292347|NCT02419755|10009623|FG001|Overall Study|Relapse|1
6292348|NCT02419755|10009622|FG000|Overall Study|Ineligible|1
6292349|NCT02419755|10009623|FG001|Overall Study|Ineligible|0
6292350|NCT02419755|10009622|FG000|Overall Study|Withdrawal by Subject|1
6292351|NCT02419755|10009623|FG001|Overall Study|Withdrawal by Subject|0
6292352|NCT02419807|10009629|FG000|Overall Study|Withdrawal by Subject|4
6292353|NCT02419807|10009629|FG000|Overall Study|Physician Decision|1
6292354|NCT02419807|10009629|FG000|Overall Study|Protocol Violation|5
6292355|NCT02419937|10009639|FG000|Overall Study|Lost to Follow-up|1
6292356|NCT02419937|10009640|FG001|Overall Study|Lost to Follow-up|0
6292357|NCT02420093|10009666|FG000|Overall Study|Withdrawal by Subject|1
6292358|NCT02420093|10009667|FG001|Overall Study|Withdrawal by Subject|1
6292359|NCT02420223|10009679|FG000|Overall Study|Adverse Event|1
6292360|NCT02420223|10009680|FG001|Overall Study|Adverse Event|0
6292361|NCT02420223|10009679|FG000|Overall Study|Physician Decision|0
6292362|NCT02420223|10009680|FG001|Overall Study|Physician Decision|2
6292363|NCT02420262|10009688|FG000|Overall Study|Adverse Event|1
6292364|NCT02420262|10009689|FG001|Overall Study|Adverse Event|0
6292365|NCT02420262|10009688|FG000|Overall Study|Withdrawal by Subject|1
6292366|NCT02420262|10009689|FG001|Overall Study|Withdrawal by Subject|4
6292367|NCT02420262|10009688|FG000|Overall Study|Unclassified|0
6292368|NCT02420262|10009689|FG001|Overall Study|Unclassified|1
6292369|NCT02420327|10009695|FG000|Overall Study|Adverse Event|7
6292370|NCT02420327|10009695|FG000|Overall Study|Pregnancy|1
6292371|NCT02420327|10009695|FG000|Overall Study|Withdrawal by Subject|6
6292372|NCT02420327|10009695|FG000|Overall Study|Lost to Follow-up|1
6292373|NCT02420327|10009695|FG000|Overall Study|Protocol Violation|1
6292374|NCT02420353|10009707|FG000|Overall Study|Withdrawal by Subject|0
6292375|NCT02420353|10009708|FG001|Overall Study|Withdrawal by Subject|1
6292376|NCT02420379|10009716|FG000|Overall Study|Withdrawal by Subject|0
6292377|NCT02420379|10009717|FG001|Overall Study|Withdrawal by Subject|3
6292378|NCT02420379|10009716|FG000|Overall Study|Unable to complete due to schooling|0
6292379|NCT02420379|10009717|FG001|Overall Study|Unable to complete due to schooling|1
6292380|NCT02420379|10009716|FG000|Overall Study|Transitioned to commercial drug|1
6292381|NCT02420379|10009717|FG001|Overall Study|Transitioned to commercial drug|0
6292382|NCT02420691|10009727|FG000|Overall Study|Adverse Event|3
6292383|NCT02420691|10009727|FG000|Overall Study|Withdrawal by Subject|3
6292384|NCT02421120|10009775|FG000|Overall Study|Adverse Event|1
6292385|NCT02421172|10009798|FG000|Period 1|Adverse Event|1
6292386|NCT02421172|10009799|FG001|Period 1|Adverse Event|0
6292387|NCT02421172|10009800|FG002|Period 1|Adverse Event|0
6292388|NCT02421172|10009801|FG003|Period 1|Adverse Event|0
6292389|NCT02421172|10009802|FG004|Period 1|Adverse Event|0
6292390|NCT02421172|10009798|FG000|Period 1|Lost to Follow-up|3
6292391|NCT02421172|10009799|FG001|Period 1|Lost to Follow-up|1
6292392|NCT02421172|10009800|FG002|Period 1|Lost to Follow-up|0
6292393|NCT02421172|10009801|FG003|Period 1|Lost to Follow-up|0
6292394|NCT02421172|10009802|FG004|Period 1|Lost to Follow-up|0
6292395|NCT02421172|10009798|FG000|Period 1|Patient/guardian decision|0
6292396|NCT02421172|10009799|FG001|Period 1|Patient/guardian decision|1
6292397|NCT02421172|10009800|FG002|Period 1|Patient/guardian decision|0
6292398|NCT02421172|10009801|FG003|Period 1|Patient/guardian decision|0
6292399|NCT02421172|10009802|FG004|Period 1|Patient/guardian decision|0
6292400|NCT02421172|10009798|FG000|Period 2|Adverse Event|0
6292401|NCT02421172|10009799|FG001|Period 2|Adverse Event|0
6292402|NCT02421172|10009800|FG002|Period 2|Adverse Event|4
6292403|NCT02421172|10009801|FG003|Period 2|Adverse Event|0
6292404|NCT02421172|10009802|FG004|Period 2|Adverse Event|0
6292405|NCT02421172|10009798|FG000|Period 2|Lost to Follow-up|0
6292406|NCT02421172|10009799|FG001|Period 2|Lost to Follow-up|0
6292407|NCT02421172|10009800|FG002|Period 2|Lost to Follow-up|0
6292408|NCT02421172|10009801|FG003|Period 2|Lost to Follow-up|1
6292409|NCT02421172|10009802|FG004|Period 2|Lost to Follow-up|0
6292410|NCT02421172|10009798|FG000|Period 2|Patient/guardian decision|0
6292411|NCT02421172|10009799|FG001|Period 2|Patient/guardian decision|0
6292412|NCT02421172|10009800|FG002|Period 2|Patient/guardian decision|3
6292413|NCT02421172|10009801|FG003|Period 2|Patient/guardian decision|2
6292414|NCT02421172|10009802|FG004|Period 2|Patient/guardian decision|1
6292415|NCT02421419|10009870|FG000|Overall Study|Physician Decision|0
6292416|NCT02421419|10009871|FG001|Overall Study|Physician Decision|0
6292417|NCT02421419|10009872|FG002|Overall Study|Physician Decision|1
6292418|NCT02421510|10009883|FG000|Overall Study|Other|4
6292419|NCT02421510|10009884|FG001|Overall Study|Other|2
6292420|NCT02421510|10009885|FG002|Overall Study|Other|3
6292421|NCT02421510|10009883|FG000|Overall Study|Protocol Violation|1
6292422|NCT02421510|10009884|FG001|Overall Study|Protocol Violation|2
6292423|NCT02421510|10009885|FG002|Overall Study|Protocol Violation|0
6292424|NCT02421510|10009883|FG000|Overall Study|Death|1
6292425|NCT02421510|10009884|FG001|Overall Study|Death|0
6292426|NCT02421510|10009885|FG002|Overall Study|Death|0
6292427|NCT02421510|10009883|FG000|Overall Study|Noncompliance with study drug|1
6292428|NCT02421510|10009884|FG001|Overall Study|Noncompliance with study drug|0
6292429|NCT02421510|10009885|FG002|Overall Study|Noncompliance with study drug|0
6292430|NCT02421510|10009883|FG000|Overall Study|Physician Decision|1
6292431|NCT02421510|10009884|FG001|Overall Study|Physician Decision|1
6292432|NCT02421510|10009885|FG002|Overall Study|Physician Decision|3
6292433|NCT02421510|10009883|FG000|Overall Study|Adverse Event|9
6292434|NCT02421510|10009884|FG001|Overall Study|Adverse Event|10
6292435|NCT02421510|10009885|FG002|Overall Study|Adverse Event|18
6292436|NCT02421510|10009883|FG000|Overall Study|Pregnancy|1
6292437|NCT02421510|10009884|FG001|Overall Study|Pregnancy|1
6292438|NCT02421510|10009885|FG002|Overall Study|Pregnancy|0
6292439|NCT02421510|10009883|FG000|Overall Study|Withdrawal by Subject|14
6292440|NCT02421510|10009884|FG001|Overall Study|Withdrawal by Subject|18
6292441|NCT02421510|10009885|FG002|Overall Study|Withdrawal by Subject|12
6292442|NCT02421510|10009883|FG000|Overall Study|Lost to Follow-up|1
6292443|NCT02421510|10009884|FG001|Overall Study|Lost to Follow-up|1
6292444|NCT02421510|10009885|FG002|Overall Study|Lost to Follow-up|0
6292445|NCT02421588|10009895|FG000|Overall Study|Non-treatment-related AE|8
6292446|NCT02421588|10009896|FG001|Overall Study|Non-treatment-related AE|8
6292447|NCT02421588|10009895|FG000|Overall Study|Progressive disease|152
6292448|NCT02421588|10009896|FG001|Overall Study|Progressive disease|135
6292449|NCT02421588|10009895|FG000|Overall Study|Death|11
6292450|NCT02421588|10009896|FG001|Overall Study|Death|3
6292451|NCT02421588|10009895|FG000|Overall Study|Physician Decision|8
6292452|NCT02421588|10009896|FG001|Overall Study|Physician Decision|17
6292453|NCT02421588|10009895|FG000|Overall Study|Other reason not specified|3
6292454|NCT02421588|10009896|FG001|Overall Study|Other reason not specified|1
6292455|NCT02421588|10009895|FG000|Overall Study|Symptomatic deterioration|13
6292456|NCT02421588|10009896|FG001|Overall Study|Symptomatic deterioration|19
6292457|NCT02421588|10009895|FG000|Overall Study|Treatment-related AE|10
6292458|NCT02421588|10009896|FG001|Overall Study|Treatment-related AE|14
6292459|NCT02421588|10009895|FG000|Overall Study|Withdrawal by Subject|14
6292460|NCT02421588|10009896|FG001|Overall Study|Withdrawal by Subject|16
6292461|NCT02421588|10009895|FG000|Overall Study|Not treated|2
6292462|NCT02421588|10009896|FG001|Overall Study|Not treated|8
6292463|NCT02421601|10009902|FG000|Overall Study|Adverse Event|4
6292464|NCT02421601|10009902|FG000|Overall Study|Lack of Efficacy|5
6292465|NCT02421601|10009902|FG000|Overall Study|Physician Decision|1
6292466|NCT02421601|10009902|FG000|Overall Study|Withdrawal by Subject|31
6292467|NCT02421601|10009902|FG000|Overall Study|Others|41
6292468|NCT02421666|10009908|FG000|6-month Follow-up|Lost to Follow-up|8
6292469|NCT02421666|10009909|FG001|6-month Follow-up|Lost to Follow-up|7
6292470|NCT02421666|10009908|FG000|6-month Follow-up|Withdrawal by Subject|5
6292471|NCT02421666|10009909|FG001|6-month Follow-up|Withdrawal by Subject|6
6292472|NCT02421666|10009908|FG000|12-month Follow-up|Lost to Follow-up|5
6292473|NCT02421666|10009909|FG001|12-month Follow-up|Lost to Follow-up|5
6292474|NCT02421666|10009908|FG000|12-month Follow-up|Withdrawal by Subject|6
6292475|NCT02421666|10009909|FG001|12-month Follow-up|Withdrawal by Subject|11
6292476|NCT02421887|10009926|FG000|Overall Study|Lost to Follow-up|5
6292477|NCT02421887|10009927|FG001|Overall Study|Lost to Follow-up|0
6292478|NCT02421887|10009926|FG000|Overall Study|Withdrawal by Subject|8
6292479|NCT02421887|10009927|FG001|Overall Study|Withdrawal by Subject|5
6292480|NCT02421887|10009926|FG000|Overall Study|Physician Decision|2
6292481|NCT02421887|10009927|FG001|Overall Study|Physician Decision|4
6292482|NCT02421887|10009926|FG000|Overall Study|Adverse Event|2
6292483|NCT02421887|10009927|FG001|Overall Study|Adverse Event|0
6292484|NCT02421952|10009933|FG000|Overall Study|Diary Not Returned|93
6292485|NCT02421952|10009933|FG000|Overall Study|Failed seriation task|13
6292486|NCT02421952|10009933|FG000|Overall Study|Subject uncooperative for baseline test|2
6292487|NCT02421952|10009933|FG000|Overall Study|Surgery cancelled|1
6292488|NCT02422186|10009942|FG000|Double-blind Induction Phase (4 Weeks)|Lost to Follow-up|1
6292489|NCT02422186|10009943|FG001|Double-blind Induction Phase (4 Weeks)|Lost to Follow-up|0
6292490|NCT02422186|10009942|FG000|Double-blind Induction Phase (4 Weeks)|Protocol Violation|0
6292491|NCT02422186|10009943|FG001|Double-blind Induction Phase (4 Weeks)|Protocol Violation|1
6292492|NCT02422186|10009942|FG000|Double-blind Induction Phase (4 Weeks)|Withdrawal by Subject|1
6292493|NCT02422186|10009943|FG001|Double-blind Induction Phase (4 Weeks)|Withdrawal by Subject|2
6292494|NCT02422186|10009942|FG000|Double-blind Induction Phase (4 Weeks)|Lack of Efficacy|3
6292495|NCT02422186|10009943|FG001|Double-blind Induction Phase (4 Weeks)|Lack of Efficacy|1
6292496|NCT02422186|10009942|FG000|Double-blind Induction Phase (4 Weeks)|Adverse Event|4
6292497|NCT02422186|10009943|FG001|Double-blind Induction Phase (4 Weeks)|Adverse Event|2
6292498|NCT02422186|10009942|FG000|Double-blind Induction Phase (4 Weeks)|Other|1
6292499|NCT02422186|10009943|FG001|Double-blind Induction Phase (4 Weeks)|Other|0
6292500|NCT02422186|10009942|FG000|Follow-up Phase (2 Weeks)|Withdrawal by Subject|1
6292501|NCT02422186|10009943|FG001|Follow-up Phase (2 Weeks)|Withdrawal by Subject|0
6292502|NCT02422186|10009942|FG000|Follow-up Phase (2 Weeks)|Other|3
6292503|NCT02422186|10009943|FG001|Follow-up Phase (2 Weeks)|Other|0
6292504|NCT02422264|10009953|FG000|Overall Study|Serious Adverse Event|1
6292505|NCT02422264|10009954|FG001|Overall Study|Serious Adverse Event|0
6292506|NCT02422264|10009953|FG000|Overall Study|Withdrawal by Subject|1
6292507|NCT02422264|10009954|FG001|Overall Study|Withdrawal by Subject|2
6292508|NCT02422264|10009953|FG000|Overall Study|Migrated/moved from study area|3
6292509|NCT02422264|10009954|FG001|Overall Study|Migrated/moved from study area|1
6292510|NCT02422264|10009953|FG000|Overall Study|Subject vaccinated outside of the study|0
6292511|NCT02422264|10009954|FG001|Overall Study|Subject vaccinated outside of the study|1
6292512|NCT02423109|10010006|FG000|Lens 1|Adverse Event|1
6292513|NCT02423109|10010007|FG001|Lens 1|Adverse Event|0
6292514|NCT02423291|10010034|FG000|Overall Study|Lack of Efficacy|14
6292515|NCT02423291|10010034|FG000|Overall Study|Adverse Event|1
5981303|NCT01286207|9570236|FG000|Overall Study|Adverse Event|27
6292516|NCT02423343|10010053|FG000|Overall Study|Withdrawal by Subject|0
6292517|NCT02423343|10010054|FG001|Overall Study|Withdrawal by Subject|1
6292518|NCT02423343|10010055|FG002|Overall Study|Withdrawal by Subject|0
6292519|NCT02423343|10010056|FG003|Overall Study|Withdrawal by Subject|0
6292520|NCT02423343|10010057|FG004|Overall Study|Withdrawal by Subject|0
6292521|NCT02423343|10010058|FG005|Overall Study|Withdrawal by Subject|0
6292522|NCT02423343|10010053|FG000|Overall Study|Progressive Disease|0
6292523|NCT02423343|10010054|FG001|Overall Study|Progressive Disease|0
6292524|NCT02423343|10010055|FG002|Overall Study|Progressive Disease|0
6292525|NCT02423343|10010056|FG003|Overall Study|Progressive Disease|0
6292526|NCT02423343|10010057|FG004|Overall Study|Progressive Disease|2
6292527|NCT02423343|10010058|FG005|Overall Study|Progressive Disease|0
6292528|NCT02423343|10010053|FG000|Overall Study|Adverse Event|0
6292529|NCT02423343|10010054|FG001|Overall Study|Adverse Event|0
6292530|NCT02423343|10010055|FG002|Overall Study|Adverse Event|0
6292531|NCT02423343|10010056|FG003|Overall Study|Adverse Event|0
6292532|NCT02423343|10010057|FG004|Overall Study|Adverse Event|2
6292533|NCT02423343|10010058|FG005|Overall Study|Adverse Event|0
6292534|NCT02423343|10010053|FG000|Overall Study|Death|0
6292535|NCT02423343|10010054|FG001|Overall Study|Death|0
6292536|NCT02423343|10010055|FG002|Overall Study|Death|0
6292537|NCT02423343|10010056|FG003|Overall Study|Death|0
6292538|NCT02423343|10010057|FG004|Overall Study|Death|1
6292539|NCT02423343|10010058|FG005|Overall Study|Death|0
6292540|NCT02423798|10010114|FG000|Overall Study|Withdrawal by Subject|3
6292541|NCT02424097|10010144|FG000|Overall Study|Lost to Follow-up|1
6292542|NCT02424097|10010145|FG001|Overall Study|Lost to Follow-up|2
6292543|NCT02424149|10010153|FG000|Overall Study|surgery cancelled|2
6292544|NCT02424149|10010154|FG001|Overall Study|surgery cancelled|0
6292545|NCT02424149|10010153|FG000|Overall Study|Withdrawal by Subject|0
6292546|NCT02424149|10010154|FG001|Overall Study|Withdrawal by Subject|1
6292547|NCT02424253|10010166|FG000|Overall Study|Other, unspecified|1
6292548|NCT02424253|10010167|FG001|Overall Study|Other, unspecified|0
6292549|NCT02424253|10010166|FG000|Overall Study|Compliance problems|1
6292550|NCT02424253|10010167|FG001|Overall Study|Compliance problems|0
6292551|NCT02424253|10010166|FG000|Overall Study|Physician Decision|2
6292552|NCT02424253|10010167|FG001|Overall Study|Physician Decision|0
6292553|NCT02424253|10010166|FG000|Overall Study|Lack of Efficacy|0
6292554|NCT02424253|10010167|FG001|Overall Study|Lack of Efficacy|7
6292555|NCT02424253|10010166|FG000|Overall Study|Adverse Event|2
6292556|NCT02424253|10010167|FG001|Overall Study|Adverse Event|0
6292557|NCT02424253|10010166|FG000|Overall Study|Consent withdrawn by subject|4
6292558|NCT02424253|10010167|FG001|Overall Study|Consent withdrawn by subject|1
6292559|NCT02424253|10010166|FG000|Overall Study|Lost to Follow-up|1
6292560|NCT02424253|10010167|FG001|Overall Study|Lost to Follow-up|1
6292561|NCT02424344|10010175|FG000|Overall Study|Lack of Efficacy|0
6292562|NCT02424344|10010176|FG001|Overall Study|Lack of Efficacy|1
6292563|NCT02424344|10010175|FG000|Overall Study|Withdrawal by Subject|2
6292564|NCT02424344|10010176|FG001|Overall Study|Withdrawal by Subject|1
6292565|NCT02424344|10010175|FG000|Overall Study|Lost to Follow-up|1
6292566|NCT02424344|10010176|FG001|Overall Study|Lost to Follow-up|0
6292567|NCT02424344|10010175|FG000|Overall Study|Adverse Event|4
6292568|NCT02424344|10010176|FG001|Overall Study|Adverse Event|8
6292569|NCT02424383|10010193|FG000|Overall Study|Withdrawal by Subject|32
6292570|NCT02424383|10010193|FG000|Overall Study|Death|170
6292571|NCT02424383|10010193|FG000|Overall Study|Sponsor's decision|3
6292572|NCT02424383|10010193|FG000|Overall Study|Investigator's decision|44
6292573|NCT02424383|10010193|FG000|Overall Study|Lost to Follow-up|81
6292574|NCT02424383|10010193|FG000|Overall Study|Other|7
6292575|NCT02424383|10010193|FG000|Overall Study|Ineligible for Major Protocol Deviation|39
6292576|NCT02424539|10010211|FG000|Overall Study|Adverse Event|0
6292577|NCT02424539|10010212|FG001|Overall Study|Adverse Event|0
6292578|NCT02424539|10010213|FG002|Overall Study|Adverse Event|1
6292579|NCT02424539|10010211|FG000|Overall Study|Physician Decision|0
6292580|NCT02424539|10010212|FG001|Overall Study|Physician Decision|0
6292581|NCT02424539|10010213|FG002|Overall Study|Physician Decision|1
6292582|NCT02424539|10010211|FG000|Overall Study|Withdrawal by Subject|3
5981304|NCT01286207|9570237|FG001|Overall Study|Adverse Event|41
6292583|NCT02424539|10010212|FG001|Overall Study|Withdrawal by Subject|1
6292584|NCT02424539|10010213|FG002|Overall Study|Withdrawal by Subject|0
6292585|NCT02424539|10010211|FG000|Overall Study|Other: Reached stopping criteria|11
6292586|NCT02424539|10010212|FG001|Overall Study|Other: Reached stopping criteria|7
6292587|NCT02424539|10010213|FG002|Overall Study|Other: Reached stopping criteria|6
6292588|NCT02424578|10010223|FG000|Overall Study|Withdrawal by Subject|0
6292589|NCT02424578|10010224|FG001|Overall Study|Withdrawal by Subject|1
6292590|NCT02424591|10010232|FG000|Overall Study|Protocol Violation|2
6292591|NCT02424591|10010233|FG001|Overall Study|Protocol Violation|3
6292592|NCT02424630|10010241|FG000|Overall Study|No rotator cuff tear|1
6292593|NCT02424630|10010242|FG001|Overall Study|No rotator cuff tear|2
6292594|NCT02424630|10010241|FG000|Overall Study|Open procedure|0
6292595|NCT02424630|10010242|FG001|Overall Study|Open procedure|1
6292596|NCT02424734|10010251|FG000|Overall Study|Treatment stopped to be discharged home|2
6292597|NCT02424734|10010252|FG001|Overall Study|Treatment stopped to be discharged home|2
6292598|NCT02424734|10010253|FG002|Overall Study|Treatment stopped to be discharged home|0
6292599|NCT02425098|10010311|FG000|Overall Study|Lost to Follow-up|7
6292600|NCT02425098|10010312|FG001|Overall Study|Lost to Follow-up|7
6292601|NCT02425098|10010311|FG000|Overall Study|Withdrawal by Subject|4
6292602|NCT02425098|10010312|FG001|Overall Study|Withdrawal by Subject|8
6292603|NCT02425098|10010311|FG000|Overall Study|Pregnancy|2
6292604|NCT02425098|10010312|FG001|Overall Study|Pregnancy|0
6292605|NCT02425098|10010311|FG000|Overall Study|Reason not Specified|0
6292606|NCT02425098|10010312|FG001|Overall Study|Reason not Specified|1
6292607|NCT02425111|10010318|FG000|Part A: Treatment Period|Pretreatment Event/Adverse Event|2
6292608|NCT02425111|10010318|FG000|Part A: Treatment Period|Lack of Efficacy|15
6292609|NCT02425111|10010318|FG000|Part A: Treatment Period|Voluntary Withdrawal|4
6292610|NCT02425111|10010318|FG000|Part A: Treatment Period|Lost to Follow-up|2
6292611|NCT02425111|10010318|FG000|Part B: Treatment Extension Period|Pretreatment Event/Adverse Event(s)|3
6292612|NCT02425111|10010318|FG000|Part B: Treatment Extension Period|Lack of Efficacy|7
6292613|NCT02425891|10010346|FG000|Overall Study|Death|332
6292614|NCT02425891|10010347|FG001|Overall Study|Death|314
6292615|NCT02425891|10010346|FG000|Overall Study|Lost to Follow-up|4
6292616|NCT02425891|10010347|FG001|Overall Study|Lost to Follow-up|6
6292617|NCT02425891|10010346|FG000|Overall Study|Non-Compliance|1
6292618|NCT02425891|10010347|FG001|Overall Study|Non-Compliance|0
6292619|NCT02425891|10010346|FG000|Overall Study|Accidentally randomized screen failure participant|0
6292620|NCT02425891|10010347|FG001|Overall Study|Accidentally randomized screen failure participant|1
6292621|NCT02425891|10010346|FG000|Overall Study|Physician Decision|0
5981305|NCT01286207|9570238|FG002|Overall Study|Adverse Event|8
5981306|NCT01286207|9570236|FG000|Overall Study|Lost to Follow-up|49
5981307|NCT01286207|9570237|FG001|Overall Study|Lost to Follow-up|43
5981308|NCT01286207|9570238|FG002|Overall Study|Lost to Follow-up|20
5981309|NCT01286207|9570236|FG000|Overall Study|Withdrawal by Subject|93
5981310|NCT01286207|9570237|FG001|Overall Study|Withdrawal by Subject|79
5981311|NCT01286207|9570238|FG002|Overall Study|Withdrawal by Subject|41
5981312|NCT01286207|9570236|FG000|Overall Study|Lack of Response|92
5981313|NCT01286207|9570237|FG001|Overall Study|Lack of Response|38
5981314|NCT01286207|9570238|FG002|Overall Study|Lack of Response|8
5981315|NCT01286207|9570236|FG000|Overall Study|Other|37
5981316|NCT01286207|9570237|FG001|Overall Study|Other|47
5981317|NCT01286207|9570238|FG002|Overall Study|Other|13
5981318|NCT01263769|9570246|FG000|Overall Study|Non-Compliant with treatment|1
5981319|NCT01227187|9570254|FG000|Overall Study|Physician Decision|0
5981320|NCT01227187|9570255|FG001|Overall Study|Physician Decision|0
5981321|NCT01227187|9570256|FG002|Overall Study|Physician Decision|0
5981322|NCT01227187|9570257|FG003|Overall Study|Physician Decision|1
5981323|NCT01222247|9570269|FG000|Overall Study|Lost to Follow-up|2
5981324|NCT01222247|9570270|FG001|Overall Study|Lost to Follow-up|2
5981325|NCT01144416|9570306|FG000|Intervention Period|Adverse Event|5
5981326|NCT01144416|9570307|FG001|Intervention Period|Adverse Event|6
5981327|NCT01144416|9570306|FG000|Intervention Period|Insufficient ovarian response|11
5981328|NCT01144416|9570307|FG001|Intervention Period|Insufficient ovarian response|17
5981329|NCT01144416|9570306|FG000|Intervention Period|Risk of OHSS|0
5981330|NCT01144416|9570307|FG001|Intervention Period|Risk of OHSS|1
5981331|NCT01144416|9570306|FG000|Intervention Period|Too high ovarian response|4
5981332|NCT01144416|9570307|FG001|Intervention Period|Too high ovarian response|2
5981333|NCT01144416|9570306|FG000|Intervention Period|No/too few/bad oocytes|7
5981334|NCT01144416|9570307|FG001|Intervention Period|No/too few/bad oocytes|5
5981335|NCT01144416|9570306|FG000|Intervention Period|No or abnormal fertilization|25
5981336|NCT01144416|9570307|FG001|Intervention Period|No or abnormal fertilization|10
5981337|NCT01144416|9570306|FG000|Intervention Period|No/too few/bad quality embryos|3
5981338|NCT01144416|9570307|FG001|Intervention Period|No/too few/bad quality embryos|3
5981339|NCT01144416|9570306|FG000|Intervention Period|Other|7
5981340|NCT01144416|9570307|FG001|Intervention Period|Other|5
5981341|NCT01140048|9570317|FG000|Overall Study|Physician Decision|1
5981342|NCT01140048|9570317|FG000|Overall Study|Withdrawal by Subject|13
5981343|NCT01140048|9570317|FG000|Overall Study|Lost to Follow-up|31
5981344|NCT01065779|9570332|FG000|Overall Study|Duplicate Investigation|1
5981345|NCT01065779|9570332|FG000|Overall Study|Investigation Before Contract Date|37
5981346|NCT01065779|9570332|FG000|Overall Study|Non-enrollment Period Administration|10
5981347|NCT01065779|9570332|FG000|Overall Study|Not Administered With Study Drug|17
5981348|NCT01065779|9570332|FG000|Overall Study|Failed to Follow-up|10
5981349|NCT01065779|9570332|FG000|Overall Study|Inclusion Criteria Violation|7
5981350|NCT00974571|9570339|FG000|Overall Study|Adverse Event|31
5981351|NCT00974571|9570340|FG001|Overall Study|Adverse Event|4
5981352|NCT00974571|9570341|FG002|Overall Study|Adverse Event|27
5981353|NCT00974571|9570339|FG000|Overall Study|Lack of Efficacy|3
5981354|NCT00974571|9570340|FG001|Overall Study|Lack of Efficacy|2
5981355|NCT00974571|9570341|FG002|Overall Study|Lack of Efficacy|9
5981356|NCT00974571|9570339|FG000|Overall Study|Lost to Follow-up|2
5981357|NCT00974571|9570340|FG001|Overall Study|Lost to Follow-up|1
5981358|NCT00974571|9570341|FG002|Overall Study|Lost to Follow-up|2
5981359|NCT00974571|9570339|FG000|Overall Study|Protocol Violation|13
5981360|NCT00974571|9570340|FG001|Overall Study|Protocol Violation|4
5981361|NCT00974571|9570341|FG002|Overall Study|Protocol Violation|18
5981362|NCT00974571|9570339|FG000|Overall Study|Withdrawal by Subject|14
5981363|NCT00974571|9570340|FG001|Overall Study|Withdrawal by Subject|5
5981364|NCT00974571|9570341|FG002|Overall Study|Withdrawal by Subject|16
5981365|NCT00974571|9570339|FG000|Overall Study|Patient Moved|1
6292622|NCT02425891|10010347|FG001|Overall Study|Physician Decision|1
6292623|NCT02425891|10010346|FG000|Overall Study|Protocol Violation|1
6292624|NCT02425891|10010347|FG001|Overall Study|Protocol Violation|1
6292625|NCT02425891|10010346|FG000|Overall Study|Study Terminated By Sponsor|1
6292626|NCT02425891|10010347|FG001|Overall Study|Study Terminated By Sponsor|0
6292627|NCT02425891|10010346|FG000|Overall Study|Withdrawal by Subject|27
6292628|NCT02425891|10010347|FG001|Overall Study|Withdrawal by Subject|32
6292629|NCT02425891|10010346|FG000|Overall Study|On-going in Study|79
6292630|NCT02425891|10010347|FG001|Overall Study|On-going in Study|90
6292631|NCT02425891|10010346|FG000|Overall Study|Not treated|6
6292632|NCT02425891|10010347|FG001|Overall Study|Not treated|6
6292633|NCT02426086|10010360|FG000|Overall Study|Death|33
6292634|NCT02426086|10010361|FG001|Overall Study|Death|36
6292635|NCT02426086|10010360|FG000|Overall Study|Lost to Follow-up|2
6292636|NCT02426086|10010361|FG001|Overall Study|Lost to Follow-up|0
6292637|NCT02426086|10010360|FG000|Overall Study|Study Terminated by Sponsor|5
6292638|NCT02426086|10010361|FG001|Overall Study|Study Terminated by Sponsor|14
6292639|NCT02426086|10010360|FG000|Overall Study|Withdrawal by Subject|8
6292640|NCT02426086|10010361|FG001|Overall Study|Withdrawal by Subject|9
6292641|NCT02426138|10010374|FG000|First Intervention (12 Weeks)|Withdrawal by Subject|1
6292642|NCT02426138|10010375|FG001|First Intervention (12 Weeks)|Withdrawal by Subject|1
6292643|NCT02426541|10010396|FG000|Overall Study|Protocol Violation|1
6292644|NCT02426541|10010397|FG001|Overall Study|Protocol Violation|0
6292645|NCT02426580|10010405|FG000|Overall Study|Death|2
6292646|NCT02426580|10010406|FG001|Overall Study|Death|2
6292647|NCT02426580|10010405|FG000|Overall Study|Lost to Follow-up|0
6292648|NCT02426580|10010406|FG001|Overall Study|Lost to Follow-up|9
6292649|NCT02426580|10010405|FG000|Overall Study|transfer to hemodialysis|5
6292650|NCT02426580|10010406|FG001|Overall Study|transfer to hemodialysis|5
6292651|NCT02426580|10010405|FG000|Overall Study|Kidney transplant|3
6292652|NCT02426580|10010406|FG001|Overall Study|Kidney transplant|0
6292653|NCT02426580|10010405|FG000|Overall Study|Allergic to egg white|1
6292654|NCT02426580|10010406|FG001|Overall Study|Allergic to egg white|0
6292655|NCT02426658|10010412|FG000|Overall Study|Withdrawal by Subject|1
6292656|NCT02426658|10010412|FG000|Overall Study|Patient expired before treatment|2
6292657|NCT02426918|10010430|FG000|Overall Study|Adverse Event|2
6292658|NCT02426918|10010431|FG001|Overall Study|Adverse Event|2
6292659|NCT02426918|10010432|FG002|Overall Study|Adverse Event|0
6292660|NCT02426918|10010430|FG000|Overall Study|Physician Decision|1
6292661|NCT02426918|10010431|FG001|Overall Study|Physician Decision|1
6292662|NCT02426918|10010432|FG002|Overall Study|Physician Decision|1
6292663|NCT02426918|10010430|FG000|Overall Study|Withdrawal by Subject|5
6292664|NCT02426918|10010431|FG001|Overall Study|Withdrawal by Subject|5
6292665|NCT02426918|10010432|FG002|Overall Study|Withdrawal by Subject|4
6292666|NCT02426918|10010430|FG000|Overall Study|Other|9
6292667|NCT02426918|10010431|FG001|Overall Study|Other|11
6292668|NCT02426918|10010432|FG002|Overall Study|Other|9
6292669|NCT02427100|10010442|FG000|Overall Study|Lost to Follow-up|0
6292670|NCT02427100|10010443|FG001|Overall Study|Lost to Follow-up|2
6292671|NCT02427399|10010454|FG000|Overall Study|Protocol Violation|14
6292672|NCT02427399|10010455|FG001|Overall Study|Protocol Violation|16
6292673|NCT02427399|10010456|FG002|Overall Study|Protocol Violation|12
6292674|NCT02427399|10010457|FG003|Overall Study|Protocol Violation|18
6292675|NCT02427399|10010458|FG004|Overall Study|Protocol Violation|15
6292676|NCT02427477|10010472|FG000|Period 1|Adverse Event|1
6292677|NCT02427477|10010473|FG001|Period 1|Adverse Event|0
6292678|NCT02427607|10010479|FG000|Overall Study|Withdrawal by Subject|1
6292679|NCT02427646|10010485|FG000|Overall Study|Lack of Efficacy|2
6292680|NCT02427646|10010486|FG001|Overall Study|Lack of Efficacy|3
6292681|NCT02427646|10010485|FG000|Overall Study|Physician Decision|1
6292682|NCT02427646|10010486|FG001|Overall Study|Physician Decision|4
6292683|NCT02427646|10010485|FG000|Overall Study|Protocol Violation|3
6292684|NCT02427646|10010486|FG001|Overall Study|Protocol Violation|3
6292685|NCT02427646|10010485|FG000|Overall Study|Bothersome hand weakness|2
6292686|NCT02427646|10010486|FG001|Overall Study|Bothersome hand weakness|4
6292687|NCT02427802|10010533|FG000|Overall Study|Adverse Event|11
6292688|NCT02427802|10010534|FG001|Overall Study|Adverse Event|3
6292689|NCT02427802|10010535|FG002|Overall Study|Adverse Event|7
6292690|NCT02427802|10010533|FG000|Overall Study|Death|0
6292691|NCT02427802|10010534|FG001|Overall Study|Death|4
6292692|NCT02427802|10010535|FG002|Overall Study|Death|1
6292693|NCT02427802|10010533|FG000|Overall Study|Lost to Follow-up|13
6292694|NCT02427802|10010534|FG001|Overall Study|Lost to Follow-up|8
6292695|NCT02427802|10010535|FG002|Overall Study|Lost to Follow-up|8
6292696|NCT02427802|10010533|FG000|Overall Study|Physician Decision|4
6292697|NCT02427802|10010534|FG001|Overall Study|Physician Decision|2
6292698|NCT02427802|10010535|FG002|Overall Study|Physician Decision|4
6292699|NCT02427802|10010533|FG000|Overall Study|Withdrawal by Subject|10
6292700|NCT02427802|10010534|FG001|Overall Study|Withdrawal by Subject|5
6292701|NCT02427802|10010535|FG002|Overall Study|Withdrawal by Subject|11
6292702|NCT02427802|10010533|FG000|Overall Study|Protocol Violation|3
6292703|NCT02427802|10010534|FG001|Overall Study|Protocol Violation|1
6292704|NCT02427802|10010535|FG002|Overall Study|Protocol Violation|1
6292705|NCT02427802|10010533|FG000|Overall Study|protocol specific treatment unrelated|18
6292706|NCT02427802|10010534|FG001|Overall Study|protocol specific treatment unrelated|11
6292707|NCT02427802|10010535|FG002|Overall Study|protocol specific treatment unrelated|11
6292708|NCT02427841|10010543|FG000|Overall Study|Physician Decision|8
6292709|NCT02427984|10010550|FG000|Overall Study|Lost to Follow-up|13
6292710|NCT02427984|10010551|FG001|Overall Study|Lost to Follow-up|5
6292711|NCT02427984|10010552|FG002|Overall Study|Lost to Follow-up|18
6292712|NCT02428296|10010561|FG000|Overall Study|Adverse Event|7
6292713|NCT02428296|10010561|FG000|Overall Study|Withdrawal by Subject|2
6292714|NCT02428413|10010575|FG000|Overall Study|Device to measure WAG malfunctioned|3
6292715|NCT02428413|10010576|FG001|Overall Study|Device to measure WAG malfunctioned|5
6292716|NCT02428413|10010575|FG000|Overall Study|Protocol Violation|1
6292717|NCT02428413|10010576|FG001|Overall Study|Protocol Violation|2
6292718|NCT02428413|10010575|FG000|Overall Study|Case Cancelled|2
6292719|NCT02428413|10010576|FG001|Overall Study|Case Cancelled|0
6292720|NCT02428413|10010575|FG000|Overall Study|Missed Cases|1
6292721|NCT02428413|10010576|FG001|Overall Study|Missed Cases|2
6292722|NCT02428413|10010575|FG000|Overall Study|Nurse Refusal|1
6292723|NCT02428413|10010576|FG001|Overall Study|Nurse Refusal|0
6292724|NCT02428608|10010602|FG000|Overall Study|Pregnancy|2
6292725|NCT02428608|10010602|FG000|Overall Study|Lost to Follow-up|37
6292726|NCT02428608|10010602|FG000|Overall Study|Withdrawal by Subject|2
6292727|NCT02428608|10010602|FG000|Overall Study|scheduling conflicts|15
6292728|NCT02428608|10010602|FG000|Overall Study|moved away|10
6292729|NCT02428608|10010602|FG000|Overall Study|Death|1
6292730|NCT02428608|10010602|FG000|Overall Study|various|16
6292731|NCT02428699|10010607|FG000|Washout Period 1|Screen Failure|1
6292732|NCT02428699|10010608|FG001|Washout Period 1|Screen Failure|2
6292733|NCT02428855|10010619|FG000|Overall Study|Withdrawal by Subject|2
6292734|NCT02429258|10010650|FG000|Overall Study|Withdrawal by Subject|2
6292735|NCT02429258|10010651|FG001|Overall Study|Withdrawal by Subject|0
6292736|NCT02429258|10010650|FG000|Overall Study|Protocol Violation|0
6292737|NCT02429258|10010651|FG001|Overall Study|Protocol Violation|1
6292738|NCT02429310|10010659|FG000|Overall Study|Lost to Follow-up|1
6292739|NCT02429310|10010660|FG001|Overall Study|Lost to Follow-up|2
6292740|NCT02429310|10010659|FG000|Overall Study|Protocol Violation|1
6292741|NCT02429310|10010660|FG001|Overall Study|Protocol Violation|1
6292742|NCT02429427|10010668|FG000|Overall Study|Adverse Event|220
6292743|NCT02429427|10010669|FG001|Overall Study|Adverse Event|92
6292744|NCT02429427|10010668|FG000|Overall Study|Protocol Violation|10
6292745|NCT02429427|10010669|FG001|Overall Study|Protocol Violation|6
6292746|NCT02429427|10010668|FG000|Overall Study|Lost to Follow-up|15
6292747|NCT02429427|10010669|FG001|Overall Study|Lost to Follow-up|6
6292748|NCT02429427|10010668|FG000|Overall Study|Withdrawal by Subject|64
6292749|NCT02429427|10010669|FG001|Overall Study|Withdrawal by Subject|34
6292750|NCT02429427|10010668|FG000|Overall Study|Other|62
6292751|NCT02429427|10010669|FG001|Overall Study|Other|41
6292752|NCT02429778|10010677|FG000|Overall Study|Lost to Follow-up|2
6292753|NCT02429778|10010678|FG001|Overall Study|Lost to Follow-up|0
6292754|NCT02429778|10010677|FG000|Overall Study|Withdrawal by Subject|5
6292755|NCT02429778|10010678|FG001|Overall Study|Withdrawal by Subject|0
6292756|NCT02429856|10010686|FG000|Overall Study|Death|12
6292757|NCT02429856|10010687|FG001|Overall Study|Death|13
6292758|NCT02429856|10010686|FG000|Overall Study|Lost to Follow-up|6
6292759|NCT02429856|10010687|FG001|Overall Study|Lost to Follow-up|5
6292760|NCT02429856|10010686|FG000|Overall Study|Withdrawal by Subject|1
6292761|NCT02429856|10010687|FG001|Overall Study|Withdrawal by Subject|1
6292762|NCT02429934|10010701|FG000|Overall Study|Withdrawal by Subject|0
6292763|NCT02429934|10010702|FG001|Overall Study|Withdrawal by Subject|2
6292764|NCT02429934|10010701|FG000|Overall Study|Adverse Event|2
6292765|NCT02429934|10010702|FG001|Overall Study|Adverse Event|0
6292766|NCT02429934|10010701|FG000|Overall Study|Lost to Follow-up|1
6292767|NCT02429934|10010702|FG001|Overall Study|Lost to Follow-up|1
6292768|NCT02429934|10010701|FG000|Overall Study|Physician Decision|1
6292769|NCT02429934|10010702|FG001|Overall Study|Physician Decision|0
6292770|NCT02430311|10010725|FG000|Part A|Adverse Event|0
6292771|NCT02430311|10010726|FG001|Part A|Adverse Event|1
6292772|NCT02430311|10010725|FG000|Part A|Withdrawal by Subject|1
6292773|NCT02430311|10010726|FG001|Part A|Withdrawal by Subject|0
6292774|NCT02430311|10010725|FG000|Part B|Meet study-specific withdrawal criteria|6
6292775|NCT02430311|10010726|FG001|Part B|Meet study-specific withdrawal criteria|6
6292776|NCT02430311|10010725|FG000|Part B|Withdrawal by Subject|2
6292777|NCT02430311|10010726|FG001|Part B|Withdrawal by Subject|2
6292778|NCT02430311|10010725|FG000|Part B|Adverse Event|1
6292779|NCT02430311|10010726|FG001|Part B|Adverse Event|0
6292780|NCT02430311|10010725|FG000|Part B|Death|1
6292781|NCT02430311|10010726|FG001|Part B|Death|0
6292782|NCT02430480|10010763|FG000|Overall Study|Death|1
6292783|NCT02430480|10010763|FG000|Overall Study|Anesthesia concerns|1
6292784|NCT02430480|10010763|FG000|Overall Study|Progressed on treatment|1
6292785|NCT02430870|10010791|FG000|Part 2|Voluntary Withdrawal|0
6292786|NCT02430870|10010792|FG001|Part 2|Voluntary Withdrawal|0
6292787|NCT02430870|10010793|FG002|Part 2|Voluntary Withdrawal|0
6292788|NCT02430870|10010794|FG003|Part 2|Voluntary Withdrawal|0
6292789|NCT02430870|10010795|FG004|Part 2|Voluntary Withdrawal|0
6292790|NCT02430870|10010796|FG005|Part 2|Voluntary Withdrawal|0
6292791|NCT02430870|10010797|FG006|Part 2|Voluntary Withdrawal|1
6292792|NCT02430870|10010798|FG007|Part 2|Voluntary Withdrawal|0
6292793|NCT02430870|10010791|FG000|Part 2|Other Reason Not Specified|0
6292794|NCT02430870|10010792|FG001|Part 2|Other Reason Not Specified|0
6292795|NCT02430870|10010793|FG002|Part 2|Other Reason Not Specified|0
6292796|NCT02430870|10010794|FG003|Part 2|Other Reason Not Specified|0
6292797|NCT02430870|10010795|FG004|Part 2|Other Reason Not Specified|0
6292798|NCT02430870|10010796|FG005|Part 2|Other Reason Not Specified|0
6292799|NCT02430870|10010797|FG006|Part 2|Other Reason Not Specified|0
6292800|NCT02430870|10010798|FG007|Part 2|Other Reason Not Specified|1
6292801|NCT02431260|10010856|FG000|Overall Study|Subject Decision|0
6292802|NCT02431260|10010857|FG001|Overall Study|Subject Decision|1
6292803|NCT02431260|10010858|FG002|Overall Study|Subject Decision|1
6292804|NCT02431260|10010859|FG003|Overall Study|Subject Decision|0
6292805|NCT02431260|10010860|FG004|Overall Study|Subject Decision|0
6292806|NCT02431260|10010861|FG005|Overall Study|Subject Decision|0
6292807|NCT02431260|10010862|FG006|Overall Study|Subject Decision|0
6292808|NCT02431260|10010863|FG007|Overall Study|Subject Decision|0
6292809|NCT02431260|10010864|FG008|Overall Study|Subject Decision|1
6292810|NCT02431260|10010865|FG009|Overall Study|Subject Decision|1
6292811|NCT02431260|10010866|FG010|Overall Study|Subject Decision|0
6292812|NCT02431260|10010867|FG011|Overall Study|Subject Decision|1
6292813|NCT02431260|10010868|FG012|Overall Study|Subject Decision|0
6292814|NCT02431260|10010869|FG013|Overall Study|Subject Decision|0
6292815|NCT02431260|10010856|FG000|Overall Study|Death|4
6292816|NCT02431260|10010857|FG001|Overall Study|Death|4
6292817|NCT02431260|10010858|FG002|Overall Study|Death|3
6292818|NCT02431260|10010859|FG003|Overall Study|Death|4
6292819|NCT02431260|10010860|FG004|Overall Study|Death|2
6292820|NCT02431260|10010861|FG005|Overall Study|Death|2
6292821|NCT02431260|10010862|FG006|Overall Study|Death|3
6292822|NCT02431260|10010863|FG007|Overall Study|Death|1
6292823|NCT02431260|10010864|FG008|Overall Study|Death|6
6292824|NCT02431260|10010865|FG009|Overall Study|Death|6
6292825|NCT02431260|10010866|FG010|Overall Study|Death|3
6292826|NCT02431260|10010867|FG011|Overall Study|Death|2
6292827|NCT02431260|10010868|FG012|Overall Study|Death|5
6292828|NCT02431260|10010869|FG013|Overall Study|Death|1
6292829|NCT02431260|10010856|FG000|Overall Study|Lost to Follow-up|0
6292830|NCT02431260|10010857|FG001|Overall Study|Lost to Follow-up|0
6292831|NCT02431260|10010858|FG002|Overall Study|Lost to Follow-up|0
6292832|NCT02431260|10010859|FG003|Overall Study|Lost to Follow-up|0
6292833|NCT02431260|10010860|FG004|Overall Study|Lost to Follow-up|0
6292834|NCT02431260|10010861|FG005|Overall Study|Lost to Follow-up|1
6292835|NCT02431260|10010862|FG006|Overall Study|Lost to Follow-up|0
6292836|NCT02431260|10010863|FG007|Overall Study|Lost to Follow-up|0
6292837|NCT02431260|10010864|FG008|Overall Study|Lost to Follow-up|0
6292838|NCT02431260|10010865|FG009|Overall Study|Lost to Follow-up|0
6292839|NCT02431260|10010866|FG010|Overall Study|Lost to Follow-up|0
6292840|NCT02431260|10010867|FG011|Overall Study|Lost to Follow-up|0
6292841|NCT02431260|10010868|FG012|Overall Study|Lost to Follow-up|0
6292842|NCT02431260|10010869|FG013|Overall Study|Lost to Follow-up|0
6292843|NCT02431260|10010856|FG000|Overall Study|Study Terminated by the Sponsor|0
6292844|NCT02431260|10010857|FG001|Overall Study|Study Terminated by the Sponsor|0
6292845|NCT02431260|10010858|FG002|Overall Study|Study Terminated by the Sponsor|2
6292846|NCT02431260|10010859|FG003|Overall Study|Study Terminated by the Sponsor|1
6292847|NCT02431260|10010860|FG004|Overall Study|Study Terminated by the Sponsor|1
6292848|NCT02431260|10010861|FG005|Overall Study|Study Terminated by the Sponsor|0
6292849|NCT02431260|10010862|FG006|Overall Study|Study Terminated by the Sponsor|1
6292850|NCT02431260|10010863|FG007|Overall Study|Study Terminated by the Sponsor|2
6292851|NCT02431260|10010864|FG008|Overall Study|Study Terminated by the Sponsor|1
6292852|NCT02431260|10010865|FG009|Overall Study|Study Terminated by the Sponsor|1
6292853|NCT02431260|10010866|FG010|Overall Study|Study Terminated by the Sponsor|1
6292854|NCT02431260|10010867|FG011|Overall Study|Study Terminated by the Sponsor|0
6292855|NCT02431260|10010868|FG012|Overall Study|Study Terminated by the Sponsor|4
6292856|NCT02431260|10010869|FG013|Overall Study|Study Terminated by the Sponsor|0
6292857|NCT02431260|10010856|FG000|Overall Study|Physician Decision|0
6292858|NCT02431260|10010857|FG001|Overall Study|Physician Decision|0
6292859|NCT02431260|10010858|FG002|Overall Study|Physician Decision|0
6292860|NCT02431260|10010859|FG003|Overall Study|Physician Decision|0
6292861|NCT02431260|10010860|FG004|Overall Study|Physician Decision|0
6292862|NCT02431260|10010861|FG005|Overall Study|Physician Decision|1
6292863|NCT02431260|10010862|FG006|Overall Study|Physician Decision|0
6292864|NCT02431260|10010863|FG007|Overall Study|Physician Decision|0
6292865|NCT02431260|10010864|FG008|Overall Study|Physician Decision|0
6292866|NCT02431260|10010865|FG009|Overall Study|Physician Decision|0
6292867|NCT02431260|10010866|FG010|Overall Study|Physician Decision|0
6292868|NCT02431260|10010867|FG011|Overall Study|Physician Decision|0
6292869|NCT02431260|10010868|FG012|Overall Study|Physician Decision|0
6292870|NCT02431260|10010869|FG013|Overall Study|Physician Decision|0
6292871|NCT02431260|10010856|FG000|Overall Study|Other Unspecified|0
6292872|NCT02431260|10010857|FG001|Overall Study|Other Unspecified|0
6292873|NCT02431260|10010858|FG002|Overall Study|Other Unspecified|0
6292874|NCT02431260|10010859|FG003|Overall Study|Other Unspecified|0
6292875|NCT02431260|10010860|FG004|Overall Study|Other Unspecified|0
6292876|NCT02431260|10010861|FG005|Overall Study|Other Unspecified|0
6292877|NCT02431260|10010862|FG006|Overall Study|Other Unspecified|0
6292878|NCT02431260|10010863|FG007|Overall Study|Other Unspecified|0
6292879|NCT02431260|10010864|FG008|Overall Study|Other Unspecified|0
6292880|NCT02431260|10010865|FG009|Overall Study|Other Unspecified|0
6292881|NCT02431260|10010866|FG010|Overall Study|Other Unspecified|0
6292882|NCT02431260|10010867|FG011|Overall Study|Other Unspecified|1
6292883|NCT02431260|10010868|FG012|Overall Study|Other Unspecified|1
6292884|NCT02431260|10010869|FG013|Overall Study|Other Unspecified|0
6292885|NCT02431364|10010934|FG000|Overall Study|Adverse Event|0
6292886|NCT02431364|10010935|FG001|Overall Study|Adverse Event|1
6292887|NCT02431364|10010936|FG002|Overall Study|Adverse Event|0
6292888|NCT02431364|10010937|FG003|Overall Study|Adverse Event|0
6292889|NCT02431364|10010938|FG004|Overall Study|Adverse Event|0
6292890|NCT02431364|10010934|FG000|Overall Study|Randomized but never treated|0
6292891|NCT02431364|10010935|FG001|Overall Study|Randomized but never treated|0
6292892|NCT02431364|10010936|FG002|Overall Study|Randomized but never treated|0
6292893|NCT02431364|10010937|FG003|Overall Study|Randomized but never treated|1
6292894|NCT02431364|10010938|FG004|Overall Study|Randomized but never treated|0
6292895|NCT02431468|10010966|FG000|Overall Study|Adverse Event|2
6292896|NCT02431468|10010967|FG001|Overall Study|Adverse Event|4
6292897|NCT02431468|10010968|FG002|Overall Study|Adverse Event|5
6292898|NCT02431468|10010966|FG000|Overall Study|Withdrawal by Subject|4
6292899|NCT02431468|10010967|FG001|Overall Study|Withdrawal by Subject|12
6292900|NCT02431468|10010968|FG002|Overall Study|Withdrawal by Subject|2
6292901|NCT02431468|10010966|FG000|Overall Study|noncompliance, investigator termination,|2
6292902|NCT02431468|10010967|FG001|Overall Study|noncompliance, investigator termination,|2
6292903|NCT02431468|10010968|FG002|Overall Study|noncompliance, investigator termination,|2
6292904|NCT02431533|10010984|FG000|Overall Study|Withdrawal by Subject|1
6292905|NCT02431533|10010985|FG001|Overall Study|Withdrawal by Subject|3
6292906|NCT02431533|10010984|FG000|Overall Study|Developed Exclusionary criteria|1
6292907|NCT02431533|10010985|FG001|Overall Study|Developed Exclusionary criteria|0
6292908|NCT02431559|10010995|FG000|Overall Study|Adverse Event|0
6292909|NCT02431559|10010996|FG001|Overall Study|Adverse Event|1
6292910|NCT02431559|10010997|FG002|Overall Study|Adverse Event|0
6292911|NCT02431559|10010998|FG003|Overall Study|Adverse Event|4
6292912|NCT02431559|10010995|FG000|Overall Study|Progressive disease|2
6292913|NCT02431559|10010996|FG001|Overall Study|Progressive disease|1
6292914|NCT02431559|10010997|FG002|Overall Study|Progressive disease|4
6292915|NCT02431559|10010998|FG003|Overall Study|Progressive disease|22
6292916|NCT02431559|10010995|FG000|Overall Study|Withdrawal by Subject|0
6292917|NCT02431559|10010996|FG001|Overall Study|Withdrawal by Subject|1
6292918|NCT02431559|10010997|FG002|Overall Study|Withdrawal by Subject|0
6292919|NCT02431559|10010998|FG003|Overall Study|Withdrawal by Subject|4
6292920|NCT02431559|10010995|FG000|Overall Study|Physician Decision|0
6292921|NCT02431559|10010996|FG001|Overall Study|Physician Decision|0
6292922|NCT02431559|10010997|FG002|Overall Study|Physician Decision|0
6292923|NCT02431559|10010998|FG003|Overall Study|Physician Decision|1
6292924|NCT02431676|10011059|FG000|Overall Study|no lab obtained|0
6292925|NCT02431676|10011060|FG001|Overall Study|no lab obtained|1
6292926|NCT02431676|10011061|FG002|Overall Study|no lab obtained|2
6292927|NCT02431793|10011087|FG000|Overall Study|Ineligible doe to not filling Rx|11
6292928|NCT02431793|10011088|FG001|Overall Study|Ineligible doe to not filling Rx|7
6292929|NCT02431793|10011089|FG002|Overall Study|Ineligible doe to not filling Rx|8
6292930|NCT02431793|10011087|FG000|Overall Study|Withdrawal by Subject|7
6292931|NCT02431793|10011088|FG001|Overall Study|Withdrawal by Subject|5
6292932|NCT02431793|10011089|FG002|Overall Study|Withdrawal by Subject|5
6292933|NCT02431793|10011087|FG000|Overall Study|Lost to Follow-up|101
6292934|NCT02431793|10011088|FG001|Overall Study|Lost to Follow-up|122
6292935|NCT02431793|10011089|FG002|Overall Study|Lost to Follow-up|104
6292936|NCT02431806|10011101|FG000|Double-blind Treatment Period|Did not Receive Treatment|1
6292937|NCT02431806|10011102|FG001|Double-blind Treatment Period|Did not Receive Treatment|2
6292938|NCT02431806|10011103|FG002|Double-blind Treatment Period|Did not Receive Treatment|1
6292939|NCT02431806|10011104|FG003|Double-blind Treatment Period|Did not Receive Treatment|1
6292940|NCT02431806|10011101|FG000|Double-blind Treatment Period|Adverse Event|4
6292941|NCT02431806|10011102|FG001|Double-blind Treatment Period|Adverse Event|7
6292942|NCT02431806|10011103|FG002|Double-blind Treatment Period|Adverse Event|11
6292943|NCT02431806|10011104|FG003|Double-blind Treatment Period|Adverse Event|7
6292944|NCT02431806|10011101|FG000|Double-blind Treatment Period|Lack of Efficacy|2
6292945|NCT02431806|10011102|FG001|Double-blind Treatment Period|Lack of Efficacy|0
6292946|NCT02431806|10011103|FG002|Double-blind Treatment Period|Lack of Efficacy|2
6292947|NCT02431806|10011104|FG003|Double-blind Treatment Period|Lack of Efficacy|2
6292948|NCT02431806|10011101|FG000|Double-blind Treatment Period|Withdrawal of Consent|10
6292949|NCT02431806|10011102|FG001|Double-blind Treatment Period|Withdrawal of Consent|7
6292950|NCT02431806|10011103|FG002|Double-blind Treatment Period|Withdrawal of Consent|5
6292951|NCT02431806|10011104|FG003|Double-blind Treatment Period|Withdrawal of Consent|5
6292952|NCT02431806|10011101|FG000|Double-blind Treatment Period|Lost to Follow-up|7
6292953|NCT02431806|10011102|FG001|Double-blind Treatment Period|Lost to Follow-up|4
6292954|NCT02431806|10011103|FG002|Double-blind Treatment Period|Lost to Follow-up|5
6292955|NCT02431806|10011104|FG003|Double-blind Treatment Period|Lost to Follow-up|8
6292956|NCT02431806|10011101|FG000|Double-blind Treatment Period|Investigational Product Non-compliance|1
6292957|NCT02431806|10011102|FG001|Double-blind Treatment Period|Investigational Product Non-compliance|0
6292958|NCT02431806|10011103|FG002|Double-blind Treatment Period|Investigational Product Non-compliance|3
6292959|NCT02431806|10011104|FG003|Double-blind Treatment Period|Investigational Product Non-compliance|1
6292960|NCT02431806|10011101|FG000|Double-blind Treatment Period|Reason Not Specified|0
6292961|NCT02431806|10011102|FG001|Double-blind Treatment Period|Reason Not Specified|1
6292962|NCT02431806|10011103|FG002|Double-blind Treatment Period|Reason Not Specified|5
6292963|NCT02431806|10011104|FG003|Double-blind Treatment Period|Reason Not Specified|2
6292964|NCT02432040|10011116|FG000|Overall Study|Lack of Efficacy|3
6292965|NCT02432040|10011117|FG001|Overall Study|Lack of Efficacy|0
6292966|NCT02432040|10011116|FG000|Overall Study|Lost to Follow-up|4
6292967|NCT02432040|10011117|FG001|Overall Study|Lost to Follow-up|5
6292968|NCT02432040|10011116|FG000|Overall Study|Physician Decision|1
6292969|NCT02432040|10011117|FG001|Overall Study|Physician Decision|1
6292970|NCT02432105|10011126|FG000|Overall Study|Lost to Follow-up|1
6292971|NCT02432105|10011127|FG001|Overall Study|Lost to Follow-up|1
6292972|NCT02432105|10011128|FG002|Overall Study|Lost to Follow-up|0
6292973|NCT02432105|10011126|FG000|Overall Study|Withdrawal by Subject|1
6292974|NCT02432105|10011127|FG001|Overall Study|Withdrawal by Subject|0
6292975|NCT02432105|10011128|FG002|Overall Study|Withdrawal by Subject|1
6292976|NCT02432105|10011126|FG000|Overall Study|Culture positive for yeast|0
6292977|NCT02432105|10011127|FG001|Overall Study|Culture positive for yeast|1
6292978|NCT02432105|10011128|FG002|Overall Study|Culture positive for yeast|0
6292979|NCT02432105|10011126|FG000|Overall Study|Randomized in error|0
6292980|NCT02432105|10011127|FG001|Overall Study|Randomized in error|0
6292981|NCT02432105|10011128|FG002|Overall Study|Randomized in error|2
6292982|NCT02432144|10011137|FG000|Overall Study|Participant Non-Compliance|1
6292983|NCT02432235|10011170|FG000|Overall Study|Death|1
6292984|NCT02432235|10011171|FG001|Overall Study|Death|1
6292985|NCT02432235|10011172|FG002|Overall Study|Death|2
6292986|NCT02432235|10011173|FG003|Overall Study|Death|2
6292987|NCT02432235|10011174|FG004|Overall Study|Death|1
6292988|NCT02432235|10011175|FG005|Overall Study|Death|3
6292989|NCT02432235|10011176|FG006|Overall Study|Death|11
6292990|NCT02432235|10011177|FG007|Overall Study|Death|15
6292991|NCT02432235|10011178|FG008|Overall Study|Death|15
6292992|NCT02432235|10011179|FG009|Overall Study|Death|3
6292993|NCT02432235|10011180|FG010|Overall Study|Death|1
6292994|NCT02432235|10011181|FG011|Overall Study|Death|0
6292995|NCT02432235|10011170|FG000|Overall Study|Withdrawal by Subject|0
6292996|NCT02432235|10011171|FG001|Overall Study|Withdrawal by Subject|1
6292997|NCT02432235|10011172|FG002|Overall Study|Withdrawal by Subject|0
6292998|NCT02432235|10011173|FG003|Overall Study|Withdrawal by Subject|0
6292999|NCT02432235|10011174|FG004|Overall Study|Withdrawal by Subject|0
6293000|NCT02432235|10011175|FG005|Overall Study|Withdrawal by Subject|2
6293001|NCT02432235|10011176|FG006|Overall Study|Withdrawal by Subject|5
6293002|NCT02432235|10011177|FG007|Overall Study|Withdrawal by Subject|3
6293003|NCT02432235|10011178|FG008|Overall Study|Withdrawal by Subject|1
6293004|NCT02432235|10011179|FG009|Overall Study|Withdrawal by Subject|0
6293005|NCT02432235|10011180|FG010|Overall Study|Withdrawal by Subject|0
6293006|NCT02432235|10011181|FG011|Overall Study|Withdrawal by Subject|0
6293007|NCT02432235|10011170|FG000|Overall Study|Lost to Follow-up|0
6293008|NCT02432235|10011171|FG001|Overall Study|Lost to Follow-up|0
6293009|NCT02432235|10011172|FG002|Overall Study|Lost to Follow-up|0
6293010|NCT02432235|10011173|FG003|Overall Study|Lost to Follow-up|0
6293011|NCT02432235|10011174|FG004|Overall Study|Lost to Follow-up|0
6293012|NCT02432235|10011175|FG005|Overall Study|Lost to Follow-up|1
6293013|NCT02432235|10011176|FG006|Overall Study|Lost to Follow-up|0
6293014|NCT02432235|10011177|FG007|Overall Study|Lost to Follow-up|0
6293015|NCT02432235|10011178|FG008|Overall Study|Lost to Follow-up|1
6293016|NCT02432235|10011179|FG009|Overall Study|Lost to Follow-up|0
6293017|NCT02432235|10011180|FG010|Overall Study|Lost to Follow-up|0
6293018|NCT02432235|10011181|FG011|Overall Study|Lost to Follow-up|0
6293019|NCT02432235|10011170|FG000|Overall Study|Miscellaneous|0
6293020|NCT02432235|10011171|FG001|Overall Study|Miscellaneous|0
6293021|NCT02432235|10011172|FG002|Overall Study|Miscellaneous|0
6293022|NCT02432235|10011173|FG003|Overall Study|Miscellaneous|0
6293023|NCT02432235|10011174|FG004|Overall Study|Miscellaneous|1
6293024|NCT02432235|10011175|FG005|Overall Study|Miscellaneous|6
6293025|NCT02432235|10011176|FG006|Overall Study|Miscellaneous|2
6293026|NCT02432235|10011177|FG007|Overall Study|Miscellaneous|2
6293027|NCT02432235|10011178|FG008|Overall Study|Miscellaneous|4
6293028|NCT02432235|10011179|FG009|Overall Study|Miscellaneous|0
6293029|NCT02432235|10011180|FG010|Overall Study|Miscellaneous|0
6293030|NCT02432235|10011181|FG011|Overall Study|Miscellaneous|1
6293031|NCT02432274|10011217|FG000|Overall Study|Radiological Disease Progression|3
6293032|NCT02432274|10011218|FG001|Overall Study|Radiological Disease Progression|4
6293033|NCT02432274|10011219|FG002|Overall Study|Radiological Disease Progression|7
6293034|NCT02432274|10011220|FG003|Overall Study|Radiological Disease Progression|0
6293035|NCT02432274|10011221|FG004|Overall Study|Radiological Disease Progression|24
6293036|NCT02432274|10011222|FG005|Overall Study|Radiological Disease Progression|6
6293037|NCT02432274|10011223|FG006|Overall Study|Radiological Disease Progression|11
6293038|NCT02432274|10011224|FG007|Overall Study|Radiological Disease Progression|9
6293039|NCT02432274|10011217|FG000|Overall Study|Clinical Disease Progression|0
6293040|NCT02432274|10011218|FG001|Overall Study|Clinical Disease Progression|4
6293041|NCT02432274|10011219|FG002|Overall Study|Clinical Disease Progression|1
6293042|NCT02432274|10011220|FG003|Overall Study|Clinical Disease Progression|0
6293043|NCT02432274|10011221|FG004|Overall Study|Clinical Disease Progression|1
6293044|NCT02432274|10011222|FG005|Overall Study|Clinical Disease Progression|0
6293045|NCT02432274|10011223|FG006|Overall Study|Clinical Disease Progression|0
6293046|NCT02432274|10011224|FG007|Overall Study|Clinical Disease Progression|1
6293047|NCT02432274|10011217|FG000|Overall Study|Adverse Event|0
6293048|NCT02432274|10011218|FG001|Overall Study|Adverse Event|0
6293049|NCT02432274|10011219|FG002|Overall Study|Adverse Event|1
6293050|NCT02432274|10011220|FG003|Overall Study|Adverse Event|0
6293051|NCT02432274|10011221|FG004|Overall Study|Adverse Event|1
6293052|NCT02432274|10011222|FG005|Overall Study|Adverse Event|0
6293053|NCT02432274|10011223|FG006|Overall Study|Adverse Event|2
6293054|NCT02432274|10011224|FG007|Overall Study|Adverse Event|0
6293055|NCT02432274|10011217|FG000|Overall Study|Withdrawal by Subject|0
6293056|NCT02432274|10011218|FG001|Overall Study|Withdrawal by Subject|0
6293057|NCT02432274|10011219|FG002|Overall Study|Withdrawal by Subject|0
6293058|NCT02432274|10011220|FG003|Overall Study|Withdrawal by Subject|0
6293059|NCT02432274|10011221|FG004|Overall Study|Withdrawal by Subject|2
6293060|NCT02432274|10011222|FG005|Overall Study|Withdrawal by Subject|0
6293061|NCT02432274|10011223|FG006|Overall Study|Withdrawal by Subject|1
6293062|NCT02432274|10011224|FG007|Overall Study|Withdrawal by Subject|2
6293063|NCT02432274|10011217|FG000|Overall Study|Participant Choice|0
6293064|NCT02432274|10011218|FG001|Overall Study|Participant Choice|0
6293065|NCT02432274|10011219|FG002|Overall Study|Participant Choice|1
6293066|NCT02432274|10011220|FG003|Overall Study|Participant Choice|0
6293067|NCT02432274|10011221|FG004|Overall Study|Participant Choice|0
6293068|NCT02432274|10011222|FG005|Overall Study|Participant Choice|0
6293069|NCT02432274|10011223|FG006|Overall Study|Participant Choice|1
6293070|NCT02432274|10011224|FG007|Overall Study|Participant Choice|0
6293071|NCT02432274|10011217|FG000|Overall Study|Other than specified|0
6293072|NCT02432274|10011218|FG001|Overall Study|Other than specified|1
6293073|NCT02432274|10011219|FG002|Overall Study|Other than specified|0
6293074|NCT02432274|10011220|FG003|Overall Study|Other than specified|0
6293075|NCT02432274|10011221|FG004|Overall Study|Other than specified|0
6293076|NCT02432274|10011222|FG005|Overall Study|Other than specified|1
6293077|NCT02432274|10011223|FG006|Overall Study|Other than specified|0
6293078|NCT02432274|10011224|FG007|Overall Study|Other than specified|1
6293079|NCT02432274|10011217|FG000|Overall Study|Ongoing|0
6293080|NCT02432274|10011218|FG001|Overall Study|Ongoing|0
6293081|NCT02432274|10011219|FG002|Overall Study|Ongoing|1
6293082|NCT02432274|10011220|FG003|Overall Study|Ongoing|1
6293083|NCT02432274|10011221|FG004|Overall Study|Ongoing|3
6293084|NCT02432274|10011222|FG005|Overall Study|Ongoing|0
6293085|NCT02432274|10011223|FG006|Overall Study|Ongoing|0
6293086|NCT02432274|10011224|FG007|Overall Study|Ongoing|7
6293087|NCT02432703|10011280|FG000|Overall Study|Adverse Event|1
6293088|NCT02432703|10011281|FG001|Overall Study|Adverse Event|4
6293089|NCT02432703|10011280|FG000|Overall Study|Lack of Efficacy|1
6293090|NCT02432703|10011281|FG001|Overall Study|Lack of Efficacy|0
6293091|NCT02432703|10011280|FG000|Overall Study|Lost to Follow-up|5
6293092|NCT02432703|10011281|FG001|Overall Study|Lost to Follow-up|3
6293093|NCT02432703|10011280|FG000|Overall Study|Withdrawal by Subject|9
6293094|NCT02432703|10011281|FG001|Overall Study|Withdrawal by Subject|6
6293095|NCT02432703|10011280|FG000|Overall Study|Other|6
6293096|NCT02432703|10011281|FG001|Overall Study|Other|5
5981366|NCT00974571|9570340|FG001|Overall Study|Patient Moved|0
6293097|NCT02433080|10011308|FG000|Overall Study|Lost to Follow-up|1
6293098|NCT02433080|10011309|FG001|Overall Study|Lost to Follow-up|2
6293099|NCT02433080|10011308|FG000|Overall Study|Withdrawal by Subject|0
6293100|NCT02433080|10011309|FG001|Overall Study|Withdrawal by Subject|2
6293101|NCT02433288|10011318|FG000|Overall Study|Severe non-compliance to protocol|13
6293102|NCT02433288|10011319|FG001|Overall Study|Severe non-compliance to protocol|7
6293103|NCT02433288|10011318|FG000|Overall Study|Eligibility criteria not fullfilled|7
6293104|NCT02433288|10011319|FG001|Overall Study|Eligibility criteria not fullfilled|3
6293105|NCT02433288|10011318|FG000|Overall Study|Withdrawal by Subject|101
6293106|NCT02433288|10011319|FG001|Overall Study|Withdrawal by Subject|99
6293107|NCT02433288|10011318|FG000|Overall Study|Lost to Follow-up|2
6293108|NCT02433288|10011319|FG001|Overall Study|Lost to Follow-up|14
6293109|NCT02433288|10011318|FG000|Overall Study|Death|0
6293110|NCT02433288|10011319|FG001|Overall Study|Death|3
6293111|NCT02433340|10011329|FG000|Overall Study|Adverse Event|0
6293112|NCT02433340|10011330|FG001|Overall Study|Adverse Event|0
6293113|NCT02433340|10011331|FG002|Overall Study|Adverse Event|1
6293114|NCT02433340|10011332|FG003|Overall Study|Adverse Event|0
6293115|NCT02433340|10011329|FG000|Overall Study|Withdrawal by Subject|1
6293116|NCT02433340|10011330|FG001|Overall Study|Withdrawal by Subject|0
6293117|NCT02433340|10011331|FG002|Overall Study|Withdrawal by Subject|1
6293118|NCT02433340|10011332|FG003|Overall Study|Withdrawal by Subject|2
6293119|NCT02433340|10011329|FG000|Overall Study|Lost to Follow-up|0
6293120|NCT02433340|10011330|FG001|Overall Study|Lost to Follow-up|1
6293121|NCT02433340|10011331|FG002|Overall Study|Lost to Follow-up|0
6293122|NCT02433340|10011332|FG003|Overall Study|Lost to Follow-up|0
6293123|NCT02433340|10011329|FG000|Overall Study|Required Alternative/Prohibited Therapy|1
6293124|NCT02433340|10011330|FG001|Overall Study|Required Alternative/Prohibited Therapy|0
6293125|NCT02433340|10011331|FG002|Overall Study|Required Alternative/Prohibited Therapy|0
6293126|NCT02433340|10011332|FG003|Overall Study|Required Alternative/Prohibited Therapy|0
6293127|NCT02433340|10011329|FG000|Overall Study|Other|0
6293128|NCT02433340|10011330|FG001|Overall Study|Other|1
6293129|NCT02433340|10011331|FG002|Overall Study|Other|0
6293130|NCT02433340|10011332|FG003|Overall Study|Other|0
6293131|NCT02433379|10011353|FG000|Overall Study|Screen Failures|55
6293132|NCT02433379|10011353|FG000|Overall Study|Death|57
6293133|NCT02433379|10011353|FG000|Overall Study|Total Withdrawals|209
6293134|NCT02433483|10011359|FG000|Overall Study|Unacceptable toxicity|1
6293135|NCT02433483|10011359|FG000|Overall Study|Other antineoplastic therapy/HSCT|1
6293136|NCT02433678|10011390|FG000|Overall Study|Lost to Follow-up|1
6293137|NCT02433678|10011391|FG001|Overall Study|Lost to Follow-up|2
6293138|NCT02433834|10011397|FG000|Overall Study|Protocol-specified criteria|7
6293139|NCT02433834|10011397|FG000|Overall Study|Protocol Violation|3
6293140|NCT02433834|10011397|FG000|Overall Study|Lost to Follow-up|6
6293141|NCT02433834|10011397|FG000|Overall Study|Withdrawal by Subject|14
6293142|NCT02433834|10011397|FG000|Overall Study|Adverse Event|6
6293143|NCT02433834|10011397|FG000|Overall Study|Physician Decision|1
6293144|NCT02434081|10011417|FG000|Overall Study|Death (never started treatment)|2
6293145|NCT02434081|10011417|FG000|Overall Study|Death|2
6293146|NCT02434081|10011417|FG000|Overall Study|Progression|20
6293147|NCT02434081|10011417|FG000|Overall Study|Adverse Event|20
6293148|NCT02434081|10011417|FG000|Overall Study|Physician Decision|2
6293149|NCT02434081|10011417|FG000|Overall Study|Withdrawal by Subject|1
6293150|NCT02434081|10011417|FG000|Overall Study|Patient did not receive treatment for more than six weeks|1
6293151|NCT02434328|10011423|FG000|Overall Study|Adverse Event|9
6293152|NCT02434328|10011424|FG001|Overall Study|Adverse Event|4
6293153|NCT02434328|10011423|FG000|Overall Study|Lack of Efficacy|0
6293154|NCT02434328|10011424|FG001|Overall Study|Lack of Efficacy|2
6293155|NCT02434328|10011423|FG000|Overall Study|Physician Decision|0
6293156|NCT02434328|10011424|FG001|Overall Study|Physician Decision|1
6293157|NCT02434328|10011423|FG000|Overall Study|Withdrawal by Subject|12
6293158|NCT02434328|10011424|FG001|Overall Study|Withdrawal by Subject|21
6293159|NCT02434328|10011423|FG000|Overall Study|Death|4
6293160|NCT02434328|10011424|FG001|Overall Study|Death|7
6293161|NCT02434328|10011423|FG000|Overall Study|Lost to Follow-up|1
6293162|NCT02434328|10011424|FG001|Overall Study|Lost to Follow-up|6
6293163|NCT02434328|10011423|FG000|Overall Study|Other|4
6293164|NCT02434328|10011424|FG001|Overall Study|Other|1
6293165|NCT02434471|10011431|FG000|Overall Study|Physician Decision|9
6293166|NCT02434770|10011456|FG000|Week 1 to Week 18|Lost to Follow-up|0
6293167|NCT02434770|10011457|FG001|Week 1 to Week 18|Lost to Follow-up|0
6293168|NCT02434770|10011458|FG002|Week 1 to Week 18|Lost to Follow-up|2
6293169|NCT02434770|10011456|FG000|Week 1 to Week 18|Withdrawal by Subject|6
6293170|NCT02434770|10011457|FG001|Week 1 to Week 18|Withdrawal by Subject|12
6293171|NCT02434770|10011458|FG002|Week 1 to Week 18|Withdrawal by Subject|5
6293172|NCT02434770|10011456|FG000|Week 1 to Week 18|Received Non-study Polio Vaccine|8
6293173|NCT02434770|10011457|FG001|Week 1 to Week 18|Received Non-study Polio Vaccine|10
6293174|NCT02434770|10011458|FG002|Week 1 to Week 18|Received Non-study Polio Vaccine|9
6293175|NCT02434770|10011456|FG000|Week 1 to Week 18|Relocated Out of Study Area|0
6293176|NCT02434770|10011457|FG001|Week 1 to Week 18|Relocated Out of Study Area|0
6293177|NCT02434770|10011458|FG002|Week 1 to Week 18|Relocated Out of Study Area|1
6293178|NCT02434770|10011456|FG000|Week 1 to Week 18|Death|1
6293179|NCT02434770|10011457|FG001|Week 1 to Week 18|Death|0
6293180|NCT02434770|10011458|FG002|Week 1 to Week 18|Death|0
6293181|NCT02434770|10011456|FG000|Week 18 to Week|Lost to Follow-up|2
6293182|NCT02434770|10011457|FG001|Week 18 to Week|Lost to Follow-up|2
6293183|NCT02434770|10011458|FG002|Week 18 to Week|Lost to Follow-up|1
6293184|NCT02434770|10011456|FG000|Week 18 to Week|Withdrawal by Subject|0
6293185|NCT02434770|10011457|FG001|Week 18 to Week|Withdrawal by Subject|0
6293186|NCT02434770|10011458|FG002|Week 18 to Week|Withdrawal by Subject|2
6293187|NCT02434770|10011456|FG000|Week 18 to Week|Received Non-study Polio Vaccine|6
6293188|NCT02434770|10011457|FG001|Week 18 to Week|Received Non-study Polio Vaccine|6
6293189|NCT02434770|10011458|FG002|Week 18 to Week|Received Non-study Polio Vaccine|3
6293190|NCT02434939|10011470|FG000|Overall Study|Lack of Efficacy|34
6293191|NCT02434939|10011471|FG001|Overall Study|Lack of Efficacy|48
6293192|NCT02434939|10011470|FG000|Overall Study|Withdrawal by Subject|3
6293193|NCT02434939|10011471|FG001|Overall Study|Withdrawal by Subject|0
6293194|NCT02434939|10011470|FG000|Overall Study|Adverse Event|0
6293195|NCT02434939|10011471|FG001|Overall Study|Adverse Event|1
6293196|NCT02435069|10011478|FG000|Dose Response - First Intervention|Adverse Event|0
6293197|NCT02435069|10011479|FG001|Dose Response - First Intervention|Adverse Event|1
6293198|NCT02435069|10011480|FG002|Dose Response - First Intervention|Adverse Event|1
6293199|NCT02435069|10011481|FG003|Dose Response - First Intervention|Adverse Event|0
6293200|NCT02435069|10011482|FG004|Dose Response - First Intervention|Adverse Event|0
6293201|NCT02435069|10011478|FG000|Effectiveness - Second Intervention|Lack of Efficacy|0
6293202|NCT02435069|10011479|FG001|Effectiveness - Second Intervention|Lack of Efficacy|0
6293203|NCT02435069|10011480|FG002|Effectiveness - Second Intervention|Lack of Efficacy|0
6293204|NCT02435069|10011481|FG003|Effectiveness - Second Intervention|Lack of Efficacy|0
6293205|NCT02435069|10011482|FG004|Effectiveness - Second Intervention|Lack of Efficacy|1
6293206|NCT02435147|10011502|FG000|Overall Study|non-evaluable DXA scan|11
6293207|NCT02435277|10011510|FG000|Overall Study|Adverse Event|1
6293208|NCT02435277|10011511|FG001|Overall Study|Adverse Event|1
6293209|NCT02435277|10011512|FG002|Overall Study|Adverse Event|0
6293210|NCT02435277|10011513|FG003|Overall Study|Adverse Event|0
6293211|NCT02435277|10011510|FG000|Overall Study|Withdrawal by Subject|1
6293212|NCT02435277|10011511|FG001|Overall Study|Withdrawal by Subject|0
6293213|NCT02435277|10011512|FG002|Overall Study|Withdrawal by Subject|0
6293214|NCT02435277|10011513|FG003|Overall Study|Withdrawal by Subject|0
6293215|NCT02435381|10011523|FG000|Overall Study|Lost to Follow-up|2
6293216|NCT02435381|10011524|FG001|Overall Study|Lost to Follow-up|1
6293217|NCT02435680|10011552|FG000|Overall Study|Physician Decision|3
6293218|NCT02435680|10011553|FG001|Overall Study|Physician Decision|0
6293219|NCT02435680|10011554|FG002|Overall Study|Physician Decision|0
6293220|NCT02435680|10011552|FG000|Overall Study|subject / guardian decision|0
6293221|NCT02435680|10011553|FG001|Overall Study|subject / guardian decision|3
6293222|NCT02435680|10011554|FG002|Overall Study|subject / guardian decision|2
6293223|NCT02435680|10011552|FG000|Overall Study|Adverse Event|8
6293224|NCT02435680|10011553|FG001|Overall Study|Adverse Event|3
6293225|NCT02435680|10011554|FG002|Overall Study|Adverse Event|2
6293226|NCT02435680|10011552|FG000|Overall Study|progressive disease|10
6293227|NCT02435680|10011553|FG001|Overall Study|progressive disease|7
6293228|NCT02435680|10011554|FG002|Overall Study|progressive disease|11
6293229|NCT02435680|10011552|FG000|Overall Study|not treated|0
6293230|NCT02435680|10011553|FG001|Overall Study|not treated|0
6293231|NCT02435680|10011554|FG002|Overall Study|not treated|1
6293232|NCT02435836|10011575|FG000|Overall Study|Lost to Follow-up|21
6293233|NCT02435836|10011575|FG000|Overall Study|Lack of Efficacy|1
6293234|NCT02435836|10011575|FG000|Overall Study|Withdrawal by Subject|236
6293235|NCT02435836|10011575|FG000|Overall Study|Insufficient Clinical Response|26
6293236|NCT02435836|10011575|FG000|Overall Study|Adverse Event|44
6293237|NCT02435836|10011575|FG000|Overall Study|Sponsor discontinued trial|167
6293238|NCT02435836|10011575|FG000|Overall Study|Noncompliance|27
6293239|NCT02435836|10011575|FG000|Overall Study|Protocol Violation|6
6293240|NCT02435836|10011575|FG000|Overall Study|Met Withdrawal Criteria|7
6293241|NCT02435836|10011575|FG000|Overall Study|AE of Worsening Schizophrenia|96
6293242|NCT02435914|10011588|FG000|Overall Study|Ocular Adverse Event|1
6293243|NCT02435914|10011589|FG001|Overall Study|Ocular Adverse Event|0
6293244|NCT02435914|10011590|FG002|Overall Study|Ocular Adverse Event|0
6293245|NCT02435914|10011591|FG003|Overall Study|Ocular Adverse Event|0
6293246|NCT02435914|10011588|FG000|Overall Study|Withdrawal by Subject|0
6293247|NCT02435914|10011589|FG001|Overall Study|Withdrawal by Subject|1
6293248|NCT02435914|10011590|FG002|Overall Study|Withdrawal by Subject|0
6293249|NCT02435914|10011591|FG003|Overall Study|Withdrawal by Subject|0
6293250|NCT02435914|10011588|FG000|Overall Study|Other Miscellaneous Reason|0
6293251|NCT02435914|10011589|FG001|Overall Study|Other Miscellaneous Reason|0
6293252|NCT02435914|10011590|FG002|Overall Study|Other Miscellaneous Reason|1
6293253|NCT02435914|10011591|FG003|Overall Study|Other Miscellaneous Reason|0
6293254|NCT02435966|10011604|FG000|Overall Study|Withdrawal by Subject|0
6293255|NCT02435966|10011605|FG001|Overall Study|Withdrawal by Subject|1
6293256|NCT02435966|10011606|FG002|Overall Study|Withdrawal by Subject|0
6293257|NCT02435992|10011619|FG000|Overall Study|non compliance with protocol|2
6293258|NCT02435992|10011620|FG001|Overall Study|non compliance with protocol|0
6293259|NCT02435992|10011621|FG002|Overall Study|non compliance with protocol|1
6293260|NCT02435992|10011622|FG003|Overall Study|non compliance with protocol|0
6293261|NCT02435992|10011623|FG004|Overall Study|non compliance with protocol|0
6293262|NCT02435992|10011619|FG000|Overall Study|Adverse Event|11
6293263|NCT02435992|10011620|FG001|Overall Study|Adverse Event|6
6293264|NCT02435992|10011621|FG002|Overall Study|Adverse Event|12
6293265|NCT02435992|10011622|FG003|Overall Study|Adverse Event|0
6293266|NCT02435992|10011623|FG004|Overall Study|Adverse Event|0
6293267|NCT02435992|10011619|FG000|Overall Study|Lack of Efficacy|4
6293268|NCT02435992|10011620|FG001|Overall Study|Lack of Efficacy|10
6293269|NCT02435992|10011621|FG002|Overall Study|Lack of Efficacy|9
6293270|NCT02435992|10011622|FG003|Overall Study|Lack of Efficacy|0
6293271|NCT02435992|10011623|FG004|Overall Study|Lack of Efficacy|0
6293272|NCT02435992|10011619|FG000|Overall Study|Withdrawal by Subject|10
6293273|NCT02435992|10011620|FG001|Overall Study|Withdrawal by Subject|8
6293274|NCT02435992|10011621|FG002|Overall Study|Withdrawal by Subject|20
6293275|NCT02435992|10011622|FG003|Overall Study|Withdrawal by Subject|0
6293276|NCT02435992|10011623|FG004|Overall Study|Withdrawal by Subject|0
6293277|NCT02435992|10011619|FG000|Overall Study|Other Reason|1
6293278|NCT02435992|10011620|FG001|Overall Study|Other Reason|0
6293279|NCT02435992|10011621|FG002|Overall Study|Other Reason|0
6293280|NCT02435992|10011622|FG003|Overall Study|Other Reason|0
6293281|NCT02435992|10011623|FG004|Overall Study|Other Reason|0
6293282|NCT02435992|10011619|FG000|Overall Study|Physician Decision|0
6293283|NCT02435992|10011620|FG001|Overall Study|Physician Decision|0
6293284|NCT02435992|10011621|FG002|Overall Study|Physician Decision|1
6293285|NCT02435992|10011622|FG003|Overall Study|Physician Decision|0
6293286|NCT02435992|10011623|FG004|Overall Study|Physician Decision|0
6293287|NCT02436005|10011635|FG000|Second Intervention|Adverse Event|0
6293288|NCT02436005|10011636|FG001|Second Intervention|Adverse Event|1
6293289|NCT02436135|10011651|FG000|Overall Study|Progressive Disease|3
6293290|NCT02436135|10011652|FG001|Overall Study|Progressive Disease|1
6293291|NCT02436135|10011651|FG000|Overall Study|Investigator Discretion|1
6293292|NCT02436135|10011652|FG001|Overall Study|Investigator Discretion|2
6293293|NCT02436135|10011651|FG000|Overall Study|Adverse Event|1
6293294|NCT02436135|10011652|FG001|Overall Study|Adverse Event|0
6293295|NCT02436135|10011651|FG000|Overall Study|Withdrawal by Participant|1
6293296|NCT02436135|10011652|FG001|Overall Study|Withdrawal by Participant|0
6293297|NCT02436135|10011651|FG000|Overall Study|Study Terminated By Sponsor|0
6293298|NCT02436135|10011652|FG001|Overall Study|Study Terminated By Sponsor|1
6293299|NCT02436200|10011658|FG000|Overall Study|Significant outlier|1
6293300|NCT02436239|10011666|FG000|Open-Lable Treatment Period|Adverse Event|12
6293301|NCT02436239|10011667|FG001|Open-Lable Treatment Period|Adverse Event|3
6293302|NCT02436239|10011668|FG002|Open-Lable Treatment Period|Adverse Event|4
6293303|NCT02436239|10011669|FG003|Open-Lable Treatment Period|Adverse Event|2
6293304|NCT02436239|10011666|FG000|Open-Lable Treatment Period|Lack of Efficacy|1
6293305|NCT02436239|10011667|FG001|Open-Lable Treatment Period|Lack of Efficacy|6
6293306|NCT02436239|10011668|FG002|Open-Lable Treatment Period|Lack of Efficacy|6
6293307|NCT02436239|10011669|FG003|Open-Lable Treatment Period|Lack of Efficacy|1
6293308|NCT02436239|10011666|FG000|Open-Lable Treatment Period|Withdrawal by Subject|10
6293309|NCT02436239|10011667|FG001|Open-Lable Treatment Period|Withdrawal by Subject|15
6293310|NCT02436239|10011668|FG002|Open-Lable Treatment Period|Withdrawal by Subject|9
6293311|NCT02436239|10011669|FG003|Open-Lable Treatment Period|Withdrawal by Subject|0
6293312|NCT02436239|10011666|FG000|Open-Lable Treatment Period|Lost to Follow-up|4
6293313|NCT02436239|10011667|FG001|Open-Lable Treatment Period|Lost to Follow-up|2
6293314|NCT02436239|10011668|FG002|Open-Lable Treatment Period|Lost to Follow-up|4
6293315|NCT02436239|10011669|FG003|Open-Lable Treatment Period|Lost to Follow-up|1
6293316|NCT02436239|10011666|FG000|Open-Lable Treatment Period|Protocol Violation|0
6293317|NCT02436239|10011667|FG001|Open-Lable Treatment Period|Protocol Violation|1
6293318|NCT02436239|10011668|FG002|Open-Lable Treatment Period|Protocol Violation|1
6293319|NCT02436239|10011669|FG003|Open-Lable Treatment Period|Protocol Violation|0
6293320|NCT02436239|10011666|FG000|Open-Lable Treatment Period|Noncompliance with Study Drug|5
6293321|NCT02436239|10011667|FG001|Open-Lable Treatment Period|Noncompliance with Study Drug|6
6293322|NCT02436239|10011668|FG002|Open-Lable Treatment Period|Noncompliance with Study Drug|3
6293323|NCT02436239|10011669|FG003|Open-Lable Treatment Period|Noncompliance with Study Drug|1
6293324|NCT02436239|10011666|FG000|Open-Lable Treatment Period|Other Reason|1
6293325|NCT02436239|10011667|FG001|Open-Lable Treatment Period|Other Reason|1
6293326|NCT02436239|10011668|FG002|Open-Lable Treatment Period|Other Reason|0
6293327|NCT02436239|10011669|FG003|Open-Lable Treatment Period|Other Reason|0
6293328|NCT02436239|10011666|FG000|Down-Taper Period|Withdrawal by Subject|4
6293329|NCT02436239|10011667|FG001|Down-Taper Period|Withdrawal by Subject|4
6293330|NCT02436239|10011668|FG002|Down-Taper Period|Withdrawal by Subject|1
6293331|NCT02436239|10011669|FG003|Down-Taper Period|Withdrawal by Subject|2
6293332|NCT02436304|10011682|FG000|Overall Study|Lost to Follow-up|0
6293333|NCT02436304|10011683|FG001|Overall Study|Lost to Follow-up|1
6293334|NCT02436304|10011684|FG002|Overall Study|Lost to Follow-up|0
6293335|NCT02436304|10011682|FG000|Overall Study|Withdrawal by Subject|0
6293336|NCT02436304|10011683|FG001|Overall Study|Withdrawal by Subject|1
6293337|NCT02436304|10011684|FG002|Overall Study|Withdrawal by Subject|0
6293338|NCT02436304|10011682|FG000|Overall Study|Randomized in error didn't meet I/E crit|0
6293339|NCT02436304|10011683|FG001|Overall Study|Randomized in error didn't meet I/E crit|0
6293340|NCT02436304|10011684|FG002|Overall Study|Randomized in error didn't meet I/E crit|1
6293341|NCT02436330|10011695|FG000|Cohort 1|Lost to Follow-up|5
6293342|NCT02436330|10011696|FG001|Cohort 1|Lost to Follow-up|2
6293343|NCT02436330|10011695|FG000|Cohort 1|Withdrawal by Subject|0
6293344|NCT02436330|10011696|FG001|Cohort 1|Withdrawal by Subject|1
6293345|NCT02436330|10011695|FG000|Cohort 2|Lost to Follow-up|2
6293346|NCT02436330|10011696|FG001|Cohort 2|Lost to Follow-up|0
6293347|NCT02436330|10011695|FG000|Cohort 2|Withdrawal by Subject|2
6293348|NCT02436330|10011696|FG001|Cohort 2|Withdrawal by Subject|3
6293349|NCT02436330|10011695|FG000|Cohort 3|Lost to Follow-up|1
6293350|NCT02436330|10011696|FG001|Cohort 3|Lost to Follow-up|0
6293351|NCT02436330|10011695|FG000|Cohort 3|Withdrawal by Subject|4
6293352|NCT02436330|10011696|FG001|Cohort 3|Withdrawal by Subject|0
6293353|NCT02436330|10011695|FG000|Cohort 4|Lost to Follow-up|1
6293354|NCT02436330|10011696|FG001|Cohort 4|Lost to Follow-up|0
6293355|NCT02436330|10011695|FG000|Cohort 4|Withdrawal by Subject|1
6293356|NCT02436330|10011696|FG001|Cohort 4|Withdrawal by Subject|0
6293357|NCT02436330|10011695|FG000|Cohort 5|Lost to Follow-up|3
6293358|NCT02436330|10011696|FG001|Cohort 5|Lost to Follow-up|2
6293359|NCT02436330|10011695|FG000|Cohort 5|Withdrawal by Subject|3
6293360|NCT02436330|10011696|FG001|Cohort 5|Withdrawal by Subject|2
6293361|NCT02436330|10011695|FG000|Cohort 6|Lost to Follow-up|2
6293362|NCT02436330|10011696|FG001|Cohort 6|Lost to Follow-up|0
6293363|NCT02436330|10011695|FG000|Cohort 6|Withdrawal by Subject|1
6293364|NCT02436330|10011696|FG001|Cohort 6|Withdrawal by Subject|1
6293365|NCT02436356|10011711|FG000|Overall Study|Excluded by MRI Screening|0
6293366|NCT02436356|10011712|FG001|Overall Study|Excluded by MRI Screening|0
6293367|NCT02436356|10011713|FG002|Overall Study|Excluded by MRI Screening|2
6293368|NCT02436356|10011711|FG000|Overall Study|Lost to Follow-up|0
6293369|NCT02436356|10011712|FG001|Overall Study|Lost to Follow-up|1
6293370|NCT02436356|10011713|FG002|Overall Study|Lost to Follow-up|0
6293371|NCT02436356|10011711|FG000|Overall Study|Surgical Approach (Dorsal not volar)|1
6293372|NCT02436356|10011712|FG001|Overall Study|Surgical Approach (Dorsal not volar)|0
6293373|NCT02436356|10011713|FG002|Overall Study|Surgical Approach (Dorsal not volar)|0
6293374|NCT02436356|10011711|FG000|Overall Study|Excluded due to other medical conditions|3
6293375|NCT02436356|10011712|FG001|Overall Study|Excluded due to other medical conditions|0
6293376|NCT02436356|10011713|FG002|Overall Study|Excluded due to other medical conditions|0
6293377|NCT02436356|10011711|FG000|Overall Study|Withdrawal by Subject|1
6293378|NCT02436356|10011712|FG001|Overall Study|Withdrawal by Subject|0
6293379|NCT02436356|10011713|FG002|Overall Study|Withdrawal by Subject|0
6293380|NCT02436408|10011726|FG000|Overall Study|Death|1
6293381|NCT02436577|10011736|FG000|Overall Study|Protocol Deviation|0
6293382|NCT02436577|10011737|FG001|Overall Study|Protocol Deviation|1
6293383|NCT02436577|10011738|FG002|Overall Study|Protocol Deviation|0
6293384|NCT02436577|10011739|FG003|Overall Study|Protocol Deviation|0
6293385|NCT02436577|10011740|FG004|Overall Study|Protocol Deviation|0
6293386|NCT02436577|10011741|FG005|Overall Study|Protocol Deviation|0
6293387|NCT02436681|10011761|FG000|Overall Study|Lost to Follow-up|10
6293388|NCT02436681|10011761|FG000|Overall Study|Withdrawal by Subject|2
6293389|NCT02436681|10011761|FG000|Overall Study|Death|2
6293390|NCT02436759|10011767|FG000|Overall Study|Adverse Event|3
6293391|NCT02436759|10011768|FG001|Overall Study|Adverse Event|0
6293392|NCT02436759|10011767|FG000|Overall Study|Protocol Violation|1
6293393|NCT02436759|10011768|FG001|Overall Study|Protocol Violation|0
6293394|NCT02436759|10011767|FG000|Overall Study|Withdrawal by Subject|0
6293395|NCT02436759|10011768|FG001|Overall Study|Withdrawal by Subject|1
6293396|NCT02436811|10011777|FG000|Overall Study|Lost to Follow-up|2
6293397|NCT02436811|10011778|FG001|Overall Study|Lost to Follow-up|9
6293398|NCT02436811|10011779|FG002|Overall Study|Lost to Follow-up|7
6293399|NCT02436876|10011791|FG000|Overall Study|Lost to Follow-up|0
6293400|NCT02436876|10011792|FG001|Overall Study|Lost to Follow-up|1
6293401|NCT02436876|10011793|FG002|Overall Study|Lost to Follow-up|1
6293402|NCT02436876|10011794|FG003|Overall Study|Lost to Follow-up|1
6293403|NCT02436876|10011791|FG000|Overall Study|Withdrawal by Subject|1
6293404|NCT02436876|10011792|FG001|Overall Study|Withdrawal by Subject|0
6293405|NCT02436876|10011793|FG002|Overall Study|Withdrawal by Subject|0
6293406|NCT02436876|10011794|FG003|Overall Study|Withdrawal by Subject|1
6293407|NCT02436876|10011791|FG000|Overall Study|Physician Decision|0
6293408|NCT02436876|10011792|FG001|Overall Study|Physician Decision|2
6293409|NCT02436876|10011793|FG002|Overall Study|Physician Decision|1
6293410|NCT02436876|10011794|FG003|Overall Study|Physician Decision|0
6293411|NCT02436876|10011791|FG000|Overall Study|Inadequate amount of study drug available for randomization|0
6293412|NCT02436876|10011792|FG001|Overall Study|Inadequate amount of study drug available for randomization|1
6293413|NCT02436876|10011793|FG002|Overall Study|Inadequate amount of study drug available for randomization|0
6293414|NCT02436876|10011794|FG003|Overall Study|Inadequate amount of study drug available for randomization|0
6293415|NCT02436889|10011811|FG000|Overall Study|No improvement in symptoms|1
6293416|NCT02436889|10011812|FG001|Overall Study|No improvement in symptoms|0
6293417|NCT02436889|10011811|FG000|Overall Study|Does not like/could not tolerate medicat|0
6293418|NCT02436889|10011812|FG001|Overall Study|Does not like/could not tolerate medicat|1
6293419|NCT02436915|10011820|FG000|Overall Study|Withdrawal by Subject|0
6293420|NCT02436915|10011821|FG001|Overall Study|Withdrawal by Subject|1
6293421|NCT02437084|10011829|FG000|Overall Study|Withdrawal by Subject|2
6293422|NCT02437084|10011829|FG000|Overall Study|Physician Decision|1
6293423|NCT02437162|10011836|FG000|Overall Study|Protocol Violation|0
6293424|NCT02437162|10011837|FG001|Overall Study|Protocol Violation|1
6293425|NCT02437162|10011838|FG002|Overall Study|Protocol Violation|0
6293426|NCT02437162|10011836|FG000|Overall Study|Randomized but not treated|0
6293427|NCT02437162|10011837|FG001|Overall Study|Randomized but not treated|0
6293428|NCT02437162|10011838|FG002|Overall Study|Randomized but not treated|1
6293429|NCT02437162|10011836|FG000|Overall Study|Study discontinued by Sponsor|93
6293430|NCT02437162|10011837|FG001|Overall Study|Study discontinued by Sponsor|98
6293431|NCT02437162|10011838|FG002|Overall Study|Study discontinued by Sponsor|97
6293432|NCT02437162|10011836|FG000|Overall Study|Withdrawal by Subject|13
6293433|NCT02437162|10011837|FG001|Overall Study|Withdrawal by Subject|7
6293434|NCT02437162|10011838|FG002|Overall Study|Withdrawal by Subject|9
6293435|NCT02437162|10011836|FG000|Overall Study|Adverse Event|0
6293436|NCT02437162|10011837|FG001|Overall Study|Adverse Event|1
6293437|NCT02437162|10011838|FG002|Overall Study|Adverse Event|0
6293438|NCT02437162|10011836|FG000|Overall Study|Lost to Follow-up|1
6293439|NCT02437162|10011837|FG001|Overall Study|Lost to Follow-up|0
6293440|NCT02437162|10011838|FG002|Overall Study|Lost to Follow-up|1
6293441|NCT02437162|10011836|FG000|Overall Study|Death|0
6293442|NCT02437162|10011837|FG001|Overall Study|Death|1
6293443|NCT02437162|10011838|FG002|Overall Study|Death|0
6293444|NCT02437162|10011836|FG000|Overall Study|Other|0
6293445|NCT02437162|10011837|FG001|Overall Study|Other|0
6293446|NCT02437162|10011838|FG002|Overall Study|Other|1
6293447|NCT02437188|10011853|FG000|Overall Study|Randomized but did not receive surgery|4
6293448|NCT02437188|10011854|FG001|Overall Study|Randomized but did not receive surgery|8
6293449|NCT02437188|10011853|FG000|Overall Study|Adverse Event|0
6293450|NCT02437188|10011854|FG001|Overall Study|Adverse Event|1
6293451|NCT02437305|10011876|FG000|Overall Study|Lost to Follow-up|18
6293452|NCT02437305|10011877|FG001|Overall Study|Lost to Follow-up|12
6293453|NCT02437409|10011896|FG000|Overall Study|Withdrawal by Subject|3
6293454|NCT02437409|10011896|FG000|Overall Study|Screening failure|12
6293455|NCT02437513|10011910|FG000|Overall Study|Withdrawal by Subject|2
6293456|NCT02437864|10011921|FG000|Overall Study|Protocol Violation|4
6293457|NCT02437864|10011922|FG001|Overall Study|Protocol Violation|0
6293458|NCT02437890|10011933|FG000|Overall Study|Non-compliance to study drug|0
6293459|NCT02437890|10011934|FG001|Overall Study|Non-compliance to study drug|1
6293460|NCT02437890|10011935|FG002|Overall Study|Non-compliance to study drug|0
6293461|NCT02437890|10011936|FG003|Overall Study|Non-compliance to study drug|0
6293462|NCT02437890|10011937|FG004|Overall Study|Non-compliance to study drug|1
6293463|NCT02437890|10011933|FG000|Overall Study|Sponsor's decision|1
6293464|NCT02437890|10011934|FG001|Overall Study|Sponsor's decision|1
6293465|NCT02437890|10011935|FG002|Overall Study|Sponsor's decision|4
6293466|NCT02437890|10011936|FG003|Overall Study|Sponsor's decision|0
6293467|NCT02437890|10011937|FG004|Overall Study|Sponsor's decision|2
6293468|NCT02437890|10011933|FG000|Overall Study|Physician Decision|0
6293469|NCT02437890|10011934|FG001|Overall Study|Physician Decision|0
6293470|NCT02437890|10011935|FG002|Overall Study|Physician Decision|0
6293471|NCT02437890|10011936|FG003|Overall Study|Physician Decision|1
6293472|NCT02437890|10011937|FG004|Overall Study|Physician Decision|0
6293473|NCT02437890|10011933|FG000|Overall Study|Unable to attend visit(s)|1
5981367|NCT00974571|9570341|FG002|Overall Study|Patient Moved|1
5981368|NCT00974571|9570339|FG000|Overall Study|Other|4
5981369|NCT00974571|9570340|FG001|Overall Study|Other|0
5981370|NCT00974571|9570341|FG002|Overall Study|Other|10
5981371|NCT00972738|9570352|FG000|Overall Study|Adverse Event|7
5981372|NCT00972738|9570353|FG001|Overall Study|Adverse Event|1
5981373|NCT00972738|9570354|FG002|Overall Study|Adverse Event|8
5981374|NCT00972738|9570352|FG000|Overall Study|Protocol Violation|2
5981375|NCT00972738|9570353|FG001|Overall Study|Protocol Violation|1
5981376|NCT00972738|9570354|FG002|Overall Study|Protocol Violation|3
5981377|NCT00972738|9570352|FG000|Overall Study|Lost to Follow-up|1
5981378|NCT00972738|9570353|FG001|Overall Study|Lost to Follow-up|0
5981379|NCT00972738|9570354|FG002|Overall Study|Lost to Follow-up|1
5981380|NCT00972738|9570352|FG000|Overall Study|Lack of Efficacy|5
5981381|NCT00972738|9570353|FG001|Overall Study|Lack of Efficacy|1
5981382|NCT00972738|9570354|FG002|Overall Study|Lack of Efficacy|11
5981383|NCT00972738|9570352|FG000|Overall Study|Withdrawal by Subject|5
5981384|NCT00972738|9570353|FG001|Overall Study|Withdrawal by Subject|1
5981385|NCT00972738|9570354|FG002|Overall Study|Withdrawal by Subject|4
5981386|NCT00972738|9570352|FG000|Overall Study|Moved|0
5981387|NCT00972738|9570353|FG001|Overall Study|Moved|0
5981388|NCT00972738|9570354|FG002|Overall Study|Moved|1
5981389|NCT00972738|9570352|FG000|Overall Study|Other|1
5981390|NCT00972738|9570353|FG001|Overall Study|Other|2
5981391|NCT00972738|9570354|FG002|Overall Study|Other|1
5981392|NCT00968201|9570364|FG000|Base Study - (Period II)|Adverse Event|8
5981393|NCT00968201|9570365|FG001|Base Study - (Period II)|Adverse Event|0
5981394|NCT00968201|9570366|FG002|Base Study - (Period II)|Adverse Event|16
5981395|NCT00968201|9570364|FG000|Base Study - (Period II)|Lack of Efficacy|0
5981396|NCT00968201|9570365|FG001|Base Study - (Period II)|Lack of Efficacy|0
5981397|NCT00968201|9570366|FG002|Base Study - (Period II)|Lack of Efficacy|1
5981398|NCT00968201|9570364|FG000|Base Study - (Period II)|Lost to Follow-up|2
5981399|NCT00968201|9570365|FG001|Base Study - (Period II)|Lost to Follow-up|0
5981400|NCT00968201|9570366|FG002|Base Study - (Period II)|Lost to Follow-up|7
5981401|NCT00968201|9570364|FG000|Base Study - (Period II)|Protocol Violation|12
5981402|NCT00968201|9570365|FG001|Base Study - (Period II)|Protocol Violation|0
5981403|NCT00968201|9570366|FG002|Base Study - (Period II)|Protocol Violation|12
5981404|NCT00968201|9570364|FG000|Base Study - (Period II)|Withdrawal by Subject|4
6293474|NCT02437890|10011934|FG001|Overall Study|Unable to attend visit(s)|0
6293475|NCT02437890|10011935|FG002|Overall Study|Unable to attend visit(s)|0
6293476|NCT02437890|10011936|FG003|Overall Study|Unable to attend visit(s)|0
6293477|NCT02437890|10011937|FG004|Overall Study|Unable to attend visit(s)|0
6293478|NCT02437890|10011933|FG000|Overall Study|Lack of Efficacy|1
6293479|NCT02437890|10011934|FG001|Overall Study|Lack of Efficacy|3
6293480|NCT02437890|10011935|FG002|Overall Study|Lack of Efficacy|0
6293481|NCT02437890|10011936|FG003|Overall Study|Lack of Efficacy|3
6293482|NCT02437890|10011937|FG004|Overall Study|Lack of Efficacy|1
6293483|NCT02437890|10011933|FG000|Overall Study|Adverse Event|4
6293484|NCT02437890|10011934|FG001|Overall Study|Adverse Event|9
6293485|NCT02437890|10011935|FG002|Overall Study|Adverse Event|5
6293486|NCT02437890|10011936|FG003|Overall Study|Adverse Event|11
6293487|NCT02437890|10011937|FG004|Overall Study|Adverse Event|7
6293488|NCT02437890|10011933|FG000|Overall Study|Withdrawal by Subject|1
6293489|NCT02437890|10011934|FG001|Overall Study|Withdrawal by Subject|2
6293490|NCT02437890|10011935|FG002|Overall Study|Withdrawal by Subject|6
6293491|NCT02437890|10011936|FG003|Overall Study|Withdrawal by Subject|5
6293492|NCT02437890|10011937|FG004|Overall Study|Withdrawal by Subject|5
6293493|NCT02437890|10011933|FG000|Overall Study|Death|0
6293494|NCT02437890|10011934|FG001|Overall Study|Death|0
6293495|NCT02437890|10011935|FG002|Overall Study|Death|0
6293496|NCT02437890|10011936|FG003|Overall Study|Death|2
6293497|NCT02437890|10011937|FG004|Overall Study|Death|0
6293498|NCT02437903|10011953|FG000|Overall Study|Adverse Event|1
6293499|NCT02437903|10011953|FG000|Overall Study|Withdrawal by Subject|1
6293500|NCT02437903|10011953|FG000|Overall Study|Lost to Follow-up|3
6293501|NCT02438137|10011960|FG000|Overall Study|Lost to Follow-up|3
6293502|NCT02438137|10011961|FG001|Overall Study|Lost to Follow-up|2
6293503|NCT02438137|10011960|FG000|Overall Study|Adverse Event|1
6293504|NCT02438137|10011961|FG001|Overall Study|Adverse Event|0
6293505|NCT02438137|10011960|FG000|Overall Study|Withdrawal by Subject|4
6293506|NCT02438137|10011961|FG001|Overall Study|Withdrawal by Subject|3
6293507|NCT02438137|10011960|FG000|Overall Study|Physician Decision|0
6293508|NCT02438137|10011961|FG001|Overall Study|Physician Decision|1
6293509|NCT02438280|10011971|FG000|Overall Study|Physician Decision|1
6293510|NCT02438280|10011972|FG001|Overall Study|Physician Decision|0
6293511|NCT02438371|10011981|FG000|Overall Study|Lost to Follow-up|3
6293512|NCT02438371|10011982|FG001|Overall Study|Lost to Follow-up|2
6293513|NCT02438371|10011981|FG000|Overall Study|Withdrawal by Subject|1
6293514|NCT02438371|10011982|FG001|Overall Study|Withdrawal by Subject|1
6293515|NCT02438384|10011991|FG000|Overall Study|Lost to Follow-up|8
6293516|NCT02438384|10011992|FG001|Overall Study|Lost to Follow-up|6
6293517|NCT02438384|10011993|FG002|Overall Study|Lost to Follow-up|4
6293518|NCT02438787|10012042|FG000|Overall Study|Adverse Event|1
6293519|NCT02438787|10012043|FG001|Overall Study|Adverse Event|0
6293520|NCT02438787|10012044|FG002|Overall Study|Adverse Event|2
6293521|NCT02438787|10012042|FG000|Overall Study|Lack of Efficacy|1
6293522|NCT02438787|10012043|FG001|Overall Study|Lack of Efficacy|2
6293523|NCT02438787|10012044|FG002|Overall Study|Lack of Efficacy|0
6293524|NCT02438787|10012042|FG000|Overall Study|Lost to Follow-up|0
6293525|NCT02438787|10012043|FG001|Overall Study|Lost to Follow-up|1
6293526|NCT02438787|10012044|FG002|Overall Study|Lost to Follow-up|0
6293527|NCT02438787|10012042|FG000|Overall Study|Protocol Violation|0
6293528|NCT02438787|10012043|FG001|Overall Study|Protocol Violation|0
6293529|NCT02438787|10012044|FG002|Overall Study|Protocol Violation|1
6293530|NCT02438787|10012042|FG000|Overall Study|Withdrawal by Subject|15
6293531|NCT02438787|10012043|FG001|Overall Study|Withdrawal by Subject|7
6293532|NCT02438787|10012044|FG002|Overall Study|Withdrawal by Subject|10
6293533|NCT02438787|10012042|FG000|Overall Study|Study discontinued by sponsor|64
6293534|NCT02438787|10012043|FG001|Overall Study|Study discontinued by sponsor|72
6293535|NCT02438787|10012044|FG002|Overall Study|Study discontinued by sponsor|69
6293536|NCT02438787|10012042|FG000|Overall Study|Other|0
6293537|NCT02438787|10012043|FG001|Overall Study|Other|1
6293538|NCT02438787|10012044|FG002|Overall Study|Other|0
6293539|NCT02438787|10012042|FG000|Overall Study|Site terminated by sponsor|0
6293540|NCT02438787|10012043|FG001|Overall Study|Site terminated by sponsor|0
6293541|NCT02438787|10012044|FG002|Overall Study|Site terminated by sponsor|1
6293542|NCT02438813|10012057|FG000|Overall Study|Patient Decision|59
6293543|NCT02438813|10012057|FG000|Overall Study|Patient Lost to Follow-Up|137
6293544|NCT02438813|10012057|FG000|Overall Study|Study Ended by Sponsor|80
6293545|NCT02438813|10012057|FG000|Overall Study|Patients Not Treated/No EOT Visit|249
6293546|NCT02438826|10012073|FG000|Double-Blind Treatment Phase|Adverse Event|1
6293547|NCT02438826|10012074|FG001|Double-Blind Treatment Phase|Adverse Event|1
6293548|NCT02438826|10012075|FG002|Double-Blind Treatment Phase|Adverse Event|0
6293549|NCT02438826|10012076|FG003|Double-Blind Treatment Phase|Adverse Event|0
6293550|NCT02438826|10012073|FG000|Double-Blind Treatment Phase|Lack of Efficacy|1
6293551|NCT02438826|10012074|FG001|Double-Blind Treatment Phase|Lack of Efficacy|0
6293552|NCT02438826|10012075|FG002|Double-Blind Treatment Phase|Lack of Efficacy|0
6293553|NCT02438826|10012076|FG003|Double-Blind Treatment Phase|Lack of Efficacy|0
6293554|NCT02438826|10012073|FG000|Double-Blind Treatment Phase|Withdrawal by Subject|1
6293555|NCT02438826|10012074|FG001|Double-Blind Treatment Phase|Withdrawal by Subject|1
6293556|NCT02438826|10012075|FG002|Double-Blind Treatment Phase|Withdrawal by Subject|0
6293557|NCT02438826|10012076|FG003|Double-Blind Treatment Phase|Withdrawal by Subject|0
6293558|NCT02438826|10012073|FG000|Double-Blind Treatment Phase|Protocol Violation|1
6293559|NCT02438826|10012074|FG001|Double-Blind Treatment Phase|Protocol Violation|2
6293560|NCT02438826|10012075|FG002|Double-Blind Treatment Phase|Protocol Violation|0
6293561|NCT02438826|10012076|FG003|Double-Blind Treatment Phase|Protocol Violation|0
6293562|NCT02438826|10012073|FG000|Double-Blind Treatment Phase|Screen Failure|2
6293563|NCT02438826|10012074|FG001|Double-Blind Treatment Phase|Screen Failure|0
6293564|NCT02438826|10012075|FG002|Double-Blind Treatment Phase|Screen Failure|0
6293565|NCT02438826|10012076|FG003|Double-Blind Treatment Phase|Screen Failure|0
6293566|NCT02438826|10012073|FG000|Open-Label Treatment Phase|Adverse Event|11
6293567|NCT02438826|10012074|FG001|Open-Label Treatment Phase|Adverse Event|6
6293568|NCT02438826|10012075|FG002|Open-Label Treatment Phase|Adverse Event|0
6293569|NCT02438826|10012076|FG003|Open-Label Treatment Phase|Adverse Event|0
6293570|NCT02438826|10012073|FG000|Open-Label Treatment Phase|Lack of Efficacy|27
6293571|NCT02438826|10012074|FG001|Open-Label Treatment Phase|Lack of Efficacy|18
6293572|NCT02438826|10012075|FG002|Open-Label Treatment Phase|Lack of Efficacy|0
6293573|NCT02438826|10012076|FG003|Open-Label Treatment Phase|Lack of Efficacy|0
6293574|NCT02438826|10012073|FG000|Open-Label Treatment Phase|Lost to Follow-up|0
6293575|NCT02438826|10012074|FG001|Open-Label Treatment Phase|Lost to Follow-up|2
6293576|NCT02438826|10012075|FG002|Open-Label Treatment Phase|Lost to Follow-up|0
6293577|NCT02438826|10012076|FG003|Open-Label Treatment Phase|Lost to Follow-up|0
6293578|NCT02438826|10012073|FG000|Open-Label Treatment Phase|Withdrawal by Subject|6
6293579|NCT02438826|10012074|FG001|Open-Label Treatment Phase|Withdrawal by Subject|7
6293580|NCT02438826|10012075|FG002|Open-Label Treatment Phase|Withdrawal by Subject|0
6293581|NCT02438826|10012076|FG003|Open-Label Treatment Phase|Withdrawal by Subject|0
6293582|NCT02438826|10012073|FG000|Post-Treatment Phase|Adverse Event|3
6293583|NCT02438826|10012074|FG001|Post-Treatment Phase|Adverse Event|0
6293584|NCT02438826|10012075|FG002|Post-Treatment Phase|Adverse Event|0
6293585|NCT02438826|10012076|FG003|Post-Treatment Phase|Adverse Event|0
6293586|NCT02438826|10012073|FG000|Post-Treatment Phase|Lack of Efficacy|4
6293587|NCT02438826|10012074|FG001|Post-Treatment Phase|Lack of Efficacy|0
6293588|NCT02438826|10012075|FG002|Post-Treatment Phase|Lack of Efficacy|0
6293589|NCT02438826|10012076|FG003|Post-Treatment Phase|Lack of Efficacy|0
6293590|NCT02438826|10012073|FG000|Post-Treatment Phase|Physician Decision|1
6293591|NCT02438826|10012074|FG001|Post-Treatment Phase|Physician Decision|0
6293592|NCT02438826|10012075|FG002|Post-Treatment Phase|Physician Decision|0
6293593|NCT02438826|10012076|FG003|Post-Treatment Phase|Physician Decision|0
6293594|NCT02438826|10012073|FG000|Post-Treatment Phase|Withdrawal by Subject|1
6293595|NCT02438826|10012074|FG001|Post-Treatment Phase|Withdrawal by Subject|1
6293596|NCT02438826|10012075|FG002|Post-Treatment Phase|Withdrawal by Subject|0
6293597|NCT02438826|10012076|FG003|Post-Treatment Phase|Withdrawal by Subject|0
6293598|NCT02439138|10012091|FG000|Overall Study|Adverse Event|1
6293599|NCT02439138|10012091|FG000|Overall Study|PI decision to terminate the study|2
6293600|NCT02439320|10012119|FG000|Overall Study|Adverse Event|0
6293601|NCT02439320|10012120|FG001|Overall Study|Adverse Event|2
6293602|NCT02439320|10012121|FG002|Overall Study|Adverse Event|0
6293603|NCT02439320|10012119|FG000|Overall Study|Lost to Follow-up|37
6293604|NCT02439320|10012120|FG001|Overall Study|Lost to Follow-up|34
6293605|NCT02439320|10012121|FG002|Overall Study|Lost to Follow-up|42
6293606|NCT02439320|10012119|FG000|Overall Study|Death|0
6293607|NCT02439320|10012120|FG001|Overall Study|Death|1
6293608|NCT02439320|10012121|FG002|Overall Study|Death|0
6293609|NCT02439320|10012119|FG000|Overall Study|Noncompliance with Protocol|10
6293610|NCT02439320|10012120|FG001|Overall Study|Noncompliance with Protocol|11
6293611|NCT02439320|10012121|FG002|Overall Study|Noncompliance with Protocol|7
6293612|NCT02439320|10012119|FG000|Overall Study|Pregnancy|0
6293613|NCT02439320|10012120|FG001|Overall Study|Pregnancy|1
6293614|NCT02439320|10012121|FG002|Overall Study|Pregnancy|1
6293615|NCT02439320|10012119|FG000|Overall Study|Withdrawal by Subject|12
6293616|NCT02439320|10012120|FG001|Overall Study|Withdrawal by Subject|16
6293617|NCT02439320|10012121|FG002|Overall Study|Withdrawal by Subject|14
6293618|NCT02439320|10012119|FG000|Overall Study|Physician Decision|2
6136888|NCT01004432|9766962|FG004|OL Study Extension (Week 52 - 76)|Adverse Event|2
6136889|NCT01004432|9766958|FG000|OL Study Extension (Week 52 - 76)|Protocol Violation|0
6136890|NCT01004432|9766959|FG001|OL Study Extension (Week 52 - 76)|Protocol Violation|0
6136891|NCT01004432|9766960|FG002|OL Study Extension (Week 52 - 76)|Protocol Violation|0
6136892|NCT01004432|9766961|FG003|OL Study Extension (Week 52 - 76)|Protocol Violation|0
6136893|NCT01004432|9766962|FG004|OL Study Extension (Week 52 - 76)|Protocol Violation|4
6136894|NCT01004432|9766958|FG000|OL Study Extension (Week 52 - 76)|Withdrawal by Subject|0
6136895|NCT01004432|9766959|FG001|OL Study Extension (Week 52 - 76)|Withdrawal by Subject|0
6136896|NCT01004432|9766960|FG002|OL Study Extension (Week 52 - 76)|Withdrawal by Subject|0
6136897|NCT01004432|9766961|FG003|OL Study Extension (Week 52 - 76)|Withdrawal by Subject|0
6136898|NCT01004432|9766962|FG004|OL Study Extension (Week 52 - 76)|Withdrawal by Subject|2
6136899|NCT01004432|9766958|FG000|OL Study Extension (Week 52 - 76)|Lack of Efficacy|0
6136900|NCT01004432|9766959|FG001|OL Study Extension (Week 52 - 76)|Lack of Efficacy|0
6136901|NCT01004432|9766960|FG002|OL Study Extension (Week 52 - 76)|Lack of Efficacy|0
6136902|NCT01004432|9766961|FG003|OL Study Extension (Week 52 - 76)|Lack of Efficacy|0
6136903|NCT01004432|9766962|FG004|OL Study Extension (Week 52 - 76)|Lack of Efficacy|10
6293619|NCT02439320|10012120|FG001|Overall Study|Physician Decision|1
6293620|NCT02439320|10012121|FG002|Overall Study|Physician Decision|0
6293621|NCT02439320|10012119|FG000|Overall Study|Sponsor Request|0
6293622|NCT02439320|10012120|FG001|Overall Study|Sponsor Request|2
6293623|NCT02439320|10012121|FG002|Overall Study|Sponsor Request|1
6293624|NCT02439320|10012119|FG000|Overall Study|Randomization Failure|35
6293625|NCT02439320|10012120|FG001|Overall Study|Randomization Failure|46
6293626|NCT02439320|10012121|FG002|Overall Study|Randomization Failure|34
6293627|NCT02440568|10012209|FG000|Overall Study|Death|1
6293628|NCT02440568|10012210|FG001|Overall Study|Death|3
6293629|NCT02440568|10012211|FG002|Overall Study|Death|4
6293630|NCT02440568|10012212|FG003|Overall Study|Death|2
6293631|NCT02440568|10012209|FG000|Overall Study|Lack of Efficacy|2
6293632|NCT02440568|10012210|FG001|Overall Study|Lack of Efficacy|0
6293633|NCT02440568|10012211|FG002|Overall Study|Lack of Efficacy|1
6293634|NCT02440568|10012212|FG003|Overall Study|Lack of Efficacy|0
6293635|NCT02440568|10012209|FG000|Overall Study|Lost to Follow-up|1
6293636|NCT02440568|10012210|FG001|Overall Study|Lost to Follow-up|0
6293637|NCT02440568|10012211|FG002|Overall Study|Lost to Follow-up|0
6293638|NCT02440568|10012212|FG003|Overall Study|Lost to Follow-up|0
6293639|NCT02440594|10012231|FG000|Overall Study|Lost to Follow-up|34
6293640|NCT02440594|10012232|FG001|Overall Study|Lost to Follow-up|33
6293641|NCT02440594|10012233|FG002|Overall Study|Lost to Follow-up|54
6293642|NCT02440594|10012234|FG003|Overall Study|Lost to Follow-up|47
6293643|NCT02440594|10012235|FG004|Overall Study|Lost to Follow-up|5
6293644|NCT02440594|10012236|FG005|Overall Study|Lost to Follow-up|4
6293645|NCT02440594|10012237|FG006|Overall Study|Lost to Follow-up|28
6293646|NCT02440594|10012238|FG007|Overall Study|Lost to Follow-up|48
6293647|NCT02440594|10012231|FG000|Overall Study|Cognitive Impairment/Communication Issue|14
6293648|NCT02440594|10012232|FG001|Overall Study|Cognitive Impairment/Communication Issue|6
6293649|NCT02440594|10012233|FG002|Overall Study|Cognitive Impairment/Communication Issue|4
6293650|NCT02440594|10012234|FG003|Overall Study|Cognitive Impairment/Communication Issue|4
6293651|NCT02440594|10012235|FG004|Overall Study|Cognitive Impairment/Communication Issue|2
6293652|NCT02440594|10012236|FG005|Overall Study|Cognitive Impairment/Communication Issue|1
6293653|NCT02440594|10012237|FG006|Overall Study|Cognitive Impairment/Communication Issue|0
6293654|NCT02440594|10012238|FG007|Overall Study|Cognitive Impairment/Communication Issue|0
6293655|NCT02440594|10012231|FG000|Overall Study|Withdrawal by Subject|81
6293656|NCT02440594|10012232|FG001|Overall Study|Withdrawal by Subject|67
6293657|NCT02440594|10012233|FG002|Overall Study|Withdrawal by Subject|59
6293658|NCT02440594|10012234|FG003|Overall Study|Withdrawal by Subject|38
6293659|NCT02440594|10012235|FG004|Overall Study|Withdrawal by Subject|2
6293660|NCT02440594|10012236|FG005|Overall Study|Withdrawal by Subject|2
6293661|NCT02440594|10012237|FG006|Overall Study|Withdrawal by Subject|7
6293662|NCT02440594|10012238|FG007|Overall Study|Withdrawal by Subject|7
6293663|NCT02440594|10012231|FG000|Overall Study|Administratively w/drawn|3
6293664|NCT02440594|10012232|FG001|Overall Study|Administratively w/drawn|2
6293665|NCT02440594|10012233|FG002|Overall Study|Administratively w/drawn|0
6293666|NCT02440594|10012234|FG003|Overall Study|Administratively w/drawn|0
6293667|NCT02440594|10012235|FG004|Overall Study|Administratively w/drawn|0
6293668|NCT02440594|10012236|FG005|Overall Study|Administratively w/drawn|0
6293669|NCT02440594|10012237|FG006|Overall Study|Administratively w/drawn|2
6293670|NCT02440594|10012238|FG007|Overall Study|Administratively w/drawn|1
6293671|NCT02440789|10012280|FG000|Overall Study|Withdrawal by Subject|3
6293672|NCT02440789|10012280|FG000|Overall Study|Not willing to adhere to reqs|1
6293673|NCT02441114|10012288|FG000|Washout2|Withdrawal by Subject|4
6293674|NCT02441179|10012294|FG000|Overall Study|Withdrawal by Subject|1
6293675|NCT02441179|10012295|FG001|Overall Study|Withdrawal by Subject|1
6293676|NCT02441218|10012304|FG000|Overall Study|Death|503
6293677|NCT02441218|10012305|FG001|Overall Study|Death|553
6293678|NCT02441218|10012304|FG000|Overall Study|Withdrawal by Subject|73
6293679|NCT02441218|10012305|FG001|Overall Study|Withdrawal by Subject|58
6293680|NCT02441218|10012304|FG000|Overall Study|Lost to Follow-up|2
6293681|NCT02441218|10012305|FG001|Overall Study|Lost to Follow-up|1
6293682|NCT02441283|10012311|FG000|Overall Study|Withdrew consent|15
6293683|NCT02441283|10012311|FG000|Overall Study|Lost to Follow-up|42
6293684|NCT02441283|10012311|FG000|Overall Study|Death|1
6293685|NCT02441283|10012311|FG000|Overall Study|Other, not specified|32
6293686|NCT02441309|10012318|FG000|Overall Study|Disease progression|2
6293687|NCT02441309|10012319|FG001|Overall Study|Disease progression|1
6293688|NCT02441309|10012320|FG002|Overall Study|Disease progression|2
6293689|NCT02441309|10012318|FG000|Overall Study|Adverse Event|0
6293690|NCT02441309|10012319|FG001|Overall Study|Adverse Event|1
6293691|NCT02441309|10012320|FG002|Overall Study|Adverse Event|0
6293692|NCT02441309|10012318|FG000|Overall Study|Withdrawal by Subject|1
6293693|NCT02441309|10012319|FG001|Overall Study|Withdrawal by Subject|0
6293694|NCT02441309|10012320|FG002|Overall Study|Withdrawal by Subject|1
6293695|NCT02441517|10012331|FG000|Overall Study|Lost to Follow-up|1
6293696|NCT02441517|10012331|FG000|Overall Study|Withdrawal by Subject|2
6293697|NCT02441517|10012331|FG000|Overall Study|Study Terminated by Sponsor|1
6293698|NCT02441946|10012338|FG000|Cycle 1 Period 1 (2 Weeks)|Adverse Event|1
6293699|NCT02441946|10012339|FG001|Cycle 1 Period 1 (2 Weeks)|Adverse Event|1
6293700|NCT02441946|10012340|FG002|Cycle 1 Period 1 (2 Weeks)|Adverse Event|0
6293701|NCT02441946|10012338|FG000|Cycle 1 Period 1 (2 Weeks)|Physician Decision|1
6293702|NCT02441946|10012339|FG001|Cycle 1 Period 1 (2 Weeks)|Physician Decision|0
6293703|NCT02441946|10012340|FG002|Cycle 1 Period 1 (2 Weeks)|Physician Decision|0
6293704|NCT02441946|10012338|FG000|Cycle 1 Period 1 (2 Weeks)|Withdrawal by Subject|0
6293705|NCT02441946|10012339|FG001|Cycle 1 Period 1 (2 Weeks)|Withdrawal by Subject|3
6293706|NCT02441946|10012340|FG002|Cycle 1 Period 1 (2 Weeks)|Withdrawal by Subject|0
6293707|NCT02441946|10012338|FG000|Cycle 1 Period 1 (2 Weeks)|Never Treated|0
6293708|NCT02441946|10012339|FG001|Cycle 1 Period 1 (2 Weeks)|Never Treated|1
6293709|NCT02441946|10012340|FG002|Cycle 1 Period 1 (2 Weeks)|Never Treated|0
6293710|NCT02441946|10012338|FG000|Cycle 2-5 Period 2 (14 Weeks)|Adverse Event|15
6293711|NCT02441946|10012339|FG001|Cycle 2-5 Period 2 (14 Weeks)|Adverse Event|0
6293712|NCT02441946|10012340|FG002|Cycle 2-5 Period 2 (14 Weeks)|Adverse Event|0
6293713|NCT02441946|10012338|FG000|Cycle 2-5 Period 2 (14 Weeks)|Noncompliance with study drug|1
6293714|NCT02441946|10012339|FG001|Cycle 2-5 Period 2 (14 Weeks)|Noncompliance with study drug|0
6293715|NCT02441946|10012340|FG002|Cycle 2-5 Period 2 (14 Weeks)|Noncompliance with study drug|0
6293716|NCT02441946|10012338|FG000|Cycle 2-5 Period 2 (14 Weeks)|Physician Decision|1
6293717|NCT02441946|10012339|FG001|Cycle 2-5 Period 2 (14 Weeks)|Physician Decision|0
6293718|NCT02441946|10012340|FG002|Cycle 2-5 Period 2 (14 Weeks)|Physician Decision|0
6293719|NCT02441946|10012338|FG000|Cycle 2-5 Period 2 (14 Weeks)|Protocol Deviation|1
6293720|NCT02441946|10012339|FG001|Cycle 2-5 Period 2 (14 Weeks)|Protocol Deviation|0
6293721|NCT02441946|10012340|FG002|Cycle 2-5 Period 2 (14 Weeks)|Protocol Deviation|0
6293722|NCT02441946|10012338|FG000|Cycle 2-5 Period 2 (14 Weeks)|Withdrawal by Subject|9
6293723|NCT02441946|10012339|FG001|Cycle 2-5 Period 2 (14 Weeks)|Withdrawal by Subject|0
6293724|NCT02441946|10012340|FG002|Cycle 2-5 Period 2 (14 Weeks)|Withdrawal by Subject|0
6293725|NCT02441946|10012338|FG000|Extension Period (8 Weeks)|Adverse Event|1
6293726|NCT02441946|10012339|FG001|Extension Period (8 Weeks)|Adverse Event|0
6293727|NCT02441946|10012340|FG002|Extension Period (8 Weeks)|Adverse Event|0
6293728|NCT02441946|10012338|FG000|Extension Period (8 Weeks)|Withdrawal by Subject|1
6293729|NCT02441946|10012339|FG001|Extension Period (8 Weeks)|Withdrawal by Subject|0
6293730|NCT02441946|10012340|FG002|Extension Period (8 Weeks)|Withdrawal by Subject|0
6293731|NCT02442206|10012353|FG000|Period 1|Adverse Event|1
6293732|NCT02442206|10012354|FG001|Period 1|Adverse Event|1
6293733|NCT02442206|10012353|FG000|Period 1|withdrew consent|0
6293734|NCT02442206|10012354|FG001|Period 1|withdrew consent|1
6293735|NCT02442206|10012353|FG000|Period 1|COPD exacerbation|0
6293736|NCT02442206|10012354|FG001|Period 1|COPD exacerbation|1
6293737|NCT02442206|10012353|FG000|Period 2|Adverse Event|1
6293738|NCT02442206|10012354|FG001|Period 2|Adverse Event|0
6293739|NCT02442271|10012361|FG000|Overall Study|Adverse Event|1
6293740|NCT02442271|10012361|FG000|Overall Study|Withdrew Consent|1
6293741|NCT02442271|10012361|FG000|Overall Study|Lost to Follow-up|1
6293742|NCT02442271|10012361|FG000|Overall Study|Other|1
6293743|NCT02442284|10012379|FG000|Overall Study|Adverse Event|1
6293744|NCT02442284|10012379|FG000|Overall Study|Withdrew Consent|2
6293745|NCT02442284|10012379|FG000|Overall Study|Lost to Follow-up|3
6293746|NCT02442284|10012379|FG000|Overall Study|Other|1
6293747|NCT02442310|10012383|FG000|Overall Study|Adverse Event|2
6293748|NCT02442310|10012383|FG000|Overall Study|Withdrawal by Subject|1
6293749|NCT02442336|10012393|FG000|Overall Study|6 patients assisted with the intervention development only.|6
6293750|NCT02442336|10012393|FG000|Overall Study|Of the 74 who consented, 19 did not complete baseline assessment and were withdrawn from the study.|19
6293751|NCT02442336|10012393|FG000|Overall Study|Lost to Follow-up|11
6293752|NCT02442622|10012399|FG000|Overall Study|Withdrawal by Subject|3
6293753|NCT02442622|10012400|FG001|Overall Study|Withdrawal by Subject|1
6293754|NCT02442804|10012431|FG000|Overall Study|Withdrawal by Subject|0
6293755|NCT02442804|10012432|FG001|Overall Study|Withdrawal by Subject|1
6293756|NCT02442804|10012431|FG000|Overall Study|Adverse Event|1
6293757|NCT02442804|10012432|FG001|Overall Study|Adverse Event|0
6293758|NCT02442830|10012440|FG000|Overall Study|Technical Failure|0
6293759|NCT02442830|10012441|FG001|Overall Study|Technical Failure|1
6293760|NCT02443103|10012487|FG000|Overall Study|Adverse Event|2
6293761|NCT02443103|10012487|FG000|Overall Study|Noncompliance|1
6293762|NCT02443155|10012495|FG000|Overall Study|Adverse Event|3
6293763|NCT02443155|10012496|FG001|Overall Study|Adverse Event|4
6293764|NCT02443155|10012497|FG002|Overall Study|Adverse Event|1
6293765|NCT02443155|10012498|FG003|Overall Study|Adverse Event|2
6293766|NCT02443155|10012495|FG000|Overall Study|Unclassified|0
6293767|NCT02443155|10012496|FG001|Overall Study|Unclassified|0
6293768|NCT02443155|10012497|FG002|Overall Study|Unclassified|2
6293769|NCT02443155|10012498|FG003|Overall Study|Unclassified|1
6293770|NCT02443155|10012495|FG000|Overall Study|Withdrawal by Subject|4
6293771|NCT02443155|10012496|FG001|Overall Study|Withdrawal by Subject|7
6293772|NCT02443155|10012497|FG002|Overall Study|Withdrawal by Subject|3
6293773|NCT02443155|10012498|FG003|Overall Study|Withdrawal by Subject|9
6293774|NCT02443155|10012495|FG000|Overall Study|Pregnancy|3
6293775|NCT02443155|10012496|FG001|Overall Study|Pregnancy|1
6293776|NCT02443155|10012497|FG002|Overall Study|Pregnancy|1
6293777|NCT02443155|10012498|FG003|Overall Study|Pregnancy|2
6293778|NCT02443155|10012495|FG000|Overall Study|Lost to Follow-up|1
6293779|NCT02443155|10012496|FG001|Overall Study|Lost to Follow-up|2
6293780|NCT02443155|10012497|FG002|Overall Study|Lost to Follow-up|0
6293781|NCT02443155|10012498|FG003|Overall Study|Lost to Follow-up|1
6293782|NCT02443155|10012495|FG000|Overall Study|Protocol Violation|1
6293783|NCT02443155|10012496|FG001|Overall Study|Protocol Violation|0
6293784|NCT02443155|10012497|FG002|Overall Study|Protocol Violation|1
6293785|NCT02443155|10012498|FG003|Overall Study|Protocol Violation|1
6293786|NCT02443155|10012495|FG000|Overall Study|Death|0
6293787|NCT02443155|10012496|FG001|Overall Study|Death|0
6293788|NCT02443155|10012497|FG002|Overall Study|Death|1
6293789|NCT02443155|10012498|FG003|Overall Study|Death|0
6293790|NCT02443298|10012511|FG000|Overall Study|Adverse Event|3
6293791|NCT02443298|10012512|FG001|Overall Study|Adverse Event|3
6293792|NCT02443298|10012511|FG000|Overall Study|Withdrawal by Subject|1
6293793|NCT02443298|10012512|FG001|Overall Study|Withdrawal by Subject|2
6293794|NCT02443337|10012520|FG000|Overall Study|Adverse Event|0
6293795|NCT02443337|10012521|FG001|Overall Study|Adverse Event|1
6293796|NCT02443337|10012520|FG000|Overall Study|Clinical Progressive Disease|3
6293797|NCT02443337|10012521|FG001|Overall Study|Clinical Progressive Disease|0
6293798|NCT02443337|10012520|FG000|Overall Study|Withdrawal by Subject|2
6293799|NCT02443337|10012521|FG001|Overall Study|Withdrawal by Subject|1
6293800|NCT02443402|10012534|FG000|Overall Study|Withdrawal by Subject|3
6293801|NCT02443402|10012535|FG001|Overall Study|Withdrawal by Subject|1
6293802|NCT02443402|10012534|FG000|Overall Study|Screen Failure|1
6293803|NCT02443402|10012535|FG001|Overall Study|Screen Failure|2
6293804|NCT02443688|10012566|FG000|Overall Study|Adverse Event|2
6293805|NCT02443688|10012567|FG001|Overall Study|Adverse Event|3
6293806|NCT02443688|10012568|FG002|Overall Study|Adverse Event|2
6293807|NCT02443688|10012566|FG000|Overall Study|Lost to Follow-up|1
6293808|NCT02443688|10012567|FG001|Overall Study|Lost to Follow-up|0
6293809|NCT02443688|10012568|FG002|Overall Study|Lost to Follow-up|0
6293810|NCT02443688|10012566|FG000|Overall Study|Physician Decision|3
6293811|NCT02443688|10012567|FG001|Overall Study|Physician Decision|0
6293812|NCT02443688|10012568|FG002|Overall Study|Physician Decision|1
6293813|NCT02443688|10012566|FG000|Overall Study|Pregnancy|0
6293814|NCT02443688|10012567|FG001|Overall Study|Pregnancy|0
6293815|NCT02443688|10012568|FG002|Overall Study|Pregnancy|1
6293816|NCT02443688|10012566|FG000|Overall Study|Withdrawal by Subject|3
6293817|NCT02443688|10012567|FG001|Overall Study|Withdrawal by Subject|3
6293818|NCT02443688|10012568|FG002|Overall Study|Withdrawal by Subject|4
6293819|NCT02443688|10012566|FG000|Overall Study|Non-compliance with study drug|1
6293820|NCT02443688|10012567|FG001|Overall Study|Non-compliance with study drug|2
6293821|NCT02443688|10012568|FG002|Overall Study|Non-compliance with study drug|4
6293822|NCT02443688|10012566|FG000|Overall Study|Sponsor Request|2
6293823|NCT02443688|10012567|FG001|Overall Study|Sponsor Request|1
6293824|NCT02443688|10012568|FG002|Overall Study|Sponsor Request|0
6293825|NCT02443740|10012584|FG000|Intervention Period 1 (3 Days)|Adverse Event|0
6293826|NCT02443740|10012585|FG001|Intervention Period 1 (3 Days)|Adverse Event|0
6293827|NCT02443740|10012586|FG002|Intervention Period 1 (3 Days)|Adverse Event|0
6293828|NCT02443740|10012587|FG003|Intervention Period 1 (3 Days)|Adverse Event|0
6293829|NCT02443740|10012588|FG004|Intervention Period 1 (3 Days)|Adverse Event|0
6293830|NCT02443740|10012589|FG005|Intervention Period 1 (3 Days)|Adverse Event|1
6293831|NCT02443740|10012590|FG006|Intervention Period 1 (3 Days)|Adverse Event|0
6293832|NCT02443740|10012591|FG007|Intervention Period 1 (3 Days)|Adverse Event|0
6293833|NCT02443740|10012592|FG008|Intervention Period 1 (3 Days)|Adverse Event|0
6293834|NCT02443740|10012593|FG009|Intervention Period 1 (3 Days)|Adverse Event|0
6293835|NCT02443740|10012594|FG010|Intervention Period 1 (3 Days)|Adverse Event|0
6293836|NCT02443740|10012584|FG000|Intervention Period 1 (3 Days)|Protocol Violation|1
6293837|NCT02443740|10012585|FG001|Intervention Period 1 (3 Days)|Protocol Violation|0
6293838|NCT02443740|10012586|FG002|Intervention Period 1 (3 Days)|Protocol Violation|0
6293839|NCT02443740|10012587|FG003|Intervention Period 1 (3 Days)|Protocol Violation|0
6293840|NCT02443740|10012588|FG004|Intervention Period 1 (3 Days)|Protocol Violation|0
6293841|NCT02443740|10012589|FG005|Intervention Period 1 (3 Days)|Protocol Violation|0
6293842|NCT02443740|10012590|FG006|Intervention Period 1 (3 Days)|Protocol Violation|1
6293843|NCT02443740|10012591|FG007|Intervention Period 1 (3 Days)|Protocol Violation|0
6293844|NCT02443740|10012592|FG008|Intervention Period 1 (3 Days)|Protocol Violation|0
6293845|NCT02443740|10012593|FG009|Intervention Period 1 (3 Days)|Protocol Violation|0
6293846|NCT02443740|10012594|FG010|Intervention Period 1 (3 Days)|Protocol Violation|0
6293847|NCT02443740|10012584|FG000|Intervention Period 1 (3 Days)|Withdrawal by Subject|0
6293848|NCT02443740|10012585|FG001|Intervention Period 1 (3 Days)|Withdrawal by Subject|0
6293849|NCT02443740|10012586|FG002|Intervention Period 1 (3 Days)|Withdrawal by Subject|0
6293850|NCT02443740|10012587|FG003|Intervention Period 1 (3 Days)|Withdrawal by Subject|0
6293851|NCT02443740|10012588|FG004|Intervention Period 1 (3 Days)|Withdrawal by Subject|0
6293852|NCT02443740|10012589|FG005|Intervention Period 1 (3 Days)|Withdrawal by Subject|1
6293853|NCT02443740|10012590|FG006|Intervention Period 1 (3 Days)|Withdrawal by Subject|0
6293854|NCT02443740|10012591|FG007|Intervention Period 1 (3 Days)|Withdrawal by Subject|0
6293855|NCT02443740|10012592|FG008|Intervention Period 1 (3 Days)|Withdrawal by Subject|0
6293856|NCT02443740|10012593|FG009|Intervention Period 1 (3 Days)|Withdrawal by Subject|0
6293857|NCT02443740|10012594|FG010|Intervention Period 1 (3 Days)|Withdrawal by Subject|0
6293858|NCT02443805|10012635|FG000|Overall Study|Adverse Event|100
6293859|NCT02443805|10012636|FG001|Overall Study|Adverse Event|18
6293860|NCT02443805|10012635|FG000|Overall Study|Withdrawal by Subject|73
6293861|NCT02443805|10012636|FG001|Overall Study|Withdrawal by Subject|74
6293862|NCT02443805|10012635|FG000|Overall Study|Lost to Follow-up|19
6293863|NCT02443805|10012636|FG001|Overall Study|Lost to Follow-up|14
6293864|NCT02443805|10012635|FG000|Overall Study|Pregnancy|6
6293865|NCT02443805|10012636|FG001|Overall Study|Pregnancy|5
6293866|NCT02443805|10012635|FG000|Overall Study|Protocol Violation|2
6293867|NCT02443805|10012636|FG001|Overall Study|Protocol Violation|4
6293868|NCT02443805|10012635|FG000|Overall Study|Lack of Efficacy|1
6293869|NCT02443805|10012636|FG001|Overall Study|Lack of Efficacy|1
6293870|NCT02443805|10012635|FG000|Overall Study|Non-compliance with study drug|6
6293871|NCT02443805|10012636|FG001|Overall Study|Non-compliance with study drug|4
6293872|NCT02443805|10012635|FG000|Overall Study|Withdrawal by parent/guardian|3
6293873|NCT02443805|10012636|FG001|Overall Study|Withdrawal by parent/guardian|5
6293874|NCT02443805|10012635|FG000|Overall Study|Any other reason not above-mentioned|3
6293875|NCT02443805|10012636|FG001|Overall Study|Any other reason not above-mentioned|2
6293876|NCT02443883|10012646|FG000|Overall Study|Adverse Event|0
6293877|NCT02443883|10012647|FG001|Overall Study|Adverse Event|1
6293878|NCT02443883|10012648|FG002|Overall Study|Adverse Event|0
6293879|NCT02443883|10012649|FG003|Overall Study|Adverse Event|0
6293880|NCT02443883|10012646|FG000|Overall Study|Lost to Follow-up|3
6293881|NCT02443883|10012647|FG001|Overall Study|Lost to Follow-up|2
6293882|NCT02443883|10012648|FG002|Overall Study|Lost to Follow-up|1
6293883|NCT02443883|10012649|FG003|Overall Study|Lost to Follow-up|0
6293884|NCT02443883|10012646|FG000|Overall Study|Physician Decision|1
6293885|NCT02443883|10012647|FG001|Overall Study|Physician Decision|1
6293886|NCT02443883|10012648|FG002|Overall Study|Physician Decision|0
6293887|NCT02443883|10012649|FG003|Overall Study|Physician Decision|3
6293888|NCT02443883|10012646|FG000|Overall Study|Withdrawal by Subject|1
6293889|NCT02443883|10012647|FG001|Overall Study|Withdrawal by Subject|0
6293890|NCT02443883|10012648|FG002|Overall Study|Withdrawal by Subject|0
6293891|NCT02443883|10012649|FG003|Overall Study|Withdrawal by Subject|2
6293892|NCT02443883|10012646|FG000|Overall Study|Randomized, but never treated|1
6293893|NCT02443883|10012647|FG001|Overall Study|Randomized, but never treated|0
6293894|NCT02443883|10012648|FG002|Overall Study|Randomized, but never treated|0
6293895|NCT02443883|10012649|FG003|Overall Study|Randomized, but never treated|0
6293896|NCT02444182|10012672|FG000|Overall Study|non-compliance|2
6293897|NCT02444182|10012673|FG001|Overall Study|non-compliance|1
6293898|NCT02444182|10012672|FG000|Overall Study|Lost to Follow-up|0
6293899|NCT02444182|10012673|FG001|Overall Study|Lost to Follow-up|4
6293900|NCT02444533|10012690|FG000|Overall Study|Not able to complete forms|0
6293901|NCT02444533|10012691|FG001|Overall Study|Not able to complete forms|2
6293902|NCT02444533|10012690|FG000|Overall Study|Only gave post-procedure complications|2
6293903|NCT02444533|10012691|FG001|Overall Study|Only gave post-procedure complications|2
6293904|NCT02444793|10012733|FG000|Overall Study|Lost to Follow-up|2
6293905|NCT02444793|10012734|FG001|Overall Study|Lost to Follow-up|2
6293906|NCT02444793|10012735|FG002|Overall Study|Lost to Follow-up|0
6293907|NCT02444793|10012736|FG003|Overall Study|Lost to Follow-up|0
6293908|NCT02444793|10012733|FG000|Overall Study|Death|0
6293909|NCT02444793|10012734|FG001|Overall Study|Death|3
6293910|NCT02444793|10012735|FG002|Overall Study|Death|0
6293911|NCT02444793|10012736|FG003|Overall Study|Death|0
6293912|NCT02444793|10012733|FG000|Overall Study|Other|0
6293913|NCT02444793|10012734|FG001|Overall Study|Other|0
6293914|NCT02444793|10012735|FG002|Overall Study|Other|2
6293915|NCT02444793|10012736|FG003|Overall Study|Other|0
6293916|NCT02444793|10012733|FG000|Overall Study|Objective progression or relapse|9
6293917|NCT02444793|10012734|FG001|Overall Study|Objective progression or relapse|1
6293918|NCT02444793|10012735|FG002|Overall Study|Objective progression or relapse|2
6293919|NCT02444793|10012736|FG003|Overall Study|Objective progression or relapse|3
6293920|NCT02445573|10012807|FG000|Overall Study|Withdrawal by Subject|1
6293921|NCT02445573|10012808|FG001|Overall Study|Withdrawal by Subject|1
6293922|NCT02445573|10012807|FG000|Overall Study|Lost to Follow-up|0
6293923|NCT02445573|10012808|FG001|Overall Study|Lost to Follow-up|1
6293924|NCT02445586|10012814|FG000|Overall Study|Death|14
6293925|NCT02445586|10012814|FG000|Overall Study|Withdrawal by Subject|13
6293926|NCT02445586|10012814|FG000|Overall Study|Disease Progression|10
6293927|NCT02445586|10012814|FG000|Overall Study|Protocol Violation|1
6293928|NCT02445586|10012814|FG000|Overall Study|Medical Condition|1
6293929|NCT02445755|10012823|FG000|Overall Study|Withdrawal by Subject|2
6293930|NCT02445755|10012823|FG000|Overall Study|Protocol Violation|6
6293931|NCT02445755|10012823|FG000|Overall Study|Screen Failure|5
6293932|NCT02445794|10012834|FG000|Overall Study|Adverse Event|0
6293933|NCT02445794|10012835|FG001|Overall Study|Adverse Event|0
6293934|NCT02445794|10012836|FG002|Overall Study|Adverse Event|2
6293935|NCT02445794|10012837|FG003|Overall Study|Adverse Event|0
6293936|NCT02445963|10012891|FG000|Overall Study|Lost to Follow-up|1
6293937|NCT02445963|10012892|FG001|Overall Study|Lost to Follow-up|0
6293938|NCT02445963|10012893|FG002|Overall Study|Lost to Follow-up|0
6293939|NCT02445963|10012894|FG003|Overall Study|Lost to Follow-up|0
6293940|NCT02445963|10012891|FG000|Overall Study|Change in employment|1
6293941|NCT02445963|10012892|FG001|Overall Study|Change in employment|0
6293942|NCT02445963|10012893|FG002|Overall Study|Change in employment|0
6293943|NCT02445963|10012894|FG003|Overall Study|Change in employment|0
6293944|NCT02445963|10012891|FG000|Overall Study|Symptoms post-vaccination|0
6293945|NCT02445963|10012892|FG001|Overall Study|Symptoms post-vaccination|0
6293946|NCT02445963|10012893|FG002|Overall Study|Symptoms post-vaccination|1
6293947|NCT02445963|10012894|FG003|Overall Study|Symptoms post-vaccination|0
6293948|NCT02446015|10012908|FG000|Overall Study|Adverse Event|0
6293949|NCT02446015|10012909|FG001|Overall Study|Adverse Event|1
6293950|NCT02446015|10012908|FG000|Overall Study|Withdrawal by Subject|1
6293951|NCT02446015|10012909|FG001|Overall Study|Withdrawal by Subject|0
6293952|NCT02446171|10012920|FG000|Overall Study|Withdrawal by Subject|0
6293953|NCT02446171|10012921|FG001|Overall Study|Withdrawal by Subject|0
6293954|NCT02446171|10012922|FG002|Overall Study|Withdrawal by Subject|2
6293955|NCT02446171|10012923|FG003|Overall Study|Withdrawal by Subject|0
6293956|NCT02446418|10012962|FG000|Overall Study|Adverse Event|4
6293957|NCT02446418|10012963|FG001|Overall Study|Adverse Event|8
6293958|NCT02446418|10012962|FG000|Overall Study|Physician Decision|5
6293959|NCT02446418|10012963|FG001|Overall Study|Physician Decision|1
5981405|NCT00968201|9570365|FG001|Base Study - (Period II)|Withdrawal by Subject|0
5981406|NCT00968201|9570366|FG002|Base Study - (Period II)|Withdrawal by Subject|8
5981407|NCT00968201|9570364|FG000|Base Study - (Period II)|Site Error|0
5981408|NCT00968201|9570365|FG001|Base Study - (Period II)|Site Error|0
5981409|NCT00968201|9570366|FG002|Base Study - (Period II)|Site Error|1
5981410|NCT00968201|9570364|FG000|Extension Study - (Period III)|Adverse Event|0
5981411|NCT00968201|9570365|FG001|Extension Study - (Period III)|Adverse Event|5
5981412|NCT00968201|9570366|FG002|Extension Study - (Period III)|Adverse Event|22
5981413|NCT00968201|9570364|FG000|Extension Study - (Period III)|Lost to Follow-up|0
5981414|NCT00968201|9570365|FG001|Extension Study - (Period III)|Lost to Follow-up|7
5981415|NCT00968201|9570366|FG002|Extension Study - (Period III)|Lost to Follow-up|13
5981416|NCT00968201|9570364|FG000|Extension Study - (Period III)|Protocol Violation|0
5981417|NCT00968201|9570365|FG001|Extension Study - (Period III)|Protocol Violation|17
6136904|NCT01004614|9766980|FG000|Washout|Withdrawal by Subject|0
6293960|NCT02446418|10012962|FG000|Overall Study|Withdrawal by Subject|3
6293961|NCT02446418|10012963|FG001|Overall Study|Withdrawal by Subject|3
6293962|NCT02446418|10012962|FG000|Overall Study|Lost to Follow-up|2
6293963|NCT02446418|10012963|FG001|Overall Study|Lost to Follow-up|2
6293964|NCT02446418|10012962|FG000|Overall Study|Protocol Violation|1
6293965|NCT02446418|10012963|FG001|Overall Study|Protocol Violation|2
6293966|NCT02446418|10012962|FG000|Overall Study|Lack of Efficacy|2
6293967|NCT02446418|10012963|FG001|Overall Study|Lack of Efficacy|0
6293968|NCT02446418|10012962|FG000|Overall Study|Protocol defined stopping criteria reach|1
6293969|NCT02446418|10012963|FG001|Overall Study|Protocol defined stopping criteria reach|0
6293970|NCT02446691|10012995|FG000|Overall Study|Withdrawal by Subject|2
6293971|NCT02446691|10012995|FG000|Overall Study|Lost to Follow-up|8
6293972|NCT02446691|10012995|FG000|Overall Study|Protocol Violation|1
6293973|NCT02446717|10013004|FG000|Overall Study|Adverse Event|0
6293974|NCT02446717|10013005|FG001|Overall Study|Adverse Event|0
6293975|NCT02446717|10013006|FG002|Overall Study|Adverse Event|1
6293976|NCT02446717|10013007|FG003|Overall Study|Adverse Event|0
6293977|NCT02446717|10013008|FG004|Overall Study|Adverse Event|0
6293978|NCT02446717|10013004|FG000|Overall Study|Lost to Follow-up|0
6293979|NCT02446717|10013005|FG001|Overall Study|Lost to Follow-up|1
6293980|NCT02446717|10013006|FG002|Overall Study|Lost to Follow-up|1
6293981|NCT02446717|10013007|FG003|Overall Study|Lost to Follow-up|0
6293982|NCT02446717|10013008|FG004|Overall Study|Lost to Follow-up|1
6293983|NCT02446717|10013004|FG000|Overall Study|Withdrew consent|0
6293984|NCT02446717|10013005|FG001|Overall Study|Withdrew consent|0
6293985|NCT02446717|10013006|FG002|Overall Study|Withdrew consent|0
6293986|NCT02446717|10013007|FG003|Overall Study|Withdrew consent|1
6293987|NCT02446717|10013008|FG004|Overall Study|Withdrew consent|0
6293988|NCT02446743|10013022|FG000|Overall Study|Withdrawal by Subject|1
6293989|NCT02446743|10013023|FG001|Overall Study|Withdrawal by Subject|1
6293990|NCT02446743|10013022|FG000|Overall Study|Lost to Follow-up|1
6293991|NCT02446743|10013023|FG001|Overall Study|Lost to Follow-up|0
6293992|NCT02446743|10013022|FG000|Overall Study|Adverse Event|1
6293993|NCT02446743|10013023|FG001|Overall Study|Adverse Event|1
6293994|NCT02446743|10013022|FG000|Overall Study|Other|2
6293995|NCT02446743|10013023|FG001|Overall Study|Other|3
6293996|NCT02446769|10013038|FG000|Screening Period|Screen Failure|11
6293997|NCT02446769|10013039|FG001|Screening Period|Screen Failure|0
6293998|NCT02446769|10013040|FG002|Screening Period|Screen Failure|0
6293999|NCT02446769|10013038|FG000|Study Period|Randomized in Error|0
6294000|NCT02446769|10013039|FG001|Study Period|Randomized in Error|2
6294001|NCT02446769|10013040|FG002|Study Period|Randomized in Error|0
6294002|NCT02446886|10013058|FG000|Overall Study|Adverse Event|1
6294003|NCT02446886|10013059|FG001|Overall Study|Adverse Event|3
6294004|NCT02446886|10013058|FG000|Overall Study|Withdrawal by Subject|1
6294005|NCT02446886|10013059|FG001|Overall Study|Withdrawal by Subject|1
6294006|NCT02446899|10013068|FG000|Overall Study|Adverse Event|4
6294007|NCT02446899|10013069|FG001|Overall Study|Adverse Event|7
6294008|NCT02446899|10013068|FG000|Overall Study|Condition Under Investigation Worsened|1
6294009|NCT02446899|10013069|FG001|Overall Study|Condition Under Investigation Worsened|4
6294010|NCT02446899|10013068|FG000|Overall Study|Study Specific Withdrawal Criteria|1
6294011|NCT02446899|10013069|FG001|Overall Study|Study Specific Withdrawal Criteria|0
6294012|NCT02446899|10013068|FG000|Overall Study|Lack of Efficacy|2
6294013|NCT02446899|10013069|FG001|Overall Study|Lack of Efficacy|8
6294014|NCT02446899|10013068|FG000|Overall Study|Lost to Follow-up|1
6294015|NCT02446899|10013069|FG001|Overall Study|Lost to Follow-up|3
6294016|NCT02446899|10013068|FG000|Overall Study|Severe Non-Compliance to Protocol|0
6294017|NCT02446899|10013069|FG001|Overall Study|Severe Non-Compliance to Protocol|1
6294018|NCT02446899|10013068|FG000|Overall Study|Withdrawal by Subject|11
6294019|NCT02446899|10013069|FG001|Overall Study|Withdrawal by Subject|19
6294020|NCT02446899|10013068|FG000|Overall Study|Miscellaneous|5
6294021|NCT02446899|10013069|FG001|Overall Study|Miscellaneous|4
6294022|NCT02446899|10013068|FG000|Overall Study|Failure to Meet Randomization Criteria|0
6294023|NCT02446899|10013069|FG001|Overall Study|Failure to Meet Randomization Criteria|2
6294024|NCT02446912|10013078|FG000|Overall Study|Adverse Event|3
6294025|NCT02446912|10013079|FG001|Overall Study|Adverse Event|13
6294026|NCT02446912|10013080|FG002|Overall Study|Adverse Event|5
6294027|NCT02446912|10013078|FG000|Overall Study|Condition under investigation worsened|0
6294028|NCT02446912|10013079|FG001|Overall Study|Condition under investigation worsened|1
6294029|NCT02446912|10013080|FG002|Overall Study|Condition under investigation worsened|1
6294030|NCT02446912|10013078|FG000|Overall Study|Study-specific withdrawal criteria|1
6294031|NCT02446912|10013079|FG001|Overall Study|Study-specific withdrawal criteria|0
6294032|NCT02446912|10013080|FG002|Overall Study|Study-specific withdrawal criteria|0
6294033|NCT02446912|10013078|FG000|Overall Study|Lack of Efficacy|1
6294034|NCT02446912|10013079|FG001|Overall Study|Lack of Efficacy|4
6294035|NCT02446912|10013080|FG002|Overall Study|Lack of Efficacy|7
6294036|NCT02446912|10013078|FG000|Overall Study|Lost to Follow-up|0
6294037|NCT02446912|10013079|FG001|Overall Study|Lost to Follow-up|0
6294038|NCT02446912|10013080|FG002|Overall Study|Lost to Follow-up|2
6294039|NCT02446912|10013078|FG000|Overall Study|Severe non-compliance to protocol|1
6294040|NCT02446912|10013079|FG001|Overall Study|Severe non-compliance to protocol|0
6294041|NCT02446912|10013080|FG002|Overall Study|Severe non-compliance to protocol|1
6294042|NCT02446912|10013078|FG000|Overall Study|Withdrawal by Subject|10
6294043|NCT02446912|10013079|FG001|Overall Study|Withdrawal by Subject|15
6294044|NCT02446912|10013080|FG002|Overall Study|Withdrawal by Subject|15
6294045|NCT02446912|10013078|FG000|Overall Study|Miscellaneous|2
6294046|NCT02446912|10013079|FG001|Overall Study|Miscellaneous|2
6294047|NCT02446912|10013080|FG002|Overall Study|Miscellaneous|4
6294048|NCT02446990|10013090|FG000|Overall Study|Death|485
6294049|NCT02446990|10013091|FG001|Overall Study|Death|458
6294050|NCT02446990|10013090|FG000|Overall Study|Lost to Follow-up|3
6294051|NCT02446990|10013091|FG001|Overall Study|Lost to Follow-up|1
6294052|NCT02446990|10013090|FG000|Overall Study|Physician Decision|1
6294053|NCT02446990|10013091|FG001|Overall Study|Physician Decision|0
6294054|NCT02446990|10013090|FG000|Overall Study|Withdrawal by Subject|231
6294055|NCT02446990|10013091|FG001|Overall Study|Withdrawal by Subject|199
6294056|NCT02447003|10013099|FG000|Overall Study|Other|0
6294057|NCT02447003|10013100|FG001|Overall Study|Other|4
6294058|NCT02447003|10013099|FG000|Overall Study|Site discontinued|0
6294059|NCT02447003|10013100|FG001|Overall Study|Site discontinued|2
6294060|NCT02447003|10013099|FG000|Overall Study|Physician Decision|0
6294061|NCT02447003|10013100|FG001|Overall Study|Physician Decision|1
6294062|NCT02447003|10013099|FG000|Overall Study|Withdrawal by Subject|4
6294063|NCT02447003|10013100|FG001|Overall Study|Withdrawal by Subject|3
6294064|NCT02447003|10013099|FG000|Overall Study|Sponsor Decision|6
6294065|NCT02447003|10013100|FG001|Overall Study|Sponsor Decision|11
6294066|NCT02447003|10013099|FG000|Overall Study|Progressive Disease|1
6294067|NCT02447003|10013100|FG001|Overall Study|Progressive Disease|0
6294068|NCT02447003|10013099|FG000|Overall Study|Lost to Follow-up|5
6294069|NCT02447003|10013100|FG001|Overall Study|Lost to Follow-up|0
6294070|NCT02447003|10013099|FG000|Overall Study|Death|154
6294071|NCT02447003|10013100|FG001|Overall Study|Death|63
6294072|NCT02447029|10013110|FG000|Overall Study|Withdrawal by Subject|3
6294073|NCT02447029|10013111|FG001|Overall Study|Withdrawal by Subject|2
6294074|NCT02447081|10013117|FG000|Overall Study|Death|161
6294075|NCT02447081|10013117|FG000|Overall Study|Lost to Follow-up|36
6294076|NCT02447081|10013117|FG000|Overall Study|Visit not completed|17
6294077|NCT02447081|10013117|FG000|Overall Study|unsuccessful implant procedure|10
6294078|NCT02447172|10013124|FG000|Overall Study|Adverse Event|11
6294079|NCT02447172|10013125|FG001|Overall Study|Adverse Event|8
6294080|NCT02447172|10013126|FG002|Overall Study|Adverse Event|7
6294081|NCT02447172|10013124|FG000|Overall Study|Death|3
6294082|NCT02447172|10013125|FG001|Overall Study|Death|1
6294083|NCT02447172|10013126|FG002|Overall Study|Death|0
6294084|NCT02447172|10013124|FG000|Overall Study|Protocol Violation|2
6294085|NCT02447172|10013125|FG001|Overall Study|Protocol Violation|1
6294086|NCT02447172|10013126|FG002|Overall Study|Protocol Violation|2
6294087|NCT02447172|10013124|FG000|Overall Study|Lost to Follow-up|7
6294088|NCT02447172|10013125|FG001|Overall Study|Lost to Follow-up|4
6294089|NCT02447172|10013126|FG002|Overall Study|Lost to Follow-up|4
6294090|NCT02447172|10013124|FG000|Overall Study|Withdrawal by Subject|5
6294091|NCT02447172|10013125|FG001|Overall Study|Withdrawal by Subject|1
6294092|NCT02447172|10013126|FG002|Overall Study|Withdrawal by Subject|3
6294093|NCT02447172|10013124|FG000|Overall Study|protocol specific treatment unrelated|3
6294094|NCT02447172|10013125|FG001|Overall Study|protocol specific treatment unrelated|0
6294095|NCT02447172|10013126|FG002|Overall Study|protocol specific treatment unrelated|2
6294096|NCT02447250|10013134|FG000|Second Dose (270 mcg Albuterol)|elevated HR with first dose|1
6294097|NCT02447250|10013134|FG000|Third Dose (360 mcg Albuterol)|Clinically unstable, unable to do PFT|1
6294098|NCT02447250|10013134|FG000|Third Dose (360 mcg Albuterol)|Elevated HR with 2nd dose|4
6294099|NCT02447302|10013142|FG000|Overall Study|Physician Decision|1
6294100|NCT02447302|10013143|FG001|Overall Study|Physician Decision|0
6294101|NCT02447302|10013144|FG002|Overall Study|Physician Decision|0
6294102|NCT02447302|10013142|FG000|Overall Study|Adverse Event|4
6294103|NCT02447302|10013143|FG001|Overall Study|Adverse Event|3
6294104|NCT02447302|10013144|FG002|Overall Study|Adverse Event|0
6294105|NCT02447302|10013142|FG000|Overall Study|Withdrawal by Subject|0
6294106|NCT02447302|10013143|FG001|Overall Study|Withdrawal by Subject|1
6294107|NCT02447302|10013144|FG002|Overall Study|Withdrawal by Subject|5
6294108|NCT02447302|10013142|FG000|Overall Study|Sponsor Decision|0
6294109|NCT02447302|10013143|FG001|Overall Study|Sponsor Decision|0
6294110|NCT02447302|10013144|FG002|Overall Study|Sponsor Decision|1
6294111|NCT02447328|10013152|FG000|Overall Study|Withdrawal by Subject|1
6294112|NCT02447432|10013158|FG000|Epoch 001|Adverse Event|1
6294113|NCT02447432|10013159|FG001|Epoch 001|Adverse Event|1
6294114|NCT02447432|10013158|FG000|Epoch 001|Withdrawal by Subject|0
6294115|NCT02447432|10013159|FG001|Epoch 001|Withdrawal by Subject|4
6294116|NCT02447432|10013158|FG000|Epoch 001|Migrated/moved from study area|3
6294117|NCT02447432|10013159|FG001|Epoch 001|Migrated/moved from study area|5
6294118|NCT02447432|10013158|FG000|Epoch 001|Lost to Follow-up|1
6294119|NCT02447432|10013159|FG001|Epoch 001|Lost to Follow-up|3
6294120|NCT02447458|10013171|FG000|Overall Study|Other|0
6294121|NCT02447458|10013172|FG001|Overall Study|Other|0
6294122|NCT02447458|10013173|FG002|Overall Study|Other|1
6294123|NCT02447458|10013174|FG003|Overall Study|Other|0
6294124|NCT02447458|10013175|FG004|Overall Study|Other|0
6294125|NCT02447458|10013176|FG005|Overall Study|Other|0
6294126|NCT02447497|10013199|FG000|Overall Study|Did not meet treatment day baseline.|6
6294127|NCT02447497|10013200|FG001|Overall Study|Did not meet treatment day baseline.|5
6294128|NCT02447497|10013201|FG002|Overall Study|Did not meet treatment day baseline.|2
6294129|NCT02447497|10013202|FG003|Overall Study|Did not meet treatment day baseline.|2
6294130|NCT02447497|10013199|FG000|Overall Study|Dressing was compromised|0
6294131|NCT02447497|10013200|FG001|Overall Study|Dressing was compromised|1
6294132|NCT02447497|10013201|FG002|Overall Study|Dressing was compromised|0
6294133|NCT02447497|10013202|FG003|Overall Study|Dressing was compromised|0
6294134|NCT02447718|10013226|FG000|Overall Study|Lost to Follow-up|8
6294135|NCT02447718|10013227|FG001|Overall Study|Lost to Follow-up|0
6294136|NCT02447718|10013226|FG000|Overall Study|Withdrawal by Subject|3
6294137|NCT02447718|10013227|FG001|Overall Study|Withdrawal by Subject|0
6294138|NCT02447718|10013226|FG000|Overall Study|Screen Failure|1
6294139|NCT02447718|10013227|FG001|Overall Study|Screen Failure|0
6294140|NCT02447744|10013236|FG000|Overall Study|Withdrawal by Subject|3
6294141|NCT02447744|10013237|FG001|Overall Study|Withdrawal by Subject|1
6294142|NCT02447744|10013236|FG000|Overall Study|Data not collected b/c logistic reasons|3
6294143|NCT02447744|10013237|FG001|Overall Study|Data not collected b/c logistic reasons|0
6294144|NCT02447848|10013243|FG000|Overall Study|Patient discharged|3
6294145|NCT02447848|10013243|FG000|Overall Study|Lack of Efficacy|4
6294146|NCT02447848|10013243|FG000|Overall Study|Withdrawal by Subject|4
6294147|NCT02447952|10013251|FG000|Overall Study|Adverse Event|2
6294148|NCT02447952|10013251|FG000|Overall Study|Physician Decision|1
6294149|NCT02447952|10013251|FG000|Overall Study|Withdrawal by Subject|4
6294150|NCT02447991|10013257|FG000|Overall Study|Withdrawn by subject - no data|0
6294151|NCT02447991|10013258|FG001|Overall Study|Withdrawn by subject - no data|2
6294152|NCT02447991|10013257|FG000|Overall Study|Withdrawn by Subject - with data|4
6294153|NCT02447991|10013258|FG001|Overall Study|Withdrawn by Subject - with data|4
6294154|NCT02447991|10013257|FG000|Overall Study|Lost to Follow-up - no data|3
6294155|NCT02447991|10013258|FG001|Overall Study|Lost to Follow-up - no data|6
6294156|NCT02447991|10013257|FG000|Overall Study|Lost to follow-up - with data|0
6294157|NCT02447991|10013258|FG001|Overall Study|Lost to follow-up - with data|3
6294158|NCT02447991|10013257|FG000|Overall Study|End of study - no treatment results|3
6294159|NCT02447991|10013258|FG001|Overall Study|End of study - no treatment results|6
6294160|NCT02447991|10013257|FG000|Overall Study|End of study - partial treatment results|0
6294161|NCT02447991|10013258|FG001|Overall Study|End of study - partial treatment results|9
6294162|NCT02448043|10013270|FG000|Overall Study|Withdrawal by Subject|2
6294163|NCT02448043|10013271|FG001|Overall Study|Withdrawal by Subject|2
6294164|NCT02448043|10013270|FG000|Overall Study|Protocol Violation|1
6294165|NCT02448043|10013271|FG001|Overall Study|Protocol Violation|2
6294166|NCT02448446|10013330|FG000|Overall Study|Withdrawal by Subject|1
6294167|NCT02448446|10013331|FG001|Overall Study|Withdrawal by Subject|0
6294168|NCT02448537|10013340|FG000|Overall Study|Withdrawal by Subject|1
6294169|NCT02448537|10013341|FG001|Overall Study|Withdrawal by Subject|1
6294170|NCT02448537|10013342|FG002|Overall Study|Withdrawal by Subject|1
6294171|NCT02448563|10013354|FG000|Overall Study|Lost to Follow-up|16
6294172|NCT02448563|10013355|FG001|Overall Study|Lost to Follow-up|10
6294173|NCT02448563|10013354|FG000|Overall Study|Withdrawal by Subject|0
6294174|NCT02448563|10013355|FG001|Overall Study|Withdrawal by Subject|1
6294175|NCT02448706|10013394|FG000|Overall Study|Withdrawal by Subject|4
6294176|NCT02448706|10013395|FG001|Overall Study|Withdrawal by Subject|3
6294177|NCT02448706|10013394|FG000|Overall Study|Protocol Violation|1
6294178|NCT02448706|10013395|FG001|Overall Study|Protocol Violation|1
6294179|NCT02448719|10013414|FG000|Overall Study|Withdrawal by Subject|0
6294180|NCT02448719|10013415|FG001|Overall Study|Withdrawal by Subject|0
6294181|NCT02448719|10013416|FG002|Overall Study|Withdrawal by Subject|0
6294182|NCT02448719|10013417|FG003|Overall Study|Withdrawal by Subject|0
6294183|NCT02448719|10013418|FG004|Overall Study|Withdrawal by Subject|1
6294184|NCT02448719|10013419|FG005|Overall Study|Withdrawal by Subject|0
6294185|NCT02448719|10013420|FG006|Overall Study|Withdrawal by Subject|0
6294186|NCT02448719|10013421|FG007|Overall Study|Withdrawal by Subject|0
6294187|NCT02448719|10013422|FG008|Overall Study|Withdrawal by Subject|0
6294188|NCT02448719|10013423|FG009|Overall Study|Withdrawal by Subject|0
6294189|NCT02448719|10013424|FG010|Overall Study|Withdrawal by Subject|0
6294190|NCT02448771|10013485|FG000|Overall Study|Disease Progression|30
6294191|NCT02448771|10013485|FG000|Overall Study|Unacceptable Toxicity|1
6294192|NCT02448771|10013485|FG000|Overall Study|Physician Decision|3
6294193|NCT02448771|10013485|FG000|Overall Study|Started new therapy|2
6294194|NCT02448810|10013498|FG000|Overall Study|Adverse Event|0
6294195|NCT02448810|10013499|FG001|Overall Study|Adverse Event|0
6294196|NCT02448810|10013500|FG002|Overall Study|Adverse Event|1
6294197|NCT02448810|10013501|FG003|Overall Study|Adverse Event|0
6294198|NCT02448810|10013502|FG004|Overall Study|Adverse Event|0
6294199|NCT02448810|10013503|FG005|Overall Study|Adverse Event|0
6294200|NCT02448810|10013504|FG006|Overall Study|Adverse Event|0
6294201|NCT02448810|10013505|FG007|Overall Study|Adverse Event|0
6294202|NCT02448810|10013498|FG000|Overall Study|Withdrawal by Subject|0
6294203|NCT02448810|10013499|FG001|Overall Study|Withdrawal by Subject|0
6294204|NCT02448810|10013500|FG002|Overall Study|Withdrawal by Subject|1
6294205|NCT02448810|10013501|FG003|Overall Study|Withdrawal by Subject|0
6294206|NCT02448810|10013502|FG004|Overall Study|Withdrawal by Subject|3
6294207|NCT02448810|10013503|FG005|Overall Study|Withdrawal by Subject|5
6294208|NCT02448810|10013504|FG006|Overall Study|Withdrawal by Subject|0
6294209|NCT02448810|10013505|FG007|Overall Study|Withdrawal by Subject|2
6294210|NCT02448810|10013498|FG000|Overall Study|Other (study terminated by sponsor)|0
6294211|NCT02448810|10013499|FG001|Overall Study|Other (study terminated by sponsor)|0
6294212|NCT02448810|10013500|FG002|Overall Study|Other (study terminated by sponsor)|0
6294213|NCT02448810|10013501|FG003|Overall Study|Other (study terminated by sponsor)|0
6294214|NCT02448810|10013502|FG004|Overall Study|Other (study terminated by sponsor)|4
6294215|NCT02448810|10013503|FG005|Overall Study|Other (study terminated by sponsor)|2
6294216|NCT02448810|10013504|FG006|Overall Study|Other (study terminated by sponsor)|2
6294217|NCT02448810|10013505|FG007|Overall Study|Other (study terminated by sponsor)|1
6294218|NCT02448810|10013498|FG000|Overall Study|Death|1
6294219|NCT02448810|10013499|FG001|Overall Study|Death|0
6294220|NCT02448810|10013500|FG002|Overall Study|Death|1
6294221|NCT02448810|10013501|FG003|Overall Study|Death|0
6294222|NCT02448810|10013502|FG004|Overall Study|Death|1
6294223|NCT02448810|10013503|FG005|Overall Study|Death|0
6294224|NCT02448810|10013504|FG006|Overall Study|Death|0
6294225|NCT02448810|10013505|FG007|Overall Study|Death|0
6294226|NCT02448810|10013498|FG000|Overall Study|Other (Progressive disease)|2
6294227|NCT02448810|10013499|FG001|Overall Study|Other (Progressive disease)|2
6294228|NCT02448810|10013500|FG002|Overall Study|Other (Progressive disease)|0
6294229|NCT02448810|10013501|FG003|Overall Study|Other (Progressive disease)|3
6294230|NCT02448810|10013502|FG004|Overall Study|Other (Progressive disease)|23
6294231|NCT02448810|10013503|FG005|Overall Study|Other (Progressive disease)|9
6294232|NCT02448810|10013504|FG006|Overall Study|Other (Progressive disease)|14
6294233|NCT02448810|10013505|FG007|Overall Study|Other (Progressive disease)|5
6294234|NCT02448810|10013498|FG000|Overall Study|Lost to Follow-up|0
6294235|NCT02448810|10013499|FG001|Overall Study|Lost to Follow-up|1
6294236|NCT02448810|10013500|FG002|Overall Study|Lost to Follow-up|0
6294237|NCT02448810|10013501|FG003|Overall Study|Lost to Follow-up|0
6294238|NCT02448810|10013502|FG004|Overall Study|Lost to Follow-up|0
6294239|NCT02448810|10013503|FG005|Overall Study|Lost to Follow-up|0
6294240|NCT02448810|10013504|FG006|Overall Study|Lost to Follow-up|0
6294241|NCT02448810|10013505|FG007|Overall Study|Lost to Follow-up|0
6294242|NCT02448810|10013498|FG000|Overall Study|Other (unspecified)|0
6294243|NCT02448810|10013499|FG001|Overall Study|Other (unspecified)|0
6294244|NCT02448810|10013500|FG002|Overall Study|Other (unspecified)|0
6294245|NCT02448810|10013501|FG003|Overall Study|Other (unspecified)|0
6294246|NCT02448810|10013502|FG004|Overall Study|Other (unspecified)|0
6294247|NCT02448810|10013503|FG005|Overall Study|Other (unspecified)|0
6294248|NCT02448810|10013504|FG006|Overall Study|Other (unspecified)|2
6294249|NCT02448810|10013505|FG007|Overall Study|Other (unspecified)|0
6294250|NCT02448875|10013539|FG000|Overall Study|Adverse Event|2
6294251|NCT02448875|10013540|FG001|Overall Study|Adverse Event|1
6294252|NCT02448875|10013541|FG002|Overall Study|Adverse Event|0
6294253|NCT02448875|10013539|FG000|Overall Study|Lost to Follow-up|1
6294254|NCT02448875|10013540|FG001|Overall Study|Lost to Follow-up|0
6294255|NCT02448875|10013541|FG002|Overall Study|Lost to Follow-up|0
6294256|NCT02448875|10013539|FG000|Overall Study|Investigator Decision|3
6294257|NCT02448875|10013540|FG001|Overall Study|Investigator Decision|0
6294258|NCT02448875|10013541|FG002|Overall Study|Investigator Decision|1
6294259|NCT02448875|10013539|FG000|Overall Study|Withdrawal by Subject|1
6294260|NCT02448875|10013540|FG001|Overall Study|Withdrawal by Subject|0
6294261|NCT02448875|10013541|FG002|Overall Study|Withdrawal by Subject|0
6294262|NCT02449018|10013562|FG000|Overall Study|Abnormal laboratory value|0
6294263|NCT02449018|10013563|FG001|Overall Study|Abnormal laboratory value|1
6294264|NCT02449018|10013562|FG000|Overall Study|Administrative problems|1
6294265|NCT02449018|10013563|FG001|Overall Study|Administrative problems|0
6294266|NCT02449018|10013562|FG000|Overall Study|Adverse Event|5
6294267|NCT02449018|10013563|FG001|Overall Study|Adverse Event|1
6294268|NCT02449018|10013562|FG000|Overall Study|Protocol deviation|4
6294269|NCT02449018|10013563|FG001|Overall Study|Protocol deviation|0
6294270|NCT02449018|10013562|FG000|Overall Study|Patient decision|2
6294271|NCT02449018|10013563|FG001|Overall Study|Patient decision|0
6294272|NCT02449044|10013569|FG000|Overall Study|Lost to Follow-up|2
6294273|NCT02449044|10013569|FG000|Overall Study|Withdrawal by Subject|13
6294274|NCT02449044|10013569|FG000|Overall Study|Adverse Event|30
6294275|NCT02449044|10013569|FG000|Overall Study|Met Withdrawal Criteria|7
6294276|NCT02449044|10013569|FG000|Overall Study|Physician Decision|9
6294277|NCT02449044|10013569|FG000|Overall Study|Sponsor Discontinued Trial|3
6136905|NCT01004614|9766981|FG001|Washout|Withdrawal by Subject|1
6294278|NCT02449889|10013634|FG000|Overall Study|Adverse Event|1
6294279|NCT02449889|10013635|FG001|Overall Study|Adverse Event|2
6294280|NCT02449889|10013636|FG002|Overall Study|Adverse Event|0
6294281|NCT02449889|10013634|FG000|Overall Study|Protocol Violation|0
6294282|NCT02449889|10013635|FG001|Overall Study|Protocol Violation|4
6294283|NCT02449889|10013636|FG002|Overall Study|Protocol Violation|1
6294284|NCT02449902|10013646|FG000|Overall Study|Adverse Event|0
6294285|NCT02449902|10013647|FG001|Overall Study|Adverse Event|1
6294286|NCT02449902|10013646|FG000|Overall Study|Withdrawal by Subject|0
6294287|NCT02449902|10013647|FG001|Overall Study|Withdrawal by Subject|1
6294288|NCT02449915|10013657|FG000|Overall Study|Exclusion criteria - drug use|1
6294289|NCT02449915|10013658|FG001|Overall Study|Exclusion criteria - drug use|0
6294290|NCT02449915|10013657|FG000|Overall Study|Withdrawal by Subject|0
6294291|NCT02449915|10013658|FG001|Overall Study|Withdrawal by Subject|2
6294292|NCT02449915|10013657|FG000|Overall Study|Intraoperative surgical findings|1
6294293|NCT02449915|10013658|FG001|Overall Study|Intraoperative surgical findings|1
6294294|NCT02449915|10013657|FG000|Overall Study|Abnormal preop lab|0
6294295|NCT02449915|10013658|FG001|Overall Study|Abnormal preop lab|1
6294296|NCT02450487|10013673|FG000|Overall Study|Lost to Follow-up|3
6294297|NCT02450526|10013682|FG000|DB Period (Cycle 1)|Adverse Event|0
6294298|NCT02450526|10013683|FG001|DB Period (Cycle 1)|Adverse Event|0
6294299|NCT02450526|10013684|FG002|DB Period (Cycle 1)|Adverse Event|2
6294300|NCT02450526|10013685|FG003|DB Period (Cycle 1)|Adverse Event|0
6294301|NCT02450526|10013686|FG004|DB Period (Cycle 1)|Adverse Event|0
6294302|NCT02450526|10013682|FG000|DB Period (Cycle 1)|Withdrawal by Subject|28
6294303|NCT02450526|10013683|FG001|DB Period (Cycle 1)|Withdrawal by Subject|3
6294304|NCT02450526|10013684|FG002|DB Period (Cycle 1)|Withdrawal by Subject|8
6294305|NCT02450526|10013685|FG003|DB Period (Cycle 1)|Withdrawal by Subject|1
6294306|NCT02450526|10013686|FG004|DB Period (Cycle 1)|Withdrawal by Subject|0
6294307|NCT02450526|10013682|FG000|DB Period (Cycle 1)|Lost to Follow-up|1
6294308|NCT02450526|10013683|FG001|DB Period (Cycle 1)|Lost to Follow-up|0
6294309|NCT02450526|10013684|FG002|DB Period (Cycle 1)|Lost to Follow-up|0
6294310|NCT02450526|10013685|FG003|DB Period (Cycle 1)|Lost to Follow-up|0
6294311|NCT02450526|10013686|FG004|DB Period (Cycle 1)|Lost to Follow-up|0
6294312|NCT02450526|10013682|FG000|DB Period (Cycle 1)|Protocol Violation|2
6294313|NCT02450526|10013683|FG001|DB Period (Cycle 1)|Protocol Violation|0
6294314|NCT02450526|10013684|FG002|DB Period (Cycle 1)|Protocol Violation|0
6294315|NCT02450526|10013685|FG003|DB Period (Cycle 1)|Protocol Violation|1
6294316|NCT02450526|10013686|FG004|DB Period (Cycle 1)|Protocol Violation|0
6294317|NCT02450526|10013682|FG000|OL Period (Cycles 2-5)|Adverse Event|0
6294318|NCT02450526|10013683|FG001|OL Period (Cycles 2-5)|Adverse Event|0
6294319|NCT02450526|10013684|FG002|OL Period (Cycles 2-5)|Adverse Event|0
6294320|NCT02450526|10013685|FG003|OL Period (Cycles 2-5)|Adverse Event|0
6294321|NCT02450526|10013686|FG004|OL Period (Cycles 2-5)|Adverse Event|2
6294322|NCT02450526|10013682|FG000|OL Period (Cycles 2-5)|Withdrawal by Subject|0
6294323|NCT02450526|10013683|FG001|OL Period (Cycles 2-5)|Withdrawal by Subject|0
6294324|NCT02450526|10013684|FG002|OL Period (Cycles 2-5)|Withdrawal by Subject|0
6294325|NCT02450526|10013685|FG003|OL Period (Cycles 2-5)|Withdrawal by Subject|0
6294326|NCT02450526|10013686|FG004|OL Period (Cycles 2-5)|Withdrawal by Subject|31
6294327|NCT02450526|10013682|FG000|OL Period (Cycles 2-5)|Lack of Efficacy|0
6294328|NCT02450526|10013683|FG001|OL Period (Cycles 2-5)|Lack of Efficacy|0
6294329|NCT02450526|10013684|FG002|OL Period (Cycles 2-5)|Lack of Efficacy|0
6294330|NCT02450526|10013685|FG003|OL Period (Cycles 2-5)|Lack of Efficacy|0
6294331|NCT02450526|10013686|FG004|OL Period (Cycles 2-5)|Lack of Efficacy|1
6294332|NCT02450526|10013682|FG000|OL Period (Cycles 2-5)|Protocol Violation|0
6294333|NCT02450526|10013683|FG001|OL Period (Cycles 2-5)|Protocol Violation|0
6294334|NCT02450526|10013684|FG002|OL Period (Cycles 2-5)|Protocol Violation|0
6294335|NCT02450526|10013685|FG003|OL Period (Cycles 2-5)|Protocol Violation|0
6294336|NCT02450526|10013686|FG004|OL Period (Cycles 2-5)|Protocol Violation|7
6294337|NCT02450539|10013708|FG000|Overall Study|Withdrawal by Subject|12
6294338|NCT02450539|10013709|FG001|Overall Study|Withdrawal by Subject|6
6294339|NCT02450539|10013708|FG000|Overall Study|Lost to Follow-up|4
6294340|NCT02450539|10013709|FG001|Overall Study|Lost to Follow-up|1
6294341|NCT02450552|10013721|FG000|Overall Study|Withdrawal by Subject|4
6294342|NCT02450552|10013722|FG001|Overall Study|Withdrawal by Subject|0
6294343|NCT02450552|10013723|FG002|Overall Study|Withdrawal by Subject|4
6294344|NCT02450552|10013721|FG000|Overall Study|Physician Decision|1
6294345|NCT02450552|10013722|FG001|Overall Study|Physician Decision|0
6294346|NCT02450552|10013723|FG002|Overall Study|Physician Decision|1
6294347|NCT02450578|10013735|FG000|Overall Study|ECG abnormality so not treated|1
6294348|NCT02450578|10013736|FG001|Overall Study|ECG abnormality so not treated|0
6294349|NCT02450578|10013737|FG002|Overall Study|ECG abnormality so not treated|0
6294350|NCT02450578|10013738|FG003|Overall Study|ECG abnormality so not treated|0
6294351|NCT02450903|10013776|FG000|Overall Study|Adverse Event|3
6294352|NCT02450903|10013776|FG000|Overall Study|Progressive disease|15
6294353|NCT02450903|10013776|FG000|Overall Study|Switched to commercial drug|1
6294354|NCT02450903|10013776|FG000|Overall Study|Subject/guardian decision|1
6294355|NCT02451007|10013780|FG000|Overall Study|Withdrawal by Subject|4
6294356|NCT02451007|10013780|FG000|Overall Study|Adverse Event|1
6294357|NCT02451007|10013780|FG000|Overall Study|Disease Progression|2
6294358|NCT02451124|10013784|FG000|Overall Study|Withdrawal by Subject|1
6294359|NCT02451137|10013794|FG000|Overall Study|Randomized but not treated|19
6294360|NCT02451137|10013795|FG001|Overall Study|Randomized but not treated|27
6294361|NCT02451137|10013794|FG000|Overall Study|Adverse Event|43
6294362|NCT02451137|10013795|FG001|Overall Study|Adverse Event|42
6294363|NCT02451137|10013794|FG000|Overall Study|Lack of Efficacy|4
6294364|NCT02451137|10013795|FG001|Overall Study|Lack of Efficacy|9
6294365|NCT02451137|10013794|FG000|Overall Study|Participant decision:discontinue insulin|41
6294366|NCT02451137|10013795|FG001|Overall Study|Participant decision:discontinue insulin|43
6294367|NCT02451137|10013794|FG000|Overall Study|Hypoglycemia|2
6294368|NCT02451137|10013795|FG001|Overall Study|Hypoglycemia|1
6294369|NCT02451137|10013794|FG000|Overall Study|Investigator's decision|23
6294370|NCT02451137|10013795|FG001|Overall Study|Investigator's decision|19
6294371|NCT02451137|10013794|FG000|Overall Study|Lost to Follow-up|53
6294372|NCT02451137|10013795|FG001|Overall Study|Lost to Follow-up|61
6294373|NCT02451137|10013794|FG000|Overall Study|Physician Decision|6
6294374|NCT02451137|10013795|FG001|Overall Study|Physician Decision|5
6294375|NCT02451137|10013794|FG000|Overall Study|Sponsor decision|13
6294376|NCT02451137|10013795|FG001|Overall Study|Sponsor decision|25
6294377|NCT02451137|10013794|FG000|Overall Study|Withdrawal by Subject|40
6294378|NCT02451137|10013795|FG001|Overall Study|Withdrawal by Subject|63
6294379|NCT02451137|10013794|FG000|Overall Study|Other than specified above|2
6294380|NCT02451137|10013795|FG001|Overall Study|Other than specified above|3
6294381|NCT02451670|10013853|FG000|Overall Study|Did not have qualifying follow-up visit.|714
6294382|NCT02451670|10013854|FG001|Overall Study|Did not have qualifying follow-up visit.|696
6294383|NCT02451696|10013862|FG000|Overall Study|Surgery postponed|1
6294384|NCT02451696|10013863|FG001|Overall Study|Surgery postponed|0
6294385|NCT02451917|10013883|FG000|First Intervention (24 Weeks)|Lost to Follow-up|2
6294386|NCT02451917|10013884|FG001|First Intervention (24 Weeks)|Lost to Follow-up|0
6294387|NCT02451917|10013883|FG000|First Intervention (24 Weeks)|Death|0
6294388|NCT02451917|10013884|FG001|First Intervention (24 Weeks)|Death|1
6294389|NCT02451917|10013883|FG000|First Intervention (24 Weeks)|Adverse Event|0
6294390|NCT02451917|10013884|FG001|First Intervention (24 Weeks)|Adverse Event|2
6294391|NCT02451930|10013896|FG000|Overall Study|Death|0
6294392|NCT02451930|10013897|FG001|Overall Study|Death|15
6294393|NCT02451930|10013896|FG000|Overall Study|Lost to Follow-up|0
6294394|NCT02451930|10013897|FG001|Overall Study|Lost to Follow-up|3
6294395|NCT02451930|10013896|FG000|Overall Study|Sponsor Decision|2
6294396|NCT02451930|10013897|FG001|Overall Study|Sponsor Decision|10
6294397|NCT02451930|10013896|FG000|Overall Study|Withdrawal by Subject|0
6294398|NCT02451930|10013897|FG001|Overall Study|Withdrawal by Subject|1
6294399|NCT02451930|10013896|FG000|Overall Study|Other|0
6294400|NCT02451930|10013897|FG001|Overall Study|Other|1
6294401|NCT02452034|10013928|FG000|Overall Study|Adverse Event|0
6294402|NCT02452034|10013929|FG001|Overall Study|Adverse Event|0
6294403|NCT02452034|10013930|FG002|Overall Study|Adverse Event|0
6294404|NCT02452034|10013931|FG003|Overall Study|Adverse Event|0
6294405|NCT02452034|10013932|FG004|Overall Study|Adverse Event|0
6294406|NCT02452034|10013933|FG005|Overall Study|Adverse Event|1
6294407|NCT02452034|10013928|FG000|Overall Study|Death|0
6294408|NCT02452034|10013929|FG001|Overall Study|Death|0
6294409|NCT02452034|10013930|FG002|Overall Study|Death|0
6294410|NCT02452034|10013931|FG003|Overall Study|Death|0
6294411|NCT02452034|10013932|FG004|Overall Study|Death|1
6294412|NCT02452034|10013933|FG005|Overall Study|Death|1
6294413|NCT02452034|10013928|FG000|Overall Study|Physician Decision|0
6294414|NCT02452034|10013929|FG001|Overall Study|Physician Decision|1
6294415|NCT02452034|10013930|FG002|Overall Study|Physician Decision|1
6294416|NCT02452034|10013931|FG003|Overall Study|Physician Decision|0
6294417|NCT02452034|10013932|FG004|Overall Study|Physician Decision|0
6294418|NCT02452034|10013933|FG005|Overall Study|Physician Decision|0
6294419|NCT02452034|10013928|FG000|Overall Study|Protocol Violation|0
6294420|NCT02452034|10013929|FG001|Overall Study|Protocol Violation|0
6294421|NCT02452034|10013930|FG002|Overall Study|Protocol Violation|0
6294422|NCT02452034|10013931|FG003|Overall Study|Protocol Violation|0
6294423|NCT02452034|10013932|FG004|Overall Study|Protocol Violation|0
6294424|NCT02452034|10013933|FG005|Overall Study|Protocol Violation|1
6294425|NCT02452034|10013928|FG000|Overall Study|Screen Failure|1
6294426|NCT02452034|10013929|FG001|Overall Study|Screen Failure|0
6294427|NCT02452034|10013930|FG002|Overall Study|Screen Failure|0
6294428|NCT02452034|10013931|FG003|Overall Study|Screen Failure|1
6294429|NCT02452034|10013932|FG004|Overall Study|Screen Failure|0
6294430|NCT02452034|10013933|FG005|Overall Study|Screen Failure|0
6294431|NCT02452034|10013928|FG000|Overall Study|Withdrawn by Parent/Guardian|1
6294432|NCT02452034|10013929|FG001|Overall Study|Withdrawn by Parent/Guardian|0
6294433|NCT02452034|10013930|FG002|Overall Study|Withdrawn by Parent/Guardian|0
6294434|NCT02452034|10013931|FG003|Overall Study|Withdrawn by Parent/Guardian|0
6294435|NCT02452034|10013932|FG004|Overall Study|Withdrawn by Parent/Guardian|0
6294436|NCT02452034|10013933|FG005|Overall Study|Withdrawn by Parent/Guardian|0
6294437|NCT02452047|10013950|FG000|Overall Study|Adverse Event|0
6294438|NCT02452047|10013951|FG001|Overall Study|Adverse Event|1
6294439|NCT02452047|10013952|FG002|Overall Study|Adverse Event|1
6294440|NCT02452047|10013950|FG000|Overall Study|Death|1
6294441|NCT02452047|10013951|FG001|Overall Study|Death|3
6294442|NCT02452047|10013952|FG002|Overall Study|Death|1
6294443|NCT02452047|10013950|FG000|Overall Study|Physician Decision|1
6294444|NCT02452047|10013951|FG001|Overall Study|Physician Decision|0
6294445|NCT02452047|10013952|FG002|Overall Study|Physician Decision|0
6294446|NCT02452047|10013950|FG000|Overall Study|Lost to Follow-up|1
6294447|NCT02452047|10013951|FG001|Overall Study|Lost to Follow-up|1
6294448|NCT02452047|10013952|FG002|Overall Study|Lost to Follow-up|0
6294449|NCT02452047|10013950|FG000|Overall Study|Withdrawal by Subject|1
6294450|NCT02452047|10013951|FG001|Overall Study|Withdrawal by Subject|0
6294451|NCT02452047|10013952|FG002|Overall Study|Withdrawal by Subject|0
6294452|NCT02452190|10013971|FG000|Overall Study|Withdrawal by Sponsor|1
6294453|NCT02452190|10013972|FG001|Overall Study|Withdrawal by Sponsor|3
6294454|NCT02452190|10013971|FG000|Overall Study|Pregnancy|1
6294455|NCT02452190|10013972|FG001|Overall Study|Pregnancy|0
6294456|NCT02452190|10013971|FG000|Overall Study|Investigator's Decision|2
6294457|NCT02452190|10013972|FG001|Overall Study|Investigator's Decision|0
6294458|NCT02452190|10013971|FG000|Overall Study|Lack of Efficacy|3
6294459|NCT02452190|10013972|FG001|Overall Study|Lack of Efficacy|1
6294460|NCT02452190|10013971|FG000|Overall Study|Lost to Follow-up|4
6294461|NCT02452190|10013972|FG001|Overall Study|Lost to Follow-up|3
6294462|NCT02452190|10013971|FG000|Overall Study|Adverse Event|2
6294463|NCT02452190|10013972|FG001|Overall Study|Adverse Event|5
6294464|NCT02452190|10013971|FG000|Overall Study|Withdrawal by Subject|20
6294465|NCT02452190|10013972|FG001|Overall Study|Withdrawal by Subject|11
6294466|NCT02452190|10013971|FG000|Overall Study|Noncompliance with study drug|1
6294467|NCT02452190|10013972|FG001|Overall Study|Noncompliance with study drug|0
6294468|NCT02452190|10013971|FG000|Overall Study|Participant traveled abroad|1
6294469|NCT02452190|10013972|FG001|Overall Study|Participant traveled abroad|0
6294470|NCT02452190|10013971|FG000|Overall Study|Death|0
6294471|NCT02452190|10013972|FG001|Overall Study|Death|1
6294472|NCT02452320|10013980|FG000|Overall Study|Adverse Event|0
6294473|NCT02452320|10013981|FG001|Overall Study|Adverse Event|1
6294474|NCT02452424|10014002|FG000|Overall Study|Death|2
6294475|NCT02452424|10014003|FG001|Overall Study|Death|2
6294476|NCT02452424|10014004|FG002|Overall Study|Death|2
6294477|NCT02452424|10014005|FG003|Overall Study|Death|6
6294478|NCT02452424|10014006|FG004|Overall Study|Death|2
6294479|NCT02452424|10014007|FG005|Overall Study|Death|0
6294480|NCT02452424|10014008|FG006|Overall Study|Death|5
6294481|NCT02452424|10014009|FG007|Overall Study|Death|1
6294482|NCT02452424|10014010|FG008|Overall Study|Death|3
6294483|NCT02452424|10014011|FG009|Overall Study|Death|1
6294484|NCT02452424|10014012|FG010|Overall Study|Death|0
6294485|NCT02452424|10014002|FG000|Overall Study|Lost to Follow-up|0
6294486|NCT02452424|10014003|FG001|Overall Study|Lost to Follow-up|1
6294487|NCT02452424|10014004|FG002|Overall Study|Lost to Follow-up|1
6294488|NCT02452424|10014005|FG003|Overall Study|Lost to Follow-up|0
6294489|NCT02452424|10014006|FG004|Overall Study|Lost to Follow-up|0
6294490|NCT02452424|10014007|FG005|Overall Study|Lost to Follow-up|0
6294491|NCT02452424|10014008|FG006|Overall Study|Lost to Follow-up|0
6294492|NCT02452424|10014009|FG007|Overall Study|Lost to Follow-up|0
6294493|NCT02452424|10014010|FG008|Overall Study|Lost to Follow-up|0
6294494|NCT02452424|10014011|FG009|Overall Study|Lost to Follow-up|0
6294495|NCT02452424|10014012|FG010|Overall Study|Lost to Follow-up|0
6294496|NCT02452424|10014002|FG000|Overall Study|Withdrawal by Subject|0
6294497|NCT02452424|10014003|FG001|Overall Study|Withdrawal by Subject|0
6294498|NCT02452424|10014004|FG002|Overall Study|Withdrawal by Subject|3
6294499|NCT02452424|10014005|FG003|Overall Study|Withdrawal by Subject|2
6294500|NCT02452424|10014006|FG004|Overall Study|Withdrawal by Subject|0
6294501|NCT02452424|10014007|FG005|Overall Study|Withdrawal by Subject|0
6294502|NCT02452424|10014008|FG006|Overall Study|Withdrawal by Subject|1
6294503|NCT02452424|10014009|FG007|Overall Study|Withdrawal by Subject|0
6294504|NCT02452424|10014010|FG008|Overall Study|Withdrawal by Subject|1
6294505|NCT02452424|10014011|FG009|Overall Study|Withdrawal by Subject|1
6294506|NCT02452424|10014012|FG010|Overall Study|Withdrawal by Subject|0
6294507|NCT02452424|10014002|FG000|Overall Study|Other|0
6294508|NCT02452424|10014003|FG001|Overall Study|Other|0
6294509|NCT02452424|10014004|FG002|Overall Study|Other|1
6294510|NCT02452424|10014005|FG003|Overall Study|Other|0
6294511|NCT02452424|10014006|FG004|Overall Study|Other|0
6294512|NCT02452424|10014007|FG005|Overall Study|Other|1
6294513|NCT02452424|10014008|FG006|Overall Study|Other|4
6294514|NCT02452424|10014009|FG007|Overall Study|Other|3
6294515|NCT02452424|10014010|FG008|Overall Study|Other|0
6294516|NCT02452424|10014011|FG009|Overall Study|Other|0
6294517|NCT02452424|10014012|FG010|Overall Study|Other|1
6294518|NCT02452424|10014002|FG000|Overall Study|Progressive disease (per RECIST)|0
6294519|NCT02452424|10014003|FG001|Overall Study|Progressive disease (per RECIST)|0
6294520|NCT02452424|10014004|FG002|Overall Study|Progressive disease (per RECIST)|0
6294521|NCT02452424|10014005|FG003|Overall Study|Progressive disease (per RECIST)|0
6294522|NCT02452424|10014006|FG004|Overall Study|Progressive disease (per RECIST)|0
6294523|NCT02452424|10014007|FG005|Overall Study|Progressive disease (per RECIST)|0
6294524|NCT02452424|10014008|FG006|Overall Study|Progressive disease (per RECIST)|0
6294525|NCT02452424|10014009|FG007|Overall Study|Progressive disease (per RECIST)|0
6294526|NCT02452424|10014010|FG008|Overall Study|Progressive disease (per RECIST)|2
6294527|NCT02452424|10014011|FG009|Overall Study|Progressive disease (per RECIST)|0
6294528|NCT02452424|10014012|FG010|Overall Study|Progressive disease (per RECIST)|0
6294529|NCT02452424|10014002|FG000|Overall Study|Adverse Event|0
6294530|NCT02452424|10014003|FG001|Overall Study|Adverse Event|0
6294531|NCT02452424|10014004|FG002|Overall Study|Adverse Event|0
6294532|NCT02452424|10014005|FG003|Overall Study|Adverse Event|0
6294533|NCT02452424|10014006|FG004|Overall Study|Adverse Event|0
6294534|NCT02452424|10014007|FG005|Overall Study|Adverse Event|0
6294535|NCT02452424|10014008|FG006|Overall Study|Adverse Event|0
6294536|NCT02452424|10014009|FG007|Overall Study|Adverse Event|0
6294537|NCT02452424|10014010|FG008|Overall Study|Adverse Event|0
6294538|NCT02452424|10014011|FG009|Overall Study|Adverse Event|0
6294539|NCT02452424|10014012|FG010|Overall Study|Adverse Event|1
6294540|NCT02452463|10014041|FG000|Overall Study|Death|1
6294541|NCT02452463|10014042|FG001|Overall Study|Death|0
6294542|NCT02452463|10014043|FG002|Overall Study|Death|0
6294543|NCT02452463|10014041|FG000|Overall Study|Study Suspended|1
6294544|NCT02452463|10014042|FG001|Overall Study|Study Suspended|0
6294545|NCT02452463|10014043|FG002|Overall Study|Study Suspended|0
6294546|NCT02452463|10014041|FG000|Overall Study|Recommended by DSMB|0
6294547|NCT02452463|10014042|FG001|Overall Study|Recommended by DSMB|1
6294548|NCT02452463|10014043|FG002|Overall Study|Recommended by DSMB|0
6294549|NCT02452463|10014041|FG000|Overall Study|Withdrawal by Subject|0
6294550|NCT02452463|10014042|FG001|Overall Study|Withdrawal by Subject|1
6294551|NCT02452463|10014043|FG002|Overall Study|Withdrawal by Subject|0
6294552|NCT02452476|10014053|FG000|Overall Study|Death|4
6294553|NCT02452476|10014054|FG001|Overall Study|Death|7
6294554|NCT02452476|10014053|FG000|Overall Study|Lost to Follow-up|1
6294555|NCT02452476|10014054|FG001|Overall Study|Lost to Follow-up|1
6294556|NCT02452476|10014053|FG000|Overall Study|Physician Decision|1
6294557|NCT02452476|10014054|FG001|Overall Study|Physician Decision|1
6294558|NCT02452476|10014053|FG000|Overall Study|Not treated|5
6294559|NCT02452476|10014054|FG001|Overall Study|Not treated|1
6294560|NCT02452762|10014071|FG000|Overall Study|Received >1 loading dose of cholecalciferol and analyzed separately|4
6294561|NCT02452762|10014072|FG001|Overall Study|Received >1 loading dose of cholecalciferol and analyzed separately|3
6294562|NCT02452762|10014071|FG000|Overall Study|Withdrawal by Subject|1
6294563|NCT02452762|10014072|FG001|Overall Study|Withdrawal by Subject|0
6294564|NCT02452892|10014087|FG000|Week 1 Initial Randommization|Adverse Event|1
6294565|NCT02452892|10014088|FG001|Week 1 Initial Randommization|Adverse Event|0
6294566|NCT02452892|10014089|FG002|Week 1 Initial Randommization|Adverse Event|0
6294567|NCT02452892|10014090|FG003|Week 1 Initial Randommization|Adverse Event|0
6294568|NCT02452892|10014087|FG000|Week 1 Initial Randommization|Lost to Follow-up|0
6294569|NCT02452892|10014088|FG001|Week 1 Initial Randommization|Lost to Follow-up|0
6294570|NCT02452892|10014089|FG002|Week 1 Initial Randommization|Lost to Follow-up|1
6294571|NCT02452892|10014090|FG003|Week 1 Initial Randommization|Lost to Follow-up|0
6294572|NCT02452892|10014087|FG000|Week 2 Stratification & Re-Randomization|Withdrawal by Subject|0
6294573|NCT02452892|10014088|FG001|Week 2 Stratification & Re-Randomization|Withdrawal by Subject|0
6294574|NCT02452892|10014089|FG002|Week 2 Stratification & Re-Randomization|Withdrawal by Subject|0
6294575|NCT02452892|10014090|FG003|Week 2 Stratification & Re-Randomization|Withdrawal by Subject|2
6294576|NCT02452892|10014087|FG000|Week 2 Stratification & Re-Randomization|Lost to Follow-up|2
6294577|NCT02452892|10014088|FG001|Week 2 Stratification & Re-Randomization|Lost to Follow-up|0
6294578|NCT02452892|10014089|FG002|Week 2 Stratification & Re-Randomization|Lost to Follow-up|0
6294579|NCT02452892|10014090|FG003|Week 2 Stratification & Re-Randomization|Lost to Follow-up|0
6294580|NCT02452892|10014087|FG000|Follow-up|Withdrawal by Subject|0
6294581|NCT02452892|10014088|FG001|Follow-up|Withdrawal by Subject|0
6294582|NCT02452892|10014089|FG002|Follow-up|Withdrawal by Subject|0
6294583|NCT02452892|10014090|FG003|Follow-up|Withdrawal by Subject|1
6294584|NCT02452892|10014087|FG000|Follow-up|Subject left town on Day 42|1
6294585|NCT02452892|10014088|FG001|Follow-up|Subject left town on Day 42|0
6294586|NCT02452892|10014089|FG002|Follow-up|Subject left town on Day 42|0
6294587|NCT02452892|10014090|FG003|Follow-up|Subject left town on Day 42|0
6294588|NCT02453048|10014123|FG000|Overall Study|Only part of initial 6 mo. study|0
6294589|NCT02453048|10014124|FG001|Overall Study|Only part of initial 6 mo. study|0
6294590|NCT02453048|10014125|FG002|Overall Study|Only part of initial 6 mo. study|0
6294591|NCT02453048|10014126|FG003|Overall Study|Only part of initial 6 mo. study|0
6294592|NCT02453048|10014127|FG004|Overall Study|Only part of initial 6 mo. study|6
6294593|NCT02453048|10014123|FG000|Overall Study|Lost to Follow-up|0
6294594|NCT02453048|10014124|FG001|Overall Study|Lost to Follow-up|1
6294595|NCT02453048|10014125|FG002|Overall Study|Lost to Follow-up|2
6294596|NCT02453048|10014126|FG003|Overall Study|Lost to Follow-up|0
6294597|NCT02453048|10014127|FG004|Overall Study|Lost to Follow-up|0
6294598|NCT02453191|10014143|FG000|Overall Study|Withdrawal by Subject|1
6294599|NCT02453256|10014149|FG000|Double Blind Period|Death|1
6294600|NCT02453256|10014150|FG001|Double Blind Period|Death|1
6294601|NCT02453256|10014149|FG000|Double Blind Period|Adverse Event|3
6294602|NCT02453256|10014150|FG001|Double Blind Period|Adverse Event|2
6294603|NCT02453256|10014149|FG000|Double Blind Period|Withdrawal by Subject|9
6294604|NCT02453256|10014150|FG001|Double Blind Period|Withdrawal by Subject|5
6294605|NCT02453256|10014149|FG000|Double Blind Period|Other|0
6294606|NCT02453256|10014150|FG001|Double Blind Period|Other|1
6294607|NCT02453256|10014149|FG000|Open Label Period|Adverse Event|1
6294608|NCT02453256|10014150|FG001|Open Label Period|Adverse Event|3
6294609|NCT02453256|10014149|FG000|Open Label Period|Death|0
6294610|NCT02453256|10014150|FG001|Open Label Period|Death|1
6294611|NCT02453256|10014149|FG000|Open Label Period|Lost to Follow-up|1
6294612|NCT02453256|10014150|FG001|Open Label Period|Lost to Follow-up|0
6294613|NCT02453256|10014149|FG000|Open Label Period|Other|0
6294614|NCT02453256|10014150|FG001|Open Label Period|Other|2
6294615|NCT02453256|10014149|FG000|Open Label Period|Withdrawal by Subject|5
6294616|NCT02453256|10014150|FG001|Open Label Period|Withdrawal by Subject|1
6294617|NCT02453282|10014166|FG000|Overall Study|Death|275
6294618|NCT02453282|10014167|FG001|Overall Study|Death|277
6294619|NCT02453282|10014168|FG002|Overall Study|Death|296
6294620|NCT02453282|10014166|FG000|Overall Study|Lost to Follow-up|1
6294621|NCT02453282|10014167|FG001|Overall Study|Lost to Follow-up|0
6294622|NCT02453282|10014168|FG002|Overall Study|Lost to Follow-up|2
6294623|NCT02453282|10014166|FG000|Overall Study|Withdrawal by Subject|12
6294624|NCT02453282|10014167|FG001|Overall Study|Withdrawal by Subject|10
6294625|NCT02453282|10014168|FG002|Overall Study|Withdrawal by Subject|11
6294626|NCT02453282|10014166|FG000|Overall Study|Participants ongoing at data cut-off|85
6294627|NCT02453282|10014167|FG001|Overall Study|Participants ongoing at data cut-off|84
6294628|NCT02453282|10014168|FG002|Overall Study|Participants ongoing at data cut-off|62
6294629|NCT02453282|10014166|FG000|Overall Study|Other|1
6294630|NCT02453282|10014167|FG001|Overall Study|Other|1
6294631|NCT02453282|10014168|FG002|Overall Study|Other|1
6294632|NCT02453321|10014181|FG000|Overall Study|Weakness|1
6294633|NCT02453321|10014182|FG001|Overall Study|Weakness|1
6294634|NCT02453321|10014183|FG002|Overall Study|Weakness|2
6294635|NCT02453321|10014181|FG000|Overall Study|Deep Venous Thrombosis|0
6294636|NCT02453321|10014182|FG001|Overall Study|Deep Venous Thrombosis|1
6294637|NCT02453321|10014183|FG002|Overall Study|Deep Venous Thrombosis|0
6294638|NCT02453334|10014196|FG000|Overall Study|Death|15
6294639|NCT02453334|10014197|FG001|Overall Study|Death|13
6294640|NCT02453334|10014196|FG000|Overall Study|Adverse Event|2
6294641|NCT02453334|10014197|FG001|Overall Study|Adverse Event|1
6294642|NCT02453334|10014196|FG000|Overall Study|Lost to Follow-up|5
6294643|NCT02453334|10014197|FG001|Overall Study|Lost to Follow-up|9
6294644|NCT02453334|10014196|FG000|Overall Study|Physician Decision|1
6294645|NCT02453334|10014197|FG001|Overall Study|Physician Decision|0
6294646|NCT02453334|10014196|FG000|Overall Study|Withdrawal by Subject|17
6294647|NCT02453334|10014197|FG001|Overall Study|Withdrawal by Subject|13
6294648|NCT02453334|10014196|FG000|Overall Study|Other reason|1
6294649|NCT02453334|10014197|FG001|Overall Study|Other reason|4
6294650|NCT02453386|10014223|FG000|Overall Study|Adverse Event|22
6294651|NCT02453386|10014224|FG001|Overall Study|Adverse Event|30
6294652|NCT02453386|10014225|FG002|Overall Study|Adverse Event|15
6294653|NCT02453386|10014223|FG000|Overall Study|Protocol Violation|1
6294654|NCT02453386|10014224|FG001|Overall Study|Protocol Violation|0
6294655|NCT02453386|10014225|FG002|Overall Study|Protocol Violation|1
6294656|NCT02453386|10014223|FG000|Overall Study|Withdrawal by Subject|10
6294657|NCT02453386|10014224|FG001|Overall Study|Withdrawal by Subject|9
6294658|NCT02453386|10014225|FG002|Overall Study|Withdrawal by Subject|9
6294659|NCT02453386|10014223|FG000|Overall Study|Sponsor Terminated Study|14
6294660|NCT02453386|10014224|FG001|Overall Study|Sponsor Terminated Study|8
6294661|NCT02453386|10014225|FG002|Overall Study|Sponsor Terminated Study|11
6294662|NCT02453386|10014223|FG000|Overall Study|Subject Terminated by Sponsor|1
6294663|NCT02453386|10014224|FG001|Overall Study|Subject Terminated by Sponsor|1
6294664|NCT02453386|10014225|FG002|Overall Study|Subject Terminated by Sponsor|1
6294665|NCT02453386|10014223|FG000|Overall Study|Sponsor Terminated by Investigator|0
6294666|NCT02453386|10014224|FG001|Overall Study|Sponsor Terminated by Investigator|1
6294667|NCT02453386|10014225|FG002|Overall Study|Sponsor Terminated by Investigator|2
6294668|NCT02453386|10014223|FG000|Overall Study|Lost to Follow-up|0
6294669|NCT02453386|10014224|FG001|Overall Study|Lost to Follow-up|0
6294670|NCT02453386|10014225|FG002|Overall Study|Lost to Follow-up|1
6294671|NCT02453386|10014223|FG000|Overall Study|Other|1
6294672|NCT02453386|10014224|FG001|Overall Study|Other|0
6294673|NCT02453386|10014225|FG002|Overall Study|Other|1
6294674|NCT02453555|10014242|FG000|24-week Double-blind Treatment Period|Adverse Event|2
6294675|NCT02453555|10014243|FG001|24-week Double-blind Treatment Period|Adverse Event|0
6294676|NCT02453555|10014244|FG002|24-week Double-blind Treatment Period|Adverse Event|0
6294677|NCT02453555|10014245|FG003|24-week Double-blind Treatment Period|Adverse Event|0
6294678|NCT02453555|10014246|FG004|24-week Double-blind Treatment Period|Adverse Event|0
6294679|NCT02453555|10014247|FG005|24-week Double-blind Treatment Period|Adverse Event|0
6294680|NCT02453555|10014242|FG000|24-week Double-blind Treatment Period|Lost to Follow-up|1
6294681|NCT02453555|10014243|FG001|24-week Double-blind Treatment Period|Lost to Follow-up|0
6294682|NCT02453555|10014244|FG002|24-week Double-blind Treatment Period|Lost to Follow-up|0
6294683|NCT02453555|10014245|FG003|24-week Double-blind Treatment Period|Lost to Follow-up|0
6294684|NCT02453555|10014246|FG004|24-week Double-blind Treatment Period|Lost to Follow-up|0
6294685|NCT02453555|10014247|FG005|24-week Double-blind Treatment Period|Lost to Follow-up|0
6294686|NCT02453555|10014242|FG000|24-week Double-blind Treatment Period|Withdrawal by Subject|2
6294687|NCT02453555|10014243|FG001|24-week Double-blind Treatment Period|Withdrawal by Subject|4
6294688|NCT02453555|10014244|FG002|24-week Double-blind Treatment Period|Withdrawal by Subject|0
6294689|NCT02453555|10014245|FG003|24-week Double-blind Treatment Period|Withdrawal by Subject|0
6294690|NCT02453555|10014246|FG004|24-week Double-blind Treatment Period|Withdrawal by Subject|0
6294691|NCT02453555|10014247|FG005|24-week Double-blind Treatment Period|Withdrawal by Subject|0
6294692|NCT02453555|10014242|FG000|24-week Double-blind Treatment Period|Other than specified above|0
6294693|NCT02453555|10014243|FG001|24-week Double-blind Treatment Period|Other than specified above|3
6294694|NCT02453555|10014244|FG002|24-week Double-blind Treatment Period|Other than specified above|0
6294695|NCT02453555|10014245|FG003|24-week Double-blind Treatment Period|Other than specified above|0
6294696|NCT02453555|10014246|FG004|24-week Double-blind Treatment Period|Other than specified above|0
6294697|NCT02453555|10014247|FG005|24-week Double-blind Treatment Period|Other than specified above|0
6294698|NCT02453555|10014242|FG000|Extension Period|Adverse Event|0
6294699|NCT02453555|10014243|FG001|Extension Period|Adverse Event|0
6294700|NCT02453555|10014244|FG002|Extension Period|Adverse Event|1
6294701|NCT02453555|10014245|FG003|Extension Period|Adverse Event|2
6294702|NCT02453555|10014246|FG004|Extension Period|Adverse Event|1
6294703|NCT02453555|10014247|FG005|Extension Period|Adverse Event|1
6294704|NCT02453555|10014242|FG000|Extension Period|Protocol Violation|0
6294705|NCT02453555|10014243|FG001|Extension Period|Protocol Violation|0
6294706|NCT02453555|10014244|FG002|Extension Period|Protocol Violation|1
6294707|NCT02453555|10014245|FG003|Extension Period|Protocol Violation|0
6294708|NCT02453555|10014246|FG004|Extension Period|Protocol Violation|0
6294709|NCT02453555|10014247|FG005|Extension Period|Protocol Violation|0
6294710|NCT02453555|10014242|FG000|Extension Period|Withdrawal by Subject|0
6294711|NCT02453555|10014243|FG001|Extension Period|Withdrawal by Subject|0
6294712|NCT02453555|10014244|FG002|Extension Period|Withdrawal by Subject|1
6294713|NCT02453555|10014245|FG003|Extension Period|Withdrawal by Subject|0
6294714|NCT02453555|10014246|FG004|Extension Period|Withdrawal by Subject|0
6294715|NCT02453555|10014247|FG005|Extension Period|Withdrawal by Subject|0
6294716|NCT02453685|10014291|FG000|Overall Study|Adverse Event|0
6294717|NCT02453685|10014292|FG001|Overall Study|Adverse Event|1
6294718|NCT02453685|10014291|FG000|Overall Study|Protocol Violation|7
6294719|NCT02453685|10014292|FG001|Overall Study|Protocol Violation|4
6294720|NCT02453685|10014291|FG000|Overall Study|Lost to Follow-up|0
6294721|NCT02453685|10014292|FG001|Overall Study|Lost to Follow-up|1
6294722|NCT02453685|10014291|FG000|Overall Study|Withdrawal by Subject|8
6294723|NCT02453685|10014292|FG001|Overall Study|Withdrawal by Subject|4
5981418|NCT00968201|9570366|FG002|Extension Study - (Period III)|Protocol Violation|14
5981419|NCT00968201|9570364|FG000|Extension Study - (Period III)|Withdrawal by Subject|0
5981420|NCT00968201|9570365|FG001|Extension Study - (Period III)|Withdrawal by Subject|20
5981421|NCT00968201|9570366|FG002|Extension Study - (Period III)|Withdrawal by Subject|40
5981422|NCT00968201|9570364|FG000|Extension Study - (Period III)|Patient Relocated|0
5981423|NCT00968201|9570365|FG001|Extension Study - (Period III)|Patient Relocated|1
5981424|NCT00968201|9570366|FG002|Extension Study - (Period III)|Patient Relocated|1
5981425|NCT00968201|9570364|FG000|Extension Study - (Period III)|Noncompliance|0
5981426|NCT00968201|9570365|FG001|Extension Study - (Period III)|Noncompliance|0
5981427|NCT00968201|9570366|FG002|Extension Study - (Period III)|Noncompliance|3
5981428|NCT00968201|9570364|FG000|Extension Study - (Period III)|Other|0
5981429|NCT00968201|9570365|FG001|Extension Study - (Period III)|Other|0
5981430|NCT00968201|9570366|FG002|Extension Study - (Period III)|Other|2
5981431|NCT00968201|9570364|FG000|Extension Study - (Period III)|Study Terminated for Admin Reasons|0
5981432|NCT00968201|9570365|FG001|Extension Study - (Period III)|Study Terminated for Admin Reasons|74
5981433|NCT00968201|9570366|FG002|Extension Study - (Period III)|Study Terminated for Admin Reasons|185
5981434|NCT00968149|9570377|FG000|Overall Study|Adverse Event|5
5981435|NCT00968149|9570378|FG001|Overall Study|Adverse Event|1
5981436|NCT00968149|9570377|FG000|Overall Study|Lack of Efficacy|0
5981437|NCT00968149|9570378|FG001|Overall Study|Lack of Efficacy|4
5981438|NCT00968149|9570377|FG000|Overall Study|Lost to Follow-up|0
5981439|NCT00968149|9570378|FG001|Overall Study|Lost to Follow-up|1
5981440|NCT00968149|9570377|FG000|Overall Study|Protocol Violation|4
5981441|NCT00968149|9570378|FG001|Overall Study|Protocol Violation|0
5981442|NCT00968149|9570377|FG000|Overall Study|Withdrawal by Subject|2
5981443|NCT00968149|9570378|FG001|Overall Study|Withdrawal by Subject|0
6063498|NCT00506415|9664784|FG000|Double Blind (Maximum 48 Weeks )|Lost to Follow-up|0
6063499|NCT00506415|9664785|FG001|Double Blind (Maximum 48 Weeks )|Lost to Follow-up|4
6063500|NCT00506415|9664786|FG002|Double Blind (Maximum 48 Weeks )|Lost to Follow-up|6
6063501|NCT00506415|9664787|FG003|Double Blind (Maximum 48 Weeks )|Lost to Follow-up|0
6063502|NCT00506415|9664784|FG000|Double Blind (Maximum 48 Weeks )|Withdrawal by Subject|0
6063503|NCT00506415|9664785|FG001|Double Blind (Maximum 48 Weeks )|Withdrawal by Subject|20
6063504|NCT00506415|9664786|FG002|Double Blind (Maximum 48 Weeks )|Withdrawal by Subject|17
6063505|NCT00506415|9664787|FG003|Double Blind (Maximum 48 Weeks )|Withdrawal by Subject|0
6063506|NCT00506415|9664784|FG000|Double Blind (Maximum 48 Weeks )|Administrative problems|0
6063507|NCT00506415|9664785|FG001|Double Blind (Maximum 48 Weeks )|Administrative problems|3
6063508|NCT00506415|9664786|FG002|Double Blind (Maximum 48 Weeks )|Administrative problems|2
6063509|NCT00506415|9664787|FG003|Double Blind (Maximum 48 Weeks )|Administrative problems|0
6063510|NCT00506415|9664784|FG000|Double Blind (Maximum 48 Weeks )|Condition no longer requires study drug|0
6063511|NCT00506415|9664785|FG001|Double Blind (Maximum 48 Weeks )|Condition no longer requires study drug|0
6063512|NCT00506415|9664786|FG002|Double Blind (Maximum 48 Weeks )|Condition no longer requires study drug|1
6063513|NCT00506415|9664787|FG003|Double Blind (Maximum 48 Weeks )|Condition no longer requires study drug|0
6136906|NCT01004614|9766982|FG002|Washout|Withdrawal by Subject|0
6294724|NCT02453685|10014291|FG000|Overall Study|Unclassified|4
6294725|NCT02453685|10014292|FG001|Overall Study|Unclassified|2
6294726|NCT02453711|10014307|FG000|Overall Study|Withdrawal by Subject|5
6294727|NCT02453711|10014308|FG001|Overall Study|Withdrawal by Subject|4
6294728|NCT02453711|10014309|FG002|Overall Study|Withdrawal by Subject|6
6294729|NCT02453711|10014310|FG003|Overall Study|Withdrawal by Subject|4
6294730|NCT02453711|10014311|FG004|Overall Study|Withdrawal by Subject|1
6294731|NCT02453711|10014312|FG005|Overall Study|Withdrawal by Subject|1
6294732|NCT02453711|10014313|FG006|Overall Study|Withdrawal by Subject|0
6294733|NCT02453711|10014314|FG007|Overall Study|Withdrawal by Subject|1
6294734|NCT02453711|10014315|FG008|Overall Study|Withdrawal by Subject|7
6294735|NCT02453711|10014307|FG000|Overall Study|Lost to Follow-up|5
6294736|NCT02453711|10014308|FG001|Overall Study|Lost to Follow-up|3
6294737|NCT02453711|10014309|FG002|Overall Study|Lost to Follow-up|2
6294738|NCT02453711|10014310|FG003|Overall Study|Lost to Follow-up|3
6294739|NCT02453711|10014311|FG004|Overall Study|Lost to Follow-up|1
6294740|NCT02453711|10014312|FG005|Overall Study|Lost to Follow-up|5
6294741|NCT02453711|10014313|FG006|Overall Study|Lost to Follow-up|2
6294742|NCT02453711|10014314|FG007|Overall Study|Lost to Follow-up|6
6294743|NCT02453711|10014315|FG008|Overall Study|Lost to Follow-up|6
6294744|NCT02453711|10014307|FG000|Overall Study|Death|0
6294745|NCT02453711|10014308|FG001|Overall Study|Death|0
6294746|NCT02453711|10014309|FG002|Overall Study|Death|0
6294747|NCT02453711|10014310|FG003|Overall Study|Death|0
6294748|NCT02453711|10014311|FG004|Overall Study|Death|0
6294749|NCT02453711|10014312|FG005|Overall Study|Death|0
6294750|NCT02453711|10014313|FG006|Overall Study|Death|1
6294751|NCT02453711|10014314|FG007|Overall Study|Death|0
6294752|NCT02453711|10014315|FG008|Overall Study|Death|0
6294753|NCT02453711|10014307|FG000|Overall Study|Unclassified|1
6294754|NCT02453711|10014308|FG001|Overall Study|Unclassified|0
6294755|NCT02453711|10014309|FG002|Overall Study|Unclassified|1
6294756|NCT02453711|10014310|FG003|Overall Study|Unclassified|0
6294757|NCT02453711|10014311|FG004|Overall Study|Unclassified|0
6294758|NCT02453711|10014312|FG005|Overall Study|Unclassified|0
6294759|NCT02453711|10014313|FG006|Overall Study|Unclassified|0
6294760|NCT02453711|10014314|FG007|Overall Study|Unclassified|0
6294761|NCT02453711|10014315|FG008|Overall Study|Unclassified|0
6294762|NCT02453841|10014342|FG000|Overall Study|Protocol Violation|1
6294763|NCT02453841|10014342|FG000|Overall Study|Unable to obtain blood samples|2
6294764|NCT02454101|10014354|FG000|Overall Study|Adverse Event|2
6294765|NCT02454101|10014355|FG001|Overall Study|Adverse Event|3
6294766|NCT02454101|10014354|FG000|Overall Study|Lost to Follow-up|3
6294767|NCT02454101|10014355|FG001|Overall Study|Lost to Follow-up|4
6294768|NCT02454478|10014417|FG000|Overall Study|Incomplete DLT Evaluation|1
6294769|NCT02454530|10014423|FG000|Overall Study|Other|8
6294770|NCT02454530|10014424|FG001|Overall Study|Other|13
6294771|NCT02454530|10014423|FG000|Overall Study|Missing information|56
6294772|NCT02454530|10014424|FG001|Overall Study|Missing information|69
6294773|NCT02454530|10014423|FG000|Overall Study|Death|2
6294774|NCT02454530|10014424|FG001|Overall Study|Death|41
6294775|NCT02454530|10014423|FG000|Overall Study|Lost to Follow-up|4
6294776|NCT02454530|10014424|FG001|Overall Study|Lost to Follow-up|4
6294777|NCT02454608|10014434|FG000|Double-Blind Period|Lack of Efficacy|0
6294778|NCT02454608|10014435|FG001|Double-Blind Period|Lack of Efficacy|2
6294779|NCT02454608|10014436|FG002|Double-Blind Period|Lack of Efficacy|0
6294780|NCT02454608|10014434|FG000|Open Label Period|Lost to Follow-up|0
6294781|NCT02454608|10014435|FG001|Open Label Period|Lost to Follow-up|0
6294782|NCT02454608|10014436|FG002|Open Label Period|Lost to Follow-up|11
6294783|NCT02454608|10014434|FG000|Open Label Period|Withdrawal by Subject|0
6294784|NCT02454608|10014435|FG001|Open Label Period|Withdrawal by Subject|0
6294785|NCT02454608|10014436|FG002|Open Label Period|Withdrawal by Subject|8
6294786|NCT02454959|10014444|FG000|Overall Study|Protocol-Specified Criteria|3
6294787|NCT02454959|10014444|FG000|Overall Study|Physician Decision|1
6294788|NCT02454959|10014444|FG000|Overall Study|Withdrawal by Subject|3
6294789|NCT02454959|10014444|FG000|Overall Study|Adverse Event|2
6294790|NCT02454972|10014459|FG000|Overall Study|Progressive disease|17
6294791|NCT02454972|10014460|FG001|Overall Study|Progressive disease|16
6294792|NCT02454972|10014461|FG002|Overall Study|Progressive disease|59
6294793|NCT02454972|10014462|FG003|Overall Study|Progressive disease|23
6294794|NCT02454972|10014463|FG004|Overall Study|Progressive disease|16
6294795|NCT02454972|10014464|FG005|Overall Study|Progressive disease|12
6294796|NCT02454972|10014465|FG006|Overall Study|Progressive disease|19
6294797|NCT02454972|10014466|FG007|Overall Study|Progressive disease|27
6294798|NCT02454972|10014467|FG008|Overall Study|Progressive disease|84
6294799|NCT02454972|10014459|FG000|Overall Study|Death|0
6294800|NCT02454972|10014460|FG001|Overall Study|Death|0
6294801|NCT02454972|10014461|FG002|Overall Study|Death|5
6294802|NCT02454972|10014462|FG003|Overall Study|Death|1
6294803|NCT02454972|10014463|FG004|Overall Study|Death|0
6294804|NCT02454972|10014464|FG005|Overall Study|Death|0
6294805|NCT02454972|10014465|FG006|Overall Study|Death|0
6294806|NCT02454972|10014466|FG007|Overall Study|Death|0
6294807|NCT02454972|10014467|FG008|Overall Study|Death|2
6294808|NCT02454972|10014459|FG000|Overall Study|Physician Decision|0
6294809|NCT02454972|10014460|FG001|Overall Study|Physician Decision|1
6294810|NCT02454972|10014461|FG002|Overall Study|Physician Decision|2
6294811|NCT02454972|10014462|FG003|Overall Study|Physician Decision|1
6294812|NCT02454972|10014463|FG004|Overall Study|Physician Decision|2
6294813|NCT02454972|10014464|FG005|Overall Study|Physician Decision|0
6294814|NCT02454972|10014465|FG006|Overall Study|Physician Decision|0
6294815|NCT02454972|10014466|FG007|Overall Study|Physician Decision|1
6294816|NCT02454972|10014467|FG008|Overall Study|Physician Decision|4
6294817|NCT02454972|10014459|FG000|Overall Study|Non treatment-related adverse event|2
6294818|NCT02454972|10014460|FG001|Overall Study|Non treatment-related adverse event|0
6294819|NCT02454972|10014461|FG002|Overall Study|Non treatment-related adverse event|1
6294820|NCT02454972|10014462|FG003|Overall Study|Non treatment-related adverse event|0
6294821|NCT02454972|10014463|FG004|Overall Study|Non treatment-related adverse event|0
6294822|NCT02454972|10014464|FG005|Overall Study|Non treatment-related adverse event|1
6294823|NCT02454972|10014465|FG006|Overall Study|Non treatment-related adverse event|0
6294824|NCT02454972|10014466|FG007|Overall Study|Non treatment-related adverse event|1
6294825|NCT02454972|10014467|FG008|Overall Study|Non treatment-related adverse event|0
6294826|NCT02454972|10014459|FG000|Overall Study|Treatment-related adverse events|0
6294827|NCT02454972|10014460|FG001|Overall Study|Treatment-related adverse events|1
6294828|NCT02454972|10014461|FG002|Overall Study|Treatment-related adverse events|1
6294829|NCT02454972|10014462|FG003|Overall Study|Treatment-related adverse events|0
6294830|NCT02454972|10014463|FG004|Overall Study|Treatment-related adverse events|2
6294831|NCT02454972|10014464|FG005|Overall Study|Treatment-related adverse events|0
6294832|NCT02454972|10014465|FG006|Overall Study|Treatment-related adverse events|0
6294833|NCT02454972|10014466|FG007|Overall Study|Treatment-related adverse events|2
6294834|NCT02454972|10014467|FG008|Overall Study|Treatment-related adverse events|2
6294835|NCT02454972|10014459|FG000|Overall Study|Patient moves to compassionate use|0
6294836|NCT02454972|10014460|FG001|Overall Study|Patient moves to compassionate use|0
6294837|NCT02454972|10014461|FG002|Overall Study|Patient moves to compassionate use|0
6294838|NCT02454972|10014462|FG003|Overall Study|Patient moves to compassionate use|0
6294839|NCT02454972|10014463|FG004|Overall Study|Patient moves to compassionate use|0
6294840|NCT02454972|10014464|FG005|Overall Study|Patient moves to compassionate use|0
6294841|NCT02454972|10014465|FG006|Overall Study|Patient moves to compassionate use|2
6294842|NCT02454972|10014466|FG007|Overall Study|Patient moves to compassionate use|0
6294843|NCT02454972|10014467|FG008|Overall Study|Patient moves to compassionate use|11
6294844|NCT02454972|10014459|FG000|Overall Study|Withdrawal by Subject|0
6294845|NCT02454972|10014460|FG001|Overall Study|Withdrawal by Subject|1
6294846|NCT02454972|10014461|FG002|Overall Study|Withdrawal by Subject|5
6294847|NCT02454972|10014462|FG003|Overall Study|Withdrawal by Subject|2
6294848|NCT02454972|10014463|FG004|Overall Study|Withdrawal by Subject|3
6294849|NCT02454972|10014464|FG005|Overall Study|Withdrawal by Subject|2
6294850|NCT02454972|10014465|FG006|Overall Study|Withdrawal by Subject|0
6294851|NCT02454972|10014466|FG007|Overall Study|Withdrawal by Subject|1
6294852|NCT02454972|10014467|FG008|Overall Study|Withdrawal by Subject|2
6294853|NCT02454972|10014459|FG000|Overall Study|Multiple delay/holds on treatment|0
6294854|NCT02454972|10014460|FG001|Overall Study|Multiple delay/holds on treatment|0
6294855|NCT02454972|10014461|FG002|Overall Study|Multiple delay/holds on treatment|0
6294856|NCT02454972|10014462|FG003|Overall Study|Multiple delay/holds on treatment|1
6294857|NCT02454972|10014463|FG004|Overall Study|Multiple delay/holds on treatment|0
6294858|NCT02454972|10014464|FG005|Overall Study|Multiple delay/holds on treatment|0
6294859|NCT02454972|10014465|FG006|Overall Study|Multiple delay/holds on treatment|0
6294860|NCT02454972|10014466|FG007|Overall Study|Multiple delay/holds on treatment|0
6294861|NCT02454972|10014467|FG008|Overall Study|Multiple delay/holds on treatment|0
6294862|NCT02454972|10014459|FG000|Overall Study|Never treated|0
6294863|NCT02454972|10014460|FG001|Overall Study|Never treated|0
6294864|NCT02454972|10014461|FG002|Overall Study|Never treated|3
6294865|NCT02454972|10014462|FG003|Overall Study|Never treated|1
6294866|NCT02454972|10014463|FG004|Overall Study|Never treated|1
6294867|NCT02454972|10014464|FG005|Overall Study|Never treated|0
6294868|NCT02454972|10014465|FG006|Overall Study|Never treated|0
6294869|NCT02454972|10014466|FG007|Overall Study|Never treated|0
6294870|NCT02454972|10014467|FG008|Overall Study|Never treated|5
6294871|NCT02455050|10014483|FG000|Treatment Period 1|Lost to Follow-up|1
6294872|NCT02455050|10014484|FG001|Treatment Period 1|Lost to Follow-up|1
6294873|NCT02455050|10014485|FG002|Treatment Period 1|Lost to Follow-up|1
6294874|NCT02455050|10014486|FG003|Treatment Period 1|Lost to Follow-up|2
6294875|NCT02455050|10014483|FG000|Treatment Period 2|Lost to Follow-up|1
6294876|NCT02455050|10014484|FG001|Treatment Period 2|Lost to Follow-up|0
6294877|NCT02455050|10014485|FG002|Treatment Period 2|Lost to Follow-up|2
6294878|NCT02455050|10014486|FG003|Treatment Period 2|Lost to Follow-up|1
6294879|NCT02455076|10014511|FG000|Inpatient|Withdrawal by Subject|1
6294880|NCT02455076|10014512|FG001|Inpatient|Withdrawal by Subject|0
6294881|NCT02455076|10014513|FG002|Inpatient|Withdrawal by Subject|0
6294882|NCT02455076|10014514|FG003|Inpatient|Withdrawal by Subject|0
6294883|NCT02455076|10014515|FG004|Inpatient|Withdrawal by Subject|0
6294884|NCT02455076|10014511|FG000|Inpatient|Discharged <24 h after admission|0
6294885|NCT02455076|10014512|FG001|Inpatient|Discharged <24 h after admission|1
6294886|NCT02455076|10014513|FG002|Inpatient|Discharged <24 h after admission|0
6294887|NCT02455076|10014514|FG003|Inpatient|Discharged <24 h after admission|0
6294888|NCT02455076|10014515|FG004|Inpatient|Discharged <24 h after admission|0
6294889|NCT02455076|10014511|FG000|Inpatient|Adverse Event|3
6294890|NCT02455076|10014512|FG001|Inpatient|Adverse Event|0
6294891|NCT02455076|10014513|FG002|Inpatient|Adverse Event|0
6294892|NCT02455076|10014514|FG003|Inpatient|Adverse Event|0
6294893|NCT02455076|10014515|FG004|Inpatient|Adverse Event|0
6294894|NCT02455076|10014511|FG000|Outpatient|Adverse Event|0
6294895|NCT02455076|10014512|FG001|Outpatient|Adverse Event|0
6294896|NCT02455076|10014513|FG002|Outpatient|Adverse Event|0
6294897|NCT02455076|10014514|FG003|Outpatient|Adverse Event|5
6294898|NCT02455076|10014515|FG004|Outpatient|Adverse Event|0
6294899|NCT02455076|10014511|FG000|Outpatient|Lost to Follow-up|0
6294900|NCT02455076|10014512|FG001|Outpatient|Lost to Follow-up|0
6294901|NCT02455076|10014513|FG002|Outpatient|Lost to Follow-up|0
6294902|NCT02455076|10014514|FG003|Outpatient|Lost to Follow-up|1
6294903|NCT02455076|10014515|FG004|Outpatient|Lost to Follow-up|12
6294904|NCT02455336|10014533|FG000|Overall Study|Withdrawal by Subject|0
6294905|NCT02455336|10014534|FG001|Overall Study|Withdrawal by Subject|2
6294906|NCT02455336|10014533|FG000|Overall Study|Adverse Event|3
6294907|NCT02455336|10014534|FG001|Overall Study|Adverse Event|0
6294908|NCT02455336|10014533|FG000|Overall Study|Non-responder to treatment|2
6294909|NCT02455336|10014534|FG001|Overall Study|Non-responder to treatment|0
6294910|NCT02455388|10014542|FG000|Overall Study|Protocol Violation|1
6294911|NCT02455388|10014543|FG001|Overall Study|Protocol Violation|0
6294912|NCT02455388|10014544|FG002|Overall Study|Protocol Violation|4
6294913|NCT02455388|10014542|FG000|Overall Study|Withdrawal by Subject|0
6294914|NCT02455388|10014543|FG001|Overall Study|Withdrawal by Subject|0
6294915|NCT02455388|10014544|FG002|Overall Study|Withdrawal by Subject|7
6294916|NCT02455518|10014560|FG000|Overall Study|Protocol Violation|0
6294917|NCT02455518|10014561|FG001|Overall Study|Protocol Violation|1
6294918|NCT02455518|10014562|FG002|Overall Study|Protocol Violation|1
6294919|NCT02455518|10014563|FG003|Overall Study|Protocol Violation|3
6294920|NCT02456103|10014573|FG000|Overall Study|Study Closure|207
6294921|NCT02456103|10014573|FG000|Overall Study|Physician Decision|1
6294922|NCT02456103|10014573|FG000|Overall Study|Required prohibited medications|5
6294923|NCT02456103|10014573|FG000|Overall Study|Protocol Violation|1
6294924|NCT02456103|10014573|FG000|Overall Study|Adverse Event|5
6294925|NCT02456103|10014573|FG000|Overall Study|Abnormal Laboratory Value|2
6294926|NCT02456103|10014573|FG000|Overall Study|Lost to Follow-up|1
6294927|NCT02456103|10014573|FG000|Overall Study|Withdrawal by Subject|24
6294928|NCT02456636|10014580|FG000|Overall Study|Death|0
6294929|NCT02456636|10014581|FG001|Overall Study|Death|3
6294930|NCT02456636|10014582|FG002|Overall Study|Death|0
6294931|NCT02456636|10014580|FG000|Overall Study|Pregnancy|1
6294932|NCT02456636|10014581|FG001|Overall Study|Pregnancy|3
6294933|NCT02456636|10014582|FG002|Overall Study|Pregnancy|5
6294934|NCT02456636|10014580|FG000|Overall Study|Physician Decision|4
6294935|NCT02456636|10014581|FG001|Overall Study|Physician Decision|5
6294936|NCT02456636|10014582|FG002|Overall Study|Physician Decision|4
6294937|NCT02456636|10014580|FG000|Overall Study|Withdrawal by Subject|13
6294938|NCT02456636|10014581|FG001|Overall Study|Withdrawal by Subject|14
6294939|NCT02456636|10014582|FG002|Overall Study|Withdrawal by Subject|16
6294940|NCT02456636|10014580|FG000|Overall Study|Lost to Follow-up|50
6294941|NCT02456636|10014581|FG001|Overall Study|Lost to Follow-up|44
6294942|NCT02456636|10014582|FG002|Overall Study|Lost to Follow-up|50
6294943|NCT02456662|10014592|FG000|Overall Study|Lost to Follow-up|2
6294944|NCT02456662|10014593|FG001|Overall Study|Lost to Follow-up|1
6294945|NCT02456727|10014601|FG000|Overall Study|Lost to Follow-up|63
6294946|NCT02456727|10014602|FG001|Overall Study|Lost to Follow-up|65
6294947|NCT02456727|10014601|FG000|Overall Study|Death|2
6294948|NCT02456727|10014602|FG001|Overall Study|Death|1
6294949|NCT02456727|10014601|FG000|Overall Study|Withdrawal by Subject|1
6294950|NCT02456727|10014602|FG001|Overall Study|Withdrawal by Subject|10
6294951|NCT02456727|10014601|FG000|Overall Study|Never Initiated Treatment|43
6294952|NCT02456727|10014602|FG001|Overall Study|Never Initiated Treatment|30
6294953|NCT02456909|10014635|FG000|Overall Study|Did not receive allocated intervention|24
6294954|NCT02456909|10014636|FG001|Overall Study|Did not receive allocated intervention|26
6294955|NCT02456909|10014635|FG000|Overall Study|Did not complete the primary outcome|0
6294956|NCT02456909|10014636|FG001|Overall Study|Did not complete the primary outcome|1
6294957|NCT02457065|10014644|FG000|Overall Study|Lost to Follow-up|9
6294958|NCT02457065|10014645|FG001|Overall Study|Lost to Follow-up|11
6294959|NCT02457182|10014653|FG000|Overall Study|Lost to Follow-up|1
6294960|NCT02457182|10014654|FG001|Overall Study|Lost to Follow-up|0
6294961|NCT02457195|10014660|FG000|Overall Study|Adverse Event|3
6294962|NCT02457195|10014660|FG000|Overall Study|Protocol Violation|2
6294963|NCT02457195|10014660|FG000|Overall Study|Withdrawal by Subject|4
6294964|NCT02457247|10014668|FG000|Period 1|Pretreatment Event/Adverse Event|0
6294965|NCT02457247|10014669|FG001|Period 1|Pretreatment Event/Adverse Event|1
6294966|NCT02457247|10014670|FG002|Period 1|Pretreatment Event/Adverse Event|0
6294967|NCT02457247|10014671|FG003|Period 1|Pretreatment Event/Adverse Event|0
6294968|NCT02457247|10014668|FG000|Period 1|Significant Protocol Deviation|1
6294969|NCT02457247|10014669|FG001|Period 1|Significant Protocol Deviation|1
6294970|NCT02457247|10014670|FG002|Period 1|Significant Protocol Deviation|0
6294971|NCT02457247|10014671|FG003|Period 1|Significant Protocol Deviation|0
6294972|NCT02457247|10014668|FG000|Period 1|Voluntary Withdrawal|1
6294973|NCT02457247|10014669|FG001|Period 1|Voluntary Withdrawal|0
6294974|NCT02457247|10014670|FG002|Period 1|Voluntary Withdrawal|0
6294975|NCT02457247|10014671|FG003|Period 1|Voluntary Withdrawal|0
6294976|NCT02457247|10014668|FG000|Period 2|Pretreatment Event/Adverse Event|0
6294977|NCT02457247|10014669|FG001|Period 2|Pretreatment Event/Adverse Event|1
6294978|NCT02457247|10014670|FG002|Period 2|Pretreatment Event/Adverse Event|0
6294979|NCT02457247|10014671|FG003|Period 2|Pretreatment Event/Adverse Event|0
6294980|NCT02457247|10014668|FG000|Period 2|Significant Protocol Deviation|1
6294981|NCT02457247|10014669|FG001|Period 2|Significant Protocol Deviation|0
6294982|NCT02457247|10014670|FG002|Period 2|Significant Protocol Deviation|0
6294983|NCT02457247|10014671|FG003|Period 2|Significant Protocol Deviation|0
6294984|NCT02457247|10014668|FG000|Period 2|Lost to Follow-up|0
6294985|NCT02457247|10014669|FG001|Period 2|Lost to Follow-up|1
6294986|NCT02457247|10014670|FG002|Period 2|Lost to Follow-up|0
6294987|NCT02457247|10014671|FG003|Period 2|Lost to Follow-up|0
6294988|NCT02457247|10014668|FG000|Period 2|Voluntary Withdrawal|1
6294989|NCT02457247|10014669|FG001|Period 2|Voluntary Withdrawal|1
6294990|NCT02457247|10014670|FG002|Period 2|Voluntary Withdrawal|0
6294991|NCT02457247|10014671|FG003|Period 2|Voluntary Withdrawal|0
6294992|NCT02457325|10014703|FG000|First Intervention (1 Day)|Lost to Follow-up|2
6294993|NCT02457325|10014704|FG001|First Intervention (1 Day)|Lost to Follow-up|2
6294994|NCT02457520|10014721|FG000|Active Treatment Phase|Adverse Event|10
6294995|NCT02457520|10014721|FG000|Active Treatment Phase|Lost to Follow-up|8
6294996|NCT02457520|10014721|FG000|Active Treatment Phase|Non-compliance with Study Treatment|3
6294997|NCT02457520|10014721|FG000|Active Treatment Phase|other|4
6294998|NCT02457520|10014721|FG000|Active Treatment Phase|Physician Decision|1
6294999|NCT02457520|10014721|FG000|Active Treatment Phase|Protocol Violation|1
6295000|NCT02457520|10014721|FG000|Active Treatment Phase|Withdrawal by Subject|7
6295001|NCT02457520|10014721|FG000|Post-treatment Period|Other: Retreatment Required|7
6295002|NCT02457520|10014721|FG000|Post-treatment Period|Lost to Follow-up|23
6295003|NCT02457520|10014721|FG000|Post-treatment Period|Other|3
6295004|NCT02457520|10014721|FG000|Post-treatment Period|Physician Decision|1
6295005|NCT02457520|10014721|FG000|Post-treatment Period|Withdrawal by Subject|14
6295006|NCT02457546|10014753|FG000|Overall Study|Other reasons|4
6295007|NCT02457546|10014754|FG001|Overall Study|Other reasons|1
6295008|NCT02457546|10014753|FG000|Overall Study|Refused to complete study/procedures|1
6295009|NCT02457546|10014754|FG001|Overall Study|Refused to complete study/procedures|1
6295010|NCT02457546|10014753|FG000|Overall Study|Lost to Follow-up|4
6295011|NCT02457546|10014754|FG001|Overall Study|Lost to Follow-up|1
6295012|NCT02457546|10014753|FG000|Overall Study|Adverse Event|0
6295013|NCT02457546|10014754|FG001|Overall Study|Adverse Event|1
6295014|NCT02457611|10014760|FG000|Overall Study|Lost to Follow-up|3
6295015|NCT02457637|10014764|FG000|Clinic or Telephone Follow-up|Lost to Follow-up|71
6295016|NCT02457793|10014779|FG000|Overall Study|Reason not specified|0
6295017|NCT02457793|10014780|FG001|Overall Study|Reason not specified|0
6295018|NCT02457793|10014781|FG002|Overall Study|Reason not specified|0
6295019|NCT02457793|10014782|FG003|Overall Study|Reason not specified|1
6295020|NCT02457793|10014783|FG004|Overall Study|Reason not specified|1
6295021|NCT02457793|10014784|FG005|Overall Study|Reason not specified|1
6295022|NCT02457793|10014779|FG000|Overall Study|Withdrawal by Subject|0
6295023|NCT02457793|10014780|FG001|Overall Study|Withdrawal by Subject|4
6295024|NCT02457793|10014781|FG002|Overall Study|Withdrawal by Subject|2
6295025|NCT02457793|10014782|FG003|Overall Study|Withdrawal by Subject|2
6295026|NCT02457793|10014783|FG004|Overall Study|Withdrawal by Subject|2
6295027|NCT02457793|10014784|FG005|Overall Study|Withdrawal by Subject|2
6295028|NCT02457793|10014779|FG000|Overall Study|Adverse Event|0
6295029|NCT02457793|10014780|FG001|Overall Study|Adverse Event|0
6295030|NCT02457793|10014781|FG002|Overall Study|Adverse Event|0
6295031|NCT02457793|10014782|FG003|Overall Study|Adverse Event|1
6295032|NCT02457793|10014783|FG004|Overall Study|Adverse Event|0
6295033|NCT02457793|10014784|FG005|Overall Study|Adverse Event|0
6295034|NCT02457793|10014779|FG000|Overall Study|Physician Decision|1
6295035|NCT02457793|10014780|FG001|Overall Study|Physician Decision|0
6295036|NCT02457793|10014781|FG002|Overall Study|Physician Decision|1
6295037|NCT02457793|10014782|FG003|Overall Study|Physician Decision|1
6295038|NCT02457793|10014783|FG004|Overall Study|Physician Decision|1
6295039|NCT02457793|10014784|FG005|Overall Study|Physician Decision|3
6295040|NCT02457819|10014799|FG000|Overall Study|reason not given|8
6295041|NCT02457819|10014799|FG000|Overall Study|Withdrawal by Subject|24
6295042|NCT02457819|10014799|FG000|Overall Study|Protocol Violation|1
6295043|NCT02457819|10014799|FG000|Overall Study|non compliance with study drug|4
6295044|NCT02457819|10014799|FG000|Overall Study|Lost to Follow-up|10
6295045|NCT02457819|10014799|FG000|Overall Study|Lack of Efficacy|19
6295046|NCT02457819|10014799|FG000|Overall Study|Adverse Event|33
5981444|NCT00963469|9570387|FG000|Overall Study|Adverse Event|15
6295047|NCT02458092|10014809|FG000|Overall Study|Withdrawal by Subject|1
6295048|NCT02458092|10014810|FG001|Overall Study|Withdrawal by Subject|0
6295049|NCT02458287|10014825|FG000|Overall Study|Adverse Event|0
6295050|NCT02458287|10014826|FG001|Overall Study|Adverse Event|0
6295051|NCT02458287|10014827|FG002|Overall Study|Adverse Event|0
6295052|NCT02458287|10014828|FG003|Overall Study|Adverse Event|1
6295053|NCT02458287|10014825|FG000|Overall Study|Lost to Follow-up|0
6295054|NCT02458287|10014826|FG001|Overall Study|Lost to Follow-up|1
6295055|NCT02458287|10014827|FG002|Overall Study|Lost to Follow-up|1
6295056|NCT02458287|10014828|FG003|Overall Study|Lost to Follow-up|0
6295057|NCT02458287|10014825|FG000|Overall Study|Protocol Violation|0
6295058|NCT02458287|10014826|FG001|Overall Study|Protocol Violation|1
6295059|NCT02458287|10014827|FG002|Overall Study|Protocol Violation|0
6295060|NCT02458287|10014828|FG003|Overall Study|Protocol Violation|0
6295061|NCT02458287|10014825|FG000|Overall Study|Withdrawal by Subject|0
6295062|NCT02458287|10014826|FG001|Overall Study|Withdrawal by Subject|2
6295063|NCT02458287|10014827|FG002|Overall Study|Withdrawal by Subject|2
6295064|NCT02458287|10014828|FG003|Overall Study|Withdrawal by Subject|1
6295065|NCT02458287|10014825|FG000|Overall Study|Relocated Out of State|0
6295066|NCT02458287|10014826|FG001|Overall Study|Relocated Out of State|0
6295067|NCT02458287|10014827|FG002|Overall Study|Relocated Out of State|0
6295068|NCT02458287|10014828|FG003|Overall Study|Relocated Out of State|1
6295069|NCT02458469|10014860|FG000|First Intervention (2 Weeks)|Lost to Follow-up|0
6295070|NCT02458469|10014861|FG001|First Intervention (2 Weeks)|Lost to Follow-up|0
6295071|NCT02458469|10014862|FG002|First Intervention (2 Weeks)|Lost to Follow-up|1
6295072|NCT02458469|10014863|FG003|First Intervention (2 Weeks)|Lost to Follow-up|0
6295073|NCT02458469|10014864|FG004|First Intervention (2 Weeks)|Lost to Follow-up|0
6295074|NCT02458469|10014865|FG005|First Intervention (2 Weeks)|Lost to Follow-up|0
6295075|NCT02458469|10014860|FG000|First Intervention (2 Weeks)|Physician Decision|1
6295076|NCT02458469|10014861|FG001|First Intervention (2 Weeks)|Physician Decision|0
6295077|NCT02458469|10014862|FG002|First Intervention (2 Weeks)|Physician Decision|0
6295078|NCT02458469|10014863|FG003|First Intervention (2 Weeks)|Physician Decision|0
6295079|NCT02458469|10014864|FG004|First Intervention (2 Weeks)|Physician Decision|0
6295080|NCT02458469|10014865|FG005|First Intervention (2 Weeks)|Physician Decision|0
6295081|NCT02458469|10014860|FG000|Second Intervention (2 Weeks)|Withdrawal by Subject|0
6295082|NCT02458469|10014861|FG001|Second Intervention (2 Weeks)|Withdrawal by Subject|0
6295083|NCT02458469|10014862|FG002|Second Intervention (2 Weeks)|Withdrawal by Subject|0
6295084|NCT02458469|10014863|FG003|Second Intervention (2 Weeks)|Withdrawal by Subject|0
6295085|NCT02458469|10014864|FG004|Second Intervention (2 Weeks)|Withdrawal by Subject|0
6295086|NCT02458469|10014865|FG005|Second Intervention (2 Weeks)|Withdrawal by Subject|1
6295087|NCT02458638|10014873|FG000|Overall Study|Death|309
6295088|NCT02458638|10014873|FG000|Overall Study|End of Cohort/End of Study|67
6295089|NCT02458638|10014873|FG000|Overall Study|Lost to Follow-up|31
6295090|NCT02458638|10014873|FG000|Overall Study|Other Reasons|4
6295091|NCT02458638|10014873|FG000|Overall Study|Physician Decision|1
6295092|NCT02458638|10014873|FG000|Overall Study|Withdrawal by Subject|47
6295093|NCT02459093|10014897|FG000|Overall Study|Protocol Violation|6
6295094|NCT02459093|10014898|FG001|Overall Study|Protocol Violation|11
6295095|NCT02459093|10014897|FG000|Overall Study|Lost to Follow-up|6
6295096|NCT02459093|10014898|FG001|Overall Study|Lost to Follow-up|7
6295097|NCT02459262|10014928|FG000|Overall Study|Withdrawal by Subject|0
6295098|NCT02459262|10014929|FG001|Overall Study|Withdrawal by Subject|0
6295099|NCT02459262|10014930|FG002|Overall Study|Withdrawal by Subject|0
6295100|NCT02459262|10014931|FG003|Overall Study|Withdrawal by Subject|0
6295101|NCT02459262|10014932|FG004|Overall Study|Withdrawal by Subject|0
6295102|NCT02459262|10014933|FG005|Overall Study|Withdrawal by Subject|0
6295103|NCT02459262|10014934|FG006|Overall Study|Withdrawal by Subject|0
6295104|NCT02459262|10014935|FG007|Overall Study|Withdrawal by Subject|0
6295105|NCT02459262|10014936|FG008|Overall Study|Withdrawal by Subject|0
6295106|NCT02459262|10014937|FG009|Overall Study|Withdrawal by Subject|1
6295107|NCT02459262|10014938|FG010|Overall Study|Withdrawal by Subject|0
6295108|NCT02459418|10014973|FG000|Overall Study|Exclusion Criteria|4
6295109|NCT02459418|10014974|FG001|Overall Study|Exclusion Criteria|0
6295110|NCT02459418|10014973|FG000|Overall Study|Protocol Violation|0
6295111|NCT02459418|10014974|FG001|Overall Study|Protocol Violation|2
6295112|NCT02459418|10014973|FG000|Overall Study|Physician Decision|0
6295113|NCT02459418|10014974|FG001|Overall Study|Physician Decision|2
6295114|NCT02459418|10014973|FG000|Overall Study|Endometrial thickness of >5 mm|1
6295115|NCT02459418|10014974|FG001|Overall Study|Endometrial thickness of >5 mm|0
5981445|NCT00963469|9570388|FG001|Overall Study|Adverse Event|11
5981446|NCT00963469|9570389|FG002|Overall Study|Adverse Event|1
6063514|NCT00506415|9664784|FG000|Extended Open Label (Maximum 48 Weeks)|Administrative problems|0
6295116|NCT02459418|10014973|FG000|Overall Study|Adverse Event|0
6295117|NCT02459418|10014974|FG001|Overall Study|Adverse Event|1
6295118|NCT02459418|10014973|FG000|Overall Study|Withdrawal by Subject|1
6295119|NCT02459418|10014974|FG001|Overall Study|Withdrawal by Subject|1
6295120|NCT02459418|10014973|FG000|Overall Study|Elevated Creatine Kinase|1
6295121|NCT02459418|10014974|FG001|Overall Study|Elevated Creatine Kinase|0
6295122|NCT02459418|10014973|FG000|Overall Study|Abnormal Transvaginal Ultrasound|1
6295123|NCT02459418|10014974|FG001|Overall Study|Abnormal Transvaginal Ultrasound|0
6295124|NCT02459587|10014985|FG000|3-Month Follow-up Assessment|Death|0
6295125|NCT02459587|10014986|FG001|3-Month Follow-up Assessment|Death|2
6295126|NCT02459587|10014985|FG000|3-Month Follow-up Assessment|Withdrawal by Subject|3
6295127|NCT02459587|10014986|FG001|3-Month Follow-up Assessment|Withdrawal by Subject|3
6295128|NCT02459587|10014985|FG000|3-Month Follow-up Assessment|Lost to Follow-up|27
6295129|NCT02459587|10014986|FG001|3-Month Follow-up Assessment|Lost to Follow-up|22
6295130|NCT02459587|10014985|FG000|3-Month Follow-up Assessment|Researcher withdrew|2
6295131|NCT02459587|10014986|FG001|3-Month Follow-up Assessment|Researcher withdrew|4
6295132|NCT02459587|10014985|FG000|6-month Follow-up Assessment|Death|2
6295133|NCT02459587|10014986|FG001|6-month Follow-up Assessment|Death|1
6295134|NCT02459587|10014985|FG000|6-month Follow-up Assessment|Withdrawal by Subject|1
6295135|NCT02459587|10014986|FG001|6-month Follow-up Assessment|Withdrawal by Subject|2
6295136|NCT02459587|10014985|FG000|6-month Follow-up Assessment|Lost to Follow-up|21
6295137|NCT02459587|10014986|FG001|6-month Follow-up Assessment|Lost to Follow-up|22
6295138|NCT02459587|10014985|FG000|12-month Follow-up Assessment|Death|2
6295139|NCT02459587|10014986|FG001|12-month Follow-up Assessment|Death|0
6295140|NCT02459587|10014985|FG000|12-month Follow-up Assessment|Withdrawal by Subject|2
6295141|NCT02459587|10014986|FG001|12-month Follow-up Assessment|Withdrawal by Subject|4
6295142|NCT02459587|10014985|FG000|12-month Follow-up Assessment|Lost to Follow-up|18
5981447|NCT00963469|9570387|FG000|Overall Study|Lack of Efficacy|10
5981448|NCT00963469|9570388|FG001|Overall Study|Lack of Efficacy|7
5981449|NCT00963469|9570389|FG002|Overall Study|Lack of Efficacy|2
5981450|NCT00963469|9570387|FG000|Overall Study|Lost to Follow-up|1
5981451|NCT00963469|9570388|FG001|Overall Study|Lost to Follow-up|1
5981452|NCT00963469|9570389|FG002|Overall Study|Lost to Follow-up|0
5981453|NCT00963469|9570387|FG000|Overall Study|Protocol Violation|5
5981454|NCT00963469|9570388|FG001|Overall Study|Protocol Violation|5
5981455|NCT00963469|9570389|FG002|Overall Study|Protocol Violation|3
5981456|NCT00963469|9570387|FG000|Overall Study|Withdrawal by Subject|4
5981457|NCT00963469|9570388|FG001|Overall Study|Withdrawal by Subject|1
5981458|NCT00963469|9570389|FG002|Overall Study|Withdrawal by Subject|1
5981459|NCT00963469|9570387|FG000|Overall Study|Pre-randomization Adverse Event|1
5981460|NCT00963469|9570388|FG001|Overall Study|Pre-randomization Adverse Event|2
5981461|NCT00963469|9570389|FG002|Overall Study|Pre-randomization Adverse Event|0
5981462|NCT00963469|9570387|FG000|Overall Study|Moved|1
5981463|NCT00963469|9570388|FG001|Overall Study|Moved|0
5981464|NCT00963469|9570389|FG002|Overall Study|Moved|0
5981465|NCT00963469|9570387|FG000|Overall Study|Site closed (local pollen Season ended)|4
5981466|NCT00963469|9570388|FG001|Overall Study|Site closed (local pollen Season ended)|1
5981467|NCT00963469|9570389|FG002|Overall Study|Site closed (local pollen Season ended)|3
5981468|NCT00960141|9570400|FG000|Overall Study|Adverse Event|4
5981469|NCT00960141|9570401|FG001|Overall Study|Adverse Event|8
5981470|NCT00960141|9570402|FG002|Overall Study|Adverse Event|2
5981471|NCT00960141|9570400|FG000|Overall Study|Lack of Efficacy|3
5981472|NCT00960141|9570401|FG001|Overall Study|Lack of Efficacy|4
5981473|NCT00960141|9570402|FG002|Overall Study|Lack of Efficacy|2
5981474|NCT00960141|9570400|FG000|Overall Study|Lost to Follow-up|1
5981475|NCT00960141|9570401|FG001|Overall Study|Lost to Follow-up|0
5981476|NCT00960141|9570402|FG002|Overall Study|Lost to Follow-up|0
5981477|NCT00960141|9570400|FG000|Overall Study|Protocol Violation|1
5981478|NCT00960141|9570401|FG001|Overall Study|Protocol Violation|3
5981479|NCT00960141|9570402|FG002|Overall Study|Protocol Violation|2
5981480|NCT00960141|9570400|FG000|Overall Study|Withdrawal by Subject|1
5981481|NCT00960141|9570401|FG001|Overall Study|Withdrawal by Subject|2
5981482|NCT00960141|9570402|FG002|Overall Study|Withdrawal by Subject|1
5981483|NCT00943683|9570412|FG000|Overall Study|Adverse Event|3
5981484|NCT00943683|9570413|FG001|Overall Study|Adverse Event|3
5981485|NCT00943683|9570412|FG000|Overall Study|Lost to Follow-up|1
5981486|NCT00943683|9570413|FG001|Overall Study|Lost to Follow-up|1
5981487|NCT00943683|9570412|FG000|Overall Study|Protocol Violation|1
5981488|NCT00943683|9570413|FG001|Overall Study|Protocol Violation|2
5981489|NCT00943683|9570412|FG000|Overall Study|Withdrawal by Subject|1
5981490|NCT00943683|9570413|FG001|Overall Study|Withdrawal by Subject|0
5981491|NCT00943683|9570412|FG000|Overall Study|Patient Moved|1
5981492|NCT00943683|9570413|FG001|Overall Study|Patient Moved|0
5981493|NCT00943397|9570421|FG000|Overall Study|Adverse Event|0
6295143|NCT02459587|10014986|FG001|12-month Follow-up Assessment|Lost to Follow-up|22
6295144|NCT02459587|10014985|FG000|12-month Follow-up Assessment|Researcher withdrew|0
6295145|NCT02459587|10014986|FG001|12-month Follow-up Assessment|Researcher withdrew|1
6295146|NCT02459665|10014997|FG000|Overall Study|Withdrawal by Subject|0
6295147|NCT02459665|10014998|FG001|Overall Study|Withdrawal by Subject|1
6295148|NCT02459665|10014999|FG002|Overall Study|Withdrawal by Subject|1
6295149|NCT02459665|10015000|FG003|Overall Study|Withdrawal by Subject|2
6295150|NCT02459899|10015034|FG000|Overall Study|Adverse Event|1
6295151|NCT02459899|10015035|FG001|Overall Study|Adverse Event|1
6295152|NCT02459899|10015036|FG002|Overall Study|Adverse Event|0
6295153|NCT02459899|10015037|FG003|Overall Study|Adverse Event|0
6295154|NCT02459899|10015034|FG000|Overall Study|Lost to Follow-up|1
6295155|NCT02459899|10015035|FG001|Overall Study|Lost to Follow-up|2
6295156|NCT02459899|10015036|FG002|Overall Study|Lost to Follow-up|0
6295157|NCT02459899|10015037|FG003|Overall Study|Lost to Follow-up|1
6295158|NCT02459899|10015034|FG000|Overall Study|Non-compliance with the treatment|0
6295159|NCT02459899|10015035|FG001|Overall Study|Non-compliance with the treatment|0
6295160|NCT02459899|10015036|FG002|Overall Study|Non-compliance with the treatment|0
6295161|NCT02459899|10015037|FG003|Overall Study|Non-compliance with the treatment|1
6295162|NCT02459899|10015034|FG000|Overall Study|Withdrawal by Subject|1
6295163|NCT02459899|10015035|FG001|Overall Study|Withdrawal by Subject|3
6295164|NCT02459899|10015036|FG002|Overall Study|Withdrawal by Subject|0
6295165|NCT02459899|10015037|FG003|Overall Study|Withdrawal by Subject|0
6295166|NCT02459951|10015047|FG000|Overall Study|Unable to meet holding requirement|1
6295167|NCT02459964|10015055|FG000|Overall Study|Withdrawal by Subject|0
6295168|NCT02459964|10015056|FG001|Overall Study|Withdrawal by Subject|0
6295169|NCT02459964|10015057|FG002|Overall Study|Withdrawal by Subject|1
6295170|NCT02459964|10015055|FG000|Overall Study|Abnormal EKG changes|0
6295171|NCT02459964|10015056|FG001|Overall Study|Abnormal EKG changes|0
6295172|NCT02459964|10015057|FG002|Overall Study|Abnormal EKG changes|1
6295173|NCT02460263|10015070|FG000|Transition Period|Withdrawal by Subject|1
6295174|NCT02460263|10015070|FG000|Transition Period|Death|1
6295175|NCT02460380|10015080|FG000|Overall Study|Withdrawal by Subject|10
6295176|NCT02460380|10015081|FG001|Overall Study|Withdrawal by Subject|5
6295177|NCT02460562|10015090|FG000|Overall Study|Lost to Follow-up|15
6295178|NCT02460562|10015091|FG001|Overall Study|Lost to Follow-up|16
6295179|NCT02460575|10015099|FG000|Overall Study|Lost to Follow-up|1
6295180|NCT02460575|10015100|FG001|Overall Study|Lost to Follow-up|0
6295181|NCT02460679|10015115|FG000|Overall Study|Investigator Decision|1
6295182|NCT02460679|10015115|FG000|Overall Study|Withdrawal by Subject|4
6295183|NCT02460822|10015119|FG000|Overall Study|Withdrawal by Subject|1
6295184|NCT02460978|10015126|FG000|Overall Study|Adverse Event|17
6295185|NCT02460978|10015127|FG001|Overall Study|Adverse Event|11
6295186|NCT02460978|10015128|FG002|Overall Study|Adverse Event|11
6295187|NCT02460978|10015126|FG000|Overall Study|Withdrawal by Subject|5
6295188|NCT02460978|10015127|FG001|Overall Study|Withdrawal by Subject|5
6295189|NCT02460978|10015128|FG002|Overall Study|Withdrawal by Subject|14
6295190|NCT02460978|10015126|FG000|Overall Study|Lost to Follow-up|2
6295191|NCT02460978|10015127|FG001|Overall Study|Lost to Follow-up|3
6295192|NCT02460978|10015128|FG002|Overall Study|Lost to Follow-up|1
6295193|NCT02460978|10015126|FG000|Overall Study|Protocol Violation|1
6295194|NCT02460978|10015127|FG001|Overall Study|Protocol Violation|1
6295195|NCT02460978|10015128|FG002|Overall Study|Protocol Violation|1
6295196|NCT02460978|10015126|FG000|Overall Study|Discontinued due to DKA/hypoglycemia|2
6295197|NCT02460978|10015127|FG001|Overall Study|Discontinued due to DKA/hypoglycemia|5
6295198|NCT02460978|10015128|FG002|Overall Study|Discontinued due to DKA/hypoglycemia|4
6295199|NCT02460978|10015126|FG000|Overall Study|Pregnancy|0
6295200|NCT02460978|10015127|FG001|Overall Study|Pregnancy|0
6295201|NCT02460978|10015128|FG002|Overall Study|Pregnancy|2
6295202|NCT02460991|10015138|FG000|Overall Study|Withdrawal by Subject|0
6295203|NCT02460991|10015139|FG001|Overall Study|Withdrawal by Subject|2
6295204|NCT02461134|10015150|FG000|Overall Study|Adverse Event|1
6295205|NCT02461160|10015167|FG000|Overall Study|Lost to Follow-up|0
6295206|NCT02461160|10015168|FG001|Overall Study|Lost to Follow-up|0
6295207|NCT02461160|10015169|FG002|Overall Study|Lost to Follow-up|0
6295208|NCT02461160|10015170|FG003|Overall Study|Lost to Follow-up|0
6295209|NCT02461160|10015171|FG004|Overall Study|Lost to Follow-up|0
6295210|NCT02461160|10015172|FG005|Overall Study|Lost to Follow-up|0
6295211|NCT02461160|10015173|FG006|Overall Study|Lost to Follow-up|0
6295212|NCT02461160|10015174|FG007|Overall Study|Lost to Follow-up|1
6295213|NCT02461160|10015175|FG008|Overall Study|Lost to Follow-up|0
6295214|NCT02461160|10015176|FG009|Overall Study|Lost to Follow-up|0
6295215|NCT02461160|10015177|FG010|Overall Study|Lost to Follow-up|0
6295216|NCT02461160|10015178|FG011|Overall Study|Lost to Follow-up|0
6295217|NCT02461160|10015179|FG012|Overall Study|Lost to Follow-up|0
6295218|NCT02461290|10015228|FG000|Overall Study|Withdrawn for Inadequate Clinical Stage|7
6295219|NCT02461290|10015228|FG000|Overall Study|Lost to Follow-up|3
6295220|NCT02461589|10015274|FG000|Overall Study|Withdrawal by Subject|5
6295221|NCT02461589|10015275|FG001|Overall Study|Withdrawal by Subject|1
6295222|NCT02461589|10015276|FG002|Overall Study|Withdrawal by Subject|3
6295223|NCT02461589|10015277|FG003|Overall Study|Withdrawal by Subject|2
6295224|NCT02461589|10015278|FG004|Overall Study|Withdrawal by Subject|1
6295225|NCT02461589|10015279|FG005|Overall Study|Withdrawal by Subject|2
6295226|NCT02461589|10015280|FG006|Overall Study|Withdrawal by Subject|1
6295227|NCT02461589|10015281|FG007|Overall Study|Withdrawal by Subject|3
6295228|NCT02461589|10015282|FG008|Overall Study|Withdrawal by Subject|3
6295229|NCT02461589|10015283|FG009|Overall Study|Withdrawal by Subject|1
6295230|NCT02461589|10015274|FG000|Overall Study|Lost to Follow-up|0
6295231|NCT02461589|10015275|FG001|Overall Study|Lost to Follow-up|0
6295232|NCT02461589|10015276|FG002|Overall Study|Lost to Follow-up|2
6295233|NCT02461589|10015277|FG003|Overall Study|Lost to Follow-up|3
6295234|NCT02461589|10015278|FG004|Overall Study|Lost to Follow-up|1
6295235|NCT02461589|10015279|FG005|Overall Study|Lost to Follow-up|1
6295236|NCT02461589|10015280|FG006|Overall Study|Lost to Follow-up|3
6295237|NCT02461589|10015281|FG007|Overall Study|Lost to Follow-up|1
6295238|NCT02461589|10015282|FG008|Overall Study|Lost to Follow-up|3
6295239|NCT02461589|10015283|FG009|Overall Study|Lost to Follow-up|1
6295240|NCT02461589|10015274|FG000|Overall Study|Death|0
6295241|NCT02461589|10015275|FG001|Overall Study|Death|0
6295242|NCT02461589|10015276|FG002|Overall Study|Death|0
6295243|NCT02461589|10015277|FG003|Overall Study|Death|0
6295244|NCT02461589|10015278|FG004|Overall Study|Death|0
6295245|NCT02461589|10015279|FG005|Overall Study|Death|0
6295246|NCT02461589|10015280|FG006|Overall Study|Death|0
6295247|NCT02461589|10015281|FG007|Overall Study|Death|1
6295248|NCT02461589|10015282|FG008|Overall Study|Death|0
6295249|NCT02461589|10015283|FG009|Overall Study|Death|0
6295250|NCT02461589|10015274|FG000|Overall Study|Unclassified|0
6295251|NCT02461589|10015275|FG001|Overall Study|Unclassified|0
6295252|NCT02461589|10015276|FG002|Overall Study|Unclassified|0
6295253|NCT02461589|10015277|FG003|Overall Study|Unclassified|0
6295254|NCT02461589|10015278|FG004|Overall Study|Unclassified|0
6295255|NCT02461589|10015279|FG005|Overall Study|Unclassified|0
6295256|NCT02461589|10015280|FG006|Overall Study|Unclassified|1
6295257|NCT02461589|10015281|FG007|Overall Study|Unclassified|0
6295258|NCT02461589|10015282|FG008|Overall Study|Unclassified|0
6295259|NCT02461589|10015283|FG009|Overall Study|Unclassified|2
6295260|NCT02461589|10015274|FG000|Overall Study|Missing follow-up information|1
6295261|NCT02461589|10015275|FG001|Overall Study|Missing follow-up information|1
6295262|NCT02461589|10015276|FG002|Overall Study|Missing follow-up information|0
6295263|NCT02461589|10015277|FG003|Overall Study|Missing follow-up information|0
6295264|NCT02461589|10015278|FG004|Overall Study|Missing follow-up information|0
6295265|NCT02461589|10015279|FG005|Overall Study|Missing follow-up information|0
6295266|NCT02461589|10015280|FG006|Overall Study|Missing follow-up information|1
6295267|NCT02461589|10015281|FG007|Overall Study|Missing follow-up information|0
6295268|NCT02461589|10015282|FG008|Overall Study|Missing follow-up information|0
6295269|NCT02461589|10015283|FG009|Overall Study|Missing follow-up information|0
6295270|NCT02461589|10015274|FG000|Overall Study|Withdrawal from trial before exposure|0
6295271|NCT02461589|10015275|FG001|Overall Study|Withdrawal from trial before exposure|0
6295272|NCT02461589|10015276|FG002|Overall Study|Withdrawal from trial before exposure|0
6295273|NCT02461589|10015277|FG003|Overall Study|Withdrawal from trial before exposure|0
6295274|NCT02461589|10015278|FG004|Overall Study|Withdrawal from trial before exposure|0
6295275|NCT02461589|10015279|FG005|Overall Study|Withdrawal from trial before exposure|0
6295276|NCT02461589|10015280|FG006|Overall Study|Withdrawal from trial before exposure|0
6295277|NCT02461589|10015281|FG007|Overall Study|Withdrawal from trial before exposure|0
6295278|NCT02461589|10015282|FG008|Overall Study|Withdrawal from trial before exposure|0
6295279|NCT02461589|10015283|FG009|Overall Study|Withdrawal from trial before exposure|1
6295280|NCT02461628|10015307|FG000|Overall Study|Refused to complete survey|4
6295281|NCT02461628|10015308|FG001|Overall Study|Refused to complete survey|7
6295282|NCT02461745|10015325|FG000|Overall Study|Lack of Efficacy|9
6295283|NCT02461745|10015326|FG001|Overall Study|Lack of Efficacy|1
6295284|NCT02461745|10015325|FG000|Overall Study|Lost to Follow-up|2
6295285|NCT02461745|10015326|FG001|Overall Study|Lost to Follow-up|2
6295286|NCT02461745|10015325|FG000|Overall Study|Withdrawal by Subject|3
6295287|NCT02461745|10015326|FG001|Overall Study|Withdrawal by Subject|1
6295288|NCT02461758|10015338|FG000|Overall Study|Lost to Follow-up|0
6295289|NCT02461758|10015339|FG001|Overall Study|Lost to Follow-up|1
6295290|NCT02461758|10015340|FG002|Overall Study|Lost to Follow-up|1
6295291|NCT02461758|10015341|FG003|Overall Study|Lost to Follow-up|0
6295292|NCT02462057|10015389|FG000|Overall Study|Left Vitality|32
6295293|NCT02462057|10015390|FG001|Overall Study|Left Vitality|27
6295294|NCT02462057|10015391|FG002|Overall Study|Left Vitality|23
6295295|NCT02462057|10015392|FG003|Overall Study|Left Vitality|35
6295296|NCT02462057|10015393|FG004|Overall Study|Left Vitality|33
6295297|NCT02462057|10015389|FG000|Overall Study|Joined HealthyFood Before Intervention|22
6295298|NCT02462057|10015390|FG001|Overall Study|Joined HealthyFood Before Intervention|13
6295299|NCT02462057|10015391|FG002|Overall Study|Joined HealthyFood Before Intervention|23
6295300|NCT02462057|10015392|FG003|Overall Study|Joined HealthyFood Before Intervention|16
6295301|NCT02462057|10015393|FG004|Overall Study|Joined HealthyFood Before Intervention|17
6295302|NCT02462083|10015414|FG000|Overall Study|Sponsor request|39
6295303|NCT02462083|10015414|FG000|Overall Study|Withdrawal by Subject|87
6295304|NCT02462083|10015414|FG000|Overall Study|Lost to Follow-up|41
6295305|NCT02462083|10015414|FG000|Overall Study|Lack of Efficacy|151
6295306|NCT02462083|10015414|FG000|Overall Study|Pregnancy|1
6295307|NCT02462083|10015414|FG000|Overall Study|Protocol Violation|6
6295308|NCT02462083|10015414|FG000|Overall Study|Adverse Event|33
6295309|NCT02462083|10015414|FG000|Overall Study|Worsening condition|16
6295310|NCT02462083|10015414|FG000|Overall Study|Other than specified|45
6295311|NCT02462473|10015463|FG000|Overall Study|Death|1
6295312|NCT02462473|10015463|FG000|Overall Study|Other|3
6295313|NCT02462486|10015470|FG000|Overall Study|Screen Failure:Missed Exclusion Criteria|1
6295314|NCT02462486|10015471|FG001|Overall Study|Screen Failure:Missed Exclusion Criteria|1
6295315|NCT02462486|10015472|FG002|Overall Study|Screen Failure:Missed Exclusion Criteria|3
6295316|NCT02462486|10015470|FG000|Overall Study|Adverse Event|53
6295317|NCT02462486|10015471|FG001|Overall Study|Adverse Event|48
6295318|NCT02462486|10015472|FG002|Overall Study|Adverse Event|21
6295319|NCT02462486|10015470|FG000|Overall Study|Lack of Efficacy|6
6295320|NCT02462486|10015471|FG001|Overall Study|Lack of Efficacy|12
6295321|NCT02462486|10015472|FG002|Overall Study|Lack of Efficacy|3
6295322|NCT02462486|10015470|FG000|Overall Study|Lost to Follow-up|3
6295323|NCT02462486|10015471|FG001|Overall Study|Lost to Follow-up|4
6295324|NCT02462486|10015472|FG002|Overall Study|Lost to Follow-up|2
6295325|NCT02462486|10015470|FG000|Overall Study|Withdrawal by Subject|25
6295326|NCT02462486|10015471|FG001|Overall Study|Withdrawal by Subject|22
6295327|NCT02462486|10015472|FG002|Overall Study|Withdrawal by Subject|19
6295328|NCT02462486|10015470|FG000|Overall Study|Protocol Violation|3
6295329|NCT02462486|10015471|FG001|Overall Study|Protocol Violation|1
6295330|NCT02462486|10015472|FG002|Overall Study|Protocol Violation|1
6295331|NCT02462486|10015470|FG000|Overall Study|Reason not Specified|3
6295332|NCT02462486|10015471|FG001|Overall Study|Reason not Specified|4
6295333|NCT02462486|10015472|FG002|Overall Study|Reason not Specified|3
6295334|NCT02462720|10015480|FG000|Part 2|Withdrawal by Subject|1
6295335|NCT02462720|10015481|FG001|Part 2|Withdrawal by Subject|0
6295336|NCT02462720|10015480|FG000|Part 2|Protocol Violation|0
6295337|NCT02462720|10015481|FG001|Part 2|Protocol Violation|1
6295338|NCT02462759|10015491|FG000|Part 1: Double Blind|Death|1
6295339|NCT02462759|10015492|FG001|Part 1: Double Blind|Death|0
6295340|NCT02462759|10015493|FG002|Part 1: Double Blind|Death|0
6295341|NCT02462928|10015507|FG000|Overall Study|Screen Failure:Missed Exclusion Criteria|1
6295342|NCT02462928|10015508|FG001|Overall Study|Screen Failure:Missed Exclusion Criteria|1
6295343|NCT02462928|10015509|FG002|Overall Study|Screen Failure:Missed Exclusion Criteria|2
6295344|NCT02462928|10015507|FG000|Overall Study|Adverse Event|47
6295345|NCT02462928|10015508|FG001|Overall Study|Adverse Event|51
6295346|NCT02462928|10015509|FG002|Overall Study|Adverse Event|25
6295347|NCT02462928|10015507|FG000|Overall Study|Lack of Efficacy|3
6295348|NCT02462928|10015508|FG001|Overall Study|Lack of Efficacy|8
6295349|NCT02462928|10015509|FG002|Overall Study|Lack of Efficacy|3
6295350|NCT02462928|10015507|FG000|Overall Study|Lost to Follow-up|4
6295351|NCT02462928|10015508|FG001|Overall Study|Lost to Follow-up|4
6295352|NCT02462928|10015509|FG002|Overall Study|Lost to Follow-up|1
6295353|NCT02462928|10015507|FG000|Overall Study|Withdrawal by Patient|31
6295354|NCT02462928|10015508|FG001|Overall Study|Withdrawal by Patient|21
6295355|NCT02462928|10015509|FG002|Overall Study|Withdrawal by Patient|21
6295356|NCT02462928|10015507|FG000|Overall Study|Protocol Violation|0
6295357|NCT02462928|10015508|FG001|Overall Study|Protocol Violation|1
6295358|NCT02462928|10015509|FG002|Overall Study|Protocol Violation|0
6295359|NCT02462928|10015507|FG000|Overall Study|Reason not Specified|4
6295360|NCT02462928|10015508|FG001|Overall Study|Reason not Specified|6
6295361|NCT02462928|10015509|FG002|Overall Study|Reason not Specified|5
6295362|NCT02463032|10015532|FG000|Overall Study|Lack of Efficacy|61
6295363|NCT02463032|10015533|FG001|Overall Study|Lack of Efficacy|50
6295364|NCT02463032|10015532|FG000|Overall Study|Death|8
6295365|NCT02463032|10015533|FG001|Overall Study|Death|8
6295366|NCT02463032|10015532|FG000|Overall Study|Adverse Event|2
6295367|NCT02463032|10015533|FG001|Overall Study|Adverse Event|6
6295368|NCT02463071|10015542|FG000|Overall Study|Adverse Event|3
6295369|NCT02463071|10015543|FG001|Overall Study|Adverse Event|5
6295370|NCT02463071|10015544|FG002|Overall Study|Adverse Event|1
6295371|NCT02463071|10015542|FG000|Overall Study|Death|1
6295372|NCT02463071|10015543|FG001|Overall Study|Death|0
6295373|NCT02463071|10015544|FG002|Overall Study|Death|0
5981494|NCT00943397|9570422|FG001|Overall Study|Adverse Event|6
5981495|NCT00943397|9570421|FG000|Overall Study|Lost to Follow-up|0
5981496|NCT00943397|9570422|FG001|Overall Study|Lost to Follow-up|4
5981497|NCT00943397|9570421|FG000|Overall Study|Protocol Violation|2
5981498|NCT00943397|9570422|FG001|Overall Study|Protocol Violation|5
5981499|NCT00943397|9570421|FG000|Overall Study|Withdrawal by Subject|1
5981500|NCT00943397|9570422|FG001|Overall Study|Withdrawal by Subject|1
5981501|NCT00943397|9570421|FG000|Overall Study|Site terminated and other|12
5981502|NCT00943397|9570422|FG001|Overall Study|Site terminated and other|56
5981503|NCT00937937|9570428|FG000|Overall Study|Adverse Event|6
5981504|NCT00937937|9570428|FG000|Overall Study|Withdrawal by Subject|2
5981505|NCT00937937|9570428|FG000|Overall Study|Progression/relapse|61
5981506|NCT00937937|9570428|FG000|Overall Study|Death|1
5981507|NCT00937937|9570428|FG000|Overall Study|Other|2
5981508|NCT00911547|9570437|FG000|Overall Study|Adverse Event|8
5981509|NCT00911547|9570438|FG001|Overall Study|Adverse Event|27
5981510|NCT00911547|9570439|FG002|Overall Study|Adverse Event|11
5981511|NCT00911547|9570440|FG003|Overall Study|Adverse Event|6
5981512|NCT00911547|9570437|FG000|Overall Study|Lost to Follow-up|0
5981513|NCT00911547|9570438|FG001|Overall Study|Lost to Follow-up|0
5981514|NCT00911547|9570439|FG002|Overall Study|Lost to Follow-up|2
5981515|NCT00911547|9570440|FG003|Overall Study|Lost to Follow-up|1
5981516|NCT00911547|9570437|FG000|Overall Study|Protocol Violation|0
5981517|NCT00911547|9570438|FG001|Overall Study|Protocol Violation|5
5981518|NCT00911547|9570439|FG002|Overall Study|Protocol Violation|5
5981519|NCT00911547|9570440|FG003|Overall Study|Protocol Violation|1
5981520|NCT00911547|9570437|FG000|Overall Study|Withdrawal by Subject|3
5981521|NCT00911547|9570438|FG001|Overall Study|Withdrawal by Subject|10
5981522|NCT00911547|9570439|FG002|Overall Study|Withdrawal by Subject|4
5981523|NCT00911547|9570440|FG003|Overall Study|Withdrawal by Subject|8
5981524|NCT00899379|9570455|FG000|Overall Study|Adverse Event|2
5981525|NCT00899379|9570456|FG001|Overall Study|Adverse Event|2
5981526|NCT00899379|9570457|FG002|Overall Study|Adverse Event|1
5981527|NCT00899379|9570458|FG003|Overall Study|Adverse Event|1
5981528|NCT00899379|9570459|FG004|Overall Study|Adverse Event|2
5981529|NCT00899379|9570455|FG000|Overall Study|Lack of Efficacy|0
5981530|NCT00899379|9570456|FG001|Overall Study|Lack of Efficacy|4
5981531|NCT00899379|9570457|FG002|Overall Study|Lack of Efficacy|3
6295374|NCT02463071|10015542|FG000|Overall Study|Eligibility criteria not fulfilled|1
6295375|NCT02463071|10015543|FG001|Overall Study|Eligibility criteria not fulfilled|0
6295376|NCT02463071|10015544|FG002|Overall Study|Eligibility criteria not fulfilled|0
6295377|NCT02463071|10015542|FG000|Overall Study|Reason not specified|7
6295378|NCT02463071|10015543|FG001|Overall Study|Reason not specified|9
6295379|NCT02463071|10015544|FG002|Overall Study|Reason not specified|4
6295380|NCT02463071|10015542|FG000|Overall Study|Protocol Violation|0
6295381|NCT02463071|10015543|FG001|Overall Study|Protocol Violation|2
6295382|NCT02463071|10015544|FG002|Overall Study|Protocol Violation|0
6295383|NCT02463071|10015542|FG000|Overall Study|Lost to Follow-up|0
6295384|NCT02463071|10015543|FG001|Overall Study|Lost to Follow-up|0
6295385|NCT02463071|10015544|FG002|Overall Study|Lost to Follow-up|1
6295386|NCT02463097|10015552|FG000|Overall Study|Withdrawal by Subject|1
6295387|NCT02463331|10015562|FG000|Overall Study|Adverse Event|4
6295388|NCT02463331|10015563|FG001|Overall Study|Adverse Event|2
6295389|NCT02463331|10015562|FG000|Overall Study|Lost to Follow-up|1
6295390|NCT02463331|10015563|FG001|Overall Study|Lost to Follow-up|1
6295391|NCT02463331|10015562|FG000|Overall Study|Pregnancy|2
6295392|NCT02463331|10015563|FG001|Overall Study|Pregnancy|3
6295393|NCT02463331|10015562|FG000|Overall Study|Lack of Efficacy|6
6295394|NCT02463331|10015563|FG001|Overall Study|Lack of Efficacy|0
6295395|NCT02463331|10015562|FG000|Overall Study|Physician Decision|3
6295396|NCT02463331|10015563|FG001|Overall Study|Physician Decision|0
6295397|NCT02463357|10015574|FG000|Overall Study|Withdrawal by Subject|1
6295398|NCT02463357|10015575|FG001|Overall Study|Withdrawal by Subject|0
6295399|NCT02463357|10015576|FG002|Overall Study|Withdrawal by Subject|0
6295400|NCT02463357|10015577|FG003|Overall Study|Withdrawal by Subject|0
6295401|NCT02463357|10015578|FG004|Overall Study|Withdrawal by Subject|0
6295402|NCT02463357|10015574|FG000|Overall Study|Withdrawal by Subject|0
6295403|NCT02463357|10015575|FG001|Overall Study|Withdrawal by Subject|0
6295404|NCT02463357|10015576|FG002|Overall Study|Withdrawal by Subject|0
6295405|NCT02463357|10015577|FG003|Overall Study|Withdrawal by Subject|0
6295406|NCT02463357|10015578|FG004|Overall Study|Withdrawal by Subject|1
6295407|NCT02463409|10015590|FG000|Overall Study|Withdrawal by Subject|1
6295408|NCT02463409|10015590|FG000|Overall Study|Screen failure|1
6295409|NCT02464059|10015617|FG000|Overall Study|Lost to Follow-up|6
6295410|NCT02465034|10015692|FG000|Overall Study|Withdrawal by Subject|1
6295411|NCT02465034|10015693|FG001|Overall Study|Withdrawal by Subject|1
6295412|NCT02465034|10015692|FG000|Overall Study|Screen fail|2
6295413|NCT02465034|10015693|FG001|Overall Study|Screen fail|0
6295414|NCT02465034|10015692|FG000|Overall Study|Could not be scheduled for study visit|0
6295415|NCT02465034|10015693|FG001|Overall Study|Could not be scheduled for study visit|5
6295416|NCT02465203|10015732|FG000|Overall Study|Protocol Violation|1
6295417|NCT02465203|10015733|FG001|Overall Study|Protocol Violation|1
6295418|NCT02465203|10015734|FG002|Overall Study|Protocol Violation|1
6295419|NCT02465203|10015732|FG000|Overall Study|Study terminated by sponsor|50
6295420|NCT02465203|10015733|FG001|Overall Study|Study terminated by sponsor|34
6295421|NCT02465203|10015734|FG002|Overall Study|Study terminated by sponsor|11
6295422|NCT02465203|10015732|FG000|Overall Study|New therapy for study indication|4
6295423|NCT02465203|10015733|FG001|Overall Study|New therapy for study indication|0
6295424|NCT02465203|10015734|FG002|Overall Study|New therapy for study indication|0
6295425|NCT02465203|10015732|FG000|Overall Study|Patient/guardian decision|1
6295426|NCT02465203|10015733|FG001|Overall Study|Patient/guardian decision|1
6295427|NCT02465203|10015734|FG002|Overall Study|Patient/guardian decision|1
6295428|NCT02465437|10015775|FG000|Overall Study|Physician Decision|0
6295429|NCT02465437|10015776|FG001|Overall Study|Physician Decision|0
6295430|NCT02465437|10015777|FG002|Overall Study|Physician Decision|1
6295431|NCT02465437|10015778|FG003|Overall Study|Physician Decision|0
6295432|NCT02465437|10015775|FG000|Overall Study|Withdrawal by Subject|1
6295433|NCT02465437|10015776|FG001|Overall Study|Withdrawal by Subject|0
6295434|NCT02465437|10015777|FG002|Overall Study|Withdrawal by Subject|0
6295435|NCT02465437|10015778|FG003|Overall Study|Withdrawal by Subject|1
6295436|NCT02465437|10015775|FG000|Overall Study|Adverse Event|0
6295437|NCT02465437|10015776|FG001|Overall Study|Adverse Event|1
6295438|NCT02465437|10015777|FG002|Overall Study|Adverse Event|0
6295439|NCT02465437|10015778|FG003|Overall Study|Adverse Event|0
6295440|NCT02465463|10015814|FG000|Overall Study|Lost to Follow-up|2
6295441|NCT02465463|10015815|FG001|Overall Study|Lost to Follow-up|1
6295442|NCT02465463|10015814|FG000|Overall Study|Death|1
6295443|NCT02465463|10015815|FG001|Overall Study|Death|0
6295444|NCT02465463|10015814|FG000|Overall Study|Protocol Violation|1
6295445|NCT02465463|10015815|FG001|Overall Study|Protocol Violation|0
6295446|NCT02465489|10015822|FG000|Overall Study|Adverse Event|5
6295447|NCT02465515|10015836|FG000|Overall Study|Investigator site closed|4
6295448|NCT02465515|10015837|FG001|Overall Study|Investigator site closed|5
6295449|NCT02465515|10015836|FG000|Overall Study|Withdrawal by Subject|74
6295450|NCT02465515|10015837|FG001|Overall Study|Withdrawal by Subject|43
6295451|NCT02465515|10015836|FG000|Overall Study|Physician Decision|8
6295452|NCT02465515|10015837|FG001|Overall Study|Physician Decision|12
6295453|NCT02465515|10015836|FG000|Overall Study|Lost to Follow-up|68
6295454|NCT02465515|10015837|FG001|Overall Study|Lost to Follow-up|51
6295455|NCT02465528|10015847|FG000|Overall Study|Progressive disease|0
6295456|NCT02465528|10015848|FG001|Overall Study|Progressive disease|2
6295457|NCT02465528|10015849|FG002|Overall Study|Progressive disease|9
6295458|NCT02465528|10015850|FG003|Overall Study|Progressive disease|4
6295459|NCT02465528|10015847|FG000|Overall Study|Study terminated by sponsor|1
6295460|NCT02465528|10015848|FG001|Overall Study|Study terminated by sponsor|2
6295461|NCT02465528|10015849|FG002|Overall Study|Study terminated by sponsor|0
6295462|NCT02465528|10015850|FG003|Overall Study|Study terminated by sponsor|0
6295463|NCT02465528|10015847|FG000|Overall Study|Withdrawal by Subject|0
6295464|NCT02465528|10015848|FG001|Overall Study|Withdrawal by Subject|0
6295465|NCT02465528|10015849|FG002|Overall Study|Withdrawal by Subject|2
6295466|NCT02465528|10015850|FG003|Overall Study|Withdrawal by Subject|0
6295467|NCT02465528|10015847|FG000|Overall Study|Adverse Event|0
6295468|NCT02465528|10015848|FG001|Overall Study|Adverse Event|0
6295469|NCT02465528|10015849|FG002|Overall Study|Adverse Event|0
6295470|NCT02465528|10015850|FG003|Overall Study|Adverse Event|1
6295471|NCT02465528|10015847|FG000|Overall Study|Physician Decision|0
6295472|NCT02465528|10015848|FG001|Overall Study|Physician Decision|0
6295473|NCT02465528|10015849|FG002|Overall Study|Physician Decision|1
6295474|NCT02465528|10015850|FG003|Overall Study|Physician Decision|0
6295475|NCT02465567|10015866|FG000|Overall Study|Adverse Event|118
6295476|NCT02465567|10015867|FG001|Overall Study|Adverse Event|113
6295477|NCT02465567|10015868|FG002|Overall Study|Adverse Event|147
6295478|NCT02465567|10015869|FG003|Overall Study|Adverse Event|138
6295479|NCT02465567|10015866|FG000|Overall Study|Lack of Efficacy|103
6295480|NCT02465567|10015867|FG001|Overall Study|Lack of Efficacy|102
6295481|NCT02465567|10015868|FG002|Overall Study|Lack of Efficacy|171
6295482|NCT02465567|10015869|FG003|Overall Study|Lack of Efficacy|135
6295483|NCT02465567|10015866|FG000|Overall Study|Withdrawal by Subject|104
6295484|NCT02465567|10015867|FG001|Overall Study|Withdrawal by Subject|94
6295485|NCT02465567|10015868|FG002|Overall Study|Withdrawal by Subject|123
6295486|NCT02465567|10015869|FG003|Overall Study|Withdrawal by Subject|130
6295487|NCT02465567|10015866|FG000|Overall Study|Physician Decision|23
6295488|NCT02465567|10015867|FG001|Overall Study|Physician Decision|33
6295489|NCT02465567|10015868|FG002|Overall Study|Physician Decision|38
6295490|NCT02465567|10015869|FG003|Overall Study|Physician Decision|28
6295491|NCT02465567|10015866|FG000|Overall Study|Major Protocol Deviation|24
6295492|NCT02465567|10015867|FG001|Overall Study|Major Protocol Deviation|26
6295493|NCT02465567|10015868|FG002|Overall Study|Major Protocol Deviation|22
6295494|NCT02465567|10015869|FG003|Overall Study|Major Protocol Deviation|25
6295495|NCT02465567|10015866|FG000|Overall Study|Lost to Follow-up|25
6295496|NCT02465567|10015867|FG001|Overall Study|Lost to Follow-up|21
6295497|NCT02465567|10015868|FG002|Overall Study|Lost to Follow-up|19
6295498|NCT02465567|10015869|FG003|Overall Study|Lost to Follow-up|15
6295499|NCT02465567|10015866|FG000|Overall Study|Protocol Specified Criteria|20
6295500|NCT02465567|10015867|FG001|Overall Study|Protocol Specified Criteria|10
6295501|NCT02465567|10015868|FG002|Overall Study|Protocol Specified Criteria|9
6295502|NCT02465567|10015869|FG003|Overall Study|Protocol Specified Criteria|12
6295503|NCT02465567|10015866|FG000|Overall Study|Administrative Reasons|12
6295504|NCT02465567|10015867|FG001|Overall Study|Administrative Reasons|9
6295505|NCT02465567|10015868|FG002|Overall Study|Administrative Reasons|11
6295506|NCT02465567|10015869|FG003|Overall Study|Administrative Reasons|5
6295507|NCT02465567|10015866|FG000|Overall Study|Randomized but not treated|1
6295508|NCT02465567|10015867|FG001|Overall Study|Randomized but not treated|5
6295509|NCT02465567|10015868|FG002|Overall Study|Randomized but not treated|4
6295510|NCT02465567|10015869|FG003|Overall Study|Randomized but not treated|5
6295511|NCT02465567|10015866|FG000|Overall Study|enrolled in >1 studies|18
6295512|NCT02465567|10015867|FG001|Overall Study|enrolled in >1 studies|11
6295513|NCT02465567|10015868|FG002|Overall Study|enrolled in >1 studies|19
6295514|NCT02465567|10015869|FG003|Overall Study|enrolled in >1 studies|15
6295515|NCT02465567|10015866|FG000|Overall Study|missing PI Signature|1
6295516|NCT02465567|10015867|FG001|Overall Study|missing PI Signature|0
6295517|NCT02465567|10015868|FG002|Overall Study|missing PI Signature|0
6295518|NCT02465567|10015869|FG003|Overall Study|missing PI Signature|0
6295519|NCT02465866|10015893|FG000|Period 3|Withdrawal by Subject|0
6295520|NCT02465866|10015894|FG001|Period 3|Withdrawal by Subject|1
6295521|NCT02465866|10015895|FG002|Period 3|Withdrawal by Subject|0
6295522|NCT02465866|10015896|FG003|Period 3|Withdrawal by Subject|0
6295523|NCT02465931|10015908|FG000|Overall Study|Lost to Follow-up|9
6295524|NCT02465931|10015909|FG001|Overall Study|Lost to Follow-up|11
6295525|NCT02465931|10015908|FG000|Overall Study|Protocol Violation|1
6295526|NCT02465931|10015909|FG001|Overall Study|Protocol Violation|0
6295527|NCT02465931|10015908|FG000|Overall Study|Withdrawal by Subject|1
6295528|NCT02465931|10015909|FG001|Overall Study|Withdrawal by Subject|0
6295529|NCT02466386|10015940|FG000|Overall Study|Adverse Event|5
6295530|NCT02466386|10015940|FG000|Overall Study|Protocol Violation|2
6295531|NCT02466386|10015940|FG000|Overall Study|Withdrawal by Subject|14
6295532|NCT02466386|10015940|FG000|Overall Study|Lost to Follow-up|5
6295533|NCT02466386|10015940|FG000|Overall Study|Lack of Efficacy|8
6295534|NCT02466386|10015940|FG000|Overall Study|Other|10
5981532|NCT00899379|9570458|FG003|Overall Study|Lack of Efficacy|0
5981533|NCT00899379|9570459|FG004|Overall Study|Lack of Efficacy|1
5981534|NCT00899379|9570455|FG000|Overall Study|Lost to Follow-up|9
6295535|NCT02466399|10015946|FG000|Overall Study|Adverse Event|1
6295536|NCT02466399|10015947|FG001|Overall Study|Adverse Event|0
6295537|NCT02466399|10015946|FG000|Overall Study|Early exit due to family emergency|1
6295538|NCT02466399|10015947|FG001|Overall Study|Early exit due to family emergency|0
6295539|NCT02466425|10015965|FG000|Overall Study|Adverse Event|3
6295540|NCT02466425|10015966|FG001|Overall Study|Adverse Event|11
6295541|NCT02466425|10015965|FG000|Overall Study|Lack of Efficacy|4
6295542|NCT02466425|10015966|FG001|Overall Study|Lack of Efficacy|1
6295543|NCT02466425|10015965|FG000|Overall Study|Lost to Follow-up|3
6295544|NCT02466425|10015966|FG001|Overall Study|Lost to Follow-up|0
6295545|NCT02466425|10015965|FG000|Overall Study|Protocol Violation|1
6295546|NCT02466425|10015966|FG001|Overall Study|Protocol Violation|0
6295547|NCT02466425|10015965|FG000|Overall Study|Withdrawal by Subject|0
6295548|NCT02466425|10015966|FG001|Overall Study|Withdrawal by Subject|1
6295549|NCT02466425|10015965|FG000|Overall Study|Other|1
6295550|NCT02466425|10015966|FG001|Overall Study|Other|3
6295551|NCT02466425|10015965|FG000|Overall Study|Withdrawal by Parent/Guardian|2
6295552|NCT02466425|10015966|FG001|Overall Study|Withdrawal by Parent/Guardian|0
6295553|NCT02466516|10015977|FG000|Overall Study|Adverse Event|1
6295554|NCT02466516|10015978|FG001|Overall Study|Adverse Event|1
6295555|NCT02466516|10015979|FG002|Overall Study|Adverse Event|0
6295556|NCT02466516|10015980|FG003|Overall Study|Adverse Event|0
6295557|NCT02466516|10015981|FG004|Overall Study|Adverse Event|0
6295558|NCT02466516|10015977|FG000|Overall Study|Withdrew Consent|1
6295559|NCT02466516|10015978|FG001|Overall Study|Withdrew Consent|0
6295560|NCT02466516|10015979|FG002|Overall Study|Withdrew Consent|0
6295561|NCT02466516|10015980|FG003|Overall Study|Withdrew Consent|0
6295562|NCT02466516|10015981|FG004|Overall Study|Withdrew Consent|0
6295563|NCT02466516|10015977|FG000|Overall Study|Lost to Follow-up|2
6295564|NCT02466516|10015978|FG001|Overall Study|Lost to Follow-up|0
6295565|NCT02466516|10015979|FG002|Overall Study|Lost to Follow-up|1
6295566|NCT02466516|10015980|FG003|Overall Study|Lost to Follow-up|0
6295567|NCT02466516|10015981|FG004|Overall Study|Lost to Follow-up|0
6295568|NCT02466555|10015993|FG000|Overall Study|Lost to Follow-up|2
6295569|NCT02466659|10016016|FG000|Overall Study|Lost to Follow-up|5
6295570|NCT02466659|10016017|FG001|Overall Study|Lost to Follow-up|2
6295571|NCT02467192|10016056|FG000|Overall Study|Death|1
6295572|NCT02467192|10016056|FG000|Overall Study|revealed to have pneumonia before|2
6295573|NCT02468193|10016139|FG000|Overall Study|Adverse Event|4
6295574|NCT02468193|10016139|FG000|Overall Study|Subject/ Guardian decision|2
6295575|NCT02468557|10016159|FG000|Overall Study|Adverse Event|1
6295576|NCT02468557|10016159|FG000|Overall Study|Death|1
6295577|NCT02468557|10016159|FG000|Overall Study|Study Terminated by Sponsor, Regulatory Agency or Institutional Review Board/ Ethics Committee|10
6295578|NCT02468557|10016159|FG000|Overall Study|All Enrolled but Never Dosed|4
6295579|NCT02468648|10016176|FG000|Overall Study|Death|1
6295580|NCT02468674|10016189|FG000|Overall Study|Adverse Event|0
6295581|NCT02468674|10016190|FG001|Overall Study|Adverse Event|0
6295582|NCT02468674|10016191|FG002|Overall Study|Adverse Event|0
6295583|NCT02468674|10016192|FG003|Overall Study|Adverse Event|1
6295584|NCT02468674|10016193|FG004|Overall Study|Adverse Event|0
6295585|NCT02468674|10016194|FG005|Overall Study|Adverse Event|1
6295586|NCT02468674|10016195|FG006|Overall Study|Adverse Event|0
6295587|NCT02468674|10016196|FG007|Overall Study|Adverse Event|0
6295588|NCT02468674|10016197|FG008|Overall Study|Adverse Event|0
6295589|NCT02468674|10016189|FG000|Overall Study|Lost to Follow-up|1
6295590|NCT02468674|10016190|FG001|Overall Study|Lost to Follow-up|0
6295591|NCT02468674|10016191|FG002|Overall Study|Lost to Follow-up|0
6295592|NCT02468674|10016192|FG003|Overall Study|Lost to Follow-up|0
6295593|NCT02468674|10016193|FG004|Overall Study|Lost to Follow-up|0
6295594|NCT02468674|10016194|FG005|Overall Study|Lost to Follow-up|0
6295595|NCT02468674|10016195|FG006|Overall Study|Lost to Follow-up|0
6295596|NCT02468674|10016196|FG007|Overall Study|Lost to Follow-up|1
6295597|NCT02468674|10016197|FG008|Overall Study|Lost to Follow-up|1
6295598|NCT02468674|10016189|FG000|Overall Study|Physician Decision|0
6295599|NCT02468674|10016190|FG001|Overall Study|Physician Decision|0
6295600|NCT02468674|10016191|FG002|Overall Study|Physician Decision|0
6295601|NCT02468674|10016192|FG003|Overall Study|Physician Decision|0
6295602|NCT02468674|10016193|FG004|Overall Study|Physician Decision|0
6295603|NCT02468674|10016194|FG005|Overall Study|Physician Decision|0
6295604|NCT02468674|10016195|FG006|Overall Study|Physician Decision|1
6295605|NCT02468674|10016196|FG007|Overall Study|Physician Decision|0
6295606|NCT02468674|10016197|FG008|Overall Study|Physician Decision|0
6295607|NCT02468674|10016189|FG000|Overall Study|Patient/Guardian Decision|0
6295608|NCT02468674|10016190|FG001|Overall Study|Patient/Guardian Decision|0
6295609|NCT02468674|10016191|FG002|Overall Study|Patient/Guardian Decision|0
6295610|NCT02468674|10016192|FG003|Overall Study|Patient/Guardian Decision|0
6295611|NCT02468674|10016193|FG004|Overall Study|Patient/Guardian Decision|1
6295612|NCT02468674|10016194|FG005|Overall Study|Patient/Guardian Decision|0
6295613|NCT02468674|10016195|FG006|Overall Study|Patient/Guardian Decision|0
6295614|NCT02468674|10016196|FG007|Overall Study|Patient/Guardian Decision|2
6295615|NCT02468674|10016197|FG008|Overall Study|Patient/Guardian Decision|1
6295616|NCT02468674|10016189|FG000|Overall Study|Protocol Deviation|0
6295617|NCT02468674|10016190|FG001|Overall Study|Protocol Deviation|0
6295618|NCT02468674|10016191|FG002|Overall Study|Protocol Deviation|0
6295619|NCT02468674|10016192|FG003|Overall Study|Protocol Deviation|0
6295620|NCT02468674|10016193|FG004|Overall Study|Protocol Deviation|0
6295621|NCT02468674|10016194|FG005|Overall Study|Protocol Deviation|0
6295622|NCT02468674|10016195|FG006|Overall Study|Protocol Deviation|0
6295623|NCT02468674|10016196|FG007|Overall Study|Protocol Deviation|1
6295624|NCT02468674|10016197|FG008|Overall Study|Protocol Deviation|1
6295625|NCT02468934|10016239|FG000|Overall Study|Withdrawal by Subject|4
6295626|NCT02468934|10016239|FG000|Overall Study|Screen Failure|3
6295627|NCT02469038|10016247|FG000|Overall Study|Physician Decision|4
6295628|NCT02469038|10016248|FG001|Overall Study|Physician Decision|5
6295629|NCT02469064|10016256|FG000|Overall Study|Request not to receive intervention.|1
6295630|NCT02469064|10016257|FG001|Overall Study|Request not to receive intervention.|3
6295631|NCT02469077|10016265|FG000|Post Randomization/Intervention Period|Scheduling issues|3
6295632|NCT02469077|10016266|FG001|Post Randomization/Intervention Period|Scheduling issues|2
6295633|NCT02469077|10016265|FG000|Post Randomization/Intervention Period|Relocated|1
6295634|NCT02469077|10016266|FG001|Post Randomization/Intervention Period|Relocated|1
6295635|NCT02469077|10016265|FG000|Post Randomization/Intervention Period|Conflicting health issues|0
6295636|NCT02469077|10016266|FG001|Post Randomization/Intervention Period|Conflicting health issues|1
6295637|NCT02469077|10016265|FG000|Post Intervention /Followup|Withdrawal by Subject|2
6295638|NCT02469077|10016266|FG001|Post Intervention /Followup|Withdrawal by Subject|1
6295639|NCT02469090|10016278|FG000|Period 1: Dose Titration Phase|Adverse Event|12
6295640|NCT02469090|10016279|FG001|Period 1: Dose Titration Phase|Adverse Event|0
6295641|NCT02469090|10016280|FG002|Period 1: Dose Titration Phase|Adverse Event|0
6295642|NCT02469090|10016278|FG000|Period 1: Dose Titration Phase|Withdrawal by Subject|8
6295643|NCT02469090|10016279|FG001|Period 1: Dose Titration Phase|Withdrawal by Subject|0
6295644|NCT02469090|10016280|FG002|Period 1: Dose Titration Phase|Withdrawal by Subject|0
6295645|NCT02469090|10016278|FG000|Period 1: Dose Titration Phase|Lost to Follow-up|1
6295646|NCT02469090|10016279|FG001|Period 1: Dose Titration Phase|Lost to Follow-up|0
6295647|NCT02469090|10016280|FG002|Period 1: Dose Titration Phase|Lost to Follow-up|0
6295648|NCT02469090|10016278|FG000|Period 1: Dose Titration Phase|Lack of Efficacy|11
6295649|NCT02469090|10016279|FG001|Period 1: Dose Titration Phase|Lack of Efficacy|0
6295650|NCT02469090|10016280|FG002|Period 1: Dose Titration Phase|Lack of Efficacy|0
6295651|NCT02469090|10016278|FG000|Period 2: Maintenance Treatment Phase|Adverse Event|0
6295652|NCT02469090|10016279|FG001|Period 2: Maintenance Treatment Phase|Adverse Event|5
6295653|NCT02469090|10016280|FG002|Period 2: Maintenance Treatment Phase|Adverse Event|15
6295654|NCT02469090|10016278|FG000|Period 2: Maintenance Treatment Phase|Withdrawal by Subject|0
6295655|NCT02469090|10016279|FG001|Period 2: Maintenance Treatment Phase|Withdrawal by Subject|3
6295656|NCT02469090|10016280|FG002|Period 2: Maintenance Treatment Phase|Withdrawal by Subject|4
6295657|NCT02469090|10016278|FG000|Period 2: Maintenance Treatment Phase|Lack of Efficacy|0
6295658|NCT02469090|10016279|FG001|Period 2: Maintenance Treatment Phase|Lack of Efficacy|1
6295659|NCT02469090|10016280|FG002|Period 2: Maintenance Treatment Phase|Lack of Efficacy|0
6295660|NCT02469090|10016278|FG000|Period 2: Maintenance Treatment Phase|Death|0
6295661|NCT02469090|10016279|FG001|Period 2: Maintenance Treatment Phase|Death|0
6295662|NCT02469090|10016280|FG002|Period 2: Maintenance Treatment Phase|Death|1
6295663|NCT02469168|10016293|FG000|Overall Study|Trial closed|1
6295664|NCT02469168|10016294|FG001|Overall Study|Trial closed|0
6295665|NCT02469246|10016302|FG000|Double-Blind Phase|Randomized and Never Treated|5
6295666|NCT02469246|10016303|FG001|Double-Blind Phase|Randomized and Never Treated|6
6295667|NCT02469246|10016302|FG000|Double-Blind Phase|Adverse Event|12
6295668|NCT02469246|10016303|FG001|Double-Blind Phase|Adverse Event|9
6295669|NCT02469246|10016302|FG000|Double-Blind Phase|Death|2
6295670|NCT02469246|10016303|FG001|Double-Blind Phase|Death|0
6295671|NCT02469246|10016302|FG000|Double-Blind Phase|Lack of Efficacy|2
6295672|NCT02469246|10016303|FG001|Double-Blind Phase|Lack of Efficacy|1
6295673|NCT02469246|10016302|FG000|Double-Blind Phase|Investigator's Discretion|8
6295674|NCT02469246|10016303|FG001|Double-Blind Phase|Investigator's Discretion|8
6295675|NCT02469246|10016302|FG000|Double-Blind Phase|Non-Compliance with Study Drug|3
6295676|NCT02469246|10016303|FG001|Double-Blind Phase|Non-Compliance with Study Drug|1
6295677|NCT02469246|10016302|FG000|Double-Blind Phase|Protocol Violation|1
6295678|NCT02469246|10016303|FG001|Double-Blind Phase|Protocol Violation|1
6295679|NCT02469246|10016302|FG000|Double-Blind Phase|Withdrew Consent|25
6295680|NCT02469246|10016303|FG001|Double-Blind Phase|Withdrew Consent|25
6295681|NCT02469246|10016302|FG000|Double-Blind Phase|Lost to Follow-up|9
6295682|NCT02469246|10016303|FG001|Double-Blind Phase|Lost to Follow-up|5
6295683|NCT02469298|10016315|FG000|Overall Study|Protocol Violation|0
6295684|NCT02469298|10016316|FG001|Overall Study|Protocol Violation|1
6295685|NCT02469298|10016317|FG002|Overall Study|Protocol Violation|1
6295686|NCT02469298|10016318|FG003|Overall Study|Protocol Violation|0
6295687|NCT02469298|10016315|FG000|Overall Study|Lost to Follow-up|1
6295688|NCT02469298|10016316|FG001|Overall Study|Lost to Follow-up|0
6295689|NCT02469298|10016317|FG002|Overall Study|Lost to Follow-up|1
6295690|NCT02469298|10016318|FG003|Overall Study|Lost to Follow-up|0
6295691|NCT02469298|10016315|FG000|Overall Study|Physician Decision|0
6295692|NCT02469298|10016316|FG001|Overall Study|Physician Decision|0
6295693|NCT02469298|10016317|FG002|Overall Study|Physician Decision|0
6295694|NCT02469298|10016318|FG003|Overall Study|Physician Decision|1
6295695|NCT02469298|10016315|FG000|Overall Study|Withdrawal by Subject|0
6295696|NCT02469298|10016316|FG001|Overall Study|Withdrawal by Subject|0
6295697|NCT02469298|10016317|FG002|Overall Study|Withdrawal by Subject|0
6295698|NCT02469298|10016318|FG003|Overall Study|Withdrawal by Subject|1
6295699|NCT02469610|10016355|FG000|Overall Study|Death|1
6295700|NCT02469610|10016356|FG001|Overall Study|Death|0
6295701|NCT02469610|10016355|FG000|Overall Study|Lost to Follow-up|1
6295702|NCT02469610|10016356|FG001|Overall Study|Lost to Follow-up|0
6295703|NCT02469610|10016355|FG000|Overall Study|exclusion criteria|2
6295704|NCT02469610|10016356|FG001|Overall Study|exclusion criteria|1
6295705|NCT02469623|10016362|FG000|Overall Study|Not consented for long-term follow-up|4
6295706|NCT02469623|10016362|FG000|Overall Study|Lost to Follow-up|4
6295707|NCT02469623|10016362|FG000|Overall Study|Withdrawal by Subject|2
6295708|NCT02469623|10016362|FG000|Overall Study|Death|3
6295709|NCT02469857|10016382|FG000|Overall Study|Death|24
6295710|NCT02469857|10016383|FG001|Overall Study|Death|29
6295711|NCT02469857|10016382|FG000|Overall Study|Discontinuation|1
6295712|NCT02469857|10016383|FG001|Overall Study|Discontinuation|3
6295713|NCT02469896|10016405|FG000|Overall Study|Withdrawal by Subject|2
6295714|NCT02469896|10016406|FG001|Overall Study|Withdrawal by Subject|0
6295715|NCT02469961|10016418|FG000|Overall Study|Physician Decision|4
6295716|NCT02469961|10016419|FG001|Overall Study|Physician Decision|1
6295717|NCT02470403|10016473|FG000|Overall Study|Adverse Event|1
6295718|NCT02470403|10016474|FG001|Overall Study|Adverse Event|0
6295719|NCT02470403|10016475|FG002|Overall Study|Adverse Event|0
6295720|NCT02470403|10016476|FG003|Overall Study|Adverse Event|0
6295721|NCT02470403|10016477|FG004|Overall Study|Adverse Event|0
6295722|NCT02470403|10016473|FG000|Overall Study|Lost to Follow-up|0
6295723|NCT02470403|10016474|FG001|Overall Study|Lost to Follow-up|1
6295724|NCT02470403|10016475|FG002|Overall Study|Lost to Follow-up|0
6295725|NCT02470403|10016476|FG003|Overall Study|Lost to Follow-up|0
6295726|NCT02470403|10016477|FG004|Overall Study|Lost to Follow-up|0
6295727|NCT02470403|10016473|FG000|Overall Study|Subject/guardian decision|1
6295728|NCT02470403|10016474|FG001|Overall Study|Subject/guardian decision|0
6295729|NCT02470403|10016475|FG002|Overall Study|Subject/guardian decision|0
6295730|NCT02470403|10016476|FG003|Overall Study|Subject/guardian decision|4
6295731|NCT02470403|10016477|FG004|Overall Study|Subject/guardian decision|0
6295732|NCT02470429|10016494|FG000|Overall Study|Adverse Event|1
6295733|NCT02470429|10016495|FG001|Overall Study|Adverse Event|0
6295734|NCT02470429|10016494|FG000|Overall Study|Withdrawal by Subject|1
6295735|NCT02470429|10016495|FG001|Overall Study|Withdrawal by Subject|0
6295736|NCT02470585|10016509|FG000|Overall Study|Death|82
6295737|NCT02470585|10016510|FG001|Overall Study|Death|87
6295738|NCT02470585|10016511|FG002|Overall Study|Death|86
6295739|NCT02470585|10016509|FG000|Overall Study|Withdrawal by Subject|19
6295740|NCT02470585|10016510|FG001|Overall Study|Withdrawal by Subject|21
6295741|NCT02470585|10016511|FG002|Overall Study|Withdrawal by Subject|29
6295742|NCT02470585|10016509|FG000|Overall Study|Lost to Follow-up|2
6295743|NCT02470585|10016510|FG001|Overall Study|Lost to Follow-up|5
6295744|NCT02470585|10016511|FG002|Overall Study|Lost to Follow-up|4
6295745|NCT02470585|10016509|FG000|Overall Study|Other|4
6295746|NCT02470585|10016510|FG001|Overall Study|Other|4
6295747|NCT02470585|10016511|FG002|Overall Study|Other|6
6295748|NCT02470806|10016537|FG000|Overall Study|Lost to Follow-up|1
6295749|NCT02470806|10016538|FG001|Overall Study|Lost to Follow-up|1
6295750|NCT02470806|10016537|FG000|Overall Study|Adverse Event|5
6295751|NCT02470806|10016538|FG001|Overall Study|Adverse Event|2
6295752|NCT02470806|10016537|FG000|Overall Study|Protocol Violation|4
6295753|NCT02470806|10016538|FG001|Overall Study|Protocol Violation|11
6295754|NCT02470806|10016537|FG000|Overall Study|Physician Decision|0
6295755|NCT02470806|10016538|FG001|Overall Study|Physician Decision|3
6295756|NCT02470806|10016537|FG000|Overall Study|Withdrawal by Subject|3
6295757|NCT02470806|10016538|FG001|Overall Study|Withdrawal by Subject|10
6295758|NCT02470806|10016537|FG000|Overall Study|Lack of Efficacy|5
6295759|NCT02470806|10016538|FG001|Overall Study|Lack of Efficacy|15
6295760|NCT02471014|10016562|FG000|Overall Study|Lost to Follow-up|2
6295761|NCT02471014|10016563|FG001|Overall Study|Lost to Follow-up|2
6295762|NCT02471183|10016569|FG000|Main Treatment Period|Adverse Event|1
6295763|NCT02471183|10016569|FG000|Main Treatment Period|Withdrawal by Subject|1
6295764|NCT02471183|10016569|FG000|Extended Treatment Period|Lack of Efficacy|1
6295765|NCT02471404|10016584|FG000|Overall Study|Adverse Event|7
6295766|NCT02471404|10016585|FG001|Overall Study|Adverse Event|1
6295767|NCT02471404|10016586|FG002|Overall Study|Adverse Event|2
6295768|NCT02471404|10016584|FG000|Overall Study|Developed Study Withdrawal Criteria|4
6295769|NCT02471404|10016585|FG001|Overall Study|Developed Study Withdrawal Criteria|1
6295770|NCT02471404|10016586|FG002|Overall Study|Developed Study Withdrawal Criteria|2
6295771|NCT02471404|10016584|FG000|Overall Study|Failure to Meet Randomization Criteria|2
6295772|NCT02471404|10016585|FG001|Overall Study|Failure to Meet Randomization Criteria|0
6295773|NCT02471404|10016586|FG002|Overall Study|Failure to Meet Randomization Criteria|1
6295774|NCT02471404|10016584|FG000|Overall Study|Lost to Follow-up|1
6295775|NCT02471404|10016585|FG001|Overall Study|Lost to Follow-up|1
6295776|NCT02471404|10016586|FG002|Overall Study|Lost to Follow-up|3
6295777|NCT02471404|10016584|FG000|Overall Study|Protocol Violation|1
6295778|NCT02471404|10016585|FG001|Overall Study|Protocol Violation|0
6295779|NCT02471404|10016586|FG002|Overall Study|Protocol Violation|0
6295780|NCT02471404|10016584|FG000|Overall Study|Withdrawal by Subject|8
6295781|NCT02471404|10016585|FG001|Overall Study|Withdrawal by Subject|4
6295782|NCT02471404|10016586|FG002|Overall Study|Withdrawal by Subject|5
6295783|NCT02471404|10016584|FG000|Overall Study|Other reasons not specified|10
6295784|NCT02471404|10016585|FG001|Overall Study|Other reasons not specified|7
6295785|NCT02471404|10016586|FG002|Overall Study|Other reasons not specified|12
6295786|NCT02471586|10016606|FG000|Overall Study|Lost to Follow-up|3
6295787|NCT02471586|10016607|FG001|Overall Study|Lost to Follow-up|8
6295788|NCT02471586|10016608|FG002|Overall Study|Lost to Follow-up|4
6295789|NCT02471586|10016606|FG000|Overall Study|Death|2
6295790|NCT02471586|10016607|FG001|Overall Study|Death|2
6295791|NCT02471586|10016608|FG002|Overall Study|Death|0
6295792|NCT02471612|10016618|FG000|Overall Study|Lost to Follow-up|2
6295793|NCT02471716|10016649|FG000|Overall Study|Withdrawal by Subject|0
6295794|NCT02471716|10016650|FG001|Overall Study|Withdrawal by Subject|1
6295795|NCT02471716|10016651|FG002|Overall Study|Withdrawal by Subject|0
6295796|NCT02471716|10016652|FG003|Overall Study|Withdrawal by Subject|2
6295797|NCT02471716|10016653|FG004|Overall Study|Withdrawal by Subject|5
6295798|NCT02471716|10016649|FG000|Overall Study|Study Terminiated by sponsor|0
6295799|NCT02471716|10016650|FG001|Overall Study|Study Terminiated by sponsor|0
6295800|NCT02471716|10016651|FG002|Overall Study|Study Terminiated by sponsor|0
6295801|NCT02471716|10016652|FG003|Overall Study|Study Terminiated by sponsor|1
6295802|NCT02471716|10016653|FG004|Overall Study|Study Terminiated by sponsor|0
6295803|NCT02471716|10016649|FG000|Overall Study|Lost to Follow-up|0
6295804|NCT02471716|10016650|FG001|Overall Study|Lost to Follow-up|0
6295805|NCT02471716|10016651|FG002|Overall Study|Lost to Follow-up|0
6295806|NCT02471716|10016652|FG003|Overall Study|Lost to Follow-up|3
6295807|NCT02471716|10016653|FG004|Overall Study|Lost to Follow-up|2
6295808|NCT02471716|10016649|FG000|Overall Study|Death|0
6295809|NCT02471716|10016650|FG001|Overall Study|Death|0
6295810|NCT02471716|10016651|FG002|Overall Study|Death|0
6295811|NCT02471716|10016652|FG003|Overall Study|Death|1
6295812|NCT02471716|10016653|FG004|Overall Study|Death|0
6295813|NCT02471716|10016649|FG000|Overall Study|Other|0
6295814|NCT02471716|10016650|FG001|Overall Study|Other|0
6295815|NCT02471716|10016651|FG002|Overall Study|Other|0
6295816|NCT02471716|10016652|FG003|Overall Study|Other|8
6295817|NCT02471716|10016653|FG004|Overall Study|Other|9
6295818|NCT02471755|10016669|FG000|Overall Study|Withdrawal by Subject|1
6295819|NCT02471755|10016670|FG001|Overall Study|Withdrawal by Subject|0
6295820|NCT02471755|10016669|FG000|Overall Study|Lost to Follow-up|0
6295821|NCT02471755|10016670|FG001|Overall Study|Lost to Follow-up|1
6295822|NCT02472145|10016679|FG000|Overall Study|Death|10
6295823|NCT02472145|10016680|FG001|Overall Study|Death|101
6295824|NCT02472145|10016681|FG002|Overall Study|Death|99
6295825|NCT02472145|10016679|FG000|Overall Study|Lost to Follow-up|0
6295826|NCT02472145|10016680|FG001|Overall Study|Lost to Follow-up|1
6295827|NCT02472145|10016681|FG002|Overall Study|Lost to Follow-up|0
6295828|NCT02472145|10016679|FG000|Overall Study|Withdrawal by Subject|0
6295829|NCT02472145|10016680|FG001|Overall Study|Withdrawal by Subject|9
6295830|NCT02472145|10016681|FG002|Overall Study|Withdrawal by Subject|13
6295831|NCT02472145|10016679|FG000|Overall Study|Sponsor decision|0
6295832|NCT02472145|10016680|FG001|Overall Study|Sponsor decision|3
6295833|NCT02472145|10016681|FG002|Overall Study|Sponsor decision|2
6295834|NCT02472145|10016679|FG000|Overall Study|Other|0
6295835|NCT02472145|10016680|FG001|Overall Study|Other|45
6295836|NCT02472145|10016681|FG002|Overall Study|Other|43
6295837|NCT02472353|10016721|FG000|Overall Study|Lost to Follow-up|1
6295838|NCT02472353|10016722|FG001|Overall Study|Lost to Follow-up|1
6295839|NCT02472353|10016721|FG000|Overall Study|Withdrawal by Subject|2
6295840|NCT02472353|10016722|FG001|Overall Study|Withdrawal by Subject|1
6295841|NCT02472353|10016721|FG000|Overall Study|Study Termination|1
6295842|NCT02472353|10016722|FG001|Overall Study|Study Termination|4
6295843|NCT02472366|10016730|FG000|Overall Study|Lost to Follow-up|1
6295844|NCT02472366|10016731|FG001|Overall Study|Lost to Follow-up|0
6295845|NCT02472405|10016737|FG000|Overall Study|Lost to Follow-up|9
6295846|NCT02472405|10016737|FG000|Overall Study|Adverse Event|1
6295847|NCT02472652|10016763|FG000|Overall Study|Lost to Follow-up|1
6295848|NCT02472756|10016776|FG000|Induction (Approximately 6 Months)|Adverse Event|1
6295849|NCT02472756|10016776|FG000|Induction (Approximately 6 Months)|Enrolled But Not Treated|1
6295850|NCT02472756|10016776|FG000|Maintenance (Approximately 2 Years)|Lack of Drug|7
6295851|NCT02472756|10016776|FG000|Maintenance (Approximately 2 Years)|Progression Disease|2
6295852|NCT02472756|10016776|FG000|Maintenance (Approximately 2 Years)|Adverse Event|1
6295853|NCT02472795|10016785|FG000|Overall Study|Adverse Event|0
6295854|NCT02472795|10016786|FG001|Overall Study|Adverse Event|1
6295855|NCT02472795|10016787|FG002|Overall Study|Adverse Event|0
6295856|NCT02472795|10016788|FG003|Overall Study|Adverse Event|0
6295857|NCT02472795|10016789|FG004|Overall Study|Adverse Event|2
6295858|NCT02472795|10016785|FG000|Overall Study|Withdrawal by Subject|0
6295859|NCT02472795|10016786|FG001|Overall Study|Withdrawal by Subject|0
6295860|NCT02472795|10016787|FG002|Overall Study|Withdrawal by Subject|0
6295861|NCT02472795|10016788|FG003|Overall Study|Withdrawal by Subject|0
6295862|NCT02472795|10016789|FG004|Overall Study|Withdrawal by Subject|1
6295863|NCT02472847|10016803|FG000|Overall Study|Withdrawal by Subject|1
6295864|NCT02472847|10016804|FG001|Overall Study|Withdrawal by Subject|5
6295865|NCT02472886|10016813|FG000|Overall Study|Lack of Efficacy|0
6295866|NCT02472886|10016814|FG001|Overall Study|Lack of Efficacy|2
6295867|NCT02472886|10016815|FG002|Overall Study|Lack of Efficacy|1
6295868|NCT02472977|10016831|FG000|Overall Study|Disease progression|4
6295869|NCT02472977|10016832|FG001|Overall Study|Disease progression|25
6295870|NCT02472977|10016833|FG002|Overall Study|Disease progression|6
6295871|NCT02472977|10016831|FG000|Overall Study|Withdrawal by Subject|0
6295872|NCT02472977|10016832|FG001|Overall Study|Withdrawal by Subject|1
6295873|NCT02472977|10016833|FG002|Overall Study|Withdrawal by Subject|0
6295874|NCT02472977|10016831|FG000|Overall Study|Study drug toxicity|2
6295875|NCT02472977|10016832|FG001|Overall Study|Study drug toxicity|0
6295876|NCT02472977|10016833|FG002|Overall Study|Study drug toxicity|2
6295877|NCT02472977|10016831|FG000|Overall Study|Subject request to discontinue treatment|0
6295878|NCT02472977|10016832|FG001|Overall Study|Subject request to discontinue treatment|1
6295879|NCT02472977|10016833|FG002|Overall Study|Subject request to discontinue treatment|0
6295880|NCT02473250|10016841|FG000|Overall Study|Lost to Follow-up|10
6295881|NCT02473250|10016841|FG000|Overall Study|Physician Decision|5
6295882|NCT02473250|10016841|FG000|Overall Study|Did not tolerate medication washout|3
6295883|NCT02473250|10016841|FG000|Overall Study|Antidepressant effect of divalproex|2
6295884|NCT02473289|10016848|FG000|Overall Study|Adverse Event|2
6295885|NCT02473289|10016849|FG001|Overall Study|Adverse Event|3
6295886|NCT02473289|10016848|FG000|Overall Study|Lost to Follow-up|1
6295887|NCT02473289|10016849|FG001|Overall Study|Lost to Follow-up|1
6295888|NCT02473289|10016848|FG000|Overall Study|Protocol Violation|0
6295889|NCT02473289|10016849|FG001|Overall Study|Protocol Violation|1
6295890|NCT02473289|10016848|FG000|Overall Study|Withdrawal of consent|6
6295891|NCT02473289|10016849|FG001|Overall Study|Withdrawal of consent|7
6295892|NCT02473289|10016848|FG000|Overall Study|Treatment Unblinded + Adverse event|0
6295893|NCT02473289|10016849|FG001|Overall Study|Treatment Unblinded + Adverse event|1
6295894|NCT02473289|10016848|FG000|Overall Study|Other|2
6295895|NCT02473289|10016849|FG001|Overall Study|Other|0
6295896|NCT02473367|10016855|FG000|Wait 1|Withdrawal by Subject|1
6295897|NCT02473367|10016855|FG000|Period 4|Lost to Follow-up|1
6295898|NCT02473393|10016869|FG000|Overall Study|Adverse Event|0
6295899|NCT02473393|10016870|FG001|Overall Study|Adverse Event|0
6295900|NCT02473393|10016871|FG002|Overall Study|Adverse Event|1
6295901|NCT02473393|10016872|FG003|Overall Study|Adverse Event|0
6295902|NCT02473393|10016869|FG000|Overall Study|Withdrawal by Subject|0
6295903|NCT02473393|10016870|FG001|Overall Study|Withdrawal by Subject|0
6295904|NCT02473393|10016871|FG002|Overall Study|Withdrawal by Subject|1
6295905|NCT02473393|10016872|FG003|Overall Study|Withdrawal by Subject|1
6295906|NCT02473471|10016882|FG000|Overall Study|poor oral hygiene|2
6295907|NCT02473471|10016882|FG000|Overall Study|Lost to Follow-up|1
6295908|NCT02473510|10016894|FG000|Overall Study|Lost to Follow-up|1
6295909|NCT02473510|10016895|FG001|Overall Study|Lost to Follow-up|2
6295910|NCT02473614|10016901|FG000|First Intervention (3 Weeks)|Job duties/lack of transportation|1
6295911|NCT02473614|10016902|FG001|First Intervention (3 Weeks)|Job duties/lack of transportation|0
6295912|NCT02473640|10016909|FG000|Treatment Period 1|Adverse Event|1
6295913|NCT02473913|10016937|FG000|Overall Study|Lost to Follow-up|3
6295914|NCT02473913|10016938|FG001|Overall Study|Lost to Follow-up|3
6295915|NCT02473952|10016946|FG000|Overall Study|Adverse Event|2
6295916|NCT02473952|10016947|FG001|Overall Study|Adverse Event|2
6295917|NCT02473952|10016946|FG000|Overall Study|Withdrawal by Subject|0
6295918|NCT02473952|10016947|FG001|Overall Study|Withdrawal by Subject|6
6295919|NCT02473965|10016955|FG000|Overall Study|Adverse Event|6
6295920|NCT02473965|10016956|FG001|Overall Study|Adverse Event|4
6295921|NCT02473965|10016955|FG000|Overall Study|MG worsening|4
6295922|NCT02473965|10016956|FG001|Overall Study|MG worsening|1
6295923|NCT02473965|10016955|FG000|Overall Study|Withdrawal by Subject|2
6295924|NCT02473965|10016956|FG001|Overall Study|Withdrawal by Subject|3
6295925|NCT02473965|10016955|FG000|Overall Study|Physician Decision|0
6295926|NCT02473965|10016956|FG001|Overall Study|Physician Decision|2
6295927|NCT02474069|10016966|FG000|Selection Phase (SP)|Adverse Event|8
6295928|NCT02474069|10016967|FG001|Selection Phase (SP)|Adverse Event|0
6295929|NCT02474069|10016968|FG002|Selection Phase (SP)|Adverse Event|0
6295930|NCT02474069|10016966|FG000|Selection Phase (SP)|Lack of Efficacy|1
6295931|NCT02474069|10016967|FG001|Selection Phase (SP)|Lack of Efficacy|0
6295932|NCT02474069|10016968|FG002|Selection Phase (SP)|Lack of Efficacy|0
6295933|NCT02474069|10016966|FG000|Selection Phase (SP)|Lost to Follow-up|4
6295934|NCT02474069|10016967|FG001|Selection Phase (SP)|Lost to Follow-up|0
6295935|NCT02474069|10016968|FG002|Selection Phase (SP)|Lost to Follow-up|0
6295936|NCT02474069|10016966|FG000|Selection Phase (SP)|Physician Decision|1
6295937|NCT02474069|10016967|FG001|Selection Phase (SP)|Physician Decision|0
6295938|NCT02474069|10016968|FG002|Selection Phase (SP)|Physician Decision|0
6295939|NCT02474069|10016966|FG000|Selection Phase (SP)|Protocol Violation|1
6295940|NCT02474069|10016967|FG001|Selection Phase (SP)|Protocol Violation|0
6295941|NCT02474069|10016968|FG002|Selection Phase (SP)|Protocol Violation|0
6295942|NCT02474069|10016966|FG000|Selection Phase (SP)|No longer requires treatment|1
6295943|NCT02474069|10016967|FG001|Selection Phase (SP)|No longer requires treatment|0
6295944|NCT02474069|10016968|FG002|Selection Phase (SP)|No longer requires treatment|0
6295945|NCT02474069|10016966|FG000|Selection Phase (SP)|Technical Problem|1
6295946|NCT02474069|10016967|FG001|Selection Phase (SP)|Technical Problem|0
6295947|NCT02474069|10016968|FG002|Selection Phase (SP)|Technical Problem|0
6295948|NCT02474069|10016966|FG000|Selection Phase (SP)|Withdrawal by Subject|3
6295949|NCT02474069|10016967|FG001|Selection Phase (SP)|Withdrawal by Subject|0
6295950|NCT02474069|10016968|FG002|Selection Phase (SP)|Withdrawal by Subject|0
6295951|NCT02474069|10016966|FG000|Selection Phase (SP)|Withdrawal of Informed Consent|3
6295952|NCT02474069|10016967|FG001|Selection Phase (SP)|Withdrawal of Informed Consent|0
6295953|NCT02474069|10016968|FG002|Selection Phase (SP)|Withdrawal of Informed Consent|0
6295954|NCT02474069|10016966|FG000|Comparative Dosing Phase (CDP)|Adverse Event|0
6295955|NCT02474069|10016967|FG001|Comparative Dosing Phase (CDP)|Adverse Event|3
6295956|NCT02474069|10016968|FG002|Comparative Dosing Phase (CDP)|Adverse Event|2
6295957|NCT02474069|10016966|FG000|Comparative Dosing Phase (CDP)|Lost to Follow-up|0
6295958|NCT02474069|10016967|FG001|Comparative Dosing Phase (CDP)|Lost to Follow-up|4
6295959|NCT02474069|10016968|FG002|Comparative Dosing Phase (CDP)|Lost to Follow-up|1
6295960|NCT02474069|10016966|FG000|Comparative Dosing Phase (CDP)|Withdrawal by Subject|0
6295961|NCT02474069|10016967|FG001|Comparative Dosing Phase (CDP)|Withdrawal by Subject|0
6295962|NCT02474069|10016968|FG002|Comparative Dosing Phase (CDP)|Withdrawal by Subject|1
6295963|NCT02474069|10016966|FG000|Comparative Dosing Phase (CDP)|Withdrawal of informed Consent|0
6295964|NCT02474069|10016967|FG001|Comparative Dosing Phase (CDP)|Withdrawal of informed Consent|2
6295965|NCT02474069|10016968|FG002|Comparative Dosing Phase (CDP)|Withdrawal of informed Consent|2
6295966|NCT02474082|10016980|FG000|Overall Study|Adverse Event|2
6295967|NCT02474082|10016981|FG001|Overall Study|Adverse Event|32
6295968|NCT02474082|10016980|FG000|Overall Study|Withdrawal of informed consent|1
6295969|NCT02474082|10016981|FG001|Overall Study|Withdrawal of informed consent|11
6295970|NCT02474082|10016980|FG000|Overall Study|Lost to Follow-up|2
6295971|NCT02474082|10016981|FG001|Overall Study|Lost to Follow-up|2
6295972|NCT02474082|10016980|FG000|Overall Study|Dose tapering not achieved|0
6295973|NCT02474082|10016981|FG001|Overall Study|Dose tapering not achieved|4
6295974|NCT02474082|10016980|FG000|Overall Study|Participant/guardian decision|1
6295975|NCT02474082|10016981|FG001|Overall Study|Participant/guardian decision|2
6295976|NCT02474082|10016980|FG000|Overall Study|Non-compliance with study treatment|0
6295977|NCT02474082|10016981|FG001|Overall Study|Non-compliance with study treatment|2
6295978|NCT02474082|10016980|FG000|Overall Study|Protocol deviation|0
6295979|NCT02474082|10016981|FG001|Overall Study|Protocol deviation|1
6295980|NCT02474199|10016989|FG000|Overall Study|Lost to Follow-up|1
6295981|NCT02474199|10016990|FG001|Overall Study|Lost to Follow-up|0
6295982|NCT02474199|10016991|FG002|Overall Study|Lost to Follow-up|0
6295983|NCT02474199|10016992|FG003|Overall Study|Lost to Follow-up|0
6295984|NCT02474199|10016989|FG000|Overall Study|Withdrawal by Subject|1
6295985|NCT02474199|10016990|FG001|Overall Study|Withdrawal by Subject|2
6295986|NCT02474199|10016991|FG002|Overall Study|Withdrawal by Subject|0
6295987|NCT02474199|10016992|FG003|Overall Study|Withdrawal by Subject|1
6295988|NCT02474199|10016989|FG000|Overall Study|Did not receive Tregs due to insufficient manufacture|0
6295989|NCT02474199|10016990|FG001|Overall Study|Did not receive Tregs due to insufficient manufacture|1
6295990|NCT02474199|10016991|FG002|Overall Study|Did not receive Tregs due to insufficient manufacture|0
6295991|NCT02474199|10016992|FG003|Overall Study|Did not receive Tregs due to insufficient manufacture|0
6295992|NCT02474199|10016989|FG000|Overall Study|Did not meet eligibility criteria|0
6295993|NCT02474199|10016990|FG001|Overall Study|Did not meet eligibility criteria|0
6295994|NCT02474199|10016991|FG002|Overall Study|Did not meet eligibility criteria|2
6295995|NCT02474199|10016992|FG003|Overall Study|Did not meet eligibility criteria|2
6295996|NCT02474355|10016999|FG000|Overall Study|Other|43
6295997|NCT02474355|10016999|FG000|Overall Study|Eligibility Criteria not Fulfilled|2
6295998|NCT02474355|10016999|FG000|Overall Study|Lost to Follow-up|98
6295999|NCT02474355|10016999|FG000|Overall Study|Withdrawal by Subject|124
6296000|NCT02474355|10016999|FG000|Overall Study|Death|1361
6296001|NCT02474589|10017049|FG000|Overall Study|Adverse Event|6
6296002|NCT02474589|10017050|FG001|Overall Study|Adverse Event|2
6296003|NCT02474589|10017049|FG000|Overall Study|Lost to Follow-up|6
6296004|NCT02474589|10017050|FG001|Overall Study|Lost to Follow-up|1
6296005|NCT02474589|10017049|FG000|Overall Study|Protocol Violation|4
6296006|NCT02474589|10017050|FG001|Overall Study|Protocol Violation|1
6296007|NCT02474589|10017049|FG000|Overall Study|Withdrawal by Subject|4
6296008|NCT02474589|10017050|FG001|Overall Study|Withdrawal by Subject|0
6296009|NCT02474589|10017049|FG000|Overall Study|Inability to complete study procedures|5
6296010|NCT02474589|10017050|FG001|Overall Study|Inability to complete study procedures|1
6296011|NCT02475265|10017086|FG000|Overall Study|Physician Decision|1
6296012|NCT02475265|10017086|FG000|Overall Study|Withdrawal by Subject|2
6296013|NCT02475278|10017090|FG000|Overall Study|Lost to Follow-up|1
6296014|NCT02475278|10017090|FG000|Overall Study|Reason Not Specified|1
6296015|NCT02475369|10017094|FG000|Run-in Washout Period #1 (7 Days)|Sponsor terminated study prematurely|7
6296016|NCT02475369|10017095|FG001|Run-in Washout Period #1 (7 Days)|Sponsor terminated study prematurely|2
6296017|NCT02475395|10017108|FG000|Overall Study|Protocol Violation|30
6296018|NCT02475395|10017109|FG001|Overall Study|Protocol Violation|3
6296019|NCT02475564|10017117|FG000|Overall Study|Withdrawal by Subject|1
6296020|NCT02475564|10017118|FG001|Overall Study|Withdrawal by Subject|0
6296021|NCT02475564|10017117|FG000|Overall Study|Lost to Follow-up|2
6296022|NCT02475564|10017118|FG001|Overall Study|Lost to Follow-up|1
6296023|NCT02475564|10017117|FG000|Overall Study|Intense Menstrual bleeding|1
6296024|NCT02475564|10017118|FG001|Overall Study|Intense Menstrual bleeding|0
6296025|NCT02475629|10017124|FG000|Overall Study|Adverse Event|1
6296026|NCT02475629|10017124|FG000|Overall Study|Death|4
6296027|NCT02475629|10017124|FG000|Overall Study|Physician Decision|1
6296028|NCT02475629|10017124|FG000|Overall Study|Withdrawal by Subject|1
6296029|NCT02475629|10017124|FG000|Overall Study|Lost to Follow-up|1
6296030|NCT02475629|10017124|FG000|Overall Study|Subject non-compliance|1
6296031|NCT02475655|10017130|FG000|Overall Study|Lost to Follow-up|0
6296032|NCT02475655|10017131|FG001|Overall Study|Lost to Follow-up|1
6296033|NCT02475733|10017139|FG000|Overall Study|Withdrawal by Subject|1
6296034|NCT02475733|10017140|FG001|Overall Study|Withdrawal by Subject|0
6296035|NCT02475733|10017139|FG000|Overall Study|Physician Decision|1
6296036|NCT02475733|10017140|FG001|Overall Study|Physician Decision|0
6296037|NCT02475850|10017157|FG000|Overall Study|Death|155
6296038|NCT02475850|10017158|FG001|Overall Study|Death|141
6296039|NCT02475850|10017157|FG000|Overall Study|Lost to Follow-up|217
6296040|NCT02475850|10017158|FG001|Overall Study|Lost to Follow-up|188
6296041|NCT02475850|10017157|FG000|Overall Study|Withdrawal by Subject|221
6296042|NCT02475850|10017158|FG001|Overall Study|Withdrawal by Subject|155
6296043|NCT02475954|10017167|FG000|Overall Study|Withdrawal by Subject|2
6296044|NCT02475954|10017168|FG001|Overall Study|Withdrawal by Subject|2
6296045|NCT02475954|10017167|FG000|Overall Study|Lost to Follow-up|11
6296046|NCT02475954|10017168|FG001|Overall Study|Lost to Follow-up|9
6296047|NCT02475954|10017167|FG000|Overall Study|Death|1
6296048|NCT02475954|10017168|FG001|Overall Study|Death|1
6296049|NCT02475980|10017175|FG000|Overall Study|Lost to Follow-up|4
6296050|NCT02475980|10017175|FG000|Overall Study|Withdrawal by Subject|1
6296051|NCT02476175|10017195|FG000|Overall Study|Adverse Event|2
6296052|NCT02476422|10017212|FG000|Overall Study|Subject/guardian decision|0
6296053|NCT02476422|10017213|FG001|Overall Study|Subject/guardian decision|1
6296054|NCT02476578|10017247|FG000|Overall Study|Died before Email was sent (<9.11.2015)|35
6296055|NCT02476578|10017248|FG001|Overall Study|Died before Email was sent (<9.11.2015)|43
6296056|NCT02476578|10017247|FG000|Overall Study|Lost to Follow-up|6
6296057|NCT02476578|10017248|FG001|Overall Study|Lost to Follow-up|13
6296058|NCT02476617|10017254|FG000|Overall Study|Adverse Event|1
6296059|NCT02476617|10017254|FG000|Overall Study|Lost to Follow-up|1
6296060|NCT02477020|10017279|FG000|Overall Study|Pretreatment Event/Adverse Event|6
6296061|NCT02477020|10017280|FG001|Overall Study|Pretreatment Event/Adverse Event|6
6296062|NCT02477020|10017279|FG000|Overall Study|Voluntary Withdrawal|7
6296063|NCT02477020|10017280|FG001|Overall Study|Voluntary Withdrawal|16
6296064|NCT02477020|10017279|FG000|Overall Study|Reason not Specified|3
6296065|NCT02477020|10017280|FG001|Overall Study|Reason not Specified|1
6296066|NCT02477020|10017279|FG000|Overall Study|Lack of Efficacy|14
6296067|NCT02477020|10017280|FG001|Overall Study|Lack of Efficacy|5
6296068|NCT02477111|10017286|FG000|Overall Study|Death|5
6296069|NCT02477111|10017286|FG000|Overall Study|Withdrawal by Subject|2
6296070|NCT02477111|10017286|FG000|Overall Study|missed visit|4
6296071|NCT02477215|10017296|FG000|Dose Escalation Phase|Physician Decision|1
6296072|NCT02477215|10017297|FG001|Dose Escalation Phase|Physician Decision|2
6296073|NCT02477215|10017298|FG002|Dose Escalation Phase|Physician Decision|0
6296074|NCT02477215|10017296|FG000|Fixed Dose Phase|Physician Decision|0
6296075|NCT02477215|10017297|FG001|Fixed Dose Phase|Physician Decision|7
6296076|NCT02477215|10017298|FG002|Fixed Dose Phase|Physician Decision|0
6296077|NCT02477332|10017329|FG000|Overall Study|Adverse Event|0
6296078|NCT02477332|10017330|FG001|Overall Study|Adverse Event|1
6296079|NCT02477332|10017331|FG002|Overall Study|Adverse Event|1
6296080|NCT02477332|10017332|FG003|Overall Study|Adverse Event|2
6296081|NCT02477332|10017333|FG004|Overall Study|Adverse Event|1
6296082|NCT02477332|10017334|FG005|Overall Study|Adverse Event|2
6296083|NCT02477332|10017329|FG000|Overall Study|Lack of Efficacy|1
6296084|NCT02477332|10017330|FG001|Overall Study|Lack of Efficacy|2
6296085|NCT02477332|10017331|FG002|Overall Study|Lack of Efficacy|1
6296086|NCT02477332|10017332|FG003|Overall Study|Lack of Efficacy|2
6296087|NCT02477332|10017333|FG004|Overall Study|Lack of Efficacy|1
6296088|NCT02477332|10017334|FG005|Overall Study|Lack of Efficacy|1
6296089|NCT02477332|10017329|FG000|Overall Study|Non-compliance with study treatment|0
6296090|NCT02477332|10017330|FG001|Overall Study|Non-compliance with study treatment|1
6296091|NCT02477332|10017331|FG002|Overall Study|Non-compliance with study treatment|2
6296092|NCT02477332|10017332|FG003|Overall Study|Non-compliance with study treatment|0
6296093|NCT02477332|10017333|FG004|Overall Study|Non-compliance with study treatment|0
6296094|NCT02477332|10017334|FG005|Overall Study|Non-compliance with study treatment|0
6296095|NCT02477332|10017329|FG000|Overall Study|Pregnancy|0
6296096|NCT02477332|10017330|FG001|Overall Study|Pregnancy|0
6296097|NCT02477332|10017331|FG002|Overall Study|Pregnancy|0
6296098|NCT02477332|10017332|FG003|Overall Study|Pregnancy|1
6296099|NCT02477332|10017333|FG004|Overall Study|Pregnancy|0
6296100|NCT02477332|10017334|FG005|Overall Study|Pregnancy|0
6296101|NCT02477332|10017329|FG000|Overall Study|Protocol Violation|2
6296102|NCT02477332|10017330|FG001|Overall Study|Protocol Violation|0
6296103|NCT02477332|10017331|FG002|Overall Study|Protocol Violation|3
6296104|NCT02477332|10017332|FG003|Overall Study|Protocol Violation|3
6296105|NCT02477332|10017333|FG004|Overall Study|Protocol Violation|1
6296106|NCT02477332|10017334|FG005|Overall Study|Protocol Violation|1
6296107|NCT02477332|10017329|FG000|Overall Study|Technical problems|0
6296108|NCT02477332|10017330|FG001|Overall Study|Technical problems|0
6296109|NCT02477332|10017331|FG002|Overall Study|Technical problems|1
6296110|NCT02477332|10017332|FG003|Overall Study|Technical problems|0
6296111|NCT02477332|10017333|FG004|Overall Study|Technical problems|0
6296112|NCT02477332|10017334|FG005|Overall Study|Technical problems|0
6296113|NCT02477332|10017329|FG000|Overall Study|Lost to Follow-up|0
6296114|NCT02477332|10017330|FG001|Overall Study|Lost to Follow-up|0
6296115|NCT02477332|10017331|FG002|Overall Study|Lost to Follow-up|2
6296116|NCT02477332|10017332|FG003|Overall Study|Lost to Follow-up|0
6296117|NCT02477332|10017333|FG004|Overall Study|Lost to Follow-up|0
6296118|NCT02477332|10017334|FG005|Overall Study|Lost to Follow-up|0
6296119|NCT02477332|10017329|FG000|Overall Study|Physician Decision|0
6296120|NCT02477332|10017330|FG001|Overall Study|Physician Decision|0
6296121|NCT02477332|10017331|FG002|Overall Study|Physician Decision|1
6296122|NCT02477332|10017332|FG003|Overall Study|Physician Decision|3
6296123|NCT02477332|10017333|FG004|Overall Study|Physician Decision|0
6296124|NCT02477332|10017334|FG005|Overall Study|Physician Decision|1
6296125|NCT02477332|10017329|FG000|Overall Study|Withdrawal by Subject|0
6296126|NCT02477332|10017330|FG001|Overall Study|Withdrawal by Subject|3
6296127|NCT02477332|10017331|FG002|Overall Study|Withdrawal by Subject|1
6296128|NCT02477332|10017332|FG003|Overall Study|Withdrawal by Subject|2
6296129|NCT02477332|10017333|FG004|Overall Study|Withdrawal by Subject|1
6296130|NCT02477332|10017334|FG005|Overall Study|Withdrawal by Subject|0
6296131|NCT02477527|10017359|FG000|Overall Study|Lost to Follow-up|2
6296132|NCT02477527|10017359|FG000|Overall Study|Withdrawal by Subject|1
6296133|NCT02477527|10017359|FG000|Overall Study|Screen Failure|3
6296134|NCT02477553|10017365|FG000|Overall Study|Screening up-to-date|12
6296135|NCT02477553|10017366|FG001|Overall Study|Screening up-to-date|13
6296136|NCT02477553|10017365|FG000|Overall Study|No MD visit|1
6296137|NCT02477553|10017366|FG001|Overall Study|No MD visit|1
6296138|NCT02477553|10017365|FG000|Overall Study|Workup consistent w/CRC|1
6296139|NCT02477553|10017366|FG001|Overall Study|Workup consistent w/CRC|1
6296140|NCT02477553|10017365|FG000|Overall Study|Technical issues with intervention|2
6296141|NCT02477553|10017366|FG001|Overall Study|Technical issues with intervention|0
6296142|NCT02477553|10017365|FG000|Overall Study|Elevated risk for CRC|2
6296143|NCT02477553|10017366|FG001|Overall Study|Elevated risk for CRC|2
6296144|NCT02477553|10017365|FG000|Overall Study|MD advised against screening|1
6296145|NCT02477553|10017366|FG001|Overall Study|MD advised against screening|3
6296146|NCT02477553|10017365|FG000|Overall Study|patient deceased|1
6296147|NCT02477553|10017366|FG001|Overall Study|patient deceased|0
6296148|NCT02477605|10017374|FG000|Overall Study|Discontinued prior to treatment|1
6296149|NCT02477605|10017375|FG001|Overall Study|Discontinued prior to treatment|0
6296150|NCT02477605|10017374|FG000|Overall Study|Lost to Follow-up|0
6296151|NCT02477605|10017375|FG001|Overall Study|Lost to Follow-up|2
6296152|NCT02477605|10017374|FG000|Overall Study|Withdrawal by Subject|0
6296153|NCT02477605|10017375|FG001|Overall Study|Withdrawal by Subject|1
6296154|NCT02477605|10017374|FG000|Overall Study|Administered gas during surgery|0
6296155|NCT02477605|10017375|FG001|Overall Study|Administered gas during surgery|1
6296156|NCT02477670|10017387|FG000|Stage 1|Adverse Event|2
6296157|NCT02477670|10017388|FG001|Stage 1|Adverse Event|7
6296158|NCT02477670|10017389|FG002|Stage 1|Adverse Event|0
6296159|NCT02477670|10017390|FG003|Stage 1|Adverse Event|0
6296160|NCT02477670|10017391|FG004|Stage 1|Adverse Event|0
6296161|NCT02477670|10017392|FG005|Stage 1|Adverse Event|0
6296162|NCT02477670|10017393|FG006|Stage 1|Adverse Event|0
6296163|NCT02477670|10017387|FG000|Stage 1|Lost to Follow-up|0
6296164|NCT02477670|10017388|FG001|Stage 1|Lost to Follow-up|2
6296165|NCT02477670|10017389|FG002|Stage 1|Lost to Follow-up|0
6296166|NCT02477670|10017390|FG003|Stage 1|Lost to Follow-up|0
6296167|NCT02477670|10017391|FG004|Stage 1|Lost to Follow-up|0
6296168|NCT02477670|10017392|FG005|Stage 1|Lost to Follow-up|0
6296169|NCT02477670|10017393|FG006|Stage 1|Lost to Follow-up|0
6296170|NCT02477670|10017387|FG000|Stage 1|Withdrawal by Subject|1
6296171|NCT02477670|10017388|FG001|Stage 1|Withdrawal by Subject|2
6296172|NCT02477670|10017389|FG002|Stage 1|Withdrawal by Subject|0
6296173|NCT02477670|10017390|FG003|Stage 1|Withdrawal by Subject|0
6296174|NCT02477670|10017391|FG004|Stage 1|Withdrawal by Subject|0
6296175|NCT02477670|10017392|FG005|Stage 1|Withdrawal by Subject|0
6296176|NCT02477670|10017393|FG006|Stage 1|Withdrawal by Subject|0
6296177|NCT02477670|10017387|FG000|Stage 1|Non-compliance with Study Drug|1
6296178|NCT02477670|10017388|FG001|Stage 1|Non-compliance with Study Drug|2
6296179|NCT02477670|10017389|FG002|Stage 1|Non-compliance with Study Drug|0
6296180|NCT02477670|10017390|FG003|Stage 1|Non-compliance with Study Drug|0
6296181|NCT02477670|10017391|FG004|Stage 1|Non-compliance with Study Drug|0
6296182|NCT02477670|10017392|FG005|Stage 1|Non-compliance with Study Drug|0
6296183|NCT02477670|10017393|FG006|Stage 1|Non-compliance with Study Drug|0
6296184|NCT02477670|10017387|FG000|Stage 2|Adverse Event|0
6296185|NCT02477670|10017388|FG001|Stage 2|Adverse Event|0
6296186|NCT02477670|10017389|FG002|Stage 2|Adverse Event|1
6296187|NCT02477670|10017390|FG003|Stage 2|Adverse Event|0
6296188|NCT02477670|10017391|FG004|Stage 2|Adverse Event|0
6296189|NCT02477670|10017392|FG005|Stage 2|Adverse Event|0
6296190|NCT02477670|10017393|FG006|Stage 2|Adverse Event|0
6296191|NCT02477670|10017387|FG000|Stage 2|Antipsychotic Medication Changed|0
6296192|NCT02477670|10017388|FG001|Stage 2|Antipsychotic Medication Changed|0
6296193|NCT02477670|10017389|FG002|Stage 2|Antipsychotic Medication Changed|1
6296194|NCT02477670|10017390|FG003|Stage 2|Antipsychotic Medication Changed|0
6296195|NCT02477670|10017391|FG004|Stage 2|Antipsychotic Medication Changed|0
6296196|NCT02477670|10017392|FG005|Stage 2|Antipsychotic Medication Changed|0
6296197|NCT02477670|10017393|FG006|Stage 2|Antipsychotic Medication Changed|0
6296198|NCT02477670|10017387|FG000|Stage 2|Withdrawal by Subject|0
6296199|NCT02477670|10017388|FG001|Stage 2|Withdrawal by Subject|0
6296200|NCT02477670|10017389|FG002|Stage 2|Withdrawal by Subject|0
6296201|NCT02477670|10017390|FG003|Stage 2|Withdrawal by Subject|1
6296202|NCT02477670|10017391|FG004|Stage 2|Withdrawal by Subject|0
6296203|NCT02477670|10017392|FG005|Stage 2|Withdrawal by Subject|0
6296204|NCT02477670|10017393|FG006|Stage 2|Withdrawal by Subject|0
6296205|NCT02477800|10017411|FG000|Placebo-Controlled Period|Adverse Event|16
6296206|NCT02477800|10017412|FG001|Placebo-Controlled Period|Adverse Event|25
6296207|NCT02477800|10017413|FG002|Placebo-Controlled Period|Adverse Event|28
6296208|NCT02477800|10017414|FG003|Placebo-Controlled Period|Adverse Event|0
6296209|NCT02477800|10017415|FG004|Placebo-Controlled Period|Adverse Event|0
6296210|NCT02477800|10017416|FG005|Placebo-Controlled Period|Adverse Event|0
6296211|NCT02477800|10017417|FG006|Placebo-Controlled Period|Adverse Event|0
6296212|NCT02477800|10017411|FG000|Placebo-Controlled Period|Change of Treatment|1
6296213|NCT02477800|10017412|FG001|Placebo-Controlled Period|Change of Treatment|2
6296214|NCT02477800|10017413|FG002|Placebo-Controlled Period|Change of Treatment|1
6296215|NCT02477800|10017414|FG003|Placebo-Controlled Period|Change of Treatment|0
6296216|NCT02477800|10017415|FG004|Placebo-Controlled Period|Change of Treatment|0
6296217|NCT02477800|10017416|FG005|Placebo-Controlled Period|Change of Treatment|0
6296218|NCT02477800|10017417|FG006|Placebo-Controlled Period|Change of Treatment|0
6296219|NCT02477800|10017411|FG000|Placebo-Controlled Period|Consent Withdrawn|26
6296220|NCT02477800|10017412|FG001|Placebo-Controlled Period|Consent Withdrawn|16
6296221|NCT02477800|10017413|FG002|Placebo-Controlled Period|Consent Withdrawn|27
6296222|NCT02477800|10017414|FG003|Placebo-Controlled Period|Consent Withdrawn|0
6296223|NCT02477800|10017415|FG004|Placebo-Controlled Period|Consent Withdrawn|0
6296224|NCT02477800|10017416|FG005|Placebo-Controlled Period|Consent Withdrawn|0
6296225|NCT02477800|10017417|FG006|Placebo-Controlled Period|Consent Withdrawn|0
6296226|NCT02477800|10017411|FG000|Placebo-Controlled Period|Death|0
6296227|NCT02477800|10017412|FG001|Placebo-Controlled Period|Death|3
6296228|NCT02477800|10017413|FG002|Placebo-Controlled Period|Death|2
6296229|NCT02477800|10017414|FG003|Placebo-Controlled Period|Death|0
6296230|NCT02477800|10017415|FG004|Placebo-Controlled Period|Death|0
6296231|NCT02477800|10017416|FG005|Placebo-Controlled Period|Death|0
6296232|NCT02477800|10017417|FG006|Placebo-Controlled Period|Death|0
6296233|NCT02477800|10017411|FG000|Placebo-Controlled Period|Disease Progression|1
6296234|NCT02477800|10017412|FG001|Placebo-Controlled Period|Disease Progression|0
6296235|NCT02477800|10017413|FG002|Placebo-Controlled Period|Disease Progression|1
6296236|NCT02477800|10017414|FG003|Placebo-Controlled Period|Disease Progression|0
6296237|NCT02477800|10017415|FG004|Placebo-Controlled Period|Disease Progression|0
6296238|NCT02477800|10017416|FG005|Placebo-Controlled Period|Disease Progression|0
6296239|NCT02477800|10017417|FG006|Placebo-Controlled Period|Disease Progression|0
6296240|NCT02477800|10017411|FG000|Placebo-Controlled Period|Investigator Decision|3
5981535|NCT00899379|9570456|FG001|Overall Study|Lost to Follow-up|3
6296241|NCT02477800|10017412|FG001|Placebo-Controlled Period|Investigator Decision|2
6296242|NCT02477800|10017413|FG002|Placebo-Controlled Period|Investigator Decision|1
6296243|NCT02477800|10017414|FG003|Placebo-Controlled Period|Investigator Decision|0
6296244|NCT02477800|10017415|FG004|Placebo-Controlled Period|Investigator Decision|0
6296245|NCT02477800|10017416|FG005|Placebo-Controlled Period|Investigator Decision|0
6296246|NCT02477800|10017417|FG006|Placebo-Controlled Period|Investigator Decision|0
6296247|NCT02477800|10017411|FG000|Placebo-Controlled Period|Lost to Follow-up|1
6296248|NCT02477800|10017412|FG001|Placebo-Controlled Period|Lost to Follow-up|3
6296249|NCT02477800|10017413|FG002|Placebo-Controlled Period|Lost to Follow-up|3
6296250|NCT02477800|10017414|FG003|Placebo-Controlled Period|Lost to Follow-up|0
6296251|NCT02477800|10017415|FG004|Placebo-Controlled Period|Lost to Follow-up|0
6296252|NCT02477800|10017416|FG005|Placebo-Controlled Period|Lost to Follow-up|0
6296253|NCT02477800|10017417|FG006|Placebo-Controlled Period|Lost to Follow-up|0
6296254|NCT02477800|10017411|FG000|Placebo-Controlled Period|Relocation|2
6296255|NCT02477800|10017412|FG001|Placebo-Controlled Period|Relocation|0
6296256|NCT02477800|10017413|FG002|Placebo-Controlled Period|Relocation|0
6296257|NCT02477800|10017414|FG003|Placebo-Controlled Period|Relocation|0
6296258|NCT02477800|10017415|FG004|Placebo-Controlled Period|Relocation|0
6296259|NCT02477800|10017416|FG005|Placebo-Controlled Period|Relocation|0
6296260|NCT02477800|10017417|FG006|Placebo-Controlled Period|Relocation|0
6296261|NCT02477800|10017411|FG000|Placebo-Controlled Period|Site Terminated by Investigator|1
6296262|NCT02477800|10017412|FG001|Placebo-Controlled Period|Site Terminated by Investigator|1
6296263|NCT02477800|10017413|FG002|Placebo-Controlled Period|Site Terminated by Investigator|1
6296264|NCT02477800|10017414|FG003|Placebo-Controlled Period|Site Terminated by Investigator|0
6296265|NCT02477800|10017415|FG004|Placebo-Controlled Period|Site Terminated by Investigator|0
6296266|NCT02477800|10017416|FG005|Placebo-Controlled Period|Site Terminated by Investigator|0
5981536|NCT00899379|9570457|FG002|Overall Study|Lost to Follow-up|0
5981537|NCT00899379|9570458|FG003|Overall Study|Lost to Follow-up|6
5981538|NCT00899379|9570459|FG004|Overall Study|Lost to Follow-up|2
5981539|NCT00899379|9570455|FG000|Overall Study|Protocol Violation|0
5981540|NCT00899379|9570456|FG001|Overall Study|Protocol Violation|0
5981541|NCT00899379|9570457|FG002|Overall Study|Protocol Violation|1
5981542|NCT00899379|9570458|FG003|Overall Study|Protocol Violation|1
5981543|NCT00899379|9570459|FG004|Overall Study|Protocol Violation|0
5981544|NCT00899379|9570455|FG000|Overall Study|Withdrawal by Subject|2
5981545|NCT00899379|9570456|FG001|Overall Study|Withdrawal by Subject|4
5981546|NCT00899379|9570457|FG002|Overall Study|Withdrawal by Subject|2
5981547|NCT00899379|9570458|FG003|Overall Study|Withdrawal by Subject|3
5981548|NCT00899379|9570459|FG004|Overall Study|Withdrawal by Subject|6
5981549|NCT00899379|9570455|FG000|Overall Study|Pregnancy|0
5981550|NCT00899379|9570456|FG001|Overall Study|Pregnancy|0
5981551|NCT00899379|9570457|FG002|Overall Study|Pregnancy|1
5981552|NCT00899379|9570458|FG003|Overall Study|Pregnancy|0
5981553|NCT00899379|9570459|FG004|Overall Study|Pregnancy|1
5981554|NCT00899379|9570455|FG000|Overall Study|Patient Uncooperative|0
5981555|NCT00899379|9570456|FG001|Overall Study|Patient Uncooperative|1
5981556|NCT00899379|9570457|FG002|Overall Study|Patient Uncooperative|0
5981557|NCT00899379|9570458|FG003|Overall Study|Patient Uncooperative|1
5981558|NCT00899379|9570459|FG004|Overall Study|Patient Uncooperative|2
5981559|NCT00899379|9570455|FG000|Overall Study|Abnormal Baseline ECG|0
5981560|NCT00899379|9570456|FG001|Overall Study|Abnormal Baseline ECG|0
5981561|NCT00899379|9570457|FG002|Overall Study|Abnormal Baseline ECG|0
5981562|NCT00899379|9570458|FG003|Overall Study|Abnormal Baseline ECG|1
5981563|NCT00899379|9570459|FG004|Overall Study|Abnormal Baseline ECG|0
5981564|NCT00899379|9570455|FG000|Overall Study|No Longer Met Inc/Exc Criteria|1
5981565|NCT00899379|9570456|FG001|Overall Study|No Longer Met Inc/Exc Criteria|1
5981566|NCT00899379|9570457|FG002|Overall Study|No Longer Met Inc/Exc Criteria|1
5981567|NCT00899379|9570458|FG003|Overall Study|No Longer Met Inc/Exc Criteria|0
5981568|NCT00899379|9570459|FG004|Overall Study|No Longer Met Inc/Exc Criteria|0
5981569|NCT00899379|9570455|FG000|Overall Study|Not Completed/Entered Extn|5
5981570|NCT00899379|9570456|FG001|Overall Study|Not Completed/Entered Extn|1
5981571|NCT00899379|9570457|FG002|Overall Study|Not Completed/Entered Extn|6
5981572|NCT00899379|9570458|FG003|Overall Study|Not Completed/Entered Extn|4
5981573|NCT00899379|9570459|FG004|Overall Study|Not Completed/Entered Extn|3
5981574|NCT00899379|9570455|FG000|Overall Study|Study Terminated|3
5981575|NCT00899379|9570456|FG001|Overall Study|Study Terminated|0
5981576|NCT00899379|9570457|FG002|Overall Study|Study Terminated|3
5981577|NCT00899379|9570458|FG003|Overall Study|Study Terminated|3
5981578|NCT00899379|9570459|FG004|Overall Study|Study Terminated|1
5981579|NCT00899379|9570455|FG000|Overall Study|Lost to Follow-up|3
5981580|NCT00899379|9570456|FG001|Overall Study|Lost to Follow-up|1
5981581|NCT00899379|9570457|FG002|Overall Study|Lost to Follow-up|0
5981582|NCT00899379|9570458|FG003|Overall Study|Lost to Follow-up|2
5981583|NCT00899379|9570459|FG004|Overall Study|Lost to Follow-up|5
5981584|NCT00899379|9570455|FG000|Overall Study|Withdrawal by Subject|4
5981585|NCT00899379|9570456|FG001|Overall Study|Withdrawal by Subject|7
5981586|NCT00899379|9570457|FG002|Overall Study|Withdrawal by Subject|4
5981587|NCT00899379|9570458|FG003|Overall Study|Withdrawal by Subject|7
5981588|NCT00899379|9570459|FG004|Overall Study|Withdrawal by Subject|2
5981589|NCT00899379|9570455|FG000|Overall Study|Pregnancy|1
5981590|NCT00899379|9570456|FG001|Overall Study|Pregnancy|0
5981591|NCT00899379|9570457|FG002|Overall Study|Pregnancy|0
5981592|NCT00899379|9570458|FG003|Overall Study|Pregnancy|0
5981593|NCT00899379|9570459|FG004|Overall Study|Pregnancy|0
5981594|NCT00899379|9570455|FG000|Overall Study|Patient Uncooperative|0
5981595|NCT00899379|9570456|FG001|Overall Study|Patient Uncooperative|0
5981596|NCT00899379|9570457|FG002|Overall Study|Patient Uncooperative|0
5981597|NCT00899379|9570458|FG003|Overall Study|Patient Uncooperative|1
5981598|NCT00899379|9570459|FG004|Overall Study|Patient Uncooperative|0
5981599|NCT00899379|9570455|FG000|Overall Study|Abnormal Prestudy Labs|0
5981600|NCT00899379|9570456|FG001|Overall Study|Abnormal Prestudy Labs|0
6296267|NCT02477800|10017417|FG006|Placebo-Controlled Period|Site Terminated by Investigator|0
6296268|NCT02477800|10017411|FG000|Placebo-Controlled Period|Site Terminated by Sponsor|2
6296269|NCT02477800|10017412|FG001|Placebo-Controlled Period|Site Terminated by Sponsor|1
6296270|NCT02477800|10017413|FG002|Placebo-Controlled Period|Site Terminated by Sponsor|0
6296271|NCT02477800|10017414|FG003|Placebo-Controlled Period|Site Terminated by Sponsor|0
6296272|NCT02477800|10017415|FG004|Placebo-Controlled Period|Site Terminated by Sponsor|0
6296273|NCT02477800|10017416|FG005|Placebo-Controlled Period|Site Terminated by Sponsor|0
6296274|NCT02477800|10017417|FG006|Placebo-Controlled Period|Site Terminated by Sponsor|0
6296275|NCT02477800|10017411|FG000|Placebo-Controlled Period|Study Visit Burden|5
6296276|NCT02477800|10017412|FG001|Placebo-Controlled Period|Study Visit Burden|3
6296277|NCT02477800|10017413|FG002|Placebo-Controlled Period|Study Visit Burden|11
6296278|NCT02477800|10017414|FG003|Placebo-Controlled Period|Study Visit Burden|0
5981601|NCT00899379|9570457|FG002|Overall Study|Abnormal Prestudy Labs|0
5981602|NCT00899379|9570458|FG003|Overall Study|Abnormal Prestudy Labs|0
5981603|NCT00899379|9570459|FG004|Overall Study|Abnormal Prestudy Labs|2
5981604|NCT00899379|9570455|FG000|Overall Study|Abnormal Baseline ECG|0
5981605|NCT00899379|9570456|FG001|Overall Study|Abnormal Baseline ECG|0
5981606|NCT00899379|9570457|FG002|Overall Study|Abnormal Baseline ECG|1
5981607|NCT00899379|9570458|FG003|Overall Study|Abnormal Baseline ECG|1
5981608|NCT00899379|9570459|FG004|Overall Study|Abnormal Baseline ECG|0
5981609|NCT00899379|9570455|FG000|Overall Study|No Attack Pretreatment|3
5981610|NCT00899379|9570456|FG001|Overall Study|No Attack Pretreatment|5
5981611|NCT00899379|9570457|FG002|Overall Study|No Attack Pretreatment|5
5981612|NCT00899379|9570458|FG003|Overall Study|No Attack Pretreatment|6
5981613|NCT00899379|9570459|FG004|Overall Study|No Attack Pretreatment|4
5981614|NCT00899379|9570455|FG000|Overall Study|No Longer Met Inc/Exc Criteria|1
5981615|NCT00899379|9570456|FG001|Overall Study|No Longer Met Inc/Exc Criteria|0
5981616|NCT00899379|9570457|FG002|Overall Study|No Longer Met Inc/Exc Criteria|0
5981617|NCT00899379|9570458|FG003|Overall Study|No Longer Met Inc/Exc Criteria|0
6296279|NCT02477800|10017415|FG004|Placebo-Controlled Period|Study Visit Burden|0
6296280|NCT02477800|10017416|FG005|Placebo-Controlled Period|Study Visit Burden|0
6296281|NCT02477800|10017417|FG006|Placebo-Controlled Period|Study Visit Burden|0
6296282|NCT02477800|10017411|FG000|Placebo-Controlled Period|Withdrawal by Parent/Guardian|1
6296283|NCT02477800|10017412|FG001|Placebo-Controlled Period|Withdrawal by Parent/Guardian|5
6296284|NCT02477800|10017413|FG002|Placebo-Controlled Period|Withdrawal by Parent/Guardian|3
6296285|NCT02477800|10017414|FG003|Placebo-Controlled Period|Withdrawal by Parent/Guardian|0
6296286|NCT02477800|10017415|FG004|Placebo-Controlled Period|Withdrawal by Parent/Guardian|0
6296287|NCT02477800|10017416|FG005|Placebo-Controlled Period|Withdrawal by Parent/Guardian|0
6296288|NCT02477800|10017417|FG006|Placebo-Controlled Period|Withdrawal by Parent/Guardian|0
6296289|NCT02477800|10017411|FG000|Placebo-Controlled Period|Reason not Specified|161
6296290|NCT02477800|10017412|FG001|Placebo-Controlled Period|Reason not Specified|161
6296291|NCT02477800|10017413|FG002|Placebo-Controlled Period|Reason not Specified|189
6296292|NCT02477800|10017414|FG003|Placebo-Controlled Period|Reason not Specified|0
6296293|NCT02477800|10017415|FG004|Placebo-Controlled Period|Reason not Specified|0
6296294|NCT02477800|10017416|FG005|Placebo-Controlled Period|Reason not Specified|0
6296295|NCT02477800|10017417|FG006|Placebo-Controlled Period|Reason not Specified|0
6296296|NCT02477800|10017411|FG000|Long Term Extension Period|Adverse Event|0
6296297|NCT02477800|10017412|FG001|Long Term Extension Period|Adverse Event|0
6296298|NCT02477800|10017413|FG002|Long Term Extension Period|Adverse Event|0
6296299|NCT02477800|10017414|FG003|Long Term Extension Period|Adverse Event|6
6296300|NCT02477800|10017415|FG004|Long Term Extension Period|Adverse Event|2
6296301|NCT02477800|10017416|FG005|Long Term Extension Period|Adverse Event|4
6296302|NCT02477800|10017417|FG006|Long Term Extension Period|Adverse Event|3
6296303|NCT02477800|10017411|FG000|Long Term Extension Period|Death|0
6296304|NCT02477800|10017412|FG001|Long Term Extension Period|Death|0
6296305|NCT02477800|10017413|FG002|Long Term Extension Period|Death|0
6296306|NCT02477800|10017414|FG003|Long Term Extension Period|Death|1
6296307|NCT02477800|10017415|FG004|Long Term Extension Period|Death|1
6296308|NCT02477800|10017416|FG005|Long Term Extension Period|Death|1
6296309|NCT02477800|10017417|FG006|Long Term Extension Period|Death|2
6296310|NCT02477800|10017411|FG000|Long Term Extension Period|Consent Withdrawn|0
6296311|NCT02477800|10017412|FG001|Long Term Extension Period|Consent Withdrawn|0
6296312|NCT02477800|10017413|FG002|Long Term Extension Period|Consent Withdrawn|0
6296313|NCT02477800|10017414|FG003|Long Term Extension Period|Consent Withdrawn|10
6296314|NCT02477800|10017415|FG004|Long Term Extension Period|Consent Withdrawn|4
6296315|NCT02477800|10017416|FG005|Long Term Extension Period|Consent Withdrawn|13
6296316|NCT02477800|10017417|FG006|Long Term Extension Period|Consent Withdrawn|16
6296317|NCT02477800|10017411|FG000|Long Term Extension Period|Disease Progression|0
6296318|NCT02477800|10017412|FG001|Long Term Extension Period|Disease Progression|0
6296319|NCT02477800|10017413|FG002|Long Term Extension Period|Disease Progression|0
6296320|NCT02477800|10017414|FG003|Long Term Extension Period|Disease Progression|3
6296321|NCT02477800|10017415|FG004|Long Term Extension Period|Disease Progression|1
6296322|NCT02477800|10017416|FG005|Long Term Extension Period|Disease Progression|1
6296323|NCT02477800|10017417|FG006|Long Term Extension Period|Disease Progression|0
6296324|NCT02477800|10017411|FG000|Long Term Extension Period|Investigator Decision|0
6296325|NCT02477800|10017412|FG001|Long Term Extension Period|Investigator Decision|0
6296326|NCT02477800|10017413|FG002|Long Term Extension Period|Investigator Decision|0
6296327|NCT02477800|10017414|FG003|Long Term Extension Period|Investigator Decision|0
6296328|NCT02477800|10017415|FG004|Long Term Extension Period|Investigator Decision|0
6296329|NCT02477800|10017416|FG005|Long Term Extension Period|Investigator Decision|0
6296330|NCT02477800|10017417|FG006|Long Term Extension Period|Investigator Decision|2
6296331|NCT02477800|10017411|FG000|Long Term Extension Period|Lost to Follow-up|0
6296332|NCT02477800|10017412|FG001|Long Term Extension Period|Lost to Follow-up|0
5981618|NCT00899379|9570459|FG004|Overall Study|No Longer Met Inc/Exc Criteria|0
5981619|NCT00899379|9570455|FG000|Overall Study|Inc/Exc Criteria Not Met|0
5981620|NCT00899379|9570456|FG001|Overall Study|Inc/Exc Criteria Not Met|0
5981621|NCT00899379|9570457|FG002|Overall Study|Inc/Exc Criteria Not Met|1
5981622|NCT00899379|9570458|FG003|Overall Study|Inc/Exc Criteria Not Met|0
5981623|NCT00899379|9570459|FG004|Overall Study|Inc/Exc Criteria Not Met|0
5981624|NCT00898677|9570469|FG000|Overall Study|Adverse Event|0
5981625|NCT00898677|9570470|FG001|Overall Study|Adverse Event|0
5981626|NCT00898677|9570471|FG002|Overall Study|Adverse Event|1
5981627|NCT00898677|9570472|FG003|Overall Study|Adverse Event|0
5981628|NCT00898677|9570469|FG000|Overall Study|Lost to Follow-up|0
5981629|NCT00898677|9570470|FG001|Overall Study|Lost to Follow-up|0
5981630|NCT00898677|9570471|FG002|Overall Study|Lost to Follow-up|2
5981631|NCT00898677|9570472|FG003|Overall Study|Lost to Follow-up|0
5981632|NCT00898677|9570469|FG000|Overall Study|Protocol Violation|1
5981633|NCT00898677|9570470|FG001|Overall Study|Protocol Violation|1
5981634|NCT00898677|9570471|FG002|Overall Study|Protocol Violation|2
5981635|NCT00898677|9570472|FG003|Overall Study|Protocol Violation|0
5981636|NCT00898677|9570469|FG000|Overall Study|Withdrawal by Subject|0
5981637|NCT00898677|9570470|FG001|Overall Study|Withdrawal by Subject|0
5981638|NCT00898677|9570471|FG002|Overall Study|Withdrawal by Subject|0
5981639|NCT00898677|9570472|FG003|Overall Study|Withdrawal by Subject|1
5981640|NCT00898677|9570469|FG000|Overall Study|Not Treated: Adverse Event|0
5981641|NCT00898677|9570470|FG001|Overall Study|Not Treated: Adverse Event|2
5981642|NCT00898677|9570471|FG002|Overall Study|Not Treated: Adverse Event|1
5981643|NCT00898677|9570472|FG003|Overall Study|Not Treated: Adverse Event|0
5981644|NCT00898677|9570469|FG000|Overall Study|Not Treated: Lost to Follow-Up|0
5981645|NCT00898677|9570470|FG001|Overall Study|Not Treated: Lost to Follow-Up|5
5981646|NCT00898677|9570471|FG002|Overall Study|Not Treated: Lost to Follow-Up|5
5981647|NCT00898677|9570472|FG003|Overall Study|Not Treated: Lost to Follow-Up|2
5981648|NCT00898677|9570469|FG000|Overall Study|Not Treated: Pregnancy|0
5981649|NCT00898677|9570470|FG001|Overall Study|Not Treated: Pregnancy|0
5981650|NCT00898677|9570471|FG002|Overall Study|Not Treated: Pregnancy|1
5981651|NCT00898677|9570472|FG003|Overall Study|Not Treated: Pregnancy|0
5981652|NCT00898677|9570469|FG000|Overall Study|Not Treated: Protocol Violation|2
5981653|NCT00898677|9570470|FG001|Overall Study|Not Treated: Protocol Violation|0
5981654|NCT00898677|9570471|FG002|Overall Study|Not Treated: Protocol Violation|2
5981655|NCT00898677|9570472|FG003|Overall Study|Not Treated: Protocol Violation|0
5981656|NCT00898677|9570469|FG000|Overall Study|Not Treated: Withdraw by Subject|2
5981657|NCT00898677|9570470|FG001|Overall Study|Not Treated: Withdraw by Subject|16
5981658|NCT00898677|9570471|FG002|Overall Study|Not Treated: Withdraw by Subject|11
5981659|NCT00898677|9570472|FG003|Overall Study|Not Treated: Withdraw by Subject|3
5981660|NCT00898677|9570469|FG000|Overall Study|Not Treated: Patient uncooperative|2
5981661|NCT00898677|9570470|FG001|Overall Study|Not Treated: Patient uncooperative|3
5981662|NCT00898677|9570471|FG002|Overall Study|Not Treated: Patient uncooperative|1
5981663|NCT00898677|9570472|FG003|Overall Study|Not Treated: Patient uncooperative|0
5981664|NCT00898677|9570469|FG000|Overall Study|Not Treated: Abnormal Prestudy Labs|0
5981665|NCT00898677|9570470|FG001|Overall Study|Not Treated: Abnormal Prestudy Labs|0
5981666|NCT00898677|9570471|FG002|Overall Study|Not Treated: Abnormal Prestudy Labs|0
5981667|NCT00898677|9570472|FG003|Overall Study|Not Treated: Abnormal Prestudy Labs|1
5981668|NCT00898677|9570469|FG000|Overall Study|Not Treated: Abnormal Baseline ECG|1
5981669|NCT00898677|9570470|FG001|Overall Study|Not Treated: Abnormal Baseline ECG|0
5981670|NCT00898677|9570471|FG002|Overall Study|Not Treated: Abnormal Baseline ECG|0
5981671|NCT00898677|9570472|FG003|Overall Study|Not Treated: Abnormal Baseline ECG|0
5981672|NCT00898677|9570469|FG000|Overall Study|Not Treated: No Longer Met Inc Criteria|0
5981673|NCT00898677|9570470|FG001|Overall Study|Not Treated: No Longer Met Inc Criteria|3
5981674|NCT00898677|9570471|FG002|Overall Study|Not Treated: No Longer Met Inc Criteria|1
5981675|NCT00898677|9570472|FG003|Overall Study|Not Treated: No Longer Met Inc Criteria|0
5981676|NCT00898677|9570469|FG000|Overall Study|Not Treated: Lack of Migraine Attack|9
5981677|NCT00898677|9570470|FG001|Overall Study|Not Treated: Lack of Migraine Attack|39
5981678|NCT00898677|9570471|FG002|Overall Study|Not Treated: Lack of Migraine Attack|43
5981679|NCT00898677|9570472|FG003|Overall Study|Not Treated: Lack of Migraine Attack|12
5981680|NCT00898677|9570469|FG000|Overall Study|Not Treated: Other (Not Specified)|0
5981681|NCT00898677|9570470|FG001|Overall Study|Not Treated: Other (Not Specified)|0
5981682|NCT00898677|9570471|FG002|Overall Study|Not Treated: Other (Not Specified)|2
5981683|NCT00898677|9570472|FG003|Overall Study|Not Treated: Other (Not Specified)|0
5981684|NCT00897949|9570485|FG000|Overall Study|Adverse Event|1
5981685|NCT00897949|9570486|FG001|Overall Study|Adverse Event|1
5981686|NCT00897949|9570487|FG002|Overall Study|Adverse Event|0
5981687|NCT00897949|9570485|FG000|Overall Study|Lost to Follow-up|0
5981688|NCT00897949|9570486|FG001|Overall Study|Lost to Follow-up|2
5981689|NCT00897949|9570487|FG002|Overall Study|Lost to Follow-up|1
6296333|NCT02477800|10017413|FG002|Long Term Extension Period|Lost to Follow-up|0
6296334|NCT02477800|10017414|FG003|Long Term Extension Period|Lost to Follow-up|0
6296335|NCT02477800|10017415|FG004|Long Term Extension Period|Lost to Follow-up|1
6296336|NCT02477800|10017416|FG005|Long Term Extension Period|Lost to Follow-up|3
6296337|NCT02477800|10017417|FG006|Long Term Extension Period|Lost to Follow-up|0
6296338|NCT02477800|10017411|FG000|Long Term Extension Period|Site Terminated By Sponsor|0
6296339|NCT02477800|10017412|FG001|Long Term Extension Period|Site Terminated By Sponsor|0
6296340|NCT02477800|10017413|FG002|Long Term Extension Period|Site Terminated By Sponsor|0
6296341|NCT02477800|10017414|FG003|Long Term Extension Period|Site Terminated By Sponsor|0
6296342|NCT02477800|10017415|FG004|Long Term Extension Period|Site Terminated By Sponsor|0
6296343|NCT02477800|10017416|FG005|Long Term Extension Period|Site Terminated By Sponsor|2
6296344|NCT02477800|10017417|FG006|Long Term Extension Period|Site Terminated By Sponsor|1
6296345|NCT02477800|10017411|FG000|Long Term Extension Period|Study Visit Burden|0
6296346|NCT02477800|10017412|FG001|Long Term Extension Period|Study Visit Burden|0
6296347|NCT02477800|10017413|FG002|Long Term Extension Period|Study Visit Burden|0
6296348|NCT02477800|10017414|FG003|Long Term Extension Period|Study Visit Burden|3
6296349|NCT02477800|10017415|FG004|Long Term Extension Period|Study Visit Burden|0
6296350|NCT02477800|10017416|FG005|Long Term Extension Period|Study Visit Burden|2
6296351|NCT02477800|10017417|FG006|Long Term Extension Period|Study Visit Burden|2
6296352|NCT02477800|10017411|FG000|Long Term Extension Period|Withdrawal by Parent/Guardian|0
6296353|NCT02477800|10017412|FG001|Long Term Extension Period|Withdrawal by Parent/Guardian|0
6296354|NCT02477800|10017413|FG002|Long Term Extension Period|Withdrawal by Parent/Guardian|0
6296355|NCT02477800|10017414|FG003|Long Term Extension Period|Withdrawal by Parent/Guardian|1
6296356|NCT02477800|10017415|FG004|Long Term Extension Period|Withdrawal by Parent/Guardian|3
6296357|NCT02477800|10017416|FG005|Long Term Extension Period|Withdrawal by Parent/Guardian|3
6296358|NCT02477800|10017417|FG006|Long Term Extension Period|Withdrawal by Parent/Guardian|1
6296359|NCT02477800|10017411|FG000|Long Term Extension Period|Reason not Specified|0
6296360|NCT02477800|10017412|FG001|Long Term Extension Period|Reason not Specified|0
6296361|NCT02477800|10017413|FG002|Long Term Extension Period|Reason not Specified|0
6296362|NCT02477800|10017414|FG003|Long Term Extension Period|Reason not Specified|126
6296363|NCT02477800|10017415|FG004|Long Term Extension Period|Reason not Specified|140
6296364|NCT02477800|10017416|FG005|Long Term Extension Period|Reason not Specified|270
6296365|NCT02477800|10017417|FG006|Long Term Extension Period|Reason not Specified|224
6296366|NCT02477839|10017431|FG000|Overall Study|Adverse Event|0
6296367|NCT02477839|10017432|FG001|Overall Study|Adverse Event|1
6296368|NCT02477839|10017431|FG000|Overall Study|Protocol Violation|0
6296369|NCT02477839|10017432|FG001|Overall Study|Protocol Violation|2
6296370|NCT02477839|10017431|FG000|Overall Study|Withdrawal by Subject|3
6296371|NCT02477839|10017432|FG001|Overall Study|Withdrawal by Subject|3
6296372|NCT02477839|10017431|FG000|Overall Study|Participant had PGS during V6|0
6296373|NCT02477839|10017432|FG001|Overall Study|Participant had PGS during V6|1
6296374|NCT02477839|10017431|FG000|Overall Study|Parents decided to stop medication|0
6296375|NCT02477839|10017432|FG001|Overall Study|Parents decided to stop medication|1
6296376|NCT02477839|10017431|FG000|Overall Study|Lack of tolerability|0
6296377|NCT02477839|10017432|FG001|Overall Study|Lack of tolerability|1
6296378|NCT02477839|10017431|FG000|Overall Study|Exclusion criterion|0
6296379|NCT02477839|10017432|FG001|Overall Study|Exclusion criterion|1
6296380|NCT02478164|10017440|FG000|Overall Study|Lack of Efficacy|13
6296381|NCT02478164|10017440|FG000|Overall Study|Adverse Event|1
6296382|NCT02478164|10017440|FG000|Overall Study|Withdrawal by Subject|1
6296383|NCT02478359|10017446|FG000|Overall Study|Disenrolled from health plan|106
6296384|NCT02478359|10017447|FG001|Overall Study|Disenrolled from health plan|65
6296385|NCT02478372|10017457|FG000|Overall Study|Protocol Violation|12
6296386|NCT02478372|10017458|FG001|Overall Study|Protocol Violation|8
6296387|NCT02478372|10017457|FG000|Overall Study|Lost to Follow-up|1
6296388|NCT02478372|10017458|FG001|Overall Study|Lost to Follow-up|4
6296389|NCT02478372|10017457|FG000|Overall Study|Death|0
6296390|NCT02478372|10017458|FG001|Overall Study|Death|2
6296391|NCT02478398|10017466|FG000|Overall Study|Adverse Event|20
6296392|NCT02478398|10017467|FG001|Overall Study|Adverse Event|5
6296393|NCT02478398|10017466|FG000|Overall Study|Lost to Follow-up|5
6296394|NCT02478398|10017467|FG001|Overall Study|Lost to Follow-up|4
6296395|NCT02478398|10017466|FG000|Overall Study|Non-Compliance With Study Drug|5
6296396|NCT02478398|10017467|FG001|Overall Study|Non-Compliance With Study Drug|1
6296397|NCT02478398|10017466|FG000|Overall Study|Protocol Violation|3
6296398|NCT02478398|10017467|FG001|Overall Study|Protocol Violation|1
6296399|NCT02478398|10017466|FG000|Overall Study|Withdrawal By Parent/Guardian|9
6296400|NCT02478398|10017467|FG001|Overall Study|Withdrawal By Parent/Guardian|6
6296401|NCT02478398|10017466|FG000|Overall Study|Withdrawal By Participant|10
6296402|NCT02478398|10017467|FG001|Overall Study|Withdrawal By Participant|4
6296403|NCT02478463|10017474|FG000|Treatment Period 1 (Up to Day 29)|Physician Decision|1
6296404|NCT02478463|10017474|FG000|Washout Period (Up to 42 Days)|Lost to Follow-up|1
6296405|NCT02478463|10017474|FG000|Treatment Period 2 (Up to 52 Weeks)|Withdrawal by Subject|1
6296406|NCT02478632|10017502|FG000|Early Switch Phase (Up to Week 52)|Withdrawal from parent study|4
6296407|NCT02478632|10017503|FG001|Early Switch Phase (Up to Week 52)|Withdrawal from parent study|5
6296408|NCT02478632|10017502|FG000|Late Switch Phase (Week 52 to Week 148)|Withdrawal from parent study|2
6296409|NCT02478632|10017503|FG001|Late Switch Phase (Week 52 to Week 148)|Withdrawal from parent study|3
6296410|NCT02478632|10017502|FG000|Late Switch Phase (Week 52 to Week 148)|Prohibited medication use|5
6296411|NCT02478632|10017503|FG001|Late Switch Phase (Week 52 to Week 148)|Prohibited medication use|1
6296412|NCT02479139|10017523|FG000|Overall Study|Lost to Follow-up|2
6296413|NCT02479139|10017524|FG001|Overall Study|Lost to Follow-up|4
6296414|NCT02479139|10017525|FG002|Overall Study|Lost to Follow-up|4
6296415|NCT02479139|10017526|FG003|Overall Study|Lost to Follow-up|2
6296416|NCT02479139|10017527|FG004|Overall Study|Lost to Follow-up|3
6296417|NCT02479139|10017528|FG005|Overall Study|Lost to Follow-up|5
6296418|NCT02479139|10017523|FG000|Overall Study|Withdrew Consent|5
6296419|NCT02479139|10017524|FG001|Overall Study|Withdrew Consent|6
6296420|NCT02479139|10017525|FG002|Overall Study|Withdrew Consent|1
6296421|NCT02479139|10017526|FG003|Overall Study|Withdrew Consent|4
6296422|NCT02479139|10017527|FG004|Overall Study|Withdrew Consent|1
6296423|NCT02479139|10017528|FG005|Overall Study|Withdrew Consent|1
6296424|NCT02479139|10017523|FG000|Overall Study|Treatment Failure/Lack of Efficacy|0
6296425|NCT02479139|10017524|FG001|Overall Study|Treatment Failure/Lack of Efficacy|0
6296426|NCT02479139|10017525|FG002|Overall Study|Treatment Failure/Lack of Efficacy|1
6296427|NCT02479139|10017526|FG003|Overall Study|Treatment Failure/Lack of Efficacy|0
6296428|NCT02479139|10017527|FG004|Overall Study|Treatment Failure/Lack of Efficacy|0
6296429|NCT02479139|10017528|FG005|Overall Study|Treatment Failure/Lack of Efficacy|0
6296430|NCT02479139|10017523|FG000|Overall Study|Other Miscellaneous Reasons|1
6296431|NCT02479139|10017524|FG001|Overall Study|Other Miscellaneous Reasons|0
6296432|NCT02479139|10017525|FG002|Overall Study|Other Miscellaneous Reasons|1
6296433|NCT02479139|10017526|FG003|Overall Study|Other Miscellaneous Reasons|1
6296434|NCT02479139|10017527|FG004|Overall Study|Other Miscellaneous Reasons|1
6296435|NCT02479139|10017528|FG005|Overall Study|Other Miscellaneous Reasons|0
6296436|NCT02479412|10017551|FG000|Overall Study|Adverse Event|0
6296437|NCT02479412|10017552|FG001|Overall Study|Adverse Event|0
6296438|NCT02479412|10017553|FG002|Overall Study|Adverse Event|1
6296439|NCT02479412|10017554|FG003|Overall Study|Adverse Event|0
6296440|NCT02479412|10017555|FG004|Overall Study|Adverse Event|0
6296441|NCT02479412|10017556|FG005|Overall Study|Adverse Event|0
6296442|NCT02479412|10017557|FG006|Overall Study|Adverse Event|0
6296443|NCT02479412|10017558|FG007|Overall Study|Adverse Event|0
6296444|NCT02479412|10017559|FG008|Overall Study|Adverse Event|0
6296445|NCT02479412|10017551|FG000|Overall Study|Study-specific withdrawal criteria|0
6296446|NCT02479412|10017552|FG001|Overall Study|Study-specific withdrawal criteria|0
6296447|NCT02479412|10017553|FG002|Overall Study|Study-specific withdrawal criteria|1
6296448|NCT02479412|10017554|FG003|Overall Study|Study-specific withdrawal criteria|1
6296449|NCT02479412|10017555|FG004|Overall Study|Study-specific withdrawal criteria|0
6296450|NCT02479412|10017556|FG005|Overall Study|Study-specific withdrawal criteria|0
6296451|NCT02479412|10017557|FG006|Overall Study|Study-specific withdrawal criteria|0
6296452|NCT02479412|10017558|FG007|Overall Study|Study-specific withdrawal criteria|1
6296453|NCT02479412|10017559|FG008|Overall Study|Study-specific withdrawal criteria|1
6296454|NCT02479412|10017551|FG000|Overall Study|Randomization to wrong PK sampling group|0
6296455|NCT02479412|10017552|FG001|Overall Study|Randomization to wrong PK sampling group|0
6296456|NCT02479412|10017553|FG002|Overall Study|Randomization to wrong PK sampling group|0
6296457|NCT02479412|10017554|FG003|Overall Study|Randomization to wrong PK sampling group|0
6296458|NCT02479412|10017555|FG004|Overall Study|Randomization to wrong PK sampling group|1
6296459|NCT02479412|10017556|FG005|Overall Study|Randomization to wrong PK sampling group|0
6296460|NCT02479412|10017557|FG006|Overall Study|Randomization to wrong PK sampling group|0
6296461|NCT02479412|10017558|FG007|Overall Study|Randomization to wrong PK sampling group|0
6296462|NCT02479412|10017559|FG008|Overall Study|Randomization to wrong PK sampling group|0
6296463|NCT02479802|10017584|FG000|Overall Study|Lost to Follow-up|1
6296464|NCT02479802|10017584|FG000|Overall Study|Adverse Event|1
6296465|NCT02479880|10017590|FG000|Overall Study|Study Terminated by Sponsor|13
6296466|NCT02479880|10017591|FG001|Overall Study|Study Terminated by Sponsor|12
6296467|NCT02479880|10017590|FG000|Overall Study|Pregnancy|0
6296468|NCT02479880|10017591|FG001|Overall Study|Pregnancy|1
6296469|NCT02480010|10017599|FG000|Overall Study|Adverse Event|3
6296470|NCT02480010|10017600|FG001|Overall Study|Adverse Event|1
6296471|NCT02480010|10017599|FG000|Overall Study|Death|1
6296472|NCT02480010|10017600|FG001|Overall Study|Death|0
6296473|NCT02480010|10017599|FG000|Overall Study|Insufficient therapeutic response|31
6296474|NCT02480010|10017600|FG001|Overall Study|Insufficient therapeutic response|29
6296475|NCT02480010|10017599|FG000|Overall Study|Refused Treatment|0
6296476|NCT02480010|10017600|FG001|Overall Study|Refused Treatment|3
6296477|NCT02480114|10017608|FG000|Overall Study|Not completing surveys|3
6296478|NCT02480114|10017609|FG001|Overall Study|Not completing surveys|2
6296479|NCT02480114|10017608|FG000|Overall Study|Withdrawal by Subject|2
6296480|NCT02480114|10017609|FG001|Overall Study|Withdrawal by Subject|4
6296481|NCT02480114|10017608|FG000|Overall Study|Disease progression|3
6296482|NCT02480114|10017609|FG001|Overall Study|Disease progression|0
6296483|NCT02480114|10017608|FG000|Overall Study|Improper completion of survey|1
6296484|NCT02480114|10017609|FG001|Overall Study|Improper completion of survey|1
6296485|NCT02480114|10017608|FG000|Overall Study|Not eligible|0
6296486|NCT02480114|10017609|FG001|Overall Study|Not eligible|1
6296487|NCT02480153|10017617|FG000|Period 1: First Dose to Week 26 Pre-dose|Insufficient Clinical response|0
6296488|NCT02480153|10017618|FG001|Period 1: First Dose to Week 26 Pre-dose|Insufficient Clinical response|1
6296489|NCT02480153|10017619|FG002|Period 1: First Dose to Week 26 Pre-dose|Insufficient Clinical response|0
6296490|NCT02480153|10017617|FG000|Period 1: First Dose to Week 26 Pre-dose|Non-compliance with study treatment|0
6296491|NCT02480153|10017618|FG001|Period 1: First Dose to Week 26 Pre-dose|Non-compliance with study treatment|1
6296492|NCT02480153|10017619|FG002|Period 1: First Dose to Week 26 Pre-dose|Non-compliance with study treatment|0
6296493|NCT02480153|10017617|FG000|Period 1: First Dose to Week 26 Pre-dose|Adverse Event|1
6296494|NCT02480153|10017618|FG001|Period 1: First Dose to Week 26 Pre-dose|Adverse Event|2
6296495|NCT02480153|10017619|FG002|Period 1: First Dose to Week 26 Pre-dose|Adverse Event|0
6296496|NCT02480153|10017617|FG000|Period 1: First Dose to Week 26 Pre-dose|Withdrawal by Subject|3
6296497|NCT02480153|10017618|FG001|Period 1: First Dose to Week 26 Pre-dose|Withdrawal by Subject|8
6296498|NCT02480153|10017619|FG002|Period 1: First Dose to Week 26 Pre-dose|Withdrawal by Subject|0
6296499|NCT02480153|10017617|FG000|Period 1: First Dose to Week 26 Pre-dose|Other|0
6296500|NCT02480153|10017618|FG001|Period 1: First Dose to Week 26 Pre-dose|Other|1
6296501|NCT02480153|10017619|FG002|Period 1: First Dose to Week 26 Pre-dose|Other|0
6296502|NCT02480153|10017617|FG000|Period 1: First Dose to Week 26 Pre-dose|Death|0
6296503|NCT02480153|10017618|FG001|Period 1: First Dose to Week 26 Pre-dose|Death|1
6296504|NCT02480153|10017619|FG002|Period 1: First Dose to Week 26 Pre-dose|Death|0
6296505|NCT02480153|10017617|FG000|Period 1: First Dose to Week 26 Pre-dose|Lost to Follow-up|0
6296506|NCT02480153|10017618|FG001|Period 1: First Dose to Week 26 Pre-dose|Lost to Follow-up|2
6296507|NCT02480153|10017619|FG002|Period 1: First Dose to Week 26 Pre-dose|Lost to Follow-up|0
6296508|NCT02480153|10017617|FG000|Period 2: Week 26 to Week 52 Pre-dose|Insufficient clinical response|4
6296509|NCT02480153|10017618|FG001|Period 2: Week 26 to Week 52 Pre-dose|Insufficient clinical response|1
6296510|NCT02480153|10017619|FG002|Period 2: Week 26 to Week 52 Pre-dose|Insufficient clinical response|3
6296511|NCT02480153|10017617|FG000|Period 2: Week 26 to Week 52 Pre-dose|Non-compliance with study treatment|0
6296512|NCT02480153|10017618|FG001|Period 2: Week 26 to Week 52 Pre-dose|Non-compliance with study treatment|1
6296513|NCT02480153|10017619|FG002|Period 2: Week 26 to Week 52 Pre-dose|Non-compliance with study treatment|0
6296514|NCT02480153|10017617|FG000|Period 2: Week 26 to Week 52 Pre-dose|Withdrawal by Subject|8
6296515|NCT02480153|10017618|FG001|Period 2: Week 26 to Week 52 Pre-dose|Withdrawal by Subject|3
6296516|NCT02480153|10017619|FG002|Period 2: Week 26 to Week 52 Pre-dose|Withdrawal by Subject|1
6296517|NCT02480153|10017617|FG000|Period 2: Week 26 to Week 52 Pre-dose|Adverse Event|6
6296518|NCT02480153|10017618|FG001|Period 2: Week 26 to Week 52 Pre-dose|Adverse Event|7
6296519|NCT02480153|10017619|FG002|Period 2: Week 26 to Week 52 Pre-dose|Adverse Event|3
6296520|NCT02480153|10017617|FG000|Period 2: Week 26 to Week 52 Pre-dose|Other|2
6296521|NCT02480153|10017618|FG001|Period 2: Week 26 to Week 52 Pre-dose|Other|0
6296522|NCT02480153|10017619|FG002|Period 2: Week 26 to Week 52 Pre-dose|Other|0
6296523|NCT02480153|10017617|FG000|Period 2: Week 26 to Week 52 Pre-dose|Lost to Follow-up|0
6296524|NCT02480153|10017618|FG001|Period 2: Week 26 to Week 52 Pre-dose|Lost to Follow-up|1
6296525|NCT02480153|10017619|FG002|Period 2: Week 26 to Week 52 Pre-dose|Lost to Follow-up|0
6296526|NCT02480153|10017617|FG000|Period 3: Week 52 Dosing to Week 78|Withdrawal by Subject|3
6296527|NCT02480153|10017618|FG001|Period 3: Week 52 Dosing to Week 78|Withdrawal by Subject|2
6296528|NCT02480153|10017619|FG002|Period 3: Week 52 Dosing to Week 78|Withdrawal by Subject|1
6296529|NCT02480153|10017617|FG000|Period 3: Week 52 Dosing to Week 78|Lost to Follow-up|4
6296530|NCT02480153|10017618|FG001|Period 3: Week 52 Dosing to Week 78|Lost to Follow-up|0
6296531|NCT02480153|10017619|FG002|Period 3: Week 52 Dosing to Week 78|Lost to Follow-up|1
6296532|NCT02480153|10017617|FG000|Period 3: Week 52 Dosing to Week 78|Other|0
6296533|NCT02480153|10017618|FG001|Period 3: Week 52 Dosing to Week 78|Other|0
6296534|NCT02480153|10017619|FG002|Period 3: Week 52 Dosing to Week 78|Other|1
6296535|NCT02480153|10017617|FG000|Period 3: Week 52 Dosing to Week 78|Adverse Event|0
6296536|NCT02480153|10017618|FG001|Period 3: Week 52 Dosing to Week 78|Adverse Event|0
6296537|NCT02480153|10017619|FG002|Period 3: Week 52 Dosing to Week 78|Adverse Event|1
6296538|NCT02480153|10017617|FG000|Period 3: Week 52 Dosing to Week 78|Death|0
6296539|NCT02480153|10017618|FG001|Period 3: Week 52 Dosing to Week 78|Death|1
6296540|NCT02480153|10017619|FG002|Period 3: Week 52 Dosing to Week 78|Death|0
6296541|NCT02480621|10017689|FG000|Randomization|Withdrawal by Subject|1
6296542|NCT02480621|10017690|FG001|Randomization|Withdrawal by Subject|0
6296543|NCT02480621|10017689|FG000|Randomization|Surgeon did not give intervention|0
6296544|NCT02480621|10017690|FG001|Randomization|Surgeon did not give intervention|1
6296545|NCT02480621|10017689|FG000|Follow Up|Lost to Follow-up|4
6296546|NCT02480621|10017690|FG001|Follow Up|Lost to Follow-up|2
6296547|NCT02480712|10017696|FG000|Overall Study|Enrolled but Never Treated|1
6296548|NCT02480712|10017696|FG000|Overall Study|Lost to Follow-up|5
6296549|NCT02480712|10017696|FG000|Overall Study|Withdrew Consent|3
6296550|NCT02480712|10017696|FG000|Overall Study|Death|1
6296551|NCT02480712|10017696|FG000|Overall Study|Lack of Efficacy|1
6296552|NCT02480764|10017709|FG000|Overall Study|Pretreatment Event/Adverse Event|3
6296553|NCT02480764|10017710|FG001|Overall Study|Pretreatment Event/Adverse Event|6
6296554|NCT02480764|10017711|FG002|Overall Study|Pretreatment Event/Adverse Event|3
6296555|NCT02480764|10017709|FG000|Overall Study|Major Protocol Deviation|1
6296556|NCT02480764|10017710|FG001|Overall Study|Major Protocol Deviation|4
6296557|NCT02480764|10017711|FG002|Overall Study|Major Protocol Deviation|3
6296558|NCT02480764|10017709|FG000|Overall Study|Lost to Follow-up|0
6296559|NCT02480764|10017710|FG001|Overall Study|Lost to Follow-up|1
6296560|NCT02480764|10017711|FG002|Overall Study|Lost to Follow-up|2
6296561|NCT02480764|10017709|FG000|Overall Study|Voluntary Withdrawal|6
6296562|NCT02480764|10017710|FG001|Overall Study|Voluntary Withdrawal|5
6296563|NCT02480764|10017711|FG002|Overall Study|Voluntary Withdrawal|10
6296564|NCT02480764|10017709|FG000|Overall Study|Lack of Efficacy|0
6296565|NCT02480764|10017710|FG001|Overall Study|Lack of Efficacy|3
6296566|NCT02480764|10017711|FG002|Overall Study|Lack of Efficacy|3
6296567|NCT02480764|10017709|FG000|Overall Study|Reason not Specified|0
6296568|NCT02480764|10017710|FG001|Overall Study|Reason not Specified|1
6296569|NCT02480764|10017711|FG002|Overall Study|Reason not Specified|0
6296570|NCT02481050|10017734|FG000|Overall Study|Adverse Event|1
6296571|NCT02481050|10017734|FG000|Overall Study|Disease Progression|47
6296572|NCT02481050|10017734|FG000|Overall Study|Withdrawal by Subject|7
6296573|NCT02481050|10017734|FG000|Overall Study|Other|3
6296574|NCT02481869|10017879|FG000|Overall Study|Lost to Follow-up|3
6296575|NCT02481869|10017880|FG001|Overall Study|Lost to Follow-up|4
6296576|NCT02481869|10017879|FG000|Overall Study|Withdrawal by Subject|2
6296577|NCT02481869|10017880|FG001|Overall Study|Withdrawal by Subject|0
6296578|NCT02481934|10017887|FG000|Overall Study|Death|2
6296579|NCT02481947|10017893|FG000|Overall Study|Withdrawal by Subject|24
6296580|NCT02481947|10017894|FG001|Overall Study|Withdrawal by Subject|10
6296581|NCT02481947|10017893|FG000|Overall Study|Lost to Follow-up|11
6296582|NCT02481947|10017894|FG001|Overall Study|Lost to Follow-up|5
6296583|NCT02481947|10017893|FG000|Overall Study|Adverse Event|6
6296584|NCT02481947|10017894|FG001|Overall Study|Adverse Event|11
6296585|NCT02481947|10017893|FG000|Overall Study|Physician Decision|4
6296586|NCT02481947|10017894|FG001|Overall Study|Physician Decision|5
6296587|NCT02481947|10017893|FG000|Overall Study|Protocol Violation|1
6296588|NCT02481947|10017894|FG001|Overall Study|Protocol Violation|5
6296589|NCT02482129|10017911|FG000|Overall Study|Adverse Event-prior to treatment|0
6296590|NCT02482129|10017912|FG001|Overall Study|Adverse Event-prior to treatment|1
6296591|NCT02482129|10017911|FG000|Overall Study|Withdrawal by subject-prior to treatment|0
6296592|NCT02482129|10017912|FG001|Overall Study|Withdrawal by subject-prior to treatment|1
6296593|NCT02482129|10017911|FG000|Overall Study|Unable to draw blood-prior to treatment|1
6296594|NCT02482129|10017912|FG001|Overall Study|Unable to draw blood-prior to treatment|0
6296595|NCT02482129|10017911|FG000|Overall Study|Criteria not met-prior to treatment|1
6296596|NCT02482129|10017912|FG001|Overall Study|Criteria not met-prior to treatment|0
6296597|NCT02482129|10017911|FG000|Overall Study|Adverse Event|1
6296598|NCT02482129|10017912|FG001|Overall Study|Adverse Event|0
6296599|NCT02482129|10017911|FG000|Overall Study|Withdrawal by Subject|2
6296600|NCT02482129|10017912|FG001|Overall Study|Withdrawal by Subject|0
6296601|NCT02482129|10017911|FG000|Overall Study|Criteria not met|1
6296602|NCT02482129|10017912|FG001|Overall Study|Criteria not met|0
6296603|NCT02482298|10017923|FG000|Overall Study|Withdrawal by Subject|2
6296604|NCT02482298|10017924|FG001|Overall Study|Withdrawal by Subject|1
6296605|NCT02482298|10017925|FG002|Overall Study|Withdrawal by Subject|2
6296606|NCT02482298|10017923|FG000|Overall Study|Did Not Fulfill Randomization Criteria|0
6296607|NCT02482298|10017924|FG001|Overall Study|Did Not Fulfill Randomization Criteria|1
6296608|NCT02482298|10017925|FG002|Overall Study|Did Not Fulfill Randomization Criteria|0
6296609|NCT02482298|10017923|FG000|Overall Study|Dev. of Study-Spec. Withdrawal Criteria|0
6296610|NCT02482298|10017924|FG001|Overall Study|Dev. of Study-Spec. Withdrawal Criteria|0
6296611|NCT02482298|10017925|FG002|Overall Study|Dev. of Study-Spec. Withdrawal Criteria|1
6296612|NCT02482298|10017923|FG000|Overall Study|Lost to Follow-up|0
6296613|NCT02482298|10017924|FG001|Overall Study|Lost to Follow-up|1
6296614|NCT02482298|10017925|FG002|Overall Study|Lost to Follow-up|0
6296615|NCT02482428|10017938|FG000|Overall Study|Lost to Follow-up|4
6296616|NCT02482428|10017939|FG001|Overall Study|Lost to Follow-up|9
6296617|NCT02482428|10017940|FG002|Overall Study|Lost to Follow-up|1
6296618|NCT02482428|10017941|FG003|Overall Study|Lost to Follow-up|2
6296619|NCT02482428|10017942|FG004|Overall Study|Lost to Follow-up|4
6296620|NCT02482428|10017938|FG000|Overall Study|Physician Decision|0
6296621|NCT02482428|10017939|FG001|Overall Study|Physician Decision|0
6296622|NCT02482428|10017940|FG002|Overall Study|Physician Decision|0
6296623|NCT02482428|10017941|FG003|Overall Study|Physician Decision|0
6296624|NCT02482428|10017942|FG004|Overall Study|Physician Decision|1
6296625|NCT02482428|10017938|FG000|Overall Study|protocol deviation|1
6296626|NCT02482428|10017939|FG001|Overall Study|protocol deviation|1
6296627|NCT02482428|10017940|FG002|Overall Study|protocol deviation|0
6296628|NCT02482428|10017941|FG003|Overall Study|protocol deviation|0
6296629|NCT02482428|10017942|FG004|Overall Study|protocol deviation|0
6296630|NCT02482428|10017938|FG000|Overall Study|subject/guardian decision|4
6296631|NCT02482428|10017939|FG001|Overall Study|subject/guardian decision|2
6296632|NCT02482428|10017940|FG002|Overall Study|subject/guardian decision|0
6296633|NCT02482428|10017941|FG003|Overall Study|subject/guardian decision|0
6296634|NCT02482428|10017942|FG004|Overall Study|subject/guardian decision|2
6296635|NCT02482571|10017956|FG000|Overall Study|Adverse Event|1
6296636|NCT02482571|10017956|FG000|Overall Study|Scanner or Respiract failure|3
6296637|NCT02482571|10017956|FG000|Overall Study|Withdrawal by Subject|4
6296638|NCT02482805|10018012|FG000|Overall Study|Lost to Follow-up|4
6296639|NCT02482805|10018013|FG001|Overall Study|Lost to Follow-up|4
6296640|NCT02482805|10018014|FG002|Overall Study|Lost to Follow-up|0
6296641|NCT02482935|10018037|FG000|Period 1|Withdrawal by Subject|1
6296642|NCT02482935|10018038|FG001|Period 1|Withdrawal by Subject|0
6296643|NCT02483416|10018053|FG000|Overall Study|Other reason|0
6296644|NCT02483416|10018054|FG001|Overall Study|Other reason|1
6296645|NCT02483416|10018053|FG000|Overall Study|Treatment stop|3
6296646|NCT02483416|10018054|FG001|Overall Study|Treatment stop|0
6296647|NCT02483520|10018063|FG000|Overall Study|Lost to Follow-up|3
6296648|NCT02483520|10018064|FG001|Overall Study|Lost to Follow-up|4
6296649|NCT02483520|10018063|FG000|Overall Study|Withdrawal by Subject|4
6296650|NCT02483520|10018064|FG001|Overall Study|Withdrawal by Subject|14
6296651|NCT02483520|10018063|FG000|Overall Study|Hospitalized|2
6296652|NCT02483520|10018064|FG001|Overall Study|Hospitalized|3
6296653|NCT02483520|10018063|FG000|Overall Study|Moved to LTC|2
6296654|NCT02483520|10018064|FG001|Overall Study|Moved to LTC|3
6296655|NCT02483572|10018072|FG000|Overall Study|Withdrawal by Subject|1
6296656|NCT02483572|10018073|FG001|Overall Study|Withdrawal by Subject|0
6296657|NCT02483572|10018072|FG000|Overall Study|Lost to Follow-up|1
6296658|NCT02483572|10018073|FG001|Overall Study|Lost to Follow-up|0
6296659|NCT02483572|10018072|FG000|Overall Study|Physician Decision|0
6296660|NCT02483572|10018073|FG001|Overall Study|Physician Decision|1
6296661|NCT02483611|10018082|FG000|Overall Study|Protocol Violation|0
6296662|NCT02483611|10018083|FG001|Overall Study|Protocol Violation|0
6296663|NCT02483611|10018084|FG002|Overall Study|Protocol Violation|1
6296664|NCT02483975|10018103|FG000|Overall Study|Adverse Event|0
6296665|NCT02483975|10018104|FG001|Overall Study|Adverse Event|1
6296666|NCT02483975|10018103|FG000|Overall Study|Lost to Follow-up|0
6296667|NCT02483975|10018104|FG001|Overall Study|Lost to Follow-up|1
6296668|NCT02483975|10018103|FG000|Overall Study|Physician Decision|2
6296669|NCT02483975|10018104|FG001|Overall Study|Physician Decision|0
6296670|NCT02484547|10018126|FG000|Placebo-Controlled Period|Adverse Event|10
6296671|NCT02484547|10018127|FG001|Placebo-Controlled Period|Adverse Event|13
6296672|NCT02484547|10018128|FG002|Placebo-Controlled Period|Adverse Event|20
6296673|NCT02484547|10018129|FG003|Placebo-Controlled Period|Adverse Event|0
6296674|NCT02484547|10018130|FG004|Placebo-Controlled Period|Adverse Event|0
6296675|NCT02484547|10018131|FG005|Placebo-Controlled Period|Adverse Event|0
6296676|NCT02484547|10018132|FG006|Placebo-Controlled Period|Adverse Event|0
6296677|NCT02484547|10018126|FG000|Placebo-Controlled Period|Change of Treatment|0
6296678|NCT02484547|10018127|FG001|Placebo-Controlled Period|Change of Treatment|0
6296679|NCT02484547|10018128|FG002|Placebo-Controlled Period|Change of Treatment|1
6296680|NCT02484547|10018129|FG003|Placebo-Controlled Period|Change of Treatment|0
6296681|NCT02484547|10018130|FG004|Placebo-Controlled Period|Change of Treatment|0
6296682|NCT02484547|10018131|FG005|Placebo-Controlled Period|Change of Treatment|0
6296683|NCT02484547|10018132|FG006|Placebo-Controlled Period|Change of Treatment|0
6296684|NCT02484547|10018126|FG000|Placebo-Controlled Period|Consent Withdrawn|15
6296685|NCT02484547|10018127|FG001|Placebo-Controlled Period|Consent Withdrawn|32
6296686|NCT02484547|10018128|FG002|Placebo-Controlled Period|Consent Withdrawn|26
6296687|NCT02484547|10018129|FG003|Placebo-Controlled Period|Consent Withdrawn|0
6296688|NCT02484547|10018130|FG004|Placebo-Controlled Period|Consent Withdrawn|0
6296689|NCT02484547|10018131|FG005|Placebo-Controlled Period|Consent Withdrawn|0
6296690|NCT02484547|10018132|FG006|Placebo-Controlled Period|Consent Withdrawn|0
6296691|NCT02484547|10018126|FG000|Placebo-Controlled Period|Death|5
6296692|NCT02484547|10018127|FG001|Placebo-Controlled Period|Death|0
6296693|NCT02484547|10018128|FG002|Placebo-Controlled Period|Death|6
6296694|NCT02484547|10018129|FG003|Placebo-Controlled Period|Death|0
6296695|NCT02484547|10018130|FG004|Placebo-Controlled Period|Death|0
6296696|NCT02484547|10018131|FG005|Placebo-Controlled Period|Death|0
6296697|NCT02484547|10018132|FG006|Placebo-Controlled Period|Death|0
6296698|NCT02484547|10018126|FG000|Placebo-Controlled Period|Disease Progression|2
6296699|NCT02484547|10018127|FG001|Placebo-Controlled Period|Disease Progression|0
6296700|NCT02484547|10018128|FG002|Placebo-Controlled Period|Disease Progression|1
6296701|NCT02484547|10018129|FG003|Placebo-Controlled Period|Disease Progression|0
6296702|NCT02484547|10018130|FG004|Placebo-Controlled Period|Disease Progression|0
6296703|NCT02484547|10018131|FG005|Placebo-Controlled Period|Disease Progression|0
6296704|NCT02484547|10018132|FG006|Placebo-Controlled Period|Disease Progression|0
6296705|NCT02484547|10018126|FG000|Placebo-Controlled Period|Investigator Decision|2
6296706|NCT02484547|10018127|FG001|Placebo-Controlled Period|Investigator Decision|2
6296707|NCT02484547|10018128|FG002|Placebo-Controlled Period|Investigator Decision|5
6296708|NCT02484547|10018129|FG003|Placebo-Controlled Period|Investigator Decision|0
6296709|NCT02484547|10018130|FG004|Placebo-Controlled Period|Investigator Decision|0
6296710|NCT02484547|10018131|FG005|Placebo-Controlled Period|Investigator Decision|0
6296711|NCT02484547|10018132|FG006|Placebo-Controlled Period|Investigator Decision|0
6296712|NCT02484547|10018126|FG000|Placebo-Controlled Period|Lost to Follow-up|3
6296713|NCT02484547|10018127|FG001|Placebo-Controlled Period|Lost to Follow-up|1
6296714|NCT02484547|10018128|FG002|Placebo-Controlled Period|Lost to Follow-up|3
6296715|NCT02484547|10018129|FG003|Placebo-Controlled Period|Lost to Follow-up|0
6296716|NCT02484547|10018130|FG004|Placebo-Controlled Period|Lost to Follow-up|0
6296717|NCT02484547|10018131|FG005|Placebo-Controlled Period|Lost to Follow-up|0
6296718|NCT02484547|10018132|FG006|Placebo-Controlled Period|Lost to Follow-up|0
6296719|NCT02484547|10018126|FG000|Placebo-Controlled Period|Relocation|1
6296720|NCT02484547|10018127|FG001|Placebo-Controlled Period|Relocation|1
6296721|NCT02484547|10018128|FG002|Placebo-Controlled Period|Relocation|1
6296722|NCT02484547|10018129|FG003|Placebo-Controlled Period|Relocation|0
6296723|NCT02484547|10018130|FG004|Placebo-Controlled Period|Relocation|0
6296724|NCT02484547|10018131|FG005|Placebo-Controlled Period|Relocation|0
6296725|NCT02484547|10018132|FG006|Placebo-Controlled Period|Relocation|0
6296726|NCT02484547|10018126|FG000|Placebo-Controlled Period|Study Visit Burden|2
6296727|NCT02484547|10018127|FG001|Placebo-Controlled Period|Study Visit Burden|8
6296728|NCT02484547|10018128|FG002|Placebo-Controlled Period|Study Visit Burden|5
6296729|NCT02484547|10018129|FG003|Placebo-Controlled Period|Study Visit Burden|0
6296730|NCT02484547|10018130|FG004|Placebo-Controlled Period|Study Visit Burden|0
6296731|NCT02484547|10018131|FG005|Placebo-Controlled Period|Study Visit Burden|0
6296732|NCT02484547|10018132|FG006|Placebo-Controlled Period|Study Visit Burden|0
6296733|NCT02484547|10018126|FG000|Placebo-Controlled Period|Withdrawal by Parent/Guardian|4
6296734|NCT02484547|10018127|FG001|Placebo-Controlled Period|Withdrawal by Parent/Guardian|1
6296735|NCT02484547|10018128|FG002|Placebo-Controlled Period|Withdrawal by Parent/Guardian|1
6296736|NCT02484547|10018129|FG003|Placebo-Controlled Period|Withdrawal by Parent/Guardian|0
6296737|NCT02484547|10018130|FG004|Placebo-Controlled Period|Withdrawal by Parent/Guardian|0
6296738|NCT02484547|10018131|FG005|Placebo-Controlled Period|Withdrawal by Parent/Guardian|0
6296739|NCT02484547|10018132|FG006|Placebo-Controlled Period|Withdrawal by Parent/Guardian|0
6296740|NCT02484547|10018126|FG000|Placebo-Controlled Period|Reason not Specified|216
6296741|NCT02484547|10018127|FG001|Placebo-Controlled Period|Reason not Specified|194
6296742|NCT02484547|10018128|FG002|Placebo-Controlled Period|Reason not Specified|183
6296743|NCT02484547|10018129|FG003|Placebo-Controlled Period|Reason not Specified|0
6296744|NCT02484547|10018130|FG004|Placebo-Controlled Period|Reason not Specified|0
6296745|NCT02484547|10018131|FG005|Placebo-Controlled Period|Reason not Specified|0
6296746|NCT02484547|10018132|FG006|Placebo-Controlled Period|Reason not Specified|0
6296747|NCT02484547|10018126|FG000|Long-Term Extension Period|Adverse Event|0
6296748|NCT02484547|10018127|FG001|Long-Term Extension Period|Adverse Event|0
6296749|NCT02484547|10018128|FG002|Long-Term Extension Period|Adverse Event|0
6296750|NCT02484547|10018129|FG003|Long-Term Extension Period|Adverse Event|0
6296751|NCT02484547|10018130|FG004|Long-Term Extension Period|Adverse Event|1
6296752|NCT02484547|10018131|FG005|Long-Term Extension Period|Adverse Event|3
6296753|NCT02484547|10018132|FG006|Long-Term Extension Period|Adverse Event|2
6296754|NCT02484547|10018126|FG000|Long-Term Extension Period|Death|0
6296755|NCT02484547|10018127|FG001|Long-Term Extension Period|Death|0
6296756|NCT02484547|10018128|FG002|Long-Term Extension Period|Death|0
6296757|NCT02484547|10018129|FG003|Long-Term Extension Period|Death|0
6296758|NCT02484547|10018130|FG004|Long-Term Extension Period|Death|0
6296759|NCT02484547|10018131|FG005|Long-Term Extension Period|Death|3
6296760|NCT02484547|10018132|FG006|Long-Term Extension Period|Death|0
6296761|NCT02484547|10018126|FG000|Long-Term Extension Period|Disease Progression|0
6296762|NCT02484547|10018127|FG001|Long-Term Extension Period|Disease Progression|0
6296763|NCT02484547|10018128|FG002|Long-Term Extension Period|Disease Progression|0
6296764|NCT02484547|10018129|FG003|Long-Term Extension Period|Disease Progression|0
6296765|NCT02484547|10018130|FG004|Long-Term Extension Period|Disease Progression|2
6296766|NCT02484547|10018131|FG005|Long-Term Extension Period|Disease Progression|4
6296767|NCT02484547|10018132|FG006|Long-Term Extension Period|Disease Progression|0
6296768|NCT02484547|10018126|FG000|Long-Term Extension Period|Lost to Follow-up|0
6296769|NCT02484547|10018127|FG001|Long-Term Extension Period|Lost to Follow-up|0
6296770|NCT02484547|10018128|FG002|Long-Term Extension Period|Lost to Follow-up|0
6296771|NCT02484547|10018129|FG003|Long-Term Extension Period|Lost to Follow-up|1
6296772|NCT02484547|10018130|FG004|Long-Term Extension Period|Lost to Follow-up|1
6296773|NCT02484547|10018131|FG005|Long-Term Extension Period|Lost to Follow-up|2
6296774|NCT02484547|10018132|FG006|Long-Term Extension Period|Lost to Follow-up|0
6296775|NCT02484547|10018126|FG000|Long-Term Extension Period|Loss of Capacity|0
6296776|NCT02484547|10018127|FG001|Long-Term Extension Period|Loss of Capacity|0
6296777|NCT02484547|10018128|FG002|Long-Term Extension Period|Loss of Capacity|0
6296778|NCT02484547|10018129|FG003|Long-Term Extension Period|Loss of Capacity|0
6296779|NCT02484547|10018130|FG004|Long-Term Extension Period|Loss of Capacity|1
6296780|NCT02484547|10018131|FG005|Long-Term Extension Period|Loss of Capacity|0
6296781|NCT02484547|10018132|FG006|Long-Term Extension Period|Loss of Capacity|0
6296782|NCT02484547|10018126|FG000|Long-Term Extension Period|Change of Treatment|0
6296783|NCT02484547|10018127|FG001|Long-Term Extension Period|Change of Treatment|0
6296784|NCT02484547|10018128|FG002|Long-Term Extension Period|Change of Treatment|0
6296785|NCT02484547|10018129|FG003|Long-Term Extension Period|Change of Treatment|0
6296786|NCT02484547|10018130|FG004|Long-Term Extension Period|Change of Treatment|0
6296787|NCT02484547|10018131|FG005|Long-Term Extension Period|Change of Treatment|0
6296788|NCT02484547|10018132|FG006|Long-Term Extension Period|Change of Treatment|1
6296789|NCT02484547|10018126|FG000|Long-Term Extension Period|Consent Withdrawn|0
6296790|NCT02484547|10018127|FG001|Long-Term Extension Period|Consent Withdrawn|0
6296791|NCT02484547|10018128|FG002|Long-Term Extension Period|Consent Withdrawn|0
6296792|NCT02484547|10018129|FG003|Long-Term Extension Period|Consent Withdrawn|6
6296793|NCT02484547|10018130|FG004|Long-Term Extension Period|Consent Withdrawn|7
6296794|NCT02484547|10018131|FG005|Long-Term Extension Period|Consent Withdrawn|13
6296795|NCT02484547|10018132|FG006|Long-Term Extension Period|Consent Withdrawn|17
6296796|NCT02484547|10018126|FG000|Long-Term Extension Period|Investigator Decision|0
6296797|NCT02484547|10018127|FG001|Long-Term Extension Period|Investigator Decision|0
6296798|NCT02484547|10018128|FG002|Long-Term Extension Period|Investigator Decision|0
6296799|NCT02484547|10018129|FG003|Long-Term Extension Period|Investigator Decision|2
6296800|NCT02484547|10018130|FG004|Long-Term Extension Period|Investigator Decision|1
6296801|NCT02484547|10018131|FG005|Long-Term Extension Period|Investigator Decision|0
6296802|NCT02484547|10018132|FG006|Long-Term Extension Period|Investigator Decision|1
6296803|NCT02484547|10018126|FG000|Long-Term Extension Period|Relocation|0
6296804|NCT02484547|10018127|FG001|Long-Term Extension Period|Relocation|0
6296805|NCT02484547|10018128|FG002|Long-Term Extension Period|Relocation|0
6296806|NCT02484547|10018129|FG003|Long-Term Extension Period|Relocation|1
6296807|NCT02484547|10018130|FG004|Long-Term Extension Period|Relocation|1
6296808|NCT02484547|10018131|FG005|Long-Term Extension Period|Relocation|0
6296809|NCT02484547|10018132|FG006|Long-Term Extension Period|Relocation|0
6296810|NCT02484547|10018126|FG000|Long-Term Extension Period|Study Visit Burden|0
6296811|NCT02484547|10018127|FG001|Long-Term Extension Period|Study Visit Burden|0
6296812|NCT02484547|10018128|FG002|Long-Term Extension Period|Study Visit Burden|0
6296813|NCT02484547|10018129|FG003|Long-Term Extension Period|Study Visit Burden|2
6296814|NCT02484547|10018130|FG004|Long-Term Extension Period|Study Visit Burden|0
6296815|NCT02484547|10018131|FG005|Long-Term Extension Period|Study Visit Burden|0
6296816|NCT02484547|10018132|FG006|Long-Term Extension Period|Study Visit Burden|3
6296817|NCT02484547|10018126|FG000|Long-Term Extension Period|Withdrawal by Parent/Guardian|0
6296818|NCT02484547|10018127|FG001|Long-Term Extension Period|Withdrawal by Parent/Guardian|0
6296819|NCT02484547|10018128|FG002|Long-Term Extension Period|Withdrawal by Parent/Guardian|0
6296820|NCT02484547|10018129|FG003|Long-Term Extension Period|Withdrawal by Parent/Guardian|0
6296821|NCT02484547|10018130|FG004|Long-Term Extension Period|Withdrawal by Parent/Guardian|1
6296822|NCT02484547|10018131|FG005|Long-Term Extension Period|Withdrawal by Parent/Guardian|3
6296823|NCT02484547|10018132|FG006|Long-Term Extension Period|Withdrawal by Parent/Guardian|2
6296824|NCT02484547|10018126|FG000|Long-Term Extension Period|Reason not Specified|0
6296825|NCT02484547|10018127|FG001|Long-Term Extension Period|Reason not Specified|0
6296826|NCT02484547|10018128|FG002|Long-Term Extension Period|Reason not Specified|0
6296827|NCT02484547|10018129|FG003|Long-Term Extension Period|Reason not Specified|119
6296828|NCT02484547|10018130|FG004|Long-Term Extension Period|Reason not Specified|117
6296829|NCT02484547|10018131|FG005|Long-Term Extension Period|Reason not Specified|223
6296830|NCT02484547|10018132|FG006|Long-Term Extension Period|Reason not Specified|231
6296831|NCT02484651|10018146|FG000|Overall Study|Patients' data files were corrupted.|1
6296832|NCT02484651|10018147|FG001|Overall Study|Patients' data files were corrupted.|1
6296833|NCT02484651|10018146|FG000|Overall Study|BIS monitoring failed.|1
6296834|NCT02484651|10018147|FG001|Overall Study|BIS monitoring failed.|1
6296835|NCT02484651|10018146|FG000|Overall Study|Time of the procedure less than 90 min.|1
6296836|NCT02484651|10018147|FG001|Overall Study|Time of the procedure less than 90 min.|2
6296837|NCT02484690|10018159|FG000|Overall Study|Adverse Event|1
6296838|NCT02484690|10018160|FG001|Overall Study|Adverse Event|3
6296839|NCT02484690|10018161|FG002|Overall Study|Adverse Event|0
6296840|NCT02484690|10018162|FG003|Overall Study|Adverse Event|0
6296841|NCT02484690|10018163|FG004|Overall Study|Adverse Event|5
6296842|NCT02484690|10018159|FG000|Overall Study|Death|0
6296843|NCT02484690|10018160|FG001|Overall Study|Death|0
6296844|NCT02484690|10018161|FG002|Overall Study|Death|0
6296845|NCT02484690|10018162|FG003|Overall Study|Death|0
6296846|NCT02484690|10018163|FG004|Overall Study|Death|1
6296847|NCT02484690|10018159|FG000|Overall Study|Withdrawal by Subject|1
6296848|NCT02484690|10018160|FG001|Overall Study|Withdrawal by Subject|3
6296849|NCT02484690|10018161|FG002|Overall Study|Withdrawal by Subject|1
6296850|NCT02484690|10018162|FG003|Overall Study|Withdrawal by Subject|2
6296851|NCT02484690|10018163|FG004|Overall Study|Withdrawal by Subject|0
6296852|NCT02484690|10018159|FG000|Overall Study|Physician Decision|2
6296853|NCT02484690|10018160|FG001|Overall Study|Physician Decision|0
6296854|NCT02484690|10018161|FG002|Overall Study|Physician Decision|1
6296855|NCT02484690|10018162|FG003|Overall Study|Physician Decision|0
6296856|NCT02484690|10018163|FG004|Overall Study|Physician Decision|0
6296857|NCT02484690|10018159|FG000|Overall Study|Lost to Follow-up|0
6296858|NCT02484690|10018160|FG001|Overall Study|Lost to Follow-up|0
6296859|NCT02484690|10018161|FG002|Overall Study|Lost to Follow-up|1
6296860|NCT02484690|10018162|FG003|Overall Study|Lost to Follow-up|0
6296861|NCT02484690|10018163|FG004|Overall Study|Lost to Follow-up|0
6296862|NCT02484729|10018186|FG000|Overall Study|Failure of IntelliCap Error|0
6296863|NCT02484729|10018187|FG001|Overall Study|Failure of IntelliCap Error|0
6296864|NCT02484729|10018188|FG002|Overall Study|Failure of IntelliCap Error|0
6296865|NCT02484729|10018189|FG003|Overall Study|Failure of IntelliCap Error|0
6296866|NCT02484729|10018190|FG004|Overall Study|Failure of IntelliCap Error|0
5981690|NCT00897949|9570485|FG000|Overall Study|Protocol Violation|6
5981691|NCT00897949|9570486|FG001|Overall Study|Protocol Violation|3
5981692|NCT00897949|9570487|FG002|Overall Study|Protocol Violation|1
5981693|NCT00897949|9570485|FG000|Overall Study|Withdrawal by Subject|1
5981694|NCT00897949|9570486|FG001|Overall Study|Withdrawal by Subject|2
5981695|NCT00897949|9570487|FG002|Overall Study|Withdrawal by Subject|0
5981696|NCT00897949|9570485|FG000|Overall Study|Patient Uncoorperative|0
5981697|NCT00897949|9570486|FG001|Overall Study|Patient Uncoorperative|2
5981698|NCT00897949|9570487|FG002|Overall Study|Patient Uncoorperative|1
5981699|NCT00897949|9570485|FG000|Overall Study|Lost to Follow-up|30
5981700|NCT00897949|9570486|FG001|Overall Study|Lost to Follow-up|23
5981701|NCT00897949|9570487|FG002|Overall Study|Lost to Follow-up|17
5981702|NCT00897949|9570485|FG000|Overall Study|Withdrawal by Subject|24
5981703|NCT00897949|9570486|FG001|Overall Study|Withdrawal by Subject|31
5981704|NCT00897949|9570487|FG002|Overall Study|Withdrawal by Subject|17
5981705|NCT00897949|9570485|FG000|Overall Study|Abnormal Prestudy Labs|2
5981706|NCT00897949|9570486|FG001|Overall Study|Abnormal Prestudy Labs|3
5981707|NCT00897949|9570487|FG002|Overall Study|Abnormal Prestudy Labs|4
5981708|NCT00897949|9570485|FG000|Overall Study|Abnormal Baseline ECG|2
5981709|NCT00897949|9570486|FG001|Overall Study|Abnormal Baseline ECG|2
5981710|NCT00897949|9570487|FG002|Overall Study|Abnormal Baseline ECG|4
5981711|NCT00897949|9570485|FG000|Overall Study|Need for Concom. Med.|0
5981712|NCT00897949|9570486|FG001|Overall Study|Need for Concom. Med.|1
5981713|NCT00897949|9570487|FG002|Overall Study|Need for Concom. Med.|1
5981714|NCT00897949|9570485|FG000|Overall Study|Lack of Migraine Attack|29
5981715|NCT00897949|9570486|FG001|Overall Study|Lack of Migraine Attack|30
5981716|NCT00897949|9570487|FG002|Overall Study|Lack of Migraine Attack|19
5981717|NCT00897949|9570485|FG000|Overall Study|Did not take study drug|9
5981718|NCT00897949|9570486|FG001|Overall Study|Did not take study drug|3
5981719|NCT00897949|9570487|FG002|Overall Study|Did not take study drug|4
5981720|NCT00897104|9570504|FG000|Overall Study|Lost to Follow-up|12
5981721|NCT00897104|9570505|FG001|Overall Study|Lost to Follow-up|17
5981722|NCT00897104|9570506|FG002|Overall Study|Lost to Follow-up|2
5981723|NCT00897104|9570504|FG000|Overall Study|Pregnancy|0
5981724|NCT00897104|9570505|FG001|Overall Study|Pregnancy|1
5981725|NCT00897104|9570506|FG002|Overall Study|Pregnancy|0
5981726|NCT00897104|9570504|FG000|Overall Study|Protocol Violation|0
5981727|NCT00897104|9570505|FG001|Overall Study|Protocol Violation|1
5981728|NCT00897104|9570506|FG002|Overall Study|Protocol Violation|0
5981729|NCT00897104|9570504|FG000|Overall Study|Withdrawal by Subject|23
5981730|NCT00897104|9570505|FG001|Overall Study|Withdrawal by Subject|27
5981731|NCT00897104|9570506|FG002|Overall Study|Withdrawal by Subject|3
5981732|NCT00897104|9570504|FG000|Overall Study|Abnormal Prestudy Labs|2
5981733|NCT00897104|9570505|FG001|Overall Study|Abnormal Prestudy Labs|0
5981734|NCT00897104|9570506|FG002|Overall Study|Abnormal Prestudy Labs|0
5981735|NCT00897104|9570504|FG000|Overall Study|Abnormal Baseline ECG|2
5981736|NCT00897104|9570505|FG001|Overall Study|Abnormal Baseline ECG|2
5981737|NCT00897104|9570506|FG002|Overall Study|Abnormal Baseline ECG|0
5981738|NCT00897104|9570504|FG000|Overall Study|Need for Concom. Med.|0
5981739|NCT00897104|9570505|FG001|Overall Study|Need for Concom. Med.|1
5981740|NCT00897104|9570506|FG002|Overall Study|Need for Concom. Med.|1
5981741|NCT00897104|9570504|FG000|Overall Study|Lack of Migraine Attack|20
5981742|NCT00897104|9570505|FG001|Overall Study|Lack of Migraine Attack|22
6296867|NCT02484729|10018191|FG005|Overall Study|Failure of IntelliCap Error|0
6296868|NCT02484729|10018192|FG006|Overall Study|Failure of IntelliCap Error|0
6296869|NCT02484729|10018193|FG007|Overall Study|Failure of IntelliCap Error|0
6296870|NCT02484729|10018194|FG008|Overall Study|Failure of IntelliCap Error|0
6296871|NCT02484729|10018195|FG009|Overall Study|Failure of IntelliCap Error|1
6296872|NCT02484911|10018272|FG000|Overall Study|Withdrawal by Subject|2
6296873|NCT02484911|10018273|FG001|Overall Study|Withdrawal by Subject|1
6296874|NCT02484911|10018272|FG000|Overall Study|Protocol Violation|2
6296875|NCT02484911|10018273|FG001|Overall Study|Protocol Violation|1
6296876|NCT02485158|10018280|FG000|Overall Study|Withdrawal by Subject|3
6296877|NCT02485158|10018280|FG000|Overall Study|expected drug side effect|1
6296878|NCT02485301|10018291|FG000|Overall Study|Serious Adverse Events|2
6296879|NCT02485301|10018292|FG001|Overall Study|Serious Adverse Events|1
6296880|NCT02485301|10018291|FG000|Overall Study|Protocol Violation|0
6296881|NCT02485301|10018292|FG001|Overall Study|Protocol Violation|1
6296882|NCT02485301|10018291|FG000|Overall Study|Withdrawal by Subject|6
6296883|NCT02485301|10018292|FG001|Overall Study|Withdrawal by Subject|7
6296884|NCT02485301|10018291|FG000|Overall Study|Migrated/moved from study area|10
6296885|NCT02485301|10018292|FG001|Overall Study|Migrated/moved from study area|19
6296886|NCT02485301|10018291|FG000|Overall Study|Lost to Follow-up|17
6296887|NCT02485301|10018292|FG001|Overall Study|Lost to Follow-up|17
6296888|NCT02485301|10018291|FG000|Overall Study|Other|3
6296889|NCT02485301|10018292|FG001|Overall Study|Other|4
6296890|NCT02485353|10018298|FG000|Overall Study|Death|1
6296891|NCT02485353|10018298|FG000|Overall Study|Disease Progression|1
6296892|NCT02485483|10018304|FG000|Overall Study|Depression at baseline|15
6296893|NCT02485483|10018305|FG001|Overall Study|Depression at baseline|0
6296894|NCT02485483|10018304|FG000|Overall Study|Discontinued after baseline|39
6296895|NCT02485483|10018305|FG001|Overall Study|Discontinued after baseline|0
6296896|NCT02485704|10018326|FG000|Overall Study|Lost to Follow-up|4
6296897|NCT02485704|10018327|FG001|Overall Study|Lost to Follow-up|5
6296898|NCT02485704|10018326|FG000|Overall Study|Withdrawal by Subject|0
6296899|NCT02485704|10018327|FG001|Overall Study|Withdrawal by Subject|3
6296900|NCT02485704|10018326|FG000|Overall Study|Did Not Meet Inclusion Criteria #2|1
6296901|NCT02485704|10018327|FG001|Overall Study|Did Not Meet Inclusion Criteria #2|0
6296902|NCT02485717|10018336|FG000|Overall Study|Lost to Follow-up|6
6296903|NCT02485717|10018337|FG001|Overall Study|Lost to Follow-up|0
6296904|NCT02485717|10018338|FG002|Overall Study|Lost to Follow-up|0
6296905|NCT02485717|10018336|FG000|Overall Study|Withdrawal by Subject|0
6296906|NCT02485717|10018337|FG001|Overall Study|Withdrawal by Subject|0
6296907|NCT02485717|10018338|FG002|Overall Study|Withdrawal by Subject|1
6296908|NCT02485717|10018336|FG000|Overall Study|Did Not Meet Exclusion Criteria #2|0
6296909|NCT02485717|10018337|FG001|Overall Study|Did Not Meet Exclusion Criteria #2|1
6296910|NCT02485717|10018338|FG002|Overall Study|Did Not Meet Exclusion Criteria #2|0
6296911|NCT02485717|10018336|FG000|Overall Study|Did Not Meet Exclusion Criteria #12|0
6296912|NCT02485717|10018337|FG001|Overall Study|Did Not Meet Exclusion Criteria #12|1
6296913|NCT02485717|10018338|FG002|Overall Study|Did Not Meet Exclusion Criteria #12|0
6296914|NCT02485925|10018361|FG000|Overall Study|Withdrawal by Subject|3
6296915|NCT02485925|10018361|FG000|Overall Study|Death|1
6296916|NCT02485925|10018361|FG000|Overall Study|Lost to Follow-up|11
6296917|NCT02486302|10018398|FG000|Overall Study|Discontinued prematurely|410
6296918|NCT02486302|10018398|FG000|Overall Study|Documentation not completed|255
6296919|NCT02486302|10018398|FG000|Overall Study|Excluded due to legal reasons|8
6296920|NCT02486302|10018398|FG000|Overall Study|Not treated|3
6296921|NCT02486406|10018424|FG000|Overall Study|Withdrew consent|1
6296922|NCT02486406|10018425|FG001|Overall Study|Withdrew consent|0
6296923|NCT02486406|10018426|FG002|Overall Study|Withdrew consent|0
6296924|NCT02486406|10018427|FG003|Overall Study|Withdrew consent|1
6296925|NCT02486406|10018424|FG000|Overall Study|Lost to Follow-up|1
6296926|NCT02486406|10018425|FG001|Overall Study|Lost to Follow-up|3
6296927|NCT02486406|10018426|FG002|Overall Study|Lost to Follow-up|1
6296928|NCT02486406|10018427|FG003|Overall Study|Lost to Follow-up|3
6296929|NCT02486406|10018424|FG000|Overall Study|Other, not specified|0
6296930|NCT02486406|10018425|FG001|Overall Study|Other, not specified|0
6296931|NCT02486406|10018426|FG002|Overall Study|Other, not specified|1
6296932|NCT02486406|10018427|FG003|Overall Study|Other, not specified|0
6296933|NCT02486588|10018465|FG000|Overall Study|Randomized in error- ineligible|738
6296934|NCT02486588|10018466|FG001|Overall Study|Randomized in error- ineligible|750
6296935|NCT02486588|10018467|FG002|Overall Study|Randomized in error- ineligible|755
6296936|NCT02486588|10018468|FG003|Overall Study|Randomized in error- ineligible|738
6296937|NCT02486588|10018469|FG004|Overall Study|Randomized in error- ineligible|746
6296938|NCT02486588|10018470|FG005|Overall Study|Randomized in error- ineligible|746
6296939|NCT02486627|10018491|FG000|Overall Study|Death|1
6296940|NCT02486627|10018492|FG001|Overall Study|Death|0
6296941|NCT02486627|10018491|FG000|Overall Study|Other Unspecified|0
6296942|NCT02486627|10018492|FG001|Overall Study|Other Unspecified|2
6296943|NCT02486627|10018491|FG000|Overall Study|Consent Withdrawn by Participant|4
6296944|NCT02486627|10018492|FG001|Overall Study|Consent Withdrawn by Participant|3
6296945|NCT02486627|10018491|FG000|Overall Study|Significant Participant Noncompliance|1
6296946|NCT02486627|10018492|FG001|Overall Study|Significant Participant Noncompliance|1
6296947|NCT02486627|10018491|FG000|Overall Study|Lost to Follow-up|1
6296948|NCT02486627|10018492|FG001|Overall Study|Lost to Follow-up|3
6296949|NCT02486653|10018500|FG000|Overall Study|Withdrawal by Subject|1
6296950|NCT02486653|10018501|FG001|Overall Study|Withdrawal by Subject|3
6296951|NCT02486653|10018500|FG000|Overall Study|Protocol Violation|1
6296952|NCT02486653|10018501|FG001|Overall Study|Protocol Violation|0
6296953|NCT02486653|10018500|FG000|Overall Study|surgery cancelled|4
6296954|NCT02486653|10018501|FG001|Overall Study|surgery cancelled|1
6296955|NCT02486692|10018509|FG000|Overall Study|did not login for randomization|4
6296956|NCT02486692|10018510|FG001|Overall Study|did not login for randomization|7
6296957|NCT02486757|10018516|FG000|Overall Study|Lost to Follow-up|1
6296958|NCT02486796|10018522|FG000|Overall Study|Withdrawal by Subject|1
6296959|NCT02486796|10018523|FG001|Overall Study|Withdrawal by Subject|1
6296960|NCT02486796|10018522|FG000|Overall Study|Physician Decision|1
6296961|NCT02486796|10018523|FG001|Overall Study|Physician Decision|0
6296962|NCT02486952|10018538|FG000|Overall Study|Not Started Induction Therapy|3
6296963|NCT02486952|10018538|FG000|Overall Study|Adverse Event|1
6296964|NCT02486952|10018538|FG000|Overall Study|Death|15
6296965|NCT02486952|10018538|FG000|Overall Study|Lack of Efficacy|3
6296966|NCT02486952|10018538|FG000|Overall Study|Lost to Follow-up|26
6296967|NCT02486952|10018538|FG000|Overall Study|Other|2
6296968|NCT02487030|10018549|FG000|Overall Study|Lack of Efficacy|2
6296969|NCT02487030|10018550|FG001|Overall Study|Lack of Efficacy|4
6296970|NCT02487030|10018551|FG002|Overall Study|Lack of Efficacy|1
6296971|NCT02487030|10018552|FG003|Overall Study|Lack of Efficacy|0
6296972|NCT02487030|10018553|FG004|Overall Study|Lack of Efficacy|1
6296973|NCT02487030|10018554|FG005|Overall Study|Lack of Efficacy|0
6296974|NCT02487030|10018555|FG006|Overall Study|Lack of Efficacy|0
6296975|NCT02487030|10018549|FG000|Overall Study|Lost to Follow-up|0
6296976|NCT02487030|10018550|FG001|Overall Study|Lost to Follow-up|0
6296977|NCT02487030|10018551|FG002|Overall Study|Lost to Follow-up|1
6296978|NCT02487030|10018552|FG003|Overall Study|Lost to Follow-up|1
6296979|NCT02487030|10018553|FG004|Overall Study|Lost to Follow-up|0
6296980|NCT02487030|10018554|FG005|Overall Study|Lost to Follow-up|1
6296981|NCT02487030|10018555|FG006|Overall Study|Lost to Follow-up|0
6296982|NCT02487030|10018549|FG000|Overall Study|Adverse Event|0
6296983|NCT02487030|10018550|FG001|Overall Study|Adverse Event|0
6296984|NCT02487030|10018551|FG002|Overall Study|Adverse Event|0
6296985|NCT02487030|10018552|FG003|Overall Study|Adverse Event|1
6296986|NCT02487030|10018553|FG004|Overall Study|Adverse Event|0
6296987|NCT02487030|10018554|FG005|Overall Study|Adverse Event|0
6296988|NCT02487030|10018555|FG006|Overall Study|Adverse Event|0
6296989|NCT02487030|10018549|FG000|Overall Study|Death|0
6296990|NCT02487030|10018550|FG001|Overall Study|Death|0
6296991|NCT02487030|10018551|FG002|Overall Study|Death|0
6296992|NCT02487030|10018552|FG003|Overall Study|Death|0
6296993|NCT02487030|10018553|FG004|Overall Study|Death|1
6296994|NCT02487030|10018554|FG005|Overall Study|Death|0
6296995|NCT02487030|10018555|FG006|Overall Study|Death|0
6296996|NCT02487199|10018579|FG000|Overall Study|Withdrew Consent|0
6296997|NCT02487199|10018580|FG001|Overall Study|Withdrew Consent|1
6296998|NCT02487446|10018611|FG000|Period 1|Physician Decision|0
6296999|NCT02487446|10018612|FG001|Period 1|Physician Decision|1
6297000|NCT02487446|10018611|FG000|Period 1|Lack of Efficacy|1
6297001|NCT02487446|10018612|FG001|Period 1|Lack of Efficacy|0
6297002|NCT02487446|10018611|FG000|Period 1|Protocol deviation|3
6297003|NCT02487446|10018612|FG001|Period 1|Protocol deviation|2
6297004|NCT02487446|10018611|FG000|Period 1|Lost to Follow-up|2
6297005|NCT02487446|10018612|FG001|Period 1|Lost to Follow-up|0
6297006|NCT02487446|10018611|FG000|Period 1|Withdrawal by Subject|2
6297007|NCT02487446|10018612|FG001|Period 1|Withdrawal by Subject|0
6297008|NCT02487446|10018611|FG000|Period 1|Adverse Event|5
6297009|NCT02487446|10018612|FG001|Period 1|Adverse Event|5
6297010|NCT02487446|10018611|FG000|Washout|Lost to Follow-up|0
6297011|NCT02487446|10018612|FG001|Washout|Lost to Follow-up|2
6297012|NCT02487446|10018611|FG000|Washout|Withdrawal by Subject|1
6297013|NCT02487446|10018612|FG001|Washout|Withdrawal by Subject|4
6297014|NCT02487446|10018611|FG000|Washout|Adverse Event|2
6297015|NCT02487446|10018612|FG001|Washout|Adverse Event|2
6297016|NCT02487446|10018611|FG000|Period 2|Protocol deviation|0
6297017|NCT02487446|10018612|FG001|Period 2|Protocol deviation|1
6297018|NCT02487446|10018611|FG000|Period 2|Lost to Follow-up|1
6297019|NCT02487446|10018612|FG001|Period 2|Lost to Follow-up|1
6297020|NCT02487446|10018611|FG000|Period 2|Withdrawal by Subject|1
6297021|NCT02487446|10018612|FG001|Period 2|Withdrawal by Subject|1
6297022|NCT02487446|10018611|FG000|Period 2|Adverse Event|6
6297023|NCT02487446|10018612|FG001|Period 2|Adverse Event|2
6297024|NCT02487472|10018619|FG000|Overall Study|Did not complete telephonic interviews|9
6297025|NCT02487472|10018619|FG000|Overall Study|Other|2
6297026|NCT02487498|10018634|FG000|Period: Period 1|Adverse Event|2
6297027|NCT02487498|10018635|FG001|Period: Period 1|Adverse Event|4
6297028|NCT02487498|10018634|FG000|Period: Period 1|Subject/guardian decision|2
6297029|NCT02487498|10018635|FG001|Period: Period 1|Subject/guardian decision|4
6297030|NCT02487498|10018634|FG000|Period: Period 1|Lost to Follow-up|0
6297031|NCT02487498|10018635|FG001|Period: Period 1|Lost to Follow-up|2
6297032|NCT02487498|10018634|FG000|Period: Period 1|Lack of Efficacy|1
6297033|NCT02487498|10018635|FG001|Period: Period 1|Lack of Efficacy|0
6297034|NCT02487498|10018634|FG000|Period: Period 1|Physician Decision|0
6297035|NCT02487498|10018635|FG001|Period: Period 1|Physician Decision|1
6297036|NCT02487498|10018634|FG000|Period: Period 1|Protocol deviation|1
6297037|NCT02487498|10018635|FG001|Period: Period 1|Protocol deviation|0
6297038|NCT02487498|10018634|FG000|Period: Washout|Subject/guardian decision|0
6297039|NCT02487498|10018635|FG001|Period: Washout|Subject/guardian decision|5
6297040|NCT02487498|10018634|FG000|Period: Washout|Lack of Efficacy|1
6297041|NCT02487498|10018635|FG001|Period: Washout|Lack of Efficacy|1
6297042|NCT02487498|10018634|FG000|Period: Washout|Physician Decision|1
6297043|NCT02487498|10018635|FG001|Period: Washout|Physician Decision|0
6297044|NCT02487498|10018634|FG000|Period: Washout|Non-compliance with study treatment|0
6297045|NCT02487498|10018635|FG001|Period: Washout|Non-compliance with study treatment|1
6297046|NCT02487498|10018634|FG000|Period: Period 2|Adverse Event|2
6297047|NCT02487498|10018635|FG001|Period: Period 2|Adverse Event|2
6297048|NCT02487498|10018634|FG000|Period: Period 2|Subject/guardian decision|2
6297049|NCT02487498|10018635|FG001|Period: Period 2|Subject/guardian decision|1
6297050|NCT02487498|10018634|FG000|Period: Period 2|Lost to Follow-up|1
6297051|NCT02487498|10018635|FG001|Period: Period 2|Lost to Follow-up|1
6297052|NCT02487498|10018634|FG000|Period: Period 2|Death|0
6297053|NCT02487498|10018635|FG001|Period: Period 2|Death|1
6297054|NCT02487498|10018634|FG000|Period: Period 2|Physician Decision|1
6297055|NCT02487498|10018635|FG001|Period: Period 2|Physician Decision|0
6297056|NCT02487771|10018660|FG000|Overall Study|Lost to Follow-up|2
6297057|NCT02487771|10018661|FG001|Overall Study|Lost to Follow-up|3
6297058|NCT02487771|10018660|FG000|Overall Study|Moved out of area|5
6297059|NCT02487771|10018661|FG001|Overall Study|Moved out of area|6
6297060|NCT02487771|10018660|FG000|Overall Study|Withdrawal by Subject|3
6297061|NCT02487771|10018661|FG001|Overall Study|Withdrawal by Subject|5
6297062|NCT02487810|10018669|FG000|Overall Study|Withdrawal by Subject|1
6297063|NCT02487810|10018670|FG001|Overall Study|Withdrawal by Subject|0
6297064|NCT02488005|10018693|FG000|Overall Study|Lost to Follow-up|2
6297065|NCT02488109|10018708|FG000|Treatment in Hospital|Withdrawal by Subject|0
6297066|NCT02488109|10018709|FG001|Treatment in Hospital|Withdrawal by Subject|5
6297067|NCT02488109|10018708|FG000|12-month Follow-Up|Lost to Follow-up|4
6297068|NCT02488109|10018709|FG001|12-month Follow-Up|Lost to Follow-up|7
6297069|NCT02488239|10018717|FG000|Overall Study|Death|3
6297070|NCT02488239|10018717|FG000|Overall Study|Withdrawal by Subject|3
6297071|NCT02488239|10018717|FG000|Overall Study|Physician Decision|2
6297072|NCT02488239|10018717|FG000|Overall Study|Consent ineligible|1
6297073|NCT02488239|10018717|FG000|Overall Study|Did not undergo implant procedure|1
6297074|NCT02488330|10018735|FG000|Overall Study|Adverse Event|1
6297075|NCT02488330|10018735|FG000|Overall Study|Physician Decision|2
6297076|NCT02488330|10018735|FG000|Overall Study|Death|2
6297077|NCT02488330|10018735|FG000|Overall Study|Disease Progression|3
6297078|NCT02488330|10018735|FG000|Overall Study|Study Termination by Sponsor|4
6297079|NCT02488681|10018739|FG000|Overall Study|Implant unsuccessful|7
6297080|NCT02488824|10018745|FG000|Overall Study|Adverse Event|1
6297081|NCT02488824|10018746|FG001|Overall Study|Adverse Event|1
6297082|NCT02488915|10018752|FG000|Overall Study|Death|21
6297083|NCT02488915|10018752|FG000|Overall Study|Lost to Follow-up|4
6297084|NCT02488915|10018752|FG000|Overall Study|Withdrawal by Subject|1
6297085|NCT02488980|10018759|FG000|Overall Study|Protocol Violation|2
6297086|NCT02488980|10018760|FG001|Overall Study|Protocol Violation|2
6297087|NCT02488980|10018761|FG002|Overall Study|Protocol Violation|2
6297088|NCT02489045|10018769|FG000|Overall Study|unable to collect usable data|53
6297089|NCT02489045|10018769|FG000|Follow-up|Lost to Follow-up|10
6297090|NCT02489279|10018803|FG000|Overall Study|Lost to Follow-up|12
6297091|NCT02489279|10018804|FG001|Overall Study|Lost to Follow-up|10
6297092|NCT02489344|10018810|FG000|ACT13739 (Initial Study): 26 Weeks|Adverse Event|1
6297093|NCT02489344|10018810|FG000|ACT13739 (Initial Study): 26 Weeks|Lost to Follow-up|1
6297094|NCT02489344|10018810|FG000|LTS14116 (Extension Study): 31 Months|Adverse Event|1
6297095|NCT02489344|10018810|FG000|LTS14116 (Extension Study): 31 Months|Treatment completed/Study not completed|2
6297096|NCT02489500|10018820|FG000|Overall Study|Death|1
6297097|NCT02489500|10018821|FG001|Overall Study|Death|1
6297098|NCT02489630|10018829|FG000|Overall Study|Oversedation|1
6297099|NCT02489630|10018830|FG001|Overall Study|Oversedation|1
6297100|NCT02489630|10018829|FG000|Overall Study|Time to med. admin. > protocol limit|1
6297101|NCT02489630|10018830|FG001|Overall Study|Time to med. admin. > protocol limit|1
6297102|NCT02489773|10018847|FG000|Overall Study|Lost to Follow-up|4
6297103|NCT02489773|10018848|FG001|Overall Study|Lost to Follow-up|1
6297104|NCT02489773|10018847|FG000|Overall Study|Physician Decision|1
6297105|NCT02489773|10018848|FG001|Overall Study|Physician Decision|0
6297106|NCT02489773|10018847|FG000|Overall Study|Withdrawal by Subject|1
6297107|NCT02489773|10018848|FG001|Overall Study|Withdrawal by Subject|0
6297108|NCT02489773|10018847|FG000|Overall Study|Leave the country or the state|1
6297109|NCT02489773|10018848|FG001|Overall Study|Leave the country or the state|1
6297110|NCT02489799|10018856|FG000|Overall Study|Lost to Follow-up|4
6297111|NCT02489799|10018857|FG001|Overall Study|Lost to Follow-up|1
6297112|NCT02489799|10018856|FG000|Overall Study|Failure to Maintain Eligibility|4
6297113|NCT02489799|10018857|FG001|Overall Study|Failure to Maintain Eligibility|6
6297114|NCT02489799|10018856|FG000|Overall Study|Withdrawal by Subject|1
6297115|NCT02489799|10018857|FG001|Overall Study|Withdrawal by Subject|1
6297116|NCT02489799|10018856|FG000|Overall Study|Death|0
6297117|NCT02489799|10018857|FG001|Overall Study|Death|1
6297118|NCT02489968|10018865|FG000|Open-label Treatment Period|Adverse Event|14
6297119|NCT02489968|10018866|FG001|Open-label Treatment Period|Adverse Event|7
6297120|NCT02489968|10018867|FG002|Open-label Treatment Period|Adverse Event|0
6297121|NCT02489968|10018868|FG003|Open-label Treatment Period|Adverse Event|0
6297122|NCT02489968|10018869|FG004|Open-label Treatment Period|Adverse Event|0
6297123|NCT02489968|10018870|FG005|Open-label Treatment Period|Adverse Event|0
6297124|NCT02489968|10018865|FG000|Open-label Treatment Period|Protocol Violation|2
6297125|NCT02489968|10018866|FG001|Open-label Treatment Period|Protocol Violation|2
6297126|NCT02489968|10018867|FG002|Open-label Treatment Period|Protocol Violation|0
6297127|NCT02489968|10018868|FG003|Open-label Treatment Period|Protocol Violation|0
6297128|NCT02489968|10018869|FG004|Open-label Treatment Period|Protocol Violation|0
6297129|NCT02489968|10018870|FG005|Open-label Treatment Period|Protocol Violation|0
6297130|NCT02489968|10018865|FG000|Open-label Treatment Period|Lost to Follow-up|0
6297131|NCT02489968|10018866|FG001|Open-label Treatment Period|Lost to Follow-up|3
6297132|NCT02489968|10018867|FG002|Open-label Treatment Period|Lost to Follow-up|0
6297133|NCT02489968|10018868|FG003|Open-label Treatment Period|Lost to Follow-up|0
6297134|NCT02489968|10018869|FG004|Open-label Treatment Period|Lost to Follow-up|0
6297135|NCT02489968|10018870|FG005|Open-label Treatment Period|Lost to Follow-up|0
6297136|NCT02489968|10018865|FG000|Open-label Treatment Period|Withdrawal by Subject|4
6297137|NCT02489968|10018866|FG001|Open-label Treatment Period|Withdrawal by Subject|7
6297138|NCT02489968|10018867|FG002|Open-label Treatment Period|Withdrawal by Subject|0
6297139|NCT02489968|10018868|FG003|Open-label Treatment Period|Withdrawal by Subject|0
6297140|NCT02489968|10018869|FG004|Open-label Treatment Period|Withdrawal by Subject|0
6297141|NCT02489968|10018870|FG005|Open-label Treatment Period|Withdrawal by Subject|0
6297142|NCT02489968|10018865|FG000|Open-label Treatment Period|Other than specified above|204
6297143|NCT02489968|10018866|FG001|Open-label Treatment Period|Other than specified above|189
6297144|NCT02489968|10018867|FG002|Open-label Treatment Period|Other than specified above|0
6297145|NCT02489968|10018868|FG003|Open-label Treatment Period|Other than specified above|0
6297146|NCT02489968|10018869|FG004|Open-label Treatment Period|Other than specified above|0
6297147|NCT02489968|10018870|FG005|Open-label Treatment Period|Other than specified above|0
6297148|NCT02489968|10018865|FG000|Double-blind Treatment Period|Adverse Event|0
6297149|NCT02489968|10018866|FG001|Double-blind Treatment Period|Adverse Event|0
6297150|NCT02489968|10018867|FG002|Double-blind Treatment Period|Adverse Event|2
6297151|NCT02489968|10018868|FG003|Double-blind Treatment Period|Adverse Event|6
6297152|NCT02489968|10018869|FG004|Double-blind Treatment Period|Adverse Event|4
6297153|NCT02489968|10018870|FG005|Double-blind Treatment Period|Adverse Event|5
6297154|NCT02489968|10018865|FG000|Double-blind Treatment Period|Protocol Violation|0
6297155|NCT02489968|10018866|FG001|Double-blind Treatment Period|Protocol Violation|0
6297156|NCT02489968|10018867|FG002|Double-blind Treatment Period|Protocol Violation|0
6297157|NCT02489968|10018868|FG003|Double-blind Treatment Period|Protocol Violation|0
6297158|NCT02489968|10018869|FG004|Double-blind Treatment Period|Protocol Violation|1
6297159|NCT02489968|10018870|FG005|Double-blind Treatment Period|Protocol Violation|1
6297160|NCT02489968|10018865|FG000|Double-blind Treatment Period|Withdrawal by Subject|0
6297161|NCT02489968|10018866|FG001|Double-blind Treatment Period|Withdrawal by Subject|0
6297162|NCT02489968|10018867|FG002|Double-blind Treatment Period|Withdrawal by Subject|0
6297163|NCT02489968|10018868|FG003|Double-blind Treatment Period|Withdrawal by Subject|2
6297164|NCT02489968|10018869|FG004|Double-blind Treatment Period|Withdrawal by Subject|0
6297165|NCT02489968|10018870|FG005|Double-blind Treatment Period|Withdrawal by Subject|2
6297166|NCT02489968|10018865|FG000|Double-blind Treatment Period|Other than specified above|0
6297167|NCT02489968|10018866|FG001|Double-blind Treatment Period|Other than specified above|0
6297168|NCT02489968|10018867|FG002|Double-blind Treatment Period|Other than specified above|0
6297169|NCT02489968|10018868|FG003|Double-blind Treatment Period|Other than specified above|0
6297170|NCT02489968|10018869|FG004|Double-blind Treatment Period|Other than specified above|1
6297171|NCT02489968|10018870|FG005|Double-blind Treatment Period|Other than specified above|0
6297172|NCT02489981|10018882|FG000|Overall Study|Adverse Event|21
6297173|NCT02489981|10018882|FG000|Overall Study|Insufficient effectiveness|16
6297174|NCT02489981|10018882|FG000|Overall Study|Improved|31
6297175|NCT02489981|10018882|FG000|Overall Study|Lost to Follow-up|31
6297176|NCT02489981|10018882|FG000|Overall Study|Other than listed|28
6297177|NCT02490371|10018897|FG000|Overall Study|Lost to Follow-up|1
6297178|NCT02490371|10018898|FG001|Overall Study|Lost to Follow-up|1
6297179|NCT02490475|10018908|FG000|Period 1: First 6 Cycles|Adverse Event|2
6297180|NCT02490475|10018909|FG001|Period 1: First 6 Cycles|Adverse Event|1
6297181|NCT02490475|10018910|FG002|Period 1: First 6 Cycles|Adverse Event|0
6297182|NCT02490475|10018911|FG003|Period 1: First 6 Cycles|Adverse Event|1
6297183|NCT02490475|10018908|FG000|Period 1: First 6 Cycles|Insufficient Therapeutic Response|2
6297184|NCT02490475|10018909|FG001|Period 1: First 6 Cycles|Insufficient Therapeutic Response|0
6297185|NCT02490475|10018910|FG002|Period 1: First 6 Cycles|Insufficient Therapeutic Response|2
6297186|NCT02490475|10018911|FG003|Period 1: First 6 Cycles|Insufficient Therapeutic Response|2
6297187|NCT02490475|10018908|FG000|Period 1: First 6 Cycles|Refused Treatment|1
6297188|NCT02490475|10018909|FG001|Period 1: First 6 Cycles|Refused Treatment|0
6297189|NCT02490475|10018910|FG002|Period 1: First 6 Cycles|Refused Treatment|0
6297190|NCT02490475|10018911|FG003|Period 1: First 6 Cycles|Refused Treatment|0
6297191|NCT02490475|10018908|FG000|Period 1: First 6 Cycles|Completed 6 Cycles of Therapy|1
6297192|NCT02490475|10018909|FG001|Period 1: First 6 Cycles|Completed 6 Cycles of Therapy|1
6297193|NCT02490475|10018910|FG002|Period 1: First 6 Cycles|Completed 6 Cycles of Therapy|4
6297194|NCT02490475|10018911|FG003|Period 1: First 6 Cycles|Completed 6 Cycles of Therapy|2
6297195|NCT02490475|10018908|FG000|Period 2: Extension Phase|Insufficient Therapeutic Response|1
6297196|NCT02490475|10018909|FG001|Period 2: Extension Phase|Insufficient Therapeutic Response|0
6297197|NCT02490475|10018910|FG002|Period 2: Extension Phase|Insufficient Therapeutic Response|2
6297198|NCT02490475|10018911|FG003|Period 2: Extension Phase|Insufficient Therapeutic Response|0
6297199|NCT02490475|10018908|FG000|Period 2: Extension Phase|Refused Treatment|0
6297200|NCT02490475|10018909|FG001|Period 2: Extension Phase|Refused Treatment|0
6297201|NCT02490475|10018910|FG002|Period 2: Extension Phase|Refused Treatment|0
6297202|NCT02490475|10018911|FG003|Period 2: Extension Phase|Refused Treatment|1
6297203|NCT02490475|10018908|FG000|Period 2: Extension Phase|Adverse Event|0
6297204|NCT02490475|10018909|FG001|Period 2: Extension Phase|Adverse Event|0
6297205|NCT02490475|10018910|FG002|Period 2: Extension Phase|Adverse Event|1
6297206|NCT02490475|10018911|FG003|Period 2: Extension Phase|Adverse Event|0
6297207|NCT02490878|10018952|FG000|Overall Study|deemed ineligible|0
6297208|NCT02490878|10018953|FG001|Overall Study|deemed ineligible|1
6297209|NCT02490878|10018952|FG000|Overall Study|progression prior to treatment|0
6297210|NCT02490878|10018953|FG001|Overall Study|progression prior to treatment|1
6297211|NCT02490878|10018952|FG000|Overall Study|only submitted baseline QOL|0
6297212|NCT02490878|10018953|FG001|Overall Study|only submitted baseline QOL|1
6297213|NCT02491073|10018961|FG000|Overall Study|screen failure|1
6297214|NCT02491073|10018962|FG001|Overall Study|screen failure|0
6297215|NCT02491463|10019005|FG000|Overall Study|Withdrawal by Subject|1
6297216|NCT02491463|10019006|FG001|Overall Study|Withdrawal by Subject|2
6297217|NCT02491463|10019007|FG002|Overall Study|Withdrawal by Subject|0
6297218|NCT02491463|10019008|FG003|Overall Study|Withdrawal by Subject|0
6297219|NCT02491463|10019005|FG000|Overall Study|Migrated/moved from study area|1
6297220|NCT02491463|10019006|FG001|Overall Study|Migrated/moved from study area|5
6297221|NCT02491463|10019007|FG002|Overall Study|Migrated/moved from study area|1
6297222|NCT02491463|10019008|FG003|Overall Study|Migrated/moved from study area|1
6297223|NCT02491463|10019005|FG000|Overall Study|Lost to Follow-up|0
6297224|NCT02491463|10019006|FG001|Overall Study|Lost to Follow-up|3
6297225|NCT02491463|10019007|FG002|Overall Study|Lost to Follow-up|3
6297226|NCT02491463|10019008|FG003|Overall Study|Lost to Follow-up|0
6297227|NCT02491671|10019020|FG000|Overall Study|Adverse Event|6
6297228|NCT02491671|10019021|FG001|Overall Study|Adverse Event|8
6297229|NCT02491671|10019020|FG000|Overall Study|Death|0
6297230|NCT02491671|10019021|FG001|Overall Study|Death|2
6297231|NCT02491671|10019020|FG000|Overall Study|Use of sealants other than Hemopatch|5
6297232|NCT02491671|10019021|FG001|Overall Study|Use of sealants other than Hemopatch|3
6297233|NCT02491684|10019029|FG000|Treatment Phase|Adverse Event|2
6297234|NCT02491684|10019030|FG001|Treatment Phase|Adverse Event|2
6297235|NCT02491684|10019029|FG000|Treatment Phase|Incorrect randomisation|1
6297236|NCT02491684|10019030|FG001|Treatment Phase|Incorrect randomisation|0
6297237|NCT02491684|10019029|FG000|Treatment Phase|Investigator and Sponsor decision|0
6297238|NCT02491684|10019030|FG001|Treatment Phase|Investigator and Sponsor decision|1
6297239|NCT02491892|10019047|FG000|Overall Study|Adverse Event|1
6297240|NCT02491892|10019048|FG001|Overall Study|Adverse Event|1
6297241|NCT02491892|10019047|FG000|Overall Study|Death|1
6297242|NCT02491892|10019048|FG001|Overall Study|Death|1
6297243|NCT02491892|10019047|FG000|Overall Study|Lack of Efficacy|37
6297244|NCT02491892|10019048|FG001|Overall Study|Lack of Efficacy|36
6297245|NCT02491892|10019047|FG000|Overall Study|Refused Treatment|1
6297246|NCT02491892|10019048|FG001|Overall Study|Refused Treatment|0
6297247|NCT02491892|10019047|FG000|Overall Study|Lost to Follow-up|1
6297248|NCT02491892|10019048|FG001|Overall Study|Lost to Follow-up|0
6297249|NCT02492100|10019058|FG000|Overall Study|Death|1
6297250|NCT02492763|10019093|FG000|Overall Study|Withdrawal by Subject|0
6297251|NCT02492763|10019094|FG001|Overall Study|Withdrawal by Subject|2
6297252|NCT02492763|10019095|FG002|Overall Study|Withdrawal by Subject|1
6297253|NCT02492763|10019096|FG003|Overall Study|Withdrawal by Subject|0
6297254|NCT02492763|10019093|FG000|Overall Study|Adverse Event|3
6297255|NCT02492763|10019094|FG001|Overall Study|Adverse Event|1
6297256|NCT02492763|10019095|FG002|Overall Study|Adverse Event|1
6297257|NCT02492763|10019096|FG003|Overall Study|Adverse Event|2
6297258|NCT02492763|10019093|FG000|Overall Study|Death|0
6297259|NCT02492763|10019094|FG001|Overall Study|Death|0
6297260|NCT02492763|10019095|FG002|Overall Study|Death|1
6297261|NCT02492763|10019096|FG003|Overall Study|Death|0
6297262|NCT02492763|10019093|FG000|Overall Study|Hyperglycemia Discontinuation Criteria|0
6297263|NCT02492763|10019094|FG001|Overall Study|Hyperglycemia Discontinuation Criteria|1
6297264|NCT02492763|10019095|FG002|Overall Study|Hyperglycemia Discontinuation Criteria|0
6297265|NCT02492763|10019096|FG003|Overall Study|Hyperglycemia Discontinuation Criteria|0
6297266|NCT02492763|10019093|FG000|Overall Study|Lost to Follow-up|0
6297267|NCT02492763|10019094|FG001|Overall Study|Lost to Follow-up|0
6297268|NCT02492763|10019095|FG002|Overall Study|Lost to Follow-up|1
6297269|NCT02492763|10019096|FG003|Overall Study|Lost to Follow-up|0
6297270|NCT02492763|10019093|FG000|Overall Study|Non-Compliance With Study Drug|0
6297271|NCT02492763|10019094|FG001|Overall Study|Non-Compliance With Study Drug|1
6297272|NCT02492763|10019095|FG002|Overall Study|Non-Compliance With Study Drug|0
6297273|NCT02492763|10019096|FG003|Overall Study|Non-Compliance With Study Drug|0
6297274|NCT02492763|10019093|FG000|Overall Study|Screen Failure|0
6297275|NCT02492763|10019094|FG001|Overall Study|Screen Failure|0
6297276|NCT02492763|10019095|FG002|Overall Study|Screen Failure|0
6297277|NCT02492763|10019096|FG003|Overall Study|Screen Failure|1
6297278|NCT02492763|10019093|FG000|Overall Study|Study Terminated by Sponsor|13
6297279|NCT02492763|10019094|FG001|Overall Study|Study Terminated by Sponsor|10
6297280|NCT02492763|10019095|FG002|Overall Study|Study Terminated by Sponsor|6
6297281|NCT02492763|10019096|FG003|Overall Study|Study Terminated by Sponsor|10
6297282|NCT02492841|10019113|FG000|Overall Study|Lost to Follow-up|34
6297283|NCT02492841|10019114|FG001|Overall Study|Lost to Follow-up|31
6297284|NCT02492841|10019115|FG002|Overall Study|Lost to Follow-up|35
6297285|NCT02492880|10019135|FG000|Overall Study|Lost to Follow-up|1
6297286|NCT02492880|10019135|FG000|Overall Study|Protocol Violation|1
6297287|NCT02492958|10019143|FG000|Overall Study|Withdrawal by Subject|0
6297288|NCT02492958|10019144|FG001|Overall Study|Withdrawal by Subject|0
6297289|NCT02492958|10019145|FG002|Overall Study|Withdrawal by Subject|1
6297290|NCT02492958|10019146|FG003|Overall Study|Withdrawal by Subject|0
6297291|NCT02492958|10019143|FG000|Overall Study|Adverse Event|1
6297292|NCT02492958|10019144|FG001|Overall Study|Adverse Event|0
6297293|NCT02492958|10019145|FG002|Overall Study|Adverse Event|1
6297294|NCT02492958|10019146|FG003|Overall Study|Adverse Event|0
6297295|NCT02492984|10019158|FG000|Overall Study|Adverse Event|1
6297296|NCT02492984|10019159|FG001|Overall Study|Adverse Event|0
6297297|NCT02492984|10019158|FG000|Overall Study|Protocol Violation|1
6297298|NCT02492984|10019159|FG001|Overall Study|Protocol Violation|0
6297299|NCT02492984|10019158|FG000|Overall Study|Withdrawal by Subject|1
6297300|NCT02492984|10019159|FG001|Overall Study|Withdrawal by Subject|0
6297301|NCT02492997|10019170|FG000|Overall Study|Withdrawal by Subject|1
6297302|NCT02492997|10019171|FG001|Overall Study|Withdrawal by Subject|0
6297303|NCT02492997|10019170|FG000|Overall Study|Gained Weight|1
6297304|NCT02492997|10019171|FG001|Overall Study|Gained Weight|0
6297305|NCT02492997|10019170|FG000|Overall Study|Lost to Follow-up|0
6297306|NCT02492997|10019171|FG001|Overall Study|Lost to Follow-up|1
6297307|NCT02493062|10019190|FG000|Overall Study|Physician Decision|12
6297308|NCT02493127|10019200|FG000|Overall Study|Lost to Follow-up|1
6297309|NCT02493127|10019201|FG001|Overall Study|Lost to Follow-up|1
6297310|NCT02493361|10019218|FG000|Overall Study|Withdrawal by Subject|3
6297311|NCT02493517|10019237|FG000|Overall Study|Protocol Violation|1
6297312|NCT02493517|10019238|FG001|Overall Study|Protocol Violation|2
6297313|NCT02493517|10019237|FG000|Overall Study|Withdrawal by Subject|1
6297314|NCT02493517|10019238|FG001|Overall Study|Withdrawal by Subject|2
6297315|NCT02493517|10019237|FG000|Overall Study|Adverse Event|0
6297316|NCT02493517|10019238|FG001|Overall Study|Adverse Event|2
6297317|NCT02493517|10019237|FG000|Overall Study|Missed study visit|0
6297318|NCT02493517|10019238|FG001|Overall Study|Missed study visit|1
6297319|NCT02493660|10019266|FG000|Overall Study|Physician Decision|0
6297320|NCT02493660|10019267|FG001|Overall Study|Physician Decision|1
6297321|NCT02493712|10019276|FG000|Overall Study|Withdrawal by Subject|1
6297322|NCT02493712|10019277|FG001|Overall Study|Withdrawal by Subject|0
6297323|NCT02493712|10019278|FG002|Overall Study|Withdrawal by Subject|2
6297324|NCT02493712|10019276|FG000|Overall Study|Protocol Violation|0
6297325|NCT02493712|10019277|FG001|Overall Study|Protocol Violation|0
6297326|NCT02493712|10019278|FG002|Overall Study|Protocol Violation|1
6297327|NCT02493712|10019276|FG000|Overall Study|Lost to Follow-up|1
6297328|NCT02493712|10019277|FG001|Overall Study|Lost to Follow-up|0
6297329|NCT02493712|10019278|FG002|Overall Study|Lost to Follow-up|0
6297330|NCT02493712|10019276|FG000|Overall Study|Physician Decision|0
6297331|NCT02493712|10019277|FG001|Overall Study|Physician Decision|1
6297332|NCT02493712|10019278|FG002|Overall Study|Physician Decision|0
6297333|NCT02493712|10019276|FG000|Overall Study|Lack of Efficacy|0
6297334|NCT02493712|10019277|FG001|Overall Study|Lack of Efficacy|5
6297335|NCT02493712|10019278|FG002|Overall Study|Lack of Efficacy|3
6297336|NCT02493764|10019288|FG000|Overall Study|Adverse Event|2
6297337|NCT02493764|10019289|FG001|Overall Study|Adverse Event|2
6297338|NCT02493764|10019288|FG000|Overall Study|Death|44
6297339|NCT02493764|10019289|FG001|Overall Study|Death|58
6297340|NCT02493764|10019288|FG000|Overall Study|Lost to Follow-up|2
6297341|NCT02493764|10019289|FG001|Overall Study|Lost to Follow-up|1
6297342|NCT02493764|10019288|FG000|Overall Study|Protocol Violation|6
6297343|NCT02493764|10019289|FG001|Overall Study|Protocol Violation|7
6297344|NCT02493764|10019288|FG000|Overall Study|Physician Decision|1
6297345|NCT02493764|10019289|FG001|Overall Study|Physician Decision|1
6297346|NCT02493764|10019288|FG000|Overall Study|Participant moved|17
6297347|NCT02493764|10019289|FG001|Overall Study|Participant moved|5
6297348|NCT02493764|10019288|FG000|Overall Study|Withdrawal parent/guardian|0
6297349|NCT02493764|10019289|FG001|Overall Study|Withdrawal parent/guardian|1
6297350|NCT02493764|10019288|FG000|Overall Study|Withdrawal by Subject|11
6297351|NCT02493764|10019289|FG001|Overall Study|Withdrawal by Subject|7
6297352|NCT02493777|10019297|FG000|Overall Study|Lost to Follow-up|0
6297353|NCT02493777|10019298|FG001|Overall Study|Lost to Follow-up|1
6297354|NCT02493855|10019307|FG000|Overall Study|Non-compliance|1
6297355|NCT02493855|10019308|FG001|Overall Study|Non-compliance|0
6297356|NCT02493855|10019309|FG002|Overall Study|Non-compliance|0
6297357|NCT02493855|10019307|FG000|Overall Study|Adverse Event|0
6297358|NCT02493855|10019308|FG001|Overall Study|Adverse Event|1
6297359|NCT02493855|10019309|FG002|Overall Study|Adverse Event|0
6297360|NCT02493855|10019307|FG000|Overall Study|Withdrawal by Subject|1
6297361|NCT02493855|10019308|FG001|Overall Study|Withdrawal by Subject|0
6297362|NCT02493855|10019309|FG002|Overall Study|Withdrawal by Subject|0
6297363|NCT02493868|10019317|FG000|Induction Phase: DE Participants|Adverse Event|22
6297364|NCT02493868|10019318|FG001|Induction Phase: DE Participants|Adverse Event|0
6297365|NCT02493868|10019317|FG000|Induction Phase: DE Participants|Lost to Follow-up|1
6297366|NCT02493868|10019318|FG001|Induction Phase: DE Participants|Lost to Follow-up|0
6297367|NCT02493868|10019317|FG000|Induction Phase: DE Participants|Lack of Efficacy|2
6297368|NCT02493868|10019318|FG001|Induction Phase: DE Participants|Lack of Efficacy|0
6297369|NCT02493868|10019317|FG000|Induction Phase: DE Participants|Protocol Violation|2
6297370|NCT02493868|10019318|FG001|Induction Phase: DE Participants|Protocol Violation|0
6297371|NCT02493868|10019317|FG000|Induction Phase: DE Participants|Withdrawal by Subject|15
6297372|NCT02493868|10019318|FG001|Induction Phase: DE Participants|Withdrawal by Subject|0
6297373|NCT02493868|10019317|FG000|Induction Phase: DE Participants|Not meet criteria to continue next phase|114
6297374|NCT02493868|10019318|FG001|Induction Phase: DE Participants|Not meet criteria to continue next phase|0
6297375|NCT02493868|10019317|FG000|Induction Phase: DE Participants|Other|8
6297376|NCT02493868|10019318|FG001|Induction Phase: DE Participants|Other|0
6297377|NCT02493868|10019317|FG000|Optimization Phase: DE+TE Participants|Adverse Event|5
6297378|NCT02493868|10019318|FG001|Optimization Phase: DE+TE Participants|Adverse Event|0
6297379|NCT02493868|10019317|FG000|Optimization Phase: DE+TE Participants|Lost to Follow-up|2
6297380|NCT02493868|10019318|FG001|Optimization Phase: DE+TE Participants|Lost to Follow-up|1
6297381|NCT02493868|10019317|FG000|Optimization Phase: DE+TE Participants|Lack of Efficacy|8
6297382|NCT02493868|10019318|FG001|Optimization Phase: DE+TE Participants|Lack of Efficacy|0
6297383|NCT02493868|10019317|FG000|Optimization Phase: DE+TE Participants|Protocol Violation|4
6297384|NCT02493868|10019318|FG001|Optimization Phase: DE+TE Participants|Protocol Violation|1
6297385|NCT02493868|10019317|FG000|Optimization Phase: DE+TE Participants|Withdrawal by Subject|8
6297386|NCT02493868|10019318|FG001|Optimization Phase: DE+TE Participants|Withdrawal by Subject|3
6297387|NCT02493868|10019317|FG000|Optimization Phase: DE+TE Participants|MADRS >= 22 for 2 Consecutive Visit|14
6297388|NCT02493868|10019318|FG001|Optimization Phase: DE+TE Participants|MADRS >= 22 for 2 Consecutive Visit|5
6297389|NCT02493868|10019317|FG000|Optimization Phase: DE+TE Participants|Not meet criteria to continue next phase|107
6297390|NCT02493868|10019318|FG001|Optimization Phase: DE+TE Participants|Not meet criteria to continue next phase|20
6297391|NCT02493868|10019317|FG000|Optimization Phase: DE+TE Participants|Other|10
6297392|NCT02493868|10019318|FG001|Optimization Phase: DE+TE Participants|Other|2
6297393|NCT02493868|10019317|FG000|Maintenance Phase: DE+TE Participants|Adverse Event|1
6297394|NCT02493868|10019318|FG001|Maintenance Phase: DE+TE Participants|Adverse Event|4
6297395|NCT02493868|10019317|FG000|Maintenance Phase: DE+TE Participants|Lost to Follow-up|1
6297396|NCT02493868|10019318|FG001|Maintenance Phase: DE+TE Participants|Lost to Follow-up|0
6297397|NCT02493868|10019317|FG000|Maintenance Phase: DE+TE Participants|Protocol Violation|1
6297398|NCT02493868|10019318|FG001|Maintenance Phase: DE+TE Participants|Protocol Violation|1
6297399|NCT02493868|10019317|FG000|Maintenance Phase: DE+TE Participants|Withdrawal by Subject|5
6297400|NCT02493868|10019318|FG001|Maintenance Phase: DE+TE Participants|Withdrawal by Subject|7
6297401|NCT02493868|10019317|FG000|Maintenance Phase: DE+TE Participants|Pregnancy|1
6297402|NCT02493868|10019318|FG001|Maintenance Phase: DE+TE Participants|Pregnancy|0
6297403|NCT02493868|10019317|FG000|Maintenance Phase: DE+TE Participants|Non Compliance with Study Drug|0
6297404|NCT02493868|10019318|FG001|Maintenance Phase: DE+TE Participants|Non Compliance with Study Drug|1
6297405|NCT02493868|10019317|FG000|Maintenance Phase: DE+TE Participants|Other|4
6297406|NCT02493868|10019318|FG001|Maintenance Phase: DE+TE Participants|Other|9
6297407|NCT02493868|10019317|FG000|Follow-up Phase|Lost to Follow-up|1
6297408|NCT02493868|10019318|FG001|Follow-up Phase|Lost to Follow-up|0
6297409|NCT02493868|10019317|FG000|Follow-up Phase|Withdrawal by Subject|3
6297410|NCT02493868|10019318|FG001|Follow-up Phase|Withdrawal by Subject|0
6297411|NCT02493868|10019317|FG000|Follow-up Phase|Investigator Decision|5
6297412|NCT02493868|10019318|FG001|Follow-up Phase|Investigator Decision|1
6297413|NCT02493868|10019317|FG000|Follow-up Phase|Other|2
6297414|NCT02493868|10019318|FG001|Follow-up Phase|Other|1
6297415|NCT02493946|10019333|FG000|DB Period|Withdrawal by Subject|8
6297416|NCT02493946|10019334|FG001|DB Period|Withdrawal by Subject|5
6297417|NCT02493946|10019335|FG002|DB Period|Withdrawal by Subject|0
6297418|NCT02493946|10019333|FG000|Open Label Period|Withdrawal by Subject|0
6297419|NCT02493946|10019334|FG001|Open Label Period|Withdrawal by Subject|0
6297420|NCT02493946|10019335|FG002|Open Label Period|Withdrawal by Subject|74
6297421|NCT02493946|10019333|FG000|Open Label Period|Adverse Event|0
6297422|NCT02493946|10019334|FG001|Open Label Period|Adverse Event|0
6297423|NCT02493946|10019335|FG002|Open Label Period|Adverse Event|4
6297424|NCT02493946|10019333|FG000|Open Label Period|Lost to Follow-up|0
6297425|NCT02493946|10019334|FG001|Open Label Period|Lost to Follow-up|0
6297426|NCT02493946|10019335|FG002|Open Label Period|Lost to Follow-up|1
6297427|NCT02493946|10019333|FG000|Open Label Period|Investigator decision, non-compliance|0
6297428|NCT02493946|10019334|FG001|Open Label Period|Investigator decision, non-compliance|0
6297429|NCT02493946|10019335|FG002|Open Label Period|Investigator decision, non-compliance|2
6297430|NCT02493946|10019333|FG000|Open Label Period|Investigator decision, non-availability|0
6297431|NCT02493946|10019334|FG001|Open Label Period|Investigator decision, non-availability|0
6297432|NCT02493946|10019335|FG002|Open Label Period|Investigator decision, non-availability|1
6297433|NCT02493946|10019333|FG000|Open Label Period|Pregnancy|0
5981743|NCT00897104|9570506|FG002|Overall Study|Lack of Migraine Attack|1
5981744|NCT00897104|9570504|FG000|Overall Study|No Longer Met Inc/Exc Criteria|1
5981745|NCT00897104|9570505|FG001|Overall Study|No Longer Met Inc/Exc Criteria|0
5981746|NCT00897104|9570506|FG002|Overall Study|No Longer Met Inc/Exc Criteria|0
5981747|NCT00897104|9570504|FG000|Overall Study|Other|3
5981748|NCT00897104|9570505|FG001|Overall Study|Other|0
5981749|NCT00897104|9570506|FG002|Overall Study|Other|0
5981750|NCT00897104|9570504|FG000|Overall Study|Protocol Violation|1
5981751|NCT00897104|9570505|FG001|Overall Study|Protocol Violation|0
5981752|NCT00897104|9570506|FG002|Overall Study|Protocol Violation|0
5981753|NCT00897104|9570504|FG000|Overall Study|Withdrawal by Subject|0
5981754|NCT00897104|9570505|FG001|Overall Study|Withdrawal by Subject|0
5981755|NCT00897104|9570506|FG002|Overall Study|Withdrawal by Subject|1
5981756|NCT00803790|9570516|FG000|Period 1|Adverse Event|0
5981757|NCT00803790|9570517|FG001|Period 1|Adverse Event|1
5981758|NCT00803790|9570518|FG002|Period 1|Adverse Event|0
5981759|NCT00803790|9570519|FG003|Period 1|Adverse Event|0
5981760|NCT00803790|9570516|FG000|Period 1|Lost to Follow-up|1
5981761|NCT00803790|9570517|FG001|Period 1|Lost to Follow-up|2
5981762|NCT00803790|9570518|FG002|Period 1|Lost to Follow-up|0
5981763|NCT00803790|9570519|FG003|Period 1|Lost to Follow-up|0
5981764|NCT00803790|9570516|FG000|Period 1|Withdrawal by Subject|8
5981765|NCT00803790|9570517|FG001|Period 1|Withdrawal by Subject|6
5981766|NCT00803790|9570518|FG002|Period 1|Withdrawal by Subject|0
5981767|NCT00803790|9570519|FG003|Period 1|Withdrawal by Subject|0
5981768|NCT00803790|9570516|FG000|Period 1|positive drug screen or personal reasons|0
5981769|NCT00803790|9570517|FG001|Period 1|positive drug screen or personal reasons|3
5981770|NCT00803790|9570518|FG002|Period 1|positive drug screen or personal reasons|0
5981771|NCT00803790|9570519|FG003|Period 1|positive drug screen or personal reasons|4
5981772|NCT00803790|9570516|FG000|Period 1|Protocol Violation|0
5981773|NCT00803790|9570517|FG001|Period 1|Protocol Violation|0
5981774|NCT00803790|9570518|FG002|Period 1|Protocol Violation|1
5981775|NCT00803790|9570519|FG003|Period 1|Protocol Violation|0
5981776|NCT00803790|9570516|FG000|Period 2|Adverse Event|0
5981777|NCT00803790|9570517|FG001|Period 2|Adverse Event|0
6297434|NCT02493946|10019334|FG001|Open Label Period|Pregnancy|0
6297435|NCT02493946|10019335|FG002|Open Label Period|Pregnancy|3
6297436|NCT02493946|10019333|FG000|Open Label Period|Site error|0
6297437|NCT02493946|10019334|FG001|Open Label Period|Site error|0
6297438|NCT02493946|10019335|FG002|Open Label Period|Site error|1
6297439|NCT02494401|10019389|FG000|Overall Study|Lost to Follow-up|22
6297440|NCT02494401|10019390|FG001|Overall Study|Lost to Follow-up|25
6297441|NCT02494401|10019389|FG000|Overall Study|Withdrawal by Subject|3
6297442|NCT02494401|10019390|FG001|Overall Study|Withdrawal by Subject|2
6297443|NCT02494583|10019416|FG000|Overall Study|Death|195
6297444|NCT02494583|10019417|FG001|Overall Study|Death|189
6297445|NCT02494583|10019418|FG002|Overall Study|Death|201
6297446|NCT02494583|10019416|FG000|Overall Study|Lost to Follow-up|1
6297447|NCT02494583|10019417|FG001|Overall Study|Lost to Follow-up|0
6297448|NCT02494583|10019418|FG002|Overall Study|Lost to Follow-up|0
6297449|NCT02494583|10019416|FG000|Overall Study|Protocol Violation|1
6297450|NCT02494583|10019417|FG001|Overall Study|Protocol Violation|2
6297451|NCT02494583|10019418|FG002|Overall Study|Protocol Violation|0
6297452|NCT02494583|10019416|FG000|Overall Study|Withdrawal by Subject|3
6297453|NCT02494583|10019417|FG001|Overall Study|Withdrawal by Subject|15
6297454|NCT02494583|10019418|FG002|Overall Study|Withdrawal by Subject|15
6297455|NCT02494583|10019416|FG000|Overall Study|Ongoing in Study|56
6297456|NCT02494583|10019417|FG001|Overall Study|Ongoing in Study|51
6297457|NCT02494583|10019418|FG002|Overall Study|Ongoing in Study|34
6297458|NCT02494596|10019426|FG000|Overall Study|Insufficient Therapeutic Response|3
6297459|NCT02494596|10019427|FG001|Overall Study|Insufficient Therapeutic Response|3
6297460|NCT02494596|10019428|FG002|Overall Study|Insufficient Therapeutic Response|1
6297461|NCT02494596|10019426|FG000|Overall Study|Adverse Event|0
6297462|NCT02494596|10019427|FG001|Overall Study|Adverse Event|1
6297463|NCT02494596|10019428|FG002|Overall Study|Adverse Event|0
6297464|NCT02494596|10019426|FG000|Overall Study|Refused Treatment|0
6297465|NCT02494596|10019427|FG001|Overall Study|Refused Treatment|1
6297466|NCT02494596|10019428|FG002|Overall Study|Refused Treatment|0
6297467|NCT02494778|10019443|FG000|Overall Study|Death|3
6297468|NCT02494778|10019443|FG000|Overall Study|Other|173
6297469|NCT02494778|10019443|FG000|Overall Study|Lack of Efficacy|4
6297470|NCT02494778|10019443|FG000|Overall Study|Adverse Event|18
6297471|NCT02494778|10019443|FG000|Overall Study|Withdrawal by Subject|20
6297472|NCT02494778|10019443|FG000|Overall Study|Lost to Follow-up|2
6297473|NCT02494778|10019443|FG000|Overall Study|Noncompliant with study drug admin.|1
6297474|NCT02495025|10019458|FG000|Overall Study|Lost to Follow-up|21
6297475|NCT02495025|10019459|FG001|Overall Study|Lost to Follow-up|14
6297476|NCT02495025|10019458|FG000|Overall Study|Withdrawal by Subject|5
6297477|NCT02495025|10019459|FG001|Overall Study|Withdrawal by Subject|0
6297478|NCT02495168|10019492|FG000|Overall Study|Other than Specified|18
6297479|NCT02495168|10019493|FG001|Overall Study|Other than Specified|22
6297480|NCT02495168|10019494|FG002|Overall Study|Other than Specified|5
6297481|NCT02495168|10019492|FG000|Overall Study|Did not Complete Final Visit On Time|4
6297482|NCT02495168|10019493|FG001|Overall Study|Did not Complete Final Visit On Time|3
6297483|NCT02495168|10019494|FG002|Overall Study|Did not Complete Final Visit On Time|2
6297484|NCT02495168|10019492|FG000|Overall Study|Physician Decision|1
6297485|NCT02495168|10019493|FG001|Overall Study|Physician Decision|1
6297486|NCT02495168|10019494|FG002|Overall Study|Physician Decision|0
6297487|NCT02495168|10019492|FG000|Overall Study|Lost to Follow-up|10
6297488|NCT02495168|10019493|FG001|Overall Study|Lost to Follow-up|6
6297489|NCT02495168|10019494|FG002|Overall Study|Lost to Follow-up|1
6297490|NCT02495168|10019492|FG000|Overall Study|Withdrawal by Subject|1
6297491|NCT02495168|10019493|FG001|Overall Study|Withdrawal by Subject|4
6297492|NCT02495168|10019494|FG002|Overall Study|Withdrawal by Subject|2
6297493|NCT02495168|10019492|FG000|Overall Study|Protocol Violation|0
6297494|NCT02495168|10019493|FG001|Overall Study|Protocol Violation|10
6297495|NCT02495168|10019494|FG002|Overall Study|Protocol Violation|1
6297496|NCT02495168|10019492|FG000|Overall Study|Adverse Event|4
6297497|NCT02495168|10019493|FG001|Overall Study|Adverse Event|8
6297498|NCT02495168|10019494|FG002|Overall Study|Adverse Event|3
6297499|NCT02495168|10019492|FG000|Overall Study|Lack of Efficacy|0
6297500|NCT02495168|10019493|FG001|Overall Study|Lack of Efficacy|0
6297501|NCT02495168|10019494|FG002|Overall Study|Lack of Efficacy|3
6297502|NCT02495233|10019504|FG000|Overall Study|Miscellaneous|0
6297503|NCT02495233|10019505|FG001|Overall Study|Miscellaneous|1
6297504|NCT02495389|10019524|FG000|Overall Study|Withdrawal by Subject|40
6297505|NCT02495844|10019568|FG000|Overall Study|Lack of Efficacy|1
6297506|NCT02495844|10019569|FG001|Overall Study|Lack of Efficacy|2
6297507|NCT02495844|10019568|FG000|Overall Study|AE, non-fatal|0
6297508|NCT02495844|10019569|FG001|Overall Study|AE, non-fatal|1
6297509|NCT02495844|10019568|FG000|Overall Study|Hepatitis Positivity|0
6297510|NCT02495844|10019569|FG001|Overall Study|Hepatitis Positivity|1
6297511|NCT02495857|10019580|FG000|Overall Study|Adverse Event|5
6297512|NCT02495857|10019581|FG001|Overall Study|Adverse Event|0
6297513|NCT02495857|10019582|FG002|Overall Study|Adverse Event|1
6297514|NCT02495857|10019580|FG000|Overall Study|Withdrawal by Subject|9
6297515|NCT02495857|10019581|FG001|Overall Study|Withdrawal by Subject|6
6297516|NCT02495857|10019582|FG002|Overall Study|Withdrawal by Subject|10
6297517|NCT02495857|10019580|FG000|Overall Study|Physician Decision|0
6297518|NCT02495857|10019581|FG001|Overall Study|Physician Decision|1
6297519|NCT02495857|10019582|FG002|Overall Study|Physician Decision|0
6297520|NCT02495857|10019580|FG000|Overall Study|Protocol Violation|1
6297521|NCT02495857|10019581|FG001|Overall Study|Protocol Violation|1
6297522|NCT02495857|10019582|FG002|Overall Study|Protocol Violation|2
6297523|NCT02495857|10019580|FG000|Overall Study|Lost to Follow-up|4
6297524|NCT02495857|10019581|FG001|Overall Study|Lost to Follow-up|5
6297525|NCT02495857|10019582|FG002|Overall Study|Lost to Follow-up|3
6297526|NCT02495857|10019580|FG000|Overall Study|Other|3
6297527|NCT02495857|10019581|FG001|Overall Study|Other|3
6297528|NCT02495857|10019582|FG002|Overall Study|Other|2
6297529|NCT02495883|10019592|FG000|Overall Study|Excessive head motion|1
6297530|NCT02495883|10019593|FG001|Overall Study|Excessive head motion|0
6297531|NCT02495948|10019598|FG000|Period 1, First 30 Days of Wear|Adverse Event|0
6297532|NCT02495948|10019599|FG001|Period 1, First 30 Days of Wear|Adverse Event|1
6297533|NCT02495948|10019598|FG000|Period 2, Second 30 Days of Wear|Withdrawal by Subject|1
6297534|NCT02495948|10019599|FG001|Period 2, Second 30 Days of Wear|Withdrawal by Subject|1
6297535|NCT02496000|10019609|FG000|Overall Study|Withdrawal by Subject|1
6297536|NCT02496000|10019610|FG001|Overall Study|Withdrawal by Subject|2
6297537|NCT02496000|10019611|FG002|Overall Study|Withdrawal by Subject|0
6297538|NCT02496000|10019609|FG000|Overall Study|Lost to Follow-up|1
6297539|NCT02496000|10019610|FG001|Overall Study|Lost to Follow-up|0
6297540|NCT02496000|10019611|FG002|Overall Study|Lost to Follow-up|1
6297541|NCT02496000|10019609|FG000|Overall Study|Protocol Violation|0
6297542|NCT02496000|10019610|FG001|Overall Study|Protocol Violation|0
6297543|NCT02496000|10019611|FG002|Overall Study|Protocol Violation|1
6297544|NCT02496000|10019609|FG000|Overall Study|Non-compliance or lack of cooperation|0
6297545|NCT02496000|10019610|FG001|Overall Study|Non-compliance or lack of cooperation|2
6297546|NCT02496000|10019611|FG002|Overall Study|Non-compliance or lack of cooperation|0
6297547|NCT02496000|10019609|FG000|Overall Study|undetermined|0
6297548|NCT02496000|10019610|FG001|Overall Study|undetermined|1
6297549|NCT02496000|10019611|FG002|Overall Study|undetermined|0
6297550|NCT02496091|10019620|FG000|Overall Study|Eligibility criteria not fulfilled|2
6297551|NCT02496221|10019625|FG000|Treatment Period 2 - 4 Days|Adverse Event|0
6297552|NCT02496221|10019626|FG001|Treatment Period 2 - 4 Days|Adverse Event|1
6297553|NCT02496221|10019625|FG000|Treatment Period 2 - 4 Days|Protocol Violation|1
6297554|NCT02496221|10019626|FG001|Treatment Period 2 - 4 Days|Protocol Violation|0
6297555|NCT02496221|10019625|FG000|Treatment Period 2 - 4 Days|Physician Decision|1
6297556|NCT02496221|10019626|FG001|Treatment Period 2 - 4 Days|Physician Decision|0
6297557|NCT02496533|10019636|FG000|Overall Study|Lack of data on outcome|3
6297558|NCT02496533|10019637|FG001|Overall Study|Lack of data on outcome|0
6297559|NCT02496533|10019636|FG000|Overall Study|Patient did not complete all measures|0
6297560|NCT02496533|10019637|FG001|Overall Study|Patient did not complete all measures|4
6297561|NCT02496533|10019636|FG000|Overall Study|Late for radiologic testing|0
6297562|NCT02496533|10019637|FG001|Overall Study|Late for radiologic testing|2
6297563|NCT02496702|10019645|FG000|Overall Study|Lost to Follow-up|8
6297564|NCT02496702|10019646|FG001|Overall Study|Lost to Follow-up|6
6297565|NCT02496702|10019645|FG000|Overall Study|Only partially tested|0
6297566|NCT02496702|10019646|FG001|Overall Study|Only partially tested|2
6297567|NCT02496767|10019656|FG000|Open-label Lead-in Phase|Adverse Event|176
6297568|NCT02496767|10019657|FG001|Open-label Lead-in Phase|Adverse Event|0
6297569|NCT02496767|10019658|FG002|Open-label Lead-in Phase|Adverse Event|0
6297570|NCT02496767|10019659|FG003|Open-label Lead-in Phase|Adverse Event|0
6297571|NCT02496767|10019660|FG004|Open-label Lead-in Phase|Adverse Event|0
6297572|NCT02496767|10019661|FG005|Open-label Lead-in Phase|Adverse Event|0
6297573|NCT02496767|10019662|FG006|Open-label Lead-in Phase|Adverse Event|0
6297574|NCT02496767|10019663|FG007|Open-label Lead-in Phase|Adverse Event|0
6297575|NCT02496767|10019656|FG000|Open-label Lead-in Phase|Protocol Violation|2
6297576|NCT02496767|10019657|FG001|Open-label Lead-in Phase|Protocol Violation|0
6297577|NCT02496767|10019658|FG002|Open-label Lead-in Phase|Protocol Violation|0
6297578|NCT02496767|10019659|FG003|Open-label Lead-in Phase|Protocol Violation|0
6297579|NCT02496767|10019660|FG004|Open-label Lead-in Phase|Protocol Violation|0
6297580|NCT02496767|10019661|FG005|Open-label Lead-in Phase|Protocol Violation|0
6297581|NCT02496767|10019662|FG006|Open-label Lead-in Phase|Protocol Violation|0
6297582|NCT02496767|10019663|FG007|Open-label Lead-in Phase|Protocol Violation|0
6297583|NCT02496767|10019656|FG000|Open-label Lead-in Phase|Lost to Follow-up|1
6297584|NCT02496767|10019657|FG001|Open-label Lead-in Phase|Lost to Follow-up|0
6297585|NCT02496767|10019658|FG002|Open-label Lead-in Phase|Lost to Follow-up|0
6297586|NCT02496767|10019659|FG003|Open-label Lead-in Phase|Lost to Follow-up|0
6297587|NCT02496767|10019660|FG004|Open-label Lead-in Phase|Lost to Follow-up|0
6297588|NCT02496767|10019661|FG005|Open-label Lead-in Phase|Lost to Follow-up|0
6297589|NCT02496767|10019662|FG006|Open-label Lead-in Phase|Lost to Follow-up|0
6297590|NCT02496767|10019663|FG007|Open-label Lead-in Phase|Lost to Follow-up|0
6297591|NCT02496767|10019656|FG000|Double-blind, Placebo-controlled Phase|Adverse Event|0
6297592|NCT02496767|10019657|FG001|Double-blind, Placebo-controlled Phase|Adverse Event|13
6297593|NCT02496767|10019658|FG002|Double-blind, Placebo-controlled Phase|Adverse Event|23
6297594|NCT02496767|10019659|FG003|Double-blind, Placebo-controlled Phase|Adverse Event|43
6297595|NCT02496767|10019660|FG004|Double-blind, Placebo-controlled Phase|Adverse Event|43
6297596|NCT02496767|10019661|FG005|Double-blind, Placebo-controlled Phase|Adverse Event|0
6297597|NCT02496767|10019662|FG006|Double-blind, Placebo-controlled Phase|Adverse Event|0
6297598|NCT02496767|10019663|FG007|Double-blind, Placebo-controlled Phase|Adverse Event|0
6297599|NCT02496767|10019656|FG000|Double-blind, Placebo-controlled Phase|Progressive disease|0
6297600|NCT02496767|10019657|FG001|Double-blind, Placebo-controlled Phase|Progressive disease|13
6297601|NCT02496767|10019658|FG002|Double-blind, Placebo-controlled Phase|Progressive disease|9
6297602|NCT02496767|10019659|FG003|Double-blind, Placebo-controlled Phase|Progressive disease|8
6297603|NCT02496767|10019660|FG004|Double-blind, Placebo-controlled Phase|Progressive disease|14
6297604|NCT02496767|10019661|FG005|Double-blind, Placebo-controlled Phase|Progressive disease|0
6297605|NCT02496767|10019662|FG006|Double-blind, Placebo-controlled Phase|Progressive disease|0
6297606|NCT02496767|10019663|FG007|Double-blind, Placebo-controlled Phase|Progressive disease|0
6297607|NCT02496767|10019656|FG000|Double-blind, Placebo-controlled Phase|Death|0
6297608|NCT02496767|10019657|FG001|Double-blind, Placebo-controlled Phase|Death|10
6297609|NCT02496767|10019658|FG002|Double-blind, Placebo-controlled Phase|Death|6
6297610|NCT02496767|10019659|FG003|Double-blind, Placebo-controlled Phase|Death|2
6297611|NCT02496767|10019660|FG004|Double-blind, Placebo-controlled Phase|Death|4
6297612|NCT02496767|10019661|FG005|Double-blind, Placebo-controlled Phase|Death|0
6297613|NCT02496767|10019662|FG006|Double-blind, Placebo-controlled Phase|Death|0
6297614|NCT02496767|10019663|FG007|Double-blind, Placebo-controlled Phase|Death|0
6297615|NCT02496767|10019656|FG000|Double-blind, Placebo-controlled Phase|Various|0
6297616|NCT02496767|10019657|FG001|Double-blind, Placebo-controlled Phase|Various|9
6297617|NCT02496767|10019658|FG002|Double-blind, Placebo-controlled Phase|Various|4
6297618|NCT02496767|10019659|FG003|Double-blind, Placebo-controlled Phase|Various|5
6297619|NCT02496767|10019660|FG004|Double-blind, Placebo-controlled Phase|Various|2
6297620|NCT02496767|10019661|FG005|Double-blind, Placebo-controlled Phase|Various|0
6297621|NCT02496767|10019662|FG006|Double-blind, Placebo-controlled Phase|Various|0
6297622|NCT02496767|10019663|FG007|Double-blind, Placebo-controlled Phase|Various|0
6297623|NCT02496767|10019656|FG000|Double-blind, Placebo-controlled Phase|Withdrawal by Subject|0
6297624|NCT02496767|10019657|FG001|Double-blind, Placebo-controlled Phase|Withdrawal by Subject|4
6297625|NCT02496767|10019658|FG002|Double-blind, Placebo-controlled Phase|Withdrawal by Subject|3
6297626|NCT02496767|10019659|FG003|Double-blind, Placebo-controlled Phase|Withdrawal by Subject|1
6297627|NCT02496767|10019660|FG004|Double-blind, Placebo-controlled Phase|Withdrawal by Subject|2
6297628|NCT02496767|10019661|FG005|Double-blind, Placebo-controlled Phase|Withdrawal by Subject|0
6297629|NCT02496767|10019662|FG006|Double-blind, Placebo-controlled Phase|Withdrawal by Subject|0
6297630|NCT02496767|10019663|FG007|Double-blind, Placebo-controlled Phase|Withdrawal by Subject|0
6297631|NCT02496767|10019656|FG000|Double-blind, Placebo-controlled Phase|Physician Decision|0
6297632|NCT02496767|10019657|FG001|Double-blind, Placebo-controlled Phase|Physician Decision|4
6297633|NCT02496767|10019658|FG002|Double-blind, Placebo-controlled Phase|Physician Decision|1
6297634|NCT02496767|10019659|FG003|Double-blind, Placebo-controlled Phase|Physician Decision|0
6297635|NCT02496767|10019660|FG004|Double-blind, Placebo-controlled Phase|Physician Decision|0
6297636|NCT02496767|10019661|FG005|Double-blind, Placebo-controlled Phase|Physician Decision|0
6297637|NCT02496767|10019662|FG006|Double-blind, Placebo-controlled Phase|Physician Decision|0
6297638|NCT02496767|10019663|FG007|Double-blind, Placebo-controlled Phase|Physician Decision|0
6297639|NCT02496767|10019656|FG000|Double-blind, Placebo-controlled Phase|Lost to Follow-up|0
6297640|NCT02496767|10019657|FG001|Double-blind, Placebo-controlled Phase|Lost to Follow-up|2
6297641|NCT02496767|10019658|FG002|Double-blind, Placebo-controlled Phase|Lost to Follow-up|0
6297642|NCT02496767|10019659|FG003|Double-blind, Placebo-controlled Phase|Lost to Follow-up|2
6297643|NCT02496767|10019660|FG004|Double-blind, Placebo-controlled Phase|Lost to Follow-up|1
5981778|NCT00803790|9570518|FG002|Period 2|Adverse Event|1
5981779|NCT00803790|9570519|FG003|Period 2|Adverse Event|1
5981780|NCT00803790|9570516|FG000|Period 2|Withdrawal by Subject|1
5981781|NCT00803790|9570517|FG001|Period 2|Withdrawal by Subject|0
5981782|NCT00803790|9570518|FG002|Period 2|Withdrawal by Subject|0
5981783|NCT00803790|9570519|FG003|Period 2|Withdrawal by Subject|0
5981784|NCT00803790|9570516|FG000|Period 2|Positive Drug Screen or Personal Reasons|1
5981785|NCT00803790|9570517|FG001|Period 2|Positive Drug Screen or Personal Reasons|0
5981786|NCT00803790|9570518|FG002|Period 2|Positive Drug Screen or Personal Reasons|0
5981787|NCT00803790|9570519|FG003|Period 2|Positive Drug Screen or Personal Reasons|0
5981788|NCT00725491|9570532|FG000|Overall Study|Adverse Event|3
5981789|NCT00725491|9570533|FG001|Overall Study|Adverse Event|2
5981790|NCT00725491|9570532|FG000|Overall Study|Pregnancy|0
5981791|NCT00725491|9570533|FG001|Overall Study|Pregnancy|3
5981792|NCT00725491|9570532|FG000|Overall Study|Risk for hyperstimulation|2
5981793|NCT00725491|9570533|FG001|Overall Study|Risk for hyperstimulation|9
5981794|NCT00725491|9570532|FG000|Overall Study|No/too few oocytes/bad quality oocytes|1
5981795|NCT00725491|9570533|FG001|Overall Study|No/too few oocytes/bad quality oocytes|1
5981796|NCT00725491|9570532|FG000|Overall Study|Fertilization failure|0
5981797|NCT00725491|9570533|FG001|Overall Study|Fertilization failure|1
5981798|NCT00725491|9570532|FG000|Overall Study|No/too few embryos/ bad quality embryos|3
5981799|NCT00725491|9570533|FG001|Overall Study|No/too few embryos/ bad quality embryos|2
5981800|NCT00703014|9570541|FG000|Mothers Follow Up Trial P05712|Did not complete follow up in P05712|33
5981801|NCT00703014|9570542|FG001|Mothers Follow Up Trial P05712|Did not complete follow up in P05712|32
5981802|NCT00703014|9570543|FG002|Mothers Follow Up Trial P05712|Did not complete follow up in P05712|0
5981803|NCT00703014|9570544|FG003|Mothers Follow Up Trial P05712|Did not complete follow up in P05712|0
6297644|NCT02496767|10019661|FG005|Double-blind, Placebo-controlled Phase|Lost to Follow-up|0
6297645|NCT02496767|10019662|FG006|Double-blind, Placebo-controlled Phase|Lost to Follow-up|0
6297646|NCT02496767|10019663|FG007|Double-blind, Placebo-controlled Phase|Lost to Follow-up|0
6297647|NCT02496767|10019656|FG000|Double-blind, Placebo-controlled Phase|Protocol Violation|0
6297648|NCT02496767|10019657|FG001|Double-blind, Placebo-controlled Phase|Protocol Violation|1
6297649|NCT02496767|10019658|FG002|Double-blind, Placebo-controlled Phase|Protocol Violation|0
6297650|NCT02496767|10019659|FG003|Double-blind, Placebo-controlled Phase|Protocol Violation|0
6297651|NCT02496767|10019660|FG004|Double-blind, Placebo-controlled Phase|Protocol Violation|0
6297652|NCT02496767|10019661|FG005|Double-blind, Placebo-controlled Phase|Protocol Violation|0
6297653|NCT02496767|10019662|FG006|Double-blind, Placebo-controlled Phase|Protocol Violation|0
6297654|NCT02496767|10019663|FG007|Double-blind, Placebo-controlled Phase|Protocol Violation|0
6297655|NCT02496767|10019656|FG000|Double-blind, Withdrawal Phase|Progressive disease|0
6297656|NCT02496767|10019657|FG001|Double-blind, Withdrawal Phase|Progressive disease|0
6297657|NCT02496767|10019658|FG002|Double-blind, Withdrawal Phase|Progressive disease|0
6297658|NCT02496767|10019659|FG003|Double-blind, Withdrawal Phase|Progressive disease|0
6297659|NCT02496767|10019660|FG004|Double-blind, Withdrawal Phase|Progressive disease|0
6297660|NCT02496767|10019661|FG005|Double-blind, Withdrawal Phase|Progressive disease|4
6297661|NCT02496767|10019662|FG006|Double-blind, Withdrawal Phase|Progressive disease|0
6297662|NCT02496767|10019663|FG007|Double-blind, Withdrawal Phase|Progressive disease|1
6297663|NCT02496767|10019656|FG000|Double-blind, Withdrawal Phase|Adverse Event|0
6297664|NCT02496767|10019657|FG001|Double-blind, Withdrawal Phase|Adverse Event|0
6297665|NCT02496767|10019658|FG002|Double-blind, Withdrawal Phase|Adverse Event|0
6297666|NCT02496767|10019659|FG003|Double-blind, Withdrawal Phase|Adverse Event|0
6297667|NCT02496767|10019660|FG004|Double-blind, Withdrawal Phase|Adverse Event|0
6297668|NCT02496767|10019661|FG005|Double-blind, Withdrawal Phase|Adverse Event|1
6297669|NCT02496767|10019662|FG006|Double-blind, Withdrawal Phase|Adverse Event|2
6297670|NCT02496767|10019663|FG007|Double-blind, Withdrawal Phase|Adverse Event|1
6297671|NCT02496767|10019656|FG000|Double-blind, Withdrawal Phase|Death|0
6297672|NCT02496767|10019657|FG001|Double-blind, Withdrawal Phase|Death|0
6297673|NCT02496767|10019658|FG002|Double-blind, Withdrawal Phase|Death|0
6297674|NCT02496767|10019659|FG003|Double-blind, Withdrawal Phase|Death|0
6297675|NCT02496767|10019660|FG004|Double-blind, Withdrawal Phase|Death|0
6297676|NCT02496767|10019661|FG005|Double-blind, Withdrawal Phase|Death|0
6297677|NCT02496767|10019662|FG006|Double-blind, Withdrawal Phase|Death|1
6297678|NCT02496767|10019663|FG007|Double-blind, Withdrawal Phase|Death|2
6297679|NCT02496767|10019656|FG000|Double-blind, Withdrawal Phase|Withdrawal by Subject|0
6297680|NCT02496767|10019657|FG001|Double-blind, Withdrawal Phase|Withdrawal by Subject|0
6297681|NCT02496767|10019658|FG002|Double-blind, Withdrawal Phase|Withdrawal by Subject|0
6297682|NCT02496767|10019659|FG003|Double-blind, Withdrawal Phase|Withdrawal by Subject|0
6297683|NCT02496767|10019660|FG004|Double-blind, Withdrawal Phase|Withdrawal by Subject|0
6297684|NCT02496767|10019661|FG005|Double-blind, Withdrawal Phase|Withdrawal by Subject|1
6297685|NCT02496767|10019662|FG006|Double-blind, Withdrawal Phase|Withdrawal by Subject|1
6297686|NCT02496767|10019663|FG007|Double-blind, Withdrawal Phase|Withdrawal by Subject|1
6297687|NCT02496884|10019681|FG000|Overall Study|Counted twice as enrolled|2
6297688|NCT02496884|10019682|FG001|Overall Study|Counted twice as enrolled|0
6297689|NCT02496884|10019683|FG002|Overall Study|Counted twice as enrolled|0
6297690|NCT02496884|10019684|FG003|Overall Study|Counted twice as enrolled|0
6297691|NCT02496884|10019681|FG000|Overall Study|Withdrawal by Subject|0
6297692|NCT02496884|10019682|FG001|Overall Study|Withdrawal by Subject|3
6297693|NCT02496884|10019683|FG002|Overall Study|Withdrawal by Subject|0
6297694|NCT02496884|10019684|FG003|Overall Study|Withdrawal by Subject|0
6297695|NCT02497001|10019698|FG000|Overall Study|Lost to Follow-up|10
6297696|NCT02497001|10019699|FG001|Overall Study|Lost to Follow-up|2
6297697|NCT02497001|10019700|FG002|Overall Study|Lost to Follow-up|0
6297698|NCT02497001|10019701|FG003|Overall Study|Lost to Follow-up|2
6297699|NCT02497001|10019698|FG000|Overall Study|Adverse Event|28
6297700|NCT02497001|10019699|FG001|Overall Study|Adverse Event|30
6297701|NCT02497001|10019700|FG002|Overall Study|Adverse Event|11
6297702|NCT02497001|10019701|FG003|Overall Study|Adverse Event|11
6297703|NCT02497001|10019698|FG000|Overall Study|Withdrawal by Subject|14
6297704|NCT02497001|10019699|FG001|Overall Study|Withdrawal by Subject|37
6297705|NCT02497001|10019700|FG002|Overall Study|Withdrawal by Subject|19
6297706|NCT02497001|10019701|FG003|Overall Study|Withdrawal by Subject|15
6297707|NCT02497001|10019698|FG000|Overall Study|Physician Decision|5
6297708|NCT02497001|10019699|FG001|Overall Study|Physician Decision|11
6297709|NCT02497001|10019700|FG002|Overall Study|Physician Decision|5
6297710|NCT02497001|10019701|FG003|Overall Study|Physician Decision|1
6297711|NCT02497001|10019698|FG000|Overall Study|subjects that were not treated|1
6297712|NCT02497001|10019699|FG001|Overall Study|subjects that were not treated|2
6297713|NCT02497001|10019700|FG002|Overall Study|subjects that were not treated|2
6297714|NCT02497001|10019701|FG003|Overall Study|subjects that were not treated|1
6297715|NCT02497001|10019698|FG000|Overall Study|Major Protocol Deviation|3
6297716|NCT02497001|10019699|FG001|Overall Study|Major Protocol Deviation|4
6297717|NCT02497001|10019700|FG002|Overall Study|Major Protocol Deviation|4
6297718|NCT02497001|10019701|FG003|Overall Study|Major Protocol Deviation|4
6136907|NCT01004614|9766983|FG003|Washout|Withdrawal by Subject|0
6297719|NCT02497001|10019698|FG000|Overall Study|Lack of Efficacy|10
6297720|NCT02497001|10019699|FG001|Overall Study|Lack of Efficacy|16
6297721|NCT02497001|10019700|FG002|Overall Study|Lack of Efficacy|6
6297722|NCT02497001|10019701|FG003|Overall Study|Lack of Efficacy|6
6297723|NCT02497001|10019698|FG000|Overall Study|Protocol Violation|3
6297724|NCT02497001|10019699|FG001|Overall Study|Protocol Violation|1
6297725|NCT02497001|10019700|FG002|Overall Study|Protocol Violation|3
6297726|NCT02497001|10019701|FG003|Overall Study|Protocol Violation|1
6297727|NCT02497287|10019751|FG000|Induction Phase (4 Weeks)|Did Not Met Criteria for OP/MA Phase|84
6297728|NCT02497287|10019751|FG000|Induction Phase (4 Weeks)|Adverse Event|52
6297729|NCT02497287|10019751|FG000|Induction Phase (4 Weeks)|Withdrawal by Subject|22
6297730|NCT02497287|10019751|FG000|Induction Phase (4 Weeks)|Lack of Efficacy|21
6297731|NCT02497287|10019751|FG000|Induction Phase (4 Weeks)|Other|13
6297732|NCT02497287|10019751|FG000|Induction Phase (4 Weeks)|Lost to Follow-up|5
6297733|NCT02497287|10019751|FG000|Induction Phase (4 Weeks)|Protocol Violation|1
6297734|NCT02497287|10019751|FG000|Induction Phase (4 Weeks)|Non-Compliance with Study Drug|1
6297735|NCT02497287|10019751|FG000|Optimization/Maintenance (48 Weeks)|Study Terminated by Sponsor|331
6297736|NCT02497287|10019751|FG000|Optimization/Maintenance (48 Weeks)|Withdrawal by Subject|30
6297737|NCT02497287|10019751|FG000|Optimization/Maintenance (48 Weeks)|Adverse Event|25
6297738|NCT02497287|10019751|FG000|Optimization/Maintenance (48 Weeks)|Lack of Efficacy|25
6297739|NCT02497287|10019751|FG000|Optimization/Maintenance (48 Weeks)|Other|21
6297740|NCT02497287|10019751|FG000|Optimization/Maintenance (48 Weeks)|Lost to Follow-up|10
6297741|NCT02497287|10019751|FG000|Optimization/Maintenance (48 Weeks)|Protocol Violation|3
6297742|NCT02497287|10019751|FG000|Optimization/Maintenance (48 Weeks)|Missed Assessment or Treatment Sessions|3
6297743|NCT02497287|10019751|FG000|Optimization/Maintenance (48 Weeks)|Pregnancy|2
6297744|NCT02497287|10019751|FG000|Optimization/Maintenance (48 Weeks)|Death|2
6297745|NCT02497287|10019751|FG000|Optimization/Maintenance (48 Weeks)|Non-Compliance with Study Drug|1
6297746|NCT02497287|10019751|FG000|Follow-up Phase (4 Week)|PI Decision|12
6297747|NCT02497287|10019751|FG000|Follow-up Phase (4 Week)|Withdrawal by Subject|10
6297748|NCT02497287|10019751|FG000|Follow-up Phase (4 Week)|Lost to Follow-up|5
6297749|NCT02497287|10019751|FG000|Follow-up Phase (4 Week)|Adverse Event|3
6297750|NCT02497287|10019751|FG000|Follow-up Phase (4 Week)|Other|1
6297751|NCT02497391|10019757|FG000|Period 2 (14 Days)|Withdrawal by Subject|1
6297752|NCT02497391|10019758|FG001|Period 2 (14 Days)|Withdrawal by Subject|0
6297753|NCT02497391|10019759|FG002|Period 2 (14 Days)|Withdrawal by Subject|1
6297754|NCT02497391|10019760|FG003|Period 2 (14 Days)|Withdrawal by Subject|0
6297755|NCT02497391|10019761|FG004|Period 2 (14 Days)|Withdrawal by Subject|0
6297756|NCT02497391|10019762|FG005|Period 2 (14 Days)|Withdrawal by Subject|0
6297757|NCT02497391|10019757|FG000|Period 2 (14 Days)|Sponsor Decision|3
6297758|NCT02497391|10019758|FG001|Period 2 (14 Days)|Sponsor Decision|1
6297759|NCT02497391|10019759|FG002|Period 2 (14 Days)|Sponsor Decision|2
6297760|NCT02497391|10019760|FG003|Period 2 (14 Days)|Sponsor Decision|3
6297761|NCT02497391|10019761|FG004|Period 2 (14 Days)|Sponsor Decision|2
6297762|NCT02497391|10019762|FG005|Period 2 (14 Days)|Sponsor Decision|3
6297763|NCT02497391|10019757|FG000|Period 3 (14 Days)|Adverse Event|0
6297764|NCT02497391|10019758|FG001|Period 3 (14 Days)|Adverse Event|1
6297765|NCT02497391|10019759|FG002|Period 3 (14 Days)|Adverse Event|0
6297766|NCT02497391|10019760|FG003|Period 3 (14 Days)|Adverse Event|0
6297767|NCT02497391|10019761|FG004|Period 3 (14 Days)|Adverse Event|0
6297768|NCT02497391|10019762|FG005|Period 3 (14 Days)|Adverse Event|0
6297769|NCT02497391|10019757|FG000|Period 3 (14 Days)|Sponsor Decision|0
6297770|NCT02497391|10019758|FG001|Period 3 (14 Days)|Sponsor Decision|0
6297771|NCT02497391|10019759|FG002|Period 3 (14 Days)|Sponsor Decision|0
6297772|NCT02497391|10019760|FG003|Period 3 (14 Days)|Sponsor Decision|0
6297773|NCT02497391|10019761|FG004|Period 3 (14 Days)|Sponsor Decision|1
6297774|NCT02497391|10019762|FG005|Period 3 (14 Days)|Sponsor Decision|0
6297775|NCT02497391|10019757|FG000|Period 3 (14 Days)|Withdrawal by Subject|0
6297776|NCT02497391|10019758|FG001|Period 3 (14 Days)|Withdrawal by Subject|0
6297777|NCT02497391|10019759|FG002|Period 3 (14 Days)|Withdrawal by Subject|1
6297778|NCT02497391|10019760|FG003|Period 3 (14 Days)|Withdrawal by Subject|0
6297779|NCT02497391|10019761|FG004|Period 3 (14 Days)|Withdrawal by Subject|0
6297780|NCT02497391|10019762|FG005|Period 3 (14 Days)|Withdrawal by Subject|0
6297781|NCT02497404|10019770|FG000|Overall Study|Adverse Event|1
6297782|NCT02497469|10019776|FG000|Overall Study|Randomized but not Treated|0
6297783|NCT02497469|10019777|FG001|Overall Study|Randomized but not Treated|2
6297784|NCT02497469|10019776|FG000|Overall Study|Pretreatment Event/Adverse Event|18
6297785|NCT02497469|10019777|FG001|Overall Study|Pretreatment Event/Adverse Event|16
6297786|NCT02497469|10019776|FG000|Overall Study|Leukopenia or Lymphopenia|1
6297787|NCT02497469|10019777|FG001|Overall Study|Leukopenia or Lymphopenia|0
6297788|NCT02497469|10019776|FG000|Overall Study|Significant Protocol Deviation|4
6297789|NCT02497469|10019777|FG001|Overall Study|Significant Protocol Deviation|5
6297790|NCT02497469|10019776|FG000|Overall Study|Lost to Follow-up|14
6297791|NCT02497469|10019777|FG001|Overall Study|Lost to Follow-up|4
6297792|NCT02497469|10019776|FG000|Overall Study|Voluntary Withdrawal|39
6297793|NCT02497469|10019777|FG001|Overall Study|Voluntary Withdrawal|41
6297794|NCT02497469|10019776|FG000|Overall Study|Pregnancy|1
6297795|NCT02497469|10019777|FG001|Overall Study|Pregnancy|1
6297796|NCT02497469|10019776|FG000|Overall Study|Lack of Efficacy|86
6297797|NCT02497469|10019777|FG001|Overall Study|Lack of Efficacy|40
6297798|NCT02497469|10019776|FG000|Overall Study|Reason not Specified|6
6297799|NCT02497469|10019777|FG001|Overall Study|Reason not Specified|6
6297800|NCT02497755|10019785|FG000|Overall Study|Protocol Violation|1
6297801|NCT02497755|10019786|FG001|Overall Study|Protocol Violation|0
6297802|NCT02497781|10019795|FG000|Overall Study|Withdrawal by Subject|2
6297803|NCT02497781|10019796|FG001|Overall Study|Withdrawal by Subject|0
6297804|NCT02497781|10019795|FG000|Overall Study|Lack of Efficacy|0
6297805|NCT02497781|10019796|FG001|Overall Study|Lack of Efficacy|1
6297806|NCT02497781|10019795|FG000|Overall Study|Randomised but not treated|1
6297807|NCT02497781|10019796|FG001|Overall Study|Randomised but not treated|1
6297808|NCT02497781|10019795|FG000|Overall Study|Lost to Follow-up|1
6297809|NCT02497781|10019796|FG001|Overall Study|Lost to Follow-up|1
6297810|NCT02497976|10019812|FG000|Overall Study|Withdrawal by Subject|2
6297811|NCT02497976|10019813|FG001|Overall Study|Withdrawal by Subject|0
6297812|NCT02497976|10019812|FG000|Overall Study|Moved out of area|0
6297813|NCT02497976|10019813|FG001|Overall Study|Moved out of area|1
6297814|NCT02498067|10019819|FG000|Overall Study|Lost to Follow-up|22
6297815|NCT02498067|10019819|FG000|Overall Study|Did not meet inclusion criteria|11
6297816|NCT02498236|10019833|FG000|Overall Study|Did not show for testing|1
6297817|NCT02498236|10019834|FG001|Overall Study|Did not show for testing|0
6297818|NCT02498236|10019835|FG002|Overall Study|Did not show for testing|0
6297819|NCT02498236|10019836|FG003|Overall Study|Did not show for testing|0
6297820|NCT02498236|10019837|FG004|Overall Study|Did not show for testing|0
6297821|NCT02498236|10019838|FG005|Overall Study|Did not show for testing|0
6297822|NCT02498236|10019839|FG006|Overall Study|Did not show for testing|0
6297823|NCT02498236|10019840|FG007|Overall Study|Did not show for testing|1
6297824|NCT02498236|10019833|FG000|Overall Study|Equipment failure|0
6297825|NCT02498236|10019834|FG001|Overall Study|Equipment failure|0
6297826|NCT02498236|10019835|FG002|Overall Study|Equipment failure|0
6297827|NCT02498236|10019836|FG003|Overall Study|Equipment failure|0
6297828|NCT02498236|10019837|FG004|Overall Study|Equipment failure|0
6297829|NCT02498236|10019838|FG005|Overall Study|Equipment failure|0
6297830|NCT02498236|10019839|FG006|Overall Study|Equipment failure|1
6297831|NCT02498236|10019840|FG007|Overall Study|Equipment failure|0
6297832|NCT02498236|10019833|FG000|Overall Study|Withdrawal by Subject|0
6297833|NCT02498236|10019834|FG001|Overall Study|Withdrawal by Subject|0
6297834|NCT02498236|10019835|FG002|Overall Study|Withdrawal by Subject|0
6297835|NCT02498236|10019836|FG003|Overall Study|Withdrawal by Subject|0
6297836|NCT02498236|10019837|FG004|Overall Study|Withdrawal by Subject|1
6297837|NCT02498236|10019838|FG005|Overall Study|Withdrawal by Subject|0
6297838|NCT02498236|10019839|FG006|Overall Study|Withdrawal by Subject|0
6297839|NCT02498236|10019840|FG007|Overall Study|Withdrawal by Subject|0
6297840|NCT02498418|10019864|FG000|Overall Study|Lack of Efficacy|0
6297841|NCT02498418|10019865|FG001|Overall Study|Lack of Efficacy|0
6297842|NCT02498418|10019866|FG002|Overall Study|Lack of Efficacy|1
6297843|NCT02498418|10019864|FG000|Overall Study|Withdrawal by Subject|2
6297844|NCT02498418|10019865|FG001|Overall Study|Withdrawal by Subject|0
6297845|NCT02498418|10019866|FG002|Overall Study|Withdrawal by Subject|3
6297846|NCT02498418|10019864|FG000|Overall Study|Lost to Follow-up|0
6297847|NCT02498418|10019865|FG001|Overall Study|Lost to Follow-up|1
6297848|NCT02498418|10019866|FG002|Overall Study|Lost to Follow-up|1
6297849|NCT02498418|10019864|FG000|Overall Study|Participant taken prohibited medication|0
6297850|NCT02498418|10019865|FG001|Overall Study|Participant taken prohibited medication|1
6297851|NCT02498418|10019866|FG002|Overall Study|Participant taken prohibited medication|1
6297852|NCT02498652|10019894|FG000|Overall Study|Protocol Violation|0
6297853|NCT02498652|10019895|FG001|Overall Study|Protocol Violation|1
6297854|NCT02498678|10019921|FG000|Overall Study|interference from the surgical team|0
6297855|NCT02498678|10019922|FG001|Overall Study|interference from the surgical team|2
6297856|NCT02498821|10019939|FG000|Overall Study|Screen failure|3
6297857|NCT02498821|10019940|FG001|Overall Study|Screen failure|5
6297858|NCT02499029|10019957|FG000|Overall Study|Lost to Follow-up|2
6297859|NCT02499029|10019958|FG001|Overall Study|Lost to Follow-up|2
6297860|NCT02499029|10019957|FG000|Overall Study|Physician Decision|2
6297861|NCT02499029|10019958|FG001|Overall Study|Physician Decision|1
6297862|NCT02499029|10019957|FG000|Overall Study|Death|1
6297863|NCT02499029|10019958|FG001|Overall Study|Death|0
6297864|NCT02499120|10019970|FG000|Overall Study|Death|45
6297865|NCT02499120|10019971|FG001|Overall Study|Death|42
6297866|NCT02499120|10019970|FG000|Overall Study|Lost to Follow-up|1
6297867|NCT02499120|10019971|FG001|Overall Study|Lost to Follow-up|2
6297868|NCT02499120|10019970|FG000|Overall Study|Participant refused further follow-up|1
6297869|NCT02499120|10019971|FG001|Overall Study|Participant refused further follow-up|0
6297870|NCT02499120|10019970|FG000|Overall Study|Withdrawal by Subject|2
6297871|NCT02499120|10019971|FG001|Overall Study|Withdrawal by Subject|5
6297872|NCT02499120|10019970|FG000|Overall Study|Other|1
6297873|NCT02499120|10019971|FG001|Overall Study|Other|0
6297874|NCT02499120|10019970|FG000|Overall Study|Ongoing on study|15
6297875|NCT02499120|10019971|FG001|Overall Study|Ongoing on study|11
6297876|NCT02499146|10019977|FG000|Overall Study|Lost to Follow-up|1
6297877|NCT02499146|10019977|FG000|Overall Study|Withdrawal by Subject|1
6297878|NCT02499146|10019977|FG000|Overall Study|Other|2
6297879|NCT02499146|10019977|FG000|Overall Study|Ongoing at date of cut-off|9
6297880|NCT02499146|10019977|FG000|Overall Study|Began other treatment/therapy|13
6297881|NCT02499159|10019983|FG000|Randomization|Protocol Violation|1
6297882|NCT02499159|10019984|FG001|Randomization|Protocol Violation|1
6297883|NCT02499159|10019983|FG000|30-Day Follow-Up Phone Call|Withdrawal by Subject|1
6297884|NCT02499159|10019984|FG001|30-Day Follow-Up Phone Call|Withdrawal by Subject|1
6297885|NCT02499159|10019983|FG000|30-Day Follow-Up Phone Call|Lost to Follow-up|3
6297886|NCT02499159|10019984|FG001|30-Day Follow-Up Phone Call|Lost to Follow-up|1
6297887|NCT02499159|10019983|FG000|30-Day Follow-Up Phone Call|Withdrawal due to ineligibility|2
6297888|NCT02499159|10019984|FG001|30-Day Follow-Up Phone Call|Withdrawal due to ineligibility|0
6297889|NCT02499159|10019983|FG000|30-Day Follow-Up Phone Call|Other|1
6297890|NCT02499159|10019984|FG001|30-Day Follow-Up Phone Call|Other|0
6297891|NCT02499172|10019994|FG000|Overall Study|Financial reason|0
6297892|NCT02499172|10019995|FG001|Overall Study|Financial reason|0
6297893|NCT02499172|10019996|FG002|Overall Study|Financial reason|523
6297894|NCT02499172|10019997|FG003|Overall Study|Financial reason|436
6297895|NCT02499172|10019994|FG000|Overall Study|Lost to Follow-up|65
6297896|NCT02499172|10019995|FG001|Overall Study|Lost to Follow-up|64
6297897|NCT02499172|10019996|FG002|Overall Study|Lost to Follow-up|0
6297898|NCT02499172|10019997|FG003|Overall Study|Lost to Follow-up|0
6297899|NCT02499263|10020007|FG000|Overall Study|Lost to Follow-up|9
6297900|NCT02499263|10020007|FG000|Overall Study|Participant's withdrawal of consent|4
6297901|NCT02499263|10020007|FG000|Overall Study|Lack of Efficacy|22
6297902|NCT02499263|10020007|FG000|Overall Study|investigator's judgment|12
6297903|NCT02499263|10020007|FG000|Overall Study|Adverse Events/Serious Adverse Events|11
6297904|NCT02499263|10020007|FG000|Overall Study|Participant's decision|3
6297905|NCT02499263|10020007|FG000|Overall Study|Pregnancy|1
6297906|NCT02499406|10020015|FG000|Overall Study|missed 3 treatment sessions|4
6297907|NCT02499575|10020038|FG000|Overall Study|Protocol Violation|0
6297908|NCT02499575|10020039|FG001|Overall Study|Protocol Violation|1
6297909|NCT02499770|10020051|FG000|Overall Study|Death|17
6297910|NCT02499770|10020052|FG001|Overall Study|Death|56
6297911|NCT02499770|10020051|FG000|Overall Study|Study completion|1
6297912|NCT02499770|10020052|FG001|Overall Study|Study completion|10
6297913|NCT02499770|10020051|FG000|Overall Study|Withdrawal by Subject|0
6297914|NCT02499770|10020052|FG001|Overall Study|Withdrawal by Subject|7
6297915|NCT02499770|10020051|FG000|Overall Study|Lost to Follow-up|0
6297916|NCT02499770|10020052|FG001|Overall Study|Lost to Follow-up|2
6297917|NCT02499770|10020051|FG000|Overall Study|Subject declined further treatment|1
6297918|NCT02499770|10020052|FG001|Overall Study|Subject declined further treatment|0
6297919|NCT02499770|10020051|FG000|Overall Study|Withdrawn by PI for compassionate reason|0
6297920|NCT02499770|10020052|FG001|Overall Study|Withdrawn by PI for compassionate reason|1
6297921|NCT02499770|10020051|FG000|Overall Study|Randomized but not enrolled|0
5981804|NCT00703014|9570541|FG000|Fetuses/Infants Follow Up Trial P05712|Did not complete follow up in P05712|0
5981805|NCT00703014|9570542|FG001|Fetuses/Infants Follow Up Trial P05712|Did not complete follow up in P05712|0
5981806|NCT00703014|9570543|FG002|Fetuses/Infants Follow Up Trial P05712|Did not complete follow up in P05712|47
5981807|NCT00703014|9570544|FG003|Fetuses/Infants Follow Up Trial P05712|Did not complete follow up in P05712|42
5981808|NCT00702845|9570556|FG000|Overall Study|No/too few/bad quality oocytes retrieved|2
5981809|NCT00702845|9570557|FG001|Overall Study|No/too few/bad quality oocytes retrieved|2
5981810|NCT00702845|9570556|FG000|Overall Study|Too high ovarian response|5
5981811|NCT00702845|9570557|FG001|Overall Study|Too high ovarian response|1
5981812|NCT00702845|9570556|FG000|Overall Study|Risk of ovarian hyperstimulation synd.|1
5981813|NCT00702845|9570557|FG001|Overall Study|Risk of ovarian hyperstimulation synd.|0
5981814|NCT00702845|9570556|FG000|Overall Study|Insufficient ovarian response|1
5981815|NCT00702845|9570557|FG001|Overall Study|Insufficient ovarian response|0
5981816|NCT00702845|9570556|FG000|Overall Study|No/too few/bad quality embryos retrieved|7
5981817|NCT00702845|9570557|FG001|Overall Study|No/too few/bad quality embryos retrieved|1
5981818|NCT00702845|9570556|FG000|Overall Study|No or abnormal fertilization|4
5981819|NCT00702845|9570557|FG001|Overall Study|No or abnormal fertilization|2
5981820|NCT00702845|9570556|FG000|Overall Study|Patient's decision|2
5981821|NCT00702845|9570557|FG001|Overall Study|Patient's decision|1
5981822|NCT00702845|9570556|FG000|Overall Study|Not randomized|0
5981823|NCT00702845|9570557|FG001|Overall Study|Not randomized|1
5981824|NCT00702520|9570592|FG000|Base Study P05788 - Assigned Treatment|Spontaneous pregnancy|0
5981825|NCT00702520|9570593|FG001|Base Study P05788 - Assigned Treatment|Spontaneous pregnancy|1
5981826|NCT00702520|9570594|FG002|Base Study P05788 - Assigned Treatment|Spontaneous pregnancy|0
5981827|NCT00702520|9570595|FG003|Base Study P05788 - Assigned Treatment|Spontaneous pregnancy|0
5981828|NCT00702520|9570592|FG000|Base Study P05788 - Embryo Transfer|No embryo transfer|3
5981829|NCT00702520|9570593|FG001|Base Study P05788 - Embryo Transfer|No embryo transfer|6
5981830|NCT00702520|9570594|FG002|Base Study P05788 - Embryo Transfer|No embryo transfer|0
5981831|NCT00702520|9570595|FG003|Base Study P05788 - Embryo Transfer|No embryo transfer|0
5981832|NCT00702520|9570592|FG000|Base Study P05788 - Follow-Up|No ongoing pregnancy at 10 weeks|15
5981833|NCT00702520|9570593|FG001|Base Study P05788 - Follow-Up|No ongoing pregnancy at 10 weeks|10
5981834|NCT00702520|9570594|FG002|Base Study P05788 - Follow-Up|No ongoing pregnancy at 10 weeks|0
5981835|NCT00702520|9570595|FG003|Base Study P05788 - Follow-Up|No ongoing pregnancy at 10 weeks|0
6297922|NCT02499770|10020052|FG001|Overall Study|Randomized but not enrolled|1
6297923|NCT02499783|10020066|FG000|DB Period/Placebo-Controlled: Weeks 0-4|Adverse Event|2
6297924|NCT02499783|10020067|FG001|DB Period/Placebo-Controlled: Weeks 0-4|Adverse Event|4
6297925|NCT02499783|10020068|FG002|DB Period/Placebo-Controlled: Weeks 0-4|Adverse Event|0
6297926|NCT02499783|10020066|FG000|DB Period/Placebo-Controlled: Weeks 0-4|Withdrew Consent|1
6297927|NCT02499783|10020067|FG001|DB Period/Placebo-Controlled: Weeks 0-4|Withdrew Consent|0
6297928|NCT02499783|10020068|FG002|DB Period/Placebo-Controlled: Weeks 0-4|Withdrew Consent|0
6297929|NCT02499783|10020066|FG000|DB Period/Placebo-Controlled: Weeks 0-4|Other|1
6297930|NCT02499783|10020067|FG001|DB Period/Placebo-Controlled: Weeks 0-4|Other|1
6297931|NCT02499783|10020068|FG002|DB Period/Placebo-Controlled: Weeks 0-4|Other|0
6297932|NCT02499783|10020066|FG000|DB Period: Weeks 0-8|Adverse Event|8
6297933|NCT02499783|10020067|FG001|DB Period: Weeks 0-8|Adverse Event|6
6297934|NCT02499783|10020068|FG002|DB Period: Weeks 0-8|Adverse Event|0
6297935|NCT02499783|10020066|FG000|DB Period: Weeks 0-8|Withdrew Consent|1
6297936|NCT02499783|10020067|FG001|DB Period: Weeks 0-8|Withdrew Consent|0
6297937|NCT02499783|10020068|FG002|DB Period: Weeks 0-8|Withdrew Consent|0
6297938|NCT02499783|10020066|FG000|DB Period: Weeks 0-8|Other|1
6297939|NCT02499783|10020067|FG001|DB Period: Weeks 0-8|Other|1
6297940|NCT02499783|10020068|FG002|DB Period: Weeks 0-8|Other|0
6297941|NCT02499783|10020066|FG000|Open Label Period: Weeks 8 to 26|Adverse Event|0
6297942|NCT02499783|10020067|FG001|Open Label Period: Weeks 8 to 26|Adverse Event|0
6297943|NCT02499783|10020068|FG002|Open Label Period: Weeks 8 to 26|Adverse Event|16
6297944|NCT02499783|10020066|FG000|Open Label Period: Weeks 8 to 26|Withdrew Consent|0
6297945|NCT02499783|10020067|FG001|Open Label Period: Weeks 8 to 26|Withdrew Consent|0
6297946|NCT02499783|10020068|FG002|Open Label Period: Weeks 8 to 26|Withdrew Consent|2
6297947|NCT02499783|10020066|FG000|Open Label Period: Weeks 8 to 26|Lack of Efficacy|0
6297948|NCT02499783|10020067|FG001|Open Label Period: Weeks 8 to 26|Lack of Efficacy|0
6297949|NCT02499783|10020068|FG002|Open Label Period: Weeks 8 to 26|Lack of Efficacy|9
6297950|NCT02499783|10020066|FG000|Open Label Period: Weeks 8 to 26|Subject Noncompliance|0
6297951|NCT02499783|10020067|FG001|Open Label Period: Weeks 8 to 26|Subject Noncompliance|0
6297952|NCT02499783|10020068|FG002|Open Label Period: Weeks 8 to 26|Subject Noncompliance|2
6297953|NCT02499952|10020078|FG000|Overall Study|Lost to Follow-up|1
6297954|NCT02499952|10020078|FG000|Overall Study|Death|9
6297955|NCT02500043|10020084|FG000|Overall Study|Randomized, but not Treated|2
6297956|NCT02500043|10020085|FG001|Overall Study|Randomized, but not Treated|2
6297957|NCT02500043|10020084|FG000|Overall Study|Ongoing at Date of Cut-Off|19
6297958|NCT02500043|10020085|FG001|Overall Study|Ongoing at Date of Cut-Off|3
6297959|NCT02500043|10020084|FG000|Overall Study|Adverse Event|33
6297960|NCT02500043|10020085|FG001|Overall Study|Adverse Event|11
6297961|NCT02500043|10020084|FG000|Overall Study|Clinical Progression|54
6297962|NCT02500043|10020085|FG001|Overall Study|Clinical Progression|35
6297963|NCT02500043|10020084|FG000|Overall Study|Radiological Progression|192
6297964|NCT02500043|10020085|FG001|Overall Study|Radiological Progression|110
6297965|NCT02500043|10020084|FG000|Overall Study|Physician's Decision|11
6297966|NCT02500043|10020085|FG001|Overall Study|Physician's Decision|3
6297967|NCT02500043|10020084|FG000|Overall Study|Withdrawal by Subject|14
6297968|NCT02500043|10020085|FG001|Overall Study|Withdrawal by Subject|4
6297969|NCT02500043|10020084|FG000|Overall Study|Death|11
6297970|NCT02500043|10020085|FG001|Overall Study|Death|2
6297971|NCT02500043|10020084|FG000|Overall Study|Protocol Deviation|1
6297972|NCT02500043|10020085|FG001|Overall Study|Protocol Deviation|0
6297973|NCT02500056|10020093|FG000|Overall Study|Lost to Follow-up|3
6297974|NCT02500056|10020094|FG001|Overall Study|Lost to Follow-up|7
6297975|NCT02500056|10020093|FG000|Overall Study|Recurrence|1
6297976|NCT02500056|10020094|FG001|Overall Study|Recurrence|0
6297977|NCT02500056|10020093|FG000|Overall Study|Death|3
6297978|NCT02500056|10020094|FG001|Overall Study|Death|1
6297979|NCT02500537|10020109|FG000|Overall Study|Death|2
6297980|NCT02500537|10020110|FG001|Overall Study|Death|0
6297981|NCT02500537|10020109|FG000|Overall Study|Lost to Follow-up|0
6297982|NCT02500537|10020110|FG001|Overall Study|Lost to Follow-up|1
6297983|NCT02500537|10020109|FG000|Overall Study|Withdrawal by Subject|1
6297984|NCT02500537|10020110|FG001|Overall Study|Withdrawal by Subject|0
6297985|NCT02500550|10020117|FG000|Overall Study|Death|7
6297986|NCT02500641|10020145|FG000|Overall Study|Adverse Event|0
6297987|NCT02500641|10020146|FG001|Overall Study|Adverse Event|2
6297988|NCT02500641|10020145|FG000|Overall Study|Withdrawal by Subject|4
6297989|NCT02500641|10020146|FG001|Overall Study|Withdrawal by Subject|5
6297990|NCT02500641|10020145|FG000|Overall Study|Unable to follow study procedures|3
6297991|NCT02500641|10020146|FG001|Overall Study|Unable to follow study procedures|2
6297992|NCT02500641|10020145|FG000|Overall Study|Protocol Violation|1
6297993|NCT02500641|10020146|FG001|Overall Study|Protocol Violation|2
6297994|NCT02500641|10020145|FG000|Overall Study|Lost to Follow-up|1
6297995|NCT02500641|10020146|FG001|Overall Study|Lost to Follow-up|0
6297996|NCT02500641|10020145|FG000|Overall Study|Sponsor decision|1
6297997|NCT02500641|10020146|FG001|Overall Study|Sponsor decision|0
6297998|NCT02500641|10020145|FG000|Overall Study|Non compliance to study drug|0
6297999|NCT02500641|10020146|FG001|Overall Study|Non compliance to study drug|1
6298000|NCT02500706|10020155|FG000|Overall Study|Adverse Event|0
6298001|NCT02500706|10020156|FG001|Overall Study|Adverse Event|0
6298002|NCT02500706|10020157|FG002|Overall Study|Adverse Event|1
6298003|NCT02500706|10020155|FG000|Overall Study|Lost to Follow-up|0
6298004|NCT02500706|10020156|FG001|Overall Study|Lost to Follow-up|1
6298005|NCT02500706|10020157|FG002|Overall Study|Lost to Follow-up|1
6298006|NCT02500706|10020155|FG000|Overall Study|Withdrawal by Subject|4
6298007|NCT02500706|10020156|FG001|Overall Study|Withdrawal by Subject|6
6298008|NCT02500706|10020157|FG002|Overall Study|Withdrawal by Subject|4
6298009|NCT02500706|10020155|FG000|Overall Study|Unclassified|0
6298010|NCT02500706|10020156|FG001|Overall Study|Unclassified|0
6298011|NCT02500706|10020157|FG002|Overall Study|Unclassified|1
6298012|NCT02500719|10020167|FG000|Overall Study|Lost to Follow-up|2
6298013|NCT02500719|10020168|FG001|Overall Study|Lost to Follow-up|3
6298014|NCT02500719|10020167|FG000|Overall Study|Trauma history|1
6298015|NCT02500719|10020168|FG001|Overall Study|Trauma history|0
6298016|NCT02500719|10020167|FG000|Overall Study|MRI data found to be unusable during analysis|0
6298017|NCT02500719|10020168|FG001|Overall Study|MRI data found to be unusable during analysis|1
6298018|NCT02500719|10020167|FG000|Overall Study|Did not meet criteria for PTSD|0
6298019|NCT02500719|10020168|FG001|Overall Study|Did not meet criteria for PTSD|1
6298020|NCT02500719|10020167|FG000|Overall Study|Claustrophobia|0
6298021|NCT02500719|10020168|FG001|Overall Study|Claustrophobia|1
6298022|NCT02500719|10020167|FG000|Overall Study|History of head trauma|0
6298023|NCT02500719|10020168|FG001|Overall Study|History of head trauma|1
6298024|NCT02500732|10020176|FG000|Overall Study|Physician Decision|0
6298025|NCT02500732|10020177|FG001|Overall Study|Physician Decision|1
6298026|NCT02500758|10020185|FG000|First Intervention (2 Minutes)|Withdrawal by Subject|0
6298027|NCT02500758|10020186|FG001|First Intervention (2 Minutes)|Withdrawal by Subject|1
6298028|NCT02500758|10020185|FG000|Washout (1 Week)|Lost to Follow-up|2
6298029|NCT02500758|10020186|FG001|Washout (1 Week)|Lost to Follow-up|2
6298030|NCT02500758|10020185|FG000|Second Intervention (2 Minutes)|Withdrawal by Subject|2
6298031|NCT02500758|10020186|FG001|Second Intervention (2 Minutes)|Withdrawal by Subject|0
6298032|NCT02500758|10020185|FG000|Second Intervention (2 Minutes)|Lost to Follow-up|0
6298033|NCT02500758|10020186|FG001|Second Intervention (2 Minutes)|Lost to Follow-up|1
6298034|NCT02500758|10020185|FG000|Second Intervention (2 Minutes)|Protocol Violation|1
6298035|NCT02500758|10020186|FG001|Second Intervention (2 Minutes)|Protocol Violation|1
6298036|NCT02500979|10020208|FG000|Period 1|Hyperglycemia|1
6298037|NCT02500979|10020209|FG001|Period 1|Hyperglycemia|0
6298038|NCT02500979|10020208|FG000|Period 1|Severe non-compliance to protocol|0
6298039|NCT02500979|10020209|FG001|Period 1|Severe non-compliance to protocol|1
6298040|NCT02500979|10020208|FG000|Period 1|Adverse Event|1
6298041|NCT02500979|10020209|FG001|Period 1|Adverse Event|0
6298042|NCT02500979|10020208|FG000|Period 1|Subject decision|2
6298043|NCT02500979|10020209|FG001|Period 1|Subject decision|0
6298044|NCT02500979|10020208|FG000|Period 2|Change in risk|1
6298045|NCT02500979|10020209|FG001|Period 2|Change in risk|0
6298046|NCT02501161|10020227|FG000|Overall Study|Adverse Event|2
6298047|NCT02501161|10020228|FG001|Overall Study|Adverse Event|6
6298048|NCT02501161|10020227|FG000|Overall Study|Lost to Follow-up|7
6298049|NCT02501161|10020228|FG001|Overall Study|Lost to Follow-up|4
6298050|NCT02501161|10020227|FG000|Overall Study|Withdrawal by Subject|10
6298051|NCT02501161|10020228|FG001|Overall Study|Withdrawal by Subject|15
6298052|NCT02501161|10020227|FG000|Overall Study|Other|3
6298053|NCT02501161|10020228|FG001|Overall Study|Other|0
6298054|NCT02501473|10020258|FG000|Overall Study|Study Terminated|2
6298055|NCT02501473|10020259|FG001|Overall Study|Study Terminated|3
6298056|NCT02501473|10020260|FG002|Overall Study|Study Terminated|7
6298057|NCT02501473|10020261|FG003|Overall Study|Study Terminated|9
6298058|NCT02501473|10020262|FG004|Overall Study|Study Terminated|2
6298059|NCT02501473|10020263|FG005|Overall Study|Study Terminated|10
6298060|NCT02501473|10020264|FG006|Overall Study|Study Terminated|1
6298061|NCT02501473|10020265|FG007|Overall Study|Study Terminated|0
6298062|NCT02501473|10020258|FG000|Overall Study|Withdrawal by Subject|0
6298063|NCT02501473|10020259|FG001|Overall Study|Withdrawal by Subject|0
6298064|NCT02501473|10020260|FG002|Overall Study|Withdrawal by Subject|3
6298065|NCT02501473|10020261|FG003|Overall Study|Withdrawal by Subject|3
6298066|NCT02501473|10020262|FG004|Overall Study|Withdrawal by Subject|2
6298067|NCT02501473|10020263|FG005|Overall Study|Withdrawal by Subject|2
6298068|NCT02501473|10020264|FG006|Overall Study|Withdrawal by Subject|0
6298069|NCT02501473|10020265|FG007|Overall Study|Withdrawal by Subject|0
6298070|NCT02501473|10020258|FG000|Overall Study|Death|0
6298071|NCT02501473|10020259|FG001|Overall Study|Death|0
6298072|NCT02501473|10020260|FG002|Overall Study|Death|1
6298073|NCT02501473|10020261|FG003|Overall Study|Death|1
6298074|NCT02501473|10020262|FG004|Overall Study|Death|0
6298075|NCT02501473|10020263|FG005|Overall Study|Death|1
6298076|NCT02501473|10020264|FG006|Overall Study|Death|0
6298077|NCT02501473|10020265|FG007|Overall Study|Death|0
6298078|NCT02501473|10020258|FG000|Overall Study|Lost to Follow-up|1
6298079|NCT02501473|10020259|FG001|Overall Study|Lost to Follow-up|0
6298080|NCT02501473|10020260|FG002|Overall Study|Lost to Follow-up|1
6298081|NCT02501473|10020261|FG003|Overall Study|Lost to Follow-up|0
6298082|NCT02501473|10020262|FG004|Overall Study|Lost to Follow-up|0
6298083|NCT02501473|10020263|FG005|Overall Study|Lost to Follow-up|1
6298084|NCT02501473|10020264|FG006|Overall Study|Lost to Follow-up|0
6298085|NCT02501473|10020265|FG007|Overall Study|Lost to Follow-up|0
6298086|NCT02501473|10020258|FG000|Overall Study|Reason not specified|0
6298087|NCT02501473|10020259|FG001|Overall Study|Reason not specified|0
6298088|NCT02501473|10020260|FG002|Overall Study|Reason not specified|1
6298089|NCT02501473|10020261|FG003|Overall Study|Reason not specified|1
6298090|NCT02501473|10020262|FG004|Overall Study|Reason not specified|0
6298091|NCT02501473|10020263|FG005|Overall Study|Reason not specified|0
6298092|NCT02501473|10020264|FG006|Overall Study|Reason not specified|0
6298093|NCT02501473|10020265|FG007|Overall Study|Reason not specified|0
6298094|NCT02501629|10020299|FG000|Overall Study|Death|0
6298095|NCT02501629|10020300|FG001|Overall Study|Death|1
6298096|NCT02501629|10020299|FG000|Overall Study|Withdrawn from study by sponsor|1
6298097|NCT02501629|10020300|FG001|Overall Study|Withdrawn from study by sponsor|0
6298098|NCT02501629|10020299|FG000|Overall Study|Early termination by sponsor|1
6298099|NCT02501629|10020300|FG001|Overall Study|Early termination by sponsor|0
6298100|NCT02501629|10020299|FG000|Overall Study|Withdrawal by Subject|3
6298101|NCT02501629|10020300|FG001|Overall Study|Withdrawal by Subject|5
6298102|NCT02501629|10020299|FG000|Overall Study|Subject did not return to site|0
6298103|NCT02501629|10020300|FG001|Overall Study|Subject did not return to site|1
6298104|NCT02501642|10020308|FG000|Overall Study|Lost to Follow-up|7
6298105|NCT02501642|10020309|FG001|Overall Study|Lost to Follow-up|11
6298106|NCT02501811|10020319|FG000|Overall Study|Death|1
6298107|NCT02501811|10020320|FG001|Overall Study|Death|3
6298108|NCT02501811|10020321|FG002|Overall Study|Death|2
6298109|NCT02501811|10020322|FG003|Overall Study|Death|3
6298110|NCT02501811|10020319|FG000|Overall Study|Withdrawal by Subject|3
6298111|NCT02501811|10020320|FG001|Overall Study|Withdrawal by Subject|3
6298112|NCT02501811|10020321|FG002|Overall Study|Withdrawal by Subject|2
6298113|NCT02501811|10020322|FG003|Overall Study|Withdrawal by Subject|3
6298114|NCT02501811|10020319|FG000|Overall Study|Lost to Follow-up|0
6298115|NCT02501811|10020320|FG001|Overall Study|Lost to Follow-up|0
6298116|NCT02501811|10020321|FG002|Overall Study|Lost to Follow-up|2
6298117|NCT02501811|10020322|FG003|Overall Study|Lost to Follow-up|1
5981836|NCT00697255|9570634|FG000|Stage 1a|Insufficient ovarian response|1
5981837|NCT00697255|9570635|FG001|Stage 1a|Insufficient ovarian response|0
5981838|NCT00697255|9570634|FG000|Stage 1a|Multifollicular growth|1
5981839|NCT00697255|9570635|FG001|Stage 1a|Multifollicular growth|0
5981840|NCT00697255|9570634|FG000|Stage 1a|Not growing of dominant follicle|1
5981841|NCT00697255|9570635|FG001|Stage 1a|Not growing of dominant follicle|0
5981842|NCT00697255|9570634|FG000|Stage 1b|Not growing of dominant follicle|0
5981843|NCT00697255|9570635|FG001|Stage 1b|Not growing of dominant follicle|1
5981844|NCT00697255|9570634|FG000|Stage 1b|Insufficient ovarian response|0
5981845|NCT00697255|9570635|FG001|Stage 1b|Insufficient ovarian response|1
5981846|NCT00696878|9570641|FG000|Overall Study|Adverse Event|8
6298118|NCT02501902|10020340|FG000|Overall Study|Subject Refused Further Follow-up|0
6298119|NCT02501902|10020341|FG001|Overall Study|Subject Refused Further Follow-up|0
6298120|NCT02501902|10020342|FG002|Overall Study|Subject Refused Further Follow-up|0
6298121|NCT02501902|10020343|FG003|Overall Study|Subject Refused Further Follow-up|0
6298122|NCT02501902|10020344|FG004|Overall Study|Subject Refused Further Follow-up|0
6298123|NCT02501902|10020345|FG005|Overall Study|Subject Refused Further Follow-up|0
6298124|NCT02501902|10020346|FG006|Overall Study|Subject Refused Further Follow-up|0
6298125|NCT02501902|10020347|FG007|Overall Study|Subject Refused Further Follow-up|1
6298126|NCT02501902|10020340|FG000|Overall Study|Study Terminated by Sponsor|0
6298127|NCT02501902|10020341|FG001|Overall Study|Study Terminated by Sponsor|3
6298128|NCT02501902|10020342|FG002|Overall Study|Study Terminated by Sponsor|0
6298129|NCT02501902|10020343|FG003|Overall Study|Study Terminated by Sponsor|1
6298130|NCT02501902|10020344|FG004|Overall Study|Study Terminated by Sponsor|1
6298131|NCT02501902|10020345|FG005|Overall Study|Study Terminated by Sponsor|0
6298132|NCT02501902|10020346|FG006|Overall Study|Study Terminated by Sponsor|2
6298133|NCT02501902|10020347|FG007|Overall Study|Study Terminated by Sponsor|4
6298134|NCT02501902|10020340|FG000|Overall Study|Death|3
6298135|NCT02501902|10020341|FG001|Overall Study|Death|4
6298136|NCT02501902|10020342|FG002|Overall Study|Death|4
6298137|NCT02501902|10020343|FG003|Overall Study|Death|10
6298138|NCT02501902|10020344|FG004|Overall Study|Death|10
6298139|NCT02501902|10020345|FG005|Overall Study|Death|11
6298140|NCT02501902|10020346|FG006|Overall Study|Death|7
6298141|NCT02501902|10020347|FG007|Overall Study|Death|15
6298142|NCT02501928|10020373|FG000|Overall Study|Withdrawal By Parent/Guardian|0
6298143|NCT02501928|10020374|FG001|Overall Study|Withdrawal By Parent/Guardian|0
6298144|NCT02501928|10020375|FG002|Overall Study|Withdrawal By Parent/Guardian|0
6298145|NCT02501928|10020376|FG003|Overall Study|Withdrawal By Parent/Guardian|0
6298146|NCT02501928|10020377|FG004|Overall Study|Withdrawal By Parent/Guardian|1
6298147|NCT02501928|10020378|FG005|Overall Study|Withdrawal By Parent/Guardian|0
6298148|NCT02502097|10020403|FG000|Period 1|Adverse Event|0
6298149|NCT02502097|10020404|FG001|Period 1|Adverse Event|0
6298150|NCT02502097|10020405|FG002|Period 1|Adverse Event|1
6298151|NCT02502097|10020406|FG003|Period 1|Adverse Event|0
6298152|NCT02502097|10020403|FG000|Wash Out Period|Adverse Event|0
6298153|NCT02502097|10020404|FG001|Wash Out Period|Adverse Event|1
6298154|NCT02502097|10020405|FG002|Wash Out Period|Adverse Event|1
6298155|NCT02502097|10020406|FG003|Wash Out Period|Adverse Event|1
6298156|NCT02502097|10020403|FG000|Period 2|Adverse Event|0
6298157|NCT02502097|10020404|FG001|Period 2|Adverse Event|0
6298158|NCT02502097|10020405|FG002|Period 2|Adverse Event|1
6298159|NCT02502097|10020406|FG003|Period 2|Adverse Event|0
6298160|NCT02502149|10020413|FG000|Intermediate|Discontinued prematurely|1
6298161|NCT02502149|10020414|FG001|Intermediate|Discontinued prematurely|0
6298162|NCT02502149|10020415|FG002|Intermediate|Discontinued prematurely|0
6298163|NCT02502149|10020416|FG003|Intermediate|Discontinued prematurely|0
6298164|NCT02502149|10020417|FG004|Intermediate|Discontinued prematurely|0
6298165|NCT02502526|10020459|FG000|Overall Study|Lost to Follow-up|2
6298166|NCT02502526|10020460|FG001|Overall Study|Lost to Follow-up|2
6298167|NCT02502526|10020461|FG002|Overall Study|Lost to Follow-up|3
6298168|NCT02502526|10020459|FG000|Overall Study|Withdrawal by Subject|0
6298169|NCT02502526|10020460|FG001|Overall Study|Withdrawal by Subject|1
6298170|NCT02502526|10020461|FG002|Overall Study|Withdrawal by Subject|1
6298171|NCT02502526|10020459|FG000|Overall Study|Disqualified due to cataract grading|0
6298172|NCT02502526|10020460|FG001|Overall Study|Disqualified due to cataract grading|0
6298173|NCT02502526|10020461|FG002|Overall Study|Disqualified due to cataract grading|1
6298174|NCT02502526|10020459|FG000|Overall Study|Enrollment suspension|4
6298175|NCT02502526|10020460|FG001|Overall Study|Enrollment suspension|1
6298176|NCT02502526|10020461|FG002|Overall Study|Enrollment suspension|1
6298177|NCT02502734|10020470|FG000|Double-blind Treatment Period 1|Adverse Event|1
6298178|NCT02502734|10020471|FG001|Double-blind Treatment Period 1|Adverse Event|0
6298179|NCT02502734|10020470|FG000|Washout Period|Adverse Event|1
6298180|NCT02502734|10020471|FG001|Washout Period|Adverse Event|0
6298181|NCT02502864|10020479|FG000|Overall Study|Withdrawal by Subject|1
6298182|NCT02503085|10020483|FG000|Period 2: Washout (3 to 7 Days)|Adverse Event|1
6298183|NCT02503085|10020484|FG001|Period 2: Washout (3 to 7 Days)|Adverse Event|0
6298184|NCT02503085|10020485|FG002|Period 2: Washout (3 to 7 Days)|Adverse Event|1
6298185|NCT02503085|10020486|FG003|Period 2: Washout (3 to 7 Days)|Adverse Event|0
6298186|NCT02503202|10020498|FG000|Base Study: Up to Month 6|Death|1
6298187|NCT02503202|10020499|FG001|Base Study: Up to Month 6|Death|1
6298188|NCT02503202|10020500|FG002|Base Study: Up to Month 6|Death|0
6298189|NCT02503202|10020501|FG003|Base Study: Up to Month 6|Death|0
6298190|NCT02503202|10020502|FG004|Base Study: Up to Month 6|Death|0
6298191|NCT02503202|10020498|FG000|Base Study: Up to Month 6|Lost to Follow-up|11
6298192|NCT02503202|10020499|FG001|Base Study: Up to Month 6|Lost to Follow-up|8
6298193|NCT02503202|10020500|FG002|Base Study: Up to Month 6|Lost to Follow-up|10
6298194|NCT02503202|10020501|FG003|Base Study: Up to Month 6|Lost to Follow-up|5
6298195|NCT02503202|10020502|FG004|Base Study: Up to Month 6|Lost to Follow-up|1
6298196|NCT02503202|10020498|FG000|Base Study: Up to Month 6|Physician Decision|0
6298197|NCT02503202|10020499|FG001|Base Study: Up to Month 6|Physician Decision|0
6298198|NCT02503202|10020500|FG002|Base Study: Up to Month 6|Physician Decision|0
6298199|NCT02503202|10020501|FG003|Base Study: Up to Month 6|Physician Decision|0
6298200|NCT02503202|10020502|FG004|Base Study: Up to Month 6|Physician Decision|1
6298201|NCT02503202|10020498|FG000|Base Study: Up to Month 6|Withdrawal by Subject|6
6298202|NCT02503202|10020499|FG001|Base Study: Up to Month 6|Withdrawal by Subject|3
6298203|NCT02503202|10020500|FG002|Base Study: Up to Month 6|Withdrawal by Subject|4
6298204|NCT02503202|10020501|FG003|Base Study: Up to Month 6|Withdrawal by Subject|4
6298205|NCT02503202|10020502|FG004|Base Study: Up to Month 6|Withdrawal by Subject|1
6298206|NCT02503202|10020498|FG000|Base Study: Up to Month 6|Randomized not vaccinated|0
6298207|NCT02503202|10020499|FG001|Base Study: Up to Month 6|Randomized not vaccinated|0
6298208|NCT02503202|10020500|FG002|Base Study: Up to Month 6|Randomized not vaccinated|1
6298209|NCT02503202|10020501|FG003|Base Study: Up to Month 6|Randomized not vaccinated|2
6298210|NCT02503202|10020502|FG004|Base Study: Up to Month 6|Randomized not vaccinated|0
6298211|NCT02503202|10020498|FG000|Extension: Month 6 to 24|Protocol Violation|0
6298212|NCT02503202|10020499|FG001|Extension: Month 6 to 24|Protocol Violation|0
6298213|NCT02503202|10020500|FG002|Extension: Month 6 to 24|Protocol Violation|0
6298214|NCT02503202|10020501|FG003|Extension: Month 6 to 24|Protocol Violation|1
6298215|NCT02503202|10020502|FG004|Extension: Month 6 to 24|Protocol Violation|0
6298216|NCT02503202|10020498|FG000|Extension: Month 6 to 24|Death|1
6298217|NCT02503202|10020499|FG001|Extension: Month 6 to 24|Death|0
6298218|NCT02503202|10020500|FG002|Extension: Month 6 to 24|Death|0
6298219|NCT02503202|10020501|FG003|Extension: Month 6 to 24|Death|0
6298220|NCT02503202|10020502|FG004|Extension: Month 6 to 24|Death|0
6298221|NCT02503202|10020498|FG000|Extension: Month 6 to 24|Lost to Follow-up|4
6298222|NCT02503202|10020499|FG001|Extension: Month 6 to 24|Lost to Follow-up|8
6298223|NCT02503202|10020500|FG002|Extension: Month 6 to 24|Lost to Follow-up|6
6298224|NCT02503202|10020501|FG003|Extension: Month 6 to 24|Lost to Follow-up|10
6298225|NCT02503202|10020502|FG004|Extension: Month 6 to 24|Lost to Follow-up|1
6298226|NCT02503202|10020498|FG000|Extension: Month 6 to 24|Physician Decision|1
6298227|NCT02503202|10020499|FG001|Extension: Month 6 to 24|Physician Decision|0
6298228|NCT02503202|10020500|FG002|Extension: Month 6 to 24|Physician Decision|1
6298229|NCT02503202|10020501|FG003|Extension: Month 6 to 24|Physician Decision|3
6298230|NCT02503202|10020502|FG004|Extension: Month 6 to 24|Physician Decision|0
6298231|NCT02503202|10020498|FG000|Extension: Month 6 to 24|Withdrawal by Subject|5
6298232|NCT02503202|10020499|FG001|Extension: Month 6 to 24|Withdrawal by Subject|8
6298233|NCT02503202|10020500|FG002|Extension: Month 6 to 24|Withdrawal by Subject|2
6298234|NCT02503202|10020501|FG003|Extension: Month 6 to 24|Withdrawal by Subject|4
6298235|NCT02503202|10020502|FG004|Extension: Month 6 to 24|Withdrawal by Subject|0
6298236|NCT02503215|10020514|FG000|Overall Study|Unable to wear compression stockings|1
6298237|NCT02503215|10020514|FG000|Overall Study|Unable to use positive airway pressure|2
6298238|NCT02503332|10020531|FG000|Overall Study|Adverse Event|17
6298239|NCT02503332|10020532|FG001|Overall Study|Adverse Event|5
6298240|NCT02503332|10020533|FG002|Overall Study|Adverse Event|3
6298241|NCT02503332|10020534|FG003|Overall Study|Adverse Event|1
6298242|NCT02503332|10020531|FG000|Overall Study|Investigator's Decision|5
6298243|NCT02503332|10020532|FG001|Overall Study|Investigator's Decision|1
6298244|NCT02503332|10020533|FG002|Overall Study|Investigator's Decision|0
6298245|NCT02503332|10020534|FG003|Overall Study|Investigator's Decision|0
6298246|NCT02503332|10020531|FG000|Overall Study|Sponsor's Decision|1
6298247|NCT02503332|10020532|FG001|Overall Study|Sponsor's Decision|0
6298248|NCT02503332|10020533|FG002|Overall Study|Sponsor's Decision|0
6298249|NCT02503332|10020534|FG003|Overall Study|Sponsor's Decision|1
6298250|NCT02503332|10020531|FG000|Overall Study|Subject Request|6
6298251|NCT02503332|10020532|FG001|Overall Study|Subject Request|5
6298252|NCT02503332|10020533|FG002|Overall Study|Subject Request|2
6298253|NCT02503332|10020534|FG003|Overall Study|Subject Request|1
6298254|NCT02503332|10020531|FG000|Overall Study|Death|0
6298255|NCT02503332|10020532|FG001|Overall Study|Death|2
6298256|NCT02503332|10020533|FG002|Overall Study|Death|2
6298257|NCT02503332|10020534|FG003|Overall Study|Death|0
6298258|NCT02503332|10020531|FG000|Overall Study|Other|5
6298259|NCT02503332|10020532|FG001|Overall Study|Other|6
6298260|NCT02503332|10020533|FG002|Overall Study|Other|1
6298261|NCT02503332|10020534|FG003|Overall Study|Other|1
6298262|NCT02503501|10020564|FG000|Overall Study|Physician Decision|1
6298263|NCT02503501|10020565|FG001|Overall Study|Physician Decision|0
6298264|NCT02503501|10020564|FG000|Overall Study|Protocol Violation|0
6298265|NCT02503501|10020565|FG001|Overall Study|Protocol Violation|1
6298266|NCT02503501|10020564|FG000|Overall Study|Withdrawal by Subject|0
6298267|NCT02503501|10020565|FG001|Overall Study|Withdrawal by Subject|2
6298268|NCT02503540|10020571|FG000|Overall Study|Death|2
6298269|NCT02503540|10020571|FG000|Overall Study|Withdrawal by Subject|1
6298270|NCT02503787|10020585|FG000|Enrollment|Withdrawal by Subject|6
6298271|NCT02503787|10020585|FG000|Enrollment|Inclusion/exclusion criteria not met|4
6298272|NCT02503787|10020585|FG000|Enrollment|Physician Decision|2
6298273|NCT02503787|10020585|FG000|Enrollment|Insurance issue|2
6298274|NCT02503787|10020585|FG000|Enrollment|Lost to Follow-up|1
6298275|NCT02503787|10020585|FG000|Enrollment|Study closure|1
6298276|NCT02503787|10020585|FG000|Enrollment|Adverse Event|1
6298277|NCT02503787|10020585|FG000|Enrollment|Protocol Violation|1
6298278|NCT02503787|10020585|FG000|Enrollment|Inability to implant system|1
6298279|NCT02503787|10020585|FG000|Enrollment|Unable to be programmed|1
6298280|NCT02503787|10020585|FG000|Device Trial (HD Programming Trial)|Lack of Efficacy|6
6298281|NCT02503787|10020585|FG000|Device Trial (HD Programming Trial)|Withdrawal by Subject|1
6298282|NCT02503787|10020585|FG000|Successful Trial (≥50% Pain Relief)|Withdrawal by Subject|3
6298283|NCT02503787|10020585|FG000|Successful Trial (≥50% Pain Relief)|Physician Decision|2
6298284|NCT02503787|10020585|FG000|Implant to 3 Month Endpoint|Adverse Event|2
6298285|NCT02503787|10020585|FG000|Implant to 3 Month Endpoint|Withdrawal by Subject|1
6298286|NCT02503865|10020609|FG000|Overall Study|Moved out of area|1
6298287|NCT02503865|10020610|FG001|Overall Study|Moved out of area|8
6298288|NCT02503865|10020611|FG002|Overall Study|Moved out of area|0
6298289|NCT02503865|10020609|FG000|Overall Study|Refused treatment|4
6298290|NCT02503865|10020610|FG001|Overall Study|Refused treatment|39
6298291|NCT02503865|10020611|FG002|Overall Study|Refused treatment|2
6298292|NCT02504216|10020631|FG000|Overall Study|Lost to Follow-up|3
6298293|NCT02504216|10020632|FG001|Overall Study|Lost to Follow-up|3
6298294|NCT02504216|10020631|FG000|Overall Study|Withdrawal by Subject|8
6298295|NCT02504216|10020632|FG001|Overall Study|Withdrawal by Subject|12
6298296|NCT02504268|10020641|FG000|Overall Study|Adverse Event|18
6298297|NCT02504268|10020642|FG001|Overall Study|Adverse Event|8
6298298|NCT02504268|10020643|FG002|Overall Study|Adverse Event|14
6298299|NCT02504268|10020644|FG003|Overall Study|Adverse Event|0
6298300|NCT02504268|10020645|FG004|Overall Study|Adverse Event|0
6298301|NCT02504268|10020646|FG005|Overall Study|Adverse Event|0
6298302|NCT02504268|10020647|FG006|Overall Study|Adverse Event|0
6298303|NCT02504268|10020648|FG007|Overall Study|Adverse Event|0
6298304|NCT02504268|10020649|FG008|Overall Study|Adverse Event|0
6298305|NCT02504268|10020641|FG000|Overall Study|Withdrawal of Consent|11
6298306|NCT02504268|10020642|FG001|Overall Study|Withdrawal of Consent|10
6298307|NCT02504268|10020643|FG002|Overall Study|Withdrawal of Consent|3
6298308|NCT02504268|10020644|FG003|Overall Study|Withdrawal of Consent|0
6298309|NCT02504268|10020645|FG004|Overall Study|Withdrawal of Consent|0
6298310|NCT02504268|10020646|FG005|Overall Study|Withdrawal of Consent|0
6298311|NCT02504268|10020647|FG006|Overall Study|Withdrawal of Consent|0
6298312|NCT02504268|10020648|FG007|Overall Study|Withdrawal of Consent|0
5981847|NCT00696878|9570641|FG000|Overall Study|Withdrawal by Subject|87
5981848|NCT00696878|9570641|FG000|Overall Study|Stop Treat Cycle 3 not for Adverse Event|18
5981849|NCT00696878|9570641|FG000|Overall Study|Pregnant prior to Treat Cycle 3|304
5981850|NCT00696878|9570641|FG000|Overall Study|Trial stopped|32
5981851|NCT00696878|9570641|FG000|Overall Study|Other reason (not specified)|55
5981852|NCT00696800|9570647|FG000|Overall Study|Adverse Event|16
5981853|NCT00696800|9570648|FG001|Overall Study|Adverse Event|3
5981854|NCT00696800|9570647|FG000|Overall Study|Insufficient compliance with medication|2
5981855|NCT00696800|9570648|FG001|Overall Study|Insufficient compliance with medication|1
5981856|NCT00696800|9570647|FG000|Overall Study|Insufficient ovarian response on Day 8|4
5981857|NCT00696800|9570648|FG001|Overall Study|Insufficient ovarian response on Day 8|1
5981858|NCT00696800|9570647|FG000|Overall Study|Insufficient ovarian response|4
5981859|NCT00696800|9570648|FG001|Overall Study|Insufficient ovarian response|1
5981860|NCT00696800|9570647|FG000|Overall Study|Risk Ovarian Hyperstimulation Syndrome|8
5981861|NCT00696800|9570648|FG001|Overall Study|Risk Ovarian Hyperstimulation Syndrome|2
5981862|NCT00696800|9570647|FG000|Overall Study|Too high ovarian response|6
5981863|NCT00696800|9570648|FG001|Overall Study|Too high ovarian response|1
5981864|NCT00696800|9570647|FG000|Overall Study|No/too few/bad quality oocytes|4
5981865|NCT00696800|9570648|FG001|Overall Study|No/too few/bad quality oocytes|3
5981866|NCT00696800|9570647|FG000|Overall Study|No/abnormal fertilization|11
5981867|NCT00696800|9570648|FG001|Overall Study|No/abnormal fertilization|13
5981868|NCT00696800|9570647|FG000|Overall Study|No/too few/bad quality embryos|24
5981869|NCT00696800|9570648|FG001|Overall Study|No/too few/bad quality embryos|18
5981870|NCT00696800|9570647|FG000|Overall Study|Other Reasons|5
5981871|NCT00696800|9570648|FG001|Overall Study|Other Reasons|3
5981872|NCT00696800|9570647|FG000|Overall Study|Not treated|1
5981873|NCT00696800|9570648|FG001|Overall Study|Not treated|2
5981874|NCT00616967|9570656|FG000|Overall Study|Withdrawal by Subject|0
5981875|NCT00616967|9570657|FG001|Overall Study|Withdrawal by Subject|0
5981876|NCT00616967|9570658|FG002|Overall Study|Withdrawal by Subject|1
5981877|NCT00461032|9570678|FG000|Overall Study|Adverse Event|5
5981878|NCT00461032|9570679|FG001|Overall Study|Adverse Event|6
5981879|NCT00461032|9570678|FG000|Overall Study|Lack of Efficacy|5
5981880|NCT00461032|9570679|FG001|Overall Study|Lack of Efficacy|1
5981881|NCT00461032|9570678|FG000|Overall Study|Lost to Follow-up|7
5981882|NCT00461032|9570679|FG001|Overall Study|Lost to Follow-up|12
5981883|NCT00461032|9570678|FG000|Overall Study|Protocol Violation|4
5981884|NCT00461032|9570679|FG001|Overall Study|Protocol Violation|4
5981885|NCT00461032|9570678|FG000|Overall Study|Withdrawal by Subject|7
5981886|NCT00461032|9570679|FG001|Overall Study|Withdrawal by Subject|15
5981887|NCT00461032|9570678|FG000|Overall Study|Patient Moved or Relocated|2
5981888|NCT00461032|9570679|FG001|Overall Study|Patient Moved or Relocated|1
5981889|NCT00461032|9570678|FG000|Overall Study|Other|7
5981890|NCT00461032|9570679|FG001|Overall Study|Other|5
5981891|NCT00289874|9570700|FG000|Overall Study|Adverse Event|1
5981892|NCT00289874|9570701|FG001|Overall Study|Adverse Event|5
5981893|NCT00289874|9570700|FG000|Overall Study|Lost to Follow-up|1
5981894|NCT00289874|9570701|FG001|Overall Study|Lost to Follow-up|1
5981895|NCT00289874|9570700|FG000|Overall Study|Protocol Violation|3
5981896|NCT00289874|9570701|FG001|Overall Study|Protocol Violation|2
5981897|NCT00289874|9570700|FG000|Overall Study|Did not meet eligibility|1
5981898|NCT00289874|9570701|FG001|Overall Study|Did not meet eligibility|0
6298313|NCT02504268|10020649|FG008|Overall Study|Withdrawal of Consent|0
6298314|NCT02504268|10020641|FG000|Overall Study|Pregnancy|2
6298315|NCT02504268|10020642|FG001|Overall Study|Pregnancy|0
6298316|NCT02504268|10020643|FG002|Overall Study|Pregnancy|0
6298317|NCT02504268|10020644|FG003|Overall Study|Pregnancy|0
6298318|NCT02504268|10020645|FG004|Overall Study|Pregnancy|0
6298319|NCT02504268|10020646|FG005|Overall Study|Pregnancy|0
6298320|NCT02504268|10020647|FG006|Overall Study|Pregnancy|0
6298321|NCT02504268|10020648|FG007|Overall Study|Pregnancy|0
6298322|NCT02504268|10020649|FG008|Overall Study|Pregnancy|0
6298323|NCT02504268|10020641|FG000|Overall Study|Lost to Follow-up|3
6298324|NCT02504268|10020642|FG001|Overall Study|Lost to Follow-up|6
6298325|NCT02504268|10020643|FG002|Overall Study|Lost to Follow-up|4
6298326|NCT02504268|10020644|FG003|Overall Study|Lost to Follow-up|0
6298327|NCT02504268|10020645|FG004|Overall Study|Lost to Follow-up|0
6298328|NCT02504268|10020646|FG005|Overall Study|Lost to Follow-up|0
6298329|NCT02504268|10020647|FG006|Overall Study|Lost to Follow-up|0
6298330|NCT02504268|10020648|FG007|Overall Study|Lost to Follow-up|0
6298331|NCT02504268|10020649|FG008|Overall Study|Lost to Follow-up|0
6298332|NCT02504268|10020641|FG000|Overall Study|Death|1
6298333|NCT02504268|10020642|FG001|Overall Study|Death|1
6298334|NCT02504268|10020643|FG002|Overall Study|Death|0
6298335|NCT02504268|10020644|FG003|Overall Study|Death|0
6298336|NCT02504268|10020645|FG004|Overall Study|Death|0
6298337|NCT02504268|10020646|FG005|Overall Study|Death|0
6298338|NCT02504268|10020647|FG006|Overall Study|Death|0
6298339|NCT02504268|10020648|FG007|Overall Study|Death|0
6298340|NCT02504268|10020649|FG008|Overall Study|Death|0
6298341|NCT02504268|10020641|FG000|Overall Study|Subject Request to Discontinue|11
6298342|NCT02504268|10020642|FG001|Overall Study|Subject Request to Discontinue|3
6298343|NCT02504268|10020643|FG002|Overall Study|Subject Request to Discontinue|6
6298344|NCT02504268|10020644|FG003|Overall Study|Subject Request to Discontinue|0
6298345|NCT02504268|10020645|FG004|Overall Study|Subject Request to Discontinue|0
6298346|NCT02504268|10020646|FG005|Overall Study|Subject Request to Discontinue|0
6298347|NCT02504268|10020647|FG006|Overall Study|Subject Request to Discontinue|0
6298348|NCT02504268|10020648|FG007|Overall Study|Subject Request to Discontinue|0
6298349|NCT02504268|10020649|FG008|Overall Study|Subject Request to Discontinue|0
6298350|NCT02504268|10020641|FG000|Overall Study|No Longer Meets Study Criteria|2
6298351|NCT02504268|10020642|FG001|Overall Study|No Longer Meets Study Criteria|3
6298352|NCT02504268|10020643|FG002|Overall Study|No Longer Meets Study Criteria|0
6298353|NCT02504268|10020644|FG003|Overall Study|No Longer Meets Study Criteria|0
6298354|NCT02504268|10020645|FG004|Overall Study|No Longer Meets Study Criteria|0
6298355|NCT02504268|10020646|FG005|Overall Study|No Longer Meets Study Criteria|0
6298356|NCT02504268|10020647|FG006|Overall Study|No Longer Meets Study Criteria|0
6298357|NCT02504268|10020648|FG007|Overall Study|No Longer Meets Study Criteria|0
6298358|NCT02504268|10020649|FG008|Overall Study|No Longer Meets Study Criteria|0
6298359|NCT02504268|10020641|FG000|Overall Study|Lack of Efficacy|11
6298360|NCT02504268|10020642|FG001|Overall Study|Lack of Efficacy|35
6298361|NCT02504268|10020643|FG002|Overall Study|Lack of Efficacy|9
6298362|NCT02504268|10020644|FG003|Overall Study|Lack of Efficacy|0
6298363|NCT02504268|10020645|FG004|Overall Study|Lack of Efficacy|0
6298364|NCT02504268|10020646|FG005|Overall Study|Lack of Efficacy|0
6298365|NCT02504268|10020647|FG006|Overall Study|Lack of Efficacy|0
6298366|NCT02504268|10020648|FG007|Overall Study|Lack of Efficacy|0
6298367|NCT02504268|10020649|FG008|Overall Study|Lack of Efficacy|0
6298368|NCT02504268|10020641|FG000|Overall Study|Poor/Non-Compliance|3
6298369|NCT02504268|10020642|FG001|Overall Study|Poor/Non-Compliance|2
6298370|NCT02504268|10020643|FG002|Overall Study|Poor/Non-Compliance|3
6298371|NCT02504268|10020644|FG003|Overall Study|Poor/Non-Compliance|0
6298372|NCT02504268|10020645|FG004|Overall Study|Poor/Non-Compliance|0
6298373|NCT02504268|10020646|FG005|Overall Study|Poor/Non-Compliance|0
6298374|NCT02504268|10020647|FG006|Overall Study|Poor/Non-Compliance|0
6298375|NCT02504268|10020648|FG007|Overall Study|Poor/Non-Compliance|0
6298376|NCT02504268|10020649|FG008|Overall Study|Poor/Non-Compliance|0
6298377|NCT02504268|10020641|FG000|Overall Study|Not Disclosed|1
6298378|NCT02504268|10020642|FG001|Overall Study|Not Disclosed|0
6298379|NCT02504268|10020643|FG002|Overall Study|Not Disclosed|2
6298380|NCT02504268|10020644|FG003|Overall Study|Not Disclosed|0
6298381|NCT02504268|10020645|FG004|Overall Study|Not Disclosed|0
6298382|NCT02504268|10020646|FG005|Overall Study|Not Disclosed|0
6298383|NCT02504268|10020647|FG006|Overall Study|Not Disclosed|0
6298384|NCT02504268|10020648|FG007|Overall Study|Not Disclosed|0
6298385|NCT02504268|10020649|FG008|Overall Study|Not Disclosed|0
6298386|NCT02504294|10020671|FG000|Overall Study|Adverse Event|15
6298387|NCT02504294|10020672|FG001|Overall Study|Adverse Event|12
6298388|NCT02504294|10020671|FG000|Overall Study|Withdrawal by Subject|7
6298389|NCT02504294|10020672|FG001|Overall Study|Withdrawal by Subject|1
6298390|NCT02504294|10020671|FG000|Overall Study|Protocol Violation|27
6298391|NCT02504294|10020672|FG001|Overall Study|Protocol Violation|26
6298392|NCT02504294|10020671|FG000|Overall Study|Physician Decision|1
6298393|NCT02504294|10020672|FG001|Overall Study|Physician Decision|2
6298394|NCT02504294|10020671|FG000|Overall Study|Lost to Follow-up|6
6298395|NCT02504294|10020672|FG001|Overall Study|Lost to Follow-up|7
6298396|NCT02504320|10020682|FG000|Treatment Period 1|Positive Drug Screen|0
6298397|NCT02504320|10020683|FG001|Treatment Period 1|Positive Drug Screen|0
6298398|NCT02504320|10020684|FG002|Treatment Period 1|Positive Drug Screen|1
6298399|NCT02504320|10020685|FG003|Treatment Period 1|Positive Drug Screen|0
6298400|NCT02504320|10020682|FG000|Treatment Period 2|Positive Drug Screen|0
6298401|NCT02504320|10020683|FG001|Treatment Period 2|Positive Drug Screen|1
6298402|NCT02504320|10020684|FG002|Treatment Period 2|Positive Drug Screen|0
6298403|NCT02504320|10020685|FG003|Treatment Period 2|Positive Drug Screen|0
6298404|NCT02504320|10020682|FG000|Treatment Period 3|Positive Drug Screen|0
6298405|NCT02504320|10020683|FG001|Treatment Period 3|Positive Drug Screen|0
6298406|NCT02504320|10020684|FG002|Treatment Period 3|Positive Drug Screen|0
6298407|NCT02504320|10020685|FG003|Treatment Period 3|Positive Drug Screen|1
6298408|NCT02504320|10020682|FG000|Treatment Period 3|Adverse Event|0
6298409|NCT02504320|10020683|FG001|Treatment Period 3|Adverse Event|0
6298410|NCT02504320|10020684|FG002|Treatment Period 3|Adverse Event|1
6298411|NCT02504320|10020685|FG003|Treatment Period 3|Adverse Event|0
6298412|NCT02504424|10020695|FG000|Overall Study|Withdrawal by Subject|2
6298413|NCT02504502|10020702|FG000|Routine Care vs. Enhanced Report|Lost to Follow-up|4
6298414|NCT02504502|10020703|FG001|Routine Care vs. Enhanced Report|Lost to Follow-up|7
6298415|NCT02504502|10020702|FG000|Crossover to Enhanced Report|Lost to Follow-up|5
6298416|NCT02504502|10020703|FG001|Crossover to Enhanced Report|Lost to Follow-up|0
6298417|NCT02504541|10020709|FG000|Overall Study|Adverse Event|4
6298418|NCT02504541|10020709|FG000|Overall Study|Withdrawal by Subject|4
6298419|NCT02504541|10020709|FG000|Overall Study|Lost to Follow-up|1
6298420|NCT02504541|10020709|FG000|Overall Study|Met Stopping Criteria|1
6298421|NCT02504541|10020709|FG000|Overall Study|Protocol Violation|2
6298422|NCT02504541|10020709|FG000|Overall Study|Termination by Sponsor|1
6298423|NCT02504541|10020709|FG000|Overall Study|Other|2
6298424|NCT02504541|10020709|FG000|Overall Study|Multiple|5
6298425|NCT02504671|10020742|FG000|Overall Study|Withdrawal by Subject|1
6298426|NCT02504671|10020743|FG001|Overall Study|Withdrawal by Subject|5
6298427|NCT02504671|10020744|FG002|Overall Study|Withdrawal by Subject|4
6298428|NCT02504671|10020745|FG003|Overall Study|Withdrawal by Subject|4
6298429|NCT02504671|10020746|FG004|Overall Study|Withdrawal by Subject|5
6298430|NCT02504671|10020747|FG005|Overall Study|Withdrawal by Subject|3
6298431|NCT02504671|10020742|FG000|Overall Study|Lack of Efficacy|1
6298432|NCT02504671|10020743|FG001|Overall Study|Lack of Efficacy|3
6298433|NCT02504671|10020744|FG002|Overall Study|Lack of Efficacy|1
6298434|NCT02504671|10020745|FG003|Overall Study|Lack of Efficacy|0
6298435|NCT02504671|10020746|FG004|Overall Study|Lack of Efficacy|4
6298436|NCT02504671|10020747|FG005|Overall Study|Lack of Efficacy|4
6298437|NCT02504671|10020742|FG000|Overall Study|Adverse Event|1
6298438|NCT02504671|10020743|FG001|Overall Study|Adverse Event|1
6298439|NCT02504671|10020744|FG002|Overall Study|Adverse Event|0
6298440|NCT02504671|10020745|FG003|Overall Study|Adverse Event|1
6298441|NCT02504671|10020746|FG004|Overall Study|Adverse Event|0
6298442|NCT02504671|10020747|FG005|Overall Study|Adverse Event|2
6298443|NCT02504671|10020742|FG000|Overall Study|Protocol Violation|2
6298444|NCT02504671|10020743|FG001|Overall Study|Protocol Violation|1
6298445|NCT02504671|10020744|FG002|Overall Study|Protocol Violation|0
6298446|NCT02504671|10020745|FG003|Overall Study|Protocol Violation|0
6298447|NCT02504671|10020746|FG004|Overall Study|Protocol Violation|0
6298448|NCT02504671|10020747|FG005|Overall Study|Protocol Violation|1
6298449|NCT02504671|10020742|FG000|Overall Study|Lost to Follow-up|0
6298450|NCT02504671|10020743|FG001|Overall Study|Lost to Follow-up|0
6298451|NCT02504671|10020744|FG002|Overall Study|Lost to Follow-up|2
6298452|NCT02504671|10020745|FG003|Overall Study|Lost to Follow-up|0
6298453|NCT02504671|10020746|FG004|Overall Study|Lost to Follow-up|0
6298454|NCT02504671|10020747|FG005|Overall Study|Lost to Follow-up|1
6298455|NCT02504671|10020742|FG000|Overall Study|Protocol defined stopping criteria|7
6298456|NCT02504671|10020743|FG001|Overall Study|Protocol defined stopping criteria|4
6298457|NCT02504671|10020744|FG002|Overall Study|Protocol defined stopping criteria|3
6298458|NCT02504671|10020745|FG003|Overall Study|Protocol defined stopping criteria|5
6298459|NCT02504671|10020746|FG004|Overall Study|Protocol defined stopping criteria|3
6298460|NCT02504671|10020747|FG005|Overall Study|Protocol defined stopping criteria|3
6298461|NCT02504827|10020779|FG000|Overall Study|Could not produce sputum|1
6298462|NCT02504892|10020783|FG000|Overall Study|Adverse event-pneumonitis|2
6298463|NCT02505217|10020798|FG000|Overall Study|Withdrawal by Subject|1
6298464|NCT02505217|10020799|FG001|Overall Study|Withdrawal by Subject|2
6298465|NCT02505334|10020811|FG000|Main Treatment Period|Adverse Event|3
6298466|NCT02505334|10020812|FG001|Main Treatment Period|Adverse Event|3
6298467|NCT02505334|10020811|FG000|Main Treatment Period|Lack of Efficacy|7
6298468|NCT02505334|10020812|FG001|Main Treatment Period|Lack of Efficacy|17
6298469|NCT02505334|10020811|FG000|Main Treatment Period|Protocol Violation|0
6298470|NCT02505334|10020812|FG001|Main Treatment Period|Protocol Violation|1
6298471|NCT02505334|10020811|FG000|Main Treatment Period|Withdrawal by Subject|1
6298472|NCT02505334|10020812|FG001|Main Treatment Period|Withdrawal by Subject|8
6298473|NCT02505334|10020811|FG000|Main Treatment Period|Unclassified|4
6298474|NCT02505334|10020812|FG001|Main Treatment Period|Unclassified|10
6298475|NCT02505334|10020811|FG000|Extension Treatment Period|Adverse Event|5
6298476|NCT02505334|10020812|FG001|Extension Treatment Period|Adverse Event|0
6298477|NCT02505334|10020811|FG000|Extension Treatment Period|Lack of Efficacy|4
6298478|NCT02505334|10020812|FG001|Extension Treatment Period|Lack of Efficacy|0
6298479|NCT02505334|10020811|FG000|Extension Treatment Period|Withdrawal by Subject|6
6298480|NCT02505334|10020812|FG001|Extension Treatment Period|Withdrawal by Subject|0
6298481|NCT02505334|10020811|FG000|Extension Treatment Period|Unclassified|3
6298482|NCT02505334|10020812|FG001|Extension Treatment Period|Unclassified|0
6298483|NCT02505542|10020818|FG000|Part A: Open-Label Period|Adverse Event|31
6298484|NCT02505542|10020819|FG001|Part A: Open-Label Period|Adverse Event|0
6298485|NCT02505542|10020820|FG002|Part A: Open-Label Period|Adverse Event|0
6298486|NCT02505542|10020821|FG003|Part A: Open-Label Period|Adverse Event|0
6298487|NCT02505542|10020818|FG000|Part A: Open-Label Period|Lack of Efficacy|5
6298488|NCT02505542|10020819|FG001|Part A: Open-Label Period|Lack of Efficacy|0
6298489|NCT02505542|10020820|FG002|Part A: Open-Label Period|Lack of Efficacy|0
6298490|NCT02505542|10020821|FG003|Part A: Open-Label Period|Lack of Efficacy|0
6298491|NCT02505542|10020818|FG000|Part A: Open-Label Period|Protocol Violation|1
6298492|NCT02505542|10020819|FG001|Part A: Open-Label Period|Protocol Violation|0
6298493|NCT02505542|10020820|FG002|Part A: Open-Label Period|Protocol Violation|0
6298494|NCT02505542|10020821|FG003|Part A: Open-Label Period|Protocol Violation|0
6298495|NCT02505542|10020818|FG000|Part A: Open-Label Period|Lost to Follow-up|5
6298496|NCT02505542|10020819|FG001|Part A: Open-Label Period|Lost to Follow-up|0
6298497|NCT02505542|10020820|FG002|Part A: Open-Label Period|Lost to Follow-up|0
6298498|NCT02505542|10020821|FG003|Part A: Open-Label Period|Lost to Follow-up|0
6298499|NCT02505542|10020818|FG000|Part A: Open-Label Period|Withdrawal by Subject|27
6298500|NCT02505542|10020819|FG001|Part A: Open-Label Period|Withdrawal by Subject|0
6298501|NCT02505542|10020820|FG002|Part A: Open-Label Period|Withdrawal by Subject|0
6298502|NCT02505542|10020821|FG003|Part A: Open-Label Period|Withdrawal by Subject|0
6298503|NCT02505542|10020818|FG000|Part A: Open-Label Period|New medical history available|1
6298504|NCT02505542|10020819|FG001|Part A: Open-Label Period|New medical history available|0
6298505|NCT02505542|10020820|FG002|Part A: Open-Label Period|New medical history available|0
6298506|NCT02505542|10020821|FG003|Part A: Open-Label Period|New medical history available|0
6298507|NCT02505542|10020818|FG000|Part A: Open-Label Period|Participant did not attend week 48 visit|1
6298508|NCT02505542|10020819|FG001|Part A: Open-Label Period|Participant did not attend week 48 visit|0
6298509|NCT02505542|10020820|FG002|Part A: Open-Label Period|Participant did not attend week 48 visit|0
6298510|NCT02505542|10020821|FG003|Part A: Open-Label Period|Participant did not attend week 48 visit|0
6298511|NCT02505542|10020818|FG000|Part A: Open-Label Period|Pregnancy|2
6298512|NCT02505542|10020819|FG001|Part A: Open-Label Period|Pregnancy|0
6298513|NCT02505542|10020820|FG002|Part A: Open-Label Period|Pregnancy|0
6298514|NCT02505542|10020821|FG003|Part A: Open-Label Period|Pregnancy|0
6298515|NCT02505542|10020818|FG000|Part A: Open-Label Period|Sponsor directive|1
6298516|NCT02505542|10020819|FG001|Part A: Open-Label Period|Sponsor directive|0
6298517|NCT02505542|10020820|FG002|Part A: Open-Label Period|Sponsor directive|0
6298518|NCT02505542|10020821|FG003|Part A: Open-Label Period|Sponsor directive|0
6298519|NCT02505542|10020818|FG000|Part A: Open-Label Period|Medical monitor decision|1
6298520|NCT02505542|10020819|FG001|Part A: Open-Label Period|Medical monitor decision|0
6298521|NCT02505542|10020820|FG002|Part A: Open-Label Period|Medical monitor decision|0
6298522|NCT02505542|10020821|FG003|Part A: Open-Label Period|Medical monitor decision|0
6298523|NCT02505542|10020818|FG000|Part A: Open-Label Period|Screening failure (detected too late)|1
6298524|NCT02505542|10020819|FG001|Part A: Open-Label Period|Screening failure (detected too late)|0
6298525|NCT02505542|10020820|FG002|Part A: Open-Label Period|Screening failure (detected too late)|0
6298526|NCT02505542|10020821|FG003|Part A: Open-Label Period|Screening failure (detected too late)|0
6298527|NCT02505542|10020818|FG000|Part A: Open-Label Period|Non-compliance|1
6298528|NCT02505542|10020819|FG001|Part A: Open-Label Period|Non-compliance|0
6298529|NCT02505542|10020820|FG002|Part A: Open-Label Period|Non-compliance|0
6298530|NCT02505542|10020821|FG003|Part A: Open-Label Period|Non-compliance|0
6298531|NCT02505542|10020818|FG000|Completed Part A, Did Not Enter Part B|Lack of Efficacy|2
6298532|NCT02505542|10020819|FG001|Completed Part A, Did Not Enter Part B|Lack of Efficacy|0
6298533|NCT02505542|10020820|FG002|Completed Part A, Did Not Enter Part B|Lack of Efficacy|0
6298534|NCT02505542|10020821|FG003|Completed Part A, Did Not Enter Part B|Lack of Efficacy|0
6298535|NCT02505542|10020818|FG000|Completed Part A, Did Not Enter Part B|Withdrawal by Subject|3
6298536|NCT02505542|10020819|FG001|Completed Part A, Did Not Enter Part B|Withdrawal by Subject|0
6298537|NCT02505542|10020820|FG002|Completed Part A, Did Not Enter Part B|Withdrawal by Subject|0
6298538|NCT02505542|10020821|FG003|Completed Part A, Did Not Enter Part B|Withdrawal by Subject|0
6298539|NCT02505542|10020818|FG000|Completed Part A, Did Not Enter Part B|The subject was not eligible for Part B|341
6298540|NCT02505542|10020819|FG001|Completed Part A, Did Not Enter Part B|The subject was not eligible for Part B|0
6298541|NCT02505542|10020820|FG002|Completed Part A, Did Not Enter Part B|The subject was not eligible for Part B|0
6298542|NCT02505542|10020821|FG003|Completed Part A, Did Not Enter Part B|The subject was not eligible for Part B|0
6298543|NCT02505542|10020818|FG000|Part B: Double-Blind Period|Adverse Event|0
6298544|NCT02505542|10020819|FG001|Part B: Double-Blind Period|Adverse Event|0
6298545|NCT02505542|10020820|FG002|Part B: Double-Blind Period|Adverse Event|1
6298546|NCT02505542|10020821|FG003|Part B: Double-Blind Period|Adverse Event|3
6298547|NCT02505542|10020818|FG000|Part B: Double-Blind Period|Lost to Follow-up|0
6298548|NCT02505542|10020819|FG001|Part B: Double-Blind Period|Lost to Follow-up|0
6298549|NCT02505542|10020820|FG002|Part B: Double-Blind Period|Lost to Follow-up|0
6298550|NCT02505542|10020821|FG003|Part B: Double-Blind Period|Lost to Follow-up|1
6298551|NCT02505542|10020818|FG000|Part B: Double-Blind Period|Withdrawal by Subject|0
6298552|NCT02505542|10020819|FG001|Part B: Double-Blind Period|Withdrawal by Subject|8
6298553|NCT02505542|10020820|FG002|Part B: Double-Blind Period|Withdrawal by Subject|7
6298554|NCT02505542|10020821|FG003|Part B: Double-Blind Period|Withdrawal by Subject|2
6298555|NCT02505542|10020818|FG000|Part B: Double-Blind Period|Planning pregnancy|0
6298556|NCT02505542|10020819|FG001|Part B: Double-Blind Period|Planning pregnancy|1
6298557|NCT02505542|10020820|FG002|Part B: Double-Blind Period|Planning pregnancy|0
6298558|NCT02505542|10020821|FG003|Part B: Double-Blind Period|Planning pregnancy|0
6298559|NCT02505542|10020818|FG000|Part B: Double-Blind Period|Week 94 missed|0
6298560|NCT02505542|10020819|FG001|Part B: Double-Blind Period|Week 94 missed|0
6298561|NCT02505542|10020820|FG002|Part B: Double-Blind Period|Week 94 missed|1
6298562|NCT02505542|10020821|FG003|Part B: Double-Blind Period|Week 94 missed|0
6298563|NCT02505542|10020818|FG000|Part B: Double-Blind Period|Patient was moved from the country|0
6298564|NCT02505542|10020819|FG001|Part B: Double-Blind Period|Patient was moved from the country|0
6298565|NCT02505542|10020820|FG002|Part B: Double-Blind Period|Patient was moved from the country|0
6298566|NCT02505542|10020821|FG003|Part B: Double-Blind Period|Patient was moved from the country|1
6298567|NCT02505542|10020818|FG000|Part B: Double-Blind Period|Lack of Efficacy|0
6298568|NCT02505542|10020819|FG001|Part B: Double-Blind Period|Lack of Efficacy|1
6298569|NCT02505542|10020820|FG002|Part B: Double-Blind Period|Lack of Efficacy|0
6298570|NCT02505542|10020821|FG003|Part B: Double-Blind Period|Lack of Efficacy|0
6298571|NCT02505542|10020818|FG000|Part B: Double-Blind Period|Miscalculation|0
6298572|NCT02505542|10020819|FG001|Part B: Double-Blind Period|Miscalculation|1
6298573|NCT02505542|10020820|FG002|Part B: Double-Blind Period|Miscalculation|0
6298574|NCT02505542|10020821|FG003|Part B: Double-Blind Period|Miscalculation|0
6298575|NCT02505542|10020818|FG000|Part B: Double-Blind Period|Subject did not complete all visits|0
6298576|NCT02505542|10020819|FG001|Part B: Double-Blind Period|Subject did not complete all visits|1
6298577|NCT02505542|10020820|FG002|Part B: Double-Blind Period|Subject did not complete all visits|0
6298578|NCT02505542|10020821|FG003|Part B: Double-Blind Period|Subject did not complete all visits|0
6298579|NCT02505867|10020849|FG000|Overall Study|Lack of Efficacy|6
6298580|NCT02505867|10020850|FG001|Overall Study|Lack of Efficacy|6
6298581|NCT02505945|10020867|FG000|Overall Study|Withdrawal by Subject|13
6298582|NCT02505945|10020868|FG001|Overall Study|Withdrawal by Subject|2
6298583|NCT02505945|10020867|FG000|Overall Study|Adverse Event|1
6298584|NCT02505945|10020868|FG001|Overall Study|Adverse Event|0
6298585|NCT02505945|10020867|FG000|Overall Study|Physician Decision|2
6298586|NCT02505945|10020868|FG001|Overall Study|Physician Decision|1
6298587|NCT02505945|10020867|FG000|Overall Study|Lost to Follow-up|6
6298588|NCT02505945|10020868|FG001|Overall Study|Lost to Follow-up|1
6298589|NCT02506036|10020876|FG000|First Intervention (4-6 Weeks)|Death|1
6298590|NCT02506036|10020877|FG001|First Intervention (4-6 Weeks)|Death|0
6298591|NCT02506036|10020876|FG000|First Intervention (4-6 Weeks)|Lost to Follow-up|0
6298592|NCT02506036|10020877|FG001|First Intervention (4-6 Weeks)|Lost to Follow-up|1
6298593|NCT02506036|10020876|FG000|First Intervention (4-6 Weeks)|Withdrawal by Subject|0
6298594|NCT02506036|10020877|FG001|First Intervention (4-6 Weeks)|Withdrawal by Subject|1
6298595|NCT02506257|10020900|FG000|Overall Study|Adverse Event|0
6298596|NCT02506257|10020901|FG001|Overall Study|Adverse Event|2
6298597|NCT02506257|10020902|FG002|Overall Study|Adverse Event|3
6298598|NCT02506257|10020903|FG003|Overall Study|Adverse Event|0
6298599|NCT02506257|10020900|FG000|Overall Study|Protocol Violation|0
6298600|NCT02506257|10020901|FG001|Overall Study|Protocol Violation|0
6298601|NCT02506257|10020902|FG002|Overall Study|Protocol Violation|1
6298602|NCT02506257|10020903|FG003|Overall Study|Protocol Violation|0
6298603|NCT02506816|10020986|FG000|Overall Study|Adverse Event|3
6298604|NCT02506881|10021007|FG000|First Intervention (Day 1)|Protocol Violation|0
6298605|NCT02506881|10021008|FG001|First Intervention (Day 1)|Protocol Violation|0
6298606|NCT02506881|10021009|FG002|First Intervention (Day 1)|Protocol Violation|1
6298607|NCT02506881|10021010|FG003|First Intervention (Day 1)|Protocol Violation|0
6298608|NCT02506881|10021007|FG000|First Intervention (Day 1)|Withdrawal by Subject|1
6298609|NCT02506881|10021008|FG001|First Intervention (Day 1)|Withdrawal by Subject|0
6298610|NCT02506881|10021009|FG002|First Intervention (Day 1)|Withdrawal by Subject|0
6298611|NCT02506881|10021010|FG003|First Intervention (Day 1)|Withdrawal by Subject|0
6298612|NCT02506881|10021007|FG000|First Intervention (Day 1)|Violation of blood storage conditions|0
6298613|NCT02506881|10021008|FG001|First Intervention (Day 1)|Violation of blood storage conditions|0
6298614|NCT02506881|10021009|FG002|First Intervention (Day 1)|Violation of blood storage conditions|12
6298615|NCT02506881|10021010|FG003|First Intervention (Day 1)|Violation of blood storage conditions|12
6298616|NCT02507219|10021037|FG000|Overall Study|Physician Decision|1
6298617|NCT02507219|10021038|FG001|Overall Study|Physician Decision|0
6298618|NCT02507219|10021039|FG002|Overall Study|Physician Decision|0
6298619|NCT02507219|10021040|FG003|Overall Study|Physician Decision|0
6298620|NCT02507219|10021041|FG004|Overall Study|Physician Decision|0
6298621|NCT02507219|10021042|FG005|Overall Study|Physician Decision|0
6298622|NCT02507219|10021037|FG000|Overall Study|Withdrawal by Subject|0
6298623|NCT02507219|10021038|FG001|Overall Study|Withdrawal by Subject|0
6298624|NCT02507219|10021039|FG002|Overall Study|Withdrawal by Subject|0
6298625|NCT02507219|10021040|FG003|Overall Study|Withdrawal by Subject|0
6298626|NCT02507219|10021041|FG004|Overall Study|Withdrawal by Subject|1
6298627|NCT02507219|10021042|FG005|Overall Study|Withdrawal by Subject|0
6298628|NCT02507297|10021052|FG000|Overall Study|Withdrawal by Subject|1
6298629|NCT02507297|10021053|FG001|Overall Study|Withdrawal by Subject|0
6298630|NCT02507297|10021052|FG000|Overall Study|Lost to Follow-up|0
6298631|NCT02507297|10021053|FG001|Overall Study|Lost to Follow-up|1
6298632|NCT02507349|10021061|FG000|Overall Study|Death|12
6298633|NCT02507349|10021062|FG001|Overall Study|Death|16
6298634|NCT02507349|10021061|FG000|Overall Study|Withdrawal by Subject|1
6298635|NCT02507349|10021062|FG001|Overall Study|Withdrawal by Subject|1
6298636|NCT02507349|10021061|FG000|Overall Study|Lost to Follow-up|174
6298637|NCT02507349|10021062|FG001|Overall Study|Lost to Follow-up|144
6298638|NCT02507375|10021070|FG000|Overall Study|Progressive Disease|4
6298639|NCT02507375|10021071|FG001|Overall Study|Progressive Disease|5
6298640|NCT02507375|10021070|FG000|Overall Study|Death|0
6298641|NCT02507375|10021071|FG001|Overall Study|Death|1
6298642|NCT02507375|10021070|FG000|Overall Study|Refused treatment|0
6298643|NCT02507375|10021071|FG001|Overall Study|Refused treatment|1
6298644|NCT02507375|10021070|FG000|Overall Study|Adverse Event|0
6298645|NCT02507375|10021071|FG001|Overall Study|Adverse Event|1
6298646|NCT02507752|10021091|FG000|Overall Study|Adverse Event|1
6298647|NCT02507752|10021091|FG000|Overall Study|Protocol Violation|6
6298648|NCT02507752|10021091|FG000|Overall Study|Lost to Follow-up|7
6298649|NCT02507752|10021091|FG000|Overall Study|Infusion reaction at first infusion|1
6298650|NCT02507752|10021091|FG000|Overall Study|Participant didn't perform visit Week 12|1
6298651|NCT02507752|10021091|FG000|Overall Study|Participant didn't perform visit Week 24|1
6298652|NCT02508116|10021110|FG000|Overall Study|Lost to Follow-up|2
6298653|NCT02508116|10021111|FG001|Overall Study|Lost to Follow-up|3
6298654|NCT02508116|10021110|FG000|Overall Study|Withdrawal by Subject|3
6298655|NCT02508116|10021111|FG001|Overall Study|Withdrawal by Subject|2
6298656|NCT02508116|10021110|FG000|Overall Study|Protocol Violation|1
6298657|NCT02508116|10021111|FG001|Overall Study|Protocol Violation|2
6298658|NCT02508116|10021110|FG000|Overall Study|Physician Decision|2
6298659|NCT02508116|10021111|FG001|Overall Study|Physician Decision|0
6298660|NCT02508194|10021119|FG000|Overall Study|Death|5
6298661|NCT02508194|10021120|FG001|Overall Study|Death|3
6298662|NCT02508194|10021119|FG000|Overall Study|Lost to Follow-up|25
6298663|NCT02508194|10021120|FG001|Overall Study|Lost to Follow-up|18
6298664|NCT02508194|10021119|FG000|Overall Study|Withdrawal by Subject|20
6298665|NCT02508194|10021120|FG001|Overall Study|Withdrawal by Subject|18
6298666|NCT02508194|10021119|FG000|Overall Study|Error in Randomization|1
6298667|NCT02508194|10021120|FG001|Overall Study|Error in Randomization|3
6298668|NCT02508194|10021119|FG000|Overall Study|Principal Investigator Decision|1
6298669|NCT02508194|10021120|FG001|Overall Study|Principal Investigator Decision|2
6298670|NCT02508428|10021159|FG000|Overall Study|Death|32
6298671|NCT02508428|10021160|FG001|Overall Study|Death|33
6298672|NCT02508428|10021159|FG000|Overall Study|Liner revised|3
6298673|NCT02508428|10021160|FG001|Overall Study|Liner revised|19
6298674|NCT02508428|10021159|FG000|Overall Study|Incomplete follow-up|17
6298675|NCT02508428|10021160|FG001|Overall Study|Incomplete follow-up|15
6298676|NCT02508532|10021182|FG000|Part 1 - Dose Determining Period|did not complete >21 days of treatment|0
6298677|NCT02508532|10021183|FG001|Part 1 - Dose Determining Period|did not complete >21 days of treatment|0
6298678|NCT02508532|10021184|FG002|Part 1 - Dose Determining Period|did not complete >21 days of treatment|0
6298679|NCT02508532|10021185|FG003|Part 1 - Dose Determining Period|did not complete >21 days of treatment|0
6298680|NCT02508532|10021186|FG004|Part 1 - Dose Determining Period|did not complete >21 days of treatment|0
6298681|NCT02508532|10021187|FG005|Part 1 - Dose Determining Period|did not complete >21 days of treatment|0
6298682|NCT02508532|10021188|FG006|Part 1 - Dose Determining Period|did not complete >21 days of treatment|1
6298683|NCT02508532|10021189|FG007|Part 1 - Dose Determining Period|did not complete >21 days of treatment|0
6298684|NCT02508532|10021190|FG008|Part 1 - Dose Determining Period|did not complete >21 days of treatment|0
6298685|NCT02508532|10021182|FG000|Part 1 - Dose Determining Period|Not Evaluable|0
6298686|NCT02508532|10021183|FG001|Part 1 - Dose Determining Period|Not Evaluable|0
6298687|NCT02508532|10021184|FG002|Part 1 - Dose Determining Period|Not Evaluable|0
6298688|NCT02508532|10021185|FG003|Part 1 - Dose Determining Period|Not Evaluable|0
6298689|NCT02508532|10021186|FG004|Part 1 - Dose Determining Period|Not Evaluable|0
6298690|NCT02508532|10021187|FG005|Part 1 - Dose Determining Period|Not Evaluable|0
6298691|NCT02508532|10021188|FG006|Part 1 - Dose Determining Period|Not Evaluable|0
6298692|NCT02508532|10021189|FG007|Part 1 - Dose Determining Period|Not Evaluable|1
6298693|NCT02508532|10021190|FG008|Part 1 - Dose Determining Period|Not Evaluable|0
6298694|NCT02508532|10021182|FG000|Part 2 - Treatment|Disease Progression|0
6298695|NCT02508532|10021183|FG001|Part 2 - Treatment|Disease Progression|0
6298696|NCT02508532|10021184|FG002|Part 2 - Treatment|Disease Progression|0
6298697|NCT02508532|10021185|FG003|Part 2 - Treatment|Disease Progression|0
6298698|NCT02508532|10021186|FG004|Part 2 - Treatment|Disease Progression|0
6298699|NCT02508532|10021187|FG005|Part 2 - Treatment|Disease Progression|0
6298700|NCT02508532|10021188|FG006|Part 2 - Treatment|Disease Progression|0
6298701|NCT02508532|10021189|FG007|Part 2 - Treatment|Disease Progression|0
6298702|NCT02508532|10021190|FG008|Part 2 - Treatment|Disease Progression|118
6298703|NCT02508532|10021182|FG000|Part 2 - Treatment|Adverse Event|0
6298704|NCT02508532|10021183|FG001|Part 2 - Treatment|Adverse Event|0
6298705|NCT02508532|10021184|FG002|Part 2 - Treatment|Adverse Event|0
6298706|NCT02508532|10021185|FG003|Part 2 - Treatment|Adverse Event|0
6298707|NCT02508532|10021186|FG004|Part 2 - Treatment|Adverse Event|0
6298708|NCT02508532|10021187|FG005|Part 2 - Treatment|Adverse Event|0
6298709|NCT02508532|10021188|FG006|Part 2 - Treatment|Adverse Event|0
6298710|NCT02508532|10021189|FG007|Part 2 - Treatment|Adverse Event|0
6298711|NCT02508532|10021190|FG008|Part 2 - Treatment|Adverse Event|49
6298712|NCT02508532|10021182|FG000|Part 2 - Treatment|Physician Decision|0
6298713|NCT02508532|10021183|FG001|Part 2 - Treatment|Physician Decision|0
6298714|NCT02508532|10021184|FG002|Part 2 - Treatment|Physician Decision|0
6298715|NCT02508532|10021185|FG003|Part 2 - Treatment|Physician Decision|0
6298716|NCT02508532|10021186|FG004|Part 2 - Treatment|Physician Decision|0
6298717|NCT02508532|10021187|FG005|Part 2 - Treatment|Physician Decision|0
6298718|NCT02508532|10021188|FG006|Part 2 - Treatment|Physician Decision|0
6298719|NCT02508532|10021189|FG007|Part 2 - Treatment|Physician Decision|0
6298720|NCT02508532|10021190|FG008|Part 2 - Treatment|Physician Decision|12
6298721|NCT02508532|10021182|FG000|Part 2 - Treatment|Administrative|0
6298722|NCT02508532|10021183|FG001|Part 2 - Treatment|Administrative|0
6298723|NCT02508532|10021184|FG002|Part 2 - Treatment|Administrative|0
6298724|NCT02508532|10021185|FG003|Part 2 - Treatment|Administrative|0
6298725|NCT02508532|10021186|FG004|Part 2 - Treatment|Administrative|0
6298726|NCT02508532|10021187|FG005|Part 2 - Treatment|Administrative|0
6298727|NCT02508532|10021188|FG006|Part 2 - Treatment|Administrative|0
6298728|NCT02508532|10021189|FG007|Part 2 - Treatment|Administrative|0
6298729|NCT02508532|10021190|FG008|Part 2 - Treatment|Administrative|3
6298730|NCT02508532|10021182|FG000|Part 2 - Treatment|Sponsor Decision|0
6298731|NCT02508532|10021183|FG001|Part 2 - Treatment|Sponsor Decision|0
6298732|NCT02508532|10021184|FG002|Part 2 - Treatment|Sponsor Decision|0
6298733|NCT02508532|10021185|FG003|Part 2 - Treatment|Sponsor Decision|0
6298734|NCT02508532|10021186|FG004|Part 2 - Treatment|Sponsor Decision|0
6298735|NCT02508532|10021187|FG005|Part 2 - Treatment|Sponsor Decision|0
6298736|NCT02508532|10021188|FG006|Part 2 - Treatment|Sponsor Decision|0
6298737|NCT02508532|10021189|FG007|Part 2 - Treatment|Sponsor Decision|0
6298738|NCT02508532|10021190|FG008|Part 2 - Treatment|Sponsor Decision|28
6298739|NCT02508532|10021182|FG000|Part 2 - Treatment|Death|0
6298740|NCT02508532|10021183|FG001|Part 2 - Treatment|Death|0
6298741|NCT02508532|10021184|FG002|Part 2 - Treatment|Death|0
5981899|NCT00250458|9570709|FG000|Overall Study|Lost to Follow-up|4
5981900|NCT00250458|9570710|FG001|Overall Study|Lost to Follow-up|2
5981901|NCT00250458|9570709|FG000|Overall Study|Protocol Violation|0
5981902|NCT00250458|9570710|FG001|Overall Study|Protocol Violation|1
5981903|NCT00250458|9570709|FG000|Overall Study|Withdrawal by Subject|4
5981904|NCT00250458|9570710|FG001|Overall Study|Withdrawal by Subject|2
5981905|NCT00250458|9570709|FG000|Overall Study|Lack of Migraine Attack|20
5981906|NCT00250458|9570710|FG001|Overall Study|Lack of Migraine Attack|9
5981907|NCT00250458|9570709|FG000|Overall Study|Qualifying migraine but did not treat|3
5981908|NCT00250458|9570710|FG001|Overall Study|Qualifying migraine but did not treat|3
5981909|NCT00250458|9570709|FG000|Overall Study|Other|1
5981910|NCT00250458|9570710|FG001|Overall Study|Other|0
5981911|NCT00245570|9570716|FG000|Washout Between Periods III and IV|Adverse Event|0
5981912|NCT00245570|9570717|FG001|Washout Between Periods III and IV|Adverse Event|1
5981913|NCT00245570|9570718|FG002|Washout Between Periods III and IV|Adverse Event|0
5981914|NCT00245570|9570719|FG003|Washout Between Periods III and IV|Adverse Event|0
5981915|NCT00245570|9570720|FG004|Washout Between Periods III and IV|Adverse Event|0
5981916|NCT00245570|9570721|FG005|Washout Between Periods III and IV|Adverse Event|0
5981917|NCT00092131|9570745|FG000|Treatment Period I|Adverse Event|1
5981918|NCT00092131|9570746|FG001|Treatment Period I|Adverse Event|0
5981919|NCT00092131|9570745|FG000|Treatment Period II|Adverse Event|0
5981920|NCT00092131|9570746|FG001|Treatment Period II|Adverse Event|1
5981921|NCT00092118|9570754|FG000|Overall Study|Adverse Event|35
5981922|NCT00092118|9570755|FG001|Overall Study|Adverse Event|32
5981923|NCT00092118|9570754|FG000|Overall Study|Lack of Efficacy|12
5981924|NCT00092118|9570755|FG001|Overall Study|Lack of Efficacy|14
5981925|NCT00092118|9570754|FG000|Overall Study|Lost to Follow-up|4
5981926|NCT00092118|9570755|FG001|Overall Study|Lost to Follow-up|3
5981927|NCT00092118|9570754|FG000|Overall Study|Protocol Violation|23
5981928|NCT00092118|9570755|FG001|Overall Study|Protocol Violation|25
5981929|NCT00092118|9570754|FG000|Overall Study|Withdrawal by Subject|4
5981930|NCT00092118|9570755|FG001|Overall Study|Withdrawal by Subject|10
5981931|NCT00092118|9570754|FG000|Overall Study|Other|6
5981932|NCT00092118|9570755|FG001|Overall Study|Other|5
5981933|NCT00090142|9570761|FG000|Treatment Period I|Lost to Follow-up|1
5981934|NCT00090142|9570762|FG001|Treatment Period I|Lost to Follow-up|2
5981935|NCT00090142|9570761|FG000|Treatment Period I|Protocol Violation|2
5981936|NCT00090142|9570762|FG001|Treatment Period I|Protocol Violation|0
5981937|NCT00090142|9570761|FG000|Treatment Period I|Withdrawal by Subject|2
5981938|NCT00090142|9570762|FG001|Treatment Period I|Withdrawal by Subject|0
5981939|NCT00090142|9570761|FG000|Treatment Period I|Other|0
5981940|NCT00090142|9570762|FG001|Treatment Period I|Other|1
5981941|NCT00090142|9570761|FG000|Treatment Period II|Other|1
5981942|NCT00090142|9570762|FG001|Treatment Period II|Other|0
6298742|NCT02508532|10021185|FG003|Part 2 - Treatment|Death|0
6298743|NCT02508532|10021186|FG004|Part 2 - Treatment|Death|0
6298744|NCT02508532|10021187|FG005|Part 2 - Treatment|Death|0
6063515|NCT00506415|9664785|FG001|Extended Open Label (Maximum 48 Weeks)|Administrative problems|0
6063516|NCT00506415|9664786|FG002|Extended Open Label (Maximum 48 Weeks)|Administrative problems|0
6063517|NCT00506415|9664787|FG003|Extended Open Label (Maximum 48 Weeks)|Administrative problems|4
6063518|NCT00506415|9664784|FG000|Extended Open Label (Maximum 48 Weeks)|Adverse Event|0
6063519|NCT00506415|9664785|FG001|Extended Open Label (Maximum 48 Weeks)|Adverse Event|0
6298745|NCT02508532|10021188|FG006|Part 2 - Treatment|Death|0
6298746|NCT02508532|10021189|FG007|Part 2 - Treatment|Death|0
6298747|NCT02508532|10021190|FG008|Part 2 - Treatment|Death|1
6298748|NCT02508532|10021182|FG000|Part 2 - Treatment|Withdrawal by Subject|0
6298749|NCT02508532|10021183|FG001|Part 2 - Treatment|Withdrawal by Subject|0
6298750|NCT02508532|10021184|FG002|Part 2 - Treatment|Withdrawal by Subject|0
6298751|NCT02508532|10021185|FG003|Part 2 - Treatment|Withdrawal by Subject|0
6298752|NCT02508532|10021186|FG004|Part 2 - Treatment|Withdrawal by Subject|0
6298753|NCT02508532|10021187|FG005|Part 2 - Treatment|Withdrawal by Subject|0
6298754|NCT02508532|10021188|FG006|Part 2 - Treatment|Withdrawal by Subject|0
6298755|NCT02508532|10021189|FG007|Part 2 - Treatment|Withdrawal by Subject|0
6298756|NCT02508532|10021190|FG008|Part 2 - Treatment|Withdrawal by Subject|6
6298757|NCT02508532|10021182|FG000|Part 1 and Part 2 End of Study|Disease Progression|2
6298758|NCT02508532|10021183|FG001|Part 1 and Part 2 End of Study|Disease Progression|0
6298759|NCT02508532|10021184|FG002|Part 1 and Part 2 End of Study|Disease Progression|0
6298760|NCT02508532|10021185|FG003|Part 1 and Part 2 End of Study|Disease Progression|0
6298761|NCT02508532|10021186|FG004|Part 1 and Part 2 End of Study|Disease Progression|0
6298762|NCT02508532|10021187|FG005|Part 1 and Part 2 End of Study|Disease Progression|0
6298763|NCT02508532|10021188|FG006|Part 1 and Part 2 End of Study|Disease Progression|0
6298764|NCT02508532|10021189|FG007|Part 1 and Part 2 End of Study|Disease Progression|1
6298765|NCT02508532|10021190|FG008|Part 1 and Part 2 End of Study|Disease Progression|6
6298766|NCT02508532|10021182|FG000|Part 1 and Part 2 End of Study|Adverse Event|1
6298767|NCT02508532|10021183|FG001|Part 1 and Part 2 End of Study|Adverse Event|0
6298768|NCT02508532|10021184|FG002|Part 1 and Part 2 End of Study|Adverse Event|1
6298769|NCT02508532|10021185|FG003|Part 1 and Part 2 End of Study|Adverse Event|0
6298770|NCT02508532|10021186|FG004|Part 1 and Part 2 End of Study|Adverse Event|0
6298771|NCT02508532|10021187|FG005|Part 1 and Part 2 End of Study|Adverse Event|0
6298772|NCT02508532|10021188|FG006|Part 1 and Part 2 End of Study|Adverse Event|0
6298773|NCT02508532|10021189|FG007|Part 1 and Part 2 End of Study|Adverse Event|0
6298774|NCT02508532|10021190|FG008|Part 1 and Part 2 End of Study|Adverse Event|2
6298775|NCT02508532|10021182|FG000|Part 1 and Part 2 End of Study|Death|0
6298776|NCT02508532|10021183|FG001|Part 1 and Part 2 End of Study|Death|4
6298777|NCT02508532|10021184|FG002|Part 1 and Part 2 End of Study|Death|2
6298778|NCT02508532|10021185|FG003|Part 1 and Part 2 End of Study|Death|4
6298779|NCT02508532|10021186|FG004|Part 1 and Part 2 End of Study|Death|3
6298780|NCT02508532|10021187|FG005|Part 1 and Part 2 End of Study|Death|0
6298781|NCT02508532|10021188|FG006|Part 1 and Part 2 End of Study|Death|0
6298782|NCT02508532|10021189|FG007|Part 1 and Part 2 End of Study|Death|1
6298783|NCT02508532|10021190|FG008|Part 1 and Part 2 End of Study|Death|111
6298784|NCT02508532|10021182|FG000|Part 1 and Part 2 End of Study|Lost to Follow-up|1
6298785|NCT02508532|10021183|FG001|Part 1 and Part 2 End of Study|Lost to Follow-up|1
6298786|NCT02508532|10021184|FG002|Part 1 and Part 2 End of Study|Lost to Follow-up|1
6298787|NCT02508532|10021185|FG003|Part 1 and Part 2 End of Study|Lost to Follow-up|0
6298788|NCT02508532|10021186|FG004|Part 1 and Part 2 End of Study|Lost to Follow-up|0
6298789|NCT02508532|10021187|FG005|Part 1 and Part 2 End of Study|Lost to Follow-up|0
6298790|NCT02508532|10021188|FG006|Part 1 and Part 2 End of Study|Lost to Follow-up|0
6298791|NCT02508532|10021189|FG007|Part 1 and Part 2 End of Study|Lost to Follow-up|0
6298792|NCT02508532|10021190|FG008|Part 1 and Part 2 End of Study|Lost to Follow-up|6
6298793|NCT02508532|10021182|FG000|Part 1 and Part 2 End of Study|Withdrawal by Subject|0
6298794|NCT02508532|10021183|FG001|Part 1 and Part 2 End of Study|Withdrawal by Subject|0
6298795|NCT02508532|10021184|FG002|Part 1 and Part 2 End of Study|Withdrawal by Subject|0
6298796|NCT02508532|10021185|FG003|Part 1 and Part 2 End of Study|Withdrawal by Subject|0
6298797|NCT02508532|10021186|FG004|Part 1 and Part 2 End of Study|Withdrawal by Subject|0
6298798|NCT02508532|10021187|FG005|Part 1 and Part 2 End of Study|Withdrawal by Subject|0
6298799|NCT02508532|10021188|FG006|Part 1 and Part 2 End of Study|Withdrawal by Subject|0
6298800|NCT02508532|10021189|FG007|Part 1 and Part 2 End of Study|Withdrawal by Subject|0
6298801|NCT02508532|10021190|FG008|Part 1 and Part 2 End of Study|Withdrawal by Subject|15
6298802|NCT02508532|10021182|FG000|Part 1 and Part 2 End of Study|Physician Decision|0
6298803|NCT02508532|10021183|FG001|Part 1 and Part 2 End of Study|Physician Decision|0
6298804|NCT02508532|10021184|FG002|Part 1 and Part 2 End of Study|Physician Decision|1
6298805|NCT02508532|10021185|FG003|Part 1 and Part 2 End of Study|Physician Decision|0
6298806|NCT02508532|10021186|FG004|Part 1 and Part 2 End of Study|Physician Decision|1
6298807|NCT02508532|10021187|FG005|Part 1 and Part 2 End of Study|Physician Decision|0
6298808|NCT02508532|10021188|FG006|Part 1 and Part 2 End of Study|Physician Decision|0
6298809|NCT02508532|10021189|FG007|Part 1 and Part 2 End of Study|Physician Decision|0
6298810|NCT02508532|10021190|FG008|Part 1 and Part 2 End of Study|Physician Decision|8
6298811|NCT02508532|10021182|FG000|Part 1 and Part 2 End of Study|Initiation of another therapy|0
6298812|NCT02508532|10021183|FG001|Part 1 and Part 2 End of Study|Initiation of another therapy|0
6298813|NCT02508532|10021184|FG002|Part 1 and Part 2 End of Study|Initiation of another therapy|0
6298814|NCT02508532|10021185|FG003|Part 1 and Part 2 End of Study|Initiation of another therapy|0
6298815|NCT02508532|10021186|FG004|Part 1 and Part 2 End of Study|Initiation of another therapy|0
6298816|NCT02508532|10021187|FG005|Part 1 and Part 2 End of Study|Initiation of another therapy|0
6298817|NCT02508532|10021188|FG006|Part 1 and Part 2 End of Study|Initiation of another therapy|0
6298818|NCT02508532|10021189|FG007|Part 1 and Part 2 End of Study|Initiation of another therapy|0
6298819|NCT02508532|10021190|FG008|Part 1 and Part 2 End of Study|Initiation of another therapy|1
6298820|NCT02508532|10021182|FG000|Part 1 and Part 2 End of Study|Sponsor Decision|2
6298821|NCT02508532|10021183|FG001|Part 1 and Part 2 End of Study|Sponsor Decision|1
6298822|NCT02508532|10021184|FG002|Part 1 and Part 2 End of Study|Sponsor Decision|1
6298823|NCT02508532|10021185|FG003|Part 1 and Part 2 End of Study|Sponsor Decision|2
6298824|NCT02508532|10021186|FG004|Part 1 and Part 2 End of Study|Sponsor Decision|2
6298825|NCT02508532|10021187|FG005|Part 1 and Part 2 End of Study|Sponsor Decision|0
6298826|NCT02508532|10021188|FG006|Part 1 and Part 2 End of Study|Sponsor Decision|0
6298827|NCT02508532|10021189|FG007|Part 1 and Part 2 End of Study|Sponsor Decision|1
6298828|NCT02508532|10021190|FG008|Part 1 and Part 2 End of Study|Sponsor Decision|67
6298829|NCT02508532|10021182|FG000|Part 1 and Part 2 End of Study|Continuing in study|0
6298830|NCT02508532|10021183|FG001|Part 1 and Part 2 End of Study|Continuing in study|0
6298831|NCT02508532|10021184|FG002|Part 1 and Part 2 End of Study|Continuing in study|0
6298832|NCT02508532|10021185|FG003|Part 1 and Part 2 End of Study|Continuing in study|0
6298833|NCT02508532|10021186|FG004|Part 1 and Part 2 End of Study|Continuing in study|0
6298834|NCT02508532|10021187|FG005|Part 1 and Part 2 End of Study|Continuing in study|0
6298835|NCT02508532|10021188|FG006|Part 1 and Part 2 End of Study|Continuing in study|0
6298836|NCT02508532|10021189|FG007|Part 1 and Part 2 End of Study|Continuing in study|0
6298837|NCT02508532|10021190|FG008|Part 1 and Part 2 End of Study|Continuing in study|1
6298838|NCT02508649|10021227|FG000|Overall Study|Withdrawal by Subject|4
6298839|NCT02508649|10021228|FG001|Overall Study|Withdrawal by Subject|6
6298840|NCT02508649|10021229|FG002|Overall Study|Withdrawal by Subject|5
6298841|NCT02508649|10021230|FG003|Overall Study|Withdrawal by Subject|6
6298842|NCT02508649|10021227|FG000|Overall Study|Investigator withdrew the subject|1
6298843|NCT02508649|10021228|FG001|Overall Study|Investigator withdrew the subject|2
6298844|NCT02508649|10021229|FG002|Overall Study|Investigator withdrew the subject|1
6298845|NCT02508649|10021230|FG003|Overall Study|Investigator withdrew the subject|0
6298846|NCT02508649|10021227|FG000|Overall Study|Post randomization screening failure|12
6298847|NCT02508649|10021228|FG001|Overall Study|Post randomization screening failure|4
6298848|NCT02508649|10021229|FG002|Overall Study|Post randomization screening failure|9
6298849|NCT02508649|10021230|FG003|Overall Study|Post randomization screening failure|3
6298850|NCT02508649|10021227|FG000|Overall Study|Lost to Follow-up|1
6298851|NCT02508649|10021228|FG001|Overall Study|Lost to Follow-up|1
6298852|NCT02508649|10021229|FG002|Overall Study|Lost to Follow-up|0
6298853|NCT02508649|10021230|FG003|Overall Study|Lost to Follow-up|1
6298854|NCT02508701|10021247|FG000|Overall Study|Lost to Follow-up|9
6298855|NCT02508701|10021248|FG001|Overall Study|Lost to Follow-up|5
6298856|NCT02508701|10021249|FG002|Overall Study|Lost to Follow-up|5
6298857|NCT02508701|10021250|FG003|Overall Study|Lost to Follow-up|3
6298858|NCT02508935|10021264|FG000|Overall Study|Withdrawal by Subject|1
6298859|NCT02508935|10021264|FG000|Overall Study|Withdrawal by Caregiver|8
6298860|NCT02508935|10021264|FG000|Overall Study|Pain Score <4|1
6298861|NCT02508935|10021264|FG000|Overall Study|Emesis|3
6298862|NCT02508935|10021264|FG000|Overall Study|Adverse Event|3
6298863|NCT02508935|10021264|FG000|Overall Study|Protocol Violation|1
6298864|NCT02508935|10021264|FG000|Overall Study|Physician Decision|1
6298865|NCT02508935|10021264|FG000|Overall Study|Trial terminated by sponsor|5
6298866|NCT02509026|10021270|FG000|Induction Period (24 Weeks)|Adverse Event|5
6298867|NCT02509026|10021270|FG000|Induction Period (24 Weeks)|Eligibility Criteria|5
6298868|NCT02509026|10021270|FG000|Induction Period (24 Weeks)|Lack of Efficacy|6
6298869|NCT02509026|10021270|FG000|Induction Period (24 Weeks)|Lost to Follow-up|1
6298870|NCT02509026|10021270|FG000|Induction Period (24 Weeks)|Other|2
6298871|NCT02509026|10021270|FG000|Induction Period (24 Weeks)|Protocol Violation|1
6298872|NCT02509026|10021270|FG000|Induction Period (24 Weeks)|Withdrawal by Subject|1
6298873|NCT02509026|10021270|FG000|Induction Period (24 Weeks)|Enrolled but not treated|1
6298874|NCT02509026|10021270|FG000|Withdrawal Period (40 Weeks)|Protocol Violation|2
6298875|NCT02509026|10021270|FG000|Withdrawal Period (40 Weeks)|Withdrawal by Subject|5
6298876|NCT02509026|10021270|FG000|Retreatment Period (12 Weeks)|Lost to Follow-up|1
6298877|NCT02509026|10021270|FG000|Retreatment Period (12 Weeks)|Withdrawal by Subject|2
6298878|NCT02509026|10021270|FG000|Retreatment Period (12 Weeks)|Enrolled but not treated|1
6298879|NCT02509078|10021319|FG000|Overall Study|Protocol Violation|1
6298880|NCT02509078|10021320|FG001|Overall Study|Protocol Violation|1
6298881|NCT02509117|10021338|FG000|Period 1-Part A:4 Days; Part B,C:19 Days|Randomized, not treated|0
6298882|NCT02509117|10021339|FG001|Period 1-Part A:4 Days; Part B,C:19 Days|Randomized, not treated|1
6298883|NCT02509117|10021340|FG002|Period 1-Part A:4 Days; Part B,C:19 Days|Randomized, not treated|0
6298884|NCT02509117|10021341|FG003|Period 1-Part A:4 Days; Part B,C:19 Days|Randomized, not treated|0
6298885|NCT02509117|10021342|FG004|Period 1-Part A:4 Days; Part B,C:19 Days|Randomized, not treated|0
6298886|NCT02509117|10021343|FG005|Period 1-Part A:4 Days; Part B,C:19 Days|Randomized, not treated|0
6298887|NCT02509117|10021344|FG006|Period 1-Part A:4 Days; Part B,C:19 Days|Randomized, not treated|0
6298888|NCT02509117|10021345|FG007|Period 1-Part A:4 Days; Part B,C:19 Days|Randomized, not treated|0
6298889|NCT02509117|10021346|FG008|Period 1-Part A:4 Days; Part B,C:19 Days|Randomized, not treated|0
6298890|NCT02509117|10021347|FG009|Period 1-Part A:4 Days; Part B,C:19 Days|Randomized, not treated|0
6298891|NCT02509117|10021338|FG000|Period 1-Part A:4 Days; Part B,C:19 Days|Investigator's Discretion|0
6298892|NCT02509117|10021339|FG001|Period 1-Part A:4 Days; Part B,C:19 Days|Investigator's Discretion|0
5981943|NCT04771013|9570774|FG000|Overall Study|Withdrawal by Subject|2
6298893|NCT02509117|10021340|FG002|Period 1-Part A:4 Days; Part B,C:19 Days|Investigator's Discretion|0
6298894|NCT02509117|10021341|FG003|Period 1-Part A:4 Days; Part B,C:19 Days|Investigator's Discretion|0
6298895|NCT02509117|10021342|FG004|Period 1-Part A:4 Days; Part B,C:19 Days|Investigator's Discretion|0
6298896|NCT02509117|10021343|FG005|Period 1-Part A:4 Days; Part B,C:19 Days|Investigator's Discretion|0
6298897|NCT02509117|10021344|FG006|Period 1-Part A:4 Days; Part B,C:19 Days|Investigator's Discretion|0
6298898|NCT02509117|10021345|FG007|Period 1-Part A:4 Days; Part B,C:19 Days|Investigator's Discretion|0
6298899|NCT02509117|10021346|FG008|Period 1-Part A:4 Days; Part B,C:19 Days|Investigator's Discretion|0
6298900|NCT02509117|10021347|FG009|Period 1-Part A:4 Days; Part B,C:19 Days|Investigator's Discretion|1
6298901|NCT02509117|10021338|FG000|Period 1-Part A:4 Days; Part B,C:19 Days|Withdrawal by Subject|0
6298902|NCT02509117|10021339|FG001|Period 1-Part A:4 Days; Part B,C:19 Days|Withdrawal by Subject|0
6298903|NCT02509117|10021340|FG002|Period 1-Part A:4 Days; Part B,C:19 Days|Withdrawal by Subject|0
6298904|NCT02509117|10021341|FG003|Period 1-Part A:4 Days; Part B,C:19 Days|Withdrawal by Subject|0
6298905|NCT02509117|10021342|FG004|Period 1-Part A:4 Days; Part B,C:19 Days|Withdrawal by Subject|0
6298906|NCT02509117|10021343|FG005|Period 1-Part A:4 Days; Part B,C:19 Days|Withdrawal by Subject|0
6298907|NCT02509117|10021344|FG006|Period 1-Part A:4 Days; Part B,C:19 Days|Withdrawal by Subject|0
6298908|NCT02509117|10021345|FG007|Period 1-Part A:4 Days; Part B,C:19 Days|Withdrawal by Subject|0
6298909|NCT02509117|10021346|FG008|Period 1-Part A:4 Days; Part B,C:19 Days|Withdrawal by Subject|0
6298910|NCT02509117|10021347|FG009|Period 1-Part A:4 Days; Part B,C:19 Days|Withdrawal by Subject|1
6298911|NCT02509156|10021387|FG000|Randomized Phase|Death|1
6298912|NCT02509156|10021388|FG001|Randomized Phase|Death|0
6298913|NCT02509156|10021387|FG000|Randomized Phase|Withdrawal by Subject|1
6298914|NCT02509156|10021388|FG001|Randomized Phase|Withdrawal by Subject|1
6298915|NCT02510001|10021457|FG000|Overall Study|Early disease progression|0
6298916|NCT02510001|10021458|FG001|Overall Study|Early disease progression|0
6298917|NCT02510001|10021459|FG002|Overall Study|Early disease progression|0
6298918|NCT02510001|10021460|FG003|Overall Study|Early disease progression|1
6298919|NCT02510001|10021461|FG004|Overall Study|Early disease progression|1
6298920|NCT02510001|10021462|FG005|Overall Study|Early disease progression|1
6298921|NCT02510001|10021463|FG006|Overall Study|Early disease progression|0
6298922|NCT02510001|10021464|FG007|Overall Study|Early disease progression|0
6298923|NCT02510001|10021457|FG000|Overall Study|Adverse Event|0
6298924|NCT02510001|10021458|FG001|Overall Study|Adverse Event|0
6298925|NCT02510001|10021459|FG002|Overall Study|Adverse Event|0
6298926|NCT02510001|10021460|FG003|Overall Study|Adverse Event|1
6298927|NCT02510001|10021461|FG004|Overall Study|Adverse Event|2
6298928|NCT02510001|10021462|FG005|Overall Study|Adverse Event|1
6298929|NCT02510001|10021463|FG006|Overall Study|Adverse Event|2
6298930|NCT02510001|10021464|FG007|Overall Study|Adverse Event|5
6298931|NCT02510001|10021457|FG000|Overall Study|Physician Decision|0
6298932|NCT02510001|10021458|FG001|Overall Study|Physician Decision|0
6298933|NCT02510001|10021459|FG002|Overall Study|Physician Decision|0
6298934|NCT02510001|10021460|FG003|Overall Study|Physician Decision|0
6298935|NCT02510001|10021461|FG004|Overall Study|Physician Decision|1
6298936|NCT02510001|10021462|FG005|Overall Study|Physician Decision|0
6298937|NCT02510001|10021463|FG006|Overall Study|Physician Decision|0
6298938|NCT02510001|10021464|FG007|Overall Study|Physician Decision|0
6298939|NCT02510001|10021457|FG000|Overall Study|Withdrawal by Subject|0
6298940|NCT02510001|10021458|FG001|Overall Study|Withdrawal by Subject|0
6298941|NCT02510001|10021459|FG002|Overall Study|Withdrawal by Subject|0
6298942|NCT02510001|10021460|FG003|Overall Study|Withdrawal by Subject|0
6298943|NCT02510001|10021461|FG004|Overall Study|Withdrawal by Subject|0
6298944|NCT02510001|10021462|FG005|Overall Study|Withdrawal by Subject|0
6298945|NCT02510001|10021463|FG006|Overall Study|Withdrawal by Subject|0
6298946|NCT02510001|10021464|FG007|Overall Study|Withdrawal by Subject|2
6298947|NCT02510014|10021502|FG000|Run-In Period (Days -14 to Day -1)|Adverse Event|1
6298948|NCT02510014|10021503|FG001|Run-In Period (Days -14 to Day -1)|Adverse Event|1
6298949|NCT02510014|10021502|FG000|Run-In Period (Days -14 to Day -1)|Withdrawal symptoms|1
6298950|NCT02510014|10021503|FG001|Run-In Period (Days -14 to Day -1)|Withdrawal symptoms|0
6298951|NCT02510014|10021502|FG000|Run-In Period (Days -14 to Day -1)|Lost to Follow-up|44
6298952|NCT02510014|10021503|FG001|Run-In Period (Days -14 to Day -1)|Lost to Follow-up|3
6298953|NCT02510014|10021502|FG000|Run-In Period (Days -14 to Day -1)|Physician Decision|0
6298954|NCT02510014|10021503|FG001|Run-In Period (Days -14 to Day -1)|Physician Decision|1
6298955|NCT02510014|10021502|FG000|Run-In Period (Days -14 to Day -1)|Withdrawal by Subject|22
6298956|NCT02510014|10021503|FG001|Run-In Period (Days -14 to Day -1)|Withdrawal by Subject|3
6298957|NCT02510014|10021502|FG000|Run-In Period (Days -14 to Day -1)|Withdrawn by the investigator|7
6298958|NCT02510014|10021503|FG001|Run-In Period (Days -14 to Day -1)|Withdrawn by the investigator|1
6298959|NCT02510014|10021502|FG000|Run-In Period (Days -14 to Day -1)|Protocol Violation|2
6298960|NCT02510014|10021503|FG001|Run-In Period (Days -14 to Day -1)|Protocol Violation|0
5981944|NCT04771013|9570775|FG001|Overall Study|Withdrawal by Subject|0
5981945|NCT04771013|9570774|FG000|Overall Study|Death|0
5981946|NCT04771013|9570775|FG001|Overall Study|Death|5
5981947|NCT04771013|9570774|FG000|Overall Study|Referred to another hospital before day 20|0
5981948|NCT04771013|9570775|FG001|Overall Study|Referred to another hospital before day 20|1
6063520|NCT00506415|9664786|FG002|Extended Open Label (Maximum 48 Weeks)|Adverse Event|0
6063521|NCT00506415|9664787|FG003|Extended Open Label (Maximum 48 Weeks)|Adverse Event|18
6298961|NCT02510014|10021502|FG000|Run-In Period (Days -14 to Day -1)|Other|19
6298962|NCT02510014|10021503|FG001|Run-In Period (Days -14 to Day -1)|Other|1
6298963|NCT02510014|10021502|FG000|Treatment Period|Adverse Event|11
6298964|NCT02510014|10021503|FG001|Treatment Period|Adverse Event|4
6298965|NCT02510014|10021502|FG000|Treatment Period|Withdrawal symptoms|3
6298966|NCT02510014|10021503|FG001|Treatment Period|Withdrawal symptoms|0
6298967|NCT02510014|10021502|FG000|Treatment Period|Lost to Follow-up|80
6298968|NCT02510014|10021503|FG001|Treatment Period|Lost to Follow-up|19
6298969|NCT02510014|10021502|FG000|Treatment Period|Physician Decision|5
6298970|NCT02510014|10021503|FG001|Treatment Period|Physician Decision|0
6298971|NCT02510014|10021502|FG000|Treatment Period|Withdrawal by Subject|67
6298972|NCT02510014|10021503|FG001|Treatment Period|Withdrawal by Subject|24
6298973|NCT02510014|10021502|FG000|Treatment Period|Withdrawn by the investigator|7
6298974|NCT02510014|10021503|FG001|Treatment Period|Withdrawn by the investigator|1
6298975|NCT02510014|10021502|FG000|Treatment Period|Protocol Violation|4
6298976|NCT02510014|10021503|FG001|Treatment Period|Protocol Violation|4
6298977|NCT02510014|10021502|FG000|Treatment Period|Incarceration, pregnancy, misc|29
6298978|NCT02510014|10021503|FG001|Treatment Period|Incarceration, pregnancy, misc|5
6298979|NCT02510664|10021521|FG000|Overall Study|Transferred Care|9
6298980|NCT02510664|10021522|FG001|Overall Study|Transferred Care|9
6298981|NCT02510664|10021523|FG002|Overall Study|Transferred Care|0
6298982|NCT02510664|10021521|FG000|Overall Study|Provider Retired/No Time to Reschedule|10
6298983|NCT02510664|10021522|FG001|Overall Study|Provider Retired/No Time to Reschedule|10
6298984|NCT02510664|10021523|FG002|Overall Study|Provider Retired/No Time to Reschedule|0
6298985|NCT02510664|10021521|FG000|Overall Study|Time Constraints|1
6298986|NCT02510664|10021522|FG001|Overall Study|Time Constraints|1
6298987|NCT02510664|10021523|FG002|Overall Study|Time Constraints|0
5981949|NCT04497987|9570783|FG000|Overall Study|Adverse Event|1
6298988|NCT02510794|10021540|FG000|Overall Study|Adverse Event|0
6298989|NCT02510794|10021541|FG001|Overall Study|Adverse Event|1
6298990|NCT02510794|10021542|FG002|Overall Study|Adverse Event|0
6298991|NCT02510794|10021543|FG003|Overall Study|Adverse Event|0
6298992|NCT02510794|10021540|FG000|Overall Study|Death|1
6298993|NCT02510794|10021541|FG001|Overall Study|Death|2
6298994|NCT02510794|10021542|FG002|Overall Study|Death|1
6298995|NCT02510794|10021543|FG003|Overall Study|Death|1
6298996|NCT02510794|10021540|FG000|Overall Study|Lack of Efficacy|3
6298997|NCT02510794|10021541|FG001|Overall Study|Lack of Efficacy|1
6298998|NCT02510794|10021542|FG002|Overall Study|Lack of Efficacy|1
6298999|NCT02510794|10021543|FG003|Overall Study|Lack of Efficacy|0
6299000|NCT02510794|10021540|FG000|Overall Study|Participant moved out of the area|0
6299001|NCT02510794|10021541|FG001|Overall Study|Participant moved out of the area|0
6299002|NCT02510794|10021542|FG002|Overall Study|Participant moved out of the area|0
6299003|NCT02510794|10021543|FG003|Overall Study|Participant moved out of the area|1
6299004|NCT02510794|10021540|FG000|Overall Study|Physician Decision|3
6299005|NCT02510794|10021541|FG001|Overall Study|Physician Decision|0
6299006|NCT02510794|10021542|FG002|Overall Study|Physician Decision|0
6299007|NCT02510794|10021543|FG003|Overall Study|Physician Decision|0
6299008|NCT02510794|10021540|FG000|Overall Study|Protocol Violation|0
6299009|NCT02510794|10021541|FG001|Overall Study|Protocol Violation|0
6299010|NCT02510794|10021542|FG002|Overall Study|Protocol Violation|1
6299011|NCT02510794|10021543|FG003|Overall Study|Protocol Violation|0
6299012|NCT02510794|10021540|FG000|Overall Study|Withdrawal by Subject|1
6299013|NCT02510794|10021541|FG001|Overall Study|Withdrawal by Subject|2
6299014|NCT02510794|10021542|FG002|Overall Study|Withdrawal by Subject|4
6299015|NCT02510794|10021543|FG003|Overall Study|Withdrawal by Subject|3
6299016|NCT02510820|10021555|FG000|First Intervention (4 Weeks)|Withdrawal by Subject|0
6299017|NCT02510820|10021556|FG001|First Intervention (4 Weeks)|Withdrawal by Subject|1
6299018|NCT02510820|10021555|FG000|Second Intervention (4 Weeks)|Withdrawal by Subject|1
6299019|NCT02510820|10021556|FG001|Second Intervention (4 Weeks)|Withdrawal by Subject|0
6299020|NCT02511184|10021565|FG000|Overall Study|Death|1
6299021|NCT02511184|10021566|FG001|Overall Study|Death|0
6299022|NCT02511184|10021565|FG000|Overall Study|Lost to Follow-up|0
6299023|NCT02511184|10021566|FG001|Overall Study|Lost to Follow-up|1
6299024|NCT02511184|10021565|FG000|Overall Study|Study terminated by sponsor|1
6299025|NCT02511184|10021566|FG001|Overall Study|Study terminated by sponsor|5
6299026|NCT02511184|10021565|FG000|Overall Study|Withdrawal by Subject|0
6299027|NCT02511184|10021566|FG001|Overall Study|Withdrawal by Subject|1
6299028|NCT02511431|10021592|FG000|Treatment|Lost to Follow-up|0
6299029|NCT02511431|10021593|FG001|Treatment|Lost to Follow-up|0
6299030|NCT02511431|10021594|FG002|Treatment|Lost to Follow-up|1
6299031|NCT02511431|10021595|FG003|Treatment|Lost to Follow-up|0
6299032|NCT02511431|10021596|FG004|Treatment|Lost to Follow-up|0
6299033|NCT02511431|10021597|FG005|Treatment|Lost to Follow-up|1
6299034|NCT02511678|10021648|FG000|Overall Study|Withdrawal by Subject|2
6299035|NCT02511678|10021648|FG000|Overall Study|Lost to Follow-up|4
6299036|NCT02511678|10021648|FG000|Overall Study|Death|19
6299037|NCT02511678|10021648|FG000|Overall Study|Adverse Event|1
6299038|NCT02511678|10021648|FG000|Overall Study|Targeted Therapy to Index Tumor Required|5
6299039|NCT02511678|10021648|FG000|Overall Study|Oncologist Cancelled Study Cryoablation|1
6299040|NCT02511678|10021648|FG000|Overall Study|Required Radiofrequency Ablation|1
6299041|NCT02511678|10021648|FG000|Overall Study|Biopsy was Negative|1
6299042|NCT02511678|10021648|FG000|Overall Study|Protocol Violation|1
6299043|NCT02511678|10021648|FG000|Overall Study|Received Radiation Treatment|1
6299044|NCT02511782|10021672|FG000|Overall Study|Withdrawal by Subject|1
6299045|NCT02511782|10021673|FG001|Overall Study|Withdrawal by Subject|0
6299046|NCT02511782|10021674|FG002|Overall Study|Withdrawal by Subject|0
6299047|NCT02512042|10021684|FG000|Overall Study|Adverse Event|0
6299048|NCT02512042|10021685|FG001|Overall Study|Adverse Event|4
6299049|NCT02512042|10021684|FG000|Overall Study|Withdrawal by Subject|6
6299050|NCT02512042|10021685|FG001|Overall Study|Withdrawal by Subject|6
6299051|NCT02512042|10021684|FG000|Overall Study|Non-compliance with study drug|1
6299052|NCT02512042|10021685|FG001|Overall Study|Non-compliance with study drug|2
6299053|NCT02512042|10021684|FG000|Overall Study|Lost to Follow-up|5
6299054|NCT02512042|10021685|FG001|Overall Study|Lost to Follow-up|2
6299055|NCT02512042|10021684|FG000|Overall Study|Other|11
6299056|NCT02512042|10021685|FG001|Overall Study|Other|11
6299057|NCT02512068|10021693|FG000|Overall Study|Pretreatment Event/Adverse Event|8
6299058|NCT02512068|10021694|FG001|Overall Study|Pretreatment Event/Adverse Event|6
6299059|NCT02512068|10021693|FG000|Overall Study|Major Protocol Deviation|1
6299060|NCT02512068|10021694|FG001|Overall Study|Major Protocol Deviation|0
6299061|NCT02512068|10021693|FG000|Overall Study|Voluntary Withdrawal|0
6299062|NCT02512068|10021694|FG001|Overall Study|Voluntary Withdrawal|1
6299063|NCT02512068|10021693|FG000|Overall Study|Lack of Efficacy|0
6299064|NCT02512068|10021694|FG001|Overall Study|Lack of Efficacy|1
6299065|NCT02512068|10021693|FG000|Overall Study|Reason Not Specified|3
6299066|NCT02512068|10021694|FG001|Overall Study|Reason Not Specified|5
6299067|NCT02512302|10021722|FG000|Period 1|Adverse Event|0
6299068|NCT02512302|10021723|FG001|Period 1|Adverse Event|1
6299069|NCT02512302|10021724|FG002|Period 1|Adverse Event|0
6299070|NCT02512302|10021725|FG003|Period 1|Adverse Event|0
6299071|NCT02512302|10021726|FG004|Period 1|Adverse Event|0
6299072|NCT02512302|10021727|FG005|Period 1|Adverse Event|0
6299073|NCT02512302|10021728|FG006|Period 1|Adverse Event|0
6299074|NCT02512302|10021729|FG007|Period 1|Adverse Event|0
6299075|NCT02512302|10021730|FG008|Period 1|Adverse Event|0
6299076|NCT02512302|10021731|FG009|Period 1|Adverse Event|0
6299077|NCT02512302|10021722|FG000|Period 2|Adverse Event|0
6299078|NCT02512302|10021723|FG001|Period 2|Adverse Event|0
6299079|NCT02512302|10021724|FG002|Period 2|Adverse Event|0
6299080|NCT02512302|10021725|FG003|Period 2|Adverse Event|0
6299081|NCT02512302|10021726|FG004|Period 2|Adverse Event|0
6299082|NCT02512302|10021727|FG005|Period 2|Adverse Event|0
6299083|NCT02512302|10021728|FG006|Period 2|Adverse Event|0
6299084|NCT02512302|10021729|FG007|Period 2|Adverse Event|0
6299085|NCT02512302|10021730|FG008|Period 2|Adverse Event|0
6299086|NCT02512302|10021731|FG009|Period 2|Adverse Event|1
6299087|NCT02512302|10021722|FG000|Period 3|Lost to Follow-up|0
6299088|NCT02512302|10021723|FG001|Period 3|Lost to Follow-up|0
6299089|NCT02512302|10021724|FG002|Period 3|Lost to Follow-up|1
6299090|NCT02512302|10021725|FG003|Period 3|Lost to Follow-up|0
6299091|NCT02512302|10021726|FG004|Period 3|Lost to Follow-up|0
6299092|NCT02512302|10021727|FG005|Period 3|Lost to Follow-up|0
6299093|NCT02512302|10021728|FG006|Period 3|Lost to Follow-up|0
6299094|NCT02512302|10021729|FG007|Period 3|Lost to Follow-up|0
6299095|NCT02512302|10021730|FG008|Period 3|Lost to Follow-up|0
6299096|NCT02512302|10021731|FG009|Period 3|Lost to Follow-up|0
6299097|NCT02512302|10021722|FG000|Period 4|Adverse Event|0
6299098|NCT02512302|10021723|FG001|Period 4|Adverse Event|0
6299099|NCT02512302|10021724|FG002|Period 4|Adverse Event|0
6299100|NCT02512302|10021725|FG003|Period 4|Adverse Event|0
6299101|NCT02512302|10021726|FG004|Period 4|Adverse Event|0
6299102|NCT02512302|10021727|FG005|Period 4|Adverse Event|0
6299103|NCT02512302|10021728|FG006|Period 4|Adverse Event|1
6299104|NCT02512302|10021729|FG007|Period 4|Adverse Event|0
6299105|NCT02512302|10021730|FG008|Period 4|Adverse Event|0
6299106|NCT02512302|10021731|FG009|Period 4|Adverse Event|0
6299107|NCT02512861|10021826|FG000|Overall Study|Protocol Violation|3
6299108|NCT02512861|10021827|FG001|Overall Study|Protocol Violation|7
6299109|NCT02512861|10021826|FG000|Overall Study|Physician Decision|3
6299110|NCT02512861|10021827|FG001|Overall Study|Physician Decision|1
6299111|NCT02512861|10021826|FG000|Overall Study|Withdrawal by Subject|0
6299112|NCT02512861|10021827|FG001|Overall Study|Withdrawal by Subject|1
6299113|NCT02512965|10021849|FG000|Overall Study|Withdrawal by Subject|0
6299114|NCT02512965|10021850|FG001|Overall Study|Withdrawal by Subject|4
6299115|NCT02513160|10021880|FG000|Run-In Period (Days -14 to Day -1)|Inclusion criteria not met|33
6299116|NCT02513160|10021881|FG001|Run-In Period (Days -14 to Day -1)|Inclusion criteria not met|0
6299117|NCT02513160|10021882|FG002|Run-In Period (Days -14 to Day -1)|Inclusion criteria not met|0
6299118|NCT02513160|10021883|FG003|Run-In Period (Days -14 to Day -1)|Inclusion criteria not met|0
6299119|NCT02513160|10021880|FG000|Run-In Period (Days -14 to Day -1)|Failure to meet randomization criteria|214
6299120|NCT02513160|10021881|FG001|Run-In Period (Days -14 to Day -1)|Failure to meet randomization criteria|0
6299121|NCT02513160|10021882|FG002|Run-In Period (Days -14 to Day -1)|Failure to meet randomization criteria|0
6299122|NCT02513160|10021883|FG003|Run-In Period (Days -14 to Day -1)|Failure to meet randomization criteria|0
6299123|NCT02513160|10021880|FG000|Run-In Period (Days -14 to Day -1)|Exclusion criteria met|6
6299124|NCT02513160|10021881|FG001|Run-In Period (Days -14 to Day -1)|Exclusion criteria met|0
6299125|NCT02513160|10021882|FG002|Run-In Period (Days -14 to Day -1)|Exclusion criteria met|0
6299126|NCT02513160|10021883|FG003|Run-In Period (Days -14 to Day -1)|Exclusion criteria met|0
6299127|NCT02513160|10021880|FG000|Run-In Period (Days -14 to Day -1)|Adverse Event|4
6299128|NCT02513160|10021881|FG001|Run-In Period (Days -14 to Day -1)|Adverse Event|0
6299129|NCT02513160|10021882|FG002|Run-In Period (Days -14 to Day -1)|Adverse Event|0
6299130|NCT02513160|10021883|FG003|Run-In Period (Days -14 to Day -1)|Adverse Event|0
6299131|NCT02513160|10021880|FG000|Run-In Period (Days -14 to Day -1)|Withdrawal by Subject|20
6299132|NCT02513160|10021881|FG001|Run-In Period (Days -14 to Day -1)|Withdrawal by Subject|0
6299133|NCT02513160|10021882|FG002|Run-In Period (Days -14 to Day -1)|Withdrawal by Subject|0
6299134|NCT02513160|10021883|FG003|Run-In Period (Days -14 to Day -1)|Withdrawal by Subject|0
6299135|NCT02513160|10021880|FG000|Run-In Period (Days -14 to Day -1)|Site reached randomization limit|1
6299136|NCT02513160|10021881|FG001|Run-In Period (Days -14 to Day -1)|Site reached randomization limit|0
6299137|NCT02513160|10021882|FG002|Run-In Period (Days -14 to Day -1)|Site reached randomization limit|0
6299138|NCT02513160|10021883|FG003|Run-In Period (Days -14 to Day -1)|Site reached randomization limit|0
6299139|NCT02513160|10021880|FG000|Run-In Period (Days -14 to Day -1)|Lost to Follow-up|10
6299140|NCT02513160|10021881|FG001|Run-In Period (Days -14 to Day -1)|Lost to Follow-up|0
6299141|NCT02513160|10021882|FG002|Run-In Period (Days -14 to Day -1)|Lost to Follow-up|0
6299142|NCT02513160|10021883|FG003|Run-In Period (Days -14 to Day -1)|Lost to Follow-up|0
6299143|NCT02513160|10021880|FG000|Treatment Period (Day 0 to Week 6)|Withdrawal by Subject|2
6299144|NCT02513160|10021881|FG001|Treatment Period (Day 0 to Week 6)|Withdrawal by Subject|2
6299145|NCT02513160|10021882|FG002|Treatment Period (Day 0 to Week 6)|Withdrawal by Subject|0
6299146|NCT02513160|10021883|FG003|Treatment Period (Day 0 to Week 6)|Withdrawal by Subject|1
6299147|NCT02513160|10021880|FG000|Treatment Period (Day 0 to Week 6)|Noncompliance|1
6299148|NCT02513160|10021881|FG001|Treatment Period (Day 0 to Week 6)|Noncompliance|0
6299149|NCT02513160|10021882|FG002|Treatment Period (Day 0 to Week 6)|Noncompliance|0
6299150|NCT02513160|10021883|FG003|Treatment Period (Day 0 to Week 6)|Noncompliance|0
6299151|NCT02513160|10021880|FG000|Treatment Period (Day 0 to Week 6)|Lost to Follow-up|2
6299152|NCT02513160|10021881|FG001|Treatment Period (Day 0 to Week 6)|Lost to Follow-up|1
6299153|NCT02513160|10021882|FG002|Treatment Period (Day 0 to Week 6)|Lost to Follow-up|1
6299154|NCT02513160|10021883|FG003|Treatment Period (Day 0 to Week 6)|Lost to Follow-up|1
6299155|NCT02513160|10021880|FG000|Treatment Period (Day 0 to Week 6)|Lack of Efficacy|1
6299156|NCT02513160|10021881|FG001|Treatment Period (Day 0 to Week 6)|Lack of Efficacy|0
6299157|NCT02513160|10021882|FG002|Treatment Period (Day 0 to Week 6)|Lack of Efficacy|0
6299158|NCT02513160|10021883|FG003|Treatment Period (Day 0 to Week 6)|Lack of Efficacy|0
6299159|NCT02513160|10021880|FG000|Treatment Period (Day 0 to Week 6)|Did not meet exclusion criteria|0
6299160|NCT02513160|10021881|FG001|Treatment Period (Day 0 to Week 6)|Did not meet exclusion criteria|1
6299161|NCT02513160|10021882|FG002|Treatment Period (Day 0 to Week 6)|Did not meet exclusion criteria|0
6299162|NCT02513160|10021883|FG003|Treatment Period (Day 0 to Week 6)|Did not meet exclusion criteria|0
6299163|NCT02513459|10021913|FG000|Overall Study|Adverse Event|7
6299164|NCT02513459|10021913|FG000|Overall Study|Withdrew consent|5
6299165|NCT02513459|10021913|FG000|Overall Study|Loss of efficacy|2
6299166|NCT02513459|10021913|FG000|Overall Study|Pregnancy|2
6299167|NCT02513459|10021913|FG000|Overall Study|Subject decision|2
6299168|NCT02513459|10021913|FG000|Overall Study|Lack of response|1
6299169|NCT02513459|10021913|FG000|Overall Study|Reproductive plans|1
6299170|NCT02513459|10021913|FG000|Overall Study|Surgery planned-- not done|1
6299171|NCT02513550|10021934|FG000|Double Blind Treatment Period|Withdrawal by Subject|11
6299172|NCT02513550|10021935|FG001|Double Blind Treatment Period|Withdrawal by Subject|11
6299173|NCT02513550|10021936|FG002|Double Blind Treatment Period|Withdrawal by Subject|25
6299174|NCT02513550|10021937|FG003|Double Blind Treatment Period|Withdrawal by Subject|0
6299175|NCT02513550|10021938|FG004|Double Blind Treatment Period|Withdrawal by Subject|0
6299176|NCT02513550|10021939|FG005|Double Blind Treatment Period|Withdrawal by Subject|0
6299177|NCT02513550|10021934|FG000|Double Blind Treatment Period|Adverse Event|5
6299178|NCT02513550|10021935|FG001|Double Blind Treatment Period|Adverse Event|13
6299179|NCT02513550|10021936|FG002|Double Blind Treatment Period|Adverse Event|17
6299180|NCT02513550|10021937|FG003|Double Blind Treatment Period|Adverse Event|0
6299181|NCT02513550|10021938|FG004|Double Blind Treatment Period|Adverse Event|1
6299182|NCT02513550|10021939|FG005|Double Blind Treatment Period|Adverse Event|0
6299183|NCT02513550|10021934|FG000|Double Blind Treatment Period|Lost to Follow-up|9
6299184|NCT02513550|10021935|FG001|Double Blind Treatment Period|Lost to Follow-up|7
6299185|NCT02513550|10021936|FG002|Double Blind Treatment Period|Lost to Follow-up|11
6299186|NCT02513550|10021937|FG003|Double Blind Treatment Period|Lost to Follow-up|0
6299187|NCT02513550|10021938|FG004|Double Blind Treatment Period|Lost to Follow-up|0
6299188|NCT02513550|10021939|FG005|Double Blind Treatment Period|Lost to Follow-up|1
6299189|NCT02513550|10021934|FG000|Double Blind Treatment Period|Lack of Efficacy|4
6299190|NCT02513550|10021935|FG001|Double Blind Treatment Period|Lack of Efficacy|5
6299191|NCT02513550|10021936|FG002|Double Blind Treatment Period|Lack of Efficacy|6
6299192|NCT02513550|10021937|FG003|Double Blind Treatment Period|Lack of Efficacy|0
6299193|NCT02513550|10021938|FG004|Double Blind Treatment Period|Lack of Efficacy|0
6299194|NCT02513550|10021939|FG005|Double Blind Treatment Period|Lack of Efficacy|0
6299195|NCT02513550|10021934|FG000|Double Blind Treatment Period|Protocol Violation|1
6299196|NCT02513550|10021935|FG001|Double Blind Treatment Period|Protocol Violation|1
6299197|NCT02513550|10021936|FG002|Double Blind Treatment Period|Protocol Violation|4
6299198|NCT02513550|10021937|FG003|Double Blind Treatment Period|Protocol Violation|0
6299199|NCT02513550|10021938|FG004|Double Blind Treatment Period|Protocol Violation|0
6299200|NCT02513550|10021939|FG005|Double Blind Treatment Period|Protocol Violation|0
6299201|NCT02513550|10021934|FG000|Double Blind Treatment Period|Physician Decision|2
6299202|NCT02513550|10021935|FG001|Double Blind Treatment Period|Physician Decision|0
6299203|NCT02513550|10021936|FG002|Double Blind Treatment Period|Physician Decision|4
6299204|NCT02513550|10021937|FG003|Double Blind Treatment Period|Physician Decision|0
6299205|NCT02513550|10021938|FG004|Double Blind Treatment Period|Physician Decision|0
6299206|NCT02513550|10021939|FG005|Double Blind Treatment Period|Physician Decision|0
6299207|NCT02513550|10021934|FG000|Double Blind Treatment Period|Site terminated by sponsor|1
6299208|NCT02513550|10021935|FG001|Double Blind Treatment Period|Site terminated by sponsor|1
6299209|NCT02513550|10021936|FG002|Double Blind Treatment Period|Site terminated by sponsor|3
6299210|NCT02513550|10021937|FG003|Double Blind Treatment Period|Site terminated by sponsor|0
6299211|NCT02513550|10021938|FG004|Double Blind Treatment Period|Site terminated by sponsor|0
6299212|NCT02513550|10021939|FG005|Double Blind Treatment Period|Site terminated by sponsor|0
6299213|NCT02513550|10021934|FG000|Double Blind Treatment Period|Met exclusion criteria and was not dosed|0
6299214|NCT02513550|10021935|FG001|Double Blind Treatment Period|Met exclusion criteria and was not dosed|0
6299215|NCT02513550|10021936|FG002|Double Blind Treatment Period|Met exclusion criteria and was not dosed|1
6299216|NCT02513550|10021937|FG003|Double Blind Treatment Period|Met exclusion criteria and was not dosed|0
6299217|NCT02513550|10021938|FG004|Double Blind Treatment Period|Met exclusion criteria and was not dosed|0
6299218|NCT02513550|10021939|FG005|Double Blind Treatment Period|Met exclusion criteria and was not dosed|0
6299219|NCT02513550|10021934|FG000|Double Blind Treatment Period|Due to personal business|2
6299220|NCT02513550|10021935|FG001|Double Blind Treatment Period|Due to personal business|0
6299221|NCT02513550|10021936|FG002|Double Blind Treatment Period|Due to personal business|1
6299222|NCT02513550|10021937|FG003|Double Blind Treatment Period|Due to personal business|0
6299223|NCT02513550|10021938|FG004|Double Blind Treatment Period|Due to personal business|0
6299224|NCT02513550|10021939|FG005|Double Blind Treatment Period|Due to personal business|0
6299225|NCT02513550|10021934|FG000|Double Blind Treatment Period|Death|1
6299226|NCT02513550|10021935|FG001|Double Blind Treatment Period|Death|0
6299227|NCT02513550|10021936|FG002|Double Blind Treatment Period|Death|2
6299228|NCT02513550|10021937|FG003|Double Blind Treatment Period|Death|0
6299229|NCT02513550|10021938|FG004|Double Blind Treatment Period|Death|0
6299230|NCT02513550|10021939|FG005|Double Blind Treatment Period|Death|0
6299231|NCT02513550|10021934|FG000|Post-Treatment Follow-up Period|Withdrawal by Subject|12
6299232|NCT02513550|10021935|FG001|Post-Treatment Follow-up Period|Withdrawal by Subject|20
6299233|NCT02513550|10021936|FG002|Post-Treatment Follow-up Period|Withdrawal by Subject|26
6299234|NCT02513550|10021937|FG003|Post-Treatment Follow-up Period|Withdrawal by Subject|0
6299235|NCT02513550|10021938|FG004|Post-Treatment Follow-up Period|Withdrawal by Subject|0
6299236|NCT02513550|10021939|FG005|Post-Treatment Follow-up Period|Withdrawal by Subject|0
6299237|NCT02513550|10021934|FG000|Post-Treatment Follow-up Period|Early terminated but completed follow-up|12
6299238|NCT02513550|10021935|FG001|Post-Treatment Follow-up Period|Early terminated but completed follow-up|16
6299239|NCT02513550|10021936|FG002|Post-Treatment Follow-up Period|Early terminated but completed follow-up|20
6299240|NCT02513550|10021937|FG003|Post-Treatment Follow-up Period|Early terminated but completed follow-up|0
6299241|NCT02513550|10021938|FG004|Post-Treatment Follow-up Period|Early terminated but completed follow-up|0
6299242|NCT02513550|10021939|FG005|Post-Treatment Follow-up Period|Early terminated but completed follow-up|0
6299243|NCT02513550|10021934|FG000|Post-Treatment Follow-up Period|Lost to Follow-up|4
6299244|NCT02513550|10021935|FG001|Post-Treatment Follow-up Period|Lost to Follow-up|2
5981950|NCT04497987|9570784|FG001|Overall Study|Adverse Event|0
5981951|NCT04497987|9570783|FG000|Overall Study|Death|21
5981952|NCT04497987|9570784|FG001|Overall Study|Death|13
5981953|NCT04497987|9570783|FG000|Overall Study|Lost to Follow-up|19
5981954|NCT04497987|9570784|FG001|Overall Study|Lost to Follow-up|17
5981955|NCT04497987|9570783|FG000|Overall Study|Other - as reported by the investigator|22
5981956|NCT04497987|9570784|FG001|Overall Study|Other - as reported by the investigator|16
5981957|NCT04497987|9570783|FG000|Overall Study|Physician Decision|1
5981958|NCT04497987|9570784|FG001|Overall Study|Physician Decision|0
5981959|NCT04497987|9570783|FG000|Overall Study|Withdrawal by Subject|35
5981960|NCT04497987|9570784|FG001|Overall Study|Withdrawal by Subject|21
5981961|NCT03512210|9570840|FG000|Step 1: MINMON Intervention|Lost to Follow-up|3
5981962|NCT03512210|9570840|FG000|Step 1: MINMON Intervention|Protocol Violation|1
5981963|NCT03512210|9570840|FG000|Step 2:Post-MINMON|Death|2
5981964|NCT03512210|9570840|FG000|Step 2:Post-MINMON|Lost to Follow-up|30
5981965|NCT03512210|9570840|FG000|Step 2:Post-MINMON|Withdrawal by Subject|2
6063522|NCT00506415|9664784|FG000|Extended Open Label (Maximum 48 Weeks)|Lost to Follow-up|0
6063523|NCT00506415|9664785|FG001|Extended Open Label (Maximum 48 Weeks)|Lost to Follow-up|0
6063524|NCT00506415|9664786|FG002|Extended Open Label (Maximum 48 Weeks)|Lost to Follow-up|0
6063525|NCT00506415|9664787|FG003|Extended Open Label (Maximum 48 Weeks)|Lost to Follow-up|8
6063526|NCT00506415|9664784|FG000|Extended Open Label (Maximum 48 Weeks)|Withdrawal by Subject|0
6063527|NCT00506415|9664785|FG001|Extended Open Label (Maximum 48 Weeks)|Withdrawal by Subject|0
6063528|NCT00506415|9664786|FG002|Extended Open Label (Maximum 48 Weeks)|Withdrawal by Subject|0
6063529|NCT00506415|9664787|FG003|Extended Open Label (Maximum 48 Weeks)|Withdrawal by Subject|14
6063530|NCT00506415|9664784|FG000|Extended Open Label (Maximum 48 Weeks)|Protocol Violation|0
6063531|NCT00506415|9664785|FG001|Extended Open Label (Maximum 48 Weeks)|Protocol Violation|0
6063532|NCT00506415|9664786|FG002|Extended Open Label (Maximum 48 Weeks)|Protocol Violation|0
6063533|NCT00506415|9664787|FG003|Extended Open Label (Maximum 48 Weeks)|Protocol Violation|5
6063534|NCT00506415|9664784|FG000|Extended Open Label (Maximum 48 Weeks)|Unsatisfactory therapeutic effect|0
6063535|NCT00506415|9664785|FG001|Extended Open Label (Maximum 48 Weeks)|Unsatisfactory therapeutic effect|0
6063536|NCT00506415|9664786|FG002|Extended Open Label (Maximum 48 Weeks)|Unsatisfactory therapeutic effect|0
6063537|NCT00506415|9664787|FG003|Extended Open Label (Maximum 48 Weeks)|Unsatisfactory therapeutic effect|6
6063538|NCT00506415|9664784|FG000|Extended Open Label (Maximum 48 Weeks)|Death|0
6063539|NCT00506415|9664785|FG001|Extended Open Label (Maximum 48 Weeks)|Death|0
6063540|NCT00506415|9664786|FG002|Extended Open Label (Maximum 48 Weeks)|Death|0
6063541|NCT00506415|9664787|FG003|Extended Open Label (Maximum 48 Weeks)|Death|7
6063542|NCT00506441|9664800|FG000|Period 1; Open-label Period|Adverse Event|21
6063543|NCT00506441|9664801|FG001|Period 1; Open-label Period|Adverse Event|0
6063544|NCT00506441|9664800|FG000|Period 1; Open-label Period|Lack of Efficacy|13
6063545|NCT00506441|9664801|FG001|Period 1; Open-label Period|Lack of Efficacy|0
6063546|NCT00506441|9664800|FG000|Period 1; Open-label Period|Lost to Follow-up|2
6063547|NCT00506441|9664801|FG001|Period 1; Open-label Period|Lost to Follow-up|0
6063548|NCT00506441|9664800|FG000|Period 1; Open-label Period|Physician Decision|5
6063549|NCT00506441|9664801|FG001|Period 1; Open-label Period|Physician Decision|0
6063550|NCT00506441|9664800|FG000|Period 1; Open-label Period|Protocol Violation|9
6063551|NCT00506441|9664801|FG001|Period 1; Open-label Period|Protocol Violation|0
6063552|NCT00506441|9664800|FG000|Period 1; Open-label Period|Withdrawal by Subject|13
6063553|NCT00506441|9664801|FG001|Period 1; Open-label Period|Withdrawal by Subject|0
6063554|NCT00506441|9664800|FG000|Period 1; Open-label Period|Other Reasons|13
6063555|NCT00506441|9664801|FG001|Period 1; Open-label Period|Other Reasons|0
6063556|NCT00506441|9664800|FG000|Period 2; Double-blind Period|Adverse Event|0
6299245|NCT02513550|10021936|FG002|Post-Treatment Follow-up Period|Lost to Follow-up|7
6299246|NCT02513550|10021937|FG003|Post-Treatment Follow-up Period|Lost to Follow-up|0
6299247|NCT02513550|10021938|FG004|Post-Treatment Follow-up Period|Lost to Follow-up|0
6299248|NCT02513550|10021939|FG005|Post-Treatment Follow-up Period|Lost to Follow-up|0
6299249|NCT02513550|10021934|FG000|Post-Treatment Follow-up Period|Adverse Event|1
6299250|NCT02513550|10021935|FG001|Post-Treatment Follow-up Period|Adverse Event|1
6299251|NCT02513550|10021936|FG002|Post-Treatment Follow-up Period|Adverse Event|4
6299252|NCT02513550|10021937|FG003|Post-Treatment Follow-up Period|Adverse Event|0
6299253|NCT02513550|10021938|FG004|Post-Treatment Follow-up Period|Adverse Event|0
6299254|NCT02513550|10021939|FG005|Post-Treatment Follow-up Period|Adverse Event|0
6299255|NCT02513550|10021934|FG000|Post-Treatment Follow-up Period|Physician Decision|2
6299256|NCT02513550|10021935|FG001|Post-Treatment Follow-up Period|Physician Decision|0
6299257|NCT02513550|10021936|FG002|Post-Treatment Follow-up Period|Physician Decision|0
6299258|NCT02513550|10021937|FG003|Post-Treatment Follow-up Period|Physician Decision|0
6299259|NCT02513550|10021938|FG004|Post-Treatment Follow-up Period|Physician Decision|0
6299260|NCT02513550|10021939|FG005|Post-Treatment Follow-up Period|Physician Decision|0
6299261|NCT02513550|10021934|FG000|Post-Treatment Follow-up Period|Death|0
6299262|NCT02513550|10021935|FG001|Post-Treatment Follow-up Period|Death|0
6299263|NCT02513550|10021936|FG002|Post-Treatment Follow-up Period|Death|1
6299264|NCT02513550|10021937|FG003|Post-Treatment Follow-up Period|Death|0
6299265|NCT02513550|10021938|FG004|Post-Treatment Follow-up Period|Death|0
6299266|NCT02513550|10021939|FG005|Post-Treatment Follow-up Period|Death|0
6299267|NCT02513550|10021934|FG000|Post-Treatment Follow-up Period|Subject move out of town|0
6299268|NCT02513550|10021935|FG001|Post-Treatment Follow-up Period|Subject move out of town|0
6299269|NCT02513550|10021936|FG002|Post-Treatment Follow-up Period|Subject move out of town|1
6299270|NCT02513550|10021937|FG003|Post-Treatment Follow-up Period|Subject move out of town|0
6299271|NCT02513550|10021938|FG004|Post-Treatment Follow-up Period|Subject move out of town|0
6299272|NCT02513550|10021939|FG005|Post-Treatment Follow-up Period|Subject move out of town|0
6299273|NCT02513550|10021934|FG000|Post-Treatment Follow-up Period|Subject did not come for Visit-802|0
6299274|NCT02513550|10021935|FG001|Post-Treatment Follow-up Period|Subject did not come for Visit-802|0
6299275|NCT02513550|10021936|FG002|Post-Treatment Follow-up Period|Subject did not come for Visit-802|3
6299276|NCT02513550|10021937|FG003|Post-Treatment Follow-up Period|Subject did not come for Visit-802|0
6299277|NCT02513550|10021938|FG004|Post-Treatment Follow-up Period|Subject did not come for Visit-802|0
6299278|NCT02513550|10021939|FG005|Post-Treatment Follow-up Period|Subject did not come for Visit-802|0
6299279|NCT02513550|10021934|FG000|Post-Treatment Follow-up Period|Labor Reasons|0
6299280|NCT02513550|10021935|FG001|Post-Treatment Follow-up Period|Labor Reasons|0
6299281|NCT02513550|10021936|FG002|Post-Treatment Follow-up Period|Labor Reasons|1
6299282|NCT02513550|10021937|FG003|Post-Treatment Follow-up Period|Labor Reasons|0
6299283|NCT02513550|10021938|FG004|Post-Treatment Follow-up Period|Labor Reasons|0
6299284|NCT02513550|10021939|FG005|Post-Treatment Follow-up Period|Labor Reasons|0
6299285|NCT02513732|10021969|FG000|Overall Study|Lost to Follow-up|11
6299286|NCT02513732|10021969|FG000|Overall Study|Death|9
6299287|NCT02513732|10021969|FG000|Overall Study|Changing hospital|2
6299288|NCT02513745|10021975|FG000|Overall Study|Criteria at time of surgery not met.|3
6299289|NCT02513745|10021976|FG001|Overall Study|Criteria at time of surgery not met.|3
6299290|NCT02513771|10021984|FG000|Overall Study|Lost to Follow-up|1
6299291|NCT02513771|10021985|FG001|Overall Study|Lost to Follow-up|1
6299292|NCT02513771|10021984|FG000|Overall Study|Not being able to get to clinic|1
6299293|NCT02513771|10021985|FG001|Overall Study|Not being able to get to clinic|0
6299294|NCT02513823|10021991|FG000|Overall Study|Lost to Follow-up|4
6299295|NCT02513823|10021991|FG000|Overall Study|Physician Decision|1
6299296|NCT02514122|10022033|FG000|Overall Study|Withdrawal by Subject|2
6299297|NCT02514122|10022034|FG001|Overall Study|Withdrawal by Subject|0
6299298|NCT02514174|10022040|FG000|Overall Study|Patient refused to continue medication|1
6299299|NCT02514174|10022040|FG000|Overall Study|Adverse Event|2
6299300|NCT02514174|10022040|FG000|Overall Study|Study closed by sponsor|9
6299301|NCT02514174|10022040|FG000|Overall Study|Progressive disease|11
6299302|NCT02514174|10022040|FG000|Overall Study|Treatment change|1
6299303|NCT02514174|10022040|FG000|Overall Study|Treated off study with Afatinib.|1
6299304|NCT02514473|10022046|FG000|Overall Study|Adverse Event|0
6299305|NCT02514473|10022047|FG001|Overall Study|Adverse Event|2
6299306|NCT02514473|10022046|FG000|Overall Study|Withdrawal by Subject|2
6299307|NCT02514473|10022047|FG001|Overall Study|Withdrawal by Subject|1
6299308|NCT02514473|10022046|FG000|Overall Study|Lost to Follow-up|0
6299309|NCT02514473|10022047|FG001|Overall Study|Lost to Follow-up|1
6299310|NCT02514473|10022046|FG000|Overall Study|Other|1
6299311|NCT02514473|10022047|FG001|Overall Study|Other|1
6299312|NCT02514551|10022056|FG000|Overall Study|Lost to Follow-up|0
6299313|NCT02514551|10022057|FG001|Overall Study|Lost to Follow-up|1
6299314|NCT02514551|10022056|FG000|Overall Study|Participant Never Treated|0
6299315|NCT02514551|10022057|FG001|Overall Study|Participant Never Treated|2
6299316|NCT02514577|10022066|FG000|Overall Study|Lost to Follow-up|6
6299317|NCT02514577|10022067|FG001|Overall Study|Lost to Follow-up|6
6299318|NCT02514577|10022066|FG000|Overall Study|Protocol Violation|1
6299319|NCT02514577|10022067|FG001|Overall Study|Protocol Violation|0
6299320|NCT02514577|10022066|FG000|Overall Study|Withdrawal by Subject|6
6299321|NCT02514577|10022067|FG001|Overall Study|Withdrawal by Subject|6
6299322|NCT02514577|10022066|FG000|Overall Study|Adverse Event|1
6299323|NCT02514577|10022067|FG001|Overall Study|Adverse Event|1
6299324|NCT02514746|10022075|FG000|Overall Study|Chronically Ill|1
6299325|NCT02514746|10022076|FG001|Overall Study|Chronically Ill|2
6299326|NCT02514746|10022075|FG000|Overall Study|Physician Decision|4
6299327|NCT02514746|10022076|FG001|Overall Study|Physician Decision|2
6299328|NCT02514746|10022075|FG000|Overall Study|Withdrawal by Subject|12
6299329|NCT02514746|10022076|FG001|Overall Study|Withdrawal by Subject|10
6299330|NCT02514746|10022075|FG000|Overall Study|Other|5
6299331|NCT02514746|10022076|FG001|Overall Study|Other|1
6299332|NCT02514772|10022086|FG000|Overall Study|Adverse Event|1
6299333|NCT02514772|10022087|FG001|Overall Study|Adverse Event|0
6299334|NCT02514772|10022086|FG000|Overall Study|Death|0
6299335|NCT02514772|10022087|FG001|Overall Study|Death|1
6299336|NCT02514772|10022086|FG000|Overall Study|Withdrawal by Subject|2
6299337|NCT02514772|10022087|FG001|Overall Study|Withdrawal by Subject|1
6299338|NCT02514824|10022097|FG000|Overall Study|Withdrawal by Subject|1
6299339|NCT02514824|10022098|FG001|Overall Study|Withdrawal by Subject|0
6299340|NCT02514824|10022099|FG002|Overall Study|Withdrawal by Subject|0
6299341|NCT02514824|10022100|FG003|Overall Study|Withdrawal by Subject|0
6299342|NCT02514824|10022097|FG000|Overall Study|Dose-Limiting Toxicity|0
6299343|NCT02514824|10022098|FG001|Overall Study|Dose-Limiting Toxicity|1
6299344|NCT02514824|10022099|FG002|Overall Study|Dose-Limiting Toxicity|0
6299345|NCT02514824|10022100|FG003|Overall Study|Dose-Limiting Toxicity|0
6299346|NCT02515045|10022118|FG000|Overall Study|Adverse Event|0
6299347|NCT02515045|10022119|FG001|Overall Study|Adverse Event|3
6299348|NCT02515045|10022120|FG002|Overall Study|Adverse Event|3
6299349|NCT02515045|10022118|FG000|Overall Study|Lost to Follow-up|0
6299350|NCT02515045|10022119|FG001|Overall Study|Lost to Follow-up|1
6299351|NCT02515045|10022120|FG002|Overall Study|Lost to Follow-up|1
6299352|NCT02515097|10022139|FG000|Overall Study|Lost to Follow-up|4
6299353|NCT02515097|10022140|FG001|Overall Study|Lost to Follow-up|2
6299354|NCT02515097|10022139|FG000|Overall Study|Withdrawal by Subject|1
6299355|NCT02515097|10022140|FG001|Overall Study|Withdrawal by Subject|3
6299356|NCT02515097|10022139|FG000|Overall Study|Adverse Event|2
6299357|NCT02515097|10022140|FG001|Overall Study|Adverse Event|1
6299358|NCT02515279|10022155|FG000|Overall Study|Adverse Event|7
6299359|NCT02515279|10022155|FG000|Overall Study|Lack of Efficacy|31
6299360|NCT02515279|10022155|FG000|Overall Study|Lost to Follow-up|9
6299361|NCT02515279|10022155|FG000|Overall Study|Withdrawal by Subject|18
6299362|NCT02515279|10022155|FG000|Overall Study|End-of-treatment visit not attended|17
6299363|NCT02515279|10022155|FG000|Overall Study|Other|22
6299364|NCT02515331|10022175|FG000|Overall Study|Withdrawal by Subject|0
6299365|NCT02515331|10022176|FG001|Overall Study|Withdrawal by Subject|0
6299366|NCT02515331|10022177|FG002|Overall Study|Withdrawal by Subject|1
6299367|NCT02515331|10022175|FG000|Overall Study|Protocol deviation|0
6299368|NCT02515331|10022176|FG001|Overall Study|Protocol deviation|0
6299369|NCT02515331|10022177|FG002|Overall Study|Protocol deviation|3
6299370|NCT02515331|10022175|FG000|Overall Study|Adverse Event|2
6299371|NCT02515331|10022176|FG001|Overall Study|Adverse Event|0
6299372|NCT02515331|10022177|FG002|Overall Study|Adverse Event|0
6299373|NCT02515630|10022187|FG000|Overall Study|Withdrawal by Subject|5
6299374|NCT02515630|10022187|FG000|Overall Study|Adverse Event|4
6299375|NCT02515630|10022187|FG000|Overall Study|Physician Decision|4
6299376|NCT02515630|10022187|FG000|Overall Study|Death|2
6299377|NCT02515630|10022187|FG000|Overall Study|Disease Progression|1
6299378|NCT02515669|10022207|FG000|228 Week Open-Label Phase|Other|0
6299379|NCT02515669|10022208|FG001|228 Week Open-Label Phase|Other|0
6299380|NCT02515669|10022209|FG002|228 Week Open-Label Phase|Other|1
6299381|NCT02515669|10022210|FG003|228 Week Open-Label Phase|Other|4
6299382|NCT02515669|10022207|FG000|228 Week Open-Label Phase|Lack of Efficacy|0
6299383|NCT02515669|10022208|FG001|228 Week Open-Label Phase|Lack of Efficacy|0
6299384|NCT02515669|10022209|FG002|228 Week Open-Label Phase|Lack of Efficacy|1
6299385|NCT02515669|10022210|FG003|228 Week Open-Label Phase|Lack of Efficacy|0
6299386|NCT02515669|10022207|FG000|228 Week Open-Label Phase|Subject Request to Discontinue Treatment|0
6299387|NCT02515669|10022208|FG001|228 Week Open-Label Phase|Subject Request to Discontinue Treatment|0
6299388|NCT02515669|10022209|FG002|228 Week Open-Label Phase|Subject Request to Discontinue Treatment|2
6299389|NCT02515669|10022210|FG003|228 Week Open-Label Phase|Subject Request to Discontinue Treatment|3
6299390|NCT02515669|10022207|FG000|228 Week Open-Label Phase|Administrative Reason by Sponsor|0
6299391|NCT02515669|10022208|FG001|228 Week Open-Label Phase|Administrative Reason by Sponsor|7
6299392|NCT02515669|10022209|FG002|228 Week Open-Label Phase|Administrative Reason by Sponsor|2
6299393|NCT02515669|10022210|FG003|228 Week Open-Label Phase|Administrative Reason by Sponsor|17
6299394|NCT02515669|10022207|FG000|228 Week Open-Label Phase|Missing|0
6299395|NCT02515669|10022208|FG001|228 Week Open-Label Phase|Missing|2
6299396|NCT02515669|10022209|FG002|228 Week Open-Label Phase|Missing|2
6299397|NCT02515669|10022210|FG003|228 Week Open-Label Phase|Missing|2
6299398|NCT02515942|10022273|FG000|Overall Study|Adverse Event|5
6299399|NCT02515942|10022274|FG001|Overall Study|Adverse Event|0
6299400|NCT02515942|10022275|FG002|Overall Study|Adverse Event|0
6299401|NCT02515942|10022273|FG000|Overall Study|Death|0
6299402|NCT02515942|10022274|FG001|Overall Study|Death|0
6299403|NCT02515942|10022275|FG002|Overall Study|Death|1
6299404|NCT02515942|10022273|FG000|Overall Study|Lack of Efficacy|0
6299405|NCT02515942|10022274|FG001|Overall Study|Lack of Efficacy|0
6299406|NCT02515942|10022275|FG002|Overall Study|Lack of Efficacy|1
6299407|NCT02515942|10022273|FG000|Overall Study|Lost to Follow-up|2
6299408|NCT02515942|10022274|FG001|Overall Study|Lost to Follow-up|0
6299409|NCT02515942|10022275|FG002|Overall Study|Lost to Follow-up|0
6299410|NCT02515942|10022273|FG000|Overall Study|Withdrawal by Subject|0
6299411|NCT02515942|10022274|FG001|Overall Study|Withdrawal by Subject|3
6299412|NCT02515942|10022275|FG002|Overall Study|Withdrawal by Subject|2
6299413|NCT02515994|10022287|FG000|Overall Study|Protocol Violation|3
6299414|NCT02515994|10022288|FG001|Overall Study|Protocol Violation|5
6299415|NCT02515994|10022287|FG000|Overall Study|No Longer Meets Eligibility Criteria|2
6299416|NCT02515994|10022288|FG001|Overall Study|No Longer Meets Eligibility Criteria|1
6299417|NCT02515994|10022287|FG000|Overall Study|Adverse Event|3
6299418|NCT02515994|10022288|FG001|Overall Study|Adverse Event|1
6299419|NCT02515994|10022287|FG000|Overall Study|Withdrawal by Subject|2
6299420|NCT02515994|10022288|FG001|Overall Study|Withdrawal by Subject|0
6299421|NCT02516098|10022310|FG000|Period 1|Protocol Violation|1
6299422|NCT02516098|10022311|FG001|Period 1|Protocol Violation|0
6299423|NCT02516098|10022310|FG000|Washout After Period 1|Adverse Event|0
6299424|NCT02516098|10022311|FG001|Washout After Period 1|Adverse Event|1
6299425|NCT02516098|10022310|FG000|Period 2|Withdrawal by Subject|0
6299426|NCT02516098|10022311|FG001|Period 2|Withdrawal by Subject|1
6299427|NCT02516163|10022323|FG000|Overall Study|Withdrawal by Subject|1
6299428|NCT02516163|10022323|FG000|Overall Study|Failed MRI/incorrect MRI protocol|11
6299429|NCT02516163|10022323|FG000|Overall Study|Unfit/delay in surgery|3
6299430|NCT02516163|10022323|FG000|Overall Study|Use of incorrect measurement technique|5
6299431|NCT02516163|10022323|FG000|Overall Study|Data not recorded|2
6299432|NCT02516163|10022323|FG000|Overall Study|MRI contraindication exclusion|6
6299433|NCT02516202|10022330|FG000|Overall Study|Withdrawal by Subject|1
6299434|NCT02516202|10022331|FG001|Overall Study|Withdrawal by Subject|0
6299435|NCT02516202|10022332|FG002|Overall Study|Withdrawal by Subject|1
6299436|NCT02516202|10022330|FG000|Overall Study|Lost to Follow-up|1
6299437|NCT02516202|10022331|FG001|Overall Study|Lost to Follow-up|1
6299438|NCT02516202|10022332|FG002|Overall Study|Lost to Follow-up|1
6299439|NCT02516202|10022330|FG000|Overall Study|Stopped Follow-up|0
6299440|NCT02516202|10022331|FG001|Overall Study|Stopped Follow-up|0
6299441|NCT02516202|10022332|FG002|Overall Study|Stopped Follow-up|1
6299442|NCT02516306|10022342|FG000|Period 2: Day 8 - 91|Protocol Violation|1
6299443|NCT02516306|10022343|FG001|Period 2: Day 8 - 91|Protocol Violation|2
6299444|NCT02516332|10022352|FG000|Overall Study|Withdrawal by Subject|2
6299445|NCT02516332|10022353|FG001|Overall Study|Withdrawal by Subject|1
6299446|NCT02516332|10022354|FG002|Overall Study|Withdrawal by Subject|2
6299447|NCT02516410|10022364|FG000|Overall Study|Adverse Event|0
6299448|NCT02516410|10022365|FG001|Overall Study|Adverse Event|1
6299449|NCT02516410|10022364|FG000|Overall Study|Withdrawal by Subject|0
6299450|NCT02516410|10022365|FG001|Overall Study|Withdrawal by Subject|1
6299451|NCT02516592|10022378|FG000|Overall Study|Patient withdrew consent|5
6299452|NCT02516592|10022379|FG001|Overall Study|Patient withdrew consent|2
6299453|NCT02516592|10022378|FG000|Overall Study|Protocol deviation|4
6299454|NCT02516592|10022379|FG001|Overall Study|Protocol deviation|4
6299455|NCT02516592|10022378|FG000|Overall Study|Lost to Follow-up|2
6299456|NCT02516592|10022379|FG001|Overall Study|Lost to Follow-up|3
6299457|NCT02516592|10022378|FG000|Overall Study|Patient/guardian decision|2
6299458|NCT02516592|10022379|FG001|Overall Study|Patient/guardian decision|1
6299459|NCT02516592|10022378|FG000|Overall Study|Adverse Event|1
6299460|NCT02516592|10022379|FG001|Overall Study|Adverse Event|2
6299461|NCT02516592|10022378|FG000|Overall Study|Abnormal test procedure result|1
6299462|NCT02516592|10022379|FG001|Overall Study|Abnormal test procedure result|0
6299463|NCT02516592|10022378|FG000|Overall Study|Death|1
6299464|NCT02516592|10022379|FG001|Overall Study|Death|1
6299465|NCT02516605|10022390|FG000|Overall Study|Protocol Violation|0
6299466|NCT02516605|10022391|FG001|Overall Study|Protocol Violation|0
6299467|NCT02516605|10022392|FG002|Overall Study|Protocol Violation|0
6299468|NCT02516605|10022393|FG003|Overall Study|Protocol Violation|0
6299469|NCT02516605|10022394|FG004|Overall Study|Protocol Violation|1
6299470|NCT02516605|10022390|FG000|Overall Study|Withdrawal by Subject|0
6299471|NCT02516605|10022391|FG001|Overall Study|Withdrawal by Subject|0
6299472|NCT02516605|10022392|FG002|Overall Study|Withdrawal by Subject|0
6299473|NCT02516605|10022393|FG003|Overall Study|Withdrawal by Subject|1
6299474|NCT02516605|10022394|FG004|Overall Study|Withdrawal by Subject|0
6299475|NCT02516982|10022414|FG000|Overall Study|Called in to antenatal appointment|32
6299476|NCT02516982|10022415|FG001|Overall Study|Called in to antenatal appointment|35
6299477|NCT02516982|10022416|FG002|Overall Study|Called in to antenatal appointment|0
6299478|NCT02516982|10022417|FG003|Overall Study|Called in to antenatal appointment|0
6299479|NCT02516982|10022414|FG000|Overall Study|Withdrawal by Subject|0
6299480|NCT02516982|10022415|FG001|Overall Study|Withdrawal by Subject|0
6299481|NCT02516982|10022416|FG002|Overall Study|Withdrawal by Subject|1
6299482|NCT02516982|10022417|FG003|Overall Study|Withdrawal by Subject|2
6299483|NCT02516982|10022414|FG000|Overall Study|Protocol Violation|0
6299484|NCT02516982|10022415|FG001|Overall Study|Protocol Violation|0
6299485|NCT02516982|10022416|FG002|Overall Study|Protocol Violation|1
6299486|NCT02516982|10022417|FG003|Overall Study|Protocol Violation|1
6299487|NCT02516982|10022414|FG000|Overall Study|Did not install the app|0
6299488|NCT02516982|10022415|FG001|Overall Study|Did not install the app|0
6299489|NCT02516982|10022416|FG002|Overall Study|Did not install the app|46
6299490|NCT02516982|10022417|FG003|Overall Study|Did not install the app|47
6299491|NCT02517268|10022443|FG000|Overall Study|Withdrawal by Subject|1
6299492|NCT02517268|10022444|FG001|Overall Study|Withdrawal by Subject|0
6299493|NCT02517463|10022452|FG000|Overall Study|Lost to Follow-up|5
6299494|NCT02517463|10022453|FG001|Overall Study|Lost to Follow-up|2
6299495|NCT02517515|10022461|FG000|Overall Study|Adverse Event|0
6299496|NCT02517515|10022462|FG001|Overall Study|Adverse Event|1
6299497|NCT02517515|10022461|FG000|Overall Study|Withdrew Consent|0
6299498|NCT02517515|10022462|FG001|Overall Study|Withdrew Consent|1
6299499|NCT02517515|10022461|FG000|Overall Study|Lost to Follow-up|1
6299500|NCT02517515|10022462|FG001|Overall Study|Lost to Follow-up|0
6299501|NCT02517515|10022461|FG000|Overall Study|Other|1
6299502|NCT02517515|10022462|FG001|Overall Study|Other|0
6299503|NCT02517528|10022469|FG000|Overall Study|Withdrawal by Subject|1
6299504|NCT02517541|10022473|FG000|Baseline Period (Own Product)|Protocol Violation|1
6299505|NCT02517541|10022473|FG000|Test Period (SenSura Mio Convex Soft)|Adverse Event|3
6299506|NCT02517541|10022473|FG000|Test Period (SenSura Mio Convex Soft)|Lack of Efficacy|2
6299507|NCT02517541|10022473|FG000|Test Period (SenSura Mio Convex Soft)|Protocol Violation|1
6299508|NCT02517541|10022473|FG000|Test Period (SenSura Mio Convex Soft)|Withdrawal by Subject|4
6299509|NCT02517541|10022473|FG000|Test Period (SenSura Mio Convex Soft)|One subjects was not suited for the tes|2
6299510|NCT02517866|10022508|FG000|Overall Study|Pretreatment Event/Adverse Event|9
6299511|NCT02517866|10022509|FG001|Overall Study|Pretreatment Event/Adverse Event|2
6299512|NCT02517866|10022510|FG002|Overall Study|Pretreatment Event/Adverse Event|0
6299513|NCT02517866|10022508|FG000|Overall Study|Significant Protocol Deviation|4
6299514|NCT02517866|10022509|FG001|Overall Study|Significant Protocol Deviation|1
6299515|NCT02517866|10022510|FG002|Overall Study|Significant Protocol Deviation|0
6299516|NCT02517866|10022508|FG000|Overall Study|Lost to Follow-up|1
6299517|NCT02517866|10022509|FG001|Overall Study|Lost to Follow-up|0
6299518|NCT02517866|10022510|FG002|Overall Study|Lost to Follow-up|0
6299519|NCT02517866|10022508|FG000|Overall Study|Voluntary Withdrawal|2
6299520|NCT02517866|10022509|FG001|Overall Study|Voluntary Withdrawal|2
6299521|NCT02517866|10022510|FG002|Overall Study|Voluntary Withdrawal|0
6299522|NCT02517866|10022508|FG000|Overall Study|Investigator Decision|2
6299523|NCT02517866|10022509|FG001|Overall Study|Investigator Decision|1
6299524|NCT02517866|10022510|FG002|Overall Study|Investigator Decision|0
6299525|NCT02517866|10022508|FG000|Overall Study|Reason not specified|2
6299526|NCT02517866|10022509|FG001|Overall Study|Reason not specified|0
6299527|NCT02517866|10022510|FG002|Overall Study|Reason not specified|0
6299528|NCT02517905|10022522|FG000|Overall Study|Lost to Follow-up|4
6299529|NCT02517905|10022523|FG001|Overall Study|Lost to Follow-up|0
6299530|NCT02517905|10022522|FG000|Overall Study|Withdrawal by Subject|4
6299531|NCT02517905|10022523|FG001|Overall Study|Withdrawal by Subject|0
6299532|NCT02517905|10022522|FG000|Overall Study|Screen failure|2
6299533|NCT02517905|10022523|FG001|Overall Study|Screen failure|2
6299534|NCT02518048|10022538|FG000|Overall Study|Withdrawal by Subject|1
6299535|NCT02518113|10022547|FG000|Overall Study|Adverse Event|1
6299536|NCT02518113|10022548|FG001|Overall Study|Adverse Event|0
6299537|NCT02518113|10022549|FG002|Overall Study|Adverse Event|1
6299538|NCT02518113|10022550|FG003|Overall Study|Adverse Event|0
6299539|NCT02518113|10022547|FG000|Overall Study|Death|1
6299540|NCT02518113|10022548|FG001|Overall Study|Death|2
6299541|NCT02518113|10022549|FG002|Overall Study|Death|0
6299542|NCT02518113|10022550|FG003|Overall Study|Death|0
6299543|NCT02518113|10022547|FG000|Overall Study|Physician Decision|0
6299544|NCT02518113|10022548|FG001|Overall Study|Physician Decision|1
6299545|NCT02518113|10022549|FG002|Overall Study|Physician Decision|0
6299546|NCT02518113|10022550|FG003|Overall Study|Physician Decision|0
6299547|NCT02518113|10022547|FG000|Overall Study|Progressive Disease|1
6299548|NCT02518113|10022548|FG001|Overall Study|Progressive Disease|2
6299549|NCT02518113|10022549|FG002|Overall Study|Progressive Disease|3
6299550|NCT02518113|10022550|FG003|Overall Study|Progressive Disease|0
6299551|NCT02518464|10022584|FG000|Overall Study|Adverse Event|2
6299552|NCT02518490|10022588|FG000|Overall Study|Withdrawal by Subject|1
6299553|NCT02518490|10022589|FG001|Overall Study|Withdrawal by Subject|1
6299554|NCT02518620|10022598|FG000|Overall Study|Adverse Event|23
6299555|NCT02518620|10022599|FG001|Overall Study|Adverse Event|11
6299556|NCT02518620|10022598|FG000|Overall Study|Lack of Efficacy|2
6299557|NCT02518620|10022599|FG001|Overall Study|Lack of Efficacy|0
6299558|NCT02518620|10022598|FG000|Overall Study|Non-Compliance with Study Drug|1
6299559|NCT02518620|10022599|FG001|Overall Study|Non-Compliance with Study Drug|0
6299560|NCT02518620|10022598|FG000|Overall Study|Physician Decision|1
6299561|NCT02518620|10022599|FG001|Overall Study|Physician Decision|1
6299562|NCT02518620|10022598|FG000|Overall Study|Sponsor's Decision|0
6299563|NCT02518620|10022599|FG001|Overall Study|Sponsor's Decision|3
6299564|NCT02518620|10022598|FG000|Overall Study|Lost to Follow-up|1
6299565|NCT02518620|10022599|FG001|Overall Study|Lost to Follow-up|1
6299566|NCT02518620|10022598|FG000|Overall Study|Withdrawal by Subject|17
6299567|NCT02518620|10022599|FG001|Overall Study|Withdrawal by Subject|9
6299568|NCT02518620|10022598|FG000|Overall Study|Death|1
6299569|NCT02518620|10022599|FG001|Overall Study|Death|0
6299570|NCT02518620|10022598|FG000|Overall Study|Pregnancy Wish|3
6299571|NCT02518620|10022599|FG001|Overall Study|Pregnancy Wish|0
6299572|NCT02518620|10022598|FG000|Overall Study|Pregnancy|1
6299573|NCT02518620|10022599|FG001|Overall Study|Pregnancy|0
6299574|NCT02518620|10022598|FG000|Overall Study|Relocation|2
6299575|NCT02518620|10022599|FG001|Overall Study|Relocation|1
6299576|NCT02518685|10022609|FG000|Overall Study|Adverse Event|29
6299577|NCT02518685|10022610|FG001|Overall Study|Adverse Event|1
6299578|NCT02518685|10022609|FG000|Overall Study|Withdrawal by Subject|10
6299579|NCT02518685|10022610|FG001|Overall Study|Withdrawal by Subject|3
6299580|NCT02518685|10022609|FG000|Overall Study|relocation, study fatigue|7
6299581|NCT02518685|10022610|FG001|Overall Study|relocation, study fatigue|2
6299582|NCT02518685|10022609|FG000|Overall Study|Pregnancy|1
6299583|NCT02518685|10022610|FG001|Overall Study|Pregnancy|0
6299584|NCT02518685|10022609|FG000|Overall Study|Physician Decision|1
6299585|NCT02518685|10022610|FG001|Overall Study|Physician Decision|0
6299586|NCT02518685|10022609|FG000|Overall Study|Lost to Follow-up|1
6299587|NCT02518685|10022610|FG001|Overall Study|Lost to Follow-up|4
6299588|NCT02518919|10022620|FG000|Overall Study|Protocol Violation|1
6299589|NCT02518919|10022621|FG001|Overall Study|Protocol Violation|1
6299590|NCT02518919|10022622|FG002|Overall Study|Protocol Violation|2
6299591|NCT02518971|10022632|FG000|Overall Study|Lost to Follow-up|0
6299592|NCT02518971|10022633|FG001|Overall Study|Lost to Follow-up|1
6299593|NCT02518971|10022632|FG000|Overall Study|Physician Decision|6
6299594|NCT02518971|10022633|FG001|Overall Study|Physician Decision|6
6299595|NCT02518971|10022632|FG000|Overall Study|Protocol Violation|6
6299596|NCT02518971|10022633|FG001|Overall Study|Protocol Violation|4
6299597|NCT02518971|10022632|FG000|Overall Study|Withdrawal by Subject|4
6299598|NCT02518971|10022633|FG001|Overall Study|Withdrawal by Subject|5
6299599|NCT02518971|10022632|FG000|Overall Study|Side effects|1
6299600|NCT02518971|10022633|FG001|Overall Study|Side effects|0
6299601|NCT02518971|10022632|FG000|Overall Study|medication lost in mail|0
6299602|NCT02518971|10022633|FG001|Overall Study|medication lost in mail|1
6299603|NCT02518971|10022632|FG000|Overall Study|eligibility criteria no longer met|6
6299604|NCT02518971|10022633|FG001|Overall Study|eligibility criteria no longer met|3
6299605|NCT02519231|10022688|FG000|Overall Study|Lost to Follow-up|2
6299606|NCT02519231|10022689|FG001|Overall Study|Lost to Follow-up|5
6299607|NCT02519231|10022688|FG000|Overall Study|Withdrawal by Subject|0
6299608|NCT02519231|10022689|FG001|Overall Study|Withdrawal by Subject|1
6299609|NCT02519504|10022716|FG000|Overall Study|Protocol Violation|6
6299610|NCT02519504|10022717|FG001|Overall Study|Protocol Violation|5
6299611|NCT02519504|10022716|FG000|Overall Study|Ineligible for direct testing|12
6299612|NCT02519504|10022717|FG001|Overall Study|Ineligible for direct testing|12
6299613|NCT02519504|10022716|FG000|Overall Study|Did not participate in direct testing|95
6299614|NCT02519504|10022717|FG001|Overall Study|Did not participate in direct testing|86
6299615|NCT02519595|10022726|FG000|Overall Study|Protocol Violation|8
6299616|NCT02519595|10022727|FG001|Overall Study|Protocol Violation|22
6299617|NCT02519595|10022728|FG002|Overall Study|Protocol Violation|16
6299618|NCT02519842|10022751|FG000|Base Study: Cycle 1|Screening Failure|1
6299619|NCT02519842|10022752|FG001|Base Study: Cycle 1|Screening Failure|1
6299620|NCT02519842|10022753|FG002|Base Study: Cycle 1|Screening Failure|0
6299621|NCT02519842|10022751|FG000|Base Study: Cycle 1|Adverse Event|1
6299622|NCT02519842|10022752|FG001|Base Study: Cycle 1|Adverse Event|0
6299623|NCT02519842|10022753|FG002|Base Study: Cycle 1|Adverse Event|0
6299624|NCT02519842|10022751|FG000|Base Study: Cycle 1|Withdrawn by Parent/Guardian|0
6299625|NCT02519842|10022752|FG001|Base Study: Cycle 1|Withdrawn by Parent/Guardian|1
6299626|NCT02519842|10022753|FG002|Base Study: Cycle 1|Withdrawn by Parent/Guardian|0
6299627|NCT02519842|10022751|FG000|Base Study: Cycle 1|Non-compliance with Study Drug|0
6299628|NCT02519842|10022752|FG001|Base Study: Cycle 1|Non-compliance with Study Drug|1
6299629|NCT02519842|10022753|FG002|Base Study: Cycle 1|Non-compliance with Study Drug|0
6299630|NCT02519842|10022751|FG000|Optional Extension: Cycles 2-6|Physician Decision|0
6299631|NCT02519842|10022752|FG001|Optional Extension: Cycles 2-6|Physician Decision|0
6299632|NCT02519842|10022753|FG002|Optional Extension: Cycles 2-6|Physician Decision|5
6299633|NCT02519842|10022751|FG000|Optional Extension: Cycles 2-6|Adverse Event|0
6299634|NCT02519842|10022752|FG001|Optional Extension: Cycles 2-6|Adverse Event|0
6299635|NCT02519842|10022753|FG002|Optional Extension: Cycles 2-6|Adverse Event|1
6299636|NCT02519842|10022751|FG000|Optional Extension: Cycles 2-6|Withdrawal by Parent/Guardian|0
6299637|NCT02519842|10022752|FG001|Optional Extension: Cycles 2-6|Withdrawal by Parent/Guardian|0
6299638|NCT02519842|10022753|FG002|Optional Extension: Cycles 2-6|Withdrawal by Parent/Guardian|3
6299639|NCT02519842|10022751|FG000|Optional Extension: Cycles 2-6|Withdrawal by Subject|0
6299640|NCT02519842|10022752|FG001|Optional Extension: Cycles 2-6|Withdrawal by Subject|0
6299641|NCT02519842|10022753|FG002|Optional Extension: Cycles 2-6|Withdrawal by Subject|1
6299642|NCT02519842|10022751|FG000|Optional Extension: Cycles 2-6|Death|0
6299643|NCT02519842|10022752|FG001|Optional Extension: Cycles 2-6|Death|0
6299644|NCT02519842|10022753|FG002|Optional Extension: Cycles 2-6|Death|1
6299645|NCT02519842|10022751|FG000|Optional Extension: Cycles 2-6|Did Not Respond to Chemotherapy|0
6299646|NCT02519842|10022752|FG001|Optional Extension: Cycles 2-6|Did Not Respond to Chemotherapy|0
6299647|NCT02519842|10022753|FG002|Optional Extension: Cycles 2-6|Did Not Respond to Chemotherapy|2
6299648|NCT02519842|10022751|FG000|Optional Extension: Cycles 2-6|Completed Chemotherapy|0
6299649|NCT02519842|10022752|FG001|Optional Extension: Cycles 2-6|Completed Chemotherapy|0
6299650|NCT02519842|10022753|FG002|Optional Extension: Cycles 2-6|Completed Chemotherapy|13
6299651|NCT02519842|10022751|FG000|Optional Extension: Cycles 2-6|Enrollment Terminated at Site|0
6299652|NCT02519842|10022752|FG001|Optional Extension: Cycles 2-6|Enrollment Terminated at Site|0
6299653|NCT02519842|10022753|FG002|Optional Extension: Cycles 2-6|Enrollment Terminated at Site|1
6299654|NCT02519842|10022751|FG000|Optional Extension: Cycles 2-6|Cycle Eligibility Criteria Not Met|0
6299655|NCT02519842|10022752|FG001|Optional Extension: Cycles 2-6|Cycle Eligibility Criteria Not Met|0
6299656|NCT02519842|10022753|FG002|Optional Extension: Cycles 2-6|Cycle Eligibility Criteria Not Met|2
6299657|NCT02519855|10022763|FG000|Overall Study|Adverse Event|0
6299658|NCT02519855|10022764|FG001|Overall Study|Adverse Event|1
6299659|NCT02519855|10022763|FG000|Overall Study|Lost to Follow-up|3
6299660|NCT02519855|10022764|FG001|Overall Study|Lost to Follow-up|3
6299661|NCT02520089|10022772|FG000|Overall Study|Lost to Follow-up|3
6299662|NCT02520089|10022773|FG001|Overall Study|Lost to Follow-up|4
6299663|NCT02520284|10022782|FG000|Blinded Induction Phase: Up to Week 8|Adverse Event|1
6299664|NCT02520284|10022783|FG001|Blinded Induction Phase: Up to Week 8|Adverse Event|3
6299665|NCT02520284|10022784|FG002|Blinded Induction Phase: Up to Week 8|Adverse Event|0
6299666|NCT02520284|10022782|FG000|Blinded Induction Phase: Up to Week 8|Withdrew Consent|1
6299667|NCT02520284|10022783|FG001|Blinded Induction Phase: Up to Week 8|Withdrew Consent|1
6299668|NCT02520284|10022784|FG002|Blinded Induction Phase: Up to Week 8|Withdrew Consent|1
6299669|NCT02520284|10022782|FG000|Blinded Induction Phase: Up to Week 8|Study Terminated by Sponsor|0
6299670|NCT02520284|10022783|FG001|Blinded Induction Phase: Up to Week 8|Study Terminated by Sponsor|0
6299671|NCT02520284|10022784|FG002|Blinded Induction Phase: Up to Week 8|Study Terminated by Sponsor|1
6299672|NCT02520284|10022782|FG000|Blinded Maintenance Phase: Up to Week 51|Study Terminated by Sponsor|17
6299673|NCT02520284|10022783|FG001|Blinded Maintenance Phase: Up to Week 51|Study Terminated by Sponsor|11
6299674|NCT02520284|10022784|FG002|Blinded Maintenance Phase: Up to Week 51|Study Terminated by Sponsor|15
6299675|NCT02520284|10022782|FG000|Blinded Maintenance Phase: Up to Week 51|Disease Worsening|2
6299676|NCT02520284|10022783|FG001|Blinded Maintenance Phase: Up to Week 51|Disease Worsening|2
6299677|NCT02520284|10022784|FG002|Blinded Maintenance Phase: Up to Week 51|Disease Worsening|3
6299678|NCT02520284|10022782|FG000|Blinded Maintenance Phase: Up to Week 51|Adverse Event|1
6299679|NCT02520284|10022783|FG001|Blinded Maintenance Phase: Up to Week 51|Adverse Event|1
6299680|NCT02520284|10022784|FG002|Blinded Maintenance Phase: Up to Week 51|Adverse Event|0
6299681|NCT02520284|10022782|FG000|Blinded Maintenance Phase: Up to Week 51|Disposition Error|0
6299682|NCT02520284|10022783|FG001|Blinded Maintenance Phase: Up to Week 51|Disposition Error|2
6299683|NCT02520284|10022784|FG002|Blinded Maintenance Phase: Up to Week 51|Disposition Error|0
6299684|NCT02520284|10022782|FG000|Open-Label MaintenancePhase: Upto Week51|Study Terminated by Sponsor|25
6299685|NCT02520284|10022783|FG001|Open-Label MaintenancePhase: Upto Week51|Study Terminated by Sponsor|29
6299686|NCT02520284|10022784|FG002|Open-Label MaintenancePhase: Upto Week51|Study Terminated by Sponsor|28
6299687|NCT02520284|10022782|FG000|Open-Label MaintenancePhase: Upto Week51|Withdrew Consent|3
6299688|NCT02520284|10022783|FG001|Open-Label MaintenancePhase: Upto Week51|Withdrew Consent|4
6299689|NCT02520284|10022784|FG002|Open-Label MaintenancePhase: Upto Week51|Withdrew Consent|2
6299690|NCT02520284|10022782|FG000|Open-Label MaintenancePhase: Upto Week51|Adverse Event|2
6299691|NCT02520284|10022783|FG001|Open-Label MaintenancePhase: Upto Week51|Adverse Event|1
6299692|NCT02520284|10022784|FG002|Open-Label MaintenancePhase: Upto Week51|Adverse Event|3
6299693|NCT02520284|10022782|FG000|Open-Label MaintenancePhase: Upto Week51|Investigator's Discretion|2
6299694|NCT02520284|10022783|FG001|Open-Label MaintenancePhase: Upto Week51|Investigator's Discretion|1
6299695|NCT02520284|10022784|FG002|Open-Label MaintenancePhase: Upto Week51|Investigator's Discretion|1
6299696|NCT02520310|10022798|FG000|At 6 Months Clinical Follow-up|Death|1
6299697|NCT02520310|10022798|FG000|At 1 Year Clinical Follow-up|Withdrawal by Subject|1
6299698|NCT02520310|10022798|FG000|AT 3 Year Clinical Follow-up|Death|2
6299699|NCT02520310|10022798|FG000|AT 3 Year Clinical Follow-up|Withdrawal by Subject|2
6299700|NCT02520310|10022798|FG000|AT 4 Year Clinical Follow-up|Death|1
6299701|NCT02520310|10022798|FG000|AT 4 Year Clinical Follow-up|missed visit|1
6299702|NCT02520388|10022806|FG000|Overall Study|Physician Decision|1
6299703|NCT02520388|10022807|FG001|Overall Study|Physician Decision|0
6299704|NCT02520388|10022806|FG000|Overall Study|Subject or parent/guardian request|0
6299705|NCT02520388|10022807|FG001|Overall Study|Subject or parent/guardian request|6
6299706|NCT02520388|10022806|FG000|Overall Study|Adverse Event|1
6299707|NCT02520388|10022807|FG001|Overall Study|Adverse Event|4
6299708|NCT02520388|10022806|FG000|Overall Study|Lost to Follow-up|3
6299709|NCT02520388|10022807|FG001|Overall Study|Lost to Follow-up|2
6299710|NCT02520388|10022806|FG000|Overall Study|Other (reason not defined)|4
6299711|NCT02520388|10022807|FG001|Overall Study|Other (reason not defined)|4
6299712|NCT02520531|10022838|FG000|Overall Study|Revision of study device components|2
6299713|NCT02520531|10022839|FG001|Overall Study|Revision of study device components|2
6299714|NCT02520531|10022838|FG000|Overall Study|Death|1
6299715|NCT02520531|10022839|FG001|Overall Study|Death|2
6299716|NCT02520531|10022838|FG000|Overall Study|Lost to Follow-up|1
6299717|NCT02520531|10022839|FG001|Overall Study|Lost to Follow-up|1
6299718|NCT02520531|10022838|FG000|Overall Study|Meet exclusion criterion|0
6299719|NCT02520531|10022839|FG001|Overall Study|Meet exclusion criterion|1
6299720|NCT02520531|10022838|FG000|Overall Study|Withdrawal by Subject|1
6299721|NCT02520531|10022839|FG001|Overall Study|Withdrawal by Subject|0
6299722|NCT02520531|10022838|FG000|Overall Study|Not study device|1
6299723|NCT02520531|10022839|FG001|Overall Study|Not study device|0
6299724|NCT02521376|10022871|FG000|Overall Study|Enrolled, But Not Treated|1
6299725|NCT02521376|10022872|FG001|Overall Study|Enrolled, But Not Treated|0
6299726|NCT02521376|10022873|FG002|Overall Study|Enrolled, But Not Treated|0
6299727|NCT02521376|10022874|FG003|Overall Study|Enrolled, But Not Treated|0
6299728|NCT02521792|10022912|FG000|Overall Study|Study Terminated|6
6299729|NCT02521870|10022924|FG000|Phase 1: Dose Escalation|Withdrawal by Subject|0
6299730|NCT02521870|10022925|FG001|Phase 1: Dose Escalation|Withdrawal by Subject|1
6299731|NCT02521870|10022926|FG002|Phase 1: Dose Escalation|Withdrawal by Subject|0
6299732|NCT02521870|10022927|FG003|Phase 1: Dose Escalation|Withdrawal by Subject|0
6299733|NCT02521870|10022928|FG004|Phase 1: Dose Escalation|Withdrawal by Subject|0
6299734|NCT02521870|10022929|FG005|Phase 1: Dose Escalation|Withdrawal by Subject|0
6299735|NCT02521870|10022930|FG006|Phase 1: Dose Escalation|Withdrawal by Subject|0
6299736|NCT02521870|10022931|FG007|Phase 1: Dose Escalation|Withdrawal by Subject|0
6299737|NCT02521870|10022932|FG008|Phase 1: Dose Escalation|Withdrawal by Subject|0
6299738|NCT02521870|10022933|FG009|Phase 1: Dose Escalation|Withdrawal by Subject|0
6299739|NCT02521870|10022934|FG010|Phase 1: Dose Escalation|Withdrawal by Subject|0
6299740|NCT02521870|10022935|FG011|Phase 1: Dose Escalation|Withdrawal by Subject|0
6299741|NCT02521870|10022924|FG000|Phase 1: Dose Escalation|Adverse Event|2
6299742|NCT02521870|10022925|FG001|Phase 1: Dose Escalation|Adverse Event|1
6299743|NCT02521870|10022926|FG002|Phase 1: Dose Escalation|Adverse Event|0
6299744|NCT02521870|10022927|FG003|Phase 1: Dose Escalation|Adverse Event|0
6299745|NCT02521870|10022928|FG004|Phase 1: Dose Escalation|Adverse Event|0
6299746|NCT02521870|10022929|FG005|Phase 1: Dose Escalation|Adverse Event|0
6299747|NCT02521870|10022930|FG006|Phase 1: Dose Escalation|Adverse Event|0
6299748|NCT02521870|10022931|FG007|Phase 1: Dose Escalation|Adverse Event|0
6299749|NCT02521870|10022932|FG008|Phase 1: Dose Escalation|Adverse Event|0
6299750|NCT02521870|10022933|FG009|Phase 1: Dose Escalation|Adverse Event|0
6299751|NCT02521870|10022934|FG010|Phase 1: Dose Escalation|Adverse Event|0
6299752|NCT02521870|10022935|FG011|Phase 1: Dose Escalation|Adverse Event|0
6299753|NCT02521870|10022924|FG000|Phase 1: Dose Escalation|Progressive Disease|3
6299754|NCT02521870|10022925|FG001|Phase 1: Dose Escalation|Progressive Disease|2
6299755|NCT02521870|10022926|FG002|Phase 1: Dose Escalation|Progressive Disease|4
6299756|NCT02521870|10022927|FG003|Phase 1: Dose Escalation|Progressive Disease|6
6299757|NCT02521870|10022928|FG004|Phase 1: Dose Escalation|Progressive Disease|0
6299758|NCT02521870|10022929|FG005|Phase 1: Dose Escalation|Progressive Disease|0
6299759|NCT02521870|10022930|FG006|Phase 1: Dose Escalation|Progressive Disease|0
6299760|NCT02521870|10022931|FG007|Phase 1: Dose Escalation|Progressive Disease|0
6299761|NCT02521870|10022932|FG008|Phase 1: Dose Escalation|Progressive Disease|0
6299762|NCT02521870|10022933|FG009|Phase 1: Dose Escalation|Progressive Disease|0
6299763|NCT02521870|10022934|FG010|Phase 1: Dose Escalation|Progressive Disease|0
6299764|NCT02521870|10022935|FG011|Phase 1: Dose Escalation|Progressive Disease|0
6299765|NCT02521870|10022924|FG000|Phase 2: Dose Expansion|Withdrawal by Subject|0
6299766|NCT02521870|10022925|FG001|Phase 2: Dose Expansion|Withdrawal by Subject|0
6299767|NCT02521870|10022926|FG002|Phase 2: Dose Expansion|Withdrawal by Subject|0
6299768|NCT02521870|10022927|FG003|Phase 2: Dose Expansion|Withdrawal by Subject|0
6299769|NCT02521870|10022928|FG004|Phase 2: Dose Expansion|Withdrawal by Subject|5
6299770|NCT02521870|10022929|FG005|Phase 2: Dose Expansion|Withdrawal by Subject|1
6299771|NCT02521870|10022930|FG006|Phase 2: Dose Expansion|Withdrawal by Subject|1
6299772|NCT02521870|10022931|FG007|Phase 2: Dose Expansion|Withdrawal by Subject|0
6299773|NCT02521870|10022932|FG008|Phase 2: Dose Expansion|Withdrawal by Subject|1
6299774|NCT02521870|10022933|FG009|Phase 2: Dose Expansion|Withdrawal by Subject|1
6299775|NCT02521870|10022934|FG010|Phase 2: Dose Expansion|Withdrawal by Subject|2
6299776|NCT02521870|10022935|FG011|Phase 2: Dose Expansion|Withdrawal by Subject|0
6299777|NCT02521870|10022924|FG000|Phase 2: Dose Expansion|Adverse Event|0
6299778|NCT02521870|10022925|FG001|Phase 2: Dose Expansion|Adverse Event|0
6299779|NCT02521870|10022926|FG002|Phase 2: Dose Expansion|Adverse Event|0
6299780|NCT02521870|10022927|FG003|Phase 2: Dose Expansion|Adverse Event|0
6299781|NCT02521870|10022928|FG004|Phase 2: Dose Expansion|Adverse Event|11
6299782|NCT02521870|10022929|FG005|Phase 2: Dose Expansion|Adverse Event|2
6299783|NCT02521870|10022930|FG006|Phase 2: Dose Expansion|Adverse Event|0
6299784|NCT02521870|10022931|FG007|Phase 2: Dose Expansion|Adverse Event|1
6299785|NCT02521870|10022932|FG008|Phase 2: Dose Expansion|Adverse Event|5
6299786|NCT02521870|10022933|FG009|Phase 2: Dose Expansion|Adverse Event|0
6299787|NCT02521870|10022934|FG010|Phase 2: Dose Expansion|Adverse Event|1
6299788|NCT02521870|10022935|FG011|Phase 2: Dose Expansion|Adverse Event|0
6299789|NCT02521870|10022924|FG000|Phase 2: Dose Expansion|Progressive Disease|0
6299790|NCT02521870|10022925|FG001|Phase 2: Dose Expansion|Progressive Disease|0
6299791|NCT02521870|10022926|FG002|Phase 2: Dose Expansion|Progressive Disease|0
6299792|NCT02521870|10022927|FG003|Phase 2: Dose Expansion|Progressive Disease|0
6299793|NCT02521870|10022928|FG004|Phase 2: Dose Expansion|Progressive Disease|22
6299794|NCT02521870|10022929|FG005|Phase 2: Dose Expansion|Progressive Disease|18
6299795|NCT02521870|10022930|FG006|Phase 2: Dose Expansion|Progressive Disease|17
6299796|NCT02521870|10022931|FG007|Phase 2: Dose Expansion|Progressive Disease|7
6299797|NCT02521870|10022932|FG008|Phase 2: Dose Expansion|Progressive Disease|5
6299798|NCT02521870|10022933|FG009|Phase 2: Dose Expansion|Progressive Disease|17
6299799|NCT02521870|10022934|FG010|Phase 2: Dose Expansion|Progressive Disease|17
6299800|NCT02521870|10022935|FG011|Phase 2: Dose Expansion|Progressive Disease|21
6299801|NCT02521870|10022924|FG000|Phase 2: Dose Expansion|Death|0
6299802|NCT02521870|10022925|FG001|Phase 2: Dose Expansion|Death|0
6299803|NCT02521870|10022926|FG002|Phase 2: Dose Expansion|Death|0
5981966|NCT03180307|9570881|FG000|Overall Study|Lost to Follow-up|2
5981967|NCT03180307|9570882|FG001|Overall Study|Lost to Follow-up|0
5981968|NCT03180307|9570881|FG000|Overall Study|Death|1
5981969|NCT03180307|9570882|FG001|Overall Study|Death|0
5981970|NCT03180307|9570881|FG000|Overall Study|Majority of which were disease too extensive and camera not used|3
5981971|NCT03180307|9570882|FG001|Overall Study|Majority of which were disease too extensive and camera not used|0
5981972|NCT02668822|9570901|FG000|Overall Study|Protocol Violation|2
5981973|NCT02668822|9570902|FG001|Overall Study|Protocol Violation|0
5981974|NCT02668822|9570901|FG000|Overall Study|Study Terminated by Sponsor|7
5981975|NCT02668822|9570902|FG001|Overall Study|Study Terminated by Sponsor|9
5981976|NCT02668783|9570910|FG000|Overall Study|Pregnancy|0
5981977|NCT02668783|9570911|FG001|Overall Study|Pregnancy|1
5981978|NCT02668783|9570910|FG000|Overall Study|Protocol Violation|2
5981979|NCT02668783|9570911|FG001|Overall Study|Protocol Violation|1
5981980|NCT02668783|9570910|FG000|Overall Study|Study terminated by sponsor|9
5981981|NCT02668783|9570911|FG001|Overall Study|Study terminated by sponsor|10
5981982|NCT02668783|9570910|FG000|Overall Study|Subject moved|1
5981983|NCT02668783|9570911|FG001|Overall Study|Subject moved|0
5981984|NCT02668783|9570910|FG000|Overall Study|Withdrawal by Subject|1
5981985|NCT02668783|9570911|FG001|Overall Study|Withdrawal by Subject|0
5981986|NCT02616146|9570919|FG000|Overall Study|Adverse Event|64
5981987|NCT02616146|9570920|FG001|Overall Study|Adverse Event|24
5981988|NCT02616146|9570919|FG000|Overall Study|Lost to Follow-up|23
5981989|NCT02616146|9570920|FG001|Overall Study|Lost to Follow-up|13
5981990|NCT02616146|9570919|FG000|Overall Study|Non-compliance with study protocol|2
5981991|NCT02616146|9570920|FG001|Overall Study|Non-compliance with study protocol|0
5981992|NCT02616146|9570919|FG000|Overall Study|Non-compliance with study drug|4
5981993|NCT02616146|9570920|FG001|Overall Study|Non-compliance with study drug|2
5981994|NCT02616146|9570919|FG000|Overall Study|Pregnancy|2
5981995|NCT02616146|9570920|FG001|Overall Study|Pregnancy|2
5981996|NCT02616146|9570919|FG000|Overall Study|Pregnancy wish|3
5981997|NCT02616146|9570920|FG001|Overall Study|Pregnancy wish|0
5981998|NCT02616146|9570919|FG000|Overall Study|Protocol Violation|6
5981999|NCT02616146|9570920|FG001|Overall Study|Protocol Violation|3
5982000|NCT02616146|9570919|FG000|Overall Study|Study terminated by sponsor|1372
5982001|NCT02616146|9570920|FG001|Overall Study|Study terminated by sponsor|432
5982002|NCT02616146|9570919|FG000|Overall Study|Participant moved|4
5982003|NCT02616146|9570920|FG001|Overall Study|Participant moved|3
5982004|NCT02616146|9570919|FG000|Overall Study|Withdrawal by Subject|30
5982005|NCT02616146|9570920|FG001|Overall Study|Withdrawal by Subject|24
5982006|NCT02616146|9570919|FG000|Overall Study|Physician Decision|2
5982007|NCT02616146|9570920|FG001|Overall Study|Physician Decision|1
5982008|NCT02524288|9570939|FG000|Overall Study|Adverse Event|115
5982009|NCT02524288|9570939|FG000|Overall Study|Lost to Follow-up|216
5982010|NCT02524288|9570939|FG000|Overall Study|Non-Compliance With Protocol|32
5982011|NCT02524288|9570939|FG000|Overall Study|Non-Compliance With Study Drug|14
5982012|NCT02524288|9570939|FG000|Overall Study|Pregnancy Wish|6
5982013|NCT02524288|9570939|FG000|Overall Study|Protocol Violation|6
5982014|NCT02524288|9570939|FG000|Overall Study|Screen Failure|2
5982015|NCT02524288|9570939|FG000|Overall Study|Site Discontinued Study Participation|1
5982016|NCT02524288|9570939|FG000|Overall Study|Study Terminated By Sponsor|1417
5982017|NCT02524288|9570939|FG000|Overall Study|Subject Moved|32
5982018|NCT02524288|9570939|FG000|Overall Study|Withdrawal by Subject|76
5982019|NCT02524288|9570939|FG000|Overall Study|Pregnancy|22
5982020|NCT02524288|9570939|FG000|Overall Study|Physician Decision|2
5982021|NCT02489942|9570943|FG000|Overall Study|Request by patient|602
5982022|NCT02489942|9570943|FG000|Overall Study|Improvement/remission|157
5982023|NCT02489942|9570943|FG000|Overall Study|No change/Progressive disease|263
5982024|NCT02489942|9570943|FG000|Overall Study|Adverse Event|522
5982025|NCT02489942|9570943|FG000|Overall Study|Other personal reasons|1218
5982026|NCT02489942|9570943|FG000|Overall Study|Lost to Follow-up|456
5982027|NCT02489942|9570943|FG000|Overall Study|Not continuously investigated|7
6299804|NCT02521870|10022927|FG003|Phase 2: Dose Expansion|Death|0
6299805|NCT02521870|10022928|FG004|Phase 2: Dose Expansion|Death|1
6299806|NCT02521870|10022929|FG005|Phase 2: Dose Expansion|Death|1
6299807|NCT02521870|10022930|FG006|Phase 2: Dose Expansion|Death|3
6299808|NCT02521870|10022931|FG007|Phase 2: Dose Expansion|Death|1
6299809|NCT02521870|10022932|FG008|Phase 2: Dose Expansion|Death|1
6299810|NCT02521870|10022933|FG009|Phase 2: Dose Expansion|Death|5
6299811|NCT02521870|10022934|FG010|Phase 2: Dose Expansion|Death|2
6299812|NCT02521870|10022935|FG011|Phase 2: Dose Expansion|Death|2
6299813|NCT02521870|10022924|FG000|Phase 2: Dose Expansion|Other|0
6299814|NCT02521870|10022925|FG001|Phase 2: Dose Expansion|Other|0
6299815|NCT02521870|10022926|FG002|Phase 2: Dose Expansion|Other|0
6299816|NCT02521870|10022927|FG003|Phase 2: Dose Expansion|Other|0
6299817|NCT02521870|10022928|FG004|Phase 2: Dose Expansion|Other|10
6299818|NCT02521870|10022929|FG005|Phase 2: Dose Expansion|Other|3
6299819|NCT02521870|10022930|FG006|Phase 2: Dose Expansion|Other|2
6299820|NCT02521870|10022931|FG007|Phase 2: Dose Expansion|Other|0
6299821|NCT02521870|10022932|FG008|Phase 2: Dose Expansion|Other|10
6299822|NCT02521870|10022933|FG009|Phase 2: Dose Expansion|Other|5
6299823|NCT02521870|10022934|FG010|Phase 2: Dose Expansion|Other|1
6299824|NCT02521870|10022935|FG011|Phase 2: Dose Expansion|Other|7
6299825|NCT02521870|10022924|FG000|Phase 2: Dose Expansion|Lost to Follow-up|0
6299826|NCT02521870|10022925|FG001|Phase 2: Dose Expansion|Lost to Follow-up|0
6299827|NCT02521870|10022926|FG002|Phase 2: Dose Expansion|Lost to Follow-up|0
6299828|NCT02521870|10022927|FG003|Phase 2: Dose Expansion|Lost to Follow-up|0
6299829|NCT02521870|10022928|FG004|Phase 2: Dose Expansion|Lost to Follow-up|1
6299830|NCT02521870|10022929|FG005|Phase 2: Dose Expansion|Lost to Follow-up|0
6299831|NCT02521870|10022930|FG006|Phase 2: Dose Expansion|Lost to Follow-up|0
6299832|NCT02521870|10022931|FG007|Phase 2: Dose Expansion|Lost to Follow-up|0
6299833|NCT02521870|10022932|FG008|Phase 2: Dose Expansion|Lost to Follow-up|0
6299834|NCT02521870|10022933|FG009|Phase 2: Dose Expansion|Lost to Follow-up|0
6299835|NCT02521870|10022934|FG010|Phase 2: Dose Expansion|Lost to Follow-up|0
6299836|NCT02521870|10022935|FG011|Phase 2: Dose Expansion|Lost to Follow-up|0
6299837|NCT02521870|10022924|FG000|Phase 2: Dose Expansion|Non-Compliance with Study Drug|0
5982028|NCT02489942|9570943|FG000|Overall Study|Patient started jardiance treatment out of registration period|1
5982029|NCT02489942|9570943|FG000|Overall Study|Multiple registration|1
5982030|NCT02489942|9570943|FG000|Overall Study|No patient visit after entry|100
5982031|NCT02489942|9570943|FG000|Overall Study|No treatment with Jardiance|2
5982032|NCT02489942|9570943|FG000|Overall Study|Patient received Jardiance before registration|1
5982033|NCT02489942|9570943|FG000|Overall Study|No CRF collected|86
5982034|NCT02409342|9570949|FG000|Overall Study|Death|181
5982035|NCT02409342|9570950|FG001|Overall Study|Death|174
5982036|NCT02409342|9570949|FG000|Overall Study|Withdrawal by Subject|24
5982037|NCT02409342|9570950|FG001|Overall Study|Withdrawal by Subject|16
5982038|NCT02409342|9570949|FG000|Overall Study|On-going in study|79
5982039|NCT02409342|9570950|FG001|Overall Study|On-going in study|92
5982040|NCT02409342|9570949|FG000|Overall Study|Lost to Follow-up|3
5982041|NCT02409342|9570950|FG001|Overall Study|Lost to Follow-up|3
5982042|NCT02275546|9570967|FG000|Treatment Period 2|Withdrawal by Subject|2
5982043|NCT02275546|9570968|FG001|Treatment Period 2|Withdrawal by Subject|1
5982044|NCT02275546|9570967|FG000|Treatment Period 2|Protocol Violation|0
5982045|NCT02275546|9570968|FG001|Treatment Period 2|Protocol Violation|1
5982046|NCT02077166|9570981|FG000|Overall Study|Death|6
5982047|NCT02077166|9570982|FG001|Overall Study|Death|7
5982048|NCT02077166|9570983|FG002|Overall Study|Death|5
5982049|NCT02077166|9570984|FG003|Overall Study|Death|6
5982050|NCT02077166|9570985|FG004|Overall Study|Death|4
5982051|NCT02077166|9570986|FG005|Overall Study|Death|32
5982052|NCT02077166|9570987|FG006|Overall Study|Death|22
5982053|NCT02077166|9570981|FG000|Overall Study|Study Closure by Sponsor|3
5982054|NCT02077166|9570982|FG001|Overall Study|Study Closure by Sponsor|0
5982055|NCT02077166|9570983|FG002|Overall Study|Study Closure by Sponsor|2
5982056|NCT02077166|9570984|FG003|Overall Study|Study Closure by Sponsor|2
5982057|NCT02077166|9570985|FG004|Overall Study|Study Closure by Sponsor|2
5982058|NCT02077166|9570986|FG005|Overall Study|Study Closure by Sponsor|12
5982059|NCT02077166|9570987|FG006|Overall Study|Study Closure by Sponsor|4
5982060|NCT02077166|9570981|FG000|Overall Study|Lost to Follow-up|0
5982061|NCT02077166|9570982|FG001|Overall Study|Lost to Follow-up|0
5982062|NCT02077166|9570983|FG002|Overall Study|Lost to Follow-up|0
5982063|NCT02077166|9570984|FG003|Overall Study|Lost to Follow-up|0
5982064|NCT02077166|9570985|FG004|Overall Study|Lost to Follow-up|0
5982065|NCT02077166|9570986|FG005|Overall Study|Lost to Follow-up|1
5982066|NCT02077166|9570987|FG006|Overall Study|Lost to Follow-up|0
5982067|NCT02077166|9570981|FG000|Overall Study|Withdrawal by Subject|3
5982068|NCT02077166|9570982|FG001|Overall Study|Withdrawal by Subject|0
5982069|NCT02077166|9570983|FG002|Overall Study|Withdrawal by Subject|1
5982070|NCT02077166|9570984|FG003|Overall Study|Withdrawal by Subject|1
5982071|NCT02077166|9570985|FG004|Overall Study|Withdrawal by Subject|1
5982072|NCT02077166|9570986|FG005|Overall Study|Withdrawal by Subject|3
5982073|NCT02077166|9570987|FG006|Overall Study|Withdrawal by Subject|0
5982074|NCT02077166|9570981|FG000|Overall Study|Other, Not Specified|0
5982075|NCT02077166|9570982|FG001|Overall Study|Other, Not Specified|0
5982076|NCT02077166|9570983|FG002|Overall Study|Other, Not Specified|1
5982077|NCT02077166|9570984|FG003|Overall Study|Other, Not Specified|0
5982078|NCT02077166|9570985|FG004|Overall Study|Other, Not Specified|1
5982079|NCT02077166|9570986|FG005|Overall Study|Other, Not Specified|7
6299838|NCT02521870|10022925|FG001|Phase 2: Dose Expansion|Non-Compliance with Study Drug|0
6299839|NCT02521870|10022926|FG002|Phase 2: Dose Expansion|Non-Compliance with Study Drug|0
6299840|NCT02521870|10022927|FG003|Phase 2: Dose Expansion|Non-Compliance with Study Drug|0
6299841|NCT02521870|10022928|FG004|Phase 2: Dose Expansion|Non-Compliance with Study Drug|2
6299842|NCT02521870|10022929|FG005|Phase 2: Dose Expansion|Non-Compliance with Study Drug|0
6299843|NCT02521870|10022930|FG006|Phase 2: Dose Expansion|Non-Compliance with Study Drug|0
6299844|NCT02521870|10022931|FG007|Phase 2: Dose Expansion|Non-Compliance with Study Drug|0
6299845|NCT02521870|10022932|FG008|Phase 2: Dose Expansion|Non-Compliance with Study Drug|0
6299846|NCT02521870|10022933|FG009|Phase 2: Dose Expansion|Non-Compliance with Study Drug|0
6299847|NCT02521870|10022934|FG010|Phase 2: Dose Expansion|Non-Compliance with Study Drug|0
6299848|NCT02521870|10022935|FG011|Phase 2: Dose Expansion|Non-Compliance with Study Drug|0
6299849|NCT02521948|10022965|FG000|Overall Study|Adverse Event|2
6299850|NCT02521948|10022965|FG000|Overall Study|Death|4
6299851|NCT02521948|10022965|FG000|Overall Study|Lost to Follow-up|1
6299852|NCT02521948|10022965|FG000|Overall Study|Did not attend one or both follow-ups|6
6299853|NCT02522286|10023002|FG000|Overall Study|Withdrawal by Subject|3
6299854|NCT02522286|10023003|FG001|Overall Study|Withdrawal by Subject|0
6299855|NCT02522286|10023004|FG002|Overall Study|Withdrawal by Subject|0
6299856|NCT02522286|10023005|FG003|Overall Study|Withdrawal by Subject|3
6299857|NCT02522299|10023017|FG000|Overall Study|Adverse Event|2
6299858|NCT02522299|10023018|FG001|Overall Study|Adverse Event|0
6299859|NCT02522299|10023017|FG000|Overall Study|Physician Decision|0
6299860|NCT02522299|10023018|FG001|Overall Study|Physician Decision|1
6299861|NCT02522299|10023017|FG000|Overall Study|Withdrawal by Subject|2
6299862|NCT02522299|10023018|FG001|Overall Study|Withdrawal by Subject|0
6299863|NCT02522325|10023038|FG000|Overall Study|Adverse Event|0
6299864|NCT02522325|10023039|FG001|Overall Study|Adverse Event|1
6299865|NCT02522377|10023047|FG000|Overall Study|Withdrawal by Subject|1
6299866|NCT02522377|10023048|FG001|Overall Study|Withdrawal by Subject|0
6299867|NCT02522377|10023047|FG000|Overall Study|Remission Achieved|3
6299868|NCT02522377|10023048|FG001|Overall Study|Remission Achieved|0
6299869|NCT02522403|10023056|FG000|Overall Study|Lost to Follow-up|2
6299870|NCT02522403|10023057|FG001|Overall Study|Lost to Follow-up|2
6299871|NCT02522403|10023056|FG000|Overall Study|Withdrawal by Subject|2
6299872|NCT02522403|10023057|FG001|Overall Study|Withdrawal by Subject|4
6299873|NCT02522481|10023072|FG000|Overall Study|discontinued|1
6299874|NCT02522481|10023072|FG000|Overall Study|Not dosed|2
6299875|NCT02522494|10023085|FG000|Overall Study|Lost to Follow-up|6
6299876|NCT02522494|10023086|FG001|Overall Study|Lost to Follow-up|2
6299877|NCT02522494|10023085|FG000|Overall Study|Withdrawal by Subject|1
6299878|NCT02522494|10023086|FG001|Overall Study|Withdrawal by Subject|0
6299879|NCT02522494|10023085|FG000|Overall Study|CVT visit cancelled or no-show for CVT visit|6
6299880|NCT02522494|10023086|FG001|Overall Study|CVT visit cancelled or no-show for CVT visit|2
6299881|NCT02522494|10023085|FG000|Overall Study|Participant did not watch the video|1
6299882|NCT02522494|10023086|FG001|Overall Study|Participant did not watch the video|0
6299883|NCT02522494|10023085|FG000|Overall Study|Death|0
6299884|NCT02522494|10023086|FG001|Overall Study|Death|1
6299885|NCT02522624|10023094|FG000|Overall Study|Technical failure|1
6299886|NCT02522624|10023095|FG001|Overall Study|Technical failure|0
6299887|NCT02522728|10023103|FG000|Overall Study|Withdrawal by Subject|6
6299888|NCT02522728|10023104|FG001|Overall Study|Withdrawal by Subject|6
6299889|NCT02522728|10023103|FG000|Overall Study|Death|4
6299890|NCT02522728|10023104|FG001|Overall Study|Death|3
6299891|NCT02522728|10023103|FG000|Overall Study|Adverse Event|2
6299892|NCT02522728|10023104|FG001|Overall Study|Adverse Event|1
6299893|NCT02522728|10023103|FG000|Overall Study|Did not receive randomized study device|0
6299894|NCT02522728|10023104|FG001|Overall Study|Did not receive randomized study device|1
6299895|NCT02522767|10023112|FG000|Double-blind|Withdrawal by Subject|8
6299896|NCT02522767|10023113|FG001|Double-blind|Withdrawal by Subject|11
6299897|NCT02522767|10023112|FG000|Double-blind|Lost to Follow-up|1
6299898|NCT02522767|10023113|FG001|Double-blind|Lost to Follow-up|0
6299899|NCT02522767|10023112|FG000|Double-blind|Adverse Event|1
6299900|NCT02522767|10023113|FG001|Double-blind|Adverse Event|10
6299901|NCT02522767|10023112|FG000|Double-blind|Protocol Violation|0
6299902|NCT02522767|10023113|FG001|Double-blind|Protocol Violation|1
6299903|NCT02522767|10023112|FG000|Double-blind|Lack of Efficacy|0
6299904|NCT02522767|10023113|FG001|Double-blind|Lack of Efficacy|2
6299905|NCT02522767|10023112|FG000|Double-blind|Protocol Deviation|1
6299906|NCT02522767|10023113|FG001|Double-blind|Protocol Deviation|0
6299907|NCT02522767|10023112|FG000|Open-label|Withdrawal by Subject|2
6299908|NCT02522767|10023113|FG001|Open-label|Withdrawal by Subject|3
6299909|NCT02522767|10023112|FG000|Open-label|Lost to Follow-up|0
6299910|NCT02522767|10023113|FG001|Open-label|Lost to Follow-up|1
6299911|NCT02522767|10023112|FG000|Open-label|Adverse Event|2
6299912|NCT02522767|10023113|FG001|Open-label|Adverse Event|1
6299913|NCT02522767|10023112|FG000|Open-label|Lack of Efficacy|1
6299914|NCT02522767|10023113|FG001|Open-label|Lack of Efficacy|1
6299915|NCT02522767|10023112|FG000|Open-label|Protocol Violation|0
6299916|NCT02522767|10023113|FG001|Open-label|Protocol Violation|1
6299917|NCT02522780|10023123|FG000|Overall Study|Consent withdrawn by subject|5
6299918|NCT02522780|10023124|FG001|Overall Study|Consent withdrawn by subject|7
6299919|NCT02522780|10023123|FG000|Overall Study|Protocol deviation|1
6299920|NCT02522780|10023124|FG001|Overall Study|Protocol deviation|3
6299921|NCT02522780|10023123|FG000|Overall Study|Subject refused endoscopic procedure|0
6299922|NCT02522780|10023124|FG001|Overall Study|Subject refused endoscopic procedure|1
6299923|NCT02522780|10023123|FG000|Overall Study|Adverse event, non-fatal|11
6299924|NCT02522780|10023124|FG001|Overall Study|Adverse event, non-fatal|16
6299925|NCT02522884|10023140|FG000|Overall Study|Withdrawal by Subject|6
6299926|NCT02522884|10023140|FG000|Overall Study|Death|3
6299927|NCT02522884|10023140|FG000|Overall Study|Missed 12-month Follow-up|9
6299928|NCT02523599|10023176|FG000|Overall Study|Adverse Event|1
6299929|NCT02523599|10023177|FG001|Overall Study|Adverse Event|0
6299930|NCT02523599|10023176|FG000|Overall Study|Physician Decision|1
6299931|NCT02523599|10023177|FG001|Overall Study|Physician Decision|0
6299932|NCT02523599|10023176|FG000|Overall Study|Lost to Follow-up|4
6299933|NCT02523599|10023177|FG001|Overall Study|Lost to Follow-up|1
6299934|NCT02523599|10023176|FG000|Overall Study|Did not return for Day 30 visit|2
6299935|NCT02523599|10023177|FG001|Overall Study|Did not return for Day 30 visit|0
6299936|NCT02524145|10023226|FG000|Overall Study|Withdrawal by Subject|2
6299937|NCT02524145|10023227|FG001|Overall Study|Withdrawal by Subject|2
6299938|NCT02524145|10023228|FG002|Overall Study|Withdrawal by Subject|3
6299939|NCT02524158|10023238|FG000|12-weeks Assessment|Withdrawal by Subject|1
6299940|NCT02524158|10023239|FG001|12-weeks Assessment|Withdrawal by Subject|1
6299941|NCT02524158|10023238|FG000|12-weeks Assessment|Lost to Follow-up|18
6299942|NCT02524158|10023239|FG001|12-weeks Assessment|Lost to Follow-up|12
6299943|NCT02524158|10023238|FG000|6-month Assessment|Withdrawal by Subject|1
6299944|NCT02524158|10023239|FG001|6-month Assessment|Withdrawal by Subject|1
6299945|NCT02524158|10023238|FG000|6-month Assessment|Lost to Follow-up|21
6299946|NCT02524158|10023239|FG001|6-month Assessment|Lost to Follow-up|20
6299947|NCT02524665|10023268|FG000|Overall Study|Lost to Follow-up|1
6299948|NCT02524730|10023273|FG000|Overall Study|Lost to Follow-up|5
6299949|NCT02524730|10023273|FG000|Overall Study|Withdrawal by Subject|18
6299950|NCT02524730|10023273|FG000|Overall Study|Death|10
6299951|NCT02524730|10023273|FG000|Overall Study|Adverse Event|8
6299952|NCT02524730|10023273|FG000|Overall Study|Protocol Violation|1
6299953|NCT02524730|10023273|FG000|Overall Study|Subjects received Scorpio NRG PS (Posterior Stabilizing)|4
6299954|NCT02524847|10023281|FG000|Overall Study|Adverse Event|4
6299955|NCT02524847|10023281|FG000|Overall Study|Unsatisfactory Therapeutic Effect|4
6299956|NCT02524847|10023281|FG000|Overall Study|Condition no Longer Requires Treatment|4
6299957|NCT02524847|10023281|FG000|Overall Study|Death|1
6299958|NCT02524847|10023281|FG000|Overall Study|Reason not Specified|1
6299959|NCT02525094|10023324|FG000|Overall Study|Lost to Follow-up|2
6299960|NCT02525094|10023325|FG001|Overall Study|Lost to Follow-up|1
6299961|NCT02525094|10023324|FG000|Overall Study|Withdrawal by Subject|5
6299962|NCT02525094|10023325|FG001|Overall Study|Withdrawal by Subject|6
6299963|NCT02525094|10023324|FG000|Overall Study|Not Treated|1
6299964|NCT02525094|10023325|FG001|Overall Study|Not Treated|1
6299965|NCT02525133|10023334|FG000|Overall Study|Adverse Event|0
6299966|NCT02525133|10023335|FG001|Overall Study|Adverse Event|1
6299967|NCT02525133|10023334|FG000|Overall Study|Death|0
6299968|NCT02525133|10023335|FG001|Overall Study|Death|1
6299969|NCT02525133|10023334|FG000|Overall Study|did not meet randomization criteria|1
6299970|NCT02525133|10023335|FG001|Overall Study|did not meet randomization criteria|0
6299971|NCT02525133|10023334|FG000|Overall Study|Lost to Follow-up|5
6299972|NCT02525133|10023335|FG001|Overall Study|Lost to Follow-up|1
6299973|NCT02525133|10023334|FG000|Overall Study|randomized not enrolled|3
6299974|NCT02525133|10023335|FG001|Overall Study|randomized not enrolled|0
6299975|NCT02525133|10023334|FG000|Overall Study|Withdrawal by Subject|1
6299976|NCT02525133|10023335|FG001|Overall Study|Withdrawal by Subject|0
6299977|NCT02525471|10023347|FG000|Overall Study|Screen Failure|6
6299978|NCT02525471|10023347|FG000|Overall Study|Withdrawal by Subject|4
6299979|NCT02525471|10023347|FG000|Overall Study|Death|1
6299980|NCT02525588|10023393|FG000|Overall Study|Death|3
6299981|NCT02525588|10023394|FG001|Overall Study|Death|1
6299982|NCT02525588|10023393|FG000|Overall Study|Lost to Follow-up|2
6299983|NCT02525588|10023394|FG001|Overall Study|Lost to Follow-up|0
6299984|NCT02525588|10023393|FG000|Overall Study|Withdrawal by Subject|1
6299985|NCT02525588|10023394|FG001|Overall Study|Withdrawal by Subject|1
6299986|NCT02525588|10023393|FG000|Overall Study|Adverse Event|0
6299987|NCT02525588|10023394|FG001|Overall Study|Adverse Event|1
6299988|NCT02525627|10023402|FG000|Overall Study|Revision|1
6299989|NCT02525627|10023403|FG001|Overall Study|Revision|1
6299990|NCT02525627|10023402|FG000|Overall Study|Withdrawal by Subject|1
6299991|NCT02525627|10023403|FG001|Overall Study|Withdrawal by Subject|2
6299992|NCT02525627|10023402|FG000|Overall Study|Death|1
6299993|NCT02525627|10023403|FG001|Overall Study|Death|0
6299994|NCT02525627|10023402|FG000|Overall Study|Site terminated|11
6299995|NCT02525627|10023403|FG001|Overall Study|Site terminated|10
6299996|NCT02525744|10023422|FG000|Period 1|Physician Decision|0
6299997|NCT02525744|10023423|FG001|Period 1|Physician Decision|0
6299998|NCT02525744|10023424|FG002|Period 1|Physician Decision|1
6299999|NCT02525744|10023425|FG003|Period 1|Physician Decision|0
6300000|NCT02525744|10023422|FG000|Period 3|Adverse Event|0
6300001|NCT02525744|10023423|FG001|Period 3|Adverse Event|1
6300002|NCT02525744|10023424|FG002|Period 3|Adverse Event|0
6300003|NCT02525744|10023425|FG003|Period 3|Adverse Event|0
6300004|NCT02525744|10023422|FG000|Period 4|Withdrawal by Subject|1
6300005|NCT02525744|10023423|FG001|Period 4|Withdrawal by Subject|0
6300006|NCT02525744|10023424|FG002|Period 4|Withdrawal by Subject|0
6300007|NCT02525744|10023425|FG003|Period 4|Withdrawal by Subject|0
6300008|NCT02525744|10023422|FG000|Period 5|Physician Decision|1
6300009|NCT02525744|10023423|FG001|Period 5|Physician Decision|0
6300010|NCT02525744|10023424|FG002|Period 5|Physician Decision|0
6300011|NCT02525744|10023425|FG003|Period 5|Physician Decision|0
6300012|NCT02525861|10023437|FG000|Overall Study|Adverse Event|1
6300013|NCT02525861|10023438|FG001|Overall Study|Adverse Event|0
6300014|NCT02525861|10023437|FG000|Overall Study|Withdrawal by Subject|0
6300015|NCT02525861|10023438|FG001|Overall Study|Withdrawal by Subject|1
6300016|NCT02525861|10023437|FG000|Overall Study|Physician Decision|0
6300017|NCT02525861|10023438|FG001|Overall Study|Physician Decision|1
6300018|NCT02525874|10023446|FG000|Overall Study|Other|1
6300019|NCT02525874|10023446|FG000|Overall Study|Investigator Decision|1
6300020|NCT02525874|10023446|FG000|Overall Study|Consent withdrawn|22
6300021|NCT02525874|10023446|FG000|Overall Study|Non-compliance with study drug|3
6300022|NCT02525874|10023446|FG000|Overall Study|Adverse Event|17
6300023|NCT02525874|10023446|FG000|Overall Study|Lost to Follow-up|7
6300024|NCT02525874|10023446|FG000|Overall Study|Disease progression, defined by protocol|2
6300025|NCT02525874|10023446|FG000|Overall Study|Disease relapse|4
6300026|NCT02525874|10023446|FG000|Overall Study|Alternative Treatment for MS|2
6300027|NCT02525874|10023446|FG000|Overall Study|New lesions in Brain|1
6300028|NCT02526160|10023452|FG000|Double-Blind (Placebo-Controlled) Period|Withdrawal by Subject|0
6300029|NCT02526160|10023453|FG001|Double-Blind (Placebo-Controlled) Period|Withdrawal by Subject|1
6300030|NCT02526160|10023452|FG000|Open-label Treatment Continuation Period|Withdrawal by Subject|0
6300031|NCT02526160|10023453|FG001|Open-label Treatment Continuation Period|Withdrawal by Subject|1
6300032|NCT02526160|10023452|FG000|Open-label Treatment Continuation Period|Other, Not Specified|3
6300033|NCT02526160|10023453|FG001|Open-label Treatment Continuation Period|Other, Not Specified|3
6300034|NCT02526160|10023452|FG000|Open-Label Treatment Extension Period I|Death|0
6300035|NCT02526160|10023453|FG001|Open-Label Treatment Extension Period I|Death|1
6300036|NCT02526160|10023452|FG000|Open-Label Treatment Extension Period I|Other, Not Specified|3
6300037|NCT02526160|10023453|FG001|Open-Label Treatment Extension Period I|Other, Not Specified|1
6300038|NCT02526160|10023452|FG000|Open-Label Treatment Extension Period I|Withdrawal by Subject|0
6300039|NCT02526160|10023453|FG001|Open-Label Treatment Extension Period I|Withdrawal by Subject|1
6300040|NCT02526160|10023452|FG000|Open-Label Treatment Extension Period I|Lost to Follow-up|0
6300041|NCT02526160|10023453|FG001|Open-Label Treatment Extension Period I|Lost to Follow-up|1
6300042|NCT02526160|10023452|FG000|Open-Label Treatment Extension Period II|Other, Not Specified|1
6300043|NCT02526160|10023453|FG001|Open-Label Treatment Extension Period II|Other, Not Specified|0
6300044|NCT02526212|10023466|FG000|Overall Study|Incarceration|1
6300045|NCT02526212|10023467|FG001|Overall Study|Incarceration|0
6300046|NCT02526212|10023466|FG000|Overall Study|Lost to Follow-up|1
6300047|NCT02526212|10023467|FG001|Overall Study|Lost to Follow-up|0
6300048|NCT02526212|10023466|FG000|Overall Study|Death|0
6300049|NCT02526212|10023467|FG001|Overall Study|Death|1
6300050|NCT02526290|10023493|FG000|Overall Study|Adverse Event|3
6300051|NCT02526290|10023493|FG000|Overall Study|Withdrawal by Subject|4
6300052|NCT02526290|10023493|FG000|Overall Study|Physician Decision|1
6300053|NCT02526524|10023503|FG000|Overall Study|Withdrawal by Subject|3
6300054|NCT02526524|10023504|FG001|Overall Study|Withdrawal by Subject|3
6300055|NCT02526524|10023505|FG002|Overall Study|Withdrawal by Subject|6
6300056|NCT02526524|10023506|FG003|Overall Study|Withdrawal by Subject|1
6300057|NCT02526524|10023507|FG004|Overall Study|Withdrawal by Subject|9
6300058|NCT02526524|10023508|FG005|Overall Study|Withdrawal by Subject|5
6300059|NCT02526524|10023503|FG000|Overall Study|Adverse Event|3
6300060|NCT02526524|10023504|FG001|Overall Study|Adverse Event|2
6300061|NCT02526524|10023505|FG002|Overall Study|Adverse Event|4
6300062|NCT02526524|10023506|FG003|Overall Study|Adverse Event|2
6300063|NCT02526524|10023507|FG004|Overall Study|Adverse Event|6
6300064|NCT02526524|10023508|FG005|Overall Study|Adverse Event|8
6300065|NCT02526524|10023503|FG000|Overall Study|Lost to Follow-up|2
6300066|NCT02526524|10023504|FG001|Overall Study|Lost to Follow-up|3
6300067|NCT02526524|10023505|FG002|Overall Study|Lost to Follow-up|8
6300068|NCT02526524|10023506|FG003|Overall Study|Lost to Follow-up|1
6300069|NCT02526524|10023507|FG004|Overall Study|Lost to Follow-up|2
6300070|NCT02526524|10023508|FG005|Overall Study|Lost to Follow-up|5
6300071|NCT02526524|10023503|FG000|Overall Study|Protocol Violation|3
6300072|NCT02526524|10023504|FG001|Overall Study|Protocol Violation|1
6300073|NCT02526524|10023505|FG002|Overall Study|Protocol Violation|5
6300074|NCT02526524|10023506|FG003|Overall Study|Protocol Violation|3
6300075|NCT02526524|10023507|FG004|Overall Study|Protocol Violation|4
6300076|NCT02526524|10023508|FG005|Overall Study|Protocol Violation|3
6300077|NCT02526524|10023503|FG000|Overall Study|Loss of Glucose Control|0
6300078|NCT02526524|10023504|FG001|Overall Study|Loss of Glucose Control|0
6300079|NCT02526524|10023505|FG002|Overall Study|Loss of Glucose Control|3
6300080|NCT02526524|10023506|FG003|Overall Study|Loss of Glucose Control|0
6300081|NCT02526524|10023507|FG004|Overall Study|Loss of Glucose Control|2
6300082|NCT02526524|10023508|FG005|Overall Study|Loss of Glucose Control|0
6300083|NCT02526524|10023503|FG000|Overall Study|Physician Decision|0
6300084|NCT02526524|10023504|FG001|Overall Study|Physician Decision|0
6300085|NCT02526524|10023505|FG002|Overall Study|Physician Decision|0
6300086|NCT02526524|10023506|FG003|Overall Study|Physician Decision|0
6300087|NCT02526524|10023507|FG004|Overall Study|Physician Decision|1
6300088|NCT02526524|10023508|FG005|Overall Study|Physician Decision|0
6300089|NCT02526524|10023503|FG000|Overall Study|Sponsor Decision|1
6300090|NCT02526524|10023504|FG001|Overall Study|Sponsor Decision|0
6300091|NCT02526524|10023505|FG002|Overall Study|Sponsor Decision|0
6300092|NCT02526524|10023506|FG003|Overall Study|Sponsor Decision|0
6300093|NCT02526524|10023507|FG004|Overall Study|Sponsor Decision|0
6300094|NCT02526524|10023508|FG005|Overall Study|Sponsor Decision|0
6300095|NCT02526550|10023522|FG000|Overall Study|Lost to Follow-up|1
6300096|NCT02526693|10023561|FG000|Overall Study|Physician Decision|3
6300097|NCT02526693|10023562|FG001|Overall Study|Physician Decision|1
6300098|NCT02527148|10023574|FG000|Overall Study|Did not receive study intervention|1
6300099|NCT02527148|10023575|FG001|Overall Study|Did not receive study intervention|0
6300100|NCT02527161|10023583|FG000|Overall Study|Failed MRI|52
6300101|NCT02527161|10023583|FG000|Overall Study|Withdrawal by Subject|19
6300102|NCT02527161|10023583|FG000|Overall Study|Delay in or unfit for surgery|16
6300103|NCT02527161|10023583|FG000|Overall Study|MRI contraindication|6
6300104|NCT02527161|10023583|FG000|Overall Study|Consent violation|4
6300105|NCT02527161|10023583|FG000|Overall Study|Only Recruited to Part A|27
6300106|NCT02527161|10023583|FG000|Overall Study|Physician Decision|1
6300107|NCT02527161|10023583|FG000|Overall Study|Adverse Event|1
6300108|NCT02527161|10023583|FG000|Overall Study|Lost to Follow-up|6
6300109|NCT02527343|10023599|FG000|RT Period: Weeks 1 to 52|Investigator Judgement|1
6300110|NCT02527343|10023600|FG001|RT Period: Weeks 1 to 52|Investigator Judgement|0
6300111|NCT02527343|10023601|FG002|RT Period: Weeks 1 to 52|Investigator Judgement|0
6300112|NCT02527343|10023602|FG003|RT Period: Weeks 1 to 52|Investigator Judgement|0
6300113|NCT02527343|10023603|FG004|RT Period: Weeks 1 to 52|Investigator Judgement|0
6300114|NCT02527343|10023604|FG005|RT Period: Weeks 1 to 52|Investigator Judgement|0
6300115|NCT02527343|10023599|FG000|RT Period: Weeks 1 to 52|Voluntary withdrawal|1
6300116|NCT02527343|10023600|FG001|RT Period: Weeks 1 to 52|Voluntary withdrawal|0
6300117|NCT02527343|10023601|FG002|RT Period: Weeks 1 to 52|Voluntary withdrawal|0
6300118|NCT02527343|10023602|FG003|RT Period: Weeks 1 to 52|Voluntary withdrawal|0
6300119|NCT02527343|10023603|FG004|RT Period: Weeks 1 to 52|Voluntary withdrawal|0
6300120|NCT02527343|10023604|FG005|RT Period: Weeks 1 to 52|Voluntary withdrawal|0
6300121|NCT02527343|10023599|FG000|RT Period: Weeks 1 to 52|Adverse Event (AE) or Serious Adverse Event (SAE)|0
6300122|NCT02527343|10023600|FG001|RT Period: Weeks 1 to 52|Adverse Event (AE) or Serious Adverse Event (SAE)|4
6300123|NCT02527343|10023601|FG002|RT Period: Weeks 1 to 52|Adverse Event (AE) or Serious Adverse Event (SAE)|0
6300124|NCT02527343|10023602|FG003|RT Period: Weeks 1 to 52|Adverse Event (AE) or Serious Adverse Event (SAE)|0
6300125|NCT02527343|10023603|FG004|RT Period: Weeks 1 to 52|Adverse Event (AE) or Serious Adverse Event (SAE)|0
6300126|NCT02527343|10023604|FG005|RT Period: Weeks 1 to 52|Adverse Event (AE) or Serious Adverse Event (SAE)|0
6300127|NCT02527343|10023599|FG000|RT Period: Weeks 1 to 52|Other|4
6300128|NCT02527343|10023600|FG001|RT Period: Weeks 1 to 52|Other|3
6300129|NCT02527343|10023601|FG002|RT Period: Weeks 1 to 52|Other|0
6300130|NCT02527343|10023602|FG003|RT Period: Weeks 1 to 52|Other|0
6300131|NCT02527343|10023603|FG004|RT Period: Weeks 1 to 52|Other|0
6300132|NCT02527343|10023604|FG005|RT Period: Weeks 1 to 52|Other|0
6300133|NCT02527343|10023599|FG000|RT Post Treatment Follow-up: Weeks 54-65|AE or SAE|0
6300134|NCT02527343|10023600|FG001|RT Post Treatment Follow-up: Weeks 54-65|AE or SAE|0
6300135|NCT02527343|10023601|FG002|RT Post Treatment Follow-up: Weeks 54-65|AE or SAE|1
6300136|NCT02527343|10023602|FG003|RT Post Treatment Follow-up: Weeks 54-65|AE or SAE|0
6300137|NCT02527343|10023603|FG004|RT Post Treatment Follow-up: Weeks 54-65|AE or SAE|0
6300138|NCT02527343|10023604|FG005|RT Post Treatment Follow-up: Weeks 54-65|AE or SAE|0
6300139|NCT02527343|10023599|FG000|RT Post Treatment Follow-up: Weeks 54-65|Other|0
6300140|NCT02527343|10023600|FG001|RT Post Treatment Follow-up: Weeks 54-65|Other|0
6300141|NCT02527343|10023601|FG002|RT Post Treatment Follow-up: Weeks 54-65|Other|0
6300142|NCT02527343|10023602|FG003|RT Post Treatment Follow-up: Weeks 54-65|Other|2
6300143|NCT02527343|10023603|FG004|RT Post Treatment Follow-up: Weeks 54-65|Other|0
6300144|NCT02527343|10023604|FG005|RT Post Treatment Follow-up: Weeks 54-65|Other|0
6300145|NCT02527343|10023599|FG000|OLE Period-Year 1: Week 53 to 104|Investigator Judgement|0
6300146|NCT02527343|10023600|FG001|OLE Period-Year 1: Week 53 to 104|Investigator Judgement|0
6300147|NCT02527343|10023601|FG002|OLE Period-Year 1: Week 53 to 104|Investigator Judgement|0
6300148|NCT02527343|10023602|FG003|OLE Period-Year 1: Week 53 to 104|Investigator Judgement|0
6300149|NCT02527343|10023603|FG004|OLE Period-Year 1: Week 53 to 104|Investigator Judgement|1
6300150|NCT02527343|10023604|FG005|OLE Period-Year 1: Week 53 to 104|Investigator Judgement|0
6300151|NCT02527343|10023599|FG000|OLE Period-Year 1: Week 53 to 104|Voluntary Withdrawal|0
6300152|NCT02527343|10023600|FG001|OLE Period-Year 1: Week 53 to 104|Voluntary Withdrawal|0
6300153|NCT02527343|10023601|FG002|OLE Period-Year 1: Week 53 to 104|Voluntary Withdrawal|0
6300154|NCT02527343|10023602|FG003|OLE Period-Year 1: Week 53 to 104|Voluntary Withdrawal|0
6300155|NCT02527343|10023603|FG004|OLE Period-Year 1: Week 53 to 104|Voluntary Withdrawal|3
6300156|NCT02527343|10023604|FG005|OLE Period-Year 1: Week 53 to 104|Voluntary Withdrawal|1
6300157|NCT02527343|10023599|FG000|OLE Period-Year 1: Week 53 to 104|AE or SAE|0
6300158|NCT02527343|10023600|FG001|OLE Period-Year 1: Week 53 to 104|AE or SAE|0
6300159|NCT02527343|10023601|FG002|OLE Period-Year 1: Week 53 to 104|AE or SAE|0
5982080|NCT02077166|9570987|FG006|Overall Study|Other, Not Specified|8
6300160|NCT02527343|10023602|FG003|OLE Period-Year 1: Week 53 to 104|AE or SAE|0
6300161|NCT02527343|10023603|FG004|OLE Period-Year 1: Week 53 to 104|AE or SAE|2
6300162|NCT02527343|10023604|FG005|OLE Period-Year 1: Week 53 to 104|AE or SAE|1
6300163|NCT02527343|10023599|FG000|OLE Period-Year 1: Week 53 to 104|Other|0
6300164|NCT02527343|10023600|FG001|OLE Period-Year 1: Week 53 to 104|Other|0
6300165|NCT02527343|10023601|FG002|OLE Period-Year 1: Week 53 to 104|Other|0
6300166|NCT02527343|10023602|FG003|OLE Period-Year 1: Week 53 to 104|Other|0
6300167|NCT02527343|10023603|FG004|OLE Period-Year 1: Week 53 to 104|Other|5
6300168|NCT02527343|10023604|FG005|OLE Period-Year 1: Week 53 to 104|Other|7
6300169|NCT02527343|10023599|FG000|OLE Period-Year 2: Week 105 to 156|Other|0
6300170|NCT02527343|10023600|FG001|OLE Period-Year 2: Week 105 to 156|Other|0
6300171|NCT02527343|10023601|FG002|OLE Period-Year 2: Week 105 to 156|Other|0
6300172|NCT02527343|10023602|FG003|OLE Period-Year 2: Week 105 to 156|Other|0
6300173|NCT02527343|10023603|FG004|OLE Period-Year 2: Week 105 to 156|Other|1
6300174|NCT02527343|10023604|FG005|OLE Period-Year 2: Week 105 to 156|Other|2
6300175|NCT02527343|10023599|FG000|PT Follow-up: Weeks 104 to 169|Voluntary withdrawal|0
6300176|NCT02527343|10023600|FG001|PT Follow-up: Weeks 104 to 169|Voluntary withdrawal|0
6300177|NCT02527343|10023601|FG002|PT Follow-up: Weeks 104 to 169|Voluntary withdrawal|0
6300178|NCT02527343|10023602|FG003|PT Follow-up: Weeks 104 to 169|Voluntary withdrawal|0
6300179|NCT02527343|10023603|FG004|PT Follow-up: Weeks 104 to 169|Voluntary withdrawal|1
6300180|NCT02527343|10023604|FG005|PT Follow-up: Weeks 104 to 169|Voluntary withdrawal|0
6300181|NCT02527343|10023599|FG000|PT Follow-up: Weeks 104 to 169|Other|0
6300182|NCT02527343|10023600|FG001|PT Follow-up: Weeks 104 to 169|Other|0
6300183|NCT02527343|10023601|FG002|PT Follow-up: Weeks 104 to 169|Other|0
6300184|NCT02527343|10023602|FG003|PT Follow-up: Weeks 104 to 169|Other|0
6300185|NCT02527343|10023603|FG004|PT Follow-up: Weeks 104 to 169|Other|0
6300186|NCT02527343|10023604|FG005|PT Follow-up: Weeks 104 to 169|Other|1
6300187|NCT02527421|10023621|FG000|Overall Study|Withdrawal by Subject|1
6300188|NCT02527421|10023622|FG001|Overall Study|Withdrawal by Subject|0
6300189|NCT02528188|10023655|FG000|Overall Study|Adverse Event|23
6300190|NCT02528188|10023656|FG001|Overall Study|Adverse Event|22
6300191|NCT02528188|10023657|FG002|Overall Study|Adverse Event|8
6300192|NCT02528188|10023655|FG000|Overall Study|Protocol Violation|4
6300193|NCT02528188|10023656|FG001|Overall Study|Protocol Violation|6
6300194|NCT02528188|10023657|FG002|Overall Study|Protocol Violation|4
6300195|NCT02528188|10023655|FG000|Overall Study|Lack of Efficacy|19
6300196|NCT02528188|10023656|FG001|Overall Study|Lack of Efficacy|21
6300197|NCT02528188|10023657|FG002|Overall Study|Lack of Efficacy|22
6300198|NCT02528188|10023655|FG000|Overall Study|Withdrawal by Subject|97
6300199|NCT02528188|10023656|FG001|Overall Study|Withdrawal by Subject|104
6300200|NCT02528188|10023657|FG002|Overall Study|Withdrawal by Subject|100
6300201|NCT02528188|10023655|FG000|Overall Study|Lost to Follow-up|25
6300202|NCT02528188|10023656|FG001|Overall Study|Lost to Follow-up|21
6300203|NCT02528188|10023657|FG002|Overall Study|Lost to Follow-up|31
6300204|NCT02528188|10023655|FG000|Overall Study|Death|4
6300205|NCT02528188|10023656|FG001|Overall Study|Death|4
6300206|NCT02528188|10023657|FG002|Overall Study|Death|0
6300207|NCT02528188|10023655|FG000|Overall Study|Other|89
6300208|NCT02528188|10023656|FG001|Overall Study|Other|91
6300209|NCT02528188|10023657|FG002|Overall Study|Other|74
6300210|NCT02528188|10023655|FG000|Overall Study|Randomized but not treated|6
6300211|NCT02528188|10023656|FG001|Overall Study|Randomized but not treated|7
6300212|NCT02528188|10023657|FG002|Overall Study|Randomized but not treated|12
6300213|NCT02528214|10023667|FG000|Overall Study|Protocol Violation|0
6300214|NCT02528214|10023668|FG001|Overall Study|Protocol Violation|1
6300215|NCT02528214|10023667|FG000|Overall Study|Adverse Event|0
6300216|NCT02528214|10023668|FG001|Overall Study|Adverse Event|1
6300217|NCT02528214|10023667|FG000|Overall Study|Other than specified above|0
6300218|NCT02528214|10023668|FG001|Overall Study|Other than specified above|1
6300219|NCT02528253|10023680|FG000|Overall Study|Adverse Event|3
6300220|NCT02528253|10023681|FG001|Overall Study|Adverse Event|4
6300221|NCT02528253|10023682|FG002|Overall Study|Adverse Event|4
6300222|NCT02528253|10023683|FG003|Overall Study|Adverse Event|8
6300223|NCT02528253|10023684|FG004|Overall Study|Adverse Event|18
6300224|NCT02528253|10023680|FG000|Overall Study|Death|2
6300225|NCT02528253|10023681|FG001|Overall Study|Death|2
6300226|NCT02528253|10023682|FG002|Overall Study|Death|1
6300227|NCT02528253|10023683|FG003|Overall Study|Death|0
5982081|NCT01891344|9571012|FG000|Overall Study|Ongoing|6
6300228|NCT02528253|10023684|FG004|Overall Study|Death|1
6300229|NCT02528253|10023680|FG000|Overall Study|Insufficient clinical response|7
6300230|NCT02528253|10023681|FG001|Overall Study|Insufficient clinical response|10
6300231|NCT02528253|10023682|FG002|Overall Study|Insufficient clinical response|13
6300232|NCT02528253|10023683|FG003|Overall Study|Insufficient clinical response|12
6300233|NCT02528253|10023684|FG004|Overall Study|Insufficient clinical response|16
6300234|NCT02528253|10023680|FG000|Overall Study|Lost to Follow-up|16
6300235|NCT02528253|10023681|FG001|Overall Study|Lost to Follow-up|9
6300236|NCT02528253|10023682|FG002|Overall Study|Lost to Follow-up|31
6300237|NCT02528253|10023683|FG003|Overall Study|Lost to Follow-up|16
6300238|NCT02528253|10023684|FG004|Overall Study|Lost to Follow-up|34
6300239|NCT02528253|10023680|FG000|Overall Study|Other|21
6300240|NCT02528253|10023681|FG001|Overall Study|Other|22
6300241|NCT02528253|10023682|FG002|Overall Study|Other|58
6300242|NCT02528253|10023683|FG003|Overall Study|Other|52
6300243|NCT02528253|10023684|FG004|Overall Study|Other|76
6300244|NCT02528253|10023680|FG000|Overall Study|Withdrawal by Subject|25
6300245|NCT02528253|10023681|FG001|Overall Study|Withdrawal by Subject|20
6300246|NCT02528253|10023682|FG002|Overall Study|Withdrawal by Subject|29
6300247|NCT02528253|10023683|FG003|Overall Study|Withdrawal by Subject|48
6300248|NCT02528253|10023684|FG004|Overall Study|Withdrawal by Subject|73
6300249|NCT02528253|10023680|FG000|Overall Study|Protocol Violation|1
6300250|NCT02528253|10023681|FG001|Overall Study|Protocol Violation|2
6300251|NCT02528253|10023682|FG002|Overall Study|Protocol Violation|4
6300252|NCT02528253|10023683|FG003|Overall Study|Protocol Violation|0
6300253|NCT02528253|10023684|FG004|Overall Study|Protocol Violation|4
6300254|NCT02528253|10023680|FG000|Overall Study|Withdrawn Due to Pregnancy|0
6300255|NCT02528253|10023681|FG001|Overall Study|Withdrawn Due to Pregnancy|1
6300256|NCT02528253|10023682|FG002|Overall Study|Withdrawn Due to Pregnancy|0
6300257|NCT02528253|10023683|FG003|Overall Study|Withdrawn Due to Pregnancy|0
6300258|NCT02528253|10023684|FG004|Overall Study|Withdrawn Due to Pregnancy|1
5982082|NCT01891344|9571013|FG001|Overall Study|Ongoing|2
5982083|NCT01891344|9571014|FG002|Overall Study|Ongoing|0
5982084|NCT01891344|9571015|FG003|Overall Study|Ongoing|1
5982085|NCT01891344|9571016|FG004|Overall Study|Ongoing|4
5982086|NCT01891344|9571017|FG005|Overall Study|Ongoing|1
5982087|NCT01891344|9571018|FG006|Overall Study|Ongoing|0
5982088|NCT01891344|9571019|FG007|Overall Study|Ongoing|0
5982089|NCT01847274|9571041|FG000|Overall Study|Adverse Event|17
5982090|NCT01847274|9571042|FG001|Overall Study|Adverse Event|1
5982091|NCT01847274|9571043|FG002|Overall Study|Adverse Event|33
5982092|NCT01847274|9571044|FG003|Overall Study|Adverse Event|2
5982093|NCT01847274|9571041|FG000|Overall Study|Withdrawal by Subject|8
5982094|NCT01847274|9571042|FG001|Overall Study|Withdrawal by Subject|8
5982095|NCT01847274|9571043|FG002|Overall Study|Withdrawal by Subject|11
5982096|NCT01847274|9571044|FG003|Overall Study|Withdrawal by Subject|1
5982097|NCT01847274|9571041|FG000|Overall Study|Disease Progression|63
5982098|NCT01847274|9571042|FG001|Overall Study|Disease Progression|49
5982099|NCT01847274|9571043|FG002|Overall Study|Disease Progression|129
5982100|NCT01847274|9571044|FG003|Overall Study|Disease Progression|98
5982101|NCT01847274|9571041|FG000|Overall Study|Treatment Associated Risk|0
5982102|NCT01847274|9571042|FG001|Overall Study|Treatment Associated Risk|2
5982103|NCT01847274|9571043|FG002|Overall Study|Treatment Associated Risk|2
5982104|NCT01847274|9571044|FG003|Overall Study|Treatment Associated Risk|0
5982105|NCT01847274|9571041|FG000|Overall Study|Other Reasons|3
5982106|NCT01847274|9571042|FG001|Overall Study|Other Reasons|1
5982107|NCT01847274|9571043|FG002|Overall Study|Other Reasons|11
5982108|NCT01847274|9571044|FG003|Overall Study|Other Reasons|3
5982109|NCT01847274|9571041|FG000|Overall Study|Non Compliance|0
5982110|NCT01847274|9571042|FG001|Overall Study|Non Compliance|0
5982111|NCT01847274|9571043|FG002|Overall Study|Non Compliance|2
5982112|NCT01847274|9571044|FG003|Overall Study|Non Compliance|0
5982113|NCT01670656|9571059|FG000|Overall Study|Non-compliance with study drug|0
5982114|NCT01670656|9571060|FG001|Overall Study|Non-compliance with study drug|0
5982115|NCT01670656|9571061|FG002|Overall Study|Non-compliance with study drug|3
5982116|NCT01670656|9571062|FG003|Overall Study|Non-compliance with study drug|0
5982117|NCT01670656|9571063|FG004|Overall Study|Non-compliance with study drug|1
5982118|NCT01670656|9571059|FG000|Overall Study|Pregnancy|0
5982119|NCT01670656|9571060|FG001|Overall Study|Pregnancy|0
5982120|NCT01670656|9571061|FG002|Overall Study|Pregnancy|0
5982121|NCT01670656|9571062|FG003|Overall Study|Pregnancy|0
5982122|NCT01670656|9571063|FG004|Overall Study|Pregnancy|1
5982123|NCT01670656|9571059|FG000|Overall Study|Withdrawal by Subject|1
5982124|NCT01670656|9571060|FG001|Overall Study|Withdrawal by Subject|1
5982125|NCT01670656|9571061|FG002|Overall Study|Withdrawal by Subject|0
5982126|NCT01670656|9571062|FG003|Overall Study|Withdrawal by Subject|0
5982127|NCT01670656|9571063|FG004|Overall Study|Withdrawal by Subject|0
5982128|NCT01670656|9571059|FG000|Overall Study|Non-compliance with protocol|0
5982129|NCT01670656|9571060|FG001|Overall Study|Non-compliance with protocol|3
5982130|NCT01670656|9571061|FG002|Overall Study|Non-compliance with protocol|1
5982131|NCT01670656|9571062|FG003|Overall Study|Non-compliance with protocol|1
5982132|NCT01670656|9571063|FG004|Overall Study|Non-compliance with protocol|2
5982133|NCT01670656|9571059|FG000|Overall Study|Adverse Event|2
5982134|NCT01670656|9571060|FG001|Overall Study|Adverse Event|2
5982135|NCT01670656|9571061|FG002|Overall Study|Adverse Event|2
5982136|NCT01670656|9571062|FG003|Overall Study|Adverse Event|3
5982137|NCT01670656|9571063|FG004|Overall Study|Adverse Event|3
5982138|NCT01670656|9571059|FG000|Overall Study|Subject withdrew consent|0
5982139|NCT01670656|9571060|FG001|Overall Study|Subject withdrew consent|1
6136908|NCT01004822|9767040|FG000|Overall Study|Objective progression or relapse|3
6300259|NCT02528305|10023715|FG000|Overall Study|Withdrawal by Subject|1
6300260|NCT02528305|10023715|FG000|Overall Study|Adverse Event|1
6300261|NCT02528305|10023715|FG000|Overall Study|Physician Decision|1
6300262|NCT02528331|10023742|FG000|Overall Study|Withdrawal by Subject|2
6300263|NCT02528357|10023765|FG000|Part1:Monotherapy(Up to Maximum 39weeks)|Lost to Follow-up|0
6300264|NCT02528357|10023766|FG001|Part1:Monotherapy(Up to Maximum 39weeks)|Lost to Follow-up|1
6300265|NCT02528357|10023767|FG002|Part1:Monotherapy(Up to Maximum 39weeks)|Lost to Follow-up|0
6300266|NCT02528357|10023768|FG003|Part1:Monotherapy(Up to Maximum 39weeks)|Lost to Follow-up|0
6300267|NCT02528357|10023769|FG004|Part1:Monotherapy(Up to Maximum 39weeks)|Lost to Follow-up|0
6300268|NCT02528357|10023770|FG005|Part1:Monotherapy(Up to Maximum 39weeks)|Lost to Follow-up|0
6300269|NCT02528357|10023771|FG006|Part1:Monotherapy(Up to Maximum 39weeks)|Lost to Follow-up|0
6300270|NCT02528357|10023772|FG007|Part1:Monotherapy(Up to Maximum 39weeks)|Lost to Follow-up|0
6300271|NCT02528357|10023773|FG008|Part1:Monotherapy(Up to Maximum 39weeks)|Lost to Follow-up|0
6300272|NCT02528357|10023774|FG009|Part1:Monotherapy(Up to Maximum 39weeks)|Lost to Follow-up|0
6300273|NCT02528357|10023775|FG010|Part1:Monotherapy(Up to Maximum 39weeks)|Lost to Follow-up|0
6300274|NCT02528357|10023776|FG011|Part1:Monotherapy(Up to Maximum 39weeks)|Lost to Follow-up|0
6300275|NCT02528357|10023777|FG012|Part1:Monotherapy(Up to Maximum 39weeks)|Lost to Follow-up|0
6300276|NCT02528357|10023778|FG013|Part1:Monotherapy(Up to Maximum 39weeks)|Lost to Follow-up|0
6300277|NCT02528357|10023779|FG014|Part1:Monotherapy(Up to Maximum 39weeks)|Lost to Follow-up|0
6300278|NCT02528357|10023780|FG015|Part1:Monotherapy(Up to Maximum 39weeks)|Lost to Follow-up|0
6300279|NCT02528357|10023781|FG016|Part1:Monotherapy(Up to Maximum 39weeks)|Lost to Follow-up|0
6300280|NCT02528357|10023782|FG017|Part1:Monotherapy(Up to Maximum 39weeks)|Lost to Follow-up|0
6300281|NCT02528357|10023783|FG018|Part1:Monotherapy(Up to Maximum 39weeks)|Lost to Follow-up|0
6300282|NCT02528357|10023765|FG000|Part1:Monotherapy(Up to Maximum 39weeks)|Physician Decision|0
6300283|NCT02528357|10023766|FG001|Part1:Monotherapy(Up to Maximum 39weeks)|Physician Decision|0
6300284|NCT02528357|10023767|FG002|Part1:Monotherapy(Up to Maximum 39weeks)|Physician Decision|0
6300285|NCT02528357|10023768|FG003|Part1:Monotherapy(Up to Maximum 39weeks)|Physician Decision|1
6300286|NCT02528357|10023769|FG004|Part1:Monotherapy(Up to Maximum 39weeks)|Physician Decision|0
6300287|NCT02528357|10023770|FG005|Part1:Monotherapy(Up to Maximum 39weeks)|Physician Decision|2
6300288|NCT02528357|10023771|FG006|Part1:Monotherapy(Up to Maximum 39weeks)|Physician Decision|0
6300289|NCT02528357|10023772|FG007|Part1:Monotherapy(Up to Maximum 39weeks)|Physician Decision|1
6300290|NCT02528357|10023773|FG008|Part1:Monotherapy(Up to Maximum 39weeks)|Physician Decision|0
6300291|NCT02528357|10023774|FG009|Part1:Monotherapy(Up to Maximum 39weeks)|Physician Decision|0
6300292|NCT02528357|10023775|FG010|Part1:Monotherapy(Up to Maximum 39weeks)|Physician Decision|0
6300293|NCT02528357|10023776|FG011|Part1:Monotherapy(Up to Maximum 39weeks)|Physician Decision|0
6300294|NCT02528357|10023777|FG012|Part1:Monotherapy(Up to Maximum 39weeks)|Physician Decision|0
6300295|NCT02528357|10023778|FG013|Part1:Monotherapy(Up to Maximum 39weeks)|Physician Decision|0
6300296|NCT02528357|10023779|FG014|Part1:Monotherapy(Up to Maximum 39weeks)|Physician Decision|0
6300297|NCT02528357|10023780|FG015|Part1:Monotherapy(Up to Maximum 39weeks)|Physician Decision|0
6300298|NCT02528357|10023781|FG016|Part1:Monotherapy(Up to Maximum 39weeks)|Physician Decision|0
6300299|NCT02528357|10023782|FG017|Part1:Monotherapy(Up to Maximum 39weeks)|Physician Decision|0
6300300|NCT02528357|10023783|FG018|Part1:Monotherapy(Up to Maximum 39weeks)|Physician Decision|0
6300301|NCT02528357|10023765|FG000|Part1:Monotherapy(Up to Maximum 39weeks)|Withdrawal by Subject|0
6300302|NCT02528357|10023766|FG001|Part1:Monotherapy(Up to Maximum 39weeks)|Withdrawal by Subject|0
6300303|NCT02528357|10023767|FG002|Part1:Monotherapy(Up to Maximum 39weeks)|Withdrawal by Subject|2
6300304|NCT02528357|10023768|FG003|Part1:Monotherapy(Up to Maximum 39weeks)|Withdrawal by Subject|0
6300305|NCT02528357|10023769|FG004|Part1:Monotherapy(Up to Maximum 39weeks)|Withdrawal by Subject|3
6300306|NCT02528357|10023770|FG005|Part1:Monotherapy(Up to Maximum 39weeks)|Withdrawal by Subject|0
6300307|NCT02528357|10023771|FG006|Part1:Monotherapy(Up to Maximum 39weeks)|Withdrawal by Subject|2
6300308|NCT02528357|10023772|FG007|Part1:Monotherapy(Up to Maximum 39weeks)|Withdrawal by Subject|1
6300309|NCT02528357|10023773|FG008|Part1:Monotherapy(Up to Maximum 39weeks)|Withdrawal by Subject|0
6300310|NCT02528357|10023774|FG009|Part1:Monotherapy(Up to Maximum 39weeks)|Withdrawal by Subject|0
6300311|NCT02528357|10023775|FG010|Part1:Monotherapy(Up to Maximum 39weeks)|Withdrawal by Subject|0
6300312|NCT02528357|10023776|FG011|Part1:Monotherapy(Up to Maximum 39weeks)|Withdrawal by Subject|0
6300313|NCT02528357|10023777|FG012|Part1:Monotherapy(Up to Maximum 39weeks)|Withdrawal by Subject|0
6300314|NCT02528357|10023778|FG013|Part1:Monotherapy(Up to Maximum 39weeks)|Withdrawal by Subject|0
6300315|NCT02528357|10023779|FG014|Part1:Monotherapy(Up to Maximum 39weeks)|Withdrawal by Subject|0
6300316|NCT02528357|10023780|FG015|Part1:Monotherapy(Up to Maximum 39weeks)|Withdrawal by Subject|0
6300317|NCT02528357|10023781|FG016|Part1:Monotherapy(Up to Maximum 39weeks)|Withdrawal by Subject|0
6300318|NCT02528357|10023782|FG017|Part1:Monotherapy(Up to Maximum 39weeks)|Withdrawal by Subject|0
6300319|NCT02528357|10023783|FG018|Part1:Monotherapy(Up to Maximum 39weeks)|Withdrawal by Subject|0
6300320|NCT02528357|10023765|FG000|Part1:Monotherapy(Up to Maximum 39weeks)|Follow-up assessments removed (Protocol Amendment 4)|0
6300321|NCT02528357|10023766|FG001|Part1:Monotherapy(Up to Maximum 39weeks)|Follow-up assessments removed (Protocol Amendment 4)|0
6300322|NCT02528357|10023767|FG002|Part1:Monotherapy(Up to Maximum 39weeks)|Follow-up assessments removed (Protocol Amendment 4)|0
6136909|NCT01004822|9767041|FG001|Overall Study|Objective progression or relapse|3
6300323|NCT02528357|10023768|FG003|Part1:Monotherapy(Up to Maximum 39weeks)|Follow-up assessments removed (Protocol Amendment 4)|0
6300324|NCT02528357|10023769|FG004|Part1:Monotherapy(Up to Maximum 39weeks)|Follow-up assessments removed (Protocol Amendment 4)|1
6300325|NCT02528357|10023770|FG005|Part1:Monotherapy(Up to Maximum 39weeks)|Follow-up assessments removed (Protocol Amendment 4)|0
6300326|NCT02528357|10023771|FG006|Part1:Monotherapy(Up to Maximum 39weeks)|Follow-up assessments removed (Protocol Amendment 4)|0
6300327|NCT02528357|10023772|FG007|Part1:Monotherapy(Up to Maximum 39weeks)|Follow-up assessments removed (Protocol Amendment 4)|0
6300328|NCT02528357|10023773|FG008|Part1:Monotherapy(Up to Maximum 39weeks)|Follow-up assessments removed (Protocol Amendment 4)|0
6300329|NCT02528357|10023774|FG009|Part1:Monotherapy(Up to Maximum 39weeks)|Follow-up assessments removed (Protocol Amendment 4)|0
6300330|NCT02528357|10023775|FG010|Part1:Monotherapy(Up to Maximum 39weeks)|Follow-up assessments removed (Protocol Amendment 4)|0
6300331|NCT02528357|10023776|FG011|Part1:Monotherapy(Up to Maximum 39weeks)|Follow-up assessments removed (Protocol Amendment 4)|0
6300332|NCT02528357|10023777|FG012|Part1:Monotherapy(Up to Maximum 39weeks)|Follow-up assessments removed (Protocol Amendment 4)|0
6300333|NCT02528357|10023778|FG013|Part1:Monotherapy(Up to Maximum 39weeks)|Follow-up assessments removed (Protocol Amendment 4)|0
6300334|NCT02528357|10023779|FG014|Part1:Monotherapy(Up to Maximum 39weeks)|Follow-up assessments removed (Protocol Amendment 4)|0
6300335|NCT02528357|10023780|FG015|Part1:Monotherapy(Up to Maximum 39weeks)|Follow-up assessments removed (Protocol Amendment 4)|0
6300336|NCT02528357|10023781|FG016|Part1:Monotherapy(Up to Maximum 39weeks)|Follow-up assessments removed (Protocol Amendment 4)|0
6300337|NCT02528357|10023782|FG017|Part1:Monotherapy(Up to Maximum 39weeks)|Follow-up assessments removed (Protocol Amendment 4)|0
6300338|NCT02528357|10023783|FG018|Part1:Monotherapy(Up to Maximum 39weeks)|Follow-up assessments removed (Protocol Amendment 4)|0
6300339|NCT02528357|10023765|FG000|Part2A:Comb. Th. (Up to Maximum 105wks)|Investigator site closed|0
6300340|NCT02528357|10023766|FG001|Part2A:Comb. Th. (Up to Maximum 105wks)|Investigator site closed|0
6300341|NCT02528357|10023767|FG002|Part2A:Comb. Th. (Up to Maximum 105wks)|Investigator site closed|0
6300342|NCT02528357|10023768|FG003|Part2A:Comb. Th. (Up to Maximum 105wks)|Investigator site closed|0
6300343|NCT02528357|10023769|FG004|Part2A:Comb. Th. (Up to Maximum 105wks)|Investigator site closed|0
6300344|NCT02528357|10023770|FG005|Part2A:Comb. Th. (Up to Maximum 105wks)|Investigator site closed|0
6300345|NCT02528357|10023771|FG006|Part2A:Comb. Th. (Up to Maximum 105wks)|Investigator site closed|0
6300346|NCT02528357|10023772|FG007|Part2A:Comb. Th. (Up to Maximum 105wks)|Investigator site closed|0
6300347|NCT02528357|10023773|FG008|Part2A:Comb. Th. (Up to Maximum 105wks)|Investigator site closed|0
6300348|NCT02528357|10023774|FG009|Part2A:Comb. Th. (Up to Maximum 105wks)|Investigator site closed|0
6300349|NCT02528357|10023775|FG010|Part2A:Comb. Th. (Up to Maximum 105wks)|Investigator site closed|0
6300350|NCT02528357|10023776|FG011|Part2A:Comb. Th. (Up to Maximum 105wks)|Investigator site closed|0
6300351|NCT02528357|10023777|FG012|Part2A:Comb. Th. (Up to Maximum 105wks)|Investigator site closed|0
6300352|NCT02528357|10023778|FG013|Part2A:Comb. Th. (Up to Maximum 105wks)|Investigator site closed|1
6300353|NCT02528357|10023779|FG014|Part2A:Comb. Th. (Up to Maximum 105wks)|Investigator site closed|5
6300354|NCT02528357|10023780|FG015|Part2A:Comb. Th. (Up to Maximum 105wks)|Investigator site closed|0
6300355|NCT02528357|10023781|FG016|Part2A:Comb. Th. (Up to Maximum 105wks)|Investigator site closed|0
6300356|NCT02528357|10023782|FG017|Part2A:Comb. Th. (Up to Maximum 105wks)|Investigator site closed|0
6300357|NCT02528357|10023783|FG018|Part2A:Comb. Th. (Up to Maximum 105wks)|Investigator site closed|0
6300358|NCT02528357|10023765|FG000|Part2A:Comb. Th. (Up to Maximum 105wks)|Physician Decision|0
6300359|NCT02528357|10023766|FG001|Part2A:Comb. Th. (Up to Maximum 105wks)|Physician Decision|0
6300360|NCT02528357|10023767|FG002|Part2A:Comb. Th. (Up to Maximum 105wks)|Physician Decision|0
6300361|NCT02528357|10023768|FG003|Part2A:Comb. Th. (Up to Maximum 105wks)|Physician Decision|0
6300362|NCT02528357|10023769|FG004|Part2A:Comb. Th. (Up to Maximum 105wks)|Physician Decision|0
6300363|NCT02528357|10023770|FG005|Part2A:Comb. Th. (Up to Maximum 105wks)|Physician Decision|0
6300364|NCT02528357|10023771|FG006|Part2A:Comb. Th. (Up to Maximum 105wks)|Physician Decision|0
6300365|NCT02528357|10023772|FG007|Part2A:Comb. Th. (Up to Maximum 105wks)|Physician Decision|0
6300366|NCT02528357|10023773|FG008|Part2A:Comb. Th. (Up to Maximum 105wks)|Physician Decision|0
6300367|NCT02528357|10023774|FG009|Part2A:Comb. Th. (Up to Maximum 105wks)|Physician Decision|0
6300368|NCT02528357|10023775|FG010|Part2A:Comb. Th. (Up to Maximum 105wks)|Physician Decision|0
6300369|NCT02528357|10023776|FG011|Part2A:Comb. Th. (Up to Maximum 105wks)|Physician Decision|0
6300370|NCT02528357|10023777|FG012|Part2A:Comb. Th. (Up to Maximum 105wks)|Physician Decision|0
6300371|NCT02528357|10023778|FG013|Part2A:Comb. Th. (Up to Maximum 105wks)|Physician Decision|1
6300372|NCT02528357|10023779|FG014|Part2A:Comb. Th. (Up to Maximum 105wks)|Physician Decision|0
6300373|NCT02528357|10023780|FG015|Part2A:Comb. Th. (Up to Maximum 105wks)|Physician Decision|0
6300374|NCT02528357|10023781|FG016|Part2A:Comb. Th. (Up to Maximum 105wks)|Physician Decision|0
6300375|NCT02528357|10023782|FG017|Part2A:Comb. Th. (Up to Maximum 105wks)|Physician Decision|0
6300376|NCT02528357|10023783|FG018|Part2A:Comb. Th. (Up to Maximum 105wks)|Physician Decision|0
6300377|NCT02528357|10023765|FG000|Part2A:Comb. Th. (Up to Maximum 105wks)|Withdrawal by Subject|0
6300378|NCT02528357|10023766|FG001|Part2A:Comb. Th. (Up to Maximum 105wks)|Withdrawal by Subject|0
6300379|NCT02528357|10023767|FG002|Part2A:Comb. Th. (Up to Maximum 105wks)|Withdrawal by Subject|0
6300380|NCT02528357|10023768|FG003|Part2A:Comb. Th. (Up to Maximum 105wks)|Withdrawal by Subject|0
6300381|NCT02528357|10023769|FG004|Part2A:Comb. Th. (Up to Maximum 105wks)|Withdrawal by Subject|0
6300382|NCT02528357|10023770|FG005|Part2A:Comb. Th. (Up to Maximum 105wks)|Withdrawal by Subject|0
6300383|NCT02528357|10023771|FG006|Part2A:Comb. Th. (Up to Maximum 105wks)|Withdrawal by Subject|0
5982140|NCT01670656|9571061|FG002|Overall Study|Subject withdrew consent|2
5982141|NCT01670656|9571062|FG003|Overall Study|Subject withdrew consent|1
5982142|NCT01670656|9571063|FG004|Overall Study|Subject withdrew consent|1
5982143|NCT01670656|9571059|FG000|Overall Study|Lost to Follow-up|0
5982144|NCT01670656|9571060|FG001|Overall Study|Lost to Follow-up|0
5982145|NCT01670656|9571061|FG002|Overall Study|Lost to Follow-up|0
5982146|NCT01670656|9571062|FG003|Overall Study|Lost to Follow-up|0
5982147|NCT01670656|9571063|FG004|Overall Study|Lost to Follow-up|3
5982148|NCT01670656|9571059|FG000|Overall Study|Subject moved|0
5982149|NCT01670656|9571060|FG001|Overall Study|Subject moved|0
5982150|NCT01670656|9571061|FG002|Overall Study|Subject moved|0
5982151|NCT01670656|9571062|FG003|Overall Study|Subject moved|1
5982152|NCT01670656|9571063|FG004|Overall Study|Subject moved|0
5982153|NCT01501955|9571077|FG000|Overall Study|Withdrawal by Subject|1
5982154|NCT01501955|9571078|FG001|Overall Study|Withdrawal by Subject|0
5982155|NCT01501955|9571077|FG000|Overall Study|Adverse Event|1
5982156|NCT01501955|9571078|FG001|Overall Study|Adverse Event|3
5982157|NCT01335399|9571086|FG000|Pre-treatment Period|No longer meeting study criteria|0
5982158|NCT01335399|9571087|FG001|Pre-treatment Period|No longer meeting study criteria|1
5982159|NCT01335399|9571086|FG000|Pre-treatment Period|Participant request to discontinue|0
5982160|NCT01335399|9571087|FG001|Pre-treatment Period|Participant request to discontinue|1
5982161|NCT01335399|9571086|FG000|Pre-treatment Period|Adverse event unrelated to study drug|0
5982162|NCT01335399|9571087|FG001|Pre-treatment Period|Adverse event unrelated to study drug|1
5982163|NCT01335399|9571086|FG000|Pre-treatment Period|Consent withdrawal|3
5982164|NCT01335399|9571087|FG001|Pre-treatment Period|Consent withdrawal|0
5982165|NCT01335399|9571086|FG000|Treatment Period|Disease progression|114
5982166|NCT01335399|9571087|FG001|Treatment Period|Disease progression|141
5982167|NCT01335399|9571086|FG000|Treatment Period|Adverse event unrelated to study drug|105
5982168|NCT01335399|9571087|FG001|Treatment Period|Adverse event unrelated to study drug|65
5982169|NCT01335399|9571086|FG000|Treatment Period|Study drug toxicity|51
5982170|NCT01335399|9571087|FG001|Treatment Period|Study drug toxicity|64
5982171|NCT01335399|9571086|FG000|Treatment Period|Participant request to discontinue|27
5982172|NCT01335399|9571087|FG001|Treatment Period|Participant request to discontinue|21
5982173|NCT01335399|9571086|FG000|Treatment Period|Other reasons|14
5982174|NCT01335399|9571087|FG001|Treatment Period|Other reasons|26
5982175|NCT01335399|9571086|FG000|Treatment Period|Consent withdrawal|10
5982176|NCT01335399|9571087|FG001|Treatment Period|Consent withdrawal|6
5982177|NCT01335399|9571086|FG000|Treatment Period|Death|7
5982178|NCT01335399|9571087|FG001|Treatment Period|Death|8
5982179|NCT01335399|9571086|FG000|Treatment Period|Poor/Non-compliance|3
5982180|NCT01335399|9571087|FG001|Treatment Period|Poor/Non-compliance|4
5982181|NCT01335399|9571086|FG000|Treatment Period|Lost to Follow-up|0
5982182|NCT01335399|9571087|FG001|Treatment Period|Lost to Follow-up|2
5982183|NCT01335399|9571086|FG000|Treatment Period|Maximum clinical benefit|1
5982184|NCT01335399|9571087|FG001|Treatment Period|Maximum clinical benefit|1
5982185|NCT01335399|9571086|FG000|Treatment Period|No longer meet study criteria|0
5982186|NCT01335399|9571087|FG001|Treatment Period|No longer meet study criteria|1
5982187|NCT01335399|9571086|FG000|Treatment Period|Not reported|1
5982188|NCT01335399|9571087|FG001|Treatment Period|Not reported|0
5982189|NCT01277211|9571095|FG000|Overall Study|Adverse Event|60
5982190|NCT01277211|9571096|FG001|Overall Study|Adverse Event|22
5982191|NCT01277211|9571095|FG000|Overall Study|Pregnancy|9
5982192|NCT01277211|9571096|FG001|Overall Study|Pregnancy|4
5982193|NCT01277211|9571095|FG000|Overall Study|Lost to Follow-up|14
5982194|NCT01277211|9571096|FG001|Overall Study|Lost to Follow-up|9
5982195|NCT01277211|9571095|FG000|Overall Study|Did not wish to continue|17
5982196|NCT01277211|9571096|FG001|Overall Study|Did not wish to continue|0
5982197|NCT01277211|9571095|FG000|Overall Study|Withdrew Consent|9
5982198|NCT01277211|9571096|FG001|Overall Study|Withdrew Consent|9
5982199|NCT01277211|9571095|FG000|Overall Study|Non-compliance with protocol|13
5982200|NCT01277211|9571096|FG001|Overall Study|Non-compliance with protocol|4
5982201|NCT01277211|9571095|FG000|Overall Study|Did not meet protocol eligibility|1
5982202|NCT01277211|9571096|FG001|Overall Study|Did not meet protocol eligibility|0
5982203|NCT01277211|9571095|FG000|Overall Study|Administrative|3
5982204|NCT01277211|9571096|FG001|Overall Study|Administrative|0
5982205|NCT01277211|9571095|FG000|Overall Study|Pregnancy wish|0
5982206|NCT01277211|9571096|FG001|Overall Study|Pregnancy wish|2
5982207|NCT01277211|9571095|FG000|Overall Study|Discontinued prior to treatment|24
5982208|NCT01277211|9571096|FG001|Overall Study|Discontinued prior to treatment|13
5982209|NCT01244828|9571106|FG000|Overall Study|Adverse Event|37
5982210|NCT01244828|9571106|FG000|Overall Study|Withdrawal by Subject|31
5982211|NCT01244828|9571106|FG000|Overall Study|Lack of Efficacy|7
5982212|NCT01244828|9571106|FG000|Overall Study|Lost to Follow-up|2
5982213|NCT01244828|9571106|FG000|Overall Study|Other reason (not specified)|1
5982214|NCT01207492|9571110|FG000|Overall Study|Still on study|1
5982215|NCT01207492|9571110|FG000|Overall Study|Withdrawal by Subject|9
5982216|NCT01207492|9571110|FG000|Overall Study|Physician Decision|1
5982217|NCT01207492|9571110|FG000|Overall Study|Progressive disease|3
6300384|NCT02528357|10023772|FG007|Part2A:Comb. Th. (Up to Maximum 105wks)|Withdrawal by Subject|0
6300385|NCT02528357|10023773|FG008|Part2A:Comb. Th. (Up to Maximum 105wks)|Withdrawal by Subject|0
6300386|NCT02528357|10023774|FG009|Part2A:Comb. Th. (Up to Maximum 105wks)|Withdrawal by Subject|0
6300387|NCT02528357|10023775|FG010|Part2A:Comb. Th. (Up to Maximum 105wks)|Withdrawal by Subject|3
6300388|NCT02528357|10023776|FG011|Part2A:Comb. Th. (Up to Maximum 105wks)|Withdrawal by Subject|0
6300389|NCT02528357|10023777|FG012|Part2A:Comb. Th. (Up to Maximum 105wks)|Withdrawal by Subject|1
6300390|NCT02528357|10023778|FG013|Part2A:Comb. Th. (Up to Maximum 105wks)|Withdrawal by Subject|3
6300391|NCT02528357|10023779|FG014|Part2A:Comb. Th. (Up to Maximum 105wks)|Withdrawal by Subject|1
6300392|NCT02528357|10023780|FG015|Part2A:Comb. Th. (Up to Maximum 105wks)|Withdrawal by Subject|0
6300393|NCT02528357|10023781|FG016|Part2A:Comb. Th. (Up to Maximum 105wks)|Withdrawal by Subject|0
6300394|NCT02528357|10023782|FG017|Part2A:Comb. Th. (Up to Maximum 105wks)|Withdrawal by Subject|0
6300395|NCT02528357|10023783|FG018|Part2A:Comb. Th. (Up to Maximum 105wks)|Withdrawal by Subject|0
6300396|NCT02528357|10023765|FG000|Part2A:Comb. Th. (Up to Maximum 105wks)|Follow-up assessments removed (Protocol Amendment 4)|0
6300397|NCT02528357|10023766|FG001|Part2A:Comb. Th. (Up to Maximum 105wks)|Follow-up assessments removed (Protocol Amendment 4)|0
6300398|NCT02528357|10023767|FG002|Part2A:Comb. Th. (Up to Maximum 105wks)|Follow-up assessments removed (Protocol Amendment 4)|0
6300399|NCT02528357|10023768|FG003|Part2A:Comb. Th. (Up to Maximum 105wks)|Follow-up assessments removed (Protocol Amendment 4)|0
6300400|NCT02528357|10023769|FG004|Part2A:Comb. Th. (Up to Maximum 105wks)|Follow-up assessments removed (Protocol Amendment 4)|0
6300401|NCT02528357|10023770|FG005|Part2A:Comb. Th. (Up to Maximum 105wks)|Follow-up assessments removed (Protocol Amendment 4)|0
6300402|NCT02528357|10023771|FG006|Part2A:Comb. Th. (Up to Maximum 105wks)|Follow-up assessments removed (Protocol Amendment 4)|0
6300403|NCT02528357|10023772|FG007|Part2A:Comb. Th. (Up to Maximum 105wks)|Follow-up assessments removed (Protocol Amendment 4)|0
6300404|NCT02528357|10023773|FG008|Part2A:Comb. Th. (Up to Maximum 105wks)|Follow-up assessments removed (Protocol Amendment 4)|1
6300405|NCT02528357|10023774|FG009|Part2A:Comb. Th. (Up to Maximum 105wks)|Follow-up assessments removed (Protocol Amendment 4)|1
6300406|NCT02528357|10023775|FG010|Part2A:Comb. Th. (Up to Maximum 105wks)|Follow-up assessments removed (Protocol Amendment 4)|0
6300407|NCT02528357|10023776|FG011|Part2A:Comb. Th. (Up to Maximum 105wks)|Follow-up assessments removed (Protocol Amendment 4)|3
6300408|NCT02528357|10023777|FG012|Part2A:Comb. Th. (Up to Maximum 105wks)|Follow-up assessments removed (Protocol Amendment 4)|4
6300409|NCT02528357|10023778|FG013|Part2A:Comb. Th. (Up to Maximum 105wks)|Follow-up assessments removed (Protocol Amendment 4)|1
6300410|NCT02528357|10023779|FG014|Part2A:Comb. Th. (Up to Maximum 105wks)|Follow-up assessments removed (Protocol Amendment 4)|1
6300411|NCT02528357|10023780|FG015|Part2A:Comb. Th. (Up to Maximum 105wks)|Follow-up assessments removed (Protocol Amendment 4)|0
6300412|NCT02528357|10023781|FG016|Part2A:Comb. Th. (Up to Maximum 105wks)|Follow-up assessments removed (Protocol Amendment 4)|0
6300413|NCT02528357|10023782|FG017|Part2A:Comb. Th. (Up to Maximum 105wks)|Follow-up assessments removed (Protocol Amendment 4)|0
6300414|NCT02528357|10023783|FG018|Part2A:Comb. Th. (Up to Maximum 105wks)|Follow-up assessments removed (Protocol Amendment 4)|0
6300415|NCT02528357|10023765|FG000|Part2B:Expan. Coh.(Up to Maximum 33 Wks)|Withdrawal by Subject|0
6300416|NCT02528357|10023766|FG001|Part2B:Expan. Coh.(Up to Maximum 33 Wks)|Withdrawal by Subject|0
6300417|NCT02528357|10023767|FG002|Part2B:Expan. Coh.(Up to Maximum 33 Wks)|Withdrawal by Subject|0
6300418|NCT02528357|10023768|FG003|Part2B:Expan. Coh.(Up to Maximum 33 Wks)|Withdrawal by Subject|0
6300419|NCT02528357|10023769|FG004|Part2B:Expan. Coh.(Up to Maximum 33 Wks)|Withdrawal by Subject|0
6300420|NCT02528357|10023770|FG005|Part2B:Expan. Coh.(Up to Maximum 33 Wks)|Withdrawal by Subject|0
6300421|NCT02528357|10023771|FG006|Part2B:Expan. Coh.(Up to Maximum 33 Wks)|Withdrawal by Subject|0
6300422|NCT02528357|10023772|FG007|Part2B:Expan. Coh.(Up to Maximum 33 Wks)|Withdrawal by Subject|0
6300423|NCT02528357|10023773|FG008|Part2B:Expan. Coh.(Up to Maximum 33 Wks)|Withdrawal by Subject|0
6300424|NCT02528357|10023774|FG009|Part2B:Expan. Coh.(Up to Maximum 33 Wks)|Withdrawal by Subject|0
6300425|NCT02528357|10023775|FG010|Part2B:Expan. Coh.(Up to Maximum 33 Wks)|Withdrawal by Subject|0
6300426|NCT02528357|10023776|FG011|Part2B:Expan. Coh.(Up to Maximum 33 Wks)|Withdrawal by Subject|0
6300427|NCT02528357|10023777|FG012|Part2B:Expan. Coh.(Up to Maximum 33 Wks)|Withdrawal by Subject|0
6300428|NCT02528357|10023778|FG013|Part2B:Expan. Coh.(Up to Maximum 33 Wks)|Withdrawal by Subject|0
6300429|NCT02528357|10023779|FG014|Part2B:Expan. Coh.(Up to Maximum 33 Wks)|Withdrawal by Subject|0
6300430|NCT02528357|10023780|FG015|Part2B:Expan. Coh.(Up to Maximum 33 Wks)|Withdrawal by Subject|0
6300431|NCT02528357|10023781|FG016|Part2B:Expan. Coh.(Up to Maximum 33 Wks)|Withdrawal by Subject|2
6300432|NCT02528357|10023782|FG017|Part2B:Expan. Coh.(Up to Maximum 33 Wks)|Withdrawal by Subject|0
6300433|NCT02528357|10023783|FG018|Part2B:Expan. Coh.(Up to Maximum 33 Wks)|Withdrawal by Subject|0
6300434|NCT02528357|10023765|FG000|Part2B:Expan. Coh.(Up to Maximum 33 Wks)|Follow-up assessments removed (Protocol Amendment 4)|0
6300435|NCT02528357|10023766|FG001|Part2B:Expan. Coh.(Up to Maximum 33 Wks)|Follow-up assessments removed (Protocol Amendment 4)|0
6300436|NCT02528357|10023767|FG002|Part2B:Expan. Coh.(Up to Maximum 33 Wks)|Follow-up assessments removed (Protocol Amendment 4)|0
6300437|NCT02528357|10023768|FG003|Part2B:Expan. Coh.(Up to Maximum 33 Wks)|Follow-up assessments removed (Protocol Amendment 4)|0
6300438|NCT02528357|10023769|FG004|Part2B:Expan. Coh.(Up to Maximum 33 Wks)|Follow-up assessments removed (Protocol Amendment 4)|0
6300439|NCT02528357|10023770|FG005|Part2B:Expan. Coh.(Up to Maximum 33 Wks)|Follow-up assessments removed (Protocol Amendment 4)|0
6300440|NCT02528357|10023771|FG006|Part2B:Expan. Coh.(Up to Maximum 33 Wks)|Follow-up assessments removed (Protocol Amendment 4)|0
6300441|NCT02528357|10023772|FG007|Part2B:Expan. Coh.(Up to Maximum 33 Wks)|Follow-up assessments removed (Protocol Amendment 4)|0
6300442|NCT02528357|10023773|FG008|Part2B:Expan. Coh.(Up to Maximum 33 Wks)|Follow-up assessments removed (Protocol Amendment 4)|0
6300443|NCT02528357|10023774|FG009|Part2B:Expan. Coh.(Up to Maximum 33 Wks)|Follow-up assessments removed (Protocol Amendment 4)|0
6300444|NCT02528357|10023775|FG010|Part2B:Expan. Coh.(Up to Maximum 33 Wks)|Follow-up assessments removed (Protocol Amendment 4)|0
6300445|NCT02528357|10023776|FG011|Part2B:Expan. Coh.(Up to Maximum 33 Wks)|Follow-up assessments removed (Protocol Amendment 4)|0
6300446|NCT02528357|10023777|FG012|Part2B:Expan. Coh.(Up to Maximum 33 Wks)|Follow-up assessments removed (Protocol Amendment 4)|0
6300447|NCT02528357|10023778|FG013|Part2B:Expan. Coh.(Up to Maximum 33 Wks)|Follow-up assessments removed (Protocol Amendment 4)|0
6300448|NCT02528357|10023779|FG014|Part2B:Expan. Coh.(Up to Maximum 33 Wks)|Follow-up assessments removed (Protocol Amendment 4)|0
6300449|NCT02528357|10023780|FG015|Part2B:Expan. Coh.(Up to Maximum 33 Wks)|Follow-up assessments removed (Protocol Amendment 4)|0
6300450|NCT02528357|10023781|FG016|Part2B:Expan. Coh.(Up to Maximum 33 Wks)|Follow-up assessments removed (Protocol Amendment 4)|1
6300451|NCT02528357|10023782|FG017|Part2B:Expan. Coh.(Up to Maximum 33 Wks)|Follow-up assessments removed (Protocol Amendment 4)|4
6300452|NCT02528357|10023783|FG018|Part2B:Expan. Coh.(Up to Maximum 33 Wks)|Follow-up assessments removed (Protocol Amendment 4)|3
6300453|NCT02528942|10023854|FG000|Overall Study|Did not meet imaging criteria|9
6300454|NCT02528942|10023854|FG000|Overall Study|Lost to Follow-up|25
6300455|NCT02529137|10023867|FG000|Overall Study|Discontinuation for different reasons|8
6300456|NCT02529488|10023872|FG000|Overall Study|Adverse Event|1
6300457|NCT02529488|10023872|FG000|Overall Study|Death|3
6300458|NCT02529553|10023889|FG000|Overall Study|Progressive Disease|1
6300459|NCT02529553|10023890|FG001|Overall Study|Progressive Disease|0
6300460|NCT02529553|10023891|FG002|Overall Study|Progressive Disease|1
6300461|NCT02529553|10023892|FG003|Overall Study|Progressive Disease|3
6300462|NCT02529553|10023893|FG004|Overall Study|Progressive Disease|2
6300463|NCT02529553|10023894|FG005|Overall Study|Progressive Disease|3
6300464|NCT02529553|10023895|FG006|Overall Study|Progressive Disease|3
6300465|NCT02529553|10023896|FG007|Overall Study|Progressive Disease|5
6300466|NCT02529553|10023897|FG008|Overall Study|Progressive Disease|3
6300467|NCT02529553|10023889|FG000|Overall Study|Physician Decision|0
6300468|NCT02529553|10023890|FG001|Overall Study|Physician Decision|1
6300469|NCT02529553|10023891|FG002|Overall Study|Physician Decision|0
6300470|NCT02529553|10023892|FG003|Overall Study|Physician Decision|0
6300471|NCT02529553|10023893|FG004|Overall Study|Physician Decision|1
6300472|NCT02529553|10023894|FG005|Overall Study|Physician Decision|0
6300473|NCT02529553|10023895|FG006|Overall Study|Physician Decision|0
6300474|NCT02529553|10023896|FG007|Overall Study|Physician Decision|0
6300475|NCT02529553|10023897|FG008|Overall Study|Physician Decision|0
6300476|NCT02529553|10023889|FG000|Overall Study|Withdrawal by Subject|0
6300477|NCT02529553|10023890|FG001|Overall Study|Withdrawal by Subject|0
6300478|NCT02529553|10023891|FG002|Overall Study|Withdrawal by Subject|0
6300479|NCT02529553|10023892|FG003|Overall Study|Withdrawal by Subject|0
6300480|NCT02529553|10023893|FG004|Overall Study|Withdrawal by Subject|0
6300481|NCT02529553|10023894|FG005|Overall Study|Withdrawal by Subject|1
6300482|NCT02529553|10023895|FG006|Overall Study|Withdrawal by Subject|0
6300483|NCT02529553|10023896|FG007|Overall Study|Withdrawal by Subject|1
6300484|NCT02529553|10023897|FG008|Overall Study|Withdrawal by Subject|0
6300485|NCT02529995|10023920|FG000|Part A|Ongoing Study at Data Cut-off|14
6300486|NCT02529995|10023921|FG001|Part A|Ongoing Study at Data Cut-off|16
6300487|NCT02529995|10023920|FG000|Part A|Discontinued Study|1
6300488|NCT02529995|10023921|FG001|Part A|Discontinued Study|0
6300489|NCT02529995|10023920|FG000|Part B|Ongoing Study at Data Cut-off|0
6300490|NCT02529995|10023921|FG001|Part B|Ongoing Study at Data Cut-off|7
6300491|NCT02529995|10023920|FG000|Part B|Discontinued Study|6
6300492|NCT02529995|10023921|FG001|Part B|Discontinued Study|5
6300493|NCT02530125|10023927|FG000|Completed Treatment|Early termination of study|1
6300494|NCT02530125|10023927|FG000|Followed for Survival for 2 Years|Early termination of study|3
6300495|NCT02530242|10023942|FG000|Overall Study|excluded due to asthma and oxcarbazepine|0
6300496|NCT02530242|10023943|FG001|Overall Study|excluded due to asthma and oxcarbazepine|1
6300497|NCT02530385|10023971|FG000|Overall Study|Withdrawal by Subject|0
6300498|NCT02530385|10023972|FG001|Overall Study|Withdrawal by Subject|1
6300499|NCT02530619|10024062|FG000|Registered for Study|Withdrawal by Subject|2
6300500|NCT02530619|10024062|FG000|Continued Treatment Cycles 2 Through 6|Adverse Event|2
6300501|NCT02530619|10024062|FG000|Continued Treatment Cycles 2 Through 6|Withdrawal by Subject|2
6300502|NCT02530619|10024062|FG000|Continued Treatment Cycles 2 Through 6|Progressive Disease|4
6300503|NCT02530619|10024062|FG000|Continued Treatment Cycles 2 Through 6|Lack of Efficacy|2
6300504|NCT02530619|10024062|FG000|Follow-up Period (6 Months)|Death|4
6300505|NCT02530619|10024062|FG000|Follow-up Period (6 Months)|Lost to Follow-up|2
6300506|NCT02530619|10024062|FG000|Follow-up Period (6 Months)|Withdrawal by Subject|5
6300507|NCT02530671|10024068|FG000|Overall Study|Lost to Follow-up|2
6300508|NCT02530671|10024069|FG001|Overall Study|Lost to Follow-up|0
6300509|NCT02530671|10024068|FG000|Overall Study|Withdrawal by Subject|1
6300510|NCT02530671|10024069|FG001|Overall Study|Withdrawal by Subject|0
6300511|NCT02530905|10024077|FG000|Open Label Extension Period (132 Weeks)|Withdrawal by Subject|0
6300512|NCT02530905|10024078|FG001|Open Label Extension Period (132 Weeks)|Withdrawal by Subject|0
6300513|NCT02530905|10024079|FG002|Open Label Extension Period (132 Weeks)|Withdrawal by Subject|1
5982218|NCT01207492|9571110|FG000|Overall Study|Toxicity|1
6300514|NCT02530970|10024101|FG000|Overall Study|Adverse Event|8
6300515|NCT02530970|10024101|FG000|Overall Study|Lost to Follow-up|88
6300516|NCT02530970|10024101|FG000|Overall Study|Physician Decision|5
6300517|NCT02530970|10024101|FG000|Overall Study|Withdrawal by Subject|14
6300518|NCT02530970|10024101|FG000|Overall Study|Death|6
6300519|NCT02530970|10024101|FG000|Overall Study|Hospitalization|1
6300520|NCT02530970|10024101|FG000|Overall Study|Insurance|2
6300521|NCT02530970|10024101|FG000|Overall Study|Explant|2
6300522|NCT02530970|10024101|FG000|Overall Study|Change in Provider|5
6300523|NCT02530970|10024101|FG000|Overall Study|Relocation|3
6300524|NCT02531035|10024127|FG000|Overall Study|Death|0
6300525|NCT02531035|10024128|FG001|Overall Study|Death|1
6300526|NCT02531035|10024127|FG000|Overall Study|Protocol Violation|1
6300527|NCT02531035|10024128|FG001|Overall Study|Protocol Violation|1
6300528|NCT02531035|10024127|FG000|Overall Study|Noncompliance with study drug|8
6300529|NCT02531035|10024128|FG001|Overall Study|Noncompliance with study drug|3
6300530|NCT02531035|10024127|FG000|Overall Study|Physician Decision|1
6300531|NCT02531035|10024128|FG001|Overall Study|Physician Decision|0
6300532|NCT02531035|10024127|FG000|Overall Study|Adverse Event|16
6300533|NCT02531035|10024128|FG001|Overall Study|Adverse Event|45
6300534|NCT02531035|10024127|FG000|Overall Study|Other|3
6300535|NCT02531035|10024128|FG001|Overall Study|Other|2
6300536|NCT02531035|10024127|FG000|Overall Study|Withdrawal by Subject|42
6300537|NCT02531035|10024128|FG001|Overall Study|Withdrawal by Subject|32
6300538|NCT02531035|10024127|FG000|Overall Study|Lost to Follow-up|8
6300539|NCT02531035|10024128|FG001|Overall Study|Lost to Follow-up|10
6300540|NCT02531035|10024127|FG000|Overall Study|Randomized, not treated|2
6300541|NCT02531035|10024128|FG001|Overall Study|Randomized, not treated|1
6300542|NCT02531113|10024134|FG000|Induction Period: Week 0 to 12|Adverse Event|4
6300543|NCT02531113|10024134|FG000|Induction Period: Week 0 to 12|Lack of Efficacy|4
6300544|NCT02531113|10024134|FG000|Induction Period: Week 0 to 12|Withdrawal by Subject|3
6300545|NCT02531113|10024134|FG000|Extension Period: Week 12 up to Week 160|Physician Decision|2
6300546|NCT02531113|10024134|FG000|Extension Period: Week 12 up to Week 160|Adverse Event|5
6300547|NCT02531113|10024134|FG000|Extension Period: Week 12 up to Week 160|Lack of Efficacy|19
6300548|NCT02531113|10024134|FG000|Extension Period: Week 12 up to Week 160|Withdrawal by Subject|11
6300549|NCT02531113|10024134|FG000|Extension Period: Week 12 up to Week 160|Pregnancy|1
6300550|NCT02531373|10024156|FG000|Overall Study|Lack of Efficacy|0
6300551|NCT02531373|10024157|FG001|Overall Study|Lack of Efficacy|0
6300552|NCT02531373|10024158|FG002|Overall Study|Lack of Efficacy|0
6300553|NCT02531373|10024159|FG003|Overall Study|Lack of Efficacy|0
6300554|NCT02531373|10024160|FG004|Overall Study|Lack of Efficacy|3
6300555|NCT02531373|10024161|FG005|Overall Study|Lack of Efficacy|2
6300556|NCT02531373|10024162|FG006|Overall Study|Lack of Efficacy|4
6300557|NCT02531373|10024163|FG007|Overall Study|Lack of Efficacy|8
6300558|NCT02531373|10024164|FG008|Overall Study|Lack of Efficacy|5
6300559|NCT02531373|10024156|FG000|Overall Study|Lost to Follow-up|0
6300560|NCT02531373|10024157|FG001|Overall Study|Lost to Follow-up|0
6300561|NCT02531373|10024158|FG002|Overall Study|Lost to Follow-up|0
6300562|NCT02531373|10024159|FG003|Overall Study|Lost to Follow-up|0
6300563|NCT02531373|10024160|FG004|Overall Study|Lost to Follow-up|0
6300564|NCT02531373|10024161|FG005|Overall Study|Lost to Follow-up|2
6300565|NCT02531373|10024162|FG006|Overall Study|Lost to Follow-up|2
6300566|NCT02531373|10024163|FG007|Overall Study|Lost to Follow-up|0
6300567|NCT02531373|10024164|FG008|Overall Study|Lost to Follow-up|0
6300568|NCT02531373|10024156|FG000|Overall Study|Physician Decision|0
6300569|NCT02531373|10024157|FG001|Overall Study|Physician Decision|0
6300570|NCT02531373|10024158|FG002|Overall Study|Physician Decision|0
6300571|NCT02531373|10024159|FG003|Overall Study|Physician Decision|0
6300572|NCT02531373|10024160|FG004|Overall Study|Physician Decision|2
6300573|NCT02531373|10024161|FG005|Overall Study|Physician Decision|1
6300574|NCT02531373|10024162|FG006|Overall Study|Physician Decision|0
6300575|NCT02531373|10024163|FG007|Overall Study|Physician Decision|0
6300576|NCT02531373|10024164|FG008|Overall Study|Physician Decision|0
6300577|NCT02531373|10024156|FG000|Overall Study|Protocol Violation|0
6300578|NCT02531373|10024157|FG001|Overall Study|Protocol Violation|0
6300579|NCT02531373|10024158|FG002|Overall Study|Protocol Violation|0
6300580|NCT02531373|10024159|FG003|Overall Study|Protocol Violation|0
6300581|NCT02531373|10024160|FG004|Overall Study|Protocol Violation|0
6300582|NCT02531373|10024161|FG005|Overall Study|Protocol Violation|1
6300583|NCT02531373|10024162|FG006|Overall Study|Protocol Violation|1
6300584|NCT02531373|10024163|FG007|Overall Study|Protocol Violation|0
6300585|NCT02531373|10024164|FG008|Overall Study|Protocol Violation|1
6300586|NCT02531373|10024156|FG000|Overall Study|Withdrawal by Parent/Guardian|0
6300587|NCT02531373|10024157|FG001|Overall Study|Withdrawal by Parent/Guardian|0
6300588|NCT02531373|10024158|FG002|Overall Study|Withdrawal by Parent/Guardian|0
6300589|NCT02531373|10024159|FG003|Overall Study|Withdrawal by Parent/Guardian|0
6300590|NCT02531373|10024160|FG004|Overall Study|Withdrawal by Parent/Guardian|0
6300591|NCT02531373|10024161|FG005|Overall Study|Withdrawal by Parent/Guardian|3
6300592|NCT02531373|10024162|FG006|Overall Study|Withdrawal by Parent/Guardian|4
6300593|NCT02531373|10024163|FG007|Overall Study|Withdrawal by Parent/Guardian|1
6300594|NCT02531373|10024164|FG008|Overall Study|Withdrawal by Parent/Guardian|3
6300595|NCT02531373|10024156|FG000|Overall Study|Withdrawal by Subject|0
6300596|NCT02531373|10024157|FG001|Overall Study|Withdrawal by Subject|0
6300597|NCT02531373|10024158|FG002|Overall Study|Withdrawal by Subject|0
6300598|NCT02531373|10024159|FG003|Overall Study|Withdrawal by Subject|0
6300599|NCT02531373|10024160|FG004|Overall Study|Withdrawal by Subject|3
6300600|NCT02531373|10024161|FG005|Overall Study|Withdrawal by Subject|0
6300601|NCT02531373|10024162|FG006|Overall Study|Withdrawal by Subject|0
6300602|NCT02531373|10024163|FG007|Overall Study|Withdrawal by Subject|0
6300603|NCT02531373|10024164|FG008|Overall Study|Withdrawal by Subject|0
6300604|NCT02531438|10024187|FG000|Overall Study|Adverse Event|7
6300605|NCT02531438|10024188|FG001|Overall Study|Adverse Event|9
6300606|NCT02531438|10024187|FG000|Overall Study|Lost to Follow-up|0
6300607|NCT02531438|10024188|FG001|Overall Study|Lost to Follow-up|3
6300608|NCT02531438|10024187|FG000|Overall Study|Withdrawal by Subject|7
6300609|NCT02531438|10024188|FG001|Overall Study|Withdrawal by Subject|8
6300610|NCT02531438|10024187|FG000|Overall Study|Physician Decision|0
6300611|NCT02531438|10024188|FG001|Overall Study|Physician Decision|1
6300612|NCT02531438|10024187|FG000|Overall Study|Death|6
6300613|NCT02531438|10024188|FG001|Overall Study|Death|3
6300614|NCT02531438|10024187|FG000|Overall Study|Randomized, but Not Treated|4
6300615|NCT02531438|10024188|FG001|Overall Study|Randomized, but Not Treated|0
6300616|NCT02531438|10024187|FG000|Overall Study|Missed EOT/PTE Visit|5
6300617|NCT02531438|10024188|FG001|Overall Study|Missed EOT/PTE Visit|2
6300618|NCT02531438|10024187|FG000|Overall Study|Randomized with Exclusion Criteria|1
6300619|NCT02531438|10024188|FG001|Overall Study|Randomized with Exclusion Criteria|0
6300620|NCT02531633|10024199|FG000|Part A (52 Weeks)|Sponsor request|24
6300621|NCT02531633|10024200|FG001|Part A (52 Weeks)|Sponsor request|24
6300622|NCT02531633|10024201|FG002|Part A (52 Weeks)|Sponsor request|18
6300623|NCT02531633|10024202|FG003|Part A (52 Weeks)|Sponsor request|18
6300624|NCT02531633|10024203|FG004|Part A (52 Weeks)|Sponsor request|19
6300625|NCT02531633|10024204|FG005|Part A (52 Weeks)|Sponsor request|0
6300626|NCT02531633|10024205|FG006|Part A (52 Weeks)|Sponsor request|0
6300627|NCT02531633|10024206|FG007|Part A (52 Weeks)|Sponsor request|0
6300628|NCT02531633|10024207|FG008|Part A (52 Weeks)|Sponsor request|0
6300629|NCT02531633|10024208|FG009|Part A (52 Weeks)|Sponsor request|0
6300630|NCT02531633|10024199|FG000|Part A (52 Weeks)|Protocol Violation|1
6300631|NCT02531633|10024200|FG001|Part A (52 Weeks)|Protocol Violation|0
6300632|NCT02531633|10024201|FG002|Part A (52 Weeks)|Protocol Violation|0
6300633|NCT02531633|10024202|FG003|Part A (52 Weeks)|Protocol Violation|0
6300634|NCT02531633|10024203|FG004|Part A (52 Weeks)|Protocol Violation|0
6300635|NCT02531633|10024204|FG005|Part A (52 Weeks)|Protocol Violation|0
6300636|NCT02531633|10024205|FG006|Part A (52 Weeks)|Protocol Violation|0
6300637|NCT02531633|10024206|FG007|Part A (52 Weeks)|Protocol Violation|0
6300638|NCT02531633|10024207|FG008|Part A (52 Weeks)|Protocol Violation|0
6300639|NCT02531633|10024208|FG009|Part A (52 Weeks)|Protocol Violation|0
6300640|NCT02531633|10024199|FG000|Part A (52 Weeks)|Lost to Follow-up|0
6300641|NCT02531633|10024200|FG001|Part A (52 Weeks)|Lost to Follow-up|0
6300642|NCT02531633|10024201|FG002|Part A (52 Weeks)|Lost to Follow-up|0
6300643|NCT02531633|10024202|FG003|Part A (52 Weeks)|Lost to Follow-up|0
6300644|NCT02531633|10024203|FG004|Part A (52 Weeks)|Lost to Follow-up|1
6300645|NCT02531633|10024204|FG005|Part A (52 Weeks)|Lost to Follow-up|0
6300646|NCT02531633|10024205|FG006|Part A (52 Weeks)|Lost to Follow-up|0
6300647|NCT02531633|10024206|FG007|Part A (52 Weeks)|Lost to Follow-up|0
6300648|NCT02531633|10024207|FG008|Part A (52 Weeks)|Lost to Follow-up|0
6300649|NCT02531633|10024208|FG009|Part A (52 Weeks)|Lost to Follow-up|0
6300650|NCT02531633|10024199|FG000|Part A (52 Weeks)|Physician Decision|1
6300651|NCT02531633|10024200|FG001|Part A (52 Weeks)|Physician Decision|4
6300652|NCT02531633|10024201|FG002|Part A (52 Weeks)|Physician Decision|3
6300653|NCT02531633|10024202|FG003|Part A (52 Weeks)|Physician Decision|1
6300654|NCT02531633|10024203|FG004|Part A (52 Weeks)|Physician Decision|0
6300655|NCT02531633|10024204|FG005|Part A (52 Weeks)|Physician Decision|0
6300656|NCT02531633|10024205|FG006|Part A (52 Weeks)|Physician Decision|0
6300657|NCT02531633|10024206|FG007|Part A (52 Weeks)|Physician Decision|0
6300658|NCT02531633|10024207|FG008|Part A (52 Weeks)|Physician Decision|0
6300659|NCT02531633|10024208|FG009|Part A (52 Weeks)|Physician Decision|0
6300660|NCT02531633|10024199|FG000|Part A (52 Weeks)|Withdrawal by Subject|6
6300661|NCT02531633|10024200|FG001|Part A (52 Weeks)|Withdrawal by Subject|6
6300662|NCT02531633|10024201|FG002|Part A (52 Weeks)|Withdrawal by Subject|1
6300663|NCT02531633|10024202|FG003|Part A (52 Weeks)|Withdrawal by Subject|3
6300664|NCT02531633|10024203|FG004|Part A (52 Weeks)|Withdrawal by Subject|3
6300665|NCT02531633|10024204|FG005|Part A (52 Weeks)|Withdrawal by Subject|0
6300666|NCT02531633|10024205|FG006|Part A (52 Weeks)|Withdrawal by Subject|0
6300667|NCT02531633|10024206|FG007|Part A (52 Weeks)|Withdrawal by Subject|0
6300668|NCT02531633|10024207|FG008|Part A (52 Weeks)|Withdrawal by Subject|0
6300669|NCT02531633|10024208|FG009|Part A (52 Weeks)|Withdrawal by Subject|0
6300670|NCT02531633|10024199|FG000|Part A (52 Weeks)|Other|2
6300671|NCT02531633|10024200|FG001|Part A (52 Weeks)|Other|0
6300672|NCT02531633|10024201|FG002|Part A (52 Weeks)|Other|0
6300673|NCT02531633|10024202|FG003|Part A (52 Weeks)|Other|0
6300674|NCT02531633|10024203|FG004|Part A (52 Weeks)|Other|0
6300675|NCT02531633|10024204|FG005|Part A (52 Weeks)|Other|0
6300676|NCT02531633|10024205|FG006|Part A (52 Weeks)|Other|0
6300677|NCT02531633|10024206|FG007|Part A (52 Weeks)|Other|0
6300678|NCT02531633|10024207|FG008|Part A (52 Weeks)|Other|0
6300679|NCT02531633|10024208|FG009|Part A (52 Weeks)|Other|0
6300680|NCT02531633|10024199|FG000|Part B (104 Weeks)|Sponsor request|0
6300681|NCT02531633|10024200|FG001|Part B (104 Weeks)|Sponsor request|0
6300682|NCT02531633|10024201|FG002|Part B (104 Weeks)|Sponsor request|0
6300683|NCT02531633|10024202|FG003|Part B (104 Weeks)|Sponsor request|0
6300684|NCT02531633|10024203|FG004|Part B (104 Weeks)|Sponsor request|0
6300685|NCT02531633|10024204|FG005|Part B (104 Weeks)|Sponsor request|8
6300686|NCT02531633|10024205|FG006|Part B (104 Weeks)|Sponsor request|5
6300687|NCT02531633|10024206|FG007|Part B (104 Weeks)|Sponsor request|3
6300688|NCT02531633|10024207|FG008|Part B (104 Weeks)|Sponsor request|5
6300689|NCT02531633|10024208|FG009|Part B (104 Weeks)|Sponsor request|4
6300690|NCT02531633|10024199|FG000|Part B (104 Weeks)|Lost to Follow-up|0
6300691|NCT02531633|10024200|FG001|Part B (104 Weeks)|Lost to Follow-up|0
6300692|NCT02531633|10024201|FG002|Part B (104 Weeks)|Lost to Follow-up|0
6300693|NCT02531633|10024202|FG003|Part B (104 Weeks)|Lost to Follow-up|0
6300694|NCT02531633|10024203|FG004|Part B (104 Weeks)|Lost to Follow-up|0
6300695|NCT02531633|10024204|FG005|Part B (104 Weeks)|Lost to Follow-up|0
6300696|NCT02531633|10024205|FG006|Part B (104 Weeks)|Lost to Follow-up|0
6300697|NCT02531633|10024206|FG007|Part B (104 Weeks)|Lost to Follow-up|1
6300698|NCT02531633|10024207|FG008|Part B (104 Weeks)|Lost to Follow-up|0
6300699|NCT02531633|10024208|FG009|Part B (104 Weeks)|Lost to Follow-up|0
6300700|NCT02531646|10024251|FG000|Overall Study|equip. image processing issue|5
6300701|NCT02531646|10024252|FG001|Overall Study|equip. image processing issue|1
6300702|NCT02531646|10024253|FG002|Overall Study|equip. image processing issue|0
6300703|NCT02531698|10024263|FG000|Overall Study|Adverse Event|2
6300704|NCT02531698|10024264|FG001|Overall Study|Adverse Event|1
6300705|NCT02531698|10024263|FG000|Overall Study|Withdrawal by Subject|6
6300706|NCT02531698|10024264|FG001|Overall Study|Withdrawal by Subject|1
6300707|NCT02531698|10024263|FG000|Overall Study|Protocol Violation|2
6300708|NCT02531698|10024264|FG001|Overall Study|Protocol Violation|0
6300709|NCT02531698|10024263|FG000|Overall Study|Lost to Follow-up|1
6300710|NCT02531698|10024264|FG001|Overall Study|Lost to Follow-up|0
6300711|NCT02531802|10024300|FG000|Received Vaccination 2|Medication interfering with study taken|0
6300712|NCT02531802|10024301|FG001|Received Vaccination 2|Medication interfering with study taken|0
6300713|NCT02531802|10024302|FG002|Received Vaccination 2|Medication interfering with study taken|1
6300714|NCT02531802|10024303|FG003|Received Vaccination 2|Medication interfering with study taken|0
6300715|NCT02531802|10024304|FG004|Received Vaccination 2|Medication interfering with study taken|0
6300716|NCT02531802|10024305|FG005|Received Vaccination 2|Medication interfering with study taken|0
6300717|NCT02531802|10024306|FG006|Received Vaccination 2|Medication interfering with study taken|0
6300718|NCT02531802|10024307|FG007|Received Vaccination 2|Medication interfering with study taken|0
6300719|NCT02531802|10024308|FG008|Received Vaccination 2|Medication interfering with study taken|0
6300720|NCT02531802|10024309|FG009|Received Vaccination 2|Medication interfering with study taken|1
6300721|NCT02531802|10024310|FG010|Received Vaccination 2|Medication interfering with study taken|1
6300722|NCT02531802|10024311|FG011|Received Vaccination 2|Medication interfering with study taken|0
6300723|NCT02531802|10024312|FG012|Received Vaccination 2|Medication interfering with study taken|1
6300724|NCT02531802|10024313|FG013|Received Vaccination 2|Medication interfering with study taken|0
6300725|NCT02531802|10024314|FG014|Received Vaccination 2|Medication interfering with study taken|0
6300726|NCT02531802|10024315|FG015|Received Vaccination 2|Medication interfering with study taken|0
6300727|NCT02531802|10024316|FG016|Received Vaccination 2|Medication interfering with study taken|0
6300728|NCT02531802|10024317|FG017|Received Vaccination 2|Medication interfering with study taken|0
6300729|NCT02531802|10024318|FG018|Received Vaccination 2|Medication interfering with study taken|1
6300730|NCT02531802|10024319|FG019|Received Vaccination 2|Medication interfering with study taken|0
6300731|NCT02531802|10024320|FG020|Received Vaccination 2|Medication interfering with study taken|0
6300732|NCT02531802|10024300|FG000|Received Vaccination 2|Physician Decision|0
6300733|NCT02531802|10024301|FG001|Received Vaccination 2|Physician Decision|0
6300734|NCT02531802|10024302|FG002|Received Vaccination 2|Physician Decision|0
6300735|NCT02531802|10024303|FG003|Received Vaccination 2|Physician Decision|0
6300736|NCT02531802|10024304|FG004|Received Vaccination 2|Physician Decision|0
6300737|NCT02531802|10024305|FG005|Received Vaccination 2|Physician Decision|1
6300738|NCT02531802|10024306|FG006|Received Vaccination 2|Physician Decision|0
6300739|NCT02531802|10024307|FG007|Received Vaccination 2|Physician Decision|0
6300740|NCT02531802|10024308|FG008|Received Vaccination 2|Physician Decision|0
6300741|NCT02531802|10024309|FG009|Received Vaccination 2|Physician Decision|2
6300742|NCT02531802|10024310|FG010|Received Vaccination 2|Physician Decision|0
6300743|NCT02531802|10024311|FG011|Received Vaccination 2|Physician Decision|0
6300744|NCT02531802|10024312|FG012|Received Vaccination 2|Physician Decision|0
6300745|NCT02531802|10024313|FG013|Received Vaccination 2|Physician Decision|1
6300746|NCT02531802|10024314|FG014|Received Vaccination 2|Physician Decision|0
6300747|NCT02531802|10024315|FG015|Received Vaccination 2|Physician Decision|0
6300748|NCT02531802|10024316|FG016|Received Vaccination 2|Physician Decision|0
6300749|NCT02531802|10024317|FG017|Received Vaccination 2|Physician Decision|1
6300750|NCT02531802|10024318|FG018|Received Vaccination 2|Physician Decision|0
6300751|NCT02531802|10024319|FG019|Received Vaccination 2|Physician Decision|0
6300752|NCT02531802|10024320|FG020|Received Vaccination 2|Physician Decision|0
6300753|NCT02531802|10024300|FG000|Received Vaccination 2|Adverse Event|0
6300754|NCT02531802|10024301|FG001|Received Vaccination 2|Adverse Event|0
6300755|NCT02531802|10024302|FG002|Received Vaccination 2|Adverse Event|0
6300756|NCT02531802|10024303|FG003|Received Vaccination 2|Adverse Event|0
6300757|NCT02531802|10024304|FG004|Received Vaccination 2|Adverse Event|0
6300758|NCT02531802|10024305|FG005|Received Vaccination 2|Adverse Event|2
6300759|NCT02531802|10024306|FG006|Received Vaccination 2|Adverse Event|0
6300760|NCT02531802|10024307|FG007|Received Vaccination 2|Adverse Event|0
6300761|NCT02531802|10024308|FG008|Received Vaccination 2|Adverse Event|0
6300762|NCT02531802|10024309|FG009|Received Vaccination 2|Adverse Event|0
6300763|NCT02531802|10024310|FG010|Received Vaccination 2|Adverse Event|0
6300764|NCT02531802|10024311|FG011|Received Vaccination 2|Adverse Event|0
6300765|NCT02531802|10024312|FG012|Received Vaccination 2|Adverse Event|0
6300766|NCT02531802|10024313|FG013|Received Vaccination 2|Adverse Event|0
6300767|NCT02531802|10024314|FG014|Received Vaccination 2|Adverse Event|0
6300768|NCT02531802|10024315|FG015|Received Vaccination 2|Adverse Event|0
6300769|NCT02531802|10024316|FG016|Received Vaccination 2|Adverse Event|0
6300770|NCT02531802|10024317|FG017|Received Vaccination 2|Adverse Event|2
6300771|NCT02531802|10024318|FG018|Received Vaccination 2|Adverse Event|1
6300772|NCT02531802|10024319|FG019|Received Vaccination 2|Adverse Event|0
6300773|NCT02531802|10024320|FG020|Received Vaccination 2|Adverse Event|1
6300774|NCT02531802|10024300|FG000|Received Vaccination 2|Withdrawal by Subject|0
6300775|NCT02531802|10024301|FG001|Received Vaccination 2|Withdrawal by Subject|0
6300776|NCT02531802|10024302|FG002|Received Vaccination 2|Withdrawal by Subject|0
6300777|NCT02531802|10024303|FG003|Received Vaccination 2|Withdrawal by Subject|0
6300778|NCT02531802|10024304|FG004|Received Vaccination 2|Withdrawal by Subject|0
6300779|NCT02531802|10024305|FG005|Received Vaccination 2|Withdrawal by Subject|0
6300780|NCT02531802|10024306|FG006|Received Vaccination 2|Withdrawal by Subject|0
6300781|NCT02531802|10024307|FG007|Received Vaccination 2|Withdrawal by Subject|0
6300782|NCT02531802|10024308|FG008|Received Vaccination 2|Withdrawal by Subject|0
6300783|NCT02531802|10024309|FG009|Received Vaccination 2|Withdrawal by Subject|0
6300784|NCT02531802|10024310|FG010|Received Vaccination 2|Withdrawal by Subject|1
6300785|NCT02531802|10024311|FG011|Received Vaccination 2|Withdrawal by Subject|0
6300786|NCT02531802|10024312|FG012|Received Vaccination 2|Withdrawal by Subject|1
6300787|NCT02531802|10024313|FG013|Received Vaccination 2|Withdrawal by Subject|1
6300788|NCT02531802|10024314|FG014|Received Vaccination 2|Withdrawal by Subject|1
6300789|NCT02531802|10024315|FG015|Received Vaccination 2|Withdrawal by Subject|0
6300790|NCT02531802|10024316|FG016|Received Vaccination 2|Withdrawal by Subject|0
6300791|NCT02531802|10024317|FG017|Received Vaccination 2|Withdrawal by Subject|1
6300792|NCT02531802|10024318|FG018|Received Vaccination 2|Withdrawal by Subject|1
6300793|NCT02531802|10024319|FG019|Received Vaccination 2|Withdrawal by Subject|1
6300794|NCT02531802|10024320|FG020|Received Vaccination 2|Withdrawal by Subject|0
6300795|NCT02532179|10024421|FG000|Overall Study|Lost to Follow-up|1
6300796|NCT02532179|10024421|FG000|Overall Study|Pregnancy|1
6300797|NCT02532179|10024421|FG000|Overall Study|Subject received depot steroid injection|1
6300798|NCT02532283|10024427|FG000|Overall Study|Adverse Event|0
6300799|NCT02532283|10024428|FG001|Overall Study|Adverse Event|1
6300800|NCT02532283|10024427|FG000|Overall Study|Death|1
6300801|NCT02532283|10024428|FG001|Overall Study|Death|0
6300802|NCT02532283|10024427|FG000|Overall Study|Lost to Follow-up|0
6300803|NCT02532283|10024428|FG001|Overall Study|Lost to Follow-up|1
6300804|NCT02532283|10024427|FG000|Overall Study|Withdrawal by Subject|8
6300805|NCT02532283|10024428|FG001|Overall Study|Withdrawal by Subject|3
6300806|NCT02532374|10024436|FG000|Overall Study|Withdrawal by Subject|1
6300807|NCT02532374|10024436|FG000|Overall Study|Physician Decision|1
6300808|NCT02532465|10024450|FG000|Overall Study|Protocol Violation|1
6300809|NCT02532465|10024451|FG001|Overall Study|Protocol Violation|0
6300810|NCT02532465|10024450|FG000|Overall Study|Lack of Efficacy|0
6300811|NCT02532465|10024451|FG001|Overall Study|Lack of Efficacy|1
6300812|NCT02532517|10024457|FG000|Overall Study|Did not complete 24-Month visit|4
6300813|NCT02532517|10024457|FG000|Overall Study|Failed Angiographic eligibility|1
6300814|NCT02532517|10024457|FG000|Overall Study|Lost to Follow-up|4
6300815|NCT02532517|10024457|FG000|Overall Study|Withdrawal by Subject|4
6300816|NCT02532517|10024457|FG000|Overall Study|Death|4
6300817|NCT02532543|10024465|FG000|Overall Study|Lost to Follow-up|0
6300818|NCT02532543|10024466|FG001|Overall Study|Lost to Follow-up|0
6300819|NCT02532543|10024467|FG002|Overall Study|Lost to Follow-up|1
6300820|NCT02532543|10024468|FG003|Overall Study|Lost to Follow-up|0
6300821|NCT02532647|10024491|FG000|Overall Study|Did not receive trial medication|1
6300822|NCT02532647|10024492|FG001|Overall Study|Did not receive trial medication|0
6300823|NCT02532647|10024493|FG002|Overall Study|Did not receive trial medication|1
6300824|NCT02532764|10024511|FG000|Multiple Ascending Dose (MAD) Cohorst|Met stopping criteria|0
6300825|NCT02532764|10024512|FG001|Multiple Ascending Dose (MAD) Cohorst|Met stopping criteria|0
6300826|NCT02532764|10024513|FG002|Multiple Ascending Dose (MAD) Cohorst|Met stopping criteria|0
6300827|NCT02532764|10024514|FG003|Multiple Ascending Dose (MAD) Cohorst|Met stopping criteria|0
6300828|NCT02532764|10024515|FG004|Multiple Ascending Dose (MAD) Cohorst|Met stopping criteria|0
6300829|NCT02532764|10024516|FG005|Multiple Ascending Dose (MAD) Cohorst|Met stopping criteria|0
6300830|NCT02532764|10024517|FG006|Multiple Ascending Dose (MAD) Cohorst|Met stopping criteria|0
6300831|NCT02532764|10024518|FG007|Multiple Ascending Dose (MAD) Cohorst|Met stopping criteria|1
6300832|NCT02532764|10024519|FG008|Multiple Ascending Dose (MAD) Cohorst|Met stopping criteria|1
6300833|NCT02532764|10024520|FG009|Multiple Ascending Dose (MAD) Cohorst|Met stopping criteria|1
6300834|NCT02532855|10024549|FG000|Overall Study|Lost to Follow-up|4
6300835|NCT02532855|10024550|FG001|Overall Study|Lost to Follow-up|3
6300836|NCT02532855|10024549|FG000|Overall Study|Withdrawal by Subject|4
6300837|NCT02532855|10024550|FG001|Overall Study|Withdrawal by Subject|8
6300838|NCT02532972|10024565|FG000|Overall Study|Withdrawal by Subject|1
6300839|NCT02533180|10024609|FG000|Overall Study|Death|0
6300840|NCT02533180|10024610|FG001|Overall Study|Death|1
6300841|NCT02533180|10024609|FG000|Overall Study|Lost to Follow-up|0
6300842|NCT02533180|10024610|FG001|Overall Study|Lost to Follow-up|1
6300843|NCT02533180|10024609|FG000|Overall Study|Physician Decision|0
6300844|NCT02533180|10024610|FG001|Overall Study|Physician Decision|1
6300845|NCT02533180|10024609|FG000|Overall Study|Withdrawal by Subject|2
6300846|NCT02533180|10024610|FG001|Overall Study|Withdrawal by Subject|4
6300847|NCT02533180|10024609|FG000|Overall Study|Screen Failure|37
6300848|NCT02533180|10024610|FG001|Overall Study|Screen Failure|0
6300849|NCT02533180|10024609|FG000|Overall Study|Protocol Deviation|0
6300850|NCT02533180|10024610|FG001|Overall Study|Protocol Deviation|1
6300851|NCT02533180|10024609|FG000|Overall Study|On Study|0
6300852|NCT02533180|10024610|FG001|Overall Study|On Study|39
6300853|NCT02533258|10024615|FG000|Overall Study|Adverse Event|1
6300854|NCT02533258|10024615|FG000|Overall Study|Death|2
6300855|NCT02533258|10024615|FG000|Overall Study|Other|1
6300856|NCT02533258|10024615|FG000|Overall Study|Economic factor|1
6300857|NCT02533258|10024615|FG000|Overall Study|Progression of pleural effusion|1
6300858|NCT02533258|10024615|FG000|Overall Study|Lack of Efficacy|2
6300859|NCT02533375|10024619|FG000|Overall Study|Lack of Efficacy|3
6300860|NCT02533375|10024619|FG000|Overall Study|Adverse Event|2
6300861|NCT02533401|10024623|FG000|Overall Study|Adverse Event/Intercurrent Disease|3
6300862|NCT02533401|10024623|FG000|Overall Study|Death|5
6300863|NCT02533401|10024623|FG000|Overall Study|Insufficient Response/Progressed Disease|1
6300864|NCT02533401|10024623|FG000|Overall Study|Lost to Follow-up|1
6300865|NCT02533401|10024623|FG000|Overall Study|Violation of Selection Criteria|1
6300866|NCT02533453|10024634|FG000|Overall Study|Adverse Event|6
6300867|NCT02533453|10024634|FG000|Overall Study|Protocol Violation|1
6300868|NCT02533453|10024634|FG000|Overall Study|Withdrawal by Subject|2
6300869|NCT02533570|10024659|FG000|Overall Study|Adverse Event|0
6300870|NCT02533570|10024660|FG001|Overall Study|Adverse Event|1
6300871|NCT02533570|10024661|FG002|Overall Study|Adverse Event|1
6300872|NCT02533674|10024677|FG000|Dose Level I|Progressive disease|1
6300873|NCT02533674|10024678|FG001|Dose Level I|Progressive disease|0
6300874|NCT02533674|10024679|FG002|Dose Level I|Progressive disease|0
6300875|NCT02533674|10024680|FG003|Dose Level I|Progressive disease|0
6300876|NCT02533674|10024681|FG004|Dose Level I|Progressive disease|0
6300877|NCT02533674|10024682|FG005|Dose Level I|Progressive disease|0
6300878|NCT02533674|10024683|FG006|Dose Level I|Progressive disease|0
6300879|NCT02533674|10024684|FG007|Dose Level I|Progressive disease|0
6300880|NCT02533674|10024677|FG000|Dose Level I|Withdrawal by Subject|1
6300881|NCT02533674|10024678|FG001|Dose Level I|Withdrawal by Subject|0
6300882|NCT02533674|10024679|FG002|Dose Level I|Withdrawal by Subject|0
6300883|NCT02533674|10024680|FG003|Dose Level I|Withdrawal by Subject|0
6300884|NCT02533674|10024681|FG004|Dose Level I|Withdrawal by Subject|0
6300885|NCT02533674|10024682|FG005|Dose Level I|Withdrawal by Subject|0
6300886|NCT02533674|10024683|FG006|Dose Level I|Withdrawal by Subject|0
6300887|NCT02533674|10024684|FG007|Dose Level I|Withdrawal by Subject|0
6300888|NCT02533674|10024677|FG000|Dose Level I|Physician Decision|1
6300889|NCT02533674|10024678|FG001|Dose Level I|Physician Decision|0
6300890|NCT02533674|10024679|FG002|Dose Level I|Physician Decision|0
6300891|NCT02533674|10024680|FG003|Dose Level I|Physician Decision|0
6300892|NCT02533674|10024681|FG004|Dose Level I|Physician Decision|0
6300893|NCT02533674|10024682|FG005|Dose Level I|Physician Decision|0
6300894|NCT02533674|10024683|FG006|Dose Level I|Physician Decision|0
6300895|NCT02533674|10024684|FG007|Dose Level I|Physician Decision|0
6300896|NCT02533674|10024677|FG000|Dose Level I|Death|1
6300897|NCT02533674|10024678|FG001|Dose Level I|Death|0
6300898|NCT02533674|10024679|FG002|Dose Level I|Death|0
6300899|NCT02533674|10024680|FG003|Dose Level I|Death|0
6300900|NCT02533674|10024681|FG004|Dose Level I|Death|0
6300901|NCT02533674|10024682|FG005|Dose Level I|Death|0
6300902|NCT02533674|10024683|FG006|Dose Level I|Death|0
6300903|NCT02533674|10024684|FG007|Dose Level I|Death|0
6300904|NCT02533674|10024677|FG000|Dose Level I|Never Treated|1
6300905|NCT02533674|10024678|FG001|Dose Level I|Never Treated|0
6300906|NCT02533674|10024679|FG002|Dose Level I|Never Treated|0
6300907|NCT02533674|10024680|FG003|Dose Level I|Never Treated|0
6300908|NCT02533674|10024681|FG004|Dose Level I|Never Treated|0
6300909|NCT02533674|10024682|FG005|Dose Level I|Never Treated|0
6300910|NCT02533674|10024683|FG006|Dose Level I|Never Treated|0
6300911|NCT02533674|10024684|FG007|Dose Level I|Never Treated|0
6300912|NCT02533674|10024677|FG000|Dose Level II|Progressive disease|0
6300913|NCT02533674|10024678|FG001|Dose Level II|Progressive disease|3
6300914|NCT02533674|10024679|FG002|Dose Level II|Progressive disease|0
6300915|NCT02533674|10024680|FG003|Dose Level II|Progressive disease|0
6300916|NCT02533674|10024681|FG004|Dose Level II|Progressive disease|0
6300917|NCT02533674|10024682|FG005|Dose Level II|Progressive disease|0
6300918|NCT02533674|10024683|FG006|Dose Level II|Progressive disease|0
6300919|NCT02533674|10024684|FG007|Dose Level II|Progressive disease|0
6300920|NCT02533674|10024677|FG000|Dose Level II|Withdrawal by Subject|0
6300921|NCT02533674|10024678|FG001|Dose Level II|Withdrawal by Subject|1
6300922|NCT02533674|10024679|FG002|Dose Level II|Withdrawal by Subject|0
6300923|NCT02533674|10024680|FG003|Dose Level II|Withdrawal by Subject|0
6300924|NCT02533674|10024681|FG004|Dose Level II|Withdrawal by Subject|0
6300925|NCT02533674|10024682|FG005|Dose Level II|Withdrawal by Subject|0
6300926|NCT02533674|10024683|FG006|Dose Level II|Withdrawal by Subject|0
6300927|NCT02533674|10024684|FG007|Dose Level II|Withdrawal by Subject|0
6300928|NCT02533674|10024677|FG000|Dose Level II|Treatment-related AE|0
6300929|NCT02533674|10024678|FG001|Dose Level II|Treatment-related AE|1
6300930|NCT02533674|10024679|FG002|Dose Level II|Treatment-related AE|0
6300931|NCT02533674|10024680|FG003|Dose Level II|Treatment-related AE|0
6300932|NCT02533674|10024681|FG004|Dose Level II|Treatment-related AE|0
6300933|NCT02533674|10024682|FG005|Dose Level II|Treatment-related AE|0
6300934|NCT02533674|10024683|FG006|Dose Level II|Treatment-related AE|0
6300935|NCT02533674|10024684|FG007|Dose Level II|Treatment-related AE|0
6300936|NCT02533674|10024677|FG000|Dose Level II|Physician Decision|0
6300937|NCT02533674|10024678|FG001|Dose Level II|Physician Decision|1
6300938|NCT02533674|10024679|FG002|Dose Level II|Physician Decision|0
6300939|NCT02533674|10024680|FG003|Dose Level II|Physician Decision|0
6300940|NCT02533674|10024681|FG004|Dose Level II|Physician Decision|0
6300941|NCT02533674|10024682|FG005|Dose Level II|Physician Decision|0
6300942|NCT02533674|10024683|FG006|Dose Level II|Physician Decision|0
6300943|NCT02533674|10024684|FG007|Dose Level II|Physician Decision|0
6300944|NCT02533674|10024677|FG000|Dose Level II|Non-treatment-related AE|0
6300945|NCT02533674|10024678|FG001|Dose Level II|Non-treatment-related AE|1
6300946|NCT02533674|10024679|FG002|Dose Level II|Non-treatment-related AE|0
6300947|NCT02533674|10024680|FG003|Dose Level II|Non-treatment-related AE|0
6300948|NCT02533674|10024681|FG004|Dose Level II|Non-treatment-related AE|0
6300949|NCT02533674|10024682|FG005|Dose Level II|Non-treatment-related AE|0
6300950|NCT02533674|10024683|FG006|Dose Level II|Non-treatment-related AE|0
6300951|NCT02533674|10024684|FG007|Dose Level II|Non-treatment-related AE|0
6300952|NCT02533674|10024677|FG000|Dose Level III|Progressive disease|0
6300953|NCT02533674|10024678|FG001|Dose Level III|Progressive disease|0
6300954|NCT02533674|10024679|FG002|Dose Level III|Progressive disease|2
6300955|NCT02533674|10024680|FG003|Dose Level III|Progressive disease|0
6300956|NCT02533674|10024681|FG004|Dose Level III|Progressive disease|0
6300957|NCT02533674|10024682|FG005|Dose Level III|Progressive disease|0
6300958|NCT02533674|10024683|FG006|Dose Level III|Progressive disease|0
6300959|NCT02533674|10024684|FG007|Dose Level III|Progressive disease|0
6300960|NCT02533674|10024677|FG000|Dose Level III|Withdrawal by Subject|0
6300961|NCT02533674|10024678|FG001|Dose Level III|Withdrawal by Subject|0
6300962|NCT02533674|10024679|FG002|Dose Level III|Withdrawal by Subject|1
6300963|NCT02533674|10024680|FG003|Dose Level III|Withdrawal by Subject|0
6300964|NCT02533674|10024681|FG004|Dose Level III|Withdrawal by Subject|0
6300965|NCT02533674|10024682|FG005|Dose Level III|Withdrawal by Subject|0
6300966|NCT02533674|10024683|FG006|Dose Level III|Withdrawal by Subject|0
6300967|NCT02533674|10024684|FG007|Dose Level III|Withdrawal by Subject|0
6300968|NCT02533674|10024677|FG000|Dose Level III|Treatment-related AE|0
6300969|NCT02533674|10024678|FG001|Dose Level III|Treatment-related AE|0
6300970|NCT02533674|10024679|FG002|Dose Level III|Treatment-related AE|1
6300971|NCT02533674|10024680|FG003|Dose Level III|Treatment-related AE|0
6300972|NCT02533674|10024681|FG004|Dose Level III|Treatment-related AE|0
6300973|NCT02533674|10024682|FG005|Dose Level III|Treatment-related AE|0
6300974|NCT02533674|10024683|FG006|Dose Level III|Treatment-related AE|0
6300975|NCT02533674|10024684|FG007|Dose Level III|Treatment-related AE|0
6300976|NCT02533674|10024677|FG000|Dose Level IV|Progressive disease|0
6300977|NCT02533674|10024678|FG001|Dose Level IV|Progressive disease|0
6300978|NCT02533674|10024679|FG002|Dose Level IV|Progressive disease|0
6300979|NCT02533674|10024680|FG003|Dose Level IV|Progressive disease|3
6300980|NCT02533674|10024681|FG004|Dose Level IV|Progressive disease|0
6300981|NCT02533674|10024682|FG005|Dose Level IV|Progressive disease|0
6300982|NCT02533674|10024683|FG006|Dose Level IV|Progressive disease|0
6300983|NCT02533674|10024684|FG007|Dose Level IV|Progressive disease|0
6300984|NCT02533674|10024677|FG000|Dose Level IV|Withdrawal by Subject|0
6300985|NCT02533674|10024678|FG001|Dose Level IV|Withdrawal by Subject|0
6300986|NCT02533674|10024679|FG002|Dose Level IV|Withdrawal by Subject|0
6300987|NCT02533674|10024680|FG003|Dose Level IV|Withdrawal by Subject|1
6300988|NCT02533674|10024681|FG004|Dose Level IV|Withdrawal by Subject|0
6300989|NCT02533674|10024682|FG005|Dose Level IV|Withdrawal by Subject|0
6300990|NCT02533674|10024683|FG006|Dose Level IV|Withdrawal by Subject|0
6300991|NCT02533674|10024684|FG007|Dose Level IV|Withdrawal by Subject|0
6300992|NCT02533674|10024677|FG000|Dose Level IV|Physician Decision|0
6300993|NCT02533674|10024678|FG001|Dose Level IV|Physician Decision|0
6300994|NCT02533674|10024679|FG002|Dose Level IV|Physician Decision|0
6300995|NCT02533674|10024680|FG003|Dose Level IV|Physician Decision|1
6300996|NCT02533674|10024681|FG004|Dose Level IV|Physician Decision|0
6300997|NCT02533674|10024682|FG005|Dose Level IV|Physician Decision|0
6300998|NCT02533674|10024683|FG006|Dose Level IV|Physician Decision|0
6300999|NCT02533674|10024684|FG007|Dose Level IV|Physician Decision|0
6301000|NCT02533674|10024677|FG000|Dose Level V|Progressive disease|0
6301001|NCT02533674|10024678|FG001|Dose Level V|Progressive disease|0
6301002|NCT02533674|10024679|FG002|Dose Level V|Progressive disease|0
6301003|NCT02533674|10024680|FG003|Dose Level V|Progressive disease|0
6301004|NCT02533674|10024681|FG004|Dose Level V|Progressive disease|3
6301005|NCT02533674|10024682|FG005|Dose Level V|Progressive disease|0
6301006|NCT02533674|10024683|FG006|Dose Level V|Progressive disease|0
6301007|NCT02533674|10024684|FG007|Dose Level V|Progressive disease|0
6301008|NCT02533674|10024677|FG000|Dose Level V|Withdrawal by Subject|0
6301009|NCT02533674|10024678|FG001|Dose Level V|Withdrawal by Subject|0
6301010|NCT02533674|10024679|FG002|Dose Level V|Withdrawal by Subject|0
6301011|NCT02533674|10024680|FG003|Dose Level V|Withdrawal by Subject|0
6301012|NCT02533674|10024681|FG004|Dose Level V|Withdrawal by Subject|1
6301013|NCT02533674|10024682|FG005|Dose Level V|Withdrawal by Subject|0
6301014|NCT02533674|10024683|FG006|Dose Level V|Withdrawal by Subject|0
6301015|NCT02533674|10024684|FG007|Dose Level V|Withdrawal by Subject|0
6301016|NCT02533674|10024677|FG000|Dose Level V|Physician Decision|0
6301017|NCT02533674|10024678|FG001|Dose Level V|Physician Decision|0
6301018|NCT02533674|10024679|FG002|Dose Level V|Physician Decision|0
6301019|NCT02533674|10024680|FG003|Dose Level V|Physician Decision|0
6301020|NCT02533674|10024681|FG004|Dose Level V|Physician Decision|1
6301021|NCT02533674|10024682|FG005|Dose Level V|Physician Decision|0
6301022|NCT02533674|10024683|FG006|Dose Level V|Physician Decision|0
5982219|NCT01181778|9571114|FG000|Overall Study|Physician Decision|48
5982220|NCT01047540|9571125|FG000|Overall Study|Protocol Violation|1
5982221|NCT01047540|9571126|FG001|Overall Study|Protocol Violation|0
5982222|NCT01047540|9571127|FG002|Overall Study|Protocol Violation|0
5982223|NCT01047540|9571128|FG003|Overall Study|Protocol Violation|0
5982224|NCT01047540|9571129|FG004|Overall Study|Protocol Violation|0
5982225|NCT01047540|9571125|FG000|Overall Study|Lost to Follow-up|1
5982226|NCT01047540|9571126|FG001|Overall Study|Lost to Follow-up|0
5982227|NCT01047540|9571127|FG002|Overall Study|Lost to Follow-up|0
5982228|NCT01047540|9571128|FG003|Overall Study|Lost to Follow-up|0
5982229|NCT01047540|9571129|FG004|Overall Study|Lost to Follow-up|0
5982230|NCT01047540|9571125|FG000|Overall Study|Withdrawal by Subject|1
5982231|NCT01047540|9571126|FG001|Overall Study|Withdrawal by Subject|0
5982232|NCT01047540|9571127|FG002|Overall Study|Withdrawal by Subject|3
5982233|NCT01047540|9571128|FG003|Overall Study|Withdrawal by Subject|0
5982234|NCT01047540|9571129|FG004|Overall Study|Withdrawal by Subject|1
5982235|NCT01047540|9571125|FG000|Overall Study|Pregnancy|1
5982236|NCT01047540|9571126|FG001|Overall Study|Pregnancy|0
5982237|NCT01047540|9571127|FG002|Overall Study|Pregnancy|0
5982238|NCT01047540|9571128|FG003|Overall Study|Pregnancy|0
5982239|NCT01047540|9571129|FG004|Overall Study|Pregnancy|0
5982240|NCT01047540|9571125|FG000|Overall Study|Adverse Event|1
5982241|NCT01047540|9571126|FG001|Overall Study|Adverse Event|0
5982242|NCT01047540|9571127|FG002|Overall Study|Adverse Event|0
5982243|NCT01047540|9571128|FG003|Overall Study|Adverse Event|0
5982244|NCT01047540|9571129|FG004|Overall Study|Adverse Event|0
6063557|NCT00506441|9664801|FG001|Period 2; Double-blind Period|Adverse Event|1
6063558|NCT00506441|9664800|FG000|Period 2; Double-blind Period|Lack of Efficacy|0
6063559|NCT00506441|9664801|FG001|Period 2; Double-blind Period|Lack of Efficacy|2
6063560|NCT00506441|9664800|FG000|Period 2; Double-blind Period|Physician Decision|1
6063561|NCT00506441|9664801|FG001|Period 2; Double-blind Period|Physician Decision|1
6063562|NCT00506441|9664800|FG000|Period 2; Double-blind Period|Withdrawal by Subject|1
6063563|NCT00506441|9664801|FG001|Period 2; Double-blind Period|Withdrawal by Subject|0
6063564|NCT00506441|9664800|FG000|Period 2; Double-blind Period|Other Reason|1
6063565|NCT00506441|9664801|FG001|Period 2; Double-blind Period|Other Reason|1
6063566|NCT00506454|9664811|FG000|Overall Study|Withdrawal by Subject|1
6063567|NCT00506454|9664812|FG001|Overall Study|Withdrawal by Subject|1
6063568|NCT00506493|9664818|FG000|Overall Study|Death|6
6063569|NCT00506493|9664818|FG000|Overall Study|Withdrawal by Subject|5
6063570|NCT00506519|9664827|FG000|Overall Study|Death|4
6063571|NCT00506519|9664828|FG001|Overall Study|Death|6
6063572|NCT00506519|9664829|FG002|Overall Study|Death|0
6063573|NCT00506519|9664827|FG000|Overall Study|Adverse Event|1
6063574|NCT00506519|9664828|FG001|Overall Study|Adverse Event|0
6063575|NCT00506519|9664829|FG002|Overall Study|Adverse Event|0
6063576|NCT00506662|9664846|FG000|Overall Study|Adverse Event|0
6063577|NCT00506662|9664847|FG001|Overall Study|Adverse Event|2
6063578|NCT00506662|9664846|FG000|Overall Study|Lack of Efficacy|1
6063579|NCT00506662|9664847|FG001|Overall Study|Lack of Efficacy|0
6063580|NCT00506662|9664846|FG000|Overall Study|Protocol Violation|2
6063581|NCT00506662|9664847|FG001|Overall Study|Protocol Violation|4
6063582|NCT00506662|9664846|FG000|Overall Study|Trial terminated|10
6063583|NCT00506662|9664847|FG001|Overall Study|Trial terminated|16
6063584|NCT00506662|9664846|FG000|Overall Study|Not recorded|4
6063585|NCT00506662|9664847|FG001|Overall Study|Not recorded|6
6063586|NCT00506753|9664875|FG000|Overall Study|Lost to Follow-up|21
6063587|NCT00506753|9664876|FG001|Overall Study|Lost to Follow-up|15
6063588|NCT00506779|9664884|FG000|Overall Study|Withdrawal by Subject|1
6063589|NCT00506779|9664885|FG001|Overall Study|Withdrawal by Subject|0
6063590|NCT00506779|9664886|FG002|Overall Study|Withdrawal by Subject|1
6063591|NCT00506779|9664887|FG003|Overall Study|Withdrawal by Subject|0
6063592|NCT00506779|9664884|FG000|Overall Study|Adverse Event|0
6063593|NCT00506779|9664885|FG001|Overall Study|Adverse Event|1
6063594|NCT00506779|9664886|FG002|Overall Study|Adverse Event|1
6063595|NCT00506779|9664887|FG003|Overall Study|Adverse Event|1
6063596|NCT00506831|9664898|FG000|Overall Study|Death|1
6301023|NCT02533674|10024684|FG007|Dose Level V|Physician Decision|0
6301024|NCT02533674|10024677|FG000|Dose Level VI|Progressive disease|0
6301025|NCT02533674|10024678|FG001|Dose Level VI|Progressive disease|0
6063597|NCT00506831|9664898|FG000|Overall Study|Withdrawal by Subject|1
6301026|NCT02533674|10024679|FG002|Dose Level VI|Progressive disease|0
6301027|NCT02533674|10024680|FG003|Dose Level VI|Progressive disease|0
6301028|NCT02533674|10024681|FG004|Dose Level VI|Progressive disease|0
6301029|NCT02533674|10024682|FG005|Dose Level VI|Progressive disease|7
6301030|NCT02533674|10024683|FG006|Dose Level VI|Progressive disease|0
6301031|NCT02533674|10024684|FG007|Dose Level VI|Progressive disease|0
6301032|NCT02533674|10024677|FG000|Dose Level VI|Withdrawal by Subject|0
6301033|NCT02533674|10024678|FG001|Dose Level VI|Withdrawal by Subject|0
6301034|NCT02533674|10024679|FG002|Dose Level VI|Withdrawal by Subject|0
6301035|NCT02533674|10024680|FG003|Dose Level VI|Withdrawal by Subject|0
6301036|NCT02533674|10024681|FG004|Dose Level VI|Withdrawal by Subject|0
6301037|NCT02533674|10024682|FG005|Dose Level VI|Withdrawal by Subject|1
6301038|NCT02533674|10024683|FG006|Dose Level VI|Withdrawal by Subject|0
6301039|NCT02533674|10024684|FG007|Dose Level VI|Withdrawal by Subject|0
6301040|NCT02533674|10024677|FG000|Dose Level VI|Treatment-related AE|0
6301041|NCT02533674|10024678|FG001|Dose Level VI|Treatment-related AE|0
6301042|NCT02533674|10024679|FG002|Dose Level VI|Treatment-related AE|0
6301043|NCT02533674|10024680|FG003|Dose Level VI|Treatment-related AE|0
6301044|NCT02533674|10024681|FG004|Dose Level VI|Treatment-related AE|0
6301045|NCT02533674|10024682|FG005|Dose Level VI|Treatment-related AE|1
6301046|NCT02533674|10024683|FG006|Dose Level VI|Treatment-related AE|0
6301047|NCT02533674|10024684|FG007|Dose Level VI|Treatment-related AE|0
6301048|NCT02533674|10024677|FG000|Dose Level VII|Progressive disease|0
6301049|NCT02533674|10024678|FG001|Dose Level VII|Progressive disease|0
6301050|NCT02533674|10024679|FG002|Dose Level VII|Progressive disease|0
6301051|NCT02533674|10024680|FG003|Dose Level VII|Progressive disease|0
6301052|NCT02533674|10024681|FG004|Dose Level VII|Progressive disease|0
6301053|NCT02533674|10024682|FG005|Dose Level VII|Progressive disease|0
6301054|NCT02533674|10024683|FG006|Dose Level VII|Progressive disease|10
6301055|NCT02533674|10024684|FG007|Dose Level VII|Progressive disease|0
6301056|NCT02533674|10024677|FG000|Dose Level VII|Withdrawal by Subject|0
6301057|NCT02533674|10024678|FG001|Dose Level VII|Withdrawal by Subject|0
6301058|NCT02533674|10024679|FG002|Dose Level VII|Withdrawal by Subject|0
6301059|NCT02533674|10024680|FG003|Dose Level VII|Withdrawal by Subject|0
6301060|NCT02533674|10024681|FG004|Dose Level VII|Withdrawal by Subject|0
6301061|NCT02533674|10024682|FG005|Dose Level VII|Withdrawal by Subject|0
6301062|NCT02533674|10024683|FG006|Dose Level VII|Withdrawal by Subject|3
6301063|NCT02533674|10024684|FG007|Dose Level VII|Withdrawal by Subject|0
6301064|NCT02533674|10024677|FG000|Dose Level VII|Treatment-related AE|0
6301065|NCT02533674|10024678|FG001|Dose Level VII|Treatment-related AE|0
6301066|NCT02533674|10024679|FG002|Dose Level VII|Treatment-related AE|0
6301067|NCT02533674|10024680|FG003|Dose Level VII|Treatment-related AE|0
6301068|NCT02533674|10024681|FG004|Dose Level VII|Treatment-related AE|0
6301069|NCT02533674|10024682|FG005|Dose Level VII|Treatment-related AE|0
6301070|NCT02533674|10024683|FG006|Dose Level VII|Treatment-related AE|1
6301071|NCT02533674|10024684|FG007|Dose Level VII|Treatment-related AE|0
6301072|NCT02533674|10024677|FG000|Dose Level VII|Death|0
6301073|NCT02533674|10024678|FG001|Dose Level VII|Death|0
6301074|NCT02533674|10024679|FG002|Dose Level VII|Death|0
5982245|NCT00778999|9571174|FG000|Overall Study|Discontinuation: no embryo transfer|14
5982246|NCT00778999|9571175|FG001|Overall Study|Discontinuation: no embryo transfer|14
5982247|NCT00778999|9571174|FG000|Overall Study|Did not receive recFSH|14
5982248|NCT00778999|9571175|FG001|Overall Study|Did not receive recFSH|20
5982249|NCT00620464|9571183|FG000|Overall Study|Adverse Event|15
5982250|NCT00620464|9571184|FG001|Overall Study|Adverse Event|17
5982251|NCT00620464|9571183|FG000|Overall Study|Lost to Follow-up|1
5982252|NCT00620464|9571184|FG001|Overall Study|Lost to Follow-up|1
5982253|NCT00620464|9571183|FG000|Overall Study|Planning Pregnancy|1
5982254|NCT00620464|9571184|FG001|Overall Study|Planning Pregnancy|4
5982255|NCT00620464|9571183|FG000|Overall Study|Personal|2
5982256|NCT00620464|9571184|FG001|Overall Study|Personal|2
5982257|NCT00620464|9571183|FG000|Overall Study|Used prohibited medication|1
5982258|NCT00620464|9571184|FG001|Overall Study|Used prohibited medication|0
5982259|NCT00620035|9571190|FG000|Overall Study|Adverse Event|106
5982260|NCT00620035|9571190|FG000|Overall Study|Withdrawal of Informed Consent|1
5982261|NCT00620035|9571190|FG000|Overall Study|Other Reason|38
5982262|NCT00210249|9571194|FG000|Overall Study|Lost to Follow-up|5
5982263|NCT00210249|9571194|FG000|Overall Study|Protocol Violation|11
6063598|NCT00506883|9664910|FG000|Overall Study|Lost to Follow-up|1
6063599|NCT00506883|9664911|FG001|Overall Study|Lost to Follow-up|1
6063600|NCT00506883|9664912|FG002|Overall Study|Lost to Follow-up|1
6063601|NCT00506883|9664910|FG000|Overall Study|Withdrawal by Subject|1
6063602|NCT00506883|9664911|FG001|Overall Study|Withdrawal by Subject|0
6063603|NCT00506883|9664912|FG002|Overall Study|Withdrawal by Subject|1
6063604|NCT00506883|9664910|FG000|Overall Study|Lack of Efficacy|0
6063605|NCT00506883|9664911|FG001|Overall Study|Lack of Efficacy|1
6063606|NCT00506883|9664912|FG002|Overall Study|Lack of Efficacy|1
6063607|NCT00506883|9664910|FG000|Overall Study|Other|5
6063608|NCT00506883|9664911|FG001|Overall Study|Other|1
6063609|NCT00506883|9664912|FG002|Overall Study|Other|1
6063610|NCT00506922|9664925|FG000|Overall Study|Physician Decision|0
6063611|NCT00506922|9664926|FG001|Overall Study|Physician Decision|0
6063612|NCT00506922|9664927|FG002|Overall Study|Physician Decision|0
6063613|NCT00506922|9664928|FG003|Overall Study|Physician Decision|2
6301075|NCT02533674|10024680|FG003|Dose Level VII|Death|0
6301076|NCT02533674|10024681|FG004|Dose Level VII|Death|0
6301077|NCT02533674|10024682|FG005|Dose Level VII|Death|0
6301078|NCT02533674|10024683|FG006|Dose Level VII|Death|2
6301079|NCT02533674|10024684|FG007|Dose Level VII|Death|0
6301080|NCT02533674|10024677|FG000|Dose Level VIII|Progressive disease|0
6301081|NCT02533674|10024678|FG001|Dose Level VIII|Progressive disease|0
6301082|NCT02533674|10024679|FG002|Dose Level VIII|Progressive disease|0
6301083|NCT02533674|10024680|FG003|Dose Level VIII|Progressive disease|0
6301084|NCT02533674|10024681|FG004|Dose Level VIII|Progressive disease|0
6301085|NCT02533674|10024682|FG005|Dose Level VIII|Progressive disease|0
6301086|NCT02533674|10024683|FG006|Dose Level VIII|Progressive disease|0
6301087|NCT02533674|10024684|FG007|Dose Level VIII|Progressive disease|3
6301088|NCT02533674|10024677|FG000|Dose Level VIII|Withdrawal by Subject|0
6301089|NCT02533674|10024678|FG001|Dose Level VIII|Withdrawal by Subject|0
6301090|NCT02533674|10024679|FG002|Dose Level VIII|Withdrawal by Subject|0
6301091|NCT02533674|10024680|FG003|Dose Level VIII|Withdrawal by Subject|0
6301092|NCT02533674|10024681|FG004|Dose Level VIII|Withdrawal by Subject|0
6301093|NCT02533674|10024682|FG005|Dose Level VIII|Withdrawal by Subject|0
6301094|NCT02533674|10024683|FG006|Dose Level VIII|Withdrawal by Subject|0
6301095|NCT02533674|10024684|FG007|Dose Level VIII|Withdrawal by Subject|1
6301096|NCT02533674|10024677|FG000|Dose Level VIII|Treatment-related AE|0
6301097|NCT02533674|10024678|FG001|Dose Level VIII|Treatment-related AE|0
6301098|NCT02533674|10024679|FG002|Dose Level VIII|Treatment-related AE|0
6301099|NCT02533674|10024680|FG003|Dose Level VIII|Treatment-related AE|0
6301100|NCT02533674|10024681|FG004|Dose Level VIII|Treatment-related AE|0
6301101|NCT02533674|10024682|FG005|Dose Level VIII|Treatment-related AE|0
6301102|NCT02533674|10024683|FG006|Dose Level VIII|Treatment-related AE|0
6301103|NCT02533674|10024684|FG007|Dose Level VIII|Treatment-related AE|1
6301104|NCT02533674|10024677|FG000|Dose Level VIII|Never treated|0
6301105|NCT02533674|10024678|FG001|Dose Level VIII|Never treated|0
6301106|NCT02533674|10024679|FG002|Dose Level VIII|Never treated|0
6301107|NCT02533674|10024680|FG003|Dose Level VIII|Never treated|0
6301108|NCT02533674|10024681|FG004|Dose Level VIII|Never treated|0
6301109|NCT02533674|10024682|FG005|Dose Level VIII|Never treated|0
6301110|NCT02533674|10024683|FG006|Dose Level VIII|Never treated|0
6301111|NCT02533674|10024684|FG007|Dose Level VIII|Never treated|1
6301112|NCT02533999|10024731|FG000|Overall Study|Lost to Follow-up|3
6301113|NCT02533999|10024732|FG001|Overall Study|Lost to Follow-up|5
6301114|NCT02533999|10024731|FG000|Overall Study|Protocol Violation|3
6301115|NCT02533999|10024732|FG001|Overall Study|Protocol Violation|0
6301116|NCT02533999|10024731|FG000|Overall Study|Adverse Event|0
6301117|NCT02533999|10024732|FG001|Overall Study|Adverse Event|1
6301118|NCT02533999|10024731|FG000|Overall Study|Randomized but intervention not received|0
6301119|NCT02533999|10024732|FG001|Overall Study|Randomized but intervention not received|1
6301120|NCT02534324|10024756|FG000|Overall Study|Protocol Violation|4
6301121|NCT02534324|10024757|FG001|Overall Study|Protocol Violation|1
6301122|NCT02534324|10024756|FG000|Overall Study|Lost to Follow-up|20
6301123|NCT02534324|10024757|FG001|Overall Study|Lost to Follow-up|7
6301124|NCT02534324|10024756|FG000|Overall Study|Adverse Event|1
6301125|NCT02534324|10024757|FG001|Overall Study|Adverse Event|0
6301126|NCT02534350|10024765|FG000|Overall Study|Randomized But Not Treated|1
6301127|NCT02534350|10024766|FG001|Overall Study|Randomized But Not Treated|0
6301128|NCT02534350|10024765|FG000|Overall Study|Protocol Violation|1
6301129|NCT02534350|10024766|FG001|Overall Study|Protocol Violation|0
6301130|NCT02534350|10024765|FG000|Overall Study|Withdrew Consent|2
6301131|NCT02534350|10024766|FG001|Overall Study|Withdrew Consent|0
6301132|NCT02534493|10024772|FG000|Overall Study|Lost to Follow-up|1
6301133|NCT02534493|10024772|FG000|Overall Study|Withdrawal by Subject|1
6301134|NCT02534883|10024780|FG000|Overall Study|Early Termination|8
6301135|NCT02534883|10024781|FG001|Overall Study|Early Termination|3
6301136|NCT02534896|10024790|FG000|Overall Study|Adverse Event|2
6301137|NCT02534896|10024791|FG001|Overall Study|Adverse Event|1
6301138|NCT02534896|10024792|FG002|Overall Study|Adverse Event|1
6301139|NCT02534896|10024790|FG000|Overall Study|Insufficient therapeutic response|2
6301140|NCT02534896|10024791|FG001|Overall Study|Insufficient therapeutic response|0
6301141|NCT02534896|10024792|FG002|Overall Study|Insufficient therapeutic response|0
6301142|NCT02534935|10024803|FG000|Stage 1: 24 Months|Withdrawal by Subject|0
6301143|NCT02534935|10024804|FG001|Stage 1: 24 Months|Withdrawal by Subject|3
6301144|NCT02534935|10024805|FG002|Stage 1: 24 Months|Withdrawal by Subject|3
6301145|NCT02534935|10024803|FG000|Stage 1: 24 Months|No longer willing to participate in study|0
6301146|NCT02534935|10024804|FG001|Stage 1: 24 Months|No longer willing to participate in study|1
6301147|NCT02534935|10024805|FG002|Stage 1: 24 Months|No longer willing to participate in study|1
6301148|NCT02534935|10024803|FG000|Stage 1: 24 Months|No longer meets eligibility criteria|0
6301149|NCT02534935|10024804|FG001|Stage 1: 24 Months|No longer meets eligibility criteria|3
6301150|NCT02534935|10024805|FG002|Stage 1: 24 Months|No longer meets eligibility criteria|0
6301151|NCT02534935|10024803|FG000|Stage 1: 24 Months|Lost to Follow-up|0
6301152|NCT02534935|10024804|FG001|Stage 1: 24 Months|Lost to Follow-up|1
6301153|NCT02534935|10024805|FG002|Stage 1: 24 Months|Lost to Follow-up|1
6301154|NCT02534935|10024803|FG000|Stage 1: 24 Months|Adverse Event|0
6301155|NCT02534935|10024804|FG001|Stage 1: 24 Months|Adverse Event|2
5982264|NCT03692871|9571217|FG000|Overall Study|Death|1
5982265|NCT03692871|9571218|FG001|Overall Study|Death|1
6301156|NCT02534935|10024805|FG002|Stage 1: 24 Months|Adverse Event|0
6301157|NCT02534935|10024803|FG000|Stage 2: 8 Months|Moved away/parents resigned from study|0
6301158|NCT02534935|10024804|FG001|Stage 2: 8 Months|Moved away/parents resigned from study|4
6301159|NCT02534935|10024805|FG002|Stage 2: 8 Months|Moved away/parents resigned from study|0
6301160|NCT02534935|10024803|FG000|Stage 2: Booster Phase (6 Months)|Not received booster vaccination|0
6301161|NCT02534935|10024804|FG001|Stage 2: Booster Phase (6 Months)|Not received booster vaccination|1
6301162|NCT02534935|10024805|FG002|Stage 2: Booster Phase (6 Months)|Not received booster vaccination|0
6301163|NCT02535000|10024833|FG000|Overall Study|Cancellation of surgery.|1
6301164|NCT02535000|10024834|FG001|Overall Study|Cancellation of surgery.|2
6301165|NCT02535364|10024854|FG000|Part A Screening Through Leukapheresis|Failure to meet criteria for Part A|22
6301166|NCT02535364|10024854|FG000|Part A Screening Through Leukapheresis|Study placed on clinical hold by FDA|2
6301167|NCT02535364|10024854|FG000|Part A Screening Through Leukapheresis|Disease progression|1
6301168|NCT02535364|10024854|FG000|Part B Screening|Study placed on clinical hold by FDA|7
6301169|NCT02535364|10024854|FG000|Part B Screening|Unable to manufacture JCAR015|3
6301170|NCT02535364|10024854|FG000|Part B Screening|Death|2
6301171|NCT02535364|10024854|FG000|Part B Screening|Physician Decision|1
6301172|NCT02535364|10024854|FG000|Part B Screening|Withdrawal by Subject|1
6301173|NCT02535364|10024854|FG000|Part B Screening|Adverse Event|1
6301174|NCT02535364|10024854|FG000|Part B Screening|Change in diagnosis, no longer eligible|2
6301175|NCT02535364|10024854|FG000|Study Treatment|Death|1
6301176|NCT02535364|10024854|FG000|Study Treatment|Study placed on clinical hold by FDA|1
6301177|NCT02535364|10024854|FG000|12-Month Follow-up Period|Disease progression|22
6301178|NCT02535364|10024854|FG000|12-Month Follow-up Period|Death|5
6301179|NCT02535364|10024854|FG000|12-Month Follow-up Period|Underwent stem cell transplant|5
6301180|NCT02535364|10024854|FG000|12-Month Follow-up Period|Subject received alternative therapy|2
6301181|NCT02535364|10024854|FG000|12-Month Follow-up Period|Subject transferred to hospice|1
6301182|NCT02535416|10024867|FG000|Overall Study|Family bereavement overseas|1
6301183|NCT02535416|10024868|FG001|Overall Study|Family bereavement overseas|0
6301184|NCT02535416|10024869|FG002|Overall Study|Family bereavement overseas|0
6301185|NCT02535416|10024870|FG003|Overall Study|Family bereavement overseas|0
6301186|NCT02535416|10024871|FG004|Overall Study|Family bereavement overseas|0
6301187|NCT02535416|10024872|FG005|Overall Study|Family bereavement overseas|0
6301188|NCT02535416|10024873|FG006|Overall Study|Family bereavement overseas|0
6301189|NCT02535416|10024874|FG007|Overall Study|Family bereavement overseas|0
6301190|NCT02535416|10024875|FG008|Overall Study|Family bereavement overseas|0
6301191|NCT02535715|10024927|FG000|Overall Study|Withdrawal by Subject|0
6301192|NCT02535715|10024928|FG001|Overall Study|Withdrawal by Subject|0
6301193|NCT02535715|10024929|FG002|Overall Study|Withdrawal by Subject|1
6301194|NCT02535741|10024940|FG000|Overall Study|Adverse Event|3
6301195|NCT02535741|10024940|FG000|Overall Study|Withdrawal by Subject|9
6301196|NCT02535741|10024940|FG000|Overall Study|Lost to Follow-up|10
6301197|NCT02535741|10024940|FG000|Overall Study|Exclusion criteria: Bilateral implant|4
6301198|NCT02535741|10024940|FG000|Overall Study|Missing data|6
6301199|NCT02536313|10025005|FG000|Overall Study|Lack of Efficacy|0
6301200|NCT02536313|10025006|FG001|Overall Study|Lack of Efficacy|1
6301201|NCT02536378|10025016|FG000|Overall Study|Physician Decision|0
6301202|NCT02536378|10025017|FG001|Overall Study|Physician Decision|2
6301203|NCT02536378|10025016|FG000|Overall Study|Withdrawal by Subject|0
6301204|NCT02536378|10025017|FG001|Overall Study|Withdrawal by Subject|1
6301205|NCT02536378|10025016|FG000|Overall Study|Death|1
6301206|NCT02536378|10025017|FG001|Overall Study|Death|2
6301207|NCT02536378|10025016|FG000|Overall Study|Patient refused further follow up|6
6301208|NCT02536378|10025017|FG001|Overall Study|Patient refused further follow up|2
6301209|NCT02536404|10025027|FG000|Overall Study|Adverse Event|5
6301210|NCT02536404|10025028|FG001|Overall Study|Adverse Event|0
6301211|NCT02536404|10025027|FG000|Overall Study|Withdrawal by Subject|4
6301212|NCT02536404|10025028|FG001|Overall Study|Withdrawal by Subject|1
6301213|NCT02536404|10025027|FG000|Overall Study|Physician Decision|10
6301214|NCT02536404|10025028|FG001|Overall Study|Physician Decision|0
6301215|NCT02536404|10025027|FG000|Overall Study|Sponsor decision|1
6301216|NCT02536404|10025028|FG001|Overall Study|Sponsor decision|0
6301217|NCT02536508|10025037|FG000|Overall Study|Withdrawal by Subject|18
6301218|NCT02536508|10025038|FG001|Overall Study|Withdrawal by Subject|13
6301219|NCT02536508|10025039|FG002|Overall Study|Withdrawal by Subject|7
6301220|NCT02536508|10025037|FG000|Overall Study|Adverse Event|14
6301221|NCT02536508|10025038|FG001|Overall Study|Adverse Event|13
6301222|NCT02536508|10025039|FG002|Overall Study|Adverse Event|6
6301223|NCT02536508|10025037|FG000|Overall Study|Lost to Follow-up|12
6301224|NCT02536508|10025038|FG001|Overall Study|Lost to Follow-up|4
6301225|NCT02536508|10025039|FG002|Overall Study|Lost to Follow-up|0
6301226|NCT02536508|10025037|FG000|Overall Study|Lack of Efficacy|3
6301227|NCT02536508|10025038|FG001|Overall Study|Lack of Efficacy|5
6301228|NCT02536508|10025039|FG002|Overall Study|Lack of Efficacy|4
6301229|NCT02536508|10025037|FG000|Overall Study|Protocol Discontinuation Criteria|3
6301230|NCT02536508|10025038|FG001|Overall Study|Protocol Discontinuation Criteria|2
6301231|NCT02536508|10025039|FG002|Overall Study|Protocol Discontinuation Criteria|2
6301232|NCT02536508|10025037|FG000|Overall Study|Physician Decision|0
6301233|NCT02536508|10025038|FG001|Overall Study|Physician Decision|4
6301234|NCT02536508|10025039|FG002|Overall Study|Physician Decision|2
6301235|NCT02536508|10025037|FG000|Overall Study|Major Protocol Deviation|2
6301236|NCT02536508|10025038|FG001|Overall Study|Major Protocol Deviation|2
6301237|NCT02536508|10025039|FG002|Overall Study|Major Protocol Deviation|2
6301238|NCT02536508|10025037|FG000|Overall Study|Administrative Reasons|0
6301239|NCT02536508|10025038|FG001|Overall Study|Administrative Reasons|1
6301240|NCT02536508|10025039|FG002|Overall Study|Administrative Reasons|0
6301241|NCT02536664|10025049|FG000|Overall Study|Inadequate completion of documentation|2
6301242|NCT02536664|10025050|FG001|Overall Study|Inadequate completion of documentation|4
6301243|NCT02536664|10025049|FG000|Overall Study|Progression|13
6301244|NCT02536664|10025050|FG001|Overall Study|Progression|18
6301245|NCT02536664|10025049|FG000|Overall Study|Death due to lymphoma|2
6301246|NCT02536664|10025050|FG001|Overall Study|Death due to lymphoma|1
6301247|NCT02536664|10025049|FG000|Overall Study|Death due to other reason|3
6301248|NCT02536664|10025050|FG001|Overall Study|Death due to other reason|2
6301249|NCT02536664|10025049|FG000|Overall Study|Intolerability|8
6301250|NCT02536664|10025050|FG001|Overall Study|Intolerability|6
6301251|NCT02536664|10025049|FG000|Overall Study|Withdrawal by Subject|8
6301252|NCT02536664|10025050|FG001|Overall Study|Withdrawal by Subject|5
6301253|NCT02536664|10025049|FG000|Overall Study|Other|18
6301254|NCT02536664|10025050|FG001|Overall Study|Other|24
6301255|NCT02536664|10025049|FG000|Overall Study|Missing|53
6301256|NCT02536664|10025050|FG001|Overall Study|Missing|20
6301257|NCT02536781|10025058|FG000|Overall Study|Lost to Follow-up|2
6301258|NCT02536781|10025059|FG001|Overall Study|Lost to Follow-up|0
6301259|NCT02536833|10025069|FG000|Overall Study|Discontinued Before Treatment|0
6301260|NCT02536833|10025070|FG001|Overall Study|Discontinued Before Treatment|0
6301261|NCT02536833|10025071|FG002|Overall Study|Discontinued Before Treatment|1
6301262|NCT02536833|10025072|FG003|Overall Study|Discontinued Before Treatment|2
6301263|NCT02536833|10025069|FG000|Overall Study|Adverse Event|1
6301264|NCT02536833|10025070|FG001|Overall Study|Adverse Event|3
6301265|NCT02536833|10025071|FG002|Overall Study|Adverse Event|4
6301266|NCT02536833|10025072|FG003|Overall Study|Adverse Event|1
6301267|NCT02536833|10025069|FG000|Overall Study|Lost to Follow-up|2
6301268|NCT02536833|10025070|FG001|Overall Study|Lost to Follow-up|1
6301269|NCT02536833|10025071|FG002|Overall Study|Lost to Follow-up|2
6301270|NCT02536833|10025072|FG003|Overall Study|Lost to Follow-up|2
6301271|NCT02536833|10025069|FG000|Overall Study|Physician Decision|0
6301272|NCT02536833|10025070|FG001|Overall Study|Physician Decision|0
6301273|NCT02536833|10025071|FG002|Overall Study|Physician Decision|0
6301274|NCT02536833|10025072|FG003|Overall Study|Physician Decision|1
6301275|NCT02536833|10025069|FG000|Overall Study|Site Terminated by Sponsor|2
6301276|NCT02536833|10025070|FG001|Overall Study|Site Terminated by Sponsor|2
6301277|NCT02536833|10025071|FG002|Overall Study|Site Terminated by Sponsor|2
6301278|NCT02536833|10025072|FG003|Overall Study|Site Terminated by Sponsor|2
6301279|NCT02536833|10025069|FG000|Overall Study|Subject Non-Compliance|0
6301280|NCT02536833|10025070|FG001|Overall Study|Subject Non-Compliance|1
6301281|NCT02536833|10025071|FG002|Overall Study|Subject Non-Compliance|1
6301282|NCT02536833|10025072|FG003|Overall Study|Subject Non-Compliance|0
6301283|NCT02536833|10025069|FG000|Overall Study|Withdrawal by Subject|4
6301284|NCT02536833|10025070|FG001|Overall Study|Withdrawal by Subject|3
6301285|NCT02536833|10025071|FG002|Overall Study|Withdrawal by Subject|5
6301286|NCT02536833|10025072|FG003|Overall Study|Withdrawal by Subject|11
6301287|NCT02536846|10025083|FG000|Overall Study|Withdrawal by Subject|1
6301288|NCT02536963|10025088|FG000|Overall Study|Withdrawal by Subject|18
6301289|NCT02536976|10025094|FG000|Overall Study|Physician Decision|0
6301290|NCT02536976|10025095|FG001|Overall Study|Physician Decision|1
5982266|NCT03692871|9571217|FG000|Overall Study|Lost to Follow-up|24
6301291|NCT02537015|10025103|FG000|Overall Study|Adverse Event|3
6301292|NCT02537015|10025103|FG000|Overall Study|Withdrawal by Subject|2
6301293|NCT02537015|10025103|FG000|Overall Study|Other Miscellaneous Reasons|1
6301294|NCT02537431|10025107|FG000|Open-Label Period (Week 0 to Week 48)|Withdrawal by Subject|1
6301295|NCT02537522|10025120|FG000|Phase I - Contralateral|Subject no longer eligible|15
6301296|NCT02537522|10025121|FG001|Phase I - Contralateral|Subject no longer eligible|7
6301297|NCT02537522|10025122|FG002|Phase I - Contralateral|Subject no longer eligible|0
6301298|NCT02537522|10025123|FG003|Phase I - Contralateral|Subject no longer eligible|0
6301299|NCT02537522|10025120|FG000|Phase I - Contralateral|Withdrawal by Subject|0
6301300|NCT02537522|10025121|FG001|Phase I - Contralateral|Withdrawal by Subject|1
5982267|NCT03692871|9571218|FG001|Overall Study|Lost to Follow-up|9
5982268|NCT03692871|9571217|FG000|Overall Study|Physician Decision|22
5982269|NCT03692871|9571218|FG001|Overall Study|Physician Decision|7
5982270|NCT03692871|9571217|FG000|Overall Study|Protocol Deviation|1
5982271|NCT03692871|9571218|FG001|Overall Study|Protocol Deviation|0
5982272|NCT03692871|9571217|FG000|Overall Study|Withdrawal by Parent/Guardian|77
5982273|NCT03692871|9571218|FG001|Overall Study|Withdrawal by Parent/Guardian|20
6063614|NCT00506922|9664929|FG004|Overall Study|Physician Decision|0
6063615|NCT00506922|9664925|FG000|Overall Study|Withdrawal by Subject|0
6063616|NCT00506922|9664926|FG001|Overall Study|Withdrawal by Subject|0
6063617|NCT00506922|9664927|FG002|Overall Study|Withdrawal by Subject|0
6063618|NCT00506922|9664928|FG003|Overall Study|Withdrawal by Subject|0
6063619|NCT00506922|9664929|FG004|Overall Study|Withdrawal by Subject|1
6063620|NCT00506948|9664937|FG000|Overall Study|Death|4
6063621|NCT00506948|9664937|FG000|Overall Study|Adverse Event|5
6063622|NCT00506948|9664937|FG000|Overall Study|Physician Decision|1
6063623|NCT00507026|9664944|FG000|Overall Study|Lack of Efficacy|6
6063624|NCT00507026|9664945|FG001|Overall Study|Lack of Efficacy|4
6063625|NCT00507026|9664946|FG002|Overall Study|Lack of Efficacy|21
6063626|NCT00507026|9664944|FG000|Overall Study|Withdrawal by Subject|2
6063627|NCT00507026|9664945|FG001|Overall Study|Withdrawal by Subject|0
6063628|NCT00507026|9664946|FG002|Overall Study|Withdrawal by Subject|0
6063629|NCT00507026|9664944|FG000|Overall Study|Investigator Decision|1
6063630|NCT00507026|9664945|FG001|Overall Study|Investigator Decision|0
6063631|NCT00507026|9664946|FG002|Overall Study|Investigator Decision|0
6063632|NCT00507026|9664944|FG000|Overall Study|Adverse Event|2
6063633|NCT00507026|9664945|FG001|Overall Study|Adverse Event|0
6063634|NCT00507026|9664946|FG002|Overall Study|Adverse Event|0
6063635|NCT00507026|9664944|FG000|Overall Study|Protocol Violation|1
6063636|NCT00507026|9664945|FG001|Overall Study|Protocol Violation|0
6063637|NCT00507026|9664946|FG002|Overall Study|Protocol Violation|0
6063638|NCT00507026|9664944|FG000|Overall Study|Other|1
6063639|NCT00507026|9664945|FG001|Overall Study|Other|0
6063640|NCT00507026|9664946|FG002|Overall Study|Other|0
6063641|NCT00507130|9664958|FG000|Overall Study|Lost to Follow-up|0
6063642|NCT00507130|9664959|FG001|Overall Study|Lost to Follow-up|0
6063643|NCT00507130|9664960|FG002|Overall Study|Lost to Follow-up|1
6063644|NCT00507130|9664961|FG003|Overall Study|Lost to Follow-up|1
6063645|NCT00507130|9664958|FG000|Overall Study|SERIOUS EVENT OF ASTHMA EXACERBATION|1
6063646|NCT00507130|9664959|FG001|Overall Study|SERIOUS EVENT OF ASTHMA EXACERBATION|0
6063647|NCT00507130|9664960|FG002|Overall Study|SERIOUS EVENT OF ASTHMA EXACERBATION|0
6063648|NCT00507130|9664961|FG003|Overall Study|SERIOUS EVENT OF ASTHMA EXACERBATION|0
6063649|NCT00507416|9664983|FG000|Overall Study|Adverse Event|58
6063650|NCT00507416|9664984|FG001|Overall Study|Adverse Event|67
6063651|NCT00507416|9664985|FG002|Overall Study|Adverse Event|65
6063652|NCT00507416|9664983|FG000|Overall Study|Protocol Violation|1
6063653|NCT00507416|9664984|FG001|Overall Study|Protocol Violation|2
6063654|NCT00507416|9664985|FG002|Overall Study|Protocol Violation|0
6063655|NCT00507416|9664983|FG000|Overall Study|Lack ofEfficacy / Physician Decision|7
6063656|NCT00507416|9664984|FG001|Overall Study|Lack ofEfficacy / Physician Decision|7
6063657|NCT00507416|9664985|FG002|Overall Study|Lack ofEfficacy / Physician Decision|8
6063658|NCT00507416|9664983|FG000|Overall Study|Progressive Disease|20
6063659|NCT00507416|9664984|FG001|Overall Study|Progressive Disease|10
6063660|NCT00507416|9664985|FG002|Overall Study|Progressive Disease|13
6063661|NCT00507416|9664983|FG000|Overall Study|Patient declined further treatment|18
6063662|NCT00507416|9664984|FG001|Overall Study|Patient declined further treatment|14
6063663|NCT00507416|9664985|FG002|Overall Study|Patient declined further treatment|11
6063664|NCT00507416|9664983|FG000|Overall Study|Other|11
6063665|NCT00507416|9664984|FG001|Overall Study|Other|16
6063666|NCT00507416|9664985|FG002|Overall Study|Other|13
6063667|NCT00507416|9664983|FG000|Overall Study|Did not Receive Study Treatment|3
6063668|NCT00507416|9664984|FG001|Overall Study|Did not Receive Study Treatment|9
6063669|NCT00507416|9664985|FG002|Overall Study|Did not Receive Study Treatment|4
6063670|NCT00507429|9664995|FG000|Treatment Phase|Disease Progression|12
6063671|NCT00507429|9664996|FG001|Treatment Phase|Disease Progression|5
6063672|NCT00507429|9664995|FG000|Treatment Phase|Adverse Event|12
6063673|NCT00507429|9664996|FG001|Treatment Phase|Adverse Event|5
6063674|NCT00507429|9664995|FG000|Treatment Phase|Withdrawal by Subject|3
6063675|NCT00507429|9664996|FG001|Treatment Phase|Withdrawal by Subject|3
6063676|NCT00507429|9664995|FG000|Treatment Phase|Physician Decision|4
6063677|NCT00507429|9664996|FG001|Treatment Phase|Physician Decision|2
6063678|NCT00507429|9664995|FG000|Treatment Phase|Other|6
6063679|NCT00507429|9664996|FG001|Treatment Phase|Other|3
6301301|NCT02537522|10025122|FG002|Phase I - Contralateral|Withdrawal by Subject|0
6301302|NCT02537522|10025123|FG003|Phase I - Contralateral|Withdrawal by Subject|0
6301303|NCT02537522|10025120|FG000|Phase I - Contralateral|incorrect randomization|0
6301304|NCT02537522|10025121|FG001|Phase I - Contralateral|incorrect randomization|1
6301305|NCT02537522|10025122|FG002|Phase I - Contralateral|incorrect randomization|0
6301306|NCT02537522|10025123|FG003|Phase I - Contralateral|incorrect randomization|0
6301307|NCT02537522|10025120|FG000|Phase I - Contralateral|unsatisfactory lens fitting|0
6301308|NCT02537522|10025121|FG001|Phase I - Contralateral|unsatisfactory lens fitting|1
6301309|NCT02537522|10025122|FG002|Phase I - Contralateral|unsatisfactory lens fitting|0
6301310|NCT02537522|10025123|FG003|Phase I - Contralateral|unsatisfactory lens fitting|0
6301311|NCT02537522|10025120|FG000|Phase II - Period 1 Bilateral|Adverse Event|0
6301312|NCT02537522|10025121|FG001|Phase II - Period 1 Bilateral|Adverse Event|0
6301313|NCT02537522|10025122|FG002|Phase II - Period 1 Bilateral|Adverse Event|0
6301314|NCT02537522|10025123|FG003|Phase II - Period 1 Bilateral|Adverse Event|1
6301315|NCT02537574|10025132|FG000|Overall Study|Adverse Event|1
6301316|NCT02537574|10025133|FG001|Overall Study|Adverse Event|3
6301317|NCT02537574|10025134|FG002|Overall Study|Adverse Event|2
6301318|NCT02537574|10025132|FG000|Overall Study|Lost to Follow-up|40
6301319|NCT02537574|10025133|FG001|Overall Study|Lost to Follow-up|51
6301320|NCT02537574|10025134|FG002|Overall Study|Lost to Follow-up|55
6301321|NCT02537574|10025132|FG000|Overall Study|Noncompliance with study drug|0
6301322|NCT02537574|10025133|FG001|Overall Study|Noncompliance with study drug|1
6301323|NCT02537574|10025134|FG002|Overall Study|Noncompliance with study drug|1
6301324|NCT02537574|10025132|FG000|Overall Study|Physician Decision|2
6301325|NCT02537574|10025133|FG001|Overall Study|Physician Decision|0
6301326|NCT02537574|10025134|FG002|Overall Study|Physician Decision|0
6301327|NCT02537574|10025132|FG000|Overall Study|Protocol Violation|4
6301328|NCT02537574|10025133|FG001|Overall Study|Protocol Violation|2
6301329|NCT02537574|10025134|FG002|Overall Study|Protocol Violation|3
6301330|NCT02537574|10025132|FG000|Overall Study|Withdrawal by Subject|37
6301331|NCT02537574|10025133|FG001|Overall Study|Withdrawal by Subject|27
6301332|NCT02537574|10025134|FG002|Overall Study|Withdrawal by Subject|29
6301333|NCT02537574|10025132|FG000|Overall Study|Lack of Efficacy|14
6301334|NCT02537574|10025133|FG001|Overall Study|Lack of Efficacy|16
6301335|NCT02537574|10025134|FG002|Overall Study|Lack of Efficacy|15
6301336|NCT02537574|10025132|FG000|Overall Study|Duplicate Patient|1
6301337|NCT02537574|10025133|FG001|Overall Study|Duplicate Patient|0
6301338|NCT02537574|10025134|FG002|Overall Study|Duplicate Patient|0
6301339|NCT02537574|10025132|FG000|Overall Study|Patient not Stable|0
6301340|NCT02537574|10025133|FG001|Overall Study|Patient not Stable|1
6301341|NCT02537574|10025134|FG002|Overall Study|Patient not Stable|0
6301342|NCT02537574|10025132|FG000|Overall Study|Incarceration|0
6301343|NCT02537574|10025133|FG001|Overall Study|Incarceration|1
6301344|NCT02537574|10025134|FG002|Overall Study|Incarceration|0
6301345|NCT02537574|10025132|FG000|Overall Study|Failed Naloxone Challenge|0
6301346|NCT02537574|10025133|FG001|Overall Study|Failed Naloxone Challenge|1
6301347|NCT02537574|10025134|FG002|Overall Study|Failed Naloxone Challenge|0
6301348|NCT02537574|10025132|FG000|Overall Study|Transportation Issues|0
6301349|NCT02537574|10025133|FG001|Overall Study|Transportation Issues|0
6301350|NCT02537574|10025134|FG002|Overall Study|Transportation Issues|1
6301351|NCT02537574|10025132|FG000|Overall Study|Subject did not want last Vivitrol Injec|0
6301352|NCT02537574|10025133|FG001|Overall Study|Subject did not want last Vivitrol Injec|0
6301353|NCT02537574|10025134|FG002|Overall Study|Subject did not want last Vivitrol Injec|1
6301354|NCT02537574|10025132|FG000|Overall Study|Noncompliance with Protocol|0
6301355|NCT02537574|10025133|FG001|Overall Study|Noncompliance with Protocol|0
6301356|NCT02537574|10025134|FG002|Overall Study|Noncompliance with Protocol|1
6301357|NCT02538029|10025181|FG000|Overall Study|unable to complete cognitive assessments|1
6301358|NCT02538029|10025182|FG001|Overall Study|unable to complete cognitive assessments|0
6301359|NCT02538029|10025183|FG002|Overall Study|unable to complete cognitive assessments|1
6301360|NCT02538094|10025204|FG000|Intervention 1 (5 Days Per Participant)|Withdrawal by Subject|0
6301361|NCT02538094|10025205|FG001|Intervention 1 (5 Days Per Participant)|Withdrawal by Subject|1
6301362|NCT02538094|10025204|FG000|Washout (4 Weeks)|Withdrawal by Subject|0
6301363|NCT02538094|10025205|FG001|Washout (4 Weeks)|Withdrawal by Subject|1
6301364|NCT02538107|10025211|FG000|Overall Study|Did not receive any Mircera dose|11
6301365|NCT02538107|10025211|FG000|Overall Study|Missing|5
6301366|NCT02538107|10025211|FG000|Overall Study|Necessity of dialysis|20
6301367|NCT02538107|10025211|FG000|Overall Study|Administration of other ESA|11
6301368|NCT02538107|10025211|FG000|Overall Study|No further treatment necessary|18
6301369|NCT02538107|10025211|FG000|Overall Study|Withdrawal by Subject|17
6301370|NCT02538107|10025211|FG000|Overall Study|Death|4
6301371|NCT02538107|10025211|FG000|Overall Study|Administrative reason|5
6301372|NCT02538107|10025211|FG000|Overall Study|Adverse Event|4
6301373|NCT02538107|10025211|FG000|Overall Study|Surgery|1
6301374|NCT02538107|10025211|FG000|Overall Study|Other|7
6301375|NCT02538107|10025211|FG000|Overall Study|Not recorded|7
6301376|NCT02538341|10025227|FG000|Overall Study|Lost to Follow-up|51
6301377|NCT02538341|10025228|FG001|Overall Study|Lost to Follow-up|46
6301378|NCT02538341|10025227|FG000|Overall Study|Withdrawal by Subject|3
6301379|NCT02538341|10025228|FG001|Overall Study|Withdrawal by Subject|1
6301380|NCT02538341|10025227|FG000|Overall Study|Death|2
6301381|NCT02538341|10025228|FG001|Overall Study|Death|0
6301382|NCT02538471|10025252|FG000|Overall Study|Progression of disease|2
6301383|NCT02538614|10025265|FG000|Overall Study|Progressive Disease|2
6301384|NCT02538900|10025296|FG000|Overall Study|Death|2
6301385|NCT02538900|10025297|FG001|Overall Study|Death|2
6301386|NCT02538900|10025298|FG002|Overall Study|Death|2
6301387|NCT02538900|10025296|FG000|Overall Study|Withdrawal by Subject|18
6301388|NCT02538900|10025297|FG001|Overall Study|Withdrawal by Subject|16
6301389|NCT02538900|10025298|FG002|Overall Study|Withdrawal by Subject|15
6301390|NCT02538965|10025306|FG000|Treatment Period|Other = Death due to disease progression|1
6301391|NCT02538965|10025306|FG000|Treatment Period|Adverse Event|2
6301392|NCT02538965|10025306|FG000|Treatment Period|Withdrawal by Parent/Guardian|2
6301393|NCT02538965|10025306|FG000|Treatment Period|Treatment Failure|9
6301394|NCT02538965|10025306|FG000|Treatment Period|Disease Progression|1
6301395|NCT02538965|10025306|FG000|Treatment Period|Physician Decision|2
6301396|NCT02538965|10025306|FG000|Follow-Up Period|Other = Death due to disease progression|13
6301397|NCT02538965|10025306|FG000|Follow-Up Period|Withdrawal by Parent|4
6301398|NCT02539134|10025325|FG000|Overall Study|Lost to Follow-up|1
6301399|NCT02539134|10025326|FG001|Overall Study|Lost to Follow-up|0
6301400|NCT02539134|10025327|FG002|Overall Study|Lost to Follow-up|0
6301401|NCT02539134|10025328|FG003|Overall Study|Lost to Follow-up|0
6301402|NCT02539134|10025329|FG004|Overall Study|Lost to Follow-up|0
6301403|NCT02539134|10025330|FG005|Overall Study|Lost to Follow-up|0
6301404|NCT02539368|10025363|FG000|Overall Study|Death|4
6301405|NCT02539368|10025364|FG001|Overall Study|Death|2
6301406|NCT02539368|10025365|FG002|Overall Study|Death|1
6301407|NCT02539368|10025366|FG003|Overall Study|Death|0
6301408|NCT02539368|10025367|FG004|Overall Study|Death|0
6301409|NCT02539368|10025363|FG000|Overall Study|Withdrawal by Subject|44
6301410|NCT02539368|10025364|FG001|Overall Study|Withdrawal by Subject|35
6301411|NCT02539368|10025365|FG002|Overall Study|Withdrawal by Subject|9
6301412|NCT02539368|10025366|FG003|Overall Study|Withdrawal by Subject|1
6301413|NCT02539368|10025367|FG004|Overall Study|Withdrawal by Subject|3
6301414|NCT02539368|10025363|FG000|Overall Study|Physician Decision|49
6301415|NCT02539368|10025364|FG001|Overall Study|Physician Decision|15
6301416|NCT02539368|10025365|FG002|Overall Study|Physician Decision|7
6301417|NCT02539368|10025366|FG003|Overall Study|Physician Decision|0
6301418|NCT02539368|10025367|FG004|Overall Study|Physician Decision|2
6301419|NCT02539368|10025363|FG000|Overall Study|Lost to Follow-up|96
6301420|NCT02539368|10025364|FG001|Overall Study|Lost to Follow-up|21
6301421|NCT02539368|10025365|FG002|Overall Study|Lost to Follow-up|16
6301422|NCT02539368|10025366|FG003|Overall Study|Lost to Follow-up|4
6301423|NCT02539368|10025367|FG004|Overall Study|Lost to Follow-up|3
6301424|NCT02539368|10025363|FG000|Overall Study|Adverse Event|44
6301425|NCT02539368|10025364|FG001|Overall Study|Adverse Event|5
6301426|NCT02539368|10025365|FG002|Overall Study|Adverse Event|9
6301427|NCT02539368|10025366|FG003|Overall Study|Adverse Event|0
6301428|NCT02539368|10025367|FG004|Overall Study|Adverse Event|3
6301429|NCT02539368|10025363|FG000|Overall Study|Participant Non-compliant|13
6301430|NCT02539368|10025364|FG001|Overall Study|Participant Non-compliant|2
6301431|NCT02539368|10025365|FG002|Overall Study|Participant Non-compliant|1
6301432|NCT02539368|10025366|FG003|Overall Study|Participant Non-compliant|1
6301433|NCT02539368|10025367|FG004|Overall Study|Participant Non-compliant|0
6301434|NCT02539368|10025363|FG000|Overall Study|Other|145
6301435|NCT02539368|10025364|FG001|Overall Study|Other|18
6301436|NCT02539368|10025365|FG002|Overall Study|Other|24
6301437|NCT02539368|10025366|FG003|Overall Study|Other|1
6301438|NCT02539368|10025367|FG004|Overall Study|Other|3
6301439|NCT02539368|10025363|FG000|Overall Study|Missing|10
6301440|NCT02539368|10025364|FG001|Overall Study|Missing|3
6301441|NCT02539368|10025365|FG002|Overall Study|Missing|0
6301442|NCT02539368|10025366|FG003|Overall Study|Missing|0
6301443|NCT02539368|10025367|FG004|Overall Study|Missing|0
6301444|NCT02539797|10025400|FG000|Overall Study|Lost to Follow-up|0
6301445|NCT02539797|10025401|FG001|Overall Study|Lost to Follow-up|1
6301446|NCT02539797|10025402|FG002|Overall Study|Lost to Follow-up|0
6301447|NCT02540083|10025425|FG000|Overall Study|Withdrawal by Subject|16
6301448|NCT02540213|10025446|FG000|Overall Study|Death/adverse event|18
6301449|NCT02540213|10025446|FG000|Overall Study|Administrative reasons|3
6301450|NCT02540213|10025446|FG000|Overall Study|Kidney transplant|3
6301451|NCT02540213|10025446|FG000|Overall Study|Lack of Efficacy|6
6301452|NCT02540213|10025446|FG000|Overall Study|Consent withdrawn|7
6301453|NCT02540213|10025446|FG000|Overall Study|Enrolled but not treated|2
6301454|NCT02540265|10025462|FG000|Overall Study|Lost to Follow-up|0
6301455|NCT02540265|10025463|FG001|Overall Study|Lost to Follow-up|0
6301456|NCT02540265|10025464|FG002|Overall Study|Lost to Follow-up|1
6301457|NCT02540291|10025476|FG000|Overall Study|Death|7
6301458|NCT02540291|10025477|FG001|Overall Study|Death|7
6301459|NCT02540291|10025478|FG002|Overall Study|Death|5
6301460|NCT02540291|10025479|FG003|Overall Study|Death|7
6301461|NCT02540291|10025476|FG000|Overall Study|Lost to Follow-up|0
6301462|NCT02540291|10025477|FG001|Overall Study|Lost to Follow-up|0
6301463|NCT02540291|10025478|FG002|Overall Study|Lost to Follow-up|1
6301464|NCT02540291|10025479|FG003|Overall Study|Lost to Follow-up|0
6301465|NCT02540291|10025476|FG000|Overall Study|Withdrawal Of Consent|0
6301466|NCT02540291|10025477|FG001|Overall Study|Withdrawal Of Consent|1
6301467|NCT02540291|10025478|FG002|Overall Study|Withdrawal Of Consent|0
6301468|NCT02540291|10025479|FG003|Overall Study|Withdrawal Of Consent|0
6301469|NCT02540291|10025476|FG000|Overall Study|Study Terminated By Sponsor|1
6301470|NCT02540291|10025477|FG001|Overall Study|Study Terminated By Sponsor|0
6301471|NCT02540291|10025478|FG002|Overall Study|Study Terminated By Sponsor|0
6301472|NCT02540291|10025479|FG003|Overall Study|Study Terminated By Sponsor|0
6301473|NCT02540291|10025476|FG000|Overall Study|Other|0
6301474|NCT02540291|10025477|FG001|Overall Study|Other|0
6301475|NCT02540291|10025478|FG002|Overall Study|Other|1
6301476|NCT02540291|10025479|FG003|Overall Study|Other|0
6301477|NCT02540356|10025493|FG000|Overall Study|Terminated due to disease progression|1
6301478|NCT02540356|10025494|FG001|Overall Study|Terminated due to disease progression|0
6301479|NCT02540538|10025511|FG000|Overall Study|Pregnancy|0
6301480|NCT02540538|10025512|FG001|Overall Study|Pregnancy|1
6301481|NCT02540538|10025513|FG002|Overall Study|Pregnancy|0
6301482|NCT02540668|10025531|FG000|Period 2 - LY3314814 and Warfarin|Physician Decision|0
6301483|NCT02540668|10025532|FG001|Period 2 - LY3314814 and Warfarin|Physician Decision|1
6301484|NCT02540850|10025551|FG000|Overall Study|Lost to Follow-up|69
6301485|NCT02540850|10025552|FG001|Overall Study|Lost to Follow-up|66
6301486|NCT02540850|10025553|FG002|Overall Study|Lost to Follow-up|34
6301487|NCT02540954|10025563|FG000|Overall Study|Physician Decision|3
6301488|NCT02540954|10025564|FG001|Overall Study|Physician Decision|1
6301489|NCT02540954|10025563|FG000|Overall Study|Withdrawal by Subject|6
6301490|NCT02540954|10025564|FG001|Overall Study|Withdrawal by Subject|5
6301491|NCT02540954|10025563|FG000|Overall Study|Lost to Follow-up|1
6301492|NCT02540954|10025564|FG001|Overall Study|Lost to Follow-up|1
6301493|NCT02540954|10025563|FG000|Overall Study|Adverse Event|4
6301494|NCT02540954|10025564|FG001|Overall Study|Adverse Event|2
6301495|NCT02540954|10025563|FG000|Overall Study|Death|0
6301496|NCT02540954|10025564|FG001|Overall Study|Death|3
6301497|NCT02540954|10025563|FG000|Overall Study|Treatment failure|1
6301498|NCT02540954|10025564|FG001|Overall Study|Treatment failure|0
6301499|NCT02540954|10025563|FG000|Overall Study|Other reason|4
6301500|NCT02540954|10025564|FG001|Overall Study|Other reason|2
6301501|NCT02540993|10025572|FG000|Overall Study|Lost to Follow-up|5
6301502|NCT02540993|10025573|FG001|Overall Study|Lost to Follow-up|3
6301503|NCT02540993|10025572|FG000|Overall Study|Withdrawal by Subject|4
6301504|NCT02540993|10025573|FG001|Overall Study|Withdrawal by Subject|6
6301505|NCT02540993|10025572|FG000|Overall Study|GCP violations|33
6301506|NCT02540993|10025573|FG001|Overall Study|GCP violations|27
6301507|NCT02541604|10025611|FG000|Overall Study|Death|6
6301508|NCT02541604|10025612|FG001|Overall Study|Death|5
6301509|NCT02541604|10025613|FG002|Overall Study|Death|7
6301510|NCT02541604|10025614|FG003|Overall Study|Death|2
6301511|NCT02541604|10025615|FG004|Overall Study|Death|9
6301512|NCT02541604|10025616|FG005|Overall Study|Death|8
6301513|NCT02541604|10025617|FG006|Overall Study|Death|9
6301514|NCT02541604|10025618|FG007|Overall Study|Death|9
6301515|NCT02541604|10025619|FG008|Overall Study|Death|3
6301516|NCT02541604|10025620|FG009|Overall Study|Death|4
6301517|NCT02541604|10025621|FG010|Overall Study|Death|2
6301518|NCT02541604|10025622|FG011|Overall Study|Death|3
6301519|NCT02541604|10025611|FG000|Overall Study|Lost to Follow-up|2
6301520|NCT02541604|10025612|FG001|Overall Study|Lost to Follow-up|0
6301521|NCT02541604|10025613|FG002|Overall Study|Lost to Follow-up|1
6301522|NCT02541604|10025614|FG003|Overall Study|Lost to Follow-up|0
6301523|NCT02541604|10025615|FG004|Overall Study|Lost to Follow-up|0
6301524|NCT02541604|10025616|FG005|Overall Study|Lost to Follow-up|1
6301525|NCT02541604|10025617|FG006|Overall Study|Lost to Follow-up|1
6301526|NCT02541604|10025618|FG007|Overall Study|Lost to Follow-up|0
6301527|NCT02541604|10025619|FG008|Overall Study|Lost to Follow-up|0
6301528|NCT02541604|10025620|FG009|Overall Study|Lost to Follow-up|0
6301529|NCT02541604|10025621|FG010|Overall Study|Lost to Follow-up|0
6301530|NCT02541604|10025622|FG011|Overall Study|Lost to Follow-up|0
6301531|NCT02541604|10025611|FG000|Overall Study|Withdrawal by Subject|2
6301532|NCT02541604|10025612|FG001|Overall Study|Withdrawal by Subject|0
6301533|NCT02541604|10025613|FG002|Overall Study|Withdrawal by Subject|1
6301534|NCT02541604|10025614|FG003|Overall Study|Withdrawal by Subject|0
6301535|NCT02541604|10025615|FG004|Overall Study|Withdrawal by Subject|1
6301536|NCT02541604|10025616|FG005|Overall Study|Withdrawal by Subject|1
6301537|NCT02541604|10025617|FG006|Overall Study|Withdrawal by Subject|0
6301538|NCT02541604|10025618|FG007|Overall Study|Withdrawal by Subject|0
6301539|NCT02541604|10025619|FG008|Overall Study|Withdrawal by Subject|1
6301540|NCT02541604|10025620|FG009|Overall Study|Withdrawal by Subject|0
6301541|NCT02541604|10025621|FG010|Overall Study|Withdrawal by Subject|0
6301542|NCT02541604|10025622|FG011|Overall Study|Withdrawal by Subject|0
6301543|NCT02541604|10025611|FG000|Overall Study|Study Terminated by Sponsor|1
6301544|NCT02541604|10025612|FG001|Overall Study|Study Terminated by Sponsor|4
6301545|NCT02541604|10025613|FG002|Overall Study|Study Terminated by Sponsor|2
6301546|NCT02541604|10025614|FG003|Overall Study|Study Terminated by Sponsor|1
6301547|NCT02541604|10025615|FG004|Overall Study|Study Terminated by Sponsor|0
6063680|NCT00507429|9664995|FG000|Maintenance Phase|Progressive Disease|14
6301548|NCT02541604|10025616|FG005|Overall Study|Study Terminated by Sponsor|0
6301549|NCT02541604|10025617|FG006|Overall Study|Study Terminated by Sponsor|0
6301550|NCT02541604|10025618|FG007|Overall Study|Study Terminated by Sponsor|0
6301551|NCT02541604|10025619|FG008|Overall Study|Study Terminated by Sponsor|0
6301552|NCT02541604|10025620|FG009|Overall Study|Study Terminated by Sponsor|0
6301553|NCT02541604|10025621|FG010|Overall Study|Study Terminated by Sponsor|0
6301554|NCT02541604|10025622|FG011|Overall Study|Study Terminated by Sponsor|0
6301555|NCT02541604|10025611|FG000|Overall Study|Medical condition may jeopardize safety|0
6301556|NCT02541604|10025612|FG001|Overall Study|Medical condition may jeopardize safety|0
6301557|NCT02541604|10025613|FG002|Overall Study|Medical condition may jeopardize safety|0
6301558|NCT02541604|10025614|FG003|Overall Study|Medical condition may jeopardize safety|0
6301559|NCT02541604|10025615|FG004|Overall Study|Medical condition may jeopardize safety|0
6301560|NCT02541604|10025616|FG005|Overall Study|Medical condition may jeopardize safety|0
6301561|NCT02541604|10025617|FG006|Overall Study|Medical condition may jeopardize safety|0
6301562|NCT02541604|10025618|FG007|Overall Study|Medical condition may jeopardize safety|1
6301563|NCT02541604|10025619|FG008|Overall Study|Medical condition may jeopardize safety|0
6301564|NCT02541604|10025620|FG009|Overall Study|Medical condition may jeopardize safety|0
6301565|NCT02541604|10025621|FG010|Overall Study|Medical condition may jeopardize safety|0
6301566|NCT02541604|10025622|FG011|Overall Study|Medical condition may jeopardize safety|0
6301567|NCT02541669|10025676|FG000|Double-Blinded Treatment Period|Withdrawal by Subject|0
6301568|NCT02541669|10025677|FG001|Double-Blinded Treatment Period|Withdrawal by Subject|0
6301569|NCT02541669|10025678|FG002|Double-Blinded Treatment Period|Withdrawal by Subject|1
6301570|NCT02541669|10025679|FG003|Double-Blinded Treatment Period|Withdrawal by Subject|0
6301571|NCT02541669|10025680|FG004|Double-Blinded Treatment Period|Withdrawal by Subject|1
6301572|NCT02541903|10025710|FG000|Overall Study|Death|1
6301573|NCT02542072|10025733|FG000|First Intervention (1 Month)|Adverse Event|1
6301574|NCT02542072|10025734|FG001|First Intervention (1 Month)|Adverse Event|1
6301575|NCT02542072|10025733|FG000|First Intervention (1 Month)|Lost to Follow-up|2
6301576|NCT02542072|10025734|FG001|First Intervention (1 Month)|Lost to Follow-up|0
6301577|NCT02542072|10025733|FG000|First Intervention (1 Month)|Lens discomfort|1
6301578|NCT02542072|10025734|FG001|First Intervention (1 Month)|Lens discomfort|2
6301579|NCT02542072|10025733|FG000|First Intervention (1 Month)|Protocol Violation|1
6301580|NCT02542072|10025734|FG001|First Intervention (1 Month)|Protocol Violation|0
6301581|NCT02542072|10025733|FG000|Second Intervention (1 Month)|Lost to Follow-up|1
6301582|NCT02542072|10025734|FG001|Second Intervention (1 Month)|Lost to Follow-up|0
6301583|NCT02542072|10025733|FG000|Second Intervention (1 Month)|Lens discomfort|1
6301584|NCT02542072|10025734|FG001|Second Intervention (1 Month)|Lens discomfort|0
6301585|NCT02542605|10025809|FG000|Part B: Challenge Phase|Sponsor decision|1
6301586|NCT02542605|10025810|FG001|Part B: Challenge Phase|Sponsor decision|0
6301587|NCT02542605|10025811|FG002|Part B: Challenge Phase|Sponsor decision|0
6301588|NCT02542605|10025809|FG000|Part B: Randomization Phase|Withdrawal by Subject|0
6301589|NCT02542605|10025810|FG001|Part B: Randomization Phase|Withdrawal by Subject|0
6301590|NCT02542605|10025811|FG002|Part B: Randomization Phase|Withdrawal by Subject|1
6301591|NCT02542631|10025822|FG000|Overall Study|Adverse Event|1
6301592|NCT02542631|10025823|FG001|Overall Study|Adverse Event|1
6301593|NCT02542631|10025822|FG000|Overall Study|Sponsor Termination|1
6301594|NCT02542631|10025823|FG001|Overall Study|Sponsor Termination|0
6301595|NCT02542631|10025822|FG000|Overall Study|Withdrawal by Subject|11
6301596|NCT02542631|10025823|FG001|Overall Study|Withdrawal by Subject|16
6301597|NCT02542631|10025822|FG000|Overall Study|Protocol Violation|1
6301598|NCT02542631|10025823|FG001|Overall Study|Protocol Violation|1
6301599|NCT02542631|10025822|FG000|Overall Study|Physician Decision|6
6301600|NCT02542631|10025823|FG001|Overall Study|Physician Decision|4
6301601|NCT02542631|10025822|FG000|Overall Study|Lost to Follow-up|6
6301602|NCT02542631|10025823|FG001|Overall Study|Lost to Follow-up|5
6301603|NCT02542631|10025822|FG000|Overall Study|Death|1
6301604|NCT02542631|10025823|FG001|Overall Study|Death|2
6301605|NCT02542631|10025822|FG000|Overall Study|Other|2
6301606|NCT02542631|10025823|FG001|Overall Study|Other|1
6301607|NCT02542631|10025822|FG000|Overall Study|Used Prohibited Medication|2
6301608|NCT02542631|10025823|FG001|Overall Study|Used Prohibited Medication|1
6301609|NCT02542865|10025838|FG000|Overall Study|Identified as screen failure|1
6301610|NCT02542865|10025839|FG001|Overall Study|Identified as screen failure|0
6301611|NCT02542865|10025838|FG000|Overall Study|Withdrawal by Subject|16
6301612|NCT02542865|10025839|FG001|Overall Study|Withdrawal by Subject|0
6301613|NCT02542943|10025848|FG000|Overall Study|Lost to Follow-up|1
6301614|NCT02542943|10025849|FG001|Overall Study|Lost to Follow-up|0
6301615|NCT02542943|10025850|FG002|Overall Study|Lost to Follow-up|0
6301616|NCT02542943|10025848|FG000|Overall Study|Withdrawal by Subject|0
6301617|NCT02542943|10025849|FG001|Overall Study|Withdrawal by Subject|1
6301618|NCT02542943|10025850|FG002|Overall Study|Withdrawal by Subject|0
6301619|NCT02543203|10025861|FG000|Overall Study|Unpalatable Fragrance|2
5982274|NCT03626168|9571226|FG000|First Intervention (4 Weeks)|Withdrawal by Subject|1
5982275|NCT03626168|9571227|FG001|First Intervention (4 Weeks)|Withdrawal by Subject|0
5982276|NCT03626168|9571226|FG000|First Intervention (4 Weeks)|Began a medication that precluded participation|0
5982277|NCT03626168|9571227|FG001|First Intervention (4 Weeks)|Began a medication that precluded participation|1
5982278|NCT03626168|9571226|FG000|Second Intervention (4 Weeks)|Withdrawal by Subject|0
5982279|NCT03626168|9571227|FG001|Second Intervention (4 Weeks)|Withdrawal by Subject|2
5982280|NCT04579393|9571253|FG000|Overall Study|Withdrawal by Subject|2
5982281|NCT04579393|9571254|FG001|Overall Study|Withdrawal by Subject|2
5982282|NCT04579393|9571253|FG000|Overall Study|Death|1
5982283|NCT04579393|9571254|FG001|Overall Study|Death|3
5982284|NCT04325906|9571272|FG000|Overall Study|Withdrawal by Subject|2
6301620|NCT02543203|10025862|FG001|Overall Study|Unpalatable Fragrance|2
6301621|NCT02543203|10025861|FG000|Overall Study|Lost to Follow-up|1
6301622|NCT02543203|10025862|FG001|Overall Study|Lost to Follow-up|0
6301623|NCT02543203|10025861|FG000|Overall Study|Increased Irritability|1
6301624|NCT02543203|10025862|FG001|Overall Study|Increased Irritability|0
6301625|NCT02543203|10025861|FG000|Overall Study|Family|1
6301626|NCT02543203|10025862|FG001|Overall Study|Family|2
6301627|NCT02543203|10025861|FG000|Overall Study|Negative Behavior|1
6301628|NCT02543203|10025862|FG001|Overall Study|Negative Behavior|0
6301629|NCT02543203|10025861|FG000|Overall Study|Withdrawal by Subject|0
6301630|NCT02543203|10025862|FG001|Overall Study|Withdrawal by Subject|1
6301631|NCT02543294|10025876|FG000|Overall Study|Lost to Follow-up|3
6301632|NCT02543294|10025876|FG000|Overall Study|Physician Decision|2
6301633|NCT02543294|10025876|FG000|Overall Study|Withdrawal by Subject|7
6301634|NCT02543346|10025881|FG000|Second Priming Visit|Withdrawal by Subject|0
6301635|NCT02543346|10025882|FG001|Second Priming Visit|Withdrawal by Subject|2
6301636|NCT02543346|10025883|FG002|Second Priming Visit|Withdrawal by Subject|2
6301637|NCT02543346|10025884|FG003|Second Priming Visit|Withdrawal by Subject|2
6301638|NCT02543346|10025881|FG000|Second Priming Visit|Adverse Event|1
6301639|NCT02543346|10025882|FG001|Second Priming Visit|Adverse Event|0
6301640|NCT02543346|10025883|FG002|Second Priming Visit|Adverse Event|0
6301641|NCT02543346|10025884|FG003|Second Priming Visit|Adverse Event|0
6301642|NCT02543528|10025907|FG000|Adaptation Period|Unsatisfactory Lens Fitting|0
6301643|NCT02543528|10025908|FG001|Adaptation Period|Unsatisfactory Lens Fitting|0
6301644|NCT02543528|10025909|FG002|Adaptation Period|Unsatisfactory Lens Fitting|0
6301645|NCT02543528|10025910|FG003|Adaptation Period|Unsatisfactory Lens Fitting|0
6301646|NCT02543528|10025911|FG004|Adaptation Period|Unsatisfactory Lens Fitting|2
6301647|NCT02543528|10025907|FG000|Adaptation Period|Lens Handling Difficultes|0
6301648|NCT02543528|10025908|FG001|Adaptation Period|Lens Handling Difficultes|0
6301649|NCT02543528|10025909|FG002|Adaptation Period|Lens Handling Difficultes|0
6301650|NCT02543528|10025910|FG003|Adaptation Period|Lens Handling Difficultes|0
6301651|NCT02543528|10025911|FG004|Adaptation Period|Lens Handling Difficultes|8
6301652|NCT02543528|10025907|FG000|Adaptation Period|Lost to Follow-up|0
6301653|NCT02543528|10025908|FG001|Adaptation Period|Lost to Follow-up|0
6301654|NCT02543528|10025909|FG002|Adaptation Period|Lost to Follow-up|0
6301655|NCT02543528|10025910|FG003|Adaptation Period|Lost to Follow-up|0
5982285|NCT04325906|9571273|FG001|Overall Study|Withdrawal by Subject|0
6063681|NCT00507429|9664996|FG001|Maintenance Phase|Progressive Disease|0
6136910|NCT01004822|9767042|FG002|Overall Study|Objective progression or relapse|0
6136911|NCT01004822|9767043|FG003|Overall Study|Objective progression or relapse|1
6136912|NCT01004822|9767044|FG004|Overall Study|Objective progression or relapse|2
6136913|NCT01004822|9767045|FG005|Overall Study|Objective progression or relapse|2
6136914|NCT01004822|9767046|FG006|Overall Study|Objective progression or relapse|1
6136915|NCT01004822|9767047|FG007|Overall Study|Objective progression or relapse|4
6136916|NCT01004822|9767040|FG000|Overall Study|Global deterioration of health status|0
6136917|NCT01004822|9767041|FG001|Overall Study|Global deterioration of health status|0
6136918|NCT01004822|9767042|FG002|Overall Study|Global deterioration of health status|0
6136919|NCT01004822|9767043|FG003|Overall Study|Global deterioration of health status|1
6136920|NCT01004822|9767044|FG004|Overall Study|Global deterioration of health status|0
6136921|NCT01004822|9767045|FG005|Overall Study|Global deterioration of health status|0
6136922|NCT01004822|9767046|FG006|Overall Study|Global deterioration of health status|1
6136923|NCT01004822|9767047|FG007|Overall Study|Global deterioration of health status|0
6136924|NCT01004822|9767040|FG000|Overall Study|No longer willing to continue|0
6136925|NCT01004822|9767041|FG001|Overall Study|No longer willing to continue|0
6136926|NCT01004822|9767042|FG002|Overall Study|No longer willing to continue|0
6136927|NCT01004822|9767043|FG003|Overall Study|No longer willing to continue|1
6136928|NCT01004822|9767044|FG004|Overall Study|No longer willing to continue|2
6136929|NCT01004822|9767045|FG005|Overall Study|No longer willing to continue|1
6136930|NCT01004822|9767046|FG006|Overall Study|No longer willing to continue|1
6136931|NCT01004822|9767047|FG007|Overall Study|No longer willing to continue|0
6136932|NCT01004822|9767040|FG000|Overall Study|Adverse Event|0
6136933|NCT01004822|9767041|FG001|Overall Study|Adverse Event|0
6136934|NCT01004822|9767042|FG002|Overall Study|Adverse Event|0
6136935|NCT01004822|9767043|FG003|Overall Study|Adverse Event|0
6136936|NCT01004822|9767044|FG004|Overall Study|Adverse Event|0
6136937|NCT01004822|9767045|FG005|Overall Study|Adverse Event|0
6136938|NCT01004822|9767046|FG006|Overall Study|Adverse Event|1
6136939|NCT01004822|9767047|FG007|Overall Study|Adverse Event|1
6136940|NCT01004822|9767040|FG000|Overall Study|Other|0
6136941|NCT01004822|9767041|FG001|Overall Study|Other|0
6136942|NCT01004822|9767042|FG002|Overall Study|Other|4
6136943|NCT01004822|9767043|FG003|Overall Study|Other|1
6136944|NCT01004822|9767044|FG004|Overall Study|Other|0
6136945|NCT01004822|9767045|FG005|Overall Study|Other|1
6136946|NCT01004822|9767046|FG006|Overall Study|Other|0
6136947|NCT01004822|9767047|FG007|Overall Study|Other|0
6301656|NCT02543528|10025911|FG004|Adaptation Period|Lost to Follow-up|14
6136948|NCT01004848|9767069|FG000|Overall Study|Lost to Follow-up|55
6136949|NCT01004848|9767070|FG001|Overall Study|Lost to Follow-up|45
6136950|NCT01005251|9767093|FG000|Overall Study|Withdrawal by Subject|2
6301657|NCT02543528|10025907|FG000|Adaptation Period|Adverse Event|0
6301658|NCT02543528|10025908|FG001|Adaptation Period|Adverse Event|0
6301659|NCT02543528|10025909|FG002|Adaptation Period|Adverse Event|0
6301660|NCT02543528|10025910|FG003|Adaptation Period|Adverse Event|0
6301661|NCT02543528|10025911|FG004|Adaptation Period|Adverse Event|2
6301662|NCT02543528|10025907|FG000|Extended Wear Period|Adverse Event|17
6301663|NCT02543528|10025908|FG001|Extended Wear Period|Adverse Event|11
6301664|NCT02543528|10025909|FG002|Extended Wear Period|Adverse Event|16
6301665|NCT02543528|10025910|FG003|Extended Wear Period|Adverse Event|3
6301666|NCT02543528|10025911|FG004|Extended Wear Period|Adverse Event|0
6301667|NCT02543528|10025907|FG000|Extended Wear Period|Missed too many scheduled visits|0
6301668|NCT02543528|10025908|FG001|Extended Wear Period|Missed too many scheduled visits|0
6301669|NCT02543528|10025909|FG002|Extended Wear Period|Missed too many scheduled visits|1
6301670|NCT02543528|10025910|FG003|Extended Wear Period|Missed too many scheduled visits|3
6301671|NCT02543528|10025911|FG004|Extended Wear Period|Missed too many scheduled visits|0
6301672|NCT02543528|10025907|FG000|Extended Wear Period|Unsatisfactory Lens Fitting|1
6301673|NCT02543528|10025908|FG001|Extended Wear Period|Unsatisfactory Lens Fitting|0
6301674|NCT02543528|10025909|FG002|Extended Wear Period|Unsatisfactory Lens Fitting|0
6301675|NCT02543528|10025910|FG003|Extended Wear Period|Unsatisfactory Lens Fitting|0
6301676|NCT02543528|10025911|FG004|Extended Wear Period|Unsatisfactory Lens Fitting|0
6301677|NCT02543528|10025907|FG000|Extended Wear Period|Lost to Follow-up|0
6301678|NCT02543528|10025908|FG001|Extended Wear Period|Lost to Follow-up|1
6301679|NCT02543528|10025909|FG002|Extended Wear Period|Lost to Follow-up|2
6301680|NCT02543528|10025910|FG003|Extended Wear Period|Lost to Follow-up|1
6301681|NCT02543528|10025911|FG004|Extended Wear Period|Lost to Follow-up|0
6301682|NCT02543528|10025907|FG000|Extended Wear Period|Withdrawal by Subject|10
6301683|NCT02543528|10025908|FG001|Extended Wear Period|Withdrawal by Subject|9
6301684|NCT02543528|10025909|FG002|Extended Wear Period|Withdrawal by Subject|4
6301685|NCT02543528|10025910|FG003|Extended Wear Period|Withdrawal by Subject|5
6301686|NCT02543528|10025911|FG004|Extended Wear Period|Withdrawal by Subject|0
6301687|NCT02543658|10025936|FG000|Overall Study|Lack of Efficacy|0
6301688|NCT02543658|10025937|FG001|Overall Study|Lack of Efficacy|4
6301689|NCT02543801|10025959|FG000|Overall Study|Protocol Violation|1
6301690|NCT02543801|10025960|FG001|Overall Study|Protocol Violation|2
6301691|NCT02543801|10025961|FG002|Overall Study|Protocol Violation|0
6301692|NCT02543801|10025962|FG003|Overall Study|Protocol Violation|0
6301693|NCT02543892|10025990|FG000|Received Vaccination 2|Withdrawal by Subject|1
6301694|NCT02543892|10025991|FG001|Received Vaccination 2|Withdrawal by Subject|0
6301695|NCT02543892|10025992|FG002|Received Vaccination 2|Withdrawal by Subject|0
6301696|NCT02543892|10025993|FG003|Received Vaccination 2|Withdrawal by Subject|0
6301697|NCT02543892|10025994|FG004|Received Vaccination 2|Withdrawal by Subject|0
6301698|NCT02543892|10025995|FG005|Received Vaccination 2|Withdrawal by Subject|0
6301699|NCT02543892|10025996|FG006|Received Vaccination 2|Withdrawal by Subject|0
6301700|NCT02543892|10025997|FG007|Received Vaccination 2|Withdrawal by Subject|1
6301701|NCT02543892|10025990|FG000|Received Vaccination 2|Physician Decision|0
6301702|NCT02543892|10025991|FG001|Received Vaccination 2|Physician Decision|0
6301703|NCT02543892|10025992|FG002|Received Vaccination 2|Physician Decision|0
6301704|NCT02543892|10025993|FG003|Received Vaccination 2|Physician Decision|0
6301705|NCT02543892|10025994|FG004|Received Vaccination 2|Physician Decision|0
6301706|NCT02543892|10025995|FG005|Received Vaccination 2|Physician Decision|1
6301707|NCT02543892|10025996|FG006|Received Vaccination 2|Physician Decision|0
6301708|NCT02543892|10025997|FG007|Received Vaccination 2|Physician Decision|0
6301709|NCT02543892|10025990|FG000|Received Vaccination 2|Adverse Event|0
6301710|NCT02543892|10025991|FG001|Received Vaccination 2|Adverse Event|1
6301711|NCT02543892|10025992|FG002|Received Vaccination 2|Adverse Event|0
6301712|NCT02543892|10025993|FG003|Received Vaccination 2|Adverse Event|0
6301713|NCT02543892|10025994|FG004|Received Vaccination 2|Adverse Event|0
6301714|NCT02543892|10025995|FG005|Received Vaccination 2|Adverse Event|0
6301715|NCT02543892|10025996|FG006|Received Vaccination 2|Adverse Event|0
6301716|NCT02543892|10025997|FG007|Received Vaccination 2|Adverse Event|0
6301717|NCT02543892|10025990|FG000|Had Immunology Data|Withdrawal by Subject|0
6301718|NCT02543892|10025991|FG001|Had Immunology Data|Withdrawal by Subject|0
6301719|NCT02543892|10025992|FG002|Had Immunology Data|Withdrawal by Subject|0
6301720|NCT02543892|10025993|FG003|Had Immunology Data|Withdrawal by Subject|0
6301721|NCT02543892|10025994|FG004|Had Immunology Data|Withdrawal by Subject|0
6301722|NCT02543892|10025995|FG005|Had Immunology Data|Withdrawal by Subject|0
6301723|NCT02543892|10025996|FG006|Had Immunology Data|Withdrawal by Subject|1
6301724|NCT02543892|10025997|FG007|Had Immunology Data|Withdrawal by Subject|0
6301725|NCT02543918|10026022|FG000|Overall Study|Never treated|0
6301726|NCT02543918|10026023|FG001|Overall Study|Never treated|1
6301727|NCT02543918|10026022|FG000|Overall Study|Lost to Follow-up|1
6301728|NCT02543918|10026023|FG001|Overall Study|Lost to Follow-up|1
6301729|NCT02543918|10026022|FG000|Overall Study|Withdrawal by Subject|1
6301730|NCT02543918|10026023|FG001|Overall Study|Withdrawal by Subject|1
6301731|NCT02543918|10026022|FG000|Overall Study|Adverse Event|1
6301732|NCT02543918|10026023|FG001|Overall Study|Adverse Event|1
6301733|NCT02544113|10026031|FG000|Overall Study|Death|3
6301734|NCT02544113|10026032|FG001|Overall Study|Death|4
6301735|NCT02544152|10026040|FG000|Overall Study|Adverse Event|0
6301736|NCT02544152|10026041|FG001|Overall Study|Adverse Event|4
6301737|NCT02544152|10026040|FG000|Overall Study|Withdrawal by Subject|0
6301738|NCT02544152|10026041|FG001|Overall Study|Withdrawal by Subject|3
6301739|NCT02544152|10026040|FG000|Overall Study|Other|1
6301740|NCT02544152|10026041|FG001|Overall Study|Other|0
6301741|NCT02544217|10026053|FG000|Overall Study|Withdrawal by Subject|1
6301742|NCT02544217|10026054|FG001|Overall Study|Withdrawal by Subject|1
6301743|NCT02544217|10026055|FG002|Overall Study|Withdrawal by Subject|0
6301744|NCT02544217|10026056|FG003|Overall Study|Withdrawal by Subject|0
6301745|NCT02544217|10026057|FG004|Overall Study|Withdrawal by Subject|0
6301746|NCT02544217|10026058|FG005|Overall Study|Withdrawal by Subject|0
6301747|NCT02544321|10026127|FG000|Overall Study|Withdrawal by Subject|1
6301748|NCT02544321|10026128|FG001|Overall Study|Withdrawal by Subject|2
6301749|NCT02544321|10026127|FG000|Overall Study|Adverse Event|1
6301750|NCT02544321|10026128|FG001|Overall Study|Adverse Event|1
6301751|NCT02544321|10026127|FG000|Overall Study|Protocol Violation|0
6301752|NCT02544321|10026128|FG001|Overall Study|Protocol Violation|1
6301753|NCT02544451|10026146|FG000|Treatment Period 1 (96 Weeks)|Adverse Event|1
6301754|NCT02544451|10026147|FG001|Treatment Period 1 (96 Weeks)|Adverse Event|6
6301755|NCT02544451|10026148|FG002|Treatment Period 1 (96 Weeks)|Adverse Event|0
6301756|NCT02544451|10026149|FG003|Treatment Period 1 (96 Weeks)|Adverse Event|0
6301757|NCT02544451|10026146|FG000|Treatment Period 1 (96 Weeks)|Withdrawal of consent (not due to AE)|3
6301758|NCT02544451|10026147|FG001|Treatment Period 1 (96 Weeks)|Withdrawal of consent (not due to AE)|2
6301759|NCT02544451|10026148|FG002|Treatment Period 1 (96 Weeks)|Withdrawal of consent (not due to AE)|1
6301760|NCT02544451|10026149|FG003|Treatment Period 1 (96 Weeks)|Withdrawal of consent (not due to AE)|0
6301761|NCT02544451|10026146|FG000|Treatment Period 1 (96 Weeks)|Lost to Follow-up|2
6301762|NCT02544451|10026147|FG001|Treatment Period 1 (96 Weeks)|Lost to Follow-up|0
6301763|NCT02544451|10026148|FG002|Treatment Period 1 (96 Weeks)|Lost to Follow-up|0
6301764|NCT02544451|10026149|FG003|Treatment Period 1 (96 Weeks)|Lost to Follow-up|0
6301765|NCT02544451|10026146|FG000|Treatment Period 1 (96 Weeks)|Physician Decision|4
6301766|NCT02544451|10026147|FG001|Treatment Period 1 (96 Weeks)|Physician Decision|0
6301767|NCT02544451|10026148|FG002|Treatment Period 1 (96 Weeks)|Physician Decision|0
6301768|NCT02544451|10026149|FG003|Treatment Period 1 (96 Weeks)|Physician Decision|0
6301769|NCT02544451|10026146|FG000|Treatment Period 1 (96 Weeks)|Other|4
6301770|NCT02544451|10026147|FG001|Treatment Period 1 (96 Weeks)|Other|4
6301771|NCT02544451|10026148|FG002|Treatment Period 1 (96 Weeks)|Other|0
6301772|NCT02544451|10026149|FG003|Treatment Period 1 (96 Weeks)|Other|0
6301773|NCT02544451|10026146|FG000|Treatment Period 2 (168 Weeks)|Commercial drug is available for subject|0
6301774|NCT02544451|10026147|FG001|Treatment Period 2 (168 Weeks)|Commercial drug is available for subject|0
6301775|NCT02544451|10026148|FG002|Treatment Period 2 (168 Weeks)|Commercial drug is available for subject|0
6301776|NCT02544451|10026149|FG003|Treatment Period 2 (168 Weeks)|Commercial drug is available for subject|10
6301777|NCT02544633|10026176|FG000|Treatment Period|Patient Still on Treatment/Study|0
6301778|NCT02544633|10026177|FG001|Treatment Period|Patient Still on Treatment/Study|1
6301779|NCT02544633|10026178|FG002|Treatment Period|Patient Still on Treatment/Study|1
6301780|NCT02544633|10026179|FG003|Treatment Period|Patient Still on Treatment/Study|0
6301781|NCT02544633|10026176|FG000|Treatment Period|Adverse Event|7
6301782|NCT02544633|10026177|FG001|Treatment Period|Adverse Event|4
6301783|NCT02544633|10026178|FG002|Treatment Period|Adverse Event|0
6301784|NCT02544633|10026179|FG003|Treatment Period|Adverse Event|5
6301785|NCT02544633|10026176|FG000|Treatment Period|Lack of Efficacy|17
6301786|NCT02544633|10026177|FG001|Treatment Period|Lack of Efficacy|11
6301787|NCT02544633|10026178|FG002|Treatment Period|Lack of Efficacy|5
6301788|NCT02544633|10026179|FG003|Treatment Period|Lack of Efficacy|5
6301789|NCT02544633|10026176|FG000|Treatment Period|Global Deterioration of Health|3
6301790|NCT02544633|10026177|FG001|Treatment Period|Global Deterioration of Health|3
6301791|NCT02544633|10026178|FG002|Treatment Period|Global Deterioration of Health|0
6301792|NCT02544633|10026179|FG003|Treatment Period|Global Deterioration of Health|1
6063682|NCT00507442|9665008|FG000|Overall Study|Adverse Event|8
6063683|NCT00507442|9665009|FG001|Overall Study|Adverse Event|11
6063684|NCT00507442|9665010|FG002|Overall Study|Adverse Event|4
6063685|NCT00507442|9665011|FG003|Overall Study|Adverse Event|1
6063686|NCT00507442|9665008|FG000|Overall Study|Protocol Violation|0
6063687|NCT00507442|9665009|FG001|Overall Study|Protocol Violation|1
6063688|NCT00507442|9665010|FG002|Overall Study|Protocol Violation|0
6063689|NCT00507442|9665011|FG003|Overall Study|Protocol Violation|0
6063690|NCT00507442|9665008|FG000|Overall Study|Lost to Follow-up|0
6063691|NCT00507442|9665009|FG001|Overall Study|Lost to Follow-up|0
6063692|NCT00507442|9665010|FG002|Overall Study|Lost to Follow-up|1
6063693|NCT00507442|9665011|FG003|Overall Study|Lost to Follow-up|0
6063694|NCT00507442|9665008|FG000|Overall Study|Physician Decision|0
6063695|NCT00507442|9665009|FG001|Overall Study|Physician Decision|2
6063696|NCT00507442|9665010|FG002|Overall Study|Physician Decision|4
6063697|NCT00507442|9665011|FG003|Overall Study|Physician Decision|1
6063698|NCT00507442|9665008|FG000|Overall Study|Progressive Disease|2
6063699|NCT00507442|9665009|FG001|Overall Study|Progressive Disease|4
6063700|NCT00507442|9665010|FG002|Overall Study|Progressive Disease|2
6063701|NCT00507442|9665011|FG003|Overall Study|Progressive Disease|0
6063702|NCT00507442|9665008|FG000|Overall Study|Withdrawal by Subject|4
6063703|NCT00507442|9665009|FG001|Overall Study|Withdrawal by Subject|4
6063704|NCT00507442|9665010|FG002|Overall Study|Withdrawal by Subject|2
6063705|NCT00507442|9665011|FG003|Overall Study|Withdrawal by Subject|1
6063706|NCT00507442|9665008|FG000|Overall Study|Other|2
6301793|NCT02544633|10026176|FG000|Treatment Period|Withdrawal by Subject|1
6301794|NCT02544633|10026177|FG001|Treatment Period|Withdrawal by Subject|0
6301795|NCT02544633|10026178|FG002|Treatment Period|Withdrawal by Subject|0
6301796|NCT02544633|10026179|FG003|Treatment Period|Withdrawal by Subject|0
6301797|NCT02544633|10026176|FG000|Treatment Period|Lost to Follow-up|0
6301798|NCT02544633|10026177|FG001|Treatment Period|Lost to Follow-up|1
6301799|NCT02544633|10026178|FG002|Treatment Period|Lost to Follow-up|0
6301800|NCT02544633|10026179|FG003|Treatment Period|Lost to Follow-up|0
6301801|NCT02544633|10026176|FG000|Treatment Period|Death|0
6301802|NCT02544633|10026177|FG001|Treatment Period|Death|0
6301803|NCT02544633|10026178|FG002|Treatment Period|Death|1
6301804|NCT02544633|10026179|FG003|Treatment Period|Death|0
6301805|NCT02544633|10026176|FG000|Treatment Period|Non-compliance|0
6301806|NCT02544633|10026177|FG001|Treatment Period|Non-compliance|0
6301807|NCT02544633|10026178|FG002|Treatment Period|Non-compliance|1
6301808|NCT02544633|10026179|FG003|Treatment Period|Non-compliance|0
6301809|NCT02544633|10026176|FG000|Treatment Period|Clinical Disease Progression|0
6301810|NCT02544633|10026177|FG001|Treatment Period|Clinical Disease Progression|0
6301811|NCT02544633|10026178|FG002|Treatment Period|Clinical Disease Progression|0
6301812|NCT02544633|10026179|FG003|Treatment Period|Clinical Disease Progression|1
6301813|NCT02544633|10026176|FG000|Survival Follow-up Period|Death|12
6301814|NCT02544633|10026177|FG001|Survival Follow-up Period|Death|14
6301815|NCT02544633|10026178|FG002|Survival Follow-up Period|Death|3
6301816|NCT02544633|10026179|FG003|Survival Follow-up Period|Death|9
6301817|NCT02544633|10026176|FG000|Survival Follow-up Period|Lost to Follow-up|0
6301818|NCT02544633|10026177|FG001|Survival Follow-up Period|Lost to Follow-up|1
6301819|NCT02544633|10026178|FG002|Survival Follow-up Period|Lost to Follow-up|1
6301820|NCT02544633|10026179|FG003|Survival Follow-up Period|Lost to Follow-up|0
6301821|NCT02544633|10026176|FG000|Survival Follow-up Period|Withdrawal by Subject|4
6301822|NCT02544633|10026177|FG001|Survival Follow-up Period|Withdrawal by Subject|0
6301823|NCT02544633|10026178|FG002|Survival Follow-up Period|Withdrawal by Subject|1
6301824|NCT02544633|10026179|FG003|Survival Follow-up Period|Withdrawal by Subject|0
6301825|NCT02544633|10026176|FG000|Survival Follow-up Period|Study Terminated by Sponsor|12
6301826|NCT02544633|10026177|FG001|Survival Follow-up Period|Study Terminated by Sponsor|4
6301827|NCT02544633|10026178|FG002|Survival Follow-up Period|Study Terminated by Sponsor|2
6301828|NCT02544633|10026179|FG003|Survival Follow-up Period|Study Terminated by Sponsor|3
6301829|NCT02544763|10026204|FG000|Overall Study|Adverse Event|8
6301830|NCT02544763|10026205|FG001|Overall Study|Adverse Event|8
6301831|NCT02544763|10026206|FG002|Overall Study|Adverse Event|0
6301832|NCT02544763|10026204|FG000|Overall Study|Withdrawn by parent/guardian|1
6301833|NCT02544763|10026205|FG001|Overall Study|Withdrawn by parent/guardian|1
6301834|NCT02544763|10026206|FG002|Overall Study|Withdrawn by parent/guardian|1
6301835|NCT02544763|10026204|FG000|Overall Study|Met withdrawal criteria|0
6301836|NCT02544763|10026205|FG001|Overall Study|Met withdrawal criteria|2
6301837|NCT02544763|10026206|FG002|Overall Study|Met withdrawal criteria|0
6301838|NCT02544763|10026204|FG000|Overall Study|Physician Decision|0
6301839|NCT02544763|10026205|FG001|Overall Study|Physician Decision|1
6301840|NCT02544763|10026206|FG002|Overall Study|Physician Decision|0
6301841|NCT02544763|10026204|FG000|Overall Study|Difficulties taking IMP|1
6301842|NCT02544763|10026205|FG001|Overall Study|Difficulties taking IMP|0
6301843|NCT02544763|10026206|FG002|Overall Study|Difficulties taking IMP|0
6301844|NCT02545075|10026225|FG000|Randomization|Lost to Follow-up|0
6301845|NCT02545075|10026226|FG001|Randomization|Lost to Follow-up|1
6301846|NCT02545075|10026225|FG000|Randomization|Withdrawal by Subject|0
6301847|NCT02545075|10026226|FG001|Randomization|Withdrawal by Subject|6
6301848|NCT02545075|10026225|FG000|Treatment|Disease progression|71
6301849|NCT02545075|10026226|FG001|Treatment|Disease progression|32
6301850|NCT02545075|10026225|FG000|Treatment|Participant dicontinued study treatment|7
6301851|NCT02545075|10026226|FG001|Treatment|Participant dicontinued study treatment|9
6301852|NCT02545075|10026225|FG000|Treatment|Withdrawal by Subject|1
6301853|NCT02545075|10026226|FG001|Treatment|Withdrawal by Subject|0
6301854|NCT02545075|10026225|FG000|Treatment|Adverse event not related to study drug|1
6301855|NCT02545075|10026226|FG001|Treatment|Adverse event not related to study drug|0
6301856|NCT02545075|10026225|FG000|Treatment|Death|1
6301857|NCT02545075|10026226|FG001|Treatment|Death|0
6301858|NCT02545075|10026225|FG000|Treatment|Participant drug toxicity|1
6301859|NCT02545075|10026226|FG001|Treatment|Participant drug toxicity|0
6301860|NCT02545075|10026225|FG000|Treatment|Completed treatment|40
6301861|NCT02545075|10026226|FG001|Treatment|Completed treatment|12
6301862|NCT02545270|10026239|FG000|Overall Study|technical difficulties|0
6301863|NCT02545270|10026240|FG001|Overall Study|technical difficulties|1
6301864|NCT02545270|10026241|FG002|Overall Study|technical difficulties|0
6301865|NCT02545270|10026239|FG000|Overall Study|Videos being too similar to other|0
6301866|NCT02545270|10026240|FG001|Overall Study|Videos being too similar to other|0
6301867|NCT02545270|10026241|FG002|Overall Study|Videos being too similar to other|2
6301868|NCT02545322|10026250|FG000|Overall Study|Withdrawal by Subject|3
6301869|NCT02545504|10026256|FG000|Overall Study|Death|174
6301870|NCT02545504|10026257|FG001|Overall Study|Death|168
6301871|NCT02545504|10026256|FG000|Overall Study|Unknown reason|30
6301872|NCT02545504|10026257|FG001|Overall Study|Unknown reason|32
6301873|NCT02545504|10026256|FG000|Overall Study|Withdrew consent|9
6301874|NCT02545504|10026257|FG001|Overall Study|Withdrew consent|11
6301875|NCT02545504|10026256|FG000|Overall Study|Investigator's discretion|3
6301876|NCT02545504|10026257|FG001|Overall Study|Investigator's discretion|1
6301877|NCT02545504|10026256|FG000|Overall Study|Lost to Follow-up|2
6301878|NCT02545504|10026257|FG001|Overall Study|Lost to Follow-up|2
6301879|NCT02545543|10026269|FG000|Overall Study|Lost to Follow-up|67
6301880|NCT02545543|10026270|FG001|Overall Study|Lost to Follow-up|25
6301881|NCT02545543|10026269|FG000|Overall Study|Physician Decision|3
6301882|NCT02545543|10026270|FG001|Overall Study|Physician Decision|0
6301883|NCT02545543|10026269|FG000|Overall Study|Withdrawal by Subject|9
6301884|NCT02545543|10026270|FG001|Overall Study|Withdrawal by Subject|8
6301885|NCT02545543|10026269|FG000|Overall Study|Noncomplaince|1
6301886|NCT02545543|10026270|FG001|Overall Study|Noncomplaince|0
6301887|NCT02545543|10026269|FG000|Overall Study|Enrolment of subject at >1 study site|1
6301888|NCT02545543|10026270|FG001|Overall Study|Enrolment of subject at >1 study site|1
6301889|NCT02545933|10026304|FG000|Overall Study|Adverse Event|3
6301890|NCT02545933|10026305|FG001|Overall Study|Adverse Event|0
6301891|NCT02545933|10026306|FG002|Overall Study|Adverse Event|0
6301892|NCT02545933|10026304|FG000|Overall Study|Withdrawal by Subject|2
6301893|NCT02545933|10026305|FG001|Overall Study|Withdrawal by Subject|3
6301894|NCT02545933|10026306|FG002|Overall Study|Withdrawal by Subject|3
6301895|NCT02545933|10026304|FG000|Overall Study|Protocol Violation|1
6301896|NCT02545933|10026305|FG001|Overall Study|Protocol Violation|0
6301897|NCT02545933|10026306|FG002|Overall Study|Protocol Violation|1
6301898|NCT02546193|10026316|FG000|Overall Study|Withdrawal by Subject|2
6301899|NCT02546193|10026317|FG001|Overall Study|Withdrawal by Subject|0
6301900|NCT02546193|10026318|FG002|Overall Study|Withdrawal by Subject|1
6301901|NCT02546193|10026319|FG003|Overall Study|Withdrawal by Subject|0
6301902|NCT02546193|10026316|FG000|Overall Study|Not eligible at time of induction|4
6301903|NCT02546193|10026317|FG001|Overall Study|Not eligible at time of induction|6
6301904|NCT02546193|10026318|FG002|Overall Study|Not eligible at time of induction|1
6301905|NCT02546193|10026319|FG003|Overall Study|Not eligible at time of induction|0
6301906|NCT02546323|10026327|FG000|Overall Study|Withdrawal by Subject|36
6301907|NCT02546323|10026328|FG001|Overall Study|Withdrawal by Subject|33
6301908|NCT02546323|10026327|FG000|Overall Study|Eligibility Criteria not Fulfilled|0
6301909|NCT02546323|10026328|FG001|Overall Study|Eligibility Criteria not Fulfilled|1
6301910|NCT02546323|10026327|FG000|Overall Study|Adverse Event|17
6301911|NCT02546323|10026328|FG001|Overall Study|Adverse Event|11
6301912|NCT02546323|10026327|FG000|Overall Study|Patient Specific Reasons|1
6301913|NCT02546323|10026328|FG001|Overall Study|Patient Specific Reasons|2
6301914|NCT02546323|10026327|FG000|Overall Study|Lost to Follow-up|2
6301915|NCT02546323|10026328|FG001|Overall Study|Lost to Follow-up|3
6301916|NCT02546323|10026327|FG000|Overall Study|Non-compliance with Study Drug|2
6301917|NCT02546323|10026328|FG001|Overall Study|Non-compliance with Study Drug|2
6301918|NCT02546323|10026327|FG000|Overall Study|Met Withdrawal Criteria|2
6301919|NCT02546323|10026328|FG001|Overall Study|Met Withdrawal Criteria|14
6301920|NCT02546362|10026334|FG000|4-week Treatment Period|Lost to Follow-up|1
6301921|NCT02546362|10026334|FG000|4-week Treatment Period|Change in medication|2
6301922|NCT02546362|10026334|FG000|12-week Treatment Period|Withdrawal by Subject|6
6301923|NCT02546362|10026334|FG000|12-week Treatment Period|Lost to Follow-up|2
6301924|NCT02546362|10026334|FG000|12-week Treatment Period|Change in medication|1
6301925|NCT02546544|10026352|FG000|Overall Study|Disease Progression|14
6301926|NCT02546544|10026352|FG000|Overall Study|Adverse Event|1
6301927|NCT02546544|10026352|FG000|Overall Study|Withdrawal by Subject|1
6301928|NCT02546609|10026372|FG000|Overall Study|Withdrawal by Subject|0
6301929|NCT02546609|10026373|FG001|Overall Study|Withdrawal by Subject|1
6301930|NCT02546609|10026374|FG002|Overall Study|Withdrawal by Subject|2
6301931|NCT02546609|10026372|FG000|Overall Study|Adverse Event|0
6301932|NCT02546609|10026373|FG001|Overall Study|Adverse Event|6
6301933|NCT02546609|10026374|FG002|Overall Study|Adverse Event|1
6301934|NCT02546609|10026372|FG000|Overall Study|Protocol Violation|0
6301935|NCT02546609|10026373|FG001|Overall Study|Protocol Violation|1
6301936|NCT02546609|10026374|FG002|Overall Study|Protocol Violation|1
6301937|NCT02546609|10026372|FG000|Overall Study|Lost to Follow-up|2
6301938|NCT02546609|10026373|FG001|Overall Study|Lost to Follow-up|3
6301939|NCT02546609|10026374|FG002|Overall Study|Lost to Follow-up|1
6301940|NCT02546609|10026372|FG000|Overall Study|travel or work schedule restriction|0
6301941|NCT02546609|10026373|FG001|Overall Study|travel or work schedule restriction|0
6301942|NCT02546609|10026374|FG002|Overall Study|travel or work schedule restriction|2
6301943|NCT02546765|10026386|FG000|Overall Study|Withdrawal by Subject|0
6301944|NCT02546765|10026387|FG001|Overall Study|Withdrawal by Subject|1
6301945|NCT02546765|10026388|FG002|Overall Study|Withdrawal by Subject|0
6301946|NCT02546765|10026389|FG003|Overall Study|Withdrawal by Subject|0
6301947|NCT02546856|10026412|FG000|4 Months Evaluation|Death|2
6301948|NCT02546856|10026413|FG001|4 Months Evaluation|Death|3
6301949|NCT02546856|10026412|FG000|4 Months Evaluation|Withdrawal by Subject|2
6301950|NCT02546856|10026413|FG001|4 Months Evaluation|Withdrawal by Subject|3
6301951|NCT02546856|10026412|FG000|4 Months Evaluation|Lost to Follow-up|3
6301952|NCT02546856|10026413|FG001|4 Months Evaluation|Lost to Follow-up|3
6301953|NCT02546856|10026412|FG000|4 Months Evaluation|Physician Decision|3
6301954|NCT02546856|10026413|FG001|4 Months Evaluation|Physician Decision|0
6301955|NCT02546856|10026412|FG000|4 Months Evaluation|Working or living abroad|5
6301956|NCT02546856|10026413|FG001|4 Months Evaluation|Working or living abroad|1
6301957|NCT02546856|10026412|FG000|4 Months Evaluation|reasons not due to titration|4
6301958|NCT02546856|10026413|FG001|4 Months Evaluation|reasons not due to titration|1
6301959|NCT02546856|10026412|FG000|4 Months Evaluation|HF Unit not active in summer|1
6301960|NCT02546856|10026413|FG001|4 Months Evaluation|HF Unit not active in summer|0
6301961|NCT02546856|10026412|FG000|6 Months Evaluation|Death|1
6301962|NCT02546856|10026413|FG001|6 Months Evaluation|Death|1
6301963|NCT02546856|10026412|FG000|6 Months Evaluation|Lost to Follow-up|1
6301964|NCT02546856|10026413|FG001|6 Months Evaluation|Lost to Follow-up|1
6301965|NCT02546856|10026412|FG000|6 Months Evaluation|Working or living abroad|6
6301966|NCT02546856|10026413|FG001|6 Months Evaluation|Working or living abroad|4
6301967|NCT02546856|10026412|FG000|6 Months Evaluation|reasons not due to titration|0
6301968|NCT02546856|10026413|FG001|6 Months Evaluation|reasons not due to titration|1
6301969|NCT02547038|10026442|FG000|Overall Study|Lost to Follow-up|3
6301970|NCT02547038|10026443|FG001|Overall Study|Lost to Follow-up|2
6301971|NCT02547220|10026460|FG000|Overall Study|Withdrawal by Subject|1
6301972|NCT02547220|10026461|FG001|Overall Study|Withdrawal by Subject|0
6301973|NCT02547220|10026460|FG000|Overall Study|Study terminated by sponsor|18
6301974|NCT02547220|10026461|FG001|Overall Study|Study terminated by sponsor|20
6301975|NCT02547233|10026469|FG000|3-day Treatment and 8-week Follow-up|Adverse Event|1
6301976|NCT02547233|10026470|FG001|3-day Treatment and 8-week Follow-up|Adverse Event|0
6301977|NCT02547233|10026469|FG000|3-day Treatment and 8-week Follow-up|Unacceptable Local Skin Response|1
6301978|NCT02547233|10026470|FG001|3-day Treatment and 8-week Follow-up|Unacceptable Local Skin Response|0
6301979|NCT02547233|10026469|FG000|3-day Treatment and 8-week Follow-up|Withdrawal by Subject|0
6301980|NCT02547233|10026470|FG001|3-day Treatment and 8-week Follow-up|Withdrawal by Subject|9
6301981|NCT02547233|10026469|FG000|3-day Treatment and 8-week Follow-up|Lost to Follow-up|0
6301982|NCT02547233|10026470|FG001|3-day Treatment and 8-week Follow-up|Lost to Follow-up|1
6301983|NCT02547233|10026469|FG000|12-month Follow-up|Withdrawal by Subject|10
6301984|NCT02547233|10026470|FG001|12-month Follow-up|Withdrawal by Subject|10
6301985|NCT02547233|10026469|FG000|12-month Follow-up|Lost to Follow-up|3
6301986|NCT02547233|10026470|FG001|12-month Follow-up|Lost to Follow-up|3
6301987|NCT02547233|10026469|FG000|12-month Follow-up|Lack of Efficacy|1
6301988|NCT02547233|10026470|FG001|12-month Follow-up|Lack of Efficacy|2
6301989|NCT02547233|10026469|FG000|12-month Follow-up|Protocol Violation|0
6301990|NCT02547233|10026470|FG001|12-month Follow-up|Protocol Violation|1
6301991|NCT02547233|10026469|FG000|12-month Follow-up|Other|0
6301992|NCT02547233|10026470|FG001|12-month Follow-up|Other|1
6301993|NCT02547363|10026480|FG000|3-day Treatment and 8-week Follow-up|Adverse Event|0
6301994|NCT02547363|10026481|FG001|3-day Treatment and 8-week Follow-up|Adverse Event|1
6301995|NCT02547363|10026480|FG000|3-day Treatment and 8-week Follow-up|Withdrawal by Subject|2
6301996|NCT02547363|10026481|FG001|3-day Treatment and 8-week Follow-up|Withdrawal by Subject|8
6301997|NCT02547363|10026480|FG000|3-day Treatment and 8-week Follow-up|Lost to Follow-up|1
6301998|NCT02547363|10026481|FG001|3-day Treatment and 8-week Follow-up|Lost to Follow-up|1
6301999|NCT02547363|10026480|FG000|3-day Treatment and 8-week Follow-up|Other|1
6302000|NCT02547363|10026481|FG001|3-day Treatment and 8-week Follow-up|Other|1
6302001|NCT02547363|10026480|FG000|12-month Follow-up|Withdrawal by Subject|4
6302002|NCT02547363|10026481|FG001|12-month Follow-up|Withdrawal by Subject|3
6302003|NCT02547363|10026480|FG000|12-month Follow-up|Lost to Follow-up|4
6302004|NCT02547363|10026481|FG001|12-month Follow-up|Lost to Follow-up|1
6302005|NCT02547363|10026480|FG000|12-month Follow-up|Lack of Efficacy|1
6302006|NCT02547363|10026481|FG001|12-month Follow-up|Lack of Efficacy|1
6302007|NCT02547363|10026480|FG000|12-month Follow-up|Other|1
6302008|NCT02547363|10026481|FG001|12-month Follow-up|Other|0
6302009|NCT02547428|10026491|FG000|Period 1- Treatment Sequence 1 (3 Weeks)|Adverse Event|8
6302010|NCT02547428|10026492|FG001|Period 1- Treatment Sequence 1 (3 Weeks)|Adverse Event|1
6302011|NCT02547428|10026491|FG000|Period 1- Treatment Sequence 1 (3 Weeks)|Lost to Follow-up|1
6302012|NCT02547428|10026492|FG001|Period 1- Treatment Sequence 1 (3 Weeks)|Lost to Follow-up|1
6302013|NCT02547428|10026491|FG000|Period 1- Treatment Sequence 1 (3 Weeks)|Withdrawal by Subject|1
6302014|NCT02547428|10026492|FG001|Period 1- Treatment Sequence 1 (3 Weeks)|Withdrawal by Subject|1
6302015|NCT02547428|10026491|FG000|Period 1- Treatment Sequence 1 (3 Weeks)|Dosing Suspension|1
6302016|NCT02547428|10026492|FG001|Period 1- Treatment Sequence 1 (3 Weeks)|Dosing Suspension|3
6302017|NCT02547428|10026491|FG000|Period 2- Treatment Sequence 2 (3 Weeks)|Adverse Event|0
6302018|NCT02547428|10026492|FG001|Period 2- Treatment Sequence 2 (3 Weeks)|Adverse Event|3
6302019|NCT02547428|10026491|FG000|Period 2- Treatment Sequence 2 (3 Weeks)|Lost to Follow-up|0
6302020|NCT02547428|10026492|FG001|Period 2- Treatment Sequence 2 (3 Weeks)|Lost to Follow-up|3
6302021|NCT02547428|10026491|FG000|Period 2- Treatment Sequence 2 (3 Weeks)|Withdrawal by Subject|0
6302022|NCT02547428|10026492|FG001|Period 2- Treatment Sequence 2 (3 Weeks)|Withdrawal by Subject|1
6302023|NCT02547428|10026491|FG000|Period 2- Treatment Sequence 2 (3 Weeks)|Investigator Discretion|1
6302024|NCT02547428|10026492|FG001|Period 2- Treatment Sequence 2 (3 Weeks)|Investigator Discretion|0
6302025|NCT02547454|10026505|FG000|Overall Study|Due to hemodialysis|53
6302026|NCT02547454|10026505|FG000|Overall Study|Due to transplantation|1
6302027|NCT02547454|10026505|FG000|Overall Study|Due to no further need to treat|4
6302028|NCT02547454|10026505|FG000|Overall Study|Death|38
6302029|NCT02547454|10026505|FG000|Overall Study|Lost to Follow-up|26
6302030|NCT02547454|10026505|FG000|Overall Study|Other|39
6302031|NCT02547454|10026505|FG000|Overall Study|No data|11
6302032|NCT02547649|10026521|FG000|Overall Study|Lost to Follow-up|3
6302033|NCT02547649|10026522|FG001|Overall Study|Lost to Follow-up|1
6302034|NCT02547649|10026523|FG002|Overall Study|Lost to Follow-up|1
6302035|NCT02547649|10026521|FG000|Overall Study|Not vaccinated|0
6302036|NCT02547649|10026522|FG001|Overall Study|Not vaccinated|0
6302037|NCT02547649|10026523|FG002|Overall Study|Not vaccinated|1
6302038|NCT02547649|10026521|FG000|Overall Study|Withdrawal by Subject|0
6302039|NCT02547649|10026522|FG001|Overall Study|Withdrawal by Subject|4
6302040|NCT02547649|10026523|FG002|Overall Study|Withdrawal by Subject|2
6302041|NCT02547766|10026536|FG000|Overall Study|Withdrawal by Subject|1
6302042|NCT02547922|10026552|FG000|Overall Study|Withdrawal by Subject|9
6302043|NCT02547922|10026553|FG001|Overall Study|Withdrawal by Subject|6
6302044|NCT02547922|10026554|FG002|Overall Study|Withdrawal by Subject|10
6302045|NCT02547922|10026552|FG000|Overall Study|Adverse Event|3
6302046|NCT02547922|10026553|FG001|Overall Study|Adverse Event|1
6302047|NCT02547922|10026554|FG002|Overall Study|Adverse Event|2
6302048|NCT02547922|10026552|FG000|Overall Study|Lost to Follow-up|1
6302049|NCT02547922|10026553|FG001|Overall Study|Lost to Follow-up|0
6302050|NCT02547922|10026554|FG002|Overall Study|Lost to Follow-up|0
6302051|NCT02547922|10026552|FG000|Overall Study|Lack of Efficacy|5
6302052|NCT02547922|10026553|FG001|Overall Study|Lack of Efficacy|7
6302053|NCT02547922|10026554|FG002|Overall Study|Lack of Efficacy|4
6302054|NCT02547922|10026552|FG000|Overall Study|Death|1
6302055|NCT02547922|10026553|FG001|Overall Study|Death|0
6302056|NCT02547922|10026554|FG002|Overall Study|Death|0
6302057|NCT02547922|10026552|FG000|Overall Study|Non-responding completer, Not eligible for extension study, Use of any restricted Medications|4
6302058|NCT02547922|10026553|FG001|Overall Study|Non-responding completer, Not eligible for extension study, Use of any restricted Medications|8
6302059|NCT02547922|10026554|FG002|Overall Study|Non-responding completer, Not eligible for extension study, Use of any restricted Medications|9
6302060|NCT02547922|10026552|FG000|Overall Study|TECHNICAL PROBLEMS|1
6302061|NCT02547922|10026553|FG001|Overall Study|TECHNICAL PROBLEMS|0
6302062|NCT02547922|10026554|FG002|Overall Study|TECHNICAL PROBLEMS|0
6302063|NCT02547922|10026552|FG000|Overall Study|PROGRESSIVE DISEASE|1
6302064|NCT02547922|10026553|FG001|Overall Study|PROGRESSIVE DISEASE|0
6302065|NCT02547922|10026554|FG002|Overall Study|PROGRESSIVE DISEASE|2
6302066|NCT02547922|10026552|FG000|Overall Study|Physician Decision|2
6302067|NCT02547922|10026553|FG001|Overall Study|Physician Decision|1
6302068|NCT02547922|10026554|FG002|Overall Study|Physician Decision|2
6302069|NCT02547922|10026552|FG000|Overall Study|Patients did not receive IP|1
6302070|NCT02547922|10026553|FG001|Overall Study|Patients did not receive IP|1
6302071|NCT02547922|10026554|FG002|Overall Study|Patients did not receive IP|0
6302072|NCT02547935|10026571|FG000|Overall Study|Other|0
6302073|NCT02547935|10026572|FG001|Overall Study|Other|1
6302074|NCT02547935|10026573|FG002|Overall Study|Other|0
6302075|NCT02547935|10026571|FG000|Overall Study|Withdrawal by Subject|2
6302076|NCT02547935|10026572|FG001|Overall Study|Withdrawal by Subject|3
6302077|NCT02547935|10026573|FG002|Overall Study|Withdrawal by Subject|4
6302078|NCT02547935|10026571|FG000|Overall Study|Screen Failure|2
6302079|NCT02547935|10026572|FG001|Overall Study|Screen Failure|0
6302080|NCT02547935|10026573|FG002|Overall Study|Screen Failure|0
6302081|NCT02547935|10026571|FG000|Overall Study|Physician Decision|0
6302082|NCT02547935|10026572|FG001|Overall Study|Physician Decision|1
6302083|NCT02547935|10026573|FG002|Overall Study|Physician Decision|0
6302084|NCT02547935|10026571|FG000|Overall Study|Lost to Follow-up|0
6302085|NCT02547935|10026572|FG001|Overall Study|Lost to Follow-up|2
6302086|NCT02547935|10026573|FG002|Overall Study|Lost to Follow-up|1
6302087|NCT02547935|10026571|FG000|Overall Study|Death|1
6302088|NCT02547935|10026572|FG001|Overall Study|Death|1
6302089|NCT02547935|10026573|FG002|Overall Study|Death|0
6302090|NCT02547974|10026587|FG000|Overall Study|Withdrawal by Subject|1
6302091|NCT02547974|10026588|FG001|Overall Study|Withdrawal by Subject|0
6302092|NCT02547974|10026589|FG002|Overall Study|Withdrawal by Subject|0
6302093|NCT02547974|10026590|FG003|Overall Study|Withdrawal by Subject|0
6302094|NCT02547987|10026603|FG000|Overall Study|Withdrawal by Subject|1
6302095|NCT02547987|10026603|FG000|Overall Study|Adverse Event|2
6302096|NCT02548078|10026609|FG000|Overall Study|Serious adverse event/Adverse event|1
6302097|NCT02548078|10026610|FG001|Overall Study|Serious adverse event/Adverse event|0
6302098|NCT02548078|10026609|FG000|Overall Study|Moved from study area|3
6302099|NCT02548078|10026610|FG001|Overall Study|Moved from study area|3
6302100|NCT02548078|10026609|FG000|Overall Study|Lost to Follow-up|1
6302101|NCT02548078|10026610|FG001|Overall Study|Lost to Follow-up|3
6302102|NCT02548156|10026623|FG000|Washout Period 1|Lost to Follow-up|0
6302103|NCT02548156|10026624|FG001|Washout Period 1|Lost to Follow-up|0
6302104|NCT02548156|10026625|FG002|Washout Period 1|Lost to Follow-up|0
6302105|NCT02548156|10026626|FG003|Washout Period 1|Lost to Follow-up|0
6302106|NCT02548156|10026627|FG004|Washout Period 1|Lost to Follow-up|1
6302107|NCT02548156|10026628|FG005|Washout Period 1|Lost to Follow-up|0
6302108|NCT02548455|10026669|FG000|Overall Study|Withdrawal by Subject|27
6302109|NCT02548455|10026669|FG000|Overall Study|Death|26
6302110|NCT02548455|10026669|FG000|Overall Study|Lost to Follow-up|14
6302111|NCT02548455|10026669|FG000|Overall Study|Visit not completed|173
6302112|NCT02548585|10026680|FG000|Overall Study|Withdrawal by Subject|0
6302113|NCT02548585|10026681|FG001|Overall Study|Withdrawal by Subject|0
6302114|NCT02548585|10026682|FG002|Overall Study|Withdrawal by Subject|0
6302115|NCT02548585|10026683|FG003|Overall Study|Withdrawal by Subject|0
6302116|NCT02548585|10026684|FG004|Overall Study|Withdrawal by Subject|0
6302117|NCT02548585|10026685|FG005|Overall Study|Withdrawal by Subject|1
6302118|NCT02548585|10026686|FG006|Overall Study|Withdrawal by Subject|0
6302119|NCT02548585|10026680|FG000|Overall Study|Lost to Follow-up|1
6302120|NCT02548585|10026681|FG001|Overall Study|Lost to Follow-up|0
6302121|NCT02548585|10026682|FG002|Overall Study|Lost to Follow-up|0
6302122|NCT02548585|10026683|FG003|Overall Study|Lost to Follow-up|0
6302123|NCT02548585|10026684|FG004|Overall Study|Lost to Follow-up|0
6302124|NCT02548585|10026685|FG005|Overall Study|Lost to Follow-up|0
6302125|NCT02548585|10026686|FG006|Overall Study|Lost to Follow-up|0
6302126|NCT02548585|10026680|FG000|Overall Study|Other|1
6302127|NCT02548585|10026681|FG001|Overall Study|Other|0
5982286|NCT04203667|9571283|FG000|Overall Study|Withdrawal by Subject|1
5982287|NCT04203667|9571283|FG000|Overall Study|Lost to Follow-up|1
5982288|NCT04203667|9571283|FG000|Overall Study|Death|1
5982289|NCT04203667|9571283|FG000|Overall Study|PI left center and never scheduled 90 day follow-up visit.|1
6063707|NCT00507442|9665009|FG001|Overall Study|Other|5
6063708|NCT00507442|9665010|FG002|Overall Study|Other|2
6063709|NCT00507442|9665011|FG003|Overall Study|Other|2
6063710|NCT00507455|9665028|FG000|Overall Study|Adverse Event|3
6063711|NCT00507455|9665029|FG001|Overall Study|Adverse Event|3
6063712|NCT00507455|9665030|FG002|Overall Study|Adverse Event|6
6063713|NCT00507455|9665028|FG000|Overall Study|Withdrawal by Subject|2
6063714|NCT00507455|9665029|FG001|Overall Study|Withdrawal by Subject|1
6063715|NCT00507455|9665030|FG002|Overall Study|Withdrawal by Subject|2
6063716|NCT00507455|9665028|FG000|Overall Study|Protocol Violation|4
6063717|NCT00507455|9665029|FG001|Overall Study|Protocol Violation|1
6063718|NCT00507455|9665030|FG002|Overall Study|Protocol Violation|1
6063719|NCT00507455|9665028|FG000|Overall Study|Lost to Follow-up|2
6063720|NCT00507455|9665029|FG001|Overall Study|Lost to Follow-up|0
6063721|NCT00507455|9665030|FG002|Overall Study|Lost to Follow-up|2
6063722|NCT00507455|9665028|FG000|Overall Study|Lack of Efficacy|0
6063723|NCT00507455|9665029|FG001|Overall Study|Lack of Efficacy|1
6063724|NCT00507455|9665030|FG002|Overall Study|Lack of Efficacy|0
6063725|NCT00507455|9665028|FG000|Overall Study|Other - miscellaneous reason|1
6063726|NCT00507455|9665029|FG001|Overall Study|Other - miscellaneous reason|0
6063727|NCT00507455|9665030|FG002|Overall Study|Other - miscellaneous reason|1
6063728|NCT00507507|9665040|FG000|Treatment Period|Lost to Follow-up|0
6063729|NCT00507507|9665041|FG001|Treatment Period|Lost to Follow-up|2
6063730|NCT00507507|9665040|FG000|Treatment Period|Physician Decision|4
6063731|NCT00507507|9665041|FG001|Treatment Period|Physician Decision|1
6063732|NCT00507507|9665040|FG000|Treatment Period|Protocol Violation|1
6063733|NCT00507507|9665041|FG001|Treatment Period|Protocol Violation|2
6063734|NCT00507507|9665040|FG000|Treatment Period|Adverse Event|1
6063735|NCT00507507|9665041|FG001|Treatment Period|Adverse Event|1
6063736|NCT00507507|9665040|FG000|Treatment Period|Withdrawal by Subject|46
6063737|NCT00507507|9665041|FG001|Treatment Period|Withdrawal by Subject|47
6063738|NCT00507507|9665040|FG000|24-week Treatment-free Follow-up Period|Physician Decision|1
6063739|NCT00507507|9665041|FG001|24-week Treatment-free Follow-up Period|Physician Decision|0
6063740|NCT00507507|9665040|FG000|24-week Treatment-free Follow-up Period|Adverse Event|0
6063741|NCT00507507|9665041|FG001|24-week Treatment-free Follow-up Period|Adverse Event|1
6063742|NCT00507507|9665040|FG000|24-week Treatment-free Follow-up Period|Withdrawal by Subject|9
6063743|NCT00507507|9665041|FG001|24-week Treatment-free Follow-up Period|Withdrawal by Subject|16
6063744|NCT00507546|9665051|FG000|Overall Study|Withdrawal by Subject|1
6063745|NCT00507546|9665052|FG001|Overall Study|Withdrawal by Subject|0
6063746|NCT00507546|9665051|FG000|Overall Study|Protocol Violation|1
6063747|NCT00507546|9665052|FG001|Overall Study|Protocol Violation|0
6063748|NCT00507546|9665051|FG000|Overall Study|Physician Decision|0
6063749|NCT00507546|9665052|FG001|Overall Study|Physician Decision|1
6063750|NCT00507689|9665067|FG000|Pre-Randomization Period|Adverse Event|1
6063751|NCT00507689|9665068|FG001|Pre-Randomization Period|Adverse Event|0
6063752|NCT00507689|9665067|FG000|Pre-Randomization Period|Physician Decision|1
6063753|NCT00507689|9665068|FG001|Pre-Randomization Period|Physician Decision|0
6063754|NCT00507689|9665067|FG000|Pre-Randomization Period|Withdrawal by Subject|1
6063755|NCT00507689|9665068|FG001|Pre-Randomization Period|Withdrawal by Subject|0
6063756|NCT00507689|9665067|FG000|Randomized Period|Adverse Event|1
6302128|NCT02548585|10026682|FG002|Overall Study|Other|0
6302129|NCT02548585|10026683|FG003|Overall Study|Other|2
6302130|NCT02548585|10026684|FG004|Overall Study|Other|3
6302131|NCT02548585|10026685|FG005|Overall Study|Other|0
6302132|NCT02548585|10026686|FG006|Overall Study|Other|1
6302133|NCT02548585|10026680|FG000|Overall Study|Randomized but not treated|0
6302134|NCT02548585|10026681|FG001|Overall Study|Randomized but not treated|0
6302135|NCT02548585|10026682|FG002|Overall Study|Randomized but not treated|0
6302136|NCT02548585|10026683|FG003|Overall Study|Randomized but not treated|0
6302137|NCT02548585|10026684|FG004|Overall Study|Randomized but not treated|0
6302138|NCT02548585|10026685|FG005|Overall Study|Randomized but not treated|1
6302139|NCT02548585|10026686|FG006|Overall Study|Randomized but not treated|0
6302140|NCT02548650|10026729|FG000|Triple Therapy|Adverse Event|1
6302141|NCT02548650|10026730|FG001|Triple Therapy|Adverse Event|0
6302142|NCT02548650|10026729|FG000|Triple Therapy|Withdrawal by Subject|0
6302143|NCT02548650|10026730|FG001|Triple Therapy|Withdrawal by Subject|4
6302144|NCT02548650|10026729|FG000|Double Therapy|Adverse Event|1
6302145|NCT02548650|10026730|FG001|Double Therapy|Adverse Event|1
6302146|NCT02548650|10026729|FG000|Double Therapy|Withdrawal by Subject|0
6302147|NCT02548650|10026730|FG001|Double Therapy|Withdrawal by Subject|1
6302148|NCT02548962|10026769|FG000|Overall Study|Withdrawal by Subject|1
6302149|NCT02548962|10026770|FG001|Overall Study|Withdrawal by Subject|0
6302150|NCT02549027|10026805|FG000|Washout After Period 4|Withdrawal by Subject|0
6302151|NCT02549027|10026806|FG001|Washout After Period 4|Withdrawal by Subject|1
6302152|NCT02549027|10026807|FG002|Washout After Period 4|Withdrawal by Subject|1
6302153|NCT02549027|10026808|FG003|Washout After Period 4|Withdrawal by Subject|1
6302154|NCT02549027|10026809|FG004|Washout After Period 4|Withdrawal by Subject|0
6302155|NCT02549027|10026810|FG005|Washout After Period 4|Withdrawal by Subject|0
6302156|NCT02549027|10026805|FG000|Period 5 - MK-6096 or Placebo|Protocol Violation|0
6302157|NCT02549027|10026806|FG001|Period 5 - MK-6096 or Placebo|Protocol Violation|0
6302158|NCT02549027|10026807|FG002|Period 5 - MK-6096 or Placebo|Protocol Violation|0
6302159|NCT02549027|10026808|FG003|Period 5 - MK-6096 or Placebo|Protocol Violation|0
6302160|NCT02549027|10026809|FG004|Period 5 - MK-6096 or Placebo|Protocol Violation|2
6302161|NCT02549027|10026810|FG005|Period 5 - MK-6096 or Placebo|Protocol Violation|0
6302162|NCT02549196|10026841|FG000|Overall Study|Protocol Violation|0
6302163|NCT02549196|10026842|FG001|Overall Study|Protocol Violation|0
6302164|NCT02549196|10026843|FG002|Overall Study|Protocol Violation|0
6302165|NCT02549196|10026844|FG003|Overall Study|Protocol Violation|1
6302166|NCT02549196|10026841|FG000|Overall Study|Withdrawal by Subject|1
6302167|NCT02549196|10026842|FG001|Overall Study|Withdrawal by Subject|0
6302168|NCT02549196|10026843|FG002|Overall Study|Withdrawal by Subject|1
6302169|NCT02549196|10026844|FG003|Overall Study|Withdrawal by Subject|0
6302170|NCT02549287|10026856|FG000|Overall Study|Lost to Follow-up|65
6302171|NCT02549287|10026857|FG001|Overall Study|Lost to Follow-up|26
6302172|NCT02549287|10026856|FG000|Overall Study|Withdrawal by Subject|15
6302173|NCT02549287|10026857|FG001|Overall Study|Withdrawal by Subject|6
6302174|NCT02549339|10026865|FG000|3-day Treatment and 8-week Follow-up|Protocol Violation|2
6302175|NCT02549339|10026866|FG001|3-day Treatment and 8-week Follow-up|Protocol Violation|0
6302176|NCT02549339|10026865|FG000|3-day Treatment and 8-week Follow-up|Withdrawal by Subject|1
6302177|NCT02549339|10026866|FG001|3-day Treatment and 8-week Follow-up|Withdrawal by Subject|3
6302178|NCT02549339|10026865|FG000|3-day Treatment and 8-week Follow-up|Other|1
6302179|NCT02549339|10026866|FG001|3-day Treatment and 8-week Follow-up|Other|0
6302180|NCT02549339|10026865|FG000|3-day Treatment and 8-week Follow-up|Lost to Follow-up|0
6302181|NCT02549339|10026866|FG001|3-day Treatment and 8-week Follow-up|Lost to Follow-up|2
6302182|NCT02549339|10026865|FG000|12-month Follow-up|Lack of Efficacy|0
6302183|NCT02549339|10026866|FG001|12-month Follow-up|Lack of Efficacy|2
6302184|NCT02549339|10026865|FG000|12-month Follow-up|Withdrawal by Subject|8
6302185|NCT02549339|10026866|FG001|12-month Follow-up|Withdrawal by Subject|3
6302186|NCT02549339|10026865|FG000|12-month Follow-up|Lost to Follow-up|1
6302187|NCT02549339|10026866|FG001|12-month Follow-up|Lost to Follow-up|3
6302188|NCT02549339|10026865|FG000|12-month Follow-up|Other|0
6302189|NCT02549339|10026866|FG001|12-month Follow-up|Other|3
6302190|NCT02549352|10026876|FG000|3-day Treatment and 8-week Follow-up|Adverse Event|0
6302191|NCT02549352|10026877|FG001|3-day Treatment and 8-week Follow-up|Adverse Event|1
6302192|NCT02549352|10026876|FG000|3-day Treatment and 8-week Follow-up|Withdrawal by Subject|2
6302193|NCT02549352|10026877|FG001|3-day Treatment and 8-week Follow-up|Withdrawal by Subject|3
6302194|NCT02549352|10026876|FG000|3-day Treatment and 8-week Follow-up|Other|0
6302195|NCT02549352|10026877|FG001|3-day Treatment and 8-week Follow-up|Other|2
6302196|NCT02549352|10026876|FG000|12-month Follow-up|Withdrawal by Subject|4
6302197|NCT02549352|10026877|FG001|12-month Follow-up|Withdrawal by Subject|5
6302198|NCT02549352|10026876|FG000|12-month Follow-up|Lost to Follow-up|3
6302199|NCT02549352|10026877|FG001|12-month Follow-up|Lost to Follow-up|2
6302200|NCT02549352|10026876|FG000|12-month Follow-up|Death|0
6302201|NCT02549352|10026877|FG001|12-month Follow-up|Death|1
6302202|NCT02549352|10026876|FG000|12-month Follow-up|Protocol Violation|0
6302203|NCT02549352|10026877|FG001|12-month Follow-up|Protocol Violation|1
6302204|NCT02549352|10026876|FG000|12-month Follow-up|Other|1
6302205|NCT02549352|10026877|FG001|12-month Follow-up|Other|3
6302206|NCT02549573|10026907|FG000|Overall Study|Withdrawal by Subject|0
6302207|NCT02549573|10026908|FG001|Overall Study|Withdrawal by Subject|2
6302208|NCT02549573|10026907|FG000|Overall Study|Protocol Violation|0
6302209|NCT02549573|10026908|FG001|Overall Study|Protocol Violation|1
6302210|NCT02549859|10026914|FG000|Long-term 60 Hz DBS|Study Closed|1
6302211|NCT02550106|10026922|FG000|Overall Study|Adverse Event|1
6302212|NCT02550106|10026922|FG000|Overall Study|Lack of Efficacy|3
6302213|NCT02550106|10026922|FG000|Overall Study|Protocol Violation|6
6302214|NCT02550106|10026922|FG000|Overall Study|Withdrawal by Subject|2
6302215|NCT02550795|10026957|FG000|Overall Study|Physician Decision|0
6302216|NCT02550795|10026958|FG001|Overall Study|Physician Decision|1
6302217|NCT02550795|10026959|FG002|Overall Study|Physician Decision|0
6302218|NCT02550938|10026971|FG000|Overall Study|Lost to Follow-up|8
6302219|NCT02550938|10026972|FG001|Overall Study|Lost to Follow-up|7
6063757|NCT00507689|9665068|FG001|Randomized Period|Adverse Event|1
6063758|NCT00507689|9665067|FG000|Randomized Period|Withdrawal by Subject|0
6063759|NCT00507689|9665068|FG001|Randomized Period|Withdrawal by Subject|1
6063760|NCT00507728|9665078|FG000|Randomization to Month 3|Lost to Follow-up|15
6063761|NCT00507728|9665079|FG001|Randomization to Month 3|Lost to Follow-up|14
6063762|NCT00507728|9665080|FG002|Randomization to Month 3|Lost to Follow-up|20
6063763|NCT00507728|9665078|FG000|From 3 Months to 6 Months|Lost to Follow-up|6
6063764|NCT00507728|9665079|FG001|From 3 Months to 6 Months|Lost to Follow-up|10
6063765|NCT00507728|9665080|FG002|From 3 Months to 6 Months|Lost to Follow-up|9
6063766|NCT00507819|9665098|FG000|Washout (6 Weeks)|Withdrawal by Subject|1
6063767|NCT00507819|9665099|FG001|Washout (6 Weeks)|Withdrawal by Subject|0
6063768|NCT00508001|9665108|FG000|Overall Study|Adverse Event|2
6063769|NCT00508001|9665109|FG001|Overall Study|Adverse Event|0
6063770|NCT00508001|9665110|FG002|Overall Study|Adverse Event|4
6063771|NCT00508001|9665108|FG000|Overall Study|condition under investigation worsened|13
6063772|NCT00508001|9665109|FG001|Overall Study|condition under investigation worsened|7
6063773|NCT00508001|9665110|FG002|Overall Study|condition under investigation worsened|1
6136951|NCT01005251|9767094|FG001|Overall Study|Withdrawal by Subject|5
6136952|NCT01005251|9767095|FG002|Overall Study|Withdrawal by Subject|3
6136953|NCT01005251|9767096|FG003|Overall Study|Withdrawal by Subject|4
6136954|NCT01005251|9767097|FG004|Overall Study|Withdrawal by Subject|9
6136955|NCT01005251|9767093|FG000|Overall Study|Eligibility criteria not fulfilled|4
6136956|NCT01005251|9767094|FG001|Overall Study|Eligibility criteria not fulfilled|0
6136957|NCT01005251|9767095|FG002|Overall Study|Eligibility criteria not fulfilled|4
6136958|NCT01005251|9767096|FG003|Overall Study|Eligibility criteria not fulfilled|1
6136959|NCT01005251|9767097|FG004|Overall Study|Eligibility criteria not fulfilled|0
6136960|NCT01005251|9767093|FG000|Overall Study|Adverse Event|2
6136961|NCT01005251|9767094|FG001|Overall Study|Adverse Event|6
6136962|NCT01005251|9767095|FG002|Overall Study|Adverse Event|8
6136963|NCT01005251|9767096|FG003|Overall Study|Adverse Event|5
6136964|NCT01005251|9767097|FG004|Overall Study|Adverse Event|4
6136965|NCT01005251|9767093|FG000|Overall Study|Protocol Violation|1
6136966|NCT01005251|9767094|FG001|Overall Study|Protocol Violation|0
6136967|NCT01005251|9767095|FG002|Overall Study|Protocol Violation|0
6136968|NCT01005251|9767096|FG003|Overall Study|Protocol Violation|0
6136969|NCT01005251|9767097|FG004|Overall Study|Protocol Violation|2
6136970|NCT01005251|9767093|FG000|Overall Study|Developed study-specific withdrawal crit|2
6136971|NCT01005251|9767094|FG001|Overall Study|Developed study-specific withdrawal crit|0
6136972|NCT01005251|9767095|FG002|Overall Study|Developed study-specific withdrawal crit|3
6136973|NCT01005251|9767096|FG003|Overall Study|Developed study-specific withdrawal crit|0
6136974|NCT01005251|9767097|FG004|Overall Study|Developed study-specific withdrawal crit|1
6136975|NCT01005251|9767093|FG000|Overall Study|Lost to Follow-up|1
6136976|NCT01005251|9767094|FG001|Overall Study|Lost to Follow-up|4
6136977|NCT01005251|9767095|FG002|Overall Study|Lost to Follow-up|2
6136978|NCT01005251|9767096|FG003|Overall Study|Lost to Follow-up|0
6136979|NCT01005251|9767097|FG004|Overall Study|Lost to Follow-up|0
6136980|NCT01005251|9767093|FG000|Overall Study|Physician Decision|0
6136981|NCT01005251|9767094|FG001|Overall Study|Physician Decision|0
6136982|NCT01005251|9767095|FG002|Overall Study|Physician Decision|0
6136983|NCT01005251|9767096|FG003|Overall Study|Physician Decision|0
6136984|NCT01005251|9767097|FG004|Overall Study|Physician Decision|2
6136985|NCT01005251|9767093|FG000|Overall Study|Patient moved|1
6136986|NCT01005251|9767094|FG001|Overall Study|Patient moved|0
6136987|NCT01005251|9767095|FG002|Overall Study|Patient moved|0
6136988|NCT01005251|9767096|FG003|Overall Study|Patient moved|0
6136989|NCT01005251|9767097|FG004|Overall Study|Patient moved|0
6136990|NCT01005251|9767093|FG000|Overall Study|Wrong drug dispensed|0
6136991|NCT01005251|9767094|FG001|Overall Study|Wrong drug dispensed|1
6136992|NCT01005251|9767095|FG002|Overall Study|Wrong drug dispensed|0
6136993|NCT01005251|9767096|FG003|Overall Study|Wrong drug dispensed|0
6136994|NCT01005251|9767097|FG004|Overall Study|Wrong drug dispensed|0
6136995|NCT01005251|9767093|FG000|Overall Study|Randomized in error|0
6136996|NCT01005251|9767094|FG001|Overall Study|Randomized in error|0
6136997|NCT01005251|9767095|FG002|Overall Study|Randomized in error|1
6136998|NCT01005251|9767096|FG003|Overall Study|Randomized in error|1
6136999|NCT01005251|9767097|FG004|Overall Study|Randomized in error|0
6137000|NCT01005251|9767093|FG000|Overall Study|Lack of Efficacy|0
6137001|NCT01005251|9767094|FG001|Overall Study|Lack of Efficacy|0
6302220|NCT02550938|10026973|FG002|Overall Study|Lost to Follow-up|12
6302221|NCT02550938|10026974|FG003|Overall Study|Lost to Follow-up|11
6063774|NCT00508001|9665108|FG000|Overall Study|Death|0
6063775|NCT00508001|9665109|FG001|Overall Study|Death|1
6063776|NCT00508001|9665110|FG002|Overall Study|Death|1
6063777|NCT00508001|9665108|FG000|Overall Study|Withdrawal by Subject|4
6302222|NCT02551055|10026991|FG000|Overall Study|Death|2
6302223|NCT02551055|10026992|FG001|Overall Study|Death|4
6302224|NCT02551055|10026993|FG002|Overall Study|Death|2
6302225|NCT02551055|10026994|FG003|Overall Study|Death|2
6302226|NCT02551055|10026995|FG004|Overall Study|Death|2
6302227|NCT02551055|10026996|FG005|Overall Study|Death|1
6302228|NCT02551055|10026997|FG006|Overall Study|Death|2
6302229|NCT02551055|10026998|FG007|Overall Study|Death|0
6302230|NCT02551055|10026991|FG000|Overall Study|Study Terminated by Sponsor|1
6302231|NCT02551055|10026992|FG001|Overall Study|Study Terminated by Sponsor|1
6302232|NCT02551055|10026993|FG002|Overall Study|Study Terminated by Sponsor|0
6302233|NCT02551055|10026994|FG003|Overall Study|Study Terminated by Sponsor|2
6302234|NCT02551055|10026995|FG004|Overall Study|Study Terminated by Sponsor|2
6302235|NCT02551055|10026996|FG005|Overall Study|Study Terminated by Sponsor|0
6302236|NCT02551055|10026997|FG006|Overall Study|Study Terminated by Sponsor|0
6302237|NCT02551055|10026998|FG007|Overall Study|Study Terminated by Sponsor|0
6302238|NCT02551055|10026991|FG000|Overall Study|Withdrawal by Subject|1
6302239|NCT02551055|10026992|FG001|Overall Study|Withdrawal by Subject|1
6302240|NCT02551055|10026993|FG002|Overall Study|Withdrawal by Subject|0
6302241|NCT02551055|10026994|FG003|Overall Study|Withdrawal by Subject|1
6302242|NCT02551055|10026995|FG004|Overall Study|Withdrawal by Subject|2
6302243|NCT02551055|10026996|FG005|Overall Study|Withdrawal by Subject|0
6302244|NCT02551055|10026997|FG006|Overall Study|Withdrawal by Subject|0
6302245|NCT02551055|10026998|FG007|Overall Study|Withdrawal by Subject|0
6302246|NCT02551055|10026991|FG000|Overall Study|Reason not specified|0
6302247|NCT02551055|10026992|FG001|Overall Study|Reason not specified|0
6302248|NCT02551055|10026993|FG002|Overall Study|Reason not specified|0
6302249|NCT02551055|10026994|FG003|Overall Study|Reason not specified|0
6302250|NCT02551055|10026995|FG004|Overall Study|Reason not specified|1
6302251|NCT02551055|10026996|FG005|Overall Study|Reason not specified|0
6302252|NCT02551055|10026997|FG006|Overall Study|Reason not specified|1
6302253|NCT02551055|10026998|FG007|Overall Study|Reason not specified|0
6302254|NCT02551159|10027028|FG000|Overall Study|Death|352
6302255|NCT02551159|10027029|FG001|Overall Study|Death|174
6302256|NCT02551159|10027030|FG002|Overall Study|Death|161
6302257|NCT02551159|10027028|FG000|Overall Study|Withdrawal by Subject|8
6302258|NCT02551159|10027029|FG001|Overall Study|Withdrawal by Subject|5
6302259|NCT02551159|10027030|FG002|Overall Study|Withdrawal by Subject|16
6302260|NCT02551159|10027028|FG000|Overall Study|Patients alive or lost to follow-up at DCO|53
6302261|NCT02551159|10027029|FG001|Overall Study|Patients alive or lost to follow-up at DCO|25
6302262|NCT02551159|10027030|FG002|Overall Study|Patients alive or lost to follow-up at DCO|29
6302263|NCT02551666|10027060|FG000|Overall Study|Withdrawal by Subject|1
6302264|NCT02551666|10027061|FG001|Overall Study|Withdrawal by Subject|3
6302265|NCT02551692|10027070|FG000|Overall Study|Lost to Follow-up|0
6302266|NCT02551692|10027071|FG001|Overall Study|Lost to Follow-up|1
6302267|NCT02551692|10027072|FG002|Overall Study|Lost to Follow-up|4
6302268|NCT02551692|10027070|FG000|Overall Study|Withdrawal by Subject|1
6302269|NCT02551692|10027071|FG001|Overall Study|Withdrawal by Subject|0
6302270|NCT02551692|10027072|FG002|Overall Study|Withdrawal by Subject|1
6302271|NCT02551731|10027080|FG000|Overall Study|Withdrawal by Subject|2
6302272|NCT02551874|10027136|FG000|Overall Study|Lost to Follow-up|0
6302273|NCT02551874|10027137|FG001|Overall Study|Lost to Follow-up|2
6302274|NCT02551874|10027136|FG000|Overall Study|Pregnancy|0
6302275|NCT02551874|10027137|FG001|Overall Study|Pregnancy|1
6302276|NCT02551874|10027136|FG000|Overall Study|Reason not reported|10
6302277|NCT02551874|10027137|FG001|Overall Study|Reason not reported|4
6302278|NCT02551874|10027136|FG000|Overall Study|Did not receive randomized treatment|0
6302279|NCT02551874|10027137|FG001|Overall Study|Did not receive randomized treatment|7
6302280|NCT02551874|10027136|FG000|Overall Study|Did not enter long-term study|18
6302281|NCT02551874|10027137|FG001|Overall Study|Did not enter long-term study|25
6302282|NCT02552121|10027164|FG000|Part 1: Dose Level 1 (Weeks 1-16)|Disease Progression|2
6302283|NCT02552121|10027165|FG001|Part 1: Dose Level 1 (Weeks 1-16)|Disease Progression|0
6302284|NCT02552121|10027166|FG002|Part 1: Dose Level 1 (Weeks 1-16)|Disease Progression|0
5982290|NCT03679884|9571297|FG000|Overall Study|Other|12
5982291|NCT03679884|9571298|FG001|Overall Study|Other|12
5982292|NCT03679884|9571299|FG002|Overall Study|Other|12
5982293|NCT03679884|9571300|FG003|Overall Study|Other|7
5982294|NCT03679884|9571301|FG004|Overall Study|Other|8
5982295|NCT03679884|9571297|FG000|Overall Study|Lack of Efficacy|15
5982296|NCT03679884|9571298|FG001|Overall Study|Lack of Efficacy|29
5982297|NCT03679884|9571299|FG002|Overall Study|Lack of Efficacy|13
5982298|NCT03679884|9571300|FG003|Overall Study|Lack of Efficacy|29
5982299|NCT03679884|9571301|FG004|Overall Study|Lack of Efficacy|10
5982300|NCT03679884|9571297|FG000|Overall Study|Death|1
5982301|NCT03679884|9571298|FG001|Overall Study|Death|0
5982302|NCT03679884|9571299|FG002|Overall Study|Death|0
5982303|NCT03679884|9571300|FG003|Overall Study|Death|0
5982304|NCT03679884|9571301|FG004|Overall Study|Death|0
5982305|NCT03679884|9571297|FG000|Overall Study|Adverse Event|2
5982306|NCT03679884|9571298|FG001|Overall Study|Adverse Event|10
5982307|NCT03679884|9571299|FG002|Overall Study|Adverse Event|9
5982308|NCT03679884|9571300|FG003|Overall Study|Adverse Event|6
5982309|NCT03679884|9571301|FG004|Overall Study|Adverse Event|6
5982310|NCT03679884|9571297|FG000|Overall Study|Withdrawal by Subject|12
5982311|NCT03679884|9571298|FG001|Overall Study|Withdrawal by Subject|23
6302285|NCT02552121|10027167|FG003|Part 1: Dose Level 1 (Weeks 1-16)|Disease Progression|0
6302286|NCT02552121|10027168|FG004|Part 1: Dose Level 1 (Weeks 1-16)|Disease Progression|0
6302287|NCT02552121|10027169|FG005|Part 1: Dose Level 1 (Weeks 1-16)|Disease Progression|0
6302288|NCT02552121|10027170|FG006|Part 1: Dose Level 1 (Weeks 1-16)|Disease Progression|0
6302289|NCT02552121|10027171|FG007|Part 1: Dose Level 1 (Weeks 1-16)|Disease Progression|0
6302290|NCT02552121|10027164|FG000|Part 1: Dose Level 1 (Weeks 1-16)|Adverse Event|1
6302291|NCT02552121|10027165|FG001|Part 1: Dose Level 1 (Weeks 1-16)|Adverse Event|0
6302292|NCT02552121|10027166|FG002|Part 1: Dose Level 1 (Weeks 1-16)|Adverse Event|0
6302293|NCT02552121|10027167|FG003|Part 1: Dose Level 1 (Weeks 1-16)|Adverse Event|0
6302294|NCT02552121|10027168|FG004|Part 1: Dose Level 1 (Weeks 1-16)|Adverse Event|0
6302295|NCT02552121|10027169|FG005|Part 1: Dose Level 1 (Weeks 1-16)|Adverse Event|0
6302296|NCT02552121|10027170|FG006|Part 1: Dose Level 1 (Weeks 1-16)|Adverse Event|0
6302297|NCT02552121|10027171|FG007|Part 1: Dose Level 1 (Weeks 1-16)|Adverse Event|0
6302298|NCT02552121|10027164|FG000|Part 1: Dose Level 2 (Week 17-48)|Patient Choice|0
6302299|NCT02552121|10027165|FG001|Part 1: Dose Level 2 (Week 17-48)|Patient Choice|1
6302300|NCT02552121|10027166|FG002|Part 1: Dose Level 2 (Week 17-48)|Patient Choice|0
6302301|NCT02552121|10027167|FG003|Part 1: Dose Level 2 (Week 17-48)|Patient Choice|0
6302302|NCT02552121|10027168|FG004|Part 1: Dose Level 2 (Week 17-48)|Patient Choice|0
6302303|NCT02552121|10027169|FG005|Part 1: Dose Level 2 (Week 17-48)|Patient Choice|0
6302304|NCT02552121|10027170|FG006|Part 1: Dose Level 2 (Week 17-48)|Patient Choice|0
6302305|NCT02552121|10027171|FG007|Part 1: Dose Level 2 (Week 17-48)|Patient Choice|0
6302306|NCT02552121|10027164|FG000|Part 1: Dose Level 2 (Week 17-48)|Investigator Judgment|0
6302307|NCT02552121|10027165|FG001|Part 1: Dose Level 2 (Week 17-48)|Investigator Judgment|2
6302308|NCT02552121|10027166|FG002|Part 1: Dose Level 2 (Week 17-48)|Investigator Judgment|0
6302309|NCT02552121|10027167|FG003|Part 1: Dose Level 2 (Week 17-48)|Investigator Judgment|0
6302310|NCT02552121|10027168|FG004|Part 1: Dose Level 2 (Week 17-48)|Investigator Judgment|0
6302311|NCT02552121|10027169|FG005|Part 1: Dose Level 2 (Week 17-48)|Investigator Judgment|0
6302312|NCT02552121|10027170|FG006|Part 1: Dose Level 2 (Week 17-48)|Investigator Judgment|0
6302313|NCT02552121|10027171|FG007|Part 1: Dose Level 2 (Week 17-48)|Investigator Judgment|0
6302314|NCT02552121|10027164|FG000|Part 1: Dose Level 2 (Week 17-48)|Disease Progression|0
6302315|NCT02552121|10027165|FG001|Part 1: Dose Level 2 (Week 17-48)|Disease Progression|2
6302316|NCT02552121|10027166|FG002|Part 1: Dose Level 2 (Week 17-48)|Disease Progression|0
6302317|NCT02552121|10027167|FG003|Part 1: Dose Level 2 (Week 17-48)|Disease Progression|0
6302318|NCT02552121|10027168|FG004|Part 1: Dose Level 2 (Week 17-48)|Disease Progression|0
6302319|NCT02552121|10027169|FG005|Part 1: Dose Level 2 (Week 17-48)|Disease Progression|0
6302320|NCT02552121|10027170|FG006|Part 1: Dose Level 2 (Week 17-48)|Disease Progression|0
6302321|NCT02552121|10027171|FG007|Part 1: Dose Level 2 (Week 17-48)|Disease Progression|0
6302322|NCT02552121|10027164|FG000|Part 1: Dose Level 2 (Week 17-48)|Miscellaneous|0
6302323|NCT02552121|10027165|FG001|Part 1: Dose Level 2 (Week 17-48)|Miscellaneous|1
6302324|NCT02552121|10027166|FG002|Part 1: Dose Level 2 (Week 17-48)|Miscellaneous|0
6302325|NCT02552121|10027167|FG003|Part 1: Dose Level 2 (Week 17-48)|Miscellaneous|0
6302326|NCT02552121|10027168|FG004|Part 1: Dose Level 2 (Week 17-48)|Miscellaneous|0
6302327|NCT02552121|10027169|FG005|Part 1: Dose Level 2 (Week 17-48)|Miscellaneous|0
6302328|NCT02552121|10027170|FG006|Part 1: Dose Level 2 (Week 17-48)|Miscellaneous|0
6302329|NCT02552121|10027171|FG007|Part 1: Dose Level 2 (Week 17-48)|Miscellaneous|0
6302330|NCT02552121|10027164|FG000|Part 2: Cohort Expansion|Patient Choice|0
6302331|NCT02552121|10027165|FG001|Part 2: Cohort Expansion|Patient Choice|0
6302332|NCT02552121|10027166|FG002|Part 2: Cohort Expansion|Patient Choice|1
6302333|NCT02552121|10027167|FG003|Part 2: Cohort Expansion|Patient Choice|0
6302334|NCT02552121|10027168|FG004|Part 2: Cohort Expansion|Patient Choice|0
6302335|NCT02552121|10027169|FG005|Part 2: Cohort Expansion|Patient Choice|0
6302336|NCT02552121|10027170|FG006|Part 2: Cohort Expansion|Patient Choice|1
6302337|NCT02552121|10027171|FG007|Part 2: Cohort Expansion|Patient Choice|0
6302338|NCT02552121|10027164|FG000|Part 2: Cohort Expansion|Disease Progression|0
6302339|NCT02552121|10027165|FG001|Part 2: Cohort Expansion|Disease Progression|0
6302340|NCT02552121|10027166|FG002|Part 2: Cohort Expansion|Disease Progression|3
6302341|NCT02552121|10027167|FG003|Part 2: Cohort Expansion|Disease Progression|2
6302342|NCT02552121|10027168|FG004|Part 2: Cohort Expansion|Disease Progression|1
6302343|NCT02552121|10027169|FG005|Part 2: Cohort Expansion|Disease Progression|4
6302344|NCT02552121|10027170|FG006|Part 2: Cohort Expansion|Disease Progression|0
6302345|NCT02552121|10027171|FG007|Part 2: Cohort Expansion|Disease Progression|3
6302346|NCT02552121|10027164|FG000|Part 2: Cohort Expansion|Adverse Event|0
6302347|NCT02552121|10027165|FG001|Part 2: Cohort Expansion|Adverse Event|0
6302348|NCT02552121|10027166|FG002|Part 2: Cohort Expansion|Adverse Event|6
6302349|NCT02552121|10027167|FG003|Part 2: Cohort Expansion|Adverse Event|1
6302350|NCT02552121|10027168|FG004|Part 2: Cohort Expansion|Adverse Event|0
6302351|NCT02552121|10027169|FG005|Part 2: Cohort Expansion|Adverse Event|0
6302352|NCT02552121|10027170|FG006|Part 2: Cohort Expansion|Adverse Event|0
6302353|NCT02552121|10027171|FG007|Part 2: Cohort Expansion|Adverse Event|0
6302354|NCT02552121|10027164|FG000|Part 2: Cohort Expansion|Death|0
6302355|NCT02552121|10027165|FG001|Part 2: Cohort Expansion|Death|0
6302356|NCT02552121|10027166|FG002|Part 2: Cohort Expansion|Death|1
6302357|NCT02552121|10027167|FG003|Part 2: Cohort Expansion|Death|0
6302358|NCT02552121|10027168|FG004|Part 2: Cohort Expansion|Death|0
6302359|NCT02552121|10027169|FG005|Part 2: Cohort Expansion|Death|0
6302360|NCT02552121|10027170|FG006|Part 2: Cohort Expansion|Death|0
6302361|NCT02552121|10027171|FG007|Part 2: Cohort Expansion|Death|0
6302362|NCT02552147|10027203|FG000|First Intervention (7 Days)|Protocol Violation|1
6302363|NCT02552147|10027204|FG001|First Intervention (7 Days)|Protocol Violation|0
6302364|NCT02552147|10027203|FG000|Second Intervention (7 Days)|Protocol Violation|2
6302365|NCT02552147|10027204|FG001|Second Intervention (7 Days)|Protocol Violation|0
6302366|NCT02552225|10027212|FG000|Overall Study|Withdrawal by Subject|1
6302367|NCT02552225|10027213|FG001|Overall Study|Withdrawal by Subject|0
6302368|NCT02552238|10027219|FG000|Overall Study|Withdrawal by Subject|2
6302369|NCT02552238|10027219|FG000|Overall Study|Adverse Event|2
6302370|NCT02552303|10027234|FG000|Allocation|Withdrawal by Subject|2
6302371|NCT02552303|10027235|FG001|Allocation|Withdrawal by Subject|1
6302372|NCT02552303|10027236|FG002|Allocation|Withdrawal by Subject|1
6302373|NCT02552303|10027237|FG003|Allocation|Withdrawal by Subject|1
6302374|NCT02552303|10027234|FG000|Allocation|ineligible|1
6302375|NCT02552303|10027235|FG001|Allocation|ineligible|1
6302376|NCT02552303|10027236|FG002|Allocation|ineligible|0
6302377|NCT02552303|10027237|FG003|Allocation|ineligible|0
6302378|NCT02552303|10027234|FG000|Follow-Up|Lost to Follow-up|0
6302379|NCT02552303|10027235|FG001|Follow-Up|Lost to Follow-up|0
6302380|NCT02552303|10027236|FG002|Follow-Up|Lost to Follow-up|1
6302381|NCT02552303|10027237|FG003|Follow-Up|Lost to Follow-up|0
6302382|NCT02552303|10027234|FG000|Follow-Up|ineligible|0
6302383|NCT02552303|10027235|FG001|Follow-Up|ineligible|2
6302384|NCT02552303|10027236|FG002|Follow-Up|ineligible|0
6302385|NCT02552303|10027237|FG003|Follow-Up|ineligible|0
6302386|NCT02552316|10027247|FG000|Overall Study|Withdrawal by Subject|1
6302387|NCT02552316|10027247|FG000|Overall Study|Withdrawal due to non-compliance|1
6302388|NCT02552355|10027299|FG000|Overall Study|Adverse Event|0
6302389|NCT02552355|10027300|FG001|Overall Study|Adverse Event|2
6302390|NCT02552355|10027301|FG002|Overall Study|Adverse Event|2
6302391|NCT02552355|10027302|FG003|Overall Study|Adverse Event|0
6302392|NCT02552355|10027299|FG000|Overall Study|Withdrawal by Subject|0
6302393|NCT02552355|10027300|FG001|Overall Study|Withdrawal by Subject|0
6302394|NCT02552355|10027301|FG002|Overall Study|Withdrawal by Subject|0
6302395|NCT02552355|10027302|FG003|Overall Study|Withdrawal by Subject|1
6302396|NCT02552732|10027317|FG000|Overall Study|Lost to Follow-up|2
6302397|NCT02552732|10027317|FG000|Overall Study|Physician Decision|1
6302398|NCT02552732|10027317|FG000|Overall Study|Day 1 SpO2 > 96%|1
6302399|NCT02552732|10027317|FG000|Overall Study|Withdrawal by Subject|6
6302400|NCT02552888|10027333|FG000|Overall Study|Lost to Follow-up|1
6302401|NCT02552888|10027334|FG001|Overall Study|Lost to Follow-up|1
6302402|NCT02552966|10027344|FG000|Overall Study|Lost to Follow-up|2
6302403|NCT02552966|10027344|FG000|Overall Study|Withdrawal by Subject|3
6302404|NCT02553317|10027354|FG000|Overall Treatment Period + Follow-up|Withdrawn by legal representative|0
6302405|NCT02553317|10027355|FG001|Overall Treatment Period + Follow-up|Withdrawn by legal representative|1
6302406|NCT02553317|10027354|FG000|Overall Treatment Period + Follow-up|Physician Decision|2
6302407|NCT02553317|10027355|FG001|Overall Treatment Period + Follow-up|Physician Decision|4
6302408|NCT02553317|10027354|FG000|Overall Treatment Period + Follow-up|Non-compliance with study drug|0
6302409|NCT02553317|10027355|FG001|Overall Treatment Period + Follow-up|Non-compliance with study drug|1
6302410|NCT02553317|10027354|FG000|Overall Treatment Period + Follow-up|Death|1
6302411|NCT02553317|10027355|FG001|Overall Treatment Period + Follow-up|Death|3
6302412|NCT02553317|10027354|FG000|Overall Treatment Period + Follow-up|Adverse Event|6
6302413|NCT02553317|10027355|FG001|Overall Treatment Period + Follow-up|Adverse Event|5
6302414|NCT02553317|10027354|FG000|Overall Treatment Period + Follow-up|Withdrawal by Subject|4
6302415|NCT02553317|10027355|FG001|Overall Treatment Period + Follow-up|Withdrawal by Subject|5
6302416|NCT02553317|10027354|FG000|Overall Treatment Period + Follow-up|Lost to Follow-up|0
6302417|NCT02553317|10027355|FG001|Overall Treatment Period + Follow-up|Lost to Follow-up|1
6302418|NCT02553317|10027354|FG000|Overall Treatment Period + Follow-up|Diagnosed as non-TTP patient|1
6302419|NCT02553317|10027355|FG001|Overall Treatment Period + Follow-up|Diagnosed as non-TTP patient|1
6302420|NCT02553317|10027354|FG000|Overall Treatment Period + Follow-up|Protocol Violation|0
6302421|NCT02553317|10027355|FG001|Overall Treatment Period + Follow-up|Protocol Violation|1
6302422|NCT02553317|10027354|FG000|Overall Treatment Period + Follow-up|Withdrew treatment, agreed for ET visit|0
6302423|NCT02553317|10027355|FG001|Overall Treatment Period + Follow-up|Withdrew treatment, agreed for ET visit|1
6302424|NCT02553330|10027365|FG000|Overall Study|Study Terminated by Sponsor|2
6302425|NCT02553330|10027366|FG001|Overall Study|Study Terminated by Sponsor|13
6302426|NCT02553330|10027367|FG002|Overall Study|Study Terminated by Sponsor|12
6302427|NCT02553330|10027365|FG000|Overall Study|Withdrawal by Subject|3
6302428|NCT02553330|10027366|FG001|Overall Study|Withdrawal by Subject|19
6302429|NCT02553330|10027367|FG002|Overall Study|Withdrawal by Subject|21
6302430|NCT02553330|10027365|FG000|Overall Study|Other|0
6302431|NCT02553330|10027366|FG001|Overall Study|Other|1
6302432|NCT02553330|10027367|FG002|Overall Study|Other|0
6302433|NCT02553330|10027365|FG000|Overall Study|Non compliance to study treatment|0
6302434|NCT02553330|10027366|FG001|Overall Study|Non compliance to study treatment|1
6302435|NCT02553330|10027367|FG002|Overall Study|Non compliance to study treatment|0
6302436|NCT02553330|10027365|FG000|Overall Study|Adverse Event|0
6302437|NCT02553330|10027366|FG001|Overall Study|Adverse Event|1
6302438|NCT02553330|10027367|FG002|Overall Study|Adverse Event|0
6302439|NCT02553330|10027365|FG000|Overall Study|Lost to Follow-up|0
6302440|NCT02553330|10027366|FG001|Overall Study|Lost to Follow-up|4
6302441|NCT02553330|10027367|FG002|Overall Study|Lost to Follow-up|4
6302442|NCT02553421|10027388|FG000|Overall Study|Lost to Follow-up|21
6302443|NCT02553421|10027389|FG001|Overall Study|Lost to Follow-up|1
6302444|NCT02553421|10027388|FG000|Overall Study|Incomplete or Insufficient Data Collecte|5
6302445|NCT02553421|10027389|FG001|Overall Study|Incomplete or Insufficient Data Collecte|0
6302446|NCT02553421|10027388|FG000|Overall Study|Improper Device Placement|3
6302447|NCT02553421|10027389|FG001|Overall Study|Improper Device Placement|0
6302448|NCT02553499|10027410|FG000|Overall Study|Adverse Event|0
6302449|NCT02553499|10027411|FG001|Overall Study|Adverse Event|0
6302450|NCT02553499|10027412|FG002|Overall Study|Adverse Event|0
6302451|NCT02553499|10027413|FG003|Overall Study|Adverse Event|0
6302452|NCT02553499|10027414|FG004|Overall Study|Adverse Event|0
6302453|NCT02553499|10027415|FG005|Overall Study|Adverse Event|0
6302454|NCT02553499|10027416|FG006|Overall Study|Adverse Event|1
6302455|NCT02553499|10027417|FG007|Overall Study|Adverse Event|1
6302456|NCT02553499|10027418|FG008|Overall Study|Adverse Event|0
6302457|NCT02553499|10027419|FG009|Overall Study|Adverse Event|0
6302458|NCT02553499|10027420|FG010|Overall Study|Adverse Event|0
6302459|NCT02553499|10027421|FG011|Overall Study|Adverse Event|0
6302460|NCT02553499|10027422|FG012|Overall Study|Adverse Event|0
6302461|NCT02553499|10027423|FG013|Overall Study|Adverse Event|1
6302462|NCT02553499|10027410|FG000|Overall Study|Death|0
6302463|NCT02553499|10027411|FG001|Overall Study|Death|1
6302464|NCT02553499|10027412|FG002|Overall Study|Death|1
6302465|NCT02553499|10027413|FG003|Overall Study|Death|0
6302466|NCT02553499|10027414|FG004|Overall Study|Death|1
6302467|NCT02553499|10027415|FG005|Overall Study|Death|2
6302468|NCT02553499|10027416|FG006|Overall Study|Death|0
6302469|NCT02553499|10027417|FG007|Overall Study|Death|0
6302470|NCT02553499|10027418|FG008|Overall Study|Death|0
6302471|NCT02553499|10027419|FG009|Overall Study|Death|0
6302472|NCT02553499|10027420|FG010|Overall Study|Death|1
6302473|NCT02553499|10027421|FG011|Overall Study|Death|0
6302474|NCT02553499|10027422|FG012|Overall Study|Death|0
6302475|NCT02553499|10027423|FG013|Overall Study|Death|0
6302476|NCT02553499|10027410|FG000|Overall Study|Lost to Follow-up|0
6302477|NCT02553499|10027411|FG001|Overall Study|Lost to Follow-up|0
6302478|NCT02553499|10027412|FG002|Overall Study|Lost to Follow-up|0
6302479|NCT02553499|10027413|FG003|Overall Study|Lost to Follow-up|0
6302480|NCT02553499|10027414|FG004|Overall Study|Lost to Follow-up|0
6302481|NCT02553499|10027415|FG005|Overall Study|Lost to Follow-up|0
6302482|NCT02553499|10027416|FG006|Overall Study|Lost to Follow-up|1
6302483|NCT02553499|10027417|FG007|Overall Study|Lost to Follow-up|0
6302484|NCT02553499|10027418|FG008|Overall Study|Lost to Follow-up|0
6302485|NCT02553499|10027419|FG009|Overall Study|Lost to Follow-up|0
6302486|NCT02553499|10027420|FG010|Overall Study|Lost to Follow-up|0
6302487|NCT02553499|10027421|FG011|Overall Study|Lost to Follow-up|0
6302488|NCT02553499|10027422|FG012|Overall Study|Lost to Follow-up|0
6302489|NCT02553499|10027423|FG013|Overall Study|Lost to Follow-up|0
6302490|NCT02553499|10027410|FG000|Overall Study|Physician Decision|0
6302491|NCT02553499|10027411|FG001|Overall Study|Physician Decision|1
6302492|NCT02553499|10027412|FG002|Overall Study|Physician Decision|1
6302493|NCT02553499|10027413|FG003|Overall Study|Physician Decision|0
6302494|NCT02553499|10027414|FG004|Overall Study|Physician Decision|1
6302495|NCT02553499|10027415|FG005|Overall Study|Physician Decision|0
6302496|NCT02553499|10027416|FG006|Overall Study|Physician Decision|0
6302497|NCT02553499|10027417|FG007|Overall Study|Physician Decision|1
6302498|NCT02553499|10027418|FG008|Overall Study|Physician Decision|1
6302499|NCT02553499|10027419|FG009|Overall Study|Physician Decision|2
6302500|NCT02553499|10027420|FG010|Overall Study|Physician Decision|1
6302501|NCT02553499|10027421|FG011|Overall Study|Physician Decision|3
6302502|NCT02553499|10027422|FG012|Overall Study|Physician Decision|1
6302503|NCT02553499|10027423|FG013|Overall Study|Physician Decision|0
6302504|NCT02553499|10027410|FG000|Overall Study|Progressive Disease|0
6302505|NCT02553499|10027411|FG001|Overall Study|Progressive Disease|0
6302506|NCT02553499|10027412|FG002|Overall Study|Progressive Disease|0
6302507|NCT02553499|10027413|FG003|Overall Study|Progressive Disease|2
6302508|NCT02553499|10027414|FG004|Overall Study|Progressive Disease|1
6302509|NCT02553499|10027415|FG005|Overall Study|Progressive Disease|1
6302510|NCT02553499|10027416|FG006|Overall Study|Progressive Disease|1
6302511|NCT02553499|10027417|FG007|Overall Study|Progressive Disease|0
6302512|NCT02553499|10027418|FG008|Overall Study|Progressive Disease|0
6302513|NCT02553499|10027419|FG009|Overall Study|Progressive Disease|1
6302514|NCT02553499|10027420|FG010|Overall Study|Progressive Disease|0
6302515|NCT02553499|10027421|FG011|Overall Study|Progressive Disease|0
6302516|NCT02553499|10027422|FG012|Overall Study|Progressive Disease|2
6302517|NCT02553499|10027423|FG013|Overall Study|Progressive Disease|1
6302518|NCT02553499|10027410|FG000|Overall Study|Study Terminated by Sponsor|0
6302519|NCT02553499|10027411|FG001|Overall Study|Study Terminated by Sponsor|0
6302520|NCT02553499|10027412|FG002|Overall Study|Study Terminated by Sponsor|0
6302521|NCT02553499|10027413|FG003|Overall Study|Study Terminated by Sponsor|0
6302522|NCT02553499|10027414|FG004|Overall Study|Study Terminated by Sponsor|0
6302523|NCT02553499|10027415|FG005|Overall Study|Study Terminated by Sponsor|0
6302524|NCT02553499|10027416|FG006|Overall Study|Study Terminated by Sponsor|0
6302525|NCT02553499|10027417|FG007|Overall Study|Study Terminated by Sponsor|0
6302526|NCT02553499|10027418|FG008|Overall Study|Study Terminated by Sponsor|1
6302527|NCT02553499|10027419|FG009|Overall Study|Study Terminated by Sponsor|0
6302528|NCT02553499|10027420|FG010|Overall Study|Study Terminated by Sponsor|0
6302529|NCT02553499|10027421|FG011|Overall Study|Study Terminated by Sponsor|0
6302530|NCT02553499|10027422|FG012|Overall Study|Study Terminated by Sponsor|0
6302531|NCT02553499|10027423|FG013|Overall Study|Study Terminated by Sponsor|0
6302532|NCT02553499|10027410|FG000|Overall Study|Withdrawal by Subject|2
6302533|NCT02553499|10027411|FG001|Overall Study|Withdrawal by Subject|0
6302534|NCT02553499|10027412|FG002|Overall Study|Withdrawal by Subject|0
6302535|NCT02553499|10027413|FG003|Overall Study|Withdrawal by Subject|0
6302536|NCT02553499|10027414|FG004|Overall Study|Withdrawal by Subject|0
6302537|NCT02553499|10027415|FG005|Overall Study|Withdrawal by Subject|0
6302538|NCT02553499|10027416|FG006|Overall Study|Withdrawal by Subject|0
6302539|NCT02553499|10027417|FG007|Overall Study|Withdrawal by Subject|1
6302540|NCT02553499|10027418|FG008|Overall Study|Withdrawal by Subject|1
6302541|NCT02553499|10027419|FG009|Overall Study|Withdrawal by Subject|0
6302542|NCT02553499|10027420|FG010|Overall Study|Withdrawal by Subject|1
6302543|NCT02553499|10027421|FG011|Overall Study|Withdrawal by Subject|0
6302544|NCT02553499|10027422|FG012|Overall Study|Withdrawal by Subject|0
6302545|NCT02553499|10027423|FG013|Overall Study|Withdrawal by Subject|0
6302546|NCT02553538|10027460|FG000|Overall Study|Could Not Reach by Telephone|133
6302547|NCT02553538|10027461|FG001|Overall Study|Could Not Reach by Telephone|0
6302548|NCT02553538|10027460|FG000|Overall Study|Died or Left Network|54
6302549|NCT02553538|10027461|FG001|Overall Study|Died or Left Network|56
6302550|NCT02553629|10027469|FG000|Overall Study|Logistic reasons|3
6302551|NCT02553629|10027470|FG001|Overall Study|Logistic reasons|6
6302552|NCT02553772|10027487|FG000|Overall Study|Adverse Event|2
6302553|NCT02553772|10027488|FG001|Overall Study|Adverse Event|3
6302554|NCT02553772|10027487|FG000|Overall Study|Lost to Follow-up|2
6302555|NCT02553772|10027488|FG001|Overall Study|Lost to Follow-up|1
6302556|NCT02553772|10027487|FG000|Overall Study|Withdrawal of Consent|1
6302557|NCT02553772|10027488|FG001|Overall Study|Withdrawal of Consent|1
6302558|NCT02553772|10027487|FG000|Overall Study|Lack of Efficacy|1
6302559|NCT02553772|10027488|FG001|Overall Study|Lack of Efficacy|0
6302560|NCT02553772|10027487|FG000|Overall Study|Other Miscellaneous Reasons|0
6302561|NCT02553772|10027488|FG001|Overall Study|Other Miscellaneous Reasons|1
6302562|NCT02553928|10027500|FG000|Overall Study|Adverse Event|2
6302563|NCT02553928|10027501|FG001|Overall Study|Adverse Event|1
6302564|NCT02553928|10027500|FG000|Overall Study|Lost to Follow-up|0
6302565|NCT02553928|10027501|FG001|Overall Study|Lost to Follow-up|1
6302566|NCT02553928|10027500|FG000|Overall Study|Administrative reason(s)|0
6302567|NCT02553928|10027501|FG001|Overall Study|Administrative reason(s)|1
6302568|NCT02554019|10027511|FG000|Overall Study|Withdrawal by Subject|1
6302569|NCT02554019|10027512|FG001|Overall Study|Withdrawal by Subject|0
6302570|NCT02554019|10027513|FG002|Overall Study|Withdrawal by Subject|2
6302571|NCT02554019|10027511|FG000|Overall Study|Adverse Event|1
6302572|NCT02554019|10027512|FG001|Overall Study|Adverse Event|0
6302573|NCT02554019|10027513|FG002|Overall Study|Adverse Event|0
6302574|NCT02554279|10027523|FG000|Overall Study|Adverse Event|2
6302575|NCT02554279|10027524|FG001|Overall Study|Adverse Event|5
6302576|NCT02554279|10027523|FG000|Overall Study|Lost to Follow-up|3
6302577|NCT02554279|10027524|FG001|Overall Study|Lost to Follow-up|2
6302578|NCT02554279|10027523|FG000|Overall Study|Withdrawal by Subject|6
6302579|NCT02554279|10027524|FG001|Overall Study|Withdrawal by Subject|4
6302580|NCT02554279|10027523|FG000|Overall Study|Protocol Violation|2
6302581|NCT02554279|10027524|FG001|Overall Study|Protocol Violation|1
6302582|NCT02554279|10027523|FG000|Overall Study|Other reason|19
6302583|NCT02554279|10027524|FG001|Overall Study|Other reason|6
6302584|NCT02554474|10027549|FG000|Overall Study|Protocol Violation|1
6302585|NCT02554474|10027550|FG001|Overall Study|Protocol Violation|1
6302586|NCT02554474|10027549|FG000|Overall Study|Health issue not related to the study|1
6302587|NCT02554474|10027550|FG001|Overall Study|Health issue not related to the study|0
6302588|NCT02554474|10027549|FG000|Overall Study|Withdrawal by Subject|1
6302589|NCT02554474|10027550|FG001|Overall Study|Withdrawal by Subject|1
6302590|NCT02554513|10027556|FG000|First Treatment Phase (7 Weeks)|Withdrawal by Subject|0
6302591|NCT02554513|10027557|FG001|First Treatment Phase (7 Weeks)|Withdrawal by Subject|1
6302592|NCT02554656|10027569|FG000|Overall Study|Protocol Violation|3
6302593|NCT02554682|10027583|FG000|Overall Study|Lost to Follow-up|11
6302594|NCT02554682|10027584|FG001|Overall Study|Lost to Follow-up|9
6302595|NCT02554682|10027585|FG002|Overall Study|Lost to Follow-up|4
6302596|NCT02554682|10027586|FG003|Overall Study|Lost to Follow-up|3
6302597|NCT02554682|10027587|FG004|Overall Study|Lost to Follow-up|2
6302598|NCT02554682|10027588|FG005|Overall Study|Lost to Follow-up|1
6302599|NCT02554682|10027589|FG006|Overall Study|Lost to Follow-up|6
6302600|NCT02554682|10027590|FG007|Overall Study|Lost to Follow-up|6
6302601|NCT02554682|10027591|FG008|Overall Study|Lost to Follow-up|2
6302602|NCT02554682|10027592|FG009|Overall Study|Lost to Follow-up|2
6302603|NCT02554682|10027583|FG000|Overall Study|Withdrawal by Subject|2
6302604|NCT02554682|10027584|FG001|Overall Study|Withdrawal by Subject|1
6302605|NCT02554682|10027585|FG002|Overall Study|Withdrawal by Subject|0
6302606|NCT02554682|10027586|FG003|Overall Study|Withdrawal by Subject|0
6302607|NCT02554682|10027587|FG004|Overall Study|Withdrawal by Subject|0
6302608|NCT02554682|10027588|FG005|Overall Study|Withdrawal by Subject|0
6302609|NCT02554682|10027589|FG006|Overall Study|Withdrawal by Subject|0
6302610|NCT02554682|10027590|FG007|Overall Study|Withdrawal by Subject|0
6302611|NCT02554682|10027591|FG008|Overall Study|Withdrawal by Subject|0
6302612|NCT02554682|10027592|FG009|Overall Study|Withdrawal by Subject|0
6302613|NCT02554682|10027583|FG000|Overall Study|Physician Decision|2
6302614|NCT02554682|10027584|FG001|Overall Study|Physician Decision|2
6302615|NCT02554682|10027585|FG002|Overall Study|Physician Decision|0
6302616|NCT02554682|10027586|FG003|Overall Study|Physician Decision|0
6302617|NCT02554682|10027587|FG004|Overall Study|Physician Decision|0
6302618|NCT02554682|10027588|FG005|Overall Study|Physician Decision|0
6302619|NCT02554682|10027589|FG006|Overall Study|Physician Decision|0
6302620|NCT02554682|10027590|FG007|Overall Study|Physician Decision|0
6302621|NCT02554682|10027591|FG008|Overall Study|Physician Decision|0
6302622|NCT02554682|10027592|FG009|Overall Study|Physician Decision|0
6302623|NCT02554721|10027622|FG000|Overall Study|Adverse Event|1
6302624|NCT02554721|10027623|FG001|Overall Study|Adverse Event|0
6302625|NCT02554721|10027624|FG002|Overall Study|Adverse Event|0
6302626|NCT02554721|10027625|FG003|Overall Study|Adverse Event|0
6302627|NCT02554721|10027626|FG004|Overall Study|Adverse Event|1
6302628|NCT02554721|10027622|FG000|Overall Study|Noncompliance|0
6302629|NCT02554721|10027623|FG001|Overall Study|Noncompliance|0
6302630|NCT02554721|10027624|FG002|Overall Study|Noncompliance|0
6302631|NCT02554721|10027625|FG003|Overall Study|Noncompliance|0
6302632|NCT02554721|10027626|FG004|Overall Study|Noncompliance|1
6302633|NCT02554786|10027650|FG000|Overall Study|Subject/guardian decision|29
6302634|NCT02554786|10027651|FG001|Overall Study|Subject/guardian decision|17
6302635|NCT02554786|10027652|FG002|Overall Study|Subject/guardian decision|18
6302636|NCT02554786|10027653|FG003|Overall Study|Subject/guardian decision|30
6302637|NCT02554786|10027654|FG004|Overall Study|Subject/guardian decision|20
6302638|NCT02554786|10027650|FG000|Overall Study|Lost to Follow-up|4
6302639|NCT02554786|10027651|FG001|Overall Study|Lost to Follow-up|3
6302640|NCT02554786|10027652|FG002|Overall Study|Lost to Follow-up|4
6302641|NCT02554786|10027653|FG003|Overall Study|Lost to Follow-up|2
6302642|NCT02554786|10027654|FG004|Overall Study|Lost to Follow-up|2
6302643|NCT02554786|10027650|FG000|Overall Study|Protocol deviation|1
6302644|NCT02554786|10027651|FG001|Overall Study|Protocol deviation|3
6302645|NCT02554786|10027652|FG002|Overall Study|Protocol deviation|3
6302646|NCT02554786|10027653|FG003|Overall Study|Protocol deviation|4
6302647|NCT02554786|10027654|FG004|Overall Study|Protocol deviation|2
6302648|NCT02554786|10027650|FG000|Overall Study|Technical problems|1
6302649|NCT02554786|10027651|FG001|Overall Study|Technical problems|1
6302650|NCT02554786|10027652|FG002|Overall Study|Technical problems|0
6302651|NCT02554786|10027653|FG003|Overall Study|Technical problems|2
6302652|NCT02554786|10027654|FG004|Overall Study|Technical problems|1
6302653|NCT02554786|10027650|FG000|Overall Study|Adverse Event|0
6302654|NCT02554786|10027651|FG001|Overall Study|Adverse Event|0
6302655|NCT02554786|10027652|FG002|Overall Study|Adverse Event|0
6302656|NCT02554786|10027653|FG003|Overall Study|Adverse Event|0
6302657|NCT02554786|10027654|FG004|Overall Study|Adverse Event|2
6302658|NCT02554786|10027650|FG000|Overall Study|Death|0
6302659|NCT02554786|10027651|FG001|Overall Study|Death|0
6302660|NCT02554786|10027652|FG002|Overall Study|Death|0
6302661|NCT02554786|10027653|FG003|Overall Study|Death|1
6302662|NCT02554786|10027654|FG004|Overall Study|Death|0
6302663|NCT02554786|10027650|FG000|Overall Study|Non-compliance with study treatment|0
6302664|NCT02554786|10027651|FG001|Overall Study|Non-compliance with study treatment|1
6302665|NCT02554786|10027652|FG002|Overall Study|Non-compliance with study treatment|1
6302666|NCT02554786|10027653|FG003|Overall Study|Non-compliance with study treatment|0
6302667|NCT02554786|10027654|FG004|Overall Study|Non-compliance with study treatment|1
6302668|NCT02554786|10027650|FG000|Overall Study|Physician Decision|0
6302669|NCT02554786|10027651|FG001|Overall Study|Physician Decision|1
6302670|NCT02554786|10027652|FG002|Overall Study|Physician Decision|4
6302671|NCT02554786|10027653|FG003|Overall Study|Physician Decision|1
6302672|NCT02554786|10027654|FG004|Overall Study|Physician Decision|1
6302673|NCT02554786|10027650|FG000|Overall Study|Pregnancy|0
6302674|NCT02554786|10027651|FG001|Overall Study|Pregnancy|0
6302675|NCT02554786|10027652|FG002|Overall Study|Pregnancy|0
6302676|NCT02554786|10027653|FG003|Overall Study|Pregnancy|1
6302677|NCT02554786|10027654|FG004|Overall Study|Pregnancy|1
6302678|NCT02554877|10027683|FG000|Overall Study|Adverse Event|2
6302679|NCT02554877|10027684|FG001|Overall Study|Adverse Event|0
6302680|NCT02554877|10027685|FG002|Overall Study|Adverse Event|0
6302681|NCT02554877|10027686|FG003|Overall Study|Adverse Event|1
6302682|NCT02554877|10027683|FG000|Overall Study|Lost to Follow-up|1
6302683|NCT02554877|10027684|FG001|Overall Study|Lost to Follow-up|1
6302684|NCT02554877|10027685|FG002|Overall Study|Lost to Follow-up|1
6302685|NCT02554877|10027686|FG003|Overall Study|Lost to Follow-up|2
6302686|NCT02554877|10027683|FG000|Overall Study|Did not meet entrance criteria|0
6302687|NCT02554877|10027684|FG001|Overall Study|Did not meet entrance criteria|0
6302688|NCT02554877|10027685|FG002|Overall Study|Did not meet entrance criteria|1
6302689|NCT02554877|10027686|FG003|Overall Study|Did not meet entrance criteria|0
6302690|NCT02554877|10027683|FG000|Overall Study|No longer met eligibility criteria|1
6302691|NCT02554877|10027684|FG001|Overall Study|No longer met eligibility criteria|0
6302692|NCT02554877|10027685|FG002|Overall Study|No longer met eligibility criteria|1
6302693|NCT02554877|10027686|FG003|Overall Study|No longer met eligibility criteria|1
6302694|NCT02554877|10027683|FG000|Overall Study|Protocol Violation|3
6302695|NCT02554877|10027684|FG001|Overall Study|Protocol Violation|1
6302696|NCT02554877|10027685|FG002|Overall Study|Protocol Violation|1
6302697|NCT02554877|10027686|FG003|Overall Study|Protocol Violation|0
6302698|NCT02554877|10027683|FG000|Overall Study|Other|1
6302699|NCT02554877|10027684|FG001|Overall Study|Other|3
6302700|NCT02554877|10027685|FG002|Overall Study|Other|0
6302701|NCT02554877|10027686|FG003|Overall Study|Other|3
6302702|NCT02554877|10027683|FG000|Overall Study|Insufficient clinical response|4
6302703|NCT02554877|10027684|FG001|Overall Study|Insufficient clinical response|0
6302704|NCT02554877|10027685|FG002|Overall Study|Insufficient clinical response|0
6302705|NCT02554877|10027686|FG003|Overall Study|Insufficient clinical response|0
6302706|NCT02554877|10027683|FG000|Overall Study|No longer willing to participate|0
6302707|NCT02554877|10027684|FG001|Overall Study|No longer willing to participate|2
6302708|NCT02554877|10027685|FG002|Overall Study|No longer willing to participate|2
6302709|NCT02554877|10027686|FG003|Overall Study|No longer willing to participate|0
6302710|NCT02554890|10027698|FG000|Double-blind|Adverse Event|45
6302711|NCT02554890|10027699|FG001|Double-blind|Adverse Event|51
6302712|NCT02554890|10027698|FG000|Double-blind|Death|6
6302713|NCT02554890|10027699|FG001|Double-blind|Death|4
6302714|NCT02554890|10027698|FG000|Double-blind|Protocol Violation|1
6302715|NCT02554890|10027699|FG001|Double-blind|Protocol Violation|1
6302716|NCT02554890|10027698|FG000|Double-blind|Physician Decision|4
6302717|NCT02554890|10027699|FG001|Double-blind|Physician Decision|3
6302718|NCT02554890|10027698|FG000|Double-blind|Subject/Guardian decision|21
6302719|NCT02554890|10027699|FG001|Double-blind|Subject/Guardian decision|16
6302720|NCT02554890|10027698|FG000|Double-blind|Lost to Follow-up|7
6302721|NCT02554890|10027699|FG001|Double-blind|Lost to Follow-up|5
6302722|NCT02554890|10027698|FG000|Double-blind|Technical problems|1
6302723|NCT02554890|10027699|FG001|Double-blind|Technical problems|0
6302724|NCT02554890|10027698|FG000|Double-blind|Withdrawal by Subject|5
6302725|NCT02554890|10027699|FG001|Double-blind|Withdrawal by Subject|6
6302726|NCT02554890|10027698|FG000|Double-blind|Noncompliance with study treatment|6
6302727|NCT02554890|10027699|FG001|Double-blind|Noncompliance with study treatment|5
6302728|NCT02554890|10027698|FG000|Open-label|Adverse Event|0
6063778|NCT00508001|9665109|FG001|Overall Study|Withdrawal by Subject|4
6063779|NCT00508001|9665110|FG002|Overall Study|Withdrawal by Subject|1
6063780|NCT00508027|9665118|FG000|Dose Level 1|Lost to Follow-up|4
6063781|NCT00508027|9665118|FG000|Dose Level 1|Withdrawal by Subject|2
6063782|NCT00508027|9665118|FG000|Dose Level 1|Physician Decision|2
6063783|NCT00508027|9665118|FG000|Dose Level 2|Lost to Follow-up|2
6063784|NCT00508027|9665118|FG000|Dose Level 2|Withdrawal by Subject|2
6063785|NCT00508144|9665151|FG000|Overall Study|Not eligible|6
6063786|NCT00508144|9665151|FG000|Overall Study|Death|5
6063787|NCT00508157|9665157|FG000|Overall Study|Adverse Event|0
6063788|NCT00508157|9665158|FG001|Overall Study|Adverse Event|1
6063789|NCT00508157|9665157|FG000|Overall Study|Subject Withdrew Consent|1
6063790|NCT00508157|9665158|FG001|Overall Study|Subject Withdrew Consent|0
6063791|NCT00508157|9665157|FG000|Overall Study|Lost to Follow-up|1
6063792|NCT00508157|9665158|FG001|Overall Study|Lost to Follow-up|0
6063793|NCT00508157|9665157|FG000|Overall Study|Subject no longer met study criteria|0
6063794|NCT00508157|9665158|FG001|Overall Study|Subject no longer met study criteria|1
6063795|NCT00508157|9665157|FG000|Overall Study|Other known cause|0
6063796|NCT00508157|9665158|FG001|Overall Study|Other known cause|1
6063797|NCT00508261|9665184|FG000|Overall Study|Other|0
6063798|NCT00508261|9665185|FG001|Overall Study|Other|1
6063799|NCT00508261|9665186|FG002|Overall Study|Other|1
6063800|NCT00508261|9665187|FG003|Overall Study|Other|0
6063801|NCT00508261|9665184|FG000|Overall Study|Serious Adverse Event|0
6063802|NCT00508261|9665185|FG001|Overall Study|Serious Adverse Event|1
6063803|NCT00508261|9665186|FG002|Overall Study|Serious Adverse Event|0
6063804|NCT00508261|9665187|FG003|Overall Study|Serious Adverse Event|0
6063805|NCT00508261|9665184|FG000|Overall Study|Withdrawal by Subject|3
6302729|NCT02554890|10027699|FG001|Open-label|Adverse Event|30
6302730|NCT02554890|10027698|FG000|Open-label|Death|0
6302731|NCT02554890|10027699|FG001|Open-label|Death|1
6302732|NCT02554890|10027698|FG000|Open-label|Physician Decision|0
6302733|NCT02554890|10027699|FG001|Open-label|Physician Decision|1
6302734|NCT02554890|10027698|FG000|Open-label|Subject/Guardian decision|0
6302735|NCT02554890|10027699|FG001|Open-label|Subject/Guardian decision|11
6302736|NCT02554890|10027698|FG000|Open-label|Lost to Follow-up|0
6302737|NCT02554890|10027699|FG001|Open-label|Lost to Follow-up|7
6302738|NCT02554890|10027698|FG000|Open-label|Technical problems|0
6302739|NCT02554890|10027699|FG001|Open-label|Technical problems|1
6302740|NCT02554890|10027698|FG000|Open-label|Withdrawal by Subject|0
6302741|NCT02554890|10027699|FG001|Open-label|Withdrawal by Subject|1
6302742|NCT02554903|10027709|FG000|Overall Study|Death|1
6302743|NCT02554903|10027710|FG001|Overall Study|Death|1
6302744|NCT02554903|10027709|FG000|Overall Study|Physician Decision|2
6302745|NCT02554903|10027710|FG001|Overall Study|Physician Decision|2
6302746|NCT02554903|10027709|FG000|Overall Study|Heart Transplant|1
6302747|NCT02554903|10027710|FG001|Overall Study|Heart Transplant|2
6302748|NCT02554929|10027719|FG000|Overall Study|Lost to Follow-up|4
6302749|NCT02554929|10027720|FG001|Overall Study|Lost to Follow-up|4
6302750|NCT02554929|10027719|FG000|Overall Study|Withdrawal by Subject|2
6302751|NCT02554929|10027720|FG001|Overall Study|Withdrawal by Subject|8
6302752|NCT02554981|10027726|FG000|Overall Study|Adverse Event|1
6302753|NCT02554981|10027726|FG000|Overall Study|Administrative Reasons|1
6302754|NCT02554981|10027726|FG000|Overall Study|Other Miscellaneous Reasons|3
6302755|NCT02555215|10027741|FG000|Overall Study|Other|1
6302756|NCT02555215|10027741|FG000|Overall Study|Investigator Decision|2
6302757|NCT02555371|10027771|FG000|PartA(Upto 132W)+PartB(Upto 8W)|Adverse Event|1
6302758|NCT02555371|10027772|FG001|PartA(Upto 132W)+PartB(Upto 8W)|Adverse Event|0
6302759|NCT02555371|10027773|FG002|PartA(Upto 132W)+PartB(Upto 8W)|Adverse Event|0
6302760|NCT02555371|10027774|FG003|PartA(Upto 132W)+PartB(Upto 8W)|Adverse Event|0
6302761|NCT02555371|10027775|FG004|PartA(Upto 132W)+PartB(Upto 8W)|Adverse Event|0
6302762|NCT02555371|10027771|FG000|PartA(Upto 132W)+PartB(Upto 8W)|Failure to meet continuation criteria|2
6302763|NCT02555371|10027772|FG001|PartA(Upto 132W)+PartB(Upto 8W)|Failure to meet continuation criteria|0
6302764|NCT02555371|10027773|FG002|PartA(Upto 132W)+PartB(Upto 8W)|Failure to meet continuation criteria|0
6302765|NCT02555371|10027774|FG003|PartA(Upto 132W)+PartB(Upto 8W)|Failure to meet continuation criteria|0
6302766|NCT02555371|10027775|FG004|PartA(Upto 132W)+PartB(Upto 8W)|Failure to meet continuation criteria|0
6302767|NCT02555371|10027771|FG000|PartA(Upto 132W)+PartB(Upto 8W)|Withdrawal by Subject|5
6302768|NCT02555371|10027772|FG001|PartA(Upto 132W)+PartB(Upto 8W)|Withdrawal by Subject|0
6302769|NCT02555371|10027773|FG002|PartA(Upto 132W)+PartB(Upto 8W)|Withdrawal by Subject|0
6302770|NCT02555371|10027774|FG003|PartA(Upto 132W)+PartB(Upto 8W)|Withdrawal by Subject|0
6302771|NCT02555371|10027775|FG004|PartA(Upto 132W)+PartB(Upto 8W)|Withdrawal by Subject|0
6302772|NCT02555371|10027771|FG000|PartA(Upto 132W)+PartB(Upto 8W)|Physician Decision|1
6302773|NCT02555371|10027772|FG001|PartA(Upto 132W)+PartB(Upto 8W)|Physician Decision|0
6302774|NCT02555371|10027773|FG002|PartA(Upto 132W)+PartB(Upto 8W)|Physician Decision|0
6302775|NCT02555371|10027774|FG003|PartA(Upto 132W)+PartB(Upto 8W)|Physician Decision|0
6302776|NCT02555371|10027775|FG004|PartA(Upto 132W)+PartB(Upto 8W)|Physician Decision|0
6302777|NCT02555371|10027771|FG000|PartA(Upto 132W)+PartB(Upto 8W)|Lack of Efficacy|2
6302778|NCT02555371|10027772|FG001|PartA(Upto 132W)+PartB(Upto 8W)|Lack of Efficacy|0
6302779|NCT02555371|10027773|FG002|PartA(Upto 132W)+PartB(Upto 8W)|Lack of Efficacy|0
6302780|NCT02555371|10027774|FG003|PartA(Upto 132W)+PartB(Upto 8W)|Lack of Efficacy|0
6302781|NCT02555371|10027775|FG004|PartA(Upto 132W)+PartB(Upto 8W)|Lack of Efficacy|0
6302782|NCT02555371|10027771|FG000|Part C (DB Period: Up to 52W)|Switched to Part D treatment|0
6302783|NCT02555371|10027772|FG001|Part C (DB Period: Up to 52W)|Switched to Part D treatment|84
6302784|NCT02555371|10027773|FG002|Part C (DB Period: Up to 52W)|Switched to Part D treatment|45
6302785|NCT02555371|10027774|FG003|Part C (DB Period: Up to 52W)|Switched to Part D treatment|0
6302786|NCT02555371|10027775|FG004|Part C (DB Period: Up to 52W)|Switched to Part D treatment|0
6302787|NCT02555371|10027771|FG000|Part C (DB Period: Up to 52W)|Withdrawal by Subject|0
6302788|NCT02555371|10027772|FG001|Part C (DB Period: Up to 52W)|Withdrawal by Subject|2
6302789|NCT02555371|10027773|FG002|Part C (DB Period: Up to 52W)|Withdrawal by Subject|2
6302790|NCT02555371|10027774|FG003|Part C (DB Period: Up to 52W)|Withdrawal by Subject|0
6302791|NCT02555371|10027775|FG004|Part C (DB Period: Up to 52W)|Withdrawal by Subject|0
6302792|NCT02555371|10027771|FG000|Part C (DB Period: Up to 52W)|Lack of Efficacy|0
6302793|NCT02555371|10027772|FG001|Part C (DB Period: Up to 52W)|Lack of Efficacy|1
6302794|NCT02555371|10027773|FG002|Part C (DB Period: Up to 52W)|Lack of Efficacy|0
6302795|NCT02555371|10027774|FG003|Part C (DB Period: Up to 52W)|Lack of Efficacy|0
6302796|NCT02555371|10027775|FG004|Part C (DB Period: Up to 52W)|Lack of Efficacy|0
6302797|NCT02555371|10027771|FG000|Part C (DB Period: Up to 52W)|Adverse Event|0
6302798|NCT02555371|10027772|FG001|Part C (DB Period: Up to 52W)|Adverse Event|2
6302799|NCT02555371|10027773|FG002|Part C (DB Period: Up to 52W)|Adverse Event|1
6302800|NCT02555371|10027774|FG003|Part C (DB Period: Up to 52W)|Adverse Event|0
6302801|NCT02555371|10027775|FG004|Part C (DB Period: Up to 52W)|Adverse Event|0
6302802|NCT02555371|10027771|FG000|PartD(OL: 52W Post-randomization PartC)|Withdrawal by Subject|0
6302803|NCT02555371|10027772|FG001|PartD(OL: 52W Post-randomization PartC)|Withdrawal by Subject|0
6302804|NCT02555371|10027773|FG002|PartD(OL: 52W Post-randomization PartC)|Withdrawal by Subject|0
6302805|NCT02555371|10027774|FG003|PartD(OL: 52W Post-randomization PartC)|Withdrawal by Subject|1
6302806|NCT02555371|10027775|FG004|PartD(OL: 52W Post-randomization PartC)|Withdrawal by Subject|0
6302807|NCT02555371|10027771|FG000|PartD(OL: 52W Post-randomization PartC)|Physician Decision|0
6302808|NCT02555371|10027772|FG001|PartD(OL: 52W Post-randomization PartC)|Physician Decision|0
6302809|NCT02555371|10027773|FG002|PartD(OL: 52W Post-randomization PartC)|Physician Decision|0
6302810|NCT02555371|10027774|FG003|PartD(OL: 52W Post-randomization PartC)|Physician Decision|2
6302811|NCT02555371|10027775|FG004|PartD(OL: 52W Post-randomization PartC)|Physician Decision|0
6302812|NCT02555371|10027771|FG000|PartD(OL: 52W Post-randomization PartC)|Lost to Follow-up|0
6302813|NCT02555371|10027772|FG001|PartD(OL: 52W Post-randomization PartC)|Lost to Follow-up|0
6302814|NCT02555371|10027773|FG002|PartD(OL: 52W Post-randomization PartC)|Lost to Follow-up|0
6302815|NCT02555371|10027774|FG003|PartD(OL: 52W Post-randomization PartC)|Lost to Follow-up|0
6302816|NCT02555371|10027775|FG004|PartD(OL: 52W Post-randomization PartC)|Lost to Follow-up|2
6302817|NCT02555371|10027771|FG000|PartD(OL: 52W Post-randomization PartC)|Lack of Efficacy|0
6302818|NCT02555371|10027772|FG001|PartD(OL: 52W Post-randomization PartC)|Lack of Efficacy|0
6302819|NCT02555371|10027773|FG002|PartD(OL: 52W Post-randomization PartC)|Lack of Efficacy|0
6302820|NCT02555371|10027774|FG003|PartD(OL: 52W Post-randomization PartC)|Lack of Efficacy|0
6302821|NCT02555371|10027775|FG004|PartD(OL: 52W Post-randomization PartC)|Lack of Efficacy|1
6302822|NCT02555371|10027771|FG000|PartD(OL: 52W Post-randomization PartC)|Adverse Event|0
6302823|NCT02555371|10027772|FG001|PartD(OL: 52W Post-randomization PartC)|Adverse Event|0
6302824|NCT02555371|10027773|FG002|PartD(OL: 52W Post-randomization PartC)|Adverse Event|0
6302825|NCT02555371|10027774|FG003|PartD(OL: 52W Post-randomization PartC)|Adverse Event|1
6302826|NCT02555371|10027775|FG004|PartD(OL: 52W Post-randomization PartC)|Adverse Event|0
6302827|NCT02555618|10027790|FG000|Overall Study|Sponsor's Circumstances|1
6302828|NCT02555618|10027791|FG001|Overall Study|Sponsor's Circumstances|0
6302829|NCT02555683|10027804|FG000|Overall Study|Physician Decision|1
6302830|NCT02555683|10027805|FG001|Overall Study|Physician Decision|0
6302831|NCT02555683|10027806|FG002|Overall Study|Physician Decision|2
6302832|NCT02555683|10027804|FG000|Overall Study|Lost to Follow-up|2
6302833|NCT02555683|10027805|FG001|Overall Study|Lost to Follow-up|1
6302834|NCT02555683|10027806|FG002|Overall Study|Lost to Follow-up|2
6302835|NCT02555683|10027804|FG000|Overall Study|Technical Problems|1
6302836|NCT02555683|10027805|FG001|Overall Study|Technical Problems|1
6302837|NCT02555683|10027806|FG002|Overall Study|Technical Problems|0
6302838|NCT02555683|10027804|FG000|Overall Study|Protocol deviation|0
6302839|NCT02555683|10027805|FG001|Overall Study|Protocol deviation|1
6302840|NCT02555683|10027806|FG002|Overall Study|Protocol deviation|0
6302841|NCT02555683|10027804|FG000|Overall Study|Lack of Efficacy|2
6302842|NCT02555683|10027805|FG001|Overall Study|Lack of Efficacy|0
6302843|NCT02555683|10027806|FG002|Overall Study|Lack of Efficacy|0
6302844|NCT02555683|10027804|FG000|Overall Study|Death|0
6302845|NCT02555683|10027805|FG001|Overall Study|Death|1
6302846|NCT02555683|10027806|FG002|Overall Study|Death|2
6302847|NCT02555683|10027804|FG000|Overall Study|Adverse Event|1
6302848|NCT02555683|10027805|FG001|Overall Study|Adverse Event|0
6302849|NCT02555683|10027806|FG002|Overall Study|Adverse Event|1
6302850|NCT02555683|10027804|FG000|Overall Study|Subject/guardian decision|12
6302851|NCT02555683|10027805|FG001|Overall Study|Subject/guardian decision|12
6302852|NCT02555683|10027806|FG002|Overall Study|Subject/guardian decision|22
6302853|NCT02555683|10027804|FG000|Overall Study|Death post Treatment/safety period|0
6302854|NCT02555683|10027805|FG001|Overall Study|Death post Treatment/safety period|1
6302855|NCT02555683|10027806|FG002|Overall Study|Death post Treatment/safety period|0
6302856|NCT02555722|10027816|FG000|Week 2|Adverse Event|0
6302857|NCT02555722|10027817|FG001|Week 2|Adverse Event|1
6302858|NCT02555722|10027816|FG000|Week 2|Withdrawal by Subject|1
6302859|NCT02555722|10027817|FG001|Week 2|Withdrawal by Subject|0
6302860|NCT02555722|10027816|FG000|Month 1|Lens Discomfort|1
6302861|NCT02555722|10027817|FG001|Month 1|Lens Discomfort|0
6302862|NCT02555722|10027816|FG000|Month 2|Withdrawal by Subject|3
5982312|NCT03679884|9571299|FG002|Overall Study|Withdrawal by Subject|8
5982313|NCT03679884|9571300|FG003|Overall Study|Withdrawal by Subject|8
5982314|NCT03679884|9571301|FG004|Overall Study|Withdrawal by Subject|9
5982315|NCT03679884|9571297|FG000|Overall Study|Lost to Follow-up|1
5982316|NCT03679884|9571298|FG001|Overall Study|Lost to Follow-up|4
5982317|NCT03679884|9571299|FG002|Overall Study|Lost to Follow-up|2
5982318|NCT03679884|9571300|FG003|Overall Study|Lost to Follow-up|0
5982319|NCT03679884|9571301|FG004|Overall Study|Lost to Follow-up|3
5982320|NCT03653026|9571315|FG000|Part 1: Placebo-controlled Period|Adverse Event|5
5982321|NCT03653026|9571316|FG001|Part 1: Placebo-controlled Period|Adverse Event|6
5982322|NCT03653026|9571317|FG002|Part 1: Placebo-controlled Period|Adverse Event|0
5982323|NCT03653026|9571318|FG003|Part 1: Placebo-controlled Period|Adverse Event|0
5982324|NCT03653026|9571315|FG000|Part 1: Placebo-controlled Period|Withdrawal by Subject|6
5982325|NCT03653026|9571316|FG001|Part 1: Placebo-controlled Period|Withdrawal by Subject|4
5982326|NCT03653026|9571317|FG002|Part 1: Placebo-controlled Period|Withdrawal by Subject|0
5982327|NCT03653026|9571318|FG003|Part 1: Placebo-controlled Period|Withdrawal by Subject|0
5982328|NCT03653026|9571315|FG000|Part 1: Placebo-controlled Period|Other|0
5982329|NCT03653026|9571316|FG001|Part 1: Placebo-controlled Period|Other|3
5982330|NCT03653026|9571317|FG002|Part 1: Placebo-controlled Period|Other|0
5982331|NCT03653026|9571318|FG003|Part 1: Placebo-controlled Period|Other|0
5982332|NCT03653026|9571315|FG000|Part 2: Open-label Extension|Adverse Event|0
5982333|NCT03653026|9571316|FG001|Part 2: Open-label Extension|Adverse Event|0
5982334|NCT03653026|9571317|FG002|Part 2: Open-label Extension|Adverse Event|1
5982335|NCT03653026|9571318|FG003|Part 2: Open-label Extension|Adverse Event|1
5982336|NCT03653026|9571315|FG000|Part 2: Open-label Extension|Withdrawal by Subject|0
5982337|NCT03653026|9571316|FG001|Part 2: Open-label Extension|Withdrawal by Subject|0
5982338|NCT03653026|9571317|FG002|Part 2: Open-label Extension|Withdrawal by Subject|1
5982339|NCT03653026|9571318|FG003|Part 2: Open-label Extension|Withdrawal by Subject|2
5982340|NCT03653026|9571315|FG000|Part 2: Open-label Extension|Other|0
5982341|NCT03653026|9571316|FG001|Part 2: Open-label Extension|Other|0
5982342|NCT03653026|9571317|FG002|Part 2: Open-label Extension|Other|1
5982343|NCT03653026|9571318|FG003|Part 2: Open-label Extension|Other|2
6063806|NCT00508261|9665185|FG001|Overall Study|Withdrawal by Subject|4
6063807|NCT00508261|9665186|FG002|Overall Study|Withdrawal by Subject|4
6063808|NCT00508261|9665187|FG003|Overall Study|Withdrawal by Subject|0
6063809|NCT00508261|9665184|FG000|Overall Study|Migrated/ moved from study area|0
6063810|NCT00508261|9665185|FG001|Overall Study|Migrated/ moved from study area|1
6063811|NCT00508261|9665186|FG002|Overall Study|Migrated/ moved from study area|0
6063812|NCT00508261|9665187|FG003|Overall Study|Migrated/ moved from study area|0
6063813|NCT00508261|9665184|FG000|Overall Study|Lost to Follow-up|0
6063814|NCT00508261|9665185|FG001|Overall Study|Lost to Follow-up|1
6063815|NCT00508261|9665186|FG002|Overall Study|Lost to Follow-up|1
6063816|NCT00508261|9665187|FG003|Overall Study|Lost to Follow-up|1
6063817|NCT00508274|9665201|FG000|Overall Study|Adverse Event|5
6063818|NCT00508274|9665201|FG000|Overall Study|Death|7
6063819|NCT00508274|9665201|FG000|Overall Study|Disease progression|32
6063820|NCT00508274|9665201|FG000|Overall Study|Withdrawal by Subject|1
6063821|NCT00508274|9665201|FG000|Overall Study|Subject received new anti-cancer chemotherapy/traditional Chinese medicine|2
6063822|NCT00508274|9665201|FG000|Overall Study|Missing|3
6063823|NCT00508391|9665216|FG000|First Treatment|Withdrawal by Subject|6
6063824|NCT00508391|9665217|FG001|First Treatment|Withdrawal by Subject|3
6063825|NCT00508391|9665216|FG000|Second Treatment|Withdrawal by Subject|2
6063826|NCT00508391|9665217|FG001|Second Treatment|Withdrawal by Subject|0
6063827|NCT00508404|9665225|FG000|Overall Study|Ongoing at Data Cut-off|12
6063828|NCT00508404|9665225|FG000|Overall Study|Adverse Event|2
6063829|NCT00508404|9665225|FG000|Overall Study|Death|16
6063830|NCT00508404|9665225|FG000|Overall Study|Physician Decision|2
6063831|NCT00508404|9665225|FG000|Overall Study|Withdrawal by Subject|3
6063832|NCT00508404|9665225|FG000|Overall Study|Protocol-specified Criteria|2
6063833|NCT00508404|9665225|FG000|Overall Study|Lost to Follow-up|2
6063834|NCT00508404|9665225|FG000|Overall Study|Other - Not Specified|3
6063835|NCT00508482|9665242|FG000|Over 4 Weeks of Treatment|Changed mind, didn't want to participate|9
6137002|NCT01005251|9767095|FG002|Overall Study|Lack of Efficacy|1
6302863|NCT02555722|10027817|FG001|Month 2|Withdrawal by Subject|0
6302864|NCT02555722|10027816|FG000|Month 2|Lost to Follow-up|1
6302865|NCT02555722|10027817|FG001|Month 2|Lost to Follow-up|0
6302866|NCT02555878|10027848|FG000|Overall Study|Lost to Follow-up|2
6302867|NCT02555878|10027849|FG001|Overall Study|Lost to Follow-up|3
6302868|NCT02555878|10027848|FG000|Overall Study|Withdrawal by Subject|48
6302869|NCT02555878|10027849|FG001|Overall Study|Withdrawal by Subject|48
6302870|NCT02555878|10027848|FG000|Overall Study|Adverse Event|12
6302871|NCT02555878|10027849|FG001|Overall Study|Adverse Event|8
6302872|NCT02555878|10027848|FG000|Overall Study|Death|74
6302873|NCT02555878|10027849|FG001|Overall Study|Death|59
6302874|NCT02555878|10027848|FG000|Overall Study|Protocol Violation|1
6302875|NCT02555878|10027849|FG001|Overall Study|Protocol Violation|2
6302876|NCT02555878|10027848|FG000|Overall Study|Physician Decision|12
6302877|NCT02555878|10027849|FG001|Overall Study|Physician Decision|13
6302878|NCT02555878|10027848|FG000|Overall Study|Other|17
6302879|NCT02555878|10027849|FG001|Overall Study|Other|17
6302880|NCT02556138|10027874|FG000|Overall Study|Withdrawal by Subject|1
6302881|NCT02556177|10027880|FG000|Overall Study|Subjects did not complete all 4 visits|283
6302882|NCT02556177|10027881|FG001|Overall Study|Subjects did not complete all 4 visits|61
6302883|NCT02556203|10027889|FG000|Overall Study|Withdrawal by Subject|21
6302884|NCT02556203|10027890|FG001|Overall Study|Withdrawal by Subject|21
6302885|NCT02556203|10027889|FG000|Overall Study|Lost to Follow-up|5
6302886|NCT02556203|10027890|FG001|Overall Study|Lost to Follow-up|5
6302887|NCT02556203|10027889|FG000|Overall Study|Adverse Event|1
6302888|NCT02556203|10027890|FG001|Overall Study|Adverse Event|0
6302889|NCT02556255|10027896|FG000|Overall Study|Lost to Follow-up|4
6302890|NCT02556307|10027900|FG000|Overall Study|Premature treatment interruption|11
6302891|NCT02556307|10027900|FG000|Overall Study|Lost to Follow-up|36
6302892|NCT02556307|10027900|FG000|Overall Study|Change to triple therapy|4
6302893|NCT02556307|10027900|FG000|Overall Study|Enrolled but not treated|2
6302894|NCT02556632|10027929|FG000|Overall Study|Lost to Follow-up|1
6302895|NCT02556632|10027930|FG001|Overall Study|Lost to Follow-up|0
6302896|NCT02556632|10027931|FG002|Overall Study|Lost to Follow-up|0
6302897|NCT02556632|10027929|FG000|Overall Study|Disliked Intervention|1
6302898|NCT02556632|10027930|FG001|Overall Study|Disliked Intervention|1
6302899|NCT02556632|10027931|FG002|Overall Study|Disliked Intervention|1
6302900|NCT02556632|10027929|FG000|Overall Study|No Reason|1
6302901|NCT02556632|10027930|FG001|Overall Study|No Reason|0
6302902|NCT02556632|10027931|FG002|Overall Study|No Reason|1
6302903|NCT02556632|10027929|FG000|Overall Study|Personal Issues|0
6302904|NCT02556632|10027930|FG001|Overall Study|Personal Issues|1
6302905|NCT02556632|10027931|FG002|Overall Study|Personal Issues|1
6302906|NCT02556632|10027929|FG000|Overall Study|Changed Mind|0
6302907|NCT02556632|10027930|FG001|Overall Study|Changed Mind|1
6302908|NCT02556632|10027931|FG002|Overall Study|Changed Mind|0
6302909|NCT02556632|10027929|FG000|Overall Study|Withdrew (Unrelated Medical)|1
6302910|NCT02556632|10027930|FG001|Overall Study|Withdrew (Unrelated Medical)|0
6302911|NCT02556632|10027931|FG002|Overall Study|Withdrew (Unrelated Medical)|0
6302912|NCT02556632|10027929|FG000|Overall Study|Unrelated Adverse Event|1
6302913|NCT02556632|10027930|FG001|Overall Study|Unrelated Adverse Event|0
6302914|NCT02556632|10027931|FG002|Overall Study|Unrelated Adverse Event|3
6302915|NCT02556632|10027929|FG000|Overall Study|Related Adverse Event|0
6063836|NCT00508482|9665243|FG001|Over 4 Weeks of Treatment|Changed mind, didn't want to participate|7
6063837|NCT00508482|9665244|FG002|Over 4 Weeks of Treatment|Changed mind, didn't want to participate|4
6063838|NCT00508482|9665242|FG000|Over 4 Weeks of Treatment|Lost to Follow-up|12
6063839|NCT00508482|9665243|FG001|Over 4 Weeks of Treatment|Lost to Follow-up|10
6063840|NCT00508482|9665244|FG002|Over 4 Weeks of Treatment|Lost to Follow-up|16
6063841|NCT00508482|9665242|FG000|at the 4th Week of Follow-up|Lost to Follow-up|20
6063842|NCT00508482|9665243|FG001|at the 4th Week of Follow-up|Lost to Follow-up|6
6063843|NCT00508482|9665244|FG002|at the 4th Week of Follow-up|Lost to Follow-up|1
6063844|NCT00508651|9665259|FG000|Overall Study|Lost to Follow-up|3
6063845|NCT00508651|9665260|FG001|Overall Study|Lost to Follow-up|1
6063846|NCT00508651|9665259|FG000|Overall Study|Withdrawal by Subject|1
6063847|NCT00508651|9665260|FG001|Overall Study|Withdrawal by Subject|1
6063848|NCT00508742|9665277|FG000|Period 1: Infant Series|Adverse Event|5
6063849|NCT00508742|9665278|FG001|Period 1: Infant Series|Adverse Event|4
6063850|NCT00508742|9665277|FG000|Period 1: Infant Series|Protocol Violation|1
6063851|NCT00508742|9665278|FG001|Period 1: Infant Series|Protocol Violation|0
6063852|NCT00508742|9665277|FG000|Period 1: Infant Series|Parent/Legal Guardian Request|31
6063853|NCT00508742|9665278|FG001|Period 1: Infant Series|Parent/Legal Guardian Request|40
6063854|NCT00508742|9665277|FG000|Period 1: Infant Series|Physician Decision|1
6063855|NCT00508742|9665278|FG001|Period 1: Infant Series|Physician Decision|0
6063856|NCT00508742|9665277|FG000|Period 1: Infant Series|Other|4
6063857|NCT00508742|9665278|FG001|Period 1: Infant Series|Other|1
6063858|NCT00508742|9665277|FG000|Period 2: After Infant Series|Adverse Event|2
6063859|NCT00508742|9665278|FG001|Period 2: After Infant Series|Adverse Event|6
6063860|NCT00508742|9665277|FG000|Period 2: After Infant Series|Lost to Follow-up|1
6063861|NCT00508742|9665278|FG001|Period 2: After Infant Series|Lost to Follow-up|1
6063862|NCT00508742|9665277|FG000|Period 2: After Infant Series|Protocol Violation|1
6063863|NCT00508742|9665278|FG001|Period 2: After Infant Series|Protocol Violation|0
6063864|NCT00508742|9665277|FG000|Period 2: After Infant Series|Parent/Legal Guardian Request|0
6063865|NCT00508742|9665278|FG001|Period 2: After Infant Series|Parent/Legal Guardian Request|3
6302916|NCT02556632|10027930|FG001|Overall Study|Related Adverse Event|1
6302917|NCT02556632|10027931|FG002|Overall Study|Related Adverse Event|0
6302918|NCT02556632|10027929|FG000|Overall Study|Possibly Related Adverse Event|0
6302919|NCT02556632|10027930|FG001|Overall Study|Possibly Related Adverse Event|0
6302920|NCT02556632|10027931|FG002|Overall Study|Possibly Related Adverse Event|1
6302921|NCT02556632|10027929|FG000|Overall Study|Did Not Start RT|0
6302922|NCT02556632|10027930|FG001|Overall Study|Did Not Start RT|1
6302923|NCT02556632|10027931|FG002|Overall Study|Did Not Start RT|0
6302924|NCT02556632|10027929|FG000|Overall Study|Ineligible|0
6302925|NCT02556632|10027930|FG001|Overall Study|Ineligible|1
6302926|NCT02556632|10027931|FG002|Overall Study|Ineligible|0
6302927|NCT02556632|10027929|FG000|Overall Study|Disliked Study Procedures|0
6302928|NCT02556632|10027930|FG001|Overall Study|Disliked Study Procedures|0
6302929|NCT02556632|10027931|FG002|Overall Study|Disliked Study Procedures|1
6302930|NCT02556632|10027929|FG000|Overall Study|Treatment or Change Delay|0
6302931|NCT02556632|10027930|FG001|Overall Study|Treatment or Change Delay|0
6302932|NCT02556632|10027931|FG002|Overall Study|Treatment or Change Delay|1
6302933|NCT02556775|10027943|FG000|Overall Study|Withdrawal by Subject|1
6302934|NCT02556775|10027944|FG001|Overall Study|Withdrawal by Subject|0
6302935|NCT02556775|10027945|FG002|Overall Study|Withdrawal by Subject|1
6302936|NCT02556775|10027946|FG003|Overall Study|Withdrawal by Subject|0
6302937|NCT02556775|10027943|FG000|Overall Study|Lost to Follow-up|1
6302938|NCT02556775|10027944|FG001|Overall Study|Lost to Follow-up|0
6302939|NCT02556775|10027945|FG002|Overall Study|Lost to Follow-up|0
6302940|NCT02556775|10027946|FG003|Overall Study|Lost to Follow-up|0
6302941|NCT02556801|10027971|FG000|Overall Study|Lost to Follow-up|1
6302942|NCT02556801|10027972|FG001|Overall Study|Lost to Follow-up|0
6302943|NCT02556801|10027973|FG002|Overall Study|Lost to Follow-up|2
6302944|NCT02556801|10027974|FG003|Overall Study|Lost to Follow-up|0
6302945|NCT02556801|10027971|FG000|Overall Study|Withdrawal by Subject|1
6302946|NCT02556801|10027972|FG001|Overall Study|Withdrawal by Subject|1
6302947|NCT02556801|10027973|FG002|Overall Study|Withdrawal by Subject|1
6302948|NCT02556801|10027974|FG003|Overall Study|Withdrawal by Subject|0
6302949|NCT02556801|10027971|FG000|Overall Study|Protocol Violation|0
6302950|NCT02556801|10027972|FG001|Overall Study|Protocol Violation|3
6302951|NCT02556801|10027973|FG002|Overall Study|Protocol Violation|1
6302952|NCT02556801|10027974|FG003|Overall Study|Protocol Violation|1
6302953|NCT02556801|10027971|FG000|Overall Study|Adverse Event|0
6302954|NCT02556801|10027972|FG001|Overall Study|Adverse Event|2
6302955|NCT02556801|10027973|FG002|Overall Study|Adverse Event|0
6302956|NCT02556801|10027974|FG003|Overall Study|Adverse Event|3
6302957|NCT02556801|10027971|FG000|Overall Study|Pregnancy|0
6302958|NCT02556801|10027972|FG001|Overall Study|Pregnancy|1
6302959|NCT02556801|10027973|FG002|Overall Study|Pregnancy|0
6302960|NCT02556801|10027974|FG003|Overall Study|Pregnancy|0
6302961|NCT02556801|10027971|FG000|Overall Study|Personal reasons patient|0
6302962|NCT02556801|10027972|FG001|Overall Study|Personal reasons patient|0
6302963|NCT02556801|10027973|FG002|Overall Study|Personal reasons patient|0
6302964|NCT02556801|10027974|FG003|Overall Study|Personal reasons patient|1
6302965|NCT02556918|10027986|FG000|Overall Study|Protocol Violation|5
6302966|NCT02556918|10027987|FG001|Overall Study|Protocol Violation|6
6302967|NCT02556918|10027986|FG000|Overall Study|Withdrawal by Subject|4
6302968|NCT02556918|10027987|FG001|Overall Study|Withdrawal by Subject|4
6302969|NCT02557100|10028006|FG000|Single Blind Treatment Period|Lost to Follow-up|0
6302970|NCT02557100|10028007|FG001|Single Blind Treatment Period|Lost to Follow-up|1
6302971|NCT02557100|10028008|FG002|Single Blind Treatment Period|Lost to Follow-up|0
6302972|NCT02557100|10028006|FG000|Single Blind Treatment Period|Death|0
6302973|NCT02557100|10028007|FG001|Single Blind Treatment Period|Death|1
6302974|NCT02557100|10028008|FG002|Single Blind Treatment Period|Death|0
6302975|NCT02557100|10028006|FG000|Single Blind Treatment Period|Request to Discontinue|0
6302976|NCT02557100|10028007|FG001|Single Blind Treatment Period|Request to Discontinue|1
6302977|NCT02557100|10028008|FG002|Single Blind Treatment Period|Request to Discontinue|0
6302978|NCT02557100|10028006|FG000|Single Blind Treatment Period|Adverse Event|0
6302979|NCT02557100|10028007|FG001|Single Blind Treatment Period|Adverse Event|1
6302980|NCT02557100|10028008|FG002|Single Blind Treatment Period|Adverse Event|0
6302981|NCT02557100|10028006|FG000|Transition to Open Label|Entered Cumulative Abatacept Period|40
6302982|NCT02557100|10028007|FG001|Transition to Open Label|Entered Cumulative Abatacept Period|36
6302983|NCT02557100|10028008|FG002|Transition to Open Label|Entered Cumulative Abatacept Period|0
6302984|NCT02557100|10028006|FG000|Cumulative Abatacept Period|Other Reasons|0
6302985|NCT02557100|10028007|FG001|Cumulative Abatacept Period|Other Reasons|0
6302986|NCT02557100|10028008|FG002|Cumulative Abatacept Period|Other Reasons|1
6302987|NCT02557100|10028006|FG000|Cumulative Abatacept Period|Lost to Follow-up|0
6302988|NCT02557100|10028007|FG001|Cumulative Abatacept Period|Lost to Follow-up|0
6302989|NCT02557100|10028008|FG002|Cumulative Abatacept Period|Lost to Follow-up|2
6302990|NCT02557100|10028006|FG000|Cumulative Abatacept Period|Request to Discontinue|0
6302991|NCT02557100|10028007|FG001|Cumulative Abatacept Period|Request to Discontinue|0
6063866|NCT00508742|9665277|FG000|Period 2: After Infant Series|Failed to Return|1
6063867|NCT00508742|9665278|FG001|Period 2: After Infant Series|Failed to Return|0
6063868|NCT00508742|9665277|FG000|Period 2: After Infant Series|Other|2
6302992|NCT02557100|10028008|FG002|Cumulative Abatacept Period|Request to Discontinue|1
6302993|NCT02557399|10028027|FG000|Overall Study|Adverse Event|6
6302994|NCT02557399|10028028|FG001|Overall Study|Adverse Event|5
6302995|NCT02557399|10028027|FG000|Overall Study|Protocol Violation|0
6302996|NCT02557399|10028028|FG001|Overall Study|Protocol Violation|1
6302997|NCT02557399|10028027|FG000|Overall Study|Protocol-defined stopping criteria|0
6302998|NCT02557399|10028028|FG001|Overall Study|Protocol-defined stopping criteria|1
6302999|NCT02557399|10028027|FG000|Overall Study|Withdrawal by Subject|1
6303000|NCT02557399|10028028|FG001|Overall Study|Withdrawal by Subject|1
6303001|NCT02557516|10028041|FG000|Overall Study|Adverse Event|1
6303002|NCT02557516|10028042|FG001|Overall Study|Adverse Event|0
6303003|NCT02557516|10028043|FG002|Overall Study|Adverse Event|2
6303004|NCT02557516|10028044|FG003|Overall Study|Adverse Event|1
6303005|NCT02557516|10028041|FG000|Overall Study|Disease progression|0
6303006|NCT02557516|10028042|FG001|Overall Study|Disease progression|2
6303007|NCT02557516|10028043|FG002|Overall Study|Disease progression|0
6303008|NCT02557516|10028044|FG003|Overall Study|Disease progression|0
6303009|NCT02557516|10028041|FG000|Overall Study|Physician Decision|0
6303010|NCT02557516|10028042|FG001|Overall Study|Physician Decision|2
6303011|NCT02557516|10028043|FG002|Overall Study|Physician Decision|0
6303012|NCT02557516|10028044|FG003|Overall Study|Physician Decision|0
6303013|NCT02557516|10028041|FG000|Overall Study|Sponsor decision|0
6303014|NCT02557516|10028042|FG001|Overall Study|Sponsor decision|1
6303015|NCT02557516|10028043|FG002|Overall Study|Sponsor decision|2
6303016|NCT02557516|10028044|FG003|Overall Study|Sponsor decision|8
6303017|NCT02557646|10028068|FG000|Overall Study|Adverse Event|40
6303018|NCT02557646|10028068|FG000|Overall Study|Death|1
6303019|NCT02557646|10028068|FG000|Overall Study|Lack of Efficacy|186
6303020|NCT02557646|10028068|FG000|Overall Study|Withdrawal by Subject|18
6303021|NCT02557646|10028068|FG000|Overall Study|Lost to Follow-up|17
6303022|NCT02557646|10028068|FG000|Overall Study|Other|14
6303023|NCT02558231|10028083|FG000|Overall Study|Death|4
6303024|NCT02558231|10028084|FG001|Overall Study|Death|12
6303025|NCT02558231|10028083|FG000|Overall Study|Lost to Follow-up|7
6303026|NCT02558231|10028084|FG001|Overall Study|Lost to Follow-up|4
6303027|NCT02558231|10028083|FG000|Overall Study|Withdrawal by Subject|7
6303028|NCT02558231|10028084|FG001|Overall Study|Withdrawal by Subject|4
6303029|NCT02558231|10028083|FG000|Overall Study|Physician Decision|7
6303030|NCT02558231|10028084|FG001|Overall Study|Physician Decision|5
6303031|NCT02558231|10028083|FG000|Overall Study|Sponsor Decision|0
6303032|NCT02558231|10028084|FG001|Overall Study|Sponsor Decision|1
6303033|NCT02558296|10028092|FG000|Completed the Study Through Week 24|Adverse Event|9
6303034|NCT02558296|10028093|FG001|Completed the Study Through Week 24|Adverse Event|3
6303035|NCT02558296|10028092|FG000|Completed the Study Through Week 24|Death|7
6303036|NCT02558296|10028093|FG001|Completed the Study Through Week 24|Death|7
6303037|NCT02558296|10028092|FG000|Completed the Study Through Week 24|Lost to Follow-up|8
6303038|NCT02558296|10028093|FG001|Completed the Study Through Week 24|Lost to Follow-up|1
6303039|NCT02558296|10028092|FG000|Completed the Study Through Week 24|Physician Decision|1
6303040|NCT02558296|10028093|FG001|Completed the Study Through Week 24|Physician Decision|0
6303041|NCT02558296|10028092|FG000|Completed the Study Through Week 24|Protocol Violation|1
6303042|NCT02558296|10028093|FG001|Completed the Study Through Week 24|Protocol Violation|1
6303043|NCT02558296|10028092|FG000|Completed the Study Through Week 24|Withdrawal by Subject|17
6303044|NCT02558296|10028093|FG001|Completed the Study Through Week 24|Withdrawal by Subject|13
6303045|NCT02558296|10028092|FG000|Completed the Study Through Week 24|The subject was randomized, but did not take any investigational product|1
6303046|NCT02558296|10028093|FG001|Completed the Study Through Week 24|The subject was randomized, but did not take any investigational product|0
6303047|NCT02558296|10028092|FG000|Completed the Study|Adverse Event|14
6303048|NCT02558296|10028093|FG001|Completed the Study|Adverse Event|5
6303049|NCT02558296|10028092|FG000|Completed the Study|Death|39
6303050|NCT02558296|10028093|FG001|Completed the Study|Death|25
6303051|NCT02558296|10028092|FG000|Completed the Study|Lost to Follow-up|31
6303052|NCT02558296|10028093|FG001|Completed the Study|Lost to Follow-up|23
6303053|NCT02558296|10028092|FG000|Completed the Study|Physician Decision|6
6303054|NCT02558296|10028093|FG001|Completed the Study|Physician Decision|0
6303055|NCT02558296|10028092|FG000|Completed the Study|Protocol Violation|2
6303056|NCT02558296|10028093|FG001|Completed the Study|Protocol Violation|1
6303057|NCT02558296|10028092|FG000|Completed the Study|Withdrawal by Subject|53
6303058|NCT02558296|10028093|FG001|Completed the Study|Withdrawal by Subject|31
6303059|NCT02558296|10028092|FG000|Completed the Study|The subject was randomized, but did not take any investigational product|1
6303060|NCT02558296|10028093|FG001|Completed the Study|The subject was randomized, but did not take any investigational product|0
6303061|NCT02558400|10028115|FG000|Overall Study|Adverse Event|47
6303062|NCT02558400|10028116|FG001|Overall Study|Adverse Event|53
6303063|NCT02558400|10028117|FG002|Overall Study|Adverse Event|4
6303064|NCT02558400|10028115|FG000|Overall Study|Withdrawal by Subject|13
6303065|NCT02558400|10028116|FG001|Overall Study|Withdrawal by Subject|9
6303066|NCT02558400|10028117|FG002|Overall Study|Withdrawal by Subject|8
6303067|NCT02558400|10028115|FG000|Overall Study|Non-Compliant|0
6303068|NCT02558400|10028116|FG001|Overall Study|Non-Compliant|1
6303069|NCT02558400|10028117|FG002|Overall Study|Non-Compliant|3
6303070|NCT02558400|10028115|FG000|Overall Study|Lost to Follow-up|5
6303071|NCT02558400|10028116|FG001|Overall Study|Lost to Follow-up|5
6303072|NCT02558400|10028117|FG002|Overall Study|Lost to Follow-up|4
6303073|NCT02558400|10028115|FG000|Overall Study|Lack of Efficacy|0
6303074|NCT02558400|10028116|FG001|Overall Study|Lack of Efficacy|13
6303075|NCT02558400|10028117|FG002|Overall Study|Lack of Efficacy|1
6303076|NCT02558400|10028115|FG000|Overall Study|Disallowed Concurrent Medication|6
6303077|NCT02558400|10028116|FG001|Overall Study|Disallowed Concurrent Medication|7
6303078|NCT02558400|10028117|FG002|Overall Study|Disallowed Concurrent Medication|5
6303079|NCT02558400|10028115|FG000|Overall Study|Physician Decision|2
6303080|NCT02558400|10028116|FG001|Overall Study|Physician Decision|2
6303081|NCT02558400|10028117|FG002|Overall Study|Physician Decision|0
6303082|NCT02558400|10028115|FG000|Overall Study|Protocol Violation|6
6303083|NCT02558400|10028116|FG001|Overall Study|Protocol Violation|3
6303084|NCT02558400|10028117|FG002|Overall Study|Protocol Violation|8
6303085|NCT02558400|10028115|FG000|Overall Study|Death|0
6303086|NCT02558400|10028116|FG001|Overall Study|Death|1
6303087|NCT02558400|10028117|FG002|Overall Study|Death|0
6303088|NCT02558400|10028115|FG000|Overall Study|Ineligible for the study|0
6303089|NCT02558400|10028116|FG001|Overall Study|Ineligible for the study|2
6303090|NCT02558400|10028117|FG002|Overall Study|Ineligible for the study|0
6303091|NCT02558790|10028128|FG000|Overall Study|Lost to Follow-up|2
6303092|NCT02558790|10028128|FG000|Overall Study|Physician Decision|1
6303093|NCT02558790|10028128|FG000|Overall Study|Withdrawal by Subject|1
6303094|NCT02558790|10028128|FG000|Overall Study|Screen Fail|3
6303095|NCT02558894|10028167|FG000|Overall Study|Death; any cause, entire study duration|28
6303096|NCT02558894|10028168|FG001|Overall Study|Death; any cause, entire study duration|31
6303097|NCT02558894|10028167|FG000|Overall Study|Withdrawal by Subject|2
6303098|NCT02558894|10028168|FG001|Overall Study|Withdrawal by Subject|1
6303099|NCT02558894|10028167|FG000|Overall Study|Closure of Part A|2
6303100|NCT02558894|10028168|FG001|Overall Study|Closure of Part A|1
6303101|NCT02559115|10028174|FG000|Overall Study|Withdrawal by Subject|3
6303102|NCT02559206|10028186|FG000|Overall Study|Adverse Event|0
6303103|NCT02559206|10028187|FG001|Overall Study|Adverse Event|4
6303104|NCT02559206|10028188|FG002|Overall Study|Adverse Event|1
6303105|NCT02559206|10028189|FG003|Overall Study|Adverse Event|5
6303106|NCT02559206|10028190|FG004|Overall Study|Adverse Event|3
6303107|NCT02559206|10028191|FG005|Overall Study|Adverse Event|0
6303108|NCT02559206|10028192|FG006|Overall Study|Adverse Event|1
6303109|NCT02559206|10028193|FG007|Overall Study|Adverse Event|0
6303110|NCT02559206|10028186|FG000|Overall Study|Protocol Violation|1
6303111|NCT02559206|10028187|FG001|Overall Study|Protocol Violation|0
6303112|NCT02559206|10028188|FG002|Overall Study|Protocol Violation|1
6303113|NCT02559206|10028189|FG003|Overall Study|Protocol Violation|0
6303114|NCT02559206|10028190|FG004|Overall Study|Protocol Violation|0
6303115|NCT02559206|10028191|FG005|Overall Study|Protocol Violation|2
6303116|NCT02559206|10028192|FG006|Overall Study|Protocol Violation|0
6303117|NCT02559206|10028193|FG007|Overall Study|Protocol Violation|0
6303118|NCT02559206|10028186|FG000|Overall Study|Withdrawal by Subject|3
6303119|NCT02559206|10028187|FG001|Overall Study|Withdrawal by Subject|3
6303120|NCT02559206|10028188|FG002|Overall Study|Withdrawal by Subject|1
6303121|NCT02559206|10028189|FG003|Overall Study|Withdrawal by Subject|3
6303122|NCT02559206|10028190|FG004|Overall Study|Withdrawal by Subject|5
6303123|NCT02559206|10028191|FG005|Overall Study|Withdrawal by Subject|4
6303124|NCT02559206|10028192|FG006|Overall Study|Withdrawal by Subject|1
6303125|NCT02559206|10028193|FG007|Overall Study|Withdrawal by Subject|2
6303126|NCT02559206|10028186|FG000|Overall Study|Lost to Follow-up|3
6303127|NCT02559206|10028187|FG001|Overall Study|Lost to Follow-up|5
6303128|NCT02559206|10028188|FG002|Overall Study|Lost to Follow-up|3
6303129|NCT02559206|10028189|FG003|Overall Study|Lost to Follow-up|3
6303130|NCT02559206|10028190|FG004|Overall Study|Lost to Follow-up|2
6303131|NCT02559206|10028191|FG005|Overall Study|Lost to Follow-up|5
6303132|NCT02559206|10028192|FG006|Overall Study|Lost to Follow-up|1
6303133|NCT02559206|10028193|FG007|Overall Study|Lost to Follow-up|4
6303134|NCT02559206|10028186|FG000|Overall Study|Lack of Efficacy|1
6303135|NCT02559206|10028187|FG001|Overall Study|Lack of Efficacy|0
6303136|NCT02559206|10028188|FG002|Overall Study|Lack of Efficacy|3
6303137|NCT02559206|10028189|FG003|Overall Study|Lack of Efficacy|2
6303138|NCT02559206|10028190|FG004|Overall Study|Lack of Efficacy|2
6303139|NCT02559206|10028191|FG005|Overall Study|Lack of Efficacy|3
6303140|NCT02559206|10028192|FG006|Overall Study|Lack of Efficacy|3
6303141|NCT02559206|10028193|FG007|Overall Study|Lack of Efficacy|3
6303142|NCT02559206|10028186|FG000|Overall Study|Other Not Specified|0
6303143|NCT02559206|10028187|FG001|Overall Study|Other Not Specified|0
6303144|NCT02559206|10028188|FG002|Overall Study|Other Not Specified|0
6303145|NCT02559206|10028189|FG003|Overall Study|Other Not Specified|1
6303146|NCT02559206|10028190|FG004|Overall Study|Other Not Specified|0
6303147|NCT02559206|10028191|FG005|Overall Study|Other Not Specified|0
6303148|NCT02559206|10028192|FG006|Overall Study|Other Not Specified|0
6303149|NCT02559206|10028193|FG007|Overall Study|Other Not Specified|0
6303150|NCT02559310|10028213|FG000|Overall Study|Death|4
6303151|NCT02559310|10028214|FG001|Overall Study|Death|3
6303152|NCT02559310|10028213|FG000|Overall Study|Lost to Follow-up|5
6303153|NCT02559310|10028214|FG001|Overall Study|Lost to Follow-up|3
6303154|NCT02559310|10028213|FG000|Overall Study|Physician Decision|2
6303155|NCT02559310|10028214|FG001|Overall Study|Physician Decision|1
6303156|NCT02559310|10028213|FG000|Overall Study|Withdrawal by Subject|13
6303157|NCT02559310|10028214|FG001|Overall Study|Withdrawal by Subject|9
6303158|NCT02559310|10028213|FG000|Overall Study|Sponsor Decision|0
6303159|NCT02559310|10028214|FG001|Overall Study|Sponsor Decision|1
6303160|NCT02559310|10028213|FG000|Overall Study|Randomized but not treated|3
6303161|NCT02559310|10028214|FG001|Overall Study|Randomized but not treated|2
6303162|NCT02559414|10028223|FG000|Overall Study|Lost to Follow-up|0
6303163|NCT02559414|10028224|FG001|Overall Study|Lost to Follow-up|1
6303164|NCT02559414|10028225|FG002|Overall Study|Lost to Follow-up|0
6303165|NCT02559414|10028223|FG000|Overall Study|Withdrawal by Subject|1
6303166|NCT02559414|10028224|FG001|Overall Study|Withdrawal by Subject|0
6303167|NCT02559414|10028225|FG002|Overall Study|Withdrawal by Subject|1
6303168|NCT02559414|10028223|FG000|Overall Study|Other|0
6303169|NCT02559414|10028224|FG001|Overall Study|Other|1
6303170|NCT02559414|10028225|FG002|Overall Study|Other|1
6303171|NCT02559505|10028250|FG000|Overall Study|Lost to Follow-up|23
6303172|NCT02559505|10028251|FG001|Overall Study|Lost to Follow-up|20
6303173|NCT02559505|10028250|FG000|Overall Study|Withdrawal by Subject|4
6303174|NCT02559505|10028251|FG001|Overall Study|Withdrawal by Subject|2
6303175|NCT02559570|10028274|FG000|Overall Study|Adverse Event|0
6303176|NCT02559570|10028275|FG001|Overall Study|Adverse Event|2
6303177|NCT02559570|10028276|FG002|Overall Study|Adverse Event|0
6303178|NCT02559570|10028277|FG003|Overall Study|Adverse Event|1
6303179|NCT02559570|10028278|FG004|Overall Study|Adverse Event|0
6303180|NCT02559570|10028274|FG000|Overall Study|Withdrawal of Consent|0
6303181|NCT02559570|10028275|FG001|Overall Study|Withdrawal of Consent|0
6303182|NCT02559570|10028276|FG002|Overall Study|Withdrawal of Consent|1
6303183|NCT02559570|10028277|FG003|Overall Study|Withdrawal of Consent|2
6303184|NCT02559570|10028278|FG004|Overall Study|Withdrawal of Consent|1
6303185|NCT02559570|10028274|FG000|Overall Study|Lost to Follow-up|1
6303186|NCT02559570|10028275|FG001|Overall Study|Lost to Follow-up|0
6303187|NCT02559570|10028276|FG002|Overall Study|Lost to Follow-up|0
6303188|NCT02559570|10028277|FG003|Overall Study|Lost to Follow-up|0
6303189|NCT02559570|10028278|FG004|Overall Study|Lost to Follow-up|0
6303190|NCT02559570|10028274|FG000|Overall Study|Protocol Violation|1
6303191|NCT02559570|10028275|FG001|Overall Study|Protocol Violation|0
6303192|NCT02559570|10028276|FG002|Overall Study|Protocol Violation|0
6303193|NCT02559570|10028277|FG003|Overall Study|Protocol Violation|0
6303194|NCT02559570|10028278|FG004|Overall Study|Protocol Violation|1
6303195|NCT02559570|10028274|FG000|Overall Study|Other Miscellaneous Reasons|0
6303196|NCT02559570|10028275|FG001|Overall Study|Other Miscellaneous Reasons|0
6303197|NCT02559570|10028276|FG002|Overall Study|Other Miscellaneous Reasons|1
6303198|NCT02559570|10028277|FG003|Overall Study|Other Miscellaneous Reasons|0
6303199|NCT02559570|10028278|FG004|Overall Study|Other Miscellaneous Reasons|0
6303200|NCT02559622|10028293|FG000|Overall Study|Progressive disease|0
6303201|NCT02559622|10028294|FG001|Overall Study|Progressive disease|1
6303202|NCT02559622|10028295|FG002|Overall Study|Progressive disease|0
6303203|NCT02559622|10028296|FG003|Overall Study|Progressive disease|0
6303204|NCT02559622|10028293|FG000|Overall Study|Adverse Event|0
6303205|NCT02559622|10028294|FG001|Overall Study|Adverse Event|2
6303206|NCT02559622|10028295|FG002|Overall Study|Adverse Event|2
6303207|NCT02559622|10028296|FG003|Overall Study|Adverse Event|2
6303208|NCT02559622|10028293|FG000|Overall Study|Patient/guardian decision|1
6303209|NCT02559622|10028294|FG001|Overall Study|Patient/guardian decision|2
6303210|NCT02559622|10028295|FG002|Overall Study|Patient/guardian decision|0
6303211|NCT02559622|10028296|FG003|Overall Study|Patient/guardian decision|1
6303212|NCT02559687|10028310|FG000|Overall Study|Death|103
6303213|NCT02559687|10028310|FG000|Overall Study|Withdrawal by Subject|4
6303214|NCT02559687|10028310|FG000|Overall Study|Ongoing Follow-Up|14
6303215|NCT02559713|10028314|FG000|Overall Study|Pretreatment Event/ Adverse Event|1
6303216|NCT02559817|10028323|FG000|Treatment Period|Adverse Event|1
6303217|NCT02559817|10028324|FG001|Treatment Period|Adverse Event|0
6303218|NCT02559817|10028325|FG002|Treatment Period|Adverse Event|1
6303219|NCT02559817|10028326|FG003|Treatment Period|Adverse Event|0
6303220|NCT02559817|10028327|FG004|Treatment Period|Adverse Event|0
6303221|NCT02559817|10028323|FG000|Treatment Period|Lack of Efficacy|0
6303222|NCT02559817|10028324|FG001|Treatment Period|Lack of Efficacy|1
6303223|NCT02559817|10028325|FG002|Treatment Period|Lack of Efficacy|0
6303224|NCT02559817|10028326|FG003|Treatment Period|Lack of Efficacy|0
6303225|NCT02559817|10028327|FG004|Treatment Period|Lack of Efficacy|0
6303226|NCT02559817|10028323|FG000|Treatment Period|Lost to Follow-up|0
6303227|NCT02559817|10028324|FG001|Treatment Period|Lost to Follow-up|1
6303228|NCT02559817|10028325|FG002|Treatment Period|Lost to Follow-up|0
6303229|NCT02559817|10028326|FG003|Treatment Period|Lost to Follow-up|1
6303230|NCT02559817|10028327|FG004|Treatment Period|Lost to Follow-up|0
6303231|NCT02559817|10028323|FG000|Treatment Period|Non-Compliance With Study Drug|0
6303232|NCT02559817|10028324|FG001|Treatment Period|Non-Compliance With Study Drug|0
6303233|NCT02559817|10028325|FG002|Treatment Period|Non-Compliance With Study Drug|1
6303234|NCT02559817|10028326|FG003|Treatment Period|Non-Compliance With Study Drug|0
6303235|NCT02559817|10028327|FG004|Treatment Period|Non-Compliance With Study Drug|0
6303236|NCT02559817|10028323|FG000|Treatment Period|Protocol Violation|0
6303237|NCT02559817|10028324|FG001|Treatment Period|Protocol Violation|0
6303238|NCT02559817|10028325|FG002|Treatment Period|Protocol Violation|0
6303239|NCT02559817|10028326|FG003|Treatment Period|Protocol Violation|1
6303240|NCT02559817|10028327|FG004|Treatment Period|Protocol Violation|0
6303241|NCT02559895|10028343|FG000|Overall Study|Adverse Event|3
6303242|NCT02559895|10028344|FG001|Overall Study|Adverse Event|3
6303243|NCT02559895|10028345|FG002|Overall Study|Adverse Event|2
6303244|NCT02559895|10028346|FG003|Overall Study|Adverse Event|1
6303245|NCT02559895|10028343|FG000|Overall Study|Lack of Efficacy|2
6303246|NCT02559895|10028344|FG001|Overall Study|Lack of Efficacy|3
6303247|NCT02559895|10028345|FG002|Overall Study|Lack of Efficacy|2
6303248|NCT02559895|10028346|FG003|Overall Study|Lack of Efficacy|8
6303249|NCT02559895|10028343|FG000|Overall Study|Lost to Follow-up|22
6303250|NCT02559895|10028344|FG001|Overall Study|Lost to Follow-up|16
6303251|NCT02559895|10028345|FG002|Overall Study|Lost to Follow-up|12
6303252|NCT02559895|10028346|FG003|Overall Study|Lost to Follow-up|17
6303253|NCT02559895|10028343|FG000|Overall Study|Physician Decision|1
6303254|NCT02559895|10028344|FG001|Overall Study|Physician Decision|1
6303255|NCT02559895|10028345|FG002|Overall Study|Physician Decision|3
6303256|NCT02559895|10028346|FG003|Overall Study|Physician Decision|0
6303257|NCT02559895|10028343|FG000|Overall Study|Withdrawal by Subject|16
6303258|NCT02559895|10028344|FG001|Overall Study|Withdrawal by Subject|9
6303259|NCT02559895|10028345|FG002|Overall Study|Withdrawal by Subject|20
6303260|NCT02559895|10028346|FG003|Overall Study|Withdrawal by Subject|9
6303261|NCT02559895|10028343|FG000|Overall Study|Study Burden|10
6303262|NCT02559895|10028344|FG001|Overall Study|Study Burden|16
6303263|NCT02559895|10028345|FG002|Overall Study|Study Burden|12
6303264|NCT02559895|10028346|FG003|Overall Study|Study Burden|22
6303265|NCT02559895|10028343|FG000|Overall Study|Other|1
6303266|NCT02559895|10028344|FG001|Overall Study|Other|5
6303267|NCT02559895|10028345|FG002|Overall Study|Other|3
6303268|NCT02559895|10028346|FG003|Overall Study|Other|3
6303269|NCT02560012|10028356|FG000|Overall Study|Study Terminated|2
6303270|NCT02560025|10028360|FG000|Overall Study|Ineligible after consent/ registration|3
6303271|NCT02560389|10028397|FG000|Overall Study|Lost to Follow-up|1
6303272|NCT02560389|10028398|FG001|Overall Study|Lost to Follow-up|2
6303273|NCT02560389|10028399|FG002|Overall Study|Lost to Follow-up|2
6303274|NCT02560389|10028397|FG000|Overall Study|Tested positive for illicit substance|0
6303275|NCT02560389|10028398|FG001|Overall Study|Tested positive for illicit substance|1
6303276|NCT02560389|10028399|FG002|Overall Study|Tested positive for illicit substance|0
6303277|NCT02560558|10028418|FG000|Overall Study|Adverse Event|1
6303278|NCT02560558|10028419|FG001|Overall Study|Adverse Event|0
6303279|NCT02560558|10028418|FG000|Overall Study|Death|0
6303280|NCT02560558|10028419|FG001|Overall Study|Death|2
6303281|NCT02560558|10028418|FG000|Overall Study|Lost to Follow-up|0
6303282|NCT02560558|10028419|FG001|Overall Study|Lost to Follow-up|4
6303283|NCT02560558|10028418|FG000|Overall Study|Protocol Violation|3
6303284|NCT02560558|10028419|FG001|Overall Study|Protocol Violation|0
6303285|NCT02560558|10028418|FG000|Overall Study|Withdrawal by Subject|3
6303286|NCT02560558|10028419|FG001|Overall Study|Withdrawal by Subject|0
6303287|NCT02561000|10028478|FG000|Overall Study|Withdrawal by Subject|2
6303288|NCT02561000|10028479|FG001|Overall Study|Withdrawal by Subject|3
6303289|NCT02561000|10028480|FG002|Overall Study|Withdrawal by Subject|0
6303290|NCT02561000|10028478|FG000|Overall Study|Adverse Event|0
6303291|NCT02561000|10028479|FG001|Overall Study|Adverse Event|1
6303292|NCT02561000|10028480|FG002|Overall Study|Adverse Event|0
6303293|NCT02561078|10028490|FG000|Overall Study|Adverse Event|5
6303294|NCT02561078|10028491|FG001|Overall Study|Adverse Event|2
6303295|NCT02561078|10028490|FG000|Overall Study|Death|2
6303296|NCT02561078|10028491|FG001|Overall Study|Death|1
6303297|NCT02561078|10028490|FG000|Overall Study|Lost to Follow-up|2
6303298|NCT02561078|10028491|FG001|Overall Study|Lost to Follow-up|6
6303299|NCT02561078|10028490|FG000|Overall Study|Non-Compliance with Study Drug|6
6303300|NCT02561078|10028491|FG001|Overall Study|Non-Compliance with Study Drug|3
6303301|NCT02561078|10028490|FG000|Overall Study|Physician Decision|2
6303302|NCT02561078|10028491|FG001|Overall Study|Physician Decision|3
6303303|NCT02561078|10028490|FG000|Overall Study|Withdrawal by Subject|13
6303304|NCT02561078|10028491|FG001|Overall Study|Withdrawal by Subject|10
6303305|NCT02561156|10028519|FG000|Part 2|Adverse Event|0
6303306|NCT02561156|10028520|FG001|Part 2|Adverse Event|0
6303307|NCT02561156|10028521|FG002|Part 2|Adverse Event|0
6303308|NCT02561156|10028522|FG003|Part 2|Adverse Event|0
6303309|NCT02561156|10028523|FG004|Part 2|Adverse Event|0
6303310|NCT02561156|10028524|FG005|Part 2|Adverse Event|0
6303311|NCT02561156|10028525|FG006|Part 2|Adverse Event|0
6303312|NCT02561156|10028526|FG007|Part 2|Adverse Event|0
6303313|NCT02561156|10028527|FG008|Part 2|Adverse Event|0
6303314|NCT02561156|10028528|FG009|Part 2|Adverse Event|0
6303315|NCT02561156|10028529|FG010|Part 2|Adverse Event|0
6303316|NCT02561156|10028530|FG011|Part 2|Adverse Event|1
6303317|NCT02561156|10028531|FG012|Part 2|Adverse Event|0
6303318|NCT02561195|10028581|FG000|Vaccination 1 to 3|Adverse Event|4
6303319|NCT02561195|10028582|FG001|Vaccination 1 to 3|Adverse Event|5
6303320|NCT02561195|10028583|FG002|Vaccination 1 to 3|Adverse Event|0
6303321|NCT02561195|10028584|FG003|Vaccination 1 to 3|Adverse Event|3
6303322|NCT02561195|10028585|FG004|Vaccination 1 to 3|Adverse Event|4
6303323|NCT02561195|10028586|FG005|Vaccination 1 to 3|Adverse Event|0
6303324|NCT02561195|10028587|FG006|Vaccination 1 to 3|Adverse Event|0
6303325|NCT02561195|10028588|FG007|Vaccination 1 to 3|Adverse Event|0
6303326|NCT02561195|10028589|FG008|Vaccination 1 to 3|Adverse Event|0
6303327|NCT02561195|10028590|FG009|Vaccination 1 to 3|Adverse Event|0
6303328|NCT02561195|10028591|FG010|Vaccination 1 to 3|Adverse Event|0
6303329|NCT02561195|10028592|FG011|Vaccination 1 to 3|Adverse Event|0
6303330|NCT02561195|10028593|FG012|Vaccination 1 to 3|Adverse Event|0
6303331|NCT02561195|10028594|FG013|Vaccination 1 to 3|Adverse Event|0
6303332|NCT02561195|10028581|FG000|Vaccination 1 to 3|Lost to Follow-up|3
6303333|NCT02561195|10028582|FG001|Vaccination 1 to 3|Lost to Follow-up|4
6303334|NCT02561195|10028583|FG002|Vaccination 1 to 3|Lost to Follow-up|0
6303335|NCT02561195|10028584|FG003|Vaccination 1 to 3|Lost to Follow-up|2
6303336|NCT02561195|10028585|FG004|Vaccination 1 to 3|Lost to Follow-up|3
6303337|NCT02561195|10028586|FG005|Vaccination 1 to 3|Lost to Follow-up|3
6303338|NCT02561195|10028587|FG006|Vaccination 1 to 3|Lost to Follow-up|0
6303339|NCT02561195|10028588|FG007|Vaccination 1 to 3|Lost to Follow-up|0
6303340|NCT02561195|10028589|FG008|Vaccination 1 to 3|Lost to Follow-up|0
6303341|NCT02561195|10028590|FG009|Vaccination 1 to 3|Lost to Follow-up|0
6303342|NCT02561195|10028591|FG010|Vaccination 1 to 3|Lost to Follow-up|0
6303343|NCT02561195|10028592|FG011|Vaccination 1 to 3|Lost to Follow-up|0
6303344|NCT02561195|10028593|FG012|Vaccination 1 to 3|Lost to Follow-up|0
6303345|NCT02561195|10028594|FG013|Vaccination 1 to 3|Lost to Follow-up|0
6303346|NCT02561195|10028581|FG000|Vaccination 1 to 3|No longer meets eligibility criteria|0
6303347|NCT02561195|10028582|FG001|Vaccination 1 to 3|No longer meets eligibility criteria|1
6303348|NCT02561195|10028583|FG002|Vaccination 1 to 3|No longer meets eligibility criteria|0
6303349|NCT02561195|10028584|FG003|Vaccination 1 to 3|No longer meets eligibility criteria|4
6303350|NCT02561195|10028585|FG004|Vaccination 1 to 3|No longer meets eligibility criteria|4
6303351|NCT02561195|10028586|FG005|Vaccination 1 to 3|No longer meets eligibility criteria|1
6303352|NCT02561195|10028587|FG006|Vaccination 1 to 3|No longer meets eligibility criteria|0
6303353|NCT02561195|10028588|FG007|Vaccination 1 to 3|No longer meets eligibility criteria|0
6303354|NCT02561195|10028589|FG008|Vaccination 1 to 3|No longer meets eligibility criteria|0
6303355|NCT02561195|10028590|FG009|Vaccination 1 to 3|No longer meets eligibility criteria|0
6303356|NCT02561195|10028591|FG010|Vaccination 1 to 3|No longer meets eligibility criteria|0
6303357|NCT02561195|10028592|FG011|Vaccination 1 to 3|No longer meets eligibility criteria|0
6303358|NCT02561195|10028593|FG012|Vaccination 1 to 3|No longer meets eligibility criteria|0
6303359|NCT02561195|10028594|FG013|Vaccination 1 to 3|No longer meets eligibility criteria|0
6303360|NCT02561195|10028581|FG000|Vaccination 1 to 3|No longer willing to participate|2
6303361|NCT02561195|10028582|FG001|Vaccination 1 to 3|No longer willing to participate|4
6303362|NCT02561195|10028583|FG002|Vaccination 1 to 3|No longer willing to participate|0
6303363|NCT02561195|10028584|FG003|Vaccination 1 to 3|No longer willing to participate|4
6303364|NCT02561195|10028585|FG004|Vaccination 1 to 3|No longer willing to participate|1
6303365|NCT02561195|10028586|FG005|Vaccination 1 to 3|No longer willing to participate|3
6303366|NCT02561195|10028587|FG006|Vaccination 1 to 3|No longer willing to participate|0
6303367|NCT02561195|10028588|FG007|Vaccination 1 to 3|No longer willing to participate|0
6303368|NCT02561195|10028589|FG008|Vaccination 1 to 3|No longer willing to participate|0
6303369|NCT02561195|10028590|FG009|Vaccination 1 to 3|No longer willing to participate|0
6303370|NCT02561195|10028591|FG010|Vaccination 1 to 3|No longer willing to participate|0
6303371|NCT02561195|10028592|FG011|Vaccination 1 to 3|No longer willing to participate|0
6303372|NCT02561195|10028593|FG012|Vaccination 1 to 3|No longer willing to participate|0
6303373|NCT02561195|10028594|FG013|Vaccination 1 to 3|No longer willing to participate|0
6303374|NCT02561195|10028581|FG000|Vaccination 1 to 3|Other|7
6303375|NCT02561195|10028582|FG001|Vaccination 1 to 3|Other|3
6303376|NCT02561195|10028583|FG002|Vaccination 1 to 3|Other|1
6303377|NCT02561195|10028584|FG003|Vaccination 1 to 3|Other|7
6303378|NCT02561195|10028585|FG004|Vaccination 1 to 3|Other|5
6303379|NCT02561195|10028586|FG005|Vaccination 1 to 3|Other|1
6303380|NCT02561195|10028587|FG006|Vaccination 1 to 3|Other|0
6303381|NCT02561195|10028588|FG007|Vaccination 1 to 3|Other|0
6303382|NCT02561195|10028589|FG008|Vaccination 1 to 3|Other|0
6303383|NCT02561195|10028590|FG009|Vaccination 1 to 3|Other|0
6303384|NCT02561195|10028591|FG010|Vaccination 1 to 3|Other|0
6303385|NCT02561195|10028592|FG011|Vaccination 1 to 3|Other|0
6303386|NCT02561195|10028593|FG012|Vaccination 1 to 3|Other|0
6303387|NCT02561195|10028594|FG013|Vaccination 1 to 3|Other|0
6303388|NCT02561195|10028581|FG000|Vaccination 1 to 3|Protocol Violation|1
6303389|NCT02561195|10028582|FG001|Vaccination 1 to 3|Protocol Violation|0
6303390|NCT02561195|10028583|FG002|Vaccination 1 to 3|Protocol Violation|1
6303391|NCT02561195|10028584|FG003|Vaccination 1 to 3|Protocol Violation|2
6303392|NCT02561195|10028585|FG004|Vaccination 1 to 3|Protocol Violation|5
6303393|NCT02561195|10028586|FG005|Vaccination 1 to 3|Protocol Violation|2
6303394|NCT02561195|10028587|FG006|Vaccination 1 to 3|Protocol Violation|0
6303395|NCT02561195|10028588|FG007|Vaccination 1 to 3|Protocol Violation|0
6303396|NCT02561195|10028589|FG008|Vaccination 1 to 3|Protocol Violation|0
6303397|NCT02561195|10028590|FG009|Vaccination 1 to 3|Protocol Violation|0
6303398|NCT02561195|10028591|FG010|Vaccination 1 to 3|Protocol Violation|0
6303399|NCT02561195|10028592|FG011|Vaccination 1 to 3|Protocol Violation|0
6303400|NCT02561195|10028593|FG012|Vaccination 1 to 3|Protocol Violation|0
6303401|NCT02561195|10028594|FG013|Vaccination 1 to 3|Protocol Violation|0
6303402|NCT02561195|10028581|FG000|Vaccination 1 to 3|Death|2
6303403|NCT02561195|10028582|FG001|Vaccination 1 to 3|Death|1
6303404|NCT02561195|10028583|FG002|Vaccination 1 to 3|Death|0
6303405|NCT02561195|10028584|FG003|Vaccination 1 to 3|Death|2
6303406|NCT02561195|10028585|FG004|Vaccination 1 to 3|Death|0
6303407|NCT02561195|10028586|FG005|Vaccination 1 to 3|Death|0
6303408|NCT02561195|10028587|FG006|Vaccination 1 to 3|Death|0
6303409|NCT02561195|10028588|FG007|Vaccination 1 to 3|Death|0
6303410|NCT02561195|10028589|FG008|Vaccination 1 to 3|Death|0
6303411|NCT02561195|10028590|FG009|Vaccination 1 to 3|Death|0
6303412|NCT02561195|10028591|FG010|Vaccination 1 to 3|Death|0
6303413|NCT02561195|10028592|FG011|Vaccination 1 to 3|Death|0
6303414|NCT02561195|10028593|FG012|Vaccination 1 to 3|Death|0
6303415|NCT02561195|10028594|FG013|Vaccination 1 to 3|Death|0
6303416|NCT02561195|10028581|FG000|Vaccination 1 to 3|Withdrawal by Subject|3
6303417|NCT02561195|10028582|FG001|Vaccination 1 to 3|Withdrawal by Subject|4
6303418|NCT02561195|10028583|FG002|Vaccination 1 to 3|Withdrawal by Subject|4
6303419|NCT02561195|10028584|FG003|Vaccination 1 to 3|Withdrawal by Subject|2
6303420|NCT02561195|10028585|FG004|Vaccination 1 to 3|Withdrawal by Subject|6
6303421|NCT02561195|10028586|FG005|Vaccination 1 to 3|Withdrawal by Subject|0
6303422|NCT02561195|10028587|FG006|Vaccination 1 to 3|Withdrawal by Subject|0
6303423|NCT02561195|10028588|FG007|Vaccination 1 to 3|Withdrawal by Subject|0
6303424|NCT02561195|10028589|FG008|Vaccination 1 to 3|Withdrawal by Subject|0
6303425|NCT02561195|10028590|FG009|Vaccination 1 to 3|Withdrawal by Subject|0
6303426|NCT02561195|10028591|FG010|Vaccination 1 to 3|Withdrawal by Subject|0
6303427|NCT02561195|10028592|FG011|Vaccination 1 to 3|Withdrawal by Subject|0
6303428|NCT02561195|10028593|FG012|Vaccination 1 to 3|Withdrawal by Subject|0
6303429|NCT02561195|10028594|FG013|Vaccination 1 to 3|Withdrawal by Subject|0
6303430|NCT02561195|10028581|FG000|Vaccination 1 to 3|Randomized but not treated|1
6303431|NCT02561195|10028582|FG001|Vaccination 1 to 3|Randomized but not treated|0
6303432|NCT02561195|10028583|FG002|Vaccination 1 to 3|Randomized but not treated|0
6303433|NCT02561195|10028584|FG003|Vaccination 1 to 3|Randomized but not treated|0
6303434|NCT02561195|10028585|FG004|Vaccination 1 to 3|Randomized but not treated|0
6303435|NCT02561195|10028586|FG005|Vaccination 1 to 3|Randomized but not treated|0
6303436|NCT02561195|10028587|FG006|Vaccination 1 to 3|Randomized but not treated|0
6303437|NCT02561195|10028588|FG007|Vaccination 1 to 3|Randomized but not treated|0
6303438|NCT02561195|10028589|FG008|Vaccination 1 to 3|Randomized but not treated|0
6303439|NCT02561195|10028590|FG009|Vaccination 1 to 3|Randomized but not treated|0
6303440|NCT02561195|10028591|FG010|Vaccination 1 to 3|Randomized but not treated|0
6303441|NCT02561195|10028592|FG011|Vaccination 1 to 3|Randomized but not treated|0
6303442|NCT02561195|10028593|FG012|Vaccination 1 to 3|Randomized but not treated|0
6303443|NCT02561195|10028594|FG013|Vaccination 1 to 3|Randomized but not treated|0
6303444|NCT02561195|10028581|FG000|Extension Stage (Vaccination 4)|Withdrew consent|0
6303445|NCT02561195|10028582|FG001|Extension Stage (Vaccination 4)|Withdrew consent|0
6303446|NCT02561195|10028583|FG002|Extension Stage (Vaccination 4)|Withdrew consent|0
6303447|NCT02561195|10028584|FG003|Extension Stage (Vaccination 4)|Withdrew consent|0
6303448|NCT02561195|10028585|FG004|Extension Stage (Vaccination 4)|Withdrew consent|0
6303449|NCT02561195|10028586|FG005|Extension Stage (Vaccination 4)|Withdrew consent|0
6303450|NCT02561195|10028587|FG006|Extension Stage (Vaccination 4)|Withdrew consent|0
6303451|NCT02561195|10028588|FG007|Extension Stage (Vaccination 4)|Withdrew consent|0
6303452|NCT02561195|10028589|FG008|Extension Stage (Vaccination 4)|Withdrew consent|3
6303453|NCT02561195|10028590|FG009|Extension Stage (Vaccination 4)|Withdrew consent|1
6303454|NCT02561195|10028591|FG010|Extension Stage (Vaccination 4)|Withdrew consent|2
6303455|NCT02561195|10028592|FG011|Extension Stage (Vaccination 4)|Withdrew consent|2
6303456|NCT02561195|10028593|FG012|Extension Stage (Vaccination 4)|Withdrew consent|3
6303457|NCT02561195|10028594|FG013|Extension Stage (Vaccination 4)|Withdrew consent|0
6303458|NCT02561195|10028581|FG000|Extension Stage (Vaccination 4)|Adverse Event|0
6303459|NCT02561195|10028582|FG001|Extension Stage (Vaccination 4)|Adverse Event|0
6303460|NCT02561195|10028583|FG002|Extension Stage (Vaccination 4)|Adverse Event|0
6303461|NCT02561195|10028584|FG003|Extension Stage (Vaccination 4)|Adverse Event|0
6303462|NCT02561195|10028585|FG004|Extension Stage (Vaccination 4)|Adverse Event|0
6303463|NCT02561195|10028586|FG005|Extension Stage (Vaccination 4)|Adverse Event|0
6303464|NCT02561195|10028587|FG006|Extension Stage (Vaccination 4)|Adverse Event|0
6303465|NCT02561195|10028588|FG007|Extension Stage (Vaccination 4)|Adverse Event|0
6303466|NCT02561195|10028589|FG008|Extension Stage (Vaccination 4)|Adverse Event|0
6303467|NCT02561195|10028590|FG009|Extension Stage (Vaccination 4)|Adverse Event|0
6303468|NCT02561195|10028591|FG010|Extension Stage (Vaccination 4)|Adverse Event|0
6303469|NCT02561195|10028592|FG011|Extension Stage (Vaccination 4)|Adverse Event|0
6303470|NCT02561195|10028593|FG012|Extension Stage (Vaccination 4)|Adverse Event|0
6303471|NCT02561195|10028594|FG013|Extension Stage (Vaccination 4)|Adverse Event|2
6303472|NCT02561195|10028581|FG000|Extension Stage (Vaccination 4)|Death|0
6303473|NCT02561195|10028582|FG001|Extension Stage (Vaccination 4)|Death|0
6303474|NCT02561195|10028583|FG002|Extension Stage (Vaccination 4)|Death|0
6303475|NCT02561195|10028584|FG003|Extension Stage (Vaccination 4)|Death|0
6303476|NCT02561195|10028585|FG004|Extension Stage (Vaccination 4)|Death|0
6303477|NCT02561195|10028586|FG005|Extension Stage (Vaccination 4)|Death|0
6303478|NCT02561195|10028587|FG006|Extension Stage (Vaccination 4)|Death|0
6303479|NCT02561195|10028588|FG007|Extension Stage (Vaccination 4)|Death|0
6303480|NCT02561195|10028589|FG008|Extension Stage (Vaccination 4)|Death|0
6303481|NCT02561195|10028590|FG009|Extension Stage (Vaccination 4)|Death|1
6303482|NCT02561195|10028591|FG010|Extension Stage (Vaccination 4)|Death|0
6303483|NCT02561195|10028592|FG011|Extension Stage (Vaccination 4)|Death|0
6303484|NCT02561195|10028593|FG012|Extension Stage (Vaccination 4)|Death|0
6303485|NCT02561195|10028594|FG013|Extension Stage (Vaccination 4)|Death|0
6303486|NCT02561195|10028581|FG000|Extension Stage (Vaccination 4)|Lost to Follow-up|0
6303487|NCT02561195|10028582|FG001|Extension Stage (Vaccination 4)|Lost to Follow-up|0
6303488|NCT02561195|10028583|FG002|Extension Stage (Vaccination 4)|Lost to Follow-up|0
6303489|NCT02561195|10028584|FG003|Extension Stage (Vaccination 4)|Lost to Follow-up|0
6303490|NCT02561195|10028585|FG004|Extension Stage (Vaccination 4)|Lost to Follow-up|0
6303491|NCT02561195|10028586|FG005|Extension Stage (Vaccination 4)|Lost to Follow-up|0
6303492|NCT02561195|10028587|FG006|Extension Stage (Vaccination 4)|Lost to Follow-up|1
6303493|NCT02561195|10028588|FG007|Extension Stage (Vaccination 4)|Lost to Follow-up|1
6303494|NCT02561195|10028589|FG008|Extension Stage (Vaccination 4)|Lost to Follow-up|0
6303495|NCT02561195|10028590|FG009|Extension Stage (Vaccination 4)|Lost to Follow-up|0
6303496|NCT02561195|10028591|FG010|Extension Stage (Vaccination 4)|Lost to Follow-up|2
6303497|NCT02561195|10028592|FG011|Extension Stage (Vaccination 4)|Lost to Follow-up|1
6303498|NCT02561195|10028593|FG012|Extension Stage (Vaccination 4)|Lost to Follow-up|2
6303499|NCT02561195|10028594|FG013|Extension Stage (Vaccination 4)|Lost to Follow-up|1
6303500|NCT02561195|10028581|FG000|Extension Stage (Vaccination 4)|No Longer Willing To Participate In Study|0
6303501|NCT02561195|10028582|FG001|Extension Stage (Vaccination 4)|No Longer Willing To Participate In Study|0
6303502|NCT02561195|10028583|FG002|Extension Stage (Vaccination 4)|No Longer Willing To Participate In Study|0
5982344|NCT03553498|9571332|FG000|Overall Study|Missing primary outcome|1
5982345|NCT03553498|9571333|FG001|Overall Study|Missing primary outcome|2
5982346|NCT03530293|9571341|FG000|Pre-randomization|Adverse Event|12
5982347|NCT03530293|9571342|FG001|Pre-randomization|Adverse Event|0
5982348|NCT03530293|9571343|FG002|Pre-randomization|Adverse Event|0
5982349|NCT03530293|9571341|FG000|Pre-randomization|Protocol Violation|2
5982350|NCT03530293|9571342|FG001|Pre-randomization|Protocol Violation|0
5982351|NCT03530293|9571343|FG002|Pre-randomization|Protocol Violation|0
5982352|NCT03530293|9571341|FG000|Pre-randomization|Study Terminated by Sponsor|5
5982353|NCT03530293|9571342|FG001|Pre-randomization|Study Terminated by Sponsor|0
5982354|NCT03530293|9571343|FG002|Pre-randomization|Study Terminated by Sponsor|0
5982355|NCT03530293|9571341|FG000|Pre-randomization|Withdrawal by Subject|5
5982356|NCT03530293|9571342|FG001|Pre-randomization|Withdrawal by Subject|0
5982357|NCT03530293|9571343|FG002|Pre-randomization|Withdrawal by Subject|0
5982358|NCT03530293|9571341|FG000|Randomized Withdrawal Period / Follow-up|Adverse Event|0
5982359|NCT03530293|9571342|FG001|Randomized Withdrawal Period / Follow-up|Adverse Event|2
5982360|NCT03530293|9571343|FG002|Randomized Withdrawal Period / Follow-up|Adverse Event|4
5982361|NCT03530293|9571341|FG000|Randomized Withdrawal Period / Follow-up|Protocol Violation|0
5982362|NCT03530293|9571342|FG001|Randomized Withdrawal Period / Follow-up|Protocol Violation|0
5982363|NCT03530293|9571343|FG002|Randomized Withdrawal Period / Follow-up|Protocol Violation|1
5982364|NCT03530293|9571341|FG000|Randomized Withdrawal Period / Follow-up|Withdrawal by Subject|0
5982365|NCT03530293|9571342|FG001|Randomized Withdrawal Period / Follow-up|Withdrawal by Subject|3
5982366|NCT03530293|9571343|FG002|Randomized Withdrawal Period / Follow-up|Withdrawal by Subject|2
5982367|NCT03530293|9571341|FG000|Randomized Withdrawal Period / Follow-up|Lack of Efficacy|0
5982368|NCT03530293|9571342|FG001|Randomized Withdrawal Period / Follow-up|Lack of Efficacy|2
5982369|NCT03530293|9571343|FG002|Randomized Withdrawal Period / Follow-up|Lack of Efficacy|0
5982370|NCT03530293|9571341|FG000|Randomized Withdrawal Period / Follow-up|Study Terminated by Sponsor|0
5982371|NCT03530293|9571342|FG001|Randomized Withdrawal Period / Follow-up|Study Terminated by Sponsor|10
5982372|NCT03530293|9571343|FG002|Randomized Withdrawal Period / Follow-up|Study Terminated by Sponsor|10
5982373|NCT03505749|9571352|FG000|Overall Study|Lost to Follow-up|7
5982374|NCT03505749|9571353|FG001|Overall Study|Lost to Follow-up|11
5982375|NCT03505749|9571352|FG000|Overall Study|Withdrawal by Subject|6
5982376|NCT03505749|9571353|FG001|Overall Study|Withdrawal by Subject|0
5982377|NCT03505749|9571352|FG000|Overall Study|Discharged from treatment|3
5982378|NCT03505749|9571353|FG001|Overall Study|Discharged from treatment|6
5982379|NCT03472885|9571362|FG000|Overall Study|Adverse Event|1
5982380|NCT03219164|9571377|FG000|Overall Study|Study Terminated by Sponsor|16
5982381|NCT03219164|9571378|FG001|Overall Study|Study Terminated by Sponsor|12
5982382|NCT03219164|9571377|FG000|Overall Study|Withdrew Consent by Parent/Guardian|5
5982383|NCT03219164|9571378|FG001|Overall Study|Withdrew Consent by Parent/Guardian|4
5982384|NCT03219164|9571377|FG000|Overall Study|Lost to Follow-up|1
5982385|NCT03219164|9571378|FG001|Overall Study|Lost to Follow-up|1
5982386|NCT03219164|9571377|FG000|Overall Study|Adverse Event|1
5982387|NCT03219164|9571378|FG001|Overall Study|Adverse Event|0
5982388|NCT03219164|9571377|FG000|Overall Study|Non-Compliance with Study Drug|1
5982389|NCT03219164|9571378|FG001|Overall Study|Non-Compliance with Study Drug|0
5982390|NCT03219164|9571377|FG000|Overall Study|Protocol Violation|0
5982391|NCT03219164|9571378|FG001|Overall Study|Protocol Violation|1
5982392|NCT03219164|9571377|FG000|Overall Study|Withdrew Assent|1
5982393|NCT03219164|9571378|FG001|Overall Study|Withdrew Assent|0
5982418|NCT02811861|9571414|FG000|Overall Study|Radiological Disease Progression|123
5982419|NCT02811861|9571415|FG001|Overall Study|Radiological Disease Progression|97
5982420|NCT02811861|9571416|FG002|Overall Study|Radiological Disease Progression|174
5982421|NCT02811861|9571414|FG000|Overall Study|Clinical Disease Progression|20
5982422|NCT02811861|9571415|FG001|Overall Study|Clinical Disease Progression|19
5982423|NCT02811861|9571416|FG002|Overall Study|Clinical Disease Progression|22
5982424|NCT02811861|9571414|FG000|Overall Study|Adverse Event|63
5982425|NCT02811861|9571415|FG001|Overall Study|Adverse Event|60
5982426|NCT02811861|9571416|FG002|Overall Study|Adverse Event|41
5982427|NCT02811861|9571414|FG000|Overall Study|Lost to Follow-up|0
5982428|NCT02811861|9571415|FG001|Overall Study|Lost to Follow-up|0
5982429|NCT02811861|9571416|FG002|Overall Study|Lost to Follow-up|1
5982430|NCT02811861|9571414|FG000|Overall Study|Subject Choice|29
5982431|NCT02811861|9571415|FG001|Overall Study|Subject Choice|17
5982432|NCT02811861|9571416|FG002|Overall Study|Subject Choice|23
6303503|NCT02561195|10028584|FG003|Extension Stage (Vaccination 4)|No Longer Willing To Participate In Study|0
6303504|NCT02561195|10028585|FG004|Extension Stage (Vaccination 4)|No Longer Willing To Participate In Study|0
6303505|NCT02561195|10028586|FG005|Extension Stage (Vaccination 4)|No Longer Willing To Participate In Study|0
6303506|NCT02561195|10028587|FG006|Extension Stage (Vaccination 4)|No Longer Willing To Participate In Study|0
6303507|NCT02561195|10028588|FG007|Extension Stage (Vaccination 4)|No Longer Willing To Participate In Study|0
6303508|NCT02561195|10028589|FG008|Extension Stage (Vaccination 4)|No Longer Willing To Participate In Study|0
6303509|NCT02561195|10028590|FG009|Extension Stage (Vaccination 4)|No Longer Willing To Participate In Study|0
6303510|NCT02561195|10028591|FG010|Extension Stage (Vaccination 4)|No Longer Willing To Participate In Study|0
6303511|NCT02561195|10028592|FG011|Extension Stage (Vaccination 4)|No Longer Willing To Participate In Study|1
6303512|NCT02561195|10028593|FG012|Extension Stage (Vaccination 4)|No Longer Willing To Participate In Study|1
6303513|NCT02561195|10028594|FG013|Extension Stage (Vaccination 4)|No Longer Willing To Participate In Study|1
6303514|NCT02561195|10028581|FG000|Extension Stage (Vaccination 4)|Other|0
6303515|NCT02561195|10028582|FG001|Extension Stage (Vaccination 4)|Other|0
6303516|NCT02561195|10028583|FG002|Extension Stage (Vaccination 4)|Other|0
6303517|NCT02561195|10028584|FG003|Extension Stage (Vaccination 4)|Other|0
6303518|NCT02561195|10028585|FG004|Extension Stage (Vaccination 4)|Other|0
6303519|NCT02561195|10028586|FG005|Extension Stage (Vaccination 4)|Other|0
6303520|NCT02561195|10028587|FG006|Extension Stage (Vaccination 4)|Other|0
6303521|NCT02561195|10028588|FG007|Extension Stage (Vaccination 4)|Other|0
6303522|NCT02561195|10028589|FG008|Extension Stage (Vaccination 4)|Other|0
6303523|NCT02561195|10028590|FG009|Extension Stage (Vaccination 4)|Other|0
6303524|NCT02561195|10028591|FG010|Extension Stage (Vaccination 4)|Other|2
6303525|NCT02561195|10028592|FG011|Extension Stage (Vaccination 4)|Other|2
6303526|NCT02561195|10028593|FG012|Extension Stage (Vaccination 4)|Other|1
6303527|NCT02561195|10028594|FG013|Extension Stage (Vaccination 4)|Other|0
6303528|NCT02561195|10028581|FG000|Extension Stage (Vaccination 4)|Protocol Violation|0
6303529|NCT02561195|10028582|FG001|Extension Stage (Vaccination 4)|Protocol Violation|0
6303530|NCT02561195|10028583|FG002|Extension Stage (Vaccination 4)|Protocol Violation|0
6303531|NCT02561195|10028584|FG003|Extension Stage (Vaccination 4)|Protocol Violation|0
6303532|NCT02561195|10028585|FG004|Extension Stage (Vaccination 4)|Protocol Violation|0
6303533|NCT02561195|10028586|FG005|Extension Stage (Vaccination 4)|Protocol Violation|0
6303534|NCT02561195|10028587|FG006|Extension Stage (Vaccination 4)|Protocol Violation|1
6303535|NCT02561195|10028588|FG007|Extension Stage (Vaccination 4)|Protocol Violation|0
6303536|NCT02561195|10028589|FG008|Extension Stage (Vaccination 4)|Protocol Violation|0
6303537|NCT02561195|10028590|FG009|Extension Stage (Vaccination 4)|Protocol Violation|0
6303538|NCT02561195|10028591|FG010|Extension Stage (Vaccination 4)|Protocol Violation|2
6303539|NCT02561195|10028592|FG011|Extension Stage (Vaccination 4)|Protocol Violation|1
6303540|NCT02561195|10028593|FG012|Extension Stage (Vaccination 4)|Protocol Violation|0
6303541|NCT02561195|10028594|FG013|Extension Stage (Vaccination 4)|Protocol Violation|1
6303542|NCT02561247|10028635|FG000|Overall Study|Protocol Violation|1
6303543|NCT02561247|10028635|FG000|Overall Study|Withdrawal by Subject|1
6303544|NCT02561247|10028635|FG000|Overall Study|Two filter changes required within the first 24 hours.|4
6303545|NCT02561273|10028641|FG000|Overall Study|Protocol Violation|1
6303546|NCT02561273|10028642|FG001|Overall Study|Protocol Violation|0
6303547|NCT02561455|10028677|FG000|Overall Study|Participant Transitioned to Commercial Drug|1
6303548|NCT02561455|10028678|FG001|Overall Study|Participant Transitioned to Commercial Drug|1
6303549|NCT02561455|10028679|FG002|Overall Study|Participant Transitioned to Commercial Drug|2
6303550|NCT02561455|10028680|FG003|Overall Study|Participant Transitioned to Commercial Drug|1
6303551|NCT02561455|10028677|FG000|Overall Study|Withdrawal by Subject|1
6303552|NCT02561455|10028678|FG001|Overall Study|Withdrawal by Subject|0
6303553|NCT02561455|10028679|FG002|Overall Study|Withdrawal by Subject|1
6303554|NCT02561455|10028680|FG003|Overall Study|Withdrawal by Subject|0
6303555|NCT02561455|10028677|FG000|Overall Study|Disease Progression|0
6303556|NCT02561455|10028678|FG001|Overall Study|Disease Progression|1
6303557|NCT02561455|10028679|FG002|Overall Study|Disease Progression|0
6303558|NCT02561455|10028680|FG003|Overall Study|Disease Progression|0
6303559|NCT02561572|10028704|FG000|Overall Study|Inadequate time before surgery|2
6303560|NCT02561572|10028705|FG001|Overall Study|Inadequate time before surgery|1
6303561|NCT02561572|10028704|FG000|Overall Study|Protocol Violation|0
6063869|NCT00508742|9665278|FG001|Period 2: After Infant Series|Other|1
6063870|NCT00508742|9665277|FG000|Period 3: Toddler Dose|Adverse Event|1
6137003|NCT01005251|9767096|FG003|Overall Study|Lack of Efficacy|1
6137004|NCT01005251|9767097|FG004|Overall Study|Lack of Efficacy|0
6137005|NCT01005316|9767121|FG000|Overall Study|Adverse Event|0
6137006|NCT01005316|9767122|FG001|Overall Study|Adverse Event|0
6137007|NCT01005316|9767123|FG002|Overall Study|Adverse Event|0
6137008|NCT01005316|9767124|FG003|Overall Study|Adverse Event|1
6137009|NCT01005316|9767121|FG000|Overall Study|Death|20
6137010|NCT01005316|9767122|FG001|Overall Study|Death|5
6137011|NCT01005316|9767123|FG002|Overall Study|Death|1
6137012|NCT01005316|9767124|FG003|Overall Study|Death|15
6137013|NCT01005316|9767121|FG000|Overall Study|Study Termination|5
6137014|NCT01005316|9767122|FG001|Overall Study|Study Termination|63
6137015|NCT01005316|9767123|FG002|Overall Study|Study Termination|9
6137016|NCT01005316|9767124|FG003|Overall Study|Study Termination|85
6137017|NCT01005316|9767121|FG000|Overall Study|Lost to Follow-up|1
6303562|NCT02561572|10028705|FG001|Overall Study|Protocol Violation|1
6303563|NCT02561806|10028733|FG000|Induction Period|Adverse Event|0
6303564|NCT02561806|10028734|FG001|Induction Period|Adverse Event|2
6303565|NCT02561806|10028733|FG000|Induction Period|Lack of Efficacy|1
6303566|NCT02561806|10028734|FG001|Induction Period|Lack of Efficacy|0
6303567|NCT02561806|10028733|FG000|Induction Period|Withdrawal by Subject|0
6303568|NCT02561806|10028734|FG001|Induction Period|Withdrawal by Subject|2
6303569|NCT02561806|10028733|FG000|Induction Period|Site staff became unblinded|1
6303570|NCT02561806|10028734|FG001|Induction Period|Site staff became unblinded|0
6303571|NCT02561806|10028733|FG000|Induction Period|Randomized but not treated|0
6303572|NCT02561806|10028734|FG001|Induction Period|Randomized but not treated|1
6303573|NCT02561806|10028733|FG000|Maintenance Period|Adverse Event|2
6303574|NCT02561806|10028734|FG001|Maintenance Period|Adverse Event|1
6303575|NCT02561806|10028733|FG000|Maintenance Period|Lack of Efficacy|3
6303576|NCT02561806|10028734|FG001|Maintenance Period|Lack of Efficacy|1
6303577|NCT02561806|10028733|FG000|Maintenance Period|Lost to Follow-up|2
6303578|NCT02561806|10028734|FG001|Maintenance Period|Lost to Follow-up|2
6303579|NCT02561806|10028733|FG000|Maintenance Period|Protocol Violation|1
6303580|NCT02561806|10028734|FG001|Maintenance Period|Protocol Violation|0
6303581|NCT02561806|10028733|FG000|Maintenance Period|Withdrawal by Subject|5
6303582|NCT02561806|10028734|FG001|Maintenance Period|Withdrawal by Subject|3
6303583|NCT02561806|10028733|FG000|Maintenance Period|Site staff became unblinded|0
6303584|NCT02561806|10028734|FG001|Maintenance Period|Site staff became unblinded|1
6303585|NCT02561806|10028733|FG000|Post-Treatment Follow-up|Lost to Follow-up|1
6303586|NCT02561806|10028734|FG001|Post-Treatment Follow-up|Lost to Follow-up|1
6303587|NCT02561806|10028733|FG000|Post-Treatment Follow-up|Withdrawal by Subject|1
6303588|NCT02561806|10028734|FG001|Post-Treatment Follow-up|Withdrawal by Subject|0
6303589|NCT02561832|10028757|FG000|Overall Study|Withdrawal by Subject|1
6303590|NCT02561832|10028758|FG001|Overall Study|Withdrawal by Subject|1
6303591|NCT02561832|10028757|FG000|Overall Study|Adverse Event|3
6303592|NCT02561832|10028758|FG001|Overall Study|Adverse Event|0
6303593|NCT02561832|10028757|FG000|Overall Study|Disease progression|3
6303594|NCT02561832|10028758|FG001|Overall Study|Disease progression|3
6303595|NCT02562482|10028787|FG000|Overall Study|Enrolled, but did not receive product|4
6303596|NCT02562482|10028788|FG001|Overall Study|Enrolled, but did not receive product|0
6303597|NCT02562482|10028787|FG000|Overall Study|Lost to Follow-up|9
6303598|NCT02562482|10028788|FG001|Overall Study|Lost to Follow-up|6
6303599|NCT02562482|10028787|FG000|Overall Study|Moved from area|2
6303600|NCT02562482|10028788|FG001|Overall Study|Moved from area|3
6303601|NCT02562482|10028787|FG000|Overall Study|Withdrawal by Subject|5
6303602|NCT02562482|10028788|FG001|Overall Study|Withdrawal by Subject|3
6303603|NCT02562482|10028787|FG000|Overall Study|Physician Decision|1
6303604|NCT02562482|10028788|FG001|Overall Study|Physician Decision|3
6303605|NCT02562482|10028787|FG000|Overall Study|Illness/Injury unrelated to product|0
6303606|NCT02562482|10028788|FG001|Overall Study|Illness/Injury unrelated to product|1
6303607|NCT02563067|10028853|FG000|Overall Study|Subject/guardian decision|14
6303608|NCT02563067|10028854|FG001|Overall Study|Subject/guardian decision|20
6303609|NCT02563067|10028855|FG002|Overall Study|Subject/guardian decision|16
6303610|NCT02563067|10028853|FG000|Overall Study|Physician Decision|0
6303611|NCT02563067|10028854|FG001|Overall Study|Physician Decision|1
6303612|NCT02563067|10028855|FG002|Overall Study|Physician Decision|3
6303613|NCT02563067|10028853|FG000|Overall Study|Lost to Follow-up|1
6303614|NCT02563067|10028854|FG001|Overall Study|Lost to Follow-up|2
6303615|NCT02563067|10028855|FG002|Overall Study|Lost to Follow-up|0
6303616|NCT02563067|10028853|FG000|Overall Study|Technical problems|0
6303617|NCT02563067|10028854|FG001|Overall Study|Technical problems|1
6303618|NCT02563067|10028855|FG002|Overall Study|Technical problems|0
6303619|NCT02563067|10028853|FG000|Overall Study|Lack of Efficacy|1
6303620|NCT02563067|10028854|FG001|Overall Study|Lack of Efficacy|0
6303621|NCT02563067|10028855|FG002|Overall Study|Lack of Efficacy|0
6303622|NCT02563067|10028853|FG000|Overall Study|Death|0
6303623|NCT02563067|10028854|FG001|Overall Study|Death|1
6303624|NCT02563067|10028855|FG002|Overall Study|Death|1
6303625|NCT02563067|10028853|FG000|Overall Study|Adverse Event|2
6303626|NCT02563067|10028854|FG001|Overall Study|Adverse Event|1
6303627|NCT02563067|10028855|FG002|Overall Study|Adverse Event|0
6303628|NCT02563067|10028853|FG000|Overall Study|Death post Treatment/safety period|1
6303629|NCT02563067|10028854|FG001|Overall Study|Death post Treatment/safety period|0
6303630|NCT02563067|10028855|FG002|Overall Study|Death post Treatment/safety period|0
6303631|NCT02563106|10028883|FG000|Overall Study|Withdrawal by Subject|7
6303632|NCT02563106|10028884|FG001|Overall Study|Withdrawal by Subject|8
6303633|NCT02563106|10028883|FG000|Overall Study|Adverse Event|17
6303634|NCT02563106|10028884|FG001|Overall Study|Adverse Event|15
6303635|NCT02563106|10028883|FG000|Overall Study|Protocol Violation|1
6303636|NCT02563106|10028884|FG001|Overall Study|Protocol Violation|0
6303637|NCT02563106|10028883|FG000|Overall Study|Use of non-permitted concurrent therapy|1
6303638|NCT02563106|10028884|FG001|Overall Study|Use of non-permitted concurrent therapy|2
6303639|NCT02563106|10028883|FG000|Overall Study|Lost to Follow-up|3
6303640|NCT02563106|10028884|FG001|Overall Study|Lost to Follow-up|2
6303641|NCT02563106|10028883|FG000|Overall Study|Physician Decision|3
6303642|NCT02563106|10028884|FG001|Overall Study|Physician Decision|1
6303643|NCT02563106|10028883|FG000|Overall Study|Other reason - not specified|2
6303644|NCT02563106|10028884|FG001|Overall Study|Other reason - not specified|1
6303645|NCT02563548|10028913|FG000|Dose Escalation (Up to 46 Weeks)|Adverse Event|2
6303646|NCT02563548|10028914|FG001|Dose Escalation (Up to 46 Weeks)|Adverse Event|0
6303647|NCT02563548|10028915|FG002|Dose Escalation (Up to 46 Weeks)|Adverse Event|0
6303648|NCT02563548|10028916|FG003|Dose Escalation (Up to 46 Weeks)|Adverse Event|1
6303649|NCT02563548|10028917|FG004|Dose Escalation (Up to 46 Weeks)|Adverse Event|0
6303650|NCT02563548|10028918|FG005|Dose Escalation (Up to 46 Weeks)|Adverse Event|0
6303651|NCT02563548|10028913|FG000|Dose Escalation (Up to 46 Weeks)|Radiological Progression|1
6303652|NCT02563548|10028914|FG001|Dose Escalation (Up to 46 Weeks)|Radiological Progression|2
6303653|NCT02563548|10028915|FG002|Dose Escalation (Up to 46 Weeks)|Radiological Progression|2
6303654|NCT02563548|10028916|FG003|Dose Escalation (Up to 46 Weeks)|Radiological Progression|0
6303655|NCT02563548|10028917|FG004|Dose Escalation (Up to 46 Weeks)|Radiological Progression|0
6303656|NCT02563548|10028918|FG005|Dose Escalation (Up to 46 Weeks)|Radiological Progression|0
6303657|NCT02563548|10028913|FG000|Dose Escalation (Up to 46 Weeks)|Clinical Progression|0
6303658|NCT02563548|10028914|FG001|Dose Escalation (Up to 46 Weeks)|Clinical Progression|0
6303659|NCT02563548|10028915|FG002|Dose Escalation (Up to 46 Weeks)|Clinical Progression|3
6303660|NCT02563548|10028916|FG003|Dose Escalation (Up to 46 Weeks)|Clinical Progression|0
6303661|NCT02563548|10028917|FG004|Dose Escalation (Up to 46 Weeks)|Clinical Progression|0
6303662|NCT02563548|10028918|FG005|Dose Escalation (Up to 46 Weeks)|Clinical Progression|0
6303663|NCT02563548|10028913|FG000|Dose Escalation (Up to 46 Weeks)|Withdrawal by Subject|0
6303664|NCT02563548|10028914|FG001|Dose Escalation (Up to 46 Weeks)|Withdrawal by Subject|0
6303665|NCT02563548|10028915|FG002|Dose Escalation (Up to 46 Weeks)|Withdrawal by Subject|2
6303666|NCT02563548|10028916|FG003|Dose Escalation (Up to 46 Weeks)|Withdrawal by Subject|1
6303667|NCT02563548|10028917|FG004|Dose Escalation (Up to 46 Weeks)|Withdrawal by Subject|0
6303668|NCT02563548|10028918|FG005|Dose Escalation (Up to 46 Weeks)|Withdrawal by Subject|0
6303669|NCT02563548|10028913|FG000|Dose Expansion (Up to 60 Weeks)|Adverse Event|0
6303670|NCT02563548|10028914|FG001|Dose Expansion (Up to 60 Weeks)|Adverse Event|0
6303671|NCT02563548|10028915|FG002|Dose Expansion (Up to 60 Weeks)|Adverse Event|0
6303672|NCT02563548|10028916|FG003|Dose Expansion (Up to 60 Weeks)|Adverse Event|0
6303673|NCT02563548|10028917|FG004|Dose Expansion (Up to 60 Weeks)|Adverse Event|1
6303674|NCT02563548|10028918|FG005|Dose Expansion (Up to 60 Weeks)|Adverse Event|8
6303675|NCT02563548|10028913|FG000|Dose Expansion (Up to 60 Weeks)|Radiological Progression|0
6303676|NCT02563548|10028914|FG001|Dose Expansion (Up to 60 Weeks)|Radiological Progression|0
6303677|NCT02563548|10028915|FG002|Dose Expansion (Up to 60 Weeks)|Radiological Progression|0
6303678|NCT02563548|10028916|FG003|Dose Expansion (Up to 60 Weeks)|Radiological Progression|0
6303679|NCT02563548|10028917|FG004|Dose Expansion (Up to 60 Weeks)|Radiological Progression|15
6303680|NCT02563548|10028918|FG005|Dose Expansion (Up to 60 Weeks)|Radiological Progression|3
6303681|NCT02563548|10028913|FG000|Dose Expansion (Up to 60 Weeks)|Clinical Progression|0
6303682|NCT02563548|10028914|FG001|Dose Expansion (Up to 60 Weeks)|Clinical Progression|0
6303683|NCT02563548|10028915|FG002|Dose Expansion (Up to 60 Weeks)|Clinical Progression|0
6303684|NCT02563548|10028916|FG003|Dose Expansion (Up to 60 Weeks)|Clinical Progression|0
6303685|NCT02563548|10028917|FG004|Dose Expansion (Up to 60 Weeks)|Clinical Progression|6
6303686|NCT02563548|10028918|FG005|Dose Expansion (Up to 60 Weeks)|Clinical Progression|0
6303687|NCT02563548|10028913|FG000|Dose Expansion (Up to 60 Weeks)|Withdrawal by Subject|0
6303688|NCT02563548|10028914|FG001|Dose Expansion (Up to 60 Weeks)|Withdrawal by Subject|0
6303689|NCT02563548|10028915|FG002|Dose Expansion (Up to 60 Weeks)|Withdrawal by Subject|0
6303690|NCT02563548|10028916|FG003|Dose Expansion (Up to 60 Weeks)|Withdrawal by Subject|0
6303691|NCT02563548|10028917|FG004|Dose Expansion (Up to 60 Weeks)|Withdrawal by Subject|2
6303692|NCT02563548|10028918|FG005|Dose Expansion (Up to 60 Weeks)|Withdrawal by Subject|1
6303693|NCT02563548|10028913|FG000|Dose Expansion (Up to 60 Weeks)|Investigator or Sponsor Decision|0
6303694|NCT02563548|10028914|FG001|Dose Expansion (Up to 60 Weeks)|Investigator or Sponsor Decision|0
6303695|NCT02563548|10028915|FG002|Dose Expansion (Up to 60 Weeks)|Investigator or Sponsor Decision|0
6303696|NCT02563548|10028916|FG003|Dose Expansion (Up to 60 Weeks)|Investigator or Sponsor Decision|0
6303697|NCT02563548|10028917|FG004|Dose Expansion (Up to 60 Weeks)|Investigator or Sponsor Decision|0
6303698|NCT02563548|10028918|FG005|Dose Expansion (Up to 60 Weeks)|Investigator or Sponsor Decision|2
6303699|NCT02563548|10028913|FG000|Dose Expansion (Up to 60 Weeks)|Protocol Violation|0
6303700|NCT02563548|10028914|FG001|Dose Expansion (Up to 60 Weeks)|Protocol Violation|0
6303701|NCT02563548|10028915|FG002|Dose Expansion (Up to 60 Weeks)|Protocol Violation|0
6303702|NCT02563548|10028916|FG003|Dose Expansion (Up to 60 Weeks)|Protocol Violation|0
6303703|NCT02563548|10028917|FG004|Dose Expansion (Up to 60 Weeks)|Protocol Violation|0
6303704|NCT02563548|10028918|FG005|Dose Expansion (Up to 60 Weeks)|Protocol Violation|2
6303705|NCT02563548|10028913|FG000|Dose Expansion (Up to 60 Weeks)|Increased brain lesions|0
6303706|NCT02563548|10028914|FG001|Dose Expansion (Up to 60 Weeks)|Increased brain lesions|0
6303707|NCT02563548|10028915|FG002|Dose Expansion (Up to 60 Weeks)|Increased brain lesions|0
6303708|NCT02563548|10028916|FG003|Dose Expansion (Up to 60 Weeks)|Increased brain lesions|0
6303709|NCT02563548|10028917|FG004|Dose Expansion (Up to 60 Weeks)|Increased brain lesions|0
6303710|NCT02563548|10028918|FG005|Dose Expansion (Up to 60 Weeks)|Increased brain lesions|1
6303711|NCT02563548|10028913|FG000|Dose Expansion (Up to 60 Weeks)|Enrolled but not treated|0
6303712|NCT02563548|10028914|FG001|Dose Expansion (Up to 60 Weeks)|Enrolled but not treated|0
6303713|NCT02563548|10028915|FG002|Dose Expansion (Up to 60 Weeks)|Enrolled but not treated|0
6303714|NCT02563548|10028916|FG003|Dose Expansion (Up to 60 Weeks)|Enrolled but not treated|0
6303715|NCT02563548|10028917|FG004|Dose Expansion (Up to 60 Weeks)|Enrolled but not treated|1
6303716|NCT02563548|10028918|FG005|Dose Expansion (Up to 60 Weeks)|Enrolled but not treated|0
6303717|NCT02563561|10028941|FG000|Overall Study|Histology Other than Ta, G1-G2|3
6303718|NCT02563561|10028942|FG001|Overall Study|Histology Other than Ta, G1-G2|6
6303719|NCT02563561|10028943|FG002|Overall Study|Histology Other than Ta, G1-G2|6
6303720|NCT02563561|10028941|FG000|Overall Study|Withdrew of Consent|1
6303721|NCT02563561|10028942|FG001|Overall Study|Withdrew of Consent|1
6303722|NCT02563561|10028943|FG002|Overall Study|Withdrew of Consent|2
6303723|NCT02563561|10028941|FG000|Overall Study|Lost to Follow-up|1
6303724|NCT02563561|10028942|FG001|Overall Study|Lost to Follow-up|1
6303725|NCT02563561|10028943|FG002|Overall Study|Lost to Follow-up|0
6303726|NCT02563561|10028941|FG000|Overall Study|Participant Had Recurrence and Received Therapy|4
6303727|NCT02563561|10028942|FG001|Overall Study|Participant Had Recurrence and Received Therapy|2
6303728|NCT02563561|10028943|FG002|Overall Study|Participant Had Recurrence and Received Therapy|1
6303729|NCT02563561|10028941|FG000|Overall Study|Investigator Decision|3
6303730|NCT02563561|10028942|FG001|Overall Study|Investigator Decision|4
6303731|NCT02563561|10028943|FG002|Overall Study|Investigator Decision|2
6303732|NCT02563561|10028941|FG000|Overall Study|Sponsor Decision|5
6303733|NCT02563561|10028942|FG001|Overall Study|Sponsor Decision|2
6303734|NCT02563561|10028943|FG002|Overall Study|Sponsor Decision|4
6303735|NCT02563561|10028941|FG000|Overall Study|Other|1
6303736|NCT02563561|10028942|FG001|Overall Study|Other|5
6303737|NCT02563561|10028943|FG002|Overall Study|Other|2
6303738|NCT02563899|10028979|FG000|Overall Study|Protocol Violation|1
6303739|NCT02563899|10028980|FG001|Overall Study|Protocol Violation|0
6303740|NCT02563899|10028981|FG002|Overall Study|Protocol Violation|0
6303741|NCT02563899|10028982|FG003|Overall Study|Protocol Violation|0
6303742|NCT02563899|10028979|FG000|Overall Study|Withdrawal by Subject|0
6303743|NCT02563899|10028980|FG001|Overall Study|Withdrawal by Subject|0
6303744|NCT02563899|10028981|FG002|Overall Study|Withdrawal by Subject|1
6303745|NCT02563899|10028982|FG003|Overall Study|Withdrawal by Subject|0
6303746|NCT02564042|10029030|FG000|Overall Study|Adverse Event|4
6303747|NCT02564042|10029031|FG001|Overall Study|Adverse Event|4
6303748|NCT02564042|10029032|FG002|Overall Study|Adverse Event|3
6303749|NCT02564042|10029033|FG003|Overall Study|Adverse Event|0
6303750|NCT02564042|10029034|FG004|Overall Study|Adverse Event|0
6303751|NCT02564042|10029035|FG005|Overall Study|Adverse Event|1
6303752|NCT02564042|10029030|FG000|Overall Study|Lost to Follow-up|1
6303753|NCT02564042|10029031|FG001|Overall Study|Lost to Follow-up|1
6303754|NCT02564042|10029032|FG002|Overall Study|Lost to Follow-up|1
6303755|NCT02564042|10029033|FG003|Overall Study|Lost to Follow-up|0
6303756|NCT02564042|10029034|FG004|Overall Study|Lost to Follow-up|1
6303757|NCT02564042|10029035|FG005|Overall Study|Lost to Follow-up|1
6303758|NCT02564042|10029030|FG000|Overall Study|Physician Decision|1
6303759|NCT02564042|10029031|FG001|Overall Study|Physician Decision|0
6303760|NCT02564042|10029032|FG002|Overall Study|Physician Decision|0
6303761|NCT02564042|10029033|FG003|Overall Study|Physician Decision|1
6303762|NCT02564042|10029034|FG004|Overall Study|Physician Decision|0
6303763|NCT02564042|10029035|FG005|Overall Study|Physician Decision|0
6303764|NCT02564042|10029030|FG000|Overall Study|Withdrawal by Subject|5
6303765|NCT02564042|10029031|FG001|Overall Study|Withdrawal by Subject|3
6303766|NCT02564042|10029032|FG002|Overall Study|Withdrawal by Subject|2
6303767|NCT02564042|10029033|FG003|Overall Study|Withdrawal by Subject|2
6303768|NCT02564042|10029034|FG004|Overall Study|Withdrawal by Subject|10
6303769|NCT02564042|10029035|FG005|Overall Study|Withdrawal by Subject|12
6303770|NCT02564055|10029055|FG000|Overall Study|Adverse Event|1
6303771|NCT02564055|10029056|FG001|Overall Study|Adverse Event|0
6303772|NCT02564055|10029057|FG002|Overall Study|Adverse Event|4
6303773|NCT02564055|10029058|FG003|Overall Study|Adverse Event|1
6303774|NCT02564055|10029059|FG004|Overall Study|Adverse Event|4
6303775|NCT02564055|10029060|FG005|Overall Study|Adverse Event|1
6303776|NCT02564055|10029055|FG000|Overall Study|Protocol Violation|1
6303777|NCT02564055|10029056|FG001|Overall Study|Protocol Violation|0
6303778|NCT02564055|10029057|FG002|Overall Study|Protocol Violation|0
6303779|NCT02564055|10029058|FG003|Overall Study|Protocol Violation|0
6303780|NCT02564055|10029059|FG004|Overall Study|Protocol Violation|0
6303781|NCT02564055|10029060|FG005|Overall Study|Protocol Violation|0
6303782|NCT02564055|10029055|FG000|Overall Study|Reached stopping criteria|0
6303783|NCT02564055|10029056|FG001|Overall Study|Reached stopping criteria|0
6303784|NCT02564055|10029057|FG002|Overall Study|Reached stopping criteria|0
6303785|NCT02564055|10029058|FG003|Overall Study|Reached stopping criteria|0
6303786|NCT02564055|10029059|FG004|Overall Study|Reached stopping criteria|0
6303787|NCT02564055|10029060|FG005|Overall Study|Reached stopping criteria|1
6303788|NCT02564055|10029055|FG000|Overall Study|Lost to Follow-up|0
6303789|NCT02564055|10029056|FG001|Overall Study|Lost to Follow-up|1
6303790|NCT02564055|10029057|FG002|Overall Study|Lost to Follow-up|4
6303791|NCT02564055|10029058|FG003|Overall Study|Lost to Follow-up|2
6303792|NCT02564055|10029059|FG004|Overall Study|Lost to Follow-up|1
6303793|NCT02564055|10029060|FG005|Overall Study|Lost to Follow-up|0
6303794|NCT02564055|10029055|FG000|Overall Study|Physician Decision|0
6303795|NCT02564055|10029056|FG001|Overall Study|Physician Decision|0
6303796|NCT02564055|10029057|FG002|Overall Study|Physician Decision|1
6303797|NCT02564055|10029058|FG003|Overall Study|Physician Decision|0
6303798|NCT02564055|10029059|FG004|Overall Study|Physician Decision|0
6303799|NCT02564055|10029060|FG005|Overall Study|Physician Decision|0
6303800|NCT02564055|10029055|FG000|Overall Study|Withdrawal by Subject|4
6303801|NCT02564055|10029056|FG001|Overall Study|Withdrawal by Subject|4
6303802|NCT02564055|10029057|FG002|Overall Study|Withdrawal by Subject|3
6303803|NCT02564055|10029058|FG003|Overall Study|Withdrawal by Subject|3
6303804|NCT02564055|10029059|FG004|Overall Study|Withdrawal by Subject|10
6303805|NCT02564055|10029060|FG005|Overall Study|Withdrawal by Subject|10
6303806|NCT02564120|10029079|FG000|Overall Study|Did not return release forms|160
6303807|NCT02564120|10029079|FG000|Overall Study|Death|58
6303808|NCT02564120|10029079|FG000|Overall Study|Withdrawal by Subject|204
6303809|NCT02564120|10029079|FG000|Overall Study|Other medical condition|24
6303810|NCT02564198|10029096|FG000|Overall Study|Withdrawal by Subject|2
6303811|NCT02564198|10029097|FG001|Overall Study|Withdrawal by Subject|4
6303812|NCT02564198|10029098|FG002|Overall Study|Withdrawal by Subject|0
6303813|NCT02564198|10029096|FG000|Overall Study|Adverse Event|0
6303814|NCT02564198|10029097|FG001|Overall Study|Adverse Event|1
6303815|NCT02564198|10029098|FG002|Overall Study|Adverse Event|0
6303816|NCT02564211|10029108|FG000|Overall Study|Adverse Event|4
6303817|NCT02564471|10029131|FG000|Overall Study|Adverse Event|1
6303818|NCT02564471|10029132|FG001|Overall Study|Adverse Event|0
6303819|NCT02564471|10029133|FG002|Overall Study|Adverse Event|0
6303820|NCT02564471|10029134|FG003|Overall Study|Adverse Event|0
6303821|NCT02564471|10029131|FG000|Overall Study|Withdrawal by Subject|2
6303822|NCT02564471|10029132|FG001|Overall Study|Withdrawal by Subject|1
6303823|NCT02564471|10029133|FG002|Overall Study|Withdrawal by Subject|3
6303824|NCT02564471|10029134|FG003|Overall Study|Withdrawal by Subject|0
6303825|NCT02564471|10029131|FG000|Overall Study|Lost to Follow-up|0
6303826|NCT02564471|10029132|FG001|Overall Study|Lost to Follow-up|2
6303827|NCT02564471|10029133|FG002|Overall Study|Lost to Follow-up|0
6303828|NCT02564471|10029134|FG003|Overall Study|Lost to Follow-up|0
6303829|NCT02564718|10029155|FG000|Overall Study|Withdrew from treatment|0
6303830|NCT02564718|10029156|FG001|Overall Study|Withdrew from treatment|1
6303831|NCT02564887|10029164|FG000|Overall Study|Lost to Follow-up|6
6303832|NCT02564887|10029165|FG001|Overall Study|Lost to Follow-up|0
6303833|NCT02564952|10029182|FG000|Overall Study|Adverse Event|6
6303834|NCT02564952|10029182|FG000|Overall Study|Lost to Follow-up|1
6303835|NCT02564952|10029182|FG000|Overall Study|Participant Withdrawn by Investigator|1
6303836|NCT02564952|10029182|FG000|Overall Study|Withdrawal by Subject|1
6303837|NCT02564952|10029182|FG000|Overall Study|Low Efficacy|1
6303838|NCT02564952|10029182|FG000|Overall Study|Participant Met Withdrawal Criteria|1
6303839|NCT02565108|10029188|FG000|Overall Study|Adverse Event|1
6303840|NCT02565108|10029189|FG001|Overall Study|Adverse Event|0
6303841|NCT02565108|10029188|FG000|Overall Study|Withdrew Consent|1
6303842|NCT02565108|10029189|FG001|Overall Study|Withdrew Consent|0
6303843|NCT02565147|10029197|FG000|Overall Study|Withdrawal by Subject|5
6303844|NCT02565147|10029198|FG001|Overall Study|Withdrawal by Subject|1
6303845|NCT02565147|10029197|FG000|Overall Study|Lost to Follow-up|0
6303846|NCT02565147|10029198|FG001|Overall Study|Lost to Follow-up|1
6303847|NCT02565147|10029197|FG000|Overall Study|Death|1
6303848|NCT02565147|10029198|FG001|Overall Study|Death|1
6303849|NCT02565186|10029206|FG000|Overall Study|Adverse Event|113
6303850|NCT02565186|10029207|FG001|Overall Study|Adverse Event|148
6303851|NCT02565186|10029206|FG000|Overall Study|Lost to Follow-up|102
6303852|NCT02565186|10029207|FG001|Overall Study|Lost to Follow-up|93
6303853|NCT02565186|10029206|FG000|Overall Study|Non-Compliance|57
6303854|NCT02565186|10029207|FG001|Overall Study|Non-Compliance|55
6303855|NCT02565186|10029206|FG000|Overall Study|Withdrawal by Subject|229
6303856|NCT02565186|10029207|FG001|Overall Study|Withdrawal by Subject|214
6303857|NCT02565186|10029206|FG000|Overall Study|Physician Decision|18
6303858|NCT02565186|10029207|FG001|Overall Study|Physician Decision|16
6303859|NCT02565186|10029206|FG000|Overall Study|Sponsor Request|5
6303860|NCT02565186|10029207|FG001|Overall Study|Sponsor Request|9
6303861|NCT02565186|10029206|FG000|Overall Study|Missing|1
6303862|NCT02565186|10029207|FG001|Overall Study|Missing|0
6303863|NCT02565186|10029206|FG000|Overall Study|Did Not Receive Study Drug|55
6303864|NCT02565186|10029207|FG001|Overall Study|Did Not Receive Study Drug|86
6303865|NCT02565381|10029216|FG000|Overall Study|Lost to Follow-up|1
6303866|NCT02565381|10029217|FG001|Overall Study|Lost to Follow-up|0
6303867|NCT02565381|10029218|FG002|Overall Study|Lost to Follow-up|1
6303868|NCT02565511|10029239|FG000|Overall Study|Study terminated by Sponsor|35
6303869|NCT02565511|10029240|FG001|Overall Study|Study terminated by Sponsor|22
6303870|NCT02565511|10029241|FG002|Overall Study|Study terminated by Sponsor|235
6303871|NCT02565511|10029242|FG003|Overall Study|Study terminated by Sponsor|156
6303872|NCT02565511|10029239|FG000|Overall Study|Withdrawal by Subject|3
6303873|NCT02565511|10029240|FG001|Overall Study|Withdrawal by Subject|0
6303874|NCT02565511|10029241|FG002|Overall Study|Withdrawal by Subject|12
6303875|NCT02565511|10029242|FG003|Overall Study|Withdrawal by Subject|5
6303876|NCT02565511|10029239|FG000|Overall Study|Adverse Event|0
6303877|NCT02565511|10029240|FG001|Overall Study|Adverse Event|0
6303878|NCT02565511|10029241|FG002|Overall Study|Adverse Event|1
6303879|NCT02565511|10029242|FG003|Overall Study|Adverse Event|1
6303880|NCT02565511|10029239|FG000|Overall Study|Lost to Follow-up|4
6303881|NCT02565511|10029240|FG001|Overall Study|Lost to Follow-up|1
6303882|NCT02565511|10029241|FG002|Overall Study|Lost to Follow-up|0
6303883|NCT02565511|10029242|FG003|Overall Study|Lost to Follow-up|1
6303884|NCT02565511|10029239|FG000|Overall Study|Physician Decision|0
6303885|NCT02565511|10029240|FG001|Overall Study|Physician Decision|0
6303886|NCT02565511|10029241|FG002|Overall Study|Physician Decision|0
6303887|NCT02565511|10029242|FG003|Overall Study|Physician Decision|1
6303888|NCT02565511|10029239|FG000|Overall Study|Protocol deviation|0
6303889|NCT02565511|10029240|FG001|Overall Study|Protocol deviation|0
6303890|NCT02565511|10029241|FG002|Overall Study|Protocol deviation|3
6303891|NCT02565511|10029242|FG003|Overall Study|Protocol deviation|0
6303892|NCT02565576|10029254|FG000|Overall Study|abnormal lab value|2
6303893|NCT02565576|10029255|FG001|Overall Study|abnormal lab value|0
6303894|NCT02565576|10029254|FG000|Overall Study|subject / guardian decision|1
6303895|NCT02565576|10029255|FG001|Overall Study|subject / guardian decision|3
6303896|NCT02565576|10029254|FG000|Overall Study|Lost to Follow-up|1
6303897|NCT02565576|10029255|FG001|Overall Study|Lost to Follow-up|0
6303898|NCT02565576|10029254|FG000|Overall Study|Death|0
6303899|NCT02565576|10029255|FG001|Overall Study|Death|2
6303900|NCT02565576|10029254|FG000|Overall Study|Adverse Event|1
6303901|NCT02565576|10029255|FG001|Overall Study|Adverse Event|0
6303902|NCT02565615|10029266|FG000|Overall Study|Death|0
6303903|NCT02565615|10029267|FG001|Overall Study|Death|1
6303904|NCT02565615|10029268|FG002|Overall Study|Death|0
6303905|NCT02565615|10029269|FG003|Overall Study|Death|0
6303906|NCT02565615|10029270|FG004|Overall Study|Death|4
6303907|NCT02565615|10029266|FG000|Overall Study|Not willing to participate in study|2
6303908|NCT02565615|10029267|FG001|Overall Study|Not willing to participate in study|21
6063871|NCT00508742|9665278|FG001|Period 3: Toddler Dose|Adverse Event|0
6063872|NCT00508742|9665277|FG000|Period 3: Toddler Dose|Lost to Follow-up|2
6063873|NCT00508742|9665278|FG001|Period 3: Toddler Dose|Lost to Follow-up|3
6303909|NCT02565615|10029268|FG002|Overall Study|Not willing to participate in study|0
6303910|NCT02565615|10029269|FG003|Overall Study|Not willing to participate in study|1
6303911|NCT02565615|10029270|FG004|Overall Study|Not willing to participate in study|169
6303912|NCT02565615|10029266|FG000|Overall Study|Lost to Follow-up|0
6303913|NCT02565615|10029267|FG001|Overall Study|Lost to Follow-up|4
6303914|NCT02565615|10029268|FG002|Overall Study|Lost to Follow-up|0
6303915|NCT02565615|10029269|FG003|Overall Study|Lost to Follow-up|1
6303916|NCT02565615|10029270|FG004|Overall Study|Lost to Follow-up|765
6303917|NCT02565615|10029266|FG000|Overall Study|Not meeting eligibility criteria|0
6303918|NCT02565615|10029267|FG001|Overall Study|Not meeting eligibility criteria|7
6303919|NCT02565615|10029268|FG002|Overall Study|Not meeting eligibility criteria|0
6303920|NCT02565615|10029269|FG003|Overall Study|Not meeting eligibility criteria|0
6303921|NCT02565615|10029270|FG004|Overall Study|Not meeting eligibility criteria|25
6303922|NCT02565615|10029266|FG000|Overall Study|Reason not defined|0
6303923|NCT02565615|10029267|FG001|Overall Study|Reason not defined|2
6303924|NCT02565615|10029268|FG002|Overall Study|Reason not defined|0
6303925|NCT02565615|10029269|FG003|Overall Study|Reason not defined|1
6303926|NCT02565615|10029270|FG004|Overall Study|Reason not defined|62
6303927|NCT02565615|10029266|FG000|Overall Study|Adverse Event|1
6303928|NCT02565615|10029267|FG001|Overall Study|Adverse Event|1
6303929|NCT02565615|10029268|FG002|Overall Study|Adverse Event|0
6303930|NCT02565615|10029269|FG003|Overall Study|Adverse Event|0
6303931|NCT02565615|10029270|FG004|Overall Study|Adverse Event|9
6303932|NCT02565615|10029266|FG000|Overall Study|Untreated|0
6303933|NCT02565615|10029267|FG001|Overall Study|Untreated|0
6303934|NCT02565615|10029268|FG002|Overall Study|Untreated|0
6303935|NCT02565615|10029269|FG003|Overall Study|Untreated|0
6303936|NCT02565615|10029270|FG004|Overall Study|Untreated|567
6303937|NCT02565706|10029295|FG000|Overall Study|Withdrawal by Subject|5
6303938|NCT02565706|10029296|FG001|Overall Study|Withdrawal by Subject|7
6303939|NCT02565706|10029297|FG002|Overall Study|Withdrawal by Subject|7
6303940|NCT02565706|10029298|FG003|Overall Study|Withdrawal by Subject|11
6303941|NCT02565706|10029295|FG000|Overall Study|Lost to Follow-up|72
6303942|NCT02565706|10029296|FG001|Overall Study|Lost to Follow-up|75
6303943|NCT02565706|10029297|FG002|Overall Study|Lost to Follow-up|82
6303944|NCT02565706|10029298|FG003|Overall Study|Lost to Follow-up|74
6303945|NCT02565784|10029313|FG000|First Treatment|Adverse Event|1
6303946|NCT02565784|10029313|FG000|First Treatment|Withdrawal by Subject|1
6303947|NCT02565784|10029313|FG000|Second Treatment|Withdrawal by Subject|2
6303948|NCT02565810|10029321|FG000|Overall Study|Withdrawal by Subject|1
6303949|NCT02566005|10029346|FG000|Overall Study|vaginal bleeding|0
6303950|NCT02566005|10029347|FG001|Overall Study|vaginal bleeding|1
6303951|NCT02566005|10029346|FG000|Overall Study|received foley|8
6303952|NCT02566005|10029347|FG001|Overall Study|received foley|0
6303953|NCT02566005|10029346|FG000|Overall Study|did not receive foley|0
6303954|NCT02566005|10029347|FG001|Overall Study|did not receive foley|1
6303955|NCT02566005|10029346|FG000|Overall Study|labor after randomization|0
6303956|NCT02566005|10029347|FG001|Overall Study|labor after randomization|4
6303957|NCT02566031|10029355|FG000|Overall Study|Patient/guardian decision|14
6303958|NCT02566031|10029356|FG001|Overall Study|Patient/guardian decision|7
6303959|NCT02566031|10029355|FG000|Overall Study|Protocol deviation|2
6303960|NCT02566031|10029356|FG001|Overall Study|Protocol deviation|3
6303961|NCT02566031|10029355|FG000|Overall Study|Adverse Event|3
6303962|NCT02566031|10029356|FG001|Overall Study|Adverse Event|1
6303963|NCT02566031|10029355|FG000|Overall Study|Lost to Follow-up|1
6303964|NCT02566031|10029356|FG001|Overall Study|Lost to Follow-up|1
6303965|NCT02566109|10029390|FG000|Overall Study|Withdrawal by Subject|1
6303966|NCT02566525|10029441|FG000|Overall Study|Protocol Violation|3
6303967|NCT02566525|10029442|FG001|Overall Study|Protocol Violation|5
6303968|NCT02566577|10029452|FG000|Overall Study|Withdrawal by Subject|1
6303969|NCT02566577|10029453|FG001|Overall Study|Withdrawal by Subject|1
6303970|NCT02566577|10029452|FG000|Overall Study|Equipment failure|1
6303971|NCT02566577|10029453|FG001|Overall Study|Equipment failure|1
6303972|NCT02566577|10029452|FG000|Overall Study|Physical limitation|1
6303973|NCT02566577|10029453|FG001|Overall Study|Physical limitation|0
6303974|NCT02566759|10029487|FG000|All Parts|Withdrawal by Subject|0
6303975|NCT02566759|10029488|FG001|All Parts|Withdrawal by Subject|1
6303976|NCT02566759|10029489|FG002|All Parts|Withdrawal by Subject|0
6303977|NCT02566759|10029490|FG003|All Parts|Withdrawal by Subject|0
6303978|NCT02566759|10029491|FG004|All Parts|Withdrawal by Subject|0
6303979|NCT02566759|10029492|FG005|All Parts|Withdrawal by Subject|0
6303980|NCT02566759|10029493|FG006|All Parts|Withdrawal by Subject|0
6303981|NCT02566759|10029494|FG007|All Parts|Withdrawal by Subject|0
6303982|NCT02566759|10029495|FG008|All Parts|Withdrawal by Subject|0
6303983|NCT02566759|10029496|FG009|All Parts|Withdrawal by Subject|0
6303984|NCT02566759|10029497|FG010|All Parts|Withdrawal by Subject|0
6303985|NCT02566759|10029498|FG011|All Parts|Withdrawal by Subject|0
6303986|NCT02566759|10029499|FG012|All Parts|Withdrawal by Subject|0
6303987|NCT02566759|10029500|FG013|All Parts|Withdrawal by Subject|0
6303988|NCT02566759|10029501|FG014|All Parts|Withdrawal by Subject|0
6303989|NCT02566759|10029502|FG015|All Parts|Withdrawal by Subject|0
6303990|NCT02566759|10029503|FG016|All Parts|Withdrawal by Subject|0
6303991|NCT02566759|10029487|FG000|All Parts|Adverse Event|0
6303992|NCT02566759|10029488|FG001|All Parts|Adverse Event|0
6303993|NCT02566759|10029489|FG002|All Parts|Adverse Event|0
6303994|NCT02566759|10029490|FG003|All Parts|Adverse Event|0
6303995|NCT02566759|10029491|FG004|All Parts|Adverse Event|0
6303996|NCT02566759|10029492|FG005|All Parts|Adverse Event|0
6303997|NCT02566759|10029493|FG006|All Parts|Adverse Event|0
6303998|NCT02566759|10029494|FG007|All Parts|Adverse Event|0
6303999|NCT02566759|10029495|FG008|All Parts|Adverse Event|0
6304000|NCT02566759|10029496|FG009|All Parts|Adverse Event|0
6304001|NCT02566759|10029497|FG010|All Parts|Adverse Event|0
6304002|NCT02566759|10029498|FG011|All Parts|Adverse Event|0
6304003|NCT02566759|10029499|FG012|All Parts|Adverse Event|1
6304004|NCT02566759|10029500|FG013|All Parts|Adverse Event|3
6304005|NCT02566759|10029501|FG014|All Parts|Adverse Event|0
6304006|NCT02566759|10029502|FG015|All Parts|Adverse Event|0
6304007|NCT02566759|10029503|FG016|All Parts|Adverse Event|0
6304008|NCT02566759|10029487|FG000|All Parts|Other|0
6304009|NCT02566759|10029488|FG001|All Parts|Other|0
6304010|NCT02566759|10029489|FG002|All Parts|Other|0
6304011|NCT02566759|10029490|FG003|All Parts|Other|0
6304012|NCT02566759|10029491|FG004|All Parts|Other|0
6304013|NCT02566759|10029492|FG005|All Parts|Other|0
6304014|NCT02566759|10029493|FG006|All Parts|Other|0
6304015|NCT02566759|10029494|FG007|All Parts|Other|0
6304016|NCT02566759|10029495|FG008|All Parts|Other|0
6304017|NCT02566759|10029496|FG009|All Parts|Other|0
6304018|NCT02566759|10029497|FG010|All Parts|Other|0
6304019|NCT02566759|10029498|FG011|All Parts|Other|0
6304020|NCT02566759|10029499|FG012|All Parts|Other|0
6304021|NCT02566759|10029500|FG013|All Parts|Other|2
6304022|NCT02566759|10029501|FG014|All Parts|Other|0
6304023|NCT02566759|10029502|FG015|All Parts|Other|0
6304024|NCT02566759|10029503|FG016|All Parts|Other|0
6304025|NCT02566759|10029487|FG000|Crossover Treatment (Part 4: 1 Day)|Withdrawal by Subject|0
6304026|NCT02566759|10029488|FG001|Crossover Treatment (Part 4: 1 Day)|Withdrawal by Subject|0
6304027|NCT02566759|10029489|FG002|Crossover Treatment (Part 4: 1 Day)|Withdrawal by Subject|0
6304028|NCT02566759|10029490|FG003|Crossover Treatment (Part 4: 1 Day)|Withdrawal by Subject|0
6304029|NCT02566759|10029491|FG004|Crossover Treatment (Part 4: 1 Day)|Withdrawal by Subject|0
6304030|NCT02566759|10029492|FG005|Crossover Treatment (Part 4: 1 Day)|Withdrawal by Subject|0
6304031|NCT02566759|10029493|FG006|Crossover Treatment (Part 4: 1 Day)|Withdrawal by Subject|0
6304032|NCT02566759|10029494|FG007|Crossover Treatment (Part 4: 1 Day)|Withdrawal by Subject|0
6304033|NCT02566759|10029495|FG008|Crossover Treatment (Part 4: 1 Day)|Withdrawal by Subject|0
6304034|NCT02566759|10029496|FG009|Crossover Treatment (Part 4: 1 Day)|Withdrawal by Subject|0
5982394|NCT03118570|9571389|FG000|Overall Study|Adverse Event|2
5982395|NCT03118570|9571390|FG001|Overall Study|Adverse Event|0
5982396|NCT03118570|9571391|FG002|Overall Study|Adverse Event|0
5982397|NCT03118570|9571392|FG003|Overall Study|Adverse Event|0
5982398|NCT03118570|9571393|FG004|Overall Study|Adverse Event|3
5982399|NCT03118570|9571389|FG000|Overall Study|Withdrawal by Subject|0
5982400|NCT03118570|9571390|FG001|Overall Study|Withdrawal by Subject|1
5982401|NCT03118570|9571391|FG002|Overall Study|Withdrawal by Subject|4
5982402|NCT03118570|9571392|FG003|Overall Study|Withdrawal by Subject|0
5982403|NCT03118570|9571393|FG004|Overall Study|Withdrawal by Subject|1
5982404|NCT03118570|9571389|FG000|Overall Study|Lost to Follow-up|2
5982405|NCT03118570|9571390|FG001|Overall Study|Lost to Follow-up|3
5982406|NCT03118570|9571391|FG002|Overall Study|Lost to Follow-up|1
5982407|NCT03118570|9571392|FG003|Overall Study|Lost to Follow-up|0
5982408|NCT03118570|9571393|FG004|Overall Study|Lost to Follow-up|1
5982409|NCT03118570|9571389|FG000|Overall Study|Other, Not Specified|1
5982410|NCT03118570|9571390|FG001|Overall Study|Other, Not Specified|3
5982411|NCT03118570|9571391|FG002|Overall Study|Other, Not Specified|0
5982412|NCT03118570|9571392|FG003|Overall Study|Other, Not Specified|0
5982413|NCT03118570|9571393|FG004|Overall Study|Other, Not Specified|0
5982414|NCT03094416|9571406|FG000|Run-in|Screening failure|8
5982415|NCT03094416|9571406|FG000|Run-in|Sponsor Decision To Discontinue Due To Global Covid-19 Pandemic|8
5982416|NCT03094416|9571406|FG000|Run-in|Withdrawal by Subject|3
5982417|NCT03094416|9571406|FG000|Treatment Period|Withdrawal by Subject|2
5982433|NCT02811861|9571414|FG000|Overall Study|Withdrawal by Subject|4
5982434|NCT02811861|9571415|FG001|Overall Study|Withdrawal by Subject|4
5982435|NCT02811861|9571416|FG002|Overall Study|Withdrawal by Subject|9
5982436|NCT02811861|9571414|FG000|Overall Study|Other|4
5982437|NCT02811861|9571415|FG001|Overall Study|Other|13
5982438|NCT02811861|9571416|FG002|Overall Study|Other|3
5982439|NCT02811861|9571414|FG000|Overall Study|Treatment Ongoing at Cutoff Date|112
5982440|NCT02811861|9571415|FG001|Overall Study|Treatment Ongoing at Cutoff Date|142
5982441|NCT02811861|9571416|FG002|Overall Study|Treatment Ongoing at Cutoff Date|67
5982442|NCT02811861|9571414|FG000|Overall Study|Randomized but not treated|2
5982443|NCT02811861|9571415|FG001|Overall Study|Randomized but not treated|3
5982444|NCT02811861|9571416|FG002|Overall Study|Randomized but not treated|17
6063874|NCT00508742|9665277|FG000|Period 3: Toddler Dose|Parent/Legal Guardian Request|17
6063875|NCT00508742|9665278|FG001|Period 3: Toddler Dose|Parent/Legal Guardian Request|8
6063876|NCT00508742|9665277|FG000|Period 3: Toddler Dose|Other|5
6063877|NCT00508742|9665278|FG001|Period 3: Toddler Dose|Other|4
6063878|NCT00508755|9665290|FG000|Overall Study|Withdrawal by Subject|1
6063879|NCT00508820|9665298|FG000|Overall Study|Adverse Event|6
6063880|NCT00508820|9665299|FG001|Overall Study|Adverse Event|10
6063881|NCT00508820|9665298|FG000|Overall Study|Death|6
6063882|NCT00508820|9665299|FG001|Overall Study|Death|8
6063883|NCT00508820|9665298|FG000|Overall Study|Lost to Follow-up|1
6063884|NCT00508820|9665299|FG001|Overall Study|Lost to Follow-up|1
6063885|NCT00508820|9665298|FG000|Overall Study|Physician Decision|8
6063886|NCT00508820|9665299|FG001|Overall Study|Physician Decision|2
6063887|NCT00508820|9665298|FG000|Overall Study|Pregnancy|0
6063888|NCT00508820|9665299|FG001|Overall Study|Pregnancy|2
6063889|NCT00508820|9665298|FG000|Overall Study|Protocol Violation|2
6063890|NCT00508820|9665299|FG001|Overall Study|Protocol Violation|0
6063891|NCT00508820|9665298|FG000|Overall Study|Withdrawal by Subject|10
6304035|NCT02566759|10029497|FG010|Crossover Treatment (Part 4: 1 Day)|Withdrawal by Subject|0
6304036|NCT02566759|10029498|FG011|Crossover Treatment (Part 4: 1 Day)|Withdrawal by Subject|0
6304037|NCT02566759|10029499|FG012|Crossover Treatment (Part 4: 1 Day)|Withdrawal by Subject|0
6304038|NCT02566759|10029500|FG013|Crossover Treatment (Part 4: 1 Day)|Withdrawal by Subject|0
6304039|NCT02566759|10029501|FG014|Crossover Treatment (Part 4: 1 Day)|Withdrawal by Subject|0
6304040|NCT02566759|10029502|FG015|Crossover Treatment (Part 4: 1 Day)|Withdrawal by Subject|0
6304041|NCT02566759|10029503|FG016|Crossover Treatment (Part 4: 1 Day)|Withdrawal by Subject|1
6304042|NCT02566785|10029564|FG000|Overall Study|Lost to Follow-up|0
6304043|NCT02566785|10029565|FG001|Overall Study|Lost to Follow-up|2
6304044|NCT02566785|10029564|FG000|Overall Study|Worsening condition|1
6304045|NCT02566785|10029565|FG001|Overall Study|Worsening condition|1
6304046|NCT02566889|10029573|FG000|Overall Study|Withdrawal by Subject|3
6304047|NCT02566889|10029574|FG001|Overall Study|Withdrawal by Subject|1
6304048|NCT02566889|10029573|FG000|Overall Study|Adverse Event|4
6304049|NCT02566889|10029574|FG001|Overall Study|Adverse Event|2
6304050|NCT02566889|10029573|FG000|Overall Study|Other|6
6304051|NCT02566889|10029574|FG001|Overall Study|Other|2
6304052|NCT02566902|10029581|FG000|Overall Study|Protocol Violation|2
6304053|NCT02566902|10029582|FG001|Overall Study|Protocol Violation|1
6304054|NCT02566993|10029590|FG000|Overall Study|Randomized but not treated|5
6304055|NCT02566993|10029591|FG001|Overall Study|Randomized but not treated|16
6304056|NCT02566993|10029590|FG000|Overall Study|Progressive disease|213
6304057|NCT02566993|10029591|FG001|Overall Study|Progressive disease|152
6304058|NCT02566993|10029590|FG000|Overall Study|Withdrawal by Subject|12
6304059|NCT02566993|10029591|FG001|Overall Study|Withdrawal by Subject|28
6304060|NCT02566993|10029590|FG000|Overall Study|Death|17
6304061|NCT02566993|10029591|FG001|Overall Study|Death|23
6304062|NCT02566993|10029590|FG000|Overall Study|Physician Decision|10
6304063|NCT02566993|10029591|FG001|Overall Study|Physician Decision|17
6304064|NCT02566993|10029590|FG000|Overall Study|Study drug-related adverse event|20
6304065|NCT02566993|10029591|FG001|Overall Study|Study drug-related adverse event|41
6304066|NCT02566993|10029590|FG000|Overall Study|Non study drug-related adverse event|9
6304067|NCT02566993|10029591|FG001|Overall Study|Non study drug-related adverse event|9
6304068|NCT02566993|10029590|FG000|Overall Study|Symptomatic deterioration|9
6304069|NCT02566993|10029591|FG001|Overall Study|Symptomatic deterioration|16
6304070|NCT02566993|10029590|FG000|Overall Study|End of study due to events required for OS analysis according to study protocol had been reached|9
6304071|NCT02566993|10029591|FG001|Overall Study|End of study due to events required for OS analysis according to study protocol had been reached|1
6304072|NCT02566993|10029590|FG000|Overall Study|Sponsor's decision after incorrect treatment at site|1
6304073|NCT02566993|10029591|FG001|Overall Study|Sponsor's decision after incorrect treatment at site|1
6304074|NCT02566993|10029590|FG000|Overall Study|Screening failure|2
6304075|NCT02566993|10029591|FG001|Overall Study|Screening failure|0
6304076|NCT02566993|10029590|FG000|Overall Study|Lost to Follow-up|0
6304077|NCT02566993|10029591|FG001|Overall Study|Lost to Follow-up|1
6304078|NCT02566993|10029590|FG000|Overall Study|Symptomatic deterioration, progression disease, and a decision by the Investigator|0
6304079|NCT02566993|10029591|FG001|Overall Study|Symptomatic deterioration, progression disease, and a decision by the Investigator|1
6304080|NCT02567188|10029599|FG000|Overall Study|Death|10
6304081|NCT02567188|10029599|FG000|Overall Study|Terminated Mircera Treatment|9
6304082|NCT02567188|10029599|FG000|Overall Study|Lost to Follow-up|5
6304083|NCT02567188|10029599|FG000|Overall Study|Adverse Event|1
6304084|NCT02567188|10029599|FG000|Overall Study|Withdrawal by Subject|1
6304085|NCT02567188|10029599|FG000|Overall Study|Refused Treatment/ Did not Cooperate|1
6304086|NCT02567188|10029599|FG000|Overall Study|Moved and Changed Clinic|1
6304087|NCT02567188|10029599|FG000|Overall Study|Started Hemodialysis|2
6304088|NCT02567188|10029599|FG000|Overall Study|Protocol Violation|5
6304089|NCT02567227|10029606|FG000|9 Weeks|Adverse Event|5
6304090|NCT02567227|10029607|FG001|9 Weeks|Adverse Event|5
6304091|NCT02567227|10029606|FG000|9 Weeks|Withdrawal by Subject|18
6304092|NCT02567227|10029607|FG001|9 Weeks|Withdrawal by Subject|8
6304093|NCT02567227|10029606|FG000|9 Weeks|Study suspended due to COVID-19 pandemic|11
6304094|NCT02567227|10029607|FG001|9 Weeks|Study suspended due to COVID-19 pandemic|11
6304095|NCT02567227|10029606|FG000|6 Month|Death|2
6304096|NCT02567227|10029607|FG001|6 Month|Death|0
6304097|NCT02567227|10029606|FG000|6 Month|Lost to Follow-up|43
6304098|NCT02567227|10029607|FG001|6 Month|Lost to Follow-up|40
6304099|NCT02567227|10029606|FG000|12 Months|Lost to Follow-up|31
6304100|NCT02567227|10029607|FG001|12 Months|Lost to Follow-up|32
6304101|NCT02567227|10029606|FG000|12 Months|Death|0
6304102|NCT02567227|10029607|FG001|12 Months|Death|2
6304103|NCT02567266|10029616|FG000|Overall Study|Withdrawal by Subject|10
6304104|NCT02567266|10029617|FG001|Overall Study|Withdrawal by Subject|7
6304105|NCT02567266|10029618|FG002|Overall Study|Withdrawal by Subject|6
6304106|NCT02567266|10029616|FG000|Overall Study|Lost to Follow-up|13
6304107|NCT02567266|10029617|FG001|Overall Study|Lost to Follow-up|8
6304108|NCT02567266|10029618|FG002|Overall Study|Lost to Follow-up|10
6304109|NCT02567552|10029628|FG000|Overall Study|Adverse Event|0
6304110|NCT02567552|10029629|FG001|Overall Study|Adverse Event|1
6304111|NCT02567656|10029641|FG000|Overall Study|Premature discontinuation due to PD|1
6304112|NCT02567656|10029642|FG001|Overall Study|Premature discontinuation due to PD|1
6304113|NCT02567656|10029643|FG002|Overall Study|Premature discontinuation due to PD|2
6304114|NCT02567656|10029644|FG003|Overall Study|Premature discontinuation due to PD|0
6304115|NCT02567656|10029645|FG004|Overall Study|Premature discontinuation due to PD|0
6304116|NCT02567656|10029646|FG005|Overall Study|Premature discontinuation due to PD|0
6304117|NCT02567708|10029660|FG000|Treatment Period 1 (Up to 4 Weeks)|Adverse Event|0
6304118|NCT02567708|10029661|FG001|Treatment Period 1 (Up to 4 Weeks)|Adverse Event|2
6063892|NCT00508820|9665299|FG001|Overall Study|Withdrawal by Subject|12
6063893|NCT00508820|9665298|FG000|Overall Study|Other|11
6063894|NCT00508820|9665299|FG001|Overall Study|Other|2
6063895|NCT00508820|9665298|FG000|Overall Study|Noncompliance|1
6063896|NCT00508820|9665299|FG001|Overall Study|Noncompliance|0
6063897|NCT00508820|9665298|FG000|Overall Study|Requirement for alternative therapy|7
6063898|NCT00508820|9665299|FG001|Overall Study|Requirement for alternative therapy|15
6063899|NCT00508820|9665298|FG000|Overall Study|Protocol-specified Criteria|3
6063900|NCT00508820|9665299|FG001|Overall Study|Protocol-specified Criteria|12
6063901|NCT00508924|9665309|FG000|Overall Study|Protocol Violation|0
6063902|NCT00508924|9665310|FG001|Overall Study|Protocol Violation|0
6063903|NCT00508924|9665311|FG002|Overall Study|Protocol Violation|1
6063904|NCT00508924|9665312|FG003|Overall Study|Protocol Violation|1
6063905|NCT00509028|9665328|FG000|Overall Study|Adverse Event|2
6063906|NCT00509028|9665329|FG001|Overall Study|Adverse Event|0
6063907|NCT00509028|9665328|FG000|Overall Study|Withdrawal by Subject|4
6063908|NCT00509028|9665329|FG001|Overall Study|Withdrawal by Subject|3
6063909|NCT00509028|9665328|FG000|Overall Study|Lost to Follow-up|0
6063910|NCT00509028|9665329|FG001|Overall Study|Lost to Follow-up|1
6063911|NCT00509028|9665328|FG000|Overall Study|Protocol Violation|4
6063912|NCT00509028|9665329|FG001|Overall Study|Protocol Violation|2
6063913|NCT00509028|9665328|FG000|Overall Study|Non-compliance|2
6063914|NCT00509028|9665329|FG001|Overall Study|Non-compliance|1
6063915|NCT00509067|9665341|FG000|Overall Study|Lost to Follow-up|1
6063916|NCT00509067|9665342|FG001|Overall Study|Lost to Follow-up|1
6063917|NCT00509067|9665341|FG000|Overall Study|Adverse Event|3
6063918|NCT00509067|9665342|FG001|Overall Study|Adverse Event|1
6063919|NCT00509067|9665341|FG000|Overall Study|Protocol Violation|0
6063920|NCT00509067|9665342|FG001|Overall Study|Protocol Violation|3
6063921|NCT00509093|9665352|FG000|Overall Study|Adverse Event|10
6063922|NCT00509093|9665352|FG000|Overall Study|Disease Progression|9
6063923|NCT00509093|9665352|FG000|Overall Study|Transformed into MDS|1
6063924|NCT00509093|9665352|FG000|Overall Study|Withdrawal by Subject|3
6063925|NCT00509093|9665352|FG000|Overall Study|Physician Decision|1
6063926|NCT00509106|9665358|FG000|Overall Study|Adverse Event|3
6063927|NCT00509106|9665359|FG001|Overall Study|Adverse Event|2
6063928|NCT00509106|9665358|FG000|Overall Study|Noncompliance|0
6063929|NCT00509106|9665359|FG001|Overall Study|Noncompliance|1
6063930|NCT00509106|9665358|FG000|Overall Study|At the request of sponsor/investigator|1
6063931|NCT00509106|9665359|FG001|Overall Study|At the request of sponsor/investigator|2
6063932|NCT00509106|9665358|FG000|Overall Study|Withdrew consent|4
6063933|NCT00509106|9665359|FG001|Overall Study|Withdrew consent|8
6063934|NCT00509106|9665358|FG000|Overall Study|Lost to Follow-up|16
6063935|NCT00509106|9665359|FG001|Overall Study|Lost to Follow-up|10
6063936|NCT00509106|9665358|FG000|Overall Study|Other|1
6063937|NCT00509106|9665359|FG001|Overall Study|Other|0
6063938|NCT00509106|9665358|FG000|Overall Study|Death|6
6063939|NCT00509106|9665359|FG001|Overall Study|Death|6
6063940|NCT00509145|9665367|FG000|Overall Study|Death|0
6063941|NCT00509145|9665368|FG001|Overall Study|Death|2
6063942|NCT00509145|9665367|FG000|Overall Study|Adverse Event|42
6063943|NCT00509145|9665368|FG001|Overall Study|Adverse Event|28
6063944|NCT00509145|9665367|FG000|Overall Study|Withdrawal by Subject|32
6063945|NCT00509145|9665368|FG001|Overall Study|Withdrawal by Subject|38
6063946|NCT00509145|9665367|FG000|Overall Study|Physician Decision|11
6063947|NCT00509145|9665368|FG001|Overall Study|Physician Decision|14
6063948|NCT00509145|9665367|FG000|Overall Study|Protocol Violation|1
6063949|NCT00509145|9665368|FG001|Overall Study|Protocol Violation|6
6063950|NCT00509145|9665367|FG000|Overall Study|Pregnancy|3
6063951|NCT00509145|9665368|FG001|Overall Study|Pregnancy|8
6063952|NCT00509145|9665367|FG000|Overall Study|Lost to Follow-up|6
6063953|NCT00509145|9665368|FG001|Overall Study|Lost to Follow-up|5
6063954|NCT00509145|9665367|FG000|Overall Study|Withdrawal by participant after confirmed relapse|12
6063955|NCT00509145|9665368|FG001|Overall Study|Withdrawal by participant after confirmed relapse|22
6063956|NCT00509145|9665367|FG000|Overall Study|Other|6
6063957|NCT00509145|9665368|FG001|Overall Study|Other|6
6063958|NCT00509223|9665396|FG000|Overall Study|Lost to Follow-up|1
6063959|NCT00509223|9665397|FG001|Overall Study|Lost to Follow-up|1
6063960|NCT00509223|9665396|FG000|Overall Study|Adverse Event|1
6063961|NCT00509223|9665397|FG001|Overall Study|Adverse Event|1
6063962|NCT00509223|9665396|FG000|Overall Study|Withdrawal by Subject|25
6137018|NCT01005316|9767122|FG001|Overall Study|Lost to Follow-up|3
6137019|NCT01005316|9767123|FG002|Overall Study|Lost to Follow-up|0
6137020|NCT01005316|9767124|FG003|Overall Study|Lost to Follow-up|2
6137021|NCT01005316|9767121|FG000|Overall Study|Physician Decision|6
6137022|NCT01005316|9767122|FG001|Overall Study|Physician Decision|0
6137023|NCT01005316|9767123|FG002|Overall Study|Physician Decision|0
6137024|NCT01005316|9767124|FG003|Overall Study|Physician Decision|0
6137025|NCT01005316|9767121|FG000|Overall Study|Sponsor Decision|6
6063963|NCT00509223|9665397|FG001|Overall Study|Withdrawal by Subject|6
6063964|NCT00509223|9665396|FG000|Overall Study|Including: subject change of address|5
6063965|NCT00509223|9665397|FG001|Overall Study|Including: subject change of address|2
6063966|NCT00509223|9665396|FG000|Overall Study|Did not meet revised inclusion criteria|56
6304119|NCT02567708|10029660|FG000|Treatment Period 1 (Up to 4 Weeks)|Protocol Violation|0
6304120|NCT02567708|10029661|FG001|Treatment Period 1 (Up to 4 Weeks)|Protocol Violation|1
6304121|NCT02567708|10029660|FG000|Treatment Period 1 (Up to 4 Weeks)|Other: Reached stopping criteria|2
6304122|NCT02567708|10029661|FG001|Treatment Period 1 (Up to 4 Weeks)|Other: Reached stopping criteria|0
6304123|NCT02567708|10029660|FG000|Treatment Period 2 (Up to 4 Weeks)|Other: Reached stopping criteria|0
6304124|NCT02567708|10029661|FG001|Treatment Period 2 (Up to 4 Weeks)|Other: Reached stopping criteria|3
6304125|NCT02568046|10029677|FG000|Overall Study|Adverse Event|0
6304126|NCT02568046|10029678|FG001|Overall Study|Adverse Event|1
6304127|NCT02568046|10029677|FG000|Overall Study|Death|2
6304128|NCT02568046|10029678|FG001|Overall Study|Death|0
6304129|NCT02568046|10029677|FG000|Overall Study|Progressive Disease|1
6304130|NCT02568046|10029678|FG001|Overall Study|Progressive Disease|0
6304131|NCT02568046|10029677|FG000|Overall Study|Withdrawal by Subject|2
6304132|NCT02568046|10029678|FG001|Overall Study|Withdrawal by Subject|1
6304133|NCT02568046|10029677|FG000|Overall Study|Other Events|0
6304134|NCT02568046|10029678|FG001|Overall Study|Other Events|1
6304135|NCT02568072|10029684|FG000|Overall Study|Unavailable for appointment|23
6304136|NCT02568072|10029684|FG000|Overall Study|Unable to contact|3
6304137|NCT02568072|10029684|FG000|Overall Study|Diagnosis of Long QT Syndrome|1
6304138|NCT02568072|10029684|FG000|Overall Study|Withdrawal by Subject|1
6304139|NCT02568072|10029684|FG000|Overall Study|Sustained injury, marathon not run|24
6304140|NCT02568254|10029689|FG000|Period 2|Adverse Event|0
6304141|NCT02568254|10029690|FG001|Period 2|Adverse Event|0
6304142|NCT02568254|10029691|FG002|Period 2|Adverse Event|1
6304143|NCT02568254|10029692|FG003|Period 2|Adverse Event|0
6304144|NCT02568254|10029693|FG004|Period 2|Adverse Event|0
6304145|NCT02568254|10029694|FG005|Period 2|Adverse Event|0
6304146|NCT02568254|10029689|FG000|Period 3|Unstatisfactory Lens fitting|0
6304147|NCT02568254|10029690|FG001|Period 3|Unstatisfactory Lens fitting|0
6304148|NCT02568254|10029691|FG002|Period 3|Unstatisfactory Lens fitting|0
6304149|NCT02568254|10029692|FG003|Period 3|Unstatisfactory Lens fitting|0
6304150|NCT02568254|10029693|FG004|Period 3|Unstatisfactory Lens fitting|1
6304151|NCT02568254|10029694|FG005|Period 3|Unstatisfactory Lens fitting|0
6304152|NCT02568384|10029706|FG000|Overall Study|Mobile devices incompatible with App|2
6304153|NCT02568397|10029710|FG000|Period 2|Withdrawal by Subject|0
6304154|NCT02568397|10029711|FG001|Period 2|Withdrawal by Subject|1
6304155|NCT02568397|10029710|FG000|Period 2|Physician Decision|0
6304156|NCT02568397|10029711|FG001|Period 2|Physician Decision|1
6304157|NCT02568475|10029728|FG000|Overall Study|Lost to Follow-up|40
6304158|NCT02568475|10029729|FG001|Overall Study|Lost to Follow-up|39
6304159|NCT02568475|10029728|FG000|Overall Study|Withdrawal by Subject|2
6304160|NCT02568475|10029729|FG001|Overall Study|Withdrawal by Subject|0
6304161|NCT02568475|10029728|FG000|Overall Study|Discharged home|4
6304162|NCT02568475|10029729|FG001|Overall Study|Discharged home|4
6304163|NCT02568475|10029728|FG000|Overall Study|Short-term: Discharge location unknown|4
6304164|NCT02568475|10029729|FG001|Overall Study|Short-term: Discharge location unknown|0
6304165|NCT02568475|10029728|FG000|Overall Study|Transferred to another facility|1
6304166|NCT02568475|10029729|FG001|Overall Study|Transferred to another facility|0
6304167|NCT02568683|10029748|FG000|Overall Study|Death|0
6304168|NCT02568683|10029749|FG001|Overall Study|Death|2
6304169|NCT02568683|10029748|FG000|Overall Study|Withdrew Consent|1
6304170|NCT02568683|10029749|FG001|Overall Study|Withdrew Consent|0
6304171|NCT02568683|10029748|FG000|Overall Study|Study Terminated By Sponsor|5
6304172|NCT02568683|10029749|FG001|Overall Study|Study Terminated By Sponsor|2
6304173|NCT02569398|10029777|FG000|Overall Study|Adverse Event|0
6304174|NCT02569398|10029778|FG001|Overall Study|Adverse Event|1
6304175|NCT02569398|10029779|FG002|Overall Study|Adverse Event|6
6304176|NCT02569398|10029777|FG000|Overall Study|Withdrawal by Subject|43
6304177|NCT02569398|10029778|FG001|Overall Study|Withdrawal by Subject|43
6304178|NCT02569398|10029779|FG002|Overall Study|Withdrawal by Subject|30
6304179|NCT02569398|10029777|FG000|Overall Study|Study terminated by sponsor|130
6304180|NCT02569398|10029778|FG001|Overall Study|Study terminated by sponsor|131
6304181|NCT02569398|10029779|FG002|Overall Study|Study terminated by sponsor|134
6304182|NCT02569398|10029777|FG000|Overall Study|Other|12
6304183|NCT02569398|10029778|FG001|Overall Study|Other|14
6304184|NCT02569398|10029779|FG002|Overall Study|Other|13
6304185|NCT02569437|10029798|FG000|Overall Study|Lost to Follow-up|12
6304186|NCT02569437|10029799|FG001|Overall Study|Lost to Follow-up|14
6304187|NCT02569710|10029832|FG000|Overall Study|Adverse Event|1
6304188|NCT02569710|10029833|FG001|Overall Study|Adverse Event|0
6304189|NCT02569710|10029834|FG002|Overall Study|Adverse Event|0
6304190|NCT02569710|10029835|FG003|Overall Study|Adverse Event|0
6304191|NCT02569710|10029836|FG004|Overall Study|Adverse Event|0
6304192|NCT02569710|10029837|FG005|Overall Study|Adverse Event|0
6304193|NCT02569710|10029838|FG006|Overall Study|Adverse Event|0
6304194|NCT02569710|10029839|FG007|Overall Study|Adverse Event|0
6304195|NCT02569710|10029840|FG008|Overall Study|Adverse Event|0
6304196|NCT02569710|10029841|FG009|Overall Study|Adverse Event|0
6304197|NCT02569710|10029832|FG000|Overall Study|Lost to Follow-up|0
6304198|NCT02569710|10029833|FG001|Overall Study|Lost to Follow-up|0
6304199|NCT02569710|10029834|FG002|Overall Study|Lost to Follow-up|0
6304200|NCT02569710|10029835|FG003|Overall Study|Lost to Follow-up|0
6304201|NCT02569710|10029836|FG004|Overall Study|Lost to Follow-up|0
6304202|NCT02569710|10029837|FG005|Overall Study|Lost to Follow-up|0
6304203|NCT02569710|10029838|FG006|Overall Study|Lost to Follow-up|1
6304204|NCT02569710|10029839|FG007|Overall Study|Lost to Follow-up|0
6304205|NCT02569710|10029840|FG008|Overall Study|Lost to Follow-up|1
6304206|NCT02569710|10029841|FG009|Overall Study|Lost to Follow-up|0
6304207|NCT02569710|10029832|FG000|Overall Study|Virologic failure|0
6304208|NCT02569710|10029833|FG001|Overall Study|Virologic failure|0
6304209|NCT02569710|10029834|FG002|Overall Study|Virologic failure|0
6304210|NCT02569710|10029835|FG003|Overall Study|Virologic failure|0
6304211|NCT02569710|10029836|FG004|Overall Study|Virologic failure|1
6304212|NCT02569710|10029837|FG005|Overall Study|Virologic failure|0
6304213|NCT02569710|10029838|FG006|Overall Study|Virologic failure|1
6304214|NCT02569710|10029839|FG007|Overall Study|Virologic failure|0
6304215|NCT02569710|10029840|FG008|Overall Study|Virologic failure|0
6304216|NCT02569710|10029841|FG009|Overall Study|Virologic failure|0
6304217|NCT02569710|10029832|FG000|Overall Study|Withdrawal by Subject|0
6304218|NCT02569710|10029833|FG001|Overall Study|Withdrawal by Subject|0
6304219|NCT02569710|10029834|FG002|Overall Study|Withdrawal by Subject|0
6304220|NCT02569710|10029835|FG003|Overall Study|Withdrawal by Subject|0
6304221|NCT02569710|10029836|FG004|Overall Study|Withdrawal by Subject|0
6304222|NCT02569710|10029837|FG005|Overall Study|Withdrawal by Subject|1
6304223|NCT02569710|10029838|FG006|Overall Study|Withdrawal by Subject|0
6304224|NCT02569710|10029839|FG007|Overall Study|Withdrawal by Subject|0
6304225|NCT02569710|10029840|FG008|Overall Study|Withdrawal by Subject|0
6304226|NCT02569710|10029841|FG009|Overall Study|Withdrawal by Subject|0
6304227|NCT02569801|10029880|FG000|Overall Study|Withdrawal by Subject|9
6304228|NCT02569801|10029881|FG001|Overall Study|Withdrawal by Subject|9
6304229|NCT02569801|10029880|FG000|Overall Study|Sponsor Decision|13
6304230|NCT02569801|10029881|FG001|Overall Study|Sponsor Decision|14
6304231|NCT02569801|10029880|FG000|Overall Study|Progressive Disease|2
6304232|NCT02569801|10029881|FG001|Overall Study|Progressive Disease|7
6304233|NCT02569801|10029880|FG000|Overall Study|Lost to Follow-up|0
6304234|NCT02569801|10029881|FG001|Overall Study|Lost to Follow-up|1
6304235|NCT02569801|10029880|FG000|Overall Study|Death|12
6304236|NCT02569801|10029881|FG001|Overall Study|Death|4
6304237|NCT02569853|10029889|FG000|Overall Study|Adverse Event|2
6304238|NCT02569853|10029890|FG001|Overall Study|Adverse Event|0
6304239|NCT02569853|10029889|FG000|Overall Study|Withdrawal by Subject|3
6304240|NCT02569853|10029890|FG001|Overall Study|Withdrawal by Subject|2
6304241|NCT02569853|10029889|FG000|Overall Study|Lost to Follow-up|3
6304242|NCT02569853|10029890|FG001|Overall Study|Lost to Follow-up|3
6304243|NCT02569853|10029889|FG000|Overall Study|Protocol Violation|1
6304244|NCT02569853|10029890|FG001|Overall Study|Protocol Violation|1
6304245|NCT02569853|10029889|FG000|Overall Study|Did not experience migraine attack|10
6304246|NCT02569853|10029890|FG001|Overall Study|Did not experience migraine attack|7
6304247|NCT02569853|10029889|FG000|Overall Study|Physician Decision|1
6304248|NCT02569853|10029890|FG001|Overall Study|Physician Decision|1
6304249|NCT02569996|10029905|FG000|Overall Study|Adverse Event|6
6304250|NCT02569996|10029905|FG000|Overall Study|Physician Decision|3
6304251|NCT02569996|10029905|FG000|Overall Study|Progression of the disease|18
6304252|NCT02569996|10029905|FG000|Overall Study|New anti-lymphoma treatment|1
6304253|NCT02569996|10029905|FG000|Overall Study|Non-compliance|9
6304254|NCT02569996|10029905|FG000|Overall Study|Withdrawal by Subject|5
6304255|NCT02569996|10029905|FG000|Overall Study|Lost to Follow-up|5
6304256|NCT02569996|10029905|FG000|Overall Study|Complete remission|7
6304257|NCT02569996|10029905|FG000|Overall Study|Unknown reason|1
6304258|NCT02570074|10029920|FG000|Period 2 (Second Dosing Regimen)|Lost to Follow-up|1
6304259|NCT02570074|10029921|FG001|Period 2 (Second Dosing Regimen)|Lost to Follow-up|0
6304260|NCT02570126|10029941|FG000|Overall Study|Lost to Follow-up|2
6304261|NCT02570126|10029942|FG001|Overall Study|Lost to Follow-up|0
6304262|NCT02570126|10029941|FG000|Overall Study|Unable To Arrange Visit 3|1
6304263|NCT02570126|10029942|FG001|Overall Study|Unable To Arrange Visit 3|0
6304264|NCT02570126|10029941|FG000|Overall Study|Violation Of Procedures GSK|0
6304265|NCT02570126|10029942|FG001|Overall Study|Violation Of Procedures GSK|1
6304266|NCT02570126|10029941|FG000|Overall Study|Protocol Violation|0
6304267|NCT02570126|10029942|FG001|Overall Study|Protocol Violation|1
6304268|NCT02570126|10029941|FG000|Overall Study|Withdrawal by Subject|3
6304269|NCT02570126|10029942|FG001|Overall Study|Withdrawal by Subject|7
6304270|NCT02570152|10029957|FG000|Overall Study|Protocol Violation|2
6304271|NCT02570152|10029957|FG000|Overall Study|Migrated/moved from study area|13
6304272|NCT02570165|10029968|FG000|Overall Study|Adverse Event|1
6304273|NCT02570165|10029969|FG001|Overall Study|Adverse Event|0
6304274|NCT02570165|10029970|FG002|Overall Study|Adverse Event|2
6304275|NCT02570165|10029971|FG003|Overall Study|Adverse Event|0
6304276|NCT02570165|10029972|FG004|Overall Study|Adverse Event|0
6304277|NCT02570165|10029973|FG005|Overall Study|Adverse Event|0
6304278|NCT02570165|10029974|FG006|Overall Study|Adverse Event|0
6304279|NCT02570165|10029968|FG000|Overall Study|Lack of Efficacy|0
6304280|NCT02570165|10029969|FG001|Overall Study|Lack of Efficacy|1
6304281|NCT02570165|10029970|FG002|Overall Study|Lack of Efficacy|0
6304282|NCT02570165|10029971|FG003|Overall Study|Lack of Efficacy|0
6304283|NCT02570165|10029972|FG004|Overall Study|Lack of Efficacy|4
6304284|NCT02570165|10029973|FG005|Overall Study|Lack of Efficacy|0
6304285|NCT02570165|10029974|FG006|Overall Study|Lack of Efficacy|0
6304286|NCT02570165|10029968|FG000|Overall Study|Par. Reached Stopping Criteria|1
6304287|NCT02570165|10029969|FG001|Overall Study|Par. Reached Stopping Criteria|1
6304288|NCT02570165|10029970|FG002|Overall Study|Par. Reached Stopping Criteria|0
6304289|NCT02570165|10029971|FG003|Overall Study|Par. Reached Stopping Criteria|2
6304290|NCT02570165|10029972|FG004|Overall Study|Par. Reached Stopping Criteria|1
6304291|NCT02570165|10029973|FG005|Overall Study|Par. Reached Stopping Criteria|1
6304292|NCT02570165|10029974|FG006|Overall Study|Par. Reached Stopping Criteria|0
6304293|NCT02570165|10029968|FG000|Overall Study|Lost to Follow-up|0
6304294|NCT02570165|10029969|FG001|Overall Study|Lost to Follow-up|0
6304295|NCT02570165|10029970|FG002|Overall Study|Lost to Follow-up|1
6304296|NCT02570165|10029971|FG003|Overall Study|Lost to Follow-up|1
6304297|NCT02570165|10029972|FG004|Overall Study|Lost to Follow-up|0
6304298|NCT02570165|10029973|FG005|Overall Study|Lost to Follow-up|0
6304299|NCT02570165|10029974|FG006|Overall Study|Lost to Follow-up|0
6304300|NCT02570165|10029968|FG000|Overall Study|Physician Decision|0
6304301|NCT02570165|10029969|FG001|Overall Study|Physician Decision|1
6304302|NCT02570165|10029970|FG002|Overall Study|Physician Decision|0
6304303|NCT02570165|10029971|FG003|Overall Study|Physician Decision|0
6304304|NCT02570165|10029972|FG004|Overall Study|Physician Decision|0
6304305|NCT02570165|10029973|FG005|Overall Study|Physician Decision|0
6304306|NCT02570165|10029974|FG006|Overall Study|Physician Decision|0
6304307|NCT02570165|10029968|FG000|Overall Study|Withdrawal by Subject|0
6304308|NCT02570165|10029969|FG001|Overall Study|Withdrawal by Subject|0
6304309|NCT02570165|10029970|FG002|Overall Study|Withdrawal by Subject|0
6304310|NCT02570165|10029971|FG003|Overall Study|Withdrawal by Subject|2
6304311|NCT02570165|10029972|FG004|Overall Study|Withdrawal by Subject|1
6304312|NCT02570165|10029973|FG005|Overall Study|Withdrawal by Subject|0
6304313|NCT02570165|10029974|FG006|Overall Study|Withdrawal by Subject|0
6304314|NCT02570165|10029968|FG000|Overall Study|Par. did not Meet Continuation Criteria|0
6304315|NCT02570165|10029969|FG001|Overall Study|Par. did not Meet Continuation Criteria|0
6304316|NCT02570165|10029970|FG002|Overall Study|Par. did not Meet Continuation Criteria|0
6304317|NCT02570165|10029971|FG003|Overall Study|Par. did not Meet Continuation Criteria|0
6304318|NCT02570165|10029972|FG004|Overall Study|Par. did not Meet Continuation Criteria|0
6304319|NCT02570165|10029973|FG005|Overall Study|Par. did not Meet Continuation Criteria|1
6304320|NCT02570165|10029974|FG006|Overall Study|Par. did not Meet Continuation Criteria|0
6304321|NCT02570165|10029968|FG000|Overall Study|Withdrawal Request by GSK|0
6304322|NCT02570165|10029969|FG001|Overall Study|Withdrawal Request by GSK|0
6304323|NCT02570165|10029970|FG002|Overall Study|Withdrawal Request by GSK|2
6304324|NCT02570165|10029971|FG003|Overall Study|Withdrawal Request by GSK|0
6304325|NCT02570165|10029972|FG004|Overall Study|Withdrawal Request by GSK|0
6304326|NCT02570165|10029973|FG005|Overall Study|Withdrawal Request by GSK|0
6304327|NCT02570165|10029974|FG006|Overall Study|Withdrawal Request by GSK|0
6304328|NCT02570711|10030013|FG000|Overall Study|Death|1
6304329|NCT02570711|10030014|FG001|Overall Study|Death|0
6304330|NCT02570711|10030013|FG000|Overall Study|Early Termination of Study by Sponsor|0
6304331|NCT02570711|10030014|FG001|Overall Study|Early Termination of Study by Sponsor|2
6304332|NCT02570750|10030022|FG000|Overall Study|Inclusion/exclusion criteria deviation|1
6304333|NCT02570750|10030023|FG001|Overall Study|Inclusion/exclusion criteria deviation|0
6304334|NCT02570750|10030022|FG000|Overall Study|Protocol deviation|4
6304335|NCT02570750|10030023|FG001|Overall Study|Protocol deviation|2
6304336|NCT02570750|10030022|FG000|Overall Study|Withdrawal by Subject|5
6304337|NCT02570750|10030023|FG001|Overall Study|Withdrawal by Subject|0
6304338|NCT02570750|10030022|FG000|Overall Study|Lost to Follow-up|2
6304339|NCT02570750|10030023|FG001|Overall Study|Lost to Follow-up|2
6304340|NCT02570750|10030022|FG000|Overall Study|Adverse Event|2
6304341|NCT02570750|10030023|FG001|Overall Study|Adverse Event|1
6304342|NCT02571049|10030029|FG000|Screening|Did not meet entry criteria|2
6304343|NCT02571049|10030030|FG001|Screening|Did not meet entry criteria|2
6304344|NCT02571049|10030029|FG000|Randomization|No migraine attack|0
6304345|NCT02571049|10030030|FG001|Randomization|No migraine attack|1
6304346|NCT02571049|10030029|FG000|Randomization|Adverse Event|0
6304347|NCT02571049|10030030|FG001|Randomization|Adverse Event|1
6304348|NCT02571075|10030038|FG000|Overall Study|Lost to Follow-up|20
6304349|NCT02571075|10030039|FG001|Overall Study|Lost to Follow-up|24
6304350|NCT02571244|10030069|FG000|Overall Study|Lost to Follow-up|0
6304351|NCT02571244|10030070|FG001|Overall Study|Lost to Follow-up|1
6304352|NCT02571244|10030069|FG000|Overall Study|Unable to reach out post discharge|3
6304353|NCT02571244|10030070|FG001|Overall Study|Unable to reach out post discharge|0
6304354|NCT02571452|10030090|FG000|Overall Study Treatment|Protocol Violation|0
6304355|NCT02571452|10030091|FG001|Overall Study Treatment|Protocol Violation|1
6304356|NCT02571452|10030090|FG000|Overall Study 6-Month Follow-up|Lost to Follow-up|4
6304357|NCT02571452|10030091|FG001|Overall Study 6-Month Follow-up|Lost to Follow-up|0
6304358|NCT02571452|10030090|FG000|Overall Study 6-Month Follow-up|Protocol Violation|1
6304359|NCT02571452|10030091|FG001|Overall Study 6-Month Follow-up|Protocol Violation|0
6304360|NCT02571777|10030107|FG000|Overall Study|Subject/guardian decision|34
6304361|NCT02571777|10030108|FG001|Overall Study|Subject/guardian decision|26
6304362|NCT02571777|10030109|FG002|Overall Study|Subject/guardian decision|26
6304363|NCT02571777|10030110|FG003|Overall Study|Subject/guardian decision|25
6304364|NCT02571777|10030111|FG004|Overall Study|Subject/guardian decision|27
6304365|NCT02571777|10030107|FG000|Overall Study|Protocol Deviation|2
6304366|NCT02571777|10030108|FG001|Overall Study|Protocol Deviation|3
6304367|NCT02571777|10030109|FG002|Overall Study|Protocol Deviation|4
6304368|NCT02571777|10030110|FG003|Overall Study|Protocol Deviation|8
6304369|NCT02571777|10030111|FG004|Overall Study|Protocol Deviation|4
6304370|NCT02571777|10030107|FG000|Overall Study|Death|1
6304371|NCT02571777|10030108|FG001|Overall Study|Death|1
6304372|NCT02571777|10030109|FG002|Overall Study|Death|4
6304373|NCT02571777|10030110|FG003|Overall Study|Death|0
6304374|NCT02571777|10030111|FG004|Overall Study|Death|0
6304375|NCT02571777|10030107|FG000|Overall Study|Lost to Follow-up|1
6304376|NCT02571777|10030108|FG001|Overall Study|Lost to Follow-up|1
6304377|NCT02571777|10030109|FG002|Overall Study|Lost to Follow-up|2
6304378|NCT02571777|10030110|FG003|Overall Study|Lost to Follow-up|0
6304379|NCT02571777|10030111|FG004|Overall Study|Lost to Follow-up|1
6304380|NCT02571777|10030107|FG000|Overall Study|Physician Decision|1
6304381|NCT02571777|10030108|FG001|Overall Study|Physician Decision|7
6304382|NCT02571777|10030109|FG002|Overall Study|Physician Decision|5
6304383|NCT02571777|10030110|FG003|Overall Study|Physician Decision|2
6304384|NCT02571777|10030111|FG004|Overall Study|Physician Decision|4
6304385|NCT02571777|10030107|FG000|Overall Study|Pregnancy|0
6304386|NCT02571777|10030108|FG001|Overall Study|Pregnancy|0
6304387|NCT02571777|10030109|FG002|Overall Study|Pregnancy|0
6304388|NCT02571777|10030110|FG003|Overall Study|Pregnancy|2
6304389|NCT02571777|10030111|FG004|Overall Study|Pregnancy|0
6304390|NCT02571972|10030123|FG000|Overall Study|Protocol Violation|2
6304391|NCT02571972|10030123|FG000|Overall Study|Withdrawal by Subject|2
6304392|NCT02572076|10030127|FG000|Overall Study|Protocol Violation|1
6304393|NCT02572167|10030134|FG000|Overall Study|In follow up|6
6304394|NCT02572167|10030135|FG001|Overall Study|In follow up|48
6304395|NCT02572167|10030136|FG002|Overall Study|In follow up|27
6304396|NCT02572167|10030134|FG000|Overall Study|Withdrawal by Subject|0
6304397|NCT02572167|10030135|FG001|Overall Study|Withdrawal by Subject|3
6304398|NCT02572167|10030136|FG002|Overall Study|Withdrawal by Subject|1
6304399|NCT02572167|10030134|FG000|Overall Study|Lost to Follow-up|0
6304400|NCT02572167|10030135|FG001|Overall Study|Lost to Follow-up|2
6304401|NCT02572167|10030136|FG002|Overall Study|Lost to Follow-up|1
6304402|NCT02572167|10030134|FG000|Overall Study|Death|0
6304403|NCT02572167|10030135|FG001|Overall Study|Death|3
6304404|NCT02572167|10030136|FG002|Overall Study|Death|1
6304405|NCT02572167|10030134|FG000|Overall Study|Did not meet inclusion criteria|0
6304406|NCT02572167|10030135|FG001|Overall Study|Did not meet inclusion criteria|0
6304407|NCT02572167|10030136|FG002|Overall Study|Did not meet inclusion criteria|1
6304408|NCT02572388|10030148|FG000|Overall Study|Withdrawal by Subject|1
6304409|NCT02572388|10030149|FG001|Overall Study|Withdrawal by Subject|1
6304410|NCT02572388|10030150|FG002|Overall Study|Withdrawal by Subject|2
6304411|NCT02572388|10030151|FG003|Overall Study|Withdrawal by Subject|2
6304412|NCT02572401|10030165|FG000|Overall Study|Lost to Follow-up|5
6304413|NCT02572401|10030166|FG001|Overall Study|Lost to Follow-up|8
6304414|NCT02572401|10030167|FG002|Overall Study|Lost to Follow-up|9
6304415|NCT02572401|10030168|FG003|Overall Study|Lost to Follow-up|9
6304416|NCT02572401|10030165|FG000|Overall Study|Death|0
6304417|NCT02572401|10030166|FG001|Overall Study|Death|0
6304418|NCT02572401|10030167|FG002|Overall Study|Death|0
6304419|NCT02572401|10030168|FG003|Overall Study|Death|1
6304420|NCT02572570|10030187|FG000|Overall Study|Study Terminated|27
6304421|NCT02572817|10030217|FG000|Overall Study|Death|6
6304422|NCT02572817|10030218|FG001|Overall Study|Death|3
6304423|NCT02572817|10030217|FG000|Overall Study|Lost to Follow-up|3
6304424|NCT02572817|10030218|FG001|Overall Study|Lost to Follow-up|3
6304425|NCT02573012|10030226|FG000|Overall Study|Adverse Event|5
6304426|NCT02573012|10030227|FG001|Overall Study|Adverse Event|5
6304427|NCT02573012|10030226|FG000|Overall Study|Lack of Efficacy|5
6304428|NCT02573012|10030227|FG001|Overall Study|Lack of Efficacy|4
6304429|NCT02573012|10030226|FG000|Overall Study|Non-compliance|1
6304430|NCT02573012|10030227|FG001|Overall Study|Non-compliance|2
6304431|NCT02573012|10030226|FG000|Overall Study|Withdrawal by Subject|2
6304432|NCT02573012|10030227|FG001|Overall Study|Withdrawal by Subject|2
6304433|NCT02573012|10030226|FG000|Overall Study|Study Ended per Protocol|1
6304434|NCT02573012|10030227|FG001|Overall Study|Study Ended per Protocol|0
6304435|NCT02573012|10030226|FG000|Overall Study|Physician Decision|1
6137026|NCT01005316|9767122|FG001|Overall Study|Sponsor Decision|3
6304436|NCT02573012|10030227|FG001|Overall Study|Physician Decision|2
6304437|NCT02573155|10030235|FG000|Washout Between Treatment Period 1 and 2|Physician Decision|0
6304438|NCT02573155|10030236|FG001|Washout Between Treatment Period 1 and 2|Physician Decision|1
6304439|NCT02573155|10030235|FG000|Washout Between Treatment Period 1 and 2|Withdrawal by Subject|0
6304440|NCT02573155|10030236|FG001|Washout Between Treatment Period 1 and 2|Withdrawal by Subject|1
6304441|NCT02573155|10030235|FG000|Washout Between Treatment Period 1 and 2|Adverse Event|0
6304442|NCT02573155|10030236|FG001|Washout Between Treatment Period 1 and 2|Adverse Event|3
6304443|NCT02573155|10030235|FG000|Washout Between Treatment Period 2 and 3|Sponsor's decision|1
6304444|NCT02573155|10030236|FG001|Washout Between Treatment Period 2 and 3|Sponsor's decision|0
6304445|NCT02573155|10030235|FG000|Washout Between Treatment Period 2 and 3|Adverse Event|0
6304446|NCT02573155|10030236|FG001|Washout Between Treatment Period 2 and 3|Adverse Event|2
6304447|NCT02573155|10030235|FG000|Washout Between Treatment Period 3 and 4|Stability/variability criteria not met|0
6304448|NCT02573155|10030236|FG001|Washout Between Treatment Period 3 and 4|Stability/variability criteria not met|1
6304449|NCT02573155|10030235|FG000|Washout Between Treatment Period 3 and 4|Adverse Event|0
6304450|NCT02573155|10030236|FG001|Washout Between Treatment Period 3 and 4|Adverse Event|1
6304451|NCT02573155|10030235|FG000|Washout Between Treatment Period 4 and 5|Adverse Event|0
6304452|NCT02573155|10030236|FG001|Washout Between Treatment Period 4 and 5|Adverse Event|1
6304453|NCT02573246|10030276|FG000|Overall Study|Lost to Follow-up|2
6304454|NCT02573246|10030277|FG001|Overall Study|Lost to Follow-up|0
6304455|NCT02573246|10030278|FG002|Overall Study|Lost to Follow-up|0
6304456|NCT02573246|10030279|FG003|Overall Study|Lost to Follow-up|0
6304457|NCT02573246|10030280|FG004|Overall Study|Lost to Follow-up|1
6304458|NCT02573246|10030276|FG000|Overall Study|Withdrawal by Subject|0
6304459|NCT02573246|10030277|FG001|Overall Study|Withdrawal by Subject|0
6304460|NCT02573246|10030278|FG002|Overall Study|Withdrawal by Subject|0
6304461|NCT02573246|10030279|FG003|Overall Study|Withdrawal by Subject|0
6304462|NCT02573246|10030280|FG004|Overall Study|Withdrawal by Subject|1
6304463|NCT02573246|10030276|FG000|Overall Study|Physician Decision|1
6304464|NCT02573246|10030277|FG001|Overall Study|Physician Decision|1
6304465|NCT02573246|10030278|FG002|Overall Study|Physician Decision|3
6304466|NCT02573246|10030279|FG003|Overall Study|Physician Decision|2
6304467|NCT02573246|10030280|FG004|Overall Study|Physician Decision|2
6304468|NCT02573311|10030299|FG000|Disposition for Part 1|Withdrawal by Subject|7
6304469|NCT02573311|10030300|FG001|Disposition for Part 1|Withdrawal by Subject|3
6304470|NCT02573311|10030299|FG000|Disposition for Part 2|Physician Decision|25
6304471|NCT02573311|10030300|FG001|Disposition for Part 2|Physician Decision|7
6304472|NCT02573311|10030299|FG000|Disposition for Part 2|Adverse Event|36
6304473|NCT02573311|10030300|FG001|Disposition for Part 2|Adverse Event|5
6304474|NCT02573311|10030299|FG000|Disposition for Part 2|Lost to Follow-up|76
6304475|NCT02573311|10030300|FG001|Disposition for Part 2|Lost to Follow-up|7
6304476|NCT02573311|10030299|FG000|Disposition for Part 2|Withdrawal by Subject|60
6304477|NCT02573311|10030300|FG001|Disposition for Part 2|Withdrawal by Subject|3
6304478|NCT02573311|10030299|FG000|Disposition for Part 2|Investigator decision|0
6304479|NCT02573311|10030300|FG001|Disposition for Part 2|Investigator decision|1
6304480|NCT02573311|10030299|FG000|Disposition for Part 2|Other than specified above|13
6304481|NCT02573311|10030300|FG001|Disposition for Part 2|Other than specified above|3
6304482|NCT02573350|10030308|FG000|Overall Study|Lost to Follow-up|2
6304483|NCT02573350|10030309|FG001|Overall Study|Lost to Follow-up|1
6304484|NCT02573350|10030308|FG000|Overall Study|Adverse Event|3
6304485|NCT02573350|10030309|FG001|Overall Study|Adverse Event|4
6304486|NCT02573350|10030308|FG000|Overall Study|Subject met Withdrawal Criteria|1
6304487|NCT02573350|10030309|FG001|Overall Study|Subject met Withdrawal Criteria|1
6304488|NCT02573350|10030308|FG000|Overall Study|Subject was Withdrawn from Participation by the Investigator|3
6304489|NCT02573350|10030309|FG001|Overall Study|Subject was Withdrawn from Participation by the Investigator|1
6304490|NCT02573350|10030308|FG000|Overall Study|Subject withdrew consent to participate|6
6304491|NCT02573350|10030309|FG001|Overall Study|Subject withdrew consent to participate|1
6304492|NCT02573350|10030308|FG000|Overall Study|Protocol Deviation|1
6304493|NCT02573350|10030309|FG001|Overall Study|Protocol Deviation|1
6304494|NCT02573467|10030331|FG000|Double-blind Treatment Epoch|Lack of Efficacy|0
6304495|NCT02573467|10030332|FG001|Double-blind Treatment Epoch|Lack of Efficacy|0
6304496|NCT02573467|10030333|FG002|Double-blind Treatment Epoch|Lack of Efficacy|1
6304497|NCT02573467|10030334|FG003|Double-blind Treatment Epoch|Lack of Efficacy|0
6304498|NCT02573467|10030331|FG000|Double-blind Treatment Epoch|Adverse Event|1
6304499|NCT02573467|10030332|FG001|Double-blind Treatment Epoch|Adverse Event|0
6304500|NCT02573467|10030333|FG002|Double-blind Treatment Epoch|Adverse Event|1
6304501|NCT02573467|10030334|FG003|Double-blind Treatment Epoch|Adverse Event|0
6304502|NCT02573467|10030331|FG000|Double-blind Treatment Epoch|Withdrawal by Subject|2
6304503|NCT02573467|10030332|FG001|Double-blind Treatment Epoch|Withdrawal by Subject|1
6304504|NCT02573467|10030333|FG002|Double-blind Treatment Epoch|Withdrawal by Subject|1
6304505|NCT02573467|10030334|FG003|Double-blind Treatment Epoch|Withdrawal by Subject|0
6304506|NCT02573467|10030331|FG000|Double-blind Treatment Epoch|Study Terminated by sponsor|50
6304507|NCT02573467|10030332|FG001|Double-blind Treatment Epoch|Study Terminated by sponsor|51
6304508|NCT02573467|10030333|FG002|Double-blind Treatment Epoch|Study Terminated by sponsor|48
6304509|NCT02573467|10030334|FG003|Double-blind Treatment Epoch|Study Terminated by sponsor|55
6304510|NCT02573467|10030331|FG000|Post-treatment Follow up Epoch|Death|1
6304511|NCT02573467|10030332|FG001|Post-treatment Follow up Epoch|Death|1
6304512|NCT02573467|10030333|FG002|Post-treatment Follow up Epoch|Death|0
6304513|NCT02573467|10030334|FG003|Post-treatment Follow up Epoch|Death|1
6304514|NCT02573467|10030331|FG000|Post-treatment Follow up Epoch|Withdrawal by Subject|5
6304515|NCT02573467|10030332|FG001|Post-treatment Follow up Epoch|Withdrawal by Subject|4
6304516|NCT02573467|10030333|FG002|Post-treatment Follow up Epoch|Withdrawal by Subject|9
6304517|NCT02573467|10030334|FG003|Post-treatment Follow up Epoch|Withdrawal by Subject|2
6304518|NCT02573467|10030331|FG000|Post-treatment Follow up Epoch|Technical problems|0
6304519|NCT02573467|10030332|FG001|Post-treatment Follow up Epoch|Technical problems|0
6304520|NCT02573467|10030333|FG002|Post-treatment Follow up Epoch|Technical problems|1
6304521|NCT02573467|10030334|FG003|Post-treatment Follow up Epoch|Technical problems|0
6304522|NCT02573493|10030349|FG000|Overall Study|Determined to not be eligible after enrollment|0
6304523|NCT02573493|10030350|FG001|Overall Study|Determined to not be eligible after enrollment|0
6304524|NCT02573493|10030351|FG002|Overall Study|Determined to not be eligible after enrollment|0
6304525|NCT02573493|10030352|FG003|Overall Study|Determined to not be eligible after enrollment|1
6304526|NCT02573870|10030387|FG000|Overall Study|Adverse Event|0
6304527|NCT02573870|10030388|FG001|Overall Study|Adverse Event|2
6304528|NCT02573870|10030387|FG000|Overall Study|Lack of Efficacy|0
6304529|NCT02573870|10030388|FG001|Overall Study|Lack of Efficacy|1
6304530|NCT02573870|10030387|FG000|Overall Study|Other: Reached defined stopping criteria|0
6304531|NCT02573870|10030388|FG001|Overall Study|Other: Reached defined stopping criteria|1
6304532|NCT02573870|10030387|FG000|Overall Study|Lost to Follow-up|0
6304533|NCT02573870|10030388|FG001|Overall Study|Lost to Follow-up|1
6304534|NCT02573870|10030387|FG000|Overall Study|Other: Fail to Meet Visit|0
6304535|NCT02573870|10030388|FG001|Overall Study|Other: Fail to Meet Visit|2
6304536|NCT02573883|10030396|FG000|Six Month Follow Up|Lost to Follow-up|1
6304537|NCT02573883|10030397|FG001|Six Month Follow Up|Lost to Follow-up|0
6304538|NCT02573883|10030398|FG002|Six Month Follow Up|Lost to Follow-up|0
6304539|NCT02573883|10030399|FG003|Six Month Follow Up|Lost to Follow-up|0
6304540|NCT02573883|10030396|FG000|One Year Follow Up|Lost to Follow-up|2
6304541|NCT02573883|10030397|FG001|One Year Follow Up|Lost to Follow-up|1
6304542|NCT02573883|10030398|FG002|One Year Follow Up|Lost to Follow-up|0
6304543|NCT02573883|10030399|FG003|One Year Follow Up|Lost to Follow-up|0
6304544|NCT02573948|10030414|FG000|Longitudinal Cohort|Death|9
6304545|NCT02573948|10030414|FG000|Longitudinal Cohort|Lost to Follow-up|22
6304546|NCT02573948|10030414|FG000|Longitudinal Cohort|Incarcerated|25
6304547|NCT02574078|10030434|FG000|Pre-Treatment Period|Participant no longer meets study criteria|0
6304548|NCT02574078|10030435|FG001|Pre-Treatment Period|Participant no longer meets study criteria|0
6304549|NCT02574078|10030436|FG002|Pre-Treatment Period|Participant no longer meets study criteria|0
6304550|NCT02574078|10030437|FG003|Pre-Treatment Period|Participant no longer meets study criteria|0
6304551|NCT02574078|10030438|FG004|Pre-Treatment Period|Participant no longer meets study criteria|0
6304552|NCT02574078|10030439|FG005|Pre-Treatment Period|Participant no longer meets study criteria|1
6304553|NCT02574078|10030440|FG006|Pre-Treatment Period|Participant no longer meets study criteria|2
6304554|NCT02574078|10030441|FG007|Pre-Treatment Period|Participant no longer meets study criteria|0
6304555|NCT02574078|10030442|FG008|Pre-Treatment Period|Participant no longer meets study criteria|1
6304556|NCT02574078|10030443|FG009|Pre-Treatment Period|Participant no longer meets study criteria|0
6304557|NCT02574078|10030444|FG010|Pre-Treatment Period|Participant no longer meets study criteria|0
6304558|NCT02574078|10030445|FG011|Pre-Treatment Period|Participant no longer meets study criteria|0
6304559|NCT02574078|10030446|FG012|Pre-Treatment Period|Participant no longer meets study criteria|0
6304560|NCT02574078|10030434|FG000|Pre-Treatment Period|Participant withdrew consent|0
6304561|NCT02574078|10030435|FG001|Pre-Treatment Period|Participant withdrew consent|0
6304562|NCT02574078|10030436|FG002|Pre-Treatment Period|Participant withdrew consent|0
6304563|NCT02574078|10030437|FG003|Pre-Treatment Period|Participant withdrew consent|0
6304564|NCT02574078|10030438|FG004|Pre-Treatment Period|Participant withdrew consent|0
6304565|NCT02574078|10030439|FG005|Pre-Treatment Period|Participant withdrew consent|0
6304566|NCT02574078|10030440|FG006|Pre-Treatment Period|Participant withdrew consent|0
6304567|NCT02574078|10030441|FG007|Pre-Treatment Period|Participant withdrew consent|3
6304568|NCT02574078|10030442|FG008|Pre-Treatment Period|Participant withdrew consent|0
6304569|NCT02574078|10030443|FG009|Pre-Treatment Period|Participant withdrew consent|0
6304570|NCT02574078|10030444|FG010|Pre-Treatment Period|Participant withdrew consent|2
6304571|NCT02574078|10030445|FG011|Pre-Treatment Period|Participant withdrew consent|0
6304572|NCT02574078|10030446|FG012|Pre-Treatment Period|Participant withdrew consent|0
6304573|NCT02574078|10030434|FG000|Pre-Treatment Period|Other reasons|0
6304574|NCT02574078|10030435|FG001|Pre-Treatment Period|Other reasons|0
6304575|NCT02574078|10030436|FG002|Pre-Treatment Period|Other reasons|0
6304576|NCT02574078|10030437|FG003|Pre-Treatment Period|Other reasons|0
6304577|NCT02574078|10030438|FG004|Pre-Treatment Period|Other reasons|0
6304578|NCT02574078|10030439|FG005|Pre-Treatment Period|Other reasons|0
6304579|NCT02574078|10030440|FG006|Pre-Treatment Period|Other reasons|2
6304580|NCT02574078|10030441|FG007|Pre-Treatment Period|Other reasons|0
6304581|NCT02574078|10030442|FG008|Pre-Treatment Period|Other reasons|0
6304582|NCT02574078|10030443|FG009|Pre-Treatment Period|Other reasons|0
6304583|NCT02574078|10030444|FG010|Pre-Treatment Period|Other reasons|2
6304584|NCT02574078|10030445|FG011|Pre-Treatment Period|Other reasons|0
6304585|NCT02574078|10030446|FG012|Pre-Treatment Period|Other reasons|0
6304586|NCT02574078|10030434|FG000|Pre-Treatment Period|Poor/non-compliance|0
6304587|NCT02574078|10030435|FG001|Pre-Treatment Period|Poor/non-compliance|0
6304588|NCT02574078|10030436|FG002|Pre-Treatment Period|Poor/non-compliance|0
6304589|NCT02574078|10030437|FG003|Pre-Treatment Period|Poor/non-compliance|0
6304590|NCT02574078|10030438|FG004|Pre-Treatment Period|Poor/non-compliance|0
6304591|NCT02574078|10030439|FG005|Pre-Treatment Period|Poor/non-compliance|0
6304592|NCT02574078|10030440|FG006|Pre-Treatment Period|Poor/non-compliance|0
6304593|NCT02574078|10030441|FG007|Pre-Treatment Period|Poor/non-compliance|0
6304594|NCT02574078|10030442|FG008|Pre-Treatment Period|Poor/non-compliance|0
6304595|NCT02574078|10030443|FG009|Pre-Treatment Period|Poor/non-compliance|0
6304596|NCT02574078|10030444|FG010|Pre-Treatment Period|Poor/non-compliance|0
6304597|NCT02574078|10030445|FG011|Pre-Treatment Period|Poor/non-compliance|1
6304598|NCT02574078|10030446|FG012|Pre-Treatment Period|Poor/non-compliance|0
6304599|NCT02574078|10030434|FG000|Treatment Period|Disease progression|6
6304600|NCT02574078|10030435|FG001|Treatment Period|Disease progression|4
6304601|NCT02574078|10030436|FG002|Treatment Period|Disease progression|7
6304602|NCT02574078|10030437|FG003|Treatment Period|Disease progression|18
6304603|NCT02574078|10030438|FG004|Treatment Period|Disease progression|16
6304604|NCT02574078|10030439|FG005|Treatment Period|Disease progression|26
6304605|NCT02574078|10030440|FG006|Treatment Period|Disease progression|5
6304606|NCT02574078|10030441|FG007|Treatment Period|Disease progression|9
6304607|NCT02574078|10030442|FG008|Treatment Period|Disease progression|8
6304608|NCT02574078|10030443|FG009|Treatment Period|Disease progression|5
6304609|NCT02574078|10030444|FG010|Treatment Period|Disease progression|20
6304610|NCT02574078|10030445|FG011|Treatment Period|Disease progression|29
6304611|NCT02574078|10030446|FG012|Treatment Period|Disease progression|2
6304612|NCT02574078|10030434|FG000|Treatment Period|Study drug toxicity|1
6304613|NCT02574078|10030435|FG001|Treatment Period|Study drug toxicity|1
6304614|NCT02574078|10030436|FG002|Treatment Period|Study drug toxicity|0
6304615|NCT02574078|10030437|FG003|Treatment Period|Study drug toxicity|5
6304616|NCT02574078|10030438|FG004|Treatment Period|Study drug toxicity|3
6304617|NCT02574078|10030439|FG005|Treatment Period|Study drug toxicity|1
6304618|NCT02574078|10030440|FG006|Treatment Period|Study drug toxicity|2
6304619|NCT02574078|10030441|FG007|Treatment Period|Study drug toxicity|0
6304620|NCT02574078|10030442|FG008|Treatment Period|Study drug toxicity|2
6304621|NCT02574078|10030443|FG009|Treatment Period|Study drug toxicity|1
6304622|NCT02574078|10030444|FG010|Treatment Period|Study drug toxicity|16
6304623|NCT02574078|10030445|FG011|Treatment Period|Study drug toxicity|2
6304624|NCT02574078|10030446|FG012|Treatment Period|Study drug toxicity|4
6304625|NCT02574078|10030434|FG000|Treatment Period|Death|2
6304626|NCT02574078|10030435|FG001|Treatment Period|Death|0
6304627|NCT02574078|10030436|FG002|Treatment Period|Death|0
6304628|NCT02574078|10030437|FG003|Treatment Period|Death|0
6304629|NCT02574078|10030438|FG004|Treatment Period|Death|1
6304630|NCT02574078|10030439|FG005|Treatment Period|Death|1
6304631|NCT02574078|10030440|FG006|Treatment Period|Death|1
6304632|NCT02574078|10030441|FG007|Treatment Period|Death|1
6304633|NCT02574078|10030442|FG008|Treatment Period|Death|7
6304634|NCT02574078|10030443|FG009|Treatment Period|Death|1
6304635|NCT02574078|10030444|FG010|Treatment Period|Death|0
6304636|NCT02574078|10030445|FG011|Treatment Period|Death|2
6304637|NCT02574078|10030446|FG012|Treatment Period|Death|1
6304638|NCT02574078|10030434|FG000|Treatment Period|Adverse event unrelated to drug|0
6304639|NCT02574078|10030435|FG001|Treatment Period|Adverse event unrelated to drug|0
6304640|NCT02574078|10030436|FG002|Treatment Period|Adverse event unrelated to drug|1
6304641|NCT02574078|10030437|FG003|Treatment Period|Adverse event unrelated to drug|0
6304642|NCT02574078|10030438|FG004|Treatment Period|Adverse event unrelated to drug|2
6304643|NCT02574078|10030439|FG005|Treatment Period|Adverse event unrelated to drug|3
6304644|NCT02574078|10030440|FG006|Treatment Period|Adverse event unrelated to drug|0
6304645|NCT02574078|10030441|FG007|Treatment Period|Adverse event unrelated to drug|0
6304646|NCT02574078|10030442|FG008|Treatment Period|Adverse event unrelated to drug|1
6304647|NCT02574078|10030443|FG009|Treatment Period|Adverse event unrelated to drug|2
6304648|NCT02574078|10030444|FG010|Treatment Period|Adverse event unrelated to drug|4
6304649|NCT02574078|10030445|FG011|Treatment Period|Adverse event unrelated to drug|1
6304650|NCT02574078|10030446|FG012|Treatment Period|Adverse event unrelated to drug|0
6304651|NCT02574078|10030434|FG000|Treatment Period|Administrative reason by Sponsor|0
6304652|NCT02574078|10030435|FG001|Treatment Period|Administrative reason by Sponsor|1
6304653|NCT02574078|10030436|FG002|Treatment Period|Administrative reason by Sponsor|0
6304654|NCT02574078|10030437|FG003|Treatment Period|Administrative reason by Sponsor|0
6304655|NCT02574078|10030438|FG004|Treatment Period|Administrative reason by Sponsor|0
6304656|NCT02574078|10030439|FG005|Treatment Period|Administrative reason by Sponsor|0
6304657|NCT02574078|10030440|FG006|Treatment Period|Administrative reason by Sponsor|1
6304658|NCT02574078|10030441|FG007|Treatment Period|Administrative reason by Sponsor|0
6304659|NCT02574078|10030442|FG008|Treatment Period|Administrative reason by Sponsor|0
6304660|NCT02574078|10030443|FG009|Treatment Period|Administrative reason by Sponsor|0
6304661|NCT02574078|10030444|FG010|Treatment Period|Administrative reason by Sponsor|0
6304662|NCT02574078|10030445|FG011|Treatment Period|Administrative reason by Sponsor|0
6304663|NCT02574078|10030446|FG012|Treatment Period|Administrative reason by Sponsor|3
6304664|NCT02574078|10030434|FG000|Treatment Period|Other reasons|1
6304665|NCT02574078|10030435|FG001|Treatment Period|Other reasons|0
6304666|NCT02574078|10030436|FG002|Treatment Period|Other reasons|1
6304667|NCT02574078|10030437|FG003|Treatment Period|Other reasons|3
6304668|NCT02574078|10030438|FG004|Treatment Period|Other reasons|3
6304669|NCT02574078|10030439|FG005|Treatment Period|Other reasons|1
6304670|NCT02574078|10030440|FG006|Treatment Period|Other reasons|2
6304671|NCT02574078|10030441|FG007|Treatment Period|Other reasons|1
6304672|NCT02574078|10030442|FG008|Treatment Period|Other reasons|3
6304673|NCT02574078|10030443|FG009|Treatment Period|Other reasons|1
6304674|NCT02574078|10030444|FG010|Treatment Period|Other reasons|1
6304675|NCT02574078|10030445|FG011|Treatment Period|Other reasons|3
6304676|NCT02574078|10030446|FG012|Treatment Period|Other reasons|1
6304677|NCT02574078|10030434|FG000|Treatment Period|Participant request to stop drug|0
6304678|NCT02574078|10030435|FG001|Treatment Period|Participant request to stop drug|0
6304679|NCT02574078|10030436|FG002|Treatment Period|Participant request to stop drug|0
6304680|NCT02574078|10030437|FG003|Treatment Period|Participant request to stop drug|2
6304681|NCT02574078|10030438|FG004|Treatment Period|Participant request to stop drug|4
6304682|NCT02574078|10030439|FG005|Treatment Period|Participant request to stop drug|0
6304683|NCT02574078|10030440|FG006|Treatment Period|Participant request to stop drug|1
6304684|NCT02574078|10030441|FG007|Treatment Period|Participant request to stop drug|0
6304685|NCT02574078|10030442|FG008|Treatment Period|Participant request to stop drug|3
6304686|NCT02574078|10030443|FG009|Treatment Period|Participant request to stop drug|2
6304687|NCT02574078|10030444|FG010|Treatment Period|Participant request to stop drug|2
6304688|NCT02574078|10030445|FG011|Treatment Period|Participant request to stop drug|4
6304689|NCT02574078|10030446|FG012|Treatment Period|Participant request to stop drug|1
6304690|NCT02574078|10030434|FG000|Treatment Period|Participant withdrew consent|0
6304691|NCT02574078|10030435|FG001|Treatment Period|Participant withdrew consent|0
6304692|NCT02574078|10030436|FG002|Treatment Period|Participant withdrew consent|0
6304693|NCT02574078|10030437|FG003|Treatment Period|Participant withdrew consent|0
6304694|NCT02574078|10030438|FG004|Treatment Period|Participant withdrew consent|1
6304695|NCT02574078|10030439|FG005|Treatment Period|Participant withdrew consent|1
6304696|NCT02574078|10030440|FG006|Treatment Period|Participant withdrew consent|0
6304697|NCT02574078|10030441|FG007|Treatment Period|Participant withdrew consent|1
6304698|NCT02574078|10030442|FG008|Treatment Period|Participant withdrew consent|0
6304699|NCT02574078|10030443|FG009|Treatment Period|Participant withdrew consent|2
6304700|NCT02574078|10030444|FG010|Treatment Period|Participant withdrew consent|1
6304701|NCT02574078|10030445|FG011|Treatment Period|Participant withdrew consent|4
6304702|NCT02574078|10030446|FG012|Treatment Period|Participant withdrew consent|1
6304703|NCT02574078|10030434|FG000|Treatment Period|Participant no longer meets criteria|0
6304704|NCT02574078|10030435|FG001|Treatment Period|Participant no longer meets criteria|0
6304705|NCT02574078|10030436|FG002|Treatment Period|Participant no longer meets criteria|0
6304706|NCT02574078|10030437|FG003|Treatment Period|Participant no longer meets criteria|0
6304707|NCT02574078|10030438|FG004|Treatment Period|Participant no longer meets criteria|1
6304708|NCT02574078|10030439|FG005|Treatment Period|Participant no longer meets criteria|0
6063967|NCT00509223|9665397|FG001|Overall Study|Did not meet revised inclusion criteria|62
6063968|NCT00509236|9665405|FG000|Overall Study|Adverse Event|7
6063969|NCT00509236|9665406|FG001|Overall Study|Adverse Event|9
6063970|NCT00509236|9665405|FG000|Overall Study|Withdrawal by Subject|5
6063971|NCT00509236|9665406|FG001|Overall Study|Withdrawal by Subject|10
6063972|NCT00509236|9665405|FG000|Overall Study|Protocol Violation|3
6063973|NCT00509236|9665406|FG001|Overall Study|Protocol Violation|0
6063974|NCT00509236|9665405|FG000|Overall Study|Excluded Medication|1
6063975|NCT00509236|9665406|FG001|Overall Study|Excluded Medication|1
6063976|NCT00509236|9665405|FG000|Overall Study|Scheduled Kidney Transplant|1
6063977|NCT00509236|9665406|FG001|Overall Study|Scheduled Kidney Transplant|0
6063978|NCT00509262|9665418|FG000|Overall Study|Adverse Event|16
6063979|NCT00509262|9665419|FG001|Overall Study|Adverse Event|18
6063980|NCT00509262|9665418|FG000|Overall Study|Other|2
6063981|NCT00509262|9665419|FG001|Overall Study|Other|2
6063982|NCT00509262|9665418|FG000|Overall Study|Lack of Efficacy|1
6063983|NCT00509262|9665419|FG001|Overall Study|Lack of Efficacy|0
6063984|NCT00509262|9665418|FG000|Overall Study|Lost to Follow-up|1
6063985|NCT00509262|9665419|FG001|Overall Study|Lost to Follow-up|6
6063986|NCT00509262|9665418|FG000|Overall Study|Physician Decision|1
6063987|NCT00509262|9665419|FG001|Overall Study|Physician Decision|3
6063988|NCT00509262|9665418|FG000|Overall Study|Protocol Violation|2
6063989|NCT00509262|9665419|FG001|Overall Study|Protocol Violation|2
6063990|NCT00509262|9665418|FG000|Overall Study|Withdrawal by Subject|24
6063991|NCT00509262|9665419|FG001|Overall Study|Withdrawal by Subject|11
6063992|NCT00509366|9665439|FG000|Overall Study|Not Treated (Screen Failure)|1
6063993|NCT00509366|9665440|FG001|Overall Study|Not Treated (Screen Failure)|1
6063994|NCT00509366|9665441|FG002|Overall Study|Not Treated (Screen Failure)|1
6063995|NCT00509366|9665442|FG003|Overall Study|Not Treated (Screen Failure)|0
6063996|NCT00509366|9665443|FG004|Overall Study|Not Treated (Screen Failure)|0
6063997|NCT00509769|9665480|FG000|Overall Study|Progressive disease|77
6063998|NCT00509769|9665480|FG000|Overall Study|Adverse Event|4
6063999|NCT00509769|9665480|FG000|Overall Study|Patient's decision|1
6064000|NCT00509769|9665480|FG000|Overall Study|Physician Decision|8
6064001|NCT00509769|9665480|FG000|Overall Study|Use of prohibited therapies during study|1
6064002|NCT00509795|9665488|FG000|Overall Study|Adverse Event|4
6064003|NCT00509795|9665489|FG001|Overall Study|Adverse Event|3
6064004|NCT00509795|9665490|FG002|Overall Study|Adverse Event|5
6064005|NCT00509795|9665491|FG003|Overall Study|Adverse Event|4
6064006|NCT00509795|9665488|FG000|Overall Study|Death|3
6064007|NCT00509795|9665489|FG001|Overall Study|Death|1
6304709|NCT02574078|10030440|FG006|Treatment Period|Participant no longer meets criteria|0
6304710|NCT02574078|10030441|FG007|Treatment Period|Participant no longer meets criteria|0
6304711|NCT02574078|10030442|FG008|Treatment Period|Participant no longer meets criteria|0
6304712|NCT02574078|10030443|FG009|Treatment Period|Participant no longer meets criteria|1
6304713|NCT02574078|10030444|FG010|Treatment Period|Participant no longer meets criteria|1
6304714|NCT02574078|10030445|FG011|Treatment Period|Participant no longer meets criteria|1
6304715|NCT02574078|10030446|FG012|Treatment Period|Participant no longer meets criteria|0
6304716|NCT02574078|10030434|FG000|Treatment Period|Lost to Follow-up|0
6304717|NCT02574078|10030435|FG001|Treatment Period|Lost to Follow-up|0
6304718|NCT02574078|10030436|FG002|Treatment Period|Lost to Follow-up|0
6304719|NCT02574078|10030437|FG003|Treatment Period|Lost to Follow-up|0
6304720|NCT02574078|10030438|FG004|Treatment Period|Lost to Follow-up|0
6304721|NCT02574078|10030439|FG005|Treatment Period|Lost to Follow-up|0
6304722|NCT02574078|10030440|FG006|Treatment Period|Lost to Follow-up|0
6304723|NCT02574078|10030441|FG007|Treatment Period|Lost to Follow-up|0
6304724|NCT02574078|10030442|FG008|Treatment Period|Lost to Follow-up|0
6304725|NCT02574078|10030443|FG009|Treatment Period|Lost to Follow-up|1
6304726|NCT02574078|10030444|FG010|Treatment Period|Lost to Follow-up|0
6304727|NCT02574078|10030445|FG011|Treatment Period|Lost to Follow-up|1
6304728|NCT02574078|10030446|FG012|Treatment Period|Lost to Follow-up|0
6304729|NCT02574078|10030434|FG000|Treatment Period|Maximum clinical benefit|0
6304730|NCT02574078|10030435|FG001|Treatment Period|Maximum clinical benefit|0
6304731|NCT02574078|10030436|FG002|Treatment Period|Maximum clinical benefit|0
6304732|NCT02574078|10030437|FG003|Treatment Period|Maximum clinical benefit|0
6304733|NCT02574078|10030438|FG004|Treatment Period|Maximum clinical benefit|0
6304734|NCT02574078|10030439|FG005|Treatment Period|Maximum clinical benefit|0
6304735|NCT02574078|10030440|FG006|Treatment Period|Maximum clinical benefit|0
6304736|NCT02574078|10030441|FG007|Treatment Period|Maximum clinical benefit|0
6304737|NCT02574078|10030442|FG008|Treatment Period|Maximum clinical benefit|0
6304738|NCT02574078|10030443|FG009|Treatment Period|Maximum clinical benefit|1
6304739|NCT02574078|10030444|FG010|Treatment Period|Maximum clinical benefit|0
6304740|NCT02574078|10030445|FG011|Treatment Period|Maximum clinical benefit|0
6304741|NCT02574078|10030446|FG012|Treatment Period|Maximum clinical benefit|0
6304742|NCT02574247|10030480|FG000|Overall Study|Withdrawal by Subject|1
6304743|NCT02574247|10030481|FG001|Overall Study|Withdrawal by Subject|0
6304744|NCT02574247|10030482|FG002|Overall Study|Withdrawal by Subject|0
6304745|NCT02574247|10030480|FG000|Overall Study|Did not meet inclusion criteria|4
6304746|NCT02574247|10030481|FG001|Overall Study|Did not meet inclusion criteria|3
6304747|NCT02574247|10030482|FG002|Overall Study|Did not meet inclusion criteria|5
6304748|NCT02574260|10030492|FG000|Overall Study|Disease Progression|1
6304749|NCT02574312|10030498|FG000|3 Months Follow-up|Withdrawal by Subject|1
6304750|NCT02574312|10030499|FG001|3 Months Follow-up|Withdrawal by Subject|0
6304751|NCT02574520|10030509|FG000|Overall Study|Not dosed|2
6304752|NCT02574520|10030510|FG001|Overall Study|Not dosed|0
6304753|NCT02574520|10030511|FG002|Overall Study|Not dosed|5
6304754|NCT02574520|10030512|FG003|Overall Study|Not dosed|4
6304755|NCT02574520|10030509|FG000|Overall Study|Adverse Event|0
6304756|NCT02574520|10030510|FG001|Overall Study|Adverse Event|0
6304757|NCT02574520|10030511|FG002|Overall Study|Adverse Event|0
6304758|NCT02574520|10030512|FG003|Overall Study|Adverse Event|1
6304759|NCT02574520|10030509|FG000|Overall Study|Withdrawal by Subject|0
6304760|NCT02574520|10030510|FG001|Overall Study|Withdrawal by Subject|0
6304761|NCT02574520|10030511|FG002|Overall Study|Withdrawal by Subject|0
6304762|NCT02574520|10030512|FG003|Overall Study|Withdrawal by Subject|1
6304763|NCT02574520|10030509|FG000|Overall Study|Other|0
6304764|NCT02574520|10030510|FG001|Overall Study|Other|0
6304765|NCT02574520|10030511|FG002|Overall Study|Other|0
6304766|NCT02574520|10030512|FG003|Overall Study|Other|2
6304767|NCT02574637|10030536|FG000|Double-blind Period|Adverse Event|1
6304768|NCT02574637|10030537|FG001|Double-blind Period|Adverse Event|0
6304769|NCT02574637|10030538|FG002|Double-blind Period|Adverse Event|0
6304770|NCT02574637|10030539|FG003|Double-blind Period|Adverse Event|0
6304771|NCT02574637|10030540|FG004|Double-blind Period|Adverse Event|0
6304772|NCT02574637|10030541|FG005|Double-blind Period|Adverse Event|0
6304773|NCT02574637|10030542|FG006|Double-blind Period|Adverse Event|0
6304774|NCT02574637|10030543|FG007|Double-blind Period|Adverse Event|0
6304775|NCT02574637|10030544|FG008|Double-blind Period|Adverse Event|0
6304776|NCT02574637|10030545|FG009|Double-blind Period|Adverse Event|0
6304777|NCT02574637|10030536|FG000|Double-blind Period|Lack of Efficacy|0
6304778|NCT02574637|10030537|FG001|Double-blind Period|Lack of Efficacy|0
6304779|NCT02574637|10030538|FG002|Double-blind Period|Lack of Efficacy|2
6304780|NCT02574637|10030539|FG003|Double-blind Period|Lack of Efficacy|0
6304781|NCT02574637|10030540|FG004|Double-blind Period|Lack of Efficacy|0
6304782|NCT02574637|10030541|FG005|Double-blind Period|Lack of Efficacy|0
6304783|NCT02574637|10030542|FG006|Double-blind Period|Lack of Efficacy|0
6304784|NCT02574637|10030543|FG007|Double-blind Period|Lack of Efficacy|0
6304785|NCT02574637|10030544|FG008|Double-blind Period|Lack of Efficacy|0
6304786|NCT02574637|10030545|FG009|Double-blind Period|Lack of Efficacy|0
6304787|NCT02574637|10030536|FG000|Double-blind Period|Protocol Deviation|1
6304788|NCT02574637|10030537|FG001|Double-blind Period|Protocol Deviation|0
6304789|NCT02574637|10030538|FG002|Double-blind Period|Protocol Deviation|0
6304790|NCT02574637|10030539|FG003|Double-blind Period|Protocol Deviation|0
6304791|NCT02574637|10030540|FG004|Double-blind Period|Protocol Deviation|0
6304792|NCT02574637|10030541|FG005|Double-blind Period|Protocol Deviation|0
6304793|NCT02574637|10030542|FG006|Double-blind Period|Protocol Deviation|0
6304794|NCT02574637|10030543|FG007|Double-blind Period|Protocol Deviation|0
6304795|NCT02574637|10030544|FG008|Double-blind Period|Protocol Deviation|0
6304796|NCT02574637|10030545|FG009|Double-blind Period|Protocol Deviation|0
6304797|NCT02574637|10030536|FG000|Double-blind Period|Non-Compliance With Study Drug|0
6304798|NCT02574637|10030537|FG001|Double-blind Period|Non-Compliance With Study Drug|0
6304799|NCT02574637|10030538|FG002|Double-blind Period|Non-Compliance With Study Drug|0
6304800|NCT02574637|10030539|FG003|Double-blind Period|Non-Compliance With Study Drug|1
6304801|NCT02574637|10030540|FG004|Double-blind Period|Non-Compliance With Study Drug|0
6304802|NCT02574637|10030541|FG005|Double-blind Period|Non-Compliance With Study Drug|0
6064008|NCT00509795|9665490|FG002|Overall Study|Death|2
6064009|NCT00509795|9665491|FG003|Overall Study|Death|7
6064010|NCT00509795|9665488|FG000|Overall Study|Lack of Efficacy|0
6064011|NCT00509795|9665489|FG001|Overall Study|Lack of Efficacy|0
6064012|NCT00509795|9665490|FG002|Overall Study|Lack of Efficacy|2
6064013|NCT00509795|9665491|FG003|Overall Study|Lack of Efficacy|2
6064014|NCT00509795|9665488|FG000|Overall Study|Lost to Follow-up|1
6064015|NCT00509795|9665489|FG001|Overall Study|Lost to Follow-up|2
6064016|NCT00509795|9665490|FG002|Overall Study|Lost to Follow-up|4
6064017|NCT00509795|9665491|FG003|Overall Study|Lost to Follow-up|4
6064018|NCT00509795|9665488|FG000|Overall Study|OTHER|1
6064019|NCT00509795|9665489|FG001|Overall Study|OTHER|0
6064020|NCT00509795|9665490|FG002|Overall Study|OTHER|4
6064021|NCT00509795|9665491|FG003|Overall Study|OTHER|1
6064022|NCT00509795|9665488|FG000|Overall Study|Protocol Violation|3
6064023|NCT00509795|9665489|FG001|Overall Study|Protocol Violation|0
6064024|NCT00509795|9665490|FG002|Overall Study|Protocol Violation|3
6064025|NCT00509795|9665491|FG003|Overall Study|Protocol Violation|1
6064026|NCT00509795|9665488|FG000|Overall Study|Withdrawal by Subject|10
6064027|NCT00509795|9665489|FG001|Overall Study|Withdrawal by Subject|5
6064028|NCT00509795|9665490|FG002|Overall Study|Withdrawal by Subject|7
6064029|NCT00509795|9665491|FG003|Overall Study|Withdrawal by Subject|8
6064030|NCT00509821|9665504|FG000|Study Period 1 (Induction)|Death|0
6064031|NCT00509821|9665505|FG001|Study Period 1 (Induction)|Death|1
6064032|NCT00509821|9665504|FG000|Study Period 1 (Induction)|Adverse Event|0
6064033|NCT00509821|9665505|FG001|Study Period 1 (Induction)|Adverse Event|2
6064034|NCT00509821|9665504|FG000|Study Period 1 (Induction)|Progressive Disease|0
6064035|NCT00509821|9665505|FG001|Study Period 1 (Induction)|Progressive Disease|1
6064036|NCT00509899|9665533|FG000|Overall Study|Progressive disease|1
6137027|NCT01005316|9767123|FG002|Overall Study|Sponsor Decision|0
6137028|NCT01005316|9767124|FG003|Overall Study|Sponsor Decision|0
6137029|NCT01005316|9767121|FG000|Overall Study|Withdrawal by Subject|1
6137030|NCT01005316|9767122|FG001|Overall Study|Withdrawal by Subject|1
6137031|NCT01005316|9767123|FG002|Overall Study|Withdrawal by Subject|0
6137032|NCT01005316|9767124|FG003|Overall Study|Withdrawal by Subject|2
6137033|NCT01005316|9767121|FG000|Overall Study|Consented to Another Study|2
6137034|NCT01005316|9767122|FG001|Overall Study|Consented to Another Study|0
6137035|NCT01005316|9767123|FG002|Overall Study|Consented to Another Study|0
6137036|NCT01005316|9767124|FG003|Overall Study|Consented to Another Study|0
6137037|NCT01005316|9767121|FG000|Overall Study|Delisted|8
6137038|NCT01005316|9767122|FG001|Overall Study|Delisted|0
6137039|NCT01005316|9767123|FG002|Overall Study|Delisted|0
6137040|NCT01005316|9767124|FG003|Overall Study|Delisted|0
6137041|NCT01005316|9767121|FG000|Overall Study|Transferred Care|1
6137042|NCT01005316|9767122|FG001|Overall Study|Transferred Care|0
6137043|NCT01005316|9767123|FG002|Overall Study|Transferred Care|1
6137044|NCT01005316|9767124|FG003|Overall Study|Transferred Care|3
6137045|NCT01005316|9767121|FG000|Overall Study|Retransplanted|0
6137046|NCT01005316|9767122|FG001|Overall Study|Retransplanted|1
6137047|NCT01005316|9767123|FG002|Overall Study|Retransplanted|0
6137048|NCT01005316|9767124|FG003|Overall Study|Retransplanted|0
6137049|NCT01005329|9767135|FG000|Overall Study|Ineligible or received no protocol trt.|4
6137050|NCT01005602|9767180|FG000|Overall Study|Excluded due to unreliable clinical data|1
6137051|NCT01005602|9767181|FG001|Overall Study|Excluded due to unreliable clinical data|0
6137052|NCT01005680|9767196|FG000|Overall Study|Lost to Follow-up|4
6137053|NCT01005680|9767197|FG001|Overall Study|Lost to Follow-up|6
6137054|NCT01005680|9767196|FG000|Overall Study|Withdrawal by Subject|1
6137055|NCT01005680|9767197|FG001|Overall Study|Withdrawal by Subject|4
6137056|NCT01005680|9767196|FG000|Overall Study|Physician Decision|1
6137057|NCT01005680|9767197|FG001|Overall Study|Physician Decision|1
6137058|NCT01005719|9767213|FG000|Period 1|Adverse Event|0
6137059|NCT01005719|9767214|FG001|Period 1|Adverse Event|0
6137060|NCT01005719|9767215|FG002|Period 1|Adverse Event|0
6137061|NCT01005719|9767216|FG003|Period 1|Adverse Event|1
6137062|NCT01005719|9767217|FG004|Period 1|Adverse Event|0
6137063|NCT01005719|9767218|FG005|Period 1|Adverse Event|0
6137064|NCT01005719|9767213|FG000|Period 1|Delay in completing study procedures|0
6137065|NCT01005719|9767214|FG001|Period 1|Delay in completing study procedures|0
6137066|NCT01005719|9767215|FG002|Period 1|Delay in completing study procedures|0
6304803|NCT02574637|10030542|FG006|Double-blind Period|Non-Compliance With Study Drug|0
6064037|NCT00509899|9665534|FG001|Overall Study|Progressive disease|3
6064038|NCT00509899|9665535|FG002|Overall Study|Progressive disease|5
6304804|NCT02574637|10030543|FG007|Double-blind Period|Non-Compliance With Study Drug|0
6304805|NCT02574637|10030544|FG008|Double-blind Period|Non-Compliance With Study Drug|0
6304806|NCT02574637|10030545|FG009|Double-blind Period|Non-Compliance With Study Drug|0
6304807|NCT02574637|10030536|FG000|Double-blind Period|Study Terminated By Sponsor|1
6304808|NCT02574637|10030537|FG001|Double-blind Period|Study Terminated By Sponsor|1
5982445|NCT02607930|9571444|FG000|Double-Blinded Treatment Phase|Lost to Follow-up|25
5982446|NCT02607930|9571445|FG001|Double-Blinded Treatment Phase|Lost to Follow-up|19
5982447|NCT02607930|9571446|FG002|Double-Blinded Treatment Phase|Lost to Follow-up|0
5982448|NCT02607930|9571447|FG003|Double-Blinded Treatment Phase|Lost to Follow-up|0
5982449|NCT02607930|9571444|FG000|Double-Blinded Treatment Phase|Withdrew consent|14
5982450|NCT02607930|9571445|FG001|Double-Blinded Treatment Phase|Withdrew consent|18
5982451|NCT02607930|9571446|FG002|Double-Blinded Treatment Phase|Withdrew consent|0
5982452|NCT02607930|9571447|FG003|Double-Blinded Treatment Phase|Withdrew consent|0
5982453|NCT02607930|9571444|FG000|Double-Blinded Treatment Phase|Investigator's discretion|6
5982454|NCT02607930|9571445|FG001|Double-Blinded Treatment Phase|Investigator's discretion|3
5982455|NCT02607930|9571446|FG002|Double-Blinded Treatment Phase|Investigator's discretion|0
5982456|NCT02607930|9571447|FG003|Double-Blinded Treatment Phase|Investigator's discretion|0
5982457|NCT02607930|9571444|FG000|Double-Blinded Treatment Phase|Non-compliance with study drug|3
5982458|NCT02607930|9571445|FG001|Double-Blinded Treatment Phase|Non-compliance with study drug|5
5982459|NCT02607930|9571446|FG002|Double-Blinded Treatment Phase|Non-compliance with study drug|0
5982460|NCT02607930|9571447|FG003|Double-Blinded Treatment Phase|Non-compliance with study drug|0
5982461|NCT02607930|9571444|FG000|Double-Blinded Treatment Phase|Protocol Violation|2
5982462|NCT02607930|9571445|FG001|Double-Blinded Treatment Phase|Protocol Violation|3
5982463|NCT02607930|9571446|FG002|Double-Blinded Treatment Phase|Protocol Violation|0
5982464|NCT02607930|9571447|FG003|Double-Blinded Treatment Phase|Protocol Violation|0
5982465|NCT02607930|9571444|FG000|Double-Blinded Treatment Phase|Adverse Event|0
5982466|NCT02607930|9571445|FG001|Double-Blinded Treatment Phase|Adverse Event|4
5982467|NCT02607930|9571446|FG002|Double-Blinded Treatment Phase|Adverse Event|0
5982468|NCT02607930|9571447|FG003|Double-Blinded Treatment Phase|Adverse Event|0
5982469|NCT02607930|9571444|FG000|Double-Blinded Treatment Phase|Death|2
5982470|NCT02607930|9571445|FG001|Double-Blinded Treatment Phase|Death|1
5982471|NCT02607930|9571446|FG002|Double-Blinded Treatment Phase|Death|0
5982472|NCT02607930|9571447|FG003|Double-Blinded Treatment Phase|Death|0
5982473|NCT02607930|9571444|FG000|Double-Blinded Treatment Phase|Randomized but never treated|2
5982474|NCT02607930|9571445|FG001|Double-Blinded Treatment Phase|Randomized but never treated|0
5982475|NCT02607930|9571446|FG002|Double-Blinded Treatment Phase|Randomized but never treated|0
5982476|NCT02607930|9571447|FG003|Double-Blinded Treatment Phase|Randomized but never treated|0
5982477|NCT02607930|9571444|FG000|Open-Label B/F/TAF Extension Phase|Lost to Follow-up|0
5982478|NCT02607930|9571445|FG001|Open-Label B/F/TAF Extension Phase|Lost to Follow-up|0
5982479|NCT02607930|9571446|FG002|Open-Label B/F/TAF Extension Phase|Lost to Follow-up|15
5982480|NCT02607930|9571447|FG003|Open-Label B/F/TAF Extension Phase|Lost to Follow-up|10
5982481|NCT02607930|9571444|FG000|Open-Label B/F/TAF Extension Phase|Withdrew consent|0
5982482|NCT02607930|9571445|FG001|Open-Label B/F/TAF Extension Phase|Withdrew consent|0
5982483|NCT02607930|9571446|FG002|Open-Label B/F/TAF Extension Phase|Withdrew consent|10
5982484|NCT02607930|9571447|FG003|Open-Label B/F/TAF Extension Phase|Withdrew consent|13
5982485|NCT02607930|9571444|FG000|Open-Label B/F/TAF Extension Phase|Investigator's discretion|0
5982486|NCT02607930|9571445|FG001|Open-Label B/F/TAF Extension Phase|Investigator's discretion|0
5982487|NCT02607930|9571446|FG002|Open-Label B/F/TAF Extension Phase|Investigator's discretion|2
5982488|NCT02607930|9571447|FG003|Open-Label B/F/TAF Extension Phase|Investigator's discretion|5
5982489|NCT02607930|9571444|FG000|Open-Label B/F/TAF Extension Phase|Adverse Event|0
5982490|NCT02607930|9571445|FG001|Open-Label B/F/TAF Extension Phase|Adverse Event|0
5982491|NCT02607930|9571446|FG002|Open-Label B/F/TAF Extension Phase|Adverse Event|4
5982492|NCT02607930|9571447|FG003|Open-Label B/F/TAF Extension Phase|Adverse Event|2
5982493|NCT02607930|9571444|FG000|Open-Label B/F/TAF Extension Phase|Lack of Efficacy|0
5982494|NCT02607930|9571445|FG001|Open-Label B/F/TAF Extension Phase|Lack of Efficacy|0
5982495|NCT02607930|9571446|FG002|Open-Label B/F/TAF Extension Phase|Lack of Efficacy|1
5982496|NCT02607930|9571447|FG003|Open-Label B/F/TAF Extension Phase|Lack of Efficacy|1
5982497|NCT02607930|9571444|FG000|Open-Label B/F/TAF Extension Phase|Protocol Violation|0
5982498|NCT02607930|9571445|FG001|Open-Label B/F/TAF Extension Phase|Protocol Violation|0
5982499|NCT02607930|9571446|FG002|Open-Label B/F/TAF Extension Phase|Protocol Violation|1
5982500|NCT02607930|9571447|FG003|Open-Label B/F/TAF Extension Phase|Protocol Violation|1
5982501|NCT02607930|9571444|FG000|Open-Label B/F/TAF Extension Phase|Death|0
5982502|NCT02607930|9571445|FG001|Open-Label B/F/TAF Extension Phase|Death|0
5982503|NCT02607930|9571446|FG002|Open-Label B/F/TAF Extension Phase|Death|0
5982504|NCT02607930|9571447|FG003|Open-Label B/F/TAF Extension Phase|Death|1
5982505|NCT02607930|9571444|FG000|Open-Label B/F/TAF Extension Phase|Non-compliance with study drug|0
5982506|NCT02607930|9571445|FG001|Open-Label B/F/TAF Extension Phase|Non-compliance with study drug|0
5982507|NCT02607930|9571446|FG002|Open-Label B/F/TAF Extension Phase|Non-compliance with study drug|1
5982508|NCT02607930|9571447|FG003|Open-Label B/F/TAF Extension Phase|Non-compliance with study drug|0
5982509|NCT02580058|9571460|FG000|Overall Study|Lost to Follow-up|4
5982510|NCT02580058|9571461|FG001|Overall Study|Lost to Follow-up|5
6304809|NCT02574637|10030538|FG002|Double-blind Period|Study Terminated By Sponsor|5
6304810|NCT02574637|10030539|FG003|Double-blind Period|Study Terminated By Sponsor|2
6304811|NCT02574637|10030540|FG004|Double-blind Period|Study Terminated By Sponsor|2
6304812|NCT02574637|10030541|FG005|Double-blind Period|Study Terminated By Sponsor|0
6304813|NCT02574637|10030542|FG006|Double-blind Period|Study Terminated By Sponsor|0
6304814|NCT02574637|10030543|FG007|Double-blind Period|Study Terminated By Sponsor|0
6304815|NCT02574637|10030544|FG008|Double-blind Period|Study Terminated By Sponsor|0
6304816|NCT02574637|10030545|FG009|Double-blind Period|Study Terminated By Sponsor|0
6304817|NCT02574637|10030536|FG000|Double-blind Period|Reason Not Specified|0
6304818|NCT02574637|10030537|FG001|Double-blind Period|Reason Not Specified|0
6304819|NCT02574637|10030538|FG002|Double-blind Period|Reason Not Specified|0
6304820|NCT02574637|10030539|FG003|Double-blind Period|Reason Not Specified|1
6304821|NCT02574637|10030540|FG004|Double-blind Period|Reason Not Specified|0
6304822|NCT02574637|10030541|FG005|Double-blind Period|Reason Not Specified|0
6304823|NCT02574637|10030542|FG006|Double-blind Period|Reason Not Specified|0
6304824|NCT02574637|10030543|FG007|Double-blind Period|Reason Not Specified|0
6304825|NCT02574637|10030544|FG008|Double-blind Period|Reason Not Specified|0
6304826|NCT02574637|10030545|FG009|Double-blind Period|Reason Not Specified|0
6304827|NCT02574637|10030536|FG000|Open-label (OL) Period|Adverse Event|0
6304828|NCT02574637|10030537|FG001|Open-label (OL) Period|Adverse Event|0
6304829|NCT02574637|10030538|FG002|Open-label (OL) Period|Adverse Event|0
6304830|NCT02574637|10030539|FG003|Open-label (OL) Period|Adverse Event|0
6304831|NCT02574637|10030540|FG004|Open-label (OL) Period|Adverse Event|0
6304832|NCT02574637|10030541|FG005|Open-label (OL) Period|Adverse Event|0
6304833|NCT02574637|10030542|FG006|Open-label (OL) Period|Adverse Event|0
6304834|NCT02574637|10030543|FG007|Open-label (OL) Period|Adverse Event|0
6304835|NCT02574637|10030544|FG008|Open-label (OL) Period|Adverse Event|1
6304836|NCT02574637|10030545|FG009|Open-label (OL) Period|Adverse Event|0
6304837|NCT02574637|10030536|FG000|Open-label (OL) Period|Withdrawal by Subject|0
6304838|NCT02574637|10030537|FG001|Open-label (OL) Period|Withdrawal by Subject|0
6304839|NCT02574637|10030538|FG002|Open-label (OL) Period|Withdrawal by Subject|0
6304840|NCT02574637|10030539|FG003|Open-label (OL) Period|Withdrawal by Subject|0
6304841|NCT02574637|10030540|FG004|Open-label (OL) Period|Withdrawal by Subject|0
6304842|NCT02574637|10030541|FG005|Open-label (OL) Period|Withdrawal by Subject|1
6304843|NCT02574637|10030542|FG006|Open-label (OL) Period|Withdrawal by Subject|0
6304844|NCT02574637|10030543|FG007|Open-label (OL) Period|Withdrawal by Subject|0
6304845|NCT02574637|10030544|FG008|Open-label (OL) Period|Withdrawal by Subject|0
6304846|NCT02574637|10030545|FG009|Open-label (OL) Period|Withdrawal by Subject|1
6304847|NCT02574637|10030536|FG000|Open-label (OL) Period|Study Terminated By Sponsor|0
6304848|NCT02574637|10030537|FG001|Open-label (OL) Period|Study Terminated By Sponsor|0
6304849|NCT02574637|10030538|FG002|Open-label (OL) Period|Study Terminated By Sponsor|0
6304850|NCT02574637|10030539|FG003|Open-label (OL) Period|Study Terminated By Sponsor|0
6304851|NCT02574637|10030540|FG004|Open-label (OL) Period|Study Terminated By Sponsor|0
6304852|NCT02574637|10030541|FG005|Open-label (OL) Period|Study Terminated By Sponsor|1
6304853|NCT02574637|10030542|FG006|Open-label (OL) Period|Study Terminated By Sponsor|2
6304854|NCT02574637|10030543|FG007|Open-label (OL) Period|Study Terminated By Sponsor|1
6304855|NCT02574637|10030544|FG008|Open-label (OL) Period|Study Terminated By Sponsor|1
6304856|NCT02574637|10030545|FG009|Open-label (OL) Period|Study Terminated By Sponsor|0
6304857|NCT02574845|10030576|FG000|Overall Study|Consent withdrawn further participation|0
6304858|NCT02574845|10030577|FG001|Overall Study|Consent withdrawn further participation|0
6304859|NCT02574845|10030578|FG002|Overall Study|Consent withdrawn further participation|0
6304860|NCT02574845|10030579|FG003|Overall Study|Consent withdrawn further participation|0
6304861|NCT02574845|10030580|FG004|Overall Study|Consent withdrawn further participation|1
6304862|NCT02574845|10030581|FG005|Overall Study|Consent withdrawn further participation|0
6304863|NCT02574845|10030576|FG000|Overall Study|Adverse Event|0
6304864|NCT02574845|10030577|FG001|Overall Study|Adverse Event|1
6304865|NCT02574845|10030578|FG002|Overall Study|Adverse Event|0
6304866|NCT02574845|10030579|FG003|Overall Study|Adverse Event|0
6304867|NCT02574845|10030580|FG004|Overall Study|Adverse Event|0
6304868|NCT02574845|10030581|FG005|Overall Study|Adverse Event|1
6304869|NCT02575079|10030601|FG000|Overall Study|Death|3
6304870|NCT02575079|10030602|FG001|Overall Study|Death|0
6304871|NCT02575079|10030601|FG000|Overall Study|Withdrawal by Subject|3
6304872|NCT02575079|10030602|FG001|Overall Study|Withdrawal by Subject|0
6304873|NCT02575807|10030616|FG000|Overall Study|Death|8
6304874|NCT02575807|10030617|FG001|Overall Study|Death|3
6304875|NCT02575807|10030618|FG002|Overall Study|Death|7
6304876|NCT02575807|10030619|FG003|Overall Study|Death|0
6304877|NCT02575807|10030620|FG004|Overall Study|Death|1
6304878|NCT02575807|10030616|FG000|Overall Study|Study terminated by Sponsor|0
6304879|NCT02575807|10030617|FG001|Overall Study|Study terminated by Sponsor|1
6304880|NCT02575807|10030618|FG002|Overall Study|Study terminated by Sponsor|7
6304881|NCT02575807|10030619|FG003|Overall Study|Study terminated by Sponsor|0
6304882|NCT02575807|10030620|FG004|Overall Study|Study terminated by Sponsor|1
6304883|NCT02575807|10030616|FG000|Overall Study|Terminated due to FDA clinical hold|1
6304884|NCT02575807|10030617|FG001|Overall Study|Terminated due to FDA clinical hold|0
6304885|NCT02575807|10030618|FG002|Overall Study|Terminated due to FDA clinical hold|0
6304886|NCT02575807|10030619|FG003|Overall Study|Terminated due to FDA clinical hold|0
6304887|NCT02575807|10030620|FG004|Overall Study|Terminated due to FDA clinical hold|0
6304888|NCT02575807|10030616|FG000|Overall Study|Terminated due to physician decision|0
6304889|NCT02575807|10030617|FG001|Overall Study|Terminated due to physician decision|0
6304890|NCT02575807|10030618|FG002|Overall Study|Terminated due to physician decision|1
6304891|NCT02575807|10030619|FG003|Overall Study|Terminated due to physician decision|0
6304892|NCT02575807|10030620|FG004|Overall Study|Terminated due to physician decision|0
6304893|NCT02575807|10030616|FG000|Overall Study|Subject ineligible - medical implant|0
6304894|NCT02575807|10030617|FG001|Overall Study|Subject ineligible - medical implant|0
6304895|NCT02575807|10030618|FG002|Overall Study|Subject ineligible - medical implant|0
6304896|NCT02575807|10030619|FG003|Overall Study|Subject ineligible - medical implant|1
6304897|NCT02575807|10030620|FG004|Overall Study|Subject ineligible - medical implant|0
6304898|NCT02575807|10030616|FG000|Overall Study|Withdrawal by Subject|0
6304899|NCT02575807|10030617|FG001|Overall Study|Withdrawal by Subject|0
6304900|NCT02575807|10030618|FG002|Overall Study|Withdrawal by Subject|1
6304901|NCT02575807|10030619|FG003|Overall Study|Withdrawal by Subject|1
6304902|NCT02575807|10030620|FG004|Overall Study|Withdrawal by Subject|2
6304903|NCT02575833|10030636|FG000|Overall Study|Withdrawal by Subject|0
6304904|NCT02575833|10030637|FG001|Overall Study|Withdrawal by Subject|1
6304905|NCT02575833|10030636|FG000|Overall Study|Lost to Follow-up|1
6304906|NCT02575833|10030637|FG001|Overall Study|Lost to Follow-up|0
6304907|NCT02575911|10030643|FG000|Overall Study|Lost to Follow-up|1
6304908|NCT02575950|10030655|FG000|Overall Study|Withdrawal by Subject|0
6304909|NCT02575950|10030656|FG001|Overall Study|Withdrawal by Subject|0
6304910|NCT02575950|10030657|FG002|Overall Study|Withdrawal by Subject|0
6304911|NCT02575950|10030658|FG003|Overall Study|Withdrawal by Subject|2
6304912|NCT02575950|10030655|FG000|Overall Study|Lost to Follow-up|0
6304913|NCT02575950|10030656|FG001|Overall Study|Lost to Follow-up|1
6304914|NCT02575950|10030657|FG002|Overall Study|Lost to Follow-up|0
6304915|NCT02575950|10030658|FG003|Overall Study|Lost to Follow-up|3
6304916|NCT02576054|10030670|FG000|Overall Study|Withdrawal by Subject|1
6304917|NCT02576067|10030678|FG000|Overall Study|Death|0
6304918|NCT02576067|10030679|FG001|Overall Study|Death|1
6304919|NCT02576067|10030678|FG000|Overall Study|Lack of Efficacy|1
6304920|NCT02576067|10030679|FG001|Overall Study|Lack of Efficacy|0
6304921|NCT02576067|10030678|FG000|Overall Study|Lost to Follow-up|11
6304922|NCT02576067|10030679|FG001|Overall Study|Lost to Follow-up|0
6304923|NCT02576067|10030678|FG000|Overall Study|Withdrawal by Subject|11
6304924|NCT02576067|10030679|FG001|Overall Study|Withdrawal by Subject|2
6304925|NCT02576067|10030678|FG000|Overall Study|study closure of main CIRT trial)|0
6304926|NCT02576067|10030679|FG001|Overall Study|study closure of main CIRT trial)|8
6304927|NCT02576067|10030678|FG000|Overall Study|not randomized, failed run-in|7
6304928|NCT02576067|10030679|FG001|Overall Study|not randomized, failed run-in|0
6304929|NCT02576067|10030678|FG000|Overall Study|screen failure/ re-enrolled|0
6304930|NCT02576067|10030679|FG001|Overall Study|screen failure/ re-enrolled|25
6304931|NCT02576067|10030678|FG000|Overall Study|Physician Decision|4
6304932|NCT02576067|10030679|FG001|Overall Study|Physician Decision|0
6304933|NCT02576145|10030687|FG000|Overall Study|Adverse Event|1
6304934|NCT02576145|10030688|FG001|Overall Study|Adverse Event|0
6304935|NCT02576145|10030687|FG000|Overall Study|Withdrawal by Subject|1
6304936|NCT02576145|10030688|FG001|Overall Study|Withdrawal by Subject|0
6304937|NCT02576145|10030687|FG000|Overall Study|Acute rejection|1
6304938|NCT02576145|10030688|FG001|Overall Study|Acute rejection|0
6304939|NCT02576145|10030687|FG000|Overall Study|Tetanus Titers Decreased|0
6304940|NCT02576145|10030688|FG001|Overall Study|Tetanus Titers Decreased|1
6304941|NCT02576535|10030703|FG000|Overall Study|Withdrawal by Subject|2
6304942|NCT02576587|10030709|FG000|Baseline|Equipment failure|0
6304943|NCT02576587|10030710|FG001|Baseline|Equipment failure|1
6304944|NCT02576587|10030709|FG000|Follow up Period (Case Only)|Withdrawal by Subject|25
6304945|NCT02576587|10030710|FG001|Follow up Period (Case Only)|Withdrawal by Subject|0
6304946|NCT02576587|10030709|FG000|Follow up Period (Case Only)|Not selected for follow up (AHI<15)|92
6304947|NCT02576587|10030710|FG001|Follow up Period (Case Only)|Not selected for follow up (AHI<15)|0
6304948|NCT02576587|10030709|FG000|Follow up Period (Case Only)|Controls not eligible for followup|0
6304949|NCT02576587|10030710|FG001|Follow up Period (Case Only)|Controls not eligible for followup|155
6304950|NCT02576639|10030723|FG000|Overall Study|Withdrawal by Subject|1
6304951|NCT02576639|10030724|FG001|Overall Study|Withdrawal by Subject|2
6304952|NCT02576639|10030725|FG002|Overall Study|Withdrawal by Subject|1
6304953|NCT02576639|10030726|FG003|Overall Study|Withdrawal by Subject|0
6304954|NCT02576639|10030727|FG004|Overall Study|Withdrawal by Subject|1
6304955|NCT02576639|10030723|FG000|Overall Study|Adverse Event|1
6304956|NCT02576639|10030724|FG001|Overall Study|Adverse Event|0
6304957|NCT02576639|10030725|FG002|Overall Study|Adverse Event|1
6304958|NCT02576639|10030726|FG003|Overall Study|Adverse Event|1
6304959|NCT02576639|10030727|FG004|Overall Study|Adverse Event|2
6304960|NCT02576639|10030723|FG000|Overall Study|Physician Decision|0
6304961|NCT02576639|10030724|FG001|Overall Study|Physician Decision|0
6304962|NCT02576639|10030725|FG002|Overall Study|Physician Decision|0
6304963|NCT02576639|10030726|FG003|Overall Study|Physician Decision|0
6304964|NCT02576639|10030727|FG004|Overall Study|Physician Decision|1
6304965|NCT02576652|10030743|FG000|Overall Study|Withdrawal by Subject|2
6304966|NCT02576678|10030750|FG000|Overall Study|Adverse Event|0
6304967|NCT02576678|10030751|FG001|Overall Study|Adverse Event|0
6304968|NCT02576678|10030752|FG002|Overall Study|Adverse Event|2
6304969|NCT02576678|10030750|FG000|Overall Study|Withdrawal by Subject|3
6304970|NCT02576678|10030751|FG001|Overall Study|Withdrawal by Subject|1
6304971|NCT02576678|10030752|FG002|Overall Study|Withdrawal by Subject|2
6304972|NCT02576678|10030750|FG000|Overall Study|Lost to Follow-up|0
6304973|NCT02576678|10030751|FG001|Overall Study|Lost to Follow-up|0
6304974|NCT02576678|10030752|FG002|Overall Study|Lost to Follow-up|1
6304975|NCT02576678|10030750|FG000|Overall Study|Miscellaneous|2
6304976|NCT02576678|10030751|FG001|Overall Study|Miscellaneous|0
6304977|NCT02576678|10030752|FG002|Overall Study|Miscellaneous|0
6304978|NCT02576938|10030773|FG000|Overall Study|Adverse Event|5
6304979|NCT02576938|10030774|FG001|Overall Study|Adverse Event|3
6304980|NCT02576938|10030775|FG002|Overall Study|Adverse Event|6
6304981|NCT02576938|10030773|FG000|Overall Study|Protocol Violation|1
6304982|NCT02576938|10030774|FG001|Overall Study|Protocol Violation|1
6304983|NCT02576938|10030775|FG002|Overall Study|Protocol Violation|1
6304984|NCT02576938|10030773|FG000|Overall Study|Withdrawal by Subject|3
6304985|NCT02576938|10030774|FG001|Overall Study|Withdrawal by Subject|2
6304986|NCT02576938|10030775|FG002|Overall Study|Withdrawal by Subject|4
6304987|NCT02576938|10030773|FG000|Overall Study|Lack of Efficacy|9
6304988|NCT02576938|10030774|FG001|Overall Study|Lack of Efficacy|4
6304989|NCT02576938|10030775|FG002|Overall Study|Lack of Efficacy|0
6304990|NCT02576938|10030773|FG000|Overall Study|Lost to Follow-up|2
6304991|NCT02576938|10030774|FG001|Overall Study|Lost to Follow-up|0
6304992|NCT02576938|10030775|FG002|Overall Study|Lost to Follow-up|1
6304993|NCT02576938|10030773|FG000|Overall Study|Physician Decision|0
6304994|NCT02576938|10030774|FG001|Overall Study|Physician Decision|1
6304995|NCT02576938|10030775|FG002|Overall Study|Physician Decision|0
6304996|NCT02576938|10030773|FG000|Overall Study|Met Exclusion Criteria|0
6304997|NCT02576938|10030774|FG001|Overall Study|Met Exclusion Criteria|1
6304998|NCT02576938|10030775|FG002|Overall Study|Met Exclusion Criteria|0
6304999|NCT02576951|10030789|FG000|Overall Study|Lost to Follow-up|0
6305000|NCT02576951|10030790|FG001|Overall Study|Lost to Follow-up|0
6305001|NCT02576951|10030791|FG002|Overall Study|Lost to Follow-up|2
6305002|NCT02576951|10030792|FG003|Overall Study|Lost to Follow-up|2
6305003|NCT02576951|10030789|FG000|Overall Study|Withdrawal by Subject|1
6305004|NCT02576951|10030790|FG001|Overall Study|Withdrawal by Subject|0
6305005|NCT02576951|10030791|FG002|Overall Study|Withdrawal by Subject|0
6305006|NCT02576951|10030792|FG003|Overall Study|Withdrawal by Subject|2
6305007|NCT02576951|10030789|FG000|Overall Study|Protocol Violation|0
6305008|NCT02576951|10030790|FG001|Overall Study|Protocol Violation|0
6305009|NCT02576951|10030791|FG002|Overall Study|Protocol Violation|0
6305010|NCT02576951|10030792|FG003|Overall Study|Protocol Violation|1
6305011|NCT02576977|10030806|FG000|Overall Study|Adverse Event|13
6305012|NCT02576977|10030807|FG001|Overall Study|Adverse Event|2
6305013|NCT02576977|10030806|FG000|Overall Study|Death|73
6305014|NCT02576977|10030807|FG001|Overall Study|Death|60
6305015|NCT02576977|10030806|FG000|Overall Study|Screen failure|1
6305016|NCT02576977|10030807|FG001|Overall Study|Screen failure|0
6305017|NCT02576977|10030806|FG000|Overall Study|Study Terminated at Selected Sites|27
6305018|NCT02576977|10030807|FG001|Overall Study|Study Terminated at Selected Sites|50
6305019|NCT02576977|10030806|FG000|Overall Study|Withdrawal by Subject|11
6305020|NCT02576977|10030807|FG001|Overall Study|Withdrawal by Subject|11
6305021|NCT02576977|10030806|FG000|Overall Study|Final Disposition Unknown|0
6305022|NCT02576977|10030807|FG001|Overall Study|Final Disposition Unknown|1
6305023|NCT02576977|10030806|FG000|Overall Study|Lost to Follow-up|1
6305024|NCT02576977|10030807|FG001|Overall Study|Lost to Follow-up|0
6305025|NCT02576977|10030806|FG000|Overall Study|Progressive Disease|0
6305026|NCT02576977|10030807|FG001|Overall Study|Progressive Disease|1
6305027|NCT02576990|10030815|FG000|Overall Study|Death|29
6305028|NCT02576990|10030816|FG001|Overall Study|Death|18
6305029|NCT02576990|10030815|FG000|Overall Study|Physician Decision|1
6305030|NCT02576990|10030816|FG001|Overall Study|Physician Decision|0
6305031|NCT02576990|10030815|FG000|Overall Study|Screen failure|2
6305032|NCT02576990|10030816|FG001|Overall Study|Screen failure|0
6305033|NCT02576990|10030815|FG000|Overall Study|Sponsor's decision|24
6305034|NCT02576990|10030816|FG001|Overall Study|Sponsor's decision|4
6305035|NCT02576990|10030815|FG000|Overall Study|Withdrawal by Subject|0
6305036|NCT02576990|10030816|FG001|Overall Study|Withdrawal by Subject|2
6305037|NCT02577003|10030824|FG000|Overall Study|Adverse Event|2
6305038|NCT02577003|10030825|FG001|Overall Study|Adverse Event|4
6305039|NCT02577003|10030824|FG000|Overall Study|Withdrawal by Subject|0
6305040|NCT02577003|10030825|FG001|Overall Study|Withdrawal by Subject|1
6305041|NCT02577016|10030833|FG000|Overall Study|Adverse Event|2
6305042|NCT02577016|10030834|FG001|Overall Study|Adverse Event|1
6305043|NCT02577016|10030833|FG000|Overall Study|Physician Decision|0
6305044|NCT02577016|10030834|FG001|Overall Study|Physician Decision|1
6305045|NCT02577029|10030848|FG000|Overall Study|Adverse Event|1
6305046|NCT02577029|10030849|FG001|Overall Study|Adverse Event|0
6305047|NCT02577029|10030850|FG002|Overall Study|Adverse Event|2
6305048|NCT02577029|10030851|FG003|Overall Study|Adverse Event|0
6305049|NCT02577029|10030852|FG004|Overall Study|Adverse Event|1
6305050|NCT02577029|10030853|FG005|Overall Study|Adverse Event|0
6305051|NCT02577029|10030854|FG006|Overall Study|Adverse Event|0
6305052|NCT02577029|10030855|FG007|Overall Study|Adverse Event|0
6305053|NCT02577029|10030848|FG000|Overall Study|Withdrawal by Subject|0
6305054|NCT02577029|10030849|FG001|Overall Study|Withdrawal by Subject|0
6305055|NCT02577029|10030850|FG002|Overall Study|Withdrawal by Subject|0
6305056|NCT02577029|10030851|FG003|Overall Study|Withdrawal by Subject|0
6305057|NCT02577029|10030852|FG004|Overall Study|Withdrawal by Subject|0
6305058|NCT02577029|10030853|FG005|Overall Study|Withdrawal by Subject|1
6305059|NCT02577029|10030854|FG006|Overall Study|Withdrawal by Subject|0
6305060|NCT02577029|10030855|FG007|Overall Study|Withdrawal by Subject|0
6305061|NCT02577029|10030848|FG000|Overall Study|Sponsor Termination of the Study|9
6305062|NCT02577029|10030849|FG001|Overall Study|Sponsor Termination of the Study|2
6305063|NCT02577029|10030850|FG002|Overall Study|Sponsor Termination of the Study|5
6305064|NCT02577029|10030851|FG003|Overall Study|Sponsor Termination of the Study|12
6305065|NCT02577029|10030852|FG004|Overall Study|Sponsor Termination of the Study|10
6305066|NCT02577029|10030853|FG005|Overall Study|Sponsor Termination of the Study|12
6305067|NCT02577029|10030854|FG006|Overall Study|Sponsor Termination of the Study|12
6305068|NCT02577029|10030855|FG007|Overall Study|Sponsor Termination of the Study|12
6305069|NCT02577107|10030885|FG000|Overall Study|Protocol deviation|0
6305070|NCT02577107|10030886|FG001|Overall Study|Protocol deviation|1
6305071|NCT02577146|10030892|FG000|Overall Study|Lost to Follow-up|8
6305072|NCT02577146|10030892|FG000|Overall Study|Physician Decision|3
6305073|NCT02577146|10030892|FG000|Overall Study|Screen Failure|17
6305074|NCT02577315|10030898|FG000|Treatment Period 1 (4 Days)|Withdrawal by Subject|0
6305075|NCT02577315|10030899|FG001|Treatment Period 1 (4 Days)|Withdrawal by Subject|1
6305076|NCT02577718|10030951|FG000|Overall Study|Death|6
6305077|NCT02577718|10030951|FG000|Overall Study|Withdrawal by Subject|2
6305078|NCT02577887|10030966|FG000|Overall Study|Death|93
6305079|NCT02577887|10030966|FG000|Overall Study|Protocol Violation|125
6305080|NCT02577887|10030966|FG000|Overall Study|Withdrawal by Subject|80
6305081|NCT02578186|10031005|FG000|Period 1 (First of Crossover)|Did not meet Phase 2 eligibility|4
6305082|NCT02578186|10031006|FG001|Period 1 (First of Crossover)|Did not meet Phase 2 eligibility|4
6305083|NCT02578186|10031005|FG000|Period 1 (First of Crossover)|Withdrawal by Subject|1
6305084|NCT02578186|10031006|FG001|Period 1 (First of Crossover)|Withdrawal by Subject|1
6305085|NCT02578316|10031020|FG000|Extension Phase|Progression of disease|6
6305086|NCT02578706|10031031|FG000|Overall Study|Withdrawal by Subject|1
6305087|NCT02578706|10031032|FG001|Overall Study|Withdrawal by Subject|0
6305088|NCT02578706|10031033|FG002|Overall Study|Withdrawal by Subject|0
6305089|NCT02578706|10031031|FG000|Overall Study|Lost to Follow-up|0
6305090|NCT02578706|10031032|FG001|Overall Study|Lost to Follow-up|4
6305091|NCT02578706|10031033|FG002|Overall Study|Lost to Follow-up|0
6305092|NCT02578706|10031031|FG000|Overall Study|Physician Decision|0
6305093|NCT02578706|10031032|FG001|Overall Study|Physician Decision|1
6305094|NCT02578706|10031033|FG002|Overall Study|Physician Decision|0
6305095|NCT02578862|10031053|FG000|Overall Study|Withdrawal by Subject|0
6305096|NCT02578862|10031054|FG001|Overall Study|Withdrawal by Subject|1
6305097|NCT02578862|10031053|FG000|Overall Study|Unplanned unilateral procedure|0
6305098|NCT02578862|10031054|FG001|Overall Study|Unplanned unilateral procedure|1
6305099|NCT02578940|10031069|FG000|Overall Study|Screening failure|5
6305100|NCT02578940|10031069|FG000|Overall Study|Lost to Follow-up|1
6305101|NCT02578992|10031077|FG000|Overall Study|equipment not available or malfunction|3
6305102|NCT02578992|10031078|FG001|Overall Study|equipment not available or malfunction|3
6305103|NCT02579382|10031121|FG000|Main Study Phase|Lost to Follow-up|0
6305104|NCT02579382|10031122|FG001|Main Study Phase|Lost to Follow-up|0
6305105|NCT02579382|10031123|FG002|Main Study Phase|Lost to Follow-up|2
6305106|NCT02579382|10031124|FG003|Main Study Phase|Lost to Follow-up|0
6305107|NCT02579382|10031121|FG000|Main Study Phase|Withdrew Consent|0
6305108|NCT02579382|10031122|FG001|Main Study Phase|Withdrew Consent|0
6305109|NCT02579382|10031123|FG002|Main Study Phase|Withdrew Consent|0
6305110|NCT02579382|10031124|FG003|Main Study Phase|Withdrew Consent|2
6305111|NCT02579382|10031121|FG000|Main Study Phase|Lack of Efficacy|0
6305112|NCT02579382|10031122|FG001|Main Study Phase|Lack of Efficacy|0
6305113|NCT02579382|10031123|FG002|Main Study Phase|Lack of Efficacy|0
6305114|NCT02579382|10031124|FG003|Main Study Phase|Lack of Efficacy|1
6305115|NCT02579382|10031121|FG000|Optional Treatment Extension Phase(OTEP)|Withdrew Consent|0
6305116|NCT02579382|10031122|FG001|Optional Treatment Extension Phase(OTEP)|Withdrew Consent|3
6305117|NCT02579382|10031123|FG002|Optional Treatment Extension Phase(OTEP)|Withdrew Consent|1
6305118|NCT02579382|10031124|FG003|Optional Treatment Extension Phase(OTEP)|Withdrew Consent|4
6305119|NCT02579382|10031121|FG000|Optional Treatment Extension Phase(OTEP)|Investigator's discretion|1
6305120|NCT02579382|10031122|FG001|Optional Treatment Extension Phase(OTEP)|Investigator's discretion|0
6305121|NCT02579382|10031123|FG002|Optional Treatment Extension Phase(OTEP)|Investigator's discretion|2
6305122|NCT02579382|10031124|FG003|Optional Treatment Extension Phase(OTEP)|Investigator's discretion|0
6305123|NCT02579382|10031121|FG000|Optional Treatment Extension Phase(OTEP)|Lost to Follow-up|0
6305124|NCT02579382|10031122|FG001|Optional Treatment Extension Phase(OTEP)|Lost to Follow-up|1
6305125|NCT02579382|10031123|FG002|Optional Treatment Extension Phase(OTEP)|Lost to Follow-up|1
6305126|NCT02579382|10031124|FG003|Optional Treatment Extension Phase(OTEP)|Lost to Follow-up|1
6305127|NCT02579382|10031121|FG000|Optional Treatment Extension Phase(OTEP)|Adverse Event|0
6305128|NCT02579382|10031122|FG001|Optional Treatment Extension Phase(OTEP)|Adverse Event|1
6305129|NCT02579382|10031123|FG002|Optional Treatment Extension Phase(OTEP)|Adverse Event|0
6305130|NCT02579382|10031124|FG003|Optional Treatment Extension Phase(OTEP)|Adverse Event|0
6305131|NCT02579382|10031121|FG000|Optional Treatment Extension Phase(OTEP)|Pregnancy|0
6305132|NCT02579382|10031122|FG001|Optional Treatment Extension Phase(OTEP)|Pregnancy|1
6305133|NCT02579382|10031123|FG002|Optional Treatment Extension Phase(OTEP)|Pregnancy|0
6305134|NCT02579382|10031124|FG003|Optional Treatment Extension Phase(OTEP)|Pregnancy|0
6305135|NCT02579382|10031121|FG000|Optional Treatment Extension Phase(OTEP)|Non-compliance with Study Drug|0
6305136|NCT02579382|10031122|FG001|Optional Treatment Extension Phase(OTEP)|Non-compliance with Study Drug|1
6305137|NCT02579382|10031123|FG002|Optional Treatment Extension Phase(OTEP)|Non-compliance with Study Drug|0
6305138|NCT02579382|10031124|FG003|Optional Treatment Extension Phase(OTEP)|Non-compliance with Study Drug|0
6064039|NCT00509899|9665536|FG003|Overall Study|Progressive disease|1
6064040|NCT00509899|9665537|FG004|Overall Study|Progressive disease|0
6064041|NCT00509899|9665538|FG005|Overall Study|Progressive disease|1
6064042|NCT00509899|9665539|FG006|Overall Study|Progressive disease|0
6064043|NCT00509899|9665540|FG007|Overall Study|Progressive disease|0
6064044|NCT00509899|9665533|FG000|Overall Study|Unacceptable Toxicity|1
6064045|NCT00509899|9665534|FG001|Overall Study|Unacceptable Toxicity|0
6064046|NCT00509899|9665535|FG002|Overall Study|Unacceptable Toxicity|0
6064047|NCT00509899|9665536|FG003|Overall Study|Unacceptable Toxicity|2
6064048|NCT00509899|9665537|FG004|Overall Study|Unacceptable Toxicity|0
6064049|NCT00509899|9665538|FG005|Overall Study|Unacceptable Toxicity|0
6064050|NCT00509899|9665539|FG006|Overall Study|Unacceptable Toxicity|0
6064051|NCT00509899|9665540|FG007|Overall Study|Unacceptable Toxicity|0
6064052|NCT00509899|9665533|FG000|Overall Study|Withdrawal by Subject|6
6064053|NCT00509899|9665534|FG001|Overall Study|Withdrawal by Subject|2
6064054|NCT00509899|9665535|FG002|Overall Study|Withdrawal by Subject|3
6064055|NCT00509899|9665536|FG003|Overall Study|Withdrawal by Subject|0
6064056|NCT00509899|9665537|FG004|Overall Study|Withdrawal by Subject|3
6064057|NCT00509899|9665538|FG005|Overall Study|Withdrawal by Subject|2
6064058|NCT00509899|9665539|FG006|Overall Study|Withdrawal by Subject|0
6064059|NCT00509899|9665540|FG007|Overall Study|Withdrawal by Subject|0
6064060|NCT00509899|9665533|FG000|Overall Study|Physician Decision|4
6064061|NCT00509899|9665534|FG001|Overall Study|Physician Decision|2
6064062|NCT00509899|9665535|FG002|Overall Study|Physician Decision|7
6064063|NCT00509899|9665536|FG003|Overall Study|Physician Decision|0
6064064|NCT00509899|9665537|FG004|Overall Study|Physician Decision|1
6064065|NCT00509899|9665538|FG005|Overall Study|Physician Decision|4
6064066|NCT00509899|9665539|FG006|Overall Study|Physician Decision|0
6064067|NCT00509899|9665540|FG007|Overall Study|Physician Decision|0
6064068|NCT00509899|9665533|FG000|Overall Study|Intercurrent Illness|1
6064069|NCT00509899|9665534|FG001|Overall Study|Intercurrent Illness|0
6064070|NCT00509899|9665535|FG002|Overall Study|Intercurrent Illness|0
6064071|NCT00509899|9665536|FG003|Overall Study|Intercurrent Illness|1
6137067|NCT01005719|9767216|FG003|Period 1|Delay in completing study procedures|0
6137068|NCT01005719|9767217|FG004|Period 1|Delay in completing study procedures|0
6137069|NCT01005719|9767218|FG005|Period 1|Delay in completing study procedures|1
6137070|NCT01005719|9767213|FG000|Period 2|Adverse Event|0
6137071|NCT01005719|9767214|FG001|Period 2|Adverse Event|0
6137072|NCT01005719|9767215|FG002|Period 2|Adverse Event|0
6137073|NCT01005719|9767216|FG003|Period 2|Adverse Event|0
6137074|NCT01005719|9767217|FG004|Period 2|Adverse Event|1
6137075|NCT01005719|9767218|FG005|Period 2|Adverse Event|1
6137076|NCT01005732|9767227|FG000|Overall Study|Lost to Follow-up|10
6305139|NCT02579603|10031161|FG000|Overall Study|Not treated|1
6305140|NCT02579603|10031162|FG001|Overall Study|Not treated|0
6305141|NCT02579603|10031161|FG000|Overall Study|Adverse Event|2
6305142|NCT02579603|10031162|FG001|Overall Study|Adverse Event|2
6305143|NCT02579603|10031161|FG000|Overall Study|Other than stated|1
6305144|NCT02579603|10031162|FG001|Overall Study|Other than stated|0
6305145|NCT02579616|10031169|FG000|Overall Study|Participants did not receive treatment|3
6305146|NCT02579629|10031176|FG000|Overall Study|Withdrawal by Subject|0
6305147|NCT02579629|10031177|FG001|Overall Study|Withdrawal by Subject|1
6305148|NCT02579629|10031178|FG002|Overall Study|Withdrawal by Subject|0
6305149|NCT02579629|10031176|FG000|Overall Study|Screen Failure|2
6305150|NCT02579629|10031177|FG001|Overall Study|Screen Failure|0
6305151|NCT02579629|10031178|FG002|Overall Study|Screen Failure|2
6305152|NCT02579759|10031189|FG000|Overall Study|Protocol Violation|2
6305153|NCT02579759|10031190|FG001|Overall Study|Protocol Violation|0
6305154|NCT02579759|10031191|FG002|Overall Study|Protocol Violation|0
6305155|NCT02579759|10031189|FG000|Overall Study|Other (Sponsor stopped Dose 2)|0
6305156|NCT02579759|10031190|FG001|Overall Study|Other (Sponsor stopped Dose 2)|1
6305157|NCT02579759|10031191|FG002|Overall Study|Other (Sponsor stopped Dose 2)|0
6305158|NCT02579759|10031189|FG000|Overall Study|BfArM hold|13
6305159|NCT02579759|10031190|FG001|Overall Study|BfArM hold|12
6305160|NCT02579759|10031191|FG002|Overall Study|BfArM hold|12
6305161|NCT02579759|10031189|FG000|Overall Study|Sponsor stopped Dose 2|0
6305162|NCT02579759|10031190|FG001|Overall Study|Sponsor stopped Dose 2|41
6305163|NCT02579759|10031191|FG002|Overall Study|Sponsor stopped Dose 2|0
6305164|NCT02579759|10031189|FG000|Overall Study|Non compliance|0
6305165|NCT02579759|10031190|FG001|Overall Study|Non compliance|1
6305166|NCT02579759|10031191|FG002|Overall Study|Non compliance|0
6305167|NCT02579759|10031189|FG000|Overall Study|Pregnancy|0
6305168|NCT02579759|10031190|FG001|Overall Study|Pregnancy|1
6305169|NCT02579759|10031191|FG002|Overall Study|Pregnancy|0
6305170|NCT02579759|10031189|FG000|Overall Study|Inclusion/exclusion criteria|0
6305171|NCT02579759|10031190|FG001|Overall Study|Inclusion/exclusion criteria|0
6305172|NCT02579759|10031191|FG002|Overall Study|Inclusion/exclusion criteria|1
6305173|NCT02579759|10031189|FG000|Overall Study|Adverse Event|4
6305174|NCT02579759|10031190|FG001|Overall Study|Adverse Event|3
6305175|NCT02579759|10031191|FG002|Overall Study|Adverse Event|1
6305176|NCT02579759|10031189|FG000|Overall Study|Withdrawal by Subject|3
6305177|NCT02579759|10031190|FG001|Overall Study|Withdrawal by Subject|3
6305178|NCT02579759|10031191|FG002|Overall Study|Withdrawal by Subject|5
6305179|NCT02579759|10031189|FG000|Overall Study|Lost to Follow-up|2
6305180|NCT02579759|10031190|FG001|Overall Study|Lost to Follow-up|2
6305181|NCT02579759|10031191|FG002|Overall Study|Lost to Follow-up|2
6305182|NCT02579772|10031201|FG000|Overall Study|Withdrawal by Subject|0
6305183|NCT02579772|10031202|FG001|Overall Study|Withdrawal by Subject|1
6305184|NCT02579772|10031201|FG000|Overall Study|Usage of additional antioxidants|1
6305185|NCT02579772|10031202|FG001|Overall Study|Usage of additional antioxidants|0
6305186|NCT02579772|10031201|FG000|Overall Study|flu-like illness, orthopedic trauma|1
6305187|NCT02579772|10031202|FG001|Overall Study|flu-like illness, orthopedic trauma|1
6305188|NCT02579863|10031214|FG000|Overall Study|Final Disposition Unknown|2
6305189|NCT02579863|10031215|FG001|Overall Study|Final Disposition Unknown|1
6305190|NCT02579863|10031214|FG000|Overall Study|Adverse Event|18
6305191|NCT02579863|10031215|FG001|Overall Study|Adverse Event|11
6305192|NCT02579863|10031214|FG000|Overall Study|Death|31
6305193|NCT02579863|10031215|FG001|Overall Study|Death|29
6305194|NCT02579863|10031214|FG000|Overall Study|Lost to Follow-up|2
6305195|NCT02579863|10031215|FG001|Overall Study|Lost to Follow-up|1
6305196|NCT02579863|10031214|FG000|Overall Study|Physician Decision|1
6305197|NCT02579863|10031215|FG001|Overall Study|Physician Decision|2
6305198|NCT02579863|10031214|FG000|Overall Study|Screen Failure|0
6305199|NCT02579863|10031215|FG001|Overall Study|Screen Failure|2
6305200|NCT02579863|10031214|FG000|Overall Study|Study Terminated at Selected Sites|82
6305201|NCT02579863|10031215|FG001|Overall Study|Study Terminated at Selected Sites|88
6305202|NCT02579863|10031214|FG000|Overall Study|Withdrawal by Subject|20
6305203|NCT02579863|10031215|FG001|Overall Study|Withdrawal by Subject|20
6305204|NCT02579928|10031241|FG000|Overall Study|Withdrawal by Subject|1
6305205|NCT02579928|10031242|FG001|Overall Study|Withdrawal by Subject|0
6305206|NCT02580240|10031270|FG000|Overall Study|Physician Decision|2
6305207|NCT02580240|10031271|FG001|Overall Study|Physician Decision|0
6305208|NCT02580357|10031284|FG000|Overall Study|Lost to Follow-up|2
6305209|NCT02580357|10031285|FG001|Overall Study|Lost to Follow-up|0
6305210|NCT02580357|10031286|FG002|Overall Study|Lost to Follow-up|0
6305211|NCT02580357|10031284|FG000|Overall Study|Protocol Violation|1
6305212|NCT02580357|10031285|FG001|Overall Study|Protocol Violation|0
6305213|NCT02580357|10031286|FG002|Overall Study|Protocol Violation|0
6305214|NCT02580591|10031298|FG000|Overall Study|Adverse Event|0
6305215|NCT02580591|10031299|FG001|Overall Study|Adverse Event|1
6305216|NCT02580591|10031300|FG002|Overall Study|Adverse Event|2
6305217|NCT02580591|10031301|FG003|Overall Study|Adverse Event|5
6305218|NCT02580591|10031298|FG000|Overall Study|Protocol Violation|3
6305219|NCT02580591|10031299|FG001|Overall Study|Protocol Violation|2
6305220|NCT02580591|10031300|FG002|Overall Study|Protocol Violation|1
6305221|NCT02580591|10031301|FG003|Overall Study|Protocol Violation|1
6305222|NCT02580591|10031298|FG000|Overall Study|Lost to Follow-up|5
6305223|NCT02580591|10031299|FG001|Overall Study|Lost to Follow-up|3
6305224|NCT02580591|10031300|FG002|Overall Study|Lost to Follow-up|3
6305225|NCT02580591|10031301|FG003|Overall Study|Lost to Follow-up|1
6305226|NCT02580591|10031298|FG000|Overall Study|Withdrawal by Subject|6
6305227|NCT02580591|10031299|FG001|Overall Study|Withdrawal by Subject|1
6305228|NCT02580591|10031300|FG002|Overall Study|Withdrawal by Subject|2
6305229|NCT02580591|10031301|FG003|Overall Study|Withdrawal by Subject|3
6305230|NCT02580591|10031298|FG000|Overall Study|Not treated|1
6305231|NCT02580591|10031299|FG001|Overall Study|Not treated|1
6305232|NCT02580591|10031300|FG002|Overall Study|Not treated|0
6305233|NCT02580591|10031301|FG003|Overall Study|Not treated|0
6305234|NCT02580591|10031298|FG000|Overall Study|Other than specified|3
6305235|NCT02580591|10031299|FG001|Overall Study|Other than specified|2
6305236|NCT02580591|10031300|FG002|Overall Study|Other than specified|5
6305237|NCT02580591|10031301|FG003|Overall Study|Other than specified|2
6305238|NCT02580877|10031317|FG000|Overall Study|Withdrawal by Subject|1
6305239|NCT02580877|10031318|FG001|Overall Study|Withdrawal by Subject|3
6305240|NCT02580877|10031317|FG000|Overall Study|Adverse Event|0
6305241|NCT02580877|10031318|FG001|Overall Study|Adverse Event|1
6305242|NCT02581163|10031334|FG000|Overall Study|Failure to return|15
6305243|NCT02581163|10031334|FG000|Overall Study|Insufficient virological response|3
6305244|NCT02581163|10031334|FG000|Overall Study|Withdrew consent|1
6305245|NCT02581163|10031334|FG000|Overall Study|Death|1
6305246|NCT02581163|10031334|FG000|Overall Study|Other, not specified|9
6305247|NCT02581189|10031341|FG000|Overall Study|Failure to return|36
6305248|NCT02581189|10031341|FG000|Overall Study|Withdrew consent|5
6305249|NCT02581189|10031341|FG000|Overall Study|Death|3
6305250|NCT02581189|10031341|FG000|Overall Study|Insufficient virological response|2
6305251|NCT02581189|10031341|FG000|Overall Study|Other, not specified|7
6305252|NCT02581202|10031348|FG000|Overall Study|Lack of Efficacy|2
6305253|NCT02581202|10031348|FG000|Overall Study|Withdrawal by Subject|4
6305254|NCT02581202|10031348|FG000|Overall Study|Lost to Follow-up|5
6305255|NCT02581202|10031348|FG000|Overall Study|Pregnancy|3
6305256|NCT02581345|10031355|FG000|Part 1: up to Week 16|Adverse Event|3
6305257|NCT02581345|10031356|FG001|Part 1: up to Week 16|Adverse Event|8
6305258|NCT02581345|10031357|FG002|Part 1: up to Week 16|Adverse Event|0
6305259|NCT02581345|10031358|FG003|Part 1: up to Week 16|Adverse Event|0
6305260|NCT02581345|10031355|FG000|Part 1: up to Week 16|Physician Decision|2
6305261|NCT02581345|10031356|FG001|Part 1: up to Week 16|Physician Decision|4
6305262|NCT02581345|10031357|FG002|Part 1: up to Week 16|Physician Decision|0
6305263|NCT02581345|10031358|FG003|Part 1: up to Week 16|Physician Decision|0
6305264|NCT02581345|10031355|FG000|Part 1: up to Week 16|Withdrawal by Subject|4
6305265|NCT02581345|10031356|FG001|Part 1: up to Week 16|Withdrawal by Subject|7
6305266|NCT02581345|10031357|FG002|Part 1: up to Week 16|Withdrawal by Subject|0
6305267|NCT02581345|10031358|FG003|Part 1: up to Week 16|Withdrawal by Subject|0
6305268|NCT02581345|10031355|FG000|Part 1: up to Week 16|Lost to Follow-up|2
6305269|NCT02581345|10031356|FG001|Part 1: up to Week 16|Lost to Follow-up|0
6305270|NCT02581345|10031357|FG002|Part 1: up to Week 16|Lost to Follow-up|0
6305271|NCT02581345|10031358|FG003|Part 1: up to Week 16|Lost to Follow-up|0
6305272|NCT02581345|10031355|FG000|Part 1: up to Week 16|Unspecified Reason|3
6305273|NCT02581345|10031356|FG001|Part 1: up to Week 16|Unspecified Reason|3
6305274|NCT02581345|10031357|FG002|Part 1: up to Week 16|Unspecified Reason|0
6305275|NCT02581345|10031358|FG003|Part 1: up to Week 16|Unspecified Reason|0
6305276|NCT02581345|10031355|FG000|Part 1: up to Week 16|Did Not Receive Treatment|1
6305277|NCT02581345|10031356|FG001|Part 1: up to Week 16|Did Not Receive Treatment|1
6305278|NCT02581345|10031357|FG002|Part 1: up to Week 16|Did Not Receive Treatment|0
6305279|NCT02581345|10031358|FG003|Part 1: up to Week 16|Did Not Receive Treatment|0
6305280|NCT02581345|10031355|FG000|Part 2: Week 17 to Week 47|Adverse Event|5
6305281|NCT02581345|10031356|FG001|Part 2: Week 17 to Week 47|Adverse Event|0
6305282|NCT02581345|10031357|FG002|Part 2: Week 17 to Week 47|Adverse Event|2
6305283|NCT02581345|10031358|FG003|Part 2: Week 17 to Week 47|Adverse Event|2
6305284|NCT02581345|10031355|FG000|Part 2: Week 17 to Week 47|Physician Decision|3
6305285|NCT02581345|10031356|FG001|Part 2: Week 17 to Week 47|Physician Decision|0
6305286|NCT02581345|10031357|FG002|Part 2: Week 17 to Week 47|Physician Decision|2
6305287|NCT02581345|10031358|FG003|Part 2: Week 17 to Week 47|Physician Decision|1
6305288|NCT02581345|10031355|FG000|Part 2: Week 17 to Week 47|Withdrawal by Subject|9
6305289|NCT02581345|10031356|FG001|Part 2: Week 17 to Week 47|Withdrawal by Subject|0
6305290|NCT02581345|10031357|FG002|Part 2: Week 17 to Week 47|Withdrawal by Subject|7
6305291|NCT02581345|10031358|FG003|Part 2: Week 17 to Week 47|Withdrawal by Subject|5
6305292|NCT02581345|10031355|FG000|Part 2: Week 17 to Week 47|Failure to Achieve at Least a PASI 50|8
6305293|NCT02581345|10031356|FG001|Part 2: Week 17 to Week 47|Failure to Achieve at Least a PASI 50|0
6305294|NCT02581345|10031357|FG002|Part 2: Week 17 to Week 47|Failure to Achieve at Least a PASI 50|3
6305295|NCT02581345|10031358|FG003|Part 2: Week 17 to Week 47|Failure to Achieve at Least a PASI 50|2
6305296|NCT02581345|10031355|FG000|Part 2: Week 17 to Week 47|Lost to Follow-up|2
6305297|NCT02581345|10031356|FG001|Part 2: Week 17 to Week 47|Lost to Follow-up|0
6305298|NCT02581345|10031357|FG002|Part 2: Week 17 to Week 47|Lost to Follow-up|0
6305299|NCT02581345|10031358|FG003|Part 2: Week 17 to Week 47|Lost to Follow-up|1
6305300|NCT02581345|10031355|FG000|Part 2: Week 17 to Week 47|Unspecified Reason|2
6305301|NCT02581345|10031356|FG001|Part 2: Week 17 to Week 47|Unspecified Reason|0
6305302|NCT02581345|10031357|FG002|Part 2: Week 17 to Week 47|Unspecified Reason|1
6305303|NCT02581345|10031358|FG003|Part 2: Week 17 to Week 47|Unspecified Reason|1
6305304|NCT02581410|10031386|FG000|Vaccination Phase|Adverse Event|2
6305305|NCT02581410|10031387|FG001|Vaccination Phase|Adverse Event|1
6305306|NCT02581410|10031386|FG000|Vaccination Phase|Withdrawal by Subject|0
6305307|NCT02581410|10031387|FG001|Vaccination Phase|Withdrawal by Subject|1
6305308|NCT02581410|10031386|FG000|Vaccination Phase|Migrated/moved from study area|0
6305309|NCT02581410|10031387|FG001|Vaccination Phase|Migrated/moved from study area|1
6305310|NCT02581410|10031386|FG000|End of Study Phase|Adverse Event|4
6305311|NCT02581410|10031387|FG001|End of Study Phase|Adverse Event|3
6305312|NCT02581410|10031386|FG000|End of Study Phase|Withdrawal by Subject|1
6305313|NCT02581410|10031387|FG001|End of Study Phase|Withdrawal by Subject|2
6305314|NCT02581410|10031386|FG000|End of Study Phase|Migrated/moved from study area|0
6305315|NCT02581410|10031387|FG001|End of Study Phase|Migrated/moved from study area|3
6305316|NCT02581410|10031386|FG000|End of Study Phase|Lost to Follow-up|0
6305317|NCT02581410|10031387|FG001|End of Study Phase|Lost to Follow-up|2
6305318|NCT02581410|10031386|FG000|End of Study Phase|Other-transfer of subject not completed|0
6305319|NCT02581410|10031387|FG001|End of Study Phase|Other-transfer of subject not completed|1
6305320|NCT02581488|10031405|FG000|Overall Study|Adverse Event|6
6305321|NCT02581488|10031406|FG001|Overall Study|Adverse Event|7
6305322|NCT02581488|10031405|FG000|Overall Study|Lost to Follow-up|1
6305323|NCT02581488|10031406|FG001|Overall Study|Lost to Follow-up|0
6305324|NCT02581488|10031405|FG000|Overall Study|Withdrawal by Subject|1
6305325|NCT02581488|10031406|FG001|Overall Study|Withdrawal by Subject|0
6305326|NCT02581488|10031405|FG000|Overall Study|Non-Compliance|1
6305327|NCT02581488|10031406|FG001|Overall Study|Non-Compliance|0
6305328|NCT02581488|10031405|FG000|Overall Study|Protocol Violation|0
6305329|NCT02581488|10031406|FG001|Overall Study|Protocol Violation|4
6305330|NCT02581891|10031434|FG000|Overall Study|Adverse Event|4
6305331|NCT02581891|10031435|FG001|Overall Study|Adverse Event|6
6305332|NCT02581891|10031434|FG000|Overall Study|Death|3
6305333|NCT02581891|10031435|FG001|Overall Study|Death|4
6305334|NCT02581891|10031434|FG000|Overall Study|Lost to Follow-up|1
6305335|NCT02581891|10031435|FG001|Overall Study|Lost to Follow-up|2
6305336|NCT02581891|10031434|FG000|Overall Study|Physician Decision|0
6305337|NCT02581891|10031435|FG001|Overall Study|Physician Decision|1
6305338|NCT02581891|10031434|FG000|Overall Study|Withdrawal by Subject|4
6305339|NCT02581891|10031435|FG001|Overall Study|Withdrawal by Subject|5
6305340|NCT02581891|10031434|FG000|Overall Study|Other Reasons|3
6305341|NCT02581891|10031435|FG001|Overall Study|Other Reasons|1
6305342|NCT02581891|10031434|FG000|Overall Study|Discontinued during followup|1
6305343|NCT02581891|10031435|FG001|Overall Study|Discontinued during followup|0
6305344|NCT02581995|10031442|FG000|Overall Study|Unspecified other|3
6305345|NCT02581995|10031442|FG000|Overall Study|Adverse Event|6
6305346|NCT02581995|10031442|FG000|Overall Study|Lost to Follow-up|5
6305347|NCT02581995|10031442|FG000|Overall Study|Withdrawal by participant|12
6305348|NCT02581995|10031442|FG000|Overall Study|Physician Decision|1
6305349|NCT02581995|10031442|FG000|Overall Study|Death|4
6305350|NCT02582242|10031462|FG000|Overall Study|Adverse Event|4
6305351|NCT02582242|10031463|FG001|Overall Study|Adverse Event|3
6305352|NCT02582242|10031462|FG000|Overall Study|Protocol Violation|3
6305353|NCT02582242|10031463|FG001|Overall Study|Protocol Violation|1
6305354|NCT02582242|10031462|FG000|Overall Study|Lost to Follow-up|0
6305355|NCT02582242|10031463|FG001|Overall Study|Lost to Follow-up|1
6305356|NCT02582242|10031462|FG000|Overall Study|Withdrawal by Subject|11
6305357|NCT02582242|10031463|FG001|Overall Study|Withdrawal by Subject|11
6305358|NCT02582242|10031462|FG000|Overall Study|Unclassified|2
6305359|NCT02582242|10031463|FG001|Overall Study|Unclassified|1
6305360|NCT02582255|10031471|FG000|Overall Study|Protocol Violation|0
6305361|NCT02582255|10031472|FG001|Overall Study|Protocol Violation|3
6305362|NCT02582515|10031481|FG000|Overall Study|Withdrawal by Subject|0
6305363|NCT02582515|10031482|FG001|Overall Study|Withdrawal by Subject|1
6305364|NCT02582632|10031488|FG000|Overall Study|Other|1
6305365|NCT02582658|10031492|FG000|Overall Study|Failure to Return|10
6305366|NCT02582658|10031492|FG000|Overall Study|Insufficient Virological Response|2
6305367|NCT02582658|10031492|FG000|Overall Study|Withdrawn Consent|1
6305368|NCT02582658|10031492|FG000|Overall Study|Death|1
6305369|NCT02582658|10031492|FG000|Overall Study|Not further specified|11
6305370|NCT02582671|10031496|FG000|Overall Study|Failure to return|1
6305371|NCT02582671|10031496|FG000|Overall Study|Other, not specified|1
6305372|NCT02582684|10031501|FG000|Overall Study|Unable to contact subject/parent|4
6305373|NCT02582684|10031501|FG000|Overall Study|Subject not able to get to clinic|10
6305374|NCT02582684|10031501|FG000|Overall Study|Subject withdrew consent|1
6305375|NCT02582684|10031501|FG000|Overall Study|Found to be ineligible after enrollment|2
6305376|NCT02582814|10031507|FG000|Overall Study|Study-specific withdrawal criteria|1
6305377|NCT02582814|10031508|FG001|Overall Study|Study-specific withdrawal criteria|0
6305378|NCT02582814|10031507|FG000|Overall Study|Withdrawal by Subject|4
6305379|NCT02582814|10031508|FG001|Overall Study|Withdrawal by Subject|3
6305380|NCT02582814|10031507|FG000|Overall Study|Adverse Event|4
6305381|NCT02582814|10031508|FG001|Overall Study|Adverse Event|4
6305382|NCT02582866|10031529|FG000|Overall Study|Death|1
6305383|NCT02582866|10031529|FG000|Overall Study|Lack of Efficacy|2
6305384|NCT02582866|10031529|FG000|Overall Study|Lost to Follow-up|2
6305385|NCT02582866|10031529|FG000|Overall Study|Withdrawal by Subject|7
6064072|NCT00509899|9665537|FG004|Overall Study|Intercurrent Illness|0
6064073|NCT00509899|9665538|FG005|Overall Study|Intercurrent Illness|1
6305386|NCT02582866|10031529|FG000|Overall Study|Investigator decision|5
6305387|NCT02582866|10031529|FG000|Overall Study|Participant wants to get pregnant|1
6305388|NCT02582866|10031529|FG000|Overall Study|Pregnancy|2
6305389|NCT02582866|10031529|FG000|Overall Study|Sponsor decision|1
6305390|NCT02582866|10031529|FG000|Overall Study|Withdrawal due to personal reasons|1
6305391|NCT02582983|10031537|FG000|Overall Study|Death|3
6305392|NCT02582983|10031537|FG000|Overall Study|Withdrawal by Subject|2
6305393|NCT02582983|10031537|FG000|Overall Study|Adverse Event|1
6305394|NCT02583256|10031549|FG000|Overall Study|Withdrawal by Subject|0
6305395|NCT02583256|10031550|FG001|Overall Study|Withdrawal by Subject|1
6305396|NCT02583256|10031551|FG002|Overall Study|Withdrawal by Subject|1
6305397|NCT02583256|10031552|FG003|Overall Study|Withdrawal by Subject|0
6305398|NCT02583256|10031549|FG000|Overall Study|Lost to Follow-up|1
6305399|NCT02583256|10031550|FG001|Overall Study|Lost to Follow-up|1
6305400|NCT02583256|10031551|FG002|Overall Study|Lost to Follow-up|0
6305401|NCT02583256|10031552|FG003|Overall Study|Lost to Follow-up|1
6305402|NCT02583256|10031549|FG000|Overall Study|Administrative/Other|2
6305403|NCT02583256|10031550|FG001|Overall Study|Administrative/Other|0
6305404|NCT02583256|10031551|FG002|Overall Study|Administrative/Other|1
6305405|NCT02583256|10031552|FG003|Overall Study|Administrative/Other|2
6305406|NCT02583399|10031573|FG000|Overall Study|Able to be discharged|3
6305407|NCT02583399|10031573|FG000|Overall Study|Wanted to use a restricted medication|3
6305408|NCT02583425|10031577|FG000|Screening|Did not meet entry criteria|12
6305409|NCT02583425|10031577|FG000|Baseline|Did not meet continued criteria|5
6305410|NCT02583425|10031577|FG000|Treatment Period|Adverse Event|1
6305411|NCT02583477|10031584|FG000|Overall Study|Adverse Event|0
6305412|NCT02583477|10031585|FG001|Overall Study|Adverse Event|2
6305413|NCT02583477|10031584|FG000|Overall Study|Death|1
6305414|NCT02583477|10031585|FG001|Overall Study|Death|16
6305415|NCT02583477|10031584|FG000|Overall Study|Study terminated|2
6305416|NCT02583477|10031585|FG001|Overall Study|Study terminated|2
6305417|NCT02583711|10031595|FG000|Overall Study|Withdrawal by Subject|0
6305418|NCT02583711|10031596|FG001|Overall Study|Withdrawal by Subject|10
6305419|NCT02583711|10031597|FG002|Overall Study|Withdrawal by Subject|0
6305420|NCT02584257|10031611|FG000|Period 1|Withdrawal by Subject|0
6305421|NCT02584257|10031612|FG001|Period 1|Withdrawal by Subject|0
6305422|NCT02584257|10031613|FG002|Period 1|Withdrawal by Subject|0
6305423|NCT02584257|10031614|FG003|Period 1|Withdrawal by Subject|0
6305424|NCT02584257|10031615|FG004|Period 1|Withdrawal by Subject|0
6305425|NCT02584257|10031616|FG005|Period 1|Withdrawal by Subject|0
6305426|NCT02584257|10031617|FG006|Period 1|Withdrawal by Subject|1
6305427|NCT02584257|10031618|FG007|Period 1|Withdrawal by Subject|0
6305428|NCT02584257|10031619|FG008|Period 1|Withdrawal by Subject|0
6305429|NCT02584257|10031611|FG000|Period 2|Physician Decision|1
6305430|NCT02584257|10031612|FG001|Period 2|Physician Decision|0
6305431|NCT02584257|10031613|FG002|Period 2|Physician Decision|0
6305432|NCT02584257|10031614|FG003|Period 2|Physician Decision|0
6305433|NCT02584257|10031615|FG004|Period 2|Physician Decision|0
6305434|NCT02584257|10031616|FG005|Period 2|Physician Decision|0
6305435|NCT02584257|10031617|FG006|Period 2|Physician Decision|0
6305436|NCT02584257|10031618|FG007|Period 2|Physician Decision|0
6305437|NCT02584257|10031619|FG008|Period 2|Physician Decision|0
6305438|NCT02584257|10031611|FG000|Period 2|Adverse Event|0
6305439|NCT02584257|10031612|FG001|Period 2|Adverse Event|1
6305440|NCT02584257|10031613|FG002|Period 2|Adverse Event|0
6305441|NCT02584257|10031614|FG003|Period 2|Adverse Event|0
6305442|NCT02584257|10031615|FG004|Period 2|Adverse Event|0
6305443|NCT02584257|10031616|FG005|Period 2|Adverse Event|0
6305444|NCT02584257|10031617|FG006|Period 2|Adverse Event|0
6305445|NCT02584257|10031618|FG007|Period 2|Adverse Event|0
6305446|NCT02584257|10031619|FG008|Period 2|Adverse Event|0
6305447|NCT02584452|10031633|FG000|Overall Study|Physician Decision|1
6305448|NCT02584452|10031634|FG001|Overall Study|Physician Decision|1
6305449|NCT02584452|10031633|FG000|Overall Study|Lost to Follow-up|1
6305450|NCT02584452|10031634|FG001|Overall Study|Lost to Follow-up|1
6305451|NCT02584504|10031644|FG000|Double-blind Treatment|Participant withdrew consent|0
6305452|NCT02584504|10031645|FG001|Double-blind Treatment|Participant withdrew consent|0
6305453|NCT02584504|10031646|FG002|Double-blind Treatment|Participant withdrew consent|1
6305454|NCT02584504|10031644|FG000|Double-blind Treatment|Adverse Event|0
6305455|NCT02584504|10031645|FG001|Double-blind Treatment|Adverse Event|1
6305456|NCT02584504|10031646|FG002|Double-blind Treatment|Adverse Event|0
6305457|NCT02584504|10031644|FG000|Double-blind Treatment|Family Matter|0
6305458|NCT02584504|10031645|FG001|Double-blind Treatment|Family Matter|1
6305459|NCT02584504|10031646|FG002|Double-blind Treatment|Family Matter|0
6305460|NCT02584504|10031644|FG000|Open-label Treatment|Participant withdrew consent|0
6305461|NCT02584504|10031645|FG001|Open-label Treatment|Participant withdrew consent|0
6305462|NCT02584504|10031646|FG002|Open-label Treatment|Participant withdrew consent|4
6305463|NCT02584504|10031644|FG000|Open-label Treatment|Adverse Event|2
6305464|NCT02584504|10031645|FG001|Open-label Treatment|Adverse Event|2
6305465|NCT02584504|10031646|FG002|Open-label Treatment|Adverse Event|3
6305466|NCT02584504|10031644|FG000|Open-label Treatment|Physician Decision|0
6305467|NCT02584504|10031645|FG001|Open-label Treatment|Physician Decision|1
6305468|NCT02584504|10031646|FG002|Open-label Treatment|Physician Decision|0
6305469|NCT02584504|10031644|FG000|Open-label Treatment|Entered but not treated|0
6305470|NCT02584504|10031645|FG001|Open-label Treatment|Entered but not treated|1
6305471|NCT02584504|10031646|FG002|Open-label Treatment|Entered but not treated|1
6305472|NCT02584660|10031664|FG000|Overall Study|Adverse Event|4
6305473|NCT02584660|10031665|FG001|Overall Study|Adverse Event|0
6305474|NCT02584660|10031664|FG000|Overall Study|Lost to Follow-up|3
6305475|NCT02584660|10031665|FG001|Overall Study|Lost to Follow-up|4
6305476|NCT02584660|10031664|FG000|Overall Study|Protocol Violation|0
6305477|NCT02584660|10031665|FG001|Overall Study|Protocol Violation|1
6305478|NCT02584660|10031664|FG000|Overall Study|Withdrawal by Subject|0
6305479|NCT02584660|10031665|FG001|Overall Study|Withdrawal by Subject|2
6305480|NCT02584660|10031664|FG000|Overall Study|Other|0
6305481|NCT02584660|10031665|FG001|Overall Study|Other|1
6305482|NCT02584855|10031707|FG000|Open-Label Treatment Period|Lack of Efficacy|61
6305483|NCT02584855|10031708|FG001|Open-Label Treatment Period|Lack of Efficacy|0
6305484|NCT02584855|10031709|FG002|Open-Label Treatment Period|Lack of Efficacy|0
6305485|NCT02584855|10031710|FG003|Open-Label Treatment Period|Lack of Efficacy|0
6305486|NCT02584855|10031711|FG004|Open-Label Treatment Period|Lack of Efficacy|0
6305487|NCT02584855|10031712|FG005|Open-Label Treatment Period|Lack of Efficacy|0
6305488|NCT02584855|10031707|FG000|Open-Label Treatment Period|Withdrawal by Subject|21
6305489|NCT02584855|10031708|FG001|Open-Label Treatment Period|Withdrawal by Subject|0
6305490|NCT02584855|10031709|FG002|Open-Label Treatment Period|Withdrawal by Subject|0
6305491|NCT02584855|10031710|FG003|Open-Label Treatment Period|Withdrawal by Subject|0
6305492|NCT02584855|10031711|FG004|Open-Label Treatment Period|Withdrawal by Subject|0
6305493|NCT02584855|10031712|FG005|Open-Label Treatment Period|Withdrawal by Subject|0
6305494|NCT02584855|10031707|FG000|Open-Label Treatment Period|Adverse Event|14
6305495|NCT02584855|10031708|FG001|Open-Label Treatment Period|Adverse Event|0
6305496|NCT02584855|10031709|FG002|Open-Label Treatment Period|Adverse Event|0
6305497|NCT02584855|10031710|FG003|Open-Label Treatment Period|Adverse Event|0
6305498|NCT02584855|10031711|FG004|Open-Label Treatment Period|Adverse Event|0
6305499|NCT02584855|10031712|FG005|Open-Label Treatment Period|Adverse Event|0
6305500|NCT02584855|10031707|FG000|Open-Label Treatment Period|Death|2
6305501|NCT02584855|10031708|FG001|Open-Label Treatment Period|Death|0
6305502|NCT02584855|10031709|FG002|Open-Label Treatment Period|Death|0
6305503|NCT02584855|10031710|FG003|Open-Label Treatment Period|Death|0
6305504|NCT02584855|10031711|FG004|Open-Label Treatment Period|Death|0
6305505|NCT02584855|10031712|FG005|Open-Label Treatment Period|Death|0
6305506|NCT02584855|10031707|FG000|Open-Label Treatment Period|Lost to Follow-up|1
6305507|NCT02584855|10031708|FG001|Open-Label Treatment Period|Lost to Follow-up|0
6305508|NCT02584855|10031709|FG002|Open-Label Treatment Period|Lost to Follow-up|0
6305509|NCT02584855|10031710|FG003|Open-Label Treatment Period|Lost to Follow-up|0
6305510|NCT02584855|10031711|FG004|Open-Label Treatment Period|Lost to Follow-up|0
6305511|NCT02584855|10031712|FG005|Open-Label Treatment Period|Lost to Follow-up|0
6305512|NCT02584855|10031707|FG000|Open-Label Treatment Period|Protocol Violation|1
6305513|NCT02584855|10031708|FG001|Open-Label Treatment Period|Protocol Violation|0
6305514|NCT02584855|10031709|FG002|Open-Label Treatment Period|Protocol Violation|0
6305515|NCT02584855|10031710|FG003|Open-Label Treatment Period|Protocol Violation|0
6305516|NCT02584855|10031711|FG004|Open-Label Treatment Period|Protocol Violation|0
6305517|NCT02584855|10031712|FG005|Open-Label Treatment Period|Protocol Violation|0
6305518|NCT02584855|10031707|FG000|Open-Label Treatment Period|No PI Available|2
6305519|NCT02584855|10031708|FG001|Open-Label Treatment Period|No PI Available|0
6305520|NCT02584855|10031709|FG002|Open-Label Treatment Period|No PI Available|0
6305521|NCT02584855|10031710|FG003|Open-Label Treatment Period|No PI Available|0
6305522|NCT02584855|10031711|FG004|Open-Label Treatment Period|No PI Available|0
6305523|NCT02584855|10031712|FG005|Open-Label Treatment Period|No PI Available|0
6305524|NCT02584855|10031707|FG000|Open-Label Treatment Period|Sponsor Decision|1
6305525|NCT02584855|10031708|FG001|Open-Label Treatment Period|Sponsor Decision|0
6305526|NCT02584855|10031709|FG002|Open-Label Treatment Period|Sponsor Decision|0
6305527|NCT02584855|10031710|FG003|Open-Label Treatment Period|Sponsor Decision|0
6305528|NCT02584855|10031711|FG004|Open-Label Treatment Period|Sponsor Decision|0
6305529|NCT02584855|10031712|FG005|Open-Label Treatment Period|Sponsor Decision|0
6305530|NCT02584855|10031707|FG000|Double-Blind Withdrawal Period|Withdrawal by Subject|0
6305531|NCT02584855|10031708|FG001|Double-Blind Withdrawal Period|Withdrawal by Subject|0
6305532|NCT02584855|10031709|FG002|Double-Blind Withdrawal Period|Withdrawal by Subject|2
5982511|NCT02580058|9571462|FG002|Overall Study|Lost to Follow-up|4
5982512|NCT02580058|9571460|FG000|Overall Study|Ongoing|51
5982513|NCT02580058|9571461|FG001|Overall Study|Ongoing|55
5982514|NCT02580058|9571462|FG002|Overall Study|Ongoing|46
5982515|NCT02580058|9571460|FG000|Overall Study|Withdrawal by Subject|24
5982516|NCT02580058|9571461|FG001|Overall Study|Withdrawal by Subject|26
5982517|NCT02580058|9571462|FG002|Overall Study|Withdrawal by Subject|36
6064074|NCT00509899|9665539|FG006|Overall Study|Intercurrent Illness|0
5982518|NCT02578680|9571472|FG000|Overall Study|Death|124
5982519|NCT02578680|9571473|FG001|Overall Study|Death|104
5982520|NCT02578680|9571472|FG000|Overall Study|Protocol Violation|1
5982521|NCT02578680|9571473|FG001|Overall Study|Protocol Violation|1
5982522|NCT02578680|9571472|FG000|Overall Study|Withdrawal by Parent/Guardian|1
5982523|NCT02578680|9571473|FG001|Overall Study|Withdrawal by Parent/Guardian|0
5982524|NCT02578680|9571472|FG000|Overall Study|Withdrawal by Subject|8
5982525|NCT02578680|9571473|FG001|Overall Study|Withdrawal by Subject|5
5982526|NCT02578680|9571472|FG000|Overall Study|Ongoing in Study|276
6305533|NCT02584855|10031710|FG003|Double-Blind Withdrawal Period|Withdrawal by Subject|0
6305534|NCT02584855|10031711|FG004|Double-Blind Withdrawal Period|Withdrawal by Subject|0
6305535|NCT02584855|10031712|FG005|Double-Blind Withdrawal Period|Withdrawal by Subject|0
6305536|NCT02584855|10031707|FG000|Double-Blind Withdrawal Period|Adverse Event|0
6305537|NCT02584855|10031708|FG001|Double-Blind Withdrawal Period|Adverse Event|4
6305538|NCT02584855|10031709|FG002|Double-Blind Withdrawal Period|Adverse Event|0
6305539|NCT02584855|10031710|FG003|Double-Blind Withdrawal Period|Adverse Event|1
6305540|NCT02584855|10031711|FG004|Double-Blind Withdrawal Period|Adverse Event|0
6305541|NCT02584855|10031712|FG005|Double-Blind Withdrawal Period|Adverse Event|0
6305542|NCT02584855|10031707|FG000|Double-Blind Withdrawal Period|Lack of Efficacy|0
6305543|NCT02584855|10031708|FG001|Double-Blind Withdrawal Period|Lack of Efficacy|10
6305544|NCT02584855|10031709|FG002|Double-Blind Withdrawal Period|Lack of Efficacy|0
6305545|NCT02584855|10031710|FG003|Double-Blind Withdrawal Period|Lack of Efficacy|0
6305546|NCT02584855|10031711|FG004|Double-Blind Withdrawal Period|Lack of Efficacy|0
6305547|NCT02584855|10031712|FG005|Double-Blind Withdrawal Period|Lack of Efficacy|0
6305548|NCT02584855|10031707|FG000|Double-Blind Withdrawal Period|Declined Transfer to a Different Site|0
6305549|NCT02584855|10031708|FG001|Double-Blind Withdrawal Period|Declined Transfer to a Different Site|1
6305550|NCT02584855|10031709|FG002|Double-Blind Withdrawal Period|Declined Transfer to a Different Site|0
6305551|NCT02584855|10031710|FG003|Double-Blind Withdrawal Period|Declined Transfer to a Different Site|0
6305552|NCT02584855|10031711|FG004|Double-Blind Withdrawal Period|Declined Transfer to a Different Site|0
6305553|NCT02584855|10031712|FG005|Double-Blind Withdrawal Period|Declined Transfer to a Different Site|0
6305554|NCT02584855|10031707|FG000|Post Treatment Follow-up Period|Withdrawal by Subject|0
6305555|NCT02584855|10031708|FG001|Post Treatment Follow-up Period|Withdrawal by Subject|0
6305556|NCT02584855|10031709|FG002|Post Treatment Follow-up Period|Withdrawal by Subject|0
6305557|NCT02584855|10031710|FG003|Post Treatment Follow-up Period|Withdrawal by Subject|0
6305558|NCT02584855|10031711|FG004|Post Treatment Follow-up Period|Withdrawal by Subject|7
6305559|NCT02584855|10031712|FG005|Post Treatment Follow-up Period|Withdrawal by Subject|0
6305560|NCT02584855|10031707|FG000|Post Treatment Follow-up Period|Protocol Violation|0
6305561|NCT02584855|10031708|FG001|Post Treatment Follow-up Period|Protocol Violation|0
6305562|NCT02584855|10031709|FG002|Post Treatment Follow-up Period|Protocol Violation|0
6305563|NCT02584855|10031710|FG003|Post Treatment Follow-up Period|Protocol Violation|0
6305564|NCT02584855|10031711|FG004|Post Treatment Follow-up Period|Protocol Violation|1
6305565|NCT02584855|10031712|FG005|Post Treatment Follow-up Period|Protocol Violation|0
6305566|NCT02584959|10031737|FG000|Period 1|Withdrawn from study|3
6305567|NCT02584959|10031738|FG001|Period 1|Withdrawn from study|4
6305568|NCT02584959|10031739|FG002|Period 1|Withdrawn from study|0
6305569|NCT02584959|10031737|FG000|Period 2|Withdrawn from study|6
6305570|NCT02584959|10031738|FG001|Period 2|Withdrawn from study|1
6305571|NCT02584959|10031739|FG002|Period 2|Withdrawn from study|2
6305572|NCT02585713|10031785|FG000|Overall Study|Withdrew prior to treatment|2
6305573|NCT02585713|10031786|FG001|Overall Study|Withdrew prior to treatment|7
6305574|NCT02585713|10031785|FG000|Overall Study|Other|3
6305575|NCT02585713|10031786|FG001|Overall Study|Other|1
6305576|NCT02585778|10031796|FG000|Overall Study|Adverse Event|17
6305577|NCT02585778|10031797|FG001|Overall Study|Adverse Event|4
6305578|NCT02585778|10031796|FG000|Overall Study|Participant did not wish to continue|9
6305579|NCT02585778|10031797|FG001|Overall Study|Participant did not wish to continue|4
6305580|NCT02585778|10031796|FG000|Overall Study|Poor compliance to study protocol|0
6305581|NCT02585778|10031797|FG001|Overall Study|Poor compliance to study protocol|2
6305582|NCT02585778|10031796|FG000|Overall Study|Death|0
6305583|NCT02585778|10031797|FG001|Overall Study|Death|1
6305584|NCT02585778|10031796|FG000|Overall Study|Randomized but not treated|1
6305585|NCT02585778|10031797|FG001|Overall Study|Randomized but not treated|2
6305586|NCT02585778|10031796|FG000|Overall Study|Other than specified above|6
6305587|NCT02585778|10031797|FG001|Overall Study|Other than specified above|2
6305588|NCT02585830|10031807|FG000|Overall Study|Withdrawal by Subject|3
6305589|NCT02585934|10031834|FG000|Overall Study|Lost to Follow-up|2
6305590|NCT02585934|10031835|FG001|Overall Study|Lost to Follow-up|2
6305591|NCT02585934|10031834|FG000|Overall Study|Protocol Violation|14
6305592|NCT02585934|10031835|FG001|Overall Study|Protocol Violation|11
6305593|NCT02585934|10031834|FG000|Overall Study|Adverse Event|21
6305594|NCT02585934|10031835|FG001|Overall Study|Adverse Event|22
6305595|NCT02585934|10031834|FG000|Overall Study|Physician Decision|3
6305596|NCT02585934|10031835|FG001|Overall Study|Physician Decision|2
6305597|NCT02585934|10031834|FG000|Overall Study|Withdrawal by Subject|7
6305598|NCT02585934|10031835|FG001|Overall Study|Withdrawal by Subject|21
6305599|NCT02585934|10031834|FG000|Overall Study|Lack of Efficacy|2
6305600|NCT02585934|10031835|FG001|Overall Study|Lack of Efficacy|1
6305601|NCT02585934|10031834|FG000|Overall Study|Death|2
6305602|NCT02585934|10031835|FG001|Overall Study|Death|0
6305603|NCT02585934|10031834|FG000|Overall Study|Caregiver Withdrew Consent|7
6305604|NCT02585934|10031835|FG001|Overall Study|Caregiver Withdrew Consent|7
6305605|NCT02585934|10031834|FG000|Overall Study|Sponsor Termination|1
6305606|NCT02585934|10031835|FG001|Overall Study|Sponsor Termination|2
6305607|NCT02585934|10031834|FG000|Overall Study|Another Reason|10
6305608|NCT02585934|10031835|FG001|Overall Study|Another Reason|5
6305609|NCT02585960|10031849|FG000|PK/Safety Assessment Period|Physician Decision|0
6305610|NCT02585960|10031850|FG001|PK/Safety Assessment Period|Physician Decision|1
6305611|NCT02585960|10031851|FG002|PK/Safety Assessment Period|Physician Decision|0
6305612|NCT02585960|10031849|FG000|PK/Safety Assessment Period|Withdrawal by Subject|1
6305613|NCT02585960|10031850|FG001|PK/Safety Assessment Period|Withdrawal by Subject|2
6305614|NCT02585960|10031851|FG002|PK/Safety Assessment Period|Withdrawal by Subject|5
6305615|NCT02585960|10031849|FG000|PK/Safety Assessment Period|Non-compliance to study procedures|0
6305616|NCT02585960|10031850|FG001|PK/Safety Assessment Period|Non-compliance to study procedures|2
6305617|NCT02585960|10031851|FG002|PK/Safety Assessment Period|Non-compliance to study procedures|0
6305618|NCT02585960|10031849|FG000|PK/Safety Assessment Period|Other|4
6305619|NCT02585960|10031850|FG001|PK/Safety Assessment Period|Other|4
6305620|NCT02585960|10031851|FG002|PK/Safety Assessment Period|Other|0
6305621|NCT02585960|10031849|FG000|PK/Safety Assessment Period|Withdrawn by sponsor|0
6305622|NCT02585960|10031850|FG001|PK/Safety Assessment Period|Withdrawn by sponsor|1
6305623|NCT02585960|10031851|FG002|PK/Safety Assessment Period|Withdrawn by sponsor|0
6305624|NCT02585960|10031849|FG000|PK/Safety Assessment Period|Screen Failure|0
6305625|NCT02585960|10031850|FG001|PK/Safety Assessment Period|Screen Failure|0
6305626|NCT02585960|10031851|FG002|PK/Safety Assessment Period|Screen Failure|1
6305627|NCT02585960|10031849|FG000|Prophylactic Treatment Period|Major protocol deviation|0
6305628|NCT02585960|10031850|FG001|Prophylactic Treatment Period|Major protocol deviation|4
6305629|NCT02585960|10031851|FG002|Prophylactic Treatment Period|Major protocol deviation|0
6305630|NCT02585960|10031849|FG000|Prophylactic Treatment Period|Subject less than 75% exposed to BAX 855|0
6305631|NCT02585960|10031850|FG001|Prophylactic Treatment Period|Subject less than 75% exposed to BAX 855|1
6305632|NCT02585960|10031851|FG002|Prophylactic Treatment Period|Subject less than 75% exposed to BAX 855|0
6305633|NCT02585999|10031862|FG000|Overall Study|Lost to Follow-up|1
6305634|NCT02585999|10031862|FG000|Overall Study|Protocol Violation|1
6305635|NCT02586012|10031867|FG000|Overall Study|Withdrawal by Subject|1
6305636|NCT02586012|10031868|FG001|Overall Study|Withdrawal by Subject|1
6305637|NCT02586012|10031869|FG002|Overall Study|Withdrawal by Subject|0
6305638|NCT02586012|10031870|FG003|Overall Study|Withdrawal by Subject|1
6305639|NCT02586012|10031871|FG004|Overall Study|Withdrawal by Subject|0
6305640|NCT02586012|10031872|FG005|Overall Study|Withdrawal by Subject|2
6305641|NCT02586012|10031867|FG000|Overall Study|Protocol Violation|0
6305642|NCT02586012|10031868|FG001|Overall Study|Protocol Violation|0
6305643|NCT02586012|10031869|FG002|Overall Study|Protocol Violation|0
6305644|NCT02586012|10031870|FG003|Overall Study|Protocol Violation|0
6305645|NCT02586012|10031871|FG004|Overall Study|Protocol Violation|0
6305646|NCT02586012|10031872|FG005|Overall Study|Protocol Violation|1
6305647|NCT02586012|10031867|FG000|Overall Study|study terminated|0
6305648|NCT02586012|10031868|FG001|Overall Study|study terminated|2
6305649|NCT02586012|10031869|FG002|Overall Study|study terminated|1
6305650|NCT02586012|10031870|FG003|Overall Study|study terminated|1
6305651|NCT02586012|10031871|FG004|Overall Study|study terminated|1
6305652|NCT02586012|10031872|FG005|Overall Study|study terminated|0
6305653|NCT02586064|10031883|FG000|Overall Study|Other Obligations|6
6305654|NCT02586064|10031884|FG001|Overall Study|Other Obligations|6
6305655|NCT02586064|10031883|FG000|Overall Study|Other|3
6305656|NCT02586064|10031884|FG001|Overall Study|Other|7
6305657|NCT02586064|10031883|FG000|Overall Study|Never Started|3
6305658|NCT02586064|10031884|FG001|Overall Study|Never Started|3
6305659|NCT02586064|10031883|FG000|Overall Study|Lost Interest|1
6305660|NCT02586064|10031884|FG001|Overall Study|Lost Interest|4
6305661|NCT02586064|10031883|FG000|Overall Study|Miscellaneous Life Issues|0
6305662|NCT02586064|10031884|FG001|Overall Study|Miscellaneous Life Issues|5
6305663|NCT02586064|10031883|FG000|Overall Study|Infrequent Attendance|2
6305664|NCT02586064|10031884|FG001|Overall Study|Infrequent Attendance|1
6305665|NCT02586064|10031883|FG000|Overall Study|Timed Out|2
6305666|NCT02586064|10031884|FG001|Overall Study|Timed Out|0
6305667|NCT02586064|10031883|FG000|Overall Study|AUD relapse|0
6305668|NCT02586064|10031884|FG001|Overall Study|AUD relapse|2
6305669|NCT02586064|10031883|FG000|Overall Study|Legal Issue|1
6305670|NCT02586064|10031884|FG001|Overall Study|Legal Issue|0
6305671|NCT02586077|10031893|FG000|Overall Study|Withdrawal by Subject|1
6305672|NCT02586077|10031893|FG000|Overall Study|Physician Decision|4
6305673|NCT02586077|10031893|FG000|Overall Study|Lost to Follow-up|3
6305674|NCT02586155|10031900|FG000|Overall Study|Adverse Event|2
6305675|NCT02586155|10031901|FG001|Overall Study|Adverse Event|3
6305676|NCT02586155|10031900|FG000|Overall Study|Withdrawal by Subject|31
6305677|NCT02586155|10031901|FG001|Overall Study|Withdrawal by Subject|24
6305678|NCT02586155|10031900|FG000|Overall Study|Lost to Follow-up|7
6305679|NCT02586155|10031901|FG001|Overall Study|Lost to Follow-up|13
6305680|NCT02586155|10031900|FG000|Overall Study|Death|61
6305681|NCT02586155|10031901|FG001|Overall Study|Death|72
6305682|NCT02586155|10031900|FG000|Overall Study|Other reasons|26
6305683|NCT02586155|10031901|FG001|Overall Study|Other reasons|15
6305684|NCT02586233|10031914|FG000|Overall Study|Randomized but did not receive treatment|0
6305685|NCT02586233|10031915|FG001|Overall Study|Randomized but did not receive treatment|1
6305686|NCT02586233|10031916|FG002|Overall Study|Randomized but did not receive treatment|0
6305687|NCT02586233|10031917|FG003|Overall Study|Randomized but did not receive treatment|0
6305688|NCT02586233|10031918|FG004|Overall Study|Randomized but did not receive treatment|0
6305689|NCT02586233|10031919|FG005|Overall Study|Randomized but did not receive treatment|2
6305690|NCT02586233|10031920|FG006|Overall Study|Randomized but did not receive treatment|2
6305691|NCT02586233|10031914|FG000|Overall Study|Death|0
6305692|NCT02586233|10031915|FG001|Overall Study|Death|1
6305693|NCT02586233|10031916|FG002|Overall Study|Death|0
6305694|NCT02586233|10031917|FG003|Overall Study|Death|0
6305695|NCT02586233|10031918|FG004|Overall Study|Death|2
6305696|NCT02586233|10031919|FG005|Overall Study|Death|0
6305697|NCT02586233|10031920|FG006|Overall Study|Death|0
6305698|NCT02586415|10031942|FG000|Overall Study|Death|13
6305699|NCT02586415|10031943|FG001|Overall Study|Death|23
6305700|NCT02586415|10031942|FG000|Overall Study|Lost to Follow-up|1
6305701|NCT02586415|10031943|FG001|Overall Study|Lost to Follow-up|2
6305702|NCT02586493|10031950|FG000|Overall Study|Adverse Event|4
6305703|NCT02586493|10031950|FG000|Overall Study|Protocol Violation|6
6305704|NCT02586493|10031950|FG000|Overall Study|Lost to Follow-up|1
6305705|NCT02586493|10031950|FG000|Overall Study|Withdrawal by Subject|1
6305706|NCT02586506|10031954|FG000|Overall Study|Protocol Violation|6
6305707|NCT02586506|10031954|FG000|Overall Study|Lost to Follow-up|1
6305708|NCT02586506|10031954|FG000|Overall Study|Other Reason|2
6305709|NCT02586727|10031960|FG000|Overall Study|Lost to Follow-up|1
6305710|NCT02586727|10031961|FG001|Overall Study|Lost to Follow-up|0
6305711|NCT02586805|10031971|FG000|Overall Study|Withdrawal by Subject|3
6305712|NCT02586805|10031972|FG001|Overall Study|Withdrawal by Subject|1
6305713|NCT02586805|10031973|FG002|Overall Study|Withdrawal by Subject|1
6305714|NCT02586805|10031974|FG003|Overall Study|Withdrawal by Subject|2
6305715|NCT02586805|10031971|FG000|Overall Study|Adverse Event|2
6305716|NCT02586805|10031972|FG001|Overall Study|Adverse Event|0
6305717|NCT02586805|10031973|FG002|Overall Study|Adverse Event|1
6305718|NCT02586805|10031974|FG003|Overall Study|Adverse Event|0
6305719|NCT02586805|10031971|FG000|Overall Study|Lost to Follow-up|0
6305720|NCT02586805|10031972|FG001|Overall Study|Lost to Follow-up|0
6305721|NCT02586805|10031973|FG002|Overall Study|Lost to Follow-up|1
6305722|NCT02586805|10031974|FG003|Overall Study|Lost to Follow-up|0
6305723|NCT02586805|10031971|FG000|Overall Study|Physician Decision|1
6305724|NCT02586805|10031972|FG001|Overall Study|Physician Decision|0
6305725|NCT02586805|10031973|FG002|Overall Study|Physician Decision|0
6305726|NCT02586805|10031974|FG003|Overall Study|Physician Decision|0
6305727|NCT02587065|10032008|FG000|Overall Study|Adverse Event|14
6305728|NCT02587065|10032008|FG000|Overall Study|Withdrawal of Informed Consent (IC)|5
6305729|NCT02587065|10032008|FG000|Overall Study|Non-adherence to the Protocol|3
6305730|NCT02587065|10032008|FG000|Overall Study|Discontinuation of Study Medication|2
6305731|NCT02587065|10032008|FG000|Overall Study|Reason not Specified|3
6305732|NCT02587143|10032023|FG000|Overall Study|Adverse Event|1
6305733|NCT02587143|10032024|FG001|Overall Study|Adverse Event|0
6305734|NCT02587221|10032032|FG000|Overall Study|Adverse Event|3
6305735|NCT02587221|10032033|FG001|Overall Study|Adverse Event|3
6305736|NCT02587221|10032032|FG000|Overall Study|Death|33
6305737|NCT02587221|10032033|FG001|Overall Study|Death|34
6305738|NCT02587221|10032032|FG000|Overall Study|Withdrawal by Subject|66
6305739|NCT02587221|10032033|FG001|Overall Study|Withdrawal by Subject|61
6305740|NCT02587221|10032032|FG000|Overall Study|Lost to Follow-up|21
6305741|NCT02587221|10032033|FG001|Overall Study|Lost to Follow-up|19
6305742|NCT02587221|10032032|FG000|Overall Study|Protocol Violation|6
6305743|NCT02587221|10032033|FG001|Overall Study|Protocol Violation|5
6305744|NCT02587221|10032032|FG000|Overall Study|Other Reason or Unspecified|2
6305745|NCT02587221|10032033|FG001|Overall Study|Other Reason or Unspecified|1
6305746|NCT02587234|10032041|FG000|Overall Study|Withdrawal by Subject|1
6305747|NCT02587234|10032042|FG001|Overall Study|Withdrawal by Subject|1
6305748|NCT02587234|10032041|FG000|Overall Study|Lost to Follow-up|0
6305749|NCT02587234|10032042|FG001|Overall Study|Lost to Follow-up|2
6305750|NCT02587819|10032057|FG000|Overall Study|Adverse Event|1
6305751|NCT02587819|10032057|FG000|Overall Study|Lost to Follow-up|1
6305752|NCT02587962|10032067|FG000|Overall Study|Adverse Event|0
6305753|NCT02587962|10032068|FG001|Overall Study|Adverse Event|0
6305754|NCT02587962|10032069|FG002|Overall Study|Adverse Event|1
6305755|NCT02587962|10032070|FG003|Overall Study|Adverse Event|0
6305756|NCT02587962|10032071|FG004|Overall Study|Adverse Event|0
6305757|NCT02587962|10032067|FG000|Overall Study|Withdrawal by Subject|0
6305758|NCT02587962|10032068|FG001|Overall Study|Withdrawal by Subject|0
6305759|NCT02587962|10032069|FG002|Overall Study|Withdrawal by Subject|1
6305760|NCT02587962|10032070|FG003|Overall Study|Withdrawal by Subject|1
6305761|NCT02587962|10032071|FG004|Overall Study|Withdrawal by Subject|4
6305762|NCT02587962|10032067|FG000|Overall Study|Radiological progression|2
6305763|NCT02587962|10032068|FG001|Overall Study|Radiological progression|2
6305764|NCT02587962|10032069|FG002|Overall Study|Radiological progression|2
6305765|NCT02587962|10032070|FG003|Overall Study|Radiological progression|5
6305766|NCT02587962|10032071|FG004|Overall Study|Radiological progression|10
6305767|NCT02587962|10032067|FG000|Overall Study|Clinical progression|0
6305768|NCT02587962|10032068|FG001|Overall Study|Clinical progression|1
6305769|NCT02587962|10032069|FG002|Overall Study|Clinical progression|2
6305770|NCT02587962|10032070|FG003|Overall Study|Clinical progression|0
6305771|NCT02587962|10032071|FG004|Overall Study|Clinical progression|1
6305772|NCT02588092|10032096|FG000|Overall Study|Death|4
6305773|NCT02588092|10032097|FG001|Overall Study|Death|3
6305774|NCT02588092|10032098|FG002|Overall Study|Death|3
6305775|NCT02588092|10032099|FG003|Overall Study|Death|3
6305776|NCT02588092|10032100|FG004|Overall Study|Death|2
6305777|NCT02588092|10032101|FG005|Overall Study|Death|2
6305778|NCT02588092|10032102|FG006|Overall Study|Death|2
6305779|NCT02588092|10032103|FG007|Overall Study|Death|1
6305780|NCT02588092|10032104|FG008|Overall Study|Death|5
6305781|NCT02588092|10032105|FG009|Overall Study|Death|2
6305782|NCT02588092|10032096|FG000|Overall Study|Withdrawal by Subject|0
6305783|NCT02588092|10032097|FG001|Overall Study|Withdrawal by Subject|0
6305784|NCT02588092|10032098|FG002|Overall Study|Withdrawal by Subject|0
6305785|NCT02588092|10032099|FG003|Overall Study|Withdrawal by Subject|0
6305786|NCT02588092|10032100|FG004|Overall Study|Withdrawal by Subject|0
6305787|NCT02588092|10032101|FG005|Overall Study|Withdrawal by Subject|1
6305788|NCT02588092|10032102|FG006|Overall Study|Withdrawal by Subject|1
6305789|NCT02588092|10032103|FG007|Overall Study|Withdrawal by Subject|2
6305790|NCT02588092|10032104|FG008|Overall Study|Withdrawal by Subject|0
6305791|NCT02588092|10032105|FG009|Overall Study|Withdrawal by Subject|0
6305792|NCT02588092|10032096|FG000|Overall Study|Started Another Treatment|0
6305793|NCT02588092|10032097|FG001|Overall Study|Started Another Treatment|0
6305794|NCT02588092|10032098|FG002|Overall Study|Started Another Treatment|0
6305795|NCT02588092|10032099|FG003|Overall Study|Started Another Treatment|0
6305796|NCT02588092|10032100|FG004|Overall Study|Started Another Treatment|1
6305797|NCT02588092|10032101|FG005|Overall Study|Started Another Treatment|0
6305798|NCT02588092|10032102|FG006|Overall Study|Started Another Treatment|0
6305799|NCT02588092|10032103|FG007|Overall Study|Started Another Treatment|1
6305800|NCT02588092|10032104|FG008|Overall Study|Started Another Treatment|0
6305801|NCT02588092|10032105|FG009|Overall Study|Started Another Treatment|0
6305802|NCT02588092|10032096|FG000|Overall Study|Sponsor Decision|0
6305803|NCT02588092|10032097|FG001|Overall Study|Sponsor Decision|0
6305804|NCT02588092|10032098|FG002|Overall Study|Sponsor Decision|0
6305805|NCT02588092|10032099|FG003|Overall Study|Sponsor Decision|0
6305806|NCT02588092|10032100|FG004|Overall Study|Sponsor Decision|0
6305807|NCT02588092|10032101|FG005|Overall Study|Sponsor Decision|0
6305808|NCT02588092|10032102|FG006|Overall Study|Sponsor Decision|0
6305809|NCT02588092|10032103|FG007|Overall Study|Sponsor Decision|0
6305810|NCT02588092|10032104|FG008|Overall Study|Sponsor Decision|1
6305811|NCT02588092|10032105|FG009|Overall Study|Sponsor Decision|1
5982527|NCT02578680|9571473|FG001|Overall Study|Ongoing in Study|96
6305812|NCT04960228|10032133|FG000|Overall Study|Withdrawal by Subject|216
6305813|NCT04960228|10032134|FG001|Overall Study|Withdrawal by Subject|35
6305814|NCT04960228|10032133|FG000|Overall Study|Failed attention check|69
6305815|NCT04960228|10032134|FG001|Overall Study|Failed attention check|148
6305816|NCT04960228|10032133|FG000|Overall Study|Flagged for response quality by Dynata|3
6305817|NCT04960228|10032134|FG001|Overall Study|Flagged for response quality by Dynata|3
6305818|NCT03922477|10032140|FG000|Overall Study|Death|9
6305819|NCT03922477|10032140|FG000|Overall Study|Fall leading to death prior to treatment initiation.|1
6305820|NCT03922477|10032140|FG000|Overall Study|Physician Decision|1
6305821|NCT03922477|10032140|FG000|Overall Study|Withdrawal by Subject|2
6305822|NCT03688074|10032146|FG000|Overall Study|Adverse Event|0
6305823|NCT03688074|10032147|FG001|Overall Study|Adverse Event|1
6305824|NCT03688074|10032146|FG000|Overall Study|Other|1
6305825|NCT03688074|10032147|FG001|Overall Study|Other|0
6305826|NCT03342001|10032153|FG000|Overall Study|Adverse Event|1
6305827|NCT03342001|10032153|FG000|Overall Study|Lost to Follow-up|1
6305828|NCT02859558|10032171|FG000|Step 1|Not Eligible|0
6305829|NCT02859558|10032172|FG001|Step 1|Not Eligible|0
6305830|NCT02859558|10032173|FG002|Step 1|Not Eligible|0
6305831|NCT02859558|10032174|FG003|Step 1|Not Eligible|0
6305832|NCT02859558|10032175|FG004|Step 1|Not Eligible|3
6305833|NCT02859558|10032171|FG000|Step 1|Lost to Follow-up|1
6305834|NCT02859558|10032172|FG001|Step 1|Lost to Follow-up|3
6305835|NCT02859558|10032173|FG002|Step 1|Lost to Follow-up|3
6305836|NCT02859558|10032174|FG003|Step 1|Lost to Follow-up|0
6305837|NCT02859558|10032175|FG004|Step 1|Lost to Follow-up|0
6305838|NCT02859558|10032171|FG000|Step 1|Did Not Return to Clinic|2
6305839|NCT02859558|10032172|FG001|Step 1|Did Not Return to Clinic|3
6305840|NCT02859558|10032173|FG002|Step 1|Did Not Return to Clinic|4
6305841|NCT02859558|10032174|FG003|Step 1|Did Not Return to Clinic|0
6305842|NCT02859558|10032175|FG004|Step 1|Did Not Return to Clinic|0
6305843|NCT02859558|10032171|FG000|Step 1|Moved|0
6305844|NCT02859558|10032172|FG001|Step 1|Moved|1
6305845|NCT02859558|10032173|FG002|Step 1|Moved|1
6305846|NCT02859558|10032174|FG003|Step 1|Moved|0
6305847|NCT02859558|10032175|FG004|Step 1|Moved|0
6305848|NCT02859558|10032171|FG000|Step 1|Withdrawal By Participant|1
6305849|NCT02859558|10032172|FG001|Step 1|Withdrawal By Participant|2
6305850|NCT02859558|10032173|FG002|Step 1|Withdrawal By Participant|1
6305851|NCT02859558|10032174|FG003|Step 1|Withdrawal By Participant|0
6305852|NCT02859558|10032175|FG004|Step 1|Withdrawal By Participant|0
6305853|NCT02859558|10032171|FG000|Step 1|Had to Interrupt antiretroviral (ARV)|1
6305854|NCT02859558|10032172|FG001|Step 1|Had to Interrupt antiretroviral (ARV)|0
6305855|NCT02859558|10032173|FG002|Step 1|Had to Interrupt antiretroviral (ARV)|0
6305856|NCT02859558|10032174|FG003|Step 1|Had to Interrupt antiretroviral (ARV)|0
6305857|NCT02859558|10032175|FG004|Step 1|Had to Interrupt antiretroviral (ARV)|0
6305858|NCT02859558|10032171|FG000|Step 1|Incarceration|0
6305859|NCT02859558|10032172|FG001|Step 1|Incarceration|1
6305860|NCT02859558|10032173|FG002|Step 1|Incarceration|0
6305861|NCT02859558|10032174|FG003|Step 1|Incarceration|0
6305862|NCT02859558|10032175|FG004|Step 1|Incarceration|0
6305863|NCT02859558|10032171|FG000|Step 1|Non-Adherence to Study Drug|2
6305864|NCT02859558|10032172|FG001|Step 1|Non-Adherence to Study Drug|0
6305865|NCT02859558|10032173|FG002|Step 1|Non-Adherence to Study Drug|1
6305866|NCT02859558|10032174|FG003|Step 1|Non-Adherence to Study Drug|0
6305867|NCT02859558|10032175|FG004|Step 1|Non-Adherence to Study Drug|0
6305868|NCT02859558|10032171|FG000|Step 1|Non-Adherence to Study Requirements|3
6305869|NCT02859558|10032172|FG001|Step 1|Non-Adherence to Study Requirements|1
6305870|NCT02859558|10032173|FG002|Step 1|Non-Adherence to Study Requirements|0
6305871|NCT02859558|10032174|FG003|Step 1|Non-Adherence to Study Requirements|0
6305872|NCT02859558|10032175|FG004|Step 1|Non-Adherence to Study Requirements|0
6305873|NCT02859558|10032171|FG000|Step 1|Virologic Failure|2
6305874|NCT02859558|10032172|FG001|Step 1|Virologic Failure|1
6305875|NCT02859558|10032173|FG002|Step 1|Virologic Failure|1
6305876|NCT02859558|10032174|FG003|Step 1|Virologic Failure|0
6305877|NCT02859558|10032175|FG004|Step 1|Virologic Failure|0
6305878|NCT02859558|10032171|FG000|Step 2|Active On Study|23
6305879|NCT02859558|10032172|FG001|Step 2|Active On Study|38
6064075|NCT00509899|9665540|FG007|Overall Study|Intercurrent Illness|0
6305880|NCT02859558|10032173|FG002|Step 2|Active On Study|20
6305881|NCT02859558|10032174|FG003|Step 2|Active On Study|0
6305882|NCT02859558|10032175|FG004|Step 2|Active On Study|0
6305883|NCT02859558|10032171|FG000|Step 2|Did Not Return to Clinic|2
6305884|NCT02859558|10032172|FG001|Step 2|Did Not Return to Clinic|0
6305885|NCT02859558|10032173|FG002|Step 2|Did Not Return to Clinic|0
6305886|NCT02859558|10032174|FG003|Step 2|Did Not Return to Clinic|0
6305887|NCT02859558|10032175|FG004|Step 2|Did Not Return to Clinic|0
6305888|NCT02859558|10032171|FG000|Step 2|Unexpected Closure of Site|0
6305889|NCT02859558|10032172|FG001|Step 2|Unexpected Closure of Site|1
6305890|NCT02859558|10032173|FG002|Step 2|Unexpected Closure of Site|1
6305891|NCT02859558|10032174|FG003|Step 2|Unexpected Closure of Site|0
6305892|NCT02859558|10032175|FG004|Step 2|Unexpected Closure of Site|0
6305893|NCT02818920|10032185|FG000|Overall Study|Unresectable|4
6305894|NCT02818920|10032185|FG000|Overall Study|Progressed After Neoadjuvant Therapy|1
6305895|NCT02818920|10032185|FG000|Overall Study|Went Off Study Prior to Adjuvant Therapy|8
6305896|NCT02818920|10032185|FG000|Overall Study|Adverse Event|3
6305897|NCT02818920|10032185|FG000|Overall Study|Developed Other Disease|1
6305898|NCT02818920|10032185|FG000|Overall Study|Refused Further Treatment|1
6305899|NCT02481310|10032192|FG000|Follow up|Still in follow up|0
6305900|NCT02481310|10032193|FG001|Follow up|Still in follow up|3
6305901|NCT02481310|10032194|FG002|Follow up|Still in follow up|0
6305902|NCT02343952|10032198|FG000|Study Treatment|Disease Progression|23
6305903|NCT02343952|10032198|FG000|Study Treatment|Death|3
6305904|NCT02343952|10032198|FG000|Study Treatment|Adverse Event|19
6305905|NCT02343952|10032198|FG000|Study Treatment|Withdrawal by Subject|7
6305906|NCT02343952|10032198|FG000|Study Treatment|other complicating Diseases|1
6305907|NCT02343952|10032198|FG000|Follow up|Withdrawal by Subject|3
6305908|NCT02343952|10032198|FG000|Follow up|Death|33
6305909|NCT02343952|10032198|FG000|Follow up|Patient does not meet eligibility for study.|1
6305910|NCT02343952|10032198|FG000|Follow up|Research department closed by the practice.|5
6305911|NCT02343952|10032198|FG000|Follow up|Patient went home to Russia|1
6305912|NCT02343952|10032198|FG000|Follow up|Disease Progression|1
6305913|NCT02343952|10032198|FG000|Follow up|study terminated|1
6305914|NCT02326155|10032204|FG000|Overall Study|Adverse Event|21
6305915|NCT02326155|10032205|FG001|Overall Study|Adverse Event|5
6305916|NCT02326155|10032204|FG000|Overall Study|Death|3
6305917|NCT02326155|10032205|FG001|Overall Study|Death|0
6305918|NCT02326155|10032204|FG000|Overall Study|Lack of Efficacy|49
6305919|NCT02326155|10032205|FG001|Overall Study|Lack of Efficacy|5
6305920|NCT02326155|10032204|FG000|Overall Study|Lost to Follow-up|14
6305921|NCT02326155|10032205|FG001|Overall Study|Lost to Follow-up|3
6305922|NCT02326155|10032204|FG000|Overall Study|Protocol Violation|2
6305923|NCT02326155|10032205|FG001|Overall Study|Protocol Violation|0
6305924|NCT02326155|10032204|FG000|Overall Study|Withdrawal by Subject|34
6305925|NCT02326155|10032205|FG001|Overall Study|Withdrawal by Subject|11
6305926|NCT02326155|10032204|FG000|Overall Study|Disease progression|37
6305927|NCT02326155|10032205|FG001|Overall Study|Disease progression|4
6305928|NCT02326155|10032204|FG000|Overall Study|Study close|188
6305929|NCT02326155|10032205|FG001|Overall Study|Study close|21
6305930|NCT02326155|10032204|FG000|Overall Study|except for study close|46
6305931|NCT02326155|10032205|FG001|Overall Study|except for study close|13
6305932|NCT02304367|10032211|FG000|Overall Study|Lack of Response to Bruosumab|1
6305933|NCT02304367|10032211|FG000|Overall Study|Sponsor Decision|3
6305934|NCT02304367|10032211|FG000|Overall Study|Death|2
6305935|NCT02304367|10032211|FG000|Overall Study|Physician Decision|1
6305936|NCT02304367|10032211|FG000|Overall Study|Unable to Return Due to Corona Virus Pandemic|1
6305937|NCT02588261|10032233|FG000|Overall Study|Study Terminated by Sponsor|157
6305938|NCT02588261|10032234|FG001|Overall Study|Study Terminated by Sponsor|142
6305939|NCT02588261|10032233|FG000|Overall Study|Protocol Deviation|1
6305940|NCT02588261|10032234|FG001|Overall Study|Protocol Deviation|0
6305941|NCT02588261|10032233|FG000|Overall Study|Death|1
6305942|NCT02588261|10032234|FG001|Overall Study|Death|2
6305943|NCT02588261|10032233|FG000|Overall Study|Withdrawal by Subject|12
6305944|NCT02588261|10032234|FG001|Overall Study|Withdrawal by Subject|8
6305945|NCT02588261|10032233|FG000|Overall Study|Noncompliance with Study Drug|0
6305946|NCT02588261|10032234|FG001|Overall Study|Noncompliance with Study Drug|1
6305947|NCT02588261|10032233|FG000|Overall Study|Miscellaneous|5
6305948|NCT02588261|10032234|FG001|Overall Study|Miscellaneous|4
6305949|NCT02588261|10032233|FG000|Overall Study|Progressive Disease|61
6305950|NCT02588261|10032234|FG001|Overall Study|Progressive Disease|82
6305951|NCT02588261|10032233|FG000|Overall Study|Adverse Event|29
6305952|NCT02588261|10032234|FG001|Overall Study|Adverse Event|24
6305953|NCT02588261|10032233|FG000|Overall Study|Lost to Follow-up|1
6305954|NCT02588261|10032234|FG001|Overall Study|Lost to Follow-up|0
6305955|NCT02588339|10032240|FG000|Overall Study|Withdrawal by Subject|1
6305956|NCT02588339|10032240|FG000|Overall Study|GVHD Progression prior to treatment|2
6305957|NCT02588612|10032273|FG000|Overall Study|Physician Decision|1
6305958|NCT02588612|10032273|FG000|Overall Study|Leukapheresis did not yield enough cells|1
6305959|NCT02588612|10032273|FG000|Overall Study|Failed eligibility prior to chemotherapy|2
6305960|NCT02588612|10032273|FG000|Overall Study|Death prior to T-cell infusion|1
6305961|NCT02588664|10032279|FG000|Overall Study|Death|56
6305962|NCT02588664|10032280|FG001|Overall Study|Death|55
6305963|NCT02588664|10032279|FG000|Overall Study|Lost to Follow-up|1305
6305964|NCT02588664|10032280|FG001|Overall Study|Lost to Follow-up|990
6305965|NCT02588833|10032288|FG000|Part 1|Withdrawal by Subject|1
6305966|NCT02588833|10032289|FG001|Part 1|Withdrawal by Subject|0
6305967|NCT02588833|10032288|FG000|Part 2A|Physician Decision|0
6305968|NCT02588833|10032289|FG001|Part 2A|Physician Decision|1
6305969|NCT02588833|10032288|FG000|Part 2A|Withdrawal by Subject|0
6305970|NCT02588833|10032289|FG001|Part 2A|Withdrawal by Subject|1
6305971|NCT02588833|10032288|FG000|Part 2B|Adverse Event|0
6305972|NCT02588833|10032289|FG001|Part 2B|Adverse Event|1
6305973|NCT02588833|10032288|FG000|Part 2C|Adverse Event|0
6064076|NCT00509899|9665533|FG000|Overall Study|Death|2
6305974|NCT02588833|10032289|FG001|Part 2C|Adverse Event|1
6064077|NCT00509899|9665534|FG001|Overall Study|Death|2
6305975|NCT02588833|10032288|FG000|Part 2C|Withdrawal by Subject|0
6305976|NCT02588833|10032289|FG001|Part 2C|Withdrawal by Subject|1
6305977|NCT02588833|10032288|FG000|Part 3 (Safety Follow-up)|Other|0
6305978|NCT02588833|10032289|FG001|Part 3 (Safety Follow-up)|Other|2
6305979|NCT02589405|10032329|FG000|Overall Study|Adverse Event|3
6305980|NCT02589405|10032329|FG000|Overall Study|Withdrawal by Subject|1
6305981|NCT02589626|10032335|FG000|Overall Study|Other than the reason specified|1
6305982|NCT02589626|10032336|FG001|Overall Study|Other than the reason specified|0
6305983|NCT02589626|10032335|FG000|Overall Study|Withdrawal by Subject|1
6305984|NCT02589626|10032336|FG001|Overall Study|Withdrawal by Subject|1
6305985|NCT02589626|10032335|FG000|Overall Study|Adverse Event|1
6305986|NCT02589626|10032336|FG001|Overall Study|Adverse Event|1
6305987|NCT02589639|10032345|FG000|Overall Study|Lost to Follow-up|1
6305988|NCT02589639|10032346|FG001|Overall Study|Lost to Follow-up|0
6305989|NCT02589639|10032347|FG002|Overall Study|Lost to Follow-up|0
6305990|NCT02589639|10032345|FG000|Overall Study|Protocol Violation|1
6305991|NCT02589639|10032346|FG001|Overall Study|Protocol Violation|0
6305992|NCT02589639|10032347|FG002|Overall Study|Protocol Violation|0
6305993|NCT02589639|10032345|FG000|Overall Study|Patient withdrawal, not due to AE|3
6305994|NCT02589639|10032346|FG001|Overall Study|Patient withdrawal, not due to AE|0
6305995|NCT02589639|10032347|FG002|Overall Study|Patient withdrawal, not due to AE|0
6305996|NCT02589639|10032345|FG000|Overall Study|Adverse Event|4
6305997|NCT02589639|10032346|FG001|Overall Study|Adverse Event|5
6305998|NCT02589639|10032347|FG002|Overall Study|Adverse Event|3
6305999|NCT02589639|10032345|FG000|Overall Study|Other reason than specified above|1
6306000|NCT02589639|10032346|FG001|Overall Study|Other reason than specified above|2
6306001|NCT02589639|10032347|FG002|Overall Study|Other reason than specified above|1
6306002|NCT02589639|10032345|FG000|Overall Study|Not Treated|0
6306003|NCT02589639|10032346|FG001|Overall Study|Not Treated|3
6306004|NCT02589639|10032347|FG002|Overall Study|Not Treated|0
6306005|NCT02589665|10032359|FG000|Induction Period|Did not receive drug|0
6306006|NCT02589665|10032360|FG001|Induction Period|Did not receive drug|0
6306007|NCT02589665|10032361|FG002|Induction Period|Did not receive drug|0
6306008|NCT02589665|10032362|FG003|Induction Period|Did not receive drug|1
6306009|NCT02589665|10032363|FG004|Induction Period|Did not receive drug|0
6306010|NCT02589665|10032364|FG005|Induction Period|Did not receive drug|0
6306011|NCT02589665|10032365|FG006|Induction Period|Did not receive drug|0
6306012|NCT02589665|10032366|FG007|Induction Period|Did not receive drug|0
6306013|NCT02589665|10032367|FG008|Induction Period|Did not receive drug|0
6306014|NCT02589665|10032368|FG009|Induction Period|Did not receive drug|0
6306015|NCT02589665|10032359|FG000|Induction Period|Adverse Event|3
6306016|NCT02589665|10032360|FG001|Induction Period|Adverse Event|0
6306017|NCT02589665|10032361|FG002|Induction Period|Adverse Event|2
6306018|NCT02589665|10032362|FG003|Induction Period|Adverse Event|2
6306019|NCT02589665|10032363|FG004|Induction Period|Adverse Event|0
6306020|NCT02589665|10032364|FG005|Induction Period|Adverse Event|0
6306021|NCT02589665|10032365|FG006|Induction Period|Adverse Event|0
6306022|NCT02589665|10032366|FG007|Induction Period|Adverse Event|0
6306023|NCT02589665|10032367|FG008|Induction Period|Adverse Event|0
6306024|NCT02589665|10032368|FG009|Induction Period|Adverse Event|0
6306025|NCT02589665|10032359|FG000|Induction Period|Withdrawal by Subject|0
6306026|NCT02589665|10032360|FG001|Induction Period|Withdrawal by Subject|1
6306027|NCT02589665|10032361|FG002|Induction Period|Withdrawal by Subject|0
6306028|NCT02589665|10032362|FG003|Induction Period|Withdrawal by Subject|1
6306029|NCT02589665|10032363|FG004|Induction Period|Withdrawal by Subject|0
6306030|NCT02589665|10032364|FG005|Induction Period|Withdrawal by Subject|0
6064078|NCT00509899|9665535|FG002|Overall Study|Death|3
6064079|NCT00509899|9665536|FG003|Overall Study|Death|0
6064080|NCT00509899|9665537|FG004|Overall Study|Death|1
6064081|NCT00509899|9665538|FG005|Overall Study|Death|1
6064082|NCT00509899|9665539|FG006|Overall Study|Death|1
6064083|NCT00509899|9665540|FG007|Overall Study|Death|1
6064084|NCT00509899|9665533|FG000|Overall Study|Lack of Efficacy|1
6064085|NCT00509899|9665534|FG001|Overall Study|Lack of Efficacy|0
6064086|NCT00509899|9665535|FG002|Overall Study|Lack of Efficacy|2
6064087|NCT00509899|9665536|FG003|Overall Study|Lack of Efficacy|0
6064088|NCT00509899|9665537|FG004|Overall Study|Lack of Efficacy|0
6064089|NCT00509899|9665538|FG005|Overall Study|Lack of Efficacy|1
6064090|NCT00509899|9665539|FG006|Overall Study|Lack of Efficacy|0
6064091|NCT00509899|9665540|FG007|Overall Study|Lack of Efficacy|0
6064092|NCT00509925|9665554|FG000|Overall Study|Personal reasons|0
6064093|NCT00509925|9665555|FG001|Overall Study|Personal reasons|1
6064094|NCT00510068|9665565|FG000|Double-blind Period|Disease progression|98
6064095|NCT00510068|9665566|FG001|Double-blind Period|Disease progression|169
6064096|NCT00510068|9665565|FG000|Double-blind Period|Final primary analysis|52
6064097|NCT00510068|9665566|FG001|Double-blind Period|Final primary analysis|18
6064098|NCT00510068|9665565|FG000|Double-blind Period|Adverse Event|37
6064099|NCT00510068|9665566|FG001|Double-blind Period|Adverse Event|7
6064100|NCT00510068|9665565|FG000|Double-blind Period|Withdrawal by Subject|8
6064101|NCT00510068|9665566|FG001|Double-blind Period|Withdrawal by Subject|6
6064102|NCT00510068|9665565|FG000|Double-blind Period|Death|4
6064103|NCT00510068|9665566|FG001|Double-blind Period|Death|3
6064104|NCT00510068|9665565|FG000|Double-blind Period|Abnormal test result (s)|1
6064105|NCT00510068|9665566|FG001|Double-blind Period|Abnormal test result (s)|0
6064106|NCT00510068|9665565|FG000|Double-blind Period|Lost to Follow-up|1
6064107|NCT00510068|9665566|FG001|Double-blind Period|Lost to Follow-up|0
6306031|NCT02589665|10032365|FG006|Induction Period|Withdrawal by Subject|0
6306032|NCT02589665|10032366|FG007|Induction Period|Withdrawal by Subject|0
6306033|NCT02589665|10032367|FG008|Induction Period|Withdrawal by Subject|0
6306034|NCT02589665|10032368|FG009|Induction Period|Withdrawal by Subject|0
6306035|NCT02589665|10032359|FG000|Induction Period|Protocol Violation|0
6306036|NCT02589665|10032360|FG001|Induction Period|Protocol Violation|1
6306037|NCT02589665|10032361|FG002|Induction Period|Protocol Violation|0
6306038|NCT02589665|10032362|FG003|Induction Period|Protocol Violation|0
6306039|NCT02589665|10032363|FG004|Induction Period|Protocol Violation|0
6306040|NCT02589665|10032364|FG005|Induction Period|Protocol Violation|0
6306041|NCT02589665|10032365|FG006|Induction Period|Protocol Violation|0
6306042|NCT02589665|10032366|FG007|Induction Period|Protocol Violation|0
6306043|NCT02589665|10032367|FG008|Induction Period|Protocol Violation|0
6306044|NCT02589665|10032368|FG009|Induction Period|Protocol Violation|0
6306045|NCT02589665|10032359|FG000|Maintenance Period|Rolled Over to Study AMAP (NCT03519945)|0
6306046|NCT02589665|10032360|FG001|Maintenance Period|Rolled Over to Study AMAP (NCT03519945)|0
6306047|NCT02589665|10032361|FG002|Maintenance Period|Rolled Over to Study AMAP (NCT03519945)|0
6306048|NCT02589665|10032362|FG003|Maintenance Period|Rolled Over to Study AMAP (NCT03519945)|0
6306049|NCT02589665|10032363|FG004|Maintenance Period|Rolled Over to Study AMAP (NCT03519945)|7
6306050|NCT02589665|10032364|FG005|Maintenance Period|Rolled Over to Study AMAP (NCT03519945)|41
6306051|NCT02589665|10032365|FG006|Maintenance Period|Rolled Over to Study AMAP (NCT03519945)|39
6306052|NCT02589665|10032366|FG007|Maintenance Period|Rolled Over to Study AMAP (NCT03519945)|0
6306053|NCT02589665|10032367|FG008|Maintenance Period|Rolled Over to Study AMAP (NCT03519945)|0
6306054|NCT02589665|10032368|FG009|Maintenance Period|Rolled Over to Study AMAP (NCT03519945)|0
6306055|NCT02589665|10032359|FG000|Maintenance Period|Withdrawal by Subject|0
6306056|NCT02589665|10032360|FG001|Maintenance Period|Withdrawal by Subject|0
6306057|NCT02589665|10032361|FG002|Maintenance Period|Withdrawal by Subject|0
6306058|NCT02589665|10032362|FG003|Maintenance Period|Withdrawal by Subject|0
6306059|NCT02589665|10032363|FG004|Maintenance Period|Withdrawal by Subject|4
6306060|NCT02589665|10032364|FG005|Maintenance Period|Withdrawal by Subject|2
6306061|NCT02589665|10032365|FG006|Maintenance Period|Withdrawal by Subject|4
6306062|NCT02589665|10032366|FG007|Maintenance Period|Withdrawal by Subject|0
6306063|NCT02589665|10032367|FG008|Maintenance Period|Withdrawal by Subject|0
6306064|NCT02589665|10032368|FG009|Maintenance Period|Withdrawal by Subject|0
6306065|NCT02589665|10032359|FG000|Maintenance Period|Lack of Efficacy|0
6306066|NCT02589665|10032360|FG001|Maintenance Period|Lack of Efficacy|0
6306067|NCT02589665|10032361|FG002|Maintenance Period|Lack of Efficacy|0
6306068|NCT02589665|10032362|FG003|Maintenance Period|Lack of Efficacy|0
6306069|NCT02589665|10032363|FG004|Maintenance Period|Lack of Efficacy|2
6306070|NCT02589665|10032364|FG005|Maintenance Period|Lack of Efficacy|1
6306071|NCT02589665|10032365|FG006|Maintenance Period|Lack of Efficacy|0
6306072|NCT02589665|10032366|FG007|Maintenance Period|Lack of Efficacy|0
6306073|NCT02589665|10032367|FG008|Maintenance Period|Lack of Efficacy|0
6306074|NCT02589665|10032368|FG009|Maintenance Period|Lack of Efficacy|0
6306075|NCT02589665|10032359|FG000|Maintenance Period|Adverse Event|0
6306076|NCT02589665|10032360|FG001|Maintenance Period|Adverse Event|0
6306077|NCT02589665|10032361|FG002|Maintenance Period|Adverse Event|0
6306078|NCT02589665|10032362|FG003|Maintenance Period|Adverse Event|0
6306079|NCT02589665|10032363|FG004|Maintenance Period|Adverse Event|0
6306080|NCT02589665|10032364|FG005|Maintenance Period|Adverse Event|0
6306081|NCT02589665|10032365|FG006|Maintenance Period|Adverse Event|2
6306082|NCT02589665|10032366|FG007|Maintenance Period|Adverse Event|0
6306083|NCT02589665|10032367|FG008|Maintenance Period|Adverse Event|0
6306084|NCT02589665|10032368|FG009|Maintenance Period|Adverse Event|0
6306085|NCT02589665|10032359|FG000|Maintenance Period|Lost to Follow-up|0
6306086|NCT02589665|10032360|FG001|Maintenance Period|Lost to Follow-up|0
6306087|NCT02589665|10032361|FG002|Maintenance Period|Lost to Follow-up|0
6306088|NCT02589665|10032362|FG003|Maintenance Period|Lost to Follow-up|0
6306089|NCT02589665|10032363|FG004|Maintenance Period|Lost to Follow-up|0
6306090|NCT02589665|10032364|FG005|Maintenance Period|Lost to Follow-up|1
6306091|NCT02589665|10032365|FG006|Maintenance Period|Lost to Follow-up|0
6306092|NCT02589665|10032366|FG007|Maintenance Period|Lost to Follow-up|0
6306093|NCT02589665|10032367|FG008|Maintenance Period|Lost to Follow-up|0
6306094|NCT02589665|10032368|FG009|Maintenance Period|Lost to Follow-up|0
6306095|NCT02589665|10032359|FG000|Maintenance Period|Physician Decision|0
6306096|NCT02589665|10032360|FG001|Maintenance Period|Physician Decision|0
6306097|NCT02589665|10032361|FG002|Maintenance Period|Physician Decision|0
6306098|NCT02589665|10032362|FG003|Maintenance Period|Physician Decision|0
6306099|NCT02589665|10032363|FG004|Maintenance Period|Physician Decision|0
6306100|NCT02589665|10032364|FG005|Maintenance Period|Physician Decision|1
6306101|NCT02589665|10032365|FG006|Maintenance Period|Physician Decision|0
6306102|NCT02589665|10032366|FG007|Maintenance Period|Physician Decision|0
6064108|NCT00510068|9665565|FG000|Double-blind Period|Protocol Violation|6
6306103|NCT02589665|10032367|FG008|Maintenance Period|Physician Decision|0
6306104|NCT02589665|10032368|FG009|Maintenance Period|Physician Decision|0
6306105|NCT02589665|10032359|FG000|Maintenance Period|Reason Not Collected|0
6306106|NCT02589665|10032360|FG001|Maintenance Period|Reason Not Collected|0
6306107|NCT02589665|10032361|FG002|Maintenance Period|Reason Not Collected|0
6306108|NCT02589665|10032362|FG003|Maintenance Period|Reason Not Collected|0
6306109|NCT02589665|10032363|FG004|Maintenance Period|Reason Not Collected|0
6306110|NCT02589665|10032364|FG005|Maintenance Period|Reason Not Collected|1
6306111|NCT02589665|10032365|FG006|Maintenance Period|Reason Not Collected|1
6306112|NCT02589665|10032366|FG007|Maintenance Period|Reason Not Collected|0
6306113|NCT02589665|10032367|FG008|Maintenance Period|Reason Not Collected|0
6306114|NCT02589665|10032368|FG009|Maintenance Period|Reason Not Collected|0
6306115|NCT02589665|10032359|FG000|Induction Extension Period|Adverse Event|0
6306116|NCT02589665|10032360|FG001|Induction Extension Period|Adverse Event|0
6306117|NCT02589665|10032361|FG002|Induction Extension Period|Adverse Event|0
6064109|NCT00510068|9665566|FG001|Double-blind Period|Protocol Violation|0
6064110|NCT00510068|9665565|FG000|Open-label Period|Disease Progression|124
6064111|NCT00510068|9665566|FG001|Open-label Period|Disease Progression|0
6064112|NCT00510068|9665565|FG000|Open-label Period|Adverse Event|46
6064113|NCT00510068|9665566|FG001|Open-label Period|Adverse Event|0
6064114|NCT00510068|9665565|FG000|Open-label Period|Withdrawal by Subject|21
6064115|NCT00510068|9665566|FG001|Open-label Period|Withdrawal by Subject|0
6064116|NCT00510068|9665565|FG000|Open-label Period|Administrative problems|17
6064117|NCT00510068|9665566|FG001|Open-label Period|Administrative problems|0
6064118|NCT00510068|9665565|FG000|Open-label Period|Death|7
6064119|NCT00510068|9665566|FG001|Open-label Period|Death|0
6064120|NCT00510068|9665565|FG000|Open-label Period|New cancer therapy|7
6064121|NCT00510068|9665566|FG001|Open-label Period|New cancer therapy|0
6064122|NCT00510068|9665565|FG000|Open-label Period|Protocol Violation|2
6064123|NCT00510068|9665566|FG001|Open-label Period|Protocol Violation|0
6064124|NCT00510068|9665565|FG000|Open-label Period|Abnormal laboratory value (s)|1
6064125|NCT00510068|9665566|FG001|Open-label Period|Abnormal laboratory value (s)|0
6064126|NCT00510146|9665576|FG000|Double-Blind Treatment|Adverse Event|30
6064127|NCT00510146|9665577|FG001|Double-Blind Treatment|Adverse Event|13
6064128|NCT00510146|9665576|FG000|Double-Blind Treatment|Lack of Efficacy|6
6064129|NCT00510146|9665577|FG001|Double-Blind Treatment|Lack of Efficacy|13
6064130|NCT00510146|9665576|FG000|Double-Blind Treatment|Lost to Follow-up|3
6064131|NCT00510146|9665577|FG001|Double-Blind Treatment|Lost to Follow-up|7
6064132|NCT00510146|9665576|FG000|Double-Blind Treatment|Physician Decision|6
6064133|NCT00510146|9665577|FG001|Double-Blind Treatment|Physician Decision|0
6064134|NCT00510146|9665576|FG000|Double-Blind Treatment|Protocol Violation|1
6064135|NCT00510146|9665577|FG001|Double-Blind Treatment|Protocol Violation|2
6064136|NCT00510146|9665576|FG000|Double-Blind Treatment|Withdrawal by Subject|27
6064137|NCT00510146|9665577|FG001|Double-Blind Treatment|Withdrawal by Subject|13
6064138|NCT00510146|9665576|FG000|Double-Blind Treatment|Clinical Relapse|0
6064139|NCT00510146|9665577|FG001|Double-Blind Treatment|Clinical Relapse|1
6064140|NCT00510146|9665576|FG000|Double-Blind Treatment|Entry Criteria Not Met|3
6064141|NCT00510146|9665577|FG001|Double-Blind Treatment|Entry Criteria Not Met|0
6064142|NCT00510146|9665576|FG000|Open-Label Treatment|Adverse Event|22
6064143|NCT00510146|9665577|FG001|Open-Label Treatment|Adverse Event|8
6064144|NCT00510146|9665576|FG000|Open-Label Treatment|Death|1
6064145|NCT00510146|9665577|FG001|Open-Label Treatment|Death|1
6064146|NCT00510146|9665576|FG000|Open-Label Treatment|Lack of Efficacy|4
6064147|NCT00510146|9665577|FG001|Open-Label Treatment|Lack of Efficacy|0
6064148|NCT00510146|9665576|FG000|Open-Label Treatment|Lost to Follow-up|10
6064149|NCT00510146|9665577|FG001|Open-Label Treatment|Lost to Follow-up|1
6064150|NCT00510146|9665576|FG000|Open-Label Treatment|Physician Decision|3
6064151|NCT00510146|9665577|FG001|Open-Label Treatment|Physician Decision|1
6064152|NCT00510146|9665576|FG000|Open-Label Treatment|Protocol Violation|4
6064153|NCT00510146|9665577|FG001|Open-Label Treatment|Protocol Violation|2
6064154|NCT00510146|9665576|FG000|Open-Label Treatment|Withdrawal by Subject|24
6064155|NCT00510146|9665577|FG001|Open-Label Treatment|Withdrawal by Subject|12
6064156|NCT00510146|9665576|FG000|Open-Label Treatment|Clinical Relapse|1
6064157|NCT00510146|9665577|FG001|Open-Label Treatment|Clinical Relapse|1
6064158|NCT00510146|9665576|FG000|Open-Label Treatment|Sponsor Decision|2
6064159|NCT00510146|9665577|FG001|Open-Label Treatment|Sponsor Decision|0
6064160|NCT00510198|9665587|FG000|Overall Study|Withdrawal by Subject|5
6064161|NCT00510198|9665588|FG001|Overall Study|Withdrawal by Subject|4
6064162|NCT00510276|9665602|FG000|Acute Double-Blind Phase|Adverse Event|21
6064163|NCT00510276|9665603|FG001|Acute Double-Blind Phase|Adverse Event|6
6064164|NCT00510276|9665602|FG000|Acute Double-Blind Phase|Entry Criteria Not Met|1
6064165|NCT00510276|9665603|FG001|Acute Double-Blind Phase|Entry Criteria Not Met|1
6064166|NCT00510276|9665602|FG000|Acute Double-Blind Phase|Lack of Efficacy|3
6064167|NCT00510276|9665603|FG001|Acute Double-Blind Phase|Lack of Efficacy|4
6064168|NCT00510276|9665602|FG000|Acute Double-Blind Phase|Lost to Follow-up|48
6064169|NCT00510276|9665603|FG001|Acute Double-Blind Phase|Lost to Follow-up|49
6064170|NCT00510276|9665602|FG000|Acute Double-Blind Phase|Physician Decision|0
6064171|NCT00510276|9665603|FG001|Acute Double-Blind Phase|Physician Decision|3
6064172|NCT00510276|9665602|FG000|Acute Double-Blind Phase|Protocol Violation|4
6064173|NCT00510276|9665603|FG001|Acute Double-Blind Phase|Protocol Violation|3
6064174|NCT00510276|9665602|FG000|Acute Double-Blind Phase|Sponsor Decision|2
6064175|NCT00510276|9665603|FG001|Acute Double-Blind Phase|Sponsor Decision|1
6064176|NCT00510276|9665602|FG000|Acute Double-Blind Phase|Subject Decision|26
6064177|NCT00510276|9665603|FG001|Acute Double-Blind Phase|Subject Decision|28
6064178|NCT00510276|9665602|FG000|Extension Open-Label Phase|Adverse Event|9
6064179|NCT00510276|9665603|FG001|Extension Open-Label Phase|Adverse Event|18
6064180|NCT00510276|9665602|FG000|Extension Open-Label Phase|Lack of Efficacy|2
6064181|NCT00510276|9665603|FG001|Extension Open-Label Phase|Lack of Efficacy|7
6064182|NCT00510276|9665602|FG000|Extension Open-Label Phase|Lost to Follow-up|12
6064183|NCT00510276|9665603|FG001|Extension Open-Label Phase|Lost to Follow-up|10
6064184|NCT00510276|9665602|FG000|Extension Open-Label Phase|Physician Decision|2
6306118|NCT02589665|10032362|FG003|Induction Extension Period|Adverse Event|0
6306119|NCT02589665|10032363|FG004|Induction Extension Period|Adverse Event|0
6306120|NCT02589665|10032364|FG005|Induction Extension Period|Adverse Event|0
6306121|NCT02589665|10032365|FG006|Induction Extension Period|Adverse Event|0
6306122|NCT02589665|10032366|FG007|Induction Extension Period|Adverse Event|0
6306123|NCT02589665|10032367|FG008|Induction Extension Period|Adverse Event|4
6306124|NCT02589665|10032368|FG009|Induction Extension Period|Adverse Event|0
6306125|NCT02589665|10032359|FG000|Induction Extension Period|Lack of Efficacy|0
6306126|NCT02589665|10032360|FG001|Induction Extension Period|Lack of Efficacy|0
6306127|NCT02589665|10032361|FG002|Induction Extension Period|Lack of Efficacy|0
6306128|NCT02589665|10032362|FG003|Induction Extension Period|Lack of Efficacy|0
6306129|NCT02589665|10032363|FG004|Induction Extension Period|Lack of Efficacy|0
6306130|NCT02589665|10032364|FG005|Induction Extension Period|Lack of Efficacy|0
6306131|NCT02589665|10032365|FG006|Induction Extension Period|Lack of Efficacy|0
6306132|NCT02589665|10032366|FG007|Induction Extension Period|Lack of Efficacy|0
6306133|NCT02589665|10032367|FG008|Induction Extension Period|Lack of Efficacy|3
6306134|NCT02589665|10032368|FG009|Induction Extension Period|Lack of Efficacy|0
6306135|NCT02589665|10032359|FG000|Induction Extension Period|Withdrawal by Subject|0
6306136|NCT02589665|10032360|FG001|Induction Extension Period|Withdrawal by Subject|0
6306137|NCT02589665|10032361|FG002|Induction Extension Period|Withdrawal by Subject|0
6306138|NCT02589665|10032362|FG003|Induction Extension Period|Withdrawal by Subject|0
6306139|NCT02589665|10032363|FG004|Induction Extension Period|Withdrawal by Subject|0
6306140|NCT02589665|10032364|FG005|Induction Extension Period|Withdrawal by Subject|0
6306141|NCT02589665|10032365|FG006|Induction Extension Period|Withdrawal by Subject|0
6306142|NCT02589665|10032366|FG007|Induction Extension Period|Withdrawal by Subject|2
6306143|NCT02589665|10032367|FG008|Induction Extension Period|Withdrawal by Subject|3
6306144|NCT02589665|10032368|FG009|Induction Extension Period|Withdrawal by Subject|0
6306145|NCT02589665|10032359|FG000|Induction Extension Period|Physician Decision|0
6306146|NCT02589665|10032360|FG001|Induction Extension Period|Physician Decision|0
6306147|NCT02589665|10032361|FG002|Induction Extension Period|Physician Decision|0
6306148|NCT02589665|10032362|FG003|Induction Extension Period|Physician Decision|0
6306149|NCT02589665|10032363|FG004|Induction Extension Period|Physician Decision|0
6306150|NCT02589665|10032364|FG005|Induction Extension Period|Physician Decision|0
6306151|NCT02589665|10032365|FG006|Induction Extension Period|Physician Decision|0
6306152|NCT02589665|10032366|FG007|Induction Extension Period|Physician Decision|0
6306153|NCT02589665|10032367|FG008|Induction Extension Period|Physician Decision|1
6306154|NCT02589665|10032368|FG009|Induction Extension Period|Physician Decision|0
6306155|NCT02589665|10032359|FG000|Induction Extension Period|Reason Not Collected|0
6306156|NCT02589665|10032360|FG001|Induction Extension Period|Reason Not Collected|0
6306157|NCT02589665|10032361|FG002|Induction Extension Period|Reason Not Collected|0
6306158|NCT02589665|10032362|FG003|Induction Extension Period|Reason Not Collected|0
6306159|NCT02589665|10032363|FG004|Induction Extension Period|Reason Not Collected|0
6306160|NCT02589665|10032364|FG005|Induction Extension Period|Reason Not Collected|0
6306161|NCT02589665|10032365|FG006|Induction Extension Period|Reason Not Collected|0
6306162|NCT02589665|10032366|FG007|Induction Extension Period|Reason Not Collected|0
6306163|NCT02589665|10032367|FG008|Induction Extension Period|Reason Not Collected|1
6306164|NCT02589665|10032368|FG009|Induction Extension Period|Reason Not Collected|0
6306165|NCT02589665|10032359|FG000|Maintenance Extension Period|Rolled Over to Study AMAP (NCT03519945)|0
6306166|NCT02589665|10032360|FG001|Maintenance Extension Period|Rolled Over to Study AMAP (NCT03519945)|0
6306167|NCT02589665|10032361|FG002|Maintenance Extension Period|Rolled Over to Study AMAP (NCT03519945)|0
6306168|NCT02589665|10032362|FG003|Maintenance Extension Period|Rolled Over to Study AMAP (NCT03519945)|0
6306169|NCT02589665|10032363|FG004|Maintenance Extension Period|Rolled Over to Study AMAP (NCT03519945)|0
6306170|NCT02589665|10032364|FG005|Maintenance Extension Period|Rolled Over to Study AMAP (NCT03519945)|0
6306171|NCT02589665|10032365|FG006|Maintenance Extension Period|Rolled Over to Study AMAP (NCT03519945)|0
6306172|NCT02589665|10032366|FG007|Maintenance Extension Period|Rolled Over to Study AMAP (NCT03519945)|0
6306173|NCT02589665|10032367|FG008|Maintenance Extension Period|Rolled Over to Study AMAP (NCT03519945)|0
6306174|NCT02589665|10032368|FG009|Maintenance Extension Period|Rolled Over to Study AMAP (NCT03519945)|57
6306175|NCT02589665|10032359|FG000|Maintenance Extension Period|Withdrawal by Subject|0
6306176|NCT02589665|10032360|FG001|Maintenance Extension Period|Withdrawal by Subject|0
6306177|NCT02589665|10032361|FG002|Maintenance Extension Period|Withdrawal by Subject|0
6306178|NCT02589665|10032362|FG003|Maintenance Extension Period|Withdrawal by Subject|0
6306179|NCT02589665|10032363|FG004|Maintenance Extension Period|Withdrawal by Subject|0
6306180|NCT02589665|10032364|FG005|Maintenance Extension Period|Withdrawal by Subject|0
6306181|NCT02589665|10032365|FG006|Maintenance Extension Period|Withdrawal by Subject|0
6306182|NCT02589665|10032366|FG007|Maintenance Extension Period|Withdrawal by Subject|0
6306183|NCT02589665|10032367|FG008|Maintenance Extension Period|Withdrawal by Subject|0
6306184|NCT02589665|10032368|FG009|Maintenance Extension Period|Withdrawal by Subject|4
6306185|NCT02589665|10032359|FG000|Maintenance Extension Period|Lack of Efficacy|0
6306186|NCT02589665|10032360|FG001|Maintenance Extension Period|Lack of Efficacy|0
6306187|NCT02589665|10032361|FG002|Maintenance Extension Period|Lack of Efficacy|0
6306188|NCT02589665|10032362|FG003|Maintenance Extension Period|Lack of Efficacy|0
6306189|NCT02589665|10032363|FG004|Maintenance Extension Period|Lack of Efficacy|0
6306190|NCT02589665|10032364|FG005|Maintenance Extension Period|Lack of Efficacy|0
6306191|NCT02589665|10032365|FG006|Maintenance Extension Period|Lack of Efficacy|0
6306192|NCT02589665|10032366|FG007|Maintenance Extension Period|Lack of Efficacy|0
6306193|NCT02589665|10032367|FG008|Maintenance Extension Period|Lack of Efficacy|0
6306194|NCT02589665|10032368|FG009|Maintenance Extension Period|Lack of Efficacy|4
6306195|NCT02589665|10032359|FG000|Maintenance Extension Period|Adverse Event|0
6306196|NCT02589665|10032360|FG001|Maintenance Extension Period|Adverse Event|0
6306197|NCT02589665|10032361|FG002|Maintenance Extension Period|Adverse Event|0
6306198|NCT02589665|10032362|FG003|Maintenance Extension Period|Adverse Event|0
6306199|NCT02589665|10032363|FG004|Maintenance Extension Period|Adverse Event|0
6306200|NCT02589665|10032364|FG005|Maintenance Extension Period|Adverse Event|0
6306201|NCT02589665|10032365|FG006|Maintenance Extension Period|Adverse Event|0
6306202|NCT02589665|10032366|FG007|Maintenance Extension Period|Adverse Event|0
6306203|NCT02589665|10032367|FG008|Maintenance Extension Period|Adverse Event|0
6306204|NCT02589665|10032368|FG009|Maintenance Extension Period|Adverse Event|2
6306205|NCT02589665|10032359|FG000|Maintenance Extension Period|Non-responder|0
6306206|NCT02589665|10032360|FG001|Maintenance Extension Period|Non-responder|0
6306207|NCT02589665|10032361|FG002|Maintenance Extension Period|Non-responder|0
6306208|NCT02589665|10032362|FG003|Maintenance Extension Period|Non-responder|0
6306209|NCT02589665|10032363|FG004|Maintenance Extension Period|Non-responder|0
6306210|NCT02589665|10032364|FG005|Maintenance Extension Period|Non-responder|0
6306211|NCT02589665|10032365|FG006|Maintenance Extension Period|Non-responder|0
6306212|NCT02589665|10032366|FG007|Maintenance Extension Period|Non-responder|0
6306213|NCT02589665|10032367|FG008|Maintenance Extension Period|Non-responder|0
6306214|NCT02589665|10032368|FG009|Maintenance Extension Period|Non-responder|1
6306215|NCT02590003|10032421|FG000|Overall Study|Death|1
6306216|NCT02590003|10032422|FG001|Overall Study|Death|2
6306217|NCT02590354|10032428|FG000|Phase 1|Active hepatitis B or C infection|1
6306218|NCT02590354|10032428|FG000|Phase 1|Confirmed neutrophil count <1200/µl|1
6306219|NCT02590354|10032428|FG000|Phase 1|Detectable level of HIV DNA or caRNA|75
6306220|NCT02590354|10032428|FG000|Phase 1|Subject does not want to participate|20
6306221|NCT02590354|10032428|FG000|Phase 1|Lost to Follow-up|1
6306222|NCT02590354|10032428|FG000|Phase 2 - Treatment Interruption|Lost to Follow-up|2
6306223|NCT02590406|10032435|FG000|Overall Study|Adverse Event|1
6306224|NCT02590406|10032436|FG001|Overall Study|Adverse Event|0
6306225|NCT02590406|10032435|FG000|Overall Study|Saturometer malfunction|0
6306226|NCT02590406|10032436|FG001|Overall Study|Saturometer malfunction|1
6306227|NCT02590432|10032444|FG000|Open-label Treatment Period|Adverse Event|97
6306228|NCT02590432|10032445|FG001|Open-label Treatment Period|Adverse Event|79
6306229|NCT02590432|10032446|FG002|Open-label Treatment Period|Adverse Event|0
6306230|NCT02590432|10032447|FG003|Open-label Treatment Period|Adverse Event|0
6306231|NCT02590432|10032448|FG004|Open-label Treatment Period|Adverse Event|0
6306232|NCT02590432|10032449|FG005|Open-label Treatment Period|Adverse Event|0
6306233|NCT02590432|10032450|FG006|Open-label Treatment Period|Adverse Event|0
6306234|NCT02590432|10032451|FG007|Open-label Treatment Period|Adverse Event|0
6306235|NCT02590432|10032452|FG008|Open-label Treatment Period|Adverse Event|0
6306236|NCT02590432|10032444|FG000|Open-label Treatment Period|Lack of Efficacy|14
6306237|NCT02590432|10032445|FG001|Open-label Treatment Period|Lack of Efficacy|5
6306238|NCT02590432|10032446|FG002|Open-label Treatment Period|Lack of Efficacy|0
6306239|NCT02590432|10032447|FG003|Open-label Treatment Period|Lack of Efficacy|0
6306240|NCT02590432|10032448|FG004|Open-label Treatment Period|Lack of Efficacy|0
6306241|NCT02590432|10032449|FG005|Open-label Treatment Period|Lack of Efficacy|0
6306242|NCT02590432|10032450|FG006|Open-label Treatment Period|Lack of Efficacy|0
6306243|NCT02590432|10032451|FG007|Open-label Treatment Period|Lack of Efficacy|0
6306244|NCT02590432|10032452|FG008|Open-label Treatment Period|Lack of Efficacy|0
6306245|NCT02590432|10032444|FG000|Open-label Treatment Period|Withdrawal of Consent|43
6306246|NCT02590432|10032445|FG001|Open-label Treatment Period|Withdrawal of Consent|28
6306247|NCT02590432|10032446|FG002|Open-label Treatment Period|Withdrawal of Consent|0
6306248|NCT02590432|10032447|FG003|Open-label Treatment Period|Withdrawal of Consent|0
6306249|NCT02590432|10032448|FG004|Open-label Treatment Period|Withdrawal of Consent|0
6306250|NCT02590432|10032449|FG005|Open-label Treatment Period|Withdrawal of Consent|0
6306251|NCT02590432|10032450|FG006|Open-label Treatment Period|Withdrawal of Consent|0
6306252|NCT02590432|10032451|FG007|Open-label Treatment Period|Withdrawal of Consent|0
6306253|NCT02590432|10032452|FG008|Open-label Treatment Period|Withdrawal of Consent|0
6306254|NCT02590432|10032444|FG000|Open-label Treatment Period|Lost to Follow-up|51
6306255|NCT02590432|10032445|FG001|Open-label Treatment Period|Lost to Follow-up|29
6306256|NCT02590432|10032446|FG002|Open-label Treatment Period|Lost to Follow-up|0
6306257|NCT02590432|10032447|FG003|Open-label Treatment Period|Lost to Follow-up|0
6306258|NCT02590432|10032448|FG004|Open-label Treatment Period|Lost to Follow-up|0
6306259|NCT02590432|10032449|FG005|Open-label Treatment Period|Lost to Follow-up|0
6306260|NCT02590432|10032450|FG006|Open-label Treatment Period|Lost to Follow-up|0
6306261|NCT02590432|10032451|FG007|Open-label Treatment Period|Lost to Follow-up|0
6306262|NCT02590432|10032452|FG008|Open-label Treatment Period|Lost to Follow-up|0
5982528|NCT02513485|9571481|FG000|Overall Study|Adverse Event|1
6306263|NCT02590432|10032444|FG000|Open-label Treatment Period|Protocol Violation|10
6306264|NCT02590432|10032445|FG001|Open-label Treatment Period|Protocol Violation|4
6306265|NCT02590432|10032446|FG002|Open-label Treatment Period|Protocol Violation|0
6306266|NCT02590432|10032447|FG003|Open-label Treatment Period|Protocol Violation|0
6306267|NCT02590432|10032448|FG004|Open-label Treatment Period|Protocol Violation|0
6306268|NCT02590432|10032449|FG005|Open-label Treatment Period|Protocol Violation|0
6306269|NCT02590432|10032450|FG006|Open-label Treatment Period|Protocol Violation|0
6306270|NCT02590432|10032451|FG007|Open-label Treatment Period|Protocol Violation|0
6306271|NCT02590432|10032452|FG008|Open-label Treatment Period|Protocol Violation|0
6306272|NCT02590432|10032444|FG000|Open-label Treatment Period|Non-compliance with Study Drug|7
6306273|NCT02590432|10032445|FG001|Open-label Treatment Period|Non-compliance with Study Drug|1
6306274|NCT02590432|10032446|FG002|Open-label Treatment Period|Non-compliance with Study Drug|0
6306275|NCT02590432|10032447|FG003|Open-label Treatment Period|Non-compliance with Study Drug|0
6306276|NCT02590432|10032448|FG004|Open-label Treatment Period|Non-compliance with Study Drug|0
6306277|NCT02590432|10032449|FG005|Open-label Treatment Period|Non-compliance with Study Drug|0
6306278|NCT02590432|10032450|FG006|Open-label Treatment Period|Non-compliance with Study Drug|0
6306279|NCT02590432|10032451|FG007|Open-label Treatment Period|Non-compliance with Study Drug|0
6306280|NCT02590432|10032452|FG008|Open-label Treatment Period|Non-compliance with Study Drug|0
6306281|NCT02590432|10032444|FG000|Open-label Treatment Period|Other Miscellaneous Reasons|10
6306282|NCT02590432|10032445|FG001|Open-label Treatment Period|Other Miscellaneous Reasons|6
6306283|NCT02590432|10032446|FG002|Open-label Treatment Period|Other Miscellaneous Reasons|0
6306284|NCT02590432|10032447|FG003|Open-label Treatment Period|Other Miscellaneous Reasons|0
6306285|NCT02590432|10032448|FG004|Open-label Treatment Period|Other Miscellaneous Reasons|0
6306286|NCT02590432|10032449|FG005|Open-label Treatment Period|Other Miscellaneous Reasons|0
6306287|NCT02590432|10032450|FG006|Open-label Treatment Period|Other Miscellaneous Reasons|0
6306288|NCT02590432|10032451|FG007|Open-label Treatment Period|Other Miscellaneous Reasons|0
6306289|NCT02590432|10032452|FG008|Open-label Treatment Period|Other Miscellaneous Reasons|0
6306290|NCT02590432|10032444|FG000|Double-blind Treatment Period|Adverse Event|0
6306291|NCT02590432|10032445|FG001|Double-blind Treatment Period|Adverse Event|0
6306292|NCT02590432|10032446|FG002|Double-blind Treatment Period|Adverse Event|14
6306293|NCT02590432|10032447|FG003|Double-blind Treatment Period|Adverse Event|12
6306294|NCT02590432|10032448|FG004|Double-blind Treatment Period|Adverse Event|6
6306295|NCT02590432|10032449|FG005|Double-blind Treatment Period|Adverse Event|22
6306296|NCT02590432|10032450|FG006|Double-blind Treatment Period|Adverse Event|20
6306297|NCT02590432|10032451|FG007|Double-blind Treatment Period|Adverse Event|0
6306298|NCT02590432|10032452|FG008|Double-blind Treatment Period|Adverse Event|0
6306299|NCT02590432|10032444|FG000|Double-blind Treatment Period|Lack of Efficacy|0
6306300|NCT02590432|10032445|FG001|Double-blind Treatment Period|Lack of Efficacy|0
6306301|NCT02590432|10032446|FG002|Double-blind Treatment Period|Lack of Efficacy|1
6306302|NCT02590432|10032447|FG003|Double-blind Treatment Period|Lack of Efficacy|0
6306303|NCT02590432|10032448|FG004|Double-blind Treatment Period|Lack of Efficacy|0
6306304|NCT02590432|10032449|FG005|Double-blind Treatment Period|Lack of Efficacy|0
6306305|NCT02590432|10032450|FG006|Double-blind Treatment Period|Lack of Efficacy|0
6306306|NCT02590432|10032451|FG007|Double-blind Treatment Period|Lack of Efficacy|0
6306307|NCT02590432|10032452|FG008|Double-blind Treatment Period|Lack of Efficacy|0
6306308|NCT02590432|10032444|FG000|Double-blind Treatment Period|Withdrawal of Consent|0
6306309|NCT02590432|10032445|FG001|Double-blind Treatment Period|Withdrawal of Consent|0
6306310|NCT02590432|10032446|FG002|Double-blind Treatment Period|Withdrawal of Consent|1
6306311|NCT02590432|10032447|FG003|Double-blind Treatment Period|Withdrawal of Consent|3
6306312|NCT02590432|10032448|FG004|Double-blind Treatment Period|Withdrawal of Consent|3
6306313|NCT02590432|10032449|FG005|Double-blind Treatment Period|Withdrawal of Consent|1
6306314|NCT02590432|10032450|FG006|Double-blind Treatment Period|Withdrawal of Consent|1
6306315|NCT02590432|10032451|FG007|Double-blind Treatment Period|Withdrawal of Consent|0
6306316|NCT02590432|10032452|FG008|Double-blind Treatment Period|Withdrawal of Consent|0
6306317|NCT02590432|10032444|FG000|Double-blind Treatment Period|Lost to Follow-up|0
6306318|NCT02590432|10032445|FG001|Double-blind Treatment Period|Lost to Follow-up|0
6306319|NCT02590432|10032446|FG002|Double-blind Treatment Period|Lost to Follow-up|1
6306320|NCT02590432|10032447|FG003|Double-blind Treatment Period|Lost to Follow-up|0
6306321|NCT02590432|10032448|FG004|Double-blind Treatment Period|Lost to Follow-up|0
6306322|NCT02590432|10032449|FG005|Double-blind Treatment Period|Lost to Follow-up|2
6306323|NCT02590432|10032450|FG006|Double-blind Treatment Period|Lost to Follow-up|0
6306324|NCT02590432|10032451|FG007|Double-blind Treatment Period|Lost to Follow-up|0
6306325|NCT02590432|10032452|FG008|Double-blind Treatment Period|Lost to Follow-up|0
6306326|NCT02590432|10032444|FG000|Double-blind Treatment Period|Non-compliance with Study Drug|0
6306327|NCT02590432|10032445|FG001|Double-blind Treatment Period|Non-compliance with Study Drug|0
6306328|NCT02590432|10032446|FG002|Double-blind Treatment Period|Non-compliance with Study Drug|0
6306329|NCT02590432|10032447|FG003|Double-blind Treatment Period|Non-compliance with Study Drug|0
6306330|NCT02590432|10032448|FG004|Double-blind Treatment Period|Non-compliance with Study Drug|0
6306331|NCT02590432|10032449|FG005|Double-blind Treatment Period|Non-compliance with Study Drug|1
6306332|NCT02590432|10032450|FG006|Double-blind Treatment Period|Non-compliance with Study Drug|0
6306333|NCT02590432|10032451|FG007|Double-blind Treatment Period|Non-compliance with Study Drug|0
6306334|NCT02590432|10032452|FG008|Double-blind Treatment Period|Non-compliance with Study Drug|0
6306335|NCT02590432|10032444|FG000|Dose-reduced Open Label Treatment Period|Adverse Event|0
6306336|NCT02590432|10032445|FG001|Dose-reduced Open Label Treatment Period|Adverse Event|0
6306337|NCT02590432|10032446|FG002|Dose-reduced Open Label Treatment Period|Adverse Event|0
6306338|NCT02590432|10032447|FG003|Dose-reduced Open Label Treatment Period|Adverse Event|0
6306339|NCT02590432|10032448|FG004|Dose-reduced Open Label Treatment Period|Adverse Event|0
6306340|NCT02590432|10032449|FG005|Dose-reduced Open Label Treatment Period|Adverse Event|0
6306341|NCT02590432|10032450|FG006|Dose-reduced Open Label Treatment Period|Adverse Event|0
6306342|NCT02590432|10032451|FG007|Dose-reduced Open Label Treatment Period|Adverse Event|12
6306343|NCT02590432|10032452|FG008|Dose-reduced Open Label Treatment Period|Adverse Event|15
6306344|NCT02590432|10032444|FG000|Dose-reduced Open Label Treatment Period|Lack of Efficacy|0
6306345|NCT02590432|10032445|FG001|Dose-reduced Open Label Treatment Period|Lack of Efficacy|0
6306346|NCT02590432|10032446|FG002|Dose-reduced Open Label Treatment Period|Lack of Efficacy|0
6306347|NCT02590432|10032447|FG003|Dose-reduced Open Label Treatment Period|Lack of Efficacy|0
6306348|NCT02590432|10032448|FG004|Dose-reduced Open Label Treatment Period|Lack of Efficacy|0
6306349|NCT02590432|10032449|FG005|Dose-reduced Open Label Treatment Period|Lack of Efficacy|0
6306350|NCT02590432|10032450|FG006|Dose-reduced Open Label Treatment Period|Lack of Efficacy|0
6306351|NCT02590432|10032451|FG007|Dose-reduced Open Label Treatment Period|Lack of Efficacy|1
6306352|NCT02590432|10032452|FG008|Dose-reduced Open Label Treatment Period|Lack of Efficacy|0
6306353|NCT02590432|10032444|FG000|Dose-reduced Open Label Treatment Period|Withdrawal of Consent|0
6306354|NCT02590432|10032445|FG001|Dose-reduced Open Label Treatment Period|Withdrawal of Consent|0
6306355|NCT02590432|10032446|FG002|Dose-reduced Open Label Treatment Period|Withdrawal of Consent|0
6306356|NCT02590432|10032447|FG003|Dose-reduced Open Label Treatment Period|Withdrawal of Consent|0
6306357|NCT02590432|10032448|FG004|Dose-reduced Open Label Treatment Period|Withdrawal of Consent|0
6306358|NCT02590432|10032449|FG005|Dose-reduced Open Label Treatment Period|Withdrawal of Consent|0
6306359|NCT02590432|10032450|FG006|Dose-reduced Open Label Treatment Period|Withdrawal of Consent|0
6306360|NCT02590432|10032451|FG007|Dose-reduced Open Label Treatment Period|Withdrawal of Consent|3
6306361|NCT02590432|10032452|FG008|Dose-reduced Open Label Treatment Period|Withdrawal of Consent|1
6306362|NCT02590432|10032444|FG000|Dose-reduced Open Label Treatment Period|Lost to Follow-up|0
6306363|NCT02590432|10032445|FG001|Dose-reduced Open Label Treatment Period|Lost to Follow-up|0
6306364|NCT02590432|10032446|FG002|Dose-reduced Open Label Treatment Period|Lost to Follow-up|0
6306365|NCT02590432|10032447|FG003|Dose-reduced Open Label Treatment Period|Lost to Follow-up|0
6306366|NCT02590432|10032448|FG004|Dose-reduced Open Label Treatment Period|Lost to Follow-up|0
6306367|NCT02590432|10032449|FG005|Dose-reduced Open Label Treatment Period|Lost to Follow-up|0
6306368|NCT02590432|10032450|FG006|Dose-reduced Open Label Treatment Period|Lost to Follow-up|0
6306369|NCT02590432|10032451|FG007|Dose-reduced Open Label Treatment Period|Lost to Follow-up|0
6306370|NCT02590432|10032452|FG008|Dose-reduced Open Label Treatment Period|Lost to Follow-up|1
6306371|NCT02590432|10032444|FG000|Dose-reduced Open Label Treatment Period|Protocol Violation|0
6306372|NCT02590432|10032445|FG001|Dose-reduced Open Label Treatment Period|Protocol Violation|0
6306373|NCT02590432|10032446|FG002|Dose-reduced Open Label Treatment Period|Protocol Violation|0
6306374|NCT02590432|10032447|FG003|Dose-reduced Open Label Treatment Period|Protocol Violation|0
6306375|NCT02590432|10032448|FG004|Dose-reduced Open Label Treatment Period|Protocol Violation|0
6306376|NCT02590432|10032449|FG005|Dose-reduced Open Label Treatment Period|Protocol Violation|0
6306377|NCT02590432|10032450|FG006|Dose-reduced Open Label Treatment Period|Protocol Violation|0
6306378|NCT02590432|10032451|FG007|Dose-reduced Open Label Treatment Period|Protocol Violation|0
6306379|NCT02590432|10032452|FG008|Dose-reduced Open Label Treatment Period|Protocol Violation|1
6306380|NCT02590432|10032444|FG000|Dose-reduced Open Label Treatment Period|Non-compliance with Study Drug|0
6306381|NCT02590432|10032445|FG001|Dose-reduced Open Label Treatment Period|Non-compliance with Study Drug|0
6306382|NCT02590432|10032446|FG002|Dose-reduced Open Label Treatment Period|Non-compliance with Study Drug|0
6306383|NCT02590432|10032447|FG003|Dose-reduced Open Label Treatment Period|Non-compliance with Study Drug|0
6306384|NCT02590432|10032448|FG004|Dose-reduced Open Label Treatment Period|Non-compliance with Study Drug|0
6306385|NCT02590432|10032449|FG005|Dose-reduced Open Label Treatment Period|Non-compliance with Study Drug|0
6306386|NCT02590432|10032450|FG006|Dose-reduced Open Label Treatment Period|Non-compliance with Study Drug|0
6306387|NCT02590432|10032451|FG007|Dose-reduced Open Label Treatment Period|Non-compliance with Study Drug|1
6306388|NCT02590432|10032452|FG008|Dose-reduced Open Label Treatment Period|Non-compliance with Study Drug|0
6306389|NCT02590432|10032444|FG000|Dose-reduced Open Label Treatment Period|Other Miscellaneous Reasons|0
6306390|NCT02590432|10032445|FG001|Dose-reduced Open Label Treatment Period|Other Miscellaneous Reasons|0
6306391|NCT02590432|10032446|FG002|Dose-reduced Open Label Treatment Period|Other Miscellaneous Reasons|0
6306392|NCT02590432|10032447|FG003|Dose-reduced Open Label Treatment Period|Other Miscellaneous Reasons|0
6306393|NCT02590432|10032448|FG004|Dose-reduced Open Label Treatment Period|Other Miscellaneous Reasons|0
6306394|NCT02590432|10032449|FG005|Dose-reduced Open Label Treatment Period|Other Miscellaneous Reasons|0
6306395|NCT02590432|10032450|FG006|Dose-reduced Open Label Treatment Period|Other Miscellaneous Reasons|0
6306396|NCT02590432|10032451|FG007|Dose-reduced Open Label Treatment Period|Other Miscellaneous Reasons|1
6306397|NCT02590432|10032452|FG008|Dose-reduced Open Label Treatment Period|Other Miscellaneous Reasons|0
6306398|NCT02590562|10032464|FG000|Overall Study|Did Not Meet the Inclusion Criteria|6
6306399|NCT02590588|10032474|FG000|Overall Study|Adverse Event|1
6306400|NCT02590939|10032480|FG000|Overall Study|Withdrawal by Subject|3
6306401|NCT02590939|10032481|FG001|Overall Study|Withdrawal by Subject|1
6306402|NCT02590939|10032480|FG000|Overall Study|Failed the nociceptive test|2
6306403|NCT02590939|10032481|FG001|Overall Study|Failed the nociceptive test|1
6306404|NCT02591238|10032495|FG000|Overall Study|Pregnancy|1
6306405|NCT02591238|10032496|FG001|Overall Study|Pregnancy|0
6306406|NCT02591238|10032497|FG002|Overall Study|Pregnancy|0
6306407|NCT02591238|10032498|FG003|Overall Study|Pregnancy|0
6306408|NCT02591238|10032495|FG000|Overall Study|Withdrawal by Subject|0
6306409|NCT02591238|10032496|FG001|Overall Study|Withdrawal by Subject|0
6306410|NCT02591238|10032497|FG002|Overall Study|Withdrawal by Subject|0
6306411|NCT02591238|10032498|FG003|Overall Study|Withdrawal by Subject|1
6306412|NCT02591238|10032495|FG000|Overall Study|influenza|0
6306413|NCT02591238|10032496|FG001|Overall Study|influenza|0
6306414|NCT02591238|10032497|FG002|Overall Study|influenza|0
6306415|NCT02591238|10032498|FG003|Overall Study|influenza|1
6306416|NCT02591238|10032495|FG000|Overall Study|personal circumstances|0
6306417|NCT02591238|10032496|FG001|Overall Study|personal circumstances|0
6306418|NCT02591238|10032497|FG002|Overall Study|personal circumstances|0
6306419|NCT02591238|10032498|FG003|Overall Study|personal circumstances|1
6306420|NCT02591238|10032495|FG000|Overall Study|personal circumstances|0
6306421|NCT02591238|10032496|FG001|Overall Study|personal circumstances|1
6306422|NCT02591238|10032497|FG002|Overall Study|personal circumstances|0
6306423|NCT02591238|10032498|FG003|Overall Study|personal circumstances|0
6306424|NCT02591290|10032508|FG000|Overall Study|Withdrawal by Subject|2
6306425|NCT02592018|10032531|FG000|Overall Study|Adverse Event|1
6306426|NCT02592018|10032531|FG000|Overall Study|Lost to Follow-up|1
6306427|NCT02592434|10032544|FG000|Open-Label Phase (18 Weeks)|Adverse Event|12
6306428|NCT02592434|10032545|FG001|Open-Label Phase (18 Weeks)|Adverse Event|0
6306429|NCT02592434|10032546|FG002|Open-Label Phase (18 Weeks)|Adverse Event|0
6306430|NCT02592434|10032544|FG000|Open-Label Phase (18 Weeks)|Insufficient Clinical Response|21
6306431|NCT02592434|10032545|FG001|Open-Label Phase (18 Weeks)|Insufficient Clinical Response|0
6306432|NCT02592434|10032546|FG002|Open-Label Phase (18 Weeks)|Insufficient Clinical Response|0
6306433|NCT02592434|10032544|FG000|Open-Label Phase (18 Weeks)|Other|3
6306434|NCT02592434|10032545|FG001|Open-Label Phase (18 Weeks)|Other|0
6306435|NCT02592434|10032546|FG002|Open-Label Phase (18 Weeks)|Other|0
6306436|NCT02592434|10032544|FG000|Open-Label Phase (18 Weeks)|Protocol Deviation|4
6306437|NCT02592434|10032545|FG001|Open-Label Phase (18 Weeks)|Protocol Deviation|0
6306438|NCT02592434|10032546|FG002|Open-Label Phase (18 Weeks)|Protocol Deviation|0
6306439|NCT02592434|10032544|FG000|Double Blind Phase (26 Weeks)|Adverse Event|0
6306440|NCT02592434|10032545|FG001|Double Blind Phase (26 Weeks)|Adverse Event|2
6306441|NCT02592434|10032546|FG002|Double Blind Phase (26 Weeks)|Adverse Event|2
6306442|NCT02592434|10032544|FG000|Double Blind Phase (26 Weeks)|Insufficient Clinical Response|0
6306443|NCT02592434|10032545|FG001|Double Blind Phase (26 Weeks)|Insufficient Clinical Response|22
6306444|NCT02592434|10032546|FG002|Double Blind Phase (26 Weeks)|Insufficient Clinical Response|44
6306445|NCT02592434|10032544|FG000|Double Blind Phase (26 Weeks)|Other|0
6306446|NCT02592434|10032545|FG001|Double Blind Phase (26 Weeks)|Other|1
6306447|NCT02592434|10032546|FG002|Double Blind Phase (26 Weeks)|Other|0
6306448|NCT02592434|10032544|FG000|Double Blind Phase (26 Weeks)|Protocol Deviation|0
6306449|NCT02592434|10032545|FG001|Double Blind Phase (26 Weeks)|Protocol Deviation|0
6306450|NCT02592434|10032546|FG002|Double Blind Phase (26 Weeks)|Protocol Deviation|1
6306451|NCT02592434|10032544|FG000|Double Blind Phase (26 Weeks)|Medication error without associated AEs|0
6306452|NCT02592434|10032545|FG001|Double Blind Phase (26 Weeks)|Medication error without associated AEs|1
6306453|NCT02592434|10032546|FG002|Double Blind Phase (26 Weeks)|Medication error without associated AEs|0
6306454|NCT02592434|10032544|FG000|Double Blind Phase (26 Weeks)|Withdrawal By Parent/Guardian|0
6306455|NCT02592434|10032545|FG001|Double Blind Phase (26 Weeks)|Withdrawal By Parent/Guardian|1
6306456|NCT02592434|10032546|FG002|Double Blind Phase (26 Weeks)|Withdrawal By Parent/Guardian|0
6306457|NCT02592447|10032556|FG000|Overall Study|Lost to Follow-up|1
6306458|NCT02592447|10032557|FG001|Overall Study|Lost to Follow-up|0
6306459|NCT02592447|10032556|FG000|Overall Study|Ineligible after randomization|1
6306460|NCT02592447|10032557|FG001|Overall Study|Ineligible after randomization|0
6306461|NCT02592447|10032556|FG000|Overall Study|Withdrawal by Subject|0
6306462|NCT02592447|10032557|FG001|Overall Study|Withdrawal by Subject|1
6306463|NCT02592798|10032604|FG000|Double-Blind Period 1 (DB1)|Pregnancy|1
6306464|NCT02592798|10032605|FG001|Double-Blind Period 1 (DB1)|Pregnancy|0
6306465|NCT02592798|10032604|FG000|Double-Blind Period 1 (DB1)|No longer meeting study criteria|0
6306466|NCT02592798|10032605|FG001|Double-Blind Period 1 (DB1)|No longer meeting study criteria|1
6306467|NCT02592798|10032604|FG000|Double-Blind Period 1 (DB1)|Lack of Efficacy|1
6306468|NCT02592798|10032605|FG001|Double-Blind Period 1 (DB1)|Lack of Efficacy|3
6306469|NCT02592798|10032604|FG000|Double-Blind Period 1 (DB1)|Adverse Event|1
6306470|NCT02592798|10032605|FG001|Double-Blind Period 1 (DB1)|Adverse Event|2
6306471|NCT02592798|10032604|FG000|Transition From DB1 to DB2|Skipped DB2 and moved into subsequent OLE|3
6306472|NCT02592798|10032605|FG001|Transition From DB1 to DB2|Skipped DB2 and moved into subsequent OLE|2
6306473|NCT02592798|10032604|FG000|Double-Blind Period 2 (DB2)|Other reasons|1
6306474|NCT02592798|10032605|FG001|Double-Blind Period 2 (DB2)|Other reasons|0
6306475|NCT02592798|10032604|FG000|Double-Blind Period 2 (DB2)|Participant request to discontinue|1
6306476|NCT02592798|10032605|FG001|Double-Blind Period 2 (DB2)|Participant request to discontinue|0
6306477|NCT02592798|10032604|FG000|Double-Blind Period 2 (DB2)|No longer meeting study criteria|1
6306478|NCT02592798|10032605|FG001|Double-Blind Period 2 (DB2)|No longer meeting study criteria|0
6306479|NCT02592798|10032604|FG000|Double-Blind Period 2 (DB2)|Lack of Efficacy|1
6306480|NCT02592798|10032605|FG001|Double-Blind Period 2 (DB2)|Lack of Efficacy|2
6306481|NCT02592798|10032604|FG000|Double-Blind Period 2 (DB2)|Adverse Event|1
6306482|NCT02592798|10032605|FG001|Double-Blind Period 2 (DB2)|Adverse Event|0
6306483|NCT02592798|10032604|FG000|Transition From DB2 to OLE|Other reasons|1
6306484|NCT02592798|10032605|FG001|Transition From DB2 to OLE|Other reasons|0
6306485|NCT02592798|10032604|FG000|Open Label Period (OLE)|Other reasons|0
6306486|NCT02592798|10032605|FG001|Open Label Period (OLE)|Other reasons|2
6306487|NCT02592798|10032604|FG000|Open Label Period (OLE)|Participant request to discontinue|1
6306488|NCT02592798|10032605|FG001|Open Label Period (OLE)|Participant request to discontinue|0
6306489|NCT02592798|10032604|FG000|Open Label Period (OLE)|Lost to Follow-up|0
6306490|NCT02592798|10032605|FG001|Open Label Period (OLE)|Lost to Follow-up|1
6306491|NCT02592798|10032604|FG000|Open Label Period (OLE)|Lack of Efficacy|3
6306492|NCT02592798|10032605|FG001|Open Label Period (OLE)|Lack of Efficacy|5
6306493|NCT02592798|10032604|FG000|Open Label Period (OLE)|Adverse Event|0
6306494|NCT02592798|10032605|FG001|Open Label Period (OLE)|Adverse Event|1
6306495|NCT02592876|10032620|FG000|Overall Study|Withdrawal by Subject|3
6306496|NCT02592876|10032621|FG001|Overall Study|Withdrawal by Subject|3
6306497|NCT02592876|10032620|FG000|Overall Study|Study Termination by Sponsor|32
6306498|NCT02592876|10032621|FG001|Overall Study|Study Termination by Sponsor|27
6306499|NCT02592876|10032620|FG000|Overall Study|Lost to Follow-up|0
6306500|NCT02592876|10032621|FG001|Overall Study|Lost to Follow-up|1
6306501|NCT02592876|10032620|FG000|Overall Study|Death|6
6306502|NCT02592876|10032621|FG001|Overall Study|Death|9
6306503|NCT02593097|10032652|FG000|First Intervention (12 Weeks)|Lost to Follow-up|1
6306504|NCT02593097|10032653|FG001|First Intervention (12 Weeks)|Lost to Follow-up|2
6306505|NCT02593097|10032652|FG000|First Intervention (12 Weeks)|Withdrawal by Subject|1
6306506|NCT02593097|10032653|FG001|First Intervention (12 Weeks)|Withdrawal by Subject|2
6306507|NCT02593097|10032652|FG000|Second Intervention (12 Weeks)|Lost to Follow-up|1
6306508|NCT02593097|10032653|FG001|Second Intervention (12 Weeks)|Lost to Follow-up|1
6306509|NCT02593097|10032652|FG000|Second Intervention (12 Weeks)|Lack of Efficacy|1
6306510|NCT02593097|10032653|FG001|Second Intervention (12 Weeks)|Lack of Efficacy|0
6306511|NCT02593097|10032652|FG000|Second Intervention (12 Weeks)|Withdrawal by Subject|1
6306512|NCT02593097|10032653|FG001|Second Intervention (12 Weeks)|Withdrawal by Subject|0
6306513|NCT02593149|10032661|FG000|Run-In|Didn't use CVC for at least 21 days|36
6306514|NCT02593149|10032662|FG001|Run-In|Didn't use CVC for at least 21 days|38
6306515|NCT02593149|10032661|FG000|Intervention|Didn't use CVC for at least 21 day|116
6306516|NCT02593149|10032662|FG001|Intervention|Didn't use CVC for at least 21 day|115
6306517|NCT02593305|10032671|FG000|Post 1|Comparison only group. No intervention.|0
6306518|NCT02593305|10032672|FG001|Post 1|Comparison only group. No intervention.|0
6306519|NCT02593305|10032673|FG002|Post 1|Comparison only group. No intervention.|10
6306520|NCT02593318|10032684|FG000|Overall Study|Withdrawal by Subject|1
6306521|NCT02593318|10032685|FG001|Overall Study|Withdrawal by Subject|1
6306522|NCT02593539|10032706|FG000|Overall Study|Adverse Event|1
6306523|NCT02593773|10032718|FG000|Overall Study|Voluntary Withdrawal|3
6306524|NCT02593773|10032718|FG000|Overall Study|Study Terminated by Sponsor|31
6306525|NCT02593773|10032718|FG000|Overall Study|Death|1
6306526|NCT02593825|10032724|FG000|Intervention|Lost to Follow-up|10
6306527|NCT02593825|10032725|FG001|Intervention|Lost to Follow-up|12
6306528|NCT02593864|10032733|FG000|Overall Study|Withdrawal by Subject|3
6306529|NCT02593864|10032733|FG000|Overall Study|Lost to Follow-up|3
6306530|NCT04142242|10032743|FG000|Overall Study|Non-compliance with the protocol|1
6306531|NCT04142242|10032744|FG001|Overall Study|Non-compliance with the protocol|0
6306532|NCT04142242|10032745|FG002|Overall Study|Non-compliance with the protocol|0
6306533|NCT04142242|10032746|FG003|Overall Study|Non-compliance with the protocol|0
6306534|NCT04142242|10032747|FG004|Overall Study|Non-compliance with the protocol|0
6306535|NCT04142242|10032748|FG005|Overall Study|Non-compliance with the protocol|1
6306536|NCT04142242|10032743|FG000|Overall Study|Voluntary withdrawal not due to an adverse event (AE)|0
6306537|NCT04142242|10032744|FG001|Overall Study|Voluntary withdrawal not due to an adverse event (AE)|1
6306538|NCT04142242|10032745|FG002|Overall Study|Voluntary withdrawal not due to an adverse event (AE)|0
6306539|NCT04142242|10032746|FG003|Overall Study|Voluntary withdrawal not due to an adverse event (AE)|0
6306540|NCT04142242|10032747|FG004|Overall Study|Voluntary withdrawal not due to an adverse event (AE)|0
6306541|NCT04142242|10032748|FG005|Overall Study|Voluntary withdrawal not due to an adverse event (AE)|0
6306542|NCT04142242|10032743|FG000|Overall Study|Ongoing|0
6306543|NCT04142242|10032744|FG001|Overall Study|Ongoing|0
5982529|NCT02513485|9571482|FG001|Overall Study|Adverse Event|0
5982530|NCT02476201|9571488|FG000|Overall Study|Unable to program MPP|9
5982531|NCT02476201|9571488|FG000|Overall Study|Study echo not performed|5
5982532|NCT02476201|9571488|FG000|Overall Study|Adverse Event|4
5982533|NCT02476201|9571488|FG000|Overall Study|Death|2
5982534|NCT02476201|9571488|FG000|Overall Study|Lost to Follow-up|2
5982535|NCT02476201|9571488|FG000|Overall Study|MPP programmed to OFF|2
5982536|NCT02476201|9571488|FG000|Overall Study|Withdrawal by Subject|1
5982537|NCT02476201|9571488|FG000|Overall Study|Unsuccessful implant|1
5982538|NCT02454933|9571495|FG000|Overall Study|Progressive disease|7
5982539|NCT02454933|9571496|FG001|Overall Study|Progressive disease|5
5982540|NCT02454933|9571495|FG000|Overall Study|Adverse Event|1
5982541|NCT02454933|9571496|FG001|Overall Study|Adverse Event|1
5982542|NCT02454933|9571495|FG000|Overall Study|Withdrawal by Subject|0
5982543|NCT02454933|9571496|FG001|Overall Study|Withdrawal by Subject|2
5982544|NCT02426684|9571501|FG000|Overall Study|Physician Decision|1
6064185|NCT00510276|9665603|FG001|Extension Open-Label Phase|Physician Decision|3
6064186|NCT00510276|9665602|FG000|Extension Open-Label Phase|Protocol Violation|0
6064187|NCT00510276|9665603|FG001|Extension Open-Label Phase|Protocol Violation|1
6064188|NCT00510276|9665602|FG000|Extension Open-Label Phase|Sponsor Decision|1
6064189|NCT00510276|9665603|FG001|Extension Open-Label Phase|Sponsor Decision|0
6064190|NCT00510276|9665602|FG000|Extension Open-Label Phase|Subject Decision|7
6064191|NCT00510276|9665603|FG001|Extension Open-Label Phase|Subject Decision|9
6064192|NCT00510289|9665616|FG000|Overall Study|Withdrawal by Subject|7
6064193|NCT00510289|9665616|FG000|Overall Study|Refused bone marrow biopsy|2
6064194|NCT00510289|9665616|FG000|Overall Study|Lost to Follow-up|1
6064195|NCT00510289|9665616|FG000|Overall Study|Progressed prior to starting drug|2
6064196|NCT00510458|9665621|FG000|Overall Study|5 year not evaluable/missed|21
6064197|NCT00510458|9665621|FG000|Overall Study|Death|1
6064198|NCT00510458|9665621|FG000|Overall Study|Terminated|14
6064199|NCT00510458|9665621|FG000|Overall Study|Lost to Follow-up|6
6064200|NCT00510458|9665621|FG000|Overall Study|Withdrawal by Subject|3
6064201|NCT00510458|9665621|FG000|Overall Study|Revision|2
6064202|NCT00510484|9665628|FG000|Wash-out Period|Adverse Event|0
6064203|NCT00510484|9665629|FG001|Wash-out Period|Adverse Event|1
6064204|NCT00510510|9665642|FG000|Overall Study|Adverse Event|4
6064205|NCT00510510|9665643|FG001|Overall Study|Adverse Event|3
6064206|NCT00510510|9665644|FG002|Overall Study|Adverse Event|6
6064207|NCT00510510|9665642|FG000|Overall Study|Lack of Efficacy|0
6064208|NCT00510510|9665643|FG001|Overall Study|Lack of Efficacy|1
6064209|NCT00510510|9665644|FG002|Overall Study|Lack of Efficacy|1
6064210|NCT00510510|9665642|FG000|Overall Study|Subjects no longer requires study drug|0
6064211|NCT00510510|9665643|FG001|Overall Study|Subjects no longer requires study drug|0
6064212|NCT00510510|9665644|FG002|Overall Study|Subjects no longer requires study drug|2
6064213|NCT00510510|9665642|FG000|Overall Study|Withdrawal by Subject|1
6064214|NCT00510510|9665643|FG001|Overall Study|Withdrawal by Subject|2
6064215|NCT00510510|9665644|FG002|Overall Study|Withdrawal by Subject|3
6064216|NCT00510510|9665642|FG000|Overall Study|Lost to Follow-up|0
6064217|NCT00510510|9665643|FG001|Overall Study|Lost to Follow-up|0
6064218|NCT00510510|9665644|FG002|Overall Study|Lost to Follow-up|1
6064219|NCT00510510|9665642|FG000|Overall Study|Protocol Violation|0
6064220|NCT00510510|9665643|FG001|Overall Study|Protocol Violation|3
6064221|NCT00510510|9665644|FG002|Overall Study|Protocol Violation|4
6064222|NCT00510653|9665652|FG000|Overall Study|Withdrawal by Subject|8
6064223|NCT00510653|9665652|FG000|Overall Study|Monetary|3
6064224|NCT00510692|9665658|FG000|Overall Study|Adverse Event|1
6064225|NCT00510692|9665659|FG001|Overall Study|Adverse Event|3
6064226|NCT00510692|9665658|FG000|Overall Study|Withdrawal by Subject|1
6064227|NCT00510692|9665659|FG001|Overall Study|Withdrawal by Subject|0
6064228|NCT00510718|9665674|FG000|Multiple Dose Period: 12 Weeks|Adverse Event|1
6064229|NCT00510718|9665675|FG001|Multiple Dose Period: 12 Weeks|Adverse Event|8
6064230|NCT00510718|9665674|FG000|Multiple Dose Period: 12 Weeks|PSA Disease Progression|3
6064231|NCT00510718|9665675|FG001|Multiple Dose Period: 12 Weeks|PSA Disease Progression|6
6064232|NCT00510718|9665674|FG000|Multiple Dose Period: 12 Weeks|Radiologic Disease Progression|8
6064233|NCT00510718|9665675|FG001|Multiple Dose Period: 12 Weeks|Radiologic Disease Progression|11
6137077|NCT01005732|9767227|FG000|Overall Study|Death|1
6306544|NCT04142242|10032745|FG002|Overall Study|Ongoing|31
6306545|NCT04142242|10032746|FG003|Overall Study|Ongoing|39
6306546|NCT04142242|10032747|FG004|Overall Study|Ongoing|0
6306547|NCT04142242|10032748|FG005|Overall Study|Ongoing|0
6306548|NCT03990389|10032769|FG000|Overall Study|Lost to Follow-up|3
6306549|NCT03990389|10032770|FG001|Overall Study|Lost to Follow-up|0
6306550|NCT03939312|10032776|FG000|OL Treatment Period (40 Weeks)|Withdrawal Criteria at Visit 1|43
6306551|NCT03939312|10032776|FG000|OL Treatment Period (40 Weeks)|Adverse Event|25
6306552|NCT03939312|10032776|FG000|OL Treatment Period (40 Weeks)|Lack of Efficacy|4
6306553|NCT03939312|10032776|FG000|OL Treatment Period (40 Weeks)|Withdrawal by Subject|35
6306554|NCT03939312|10032776|FG000|OL Treatment Period (40 Weeks)|Lost to Follow-up|19
6306555|NCT03939312|10032776|FG000|OL Treatment Period (40 Weeks)|Pregnancy|3
6306556|NCT03939312|10032776|FG000|OL Treatment Period (40 Weeks)|Protocol Deviation|16
6306557|NCT03939312|10032776|FG000|OL Treatment Period (40 Weeks)|Non-compliance With Study Drug|4
6306558|NCT03939312|10032776|FG000|OL Treatment Period (40 Weeks)|Site Terminated by Sponsor|3
6306559|NCT03939312|10032776|FG000|OL Treatment Period (40 Weeks)|Reason Not Specified|22
6306560|NCT03939312|10032776|FG000|Safety Follow-up 4 Weeks (Up to Week 44)|Withdrawal by Subject|12
6306561|NCT03939312|10032776|FG000|Safety Follow-up 4 Weeks (Up to Week 44)|Lost to Follow-up|4
6306562|NCT03934541|10032786|FG000|Overall Study|Study Terminated by Sponsor|0
6306563|NCT03934541|10032787|FG001|Overall Study|Study Terminated by Sponsor|1
6306564|NCT03934541|10032788|FG002|Overall Study|Study Terminated by Sponsor|0
6306565|NCT03934541|10032789|FG003|Overall Study|Study Terminated by Sponsor|0
6306566|NCT03895034|10032803|FG000|Overall Study|Lost to Follow-up|2
6306567|NCT03870477|10032807|FG000|Overall Study|Early Study Termination|1
6306568|NCT03351244|10032814|FG000|Overall Study|Adverse Event|7
6306569|NCT03351244|10032815|FG001|Overall Study|Adverse Event|11
6306570|NCT03351244|10032816|FG002|Overall Study|Adverse Event|12
6306571|NCT03351244|10032814|FG000|Overall Study|Investigator's decision|0
6306572|NCT03351244|10032815|FG001|Overall Study|Investigator's decision|0
6306573|NCT03351244|10032816|FG002|Overall Study|Investigator's decision|2
6306574|NCT03351244|10032814|FG000|Overall Study|System error|0
6306575|NCT03351244|10032815|FG001|Overall Study|System error|0
6306576|NCT03351244|10032816|FG002|Overall Study|System error|2
6306577|NCT03351244|10032814|FG000|Overall Study|COVID-19 restrictions|3
6306578|NCT03351244|10032815|FG001|Overall Study|COVID-19 restrictions|0
6306579|NCT03351244|10032816|FG002|Overall Study|COVID-19 restrictions|1
6306580|NCT03351244|10032814|FG000|Overall Study|Non-compliance|2
6306581|NCT03351244|10032815|FG001|Overall Study|Non-compliance|5
6306582|NCT03351244|10032816|FG002|Overall Study|Non-compliance|0
6306583|NCT03351244|10032814|FG000|Overall Study|Withdrawal by Subject|11
6306584|NCT03351244|10032815|FG001|Overall Study|Withdrawal by Subject|16
6306585|NCT03351244|10032816|FG002|Overall Study|Withdrawal by Subject|13
6306586|NCT03351244|10032814|FG000|Overall Study|Lost to Follow-up|2
6306587|NCT03351244|10032815|FG001|Overall Study|Lost to Follow-up|6
6306588|NCT03351244|10032816|FG002|Overall Study|Lost to Follow-up|4
6306589|NCT03351244|10032814|FG000|Overall Study|Protocol Violation|2
6306590|NCT03351244|10032815|FG001|Overall Study|Protocol Violation|2
6306591|NCT03351244|10032816|FG002|Overall Study|Protocol Violation|0
6306592|NCT02982954|10032848|FG000|Treatment Period|Disease progression|62
6306593|NCT02982954|10032849|FG001|Treatment Period|Disease progression|26
6306594|NCT02982954|10032850|FG002|Treatment Period|Disease progression|12
6306595|NCT02982954|10032851|FG003|Treatment Period|Disease progression|10
6306596|NCT02982954|10032848|FG000|Treatment Period|study drug toxicity|20
6306597|NCT02982954|10032849|FG001|Treatment Period|study drug toxicity|10
6306598|NCT02982954|10032850|FG002|Treatment Period|study drug toxicity|8
6306599|NCT02982954|10032851|FG003|Treatment Period|study drug toxicity|0
6306600|NCT02982954|10032848|FG000|Treatment Period|Death|1
6306601|NCT02982954|10032849|FG001|Treatment Period|Death|3
6306602|NCT02982954|10032850|FG002|Treatment Period|Death|2
6306603|NCT02982954|10032851|FG003|Treatment Period|Death|4
6306604|NCT02982954|10032848|FG000|Treatment Period|Adverse events unrelated to study drug|4
6306605|NCT02982954|10032849|FG001|Treatment Period|Adverse events unrelated to study drug|1
6306606|NCT02982954|10032850|FG002|Treatment Period|Adverse events unrelated to study drug|1
6306607|NCT02982954|10032851|FG003|Treatment Period|Adverse events unrelated to study drug|3
6306608|NCT02982954|10032848|FG000|Treatment Period|participant request to discontinue|2
6306609|NCT02982954|10032849|FG001|Treatment Period|participant request to discontinue|2
6306610|NCT02982954|10032850|FG002|Treatment Period|participant request to discontinue|1
6306611|NCT02982954|10032851|FG003|Treatment Period|participant request to discontinue|2
6306612|NCT02982954|10032848|FG000|Treatment Period|participant withdrew consent|1
6306613|NCT02982954|10032849|FG001|Treatment Period|participant withdrew consent|1
6306614|NCT02982954|10032850|FG002|Treatment Period|participant withdrew consent|0
6306615|NCT02982954|10032851|FG003|Treatment Period|participant withdrew consent|1
6306616|NCT02982954|10032848|FG000|Treatment Period|maximum clinical benefit|1
6306617|NCT02982954|10032849|FG001|Treatment Period|maximum clinical benefit|0
6306618|NCT02982954|10032850|FG002|Treatment Period|maximum clinical benefit|0
6306619|NCT02982954|10032851|FG003|Treatment Period|maximum clinical benefit|0
6306620|NCT02982954|10032848|FG000|Treatment Period|no longer meets study criteria|0
6306621|NCT02982954|10032849|FG001|Treatment Period|no longer meets study criteria|1
6306622|NCT02982954|10032850|FG002|Treatment Period|no longer meets study criteria|0
6306623|NCT02982954|10032851|FG003|Treatment Period|no longer meets study criteria|0
6306624|NCT02982954|10032848|FG000|Treatment Period|Admin reason by sponsor|3
6306625|NCT02982954|10032849|FG001|Treatment Period|Admin reason by sponsor|0
6306626|NCT02982954|10032850|FG002|Treatment Period|Admin reason by sponsor|0
6306627|NCT02982954|10032851|FG003|Treatment Period|Admin reason by sponsor|0
6306628|NCT02982954|10032848|FG000|Treatment Period|other reasons|12
6306629|NCT02982954|10032849|FG001|Treatment Period|other reasons|8
6306630|NCT02982954|10032850|FG002|Treatment Period|other reasons|4
6306631|NCT02982954|10032851|FG003|Treatment Period|other reasons|5
6306632|NCT02982954|10032848|FG000|Continuing in Study|Death|44
6306633|NCT02982954|10032849|FG001|Continuing in Study|Death|27
6306634|NCT02982954|10032850|FG002|Continuing in Study|Death|10
6306635|NCT02982954|10032851|FG003|Continuing in Study|Death|17
6306636|NCT02982954|10032848|FG000|Continuing in Study|participant withdrew consent|9
6306637|NCT02982954|10032849|FG001|Continuing in Study|participant withdrew consent|5
6306638|NCT02982954|10032850|FG002|Continuing in Study|participant withdrew consent|1
6306639|NCT02982954|10032851|FG003|Continuing in Study|participant withdrew consent|1
6306640|NCT02982954|10032848|FG000|Continuing in Study|Lost to Follow-up|1
6306641|NCT02982954|10032849|FG001|Continuing in Study|Lost to Follow-up|0
6306642|NCT02982954|10032850|FG002|Continuing in Study|Lost to Follow-up|0
6306643|NCT02982954|10032851|FG003|Continuing in Study|Lost to Follow-up|0
6306644|NCT02982954|10032848|FG000|Continuing in Study|other reasons|0
6306645|NCT02982954|10032849|FG001|Continuing in Study|other reasons|1
6306646|NCT02982954|10032850|FG002|Continuing in Study|other reasons|0
6306647|NCT02982954|10032851|FG003|Continuing in Study|other reasons|0
6306648|NCT02903914|10032873|FG000|Overall Study|Adverse Event|0
6306649|NCT02903914|10032874|FG001|Overall Study|Adverse Event|0
6306650|NCT02903914|10032875|FG002|Overall Study|Adverse Event|1
6306651|NCT02903914|10032876|FG003|Overall Study|Adverse Event|0
6306652|NCT02903914|10032877|FG004|Overall Study|Adverse Event|0
6306653|NCT02903914|10032878|FG005|Overall Study|Adverse Event|1
6306654|NCT02903914|10032879|FG006|Overall Study|Adverse Event|2
6306655|NCT02903914|10032880|FG007|Overall Study|Adverse Event|1
6306656|NCT02903914|10032873|FG000|Overall Study|Withdrawal by Subject|3
6306657|NCT02903914|10032874|FG001|Overall Study|Withdrawal by Subject|1
6306658|NCT02903914|10032875|FG002|Overall Study|Withdrawal by Subject|28
6306659|NCT02903914|10032876|FG003|Overall Study|Withdrawal by Subject|0
6306660|NCT02903914|10032877|FG004|Overall Study|Withdrawal by Subject|1
6306661|NCT02903914|10032878|FG005|Overall Study|Withdrawal by Subject|1
6306662|NCT02903914|10032879|FG006|Overall Study|Withdrawal by Subject|12
6306663|NCT02903914|10032880|FG007|Overall Study|Withdrawal by Subject|0
6306664|NCT02903914|10032873|FG000|Overall Study|Progressive Disease|1
6306665|NCT02903914|10032874|FG001|Overall Study|Progressive Disease|0
6306666|NCT02903914|10032875|FG002|Overall Study|Progressive Disease|4
6306667|NCT02903914|10032876|FG003|Overall Study|Progressive Disease|0
6306668|NCT02903914|10032877|FG004|Overall Study|Progressive Disease|0
6306669|NCT02903914|10032878|FG005|Overall Study|Progressive Disease|0
6306670|NCT02903914|10032879|FG006|Overall Study|Progressive Disease|2
6306671|NCT02903914|10032880|FG007|Overall Study|Progressive Disease|4
6306672|NCT02903914|10032873|FG000|Overall Study|Death|0
6306673|NCT02903914|10032874|FG001|Overall Study|Death|0
6306674|NCT02903914|10032875|FG002|Overall Study|Death|9
6306675|NCT02903914|10032876|FG003|Overall Study|Death|0
6306676|NCT02903914|10032877|FG004|Overall Study|Death|1
6306677|NCT02903914|10032878|FG005|Overall Study|Death|3
6306678|NCT02903914|10032879|FG006|Overall Study|Death|24
6306679|NCT02903914|10032880|FG007|Overall Study|Death|0
6306680|NCT02903914|10032873|FG000|Overall Study|Lost to Follow-up|0
6306681|NCT02903914|10032874|FG001|Overall Study|Lost to Follow-up|1
6306682|NCT02903914|10032875|FG002|Overall Study|Lost to Follow-up|0
6306683|NCT02903914|10032876|FG003|Overall Study|Lost to Follow-up|0
6306684|NCT02903914|10032877|FG004|Overall Study|Lost to Follow-up|2
6306685|NCT02903914|10032878|FG005|Overall Study|Lost to Follow-up|0
6306686|NCT02903914|10032879|FG006|Overall Study|Lost to Follow-up|1
6306687|NCT02903914|10032880|FG007|Overall Study|Lost to Follow-up|0
6306688|NCT02903914|10032873|FG000|Overall Study|Physician Decision|0
6306689|NCT02903914|10032874|FG001|Overall Study|Physician Decision|0
6306690|NCT02903914|10032875|FG002|Overall Study|Physician Decision|1
6064234|NCT00510718|9665674|FG000|Multiple Dose Period: 12 Weeks|Clinical Disease Progression|1
6064235|NCT00510718|9665675|FG001|Multiple Dose Period: 12 Weeks|Clinical Disease Progression|3
6064236|NCT00510718|9665674|FG000|Multiple Dose Period: 12 Weeks|Withdrawal by Subject|1
6064237|NCT00510718|9665675|FG001|Multiple Dose Period: 12 Weeks|Withdrawal by Subject|3
6064238|NCT00510718|9665674|FG000|Multiple Dose Period: 12 Weeks|Other|1
6064239|NCT00510718|9665675|FG001|Multiple Dose Period: 12 Weeks|Other|1
6064240|NCT00510783|9665700|FG000|Overall Study|Lost to Follow-up|29
6064241|NCT00510783|9665701|FG001|Overall Study|Lost to Follow-up|25
6064242|NCT00510783|9665700|FG000|Overall Study|Withdrawal by Subject|2
6064243|NCT00510783|9665701|FG001|Overall Study|Withdrawal by Subject|3
6064244|NCT00510783|9665700|FG000|Overall Study|Protocol Violation|0
6064245|NCT00510783|9665701|FG001|Overall Study|Protocol Violation|1
6064246|NCT00510835|9665723|FG000|Overall Study|Withdrawal by Subject|6
6064247|NCT00510835|9665724|FG001|Overall Study|Withdrawal by Subject|2
6064248|NCT00510835|9665725|FG002|Overall Study|Withdrawal by Subject|2
6064249|NCT00510874|9665740|FG000|Overall Study|Withdrawal by Subject|1
6064250|NCT00510874|9665741|FG001|Overall Study|Withdrawal by Subject|1
6064251|NCT00510874|9665742|FG002|Overall Study|Withdrawal by Subject|0
6064252|NCT00510874|9665743|FG003|Overall Study|Withdrawal by Subject|0
6064253|NCT00510874|9665744|FG004|Overall Study|Withdrawal by Subject|3
6064254|NCT00510874|9665745|FG005|Overall Study|Withdrawal by Subject|0
6064255|NCT00510874|9665746|FG006|Overall Study|Withdrawal by Subject|0
6064256|NCT00510874|9665740|FG000|Overall Study|Lost to Follow-up|2
6064257|NCT00510874|9665741|FG001|Overall Study|Lost to Follow-up|3
6064258|NCT00510874|9665742|FG002|Overall Study|Lost to Follow-up|1
6064259|NCT00510874|9665743|FG003|Overall Study|Lost to Follow-up|3
6064260|NCT00510874|9665744|FG004|Overall Study|Lost to Follow-up|4
6064261|NCT00510874|9665745|FG005|Overall Study|Lost to Follow-up|0
6064262|NCT00510874|9665746|FG006|Overall Study|Lost to Follow-up|1
6064263|NCT00510887|9665763|FG000|Overall Study|Lost to Follow-up|1
6064264|NCT00510952|9665769|FG000|Overall Study|Adverse Event|1
6064265|NCT00510952|9665770|FG001|Overall Study|Adverse Event|0
6064266|NCT00510952|9665769|FG000|Overall Study|Entry Criteria Not Met|3
6064267|NCT00510952|9665770|FG001|Overall Study|Entry Criteria Not Met|1
6064268|NCT00510952|9665769|FG000|Overall Study|Lost to Follow-up|5
6064269|NCT00510952|9665770|FG001|Overall Study|Lost to Follow-up|3
6064270|NCT00510952|9665769|FG000|Overall Study|Physician Decision|1
6064271|NCT00510952|9665770|FG001|Overall Study|Physician Decision|1
6064272|NCT00510952|9665769|FG000|Overall Study|Protocol Violation|7
6306691|NCT02903914|10032876|FG003|Overall Study|Physician Decision|0
6306692|NCT02903914|10032877|FG004|Overall Study|Physician Decision|0
6306693|NCT02903914|10032878|FG005|Overall Study|Physician Decision|0
6306694|NCT02903914|10032879|FG006|Overall Study|Physician Decision|1
6306695|NCT02903914|10032880|FG007|Overall Study|Physician Decision|0
6306696|NCT02903914|10032873|FG000|Overall Study|Symptomatic Deterioration|0
6306697|NCT02903914|10032874|FG001|Overall Study|Symptomatic Deterioration|0
6306698|NCT02903914|10032875|FG002|Overall Study|Symptomatic Deterioration|1
6306699|NCT02903914|10032876|FG003|Overall Study|Symptomatic Deterioration|0
6306700|NCT02903914|10032877|FG004|Overall Study|Symptomatic Deterioration|0
6306701|NCT02903914|10032878|FG005|Overall Study|Symptomatic Deterioration|0
6306702|NCT02903914|10032879|FG006|Overall Study|Symptomatic Deterioration|0
6306703|NCT02903914|10032880|FG007|Overall Study|Symptomatic Deterioration|0
6306704|NCT02903914|10032873|FG000|Overall Study|New Cancer Therapy|2
6306705|NCT02903914|10032874|FG001|Overall Study|New Cancer Therapy|2
6306706|NCT02903914|10032875|FG002|Overall Study|New Cancer Therapy|21
6306707|NCT02903914|10032876|FG003|Overall Study|New Cancer Therapy|4
6306708|NCT02903914|10032877|FG004|Overall Study|New Cancer Therapy|3
6306709|NCT02903914|10032878|FG005|Overall Study|New Cancer Therapy|6
6306710|NCT02903914|10032879|FG006|Overall Study|New Cancer Therapy|55
6306711|NCT02903914|10032880|FG007|Overall Study|New Cancer Therapy|0
6306712|NCT02903914|10032873|FG000|Overall Study|Reasoning not specified|2
6306713|NCT02903914|10032874|FG001|Overall Study|Reasoning not specified|3
6306714|NCT02903914|10032875|FG002|Overall Study|Reasoning not specified|20
6306715|NCT02903914|10032876|FG003|Overall Study|Reasoning not specified|3
6306716|NCT02903914|10032877|FG004|Overall Study|Reasoning not specified|3
6306717|NCT02903914|10032878|FG005|Overall Study|Reasoning not specified|3
6306718|NCT02903914|10032879|FG006|Overall Study|Reasoning not specified|20
6306719|NCT02903914|10032880|FG007|Overall Study|Reasoning not specified|0
6306720|NCT02727699|10032902|FG000|Overall Study|Adverse Event|2
6306721|NCT02727699|10032903|FG001|Overall Study|Adverse Event|0
6306722|NCT02727699|10032902|FG000|Overall Study|Withdrawal by Subject|5
6306723|NCT02727699|10032903|FG001|Overall Study|Withdrawal by Subject|3
6306724|NCT02727699|10032902|FG000|Overall Study|Protocol Violation|0
6306725|NCT02727699|10032903|FG001|Overall Study|Protocol Violation|1
6306726|NCT02727699|10032902|FG000|Overall Study|Physician Decision|0
6306727|NCT02727699|10032903|FG001|Overall Study|Physician Decision|1
6306728|NCT02727699|10032902|FG000|Overall Study|Lost to Follow-up|1
6306729|NCT02727699|10032903|FG001|Overall Study|Lost to Follow-up|0
6306730|NCT02727699|10032902|FG000|Overall Study|Sponsor Decision|1
6306731|NCT02727699|10032903|FG001|Overall Study|Sponsor Decision|0
6306732|NCT02640950|10032909|FG000|Overall Study|Adverse Event|1
6306733|NCT02640950|10032909|FG000|Overall Study|Withdrawal by Subject|1
6306734|NCT02230254|10032927|FG000|Overall Study|Lost to Follow-up|3
6306735|NCT01909453|10032936|FG000|Overall Study|Ongoing|118
6306736|NCT01909453|10032937|FG001|Overall Study|Ongoing|103
6306737|NCT01909453|10032938|FG002|Overall Study|Ongoing|83
6306738|NCT01909453|10032939|FG003|Overall Study|Ongoing|164
6306739|NCT01909453|10032940|FG004|Overall Study|Ongoing|50
6306740|NCT01909453|10032936|FG000|Overall Study|Death|69
6306741|NCT01909453|10032937|FG001|Overall Study|Death|74
6306742|NCT01909453|10032938|FG002|Overall Study|Death|88
6306743|NCT01909453|10032939|FG003|Overall Study|Death|86
6306744|NCT01909453|10032940|FG004|Overall Study|Death|29
6306745|NCT01909453|10032936|FG000|Overall Study|Lost to Follow-up|3
6306746|NCT01909453|10032937|FG001|Overall Study|Lost to Follow-up|4
6306747|NCT01909453|10032938|FG002|Overall Study|Lost to Follow-up|4
6306748|NCT01909453|10032939|FG003|Overall Study|Lost to Follow-up|3
6306749|NCT01909453|10032940|FG004|Overall Study|Lost to Follow-up|3
6306750|NCT01909453|10032936|FG000|Overall Study|Withdrawal by Subject|2
6306751|NCT01909453|10032937|FG001|Overall Study|Withdrawal by Subject|13
6306752|NCT01909453|10032938|FG002|Overall Study|Withdrawal by Subject|16
6306753|NCT01909453|10032939|FG003|Overall Study|Withdrawal by Subject|5
6306754|NCT01909453|10032940|FG004|Overall Study|Withdrawal by Subject|4
6306755|NCT01891396|10032961|FG000|Overall Study|Withdrawal by Subject|4
6306756|NCT01891396|10032962|FG001|Overall Study|Withdrawal by Subject|4
6306757|NCT01891396|10032963|FG002|Overall Study|Withdrawal by Subject|3
6306758|NCT01891396|10032961|FG000|Overall Study|Lost to Follow-up|0
6306759|NCT01891396|10032962|FG001|Overall Study|Lost to Follow-up|1
6306760|NCT01891396|10032963|FG002|Overall Study|Lost to Follow-up|0
6306761|NCT01589523|10032975|FG000|Overall Study|Withdrawal by Subject|1
6306762|NCT01525901|10032985|FG000|Period 2: 12 Weeks|Adverse Event|0
6306763|NCT01525901|10032986|FG001|Period 2: 12 Weeks|Adverse Event|1
6306764|NCT01525901|10032987|FG002|Period 2: 12 Weeks|Adverse Event|0
6306765|NCT01525901|10032988|FG003|Period 2: 12 Weeks|Adverse Event|0
6306766|NCT01354431|10033001|FG000|Pre-Treatment Period|Not reported|1
6306767|NCT01354431|10033002|FG001|Pre-Treatment Period|Not reported|0
6306768|NCT01354431|10033003|FG002|Pre-Treatment Period|Not reported|0
6306769|NCT01354431|10033001|FG000|Treatment Period|Disease Progression|50
6306770|NCT01354431|10033002|FG001|Treatment Period|Disease Progression|40
6306771|NCT01354431|10033003|FG002|Treatment Period|Disease Progression|44
6306772|NCT01354431|10033001|FG000|Treatment Period|Study Drug Toxicity|5
6306773|NCT01354431|10033002|FG001|Treatment Period|Study Drug Toxicity|8
6306774|NCT01354431|10033003|FG002|Treatment Period|Study Drug Toxicity|4
6306775|NCT01354431|10033001|FG000|Treatment Period|Death|0
6306776|NCT01354431|10033002|FG001|Treatment Period|Death|1
6306777|NCT01354431|10033003|FG002|Treatment Period|Death|0
6306778|NCT01354431|10033001|FG000|Treatment Period|AE unrelated to study drug|1
6306779|NCT01354431|10033002|FG001|Treatment Period|AE unrelated to study drug|2
6306780|NCT01354431|10033003|FG002|Treatment Period|AE unrelated to study drug|5
6306781|NCT01354431|10033001|FG000|Treatment Period|Participant request to discontinue|2
6306782|NCT01354431|10033002|FG001|Treatment Period|Participant request to discontinue|2
6306783|NCT01354431|10033003|FG002|Treatment Period|Participant request to discontinue|1
6306784|NCT01354431|10033001|FG000|Treatment Period|Participant withdrew consent|0
6306785|NCT01354431|10033002|FG001|Treatment Period|Participant withdrew consent|1
6306786|NCT01354431|10033003|FG002|Treatment Period|Participant withdrew consent|0
6306787|NCT01354431|10033001|FG000|Treatment Period|Participant no longer meeting study criteria|1
6306788|NCT01354431|10033002|FG001|Treatment Period|Participant no longer meeting study criteria|0
6306789|NCT01354431|10033003|FG002|Treatment Period|Participant no longer meeting study criteria|0
6306790|NCT01003691|10033015|FG000|Overall Study|Adverse Event|0
6306791|NCT01003691|10033016|FG001|Overall Study|Adverse Event|0
6306792|NCT01003691|10033017|FG002|Overall Study|Adverse Event|0
6306793|NCT01003691|10033018|FG003|Overall Study|Adverse Event|1
5982545|NCT02337751|9571507|FG000|Overall Study|Pretreatment Event/Adverse Event|2
5982546|NCT02337751|9571508|FG001|Overall Study|Pretreatment Event/Adverse Event|3
5982547|NCT02337751|9571507|FG000|Overall Study|Voluntary Withdrawal|6
5982548|NCT02337751|9571508|FG001|Overall Study|Voluntary Withdrawal|8
5982549|NCT02337751|9571507|FG000|Overall Study|Lack of Efficacy|2
5982550|NCT02337751|9571508|FG001|Overall Study|Lack of Efficacy|5
5982551|NCT02337751|9571507|FG000|Overall Study|Investigator's Judgement|1
5982552|NCT02337751|9571508|FG001|Overall Study|Investigator's Judgement|0
5982553|NCT02337725|9571517|FG000|Overall Study|Pretreatment Event/AE before Treatment|0
5982554|NCT02337725|9571518|FG001|Overall Study|Pretreatment Event/AE before Treatment|1
5982555|NCT02337725|9571517|FG000|Overall Study|Pretreatment Event/AE in Treatment|8
5982556|NCT02337725|9571518|FG001|Overall Study|Pretreatment Event/AE in Treatment|3
5982557|NCT02337725|9571517|FG000|Overall Study|Major Protocol Deviation|0
5982558|NCT02337725|9571518|FG001|Overall Study|Major Protocol Deviation|1
5982559|NCT02337725|9571517|FG000|Overall Study|Voluntary Withdrawal|14
5982560|NCT02337725|9571518|FG001|Overall Study|Voluntary Withdrawal|3
5982561|NCT02337725|9571517|FG000|Overall Study|Lack of Efficacy|4
5982562|NCT02337725|9571518|FG001|Overall Study|Lack of Efficacy|0
5982563|NCT02332655|9571524|FG000|Overall Study|Lack of Efficacy|1
5982564|NCT01994382|9571576|FG000|Overall Study|Informed consent withdrawn|0
5982565|NCT01994382|9571577|FG001|Overall Study|Informed consent withdrawn|0
5982566|NCT01994382|9571578|FG002|Overall Study|Informed consent withdrawn|0
5982567|NCT01994382|9571579|FG003|Overall Study|Informed consent withdrawn|0
5982568|NCT01994382|9571580|FG004|Overall Study|Informed consent withdrawn|0
5982569|NCT01994382|9571581|FG005|Overall Study|Informed consent withdrawn|0
5982570|NCT01994382|9571582|FG006|Overall Study|Informed consent withdrawn|1
5982571|NCT01994382|9571583|FG007|Overall Study|Informed consent withdrawn|0
5982572|NCT01994382|9571584|FG008|Overall Study|Informed consent withdrawn|0
5982573|NCT01994382|9571585|FG009|Overall Study|Informed consent withdrawn|0
5982574|NCT01994382|9571586|FG010|Overall Study|Informed consent withdrawn|0
5982575|NCT01994382|9571587|FG011|Overall Study|Informed consent withdrawn|0
5982576|NCT01994382|9571588|FG012|Overall Study|Informed consent withdrawn|0
5982577|NCT01994382|9571589|FG013|Overall Study|Informed consent withdrawn|0
5982578|NCT01994382|9571590|FG014|Overall Study|Informed consent withdrawn|0
5982579|NCT01994382|9571591|FG015|Overall Study|Informed consent withdrawn|0
5982580|NCT01994382|9571592|FG016|Overall Study|Informed consent withdrawn|0
5982581|NCT01994382|9571576|FG000|Overall Study|Progressive disease|3
5982582|NCT01994382|9571577|FG001|Overall Study|Progressive disease|4
5982583|NCT01994382|9571578|FG002|Overall Study|Progressive disease|4
5982584|NCT01994382|9571579|FG003|Overall Study|Progressive disease|3
5982585|NCT01994382|9571580|FG004|Overall Study|Progressive disease|2
5982586|NCT01994382|9571581|FG005|Overall Study|Progressive disease|3
5982587|NCT01994382|9571582|FG006|Overall Study|Progressive disease|3
5982588|NCT01994382|9571583|FG007|Overall Study|Progressive disease|6
5982589|NCT01994382|9571584|FG008|Overall Study|Progressive disease|2
5982590|NCT01994382|9571585|FG009|Overall Study|Progressive disease|2
5982591|NCT01994382|9571586|FG010|Overall Study|Progressive disease|13
5982592|NCT01994382|9571587|FG011|Overall Study|Progressive disease|8
5982593|NCT01994382|9571588|FG012|Overall Study|Progressive disease|7
5982594|NCT01994382|9571589|FG013|Overall Study|Progressive disease|3
5982595|NCT01994382|9571590|FG014|Overall Study|Progressive disease|6
5982596|NCT01994382|9571591|FG015|Overall Study|Progressive disease|44
5982597|NCT01994382|9571592|FG016|Overall Study|Progressive disease|28
5982598|NCT01994382|9571576|FG000|Overall Study|Physician Decision|0
5982599|NCT01994382|9571577|FG001|Overall Study|Physician Decision|1
5982600|NCT01994382|9571578|FG002|Overall Study|Physician Decision|0
5982601|NCT01994382|9571579|FG003|Overall Study|Physician Decision|0
5982602|NCT01994382|9571580|FG004|Overall Study|Physician Decision|0
5982603|NCT01994382|9571581|FG005|Overall Study|Physician Decision|0
5982604|NCT01994382|9571582|FG006|Overall Study|Physician Decision|0
5982605|NCT01994382|9571583|FG007|Overall Study|Physician Decision|0
5982606|NCT01994382|9571584|FG008|Overall Study|Physician Decision|0
5982607|NCT01994382|9571585|FG009|Overall Study|Physician Decision|0
5982608|NCT01994382|9571586|FG010|Overall Study|Physician Decision|3
5982609|NCT01994382|9571587|FG011|Overall Study|Physician Decision|1
5982610|NCT01994382|9571588|FG012|Overall Study|Physician Decision|1
5982611|NCT01994382|9571589|FG013|Overall Study|Physician Decision|0
5982612|NCT01994382|9571590|FG014|Overall Study|Physician Decision|1
5982613|NCT01994382|9571591|FG015|Overall Study|Physician Decision|4
5982614|NCT01994382|9571592|FG016|Overall Study|Physician Decision|2
5982615|NCT01994382|9571576|FG000|Overall Study|Death|0
5982616|NCT01994382|9571577|FG001|Overall Study|Death|0
5982617|NCT01994382|9571578|FG002|Overall Study|Death|0
5982618|NCT01994382|9571579|FG003|Overall Study|Death|0
5982619|NCT01994382|9571580|FG004|Overall Study|Death|1
5982620|NCT01994382|9571581|FG005|Overall Study|Death|0
5982621|NCT01994382|9571582|FG006|Overall Study|Death|0
5982622|NCT01994382|9571583|FG007|Overall Study|Death|0
5982623|NCT01994382|9571584|FG008|Overall Study|Death|1
5982624|NCT01994382|9571585|FG009|Overall Study|Death|1
5982625|NCT01994382|9571586|FG010|Overall Study|Death|0
5982626|NCT01994382|9571587|FG011|Overall Study|Death|0
5982627|NCT01994382|9571588|FG012|Overall Study|Death|0
5982628|NCT01994382|9571589|FG013|Overall Study|Death|0
5982629|NCT01994382|9571590|FG014|Overall Study|Death|0
5982630|NCT01994382|9571591|FG015|Overall Study|Death|1
5982631|NCT01994382|9571592|FG016|Overall Study|Death|0
5982632|NCT01994382|9571576|FG000|Overall Study|Adverse Event|0
5982633|NCT01994382|9571577|FG001|Overall Study|Adverse Event|1
5982634|NCT01994382|9571578|FG002|Overall Study|Adverse Event|2
5982635|NCT01994382|9571579|FG003|Overall Study|Adverse Event|0
5982636|NCT01994382|9571580|FG004|Overall Study|Adverse Event|0
5982637|NCT01994382|9571581|FG005|Overall Study|Adverse Event|0
5982638|NCT01994382|9571582|FG006|Overall Study|Adverse Event|0
5982639|NCT01994382|9571583|FG007|Overall Study|Adverse Event|0
5982640|NCT01994382|9571584|FG008|Overall Study|Adverse Event|0
5982641|NCT01994382|9571585|FG009|Overall Study|Adverse Event|0
5982642|NCT01994382|9571586|FG010|Overall Study|Adverse Event|15
5982643|NCT01994382|9571587|FG011|Overall Study|Adverse Event|2
5982644|NCT01994382|9571588|FG012|Overall Study|Adverse Event|7
5982645|NCT01994382|9571589|FG013|Overall Study|Adverse Event|3
5982646|NCT01994382|9571590|FG014|Overall Study|Adverse Event|17
5982647|NCT01994382|9571591|FG015|Overall Study|Adverse Event|6
5982648|NCT01994382|9571592|FG016|Overall Study|Adverse Event|3
5982649|NCT01994382|9571576|FG000|Overall Study|Other than specified|0
5982650|NCT01994382|9571577|FG001|Overall Study|Other than specified|0
5982651|NCT01994382|9571578|FG002|Overall Study|Other than specified|0
5982652|NCT01994382|9571579|FG003|Overall Study|Other than specified|0
5982653|NCT01994382|9571580|FG004|Overall Study|Other than specified|0
5982654|NCT01994382|9571581|FG005|Overall Study|Other than specified|0
5982655|NCT01994382|9571582|FG006|Overall Study|Other than specified|0
5982656|NCT01994382|9571583|FG007|Overall Study|Other than specified|0
5982657|NCT01994382|9571584|FG008|Overall Study|Other than specified|0
5982658|NCT01994382|9571585|FG009|Overall Study|Other than specified|0
5982659|NCT01994382|9571586|FG010|Overall Study|Other than specified|2
5982660|NCT01994382|9571587|FG011|Overall Study|Other than specified|0
5982661|NCT01994382|9571588|FG012|Overall Study|Other than specified|2
5982662|NCT01994382|9571589|FG013|Overall Study|Other than specified|0
5982663|NCT01994382|9571590|FG014|Overall Study|Other than specified|0
5982664|NCT01994382|9571591|FG015|Overall Study|Other than specified|4
5982665|NCT01994382|9571592|FG016|Overall Study|Other than specified|4
5982666|NCT01994382|9571576|FG000|Overall Study|Withdrawal by Subject|0
5982667|NCT01994382|9571577|FG001|Overall Study|Withdrawal by Subject|0
5982668|NCT01994382|9571578|FG002|Overall Study|Withdrawal by Subject|0
5982669|NCT01994382|9571579|FG003|Overall Study|Withdrawal by Subject|0
5982670|NCT01994382|9571580|FG004|Overall Study|Withdrawal by Subject|0
5982671|NCT01994382|9571581|FG005|Overall Study|Withdrawal by Subject|0
5982672|NCT01994382|9571582|FG006|Overall Study|Withdrawal by Subject|0
5982673|NCT01994382|9571583|FG007|Overall Study|Withdrawal by Subject|0
5982674|NCT01994382|9571584|FG008|Overall Study|Withdrawal by Subject|0
5982675|NCT01994382|9571585|FG009|Overall Study|Withdrawal by Subject|0
5982676|NCT01994382|9571586|FG010|Overall Study|Withdrawal by Subject|6
5982677|NCT01994382|9571587|FG011|Overall Study|Withdrawal by Subject|0
5982678|NCT01994382|9571588|FG012|Overall Study|Withdrawal by Subject|2
5982679|NCT01994382|9571589|FG013|Overall Study|Withdrawal by Subject|0
5982680|NCT01994382|9571590|FG014|Overall Study|Withdrawal by Subject|4
5982681|NCT01994382|9571591|FG015|Overall Study|Withdrawal by Subject|3
5982682|NCT01994382|9571592|FG016|Overall Study|Withdrawal by Subject|0
5982683|NCT01994382|9571576|FG000|Overall Study|Lost to Follow-up|0
5982684|NCT01994382|9571577|FG001|Overall Study|Lost to Follow-up|0
5982685|NCT01994382|9571578|FG002|Overall Study|Lost to Follow-up|0
5982686|NCT01994382|9571579|FG003|Overall Study|Lost to Follow-up|0
5982687|NCT01994382|9571580|FG004|Overall Study|Lost to Follow-up|0
5982688|NCT01994382|9571581|FG005|Overall Study|Lost to Follow-up|0
5982689|NCT01994382|9571582|FG006|Overall Study|Lost to Follow-up|0
5982690|NCT01994382|9571583|FG007|Overall Study|Lost to Follow-up|0
5982691|NCT01994382|9571584|FG008|Overall Study|Lost to Follow-up|0
5982692|NCT01994382|9571585|FG009|Overall Study|Lost to Follow-up|0
5982693|NCT01994382|9571586|FG010|Overall Study|Lost to Follow-up|1
5982694|NCT01994382|9571587|FG011|Overall Study|Lost to Follow-up|0
5982695|NCT01994382|9571588|FG012|Overall Study|Lost to Follow-up|0
5982696|NCT01994382|9571589|FG013|Overall Study|Lost to Follow-up|0
6064273|NCT00510952|9665770|FG001|Overall Study|Protocol Violation|4
6064274|NCT00510952|9665769|FG000|Overall Study|Sponsor Decision|1
6064275|NCT00510952|9665770|FG001|Overall Study|Sponsor Decision|0
6064276|NCT00510952|9665769|FG000|Overall Study|Withdrawal by Subject|6
6064277|NCT00510952|9665770|FG001|Overall Study|Withdrawal by Subject|7
6064278|NCT00510952|9665769|FG000|Overall Study|Did Not Receive Study Drug|2
6064279|NCT00510952|9665770|FG001|Overall Study|Did Not Receive Study Drug|0
6064280|NCT00511004|9665779|FG000|Overall Study|Lost to Follow-up|0
6064281|NCT00511004|9665780|FG001|Overall Study|Lost to Follow-up|0
6064282|NCT00511004|9665781|FG002|Overall Study|Lost to Follow-up|4
6064283|NCT00511108|9665806|FG000|Overall Study|Adverse Event|2
6064284|NCT00511108|9665807|FG001|Overall Study|Adverse Event|0
6064285|NCT00511108|9665808|FG002|Overall Study|Adverse Event|1
6064286|NCT00511108|9665809|FG003|Overall Study|Adverse Event|2
6064287|NCT00511108|9665806|FG000|Overall Study|Lost to Follow-up|0
6064288|NCT00511108|9665807|FG001|Overall Study|Lost to Follow-up|2
6064289|NCT00511108|9665808|FG002|Overall Study|Lost to Follow-up|1
6064290|NCT00511108|9665809|FG003|Overall Study|Lost to Follow-up|0
6064291|NCT00511108|9665806|FG000|Overall Study|Physician Decision|0
6064292|NCT00511108|9665807|FG001|Overall Study|Physician Decision|0
6064293|NCT00511108|9665808|FG002|Overall Study|Physician Decision|0
6064294|NCT00511108|9665809|FG003|Overall Study|Physician Decision|1
6064295|NCT00511108|9665806|FG000|Overall Study|Withdrawal by Subject|4
6064296|NCT00511108|9665807|FG001|Overall Study|Withdrawal by Subject|0
6064297|NCT00511108|9665808|FG002|Overall Study|Withdrawal by Subject|3
6064298|NCT00511108|9665809|FG003|Overall Study|Withdrawal by Subject|2
6064299|NCT00511147|9665819|FG000|Overall Study|Withdrawal by Subject|1
6064300|NCT00511147|9665819|FG000|Overall Study|Disease progression|5
6064301|NCT00511147|9665819|FG000|Overall Study|Required platelet transfusion|1
6064302|NCT00511238|9665830|FG000|Overall Study|Adverse Event|13
6064303|NCT00511238|9665831|FG001|Overall Study|Adverse Event|33
6064304|NCT00511238|9665830|FG000|Overall Study|Withdrawal by Subject|2
6064305|NCT00511238|9665831|FG001|Overall Study|Withdrawal by Subject|22
6064306|NCT00511238|9665830|FG000|Overall Study|Progressive Disease|23
6064307|NCT00511238|9665831|FG001|Overall Study|Progressive Disease|157
6064308|NCT00511238|9665830|FG000|Overall Study|various reasons|4
6064309|NCT00511238|9665831|FG001|Overall Study|various reasons|14
6064310|NCT00511472|9665849|FG000|Overall Study|Clinical Adverse Event|1
6064311|NCT00511472|9665850|FG001|Overall Study|Clinical Adverse Event|2
6064312|NCT00511472|9665849|FG000|Overall Study|Laboratory Adverse Event|0
6064313|NCT00511472|9665850|FG001|Overall Study|Laboratory Adverse Event|2
6064314|NCT00511472|9665849|FG000|Overall Study|Not reported|2
6064315|NCT00511472|9665850|FG001|Overall Study|Not reported|2
6064316|NCT00511667|9665867|FG000|Overall Study|Adverse Event|1
6064317|NCT00511667|9665868|FG001|Overall Study|Adverse Event|0
6064318|NCT00511667|9665867|FG000|Overall Study|Protocol Violation|1
6064319|NCT00511667|9665868|FG001|Overall Study|Protocol Violation|1
6064320|NCT00511667|9665867|FG000|Overall Study|Withdrawal by Subject|2
6064321|NCT00511667|9665868|FG001|Overall Study|Withdrawal by Subject|0
6064322|NCT00511667|9665867|FG000|Overall Study|Site terminated|6
6064323|NCT00511667|9665868|FG001|Overall Study|Site terminated|1
6064324|NCT00511667|9665867|FG000|Overall Study|Other|2
6064325|NCT00511667|9665868|FG001|Overall Study|Other|1
6064326|NCT00511797|9665893|FG000|Overall Study|Adverse Event|1
6064327|NCT00511797|9665894|FG001|Overall Study|Adverse Event|2
6064328|NCT00511797|9665895|FG002|Overall Study|Adverse Event|2
6064329|NCT00511797|9665896|FG003|Overall Study|Adverse Event|2
6064330|NCT00511797|9665893|FG000|Overall Study|Lost to Follow-up|1
6064331|NCT00511797|9665894|FG001|Overall Study|Lost to Follow-up|0
6064332|NCT00511797|9665895|FG002|Overall Study|Lost to Follow-up|0
6064333|NCT00511797|9665896|FG003|Overall Study|Lost to Follow-up|1
6064334|NCT00511797|9665893|FG000|Overall Study|Pregnancy|0
6064335|NCT00511797|9665894|FG001|Overall Study|Pregnancy|0
6064336|NCT00511797|9665895|FG002|Overall Study|Pregnancy|0
6064337|NCT00511797|9665896|FG003|Overall Study|Pregnancy|1
6064338|NCT00511797|9665893|FG000|Overall Study|Protocol Violation|0
6064339|NCT00511797|9665894|FG001|Overall Study|Protocol Violation|2
6064340|NCT00511797|9665895|FG002|Overall Study|Protocol Violation|2
6064341|NCT00511797|9665896|FG003|Overall Study|Protocol Violation|3
6064342|NCT00511797|9665893|FG000|Overall Study|Withdrawal by Subject|3
6064343|NCT00511797|9665894|FG001|Overall Study|Withdrawal by Subject|3
6064344|NCT00511797|9665895|FG002|Overall Study|Withdrawal by Subject|4
6064345|NCT00511797|9665896|FG003|Overall Study|Withdrawal by Subject|2
6064346|NCT00511797|9665893|FG000|Overall Study|Never dispensed|1
6064347|NCT00511797|9665894|FG001|Overall Study|Never dispensed|0
6064348|NCT00511797|9665895|FG002|Overall Study|Never dispensed|1
6064349|NCT00511797|9665896|FG003|Overall Study|Never dispensed|3
6064350|NCT00511797|9665893|FG000|Overall Study|Study drug not taken|0
6064351|NCT00511797|9665894|FG001|Overall Study|Study drug not taken|1
6064352|NCT00511797|9665895|FG002|Overall Study|Study drug not taken|0
6064353|NCT00511797|9665896|FG003|Overall Study|Study drug not taken|1
6064354|NCT00511797|9665893|FG000|Overall Study|Partially missing diary|0
6064355|NCT00511797|9665894|FG001|Overall Study|Partially missing diary|0
6064356|NCT00511797|9665895|FG002|Overall Study|Partially missing diary|1
6064357|NCT00511797|9665896|FG003|Overall Study|Partially missing diary|0
6064358|NCT00511797|9665893|FG000|Overall Study|Other (moving etc)|1
6064359|NCT00511797|9665894|FG001|Overall Study|Other (moving etc)|0
6064360|NCT00511797|9665895|FG002|Overall Study|Other (moving etc)|1
6064361|NCT00511797|9665896|FG003|Overall Study|Other (moving etc)|2
6064362|NCT00511810|9665908|FG000|Overall Study|Lost to Follow-up|1
6064363|NCT00511810|9665909|FG001|Overall Study|Lost to Follow-up|2
6064364|NCT00511810|9665908|FG000|Overall Study|Lack of Efficacy|0
6064365|NCT00511810|9665909|FG001|Overall Study|Lack of Efficacy|2
6064366|NCT00511810|9665908|FG000|Overall Study|Refused second scn|0
6064367|NCT00511810|9665909|FG001|Overall Study|Refused second scn|1
6064368|NCT00511836|9665917|FG000|Double-blind Period|Lost to Follow-up|1
6064369|NCT00511836|9665918|FG001|Double-blind Period|Lost to Follow-up|0
6064370|NCT00511875|9665942|FG000|Overall Study|Lost to Follow-up|4
6064371|NCT00511875|9665943|FG001|Overall Study|Lost to Follow-up|0
6064372|NCT00511875|9665942|FG000|Overall Study|Missing variables|1
6064373|NCT00511875|9665943|FG001|Overall Study|Missing variables|0
6064374|NCT00511901|9665951|FG000|Overall Study|Withdrawal by Subject|1
6064375|NCT00511901|9665952|FG001|Overall Study|Withdrawal by Subject|3
6064376|NCT00512096|9665971|FG000|Overall Study|Adverse Event|2
6064377|NCT00512096|9665971|FG000|Overall Study|Withdrawal by Subject|2
6064378|NCT00512096|9665971|FG000|Overall Study|Lack of Efficacy|3
6064379|NCT00512135|9665975|FG000|Overall Study|Not Treated|5
6064380|NCT00512135|9665975|FG000|Overall Study|Lack of Efficacy|2
6064381|NCT00512135|9665975|FG000|Overall Study|Adverse Event|6
6064382|NCT00512135|9665975|FG000|Overall Study|Withdrawal by Subject|22
6064383|NCT00512135|9665975|FG000|Overall Study|Lost to Follow-up|27
6064384|NCT00512135|9665975|FG000|Overall Study|Other|22
6064385|NCT00512148|9665980|FG000|Primay Study Period|Withdrawal by Subject|1
6064386|NCT00512252|9665989|FG000|Overall Study|Lost to Follow-up|0
6064387|NCT00512252|9665990|FG001|Overall Study|Lost to Follow-up|0
6064388|NCT00512252|9665991|FG002|Overall Study|Lost to Follow-up|1
6064389|NCT00512252|9665989|FG000|Overall Study|Protocol Violation|0
6064390|NCT00512252|9665990|FG001|Overall Study|Protocol Violation|0
6064391|NCT00512252|9665991|FG002|Overall Study|Protocol Violation|1
6064392|NCT00512252|9665989|FG000|Overall Study|Death|0
6064393|NCT00512252|9665990|FG001|Overall Study|Death|0
6064394|NCT00512252|9665991|FG002|Overall Study|Death|1
6064395|NCT00512707|9666019|FG000|Overall Study|Lost to Follow-up|5
6064396|NCT00512707|9666020|FG001|Overall Study|Lost to Follow-up|11
6064397|NCT00512707|9666019|FG000|Overall Study|Developed skin irritation|2
6064398|NCT00512707|9666020|FG001|Overall Study|Developed skin irritation|1
6064399|NCT00512707|9666019|FG000|Overall Study|Developed a hematocrit exceeding 0.54|2
6064400|NCT00512707|9666020|FG001|Overall Study|Developed a hematocrit exceeding 0.54|0
6064401|NCT00512707|9666019|FG000|Overall Study|Unable to tolerate the smell of the gel|1
6064402|NCT00512707|9666020|FG001|Overall Study|Unable to tolerate the smell of the gel|0
6064403|NCT00512798|9666028|FG000|Overall Study|Death|0
6064404|NCT00512798|9666029|FG001|Overall Study|Death|3
6064405|NCT00512798|9666028|FG000|Overall Study|Adverse Event|2
6064406|NCT00512798|9666029|FG001|Overall Study|Adverse Event|4
6064407|NCT00512798|9666028|FG000|Overall Study|Progression of disease|14
6064408|NCT00512798|9666029|FG001|Overall Study|Progression of disease|20
6137078|NCT01005875|9767244|FG000|Overall Study|Death|3
6137079|NCT01005901|9767261|FG000|Overall Study|Withdrawal by Subject|38
6137080|NCT01005901|9767262|FG001|Overall Study|Withdrawal by Subject|14
6137081|NCT01005901|9767261|FG000|Overall Study|Adverse Event|30
6137082|NCT01005901|9767262|FG001|Overall Study|Adverse Event|16
6137083|NCT01005901|9767261|FG000|Overall Study|Administrative problems|21
6137084|NCT01005901|9767262|FG001|Overall Study|Administrative problems|13
6137085|NCT01005901|9767261|FG000|Overall Study|Unsatisfactory therapeutic effect|5
6137086|NCT01005901|9767262|FG001|Overall Study|Unsatisfactory therapeutic effect|5
6137087|NCT01005901|9767261|FG000|Overall Study|Protocol Violation|4
6137088|NCT01005901|9767262|FG001|Overall Study|Protocol Violation|3
6137089|NCT01005901|9767261|FG000|Overall Study|Death|2
6137090|NCT01005901|9767262|FG001|Overall Study|Death|3
6137091|NCT01005901|9767261|FG000|Overall Study|Lost to Follow-up|1
6137092|NCT01005901|9767262|FG001|Overall Study|Lost to Follow-up|2
6137093|NCT01005901|9767261|FG000|Overall Study|Patient's inability to use the device|1
6137094|NCT01005901|9767262|FG001|Overall Study|Patient's inability to use the device|1
6137095|NCT01005901|9767261|FG000|Overall Study|No longer requires study drug|0
6137096|NCT01005901|9767262|FG001|Overall Study|No longer requires study drug|1
6137097|NCT01005966|9767268|FG000|Treatment Period 1 (14 Days)|Adverse Event|1
6137098|NCT01005966|9767269|FG001|Treatment Period 1 (14 Days)|Adverse Event|0
6137099|NCT01005966|9767270|FG002|Treatment Period 1 (14 Days)|Adverse Event|0
6137100|NCT01005966|9767271|FG003|Treatment Period 1 (14 Days)|Adverse Event|0
6137101|NCT01005966|9767272|FG004|Treatment Period 1 (14 Days)|Adverse Event|0
6064409|NCT00512798|9666028|FG000|Overall Study|Withdrawal by Subject|3
6064410|NCT00512798|9666029|FG001|Overall Study|Withdrawal by Subject|0
6064411|NCT00512902|9666040|FG000|Overall Study|Adverse Event|7
6064412|NCT00512902|9666040|FG000|Overall Study|Lost to Follow-up|1
6064413|NCT00513019|9666046|FG000|Overall Study|Adverse Event|1
6064414|NCT00513019|9666047|FG001|Overall Study|Adverse Event|0
6064415|NCT00513019|9666046|FG000|Overall Study|Withdrawal by Subject|4
6064416|NCT00513019|9666047|FG001|Overall Study|Withdrawal by Subject|5
6064417|NCT00513071|9666053|FG000|Overall Study|Adverse Event|1
6064418|NCT00513071|9666053|FG000|Overall Study|Withdrawal by Subject|1
6064419|NCT00513071|9666053|FG000|Overall Study|Physician Decision|3
6064420|NCT00513240|9666059|FG000|Overall Study|Did not have intended surgery|3
6064421|NCT00513240|9666060|FG001|Overall Study|Did not have intended surgery|0
6064422|NCT00513240|9666059|FG000|Overall Study|Death|3
6064423|NCT00513240|9666060|FG001|Overall Study|Death|3
6064424|NCT00513240|9666059|FG000|Overall Study|Withdrawal by Subject|7
6064425|NCT00513240|9666060|FG001|Overall Study|Withdrawal by Subject|4
6064426|NCT00513305|9666080|FG000|Overall Study|Adverse Event|6
6064427|NCT00513305|9666081|FG001|Overall Study|Adverse Event|2
6064428|NCT00513305|9666080|FG000|Overall Study|Death (through Consolidation Treatment)|2
6064429|NCT00513305|9666081|FG001|Overall Study|Death (through Consolidation Treatment)|2
6064430|NCT00513305|9666080|FG000|Overall Study|Lack of Efficacy|8
6064431|NCT00513305|9666081|FG001|Overall Study|Lack of Efficacy|13
6064432|NCT00513305|9666080|FG000|Overall Study|Withdrawal by Subject|1
6064433|NCT00513305|9666081|FG001|Overall Study|Withdrawal by Subject|2
6064434|NCT00513305|9666080|FG000|Overall Study|Disease progression|8
6064435|NCT00513305|9666081|FG001|Overall Study|Disease progression|5
6064436|NCT00513305|9666080|FG000|Overall Study|Eligible for stem cell transplant|1
6064437|NCT00513305|9666081|FG001|Overall Study|Eligible for stem cell transplant|0
6064438|NCT00513305|9666080|FG000|Overall Study|Hematologic counts did not recover|1
6064439|NCT00513305|9666081|FG001|Overall Study|Hematologic counts did not recover|0
6064440|NCT00513305|9666080|FG000|Overall Study|Physician Decision|1
6064441|NCT00513305|9666081|FG001|Overall Study|Physician Decision|0
6064442|NCT00513305|9666080|FG000|Overall Study|Persistent hypocellularity|0
6064443|NCT00513305|9666081|FG001|Overall Study|Persistent hypocellularity|1
6064444|NCT00513305|9666080|FG000|Overall Study|Sponsor Decision|0
6064445|NCT00513305|9666081|FG001|Overall Study|Sponsor Decision|2
6064446|NCT00513357|9666097|FG000|Overall Study|did not receive allocated placebo|2
6064447|NCT00513357|9666098|FG001|Overall Study|did not receive allocated placebo|3
6064448|NCT00513357|9666097|FG000|Overall Study|Adverse Event|4
6064449|NCT00513357|9666098|FG001|Overall Study|Adverse Event|2
6064450|NCT00513357|9666097|FG000|Overall Study|Death|2
6064451|NCT00513357|9666098|FG001|Overall Study|Death|0
6064452|NCT00513357|9666097|FG000|Overall Study|Withdrawal by Subject|5
6064453|NCT00513357|9666098|FG001|Overall Study|Withdrawal by Subject|4
6064454|NCT00513357|9666097|FG000|Overall Study|Disease Progression|2
6064455|NCT00513357|9666098|FG001|Overall Study|Disease Progression|1
6064456|NCT00513409|9666112|FG000|Overall Study|Adverse Event|0
6064457|NCT00513409|9666113|FG001|Overall Study|Adverse Event|1
6064458|NCT00513409|9666112|FG000|Overall Study|Withdrawal by Subject|0
6064459|NCT00513409|9666113|FG001|Overall Study|Withdrawal by Subject|2
6064460|NCT00513409|9666112|FG000|Overall Study|Lost to Follow-up|0
6064461|NCT00513409|9666113|FG001|Overall Study|Lost to Follow-up|1
6064462|NCT00513409|9666112|FG000|Overall Study|Physician Decision|1
6064463|NCT00513409|9666113|FG001|Overall Study|Physician Decision|0
6064464|NCT00513409|9666112|FG000|Overall Study|Visit 3 not done|1
6064465|NCT00513409|9666113|FG001|Overall Study|Visit 3 not done|2
6064466|NCT00513474|9666134|FG000|Overall Study|Death|6
6064467|NCT00513474|9666135|FG001|Overall Study|Death|9
6064468|NCT00513474|9666134|FG000|Overall Study|Participant Withdrew Consent|1
6064469|NCT00513474|9666135|FG001|Overall Study|Participant Withdrew Consent|0
6064470|NCT00513500|9666143|FG000|Overall Study|Lost to Follow-up|35
6064471|NCT00513500|9666144|FG001|Overall Study|Lost to Follow-up|39
6064472|NCT00513500|9666143|FG000|Overall Study|Death|2
6064473|NCT00513500|9666144|FG001|Overall Study|Death|1
6064474|NCT00513500|9666143|FG000|Overall Study|Hospitalized|4
6064475|NCT00513500|9666144|FG001|Overall Study|Hospitalized|14
6137102|NCT01005966|9767268|FG000|Treatment Period 1 (14 Days)|Protocol Violation|1
6137103|NCT01005966|9767269|FG001|Treatment Period 1 (14 Days)|Protocol Violation|0
6137104|NCT01005966|9767270|FG002|Treatment Period 1 (14 Days)|Protocol Violation|1
6137105|NCT01005966|9767271|FG003|Treatment Period 1 (14 Days)|Protocol Violation|0
6137106|NCT01005966|9767272|FG004|Treatment Period 1 (14 Days)|Protocol Violation|0
6137107|NCT01005966|9767268|FG000|Washout Period 1 (4 Days)|Withdrawal by Subject|0
6137108|NCT01005966|9767269|FG001|Washout Period 1 (4 Days)|Withdrawal by Subject|0
6137109|NCT01005966|9767270|FG002|Washout Period 1 (4 Days)|Withdrawal by Subject|0
6137110|NCT01005966|9767271|FG003|Washout Period 1 (4 Days)|Withdrawal by Subject|1
6137111|NCT01005966|9767272|FG004|Washout Period 1 (4 Days)|Withdrawal by Subject|0
6137112|NCT01005966|9767268|FG000|Treatment Period 2 (14 Days)|Adverse Event|0
6137113|NCT01005966|9767269|FG001|Treatment Period 2 (14 Days)|Adverse Event|1
6137114|NCT01005966|9767270|FG002|Treatment Period 2 (14 Days)|Adverse Event|1
6137115|NCT01005966|9767271|FG003|Treatment Period 2 (14 Days)|Adverse Event|0
6137116|NCT01005966|9767272|FG004|Treatment Period 2 (14 Days)|Adverse Event|0
6137117|NCT01005966|9767268|FG000|Treatment Period 2 (14 Days)|Protocol Violation|0
6137118|NCT01005966|9767269|FG001|Treatment Period 2 (14 Days)|Protocol Violation|0
6137119|NCT01005966|9767270|FG002|Treatment Period 2 (14 Days)|Protocol Violation|0
6137120|NCT01005966|9767271|FG003|Treatment Period 2 (14 Days)|Protocol Violation|1
6137121|NCT01005966|9767272|FG004|Treatment Period 2 (14 Days)|Protocol Violation|0
6137122|NCT01005966|9767268|FG000|Treatment Period 2 (14 Days)|Withdrawal by Subject|0
6137123|NCT01005966|9767269|FG001|Treatment Period 2 (14 Days)|Withdrawal by Subject|0
6137124|NCT01005966|9767270|FG002|Treatment Period 2 (14 Days)|Withdrawal by Subject|1
6137125|NCT01005966|9767271|FG003|Treatment Period 2 (14 Days)|Withdrawal by Subject|0
6137126|NCT01005966|9767272|FG004|Treatment Period 2 (14 Days)|Withdrawal by Subject|0
6137127|NCT01005966|9767268|FG000|Treatment Period 3 (14 Days)|Protocol Violation|0
6137128|NCT01005966|9767269|FG001|Treatment Period 3 (14 Days)|Protocol Violation|1
6137129|NCT01005966|9767270|FG002|Treatment Period 3 (14 Days)|Protocol Violation|0
6137130|NCT01005966|9767271|FG003|Treatment Period 3 (14 Days)|Protocol Violation|0
6137131|NCT01005966|9767272|FG004|Treatment Period 3 (14 Days)|Protocol Violation|1
6137132|NCT01005966|9767268|FG000|Treatment Period 4 (14 Days)|Protocol Violation|0
6137133|NCT01005966|9767269|FG001|Treatment Period 4 (14 Days)|Protocol Violation|1
6137134|NCT01005966|9767270|FG002|Treatment Period 4 (14 Days)|Protocol Violation|0
6137135|NCT01005966|9767271|FG003|Treatment Period 4 (14 Days)|Protocol Violation|0
6137136|NCT01005966|9767272|FG004|Treatment Period 4 (14 Days)|Protocol Violation|0
6137137|NCT01005966|9767268|FG000|Treatment Period 4 (14 Days)|Other Reason|0
6137138|NCT01005966|9767269|FG001|Treatment Period 4 (14 Days)|Other Reason|0
6137139|NCT01005966|9767270|FG002|Treatment Period 4 (14 Days)|Other Reason|0
6137140|NCT01005966|9767271|FG003|Treatment Period 4 (14 Days)|Other Reason|0
6137141|NCT01005966|9767272|FG004|Treatment Period 4 (14 Days)|Other Reason|1
6137142|NCT01006122|9767289|FG000|First Double-blind Intervention Period|Lost to Follow-up|0
6137143|NCT01006122|9767290|FG001|First Double-blind Intervention Period|Lost to Follow-up|2
6137144|NCT01006122|9767289|FG000|First Double-blind Intervention Period|Protocol Violation|1
6137145|NCT01006122|9767290|FG001|First Double-blind Intervention Period|Protocol Violation|1
6137146|NCT01006122|9767289|FG000|First Double-blind Intervention Period|Pregnancy|0
6137147|NCT01006122|9767290|FG001|First Double-blind Intervention Period|Pregnancy|1
6137148|NCT01006122|9767289|FG000|First Double-blind Intervention Period|Withdrawal by Subject|9
6137149|NCT01006122|9767290|FG001|First Double-blind Intervention Period|Withdrawal by Subject|8
6137150|NCT01006122|9767289|FG000|First Double-blind Intervention Period|Does not meet entrance criteria|1
6137151|NCT01006122|9767290|FG001|First Double-blind Intervention Period|Does not meet entrance criteria|0
6137152|NCT01006122|9767289|FG000|First Double-blind Intervention Period|Lack of Efficacy|2
6137153|NCT01006122|9767290|FG001|First Double-blind Intervention Period|Lack of Efficacy|1
6137154|NCT01006122|9767289|FG000|First Double-blind Intervention Period|Other|3
6137155|NCT01006122|9767290|FG001|First Double-blind Intervention Period|Other|0
6137156|NCT01006122|9767289|FG000|First Double-blind Intervention Period|Adverse Event|0
6137157|NCT01006122|9767290|FG001|First Double-blind Intervention Period|Adverse Event|4
6137158|NCT01006122|9767289|FG000|Second Double-blind Intervention Period|Adverse Event|1
6137159|NCT01006122|9767290|FG001|Second Double-blind Intervention Period|Adverse Event|1
6137160|NCT01006122|9767289|FG000|Second Double-blind Intervention Period|Protocol Violation|1
6137161|NCT01006122|9767290|FG001|Second Double-blind Intervention Period|Protocol Violation|0
6137162|NCT01006122|9767289|FG000|Second Double-blind Intervention Period|Lost to Follow-up|0
6137163|NCT01006122|9767290|FG001|Second Double-blind Intervention Period|Lost to Follow-up|3
6137164|NCT01006122|9767289|FG000|Second Double-blind Intervention Period|Withdrawal by Subject|0
6137165|NCT01006122|9767290|FG001|Second Double-blind Intervention Period|Withdrawal by Subject|2
6137166|NCT01006122|9767289|FG000|Second Double-blind Intervention Period|Death|0
6137167|NCT01006122|9767290|FG001|Second Double-blind Intervention Period|Death|1
6137168|NCT01006135|9767296|FG000|Overall Study|Adverse Event|22
6137169|NCT01006135|9767296|FG000|Overall Study|Protocol Violation|14
6137170|NCT01006135|9767296|FG000|Overall Study|Lost to Follow-up|32
6137171|NCT01006135|9767296|FG000|Overall Study|Other|72
6137172|NCT01006291|9767316|FG000|Overall Study|Adverse Event|2
6137173|NCT01006291|9767317|FG001|Overall Study|Adverse Event|1
5982697|NCT01994382|9571590|FG014|Overall Study|Lost to Follow-up|0
5982698|NCT01994382|9571591|FG015|Overall Study|Lost to Follow-up|0
5982699|NCT01994382|9571592|FG016|Overall Study|Lost to Follow-up|0
5982700|NCT01994382|9571576|FG000|Overall Study|Participants rolled over into expanded access program (NCT04757259)|0
5982701|NCT01994382|9571577|FG001|Overall Study|Participants rolled over into expanded access program (NCT04757259)|0
5982702|NCT01994382|9571578|FG002|Overall Study|Participants rolled over into expanded access program (NCT04757259)|0
5982703|NCT01994382|9571579|FG003|Overall Study|Participants rolled over into expanded access program (NCT04757259)|0
5982704|NCT01994382|9571580|FG004|Overall Study|Participants rolled over into expanded access program (NCT04757259)|0
5982705|NCT01994382|9571581|FG005|Overall Study|Participants rolled over into expanded access program (NCT04757259)|0
5982706|NCT01994382|9571582|FG006|Overall Study|Participants rolled over into expanded access program (NCT04757259)|0
5982707|NCT01994382|9571583|FG007|Overall Study|Participants rolled over into expanded access program (NCT04757259)|0
5982708|NCT01994382|9571584|FG008|Overall Study|Participants rolled over into expanded access program (NCT04757259)|0
5982709|NCT01994382|9571585|FG009|Overall Study|Participants rolled over into expanded access program (NCT04757259)|0
5982710|NCT01994382|9571586|FG010|Overall Study|Participants rolled over into expanded access program (NCT04757259)|2
5982711|NCT01994382|9571587|FG011|Overall Study|Participants rolled over into expanded access program (NCT04757259)|0
6137174|NCT01006291|9767318|FG002|Overall Study|Adverse Event|2
6137175|NCT01006291|9767316|FG000|Overall Study|Lack of Efficacy|2
6137176|NCT01006291|9767317|FG001|Overall Study|Lack of Efficacy|2
6137177|NCT01006291|9767318|FG002|Overall Study|Lack of Efficacy|1
6137178|NCT01006291|9767316|FG000|Overall Study|Protocol Violation|3
6137179|NCT01006291|9767317|FG001|Overall Study|Protocol Violation|3
6137180|NCT01006291|9767318|FG002|Overall Study|Protocol Violation|3
6137181|NCT01006291|9767316|FG000|Overall Study|Withdrawal criteria|5
6137182|NCT01006291|9767317|FG001|Overall Study|Withdrawal criteria|4
6137183|NCT01006291|9767318|FG002|Overall Study|Withdrawal criteria|4
6137184|NCT01006291|9767316|FG000|Overall Study|Other|14
6137185|NCT01006291|9767317|FG001|Overall Study|Other|14
6137186|NCT01006291|9767318|FG002|Overall Study|Other|17
6137187|NCT01006356|9767326|FG000|Overall Study|Adverse Event|6
6137188|NCT01006356|9767326|FG000|Overall Study|Physician Decision|1
6137189|NCT01006356|9767326|FG000|Overall Study|Paticipants did not cooperate|6
6137190|NCT01006356|9767326|FG000|Overall Study|Withdrawal by Subject|1
6137191|NCT01006356|9767326|FG000|Overall Study|Choice by participants|2
6137192|NCT01006356|9767326|FG000|Overall Study|Protocol Violation|3
6137193|NCT01006356|9767326|FG000|Overall Study|Other|23
6137194|NCT01006590|9767349|FG000|Overall Study|Adverse Event|2
6137195|NCT01006590|9767350|FG001|Overall Study|Adverse Event|3
6137196|NCT01006590|9767349|FG000|Overall Study|Death|1
6137197|NCT01006590|9767350|FG001|Overall Study|Death|1
6137198|NCT01006590|9767349|FG000|Overall Study|Lost to Follow-up|1
6137199|NCT01006590|9767350|FG001|Overall Study|Lost to Follow-up|1
6137200|NCT01006590|9767349|FG000|Overall Study|Protocol Violation|1
6137201|NCT01006590|9767350|FG001|Overall Study|Protocol Violation|0
6137202|NCT01006590|9767349|FG000|Overall Study|Withdrawal by Subject|4
6137203|NCT01006590|9767350|FG001|Overall Study|Withdrawal by Subject|2
6137204|NCT01006590|9767349|FG000|Overall Study|Study specific discontinuation criteria|16
6137205|NCT01006590|9767350|FG001|Overall Study|Study specific discontinuation criteria|23
6137206|NCT01006590|9767349|FG000|Overall Study|Other|3
6137207|NCT01006590|9767350|FG001|Overall Study|Other|2
6137208|NCT01006603|9767358|FG000|Overall Study|Withdrawal by Subject|17
6137209|NCT01006603|9767359|FG001|Overall Study|Withdrawal by Subject|19
6137210|NCT01006603|9767358|FG000|Overall Study|Lost to Follow-up|0
6137211|NCT01006603|9767359|FG001|Overall Study|Lost to Follow-up|1
6137212|NCT01006603|9767358|FG000|Overall Study|Safety reason|1
6137213|NCT01006603|9767359|FG001|Overall Study|Safety reason|1
6137214|NCT01006603|9767358|FG000|Overall Study|Protocol Violation|1
6137215|NCT01006603|9767359|FG001|Overall Study|Protocol Violation|3
6137216|NCT01006603|9767358|FG000|Overall Study|Incorrect enrolment|0
6137217|NCT01006603|9767359|FG001|Overall Study|Incorrect enrolment|2
6137218|NCT01006603|9767358|FG000|Overall Study|Adverse Event|15
6137219|NCT01006603|9767359|FG001|Overall Study|Adverse Event|7
6137220|NCT01006603|9767358|FG000|Overall Study|Death|1
6137221|NCT01006603|9767359|FG001|Overall Study|Death|1
6137222|NCT01006603|9767358|FG000|Overall Study|Study specific discontinuation criteria|33
6137223|NCT01006603|9767359|FG001|Overall Study|Study specific discontinuation criteria|34
6137224|NCT01006603|9767358|FG000|Overall Study|Other|3
6137225|NCT01006603|9767359|FG001|Overall Study|Other|7
6137226|NCT01006616|9767369|FG000|Period 1 (6 Months)|Adverse Event|10
6137227|NCT01006616|9767370|FG001|Period 1 (6 Months)|Adverse Event|31
6137228|NCT01006616|9767371|FG002|Period 1 (6 Months)|Adverse Event|37
6137229|NCT01006616|9767372|FG003|Period 1 (6 Months)|Adverse Event|9
6137230|NCT01006616|9767369|FG000|Period 1 (6 Months)|Lack of Efficacy|3
6137231|NCT01006616|9767370|FG001|Period 1 (6 Months)|Lack of Efficacy|4
6137232|NCT01006616|9767371|FG002|Period 1 (6 Months)|Lack of Efficacy|0
6137233|NCT01006616|9767372|FG003|Period 1 (6 Months)|Lack of Efficacy|4
6137234|NCT01006616|9767369|FG000|Period 1 (6 Months)|Lost to Follow-up|0
6137235|NCT01006616|9767370|FG001|Period 1 (6 Months)|Lost to Follow-up|0
6137236|NCT01006616|9767371|FG002|Period 1 (6 Months)|Lost to Follow-up|1
6137237|NCT01006616|9767372|FG003|Period 1 (6 Months)|Lost to Follow-up|0
6137238|NCT01006616|9767369|FG000|Period 1 (6 Months)|Withdrew, Reason Unrelated to Treatment|6
6137239|NCT01006616|9767370|FG001|Period 1 (6 Months)|Withdrew, Reason Unrelated to Treatment|5
6137240|NCT01006616|9767371|FG002|Period 1 (6 Months)|Withdrew, Reason Unrelated to Treatment|2
6137241|NCT01006616|9767372|FG003|Period 1 (6 Months)|Withdrew, Reason Unrelated to Treatment|3
6137242|NCT01006616|9767369|FG000|Period 1 (6 Months)|Withdrew, Reason Related to Treatment|0
6137243|NCT01006616|9767370|FG001|Period 1 (6 Months)|Withdrew, Reason Related to Treatment|3
6137244|NCT01006616|9767371|FG002|Period 1 (6 Months)|Withdrew, Reason Related to Treatment|1
6137245|NCT01006616|9767372|FG003|Period 1 (6 Months)|Withdrew, Reason Related to Treatment|2
6137246|NCT01006616|9767369|FG000|Period 1 (6 Months)|Withdrawal by Subject|2
6137247|NCT01006616|9767370|FG001|Period 1 (6 Months)|Withdrawal by Subject|2
6137248|NCT01006616|9767371|FG002|Period 1 (6 Months)|Withdrawal by Subject|2
6137249|NCT01006616|9767372|FG003|Period 1 (6 Months)|Withdrawal by Subject|0
6137250|NCT01006616|9767369|FG000|Period 1 (6 Months)|Did Not Meet Protocol Eligibility|5
6137251|NCT01006616|9767370|FG001|Period 1 (6 Months)|Did Not Meet Protocol Eligibility|7
6137252|NCT01006616|9767371|FG002|Period 1 (6 Months)|Did Not Meet Protocol Eligibility|5
6137253|NCT01006616|9767372|FG003|Period 1 (6 Months)|Did Not Meet Protocol Eligibility|5
6137254|NCT01006616|9767369|FG000|Period 1 (6 Months)|Noncompliance With Protocol|0
6137255|NCT01006616|9767370|FG001|Period 1 (6 Months)|Noncompliance With Protocol|2
6137256|NCT01006616|9767371|FG002|Period 1 (6 Months)|Noncompliance With Protocol|2
6137257|NCT01006616|9767372|FG003|Period 1 (6 Months)|Noncompliance With Protocol|3
6137258|NCT01006616|9767369|FG000|Period 1 (6 Months)|Not Treated|0
6137259|NCT01006616|9767370|FG001|Period 1 (6 Months)|Not Treated|0
6137260|NCT01006616|9767371|FG002|Period 1 (6 Months)|Not Treated|1
6137261|NCT01006616|9767372|FG003|Period 1 (6 Months)|Not Treated|1
6137262|NCT01006616|9767369|FG000|Period 2 (18 Months)|Adverse Event|6
6137263|NCT01006616|9767370|FG001|Period 2 (18 Months)|Adverse Event|6
6137264|NCT01006616|9767371|FG002|Period 2 (18 Months)|Adverse Event|6
6137265|NCT01006616|9767372|FG003|Period 2 (18 Months)|Adverse Event|4
6137266|NCT01006616|9767369|FG000|Period 2 (18 Months)|Lack of Efficacy|0
6137267|NCT01006616|9767370|FG001|Period 2 (18 Months)|Lack of Efficacy|0
6137268|NCT01006616|9767371|FG002|Period 2 (18 Months)|Lack of Efficacy|1
6137269|NCT01006616|9767372|FG003|Period 2 (18 Months)|Lack of Efficacy|2
6137270|NCT01006616|9767369|FG000|Period 2 (18 Months)|Lost to Follow-up|2
6137271|NCT01006616|9767370|FG001|Period 2 (18 Months)|Lost to Follow-up|0
6137272|NCT01006616|9767371|FG002|Period 2 (18 Months)|Lost to Follow-up|0
6137273|NCT01006616|9767372|FG003|Period 2 (18 Months)|Lost to Follow-up|0
6137274|NCT01006616|9767369|FG000|Period 2 (18 Months)|Withdrew, Reason Unrelated to Treatment|3
6137275|NCT01006616|9767370|FG001|Period 2 (18 Months)|Withdrew, Reason Unrelated to Treatment|0
6137276|NCT01006616|9767371|FG002|Period 2 (18 Months)|Withdrew, Reason Unrelated to Treatment|3
6137277|NCT01006616|9767372|FG003|Period 2 (18 Months)|Withdrew, Reason Unrelated to Treatment|2
6137278|NCT01006616|9767369|FG000|Period 2 (18 Months)|Withdrew, Reason Related to Treatment|0
6137279|NCT01006616|9767370|FG001|Period 2 (18 Months)|Withdrew, Reason Related to Treatment|6
6137280|NCT01006616|9767371|FG002|Period 2 (18 Months)|Withdrew, Reason Related to Treatment|1
6137281|NCT01006616|9767372|FG003|Period 2 (18 Months)|Withdrew, Reason Related to Treatment|2
6137282|NCT01006616|9767369|FG000|Period 2 (18 Months)|Withdrawal by Subject|1
6137283|NCT01006616|9767370|FG001|Period 2 (18 Months)|Withdrawal by Subject|4
6137284|NCT01006616|9767371|FG002|Period 2 (18 Months)|Withdrawal by Subject|0
6137285|NCT01006616|9767372|FG003|Period 2 (18 Months)|Withdrawal by Subject|1
6137286|NCT01006616|9767369|FG000|Period 2 (18 Months)|Noncompliance With Protocol|0
6137287|NCT01006616|9767370|FG001|Period 2 (18 Months)|Noncompliance With Protocol|1
6137288|NCT01006616|9767371|FG002|Period 2 (18 Months)|Noncompliance With Protocol|0
6137289|NCT01006616|9767372|FG003|Period 2 (18 Months)|Noncompliance With Protocol|1
6137290|NCT01006616|9767369|FG000|Period 2 (18 Months)|Study Terminated|63
6137291|NCT01006616|9767370|FG001|Period 2 (18 Months)|Study Terminated|46
6137292|NCT01006616|9767371|FG002|Period 2 (18 Months)|Study Terminated|44
6137293|NCT01006616|9767372|FG003|Period 2 (18 Months)|Study Terminated|70
6137294|NCT01006629|9767382|FG000|Overall Study|Adverse Event|1
6137295|NCT01006629|9767382|FG000|Overall Study|Parent refused to continue participation|1
6137296|NCT01006629|9767382|FG000|Overall Study|Parent unable to perform site visit|4
6137297|NCT01006707|9767395|FG000|Study Session 1|Lost to Follow-up|2
6137298|NCT01006707|9767396|FG001|Study Session 1|Lost to Follow-up|0
6137299|NCT01006707|9767397|FG002|Study Session 1|Lost to Follow-up|0
6137300|NCT01006707|9767395|FG000|Study Session 1|Could not tolerate withdrawal in scanner|3
6137301|NCT01006707|9767396|FG001|Study Session 1|Could not tolerate withdrawal in scanner|0
6137302|NCT01006707|9767397|FG002|Study Session 1|Could not tolerate withdrawal in scanner|0
6137303|NCT01006889|9767405|FG000|Overall Study|Withdrawal by Subject|3
6137304|NCT01006980|9767423|FG000|Vemurafenib and Dacarbazine|Randomized but Not Treated|1
6137305|NCT01006980|9767424|FG001|Vemurafenib and Dacarbazine|Randomized but Not Treated|45
6137306|NCT01006980|9767423|FG000|Vemurafenib and Dacarbazine|Adverse Event|25
6137307|NCT01006980|9767424|FG001|Vemurafenib and Dacarbazine|Adverse Event|5
6137308|NCT01006980|9767423|FG000|Vemurafenib and Dacarbazine|Death|13
6137309|NCT01006980|9767424|FG001|Vemurafenib and Dacarbazine|Death|12
6137310|NCT01006980|9767423|FG000|Vemurafenib and Dacarbazine|Progression|257
6137311|NCT01006980|9767424|FG001|Vemurafenib and Dacarbazine|Progression|218
6137312|NCT01006980|9767423|FG000|Vemurafenib and Dacarbazine|Withdrawal of Consent|4
6137313|NCT01006980|9767424|FG001|Vemurafenib and Dacarbazine|Withdrawal of Consent|6
6137314|NCT01006980|9767423|FG000|Vemurafenib and Dacarbazine|Refuse Treatment|9
6137315|NCT01006980|9767424|FG001|Vemurafenib and Dacarbazine|Refuse Treatment|6
6137316|NCT01006980|9767423|FG000|Vemurafenib and Dacarbazine|Protocol Violation|2
6137317|NCT01006980|9767424|FG001|Vemurafenib and Dacarbazine|Protocol Violation|3
6137318|NCT01006980|9767423|FG000|Vemurafenib and Dacarbazine|Reason Not Specified|26
6137319|NCT01006980|9767424|FG001|Vemurafenib and Dacarbazine|Reason Not Specified|43
6137320|NCT01006980|9767423|FG000|Crossover: Dacarbazine to Vemurafenib|Adverse Event|0
6137321|NCT01006980|9767424|FG001|Crossover: Dacarbazine to Vemurafenib|Adverse Event|4
6137322|NCT01006980|9767423|FG000|Crossover: Dacarbazine to Vemurafenib|Death|0
6137323|NCT01006980|9767424|FG001|Crossover: Dacarbazine to Vemurafenib|Death|4
6137324|NCT01006980|9767423|FG000|Crossover: Dacarbazine to Vemurafenib|Progression|0
6137325|NCT01006980|9767424|FG001|Crossover: Dacarbazine to Vemurafenib|Progression|65
6137326|NCT01006980|9767423|FG000|Crossover: Dacarbazine to Vemurafenib|Withdrawal of Consent|0
6137327|NCT01006980|9767424|FG001|Crossover: Dacarbazine to Vemurafenib|Withdrawal of Consent|1
6137328|NCT01006980|9767423|FG000|Crossover: Dacarbazine to Vemurafenib|Reason Not Specified|0
6137329|NCT01006980|9767424|FG001|Crossover: Dacarbazine to Vemurafenib|Reason Not Specified|10
6137330|NCT01007032|9767435|FG000|Overall Study|On Study Treatment at Cut-off Date|0
6137331|NCT01007032|9767436|FG001|Overall Study|On Study Treatment at Cut-off Date|1
6137332|NCT01007032|9767437|FG002|Overall Study|On Study Treatment at Cut-off Date|1
6137333|NCT01007032|9767438|FG003|Overall Study|On Study Treatment at Cut-off Date|0
6137334|NCT01007032|9767435|FG000|Overall Study|Withdrawal by Subject|0
6137335|NCT01007032|9767436|FG001|Overall Study|Withdrawal by Subject|0
6137336|NCT01007032|9767437|FG002|Overall Study|Withdrawal by Subject|0
6137337|NCT01007032|9767438|FG003|Overall Study|Withdrawal by Subject|1
6137338|NCT01007123|9767477|FG000|Overall Study|Adverse Event|3
6137339|NCT01007123|9767478|FG001|Overall Study|Adverse Event|4
6137340|NCT01007123|9767479|FG002|Overall Study|Adverse Event|7
6137341|NCT01007123|9767480|FG003|Overall Study|Adverse Event|1
6137342|NCT01007123|9767477|FG000|Overall Study|Lack of Efficacy|1
6137343|NCT01007123|9767478|FG001|Overall Study|Lack of Efficacy|0
6137344|NCT01007123|9767479|FG002|Overall Study|Lack of Efficacy|1
6137345|NCT01007123|9767480|FG003|Overall Study|Lack of Efficacy|4
6137346|NCT01007123|9767477|FG000|Overall Study|Protocol Violation|1
6137347|NCT01007123|9767478|FG001|Overall Study|Protocol Violation|1
6137348|NCT01007123|9767479|FG002|Overall Study|Protocol Violation|2
6137349|NCT01007123|9767480|FG003|Overall Study|Protocol Violation|1
6137350|NCT01007123|9767477|FG000|Overall Study|Withdrawal by Subject|1
6137351|NCT01007123|9767478|FG001|Overall Study|Withdrawal by Subject|0
6137352|NCT01007123|9767479|FG002|Overall Study|Withdrawal by Subject|1
6137353|NCT01007123|9767480|FG003|Overall Study|Withdrawal by Subject|0
6137354|NCT01007123|9767477|FG000|Overall Study|Lost to Follow-up|0
6137355|NCT01007123|9767478|FG001|Overall Study|Lost to Follow-up|1
6137356|NCT01007123|9767479|FG002|Overall Study|Lost to Follow-up|0
6137357|NCT01007123|9767480|FG003|Overall Study|Lost to Follow-up|0
6137358|NCT01007149|9767513|FG000|Overall Study|Administrative problems|0
6137359|NCT01007149|9767514|FG001|Overall Study|Administrative problems|1
6137360|NCT01007253|9767520|FG000|Washout Period (2 Weeks) # 3|Physician Decision|1
6137361|NCT01007253|9767521|FG001|Washout Period (2 Weeks) # 3|Physician Decision|0
6137362|NCT01007253|9767522|FG002|Washout Period (2 Weeks) # 3|Physician Decision|0
6137363|NCT01007253|9767523|FG003|Washout Period (2 Weeks) # 3|Physician Decision|0
6137364|NCT01007396|9767533|FG000|Overall Study|Lost to Follow-up|47
6137365|NCT01007435|9767541|FG000|Overall Study|Adverse Event|16
6137366|NCT01007435|9767542|FG001|Overall Study|Adverse Event|25
6137367|NCT01007435|9767543|FG002|Overall Study|Adverse Event|47
6137368|NCT01007435|9767544|FG003|Overall Study|Adverse Event|31
6137369|NCT01007435|9767541|FG000|Overall Study|Death|2
6137370|NCT01007435|9767542|FG001|Overall Study|Death|4
6137371|NCT01007435|9767543|FG002|Overall Study|Death|2
6137372|NCT01007435|9767544|FG003|Overall Study|Death|1
6137373|NCT01007435|9767541|FG000|Overall Study|Insufficient Therapeutic Response|21
6137374|NCT01007435|9767542|FG001|Overall Study|Insufficient Therapeutic Response|7
6137375|NCT01007435|9767543|FG002|Overall Study|Insufficient Therapeutic Response|2
6137376|NCT01007435|9767544|FG003|Overall Study|Insufficient Therapeutic Response|9
6137377|NCT01007435|9767541|FG000|Overall Study|Violation of Selection Criteria at Entry|3
6137378|NCT01007435|9767542|FG001|Overall Study|Violation of Selection Criteria at Entry|5
6137379|NCT01007435|9767543|FG002|Overall Study|Violation of Selection Criteria at Entry|2
6137380|NCT01007435|9767544|FG003|Overall Study|Violation of Selection Criteria at Entry|0
6137381|NCT01007435|9767541|FG000|Overall Study|Other Protocol Violation|2
6137382|NCT01007435|9767542|FG001|Overall Study|Other Protocol Violation|0
6137383|NCT01007435|9767543|FG002|Overall Study|Other Protocol Violation|1
6137384|NCT01007435|9767544|FG003|Overall Study|Other Protocol Violation|0
6137385|NCT01007435|9767541|FG000|Overall Study|Refused Treatment|13
6137386|NCT01007435|9767542|FG001|Overall Study|Refused Treatment|13
6137387|NCT01007435|9767543|FG002|Overall Study|Refused Treatment|5
6137388|NCT01007435|9767544|FG003|Overall Study|Refused Treatment|8
6137389|NCT01007435|9767541|FG000|Overall Study|Failure to Return|5
6137390|NCT01007435|9767542|FG001|Overall Study|Failure to Return|4
6137391|NCT01007435|9767543|FG002|Overall Study|Failure to Return|3
6137392|NCT01007435|9767544|FG003|Overall Study|Failure to Return|6
6137393|NCT01007435|9767541|FG000|Overall Study|Reason not Specified|1
6137394|NCT01007435|9767542|FG001|Overall Study|Reason not Specified|1
6137395|NCT01007435|9767543|FG002|Overall Study|Reason not Specified|2
6137396|NCT01007435|9767544|FG003|Overall Study|Reason not Specified|1
6137397|NCT01007448|9767556|FG000|Overall Study|Continuing Prohibited Systemic Drugs|1
6137398|NCT01007448|9767557|FG001|Overall Study|Continuing Prohibited Systemic Drugs|0
6137399|NCT01007448|9767556|FG000|Overall Study|Staph Skin Infection Flare|1
6137400|NCT01007448|9767557|FG001|Overall Study|Staph Skin Infection Flare|0
6137401|NCT01007448|9767556|FG000|Overall Study|Participant Leaving the Country|1
6137402|NCT01007448|9767557|FG001|Overall Study|Participant Leaving the Country|0
6137403|NCT01007448|9767556|FG000|Overall Study|Participant Given Prohibited Medication|1
6137404|NCT01007448|9767557|FG001|Overall Study|Participant Given Prohibited Medication|0
6137405|NCT01007448|9767556|FG000|Overall Study|Progressive Disease|1
6137406|NCT01007448|9767557|FG001|Overall Study|Progressive Disease|2
6137407|NCT01007448|9767556|FG000|Overall Study|Lack of Efficacy|2
6137408|NCT01007448|9767557|FG001|Overall Study|Lack of Efficacy|0
6137409|NCT01007448|9767556|FG000|Overall Study|Withdrawal by Subject|2
6137410|NCT01007448|9767557|FG001|Overall Study|Withdrawal by Subject|3
6137411|NCT01007448|9767556|FG000|Overall Study|Adverse Event|1
6137412|NCT01007448|9767557|FG001|Overall Study|Adverse Event|4
6137413|NCT01007552|9767567|FG000|Overall Study|Withdrawal by Subject|1
6137414|NCT01007812|9767593|FG000|Period 1, One Week|Lost to Follow-up|0
6137415|NCT01007812|9767594|FG001|Period 1, One Week|Lost to Follow-up|1
6137416|NCT01007812|9767593|FG000|Period 1, One Week|Discomfort|1
6137417|NCT01007812|9767594|FG001|Period 1, One Week|Discomfort|0
6137418|NCT01007838|9767604|FG000|Overall Study|Withdrawal by Subject|1
6137419|NCT01007838|9767605|FG001|Overall Study|Withdrawal by Subject|0
6137420|NCT01007838|9767606|FG002|Overall Study|Withdrawal by Subject|0
6137421|NCT01007838|9767607|FG003|Overall Study|Withdrawal by Subject|0
6137422|NCT01007838|9767604|FG000|Overall Study|Physician Decision|1
6137423|NCT01007838|9767605|FG001|Overall Study|Physician Decision|0
6137424|NCT01007838|9767606|FG002|Overall Study|Physician Decision|0
6137425|NCT01007838|9767607|FG003|Overall Study|Physician Decision|0
6137426|NCT01007838|9767604|FG000|Overall Study|Started home haemodialysis|1
6137427|NCT01007838|9767605|FG001|Overall Study|Started home haemodialysis|0
6137428|NCT01007838|9767606|FG002|Overall Study|Started home haemodialysis|0
6137429|NCT01007838|9767607|FG003|Overall Study|Started home haemodialysis|0
6137430|NCT01007916|9767617|FG000|Period 1, 4 Weeks of Wear|Failed inclusion/exclusion|1
6137431|NCT01007916|9767618|FG001|Period 1, 4 Weeks of Wear|Failed inclusion/exclusion|0
6137432|NCT01007916|9767617|FG000|Period 2, 4 Weeks of Wear|Relocation|1
6137433|NCT01007916|9767618|FG001|Period 2, 4 Weeks of Wear|Relocation|0
6137434|NCT01007942|9767626|FG000|Overall Study|Adverse Event|29
6137435|NCT01007942|9767627|FG001|Overall Study|Adverse Event|14
6137436|NCT01007942|9767626|FG000|Overall Study|Abnormal test procedure|0
6137437|NCT01007942|9767627|FG001|Overall Study|Abnormal test procedure|1
6137438|NCT01007942|9767626|FG000|Overall Study|Disease progression|217
6137439|NCT01007942|9767627|FG001|Overall Study|Disease progression|242
6137440|NCT01007942|9767626|FG000|Overall Study|New cancer therapy|5
6137441|NCT01007942|9767627|FG001|Overall Study|New cancer therapy|1
6137442|NCT01007942|9767626|FG000|Overall Study|Protocol Violation|1
6137443|NCT01007942|9767627|FG001|Overall Study|Protocol Violation|1
6137444|NCT01007942|9767626|FG000|Overall Study|Withdrawal by Subject|19
6137445|NCT01007942|9767627|FG001|Overall Study|Withdrawal by Subject|14
6137446|NCT01007942|9767626|FG000|Overall Study|Lost to Follow-up|1
6137447|NCT01007942|9767627|FG001|Overall Study|Lost to Follow-up|0
6137448|NCT01007942|9767626|FG000|Overall Study|Administrative problems|2
6137449|NCT01007942|9767627|FG001|Overall Study|Administrative problems|0
6137450|NCT01007942|9767626|FG000|Overall Study|Death|3
6137451|NCT01007942|9767627|FG001|Overall Study|Death|2
6137452|NCT01007942|9767626|FG000|Overall Study|Patients untreated|4
6137453|NCT01007942|9767627|FG001|Overall Study|Patients untreated|3
6137454|NCT01008150|9767668|FG000|Overall Study|did not receive study drug|1
6137455|NCT01008150|9767669|FG001|Overall Study|did not receive study drug|1
6137456|NCT01008150|9767670|FG002|Overall Study|did not receive study drug|1
6137457|NCT01008150|9767671|FG003|Overall Study|did not receive study drug|0
6137458|NCT01008410|9767706|FG000|Overall Study|Adverse Event|13
6137459|NCT01008410|9767707|FG001|Overall Study|Adverse Event|7
6137460|NCT01008410|9767706|FG000|Overall Study|Withdrawal by Subject|6
6137461|NCT01008410|9767707|FG001|Overall Study|Withdrawal by Subject|2
6137462|NCT01008410|9767706|FG000|Overall Study|Lost to Follow-up|1
6137463|NCT01008410|9767707|FG001|Overall Study|Lost to Follow-up|0
6137464|NCT01008410|9767706|FG000|Overall Study|Noncompliance|1
6137465|NCT01008410|9767707|FG001|Overall Study|Noncompliance|0
6137466|NCT01008410|9767706|FG000|Overall Study|Low Cortisol|2
6137467|NCT01008410|9767707|FG001|Overall Study|Low Cortisol|0
6137468|NCT01008410|9767706|FG000|Overall Study|Lack of Efficacy|2
6137469|NCT01008410|9767707|FG001|Overall Study|Lack of Efficacy|6
6137470|NCT01008410|9767706|FG000|Overall Study|Met Exclusion Criterion|0
6137471|NCT01008410|9767707|FG001|Overall Study|Met Exclusion Criterion|1
6137472|NCT01008423|9767715|FG000|Overall Study|Adverse Event|13
6137473|NCT01008423|9767716|FG001|Overall Study|Adverse Event|6
6137474|NCT01008423|9767715|FG000|Overall Study|Withdrawal by Subject|4
6137475|NCT01008423|9767716|FG001|Overall Study|Withdrawal by Subject|7
6137476|NCT01008423|9767715|FG000|Overall Study|Lost to Follow-up|0
6137477|NCT01008423|9767716|FG001|Overall Study|Lost to Follow-up|2
6137478|NCT01008423|9767715|FG000|Overall Study|Low Cortisol|0
6137479|NCT01008423|9767716|FG001|Overall Study|Low Cortisol|1
6137480|NCT01008423|9767715|FG000|Overall Study|Lack of Efficacy|0
6137481|NCT01008423|9767716|FG001|Overall Study|Lack of Efficacy|5
6137482|NCT01008423|9767715|FG000|Overall Study|Disease Extent 70 centimeters (cm)|1
6137483|NCT01008423|9767716|FG001|Overall Study|Disease Extent 70 centimeters (cm)|0
6137484|NCT01008423|9767715|FG000|Overall Study|Personal Conflict|1
6137485|NCT01008423|9767716|FG001|Overall Study|Personal Conflict|0
6137486|NCT01008423|9767715|FG000|Overall Study|Other|0
6137487|NCT01008423|9767716|FG001|Overall Study|Other|1
6137488|NCT01008449|9767724|FG000|Overall Study|Lost to Follow-up|29
6137489|NCT01008449|9767725|FG001|Overall Study|Lost to Follow-up|19
6137490|NCT01008475|9767742|FG000|Overall Study|Ongoing treatment at data cut-off date|0
6137491|NCT01008475|9767743|FG001|Overall Study|Ongoing treatment at data cut-off date|0
6137492|NCT01008475|9767744|FG002|Overall Study|Ongoing treatment at data cut-off date|0
6137493|NCT01008475|9767745|FG003|Overall Study|Ongoing treatment at data cut-off date|0
6137494|NCT01008475|9767746|FG004|Overall Study|Ongoing treatment at data cut-off date|5
6137495|NCT01008475|9767747|FG005|Overall Study|Ongoing treatment at data cut-off date|6
6137496|NCT01008475|9767748|FG006|Overall Study|Ongoing treatment at data cut-off date|4
6137497|NCT01008553|9767764|FG000|Period 1 (Titration Period)|Physician Decision|2
6137498|NCT01008553|9767765|FG001|Period 1 (Titration Period)|Physician Decision|0
6137499|NCT01008553|9767766|FG002|Period 1 (Titration Period)|Physician Decision|0
6137500|NCT01008553|9767764|FG000|Period 1 (Titration Period)|Adverse Event|33
6137501|NCT01008553|9767765|FG001|Period 1 (Titration Period)|Adverse Event|0
6137502|NCT01008553|9767766|FG002|Period 1 (Titration Period)|Adverse Event|0
6137503|NCT01008553|9767764|FG000|Period 1 (Titration Period)|Withdrawal by Subject|6
6137504|NCT01008553|9767765|FG001|Period 1 (Titration Period)|Withdrawal by Subject|0
6137505|NCT01008553|9767766|FG002|Period 1 (Titration Period)|Withdrawal by Subject|0
6137506|NCT01008553|9767764|FG000|Period 1 (Titration Period)|Determined to increase dosage|3
6137507|NCT01008553|9767765|FG001|Period 1 (Titration Period)|Determined to increase dosage|0
6137508|NCT01008553|9767766|FG002|Period 1 (Titration Period)|Determined to increase dosage|0
6137509|NCT01008553|9767764|FG000|Period 1 (Titration Period)|Not satisfied criteria to enter Period 2|50
6137510|NCT01008553|9767765|FG001|Period 1 (Titration Period)|Not satisfied criteria to enter Period 2|0
6137511|NCT01008553|9767766|FG002|Period 1 (Titration Period)|Not satisfied criteria to enter Period 2|0
6137512|NCT01008553|9767764|FG000|Period 1 (Titration Period)|Not appropriate for this study|1
6137513|NCT01008553|9767765|FG001|Period 1 (Titration Period)|Not appropriate for this study|0
6137514|NCT01008553|9767766|FG002|Period 1 (Titration Period)|Not appropriate for this study|0
6137515|NCT01008553|9767764|FG000|Period 2 (Double-Blind Period)|Physician Decision|0
6137516|NCT01008553|9767765|FG001|Period 2 (Double-Blind Period)|Physician Decision|1
6137517|NCT01008553|9767766|FG002|Period 2 (Double-Blind Period)|Physician Decision|2
6137518|NCT01008553|9767764|FG000|Period 2 (Double-Blind Period)|Adverse Event|0
6137519|NCT01008553|9767765|FG001|Period 2 (Double-Blind Period)|Adverse Event|14
6137520|NCT01008553|9767766|FG002|Period 2 (Double-Blind Period)|Adverse Event|4
6137521|NCT01008553|9767764|FG000|Period 2 (Double-Blind Period)|Withdrawal by Subject|0
6137522|NCT01008553|9767765|FG001|Period 2 (Double-Blind Period)|Withdrawal by Subject|2
6137523|NCT01008553|9767766|FG002|Period 2 (Double-Blind Period)|Withdrawal by Subject|2
6137524|NCT01008553|9767764|FG000|Period 2 (Double-Blind Period)|Impossible to perform required tests|0
6137525|NCT01008553|9767765|FG001|Period 2 (Double-Blind Period)|Impossible to perform required tests|1
6137526|NCT01008553|9767766|FG002|Period 2 (Double-Blind Period)|Impossible to perform required tests|0
6137527|NCT01008553|9767764|FG000|Period 2 (Double-Blind Period)|Insufficient analgesic efficacy|0
6137528|NCT01008553|9767765|FG001|Period 2 (Double-Blind Period)|Insufficient analgesic efficacy|1
6137529|NCT01008553|9767766|FG002|Period 2 (Double-Blind Period)|Insufficient analgesic efficacy|4
6137530|NCT01008553|9767764|FG000|Period 2 (Double-Blind Period)|Rescue drugs increased more than 1 times|0
6137531|NCT01008553|9767765|FG001|Period 2 (Double-Blind Period)|Rescue drugs increased more than 1 times|0
6137532|NCT01008553|9767766|FG002|Period 2 (Double-Blind Period)|Rescue drugs increased more than 1 times|3
6137533|NCT01008553|9767764|FG000|Period 2 (Double-Blind Period)|More than 3 times a day rescue treatment|0
6137534|NCT01008553|9767765|FG001|Period 2 (Double-Blind Period)|More than 3 times a day rescue treatment|0
6137535|NCT01008553|9767766|FG002|Period 2 (Double-Blind Period)|More than 3 times a day rescue treatment|1
6137536|NCT01008553|9767764|FG000|Period 2 (Double-Blind Period)|More than 15mm increase in Mean VAS|0
6137537|NCT01008553|9767765|FG001|Period 2 (Double-Blind Period)|More than 15mm increase in Mean VAS|18
6137538|NCT01008553|9767766|FG002|Period 2 (Double-Blind Period)|More than 15mm increase in Mean VAS|35
6137539|NCT01008618|9767787|FG000|Period 1 (Titration Period)|Physician Decision|2
6137540|NCT01008618|9767788|FG001|Period 1 (Titration Period)|Physician Decision|0
6137541|NCT01008618|9767789|FG002|Period 1 (Titration Period)|Physician Decision|0
6137542|NCT01008618|9767787|FG000|Period 1 (Titration Period)|Adverse Event|33
6137543|NCT01008618|9767788|FG001|Period 1 (Titration Period)|Adverse Event|0
6137544|NCT01008618|9767789|FG002|Period 1 (Titration Period)|Adverse Event|0
6137545|NCT01008618|9767787|FG000|Period 1 (Titration Period)|Withdrawal by Subject|11
6137546|NCT01008618|9767788|FG001|Period 1 (Titration Period)|Withdrawal by Subject|0
6137547|NCT01008618|9767789|FG002|Period 1 (Titration Period)|Withdrawal by Subject|0
6137548|NCT01008618|9767787|FG000|Period 1 (Titration Period)|Not satisfied criteria to enter Period 2|20
6137549|NCT01008618|9767788|FG001|Period 1 (Titration Period)|Not satisfied criteria to enter Period 2|0
6137550|NCT01008618|9767789|FG002|Period 1 (Titration Period)|Not satisfied criteria to enter Period 2|0
6137551|NCT01008618|9767787|FG000|Period 1 (Titration Period)|Aggravated symptom|2
6137552|NCT01008618|9767788|FG001|Period 1 (Titration Period)|Aggravated symptom|0
6137553|NCT01008618|9767789|FG002|Period 1 (Titration Period)|Aggravated symptom|0
6137554|NCT01008618|9767787|FG000|Period 2 (Double-Blind Period)|Adverse Event|0
6137555|NCT01008618|9767788|FG001|Period 2 (Double-Blind Period)|Adverse Event|11
6137556|NCT01008618|9767789|FG002|Period 2 (Double-Blind Period)|Adverse Event|2
6137557|NCT01008618|9767787|FG000|Period 2 (Double-Blind Period)|Withdrawal by Subject|0
6137558|NCT01008618|9767788|FG001|Period 2 (Double-Blind Period)|Withdrawal by Subject|3
6137559|NCT01008618|9767789|FG002|Period 2 (Double-Blind Period)|Withdrawal by Subject|2
6137560|NCT01008618|9767787|FG000|Period 2 (Double-Blind Period)|Physician Decision|0
6137561|NCT01008618|9767788|FG001|Period 2 (Double-Blind Period)|Physician Decision|1
6137562|NCT01008618|9767789|FG002|Period 2 (Double-Blind Period)|Physician Decision|0
6137563|NCT01008618|9767787|FG000|Period 2 (Double-Blind Period)|Insufficient analgesic efficacy|0
6137564|NCT01008618|9767788|FG001|Period 2 (Double-Blind Period)|Insufficient analgesic efficacy|0
6137565|NCT01008618|9767789|FG002|Period 2 (Double-Blind Period)|Insufficient analgesic efficacy|3
6137566|NCT01008618|9767787|FG000|Period 2 (Double-Blind Period)|More than 3 times a day rescue treatment|0
6137567|NCT01008618|9767788|FG001|Period 2 (Double-Blind Period)|More than 3 times a day rescue treatment|0
6137568|NCT01008618|9767789|FG002|Period 2 (Double-Blind Period)|More than 3 times a day rescue treatment|1
6137569|NCT01008618|9767787|FG000|Period 2 (Double-Blind Period)|More than 15mm increase in Mean VAS|0
6137570|NCT01008618|9767788|FG001|Period 2 (Double-Blind Period)|More than 15mm increase in Mean VAS|21
6137571|NCT01008618|9767789|FG002|Period 2 (Double-Blind Period)|More than 15mm increase in Mean VAS|29
6137572|NCT01008618|9767787|FG000|Period 2 (Double-Blind Period)|Not appropriate for this study|0
6137573|NCT01008618|9767788|FG001|Period 2 (Double-Blind Period)|Not appropriate for this study|0
6137574|NCT01008618|9767789|FG002|Period 2 (Double-Blind Period)|Not appropriate for this study|1
6137575|NCT01008696|9767800|FG000|Overall Study|Participant's evasion of hospital visit|5
6137576|NCT01008696|9767801|FG001|Overall Study|Participant's evasion of hospital visit|4
6137577|NCT01008696|9767800|FG000|Overall Study|Withdrawal by Subject|2
6137578|NCT01008696|9767801|FG001|Overall Study|Withdrawal by Subject|4
6137579|NCT01008696|9767800|FG000|Overall Study|Physician Decision|5
6137580|NCT01008696|9767801|FG001|Overall Study|Physician Decision|1
6137581|NCT01008696|9767800|FG000|Overall Study|Adverse Event|1
6137582|NCT01008696|9767801|FG001|Overall Study|Adverse Event|0
6137583|NCT01008696|9767800|FG000|Overall Study|Participants' non-cooperation|2
6137584|NCT01008696|9767801|FG001|Overall Study|Participants' non-cooperation|3
6137585|NCT01008696|9767800|FG000|Overall Study|Other|2
6137586|NCT01008696|9767801|FG001|Overall Study|Other|3
6137587|NCT01008696|9767800|FG000|Overall Study|Other|0
6137588|NCT01008696|9767801|FG001|Overall Study|Other|2
6137589|NCT01008748|9767817|FG000|Overall Study|Lost to Follow-up|80
6137590|NCT01008748|9767817|FG000|Overall Study|Other|1
6137591|NCT01008904|9767821|FG000|Overall Study|Lost to Follow-up|1
6137592|NCT01008904|9767821|FG000|Overall Study|Adverse Event|2
6137593|NCT01008904|9767821|FG000|Overall Study|unexpected unrelated surgery|1
6137594|NCT01008943|9767825|FG000|Overall Study|Withdrawal by Subject|1
6137595|NCT01008995|9767835|FG000|Controlled Period|Adverse Event|1
6137596|NCT01008995|9767836|FG001|Controlled Period|Adverse Event|2
6137597|NCT01008995|9767837|FG002|Controlled Period|Adverse Event|0
6137598|NCT01008995|9767838|FG003|Controlled Period|Adverse Event|0
6137599|NCT01008995|9767835|FG000|Controlled Period|Other|2
6137600|NCT01008995|9767836|FG001|Controlled Period|Other|1
6137601|NCT01008995|9767837|FG002|Controlled Period|Other|0
6137602|NCT01008995|9767838|FG003|Controlled Period|Other|0
6137603|NCT01008995|9767835|FG000|After Controlled Period|Adverse Event|0
6137604|NCT01008995|9767836|FG001|After Controlled Period|Adverse Event|0
6137605|NCT01008995|9767837|FG002|After Controlled Period|Adverse Event|1
6137606|NCT01008995|9767838|FG003|After Controlled Period|Adverse Event|1
6137607|NCT01008995|9767835|FG000|After Controlled Period|Other|0
6137608|NCT01008995|9767836|FG001|After Controlled Period|Other|0
6137609|NCT01008995|9767837|FG002|After Controlled Period|Other|1
6137610|NCT01008995|9767838|FG003|After Controlled Period|Other|0
6137611|NCT01009034|9767846|FG000|Overall Study|Lost to Follow-up|2
6137612|NCT01009034|9767846|FG000|Overall Study|Withdrawal by Subject|2
6137613|NCT01009047|9767852|FG000|Overall Study|Adverse Event|5
6137614|NCT01009047|9767853|FG001|Overall Study|Adverse Event|0
6137615|NCT01009047|9767852|FG000|Overall Study|Lost to Follow-up|0
6137616|NCT01009047|9767853|FG001|Overall Study|Lost to Follow-up|2
6137617|NCT01009047|9767852|FG000|Overall Study|Lack of Efficacy|4
6137618|NCT01009047|9767853|FG001|Overall Study|Lack of Efficacy|11
6137619|NCT01009047|9767852|FG000|Overall Study|Withdrawal by consent|16
6137620|NCT01009047|9767853|FG001|Overall Study|Withdrawal by consent|11
6137621|NCT01009047|9767852|FG000|Overall Study|Other|3
6137622|NCT01009047|9767853|FG001|Overall Study|Other|2
6137623|NCT01009060|9767861|FG000|Overall Study|Adverse Event|1
6137624|NCT01009060|9767862|FG001|Overall Study|Adverse Event|2
6137625|NCT01009060|9767861|FG000|Overall Study|Protocol Violation|0
6137626|NCT01009060|9767862|FG001|Overall Study|Protocol Violation|1
6137627|NCT01009060|9767861|FG000|Overall Study|Lost to Follow-up|1
6137628|NCT01009060|9767862|FG001|Overall Study|Lost to Follow-up|0
6137629|NCT01009060|9767861|FG000|Overall Study|Physician Decision|1
6137630|NCT01009060|9767862|FG001|Overall Study|Physician Decision|1
6137631|NCT01009060|9767861|FG000|Overall Study|Withdrawal by Subject|1
6137632|NCT01009060|9767862|FG001|Overall Study|Withdrawal by Subject|1
6137633|NCT01009086|9767875|FG000|Overall Study|Lack of Efficacy|16
6137634|NCT01009086|9767876|FG001|Overall Study|Lack of Efficacy|15
6137635|NCT01009086|9767877|FG002|Overall Study|Lack of Efficacy|9
6137636|NCT01009086|9767875|FG000|Overall Study|Lost to Follow-up|4
6137637|NCT01009086|9767876|FG001|Overall Study|Lost to Follow-up|5
6137638|NCT01009086|9767877|FG002|Overall Study|Lost to Follow-up|3
6137639|NCT01009086|9767875|FG000|Overall Study|Adverse Event|12
6137640|NCT01009086|9767876|FG001|Overall Study|Adverse Event|11
6137641|NCT01009086|9767877|FG002|Overall Study|Adverse Event|8
6137642|NCT01009086|9767875|FG000|Overall Study|Withdrawal by Subject|9
6137643|NCT01009086|9767876|FG001|Overall Study|Withdrawal by Subject|11
6137644|NCT01009086|9767877|FG002|Overall Study|Withdrawal by Subject|13
6137645|NCT01009086|9767875|FG000|Overall Study|Other|3
6137646|NCT01009086|9767876|FG001|Overall Study|Other|5
6137647|NCT01009086|9767877|FG002|Overall Study|Other|1
6137648|NCT01009099|9767892|FG000|Overall Study|Lost to Follow-up|1
6137649|NCT01009099|9767893|FG001|Overall Study|Lost to Follow-up|0
6137650|NCT01009099|9767892|FG000|Overall Study|Physician Decision|3
6137651|NCT01009099|9767893|FG001|Overall Study|Physician Decision|2
6137652|NCT01009099|9767892|FG000|Overall Study|Withdrawal by Subject|1
6137653|NCT01009099|9767893|FG001|Overall Study|Withdrawal by Subject|1
6137654|NCT01009099|9767892|FG000|Overall Study|Death|0
6137655|NCT01009099|9767893|FG001|Overall Study|Death|1
6137656|NCT01009203|9767908|FG000|Overall Study|Withdrawal by Subject|1
6137657|NCT01009203|9767908|FG000|Overall Study|Adverse Event|5
6137658|NCT01009203|9767908|FG000|Overall Study|Treatment-unrelated death|1
6137659|NCT01009281|9767912|FG000|Overall Study|Administrative problems|7
6137660|NCT01009346|9767929|FG000|Overall Study|Adverse Event|4
6137661|NCT01009463|9767938|FG000|4-week, Open-label Run-In Period|Did Not Meet Continuation Criteria|373
6137662|NCT01009463|9767939|FG001|4-week, Open-label Run-In Period|Did Not Meet Continuation Criteria|0
6137663|NCT01009463|9767940|FG002|4-week, Open-label Run-In Period|Did Not Meet Continuation Criteria|0
6137664|NCT01009463|9767941|FG003|4-week, Open-label Run-In Period|Did Not Meet Continuation Criteria|0
6137665|NCT01009463|9767942|FG004|4-week, Open-label Run-In Period|Did Not Meet Continuation Criteria|0
6137666|NCT01009463|9767938|FG000|4-week, Open-label Run-In Period|Adverse Event|10
6137667|NCT01009463|9767939|FG001|4-week, Open-label Run-In Period|Adverse Event|0
6137668|NCT01009463|9767940|FG002|4-week, Open-label Run-In Period|Adverse Event|0
6137669|NCT01009463|9767941|FG003|4-week, Open-label Run-In Period|Adverse Event|0
6137670|NCT01009463|9767942|FG004|4-week, Open-label Run-In Period|Adverse Event|0
6137671|NCT01009463|9767938|FG000|4-week, Open-label Run-In Period|Lost to Follow-up|6
6137672|NCT01009463|9767939|FG001|4-week, Open-label Run-In Period|Lost to Follow-up|0
6137673|NCT01009463|9767940|FG002|4-week, Open-label Run-In Period|Lost to Follow-up|0
6137674|NCT01009463|9767941|FG003|4-week, Open-label Run-In Period|Lost to Follow-up|0
6137675|NCT01009463|9767942|FG004|4-week, Open-label Run-In Period|Lost to Follow-up|0
6137676|NCT01009463|9767938|FG000|4-week, Open-label Run-In Period|Physician Decision|10
6137677|NCT01009463|9767939|FG001|4-week, Open-label Run-In Period|Physician Decision|0
6137678|NCT01009463|9767940|FG002|4-week, Open-label Run-In Period|Physician Decision|0
6137679|NCT01009463|9767941|FG003|4-week, Open-label Run-In Period|Physician Decision|0
6137680|NCT01009463|9767942|FG004|4-week, Open-label Run-In Period|Physician Decision|0
6137681|NCT01009463|9767938|FG000|4-week, Open-label Run-In Period|Withdrawal by Subject|50
6137682|NCT01009463|9767939|FG001|4-week, Open-label Run-In Period|Withdrawal by Subject|0
6137683|NCT01009463|9767940|FG002|4-week, Open-label Run-In Period|Withdrawal by Subject|0
6137684|NCT01009463|9767941|FG003|4-week, Open-label Run-In Period|Withdrawal by Subject|0
6137685|NCT01009463|9767942|FG004|4-week, Open-label Run-In Period|Withdrawal by Subject|0
6137686|NCT01009463|9767938|FG000|52-week, Double-blind Treatment Period|Adverse Event|0
6137687|NCT01009463|9767939|FG001|52-week, Double-blind Treatment Period|Adverse Event|22
6137688|NCT01009463|9767940|FG002|52-week, Double-blind Treatment Period|Adverse Event|25
6137689|NCT01009463|9767941|FG003|52-week, Double-blind Treatment Period|Adverse Event|29
6137690|NCT01009463|9767942|FG004|52-week, Double-blind Treatment Period|Adverse Event|31
6137691|NCT01009463|9767938|FG000|52-week, Double-blind Treatment Period|Withdrawal by Subject|0
6137692|NCT01009463|9767939|FG001|52-week, Double-blind Treatment Period|Withdrawal by Subject|34
6137693|NCT01009463|9767940|FG002|52-week, Double-blind Treatment Period|Withdrawal by Subject|18
6137694|NCT01009463|9767941|FG003|52-week, Double-blind Treatment Period|Withdrawal by Subject|17
6137695|NCT01009463|9767942|FG004|52-week, Double-blind Treatment Period|Withdrawal by Subject|22
6137696|NCT01009463|9767938|FG000|52-week, Double-blind Treatment Period|Lack of Efficacy|0
6137697|NCT01009463|9767939|FG001|52-week, Double-blind Treatment Period|Lack of Efficacy|24
6137698|NCT01009463|9767940|FG002|52-week, Double-blind Treatment Period|Lack of Efficacy|16
6137699|NCT01009463|9767941|FG003|52-week, Double-blind Treatment Period|Lack of Efficacy|11
6137700|NCT01009463|9767942|FG004|52-week, Double-blind Treatment Period|Lack of Efficacy|18
6137701|NCT01009463|9767938|FG000|52-week, Double-blind Treatment Period|Protocol Violation|0
6137702|NCT01009463|9767939|FG001|52-week, Double-blind Treatment Period|Protocol Violation|8
6137703|NCT01009463|9767940|FG002|52-week, Double-blind Treatment Period|Protocol Violation|7
6137704|NCT01009463|9767941|FG003|52-week, Double-blind Treatment Period|Protocol Violation|8
6137705|NCT01009463|9767942|FG004|52-week, Double-blind Treatment Period|Protocol Violation|7
6137706|NCT01009463|9767938|FG000|52-week, Double-blind Treatment Period|Met Protocol-Defined Stopping Criteria|0
6137707|NCT01009463|9767939|FG001|52-week, Double-blind Treatment Period|Met Protocol-Defined Stopping Criteria|10
6137708|NCT01009463|9767940|FG002|52-week, Double-blind Treatment Period|Met Protocol-Defined Stopping Criteria|14
6137709|NCT01009463|9767941|FG003|52-week, Double-blind Treatment Period|Met Protocol-Defined Stopping Criteria|13
6137710|NCT01009463|9767942|FG004|52-week, Double-blind Treatment Period|Met Protocol-Defined Stopping Criteria|10
6137711|NCT01009463|9767938|FG000|52-week, Double-blind Treatment Period|Study Closed/Terminated|0
6137712|NCT01009463|9767939|FG001|52-week, Double-blind Treatment Period|Study Closed/Terminated|2
6137713|NCT01009463|9767940|FG002|52-week, Double-blind Treatment Period|Study Closed/Terminated|0
6137714|NCT01009463|9767941|FG003|52-week, Double-blind Treatment Period|Study Closed/Terminated|1
6137715|NCT01009463|9767942|FG004|52-week, Double-blind Treatment Period|Study Closed/Terminated|0
6137716|NCT01009463|9767938|FG000|52-week, Double-blind Treatment Period|Lost to Follow-up|0
6137717|NCT01009463|9767939|FG001|52-week, Double-blind Treatment Period|Lost to Follow-up|11
6137718|NCT01009463|9767940|FG002|52-week, Double-blind Treatment Period|Lost to Follow-up|7
6137719|NCT01009463|9767941|FG003|52-week, Double-blind Treatment Period|Lost to Follow-up|6
6137720|NCT01009463|9767942|FG004|52-week, Double-blind Treatment Period|Lost to Follow-up|5
6137721|NCT01009463|9767938|FG000|52-week, Double-blind Treatment Period|Physician Decision|0
6137722|NCT01009463|9767939|FG001|52-week, Double-blind Treatment Period|Physician Decision|4
6137723|NCT01009463|9767940|FG002|52-week, Double-blind Treatment Period|Physician Decision|6
6137724|NCT01009463|9767941|FG003|52-week, Double-blind Treatment Period|Physician Decision|6
6137725|NCT01009463|9767942|FG004|52-week, Double-blind Treatment Period|Physician Decision|8
6137726|NCT01009515|9767953|FG000|Overall Study|Withdrawal by Subject|3
6137727|NCT01009554|9767959|FG000|Overall Study|Adverse Event|1
6137728|NCT01009554|9767960|FG001|Overall Study|Adverse Event|1
6137729|NCT01009554|9767959|FG000|Overall Study|Withdrawal by Subject|1
6137730|NCT01009554|9767960|FG001|Overall Study|Withdrawal by Subject|3
6137731|NCT01009554|9767959|FG000|Overall Study|Noncompliant with Study Product|0
6137732|NCT01009554|9767960|FG001|Overall Study|Noncompliant with Study Product|3
6137733|NCT01009580|9767968|FG000|Overall Study|Adverse Event|4
6137734|NCT01009580|9767969|FG001|Overall Study|Adverse Event|4
6137735|NCT01009580|9767968|FG000|Overall Study|Lack of Efficacy|0
6137736|NCT01009580|9767969|FG001|Overall Study|Lack of Efficacy|1
6137737|NCT01009580|9767968|FG000|Overall Study|Protocol Violation|2
6137738|NCT01009580|9767969|FG001|Overall Study|Protocol Violation|3
6137739|NCT01009580|9767968|FG000|Overall Study|Withdrawal Criteria|4
6137740|NCT01009580|9767969|FG001|Overall Study|Withdrawal Criteria|6
6137741|NCT01009580|9767968|FG000|Overall Study|Unclassified|17
6137742|NCT01009580|9767969|FG001|Overall Study|Unclassified|21
6137743|NCT01009645|9767988|FG000|Overall Study|Lost to Follow-up|2
6137744|NCT01009645|9767989|FG001|Overall Study|Lost to Follow-up|8
6137745|NCT01009645|9767990|FG002|Overall Study|Lost to Follow-up|4
6137746|NCT01009645|9767991|FG003|Overall Study|Lost to Follow-up|5
6137747|NCT01009814|9768017|FG000|Overall Study|No longer met study criteria|1
6137748|NCT01009814|9768018|FG001|Overall Study|No longer met study criteria|1
6137749|NCT01009814|9768019|FG002|Overall Study|No longer met study criteria|0
6137750|NCT01009814|9768020|FG003|Overall Study|No longer met study criteria|0
6137751|NCT01009814|9768021|FG004|Overall Study|No longer met study criteria|0
6137752|NCT01009840|9768037|FG000|Overall Study|Lost to Follow-up|1
6137753|NCT01009840|9768037|FG000|Overall Study|Adverse Event|4
6137754|NCT01009840|9768037|FG000|Overall Study|Subject Met Withdrawal Criteria|7
6137755|NCT01009840|9768037|FG000|Overall Study|Subject was Withdrawn by Investigator|1
6137756|NCT01009840|9768037|FG000|Overall Study|Subject Withdrew Consent to Participate|1
6137757|NCT01009983|9768054|FG000|Overall Study|necessary scans not completed|1
6137758|NCT01010061|9768073|FG000|Overall Study|Adverse Events or Intercurrent Illness|33
6137759|NCT01010061|9768074|FG001|Overall Study|Adverse Events or Intercurrent Illness|16
6137760|NCT01010061|9768073|FG000|Overall Study|Disease Progression|2
6137761|NCT01010061|9768074|FG001|Overall Study|Disease Progression|8
6137762|NCT01010061|9768073|FG000|Overall Study|Withdrew Consent|5
6137763|NCT01010061|9768074|FG001|Overall Study|Withdrew Consent|1
6137764|NCT01010061|9768073|FG000|Overall Study|Death|3
6137765|NCT01010061|9768074|FG001|Overall Study|Death|6
6137766|NCT01010061|9768073|FG000|Overall Study|Administrative/Other|0
6137767|NCT01010061|9768074|FG001|Overall Study|Administrative/Other|1
6137768|NCT01010061|9768073|FG000|Overall Study|Refused Treatment/Did Not Cooperate|2
6137769|NCT01010061|9768074|FG001|Overall Study|Refused Treatment/Did Not Cooperate|0
6137770|NCT01010061|9768073|FG000|Overall Study|Insufficient Therapeutic Response|1
6137771|NCT01010061|9768074|FG001|Overall Study|Insufficient Therapeutic Response|5
6137772|NCT01010061|9768073|FG000|Overall Study|Violation of Selection Criteria|0
6137773|NCT01010061|9768074|FG001|Overall Study|Violation of Selection Criteria|1
6137774|NCT01010061|9768073|FG000|Overall Study|Did Not Receive Treatment|2
6137775|NCT01010061|9768074|FG001|Overall Study|Did Not Receive Treatment|2
6137776|NCT01010126|9768088|FG000|Overall Study|Withdrawal by Subject|1
6137777|NCT01010126|9768089|FG001|Overall Study|Withdrawal by Subject|0
6137778|NCT01010126|9768090|FG002|Overall Study|Withdrawal by Subject|1
6137779|NCT01010126|9768091|FG003|Overall Study|Withdrawal by Subject|0
6137780|NCT01010126|9768092|FG004|Overall Study|Withdrawal by Subject|3
6137781|NCT01010126|9768093|FG005|Overall Study|Withdrawal by Subject|0
6137782|NCT01010204|9768109|FG000|Overall Study|Lost to Follow-up|2
6137783|NCT01010204|9768110|FG001|Overall Study|Lost to Follow-up|2
6137784|NCT01010204|9768109|FG000|Overall Study|Adverse Event|1
6137785|NCT01010204|9768110|FG001|Overall Study|Adverse Event|3
6137786|NCT01010204|9768109|FG000|Overall Study|Withdrawal by Subject|2
6137787|NCT01010204|9768110|FG001|Overall Study|Withdrawal by Subject|3
6137788|NCT01010204|9768109|FG000|Overall Study|psychiatric hospitalization|2
6137789|NCT01010204|9768110|FG001|Overall Study|psychiatric hospitalization|1
6137790|NCT01010217|9768121|FG000|Overall Study|Lost to Follow-up|4
6137791|NCT01010217|9768122|FG001|Overall Study|Lost to Follow-up|5
6137792|NCT01010217|9768123|FG002|Overall Study|Lost to Follow-up|1
6137793|NCT01010217|9768124|FG003|Overall Study|Lost to Follow-up|0
6137794|NCT01010217|9768125|FG004|Overall Study|Lost to Follow-up|0
6137795|NCT01010217|9768121|FG000|Overall Study|Withdrawal by Subject|1
6137796|NCT01010217|9768122|FG001|Overall Study|Withdrawal by Subject|0
6137797|NCT01010217|9768123|FG002|Overall Study|Withdrawal by Subject|0
6137798|NCT01010217|9768124|FG003|Overall Study|Withdrawal by Subject|0
6137799|NCT01010217|9768125|FG004|Overall Study|Withdrawal by Subject|0
6137800|NCT01010217|9768121|FG000|Overall Study|Physician Decision|0
6137801|NCT01010217|9768122|FG001|Overall Study|Physician Decision|0
6137802|NCT01010217|9768123|FG002|Overall Study|Physician Decision|0
6137803|NCT01010217|9768124|FG003|Overall Study|Physician Decision|6
6137804|NCT01010217|9768125|FG004|Overall Study|Physician Decision|3
6137805|NCT01010230|9768139|FG000|Overall Study|Withdrawal by Subject|6
6137806|NCT01010230|9768140|FG001|Overall Study|Withdrawal by Subject|5
6137807|NCT01010230|9768139|FG000|Overall Study|Lost to Follow-up|4
6137808|NCT01010230|9768140|FG001|Overall Study|Lost to Follow-up|2
6137809|NCT01010503|9768172|FG000|Overall Study|Adverse Event|1
6137810|NCT01010503|9768172|FG000|Overall Study|Death|1
6137811|NCT01010633|9768194|FG000|Overall Study|Adverse Event|1
6137812|NCT01010633|9768195|FG001|Overall Study|Adverse Event|1
6137813|NCT01010633|9768194|FG000|Overall Study|Protocol Violation|1
6137814|NCT01010633|9768195|FG001|Overall Study|Protocol Violation|2
6137815|NCT01010633|9768194|FG000|Overall Study|Withdrawal by Subject|2
6137816|NCT01010633|9768195|FG001|Overall Study|Withdrawal by Subject|1
6137817|NCT01010633|9768194|FG000|Overall Study|Investigator decision|0
6137818|NCT01010633|9768195|FG001|Overall Study|Investigator decision|1
6137819|NCT01010750|9768207|FG000|Second Intervention|Adverse Event|0
6137820|NCT01010750|9768208|FG001|Second Intervention|Adverse Event|1
6137821|NCT01010750|9768209|FG002|Second Intervention|Adverse Event|0
6137822|NCT01010750|9768210|FG003|Second Intervention|Adverse Event|0
6137823|NCT01010750|9768211|FG004|Second Intervention|Adverse Event|0
6137824|NCT01010750|9768212|FG005|Second Intervention|Adverse Event|0
6137825|NCT01010776|9768229|FG000|Main Phase|Withdrawal by Subject|14
6137826|NCT01010776|9768229|FG000|Main Phase|Lack of Efficacy|8
6137827|NCT01010776|9768229|FG000|Main Phase|Adverse Event|7
6137828|NCT01010776|9768229|FG000|Main Phase|Lost to Follow-up|6
6137829|NCT01010776|9768229|FG000|Main Phase|Non-compliance to study medication|5
6137830|NCT01010776|9768229|FG000|Main Phase|Selection failure|2
6137831|NCT01010776|9768229|FG000|Main Phase|Inform consent withdrawal|1
6137832|NCT01010776|9768229|FG000|Main Phase|Other|1
6137833|NCT01010776|9768229|FG000|Main Phase|Did not received study medication|5
6137834|NCT01010776|9768229|FG000|In-Between Main Phase & Extension Phase|Extension phase was optional|15
6137835|NCT01010776|9768229|FG000|Extension Phase|Other|3
6137836|NCT01010867|9768248|FG000|Overall Study|< 50% adherence to probiotic|1
6137837|NCT01010971|9768288|FG000|Overall Study|Adverse Event|2
6137838|NCT01010971|9768289|FG001|Overall Study|Adverse Event|4
6137839|NCT01010971|9768290|FG002|Overall Study|Adverse Event|3
6137840|NCT01010971|9768288|FG000|Overall Study|Withdrawal by Subject|0
6137841|NCT01010971|9768289|FG001|Overall Study|Withdrawal by Subject|2
6137842|NCT01010971|9768290|FG002|Overall Study|Withdrawal by Subject|5
6137843|NCT01010971|9768288|FG000|Overall Study|Lost to Follow-up|0
6137844|NCT01010971|9768289|FG001|Overall Study|Lost to Follow-up|2
6137845|NCT01010971|9768290|FG002|Overall Study|Lost to Follow-up|3
6137846|NCT01010971|9768288|FG000|Overall Study|Other|1
6137847|NCT01010971|9768289|FG001|Overall Study|Other|0
6137848|NCT01010971|9768290|FG002|Overall Study|Other|2
6137849|NCT01011049|9768307|FG000|Overall Study|Protocol Violation|0
6137850|NCT01011049|9768308|FG001|Overall Study|Protocol Violation|0
6137851|NCT01011049|9768309|FG002|Overall Study|Protocol Violation|2
6137852|NCT01011049|9768310|FG003|Overall Study|Protocol Violation|0
6137853|NCT01011049|9768307|FG000|Overall Study|Lost to Follow-up|1
6137854|NCT01011049|9768308|FG001|Overall Study|Lost to Follow-up|2
6137855|NCT01011049|9768309|FG002|Overall Study|Lost to Follow-up|1
6137856|NCT01011049|9768310|FG003|Overall Study|Lost to Follow-up|0
6137857|NCT01011049|9768307|FG000|Overall Study|Withdrawal by Subject|0
6137858|NCT01011049|9768308|FG001|Overall Study|Withdrawal by Subject|0
6137859|NCT01011049|9768309|FG002|Overall Study|Withdrawal by Subject|1
6137860|NCT01011049|9768310|FG003|Overall Study|Withdrawal by Subject|0
6137861|NCT01011153|9768327|FG000|Overall Study|Less than 78 cases completed|8
6137862|NCT01011153|9768328|FG001|Overall Study|Less than 78 cases completed|11
6137863|NCT01011153|9768329|FG002|Overall Study|Less than 78 cases completed|9
6137864|NCT01011283|9768375|FG000|Overall Study|Adverse Event|4
6137865|NCT01011283|9768376|FG001|Overall Study|Adverse Event|2
6137866|NCT01011283|9768375|FG000|Overall Study|Progressive Disease|0
6137867|NCT01011283|9768376|FG001|Overall Study|Progressive Disease|2
6137868|NCT01011283|9768375|FG000|Overall Study|Terminated by Sponsor|5
6137869|NCT01011283|9768376|FG001|Overall Study|Terminated by Sponsor|5
6137870|NCT01011283|9768375|FG000|Overall Study|Other|2
6137871|NCT01011283|9768376|FG001|Overall Study|Other|2
6137872|NCT01011309|9768385|FG000|Overall Study|Adverse Event|2
6137873|NCT01011309|9768386|FG001|Overall Study|Adverse Event|1
6137874|NCT01011309|9768387|FG002|Overall Study|Adverse Event|2
6137875|NCT01011309|9768385|FG000|Overall Study|Lack of Efficacy|0
6137876|NCT01011309|9768386|FG001|Overall Study|Lack of Efficacy|1
6137877|NCT01011309|9768387|FG002|Overall Study|Lack of Efficacy|0
6137878|NCT01011309|9768385|FG000|Overall Study|Protocol Violation|0
6137879|NCT01011309|9768386|FG001|Overall Study|Protocol Violation|1
6137880|NCT01011309|9768387|FG002|Overall Study|Protocol Violation|3
6137881|NCT01011335|9768399|FG000|Overall Study|Lost to Follow-up|0
6137882|NCT01011335|9768400|FG001|Overall Study|Lost to Follow-up|0
6137883|NCT01011335|9768401|FG002|Overall Study|Lost to Follow-up|1
6137884|NCT01011335|9768402|FG003|Overall Study|Lost to Follow-up|1
6137885|NCT01011335|9768403|FG004|Overall Study|Lost to Follow-up|1
6137886|NCT01011335|9768404|FG005|Overall Study|Lost to Follow-up|1
6137887|NCT01011335|9768405|FG006|Overall Study|Lost to Follow-up|2
6137888|NCT01011335|9768406|FG007|Overall Study|Lost to Follow-up|2
6137889|NCT01011335|9768407|FG008|Overall Study|Lost to Follow-up|1
6137890|NCT01011335|9768408|FG009|Overall Study|Lost to Follow-up|0
6137891|NCT01011335|9768409|FG010|Overall Study|Lost to Follow-up|0
6137892|NCT01011335|9768410|FG011|Overall Study|Lost to Follow-up|1
6137893|NCT01011335|9768411|FG012|Overall Study|Lost to Follow-up|2
6137894|NCT01011335|9768399|FG000|Overall Study|Protocol Violation|0
6137895|NCT01011335|9768400|FG001|Overall Study|Protocol Violation|1
6137896|NCT01011335|9768401|FG002|Overall Study|Protocol Violation|0
6137897|NCT01011335|9768402|FG003|Overall Study|Protocol Violation|0
6137898|NCT01011335|9768403|FG004|Overall Study|Protocol Violation|0
6137899|NCT01011335|9768404|FG005|Overall Study|Protocol Violation|0
6137900|NCT01011335|9768405|FG006|Overall Study|Protocol Violation|0
6137901|NCT01011335|9768406|FG007|Overall Study|Protocol Violation|0
6137902|NCT01011335|9768407|FG008|Overall Study|Protocol Violation|0
6137903|NCT01011335|9768408|FG009|Overall Study|Protocol Violation|0
6137904|NCT01011335|9768409|FG010|Overall Study|Protocol Violation|0
6137905|NCT01011335|9768410|FG011|Overall Study|Protocol Violation|0
6137906|NCT01011335|9768411|FG012|Overall Study|Protocol Violation|0
6137907|NCT01011335|9768399|FG000|Overall Study|Moved/deployed or no booster|1
6137908|NCT01011335|9768400|FG001|Overall Study|Moved/deployed or no booster|0
6137909|NCT01011335|9768401|FG002|Overall Study|Moved/deployed or no booster|0
6137910|NCT01011335|9768402|FG003|Overall Study|Moved/deployed or no booster|1
6137911|NCT01011335|9768403|FG004|Overall Study|Moved/deployed or no booster|0
6137912|NCT01011335|9768404|FG005|Overall Study|Moved/deployed or no booster|0
6137913|NCT01011335|9768405|FG006|Overall Study|Moved/deployed or no booster|1
6137914|NCT01011335|9768406|FG007|Overall Study|Moved/deployed or no booster|0
6137915|NCT01011335|9768407|FG008|Overall Study|Moved/deployed or no booster|1
6137916|NCT01011335|9768408|FG009|Overall Study|Moved/deployed or no booster|0
6137917|NCT01011335|9768409|FG010|Overall Study|Moved/deployed or no booster|2
6137918|NCT01011335|9768410|FG011|Overall Study|Moved/deployed or no booster|0
6137919|NCT01011335|9768411|FG012|Overall Study|Moved/deployed or no booster|0
6137920|NCT01011335|9768399|FG000|Overall Study|Adverse Event|0
6137921|NCT01011335|9768400|FG001|Overall Study|Adverse Event|0
6137922|NCT01011335|9768401|FG002|Overall Study|Adverse Event|0
6137923|NCT01011335|9768402|FG003|Overall Study|Adverse Event|0
6137924|NCT01011335|9768403|FG004|Overall Study|Adverse Event|0
6137925|NCT01011335|9768404|FG005|Overall Study|Adverse Event|0
6137926|NCT01011335|9768405|FG006|Overall Study|Adverse Event|0
6137927|NCT01011335|9768406|FG007|Overall Study|Adverse Event|0
6137928|NCT01011335|9768407|FG008|Overall Study|Adverse Event|0
6137929|NCT01011335|9768408|FG009|Overall Study|Adverse Event|0
6137930|NCT01011335|9768409|FG010|Overall Study|Adverse Event|4
6137931|NCT01011335|9768410|FG011|Overall Study|Adverse Event|0
6137932|NCT01011335|9768411|FG012|Overall Study|Adverse Event|1
6137933|NCT01011387|9768448|FG000|Overall Study|Withdrawal by Subject|3
6137934|NCT01011387|9768448|FG000|Overall Study|Adverse Event|2
6137935|NCT01011387|9768448|FG000|Overall Study|Protocol Violation|1
6137936|NCT01011439|9768468|FG000|Overall Study|Death|37
6137937|NCT01011439|9768468|FG000|Overall Study|Lost to Follow-up|4
6137938|NCT01011439|9768468|FG000|Overall Study|Withdrawal by Subject|1
6137939|NCT01011439|9768468|FG000|Overall Study|Sponsor's decision|15
6137940|NCT01011465|9768481|FG000|Overall Study|Withdrawal by Subject|2
6137941|NCT01011465|9768482|FG001|Overall Study|Withdrawal by Subject|1
6137942|NCT01011465|9768483|FG002|Overall Study|Withdrawal by Subject|0
6137943|NCT01011465|9768484|FG003|Overall Study|Withdrawal by Subject|0
6137944|NCT01011465|9768485|FG004|Overall Study|Withdrawal by Subject|1
6137945|NCT01011465|9768486|FG005|Overall Study|Withdrawal by Subject|0
6137946|NCT01011465|9768487|FG006|Overall Study|Withdrawal by Subject|1
6137947|NCT01011465|9768488|FG007|Overall Study|Withdrawal by Subject|0
6137948|NCT01011556|9768508|FG000|Overall Study|Adverse Event|1
6137949|NCT01011556|9768509|FG001|Overall Study|Adverse Event|3
6137950|NCT01011556|9768510|FG002|Overall Study|Adverse Event|2
6137951|NCT01011556|9768511|FG003|Overall Study|Adverse Event|1
6137952|NCT01011556|9768508|FG000|Overall Study|Lost to Follow-up|1
6137953|NCT01011556|9768509|FG001|Overall Study|Lost to Follow-up|0
6137954|NCT01011556|9768510|FG002|Overall Study|Lost to Follow-up|0
6137955|NCT01011556|9768511|FG003|Overall Study|Lost to Follow-up|0
6137956|NCT01011556|9768508|FG000|Overall Study|Physician Decision|1
6137957|NCT01011556|9768509|FG001|Overall Study|Physician Decision|0
6137958|NCT01011556|9768510|FG002|Overall Study|Physician Decision|0
6137959|NCT01011556|9768511|FG003|Overall Study|Physician Decision|1
6137960|NCT01011556|9768508|FG000|Overall Study|Protocol Violation|0
6137961|NCT01011556|9768509|FG001|Overall Study|Protocol Violation|1
6137962|NCT01011556|9768510|FG002|Overall Study|Protocol Violation|0
6137963|NCT01011556|9768511|FG003|Overall Study|Protocol Violation|0
6137964|NCT01011556|9768508|FG000|Overall Study|Withdrawal by Subject|1
6137965|NCT01011556|9768509|FG001|Overall Study|Withdrawal by Subject|2
6137966|NCT01011556|9768510|FG002|Overall Study|Withdrawal by Subject|4
6137967|NCT01011556|9768511|FG003|Overall Study|Withdrawal by Subject|4
6137968|NCT01011556|9768508|FG000|Overall Study|Sponsor decision|0
6137969|NCT01011556|9768509|FG001|Overall Study|Sponsor decision|1
6137970|NCT01011556|9768510|FG002|Overall Study|Sponsor decision|1
6137971|NCT01011556|9768511|FG003|Overall Study|Sponsor decision|2
6137972|NCT01011556|9768508|FG000|Overall Study|Inclusion/exclusion criteria not met|2
6137973|NCT01011556|9768509|FG001|Overall Study|Inclusion/exclusion criteria not met|1
6137974|NCT01011556|9768510|FG002|Overall Study|Inclusion/exclusion criteria not met|3
6137975|NCT01011556|9768511|FG003|Overall Study|Inclusion/exclusion criteria not met|5
6137976|NCT01011673|9768526|FG000|Randomized|Secondary headache|2
6137977|NCT01011673|9768527|FG001|Randomized|Secondary headache|1
6137978|NCT01011673|9768526|FG000|24 Hour Follow-up|Lost to Follow-up|3
6137979|NCT01011673|9768527|FG001|24 Hour Follow-up|Lost to Follow-up|3
6137980|NCT01011738|9768536|FG000|Overall Study|Death|12
6137981|NCT01011738|9768537|FG001|Overall Study|Death|3
6137982|NCT01011738|9768538|FG002|Overall Study|Death|0
6137983|NCT01011738|9768536|FG000|Overall Study|Unknown reasons|312
6137984|NCT01011738|9768537|FG001|Overall Study|Unknown reasons|291
6137985|NCT01011738|9768538|FG002|Overall Study|Unknown reasons|17
6137986|NCT01011868|9768570|FG000|After Week 18 Follow-up|Adverse Event|8
6137987|NCT01011868|9768571|FG001|After Week 18 Follow-up|Adverse Event|6
6137988|NCT01011868|9768572|FG002|After Week 18 Follow-up|Adverse Event|13
6137989|NCT01011868|9768570|FG000|After Week 18 Follow-up|Lack of Efficacy|1
6137990|NCT01011868|9768571|FG001|After Week 18 Follow-up|Lack of Efficacy|0
6137991|NCT01011868|9768572|FG002|After Week 18 Follow-up|Lack of Efficacy|0
6137992|NCT01011868|9768570|FG000|After Week 18 Follow-up|Protocol Violation|1
6137993|NCT01011868|9768571|FG001|After Week 18 Follow-up|Protocol Violation|1
6137994|NCT01011868|9768572|FG002|After Week 18 Follow-up|Protocol Violation|1
6137995|NCT01011868|9768570|FG000|After Week 18 Follow-up|Lost to Follow-up|5
6137996|NCT01011868|9768571|FG001|After Week 18 Follow-up|Lost to Follow-up|3
6137997|NCT01011868|9768572|FG002|After Week 18 Follow-up|Lost to Follow-up|0
6137998|NCT01011868|9768570|FG000|After Week 18 Follow-up|Withdrawal by Subject|6
6137999|NCT01011868|9768571|FG001|After Week 18 Follow-up|Withdrawal by Subject|3
6138000|NCT01011868|9768572|FG002|After Week 18 Follow-up|Withdrawal by Subject|0
6138001|NCT01011868|9768570|FG000|After Week 18 Follow-up|Other reason not defined above|2
6138002|NCT01011868|9768571|FG001|After Week 18 Follow-up|Other reason not defined above|3
6138003|NCT01011868|9768572|FG002|After Week 18 Follow-up|Other reason not defined above|12
6138004|NCT01011868|9768570|FG000|After Week 78 Follow-up|Adverse Event|14
6138005|NCT01011868|9768571|FG001|After Week 78 Follow-up|Adverse Event|18
6138006|NCT01011868|9768572|FG002|After Week 78 Follow-up|Adverse Event|21
6138007|NCT01011868|9768570|FG000|After Week 78 Follow-up|Lack of Efficacy|4
6138008|NCT01011868|9768571|FG001|After Week 78 Follow-up|Lack of Efficacy|0
6138009|NCT01011868|9768572|FG002|After Week 78 Follow-up|Lack of Efficacy|0
6138010|NCT01011868|9768570|FG000|After Week 78 Follow-up|Protocol Violation|9
6138011|NCT01011868|9768571|FG001|After Week 78 Follow-up|Protocol Violation|1
6138012|NCT01011868|9768572|FG002|After Week 78 Follow-up|Protocol Violation|2
6138013|NCT01011868|9768570|FG000|After Week 78 Follow-up|Lost to Follow-up|11
6138014|NCT01011868|9768571|FG001|After Week 78 Follow-up|Lost to Follow-up|6
6138015|NCT01011868|9768572|FG002|After Week 78 Follow-up|Lost to Follow-up|4
6138016|NCT01011868|9768570|FG000|After Week 78 Follow-up|Withdrawal by Subject|9
6138017|NCT01011868|9768571|FG001|After Week 78 Follow-up|Withdrawal by Subject|8
6138018|NCT01011868|9768572|FG002|After Week 78 Follow-up|Withdrawal by Subject|1
6138019|NCT01011868|9768570|FG000|After Week 78 Follow-up|Other reason not defined above|5
6138020|NCT01011868|9768571|FG001|After Week 78 Follow-up|Other reason not defined above|5
6138021|NCT01011868|9768572|FG002|After Week 78 Follow-up|Other reason not defined above|16
6138022|NCT01011907|9768586|FG000|Overall Study|Withdrawal by Subject|13
6138023|NCT01011907|9768587|FG001|Overall Study|Withdrawal by Subject|11
6138024|NCT01011907|9768586|FG000|Overall Study|Adverse Event|1
6138025|NCT01011907|9768587|FG001|Overall Study|Adverse Event|4
6138026|NCT01011933|9768593|FG000|Overall Study|Wrong cell type|1
6138027|NCT01011933|9768593|FG000|Overall Study|Improper pre-protocol Rx|1
6138028|NCT01011933|9768593|FG000|Overall Study|Inadequate pathology|1
6138029|NCT01011933|9768593|FG000|Overall Study|Never treated|1
6138030|NCT01011946|9768603|FG000|Overall Study|Transferred to another hospital|2
6138031|NCT01011946|9768603|FG000|Overall Study|No pathological lab value|1
6138032|NCT01012037|9768610|FG000|Overall Study|Adverse Event|0
6138033|NCT01012037|9768611|FG001|Overall Study|Adverse Event|8
6138034|NCT01012037|9768612|FG002|Overall Study|Adverse Event|3
6138035|NCT01012037|9768610|FG000|Overall Study|Protocol Violation|0
6138036|NCT01012037|9768611|FG001|Overall Study|Protocol Violation|3
6138037|NCT01012037|9768612|FG002|Overall Study|Protocol Violation|5
6138038|NCT01012037|9768610|FG000|Overall Study|Withdrawal by Subject|0
6138039|NCT01012037|9768611|FG001|Overall Study|Withdrawal by Subject|4
6138040|NCT01012037|9768612|FG002|Overall Study|Withdrawal by Subject|1
6138041|NCT01012037|9768610|FG000|Overall Study|Other reason (not specified)|1
6138042|NCT01012037|9768611|FG001|Overall Study|Other reason (not specified)|1
6138043|NCT01012037|9768612|FG002|Overall Study|Other reason (not specified)|1
6138044|NCT01012219|9768628|FG000|Period 1|Withdrawal by Subject|1
6138045|NCT01012219|9768628|FG000|Period 2|Withdrawal by Subject|1
6138046|NCT01012258|9768650|FG000|Overall Study|Death|14
6138047|NCT01012258|9768650|FG000|Overall Study|Lost to Follow-up|1
6138048|NCT01012258|9768650|FG000|Overall Study|Adverse Event|1
6138049|NCT01012258|9768650|FG000|Overall Study|Progressive Disease (PD)|18
6138050|NCT01012258|9768650|FG000|Overall Study|Symptomatic Deterioration|1
6138051|NCT01012258|9768650|FG000|Overall Study|Another Anti-cancer Drug Received|1
6138052|NCT01012258|9768650|FG000|Overall Study|Another Tumor Discovered|1
6138053|NCT01012258|9768650|FG000|Overall Study|Ongoing|29
6138054|NCT01012323|9768664|FG000|Overall Study|Investigator Judgment|1
6138055|NCT01012440|9768701|FG000|Overall Study|Withdrawal by Subject|2
6138056|NCT01012622|9768709|FG000|Overall Study|Withdrawal by Subject|6
6138057|NCT01012622|9768709|FG000|Overall Study|Lost to Follow-up|5
6138058|NCT01012622|9768709|FG000|Overall Study|Adverse Event|7
6138059|NCT01012622|9768709|FG000|Overall Study|non-compliance with the drug|9
6138060|NCT01012622|9768709|FG000|Overall Study|Other|1
6138061|NCT01012622|9768709|FG000|Overall Study|screening failure|1
6138062|NCT01012622|9768709|FG000|Overall Study|withdrawal of consent by a parent|2
6138063|NCT01012713|9768727|FG000|Overall Study|Lack of Efficacy|3
6138064|NCT01012739|9768732|FG000|Treatment Period 1|Adverse Event|0
6138065|NCT01012739|9768733|FG001|Treatment Period 1|Adverse Event|0
6138066|NCT01012739|9768734|FG002|Treatment Period 1|Adverse Event|0
6138067|NCT01012739|9768735|FG003|Treatment Period 1|Adverse Event|1
6138068|NCT01012739|9768732|FG000|Treatment Period 2|Abnormal test procedure results|0
6138069|NCT01012739|9768733|FG001|Treatment Period 2|Abnormal test procedure results|0
6138070|NCT01012739|9768734|FG002|Treatment Period 2|Abnormal test procedure results|0
6138071|NCT01012739|9768735|FG003|Treatment Period 2|Abnormal test procedure results|1
6138072|NCT01012765|9768746|FG000|Treatment Period 1|Adverse Event|1
6138073|NCT01012765|9768747|FG001|Treatment Period 1|Adverse Event|0
6138074|NCT01012765|9768748|FG002|Treatment Period 1|Adverse Event|1
6138075|NCT01012765|9768749|FG003|Treatment Period 1|Adverse Event|0
6138076|NCT01012765|9768750|FG004|Treatment Period 1|Adverse Event|0
6138077|NCT01012765|9768751|FG005|Treatment Period 1|Adverse Event|0
6138078|NCT01012765|9768746|FG000|Treatment Period 1|Withdrawal by Subject|2
6138079|NCT01012765|9768747|FG001|Treatment Period 1|Withdrawal by Subject|0
6138080|NCT01012765|9768748|FG002|Treatment Period 1|Withdrawal by Subject|0
6138081|NCT01012765|9768749|FG003|Treatment Period 1|Withdrawal by Subject|0
6138082|NCT01012765|9768750|FG004|Treatment Period 1|Withdrawal by Subject|0
6138083|NCT01012765|9768751|FG005|Treatment Period 1|Withdrawal by Subject|0
6138084|NCT01012765|9768746|FG000|Treatment Period 1|Administrative problems|0
6138085|NCT01012765|9768747|FG001|Treatment Period 1|Administrative problems|0
6138086|NCT01012765|9768748|FG002|Treatment Period 1|Administrative problems|1
6138087|NCT01012765|9768749|FG003|Treatment Period 1|Administrative problems|1
6138088|NCT01012765|9768750|FG004|Treatment Period 1|Administrative problems|1
6138089|NCT01012765|9768751|FG005|Treatment Period 1|Administrative problems|0
6138090|NCT01012765|9768746|FG000|Treatment Period 1|Protocol Violation|0
6138091|NCT01012765|9768747|FG001|Treatment Period 1|Protocol Violation|0
6138092|NCT01012765|9768748|FG002|Treatment Period 1|Protocol Violation|0
6138093|NCT01012765|9768749|FG003|Treatment Period 1|Protocol Violation|2
6138094|NCT01012765|9768750|FG004|Treatment Period 1|Protocol Violation|1
6138095|NCT01012765|9768751|FG005|Treatment Period 1|Protocol Violation|0
6138096|NCT01012765|9768746|FG000|Treatment Period 1|Unsatisfactory therapeutic effect|0
6138097|NCT01012765|9768747|FG001|Treatment Period 1|Unsatisfactory therapeutic effect|0
6138098|NCT01012765|9768748|FG002|Treatment Period 1|Unsatisfactory therapeutic effect|0
6138099|NCT01012765|9768749|FG003|Treatment Period 1|Unsatisfactory therapeutic effect|0
6138100|NCT01012765|9768750|FG004|Treatment Period 1|Unsatisfactory therapeutic effect|1
6138101|NCT01012765|9768751|FG005|Treatment Period 1|Unsatisfactory therapeutic effect|0
6138102|NCT01012765|9768746|FG000|Treatment Period 2|Withdrawal by Subject|1
6138103|NCT01012765|9768747|FG001|Treatment Period 2|Withdrawal by Subject|0
6138104|NCT01012765|9768748|FG002|Treatment Period 2|Withdrawal by Subject|1
6138105|NCT01012765|9768749|FG003|Treatment Period 2|Withdrawal by Subject|0
6138106|NCT01012765|9768750|FG004|Treatment Period 2|Withdrawal by Subject|1
6138107|NCT01012765|9768751|FG005|Treatment Period 2|Withdrawal by Subject|0
6138108|NCT01012765|9768746|FG000|Treatment Period 2|Abnormal laboratory value(s)|0
6138109|NCT01012765|9768747|FG001|Treatment Period 2|Abnormal laboratory value(s)|0
6138110|NCT01012765|9768748|FG002|Treatment Period 2|Abnormal laboratory value(s)|0
6138111|NCT01012765|9768749|FG003|Treatment Period 2|Abnormal laboratory value(s)|0
6138112|NCT01012765|9768750|FG004|Treatment Period 2|Abnormal laboratory value(s)|0
6138113|NCT01012765|9768751|FG005|Treatment Period 2|Abnormal laboratory value(s)|1
6138114|NCT01012765|9768746|FG000|Treatment Period 2|Adverse Event|0
6138115|NCT01012765|9768747|FG001|Treatment Period 2|Adverse Event|1
6138116|NCT01012765|9768748|FG002|Treatment Period 2|Adverse Event|1
6138117|NCT01012765|9768749|FG003|Treatment Period 2|Adverse Event|0
6138118|NCT01012765|9768750|FG004|Treatment Period 2|Adverse Event|0
6138119|NCT01012765|9768751|FG005|Treatment Period 2|Adverse Event|0
6138120|NCT01012765|9768746|FG000|Treatment Period 2|Unsatisfactory therapeutic effect|0
6138121|NCT01012765|9768747|FG001|Treatment Period 2|Unsatisfactory therapeutic effect|1
6138122|NCT01012765|9768748|FG002|Treatment Period 2|Unsatisfactory therapeutic effect|1
6138123|NCT01012765|9768749|FG003|Treatment Period 2|Unsatisfactory therapeutic effect|0
6138124|NCT01012765|9768750|FG004|Treatment Period 2|Unsatisfactory therapeutic effect|0
6138125|NCT01012765|9768751|FG005|Treatment Period 2|Unsatisfactory therapeutic effect|0
6138126|NCT01012947|9768773|FG000|Overall Study|Lost to Follow-up|131
6138127|NCT01012947|9768774|FG001|Overall Study|Lost to Follow-up|135
6138128|NCT01012947|9768775|FG002|Overall Study|Lost to Follow-up|130
6138129|NCT01012947|9768776|FG003|Overall Study|Lost to Follow-up|118
6138130|NCT01012947|9768777|FG004|Overall Study|Lost to Follow-up|142
6138131|NCT01012973|9768791|FG000|Overall Study|Adverse Event|5
6138132|NCT01012973|9768792|FG001|Overall Study|Adverse Event|5
6138133|NCT01012973|9768791|FG000|Overall Study|Lack of Efficacy|0
6138134|NCT01012973|9768792|FG001|Overall Study|Lack of Efficacy|5
6138135|NCT01012973|9768791|FG000|Overall Study|Lost to Follow-up|1
6138136|NCT01012973|9768792|FG001|Overall Study|Lost to Follow-up|0
6138137|NCT01012973|9768791|FG000|Overall Study|(Overseas travel - indefinite period)|1
6138138|NCT01012973|9768792|FG001|Overall Study|(Overseas travel - indefinite period)|0
6138139|NCT01012973|9768791|FG000|Overall Study|Increase in vis. acuity, never injected|0
6138140|NCT01012973|9768792|FG001|Overall Study|Increase in vis. acuity, never injected|1
6138141|NCT01012973|9768791|FG000|Overall Study|Protocol Violation|5
6138142|NCT01012973|9768792|FG001|Overall Study|Protocol Violation|2
6138143|NCT01012973|9768791|FG000|Overall Study|Withdrawal by Subject|4
6138144|NCT01012973|9768792|FG001|Overall Study|Withdrawal by Subject|6
6138145|NCT01012999|9768802|FG000|Overall Study|Protocol Violation|1
6138146|NCT01013207|9768819|FG000|CPAP Post Nexus (S9)|Lost to Follow-up|6
6138147|NCT01013285|9768825|FG000|Overall Study|Death|48
6138148|NCT01013285|9768826|FG001|Overall Study|Death|89
6138149|NCT01013350|9768833|FG000|Overall Study|Lost to Follow-up|15
6138150|NCT01013350|9768834|FG001|Overall Study|Lost to Follow-up|95
6138151|NCT01013350|9768833|FG000|Overall Study|Adverse Event|0
6138152|NCT01013350|9768834|FG001|Overall Study|Adverse Event|1
6138153|NCT01013350|9768833|FG000|Overall Study|Physician Decision|4
6138154|NCT01013350|9768834|FG001|Overall Study|Physician Decision|20
6138155|NCT01013350|9768833|FG000|Overall Study|Withdrawal by Subject|15
6138156|NCT01013350|9768834|FG001|Overall Study|Withdrawal by Subject|38
6138157|NCT01013350|9768833|FG000|Overall Study|Death|3
6138158|NCT01013350|9768834|FG001|Overall Study|Death|5
6138159|NCT01013350|9768833|FG000|Overall Study|Participant entered interventional study|0
6138160|NCT01013350|9768834|FG001|Overall Study|Participant entered interventional study|8
6138161|NCT01013350|9768833|FG000|Overall Study|Other|1
6138162|NCT01013350|9768834|FG001|Overall Study|Other|25
6138163|NCT01013597|9768841|FG000|Overall Study|Withdrawal by Subject|1
6138164|NCT01013740|9768847|FG000|Overall Study|Lost to Follow-up|3
6138165|NCT01013740|9768848|FG001|Overall Study|Lost to Follow-up|5
6138166|NCT01013740|9768847|FG000|Overall Study|Physician Decision|2
6138167|NCT01013740|9768848|FG001|Overall Study|Physician Decision|0
6138168|NCT01013740|9768847|FG000|Overall Study|Withdrawal by Subject|2
6138169|NCT01013740|9768848|FG001|Overall Study|Withdrawal by Subject|10
6138170|NCT01013740|9768847|FG000|Overall Study|study close / terminated : done in error|2
6138171|NCT01013740|9768848|FG001|Overall Study|study close / terminated : done in error|1
6138172|NCT01013740|9768847|FG000|Overall Study|Missing|2
6138173|NCT01013740|9768848|FG001|Overall Study|Missing|1
6138174|NCT01013740|9768847|FG000|Overall Study|Ongoing: Study records not completed|0
6138175|NCT01013740|9768848|FG001|Overall Study|Ongoing: Study records not completed|2
6138176|NCT01013753|9768856|FG000|Overall Study|Adverse Event|8
6138177|NCT01013753|9768856|FG000|Overall Study|Protocol Violation|3
6138178|NCT01013753|9768856|FG000|Overall Study|Lost to Follow-up|1
6138179|NCT01013753|9768856|FG000|Overall Study|Withdrawal by Subject|2
6138180|NCT01013753|9768856|FG000|Overall Study|Other|2
6138181|NCT01013792|9768872|FG000|Overall Study|Study suspended|2
6138182|NCT01013792|9768873|FG001|Overall Study|Study suspended|1
6138183|NCT01013792|9768872|FG000|Overall Study|Adverse Event|0
6138184|NCT01013792|9768873|FG001|Overall Study|Adverse Event|3
6138185|NCT01013792|9768872|FG000|Overall Study|Lost to Follow-up|0
6138186|NCT01013792|9768873|FG001|Overall Study|Lost to Follow-up|1
6138187|NCT01013870|9768894|FG000|Overall Study|Lost to Follow-up|1
6138188|NCT01013870|9768895|FG001|Overall Study|Lost to Follow-up|3
6138189|NCT01013883|9768903|FG000|Overall Study|Lost to Follow-up|2
6138190|NCT01013883|9768904|FG001|Overall Study|Lost to Follow-up|2
6138191|NCT01013961|9768912|FG000|Overall Study|Adverse Event|2
6138192|NCT01013961|9768913|FG001|Overall Study|Adverse Event|2
6138193|NCT01013961|9768912|FG000|Overall Study|Withdrawal by Subject|1
6138194|NCT01013961|9768913|FG001|Overall Study|Withdrawal by Subject|0
6138195|NCT01013961|9768912|FG000|Overall Study|Physician Decision|0
6138196|NCT01013961|9768913|FG001|Overall Study|Physician Decision|1
6138197|NCT01014013|9768921|FG000|Overall Study|Inclusion/Exclusion criteria not met|1
6138198|NCT01014013|9768922|FG001|Overall Study|Inclusion/Exclusion criteria not met|3
6138199|NCT01014013|9768921|FG000|Overall Study|Clinical adverse experience|4
6138200|NCT01014013|9768922|FG001|Overall Study|Clinical adverse experience|2
6138201|NCT01014013|9768921|FG000|Overall Study|Laboratory adverse experience|1
6138202|NCT01014013|9768922|FG001|Overall Study|Laboratory adverse experience|1
6138203|NCT01014013|9768921|FG000|Overall Study|Protocol Violation|1
6138204|NCT01014013|9768922|FG001|Overall Study|Protocol Violation|3
6138205|NCT01014013|9768921|FG000|Overall Study|Withdrawal by Subject|7
6138206|NCT01014013|9768922|FG001|Overall Study|Withdrawal by Subject|4
6138207|NCT01014013|9768921|FG000|Overall Study|Clinical/microbiologic failure|1
6138208|NCT01014013|9768922|FG001|Overall Study|Clinical/microbiologic failure|2
6138209|NCT01014013|9768921|FG000|Overall Study|Pathogen culture = no growth|26
6138210|NCT01014013|9768922|FG001|Overall Study|Pathogen culture = no growth|34
6138211|NCT01014013|9768921|FG000|Overall Study|Negative urine culture|2
6138212|NCT01014013|9768922|FG001|Overall Study|Negative urine culture|0
6138213|NCT01014013|9768921|FG000|Overall Study|Pathogen resistant|7
6138214|NCT01014013|9768922|FG001|Overall Study|Pathogen resistant|4
6138215|NCT01014013|9768921|FG000|Overall Study|Physician Decision|0
6138216|NCT01014013|9768922|FG001|Overall Study|Physician Decision|1
6138217|NCT01014013|9768921|FG000|Overall Study|Another antibiotic therapy required|0
6138218|NCT01014013|9768922|FG001|Overall Study|Another antibiotic therapy required|1
6138219|NCT01014013|9768921|FG000|Overall Study|Appendectomy|1
6138220|NCT01014013|9768922|FG001|Overall Study|Appendectomy|0
6138221|NCT01014013|9768921|FG000|Overall Study|Inappropriate therapy duration, < 7 Days|0
6138222|NCT01014013|9768922|FG001|Overall Study|Inappropriate therapy duration, < 7 Days|1
6138223|NCT01014143|9768967|FG000|Second Intervention|Lost to Follow-up|2
6138224|NCT01014143|9768968|FG001|Second Intervention|Lost to Follow-up|0
6138225|NCT01014143|9768969|FG002|Second Intervention|Lost to Follow-up|0
6138226|NCT01014208|9768988|FG000|Overall Study|Lost to Follow-up|2
6138227|NCT01014208|9768989|FG001|Overall Study|Lost to Follow-up|5
6138228|NCT01014208|9768988|FG000|Overall Study|Participant Withdrew Consent|12
6138229|NCT01014208|9768989|FG001|Overall Study|Participant Withdrew Consent|12
6138230|NCT01014208|9768988|FG000|Overall Study|Did Not Receive Study Drug|2
6138231|NCT01014208|9768989|FG001|Overall Study|Did Not Receive Study Drug|0
6138232|NCT01014208|9768988|FG000|Overall Study|Study Closed/terminated|78
6138233|NCT01014208|9768989|FG001|Overall Study|Study Closed/terminated|83
6138234|NCT01014442|9769014|FG000|Overall Study|Adverse Event|0
6138235|NCT01014442|9769015|FG001|Overall Study|Adverse Event|8
6138236|NCT01014442|9769014|FG000|Overall Study|Withdrawal by Subject|4
6138237|NCT01014442|9769015|FG001|Overall Study|Withdrawal by Subject|4
6138238|NCT01014442|9769014|FG000|Overall Study|Protocol Violation|2
6138239|NCT01014442|9769015|FG001|Overall Study|Protocol Violation|5
6138240|NCT01014442|9769014|FG000|Overall Study|Lack of Compliance|0
6138241|NCT01014442|9769015|FG001|Overall Study|Lack of Compliance|1
6138242|NCT01014442|9769014|FG000|Overall Study|Unspecified Reason|1
6138243|NCT01014442|9769015|FG001|Overall Study|Unspecified Reason|1
6138244|NCT01014533|9769036|FG000|Overall Study|Protocol Violation|3
6138245|NCT01014533|9769037|FG001|Overall Study|Protocol Violation|2
6138246|NCT01014533|9769036|FG000|Overall Study|Withdrawal by Subject|2
6138247|NCT01014533|9769037|FG001|Overall Study|Withdrawal by Subject|0
6138248|NCT01014533|9769036|FG000|Overall Study|unable to come to appointment|0
6138249|NCT01014533|9769037|FG001|Overall Study|unable to come to appointment|3
6138250|NCT01014585|9769048|FG000|Overall Study|Adverse Event|0
6138251|NCT01014585|9769049|FG001|Overall Study|Adverse Event|2
6138252|NCT01014585|9769050|FG002|Overall Study|Adverse Event|0
6138253|NCT01014585|9769051|FG003|Overall Study|Adverse Event|3
6138254|NCT01014585|9769048|FG000|Overall Study|Withdrawal by Subject|2
6138255|NCT01014585|9769049|FG001|Overall Study|Withdrawal by Subject|0
6138256|NCT01014585|9769050|FG002|Overall Study|Withdrawal by Subject|1
6138257|NCT01014585|9769051|FG003|Overall Study|Withdrawal by Subject|3
6138258|NCT01014585|9769048|FG000|Overall Study|Lost to Follow-up|0
6138259|NCT01014585|9769049|FG001|Overall Study|Lost to Follow-up|0
6138260|NCT01014585|9769050|FG002|Overall Study|Lost to Follow-up|0
6138261|NCT01014585|9769051|FG003|Overall Study|Lost to Follow-up|2
6138262|NCT01014585|9769048|FG000|Overall Study|Withdrawn Due to Worsening Fibromyalgia|18
6138263|NCT01014585|9769049|FG001|Overall Study|Withdrawn Due to Worsening Fibromyalgia|23
6138264|NCT01014585|9769050|FG002|Overall Study|Withdrawn Due to Worsening Fibromyalgia|22
6138265|NCT01014585|9769051|FG003|Overall Study|Withdrawn Due to Worsening Fibromyalgia|22
6138266|NCT01014624|9769063|FG000|Overall Study|Adverse Event|0
6138267|NCT01014624|9769064|FG001|Overall Study|Adverse Event|1
6138268|NCT01014624|9769063|FG000|Overall Study|Protocol Violation|1
6138269|NCT01014624|9769064|FG001|Overall Study|Protocol Violation|0
6138270|NCT01014624|9769063|FG000|Overall Study|Withdrawal by Subject|1
6138271|NCT01014624|9769064|FG001|Overall Study|Withdrawal by Subject|0
6138272|NCT01014689|9769074|FG000|Overall Study|Lack of Efficacy|0
6138273|NCT01014689|9769075|FG001|Overall Study|Lack of Efficacy|1
6138274|NCT01014689|9769074|FG000|Overall Study|Adverse Event|3
6138275|NCT01014689|9769075|FG001|Overall Study|Adverse Event|0
6138276|NCT01014689|9769074|FG000|Overall Study|Withdrawal by Subject|5
6138277|NCT01014689|9769075|FG001|Overall Study|Withdrawal by Subject|4
6138278|NCT01014689|9769074|FG000|Overall Study|Protocol Violation|1
6138279|NCT01014689|9769075|FG001|Overall Study|Protocol Violation|1
6138280|NCT01014689|9769074|FG000|Overall Study|Lost to Follow-up|3
6138281|NCT01014689|9769075|FG001|Overall Study|Lost to Follow-up|7
6138282|NCT01014689|9769074|FG000|Overall Study|Pregnancy|1
6138283|NCT01014689|9769075|FG001|Overall Study|Pregnancy|0
6138284|NCT01014910|9769107|FG000|Overall Study|Withdrawal by Subject|0
6138285|NCT01014910|9769108|FG001|Overall Study|Withdrawal by Subject|2
6138286|NCT01014975|9769185|FG000|Overall Study|Withdrawal by Subject|1
6138287|NCT01014975|9769186|FG001|Overall Study|Withdrawal by Subject|0
6138288|NCT01014975|9769187|FG002|Overall Study|Withdrawal by Subject|1
6138289|NCT01014975|9769185|FG000|Overall Study|Death|3
6138290|NCT01014975|9769186|FG001|Overall Study|Death|3
6138291|NCT01014975|9769187|FG002|Overall Study|Death|4
6138292|NCT01014975|9769185|FG000|Overall Study|Lost to Follow-up|0
6138293|NCT01014975|9769186|FG001|Overall Study|Lost to Follow-up|0
6138294|NCT01014975|9769187|FG002|Overall Study|Lost to Follow-up|1
6138295|NCT01014988|9769201|FG000|Overall Study|Adverse Event|20
6138296|NCT01014988|9769202|FG001|Overall Study|Adverse Event|0
6138297|NCT01014988|9769203|FG002|Overall Study|Adverse Event|1
6138298|NCT01014988|9769204|FG003|Overall Study|Adverse Event|0
6138299|NCT01014988|9769205|FG004|Overall Study|Adverse Event|1
6138300|NCT01014988|9769206|FG005|Overall Study|Adverse Event|3
6138301|NCT01014988|9769201|FG000|Overall Study|Lost to Follow-up|1
6138302|NCT01014988|9769202|FG001|Overall Study|Lost to Follow-up|0
6138303|NCT01014988|9769203|FG002|Overall Study|Lost to Follow-up|1
6138304|NCT01014988|9769204|FG003|Overall Study|Lost to Follow-up|0
6138305|NCT01014988|9769205|FG004|Overall Study|Lost to Follow-up|0
6138306|NCT01014988|9769206|FG005|Overall Study|Lost to Follow-up|0
6138307|NCT01014988|9769201|FG000|Overall Study|Physician Decision|1
6138308|NCT01014988|9769202|FG001|Overall Study|Physician Decision|0
6138309|NCT01014988|9769203|FG002|Overall Study|Physician Decision|0
6138310|NCT01014988|9769204|FG003|Overall Study|Physician Decision|0
6138311|NCT01014988|9769205|FG004|Overall Study|Physician Decision|0
6138312|NCT01014988|9769206|FG005|Overall Study|Physician Decision|0
6138313|NCT01014988|9769201|FG000|Overall Study|Withdrawal by Subject|1
6138314|NCT01014988|9769202|FG001|Overall Study|Withdrawal by Subject|0
6138315|NCT01014988|9769203|FG002|Overall Study|Withdrawal by Subject|0
6138316|NCT01014988|9769204|FG003|Overall Study|Withdrawal by Subject|0
6138317|NCT01014988|9769205|FG004|Overall Study|Withdrawal by Subject|0
6138318|NCT01014988|9769206|FG005|Overall Study|Withdrawal by Subject|0
6138319|NCT01015118|9769230|FG000|Overall Study|Protocol Violation|5
6138320|NCT01015118|9769231|FG001|Overall Study|Protocol Violation|6
6138321|NCT01015118|9769230|FG000|Overall Study|Withdrawal by Subject|103
6138322|NCT01015118|9769231|FG001|Overall Study|Withdrawal by Subject|27
6138323|NCT01015118|9769230|FG000|Overall Study|Other Adverse Event (AE)|141
6138324|NCT01015118|9769231|FG001|Overall Study|Other Adverse Event (AE)|33
6138325|NCT01015118|9769230|FG000|Overall Study|Worsening or AE of underlying disease|5
6138326|NCT01015118|9769231|FG001|Overall Study|Worsening or AE of underlying disease|4
6138327|NCT01015118|9769230|FG000|Overall Study|Progressive disease|364
6138328|NCT01015118|9769231|FG001|Overall Study|Progressive disease|229
6138329|NCT01015118|9769230|FG000|Overall Study|Not treated|9
6138330|NCT01015118|9769231|FG001|Overall Study|Not treated|5
6138331|NCT01015118|9769230|FG000|Overall Study|Other than stated above|42
6138332|NCT01015118|9769231|FG001|Overall Study|Other than stated above|23
6138333|NCT01015131|9769237|FG000|Overall Study|Physician Decision|1
6138334|NCT01015131|9769237|FG000|Overall Study|Protocol Violation|1
6138335|NCT01015131|9769237|FG000|Overall Study|Withdrawal by Subject|2
6138336|NCT01015131|9769237|FG000|Overall Study|Other Protocol Specified Criteria|4
6138337|NCT01015287|9769249|FG000|Overall Study|Death|21
6138338|NCT01015287|9769250|FG001|Overall Study|Death|16
6138339|NCT01015287|9769249|FG000|Overall Study|Adverse Event|1
6138340|NCT01015287|9769250|FG001|Overall Study|Adverse Event|0
6138341|NCT01015287|9769249|FG000|Overall Study|Sponsor Decision|3
6138342|NCT01015287|9769250|FG001|Overall Study|Sponsor Decision|7
6138343|NCT01015287|9769249|FG000|Overall Study|Physician Decision|19
6138344|NCT01015287|9769250|FG001|Overall Study|Physician Decision|21
6138345|NCT01015287|9769249|FG000|Overall Study|Withdrawal by Subject|14
6138346|NCT01015287|9769250|FG001|Overall Study|Withdrawal by Subject|19
6138347|NCT01015287|9769249|FG000|Overall Study|Entry Criteria not Met|11
6138348|NCT01015287|9769250|FG001|Overall Study|Entry Criteria not Met|14
6138349|NCT01015287|9769249|FG000|Overall Study|Lost to Follow-up|2
6138350|NCT01015287|9769250|FG001|Overall Study|Lost to Follow-up|1
6138351|NCT01015287|9769249|FG000|Overall Study|Protocol Violation|1
6138352|NCT01015287|9769250|FG001|Overall Study|Protocol Violation|1
6138353|NCT01015560|9769288|FG000|Overall Study|Adverse Event|1
6138354|NCT01015560|9769288|FG000|Overall Study|Not protocol specified|1
6138355|NCT01015560|9769288|FG000|Overall Study|Withdrawal by Subject|1
6138356|NCT01015612|9769301|FG000|Overall Study|Death|113
6138357|NCT01015612|9769301|FG000|Overall Study|Withdrawal by Subject|40
6138358|NCT01015638|9769307|FG000|Overall Study|Withdrawal by Subject|1
6138359|NCT01015638|9769308|FG001|Overall Study|Withdrawal by Subject|0
6138360|NCT01015677|9769317|FG000|Overall Study|Adverse Event|0
6138361|NCT01015677|9769318|FG001|Overall Study|Adverse Event|1
6138362|NCT01015677|9769319|FG002|Overall Study|Adverse Event|0
6138363|NCT01015677|9769317|FG000|Overall Study|Lack of Efficacy|0
6138364|NCT01015677|9769318|FG001|Overall Study|Lack of Efficacy|1
6138365|NCT01015677|9769319|FG002|Overall Study|Lack of Efficacy|0
6138366|NCT01015677|9769317|FG000|Overall Study|Protocol Violation|0
6138367|NCT01015677|9769318|FG001|Overall Study|Protocol Violation|1
6138368|NCT01015677|9769319|FG002|Overall Study|Protocol Violation|0
6138369|NCT01015677|9769317|FG000|Overall Study|Withdrawal by Subject|1
6138370|NCT01015677|9769318|FG001|Overall Study|Withdrawal by Subject|1
6138371|NCT01015677|9769319|FG002|Overall Study|Withdrawal by Subject|0
6138372|NCT01015703|9769332|FG000|Overall Study|Withdrawal by Subject|0
6138373|NCT01015703|9769333|FG001|Overall Study|Withdrawal by Subject|1
6138374|NCT01015703|9769334|FG002|Overall Study|Withdrawal by Subject|0
6138375|NCT01015703|9769335|FG003|Overall Study|Withdrawal by Subject|0
6138376|NCT01015703|9769336|FG004|Overall Study|Withdrawal by Subject|0
6138377|NCT01015703|9769332|FG000|Overall Study|Adverse Event|1
6138378|NCT01015703|9769333|FG001|Overall Study|Adverse Event|0
6138379|NCT01015703|9769334|FG002|Overall Study|Adverse Event|0
6138380|NCT01015703|9769335|FG003|Overall Study|Adverse Event|0
6138381|NCT01015703|9769336|FG004|Overall Study|Adverse Event|0
6138382|NCT01015703|9769332|FG000|Overall Study|Protocol Violation|1
6138383|NCT01015703|9769333|FG001|Overall Study|Protocol Violation|0
6138384|NCT01015703|9769334|FG002|Overall Study|Protocol Violation|0
6138385|NCT01015703|9769335|FG003|Overall Study|Protocol Violation|0
6138386|NCT01015703|9769336|FG004|Overall Study|Protocol Violation|0
6138387|NCT01015768|9769348|FG000|Overall Study|Some subject data unuseable|4
6138388|NCT01015768|9769349|FG001|Overall Study|Some subject data unuseable|4
6138389|NCT01015820|9769381|FG000|Overall Study|Suboptimal measurements|1
6138390|NCT01015820|9769382|FG001|Overall Study|Suboptimal measurements|0
6138391|NCT01016015|9769393|FG000|Overall Study|Not Treated|3
6138392|NCT01016015|9769393|FG000|Overall Study|Withdrawal by Subject|1
6138393|NCT01016015|9769393|FG000|Overall Study|Adverse Event|15
6138394|NCT01016067|9769399|FG000|Overall Study|Lost to Follow-up|1
6138395|NCT01016067|9769400|FG001|Overall Study|Lost to Follow-up|2
6138396|NCT01016067|9769399|FG000|Overall Study|Physician Decision|1
6138397|NCT01016067|9769400|FG001|Overall Study|Physician Decision|1
6138398|NCT01016067|9769399|FG000|Overall Study|Withdrew due to Relocation|0
6138399|NCT01016067|9769400|FG001|Overall Study|Withdrew due to Relocation|1
6138400|NCT01016132|9769415|FG000|Overall Study|Discomfort|1
6138401|NCT01016262|9769422|FG000|Double-blind Phase|Adverse Event|0
6138402|NCT01016262|9769423|FG001|Double-blind Phase|Adverse Event|0
6138403|NCT01016262|9769424|FG002|Double-blind Phase|Adverse Event|1
6138404|NCT01016262|9769425|FG003|Double-blind Phase|Adverse Event|0
6138405|NCT01016262|9769426|FG004|Double-blind Phase|Adverse Event|0
6138406|NCT01016262|9769427|FG005|Double-blind Phase|Adverse Event|0
6138407|NCT01016262|9769422|FG000|Double-blind Phase|Lack of Efficacy|1
6138408|NCT01016262|9769423|FG001|Double-blind Phase|Lack of Efficacy|0
6138409|NCT01016262|9769424|FG002|Double-blind Phase|Lack of Efficacy|5
6138410|NCT01016262|9769425|FG003|Double-blind Phase|Lack of Efficacy|0
6138411|NCT01016262|9769426|FG004|Double-blind Phase|Lack of Efficacy|0
6138412|NCT01016262|9769427|FG005|Double-blind Phase|Lack of Efficacy|0
6138413|NCT01016262|9769422|FG000|Double-blind Phase|Disease Progression|0
6138414|NCT01016262|9769423|FG001|Double-blind Phase|Disease Progression|1
6138415|NCT01016262|9769424|FG002|Double-blind Phase|Disease Progression|2
6138416|NCT01016262|9769425|FG003|Double-blind Phase|Disease Progression|0
6138417|NCT01016262|9769426|FG004|Double-blind Phase|Disease Progression|0
6138418|NCT01016262|9769427|FG005|Double-blind Phase|Disease Progression|0
6138419|NCT01016262|9769422|FG000|Double-blind Phase|Withdrawal of Informed Consent|0
6138420|NCT01016262|9769423|FG001|Double-blind Phase|Withdrawal of Informed Consent|0
6138421|NCT01016262|9769424|FG002|Double-blind Phase|Withdrawal of Informed Consent|1
6138422|NCT01016262|9769425|FG003|Double-blind Phase|Withdrawal of Informed Consent|0
6138423|NCT01016262|9769426|FG004|Double-blind Phase|Withdrawal of Informed Consent|0
6138424|NCT01016262|9769427|FG005|Double-blind Phase|Withdrawal of Informed Consent|0
6138425|NCT01016262|9769422|FG000|Open-Label Phase|Adverse Event|0
6138426|NCT01016262|9769423|FG001|Open-Label Phase|Adverse Event|0
6138427|NCT01016262|9769424|FG002|Open-Label Phase|Adverse Event|0
6138428|NCT01016262|9769425|FG003|Open-Label Phase|Adverse Event|1
6138429|NCT01016262|9769426|FG004|Open-Label Phase|Adverse Event|0
6138430|NCT01016262|9769427|FG005|Open-Label Phase|Adverse Event|0
6138431|NCT01016262|9769422|FG000|Open-Label Phase|Lost to Follow-up|0
6138432|NCT01016262|9769423|FG001|Open-Label Phase|Lost to Follow-up|0
6138433|NCT01016262|9769424|FG002|Open-Label Phase|Lost to Follow-up|0
6138434|NCT01016262|9769425|FG003|Open-Label Phase|Lost to Follow-up|0
6138435|NCT01016262|9769426|FG004|Open-Label Phase|Lost to Follow-up|1
6138436|NCT01016262|9769427|FG005|Open-Label Phase|Lost to Follow-up|0
6138437|NCT01016262|9769422|FG000|Open-Label Phase|Lack of Efficacy|0
6138438|NCT01016262|9769423|FG001|Open-Label Phase|Lack of Efficacy|0
6138439|NCT01016262|9769424|FG002|Open-Label Phase|Lack of Efficacy|0
6138440|NCT01016262|9769425|FG003|Open-Label Phase|Lack of Efficacy|1
6138441|NCT01016262|9769426|FG004|Open-Label Phase|Lack of Efficacy|0
6138442|NCT01016262|9769427|FG005|Open-Label Phase|Lack of Efficacy|0
6138443|NCT01016262|9769422|FG000|Open-Label Phase|Withdrawal of Informed Consent|0
6138444|NCT01016262|9769423|FG001|Open-Label Phase|Withdrawal of Informed Consent|0
6138445|NCT01016262|9769424|FG002|Open-Label Phase|Withdrawal of Informed Consent|0
6138446|NCT01016262|9769425|FG003|Open-Label Phase|Withdrawal of Informed Consent|0
6138447|NCT01016262|9769426|FG004|Open-Label Phase|Withdrawal of Informed Consent|1
6138448|NCT01016262|9769427|FG005|Open-Label Phase|Withdrawal of Informed Consent|0
6138449|NCT01016600|9769496|FG000|Overall Study|Did not start treatment|1
6138450|NCT01016600|9769497|FG001|Overall Study|Did not start treatment|0
6138451|NCT01016600|9769498|FG002|Overall Study|Did not start treatment|0
6138452|NCT01016600|9769499|FG003|Overall Study|Did not start treatment|0
6138453|NCT01016912|9769594|FG000|End of Treatment Period|Lack of Efficacy|0
6138454|NCT01016912|9769595|FG001|End of Treatment Period|Lack of Efficacy|1
6138455|NCT01016912|9769596|FG002|End of Treatment Period|Lack of Efficacy|0
6138456|NCT01016912|9769597|FG003|End of Treatment Period|Lack of Efficacy|4
6138457|NCT01016912|9769598|FG004|End of Treatment Period|Lack of Efficacy|4
6138458|NCT01016912|9769594|FG000|End of Treatment Period|Adverse Event|0
6138459|NCT01016912|9769595|FG001|End of Treatment Period|Adverse Event|1
6138460|NCT01016912|9769596|FG002|End of Treatment Period|Adverse Event|1
6138461|NCT01016912|9769597|FG003|End of Treatment Period|Adverse Event|0
6138462|NCT01016912|9769598|FG004|End of Treatment Period|Adverse Event|0
6138463|NCT01016912|9769594|FG000|End of Treatment Period|Completed double-blind period only|0
6138464|NCT01016912|9769595|FG001|End of Treatment Period|Completed double-blind period only|1
6138465|NCT01016912|9769596|FG002|End of Treatment Period|Completed double-blind period only|0
6138466|NCT01016912|9769597|FG003|End of Treatment Period|Completed double-blind period only|0
6138467|NCT01016912|9769598|FG004|End of Treatment Period|Completed double-blind period only|0
6138468|NCT01016912|9769594|FG000|Follow-up Period|Other reason|0
6138469|NCT01016912|9769595|FG001|Follow-up Period|Other reason|0
6138470|NCT01016912|9769596|FG002|Follow-up Period|Other reason|1
6138471|NCT01016912|9769597|FG003|Follow-up Period|Other reason|1
6138472|NCT01016912|9769598|FG004|Follow-up Period|Other reason|0
6138473|NCT01016964|9769637|FG000|Overall Study|Lost to Follow-up|3
6138474|NCT01016964|9769638|FG001|Overall Study|Lost to Follow-up|3
6138475|NCT01016977|9769646|FG000|Overall Study|Lost to Follow-up|1
6138476|NCT01016977|9769647|FG001|Overall Study|Lost to Follow-up|0
6138477|NCT01016977|9769646|FG000|Overall Study|Withdrawal by Subject|2
6138478|NCT01016977|9769647|FG001|Overall Study|Withdrawal by Subject|2
6138479|NCT01017029|9769664|FG000|Overall Study|Lost to Follow-up|1
6138480|NCT01017029|9769665|FG001|Overall Study|Lost to Follow-up|0
6138481|NCT01017029|9769664|FG000|Overall Study|Administrative problem|0
6138482|NCT01017029|9769665|FG001|Overall Study|Administrative problem|1
6138483|NCT01017029|9769664|FG000|Overall Study|Death|3
6138484|NCT01017029|9769665|FG001|Overall Study|Death|1
6138485|NCT01017120|9769682|FG000|Overall Study|Adverse Event|9
6138486|NCT01017120|9769683|FG001|Overall Study|Adverse Event|0
6138487|NCT01017120|9769682|FG000|Overall Study|Lost to Follow-up|13
6138488|NCT01017120|9769683|FG001|Overall Study|Lost to Follow-up|11
6138489|NCT01017120|9769682|FG000|Overall Study|Lack of Efficacy|1
6138490|NCT01017120|9769683|FG001|Overall Study|Lack of Efficacy|0
6138491|NCT01017120|9769682|FG000|Overall Study|Withdrawal by Subject|39
6138492|NCT01017120|9769683|FG001|Overall Study|Withdrawal by Subject|21
6138493|NCT01017120|9769682|FG000|Overall Study|Pregnancy|1
6138494|NCT01017120|9769683|FG001|Overall Study|Pregnancy|1
6138495|NCT01017120|9769682|FG000|Overall Study|Did Not Meet Eligibility Criteria|1
6138496|NCT01017120|9769683|FG001|Overall Study|Did Not Meet Eligibility Criteria|0
6138497|NCT01017120|9769682|FG000|Overall Study|Relocated Out of Town|0
6138498|NCT01017120|9769683|FG001|Overall Study|Relocated Out of Town|2
6138499|NCT01017120|9769682|FG000|Overall Study|Protocol Violation|1
6138500|NCT01017120|9769683|FG001|Overall Study|Protocol Violation|0
6138501|NCT01017120|9769682|FG000|Overall Study|Parent Unable to Provide Transportation|1
6138502|NCT01017120|9769683|FG001|Overall Study|Parent Unable to Provide Transportation|0
6138503|NCT01017146|9769691|FG000|Overall Study|Adverse Event|11
6138504|NCT01017146|9769692|FG001|Overall Study|Adverse Event|1
6138505|NCT01017146|9769691|FG000|Overall Study|Lost to Follow-up|14
6138506|NCT01017146|9769692|FG001|Overall Study|Lost to Follow-up|14
6138507|NCT01017146|9769691|FG000|Overall Study|Noncompliance with Study Product|1
6138508|NCT01017146|9769692|FG001|Overall Study|Noncompliance with Study Product|1
6138509|NCT01017146|9769691|FG000|Overall Study|Withdrawal by Subject|32
6138510|NCT01017146|9769692|FG001|Overall Study|Withdrawal by Subject|16
6138511|NCT01017146|9769691|FG000|Overall Study|Relocation|0
6138512|NCT01017146|9769692|FG001|Overall Study|Relocation|4
6138513|NCT01017146|9769691|FG000|Overall Study|Pregnancy|2
6138514|NCT01017146|9769692|FG001|Overall Study|Pregnancy|1
6138515|NCT01017146|9769691|FG000|Overall Study|Protocol Violation|2
6138516|NCT01017146|9769692|FG001|Overall Study|Protocol Violation|0
6138517|NCT01017146|9769691|FG000|Overall Study|Took Excluded Medication|2
6138518|NCT01017146|9769692|FG001|Overall Study|Took Excluded Medication|0
6138519|NCT01017146|9769691|FG000|Overall Study|Did Not Meet Eligibility Criteria|1
6138520|NCT01017146|9769692|FG001|Overall Study|Did Not Meet Eligibility Criteria|2
6138521|NCT01017146|9769691|FG000|Overall Study|Change in Work Situation|1
6138522|NCT01017146|9769692|FG001|Overall Study|Change in Work Situation|0
6138523|NCT01017549|9769730|FG000|Eligibility Through 6 Month Follow-up|Lost to Follow-up|1
6138524|NCT01017549|9769730|FG000|One-year Follow-up|Lost to Follow-up|2
6138525|NCT01017549|9769730|FG000|One-year Follow-up|Withdrawal by Subject|5
6138526|NCT01017549|9769730|FG000|5 Year Follow-up|Lost to Follow-up|9
6138527|NCT01017549|9769730|FG000|5 Year Follow-up|Mastectomy|3
6138528|NCT01017575|9769739|FG000|Overall Study|Lack of Efficacy|0
6138529|NCT01017575|9769740|FG001|Overall Study|Lack of Efficacy|1
6138530|NCT01017575|9769741|FG002|Overall Study|Lack of Efficacy|0
6138531|NCT01017575|9769742|FG003|Overall Study|Lack of Efficacy|1
6138532|NCT01017575|9769743|FG004|Overall Study|Lack of Efficacy|1
6138533|NCT01017575|9769739|FG000|Overall Study|Adverse Event|0
6138534|NCT01017575|9769740|FG001|Overall Study|Adverse Event|1
6138535|NCT01017575|9769741|FG002|Overall Study|Adverse Event|0
6138536|NCT01017575|9769742|FG003|Overall Study|Adverse Event|0
6138537|NCT01017575|9769743|FG004|Overall Study|Adverse Event|2
6138538|NCT01017575|9769739|FG000|Overall Study|Withdrawal by Subject|1
6138539|NCT01017575|9769740|FG001|Overall Study|Withdrawal by Subject|0
6138540|NCT01017575|9769741|FG002|Overall Study|Withdrawal by Subject|0
6138541|NCT01017575|9769742|FG003|Overall Study|Withdrawal by Subject|0
6138542|NCT01017575|9769743|FG004|Overall Study|Withdrawal by Subject|0
6138543|NCT01017601|9769757|FG000|Overall Study|Disease Progression|12
6138544|NCT01017601|9769758|FG001|Overall Study|Disease Progression|12
6138545|NCT01017601|9769757|FG000|Overall Study|Withdrawal by Subject|0
6138546|NCT01017601|9769758|FG001|Overall Study|Withdrawal by Subject|1
6138547|NCT01017731|9769768|FG000|Overall Study|Lost to Follow-up|2
6138548|NCT01017731|9769768|FG000|Overall Study|Withdrawal by Subject|3
6138549|NCT01017731|9769768|FG000|Overall Study|Physician Decision|2
6138550|NCT01017731|9769768|FG000|Overall Study|Adverse Event|1
6138551|NCT01017874|9769775|FG000|Overall Study|Withdrawal by Subject|23
6138552|NCT01017874|9769776|FG001|Overall Study|Withdrawal by Subject|20
6138553|NCT01017874|9769775|FG000|Overall Study|Sponsor decision|3
6138554|NCT01017874|9769776|FG001|Overall Study|Sponsor decision|1
6138555|NCT01017874|9769775|FG000|Overall Study|Lost to Follow-up|3
6138556|NCT01017874|9769776|FG001|Overall Study|Lost to Follow-up|2
6138557|NCT01017874|9769775|FG000|Overall Study|Physician Decision|1
6138558|NCT01017874|9769776|FG001|Overall Study|Physician Decision|3
6138559|NCT01017952|9769786|FG000|4-week, Open-label Run-In Period|Did Not Meet Continuation Criteria|356
6138560|NCT01017952|9769787|FG001|4-week, Open-label Run-In Period|Did Not Meet Continuation Criteria|0
6138561|NCT01017952|9769788|FG002|4-week, Open-label Run-In Period|Did Not Meet Continuation Criteria|0
6138562|NCT01017952|9769789|FG003|4-week, Open-label Run-In Period|Did Not Meet Continuation Criteria|0
6138563|NCT01017952|9769790|FG004|4-week, Open-label Run-In Period|Did Not Meet Continuation Criteria|0
6138564|NCT01017952|9769786|FG000|4-week, Open-label Run-In Period|Adverse Event|23
6138565|NCT01017952|9769787|FG001|4-week, Open-label Run-In Period|Adverse Event|0
6138566|NCT01017952|9769788|FG002|4-week, Open-label Run-In Period|Adverse Event|0
6138567|NCT01017952|9769789|FG003|4-week, Open-label Run-In Period|Adverse Event|0
6138568|NCT01017952|9769790|FG004|4-week, Open-label Run-In Period|Adverse Event|0
6138569|NCT01017952|9769786|FG000|4-week, Open-label Run-In Period|Study Closed/Tterminated|1
6138570|NCT01017952|9769787|FG001|4-week, Open-label Run-In Period|Study Closed/Tterminated|0
6138571|NCT01017952|9769788|FG002|4-week, Open-label Run-In Period|Study Closed/Tterminated|0
6138572|NCT01017952|9769789|FG003|4-week, Open-label Run-In Period|Study Closed/Tterminated|0
6138573|NCT01017952|9769790|FG004|4-week, Open-label Run-In Period|Study Closed/Tterminated|0
6138574|NCT01017952|9769786|FG000|4-week, Open-label Run-In Period|Lost to Follow-up|6
6138575|NCT01017952|9769787|FG001|4-week, Open-label Run-In Period|Lost to Follow-up|0
6138576|NCT01017952|9769788|FG002|4-week, Open-label Run-In Period|Lost to Follow-up|0
6138577|NCT01017952|9769789|FG003|4-week, Open-label Run-In Period|Lost to Follow-up|0
6138578|NCT01017952|9769790|FG004|4-week, Open-label Run-In Period|Lost to Follow-up|0
6138579|NCT01017952|9769786|FG000|4-week, Open-label Run-In Period|Physician Decision|10
6138580|NCT01017952|9769787|FG001|4-week, Open-label Run-In Period|Physician Decision|0
6138581|NCT01017952|9769788|FG002|4-week, Open-label Run-In Period|Physician Decision|0
6138582|NCT01017952|9769789|FG003|4-week, Open-label Run-In Period|Physician Decision|0
6138583|NCT01017952|9769790|FG004|4-week, Open-label Run-In Period|Physician Decision|0
6138584|NCT01017952|9769786|FG000|4-week, Open-label Run-In Period|Withdrawal by Subject|63
6138585|NCT01017952|9769787|FG001|4-week, Open-label Run-In Period|Withdrawal by Subject|0
6138586|NCT01017952|9769788|FG002|4-week, Open-label Run-In Period|Withdrawal by Subject|0
6138587|NCT01017952|9769789|FG003|4-week, Open-label Run-In Period|Withdrawal by Subject|0
6138588|NCT01017952|9769790|FG004|4-week, Open-label Run-In Period|Withdrawal by Subject|0
6138589|NCT01017952|9769786|FG000|52-week, Double-blind Treatment Period|Adverse Event|0
6138590|NCT01017952|9769787|FG001|52-week, Double-blind Treatment Period|Adverse Event|25
6138591|NCT01017952|9769788|FG002|52-week, Double-blind Treatment Period|Adverse Event|32
6138592|NCT01017952|9769789|FG003|52-week, Double-blind Treatment Period|Adverse Event|35
6138593|NCT01017952|9769790|FG004|52-week, Double-blind Treatment Period|Adverse Event|30
6138594|NCT01017952|9769786|FG000|52-week, Double-blind Treatment Period|Withdrawal by Subject|0
6138595|NCT01017952|9769787|FG001|52-week, Double-blind Treatment Period|Withdrawal by Subject|30
6138596|NCT01017952|9769788|FG002|52-week, Double-blind Treatment Period|Withdrawal by Subject|22
6138597|NCT01017952|9769789|FG003|52-week, Double-blind Treatment Period|Withdrawal by Subject|25
6138598|NCT01017952|9769790|FG004|52-week, Double-blind Treatment Period|Withdrawal by Subject|25
6138599|NCT01017952|9769786|FG000|52-week, Double-blind Treatment Period|Lack of Efficacy|0
6138600|NCT01017952|9769787|FG001|52-week, Double-blind Treatment Period|Lack of Efficacy|35
6138601|NCT01017952|9769788|FG002|52-week, Double-blind Treatment Period|Lack of Efficacy|14
6138602|NCT01017952|9769789|FG003|52-week, Double-blind Treatment Period|Lack of Efficacy|16
6138603|NCT01017952|9769790|FG004|52-week, Double-blind Treatment Period|Lack of Efficacy|14
6138604|NCT01017952|9769786|FG000|52-week, Double-blind Treatment Period|Protocol Violation|0
6138605|NCT01017952|9769787|FG001|52-week, Double-blind Treatment Period|Protocol Violation|7
6138606|NCT01017952|9769788|FG002|52-week, Double-blind Treatment Period|Protocol Violation|11
6138607|NCT01017952|9769789|FG003|52-week, Double-blind Treatment Period|Protocol Violation|9
6138608|NCT01017952|9769790|FG004|52-week, Double-blind Treatment Period|Protocol Violation|8
6138609|NCT01017952|9769786|FG000|52-week, Double-blind Treatment Period|Met Protocol-Defined Stopping Criteria|0
6138610|NCT01017952|9769787|FG001|52-week, Double-blind Treatment Period|Met Protocol-Defined Stopping Criteria|11
6138611|NCT01017952|9769788|FG002|52-week, Double-blind Treatment Period|Met Protocol-Defined Stopping Criteria|13
6138612|NCT01017952|9769789|FG003|52-week, Double-blind Treatment Period|Met Protocol-Defined Stopping Criteria|12
6138613|NCT01017952|9769790|FG004|52-week, Double-blind Treatment Period|Met Protocol-Defined Stopping Criteria|9
6138614|NCT01017952|9769786|FG000|52-week, Double-blind Treatment Period|Study Closed/Terminated|0
6138615|NCT01017952|9769787|FG001|52-week, Double-blind Treatment Period|Study Closed/Terminated|1
6138616|NCT01017952|9769788|FG002|52-week, Double-blind Treatment Period|Study Closed/Terminated|1
6138617|NCT01017952|9769789|FG003|52-week, Double-blind Treatment Period|Study Closed/Terminated|0
6138618|NCT01017952|9769790|FG004|52-week, Double-blind Treatment Period|Study Closed/Terminated|0
6138619|NCT01017952|9769786|FG000|52-week, Double-blind Treatment Period|Lost to Follow-up|0
6138620|NCT01017952|9769787|FG001|52-week, Double-blind Treatment Period|Lost to Follow-up|6
6138621|NCT01017952|9769788|FG002|52-week, Double-blind Treatment Period|Lost to Follow-up|8
6138622|NCT01017952|9769789|FG003|52-week, Double-blind Treatment Period|Lost to Follow-up|6
6138623|NCT01017952|9769790|FG004|52-week, Double-blind Treatment Period|Lost to Follow-up|10
6138624|NCT01017952|9769786|FG000|52-week, Double-blind Treatment Period|Physician Decision|0
6138625|NCT01017952|9769787|FG001|52-week, Double-blind Treatment Period|Physician Decision|10
6138626|NCT01017952|9769788|FG002|52-week, Double-blind Treatment Period|Physician Decision|8
6138627|NCT01017952|9769789|FG003|52-week, Double-blind Treatment Period|Physician Decision|9
6138628|NCT01017952|9769790|FG004|52-week, Double-blind Treatment Period|Physician Decision|7
6138629|NCT01018030|9769803|FG000|Overall Study|Adverse Event|10
6138630|NCT01018030|9769804|FG001|Overall Study|Adverse Event|5
6138631|NCT01018030|9769805|FG002|Overall Study|Adverse Event|5
6138632|NCT01018030|9769803|FG000|Overall Study|Withdrawal by Subject|2
6138633|NCT01018030|9769804|FG001|Overall Study|Withdrawal by Subject|2
6138634|NCT01018030|9769805|FG002|Overall Study|Withdrawal by Subject|4
6138635|NCT01018030|9769803|FG000|Overall Study|Lost to Follow-up|2
6138636|NCT01018030|9769804|FG001|Overall Study|Lost to Follow-up|0
6138637|NCT01018030|9769805|FG002|Overall Study|Lost to Follow-up|3
6138638|NCT01018030|9769803|FG000|Overall Study|Protocol Violation|2
6138639|NCT01018030|9769804|FG001|Overall Study|Protocol Violation|1
6138640|NCT01018030|9769805|FG002|Overall Study|Protocol Violation|0
6138641|NCT01018030|9769803|FG000|Overall Study|Physician Decision|1
6138642|NCT01018030|9769804|FG001|Overall Study|Physician Decision|0
6138643|NCT01018030|9769805|FG002|Overall Study|Physician Decision|1
6138644|NCT01018030|9769803|FG000|Overall Study|Lack of Efficacy|1
6138645|NCT01018030|9769804|FG001|Overall Study|Lack of Efficacy|0
6138646|NCT01018030|9769805|FG002|Overall Study|Lack of Efficacy|0
6138647|NCT01018030|9769803|FG000|Overall Study|Did Not Receive Study Drug|1
6138648|NCT01018030|9769804|FG001|Overall Study|Did Not Receive Study Drug|3
6138649|NCT01018030|9769805|FG002|Overall Study|Did Not Receive Study Drug|0
6138650|NCT01018186|9769868|FG000|2-week Run-in Period|Protocol Violation|1
6138651|NCT01018186|9769869|FG001|2-week Run-in Period|Protocol Violation|0
6138652|NCT01018186|9769870|FG002|2-week Run-in Period|Protocol Violation|0
6138653|NCT01018186|9769871|FG003|2-week Run-in Period|Protocol Violation|0
6138654|NCT01018186|9769868|FG000|2-week Run-in Period|Lost to Follow-up|2
6138655|NCT01018186|9769869|FG001|2-week Run-in Period|Lost to Follow-up|0
6138656|NCT01018186|9769870|FG002|2-week Run-in Period|Lost to Follow-up|0
6138657|NCT01018186|9769871|FG003|2-week Run-in Period|Lost to Follow-up|0
6138658|NCT01018186|9769868|FG000|2-week Run-in Period|Physician Decision|3
6138659|NCT01018186|9769869|FG001|2-week Run-in Period|Physician Decision|0
6138660|NCT01018186|9769870|FG002|2-week Run-in Period|Physician Decision|0
6138661|NCT01018186|9769871|FG003|2-week Run-in Period|Physician Decision|0
6138662|NCT01018186|9769868|FG000|2-week Run-in Period|Withdrawal by Subject|11
6138663|NCT01018186|9769869|FG001|2-week Run-in Period|Withdrawal by Subject|0
6138664|NCT01018186|9769870|FG002|2-week Run-in Period|Withdrawal by Subject|0
6138665|NCT01018186|9769871|FG003|2-week Run-in Period|Withdrawal by Subject|0
6138666|NCT01018186|9769868|FG000|2-week Run-in Period|Did Not Meet Continuation Criteria|97
6138667|NCT01018186|9769869|FG001|2-week Run-in Period|Did Not Meet Continuation Criteria|0
6138668|NCT01018186|9769870|FG002|2-week Run-in Period|Did Not Meet Continuation Criteria|0
6138669|NCT01018186|9769871|FG003|2-week Run-in Period|Did Not Meet Continuation Criteria|0
6138670|NCT01018186|9769868|FG000|52-week Double-blind Treatment Period|Adverse Event|0
6138671|NCT01018186|9769869|FG001|52-week Double-blind Treatment Period|Adverse Event|5
6138672|NCT01018186|9769870|FG002|52-week Double-blind Treatment Period|Adverse Event|3
6138673|NCT01018186|9769871|FG003|52-week Double-blind Treatment Period|Adverse Event|6
6138674|NCT01018186|9769868|FG000|52-week Double-blind Treatment Period|Lack of Efficacy|0
6138675|NCT01018186|9769869|FG001|52-week Double-blind Treatment Period|Lack of Efficacy|1
6138676|NCT01018186|9769870|FG002|52-week Double-blind Treatment Period|Lack of Efficacy|4
6138677|NCT01018186|9769871|FG003|52-week Double-blind Treatment Period|Lack of Efficacy|1
6138678|NCT01018186|9769868|FG000|52-week Double-blind Treatment Period|Protocol Violation|0
6138679|NCT01018186|9769869|FG001|52-week Double-blind Treatment Period|Protocol Violation|8
6138680|NCT01018186|9769870|FG002|52-week Double-blind Treatment Period|Protocol Violation|8
6138681|NCT01018186|9769871|FG003|52-week Double-blind Treatment Period|Protocol Violation|2
6138682|NCT01018186|9769868|FG000|52-week Double-blind Treatment Period|Protocol-defined Stopping Criteria|0
6138683|NCT01018186|9769869|FG001|52-week Double-blind Treatment Period|Protocol-defined Stopping Criteria|14
6138684|NCT01018186|9769870|FG002|52-week Double-blind Treatment Period|Protocol-defined Stopping Criteria|16
6138685|NCT01018186|9769871|FG003|52-week Double-blind Treatment Period|Protocol-defined Stopping Criteria|4
6138686|NCT01018186|9769868|FG000|52-week Double-blind Treatment Period|Lost to Follow-up|0
6138687|NCT01018186|9769869|FG001|52-week Double-blind Treatment Period|Lost to Follow-up|1
6138688|NCT01018186|9769870|FG002|52-week Double-blind Treatment Period|Lost to Follow-up|3
6138689|NCT01018186|9769871|FG003|52-week Double-blind Treatment Period|Lost to Follow-up|4
6138690|NCT01018186|9769868|FG000|52-week Double-blind Treatment Period|Physician Decision|0
6138691|NCT01018186|9769869|FG001|52-week Double-blind Treatment Period|Physician Decision|1
6138692|NCT01018186|9769870|FG002|52-week Double-blind Treatment Period|Physician Decision|0
6138693|NCT01018186|9769871|FG003|52-week Double-blind Treatment Period|Physician Decision|3
6138694|NCT01018186|9769868|FG000|52-week Double-blind Treatment Period|Withdrawal by Subject|0
6138695|NCT01018186|9769869|FG001|52-week Double-blind Treatment Period|Withdrawal by Subject|10
6138696|NCT01018186|9769870|FG002|52-week Double-blind Treatment Period|Withdrawal by Subject|7
6138697|NCT01018186|9769871|FG003|52-week Double-blind Treatment Period|Withdrawal by Subject|9
6138698|NCT01018264|9769885|FG000|Overall Study|Withdrawal by Subject|1
6138699|NCT01018264|9769886|FG001|Overall Study|Withdrawal by Subject|0
6138700|NCT01018264|9769885|FG000|Overall Study|Lost to Follow-up|0
6138701|NCT01018264|9769886|FG001|Overall Study|Lost to Follow-up|1
6138702|NCT01018394|9769894|FG000|Overall Study|Withdrawal by Subject|5
6138703|NCT01018394|9769895|FG001|Overall Study|Withdrawal by Subject|5
6138704|NCT01018394|9769894|FG000|Overall Study|Lost to Follow-up|4
6138705|NCT01018394|9769895|FG001|Overall Study|Lost to Follow-up|3
6138706|NCT01018511|9769931|FG000|Overall Study|Not fulfilling eligibility criteria|6
6138707|NCT01018511|9769932|FG001|Overall Study|Not fulfilling eligibility criteria|7
6138708|NCT01018511|9769933|FG002|Overall Study|Not fulfilling eligibility criteria|7
6138709|NCT01018511|9769934|FG003|Overall Study|Not fulfilling eligibility criteria|3
6138710|NCT01018511|9769931|FG000|Overall Study|Adverse Event|5
6138711|NCT01018511|9769932|FG001|Overall Study|Adverse Event|9
6138712|NCT01018511|9769933|FG002|Overall Study|Adverse Event|13
6138713|NCT01018511|9769934|FG003|Overall Study|Adverse Event|10
6138714|NCT01018511|9769931|FG000|Overall Study|Lack of Efficacy|4
6138715|NCT01018511|9769932|FG001|Overall Study|Lack of Efficacy|1
6138716|NCT01018511|9769933|FG002|Overall Study|Lack of Efficacy|1
6138717|NCT01018511|9769934|FG003|Overall Study|Lack of Efficacy|2
6138718|NCT01018511|9769931|FG000|Overall Study|Withdrawal by Subject|6
6138719|NCT01018511|9769932|FG001|Overall Study|Withdrawal by Subject|5
6138720|NCT01018511|9769933|FG002|Overall Study|Withdrawal by Subject|11
6138721|NCT01018511|9769934|FG003|Overall Study|Withdrawal by Subject|9
6138722|NCT01018511|9769931|FG000|Overall Study|Lost to Follow-up|0
6138723|NCT01018511|9769932|FG001|Overall Study|Lost to Follow-up|0
6138724|NCT01018511|9769933|FG002|Overall Study|Lost to Follow-up|1
6138725|NCT01018511|9769934|FG003|Overall Study|Lost to Follow-up|0
6138726|NCT01018511|9769931|FG000|Overall Study|Protocol Violation|5
6138727|NCT01018511|9769932|FG001|Overall Study|Protocol Violation|8
6138728|NCT01018511|9769933|FG002|Overall Study|Protocol Violation|7
6138729|NCT01018511|9769934|FG003|Overall Study|Protocol Violation|9
6138730|NCT01018511|9769931|FG000|Overall Study|Miscellaneous|0
6138731|NCT01018511|9769932|FG001|Overall Study|Miscellaneous|2
6138732|NCT01018511|9769933|FG002|Overall Study|Miscellaneous|0
6138733|NCT01018511|9769934|FG003|Overall Study|Miscellaneous|0
6138734|NCT01018680|9769952|FG000|Overall Study|Adverse Event|23
6138735|NCT01018680|9769953|FG001|Overall Study|Adverse Event|40
6138736|NCT01018680|9769952|FG000|Overall Study|Withdrawal by Subject|10
6138737|NCT01018680|9769953|FG001|Overall Study|Withdrawal by Subject|10
6138738|NCT01018680|9769952|FG000|Overall Study|Protocol Violation|5
6138739|NCT01018680|9769953|FG001|Overall Study|Protocol Violation|8
6138740|NCT01018680|9769952|FG000|Overall Study|Sponsor Decision|6
6138741|NCT01018680|9769953|FG001|Overall Study|Sponsor Decision|7
6138742|NCT01018680|9769952|FG000|Overall Study|Lack of Efficacy|8
6138743|NCT01018680|9769953|FG001|Overall Study|Lack of Efficacy|2
6138744|NCT01018680|9769952|FG000|Overall Study|Lost to Follow-up|5
6138745|NCT01018680|9769953|FG001|Overall Study|Lost to Follow-up|3
6138746|NCT01018680|9769952|FG000|Overall Study|Entry Criteria Not Met|1
6138747|NCT01018680|9769953|FG001|Overall Study|Entry Criteria Not Met|4
6138748|NCT01018680|9769952|FG000|Overall Study|Physician Decision|3
6138749|NCT01018680|9769953|FG001|Overall Study|Physician Decision|1
6138750|NCT01018732|9769962|FG000|Overall Study|Lost to Follow-up|0
6138751|NCT01018732|9769963|FG001|Overall Study|Lost to Follow-up|0
6138752|NCT01018732|9769964|FG002|Overall Study|Lost to Follow-up|3
6138753|NCT01018732|9769962|FG000|Overall Study|Protocol Violation|1
6138754|NCT01018732|9769963|FG001|Overall Study|Protocol Violation|1
6138755|NCT01018732|9769964|FG002|Overall Study|Protocol Violation|0
6138756|NCT01018732|9769962|FG000|Overall Study|Inappropriate Enrollment|0
6138757|NCT01018732|9769963|FG001|Overall Study|Inappropriate Enrollment|1
6138758|NCT01018732|9769964|FG002|Overall Study|Inappropriate Enrollment|0
6138759|NCT01018732|9769962|FG000|Overall Study|Unable to Classify|0
6138760|NCT01018732|9769963|FG001|Overall Study|Unable to Classify|0
6138761|NCT01018732|9769964|FG002|Overall Study|Unable to Classify|1
6138762|NCT01018862|9769975|FG000|Overall Study|Adverse Event|2
6138763|NCT01018862|9769976|FG001|Overall Study|Adverse Event|0
6138764|NCT01018862|9769977|FG002|Overall Study|Adverse Event|6
6138765|NCT01018862|9769975|FG000|Overall Study|Lack of Efficacy|1
6138766|NCT01018862|9769976|FG001|Overall Study|Lack of Efficacy|0
6138767|NCT01018862|9769977|FG002|Overall Study|Lack of Efficacy|2
6138768|NCT01018862|9769975|FG000|Overall Study|Lost to Follow-up|3
6138769|NCT01018862|9769976|FG001|Overall Study|Lost to Follow-up|1
6138770|NCT01018862|9769977|FG002|Overall Study|Lost to Follow-up|0
6138771|NCT01018862|9769975|FG000|Overall Study|Protocol Violation|1
6138772|NCT01018862|9769976|FG001|Overall Study|Protocol Violation|3
6138773|NCT01018862|9769977|FG002|Overall Study|Protocol Violation|3
6138774|NCT01018862|9769975|FG000|Overall Study|Withdrawal by Subject|1
6138775|NCT01018862|9769976|FG001|Overall Study|Withdrawal by Subject|2
6138776|NCT01018862|9769977|FG002|Overall Study|Withdrawal by Subject|1
6138777|NCT01018862|9769975|FG000|Overall Study|administrative problems|5
6138778|NCT01018862|9769976|FG001|Overall Study|administrative problems|4
6138779|NCT01018862|9769977|FG002|Overall Study|administrative problems|4
6138780|NCT01018953|9769985|FG000|Overall Study|Adverse Event|2
6138781|NCT01018953|9769985|FG000|Overall Study|Withdrawal by Subject|1
6138782|NCT01018953|9769985|FG000|Overall Study|Study termination by sponsor|5
6138783|NCT01018979|9769992|FG000|Overall Study|Peak CD34+ cell count in PB < 10 cell/uL|3
6138784|NCT01018979|9769993|FG001|Overall Study|Peak CD34+ cell count in PB < 10 cell/uL|9
6138785|NCT01018979|9769992|FG000|Overall Study|Not received at least one dose|0
6138786|NCT01018979|9769993|FG001|Overall Study|Not received at least one dose|1
6138787|NCT01018992|9770004|FG000|Overall Study|Adverse Event|8
6138788|NCT01018992|9770005|FG001|Overall Study|Adverse Event|3
6138789|NCT01018992|9770004|FG000|Overall Study|Withdrawal by Subject|3
6138790|NCT01018992|9770005|FG001|Overall Study|Withdrawal by Subject|8
6138791|NCT01018992|9770004|FG000|Overall Study|Protocol Violation|0
6138792|NCT01018992|9770005|FG001|Overall Study|Protocol Violation|4
6138793|NCT01018992|9770004|FG000|Overall Study|Lost to Follow-up|5
6138794|NCT01018992|9770005|FG001|Overall Study|Lost to Follow-up|1
6138795|NCT01019135|9770014|FG000|Overall Study|Did not receive allocated intervention|12
6138796|NCT01019135|9770015|FG001|Overall Study|Did not receive allocated intervention|6
6138797|NCT01019135|9770016|FG002|Overall Study|Did not receive allocated intervention|25
6138798|NCT01019135|9770014|FG000|Overall Study|Did not attend CR|8
6138799|NCT01019135|9770015|FG001|Overall Study|Did not attend CR|13
6138800|NCT01019135|9770016|FG002|Overall Study|Did not attend CR|6
6138801|NCT01019252|9770026|FG000|Initial CBT for ADHD vs. Wait List|Time constraints|2
6138802|NCT01019252|9770027|FG001|Initial CBT for ADHD vs. Wait List|Time constraints|0
6138803|NCT01019252|9770026|FG000|Initial CBT for ADHD vs. Wait List|Moved out of Boston area|1
6138804|NCT01019252|9770027|FG001|Initial CBT for ADHD vs. Wait List|Moved out of Boston area|0
6138805|NCT01019252|9770026|FG000|Wait List Cross-over to CBT for ADHD|Time constraints|0
6138806|NCT01019252|9770027|FG001|Wait List Cross-over to CBT for ADHD|Time constraints|2
6138807|NCT01019252|9770026|FG000|Wait List Cross-over to CBT for ADHD|Lost to Follow-up|0
6138808|NCT01019252|9770027|FG001|Wait List Cross-over to CBT for ADHD|Lost to Follow-up|5
6138809|NCT01019317|9770033|FG000|Overall Study|Not Eligible|4
6138810|NCT01019369|9770039|FG000|Overall Study|Lost to Follow-up|10
6138811|NCT01019369|9770040|FG001|Overall Study|Lost to Follow-up|6
6138812|NCT01019369|9770039|FG000|Overall Study|Withdrawal by Subject|0
6138813|NCT01019369|9770040|FG001|Overall Study|Withdrawal by Subject|1
6138814|NCT01019486|9770050|FG000|Overall Study|Withdrawal by Subject|1
6138815|NCT01019486|9770051|FG001|Overall Study|Withdrawal by Subject|1
6138816|NCT01019486|9770052|FG002|Overall Study|Withdrawal by Subject|1
6138817|NCT01019694|9770064|FG000|Overall Study|Adverse Event|12
6138818|NCT01019694|9770065|FG001|Overall Study|Adverse Event|16
6138819|NCT01019694|9770066|FG002|Overall Study|Adverse Event|19
6138820|NCT01019694|9770064|FG000|Overall Study|Protocol Violation|2
6138821|NCT01019694|9770065|FG001|Overall Study|Protocol Violation|6
6138822|NCT01019694|9770066|FG002|Overall Study|Protocol Violation|4
6138823|NCT01019694|9770064|FG000|Overall Study|Lost to Follow-up|5
6138824|NCT01019694|9770065|FG001|Overall Study|Lost to Follow-up|3
6138825|NCT01019694|9770066|FG002|Overall Study|Lost to Follow-up|3
6138826|NCT01019694|9770064|FG000|Overall Study|Withdrawal by Subject|4
6138827|NCT01019694|9770065|FG001|Overall Study|Withdrawal by Subject|6
6138828|NCT01019694|9770066|FG002|Overall Study|Withdrawal by Subject|12
6138829|NCT01019694|9770064|FG000|Overall Study|Not treated|0
6138830|NCT01019694|9770065|FG001|Overall Study|Not treated|2
6138831|NCT01019694|9770066|FG002|Overall Study|Not treated|3
6138832|NCT01019694|9770064|FG000|Overall Study|Other reason (not specified)|1
6138833|NCT01019694|9770065|FG001|Overall Study|Other reason (not specified)|5
6138834|NCT01019694|9770066|FG002|Overall Study|Other reason (not specified)|6
6138835|NCT01020019|9770105|FG000|Overall Study|Lost to Follow-up|21
6138836|NCT01020019|9770106|FG001|Overall Study|Lost to Follow-up|18
6138837|NCT01020019|9770105|FG000|Overall Study|Adverse Event|1
6138838|NCT01020019|9770106|FG001|Overall Study|Adverse Event|5
6138839|NCT01020019|9770105|FG000|Overall Study|not interested in treatment|4
6138840|NCT01020019|9770106|FG001|Overall Study|not interested in treatment|4
6138841|NCT01020019|9770105|FG000|Overall Study|moving|0
6138842|NCT01020019|9770106|FG001|Overall Study|moving|2
6138843|NCT01020123|9770119|FG000|Main Period|Withdrawal by Subject|6
6138844|NCT01020123|9770120|FG001|Main Period|Withdrawal by Subject|5
6138845|NCT01020123|9770121|FG002|Main Period|Withdrawal by Subject|3
6138846|NCT01020123|9770122|FG003|Main Period|Withdrawal by Subject|1
6138847|NCT01020123|9770123|FG004|Main Period|Withdrawal by Subject|6
6138848|NCT01020123|9770124|FG005|Main Period|Withdrawal by Subject|3
6138849|NCT01020123|9770125|FG006|Main Period|Withdrawal by Subject|2
6138850|NCT01020123|9770119|FG000|Main Period|Eligibility Criteria not fullfilled|0
6138851|NCT01020123|9770120|FG001|Main Period|Eligibility Criteria not fullfilled|1
6138852|NCT01020123|9770121|FG002|Main Period|Eligibility Criteria not fullfilled|0
6138853|NCT01020123|9770122|FG003|Main Period|Eligibility Criteria not fullfilled|0
6138854|NCT01020123|9770123|FG004|Main Period|Eligibility Criteria not fullfilled|1
6138855|NCT01020123|9770124|FG005|Main Period|Eligibility Criteria not fullfilled|0
6138856|NCT01020123|9770125|FG006|Main Period|Eligibility Criteria not fullfilled|0
6138857|NCT01020123|9770119|FG000|Main Period|Adverse Event|5
6138858|NCT01020123|9770120|FG001|Main Period|Adverse Event|2
6138859|NCT01020123|9770121|FG002|Main Period|Adverse Event|2
6138860|NCT01020123|9770122|FG003|Main Period|Adverse Event|1
6138861|NCT01020123|9770123|FG004|Main Period|Adverse Event|1
6138862|NCT01020123|9770124|FG005|Main Period|Adverse Event|2
6138863|NCT01020123|9770125|FG006|Main Period|Adverse Event|1
6138864|NCT01020123|9770119|FG000|Main Period|Protocol Violation|4
6138865|NCT01020123|9770120|FG001|Main Period|Protocol Violation|4
6138866|NCT01020123|9770121|FG002|Main Period|Protocol Violation|2
6138867|NCT01020123|9770122|FG003|Main Period|Protocol Violation|5
6138868|NCT01020123|9770123|FG004|Main Period|Protocol Violation|2
6138869|NCT01020123|9770124|FG005|Main Period|Protocol Violation|3
6138870|NCT01020123|9770125|FG006|Main Period|Protocol Violation|2
6138871|NCT01020123|9770119|FG000|Main Period|Lost to Follow-up|0
6138872|NCT01020123|9770120|FG001|Main Period|Lost to Follow-up|2
6138873|NCT01020123|9770121|FG002|Main Period|Lost to Follow-up|0
6138874|NCT01020123|9770122|FG003|Main Period|Lost to Follow-up|0
6138875|NCT01020123|9770123|FG004|Main Period|Lost to Follow-up|0
6138876|NCT01020123|9770124|FG005|Main Period|Lost to Follow-up|0
6138877|NCT01020123|9770125|FG006|Main Period|Lost to Follow-up|0
6138878|NCT01020123|9770119|FG000|Main Period|Unclasified|2
6138879|NCT01020123|9770120|FG001|Main Period|Unclasified|0
6138880|NCT01020123|9770121|FG002|Main Period|Unclasified|1
6138881|NCT01020123|9770122|FG003|Main Period|Unclasified|0
6138882|NCT01020123|9770123|FG004|Main Period|Unclasified|1
6138883|NCT01020123|9770124|FG005|Main Period|Unclasified|3
6138884|NCT01020123|9770125|FG006|Main Period|Unclasified|6
6138885|NCT01020123|9770119|FG000|Extention Period|Withdrawal by Subject|2
6138886|NCT01020123|9770120|FG001|Extention Period|Withdrawal by Subject|1
6138887|NCT01020123|9770121|FG002|Extention Period|Withdrawal by Subject|1
6138888|NCT01020123|9770122|FG003|Extention Period|Withdrawal by Subject|0
6138889|NCT01020123|9770123|FG004|Extention Period|Withdrawal by Subject|0
6138890|NCT01020123|9770124|FG005|Extention Period|Withdrawal by Subject|0
6138891|NCT01020123|9770125|FG006|Extention Period|Withdrawal by Subject|0
6138892|NCT01020123|9770119|FG000|Extention Period|Adverse Event|0
6138893|NCT01020123|9770120|FG001|Extention Period|Adverse Event|0
6138894|NCT01020123|9770121|FG002|Extention Period|Adverse Event|0
6138895|NCT01020123|9770122|FG003|Extention Period|Adverse Event|1
6138896|NCT01020123|9770123|FG004|Extention Period|Adverse Event|0
6138897|NCT01020123|9770124|FG005|Extention Period|Adverse Event|0
6138898|NCT01020123|9770125|FG006|Extention Period|Adverse Event|0
6138899|NCT01020123|9770119|FG000|Extention Period|Protocol Violation|1
6138900|NCT01020123|9770120|FG001|Extention Period|Protocol Violation|1
6138901|NCT01020123|9770121|FG002|Extention Period|Protocol Violation|1
6138902|NCT01020123|9770122|FG003|Extention Period|Protocol Violation|0
6138903|NCT01020123|9770123|FG004|Extention Period|Protocol Violation|0
6138904|NCT01020123|9770124|FG005|Extention Period|Protocol Violation|0
6138905|NCT01020123|9770125|FG006|Extention Period|Protocol Violation|1
6138906|NCT01020123|9770119|FG000|Extention Period|Lost to Follow-up|0
6138907|NCT01020123|9770120|FG001|Extention Period|Lost to Follow-up|0
6138908|NCT01020123|9770121|FG002|Extention Period|Lost to Follow-up|0
6138909|NCT01020123|9770122|FG003|Extention Period|Lost to Follow-up|0
6138910|NCT01020123|9770123|FG004|Extention Period|Lost to Follow-up|0
6138911|NCT01020123|9770124|FG005|Extention Period|Lost to Follow-up|2
6138912|NCT01020123|9770125|FG006|Extention Period|Lost to Follow-up|0
6138913|NCT01020305|9770142|FG000|Overall Study|Adverse Event|2
6138914|NCT01020435|9770148|FG000|Overall Study|Lost to Follow-up|0
6138915|NCT01020435|9770149|FG001|Overall Study|Lost to Follow-up|1
6138916|NCT01020448|9770156|FG000|Pre-assignment|Adverse Event|6
6138917|NCT01020448|9770156|FG000|Pre-assignment|Withdrawal by Subject|5
6138918|NCT01020448|9770156|FG000|Pre-assignment|Does Not Meet Entry Criteria|2
6138919|NCT01020448|9770156|FG000|Treatment|Adverse Event|11
6138920|NCT01020448|9770156|FG000|Treatment|Consent Withdrawn|3
6138921|NCT01020448|9770156|FG000|Treatment|Disease Progression|2
6138922|NCT01020448|9770156|FG000|Treatment|Lack of Efficacy|8
6138923|NCT01020448|9770156|FG000|Treatment|Lost to Follow-up|2
6138924|NCT01020474|9770163|FG000|Overall Study|Adverse Event|4
6138925|NCT01020474|9770164|FG001|Overall Study|Adverse Event|4
6138926|NCT01020474|9770163|FG000|Overall Study|Protocol Violation|0
6138927|NCT01020474|9770164|FG001|Overall Study|Protocol Violation|2
6138928|NCT01020474|9770163|FG000|Overall Study|Withdrawal by Subject|5
6138929|NCT01020474|9770164|FG001|Overall Study|Withdrawal by Subject|7
6138930|NCT01020474|9770163|FG000|Overall Study|Other Reasons|1
6138931|NCT01020474|9770164|FG001|Overall Study|Other Reasons|1
6138932|NCT01020474|9770163|FG000|Overall Study|Insufficient Clinical Response|0
6138933|NCT01020474|9770164|FG001|Overall Study|Insufficient Clinical Response|3
6138934|NCT01020487|9770173|FG000|Part 2 Double-blind Treatment Period|Adverse Event|0
6138935|NCT01020487|9770174|FG001|Part 2 Double-blind Treatment Period|Adverse Event|2
6138936|NCT01020487|9770175|FG002|Part 2 Double-blind Treatment Period|Adverse Event|1
6138937|NCT01020487|9770173|FG000|Part 2 Double-blind Treatment Period|Withdrawal by Subject|0
6138938|NCT01020487|9770174|FG001|Part 2 Double-blind Treatment Period|Withdrawal by Subject|0
6138939|NCT01020487|9770175|FG002|Part 2 Double-blind Treatment Period|Withdrawal by Subject|1
6138940|NCT01020487|9770173|FG000|Part 2 Double-blind Treatment Period|Required a Dose Reduction|0
6138941|NCT01020487|9770174|FG001|Part 2 Double-blind Treatment Period|Required a Dose Reduction|0
6138942|NCT01020487|9770175|FG002|Part 2 Double-blind Treatment Period|Required a Dose Reduction|3
6138943|NCT01020487|9770173|FG000|Part 2 Double-blind Treatment Period|Randomized in Error|0
6138944|NCT01020487|9770174|FG001|Part 2 Double-blind Treatment Period|Randomized in Error|0
6138945|NCT01020487|9770175|FG002|Part 2 Double-blind Treatment Period|Randomized in Error|1
6138946|NCT01020487|9770173|FG000|Part 2 Open-label Period|Adverse Event|0
6138947|NCT01020487|9770174|FG001|Part 2 Open-label Period|Adverse Event|4
6138948|NCT01020487|9770175|FG002|Part 2 Open-label Period|Adverse Event|1
6138949|NCT01020526|9770185|FG000|Overall Study|Withdrawal by Subject|5
6138950|NCT01020526|9770185|FG000|Overall Study|Other reasons|3
6138951|NCT01020526|9770185|FG000|Overall Study|Insufficient clinical response|3
6138952|NCT01020526|9770185|FG000|Overall Study|Lost to Follow-up|1
6138953|NCT01020526|9770185|FG000|Overall Study|Adverse Event|2
6138954|NCT01020747|9770200|FG000|Overall Study|Withdrawal by Subject|1
6138955|NCT01020773|9770207|FG000|Overall Study|Withdrawal by Subject|4
6138956|NCT01020773|9770208|FG001|Overall Study|Withdrawal by Subject|3
6138957|NCT01020786|9770214|FG000|Induction Period|Entry Criteria Not Met|2
6138958|NCT01020786|9770214|FG000|Induction Period|Adverse Event|10
6138959|NCT01020786|9770214|FG000|Induction Period|Progressive Disease|31
6138960|NCT01020786|9770214|FG000|Induction Period|Investigator Decision|3
6138961|NCT01020786|9770214|FG000|Induction Period|Withdrawal by Subject|3
6138962|NCT01020786|9770214|FG000|Maintenance Period|Adverse Event|8
6138963|NCT01020786|9770214|FG000|Maintenance Period|Progressive Disease|43
6138964|NCT01020786|9770214|FG000|Maintenance Period|Withdrawal by Subject|8
6138965|NCT01020786|9770214|FG000|Maintenance Period|Sponsor Decision|1
6138966|NCT01020799|9770222|FG000|Overall Study|Adverse Event|4
6138967|NCT01020799|9770223|FG001|Overall Study|Adverse Event|3
6138968|NCT01020799|9770224|FG002|Overall Study|Adverse Event|2
6138969|NCT01020799|9770222|FG000|Overall Study|non-compliance; lack of efficacy; etc.|4
6138970|NCT01020799|9770223|FG001|Overall Study|non-compliance; lack of efficacy; etc.|3
6138971|NCT01020799|9770224|FG002|Overall Study|non-compliance; lack of efficacy; etc.|0
6138972|NCT01020799|9770222|FG000|Overall Study|Protocol Violation|3
6138973|NCT01020799|9770223|FG001|Overall Study|Protocol Violation|2
6138974|NCT01020799|9770224|FG002|Overall Study|Protocol Violation|0
6138975|NCT01020799|9770222|FG000|Overall Study|Withdrawal by Subject|2
6138976|NCT01020799|9770223|FG001|Overall Study|Withdrawal by Subject|2
6138977|NCT01020799|9770224|FG002|Overall Study|Withdrawal by Subject|3
6138978|NCT01020799|9770222|FG000|Overall Study|Lost to Follow-up|6
6138979|NCT01020799|9770223|FG001|Overall Study|Lost to Follow-up|4
6138980|NCT01020799|9770224|FG002|Overall Study|Lost to Follow-up|2
6138981|NCT01020812|9770232|FG000|Overall Study|Physician Decision|1
6138982|NCT01020812|9770232|FG000|Overall Study|Withdrawal by Subject|1
6138983|NCT01020812|9770232|FG000|Overall Study|Protocol Violation|1
6138984|NCT01020838|9770236|FG000|Overall Study|Death|90
6138985|NCT01020838|9770236|FG000|Overall Study|Adverse Event|1
6138986|NCT01020838|9770236|FG000|Overall Study|Withdrawal by Subject|9
6138987|NCT01020838|9770236|FG000|Overall Study|Lost to Follow-up|6
6138988|NCT01020838|9770236|FG000|Overall Study|Most common: Study ended by sponsor|77
6138989|NCT01020877|9770251|FG000|Second Intervention|Withdrawal by Subject|1
6138990|NCT01020877|9770252|FG001|Second Intervention|Withdrawal by Subject|0
6138991|NCT01020981|9770260|FG000|Overall Study|Did not return mailed survey|74
6138992|NCT01020981|9770261|FG001|Overall Study|Did not return mailed survey|58
6138993|NCT01020981|9770260|FG000|Overall Study|Survey returned undeliverable|8
6138994|NCT01020981|9770261|FG001|Overall Study|Survey returned undeliverable|32
6138995|NCT01020981|9770260|FG000|Overall Study|Participant declined to complete survey|2
6138996|NCT01020981|9770261|FG001|Overall Study|Participant declined to complete survey|0
6138997|NCT01021007|9770271|FG000|Overall Study|Lost to Follow-up|1
6138998|NCT01021007|9770272|FG001|Overall Study|Lost to Follow-up|1
6138999|NCT01021007|9770271|FG000|Overall Study|Adverse Event|1
6139000|NCT01021007|9770272|FG001|Overall Study|Adverse Event|3
6139001|NCT01021020|9770278|FG000|Period I|Protocol Violation|1
6139002|NCT01021020|9770278|FG000|Period I|Withdrawal by Subject|1
6139003|NCT01021020|9770278|FG000|14 Day Washout Period A|Physician Decision|1
6139004|NCT01021137|9770298|FG000|Overall Study|Lost to Follow-up|9
6139005|NCT01021137|9770299|FG001|Overall Study|Lost to Follow-up|4
6139006|NCT01021137|9770300|FG002|Overall Study|Lost to Follow-up|2
6139007|NCT01021137|9770301|FG003|Overall Study|Lost to Follow-up|6
6139008|NCT01021137|9770298|FG000|Overall Study|Withdrawal by Subject|1
6139009|NCT01021137|9770299|FG001|Overall Study|Withdrawal by Subject|0
6139010|NCT01021137|9770300|FG002|Overall Study|Withdrawal by Subject|0
6139011|NCT01021137|9770301|FG003|Overall Study|Withdrawal by Subject|3
6139012|NCT01021215|9770314|FG000|Overall Study|Lost to Follow-up|3
6139013|NCT01021215|9770315|FG001|Overall Study|Lost to Follow-up|0
6139014|NCT04161131|9770326|FG000|Overall Study|Ineligible|2
6139015|NCT04161131|9770326|FG000|Overall Study|Lost to Follow-up|4
6139016|NCT04102501|9770332|FG000|Overall Study|Withdrawal by Subject|7
6139017|NCT04102501|9770333|FG001|Overall Study|Withdrawal by Subject|9
6139018|NCT04102501|9770332|FG000|Overall Study|Adverse Event|1
6139019|NCT04102501|9770333|FG001|Overall Study|Adverse Event|3
6139020|NCT03398356|9770376|FG000|Before Treatment|Lost to Follow-up|1
6139021|NCT03398356|9770377|FG001|Before Treatment|Lost to Follow-up|2
6139022|NCT03398356|9770378|FG002|Before Treatment|Lost to Follow-up|0
6139023|NCT03398356|9770376|FG000|Before Treatment|drug intolerance|2
6139024|NCT03398356|9770377|FG001|Before Treatment|drug intolerance|1
6139025|NCT03398356|9770378|FG002|Before Treatment|drug intolerance|0
6139026|NCT03398356|9770376|FG000|Before Treatment|Withdrawal by Subject|0
6139027|NCT03398356|9770377|FG001|Before Treatment|Withdrawal by Subject|5
6139028|NCT03398356|9770378|FG002|Before Treatment|Withdrawal by Subject|0
6139029|NCT03398356|9770376|FG000|Before Treatment|Physician Decision|0
6139030|NCT03398356|9770377|FG001|Before Treatment|Physician Decision|0
6139031|NCT03398356|9770378|FG002|Before Treatment|Physician Decision|11
6139032|NCT03398356|9770376|FG000|After 6 Weeks of Treatment|Physician Decision|0
6139033|NCT03398356|9770377|FG001|After 6 Weeks of Treatment|Physician Decision|2
6139034|NCT03398356|9770378|FG002|After 6 Weeks of Treatment|Physician Decision|0
6139035|NCT03365791|9770386|FG000|Overall Study|Adverse Event|5
6139036|NCT03365791|9770386|FG000|Overall Study|Death|1
6139037|NCT03365791|9770386|FG000|Overall Study|Lost to Follow-up|1
6139038|NCT03365791|9770386|FG000|Overall Study|Physician Decision|9
6139039|NCT03365791|9770386|FG000|Overall Study|Progressive disease|51
6139040|NCT03365791|9770386|FG000|Overall Study|Subject/guardian decision|5
6139041|NCT03350750|9770393|FG000|Overall Study|Death|1
6139042|NCT03350750|9770394|FG001|Overall Study|Death|1
6139043|NCT02819440|9770413|FG000|Overall Study|Adverse Event|3
6139044|NCT02819440|9770414|FG001|Overall Study|Adverse Event|1
6139045|NCT02819440|9770413|FG000|Overall Study|Lost to Follow-up|1
6139046|NCT02819440|9770414|FG001|Overall Study|Lost to Follow-up|3
6139047|NCT02819440|9770413|FG000|Overall Study|Withdrawal by Subject|9
6139048|NCT02819440|9770414|FG001|Overall Study|Withdrawal by Subject|8
6139049|NCT02782741|9770422|FG000|Blinded Treatment Period: up to Week 49|Adverse Event|0
6139050|NCT02782741|9770423|FG001|Blinded Treatment Period: up to Week 49|Adverse Event|4
6139051|NCT02782741|9770422|FG000|Blinded Treatment Period: up to Week 49|Other|0
6139052|NCT02782741|9770423|FG001|Blinded Treatment Period: up to Week 49|Other|1
6139053|NCT02782741|9770422|FG000|Open-label Long-term: Week 50 to 145|Adverse Event|2
6139054|NCT02782741|9770423|FG001|Open-label Long-term: Week 50 to 145|Adverse Event|1
6139055|NCT02782741|9770422|FG000|Open-label Long-term: Week 50 to 145|Other|1
6139056|NCT02782741|9770423|FG001|Open-label Long-term: Week 50 to 145|Other|0
6139057|NCT02782741|9770422|FG000|Open-label Long-term: Week 50 to 145|Ongoing|48
6139058|NCT02782741|9770423|FG001|Open-label Long-term: Week 50 to 145|Ongoing|43
6139059|NCT02650284|9770435|FG000|Overall Study|Lost to Follow-up|3
6139060|NCT02650284|9770436|FG001|Overall Study|Lost to Follow-up|3
6139061|NCT02650284|9770435|FG000|Overall Study|Consent incorrectly taken|0
6139062|NCT02650284|9770436|FG001|Overall Study|Consent incorrectly taken|1
6139063|NCT02647359|9770444|FG000|Stage 1: Double-Masked Period (48 Weeks)|Non-compliance with study drug|0
6139064|NCT02647359|9770445|FG001|Stage 1: Double-Masked Period (48 Weeks)|Non-compliance with study drug|1
6139065|NCT02647359|9770444|FG000|Stage 1: Double-Masked Period (48 Weeks)|Other than specified|4
6139066|NCT02647359|9770445|FG001|Stage 1: Double-Masked Period (48 Weeks)|Other than specified|0
6139067|NCT02647359|9770444|FG000|Stage 2: Open-Label Extension (96 Weeks)|Adverse Event|2
6139068|NCT02647359|9770445|FG001|Stage 2: Open-Label Extension (96 Weeks)|Adverse Event|1
6139069|NCT02647359|9770444|FG000|Stage 2: Open-Label Extension (96 Weeks)|Other than specified|8
6139070|NCT02647359|9770445|FG001|Stage 2: Open-Label Extension (96 Weeks)|Other than specified|3
6139071|NCT02647359|9770444|FG000|Open-Label Sub-Study (96 Weeks)|Lost to Follow-up|1
6139072|NCT02647359|9770445|FG001|Open-Label Sub-Study (96 Weeks)|Lost to Follow-up|0
6139073|NCT02647359|9770444|FG000|Open-Label Sub-Study (96 Weeks)|Other than specified|7
6139074|NCT02647359|9770445|FG001|Open-Label Sub-Study (96 Weeks)|Other than specified|4
6139075|NCT02485691|9770457|FG000|Overall Study|Adverse Event|25
6139076|NCT02485691|9770458|FG001|Overall Study|Adverse Event|11
6139077|NCT02485691|9770457|FG000|Overall Study|Poor compliance to protocol|0
6139078|NCT02485691|9770458|FG001|Overall Study|Poor compliance to protocol|1
6139079|NCT02485691|9770457|FG000|Overall Study|Disease progression|57
6139080|NCT02485691|9770458|FG001|Overall Study|Disease progression|92
6139081|NCT02485691|9770457|FG000|Overall Study|Investigator's decision|23
6139082|NCT02485691|9770458|FG001|Overall Study|Investigator's decision|5
6139083|NCT02485691|9770457|FG000|Overall Study|Participant's request|13
6139084|NCT02485691|9770458|FG001|Overall Study|Participant's request|6
6139085|NCT02485691|9770457|FG000|Overall Study|Other reason|8
6139086|NCT02485691|9770458|FG001|Overall Study|Other reason|9
6139087|NCT02485691|9770457|FG000|Overall Study|Randomized and not treated|3
6139088|NCT02485691|9770458|FG001|Overall Study|Randomized and not treated|2
6139089|NCT02201251|9770467|FG000|Overall Study|Adverse Event|1
6139090|NCT02201251|9770468|FG001|Overall Study|Adverse Event|1
6139091|NCT02201251|9770467|FG000|Overall Study|Protocol Violation|1
6139092|NCT02201251|9770468|FG001|Overall Study|Protocol Violation|0
6139093|NCT02201251|9770467|FG000|Overall Study|Noncompliance with Study Drug|0
6139094|NCT02201251|9770468|FG001|Overall Study|Noncompliance with Study Drug|1
6139095|NCT02201251|9770467|FG000|Overall Study|Withdrawal by Subject|2
6139096|NCT02201251|9770468|FG001|Overall Study|Withdrawal by Subject|1
6139097|NCT00529763|9770512|FG000|Overall Study|Adverse Event Unrelated to Study Drug|1
6139098|NCT00529763|9770513|FG001|Overall Study|Adverse Event Unrelated to Study Drug|3
6139099|NCT00529763|9770514|FG002|Overall Study|Adverse Event Unrelated to Study Drug|1
6139100|NCT00529763|9770512|FG000|Overall Study|Death|0
6139101|NCT00529763|9770513|FG001|Overall Study|Death|1
6139102|NCT00529763|9770514|FG002|Overall Study|Death|1
6139103|NCT00529763|9770512|FG000|Overall Study|Disease Progression|6
6139104|NCT00529763|9770513|FG001|Overall Study|Disease Progression|16
6139105|NCT00529763|9770514|FG002|Overall Study|Disease Progression|1
6139106|NCT00529763|9770512|FG000|Overall Study|Lost to Follow-up|0
6139107|NCT00529763|9770513|FG001|Overall Study|Lost to Follow-up|1
6139108|NCT00529763|9770514|FG002|Overall Study|Lost to Follow-up|1
6139109|NCT00529763|9770512|FG000|Overall Study|Stem Cell Transplant|0
6139110|NCT00529763|9770513|FG001|Overall Study|Stem Cell Transplant|3
6139111|NCT00529763|9770514|FG002|Overall Study|Stem Cell Transplant|0
6139112|NCT00529763|9770512|FG000|Overall Study|Study Drug Toxicity|1
6139113|NCT00529763|9770513|FG001|Overall Study|Study Drug Toxicity|6
6139114|NCT00529763|9770514|FG002|Overall Study|Study Drug Toxicity|1
6139115|NCT00529763|9770512|FG000|Overall Study|Patient Withdrew Consent|2
6139116|NCT00529763|9770513|FG001|Overall Study|Patient Withdrew Consent|3
6139117|NCT00529763|9770514|FG002|Overall Study|Patient Withdrew Consent|2
5982712|NCT01994382|9571588|FG012|Overall Study|Participants rolled over into expanded access program (NCT04757259)|7
5982713|NCT01994382|9571589|FG013|Overall Study|Participants rolled over into expanded access program (NCT04757259)|0
5982714|NCT01994382|9571590|FG014|Overall Study|Participants rolled over into expanded access program (NCT04757259)|0
5982715|NCT01994382|9571591|FG015|Overall Study|Participants rolled over into expanded access program (NCT04757259)|3
5982716|NCT01994382|9571592|FG016|Overall Study|Participants rolled over into expanded access program (NCT04757259)|2
5982717|NCT01994382|9571576|FG000|Overall Study|Protocol violation/noncompliance|0
5982718|NCT01994382|9571577|FG001|Overall Study|Protocol violation/noncompliance|0
5982719|NCT01994382|9571578|FG002|Overall Study|Protocol violation/noncompliance|0
5982720|NCT01994382|9571579|FG003|Overall Study|Protocol violation/noncompliance|0
5982721|NCT01994382|9571580|FG004|Overall Study|Protocol violation/noncompliance|0
5982722|NCT01994382|9571581|FG005|Overall Study|Protocol violation/noncompliance|0
5982723|NCT01994382|9571582|FG006|Overall Study|Protocol violation/noncompliance|0
5982724|NCT01994382|9571583|FG007|Overall Study|Protocol violation/noncompliance|0
5982725|NCT01994382|9571584|FG008|Overall Study|Protocol violation/noncompliance|0
5982726|NCT01994382|9571585|FG009|Overall Study|Protocol violation/noncompliance|0
5982727|NCT01994382|9571586|FG010|Overall Study|Protocol violation/noncompliance|0
5982728|NCT01994382|9571587|FG011|Overall Study|Protocol violation/noncompliance|1
5982729|NCT01994382|9571588|FG012|Overall Study|Protocol violation/noncompliance|0
5982730|NCT01994382|9571589|FG013|Overall Study|Protocol violation/noncompliance|0
5982731|NCT01994382|9571590|FG014|Overall Study|Protocol violation/noncompliance|0
5982732|NCT01994382|9571591|FG015|Overall Study|Protocol violation/noncompliance|0
5982733|NCT01994382|9571592|FG016|Overall Study|Protocol violation/noncompliance|2
5982734|NCT01994382|9571576|FG000|Overall Study|Rolled over to Phase 2a|0
5982735|NCT01994382|9571577|FG001|Overall Study|Rolled over to Phase 2a|0
5982736|NCT01994382|9571578|FG002|Overall Study|Rolled over to Phase 2a|1
5982737|NCT01994382|9571579|FG003|Overall Study|Rolled over to Phase 2a|0
5982738|NCT01994382|9571580|FG004|Overall Study|Rolled over to Phase 2a|0
5982739|NCT01994382|9571581|FG005|Overall Study|Rolled over to Phase 2a|0
5982740|NCT01994382|9571582|FG006|Overall Study|Rolled over to Phase 2a|0
5982741|NCT01994382|9571583|FG007|Overall Study|Rolled over to Phase 2a|0
5982742|NCT01994382|9571584|FG008|Overall Study|Rolled over to Phase 2a|0
5982743|NCT01994382|9571585|FG009|Overall Study|Rolled over to Phase 2a|2
5982744|NCT01994382|9571586|FG010|Overall Study|Rolled over to Phase 2a|0
5982745|NCT01994382|9571587|FG011|Overall Study|Rolled over to Phase 2a|0
5982746|NCT01994382|9571588|FG012|Overall Study|Rolled over to Phase 2a|0
5982747|NCT01994382|9571589|FG013|Overall Study|Rolled over to Phase 2a|0
5982748|NCT01994382|9571590|FG014|Overall Study|Rolled over to Phase 2a|0
5982749|NCT01994382|9571591|FG015|Overall Study|Rolled over to Phase 2a|0
5982750|NCT01994382|9571592|FG016|Overall Study|Rolled over to Phase 2a|0
6139118|NCT01021293|9770531|FG000|Overall Study|Serious Adverse Event|2
6139119|NCT01021293|9770532|FG001|Overall Study|Serious Adverse Event|1
6139120|NCT01021293|9770531|FG000|Overall Study|Adverse Event|2
6139121|NCT01021293|9770532|FG001|Overall Study|Adverse Event|1
6139122|NCT01021293|9770531|FG000|Overall Study|Withdrawal by Subject|1
6139123|NCT01021293|9770532|FG001|Overall Study|Withdrawal by Subject|3
6139124|NCT01021293|9770531|FG000|Overall Study|Migrated/moved from study area|6
6139125|NCT01021293|9770532|FG001|Overall Study|Migrated/moved from study area|18
6139126|NCT01021293|9770531|FG000|Overall Study|Lost to Follow-up|1
6139127|NCT01021293|9770532|FG001|Overall Study|Lost to Follow-up|1
6139128|NCT01021332|9770556|FG000|Overall Study|Not fulfilling incl./excl.criteria|5
6139129|NCT01021332|9770556|FG000|Overall Study|Adverse Event|43
6139130|NCT01021332|9770556|FG000|Overall Study|Lack of Efficacy|19
6139131|NCT01021332|9770556|FG000|Overall Study|Withdrawal of Consent|23
6139132|NCT01021332|9770556|FG000|Overall Study|Lost to Follow-up|4
6139133|NCT01021332|9770556|FG000|Overall Study|Protocol Violation|9
6139134|NCT01021332|9770556|FG000|Overall Study|Miscellaneous|3
6139135|NCT01021423|9770564|FG000|Overall Study|Study terminated|4
6139136|NCT01021423|9770565|FG001|Overall Study|Study terminated|5
6139137|NCT01021553|9770574|FG000|Overall Study|Adverse Event|1
6139138|NCT01021553|9770575|FG001|Overall Study|Adverse Event|0
6139139|NCT01021553|9770576|FG002|Overall Study|Adverse Event|0
6139140|NCT01021553|9770574|FG000|Overall Study|Lack of Efficacy|2
6139141|NCT01021553|9770575|FG001|Overall Study|Lack of Efficacy|2
6139142|NCT01021553|9770576|FG002|Overall Study|Lack of Efficacy|0
6139143|NCT01021553|9770574|FG000|Overall Study|Protocol Violation|0
6139144|NCT01021553|9770575|FG001|Overall Study|Protocol Violation|2
6139145|NCT01021553|9770576|FG002|Overall Study|Protocol Violation|2
6139146|NCT01021553|9770574|FG000|Overall Study|Lost to Follow-up|0
6139147|NCT01021553|9770575|FG001|Overall Study|Lost to Follow-up|0
6139148|NCT01021553|9770576|FG002|Overall Study|Lost to Follow-up|1
6139149|NCT01021553|9770574|FG000|Overall Study|Withdrawal by Subject|1
6139150|NCT01021553|9770575|FG001|Overall Study|Withdrawal by Subject|1
6139151|NCT01021553|9770576|FG002|Overall Study|Withdrawal by Subject|0
6139152|NCT01021683|9770598|FG000|Overall Study|Lack of Efficacy|12
6139153|NCT01021683|9770598|FG000|Overall Study|Recovery of neutrophil count|51
6139154|NCT01021683|9770598|FG000|Overall Study|Other|8
6139155|NCT01021748|9770611|FG000|Overall Study|Adverse Event|2
6139156|NCT01021748|9770612|FG001|Overall Study|Adverse Event|1
6139157|NCT01021748|9770613|FG002|Overall Study|Adverse Event|2
6139158|NCT01021748|9770614|FG003|Overall Study|Adverse Event|0
6139159|NCT01021748|9770615|FG004|Overall Study|Adverse Event|2
6139160|NCT01021748|9770616|FG005|Overall Study|Adverse Event|0
6139161|NCT01021748|9770617|FG006|Overall Study|Adverse Event|1
6139162|NCT01021748|9770618|FG007|Overall Study|Adverse Event|0
6139163|NCT01021748|9770619|FG008|Overall Study|Adverse Event|7
6139164|NCT01021748|9770611|FG000|Overall Study|Physician Decision|1
6139165|NCT01021748|9770612|FG001|Overall Study|Physician Decision|0
6139166|NCT01021748|9770613|FG002|Overall Study|Physician Decision|1
6139167|NCT01021748|9770614|FG003|Overall Study|Physician Decision|1
6139168|NCT01021748|9770615|FG004|Overall Study|Physician Decision|0
6139169|NCT01021748|9770616|FG005|Overall Study|Physician Decision|0
6139170|NCT01021748|9770617|FG006|Overall Study|Physician Decision|1
6139171|NCT01021748|9770618|FG007|Overall Study|Physician Decision|1
6139172|NCT01021748|9770619|FG008|Overall Study|Physician Decision|2
6139173|NCT01021748|9770611|FG000|Overall Study|Progressive Disease|3
6139174|NCT01021748|9770612|FG001|Overall Study|Progressive Disease|3
6139175|NCT01021748|9770613|FG002|Overall Study|Progressive Disease|4
6139176|NCT01021748|9770614|FG003|Overall Study|Progressive Disease|6
6139177|NCT01021748|9770615|FG004|Overall Study|Progressive Disease|7
6139178|NCT01021748|9770616|FG005|Overall Study|Progressive Disease|3
6139179|NCT01021748|9770617|FG006|Overall Study|Progressive Disease|0
6139180|NCT01021748|9770618|FG007|Overall Study|Progressive Disease|5
6139181|NCT01021748|9770619|FG008|Overall Study|Progressive Disease|6
6139182|NCT01021748|9770611|FG000|Overall Study|Withdrawal by Subject|0
6139183|NCT01021748|9770612|FG001|Overall Study|Withdrawal by Subject|0
6139184|NCT01021748|9770613|FG002|Overall Study|Withdrawal by Subject|0
6139185|NCT01021748|9770614|FG003|Overall Study|Withdrawal by Subject|0
6139186|NCT01021748|9770615|FG004|Overall Study|Withdrawal by Subject|0
6139187|NCT01021748|9770616|FG005|Overall Study|Withdrawal by Subject|0
6139188|NCT01021748|9770617|FG006|Overall Study|Withdrawal by Subject|1
6139189|NCT01021748|9770618|FG007|Overall Study|Withdrawal by Subject|0
6139190|NCT01021748|9770619|FG008|Overall Study|Withdrawal by Subject|1
6139191|NCT01021748|9770611|FG000|Overall Study|Not Treated|0
6139192|NCT01021748|9770612|FG001|Overall Study|Not Treated|1
6139193|NCT01021748|9770613|FG002|Overall Study|Not Treated|0
6139194|NCT01021748|9770614|FG003|Overall Study|Not Treated|0
6139195|NCT01021748|9770615|FG004|Overall Study|Not Treated|0
6139196|NCT01021748|9770616|FG005|Overall Study|Not Treated|0
6139197|NCT01021748|9770617|FG006|Overall Study|Not Treated|0
6139198|NCT01021748|9770618|FG007|Overall Study|Not Treated|0
6139199|NCT01021748|9770619|FG008|Overall Study|Not Treated|0
6139200|NCT01021813|9770654|FG000|DB Treatment Phase|Adverse Event|60
6139201|NCT01021813|9770655|FG001|DB Treatment Phase|Adverse Event|22
6139202|NCT01021813|9770656|FG002|DB Treatment Phase|Adverse Event|0
6139203|NCT01021813|9770657|FG003|DB Treatment Phase|Adverse Event|0
6139204|NCT01021813|9770658|FG004|DB Treatment Phase|Adverse Event|0
6139205|NCT01021813|9770654|FG000|DB Treatment Phase|Lack of Efficacy|44
6139206|NCT01021813|9770655|FG001|DB Treatment Phase|Lack of Efficacy|28
6139207|NCT01021813|9770656|FG002|DB Treatment Phase|Lack of Efficacy|0
6139208|NCT01021813|9770657|FG003|DB Treatment Phase|Lack of Efficacy|0
6139209|NCT01021813|9770658|FG004|DB Treatment Phase|Lack of Efficacy|0
6139210|NCT01021813|9770654|FG000|DB Treatment Phase|Lost to Follow-up|14
6139211|NCT01021813|9770655|FG001|DB Treatment Phase|Lost to Follow-up|12
6139212|NCT01021813|9770656|FG002|DB Treatment Phase|Lost to Follow-up|0
6139213|NCT01021813|9770657|FG003|DB Treatment Phase|Lost to Follow-up|0
6139214|NCT01021813|9770658|FG004|DB Treatment Phase|Lost to Follow-up|0
6139215|NCT01021813|9770654|FG000|DB Treatment Phase|Physician Decision|17
6139216|NCT01021813|9770655|FG001|DB Treatment Phase|Physician Decision|8
6139217|NCT01021813|9770656|FG002|DB Treatment Phase|Physician Decision|0
6139218|NCT01021813|9770657|FG003|DB Treatment Phase|Physician Decision|0
6139219|NCT01021813|9770658|FG004|DB Treatment Phase|Physician Decision|0
6139220|NCT01021813|9770654|FG000|DB Treatment Phase|Pregnancy|1
6139221|NCT01021813|9770655|FG001|DB Treatment Phase|Pregnancy|0
6139222|NCT01021813|9770656|FG002|DB Treatment Phase|Pregnancy|0
6139223|NCT01021813|9770657|FG003|DB Treatment Phase|Pregnancy|0
6139224|NCT01021813|9770658|FG004|DB Treatment Phase|Pregnancy|0
6139225|NCT01021813|9770654|FG000|DB Treatment Phase|Protocol Violation|4
6139226|NCT01021813|9770655|FG001|DB Treatment Phase|Protocol Violation|3
6139227|NCT01021813|9770656|FG002|DB Treatment Phase|Protocol Violation|0
6139228|NCT01021813|9770657|FG003|DB Treatment Phase|Protocol Violation|0
6139229|NCT01021813|9770658|FG004|DB Treatment Phase|Protocol Violation|0
6139230|NCT01021813|9770654|FG000|DB Treatment Phase|Withdrawal by Subject|60
6139231|NCT01021813|9770655|FG001|DB Treatment Phase|Withdrawal by Subject|24
6139232|NCT01021813|9770656|FG002|DB Treatment Phase|Withdrawal by Subject|0
6139233|NCT01021813|9770657|FG003|DB Treatment Phase|Withdrawal by Subject|0
6139234|NCT01021813|9770658|FG004|DB Treatment Phase|Withdrawal by Subject|0
6139235|NCT01021813|9770654|FG000|DB Randomized Discontinuation Phase|Adverse Event|0
6139236|NCT01021813|9770655|FG001|DB Randomized Discontinuation Phase|Adverse Event|0
6139237|NCT01021813|9770656|FG002|DB Randomized Discontinuation Phase|Adverse Event|0
6139238|NCT01021813|9770657|FG003|DB Randomized Discontinuation Phase|Adverse Event|3
6139239|NCT01021813|9770658|FG004|DB Randomized Discontinuation Phase|Adverse Event|1
6139240|NCT01021813|9770654|FG000|DB Randomized Discontinuation Phase|Lack of Efficacy|0
6139241|NCT01021813|9770655|FG001|DB Randomized Discontinuation Phase|Lack of Efficacy|0
6139242|NCT01021813|9770656|FG002|DB Randomized Discontinuation Phase|Lack of Efficacy|0
6139243|NCT01021813|9770657|FG003|DB Randomized Discontinuation Phase|Lack of Efficacy|1
6139244|NCT01021813|9770658|FG004|DB Randomized Discontinuation Phase|Lack of Efficacy|0
6139245|NCT01021813|9770654|FG000|DB Randomized Discontinuation Phase|Lost to Follow-up|0
6139246|NCT01021813|9770655|FG001|DB Randomized Discontinuation Phase|Lost to Follow-up|0
6139247|NCT01021813|9770656|FG002|DB Randomized Discontinuation Phase|Lost to Follow-up|0
6139248|NCT01021813|9770657|FG003|DB Randomized Discontinuation Phase|Lost to Follow-up|0
6139249|NCT01021813|9770658|FG004|DB Randomized Discontinuation Phase|Lost to Follow-up|1
6139250|NCT01021813|9770654|FG000|DB Randomized Discontinuation Phase|Protocol Violation|0
6139251|NCT01021813|9770655|FG001|DB Randomized Discontinuation Phase|Protocol Violation|0
6139252|NCT01021813|9770656|FG002|DB Randomized Discontinuation Phase|Protocol Violation|1
6139253|NCT01021813|9770657|FG003|DB Randomized Discontinuation Phase|Protocol Violation|0
6139254|NCT01021813|9770658|FG004|DB Randomized Discontinuation Phase|Protocol Violation|0
6139255|NCT01021813|9770654|FG000|DB Randomized Discontinuation Phase|Withdrawal by Subject|0
6139256|NCT01021813|9770655|FG001|DB Randomized Discontinuation Phase|Withdrawal by Subject|0
6139257|NCT01021813|9770656|FG002|DB Randomized Discontinuation Phase|Withdrawal by Subject|3
6139258|NCT01021813|9770657|FG003|DB Randomized Discontinuation Phase|Withdrawal by Subject|1
6139259|NCT01021813|9770658|FG004|DB Randomized Discontinuation Phase|Withdrawal by Subject|3
6139260|NCT01021852|9770683|FG000|Treatment Period 1|Adverse Event|3
6139261|NCT01021852|9770684|FG001|Treatment Period 1|Adverse Event|1
6139262|NCT01021852|9770685|FG002|Treatment Period 1|Adverse Event|1
6139263|NCT01021852|9770686|FG003|Treatment Period 1|Adverse Event|0
6139264|NCT01021852|9770687|FG004|Treatment Period 1|Adverse Event|2
6139265|NCT01021852|9770688|FG005|Treatment Period 1|Adverse Event|2
6139266|NCT01021852|9770689|FG006|Treatment Period 1|Adverse Event|0
6139267|NCT01021852|9770690|FG007|Treatment Period 1|Adverse Event|0
6139268|NCT01021852|9770683|FG000|Treatment Period 1|Pregnancy|0
6139269|NCT01021852|9770684|FG001|Treatment Period 1|Pregnancy|0
6139270|NCT01021852|9770685|FG002|Treatment Period 1|Pregnancy|1
6139271|NCT01021852|9770686|FG003|Treatment Period 1|Pregnancy|0
6139272|NCT01021852|9770687|FG004|Treatment Period 1|Pregnancy|0
6139273|NCT01021852|9770688|FG005|Treatment Period 1|Pregnancy|0
6139274|NCT01021852|9770689|FG006|Treatment Period 1|Pregnancy|0
6139275|NCT01021852|9770690|FG007|Treatment Period 1|Pregnancy|0
6139276|NCT01021852|9770683|FG000|Treatment Period 1|Withdrawal by Subject|0
6139277|NCT01021852|9770684|FG001|Treatment Period 1|Withdrawal by Subject|0
6139278|NCT01021852|9770685|FG002|Treatment Period 1|Withdrawal by Subject|0
6139279|NCT01021852|9770686|FG003|Treatment Period 1|Withdrawal by Subject|0
6139280|NCT01021852|9770687|FG004|Treatment Period 1|Withdrawal by Subject|1
6139281|NCT01021852|9770688|FG005|Treatment Period 1|Withdrawal by Subject|0
6139282|NCT01021852|9770689|FG006|Treatment Period 1|Withdrawal by Subject|0
6139283|NCT01021852|9770690|FG007|Treatment Period 1|Withdrawal by Subject|1
6139284|NCT01021852|9770683|FG000|Treatment Period 1|Not Treated|0
6139285|NCT01021852|9770684|FG001|Treatment Period 1|Not Treated|0
6139286|NCT01021852|9770685|FG002|Treatment Period 1|Not Treated|0
6139287|NCT01021852|9770686|FG003|Treatment Period 1|Not Treated|2
6139288|NCT01021852|9770687|FG004|Treatment Period 1|Not Treated|0
6139289|NCT01021852|9770688|FG005|Treatment Period 1|Not Treated|0
6139290|NCT01021852|9770689|FG006|Treatment Period 1|Not Treated|0
6139291|NCT01021852|9770690|FG007|Treatment Period 1|Not Treated|0
6139292|NCT01021852|9770683|FG000|Washout Period-Placebo|Adverse Event|0
6139293|NCT01021852|9770684|FG001|Washout Period-Placebo|Adverse Event|0
6139294|NCT01021852|9770685|FG002|Washout Period-Placebo|Adverse Event|0
6139295|NCT01021852|9770686|FG003|Washout Period-Placebo|Adverse Event|1
6139296|NCT01021852|9770687|FG004|Washout Period-Placebo|Adverse Event|0
6139297|NCT01021852|9770688|FG005|Washout Period-Placebo|Adverse Event|1
6139298|NCT01021852|9770689|FG006|Washout Period-Placebo|Adverse Event|0
6139299|NCT01021852|9770690|FG007|Washout Period-Placebo|Adverse Event|0
6139300|NCT01021852|9770683|FG000|Washout Period-Placebo|Lost to Follow-up|0
6139301|NCT01021852|9770684|FG001|Washout Period-Placebo|Lost to Follow-up|0
6139302|NCT01021852|9770685|FG002|Washout Period-Placebo|Lost to Follow-up|0
6139303|NCT01021852|9770686|FG003|Washout Period-Placebo|Lost to Follow-up|0
6139304|NCT01021852|9770687|FG004|Washout Period-Placebo|Lost to Follow-up|1
6139305|NCT01021852|9770688|FG005|Washout Period-Placebo|Lost to Follow-up|0
6139306|NCT01021852|9770689|FG006|Washout Period-Placebo|Lost to Follow-up|0
6139307|NCT01021852|9770690|FG007|Washout Period-Placebo|Lost to Follow-up|0
6139308|NCT01021852|9770683|FG000|Washout Period-Placebo|Protocol Violation|0
6139309|NCT01021852|9770684|FG001|Washout Period-Placebo|Protocol Violation|0
6139310|NCT01021852|9770685|FG002|Washout Period-Placebo|Protocol Violation|0
6139311|NCT01021852|9770686|FG003|Washout Period-Placebo|Protocol Violation|0
6139312|NCT01021852|9770687|FG004|Washout Period-Placebo|Protocol Violation|0
6139313|NCT01021852|9770688|FG005|Washout Period-Placebo|Protocol Violation|0
6139314|NCT01021852|9770689|FG006|Washout Period-Placebo|Protocol Violation|1
6139315|NCT01021852|9770690|FG007|Washout Period-Placebo|Protocol Violation|0
6139316|NCT01021852|9770683|FG000|Washout Period-No Drug|Adverse Event|1
6139317|NCT01021852|9770684|FG001|Washout Period-No Drug|Adverse Event|0
6139318|NCT01021852|9770685|FG002|Washout Period-No Drug|Adverse Event|0
6139319|NCT01021852|9770686|FG003|Washout Period-No Drug|Adverse Event|0
6139320|NCT01021852|9770687|FG004|Washout Period-No Drug|Adverse Event|0
6139321|NCT01021852|9770688|FG005|Washout Period-No Drug|Adverse Event|1
6139322|NCT01021852|9770689|FG006|Washout Period-No Drug|Adverse Event|0
6139323|NCT01021852|9770690|FG007|Washout Period-No Drug|Adverse Event|0
6139324|NCT01021852|9770683|FG000|Treatment Period 2|Adverse Event|0
6139325|NCT01021852|9770684|FG001|Treatment Period 2|Adverse Event|1
6139326|NCT01021852|9770685|FG002|Treatment Period 2|Adverse Event|0
6139327|NCT01021852|9770686|FG003|Treatment Period 2|Adverse Event|0
6139328|NCT01021852|9770687|FG004|Treatment Period 2|Adverse Event|1
6139329|NCT01021852|9770688|FG005|Treatment Period 2|Adverse Event|0
6139330|NCT01021852|9770689|FG006|Treatment Period 2|Adverse Event|1
6139331|NCT01021852|9770690|FG007|Treatment Period 2|Adverse Event|0
6139332|NCT01021852|9770683|FG000|Treatment Period 2|Lack of Efficacy|0
6139333|NCT01021852|9770684|FG001|Treatment Period 2|Lack of Efficacy|0
6139334|NCT01021852|9770685|FG002|Treatment Period 2|Lack of Efficacy|0
6139335|NCT01021852|9770686|FG003|Treatment Period 2|Lack of Efficacy|0
6139336|NCT01021852|9770687|FG004|Treatment Period 2|Lack of Efficacy|0
6139337|NCT01021852|9770688|FG005|Treatment Period 2|Lack of Efficacy|1
6139338|NCT01021852|9770689|FG006|Treatment Period 2|Lack of Efficacy|0
6139339|NCT01021852|9770690|FG007|Treatment Period 2|Lack of Efficacy|0
6139340|NCT01021852|9770683|FG000|Treatment Period 2|Physician Decision|0
6139341|NCT01021852|9770684|FG001|Treatment Period 2|Physician Decision|0
6139342|NCT01021852|9770685|FG002|Treatment Period 2|Physician Decision|1
6139343|NCT01021852|9770686|FG003|Treatment Period 2|Physician Decision|0
6139344|NCT01021852|9770687|FG004|Treatment Period 2|Physician Decision|0
6139345|NCT01021852|9770688|FG005|Treatment Period 2|Physician Decision|0
6139346|NCT01021852|9770689|FG006|Treatment Period 2|Physician Decision|0
6139347|NCT01021852|9770690|FG007|Treatment Period 2|Physician Decision|0
6139348|NCT01021852|9770683|FG000|Treatment Period 2|Protocol Violation|0
6139349|NCT01021852|9770684|FG001|Treatment Period 2|Protocol Violation|0
6139350|NCT01021852|9770685|FG002|Treatment Period 2|Protocol Violation|0
6139351|NCT01021852|9770686|FG003|Treatment Period 2|Protocol Violation|0
6139352|NCT01021852|9770687|FG004|Treatment Period 2|Protocol Violation|1
6139353|NCT01021852|9770688|FG005|Treatment Period 2|Protocol Violation|0
6139354|NCT01021852|9770689|FG006|Treatment Period 2|Protocol Violation|1
6139355|NCT01021852|9770690|FG007|Treatment Period 2|Protocol Violation|0
6139356|NCT01021852|9770683|FG000|Treatment Period 2|Withdrawal by Subject|0
6139357|NCT01021852|9770684|FG001|Treatment Period 2|Withdrawal by Subject|0
6139358|NCT01021852|9770685|FG002|Treatment Period 2|Withdrawal by Subject|0
6139359|NCT01021852|9770686|FG003|Treatment Period 2|Withdrawal by Subject|0
6139360|NCT01021852|9770687|FG004|Treatment Period 2|Withdrawal by Subject|0
6139361|NCT01021852|9770688|FG005|Treatment Period 2|Withdrawal by Subject|0
6139362|NCT01021852|9770689|FG006|Treatment Period 2|Withdrawal by Subject|1
6139363|NCT01021852|9770690|FG007|Treatment Period 2|Withdrawal by Subject|2
6139364|NCT01021878|9770706|FG000|Overall Study|Lost to Follow-up|4
6139365|NCT01021878|9770707|FG001|Overall Study|Lost to Follow-up|3
6139366|NCT01021878|9770706|FG000|Overall Study|Death|0
6139367|NCT01021878|9770707|FG001|Overall Study|Death|1
6139368|NCT01021878|9770706|FG000|Overall Study|Adverse Event|6
6139369|NCT01021878|9770707|FG001|Overall Study|Adverse Event|5
6139370|NCT01021878|9770706|FG000|Overall Study|Transplantation|6
6139371|NCT01021878|9770707|FG001|Overall Study|Transplantation|1
6139372|NCT01022112|9770748|FG000|Overall Study|Adverse Event|1
6139373|NCT01022112|9770749|FG001|Overall Study|Adverse Event|2
6139374|NCT01022112|9770750|FG002|Overall Study|Adverse Event|0
6139375|NCT01022112|9770751|FG003|Overall Study|Adverse Event|1
6139376|NCT01022112|9770752|FG004|Overall Study|Adverse Event|0
6139377|NCT01022112|9770748|FG000|Overall Study|Lack of Efficacy|1
6139378|NCT01022112|9770749|FG001|Overall Study|Lack of Efficacy|0
6139379|NCT01022112|9770750|FG002|Overall Study|Lack of Efficacy|0
6139380|NCT01022112|9770751|FG003|Overall Study|Lack of Efficacy|0
6139381|NCT01022112|9770752|FG004|Overall Study|Lack of Efficacy|1
6139382|NCT01022112|9770748|FG000|Overall Study|Physician Decision|0
6139383|NCT01022112|9770749|FG001|Overall Study|Physician Decision|0
6139384|NCT01022112|9770750|FG002|Overall Study|Physician Decision|1
6139385|NCT01022112|9770751|FG003|Overall Study|Physician Decision|0
6139386|NCT01022112|9770752|FG004|Overall Study|Physician Decision|1
6139387|NCT01022112|9770748|FG000|Overall Study|Withdrawal by Subject|0
6139388|NCT01022112|9770749|FG001|Overall Study|Withdrawal by Subject|1
6139389|NCT01022112|9770750|FG002|Overall Study|Withdrawal by Subject|2
6139390|NCT01022112|9770751|FG003|Overall Study|Withdrawal by Subject|2
6139391|NCT01022112|9770752|FG004|Overall Study|Withdrawal by Subject|1
6139392|NCT01022112|9770748|FG000|Overall Study|Fasting plasma glucose level increased|1
6139393|NCT01022112|9770749|FG001|Overall Study|Fasting plasma glucose level increased|0
6139394|NCT01022112|9770750|FG002|Overall Study|Fasting plasma glucose level increased|0
6139395|NCT01022112|9770751|FG003|Overall Study|Fasting plasma glucose level increased|0
6139396|NCT01022112|9770752|FG004|Overall Study|Fasting plasma glucose level increased|7
6139397|NCT01022203|9770770|FG000|Post Treatment Assessment|Withdrawal by Subject|12
6139398|NCT01022203|9770771|FG001|Post Treatment Assessment|Withdrawal by Subject|12
6139399|NCT01022203|9770770|FG000|Post Treatment Assessment|Physician Decision|2
6139400|NCT01022203|9770771|FG001|Post Treatment Assessment|Physician Decision|0
6139401|NCT01022203|9770770|FG000|Post Treatment Assessment|Adverse Event|0
6139402|NCT01022203|9770771|FG001|Post Treatment Assessment|Adverse Event|2
6139403|NCT01022203|9770770|FG000|Follow-Up Assessment|Lost to Follow-up|2
6139404|NCT01022203|9770771|FG001|Follow-Up Assessment|Lost to Follow-up|2
6139405|NCT01022424|9770807|FG000|Overall Study|Adverse Event|1
6139406|NCT01022424|9770807|FG000|Overall Study|Physician Decision|1
6139407|NCT01022424|9770807|FG000|Overall Study|eGFR under the withdrawal criteria|2
6139408|NCT01022502|9770815|FG000|Overall Study|Adverse Event|1
6139409|NCT01022502|9770815|FG000|Overall Study|employment related reasons|1
6139410|NCT01022502|9770815|FG000|Overall Study|Withdrawal by Subject|1
6139411|NCT01022580|9770832|FG000|Overall Study|Death|18
6139412|NCT01022580|9770833|FG001|Overall Study|Death|22
6139413|NCT01022762|9770847|FG000|Overall Study|Adverse Event|3
6139414|NCT01022762|9770848|FG001|Overall Study|Adverse Event|1
6139415|NCT01022762|9770847|FG000|Overall Study|Lack of Efficacy|0
6139416|NCT01022762|9770848|FG001|Overall Study|Lack of Efficacy|1
6139417|NCT01022762|9770847|FG000|Overall Study|Protocol Violation|7
6139418|NCT01022762|9770848|FG001|Overall Study|Protocol Violation|6
6139419|NCT01022762|9770847|FG000|Overall Study|Unclassified|12
6139420|NCT01022762|9770848|FG001|Overall Study|Unclassified|20
6139421|NCT01022853|9770859|FG000|Overall Study|Progressive disease|2
6139422|NCT01022853|9770860|FG001|Overall Study|Progressive disease|3
6139423|NCT01022853|9770861|FG002|Overall Study|Progressive disease|11
6139424|NCT01022853|9770862|FG003|Overall Study|Progressive disease|7
6139425|NCT01022853|9770863|FG004|Overall Study|Progressive disease|1
6139426|NCT01022853|9770859|FG000|Overall Study|Dose-limiting toxicity|0
6139427|NCT01022853|9770860|FG001|Overall Study|Dose-limiting toxicity|0
6139428|NCT01022853|9770861|FG002|Overall Study|Dose-limiting toxicity|0
6139429|NCT01022853|9770862|FG003|Overall Study|Dose-limiting toxicity|0
6139430|NCT01022853|9770863|FG004|Overall Study|Dose-limiting toxicity|1
6139431|NCT01022853|9770859|FG000|Overall Study|Withdrawal by Subject|0
6139432|NCT01022853|9770860|FG001|Overall Study|Withdrawal by Subject|1
6139433|NCT01022853|9770861|FG002|Overall Study|Withdrawal by Subject|1
6139434|NCT01022853|9770862|FG003|Overall Study|Withdrawal by Subject|1
6139435|NCT01022853|9770863|FG004|Overall Study|Withdrawal by Subject|0
6139436|NCT01022853|9770859|FG000|Overall Study|Other not stated above|1
6139437|NCT01022853|9770860|FG001|Overall Study|Other not stated above|0
6139438|NCT01022853|9770861|FG002|Overall Study|Other not stated above|1
6139439|NCT01022853|9770862|FG003|Overall Study|Other not stated above|0
6139440|NCT01022853|9770863|FG004|Overall Study|Other not stated above|0
6139441|NCT01022996|9770878|FG000|Overall Study|Adverse Event|14
6139442|NCT01022996|9770878|FG000|Overall Study|Withdrawal by Subject|3
6139443|NCT01022996|9770878|FG000|Overall Study|Lost to Follow-up|1
6139444|NCT01022996|9770878|FG000|Overall Study|Administrative problems|6
6139445|NCT01022996|9770878|FG000|Overall Study|Disease Progression|32
6139446|NCT01022996|9770878|FG000|Overall Study|Protocol Violation|1
6139447|NCT01023022|9770882|FG000|Overall Study|Death|5
6139448|NCT01023022|9770882|FG000|Overall Study|Lost to Follow-up|7
6139449|NCT01023022|9770882|FG000|Overall Study|due to technical issues|2
6139450|NCT01023035|9770889|FG000|Treatment Period|Adverse Event|27
6139451|NCT01023035|9770890|FG001|Treatment Period|Adverse Event|32
6139452|NCT01023035|9770891|FG002|Treatment Period|Adverse Event|50
6139453|NCT01023035|9770889|FG000|Treatment Period|Non-Medical Reasons|19
6139454|NCT01023035|9770890|FG001|Treatment Period|Non-Medical Reasons|22
6139455|NCT01023035|9770891|FG002|Treatment Period|Non-Medical Reasons|44
6139456|NCT01023035|9770889|FG000|Treatment Period|Treatment Failure|26
6139457|NCT01023035|9770890|FG001|Treatment Period|Treatment Failure|31
6139458|NCT01023035|9770891|FG002|Treatment Period|Treatment Failure|24
6139459|NCT01023035|9770889|FG000|Follow-up Period (up to Week 72)|Adverse Event|2
6139460|NCT01023035|9770890|FG001|Follow-up Period (up to Week 72)|Adverse Event|0
6139461|NCT01023035|9770891|FG002|Follow-up Period (up to Week 72)|Adverse Event|1
6139462|NCT01023035|9770889|FG000|Follow-up Period (up to Week 72)|Non-medical Reason|26
6139463|NCT01023035|9770890|FG001|Follow-up Period (up to Week 72)|Non-medical Reason|28
6139464|NCT01023035|9770891|FG002|Follow-up Period (up to Week 72)|Non-medical Reason|38
6139465|NCT01023061|9770901|FG000|Overall Study|Withdrawal prior to treatment|2
6139466|NCT01023217|9770937|FG000|Overall Study|Withdrawal by Subject|1
6139467|NCT01023217|9770938|FG001|Overall Study|Withdrawal by Subject|0
6139468|NCT01023256|9770948|FG000|Overall Study|Protocol Violation|2
6139469|NCT01023256|9770949|FG001|Overall Study|Protocol Violation|3
6139470|NCT01023256|9770950|FG002|Overall Study|Protocol Violation|0
6139471|NCT01023256|9770951|FG003|Overall Study|Protocol Violation|0
6139472|NCT01023256|9770948|FG000|Overall Study|Randomized but not treated|1
6139473|NCT01023256|9770949|FG001|Overall Study|Randomized but not treated|0
6139474|NCT01023256|9770950|FG002|Overall Study|Randomized but not treated|1
6139475|NCT01023256|9770951|FG003|Overall Study|Randomized but not treated|0
6139476|NCT01023256|9770948|FG000|Overall Study|Other|1
6139477|NCT01023256|9770949|FG001|Overall Study|Other|0
6139478|NCT01023256|9770950|FG002|Overall Study|Other|0
6139479|NCT01023256|9770951|FG003|Overall Study|Other|2
6139480|NCT01023256|9770948|FG000|Overall Study|Adverse Event|0
6139481|NCT01023256|9770949|FG001|Overall Study|Adverse Event|0
6139482|NCT01023256|9770950|FG002|Overall Study|Adverse Event|0
6139483|NCT01023256|9770951|FG003|Overall Study|Adverse Event|1
6139484|NCT01023256|9770948|FG000|Overall Study|Withdrawal by Subject|0
6139485|NCT01023256|9770949|FG001|Overall Study|Withdrawal by Subject|0
6139486|NCT01023256|9770950|FG002|Overall Study|Withdrawal by Subject|0
6139487|NCT01023256|9770951|FG003|Overall Study|Withdrawal by Subject|2
6139488|NCT01023269|9770964|FG000|Overall Study|early termination of the study|2
6139489|NCT01023269|9770965|FG001|Overall Study|early termination of the study|0
6139490|NCT01023308|9770971|FG000|Overall Study|Abnormal test proceedure results|3
6139491|NCT01023308|9770972|FG001|Overall Study|Abnormal test proceedure results|8
6139492|NCT01023308|9770971|FG000|Overall Study|Administrative problems|2
6139493|NCT01023308|9770972|FG001|Overall Study|Administrative problems|1
6139494|NCT01023308|9770971|FG000|Overall Study|Adverse Event|130
6139495|NCT01023308|9770972|FG001|Overall Study|Adverse Event|66
6139496|NCT01023308|9770971|FG000|Overall Study|Death|21
6139497|NCT01023308|9770972|FG001|Overall Study|Death|17
6139498|NCT01023308|9770971|FG000|Overall Study|Disease progression|82
6139499|NCT01023308|9770972|FG001|Overall Study|Disease progression|153
6139500|NCT01023308|9770971|FG000|Overall Study|New Cancer therapy|4
6139501|NCT01023308|9770972|FG001|Overall Study|New Cancer therapy|7
6139502|NCT01023308|9770971|FG000|Overall Study|Protocol Violation|3
6139503|NCT01023308|9770972|FG001|Overall Study|Protocol Violation|4
6139504|NCT01023308|9770971|FG000|Overall Study|Untreated|5
6139505|NCT01023308|9770972|FG001|Overall Study|Untreated|5
6139506|NCT01023308|9770971|FG000|Overall Study|Lost to Follow-up|1
6139507|NCT01023308|9770972|FG001|Overall Study|Lost to Follow-up|0
6139508|NCT01023308|9770971|FG000|Overall Study|Withdrawal by Subject|34
6139509|NCT01023308|9770972|FG001|Overall Study|Withdrawal by Subject|18
6139510|NCT01023516|9770989|FG000|Overall Study|Voluntary discontinuation|7
6139511|NCT01023516|9770990|FG001|Overall Study|Voluntary discontinuation|5
6139512|NCT01023516|9770989|FG000|Overall Study|Adverse Event|9
6139513|NCT01023516|9770990|FG001|Overall Study|Adverse Event|6
6139514|NCT01023516|9770989|FG000|Overall Study|Safety reason|0
6139515|NCT01023516|9770990|FG001|Overall Study|Safety reason|3
6139516|NCT01023516|9770989|FG000|Overall Study|Study-specific criteria|4
6139517|NCT01023516|9770990|FG001|Overall Study|Study-specific criteria|2
6139518|NCT01023516|9770989|FG000|Overall Study|Incorrect enrolment|4
6139519|NCT01023516|9770990|FG001|Overall Study|Incorrect enrolment|2
6139520|NCT01023581|9771016|FG000|Overall Study|Adverse Event|4
6139521|NCT01023581|9771017|FG001|Overall Study|Adverse Event|4
6139522|NCT01023581|9771018|FG002|Overall Study|Adverse Event|7
6139523|NCT01023581|9771019|FG003|Overall Study|Adverse Event|3
6139524|NCT01023581|9771020|FG004|Overall Study|Adverse Event|2
6139525|NCT01023581|9771021|FG005|Overall Study|Adverse Event|5
6139526|NCT01023581|9771022|FG006|Overall Study|Adverse Event|11
6139527|NCT01023581|9771016|FG000|Overall Study|Major protocol deviation|2
6139528|NCT01023581|9771017|FG001|Overall Study|Major protocol deviation|0
6139529|NCT01023581|9771018|FG002|Overall Study|Major protocol deviation|3
6139530|NCT01023581|9771019|FG003|Overall Study|Major protocol deviation|0
6139531|NCT01023581|9771020|FG004|Overall Study|Major protocol deviation|0
6139532|NCT01023581|9771021|FG005|Overall Study|Major protocol deviation|0
6139533|NCT01023581|9771022|FG006|Overall Study|Major protocol deviation|0
6139534|NCT01023581|9771016|FG000|Overall Study|Lost to Follow-up|4
6139535|NCT01023581|9771017|FG001|Overall Study|Lost to Follow-up|8
6139536|NCT01023581|9771018|FG002|Overall Study|Lost to Follow-up|7
6139537|NCT01023581|9771019|FG003|Overall Study|Lost to Follow-up|2
6139538|NCT01023581|9771020|FG004|Overall Study|Lost to Follow-up|5
6139539|NCT01023581|9771021|FG005|Overall Study|Lost to Follow-up|2
6139540|NCT01023581|9771022|FG006|Overall Study|Lost to Follow-up|2
6139541|NCT01023581|9771016|FG000|Overall Study|Withdrawal by Subject|13
6139542|NCT01023581|9771017|FG001|Overall Study|Withdrawal by Subject|8
6139543|NCT01023581|9771018|FG002|Overall Study|Withdrawal by Subject|16
6139544|NCT01023581|9771019|FG003|Overall Study|Withdrawal by Subject|10
6139545|NCT01023581|9771020|FG004|Overall Study|Withdrawal by Subject|6
6139546|NCT01023581|9771021|FG005|Overall Study|Withdrawal by Subject|8
6139547|NCT01023581|9771022|FG006|Overall Study|Withdrawal by Subject|5
6139548|NCT01023581|9771016|FG000|Overall Study|Pregnancy|0
6139549|NCT01023581|9771017|FG001|Overall Study|Pregnancy|0
6139550|NCT01023581|9771018|FG002|Overall Study|Pregnancy|0
6139551|NCT01023581|9771019|FG003|Overall Study|Pregnancy|2
6139552|NCT01023581|9771020|FG004|Overall Study|Pregnancy|0
6139553|NCT01023581|9771021|FG005|Overall Study|Pregnancy|1
6139554|NCT01023581|9771022|FG006|Overall Study|Pregnancy|0
6139555|NCT01023581|9771016|FG000|Overall Study|Lack of Efficacy|9
6139556|NCT01023581|9771017|FG001|Overall Study|Lack of Efficacy|3
6139557|NCT01023581|9771018|FG002|Overall Study|Lack of Efficacy|6
6139558|NCT01023581|9771019|FG003|Overall Study|Lack of Efficacy|2
6139559|NCT01023581|9771020|FG004|Overall Study|Lack of Efficacy|1
6139560|NCT01023581|9771021|FG005|Overall Study|Lack of Efficacy|2
6139561|NCT01023581|9771022|FG006|Overall Study|Lack of Efficacy|1
6139562|NCT01023581|9771016|FG000|Overall Study|Physician Decision|2
6139563|NCT01023581|9771017|FG001|Overall Study|Physician Decision|0
6139564|NCT01023581|9771018|FG002|Overall Study|Physician Decision|2
6139565|NCT01023581|9771019|FG003|Overall Study|Physician Decision|1
6139566|NCT01023581|9771020|FG004|Overall Study|Physician Decision|1
6139567|NCT01023581|9771021|FG005|Overall Study|Physician Decision|1
6139568|NCT01023581|9771022|FG006|Overall Study|Physician Decision|1
6139569|NCT01023581|9771016|FG000|Overall Study|Other|1
6139570|NCT01023581|9771017|FG001|Overall Study|Other|0
6139571|NCT01023581|9771018|FG002|Overall Study|Other|1
6139572|NCT01023581|9771019|FG003|Overall Study|Other|0
6139573|NCT01023581|9771020|FG004|Overall Study|Other|1
6139574|NCT01023581|9771021|FG005|Overall Study|Other|0
6139575|NCT01023581|9771022|FG006|Overall Study|Other|0
6139576|NCT01023659|9771041|FG000|Overall Study|Lost to Follow-up|73
6139577|NCT01023659|9771042|FG001|Overall Study|Lost to Follow-up|228
6139578|NCT01023659|9771043|FG002|Overall Study|Lost to Follow-up|99
6139579|NCT01023672|9771052|FG000|Overall Study|Worsening disease|2
6139580|NCT01023672|9771052|FG000|Overall Study|Death|1
6139581|NCT01023789|9771074|FG000|3 - Year Visit|Death|29
6139582|NCT01023789|9771074|FG000|3 - Year Visit|Withdrawal of consent|1
6139583|NCT01023789|9771074|FG000|3 - Year Visit|Lost to Follow-up|13
6139584|NCT01023815|9771082|FG000|Pre-randomization Period (Day 1 to 90)|Did not meet inclusion criteria|144
6139585|NCT01023815|9771083|FG001|Pre-randomization Period (Day 1 to 90)|Did not meet inclusion criteria|0
6139586|NCT01023815|9771084|FG002|Pre-randomization Period (Day 1 to 90)|Did not meet inclusion criteria|0
6139587|NCT01023815|9771085|FG003|Pre-randomization Period (Day 1 to 90)|Did not meet inclusion criteria|0
6139588|NCT01023815|9771082|FG000|Randomized Period (Day 90 to Month 12)|Withdrawal by Subject|0
6139589|NCT01023815|9771083|FG001|Randomized Period (Day 90 to Month 12)|Withdrawal by Subject|0
6139590|NCT01023815|9771084|FG002|Randomized Period (Day 90 to Month 12)|Withdrawal by Subject|1
6139591|NCT01023815|9771085|FG003|Randomized Period (Day 90 to Month 12)|Withdrawal by Subject|1
6139592|NCT01023815|9771082|FG000|Randomized Period (Day 90 to Month 12)|Lost to Follow-up|0
6139593|NCT01023815|9771083|FG001|Randomized Period (Day 90 to Month 12)|Lost to Follow-up|1
6139594|NCT01023815|9771084|FG002|Randomized Period (Day 90 to Month 12)|Lost to Follow-up|1
6139595|NCT01023815|9771085|FG003|Randomized Period (Day 90 to Month 12)|Lost to Follow-up|0
6139596|NCT01023815|9771082|FG000|Randomized Period (Day 90 to Month 12)|Administrative Problems|0
6139597|NCT01023815|9771083|FG001|Randomized Period (Day 90 to Month 12)|Administrative Problems|1
6139598|NCT01023815|9771084|FG002|Randomized Period (Day 90 to Month 12)|Administrative Problems|6
6139599|NCT01023815|9771085|FG003|Randomized Period (Day 90 to Month 12)|Administrative Problems|2
6139600|NCT01023815|9771082|FG000|Randomized Period (Day 90 to Month 12)|Graft Loss|0
6139601|NCT01023815|9771083|FG001|Randomized Period (Day 90 to Month 12)|Graft Loss|1
6139602|NCT01023815|9771084|FG002|Randomized Period (Day 90 to Month 12)|Graft Loss|0
6139603|NCT01023815|9771085|FG003|Randomized Period (Day 90 to Month 12)|Graft Loss|0
6139604|NCT01023958|9771105|FG000|Overall Study|Progressive disease|48
6139605|NCT01023958|9771105|FG000|Overall Study|Other adverse event|1
6139606|NCT01023958|9771105|FG000|Overall Study|Refused to continue medication|1
6139607|NCT01024036|9771120|FG000|Blinded Treatment|Adverse Event|1
6139608|NCT01024036|9771121|FG001|Blinded Treatment|Adverse Event|1
6139609|NCT01024036|9771120|FG000|Blinded Treatment|Lack of Efficacy|16
6139610|NCT01024036|9771121|FG001|Blinded Treatment|Lack of Efficacy|14
6139611|NCT01024036|9771120|FG000|Blinded Treatment|Physician Decision|1
6139612|NCT01024036|9771121|FG001|Blinded Treatment|Physician Decision|0
6139613|NCT01024036|9771120|FG000|Blinded Treatment|Death|0
6139614|NCT01024036|9771121|FG001|Blinded Treatment|Death|2
6139615|NCT01024036|9771120|FG000|Blinded Treatment|Withdrawal by Subject|4
6139616|NCT01024036|9771121|FG001|Blinded Treatment|Withdrawal by Subject|3
6139617|NCT01024036|9771120|FG000|Unblinded Treatment|Adverse Event|0
6139618|NCT01024036|9771121|FG001|Unblinded Treatment|Adverse Event|1
6139619|NCT01024036|9771120|FG000|Unblinded Treatment|Lack of Efficacy|0
6139620|NCT01024036|9771121|FG001|Unblinded Treatment|Lack of Efficacy|2
6139621|NCT01024036|9771120|FG000|Follow-Up Period|Lost to Follow-up|1
6139622|NCT01024036|9771121|FG001|Follow-Up Period|Lost to Follow-up|1
6139623|NCT01024036|9771120|FG000|Follow-Up Period|Withdrawal by Subject|0
6139624|NCT01024036|9771121|FG001|Follow-Up Period|Withdrawal by Subject|1
6139625|NCT01024036|9771120|FG000|Follow-Up Period|Adverse Event|4
6139626|NCT01024036|9771121|FG001|Follow-Up Period|Adverse Event|1
6139627|NCT01024231|9771137|FG000|Overall Study|Other Reasons|1
6139628|NCT01024231|9771138|FG001|Overall Study|Other Reasons|2
6139629|NCT01024231|9771139|FG002|Overall Study|Other Reasons|0
6139630|NCT01024231|9771140|FG003|Overall Study|Other Reasons|0
6139631|NCT01024231|9771141|FG004|Overall Study|Other Reasons|2
6139632|NCT01024231|9771142|FG005|Overall Study|Other Reasons|0
6139633|NCT01024231|9771143|FG006|Overall Study|Other Reasons|1
6139634|NCT01024231|9771137|FG000|Overall Study|Maximum Clinical Benefit|1
6139635|NCT01024231|9771138|FG001|Overall Study|Maximum Clinical Benefit|2
6139636|NCT01024231|9771139|FG002|Overall Study|Maximum Clinical Benefit|0
6139637|NCT01024231|9771140|FG003|Overall Study|Maximum Clinical Benefit|1
6139638|NCT01024231|9771141|FG004|Overall Study|Maximum Clinical Benefit|1
6139639|NCT01024231|9771142|FG005|Overall Study|Maximum Clinical Benefit|0
6139640|NCT01024231|9771143|FG006|Overall Study|Maximum Clinical Benefit|0
6139641|NCT01024231|9771137|FG000|Overall Study|Disease Progression|3
6139642|NCT01024231|9771138|FG001|Overall Study|Disease Progression|1
6139643|NCT01024231|9771139|FG002|Overall Study|Disease Progression|3
6139644|NCT01024231|9771140|FG003|Overall Study|Disease Progression|0
6139645|NCT01024231|9771141|FG004|Overall Study|Disease Progression|4
6139646|NCT01024231|9771142|FG005|Overall Study|Disease Progression|11
6139647|NCT01024231|9771143|FG006|Overall Study|Disease Progression|6
6139648|NCT01024231|9771137|FG000|Overall Study|AE unrelated to Study Drug|0
6139649|NCT01024231|9771138|FG001|Overall Study|AE unrelated to Study Drug|1
6139650|NCT01024231|9771139|FG002|Overall Study|AE unrelated to Study Drug|0
6139651|NCT01024231|9771140|FG003|Overall Study|AE unrelated to Study Drug|0
6139652|NCT01024231|9771141|FG004|Overall Study|AE unrelated to Study Drug|0
6139653|NCT01024231|9771142|FG005|Overall Study|AE unrelated to Study Drug|0
6139654|NCT01024231|9771143|FG006|Overall Study|AE unrelated to Study Drug|0
6139655|NCT01024231|9771137|FG000|Overall Study|No longer meets criteria|0
6139656|NCT01024231|9771138|FG001|Overall Study|No longer meets criteria|0
6139657|NCT01024231|9771139|FG002|Overall Study|No longer meets criteria|0
6139658|NCT01024231|9771140|FG003|Overall Study|No longer meets criteria|0
6139659|NCT01024231|9771141|FG004|Overall Study|No longer meets criteria|1
6139660|NCT01024231|9771142|FG005|Overall Study|No longer meets criteria|0
6139661|NCT01024231|9771143|FG006|Overall Study|No longer meets criteria|1
6139662|NCT01024231|9771137|FG000|Overall Study|Study Drug Toxicity|1
6139663|NCT01024231|9771138|FG001|Overall Study|Study Drug Toxicity|6
6139664|NCT01024231|9771139|FG002|Overall Study|Study Drug Toxicity|6
6139665|NCT01024231|9771140|FG003|Overall Study|Study Drug Toxicity|4
6139666|NCT01024231|9771141|FG004|Overall Study|Study Drug Toxicity|2
6139667|NCT01024231|9771142|FG005|Overall Study|Study Drug Toxicity|0
6139668|NCT01024231|9771143|FG006|Overall Study|Study Drug Toxicity|7
6139669|NCT01024231|9771137|FG000|Overall Study|Death|6
6139670|NCT01024231|9771138|FG001|Overall Study|Death|2
6139671|NCT01024231|9771139|FG002|Overall Study|Death|1
6139672|NCT01024231|9771140|FG003|Overall Study|Death|0
6139673|NCT01024231|9771141|FG004|Overall Study|Death|4
6139674|NCT01024231|9771142|FG005|Overall Study|Death|3
6139675|NCT01024231|9771143|FG006|Overall Study|Death|5
6139676|NCT01024231|9771137|FG000|Overall Study|Lost to Follow-up|0
6139677|NCT01024231|9771138|FG001|Overall Study|Lost to Follow-up|0
6139678|NCT01024231|9771139|FG002|Overall Study|Lost to Follow-up|0
6139679|NCT01024231|9771140|FG003|Overall Study|Lost to Follow-up|0
6139680|NCT01024231|9771141|FG004|Overall Study|Lost to Follow-up|0
6139681|NCT01024231|9771142|FG005|Overall Study|Lost to Follow-up|0
6139682|NCT01024231|9771143|FG006|Overall Study|Lost to Follow-up|1
6139683|NCT01024231|9771137|FG000|Overall Study|Withdrew Consent|0
6139684|NCT01024231|9771138|FG001|Overall Study|Withdrew Consent|1
6139685|NCT01024231|9771139|FG002|Overall Study|Withdrew Consent|0
6139686|NCT01024231|9771140|FG003|Overall Study|Withdrew Consent|0
6139687|NCT01024231|9771141|FG004|Overall Study|Withdrew Consent|0
6139688|NCT01024231|9771142|FG005|Overall Study|Withdrew Consent|0
6139689|NCT01024231|9771143|FG006|Overall Study|Withdrew Consent|0
6139690|NCT01024231|9771137|FG000|Overall Study|Continuing on Treatment|0
6139691|NCT01024231|9771138|FG001|Overall Study|Continuing on Treatment|0
6139692|NCT01024231|9771139|FG002|Overall Study|Continuing on Treatment|0
6139693|NCT01024231|9771140|FG003|Overall Study|Continuing on Treatment|0
6139694|NCT01024231|9771141|FG004|Overall Study|Continuing on Treatment|3
6139695|NCT01024231|9771142|FG005|Overall Study|Continuing on Treatment|2
6139696|NCT01024231|9771143|FG006|Overall Study|Continuing on Treatment|0
6139697|NCT01024244|9771169|FG000|Overall Study|Adverse Event|1
6139698|NCT01024244|9771170|FG001|Overall Study|Adverse Event|2
6139699|NCT01024244|9771171|FG002|Overall Study|Adverse Event|0
6139700|NCT01024244|9771172|FG003|Overall Study|Adverse Event|1
6139701|NCT01024244|9771173|FG004|Overall Study|Adverse Event|2
6139702|NCT01024244|9771169|FG000|Overall Study|Entry Criteria Not Met|0
6139703|NCT01024244|9771170|FG001|Overall Study|Entry Criteria Not Met|1
6139704|NCT01024244|9771171|FG002|Overall Study|Entry Criteria Not Met|0
6139705|NCT01024244|9771172|FG003|Overall Study|Entry Criteria Not Met|0
6139706|NCT01024244|9771173|FG004|Overall Study|Entry Criteria Not Met|0
6139707|NCT01024244|9771169|FG000|Overall Study|Lack of Efficacy|1
6139708|NCT01024244|9771170|FG001|Overall Study|Lack of Efficacy|0
6139709|NCT01024244|9771171|FG002|Overall Study|Lack of Efficacy|0
6139710|NCT01024244|9771172|FG003|Overall Study|Lack of Efficacy|0
6139711|NCT01024244|9771173|FG004|Overall Study|Lack of Efficacy|0
6139712|NCT01024244|9771169|FG000|Overall Study|Protocol Violation|1
6139713|NCT01024244|9771170|FG001|Overall Study|Protocol Violation|0
6139714|NCT01024244|9771171|FG002|Overall Study|Protocol Violation|0
6139715|NCT01024244|9771172|FG003|Overall Study|Protocol Violation|0
6139716|NCT01024244|9771173|FG004|Overall Study|Protocol Violation|2
6139717|NCT01024244|9771169|FG000|Overall Study|Sponsor Decision|14
6139718|NCT01024244|9771170|FG001|Overall Study|Sponsor Decision|7
6139719|NCT01024244|9771171|FG002|Overall Study|Sponsor Decision|14
6139720|NCT01024244|9771172|FG003|Overall Study|Sponsor Decision|12
6139721|NCT01024244|9771173|FG004|Overall Study|Sponsor Decision|10
6139722|NCT01024244|9771169|FG000|Overall Study|Withdrawal by Subject|0
6139723|NCT01024244|9771170|FG001|Overall Study|Withdrawal by Subject|1
6139724|NCT01024244|9771171|FG002|Overall Study|Withdrawal by Subject|0
6139725|NCT01024244|9771172|FG003|Overall Study|Withdrawal by Subject|0
6139726|NCT01024244|9771173|FG004|Overall Study|Withdrawal by Subject|0
6139727|NCT01024309|9771191|FG000|Overall Study|Physician Decision|4
6139728|NCT01024309|9771192|FG001|Overall Study|Physician Decision|0
6139729|NCT01024309|9771191|FG000|Overall Study|Withdrawal by Subject|4
6139730|NCT01024309|9771192|FG001|Overall Study|Withdrawal by Subject|4
6139731|NCT01024387|9771207|FG000|Overall Study|Radiographic Progression|29
6139732|NCT01024387|9771207|FG000|Overall Study|Symptomatic Progression|10
6139733|NCT01024387|9771207|FG000|Overall Study|Physician Decision|5
6139734|NCT01024387|9771207|FG000|Overall Study|Withdrawal by Subject|5
6139735|NCT01024387|9771207|FG000|Overall Study|Death|2
6139736|NCT01024387|9771207|FG000|Overall Study|Prolonged Treatment Delay|1
6139737|NCT01024387|9771207|FG000|Overall Study|Adverse Event|3
6139738|NCT01024387|9771207|FG000|Overall Study|Other|5
6139739|NCT01024465|9771211|FG000|Overall Study|Adverse Event|2
6139740|NCT01024465|9771211|FG000|Overall Study|Physician Decision|1
6139741|NCT01024751|9771254|FG000|Enrolled Participants|Ineligible at baseline|3
6139742|NCT01024751|9771255|FG001|Enrolled Participants|Ineligible at baseline|4
6139743|NCT01024751|9771254|FG000|Eligible Participants|Withdrawal by Subject|0
6139744|NCT01024751|9771255|FG001|Eligible Participants|Withdrawal by Subject|1
6139745|NCT01024751|9771254|FG000|Eligible Participants|Lost to Follow-up|0
6139746|NCT01024751|9771255|FG001|Eligible Participants|Lost to Follow-up|1
6139747|NCT01024751|9771254|FG000|Eligible Participants|Ineligible|0
6139748|NCT01024751|9771255|FG001|Eligible Participants|Ineligible|1
6139749|NCT01024855|9771261|FG000|Overall Study|Inclusion/exclusion criteria|1
6139750|NCT01024920|9771268|FG000|Overall Study|Progressive disease|47
6139751|NCT01024920|9771269|FG001|Overall Study|Progressive disease|25
6139752|NCT01024920|9771268|FG000|Overall Study|Adverse Event|8
6139753|NCT01024920|9771269|FG001|Overall Study|Adverse Event|4
6139754|NCT01024920|9771268|FG000|Overall Study|Lost to Follow-up|0
6139755|NCT01024920|9771269|FG001|Overall Study|Lost to Follow-up|1
6139756|NCT01024920|9771268|FG000|Overall Study|Patient refusal to continue|4
6139757|NCT01024920|9771269|FG001|Overall Study|Patient refusal to continue|0
6139758|NCT01024920|9771268|FG000|Overall Study|Other than listed|5
6139759|NCT01024920|9771269|FG001|Overall Study|Other than listed|1
6139760|NCT01024920|9771268|FG000|Overall Study|Not treated|3
6139761|NCT01024920|9771269|FG001|Overall Study|Not treated|0
6139762|NCT01024920|9771268|FG000|Overall Study|Protocol Violation|0
6139763|NCT01024920|9771269|FG001|Overall Study|Protocol Violation|1
6139764|NCT01024946|9771275|FG000|Overall Study|Screen Failure|3
6139765|NCT01024946|9771275|FG000|Overall Study|Withdrawal by Subject|1
6139766|NCT01024946|9771275|FG000|Overall Study|Adverse Event|1
6139767|NCT01024959|9771279|FG000|Overall Study|ineligible|12
6139768|NCT01024959|9771279|FG000|Overall Study|results not evaluable|12
6139769|NCT01024959|9771279|FG000|Overall Study|missing results required for analysis|17
6139770|NCT01025037|9771298|FG000|Overall Study|Adverse Event|3
6139771|NCT01025037|9771298|FG000|Overall Study|Lost to Follow-up|7
6139772|NCT01025037|9771298|FG000|Overall Study|Withdrawal by Subject|1
6139773|NCT01025154|9771306|FG000|Overall Study|Lost to Follow-up|1
6139774|NCT01025154|9771306|FG000|Overall Study|Withdrawal by Subject|1
6139775|NCT01025193|9771310|FG000|Overall Study|Protocol Violation|1
6139776|NCT01025193|9771310|FG000|Overall Study|Adverse Event|3
6139777|NCT01025232|9771320|FG000|Overall Study|Study drug no longer available|3
6139778|NCT01025232|9771321|FG001|Overall Study|Study drug no longer available|6
6139779|NCT01025284|9771330|FG000|Overall Study|Investigator Decision|0
6139780|NCT01025284|9771331|FG001|Overall Study|Investigator Decision|1
6139781|NCT01025284|9771332|FG002|Overall Study|Investigator Decision|0
6139782|NCT01025284|9771330|FG000|Overall Study|Withdrawal by Subject|0
6139783|NCT01025284|9771331|FG001|Overall Study|Withdrawal by Subject|1
6139784|NCT01025284|9771332|FG002|Overall Study|Withdrawal by Subject|0
6139785|NCT01025336|9771347|FG000|Overall Study|Protocol Violation|0
6139786|NCT01025336|9771348|FG001|Overall Study|Protocol Violation|0
6139787|NCT01025336|9771349|FG002|Overall Study|Protocol Violation|0
6139788|NCT01025336|9771350|FG003|Overall Study|Protocol Violation|2
6139789|NCT01025336|9771351|FG004|Overall Study|Protocol Violation|0
6139790|NCT01025635|9771385|FG000|Overall Study|Withdrawal by Subject|6
6139791|NCT01025635|9771386|FG001|Overall Study|Withdrawal by Subject|7
6139792|NCT01025635|9771385|FG000|Overall Study|Protocol Violation|4
6139793|NCT01025635|9771386|FG001|Overall Study|Protocol Violation|2
6139794|NCT01025635|9771385|FG000|Overall Study|Lack of Efficacy|0
6139795|NCT01025635|9771386|FG001|Overall Study|Lack of Efficacy|1
6139796|NCT01025635|9771385|FG000|Overall Study|Lost to Follow-up|9
6139797|NCT01025635|9771386|FG001|Overall Study|Lost to Follow-up|13
6139798|NCT01025635|9771385|FG000|Overall Study|Reason not known|4
6139799|NCT01025635|9771386|FG001|Overall Study|Reason not known|2
6139800|NCT01025752|9771394|FG000|Overall Study|Lost to Follow-up|7
6139801|NCT01025752|9771395|FG001|Overall Study|Lost to Follow-up|10
6139802|NCT01025752|9771394|FG000|Overall Study|Physician Decision|1
6139803|NCT01025752|9771395|FG001|Overall Study|Physician Decision|3
6139804|NCT01025817|9771470|FG000|Completed Study Medication|Adverse Event|66
6139805|NCT01025817|9771471|FG001|Completed Study Medication|Adverse Event|39
6139806|NCT01025817|9771470|FG000|Completed Study Medication|Protocol Deviation|9
6139807|NCT01025817|9771471|FG001|Completed Study Medication|Protocol Deviation|8
6139808|NCT01025817|9771470|FG000|Completed Study Medication|Withdrawal by Subject|8
6139809|NCT01025817|9771471|FG001|Completed Study Medication|Withdrawal by Subject|9
6139810|NCT01025817|9771470|FG000|Completed Study Medication|Administrative problems|7
6139811|NCT01025817|9771471|FG001|Completed Study Medication|Administrative problems|5
6139812|NCT01025817|9771470|FG000|Completed Study Medication|Unsatisfactory therapeutic effect|7
6139813|NCT01025817|9771471|FG001|Completed Study Medication|Unsatisfactory therapeutic effect|0
6139814|NCT01025817|9771470|FG000|Completed Study Medication|Abnormal test procedure|4
6139815|NCT01025817|9771471|FG001|Completed Study Medication|Abnormal test procedure|0
6139816|NCT01025817|9771470|FG000|Completed Study Medication|Graft loss|2
6139817|NCT01025817|9771471|FG001|Completed Study Medication|Graft loss|5
6139818|NCT01025817|9771470|FG000|Completed Study Medication|Death|2
6139819|NCT01025817|9771471|FG001|Completed Study Medication|Death|2
6139820|NCT01025817|9771470|FG000|Completed Study Medication|Abnormal lab values|0
6139821|NCT01025817|9771471|FG001|Completed Study Medication|Abnormal lab values|2
6139822|NCT01025817|9771470|FG000|Completed Study Medication|Subject no longer required study drug|0
6139823|NCT01025817|9771471|FG001|Completed Study Medication|Subject no longer required study drug|1
6139824|NCT01025817|9771470|FG000|Completed Study Medication|Lost to Follow-up|0
6139825|NCT01025817|9771471|FG001|Completed Study Medication|Lost to Follow-up|1
6139826|NCT01025817|9771470|FG000|Completed Study|Withdrawal by Subject|8
6139827|NCT01025817|9771471|FG001|Completed Study|Withdrawal by Subject|16
6139828|NCT01025817|9771470|FG000|Completed Study|Death|6
6139829|NCT01025817|9771471|FG001|Completed Study|Death|5
6139830|NCT01025817|9771470|FG000|Completed Study|Missing|2
6139831|NCT01025817|9771471|FG001|Completed Study|Missing|0
6139832|NCT01025817|9771470|FG000|Completed Study|Lost to Follow-up|0
6139833|NCT01025817|9771471|FG001|Completed Study|Lost to Follow-up|1
6139834|NCT01025843|9771499|FG000|Washout 4|Withdrawal by Subject|0
6139835|NCT01025843|9771500|FG001|Washout 4|Withdrawal by Subject|0
6139836|NCT01025843|9771501|FG002|Washout 4|Withdrawal by Subject|1
6139837|NCT01025843|9771502|FG003|Washout 4|Withdrawal by Subject|1
6139838|NCT01025843|9771503|FG004|Washout 4|Withdrawal by Subject|0
6139839|NCT01025843|9771504|FG005|Washout 4|Withdrawal by Subject|0
6139840|NCT01025843|9771505|FG006|Washout 4|Withdrawal by Subject|0
6139841|NCT01025843|9771506|FG007|Washout 4|Withdrawal by Subject|0
6139842|NCT01025843|9771507|FG008|Washout 4|Withdrawal by Subject|0
6139843|NCT01025843|9771508|FG009|Washout 4|Withdrawal by Subject|0
6139844|NCT01026038|9771543|FG000|Overall Study|Lost to Follow-up|1
6139845|NCT01026038|9771544|FG001|Overall Study|Lost to Follow-up|1
6139846|NCT01026038|9771545|FG002|Overall Study|Lost to Follow-up|0
6139847|NCT01026103|9771553|FG000|Overall Study|Physician Decision|1
6139848|NCT01026103|9771553|FG000|Overall Study|did not receive study device bc of error|1
6139849|NCT01026142|9771559|FG000|Overall Study|Death|136
6139850|NCT01026142|9771560|FG001|Overall Study|Death|134
6139851|NCT01026142|9771559|FG000|Overall Study|Withdrew consent or lost to follow-up|36
6139852|NCT01026142|9771560|FG001|Overall Study|Withdrew consent or lost to follow-up|29
6139853|NCT01026194|9771581|FG000|Period 1：Double Blind Period|Adverse Event|2
6139854|NCT01026194|9771582|FG001|Period 1：Double Blind Period|Adverse Event|1
6139855|NCT01026194|9771581|FG000|Period 1：Double Blind Period|Lack of Efficacy|1
6139856|NCT01026194|9771582|FG001|Period 1：Double Blind Period|Lack of Efficacy|0
6139857|NCT01026194|9771581|FG000|Period 1：Double Blind Period|Physician Decision|0
6139858|NCT01026194|9771582|FG001|Period 1：Double Blind Period|Physician Decision|4
6139859|NCT01026194|9771581|FG000|Period 2：Open-label Period|Adverse Event|4
6139860|NCT01026194|9771582|FG001|Period 2：Open-label Period|Adverse Event|5
6139861|NCT01026194|9771581|FG000|Period 2：Open-label Period|Physician Decision|3
6139862|NCT01026194|9771582|FG001|Period 2：Open-label Period|Physician Decision|1
6139863|NCT01026194|9771581|FG000|Period 2：Open-label Period|Withdrawal by Subject|0
6139864|NCT01026194|9771582|FG001|Period 2：Open-label Period|Withdrawal by Subject|4
6139865|NCT01026324|9771593|FG000|Follow up/Survival|Withdrawal by Subject|1
6139866|NCT01026324|9771594|FG001|Follow up/Survival|Withdrawal by Subject|0
6139867|NCT01026324|9771595|FG002|Follow up/Survival|Withdrawal by Subject|0
6139868|NCT01026389|9771606|FG000|Overall Study|Withdrawal by Subject|1
6139869|NCT01026389|9771607|FG001|Overall Study|Withdrawal by Subject|3
6139870|NCT01026389|9771606|FG000|Overall Study|change of treatment, patient moved|4
6139871|NCT01026389|9771607|FG001|Overall Study|change of treatment, patient moved|2
6139872|NCT01026454|9771687|FG000|Second Intervention|Pregnancy|1
6139873|NCT01026454|9771688|FG001|Second Intervention|Pregnancy|1
6139874|NCT01026493|9771702|FG000|Overall Study|Protocol Violation|0
6139875|NCT01026493|9771703|FG001|Overall Study|Protocol Violation|1
6139876|NCT01026493|9771704|FG002|Overall Study|Protocol Violation|0
6139877|NCT01026493|9771705|FG003|Overall Study|Protocol Violation|0
6139878|NCT01026493|9771706|FG004|Overall Study|Protocol Violation|2
6139879|NCT01026493|9771707|FG005|Overall Study|Protocol Violation|3
6139880|NCT01026493|9771708|FG006|Overall Study|Protocol Violation|4
6139881|NCT01026493|9771709|FG007|Overall Study|Protocol Violation|1
6139882|NCT01026792|9771741|FG000|Overall Study|Protocol Violation|1
6139883|NCT01026818|9771752|FG000|Screening Period|Entry Criteria Not Met|105
6139884|NCT01026818|9771753|FG001|Screening Period|Entry Criteria Not Met|0
6139885|NCT01026818|9771754|FG002|Screening Period|Entry Criteria Not Met|0
6139886|NCT01026818|9771755|FG003|Screening Period|Entry Criteria Not Met|0
6139887|NCT01026818|9771752|FG000|Screening Period|Withdrawal by Subject|49
6139888|NCT01026818|9771753|FG001|Screening Period|Withdrawal by Subject|0
6139889|NCT01026818|9771754|FG002|Screening Period|Withdrawal by Subject|0
6139890|NCT01026818|9771755|FG003|Screening Period|Withdrawal by Subject|0
6139891|NCT01026818|9771752|FG000|Screening Period|Protocol Deviation|3
6139892|NCT01026818|9771753|FG001|Screening Period|Protocol Deviation|0
6139893|NCT01026818|9771754|FG002|Screening Period|Protocol Deviation|0
6139894|NCT01026818|9771755|FG003|Screening Period|Protocol Deviation|0
6139895|NCT01026818|9771752|FG000|Screening Period|Adverse Event|2
6139896|NCT01026818|9771753|FG001|Screening Period|Adverse Event|0
6139897|NCT01026818|9771754|FG002|Screening Period|Adverse Event|0
6139898|NCT01026818|9771755|FG003|Screening Period|Adverse Event|0
6139899|NCT01026818|9771752|FG000|Screening Period|Physician Decision|1
6139900|NCT01026818|9771753|FG001|Screening Period|Physician Decision|0
6139901|NCT01026818|9771754|FG002|Screening Period|Physician Decision|0
6139902|NCT01026818|9771755|FG003|Screening Period|Physician Decision|0
6139903|NCT01026818|9771752|FG000|DB Treatment Period (Month 0 - 9)|Adverse Event|0
6139904|NCT01026818|9771753|FG001|DB Treatment Period (Month 0 - 9)|Adverse Event|10
6139905|NCT01026818|9771754|FG002|DB Treatment Period (Month 0 - 9)|Adverse Event|6
6139906|NCT01026818|9771755|FG003|DB Treatment Period (Month 0 - 9)|Adverse Event|4
6139907|NCT01026818|9771752|FG000|DB Treatment Period (Month 0 - 9)|Withdrawal by Subject|0
6139908|NCT01026818|9771753|FG001|DB Treatment Period (Month 0 - 9)|Withdrawal by Subject|7
6139909|NCT01026818|9771754|FG002|DB Treatment Period (Month 0 - 9)|Withdrawal by Subject|3
6139910|NCT01026818|9771755|FG003|DB Treatment Period (Month 0 - 9)|Withdrawal by Subject|3
6139911|NCT01026818|9771752|FG000|DB Treatment Period (Month 0 - 9)|Lack of Efficacy|0
6139912|NCT01026818|9771753|FG001|DB Treatment Period (Month 0 - 9)|Lack of Efficacy|3
6139913|NCT01026818|9771754|FG002|DB Treatment Period (Month 0 - 9)|Lack of Efficacy|2
6139914|NCT01026818|9771755|FG003|DB Treatment Period (Month 0 - 9)|Lack of Efficacy|6
6139915|NCT01026818|9771752|FG000|DB Treatment Period (Month 0 - 9)|Lost to Follow-up|0
6139916|NCT01026818|9771753|FG001|DB Treatment Period (Month 0 - 9)|Lost to Follow-up|3
6139917|NCT01026818|9771754|FG002|DB Treatment Period (Month 0 - 9)|Lost to Follow-up|0
6139918|NCT01026818|9771755|FG003|DB Treatment Period (Month 0 - 9)|Lost to Follow-up|4
6139919|NCT01026818|9771752|FG000|DB Treatment Period (Month 0 - 9)|Entry Criteria Not Met|0
6139920|NCT01026818|9771753|FG001|DB Treatment Period (Month 0 - 9)|Entry Criteria Not Met|2
6139921|NCT01026818|9771754|FG002|DB Treatment Period (Month 0 - 9)|Entry Criteria Not Met|9
6139922|NCT01026818|9771755|FG003|DB Treatment Period (Month 0 - 9)|Entry Criteria Not Met|7
6139923|NCT01026818|9771752|FG000|DB Treatment Period (Month 0 - 9)|Protocol Deviation|0
6139924|NCT01026818|9771753|FG001|DB Treatment Period (Month 0 - 9)|Protocol Deviation|0
6139925|NCT01026818|9771754|FG002|DB Treatment Period (Month 0 - 9)|Protocol Deviation|1
6139926|NCT01026818|9771755|FG003|DB Treatment Period (Month 0 - 9)|Protocol Deviation|2
6139927|NCT01026818|9771752|FG000|Drug-Free Washout Period (Month 9-10.5)|Entry Criteria Not Met|0
6139928|NCT01026818|9771753|FG001|Drug-Free Washout Period (Month 9-10.5)|Entry Criteria Not Met|2
6139929|NCT01026818|9771754|FG002|Drug-Free Washout Period (Month 9-10.5)|Entry Criteria Not Met|1
6139930|NCT01026818|9771755|FG003|Drug-Free Washout Period (Month 9-10.5)|Entry Criteria Not Met|2
6139931|NCT01026818|9771752|FG000|Drug-Free Washout Period (Month 9-10.5)|Lack of Efficacy|0
6139932|NCT01026818|9771753|FG001|Drug-Free Washout Period (Month 9-10.5)|Lack of Efficacy|2
6139933|NCT01026818|9771754|FG002|Drug-Free Washout Period (Month 9-10.5)|Lack of Efficacy|1
6139934|NCT01026818|9771755|FG003|Drug-Free Washout Period (Month 9-10.5)|Lack of Efficacy|2
6139935|NCT01026818|9771752|FG000|Drug-Free Washout Period (Month 9-10.5)|Adverse Event|0
6139936|NCT01026818|9771753|FG001|Drug-Free Washout Period (Month 9-10.5)|Adverse Event|1
6139937|NCT01026818|9771754|FG002|Drug-Free Washout Period (Month 9-10.5)|Adverse Event|0
6139938|NCT01026818|9771755|FG003|Drug-Free Washout Period (Month 9-10.5)|Adverse Event|0
6139939|NCT01026818|9771752|FG000|Drug-Free Washout Period (Month 9-10.5)|Lost to Follow-up|0
6139940|NCT01026818|9771753|FG001|Drug-Free Washout Period (Month 9-10.5)|Lost to Follow-up|1
6139941|NCT01026818|9771754|FG002|Drug-Free Washout Period (Month 9-10.5)|Lost to Follow-up|0
6139942|NCT01026818|9771755|FG003|Drug-Free Washout Period (Month 9-10.5)|Lost to Follow-up|2
6139943|NCT01026818|9771752|FG000|Drug-Free Washout Period (Month 9-10.5)|Physician Decision|0
6139944|NCT01026818|9771753|FG001|Drug-Free Washout Period (Month 9-10.5)|Physician Decision|1
6139945|NCT01026818|9771754|FG002|Drug-Free Washout Period (Month 9-10.5)|Physician Decision|1
6139946|NCT01026818|9771755|FG003|Drug-Free Washout Period (Month 9-10.5)|Physician Decision|0
6139947|NCT01026818|9771752|FG000|Drug-Free Washout Period (Month 9-10.5)|Sponsor Decision|0
6139948|NCT01026818|9771753|FG001|Drug-Free Washout Period (Month 9-10.5)|Sponsor Decision|1
6139949|NCT01026818|9771754|FG002|Drug-Free Washout Period (Month 9-10.5)|Sponsor Decision|0
6139950|NCT01026818|9771755|FG003|Drug-Free Washout Period (Month 9-10.5)|Sponsor Decision|0
6139951|NCT01026818|9771752|FG000|Drug-Free Washout Period (Month 9-10.5)|Withdrawal by Subject|0
6139952|NCT01026818|9771753|FG001|Drug-Free Washout Period (Month 9-10.5)|Withdrawal by Subject|1
6139953|NCT01026818|9771754|FG002|Drug-Free Washout Period (Month 9-10.5)|Withdrawal by Subject|2
6139954|NCT01026818|9771755|FG003|Drug-Free Washout Period (Month 9-10.5)|Withdrawal by Subject|0
6139955|NCT01026818|9771752|FG000|Drug-Free Washout Period (Month 9-10.5)|Death|0
6139956|NCT01026818|9771753|FG001|Drug-Free Washout Period (Month 9-10.5)|Death|0
6139957|NCT01026818|9771754|FG002|Drug-Free Washout Period (Month 9-10.5)|Death|0
6139958|NCT01026818|9771755|FG003|Drug-Free Washout Period (Month 9-10.5)|Death|1
6139959|NCT01026818|9771752|FG000|OL Period (Month 10.5 - 13.5)|Entry Criteria Not Met|0
6139960|NCT01026818|9771753|FG001|OL Period (Month 10.5 - 13.5)|Entry Criteria Not Met|2
6139961|NCT01026818|9771754|FG002|OL Period (Month 10.5 - 13.5)|Entry Criteria Not Met|0
6139962|NCT01026818|9771755|FG003|OL Period (Month 10.5 - 13.5)|Entry Criteria Not Met|0
6139963|NCT01026818|9771752|FG000|OL Period (Month 10.5 - 13.5)|Lack of Efficacy|0
6139964|NCT01026818|9771753|FG001|OL Period (Month 10.5 - 13.5)|Lack of Efficacy|1
6139965|NCT01026818|9771754|FG002|OL Period (Month 10.5 - 13.5)|Lack of Efficacy|0
6139966|NCT01026818|9771755|FG003|OL Period (Month 10.5 - 13.5)|Lack of Efficacy|0
6139967|NCT01026818|9771752|FG000|OL Period (Month 10.5 - 13.5)|Lost to Follow-up|0
6139968|NCT01026818|9771753|FG001|OL Period (Month 10.5 - 13.5)|Lost to Follow-up|1
6139969|NCT01026818|9771754|FG002|OL Period (Month 10.5 - 13.5)|Lost to Follow-up|2
6139970|NCT01026818|9771755|FG003|OL Period (Month 10.5 - 13.5)|Lost to Follow-up|1
6139971|NCT01026818|9771752|FG000|OL Period (Month 10.5 - 13.5)|Protocol Deviation|0
6139972|NCT01026818|9771753|FG001|OL Period (Month 10.5 - 13.5)|Protocol Deviation|1
6139973|NCT01026818|9771754|FG002|OL Period (Month 10.5 - 13.5)|Protocol Deviation|3
6139974|NCT01026818|9771755|FG003|OL Period (Month 10.5 - 13.5)|Protocol Deviation|1
6139975|NCT01026818|9771752|FG000|OL Period (Month 10.5 - 13.5)|Withdrawal by Subject|0
6139976|NCT01026818|9771753|FG001|OL Period (Month 10.5 - 13.5)|Withdrawal by Subject|2
6139977|NCT01026818|9771754|FG002|OL Period (Month 10.5 - 13.5)|Withdrawal by Subject|0
6139978|NCT01026818|9771755|FG003|OL Period (Month 10.5 - 13.5)|Withdrawal by Subject|1
6139979|NCT01026831|9771769|FG000|Overall Study|Adverse Event|4
6139980|NCT01026831|9771770|FG001|Overall Study|Adverse Event|3
6139981|NCT01026831|9771769|FG000|Overall Study|Lost to Follow-up|2
6139982|NCT01026831|9771770|FG001|Overall Study|Lost to Follow-up|0
6139983|NCT01026831|9771769|FG000|Overall Study|Physician Decision|1
6139984|NCT01026831|9771770|FG001|Overall Study|Physician Decision|1
6139985|NCT01026831|9771769|FG000|Overall Study|Protocol Violation|0
6139986|NCT01026831|9771770|FG001|Overall Study|Protocol Violation|2
6139987|NCT01026831|9771769|FG000|Overall Study|Withdrawal by Subject|7
6139988|NCT01026831|9771770|FG001|Overall Study|Withdrawal by Subject|5
6139989|NCT01026948|9771794|FG000|Overall Study|Physician Decision|8
6139990|NCT01026974|9771803|FG000|Overall Study|Withdrawal by Subject|0
6139991|NCT01026974|9771804|FG001|Overall Study|Withdrawal by Subject|1
6139992|NCT01026974|9771805|FG002|Overall Study|Withdrawal by Subject|7
6139993|NCT01026974|9771806|FG003|Overall Study|Withdrawal by Subject|2
6139994|NCT01026974|9771803|FG000|Overall Study|Lost to Follow-up|1
6139995|NCT01026974|9771804|FG001|Overall Study|Lost to Follow-up|1
6139996|NCT01026974|9771805|FG002|Overall Study|Lost to Follow-up|4
6139997|NCT01026974|9771806|FG003|Overall Study|Lost to Follow-up|0
6139998|NCT01026974|9771803|FG000|Overall Study|Adverse Event|0
6139999|NCT01026974|9771804|FG001|Overall Study|Adverse Event|0
6140000|NCT01026974|9771805|FG002|Overall Study|Adverse Event|0
6140001|NCT01026974|9771806|FG003|Overall Study|Adverse Event|1
6140002|NCT01026974|9771803|FG000|Overall Study|Inappropriate enrollment|0
6140003|NCT01026974|9771804|FG001|Overall Study|Inappropriate enrollment|0
6140004|NCT01026974|9771805|FG002|Overall Study|Inappropriate enrollment|1
6140005|NCT01026974|9771806|FG003|Overall Study|Inappropriate enrollment|0
6140006|NCT01027273|9771836|FG000|Overall Study|Lost to Follow-up|57
6140007|NCT01027273|9771837|FG001|Overall Study|Lost to Follow-up|31
6140008|NCT01027273|9771836|FG000|Overall Study|Death|2
6140009|NCT01027273|9771837|FG001|Overall Study|Death|2
6140010|NCT01027286|9771845|FG000|Overall Study|Unable to Obtain Required Blood Volume|1
6140011|NCT01027286|9771846|FG001|Overall Study|Unable to Obtain Required Blood Volume|0
6140012|NCT01027286|9771845|FG000|Overall Study|Lost to Follow-up|0
6140013|NCT01027286|9771846|FG001|Overall Study|Lost to Follow-up|1
6140014|NCT01027351|9771858|FG000|Overall Study|Withdrawal by Subject|1
6140015|NCT01027351|9771859|FG001|Overall Study|Withdrawal by Subject|0
6140016|NCT01027351|9771860|FG002|Overall Study|Withdrawal by Subject|1
6140017|NCT01027351|9771861|FG003|Overall Study|Withdrawal by Subject|0
6140018|NCT01027351|9771862|FG004|Overall Study|Withdrawal by Subject|3
6140019|NCT01027351|9771863|FG005|Overall Study|Withdrawal by Subject|5
6140020|NCT01027351|9771858|FG000|Overall Study|Lost to Follow-up|1
6140021|NCT01027351|9771859|FG001|Overall Study|Lost to Follow-up|1
6140022|NCT01027351|9771860|FG002|Overall Study|Lost to Follow-up|0
6140023|NCT01027351|9771861|FG003|Overall Study|Lost to Follow-up|1
6140024|NCT01027351|9771862|FG004|Overall Study|Lost to Follow-up|6
6140025|NCT01027351|9771863|FG005|Overall Study|Lost to Follow-up|0
6140026|NCT01027351|9771858|FG000|Overall Study|Inappropriate enrollment|0
6140027|NCT01027351|9771859|FG001|Overall Study|Inappropriate enrollment|0
6140028|NCT01027351|9771860|FG002|Overall Study|Inappropriate enrollment|0
6140029|NCT01027351|9771861|FG003|Overall Study|Inappropriate enrollment|0
6140030|NCT01027351|9771862|FG004|Overall Study|Inappropriate enrollment|1
6140031|NCT01027351|9771863|FG005|Overall Study|Inappropriate enrollment|0
6140032|NCT01027351|9771858|FG000|Overall Study|Protocol Violation|1
6140033|NCT01027351|9771859|FG001|Overall Study|Protocol Violation|0
6140034|NCT01027351|9771860|FG002|Overall Study|Protocol Violation|0
6140035|NCT01027351|9771861|FG003|Overall Study|Protocol Violation|1
6140036|NCT01027351|9771862|FG004|Overall Study|Protocol Violation|1
6140037|NCT01027351|9771863|FG005|Overall Study|Protocol Violation|0
6140038|NCT01027364|9771888|FG000|Overall Study|Adverse Event|1
6140039|NCT01027364|9771889|FG001|Overall Study|Adverse Event|0
6140040|NCT01027364|9771890|FG002|Overall Study|Adverse Event|1
6140041|NCT01027364|9771891|FG003|Overall Study|Adverse Event|0
6140042|NCT01027364|9771888|FG000|Overall Study|Lost to Follow-up|1
6140043|NCT01027364|9771889|FG001|Overall Study|Lost to Follow-up|0
6140044|NCT01027364|9771890|FG002|Overall Study|Lost to Follow-up|0
6140045|NCT01027364|9771891|FG003|Overall Study|Lost to Follow-up|0
6140046|NCT01027364|9771888|FG000|Overall Study|Protocol Violation|1
6140047|NCT01027364|9771889|FG001|Overall Study|Protocol Violation|0
6140048|NCT01027364|9771890|FG002|Overall Study|Protocol Violation|0
6140049|NCT01027364|9771891|FG003|Overall Study|Protocol Violation|1
6140050|NCT01027364|9771888|FG000|Overall Study|Withdrawal by Subject|1
6140051|NCT01027364|9771889|FG001|Overall Study|Withdrawal by Subject|2
6140052|NCT01027364|9771890|FG002|Overall Study|Withdrawal by Subject|0
6140053|NCT01027364|9771891|FG003|Overall Study|Withdrawal by Subject|0
6140054|NCT01027416|9771919|FG000|Overall Study|Withdrawal by Subject|0
6140055|NCT01027416|9771920|FG001|Overall Study|Withdrawal by Subject|1
6140056|NCT01027416|9771919|FG000|Overall Study|Physician Decision|1
6140057|NCT01027416|9771920|FG001|Overall Study|Physician Decision|4
6140058|NCT01027650|9771961|FG000|Overall Study|Personal Reasons|0
6140059|NCT01027650|9771962|FG001|Overall Study|Personal Reasons|0
6140060|NCT01027650|9771963|FG002|Overall Study|Personal Reasons|0
6140061|NCT01027650|9771964|FG003|Overall Study|Personal Reasons|0
6140062|NCT01027650|9771965|FG004|Overall Study|Personal Reasons|2
6140063|NCT01027650|9771966|FG005|Overall Study|Personal Reasons|1
6140064|NCT01027650|9771967|FG006|Overall Study|Personal Reasons|0
6140065|NCT01027650|9771968|FG007|Overall Study|Personal Reasons|0
6140066|NCT01027650|9771961|FG000|Overall Study|Lost to Follow-up|0
6140067|NCT01027650|9771962|FG001|Overall Study|Lost to Follow-up|0
6140068|NCT01027650|9771963|FG002|Overall Study|Lost to Follow-up|0
6140069|NCT01027650|9771964|FG003|Overall Study|Lost to Follow-up|0
6140070|NCT01027650|9771965|FG004|Overall Study|Lost to Follow-up|0
6140071|NCT01027650|9771966|FG005|Overall Study|Lost to Follow-up|0
6140072|NCT01027650|9771967|FG006|Overall Study|Lost to Follow-up|1
6140073|NCT01027650|9771968|FG007|Overall Study|Lost to Follow-up|0
6140074|NCT01027650|9771961|FG000|Overall Study|Lack of Efficacy|0
6140075|NCT01027650|9771962|FG001|Overall Study|Lack of Efficacy|0
6140076|NCT01027650|9771963|FG002|Overall Study|Lack of Efficacy|0
6140077|NCT01027650|9771964|FG003|Overall Study|Lack of Efficacy|0
6140078|NCT01027650|9771965|FG004|Overall Study|Lack of Efficacy|0
6140079|NCT01027650|9771966|FG005|Overall Study|Lack of Efficacy|1
6140080|NCT01027650|9771967|FG006|Overall Study|Lack of Efficacy|0
6140081|NCT01027650|9771968|FG007|Overall Study|Lack of Efficacy|0
6140082|NCT01027754|9771988|FG000|Overall Study|withdrew/lost to follow-up after interve|2
6140083|NCT01027754|9771989|FG001|Overall Study|withdrew/lost to follow-up after interve|3
6140084|NCT01027754|9771988|FG000|Overall Study|Withdrawal by Subject|0
6140085|NCT01027754|9771989|FG001|Overall Study|Withdrawal by Subject|5
6140086|NCT01027845|9772034|FG000|Primary Vaccination Phase|Serious Adverse Event|2
6140087|NCT01027845|9772035|FG001|Primary Vaccination Phase|Serious Adverse Event|0
6140088|NCT01027845|9772036|FG002|Primary Vaccination Phase|Serious Adverse Event|0
6140089|NCT01027845|9772037|FG003|Primary Vaccination Phase|Serious Adverse Event|0
6140090|NCT01027845|9772034|FG000|Primary Vaccination Phase|Adverse Event|1
6140091|NCT01027845|9772035|FG001|Primary Vaccination Phase|Adverse Event|0
6140092|NCT01027845|9772036|FG002|Primary Vaccination Phase|Adverse Event|0
6140093|NCT01027845|9772037|FG003|Primary Vaccination Phase|Adverse Event|0
6140094|NCT01027845|9772034|FG000|Primary Vaccination Phase|Protocol Violation|1
6140095|NCT01027845|9772035|FG001|Primary Vaccination Phase|Protocol Violation|0
6140096|NCT01027845|9772036|FG002|Primary Vaccination Phase|Protocol Violation|0
6140097|NCT01027845|9772037|FG003|Primary Vaccination Phase|Protocol Violation|0
6140098|NCT01027845|9772034|FG000|Primary Vaccination Phase|Migrated/moved from study area|0
6140099|NCT01027845|9772035|FG001|Primary Vaccination Phase|Migrated/moved from study area|1
6140100|NCT01027845|9772036|FG002|Primary Vaccination Phase|Migrated/moved from study area|0
6140101|NCT01027845|9772037|FG003|Primary Vaccination Phase|Migrated/moved from study area|0
6140102|NCT01027845|9772034|FG000|Booster Vaccination Phase|Withdrawal by Subject|1
6140103|NCT01027845|9772035|FG001|Booster Vaccination Phase|Withdrawal by Subject|0
6140104|NCT01027845|9772036|FG002|Booster Vaccination Phase|Withdrawal by Subject|0
6140105|NCT01027845|9772037|FG003|Booster Vaccination Phase|Withdrawal by Subject|0
6140106|NCT01027845|9772034|FG000|Booster Vaccination Phase|Migrated/moved from study area|1
6140107|NCT01027845|9772035|FG001|Booster Vaccination Phase|Migrated/moved from study area|0
6140108|NCT01027845|9772036|FG002|Booster Vaccination Phase|Migrated/moved from study area|0
6140109|NCT01027845|9772037|FG003|Booster Vaccination Phase|Migrated/moved from study area|0
6140110|NCT01027871|9772049|FG000|Overall Study|Physician Decision|1
6140111|NCT01027871|9772050|FG001|Overall Study|Physician Decision|5
6140112|NCT01027871|9772051|FG002|Overall Study|Physician Decision|0
6140113|NCT01027871|9772049|FG000|Overall Study|Protocol Violation|0
6140114|NCT01027871|9772050|FG001|Overall Study|Protocol Violation|2
6140115|NCT01027871|9772051|FG002|Overall Study|Protocol Violation|2
6140116|NCT01027871|9772049|FG000|Overall Study|Withdrawal by Subject|1
6140117|NCT01027871|9772050|FG001|Overall Study|Withdrawal by Subject|2
6140118|NCT01027871|9772051|FG002|Overall Study|Withdrawal by Subject|2
6140119|NCT01027871|9772049|FG000|Overall Study|Adverse Event|0
6140120|NCT01027871|9772050|FG001|Overall Study|Adverse Event|2
6140121|NCT01027871|9772051|FG002|Overall Study|Adverse Event|2
6140122|NCT01027871|9772049|FG000|Overall Study|Sponsor Decision|0
6140123|NCT01027871|9772050|FG001|Overall Study|Sponsor Decision|2
6140124|NCT01027871|9772051|FG002|Overall Study|Sponsor Decision|0
6140125|NCT01027871|9772049|FG000|Overall Study|Discontinued Prior to Treatment|0
6140126|NCT01027871|9772050|FG001|Overall Study|Discontinued Prior to Treatment|0
6140127|NCT01027871|9772051|FG002|Overall Study|Discontinued Prior to Treatment|1
6140128|NCT01027884|9772066|FG000|Overall Study|Adverse Event|2
6140129|NCT01027884|9772067|FG001|Overall Study|Adverse Event|1
6140130|NCT01027884|9772066|FG000|Overall Study|Protocol Violation|1
6140131|NCT01027884|9772067|FG001|Overall Study|Protocol Violation|0
6140132|NCT01027884|9772066|FG000|Overall Study|Non-compliance|1
6140133|NCT01027884|9772067|FG001|Overall Study|Non-compliance|1
6140134|NCT01027884|9772066|FG000|Overall Study|Withdrawal by Subject|0
6140135|NCT01027884|9772067|FG001|Overall Study|Withdrawal by Subject|1
6140136|NCT01027884|9772066|FG000|Overall Study|Lost to Follow-up|0
6140137|NCT01027884|9772067|FG001|Overall Study|Lost to Follow-up|1
6140138|NCT01027884|9772066|FG000|Overall Study|Spinal fixation surgery|0
6140139|NCT01027884|9772067|FG001|Overall Study|Spinal fixation surgery|3
6140140|NCT01027897|9772075|FG000|Overall Study|Protocol Violation|1
6140141|NCT01027897|9772075|FG000|Overall Study|Withdrawal by Subject|1
6140142|NCT01027949|9772090|FG000|Overall Study|Death|174
6140143|NCT01027949|9772090|FG000|Overall Study|Progressive Disease|163
6140144|NCT01027949|9772090|FG000|Overall Study|Adverse Event|172
6140145|NCT01027949|9772090|FG000|Overall Study|Withdrawal by Subject|113
6140146|NCT01027949|9772090|FG000|Overall Study|Lost to Follow-up|17
6140147|NCT01027949|9772090|FG000|Overall Study|Protocol Violation|13
6140148|NCT01027949|9772090|FG000|Overall Study|PI Decision|8
6140149|NCT01027949|9772090|FG000|Overall Study|Limited Study Drug Effectiveness|7
6140150|NCT01027949|9772090|FG000|Overall Study|Non-compliance with Study Procedures|7
6140151|NCT01027949|9772090|FG000|Overall Study|Lung Transplant|5
6140152|NCT01027949|9772090|FG000|Overall Study|Unable to Tolerate Study Drug|2
6140153|NCT01027949|9772090|FG000|Overall Study|Use of Excluded Medication|2
6140154|NCT01027949|9772090|FG000|Overall Study|Patient Self-discontinuation|1
6140155|NCT01027949|9772090|FG000|Overall Study|Pregnancy|1
6140156|NCT01027949|9772090|FG000|Overall Study|Surgery|1
6140157|NCT01028014|9772100|FG000|Overall Study|Lost to Follow-up|1
6140158|NCT01028014|9772101|FG001|Overall Study|Lost to Follow-up|2
6140159|NCT01028014|9772102|FG002|Overall Study|Lost to Follow-up|0
6140160|NCT01028014|9772103|FG003|Overall Study|Lost to Follow-up|1
6140161|NCT01028014|9772104|FG004|Overall Study|Lost to Follow-up|1
6140162|NCT01028014|9772105|FG005|Overall Study|Lost to Follow-up|2
6140163|NCT01028027|9772121|FG000|Overall Study|Lost to Follow-up|4
6140164|NCT01028027|9772122|FG001|Overall Study|Lost to Follow-up|1
6140165|NCT01028027|9772121|FG000|Overall Study|Withdrawal by Subject|5
6140166|NCT01028027|9772122|FG001|Overall Study|Withdrawal by Subject|3
6140167|NCT01028027|9772121|FG000|Overall Study|Adverse Event|4
6140168|NCT01028027|9772122|FG001|Overall Study|Adverse Event|7
6140169|NCT01028027|9772121|FG000|Overall Study|Protocol Violation|3
6140170|NCT01028027|9772122|FG001|Overall Study|Protocol Violation|1
6140171|NCT01028027|9772121|FG000|Overall Study|Lack of Efficacy|0
6140172|NCT01028027|9772122|FG001|Overall Study|Lack of Efficacy|1
6140173|NCT01028053|9772128|FG000|Overall Study|Screen Failure|113
6140174|NCT01028053|9772128|FG000|Overall Study|Patient Request|11
6140175|NCT01028053|9772128|FG000|Overall Study|Protocol Violation|1
6140176|NCT01028053|9772128|FG000|Overall Study|Physician Decision|2
6140177|NCT01028053|9772128|FG000|Overall Study|Technical Problem|1
6140178|NCT01028053|9772128|FG000|Overall Study|Terminated by Sponsor|1
6140179|NCT01028053|9772128|FG000|Overall Study|Various reasons|4
6140180|NCT01028222|9772153|FG000|Overall Study|Protocol deviation|1
6140181|NCT01028222|9772154|FG001|Overall Study|Protocol deviation|0
6140182|NCT01028222|9772153|FG000|Overall Study|Disease progression|33
6140183|NCT01028222|9772154|FG001|Overall Study|Disease progression|9
6140184|NCT01028222|9772153|FG000|Overall Study|Administrative problems|1
6140185|NCT01028222|9772154|FG001|Overall Study|Administrative problems|1
6140186|NCT01028222|9772153|FG000|Overall Study|Lost to Follow-up|0
6140187|NCT01028222|9772154|FG001|Overall Study|Lost to Follow-up|1
6140188|NCT01028222|9772153|FG000|Overall Study|Withdrawal by Subject|1
6140189|NCT01028222|9772154|FG001|Overall Study|Withdrawal by Subject|0
6140190|NCT01028222|9772153|FG000|Overall Study|Crossover to nilotinib w/out progression|0
6140191|NCT01028222|9772154|FG001|Overall Study|Crossover to nilotinib w/out progression|2
6140192|NCT01028222|9772153|FG000|Overall Study|Adverse Event|2
6140193|NCT01028222|9772154|FG001|Overall Study|Adverse Event|0
6140194|NCT01028352|9772161|FG000|Overall Study|Ineligible due to baseline average pain|5
6140195|NCT01028352|9772161|FG000|Overall Study|Withdrawal by Subject|1
6140196|NCT01028378|9772165|FG000|Overall Study|Lost to Follow-up|12
6140197|NCT01028378|9772165|FG000|Overall Study|Withdrawal by Subject|1
6140198|NCT01028378|9772165|FG000|Overall Study|Adminstrative Reasons|4
6140199|NCT01028391|9772171|FG000|Overall Study|Adverse Event|4
6140200|NCT01028391|9772172|FG001|Overall Study|Adverse Event|0
6140201|NCT01028391|9772171|FG000|Overall Study|Lack of Efficacy|0
6140202|NCT01028391|9772172|FG001|Overall Study|Lack of Efficacy|2
6140203|NCT01028391|9772171|FG000|Overall Study|Lost to Follow-up|3
6140204|NCT01028391|9772172|FG001|Overall Study|Lost to Follow-up|4
6140205|NCT01028391|9772171|FG000|Overall Study|Physician Decision|0
6140206|NCT01028391|9772172|FG001|Overall Study|Physician Decision|1
6140207|NCT01028391|9772171|FG000|Overall Study|Withdrawal by Subject|6
6140208|NCT01028391|9772172|FG001|Overall Study|Withdrawal by Subject|3
6140209|NCT01028391|9772171|FG000|Overall Study|Needed excluded medication|1
6140210|NCT01028391|9772172|FG001|Overall Study|Needed excluded medication|1
6140211|NCT01028560|9772180|FG000|Overall Study|Lack of Efficacy|3
6140212|NCT01028560|9772181|FG001|Overall Study|Lack of Efficacy|6
6140213|NCT01028560|9772180|FG000|Overall Study|Withdrawal by Subject|7
6140214|NCT01028560|9772181|FG001|Overall Study|Withdrawal by Subject|12
6140215|NCT01028651|9772188|FG000|Overall Study|Death|2
6140216|NCT01028651|9772188|FG000|Overall Study|Adverse Event|1
6140217|NCT01029262|9772229|FG000|Overall Study|Adverse Event|9
6140218|NCT01029262|9772230|FG001|Overall Study|Adverse Event|52
6140219|NCT01029262|9772229|FG000|Overall Study|Lack of therapeutic effect|57
6140220|NCT01029262|9772230|FG001|Overall Study|Lack of therapeutic effect|76
6140221|NCT01029262|9772229|FG000|Overall Study|Withdrawal by Subject|10
6140222|NCT01029262|9772230|FG001|Overall Study|Withdrawal by Subject|17
6140223|NCT01029262|9772229|FG000|Overall Study|Protocol Violation|2
6140224|NCT01029262|9772230|FG001|Overall Study|Protocol Violation|3
6140225|NCT01029262|9772229|FG000|Overall Study|Miscellaneous|1
6140226|NCT01029262|9772230|FG001|Overall Study|Miscellaneous|9
6140227|NCT01029262|9772229|FG000|Overall Study|Death|0
6140228|NCT01029262|9772230|FG001|Overall Study|Death|3
6140229|NCT01029340|9772246|FG000|Part B Treatment Period|Withdrawal by Subject|0
6140230|NCT01029340|9772247|FG001|Part B Treatment Period|Withdrawal by Subject|0
6140231|NCT01029340|9772248|FG002|Part B Treatment Period|Withdrawal by Subject|1
6140232|NCT01029340|9772249|FG003|Part B Treatment Period|Withdrawal by Subject|0
6140233|NCT01029340|9772250|FG004|Part B Treatment Period|Withdrawal by Subject|0
6140234|NCT01029340|9772251|FG005|Part B Treatment Period|Withdrawal by Subject|0
6140235|NCT01029340|9772246|FG000|Part B Treatment Period|Protocol Violation|0
6140236|NCT01029340|9772247|FG001|Part B Treatment Period|Protocol Violation|0
6140237|NCT01029340|9772248|FG002|Part B Treatment Period|Protocol Violation|1
6140238|NCT01029340|9772249|FG003|Part B Treatment Period|Protocol Violation|0
6140239|NCT01029340|9772250|FG004|Part B Treatment Period|Protocol Violation|0
6140240|NCT01029340|9772251|FG005|Part B Treatment Period|Protocol Violation|0
6140241|NCT01029340|9772246|FG000|Extension Period|Adverse Event|0
6140242|NCT01029340|9772247|FG001|Extension Period|Adverse Event|0
6140243|NCT01029340|9772248|FG002|Extension Period|Adverse Event|0
6140244|NCT01029340|9772249|FG003|Extension Period|Adverse Event|0
6140245|NCT01029340|9772250|FG004|Extension Period|Adverse Event|0
6140246|NCT01029340|9772251|FG005|Extension Period|Adverse Event|1
6140247|NCT01029340|9772246|FG000|Extension Period|starting another study|0
6140248|NCT01029340|9772247|FG001|Extension Period|starting another study|0
6140249|NCT01029340|9772248|FG002|Extension Period|starting another study|0
6140250|NCT01029340|9772249|FG003|Extension Period|starting another study|0
6140251|NCT01029340|9772250|FG004|Extension Period|starting another study|0
6140252|NCT01029340|9772251|FG005|Extension Period|starting another study|8
6140253|NCT01029340|9772246|FG000|Extension Period|non-compliance|0
6140254|NCT01029340|9772247|FG001|Extension Period|non-compliance|0
6140255|NCT01029340|9772248|FG002|Extension Period|non-compliance|0
6140256|NCT01029340|9772249|FG003|Extension Period|non-compliance|0
6140257|NCT01029340|9772250|FG004|Extension Period|non-compliance|0
6140258|NCT01029340|9772251|FG005|Extension Period|non-compliance|1
6140259|NCT01029340|9772246|FG000|Extension Period|Withdrawal by Subject|0
6140260|NCT01029340|9772247|FG001|Extension Period|Withdrawal by Subject|0
6140261|NCT01029340|9772248|FG002|Extension Period|Withdrawal by Subject|0
6140262|NCT01029340|9772249|FG003|Extension Period|Withdrawal by Subject|0
6140263|NCT01029340|9772250|FG004|Extension Period|Withdrawal by Subject|0
6140264|NCT01029340|9772251|FG005|Extension Period|Withdrawal by Subject|1
6140265|NCT01029340|9772246|FG000|Extension Period|Physician Decision|0
6140266|NCT01029340|9772247|FG001|Extension Period|Physician Decision|0
6140267|NCT01029340|9772248|FG002|Extension Period|Physician Decision|0
6140268|NCT01029340|9772249|FG003|Extension Period|Physician Decision|0
6140269|NCT01029340|9772250|FG004|Extension Period|Physician Decision|0
6140270|NCT01029340|9772251|FG005|Extension Period|Physician Decision|1
6140271|NCT01029353|9772268|FG000|Overall Study|Lost to Follow-up|4
6140272|NCT01029353|9772269|FG001|Overall Study|Lost to Follow-up|5
6140273|NCT01029353|9772270|FG002|Overall Study|Lost to Follow-up|5
6140274|NCT01029353|9772271|FG003|Overall Study|Lost to Follow-up|4
6140275|NCT01029353|9772268|FG000|Overall Study|Consent Withdrawn|2
6140276|NCT01029353|9772269|FG001|Overall Study|Consent Withdrawn|0
6140277|NCT01029353|9772270|FG002|Overall Study|Consent Withdrawn|0
6140278|NCT01029353|9772271|FG003|Overall Study|Consent Withdrawn|0
6140279|NCT01029353|9772268|FG000|Overall Study|Primary Outcome Indeterminate|1
6140280|NCT01029353|9772269|FG001|Overall Study|Primary Outcome Indeterminate|3
6140281|NCT01029353|9772270|FG002|Overall Study|Primary Outcome Indeterminate|2
6140282|NCT01029353|9772271|FG003|Overall Study|Primary Outcome Indeterminate|0
6140283|NCT01029366|9772283|FG000|Overall Study|Withdrawal by Subject|1
6140284|NCT01029366|9772284|FG001|Overall Study|Withdrawal by Subject|0
6140285|NCT01029366|9772283|FG000|Overall Study|Death|1
6140286|NCT01029366|9772284|FG001|Overall Study|Death|1
6140287|NCT01029366|9772283|FG000|Overall Study|disease progression|2
6140288|NCT01029366|9772284|FG001|Overall Study|disease progression|0
6140289|NCT01029366|9772283|FG000|Overall Study|manufacturing failure|0
6140290|NCT01029366|9772284|FG001|Overall Study|manufacturing failure|1
6140291|NCT01029392|9772293|FG000|Overall Study|Withdrawal by Subject|18
6140292|NCT01029392|9772294|FG001|Overall Study|Withdrawal by Subject|11
6140293|NCT01029392|9772293|FG000|Overall Study|Physician Decision|2
6140294|NCT01029392|9772294|FG001|Overall Study|Physician Decision|0
6140295|NCT01029405|9772306|FG000|Overall Study|Withdrawal by Subject|0
6140296|NCT01029405|9772307|FG001|Overall Study|Withdrawal by Subject|1
6140297|NCT01029405|9772308|FG002|Overall Study|Withdrawal by Subject|2
6140298|NCT01029405|9772309|FG003|Overall Study|Withdrawal by Subject|0
6140299|NCT01029405|9772306|FG000|Overall Study|Protocol Violation|0
6140300|NCT01029405|9772307|FG001|Overall Study|Protocol Violation|0
6140301|NCT01029405|9772308|FG002|Overall Study|Protocol Violation|0
6140302|NCT01029405|9772309|FG003|Overall Study|Protocol Violation|1
6140303|NCT01029405|9772306|FG000|Overall Study|Adverse Event|0
6140304|NCT01029405|9772307|FG001|Overall Study|Adverse Event|0
6140305|NCT01029405|9772308|FG002|Overall Study|Adverse Event|1
6140306|NCT01029405|9772309|FG003|Overall Study|Adverse Event|1
6140307|NCT01029405|9772306|FG000|Overall Study|Lost to Follow-up|2
6140308|NCT01029405|9772307|FG001|Overall Study|Lost to Follow-up|1
6140309|NCT01029405|9772308|FG002|Overall Study|Lost to Follow-up|1
6140310|NCT01029405|9772309|FG003|Overall Study|Lost to Follow-up|2
6140311|NCT01029405|9772306|FG000|Overall Study|Other|0
6140312|NCT01029405|9772307|FG001|Overall Study|Other|1
6140313|NCT01029405|9772308|FG002|Overall Study|Other|0
6140314|NCT01029405|9772309|FG003|Overall Study|Other|1
6140315|NCT01029535|9772319|FG000|Overall Study|Lost to Follow-up|24
6140316|NCT01029535|9772319|FG000|Overall Study|Protocol Violation|2
6140317|NCT01029535|9772319|FG000|Overall Study|Participant Withdrew Consent|2
6140318|NCT01029535|9772319|FG000|Overall Study|Adverse Event|1
6140319|NCT01029535|9772319|FG000|Overall Study|Use of Another Treatment|1
6140320|NCT01029535|9772319|FG000|Overall Study|Death|1
6140321|NCT01029652|9772330|FG000|Core Study (0-12 Weeks)|Unsatisfactory therapeutic effect|0
6140322|NCT01029652|9772331|FG001|Core Study (0-12 Weeks)|Unsatisfactory therapeutic effect|4
6140323|NCT01029652|9772330|FG000|Core Study (0-12 Weeks)|Patient Withdrew Consent|1
6140324|NCT01029652|9772331|FG001|Core Study (0-12 Weeks)|Patient Withdrew Consent|3
6140325|NCT01029652|9772330|FG000|Core Study (0-12 Weeks)|Lost to Follow-up|3
6140326|NCT01029652|9772331|FG001|Core Study (0-12 Weeks)|Lost to Follow-up|1
6140327|NCT01029652|9772330|FG000|Core Study (0-12 Weeks)|Administrative problems|2
6140328|NCT01029652|9772331|FG001|Core Study (0-12 Weeks)|Administrative problems|1
6140329|NCT01029652|9772330|FG000|Core Study (0-12 Weeks)|Death|0
6140330|NCT01029652|9772331|FG001|Core Study (0-12 Weeks)|Death|1
6140331|NCT01029652|9772330|FG000|Extension Study 1 (12-24 Weeks)|Unsatisfactory therapeutic effect|0
6140332|NCT01029652|9772331|FG001|Extension Study 1 (12-24 Weeks)|Unsatisfactory therapeutic effect|1
6140333|NCT01029652|9772330|FG000|Extension Study 1 (12-24 Weeks)|Lost to Follow-up|2
6140334|NCT01029652|9772331|FG001|Extension Study 1 (12-24 Weeks)|Lost to Follow-up|3
6140335|NCT01029652|9772330|FG000|Extension Study 1 (12-24 Weeks)|Protocol Deviation|1
6140336|NCT01029652|9772331|FG001|Extension Study 1 (12-24 Weeks)|Protocol Deviation|0
6140337|NCT01029652|9772330|FG000|Extension Study 1 (12-24 Weeks)|Withdrawal by Subject|0
6140338|NCT01029652|9772331|FG001|Extension Study 1 (12-24 Weeks)|Withdrawal by Subject|1
6140339|NCT01029652|9772330|FG000|Extension Study 2 (25-72 Weeks)|Death|1
6140340|NCT01029652|9772331|FG001|Extension Study 2 (25-72 Weeks)|Death|1
6140341|NCT01029652|9772330|FG000|Extension Study 2 (25-72 Weeks)|Unsatisfactory therapeutic effect|0
6140342|NCT01029652|9772331|FG001|Extension Study 2 (25-72 Weeks)|Unsatisfactory therapeutic effect|1
6140343|NCT01029652|9772330|FG000|Extension Study 2 (25-72 Weeks)|Withdrawal by Subject|0
6140344|NCT01029652|9772331|FG001|Extension Study 2 (25-72 Weeks)|Withdrawal by Subject|1
6140345|NCT01029691|9772358|FG000|Continued APAP to Delivery|Death|0
6140346|NCT01029691|9772359|FG001|Continued APAP to Delivery|Death|0
6140347|NCT01029691|9772360|FG002|Continued APAP to Delivery|Death|1
6140348|NCT01029704|9772378|FG000|Overall Study|Adverse Event|0
6140349|NCT01029704|9772379|FG001|Overall Study|Adverse Event|0
6140350|NCT01029704|9772380|FG002|Overall Study|Adverse Event|0
6140351|NCT01029704|9772381|FG003|Overall Study|Adverse Event|0
6140352|NCT01029704|9772382|FG004|Overall Study|Adverse Event|0
6140353|NCT01029704|9772383|FG005|Overall Study|Adverse Event|0
6140354|NCT01029704|9772384|FG006|Overall Study|Adverse Event|1
6140355|NCT01029704|9772385|FG007|Overall Study|Adverse Event|1
6140356|NCT01029704|9772386|FG008|Overall Study|Adverse Event|0
6140357|NCT01029704|9772378|FG000|Overall Study|Withdrawal by Subject|0
6140358|NCT01029704|9772379|FG001|Overall Study|Withdrawal by Subject|0
6140359|NCT01029704|9772380|FG002|Overall Study|Withdrawal by Subject|0
6140360|NCT01029704|9772381|FG003|Overall Study|Withdrawal by Subject|0
6140361|NCT01029704|9772382|FG004|Overall Study|Withdrawal by Subject|2
6140362|NCT01029704|9772383|FG005|Overall Study|Withdrawal by Subject|1
6140363|NCT01029704|9772384|FG006|Overall Study|Withdrawal by Subject|1
6140364|NCT01029704|9772385|FG007|Overall Study|Withdrawal by Subject|1
6140365|NCT01029704|9772386|FG008|Overall Study|Withdrawal by Subject|0
6140366|NCT01029704|9772378|FG000|Overall Study|Lost to Follow-up|0
6140367|NCT01029704|9772379|FG001|Overall Study|Lost to Follow-up|0
6140368|NCT01029704|9772380|FG002|Overall Study|Lost to Follow-up|0
6140369|NCT01029704|9772381|FG003|Overall Study|Lost to Follow-up|0
6140370|NCT01029704|9772382|FG004|Overall Study|Lost to Follow-up|0
6140371|NCT01029704|9772383|FG005|Overall Study|Lost to Follow-up|0
6140372|NCT01029704|9772384|FG006|Overall Study|Lost to Follow-up|1
6140373|NCT01029704|9772385|FG007|Overall Study|Lost to Follow-up|1
6140374|NCT01029704|9772386|FG008|Overall Study|Lost to Follow-up|1
6140375|NCT01029704|9772378|FG000|Overall Study|Lack of Efficacy|0
6140376|NCT01029704|9772379|FG001|Overall Study|Lack of Efficacy|0
6140377|NCT01029704|9772380|FG002|Overall Study|Lack of Efficacy|0
6140378|NCT01029704|9772381|FG003|Overall Study|Lack of Efficacy|0
6140379|NCT01029704|9772382|FG004|Overall Study|Lack of Efficacy|2
6140380|NCT01029704|9772383|FG005|Overall Study|Lack of Efficacy|3
6140381|NCT01029704|9772384|FG006|Overall Study|Lack of Efficacy|1
6140382|NCT01029704|9772385|FG007|Overall Study|Lack of Efficacy|2
6140383|NCT01029704|9772386|FG008|Overall Study|Lack of Efficacy|0
6140384|NCT01029704|9772378|FG000|Overall Study|Withdrawn due to major protocol violation|0
6140385|NCT01029704|9772379|FG001|Overall Study|Withdrawn due to major protocol violation|0
6140386|NCT01029704|9772380|FG002|Overall Study|Withdrawn due to major protocol violation|0
6140387|NCT01029704|9772381|FG003|Overall Study|Withdrawn due to major protocol violation|0
6140388|NCT01029704|9772382|FG004|Overall Study|Withdrawn due to major protocol violation|1
6140389|NCT01029704|9772383|FG005|Overall Study|Withdrawn due to major protocol violation|0
6140390|NCT01029704|9772384|FG006|Overall Study|Withdrawn due to major protocol violation|0
6140391|NCT01029704|9772385|FG007|Overall Study|Withdrawn due to major protocol violation|1
6140392|NCT01029704|9772386|FG008|Overall Study|Withdrawn due to major protocol violation|0
6140393|NCT01029782|9772412|FG000|Overall Study|Lost to Follow-up|2
6140394|NCT01029782|9772413|FG001|Overall Study|Lost to Follow-up|2
6140395|NCT01029782|9772412|FG000|Overall Study|Diagnosis changed|1
6140396|NCT01029782|9772413|FG001|Overall Study|Diagnosis changed|1
6140397|NCT01029782|9772412|FG000|Overall Study|Adverse Event|0
6140398|NCT01029782|9772413|FG001|Overall Study|Adverse Event|1
6140399|NCT01029782|9772412|FG000|Overall Study|Physician Decision|0
6140400|NCT01029782|9772413|FG001|Overall Study|Physician Decision|1
6140401|NCT01029782|9772412|FG000|Overall Study|Protocol Violation|0
6140402|NCT01029782|9772413|FG001|Overall Study|Protocol Violation|2
6140403|NCT01029782|9772412|FG000|Overall Study|Withdrawal by Subject|0
6140404|NCT01029782|9772413|FG001|Overall Study|Withdrawal by Subject|1
6140405|NCT01029795|9772421|FG000|Overall Study|Entry Criteria Not Met|2
6140406|NCT01029795|9772422|FG001|Overall Study|Entry Criteria Not Met|1
6140407|NCT01029795|9772421|FG000|Overall Study|Physician Decision|2
6140408|NCT01029795|9772422|FG001|Overall Study|Physician Decision|1
6140409|NCT01029795|9772421|FG000|Overall Study|Sponsor Decision|11
6140410|NCT01029795|9772422|FG001|Overall Study|Sponsor Decision|17
6140411|NCT01029795|9772421|FG000|Overall Study|Withdrawal by Subject|1
6140412|NCT01029795|9772422|FG001|Overall Study|Withdrawal by Subject|3
6140413|NCT01029886|9772430|FG000|Overall Study|Adverse Event|12
6140414|NCT01029886|9772431|FG001|Overall Study|Adverse Event|25
6140415|NCT01029886|9772430|FG000|Overall Study|Lost to Follow-up|1
6140416|NCT01029886|9772431|FG001|Overall Study|Lost to Follow-up|0
6140417|NCT01029886|9772430|FG000|Overall Study|Physician Decision|2
6140418|NCT01029886|9772431|FG001|Overall Study|Physician Decision|6
6140419|NCT01029886|9772430|FG000|Overall Study|Protocol Violation|17
6140420|NCT01029886|9772431|FG001|Overall Study|Protocol Violation|5
6140421|NCT01029886|9772430|FG000|Overall Study|Withdrawal by Subject|8
6140422|NCT01029886|9772431|FG001|Overall Study|Withdrawal by Subject|18
6140423|NCT01029886|9772430|FG000|Overall Study|Entry Criteria Not Met|13
6140424|NCT01029886|9772431|FG001|Overall Study|Entry Criteria Not Met|5
6140425|NCT01029886|9772430|FG000|Overall Study|Sponsor Decision|1
6140426|NCT01029886|9772431|FG001|Overall Study|Sponsor Decision|0
6140427|NCT01029886|9772430|FG000|Overall Study|Loss Glucose Control|7
6140428|NCT01029886|9772431|FG001|Overall Study|Loss Glucose Control|1
6140429|NCT01029925|9772450|FG000|Completion of Cycle 1 (28 Days)|Death|2
6140430|NCT01029925|9772450|FG000|Completion of Cycle 1 (28 Days)|Withdrawal by Subject|2
6140431|NCT01029925|9772450|FG000|Completion of Cycle 2 (56 Days)|off study due to disease progression|1
6140432|NCT01030133|9772456|FG000|Overall Study|failed to experience pain at level 7/10|2
6140433|NCT01030133|9772457|FG001|Overall Study|failed to experience pain at level 7/10|2
6140434|NCT01030458|9772498|FG000|Overall Study|Lost to Follow-up|9
6140435|NCT01030458|9772499|FG001|Overall Study|Lost to Follow-up|10
6140436|NCT01030458|9772498|FG000|Overall Study|Withdrawal by Subject|2
6140437|NCT01030458|9772499|FG001|Overall Study|Withdrawal by Subject|3
6140438|NCT01030458|9772498|FG000|Overall Study|Logistical reasons|9
6140439|NCT01030458|9772499|FG001|Overall Study|Logistical reasons|5
6140440|NCT01030458|9772498|FG000|Overall Study|Moved or changed job|6
6140441|NCT01030458|9772499|FG001|Overall Study|Moved or changed job|13
6140442|NCT01030458|9772498|FG000|Overall Study|Side effect of medication|1
6140443|NCT01030458|9772499|FG001|Overall Study|Side effect of medication|1
6140444|NCT01030523|9772507|FG000|Overall Study|Death|1
6140445|NCT01030523|9772508|FG001|Overall Study|Death|0
6140446|NCT01030523|9772507|FG000|Overall Study|Lost to Follow-up|4
6140447|NCT01030523|9772508|FG001|Overall Study|Lost to Follow-up|4
6140448|NCT01030523|9772507|FG000|Overall Study|Implant failure|1
6140449|NCT01030523|9772508|FG001|Overall Study|Implant failure|0
6140450|NCT01030523|9772507|FG000|Overall Study|Withdrawal by Subject|0
6140451|NCT01030523|9772508|FG001|Overall Study|Withdrawal by Subject|1
6140452|NCT01030536|9772519|FG000|Overall Study|Withdrawal by Subject|0
6140453|NCT01030536|9772520|FG001|Overall Study|Withdrawal by Subject|0
6140454|NCT01030536|9772521|FG002|Overall Study|Withdrawal by Subject|1
6140455|NCT01030536|9772522|FG003|Overall Study|Withdrawal by Subject|0
6140456|NCT01030536|9772523|FG004|Overall Study|Withdrawal by Subject|0
6140457|NCT01030536|9772519|FG000|Overall Study|undefined|1
6140458|NCT01030536|9772520|FG001|Overall Study|undefined|0
6140459|NCT01030536|9772521|FG002|Overall Study|undefined|1
6140460|NCT01030536|9772522|FG003|Overall Study|undefined|1
6140461|NCT01030536|9772523|FG004|Overall Study|undefined|0
6140462|NCT01030536|9772519|FG000|Overall Study|Adverse Event|0
6140463|NCT01030536|9772520|FG001|Overall Study|Adverse Event|3
6140464|NCT01030536|9772521|FG002|Overall Study|Adverse Event|1
6140465|NCT01030536|9772522|FG003|Overall Study|Adverse Event|0
6140466|NCT01030536|9772523|FG004|Overall Study|Adverse Event|1
6140467|NCT01030536|9772519|FG000|Overall Study|Progressive disease|6
6140468|NCT01030536|9772520|FG001|Overall Study|Progressive disease|2
6140469|NCT01030536|9772521|FG002|Overall Study|Progressive disease|3
6140470|NCT01030536|9772522|FG003|Overall Study|Progressive disease|2
6140471|NCT01030536|9772523|FG004|Overall Study|Progressive disease|0
6140472|NCT01030536|9772519|FG000|Overall Study|Death|0
6140473|NCT01030536|9772520|FG001|Overall Study|Death|1
6140474|NCT01030536|9772521|FG002|Overall Study|Death|0
6140475|NCT01030536|9772522|FG003|Overall Study|Death|0
6140476|NCT01030536|9772523|FG004|Overall Study|Death|0
6140477|NCT01030666|9772551|FG000|Overall Study|Lost to Follow-up|3
6140478|NCT01030666|9772552|FG001|Overall Study|Lost to Follow-up|2
6140479|NCT01030718|9772562|FG000|Studies CA180-031 and -036 Combined|Insufficient effect|1
6140480|NCT01030718|9772563|FG001|Studies CA180-031 and -036 Combined|Insufficient effect|1
6140481|NCT01030718|9772564|FG002|Studies CA180-031 and -036 Combined|Insufficient effect|11
6140482|NCT01030718|9772562|FG000|Studies CA180-031 and -036 Combined|Adverse Event|3
6140483|NCT01030718|9772563|FG001|Studies CA180-031 and -036 Combined|Adverse Event|5
6140484|NCT01030718|9772564|FG002|Studies CA180-031 and -036 Combined|Adverse Event|1
6140485|NCT01030718|9772562|FG000|Studies CA180-031 and -036 Combined|Death|0
6140486|NCT01030718|9772563|FG001|Studies CA180-031 and -036 Combined|Death|1
6140487|NCT01030718|9772564|FG002|Studies CA180-031 and -036 Combined|Death|0
6140488|NCT01030718|9772562|FG000|Studies CA180-031 and -036 Combined|other reasons|0
6140489|NCT01030718|9772563|FG001|Studies CA180-031 and -036 Combined|other reasons|2
6140490|NCT01030718|9772564|FG002|Studies CA180-031 and -036 Combined|other reasons|0
6140491|NCT01030718|9772562|FG000|Study CA180-036 Only|insufficient effect|1
6140492|NCT01030718|9772563|FG001|Study CA180-036 Only|insufficient effect|1
6140493|NCT01030718|9772564|FG002|Study CA180-036 Only|insufficient effect|5
6140494|NCT01030718|9772562|FG000|Study CA180-036 Only|Adverse Event|2
6140495|NCT01030718|9772563|FG001|Study CA180-036 Only|Adverse Event|3
6140496|NCT01030718|9772564|FG002|Study CA180-036 Only|Adverse Event|0
6140497|NCT01030718|9772562|FG000|Study CA180-036 Only|Death|0
6140498|NCT01030718|9772563|FG001|Study CA180-036 Only|Death|1
6140499|NCT01030718|9772564|FG002|Study CA180-036 Only|Death|0
6140500|NCT01030718|9772562|FG000|Study CA180-036 Only|Other Reasons|0
6140501|NCT01030718|9772563|FG001|Study CA180-036 Only|Other Reasons|2
6140502|NCT01030718|9772564|FG002|Study CA180-036 Only|Other Reasons|0
6140503|NCT01030822|9772594|FG000|Overall Study|Moved/migrated from study area|6
6140504|NCT01030822|9772595|FG001|Overall Study|Moved/migrated from study area|7
6140505|NCT01030822|9772596|FG002|Overall Study|Moved/migrated from study area|3
6140506|NCT01030822|9772594|FG000|Overall Study|Withdrawal by Subject|16
6140507|NCT01030822|9772595|FG001|Overall Study|Withdrawal by Subject|13
6140508|NCT01030822|9772596|FG002|Overall Study|Withdrawal by Subject|16
6140509|NCT01030822|9772594|FG000|Overall Study|Lost to Follow-up|9
6140510|NCT01030822|9772595|FG001|Overall Study|Lost to Follow-up|4
6140511|NCT01030822|9772596|FG002|Overall Study|Lost to Follow-up|7
6140512|NCT01030874|9772616|FG000|Overall Study|Withdrawal by Subject|1
6140513|NCT01030874|9772617|FG001|Overall Study|Withdrawal by Subject|0
6140514|NCT01030874|9772616|FG000|Overall Study|Discharged in first 2 weeks|17
6140515|NCT01030874|9772617|FG001|Overall Study|Discharged in first 2 weeks|16
6140516|NCT01030952|9772625|FG000|Overall Study|Protocol Violation|0
6140517|NCT01030952|9772626|FG001|Overall Study|Protocol Violation|1
6140518|NCT01030952|9772625|FG000|Overall Study|Informed consent withdrawal|1
6140519|NCT01030952|9772626|FG001|Overall Study|Informed consent withdrawal|0
6140520|NCT01030952|9772625|FG000|Overall Study|Lost to Follow-up|0
6140521|NCT01030952|9772626|FG001|Overall Study|Lost to Follow-up|1
6140522|NCT01030952|9772625|FG000|Overall Study|Unexplained|1
6140523|NCT01030952|9772626|FG001|Overall Study|Unexplained|1
6140524|NCT01030965|9772638|FG000|Overall Study|Lack of Efficacy|3
6140525|NCT01030965|9772639|FG001|Overall Study|Lack of Efficacy|2
6140526|NCT01030965|9772640|FG002|Overall Study|Lack of Efficacy|0
6140527|NCT01030965|9772641|FG003|Overall Study|Lack of Efficacy|3
6140528|NCT01030965|9772638|FG000|Overall Study|Protocol Violation|1
6140529|NCT01030965|9772639|FG001|Overall Study|Protocol Violation|1
6140530|NCT01030965|9772640|FG002|Overall Study|Protocol Violation|1
6140531|NCT01030965|9772641|FG003|Overall Study|Protocol Violation|1
6140532|NCT01030965|9772638|FG000|Overall Study|Adverse Event|0
6140533|NCT01030965|9772639|FG001|Overall Study|Adverse Event|1
6140534|NCT01030965|9772640|FG002|Overall Study|Adverse Event|2
6140535|NCT01030965|9772641|FG003|Overall Study|Adverse Event|1
6140536|NCT01030965|9772638|FG000|Overall Study|Protocol-defined Stopping Criteria|0
6140537|NCT01030965|9772639|FG001|Overall Study|Protocol-defined Stopping Criteria|1
6140538|NCT01030965|9772640|FG002|Overall Study|Protocol-defined Stopping Criteria|1
6140539|NCT01030965|9772641|FG003|Overall Study|Protocol-defined Stopping Criteria|0
6140540|NCT01030965|9772638|FG000|Overall Study|Withdrawal by Subject|0
6140541|NCT01030965|9772639|FG001|Overall Study|Withdrawal by Subject|1
6140542|NCT01030965|9772640|FG002|Overall Study|Withdrawal by Subject|0
6140543|NCT01030965|9772641|FG003|Overall Study|Withdrawal by Subject|2
6140544|NCT01031004|9772653|FG000|Overall Study|Protocol Violation|0
6140545|NCT01031004|9772654|FG001|Overall Study|Protocol Violation|1
6140546|NCT01031004|9772653|FG000|Overall Study|Lost to Follow-up|1
6140547|NCT01031004|9772654|FG001|Overall Study|Lost to Follow-up|0
6140548|NCT01031069|9772668|FG000|Overall Study|Serious Adverse Event|0
6140549|NCT01031069|9772669|FG001|Overall Study|Serious Adverse Event|1
6140550|NCT01031069|9772670|FG002|Overall Study|Serious Adverse Event|0
6140551|NCT01031069|9772671|FG003|Overall Study|Serious Adverse Event|0
6140552|NCT01031069|9772668|FG000|Overall Study|Withdrawal by Subject|2
6140553|NCT01031069|9772669|FG001|Overall Study|Withdrawal by Subject|3
6140554|NCT01031069|9772670|FG002|Overall Study|Withdrawal by Subject|18
6140555|NCT01031069|9772671|FG003|Overall Study|Withdrawal by Subject|18
6140556|NCT01031069|9772668|FG000|Overall Study|Migrated/moved from study area|1
6140557|NCT01031069|9772669|FG001|Overall Study|Migrated/moved from study area|2
6140558|NCT01031069|9772670|FG002|Overall Study|Migrated/moved from study area|1
6140559|NCT01031069|9772671|FG003|Overall Study|Migrated/moved from study area|1
6140560|NCT01031069|9772668|FG000|Overall Study|Lost to Follow-up|9
6140561|NCT01031069|9772669|FG001|Overall Study|Lost to Follow-up|5
6140562|NCT01031069|9772670|FG002|Overall Study|Lost to Follow-up|21
6140563|NCT01031069|9772671|FG003|Overall Study|Lost to Follow-up|15
6140564|NCT01031069|9772668|FG000|Overall Study|Other|0
6140565|NCT01031069|9772669|FG001|Overall Study|Other|0
6140566|NCT01031069|9772670|FG002|Overall Study|Other|1
6140567|NCT01031069|9772671|FG003|Overall Study|Other|0
6140568|NCT01031381|9772701|FG000|Overall Study|Physician Decision|3
6140569|NCT01031381|9772701|FG000|Overall Study|Withdrawal by Subject|6
6140570|NCT01031446|9772710|FG000|Overall Study|Disease Progression|38
6140571|NCT01031446|9772710|FG000|Overall Study|Adverse Event|9
6140572|NCT01031446|9772710|FG000|Overall Study|Physician Decision|4
6140573|NCT01031446|9772710|FG000|Overall Study|Withdrawal by Subject|3
6140574|NCT01031446|9772710|FG000|Overall Study|Still on treatment|1
6140575|NCT01031537|9772729|FG000|Overall Study|medical reasons not related to study|3
6140576|NCT01031537|9772729|FG000|Overall Study|Lack of Efficacy|1
6140577|NCT01031537|9772729|FG000|Overall Study|retired from NIH, met exclusion criteria|1
6140578|NCT01031537|9772729|FG000|Overall Study|moved, met exclusion criteria|10
6140579|NCT01031537|9772729|FG000|Overall Study|Withdrawal by Subject|5
6140580|NCT01031537|9772729|FG000|Overall Study|PI removal, no longer met eligibility|12
6140581|NCT01031680|9772735|FG000|Overall Study|Adverse Event|8
6140582|NCT01031680|9772736|FG001|Overall Study|Adverse Event|3
6140583|NCT01031680|9772735|FG000|Overall Study|Lost to Follow-up|2
6140584|NCT01031680|9772736|FG001|Overall Study|Lost to Follow-up|10
6140585|NCT01031680|9772735|FG000|Overall Study|Withdrawal by Subject|12
6140586|NCT01031680|9772736|FG001|Overall Study|Withdrawal by Subject|16
6140587|NCT01031680|9772735|FG000|Overall Study|Death|2
6140588|NCT01031680|9772736|FG001|Overall Study|Death|1
6140589|NCT01031680|9772735|FG000|Overall Study|Subject No Longer Meets Study Criteria|26
6140590|NCT01031680|9772736|FG001|Overall Study|Subject No Longer Meets Study Criteria|17
6140591|NCT01031680|9772735|FG000|Overall Study|Poor/Non-compliance|5
6140592|NCT01031680|9772736|FG001|Overall Study|Poor/Non-compliance|6
6140593|NCT01031680|9772735|FG000|Overall Study|Safety|1
6140594|NCT01031680|9772736|FG001|Overall Study|Safety|0
6140595|NCT01031680|9772735|FG000|Overall Study|Incorrect Enrolment|1
5982751|NCT01896531|9571637|FG000|Overall Study|Death|57
5982752|NCT01896531|9571638|FG001|Overall Study|Death|59
5982753|NCT01896531|9571637|FG000|Overall Study|Lost to Follow-up|3
5982754|NCT01896531|9571638|FG001|Overall Study|Lost to Follow-up|0
5982755|NCT01896531|9571637|FG000|Overall Study|Non-compliance|0
5982756|NCT01896531|9571638|FG001|Overall Study|Non-compliance|1
5982757|NCT01896531|9571637|FG000|Overall Study|Study Ended by Sponsor|7
5982758|NCT01896531|9571638|FG001|Overall Study|Study Ended by Sponsor|20
5982759|NCT01896531|9571637|FG000|Overall Study|Withdrawal by Subject|3
5982760|NCT01896531|9571638|FG001|Overall Study|Withdrawal by Subject|2
5982761|NCT01896531|9571637|FG000|Overall Study|Death Prior to Treatment|1
5982762|NCT01896531|9571638|FG001|Overall Study|Death Prior to Treatment|0
5982763|NCT01864603|9571646|FG000|Stage 2|DSMB design modification|86056
5982764|NCT01864603|9571647|FG001|Stage 2|DSMB design modification|92558
6140596|NCT01031680|9772736|FG001|Overall Study|Incorrect Enrolment|2
6140597|NCT01031680|9772735|FG000|Overall Study|Administrative Reason by Sponsor|0
6140598|NCT01031680|9772736|FG001|Overall Study|Administrative Reason by Sponsor|1
6140599|NCT01031680|9772735|FG000|Overall Study|Various|0
6140600|NCT01031680|9772736|FG001|Overall Study|Various|2
6140601|NCT01031706|9772744|FG000|Overall Study|Adverse Event|1
6140602|NCT01031706|9772745|FG001|Overall Study|Adverse Event|0
6140603|NCT01031706|9772744|FG000|Overall Study|Withdrawal by Subject|1
6140604|NCT01031706|9772745|FG001|Overall Study|Withdrawal by Subject|1
6140605|NCT01031836|9772763|FG000|Stage I|Adverse Event|1
6140606|NCT01031836|9772764|FG001|Stage I|Adverse Event|1
6140607|NCT01031836|9772765|FG002|Stage I|Adverse Event|0
6140608|NCT01031836|9772766|FG003|Stage I|Adverse Event|0
6140609|NCT01031836|9772767|FG004|Stage I|Adverse Event|0
6140610|NCT01031836|9772768|FG005|Stage I|Adverse Event|0
6140611|NCT01031836|9772763|FG000|Stage I|Other|0
6140612|NCT01031836|9772764|FG001|Stage I|Other|1
6140613|NCT01031836|9772765|FG002|Stage I|Other|0
6140614|NCT01031836|9772766|FG003|Stage I|Other|0
6140615|NCT01031836|9772767|FG004|Stage I|Other|0
6140616|NCT01031836|9772768|FG005|Stage I|Other|1
6140617|NCT01031836|9772763|FG000|Stage II|Adverse Event|0
6140618|NCT01031836|9772764|FG001|Stage II|Adverse Event|0
6140619|NCT01031836|9772765|FG002|Stage II|Adverse Event|2
6140620|NCT01031836|9772766|FG003|Stage II|Adverse Event|2
6140621|NCT01031836|9772767|FG004|Stage II|Adverse Event|1
6140622|NCT01031836|9772768|FG005|Stage II|Adverse Event|1
6140623|NCT01031836|9772763|FG000|Stage II|Other|2
6140624|NCT01031836|9772764|FG001|Stage II|Other|0
6140625|NCT01031836|9772765|FG002|Stage II|Other|0
6140626|NCT01031836|9772766|FG003|Stage II|Other|1
6140627|NCT01031836|9772767|FG004|Stage II|Other|1
6140628|NCT01031836|9772768|FG005|Stage II|Other|0
6140629|NCT01031979|9772798|FG000|Overall Study|Lost to Follow-up|5
6140630|NCT01031979|9772799|FG001|Overall Study|Lost to Follow-up|4
6140631|NCT01032018|9772807|FG000|Overall Study|Lost to Follow-up|6
6140632|NCT01032018|9772808|FG001|Overall Study|Lost to Follow-up|5
6140633|NCT01032018|9772807|FG000|Overall Study|Death|0
6140634|NCT01032018|9772808|FG001|Overall Study|Death|1
6140635|NCT01032044|9772816|FG000|Overall Study|Protocol Violation|14
6140636|NCT01032044|9772817|FG001|Overall Study|Protocol Violation|8
6140637|NCT01032044|9772816|FG000|Overall Study|Adverse Event|0
6140638|NCT01032044|9772817|FG001|Overall Study|Adverse Event|1
6140639|NCT01032044|9772816|FG000|Overall Study|Lost to Follow-up|11
6140640|NCT01032044|9772817|FG001|Overall Study|Lost to Follow-up|11
6140641|NCT01032070|9772825|FG000|Overall Study|Disease progression|13
6140642|NCT01032070|9772826|FG001|Overall Study|Disease progression|8
6140643|NCT01032070|9772825|FG000|Overall Study|Medical or ethical reasons|0
6140644|NCT01032070|9772826|FG001|Overall Study|Medical or ethical reasons|2
6140645|NCT01032070|9772825|FG000|Overall Study|Withdrawal by Subject|0
6140646|NCT01032070|9772826|FG001|Overall Study|Withdrawal by Subject|2
6140647|NCT01032174|9772859|FG000|Overall Study|Adverse Event|0
6140648|NCT01032174|9772860|FG001|Overall Study|Adverse Event|1
6140649|NCT01032200|9772868|FG000|Overall Study|Death|1
6140650|NCT01032200|9772869|FG001|Overall Study|Death|1
6140651|NCT01032200|9772868|FG000|Overall Study|Withdrawal by Subject|1
6140652|NCT01032200|9772869|FG001|Overall Study|Withdrawal by Subject|3
6140653|NCT01032200|9772868|FG000|Overall Study|Toxicity|0
6140654|NCT01032200|9772869|FG001|Overall Study|Toxicity|2
6140655|NCT01032200|9772868|FG000|Overall Study|Progression|1
6140656|NCT01032200|9772869|FG001|Overall Study|Progression|0
6140657|NCT01032200|9772868|FG000|Overall Study|Multiple|1
6140658|NCT01032200|9772869|FG001|Overall Study|Multiple|1
6140659|NCT01032239|9772877|FG000|Overall Study|Lost to Follow-up|3
6140660|NCT01032239|9772878|FG001|Overall Study|Lost to Follow-up|2
6140661|NCT01032239|9772877|FG000|Overall Study|Withdrawal by Subject|2
6140662|NCT01032239|9772878|FG001|Overall Study|Withdrawal by Subject|3
6140663|NCT01032239|9772877|FG000|Overall Study|Death|1
6140664|NCT01032239|9772878|FG001|Overall Study|Death|0
6140665|NCT01032239|9772877|FG000|Overall Study|Protocol Violation|1
6140666|NCT01032239|9772878|FG001|Overall Study|Protocol Violation|0
6140667|NCT01032291|9772887|FG000|Safety Lead-in|Adverse Event|1
6140668|NCT01032291|9772888|FG001|Safety Lead-in|Adverse Event|0
6140669|NCT01032291|9772889|FG002|Safety Lead-in|Adverse Event|0
6140670|NCT01032291|9772887|FG000|Safety Lead-in|Death|1
6140671|NCT01032291|9772888|FG001|Safety Lead-in|Death|0
6140672|NCT01032291|9772889|FG002|Safety Lead-in|Death|0
6140673|NCT01032291|9772887|FG000|Proof of Concept|Adverse Event|0
6140674|NCT01032291|9772888|FG001|Proof of Concept|Adverse Event|5
6140675|NCT01032291|9772889|FG002|Proof of Concept|Adverse Event|1
6140676|NCT01032291|9772887|FG000|Proof of Concept|Death|0
6140677|NCT01032291|9772888|FG001|Proof of Concept|Death|1
6140678|NCT01032291|9772889|FG002|Proof of Concept|Death|2
6140679|NCT01032291|9772887|FG000|Proof of Concept|Lack of Efficacy|0
6140680|NCT01032291|9772888|FG001|Proof of Concept|Lack of Efficacy|1
6140681|NCT01032291|9772889|FG002|Proof of Concept|Lack of Efficacy|0
6140682|NCT01032291|9772887|FG000|Proof of Concept|Never Received Study Drug|0
6140683|NCT01032291|9772888|FG001|Proof of Concept|Never Received Study Drug|1
6140684|NCT01032291|9772889|FG002|Proof of Concept|Never Received Study Drug|0
6140685|NCT01032382|9772927|FG000|Overall Study|Disease dissemination|1
6140686|NCT01032382|9772928|FG001|Overall Study|Disease dissemination|1
6140687|NCT01032382|9772927|FG000|Overall Study|Treatment failure|3
6140688|NCT01032382|9772928|FG001|Overall Study|Treatment failure|1
6140689|NCT01032382|9772927|FG000|Overall Study|Index lesion relapse|1
6140690|NCT01032382|9772928|FG001|Overall Study|Index lesion relapse|3
6140691|NCT01032629|9772943|FG000|Overall Study|Closed Site|21
6140692|NCT01032629|9772944|FG001|Overall Study|Closed Site|18
6140693|NCT01032629|9772945|FG002|Overall Study|Closed Site|16
6140694|NCT01032629|9772943|FG000|Overall Study|Withdrawal by Subject|50
6140695|NCT01032629|9772944|FG001|Overall Study|Withdrawal by Subject|36
6140696|NCT01032629|9772945|FG002|Overall Study|Withdrawal by Subject|35
6140697|NCT01032629|9772943|FG000|Overall Study|Lost to Follow-up|74
6140698|NCT01032629|9772944|FG001|Overall Study|Lost to Follow-up|47
6140699|NCT01032629|9772945|FG002|Overall Study|Lost to Follow-up|37
6140700|NCT01032837|9772986|FG000|Overall Study|Adverse event/internal illness|0
6140701|NCT01032837|9772987|FG001|Overall Study|Adverse event/internal illness|1
6140702|NCT01032837|9772988|FG002|Overall Study|Adverse event/internal illness|0
6140703|NCT01032837|9772989|FG003|Overall Study|Adverse event/internal illness|1
6140704|NCT01032837|9772986|FG000|Overall Study|Withdrew consent|0
6140705|NCT01032837|9772987|FG001|Overall Study|Withdrew consent|2
6140706|NCT01032837|9772988|FG002|Overall Study|Withdrew consent|0
6140707|NCT01032837|9772989|FG003|Overall Study|Withdrew consent|1
6140708|NCT01032837|9772986|FG000|Overall Study|Failed to return|0
6140709|NCT01032837|9772987|FG001|Overall Study|Failed to return|0
6140710|NCT01032837|9772988|FG002|Overall Study|Failed to return|1
6140711|NCT01032837|9772989|FG003|Overall Study|Failed to return|0
6140712|NCT01032837|9772986|FG000|Overall Study|Refused treatment|0
6140713|NCT01032837|9772987|FG001|Overall Study|Refused treatment|0
6140714|NCT01032837|9772988|FG002|Overall Study|Refused treatment|0
6140715|NCT01032837|9772989|FG003|Overall Study|Refused treatment|1
6140716|NCT01032889|9773006|FG000|Overall Study|Adverse Event|2
6140717|NCT01032889|9773007|FG001|Overall Study|Adverse Event|2
6140718|NCT01032889|9773008|FG002|Overall Study|Adverse Event|0
6140719|NCT01032889|9773006|FG000|Overall Study|Withdrawal of Consent|1
6140720|NCT01032889|9773007|FG001|Overall Study|Withdrawal of Consent|2
6140721|NCT01032889|9773008|FG002|Overall Study|Withdrawal of Consent|1
6140722|NCT01032889|9773006|FG000|Overall Study|Patient Request|0
6140723|NCT01032889|9773007|FG001|Overall Study|Patient Request|1
6140724|NCT01032889|9773008|FG002|Overall Study|Patient Request|0
6140725|NCT01032889|9773006|FG000|Overall Study|Lost to Follow-up|1
6140726|NCT01032889|9773007|FG001|Overall Study|Lost to Follow-up|1
6140727|NCT01032889|9773008|FG002|Overall Study|Lost to Follow-up|0
6140728|NCT01032889|9773006|FG000|Overall Study|Lack of Submental Fat|2
6140729|NCT01032889|9773007|FG001|Overall Study|Lack of Submental Fat|8
6140730|NCT01032889|9773008|FG002|Overall Study|Lack of Submental Fat|1
6140731|NCT01032889|9773006|FG000|Overall Study|Miscellaneous Reasons|2
6140732|NCT01032889|9773007|FG001|Overall Study|Miscellaneous Reasons|1
6140733|NCT01032889|9773008|FG002|Overall Study|Miscellaneous Reasons|1
6140734|NCT01032915|9773020|FG000|Overall Study|Adverse Event|2
6140735|NCT01032915|9773021|FG001|Overall Study|Adverse Event|2
6140736|NCT01032915|9773022|FG002|Overall Study|Adverse Event|1
6140737|NCT01032915|9773023|FG003|Overall Study|Adverse Event|1
6140738|NCT01032915|9773020|FG000|Overall Study|Abnormal test procedure result|0
6140739|NCT01032915|9773021|FG001|Overall Study|Abnormal test procedure result|0
6140740|NCT01032915|9773022|FG002|Overall Study|Abnormal test procedure result|1
6140741|NCT01032915|9773023|FG003|Overall Study|Abnormal test procedure result|0
6140742|NCT01032915|9773020|FG000|Overall Study|Withdrawal by Subject|0
6140743|NCT01032915|9773021|FG001|Overall Study|Withdrawal by Subject|3
6140744|NCT01032915|9773022|FG002|Overall Study|Withdrawal by Subject|1
6140745|NCT01032915|9773023|FG003|Overall Study|Withdrawal by Subject|1
6140746|NCT01032915|9773020|FG000|Overall Study|Administrative reasons|5
6140747|NCT01032915|9773021|FG001|Overall Study|Administrative reasons|6
6140748|NCT01032915|9773022|FG002|Overall Study|Administrative reasons|4
6140749|NCT01032915|9773023|FG003|Overall Study|Administrative reasons|4
6140750|NCT01032915|9773020|FG000|Overall Study|Protocol Violation|1
6140751|NCT01032915|9773021|FG001|Overall Study|Protocol Violation|0
6140752|NCT01032915|9773022|FG002|Overall Study|Protocol Violation|0
6140753|NCT01032915|9773023|FG003|Overall Study|Protocol Violation|1
6140754|NCT01033019|9773065|FG000|Overall Study|Withdrawal by Subject|1
6140755|NCT01033019|9773066|FG001|Overall Study|Withdrawal by Subject|0
6140756|NCT01033071|9773076|FG000|Overall Study|Adverse Event|28
6140757|NCT01033071|9773077|FG001|Overall Study|Adverse Event|51
6140758|NCT01033071|9773078|FG002|Overall Study|Adverse Event|26
6140759|NCT01033071|9773076|FG000|Overall Study|Protocol Violation|0
6140760|NCT01033071|9773077|FG001|Overall Study|Protocol Violation|2
6140761|NCT01033071|9773078|FG002|Overall Study|Protocol Violation|1
6140762|NCT01033071|9773076|FG000|Overall Study|Lost to Follow-up|4
6140763|NCT01033071|9773077|FG001|Overall Study|Lost to Follow-up|5
6140764|NCT01033071|9773078|FG002|Overall Study|Lost to Follow-up|5
6140765|NCT01033071|9773076|FG000|Overall Study|Withdrawal by Subject|17
6140766|NCT01033071|9773077|FG001|Overall Study|Withdrawal by Subject|14
6140767|NCT01033071|9773078|FG002|Overall Study|Withdrawal by Subject|11
6140768|NCT01033071|9773076|FG000|Overall Study|Lack of Efficacy|0
6140769|NCT01033071|9773077|FG001|Overall Study|Lack of Efficacy|1
6140770|NCT01033071|9773078|FG002|Overall Study|Lack of Efficacy|1
6140771|NCT01033071|9773076|FG000|Overall Study|Other|6
6140772|NCT01033071|9773077|FG001|Overall Study|Other|4
6140773|NCT01033071|9773078|FG002|Overall Study|Other|3
6140774|NCT01033136|9773088|FG000|Follow-Up (3 Month)|Lost to Follow-up|2
6140775|NCT01033136|9773089|FG001|Follow-Up (3 Month)|Lost to Follow-up|2
6140776|NCT01033240|9773111|FG000|Overall Study|Serious Adverse Event (SAE) or Adverse Event|10
6140777|NCT01033240|9773112|FG001|Overall Study|Serious Adverse Event (SAE) or Adverse Event|8
6140778|NCT01033240|9773113|FG002|Overall Study|Serious Adverse Event (SAE) or Adverse Event|6
6140779|NCT01033240|9773111|FG000|Overall Study|Death|2
6140780|NCT01033240|9773112|FG001|Overall Study|Death|0
6140781|NCT01033240|9773113|FG002|Overall Study|Death|0
6140782|NCT01033240|9773111|FG000|Overall Study|Withdrew Consent|2
6140783|NCT01033240|9773112|FG001|Overall Study|Withdrew Consent|9
6140784|NCT01033240|9773113|FG002|Overall Study|Withdrew Consent|2
6140785|NCT01033240|9773111|FG000|Overall Study|Disease Progression|35
6140786|NCT01033240|9773112|FG001|Overall Study|Disease Progression|32
6140787|NCT01033240|9773113|FG002|Overall Study|Disease Progression|41
6140788|NCT01033240|9773111|FG000|Overall Study|Investigator Discretion|0
6140789|NCT01033240|9773112|FG001|Overall Study|Investigator Discretion|0
6140790|NCT01033240|9773113|FG002|Overall Study|Investigator Discretion|2
6140791|NCT01033240|9773111|FG000|Overall Study|Other|0
6140792|NCT01033240|9773112|FG001|Overall Study|Other|1
6140793|NCT01033240|9773113|FG002|Overall Study|Other|2
6140794|NCT01033448|9773151|FG000|Overall Study|Withdrawal by Subject|4
6140795|NCT01033448|9773151|FG000|Overall Study|Positive HCV-RNA at week 48|1
6140796|NCT01033448|9773151|FG000|Overall Study|Lost to Follow-up|3
6140797|NCT01033448|9773151|FG000|Overall Study|Withdrew due to other reasons|3
6140798|NCT01033448|9773151|FG000|Overall Study|Unknown disposition|1
6140799|NCT01033487|9773157|FG000|Fourth Intervention Period|Adverse Event|0
6140800|NCT01033487|9773158|FG001|Fourth Intervention Period|Adverse Event|0
6140801|NCT01033487|9773159|FG002|Fourth Intervention Period|Adverse Event|0
6140802|NCT01033487|9773160|FG003|Fourth Intervention Period|Adverse Event|0
6140803|NCT01033487|9773161|FG004|Fourth Intervention Period|Adverse Event|0
6140804|NCT01033487|9773162|FG005|Fourth Intervention Period|Adverse Event|0
6140805|NCT01033487|9773163|FG006|Fourth Intervention Period|Adverse Event|0
6140806|NCT01033487|9773164|FG007|Fourth Intervention Period|Adverse Event|0
6140807|NCT01033487|9773165|FG008|Fourth Intervention Period|Adverse Event|1
6140808|NCT01033487|9773166|FG009|Fourth Intervention Period|Adverse Event|0
6140809|NCT01033643|9773189|FG000|Overall Study|Withdrew Consent|0
6140810|NCT01033643|9773190|FG001|Overall Study|Withdrew Consent|3
6140811|NCT01033643|9773191|FG002|Overall Study|Withdrew Consent|0
6140812|NCT01033643|9773192|FG003|Overall Study|Withdrew Consent|0
6140813|NCT01033643|9773193|FG004|Overall Study|Withdrew Consent|0
6140814|NCT01033643|9773194|FG005|Overall Study|Withdrew Consent|1
6140815|NCT01033734|9773208|FG000|Overall Study|Withdrawal by Subject|1
6140816|NCT01033747|9773223|FG000|Overall Study|Adverse Event|9
6140817|NCT01033747|9773224|FG001|Overall Study|Adverse Event|4
6140818|NCT01033747|9773223|FG000|Overall Study|Abnormal Laboratory Value|1
6140819|NCT01033747|9773224|FG001|Overall Study|Abnormal Laboratory Value|0
6140820|NCT01033747|9773223|FG000|Overall Study|Abnormal test procedure|0
6140821|NCT01033747|9773224|FG001|Overall Study|Abnormal test procedure|1
6140822|NCT01033747|9773223|FG000|Overall Study|Unsatisfactory therapeutic effect|14
6140823|NCT01033747|9773224|FG001|Overall Study|Unsatisfactory therapeutic effect|4
6140824|NCT01033747|9773223|FG000|Overall Study|Protocol Violation|1
6140825|NCT01033747|9773224|FG001|Overall Study|Protocol Violation|0
6140826|NCT01033747|9773223|FG000|Overall Study|Withdrawal by Subject|9
6140827|NCT01033747|9773224|FG001|Overall Study|Withdrawal by Subject|6
6140828|NCT01033747|9773223|FG000|Overall Study|Stopped at end of prolongation visit 1|1
6140829|NCT01033747|9773224|FG001|Overall Study|Stopped at end of prolongation visit 1|0
6140830|NCT01033747|9773223|FG000|Overall Study|Stopped at end of Extension 1|2
6140831|NCT01033747|9773224|FG001|Overall Study|Stopped at end of Extension 1|0
6140832|NCT01033825|9773241|FG000|Overall Study|Withdrawal by Subject|2
6140833|NCT01033825|9773242|FG001|Overall Study|Withdrawal by Subject|3
6140834|NCT01033825|9773243|FG002|Overall Study|Withdrawal by Subject|2
6140835|NCT01033825|9773244|FG003|Overall Study|Withdrawal by Subject|1
6140836|NCT01033825|9773245|FG004|Overall Study|Withdrawal by Subject|1
6140837|NCT01033825|9773246|FG005|Overall Study|Withdrawal by Subject|0
6140838|NCT01033825|9773247|FG006|Overall Study|Withdrawal by Subject|0
6140839|NCT01033825|9773241|FG000|Overall Study|Adverse Event|0
6140840|NCT01033825|9773242|FG001|Overall Study|Adverse Event|0
6140841|NCT01033825|9773243|FG002|Overall Study|Adverse Event|0
6140842|NCT01033825|9773244|FG003|Overall Study|Adverse Event|1
6140843|NCT01033825|9773245|FG004|Overall Study|Adverse Event|0
6140844|NCT01033825|9773246|FG005|Overall Study|Adverse Event|0
6140845|NCT01033825|9773247|FG006|Overall Study|Adverse Event|0
6140846|NCT01033825|9773241|FG000|Overall Study|Protocol Violation|1
6140847|NCT01033825|9773242|FG001|Overall Study|Protocol Violation|0
6140848|NCT01033825|9773243|FG002|Overall Study|Protocol Violation|0
6140849|NCT01033825|9773244|FG003|Overall Study|Protocol Violation|0
6140850|NCT01033825|9773245|FG004|Overall Study|Protocol Violation|0
6140851|NCT01033825|9773246|FG005|Overall Study|Protocol Violation|0
6140852|NCT01033825|9773247|FG006|Overall Study|Protocol Violation|0
6140853|NCT01033825|9773241|FG000|Overall Study|Other|0
6140854|NCT01033825|9773242|FG001|Overall Study|Other|0
6140855|NCT01033825|9773243|FG002|Overall Study|Other|0
6140856|NCT01033825|9773244|FG003|Overall Study|Other|0
6140857|NCT01033825|9773245|FG004|Overall Study|Other|1
6140858|NCT01033825|9773246|FG005|Overall Study|Other|0
6140859|NCT01033825|9773247|FG006|Overall Study|Other|0
6140860|NCT01033851|9773267|FG000|Overall Study|Withdrawal by Subject|3
6140861|NCT01033851|9773268|FG001|Overall Study|Withdrawal by Subject|7
6140862|NCT01033942|9773286|FG000|Overall Study|Withdrawal by Subject|1
6140863|NCT01033942|9773287|FG001|Overall Study|Withdrawal by Subject|1
6140864|NCT01033942|9773288|FG002|Overall Study|Withdrawal by Subject|1
6140865|NCT01033942|9773286|FG000|Overall Study|Lost to Follow-up|1
6140866|NCT01033942|9773287|FG001|Overall Study|Lost to Follow-up|0
6140867|NCT01033942|9773288|FG002|Overall Study|Lost to Follow-up|0
6140868|NCT01033942|9773286|FG000|Overall Study|Enrolled in Extension Study|0
6140869|NCT01033942|9773287|FG001|Overall Study|Enrolled in Extension Study|3
6140870|NCT01033942|9773288|FG002|Overall Study|Enrolled in Extension Study|0
6140871|NCT01034137|9773305|FG000|Overall Study|Adverse Event|9
6140872|NCT01034137|9773306|FG001|Overall Study|Adverse Event|10
6140873|NCT01034137|9773307|FG002|Overall Study|Adverse Event|8
6140874|NCT01034137|9773305|FG000|Overall Study|Withdrawal by Subject|4
6140875|NCT01034137|9773306|FG001|Overall Study|Withdrawal by Subject|3
6140876|NCT01034137|9773307|FG002|Overall Study|Withdrawal by Subject|3
6140877|NCT01034137|9773305|FG000|Overall Study|Lack of Efficacy|9
6140878|NCT01034137|9773306|FG001|Overall Study|Lack of Efficacy|4
6140879|NCT01034137|9773307|FG002|Overall Study|Lack of Efficacy|13
6140880|NCT01034137|9773305|FG000|Overall Study|Protocol Violation|2
6140881|NCT01034137|9773306|FG001|Overall Study|Protocol Violation|2
6140882|NCT01034137|9773307|FG002|Overall Study|Protocol Violation|1
6140883|NCT01034137|9773305|FG000|Overall Study|Refused treatment or did not cooperate|2
6140884|NCT01034137|9773306|FG001|Overall Study|Refused treatment or did not cooperate|0
6140885|NCT01034137|9773307|FG002|Overall Study|Refused treatment or did not cooperate|1
6140886|NCT01034137|9773305|FG000|Overall Study|Administrative or other|2
6140887|NCT01034137|9773306|FG001|Overall Study|Administrative or other|3
6140888|NCT01034137|9773307|FG002|Overall Study|Administrative or other|4
6140889|NCT01034163|9773318|FG000|Overall Study|Treatment completed as per protocol|8
6140890|NCT01034163|9773319|FG001|Overall Study|Treatment completed as per protocol|7
6140891|NCT01034163|9773318|FG000|Overall Study|Withdrawal by Subject|8
6140892|NCT01034163|9773319|FG001|Overall Study|Withdrawal by Subject|2
6140893|NCT01034163|9773318|FG000|Overall Study|Protocol deviation|1
6140894|NCT01034163|9773319|FG001|Overall Study|Protocol deviation|0
6140895|NCT01034163|9773318|FG000|Overall Study|Disease progression|3
6140896|NCT01034163|9773319|FG001|Overall Study|Disease progression|4
6140897|NCT01034163|9773318|FG000|Overall Study|Adverse Event|6
6140898|NCT01034163|9773319|FG001|Overall Study|Adverse Event|0
6140899|NCT01034163|9773318|FG000|Overall Study|Administrative problems|0
6140900|NCT01034163|9773319|FG001|Overall Study|Administrative problems|1
6140901|NCT01034163|9773318|FG000|Overall Study|Abnormal laboratory value|1
6140902|NCT01034163|9773319|FG001|Overall Study|Abnormal laboratory value|0
6140903|NCT01034176|9773327|FG000|Overall Study|Physician Decision|2
6140904|NCT01034176|9773328|FG001|Overall Study|Physician Decision|0
6140905|NCT01034176|9773327|FG000|Overall Study|Withdrawal by Subject|0
6140906|NCT01034176|9773328|FG001|Overall Study|Withdrawal by Subject|1
6140907|NCT01034176|9773327|FG000|Overall Study|Lost to Follow-up|0
6140908|NCT01034176|9773328|FG001|Overall Study|Lost to Follow-up|1
6140909|NCT01034358|9773334|FG000|Overall Study|Withdrawal by Subject|1
6140910|NCT01034358|9773334|FG000|Overall Study|Protocol Violation|1
6140911|NCT01034397|9773340|FG000|Overall Study|Lack of compliance|0
6140912|NCT01034397|9773341|FG001|Overall Study|Lack of compliance|1
6140913|NCT01034397|9773340|FG000|Overall Study|Lack of Efficacy|3
6140914|NCT01034397|9773341|FG001|Overall Study|Lack of Efficacy|0
6140915|NCT01034397|9773340|FG000|Overall Study|Adverse Event|4
6140916|NCT01034397|9773341|FG001|Overall Study|Adverse Event|0
6140917|NCT01034397|9773340|FG000|Overall Study|Other|0
6140918|NCT01034397|9773341|FG001|Overall Study|Other|1
6140919|NCT01034462|9773358|FG000|Overall Study|Adverse Event|7
6140920|NCT01034462|9773359|FG001|Overall Study|Adverse Event|17
6140921|NCT01034462|9773358|FG000|Overall Study|Lack of Efficacy|4
6140922|NCT01034462|9773359|FG001|Overall Study|Lack of Efficacy|4
6140923|NCT01034462|9773358|FG000|Overall Study|Protocol Violation|10
6140924|NCT01034462|9773359|FG001|Overall Study|Protocol Violation|7
6140925|NCT01034462|9773358|FG000|Overall Study|Withdrawal by Subject|9
6140926|NCT01034462|9773359|FG001|Overall Study|Withdrawal by Subject|8
6140927|NCT01034462|9773358|FG000|Overall Study|Lost to Follow-up|14
6140928|NCT01034462|9773359|FG001|Overall Study|Lost to Follow-up|16
6140929|NCT01034462|9773358|FG000|Overall Study|Other reasons|1
6140930|NCT01034462|9773359|FG001|Overall Study|Other reasons|2
6140931|NCT01034540|9773378|FG000|Overall Study|Adverse Event|0
6140932|NCT01034540|9773379|FG001|Overall Study|Adverse Event|1
6140933|NCT01034631|9773423|FG000|Phase I|Symptomatic Deterioration before Treatme|3
6140934|NCT01034631|9773424|FG001|Phase I|Symptomatic Deterioration before Treatme|0
6140935|NCT01034631|9773425|FG002|Phase I|Symptomatic Deterioration before Treatme|0
6140936|NCT01034631|9773423|FG000|Phase II|Not Evaluable per protocol|0
6140937|NCT01034631|9773424|FG001|Phase II|Not Evaluable per protocol|0
6140938|NCT01034631|9773425|FG002|Phase II|Not Evaluable per protocol|2
6140939|NCT01034631|9773423|FG000|Phase II|Determined Ineligible per protocol|0
6140940|NCT01034631|9773424|FG001|Phase II|Determined Ineligible per protocol|1
6140941|NCT01034631|9773425|FG002|Phase II|Determined Ineligible per protocol|0
6140942|NCT01034657|9773435|FG000|Core Phase|Withdrawal by Subject|1
6140943|NCT01034657|9773436|FG001|Core Phase|Withdrawal by Subject|0
6140944|NCT01034657|9773437|FG002|Core Phase|Withdrawal by Subject|0
6140945|NCT01034657|9773435|FG000|Core Phase|Lack of Efficacy|2
6140946|NCT01034657|9773436|FG001|Core Phase|Lack of Efficacy|0
6140947|NCT01034657|9773437|FG002|Core Phase|Lack of Efficacy|0
6140948|NCT01034657|9773435|FG000|Core Phase|Abnormal laboratory value|1
6140949|NCT01034657|9773436|FG001|Core Phase|Abnormal laboratory value|0
6140950|NCT01034657|9773437|FG002|Core Phase|Abnormal laboratory value|0
6140951|NCT01034657|9773435|FG000|Core Phase|Adverse Event|8
6140952|NCT01034657|9773436|FG001|Core Phase|Adverse Event|0
6140953|NCT01034657|9773437|FG002|Core Phase|Adverse Event|0
6140954|NCT01034657|9773435|FG000|Core Phase|Protocol Violation|2
6140955|NCT01034657|9773436|FG001|Core Phase|Protocol Violation|0
6140956|NCT01034657|9773437|FG002|Core Phase|Protocol Violation|0
6140957|NCT01034657|9773435|FG000|Randomized Phase|Withdrawal by Subject|0
6140958|NCT01034657|9773436|FG001|Randomized Phase|Withdrawal by Subject|2
6140959|NCT01034657|9773437|FG002|Randomized Phase|Withdrawal by Subject|0
6140960|NCT01034657|9773435|FG000|Randomized Phase|Lack of Efficacy|5
6140961|NCT01034657|9773436|FG001|Randomized Phase|Lack of Efficacy|1
6140962|NCT01034657|9773437|FG002|Randomized Phase|Lack of Efficacy|0
6140963|NCT01034657|9773435|FG000|Randomized Phase|Abnormal laboratory value|0
6140964|NCT01034657|9773436|FG001|Randomized Phase|Abnormal laboratory value|1
6140965|NCT01034657|9773437|FG002|Randomized Phase|Abnormal laboratory value|0
6140966|NCT01034657|9773435|FG000|Randomized Phase|Adverse Event|0
6140967|NCT01034657|9773436|FG001|Randomized Phase|Adverse Event|2
6140968|NCT01034657|9773437|FG002|Randomized Phase|Adverse Event|1
6140969|NCT01034709|9773449|FG000|Overall Study|Protocol Violation|9
6140970|NCT01034709|9773450|FG001|Overall Study|Protocol Violation|16
6140971|NCT01035060|9773467|FG000|Overall Study|Lost to Follow-up|0
6140972|NCT01035060|9773468|FG001|Overall Study|Lost to Follow-up|7
6140973|NCT01035060|9773467|FG000|Overall Study|Did not quality after 2nd screening|14
6140974|NCT01035060|9773468|FG001|Overall Study|Did not quality after 2nd screening|1
6140975|NCT01035060|9773467|FG000|Overall Study|Withdrawal by Subject|8
6140976|NCT01035060|9773468|FG001|Overall Study|Withdrawal by Subject|6
6140977|NCT01035060|9773467|FG000|Overall Study|Physician Decision|2
6140978|NCT01035060|9773468|FG001|Overall Study|Physician Decision|0
6140979|NCT01035138|9773487|FG000|Overall Study|Adverse Event|4
6140980|NCT01035138|9773488|FG001|Overall Study|Adverse Event|0
6140981|NCT01035138|9773489|FG002|Overall Study|Adverse Event|2
6140982|NCT01035138|9773487|FG000|Overall Study|Caregiver Decision|2
6140983|NCT01035138|9773488|FG001|Overall Study|Caregiver Decision|0
6140984|NCT01035138|9773489|FG002|Overall Study|Caregiver Decision|1
6140985|NCT01035138|9773487|FG000|Overall Study|Withdrawal by Subject|1
6140986|NCT01035138|9773488|FG001|Overall Study|Withdrawal by Subject|0
6140987|NCT01035138|9773489|FG002|Overall Study|Withdrawal by Subject|0
6140988|NCT01035138|9773487|FG000|Overall Study|Physician Decision|0
6140989|NCT01035138|9773488|FG001|Overall Study|Physician Decision|0
6140990|NCT01035138|9773489|FG002|Overall Study|Physician Decision|1
6140991|NCT01035138|9773487|FG000|Overall Study|Sponsor Decision|66
6140992|NCT01035138|9773488|FG001|Overall Study|Sponsor Decision|60
6140993|NCT01035138|9773489|FG002|Overall Study|Sponsor Decision|42
6140994|NCT01035138|9773487|FG000|Overall Study|Lost to Follow-up|0
6140995|NCT01035138|9773488|FG001|Overall Study|Lost to Follow-up|0
6140996|NCT01035138|9773489|FG002|Overall Study|Lost to Follow-up|1
6140997|NCT01035229|9773510|FG000|Overall Study|Adverse Event|61
6140998|NCT01035229|9773511|FG001|Overall Study|Adverse Event|14
6140999|NCT01035229|9773510|FG000|Overall Study|Withdrawal by Subject|20
6141000|NCT01035229|9773511|FG001|Overall Study|Withdrawal by Subject|7
6141001|NCT01035229|9773510|FG000|Overall Study|Lost to Follow-up|1
6141002|NCT01035229|9773511|FG001|Overall Study|Lost to Follow-up|0
6141003|NCT01035229|9773510|FG000|Overall Study|Administrative problems|1
6141004|NCT01035229|9773511|FG001|Overall Study|Administrative problems|1
6141005|NCT01035229|9773510|FG000|Overall Study|Death|13
6141006|NCT01035229|9773511|FG001|Overall Study|Death|5
6141007|NCT01035229|9773510|FG000|Overall Study|New cancer therapy|2
6141008|NCT01035229|9773511|FG001|Overall Study|New cancer therapy|0
6141009|NCT01035229|9773510|FG000|Overall Study|Protocol Violation|0
6141010|NCT01035229|9773511|FG001|Overall Study|Protocol Violation|2
6141011|NCT01035229|9773510|FG000|Overall Study|Sponsor's decision to end study|3
6141012|NCT01035229|9773511|FG001|Overall Study|Sponsor's decision to end study|3
6141013|NCT01035229|9773510|FG000|Overall Study|Disease Progression|261
6141014|NCT01035229|9773511|FG001|Overall Study|Disease Progression|152
6141015|NCT01035255|9773521|FG000|Overall Study|Death|724
6141016|NCT01035255|9773522|FG001|Overall Study|Death|844
6141017|NCT01035255|9773521|FG000|Overall Study|Lost to Follow-up|2
6141018|NCT01035255|9773522|FG001|Overall Study|Lost to Follow-up|5
6141019|NCT01035255|9773521|FG000|Overall Study|patient's request|15
6141020|NCT01035255|9773522|FG001|Overall Study|patient's request|13
6141021|NCT01035463|9773543|FG000|Overall Study|Adverse Event|0
6141022|NCT01035463|9773544|FG001|Overall Study|Adverse Event|0
6141023|NCT01035463|9773545|FG002|Overall Study|Adverse Event|4
6141024|NCT01035463|9773546|FG003|Overall Study|Adverse Event|1
6141025|NCT01035463|9773547|FG004|Overall Study|Adverse Event|5
6141026|NCT01035463|9773548|FG005|Overall Study|Adverse Event|7
6141027|NCT01035463|9773543|FG000|Overall Study|Withdrawal by Subject|0
6141028|NCT01035463|9773544|FG001|Overall Study|Withdrawal by Subject|2
6141029|NCT01035463|9773545|FG002|Overall Study|Withdrawal by Subject|1
6141030|NCT01035463|9773546|FG003|Overall Study|Withdrawal by Subject|0
6141031|NCT01035463|9773547|FG004|Overall Study|Withdrawal by Subject|1
6141032|NCT01035463|9773548|FG005|Overall Study|Withdrawal by Subject|4
6141033|NCT01035463|9773543|FG000|Overall Study|Disease progression|0
6141034|NCT01035463|9773544|FG001|Overall Study|Disease progression|0
6141035|NCT01035463|9773545|FG002|Overall Study|Disease progression|0
6141036|NCT01035463|9773546|FG003|Overall Study|Disease progression|0
6141037|NCT01035463|9773547|FG004|Overall Study|Disease progression|0
6141038|NCT01035463|9773548|FG005|Overall Study|Disease progression|3
6141039|NCT01035463|9773543|FG000|Overall Study|Other Malignancy|0
6141040|NCT01035463|9773544|FG001|Overall Study|Other Malignancy|0
6141041|NCT01035463|9773545|FG002|Overall Study|Other Malignancy|0
6141042|NCT01035463|9773546|FG003|Overall Study|Other Malignancy|0
6141043|NCT01035463|9773547|FG004|Overall Study|Other Malignancy|0
6141044|NCT01035463|9773548|FG005|Overall Study|Other Malignancy|2
6141045|NCT01035463|9773543|FG000|Overall Study|Other|0
6141046|NCT01035463|9773544|FG001|Overall Study|Other|0
6141047|NCT01035463|9773545|FG002|Overall Study|Other|0
6141048|NCT01035463|9773546|FG003|Overall Study|Other|1
6141049|NCT01035463|9773547|FG004|Overall Study|Other|0
6141050|NCT01035463|9773548|FG005|Overall Study|Other|2
6141051|NCT01035606|9773558|FG000|Overall Study|change in health, job demands,family|3
6141052|NCT01035606|9773559|FG001|Overall Study|change in health, job demands,family|3
6141053|NCT01035606|9773560|FG002|Overall Study|change in health, job demands,family|4
6141054|NCT01035905|9773616|FG000|Overall Study|Lack of Efficacy|1
6141055|NCT01035905|9773617|FG001|Overall Study|Lack of Efficacy|1
6141056|NCT01036022|9773639|FG000|Overall Study|Adverse Event|1
6141057|NCT01036022|9773640|FG001|Overall Study|Adverse Event|3
6141058|NCT01036022|9773641|FG002|Overall Study|Adverse Event|2
6141059|NCT01036022|9773642|FG003|Overall Study|Adverse Event|1
6141060|NCT01036022|9773643|FG004|Overall Study|Adverse Event|0
6141061|NCT01036022|9773644|FG005|Overall Study|Adverse Event|2
6141062|NCT01036022|9773639|FG000|Overall Study|Lack of Efficacy|1
6141063|NCT01036022|9773640|FG001|Overall Study|Lack of Efficacy|1
6141064|NCT01036022|9773641|FG002|Overall Study|Lack of Efficacy|1
6141065|NCT01036022|9773642|FG003|Overall Study|Lack of Efficacy|0
6141066|NCT01036022|9773643|FG004|Overall Study|Lack of Efficacy|1
6141067|NCT01036022|9773644|FG005|Overall Study|Lack of Efficacy|1
6141068|NCT01036022|9773639|FG000|Overall Study|Physician Decision|0
6141069|NCT01036022|9773640|FG001|Overall Study|Physician Decision|0
6141070|NCT01036022|9773641|FG002|Overall Study|Physician Decision|1
6141071|NCT01036022|9773642|FG003|Overall Study|Physician Decision|0
6141072|NCT01036022|9773643|FG004|Overall Study|Physician Decision|0
6141073|NCT01036022|9773644|FG005|Overall Study|Physician Decision|0
6141074|NCT01036022|9773639|FG000|Overall Study|Withdrawal by Subject|0
6141075|NCT01036022|9773640|FG001|Overall Study|Withdrawal by Subject|0
6141076|NCT01036022|9773641|FG002|Overall Study|Withdrawal by Subject|0
6141077|NCT01036022|9773642|FG003|Overall Study|Withdrawal by Subject|1
6141078|NCT01036022|9773643|FG004|Overall Study|Withdrawal by Subject|2
6141079|NCT01036022|9773644|FG005|Overall Study|Withdrawal by Subject|0
6141080|NCT01036165|9773666|FG000|Overall Study|Adverse Event|6
6141081|NCT01036165|9773666|FG000|Overall Study|Lost to Follow-up|2
6141082|NCT01036165|9773666|FG000|Overall Study|Withdrawal by Subject|3
6141083|NCT01036165|9773666|FG000|Overall Study|Device Related Issues|3
6141084|NCT01036165|9773666|FG000|Overall Study|Problems finding proper area to inject|1
6141085|NCT01036321|9773672|FG000|Overall Study|Ineligible after randomization|0
6141086|NCT01036321|9773673|FG001|Overall Study|Ineligible after randomization|1
6141087|NCT01036321|9773672|FG000|Overall Study|Withdrawal by Subject|3
6141088|NCT01036321|9773673|FG001|Overall Study|Withdrawal by Subject|2
6141089|NCT01036321|9773672|FG000|Overall Study|Adverse Event|2
6141090|NCT01036321|9773673|FG001|Overall Study|Adverse Event|1
6141091|NCT01036438|9773681|FG000|Overall Study|Adverse Event|7
6141092|NCT01036438|9773682|FG001|Overall Study|Adverse Event|8
6141093|NCT01036438|9773681|FG000|Overall Study|Death|0
6141094|NCT01036438|9773682|FG001|Overall Study|Death|1
6141095|NCT01036438|9773681|FG000|Overall Study|No effect of study treatment|3
6141096|NCT01036438|9773682|FG001|Overall Study|No effect of study treatment|1
6141097|NCT01036529|9773699|FG000|Overall Study|Adverse Event|0
6141098|NCT01036529|9773700|FG001|Overall Study|Adverse Event|1
6141099|NCT01036529|9773699|FG000|Overall Study|Lost to Follow-up|0
6141100|NCT01036529|9773700|FG001|Overall Study|Lost to Follow-up|1
6141101|NCT01036529|9773699|FG000|Overall Study|Physician Decision|1
6141102|NCT01036529|9773700|FG001|Overall Study|Physician Decision|0
6141103|NCT01036529|9773699|FG000|Overall Study|Withdrawal by Subject|1
6141104|NCT01036529|9773700|FG001|Overall Study|Withdrawal by Subject|1
6141105|NCT01036529|9773699|FG000|Overall Study|Sponsor study termination|11
6141106|NCT01036529|9773700|FG001|Overall Study|Sponsor study termination|12
6141107|NCT01036594|9773706|FG000|Run-In: Ketoconazole Only (200 mg)|Adverse Event|1
6141108|NCT01036594|9773707|FG001|Run-In: Ketoconazole Only (200 mg)|Adverse Event|0
6141109|NCT01036594|9773706|FG000|First Treatment Regimen|Withdrawal by Subject|1
6141110|NCT01036594|9773707|FG001|First Treatment Regimen|Withdrawal by Subject|0
6141111|NCT01036594|9773706|FG000|Week 12 Evaluation|Adverse Event|5
6141112|NCT01036594|9773707|FG001|Week 12 Evaluation|Adverse Event|0
6141113|NCT01036594|9773706|FG000|Week 12 Evaluation|Physician Decision|1
6141114|NCT01036594|9773707|FG001|Week 12 Evaluation|Physician Decision|0
6141115|NCT01036594|9773706|FG000|Treatment Regiments Post Week 12|Physician Decision|1
6141116|NCT01036594|9773707|FG001|Treatment Regiments Post Week 12|Physician Decision|1
6141117|NCT01036594|9773706|FG000|Treatment Regiments Post Week 12|Withdrawal by Subject|1
6141118|NCT01036594|9773707|FG001|Treatment Regiments Post Week 12|Withdrawal by Subject|0
6141119|NCT01036594|9773706|FG000|Treatment Regiments Post Week 12|Adverse Event|0
6141120|NCT01036594|9773707|FG001|Treatment Regiments Post Week 12|Adverse Event|1
6141121|NCT01036594|9773706|FG000|Treatment Regiments Post Week 12|Non-Cancer Disease Complications|0
6141122|NCT01036594|9773707|FG001|Treatment Regiments Post Week 12|Non-Cancer Disease Complications|1
6141123|NCT01036594|9773706|FG000|Treatment Regiments Post Week 12|Lack of Efficacy|0
6141124|NCT01036594|9773707|FG001|Treatment Regiments Post Week 12|Lack of Efficacy|1
6141125|NCT01036724|9773715|FG000|Overall Study|Adverse Event|1
6141126|NCT01036724|9773716|FG001|Overall Study|Adverse Event|2
6141127|NCT01036724|9773715|FG000|Overall Study|Lack of Efficacy|1
6141128|NCT01036724|9773716|FG001|Overall Study|Lack of Efficacy|1
6141129|NCT01036724|9773715|FG000|Overall Study|Protocol Violation|4
6141130|NCT01036724|9773716|FG001|Overall Study|Protocol Violation|5
6141131|NCT01036763|9773722|FG000|Overall Study|Adverse Event|25
6141132|NCT01036763|9773722|FG000|Overall Study|Lost to Follow-up|28
6141133|NCT01036763|9773722|FG000|Overall Study|Other reason (not specified)|40
6141134|NCT01037088|9773736|FG000|Overall Study|Withdrawal by Subject|3
6141135|NCT01037114|9773745|FG000|Year 20|Others|1
6141136|NCT01037127|9773751|FG000|Overall Study|Lost to Follow-up|2
6141137|NCT01037127|9773752|FG001|Overall Study|Lost to Follow-up|4
6141138|NCT01037127|9773751|FG000|Overall Study|Physician Decision|1
6141139|NCT01037127|9773752|FG001|Overall Study|Physician Decision|0
6141140|NCT01037127|9773751|FG000|Overall Study|Study Closed Terminated|2
6141141|NCT01037127|9773752|FG001|Overall Study|Study Closed Terminated|17
6141142|NCT01037218|9773783|FG000|Overall Study|Adverse Event|4
6141143|NCT01037218|9773784|FG001|Overall Study|Adverse Event|2
6141144|NCT01037218|9773785|FG002|Overall Study|Adverse Event|2
6141145|NCT01037218|9773786|FG003|Overall Study|Adverse Event|1
6141146|NCT01037218|9773783|FG000|Overall Study|Lack of Efficacy|0
6141147|NCT01037218|9773784|FG001|Overall Study|Lack of Efficacy|2
6141148|NCT01037218|9773785|FG002|Overall Study|Lack of Efficacy|1
6141149|NCT01037218|9773786|FG003|Overall Study|Lack of Efficacy|5
6141150|NCT01037218|9773783|FG000|Overall Study|Lost to Follow-up|3
6141151|NCT01037218|9773784|FG001|Overall Study|Lost to Follow-up|5
6141152|NCT01037218|9773785|FG002|Overall Study|Lost to Follow-up|4
6141153|NCT01037218|9773786|FG003|Overall Study|Lost to Follow-up|2
6141154|NCT01037218|9773783|FG000|Overall Study|Withdrawal by Subject|6
6141155|NCT01037218|9773784|FG001|Overall Study|Withdrawal by Subject|7
6141156|NCT01037218|9773785|FG002|Overall Study|Withdrawal by Subject|7
6141157|NCT01037218|9773786|FG003|Overall Study|Withdrawal by Subject|4
6141158|NCT01037218|9773783|FG000|Overall Study|Partner Withdrew Consent|0
6141159|NCT01037218|9773784|FG001|Overall Study|Partner Withdrew Consent|3
6141160|NCT01037218|9773785|FG002|Overall Study|Partner Withdrew Consent|2
6141161|NCT01037218|9773786|FG003|Overall Study|Partner Withdrew Consent|1
6141162|NCT01037218|9773783|FG000|Overall Study|Protocol Violation|0
6141163|NCT01037218|9773784|FG001|Overall Study|Protocol Violation|0
6141164|NCT01037218|9773785|FG002|Overall Study|Protocol Violation|2
6141165|NCT01037218|9773786|FG003|Overall Study|Protocol Violation|2
6141166|NCT01037218|9773783|FG000|Overall Study|Various|3
6141167|NCT01037218|9773784|FG001|Overall Study|Various|2
6141168|NCT01037218|9773785|FG002|Overall Study|Various|3
6141169|NCT01037218|9773786|FG003|Overall Study|Various|1
6141170|NCT01037244|9773800|FG000|Overall Study|Adverse Event|3
6141171|NCT01037244|9773801|FG001|Overall Study|Adverse Event|2
6141172|NCT01037244|9773802|FG002|Overall Study|Adverse Event|6
6141173|NCT01037244|9773803|FG003|Overall Study|Adverse Event|3
6141174|NCT01037244|9773800|FG000|Overall Study|Lack of Efficacy|1
6141175|NCT01037244|9773801|FG001|Overall Study|Lack of Efficacy|1
6141176|NCT01037244|9773802|FG002|Overall Study|Lack of Efficacy|0
6141177|NCT01037244|9773803|FG003|Overall Study|Lack of Efficacy|1
6141178|NCT01037244|9773800|FG000|Overall Study|Lost to Follow-up|3
6141179|NCT01037244|9773801|FG001|Overall Study|Lost to Follow-up|3
6141180|NCT01037244|9773802|FG002|Overall Study|Lost to Follow-up|4
6141181|NCT01037244|9773803|FG003|Overall Study|Lost to Follow-up|4
6141182|NCT01037244|9773800|FG000|Overall Study|Withdrawal by Subject|1
6141183|NCT01037244|9773801|FG001|Overall Study|Withdrawal by Subject|5
6141184|NCT01037244|9773802|FG002|Overall Study|Withdrawal by Subject|3
6141185|NCT01037244|9773803|FG003|Overall Study|Withdrawal by Subject|5
6141186|NCT01037244|9773800|FG000|Overall Study|Partner Withdrew Consent|2
6141187|NCT01037244|9773801|FG001|Overall Study|Partner Withdrew Consent|1
6141188|NCT01037244|9773802|FG002|Overall Study|Partner Withdrew Consent|0
6141189|NCT01037244|9773803|FG003|Overall Study|Partner Withdrew Consent|0
6141190|NCT01037244|9773800|FG000|Overall Study|Various|3
6141191|NCT01037244|9773801|FG001|Overall Study|Various|2
6141192|NCT01037244|9773802|FG002|Overall Study|Various|1
6141193|NCT01037244|9773803|FG003|Overall Study|Various|1
6141194|NCT01037413|9773850|FG000|Part A: Skin Testing|Adverse Event|1
6141195|NCT01037413|9773851|FG001|Part A: Skin Testing|Adverse Event|0
6141196|NCT01037413|9773850|FG000|Part A: Skin Testing|Protocol Violation|1
6141197|NCT01037413|9773851|FG001|Part A: Skin Testing|Protocol Violation|0
6141198|NCT01037413|9773850|FG000|Part B: Scar Revision|Withdrawal by Subject|0
6141199|NCT01037413|9773851|FG001|Part B: Scar Revision|Withdrawal by Subject|1
6141200|NCT01037413|9773850|FG000|Part B: Scar Revision|Assigned But Not Treated|0
6141201|NCT01037413|9773851|FG001|Part B: Scar Revision|Assigned But Not Treated|1
6141202|NCT01037985|9773940|FG000|Part A: Skin Testing (50 Days)|Withdrawal by Subject|3
6141203|NCT01037985|9773941|FG001|Part A: Skin Testing (50 Days)|Withdrawal by Subject|0
6141204|NCT01037985|9773940|FG000|Part A: Skin Testing (50 Days)|Physician Decision|1
6141205|NCT01037985|9773941|FG001|Part A: Skin Testing (50 Days)|Physician Decision|0
6141206|NCT01037985|9773940|FG000|Part B:Abdominoplasty Surgery (24 Weeks)|Lost to Follow-up|0
6141207|NCT01037985|9773941|FG001|Part B:Abdominoplasty Surgery (24 Weeks)|Lost to Follow-up|1
6141208|NCT01037985|9773940|FG000|Part B:Abdominoplasty Surgery (24 Weeks)|Positive Skin Sensitization|0
6141209|NCT01037985|9773941|FG001|Part B:Abdominoplasty Surgery (24 Weeks)|Positive Skin Sensitization|4
6141210|NCT01038128|9773951|FG000|Overall Study|Lack of Efficacy|1
6141211|NCT01038128|9773951|FG000|Overall Study|Lost to Follow-up|1
6141212|NCT01038128|9773951|FG000|Overall Study|Withdrawal by Subject|2
6141213|NCT01038297|9773960|FG000|Part A: Skin Testing Phase (50 Days)|Withdrawal by Subject|1
6141214|NCT01038297|9773961|FG001|Part A: Skin Testing Phase (50 Days)|Withdrawal by Subject|0
6141215|NCT01038297|9773962|FG002|Part A: Skin Testing Phase (50 Days)|Withdrawal by Subject|0
6141216|NCT01038323|9773982|FG000|Overall Study|Withdrawal by Subject|3
6141217|NCT01038323|9773983|FG001|Overall Study|Withdrawal by Subject|2
6141218|NCT01038323|9773984|FG002|Overall Study|Withdrawal by Subject|4
6141219|NCT01038427|9774013|FG000|Overall Study|Lost to follow up|1
6141220|NCT01038427|9774014|FG001|Overall Study|Lost to follow up|1
6141221|NCT01038427|9774015|FG002|Overall Study|Lost to follow up|0
6141222|NCT01038427|9774013|FG000|Overall Study|Restricted medication for seasonal allergic rhinitis|0
6141223|NCT01038427|9774014|FG001|Overall Study|Restricted medication for seasonal allergic rhinitis|0
6141224|NCT01038427|9774015|FG002|Overall Study|Restricted medication for seasonal allergic rhinitis|1
6141225|NCT01038427|9774013|FG000|Overall Study|Withdrew consent|0
6141226|NCT01038427|9774014|FG001|Overall Study|Withdrew consent|0
6141227|NCT01038427|9774015|FG002|Overall Study|Withdrew consent|1
6141228|NCT01038427|9774013|FG000|Overall Study|Adverse Event|2
6141229|NCT01038427|9774014|FG001|Overall Study|Adverse Event|2
6141230|NCT01038427|9774015|FG002|Overall Study|Adverse Event|1
6141231|NCT01038427|9774013|FG000|Overall Study|Enrolled in error|0
6141232|NCT01038427|9774014|FG001|Overall Study|Enrolled in error|1
6141233|NCT01038427|9774015|FG002|Overall Study|Enrolled in error|1
6141234|NCT01038427|9774013|FG000|Overall Study|Other|0
6141235|NCT01038427|9774014|FG001|Overall Study|Other|2
6141236|NCT01038427|9774015|FG002|Overall Study|Other|0
6141237|NCT01038609|9774041|FG000|Overall Study|Adverse Event|0
6141238|NCT01038609|9774042|FG001|Overall Study|Adverse Event|0
6141239|NCT01038609|9774043|FG002|Overall Study|Adverse Event|1
6141240|NCT01038609|9774044|FG003|Overall Study|Adverse Event|0
6141241|NCT01038609|9774045|FG004|Overall Study|Adverse Event|0
6141242|NCT01038609|9774041|FG000|Overall Study|Dosing Error|0
6141243|NCT01038609|9774042|FG001|Overall Study|Dosing Error|0
6141244|NCT01038609|9774043|FG002|Overall Study|Dosing Error|0
6141245|NCT01038609|9774044|FG003|Overall Study|Dosing Error|1
6141246|NCT01038609|9774045|FG004|Overall Study|Dosing Error|1
6141247|NCT01038609|9774041|FG000|Overall Study|Death in the Family|1
6141248|NCT01038609|9774042|FG001|Overall Study|Death in the Family|0
6141249|NCT01038609|9774043|FG002|Overall Study|Death in the Family|0
6141250|NCT01038609|9774044|FG003|Overall Study|Death in the Family|0
6141251|NCT01038609|9774045|FG004|Overall Study|Death in the Family|0
6141252|NCT01038609|9774041|FG000|Overall Study|Refusal of Blood Draws|0
6141253|NCT01038609|9774042|FG001|Overall Study|Refusal of Blood Draws|1
6141254|NCT01038609|9774043|FG002|Overall Study|Refusal of Blood Draws|0
6141255|NCT01038609|9774044|FG003|Overall Study|Refusal of Blood Draws|0
6141256|NCT01038609|9774045|FG004|Overall Study|Refusal of Blood Draws|0
6141257|NCT01038635|9774066|FG000|Overall Study|Disease Progression|2
6141258|NCT01038635|9774067|FG001|Overall Study|Disease Progression|0
6141259|NCT01038635|9774068|FG002|Overall Study|Disease Progression|0
6141260|NCT01038635|9774069|FG003|Overall Study|Disease Progression|0
6141261|NCT01038635|9774070|FG004|Overall Study|Disease Progression|0
6141262|NCT01038635|9774071|FG005|Overall Study|Disease Progression|0
6141263|NCT01038635|9774072|FG006|Overall Study|Disease Progression|1
6141264|NCT01038635|9774073|FG007|Overall Study|Disease Progression|4
6141265|NCT01038635|9774074|FG008|Overall Study|Disease Progression|0
6141266|NCT01038635|9774066|FG000|Overall Study|Death|0
6141267|NCT01038635|9774067|FG001|Overall Study|Death|0
6141268|NCT01038635|9774068|FG002|Overall Study|Death|0
6141269|NCT01038635|9774069|FG003|Overall Study|Death|0
6141270|NCT01038635|9774070|FG004|Overall Study|Death|1
6141271|NCT01038635|9774071|FG005|Overall Study|Death|0
6141272|NCT01038635|9774072|FG006|Overall Study|Death|1
6141273|NCT01038635|9774073|FG007|Overall Study|Death|1
6141274|NCT01038635|9774074|FG008|Overall Study|Death|2
6141275|NCT01038687|9774098|FG000|Overall Study|Adverse Event|0
6141276|NCT01038687|9774099|FG001|Overall Study|Adverse Event|2
6141277|NCT01038687|9774100|FG002|Overall Study|Adverse Event|1
6141278|NCT01038713|9774111|FG000|Overall Study|Patient to hospice|1
6141279|NCT01038713|9774112|FG001|Overall Study|Patient to hospice|1
6141280|NCT01038713|9774113|FG002|Overall Study|Patient to hospice|1
6141281|NCT01038713|9774111|FG000|Overall Study|Lost to Follow-up|3
6141282|NCT01038713|9774112|FG001|Overall Study|Lost to Follow-up|0
6141283|NCT01038713|9774113|FG002|Overall Study|Lost to Follow-up|0
6141284|NCT01038713|9774111|FG000|Overall Study|Neuroendocrine Tumor|0
6141285|NCT01038713|9774112|FG001|Overall Study|Neuroendocrine Tumor|1
6141286|NCT01038713|9774113|FG002|Overall Study|Neuroendocrine Tumor|0
6141287|NCT01038713|9774111|FG000|Overall Study|died from PEP|0
6141288|NCT01038713|9774112|FG001|Overall Study|died from PEP|1
6141289|NCT01038713|9774113|FG002|Overall Study|died from PEP|0
6141290|NCT01038713|9774111|FG000|Overall Study|Autoimmune Pancreatitis|1
6141291|NCT01038713|9774112|FG001|Overall Study|Autoimmune Pancreatitis|0
6141292|NCT01038713|9774113|FG002|Overall Study|Autoimmune Pancreatitis|0
6141293|NCT01038856|9774121|FG000|Overall Study|Adverse Event|2
6141294|NCT01038869|9774127|FG000|Overall Study|Withdrawal by Subject|1
6141295|NCT01038869|9774127|FG000|Overall Study|Lost to Follow-up|6
6141296|NCT01038921|9774137|FG000|Overall Study|Withdrawal by Subject|1
6141297|NCT01038921|9774138|FG001|Overall Study|Withdrawal by Subject|0
6141298|NCT01038921|9774137|FG000|Overall Study|Physician Decision|1
6141299|NCT01038921|9774138|FG001|Overall Study|Physician Decision|0
6141300|NCT01039376|9774150|FG000|Overall Study|Lost to Follow-up|5
6141301|NCT01039376|9774151|FG001|Overall Study|Lost to Follow-up|12
6141302|NCT01039376|9774150|FG000|Overall Study|Physician Decision|15
6141303|NCT01039376|9774151|FG001|Overall Study|Physician Decision|10
6141304|NCT01039376|9774150|FG000|Overall Study|Withdrawal by Subject|20
6141305|NCT01039376|9774151|FG001|Overall Study|Withdrawal by Subject|32
6141306|NCT01039376|9774150|FG000|Overall Study|Study terminated by Sponsor|90
6141307|NCT01039376|9774151|FG001|Overall Study|Study terminated by Sponsor|72
6141308|NCT01039428|9774160|FG000|Overall Study|Protocol Violation|1
6141309|NCT01039428|9774161|FG001|Overall Study|Protocol Violation|0
6141310|NCT01039428|9774160|FG000|Overall Study|Withdrawal by Subject|1
6141311|NCT01039428|9774161|FG001|Overall Study|Withdrawal by Subject|0
6141312|NCT01039519|9774178|FG000|Treatment|Progressive disease|20
6141313|NCT01039519|9774178|FG000|Treatment|Treatment failure|2
6141314|NCT01039519|9774178|FG000|Treatment|Adverse Event|3
6141315|NCT01039519|9774178|FG000|Treatment|Physician Decision|2
6141316|NCT01039519|9774178|FG000|Survival Follow-up|Death|23
6141317|NCT01039519|9774178|FG000|Survival Follow-up|Sponsor decision|4
6141318|NCT01039584|9774185|FG000|Overall Study|Withdrawal by Subject|4
6141319|NCT01039584|9774186|FG001|Overall Study|Withdrawal by Subject|2
6141320|NCT01039584|9774187|FG002|Overall Study|Withdrawal by Subject|1
6141321|NCT01039584|9774185|FG000|Overall Study|Protocol Violation|10
6141322|NCT01039584|9774186|FG001|Overall Study|Protocol Violation|4
6141323|NCT01039584|9774187|FG002|Overall Study|Protocol Violation|6
6141324|NCT01039584|9774185|FG000|Overall Study|Lost to Follow-up|5
6141325|NCT01039584|9774186|FG001|Overall Study|Lost to Follow-up|3
6141326|NCT01039584|9774187|FG002|Overall Study|Lost to Follow-up|4
6141327|NCT01039584|9774185|FG000|Overall Study|Negative Baseline culture for Candida|59
6141328|NCT01039584|9774186|FG001|Overall Study|Negative Baseline culture for Candida|59
6141329|NCT01039584|9774187|FG002|Overall Study|Negative Baseline culture for Candida|24
6141330|NCT01039584|9774185|FG000|Overall Study|Lack of Efficacy|7
6141331|NCT01039584|9774186|FG001|Overall Study|Lack of Efficacy|6
6141332|NCT01039584|9774187|FG002|Overall Study|Lack of Efficacy|10
6141333|NCT01039584|9774185|FG000|Overall Study|other|1
6141334|NCT01039584|9774186|FG001|Overall Study|other|3
6141335|NCT01039584|9774187|FG002|Overall Study|other|1
6141336|NCT01039584|9774185|FG000|Overall Study|Pap smear with significant pathology|10
6141337|NCT01039584|9774186|FG001|Overall Study|Pap smear with significant pathology|10
6141338|NCT01039584|9774187|FG002|Overall Study|Pap smear with significant pathology|3
6141339|NCT01039584|9774185|FG000|Overall Study|Positive for Chlamydia or gonorrhea|7
6141340|NCT01039584|9774186|FG001|Overall Study|Positive for Chlamydia or gonorrhea|10
6141341|NCT01039584|9774187|FG002|Overall Study|Positive for Chlamydia or gonorrhea|8
6141342|NCT01039675|9774197|FG000|Overall Study|Adverse Event|0
6141343|NCT01039675|9774198|FG001|Overall Study|Adverse Event|2
6141344|NCT01039675|9774197|FG000|Overall Study|Lack of Efficacy|0
6141345|NCT01039675|9774198|FG001|Overall Study|Lack of Efficacy|2
6141346|NCT01039675|9774197|FG000|Overall Study|Withdrawal by Subject|0
6141347|NCT01039675|9774198|FG001|Overall Study|Withdrawal by Subject|1
6141348|NCT01039675|9774197|FG000|Overall Study|Lost to Follow-up|0
6141349|NCT01039675|9774198|FG001|Overall Study|Lost to Follow-up|1
6141350|NCT01039675|9774197|FG000|Overall Study|Physician Decision|0
6141351|NCT01039675|9774198|FG001|Overall Study|Physician Decision|1
6141352|NCT01039688|9774207|FG000|Overall Study|Adverse Event|38
6141353|NCT01039688|9774208|FG001|Overall Study|Adverse Event|39
6141354|NCT01039688|9774209|FG002|Overall Study|Adverse Event|24
6141355|NCT01039688|9774207|FG000|Overall Study|Lack of Efficacy|20
6141356|NCT01039688|9774208|FG001|Overall Study|Lack of Efficacy|11
6141357|NCT01039688|9774209|FG002|Overall Study|Lack of Efficacy|26
6141358|NCT01039688|9774207|FG000|Overall Study|Lost to Follow-up|11
6141359|NCT01039688|9774208|FG001|Overall Study|Lost to Follow-up|9
6141360|NCT01039688|9774209|FG002|Overall Study|Lost to Follow-up|5
6141361|NCT01039688|9774207|FG000|Overall Study|Other|13
6141362|NCT01039688|9774208|FG001|Overall Study|Other|25
6141363|NCT01039688|9774209|FG002|Overall Study|Other|12
6141364|NCT01039688|9774207|FG000|Overall Study|Withdrawal by Subject|23
6141365|NCT01039688|9774208|FG001|Overall Study|Withdrawal by Subject|27
6141366|NCT01039688|9774209|FG002|Overall Study|Withdrawal by Subject|13
6141367|NCT01039688|9774207|FG000|Overall Study|Death|2
6141368|NCT01039688|9774208|FG001|Overall Study|Death|0
6141369|NCT01039688|9774209|FG002|Overall Study|Death|0
6141370|NCT01040130|9774233|FG000|Overall Study|Adverse Event|1
6141371|NCT01040130|9774234|FG001|Overall Study|Adverse Event|1
6141372|NCT01040130|9774235|FG002|Overall Study|Adverse Event|0
6141373|NCT01040130|9774236|FG003|Overall Study|Adverse Event|5
6141374|NCT01040130|9774237|FG004|Overall Study|Adverse Event|0
6141375|NCT01040130|9774238|FG005|Overall Study|Adverse Event|3
6141376|NCT01040130|9774233|FG000|Overall Study|Protocol Violation|0
6141377|NCT01040130|9774234|FG001|Overall Study|Protocol Violation|0
6141378|NCT01040130|9774235|FG002|Overall Study|Protocol Violation|2
6141379|NCT01040130|9774236|FG003|Overall Study|Protocol Violation|0
6141380|NCT01040130|9774237|FG004|Overall Study|Protocol Violation|0
6141381|NCT01040130|9774238|FG005|Overall Study|Protocol Violation|0
6141382|NCT01040130|9774233|FG000|Overall Study|Withdrawal by Subject|0
6141383|NCT01040130|9774234|FG001|Overall Study|Withdrawal by Subject|2
6141384|NCT01040130|9774235|FG002|Overall Study|Withdrawal by Subject|0
6141385|NCT01040130|9774236|FG003|Overall Study|Withdrawal by Subject|0
6141386|NCT01040130|9774237|FG004|Overall Study|Withdrawal by Subject|0
6141387|NCT01040130|9774238|FG005|Overall Study|Withdrawal by Subject|1
6141388|NCT01040130|9774233|FG000|Overall Study|Other reasons not listed above|2
6141389|NCT01040130|9774234|FG001|Overall Study|Other reasons not listed above|0
6141390|NCT01040130|9774235|FG002|Overall Study|Other reasons not listed above|0
6141391|NCT01040130|9774236|FG003|Overall Study|Other reasons not listed above|0
6141392|NCT01040130|9774237|FG004|Overall Study|Other reasons not listed above|0
6141393|NCT01040130|9774238|FG005|Overall Study|Other reasons not listed above|0
6141394|NCT01040169|9774250|FG000|Overall Study|Lost to Follow-up|3
6141395|NCT01040169|9774251|FG001|Overall Study|Lost to Follow-up|8
6141396|NCT01040260|9774277|FG000|Overall Study|Withdrawal by Subject|12
6141397|NCT01040260|9774278|FG001|Overall Study|Withdrawal by Subject|6
6141398|NCT01040260|9774277|FG000|Overall Study|Lost to Follow-up|3
6141399|NCT01040260|9774278|FG001|Overall Study|Lost to Follow-up|5
6141400|NCT01040351|9774286|FG000|Overall Study|poor ovarian response|1
6141401|NCT01040351|9774287|FG001|Overall Study|poor ovarian response|2
6141402|NCT01040403|9774293|FG000|Overall Study|Adverse Event|10
6141403|NCT01040403|9774293|FG000|Overall Study|Protocol Violation|2
6141404|NCT01040403|9774293|FG000|Overall Study|Lost to Follow-up|1
6141405|NCT01040403|9774293|FG000|Overall Study|Not treated|1
6141406|NCT01040403|9774293|FG000|Overall Study|Other reason not defined above|6
6141407|NCT01040689|9774312|FG000|Overall Study|Adverse Event|0
6141408|NCT01040689|9774313|FG001|Overall Study|Adverse Event|0
6141409|NCT01040689|9774314|FG002|Overall Study|Adverse Event|2
6141410|NCT01040689|9774315|FG003|Overall Study|Adverse Event|4
6141411|NCT01040689|9774312|FG000|Overall Study|Lack of Efficacy|0
6141412|NCT01040689|9774313|FG001|Overall Study|Lack of Efficacy|0
6141413|NCT01040689|9774314|FG002|Overall Study|Lack of Efficacy|1
6141414|NCT01040689|9774315|FG003|Overall Study|Lack of Efficacy|0
6141415|NCT01040689|9774312|FG000|Overall Study|Lost to Follow-up|1
6141416|NCT01040689|9774313|FG001|Overall Study|Lost to Follow-up|0
6141417|NCT01040689|9774314|FG002|Overall Study|Lost to Follow-up|0
6141418|NCT01040689|9774315|FG003|Overall Study|Lost to Follow-up|0
6141419|NCT01040689|9774312|FG000|Overall Study|Withdrawal by Subject|2
6141420|NCT01040689|9774313|FG001|Overall Study|Withdrawal by Subject|1
6141421|NCT01040689|9774314|FG002|Overall Study|Withdrawal by Subject|1
6141422|NCT01040689|9774315|FG003|Overall Study|Withdrawal by Subject|0
6141423|NCT01040689|9774312|FG000|Overall Study|Other reasons not listed above|0
6141424|NCT01040689|9774313|FG001|Overall Study|Other reasons not listed above|1
6141425|NCT01040689|9774314|FG002|Overall Study|Other reasons not listed above|0
6141426|NCT01040689|9774315|FG003|Overall Study|Other reasons not listed above|0
6141427|NCT01040728|9774330|FG000|Overall Study|Adverse Event|4
6141428|NCT01040728|9774331|FG001|Overall Study|Adverse Event|8
6141429|NCT01040728|9774332|FG002|Overall Study|Adverse Event|0
6141430|NCT01040728|9774333|FG003|Overall Study|Adverse Event|4
6141431|NCT01040728|9774330|FG000|Overall Study|Withdrawal by Subject|0
6141432|NCT01040728|9774331|FG001|Overall Study|Withdrawal by Subject|1
6141433|NCT01040728|9774332|FG002|Overall Study|Withdrawal by Subject|1
6141434|NCT01040728|9774333|FG003|Overall Study|Withdrawal by Subject|0
6141435|NCT01040728|9774330|FG000|Overall Study|Protocol Violation|0
6141436|NCT01040728|9774331|FG001|Overall Study|Protocol Violation|0
6141437|NCT01040728|9774332|FG002|Overall Study|Protocol Violation|0
6141438|NCT01040728|9774333|FG003|Overall Study|Protocol Violation|1
6141439|NCT01040728|9774330|FG000|Overall Study|Lack of Efficacy|0
6141440|NCT01040728|9774331|FG001|Overall Study|Lack of Efficacy|1
6141441|NCT01040728|9774332|FG002|Overall Study|Lack of Efficacy|0
6141442|NCT01040728|9774333|FG003|Overall Study|Lack of Efficacy|1
6141443|NCT01040728|9774330|FG000|Overall Study|Other reasons not listed above|0
6141444|NCT01040728|9774331|FG001|Overall Study|Other reasons not listed above|1
6141445|NCT01040728|9774332|FG002|Overall Study|Other reasons not listed above|0
6141446|NCT01040728|9774333|FG003|Overall Study|Other reasons not listed above|0
6141447|NCT01040780|9774351|FG000|Overall Study|Protocol Violation|1
6141448|NCT01040780|9774352|FG001|Overall Study|Protocol Violation|3
6141449|NCT01040793|9774361|FG000|Overall Study|Adverse Event|5
6141450|NCT01040793|9774362|FG001|Overall Study|Adverse Event|3
6141451|NCT01040793|9774363|FG002|Overall Study|Adverse Event|0
6141452|NCT01040793|9774364|FG003|Overall Study|Adverse Event|2
6141453|NCT01040793|9774365|FG004|Overall Study|Adverse Event|2
6141454|NCT01040793|9774366|FG005|Overall Study|Adverse Event|1
6141455|NCT01040793|9774361|FG000|Overall Study|Protocol Violation|1
6141456|NCT01040793|9774362|FG001|Overall Study|Protocol Violation|1
6141457|NCT01040793|9774363|FG002|Overall Study|Protocol Violation|1
6141458|NCT01040793|9774364|FG003|Overall Study|Protocol Violation|0
6141459|NCT01040793|9774365|FG004|Overall Study|Protocol Violation|1
6141460|NCT01040793|9774366|FG005|Overall Study|Protocol Violation|0
6141461|NCT01040793|9774361|FG000|Overall Study|Lost to Follow-up|0
6141462|NCT01040793|9774362|FG001|Overall Study|Lost to Follow-up|1
6141463|NCT01040793|9774363|FG002|Overall Study|Lost to Follow-up|1
6141464|NCT01040793|9774364|FG003|Overall Study|Lost to Follow-up|0
6141465|NCT01040793|9774365|FG004|Overall Study|Lost to Follow-up|0
6141466|NCT01040793|9774366|FG005|Overall Study|Lost to Follow-up|0
6141467|NCT01040793|9774361|FG000|Overall Study|Withdrawal by Subject|0
6141468|NCT01040793|9774362|FG001|Overall Study|Withdrawal by Subject|0
6141469|NCT01040793|9774363|FG002|Overall Study|Withdrawal by Subject|0
6141470|NCT01040793|9774364|FG003|Overall Study|Withdrawal by Subject|2
6141471|NCT01040793|9774365|FG004|Overall Study|Withdrawal by Subject|0
6141472|NCT01040793|9774366|FG005|Overall Study|Withdrawal by Subject|0
6141473|NCT01040793|9774361|FG000|Overall Study|Other reasons not listed above|0
6141474|NCT01040793|9774362|FG001|Overall Study|Other reasons not listed above|0
6141475|NCT01040793|9774363|FG002|Overall Study|Other reasons not listed above|1
6141476|NCT01040793|9774364|FG003|Overall Study|Other reasons not listed above|0
6141477|NCT01040793|9774365|FG004|Overall Study|Other reasons not listed above|1
6141478|NCT01040793|9774366|FG005|Overall Study|Other reasons not listed above|0
6141479|NCT01040832|9774387|FG000|Overall Study|Adverse Event|4
6141480|NCT01040832|9774388|FG001|Overall Study|Adverse Event|5
6141481|NCT01040832|9774387|FG000|Overall Study|Death|4
6141482|NCT01040832|9774388|FG001|Overall Study|Death|6
6141483|NCT01040832|9774387|FG000|Overall Study|Withdrawal by Subject|2
6141484|NCT01040832|9774388|FG001|Overall Study|Withdrawal by Subject|3
6141485|NCT01040832|9774387|FG000|Overall Study|Progressive disease|32
6141486|NCT01040832|9774388|FG001|Overall Study|Progressive disease|17
6141487|NCT01040832|9774387|FG000|Overall Study|Symptomatic deterioration|2
6141488|NCT01040832|9774388|FG001|Overall Study|Symptomatic deterioration|5
6141489|NCT01040832|9774387|FG000|Overall Study|Other|2
6141490|NCT01040832|9774388|FG001|Overall Study|Other|1
6141491|NCT01040845|9774396|FG000|Overall Study|Withdrawal by Subject|1
6141492|NCT01040845|9774397|FG001|Overall Study|Withdrawal by Subject|1
6141493|NCT01040845|9774396|FG000|Overall Study|Physician Decision|1
6141494|NCT01040845|9774397|FG001|Overall Study|Physician Decision|0
6141495|NCT01040871|9774419|FG000|Overall Study|Adverse Event|6
6141496|NCT01040871|9774420|FG001|Overall Study|Adverse Event|2
6141497|NCT01040871|9774419|FG000|Overall Study|Withdrawal by Subject|2
6141498|NCT01040871|9774420|FG001|Overall Study|Withdrawal by Subject|0
6141499|NCT01040871|9774419|FG000|Overall Study|Death|1
6141500|NCT01040871|9774420|FG001|Overall Study|Death|3
6141501|NCT01040871|9774419|FG000|Overall Study|Lack of Efficacy|1
6141502|NCT01040871|9774420|FG001|Overall Study|Lack of Efficacy|1
6141503|NCT01040871|9774419|FG000|Overall Study|drug supply issue|1
6141504|NCT01040871|9774420|FG001|Overall Study|drug supply issue|0
6141505|NCT01040871|9774419|FG000|Overall Study|Randomized and Not Treated|2
6141506|NCT01040871|9774420|FG001|Overall Study|Randomized and Not Treated|1
6141507|NCT01041287|9774452|FG000|Treatment Period 2 (3 Months)|Lost to Follow-up|3
6141508|NCT01041287|9774453|FG001|Treatment Period 2 (3 Months)|Lost to Follow-up|3
6141509|NCT01041287|9774452|FG000|Treatment Period 2 (3 Months)|Adverse Event|0
6141510|NCT01041287|9774453|FG001|Treatment Period 2 (3 Months)|Adverse Event|2
6141511|NCT01041404|9774461|FG000|Overall Study|Adverse Event|45
6141512|NCT01041404|9774462|FG001|Overall Study|Adverse Event|35
6141513|NCT01041404|9774461|FG000|Overall Study|Lack of Efficacy|200
6141514|NCT01041404|9774462|FG001|Overall Study|Lack of Efficacy|210
6141515|NCT01041404|9774461|FG000|Overall Study|Violation of Selection Criteria|0
6141516|NCT01041404|9774462|FG001|Overall Study|Violation of Selection Criteria|1
6141517|NCT01041404|9774461|FG000|Overall Study|Protocol Violation|4
6141518|NCT01041404|9774462|FG001|Overall Study|Protocol Violation|0
6141519|NCT01041404|9774461|FG000|Overall Study|Withdrawal by Subject|29
6141520|NCT01041404|9774462|FG001|Overall Study|Withdrawal by Subject|23
6141521|NCT01041404|9774461|FG000|Overall Study|Failure to Return|1
6141522|NCT01041404|9774462|FG001|Overall Study|Failure to Return|2
6141523|NCT01041404|9774461|FG000|Overall Study|Other|11
6141524|NCT01041404|9774462|FG001|Overall Study|Other|23
6141525|NCT01041417|9774473|FG000|Overall Study|Adverse Event|5
6141526|NCT01041417|9774474|FG001|Overall Study|Adverse Event|2
6141527|NCT01041417|9774473|FG000|Overall Study|Lost to Follow-up|1
6141528|NCT01041417|9774474|FG001|Overall Study|Lost to Follow-up|1
6141529|NCT01041417|9774473|FG000|Overall Study|Death|1
6141530|NCT01041417|9774474|FG001|Overall Study|Death|0
6141531|NCT01041495|9774484|FG000|Overall Study|Withdrawal by Subject|2
6141532|NCT01041495|9774485|FG001|Overall Study|Withdrawal by Subject|5
6141533|NCT01041495|9774484|FG000|Overall Study|Adverse Event|2
6141534|NCT01041495|9774485|FG001|Overall Study|Adverse Event|1
6141535|NCT01041495|9774484|FG000|Overall Study|Lost to Follow-up|0
6141536|NCT01041495|9774485|FG001|Overall Study|Lost to Follow-up|1
6141537|NCT01041573|9774504|FG000|Overall Study|Withdrawal by Subject|2
6141538|NCT01041573|9774505|FG001|Overall Study|Withdrawal by Subject|5
6141539|NCT01041573|9774506|FG002|Overall Study|Withdrawal by Subject|2
6141540|NCT01041573|9774507|FG003|Overall Study|Withdrawal by Subject|0
6141541|NCT01041573|9774504|FG000|Overall Study|Death|1
6141542|NCT01041573|9774505|FG001|Overall Study|Death|0
6141543|NCT01041573|9774506|FG002|Overall Study|Death|0
6141544|NCT01041573|9774507|FG003|Overall Study|Death|0
6141545|NCT01041573|9774504|FG000|Overall Study|Lost to Follow-up|0
6141546|NCT01041573|9774505|FG001|Overall Study|Lost to Follow-up|1
6141547|NCT01041573|9774506|FG002|Overall Study|Lost to Follow-up|2
6141548|NCT01041573|9774507|FG003|Overall Study|Lost to Follow-up|1
6141549|NCT01041573|9774504|FG000|Overall Study|Adverse Event|0
6141550|NCT01041573|9774505|FG001|Overall Study|Adverse Event|2
6141551|NCT01041573|9774506|FG002|Overall Study|Adverse Event|0
6141552|NCT01041573|9774507|FG003|Overall Study|Adverse Event|0
6141553|NCT01041573|9774504|FG000|Overall Study|relocation|1
6141554|NCT01041573|9774505|FG001|Overall Study|relocation|4
6141555|NCT01041573|9774506|FG002|Overall Study|relocation|3
6141556|NCT01041573|9774507|FG003|Overall Study|relocation|1
6141557|NCT01041573|9774504|FG000|Overall Study|further blood extraction|0
6141558|NCT01041573|9774505|FG001|Overall Study|further blood extraction|1
6141559|NCT01041573|9774506|FG002|Overall Study|further blood extraction|0
6141560|NCT01041573|9774507|FG003|Overall Study|further blood extraction|0
6141561|NCT01041573|9774504|FG000|Overall Study|positive to anti-HCV|1
6141562|NCT01041573|9774505|FG001|Overall Study|positive to anti-HCV|0
6141563|NCT01041573|9774506|FG002|Overall Study|positive to anti-HCV|0
6141564|NCT01041573|9774507|FG003|Overall Study|positive to anti-HCV|0
6141565|NCT01041638|9774526|FG000|Overall Study|Adverse Event|4
6141566|NCT01041638|9774526|FG000|Overall Study|Death|1
6141567|NCT01041638|9774526|FG000|Overall Study|Lack of Efficacy|7
6141568|NCT01041638|9774526|FG000|Overall Study|Physician Decision|4
6141569|NCT01041638|9774526|FG000|Overall Study|Withdrawal by Subject|11
6141570|NCT01041859|9774549|FG000|Open-Label Titration|Adverse Event|69
6141571|NCT01041859|9774550|FG001|Open-Label Titration|Adverse Event|0
6141572|NCT01041859|9774551|FG002|Open-Label Titration|Adverse Event|0
6141573|NCT01041859|9774549|FG000|Open-Label Titration|Lack of Efficacy|3
6141574|NCT01041859|9774550|FG001|Open-Label Titration|Lack of Efficacy|0
6141575|NCT01041859|9774551|FG002|Open-Label Titration|Lack of Efficacy|0
6141576|NCT01041859|9774549|FG000|Open-Label Titration|Lost to Follow-up|1
6141577|NCT01041859|9774550|FG001|Open-Label Titration|Lost to Follow-up|0
6141578|NCT01041859|9774551|FG002|Open-Label Titration|Lost to Follow-up|0
6141579|NCT01041859|9774549|FG000|Open-Label Titration|Physician Decision|1
6141580|NCT01041859|9774550|FG001|Open-Label Titration|Physician Decision|0
6141581|NCT01041859|9774551|FG002|Open-Label Titration|Physician Decision|0
6141582|NCT01041859|9774549|FG000|Open-Label Titration|Protocol Violation|1
6141583|NCT01041859|9774550|FG001|Open-Label Titration|Protocol Violation|0
6141584|NCT01041859|9774551|FG002|Open-Label Titration|Protocol Violation|0
6141585|NCT01041859|9774549|FG000|Open-Label Titration|Other|7
6141586|NCT01041859|9774550|FG001|Open-Label Titration|Other|0
6141587|NCT01041859|9774551|FG002|Open-Label Titration|Other|0
6141588|NCT01041859|9774549|FG000|Open-Label Titration|Noncompliance With Study Drug|8
5982765|NCT01399658|9571658|FG000|Overall Study|Ineligible|1
5982766|NCT01399658|9571658|FG000|Overall Study|Machine Technical Issue|3
5982767|NCT01399658|9571658|FG000|Overall Study|Standard of Care better than protocol therapy|1
5982768|NCT01399658|9571658|FG000|Overall Study|No reason given|1
5982769|NCT00919893|9571763|FG000|Overall Study|Protocol Violation|19
5982770|NCT00919893|9571764|FG001|Overall Study|Protocol Violation|9
5982771|NCT00909753|9571803|FG000|Period: Washout of 28 Days|Protocol Violation|2
6141589|NCT01041859|9774550|FG001|Open-Label Titration|Noncompliance With Study Drug|0
6141590|NCT01041859|9774551|FG002|Open-Label Titration|Noncompliance With Study Drug|0
6141591|NCT01041859|9774549|FG000|Open-Label Titration|Withdrawal by Subject|11
6141592|NCT01041859|9774550|FG001|Open-Label Titration|Withdrawal by Subject|0
6141593|NCT01041859|9774551|FG002|Open-Label Titration|Withdrawal by Subject|0
6141594|NCT01041859|9774549|FG000|Double-Blind Maintenance|Adverse Event|0
6141595|NCT01041859|9774550|FG001|Double-Blind Maintenance|Adverse Event|23
6141596|NCT01041859|9774551|FG002|Double-Blind Maintenance|Adverse Event|13
6141597|NCT01041859|9774549|FG000|Double-Blind Maintenance|Lack of Efficacy|0
6141598|NCT01041859|9774550|FG001|Double-Blind Maintenance|Lack of Efficacy|3
6141599|NCT01041859|9774551|FG002|Double-Blind Maintenance|Lack of Efficacy|11
6141600|NCT01041859|9774549|FG000|Double-Blind Maintenance|Lost to Follow-up|0
6141601|NCT01041859|9774550|FG001|Double-Blind Maintenance|Lost to Follow-up|1
6141602|NCT01041859|9774551|FG002|Double-Blind Maintenance|Lost to Follow-up|0
6141603|NCT01041859|9774549|FG000|Double-Blind Maintenance|Physician Decision|0
6141604|NCT01041859|9774550|FG001|Double-Blind Maintenance|Physician Decision|2
6141605|NCT01041859|9774551|FG002|Double-Blind Maintenance|Physician Decision|1
6141606|NCT01041859|9774549|FG000|Double-Blind Maintenance|Protocol Violation|0
6141607|NCT01041859|9774550|FG001|Double-Blind Maintenance|Protocol Violation|1
6141608|NCT01041859|9774551|FG002|Double-Blind Maintenance|Protocol Violation|3
6141609|NCT01041859|9774549|FG000|Double-Blind Maintenance|Other|0
6141610|NCT01041859|9774550|FG001|Double-Blind Maintenance|Other|6
6141611|NCT01041859|9774551|FG002|Double-Blind Maintenance|Other|2
6141612|NCT01041859|9774549|FG000|Double-Blind Maintenance|Noncompliance With Study Drug|0
6141613|NCT01041859|9774550|FG001|Double-Blind Maintenance|Noncompliance With Study Drug|2
6141614|NCT01041859|9774551|FG002|Double-Blind Maintenance|Noncompliance With Study Drug|6
6141615|NCT01041859|9774549|FG000|Double-Blind Maintenance|Withdrawal by Subject|0
6141616|NCT01041859|9774550|FG001|Double-Blind Maintenance|Withdrawal by Subject|8
6141617|NCT01041859|9774551|FG002|Double-Blind Maintenance|Withdrawal by Subject|9
6141618|NCT01041976|9774560|FG000|Overall Study|Withdrawal by Subject|3
6141619|NCT01041976|9774561|FG001|Overall Study|Withdrawal by Subject|0
6141620|NCT01041976|9774560|FG000|Overall Study|Incarceration|2
6141621|NCT01041976|9774561|FG001|Overall Study|Incarceration|0
6141622|NCT01041976|9774560|FG000|Overall Study|Death|0
6141623|NCT01041976|9774561|FG001|Overall Study|Death|4
6141624|NCT01042093|9774571|FG000|Overall Study|Protocol Violation|2
6141625|NCT01042093|9774572|FG001|Overall Study|Protocol Violation|2
6141626|NCT01042093|9774573|FG002|Overall Study|Protocol Violation|2
6141627|NCT01042093|9774574|FG003|Overall Study|Protocol Violation|3
6141628|NCT01042093|9774571|FG000|Overall Study|Withdrawal by Subject|0
6141629|NCT01042093|9774572|FG001|Overall Study|Withdrawal by Subject|0
6141630|NCT01042093|9774573|FG002|Overall Study|Withdrawal by Subject|0
6141631|NCT01042093|9774574|FG003|Overall Study|Withdrawal by Subject|1
6141632|NCT01042158|9774596|FG000|Overall Study|Physician Decision|1
6141633|NCT01042236|9774600|FG000|Treatment Period 1|Adverse Event|0
6141634|NCT01042236|9774601|FG001|Treatment Period 1|Adverse Event|1
6141635|NCT01042236|9774602|FG002|Treatment Period 1|Adverse Event|0
6141636|NCT01042236|9774603|FG003|Treatment Period 1|Adverse Event|0
6141637|NCT01042236|9774604|FG004|Treatment Period 1|Adverse Event|1
6141638|NCT01042236|9774605|FG005|Treatment Period 1|Adverse Event|0
6141639|NCT01042236|9774600|FG000|Treatment Period 3|Adverse Event|0
6141640|NCT01042236|9774601|FG001|Treatment Period 3|Adverse Event|0
6141641|NCT01042236|9774602|FG002|Treatment Period 3|Adverse Event|0
6141642|NCT01042236|9774603|FG003|Treatment Period 3|Adverse Event|1
6141643|NCT01042236|9774604|FG004|Treatment Period 3|Adverse Event|0
6141644|NCT01042236|9774605|FG005|Treatment Period 3|Adverse Event|0
6141645|NCT01042236|9774600|FG000|Treatment Period 3|Protocol Violation|0
6141646|NCT01042236|9774601|FG001|Treatment Period 3|Protocol Violation|0
6141647|NCT01042236|9774602|FG002|Treatment Period 3|Protocol Violation|0
6141648|NCT01042236|9774603|FG003|Treatment Period 3|Protocol Violation|1
6141649|NCT01042236|9774604|FG004|Treatment Period 3|Protocol Violation|0
6141650|NCT01042236|9774605|FG005|Treatment Period 3|Protocol Violation|0
6141651|NCT01042392|9774630|FG000|Period II(Randomized,Double Blinded,8wk)|Adverse Event|6
6141652|NCT01042392|9774631|FG001|Period II(Randomized,Double Blinded,8wk)|Adverse Event|0
6141653|NCT01042392|9774632|FG002|Period II(Randomized,Double Blinded,8wk)|Adverse Event|5
6141654|NCT01042392|9774633|FG003|Period II(Randomized,Double Blinded,8wk)|Adverse Event|0
6141655|NCT01042392|9774630|FG000|Period II(Randomized,Double Blinded,8wk)|Unsatisfactory therapeutic effect|1
6141656|NCT01042392|9774631|FG001|Period II(Randomized,Double Blinded,8wk)|Unsatisfactory therapeutic effect|0
6141657|NCT01042392|9774632|FG002|Period II(Randomized,Double Blinded,8wk)|Unsatisfactory therapeutic effect|0
6141658|NCT01042392|9774633|FG003|Period II(Randomized,Double Blinded,8wk)|Unsatisfactory therapeutic effect|0
6141659|NCT01042392|9774630|FG000|Period II(Randomized,Double Blinded,8wk)|Withdrawal by Subject|1
6141660|NCT01042392|9774631|FG001|Period II(Randomized,Double Blinded,8wk)|Withdrawal by Subject|0
6141661|NCT01042392|9774632|FG002|Period II(Randomized,Double Blinded,8wk)|Withdrawal by Subject|2
6141662|NCT01042392|9774633|FG003|Period II(Randomized,Double Blinded,8wk)|Withdrawal by Subject|0
6141663|NCT01042392|9774630|FG000|Period II(Randomized,Double Blinded,8wk)|Lost to Follow-up|0
6141664|NCT01042392|9774631|FG001|Period II(Randomized,Double Blinded,8wk)|Lost to Follow-up|0
6141665|NCT01042392|9774632|FG002|Period II(Randomized,Double Blinded,8wk)|Lost to Follow-up|1
6141666|NCT01042392|9774633|FG003|Period II(Randomized,Double Blinded,8wk)|Lost to Follow-up|0
6141667|NCT01042392|9774630|FG000|Period II(Randomized,Double Blinded,8wk)|Administrative problems|2
6141668|NCT01042392|9774631|FG001|Period II(Randomized,Double Blinded,8wk)|Administrative problems|0
6141669|NCT01042392|9774632|FG002|Period II(Randomized,Double Blinded,8wk)|Administrative problems|0
6141670|NCT01042392|9774633|FG003|Period II(Randomized,Double Blinded,8wk)|Administrative problems|0
6141671|NCT01042392|9774630|FG000|Period III (Unblinded,Controlled, 1 Day)|Adverse Event|0
6141672|NCT01042392|9774631|FG001|Period III (Unblinded,Controlled, 1 Day)|Adverse Event|0
6141673|NCT01042392|9774632|FG002|Period III (Unblinded,Controlled, 1 Day)|Adverse Event|1
6141674|NCT01042392|9774633|FG003|Period III (Unblinded,Controlled, 1 Day)|Adverse Event|0
6141675|NCT01042392|9774630|FG000|Period III (Unblinded,Controlled, 1 Day)|Protocol Violation|2
6141676|NCT01042392|9774631|FG001|Period III (Unblinded,Controlled, 1 Day)|Protocol Violation|0
6141677|NCT01042392|9774632|FG002|Period III (Unblinded,Controlled, 1 Day)|Protocol Violation|0
6141678|NCT01042392|9774633|FG003|Period III (Unblinded,Controlled, 1 Day)|Protocol Violation|0
6141679|NCT01042392|9774630|FG000|Period III (Unblinded,Controlled, 1 Day)|Withdrawal by Subject|0
6141680|NCT01042392|9774631|FG001|Period III (Unblinded,Controlled, 1 Day)|Withdrawal by Subject|0
6141681|NCT01042392|9774632|FG002|Period III (Unblinded,Controlled, 1 Day)|Withdrawal by Subject|2
6141682|NCT01042392|9774633|FG003|Period III (Unblinded,Controlled, 1 Day)|Withdrawal by Subject|0
6141683|NCT01042392|9774630|FG000|Period III (Unblinded,Controlled, 1 Day)|Administrative problems|0
6141684|NCT01042392|9774631|FG001|Period III (Unblinded,Controlled, 1 Day)|Administrative problems|1
6141685|NCT01042392|9774632|FG002|Period III (Unblinded,Controlled, 1 Day)|Administrative problems|1
6141686|NCT01042392|9774633|FG003|Period III (Unblinded,Controlled, 1 Day)|Administrative problems|1
6141687|NCT01042535|9774662|FG000|Overall Study|disease progression prior to treatment|3
6141688|NCT01042535|9774662|FG000|Overall Study|disease progression during treatment|3
6141689|NCT01042535|9774662|FG000|Overall Study|complications from other disease|2
6141690|NCT01042600|9774668|FG000|Overall Study|Ineligible|1
6141691|NCT01042600|9774669|FG001|Overall Study|Ineligible|0
6141692|NCT01042678|9774688|FG000|Overall Study|Physician Decision|1
6141693|NCT01042678|9774689|FG001|Overall Study|Physician Decision|0
6141694|NCT01042678|9774690|FG002|Overall Study|Physician Decision|0
6141695|NCT01042678|9774691|FG003|Overall Study|Physician Decision|0
6141696|NCT01042678|9774692|FG004|Overall Study|Physician Decision|0
6141697|NCT01042678|9774693|FG005|Overall Study|Physician Decision|0
6141698|NCT01042938|9774707|FG000|Overall Study|Withdrawal by Subject|1
6141699|NCT01042938|9774708|FG001|Overall Study|Withdrawal by Subject|1
6141700|NCT01042938|9774707|FG000|Overall Study|Protocol Violation|1
6141701|NCT01042938|9774708|FG001|Overall Study|Protocol Violation|1
6141702|NCT01042938|9774707|FG000|Overall Study|Ineligible: RTOG study conflict|1
6141703|NCT01042938|9774708|FG001|Overall Study|Ineligible: RTOG study conflict|0
6141704|NCT01042977|9774718|FG000|Overall Study|Adverse Event|4
6141705|NCT01042977|9774719|FG001|Overall Study|Adverse Event|12
6141706|NCT01042977|9774718|FG000|Overall Study|Death|2
6141707|NCT01042977|9774719|FG001|Overall Study|Death|1
6141708|NCT01042977|9774718|FG000|Overall Study|Withdrawal by Subject|8
6141709|NCT01042977|9774719|FG001|Overall Study|Withdrawal by Subject|16
6141710|NCT01042977|9774718|FG000|Overall Study|Lost to Follow-up|0
6141711|NCT01042977|9774719|FG001|Overall Study|Lost to Follow-up|2
6141712|NCT01042977|9774718|FG000|Overall Study|Poor/non-compliance|3
6141713|NCT01042977|9774719|FG001|Overall Study|Poor/non-compliance|4
6141714|NCT01042977|9774718|FG000|Overall Study|Subject no longer meets study criteria|15
6141715|NCT01042977|9774719|FG001|Overall Study|Subject no longer meets study criteria|13
6141716|NCT01042977|9774718|FG000|Overall Study|Incorrect enrollment|6
6141717|NCT01042977|9774719|FG001|Overall Study|Incorrect enrollment|4
6141718|NCT01042977|9774718|FG000|Overall Study|Safety|0
6141719|NCT01042977|9774719|FG001|Overall Study|Safety|2
6141720|NCT01042977|9774718|FG000|Overall Study|Administrative reason by sponsor|0
6141721|NCT01042977|9774719|FG001|Overall Study|Administrative reason by sponsor|1
6141722|NCT01042977|9774718|FG000|Overall Study|Various|3
6141723|NCT01042977|9774719|FG001|Overall Study|Various|0
6141724|NCT01043185|9774768|FG000|Period 6 - Third Washout Period|Protocol Violation|0
6141725|NCT01043185|9774769|FG001|Period 6 - Third Washout Period|Protocol Violation|0
6141726|NCT01043185|9774770|FG002|Period 6 - Third Washout Period|Protocol Violation|0
6141727|NCT01043185|9774771|FG003|Period 6 - Third Washout Period|Protocol Violation|0
6141728|NCT01043185|9774772|FG004|Period 6 - Third Washout Period|Protocol Violation|0
6141729|NCT01043185|9774773|FG005|Period 6 - Third Washout Period|Protocol Violation|0
6141730|NCT01043185|9774774|FG006|Period 6 - Third Washout Period|Protocol Violation|0
6141731|NCT01043185|9774775|FG007|Period 6 - Third Washout Period|Protocol Violation|0
6141732|NCT01043185|9774776|FG008|Period 6 - Third Washout Period|Protocol Violation|1
6141733|NCT01043185|9774777|FG009|Period 6 - Third Washout Period|Protocol Violation|0
6141734|NCT01043705|9774838|FG000|Overall Study|Death|28
6141735|NCT01043705|9774839|FG001|Overall Study|Death|60
6141736|NCT01043705|9774840|FG002|Overall Study|Death|26
6141737|NCT01043705|9774838|FG000|Overall Study|Lost to Follow-up|27
6141738|NCT01043705|9774839|FG001|Overall Study|Lost to Follow-up|12
6141739|NCT01043705|9774840|FG002|Overall Study|Lost to Follow-up|0
6141740|NCT01043705|9774838|FG000|Overall Study|Multiple Reasons|4
6141741|NCT01043705|9774839|FG001|Overall Study|Multiple Reasons|7
6141742|NCT01043705|9774840|FG002|Overall Study|Multiple Reasons|0
6141743|NCT01043705|9774838|FG000|Overall Study|Protocol Violation|2
6141744|NCT01043705|9774839|FG001|Overall Study|Protocol Violation|1
6141745|NCT01043705|9774840|FG002|Overall Study|Protocol Violation|0
6141746|NCT01043705|9774838|FG000|Overall Study|Withdrawal by Subject|8
6141747|NCT01043705|9774839|FG001|Overall Study|Withdrawal by Subject|6
6141748|NCT01043705|9774840|FG002|Overall Study|Withdrawal by Subject|0
6141749|NCT01043705|9774838|FG000|Overall Study|Site Closure|8
6141750|NCT01043705|9774839|FG001|Overall Study|Site Closure|0
6141751|NCT01043705|9774840|FG002|Overall Study|Site Closure|0
6141752|NCT01043705|9774838|FG000|Overall Study|Subsequent Procedure|9
6141753|NCT01043705|9774839|FG001|Overall Study|Subsequent Procedure|24
6141754|NCT01043705|9774840|FG002|Overall Study|Subsequent Procedure|29
6141755|NCT01043705|9774838|FG000|Overall Study|Adverse Event|0
6141756|NCT01043705|9774839|FG001|Overall Study|Adverse Event|2
6141757|NCT01043705|9774840|FG002|Overall Study|Adverse Event|0
6141758|NCT01043705|9774838|FG000|Overall Study|Screen Fail|21
6141759|NCT01043705|9774839|FG001|Overall Study|Screen Fail|0
6141760|NCT01043705|9774840|FG002|Overall Study|Screen Fail|0
6141761|NCT01043705|9774838|FG000|Overall Study|Other|0
6141762|NCT01043705|9774839|FG001|Overall Study|Other|19
6141763|NCT01043705|9774840|FG002|Overall Study|Other|25
6141764|NCT01043874|9774848|FG000|Overall Study|Adverse Event|3
6141765|NCT01043874|9774848|FG000|Overall Study|Withdrawal by Subject|1
6141766|NCT01043874|9774848|FG000|Overall Study|Lack of Efficacy|1
6141767|NCT01043874|9774848|FG000|Overall Study|Administrative Problems|1
6141768|NCT01044290|9774907|FG000|Follow-up 1|Death|3
6141769|NCT01044290|9774908|FG001|Follow-up 1|Death|3
6141770|NCT01044290|9774909|FG002|Follow-up 1|Death|1
6141771|NCT01044290|9774907|FG000|Follow-up 1|Withdrawal by Subject|2
6141772|NCT01044290|9774908|FG001|Follow-up 1|Withdrawal by Subject|2
6141773|NCT01044290|9774909|FG002|Follow-up 1|Withdrawal by Subject|0
6141774|NCT01044290|9774907|FG000|Follow-Up 2|Death|0
6141775|NCT01044290|9774908|FG001|Follow-Up 2|Death|1
6141776|NCT01044290|9774909|FG002|Follow-Up 2|Death|1
6141777|NCT01044290|9774907|FG000|Follow-Up 2|Withdrawal by Subject|0
6141778|NCT01044290|9774908|FG001|Follow-Up 2|Withdrawal by Subject|1
6141779|NCT01044290|9774909|FG002|Follow-Up 2|Withdrawal by Subject|1
6141780|NCT01044303|9774927|FG000|Overall Study|Lost to Follow-up|2
6141781|NCT01044433|9774934|FG000|Overall Study|Lost to Follow-up|3
6141782|NCT01044433|9774934|FG000|Overall Study|Withdrawal by Subject|3
6141783|NCT01044459|9774941|FG000|Overall Study|Withdrawal by Subject|21
6141784|NCT01044459|9774942|FG001|Overall Study|Withdrawal by Subject|28
6141785|NCT01044459|9774941|FG000|Overall Study|Terminated by Sponsor|22
6141786|NCT01044459|9774942|FG001|Overall Study|Terminated by Sponsor|21
6141787|NCT01044459|9774941|FG000|Overall Study|Adverse Event|22
6141788|NCT01044459|9774942|FG001|Overall Study|Adverse Event|20
6141789|NCT01044459|9774941|FG000|Overall Study|Lack of Efficacy|23
6141790|NCT01044459|9774942|FG001|Overall Study|Lack of Efficacy|12
6141791|NCT01044459|9774941|FG000|Overall Study|Protocol Violation|11
6141792|NCT01044459|9774942|FG001|Overall Study|Protocol Violation|16
6141793|NCT01044459|9774941|FG000|Overall Study|Other Reason|7
6141794|NCT01044459|9774942|FG001|Overall Study|Other Reason|14
6141795|NCT01044459|9774941|FG000|Overall Study|COPD exacerbation|9
6141796|NCT01044459|9774942|FG001|Overall Study|COPD exacerbation|8
6141797|NCT01044459|9774941|FG000|Overall Study|Lost to Follow-up|18
6141798|NCT01044459|9774942|FG001|Overall Study|Lost to Follow-up|12
6141799|NCT01044498|9774950|FG000|Overall Study|Withdrew consent|1
6141800|NCT01044498|9774951|FG001|Overall Study|Withdrew consent|1
6141801|NCT01044498|9774950|FG000|Overall Study|Adverse Event|1
6141802|NCT01044498|9774951|FG001|Overall Study|Adverse Event|1
6141803|NCT01044498|9774950|FG000|Overall Study|Other|1
6141804|NCT01044498|9774951|FG001|Overall Study|Other|0
6141805|NCT01044732|9775035|FG000|Overall Study|Lost to Follow-up|2
6141806|NCT01044732|9775036|FG001|Overall Study|Lost to Follow-up|1
6141807|NCT01044732|9775035|FG000|Overall Study|Physician Decision|5
6141808|NCT01044732|9775036|FG001|Overall Study|Physician Decision|3
6141809|NCT01044732|9775035|FG000|Overall Study|Protocol Violation|11
6141810|NCT01044732|9775036|FG001|Overall Study|Protocol Violation|12
6141811|NCT01044732|9775035|FG000|Overall Study|Withdrawal by Subject|0
6141812|NCT01044732|9775036|FG001|Overall Study|Withdrawal by Subject|1
6141813|NCT01044732|9775035|FG000|Overall Study|Inadequate bowel preparation|11
6141814|NCT01044732|9775036|FG001|Overall Study|Inadequate bowel preparation|17
6141815|NCT01044732|9775035|FG000|Overall Study|Inability to reach cecum|5
6141816|NCT01044732|9775036|FG001|Overall Study|Inability to reach cecum|2
6141817|NCT01044732|9775035|FG000|Overall Study|Technical error or malfunction|15
6141818|NCT01044732|9775036|FG001|Overall Study|Technical error or malfunction|14
6141819|NCT01044745|9775044|FG000|Overall Study|Ineiligible|2
6141820|NCT01045096|9775126|FG000|Overall Study|Withdrawal by Subject|2
6141821|NCT01045096|9775127|FG001|Overall Study|Withdrawal by Subject|0
6141822|NCT01045096|9775128|FG002|Overall Study|Withdrawal by Subject|0
6141823|NCT01045096|9775126|FG000|Overall Study|Other|1
6141824|NCT01045096|9775127|FG001|Overall Study|Other|0
6141825|NCT01045096|9775128|FG002|Overall Study|Other|0
6141826|NCT01045161|9775152|FG000|Part A - 12 Weeks Double Blind Treatment|Withdrawal by Subject|8
6141827|NCT01045161|9775153|FG001|Part A - 12 Weeks Double Blind Treatment|Withdrawal by Subject|12
6141828|NCT01045161|9775154|FG002|Part A - 12 Weeks Double Blind Treatment|Withdrawal by Subject|6
6141829|NCT01045161|9775152|FG000|Part A - 12 Weeks Double Blind Treatment|Adverse Event|4
6141830|NCT01045161|9775153|FG001|Part A - 12 Weeks Double Blind Treatment|Adverse Event|3
6141831|NCT01045161|9775154|FG002|Part A - 12 Weeks Double Blind Treatment|Adverse Event|8
6141832|NCT01045161|9775152|FG000|Part A - 12 Weeks Double Blind Treatment|Lack of Efficacy|6
6141833|NCT01045161|9775153|FG001|Part A - 12 Weeks Double Blind Treatment|Lack of Efficacy|3
6141834|NCT01045161|9775154|FG002|Part A - 12 Weeks Double Blind Treatment|Lack of Efficacy|2
6141835|NCT01045161|9775152|FG000|Part A - 12 Weeks Double Blind Treatment|COPD Exacerbation|4
6141836|NCT01045161|9775153|FG001|Part A - 12 Weeks Double Blind Treatment|COPD Exacerbation|1
6141837|NCT01045161|9775154|FG002|Part A - 12 Weeks Double Blind Treatment|COPD Exacerbation|6
6141838|NCT01045161|9775152|FG000|Part A - 12 Weeks Double Blind Treatment|Other Reason|3
6141839|NCT01045161|9775153|FG001|Part A - 12 Weeks Double Blind Treatment|Other Reason|3
6141840|NCT01045161|9775154|FG002|Part A - 12 Weeks Double Blind Treatment|Other Reason|3
6141841|NCT01045161|9775152|FG000|Part A - 12 Weeks Double Blind Treatment|Protocol Violation|3
6141842|NCT01045161|9775153|FG001|Part A - 12 Weeks Double Blind Treatment|Protocol Violation|4
6141843|NCT01045161|9775154|FG002|Part A - 12 Weeks Double Blind Treatment|Protocol Violation|3
6141844|NCT01045161|9775152|FG000|Part A - 12 Weeks Double Blind Treatment|Lost to Follow-up|3
6141845|NCT01045161|9775153|FG001|Part A - 12 Weeks Double Blind Treatment|Lost to Follow-up|3
6141846|NCT01045161|9775154|FG002|Part A - 12 Weeks Double Blind Treatment|Lost to Follow-up|2
6141847|NCT01045161|9775152|FG000|Part B - 40 Additional Weeks Open Label|Withdrawal by Subject|10
6141848|NCT01045161|9775153|FG001|Part B - 40 Additional Weeks Open Label|Withdrawal by Subject|7
6141849|NCT01045161|9775154|FG002|Part B - 40 Additional Weeks Open Label|Withdrawal by Subject|9
6141850|NCT01045161|9775152|FG000|Part B - 40 Additional Weeks Open Label|Adverse Event|10
6141851|NCT01045161|9775153|FG001|Part B - 40 Additional Weeks Open Label|Adverse Event|10
6141852|NCT01045161|9775154|FG002|Part B - 40 Additional Weeks Open Label|Adverse Event|7
6141853|NCT01045161|9775152|FG000|Part B - 40 Additional Weeks Open Label|Lack of Efficacy|3
6141854|NCT01045161|9775153|FG001|Part B - 40 Additional Weeks Open Label|Lack of Efficacy|5
6141855|NCT01045161|9775154|FG002|Part B - 40 Additional Weeks Open Label|Lack of Efficacy|5
6141856|NCT01045161|9775152|FG000|Part B - 40 Additional Weeks Open Label|COPD Exacerbation|1
6141857|NCT01045161|9775153|FG001|Part B - 40 Additional Weeks Open Label|COPD Exacerbation|5
6141858|NCT01045161|9775154|FG002|Part B - 40 Additional Weeks Open Label|COPD Exacerbation|1
6141859|NCT01045161|9775152|FG000|Part B - 40 Additional Weeks Open Label|Other Reason|4
6141860|NCT01045161|9775153|FG001|Part B - 40 Additional Weeks Open Label|Other Reason|2
6141861|NCT01045161|9775154|FG002|Part B - 40 Additional Weeks Open Label|Other Reason|1
6141862|NCT01045161|9775152|FG000|Part B - 40 Additional Weeks Open Label|Protocol Violation|3
6141863|NCT01045161|9775153|FG001|Part B - 40 Additional Weeks Open Label|Protocol Violation|6
6141864|NCT01045161|9775154|FG002|Part B - 40 Additional Weeks Open Label|Protocol Violation|3
6141865|NCT01045161|9775152|FG000|Part B - 40 Additional Weeks Open Label|Lost to Follow-up|5
6141866|NCT01045161|9775153|FG001|Part B - 40 Additional Weeks Open Label|Lost to Follow-up|1
6141867|NCT01045161|9775154|FG002|Part B - 40 Additional Weeks Open Label|Lost to Follow-up|6
6141868|NCT01045421|9775194|FG000|Phase 1|Progressive Disease|0
6141869|NCT01045421|9775195|FG001|Phase 1|Progressive Disease|0
6141870|NCT01045421|9775196|FG002|Phase 1|Progressive Disease|0
6141871|NCT01045421|9775197|FG003|Phase 1|Progressive Disease|0
6141872|NCT01045421|9775198|FG004|Phase 1|Progressive Disease|1
6141873|NCT01045421|9775199|FG005|Phase 1|Progressive Disease|0
6141874|NCT01045421|9775200|FG006|Phase 1|Progressive Disease|0
6141875|NCT01045421|9775201|FG007|Phase 1|Progressive Disease|0
6141876|NCT01045421|9775202|FG008|Phase 1|Progressive Disease|0
6141877|NCT01045421|9775203|FG009|Phase 1|Progressive Disease|0
6141878|NCT01045421|9775204|FG010|Phase 1|Progressive Disease|0
6141879|NCT01045421|9775194|FG000|Phase 1|Withdrawal by Subject|0
6141880|NCT01045421|9775195|FG001|Phase 1|Withdrawal by Subject|0
6141881|NCT01045421|9775196|FG002|Phase 1|Withdrawal by Subject|0
6141882|NCT01045421|9775197|FG003|Phase 1|Withdrawal by Subject|1
6141883|NCT01045421|9775198|FG004|Phase 1|Withdrawal by Subject|0
6141884|NCT01045421|9775199|FG005|Phase 1|Withdrawal by Subject|0
6141885|NCT01045421|9775200|FG006|Phase 1|Withdrawal by Subject|0
6141886|NCT01045421|9775201|FG007|Phase 1|Withdrawal by Subject|0
6141887|NCT01045421|9775202|FG008|Phase 1|Withdrawal by Subject|0
6141888|NCT01045421|9775203|FG009|Phase 1|Withdrawal by Subject|0
6141889|NCT01045421|9775204|FG010|Phase 1|Withdrawal by Subject|0
6141890|NCT01045421|9775194|FG000|Phase 2|Progressive Disease|0
6141891|NCT01045421|9775195|FG001|Phase 2|Progressive Disease|0
6141892|NCT01045421|9775196|FG002|Phase 2|Progressive Disease|0
6141893|NCT01045421|9775197|FG003|Phase 2|Progressive Disease|0
6141894|NCT01045421|9775198|FG004|Phase 2|Progressive Disease|0
6141895|NCT01045421|9775199|FG005|Phase 2|Progressive Disease|0
6141896|NCT01045421|9775200|FG006|Phase 2|Progressive Disease|0
6141897|NCT01045421|9775201|FG007|Phase 2|Progressive Disease|1
6141898|NCT01045421|9775202|FG008|Phase 2|Progressive Disease|1
6141899|NCT01045421|9775203|FG009|Phase 2|Progressive Disease|1
6141900|NCT01045421|9775204|FG010|Phase 2|Progressive Disease|1
6141901|NCT01045421|9775194|FG000|Phase 2|Death|0
6141902|NCT01045421|9775195|FG001|Phase 2|Death|0
6141903|NCT01045421|9775196|FG002|Phase 2|Death|0
6141904|NCT01045421|9775197|FG003|Phase 2|Death|0
6141905|NCT01045421|9775198|FG004|Phase 2|Death|0
6141906|NCT01045421|9775199|FG005|Phase 2|Death|0
6141907|NCT01045421|9775200|FG006|Phase 2|Death|0
6141908|NCT01045421|9775201|FG007|Phase 2|Death|1
6141909|NCT01045421|9775202|FG008|Phase 2|Death|1
6141910|NCT01045421|9775203|FG009|Phase 2|Death|2
6141911|NCT01045421|9775204|FG010|Phase 2|Death|0
6141912|NCT01045421|9775194|FG000|Phase 2|Other|0
6141913|NCT01045421|9775195|FG001|Phase 2|Other|0
6141914|NCT01045421|9775196|FG002|Phase 2|Other|0
6141915|NCT01045421|9775197|FG003|Phase 2|Other|0
6141916|NCT01045421|9775198|FG004|Phase 2|Other|0
6141917|NCT01045421|9775199|FG005|Phase 2|Other|0
6141918|NCT01045421|9775200|FG006|Phase 2|Other|0
6141919|NCT01045421|9775201|FG007|Phase 2|Other|3
6141920|NCT01045421|9775202|FG008|Phase 2|Other|0
6141921|NCT01045421|9775203|FG009|Phase 2|Other|0
6141922|NCT01045421|9775204|FG010|Phase 2|Other|1
6141923|NCT01045447|9775227|FG000|Overall Study|Adverse Event|0
6141924|NCT01045447|9775228|FG001|Overall Study|Adverse Event|1
6141925|NCT01045447|9775227|FG000|Overall Study|Lack of Efficacy|3
6141926|NCT01045447|9775228|FG001|Overall Study|Lack of Efficacy|1
6141927|NCT01045447|9775227|FG000|Overall Study|Protocol Violation|6
6141928|NCT01045447|9775228|FG001|Overall Study|Protocol Violation|3
6141929|NCT01045447|9775227|FG000|Overall Study|Withdrawal Criteria|10
6141930|NCT01045447|9775228|FG001|Overall Study|Withdrawal Criteria|10
6141931|NCT01045447|9775227|FG000|Overall Study|Unclassified|17
6141932|NCT01045447|9775228|FG001|Overall Study|Unclassified|13
6141933|NCT01045460|9775236|FG000|Overall Study|Physician Decision|3
6141934|NCT01045460|9775237|FG001|Overall Study|Physician Decision|2
6141935|NCT01045460|9775236|FG000|Overall Study|Lost to Follow-up|0
6141936|NCT01045460|9775237|FG001|Overall Study|Lost to Follow-up|1
6141937|NCT01045460|9775236|FG000|Overall Study|Lack of Efficacy|3
6141938|NCT01045460|9775237|FG001|Overall Study|Lack of Efficacy|0
6141939|NCT01045707|9775256|FG000|Main: Week 0 to 26 (NN5401-3590)|Adverse Event|5
6141940|NCT01045707|9775257|FG001|Main: Week 0 to 26 (NN5401-3590)|Adverse Event|3
6141941|NCT01045707|9775256|FG000|Main: Week 0 to 26 (NN5401-3590)|Lack of Efficacy|4
6141942|NCT01045707|9775257|FG001|Main: Week 0 to 26 (NN5401-3590)|Lack of Efficacy|2
6141943|NCT01045707|9775256|FG000|Main: Week 0 to 26 (NN5401-3590)|Protocol Violation|6
6141944|NCT01045707|9775257|FG001|Main: Week 0 to 26 (NN5401-3590)|Protocol Violation|5
6141945|NCT01045707|9775256|FG000|Main: Week 0 to 26 (NN5401-3590)|Withdrawal Criteria|22
6141946|NCT01045707|9775257|FG001|Main: Week 0 to 26 (NN5401-3590)|Withdrawal Criteria|11
6141947|NCT01045707|9775256|FG000|Main: Week 0 to 26 (NN5401-3590)|Unclassified|10
6141948|NCT01045707|9775257|FG001|Main: Week 0 to 26 (NN5401-3590)|Unclassified|11
6141949|NCT01045707|9775256|FG000|Extension: Week 27 to 52 (NN5401-3726)|Adverse Event|3
6141950|NCT01045707|9775257|FG001|Extension: Week 27 to 52 (NN5401-3726)|Adverse Event|3
6141951|NCT01045707|9775256|FG000|Extension: Week 27 to 52 (NN5401-3726)|Protocol Violation|2
6141952|NCT01045707|9775257|FG001|Extension: Week 27 to 52 (NN5401-3726)|Protocol Violation|3
6141953|NCT01045707|9775256|FG000|Extension: Week 27 to 52 (NN5401-3726)|Withdrawal criteria|2
6141954|NCT01045707|9775257|FG001|Extension: Week 27 to 52 (NN5401-3726)|Withdrawal criteria|1
6141955|NCT01045707|9775256|FG000|Extension: Week 27 to 52 (NN5401-3726)|Unclassified|6
6141956|NCT01045707|9775257|FG001|Extension: Week 27 to 52 (NN5401-3726)|Unclassified|5
6141957|NCT01045798|9775265|FG000|Overall Study|Changed to Open-Label Caspofungin|1
6141958|NCT01045798|9775266|FG001|Overall Study|Changed to Open-Label Caspofungin|0
6141959|NCT01045798|9775265|FG000|Overall Study|Invasive Fungal Infection at Baseline|0
6141960|NCT01045798|9775266|FG001|Overall Study|Invasive Fungal Infection at Baseline|1
6141961|NCT01045798|9775265|FG000|Overall Study|Changed to Other Antifungal Therapy|1
6141962|NCT01045798|9775266|FG001|Overall Study|Changed to Other Antifungal Therapy|2
6141963|NCT01045798|9775265|FG000|Overall Study|Received Systemic Antifungal Prestudy|0
6141964|NCT01045798|9775266|FG001|Overall Study|Received Systemic Antifungal Prestudy|1
6141965|NCT01045967|9775274|FG000|Second Intervention|Protocol Violation|0
6141966|NCT01045967|9775275|FG001|Second Intervention|Protocol Violation|1
6141967|NCT01045993|9775285|FG000|Overall Study|Treated-later found eligibility not met|0
6141968|NCT01045993|9775286|FG001|Overall Study|Treated-later found eligibility not met|1
6141969|NCT01045993|9775287|FG002|Overall Study|Treated-later found eligibility not met|0
6141970|NCT01045993|9775288|FG003|Overall Study|Treated-later found eligibility not met|0
6141971|NCT01046084|9775300|FG000|Third Washout of 7 Days|Withdrawal by Subject|2
6141972|NCT01046084|9775301|FG001|Third Washout of 7 Days|Withdrawal by Subject|0
6141973|NCT01046110|9775309|FG000|Overall Study|Adverse Event|9
6141974|NCT01046110|9775310|FG001|Overall Study|Adverse Event|2
6141975|NCT01046110|9775309|FG000|Overall Study|Lack of Efficacy|0
6141976|NCT01046110|9775310|FG001|Overall Study|Lack of Efficacy|1
6141977|NCT01046110|9775309|FG000|Overall Study|Protocol Violation|7
6141978|NCT01046110|9775310|FG001|Overall Study|Protocol Violation|12
6141979|NCT01046110|9775309|FG000|Overall Study|Withdrawal Criteria|3
6141980|NCT01046110|9775310|FG001|Overall Study|Withdrawal Criteria|5
6141981|NCT01046110|9775309|FG000|Overall Study|Unclassified|36
6141982|NCT01046110|9775310|FG001|Overall Study|Unclassified|35
6141983|NCT01046136|9775318|FG000|Overall Study|Withdrawal by Subject|0
6141984|NCT01046136|9775319|FG001|Overall Study|Withdrawal by Subject|4
6141985|NCT01046136|9775318|FG000|Overall Study|Physician Decision|1
6141986|NCT01046136|9775319|FG001|Overall Study|Physician Decision|1
6141987|NCT01046136|9775318|FG000|Overall Study|Lost to Follow-up|3
6141988|NCT01046136|9775319|FG001|Overall Study|Lost to Follow-up|3
6141989|NCT01046253|9775329|FG000|Second Intervention|Adverse Event|0
6141990|NCT01046253|9775330|FG001|Second Intervention|Adverse Event|1
6141991|NCT01046253|9775329|FG000|Second Intervention|Protocol Violation|0
6141992|NCT01046253|9775330|FG001|Second Intervention|Protocol Violation|1
6141993|NCT01046396|9775336|FG000|Overall Study|Withdrawal by Subject|5
6141994|NCT01046565|9775343|FG000|Overall Study|Adverse Event|2
6141995|NCT01046565|9775343|FG000|Overall Study|Withdrawal by Subject|7
6141996|NCT01046643|9775354|FG000|First Period Treatment or Placebo|Withdrawal by Subject|0
6141997|NCT01046643|9775355|FG001|First Period Treatment or Placebo|Withdrawal by Subject|1
6141998|NCT01046643|9775356|FG002|First Period Treatment or Placebo|Withdrawal by Subject|0
6141999|NCT01046643|9775357|FG003|First Period Treatment or Placebo|Withdrawal by Subject|0
6142000|NCT01046682|9775378|FG000|Overall Study|Adverse Event|2
6142001|NCT01046682|9775379|FG001|Overall Study|Adverse Event|0
6142002|NCT01046695|9775387|FG000|Overall Study|Subject had a pacemaker|0
6142003|NCT01046695|9775388|FG001|Overall Study|Subject had a pacemaker|1
6142004|NCT01046695|9775387|FG000|Overall Study|TENS interfered with the cardiac monitor|0
6142005|NCT01046695|9775388|FG001|Overall Study|TENS interfered with the cardiac monitor|1
6142006|NCT01046877|9775394|FG000|Overall Study|Exited voluntarily before tube extrusion|7
6142007|NCT01046877|9775394|FG000|Overall Study|Exited voluntarily after tube extrusion|11
6142008|NCT01046903|9775398|FG000|Overall Study|Lost to Follow-up|16
6142009|NCT01046903|9775398|FG000|Overall Study|Adverse Event|4
6142010|NCT01046903|9775398|FG000|Overall Study|Withdrawal by Subject|3
6142011|NCT01046903|9775398|FG000|Overall Study|Other|5
6142012|NCT01047007|9775406|FG000|Overall Study|Adverse Event|0
6142013|NCT01047007|9775407|FG001|Overall Study|Adverse Event|2
6142014|NCT01047007|9775408|FG002|Overall Study|Adverse Event|1
6142015|NCT01047007|9775409|FG003|Overall Study|Adverse Event|0
6142016|NCT01047007|9775406|FG000|Overall Study|Progressive Disease|2
6142017|NCT01047007|9775407|FG001|Overall Study|Progressive Disease|4
6142018|NCT01047007|9775408|FG002|Overall Study|Progressive Disease|1
6142019|NCT01047007|9775409|FG003|Overall Study|Progressive Disease|0
6142020|NCT01047293|9775435|FG000|Overall Study|DLT criteria not fulfilled|1
6142021|NCT01047293|9775436|FG001|Overall Study|DLT criteria not fulfilled|1
6142022|NCT01047293|9775437|FG002|Overall Study|DLT criteria not fulfilled|0
6142023|NCT01047293|9775438|FG003|Overall Study|DLT criteria not fulfilled|0
6142024|NCT01047306|9775447|FG000|Overall Study|Withdrawal by Subject|2
6142025|NCT01047306|9775448|FG001|Overall Study|Withdrawal by Subject|0
6142026|NCT01047306|9775447|FG000|Overall Study|Lost to Follow-up|1
6142027|NCT01047306|9775448|FG001|Overall Study|Lost to Follow-up|0
6142028|NCT01047332|9775458|FG000|Overall Study|SEMS Obstruction|11
6142029|NCT01047332|9775459|FG001|Overall Study|SEMS Obstruction|20
6142030|NCT01047332|9775458|FG000|Overall Study|Died Unobstructed|38
6142031|NCT01047332|9775459|FG001|Overall Study|Died Unobstructed|41
6142032|NCT01047332|9775458|FG000|Overall Study|Lost to Follow-up|8
6142033|NCT01047332|9775459|FG001|Overall Study|Lost to Follow-up|3
6142034|NCT01047345|9775467|FG000|Base Study|Adverse Event|3
6142035|NCT01047345|9775468|FG001|Base Study|Adverse Event|0
6142036|NCT01047345|9775469|FG002|Base Study|Adverse Event|0
6142037|NCT01047345|9775467|FG000|Base Study|Lost to Follow-up|4
6142038|NCT01047345|9775468|FG001|Base Study|Lost to Follow-up|1
6142039|NCT01047345|9775469|FG002|Base Study|Lost to Follow-up|0
6142040|NCT01047345|9775467|FG000|Base Study|Protocol Violation|3
6142041|NCT01047345|9775468|FG001|Base Study|Protocol Violation|1
6142042|NCT01047345|9775469|FG002|Base Study|Protocol Violation|0
6142043|NCT01047345|9775467|FG000|Base Study|Withdrawal by Subject|12
6142044|NCT01047345|9775468|FG001|Base Study|Withdrawal by Subject|4
6142045|NCT01047345|9775469|FG002|Base Study|Withdrawal by Subject|0
6142046|NCT01047345|9775467|FG000|Extension|Withdrawal by Subject|0
6142047|NCT01047345|9775468|FG001|Extension|Withdrawal by Subject|0
6142048|NCT01047345|9775469|FG002|Extension|Withdrawal by Subject|1
6142049|NCT01047345|9775467|FG000|Extension|Lost to Follow-up|0
6142050|NCT01047345|9775468|FG001|Extension|Lost to Follow-up|0
6142051|NCT01047345|9775469|FG002|Extension|Lost to Follow-up|5
6142052|NCT01047436|9775484|FG000|Overall Study|Protocol Violation|1
6142053|NCT01047436|9775485|FG001|Overall Study|Protocol Violation|0
6142054|NCT01047553|9775516|FG000|Overall Study|Adverse Event|10
6142055|NCT01047553|9775517|FG001|Overall Study|Adverse Event|5
6142056|NCT01047553|9775516|FG000|Overall Study|Withdrawal by Subject|4
6142057|NCT01047553|9775517|FG001|Overall Study|Withdrawal by Subject|2
6142058|NCT01047553|9775516|FG000|Overall Study|Development of Study-Specific Withdrawal|1
6142059|NCT01047553|9775517|FG001|Overall Study|Development of Study-Specific Withdrawal|1
6142060|NCT01047553|9775516|FG000|Overall Study|Lost to Follow-up|1
6142061|NCT01047553|9775517|FG001|Overall Study|Lost to Follow-up|0
6142062|NCT01047553|9775516|FG000|Overall Study|Sever Non-Compliance to Protocol|1
6142063|NCT01047553|9775517|FG001|Overall Study|Sever Non-Compliance to Protocol|0
6142064|NCT01047553|9775516|FG000|Overall Study|PI's decision|0
6142065|NCT01047553|9775517|FG001|Overall Study|PI's decision|1
6142066|NCT01048099|9775550|FG000|Patients Enrolled and Blood Collected|Patients without circulating tumor cells|57
6142067|NCT01048099|9775550|FG000|Patients Evaluated by PRO Onc Assay|Patients with no HER2 abnormality|202
6142068|NCT01048242|9775558|FG000|Overall Study|See study flow chart|4
6142069|NCT01048242|9775559|FG001|Overall Study|See study flow chart|2
6142070|NCT01048333|9775565|FG000|Wash-Out Period 2 of 2 - 7 Days|Adverse Event|0
6142071|NCT01048333|9775566|FG001|Wash-Out Period 2 of 2 - 7 Days|Adverse Event|1
6142072|NCT01048333|9775567|FG002|Wash-Out Period 2 of 2 - 7 Days|Adverse Event|0
6142073|NCT01048333|9775568|FG003|Wash-Out Period 2 of 2 - 7 Days|Adverse Event|0
6142074|NCT01048333|9775569|FG004|Wash-Out Period 2 of 2 - 7 Days|Adverse Event|0
6142075|NCT01048333|9775570|FG005|Wash-Out Period 2 of 2 - 7 Days|Adverse Event|0
6142076|NCT01048502|9775592|FG000|Overall Study|Lost to Follow-up|2
6142077|NCT01048502|9775593|FG001|Overall Study|Lost to Follow-up|0
6142078|NCT01048502|9775594|FG002|Overall Study|Lost to Follow-up|0
6142079|NCT01048502|9775595|FG003|Overall Study|Lost to Follow-up|0
6142080|NCT01048502|9775592|FG000|Overall Study|Adverse Event|1
6142081|NCT01048502|9775593|FG001|Overall Study|Adverse Event|0
6142082|NCT01048502|9775594|FG002|Overall Study|Adverse Event|0
6142083|NCT01048502|9775595|FG003|Overall Study|Adverse Event|0
6142084|NCT01048502|9775592|FG000|Overall Study|Withdrawal by Subject|1
6142085|NCT01048502|9775593|FG001|Overall Study|Withdrawal by Subject|4
6142086|NCT01048502|9775594|FG002|Overall Study|Withdrawal by Subject|5
6142087|NCT01048502|9775595|FG003|Overall Study|Withdrawal by Subject|3
6142088|NCT01048502|9775592|FG000|Overall Study|Physician Decision|0
6142089|NCT01048502|9775593|FG001|Overall Study|Physician Decision|3
6142090|NCT01048502|9775594|FG002|Overall Study|Physician Decision|0
6142091|NCT01048502|9775595|FG003|Overall Study|Physician Decision|1
6142092|NCT01048541|9775606|FG000|Overall Study|Withdrawal by Subject|1
6142093|NCT01048541|9775607|FG001|Overall Study|Withdrawal by Subject|0
6142094|NCT01048671|9775655|FG000|Overall Study|Protocol Violation|0
6142095|NCT01048671|9775656|FG001|Overall Study|Protocol Violation|1
6142096|NCT01048671|9775657|FG002|Overall Study|Protocol Violation|1
6142097|NCT01048788|9775672|FG000|Overall Study|Adverse Event|5
6142098|NCT01048788|9775673|FG001|Overall Study|Adverse Event|1
6142099|NCT01048788|9775674|FG002|Overall Study|Adverse Event|1
6142100|NCT01048788|9775672|FG000|Overall Study|Lack of Efficacy|0
6142101|NCT01048788|9775673|FG001|Overall Study|Lack of Efficacy|0
6142102|NCT01048788|9775674|FG002|Overall Study|Lack of Efficacy|1
6142103|NCT01048788|9775672|FG000|Overall Study|Withdrawal by Subject|0
6142104|NCT01048788|9775673|FG001|Overall Study|Withdrawal by Subject|1
6142105|NCT01048788|9775674|FG002|Overall Study|Withdrawal by Subject|0
6142106|NCT01048866|9775684|FG000|Overall Study|Adverse Event|1
6142107|NCT01048866|9775685|FG001|Overall Study|Adverse Event|0
6142108|NCT01048866|9775684|FG000|Overall Study|Protocol Violation|1
6142109|NCT01048866|9775685|FG001|Overall Study|Protocol Violation|0
6142110|NCT01048866|9775684|FG000|Overall Study|Physician Decision|1
6142111|NCT01048866|9775685|FG001|Overall Study|Physician Decision|0
6142112|NCT01048866|9775684|FG000|Overall Study|Withdrawal by Subject|0
6142113|NCT01048866|9775685|FG001|Overall Study|Withdrawal by Subject|2
6142114|NCT01048866|9775684|FG000|Overall Study|Lost to Follow-up|0
6142115|NCT01048866|9775685|FG001|Overall Study|Lost to Follow-up|2
6142116|NCT01048866|9775684|FG000|Overall Study|Other|1
6142117|NCT01048866|9775685|FG001|Overall Study|Other|1
6142118|NCT01048944|9775712|FG000|Overall Study|Protocol Violation|8
6142119|NCT01048944|9775713|FG001|Overall Study|Protocol Violation|10
6142120|NCT01048944|9775714|FG002|Overall Study|Protocol Violation|10
6142121|NCT01048944|9775715|FG003|Overall Study|Protocol Violation|2
6142122|NCT01049009|9775727|FG000|Treatment Period 1 (12 Weeks)|Protocol Violation|2
6142123|NCT01049009|9775728|FG001|Treatment Period 1 (12 Weeks)|Protocol Violation|2
6142124|NCT01049009|9775727|FG000|Treatment Period 1 (12 Weeks)|Lost to Follow-up|0
6142125|NCT01049009|9775728|FG001|Treatment Period 1 (12 Weeks)|Lost to Follow-up|1
6142126|NCT01049009|9775727|FG000|Treatment Period 2 (12 Weeks)|Lost to Follow-up|2
6142127|NCT01049009|9775728|FG001|Treatment Period 2 (12 Weeks)|Lost to Follow-up|3
6142128|NCT01049009|9775727|FG000|Treatment Period 2 (12 Weeks)|Protocol Violation|8
6142129|NCT01049009|9775728|FG001|Treatment Period 2 (12 Weeks)|Protocol Violation|7
6142130|NCT01049217|9775736|FG000|Overall Study|Adverse Event|2
6142131|NCT01049217|9775737|FG001|Overall Study|Adverse Event|1
6142132|NCT01049217|9775736|FG000|Overall Study|Lack of Efficacy|1
6142133|NCT01049217|9775737|FG001|Overall Study|Lack of Efficacy|1
6142134|NCT01049217|9775736|FG000|Overall Study|Lost to Follow-up|3
6142135|NCT01049217|9775737|FG001|Overall Study|Lost to Follow-up|8
6142136|NCT01049217|9775736|FG000|Overall Study|Withdrawal by Subject|4
6142137|NCT01049217|9775737|FG001|Overall Study|Withdrawal by Subject|3
6142138|NCT01049217|9775736|FG000|Overall Study|Protocol Violation|1
6142139|NCT01049217|9775737|FG001|Overall Study|Protocol Violation|3
6142140|NCT01049217|9775736|FG000|Overall Study|Pregnancy|1
6142141|NCT01049217|9775737|FG001|Overall Study|Pregnancy|0
6142142|NCT01049217|9775736|FG000|Overall Study|Study Terminated by Sponsor|43
6142143|NCT01049217|9775737|FG001|Overall Study|Study Terminated by Sponsor|43
6142144|NCT01049217|9775736|FG000|Overall Study|Other|1
6142145|NCT01049217|9775737|FG001|Overall Study|Other|2
6142146|NCT01049217|9775736|FG000|Overall Study|Randomized but not Treated|0
6142147|NCT01049217|9775737|FG001|Overall Study|Randomized but not Treated|2
6142148|NCT01049308|9775748|FG000|Pill Counts|Withdrawal by Subject|83
6142149|NCT01049334|9775757|FG000|Overall Study|Withdrawal by Subject|5
6142150|NCT01049334|9775758|FG001|Overall Study|Withdrawal by Subject|3
6142151|NCT01049334|9775757|FG000|Overall Study|Adverse Event|2
6142152|NCT01049334|9775758|FG001|Overall Study|Adverse Event|3
6142153|NCT01049334|9775757|FG000|Overall Study|Physician Decision|2
6142154|NCT01049334|9775758|FG001|Overall Study|Physician Decision|0
6142155|NCT01049334|9775757|FG000|Overall Study|Protocol Violation|0
6142156|NCT01049334|9775758|FG001|Overall Study|Protocol Violation|1
6142157|NCT01049360|9775764|FG000|Period 1|Adverse Event|0
6142158|NCT01049360|9775765|FG001|Period 1|Adverse Event|1
6142159|NCT01049360|9775766|FG002|Period 1|Adverse Event|0
6142160|NCT01049360|9775767|FG003|Period 1|Adverse Event|1
6142161|NCT01049360|9775768|FG004|Period 1|Adverse Event|0
6142162|NCT01049360|9775769|FG005|Period 1|Adverse Event|0
6142163|NCT01049360|9775770|FG006|Period 1|Adverse Event|0
6142164|NCT01049360|9775771|FG007|Period 1|Adverse Event|1
6142165|NCT01049360|9775772|FG008|Period 1|Adverse Event|0
6142166|NCT01049360|9775773|FG009|Period 1|Adverse Event|0
6142167|NCT01049360|9775774|FG010|Period 1|Adverse Event|0
6142168|NCT01049360|9775775|FG011|Period 1|Adverse Event|0
6142169|NCT01049360|9775776|FG012|Period 1|Adverse Event|1
6142170|NCT01049360|9775777|FG013|Period 1|Adverse Event|1
6142171|NCT01049360|9775778|FG014|Period 1|Adverse Event|0
6142172|NCT01049360|9775779|FG015|Period 1|Adverse Event|0
6142173|NCT01049360|9775780|FG016|Period 1|Adverse Event|1
6142174|NCT01049360|9775781|FG017|Period 1|Adverse Event|0
6142175|NCT01049360|9775782|FG018|Period 1|Adverse Event|1
6142176|NCT01049360|9775783|FG019|Period 1|Adverse Event|0
6142177|NCT01049360|9775764|FG000|Period 1|Did not meet inc/exc criteria|0
6142178|NCT01049360|9775765|FG001|Period 1|Did not meet inc/exc criteria|0
6142179|NCT01049360|9775766|FG002|Period 1|Did not meet inc/exc criteria|0
6142180|NCT01049360|9775767|FG003|Period 1|Did not meet inc/exc criteria|0
6142181|NCT01049360|9775768|FG004|Period 1|Did not meet inc/exc criteria|0
6142182|NCT01049360|9775769|FG005|Period 1|Did not meet inc/exc criteria|0
6142183|NCT01049360|9775770|FG006|Period 1|Did not meet inc/exc criteria|0
6142184|NCT01049360|9775771|FG007|Period 1|Did not meet inc/exc criteria|1
6142185|NCT01049360|9775772|FG008|Period 1|Did not meet inc/exc criteria|1
6142186|NCT01049360|9775773|FG009|Period 1|Did not meet inc/exc criteria|0
6142187|NCT01049360|9775774|FG010|Period 1|Did not meet inc/exc criteria|0
6142188|NCT01049360|9775775|FG011|Period 1|Did not meet inc/exc criteria|0
6142189|NCT01049360|9775776|FG012|Period 1|Did not meet inc/exc criteria|0
6142190|NCT01049360|9775777|FG013|Period 1|Did not meet inc/exc criteria|0
6142191|NCT01049360|9775778|FG014|Period 1|Did not meet inc/exc criteria|0
6142192|NCT01049360|9775779|FG015|Period 1|Did not meet inc/exc criteria|0
6142193|NCT01049360|9775780|FG016|Period 1|Did not meet inc/exc criteria|0
6142194|NCT01049360|9775781|FG017|Period 1|Did not meet inc/exc criteria|0
6142195|NCT01049360|9775782|FG018|Period 1|Did not meet inc/exc criteria|0
6142196|NCT01049360|9775783|FG019|Period 1|Did not meet inc/exc criteria|0
6142197|NCT01049360|9775764|FG000|Period 1|Withdrawal by Subject|0
6142198|NCT01049360|9775765|FG001|Period 1|Withdrawal by Subject|0
6142199|NCT01049360|9775766|FG002|Period 1|Withdrawal by Subject|0
6142200|NCT01049360|9775767|FG003|Period 1|Withdrawal by Subject|0
6142201|NCT01049360|9775768|FG004|Period 1|Withdrawal by Subject|0
6142202|NCT01049360|9775769|FG005|Period 1|Withdrawal by Subject|0
6142203|NCT01049360|9775770|FG006|Period 1|Withdrawal by Subject|0
6142204|NCT01049360|9775771|FG007|Period 1|Withdrawal by Subject|0
6142205|NCT01049360|9775772|FG008|Period 1|Withdrawal by Subject|1
6142206|NCT01049360|9775773|FG009|Period 1|Withdrawal by Subject|0
6142207|NCT01049360|9775774|FG010|Period 1|Withdrawal by Subject|1
6142208|NCT01049360|9775775|FG011|Period 1|Withdrawal by Subject|0
6142209|NCT01049360|9775776|FG012|Period 1|Withdrawal by Subject|1
6142210|NCT01049360|9775777|FG013|Period 1|Withdrawal by Subject|0
6142211|NCT01049360|9775778|FG014|Period 1|Withdrawal by Subject|0
6142212|NCT01049360|9775779|FG015|Period 1|Withdrawal by Subject|0
6142213|NCT01049360|9775780|FG016|Period 1|Withdrawal by Subject|0
6142214|NCT01049360|9775781|FG017|Period 1|Withdrawal by Subject|0
6142215|NCT01049360|9775782|FG018|Period 1|Withdrawal by Subject|0
6142216|NCT01049360|9775783|FG019|Period 1|Withdrawal by Subject|0
6142217|NCT01049360|9775764|FG000|Period 2|Protocol Violation|0
6142218|NCT01049360|9775765|FG001|Period 2|Protocol Violation|0
6142219|NCT01049360|9775766|FG002|Period 2|Protocol Violation|0
6142220|NCT01049360|9775767|FG003|Period 2|Protocol Violation|1
6142221|NCT01049360|9775768|FG004|Period 2|Protocol Violation|0
6142222|NCT01049360|9775769|FG005|Period 2|Protocol Violation|0
6142223|NCT01049360|9775770|FG006|Period 2|Protocol Violation|0
6142224|NCT01049360|9775771|FG007|Period 2|Protocol Violation|0
6142225|NCT01049360|9775772|FG008|Period 2|Protocol Violation|0
6142226|NCT01049360|9775773|FG009|Period 2|Protocol Violation|0
6142227|NCT01049360|9775774|FG010|Period 2|Protocol Violation|0
6142228|NCT01049360|9775775|FG011|Period 2|Protocol Violation|0
6142229|NCT01049360|9775776|FG012|Period 2|Protocol Violation|0
6142230|NCT01049360|9775777|FG013|Period 2|Protocol Violation|0
6142231|NCT01049360|9775778|FG014|Period 2|Protocol Violation|1
6142232|NCT01049360|9775779|FG015|Period 2|Protocol Violation|1
6142233|NCT01049360|9775780|FG016|Period 2|Protocol Violation|0
6142234|NCT01049360|9775781|FG017|Period 2|Protocol Violation|0
6142235|NCT01049360|9775782|FG018|Period 2|Protocol Violation|0
6142236|NCT01049360|9775783|FG019|Period 2|Protocol Violation|0
6142237|NCT01049360|9775764|FG000|Period 2|Adverse Event|0
6142238|NCT01049360|9775765|FG001|Period 2|Adverse Event|1
6142239|NCT01049360|9775766|FG002|Period 2|Adverse Event|0
6142240|NCT01049360|9775767|FG003|Period 2|Adverse Event|0
6142241|NCT01049360|9775768|FG004|Period 2|Adverse Event|0
6142242|NCT01049360|9775769|FG005|Period 2|Adverse Event|0
6142243|NCT01049360|9775770|FG006|Period 2|Adverse Event|0
6142244|NCT01049360|9775771|FG007|Period 2|Adverse Event|0
6142245|NCT01049360|9775772|FG008|Period 2|Adverse Event|1
6142246|NCT01049360|9775773|FG009|Period 2|Adverse Event|0
6142247|NCT01049360|9775774|FG010|Period 2|Adverse Event|0
6142248|NCT01049360|9775775|FG011|Period 2|Adverse Event|0
6142249|NCT01049360|9775776|FG012|Period 2|Adverse Event|0
6142250|NCT01049360|9775777|FG013|Period 2|Adverse Event|0
6142251|NCT01049360|9775778|FG014|Period 2|Adverse Event|0
6142252|NCT01049360|9775779|FG015|Period 2|Adverse Event|0
6142253|NCT01049360|9775780|FG016|Period 2|Adverse Event|0
6142254|NCT01049360|9775781|FG017|Period 2|Adverse Event|0
6142255|NCT01049360|9775782|FG018|Period 2|Adverse Event|0
6142256|NCT01049360|9775783|FG019|Period 2|Adverse Event|1
6142257|NCT01049360|9775764|FG000|Period 2|Withdrawal by Subject|0
6142258|NCT01049360|9775765|FG001|Period 2|Withdrawal by Subject|0
6142259|NCT01049360|9775766|FG002|Period 2|Withdrawal by Subject|0
6142260|NCT01049360|9775767|FG003|Period 2|Withdrawal by Subject|1
6142261|NCT01049360|9775768|FG004|Period 2|Withdrawal by Subject|0
6142262|NCT01049360|9775769|FG005|Period 2|Withdrawal by Subject|0
6142263|NCT01049360|9775770|FG006|Period 2|Withdrawal by Subject|0
6142264|NCT01049360|9775771|FG007|Period 2|Withdrawal by Subject|0
6142265|NCT01049360|9775772|FG008|Period 2|Withdrawal by Subject|0
6142266|NCT01049360|9775773|FG009|Period 2|Withdrawal by Subject|0
6142267|NCT01049360|9775774|FG010|Period 2|Withdrawal by Subject|0
6142268|NCT01049360|9775775|FG011|Period 2|Withdrawal by Subject|0
6142269|NCT01049360|9775776|FG012|Period 2|Withdrawal by Subject|0
6142270|NCT01049360|9775777|FG013|Period 2|Withdrawal by Subject|0
6142271|NCT01049360|9775778|FG014|Period 2|Withdrawal by Subject|1
6142272|NCT01049360|9775779|FG015|Period 2|Withdrawal by Subject|0
6142273|NCT01049360|9775780|FG016|Period 2|Withdrawal by Subject|0
6142274|NCT01049360|9775781|FG017|Period 2|Withdrawal by Subject|0
6142275|NCT01049360|9775782|FG018|Period 2|Withdrawal by Subject|0
6142276|NCT01049360|9775783|FG019|Period 2|Withdrawal by Subject|1
6142277|NCT01049360|9775764|FG000|Period 2|Lack of Efficacy|0
6142278|NCT01049360|9775765|FG001|Period 2|Lack of Efficacy|0
6142279|NCT01049360|9775766|FG002|Period 2|Lack of Efficacy|0
6142280|NCT01049360|9775767|FG003|Period 2|Lack of Efficacy|0
6142281|NCT01049360|9775768|FG004|Period 2|Lack of Efficacy|0
6142282|NCT01049360|9775769|FG005|Period 2|Lack of Efficacy|1
6142283|NCT01049360|9775770|FG006|Period 2|Lack of Efficacy|0
6142284|NCT01049360|9775771|FG007|Period 2|Lack of Efficacy|0
6142285|NCT01049360|9775772|FG008|Period 2|Lack of Efficacy|0
6142286|NCT01049360|9775773|FG009|Period 2|Lack of Efficacy|0
6142287|NCT01049360|9775774|FG010|Period 2|Lack of Efficacy|0
6142288|NCT01049360|9775775|FG011|Period 2|Lack of Efficacy|0
6142289|NCT01049360|9775776|FG012|Period 2|Lack of Efficacy|0
6142290|NCT01049360|9775777|FG013|Period 2|Lack of Efficacy|0
6142291|NCT01049360|9775778|FG014|Period 2|Lack of Efficacy|0
6142292|NCT01049360|9775779|FG015|Period 2|Lack of Efficacy|0
6142293|NCT01049360|9775780|FG016|Period 2|Lack of Efficacy|0
6142294|NCT01049360|9775781|FG017|Period 2|Lack of Efficacy|0
6142295|NCT01049360|9775782|FG018|Period 2|Lack of Efficacy|0
6142296|NCT01049360|9775783|FG019|Period 2|Lack of Efficacy|0
6142297|NCT01049360|9775764|FG000|Period 4|Protocol Violation|0
6142298|NCT01049360|9775765|FG001|Period 4|Protocol Violation|0
6142299|NCT01049360|9775766|FG002|Period 4|Protocol Violation|0
6142300|NCT01049360|9775767|FG003|Period 4|Protocol Violation|0
6142301|NCT01049360|9775768|FG004|Period 4|Protocol Violation|0
6142302|NCT01049360|9775769|FG005|Period 4|Protocol Violation|0
6142303|NCT01049360|9775770|FG006|Period 4|Protocol Violation|0
6142304|NCT01049360|9775771|FG007|Period 4|Protocol Violation|0
6142305|NCT01049360|9775772|FG008|Period 4|Protocol Violation|0
6142306|NCT01049360|9775773|FG009|Period 4|Protocol Violation|0
6142307|NCT01049360|9775774|FG010|Period 4|Protocol Violation|0
6142308|NCT01049360|9775775|FG011|Period 4|Protocol Violation|0
6142309|NCT01049360|9775776|FG012|Period 4|Protocol Violation|0
6142310|NCT01049360|9775777|FG013|Period 4|Protocol Violation|0
6142311|NCT01049360|9775778|FG014|Period 4|Protocol Violation|0
6142312|NCT01049360|9775779|FG015|Period 4|Protocol Violation|0
6142313|NCT01049360|9775780|FG016|Period 4|Protocol Violation|0
6142314|NCT01049360|9775781|FG017|Period 4|Protocol Violation|1
6142315|NCT01049360|9775782|FG018|Period 4|Protocol Violation|0
6142316|NCT01049360|9775783|FG019|Period 4|Protocol Violation|0
6142317|NCT01049360|9775764|FG000|Period 4|Withdrawal by Subject|0
6142318|NCT01049360|9775765|FG001|Period 4|Withdrawal by Subject|0
6142319|NCT01049360|9775766|FG002|Period 4|Withdrawal by Subject|0
6142320|NCT01049360|9775767|FG003|Period 4|Withdrawal by Subject|1
6142321|NCT01049360|9775768|FG004|Period 4|Withdrawal by Subject|0
6142322|NCT01049360|9775769|FG005|Period 4|Withdrawal by Subject|0
6142323|NCT01049360|9775770|FG006|Period 4|Withdrawal by Subject|0
6142324|NCT01049360|9775771|FG007|Period 4|Withdrawal by Subject|0
6142325|NCT01049360|9775772|FG008|Period 4|Withdrawal by Subject|0
6142326|NCT01049360|9775773|FG009|Period 4|Withdrawal by Subject|0
6142327|NCT01049360|9775774|FG010|Period 4|Withdrawal by Subject|0
6142328|NCT01049360|9775775|FG011|Period 4|Withdrawal by Subject|0
6142329|NCT01049360|9775776|FG012|Period 4|Withdrawal by Subject|0
6142330|NCT01049360|9775777|FG013|Period 4|Withdrawal by Subject|0
6142331|NCT01049360|9775778|FG014|Period 4|Withdrawal by Subject|0
6142332|NCT01049360|9775779|FG015|Period 4|Withdrawal by Subject|0
6142333|NCT01049360|9775780|FG016|Period 4|Withdrawal by Subject|0
6142334|NCT01049360|9775781|FG017|Period 4|Withdrawal by Subject|0
6142335|NCT01049360|9775782|FG018|Period 4|Withdrawal by Subject|0
6142336|NCT01049360|9775783|FG019|Period 4|Withdrawal by Subject|0
6142337|NCT01049373|9775797|FG000|Overall Study|Protocol Violation|9
6142338|NCT01049373|9775798|FG001|Overall Study|Protocol Violation|9
6142339|NCT01049373|9775797|FG000|Overall Study|Withdrawal by Subject|8
6142340|NCT01049373|9775798|FG001|Overall Study|Withdrawal by Subject|5
6142341|NCT01049373|9775797|FG000|Overall Study|Adverse Event|3
6142342|NCT01049373|9775798|FG001|Overall Study|Adverse Event|3
6142343|NCT01049373|9775797|FG000|Overall Study|Lost to Follow-up|9
6142344|NCT01049373|9775798|FG001|Overall Study|Lost to Follow-up|4
6142345|NCT01049373|9775797|FG000|Overall Study|no evaluable study values|9
6142346|NCT01049373|9775798|FG001|Overall Study|no evaluable study values|21
6142347|NCT01049373|9775797|FG000|Overall Study|Other|1
6142348|NCT01049373|9775798|FG001|Overall Study|Other|1
6142349|NCT01049373|9775797|FG000|Overall Study|Non-cooperation|0
6142350|NCT01049373|9775798|FG001|Overall Study|Non-cooperation|1
6142351|NCT01049412|9775808|FG000|Period I|Withdrawal by Subject|4
6142352|NCT01049412|9775809|FG001|Period I|Withdrawal by Subject|6
6142353|NCT01049412|9775808|FG000|Period I|Lost to Follow-up|2
6142354|NCT01049412|9775809|FG001|Period I|Lost to Follow-up|2
6142355|NCT01049412|9775808|FG000|Period I|Physician Decision|0
6142356|NCT01049412|9775809|FG001|Period I|Physician Decision|3
6142357|NCT01049412|9775808|FG000|Period I|Protocol Violation|1
6142358|NCT01049412|9775809|FG001|Period I|Protocol Violation|2
6142359|NCT01049412|9775808|FG000|Period I|Adverse Event|1
6142360|NCT01049412|9775809|FG001|Period I|Adverse Event|0
6142361|NCT01049412|9775808|FG000|Period II|Withdrawal by Subject|2
6142362|NCT01049412|9775809|FG001|Period II|Withdrawal by Subject|3
6142363|NCT01049412|9775808|FG000|Period II|Adverse Event|1
6142364|NCT01049412|9775809|FG001|Period II|Adverse Event|0
6142365|NCT01049412|9775808|FG000|Period II|Lost to Follow-up|1
6142366|NCT01049412|9775809|FG001|Period II|Lost to Follow-up|0
6142367|NCT01049503|9775823|FG000|Overall Study|Lost to Follow-up|11
6142368|NCT01049503|9775824|FG001|Overall Study|Lost to Follow-up|12
6142369|NCT01049503|9775825|FG002|Overall Study|Lost to Follow-up|24
6142370|NCT01049503|9775826|FG003|Overall Study|Lost to Follow-up|26
6142371|NCT01049503|9775827|FG004|Overall Study|Lost to Follow-up|27
6142372|NCT01049503|9775828|FG005|Overall Study|Lost to Follow-up|8
6142373|NCT01049581|9775853|FG000|Overall Study|Lost to Follow-up|2
6142374|NCT01049581|9775854|FG001|Overall Study|Lost to Follow-up|1
6142375|NCT01049919|9775878|FG000|Overall Study|Met study endpoint (major amputation, death)|36
6142376|NCT01049919|9775879|FG001|Overall Study|Met study endpoint (major amputation, death)|16
6142377|NCT01049919|9775878|FG000|Overall Study|Withdrawal by Subject|5
6142378|NCT01049919|9775879|FG001|Overall Study|Withdrawal by Subject|0
6142379|NCT01049919|9775878|FG000|Overall Study|Lost to Follow-up|6
6142380|NCT01049919|9775879|FG001|Overall Study|Lost to Follow-up|1
6142381|NCT01049919|9775878|FG000|Overall Study|Physician Decision|2
6142382|NCT01049919|9775879|FG001|Overall Study|Physician Decision|0
6142383|NCT01049919|9775878|FG000|Overall Study|Received 2nd treatment via compassionate use|1
6142384|NCT01049919|9775879|FG001|Overall Study|Received 2nd treatment via compassionate use|0
6142385|NCT01049919|9775878|FG000|Overall Study|Early study termination by sponsor.|2
6142386|NCT01049919|9775879|FG001|Overall Study|Early study termination by sponsor.|0
6142387|NCT01049984|9775908|FG000|Overall Study|Withdrawal by Subject|1
6142388|NCT01049984|9775909|FG001|Overall Study|Withdrawal by Subject|5
6142389|NCT01049984|9775908|FG000|Overall Study|Protocol Violation|3
6142390|NCT01049984|9775909|FG001|Overall Study|Protocol Violation|4
6142391|NCT01049984|9775908|FG000|Overall Study|Lost to Follow-up|2
6142392|NCT01049984|9775909|FG001|Overall Study|Lost to Follow-up|1
6142393|NCT01049984|9775908|FG000|Overall Study|Adverse Event|13
6142394|NCT01049984|9775909|FG001|Overall Study|Adverse Event|7
6142395|NCT01049984|9775908|FG000|Overall Study|Treatment failure|0
6142396|NCT01049984|9775909|FG001|Overall Study|Treatment failure|2
6142397|NCT01050062|9775917|FG000|Overall Study|Adverse Event|75
6142398|NCT01050062|9775918|FG001|Overall Study|Adverse Event|22
6142399|NCT01050062|9775917|FG000|Overall Study|Lost to Follow-up|83
6142400|NCT01050062|9775918|FG001|Overall Study|Lost to Follow-up|35
6142401|NCT01050062|9775917|FG000|Overall Study|Lack of Efficacy|22
6142402|NCT01050062|9775918|FG001|Overall Study|Lack of Efficacy|35
6142403|NCT01050062|9775917|FG000|Overall Study|Physician Decision|74
6142404|NCT01050062|9775918|FG001|Overall Study|Physician Decision|9
6142405|NCT01050062|9775917|FG000|Overall Study|Others|17
6142406|NCT01050062|9775918|FG001|Overall Study|Others|11
6142407|NCT01050205|9775937|FG000|Overall Study|Lost to Follow-up|7
6142408|NCT01050205|9775938|FG001|Overall Study|Lost to Follow-up|1
6142409|NCT01050205|9775937|FG000|Overall Study|Withdrawal by Subject|1
6142410|NCT01050205|9775938|FG001|Overall Study|Withdrawal by Subject|1
6142411|NCT01050205|9775937|FG000|Overall Study|Relocated from area|1
6142412|NCT01050205|9775938|FG001|Overall Study|Relocated from area|2
6142413|NCT01050205|9775937|FG000|Overall Study|Discontinued Intervention|2
6142414|NCT01050205|9775938|FG001|Overall Study|Discontinued Intervention|0
6142415|NCT01050257|9775956|FG000|Overall Study|Adverse Event|4
6142416|NCT01050257|9775957|FG001|Overall Study|Adverse Event|4
6142417|NCT01050257|9775958|FG002|Overall Study|Adverse Event|2
6142418|NCT01050257|9775956|FG000|Overall Study|Admin/Other (did not switch to oral)|6
6142419|NCT01050257|9775957|FG001|Overall Study|Admin/Other (did not switch to oral)|2
6142420|NCT01050257|9775958|FG002|Overall Study|Admin/Other (did not switch to oral)|2
6142421|NCT01050257|9775956|FG000|Overall Study|Withdrawal by Subject|0
6142422|NCT01050257|9775957|FG001|Overall Study|Withdrawal by Subject|3
6142423|NCT01050257|9775958|FG002|Overall Study|Withdrawal by Subject|0
6142424|NCT01050257|9775956|FG000|Overall Study|No reason specified|0
6142425|NCT01050257|9775957|FG001|Overall Study|No reason specified|0
6142426|NCT01050257|9775958|FG002|Overall Study|No reason specified|2
6142427|NCT01050257|9775956|FG000|Overall Study|Refused treatment/ Did not Cooperate|1
6142428|NCT01050257|9775957|FG001|Overall Study|Refused treatment/ Did not Cooperate|1
6142429|NCT01050257|9775958|FG002|Overall Study|Refused treatment/ Did not Cooperate|0
6142430|NCT01050257|9775956|FG000|Overall Study|Violation criteria|0
6142431|NCT01050257|9775957|FG001|Overall Study|Violation criteria|1
6142432|NCT01050257|9775958|FG002|Overall Study|Violation criteria|0
6142433|NCT01050257|9775956|FG000|Overall Study|Failure to return|0
6142434|NCT01050257|9775957|FG001|Overall Study|Failure to return|2
6142435|NCT01050257|9775958|FG002|Overall Study|Failure to return|0
6142436|NCT01050257|9775956|FG000|Overall Study|Death|0
6142437|NCT01050257|9775957|FG001|Overall Study|Death|0
6142438|NCT01050257|9775958|FG002|Overall Study|Death|1
6142439|NCT01050530|9775968|FG000|Overall Study|Adverse Event|6
6142440|NCT01050530|9775969|FG001|Overall Study|Adverse Event|3
6142441|NCT01050530|9775968|FG000|Overall Study|Lack of Efficacy|1
6142442|NCT01050530|9775969|FG001|Overall Study|Lack of Efficacy|4
6142443|NCT01050530|9775968|FG000|Overall Study|Withdrawal by Subject|0
6142444|NCT01050530|9775969|FG001|Overall Study|Withdrawal by Subject|3
6142445|NCT01050530|9775968|FG000|Overall Study|Protocol Violation|1
6142446|NCT01050530|9775969|FG001|Overall Study|Protocol Violation|0
6142447|NCT01050543|9775977|FG000|Overall Study|Withdrawal by Subject|0
6142448|NCT01050543|9775978|FG001|Overall Study|Withdrawal by Subject|2
6142449|NCT01050543|9775977|FG000|Overall Study|Protocol Violation|0
6142450|NCT01050543|9775978|FG001|Overall Study|Protocol Violation|1
6142451|NCT01050543|9775977|FG000|Overall Study|Administrative|4
6142452|NCT01050543|9775978|FG001|Overall Study|Administrative|1
6142453|NCT01050569|9775987|FG000|Overall Study|Lost to Follow-up|20
6142454|NCT01050569|9775988|FG001|Overall Study|Lost to Follow-up|14
6142455|NCT01050569|9775989|FG002|Overall Study|Lost to Follow-up|16
6142456|NCT01050569|9775987|FG000|Overall Study|Withdrawal by Subject|9
6142457|NCT01050569|9775988|FG001|Overall Study|Withdrawal by Subject|3
6142458|NCT01050569|9775989|FG002|Overall Study|Withdrawal by Subject|11
6142459|NCT01050569|9775987|FG000|Overall Study|Lack of Efficacy|5
6142460|NCT01050569|9775988|FG001|Overall Study|Lack of Efficacy|4
6142461|NCT01050569|9775989|FG002|Overall Study|Lack of Efficacy|3
6142462|NCT01050569|9775987|FG000|Overall Study|Adverse Event|1
6142463|NCT01050569|9775988|FG001|Overall Study|Adverse Event|0
6142464|NCT01050569|9775989|FG002|Overall Study|Adverse Event|0
6142465|NCT01050569|9775987|FG000|Overall Study|Physician Decision|3
6142466|NCT01050569|9775988|FG001|Overall Study|Physician Decision|3
6142467|NCT01050569|9775989|FG002|Overall Study|Physician Decision|3
6142468|NCT01050634|9776010|FG000|Overall Study|Enrolled, but Not Treated|56
6142469|NCT01050634|9776010|FG000|Overall Study|Death|2
6142470|NCT01050634|9776010|FG000|Overall Study|Adverse Event|42
6142471|NCT01050634|9776010|FG000|Overall Study|Lost to Follow-up|2
6142472|NCT01050634|9776010|FG000|Overall Study|Other|21
6142473|NCT01050634|9776010|FG000|Overall Study|Ongoing at Date of Cut-Off|5
6142474|NCT01050673|9776034|FG000|Overall Study|Physician Decision|4
6142475|NCT01050673|9776035|FG001|Overall Study|Physician Decision|5
6142476|NCT01050764|9776041|FG000|Overall Study|Death, before HSCT|1
6142477|NCT01050764|9776041|FG000|Overall Study|Donor mobilization failure, death|1
6142478|NCT01050764|9776041|FG000|Overall Study|Death after HSCT, before T-cell infusion|1
6142479|NCT01050790|9776045|FG000|Overall Study|Adverse Event|1
6142480|NCT01050816|9776050|FG000|Overall Study|Lost to Follow-up|2
6142481|NCT01050816|9776050|FG000|Overall Study|patient's refusal|2
6142482|NCT01050998|9776068|FG000|Overall Study|Adverse Event|1
6142483|NCT01050998|9776069|FG001|Overall Study|Adverse Event|0
6142484|NCT01050998|9776070|FG002|Overall Study|Adverse Event|1
6142485|NCT01050998|9776071|FG003|Overall Study|Adverse Event|0
6142486|NCT01050998|9776072|FG004|Overall Study|Adverse Event|2
6142487|NCT01050998|9776068|FG000|Overall Study|Withdrawal by Subject|0
6142488|NCT01050998|9776069|FG001|Overall Study|Withdrawal by Subject|0
6142489|NCT01050998|9776070|FG002|Overall Study|Withdrawal by Subject|0
6142490|NCT01050998|9776071|FG003|Overall Study|Withdrawal by Subject|1
6142491|NCT01050998|9776072|FG004|Overall Study|Withdrawal by Subject|3
6142492|NCT01050998|9776068|FG000|Overall Study|Other|3
6142493|NCT01050998|9776069|FG001|Overall Study|Other|2
6142494|NCT01050998|9776070|FG002|Overall Study|Other|1
6142495|NCT01050998|9776071|FG003|Overall Study|Other|1
6142496|NCT01050998|9776072|FG004|Overall Study|Other|5
6142497|NCT01050998|9776068|FG000|Overall Study|Data integrity issues|0
6142498|NCT01050998|9776069|FG001|Overall Study|Data integrity issues|0
6142499|NCT01050998|9776070|FG002|Overall Study|Data integrity issues|1
6142500|NCT01050998|9776071|FG003|Overall Study|Data integrity issues|1
6142501|NCT01050998|9776072|FG004|Overall Study|Data integrity issues|4
6142502|NCT01051063|9776090|FG000|Overall Study|Death|2
6142503|NCT01051063|9776091|FG001|Overall Study|Death|2
6142504|NCT01051063|9776090|FG000|Overall Study|Withdrawal by Subject|1
6142505|NCT01051063|9776091|FG001|Overall Study|Withdrawal by Subject|1
6142506|NCT01051063|9776090|FG000|Overall Study|Termination of the study|5
6142507|NCT01051063|9776091|FG001|Overall Study|Termination of the study|0
6142508|NCT01051063|9776090|FG000|Overall Study|Moved from the study site area|1
6142509|NCT01051063|9776091|FG001|Overall Study|Moved from the study site area|0
6142510|NCT01051063|9776090|FG000|Overall Study|Other|1
6142511|NCT01051063|9776091|FG001|Overall Study|Other|0
6142512|NCT01051063|9776090|FG000|Overall Study|Lost to Follow-up|0
6142513|NCT01051063|9776091|FG001|Overall Study|Lost to Follow-up|1
6142514|NCT01051323|9776104|FG000|Overall Study|Discontinuation of treatment|103
6142515|NCT01051323|9776104|FG000|Overall Study|Transplantation|28
6142516|NCT01051323|9776104|FG000|Overall Study|Dialysis dependency|22
6142517|NCT01051323|9776104|FG000|Overall Study|Withdrawal by Subject|13
6142518|NCT01051323|9776104|FG000|Overall Study|Lost to Follow-up|31
6142519|NCT01051323|9776104|FG000|Overall Study|Death|129
6142520|NCT01051323|9776104|FG000|Overall Study|Hospitalization|28
6142521|NCT01051323|9776104|FG000|Overall Study|Other|148
6142522|NCT01051323|9776104|FG000|Overall Study|Missing|37
6142523|NCT01051349|9776112|FG000|Overall Study|Adverse Event|88
6142524|NCT01051349|9776112|FG000|Overall Study|Consent Withdrawn|54
6142525|NCT01051349|9776112|FG000|Overall Study|Investigator Decision|6
6142526|NCT01051349|9776112|FG000|Overall Study|Lost to Follow-up|6
6142527|NCT01051349|9776112|FG000|Overall Study|Subject non-compliance|7
6142528|NCT01051349|9776112|FG000|Overall Study|Reason not Specified|12
6142529|NCT01051466|9776130|FG000|Overall Study|Adverse Event|1
6142530|NCT01051466|9776131|FG001|Overall Study|Adverse Event|0
6142531|NCT01051466|9776130|FG000|Overall Study|Lost to Follow-up|1
6142532|NCT01051466|9776131|FG001|Overall Study|Lost to Follow-up|1
6142533|NCT01051466|9776130|FG000|Overall Study|Withdrawal by Subject|5
6142534|NCT01051466|9776131|FG001|Overall Study|Withdrawal by Subject|1
6142535|NCT01051466|9776130|FG000|Overall Study|Entry Criteria Not Met|0
6142536|NCT01051466|9776131|FG001|Overall Study|Entry Criteria Not Met|3
6142537|NCT01051466|9776130|FG000|Overall Study|Physician Decision|1
6142538|NCT01051466|9776131|FG001|Overall Study|Physician Decision|0
6142539|NCT01051557|9776157|FG000|Overall Study|Physician Decision|1
6142540|NCT01051557|9776158|FG001|Overall Study|Physician Decision|0
6142541|NCT01051557|9776159|FG002|Overall Study|Physician Decision|0
6142542|NCT01051557|9776160|FG003|Overall Study|Physician Decision|0
6142543|NCT01051557|9776161|FG004|Overall Study|Physician Decision|0
6142544|NCT01051557|9776162|FG005|Overall Study|Physician Decision|0
6142545|NCT01051557|9776163|FG006|Overall Study|Physician Decision|0
6142546|NCT01051557|9776157|FG000|Overall Study|disease progression|3
6142547|NCT01051557|9776158|FG001|Overall Study|disease progression|3
6142548|NCT01051557|9776159|FG002|Overall Study|disease progression|5
6142549|NCT01051557|9776160|FG003|Overall Study|disease progression|2
6142550|NCT01051557|9776161|FG004|Overall Study|disease progression|4
6142551|NCT01051557|9776162|FG005|Overall Study|disease progression|3
6142552|NCT01051557|9776163|FG006|Overall Study|disease progression|1
6142553|NCT01051557|9776157|FG000|Overall Study|Withdrawal by Subject|0
6142554|NCT01051557|9776158|FG001|Overall Study|Withdrawal by Subject|0
6142555|NCT01051557|9776159|FG002|Overall Study|Withdrawal by Subject|1
6142556|NCT01051557|9776160|FG003|Overall Study|Withdrawal by Subject|0
6142557|NCT01051557|9776161|FG004|Overall Study|Withdrawal by Subject|2
6142558|NCT01051557|9776162|FG005|Overall Study|Withdrawal by Subject|0
6142559|NCT01051557|9776163|FG006|Overall Study|Withdrawal by Subject|1
6142560|NCT01051557|9776157|FG000|Overall Study|Adverse Event|0
6142561|NCT01051557|9776158|FG001|Overall Study|Adverse Event|0
6142562|NCT01051557|9776159|FG002|Overall Study|Adverse Event|0
6142563|NCT01051557|9776160|FG003|Overall Study|Adverse Event|1
6142564|NCT01051557|9776161|FG004|Overall Study|Adverse Event|1
6142565|NCT01051557|9776162|FG005|Overall Study|Adverse Event|3
6142566|NCT01051557|9776163|FG006|Overall Study|Adverse Event|4
6142567|NCT01051661|9776194|FG000|Overall Study|Adverse Event|1
6142568|NCT01051661|9776195|FG001|Overall Study|Adverse Event|1
6142569|NCT01051661|9776196|FG002|Overall Study|Adverse Event|1
6142570|NCT01051661|9776197|FG003|Overall Study|Adverse Event|1
6142571|NCT01051661|9776198|FG004|Overall Study|Adverse Event|0
6142572|NCT01051661|9776199|FG005|Overall Study|Adverse Event|0
6142573|NCT01051661|9776194|FG000|Overall Study|Lost to Follow-up|13
6142574|NCT01051661|9776195|FG001|Overall Study|Lost to Follow-up|22
6142575|NCT01051661|9776196|FG002|Overall Study|Lost to Follow-up|15
6142576|NCT01051661|9776197|FG003|Overall Study|Lost to Follow-up|17
6142577|NCT01051661|9776198|FG004|Overall Study|Lost to Follow-up|10
6142578|NCT01051661|9776199|FG005|Overall Study|Lost to Follow-up|24
6142579|NCT01051661|9776194|FG000|Overall Study|Migrated/moved from study area|1
6142580|NCT01051661|9776195|FG001|Overall Study|Migrated/moved from study area|6
6142581|NCT01051661|9776196|FG002|Overall Study|Migrated/moved from study area|6
6142582|NCT01051661|9776197|FG003|Overall Study|Migrated/moved from study area|8
6142583|NCT01051661|9776198|FG004|Overall Study|Migrated/moved from study area|7
6142584|NCT01051661|9776199|FG005|Overall Study|Migrated/moved from study area|3
6142585|NCT01051661|9776194|FG000|Overall Study|Refused blood sampling|0
6142586|NCT01051661|9776195|FG001|Overall Study|Refused blood sampling|0
6142587|NCT01051661|9776196|FG002|Overall Study|Refused blood sampling|0
6142588|NCT01051661|9776197|FG003|Overall Study|Refused blood sampling|0
6142589|NCT01051661|9776198|FG004|Overall Study|Refused blood sampling|0
6142590|NCT01051661|9776199|FG005|Overall Study|Refused blood sampling|1
6142591|NCT01051661|9776194|FG000|Overall Study|Data not reliable|1
6142592|NCT01051661|9776195|FG001|Overall Study|Data not reliable|0
6142593|NCT01051661|9776196|FG002|Overall Study|Data not reliable|0
6142594|NCT01051661|9776197|FG003|Overall Study|Data not reliable|0
6142595|NCT01051661|9776198|FG004|Overall Study|Data not reliable|0
6142596|NCT01051661|9776199|FG005|Overall Study|Data not reliable|1
6142597|NCT01051661|9776194|FG000|Overall Study|Unable to attend visit(s)|2
6142598|NCT01051661|9776195|FG001|Overall Study|Unable to attend visit(s)|4
6142599|NCT01051661|9776196|FG002|Overall Study|Unable to attend visit(s)|2
6142600|NCT01051661|9776197|FG003|Overall Study|Unable to attend visit(s)|1
6142601|NCT01051661|9776198|FG004|Overall Study|Unable to attend visit(s)|3
6142602|NCT01051661|9776199|FG005|Overall Study|Unable to attend visit(s)|2
6142603|NCT01051661|9776194|FG000|Overall Study|Consent not received from both parents|0
6142604|NCT01051661|9776195|FG001|Overall Study|Consent not received from both parents|0
6142605|NCT01051661|9776196|FG002|Overall Study|Consent not received from both parents|0
5982772|NCT00909753|9571804|FG001|Period: Washout of 28 Days|Protocol Violation|3
5982773|NCT00909753|9571803|FG000|Period: Second Intervention|Protocol Violation|1
5982774|NCT00909753|9571804|FG001|Period: Second Intervention|Protocol Violation|0
5982775|NCT00909610|9571817|FG000|Period: First Intervention|Adverse Event|0
5982776|NCT00909610|9571818|FG001|Period: First Intervention|Adverse Event|1
5982777|NCT00909610|9571817|FG000|Period: Washout of 28 Days|Withdrawal by Subject|3
5982778|NCT00909610|9571818|FG001|Period: Washout of 28 Days|Withdrawal by Subject|6
5982779|NCT00909610|9571817|FG000|Period: Second Intervention|Adverse Event|1
5982780|NCT00909610|9571818|FG001|Period: Second Intervention|Adverse Event|0
6142606|NCT01051661|9776197|FG003|Overall Study|Consent not received from both parents|0
6142607|NCT01051661|9776198|FG004|Overall Study|Consent not received from both parents|0
6142608|NCT01051661|9776199|FG005|Overall Study|Consent not received from both parents|1
6142609|NCT01051661|9776194|FG000|Overall Study|Failure to comply with protocol|0
6142610|NCT01051661|9776195|FG001|Overall Study|Failure to comply with protocol|0
6142611|NCT01051661|9776196|FG002|Overall Study|Failure to comply with protocol|2
6142612|NCT01051661|9776197|FG003|Overall Study|Failure to comply with protocol|0
6142613|NCT01051661|9776198|FG004|Overall Study|Failure to comply with protocol|0
6142614|NCT01051661|9776199|FG005|Overall Study|Failure to comply with protocol|0
6142615|NCT01051661|9776194|FG000|Overall Study|Subject lost legal representation|0
6142616|NCT01051661|9776195|FG001|Overall Study|Subject lost legal representation|0
6142617|NCT01051661|9776196|FG002|Overall Study|Subject lost legal representation|0
6142618|NCT01051661|9776197|FG003|Overall Study|Subject lost legal representation|0
6142619|NCT01051661|9776198|FG004|Overall Study|Subject lost legal representation|1
6142620|NCT01051661|9776199|FG005|Overall Study|Subject lost legal representation|0
6142621|NCT01051661|9776194|FG000|Overall Study|Protocol Violation|0
6142622|NCT01051661|9776195|FG001|Overall Study|Protocol Violation|0
6142623|NCT01051661|9776196|FG002|Overall Study|Protocol Violation|0
6142624|NCT01051661|9776197|FG003|Overall Study|Protocol Violation|1
6142625|NCT01051661|9776198|FG004|Overall Study|Protocol Violation|2
6142626|NCT01051661|9776199|FG005|Overall Study|Protocol Violation|1
6142627|NCT01051661|9776194|FG000|Overall Study|Withdrawal by Subject|16
6142628|NCT01051661|9776195|FG001|Overall Study|Withdrawal by Subject|30
6142629|NCT01051661|9776196|FG002|Overall Study|Withdrawal by Subject|13
6142630|NCT01051661|9776197|FG003|Overall Study|Withdrawal by Subject|28
6142631|NCT01051661|9776198|FG004|Overall Study|Withdrawal by Subject|12
6142632|NCT01051661|9776199|FG005|Overall Study|Withdrawal by Subject|34
6142633|NCT01051739|9776236|FG000|Overall Study|Death|3
6142634|NCT01051739|9776237|FG001|Overall Study|Death|3
6142635|NCT01051739|9776236|FG000|Overall Study|Withdrawal by Subject|25
6142636|NCT01051739|9776237|FG001|Overall Study|Withdrawal by Subject|10
6142637|NCT01051791|9776252|FG000|Overall Study|Failed screening|3
6142638|NCT01051791|9776252|FG000|Overall Study|Withdrawal by Subject|1
6142639|NCT01051817|9776259|FG000|Overall Study|Adverse Event|0
6142640|NCT01051817|9776260|FG001|Overall Study|Adverse Event|2
6142641|NCT01051817|9776259|FG000|Overall Study|Abnormal Test Proceedure reults|0
6142642|NCT01051817|9776260|FG001|Overall Study|Abnormal Test Proceedure reults|1
6142643|NCT01051817|9776259|FG000|Overall Study|Withdrawal by Subject|3
6142644|NCT01051817|9776260|FG001|Overall Study|Withdrawal by Subject|5
6142645|NCT01051817|9776259|FG000|Overall Study|Protocol Violation|0
6142646|NCT01051817|9776260|FG001|Overall Study|Protocol Violation|1
6142647|NCT01051856|9776268|FG000|Overall Study|Withdrawal by Subject|1
6142648|NCT01051856|9776269|FG001|Overall Study|Withdrawal by Subject|0
6142649|NCT01051960|9776275|FG000|Overall Study|Adverse Event|1
6142650|NCT01051986|9776281|FG000|Overall Study|Death|1
6142651|NCT01051986|9776282|FG001|Overall Study|Death|0
6142652|NCT01051986|9776281|FG000|Overall Study|Withdrawal by Subject|2
6142653|NCT01051986|9776282|FG001|Overall Study|Withdrawal by Subject|1
6142654|NCT01051986|9776281|FG000|Overall Study|Protocol Violation|2
6142655|NCT01051986|9776282|FG001|Overall Study|Protocol Violation|3
6142656|NCT01052012|9776294|FG000|Overall Study|Not treated|2
6142657|NCT01052012|9776295|FG001|Overall Study|Not treated|5
6142658|NCT01052012|9776296|FG002|Overall Study|Not treated|0
6142659|NCT01052012|9776297|FG003|Overall Study|Not treated|0
6142660|NCT01052012|9776298|FG004|Overall Study|Not treated|11
6142661|NCT01052012|9776299|FG005|Overall Study|Not treated|8
6142662|NCT01052012|9776294|FG000|Overall Study|Adverse Event|1
6142663|NCT01052012|9776295|FG001|Overall Study|Adverse Event|0
6142664|NCT01052012|9776296|FG002|Overall Study|Adverse Event|0
6142665|NCT01052012|9776297|FG003|Overall Study|Adverse Event|1
6142666|NCT01052012|9776298|FG004|Overall Study|Adverse Event|0
6142667|NCT01052012|9776299|FG005|Overall Study|Adverse Event|0
6142668|NCT01052012|9776294|FG000|Overall Study|Lost to Follow-up|0
6142669|NCT01052012|9776295|FG001|Overall Study|Lost to Follow-up|0
6142670|NCT01052012|9776296|FG002|Overall Study|Lost to Follow-up|0
6142671|NCT01052012|9776297|FG003|Overall Study|Lost to Follow-up|0
6142672|NCT01052012|9776298|FG004|Overall Study|Lost to Follow-up|1
6142673|NCT01052012|9776299|FG005|Overall Study|Lost to Follow-up|0
6142674|NCT01052012|9776294|FG000|Overall Study|Withdrawal by Subject|1
6142675|NCT01052012|9776295|FG001|Overall Study|Withdrawal by Subject|1
6142676|NCT01052012|9776296|FG002|Overall Study|Withdrawal by Subject|0
6142677|NCT01052012|9776297|FG003|Overall Study|Withdrawal by Subject|0
6142678|NCT01052012|9776298|FG004|Overall Study|Withdrawal by Subject|3
6142679|NCT01052012|9776299|FG005|Overall Study|Withdrawal by Subject|1
6142680|NCT01052012|9776294|FG000|Overall Study|Physician Decision|0
6142681|NCT01052012|9776295|FG001|Overall Study|Physician Decision|0
6142682|NCT01052012|9776296|FG002|Overall Study|Physician Decision|0
6142683|NCT01052012|9776297|FG003|Overall Study|Physician Decision|0
6142684|NCT01052012|9776298|FG004|Overall Study|Physician Decision|0
6142685|NCT01052012|9776299|FG005|Overall Study|Physician Decision|1
6142686|NCT01052012|9776294|FG000|Overall Study|Other|0
6142687|NCT01052012|9776295|FG001|Overall Study|Other|0
6142688|NCT01052012|9776296|FG002|Overall Study|Other|0
6142689|NCT01052012|9776297|FG003|Overall Study|Other|0
6142690|NCT01052012|9776298|FG004|Overall Study|Other|1
6142691|NCT01052012|9776299|FG005|Overall Study|Other|0
6142692|NCT01052038|9776316|FG000|Overall Study|Lost to Follow-up|2
6142693|NCT01052038|9776317|FG001|Overall Study|Lost to Follow-up|3
6142694|NCT01052038|9776318|FG002|Overall Study|Lost to Follow-up|1
6142695|NCT01052038|9776316|FG000|Overall Study|Protocol Violation|2
6142696|NCT01052038|9776317|FG001|Overall Study|Protocol Violation|3
6142697|NCT01052038|9776318|FG002|Overall Study|Protocol Violation|3
6142698|NCT01052077|9776328|FG000|Phase A|Lost to Follow-up|22
6142699|NCT01052077|9776329|FG001|Phase A|Lost to Follow-up|0
6142700|NCT01052077|9776330|FG002|Phase A|Lost to Follow-up|0
6142701|NCT01052077|9776331|FG003|Phase A|Lost to Follow-up|0
6142702|NCT01052077|9776328|FG000|Phase A|Adverse Event|32
6142703|NCT01052077|9776329|FG001|Phase A|Adverse Event|0
6142704|NCT01052077|9776330|FG002|Phase A|Adverse Event|0
6142705|NCT01052077|9776331|FG003|Phase A|Adverse Event|0
6142706|NCT01052077|9776328|FG000|Phase A|Met Withdrawal Criteria|26
6142707|NCT01052077|9776329|FG001|Phase A|Met Withdrawal Criteria|0
6142708|NCT01052077|9776330|FG002|Phase A|Met Withdrawal Criteria|0
6142709|NCT01052077|9776331|FG003|Phase A|Met Withdrawal Criteria|0
6142710|NCT01052077|9776328|FG000|Phase A|Physician Decision|10
6142711|NCT01052077|9776329|FG001|Phase A|Physician Decision|0
6142712|NCT01052077|9776330|FG002|Phase A|Physician Decision|0
6142713|NCT01052077|9776331|FG003|Phase A|Physician Decision|0
6142714|NCT01052077|9776328|FG000|Phase A|Withdrawal by Subject|29
6142715|NCT01052077|9776329|FG001|Phase A|Withdrawal by Subject|0
6142716|NCT01052077|9776330|FG002|Phase A|Withdrawal by Subject|0
6142717|NCT01052077|9776331|FG003|Phase A|Withdrawal by Subject|0
6142718|NCT01052077|9776328|FG000|Phase A|Protocol Deviation|27
6142719|NCT01052077|9776329|FG001|Phase A|Protocol Deviation|0
6142720|NCT01052077|9776330|FG002|Phase A|Protocol Deviation|0
6142721|NCT01052077|9776331|FG003|Phase A|Protocol Deviation|0
6142722|NCT01052077|9776328|FG000|Phase B|Lost to Follow-up|0
6142723|NCT01052077|9776329|FG001|Phase B|Lost to Follow-up|2
6142724|NCT01052077|9776330|FG002|Phase B|Lost to Follow-up|3
6142725|NCT01052077|9776331|FG003|Phase B|Lost to Follow-up|0
6142726|NCT01052077|9776328|FG000|Phase B|Adverse Event|0
6142727|NCT01052077|9776329|FG001|Phase B|Adverse Event|9
6142728|NCT01052077|9776330|FG002|Phase B|Adverse Event|2
6142729|NCT01052077|9776331|FG003|Phase B|Adverse Event|0
6142730|NCT01052077|9776328|FG000|Phase B|Met Withdrawal Criteria|0
6142731|NCT01052077|9776329|FG001|Phase B|Met Withdrawal Criteria|2
6142732|NCT01052077|9776330|FG002|Phase B|Met Withdrawal Criteria|1
6142733|NCT01052077|9776331|FG003|Phase B|Met Withdrawal Criteria|0
6142734|NCT01052077|9776328|FG000|Phase B|Physician Decision|0
6142735|NCT01052077|9776329|FG001|Phase B|Physician Decision|1
6142736|NCT01052077|9776330|FG002|Phase B|Physician Decision|1
6142737|NCT01052077|9776331|FG003|Phase B|Physician Decision|0
6142738|NCT01052077|9776328|FG000|Phase B|Withdrawal by Subject|0
6142739|NCT01052077|9776329|FG001|Phase B|Withdrawal by Subject|0
6142740|NCT01052077|9776330|FG002|Phase B|Withdrawal by Subject|5
6142741|NCT01052077|9776331|FG003|Phase B|Withdrawal by Subject|0
6142742|NCT01052077|9776328|FG000|Phase B|Protocol Deviation|0
6142743|NCT01052077|9776329|FG001|Phase B|Protocol Deviation|3
6142744|NCT01052077|9776330|FG002|Phase B|Protocol Deviation|4
6142745|NCT01052077|9776331|FG003|Phase B|Protocol Deviation|0
6142746|NCT01052077|9776328|FG000|Phase B|Lack of Efficacy|0
6142747|NCT01052077|9776329|FG001|Phase B|Lack of Efficacy|1
6142748|NCT01052077|9776330|FG002|Phase B|Lack of Efficacy|0
6142749|NCT01052077|9776331|FG003|Phase B|Lack of Efficacy|0
6142750|NCT01052077|9776328|FG000|Phase A+|Lost to Follow-up|0
6142751|NCT01052077|9776329|FG001|Phase A+|Lost to Follow-up|0
6142752|NCT01052077|9776330|FG002|Phase A+|Lost to Follow-up|0
6142753|NCT01052077|9776331|FG003|Phase A+|Lost to Follow-up|8
6142754|NCT01052077|9776328|FG000|Phase A+|Adverse Event|0
6142755|NCT01052077|9776329|FG001|Phase A+|Adverse Event|0
6142756|NCT01052077|9776330|FG002|Phase A+|Adverse Event|0
6142757|NCT01052077|9776331|FG003|Phase A+|Adverse Event|4
6142758|NCT01052077|9776328|FG000|Phase A+|Met Withdrawal Criteria|0
6142759|NCT01052077|9776329|FG001|Phase A+|Met Withdrawal Criteria|0
6142760|NCT01052077|9776330|FG002|Phase A+|Met Withdrawal Criteria|0
6142761|NCT01052077|9776331|FG003|Phase A+|Met Withdrawal Criteria|2
6142762|NCT01052077|9776328|FG000|Phase A+|Withdrawal by Subject|0
6142763|NCT01052077|9776329|FG001|Phase A+|Withdrawal by Subject|0
6142764|NCT01052077|9776330|FG002|Phase A+|Withdrawal by Subject|0
6142765|NCT01052077|9776331|FG003|Phase A+|Withdrawal by Subject|7
6142766|NCT01052103|9776339|FG000|Overall Study|Adverse Event|10
6142767|NCT01052103|9776340|FG001|Overall Study|Adverse Event|6
6142768|NCT01052103|9776339|FG000|Overall Study|Entry Criteria Not Met|3
6142769|NCT01052103|9776340|FG001|Overall Study|Entry Criteria Not Met|1
6142770|NCT01052103|9776339|FG000|Overall Study|Lost to Follow-up|3
6142771|NCT01052103|9776340|FG001|Overall Study|Lost to Follow-up|5
6142772|NCT01052103|9776339|FG000|Overall Study|Protocol Violation|10
6142773|NCT01052103|9776340|FG001|Overall Study|Protocol Violation|4
6142774|NCT01052103|9776339|FG000|Overall Study|Scheduling conflict|2
6142775|NCT01052103|9776340|FG001|Overall Study|Scheduling conflict|1
6142776|NCT01052103|9776339|FG000|Overall Study|Sponsor Decision|2
6142777|NCT01052103|9776340|FG001|Overall Study|Sponsor Decision|0
6142778|NCT01052103|9776339|FG000|Overall Study|Withdrawal by Subject|3
6142779|NCT01052103|9776340|FG001|Overall Study|Withdrawal by Subject|6
6142780|NCT01052103|9776339|FG000|Overall Study|Perceived Lack of Efficacy|1
6142781|NCT01052103|9776340|FG001|Overall Study|Perceived Lack of Efficacy|0
6142782|NCT01052116|9776349|FG000|Overall Study|Lost to Follow-up|11
6142783|NCT01052116|9776350|FG001|Overall Study|Lost to Follow-up|17
6142784|NCT01052116|9776349|FG000|Overall Study|Withdrawal by Subject|3
6142785|NCT01052116|9776350|FG001|Overall Study|Withdrawal by Subject|6
6142786|NCT01052116|9776349|FG000|Overall Study|Spirometry not performed|0
6142787|NCT01052116|9776350|FG001|Overall Study|Spirometry not performed|4
6142788|NCT01052272|9776369|FG000|Overall Study|Death|0
6142789|NCT01052272|9776370|FG001|Overall Study|Death|0
6142790|NCT01052272|9776371|FG002|Overall Study|Death|1
6142791|NCT01052272|9776372|FG003|Overall Study|Death|1
6142792|NCT01052272|9776369|FG000|Overall Study|Physician Decision|0
6142793|NCT01052272|9776370|FG001|Overall Study|Physician Decision|1
6142794|NCT01052272|9776371|FG002|Overall Study|Physician Decision|0
6142795|NCT01052272|9776372|FG003|Overall Study|Physician Decision|0
6142796|NCT01052272|9776369|FG000|Overall Study|patient refuses follow-up|5
6142797|NCT01052272|9776370|FG001|Overall Study|patient refuses follow-up|4
6142798|NCT01052272|9776371|FG002|Overall Study|patient refuses follow-up|2
6142799|NCT01052272|9776372|FG003|Overall Study|patient refuses follow-up|4
6142800|NCT01052272|9776369|FG000|Overall Study|Withdrawal by Subject|0
6142801|NCT01052272|9776370|FG001|Overall Study|Withdrawal by Subject|2
6142802|NCT01052272|9776371|FG002|Overall Study|Withdrawal by Subject|3
6142803|NCT01052272|9776372|FG003|Overall Study|Withdrawal by Subject|2
6142804|NCT01052272|9776369|FG000|Overall Study|placed in long-term care|0
6142805|NCT01052272|9776370|FG001|Overall Study|placed in long-term care|0
6142806|NCT01052272|9776371|FG002|Overall Study|placed in long-term care|1
6142807|NCT01052272|9776372|FG003|Overall Study|placed in long-term care|0
6142808|NCT01052272|9776369|FG000|Overall Study|decline in health|0
6142809|NCT01052272|9776370|FG001|Overall Study|decline in health|0
6142810|NCT01052272|9776371|FG002|Overall Study|decline in health|1
6142811|NCT01052272|9776372|FG003|Overall Study|decline in health|0
6142812|NCT01052428|9776384|FG000|Overall Study|Death|1
6142813|NCT01052428|9776385|FG001|Overall Study|Death|0
6142814|NCT01052428|9776384|FG000|Overall Study|Withdrawal by Subject|0
6142815|NCT01052428|9776385|FG001|Overall Study|Withdrawal by Subject|1
6142816|NCT01052480|9776393|FG000|Overall Study|Lost to Follow-up|3
6142817|NCT01052480|9776394|FG001|Overall Study|Lost to Follow-up|3
6142818|NCT01052480|9776393|FG000|Overall Study|Protocol Violation|1
6142819|NCT01052480|9776394|FG001|Overall Study|Protocol Violation|0
6142820|NCT01052480|9776393|FG000|Overall Study|Withdrawal by Subject|3
6142821|NCT01052480|9776394|FG001|Overall Study|Withdrawal by Subject|7
6142822|NCT01052480|9776393|FG000|Overall Study|Physician Decision|0
6142823|NCT01052480|9776394|FG001|Overall Study|Physician Decision|2
6142824|NCT01052480|9776393|FG000|Overall Study|Death|1
6142825|NCT01052480|9776394|FG001|Overall Study|Death|5
6142826|NCT01052493|9776400|FG000|Intervention 1 (Up to 10 Days)|Withdrawal by Subject|1
6142827|NCT01052493|9776401|FG001|Intervention 1 (Up to 10 Days)|Withdrawal by Subject|0
6142828|NCT01052493|9776402|FG002|Intervention 1 (Up to 10 Days)|Withdrawal by Subject|0
6142829|NCT01052662|9776439|FG000|Overall Study|Lost to Follow-up|15
6142830|NCT01052662|9776440|FG001|Overall Study|Lost to Follow-up|13
6142831|NCT01052662|9776441|FG002|Overall Study|Lost to Follow-up|18
6142832|NCT01052662|9776439|FG000|Overall Study|Withdrawal by Subject|3
6142833|NCT01052662|9776440|FG001|Overall Study|Withdrawal by Subject|2
6142834|NCT01052662|9776441|FG002|Overall Study|Withdrawal by Subject|1
6142835|NCT01052662|9776439|FG000|Overall Study|Pharmacy issue|1
6142836|NCT01052662|9776440|FG001|Overall Study|Pharmacy issue|3
6142837|NCT01052662|9776441|FG002|Overall Study|Pharmacy issue|3
6142838|NCT01052662|9776439|FG000|Overall Study|Adverse Event|1
6142839|NCT01052662|9776440|FG001|Overall Study|Adverse Event|1
6142840|NCT01052662|9776441|FG002|Overall Study|Adverse Event|0
6142841|NCT01052662|9776439|FG000|Overall Study|Legal Problem|2
6142842|NCT01052662|9776440|FG001|Overall Study|Legal Problem|0
6142843|NCT01052662|9776441|FG002|Overall Study|Legal Problem|0
6142844|NCT01052662|9776439|FG000|Overall Study|Administrative|0
6142845|NCT01052662|9776440|FG001|Overall Study|Administrative|3
6142846|NCT01052662|9776441|FG002|Overall Study|Administrative|0
6142847|NCT01052714|9776460|FG000|Overall Study|Adverse Event|6
6142848|NCT01052714|9776461|FG001|Overall Study|Adverse Event|3
6142849|NCT01052714|9776462|FG002|Overall Study|Adverse Event|0
6142850|NCT01052714|9776460|FG000|Overall Study|Death|1
6142851|NCT01052714|9776461|FG001|Overall Study|Death|2
6142852|NCT01052714|9776462|FG002|Overall Study|Death|0
6142853|NCT01052714|9776460|FG000|Overall Study|Lost to Follow-up|2
6142854|NCT01052714|9776461|FG001|Overall Study|Lost to Follow-up|3
6142855|NCT01052714|9776462|FG002|Overall Study|Lost to Follow-up|0
6142856|NCT01052714|9776460|FG000|Overall Study|Physician Decision|9
6142857|NCT01052714|9776461|FG001|Overall Study|Physician Decision|9
6142858|NCT01052714|9776462|FG002|Overall Study|Physician Decision|1
6142859|NCT01052714|9776460|FG000|Overall Study|Withdrawal by Subject|7
6142860|NCT01052714|9776461|FG001|Overall Study|Withdrawal by Subject|12
6142861|NCT01052714|9776462|FG002|Overall Study|Withdrawal by Subject|1
6142862|NCT01052779|9776470|FG000|Overall Study|Adverse Event|1
6142863|NCT01052779|9776471|FG001|Overall Study|Adverse Event|4
6142864|NCT01052779|9776470|FG000|Overall Study|Withdrawal by Subject|1
6142865|NCT01052779|9776471|FG001|Overall Study|Withdrawal by Subject|2
6142866|NCT01052779|9776470|FG000|Overall Study|Other-Protocol Violation|1
6142867|NCT01052779|9776471|FG001|Overall Study|Other-Protocol Violation|1
6142868|NCT01052779|9776470|FG000|Overall Study|Other-Surgery|0
6142869|NCT01052779|9776471|FG001|Overall Study|Other-Surgery|2
6142870|NCT01052779|9776470|FG000|Overall Study|Other-Missed Week 5 Visit|2
6142871|NCT01052779|9776471|FG001|Overall Study|Other-Missed Week 5 Visit|0
6142872|NCT01052844|9776488|FG000|Overall Study|Adverse Event|0
6142873|NCT01052844|9776489|FG001|Overall Study|Adverse Event|1
6142874|NCT01053247|9776650|FG000|Overall Study|Withdrawal by Subject|9
6142875|NCT01053247|9776651|FG001|Overall Study|Withdrawal by Subject|4
6142876|NCT01053247|9776652|FG002|Overall Study|Withdrawal by Subject|15
6142877|NCT01053247|9776650|FG000|Overall Study|Lack of Efficacy|1
6142878|NCT01053247|9776651|FG001|Overall Study|Lack of Efficacy|0
6142879|NCT01053247|9776652|FG002|Overall Study|Lack of Efficacy|1
6142880|NCT01053247|9776650|FG000|Overall Study|Protocol Violation|2
6142881|NCT01053247|9776651|FG001|Overall Study|Protocol Violation|1
6142882|NCT01053247|9776652|FG002|Overall Study|Protocol Violation|2
6142883|NCT01053247|9776650|FG000|Overall Study|Lost to Follow-up|8
6142884|NCT01053247|9776651|FG001|Overall Study|Lost to Follow-up|5
6142885|NCT01053247|9776652|FG002|Overall Study|Lost to Follow-up|7
6142886|NCT01053247|9776650|FG000|Overall Study|Adverse Event|0
6142887|NCT01053247|9776651|FG001|Overall Study|Adverse Event|9
6142888|NCT01053247|9776652|FG002|Overall Study|Adverse Event|3
6142889|NCT01053429|9776678|FG000|Overall Study|Adverse Event|64
6142890|NCT01053429|9776678|FG000|Overall Study|Other|309
6142891|NCT01053663|9776694|FG000|Overall Study|Death|2
6142892|NCT01053663|9776694|FG000|Overall Study|Lost to Follow-up|1
6142893|NCT01053663|9776694|FG000|Overall Study|Poor IV Access|1
6142894|NCT01053663|9776694|FG000|Overall Study|Transferred to Another Hospital|1
6142895|NCT01053663|9776694|FG000|Overall Study|Negative Influenza Diagnosis|1
6142896|NCT01053741|9776706|FG000|2nd Study Intervention|Physician Decision|0
6142897|NCT01053741|9776707|FG001|2nd Study Intervention|Physician Decision|1
6142898|NCT01053962|9776733|FG000|Pretreatment Period|Withdrew Consent (Patient/PI)|0
6142899|NCT01053962|9776734|FG001|Pretreatment Period|Withdrew Consent (Patient/PI)|0
6142900|NCT01053962|9776735|FG002|Pretreatment Period|Withdrew Consent (Patient/PI)|0
6142901|NCT01053962|9776736|FG003|Pretreatment Period|Withdrew Consent (Patient/PI)|1
6142902|NCT01053962|9776737|FG004|Pretreatment Period|Withdrew Consent (Patient/PI)|2
6142903|NCT01053962|9776733|FG000|Pretreatment Period|Venipuncture Failure|0
6142904|NCT01053962|9776734|FG001|Pretreatment Period|Venipuncture Failure|0
6142905|NCT01053962|9776735|FG002|Pretreatment Period|Venipuncture Failure|1
6142906|NCT01053962|9776736|FG003|Pretreatment Period|Venipuncture Failure|0
6142907|NCT01053962|9776737|FG004|Pretreatment Period|Venipuncture Failure|0
6142908|NCT01053962|9776733|FG000|Pretreatment Period|Failed Urine drug screen Day 1|0
6142909|NCT01053962|9776734|FG001|Pretreatment Period|Failed Urine drug screen Day 1|1
6142910|NCT01053962|9776735|FG002|Pretreatment Period|Failed Urine drug screen Day 1|0
6142911|NCT01053962|9776736|FG003|Pretreatment Period|Failed Urine drug screen Day 1|0
6142912|NCT01053962|9776737|FG004|Pretreatment Period|Failed Urine drug screen Day 1|0
6142913|NCT01053962|9776733|FG000|Pretreatment Period|Abnormal Lab values Exl 16|0
6142914|NCT01053962|9776734|FG001|Pretreatment Period|Abnormal Lab values Exl 16|0
6142915|NCT01053962|9776735|FG002|Pretreatment Period|Abnormal Lab values Exl 16|0
6142916|NCT01053962|9776736|FG003|Pretreatment Period|Abnormal Lab values Exl 16|1
6142917|NCT01053962|9776737|FG004|Pretreatment Period|Abnormal Lab values Exl 16|0
6142918|NCT01053962|9776733|FG000|Treatment Period|Lack of Efficacy|0
6142919|NCT01053962|9776734|FG001|Treatment Period|Lack of Efficacy|0
6142920|NCT01053962|9776735|FG002|Treatment Period|Lack of Efficacy|0
6142921|NCT01053962|9776736|FG003|Treatment Period|Lack of Efficacy|0
6142922|NCT01053962|9776737|FG004|Treatment Period|Lack of Efficacy|1
6142923|NCT01053962|9776733|FG000|Treatment Period|Adverse Event|0
6142924|NCT01053962|9776734|FG001|Treatment Period|Adverse Event|0
6142925|NCT01053962|9776735|FG002|Treatment Period|Adverse Event|0
6142926|NCT01053962|9776736|FG003|Treatment Period|Adverse Event|0
6142927|NCT01053962|9776737|FG004|Treatment Period|Adverse Event|1
6142928|NCT01053962|9776733|FG000|Treatment Period|Withdrawal by Subject|0
6142929|NCT01053962|9776734|FG001|Treatment Period|Withdrawal by Subject|0
6142930|NCT01053962|9776735|FG002|Treatment Period|Withdrawal by Subject|0
6142931|NCT01053962|9776736|FG003|Treatment Period|Withdrawal by Subject|0
6142932|NCT01053962|9776737|FG004|Treatment Period|Withdrawal by Subject|1
6142933|NCT01053962|9776733|FG000|Treatment Period|Noncompliance with protocol|1
6142934|NCT01053962|9776734|FG001|Treatment Period|Noncompliance with protocol|0
6142935|NCT01053962|9776735|FG002|Treatment Period|Noncompliance with protocol|0
6142936|NCT01053962|9776736|FG003|Treatment Period|Noncompliance with protocol|0
6142937|NCT01053962|9776737|FG004|Treatment Period|Noncompliance with protocol|0
6142938|NCT01053988|9776759|FG000|2-week, Single-blind Run-In Period|Did Not Meet Continuation Criteria|220
6142939|NCT01053988|9776760|FG001|2-week, Single-blind Run-In Period|Did Not Meet Continuation Criteria|0
6142940|NCT01053988|9776761|FG002|2-week, Single-blind Run-In Period|Did Not Meet Continuation Criteria|0
6142941|NCT01053988|9776762|FG003|2-week, Single-blind Run-In Period|Did Not Meet Continuation Criteria|0
6142942|NCT01053988|9776763|FG004|2-week, Single-blind Run-In Period|Did Not Meet Continuation Criteria|0
6142943|NCT01053988|9776764|FG005|2-week, Single-blind Run-In Period|Did Not Meet Continuation Criteria|0
6142944|NCT01053988|9776759|FG000|2-week, Single-blind Run-In Period|Study Closed/Terminated|98
6142945|NCT01053988|9776760|FG001|2-week, Single-blind Run-In Period|Study Closed/Terminated|0
6142946|NCT01053988|9776761|FG002|2-week, Single-blind Run-In Period|Study Closed/Terminated|0
6142947|NCT01053988|9776762|FG003|2-week, Single-blind Run-In Period|Study Closed/Terminated|0
6142948|NCT01053988|9776763|FG004|2-week, Single-blind Run-In Period|Study Closed/Terminated|0
6142949|NCT01053988|9776764|FG005|2-week, Single-blind Run-In Period|Study Closed/Terminated|0
6142950|NCT01053988|9776759|FG000|2-week, Single-blind Run-In Period|Withdrawal by Subject|30
6142951|NCT01053988|9776760|FG001|2-week, Single-blind Run-In Period|Withdrawal by Subject|0
6142952|NCT01053988|9776761|FG002|2-week, Single-blind Run-In Period|Withdrawal by Subject|0
6142953|NCT01053988|9776762|FG003|2-week, Single-blind Run-In Period|Withdrawal by Subject|0
6142954|NCT01053988|9776763|FG004|2-week, Single-blind Run-In Period|Withdrawal by Subject|0
6142955|NCT01053988|9776764|FG005|2-week, Single-blind Run-In Period|Withdrawal by Subject|0
6142956|NCT01053988|9776759|FG000|2-week, Single-blind Run-In Period|Adverse Event|6
6142957|NCT01053988|9776760|FG001|2-week, Single-blind Run-In Period|Adverse Event|0
6142958|NCT01053988|9776761|FG002|2-week, Single-blind Run-In Period|Adverse Event|0
6142959|NCT01053988|9776762|FG003|2-week, Single-blind Run-In Period|Adverse Event|0
6142960|NCT01053988|9776763|FG004|2-week, Single-blind Run-In Period|Adverse Event|0
6142961|NCT01053988|9776764|FG005|2-week, Single-blind Run-In Period|Adverse Event|0
6142962|NCT01053988|9776759|FG000|2-week, Single-blind Run-In Period|Physician Decision|5
6142963|NCT01053988|9776760|FG001|2-week, Single-blind Run-In Period|Physician Decision|0
6142964|NCT01053988|9776761|FG002|2-week, Single-blind Run-In Period|Physician Decision|0
6142965|NCT01053988|9776762|FG003|2-week, Single-blind Run-In Period|Physician Decision|0
6142966|NCT01053988|9776763|FG004|2-week, Single-blind Run-In Period|Physician Decision|0
6142967|NCT01053988|9776764|FG005|2-week, Single-blind Run-In Period|Physician Decision|0
6142968|NCT01053988|9776759|FG000|2-week, Single-blind Run-In Period|Lost to Follow-up|1
6142969|NCT01053988|9776760|FG001|2-week, Single-blind Run-In Period|Lost to Follow-up|0
6142970|NCT01053988|9776761|FG002|2-week, Single-blind Run-In Period|Lost to Follow-up|0
6142971|NCT01053988|9776762|FG003|2-week, Single-blind Run-In Period|Lost to Follow-up|0
6142972|NCT01053988|9776763|FG004|2-week, Single-blind Run-In Period|Lost to Follow-up|0
6142973|NCT01053988|9776764|FG005|2-week, Single-blind Run-In Period|Lost to Follow-up|0
6142974|NCT01053988|9776759|FG000|24-week, Double-blind Treatment Period|Adverse Event|0
6142975|NCT01053988|9776760|FG001|24-week, Double-blind Treatment Period|Adverse Event|15
6142976|NCT01053988|9776761|FG002|24-week, Double-blind Treatment Period|Adverse Event|23
6142977|NCT01053988|9776762|FG003|24-week, Double-blind Treatment Period|Adverse Event|24
6142978|NCT01053988|9776763|FG004|24-week, Double-blind Treatment Period|Adverse Event|17
6142979|NCT01053988|9776764|FG005|24-week, Double-blind Treatment Period|Adverse Event|14
6142980|NCT01053988|9776759|FG000|24-week, Double-blind Treatment Period|Lack of Efficacy-No Sub-Reason|0
6142981|NCT01053988|9776760|FG001|24-week, Double-blind Treatment Period|Lack of Efficacy-No Sub-Reason|3
6142982|NCT01053988|9776761|FG002|24-week, Double-blind Treatment Period|Lack of Efficacy-No Sub-Reason|2
6142983|NCT01053988|9776762|FG003|24-week, Double-blind Treatment Period|Lack of Efficacy-No Sub-Reason|2
6142984|NCT01053988|9776763|FG004|24-week, Double-blind Treatment Period|Lack of Efficacy-No Sub-Reason|3
6142985|NCT01053988|9776764|FG005|24-week, Double-blind Treatment Period|Lack of Efficacy-No Sub-Reason|0
6142986|NCT01053988|9776759|FG000|24-week, Double-blind Treatment Period|Lack of Efficacy-Sub-Reason Exacerbation|0
6142987|NCT01053988|9776760|FG001|24-week, Double-blind Treatment Period|Lack of Efficacy-Sub-Reason Exacerbation|17
6142988|NCT01053988|9776761|FG002|24-week, Double-blind Treatment Period|Lack of Efficacy-Sub-Reason Exacerbation|16
6142989|NCT01053988|9776762|FG003|24-week, Double-blind Treatment Period|Lack of Efficacy-Sub-Reason Exacerbation|13
6142990|NCT01053988|9776763|FG004|24-week, Double-blind Treatment Period|Lack of Efficacy-Sub-Reason Exacerbation|9
6142991|NCT01053988|9776764|FG005|24-week, Double-blind Treatment Period|Lack of Efficacy-Sub-Reason Exacerbation|12
6142992|NCT01053988|9776759|FG000|24-week, Double-blind Treatment Period|Protocol Violation|0
6142993|NCT01053988|9776760|FG001|24-week, Double-blind Treatment Period|Protocol Violation|3
6142994|NCT01053988|9776761|FG002|24-week, Double-blind Treatment Period|Protocol Violation|4
6142995|NCT01053988|9776762|FG003|24-week, Double-blind Treatment Period|Protocol Violation|2
6142996|NCT01053988|9776763|FG004|24-week, Double-blind Treatment Period|Protocol Violation|1
6142997|NCT01053988|9776764|FG005|24-week, Double-blind Treatment Period|Protocol Violation|4
6142998|NCT01053988|9776759|FG000|24-week, Double-blind Treatment Period|Met Protocol-Defined Stopping Criteria|0
6142999|NCT01053988|9776760|FG001|24-week, Double-blind Treatment Period|Met Protocol-Defined Stopping Criteria|11
6143000|NCT01053988|9776761|FG002|24-week, Double-blind Treatment Period|Met Protocol-Defined Stopping Criteria|5
6143001|NCT01053988|9776762|FG003|24-week, Double-blind Treatment Period|Met Protocol-Defined Stopping Criteria|8
6143002|NCT01053988|9776763|FG004|24-week, Double-blind Treatment Period|Met Protocol-Defined Stopping Criteria|13
6143003|NCT01053988|9776764|FG005|24-week, Double-blind Treatment Period|Met Protocol-Defined Stopping Criteria|9
6143004|NCT01053988|9776759|FG000|24-week, Double-blind Treatment Period|Lost to Follow-up|0
6143005|NCT01053988|9776760|FG001|24-week, Double-blind Treatment Period|Lost to Follow-up|4
6143006|NCT01053988|9776761|FG002|24-week, Double-blind Treatment Period|Lost to Follow-up|0
6143007|NCT01053988|9776762|FG003|24-week, Double-blind Treatment Period|Lost to Follow-up|2
6143008|NCT01053988|9776763|FG004|24-week, Double-blind Treatment Period|Lost to Follow-up|1
6143009|NCT01053988|9776764|FG005|24-week, Double-blind Treatment Period|Lost to Follow-up|3
6143010|NCT01053988|9776759|FG000|24-week, Double-blind Treatment Period|Physician Decision|0
6143011|NCT01053988|9776760|FG001|24-week, Double-blind Treatment Period|Physician Decision|5
6143012|NCT01053988|9776761|FG002|24-week, Double-blind Treatment Period|Physician Decision|2
6143013|NCT01053988|9776762|FG003|24-week, Double-blind Treatment Period|Physician Decision|5
6143014|NCT01053988|9776763|FG004|24-week, Double-blind Treatment Period|Physician Decision|5
6143015|NCT01053988|9776764|FG005|24-week, Double-blind Treatment Period|Physician Decision|4
6143016|NCT01053988|9776759|FG000|24-week, Double-blind Treatment Period|Withdrawal by Subject|0
6143017|NCT01053988|9776760|FG001|24-week, Double-blind Treatment Period|Withdrawal by Subject|11
6143018|NCT01053988|9776761|FG002|24-week, Double-blind Treatment Period|Withdrawal by Subject|9
6143019|NCT01053988|9776762|FG003|24-week, Double-blind Treatment Period|Withdrawal by Subject|7
6143020|NCT01053988|9776763|FG004|24-week, Double-blind Treatment Period|Withdrawal by Subject|10
6143021|NCT01053988|9776764|FG005|24-week, Double-blind Treatment Period|Withdrawal by Subject|9
6143022|NCT01054144|9776780|FG000|Overall Study|Death|2
6143023|NCT01054170|9776789|FG000|Overall Study|Protocol Violation|1
6143024|NCT01054170|9776790|FG001|Overall Study|Protocol Violation|0
6143025|NCT01054170|9776789|FG000|Overall Study|Withdrawal by Subject|3
6143026|NCT01054170|9776790|FG001|Overall Study|Withdrawal by Subject|2
6143027|NCT01054170|9776789|FG000|Overall Study|Adverse Event|0
6143028|NCT01054170|9776790|FG001|Overall Study|Adverse Event|4
6143029|NCT01054222|9776814|FG000|Overall Study|Lack of Efficacy|1
6143030|NCT01054222|9776814|FG000|Overall Study|Lost to Follow-up|4
6143031|NCT01054222|9776814|FG000|Overall Study|Withdrawal by Subject|6
6143032|NCT01054300|9776820|FG000|Period 1|Adverse Event|1
6143033|NCT01054300|9776821|FG001|Period 1|Adverse Event|0
6143034|NCT01054300|9776822|FG002|Period 1|Adverse Event|0
6143035|NCT01054300|9776823|FG003|Period 1|Adverse Event|0
6143036|NCT01054300|9776820|FG000|Period 2|Withdrawal by Subject|0
6143037|NCT01054300|9776821|FG001|Period 2|Withdrawal by Subject|0
6143038|NCT01054300|9776822|FG002|Period 2|Withdrawal by Subject|1
6143039|NCT01054300|9776823|FG003|Period 2|Withdrawal by Subject|0
6143040|NCT01054443|9776861|FG000|Overall Study|Withdrawal by Subject|0
6143041|NCT01054443|9776862|FG001|Overall Study|Withdrawal by Subject|0
6143042|NCT01054443|9776863|FG002|Overall Study|Withdrawal by Subject|0
6143043|NCT01054443|9776864|FG003|Overall Study|Withdrawal by Subject|1
6143044|NCT01054456|9776877|FG000|Overall Study|Other|1
6143045|NCT01054560|9776883|FG000|Overall Study|Death|10
6143046|NCT01054560|9776884|FG001|Overall Study|Death|21
6143047|NCT01054560|9776883|FG000|Overall Study|Lost to Follow-up|2
6143048|NCT01054560|9776884|FG001|Overall Study|Lost to Follow-up|5
6143049|NCT01054560|9776883|FG000|Overall Study|Withdrawal by Subject|0
6143050|NCT01054560|9776884|FG001|Overall Study|Withdrawal by Subject|2
6143051|NCT01054560|9776883|FG000|Overall Study|Physician Decision|1
6143052|NCT01054560|9776884|FG001|Overall Study|Physician Decision|0
6143053|NCT01054573|9776896|FG000|Overall Study|Adverse Event|1
6143054|NCT01054573|9776897|FG001|Overall Study|Adverse Event|0
6143055|NCT01054573|9776898|FG002|Overall Study|Adverse Event|1
6143056|NCT01054573|9776899|FG003|Overall Study|Adverse Event|1
6143057|NCT01054573|9776896|FG000|Overall Study|Lost to Follow-up|0
6143058|NCT01054573|9776897|FG001|Overall Study|Lost to Follow-up|2
6143059|NCT01054573|9776898|FG002|Overall Study|Lost to Follow-up|0
6143060|NCT01054573|9776899|FG003|Overall Study|Lost to Follow-up|0
6143061|NCT01054573|9776896|FG000|Overall Study|Withdrawal by Subject|0
6143062|NCT01054573|9776897|FG001|Overall Study|Withdrawal by Subject|2
6143063|NCT01054573|9776898|FG002|Overall Study|Withdrawal by Subject|2
6143064|NCT01054573|9776899|FG003|Overall Study|Withdrawal by Subject|1
6143065|NCT01054599|9776947|FG000|Overall Study|Dizziness due to phenytoin toxicity|1
6143066|NCT01054599|9776948|FG001|Overall Study|Dizziness due to phenytoin toxicity|0
6143067|NCT01054599|9776947|FG000|Overall Study|Protocol Violation|1
6143068|NCT01054599|9776948|FG001|Overall Study|Protocol Violation|0
6143069|NCT01054599|9776947|FG000|Overall Study|Spells/seizure-like episodes|1
6143070|NCT01054599|9776948|FG001|Overall Study|Spells/seizure-like episodes|1
6143071|NCT01054599|9776947|FG000|Overall Study|Timing/scheduling difficulties|1
6143072|NCT01054599|9776948|FG001|Overall Study|Timing/scheduling difficulties|1
6143073|NCT01054599|9776947|FG000|Overall Study|Visual impairment, WTAR <80|0
6143074|NCT01054599|9776948|FG001|Overall Study|Visual impairment, WTAR <80|1
6143075|NCT01054599|9776947|FG000|Overall Study|Lost to Follow-up|0
6143076|NCT01054599|9776948|FG001|Overall Study|Lost to Follow-up|2
6143077|NCT01054599|9776947|FG000|Overall Study|Adverse Event|0
6143078|NCT01054599|9776948|FG001|Overall Study|Adverse Event|1
6143079|NCT01054599|9776947|FG000|Overall Study|Withdrawal by Subject|0
6143080|NCT01054599|9776948|FG001|Overall Study|Withdrawal by Subject|1
6143081|NCT01054729|9776975|FG000|Overall Study|Randomized but Not Treated|0
6143082|NCT01054729|9776976|FG001|Overall Study|Randomized but Not Treated|1
6143083|NCT01054729|9776977|FG002|Overall Study|Randomized but Not Treated|0
6143084|NCT01054729|9776978|FG003|Overall Study|Randomized but Not Treated|0
6143085|NCT01054729|9776975|FG000|Overall Study|Adverse Event|1
6143086|NCT01054729|9776976|FG001|Overall Study|Adverse Event|1
6143087|NCT01054729|9776977|FG002|Overall Study|Adverse Event|2
6143088|NCT01054729|9776978|FG003|Overall Study|Adverse Event|1
6143089|NCT01054729|9776975|FG000|Overall Study|Withdrawal by Subject|1
6143090|NCT01054729|9776976|FG001|Overall Study|Withdrawal by Subject|0
6143091|NCT01054729|9776977|FG002|Overall Study|Withdrawal by Subject|1
6143092|NCT01054729|9776978|FG003|Overall Study|Withdrawal by Subject|0
6143093|NCT01054729|9776975|FG000|Overall Study|Lost to Follow-up|0
6143094|NCT01054729|9776976|FG001|Overall Study|Lost to Follow-up|1
6143095|NCT01054729|9776977|FG002|Overall Study|Lost to Follow-up|0
6143096|NCT01054729|9776978|FG003|Overall Study|Lost to Follow-up|0
6143097|NCT01054729|9776975|FG000|Overall Study|Lost to Follow-up, Later Contacted Site|0
6143098|NCT01054729|9776976|FG001|Overall Study|Lost to Follow-up, Later Contacted Site|1
6143099|NCT01054729|9776977|FG002|Overall Study|Lost to Follow-up, Later Contacted Site|0
6143100|NCT01054729|9776978|FG003|Overall Study|Lost to Follow-up, Later Contacted Site|0
6143101|NCT01054729|9776975|FG000|Overall Study|Non-responder|1
6143102|NCT01054729|9776976|FG001|Overall Study|Non-responder|0
6143103|NCT01054729|9776977|FG002|Overall Study|Non-responder|1
6143104|NCT01054729|9776978|FG003|Overall Study|Non-responder|1
6143105|NCT01054729|9776975|FG000|Overall Study|PEG/RBV Non-responder|1
6143106|NCT01054729|9776976|FG001|Overall Study|PEG/RBV Non-responder|0
6143107|NCT01054729|9776977|FG002|Overall Study|PEG/RBV Non-responder|1
6143108|NCT01054729|9776978|FG003|Overall Study|PEG/RBV Non-responder|0
6143109|NCT01054729|9776975|FG000|Overall Study|Personal/Obligations|0
6143110|NCT01054729|9776976|FG001|Overall Study|Personal/Obligations|1
6143111|NCT01054729|9776977|FG002|Overall Study|Personal/Obligations|0
6143112|NCT01054729|9776978|FG003|Overall Study|Personal/Obligations|0
6143113|NCT01054729|9776975|FG000|Overall Study|Subject moved|0
5982781|NCT00905606|9571846|FG000|Period 1|Adverse Event|0
6143114|NCT01054729|9776976|FG001|Overall Study|Subject moved|0
6143115|NCT01054729|9776977|FG002|Overall Study|Subject moved|1
6143116|NCT01054729|9776978|FG003|Overall Study|Subject moved|0
6143117|NCT01054729|9776975|FG000|Overall Study|Lack of Efficacy|0
6143118|NCT01054729|9776976|FG001|Overall Study|Lack of Efficacy|0
6143119|NCT01054729|9776977|FG002|Overall Study|Lack of Efficacy|0
6143120|NCT01054729|9776978|FG003|Overall Study|Lack of Efficacy|1
6143121|NCT01054820|9777001|FG000|Overall Study|Withdrawal by Subject|2
6143122|NCT01054846|9777007|FG000|Overall Study|Lost to Follow-up|76
6143123|NCT01054846|9777008|FG001|Overall Study|Lost to Follow-up|17
6143124|NCT01054885|9777019|FG000|2-week, Single-blind Run-In Period|Did Not Meet Continuation Criteria|246
6143125|NCT01054885|9777020|FG001|2-week, Single-blind Run-In Period|Did Not Meet Continuation Criteria|0
6143126|NCT01054885|9777021|FG002|2-week, Single-blind Run-In Period|Did Not Meet Continuation Criteria|0
6143127|NCT01054885|9777022|FG003|2-week, Single-blind Run-In Period|Did Not Meet Continuation Criteria|0
6143128|NCT01054885|9777023|FG004|2-week, Single-blind Run-In Period|Did Not Meet Continuation Criteria|0
6143129|NCT01054885|9777024|FG005|2-week, Single-blind Run-In Period|Did Not Meet Continuation Criteria|0
6143130|NCT01054885|9777025|FG006|2-week, Single-blind Run-In Period|Did Not Meet Continuation Criteria|0
6143131|NCT01054885|9777019|FG000|2-week, Single-blind Run-In Period|Physician Decision|6
6143132|NCT01054885|9777020|FG001|2-week, Single-blind Run-In Period|Physician Decision|0
6143133|NCT01054885|9777021|FG002|2-week, Single-blind Run-In Period|Physician Decision|0
6143134|NCT01054885|9777022|FG003|2-week, Single-blind Run-In Period|Physician Decision|0
6143135|NCT01054885|9777023|FG004|2-week, Single-blind Run-In Period|Physician Decision|0
6143136|NCT01054885|9777024|FG005|2-week, Single-blind Run-In Period|Physician Decision|0
6143137|NCT01054885|9777025|FG006|2-week, Single-blind Run-In Period|Physician Decision|0
6143138|NCT01054885|9777019|FG000|2-week, Single-blind Run-In Period|Withdrawal by Subject|23
6143139|NCT01054885|9777020|FG001|2-week, Single-blind Run-In Period|Withdrawal by Subject|0
6143140|NCT01054885|9777021|FG002|2-week, Single-blind Run-In Period|Withdrawal by Subject|0
6143141|NCT01054885|9777022|FG003|2-week, Single-blind Run-In Period|Withdrawal by Subject|0
6143142|NCT01054885|9777023|FG004|2-week, Single-blind Run-In Period|Withdrawal by Subject|0
6143143|NCT01054885|9777024|FG005|2-week, Single-blind Run-In Period|Withdrawal by Subject|0
6143144|NCT01054885|9777025|FG006|2-week, Single-blind Run-In Period|Withdrawal by Subject|0
6143145|NCT01054885|9777019|FG000|2-week, Single-blind Run-In Period|Lost to Follow-up|1
6143146|NCT01054885|9777020|FG001|2-week, Single-blind Run-In Period|Lost to Follow-up|0
6143147|NCT01054885|9777021|FG002|2-week, Single-blind Run-In Period|Lost to Follow-up|0
6143148|NCT01054885|9777022|FG003|2-week, Single-blind Run-In Period|Lost to Follow-up|0
6143149|NCT01054885|9777023|FG004|2-week, Single-blind Run-In Period|Lost to Follow-up|0
6143150|NCT01054885|9777024|FG005|2-week, Single-blind Run-In Period|Lost to Follow-up|0
6143151|NCT01054885|9777025|FG006|2-week, Single-blind Run-In Period|Lost to Follow-up|0
6143152|NCT01054885|9777019|FG000|2-week, Single-blind Run-In Period|Adverse Event|7
6143153|NCT01054885|9777020|FG001|2-week, Single-blind Run-In Period|Adverse Event|0
6143154|NCT01054885|9777021|FG002|2-week, Single-blind Run-In Period|Adverse Event|0
6143155|NCT01054885|9777022|FG003|2-week, Single-blind Run-In Period|Adverse Event|0
6143156|NCT01054885|9777023|FG004|2-week, Single-blind Run-In Period|Adverse Event|0
6143157|NCT01054885|9777024|FG005|2-week, Single-blind Run-In Period|Adverse Event|0
6143158|NCT01054885|9777025|FG006|2-week, Single-blind Run-In Period|Adverse Event|0
6143159|NCT01054885|9777019|FG000|2-week, Single-blind Run-In Period|Study Closed/Terminated|68
6143160|NCT01054885|9777020|FG001|2-week, Single-blind Run-In Period|Study Closed/Terminated|0
6143161|NCT01054885|9777021|FG002|2-week, Single-blind Run-In Period|Study Closed/Terminated|0
6143162|NCT01054885|9777022|FG003|2-week, Single-blind Run-In Period|Study Closed/Terminated|0
6143163|NCT01054885|9777023|FG004|2-week, Single-blind Run-In Period|Study Closed/Terminated|0
6143164|NCT01054885|9777024|FG005|2-week, Single-blind Run-In Period|Study Closed/Terminated|0
6143165|NCT01054885|9777025|FG006|2-week, Single-blind Run-In Period|Study Closed/Terminated|0
6143166|NCT01054885|9777019|FG000|24-week, Double-blind Treatment Period|Adverse Event|0
6143167|NCT01054885|9777020|FG001|24-week, Double-blind Treatment Period|Adverse Event|18
6143168|NCT01054885|9777021|FG002|24-week, Double-blind Treatment Period|Adverse Event|12
6143169|NCT01054885|9777022|FG003|24-week, Double-blind Treatment Period|Adverse Event|15
6143170|NCT01054885|9777023|FG004|24-week, Double-blind Treatment Period|Adverse Event|15
6143171|NCT01054885|9777024|FG005|24-week, Double-blind Treatment Period|Adverse Event|17
6143172|NCT01054885|9777025|FG006|24-week, Double-blind Treatment Period|Adverse Event|19
6143173|NCT01054885|9777019|FG000|24-week, Double-blind Treatment Period|Lack of Efficacy-No Sub-Reason|0
6143174|NCT01054885|9777020|FG001|24-week, Double-blind Treatment Period|Lack of Efficacy-No Sub-Reason|0
6143175|NCT01054885|9777021|FG002|24-week, Double-blind Treatment Period|Lack of Efficacy-No Sub-Reason|3
6143176|NCT01054885|9777022|FG003|24-week, Double-blind Treatment Period|Lack of Efficacy-No Sub-Reason|1
6143177|NCT01054885|9777023|FG004|24-week, Double-blind Treatment Period|Lack of Efficacy-No Sub-Reason|0
6143178|NCT01054885|9777024|FG005|24-week, Double-blind Treatment Period|Lack of Efficacy-No Sub-Reason|1
6143179|NCT01054885|9777025|FG006|24-week, Double-blind Treatment Period|Lack of Efficacy-No Sub-Reason|0
6143180|NCT01054885|9777019|FG000|24-week, Double-blind Treatment Period|Lack of Efficacy-Sub-Reason Exacerbation|0
6143181|NCT01054885|9777020|FG001|24-week, Double-blind Treatment Period|Lack of Efficacy-Sub-Reason Exacerbation|12
6143182|NCT01054885|9777021|FG002|24-week, Double-blind Treatment Period|Lack of Efficacy-Sub-Reason Exacerbation|2
6143183|NCT01054885|9777022|FG003|24-week, Double-blind Treatment Period|Lack of Efficacy-Sub-Reason Exacerbation|5
6143184|NCT01054885|9777023|FG004|24-week, Double-blind Treatment Period|Lack of Efficacy-Sub-Reason Exacerbation|11
6143185|NCT01054885|9777024|FG005|24-week, Double-blind Treatment Period|Lack of Efficacy-Sub-Reason Exacerbation|7
6143186|NCT01054885|9777025|FG006|24-week, Double-blind Treatment Period|Lack of Efficacy-Sub-Reason Exacerbation|7
6143187|NCT01054885|9777019|FG000|24-week, Double-blind Treatment Period|Protocol Violation|0
6143188|NCT01054885|9777020|FG001|24-week, Double-blind Treatment Period|Protocol Violation|7
6143189|NCT01054885|9777021|FG002|24-week, Double-blind Treatment Period|Protocol Violation|7
6143190|NCT01054885|9777022|FG003|24-week, Double-blind Treatment Period|Protocol Violation|2
6143191|NCT01054885|9777023|FG004|24-week, Double-blind Treatment Period|Protocol Violation|3
6143192|NCT01054885|9777024|FG005|24-week, Double-blind Treatment Period|Protocol Violation|8
6143193|NCT01054885|9777025|FG006|24-week, Double-blind Treatment Period|Protocol Violation|4
6143194|NCT01054885|9777019|FG000|24-week, Double-blind Treatment Period|Protocol Defined Stopping Criteria|0
6143195|NCT01054885|9777020|FG001|24-week, Double-blind Treatment Period|Protocol Defined Stopping Criteria|7
6143196|NCT01054885|9777021|FG002|24-week, Double-blind Treatment Period|Protocol Defined Stopping Criteria|12
6143197|NCT01054885|9777022|FG003|24-week, Double-blind Treatment Period|Protocol Defined Stopping Criteria|7
6143198|NCT01054885|9777023|FG004|24-week, Double-blind Treatment Period|Protocol Defined Stopping Criteria|7
6143199|NCT01054885|9777024|FG005|24-week, Double-blind Treatment Period|Protocol Defined Stopping Criteria|15
6143200|NCT01054885|9777025|FG006|24-week, Double-blind Treatment Period|Protocol Defined Stopping Criteria|12
6143201|NCT01054885|9777019|FG000|24-week, Double-blind Treatment Period|Study Closed/ Terminated|0
6143202|NCT01054885|9777020|FG001|24-week, Double-blind Treatment Period|Study Closed/ Terminated|0
6143203|NCT01054885|9777021|FG002|24-week, Double-blind Treatment Period|Study Closed/ Terminated|1
6143204|NCT01054885|9777022|FG003|24-week, Double-blind Treatment Period|Study Closed/ Terminated|0
6143205|NCT01054885|9777023|FG004|24-week, Double-blind Treatment Period|Study Closed/ Terminated|0
6143206|NCT01054885|9777024|FG005|24-week, Double-blind Treatment Period|Study Closed/ Terminated|0
6143207|NCT01054885|9777025|FG006|24-week, Double-blind Treatment Period|Study Closed/ Terminated|1
6143208|NCT01054885|9777019|FG000|24-week, Double-blind Treatment Period|Lost to Follow-up|0
6143209|NCT01054885|9777020|FG001|24-week, Double-blind Treatment Period|Lost to Follow-up|3
6143210|NCT01054885|9777021|FG002|24-week, Double-blind Treatment Period|Lost to Follow-up|2
6143211|NCT01054885|9777022|FG003|24-week, Double-blind Treatment Period|Lost to Follow-up|0
6143212|NCT01054885|9777023|FG004|24-week, Double-blind Treatment Period|Lost to Follow-up|0
6143213|NCT01054885|9777024|FG005|24-week, Double-blind Treatment Period|Lost to Follow-up|2
6143214|NCT01054885|9777025|FG006|24-week, Double-blind Treatment Period|Lost to Follow-up|1
6143215|NCT01054885|9777019|FG000|24-week, Double-blind Treatment Period|Physician Decision|0
6143216|NCT01054885|9777020|FG001|24-week, Double-blind Treatment Period|Physician Decision|4
6143217|NCT01054885|9777021|FG002|24-week, Double-blind Treatment Period|Physician Decision|1
6143218|NCT01054885|9777022|FG003|24-week, Double-blind Treatment Period|Physician Decision|6
6143219|NCT01054885|9777023|FG004|24-week, Double-blind Treatment Period|Physician Decision|3
6143220|NCT01054885|9777024|FG005|24-week, Double-blind Treatment Period|Physician Decision|1
6143221|NCT01054885|9777025|FG006|24-week, Double-blind Treatment Period|Physician Decision|1
6143222|NCT01054885|9777019|FG000|24-week, Double-blind Treatment Period|Withdrawal by Subject|0
6143223|NCT01054885|9777020|FG001|24-week, Double-blind Treatment Period|Withdrawal by Subject|8
6143224|NCT01054885|9777021|FG002|24-week, Double-blind Treatment Period|Withdrawal by Subject|9
6143225|NCT01054885|9777022|FG003|24-week, Double-blind Treatment Period|Withdrawal by Subject|7
6143226|NCT01054885|9777023|FG004|24-week, Double-blind Treatment Period|Withdrawal by Subject|3
6143227|NCT01054885|9777024|FG005|24-week, Double-blind Treatment Period|Withdrawal by Subject|9
6143228|NCT01054885|9777025|FG006|24-week, Double-blind Treatment Period|Withdrawal by Subject|2
6143229|NCT01054976|9777046|FG000|Overall Study|Adverse Event|16
6143230|NCT01054976|9777046|FG000|Overall Study|Uncooperative participations to study|7
6143231|NCT01054976|9777046|FG000|Overall Study|Withdrawal by Subject|4
6143232|NCT01054976|9777046|FG000|Overall Study|Other|8
6143233|NCT01055028|9777052|FG000|Screening|Screen Failure|1
6143234|NCT01055028|9777053|FG001|Screening|Screen Failure|1
6143235|NCT01055028|9777052|FG000|Treatment Cycles 1 to 3|Adverse Event|0
6143236|NCT01055028|9777053|FG001|Treatment Cycles 1 to 3|Adverse Event|1
6143237|NCT01055028|9777052|FG000|Treatment Cycles 1 to 3|Discontinued, < 3 cycles treatment|2
6143238|NCT01055028|9777053|FG001|Treatment Cycles 1 to 3|Discontinued, < 3 cycles treatment|2
6143239|NCT01055028|9777052|FG000|Inter-treatment Period|Did not start Cycle 4|0
6143240|NCT01055028|9777053|FG001|Inter-treatment Period|Did not start Cycle 4|3
6143241|NCT01055132|9777069|FG000|Period 1 (5-9 Days)|unsatisfactory lens fitting performance|1
6143242|NCT01055132|9777070|FG001|Period 1 (5-9 Days)|unsatisfactory lens fitting performance|0
6143243|NCT01055132|9777069|FG000|Period 2 (5-9 Days)|Unsatisfactory lens fitting performance|0
6143244|NCT01055132|9777070|FG001|Period 2 (5-9 Days)|Unsatisfactory lens fitting performance|1
6143245|NCT01055197|9777095|FG000|Overall Study|Protocol Violation|7
6143246|NCT01055197|9777096|FG001|Overall Study|Protocol Violation|2
6143247|NCT01055197|9777095|FG000|Overall Study|Withdrawal by Subject|2
6143248|NCT01055197|9777096|FG001|Overall Study|Withdrawal by Subject|0
6143249|NCT01055262|9777115|FG000|Overall Study|Adverse Event|5
6143250|NCT01055262|9777115|FG000|Overall Study|Protocol Violation|3
6143251|NCT01055262|9777115|FG000|Overall Study|Uncooperativeness|1
6143252|NCT01055314|9777121|FG000|Overall Study|Adverse Event|7
6143253|NCT01055314|9777122|FG001|Overall Study|Adverse Event|4
6143254|NCT01055314|9777121|FG000|Overall Study|Death|2
6143255|NCT01055314|9777122|FG001|Overall Study|Death|1
6143256|NCT01055314|9777121|FG000|Overall Study|Lack of Efficacy|11
6143257|NCT01055314|9777122|FG001|Overall Study|Lack of Efficacy|19
6143258|NCT01055314|9777121|FG000|Overall Study|Physician Decision|10
6143259|NCT01055314|9777122|FG001|Overall Study|Physician Decision|5
6143260|NCT01055314|9777121|FG000|Overall Study|Withdrawal by Subject|1
6143261|NCT01055314|9777122|FG001|Overall Study|Withdrawal by Subject|0
6143262|NCT01055314|9777121|FG000|Overall Study|Ineligible|3
6143263|NCT01055314|9777122|FG001|Overall Study|Ineligible|5
6143264|NCT01055314|9777121|FG000|Overall Study|Refusal of further protocol therapy|10
6143265|NCT01055314|9777122|FG001|Overall Study|Refusal of further protocol therapy|4
6143266|NCT01055314|9777121|FG000|Overall Study|No treatment|1
6143267|NCT01055314|9777122|FG001|Overall Study|No treatment|0
6143268|NCT01055457|9777139|FG000|Overall Study|Lost to Follow-up|0
6143269|NCT01055457|9777140|FG001|Overall Study|Lost to Follow-up|1
6143270|NCT01055457|9777141|FG002|Overall Study|Lost to Follow-up|0
6143271|NCT01055457|9777142|FG003|Overall Study|Lost to Follow-up|0
6143272|NCT01055457|9777143|FG004|Overall Study|Lost to Follow-up|0
6143273|NCT01055457|9777144|FG005|Overall Study|Lost to Follow-up|1
6143274|NCT01055457|9777145|FG006|Overall Study|Lost to Follow-up|0
6143275|NCT01055457|9777146|FG007|Overall Study|Lost to Follow-up|0
6143276|NCT01055457|9777147|FG008|Overall Study|Lost to Follow-up|0
6143277|NCT01055457|9777148|FG009|Overall Study|Lost to Follow-up|0
6143278|NCT01055457|9777139|FG000|Overall Study|Protocol Violation|0
6143279|NCT01055457|9777140|FG001|Overall Study|Protocol Violation|0
6143280|NCT01055457|9777141|FG002|Overall Study|Protocol Violation|1
6143281|NCT01055457|9777142|FG003|Overall Study|Protocol Violation|1
6143282|NCT01055457|9777143|FG004|Overall Study|Protocol Violation|1
6143283|NCT01055457|9777144|FG005|Overall Study|Protocol Violation|2
6143284|NCT01055457|9777145|FG006|Overall Study|Protocol Violation|1
6143285|NCT01055457|9777146|FG007|Overall Study|Protocol Violation|0
6143286|NCT01055457|9777147|FG008|Overall Study|Protocol Violation|0
6143287|NCT01055457|9777148|FG009|Overall Study|Protocol Violation|1
6143288|NCT01055457|9777139|FG000|Overall Study|Subject Disinterest|0
6143289|NCT01055457|9777140|FG001|Overall Study|Subject Disinterest|0
6143290|NCT01055457|9777141|FG002|Overall Study|Subject Disinterest|0
6143291|NCT01055457|9777142|FG003|Overall Study|Subject Disinterest|0
6143292|NCT01055457|9777143|FG004|Overall Study|Subject Disinterest|0
6143293|NCT01055457|9777144|FG005|Overall Study|Subject Disinterest|0
6143294|NCT01055457|9777145|FG006|Overall Study|Subject Disinterest|0
6143295|NCT01055457|9777146|FG007|Overall Study|Subject Disinterest|1
6143296|NCT01055457|9777147|FG008|Overall Study|Subject Disinterest|0
6143297|NCT01055457|9777148|FG009|Overall Study|Subject Disinterest|0
6143298|NCT01055457|9777139|FG000|Overall Study|Subject Ineligible|1
6143299|NCT01055457|9777140|FG001|Overall Study|Subject Ineligible|0
6143300|NCT01055457|9777141|FG002|Overall Study|Subject Ineligible|1
6143301|NCT01055457|9777142|FG003|Overall Study|Subject Ineligible|0
6143302|NCT01055457|9777143|FG004|Overall Study|Subject Ineligible|1
6143303|NCT01055457|9777144|FG005|Overall Study|Subject Ineligible|0
6143304|NCT01055457|9777145|FG006|Overall Study|Subject Ineligible|0
6143305|NCT01055457|9777146|FG007|Overall Study|Subject Ineligible|0
6143306|NCT01055457|9777147|FG008|Overall Study|Subject Ineligible|0
6143307|NCT01055457|9777148|FG009|Overall Study|Subject Ineligible|0
6143308|NCT01055457|9777139|FG000|Overall Study|Discomfort|0
6143309|NCT01055457|9777140|FG001|Overall Study|Discomfort|0
6143310|NCT01055457|9777141|FG002|Overall Study|Discomfort|0
6143311|NCT01055457|9777142|FG003|Overall Study|Discomfort|0
6143312|NCT01055457|9777143|FG004|Overall Study|Discomfort|1
6143313|NCT01055457|9777144|FG005|Overall Study|Discomfort|0
6143314|NCT01055457|9777145|FG006|Overall Study|Discomfort|0
6143315|NCT01055457|9777146|FG007|Overall Study|Discomfort|0
6143316|NCT01055457|9777147|FG008|Overall Study|Discomfort|0
6143317|NCT01055457|9777148|FG009|Overall Study|Discomfort|0
6143318|NCT01055457|9777139|FG000|Overall Study|Pregnancy|0
6143319|NCT01055457|9777140|FG001|Overall Study|Pregnancy|0
6143320|NCT01055457|9777141|FG002|Overall Study|Pregnancy|0
6143321|NCT01055457|9777142|FG003|Overall Study|Pregnancy|1
6143322|NCT01055457|9777143|FG004|Overall Study|Pregnancy|0
6143323|NCT01055457|9777144|FG005|Overall Study|Pregnancy|0
6143324|NCT01055457|9777145|FG006|Overall Study|Pregnancy|0
6143325|NCT01055457|9777146|FG007|Overall Study|Pregnancy|0
6143326|NCT01055457|9777147|FG008|Overall Study|Pregnancy|0
6143327|NCT01055457|9777148|FG009|Overall Study|Pregnancy|0
6143328|NCT01055457|9777139|FG000|Overall Study|Adverse Event|0
6143329|NCT01055457|9777140|FG001|Overall Study|Adverse Event|0
6143330|NCT01055457|9777141|FG002|Overall Study|Adverse Event|0
6143331|NCT01055457|9777142|FG003|Overall Study|Adverse Event|1
6143332|NCT01055457|9777143|FG004|Overall Study|Adverse Event|0
6143333|NCT01055457|9777144|FG005|Overall Study|Adverse Event|0
6143334|NCT01055457|9777145|FG006|Overall Study|Adverse Event|0
6143335|NCT01055457|9777146|FG007|Overall Study|Adverse Event|0
6143336|NCT01055457|9777147|FG008|Overall Study|Adverse Event|0
6143337|NCT01055457|9777148|FG009|Overall Study|Adverse Event|0
6143338|NCT01055496|9777172|FG000|Overall Study|Withdrawal by Subject|2
6143339|NCT01055496|9777173|FG001|Overall Study|Withdrawal by Subject|4
6143340|NCT01055496|9777172|FG000|Overall Study|Death|13
6143341|NCT01055496|9777173|FG001|Overall Study|Death|23
6143342|NCT01055496|9777172|FG000|Overall Study|Lost to Follow-up|0
6143343|NCT01055496|9777173|FG001|Overall Study|Lost to Follow-up|2
6143344|NCT01055496|9777172|FG000|Overall Study|Other - Unspecified|0
6143345|NCT01055496|9777173|FG001|Overall Study|Other - Unspecified|1
6143346|NCT01055613|9777202|FG000|Overall Study|No Longer Meets Eligibility Criteria|3
6143347|NCT01055613|9777203|FG001|Overall Study|No Longer Meets Eligibility Criteria|0
6143348|NCT01055613|9777202|FG000|Overall Study|Unacceptable lens fit|1
6143349|NCT01055613|9777203|FG001|Overall Study|Unacceptable lens fit|0
6143350|NCT01055613|9777202|FG000|Overall Study|Discomfort|2
6143351|NCT01055613|9777203|FG001|Overall Study|Discomfort|1
6143352|NCT01055613|9777202|FG000|Overall Study|Lost to Follow-up|1
6143353|NCT01055613|9777203|FG001|Overall Study|Lost to Follow-up|1
6143354|NCT01055613|9777202|FG000|Overall Study|Protocol Violation|1
6143355|NCT01055613|9777203|FG001|Overall Study|Protocol Violation|1
6143356|NCT01055613|9777202|FG000|Overall Study|Subject Disinterest|1
6143357|NCT01055613|9777203|FG001|Overall Study|Subject Disinterest|1
6143358|NCT01055639|9777211|FG000|Overall Study|Adverse Event|0
6143359|NCT01055639|9777212|FG001|Overall Study|Adverse Event|1
6143360|NCT01055639|9777211|FG000|Overall Study|Lack of Efficacy|0
6143361|NCT01055639|9777212|FG001|Overall Study|Lack of Efficacy|1
6143362|NCT01055639|9777211|FG000|Overall Study|Lost to Follow-up|8
6143363|NCT01055639|9777212|FG001|Overall Study|Lost to Follow-up|11
6143364|NCT01055639|9777211|FG000|Overall Study|Protocol Violation|5
6143365|NCT01055639|9777212|FG001|Overall Study|Protocol Violation|5
6143366|NCT01055639|9777211|FG000|Overall Study|Withdrawal by Subject|8
6143367|NCT01055639|9777212|FG001|Overall Study|Withdrawal by Subject|11
6143368|NCT01055834|9777256|FG000|Treatment Period I|Adverse Event|1
6143369|NCT01055834|9777257|FG001|Treatment Period I|Adverse Event|0
6143370|NCT01055886|9777268|FG000|Overall Study|Withdrawal by Subject|4
6143371|NCT01055886|9777269|FG001|Overall Study|Withdrawal by Subject|9
6143372|NCT01055886|9777268|FG000|Overall Study|Lost to Follow-up|1
6143373|NCT01055886|9777269|FG001|Overall Study|Lost to Follow-up|1
6143374|NCT01055886|9777268|FG000|Overall Study|Withdrawal by PI|0
6143375|NCT01055886|9777269|FG001|Overall Study|Withdrawal by PI|1
6143376|NCT01056107|9777288|FG000|Overall Study|Withdrawal by Subject|0
6143377|NCT01056107|9777289|FG001|Overall Study|Withdrawal by Subject|1
6143378|NCT01056107|9777290|FG002|Overall Study|Withdrawal by Subject|3
6143379|NCT01056107|9777291|FG003|Overall Study|Withdrawal by Subject|0
6143380|NCT01056263|9777312|FG000|Overall Study|Adverse Event|12
6143381|NCT01056263|9777312|FG000|Overall Study|Death|1
6143382|NCT01056263|9777312|FG000|Overall Study|Withdrawal by Subject|1
6143383|NCT01056263|9777312|FG000|Overall Study|Lack of Efficacy|29
6143384|NCT01056263|9777312|FG000|Overall Study|Progressive disease|2
6143385|NCT01056263|9777312|FG000|Overall Study|Neoplasm progression|1
6143386|NCT01056263|9777312|FG000|Overall Study|Objective progression or relapse|1
6143387|NCT01056263|9777312|FG000|Overall Study|Ongoing in study A4061008 (NCT00828919)|5
6143388|NCT01056276|9777318|FG000|Treatment Period-Cycles 1-8|Toxicity|2
6143389|NCT01056276|9777319|FG001|Treatment Period-Cycles 1-8|Toxicity|1
6143390|NCT01056276|9777318|FG000|Treatment Period-Cycles 1-8|Withdrawal by Subject|1
6143391|NCT01056276|9777319|FG001|Treatment Period-Cycles 1-8|Withdrawal by Subject|2
6143392|NCT01056276|9777318|FG000|Treatment Period-Cycles 1-8|Disease Progression|2
6143393|NCT01056276|9777319|FG001|Treatment Period-Cycles 1-8|Disease Progression|2
6143394|NCT01056276|9777318|FG000|Treatment Period-Cycles 1-8|Intercurrent Illness|1
6143395|NCT01056276|9777319|FG001|Treatment Period-Cycles 1-8|Intercurrent Illness|2
6143396|NCT01056276|9777318|FG000|Treatment Period-Cycles 1-8|Physician Decision|3
6143397|NCT01056276|9777319|FG001|Treatment Period-Cycles 1-8|Physician Decision|0
6143398|NCT01056276|9777318|FG000|Treatment Period-Cycles 1-8|Death|3
6143399|NCT01056276|9777319|FG001|Treatment Period-Cycles 1-8|Death|1
6143400|NCT01056276|9777318|FG000|Treatment Period-Cycles 1-8|Lost to Follow-up|1
6143401|NCT01056276|9777319|FG001|Treatment Period-Cycles 1-8|Lost to Follow-up|0
6143402|NCT01056276|9777318|FG000|Maintenance Therapy|Toxicity|0
6143403|NCT01056276|9777319|FG001|Maintenance Therapy|Toxicity|2
6143404|NCT01056276|9777318|FG000|Maintenance Therapy|Progressive Disease|0
6143405|NCT01056276|9777319|FG001|Maintenance Therapy|Progressive Disease|9
6143406|NCT01056276|9777318|FG000|Maintenance Therapy|Physician Decision|0
6143407|NCT01056276|9777319|FG001|Maintenance Therapy|Physician Decision|1
6143408|NCT01056276|9777318|FG000|Maintenance Therapy|Withdrawal by Subject|0
6143409|NCT01056276|9777319|FG001|Maintenance Therapy|Withdrawal by Subject|1
6143410|NCT01056276|9777318|FG000|Maintenance Therapy|Intercurrent Illness|0
6143411|NCT01056276|9777319|FG001|Maintenance Therapy|Intercurrent Illness|1
6143412|NCT01056276|9777318|FG000|Maintenance Therapy|Continuing maintenance therapy|0
6143413|NCT01056276|9777319|FG001|Maintenance Therapy|Continuing maintenance therapy|14
6143414|NCT01056289|9777330|FG000|Open-label Phase|Adverse Event|29
6143415|NCT01056289|9777331|FG001|Open-label Phase|Adverse Event|0
6143416|NCT01056289|9777332|FG002|Open-label Phase|Adverse Event|0
6143417|NCT01056289|9777333|FG003|Open-label Phase|Adverse Event|0
6143418|NCT01056289|9777330|FG000|Open-label Phase|Lost to Follow-up|30
6143419|NCT01056289|9777331|FG001|Open-label Phase|Lost to Follow-up|0
6143420|NCT01056289|9777332|FG002|Open-label Phase|Lost to Follow-up|0
6143421|NCT01056289|9777333|FG003|Open-label Phase|Lost to Follow-up|0
6143422|NCT01056289|9777330|FG000|Open-label Phase|Other|9
6143423|NCT01056289|9777331|FG001|Open-label Phase|Other|0
6143424|NCT01056289|9777332|FG002|Open-label Phase|Other|0
6143425|NCT01056289|9777333|FG003|Open-label Phase|Other|0
6143426|NCT01056289|9777330|FG000|Open-label Phase|Protocol Violation|6
6143427|NCT01056289|9777331|FG001|Open-label Phase|Protocol Violation|0
6143428|NCT01056289|9777332|FG002|Open-label Phase|Protocol Violation|0
6143429|NCT01056289|9777333|FG003|Open-label Phase|Protocol Violation|0
6143430|NCT01056289|9777330|FG000|Open-label Phase|Withdrawal by Subject|26
6143431|NCT01056289|9777331|FG001|Open-label Phase|Withdrawal by Subject|0
6143432|NCT01056289|9777332|FG002|Open-label Phase|Withdrawal by Subject|0
6143433|NCT01056289|9777333|FG003|Open-label Phase|Withdrawal by Subject|0
6143434|NCT01056289|9777330|FG000|Open-label Phase|Lack of Efficacy|18
6143435|NCT01056289|9777331|FG001|Open-label Phase|Lack of Efficacy|0
6143436|NCT01056289|9777332|FG002|Open-label Phase|Lack of Efficacy|0
6143437|NCT01056289|9777333|FG003|Open-label Phase|Lack of Efficacy|0
6143438|NCT01056289|9777330|FG000|Open-label Phase|Not randomized to Double-blind phase|1
6143439|NCT01056289|9777331|FG001|Open-label Phase|Not randomized to Double-blind phase|0
6143440|NCT01056289|9777332|FG002|Open-label Phase|Not randomized to Double-blind phase|0
6143441|NCT01056289|9777333|FG003|Open-label Phase|Not randomized to Double-blind phase|0
6143442|NCT01056289|9777330|FG000|Double-blind Phase|Adverse Event|0
6143443|NCT01056289|9777331|FG001|Double-blind Phase|Adverse Event|1
6143444|NCT01056289|9777332|FG002|Double-blind Phase|Adverse Event|2
6143445|NCT01056289|9777333|FG003|Double-blind Phase|Adverse Event|1
6143446|NCT01056289|9777330|FG000|Double-blind Phase|Lost to Follow-up|0
6143447|NCT01056289|9777331|FG001|Double-blind Phase|Lost to Follow-up|2
6143448|NCT01056289|9777332|FG002|Double-blind Phase|Lost to Follow-up|2
5982782|NCT00905606|9571847|FG001|Period 1|Adverse Event|1
5982783|NCT00905606|9571846|FG000|Washout|Withdrawal by Subject|1
5982784|NCT00905606|9571847|FG001|Washout|Withdrawal by Subject|0
5982785|NCT00905567|9571853|FG000|Washout|Withdrawal by Subject|0
5982786|NCT00905567|9571854|FG001|Washout|Withdrawal by Subject|1
5982787|NCT00905346|9571860|FG000|Period 1|Withdrawal by Subject|1
5982788|NCT00905346|9571861|FG001|Period 1|Withdrawal by Subject|0
5982789|NCT00905164|9571867|FG000|Period 1|Protocol Violation|0
5982790|NCT00905164|9571868|FG001|Period 1|Protocol Violation|1
5982791|NCT00890591|9571879|FG000|Overall Study|Lack of Efficacy|20
5982792|NCT00890409|9571887|FG000|Overall Study|Lost to Follow-up|20
5982793|NCT00890409|9571888|FG001|Overall Study|Lost to Follow-up|21
5982794|NCT00888355|9571896|FG000|Overall Study|Adverse Event|10
5982795|NCT00888355|9571897|FG001|Overall Study|Adverse Event|0
5982796|NCT00888355|9571898|FG002|Overall Study|Adverse Event|3
5982797|NCT00888355|9571899|FG003|Overall Study|Adverse Event|3
5982798|NCT00888355|9571896|FG000|Overall Study|Lack of Efficacy|9
5982799|NCT00888355|9571897|FG001|Overall Study|Lack of Efficacy|2
5982800|NCT00888355|9571898|FG002|Overall Study|Lack of Efficacy|5
5982801|NCT00888355|9571899|FG003|Overall Study|Lack of Efficacy|2
5982802|NCT00888355|9571896|FG000|Overall Study|Lost to Follow-up|0
5982803|NCT00888355|9571897|FG001|Overall Study|Lost to Follow-up|2
5982804|NCT00888355|9571898|FG002|Overall Study|Lost to Follow-up|2
5982805|NCT00888355|9571899|FG003|Overall Study|Lost to Follow-up|0
5982806|NCT00888355|9571896|FG000|Overall Study|Protocol Violation|3
5982807|NCT00888355|9571897|FG001|Overall Study|Protocol Violation|2
5982808|NCT00888355|9571898|FG002|Overall Study|Protocol Violation|1
5982809|NCT00888355|9571899|FG003|Overall Study|Protocol Violation|2
5982810|NCT00888355|9571896|FG000|Overall Study|Withdrawal by Subject|0
5982811|NCT00888355|9571897|FG001|Overall Study|Withdrawal by Subject|3
5982812|NCT00888355|9571898|FG002|Overall Study|Withdrawal by Subject|1
5982813|NCT00888355|9571899|FG003|Overall Study|Withdrawal by Subject|3
5982814|NCT00887250|9571908|FG000|Overall Study|Adverse Event|3
5982815|NCT00887250|9571909|FG001|Overall Study|Adverse Event|0
5982816|NCT00887250|9571910|FG002|Overall Study|Adverse Event|7
5982817|NCT00887250|9571908|FG000|Overall Study|Lack of Efficacy|9
5982818|NCT00887250|9571909|FG001|Overall Study|Lack of Efficacy|6
5982819|NCT00887250|9571910|FG002|Overall Study|Lack of Efficacy|1
5982820|NCT00887250|9571908|FG000|Overall Study|Lost to Follow-up|2
5982821|NCT00887250|9571909|FG001|Overall Study|Lost to Follow-up|3
5982822|NCT00887250|9571910|FG002|Overall Study|Lost to Follow-up|1
5982823|NCT00887250|9571908|FG000|Overall Study|Protocol Violation|2
5982824|NCT00887250|9571909|FG001|Overall Study|Protocol Violation|2
5982825|NCT00887250|9571910|FG002|Overall Study|Protocol Violation|1
5982826|NCT00887250|9571908|FG000|Overall Study|Withdrawal by Subject|2
5982827|NCT00887250|9571909|FG001|Overall Study|Withdrawal by Subject|1
5982828|NCT00887250|9571910|FG002|Overall Study|Withdrawal by Subject|2
5982829|NCT00887250|9571908|FG000|Overall Study|Patient uncooperative|0
5982830|NCT00887250|9571909|FG001|Overall Study|Patient uncooperative|0
5982831|NCT00887250|9571910|FG002|Overall Study|Patient uncooperative|1
5982832|NCT00886600|9571919|FG000|Double-blind Monotherapy|Adverse Event|1
5982833|NCT00886600|9571920|FG001|Double-blind Monotherapy|Adverse Event|1
5982834|NCT00886600|9571921|FG002|Double-blind Monotherapy|Adverse Event|1
5982835|NCT00886600|9571922|FG003|Double-blind Monotherapy|Adverse Event|1
5982836|NCT00886600|9571919|FG000|Double-blind Monotherapy|Protocol Violation|0
5982837|NCT00886600|9571920|FG001|Double-blind Monotherapy|Protocol Violation|0
5982838|NCT00886600|9571921|FG002|Double-blind Monotherapy|Protocol Violation|0
5982839|NCT00886600|9571922|FG003|Double-blind Monotherapy|Protocol Violation|1
5982840|NCT00886600|9571919|FG000|Double-blind Monotherapy|Withdrawal by Subject|1
5982841|NCT00886600|9571920|FG001|Double-blind Monotherapy|Withdrawal by Subject|0
5982842|NCT00886600|9571921|FG002|Double-blind Monotherapy|Withdrawal by Subject|0
5982843|NCT00886600|9571922|FG003|Double-blind Monotherapy|Withdrawal by Subject|0
5982844|NCT00886600|9571919|FG000|Combination Therapy Period|Adverse Event|0
5982845|NCT00886600|9571920|FG001|Combination Therapy Period|Adverse Event|0
5982846|NCT00886600|9571921|FG002|Combination Therapy Period|Adverse Event|1
5982847|NCT00886600|9571922|FG003|Combination Therapy Period|Adverse Event|0
5982848|NCT00886600|9571919|FG000|Combination Therapy Period|Protocol Violation|0
5982849|NCT00886600|9571920|FG001|Combination Therapy Period|Protocol Violation|0
6143449|NCT01056289|9777333|FG003|Double-blind Phase|Lost to Follow-up|2
6143450|NCT01056289|9777330|FG000|Double-blind Phase|Other|0
6143451|NCT01056289|9777331|FG001|Double-blind Phase|Other|0
6143452|NCT01056289|9777332|FG002|Double-blind Phase|Other|1
6143453|NCT01056289|9777333|FG003|Double-blind Phase|Other|2
6143454|NCT01056289|9777330|FG000|Double-blind Phase|Protocol Violation|0
6143455|NCT01056289|9777331|FG001|Double-blind Phase|Protocol Violation|0
6143456|NCT01056289|9777332|FG002|Double-blind Phase|Protocol Violation|1
6143457|NCT01056289|9777333|FG003|Double-blind Phase|Protocol Violation|1
6143458|NCT01056289|9777330|FG000|Double-blind Phase|Withdrawal by Subject|0
6143459|NCT01056289|9777331|FG001|Double-blind Phase|Withdrawal by Subject|0
6143460|NCT01056289|9777332|FG002|Double-blind Phase|Withdrawal by Subject|4
6143461|NCT01056289|9777333|FG003|Double-blind Phase|Withdrawal by Subject|2
6143462|NCT01056289|9777330|FG000|Double-blind Phase|Discontinuation symptom|0
6143463|NCT01056289|9777331|FG001|Double-blind Phase|Discontinuation symptom|1
6143464|NCT01056289|9777332|FG002|Double-blind Phase|Discontinuation symptom|2
6143465|NCT01056289|9777333|FG003|Double-blind Phase|Discontinuation symptom|2
6143466|NCT01056289|9777330|FG000|Double-blind Phase|Physician Decision|0
6143467|NCT01056289|9777331|FG001|Double-blind Phase|Physician Decision|0
6143468|NCT01056289|9777332|FG002|Double-blind Phase|Physician Decision|1
6143469|NCT01056289|9777333|FG003|Double-blind Phase|Physician Decision|0
6143470|NCT01056341|9777365|FG000|Overall Study|Treatment Intolerance|0
6143471|NCT01056341|9777366|FG001|Overall Study|Treatment Intolerance|2
6143472|NCT01056341|9777367|FG002|Overall Study|Treatment Intolerance|0
6143473|NCT01056341|9777368|FG003|Overall Study|Treatment Intolerance|2
6143474|NCT01056341|9777369|FG004|Overall Study|Treatment Intolerance|0
6143475|NCT01056341|9777365|FG000|Overall Study|Lack of Efficacy|32
6143476|NCT01056341|9777366|FG001|Overall Study|Lack of Efficacy|30
6143477|NCT01056341|9777367|FG002|Overall Study|Lack of Efficacy|7
6143478|NCT01056341|9777368|FG003|Overall Study|Lack of Efficacy|25
6143479|NCT01056341|9777369|FG004|Overall Study|Lack of Efficacy|9
6143480|NCT01056341|9777365|FG000|Overall Study|Other reasons|4
6143481|NCT01056341|9777366|FG001|Overall Study|Other reasons|4
6143482|NCT01056341|9777367|FG002|Overall Study|Other reasons|8
6143483|NCT01056341|9777368|FG003|Overall Study|Other reasons|9
6143484|NCT01056341|9777369|FG004|Overall Study|Other reasons|5
6143485|NCT01056380|9777389|FG000|Overall Study|Lost to Follow-up|2
6143486|NCT01056380|9777390|FG001|Overall Study|Lost to Follow-up|3
6143487|NCT01056484|9777400|FG000|Randomized Controlled Trial|Withdrawal by Subject|6
6143488|NCT01056484|9777401|FG001|Randomized Controlled Trial|Withdrawal by Subject|1
6143489|NCT01056484|9777400|FG000|Randomized Controlled Trial|Physician Decision|1
6143490|NCT01056484|9777401|FG001|Randomized Controlled Trial|Physician Decision|0
6143491|NCT01056484|9777400|FG000|Follow up - Non-randomized|Withdrawal by Subject|0
6143492|NCT01056484|9777401|FG001|Follow up - Non-randomized|Withdrawal by Subject|2
6143493|NCT01056510|9777410|FG000|Overall Study|Dropout Before Start of Treatment|1
6143494|NCT01056510|9777411|FG001|Overall Study|Dropout Before Start of Treatment|1
6143495|NCT01056510|9777410|FG000|Overall Study|Withdrawal by Subject|4
6143496|NCT01056510|9777411|FG001|Overall Study|Withdrawal by Subject|2
6143497|NCT01056510|9777410|FG000|Overall Study|Death|29
6143498|NCT01056510|9777411|FG001|Overall Study|Death|34
6143499|NCT01056510|9777410|FG000|Overall Study|Noncompliance|1
6143500|NCT01056510|9777411|FG001|Overall Study|Noncompliance|3
6143501|NCT01056510|9777410|FG000|Overall Study|Physician Decision|4
6143502|NCT01056510|9777411|FG001|Overall Study|Physician Decision|5
6143503|NCT01056510|9777410|FG000|Overall Study|Lost to Follow-up|5
6143504|NCT01056510|9777411|FG001|Overall Study|Lost to Follow-up|6
6143505|NCT01056510|9777410|FG000|Overall Study|Other|10
6143506|NCT01056510|9777411|FG001|Overall Study|Other|12
6143507|NCT01056510|9777410|FG000|Overall Study|Missing|0
6143508|NCT01056510|9777411|FG001|Overall Study|Missing|1
6143509|NCT01056523|9777417|FG000|Overall Study|Death|1
6143510|NCT01056523|9777418|FG001|Overall Study|Death|0
6143511|NCT01056523|9777419|FG002|Overall Study|Death|2
6143512|NCT01056523|9777420|FG003|Overall Study|Death|3
6143513|NCT01056523|9777421|FG004|Overall Study|Death|0
6143514|NCT01056523|9777422|FG005|Overall Study|Death|0
6143515|NCT01056523|9777423|FG006|Overall Study|Death|1
6143516|NCT01056536|9777431|FG000|Overall Study|Lost to Follow-up|202
6143517|NCT01056536|9777432|FG001|Overall Study|Lost to Follow-up|116
6143518|NCT01056536|9777433|FG002|Overall Study|Lost to Follow-up|248
6143519|NCT01056640|9777447|FG000|Overall Study|Withdrawal by Subject|11
6143520|NCT01056640|9777448|FG001|Overall Study|Withdrawal by Subject|8
6143521|NCT01056640|9777447|FG000|Overall Study|Death|15
6143522|NCT01056640|9777448|FG001|Overall Study|Death|4
6143523|NCT01056653|9777457|FG000|Overall Study|Lost to Follow-up|0
6143524|NCT01056653|9777458|FG001|Overall Study|Lost to Follow-up|0
6143525|NCT01056653|9777459|FG002|Overall Study|Lost to Follow-up|2
6143526|NCT01056718|9777468|FG000|Overall Study|Withdrawal by Subject|2
6143527|NCT01056718|9777468|FG000|Overall Study|Ischemia on baseline stress test|1
6143528|NCT01056822|9777475|FG000|Overall Study|Adverse Event|0
6143529|NCT01056822|9777476|FG001|Overall Study|Adverse Event|1
6143530|NCT01056822|9777475|FG000|Overall Study|Protocol Violation|6
6143531|NCT01056822|9777476|FG001|Overall Study|Protocol Violation|5
6143532|NCT01056822|9777475|FG000|Overall Study|Withdrawal by Subject|1
6143533|NCT01056822|9777476|FG001|Overall Study|Withdrawal by Subject|1
6143534|NCT01056822|9777475|FG000|Overall Study|Lost to Follow-up|1
6143535|NCT01056822|9777476|FG001|Overall Study|Lost to Follow-up|0
6143536|NCT01057251|9777511|FG000|Overall Study|Did not meet InclusionExclusion criteria|4
6143537|NCT01057251|9777512|FG001|Overall Study|Did not meet InclusionExclusion criteria|2
6143538|NCT01057251|9777511|FG000|Overall Study|Adverse Event|4
6143539|NCT01057251|9777512|FG001|Overall Study|Adverse Event|2
6143540|NCT01057251|9777511|FG000|Overall Study|Lack of Efficacy|2
6143541|NCT01057251|9777512|FG001|Overall Study|Lack of Efficacy|11
6143542|NCT01057251|9777511|FG000|Overall Study|Protocol Violation|6
6143543|NCT01057251|9777512|FG001|Overall Study|Protocol Violation|2
6143544|NCT01057251|9777511|FG000|Overall Study|Withdrawal by Subject|4
6143545|NCT01057251|9777512|FG001|Overall Study|Withdrawal by Subject|5
6143546|NCT01057251|9777511|FG000|Overall Study|Lost to Follow-up|7
6143547|NCT01057251|9777512|FG001|Overall Study|Lost to Follow-up|6
6143548|NCT01057251|9777511|FG000|Overall Study|Other Reason|1
6143549|NCT01057251|9777512|FG001|Overall Study|Other Reason|1
6143550|NCT01057394|9777539|FG000|Overall Study|Not eligible|0
6143551|NCT01057394|9777540|FG001|Overall Study|Not eligible|2
6143552|NCT01057433|9777544|FG000|Overall Study|Adverse Event|1
6143553|NCT01057589|9777548|FG000|Overall Study|Disease Progression|35
6143554|NCT01057589|9777548|FG000|Overall Study|Adverse Event|10
6143555|NCT01057589|9777548|FG000|Overall Study|Physician Decision|8
6143556|NCT01057589|9777548|FG000|Overall Study|Withdrawal by Subject|3
6143557|NCT01057589|9777548|FG000|Overall Study|Sponsor Decision|1
6143558|NCT01057589|9777548|FG000|Overall Study|Death|8
6143559|NCT01057589|9777548|FG000|Overall Study|Lost to Follow-up|1
6143560|NCT01057693|9777552|FG000|Single-Blind Phase (Up to Week 6)|Adverse Event|45
6143561|NCT01057693|9777553|FG001|Single-Blind Phase (Up to Week 6)|Adverse Event|0
6143562|NCT01057693|9777554|FG002|Single-Blind Phase (Up to Week 6)|Adverse Event|0
6143563|NCT01057693|9777552|FG000|Single-Blind Phase (Up to Week 6)|Lack of Efficacy|7
6143564|NCT01057693|9777553|FG001|Single-Blind Phase (Up to Week 6)|Lack of Efficacy|0
6143565|NCT01057693|9777554|FG002|Single-Blind Phase (Up to Week 6)|Lack of Efficacy|0
6143566|NCT01057693|9777552|FG000|Single-Blind Phase (Up to Week 6)|Lost to Follow-up|14
6143567|NCT01057693|9777553|FG001|Single-Blind Phase (Up to Week 6)|Lost to Follow-up|0
6143568|NCT01057693|9777554|FG002|Single-Blind Phase (Up to Week 6)|Lost to Follow-up|0
6143569|NCT01057693|9777552|FG000|Single-Blind Phase (Up to Week 6)|Protocol Violation|9
6143570|NCT01057693|9777553|FG001|Single-Blind Phase (Up to Week 6)|Protocol Violation|0
6143571|NCT01057693|9777554|FG002|Single-Blind Phase (Up to Week 6)|Protocol Violation|0
6143572|NCT01057693|9777552|FG000|Single-Blind Phase (Up to Week 6)|Withdrawal by Subject|22
6143573|NCT01057693|9777553|FG001|Single-Blind Phase (Up to Week 6)|Withdrawal by Subject|0
6143574|NCT01057693|9777554|FG002|Single-Blind Phase (Up to Week 6)|Withdrawal by Subject|0
6143575|NCT01057693|9777552|FG000|Single-Blind Phase (Up to Week 6)|Other|2
6143576|NCT01057693|9777553|FG001|Single-Blind Phase (Up to Week 6)|Other|0
6143577|NCT01057693|9777554|FG002|Single-Blind Phase (Up to Week 6)|Other|0
6143578|NCT01057693|9777552|FG000|Between Single-Blind and Double-Blind|Adverse Event|5
6143579|NCT01057693|9777553|FG001|Between Single-Blind and Double-Blind|Adverse Event|0
6143580|NCT01057693|9777554|FG002|Between Single-Blind and Double-Blind|Adverse Event|0
6143581|NCT01057693|9777552|FG000|Between Single-Blind and Double-Blind|Lack of Efficacy|247
6143582|NCT01057693|9777553|FG001|Between Single-Blind and Double-Blind|Lack of Efficacy|0
6143583|NCT01057693|9777554|FG002|Between Single-Blind and Double-Blind|Lack of Efficacy|0
6143584|NCT01057693|9777552|FG000|Between Single-Blind and Double-Blind|Lost to Follow-up|1
6143585|NCT01057693|9777553|FG001|Between Single-Blind and Double-Blind|Lost to Follow-up|0
6143586|NCT01057693|9777554|FG002|Between Single-Blind and Double-Blind|Lost to Follow-up|0
6143587|NCT01057693|9777552|FG000|Between Single-Blind and Double-Blind|Protocol Violation|7
6143588|NCT01057693|9777553|FG001|Between Single-Blind and Double-Blind|Protocol Violation|0
6143589|NCT01057693|9777554|FG002|Between Single-Blind and Double-Blind|Protocol Violation|0
6143590|NCT01057693|9777552|FG000|Between Single-Blind and Double-Blind|Withdrawal by Subject|4
6143591|NCT01057693|9777553|FG001|Between Single-Blind and Double-Blind|Withdrawal by Subject|0
6143592|NCT01057693|9777554|FG002|Between Single-Blind and Double-Blind|Withdrawal by Subject|0
6143593|NCT01057693|9777552|FG000|Between Single-Blind and Double-Blind|Other|6
6143594|NCT01057693|9777553|FG001|Between Single-Blind and Double-Blind|Other|0
6143595|NCT01057693|9777554|FG002|Between Single-Blind and Double-Blind|Other|0
6143596|NCT01057693|9777552|FG000|Double-Blind Phase (Week 7 to Week 19)|Adverse Event|0
6143597|NCT01057693|9777553|FG001|Double-Blind Phase (Week 7 to Week 19)|Adverse Event|8
6143598|NCT01057693|9777554|FG002|Double-Blind Phase (Week 7 to Week 19)|Adverse Event|11
6143599|NCT01057693|9777552|FG000|Double-Blind Phase (Week 7 to Week 19)|Lack of Efficacy|0
6143600|NCT01057693|9777553|FG001|Double-Blind Phase (Week 7 to Week 19)|Lack of Efficacy|3
6143601|NCT01057693|9777554|FG002|Double-Blind Phase (Week 7 to Week 19)|Lack of Efficacy|8
6143602|NCT01057693|9777552|FG000|Double-Blind Phase (Week 7 to Week 19)|Lost to Follow-up|0
6143603|NCT01057693|9777553|FG001|Double-Blind Phase (Week 7 to Week 19)|Lost to Follow-up|2
6143604|NCT01057693|9777554|FG002|Double-Blind Phase (Week 7 to Week 19)|Lost to Follow-up|5
6143605|NCT01057693|9777552|FG000|Double-Blind Phase (Week 7 to Week 19)|Protocol Violation|0
6143606|NCT01057693|9777553|FG001|Double-Blind Phase (Week 7 to Week 19)|Protocol Violation|0
6143607|NCT01057693|9777554|FG002|Double-Blind Phase (Week 7 to Week 19)|Protocol Violation|4
6143608|NCT01057693|9777552|FG000|Double-Blind Phase (Week 7 to Week 19)|Withdrawal by Subject|0
6143609|NCT01057693|9777553|FG001|Double-Blind Phase (Week 7 to Week 19)|Withdrawal by Subject|8
6143610|NCT01057693|9777554|FG002|Double-Blind Phase (Week 7 to Week 19)|Withdrawal by Subject|6
6143611|NCT01057693|9777552|FG000|Double-Blind Phase (Week 7 to Week 19)|Other|0
6143612|NCT01057693|9777553|FG001|Double-Blind Phase (Week 7 to Week 19)|Other|1
6143613|NCT01057693|9777554|FG002|Double-Blind Phase (Week 7 to Week 19)|Other|0
6143614|NCT01057693|9777552|FG000|Double-Blind Phase (Week 7 to Week 19)|Randomized, Not Treated|0
6143615|NCT01057693|9777553|FG001|Double-Blind Phase (Week 7 to Week 19)|Randomized, Not Treated|0
6143616|NCT01057693|9777554|FG002|Double-Blind Phase (Week 7 to Week 19)|Randomized, Not Treated|2
6143617|NCT01057810|9777564|FG000|Overall Study|Disease progression|156
6143618|NCT01057810|9777565|FG001|Overall Study|Disease progression|197
6143619|NCT01057810|9777564|FG000|Overall Study|Study drug toxicity|5
6143620|NCT01057810|9777565|FG001|Overall Study|Study drug toxicity|114
6143621|NCT01057810|9777564|FG000|Overall Study|Adverse event unrelated to study drug|13
6143622|NCT01057810|9777565|FG001|Overall Study|Adverse event unrelated to study drug|29
6143623|NCT01057810|9777564|FG000|Overall Study|Withdrawal by Subject|10
6143624|NCT01057810|9777565|FG001|Overall Study|Withdrawal by Subject|25
6143625|NCT01057810|9777564|FG000|Overall Study|Death|2
6143626|NCT01057810|9777565|FG001|Overall Study|Death|12
6143627|NCT01057810|9777564|FG000|Overall Study|Maximum clinical benefit|5
6143628|NCT01057810|9777565|FG001|Overall Study|Maximum clinical benefit|5
6143629|NCT01057810|9777564|FG000|Overall Study|Poor/non-compliance|0
6143630|NCT01057810|9777565|FG001|Overall Study|Poor/non-compliance|1
6143631|NCT01057810|9777564|FG000|Overall Study|No longer met study criteria|0
6143632|NCT01057810|9777565|FG001|Overall Study|No longer met study criteria|1
6143633|NCT01057810|9777564|FG000|Overall Study|Other|7
6143634|NCT01057810|9777565|FG001|Overall Study|Other|14
6143635|NCT01057862|9777573|FG000|Overall Study|Withdrawal by Subject|1
6143636|NCT01057862|9777574|FG001|Overall Study|Withdrawal by Subject|2
6143637|NCT01058005|9777603|FG000|Overall Study|Adverse Event|0
6143638|NCT01058005|9777604|FG001|Overall Study|Adverse Event|2
6143639|NCT01058005|9777605|FG002|Overall Study|Adverse Event|1
6143640|NCT01058005|9777603|FG000|Overall Study|Physician Decision|2
6143641|NCT01058005|9777604|FG001|Overall Study|Physician Decision|2
6143642|NCT01058005|9777605|FG002|Overall Study|Physician Decision|0
6143643|NCT01058005|9777603|FG000|Overall Study|Withdrawal by Subject|4
6143644|NCT01058005|9777604|FG001|Overall Study|Withdrawal by Subject|5
6143645|NCT01058005|9777605|FG002|Overall Study|Withdrawal by Subject|11
6143646|NCT01058005|9777603|FG000|Overall Study|Withdrawn Due to Study Termination|27
6143647|NCT01058005|9777604|FG001|Overall Study|Withdrawn Due to Study Termination|13
6143648|NCT01058005|9777605|FG002|Overall Study|Withdrawn Due to Study Termination|7
6143649|NCT01058005|9777603|FG000|Overall Study|Reason Missing|5
6143650|NCT01058005|9777604|FG001|Overall Study|Reason Missing|3
6143651|NCT01058005|9777605|FG002|Overall Study|Reason Missing|1
6143652|NCT01058096|9777620|FG000|Double-blind Treatment Phase|Adverse Event|11
6143653|NCT01058096|9777621|FG001|Double-blind Treatment Phase|Adverse Event|15
6143654|NCT01058096|9777620|FG000|Double-blind Treatment Phase|Insufficient Therapeutic Response|16
6143655|NCT01058096|9777621|FG001|Double-blind Treatment Phase|Insufficient Therapeutic Response|7
6143656|NCT01058096|9777620|FG000|Double-blind Treatment Phase|Protocol Violation|2
6143657|NCT01058096|9777621|FG001|Double-blind Treatment Phase|Protocol Violation|1
6143658|NCT01058096|9777620|FG000|Double-blind Treatment Phase|Withdrawal of Consent|17
6143659|NCT01058096|9777621|FG001|Double-blind Treatment Phase|Withdrawal of Consent|26
6143660|NCT01058096|9777620|FG000|Double-blind Treatment Phase|Lost to Follow-up|0
6143661|NCT01058096|9777621|FG001|Double-blind Treatment Phase|Lost to Follow-up|1
6143662|NCT01058096|9777620|FG000|Double-blind Treatment Phase|Other Unspecified|2
6143663|NCT01058096|9777621|FG001|Double-blind Treatment Phase|Other Unspecified|0
6143664|NCT01058265|9777633|FG000|Overall Study|Lost to Follow-up|11
6143665|NCT01058265|9777634|FG001|Overall Study|Lost to Follow-up|12
6143666|NCT01058304|9777642|FG000|Overall Study|Withdrawal by Subject|8
6143667|NCT01058304|9777643|FG001|Overall Study|Withdrawal by Subject|5
6143668|NCT01058304|9777642|FG000|Overall Study|Lost to Follow-up|13
6143669|NCT01058304|9777643|FG001|Overall Study|Lost to Follow-up|16
6143670|NCT01058304|9777642|FG000|Overall Study|Developed exclusion criterion|6
6143671|NCT01058304|9777643|FG001|Overall Study|Developed exclusion criterion|12
6143672|NCT01058356|9777649|FG000|Overall Study|Adverse Event|5
6143673|NCT01058356|9777649|FG000|Overall Study|Administration of contraindicated drugs|12
6143674|NCT01058356|9777649|FG000|Overall Study|Withdrawal by Subject|21
6143675|NCT01058356|9777649|FG000|Overall Study|Lost to Follow-up|4
6143676|NCT01058395|9777655|FG000|Overall Study|Death|2
6143677|NCT01058395|9777656|FG001|Overall Study|Death|1
6143678|NCT01058395|9777655|FG000|Overall Study|Lost to Follow-up|1
6143679|NCT01058395|9777656|FG001|Overall Study|Lost to Follow-up|0
6143680|NCT01058421|9777664|FG000|1 Month Outcomes|Death|10
6143681|NCT01058421|9777665|FG001|1 Month Outcomes|Death|6
6143682|NCT01058421|9777664|FG000|1 Month Outcomes|Lost to Follow-up|8
6143683|NCT01058421|9777665|FG001|1 Month Outcomes|Lost to Follow-up|7
6143684|NCT01058421|9777664|FG000|1 Month Outcomes|Remained in Hospital|5
6143685|NCT01058421|9777665|FG001|1 Month Outcomes|Remained in Hospital|12
6143686|NCT01058421|9777664|FG000|1 Month Outcomes|Remained in Other Facility|16
6143687|NCT01058421|9777665|FG001|1 Month Outcomes|Remained in Other Facility|17
6143688|NCT01058421|9777664|FG000|3 Month Outcomes|Death|3
6143689|NCT01058421|9777665|FG001|3 Month Outcomes|Death|5
6143690|NCT01058421|9777664|FG000|3 Month Outcomes|Lost to Follow-up|12
6143691|NCT01058421|9777665|FG001|3 Month Outcomes|Lost to Follow-up|11
6143692|NCT01058421|9777664|FG000|3 Month Outcomes|Remained in Hospital|0
6143693|NCT01058421|9777665|FG001|3 Month Outcomes|Remained in Hospital|2
6143694|NCT01058421|9777664|FG000|3 Month Outcomes|Remained in Other Facility|5
6143695|NCT01058421|9777665|FG001|3 Month Outcomes|Remained in Other Facility|8
6143696|NCT01058421|9777664|FG000|6 Month Outcomes|Death|2
6143697|NCT01058421|9777665|FG001|6 Month Outcomes|Death|2
6143698|NCT01058421|9777664|FG000|6 Month Outcomes|Lost to Follow-up|16
6143699|NCT01058421|9777665|FG001|6 Month Outcomes|Lost to Follow-up|21
6143700|NCT01058421|9777664|FG000|6 Month Outcomes|Remained in Other Facility|1
6143701|NCT01058421|9777665|FG001|6 Month Outcomes|Remained in Other Facility|3
6143702|NCT01058655|9777675|FG000|Overall Study|Withdrawal by Subject|1
6143703|NCT01058655|9777676|FG001|Overall Study|Withdrawal by Subject|0
6143704|NCT01058655|9777677|FG002|Overall Study|Withdrawal by Subject|3
6143705|NCT01058655|9777678|FG003|Overall Study|Withdrawal by Subject|4
6143706|NCT01058655|9777675|FG000|Overall Study|Prolonged Treatment Delay|0
6143707|NCT01058655|9777676|FG001|Overall Study|Prolonged Treatment Delay|0
6143708|NCT01058655|9777677|FG002|Overall Study|Prolonged Treatment Delay|0
6143709|NCT01058655|9777678|FG003|Overall Study|Prolonged Treatment Delay|2
6143710|NCT01058655|9777675|FG000|Overall Study|Symptomatic Deterioration|0
6143711|NCT01058655|9777676|FG001|Overall Study|Symptomatic Deterioration|0
6143712|NCT01058655|9777677|FG002|Overall Study|Symptomatic Deterioration|0
6143713|NCT01058655|9777678|FG003|Overall Study|Symptomatic Deterioration|1
6143714|NCT01058655|9777675|FG000|Overall Study|Clinical Progression (non-RECIST)|1
6143715|NCT01058655|9777676|FG001|Overall Study|Clinical Progression (non-RECIST)|0
6143716|NCT01058655|9777677|FG002|Overall Study|Clinical Progression (non-RECIST)|0
6143717|NCT01058655|9777678|FG003|Overall Study|Clinical Progression (non-RECIST)|7
6143718|NCT01058655|9777675|FG000|Overall Study|Death|0
6143719|NCT01058655|9777676|FG001|Overall Study|Death|1
6143720|NCT01058655|9777677|FG002|Overall Study|Death|1
6143721|NCT01058655|9777678|FG003|Overall Study|Death|0
6143722|NCT01058655|9777675|FG000|Overall Study|Disease Progression|1
6143723|NCT01058655|9777676|FG001|Overall Study|Disease Progression|2
6143724|NCT01058655|9777677|FG002|Overall Study|Disease Progression|4
6143725|NCT01058655|9777678|FG003|Overall Study|Disease Progression|24
6143726|NCT01058655|9777675|FG000|Overall Study|Other|0
6143727|NCT01058655|9777676|FG001|Overall Study|Other|0
6143728|NCT01058655|9777677|FG002|Overall Study|Other|0
6143729|NCT01058655|9777678|FG003|Overall Study|Other|4
6143730|NCT01058668|9777692|FG000|Double-blind Treatment Phase|Adverse Event|8
6143731|NCT01058668|9777693|FG001|Double-blind Treatment Phase|Adverse Event|15
6143732|NCT01058668|9777694|FG002|Double-blind Treatment Phase|Adverse Event|25
6143733|NCT01058668|9777692|FG000|Double-blind Treatment Phase|Insufficient Therapeutic Response|15
6143734|NCT01058668|9777693|FG001|Double-blind Treatment Phase|Insufficient Therapeutic Response|2
6143735|NCT01058668|9777694|FG002|Double-blind Treatment Phase|Insufficient Therapeutic Response|5
6143736|NCT01058668|9777692|FG000|Double-blind Treatment Phase|Protocol Violation|1
6143737|NCT01058668|9777693|FG001|Double-blind Treatment Phase|Protocol Violation|1
6143738|NCT01058668|9777694|FG002|Double-blind Treatment Phase|Protocol Violation|2
6143739|NCT01058668|9777692|FG000|Double-blind Treatment Phase|Withdrawal of Consent|14
6143740|NCT01058668|9777693|FG001|Double-blind Treatment Phase|Withdrawal of Consent|18
6143741|NCT01058668|9777694|FG002|Double-blind Treatment Phase|Withdrawal of Consent|17
6143742|NCT01058668|9777692|FG000|Double-blind Treatment Phase|Lost to Follow-up|0
6143743|NCT01058668|9777693|FG001|Double-blind Treatment Phase|Lost to Follow-up|1
6143744|NCT01058668|9777694|FG002|Double-blind Treatment Phase|Lost to Follow-up|1
6143745|NCT01058668|9777692|FG000|Double-blind Treatment Phase|Other Unspecified|1
6143746|NCT01058668|9777693|FG001|Double-blind Treatment Phase|Other Unspecified|1
6143747|NCT01058668|9777694|FG002|Double-blind Treatment Phase|Other Unspecified|0
6143748|NCT01058707|9777709|FG000|Overall Study|Disease Progression|15
6143749|NCT01058707|9777710|FG001|Overall Study|Disease Progression|20
6143750|NCT01058707|9777711|FG002|Overall Study|Disease Progression|20
6143751|NCT01058707|9777712|FG003|Overall Study|Disease Progression|15
6143752|NCT01058707|9777713|FG004|Overall Study|Disease Progression|23
6143753|NCT01058707|9777714|FG005|Overall Study|Disease Progression|10
6143754|NCT01058707|9777715|FG006|Overall Study|Disease Progression|12
6143755|NCT01058707|9777709|FG000|Overall Study|Adverse Event|11
6143756|NCT01058707|9777710|FG001|Overall Study|Adverse Event|4
6143757|NCT01058707|9777711|FG002|Overall Study|Adverse Event|7
6143758|NCT01058707|9777712|FG003|Overall Study|Adverse Event|6
6143759|NCT01058707|9777713|FG004|Overall Study|Adverse Event|7
6143760|NCT01058707|9777714|FG005|Overall Study|Adverse Event|3
6143761|NCT01058707|9777715|FG006|Overall Study|Adverse Event|1
6143762|NCT01058707|9777709|FG000|Overall Study|Subject Decision|5
6143763|NCT01058707|9777710|FG001|Overall Study|Subject Decision|3
6143764|NCT01058707|9777711|FG002|Overall Study|Subject Decision|3
6143765|NCT01058707|9777712|FG003|Overall Study|Subject Decision|1
6143766|NCT01058707|9777713|FG004|Overall Study|Subject Decision|2
6143767|NCT01058707|9777714|FG005|Overall Study|Subject Decision|3
6143768|NCT01058707|9777715|FG006|Overall Study|Subject Decision|6
6143769|NCT01058707|9777709|FG000|Overall Study|Lost to Follow-up|0
6143770|NCT01058707|9777710|FG001|Overall Study|Lost to Follow-up|0
6143771|NCT01058707|9777711|FG002|Overall Study|Lost to Follow-up|1
6143772|NCT01058707|9777712|FG003|Overall Study|Lost to Follow-up|0
6143773|NCT01058707|9777713|FG004|Overall Study|Lost to Follow-up|0
6143774|NCT01058707|9777714|FG005|Overall Study|Lost to Follow-up|0
6143775|NCT01058707|9777715|FG006|Overall Study|Lost to Follow-up|0
6143776|NCT01058707|9777709|FG000|Overall Study|Reason Not Specified|0
6143777|NCT01058707|9777710|FG001|Overall Study|Reason Not Specified|3
6143778|NCT01058707|9777711|FG002|Overall Study|Reason Not Specified|2
6143779|NCT01058707|9777712|FG003|Overall Study|Reason Not Specified|0
6143780|NCT01058707|9777713|FG004|Overall Study|Reason Not Specified|7
6143781|NCT01058707|9777714|FG005|Overall Study|Reason Not Specified|1
6143782|NCT01058707|9777715|FG006|Overall Study|Reason Not Specified|7
6143783|NCT01058863|9777753|FG000|Overall Study|Lost to Follow-up|1
6143784|NCT01058863|9777753|FG000|Overall Study|Withdrawal by Subject|1
6143785|NCT01058863|9777753|FG000|Overall Study|Sponsor requested withdrawal|1
6143786|NCT01058863|9777753|FG000|Overall Study|Randomized in error|1
6143787|NCT01059175|9777781|FG000|Overall Study|Death|17
6143788|NCT01059175|9777782|FG001|Overall Study|Death|17
6143789|NCT01059175|9777781|FG000|Overall Study|Adverse Event|4
6143790|NCT01059175|9777782|FG001|Overall Study|Adverse Event|2
6143791|NCT01059175|9777781|FG000|Overall Study|Lost to Follow-up|0
6143792|NCT01059175|9777782|FG001|Overall Study|Lost to Follow-up|1
6143793|NCT01059318|9777792|FG000|Core Study (26 Week)|Adverse Event|3
6143794|NCT01059318|9777792|FG000|Core Study (26 Week)|Withdrawal by Subject|1
6143795|NCT01059318|9777792|FG000|Extension (36 Week)|Adverse Event|3
6143796|NCT01059344|9777801|FG000|Overall Study|Adverse Event|12
6143797|NCT01059344|9777802|FG001|Overall Study|Adverse Event|30
6143798|NCT01059344|9777801|FG000|Overall Study|Withdrawal by Subject|6
6143799|NCT01059344|9777802|FG001|Overall Study|Withdrawal by Subject|9
6143800|NCT01059344|9777801|FG000|Overall Study|Lost to Follow-up|1
6143801|NCT01059344|9777802|FG001|Overall Study|Lost to Follow-up|1
6143802|NCT01059344|9777801|FG000|Overall Study|Other|3
6143803|NCT01059344|9777802|FG001|Overall Study|Other|6
6143804|NCT01059526|9777867|FG000|Overall Study|Patient enrolled but not treated|20
6143805|NCT01059526|9777868|FG001|Overall Study|Patient enrolled but not treated|17
6143806|NCT01059526|9777867|FG000|Overall Study|Adverse Event|2
6143807|NCT01059526|9777868|FG001|Overall Study|Adverse Event|2
6143808|NCT01059526|9777867|FG000|Overall Study|Protocol Violation|0
6143809|NCT01059526|9777868|FG001|Overall Study|Protocol Violation|1
6143810|NCT01059526|9777867|FG000|Overall Study|Withdrawal by Subject|3
6143811|NCT01059526|9777868|FG001|Overall Study|Withdrawal by Subject|1
6143812|NCT01059526|9777867|FG000|Overall Study|Lost to Follow-up|4
6143813|NCT01059526|9777868|FG001|Overall Study|Lost to Follow-up|1
6143814|NCT01059526|9777867|FG000|Overall Study|Patient found to be dermatographic|1
6143815|NCT01059526|9777868|FG001|Overall Study|Patient found to be dermatographic|0
6143816|NCT01059539|9777874|FG000|Overall Study|Adverse Event|66
6143817|NCT01059539|9777874|FG000|Overall Study|Insufficient Therapeutic Response|26
6143818|NCT01059539|9777874|FG000|Overall Study|Protocol Violation|55
6143819|NCT01059539|9777874|FG000|Overall Study|Withdrawal of Consent|80
6143820|NCT01059539|9777874|FG000|Overall Study|Lost to Follow-up|42
6143821|NCT01059539|9777874|FG000|Overall Study|Reason Not Specified|2
6143822|NCT01059565|9777880|FG000|24-Week Randomized Phase|Randomized but not treated|1
6143823|NCT01059565|9777881|FG001|24-Week Randomized Phase|Randomized but not treated|0
6143824|NCT01059565|9777880|FG000|24-Week Randomized Phase|Adverse Event|5
6143825|NCT01059565|9777881|FG001|24-Week Randomized Phase|Adverse Event|0
6143826|NCT01059565|9777880|FG000|24-Week Randomized Phase|Withdrawal by Subject|3
6143827|NCT01059565|9777881|FG001|24-Week Randomized Phase|Withdrawal by Subject|1
6143828|NCT01059565|9777880|FG000|24-Week Randomized Phase|Lost to Follow-up|0
6143829|NCT01059565|9777881|FG001|24-Week Randomized Phase|Lost to Follow-up|1
6143830|NCT01059565|9777880|FG000|24-Week Randomized Phase|Noncompliance with Study Drug Regimen|1
6143831|NCT01059565|9777881|FG001|24-Week Randomized Phase|Noncompliance with Study Drug Regimen|5
6143832|NCT01059565|9777880|FG000|24-Week Open-Label Phase|Adverse Event|2
6143833|NCT01059565|9777881|FG001|24-Week Open-Label Phase|Adverse Event|0
6143834|NCT01059565|9777880|FG000|24-Week Open-Label Phase|Worsening health (physician decision)|1
6143835|NCT01059565|9777881|FG001|24-Week Open-Label Phase|Worsening health (physician decision)|1
6143836|NCT01059565|9777880|FG000|24-Week Open-Label Phase|Withdrawal by Subject|1
6143837|NCT01059565|9777881|FG001|24-Week Open-Label Phase|Withdrawal by Subject|0
6143838|NCT01059565|9777880|FG000|24-Week Open-Label Phase|Subject noncompliance|1
6143839|NCT01059565|9777881|FG001|24-Week Open-Label Phase|Subject noncompliance|0
6143840|NCT01059565|9777880|FG000|24-Week Open-Label Phase|Unable to clean device (hospitalization)|0
6143841|NCT01059565|9777881|FG001|24-Week Open-Label Phase|Unable to clean device (hospitalization)|1
6143842|NCT01059565|9777880|FG000|24-Week Open-Label Phase|Pulmonologist/participant decision|0
6143843|NCT01059565|9777881|FG001|24-Week Open-Label Phase|Pulmonologist/participant decision|1
6143844|NCT01059617|9777893|FG000|Overall Study|Other|7
6143845|NCT01059617|9777894|FG001|Overall Study|Other|1
6143846|NCT01059617|9777895|FG002|Overall Study|Other|8
6143847|NCT01059617|9777896|FG003|Overall Study|Other|6
6143848|NCT01059630|9777916|FG000|Overall Study|Death|100
6143849|NCT01059630|9777917|FG001|Overall Study|Death|84
6143850|NCT01059630|9777916|FG000|Overall Study|Lost to Follow-up|4
6143851|NCT01059630|9777917|FG001|Overall Study|Lost to Follow-up|1
6143852|NCT01059630|9777916|FG000|Overall Study|Physician Decision|2
6143853|NCT01059630|9777917|FG001|Overall Study|Physician Decision|4
6143854|NCT01059630|9777916|FG000|Overall Study|Withdrawal by Subject|21
6143855|NCT01059630|9777917|FG001|Overall Study|Withdrawal by Subject|14
6143856|NCT01059643|9777923|FG000|Overall Study|Adverse Event|3
6143857|NCT01059643|9777923|FG000|Overall Study|Withdrawal by Subject|2
6143858|NCT01059643|9777923|FG000|Overall Study|Physician Decision|1
6143859|NCT01059773|9777951|FG000|Overall Study|Adverse Event|2
6143860|NCT01059773|9777952|FG001|Overall Study|Adverse Event|2
6143861|NCT01059773|9777951|FG000|Overall Study|Withdrawal by Subject|1
6143862|NCT01059773|9777952|FG001|Overall Study|Withdrawal by Subject|5
6143863|NCT01059773|9777951|FG000|Overall Study|Lost to Follow-up|1
6143864|NCT01059773|9777952|FG001|Overall Study|Lost to Follow-up|1
6143865|NCT01059773|9777951|FG000|Overall Study|Pregnancy|1
6143866|NCT01059773|9777952|FG001|Overall Study|Pregnancy|1
6143867|NCT01059773|9777951|FG000|Overall Study|Protocol Violation|6
6143868|NCT01059773|9777952|FG001|Overall Study|Protocol Violation|2
6143869|NCT01059773|9777951|FG000|Overall Study|Physician Decision|5
6143870|NCT01059773|9777952|FG001|Overall Study|Physician Decision|4
6143871|NCT01059773|9777951|FG000|Overall Study|Lack of Efficacy|3
6143872|NCT01059773|9777952|FG001|Overall Study|Lack of Efficacy|3
6143873|NCT01059773|9777951|FG000|Overall Study|Death|0
6143874|NCT01059773|9777952|FG001|Overall Study|Death|1
6143875|NCT01059773|9777951|FG000|Overall Study|Malignancy including squamous cell skin|0
6143876|NCT01059773|9777952|FG001|Overall Study|Malignancy including squamous cell skin|1
6143877|NCT01059773|9777951|FG000|Overall Study|Ineligible follow TB screening criteria|0
6143878|NCT01059773|9777952|FG001|Overall Study|Ineligible follow TB screening criteria|1
6143879|NCT01059773|9777951|FG000|Overall Study|Other|1
6143880|NCT01059773|9777952|FG001|Overall Study|Other|3
6143881|NCT01059799|9777965|FG000|Overall Study|Adverse Event|2
6143882|NCT01059799|9777966|FG001|Overall Study|Adverse Event|3
6143883|NCT01059799|9777965|FG000|Overall Study|Lack of Efficacy|1
6143884|NCT01059799|9777966|FG001|Overall Study|Lack of Efficacy|0
6143885|NCT01059799|9777965|FG000|Overall Study|Protocol Violation|3
6143886|NCT01059799|9777966|FG001|Overall Study|Protocol Violation|2
6143887|NCT01059799|9777965|FG000|Overall Study|Withdrawal criteria|13
6143888|NCT01059799|9777966|FG001|Overall Study|Withdrawal criteria|2
6143889|NCT01059799|9777965|FG000|Overall Study|Other|12
6143890|NCT01059799|9777966|FG001|Overall Study|Other|3
6143891|NCT01059812|9777974|FG000|Overall Study|Adverse Event|9
6143892|NCT01059812|9777975|FG001|Overall Study|Adverse Event|5
6143893|NCT01059812|9777974|FG000|Overall Study|Lack of Efficacy|2
6143894|NCT01059812|9777975|FG001|Overall Study|Lack of Efficacy|2
6143895|NCT01059812|9777974|FG000|Overall Study|Protocol Violation|3
6143896|NCT01059812|9777975|FG001|Overall Study|Protocol Violation|1
6143897|NCT01059812|9777974|FG000|Overall Study|Withdrawal Criteria|9
6143898|NCT01059812|9777975|FG001|Overall Study|Withdrawal Criteria|4
6143899|NCT01059812|9777974|FG000|Overall Study|Unclassified|14
6143900|NCT01059812|9777975|FG001|Overall Study|Unclassified|4
6143901|NCT01059825|9777987|FG000|Enrolled, Run-in Period|Adverse event not related to study drug|0
6143902|NCT01059825|9777988|FG001|Enrolled, Run-in Period|Adverse event not related to study drug|0
6143903|NCT01059825|9777989|FG002|Enrolled, Run-in Period|Adverse event not related to study drug|0
6143904|NCT01059825|9777990|FG003|Enrolled, Run-in Period|Adverse event not related to study drug|0
6143905|NCT01059825|9777991|FG004|Enrolled, Run-in Period|Adverse event not related to study drug|0
6143906|NCT01059825|9777992|FG005|Enrolled, Run-in Period|Adverse event not related to study drug|0
6143907|NCT01059825|9777993|FG006|Enrolled, Run-in Period|Adverse event not related to study drug|3
6143908|NCT01059825|9777987|FG000|Enrolled, Run-in Period|Did not meet entrance criteria|0
6143909|NCT01059825|9777988|FG001|Enrolled, Run-in Period|Did not meet entrance criteria|0
6143910|NCT01059825|9777989|FG002|Enrolled, Run-in Period|Did not meet entrance criteria|0
6143911|NCT01059825|9777990|FG003|Enrolled, Run-in Period|Did not meet entrance criteria|0
6143912|NCT01059825|9777991|FG004|Enrolled, Run-in Period|Did not meet entrance criteria|0
6143913|NCT01059825|9777992|FG005|Enrolled, Run-in Period|Did not meet entrance criteria|0
6143914|NCT01059825|9777993|FG006|Enrolled, Run-in Period|Did not meet entrance criteria|14
6143915|NCT01059825|9777987|FG000|Enrolled, Run-in Period|Lost to Follow-up|0
6143916|NCT01059825|9777988|FG001|Enrolled, Run-in Period|Lost to Follow-up|0
6143917|NCT01059825|9777989|FG002|Enrolled, Run-in Period|Lost to Follow-up|0
6143918|NCT01059825|9777990|FG003|Enrolled, Run-in Period|Lost to Follow-up|0
6143919|NCT01059825|9777991|FG004|Enrolled, Run-in Period|Lost to Follow-up|0
6143920|NCT01059825|9777992|FG005|Enrolled, Run-in Period|Lost to Follow-up|0
6143921|NCT01059825|9777993|FG006|Enrolled, Run-in Period|Lost to Follow-up|5
6143922|NCT01059825|9777987|FG000|Enrolled, Run-in Period|Withdrawal by Subject|0
6143923|NCT01059825|9777988|FG001|Enrolled, Run-in Period|Withdrawal by Subject|0
6143924|NCT01059825|9777989|FG002|Enrolled, Run-in Period|Withdrawal by Subject|0
6143925|NCT01059825|9777990|FG003|Enrolled, Run-in Period|Withdrawal by Subject|0
6143926|NCT01059825|9777991|FG004|Enrolled, Run-in Period|Withdrawal by Subject|0
6143927|NCT01059825|9777992|FG005|Enrolled, Run-in Period|Withdrawal by Subject|0
6143928|NCT01059825|9777993|FG006|Enrolled, Run-in Period|Withdrawal by Subject|13
6143929|NCT01059825|9777987|FG000|Enrolled, Run-in Period|Other reason not specified|0
6143930|NCT01059825|9777988|FG001|Enrolled, Run-in Period|Other reason not specified|0
6143931|NCT01059825|9777989|FG002|Enrolled, Run-in Period|Other reason not specified|0
6143932|NCT01059825|9777990|FG003|Enrolled, Run-in Period|Other reason not specified|0
6143933|NCT01059825|9777991|FG004|Enrolled, Run-in Period|Other reason not specified|0
6143934|NCT01059825|9777992|FG005|Enrolled, Run-in Period|Other reason not specified|0
6143935|NCT01059825|9777993|FG006|Enrolled, Run-in Period|Other reason not specified|7
6143936|NCT01059825|9777987|FG000|Enrolled, Run-in Period|Protocol Violation|0
6143937|NCT01059825|9777988|FG001|Enrolled, Run-in Period|Protocol Violation|0
6143938|NCT01059825|9777989|FG002|Enrolled, Run-in Period|Protocol Violation|0
6143939|NCT01059825|9777990|FG003|Enrolled, Run-in Period|Protocol Violation|0
6143940|NCT01059825|9777991|FG004|Enrolled, Run-in Period|Protocol Violation|0
6143941|NCT01059825|9777992|FG005|Enrolled, Run-in Period|Protocol Violation|0
6143942|NCT01059825|9777993|FG006|Enrolled, Run-in Period|Protocol Violation|5
6143943|NCT01059825|9777987|FG000|Treatment Period|Lost to Follow-up|2
6143944|NCT01059825|9777988|FG001|Treatment Period|Lost to Follow-up|1
6143945|NCT01059825|9777989|FG002|Treatment Period|Lost to Follow-up|0
6143946|NCT01059825|9777990|FG003|Treatment Period|Lost to Follow-up|1
6143947|NCT01059825|9777991|FG004|Treatment Period|Lost to Follow-up|2
6143948|NCT01059825|9777992|FG005|Treatment Period|Lost to Follow-up|0
6143949|NCT01059825|9777993|FG006|Treatment Period|Lost to Follow-up|0
6143950|NCT01059825|9777987|FG000|Treatment Period|Withdrawal by Subject|3
6143951|NCT01059825|9777988|FG001|Treatment Period|Withdrawal by Subject|0
6143952|NCT01059825|9777989|FG002|Treatment Period|Withdrawal by Subject|1
6143953|NCT01059825|9777990|FG003|Treatment Period|Withdrawal by Subject|5
6143954|NCT01059825|9777991|FG004|Treatment Period|Withdrawal by Subject|4
6143955|NCT01059825|9777992|FG005|Treatment Period|Withdrawal by Subject|1
6143956|NCT01059825|9777993|FG006|Treatment Period|Withdrawal by Subject|0
6143957|NCT01059825|9777987|FG000|Treatment Period|Other reason not specified|1
6143958|NCT01059825|9777988|FG001|Treatment Period|Other reason not specified|2
6143959|NCT01059825|9777989|FG002|Treatment Period|Other reason not specified|1
6143960|NCT01059825|9777990|FG003|Treatment Period|Other reason not specified|2
6143961|NCT01059825|9777991|FG004|Treatment Period|Other reason not specified|0
6143962|NCT01059825|9777992|FG005|Treatment Period|Other reason not specified|0
6143963|NCT01059825|9777993|FG006|Treatment Period|Other reason not specified|0
6143964|NCT01059825|9777987|FG000|Treatment Period|Protocol Violation|0
6143965|NCT01059825|9777988|FG001|Treatment Period|Protocol Violation|0
6143966|NCT01059825|9777989|FG002|Treatment Period|Protocol Violation|1
6143967|NCT01059825|9777990|FG003|Treatment Period|Protocol Violation|1
6143968|NCT01059825|9777991|FG004|Treatment Period|Protocol Violation|1
6143969|NCT01059825|9777992|FG005|Treatment Period|Protocol Violation|1
6143970|NCT01059825|9777993|FG006|Treatment Period|Protocol Violation|0
6143971|NCT01059825|9777987|FG000|Treatment Period|Adverse event related to study drug|1
6143972|NCT01059825|9777988|FG001|Treatment Period|Adverse event related to study drug|0
6143973|NCT01059825|9777989|FG002|Treatment Period|Adverse event related to study drug|1
6143974|NCT01059825|9777990|FG003|Treatment Period|Adverse event related to study drug|1
6143975|NCT01059825|9777991|FG004|Treatment Period|Adverse event related to study drug|0
6143976|NCT01059825|9777992|FG005|Treatment Period|Adverse event related to study drug|0
6143977|NCT01059825|9777993|FG006|Treatment Period|Adverse event related to study drug|0
6143978|NCT01059825|9777987|FG000|Treatment Period|Insufficient clinical response|3
6143979|NCT01059825|9777988|FG001|Treatment Period|Insufficient clinical response|0
6143980|NCT01059825|9777989|FG002|Treatment Period|Insufficient clinical response|0
6143981|NCT01059825|9777990|FG003|Treatment Period|Insufficient clinical response|0
6143982|NCT01059825|9777991|FG004|Treatment Period|Insufficient clinical response|0
6143983|NCT01059825|9777992|FG005|Treatment Period|Insufficient clinical response|0
6143984|NCT01059825|9777993|FG006|Treatment Period|Insufficient clinical response|0
6143985|NCT01059825|9777987|FG000|Treatment Period|Adverse event not related to study drug|0
6143986|NCT01059825|9777988|FG001|Treatment Period|Adverse event not related to study drug|1
6143987|NCT01059825|9777989|FG002|Treatment Period|Adverse event not related to study drug|2
6143988|NCT01059825|9777990|FG003|Treatment Period|Adverse event not related to study drug|1
6143989|NCT01059825|9777991|FG004|Treatment Period|Adverse event not related to study drug|1
6143990|NCT01059825|9777992|FG005|Treatment Period|Adverse event not related to study drug|1
6143991|NCT01059825|9777993|FG006|Treatment Period|Adverse event not related to study drug|0
6143992|NCT01059864|9778026|FG000|Open-Label Run-In Phase|Adverse Event|7
6143993|NCT01059864|9778027|FG001|Open-Label Run-In Phase|Adverse Event|0
6143994|NCT01059864|9778028|FG002|Open-Label Run-In Phase|Adverse Event|0
6143995|NCT01059864|9778026|FG000|Open-Label Run-In Phase|Lack of Efficacy|1
6143996|NCT01059864|9778027|FG001|Open-Label Run-In Phase|Lack of Efficacy|0
6143997|NCT01059864|9778028|FG002|Open-Label Run-In Phase|Lack of Efficacy|0
6143998|NCT01059864|9778026|FG000|Open-Label Run-In Phase|Lost to Follow-up|2
6143999|NCT01059864|9778027|FG001|Open-Label Run-In Phase|Lost to Follow-up|0
6144000|NCT01059864|9778028|FG002|Open-Label Run-In Phase|Lost to Follow-up|0
6144001|NCT01059864|9778026|FG000|Open-Label Run-In Phase|Withdrawal by Subject|1
6144002|NCT01059864|9778027|FG001|Open-Label Run-In Phase|Withdrawal by Subject|0
6144003|NCT01059864|9778028|FG002|Open-Label Run-In Phase|Withdrawal by Subject|0
6144004|NCT01059864|9778026|FG000|Open-Label Run-In Phase|Protocol Violation|2
6144005|NCT01059864|9778027|FG001|Open-Label Run-In Phase|Protocol Violation|0
6144006|NCT01059864|9778028|FG002|Open-Label Run-In Phase|Protocol Violation|0
6144007|NCT01059864|9778026|FG000|Double-Blind Treatment Phase|Adverse Event|0
6144008|NCT01059864|9778027|FG001|Double-Blind Treatment Phase|Adverse Event|3
6144009|NCT01059864|9778028|FG002|Double-Blind Treatment Phase|Adverse Event|3
6144010|NCT01059903|9778046|FG000|Period 1: First Intervention- 24 Hours|Adverse Event|1
6144011|NCT01059903|9778047|FG001|Period 1: First Intervention- 24 Hours|Adverse Event|1
6144012|NCT01060007|9778079|FG000|Overall Study|Withdrawal by Subject|1
6144013|NCT01060007|9778079|FG000|Overall Study|Inevaluable for response at surgery|3
6144014|NCT01060059|9778093|FG000|Overall Study|Adverse Event|1
6144015|NCT01060059|9778094|FG001|Overall Study|Adverse Event|1
6144016|NCT01060059|9778093|FG000|Overall Study|Death|2
6144017|NCT01060059|9778094|FG001|Overall Study|Death|3
6144018|NCT01060059|9778093|FG000|Overall Study|Lost to Follow-up|18
6144019|NCT01060059|9778094|FG001|Overall Study|Lost to Follow-up|34
6144020|NCT01060059|9778093|FG000|Overall Study|entry criteria not met|4
6144021|NCT01060059|9778094|FG001|Overall Study|entry criteria not met|3
6144022|NCT01060059|9778093|FG000|Overall Study|Withdrawal by Subject|35
6144023|NCT01060059|9778094|FG001|Overall Study|Withdrawal by Subject|23
6144024|NCT01060059|9778093|FG000|Overall Study|lack of glycemic control|2
6144025|NCT01060059|9778094|FG001|Overall Study|lack of glycemic control|1
6144026|NCT01060059|9778093|FG000|Overall Study|lack of compliance|5
6144027|NCT01060059|9778094|FG001|Overall Study|lack of compliance|2
6144028|NCT01060072|9778104|FG000|Overall Study|Adverse Event|1
6144029|NCT01060072|9778105|FG001|Overall Study|Adverse Event|1
6144030|NCT01060072|9778104|FG000|Overall Study|Physician Decision|0
6144031|NCT01060072|9778105|FG001|Overall Study|Physician Decision|2
6144032|NCT01060072|9778104|FG000|Overall Study|Protocol Violation|0
6144033|NCT01060072|9778105|FG001|Overall Study|Protocol Violation|1
6144034|NCT01060072|9778104|FG000|Overall Study|Acute cholecystitis|1
6144035|NCT01060072|9778105|FG001|Overall Study|Acute cholecystitis|0
6144036|NCT01060072|9778104|FG000|Overall Study|Excluded Medications|0
6144037|NCT01060072|9778105|FG001|Overall Study|Excluded Medications|1
6144038|NCT01060111|9778127|FG000|Overall Study|Adverse Event|9
6144039|NCT01060111|9778128|FG001|Overall Study|Adverse Event|5
6144040|NCT01060111|9778129|FG002|Overall Study|Adverse Event|18
5982850|NCT00886600|9571921|FG002|Combination Therapy Period|Protocol Violation|1
5982851|NCT00886600|9571922|FG003|Combination Therapy Period|Protocol Violation|0
5982852|NCT00882440|9571935|FG000|Overall Study|Adverse Event|2
5982853|NCT00882440|9571936|FG001|Overall Study|Adverse Event|2
5982854|NCT00882440|9571937|FG002|Overall Study|Adverse Event|2
5982855|NCT00882440|9571938|FG003|Overall Study|Adverse Event|1
5982856|NCT00882440|9571939|FG004|Overall Study|Adverse Event|1
5982857|NCT00882440|9571940|FG005|Overall Study|Adverse Event|4
5982858|NCT00882440|9571941|FG006|Overall Study|Adverse Event|2
5982859|NCT00882440|9571935|FG000|Overall Study|Lack of Efficacy|3
5982860|NCT00882440|9571936|FG001|Overall Study|Lack of Efficacy|5
5982861|NCT00882440|9571937|FG002|Overall Study|Lack of Efficacy|2
5982862|NCT00882440|9571938|FG003|Overall Study|Lack of Efficacy|0
5982863|NCT00882440|9571939|FG004|Overall Study|Lack of Efficacy|0
5982864|NCT00882440|9571940|FG005|Overall Study|Lack of Efficacy|3
5982865|NCT00882440|9571941|FG006|Overall Study|Lack of Efficacy|0
5982866|NCT00882440|9571935|FG000|Overall Study|Lost to Follow-up|2
5982867|NCT00882440|9571936|FG001|Overall Study|Lost to Follow-up|0
5982868|NCT00882440|9571937|FG002|Overall Study|Lost to Follow-up|1
5982869|NCT00882440|9571938|FG003|Overall Study|Lost to Follow-up|1
5982870|NCT00882440|9571939|FG004|Overall Study|Lost to Follow-up|1
5982871|NCT00882440|9571940|FG005|Overall Study|Lost to Follow-up|0
5982872|NCT00882440|9571941|FG006|Overall Study|Lost to Follow-up|1
5982873|NCT00882440|9571935|FG000|Overall Study|Protocol Violation|0
5982874|NCT00882440|9571936|FG001|Overall Study|Protocol Violation|0
5982875|NCT00882440|9571937|FG002|Overall Study|Protocol Violation|1
5982876|NCT00882440|9571938|FG003|Overall Study|Protocol Violation|1
5982877|NCT00882440|9571939|FG004|Overall Study|Protocol Violation|1
5982878|NCT00882440|9571940|FG005|Overall Study|Protocol Violation|0
5982879|NCT00882440|9571941|FG006|Overall Study|Protocol Violation|0
5982880|NCT00882440|9571935|FG000|Overall Study|Withdrawal by Subject|2
5982881|NCT00882440|9571936|FG001|Overall Study|Withdrawal by Subject|1
5982882|NCT00882440|9571937|FG002|Overall Study|Withdrawal by Subject|1
5982883|NCT00882440|9571938|FG003|Overall Study|Withdrawal by Subject|0
5982884|NCT00882440|9571939|FG004|Overall Study|Withdrawal by Subject|6
5982885|NCT00882440|9571940|FG005|Overall Study|Withdrawal by Subject|0
5982886|NCT00882440|9571941|FG006|Overall Study|Withdrawal by Subject|1
5982887|NCT00882440|9571935|FG000|Overall Study|Patient Uncooperative|2
5982888|NCT00882440|9571936|FG001|Overall Study|Patient Uncooperative|0
5982889|NCT00882440|9571937|FG002|Overall Study|Patient Uncooperative|0
5982890|NCT00882440|9571938|FG003|Overall Study|Patient Uncooperative|0
5982891|NCT00882440|9571939|FG004|Overall Study|Patient Uncooperative|1
5982892|NCT00882440|9571940|FG005|Overall Study|Patient Uncooperative|0
5982893|NCT00882440|9571941|FG006|Overall Study|Patient Uncooperative|0
5982894|NCT00870688|9571957|FG000|Overall Study|Lost to Follow-up|2
5982895|NCT00870688|9571957|FG000|Overall Study|Death, Unrelated|1
5982896|NCT00870688|9571957|FG000|Overall Study|Granules in the Stools|1
5982897|NCT00869128|9571960|FG000|Overall Study|lack of Compliance|6
5982898|NCT00869128|9571961|FG001|Overall Study|lack of Compliance|6
5982899|NCT00861705|9571969|FG000|Overall Study|Never Began Treatment|7
5982900|NCT00861705|9571970|FG001|Overall Study|Never Began Treatment|3
5982901|NCT00861705|9571971|FG002|Overall Study|Never Began Treatment|0
5982902|NCT00861705|9571972|FG003|Overall Study|Never Began Treatment|1
5982903|NCT00859521|9571992|FG000|Washout|Withdrawal by Subject|0
5982904|NCT00859521|9571993|FG001|Washout|Withdrawal by Subject|1
5982905|NCT00859430|9571999|FG000|First Intervention|Withdrawal by Subject|0
5982906|NCT00859430|9572000|FG001|First Intervention|Withdrawal by Subject|1
6144041|NCT01060111|9778127|FG000|Overall Study|Lack of Efficacy|2
6144042|NCT01060111|9778128|FG001|Overall Study|Lack of Efficacy|1
6144043|NCT01060111|9778129|FG002|Overall Study|Lack of Efficacy|0
6144044|NCT01060111|9778127|FG000|Overall Study|Inappropriate participant|5
6144045|NCT01060111|9778128|FG001|Overall Study|Inappropriate participant|4
6144046|NCT01060111|9778129|FG002|Overall Study|Inappropriate participant|5
6144047|NCT01060111|9778127|FG000|Overall Study|Participants' evasion for hospital visit|0
6144048|NCT01060111|9778128|FG001|Overall Study|Participants' evasion for hospital visit|3
6144049|NCT01060111|9778129|FG002|Overall Study|Participants' evasion for hospital visit|2
6144050|NCT01060111|9778127|FG000|Overall Study|Participants' non-cooperation|8
6144051|NCT01060111|9778128|FG001|Overall Study|Participants' non-cooperation|6
6144052|NCT01060111|9778129|FG002|Overall Study|Participants' non-cooperation|6
6144053|NCT01060111|9778127|FG000|Overall Study|Adverse event and insufficient effect|0
6144054|NCT01060111|9778128|FG001|Overall Study|Adverse event and insufficient effect|1
6144055|NCT01060111|9778129|FG002|Overall Study|Adverse event and insufficient effect|0
6144056|NCT01060111|9778127|FG000|Overall Study|Participants' non-cooperation|1
6144057|NCT01060111|9778128|FG001|Overall Study|Participants' non-cooperation|0
6144058|NCT01060111|9778129|FG002|Overall Study|Participants' non-cooperation|0
6144059|NCT01060111|9778127|FG000|Overall Study|Other|2
6144060|NCT01060111|9778128|FG001|Overall Study|Other|3
6144061|NCT01060111|9778129|FG002|Overall Study|Other|4
6144062|NCT01060124|9778140|FG000|Overall Study|Other|16
6144063|NCT01060124|9778140|FG000|Overall Study|Adverse Event|14
6144064|NCT01060124|9778140|FG000|Overall Study|Withdrawal by Subject|7
6144065|NCT01060150|9778144|FG000|Overall Study|Adverse Event|6
6144066|NCT01060150|9778144|FG000|Overall Study|Lost to Follow-up|1
6144067|NCT01060150|9778144|FG000|Overall Study|Protocol Violation|6
6144068|NCT01060150|9778144|FG000|Overall Study|Withdrawal by Subject|8
6144069|NCT01060150|9778144|FG000|Overall Study|Enrolled, but not treated|2
6144070|NCT01060384|9778152|FG000|Overall Study|Withdrawal by Subject|0
6144071|NCT01060384|9778153|FG001|Overall Study|Withdrawal by Subject|1
6144072|NCT01060384|9778154|FG002|Overall Study|Withdrawal by Subject|0
6144073|NCT01060384|9778155|FG003|Overall Study|Withdrawal by Subject|0
6144074|NCT01060384|9778156|FG004|Overall Study|Withdrawal by Subject|0
6144075|NCT01060384|9778152|FG000|Overall Study|Death|0
6144076|NCT01060384|9778153|FG001|Overall Study|Death|0
6144077|NCT01060384|9778154|FG002|Overall Study|Death|0
6144078|NCT01060384|9778155|FG003|Overall Study|Death|0
6144079|NCT01060384|9778156|FG004|Overall Study|Death|1
6144080|NCT01060384|9778152|FG000|Overall Study|Intercurrent illness|0
6144081|NCT01060384|9778153|FG001|Overall Study|Intercurrent illness|0
6144082|NCT01060384|9778154|FG002|Overall Study|Intercurrent illness|0
6144083|NCT01060384|9778155|FG003|Overall Study|Intercurrent illness|0
6144084|NCT01060384|9778156|FG004|Overall Study|Intercurrent illness|1
6144085|NCT01060540|9778167|FG000|Overall Study|Withdrawal by Subject|10
6144086|NCT01060540|9778168|FG001|Overall Study|Withdrawal by Subject|20
6144087|NCT01060540|9778167|FG000|Overall Study|Lost to Follow-up|52
6144088|NCT01060540|9778168|FG001|Overall Study|Lost to Follow-up|43
6144089|NCT01060540|9778167|FG000|Overall Study|Death|2
6144090|NCT01060540|9778168|FG001|Overall Study|Death|1
6144091|NCT01060540|9778167|FG000|Overall Study|Physician Decision|0
6144092|NCT01060540|9778168|FG001|Overall Study|Physician Decision|1
6144093|NCT01060553|9778176|FG000|Overall Study|Lost to Follow-up|3
6144094|NCT01060553|9778177|FG001|Overall Study|Lost to Follow-up|5
6144095|NCT01060553|9778176|FG000|Overall Study|Withdrawal by Subject|5
6144096|NCT01060553|9778177|FG001|Overall Study|Withdrawal by Subject|5
6144097|NCT01060553|9778176|FG000|Overall Study|Lack of Efficacy|1
6144098|NCT01060553|9778177|FG001|Overall Study|Lack of Efficacy|0
6144099|NCT01060670|9778193|FG000|Run In|screen failure|0
6144100|NCT01060670|9778194|FG001|Run In|screen failure|238
6144101|NCT01061008|9778204|FG000|Overall Study|Badiocephalic fistula failed|3
6144102|NCT01061008|9778205|FG001|Overall Study|Badiocephalic fistula failed|2
6144103|NCT01061008|9778204|FG000|Overall Study|Death|1
6144104|NCT01061008|9778205|FG001|Overall Study|Death|0
6144105|NCT01061008|9778204|FG000|Overall Study|Withdrawal by Subject|1
6144106|NCT01061008|9778205|FG001|Overall Study|Withdrawal by Subject|3
6144107|NCT01061008|9778204|FG000|Overall Study|Unable to exercise following surgery|1
6144108|NCT01061008|9778205|FG001|Overall Study|Unable to exercise following surgery|0
6144109|NCT01061008|9778204|FG000|Overall Study|Adverse Event|0
6144110|NCT01061008|9778205|FG001|Overall Study|Adverse Event|1
6144111|NCT01061177|9778215|FG000|Overall Study|Adverse Event|117
6144112|NCT01061177|9778215|FG000|Overall Study|Withdrawal by Subject|27
6144113|NCT01061177|9778215|FG000|Overall Study|Disease progression|17
6144114|NCT01061177|9778215|FG000|Overall Study|Protocol Violation|11
6144115|NCT01061177|9778215|FG000|Overall Study|Lost to Follow-up|9
6144116|NCT01061177|9778215|FG000|Overall Study|New cancer therapy|9
6144117|NCT01061177|9778215|FG000|Overall Study|Abnormal laboratory values|6
6144118|NCT01061177|9778215|FG000|Overall Study|Abnormal test procedure results|4
6144119|NCT01061177|9778215|FG000|Overall Study|Administratie problems|4
6144120|NCT01061177|9778215|FG000|Overall Study|Death|4
6144121|NCT01061333|9778219|FG000|Period 4: 20-day Washout|Discontinued by Study Team|0
6144122|NCT01061333|9778220|FG001|Period 4: 20-day Washout|Discontinued by Study Team|1
6144123|NCT01061359|9778231|FG000|Overall Study|Death|32
6144124|NCT01061359|9778231|FG000|Overall Study|Lost to Follow-up|1072
6144125|NCT01061359|9778231|FG000|Overall Study|Relapse|187
6144126|NCT01061359|9778231|FG000|Overall Study|Secondary neoplasm|11
6144127|NCT01061385|9778237|FG000|Overall Study|Lost to Follow-up|1
6144128|NCT01061385|9778238|FG001|Overall Study|Lost to Follow-up|0
6144129|NCT01061385|9778237|FG000|Overall Study|subject decision not related to AE|0
6144130|NCT01061385|9778238|FG001|Overall Study|subject decision not related to AE|1
6144131|NCT01061567|9778258|FG000|Overall Study|Adverse Event|32
6144132|NCT01061567|9778258|FG000|Overall Study|Death|2
6144133|NCT01061567|9778258|FG000|Overall Study|Lack of Efficacy|3
6144134|NCT01061567|9778258|FG000|Overall Study|Lost to Follow-up|24
6144135|NCT01061567|9778258|FG000|Overall Study|Protocol Violation|1
6144136|NCT01061567|9778258|FG000|Overall Study|Withdrawal by Subject|11
6144137|NCT01061567|9778258|FG000|Overall Study|Other reason than stated above|3
6144138|NCT01061606|9778262|FG000|Overall Study|Adverse Event|1
6144139|NCT01061606|9778262|FG000|Overall Study|Death|1
6144140|NCT01061606|9778262|FG000|Overall Study|Disease Progression|4
6144141|NCT01061606|9778262|FG000|Overall Study|alternative therapy|2
6144142|NCT01061671|9778268|FG000|Overall Study|Withdrawal by Subject|16
6144143|NCT01061671|9778269|FG001|Overall Study|Withdrawal by Subject|20
6144144|NCT01061671|9778268|FG000|Overall Study|Lost to Follow-up|3
6144145|NCT01061671|9778269|FG001|Overall Study|Lost to Follow-up|5
6144146|NCT01061671|9778268|FG000|Overall Study|Death|28
6144147|NCT01061671|9778269|FG001|Overall Study|Death|30
6144148|NCT01061710|9778275|FG000|Overall Study|Protocol Violation|14
6144149|NCT01061723|9778285|FG000|Overall Study|Adverse Event|0
6144150|NCT01061723|9778286|FG001|Overall Study|Adverse Event|2
6144151|NCT01061723|9778287|FG002|Overall Study|Adverse Event|5
6144152|NCT01061723|9778288|FG003|Overall Study|Adverse Event|5
6144153|NCT01061723|9778289|FG004|Overall Study|Adverse Event|2
6144154|NCT01061723|9778290|FG005|Overall Study|Adverse Event|6
6144155|NCT01061723|9778285|FG000|Overall Study|Lack of Efficacy|2
6144156|NCT01061723|9778286|FG001|Overall Study|Lack of Efficacy|3
6144157|NCT01061723|9778287|FG002|Overall Study|Lack of Efficacy|4
6144158|NCT01061723|9778288|FG003|Overall Study|Lack of Efficacy|2
6144159|NCT01061723|9778289|FG004|Overall Study|Lack of Efficacy|1
6144160|NCT01061723|9778290|FG005|Overall Study|Lack of Efficacy|1
6144161|NCT01061723|9778285|FG000|Overall Study|Randomized but not treated|0
6144162|NCT01061723|9778286|FG001|Overall Study|Randomized but not treated|0
6144163|NCT01061723|9778287|FG002|Overall Study|Randomized but not treated|0
6144164|NCT01061723|9778288|FG003|Overall Study|Randomized but not treated|0
6144165|NCT01061723|9778289|FG004|Overall Study|Randomized but not treated|0
6144166|NCT01061723|9778290|FG005|Overall Study|Randomized but not treated|1
6144167|NCT01061723|9778285|FG000|Overall Study|Other than specified above|2
6144168|NCT01061723|9778286|FG001|Overall Study|Other than specified above|1
6144169|NCT01061723|9778287|FG002|Overall Study|Other than specified above|1
6144170|NCT01061723|9778288|FG003|Overall Study|Other than specified above|1
6144171|NCT01061723|9778289|FG004|Overall Study|Other than specified above|0
6144172|NCT01061723|9778290|FG005|Overall Study|Other than specified above|1
6144173|NCT01061736|9778319|FG000|Overall Study|Dose regimen not selected|0
6144174|NCT01061736|9778320|FG001|Overall Study|Dose regimen not selected|0
6144175|NCT01061736|9778321|FG002|Overall Study|Dose regimen not selected|0
6144176|NCT01061736|9778322|FG003|Overall Study|Dose regimen not selected|0
6144177|NCT01061736|9778323|FG004|Overall Study|Dose regimen not selected|0
6144178|NCT01061736|9778324|FG005|Overall Study|Dose regimen not selected|0
6144179|NCT01061736|9778325|FG006|Overall Study|Dose regimen not selected|79
6144180|NCT01061736|9778326|FG007|Overall Study|Dose regimen not selected|0
6144181|NCT01061736|9778327|FG008|Overall Study|Dose regimen not selected|0
6144182|NCT01061736|9778328|FG009|Overall Study|Dose regimen not selected|0
6144183|NCT01061736|9778319|FG000|Overall Study|Adverse Event|13
6144184|NCT01061736|9778320|FG001|Overall Study|Adverse Event|1
6144185|NCT01061736|9778321|FG002|Overall Study|Adverse Event|3
6144186|NCT01061736|9778322|FG003|Overall Study|Adverse Event|2
6144187|NCT01061736|9778323|FG004|Overall Study|Adverse Event|4
6144188|NCT01061736|9778324|FG005|Overall Study|Adverse Event|1
6144189|NCT01061736|9778325|FG006|Overall Study|Adverse Event|4
6144190|NCT01061736|9778326|FG007|Overall Study|Adverse Event|63
6144191|NCT01061736|9778327|FG008|Overall Study|Adverse Event|67
6144192|NCT01061736|9778328|FG009|Overall Study|Adverse Event|34
6144193|NCT01061736|9778319|FG000|Overall Study|Lack of Efficacy|0
6144194|NCT01061736|9778320|FG001|Overall Study|Lack of Efficacy|2
6144195|NCT01061736|9778321|FG002|Overall Study|Lack of Efficacy|1
6144196|NCT01061736|9778322|FG003|Overall Study|Lack of Efficacy|1
6144197|NCT01061736|9778323|FG004|Overall Study|Lack of Efficacy|1
6144198|NCT01061736|9778324|FG005|Overall Study|Lack of Efficacy|2
6144199|NCT01061736|9778325|FG006|Overall Study|Lack of Efficacy|1
6144200|NCT01061736|9778326|FG007|Overall Study|Lack of Efficacy|9
6144201|NCT01061736|9778327|FG008|Overall Study|Lack of Efficacy|9
6144202|NCT01061736|9778328|FG009|Overall Study|Lack of Efficacy|10
6144203|NCT01061736|9778319|FG000|Overall Study|Poor compliance to protocol|0
6144204|NCT01061736|9778320|FG001|Overall Study|Poor compliance to protocol|0
6144205|NCT01061736|9778321|FG002|Overall Study|Poor compliance to protocol|0
6144206|NCT01061736|9778322|FG003|Overall Study|Poor compliance to protocol|0
6144207|NCT01061736|9778323|FG004|Overall Study|Poor compliance to protocol|0
6144208|NCT01061736|9778324|FG005|Overall Study|Poor compliance to protocol|0
6144209|NCT01061736|9778325|FG006|Overall Study|Poor compliance to protocol|0
6144210|NCT01061736|9778326|FG007|Overall Study|Poor compliance to protocol|2
6144211|NCT01061736|9778327|FG008|Overall Study|Poor compliance to protocol|5
6144212|NCT01061736|9778328|FG009|Overall Study|Poor compliance to protocol|9
6144213|NCT01061736|9778319|FG000|Overall Study|Not treated|0
6144214|NCT01061736|9778320|FG001|Overall Study|Not treated|0
6144215|NCT01061736|9778321|FG002|Overall Study|Not treated|0
6144216|NCT01061736|9778322|FG003|Overall Study|Not treated|0
6144217|NCT01061736|9778323|FG004|Overall Study|Not treated|1
6144218|NCT01061736|9778324|FG005|Overall Study|Not treated|0
6144219|NCT01061736|9778325|FG006|Overall Study|Not treated|0
6144220|NCT01061736|9778326|FG007|Overall Study|Not treated|2
6144221|NCT01061736|9778327|FG008|Overall Study|Not treated|1
6144222|NCT01061736|9778328|FG009|Overall Study|Not treated|0
6144223|NCT01061736|9778319|FG000|Overall Study|Other than specified above|0
6144224|NCT01061736|9778320|FG001|Overall Study|Other than specified above|1
6144225|NCT01061736|9778321|FG002|Overall Study|Other than specified above|2
6144226|NCT01061736|9778322|FG003|Overall Study|Other than specified above|0
6144227|NCT01061736|9778323|FG004|Overall Study|Other than specified above|1
6144228|NCT01061736|9778324|FG005|Overall Study|Other than specified above|0
6144229|NCT01061736|9778325|FG006|Overall Study|Other than specified above|0
6144230|NCT01061736|9778326|FG007|Overall Study|Other than specified above|18
6144231|NCT01061736|9778327|FG008|Overall Study|Other than specified above|15
6144232|NCT01061736|9778328|FG009|Overall Study|Other than specified above|21
6144233|NCT01061775|9778353|FG000|Overall Study|Physician Decision|2
6144234|NCT01061775|9778353|FG000|Overall Study|Lost to Follow-up|1
6144235|NCT01061866|9778358|FG000|Overall Study|Adverse Event|2
6144236|NCT01062061|9778379|FG000|Overall Study|Enrolled more than once|2
6144237|NCT01062061|9778379|FG000|Overall Study|Investigated before study start|13
6144238|NCT01062061|9778379|FG000|Overall Study|Outside chief indications|10
6144239|NCT01062061|9778379|FG000|Overall Study|Failed to meet inclusion criteria|2
6144240|NCT01062113|9778394|FG000|Overall Study|Adverse Event|1
6144241|NCT01062113|9778395|FG001|Overall Study|Adverse Event|0
6144242|NCT01062113|9778396|FG002|Overall Study|Adverse Event|0
6144243|NCT01062113|9778394|FG000|Overall Study|Lack of Efficacy|38
6144244|NCT01062113|9778395|FG001|Overall Study|Lack of Efficacy|22
6144245|NCT01062113|9778396|FG002|Overall Study|Lack of Efficacy|31
6144246|NCT01062113|9778394|FG000|Overall Study|Withdrawal by Subject|1
6144247|NCT01062113|9778395|FG001|Overall Study|Withdrawal by Subject|0
6144248|NCT01062113|9778396|FG002|Overall Study|Withdrawal by Subject|0
6144249|NCT01062126|9778404|FG000|Overall Study|Death|209
6144250|NCT01062126|9778404|FG000|Overall Study|All Withdrawals|324
6144251|NCT01062256|9778419|FG000|Overall Study|Adverse Event|1
6144252|NCT01062256|9778420|FG001|Overall Study|Adverse Event|0
6144253|NCT01062256|9778421|FG002|Overall Study|Adverse Event|0
6144254|NCT01062256|9778419|FG000|Overall Study|Withdrawal by Subject|1
6144255|NCT01062256|9778420|FG001|Overall Study|Withdrawal by Subject|1
6144256|NCT01062256|9778421|FG002|Overall Study|Withdrawal by Subject|1
6144257|NCT01062256|9778419|FG000|Overall Study|Ineligible|1
6144258|NCT01062256|9778420|FG001|Overall Study|Ineligible|4
6144259|NCT01062256|9778421|FG002|Overall Study|Ineligible|3
6144260|NCT01062256|9778419|FG000|Overall Study|Administrative|0
6144261|NCT01062256|9778420|FG001|Overall Study|Administrative|2
6144262|NCT01062256|9778421|FG002|Overall Study|Administrative|0
6144263|NCT01062399|9778451|FG000|Overall Study|Protocol Violation|0
6144264|NCT01062399|9778452|FG001|Overall Study|Protocol Violation|1
6144265|NCT01062399|9778453|FG002|Overall Study|Protocol Violation|0
6144266|NCT01062399|9778454|FG003|Overall Study|Protocol Violation|6
6144267|NCT01062399|9778455|FG004|Overall Study|Protocol Violation|4
6144268|NCT01062555|9778469|FG000|Phase 1|Death|10
6144269|NCT01062555|9778470|FG001|Phase 1|Death|17
6144270|NCT01062555|9778471|FG002|Phase 1|Death|0
6144271|NCT01062555|9778472|FG003|Phase 1|Death|0
6144272|NCT01062555|9778469|FG000|Phase 1|Graft Failure|12
6144273|NCT01062555|9778470|FG001|Phase 1|Graft Failure|8
6144274|NCT01062555|9778471|FG002|Phase 1|Graft Failure|0
6144275|NCT01062555|9778472|FG003|Phase 1|Graft Failure|0
6144276|NCT01062555|9778469|FG000|Phase 1|Withdrawal by Subject|1
6144277|NCT01062555|9778470|FG001|Phase 1|Withdrawal by Subject|1
6144278|NCT01062555|9778471|FG002|Phase 1|Withdrawal by Subject|0
6144279|NCT01062555|9778472|FG003|Phase 1|Withdrawal by Subject|0
6144280|NCT01062555|9778469|FG000|Phase 2|Death|0
6144281|NCT01062555|9778470|FG001|Phase 2|Death|0
6144282|NCT01062555|9778471|FG002|Phase 2|Death|8
6144283|NCT01062555|9778472|FG003|Phase 2|Death|3
6144284|NCT01062555|9778469|FG000|Phase 2|Graft failure|0
6144285|NCT01062555|9778470|FG001|Phase 2|Graft failure|0
6144286|NCT01062555|9778471|FG002|Phase 2|Graft failure|7
6144287|NCT01062555|9778472|FG003|Phase 2|Graft failure|4
6144288|NCT01062555|9778469|FG000|Phase 2|Withdrawal by Subject|0
6144289|NCT01062555|9778470|FG001|Phase 2|Withdrawal by Subject|0
6144290|NCT01062555|9778471|FG002|Phase 2|Withdrawal by Subject|0
6144291|NCT01062555|9778472|FG003|Phase 2|Withdrawal by Subject|7
6144292|NCT01062555|9778469|FG000|Phase 2|Protocol Violation|0
6144293|NCT01062555|9778470|FG001|Phase 2|Protocol Violation|0
6144294|NCT01062555|9778471|FG002|Phase 2|Protocol Violation|0
6144295|NCT01062555|9778472|FG003|Phase 2|Protocol Violation|3
6144296|NCT01062555|9778469|FG000|Phase 2|Physician Decision|0
6144297|NCT01062555|9778470|FG001|Phase 2|Physician Decision|0
6144298|NCT01062555|9778471|FG002|Phase 2|Physician Decision|0
6144299|NCT01062555|9778472|FG003|Phase 2|Physician Decision|17
6144300|NCT01062763|9778498|FG000|Overall Study|Adverse Event|3
6144301|NCT01062763|9778499|FG001|Overall Study|Adverse Event|4
6144302|NCT01062841|9778507|FG000|Overall Study|Indwelling Device Removed|41
6144303|NCT01062841|9778508|FG001|Overall Study|Indwelling Device Removed|48
6144304|NCT01062841|9778507|FG000|Overall Study|Death|3
6144305|NCT01062841|9778508|FG001|Overall Study|Death|5
6144306|NCT01062841|9778507|FG000|Overall Study|Withdrawal by Subject|2
6144307|NCT01062841|9778508|FG001|Overall Study|Withdrawal by Subject|0
6144308|NCT01062841|9778507|FG000|Overall Study|Withdrawal by Study|3
6144309|NCT01062841|9778508|FG001|Overall Study|Withdrawal by Study|0
6144310|NCT01062971|9778525|FG000|Overall Study|Protocol Violation|1
6144311|NCT01062971|9778526|FG001|Overall Study|Protocol Violation|3
6144312|NCT01062971|9778525|FG000|Overall Study|Lost to Follow-up|3
6144313|NCT01062971|9778526|FG001|Overall Study|Lost to Follow-up|4
6144314|NCT01063036|9778532|FG000|Participants Treated With Study Drug|Adverse Event|1
6144315|NCT01063036|9778532|FG000|Participants Treated With Study Drug|Protocol Violation|1
6144316|NCT01063036|9778532|FG000|Participants Treated With Study Drug|Withdrawal by Subject|2
6144317|NCT01063036|9778532|FG000|Participants Treated With Study Drug|Lost to Follow-up|1
6144318|NCT01063036|9778532|FG000|Participants Treated With Study Drug|Pregnancy|1
6144319|NCT01063036|9778532|FG000|Post Dosing Follow-up Through 24 Weeks|Lost to Follow-up|1
6144320|NCT01063036|9778532|FG000|Post Dosing Follow-up Through 24 Weeks|Withdrawal by Subject|6
6144321|NCT01063036|9778532|FG000|Post Dosing Follow-up Through 24 Weeks|Alternative therapy started|32
6144322|NCT01063062|9778551|FG000|Overall Study|Patient withdrew consent|0
6144323|NCT01063062|9778552|FG001|Overall Study|Patient withdrew consent|1
6144324|NCT01063062|9778551|FG000|Overall Study|Adverse Event|2
6144325|NCT01063062|9778552|FG001|Overall Study|Adverse Event|4
6144326|NCT01063062|9778551|FG000|Overall Study|Protocol Violation|5
6144327|NCT01063062|9778552|FG001|Overall Study|Protocol Violation|4
6144328|NCT01063062|9778551|FG000|Overall Study|Investigator's request|1
6144329|NCT01063062|9778552|FG001|Overall Study|Investigator's request|0
6144330|NCT01063062|9778551|FG000|Overall Study|Lost to Follow-up|0
6144331|NCT01063062|9778552|FG001|Overall Study|Lost to Follow-up|2
6144332|NCT01063062|9778551|FG000|Overall Study|Miscellaneous reason|0
6144333|NCT01063062|9778552|FG001|Overall Study|Miscellaneous reason|1
6144334|NCT01063153|9778574|FG000|Overall Study|Found Ineligible During Screening|2
6144335|NCT01063153|9778575|FG001|Overall Study|Found Ineligible During Screening|0
6144336|NCT01063153|9778574|FG000|Overall Study|Lost to Follow-up|0
6144337|NCT01063153|9778575|FG001|Overall Study|Lost to Follow-up|7
6144338|NCT01063153|9778574|FG000|Overall Study|Withdrawal by Subject|0
6144339|NCT01063153|9778575|FG001|Overall Study|Withdrawal by Subject|1
6144340|NCT01063153|9778574|FG000|Overall Study|Physician Decision|0
6144341|NCT01063153|9778575|FG001|Overall Study|Physician Decision|4
6144342|NCT01063283|9778587|FG000|Cycle 1|Adverse Event|2
6144343|NCT01063283|9778588|FG001|Cycle 1|Adverse Event|0
6144344|NCT01063283|9778589|FG002|Cycle 1|Adverse Event|0
6144345|NCT01063283|9778587|FG000|Cycle 1|Technical failure in data collection|1
6144346|NCT01063283|9778588|FG001|Cycle 1|Technical failure in data collection|0
6144347|NCT01063283|9778589|FG002|Cycle 1|Technical failure in data collection|0
6144348|NCT01063348|9778597|FG000|Overall Study|Lost to Follow-up|3
6144349|NCT01063348|9778598|FG001|Overall Study|Lost to Follow-up|10
6144350|NCT01063595|9778604|FG000|Enrolled in Study and Randomized|Reason not Specified|1
6144351|NCT01063595|9778605|FG001|Enrolled in Study and Randomized|Reason not Specified|0
6144352|NCT01063595|9778604|FG000|Enrolled in Study and Randomized|Adverse Event|0
6144353|NCT01063595|9778605|FG001|Enrolled in Study and Randomized|Adverse Event|1
6144354|NCT01063595|9778604|FG000|Enrolled in Study and Randomized|Withdrawn by the Investigator|0
6144355|NCT01063595|9778605|FG001|Enrolled in Study and Randomized|Withdrawn by the Investigator|1
6144356|NCT01063595|9778604|FG000|First Intervention|Adverse Event|1
6144357|NCT01063595|9778605|FG001|First Intervention|Adverse Event|4
6144358|NCT01063595|9778604|FG000|First Intervention|Withdrawal by Subject|1
6144359|NCT01063595|9778605|FG001|First Intervention|Withdrawal by Subject|0
6144360|NCT01063595|9778604|FG000|First Intervention|Reason not Specified|0
6144361|NCT01063595|9778605|FG001|First Intervention|Reason not Specified|1
6144362|NCT01063764|9778616|FG000|1st Period (From Week 8 to Week 22)|Adverse Event|4
6144363|NCT01063764|9778616|FG000|1st Period (From Week 8 to Week 22)|Lack of Efficacy|6
6144364|NCT01063764|9778616|FG000|1st Period (From Week 8 to Week 22)|Withdrawal by Subject|1
6144365|NCT01063764|9778616|FG000|2nd Period (Week 22 to the End of Study)|Adverse Event|3
6144366|NCT01063764|9778616|FG000|2nd Period (Week 22 to the End of Study)|Lack of Efficacy|9
6144367|NCT01063764|9778616|FG000|2nd Period (Week 22 to the End of Study)|Withdrawal by Subject|7
6144368|NCT01063764|9778616|FG000|2nd Period (Week 22 to the End of Study)|Protocol Violation|1
6144369|NCT01063855|9778639|FG000|Overall Study|Adverse Event|4
6144370|NCT01063855|9778640|FG001|Overall Study|Adverse Event|4
6144371|NCT01063855|9778639|FG000|Overall Study|Death|0
6144372|NCT01063855|9778640|FG001|Overall Study|Death|1
6144373|NCT01063855|9778639|FG000|Overall Study|Lost to Follow-up|8
6144374|NCT01063855|9778640|FG001|Overall Study|Lost to Follow-up|4
6144375|NCT01063855|9778639|FG000|Overall Study|Pregnancy|1
6144376|NCT01063855|9778640|FG001|Overall Study|Pregnancy|0
6144377|NCT01063855|9778639|FG000|Overall Study|Lack of Efficacy|0
6144378|NCT01063855|9778640|FG001|Overall Study|Lack of Efficacy|1
6144379|NCT01063855|9778639|FG000|Overall Study|Withdrawal by Subject|11
6144380|NCT01063855|9778640|FG001|Overall Study|Withdrawal by Subject|8
6144381|NCT01063855|9778639|FG000|Overall Study|Reason not specified|13
6144382|NCT01063855|9778640|FG001|Overall Study|Reason not specified|11
6144383|NCT01063868|9778652|FG000|Overall Study|Adverse Event|9
6144384|NCT01063868|9778653|FG001|Overall Study|Adverse Event|7
6144385|NCT01063868|9778652|FG000|Overall Study|Withdrawal by Subject|3
6144386|NCT01063868|9778653|FG001|Overall Study|Withdrawal by Subject|1
6144387|NCT01063868|9778652|FG000|Overall Study|Study Terminated By Sponsor|23
6144388|NCT01063868|9778653|FG001|Overall Study|Study Terminated By Sponsor|4
6144389|NCT01063881|9778662|FG000|Overall Study|Adverse Event|12
6144390|NCT01063881|9778663|FG001|Overall Study|Adverse Event|2
6144391|NCT01063881|9778664|FG002|Overall Study|Adverse Event|0
6144392|NCT01063881|9778662|FG000|Overall Study|Lost to Follow-up|13
6144393|NCT01063881|9778663|FG001|Overall Study|Lost to Follow-up|7
6144394|NCT01063881|9778664|FG002|Overall Study|Lost to Follow-up|1
6144395|NCT01063881|9778662|FG000|Overall Study|Withdrawal by Subject|25
6144396|NCT01063881|9778663|FG001|Overall Study|Withdrawal by Subject|1
6144397|NCT01063881|9778664|FG002|Overall Study|Withdrawal by Subject|0
6144398|NCT01063881|9778662|FG000|Overall Study|Reason for not completed not specified|5
6144399|NCT01063881|9778663|FG001|Overall Study|Reason for not completed not specified|1
6144400|NCT01063881|9778664|FG002|Overall Study|Reason for not completed not specified|0
6144401|NCT01063972|9778704|FG000|Overall Study|Death|12
6144402|NCT01063972|9778705|FG001|Overall Study|Death|11
6144403|NCT01063972|9778704|FG000|Overall Study|Incarcerated|2
6144404|NCT01063972|9778705|FG001|Overall Study|Incarcerated|1
6144405|NCT01064167|9778718|FG000|Overall Study|Protocol Violation|14
6144406|NCT01064167|9778719|FG001|Overall Study|Protocol Violation|15
6144407|NCT01064297|9778738|FG000|Overall Study|Lost to Follow-up|791
6144408|NCT01064297|9778739|FG001|Overall Study|Lost to Follow-up|48
6144409|NCT01064297|9778740|FG002|Overall Study|Lost to Follow-up|133
6144410|NCT01064310|9778757|FG000|Period 1|Adverse Event|7
6144411|NCT01064310|9778758|FG001|Period 1|Adverse Event|10
6144412|NCT01064310|9778759|FG002|Period 1|Adverse Event|0
6144413|NCT01064310|9778757|FG000|Period 1|Physician Decision|1
6144414|NCT01064310|9778758|FG001|Period 1|Physician Decision|0
6144415|NCT01064310|9778759|FG002|Period 1|Physician Decision|0
6144416|NCT01064310|9778757|FG000|Period 1|Withdrawal by Subject|2
6144417|NCT01064310|9778758|FG001|Period 1|Withdrawal by Subject|2
6144418|NCT01064310|9778759|FG002|Period 1|Withdrawal by Subject|0
6144419|NCT01064310|9778757|FG000|Period 1|Lack of Efficacy|3
6144420|NCT01064310|9778758|FG001|Period 1|Lack of Efficacy|5
6144421|NCT01064310|9778759|FG002|Period 1|Lack of Efficacy|0
6144422|NCT01064310|9778757|FG000|Period 1|Entered Open-label Period|1
6144423|NCT01064310|9778758|FG001|Period 1|Entered Open-label Period|1
6144424|NCT01064310|9778759|FG002|Period 1|Entered Open-label Period|0
6144425|NCT01064310|9778757|FG000|Period 2|Adverse Event|2
6144426|NCT01064310|9778758|FG001|Period 2|Adverse Event|1
6144427|NCT01064310|9778759|FG002|Period 2|Adverse Event|0
6144428|NCT01064310|9778757|FG000|Period 2|Physician Decision|0
6144429|NCT01064310|9778758|FG001|Period 2|Physician Decision|1
6144430|NCT01064310|9778759|FG002|Period 2|Physician Decision|0
6144431|NCT01064310|9778757|FG000|Period 2|Entered Open-label Period|1
6144432|NCT01064310|9778758|FG001|Period 2|Entered Open-label Period|0
6144433|NCT01064310|9778759|FG002|Period 2|Entered Open-label Period|0
6144434|NCT01064310|9778757|FG000|Period 2|Lack of Efficacy|1
6144435|NCT01064310|9778758|FG001|Period 2|Lack of Efficacy|4
6144436|NCT01064310|9778759|FG002|Period 2|Lack of Efficacy|0
6144437|NCT01064310|9778757|FG000|Open Label Pazopinib|Withdrawal by Subject|0
6144438|NCT01064310|9778758|FG001|Open Label Pazopinib|Withdrawal by Subject|0
6144439|NCT01064310|9778759|FG002|Open Label Pazopinib|Withdrawal by Subject|1
6144440|NCT01064310|9778757|FG000|Open Label Pazopinib|Adverse Event|0
6144441|NCT01064310|9778758|FG001|Open Label Pazopinib|Adverse Event|0
6144442|NCT01064310|9778759|FG002|Open Label Pazopinib|Adverse Event|12
6144443|NCT01064310|9778757|FG000|Open Label Pazopinib|Lack of Efficacy|0
6144444|NCT01064310|9778758|FG001|Open Label Pazopinib|Lack of Efficacy|0
6144445|NCT01064310|9778759|FG002|Open Label Pazopinib|Lack of Efficacy|51
6144446|NCT01064310|9778757|FG000|Open Label Pazopinib|Physician Decision|0
6144447|NCT01064310|9778758|FG001|Open Label Pazopinib|Physician Decision|0
6144448|NCT01064310|9778759|FG002|Open Label Pazopinib|Physician Decision|20
6144449|NCT01064401|9778783|FG000|Overall Study|Adverse Event|47
6144450|NCT01064401|9778784|FG001|Overall Study|Adverse Event|56
6144451|NCT01064401|9778783|FG000|Overall Study|Lack of Efficacy|46
6144452|NCT01064401|9778784|FG001|Overall Study|Lack of Efficacy|23
6144453|NCT01064401|9778783|FG000|Overall Study|Lost to Follow-up|12
6144454|NCT01064401|9778784|FG001|Overall Study|Lost to Follow-up|9
6144455|NCT01064401|9778783|FG000|Overall Study|Consent Withdrawn|98
6144456|NCT01064401|9778784|FG001|Overall Study|Consent Withdrawn|80
6144457|NCT01064401|9778783|FG000|Overall Study|Investigator Decision|4
6144458|NCT01064401|9778784|FG001|Overall Study|Investigator Decision|6
6144459|NCT01064401|9778783|FG000|Overall Study|Death|4
6144460|NCT01064401|9778784|FG001|Overall Study|Death|0
6144461|NCT01064401|9778783|FG000|Overall Study|Pregnancy|4
6144462|NCT01064401|9778784|FG001|Overall Study|Pregnancy|7
6144463|NCT01064401|9778783|FG000|Overall Study|Noncompliance|7
6144464|NCT01064401|9778784|FG001|Overall Study|Noncompliance|8
6144465|NCT01064401|9778783|FG000|Overall Study|Site Closure|4
6144466|NCT01064401|9778784|FG001|Overall Study|Site Closure|5
6144467|NCT01064401|9778783|FG000|Overall Study|Other|2
6144468|NCT01064401|9778784|FG001|Overall Study|Other|1
6144469|NCT01064414|9778794|FG000|Core Period: Baseline to Week 26|Adverse Event|4
6144470|NCT01064414|9778795|FG001|Core Period: Baseline to Week 26|Adverse Event|4
6144471|NCT01064414|9778796|FG002|Core Period: Baseline to Week 26|Adverse Event|2
6144472|NCT01064414|9778794|FG000|Core Period: Baseline to Week 26|Death|0
6144473|NCT01064414|9778795|FG001|Core Period: Baseline to Week 26|Death|1
6144474|NCT01064414|9778796|FG002|Core Period: Baseline to Week 26|Death|0
6144475|NCT01064414|9778794|FG000|Core Period: Baseline to Week 26|Protocol Violation|1
6144476|NCT01064414|9778795|FG001|Core Period: Baseline to Week 26|Protocol Violation|0
6144477|NCT01064414|9778796|FG002|Core Period: Baseline to Week 26|Protocol Violation|1
6144478|NCT01064414|9778794|FG000|Core Period: Baseline to Week 26|Withdrawal by Subject|4
6144479|NCT01064414|9778795|FG001|Core Period: Baseline to Week 26|Withdrawal by Subject|2
6144480|NCT01064414|9778796|FG002|Core Period: Baseline to Week 26|Withdrawal by Subject|2
6144481|NCT01064414|9778794|FG000|Core Period: Baseline to Week 26|Noncompliance with study drug|0
6144482|NCT01064414|9778795|FG001|Core Period: Baseline to Week 26|Noncompliance with study drug|1
6144483|NCT01064414|9778796|FG002|Core Period: Baseline to Week 26|Noncompliance with study drug|0
6144484|NCT01064414|9778794|FG000|Core Period: Baseline to Week 26|Other|4
6144485|NCT01064414|9778795|FG001|Core Period: Baseline to Week 26|Other|7
6144486|NCT01064414|9778796|FG002|Core Period: Baseline to Week 26|Other|2
6144487|NCT01064414|9778794|FG000|Extension Period: Week 26 to Week 52|Adverse Event|2
6144488|NCT01064414|9778795|FG001|Extension Period: Week 26 to Week 52|Adverse Event|1
6144489|NCT01064414|9778796|FG002|Extension Period: Week 26 to Week 52|Adverse Event|2
6144490|NCT01064414|9778794|FG000|Extension Period: Week 26 to Week 52|Death|0
6144491|NCT01064414|9778795|FG001|Extension Period: Week 26 to Week 52|Death|1
6144492|NCT01064414|9778796|FG002|Extension Period: Week 26 to Week 52|Death|0
6144493|NCT01064414|9778794|FG000|Extension Period: Week 26 to Week 52|Lost to Follow-up|1
6144494|NCT01064414|9778795|FG001|Extension Period: Week 26 to Week 52|Lost to Follow-up|0
6144495|NCT01064414|9778796|FG002|Extension Period: Week 26 to Week 52|Lost to Follow-up|0
6144496|NCT01064414|9778794|FG000|Extension Period: Week 26 to Week 52|Physician Decision|1
6144497|NCT01064414|9778795|FG001|Extension Period: Week 26 to Week 52|Physician Decision|0
6144498|NCT01064414|9778796|FG002|Extension Period: Week 26 to Week 52|Physician Decision|0
6144499|NCT01064414|9778794|FG000|Extension Period: Week 26 to Week 52|Withdrawal by Subject|1
6144500|NCT01064414|9778795|FG001|Extension Period: Week 26 to Week 52|Withdrawal by Subject|0
6144501|NCT01064414|9778796|FG002|Extension Period: Week 26 to Week 52|Withdrawal by Subject|1
6144502|NCT01064414|9778794|FG000|Extension Period: Week 26 to Week 52|Noncompliance with study drug|1
6144503|NCT01064414|9778795|FG001|Extension Period: Week 26 to Week 52|Noncompliance with study drug|0
6144504|NCT01064414|9778796|FG002|Extension Period: Week 26 to Week 52|Noncompliance with study drug|0
6144505|NCT01064414|9778794|FG000|Extension Period: Week 26 to Week 52|Protocol Violation|1
6144506|NCT01064414|9778795|FG001|Extension Period: Week 26 to Week 52|Protocol Violation|1
6144507|NCT01064414|9778796|FG002|Extension Period: Week 26 to Week 52|Protocol Violation|1
6144508|NCT01064414|9778794|FG000|Extension Period: Week 26 to Week 52|Other|5
6144509|NCT01064414|9778795|FG001|Extension Period: Week 26 to Week 52|Other|2
6144510|NCT01064414|9778796|FG002|Extension Period: Week 26 to Week 52|Other|1
6144511|NCT01064531|9778809|FG000|Overall Study|Lost to Follow-up|0
6144512|NCT01064531|9778810|FG001|Overall Study|Lost to Follow-up|2
6144513|NCT01064531|9778809|FG000|Overall Study|Physician Decision|0
6144514|NCT01064531|9778810|FG001|Overall Study|Physician Decision|1
6144515|NCT01064531|9778809|FG000|Overall Study|Withdrawal by Subject|2
6144516|NCT01064531|9778810|FG001|Overall Study|Withdrawal by Subject|2
6144517|NCT01064531|9778809|FG000|Overall Study|Revision due to femoral stem loosening|1
6144518|NCT01064531|9778810|FG001|Overall Study|Revision due to femoral stem loosening|0
6144519|NCT01064531|9778809|FG000|Overall Study|Revision due to dislocation|0
6144520|NCT01064531|9778810|FG001|Overall Study|Revision due to dislocation|1
6144521|NCT01064531|9778809|FG000|Overall Study|Death|0
6144522|NCT01064531|9778810|FG001|Overall Study|Death|1
6144523|NCT01064622|9778819|FG000|Randomized Phase II|Withdrawal by Subject|2
6144524|NCT01064622|9778820|FG001|Randomized Phase II|Withdrawal by Subject|2
6144525|NCT01064622|9778819|FG000|Randomized Phase II|Protocol Violation|0
6144526|NCT01064622|9778820|FG001|Randomized Phase II|Protocol Violation|1
6144527|NCT01064687|9778833|FG000|Overall Study|Adverse Event|9
6144528|NCT01064687|9778834|FG001|Overall Study|Adverse Event|4
6144529|NCT01064687|9778835|FG002|Overall Study|Adverse Event|10
6144530|NCT01064687|9778836|FG003|Overall Study|Adverse Event|3
6144531|NCT01064687|9778833|FG000|Overall Study|Death|1
6144532|NCT01064687|9778834|FG001|Overall Study|Death|1
6144533|NCT01064687|9778835|FG002|Overall Study|Death|0
6144534|NCT01064687|9778836|FG003|Overall Study|Death|0
6144535|NCT01064687|9778833|FG000|Overall Study|Entry Criteria Not Met|3
6144536|NCT01064687|9778834|FG001|Overall Study|Entry Criteria Not Met|0
6144537|NCT01064687|9778835|FG002|Overall Study|Entry Criteria Not Met|0
6144538|NCT01064687|9778836|FG003|Overall Study|Entry Criteria Not Met|0
6144539|NCT01064687|9778833|FG000|Overall Study|Lack of Efficacy|1
6144540|NCT01064687|9778834|FG001|Overall Study|Lack of Efficacy|0
6144541|NCT01064687|9778835|FG002|Overall Study|Lack of Efficacy|2
6144542|NCT01064687|9778836|FG003|Overall Study|Lack of Efficacy|3
6144543|NCT01064687|9778833|FG000|Overall Study|Lost to Follow-up|7
6144544|NCT01064687|9778834|FG001|Overall Study|Lost to Follow-up|10
6144545|NCT01064687|9778835|FG002|Overall Study|Lost to Follow-up|13
6144546|NCT01064687|9778836|FG003|Overall Study|Lost to Follow-up|5
6144547|NCT01064687|9778833|FG000|Overall Study|Physician Decision|2
6144548|NCT01064687|9778834|FG001|Overall Study|Physician Decision|2
6144549|NCT01064687|9778835|FG002|Overall Study|Physician Decision|0
6144550|NCT01064687|9778836|FG003|Overall Study|Physician Decision|0
6144551|NCT01064687|9778833|FG000|Overall Study|Protocol Violation|1
6144552|NCT01064687|9778834|FG001|Overall Study|Protocol Violation|1
6144553|NCT01064687|9778835|FG002|Overall Study|Protocol Violation|0
6144554|NCT01064687|9778836|FG003|Overall Study|Protocol Violation|1
6144555|NCT01064687|9778833|FG000|Overall Study|Sponsor Decision|0
6144556|NCT01064687|9778834|FG001|Overall Study|Sponsor Decision|0
6144557|NCT01064687|9778835|FG002|Overall Study|Sponsor Decision|3
6144558|NCT01064687|9778836|FG003|Overall Study|Sponsor Decision|0
6144559|NCT01064687|9778833|FG000|Overall Study|Withdrawal by Subject|9
6144560|NCT01064687|9778834|FG001|Overall Study|Withdrawal by Subject|7
6144561|NCT01064687|9778835|FG002|Overall Study|Withdrawal by Subject|12
6144562|NCT01064687|9778836|FG003|Overall Study|Withdrawal by Subject|5
6144563|NCT01064687|9778833|FG000|Overall Study|Treatment Noncompliance|1
6144564|NCT01064687|9778834|FG001|Overall Study|Treatment Noncompliance|1
6144565|NCT01064687|9778835|FG002|Overall Study|Treatment Noncompliance|1
6144566|NCT01064687|9778836|FG003|Overall Study|Treatment Noncompliance|0
6144567|NCT01064739|9778866|FG000|Fixed Sodium Diet + Fava Beans|Adverse Event|1
6144568|NCT01064856|9778889|FG000|Double-blind (DB) Period|Adverse Event|1
6144569|NCT01064856|9778890|FG001|Double-blind (DB) Period|Adverse Event|0
6144570|NCT01064856|9778891|FG002|Double-blind (DB) Period|Adverse Event|0
6144571|NCT01064856|9778892|FG003|Double-blind (DB) Period|Adverse Event|0
6144572|NCT01064856|9778889|FG000|Double-blind (DB) Period|Consent withdrawn by participant|1
6144573|NCT01064856|9778890|FG001|Double-blind (DB) Period|Consent withdrawn by participant|0
6144574|NCT01064856|9778891|FG002|Double-blind (DB) Period|Consent withdrawn by participant|0
6144575|NCT01064856|9778892|FG003|Double-blind (DB) Period|Consent withdrawn by participant|0
6144576|NCT01064856|9778889|FG000|Open-label (OL) Period|Adverse Event|0
6144577|NCT01064856|9778890|FG001|Open-label (OL) Period|Adverse Event|0
6144578|NCT01064856|9778891|FG002|Open-label (OL) Period|Adverse Event|12
6144579|NCT01064856|9778892|FG003|Open-label (OL) Period|Adverse Event|6
6144580|NCT01064856|9778889|FG000|Open-label (OL) Period|Consent withdrawn by participant|0
6144581|NCT01064856|9778890|FG001|Open-label (OL) Period|Consent withdrawn by participant|0
6144582|NCT01064856|9778891|FG002|Open-label (OL) Period|Consent withdrawn by participant|5
6144583|NCT01064856|9778892|FG003|Open-label (OL) Period|Consent withdrawn by participant|6
6144584|NCT01064856|9778889|FG000|Open-label (OL) Period|Lost to Follow-up|0
6144585|NCT01064856|9778890|FG001|Open-label (OL) Period|Lost to Follow-up|0
6144586|NCT01064856|9778891|FG002|Open-label (OL) Period|Lost to Follow-up|2
6144587|NCT01064856|9778892|FG003|Open-label (OL) Period|Lost to Follow-up|1
6144588|NCT01064856|9778889|FG000|Open-label (OL) Period|Other|0
6144589|NCT01064856|9778890|FG001|Open-label (OL) Period|Other|0
6144590|NCT01064856|9778891|FG002|Open-label (OL) Period|Other|7
6144591|NCT01064856|9778892|FG003|Open-label (OL) Period|Other|7
6144592|NCT01064947|9778912|FG000|Overall Study|negative culture|41
6144593|NCT01065350|9778922|FG000|Overall Study|Received incorrect drug allocation|0
6144594|NCT01065350|9778923|FG001|Overall Study|Received incorrect drug allocation|1
6144595|NCT01065597|9778971|FG000|Overall Study|Adverse Event|1
6144596|NCT01065766|9778982|FG000|Overall Study|Assessed before the contracted date|1
6144597|NCT01065766|9778982|FG000|Overall Study|Contraindication to administration|6
6144598|NCT01065766|9778982|FG000|Overall Study|Violated dosage/administration|25
6144599|NCT01065844|9778986|FG000|Overall Study|Adverse Event|5
6144600|NCT01066000|9778990|FG000|Overall Study|Protocol Violation|4
6144601|NCT01066000|9778990|FG000|Overall Study|Death|3
6144602|NCT01066000|9778990|FG000|Overall Study|Withdrawal by Subject|1
6144603|NCT01066000|9778990|FG000|Overall Study|Adverse Event|1
6144604|NCT01066039|9779000|FG000|Overall Study|Adverse Event|6
6144605|NCT01066039|9779000|FG000|Overall Study|Withdrawal by Subject|17
6144606|NCT01066039|9779000|FG000|Overall Study|Protocol Violation|2
6144607|NCT01066039|9779000|FG000|Overall Study|Inclusion/Exclusion Criteria Violation|9
6144608|NCT01066039|9779000|FG000|Overall Study|Investigator's Request|1
6144609|NCT01066039|9779000|FG000|Overall Study|Dropout due to Insulin Administration|1
6144610|NCT01066039|9779000|FG000|Overall Study|Additional Antihypertensive Required|4
6144611|NCT01066039|9779000|FG000|Overall Study|Volunteer Failed to Make the Next Visit|2
6144612|NCT01066039|9779000|FG000|Overall Study|Failure to Control Blood Pressure|1
6144613|NCT01066039|9779000|FG000|Overall Study|Drug/Dose Adjustment Required|1
6144614|NCT01066052|9779006|FG000|Overall Study|Enrolled But Not Treated|3
6144615|NCT01066052|9779007|FG001|Overall Study|Enrolled But Not Treated|0
6144616|NCT01066104|9779014|FG000|Overall Study|Adverse Event|1
6144617|NCT01066104|9779015|FG001|Overall Study|Adverse Event|1
6144618|NCT01066104|9779014|FG000|Overall Study|Protocol Violation|1
6144619|NCT01066104|9779015|FG001|Overall Study|Protocol Violation|0
6144620|NCT01066143|9779021|FG000|Overall Study|ineligible for the study|8
6144621|NCT01066156|9779025|FG000|Overall Study|ineligible|2
6144622|NCT01066156|9779025|FG000|Overall Study|Lost to Follow-up|7
6144623|NCT01066156|9779025|FG000|Overall Study|Withdrawal by Subject|1
6144624|NCT01066546|9779051|FG000|Overall Study|Study terminated by sponsor|5
6144625|NCT01066585|9779057|FG000|Overall Study|Protocol Violation|1
6144626|NCT01066585|9779058|FG001|Overall Study|Protocol Violation|0
6144627|NCT01066585|9779057|FG000|Overall Study|Withdrawal by Subject|0
6144628|NCT01066585|9779058|FG001|Overall Study|Withdrawal by Subject|3
6144629|NCT01066780|9779077|FG000|Overall Study|Withdrawn prior to ClearVoice exposure.|1
6144630|NCT01066780|9779078|FG001|Overall Study|Withdrawn prior to ClearVoice exposure.|1
6144631|NCT01066793|9779088|FG000|Overall Study|Death|4
6144632|NCT01066793|9779089|FG001|Overall Study|Death|1
6144633|NCT01066793|9779090|FG002|Overall Study|Death|1
6144634|NCT01066793|9779091|FG003|Overall Study|Death|0
6144635|NCT01066793|9779092|FG004|Overall Study|Death|0
6144636|NCT01066793|9779093|FG005|Overall Study|Death|0
6144637|NCT01066793|9779088|FG000|Overall Study|Lack of Efficacy|2
6144638|NCT01066793|9779089|FG001|Overall Study|Lack of Efficacy|1
6144639|NCT01066793|9779090|FG002|Overall Study|Lack of Efficacy|0
6144640|NCT01066793|9779091|FG003|Overall Study|Lack of Efficacy|0
6144641|NCT01066793|9779092|FG004|Overall Study|Lack of Efficacy|0
6144642|NCT01066793|9779093|FG005|Overall Study|Lack of Efficacy|0
6144643|NCT01066793|9779088|FG000|Overall Study|Lost to Follow-up|180
6144644|NCT01066793|9779089|FG001|Overall Study|Lost to Follow-up|39
6144645|NCT01066793|9779090|FG002|Overall Study|Lost to Follow-up|82
6144646|NCT01066793|9779091|FG003|Overall Study|Lost to Follow-up|16
6144647|NCT01066793|9779092|FG004|Overall Study|Lost to Follow-up|0
6144648|NCT01066793|9779093|FG005|Overall Study|Lost to Follow-up|1
6144649|NCT01066793|9779088|FG000|Overall Study|Physician Decision|3
6144650|NCT01066793|9779089|FG001|Overall Study|Physician Decision|0
6144651|NCT01066793|9779090|FG002|Overall Study|Physician Decision|0
6144652|NCT01066793|9779091|FG003|Overall Study|Physician Decision|0
6144653|NCT01066793|9779092|FG004|Overall Study|Physician Decision|0
6144654|NCT01066793|9779093|FG005|Overall Study|Physician Decision|0
6144655|NCT01066793|9779088|FG000|Overall Study|Protocol Violation|3
6144656|NCT01066793|9779089|FG001|Overall Study|Protocol Violation|2
6144657|NCT01066793|9779090|FG002|Overall Study|Protocol Violation|2
6144658|NCT01066793|9779091|FG003|Overall Study|Protocol Violation|0
6144659|NCT01066793|9779092|FG004|Overall Study|Protocol Violation|0
6144660|NCT01066793|9779093|FG005|Overall Study|Protocol Violation|0
6144661|NCT01066793|9779088|FG000|Overall Study|Withdrawal by Subject|7
6144662|NCT01066793|9779089|FG001|Overall Study|Withdrawal by Subject|4
6144663|NCT01066793|9779090|FG002|Overall Study|Withdrawal by Subject|1
6144664|NCT01066793|9779091|FG003|Overall Study|Withdrawal by Subject|0
6144665|NCT01066793|9779092|FG004|Overall Study|Withdrawal by Subject|0
6144666|NCT01066793|9779093|FG005|Overall Study|Withdrawal by Subject|0
6144667|NCT01066793|9779088|FG000|Overall Study|Early Termination|3
6144668|NCT01066793|9779089|FG001|Overall Study|Early Termination|0
6144669|NCT01066793|9779090|FG002|Overall Study|Early Termination|0
6144670|NCT01066793|9779091|FG003|Overall Study|Early Termination|0
6144671|NCT01066793|9779092|FG004|Overall Study|Early Termination|0
6144672|NCT01066793|9779093|FG005|Overall Study|Early Termination|0
6144673|NCT01066793|9779088|FG000|Overall Study|Lab test not done|7
6144674|NCT01066793|9779089|FG001|Overall Study|Lab test not done|0
6144675|NCT01066793|9779090|FG002|Overall Study|Lab test not done|0
6144676|NCT01066793|9779091|FG003|Overall Study|Lab test not done|1
6144677|NCT01066793|9779092|FG004|Overall Study|Lab test not done|0
6144678|NCT01066793|9779093|FG005|Overall Study|Lab test not done|0
6144679|NCT01066793|9779088|FG000|Overall Study|Miscellaneous|4
6144680|NCT01066793|9779089|FG001|Overall Study|Miscellaneous|5
6144681|NCT01066793|9779090|FG002|Overall Study|Miscellaneous|6
6144682|NCT01066793|9779091|FG003|Overall Study|Miscellaneous|0
6144683|NCT01066793|9779092|FG004|Overall Study|Miscellaneous|0
6144684|NCT01066793|9779093|FG005|Overall Study|Miscellaneous|0
6144685|NCT01066793|9779088|FG000|Overall Study|Non-responders|104
6144686|NCT01066793|9779089|FG001|Overall Study|Non-responders|5
6144687|NCT01066793|9779090|FG002|Overall Study|Non-responders|11
6144688|NCT01066793|9779091|FG003|Overall Study|Non-responders|25
6144689|NCT01066793|9779092|FG004|Overall Study|Non-responders|0
6144690|NCT01066793|9779093|FG005|Overall Study|Non-responders|0
6144691|NCT01066793|9779088|FG000|Overall Study|Other|15
6144692|NCT01066793|9779089|FG001|Overall Study|Other|5
6144693|NCT01066793|9779090|FG002|Overall Study|Other|6
6144694|NCT01066793|9779091|FG003|Overall Study|Other|2
6144695|NCT01066793|9779092|FG004|Overall Study|Other|0
6144696|NCT01066793|9779093|FG005|Overall Study|Other|0
6144697|NCT01066793|9779088|FG000|Overall Study|Relapse|20
6144698|NCT01066793|9779089|FG001|Overall Study|Relapse|8
6144699|NCT01066793|9779090|FG002|Overall Study|Relapse|2
6144700|NCT01066793|9779091|FG003|Overall Study|Relapse|3
6144701|NCT01066793|9779092|FG004|Overall Study|Relapse|0
6144702|NCT01066793|9779093|FG005|Overall Study|Relapse|0
6144703|NCT01066793|9779088|FG000|Overall Study|Result Not Available|1
6144704|NCT01066793|9779089|FG001|Overall Study|Result Not Available|0
6144705|NCT01066793|9779090|FG002|Overall Study|Result Not Available|0
6144706|NCT01066793|9779091|FG003|Overall Study|Result Not Available|0
6144707|NCT01066793|9779092|FG004|Overall Study|Result Not Available|0
6144708|NCT01066793|9779093|FG005|Overall Study|Result Not Available|0
6144709|NCT01066793|9779088|FG000|Overall Study|Treatment Interrupted|1
6144710|NCT01066793|9779089|FG001|Overall Study|Treatment Interrupted|1
6144711|NCT01066793|9779090|FG002|Overall Study|Treatment Interrupted|0
6144712|NCT01066793|9779091|FG003|Overall Study|Treatment Interrupted|0
6144713|NCT01066793|9779092|FG004|Overall Study|Treatment Interrupted|0
6144714|NCT01066793|9779093|FG005|Overall Study|Treatment Interrupted|0
6144715|NCT01066793|9779088|FG000|Overall Study|Treatment Never Started|18
6144716|NCT01066793|9779089|FG001|Overall Study|Treatment Never Started|5
6144717|NCT01066793|9779090|FG002|Overall Study|Treatment Never Started|4
6144718|NCT01066793|9779091|FG003|Overall Study|Treatment Never Started|1
6144719|NCT01066793|9779092|FG004|Overall Study|Treatment Never Started|0
6144720|NCT01066793|9779093|FG005|Overall Study|Treatment Never Started|0
6144721|NCT01066793|9779088|FG000|Overall Study|Treatment Stopped|2
6144722|NCT01066793|9779089|FG001|Overall Study|Treatment Stopped|1
6144723|NCT01066793|9779090|FG002|Overall Study|Treatment Stopped|0
6144724|NCT01066793|9779091|FG003|Overall Study|Treatment Stopped|1
6144725|NCT01066793|9779092|FG004|Overall Study|Treatment Stopped|0
6144726|NCT01066793|9779093|FG005|Overall Study|Treatment Stopped|0
6144727|NCT01066819|9779114|FG000|Overall Study|Adverse Event|18
6144728|NCT01066819|9779115|FG001|Overall Study|Adverse Event|1
6144729|NCT01066819|9779116|FG002|Overall Study|Adverse Event|6
6144730|NCT01066819|9779117|FG003|Overall Study|Adverse Event|0
6144731|NCT01066819|9779118|FG004|Overall Study|Adverse Event|0
6144732|NCT01066819|9779119|FG005|Overall Study|Adverse Event|0
6144733|NCT01066819|9779114|FG000|Overall Study|Death|5
6144734|NCT01066819|9779115|FG001|Overall Study|Death|0
6144735|NCT01066819|9779116|FG002|Overall Study|Death|1
6144736|NCT01066819|9779117|FG003|Overall Study|Death|0
6144737|NCT01066819|9779118|FG004|Overall Study|Death|0
6144738|NCT01066819|9779119|FG005|Overall Study|Death|0
6144739|NCT01066819|9779114|FG000|Overall Study|Lack of Efficacy|22
6144740|NCT01066819|9779115|FG001|Overall Study|Lack of Efficacy|1
6144741|NCT01066819|9779116|FG002|Overall Study|Lack of Efficacy|2
6144742|NCT01066819|9779117|FG003|Overall Study|Lack of Efficacy|1
6144743|NCT01066819|9779118|FG004|Overall Study|Lack of Efficacy|0
6144744|NCT01066819|9779119|FG005|Overall Study|Lack of Efficacy|0
6144745|NCT01066819|9779114|FG000|Overall Study|Physician Decision|6
6144746|NCT01066819|9779115|FG001|Overall Study|Physician Decision|2
6144747|NCT01066819|9779116|FG002|Overall Study|Physician Decision|3
6144748|NCT01066819|9779117|FG003|Overall Study|Physician Decision|0
6144749|NCT01066819|9779118|FG004|Overall Study|Physician Decision|0
6144750|NCT01066819|9779119|FG005|Overall Study|Physician Decision|0
6144751|NCT01066819|9779114|FG000|Overall Study|Protocol Violation|12
6144752|NCT01066819|9779115|FG001|Overall Study|Protocol Violation|6
6144753|NCT01066819|9779116|FG002|Overall Study|Protocol Violation|0
6144754|NCT01066819|9779117|FG003|Overall Study|Protocol Violation|0
6144755|NCT01066819|9779118|FG004|Overall Study|Protocol Violation|0
6144756|NCT01066819|9779119|FG005|Overall Study|Protocol Violation|0
6144757|NCT01066819|9779114|FG000|Overall Study|Withdrawal by Subject|29
6144758|NCT01066819|9779115|FG001|Overall Study|Withdrawal by Subject|11
6144759|NCT01066819|9779116|FG002|Overall Study|Withdrawal by Subject|6
6144760|NCT01066819|9779117|FG003|Overall Study|Withdrawal by Subject|0
6144761|NCT01066819|9779118|FG004|Overall Study|Withdrawal by Subject|0
6144762|NCT01066819|9779119|FG005|Overall Study|Withdrawal by Subject|0
6144763|NCT01066819|9779114|FG000|Overall Study|Administrative|6
6144764|NCT01066819|9779115|FG001|Overall Study|Administrative|4
6144765|NCT01066819|9779116|FG002|Overall Study|Administrative|2
6144766|NCT01066819|9779117|FG003|Overall Study|Administrative|0
6144767|NCT01066819|9779118|FG004|Overall Study|Administrative|0
6144768|NCT01066819|9779119|FG005|Overall Study|Administrative|0
6144769|NCT01066819|9779114|FG000|Overall Study|Not met inclusion/exclusion criteria|1
6144770|NCT01066819|9779115|FG001|Overall Study|Not met inclusion/exclusion criteria|0
6144771|NCT01066819|9779116|FG002|Overall Study|Not met inclusion/exclusion criteria|0
6144772|NCT01066819|9779117|FG003|Overall Study|Not met inclusion/exclusion criteria|0
6144773|NCT01066819|9779118|FG004|Overall Study|Not met inclusion/exclusion criteria|0
6144774|NCT01066819|9779119|FG005|Overall Study|Not met inclusion/exclusion criteria|0
6144775|NCT01066819|9779114|FG000|Overall Study|Early termination|2
6144776|NCT01066819|9779115|FG001|Overall Study|Early termination|0
6144777|NCT01066819|9779116|FG002|Overall Study|Early termination|0
6144778|NCT01066819|9779117|FG003|Overall Study|Early termination|0
6144779|NCT01066819|9779118|FG004|Overall Study|Early termination|0
6144780|NCT01066819|9779119|FG005|Overall Study|Early termination|0
6144781|NCT01066819|9779114|FG000|Overall Study|Failed to return|298
6144782|NCT01066819|9779115|FG001|Overall Study|Failed to return|107
6144783|NCT01066819|9779116|FG002|Overall Study|Failed to return|68
6144784|NCT01066819|9779117|FG003|Overall Study|Failed to return|7
6144785|NCT01066819|9779118|FG004|Overall Study|Failed to return|2
6144786|NCT01066819|9779119|FG005|Overall Study|Failed to return|3
6144787|NCT01066819|9779114|FG000|Overall Study|Lab test not done|9
6144788|NCT01066819|9779115|FG001|Overall Study|Lab test not done|0
6144789|NCT01066819|9779116|FG002|Overall Study|Lab test not done|2
6144790|NCT01066819|9779117|FG003|Overall Study|Lab test not done|1
6144791|NCT01066819|9779118|FG004|Overall Study|Lab test not done|0
6144792|NCT01066819|9779119|FG005|Overall Study|Lab test not done|0
6144793|NCT01066819|9779114|FG000|Overall Study|Miscellaneous|28
6144794|NCT01066819|9779115|FG001|Overall Study|Miscellaneous|10
6144795|NCT01066819|9779116|FG002|Overall Study|Miscellaneous|18
6144796|NCT01066819|9779117|FG003|Overall Study|Miscellaneous|1
6144797|NCT01066819|9779118|FG004|Overall Study|Miscellaneous|0
6144798|NCT01066819|9779119|FG005|Overall Study|Miscellaneous|0
6144799|NCT01066819|9779114|FG000|Overall Study|Non responders|123
6144800|NCT01066819|9779115|FG001|Overall Study|Non responders|2
6144801|NCT01066819|9779116|FG002|Overall Study|Non responders|7
6144802|NCT01066819|9779117|FG003|Overall Study|Non responders|2
6144803|NCT01066819|9779118|FG004|Overall Study|Non responders|0
6144804|NCT01066819|9779119|FG005|Overall Study|Non responders|1
6144805|NCT01066819|9779114|FG000|Overall Study|Not categorised|9
6144806|NCT01066819|9779115|FG001|Overall Study|Not categorised|2
6144807|NCT01066819|9779116|FG002|Overall Study|Not categorised|6
6144808|NCT01066819|9779117|FG003|Overall Study|Not categorised|1
6144809|NCT01066819|9779118|FG004|Overall Study|Not categorised|0
6144810|NCT01066819|9779119|FG005|Overall Study|Not categorised|0
6144811|NCT01066819|9779114|FG000|Overall Study|Relapse|16
6144812|NCT01066819|9779115|FG001|Overall Study|Relapse|4
6144813|NCT01066819|9779116|FG002|Overall Study|Relapse|3
6144814|NCT01066819|9779117|FG003|Overall Study|Relapse|0
6144815|NCT01066819|9779118|FG004|Overall Study|Relapse|0
6144816|NCT01066819|9779119|FG005|Overall Study|Relapse|0
6144817|NCT01066819|9779114|FG000|Overall Study|Results not available|1
6144818|NCT01066819|9779115|FG001|Overall Study|Results not available|0
6144819|NCT01066819|9779116|FG002|Overall Study|Results not available|0
6144820|NCT01066819|9779117|FG003|Overall Study|Results not available|0
6144821|NCT01066819|9779118|FG004|Overall Study|Results not available|0
6144822|NCT01066819|9779119|FG005|Overall Study|Results not available|0
6144823|NCT01066819|9779114|FG000|Overall Study|Screen failure|1
6144824|NCT01066819|9779115|FG001|Overall Study|Screen failure|0
6144825|NCT01066819|9779116|FG002|Overall Study|Screen failure|0
6144826|NCT01066819|9779117|FG003|Overall Study|Screen failure|0
6144827|NCT01066819|9779118|FG004|Overall Study|Screen failure|0
6144828|NCT01066819|9779119|FG005|Overall Study|Screen failure|0
6144829|NCT01066819|9779114|FG000|Overall Study|Spontaneous cure|1
6144830|NCT01066819|9779115|FG001|Overall Study|Spontaneous cure|0
6144831|NCT01066819|9779116|FG002|Overall Study|Spontaneous cure|0
6144832|NCT01066819|9779117|FG003|Overall Study|Spontaneous cure|0
6144833|NCT01066819|9779118|FG004|Overall Study|Spontaneous cure|0
6144834|NCT01066819|9779119|FG005|Overall Study|Spontaneous cure|0
6144835|NCT01066819|9779114|FG000|Overall Study|Treatment never started|85
6144836|NCT01066819|9779115|FG001|Overall Study|Treatment never started|19
6144837|NCT01066819|9779116|FG002|Overall Study|Treatment never started|19
6144838|NCT01066819|9779117|FG003|Overall Study|Treatment never started|3
6144839|NCT01066819|9779118|FG004|Overall Study|Treatment never started|2
6144840|NCT01066819|9779119|FG005|Overall Study|Treatment never started|2
6144841|NCT01066819|9779114|FG000|Overall Study|Treatment stopped|12
6144842|NCT01066819|9779115|FG001|Overall Study|Treatment stopped|1
6144843|NCT01066819|9779116|FG002|Overall Study|Treatment stopped|2
6144844|NCT01066819|9779117|FG003|Overall Study|Treatment stopped|1
6144845|NCT01066819|9779118|FG004|Overall Study|Treatment stopped|0
6144846|NCT01066819|9779119|FG005|Overall Study|Treatment stopped|0
6144847|NCT01066819|9779114|FG000|Overall Study|Other|5
6144848|NCT01066819|9779115|FG001|Overall Study|Other|1
6144849|NCT01066819|9779116|FG002|Overall Study|Other|1
6144850|NCT01066819|9779117|FG003|Overall Study|Other|0
6144851|NCT01066819|9779118|FG004|Overall Study|Other|0
6144852|NCT01066819|9779119|FG005|Overall Study|Other|0
6144853|NCT01066871|9779135|FG000|Overall Study|Lost to Follow-up|0
6144854|NCT01066871|9779136|FG001|Overall Study|Lost to Follow-up|2
6144855|NCT01066871|9779137|FG002|Overall Study|Lost to Follow-up|2
6144856|NCT01066871|9779138|FG003|Overall Study|Lost to Follow-up|0
6144857|NCT01066871|9779135|FG000|Overall Study|Protocol Violation|1
6144858|NCT01066871|9779136|FG001|Overall Study|Protocol Violation|0
6144859|NCT01066871|9779137|FG002|Overall Study|Protocol Violation|3
6144860|NCT01066871|9779138|FG003|Overall Study|Protocol Violation|2
6144861|NCT01066871|9779135|FG000|Overall Study|Lack of Efficacy|0
6144862|NCT01066871|9779136|FG001|Overall Study|Lack of Efficacy|0
6144863|NCT01066871|9779137|FG002|Overall Study|Lack of Efficacy|0
6144864|NCT01066871|9779138|FG003|Overall Study|Lack of Efficacy|1
6144865|NCT01066871|9779135|FG000|Overall Study|Withdrawal by Subject|3
6144866|NCT01066871|9779136|FG001|Overall Study|Withdrawal by Subject|1
6144867|NCT01066871|9779137|FG002|Overall Study|Withdrawal by Subject|0
6144868|NCT01066871|9779138|FG003|Overall Study|Withdrawal by Subject|0
6144869|NCT01066871|9779135|FG000|Overall Study|Other|0
6144870|NCT01066871|9779136|FG001|Overall Study|Other|2
6144871|NCT01066871|9779137|FG002|Overall Study|Other|1
6144872|NCT01066871|9779138|FG003|Overall Study|Other|2
6144873|NCT01066897|9779155|FG000|Overall Study|Withdrawal by Subject|1
6144874|NCT01066897|9779156|FG001|Overall Study|Withdrawal by Subject|0
6144875|NCT01066897|9779155|FG000|Overall Study|stopped study after developing the flu.|1
6144876|NCT01066897|9779156|FG001|Overall Study|stopped study after developing the flu.|0
6144877|NCT01066923|9779167|FG000|Overall Study|Withdrawal by Subject|3
6144878|NCT01066923|9779168|FG001|Overall Study|Withdrawal by Subject|3
6144879|NCT01066923|9779169|FG002|Overall Study|Withdrawal by Subject|8
6144880|NCT01066923|9779170|FG003|Overall Study|Withdrawal by Subject|8
6144881|NCT01066936|9779180|FG000|Overall Study|Death|2
6144882|NCT01066936|9779180|FG000|Overall Study|Device revised/removed|1
6144883|NCT01066936|9779180|FG000|Overall Study|Lost to Follow-up|3
6144884|NCT01066936|9779180|FG000|Overall Study|Withdrawal by Subject|4
6144885|NCT01067105|9779186|FG000|Overall Study|Adverse Event|14
6144886|NCT01067105|9779186|FG000|Overall Study|Protocol Violation|48
6144887|NCT01067105|9779186|FG000|Overall Study|Withdrawal by Subject|36
6144888|NCT01067105|9779186|FG000|Overall Study|Lost to Follow-up|6
6144889|NCT01067105|9779186|FG000|Overall Study|Physician Decision|6
6144890|NCT01067105|9779186|FG000|Overall Study|Other|31
6144891|NCT01067326|9779192|FG000|Overall Study|Adverse Event|0
6144892|NCT01067326|9779193|FG001|Overall Study|Adverse Event|2
6144893|NCT01067326|9779192|FG000|Overall Study|Withdrawal by Subject|1
6144894|NCT01067326|9779193|FG001|Overall Study|Withdrawal by Subject|0
6144895|NCT01067326|9779192|FG000|Overall Study|Early Study Termination|1
6144896|NCT01067326|9779193|FG001|Overall Study|Early Study Termination|1
6144897|NCT01067339|9779201|FG000|Overall Study|Withdrawal by Subject|6
6144898|NCT01067339|9779202|FG001|Overall Study|Withdrawal by Subject|5
6144899|NCT01067352|9779211|FG000|Overall Study|Withdrawal by Subject|1
6144900|NCT01067352|9779212|FG001|Overall Study|Withdrawal by Subject|2
6144901|NCT01067352|9779213|FG002|Overall Study|Withdrawal by Subject|1
6144902|NCT01067352|9779211|FG000|Overall Study|Physician Decision|0
6144903|NCT01067352|9779212|FG001|Overall Study|Physician Decision|1
6144904|NCT01067352|9779213|FG002|Overall Study|Physician Decision|0
6144905|NCT01067469|9779234|FG000|Overall Study|Withdrawal by Subject|0
6144906|NCT01067469|9779235|FG001|Overall Study|Withdrawal by Subject|1
6144907|NCT01067469|9779234|FG000|Overall Study|Disease Progression|0
6144908|NCT01067469|9779235|FG001|Overall Study|Disease Progression|1
6144909|NCT01067508|9779243|FG000|Overall Study|Physician Decision|0
6144910|NCT01067508|9779244|FG001|Overall Study|Physician Decision|1
6144911|NCT01067508|9779243|FG000|Overall Study|Withdrawal by Subject|0
6144912|NCT01067508|9779244|FG001|Overall Study|Withdrawal by Subject|1
6144913|NCT01067846|9779293|FG000|Overall Study|Lost to Follow-up|17
6144914|NCT01067846|9779294|FG001|Overall Study|Lost to Follow-up|19
6144915|NCT01067846|9779293|FG000|Overall Study|Withdrawal by Subject|1
6144916|NCT01067846|9779294|FG001|Overall Study|Withdrawal by Subject|0
6144917|NCT01067846|9779293|FG000|Overall Study|participation in other tx study|1
6144918|NCT01067846|9779294|FG001|Overall Study|participation in other tx study|0
6144919|NCT01067976|9779300|FG000|Overall Study|Study drug never administered|20
6144920|NCT01067976|9779300|FG000|Overall Study|Study prematurely discontinued|2
6144921|NCT01068158|9779320|FG000|Overall Study|Withdrawal by Subject|1
6144922|NCT01068158|9779321|FG001|Overall Study|Withdrawal by Subject|2
6144923|NCT01068158|9779320|FG000|Overall Study|Lost to Follow-up|7
6144924|NCT01068158|9779321|FG001|Overall Study|Lost to Follow-up|0
6144925|NCT01068158|9779320|FG000|Overall Study|Protocol Violation|0
6144926|NCT01068158|9779321|FG001|Overall Study|Protocol Violation|2
6144927|NCT01068262|9779331|FG000|Overall Study|Adverse Event|2
6144928|NCT01068262|9779332|FG001|Overall Study|Adverse Event|0
6144929|NCT01068262|9779333|FG002|Overall Study|Adverse Event|1
6144930|NCT01068262|9779334|FG003|Overall Study|Adverse Event|0
6144931|NCT01068262|9779331|FG000|Overall Study|Protocol Violation|1
6144932|NCT01068262|9779332|FG001|Overall Study|Protocol Violation|0
6144933|NCT01068262|9779333|FG002|Overall Study|Protocol Violation|0
6144934|NCT01068262|9779334|FG003|Overall Study|Protocol Violation|0
6144935|NCT01068262|9779331|FG000|Overall Study|Withdrawal by Subject|0
6144936|NCT01068262|9779332|FG001|Overall Study|Withdrawal by Subject|1
6144937|NCT01068262|9779333|FG002|Overall Study|Withdrawal by Subject|0
6144938|NCT01068262|9779334|FG003|Overall Study|Withdrawal by Subject|0
6144939|NCT01068418|9779347|FG000|Overall Study|Physician Decision|12
6144940|NCT01068509|9779354|FG000|Overall Study|Death|0
6144941|NCT01068509|9779355|FG001|Overall Study|Death|0
6144942|NCT01068509|9779356|FG002|Overall Study|Death|1
6144943|NCT01068509|9779354|FG000|Overall Study|Disease Progression|5
6144944|NCT01068509|9779355|FG001|Overall Study|Disease Progression|20
6144945|NCT01068509|9779356|FG002|Overall Study|Disease Progression|18
6144946|NCT01068509|9779354|FG000|Overall Study|Lost to Follow-up|1
6144947|NCT01068509|9779355|FG001|Overall Study|Lost to Follow-up|0
6144948|NCT01068509|9779356|FG002|Overall Study|Lost to Follow-up|0
6144949|NCT01068509|9779354|FG000|Overall Study|Withdrew Consent|0
6144950|NCT01068509|9779355|FG001|Overall Study|Withdrew Consent|1
6144951|NCT01068509|9779356|FG002|Overall Study|Withdrew Consent|2
6144952|NCT01068509|9779354|FG000|Overall Study|Reason Not Specified|0
6144953|NCT01068509|9779355|FG001|Overall Study|Reason Not Specified|1
6144954|NCT01068509|9779356|FG002|Overall Study|Reason Not Specified|0
6144955|NCT01068600|9779375|FG000|Overall Study|Withdrawal by Subject|5
6144956|NCT01068600|9779376|FG001|Overall Study|Withdrawal by Subject|6
6144957|NCT01068600|9779375|FG000|Overall Study|Adverse Event|3
6144958|NCT01068600|9779376|FG001|Overall Study|Adverse Event|3
6144959|NCT01068600|9779375|FG000|Overall Study|Abnormal laboratory value(s)|1
6144960|NCT01068600|9779376|FG001|Overall Study|Abnormal laboratory value(s)|0
6144961|NCT01068600|9779375|FG000|Overall Study|Lost to Follow-up|1
5982907|NCT00858702|9572006|FG000|Overall Study|Lack of Efficacy|1
6144962|NCT01068600|9779376|FG001|Overall Study|Lost to Follow-up|2
6144963|NCT01068600|9779375|FG000|Overall Study|Protocol deviation|1
6144964|NCT01068600|9779376|FG001|Overall Study|Protocol deviation|1
6144965|NCT01068600|9779375|FG000|Overall Study|Unsatisfactory therapeutic effect|0
6144966|NCT01068600|9779376|FG001|Overall Study|Unsatisfactory therapeutic effect|4
6144967|NCT01068600|9779375|FG000|Overall Study|Administrative problems|0
6144968|NCT01068600|9779376|FG001|Overall Study|Administrative problems|1
6144969|NCT01068626|9779384|FG000|Overall Study|Adverse Event|3
6144970|NCT01068626|9779385|FG001|Overall Study|Adverse Event|0
6144971|NCT01068626|9779384|FG000|Overall Study|Withdrawal by Subject|0
6144972|NCT01068626|9779385|FG001|Overall Study|Withdrawal by Subject|2
6144973|NCT01068652|9779393|FG000|Overall Study|Adverse Event|4
6144974|NCT01068652|9779394|FG001|Overall Study|Adverse Event|0
6144975|NCT01068652|9779393|FG000|Overall Study|Lack of Efficacy|0
6144976|NCT01068652|9779394|FG001|Overall Study|Lack of Efficacy|2
6144977|NCT01068652|9779393|FG000|Overall Study|Lost to Follow-up|2
6144978|NCT01068652|9779394|FG001|Overall Study|Lost to Follow-up|1
6144979|NCT01068652|9779393|FG000|Overall Study|Protocol Violation|3
6144980|NCT01068652|9779394|FG001|Overall Study|Protocol Violation|6
6144981|NCT01068652|9779393|FG000|Overall Study|Withdrawal criteria|1
6144982|NCT01068652|9779394|FG001|Overall Study|Withdrawal criteria|2
6144983|NCT01068652|9779393|FG000|Overall Study|Patient was not eligible|1
6144984|NCT01068652|9779394|FG001|Overall Study|Patient was not eligible|0
6144985|NCT01068652|9779393|FG000|Overall Study|Unclassified|7
6144986|NCT01068652|9779394|FG001|Overall Study|Unclassified|4
6144987|NCT01068665|9779402|FG000|Overall Study|Adverse Event|5
6144988|NCT01068665|9779403|FG001|Overall Study|Adverse Event|4
6144989|NCT01068665|9779402|FG000|Overall Study|Lack of Efficacy|0
6144990|NCT01068665|9779403|FG001|Overall Study|Lack of Efficacy|2
6144991|NCT01068665|9779402|FG000|Overall Study|Protocol Violation|5
6144992|NCT01068665|9779403|FG001|Overall Study|Protocol Violation|2
6144993|NCT01068665|9779402|FG000|Overall Study|Withdrawal Criteria|3
6144994|NCT01068665|9779403|FG001|Overall Study|Withdrawal Criteria|9
6144995|NCT01068665|9779402|FG000|Overall Study|Other|17
6144996|NCT01068665|9779403|FG001|Overall Study|Other|12
6144997|NCT01068678|9779411|FG000|Overall Study|Lack of Efficacy|3
6144998|NCT01068678|9779412|FG001|Overall Study|Lack of Efficacy|2
6144999|NCT01068678|9779411|FG000|Overall Study|Protocol Violation|5
6145000|NCT01068678|9779412|FG001|Overall Study|Protocol Violation|1
6145001|NCT01068678|9779411|FG000|Overall Study|Withdrawal criteria|12
6145002|NCT01068678|9779412|FG001|Overall Study|Withdrawal criteria|6
6145003|NCT01068678|9779411|FG000|Overall Study|Unclassified|18
6145004|NCT01068678|9779412|FG001|Overall Study|Unclassified|15
6145005|NCT01068717|9779418|FG000|Period 1: Treatment Schedule Phase 1|Patient withdrew; returned for period 3|1
6145006|NCT01068717|9779419|FG001|Period 1: Treatment Schedule Phase 1|Patient withdrew; returned for period 3|0
6145007|NCT01068717|9779420|FG002|Period 1: Treatment Schedule Phase 1|Patient withdrew; returned for period 3|0
6145008|NCT01068717|9779421|FG003|Period 1: Treatment Schedule Phase 1|Patient withdrew; returned for period 3|0
6145009|NCT01068730|9779435|FG000|Period 3|Personal reason|1
6145010|NCT01068730|9779436|FG001|Period 3|Personal reason|0
6145011|NCT01068730|9779437|FG002|Period 3|Personal reason|0
6145012|NCT01068730|9779438|FG003|Period 3|Personal reason|0
6145013|NCT01068730|9779435|FG000|Period 4|Family emergency|0
6145014|NCT01068730|9779436|FG001|Period 4|Family emergency|1
6145015|NCT01068730|9779437|FG002|Period 4|Family emergency|0
6145016|NCT01068730|9779438|FG003|Period 4|Family emergency|0
6145017|NCT01068743|9779455|FG000|Period 3|Adverse Event|0
6145018|NCT01068743|9779456|FG001|Period 3|Adverse Event|1
6145019|NCT01068743|9779457|FG002|Period 3|Adverse Event|0
6145020|NCT01068743|9779458|FG003|Period 3|Adverse Event|0
6145021|NCT01068769|9779471|FG000|Overall Study|Ineligible|1
6145022|NCT01068860|9779494|FG000|Overall Study|Withdrawal by Subject|0
6145023|NCT01068860|9779495|FG001|Overall Study|Withdrawal by Subject|0
6145024|NCT01068860|9779496|FG002|Overall Study|Withdrawal by Subject|0
6145025|NCT01068860|9779497|FG003|Overall Study|Withdrawal by Subject|0
6145026|NCT01068860|9779498|FG004|Overall Study|Withdrawal by Subject|0
6145027|NCT01068860|9779499|FG005|Overall Study|Withdrawal by Subject|2
6145028|NCT01068860|9779500|FG006|Overall Study|Withdrawal by Subject|0
6145029|NCT01068860|9779501|FG007|Overall Study|Withdrawal by Subject|0
6145030|NCT01068860|9779502|FG008|Overall Study|Withdrawal by Subject|0
6145031|NCT01068860|9779503|FG009|Overall Study|Withdrawal by Subject|3
6145032|NCT01068860|9779494|FG000|Overall Study|Administrative problems; misrandomized|0
6145033|NCT01068860|9779495|FG001|Overall Study|Administrative problems; misrandomized|0
6145034|NCT01068860|9779496|FG002|Overall Study|Administrative problems; misrandomized|0
6145035|NCT01068860|9779497|FG003|Overall Study|Administrative problems; misrandomized|1
6145036|NCT01068860|9779498|FG004|Overall Study|Administrative problems; misrandomized|0
6145037|NCT01068860|9779499|FG005|Overall Study|Administrative problems; misrandomized|0
6145038|NCT01068860|9779500|FG006|Overall Study|Administrative problems; misrandomized|0
6145039|NCT01068860|9779501|FG007|Overall Study|Administrative problems; misrandomized|0
6145040|NCT01068860|9779502|FG008|Overall Study|Administrative problems; misrandomized|0
6145041|NCT01068860|9779503|FG009|Overall Study|Administrative problems; misrandomized|1
6145042|NCT01068860|9779494|FG000|Overall Study|Lost to Follow-up|0
6145043|NCT01068860|9779495|FG001|Overall Study|Lost to Follow-up|1
6145044|NCT01068860|9779496|FG002|Overall Study|Lost to Follow-up|0
6145045|NCT01068860|9779497|FG003|Overall Study|Lost to Follow-up|0
6145046|NCT01068860|9779498|FG004|Overall Study|Lost to Follow-up|0
6145047|NCT01068860|9779499|FG005|Overall Study|Lost to Follow-up|0
6145048|NCT01068860|9779500|FG006|Overall Study|Lost to Follow-up|0
6145049|NCT01068860|9779501|FG007|Overall Study|Lost to Follow-up|0
6145050|NCT01068860|9779502|FG008|Overall Study|Lost to Follow-up|0
6145051|NCT01068860|9779503|FG009|Overall Study|Lost to Follow-up|0
6145052|NCT01068912|9779532|FG000|Overall Study|Adverse Event|2
6145053|NCT01068912|9779533|FG001|Overall Study|Adverse Event|3
6145054|NCT01068912|9779534|FG002|Overall Study|Adverse Event|2
6145055|NCT01068912|9779532|FG000|Overall Study|Withdrawal by Subject|5
6145056|NCT01068912|9779533|FG001|Overall Study|Withdrawal by Subject|6
6145057|NCT01068912|9779534|FG002|Overall Study|Withdrawal by Subject|6
6145058|NCT01068912|9779532|FG000|Overall Study|Lost to Follow-up|3
6145059|NCT01068912|9779533|FG001|Overall Study|Lost to Follow-up|7
6145060|NCT01068912|9779534|FG002|Overall Study|Lost to Follow-up|3
6145061|NCT01068912|9779532|FG000|Overall Study|Protocol Violation|0
6145062|NCT01068912|9779533|FG001|Overall Study|Protocol Violation|2
6145063|NCT01068912|9779534|FG002|Overall Study|Protocol Violation|0
6145064|NCT01068912|9779532|FG000|Overall Study|aggravation influenza|1
6145065|NCT01068912|9779533|FG001|Overall Study|aggravation influenza|1
6145066|NCT01068912|9779534|FG002|Overall Study|aggravation influenza|1
6145067|NCT01068912|9779532|FG000|Overall Study|other underlying illness|0
6145068|NCT01068912|9779533|FG001|Overall Study|other underlying illness|3
6145069|NCT01068912|9779534|FG002|Overall Study|other underlying illness|3
6145070|NCT01069172|9779566|FG000|Overall Study|Withdrawal by Subject|1
5982908|NCT00858702|9572007|FG001|Overall Study|Lack of Efficacy|0
5982909|NCT00858702|9572006|FG000|Overall Study|Protocol Violation|1
5982910|NCT00858702|9572007|FG001|Overall Study|Protocol Violation|1
5982911|NCT00858702|9572006|FG000|Overall Study|Other|2
5982912|NCT00858702|9572007|FG001|Overall Study|Other|1
5982913|NCT00858702|9572006|FG000|Overall Study|Withdrawal by Subject|1
5982914|NCT00858702|9572007|FG001|Overall Study|Withdrawal by Subject|0
5982915|NCT00857285|9572015|FG000|Overall Study|Adverse Event|4
5982916|NCT00857285|9572016|FG001|Overall Study|Adverse Event|2
5982917|NCT00857285|9572015|FG000|Overall Study|Lack of Efficacy|0
5982918|NCT00857285|9572016|FG001|Overall Study|Lack of Efficacy|2
5982919|NCT00857285|9572015|FG000|Overall Study|Protocol Violation|3
5982920|NCT00857285|9572016|FG001|Overall Study|Protocol Violation|1
5982921|NCT00857285|9572015|FG000|Overall Study|Withdrawal by Subject|4
5982922|NCT00857285|9572016|FG001|Overall Study|Withdrawal by Subject|0
5982923|NCT00857285|9572015|FG000|Overall Study|Randomization criteria not met|1
5982924|NCT00857285|9572016|FG001|Overall Study|Randomization criteria not met|1
5982925|NCT00850174|9572032|FG000|Washout: One Week|Withdrawal by Subject|0
5982926|NCT00850174|9572033|FG001|Washout: One Week|Withdrawal by Subject|2
5982927|NCT00850174|9572032|FG000|Second Intervention|Withdrawal by Subject|1
5982928|NCT00850174|9572033|FG001|Second Intervention|Withdrawal by Subject|0
5982929|NCT00849797|9572046|FG000|First Intervention|bad veins|1
5982930|NCT00849797|9572047|FG001|First Intervention|bad veins|0
5982931|NCT00849797|9572046|FG000|First Intervention|Adverse Event|0
5982932|NCT00849797|9572047|FG001|First Intervention|Adverse Event|1
5982933|NCT00849797|9572046|FG000|Washout: One Week|Withdrawal by Subject|0
5982934|NCT00849797|9572047|FG001|Washout: One Week|Withdrawal by Subject|2
5982935|NCT00847405|9572061|FG000|First Intervention|Adverse Event|0
5982936|NCT00847405|9572062|FG001|First Intervention|Adverse Event|1
5982937|NCT00847405|9572061|FG000|Washout of 7 Days|Withdrawal by Subject|1
5982938|NCT00847405|9572062|FG001|Washout of 7 Days|Withdrawal by Subject|0
5982939|NCT00841815|9572075|FG000|Washout|Withdrawal by Subject|0
5982940|NCT00841815|9572076|FG001|Washout|Withdrawal by Subject|1
5982941|NCT00841698|9572083|FG000|First Intervention|Withdrawal by Subject|1
5982942|NCT00841698|9572084|FG001|First Intervention|Withdrawal by Subject|0
5982943|NCT00841659|9572090|FG000|Washout: 2 Weeks|Protocol Violation|1
5982944|NCT00841659|9572091|FG001|Washout: 2 Weeks|Protocol Violation|0
5982945|NCT00841542|9572097|FG000|Period 1|Adverse Event|1
5982946|NCT00841542|9572098|FG001|Period 1|Adverse Event|0
5982947|NCT00840879|9572104|FG000|Second Intervention|Withdrawal by Subject|1
5982948|NCT00840879|9572105|FG001|Second Intervention|Withdrawal by Subject|0
5982949|NCT00840632|9572125|FG000|First Intervention|Withdrawal by Subject|0
5982950|NCT00840632|9572126|FG001|First Intervention|Withdrawal by Subject|1
5982951|NCT00840632|9572125|FG000|Washout|Withdrawal by Subject|1
5982952|NCT00840632|9572126|FG001|Washout|Withdrawal by Subject|1
5982953|NCT00840411|9572139|FG000|First Intervention|Adverse Event|1
5982954|NCT00840411|9572140|FG001|First Intervention|Adverse Event|0
5982955|NCT00840411|9572139|FG000|Washout|Withdrawal by Subject|1
5982956|NCT00840411|9572140|FG001|Washout|Withdrawal by Subject|0
5982957|NCT00840216|9572153|FG000|Washout: 7 Days|Withdrawal by Subject|1
5982958|NCT00840216|9572154|FG001|Washout: 7 Days|Withdrawal by Subject|0
5982959|NCT00840203|9572160|FG000|First Intervention|Protocol Violation|1
5982960|NCT00840203|9572161|FG001|First Intervention|Protocol Violation|1
5982961|NCT00840203|9572160|FG000|Washout|Protocol Violation|1
5982962|NCT00840203|9572161|FG001|Washout|Protocol Violation|0
5982963|NCT00840073|9572174|FG000|Second Intervention|Missed 72 hour blood draw|1
5982964|NCT00840073|9572175|FG001|Second Intervention|Missed 72 hour blood draw|1
5982965|NCT00838630|9572188|FG000|First Intervention|Adverse Event|1
5982966|NCT00838630|9572189|FG001|First Intervention|Adverse Event|0
5982967|NCT00838630|9572188|FG000|Washout: 7 Days|Protocol Violation|1
5982968|NCT00838630|9572189|FG001|Washout: 7 Days|Protocol Violation|0
5982969|NCT00838279|9572195|FG000|Washout|Protocol Violation|1
5982970|NCT00838279|9572196|FG001|Washout|Protocol Violation|0
5982971|NCT00838279|9572195|FG000|Washout|Withdrawal by Subject|0
5982972|NCT00838279|9572196|FG001|Washout|Withdrawal by Subject|1
5982973|NCT00836901|9572209|FG000|First Intervention|Withdrawal by Subject|1
5982974|NCT00836901|9572210|FG001|First Intervention|Withdrawal by Subject|0
5982975|NCT00836706|9572216|FG000|Washout: 7 Days|Withdrawal by Subject|0
5982976|NCT00836706|9572217|FG001|Washout: 7 Days|Withdrawal by Subject|1
5982977|NCT00836472|9572223|FG000|Washout|Adverse Event|1
5982978|NCT00836472|9572224|FG001|Washout|Adverse Event|2
5982979|NCT00836472|9572223|FG000|Washout|Withdrawal by Subject|1
5982980|NCT00836472|9572224|FG001|Washout|Withdrawal by Subject|1
5982981|NCT00836056|9572230|FG000|First Intervention|Adverse Event|1
5982982|NCT00836056|9572231|FG001|First Intervention|Adverse Event|0
6145071|NCT01069172|9779567|FG001|Overall Study|Withdrawal by Subject|0
6145072|NCT01069289|9779585|FG000|Overall Study|Withdrawal by Subject|15
6145073|NCT01069289|9779586|FG001|Overall Study|Withdrawal by Subject|26
6145074|NCT01069289|9779585|FG000|Overall Study|Adverse Event|21
6145075|NCT01069289|9779586|FG001|Overall Study|Adverse Event|28
6145076|NCT01069289|9779585|FG000|Overall Study|Eligibility criteria not fulfilled|2
6145077|NCT01069289|9779586|FG001|Overall Study|Eligibility criteria not fulfilled|0
6145078|NCT01069289|9779585|FG000|Overall Study|Severe non-compliance to protocol|3
6145079|NCT01069289|9779586|FG001|Overall Study|Severe non-compliance to protocol|2
6145080|NCT01069289|9779585|FG000|Overall Study|Due to deteriorating health condition|1
6145081|NCT01069289|9779586|FG001|Overall Study|Due to deteriorating health condition|0
6145082|NCT01069341|9779613|FG000|Overall Study|Lost to Follow-up|1
6145083|NCT01069419|9779625|FG000|Overall Study|Adverse Event|233
6145084|NCT01069419|9779625|FG000|Overall Study|Lack of Efficacy|332
6145085|NCT01069419|9779625|FG000|Overall Study|Lost to Follow-up|49
6145086|NCT01069419|9779625|FG000|Overall Study|Remission of disease|11
6145087|NCT01069419|9779625|FG000|Overall Study|Withdrawal by Subject|34
6145088|NCT01069419|9779625|FG000|Overall Study|Other Reason|43
6145089|NCT01069419|9779625|FG000|Overall Study|Missing termination information|13
6145090|NCT01069484|9779631|FG000|Overall Study|Death-in-near-family|1
6145091|NCT01069484|9779632|FG001|Overall Study|Death-in-near-family|0
6145092|NCT01069484|9779631|FG000|Overall Study|No specific reason|8
6145093|NCT01069484|9779632|FG001|Overall Study|No specific reason|2
6145094|NCT01069484|9779631|FG000|Overall Study|Illness mother or child|3
6145095|NCT01069484|9779632|FG001|Overall Study|Illness mother or child|1
6145096|NCT01069523|9779650|FG000|Overall Study|Withdrawal by Subject|4
6145097|NCT01069523|9779651|FG001|Overall Study|Withdrawal by Subject|7
6145098|NCT01069627|9779668|FG000|Overall Study|Disease progression|7
6145099|NCT01069627|9779668|FG000|Overall Study|Adverse Event|12
6145100|NCT01069627|9779668|FG000|Overall Study|Protocol Violation|1
6145101|NCT01069705|9779672|FG000|Overall Study|Adverse Event|1
6145102|NCT01069705|9779672|FG000|Overall Study|Withdrawal by Subject|2
6145103|NCT01069900|9779678|FG000|Overall Study|Technical problems|0
6145104|NCT01069900|9779679|FG001|Overall Study|Technical problems|1
6145105|NCT01069900|9779678|FG000|Overall Study|Lost to Follow-up|7
6145106|NCT01069900|9779679|FG001|Overall Study|Lost to Follow-up|1
6145107|NCT01069900|9779678|FG000|Overall Study|Withdrawal by Subject|6
6145108|NCT01069900|9779679|FG001|Overall Study|Withdrawal by Subject|1
6145109|NCT01069900|9779678|FG000|Overall Study|Protocol Violation|4
6145110|NCT01069900|9779679|FG001|Overall Study|Protocol Violation|1
6145111|NCT01069900|9779678|FG000|Overall Study|Insufficient Therapeutic effect|1
6145112|NCT01069900|9779679|FG001|Overall Study|Insufficient Therapeutic effect|0
6145113|NCT01069939|9779687|FG000|Randomised and Included in the Analyses|Adverse Event|17
6145114|NCT01069939|9779688|FG001|Randomised and Included in the Analyses|Adverse Event|22
6145115|NCT01069939|9779687|FG000|Randomised and Included in the Analyses|Withdrawal by Subject|15
6145116|NCT01069939|9779688|FG001|Randomised and Included in the Analyses|Withdrawal by Subject|12
6145117|NCT01069939|9779687|FG000|Randomised and Included in the Analyses|Lost to Follow-up|1
6145118|NCT01069939|9779688|FG001|Randomised and Included in the Analyses|Lost to Follow-up|1
6145119|NCT01069939|9779687|FG000|Randomised and Included in the Analyses|Protocol Violation|0
6145120|NCT01069939|9779688|FG001|Randomised and Included in the Analyses|Protocol Violation|1
6145121|NCT01069939|9779687|FG000|Randomised and Included in the Analyses|Lack of Efficacy|0
6145122|NCT01069939|9779688|FG001|Randomised and Included in the Analyses|Lack of Efficacy|1
6145123|NCT01069939|9779687|FG000|Randomised and Included in the Analyses|Study-specific withdrawal criteria|7
6145124|NCT01069939|9779688|FG001|Randomised and Included in the Analyses|Study-specific withdrawal criteria|33
6145125|NCT01069939|9779687|FG000|Randomised and Included in the Analyses|Eligibility criteria not fulfilled|4
6145126|NCT01069939|9779688|FG001|Randomised and Included in the Analyses|Eligibility criteria not fulfilled|3
6145127|NCT01069939|9779687|FG000|Randomised and Included in the Analyses|Use of prohibited concomitant drug|4
6145128|NCT01069939|9779688|FG001|Randomised and Included in the Analyses|Use of prohibited concomitant drug|2
6145129|NCT01069939|9779687|FG000|Randomised and Included in the Analyses|Physician Decision|0
6145130|NCT01069939|9779688|FG001|Randomised and Included in the Analyses|Physician Decision|2
6145131|NCT01069939|9779687|FG000|Randomised and Included in the Analyses|Removal|1
6145132|NCT01069939|9779688|FG001|Randomised and Included in the Analyses|Removal|0
6145133|NCT01070043|9779696|FG000|Run-In Phase|Did not Meet Inclusion Criteria|18
6145134|NCT01070043|9779697|FG001|Run-In Phase|Did not Meet Inclusion Criteria|0
6145135|NCT01070043|9779698|FG002|Run-In Phase|Did not Meet Inclusion Criteria|0
6145136|NCT01070043|9779696|FG000|Double-Blind Treatment|Adverse Event|0
6145137|NCT01070043|9779697|FG001|Double-Blind Treatment|Adverse Event|0
6145138|NCT01070043|9779698|FG002|Double-Blind Treatment|Adverse Event|2
6145139|NCT01070303|9779727|FG000|Overall Study|Adverse Event|39
6145140|NCT01070303|9779727|FG000|Overall Study|Withdrawal by Subject|20
6145141|NCT01070303|9779727|FG000|Overall Study|Lost to Follow-up|9
6145142|NCT01070303|9779727|FG000|Overall Study|Protocol Violation|0
6145143|NCT01070303|9779727|FG000|Overall Study|Lack of Efficacy|2
6145144|NCT01070303|9779727|FG000|Overall Study|Administrative Reason|1
6145145|NCT01070303|9779727|FG000|Overall Study|Other|18
6145146|NCT01070316|9779737|FG000|Extension Phase|Lack of Efficacy|3
6145147|NCT01070316|9779737|FG000|Extension Phase|Withdrawal by Subject|1
6145148|NCT01070329|9779743|FG000|Overall Study|Adverse Event|13
6145149|NCT01070329|9779744|FG001|Overall Study|Adverse Event|10
6145150|NCT01070329|9779743|FG000|Overall Study|Lost to Follow-up|22
6145151|NCT01070329|9779744|FG001|Overall Study|Lost to Follow-up|12
6145152|NCT01070329|9779743|FG000|Overall Study|Withdrawal by Subject|9
6145153|NCT01070329|9779744|FG001|Overall Study|Withdrawal by Subject|11
6145154|NCT01070329|9779743|FG000|Overall Study|Protocol Violation|3
6145155|NCT01070329|9779744|FG001|Overall Study|Protocol Violation|8
6145156|NCT01070329|9779743|FG000|Overall Study|Lack of Efficacy|2
6145157|NCT01070329|9779744|FG001|Overall Study|Lack of Efficacy|6
6145158|NCT01070329|9779743|FG000|Overall Study|Physician Decision|2
6145159|NCT01070329|9779744|FG001|Overall Study|Physician Decision|1
6145160|NCT01070329|9779743|FG000|Overall Study|Entry Criteria Not Met|1
6145161|NCT01070329|9779744|FG001|Overall Study|Entry Criteria Not Met|0
6145162|NCT01070329|9779743|FG000|Overall Study|Sponsor Decision|0
6145163|NCT01070329|9779744|FG001|Overall Study|Sponsor Decision|1
6145164|NCT01070381|9779750|FG000|Period 2, 1 Week of Wear|Handling|0
6145165|NCT01070381|9779751|FG001|Period 2, 1 Week of Wear|Handling|1
6145166|NCT01070381|9779750|FG000|Period 2, 1 Week of Wear|Unacceptable Vision|1
6145167|NCT01070381|9779751|FG001|Period 2, 1 Week of Wear|Unacceptable Vision|0
6145168|NCT01070394|9779757|FG000|Overall Study|Adverse Event|6
6145169|NCT01070394|9779757|FG000|Overall Study|Withdrawal by Subject|1
6145170|NCT01070550|9779769|FG000|Overall Study|Adverse Event|43
6145171|NCT01070550|9779770|FG001|Overall Study|Adverse Event|1
6145172|NCT01070550|9779771|FG002|Overall Study|Adverse Event|3
6145173|NCT01070550|9779772|FG003|Overall Study|Adverse Event|0
6145174|NCT01070550|9779773|FG004|Overall Study|Adverse Event|0
6145175|NCT01070550|9779774|FG005|Overall Study|Adverse Event|0
6145176|NCT01070550|9779769|FG000|Overall Study|Death|20
6145177|NCT01070550|9779770|FG001|Overall Study|Death|4
6145178|NCT01070550|9779771|FG002|Overall Study|Death|3
6145179|NCT01070550|9779772|FG003|Overall Study|Death|0
6145180|NCT01070550|9779773|FG004|Overall Study|Death|0
6145181|NCT01070550|9779774|FG005|Overall Study|Death|0
6145182|NCT01070550|9779769|FG000|Overall Study|Not meeting inclusion/exclusion criteria|2
6145183|NCT01070550|9779770|FG001|Overall Study|Not meeting inclusion/exclusion criteria|1
6145184|NCT01070550|9779771|FG002|Overall Study|Not meeting inclusion/exclusion criteria|1
6145185|NCT01070550|9779772|FG003|Overall Study|Not meeting inclusion/exclusion criteria|0
6145186|NCT01070550|9779773|FG004|Overall Study|Not meeting inclusion/exclusion criteria|0
6145187|NCT01070550|9779774|FG005|Overall Study|Not meeting inclusion/exclusion criteria|0
6145188|NCT01070550|9779769|FG000|Overall Study|Early termination|3
6145189|NCT01070550|9779770|FG001|Overall Study|Early termination|0
6145190|NCT01070550|9779771|FG002|Overall Study|Early termination|0
6145191|NCT01070550|9779772|FG003|Overall Study|Early termination|0
6145192|NCT01070550|9779773|FG004|Overall Study|Early termination|0
6145193|NCT01070550|9779774|FG005|Overall Study|Early termination|0
6145194|NCT01070550|9779769|FG000|Overall Study|Failed to return|450
6145195|NCT01070550|9779770|FG001|Overall Study|Failed to return|33
6145196|NCT01070550|9779771|FG002|Overall Study|Failed to return|144
6145197|NCT01070550|9779772|FG003|Overall Study|Failed to return|40
6145198|NCT01070550|9779773|FG004|Overall Study|Failed to return|1
6145199|NCT01070550|9779774|FG005|Overall Study|Failed to return|2
6145200|NCT01070550|9779769|FG000|Overall Study|Incomplete treatment|2
6145201|NCT01070550|9779770|FG001|Overall Study|Incomplete treatment|0
6145202|NCT01070550|9779771|FG002|Overall Study|Incomplete treatment|0
6145203|NCT01070550|9779772|FG003|Overall Study|Incomplete treatment|0
6145204|NCT01070550|9779773|FG004|Overall Study|Incomplete treatment|0
6145205|NCT01070550|9779774|FG005|Overall Study|Incomplete treatment|0
6145206|NCT01070550|9779769|FG000|Overall Study|Lab test not done|22
6145207|NCT01070550|9779770|FG001|Overall Study|Lab test not done|3
6145208|NCT01070550|9779771|FG002|Overall Study|Lab test not done|4
6145209|NCT01070550|9779772|FG003|Overall Study|Lab test not done|1
6145210|NCT01070550|9779773|FG004|Overall Study|Lab test not done|0
6145211|NCT01070550|9779774|FG005|Overall Study|Lab test not done|1
6145212|NCT01070550|9779769|FG000|Overall Study|Lack of Efficacy|65
6145213|NCT01070550|9779770|FG001|Overall Study|Lack of Efficacy|1
6145214|NCT01070550|9779771|FG002|Overall Study|Lack of Efficacy|5
6145215|NCT01070550|9779772|FG003|Overall Study|Lack of Efficacy|5
6145216|NCT01070550|9779773|FG004|Overall Study|Lack of Efficacy|0
6145217|NCT01070550|9779774|FG005|Overall Study|Lack of Efficacy|1
6145218|NCT01070550|9779769|FG000|Overall Study|Miscellaneous|12
6145219|NCT01070550|9779770|FG001|Overall Study|Miscellaneous|2
6145220|NCT01070550|9779771|FG002|Overall Study|Miscellaneous|3
6145221|NCT01070550|9779772|FG003|Overall Study|Miscellaneous|1
6145222|NCT01070550|9779773|FG004|Overall Study|Miscellaneous|0
6145223|NCT01070550|9779774|FG005|Overall Study|Miscellaneous|0
6145224|NCT01070550|9779769|FG000|Overall Study|New treatment started|3
6145225|NCT01070550|9779770|FG001|Overall Study|New treatment started|1
6145226|NCT01070550|9779771|FG002|Overall Study|New treatment started|0
6145227|NCT01070550|9779772|FG003|Overall Study|New treatment started|2
6145228|NCT01070550|9779773|FG004|Overall Study|New treatment started|0
6145229|NCT01070550|9779774|FG005|Overall Study|New treatment started|0
6145230|NCT01070550|9779769|FG000|Overall Study|Non-responders|493
6145231|NCT01070550|9779770|FG001|Overall Study|Non-responders|4
6145232|NCT01070550|9779771|FG002|Overall Study|Non-responders|21
6145233|NCT01070550|9779772|FG003|Overall Study|Non-responders|20
6145234|NCT01070550|9779773|FG004|Overall Study|Non-responders|0
6145235|NCT01070550|9779774|FG005|Overall Study|Non-responders|2
6145236|NCT01070550|9779769|FG000|Overall Study|Not categorized|33
6145237|NCT01070550|9779770|FG001|Overall Study|Not categorized|2
6145238|NCT01070550|9779771|FG002|Overall Study|Not categorized|6
6145239|NCT01070550|9779772|FG003|Overall Study|Not categorized|1
6145240|NCT01070550|9779773|FG004|Overall Study|Not categorized|0
6145241|NCT01070550|9779774|FG005|Overall Study|Not categorized|1
6145242|NCT01070550|9779769|FG000|Overall Study|Protocol Violation|15
6145243|NCT01070550|9779770|FG001|Overall Study|Protocol Violation|1
6145244|NCT01070550|9779771|FG002|Overall Study|Protocol Violation|1
6145245|NCT01070550|9779772|FG003|Overall Study|Protocol Violation|1
6145246|NCT01070550|9779773|FG004|Overall Study|Protocol Violation|0
6145247|NCT01070550|9779774|FG005|Overall Study|Protocol Violation|0
6145248|NCT01070550|9779769|FG000|Overall Study|Relapse|44
6145249|NCT01070550|9779770|FG001|Overall Study|Relapse|5
6145250|NCT01070550|9779771|FG002|Overall Study|Relapse|14
6145251|NCT01070550|9779772|FG003|Overall Study|Relapse|4
6145252|NCT01070550|9779773|FG004|Overall Study|Relapse|0
6145253|NCT01070550|9779774|FG005|Overall Study|Relapse|0
6145254|NCT01070550|9779769|FG000|Overall Study|Result not available|3
6145255|NCT01070550|9779770|FG001|Overall Study|Result not available|1
6145256|NCT01070550|9779771|FG002|Overall Study|Result not available|3
6145257|NCT01070550|9779772|FG003|Overall Study|Result not available|0
6145258|NCT01070550|9779773|FG004|Overall Study|Result not available|0
6145259|NCT01070550|9779774|FG005|Overall Study|Result not available|0
6145260|NCT01070550|9779769|FG000|Overall Study|Screen failure|1
6145261|NCT01070550|9779770|FG001|Overall Study|Screen failure|0
6145262|NCT01070550|9779771|FG002|Overall Study|Screen failure|0
6145263|NCT01070550|9779772|FG003|Overall Study|Screen failure|0
6145264|NCT01070550|9779773|FG004|Overall Study|Screen failure|0
6145265|NCT01070550|9779774|FG005|Overall Study|Screen failure|0
6145266|NCT01070550|9779769|FG000|Overall Study|Sponsor decision|1
6145267|NCT01070550|9779770|FG001|Overall Study|Sponsor decision|0
6145268|NCT01070550|9779771|FG002|Overall Study|Sponsor decision|0
6145269|NCT01070550|9779772|FG003|Overall Study|Sponsor decision|0
6145270|NCT01070550|9779773|FG004|Overall Study|Sponsor decision|0
6145271|NCT01070550|9779774|FG005|Overall Study|Sponsor decision|0
6145272|NCT01070550|9779769|FG000|Overall Study|Treatment duration shortened|1
6145273|NCT01070550|9779770|FG001|Overall Study|Treatment duration shortened|0
6145274|NCT01070550|9779771|FG002|Overall Study|Treatment duration shortened|0
6145275|NCT01070550|9779772|FG003|Overall Study|Treatment duration shortened|0
6145276|NCT01070550|9779773|FG004|Overall Study|Treatment duration shortened|0
6145277|NCT01070550|9779774|FG005|Overall Study|Treatment duration shortened|0
6145278|NCT01070550|9779769|FG000|Overall Study|Treatment interrupted|7
6145279|NCT01070550|9779770|FG001|Overall Study|Treatment interrupted|0
6145280|NCT01070550|9779771|FG002|Overall Study|Treatment interrupted|1
6145281|NCT01070550|9779772|FG003|Overall Study|Treatment interrupted|1
6145282|NCT01070550|9779773|FG004|Overall Study|Treatment interrupted|0
6145283|NCT01070550|9779774|FG005|Overall Study|Treatment interrupted|0
6145284|NCT01070550|9779769|FG000|Overall Study|Treatment not started|14
6145285|NCT01070550|9779770|FG001|Overall Study|Treatment not started|2
6145286|NCT01070550|9779771|FG002|Overall Study|Treatment not started|4
6145287|NCT01070550|9779772|FG003|Overall Study|Treatment not started|0
6145288|NCT01070550|9779773|FG004|Overall Study|Treatment not started|0
6145289|NCT01070550|9779774|FG005|Overall Study|Treatment not started|0
6145290|NCT01070550|9779769|FG000|Overall Study|Treatment restarted|0
6145291|NCT01070550|9779770|FG001|Overall Study|Treatment restarted|1
6145292|NCT01070550|9779771|FG002|Overall Study|Treatment restarted|0
6145293|NCT01070550|9779772|FG003|Overall Study|Treatment restarted|0
6145294|NCT01070550|9779773|FG004|Overall Study|Treatment restarted|0
6145295|NCT01070550|9779774|FG005|Overall Study|Treatment restarted|0
6145296|NCT01070550|9779769|FG000|Overall Study|Treatment stopped|3
6145297|NCT01070550|9779770|FG001|Overall Study|Treatment stopped|0
6145298|NCT01070550|9779771|FG002|Overall Study|Treatment stopped|0
6145299|NCT01070550|9779772|FG003|Overall Study|Treatment stopped|0
6145300|NCT01070550|9779773|FG004|Overall Study|Treatment stopped|0
6145301|NCT01070550|9779774|FG005|Overall Study|Treatment stopped|0
6145302|NCT01070550|9779769|FG000|Overall Study|Treatment unavailable|1
6145303|NCT01070550|9779770|FG001|Overall Study|Treatment unavailable|0
6145304|NCT01070550|9779771|FG002|Overall Study|Treatment unavailable|0
6145305|NCT01070550|9779772|FG003|Overall Study|Treatment unavailable|0
6145306|NCT01070550|9779773|FG004|Overall Study|Treatment unavailable|0
6145307|NCT01070550|9779774|FG005|Overall Study|Treatment unavailable|0
6145308|NCT01070550|9779769|FG000|Overall Study|Treatment was stopped early|7
6145309|NCT01070550|9779770|FG001|Overall Study|Treatment was stopped early|0
6145310|NCT01070550|9779771|FG002|Overall Study|Treatment was stopped early|0
6145311|NCT01070550|9779772|FG003|Overall Study|Treatment was stopped early|0
6145312|NCT01070550|9779773|FG004|Overall Study|Treatment was stopped early|0
6145313|NCT01070550|9779774|FG005|Overall Study|Treatment was stopped early|0
6145314|NCT01070550|9779769|FG000|Overall Study|Other|5
6145315|NCT01070550|9779770|FG001|Overall Study|Other|0
6145316|NCT01070550|9779771|FG002|Overall Study|Other|0
6145317|NCT01070550|9779772|FG003|Overall Study|Other|1
6145318|NCT01070550|9779773|FG004|Overall Study|Other|0
6145319|NCT01070550|9779774|FG005|Overall Study|Other|0
6145320|NCT01070550|9779769|FG000|Overall Study|Withdrawal by Subject|35
6145321|NCT01070550|9779770|FG001|Overall Study|Withdrawal by Subject|0
6145322|NCT01070550|9779771|FG002|Overall Study|Withdrawal by Subject|3
6145323|NCT01070550|9779772|FG003|Overall Study|Withdrawal by Subject|0
6145324|NCT01070550|9779773|FG004|Overall Study|Withdrawal by Subject|0
6145325|NCT01070550|9779774|FG005|Overall Study|Withdrawal by Subject|0
6145326|NCT01070771|9779798|FG000|Overall Study|Adverse Event|2
6145327|NCT01070771|9779798|FG000|Overall Study|Protocol Violation|1
6145328|NCT01070784|9779805|FG000|Overall Study|Withdrawal by Subject|6
6145329|NCT01070784|9779806|FG001|Overall Study|Withdrawal by Subject|9
6145330|NCT01070784|9779805|FG000|Overall Study|Adverse Event|14
6145331|NCT01070784|9779806|FG001|Overall Study|Adverse Event|9
6145332|NCT01070888|9779825|FG000|First Intervention (14 Days)|Adverse Event|0
6145333|NCT01070888|9779826|FG001|First Intervention (14 Days)|Adverse Event|1
6145334|NCT01070888|9779825|FG000|First Intervention (14 Days)|Lost to Follow-up|0
6145335|NCT01070888|9779826|FG001|First Intervention (14 Days)|Lost to Follow-up|1
6145336|NCT01070888|9779825|FG000|Washout (14 Days)|Physician Decision|1
6145337|NCT01070888|9779826|FG001|Washout (14 Days)|Physician Decision|0
6145338|NCT01070979|9779835|FG000|Overall Study|Adverse Event|2
6145339|NCT01070979|9779836|FG001|Overall Study|Adverse Event|3
6145340|NCT01070979|9779837|FG002|Overall Study|Adverse Event|3
6145341|NCT01070979|9779835|FG000|Overall Study|Lost to Follow-up|2
6145342|NCT01070979|9779836|FG001|Overall Study|Lost to Follow-up|1
6145343|NCT01070979|9779837|FG002|Overall Study|Lost to Follow-up|1
6145344|NCT01070979|9779835|FG000|Overall Study|Protocol Violation|0
6145345|NCT01070979|9779836|FG001|Overall Study|Protocol Violation|2
6145346|NCT01070979|9779837|FG002|Overall Study|Protocol Violation|6
6145347|NCT01070979|9779835|FG000|Overall Study|Surgery, moving, personal, abn. labs|4
6145348|NCT01070979|9779836|FG001|Overall Study|Surgery, moving, personal, abn. labs|4
6145349|NCT01070979|9779837|FG002|Overall Study|Surgery, moving, personal, abn. labs|2
6145350|NCT01070979|9779835|FG000|Overall Study|Withdrawal by Subject|3
6145351|NCT01070979|9779836|FG001|Overall Study|Withdrawal by Subject|1
6145352|NCT01070979|9779837|FG002|Overall Study|Withdrawal by Subject|1
6145353|NCT01070979|9779835|FG000|Overall Study|No study drug taken|0
6145354|NCT01070979|9779836|FG001|Overall Study|No study drug taken|1
6145355|NCT01070979|9779837|FG002|Overall Study|No study drug taken|0
6145356|NCT01071070|9779859|FG000|Overall Study|Adverse Event|0
6145357|NCT01071070|9779860|FG001|Overall Study|Adverse Event|3
6145358|NCT01071070|9779859|FG000|Overall Study|Withdrawal by Subject|1
6145359|NCT01071070|9779860|FG001|Overall Study|Withdrawal by Subject|0
6145360|NCT01071070|9779859|FG000|Overall Study|Missed 3 consecutive doses of study drug|2
6145361|NCT01071070|9779860|FG001|Overall Study|Missed 3 consecutive doses of study drug|0
6145362|NCT01071070|9779859|FG000|Overall Study|Hypercalcemia|1
6145363|NCT01071070|9779860|FG001|Overall Study|Hypercalcemia|0
6145364|NCT01071083|9779871|FG000|Overall Study|Adverse Event|1
6145365|NCT01071083|9779872|FG001|Overall Study|Adverse Event|0
6145366|NCT01071083|9779873|FG002|Overall Study|Adverse Event|1
6145367|NCT01071083|9779874|FG003|Overall Study|Adverse Event|0
6145368|NCT01071083|9779875|FG004|Overall Study|Adverse Event|1
6145369|NCT01071083|9779871|FG000|Overall Study|Withdrawal by Subject|3
6145370|NCT01071083|9779872|FG001|Overall Study|Withdrawal by Subject|0
6145371|NCT01071083|9779873|FG002|Overall Study|Withdrawal by Subject|2
6145372|NCT01071083|9779874|FG003|Overall Study|Withdrawal by Subject|0
6145373|NCT01071083|9779875|FG004|Overall Study|Withdrawal by Subject|3
6145374|NCT01071083|9779871|FG000|Overall Study|Physician Decision|1
6145375|NCT01071083|9779872|FG001|Overall Study|Physician Decision|0
6145376|NCT01071083|9779873|FG002|Overall Study|Physician Decision|0
6145377|NCT01071083|9779874|FG003|Overall Study|Physician Decision|1
6145378|NCT01071083|9779875|FG004|Overall Study|Physician Decision|1
6145379|NCT01071083|9779871|FG000|Overall Study|Early Rescue|1
6145380|NCT01071083|9779872|FG001|Overall Study|Early Rescue|0
6145381|NCT01071083|9779873|FG002|Overall Study|Early Rescue|0
6145382|NCT01071083|9779874|FG003|Overall Study|Early Rescue|0
6145383|NCT01071083|9779875|FG004|Overall Study|Early Rescue|1
6145384|NCT01071083|9779871|FG000|Overall Study|Subject Moved|0
6145385|NCT01071083|9779872|FG001|Overall Study|Subject Moved|1
6145386|NCT01071083|9779873|FG002|Overall Study|Subject Moved|0
6145387|NCT01071083|9779874|FG003|Overall Study|Subject Moved|0
6145388|NCT01071083|9779875|FG004|Overall Study|Subject Moved|0
6145389|NCT01071083|9779871|FG000|Overall Study|Images Not Usable (Motion)|0
6145390|NCT01071083|9779872|FG001|Overall Study|Images Not Usable (Motion)|1
6145391|NCT01071083|9779873|FG002|Overall Study|Images Not Usable (Motion)|0
6145392|NCT01071083|9779874|FG003|Overall Study|Images Not Usable (Motion)|0
6145393|NCT01071083|9779875|FG004|Overall Study|Images Not Usable (Motion)|0
6145394|NCT01071083|9779871|FG000|Overall Study|Did Not Meet Eligibility Criteria|0
6145395|NCT01071083|9779872|FG001|Overall Study|Did Not Meet Eligibility Criteria|0
6145396|NCT01071083|9779873|FG002|Overall Study|Did Not Meet Eligibility Criteria|1
6145397|NCT01071083|9779874|FG003|Overall Study|Did Not Meet Eligibility Criteria|1
6145398|NCT01071083|9779875|FG004|Overall Study|Did Not Meet Eligibility Criteria|1
6145399|NCT01071083|9779871|FG000|Overall Study|Did Not Want Per Protocol Treatment|0
6145400|NCT01071083|9779872|FG001|Overall Study|Did Not Want Per Protocol Treatment|0
6145401|NCT01071083|9779873|FG002|Overall Study|Did Not Want Per Protocol Treatment|1
6145402|NCT01071083|9779874|FG003|Overall Study|Did Not Want Per Protocol Treatment|0
6145403|NCT01071083|9779875|FG004|Overall Study|Did Not Want Per Protocol Treatment|1
6145404|NCT01071083|9779871|FG000|Overall Study|Subject Refused to Continue|1
6145405|NCT01071083|9779872|FG001|Overall Study|Subject Refused to Continue|0
6145406|NCT01071083|9779873|FG002|Overall Study|Subject Refused to Continue|0
6145407|NCT01071083|9779874|FG003|Overall Study|Subject Refused to Continue|0
6145408|NCT01071083|9779875|FG004|Overall Study|Subject Refused to Continue|0
6145409|NCT01071096|9779887|FG000|First Intervention (90 Days)|Lost to Follow-up|1
6145410|NCT01071096|9779888|FG001|First Intervention (90 Days)|Lost to Follow-up|0
6145411|NCT01071200|9779907|FG000|Overall Study|Lack of ovarian response|1
6145412|NCT01071200|9779908|FG001|Overall Study|Lack of ovarian response|1
6145413|NCT01071200|9779907|FG000|Overall Study|No fertilization|4
6145414|NCT01071200|9779908|FG001|Overall Study|No fertilization|0
6145415|NCT01071200|9779907|FG000|Overall Study|No oocytes retrieved|1
6145416|NCT01071200|9779908|FG001|Overall Study|No oocytes retrieved|1
6145417|NCT01071200|9779907|FG000|Overall Study|Ovarian Hyper Stimulation Syndrome|1
6145418|NCT01071200|9779908|FG001|Overall Study|Ovarian Hyper Stimulation Syndrome|0
6145419|NCT01071200|9779907|FG000|Overall Study|No viable embryos|0
6145420|NCT01071200|9779908|FG001|Overall Study|No viable embryos|1
6145421|NCT01071252|9779919|FG000|Overall Study|unsatisfactory therapeutic effect|4
6145422|NCT01071252|9779920|FG001|Overall Study|unsatisfactory therapeutic effect|6
6145423|NCT01071252|9779921|FG002|Overall Study|unsatisfactory therapeutic effect|2
6145424|NCT01071252|9779922|FG003|Overall Study|unsatisfactory therapeutic effect|0
6145425|NCT01071252|9779923|FG004|Overall Study|unsatisfactory therapeutic effect|6
6145426|NCT01071252|9779919|FG000|Overall Study|Withdrawal by Subject|8
6145427|NCT01071252|9779920|FG001|Overall Study|Withdrawal by Subject|2
6145428|NCT01071252|9779921|FG002|Overall Study|Withdrawal by Subject|1
6145429|NCT01071252|9779922|FG003|Overall Study|Withdrawal by Subject|2
6145430|NCT01071252|9779923|FG004|Overall Study|Withdrawal by Subject|3
6145431|NCT01071252|9779919|FG000|Overall Study|administrative problems|1
6145432|NCT01071252|9779920|FG001|Overall Study|administrative problems|1
6145433|NCT01071252|9779921|FG002|Overall Study|administrative problems|0
6145434|NCT01071252|9779922|FG003|Overall Study|administrative problems|2
6145435|NCT01071252|9779923|FG004|Overall Study|administrative problems|1
6145436|NCT01071252|9779919|FG000|Overall Study|Lost to Follow-up|1
6145437|NCT01071252|9779920|FG001|Overall Study|Lost to Follow-up|0
6145438|NCT01071252|9779921|FG002|Overall Study|Lost to Follow-up|1
6145439|NCT01071252|9779922|FG003|Overall Study|Lost to Follow-up|2
6145440|NCT01071252|9779923|FG004|Overall Study|Lost to Follow-up|0
6145441|NCT01071252|9779919|FG000|Overall Study|Adverse Event|1
6145442|NCT01071252|9779920|FG001|Overall Study|Adverse Event|1
6145443|NCT01071252|9779921|FG002|Overall Study|Adverse Event|0
6145444|NCT01071252|9779922|FG003|Overall Study|Adverse Event|1
6145445|NCT01071252|9779923|FG004|Overall Study|Adverse Event|0
6145446|NCT01071252|9779919|FG000|Overall Study|Death|0
6145447|NCT01071252|9779920|FG001|Overall Study|Death|0
6145448|NCT01071252|9779921|FG002|Overall Study|Death|0
6145449|NCT01071252|9779922|FG003|Overall Study|Death|0
6145450|NCT01071252|9779923|FG004|Overall Study|Death|1
6145451|NCT01071278|9779935|FG000|Overall Study|Premature Discontinuation|254
6145452|NCT01071278|9779935|FG000|Overall Study|Completion Status Unknown|459
6145453|NCT01071317|9779943|FG000|Overall Study|Lost to Follow-up|2
6145454|NCT01071317|9779944|FG001|Overall Study|Lost to Follow-up|2
6145455|NCT01071395|9779961|FG000|Overall Study|Withdrawal by Subject|2
6145456|NCT01071395|9779962|FG001|Overall Study|Withdrawal by Subject|1
6145457|NCT01071395|9779961|FG000|Overall Study|Adverse Event|3
6145458|NCT01071395|9779962|FG001|Overall Study|Adverse Event|1
6145459|NCT01071512|9779968|FG000|Overall Study|Adverse Event|1
6145460|NCT01071512|9779968|FG000|Overall Study|Development of antibodies to drug|2
6145461|NCT01071512|9779968|FG000|Overall Study|positive anti-JC virus antibody test|2
6145462|NCT01071798|9779976|FG000|Participants Who Received One Cycle|Lack of Efficacy|18
6145463|NCT01071798|9779976|FG000|Participants Who Received One Cycle|Lack of tolerability|14
6145464|NCT01071798|9779976|FG000|Participants Who Received One Cycle|Patient requirement|20
6145465|NCT01071798|9779976|FG000|Participants Who Received One Cycle|Death|5
6145466|NCT01071798|9779976|FG000|Participants Who Received One Cycle|Change of therapy|6
6145467|NCT01071798|9779976|FG000|Participants Who Received One Cycle|Severe concomitant disease|2
6145468|NCT01071798|9779976|FG000|Subpopulation Who Received Two Cycles|Remission|1
6145469|NCT01071798|9779976|FG000|Subpopulation Who Received Two Cycles|Lack of Efficacy|3
6145470|NCT01071798|9779976|FG000|Subpopulation Who Received Two Cycles|Lack of Tolerability|4
6145471|NCT01071798|9779976|FG000|Subpopulation Who Received Two Cycles|Patient Requirement|7
6145472|NCT01071915|9779990|FG000|Overall Study|Adverse Event|3
6145473|NCT01071915|9779990|FG000|Overall Study|Physician Decision|2
6145474|NCT01071915|9779990|FG000|Overall Study|Withdrawal by Subject|2
6145475|NCT01071915|9779990|FG000|Overall Study|Miscellaneous Reasons|2
6145476|NCT01071954|9779994|FG000|Overall Study|Noncompliance|4
6145477|NCT01071954|9779994|FG000|Overall Study|Adverse Event|1
6145478|NCT01071954|9779994|FG000|Overall Study|Withdrawal by Subject|11
6145479|NCT01071954|9779994|FG000|Overall Study|Requirement for Alternative Therapy|5
6145480|NCT01071954|9779994|FG000|Overall Study|Administrative Decision|5
6145481|NCT01071954|9779994|FG000|Overall Study|Protocol Specified Criteria|1
6145482|NCT01072149|9780038|FG000|Treatment Period 1 (28 Days)|Withdrawal by Subject|0
6145483|NCT01072149|9780039|FG001|Treatment Period 1 (28 Days)|Withdrawal by Subject|0
6145484|NCT01072149|9780040|FG002|Treatment Period 1 (28 Days)|Withdrawal by Subject|1
6145485|NCT01072149|9780041|FG003|Treatment Period 1 (28 Days)|Withdrawal by Subject|0
6145486|NCT01072149|9780042|FG004|Treatment Period 1 (28 Days)|Withdrawal by Subject|0
6145487|NCT01072149|9780043|FG005|Treatment Period 1 (28 Days)|Withdrawal by Subject|0
6145488|NCT01072149|9780044|FG006|Treatment Period 1 (28 Days)|Withdrawal by Subject|0
6145489|NCT01072149|9780045|FG007|Treatment Period 1 (28 Days)|Withdrawal by Subject|0
6145490|NCT01072149|9780046|FG008|Treatment Period 1 (28 Days)|Withdrawal by Subject|0
6145491|NCT01072149|9780047|FG009|Treatment Period 1 (28 Days)|Withdrawal by Subject|0
6145492|NCT01072149|9780048|FG010|Treatment Period 1 (28 Days)|Withdrawal by Subject|0
6145493|NCT01072149|9780049|FG011|Treatment Period 1 (28 Days)|Withdrawal by Subject|0
6145494|NCT01072149|9780050|FG012|Treatment Period 1 (28 Days)|Withdrawal by Subject|0
6145495|NCT01072149|9780051|FG013|Treatment Period 1 (28 Days)|Withdrawal by Subject|0
6145496|NCT01072149|9780052|FG014|Treatment Period 1 (28 Days)|Withdrawal by Subject|0
6145497|NCT01072149|9780053|FG015|Treatment Period 1 (28 Days)|Withdrawal by Subject|0
6145498|NCT01072149|9780054|FG016|Treatment Period 1 (28 Days)|Withdrawal by Subject|0
6145499|NCT01072149|9780055|FG017|Treatment Period 1 (28 Days)|Withdrawal by Subject|0
6145500|NCT01072149|9780038|FG000|Treatment Period 1 (28 Days)|Protocol Violation|0
6145501|NCT01072149|9780039|FG001|Treatment Period 1 (28 Days)|Protocol Violation|0
6145502|NCT01072149|9780040|FG002|Treatment Period 1 (28 Days)|Protocol Violation|0
6145503|NCT01072149|9780041|FG003|Treatment Period 1 (28 Days)|Protocol Violation|0
6145504|NCT01072149|9780042|FG004|Treatment Period 1 (28 Days)|Protocol Violation|0
6145505|NCT01072149|9780043|FG005|Treatment Period 1 (28 Days)|Protocol Violation|0
6145506|NCT01072149|9780044|FG006|Treatment Period 1 (28 Days)|Protocol Violation|0
6145507|NCT01072149|9780045|FG007|Treatment Period 1 (28 Days)|Protocol Violation|0
6145508|NCT01072149|9780046|FG008|Treatment Period 1 (28 Days)|Protocol Violation|0
6145509|NCT01072149|9780047|FG009|Treatment Period 1 (28 Days)|Protocol Violation|0
6145510|NCT01072149|9780048|FG010|Treatment Period 1 (28 Days)|Protocol Violation|0
6145511|NCT01072149|9780049|FG011|Treatment Period 1 (28 Days)|Protocol Violation|0
6145512|NCT01072149|9780050|FG012|Treatment Period 1 (28 Days)|Protocol Violation|0
6145513|NCT01072149|9780051|FG013|Treatment Period 1 (28 Days)|Protocol Violation|0
6145514|NCT01072149|9780052|FG014|Treatment Period 1 (28 Days)|Protocol Violation|0
6145515|NCT01072149|9780053|FG015|Treatment Period 1 (28 Days)|Protocol Violation|0
6145516|NCT01072149|9780054|FG016|Treatment Period 1 (28 Days)|Protocol Violation|0
6145517|NCT01072149|9780055|FG017|Treatment Period 1 (28 Days)|Protocol Violation|1
6145518|NCT01072149|9780038|FG000|Treatment Period 1 (28 Days)|Lost to Follow-up|0
6145519|NCT01072149|9780039|FG001|Treatment Period 1 (28 Days)|Lost to Follow-up|0
6145520|NCT01072149|9780040|FG002|Treatment Period 1 (28 Days)|Lost to Follow-up|0
6145521|NCT01072149|9780041|FG003|Treatment Period 1 (28 Days)|Lost to Follow-up|0
6145522|NCT01072149|9780042|FG004|Treatment Period 1 (28 Days)|Lost to Follow-up|0
6145523|NCT01072149|9780043|FG005|Treatment Period 1 (28 Days)|Lost to Follow-up|0
6145524|NCT01072149|9780044|FG006|Treatment Period 1 (28 Days)|Lost to Follow-up|0
6145525|NCT01072149|9780045|FG007|Treatment Period 1 (28 Days)|Lost to Follow-up|0
6145526|NCT01072149|9780046|FG008|Treatment Period 1 (28 Days)|Lost to Follow-up|0
6145527|NCT01072149|9780047|FG009|Treatment Period 1 (28 Days)|Lost to Follow-up|0
6145528|NCT01072149|9780048|FG010|Treatment Period 1 (28 Days)|Lost to Follow-up|1
6145529|NCT01072149|9780049|FG011|Treatment Period 1 (28 Days)|Lost to Follow-up|0
6145530|NCT01072149|9780050|FG012|Treatment Period 1 (28 Days)|Lost to Follow-up|0
6145531|NCT01072149|9780051|FG013|Treatment Period 1 (28 Days)|Lost to Follow-up|0
6145532|NCT01072149|9780052|FG014|Treatment Period 1 (28 Days)|Lost to Follow-up|0
6145533|NCT01072149|9780053|FG015|Treatment Period 1 (28 Days)|Lost to Follow-up|0
6145534|NCT01072149|9780054|FG016|Treatment Period 1 (28 Days)|Lost to Follow-up|0
6145535|NCT01072149|9780055|FG017|Treatment Period 1 (28 Days)|Lost to Follow-up|0
6145536|NCT01072149|9780038|FG000|Treatment Period 2 (28 Days)|Lost to Follow-up|0
6145537|NCT01072149|9780039|FG001|Treatment Period 2 (28 Days)|Lost to Follow-up|1
6145538|NCT01072149|9780040|FG002|Treatment Period 2 (28 Days)|Lost to Follow-up|0
6145539|NCT01072149|9780041|FG003|Treatment Period 2 (28 Days)|Lost to Follow-up|0
6145540|NCT01072149|9780042|FG004|Treatment Period 2 (28 Days)|Lost to Follow-up|0
6145541|NCT01072149|9780043|FG005|Treatment Period 2 (28 Days)|Lost to Follow-up|0
6145542|NCT01072149|9780044|FG006|Treatment Period 2 (28 Days)|Lost to Follow-up|0
6145543|NCT01072149|9780045|FG007|Treatment Period 2 (28 Days)|Lost to Follow-up|0
6145544|NCT01072149|9780046|FG008|Treatment Period 2 (28 Days)|Lost to Follow-up|0
6145545|NCT01072149|9780047|FG009|Treatment Period 2 (28 Days)|Lost to Follow-up|0
6145546|NCT01072149|9780048|FG010|Treatment Period 2 (28 Days)|Lost to Follow-up|0
6145547|NCT01072149|9780049|FG011|Treatment Period 2 (28 Days)|Lost to Follow-up|0
6145548|NCT01072149|9780050|FG012|Treatment Period 2 (28 Days)|Lost to Follow-up|0
6145549|NCT01072149|9780051|FG013|Treatment Period 2 (28 Days)|Lost to Follow-up|0
6145550|NCT01072149|9780052|FG014|Treatment Period 2 (28 Days)|Lost to Follow-up|0
6145551|NCT01072149|9780053|FG015|Treatment Period 2 (28 Days)|Lost to Follow-up|0
6145552|NCT01072149|9780054|FG016|Treatment Period 2 (28 Days)|Lost to Follow-up|0
6145553|NCT01072149|9780055|FG017|Treatment Period 2 (28 Days)|Lost to Follow-up|0
6145554|NCT01072149|9780038|FG000|Treatment Period 2 (28 Days)|Withdrawal by Subject|0
6145555|NCT01072149|9780039|FG001|Treatment Period 2 (28 Days)|Withdrawal by Subject|0
6145556|NCT01072149|9780040|FG002|Treatment Period 2 (28 Days)|Withdrawal by Subject|1
6145557|NCT01072149|9780041|FG003|Treatment Period 2 (28 Days)|Withdrawal by Subject|0
6145558|NCT01072149|9780042|FG004|Treatment Period 2 (28 Days)|Withdrawal by Subject|0
6145559|NCT01072149|9780043|FG005|Treatment Period 2 (28 Days)|Withdrawal by Subject|0
6145560|NCT01072149|9780044|FG006|Treatment Period 2 (28 Days)|Withdrawal by Subject|0
6145561|NCT01072149|9780045|FG007|Treatment Period 2 (28 Days)|Withdrawal by Subject|0
6145562|NCT01072149|9780046|FG008|Treatment Period 2 (28 Days)|Withdrawal by Subject|0
6145563|NCT01072149|9780047|FG009|Treatment Period 2 (28 Days)|Withdrawal by Subject|0
6145564|NCT01072149|9780048|FG010|Treatment Period 2 (28 Days)|Withdrawal by Subject|0
6145565|NCT01072149|9780049|FG011|Treatment Period 2 (28 Days)|Withdrawal by Subject|0
6145566|NCT01072149|9780050|FG012|Treatment Period 2 (28 Days)|Withdrawal by Subject|0
6145567|NCT01072149|9780051|FG013|Treatment Period 2 (28 Days)|Withdrawal by Subject|0
6145568|NCT01072149|9780052|FG014|Treatment Period 2 (28 Days)|Withdrawal by Subject|0
6145569|NCT01072149|9780053|FG015|Treatment Period 2 (28 Days)|Withdrawal by Subject|0
6145570|NCT01072149|9780054|FG016|Treatment Period 2 (28 Days)|Withdrawal by Subject|0
6145571|NCT01072149|9780055|FG017|Treatment Period 2 (28 Days)|Withdrawal by Subject|0
6145572|NCT01072149|9780038|FG000|Treatment Period 2 (28 Days)|Physician Decision|0
6145573|NCT01072149|9780039|FG001|Treatment Period 2 (28 Days)|Physician Decision|0
6145574|NCT01072149|9780040|FG002|Treatment Period 2 (28 Days)|Physician Decision|0
6145575|NCT01072149|9780041|FG003|Treatment Period 2 (28 Days)|Physician Decision|0
6145576|NCT01072149|9780042|FG004|Treatment Period 2 (28 Days)|Physician Decision|0
6145577|NCT01072149|9780043|FG005|Treatment Period 2 (28 Days)|Physician Decision|0
6145578|NCT01072149|9780044|FG006|Treatment Period 2 (28 Days)|Physician Decision|0
6145579|NCT01072149|9780045|FG007|Treatment Period 2 (28 Days)|Physician Decision|1
6145580|NCT01072149|9780046|FG008|Treatment Period 2 (28 Days)|Physician Decision|0
6145581|NCT01072149|9780047|FG009|Treatment Period 2 (28 Days)|Physician Decision|0
6145582|NCT01072149|9780048|FG010|Treatment Period 2 (28 Days)|Physician Decision|0
6145583|NCT01072149|9780049|FG011|Treatment Period 2 (28 Days)|Physician Decision|0
6145584|NCT01072149|9780050|FG012|Treatment Period 2 (28 Days)|Physician Decision|0
6145585|NCT01072149|9780051|FG013|Treatment Period 2 (28 Days)|Physician Decision|0
6145586|NCT01072149|9780052|FG014|Treatment Period 2 (28 Days)|Physician Decision|0
6145587|NCT01072149|9780053|FG015|Treatment Period 2 (28 Days)|Physician Decision|0
6145588|NCT01072149|9780054|FG016|Treatment Period 2 (28 Days)|Physician Decision|0
6145589|NCT01072149|9780055|FG017|Treatment Period 2 (28 Days)|Physician Decision|0
6145590|NCT01072149|9780038|FG000|Washout Period 2 (14 Days)|Physician Decision|1
6145591|NCT01072149|9780039|FG001|Washout Period 2 (14 Days)|Physician Decision|0
6145592|NCT01072149|9780040|FG002|Washout Period 2 (14 Days)|Physician Decision|0
6145593|NCT01072149|9780041|FG003|Washout Period 2 (14 Days)|Physician Decision|0
6145594|NCT01072149|9780042|FG004|Washout Period 2 (14 Days)|Physician Decision|0
6145595|NCT01072149|9780043|FG005|Washout Period 2 (14 Days)|Physician Decision|0
6145596|NCT01072149|9780044|FG006|Washout Period 2 (14 Days)|Physician Decision|0
6145597|NCT01072149|9780045|FG007|Washout Period 2 (14 Days)|Physician Decision|0
6145598|NCT01072149|9780046|FG008|Washout Period 2 (14 Days)|Physician Decision|0
6145599|NCT01072149|9780047|FG009|Washout Period 2 (14 Days)|Physician Decision|0
6145600|NCT01072149|9780048|FG010|Washout Period 2 (14 Days)|Physician Decision|0
6145601|NCT01072149|9780049|FG011|Washout Period 2 (14 Days)|Physician Decision|0
6145602|NCT01072149|9780050|FG012|Washout Period 2 (14 Days)|Physician Decision|0
6145603|NCT01072149|9780051|FG013|Washout Period 2 (14 Days)|Physician Decision|0
6145604|NCT01072149|9780052|FG014|Washout Period 2 (14 Days)|Physician Decision|0
6145605|NCT01072149|9780053|FG015|Washout Period 2 (14 Days)|Physician Decision|0
6145606|NCT01072149|9780054|FG016|Washout Period 2 (14 Days)|Physician Decision|0
6145607|NCT01072149|9780055|FG017|Washout Period 2 (14 Days)|Physician Decision|0
6145608|NCT01072149|9780038|FG000|Washout Period 2 (14 Days)|Withdrawal by Subject|0
6145609|NCT01072149|9780039|FG001|Washout Period 2 (14 Days)|Withdrawal by Subject|0
6145610|NCT01072149|9780040|FG002|Washout Period 2 (14 Days)|Withdrawal by Subject|0
6145611|NCT01072149|9780041|FG003|Washout Period 2 (14 Days)|Withdrawal by Subject|0
6145612|NCT01072149|9780042|FG004|Washout Period 2 (14 Days)|Withdrawal by Subject|0
6145613|NCT01072149|9780043|FG005|Washout Period 2 (14 Days)|Withdrawal by Subject|0
6145614|NCT01072149|9780044|FG006|Washout Period 2 (14 Days)|Withdrawal by Subject|0
6145615|NCT01072149|9780045|FG007|Washout Period 2 (14 Days)|Withdrawal by Subject|0
6145616|NCT01072149|9780046|FG008|Washout Period 2 (14 Days)|Withdrawal by Subject|0
6145617|NCT01072149|9780047|FG009|Washout Period 2 (14 Days)|Withdrawal by Subject|0
6145618|NCT01072149|9780048|FG010|Washout Period 2 (14 Days)|Withdrawal by Subject|0
6145619|NCT01072149|9780049|FG011|Washout Period 2 (14 Days)|Withdrawal by Subject|0
6145620|NCT01072149|9780050|FG012|Washout Period 2 (14 Days)|Withdrawal by Subject|0
6145621|NCT01072149|9780051|FG013|Washout Period 2 (14 Days)|Withdrawal by Subject|0
6145622|NCT01072149|9780052|FG014|Washout Period 2 (14 Days)|Withdrawal by Subject|0
6145623|NCT01072149|9780053|FG015|Washout Period 2 (14 Days)|Withdrawal by Subject|1
6145624|NCT01072149|9780054|FG016|Washout Period 2 (14 Days)|Withdrawal by Subject|0
6145625|NCT01072149|9780055|FG017|Washout Period 2 (14 Days)|Withdrawal by Subject|0
6145626|NCT01072149|9780038|FG000|Washout Period 2 (14 Days)|Adverse Event|0
6145627|NCT01072149|9780039|FG001|Washout Period 2 (14 Days)|Adverse Event|0
6145628|NCT01072149|9780040|FG002|Washout Period 2 (14 Days)|Adverse Event|0
6145629|NCT01072149|9780041|FG003|Washout Period 2 (14 Days)|Adverse Event|0
6145630|NCT01072149|9780042|FG004|Washout Period 2 (14 Days)|Adverse Event|0
6145631|NCT01072149|9780043|FG005|Washout Period 2 (14 Days)|Adverse Event|0
6145632|NCT01072149|9780044|FG006|Washout Period 2 (14 Days)|Adverse Event|0
6145633|NCT01072149|9780045|FG007|Washout Period 2 (14 Days)|Adverse Event|0
6145634|NCT01072149|9780046|FG008|Washout Period 2 (14 Days)|Adverse Event|0
6145635|NCT01072149|9780047|FG009|Washout Period 2 (14 Days)|Adverse Event|0
6145636|NCT01072149|9780048|FG010|Washout Period 2 (14 Days)|Adverse Event|0
6145637|NCT01072149|9780049|FG011|Washout Period 2 (14 Days)|Adverse Event|0
6145638|NCT01072149|9780050|FG012|Washout Period 2 (14 Days)|Adverse Event|0
6145639|NCT01072149|9780051|FG013|Washout Period 2 (14 Days)|Adverse Event|0
6145640|NCT01072149|9780052|FG014|Washout Period 2 (14 Days)|Adverse Event|0
6145641|NCT01072149|9780053|FG015|Washout Period 2 (14 Days)|Adverse Event|1
6145642|NCT01072149|9780054|FG016|Washout Period 2 (14 Days)|Adverse Event|0
6145643|NCT01072149|9780055|FG017|Washout Period 2 (14 Days)|Adverse Event|0
6145644|NCT01072149|9780038|FG000|Washout Period 2 (14 Days)|Lack of Efficacy|0
6145645|NCT01072149|9780039|FG001|Washout Period 2 (14 Days)|Lack of Efficacy|0
6145646|NCT01072149|9780040|FG002|Washout Period 2 (14 Days)|Lack of Efficacy|0
6145647|NCT01072149|9780041|FG003|Washout Period 2 (14 Days)|Lack of Efficacy|0
6145648|NCT01072149|9780042|FG004|Washout Period 2 (14 Days)|Lack of Efficacy|0
6145649|NCT01072149|9780043|FG005|Washout Period 2 (14 Days)|Lack of Efficacy|0
6145650|NCT01072149|9780044|FG006|Washout Period 2 (14 Days)|Lack of Efficacy|0
6145651|NCT01072149|9780045|FG007|Washout Period 2 (14 Days)|Lack of Efficacy|0
6145652|NCT01072149|9780046|FG008|Washout Period 2 (14 Days)|Lack of Efficacy|0
6145653|NCT01072149|9780047|FG009|Washout Period 2 (14 Days)|Lack of Efficacy|0
6145654|NCT01072149|9780048|FG010|Washout Period 2 (14 Days)|Lack of Efficacy|0
6145655|NCT01072149|9780049|FG011|Washout Period 2 (14 Days)|Lack of Efficacy|0
6145656|NCT01072149|9780050|FG012|Washout Period 2 (14 Days)|Lack of Efficacy|1
6145657|NCT01072149|9780051|FG013|Washout Period 2 (14 Days)|Lack of Efficacy|0
6145658|NCT01072149|9780052|FG014|Washout Period 2 (14 Days)|Lack of Efficacy|0
6145659|NCT01072149|9780053|FG015|Washout Period 2 (14 Days)|Lack of Efficacy|0
6145660|NCT01072149|9780054|FG016|Washout Period 2 (14 Days)|Lack of Efficacy|0
6145661|NCT01072149|9780055|FG017|Washout Period 2 (14 Days)|Lack of Efficacy|0
6145662|NCT01072149|9780038|FG000|Treatment Period 3 (28 Days)|Withdrawal by Subject|0
6145663|NCT01072149|9780039|FG001|Treatment Period 3 (28 Days)|Withdrawal by Subject|0
6145664|NCT01072149|9780040|FG002|Treatment Period 3 (28 Days)|Withdrawal by Subject|1
6145665|NCT01072149|9780041|FG003|Treatment Period 3 (28 Days)|Withdrawal by Subject|0
6145666|NCT01072149|9780042|FG004|Treatment Period 3 (28 Days)|Withdrawal by Subject|0
6145667|NCT01072149|9780043|FG005|Treatment Period 3 (28 Days)|Withdrawal by Subject|0
6145668|NCT01072149|9780044|FG006|Treatment Period 3 (28 Days)|Withdrawal by Subject|0
6145669|NCT01072149|9780045|FG007|Treatment Period 3 (28 Days)|Withdrawal by Subject|0
6145670|NCT01072149|9780046|FG008|Treatment Period 3 (28 Days)|Withdrawal by Subject|0
6145671|NCT01072149|9780047|FG009|Treatment Period 3 (28 Days)|Withdrawal by Subject|0
6145672|NCT01072149|9780048|FG010|Treatment Period 3 (28 Days)|Withdrawal by Subject|0
6145673|NCT01072149|9780049|FG011|Treatment Period 3 (28 Days)|Withdrawal by Subject|0
6145674|NCT01072149|9780050|FG012|Treatment Period 3 (28 Days)|Withdrawal by Subject|0
5982983|NCT00835991|9572244|FG000|First Intervention|Adverse Event|0
5982984|NCT00835991|9572245|FG001|First Intervention|Adverse Event|1
5982985|NCT00835991|9572244|FG000|Washout|Protocol Violation|0
5982986|NCT00835991|9572245|FG001|Washout|Protocol Violation|2
5982987|NCT00835991|9572244|FG000|Washout|Withdrawal by Subject|3
5982988|NCT00835991|9572245|FG001|Washout|Withdrawal by Subject|1
5982989|NCT00835796|9572251|FG000|First Intervention|Withdrawal by Subject|0
5982990|NCT00835796|9572252|FG001|First Intervention|Withdrawal by Subject|1
5982991|NCT00835705|9572258|FG000|First Intervention|Difficulty with vein|1
5982992|NCT00835705|9572259|FG001|First Intervention|Difficulty with vein|0
5982993|NCT00835705|9572258|FG000|Second Intervention|Difficulty with vein|1
5982994|NCT00835705|9572259|FG001|Second Intervention|Difficulty with vein|0
5982995|NCT00835692|9572265|FG000|First Intervention|Withdrawal by Subject|1
5982996|NCT00835692|9572266|FG001|First Intervention|Withdrawal by Subject|0
5982997|NCT00835666|9572272|FG000|Washout|Protocol Violation|1
5982998|NCT00835666|9572273|FG001|Washout|Protocol Violation|0
5982999|NCT00835666|9572272|FG000|Washout|Withdrawal by Subject|1
5983000|NCT00835666|9572273|FG001|Washout|Withdrawal by Subject|0
5983001|NCT00835640|9572279|FG000|Second Intervention|Protocol Violation|1
5983002|NCT00835640|9572280|FG001|Second Intervention|Protocol Violation|0
5983003|NCT00835575|9572300|FG000|Washout of 14 Days|Withdrawal by Subject|1
5983004|NCT00835575|9572301|FG001|Washout of 14 Days|Withdrawal by Subject|0
5983005|NCT00835549|9572307|FG000|Washout of 7 Days|Withdrawal by Subject|2
5983006|NCT00835549|9572308|FG001|Washout of 7 Days|Withdrawal by Subject|0
5983007|NCT00835536|9572314|FG000|Washout of 5 Weeks|Withdrawal by Subject|1
5983008|NCT00835536|9572315|FG001|Washout of 5 Weeks|Withdrawal by Subject|0
5983009|NCT00835406|9572335|FG000|Period: First Intervention|Adverse Event|0
5983010|NCT00835406|9572336|FG001|Period: First Intervention|Adverse Event|1
5983011|NCT00835406|9572335|FG000|Period: First Intervention|Withdrawal by Subject|2
5983012|NCT00835406|9572336|FG001|Period: First Intervention|Withdrawal by Subject|0
5983013|NCT00835406|9572335|FG000|Period: Washout of 7 Days|Withdrawal by Subject|0
5983014|NCT00835406|9572336|FG001|Period: Washout of 7 Days|Withdrawal by Subject|2
5983015|NCT00835367|9572342|FG000|Washout|Adverse Event|2
5983016|NCT00835367|9572343|FG001|Washout|Adverse Event|0
5983017|NCT00835367|9572342|FG000|Washout|Withdrawal by Subject|1
5983018|NCT00835367|9572343|FG001|Washout|Withdrawal by Subject|0
5983019|NCT00835367|9572342|FG000|Second Intervention|Adverse Event|1
5983020|NCT00835367|9572343|FG001|Second Intervention|Adverse Event|1
5983021|NCT00835354|9572349|FG000|First Intervention|Adverse Event|0
5983022|NCT00835354|9572350|FG001|First Intervention|Adverse Event|1
5983023|NCT00835263|9572363|FG000|Second Intervention|Adverse Event|1
5983024|NCT00835263|9572364|FG001|Second Intervention|Adverse Event|0
5983025|NCT00835211|9572370|FG000|First Intervention|Withdrawal by Subject|0
5983026|NCT00835211|9572371|FG001|First Intervention|Withdrawal by Subject|1
5983027|NCT00835211|9572370|FG000|Washout: 7 Days|Adverse Event|2
5983028|NCT00835211|9572371|FG001|Washout: 7 Days|Adverse Event|1
5983029|NCT00835211|9572370|FG000|Washout: 7 Days|Withdrawal by Subject|1
5983030|NCT00835211|9572371|FG001|Washout: 7 Days|Withdrawal by Subject|0
5983031|NCT00835172|9572377|FG000|Washout|Protocol Violation|0
5983032|NCT00835172|9572378|FG001|Washout|Protocol Violation|1
5983033|NCT00835081|9572391|FG000|Washout of 7 Days|Withdrawal by Subject|1
5983034|NCT00835081|9572392|FG001|Washout of 7 Days|Withdrawal by Subject|0
5983035|NCT00835042|9572398|FG000|First Intervention|Withdrawal by Subject|3
5983036|NCT00835042|9572399|FG001|First Intervention|Withdrawal by Subject|0
5983037|NCT00835042|9572398|FG000|First Intervention|Adverse Event|1
5983038|NCT00835042|9572399|FG001|First Intervention|Adverse Event|2
5983039|NCT00835042|9572398|FG000|Washout of 21 Days|Withdrawal by Subject|0
5983040|NCT00835042|9572399|FG001|Washout of 21 Days|Withdrawal by Subject|2
5983041|NCT00834873|9572426|FG000|First Intervention|Adverse Event|0
5983042|NCT00834873|9572427|FG001|First Intervention|Adverse Event|1
5983043|NCT00834795|9572433|FG000|Washout: 7 Days|Withdrawal by Subject|0
5983044|NCT00834795|9572434|FG001|Washout: 7 Days|Withdrawal by Subject|1
5983045|NCT00834795|9572433|FG000|Second Intervention|Adverse Event|1
5983046|NCT00834795|9572434|FG001|Second Intervention|Adverse Event|0
5983047|NCT00834756|9572440|FG000|First Intervention|Adverse Event|1
5983048|NCT00834756|9572441|FG001|First Intervention|Adverse Event|0
5983049|NCT00834756|9572440|FG000|Washout: 21 Days|Withdrawal by Subject|1
5983050|NCT00834756|9572441|FG001|Washout: 21 Days|Withdrawal by Subject|0
5983051|NCT00834743|9572447|FG000|Second Intervention|Withdrawal by Subject|1
5983052|NCT00834743|9572448|FG001|Second Intervention|Withdrawal by Subject|0
5983053|NCT00834717|9572454|FG000|First Intervention|Adverse Event|1
5983054|NCT00834717|9572455|FG001|First Intervention|Adverse Event|0
5983055|NCT00834717|9572454|FG000|First Intervention|Withdrawal by Subject|0
5983056|NCT00834717|9572455|FG001|First Intervention|Withdrawal by Subject|1
5983057|NCT00834639|9572461|FG000|Second Intervention|Physician Decision|0
5983058|NCT00834639|9572462|FG001|Second Intervention|Physician Decision|2
5983059|NCT00834613|9572468|FG000|First Intervention|Protocol Violation|1
5983060|NCT00834613|9572469|FG001|First Intervention|Protocol Violation|0
5983061|NCT00834587|9572475|FG000|Washout: 7 Days|Withdrawal by Subject|1
5983062|NCT00834587|9572476|FG001|Washout: 7 Days|Withdrawal by Subject|0
5983063|NCT00834522|9572503|FG000|Washout|Adverse Event|1
5983064|NCT00834522|9572504|FG001|Washout|Adverse Event|0
5983065|NCT00834522|9572503|FG000|Washout|Withdrawal by Subject|2
5983066|NCT00834522|9572504|FG001|Washout|Withdrawal by Subject|1
6145675|NCT01072149|9780051|FG013|Treatment Period 3 (28 Days)|Withdrawal by Subject|1
6145676|NCT01072149|9780052|FG014|Treatment Period 3 (28 Days)|Withdrawal by Subject|0
6145677|NCT01072149|9780053|FG015|Treatment Period 3 (28 Days)|Withdrawal by Subject|0
6145678|NCT01072149|9780054|FG016|Treatment Period 3 (28 Days)|Withdrawal by Subject|0
6145679|NCT01072149|9780055|FG017|Treatment Period 3 (28 Days)|Withdrawal by Subject|0
6145680|NCT01072201|9780076|FG000|Overall Study|Lost to Follow-up|0
6145681|NCT01072201|9780077|FG001|Overall Study|Lost to Follow-up|1
6145682|NCT01072344|9780098|FG000|Overall Study|Relasped-reached end point|7
6145683|NCT01072344|9780099|FG001|Overall Study|Relasped-reached end point|12
6145684|NCT01072344|9780098|FG000|Overall Study|Protocol Violation|1
6145685|NCT01072344|9780099|FG001|Overall Study|Protocol Violation|2
6145686|NCT01072344|9780098|FG000|Overall Study|Lost to Follow-up|3
6145687|NCT01072344|9780099|FG001|Overall Study|Lost to Follow-up|4
6145688|NCT01072357|9780107|FG000|Overall Study|Lost to Follow-up|0
6145689|NCT01072357|9780108|FG001|Overall Study|Lost to Follow-up|1
6145690|NCT01072396|9780116|FG000|Period One|Adverse Event|1
6145691|NCT01072396|9780117|FG001|Period One|Adverse Event|1
6145692|NCT01072396|9780116|FG000|Period One|Protocol Violation|2
6145693|NCT01072396|9780117|FG001|Period One|Protocol Violation|1
6145694|NCT01072396|9780116|FG000|Period One|Withdrawal by Subject|2
6145695|NCT01072396|9780117|FG001|Period One|Withdrawal by Subject|0
6145696|NCT01072396|9780116|FG000|Washout Period|Missing termination information|0
6145697|NCT01072396|9780117|FG001|Washout Period|Missing termination information|1
6145698|NCT01072396|9780116|FG000|Period Two|Adverse Event|0
5983067|NCT00834444|9572510|FG000|First Intervention|Adverse Event|1
5983068|NCT00834444|9572511|FG001|First Intervention|Adverse Event|0
5983069|NCT00834444|9572510|FG000|First Intervention|Intolerance to Venopuncture|0
5983070|NCT00834444|9572511|FG001|First Intervention|Intolerance to Venopuncture|1
5983071|NCT00834444|9572510|FG000|Washout of 7 Days|Withdrawal by Subject|0
5983072|NCT00834444|9572511|FG001|Washout of 7 Days|Withdrawal by Subject|1
5983073|NCT00834444|9572510|FG000|Second Intervention|Adverse Event|1
5983074|NCT00834444|9572511|FG001|Second Intervention|Adverse Event|0
5983075|NCT00834431|9572517|FG000|First Intervention|Adverse Event|0
5983076|NCT00834431|9572518|FG001|First Intervention|Adverse Event|1
5983077|NCT00834431|9572517|FG000|Washout of 7 Days|Withdrawal by Subject|0
5983078|NCT00834431|9572518|FG001|Washout of 7 Days|Withdrawal by Subject|1
5983079|NCT00834418|9572524|FG000|Overall Study|Adverse Event|0
5983080|NCT00834418|9572525|FG001|Overall Study|Adverse Event|2
5983081|NCT00834340|9572538|FG000|Washout|Adverse Event|1
5983082|NCT00834340|9572539|FG001|Washout|Adverse Event|0
5983083|NCT00834340|9572538|FG000|Washout|Withdrawal by Subject|1
5983084|NCT00834340|9572539|FG001|Washout|Withdrawal by Subject|0
5983085|NCT00834249|9572552|FG000|Washout: 7 Days|Withdrawal by Subject|1
5983086|NCT00834249|9572553|FG001|Washout: 7 Days|Withdrawal by Subject|1
5983087|NCT00834249|9572552|FG000|Second Intervention|Adverse Event|1
5983088|NCT00834249|9572553|FG001|Second Intervention|Adverse Event|0
5983089|NCT00834067|9572573|FG000|Washout of 21 Days|Protocol Violation|0
5983090|NCT00834067|9572574|FG001|Washout of 21 Days|Protocol Violation|1
5983091|NCT00833937|9572580|FG000|Washout|Withdrawal by Subject|1
5983092|NCT00833937|9572581|FG001|Washout|Withdrawal by Subject|0
5983093|NCT00830336|9572608|FG000|Washout: 21 Days|Withdrawal by Subject|1
5983094|NCT00830336|9572609|FG001|Washout: 21 Days|Withdrawal by Subject|0
5983095|NCT00830258|9572615|FG000|First Intervention|Adverse Event|1
5983096|NCT00830258|9572616|FG001|First Intervention|Adverse Event|0
5983097|NCT00830258|9572615|FG000|Washout: 7 Days|Protocol Violation|1
5983098|NCT00830258|9572616|FG001|Washout: 7 Days|Protocol Violation|0
5983099|NCT00830219|9572622|FG000|Washout of 7 Days|Withdrawal by Subject|1
5983100|NCT00830219|9572623|FG001|Washout of 7 Days|Withdrawal by Subject|1
5983101|NCT00830206|9572629|FG000|Washout: 21 Days|Withdrawal by Subject|1
5983102|NCT00830206|9572630|FG001|Washout: 21 Days|Withdrawal by Subject|1
5983103|NCT00830024|9572636|FG000|Washout: 7 Days|Withdrawal by Subject|1
5983104|NCT00830024|9572637|FG001|Washout: 7 Days|Withdrawal by Subject|0
5983105|NCT00829998|9572643|FG000|Washout|Adverse Event|0
5983106|NCT00829998|9572644|FG001|Washout|Adverse Event|1
5983107|NCT00829868|9572650|FG000|Washout|Physician Decision|1
5983108|NCT00829868|9572651|FG001|Washout|Physician Decision|0
5983109|NCT00829790|9572657|FG000|Washout of 14 Days|Withdrawal by Subject|0
5983110|NCT00829790|9572658|FG001|Washout of 14 Days|Withdrawal by Subject|1
5983111|NCT00829764|9572664|FG000|First Intervention|Adverse Event|1
5983112|NCT00829764|9572665|FG001|First Intervention|Adverse Event|0
5983113|NCT00829764|9572664|FG000|First Intervention|Withdrawal by Subject|1
5983114|NCT00829764|9572665|FG001|First Intervention|Withdrawal by Subject|1
5983115|NCT00829712|9572671|FG000|Washout of 7 Days|Withdrawal by Subject|0
5983116|NCT00829712|9572672|FG001|Washout of 7 Days|Withdrawal by Subject|1
5983117|NCT00829673|9572685|FG000|Washout of 7 Days|Withdrawal by Subject|1
5983118|NCT00829673|9572686|FG001|Washout of 7 Days|Withdrawal by Subject|0
5983119|NCT00829530|9572692|FG000|First Intervention|Adverse Event|0
5983120|NCT00829530|9572693|FG001|First Intervention|Adverse Event|1
5983121|NCT00829530|9572692|FG000|First Intervention|Intolerance to Venopuncture|0
5983122|NCT00829530|9572693|FG001|First Intervention|Intolerance to Venopuncture|1
5983123|NCT00829530|9572692|FG000|Second Intervention|Intolerance to Venopuncture|1
5983124|NCT00829530|9572693|FG001|Second Intervention|Intolerance to Venopuncture|0
5983125|NCT00829504|9572699|FG000|First Intervention|Adverse Event|1
5983126|NCT00829504|9572700|FG001|First Intervention|Adverse Event|0
5983127|NCT00829504|9572699|FG000|Washout of 7 Days|Withdrawal by Subject|1
5983128|NCT00829504|9572700|FG001|Washout of 7 Days|Withdrawal by Subject|0
5983129|NCT00829504|9572699|FG000|Second Intervention|Physician Decision|1
5983130|NCT00829504|9572700|FG001|Second Intervention|Physician Decision|0
5983131|NCT00829452|9572706|FG000|First Intervention|Withdrawal by Subject|0
5983132|NCT00829452|9572707|FG001|First Intervention|Withdrawal by Subject|1
5983133|NCT00829452|9572706|FG000|Washout of 42 Days|Withdrawal by Subject|0
5983134|NCT00829452|9572707|FG001|Washout of 42 Days|Withdrawal by Subject|1
5983135|NCT00829452|9572706|FG000|Second Intervention|Physician Decision|0
5983136|NCT00829452|9572707|FG001|Second Intervention|Physician Decision|1
5983137|NCT00829426|9572713|FG000|Washout: 7 Days|Withdrawal by Subject|1
5983138|NCT00829426|9572714|FG001|Washout: 7 Days|Withdrawal by Subject|0
5983139|NCT00829309|9572720|FG000|Washout: 7 Days|Protocol Violation|1
5983140|NCT00829309|9572721|FG001|Washout: 7 Days|Protocol Violation|0
5983141|NCT00828321|9572727|FG000|Washout of 42 Days|Withdrawal by Subject|2
5983142|NCT00828321|9572728|FG001|Washout of 42 Days|Withdrawal by Subject|0
5983143|NCT00828321|9572727|FG000|Second Intervention|Protocol Violation|0
5983144|NCT00828321|9572728|FG001|Second Intervention|Protocol Violation|1
5983145|NCT00806403|9572734|FG000|Overall Study|Death|4
5983146|NCT00806403|9572735|FG001|Overall Study|Death|3
5983147|NCT00796523|9572775|FG000|Overall Study|Lost to Follow-up|9
5983148|NCT00796523|9572776|FG001|Overall Study|Lost to Follow-up|7
5983149|NCT00794924|9572782|FG000|Overall Study|Lost to Follow-up|6
5983150|NCT00794924|9572783|FG001|Overall Study|Lost to Follow-up|8
5983151|NCT00794924|9572782|FG000|Overall Study|Withdrawal by Subject|48
5983152|NCT00794924|9572783|FG001|Overall Study|Withdrawal by Subject|60
5983153|NCT00794924|9572782|FG000|Overall Study|Adverse Event|6
5983154|NCT00794924|9572783|FG001|Overall Study|Adverse Event|2
5983155|NCT00794677|9572789|FG000|First Intervention|Withdrawal by Subject|2
5983156|NCT00794677|9572790|FG001|First Intervention|Withdrawal by Subject|0
6145699|NCT01072396|9780117|FG001|Period Two|Adverse Event|3
6145700|NCT01072396|9780116|FG000|Period Two|Lost to Follow-up|1
6145701|NCT01072396|9780117|FG001|Period Two|Lost to Follow-up|0
6145702|NCT01072448|9780129|FG000|Overall Study|Adverse Event|9
6145703|NCT01072448|9780130|FG001|Overall Study|Adverse Event|10
6145704|NCT01072448|9780129|FG000|Overall Study|Subject withdrew consent|4
6145705|NCT01072448|9780130|FG001|Overall Study|Subject withdrew consent|9
6145706|NCT01072448|9780129|FG000|Overall Study|Protocol deviation|3
6145707|NCT01072448|9780130|FG001|Overall Study|Protocol deviation|4
6145708|NCT01072448|9780129|FG000|Overall Study|Abnormal test procedure result(s)|1
6145709|NCT01072448|9780130|FG001|Overall Study|Abnormal test procedure result(s)|0
6145710|NCT01072448|9780129|FG000|Overall Study|Unsatisfactory therapeutic effect|1
6145711|NCT01072448|9780130|FG001|Overall Study|Unsatisfactory therapeutic effect|3
6145712|NCT01072448|9780129|FG000|Overall Study|Lost to Follow-up|1
6145713|NCT01072448|9780130|FG001|Overall Study|Lost to Follow-up|1
6145714|NCT01072448|9780129|FG000|Overall Study|Abnormal laboratory value(s)|0
6145715|NCT01072448|9780130|FG001|Overall Study|Abnormal laboratory value(s)|1
6145716|NCT01072448|9780129|FG000|Overall Study|Death|0
6145717|NCT01072448|9780130|FG001|Overall Study|Death|2
6145718|NCT01072500|9780138|FG000|Overall Study|Death|2
6145719|NCT01072500|9780139|FG001|Overall Study|Death|2
6145720|NCT01072500|9780138|FG000|Overall Study|Lost to Follow-up|5
6145721|NCT01072500|9780139|FG001|Overall Study|Lost to Follow-up|2
6145722|NCT01072500|9780138|FG000|Overall Study|Withdrawal by Subject|17
6145723|NCT01072500|9780139|FG001|Overall Study|Withdrawal by Subject|10
6145724|NCT01072539|9780147|FG000|Overall Study|Treated prior to the Site Initiation|1
6145725|NCT01072539|9780147|FG000|Overall Study|Protocol Violation|2
6145726|NCT01072630|9780159|FG000|Overall Study|Adverse Event|11
6145727|NCT01072630|9780160|FG001|Overall Study|Adverse Event|19
6145728|NCT01072630|9780161|FG002|Overall Study|Adverse Event|2
6145729|NCT01072630|9780159|FG000|Overall Study|Lack of Efficacy|10
6145730|NCT01072630|9780160|FG001|Overall Study|Lack of Efficacy|10
6145731|NCT01072630|9780161|FG002|Overall Study|Lack of Efficacy|1
6145732|NCT01072630|9780159|FG000|Overall Study|Withdrawal by Subject|8
6145733|NCT01072630|9780160|FG001|Overall Study|Withdrawal by Subject|7
6145734|NCT01072630|9780161|FG002|Overall Study|Withdrawal by Subject|2
6145735|NCT01072630|9780159|FG000|Overall Study|Protocol Violation|10
6145736|NCT01072630|9780160|FG001|Overall Study|Protocol Violation|8
6145737|NCT01072630|9780161|FG002|Overall Study|Protocol Violation|4
6145738|NCT01072630|9780159|FG000|Overall Study|Lost to Follow-up|11
6145739|NCT01072630|9780160|FG001|Overall Study|Lost to Follow-up|11
6145740|NCT01072630|9780161|FG002|Overall Study|Lost to Follow-up|1
6145741|NCT01072630|9780159|FG000|Overall Study|Noncompliance with study medication|1
6145742|NCT01072630|9780160|FG001|Overall Study|Noncompliance with study medication|1
6145743|NCT01072630|9780161|FG002|Overall Study|Noncompliance with study medication|1
6145744|NCT01072630|9780159|FG000|Overall Study|Noncompliance with study procedures|1
6145745|NCT01072630|9780160|FG001|Overall Study|Noncompliance with study procedures|2
6145746|NCT01072630|9780161|FG002|Overall Study|Noncompliance with study procedures|1
6145747|NCT01072630|9780159|FG000|Overall Study|Other|3
6145748|NCT01072630|9780160|FG001|Overall Study|Other|2
6145749|NCT01072630|9780161|FG002|Overall Study|Other|1
5983157|NCT00792116|9572796|FG000|Overall Study|Lost to Follow-up|0
5983158|NCT00792116|9572797|FG001|Overall Study|Lost to Follow-up|1
5983159|NCT00792116|9572796|FG000|Overall Study|Discontnued intervention|1
5983160|NCT00792116|9572797|FG001|Overall Study|Discontnued intervention|0
5983161|NCT00756574|9572817|FG000|Overall Study|Withdrawal by Subject|9
5983162|NCT00756574|9572818|FG001|Overall Study|Withdrawal by Subject|7
5983163|NCT00756574|9572817|FG000|Overall Study|Lost to Follow-up|4
5983164|NCT00756574|9572818|FG001|Overall Study|Lost to Follow-up|4
5983165|NCT00740480|9572825|FG000|Overall Study|Adverse Event|1
5983166|NCT00740480|9572825|FG000|Overall Study|Physician Decision|1
5983167|NCT00724698|9572828|FG000|Overall Study|Adverse Event|9
5983168|NCT00724698|9572828|FG000|Overall Study|Failure of Therapy|4
5983169|NCT00724698|9572828|FG000|Overall Study|Poor Compliance|16
5983170|NCT00724698|9572828|FG000|Overall Study|Lost to Follow-up|36
5983171|NCT00724698|9572828|FG000|Overall Study|No Info|25
5983172|NCT00711555|9572831|FG000|Overall Study|Adverse Event|3
5983173|NCT00676494|9572834|FG000|Overall Study|Missed Visit|8
5983174|NCT00676494|9572834|FG000|Overall Study|Withdrawal by Subject|6
5983175|NCT00659061|9572842|FG000|Overall Study|Migration due to political unrest|21
5983176|NCT00659061|9572843|FG001|Overall Study|Migration due to political unrest|15
5983177|NCT00581477|9572854|FG000|Overall Study|Physician Decision|2
5983178|NCT00554190|9572875|FG000|Overall Study|Termination forms not completed|10
5983179|NCT00529152|9572895|FG000|Overall Study|Adverse Event|2
5983180|NCT00529152|9572895|FG000|Overall Study|Withdrawal by Subject|2
5983181|NCT00529152|9572895|FG000|Overall Study|Lost to Follow-up|1
5983182|NCT00526227|9572898|FG000|Overall Study|Device not implanted|1
5983183|NCT00526227|9572898|FG000|Overall Study|Death|1
5983184|NCT00495131|9572918|FG000|Overall Study|Adverse Event|6
5983185|NCT00495131|9572919|FG001|Overall Study|Adverse Event|2
5983186|NCT00495131|9572918|FG000|Overall Study|Lack of Efficacy|0
5983187|NCT00495131|9572919|FG001|Overall Study|Lack of Efficacy|2
5983188|NCT00495131|9572918|FG000|Overall Study|Lost to Follow-up|0
5983189|NCT00495131|9572919|FG001|Overall Study|Lost to Follow-up|2
5983190|NCT00495131|9572918|FG000|Overall Study|Withdrawal by Subject|1
5983191|NCT00495131|9572919|FG001|Overall Study|Withdrawal by Subject|0
5983192|NCT00484419|9572933|FG000|Overall Study|Adverse Event|3
5983193|NCT00484419|9572934|FG001|Overall Study|Adverse Event|0
5983194|NCT00484419|9572935|FG002|Overall Study|Adverse Event|0
5983195|NCT00484419|9572933|FG000|Overall Study|Lost to Follow-up|1
5983196|NCT00484419|9572934|FG001|Overall Study|Lost to Follow-up|0
5983197|NCT00484419|9572935|FG002|Overall Study|Lost to Follow-up|2
5983198|NCT00484419|9572933|FG000|Overall Study|Withdrawal by Subject|3
5983199|NCT00484419|9572934|FG001|Overall Study|Withdrawal by Subject|1
5983200|NCT00484419|9572935|FG002|Overall Study|Withdrawal by Subject|1
5983201|NCT00484419|9572933|FG000|Overall Study|subject met discontinuation criteria|2
5983202|NCT00484419|9572934|FG001|Overall Study|subject met discontinuation criteria|2
5983203|NCT00484419|9572935|FG002|Overall Study|subject met discontinuation criteria|4
5983204|NCT00484419|9572933|FG000|Overall Study|required restricted medication|1
5983205|NCT00484419|9572934|FG001|Overall Study|required restricted medication|0
5983206|NCT00484419|9572935|FG002|Overall Study|required restricted medication|1
5983207|NCT00484419|9572933|FG000|Overall Study|Physician Decision|1
5983208|NCT00484419|9572934|FG001|Overall Study|Physician Decision|1
5983209|NCT00484419|9572935|FG002|Overall Study|Physician Decision|1
5983210|NCT00484419|9572933|FG000|Overall Study|subject unable to receive medication|1
5983211|NCT00484419|9572934|FG001|Overall Study|subject unable to receive medication|0
5983212|NCT00484419|9572935|FG002|Overall Study|subject unable to receive medication|0
5983213|NCT00484419|9572933|FG000|Overall Study|subject relocated|0
5983214|NCT00484419|9572934|FG001|Overall Study|subject relocated|1
5983215|NCT00484419|9572935|FG002|Overall Study|subject relocated|0
5983216|NCT00484419|9572933|FG000|Overall Study|sponsor decision, randomized in error|0
5983217|NCT00484419|9572934|FG001|Overall Study|sponsor decision, randomized in error|0
5983218|NCT00484419|9572935|FG002|Overall Study|sponsor decision, randomized in error|2
5983219|NCT00474188|9572947|FG000|Overall Study|Withdrawal by Subject|1
5983220|NCT00474188|9572947|FG000|Overall Study|Study discontinued by sponsor|5
